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TH-OR001
Dapagliflozin Reduces Albuminuria Over 2 Years in Diabetic Patients 
with Renal Impairment  Bergur V. Stefansson,2 Paola Fioretto,1 Eva K.A. 
Johnsson,2 Valerie A. Cain,3 David Sjostrom.2  1Univ of Padova, Italy; 2AZ, 
Mölndal, Sweden; 3AZ, Wilmington.
Background: Pooled clinical data has shown reductions in albuminuria during 
dapagliflozin (DAPA) treatment. This analysis explored the long term effect of DAPA on 
albuminuria and renal safety.
Methods: This is a post hoc analysis of patients with CKD3 and albuminuria (³30 mg/g) 
from study NCT00663260. Percent change in urinary albumin:creatinine ratio (UACR) was 
evaluated up to 104 weeks. At baseline 57 placebo (PBO), 53 DAPA 5 mg and 56 DAPA 
10 mg patients were identified.
Results: The baseline (BL) median (range) values for UACR, mg/g, were PBO: 180 
(30 to 9262), DAPA 5 mg: 397 (31 to 4970) and DAPA 10 mg: 179 (32 to 4792). The 
corresponding mean (SD) values for eGFR, mL/min/1.73 m2, were: 45.1 (9.37), 43.9 
(8.96) and 44.1 (11.1), respectively. A reduction in UACR was already evident at Week 1. 
At 104 weeks the mean (95% CI) PBO-corrected reduction in UACR was –44% (–71, 9.0) 
and –57% (–77, –20) for DAPA 5 and 10 mg, respectively. After adjusting for changes in 
blood pressure, HbA1c and eGFR, the reductions were largely maintained. During the 104 
week study period 7% of PBO patients regressed to normoalbuminuria, the corresponding 
numbers for DAPA 5 and 10 mg were 19 and 18%, respectively. After a transient decrease 
in eGFR in DAPA-treated patients, the DAPA 5 and 10 mg groups showed PBO-corrected 
104 week changes of 2.1 (–1.3, 5.5) and –0.7 (–4.0, 2.6) mL/min/1.73 m2. Renal adverse 
events (AEs) were more common in DAPA 10 mg treated subjects (10.7%) than in DAPA 
5 mg (1.9%) or PBO treated (3.5%) subjects, many were due to increased creatinine. There 
was no increase in serious AEs related to renal impairment in the DAPA 10 mg group (1.8%) 
compared with the PBO group (1.8%).
Conclusions: Dapagliflozin reduces UACR for up to 2 years in subjects with CKD3, 
without increases in serious renal AEs. The UACR reduction remained present after 
adjustments for changes in blood pressure, HbA1c and eGFR, indicating a direct renal 
effect independent of changes in these variables.
Funding: Pharmaceutical Company Support - AstraZeneca
TH-OR002
Structural Predictors of Loss of Renal Function in Type 2 Diabetes 
Gudeta D. Fufaa,1 E. Jennifer Weil,1 Kevin V. Lemley,2 William Knowler,1 
Frank C. Brosius,3 Berne Yee,4 Michael Mauer,5 Robert G. Nelson.1  1NIDDK; 
2Univ of Southern California; 3Univ of Michigan; 4Southwest Kidney Inst; 
5Univ of Minnesota.
Background: Diabetes is the leading cause of kidney failure in the US, but the early 
structural determinants of renal function loss in type 2 diabetes are poorly defined. We 
examined the association between morphometrically-determined renal structural variables 
and renal function loss in 111 Pima Indians with type 2 diabetes who volunteered for a 
research kidney biopsy and for annual measurement of glomerular filtration rate (GFR, 
iothalamate).
Methods: Renal function loss was defined as ≥40% loss of GFR from baseline. 
Associations with renal function loss were evaluated by Cox proportional-hazards 
regression. Hazard ratios (HR) were reported per 1 SD increment for each morphometric 
variable.
Results: Of the 111 participants (82% women, baseline mean age 46 years, diabetes 
duration 16 years, HbA1c 9.4%, GFR 147 ml/min, and median albumin/creatinine ratio 
[ACR] 41 mg/g), 51 (46%) developed renal function loss during a median follow-up of 
6.6 years (IQR=3.1-9.0). Higher mesangial fractional volume (HR=2.33, 95% CI 1.63-
3.33), percent global sclerosis (HR=1.57, 95% CI 1.18-2.09), non-podocyte cell number 
per glomerulus (HR=1.49, 95% CI 1.08-2.05), GBM width (HR=1.45, 95% CI 1.04-2.04), 
lower glomerular filtration surface density (HR=0.61, 95% CI 0.41-0.93), and reduced 
endothelial fenestrations (HR=0.67, 95% CI 0.47-0.94) were each associated with loss 
of renal function after adjustment for baseline age, sex, duration of diabetes, HbA1c and 
GFR. Although power was reduced when 14 participants with baseline GFR <90 ml/min 
were excluded from the analysis, baseline structure still predicted renal function loss.
Conclusions: Quantitative measures of glomerular structure predict loss of renal 
function in type 2 diabetes.
Funding: NIDDK Support
TH-OR003
Mitotic Catastrophe in Diabetic Nephropathy  Masanori Hara,1 Helen Liapis.2 
1Dept of Pediatrics, Yoshida Hospital, Tsubame, Niigata, Japan; 2Nephropath, 
Little Rock, AR.
Background: Podocytopenia is involved in the progression of diabetic nephropathy. 
Apoptosis is thought to be a major mechanism for loss of podocytes. However, apoptotic 
podocytes (Podo) are not seen in renal biopsy specimens with diabetes. Instead mitotic 
catastrophe (MC) is a newly recognized form of podocyte death characterized by Podo 
multinucleation, aberrant mitotic spindles and micronucleoli. Because injured podocytes 
may die and released in the urine, in this study we sought to quantitate MC in urine samples 
from diabetic patients.
Methods: Urine samples from patients with diabetes type 2 (n=41, microalbuminuria 
8, macroalbuminuria 33) were used. All samples were evaluated for the presence of urinary 
Podo by immunofluorescence (IF) using anti-podocalyxin (PCX) antibody and the only 
PCX positive Podo (PCX-podo) were selected for further immunohistochemical study. 
Urine sediments were double or triple stained by IF using antibodies against various 
podocyte antigens such as 1) PCX, nephrin, podocine and GLEPP1 (podocyte markers), 2) 
macrophages, and panleucocytes (leucocyte markers), 3) cytokeratin 8 (parietal epithelial 
marker), 4) Annexin V, cleaved caspase-3 and Tunel assay (apoptosis markers), and 5) 
phosphorylated vimentin (cell mitosis marker). Nucleus was stained with hematoxylin 
or DAPI.
Results: The PCX-podo showed various nuclear morphology such as 1) mononucleated, 
normal shape (8.7%), 2) mononucleated, large and abnormal shape (3.8 %), 3) 
multinucleated with or without micronucleoli (40.2%) 4) single nucleus and fragmented 
nuclei (10.9%) and 5) numerous fragmented nuclei (31.0%). We considered 2) and 3) as 
definitive MC, and 4) and 5) suspected MC. Apoptotic bodies were not found. 50% of 
PCX-podo were positve for GLEPP 1, while none of PCX-podo were positive for nephrin 
and podocine. None of PCX-podo were positive for leucocyte and parietal epithelial cell 
markers, annexin V, cleaved caspase-3 and Tunel assay. 10 % of PCX-podo were positive 
for phosphorylated vimentin.
Conclusions: Urine from diabetic patients contains a significant number of urinary 
Podo with MC and no Podos with apoptotic bodies. Our results indicate that the majority 
of urine podocytes in diabetic patients may be due to MC and not to apoptosis.
TH-OR004
Advanced Glycation End Products Predict Loss of Renal Function 
and Correlate with Diabetic Nephropathy Lesions in Type 2 Diabetes 
Pierre Jean Saulnier,1 Kevin M. Wheelock,1 William Knowler,1 Robert G. 
Nelson,1 Paul James Beisswenger,2 Scott K. Howell.2  1NIDDK; 2PreventAGE 
Healthcare.
Background: We examined the associations of serum advanced glycation end-products 
(AGEs) with loss of renal function and with the structural lesions of diabetic nephropathy 
in a post-hoc analysis of a clinical trial of renoprotection with losartan in Pima Indians 
with type 2 diabetes (ClinicalTrials.gov number, NCT00340678).
Methods: Free AGEs were measured at baseline in 168 subjects by LC triple quadrupole 
mass spectrometry. Glomerular filtration rate (GFR, iothalamate) was measured annually, 
and kidney biopsies were performed in 109 of the subjects 6 years later. Loss of renal 
function was defined as ≥40% loss of GFR from baseline. Multivariable associations 
between AGEs and loss of renal function were examined by Cox proportional-hazards 
regression, and between AGEs and morphometric variables by linear regression, after 
adjustment for age, sex, diabetes duration, HbA1c, treatment, albumin/creatinine ratio 
(ACR), and GFR. Hazard ratios (HR) were reported per doubling for each AGE. Linear 
regression results were reported as the difference in the structural measurement in SD 
units per doubling of AGE.
Results: Of the 168 subjects (73% women, mean age 41±11 years, diabetes duration 
11±6 years, HbA1c 9.2±2.3%, median GFR=165 ml/min(IQR=135-190), and median 
ACR=31 mg/g (IQR=14-76)), 104 (62%) lost ≥40% of their renal function during a 
median follow-up of 8.0 years (IQR=4.9-13.1). After multivariable adjustment, higher 
concentrations of carboxyethyllysine (CEL) and methylglyoxal hydroimidazolones (MGH1) 
were associated with loss of renal function (HR for CEL=1.7, 95% CI 1.1-2.5; HR for 
MGH1=1.3, 95% CI 1.1-1.7). MGH1 (β=0.23, P=0.018) and CEL (β=0.36, P=0.033) were 
also positively associated with mesangial fractional volume, and MGH1 (β=-0.27, P=0.009) 
and 3DG hydroimidazolone (3DGH) (β=-0.27, P=0.047) were inversely associated with 
total filtration surface per glomerulus.
Conclusions: Higher baseline dicarbonyl-derived AGEs are associated with loss of 
renal function and its structural correlates, including increased mesangial fractional volume 
and the corresponding loss of total filtration surface per glomerulus.
Funding: NIDDK Support
TH-OR005
Serum Amyloid A and Increased Risk of End-Stage Renal Disease and 
Death in Diabetic Kidney Disease  Brad Dieter,1 Sterling Mcpherson,2 Maryam 
Afkarian,3 Ian H. De Boer,3 Rajnish Mehrotra,3 Rick L. Meek,3 Katherine R. 
Tuttle.1,3  1Providence Health Care, Spokane, WA; 2Washington State Univ, 
Spokane, WA; 3Univ of Washington, Seattle, WA.
Background: Serum amyloid A (SAA) activates inflammation and apoptosis in kidney 
cells. SAA is also increased in the blood, urine, and kidneys of mice and people with DKD. 
The objective of this study was to determine if SAA adds to risk prediction models for 
death and end-stage renal disease (ESRD) in DKD.
Methods: Serum SAA was measured in a longitudinal cohort with type 2 diabetes 
and prevalent DKD, defined by urine protein-to-creatinine ratio >0.5 g/g (n=135). Cox-
proportional hazard models tested whether SAA was associated with a composite primary 
outcome of death and ESRD, adjusting for age, sex, race, hemoglobin A1c, diabetes 
duration, body mass index, renin-angiotensin system inhibitor use, systolic and diastolic 
blood pressure, albuminuria and estimated glomerular filtration rate (eGFR). Improvement 
in risk prediction was assessed by receiver-operating curves (ROC), goodness-of-fit, and 
Akaike’s Information Criterion (AIC).
Results: Participants were 73% Mexican-American (99/135) with mean (SD) age of 
57 (7.4) years, 55% male (75/135), mean eGFR 56 (22) ml/min/1.73m2, and median (IQR) 
urine albumin-to-creatinine of 1.9 (0.7-3.9) g/g. The incident rate for the primary outcome 
was 44 % (60/135). Risk of the composite primary outcome was higher in the 3rd tertile 
of SAA (>1.0 ug/ml) compared to the 1st tertile (<0.55 ug/ml): adjusted HR=3.7, 95 % CI 
1.7–8.3, p<0.001. The risk of death was markedly increased in the 3rd versus 1st tertile of 
SAA: adjusted HR 8.2, 95% CI 2.7-24.2, p<0.001. The C-statistic, generated from ROC 
curves, improved predictive ability of the model for the primary outcome (0.71 and 0.74, 
without versus with SAA). Goodness-of-fit and AIC also improved with inclusion of SAA.
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Conclusions: In DKD, higher serumSAA concentration is associated with increased 
risk of death and ESRD. SAA improves risk prediction when added to traditional risk 
factors. SAA is a candidate biomarker that may advance DKD risk assessment and is a 
potential therapeutic target.
Funding: Private Foundation Support
TH-OR006
Biomarkers of Early Decline in Renal Function: A Translational Study 
in Type 2 Diabetes  Jennifer W. Xu,1 Carla Cavallin,1 Sona Haku,1,2 Michael 
S. Simonson.1  1Nephrology and Hypertension, Univ Hospitals Case Medical 
Center and CWRU School of Medicine, Cleveland, OH; 2Dept of Medical 
Science and Cardiorenal Medicine, Yokohama City Univ Graduate School of 
Medicine, Yokohama, Japan.
Background: Kidney disease in type 2 diabetes (DKD) is the leading cause of end-stage 
renal disease.  Early detection and treatment of DKD can prevent or slow progression to 
end-stage disease, but identifying early decline in renal function can be problematic because 
albuminuria is insensitive. In a Phase I preclinical exploratory study we measured the 
performance of candidate biomarkers from mouse models of early renal function decline.
Methods: Patients with type 2 diabetes (median baseline eGFR = 80.3 + 29.5 ml/
min/1.73m2) were recruited into training (n=56) and independent, non-overlapping test 
(n=37) groups.  Biomarkers were measured in spot urine collections by ELISA, and 
performance was assessed as area under the receiver operating characteristic curve (AUC) 
with adjustment for clinical covariates of DKD.
Results: For classifying participants with baseline early renal function decline (eGFR 90 
– 60) vs normal function (i.e., >90), the highest performing biomarkers were: transforming 
growth factor b (TGFb, AUC + SD, 0.827 + 0.070), interleukin-6 (IL-6, 0.815 + 0.065) 
and endothelin-1 (ET-1, 0.720 + 0.082; all P < 0.01 compared to ACR, 0.465 + 0.093 and 
angiotensinogen 0.465 ± 0.090). Performance was validated in the independent test group. 
AUCs were unchanged after multivariate adjustment for age, sex, race, duration of diabetes, 
HbA1c, hypertension, cardiovascular disease, body mass index, and use of angiotensin 
converting enzyme inhibitors or receptor blockers.  In participants with eGFR 90 – 60 at 
baseline, TGFb, IL-6 and ET-1 predicted a composite renal outcome at 5 years (eGFR < 
60 OR ESRD) better than ACR (0.769 ± 0.105, 0.690 ± 0.128, and 0.793 ± 0.091,  all P < 
0.05 versus ACR, 0.520 ±0.119).
Conclusions: Urine levels of TGFb, IL-6 or ET-1 may identify patients with early 
renal function decline and aid development of novel therapeutics.
Funding: Other NIH Support - R01DK096549
TH-OR007
Primary Prevention of Albuminuria Using Renin-Angiotensin-System 
Inhibitors in Patients with Type 2 Diabetes: A Systematic Review 
and Meta-Analysis  Frederik I. Persson,1 Bianca Hemmingsen,2 Morten 
Lindhardt,1 Peter Rossing,1,3,4, Hans-Henrik Parving.3,5  1Steno Diabetes Center, 
Gentofte, Denmark; 2Copenhangen Trial Unit, Copenhagen Univ Hospital, 
Copenhagen, Denmark; 3HEALTH, Univ of Aarhus, Aarhus, Denmark; 4Novo 
Nordisk Foundation for Basic and Metabolic Research, Univ of Copenhagen, 
Copenhagen, Denmark; 5Dept of Medical Endocrinology, Rigshospitalet, 
Copenhagen Univ Hospital, Copenhagen, Denmark.
Background: Early prevention of diabetic nephropathy by way of blocking the renin 
angiotensin system (RAS) in patients with normoalbuminuria seems rational, but trials have 
so far shown conflicting results. The present meta-analysis was undertaken to investigate if 
such treatment can prevent development of microalbuminuria and also to assess whether 
available trials can provide sufficient information for such conclusions.
Methods: We searched MEDLINE, EMBASE and the Cochrane Library for double-
masked randomised controlled trials, with a population of patients with type 2 diabetes 
and normoalbuminuria, comparing angiotensin enzyme inhibitors (ACEi) or angiotensin 
receptor blockers (ARB) to placebo. At least one year of follow-up was considered 
reasonable for the development of micro- or macroalbuminuria, and studies had to have 
at least 50 participants in each arm. Random and fixed effect models were performed as 
well as trial sequential analysis.
Results: Six trials were identified and included in the analysis (n=16921). Overall risk 
of bias was low. In a fixed model analysis ACE or ARB treatment was superior to placebo 
in relation to development of microalbuminuria, relative risk 0.84 (95% CI 0.79, 0.88) 
p<0.001, I2 23%, risk difference -0.04 (-0.05, -0.03), p= 0.001. Similar results were seen 
with the random model approach. Trial sequential analysis revealed a Z-value of 6.53 and 
an information size of 4163 patients (O’Brien twosided 5% boundaries).
Conclusions: Sufficient trial data are available for the meta-analysis to conclude that 
in patients with type 2 diabetes and normoalbuminuria, ACEinhibitors or ARBs reduces 
the risk for development of microalbuminuria.
TH-OR008
The Impact of Pre-ESRD Glycemic Status on Early Post-ESRD Mortality 
Among U.S. Veterans: A Transition of Care in CKD Study  Connie Rhee,1 
Elani Streja,1 Melissa Soohoo,1 Jennie Jing,1 Danh V. Nguyen,1 Steven M. 
Brunelli,2 Gregory Brent,3 Csaba P. Kovesdy,4 Kamyar Kalantar-Zadeh.1  1UC 
Irvine; 2DaVita Clinical Research; 3UCLA; 4UTHSC.
Background: In the general population randomized controlled trials show no benefit 
and possible harm with intensive glycemic targets in diabetics. Non-dialysis dependent 
(NDD) CKD and ESRD patients experience both hypo- and hyperglycemia through 
multifactorial pathways, and studies of glycemic status and mortality in dialysis patients 
have shown mixed findings. Little is known about the net effect of kidney dysfunction on 
glucose homeostasis in NDD-CKD patients transitioning to dialysis, and how pre-ESRD 
glycemic status impacts early post-ESRD mortality.
Methods: We first examined the longitudinal trajectory of glycemic status defined 
by HbA1c during the 5-year pre-ESRD prelude period among veterans with NDD-CKD 
transitioning to dialysis from 10/2007-9/2011. In a subcohort of patients with at least one 
HbA1c measure during the 6 month prelude period, we then examined HbA1c levels 
averaged over 6 months as a continuous predictor of all-cause mortality using restricted cubic 
spline analysis. Associations with mortality in the first 3 months of ESRD were estimated 
using Cox models adjusted for age, sex, race, ethnicity, ESRD cause, and geographic region.
Results: Among 24,129 veterans transitioning to dialysis, there was a decline in mean 
HbA1c over the 5 year prelude period. Among 13,720 patients with at least one HbA1c 
in the 6 month prelude period, higher HbA1c was monotonically associated with a higher 
risk of post-ESRD death.
Conclusions: In veterans transitioning to dialysis there is a steady decline in HbA1c 
as they approach ESRD. Higher HbA1c levels in the pre-ESRD period are associated with 
higher early post-ESRD mortality. Further studies are needed to determine if glycemic-
lowering strategies in the pre-ESRD period improves post-ESRD outcomes.
Funding: NIDDK Support, Veterans Administration Support
TH-OR009
Glycemic Markers and 2-Year Diabetic Hemodialysis Outcomes from the 
Glycemic Indices in Dialysis Evaluation Study  Mark E. Williams,1 Neal 
Mittman,2 Lin Ma,3 Julia I. Brennan,4 Chinu M. Jani,4 Curtis D. Johnson,4 
Franklin W. Maddux,3 Eduardo K. Lacson.3,5  1Joslin Diabetes Center, Boston, 
MA; 2Kidney Care of Brooklyn and Queens, Brooklyn, NY; 3Fresenius Medical 
Care North America, Waltham, MA; 4Spectra Laboratories, Rockleigh, NJ; 
5Physician, Lexington, MA.
Background: Initial results from the GIDE (Glycemic Indices in Dialysis Evaluation) 
Study have added to concerns about sole reliance on hemoglobin (Hgb) A1c in patients with 
diabetes on hemodialysis (HD). We reported correlations of HgbA1c with nontraditional 
glycemic markers [albumin-adjusted and unadjusted fructosamine (AlbF; F) and glycated 
albumin (GA) or percent GA (%GA)]. One-year results indicated a potential association 
only with high AlbF and outcomes. We report here two-year outcomes.
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Methods: 1,424 active HD patients with DM from 26 FMCNA facilities with glycemic 
markers from Jan-March 2013 were followed until April, 2015. Poor glycemic control was 
based on: HgbA1c >7% (sensitivity analysis>8%), AlbF ≥ 974 µmol/g, F > 285µmol/L, 
%GA >15.7%, and GA> 300 µmol/L. Standard and Time-dependent (TD) Cox models with 
adjustment for age, sex, race, ethnicity, vintage, BMI, HD catheter, and baseline comorbid 
illnesses were utilized to determine associations between each dichotomized glycemic index 
and hospitalization/death outcomes.
Results: Poor glycemic control was found in 28% according to HgbA1c>7% (13% 
for HgbA1c>8%), but 35% by AlbF, 87% by F, 81% by %GA, and 68% by GA. Elevated 
AlbF was significantly associated with 2-year hospitalization [Standard Cox: Hazard 
Ratio (HR)=1.66, 95% CI (1.28,2.15), p=0.0001; TD Cox: HR=1.83, 95% CI (1.37,2.44), 
p<0.0001] and mortality [Standard Cox: HR=1.53, 95% CI (1.21,1.93), p=0.0004; TD 
Cox: HR=1.65, 95% CI (1.28,2.13), p=0.0001]. For all other glycemic indices, there were 
no such associations, at the proposed thresholds for glycemic control.
Conclusions: A strong association between poor glycemic control, determined by 
elevated AlbF, and worse 2-year hospitalization and mortality risks has emerged from the 
GIDE study data. Future analyses will include longer follow-up, use of continuous values 
for glycemic indices, and cardiovascular mortality outcomes.
TH-OR010
Renal Biopsy for Diabetic Nephropathy Is Useful for the Prediction of 
Cardiovascular Events – 10-Year Follow Up  Katsuhiko Morimoto, Ken-ichi 
Samejima, Masaru Matsui, Yasuhiro Akai, Miho Tagawa, Yoshihiko Saito.  First 
Dept of Internal Medicine, Nara Medical Univ, Kashihara, Japan.
Background: Diabetic nephropathy has a higher risk of cardiovascular (CV) events and 
end-stage renal disease (ESRD). However, the association between renal histopathology, 
especially vascular lesion, and CV risk in diabetic nephropathy remains to be elucidated. We 
investigated the relationship between the glomerular or vascular lesions of renal specimen 
and CV events or ESRD in the patients with biopsy-proven diabetic nephropathy.
Methods: Three hundred ninety patients with biopsy-proven diabetic nephropathy 
with type 2 diabetes were enrolled in this retrospective study. According to the Renal 
Pathological Society (RPS) classification, the glomerular lesions were divided into three 
groups as IIa, IIb, and III – IV and vascular lesions were classified into 2 groups according 
to the absence or presence of vascular involvement.
Results: The background features were as follows: mean age of 57.7 ± 11.3 years 
old, the average observation period of 9.3 ± 8.0 years. During the observation period 164 
patients had outcome of CV events and 71 patients reached ESRD. In Kaplan-Meier survival 
analysis, significant difference among different glomerular lesion class and vascular class 
was observed in terms of CV events and ESRD, respectively.
In Cox proportional hazard analysis, presence of vascular lesion in the renal tissue 
was an independent risk factor for the development of CV events (HR 2.12 [1.27 to 3.70]) 
and glomerular lesion was NOT associated with CV events. Glomerular lesions in the 
renal tissue was an independent risk factor for the development of ESRD (IIb vs. IIa, HR 
6.44 [2.39 to 20.7]; III – IV vs. IIa, HR 12.1 [4.46 to 39.2]) and vascular lesion was NOT 
associated with renal outcome.
Conclusions: Vascular lesion of renal tissue had predictive value for the development 
of CV events.
TH-OR011
Racial Differences in Hospitalization Rates Among U.S. Veterans with 
and without Chronic Kidney Disease  Jennifer L. Bragg-Gresham,1 Hal 
Morgenstern,1 Neil R. Powe,2 Deidra C. Crews,3 Nilka Rios Burrows,4 Sharon 
Saydah,4 Kara Zivin,1 Rajiv Saran.1  1KECC & SPH, Univ of Michigan, Ann 
Arbor, MI; 2Univ of California, San Francisco, CA; 3Johns Hopkins Univ, 
Baltimore, MD; 4Centers for Disease Control and Prevention, Atlanta, GA.
Background: To elucidate potential racial disparities, we examined hospitalization 
rates for black and white veterans with and without CKD, utilizing the Veterans Affairs 
Health System.
Methods: This cohort study included 2.6 million black and white veterans who 
attended ³1 outpatient visit, had a serum creatinine value during the baseline period 
(10/1/09-9/31/10), and had no indication of ESRD on 9/31/10. Cox regression was used 
to estimate the combined effects of race and CKD status on first hospitalization during 
the next 2 years, adjusting for age, gender, comorbidities, and prior hospitalization during 
the baseline period. CKD was defined by clinical diagnosis or eGFR <60 ml/min/1.73m2.
Results: Black patients were younger with a higher prevalence of diabetes, but lower 
prevalence other comorbidities, including hypertension. Although the overall prevalence 
of CKD at baseline was higher in whites (21.0% vs. 15.8%), the prevalence of a clinical 
diagnosis was higher in blacks (11.8% vs. 9.4%). The rate of first hospitalization was greater 
for blacks in both persons with and without CKD (HR=1.30, 95% CI: 1.29-1.31 & HR=1.16, 
95% CI: 1.15-1.17, respectively). The 2-year risk of hospitalization was greatest (27.9%) in 
black patients with CKD, compared with the other groups (figure; p for interaction <0.001).
Conclusions: In an integrated health-care system with presumably less disparity in 
access to care between racial groups, the 2-year risk of hospitalization was greater for 
blacks than for whites, especially among patients with CKD. Further research is warranted 
to better understand these differences.
Funding: Other U.S. Government Support
TH-OR012
Optimal Endpoint Definition for Transition in Albuminuria Stage in 
Clinical Trials  Tobias Felix Kröpelin,1 Dick de Zeeuw,1 Rudolf W. Bilous,2 
Giuseppe Remuzzi,3 Hans-Henrik Parving,4 Hiddo Jan Lambers Heerspink.1 
1Clinical Pharmacy and Pharmacology, UMCG, Groningen; 2Newcastle Univ, 
United Kingdom; 3IRCCS Mario Negri Inst for Pharmacological Research, 
Ospedale Papa Giovanni XXIII, Bergamo, Italy; 4Medical Endocrinology, Univ 
of Copenhagen, Denmark.
Background: Albuminuria transition (normo- to micro- to macroalbuminuria) is used 
as an endpoint in clinical trials that assess renoprotective drug efficacy. Current definitions 
vary between trials in: number of urine collections, requirement of a confirmation visit, 
if yes at what time, and the requirement of an additional percentage albuminuria change 
when transitions occur. We assessed the impact of these variations.
Methods: We used 3 clinical trials that tested the effect of RAS intervention on 
albuminuria class transition in diabetic patients (BENEDICT, DIRECT, IRMA 2). We 
assessed the drug effect per trial using varying transition definitions: 1) class transition 
based on either 1, 2, or 3 consecutively collected urine samples prior to each study visit, 2) 
based on a single urine sample confirmed by a next visit (within 2 - 8 weeks, next planned 
visit), 3) class transition and 10 - 40% increase in albuminuria.
Results: Neither increasing the number of urines collected at a visit, nor the inclusion of 
a confirmation visit, nor the time to the confirmation visit, nor the addition of a percentage 
albuminuria change altered the average drug effect or standard error. 
Single visit Single urine +
One urine Two urines Three urines confirmation visit
HR (SE) 
[95% CI]
HR (SE) 
[95% CI]
HR (SE) 
[95% CI]
HR (SE) 
[95% CI]
BENEDICT 0.75 (0.21)[0.50 - 1.12]
0.73 (0.22)
[0.48 - 1.12]
0.66 (0.23)
[0.42 - 1.04]
0.68 (0.34)
[0.35 - 1.32]
DIRECT 0.95 (0.06)[0.84 - 1.07]
0.96 (0.07)
[0.84 - 1.10]
0.95 (0.14)
[0.73 - 1.24]
IRMA 2 0.55 (0.20)[0.37 - 0.82]
0.64 (0.38)
[0.30 - 1.35]
Conclusions: Our results suggest that the optimal transition endpoint for a clinical 
trial measuring a drug effect can use a single urine collection per study visit. It needs to be 
tested whether more frequent study visits with albuminuria measurement would improve 
precision of the drug effect, as suggested in our previous work on quantitative albuminuria 
change (Kropelin 2014).
TH-OR013
CKD and Risk for Gastrointestinal Bleeding: The Atherosclerosis Risk in 
Communities (ARIC) Study  Junichi Ishigami, Morgan Grams, Rakhi Naik, 
Josef Coresh, Kunihiro Matsushita.  Johns Hopkins Univ.
Background: Patients on dialysis have increased risk for gastrointestinal (GI) bleeding. 
However, GI bleeding risk across the full spectrum of CKD has not been comprehensively 
investigated.
Methods: We studied 11,143 participants in the ARIC Study, a bi-ethic community-
based cohort. Baseline CKD measures (eGFR and ACR) were assessed at visit 4 (1996-
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1998), and follow-up was continued through 2011. The primary outcome was hospitalization 
with relevant ICD codes of upper- or lower-GI bleeding. Cox regression models were used 
to estimate incident rate and hazard ratios of GI bleeding, respectively.
Results: A total of 693 hospitalizations related to GI bleeding was observed during a 
median follow-up of 13.9 years (incident rate 4.9 per 1,000 person-years). After adjusting 
for potential confounders, both lower eGFR and higher ACR were independently associated 
with increased risk of GI bleeding (Table). Compared to eGFR ≥90 ml/min/1.73m2, the 
association was particularly strong in eGFR <30 ml/min/1.73m2 (HR 8.37 [5.04-13.88] 
in Model 2), but eGFR between 30-60 also reached significance (HR 1.55 [1.16-2.06]). 
Compared to ACR <10 mg/g, both microalbuminuria (30-299 mg/g) and macroalbuminuria 
(³300 mg/g) were associated with 2-2.5 greater hazard of GI bleeding (HR 2.14 [1.69-2.72] 
and 2.40 [1.59-3.62], respectively, in Model 2). Of note, high-normal albuminuria (10-29 
mg/g) was also significantly associated with GI bleeding (HR 1.36 [1.09-1.70]). These 
results were largely consistent even after adjusting for each of kidney measures (Model 3) 
or accounting for cardiovascular events and incident dialysis during follow-up.
Conclusions: Both low eGFR (<60 but especially <30 ml/min/1.73m2) and high 
ACR (particularly ³30 but also ³10 mg/g), were associated with incidence of GI bleeding, 
warranting clinical attention for GI bleeding risk among persons with even mild to 
moderate CKD. 
Funding: Other NIH Support - NHLBI
TH-OR014
Association of Body Mass Index with Clinical Outcomes in Non Dialysis 
Dependent Chronic Kidney Disease: A Systematic Review and Meta-
Analysis  Seyed-foad Ahmadi,1 Golara Zahmatkesh,1 Emad Ahmadi,1 Elani 
Streja,5 Connie Rhee,1 Luca De Nicola,3 Roberto Minutolo,3 Ana C. Ricardo,4 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2UTHSC; 3Second 
Univ Napoli, Italy; 4Univ Illinois, Chicago; 5Harvard.
Background: Previous studies have not shown a consistent link between body mass 
index (BMI) and outcomes such as mortality and kidney disease progression in non-dialysis 
dependent (NDD) CKD patients. We therefore aimed to complete a systematic review and 
meta-analysis on this subject.
Methods: We searched MEDLINE, EMBASE, Web of Science, CINAHL, and 
Cochrane CENTRAL, and screened 7,123 retrieved studies for inclusion. Two investigators 
independently selected studies using predefined criteria and assessed each study’s quality 
using the Newcastle-Ottawa Quality Assessment Scale. We meta-analyzed the results based 
on BMI classification by WHO.
Results: Ten studies with a total sample size of 484,906 were included in the systematic 
review presenting generally heterogeneous results. Through re-analysis of the largest 
reported study and quantitative data synthesis, we observed that in Stages 3–5 CKD, 
being underweight was associated with higher death risk while being overweight or obese 
class I was associated with lower death risk; however, obesity classes II or III were not 
associated with death risk. In addition, re-analysis of the largest available study showed that 
higher BMI was associated with incrementally higher risk of kidney disease progression; 
however, this association was attenuated in our pooled results. For earlier stages of CKD, 
we could not complete meta-analyses as the studies were sparse and had heterogeneous 
BMI classifications and/or referent BMI groups. 
Conclusions: Patients with stage 3–5 CKD have a differential association between 
obesity classes I–III and mortality compared with the general population, indicating an 
obesity paradox in the CKD population.
Funding: NIDDK Support
TH-OR015
Risk Factors for Cognitive Impairment in Chronic Kidney Disease – The 
Brain in Kidney Disease Study  Anne M. Murray,1,6 Elizabeth J. Bell,1 David 
S. Knopman,2 Yelena Slinin,3,4 Robert N. Foley,3 David Tupper.5  1Minneapolis 
Medical Research Foundation; 2Dept of Neurology, Mayo Clinic; 3Nephrology 
Div, U of Minnesota; 4VA Medical Center; 5Neuropsychology Section, Hennepin 
County Medical Center (HCMC); 6Geriatrics Div, HCMC.
Background: Cognitive impairment (CI) in patients with chronic kidney disease 
(CKD) poses a substantial public health burden. The extent that factors beyond estimated 
glomerular filtration rate (eGFR) contribute to the increased risk of CI in CKD has not 
been adequately measured.
Methods: We used cross-sectional data from the baseline exam (2011-2015) of the 
BRain IN Kidney disease study. Level of CI was determined using an algorithm based on 
neuropsychological tests that incorporates the DSM-IV dementia criteria. We assessed the 
relation between baseline characteristics and moderate to severe CI (yes/no) using logistic 
regression, controlling for potential confounding variables: age, gender, race, education, 
diabetes, hypertension, smoking status, cholesterol, BMI, and eGFR.
Results: The CKD cohort includes 422 community-dwelling participants (mean 
age=70, mean eGFR=34) with eGFR <60 mL/min/1.73 m2 but not on dialysis. Of these, 
149 had CI at baseline. Prior stroke, phosphorus ≥4.5 mg/dL and African American race 
were associated with a higher risk of CI. EGFR, markers of inflammation (TNFα and IL-6) 
and microalbuminuria (UACR), cholesterol and hemoglobin were not associated with CI.
Conclusions: We identified elevated phosphorus, prior stroke and African American 
race as potential risk factors for CI in community-dwelling CKD patients. Phosphorus is 
a potentially modifiable risk factor. Longitudinal analyses are needed to confirm these 
findings and identify potential preventive interventions against CI. 
Adjusted odds ratios for CI
Characteristics Unit change Odd ratios (95% confidence intervals)
EGFR ‒10 ml/min/1.73 m2 1.19 (0.99-1.44)
Prior stroke Yes vs no 1.89 (1.09-3.27)
UACR 100 mg/g 1.01 (0.99-1.03)
TNFα 3 pg/mL 1.02 (0.87-1.20)
IL-6 6 pg/mL 1.17 (0.94-1.44)
Phosphorus ≥4.5 mg/dL vs <4.5 2.42 (1.15-5.10)
Cholesterol ‒45 mg/dL 1.26 (0.99-1.61)
Hemoglobin <10.5 g/dL vs ≥10.5 1.56 (0.64-3.82)
African American Yes vs no 4.86 (2.44-9.64)
Funding: Other NIH Support - National Institute on Aging, Pharmaceutical Company 
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TH-OR016
Increased Risk of Incident Chronic Kidney Disease, Cardiovascular 
Disease and Mortality in Diabetic Patients with Comorbid Depression 
Miklos Zsolt Molnar,2 Marta Novak,1 Istvan Mucsi,1 Jun Ling Lu,2 Kamyar 
Kalantar-Zadeh,3 Csaba P. Kovesdy.2,4  1Univ Health Network, Univ of Toronto, 
Toronto, ON, Canada; 2Univ of Tenessee Health Sciences Center, Memphis, TN; 
3Univ of California, Irvine, CA; 4Veterans Affairs Medical Center, Memphis, TN.
Background: Depressed patients with diabetes have worse diabetes self-care and worse 
clinical outcomes. Here we aimed to determine the association of depression and the risk 
of incident CKD, cardio-vascular (CV) outcomes and all-cause mortality in a population 
of US veterans with diabetes mellitus (DM).
Methods: From a nationally representative prospective cohort of over 3 million US 
veterans with baseline estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2, we 
identified 933,211 diabetic patients. The associations between depression and outcomes 1): 
incident CKD; 2): incident coronary heart disease [CHD]; 3): incident ischemic stroke; 4): 
all-cause mortality were assessed using the Kaplan-Meier method, and Cox proportional 
hazard models.
Results: Mean age was 64±11 years, 97% were male and 18% African-American. 
Depression was present in 340,806 patients at enrollment. Depressed patients were 
somewhat younger (61±11 versus 65±11 years), had slightly higher eGFR (84±15 versus 
81±14 ml/min/1.73m2) but had somewhat more comorbidities at baseline. During a median 
follow-up of 7.3 years, 180,343 patients (19%) developed CKD. The presence of depression 
at enrollment was associated with 20% higher risk of incident CKD (adjusted hazard ratio 
[aHR] and 95% confidence interval [CI]: 1.20 (1.19-1.21)). Similarly, depression was 
associated with 35% higher risk of incident stroke (aHR and 95% CI: 1.35 (1.32-1.39), 
24% higher risk of incident CHD (aHR and 95% CI: 1.24 (1.22-1.27) and 25% higher risk 
of all cause mortality (aHR and 95% CI: 1.25 (1.24-1.26) during the follow-up.
Conclusions: Comorbid depression is associated with increased risk of developing 
CKD in diabetic patients. Similarly, the presence of depression is associated with worse CV 
outcomes. Appropriate intervention studies are needed to determine if treating depression 
in patients with diabetes would prevent CKD and CV disease.
Funding: Veterans Administration Support
TH-OR017
Cardiorespiratory Fitness and Neurocognitive Function in Older Adults 
with Chronic Kidney Disease  Daniel E. Weiner,3 Lindsay J. Lajoie,1,2 Eamon F. 
Fleming,3 Dylan R. Kirn,2 Shari R. Waldstein,4 Jason Kisser,4 Kieran Reid,2 Roger 
A. Fielding,2 Stephen L. Seliger.5  1Friedman School of Nutrition, Tufts Univ; 
2Human Nutrition Research Center on Aging, Tufts Univ; 3Tufts Medical Center; 
4Univ of Maryland Baltimore County; 5Univ of Maryland School of Medicine.
Background: Chronic kidney disease (CKD) is associated with an increased risk 
for neurocognitive impairment in older adults, while greater cardiorespiratory fitness 
(CRF) is associated with better neurocognitive function among healthy older adults. This 
relationship has not been adequately explored in patients with CKD. This study examines 
whether CRF, as measured by VO2peak, is associated with neurocognitive function in older 
adults with CKD stage 3b-4.
Methods: Baseline data from a multi-center randomized controlled trial of exercise 
training was used. The Mini-Mental State Exam (MMSE), Digit Symbol Substitution Test 
(DSST), Montreal Cognitive Assessment (MoCA), Trail Making Test Part A (TMT-Part 
A), and Trail Making Test Part B (TMT-Part B) were utilized to quantify neurocognitive 
function. The association between VO2peak and neurocognitive function was assessed using 
multiple linear regression, adjusted for age, sex, and education level.
Results: Among 71 participants, with mean age 68.4±7.74 years and mean 
eGFR=33.2±10.6 ml/min/1.73m2, higher VO2peak was associated with better performance 
on the MMSE (β=0.08, p=0.04), and DSST (β=0.75, p=0.03). While not statistically 
significant, directionality was similar for other cognitive tests, including the MoCA (β=0.12, 
p=0.20), TMT-Part A (β=-0.47, p=0.30) and TMT-Part B (β=-1.39, p=0.38).
Conclusions: Better cardiorespiratory fitness, as assessed by VO2peak, is associated 
with better performance on several neurocognitive tests in older adults with advanced 
CKD. Further research is needed to better understand the underlying mechanisms of this 
relationship and whether improved fitness can modify cognitive performance.
Funding: NIDDK Support
TH-OR018
Low Birth Weight and Risk of Progression to End Stage Renal Disease 
in IgA Nephropathy  Paschal Joseph Ruggajo,1,2 Einar Svarstad,2 Sabine 
Leh,3 Hans-Peter Marti,2 Anna Reisaeter,4 Bjorn Egil Vikse.2  1Dept of Internal 
Medicine, MUHAS, Dar es Salaam, Tanzania, United Republic of; 2Dept of 
Clinical Medicine, Univ of Bergen, Bergen, Norway; 3Dept of Pathology, 
Haukeland Univ Hospital, Bergen, Norway; 4Dept of Transplantation Medicine, 
Rikshospitalet, Oslo Univ Hospital, Oslo, Norway.
Background: Low Birth Weight (LBW) is a surrogate for fetal undernutrition and is 
associated with impaired nephron development in utero. Low birth weight is associated 
with fewer and larger glomeruli and increased risk of hypertension and renal disease in later 
life. In this study, we investigate whether low birth weight (LBW) and low birth weight for 
gestational age (LBW-GA) predict progression to ESRD in IgAN patients.
Methods: The Medical Birth Registry has recorded medical data for all births in Norway 
since 1967 and the Norwegian Renal Registry has recorded all patients With ESRD since 
1980. From the Norwegian Kidney Biopsy Registry we retrieved all patients who had been 
diagnosed with IgAN from 1988-2013. These registries were linked and we analysed risk 
of progression to ESRD associated with LBW (defined as less than the 10th percentile of 
gender-specific birth weight) and/or LBW-GA (defined as less than the 10th percentile of 
birth weight for gestational age) by regression statistics.
Results: We included 471 patients, of whom 74 (15.7%) developed ESRD. As 
compared to patients without LBW, patients with LBW had a hazard ratio (HR) of 2.0 
(95% confidence interval 1.0-3.7) for the total cohort, HR 2.2 (1.1-4.4) for males and HR 
1.3 (0.30-5.8) for females. Corresponding HRs for LBW-GA were 2.2 (1.1-4.2), 2.7 (1.4-
5.5) and 0.8 (0.10-5.9). After adjustments for eGFR at time of diagnosis, the association 
was lost. Further analyses showed that as compared to patients who were neither LBW nor 
LBW-GA, patients who were LBW-GA but not LBW had a HR of 1.3 (0.39-4.0), patients 
who were LBW but not LBW-GA had a HR of 1.4 (0.51-3.9) and patients who were both 
LBW and LBW-GA had a HR of 3.2 (1.5-6.8).
Conclusions: Among IgAN patients, having had low birth weight or low birth weight 
for gestational age predicted progression to ESRD. The association was only significant 
in male patients.
TH-OR019
Risks of End-Stage Renal Disease (ESRD) in the United States 
Patrick J. Albertus,1 Hal Morgenstern,1 Bruce M. Robinson,1,2 Rajiv Saran.1 
1Univ of Michigan; 2Arbor Research Collaborative for Health.
Background: Although incidence rates of ESRD are reported routinely by the USRDS, 
these are not directly relevant for individuals or providers. The objective of this study was 
to utilize incidence rate information to estimate the short- and long-term risk of ESRD by 
age, sex and race/ethnicity.
Methods: Using data from 2000 and 2013, risks/cumulative incidences were estimated 
using DevCan software developed principally to estimate risk of cancer diagnosis. This 
method uses a competing-risk framework by constructing a hypothetical cohort followed 
from birth to death. Incidence and mortality rates of ESRD were obtained from the USRDS 
and all-cause mortality rates from CDC-Wonder.
Results: Among males, the lifetime risk of ESRD from birth using 2013 data was 3.08% 
for non-Hispanic (NH) whites, 8.06% for NH blacks, 3.80% for NH Native Americans, 
5.05% for NH Asians/Pacific Islanders, and 6.23% for Hispanics. Among females, the 
lifetime risks were 2.03% for NH whites, 6.80% for NH blacks, 3.63% for NH Native 
Americans, 3.78% for NH Asian/Pacific Islanders, and 4.34% for Hispanics. The 10-year 
risk was highest at age 70 at 1.52% for males and 1.03% for females. Comparing risk 
estimates based on 2013 data to 2000 data, the lifetime risk of ESRD from birth increased 
from 3.53% to 3.96% in males and decreased from 2.96% to 2.85% in females, but these 
changes were not uniform across racial/ethnic groups. 
Conclusions: The risk of ESRD in the U.S. varies substantially among racial/ethnic 
groups for both sexes. Lifetime risks increased a little during the previous decade in males, 
but decreased slightly in females. The statistical approach used in this study could be applied 
routinely to USRDS data to estimate the probability of individuals being diagnosed with 
ESRD. To be most useful in clinical practice, this application will require additional data 
elements (e.g., comorbidities, CKD stage).
Funding: NIDDK Support
TH-OR020
The Relevance of Systolic Blood Pressure to Renal Progression: 
Observations from the Study of Heart and Renal Protection (SHARP) 
Natalie Staplin, William G. Herrington.  On behalf of the SHARP Collaborative 
Group. CTSU, Univ of Oxford.
Background: Meta-analysis of intensive versus standard blood pressure (BP) lowering 
trials has demonstrated that lower BP reduces the risk of end-stage renal disease (ESRD), but 
there is uncertainty about optimal BP targets in chronic kidney disease (CKD), particularly 
in those without albuminuria.
Methods: Systolic blood pressure (SBP), creatinine and renal outcomes were assessed 
6 monthly for 5 years among 6245 SHARP participants not on dialysis at baseline of whom 
2137 (33%) developed ESRD. Regression models adjusted for confounders assessed the 
relevance of usual SBP to ESRD and to annual rate of change in CKD-EPI eGFR. High 
BP may cause or be caused by albuminuric CKD, so analyses were performed with and 
without adjustment for albuminuria.
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Results: Each 20 mmHg higher usual SBP was associated with an average increase 
of 71% in the risk of ESRD (adjusted hazard ratio [HR] 1.71, 95% CI 1.50-1.95). The 
risk of ESRD was substantially attenuated, but remained statistically significant, after 
adjustment for albuminuria (HR 1.18, 1.02-1.35). Among those with at least 3 creatinine 
measurements, each 20 mmHg higher usual SBP was associated with a 1.3 (95% CI 1.0-
1.6) mL/min/1.73m2/year greater mean decline in eGFR, which reduced to 0.7 (0.4-1.0) 
after adjustment for albuminuria. Mean rate of reduction in eGFR was similar irrespective 
of baseline albuminuria (macroalbuminuria 0.7 [0.1-1.3]; microalbuminuria 0.6 [0.2-1.0]; 
normoalbuminuria 0.6 [0.1-1.1]). 
Conclusions: In CKD, the true relevance of SBP to renal progression is difficult 
to quantify precisely as the relative risks are substantially attenuated by adjustment for 
albuminuria (which may not be appropriate if this is on the causal pathway). Nevertheless, 
after such adjustment, higher SBP is significantly associated with renal progression 
irrespective of the presence or absence of albuminuria.
Funding: Pharmaceutical Company Support - Merck/Schering-Plough Pharmaceut-
icals (North Wales, PA, USA), Government Support - Non-U.S.
TH-OR021
The Significance of Urinary Podocalyxin Level and Urinary Podocyte 
Number in Lupus Nephritis: A Longitudinal Study  Keiju Hiromura,1 Hiroshi 
Kajiyama,2 Hidekazu Ikeuchi,1 Junya Suwa,1 Daisuke Ikuma,2 Toru Sakairi,1 
Yoriaki Kaneko,1 Akito Maeshima,1 Hiroyuki Kurosawa,3 Yoshiaki Hirayama,3 
Masanori Hara,4 Toshihide Mimura,2 Yoshihisa Nojima.1  1Dept of Medicine 
and Clinical Science, Gunma Univ, Japan; 2Dept of Rheumatology and Applied 
Immunology, Saitama Medical Univ, Japan; 3Denki Kagaku Kogyo K.K., Japan; 
4Dept of Pediatrics, Yoshida Hospital, Japan.
Background: Podocalyxin sheds in urine from injured podocytes. We have previously 
reported that urinary podocalyxin levels (U-PCX) and urinary podocytes numbers (U-POD) 
were highly elevated in active lupus nephritis (LN) before treatment (Arthritis Rheum, 2013, 
65:10 S377). In the current study, we examined the changes of U-PCX and U-POD levels 
after treatment and the impact of baseline U-PCX and U-POD on the response to treatment.
Methods: Patients with active LN (n=37), whose urinary protein levels (U-Prot) >1.0 
g/gCr and who required initiation or intensification of treatment, were examined. Early 
proteinuric remission was defined as U-Prot <0.3g/g/Cr at 3 months, which was observed 
in 15 patients.
Results: Although the significant improvement of U-Prot was observed at 1 month 
after treatment, U-PCX and U-POD decreased more gradually (Fig). A weakly positive 
correlation was found between U-PCX and U-POD (R=0.363, P=0.027), but not between 
U-Prot and U-PCX or U-POD. Multivariate logistic regression analysis showed that U-Prot 
³3g/gCr, U-PCX >600 mg/gCr and U-POD £1cell/mgCr) at baseline were risk factors for 
not achieving early proteinuric remission (OR32.4, 95%CI 2.8-373.2, P=0.005; OR 24.9, 
95%CI 1.3-455.2, P=0.030; OR 13.9, 1.2-161.2, P=0.036; respectively). The combination of 
U-Prot <3g/gCr and U-PCX <600mg/gCr at baseline predicted early proteinuric remission 
(sensitivity 80%, specificity 86%, PPV 80%, NPV 86%).
Conclusions: U-PCX and U-POD would be novel biomarkers of podocyte injury in LN.
Funding: Government Support - Non-U.S.
TH-OR022
Mycophenolate Mofetil, Azathioprine and Intravenous Cyclophosphamide 
Are Effective for Treatment of Pure Membranous Lupus Nephritis in 
Hispanic Population  Juan M. Mejia-Vilet, Ricardo Correa-Rotter.  Dept of 
Nephrology, National Science and Nutrition Inst Salvador Zubirán, Mexico 
City, Distrito Federal, Mexico.
Background: Membranous lupus nephritis (MLN) accounts for 10-20% of renal biopsy 
diagnosis in SLE patients. Its optimal treatment remains uncertain.
Methods: Treatment of 51 patients with biopsy proven MLN was retrospectively 
evaluated. Response to therapy and outcome were compared to those with proliferative 
(III or IV, n=38) and mixed-class LN (III+V / IV+V, n=112).
Results: Fifty one patients with MLN were distributed by induction drug in 3 groups: 
MMF (mean 2.6±0.4g/day), IV cyclophosphamide (5.4g/m2BSA accumulative dose), 
azathioprine (mean 2.1±0.6 mg/kg/d). Median follow-up was 44 months (IQR 15-94). At 
presentation, patients in IVC group had a trend to worse urinary protein to creatinine ratio 
(uPCR) and a longer time from symptoms to start of treatment. Complete remission rates 
at 6, 12 and 24 months were 23.1, 61.5 and 61.5% for MMF, 6.2, 14.8 and 26.9% for IVC 
and 27.3, 40.5 and 47.9 for AZA. MMF induction was superior to IVC on Kaplan-Meier 
analysis (HR 5.42, 95% CI 1.38-21.2, p=0.03), but after Cox multivariate analysis there 
was only a trend to a better complete remission with MMF (HR 3.65, 95% CI 0.94-14.2, 
p=0.061). There were no differences between groups in adverse effects and thrombotic 
events. Only two MLN patients developed ESRD on follow-up. When compared with an 
historical cohort, patients with proliferative (HR 8.83, 1.56-50.1, p=0.014) and mixed 
histological classes (HR 4.38, 1.89-10.2, p<0.001) were more likely to develop ESRD.
Conclusions: Mycophenolate mofetil, IVC and AZA are effective for induction 
treatment of MLN. At our center, there is a trend to treat severe nephrotic patients with IVC 
and less severe cases with MMF or AZA. MLN has a similar rate of response to treatment 
and better long-term outcome than proliferative and mixed classes.
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TH-OR023
Impact of Tabalumab on the Kidney in Lupus: Results from Two Phase 
3 Clinical Trials  Brad H. Rovin,1 Mary Anne Dooley,2 Jai Radhakrishnan,3 
Ellen M. Ginzler,4 Tammy Forrester,5 Pamela W. Anderson.5  1Ohio State Univ, 
Columbus, OH; 2Univ of North Carolina, Chapel Hill, NC; 3Columbia Univ, New 
York, NY; 4SUNY Downstate, Brooklyn, NY; 5Eli Lilly & Company, Indianapolis, 
IN; 6Eli Lilly & Company, Indianapolis, IN.
Background: Tabalumab (TAB) is a monoclonal antibody that neutralizes membrane 
and soluble B-cell activating factor. Two 52-week, randomized, double-blinded, placebo 
(PBO)-controlled Phase 3 trials evaluated the safety and efficacy of TAB for non-renal 
disease in lupus.
Methods: Patients with moderate-severe active lupus, but without severe active lupus 
nephritis (ie, urine protein/creatinine ratio [uPCR] of >200 mg/mmol or estimated creatinine 
clearance of <30 mL/min) were randomized 1:1:1 to TAB (120 mg subcutaneously [SC] 
every 4 weeks [Q4W] or 120 mg SC every 2 weeks [Q2W]) or PBO for 52 weeks. Serum 
creatinine (SCr), glomerular filtration rate (GFR), uPCR, and renal adverse events were 
determined monthly. Data were analyzed for the intent-to-treat (ITT) population and for 
ITT patients with a baseline uPCR >20 mg/mmol (ITT+uPCR) using an ANCOVA model.
Results: The trials enrolled 2262 patients. Baseline demographics, lupus disease 
activity, use of lupus drugs, SCr, GFR, and uPCR were similar among treatment arms. In 
the ITT and ITT+uPCR populations, there were no differences between treatment arms 
in baseline-to-endpoint change in SCr, GFR, or uPCR. Renal adverse events were not 
different among treatment arms.
ITT Tab Q2W N=597 Tab Q4W N=583 PBO N=575
ΔSCr .54±10.7 .11±9.8 .31±11.4
p-value vs PBO .549 .897
ΔGFR .17±17.6 .63±14.8 .38±16.6
p-value vs PBO .622 .805
ΔuPCR .44±53.4 -.30±51.6 1.87±44.4
p-value vs PBO .718 .517
ITT+uPCR
ΔSCr 1.68±13.0 1.42±12.1 2.73±14.4
p-value vs PBO .471 .655
ΔGFR -.87±18.9 .29±16.0 -2.14±20.7
p-value vs PBO .604 .559
ΔuPCR -12.52±85.8 -9.08±111.8 -7.53±102.9
p-value vs PBO .383 .434
Conclusions: Compared to PBO, TAB did not significantly affect SCr, GFR, or uPCR 
over 52 weeks in ITT or ITT+PCR patients. There were no significant renal safety signals.
Funding: Pharmaceutical Company Support - Eli Lilly and Company
TH-OR024
Evaluation and Validation of a Biomarker Panel in ANCA-Associated 
Renal Vasculitis  Andreas Kronbichler, Julia Kerschbaum, Georg Gründlinger, 
Johannes Leierer, Gert J. Mayer, Michael Rudnicki.  Internal Medicine IV, 
Nephrology and Hypertension, Innsbruck, Austria.
Background: Emerging studies in ANCA-associated vasculitis revealed markers of 
disease activity. The aim of the study was to evaluate and validate encouraging markers 
identified by literature search and the creation of respective panels.
Methods: 161 marker molecules were identified by a systematic literature review. 
ELISA assays were performed to validate a panel of biomarkers in an independent cross-
sectional cohort of patients with renal involvement. Active vasculitis as assessed by BVAS 
v3 was defined as BVAS v3 ≥ 1 and inactive disease as BVAS v3 of 0. Statistical analysis 
was performed with SPSS 21 ® and the Salford Predictive Modeler 7.0® was used to 
generate a biomarker panel.
Results: Our review indicated increased expression of monocyte chemotactic protein 
(MCP)-1, sC5bC9, C3a and C5a in urine, whereas GM-CSF, sFlt1, CRP, IL-17A, C5a, 
hyaluronan, C3a and IL-18 bp were identified to be diversely regulated in active and inactive 
disease in blood samples. Our cross-sectional analysis revealed increased expression of 
CRP, C5a, C3a, IL-18 bp in blood and C5a and MCP-1 in urine samples during active 
AAV (all p<0.05).
Units Active Remission p-value
CRP mg/l 18.7 6.4 <0.001
sFlt1 ng/ml 0.8 0.8 0.737
C3a ng/ml 253 135 <0.001
C5a ng/ml 10.2 6.2 0.006
IL-17A pg/ml 0.8 0.3 0.115
IL-18 bp ng/ml 8.5 5.2 0.007
Hyaluronan ng/ml 43.3 46.3 0.894
MCP-1 urine ng/ml 2.4 0.4 <0.001
C5a urine ng/ml 0.4 0.0 0.010
sC5bC9 urine ng/ml 0.0 0.0 0.639
C3a urine ng/ml 0.0 0.0 0.384
Table 1. The respective biomarker with a mean expression is given in active and inactive disease. CRP, 
C3a, C5a, IL-18 bp in plasma as well as MCP-1 and C5a in urine yielded significance (all p<0.05). 
Creation of a biomarker panel yielded a sensitivity and specificity of 76% (AUC 0.89) 
when CRP and urinary MCP-1 were added.
Conclusions: We could find a significant increase in CRP, C3a, C5a, IL-18 bp in 
blood and MCP-1 and C5a in urine samples. Moreover, we propose a biomarker panel 
comprising CRP and urinary MCP-1 in patients with ANCA-associated renal vasculitis. 
Further investigations to confirm our results are desired, including the reliability to predict 
renal relapses.
TH-OR025
Randomized Controlled Trial of Treatment Withdrawal in the Remission 
Phase of ANCA Vasculitis: The REMAIN Study  Alexandre Karras,1,4 Marten 
Segelmark,3,4 David R.W. Jayne.2,4  1Nephrology, HEGP Hospital, Paris, France; 
2Nephrology, Addenbrooke’s Hospital, Cambridge, United Kingdom; 3Dept of 
Nephrology, Linköping Univ, Sweden; 4On behalf of the EUVAS Study Group.
Background: After induction of remission, continuation of immunosuppressive and 
glucocorticoid therapy is recommended in ANCA-associated vasculitis (AAV), to reduce 
the risk of relapse. The optimal duration of immunosuppression (IS) for maintenance of 
remission is unknown.
Methods: The REMAIN study is a prospective, randomized trial conducted by the 
European Vasculitis Study (EUVAS) group. AAV patients were included after induction 
of remission with Cyclophosphamide/Prednisone (PRED) and initiation of remission 
maintenance therapy with azathioprine (AZA). They were randomized (1:1) at month 18, 
to receive either AZA/PRED until 48 months from onset of therapy (continuation group, 
C) or to discontinue IS by 24 months (withdrawal group, W). The primary endpoint was 
the rate of relapses during 30-months follow-up.
Results: 121 patients were included, 45% had antiMPO ANCA. At randomization, 
median Screat was 15 mg/l, ANCA remained detectable in 56%, median AZA dose was 
98 mg/day, median PRED dose 5.5 mg/day. The rate of relapse was higher in the W than 
in the C group (66% vs 22%, p<0.0001, OR 6.83, CI 2.79-16.69).
ANCA positivity at randomization was associated with higher relapse risk (51% vs 
31%, p=0.04, OR 2.31, CI 1.02-5.29). Renal function, ANCA specificity (MPO vs PR3) 
or age were not predictive of relapse. IS-related severe adverse events were more frequent 
in the C group (9 vs 2) but this group had better renal outcome (0 vs 5 ESRD cases).
Conclusions: Prolonged remission maintenance therapy with AZA/PRED beyond 
24 months after diagnosis reduced relapse rate. Continuation of immunosuppression was 
associated with better renal survival but not with improvement of overall patient survival.
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TH-OR026
Pharmacogenetics of Rituximab in ANCA Associated Vasculitis 
Federico Alberici,1 Rona M. Smith,1 Mariana G. Fonseca,1 Lisa C. Willcocks,1 
Rachel B. Jones,1 James E. Peters,1 Augusto Vaglio,2 Renato Alberto Sinico,4 
Julia U. Holle,11 Bo Baslund,6 Annette Bruchfeld,3 Iva Gunnarsson,3 Sophie 
Ohlsson,7 Vladimir Tesar,8 Zdenka Hruskova,8 Maria C. Cid,9 Thomas 
Neumann,10 Paul Anthony Lyons,1 Kenneth GC Smith,1 David R.W. Jayne.1 
1Dept of Medicine, Univ of Cambridge, United Kingdom; 2Univ Hospital of 
Parma, Italy; 3Karolinska Inst, Sweden; 4AO San Carlo Borromeo, Milano, Italy; 
5Rigshospitalet, Denmark; 6Lund Univ, Sweden; 7Charles Univ, Czech Republic; 
8Hospital Clinic of Barcelona, Spain; 9Univ of Jena, Germany; 10Klinikum Bad 
Bramstedt, Germany.
Background: Rituximab(RTX) is effective for induction and maintenance of remission 
in ANCA associated vasculitis(AAV); however optimal dosing approach is still unclear, 
relapse is common after discontinuation and predictors of response do not exist. This study 
assesses potential genetic determinants of response to RTX in AAV.
Methods: We included AAV-patients treated with RTX from European centers 
(primary cohort) and UK(replication cohort). Genotyping of 18 single nucleotide 
polymorphisms(SNPs) identified according to a biological rationale was performed using 
TaqMan and Sequenom platforms. End points were treatment failure rate(TF) 6 months 
after RTX and time to TF or relapse(TTR). Bonferroni correction was applied.
Results: 213 patients were enrolled in the primary and 109 in the replication cohorts. 
A SNP in the TNFSF13B gene region(BAFF) was associated to TTR in the primary 
(HR12.4,p=7x10-04) and replication cohorts (HR5.4,p=0.0024). Meta-analyses showed an 
association with both end-points. 
Primary cohort Replication cohort Meta-analysis
OR-HR p OR p OR-HR p
TF at 6 months 8 0.07 9.8 0.009 9.2 0.006
TTR 12.4 7x10-04 5.4 0.002 7.3 5.2x10-06
Carriers of the risk genotype had higher rate of detectable B cells 6 months after 
RTX (50%vs14%,p=0.0146). The association was restricted to patients historically 
PR3-ANCA positive (TF risk-OR 9,p=0.0141;TTR-HR 8.2,p=8.7x10-06) while in the 
MPO-ANCA subgroup an association with a SNP in chromosome 4 was identified (TF 
risk,p=0.03;TTR,p=0.0238).
Conclusions: We have identified a SNP that may predict response to RTX in AAV. Our 
results may suggest a role for this SNP in modulating BAFF levels.
TH-OR027
The MEST Score in IgA Nephropathy: Implications for Clinical 
Management  Sean Barbour,1,2,7 Gabriela Espino-Hernandez,2,7 Heather N. 
Reich,3,7 Rosanna Coppo,4,7 Ian Roberts,5,7 John Feehally,6,7 Daniel C. Cattran.3,7 
1Univ of BC; 2BC Renal Agency; 3Univ of Toronto; 4Univ of Turin; 5Oxford 
Univ; 6Leicester General Hospital; 7For the Oxford Derivation, North American 
Validation and VALIGA Consortia.
Background: The MEST score from the Oxford classification of IgA nephropathy 
(IgAN) is independently associated with renal outcome. Current risk stratification in IgAN 
requires clinical data over 2 years of follow-up. Using modern prediction tools, we examined 
whether combining MEST with cross-sectional clinical data at biopsy provides earlier 
risk prediction in IgAN than our current best methods that use 2 years of follow-up data.
Methods: We used a cohort of 901 adults with IgAN from the Oxford derivation, North 
American validation and VALIGA studies to analyze the risk of a 50% decrease in eGFR 
or ESRD using Cox regression models. Median follow-up was 5.6yrs. We considered the 
following covariates: clinical data at biopsy (eGFR, proteinuria, MAP) with or without 
MEST, and 2-year clinical data alone (2-year average of proteinuria/MAP, eGFR at biopsy). 
Prediction was assessed using the AIC, R2, NRI, IDI, C-statistic and calibration curves.
Results: There was significant improvement in prediction by adding MEST to clinical 
data at biopsy, and the combination predicted the outcome as well as using 2-year clinical 
data alone. Results did not change in subgroups treated or not with RAS blockade or 
immunosuppression. The figure provides examples of how using MEST with clinical data 
at biopsy can identify high or low risk groups compared to using 2-year clinical data alone.
Conclusions: These results demonstrate that combining MEST with cross-sectional 
clinical data at biopsy provides earlier risk prediction in IgAN than our current best methods, 
and should allow modification of treatment based on risk assessment using data readily 
available at the time of biopsy.
TH-OR028
Effects of Tonsillectomy Combined with Steroid Pulse Therapy upon 
IgA Nephropathy Depending on Proteinuria Status at Diagnosis 
Hiroyuki Komatsu,1 Shouichi Fujimoto,1 Yuji Sato,1 Akihiro Fukuda,1 Yoshinari 
Yasuda,2 Takashi Yasuda,3 Tetsuya Kawamura,4 Seiichi Matsuo.2  1Univ of 
Miyazaki, Miyazaki, Japan; 2Univ of Nagoya, Nagoya, Aichi, Japan; 3St. 
Marianna Univ School of Medicine, Kanagawa, Japan; 4Jikei Univ School of 
Medicine, Tokyo, Japan.
Background: Little is known about the effects of tonsillectomy combined with steroid 
pulse therapy on IgA nephropathy (IgAN) with a hard end-point and long-term observation. 
We therefore examined the effects of the combined therapy on renal outcomes of IgAN in 
a large, nationwide cohort study in Japan.
Methods: We divided 669 of 1,174 patients who were diagnosed with IgAN between 
2002 and 2004 into three groups based on their having mild (0.50 - 0.99 g/day; n = 258), 
moderate (1.00 - 1.99 g/day, n = 225), or severe (≥ 2.00 g/day; n = 186) proteinuria at 
diagnosis. Ratios of decline in renal function and urinary remission were compared among 
the three groups after receiving combined, steroid or conservative therapy during a mean 
follow-up of 6.2 ± 3.4 years.
Results: The ratio of urinary remission at final observation was significantly higher 
in the groups given combined, than steroid or conservative therapy (mild proteinuria: 
63% vs. 46% and 42%; moderate proteinuria, 52% vs. 44% and 23%; severe proteinuria, 
43% vs. 33% and 16%, respectively). In contrast, the ratio of a 50% increase in serum 
creatinine decreased more groups given combined, than steroid or conservative therapy 
(mild proteinuria, 3.7% vs. 10.8% and 14.6%; moderate proteinuria, 7.6% vs. 6.5% and 
19.8%; severe proteinuria, 16.7% vs. 25.0% and 36.8%, respectively). Cox proportional 
hazards models revealed that the combined therapy significantly prevented a 50% increase 
in serum creatinine compared with conventional therapy in the groups with moderate and 
severe proteinuria (hazards ratio, 3.64 and 3.09, respectively).
Conclusions: Tonsillectomy combined with steroid pulse therapy induces urinary 
remission and prevents the decline in renal function in patients with moderate and severe 
proteinuria.
TH-OR029
Pregnancy and IgA Nephropathy: Renal, Maternal and Fetal Outcomes 
Sehoon Park, Kyung Don Yoo, Dong Ki Kim, Kwon Wook Joo, Chun Soo 
Lim, Yon Su Kim, Hajeong Lee.  Dept of Internal Medicine, Seoul National 
Univ Hospital.
Background: Impact of pregnancy on long term renal prognosis of IgA nephropathy 
(IgAN) remains controversial. Also, there are few information about maternal and fetal 
outcomes of pregnancy in IgAN women.
Methods: This study included women with biopsy proven IgAN from 1979 to 2013 and 
all mothers with delivery record from 1999 to 2014 in Seoul National University Hospital. 
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A survey was done by medical chart review and telephone poll. Primary outcome for kidney 
was end-stage renal disease (ESRD) progression and doubling of serum creatinine. Maternal 
outcomes were preeclampsia, gestational hypertension, and proteinuria. Fetal outcomes 
were preterm birth, fetal death and fetal growth restriction (FGR). Matched analysis was 
done by 2:1 propensity score matching (PSM).
Results: A total of 803 IgAN women were enrolled including 88 patients with 166 
pregnancy experiences. In addition, 15,028 women with 17,432 pregnancies were enrolled 
as control. After PSM, no significant difference of baseline parameters was found between 
matched groups. For renal outcome, pregnancy affect neither ESRD progression nor 
creatinine doubling in overall IgAN women. However, renal progression was accelerated 
by pregnancy (HR, 2.90; 95% CI, 1.171–7.179, P = 0.023) in IgAN women with moderate 
kidney dysfunction (eGFR <60). In maternal outcome, pregnancy of IgAN showed more 
proteinuria, gestational hypertension, and preeclampsia than normal pregnancies. Moreover, 
risks of fetal death and FGR were elevated. We found that this adverse pregnancy outcomes 
of IgAN patients occurred inversely to their pregestational kidney function. Unexpectedly, 
this trend started even from preserved pregestational renal function (eGFR <75), not from 
advanced renal dysfunction.
Conclusions: We demonstrated pregnancy accelerated renal progression in IgAN 
women with impaired kidney function. Moreover, we found that IgAN women suffered 
from a substantial burden of pregnancy even in those with relatively preserved pregestational 
renal function.
TH-OR030
Semaphorin 3F (SEMA3F) Expression Is Reduced in Pregnancy 
Complicated by Preeclampsia (PE)  Giovanni Stallone, Adelaide Di Lorenzo, 
Giuseppe S. Netti, Barbara Infante, Francesca Bruno, Pantaleo Greco, Maria 
Matteo, Stefania Carlucci, Federica Trezza, Giuseppe Grandaliano.  Medical 
and Surgical Sciences, Univ of Foggia, Foggia, Italy.
Background: PE, characterized by the new onset of hypertension and proteinuria after 
20 weeks of gestation, affects 2-10% of pregnancies worldwide. It is characterized by an 
ineffective remodeling of maternal vessels perfusing the placenta. SEMA3F is a well-known 
anti-angiogenic mediator. We aimed to investigate whether SEMA3F placenta expression 
and serum and amniotic levels are modulated in PE.
Methods: To this purpose, we performed an observational single center, cohort 
study in the period from March 2013 to July 2014. We enrolled 132 consecutive pregnant 
women (PE n=13), undergoing an elective cesarean section (cross-sectional study) and 150 
consecutive pregnant women undergoing amniocentesis for routine clinical indications 
at 16-18 week of gestation (perspective study). SEMA3F concentration was evaluated 
in maternal peripheral blood, venous umbilical blood and amniotic fluid at the time of 
delivery in the first group. In addition, in this group we examined placental SEMA3F 
protein expression. We then investigated amniotic fluid SEMA3F level at 16-18 weeks of 
gestation in the second group of pregnants.
Results: SEMA3F placenta expression was significantly reduced in PE (Control 
3.2±.3 vs. PE 1.3±.6AU, p=.01). In addition, SEMA3F level at the time of delivery was 
significantly lower in serum (2.0±.4 vs 2.9±.6 ng/mL, p=.04), amniotic fluid (133.6±41.9 
vs 202.4±102.2 ng/mL, p=.01) and cord blood (.58±.27 vs .92±.20 ng/mL, p=.02) of PE 
patients compared with normal pregnant women. SEMA3F level in maternal serum was 
significantly associated with placental weight (R2=.802; p<.001) and newborn weight 
(R2=.532; p<.001) at birth. In the prospective cohort study 14 women developed PE. In this 
setting, SEMA3F level in the amniotic fluid was lower in women developing PE compared 
to women with a normal pregnancy (12.9±8.1 vs 30.1±8.0 ng/mL, p<.01).
Conclusions: Our findings demonstrate, for the first time, that SEMA3F expression is 
significantly reduced in PE and support the hypothesis that SEMA3F amniotic fluid levels 
might represent a biomarker of PE.
Funding: Government Support - Non-U.S.
TH-OR031
Efficacy in Diabetic Nephropathy in a Phase 2 Clinical Trial of Chemokine 
Receptor 2 Inhibitor CCX140-B  Richard J. Glassock,1 Elena Henkel,2 Heidrun 
Mehling,3 Christoph Hasslacher,4 Ioanna Gouni-Berthold,5 Vladimir Tesar,6 
Antonia Potarca,7 Pirow Bekker,7 Thomas J. Schall.7  1David Geffen School 
of Med; 2Technical Univ; 3Free Univ; 4Univ Heidelberg; 5Univ of Cologne; 
6Charles Univ; 7ChemoCentryx.
Background: The orally administered inhibitor of C-C chemokine receptor 2 (CCR2) 
CCX140-B blocks the deleterious effects of monocyte chemoattractant protein-1, including 
macrophage infiltration, podocyte injury and dysfunction. The aim was to test CCX140-B 
in diabetic nephropathy (DN).
Methods: This is a randomized, one-year clinical trial. Primary efficacy measure: 
change in urinary albumin:creatinine ratio (UACR) over 52 wks. Eligible patients were 
on stable ACE inhibitor or ARB, and anti-diabetic treatment for ≥8 wks prior to entry, with 
UACR 100-3000 mg/g creatinine, HbA1c 6-10%, and eGFR ³25 mL/min/1.73 m2. Patients 
were stratified based on baseline UACR and eGFR, and then randomized to receive placebo, 
5 mg, or 10 mg CCX140-B once daily (QD) plus standard of care (SOC) for 52 wks.
Results: 332 pts were enrolled. Baseline characteristics (mean±SD): 63±8 yrs, 77% 
males, BMI 33±5 kg/m2, duration of diabetes 16±8 yrs, UACR (geo mean) 461 (range 77-
2922) mg/g, eGFR 60±24 mL/min/1.73 m2. The primary endpoint was met: 5 mg CCX140-B 
QD plus SOC showed a statistically significant (p=0.01) reduction in UACR compared to 
SOC alone. The maximum effect (24% reduction) was at 12 wks, with sustained reduction 
in UACR over the full year. 10 mg CCX140-B QD did not provide further improvement in 
UACR vs. 5 mg. CCX140-B treatment showed an improvement in fasting plasma glucose 
(-1.12 mmol/L). In a covariate analysis, CCX140-B was effective on UACR across patient 
groups. In a pre-specified subgroup with high baseline UACR (>800 mg/g creatinine), 
CCX140-B resulted in a placebo-corrected 28% improvement in albuminuria over 52 wks, 
and a slower rate of decline in eGFR. CCX140-B did not affect systemic BP or body weight, 
and appeared to be well tolerated with a low overall dropout rate (10%).
Conclusions: CCX140-B improved albuminuria over 52 weeks in a broad patient 
population. Patients with high baseline UACR may benefit most from CCX140-B treatment, 
relevant for design of a renal endpoint study.
Funding: Pharmaceutical Company Support - ChemoCentryx, Inc.
TH-OR032
A First in Human Study of Implantation of Neo-Kidney Augment, an 
Autologous Selected Renal Cell Population, in Type-2 Diabetic CKD Stage 
3-4 Patients  Peter Stenvinkel,1 Torbjörn Lundgren,1 Jonas Wadstrom,1 Pontus 
Blomberg,1 Torkel Brismar,1 Randal K. Detwiler.2  1Karolinska Univ Hospital, 
Sweden; 2Univ of North Carolina.
Background: Animal models of CKD show that a selected population of bioactive renal 
cells (Selected Renal Cells; SRC) can be delivered to the kidney through intra-parenchymal 
injection resulting in a decrease in disease progression. We have used a laparoscopic 
technique to perform the first-in-human study with Neo-Kidney Augment (NKA).
Methods: 7 male type-2 diabetic (108±11kg) patients (63±6yrs) with CKD were 
selected. After evaluation of renal function and radiology they underwent renal biopsy. 
Two cores were shipped to the manufacturing plant for cell isolation, culture and product 
preparation. NKA was shipped back to the clinical centre (44-87d after biopsy) and injected 
into the left kidney.
Results: Implantation of 8 mL NKA was uneventful. 1 postop complication was 
observed (ileocecal volvolus). Infectious complications were observed in 3 patients during 
the first 3 months. Antihypertensive medication has been reduced in 3/7 during the first 
6 months. Creatinine has remained stable at 6 and 12 months after autologous renal cell 
implantation in 6/7 patients. In one patient a rise in s-creatinine has, at least partly, been 
due to prostatic hypertrophy. 2 patients have only been followed for 6 months. Kidney 
volume was stable at 3, 6, and 12 m (n5).
Conclusions: NKA was safely implanted in 7 diabetic CKD patients. Complications 
after the implantations in this population were found to be related to the surgical procedure. 
Longer follow-up and a larger number of patients is needed to reveal if this novel technique 
can arrest progression of CKD and delay the start of renal replacement therapy. Perioperative 
findings indicate that image-guided percutaneous techniques (“reversed biopsy”) could 
facilitate the procedure in this patient group.
TH-OR033
Selective Inhibition of CCR2/5 Chemokine Receptors Reduces 
Macroalbuminuria in Subjects with Type 2 Diabetes and Overt 
Nephropathy  Jeremy D. Gale,1 Steven A. Gilbert,1 Samuel S. Blumenthal,2 
Tom Elliott,4 Pablo E. Pergola,3 Kosalaram Goteti,1 Douglas Girgenti,1 Willem 
H. Scheele,1 Robert Webster,1 Christelle Huguet Perros.1  1Pfizer Inc, Cambridge, 
MA; 2Zablocki VAMC, Milwaukee, WI; 3Renal Associates PA, San Antonio, TX; 
4BCDiabetes, Vancouver, Canada.
Background: Recruitment, infiltration and activation of inflammatory cells appears 
important in diabetic nephropathy (DN). Inhibition of MCP-1/CCR2 receptor pathways 
may have renoprotective effects in DN and clinical data support a potential protective 
role of CCR5 receptors. Our hypothesis was that combined blockade of CCR2 and CCR5 
receptors could decrease proteinuria in subjects with nephropathy.
Methods: The effect on albuminuria of the novel and specific dual CCR2/5 receptor 
antagonist, PF-04634817, was assessed in a multinational, randomized, double-blind, 
placebo-controlled, parallel group trial of subjects with Type 2 diabetes and overt 
nephropathy already receiving ACEi and/or ARB. Subjects with eGFR 20-75 mL/
min/1.73m2 and urinary albumin creatinine ratio (UACR) >300mg/g (33.9 mg/mmol) at 
baseline were assigned to receive PF-04634817 200mg (150mg if baseline eGFR <30 mL/
min/1.73m2) or placebo (3:1), orally, once daily for 12 weeks.
Results: 226 subjects (mean UACR of 180.78 ± 160.53 mg/mmol Cr and mean eGFR 
of 41.46 ± 12.64 ml/min/1.73 m2 at baseline) were randomised. A modest placebo-adjusted 
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reduction in UACR of 8% (95% CI -9% to 23%) was observed in response to treatment with 
PF-04634817 using the pre-defined primary assessment of efficacy (Bayesian analysis with 
informative prior). Ad hoc analysis, of those with eGFR <60 mL/min/1.73m2 at baseline, 
showed a placebo-adjusted reduction of UACR approaching 19%. However, interpretation 
of subgroups are difficult due to the 3:1 randomization and the presence of data outliers. 
Adverse events (AEs) were mostly mild, the most common treatment-related AEs being 
nausea, acne and diarrhoea.
Conclusions: The efficacy of PF-04634817 to reduce UACR in this study appears 
modest, although may be greater in a subset of subjects with more advanced disease. This 
profile combined with good safety supports further investigation of its potential as a novel 
therapeutic strategy to improve renal outcome in DN.
Funding: Pharmaceutical Company Support - Pfizer
TH-OR034
Baricitinib in Diabetic Kidney Disease: Biomarker Analysis from a Phase 
2, Randomized, Double-Blind, Placebo-Controlled Study  Frank C. Brosius,1 
Katherine R. Tuttle,2 Sharon G. Adler,3 Matthias Kretzler,1 Ravindra L. Mehta,4 
James A. Tumlin,5 Kevin L. Duffin,6 Joseph V. Haas,6 Jiajun Liu,6 Maria E. Silk,6 
William Macias,6 Jonathan M. Janes.6  1Univ MI Med Sch, Ann Arbor; 2Univ 
WA Sch Med, Spokane; 3LA BioMed, Torrance; 4Univ CA, San Diego; 5Univ 
TN Coll Med, Chattanooga; 6Eli Lilly & Co, IN.
Background: New therapies for diabetic kidney disease (DKD) are needed as standard 
care (SC) fails to prevent progressive DKD. Baricitinib (bari) is an oral Janus Kinase 
(JAK)1/JAK2 inhibitor. The study met its primary endpoint of significantly reduced urine 
albumin/creatinine ratio (UACR) at 6 months (mo) in diabetics with albuminuria despite SC.a
Methods: To examine effects of bari treatment (tx) on key secondary endpoints: 24h 
urine protein; ³30% UACR decrease; inflammatory biomarkers: urinary interferon gamma-
induced protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), and plasma 
soluble tumor necrosis factor receptor (sTNFR) 1&2. Type 2 diabetics at high-risk for 
progressive DKD on SC were randomized to bari 0.75mg QD (n=25), 0.75mg BID (n=26), 
1.5mg QD (n=26), 4mg QD (n=25), or placebo (PBO;n=27) for 6 mo.
Results: Reductions in 24h proteinuria compared with PBO were observed at 6 mo of 
bari tx (LSM ratio vs PBO for 0.75mg BID, 1.5mg QD, 4mg QD; 0.59, 0.58, 0.60, resp. 
p<.05). Benefits were maintained during a 1-2 mo washout period. The proportion with 
³30% UACR decline was increased by bari tx. IP-10, MCP-1, and sTNFR 1&2 decreased 
in a numerically dose-dependent manner. Estimated glomerular filtration rate by cystatin 
C was unchanged. At 6 mo, only 4mg bari had decreased hemoglobin vs PBO (-1.0±0.35 
g/dL). No other safety concerns were observed.
Conclusions: Analysis of proteinuria and inflammatory biomarkers supports efficacy of 
bari in high-risk DKD. Data suggest an anti-inflammatory tx response encouraging further 
study of bari in DKD. aTuttle et al, ADA Jun 2015, Post. 114-LB.
Funding: Pharmaceutical Company Support - Eli Lilly and Company
TH-OR035
Patiromer Lowers Serum K+ and Prevents Recurrent Hyperkalemia in CKD 
Patients ≥65 Years of Age on RAAS Inhibitors  Matthew R. Weir,1 David 
A. Bushinsky,2 Martha Mayo,3 Dahlia Garza,3 Yuri Stasiv,3 Daniel J. Wilson,3 
Susan Arthur,3 Lance Berman,3 George L. Bakris.4  1Univ of Maryland; 2Univ 
of Rochester; 3Relypsa, Inc; 4Univ of Chicago.
Background: Older pts are at risk for hyperkalemia (HK) due to comorbid diseases 
and K+-altering medications. The active moiety of patiromer is a nonabsorbed K+ -binder. 
We present a prespecified subgroup analysis in pts ≥65 yr with CKD and HK on RAASi 
from a 2-part, single-blind, phase 3 patiromer trial (OPAL-HK).
Methods: Pts (n=243) with baseline (BL) serum K+ (s-K+) 5.1 to <6.5 mEq/L received 
patiromer (4.2 or 8.4 g BID) in a 4-wk treatment phase (part A); then pts with BL s-K+ 5.5 
to <6.5 mEq/L by central lab (n=107) were randomized to continue patiromer or switch to 
placebo (PBO) in an 8-wk withdrawal phase (part B). Primary endpoints were Ds-K+ from 
BL at 4 wk in part A and between-group difference in Ds-K+ from part B BL to part B wk 4.
Results: 131 (54%) pts were ≥65 yr at BL. Consistent with overall results, primary 
endpoints were significant for pts ≥65 yr (Table). Overall and in pts ≥65 yr, 76% and 73%, 
respectively, had s-K+ 3.8 to <5.1 mEq/L (2° endpoint) at part A wk 4. More PBO pts 
(p<0.001) developed recurrent HK in part B. In all pts, mild-moderate constipation was 
the most common AE in part A (11%).
Conclusions: Patiromer significantly reduced s-K+ in pts ≥65 yr and, vs. PBO, 
maintained control of s-K+.
Table. Primary Endpoint Results (mEq/L)
Treatment Phase
Mean±SE BL 
S-K+
Mean ΔS-K+±SE
(95% CI)
Overall (n=237)a 5.58±0.03 -1.01±0.03 (-1.07, -0.95) p<0.001
≥65 yr (n=126)a 5.56±0.04 -1.01±0.05 (-1.10, -0.92) p<0.001
Withdrawal Phase
Median ΔS-K+ (25th, 75th Percentile) 
from BL to Wk 4b Between-Group Difference in 
Median ΔS-K+ (95% CI)
PBO Patiromer
Overall (n=107) 0.72 (0.22, 1.22) n=52
0.00 (-0.30, 0.30) 
n=55 0.72 (0.46, 0.99) p<0.001
c
≥65 yr (n=60) 0.81 (0.51, 1.48) n=31
0.00 (-0.35, 0.30) 
n=29 0.81 (0.49, 1.14) p<0.001
c
aExcludes 6 (overall) and 5 (≥65 yr) pts with no s-K+ value at wkly visit after Day 3. bOr earlier 
timepoint if pt first had s-K+ <3.8 mEq/L or ≥5.5 mEq/L. cBetween-group difference in mean ranks 
of change.
Funding: Pharmaceutical Company Support - Relypsa, Inc
TH-OR036
The Microalbminuria Intervention Study: Effects of Different Losartan 
Combination Antihypertensive Therapy in Patients with CKD, MIDLAND-
CKD  Yoshinari Yasuda,1 Takeyuki Hiramatsu,2 Seiichi Matsuo,1 Shoichi 
Maruyama.1  1CKD Initiatives/Nephrol/CAMCR, Nagoya Univ, Nagoya, Aichi, 
Japan; 2Nephrol, Konankosei Hosp, Konan, Aichi, Japan.
Background: GUARD study reported that ACEI with a diuretic resulted in a greater 
reduction in albuminuria compared to ACEI and calcium channel blocker (CCB), however 
GFR significantly declined in ACEI and diuretic group and superiority between diuretics 
and CCB in combination with ACEI remains controversial. In addition the effect of 
combination antihypertensive therapy with ARB has not been fully evaluated. Thus the 
effect to reduce albuminuria were studied between amlodipine and HCTZ in combination 
with losartan, ARB.
Methods: Study design was randomized control trial. Eligible subjects were 
hypertensive CKD patients (aged 20-79) treated with ACEI or ARB more than 2 months, BP 
140/90 mmHg and above, and suspected albuminuria. Suspected albuminuria was defined 
as albuminuria creatinine ratio (ACR) greater than 30 mg/gCr in an single spot urinalysis, 
or ± and above in urine dipstick test more than 2 times within 1 year. Exclusion criteria 
were renal insufficiency, prescription of CCB/diuretics, cardiovascular events within 6 
months, abnormal liver function, and uncontrolled diabetes/hyperuricemia within 3 months.
Written informed consent were obtained from all patients. This study was approved by 
the ethical committee and registered to UMIN (ID: 000004062). Patients were randomly 
assigned to group A (losartan and amlodipine) or B (compounding agent of losartan and 
HCTZ12.5mg) for 6 months.
Results: 48 and 46 patients were assigned to group A and B. There was no significant 
difference in patient characteristics between 2 groups at baseline, and BP were well 
controlled in both groups. ACR were decreased in both groups at 3 and 6 months without 
statistical significance. Among patients with ACR 30mg/gCr and above, ACR was 
significantly decreased in group B compared to A at 3 and 6 months (-17.5 ± 77.4 vs 
-56.3 ± 37.3 %, p<0.01 and -27.8 ± 63.4 vs -63.8 ± 34.0 %, p<0.01). DeGFR were not 
significantly different in 2 groups.
Conclusions: Compounding agent of losartan and HCTZ was superior to losartan and 
amlodipine treatment in hypertensive CKD patients with albuminuria.
Funding: Private Foundation Support
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TH-OR037
Blood Pressure and Renal Outcomes in Diabetic Kidney Disease: Results 
from the VA NEPHRON-D Trial  David J. Leehey,1 Jane Hongyuan Zhang,2 
Nicholas Emanuele,1 Adam Whaley-Connell,3 Paul M. Palevsky,4 Robert F. 
Reilly,5 Peter Guarino,2 Linda F. Fried.4  1Edward Hines, Jr. Veterans Affairs (VA) 
Hospital, Hines, IL; 2Cooperative Studies Program Coordinating Center, VA 
Connecticut Healthcare System, West Haven, CT; 3Harry S. Truman Memorial 
VA Hospital, Columbia, MO; 4VA Pittsburgh Healthcare System, Pittsburgh, 
PA; 5VA North Texas Healthcare System, Dallas, TX; 6VA  NEPHRON-D Study 
Group.
Background: Proteinuric diabetic kidney disease (DKD) frequently progresses to 
end-stage renal disease (ESRD). Control of blood pressure (BP) delays progression, but 
the optimal BP to improve outcomes remains unclear. The objective of this analysis was to 
evaluate the relationship between BP and renal outcomes in proteinuric DKD.
Methods: BP data from all 1448 randomized participants in the VA NEPHRON-D study 
were included in a post-hoc analysis. The effects of mean on-treatment BP on the primary 
endpoint (decline in the estimated GFR (eGFR), ESRD, or death), renal endpoint (decline 
in eGFR or ESRD), rate of eGFR decline, and mortality were measured.
Results: In univariate analyses, both mean systolic BP (SBP) and mean diastolic BP 
(DBP) were strongly associated (p < 0.001) with the primary endpoint. After multivariate 
adjustment, the hazard of developing the primary endpoint increased as mean SBP rose 
from < 120 to > 150 mmHg (p=0.018); a significant increase in hazard ratio was seen when 
mean SBP was > 140 mmHg. There was also a significant effect of mean DBP on the hazard 
of developing the primary endpoint (p=0.005), with an increase in hazard ratio when mean 
DBP was > 80 mmHg. Associations between BP and both renal endpoint and rate of eGFR 
decline were similar to those with the primary endpoint. No effect of BP on mortality was 
observed, possibly because of the limited number of mortality events.
Conclusions: In patients with proteinuric DKD, mean SBP > 140 mmHg and mean 
DBP > 80 mmHg were associated with worse renal outcomes.
Funding: Veterans Administration Support
TH-OR038
Hemoglobin (HGB) Response in a Phase 2b Study of AKB-6548 for the 
Treatment of Anemia in Patients with Non-Dialysis Dependent Chronic 
Kidney Disease (NDD-CKD)  Bruce S. Spinowitz,1 Pablo E. Pergola,2 Volker 
H. Haase,3 Tasha M. Farmer,4 Charlotte S. Hartman,4 Bradley J. Maroni.4  1New 
York Hospital Queens, Flushing, NY; 2Renal Associates PA and Univ of Texas 
Health Sciences Center, San Antonio, TX; 3Vanderbilt Univ, Nashville, TN; 
4Akebia Therapeutics, Inc., Cambridge, MA.
Background: AKB-6548 is a novel, once-daily, oral hypoxia-inducible factor prolyl-
hydroxylase inhibitor (HIF-PHI) that preferentially stabilizes HIF-2α. Studies have shown 
AKB-6548 produces physiologic increases in erythropoietin, enhances iron mobilization 
and utilization, and produces a dose dependent increase in HGB.
Methods: A randomized, double-blind, placebo-controlled study assessed HGB 
response of AKB-6548 over 20 weeks in CKD subjects with anemia. 210 subjects were 
enrolled into one of 3 groups: 1) ESA naïve with HGB £10.5 g/dL, 2) previously treated with 
ESA with HGB £10.5 g/dL, or 3) actively treated with ESA with HGB ≥9.5 and £12.0 g/dL, 
and randomized (2:1) to once daily AKB-6548 or placebo. Primary endpoint was percent 
of subjects with mean HGB of ³11.0 g/dL or increase in HGB by ³1.2 g/dL from baseline.
Results: Overall, 54.9% of AKB-6548 vs. 10.3% of placebo subjects met the primary 
endpoint (p=0.0001) and mean change in HGB at end of treatment was 0.84 g/dL in the 
AKB-6548 group as compared to 0.02 g/dL in the placebo group (p=0.0054 at Week 2, 
p<0.0001 all time points Week 4 and beyond). HGB responses in the Naïve and Previously 
Treated groups were similar to each other and the overall group. In subjects converting 
from active ESA, AKB-6548 maintained a stable HGB throughout the study. HGB 
response with AKB-6548 was associated with an increase in reticulocytes and TIBC, and 
a decrease in serum hepcidin and ferritin across all three treatment groups. AKB-6548 
was generally well tolerated and overall adverse events were balanced between treatment 
groups (74.6% vs. 73.6%).
Conclusions: AKB-6548, a novel HIF-PHI being developed for the treatment of anemia 
of CKD, raised and maintained HGB, while increasing iron mobilization and utilization, 
providing a more physiologic approach to the treatment of renal anemia. This study forms 
the basis for future Phase 3 studies.
Funding: Pharmaceutical Company Support - Akebia Therapeutics, Inc.
TH-OR039
Anemia Correction with Roxadustat Improves Health Related Quality of 
Life (HRQOL) in Chronic Kidney Disease (CKD) Patients  Lynda Szczech, 
Stefan Hemmerich, Anatole Besarab, Khalil Georges Saikali, Lona Poole, 
Kin-Hung Peony Yu, Thomas B. Neff.  FibroGen, San Francisco, CA.
Background: The hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat 
is being developed for treatment of CKD anemia.This analysis of two phase 2 trials was 
undertaken to assess the effect of roxadustat on HRQOL in non-dialysis (NDD) and dialysis 
dependent (DD) CKD.
Methods: HRQOL was assessed by SF-36 and FACT-An questionnaires in efficacy-
evaluable populations in 2 open-label studies, CKD-NDD (041) and ESA-naïve incident 
CKD-DD (053). HRQOL was assessed at baseline (BL), 8 and 16 wks [end of treatment 
(EOT)] in 041 and at BL, 8 and 12 wks (EOT) in 053 [mean±SE changefrom BL (∆)]. 
Missing data were imputed by last observation carried forward.
Results: Data from 141 subjects with CKD-NDD and 55 subjects with CKD-DD were 
available. In both populations, SF-36 physical component summary and FACT-An scores 
improved compared to BL (p=0.005 & 0.001, CKD-NDD; p=0.01 & 0.02, CKD-DD). SF-
36 vitality norm-based domain scores (NBDS) and FACT-An anemia score increased by 
an average of >4 points. Benefits were seen particularly among those with low BL scores. 
In Study 053, subjects with BL SF-36 Physical Functioning NBDS <35 experienced a 
mean increase of 8.7 (p=0.005) and those with BL Vitality NBDS <50 increased by 6.7 
(p<0.0001). Subjects with BL FACT-An Anemia score<55 increased 10.3 (p=0.0001), and 
those with BL FACT-An Total Score<135 increased 16.0 (p=0.0005).
Population 
(Study) (n) Instrument
HRQOL 
Domains Baseline Δ at EOT P-value
NDD
(041) 
(n=141)
SF-36
Physical 
Functioning 
NBDS
Vitality NBDS
37.7±1.0
 
48.1±1.1
1.4±0.7
 
4.3±0.9
0.04
 
<0.0001
FACT-An
Physical Well 
Being
Anemia
21.7±0.4
54.8±1.3
1.0±0.3
4.3±1.0
0.0004
<.0001
DD
(053) 
(n=55)
SF-36
Physical 
Functioning 
NBDS
Vitality NBDS
40.0±1.4
 
47.3±1.5
3.9±1.0
 
3.7±1.2
0.0002
 
0.003
FACT-An
Physical Well 
Being
Anemia
19.3±0.8
52.4±2.1
1.6±0.7
4.9±1.6
0.03
0.003
Conclusions: Roxadustat consistently improved mean HRQOL sub- and summary 
scores. Improvements were greatest in subjects with low BL scores. Roxadustat is currently 
being evaluated in phase 3 trials in which HRQOL is further explored.
Funding: Pharmaceutical Company Support - FibroGen
TH-OR040
Hepcidin Response to Intravenous (IV) or Oral Iron in the Randomized 
FIND-CKD Trial of Patients with Non-Dialysis Dependent CKD (ND-
CKD)  Carlo A. Gaillard,1 Andreas H. Bock,2 Fernando Carrera,3 Kai-Uwe 
Eckardt,4 David B. Van Wyck,5 Sukhvinder Singh Bansal,6 Bernard Roubert,7 
Maureen Cronin,7 Simon D. Roger,8 Iain C. Macdougall.6  1Uni. of Groningen, 
Groningen, Netherlands; 2Kantonsspital, Aarau, Switzerland; 3Eurodial, 
Leiria, Portugal; 4Uni. of Erlangen-Nuremberg, Erlangen, Germany; 5Davita 
Healthcare Partners, Denver, CO; 6King’s College Hospital, London, United 
Kingdom; 7Vifor Pharma Ltd, Glattbrugg, Switzerland; 8Renal Research, 
Gosford, NSW, Australia.
Background: Hepcidin is the key regulator of iron homeostasis but its temporal 
response to iron therapy, and response to IV vs oral iron therapy, are unexplored.
Methods: In the 56-week, open-label, multicenter, prospective, randomized FIND-
CKD study, 626 anemic patients with ND-CKD and iron deficiency not receiving ESA 
therapy were randomized (1:1:2) to IV ferric carboxymaltose (FCM), targeting higher 
(400–600µg/L) or lower (100–200µg/L) ferritin, or oral iron. In a subset of patients enrolled 
in the UK, serum hepcidin was measured centrally by a validated liquid chromatography 
tandem mass spectrometry assay.
Results: 61 patients provided baseline and ³1 post-baseline hepcidin values. Mean 
(SD) baseline hepcidin level was 4.0(3.5), 7.3(6.4) and 6.5(5.6) ng/mL in the high ferritin 
FCM, low ferritin FCM and oral iron groups. The mean (SD) endpoint value (i.e. the last 
post-baseline value) was 26.0(9.1),15.7(7.7) and 16.3(11.0) ng/mL, respectively. The 
increase in hepcidin from baseline was smaller with low ferritin FCM and with oral iron 
vs high ferritin FCM up to week 52 (all p<0.05). Correlations were significant between 
the post-baseline increases in hepcidin and ferritin (r=0.70, p<0.0001), TSAT (r=0.42, 
p=0.0008) or hemoglobin (r=0.30, p=0.0295) using endpoint values across all groups. 
The increase in hepcidin levels over the 12-month study generally mirrored the cumulative 
iron dose in all groups.
Conclusions: These prospective, 1-year data from a randomized trial show that hepcidin 
levels rose in response to either IV or oral iron therapy, but that the speed and extent of 
the rise was greatest with IV iron targeting a higher ferritin level. Oral iron and IV iron 
targeting a lower ferritin level resulted in similar hepcidin levels.
Funding: Pharmaceutical Company Support - Vifor Pharma, Glattbrugg, Switzerland
J Am Soc Nephrol 26: 2015 Engineering Stem Cells Oral Abstract/Thursday
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
12A
TH-OR041
Isolation of Live Nephron Progenitors Cells Expressing Six2+ and Cited1+ 
from Human Embryonic Kidneys and Amniotic Fluid  Laura Perin,1 Stefano 
Da Sacco,1 Astgik Petrosyan,1 Matthew Edward Thornton,2 Brendan Grubbs,2 
Roger E. De Filippo.1  1Urology, Children’s Hospital Los Angeles, Los Angeles, 
CA; 2Univ of Southern California, Los Angeles, CA.
Background: In the developing kidney, formation of new nephrons relies on a small 
population of self renewing progenitors co-expressing Six2 and Cited1. Unfortunately, 
despite their essential role in the renal formation, direct isolation and expansion of human 
nephrogenic progenitor cells has not been successfully achieved and our knowledge is 
mostly based on rodent models. We have identified a small niche of Six2+Cited1+ cells 
within human amniotic fluid (hAF) and in this project we report for the first time the isolation 
and characterization of this population from both hAF and human embryonic kidneys (hEK).
Methods: Six2+ Cited1+ live cells from hAF and hEK were sorted using Smartflare 
RNA probes. RNAseq on positive and negative selections was performed immediately 
after sorting to evaluate their genetic profile without the confounding effects of cell culture. 
Integration into developing renal structures was assessed. Potential for a glomerular fate 
was tested by differentiation toward podocyte lineage.
Results: Six2+Cited1+ cells were successfully isolated from hEK (0.17%) and hAF 
(0.2%). RNASeq confirmed expression of genes such as Six2, Cited1, Osr1, suggesting a 
nephrogenic signature. Clones and subclones were derived and expanded for many passages 
in specific nephrogenic media maintaining Six2 and Cited1 expression. These populations 
were able to integrate in developing renal structures when co-cultured with dissociated/
re-aggregated hEK. Differentiation into podocyte-like cells was evaluated by expression 
of specific markers including WT1 and nephrin, deposition of collagen IV alpha3-4-5 and 
functional response to angiotensin II.
Conclusions: Our preliminary results suggest the possibility of deriving and expanding 
for the first time, Six2+Cited1+ cells from hEK as well as from an exogenous source of 
cells like hAF without genetic manipulation. This system might represent an accessible 
and novel source of nephron progenitors that can guide studies of renal cell specification, 
thus increasing our knowledge on human renal development.
Funding: Private Foundation Support
TH-OR042
Novel Noninvasive Source of Kidney Progenitor Cells with Potential 
to Differentiate into Podocytes  Fanny Oliveira Arcolino,1 Silvia Zia,1 
Katharina Held,1 Joris Vriens,1 Elli Papadimitriou,3 Benedetta Bussolati,3 Anke 
Raaijmakers,1,2 Karel Allegaert,1 Jan A. Deprest,1 Jaan Toelen,1,2 Lambertus 
P.W.J. Van den Heuvel,1,4 Elena N. Levtchenko.1,2  1Development and 
Regeneration, Catholic Univ Leuven, Leuven, Belgium; 2Dept of Pediatrics, 
Univ Hospitals Leuven, Leuven, Belgium; 3Dept of Molecular Biotechnology 
and Health Sciences, Univ of Turin, Turin, Italy; 4Dept of Pediatric Nephrology, 
Radboud UMC, Nijmegen, Netherlands.
Background: Recently, subpopulations of cells from amniotic fluid (AF) and adult urine 
were shown to express kidney progenitor cell features with multipotential of differentiation. 
We aimed to study urine of preterm neonates born before the completion of nephrogenesis 
for the presence of kidney neonatal stem/progenitor cells (nKSPC) and the ability of these 
cells to differentiate into functional podocytes.
Methods: Clonal cell lines were characterized as KSPC and KSPC-derived podocytes 
by gene expression analyses using quantitative rt-PCR and protein expression by flow 
cytometry and immunofluorescence. Podocytes differentiation was induced by incubation 
of cells in medium containing retinoic acid and vitamin D. Function of podocytes was 
assessed by albumin endocytosis and calcium influx assays. Results were compared to 
conditionally immortalized podocytes (ciPodocytes) and podocytes differentiated from 
amniotic fluid stem cells (AFSC) and adult urine progenitor cells (aUPC).
Results: nKSPCs expressed mesenchymal stem cell markers and kidney progenitor cell 
markers as SIX2, CD24, CD133, Vimentin and CITED1 maintaining these characteristics 
up to passage 17. nKSPC-derived podocytes presented mesenchymal-to-epithelial transition 
and acquired arborized cytoplasm comparable to ciPodocytes. Cells presented up-regulation 
of podocyte-specific genes and proteins and were able to endocytose albumin and uptake 
calcium via transient receptor potential cation channel, subfamily C, member 6 (TRPC6).
Conclusions: Preterm neonatal urine represents a novel noninvasive source of self-
reviewing kidney progenitor cells with potential to differentiate into functional podocytes 
and may be a promising tool for regenerative medicine aiming kidney repair and a model 
for studying renal disease.
TH-OR043
Pluripotent, Non-Tumorigenic, Human Muse Cells Integrate into 
Glomerulus to Recover Function in a Chronic Kidney Disease Mouse Model 
Nao Uchida,1 Naonori Kumagai,1 Yoshiaki Kondo,2 Shigeo Kure.1  1Pediatrics, 
Tohoku Univ School of Medicine, Sendai, Miyagi, Japan; 2Healthcare Services 
Management, Nihon Univ School of Medicine, Tokyo, Japan.
Background: As availability of transplantable kidneys is limited, stem/progenitor cell 
therapy replenishing new glomerular cells may be helpful; several pluripotent stem cell types 
have been studied, including non-tumorigenic Muse cells, collectable from the bone marrow 
as stage-specific embryonic antigen (SSEA)-3(+) cells. Here the effect of intravenously 
injected human Muse cells on a chronic kidney disease (CKD) mice model was evaluated.
Methods: Muse SSEA-3(+) and non-Muse SSEA-3(-) cells were isolated from 
bone marrow-derived mesenchymal stem cells (MSCs) using fluorescence-activated 
cell sorter. CKD was induced by intravenously injecting doxorubicin into severe 
combined immunodeficient (SCID), Balb/c mice, mimicking human focal segmental 
glomerulosclerosis. A week later, 2 × 104 cells of Muse, or non-Muse cells, or sterile vehicle 
were infused via the tail vein.
Results: In vitro, Muse cells showed specific migration activity toward the serum from 
CKD mice. After three weeks of renal lineage induction, Muse cells expressed WT1, while 
no signals were detected in non-Muse cells. In CKD-SCID mice, intravenously injected 
Muse cells migrated and integrated into the glomerulus, replacing a certain number of 
glomerular cells by differentiating into WT1-, podocin-, megsin-, and CD31-positive cells. 
This led to functional recovery, particularly in creatinine clearance at 7 weeks. In CKD-
Balb/c mice, WT1(+)- and CD31(+)-Muse cells were recognized in the glomerulus at 5 
weeks without immunosuppressant, whereas majority of these were rejected by 7 weeks. 
Significant functional recovery was observed for urine protein, creatinine clearance, and 
plasma creatinine compared with the vehicle group at 5 weeks. Attenuated glomerular 
sclerosis, interstitial fibrosis, and podocyte loss was noted in both models.
Conclusions: Muse cells are unique from other pluripotent stem cells in their high 
integration rate into the damaged glomerulus simply by intravenous injection, non-
tumorigenicity, and differentiation in vivo into glomerular cells that mediate functional 
recovery.
Funding: Pharmaceutical Company Support - Clio inc., Government Support - Non-U.S.
TH-OR044
Patient-Derived Induced Pluripotent Stem Cell (iPSC) Modeling of 
Genetic Renal Disease (GRD)  Andrew John Mallett,1,3,4 Barbara Maier,1,2 
Pei Xuan Er,1,2 Minoru Takasato,1,2 Jane Sun,5 Ernst J. Wolvetang,5 Stephen I. 
Alexander,6 Cas Simons,1 Melissa H. Little.1,2,7  1Inst for Molecular Bioscience, 
The Univ of Queensland, Brisbane, Australia; 2Murdoch Children’s Research 
Inst, Melbourne, Australia; 3Kidney Health Service & Conjoint Kidney 
Research Laboratory, Royal Brisbane and Women’s Hospital, Australia; 
4School of Medicine, UQ, Australia; 5Australian Inst of Bioengineering and 
Nanotechnology, UQ, Australia; 6Dept of Nephrology, Children’s Hospital at 
Westmead, Australia.
Background: The reprogramming of somatic cells into iPSCs provides potential 
to model human diseases in vitro, as has been demonstrated in the cardiac and neuronal 
fields. Nephrology has not yet benefited from these advancements primarily due to lack of 
a robust kidney differentiation protocol.
Methods: We aimed to generate and characterize iPSCs from patients with different 
GRDs. Families with clinically diagnosed GRD were recruited from a Renal Genetics 
Clinic for concurrent research-based massively parallel sequencing (MPS) and iPSC 
generation. One affected and unaffected member of each family was recruited. To establish 
transgene-free iPSC lines, fibroblasts were isolated via skin biopsy and reprogrammed using 
non-integrating Sendai virus (21day protocol).
Results: 7 families (14 participants) were recruited with a variety of GRD diagnoses. 
Fibroblast culture was successful in 6 families. Established iPSC lines have typical hESC-
like morphology and express pluripotency markers after 4 (TRA1-60) and 15 passages 
(NANOG). Moreover, iPCS lines have cleared the Sendai virus vectors, as confirmed by 
RT PCR after only 7 passages. G-band analysis of 2 lines from each isolation confirmed that 
each of the derived lines had maintained the normal karyotype after reprogramming. Paired 
patient and control iPSC are being redifferentiated towards kidney employing an established 
protocol. Renal organoids will be analyzed using IF, FACS and transcriptional profiling.
Conclusions: Patient derived iPSC have been generated and renal redifferentiation 
commenced. We hope to uncover the biological consequences of novel genetic variants 
causing GRD as identified via MPS, thereby beginning to explain patient phenotypes and 
disease pathogenesis.
Funding: Private Foundation Support
TH-OR045
Multi-Segmented Nephron Organoids Derived from Human Pluripotent 
Stem Cells Model Kidney Development and Injury  Ryuji Morizane, Albert Q. 
Lam, Benjamin S. Freedman, Seiji Kishi, M. Todd Valerius, Joseph V. Bonventre. 
Medicine, Brigham and Women’s Hospital, Boston, MA.
Background: Kidney differentiation from human pluripotent stem cells (hPSCs) is 
limited by the inability to generate complete nephrons, which has inhibited efforts to model 
kidney development and disease. One important problem is the low efficiency of SIX2+ 
nephron progenitor cell (NPC) generation by published protocols. We hypothesized that 
more precise recapitulation of the stages of in vivo metanephric development with hPSCs 
would result in the generation of more pure populations of NPCs with the capacity to 
form nephrons.
Methods: We developed a chemically defined protocol to direct the differentiation of 
hPSCs into NPCs that form multi-segmented nephron structures in 2D and 3D organoids, 
mimicking the stages of in vivo nephrogenesis: late primitive streak (PS), posterior 
intermediate mesoderm (IM), SIX2+ metanephric mesenchyme (NPCs), renal vesicles 
(RVs), and nephrons. hPSC-derived nephron organoids were tested for the ability to model 
kidney development and injury.
Results: Efficient differentiation of hPSCs into late PS followed by WT1+HOXD11+ 
posterior IM enabled the induction of SIX2+SALL1+WT1+PAX2+ NPCs with ~90% 
efficiency within 9 days. Treatment with Wnt and FGF signals induced differentiation into 
PAX8+LHX1+ RVs, which spontaneously differentiated into multi-segmented nephron 
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structures containing podocytes (Nephrin+PODXL+WT1+, foot process formation shown 
by EM), proximal tubules (LTL+CDH6+AQP1+), loops of Henle (CDH1+THP+), and 
distal tubules (CDH1+BRN1+) in an organized, contiguous arrangement in both 2D and 
3D culture. Inhibition of Notch signaling during organoid formation resulted in specific 
defects in proximal tubules, indicating that nephron organoids model kidney development. 
Moreover, treatment with the nephrotoxins, gentamicin or cisplatin, induced KIM-1 
expression in LTL+ tubules in a dose dependent manner.
Conclusions: We developed a novel method to differentiate hPSCs into NPCs with 
~90% efficiency within 9 days of differentiation. NPCs formed organized, contiguous, 
multi-segmented nephron structures in 2D and 3D organoids, which could be used to model 
kidney development and injury.
Funding: NIDDK Support, Government Support - Non-U.S.
TH-OR046
A Developmentally Plastic Adult Mouse Kidney Cell Line Spontaneously 
Generates Multiple Adult Kidney Structures  Tomoko Obara.  Cell Biology, 
Univ of Oklahoma Health Sciences Center, Oklahoma City, OK.
Background: Diabetic nephropathy (DN) is the leading cause of end stage renal disease 
(ESRD) in the US. Although the precise causes are not well understood, DN is characterized 
by fibrosis within the glomeruli and tubular interstitium. Dialysis and kidney transplantation 
are currently the only successful therapies for ESRD. The renal transplantation approach 
suffers from donor shortages and complications of immune rejection. New therapies for 
renal replacement are needed. At this time the derivation of kidney lineage cells from either 
mouse or human induced pluripotent stem cells leads to limited nephron-like structures. 
To date, no one has been able to regenerate or model functional nephrons from normal 
or diseased kidneys.
Methods: In this study, we explored the utility of the absence of the epigenetic regulator 
ARID3a an adult mouse kidney cell line (KKPS5) for generating nephron structures in 
both in vitro and in vivo model systems.
Results: We discovered that KKPS5 acquires renal progenitor surface markers as 
an alternative cell source and further develop into multicellular nephron-like structures 
within a few days in 3-D matrigel. Moreover, when these cells are engrafted into 
immunocompromised medaka adult kidney they formed mouse nephron structures. We are 
unaware of the existence of other cell lines that exhibit this unique multipotent property.
Conclusions: These data implicate KKPS5 cells provide a unique advantage for 
exploring kidney development. Moreover, we predict our findings will be relevant for 
future therapeutic manipulations in kidney disease.
Funding: Private Foundation Support
TH-OR047
Decellularized Renal Extracellular Matrix Scaffolds Serve as 3D Biological 
Templates for Regeneration of Nephron Structures by Human Kidney 
Cells  Joseph S. Uzarski,1 Carol Ann Deaton,2 Heather Hilary Ward,2 Angela 
Wandinger-Ness,3 Jason Wertheim.1  1Dept of Surgery, Northwestern Univ 
Feinberg School of Medicine, Chicago, IL; 2Dept of Internal Medicine, Univ of 
New Mexico HSC, Albuquerque, NM; 3Dept of Pathology, Univ of New Mexico 
HSC, Albuquerque, NM.
Background: An alternative to current renal replacement therapy options aims to utilize 
renal tissues developed ex vivo using patient-derived cells for implantation to augment or 
replace failing kidneys. Our objective was to characterize the phenotypic effects of culturing 
particular populations of human nephron-derived cells within 3D decellularized renal 
extracellular matrix scaffolds (ECMs) as a step toward regenerating functional nephrons.
Methods: Rat kidneys were perfused antegrade with detergents to completely 
remove the autologous cells. The resultant renal ECMs were injected arterially with 
select populations of immortalized or primary human renal epithelial or progenitor cells 
(RPC) and cultured using specialized perfusion bioreactors. We compared proliferation, 
metabolism, gene expression, and morphological adaptation in cells derived from different 
nephron components.
Results: Epithelial cells infused into ECMs dispersed in periglomerular tubules. Distal 
tubule-derived RCTE cells formed patent, polarized E-cadherin+ tubular structures, and 
steadily proliferated over 1 week of perfusion culture. Proximal tubule-derived RPTE 
cells similarly distributed in the tubular space, with some cells found in glomeruli and 
Bowman’s capsules. Both epithelial lines showed downregulation of EMT markers S100A4 
and vimentin after culture within renal ECMs. After 7 days, kidney-specific-cadherin was 
upregulated in RPTE cells. Injury markers KIM-1 and CD24 were downregulated in RCTE 
cells alone. Cadaver-derived CD133/1+ RPC formed tubular structures within renal ECMs, 
and gradually decreased proteolytic KIM-1 shedding over 7 days.
Conclusions: We conclude that renal ECMs have inductive properties that may 
eventually be used in concert with exogenous biological or chemical stimuli to promote 
differentiation of stem or progenitor cells into mature, functional nephron-specific 
epithelial cells.
Funding: Private Foundation Support
TH-OR048
Systems Biology of Polycystic Kidney Disease Suggests It Is a Metabolic 
Disease  Luis F. Menezes, Fang Zhou, Gregory G. Germino.  NIDDK, National 
Insts of Health, Bethesda, MD.
Background: The major gene mutated in autosomal dominant polycystic kidney disease 
was identified over 20 years ago yet its function remains poorly understood. We have used 
a systems-based approach to examine the effects of acquired loss of Pkd1 in an orthologous 
mouse model of human ADPKD as the kidneys transition from normal to cystic state.
Methods: A total of 135 Pkd1cko;Tg(Cre/Esr1) mice animals in which Pkd1 knockout 
was induced by tamoxifen at P40 were harvested between P100 and P210 and kidney/body 
weight curves were fitted for males and females separately. Gene expression in 80 kidneys 
was analyzed with Illumina arrays, followed by differential gene expression and network 
analysis. Predictions were tested using: 1) metabolite and complex lipids profiling in 14 
male kidneys; 2) diet manipulations in 33 Pkd1cko;Tg(Cre/Esr1) mice induced at P7 and 
harvested at P21 and in 52 Pkd1cko; Tg(Cdh16-cre) mice harvested at P14.
Results: We found in the P40-induction model that females were significantly protected 
from cystic kidney disease but had more severe cystic liver disease. Furthermore, the 
transcriptional profiles of normal male and female kidneys differed almost as much as those 
of normal and cystic kidneys and the differentially expressed gene modules were enriched 
for genes involved in lipid metabolism. Gene ontology of the differentially expressed genes 
common to both sexes showed enrichment for metabolic pathways. Metabolic and lipid 
profiling confirmed differences in cystic kidneys. We also found that the P7- and P40-
induced mice share common transcriptional signatures, suggesting similar mechanisms of 
cyst initiation and growth. Finally, we showed that a modest change in the lipid composition 
of diet could significantly affect the progression of disease.
Conclusions: Gene expression and network analysis accompanied by global 
metabolites and complex lipid profiling suggested that metabolic status could be a major 
regulator of disease susceptibility. By manipulating the lipid content of mouse diets we 
corroborate this hypothesis and suggest that metabolic pathways are a major component 
of polycystic kidney disease, possibly underlying some of the sex effects.
Funding: NIDDK Support
TH-OR049
Smyd2 Synergistically Activates STAT3 and NF-κB and Represses p53 to 
Promote Cyst Growth  Xiaoyan Li, Lucy Fan, Xia Zhou, James P. Calvet, 
Xiaogang Li.  Kidney Inst, Univ of Kansas Medical Center, Kansas City, KS.
Background: Protein methylation has emerged as a post-translational modification that 
exerts key roles in defining protein functions, at the level of signaling mediators and at the 
level of epigenetic regulation of transcription, in polycystic kidney disease (PKD). Smyd2, 
as a SET-domain-containing histone (lysine) methyltransferase, methylates both histone and 
non-histone proteins, including PKD associated p53, Rb and HSP90. However, the roles 
and underlying mechanisms of Smyd2 in regulating cyst development remain unknown.
Methods: To understand the role of Smyd2 in cyst growth in vivo, we generated Pkd1 
and Smyd2 double conditional knockout mice (Pkd1flox/flox:Smyd2flox/flox:Ksp-Cre), and we 
treated Pkd1nl/nl mutant mice with the Smyd2 specific inhibitor, AZ505. To identify novel 
Smyd2 target genes involved in cystogenesis, we performed ChIP-seq analysis.
Results: We found that knockout of Smyd2 or inhibition of Smyd2 with AZ505 
delayed cyst growth as seen by decreased cystic index, kidney weight (KW)/body weight 
(BW) ratios, blood urea nitrogen (BUN) levels, cyst lining epithelial cell proliferation, 
and increased cyst lining epithelial cell apoptosis in Pkd1 mutant mice (all p < 0.01). We 
further found that Pkd1 and Smyd2 double knockout mice lived longer, to a mean age of 25 
days, while Pkd1 knockout mice died at a mean age of 17 days (p < 0.001). We found that 
STAT3 and the p65 subunit of NF-κB are novel non-histone substrates of Smyd2, which 
methylates and activates them leading to increased cystic epithelial cell proliferation and 
survival. Smyd2 also regulates cystic epithelial cell apoptosis by repressing p53 activity 
and expression. Further, we identified novel Smyd2 target genes, including the primary 
cilia associated Ahi1 (Abelson helper integration site 1) gene and HYDIN gene, by ChIP-
seq analysis, which may connect Smyd2 signaling to the ciliopathy hypothesis in PKD.
Conclusions: Smyd2 promotes renal cyst growth in ADPKD through STAT3 and 
NF-κB signaling as well as p53 and ciliopathy associated signaling. Targeting Smyd2 in 
cystic renal epithelial cells may be a viable new therapy for ADPKD.
Funding: NIDDK Support
TH-OR050
Novel Insights into Polycystin-1 Function from the Xenopus Pronephric 
Kidney  Oliver Wessely, Uyen Tran.  Cellular & Molecular Medicine, Cleveland 
Clinic, Cleveland, OH.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused by 
mutations in Polycystin-1 (PKD1) or Polycystin-2 (PKD2). PKD1 is a large transmembrane, 
mechanoreceptor-like protein that forms multiprotein complexes at focal adhesions, cell–cell 
junctions and cilia. It is thought to transmit a signal to PKD2, which in turn releases calcium. 
Studies in mouse and other model organisms have led to the prevailing hypothesis that 
Polycystin-1 and Polycystin-2 regulate a range of cellular pathways, which together ensure 
that renal epithelial tubules establish and maintain a correct diameter. While there has been 
significant progress over the years, the molecular mechanism of PKD1 action is still obscure.
Methods: To address the function of PKD1 we used the Xenopus pronephros as a 
model for PKD. We knocked down Pkd1 expression using antisense morpholino oligomers 
and characterized the kidney by morphology, histology, immunofluorescence and in 
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situ hybridization. To identify functional domains we subsequently re-expressed Pkd1 
and fragments, thereof. Finally, we performed molecular analysis and binding assays to 
understand the underlying mechanism.
Results: Xenopus embryos lacking Pkd1 develop a PKD phenotype characterized by 
the formation of fluid-filled edema, dilated tubules, randomization of the mitotic spindle 
angle and increased DNA instability. This phenotype could be restored by re-expression of 
the intracellular domain of Pkd1. Moreover, structure-function analysis demonstrate that the 
G-protein binding domain is critically important for this activity. Based on this result, we 
performed binding studies with all the G-protein alpha subunits and demonstrated that Pkd1 
recruits a very select subset of G-protein alpha subunits. The importance of this interaction 
was then subsequently validated by epistasis experiments in Xenopus.
Conclusions: Together, the data support the hypothesis that the intracellular domain 
of PKD1 recruits G-proteins and that this interaction is critical for its function.
Funding: NIDDK Support
TH-OR051
A Forward Genetic Screen Identifies a Calcium-Regulated Mitochondrial 
Metabolite Carrier as a Downstream Target of Polycystin-2  Alexis Hofherr,1 
Claudia Seger,1 Terry J. Watnick,2 Michael Kottgen.1  1Dept of Medicine, Univ 
Medical Center Freiburg, Germany; 2Univ of Maryland.
Background: Polycystin-2 (aka TRPP2) is a cation channel that localizes to primary 
cilia and regulates developmental programs ranging from tubular morphogenesis to 
establishment of left-right (LR) asymmetry. Loss of TRPP2 results in polycystic kidney 
disease and randomized LR asymmetry. TRPP2-mediated calcium signals are thought to 
regulate morphogenesis. But the molecular events translating these calcium signals into 
morphogenetic programs are unknown.
Methods: To identify evolutionarily conserved core constituents of the TRPP2 signaling 
pathway, we conducted an unbiased forward genetic screen in D. melanogaster for mutants 
that phenocopy the TRPP2 loss of function phenotype. To test the conservation of newly 
identified genes in vertebrates, the function of candidate genes was investigated in zebrafish. 
The molecular function of genes was studied in mIMCD3 cells using TALEN-mediated 
gene deletion in combination with metabolomics.
Results: We identified a calcium-dependent mitochondrial metabolite carrier (MC) 
as a downstream target of TRPP2 in a large-scale mutagenesis screen for mutants that 
phenocopy loss of TRPP2 in D. melanogaster. Calcium regulation of this MC appears 
to be critical, since loss of MC in flies was rescued by wt MC, but not by MC with EF-
hand mutations, which abolish calcium binding. In zebrafish, TRPP2 is essential for the 
establishment of LR asymmetry. We show that MC is also required for the determination 
of LR asymmetry in zebrafish. Rescue experiments in flies and zebrafish suggest that 
MC acts downstream of TRPP2, which is consistent with the calcium-dependence of this 
carrier. To investigate the molecular function of MC and TRPP2, we deleted the genes in 
mIMCD3 cells. Metabolomic analyses showed that TRPP2- and MC-deficient cells display 
impaired mitochondrial metabolism and concordant changes of several metabolites which 
may contribute to morphogenetic signaling processes.
Conclusions: We show that a calcium-dependent mitochondrial metabolite carrier acts 
in a conserved pathway linking TRPP2-mediated ciliary calcium signals to mitochondrial 
metabolism in vivo.
Funding: NIDDK Support, Government Support - Non-U.S.
TH-OR052
Modeling Polycystic Kidney Disease Cystogenesis with Genome-Modified 
Human Pluripotent Stem Cells  Benjamin S. Freedman,1,2,3,5 Theodore I. 
Steinman,1,2,4,5 Jing Zhou,1,2,4,5 Joseph V. Bonventre.1,2,4,5  1Brigham and Women’s 
Hospital; 2Harvard Medical School; 3Univ of Washington School of Medicine; 
4Beth Israel Deaconess Medical Center; 5Harvard PKD Center.
Background: Human pluripotent stem cells (hPSCs) can self-renew extensively and 
differentiate into diverse tissues, including tubules expressing kidney markers. To date, 
however, no study has demonstrated a phenotype in these tubules relevant to kidney disease. 
Using the CRISPR/Cas9 genome editing system, we tested the ability of hPSC-derived 
kidney cells to model features of polycystic kidney disease (PKD) cystogenesis.
Methods: Cas9 nuclease and guide RNAs targeting PKD1 or PKD2 were transfected 
into hPSCs. Chromatogram analysis and immunoblotting indicated biallelic, frame-shift 
mutations at target sites and the absence of the corresponding full-length proteins. hPSCs 
were treated with specific growth factors to direct stepwise differentiation into kidney 
progenitor cells (SIX2+PAX2+) and subsequently proximal tubules (LTL+LRP2+). PKD 
hPSCs and derived tubules were inspected for cystogenesis phenotypes, compared to 
unmodified control cultures of otherwise identical genetic background.
Results: PKD hPSCs exhibited self-renewal and pluripotency characteristics 
comparable to isogenic controls, and differentiated into tubular organoids with similar 
efficiencies. Interestingly, in PKD hPSC cultures, we observed formation of large, 
translucent, cyst-like structures alongside tubules. Cyst-lining epithelia reacted strongly 
with LTL and surrounded hollow interior compartments devoid of cells. Time-lapse 
imaging revealed that cysts arose from a small minority of differentiating tubular structures. 
Importantly, isogenic control hPSCs, plated and differentiated in an identical manner to 
the PKD hPSCs, did not form cysts.
Conclusions: Our findings suggest that PKD-specific cyst formation from tubules can 
be reproducibly modeled in a minimal system in vitro. Cysts arise from both PKD1-/- or 
PKD2-/- hPSCs, but not from parental hPSCs of otherwise identical genetic background. 
Genome-modified hPSCs represent a new, human model in which to investigate PKD 
pathophysiology, with potential for ‘clinical trials in a dish’ to evaluate candidate 
therapeutics.
Funding: NIDDK Support, Private Foundation Support
TH-OR053
Inactivation of Ift88 Gene Rescues the Phenotype in a Genetic Model 
of Autosomal Dominant Polycystic Kidney Disease  Jing Zhou,1 Wassim 
El-jouni,1 Xiaogang Shen,1,2 Maoqing Wu,1 Ivan Barrera,1 Azadeh Tabari,1 
Nadeem Haque,1 Ilyas Yambayev.1  1Renal Div, Harvard Center for Polycystic 
Kidney Disease Research, Renal Devision, Brigham and Women’s Hospital and 
Harvard Medical School, Boston, MA; 2Nephrology Div, Zhejiang Provincial 
People’s Hospital, Hangzhou, Zhejiang Province, China.
Background: Mutations in PKD1 and PKD2 genes are responsible for autosomal 
dominant polycystic kidney disease, the most common life threatening genetic disease in 
humans. The gene products polycystin-1 (PC1) and -2 (PC2) are localized to the primary 
cilia and function as a receptor channel complex on the primary cilia.
Methods: To create an animal model for ADPKD, we deleted an exon encoding part 
of the pore region of PC2 in mice using the Cre-loxP system. To test the ciliary function 
of polycystins, we genetically disrupted cilia in mice with a mutation in Pkd2 by creating 
Ift88 and Pkd2 double knockout mice. Mice were induced at post-developmental stages 
and renal phenotypes were analyzed by histology. Western analyses and immunostaining 
methods were performed to evaluate protein levels and expression patterns.
Results: A protective effect in cystic lesions was observed in kidneys from Pkd2.Ift88 
double knockout mice when compared with Pkd2 single knockouts. Disruption of PC2 was 
validated in both Pkd2 single knockouts and Pkd2.Ift88 double knockout mice. To examine if 
there is ciliogenesis defects due to the inactivation of PC2 and Ift88, we examine the length 
of cilia in kidneys from both Pkd2 single knockout and Pkd2 and Ift88 double knockout 
mice. An increase in cilium length was detected in Pkd2 knockout mice, compared with 
wild type mice. A significant reduction of the number and length of cilia were found in 
Ift88 and Pkd2 double knockout mice. Ift88 knockout in the double knockout mice was also 
confirmed by western blot analyses. Comparative analyses of signaling events in both single 
and double knockout mice suggest the mammalian target of rapamycin (mTOR) pathway 
is activated in the early stage of cyst formation of Pkd2 single knockouts and its aberrant 
activation is rescued in Pkd2 knockout mice with Ift88 inactivation.
Conclusions:  Inactivation of IFT88 rescues the polycystic phenotype in a genetic 
mouse model of ADPKD. mTOR signal pathway, a cilium-mediated pathway, appears 
to be involved.
Funding: NIDDK Support
TH-OR054
Other Signaling Pathways Rapidly Compensate for Loss of mTORC1 in 
Driving Cystic Kidney Disease  Florian Grahammer,1 Gerd Walz,1,2 Tobias 
B. Huber.1,2,3  1Renal Div, Univ Medical Center Freiburg, Freiburg, Germany; 
2BIOSS Center for Biological Signalling Studies, Albert-Ludwigs Univ Freiburg, 
Freiburg, Germany; 3Center for Systems Biology (ZBSA), Albert-Ludwigs Univ 
Freiburg, Freiburg, Germany.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading 
monogenetic cause of end-stage renal disease. In both mice and humans, cystic kidney 
disease is consistently linked to an activation of the mTORC1 pathway. Yet, the utility of 
mTORC1 inhibitors to treat patients with ADPKD remains controversial despite promising 
preclinical data.
Methods: To conclusively define the cell-intrinsic role of mTORC1 for cyst 
development, the essential mTORC1 scaffolding protein Raptor was selectively inactivated 
in renal tubular cells lacking cilia due to deletion of Kif3A.
Results: In comparison to a rapid onset of cyst formation and renal failure in mice 
with defective ciliogenesis alone, both renal function and overall survival were strikingly 
improved in mice additionally lacking Raptor. However, eventually these mice succumbed 
to cystic kidney disease despite mTORC1 inactivation. In-depth transcriptome analysis 
showed a rapid activation of other growth-promoting pathways, overriding the effects of 
mTORC1 deletion.
Conclusions: Our findings indicate that cystic kidney disease can adopt bypass 
mechanisms frequently observed in drug-resistant cancers. Thus future clinical trials will 
need to consider combinatorial or sequential therapies to improve efficacy in patients with 
cystic kidney disease.
Funding: Government Support - Non-U.S.
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TH-OR055
ANKS3 Mutation in Nephronophtisis Patients Leads to Cilia and 
Cytoskeleton Defects In Vitro and In Vivo in Zebrafish  Gweltas Odye,1 
Marion H. Delous,1 Valentina Grampa,1 Line De grande,1 Anita Becker-heck,2 
Emilie Filhol,1 Pauline Krug,3 Flora Silbermann,1 Bertrand Knebelmann,3 
Andreas W. Sailer,2 Pierre Saint-mezard,2 Alexandre Benmerah,1 Sophie 
Saunier.1  1Inserm U1163, Imagine Inst, Paris Descartes Univ, France; 2Novartis 
Inst for Biomedical Research, Switzerland; 3APHP Necker Hospital, France.
Background: Nephronophthisis (NPH) is an heterogeneous autosomal recessive renal 
ciliopathy that represents the major hereditary cause of end stage renal disease in children. 
Causative genes encode NPHP proteins which localize at the primary cilium and in some 
cases at cell-cell junctions. Among these genes, ANKS6 is known for its implication in 
kidney development and mutations contribute to NPHP phenotype in humans.
Results: Using NGS, we identified a homozygous mutation (c.806 C>T, p.P269L) in 
ANKS3, in three siblings affected by late onset NPH with hepatic fibrosis. ANKS3 encodes 
a SAM domain and Ankyrin repeat containing protein which interacts with ANKS6, NEK8 
and NPHP3, three NPHP proteins located at the Inversin ‘Invs’ compartment (proximal 
part of the cilium) that controls essential ciliary signaling pathways during development 
and tissue homeostasis (Wnt/PCP). Surprisingly, ANKS3 did not localize at the Invs 
compartment but in apical cytoplasmic aggregates in tubular renal cells or at the basal body 
in fibroblasts. We provide evidence that the p.P269L mutation led to cilia length defects in 
patient’s fibroblasts and Anks3 knockdown IMCD3 cells, associated with disorganization 
of the Invs compartment. Moreover, it affects the interaction of ANKS3 with NPHP1 and 
led to defects in tight-junction and lumen formation in 3D culture, reminiscent of NPHP1 
knockdown. We next generated an ANKS3 zebrafish mutant (TALEN) that exhibits laterality 
defects and lethality by 2-3 weeks. Analyses within the Kupffer’s vesicle revealed normal 
number and length of cilia but motility defects likely explaining the laterality phenotype 
observed in mutant fish.
Conclusions: Altogether, these results indicate that ANKS3 plays a dual function, 
in controlling the composition of the Invs compartment and in epithelial morphogenesis, 
supporting the causative effect of the mutation in the NPH patients.
Funding: Pharmaceutical Company Support - Novartis
TH-OR056
SDCCAG8 Regulates Ciliogenesis by Mediating Endosomal Vesicle Docking 
to the Basal Body  Merlin Airik,1 Rannar Airik,1 Jang W. Cho,1 Markus 
Schueler,1 Friedhelm Hildebrandt.1,2  1Div of Nephrology, Boston Children’s 
Hospital, Boston, MA; 2Howard Hughes Medical Inst, Chevy Chase, MD.
Background: Mutations in SDCCAG8 gene cause a retinal-renal ciliopathy with 
BBS-like features in affected humans (1). Our previous characterization of the orthologous 
Sdccag8-mouse model recapitulated the retinal-renal degeneration phenotypes and identified 
impaired DNA damage response signaling as an underlying disease mechanism in the kidney 
(2). However, several other phenotypic features of Sdccag8gt/gt mice remained unexplored. 
Here we have extended our studies of SDCCAG8 function.
Methods: Immunofluorescence analysis was performed on mouse embryo cryosections 
and hTERT-RPE cell line. To identify SDCCAG8 interacting proteins at the centrosome we 
employed a proteomic strategy using stable isotope labeling with amino acids in cell culture 
(SILAC). Co-immunoprecipitation assay was performed in HEK293 cells.
Results: Sdccag8gt/gt mice have defective neural tube patterning and structural 
abnormalities of the skeleton, suggesting impaired Hedgehog (Hh) signaling. In cell culture 
studies we show that loss of Sdccag8 affects ciliogenesis and interferes with Hh signaling. 
Using SILAC-assay combined with co-immunoprecipitation and immunofluorescence 
studies we demonstrate that SDCCAG8 interacts with centriolar satellite (OFD1, AZI1), 
endosomal sorting complex proteins (RABEP2, ERC1) and non-muscle myosin motors 
(MYH9, MYH10, MYH14).
Conclusions: SDCCAG8 function is required for ciliogenesis and Hedhehog signaling. 
Our study identifies several novel components of the basal body, that interact with 
SDCCAG8. Together, our analysis suggests that SDCCAG8 function at the basal body is 
required for coupling endosomal vesicles and molecular motors to facilitate ciliogenesis.
Funding: NIDDK Support, Private Foundation Support
TH-OR057
Characterization of Cystic Kidneys in Mice Deficient in the Polarity Proteins 
DLG1 and CASK  Steven Daniel Funk, Jinzhi Wang, Moe Mahjoub, Jeffrey 
H. Miner.  Renal Div, Washington Univ School of Medicine, St. Louis, MO.
Background: Polycystic kidney disease involves dysregulation of tubular proliferation 
and cellular polarity leading to cystogenesis. Deletion of various apico-basal and planar 
cell polarity (PCP) proteins in mice, including members of the membrane-associated 
guanylate kinase (MAGUK) family, is sufficient for cytogenesis. DLG1-deficient mice 
exhibit PCP defects but only occasional unilateral renal agenesis or hypoplasia. Co-deletion 
or hypomorphic expression of DLG1 and CASK in nephron progenitors (via Six2Cre) 
induces hypoplasia and cystogenesis, respectively. This work aimed to characterize the 
cystic phenotype in DLG1+/-; CASK-/- mice.
Methods: DLG1+/-; CASK-/- kidneys were analyzed histologically by 
immunohistochemistry, western blotting, and qRT-PCR at various ages. Additionally, for 
mechanistic insight we employed a model of cystogenesis in which cell-permeant cAMP 
(8-Br-cAMP) drives tubular dilation in cultured embryonic kidneys through luminal fluid 
flux.
Results: DLG1+/-; CASK-/- mice exhibit cysts as early as 90 days with severe but 
variable pathology by 9 months. Analysis of DLG1+/-; CASK-/- tubule segments indicates 
proximal tubule origin of cysts and dysregulation of matrix proteins, but with preservation 
of apico-basal polarity. Ciliary length was up to 2-fold longer in the majority of DLG1+/-; 
CASK-/- tubules, but was longer only in dilated DLG1-/-; CASK-/- tubules. Curiously, 
whereas 8-Br-cAMP induced dilations in wild-type embryonic renal tubules, DLG1+/- or 
-/-; CASK-/- embryonic kidneys did not exhibit tubular dilations.
Conclusions: Our data indicate that DLG1 and CASK co-regulate renal development 
as well as homeostasis of renal epithelium independently of apico-basal polarity. IHC 
analysis revealed molecular features consistent with PKD phenotypes, with an unusual 
elongation of cilia. A cAMP-stimulated model of cystogenesis revealed a failure in PKA-
dependent tubular dilations in DLG1+/- or -/-; CASK-/- embryonic kidneys. Coupled with 
cilia elongation and PKA effects on ciliary function, these results indicate a previously 
unrecognized regulation of PKA by MAGUK family members in the kidney.
Funding: NIDDK Support
TH-OR058
Serum Leptin, Pre-Existing Vascular Disease, and Arteriovenous Fistula 
Maturation Failure  Jwa-kyung Kim,1 Sun Ryoung Choi,2 Mi jin Park,3 Sung 
gyun Kim.1  1Internal Medicine, Hallym Univ Sacred Heart Hospital, Kidney 
Research Inst, Anyang, Republic of Korea; 2Internal Medicine, Shamyook 
Medical Center, Seoul, Republic of Korea; 3Clinical immunology, Hallym Univ 
Sacred Heart Hospital, Anyang, Republic of Korea.
Background: Pre-existing vascular diseases is one of the important causes of 
maturation failure of arteriovenous fistula (AVF). Recently, a growing proportion of 
incident dialysis patients are obese, and leptin is regarded as a pivotal mediator between 
obesity and cardiovascular disease. This study evaluated the association between serum 
leptin and pre-existing vascular disease and AVF maturation failure in patients with end-
stage renal disease (ESRD).
Methods: Vein samples from 62 patients were collected at the time of AVF creation near 
the site of AV anastomosis. Histological (hematoxylin and eosin, and trichrome staining), 
immunohistochemical and morphometric (smooth muscle actinin [SMA], vimentin and 
desmin) studies were performed. AVF maturation failure was defined as an AVF not 
possible to use successfully for hemodialysis by the third month after its creation despite 
radiological or surgical interventions.
Results: Mean age was 63.3 ± 13.7 years and the prevalence of obesity (BMI ³25 kg/
m2) was 49.1%. Mean serum leptin levels were 2.10 ± 1.41 pg/mL (log transformed), and 
patients in the highest leptin tertile had significantly increased BMI, higher triglyceride, 
interleukin-6, and hs-CRP levels (P<001). AVF maturation failure occurred in 21 (35.6%) 
patients, and the failure rate progressively increased from the lowest to the highest leptin 
tertile (p<0.001). On histological examinations, increased leptin tertiles were closely 
associated with intimal hyperplasia (13.3±4.5 vs. 18.2±5.2 vs. 30.3±14.3 mm in each 
tertile) as well as medial fibrosis. In addition, the majority of cells within the neointima 
were positive for SMA and vimentin and negative for desmin, suggesting a myofibroblast 
phenotype. Interestingly, a number of vascular sections in lowest leptin tertile also had 
desmin-positive contractile smooth muscle cells.
Conclusions: Obesity related fistula maturation failure may be mediated by higher 
serum leptin level - associated preexisting vascular diseases in ESRD patients.
TH-OR059
Time-Dependent Endothelial Dysfunction following Arteriovenous Fistula 
Creation  Timmy C. Lee, Jennifer S. Pollock.  Univ of Alabama at Birmingham.
Background: Vascular endothelial function plays a critical role in arteriovenous 
fistula (AVF) remodeling and neointimal hyperplasia development. The goal of our study 
was to characterize the natural history of endothelial dysfunction following AVF creation.
Methods: AVFs were created using an end to side anastomosis between the femoral 
vein and artery in 12-16 week old Sprague-Dawley rats. Contralateral vessels served as 
controls. Rats were sacrificed at 1, 7, 14, and 21 days after AVF creation and vein and artery 
collected for morphometric analysis. Segments from the arterial anastomosis were isolated 
at these time points and mounted on wire myographs to assess endothelial-dependent and 
-independent function by concentration-response curves to acetylcholine (Ach) and sodium 
nitroprusside (SNP), respectively.
Results: Maximal relaxation to Ach was significantly decreased at 7 days compared 
to the contralateral control (29±12% vs 110±15%; p=0.006) (figure 1), but endothelial-
dependent function was fully restored by 21 days (94±2% vs 93±2%; p=0.598). 
Endothelial-independent response to SNP was similar to the contralateral control 
artery at 1, 7, and 14 day time points, suggesting an adequate smooth muscle cell response 
necessary for vasodilation. However, at 21 days vascular relaxation to SNP was impaired 
compared to control (84±6% vs 99±2%; p=0.047), suggesting smooth muscle dysfunction. 
Our morphometric analysis showed that the greatest change in amount of arterial and venous 
intimal hyperplasia occurs in the 1st 7 days following AVF creation.
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Conclusions: Creation of AVF results in a time-dependent endothelial dysfunction 
worse 7 days after creation. Therapies targeted at restoring endothelial function via 
increasing nitric oxide production shortly after AVF creation may help improve AVF 
remodeling and inhibit neointimal hyperplasia. Late changes in endothelial-independent 
vascular function following AVF creation needs further evaluation.
Funding: NIDDK Support, Private Foundation Support
TH-OR060
Is Preoperative Vein Morphology Associated to Vascular Access Outcome? 
Maria Guedes Marques,1 Raquel Pina,1 Joaquim Ferreira,1 Pedro Maia,1 Teresa 
Mendes,1 Emanuel Ferreira,1 Helena Pinto,1 Nuno Oliveira,1 Ana Belmira,1 
Luís Freitas,2 Armando Carreira,1 Mário Campos.2  1CHUC - Hospital Geral; 
2CHUC - HUC.
Background: Vascular access (VA) stenosis is histologically characterized as 
neointimal hyperplasia (NH).Smooth muscle cells initially proliferate in media, and migrate 
to the intima where endothelial cell proliferation and angiogenesis occur. Venous NH has 
been primarily associated with hemodynamic stress, surgical injury, grafts and cannulation. 
According to recent data, uremia is likely to exacerbate endothelial dysfunction and 
predispose to NH before VA creation. Primary end point was to evaluate preoperative vein 
morphology and how it would affect VA outcome. Secondary end points were to found if 
other demographic and clinical factors could also have any impact.
Methods: Transversal observational study performed in 26 patients with end-stage-
renal-disease. Venous specimens obtained during VA creation were evaluated for intimal 
inflammatory infiltrate/angiogenesis, media abnormalities and intima/global wall thickness. 
Postoperative clinical function and demographic parameters recorded.
Results: The majority of patients were male (84.6%); age 71.4±15.1y; 57.7% diabetic; 
50.0% had central venous catheter at surgery time; maturation occurred in 53.8%. Intimal 
angiogenesis and media abnormality were both seen in 66.7% of patients in which VA 
didn’t maturate, but only in 14.3% and 21.4% of the ones that maturated, respectively. 
Chi-square analysis showed that both previous findings were significantly associated with 
VA failure (p 0.006 and p 0.020). Intimal and global wall thicknesses were 0.0607±0.0715 
and 0.7000±0.2228mm in maturated VA; 0.2600±0.2442 and 1.0318±0.3227mm in 
nonmaturated VA, respectively (p 0.006 and p 0.005). Gender, age, diabetic status and 
catheter presence didn’t affect VA function.
Conclusions: Preexisting venous thickness, intimal angiogenesis and media 
abnormalities predispose to postoperative VA nonmaturation. It is possible that uremia 
and other pre-dialysis factors may contribute to preexisting venous abnormalities which, 
independently of the future hemodynamic stress, predispose patients to more aggressive 
NH after VA creation, contributing to inferior outcomes.
TH-OR061
The Effect of Far Infrared Therapy on the Maturation of Newly Created 
Arteriovenous Fistula and the Parameters of Inflammation, Endothelial 
Function and Oxidative Stress in Patients with Advanced Chronic Kidney 
Disease  Chih-Ching Lin.  Div of Nephrology, Dept of Medicine, Taipei Veterans 
General Hospital, Taipei, Taiwan.
Background: We had demonstrated that far infrared (FIR) therapy could improve 
the access flow and unassisted patency of arteriovenous fistula (AVF) in prevalent HD 
patients; however, the effect of FIR on the endothelial function as well as the markers of 
inflammation and oxidative stress of the newly created AVF is unknown.
Methods: We enrolled patients with advanced chronic kidney disease (CKD) by the 
definition of eGFR <20 ml/min/1.73m2. Patients were randomly and equally allocated to 
FIR group (receiving FIR therapy for 40 minutes thrice weekly for 3 months) and control 
group (without FIR therapy). This study is aimed to evaluate (1) the effect of newly-created 
AV access on the markers of inflammation (hsCRP), endothelial function [asymmetric 
dimethyl arginine (ADMA) and L-arginine], and oxidative stress [serum malondialdehyde 
(MDA), serum advanced oxidation protein products (AOPPs), blood glutathione (GSH), 
erythrocyte glutathione peroxidase (GPx), and erythrocyte superoxide dismutase (SOD) 
activities], (2) the effect of FIR on access flow and the levels of the above-mentioned 
inflammatory, endothelial and oxidative stress markers in patients with advanced CKD in 
the first 3 months after the creation of AVF.
Results: Totally, 122 advanced CKD patients finished this study with 60 in FIR group 
and 62 in control group. In comparison with control patients, the patients in FIR group 
had lower mean values of incremental change of the plasma concentrations of hs-CRP ( 
-0.68±0.93 vs. 0.39±0.46 mg/L, P=0.04) and ADMA (-0.10±0.05 vs. 0.02±0.05, P=0.02) 
but a higher incremental change of blood glutathione (2.45±2.23 vs. -0.44±0.67, P=0.031) 
and access flow of AVF from 1st to 3rd month.
Conclusions: In patients with advanced stages of CKD, AVF malfunction is associated 
with a higher level of plasma hs-CRP, ADMA and a lower level of blood glutathione at 
baseline, which could be improved by FIR therapy. Henceforth, FIR therapy improves 
blood flow and the maturation of AVF possibly through the mechanism of correcting 
inflammation, endothelial dysfunction and oxidative stress.
Funding: Government Support - Non-U.S.
TH-OR062
Use of Arteriovenous Fistula/Graft Access for Continuous Renal 
Replacement Therapy: A Single Center Experience  Anas Al Rifai, Nidhi 
Sukul, Michael Heung.  Internal Medicine-Nephrology, Univ of Michigan, 
Ann Arbor, MI.
Background: Use of arteriovenous fistula or graft (AVF/AVG) access is widely 
considered to be contraindicated for continuous renal replacement therapy (CRRT), yet 
insertion of hemodialysis (HD) catheters can carry high risk of complications in critically 
ill endstage renal disease (ESRD) patients. Here we report our single-center experience 
with using AVF/AVG access for CRRT.
Methods: Retrospective review of 43 consecutive hospitalized ESRD patients on 
maintenance HD who received CRRT in 2012. After exclusions (16 catheter-dependent at 
admission, 4 with AVF/AVG thrombosis before CRRT start), our cohort consisted of 23 
patients. Data collection included patient and treatment characteristics, and access outcomes.
Results: Mean+SD age was 57±15 yrs, 48% were male, and median HD duration was 
54 months (range 8-300); 14 (61%) patients had AVF and 9 (39%) had AVG. Most (83%) 
patients required vasopressor support at CRRT start. Mental status at CRRT initiation showed 
35% to be oriented and following commands, 9% awake but confused, and 56% sedated. 
Median duration of AVF/AVG use for CRRT was 4 days (range 2-34). Complications 
related to use of the AVF/AVG for CRRT (with subsequent requirement of HD catheter 
placement) developed in 3 patients (13%): hematoma in 2 patients with AVF and thrombosis 
of AVG in 1 patient. All 3 patients with complications had documented pre-existing access 
problems; 1 had known subclavian vein stenosis and 2 required access intervention within 
the previous 1 year. Of these three patients, 1 was awake and confused while the other 2 
were sedated. Among them, 1 required blood product transfusion for line insertion and 1 
developed a catheter-associated bloodstream infection. Of the cohort, 16 (70%) patients 
survived to hospital discharge; among the survivors, AVF/AVG access was functional at 
the time of discharge in 15 (94%) patients.
Conclusions: Our experience suggests that use of AVF/AVG for CRRT is feasible 
with a relatively low complication rate and low risk of access failure. This approach may 
aid in avoiding the potential complications associated with HD catheter insertion in ESRD 
patients with a functioning vascular access.
TH-OR063
Improvements in Time to Fistula Use in Incident Hemodialysis Patients in 
the Rapid Response Pilot Program  Karen G. Butler, John W. Larkin, Deborah 
J. Brouwer-Maier, Sandra Bodin, Michelle L. Gilliland, Michele Inglese, Lillian 
A. Pryor, Len A. Usvyat, Dugan Maddux, Franklin W. Maddux.  Clinical 
Innovation Initiatives, Fresenius Medical Care North America (FMCNA), 
Waltham, MA.
Background: It is known that use of a catheter hemodialysis (HD) access is associated 
with increased morbidity and mortality, as compared to arteriovenous fistulas (AVFs) and 
grafts (AVGs). FMCNA has initiated the Rapid Response (RR) pilot program in an attempt 
to improve time to use of AVF accesses in incident HD (iHD) patients who initiated dialysis 
with a catheter. The aim of this study was to determine if the RR program is associated 
with improvements in AVF access use in iHD patients.
Methods: In September 2014, 59 clinics initiated the RR pilot program. Clinics 
were selected by high census (>95 patients) and high catheter rates (>30%). The program 
consisted of sequential, educational modules designed to build awareness of catheter 
exposure, engage staff in standardized and simplified vascular access monitoring, and 
address lack of AVF maturation as a root cause of high catheter rates. All patients initiating 
dialysis with a catheter access were followed. Non-RR clinics in the same geographical 
location were randomly identified for controls. To determine the change in time to AVF 
use, the mean time to AVF use over 12 months at the end of each month from June 2014 
to March 2015 was calculated.
Results: 5,248 and 4,159 iHD patients starting dialysis with a catheter at RR and 
non-RR clinics were included in this analysis. The mean time to AVF use was reduced in 
RR clinics after initiation of the program in September of 2014, as compared to control 
clinics (p<0.05). 
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Conclusions: This study demonstrates improvements associated with time to AVF 
use in incident patients initiating HD with a catheter access at clinics participating in the 
RR program.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
TH-OR064
Impact of Poverty and Health Care Insurance on Arteriovenous Fistula Use 
Among Incident Hemodialysis Patients  Deepti S. Moon,1 Rahul M. Jindal,2 
Frank P. Hurst,2 Christina M. Yuan,1 Lawrence Agodoa,3 Kevin C. Abbott,1 
Robert Nee.1  1Nephrology, Walter Reed National Military Medical Center, 
Bethesda, MD; 2Uniformed Services Univ of the Health Sciences, Bethesda, 
MD; 3NIDDK, National Insts of Health, Bethesda, MD.
Background: We assessed the association of area and individual-level indicators of 
poverty and types of health care insurance on arteriovenous fistula (AVF) use among incident 
end stage renal disease (ESRD) patients initiated on hemodialysis (HD).
Methods: In this retrospective cohort study using the United States Renal Data System 
database, we identified 669,206 patients initiated on maintenance HD from January 1, 
2007 through December 31, 2012. We assessed the Medicare-Medicaid dual eligibility 
status as an indicator of individual-level poverty and ZIP code-level median household 
income (MHI) data obtained from the 2010 United States Census. We conducted logistic 
regression of AVF use at start of dialysis as the outcome variable, as reported on the 
Medical Evidence Form 2728.
Results: The proportions of dual-eligible and non-dual eligible patients who initiated 
HD with an AVF were 12.53% and 16.17%, respectively (p<0.001). Dual-eligibility was 
associated with significantly lower likelihood of AVF use upon initiation of HD (adjusted 
odds ratio [aOR] 0.91; 95% confidence interval [CI] 0.90-0.93). Patients in the lowest 
area-level MHI quintile had an aOR 0.97 (95% CI 0.95-0.99) compared to those in higher 
quintile levels. However, dual eligibility and area-level MHI were not significant in patients 
with Veterans Affairs (VA) coverage.
Conclusions: Individual and area level measures of poverty were independently 
associated with lower likelihood of AVF use at the start of HD, the only exception being 
patients with VA healthcare benefits. Efforts to improve incident AVF use may require 
focusing on pre-ESRD care to be successful. [Disclaimer: The views expressed in this paper 
are those of the authors and do not reflect the official policy of the Department of the Army, 
the Department of the Navy, the Department of Defense, or the United States government].
Funding: Other U.S. Government Support
TH-OR065
A Subset of CD64+ F4/80high CD11bint CD11cint Macrophages Protects against 
Chronic Ischemic Kidney Injury  Amrutesh Puranik,1 Sonu Kashyap,3 Mark 
A. Jensen,4 Bruce Knudsen,3 John R. Woollard,2 Tyra Witt,7 Stephen C. Textor,2 
Jeremy Stuart Duffield,5 Joseph P. Grande,3 Rob Simari,6 Lilach O. Lerman.2 
1Dept of Anesthesiology, Mayo Clinic, Rochester, MN; 2Div of Nephrology & 
Hypertension, Mayo Clinic, Rochester, MN; 3Laboratory Medicine & Pathology, 
Mayo Clinic, Rochester, MN; 4Dept of Rheumatology, Mayo Clinic, Rochester, 
MN; 5Biogen, Cambridge, MA; 6Univ of Kansas, Kansas City, KS; 7Cardiac 
Regeneration Program, Mayo Clinic, Rochester, MN.
Background: Macrophages (Mfs) have been implicated in both progression and 
resolution of renal injury. We tested the hypothesis that a specific Mfs subtype regulates 
fibrosis in chronic murine ischemic renal artery stenosis (RAS).
Methods: After 28 days of unilateral RAS in mice, stenotic kidneys were harvested 
and 3 Mfs populations (Figure 1), black circles) quantified using polychromatic flow 
cytometry by expression of the CD11b, CD11c, F4/80, MHCII, CD64, MerTK, Ly6c & 
CD206. Mouse macrophages were ablated using I.P injections of liposomal clodronate (2/
week for 28 days), and macrophage populations were flow-sorted to study gene expression 
using Taqman low-density arrays.
Results: RAS induced hypertension and post-stenotic kidney atrophy, and increased 
the total Mfs numbers in each population. Ablation with clodronate aggravated fibrosis 
(figure1 bottom graph), and increased expression of proinflammatory transcripts for 
Il6, Ifng, Il1b, Tnfa, and Nos2. Clodronate selectively ablated a sub-population of 
CD64+F4/80+CD11bintCD11cint macrophages ([figure1 middle panel, right), while 
other populations remained intact. In healthy controls, gene expression studies on this 
population demonstrate significantly higher levels of genes typically expressed by tissue-
resident Mfs (such as Myo7a, Nln, Slc48a, Pla2g15, Spi1, Csf1r, Pon3, Tlr4, Cebpa, 
Mafb, Hbp1 Mertk and Fcgr1), than monocyte-derived Mfs (figure1, circles 1 and 2) 
(CD64+F4/80+CD11bhiCD11chi/-). Flow sorted CD64+F4/80+CD11bintCD11cint macrophages 
from RAS kidneys showed increased levels of Mertk, Arg1, Agtr2, Csf1, Il10, Igf1, Angpt1 
and Vegfa, factors involved in inhibiting inflammation and promoting regeneration. These 
factors were down-regulated upon clodronate treatment.
Conclusions: CD64+F4/80+CD11bintCD11cint macrophages represent a novel population 
of protective kidney-resident macrophages that regulate the injury response in chronic 
kidney ischemia.
Funding: Private Foundation Support
TH-OR066
Spliced XBP1 Rescues Renal Interstitial Inflammation due to Loss of Sec63 
in Collecting Ducts  Yasunobu Ishikawa,1 Sorin V. Fedeles,1 Rachel Gallagher,1 
Stefan Somlo.1,2  1Internal Medicine, Yale Univ School of Medicine, New Haven, 
CT; 2Genetics, Yale Univ School of Medicine, New Haven, CT.
Background: SEC63 is one of two genes which cause human autosomal dominant 
polycystic liver disease, and is located in the membrane of the endoplasmic reticulum (ER). 
A number of disease states alter ER function and result in ER stress, thus initiating the 
unfolded protein response (UPR). UPR is mediated by three major stress sensors, IRE1α, 
PERK and ATF6. In particular, IRE1α is the most conserved of the three branches and 
phosphorylation of IRE1α results in spliced XBP1 (XBP1s), a transcription factor that 
activates transcription of chaperones and proteins involved in ER-associated degradation. 
We have shown that loss of Sec63 and Xbp1 in collecting ducts causes phosphorylation 
of IRE1α and progressive renal interstitial inflammation leading to CKD (ASN, 2014 
TH-OR162). It is known that phosphorylated IRE1α activates NFkβ, JNK and NALP3 
inflammasome. In the current work we investigated the interaction of the SEC63 and 
IRE1-XBP1 pathways and their role in CKD.
Methods: Animal models used in this study: WT (wild type), SKO (Sec63fl/fl;Pkhd1-
cre), DKO (Sec63fl/fl;Xbp1fl/fl;Pkhd1-cre) and TKO (Sec63fl/fl;Xbp1fl/fl;Ire1afl/fl;Pkhd1-cre), 
as well as DKO;Nalp3-/- and DKO expressing a cre activated ROSA-XBP1s allele. The 
kidneys were removed and analyzed at P70.
Results: Analysis of NFkβ and JNK phosphorylation states were no different between 
WT, SKO and DKO. The histology in WT and SKO kidneys appeared normal. In contrast, 
DKO mice showed many inflammatory cells in the renal interstitium with decline in 
renal function. By removing Ire1a and Nalp3-/-, respectively, on the DKO background 
did not rescue the inflammation nor ameliorate decline in renal function. In addition, 
double knockout of Sec63 and Ire1α in the collecting duct also resulted in renal interstitial 
inflammation similar to what was observed in the DKO kidneys. Re-expression of a 
human XBP1 transgene that produces spliced XBP1 on the DKO background rescued the 
inflammatory phenotype.
Conclusions: Spliced XBP1 rescues renal interstitial inflammation due to loss of 
Sec63 in collecting ducts.
TH-OR067
Specific Deletion of Rictor in Macrophages Ameliorates Macrophage 
Activation and Obstructive Nephropathy in Mice  Jiafa Ren, Chunsun Dai. 
Nanjing Medical Univ.
Background: Rictor/mTORC2 signaling is activated in both tubular and interstitial cells 
in mouse kidneys with obstructive nephropathy. Our published studies reported that Rictor/
mTORC2 signaling mediates TGFb1-induced fibroblast activation and kidney fibrosis. 
Regarding the critical role for macrophages infiltration in kidney fibrosis, deciphering the 
role and mechanisms for mTORC2 signaling in macrophage activation and its contribution 
to kidney fibrosis are very necessary.
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Methods: In this study, a mouse model with tamoxifen-induced macrophage-specific 
deletion of Rictor and primary cultural macrophages from bone marrow were employed.
Results: Here, we found that Rictor/mTORC2 signaling was activated in the kidney 
interstitial F4/80+ macrophages in mice with UUO nephropathy. A mouse model with 
tamoxifen-induced macrophage-specific deletion of Rictor was generated. Compared with 
their control littermates, the knockout kidneys developed less kidney injury, interstitial 
extracelluar matrix deposition and macrophage infiltration at 2 weeks after UUO surgery. 
In the primary cultured macrophages, compared with wild type cells, cell proliferation 
stimulated by M-CSF treatment was similar, whereas cell migration was markedly inhibited 
in Rictor-deleted macrophages. Additionally, the mRNA abundance for arginase 1, fizz1, 
and YM1 were largely induced in wild type macrophages treated with IL4, which were 
much less in Rictor-deleted macrophages.
Conclusions: Together, these results suggest that Rictor/mTORC2 signaling plays an 
important role for promoting macrophage activation and contributes to the development 
of kidney fibrosis.
Funding: Government Support - Non-U.S.
TH-OR068
Non-HLA Antibodies Targeting Angiotensin II Type 1 Receptor and 
Endothelin-1 Type A Receptor Induce mTOR Signaling and Endothelial 
Injury in Human Microvascular Endothelium  Duska Dragun, Oskar 
Wischnewski, Rusan Catar, Angelika Kusch.  Nephrology and Intensive Care 
Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
Background: Functional non-HLA antibodies (Abs) targeting G protein-coupled 
receptors Angiotensin II Type 1 (AT1R) and Endothelin-1 Type A receptor (ETAR) are 
implicated in pathogenesis of renal transplant vasculopathy. Both antibodies activate 
canonic G-protein related ERK 1/2. The molecular link between receptor stimulation and 
development of vascular obliterative lesion has not been fully established. We hypothesized 
the involvement of PI3K/Akt downstream signaling target mTOR and assessed functional 
consequences of AT1R- and ETAR-activation by non-HLA Abs.
Methods: Human microvascular endothelial cells were stimulated with AT1R-Ab and 
ETAR-Ab containing IgG from patients with obliterative vasculopathy. Phospho-specific 
antibodies against ERK and mTOR downstream targets were used to assess activation 
of mTORC1  and mTORC2. Scratch assay was employed to study effect of non-HLA-
antibodies on wound healing. Involvement of AT1R/ETAR activation in non-HLA antibody 
downstream signaling was addressed by use of specific inhibitors for AT1R (Valsartan) 
and ETAR (Sitaxentan).
Results: Signaling activity of both, mTORC1 and mTORC2, was increased after short 
and long term treatment with patient IgG compared to cells treated with IgG from healthy 
controls. This effect could be inhibited by preincubating the cells with specific inhibitors 
of AT1R and ETAR. Both, activation of mTORC1 and mTORC2 were PI3K-dependent 
and independent from ERK-activation. mTOR inhibitor rapamycin completely abolished 
non-HLA Abs induced activation of mTORC1 and in addition mTORC2 after long term 
treatment. Impaired wound healing by non-HLA Abs could be restored by either use of 
specific AT1R or ETAR inhibitors.
Conclusions: We provide evidence that functional targeting AT1R and ETAR antibodies 
induce mTORC1 and mTORC2 signalling which is independent of canonic ERK 1/2 
activation in human microvascular endothelium. Our data on impaired AT1R and ETAR-
dependent wound healing induced by non-HLA Abs may provide a translational rationale 
for therapeutic AT1R and mTOR inhibitors in patients with non-HLA Abs.
TH-OR069
Memory Effector T Cells and OX40 Signaling Could Contribute to Chronic 
T-Cell Mediated Rejection  Claudia Curci,1 Fabio Sallustio,1 Grazia Serino,1 
Giuseppe De Palma,1 Mirko Trpevski,1 M. Rossini,2 Loreto Gesualdo,2 Marco 
Quaglia,3 Paolo Rigotti,4 Francesco Paolo Schena.1  1C.A.R.S.O. Consortium, 
Bari, Italy; 2Univ of Bari, Bari, Italy; 3Univ of Eastern Piedmont, Novara, Italy; 
4Univ of Padua, Padua, Italy.
Background: Chronic T-cell Mediated Rejection (TCMR) is characterized by the 
reduction of vessel lumen with marked intimal thickening, fibrous hyperplasia and a large 
component of leukocyte infiltrate. Aim of our work was the study of gene expression profile 
in renal tissue, including the cellular infiltrate, in chronic TCMR.
Methods: We performed transcriptomics study using RNA extracted from archival 
formalin-fixed and paraffin-embedded (FFPE) renal biopsies obtained from 21 patients 
with chronic TCMR and 10 with acute TCMR. Controls were renal tissue samples from 
52 cadaveric donors (CD). Genome-wide expression profiles were generated by Illumina 
platform. Real-Time PCR and immunofluorescence were used for validation of the 
identified transcripts.
Results: Using a FC³2 and a FDR<0.05, we identified 164 genes differentially expressed 
in renal tissue of patients with chronic and 165 genes differentially expressed in acute 
TCMR, compared to CDs. Partial Least Square showed a clear difference in the gene 
expression of the three groups of biopsies. The study of gene pathways showed up-regulation 
of OX40 signaling, that is involved in the differentiation of CD8+ memory effector T cell, 
and up-regulation of KLRG1, BLIMP1 and CD25 that characterized short-lived memory 
effector T cells. Interestingly, we found that OX40 signaling was specific only for chronic 
TCMR. Next, the validation study forOX40, KLRG1, BLIMP1 demonstrated that these 
genes were expressed by CD8+ T cells in chronic but not in acute TCMR.
Conclusions: Our data suggest, for the first time, the involvement of memory committed 
CD8+ effector T cells specifically in chronic TCMR. The generation of memory effector T 
cells is mediated by OX40 pathway, that may be considered a potential target for specific 
treatment of chronic TCMR of kidney graft.
Funding: Government Support - Non-U.S.
TH-OR070
Dendritic Cell-Targeted CD40 DNA Vaccination Suppresses Th17 and 
Ameliorates Renal Injury in Experimental Autoimmune Glomerulonephritis 
Qing Li,1 Qi Cao,1 Chengshi Wang,1 Xin M. Wang,2 Yuan Min Wang,3 Stephen 
I. Alexander,3 Yiping Wang,1 David C. Harris.1  1Centre for Transplant and 
Renal Research, Westmead Millennium Inst, The Univ of Sydney, Sydney, 
Australia; 2Flow Cytometry Facility, Westmead Millennium Inst, The Univ of 
Sydney, Sydney, Australia; 3Centre for Kidney Research, Children’s Hospital 
at Westmead, Sydney, Australia.
Background: The CD40-CD154 co-stimulatory pathway is critical for T cell activation 
in autoimmune disease. Our group previously found that blocking this pathway using 
CD40 DNA vaccine enhanced by targeting dendritic cell receptor DEC205 prevent the 
development of Heymann nephritis. In this study, we used DEC-CD40 DNA vaccine to 
treat the disease and explored its effect on Th17-mediated pathogenesis of experimental 
autoimmune glomerulonephritis (EAG).
Methods: The rat EAG model was established by NC1 protein injection, and DEC-
CD40 vaccination was administered at week3 and week6 after NC1 injection. Renal function 
and histology were assessed at week12. Th subsets, key transcription factors and relevant 
cytokines in kidneys, spleens and lymph nodes were examined.
Results: Administration of DEC-CD40 DNA vaccine at week3 and week6 after NC1 
injection reduced renal structural and functional injury in EAG. DEC-CD40 vaccination 
reduced the number of Th17 cells and inhibited Th17 immune responses in kidney, spleen 
and lymph nodes, but did not alter the number of Th1, Th2 and Treg cells. Early and late 
treatment showed similar effects on kidney injury and Th17 immune responses, indicating 
DEC-CD40 vaccination has both preventative and therapeutic roles in EAG. Serum from 
rats with DEC-CD40 suppressed Th17 in vitro, but not Th1 differentiation. B cell activation 
and M1 macrophage polarization were inhibited when co-cultured with Th17 cells induced 
with DEC-CD40-EAG serum but not EAG serum.
Conclusions: DNA vaccine encoding CD40 and targeting dendritic cells ameliorates 
renal injury in both early and late stages of experimental autoimmune glomerulonephritis. Its 
preventative and therapeutic effect was associated with suppression of Th17 differentiation 
and Th17-dependent B cell activation as well as M1 macrophage polarization.
Funding: Government Support - Non-U.S.
TH-OR071
Pharmacologic Targeting of Sirtuin-1 (Sirt1) Enhances Treg Function, 
Markedly Prolongs Renal Allograft Survival and Protects against Renal 
Allograft Dysfunction  Ulf H. Beier,1 Zhonglin Wang,2 Tricia Bhatti,1 Wayne 
W. Hancock,1 Matthew H. Levine.2  1Children’s Hospital of Philadelphia, 
Philadelphia, PA; 2Univ of Pennsylvania, Philadelphia, PA.
Background: Published data show that the pharmacologic regulation of Foxp3+ 
T-regulatory (Treg) function provides safer, more consistent, potent and less expensive 
options than Treg-based cell therapy involving injection of short-lived Tregs at one or 
more times post-transplant (Tx). In the case of sirtuins biology, conditional deletion of the 
Sirt1 gene within Foxp3+ T-regulatory (Treg) cells augments Foxp3 acetylation and Treg 
suppressive function, and enhances heterotopic cardiac allograft survival.However, such 
data remain of uncertain translational significance until tested in life-supporting models 
using pharmacologic approaches in normal recipients. We now report such data.
Methods: To this end, C57BL/6 mice were engrafted with BALB/c kidneys (i.e. full 
MHC-mismatch) and underwent native nephrectomy, and blood chemistries, renal function 
and hematocrit were monitored weekly thereafter.
Results: Allograft recipients were divided into two groups, and treated with either a 
Sirt1 inhibitor, EX-527 (1 mg/kg/d for 14 days), or vehicle control. We found that allograft 
survival at 100 days post-Tx was 87.5% in the EX-527 group, but only 28.6% in control 
mice (P=0.037, Mantel-Cox test). Moreover, at 100 days post-Tx, the EX-527 treated group 
had lower BUN (71 ± 2.7 vs. 90 ± 3.6 mg/dL, P<0.001) and serum creatinine levels (0.33 
± 0.04 vs. 0.58 ± 0.02 mg/dL, P<0.001) than survivors in the control group. Histologic 
analysis of renal allografts retrieved after 100 days showed less allograft fibrosis (p=0.03) 
and less inflammation (p=0.01) in the EX-527 treated vs. control groups, respectively.
Conclusions: Pharmacologic inhibition of Sirt1 is effective at prolonging allograft 
survival and function. These data provide clear evidence that pharmacologic regulation 
of Treg function is of demonstrable value in stringent allograft models, and provide a 
compelling rationale for testing of Sirt1 inhibitors in pre-clinical models.
Funding: Other NIH Support - NIAID
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TH-OR072
A Novel IL-2 and IL-33 Hybrid Cytokine for Lupus Glomerulonephritis 
(GN) Therapy  Rahul Sharma, Marta Stremska, Chao Dai, Hongyang Wang, 
Saleh Mohammad, Sheethal Jose, Sun-sang J. Sung, Shu man Fu.  CIIR, Univ 
of Virginia, Charlottesville, VA.
Background: Autoimmune Lupus GN is caused by T-cell and immune complex (IC) 
mediated inflammation resulting in renal dysfunction. Low interleukin (IL)-2 levels and 
T-regulatory cell (Treg) deficiency is implicated in lupus GN. Based on our findings that (a) 
IL-2, which is critical for Tregs, also regulates the expression of ST2 (receptor for IL-33-a 
Th2 promoting cytokine) and (b) a major subset of Tregs express ST2; we hypothesized 
that both IL-2 and IL-33 will be beneficial for treating lupus GN by simultaneously 
promoting Tregs and Th2. Further, linking IL-2 and IL-33 in a single molecule will target 
Tregs more efficiently.
Methods: We made a recombinant hybrid cytokine (IL233) bearing activities of IL-2 
and IL-33 and tested its efficacy to treat GN using lupus prone NZM2328 female mice, 
in which disease was accelerated by injection of IFNα-expressing adenovirus (Ad-IFNα). 
NZM2328 females were injected with saline or 66pmoles/day of IL233 or IL2/IL33 alone 
or in combination for 5-days before Ad-IFNα injection.
Results: IL233 and the IL-2 and IL-33 combination protected 80% and 60% mice 
respectively from severe proteinuria and mortality, whereas 80% of mice treated with saline 
or IL-2 or IL-33 alone succumbed to severe proteinuria. IL233 treatment induced robust 
and sustained increase in Tregs. Renal histology of mice that succumbed to proteinuria 
showed glomerular hypertrophy, mesangial expansion and leukocytic infiltration, which 
were absent in IL233 treated mice. While complement deposition was similar, IL233 treated 
mice showed reduced IC deposits and skewing towards IgG2b compared to predominantly 
IgG2a deposits in the control mice. Further, treatment with IL233 (66pmoles/day for 5days) 
of mice with established proteinuria (100-300mg/dL for 2 consecutive weeks) induced 
persistent remission in 9 out of 11 mice, which survived beyond 10 months of age, when 
70% of the NZM2328 females die of severe proteinuria. IL233 treated mice had higher 
circulating IgG2b without any symptoms of allergic diseases.
Conclusions: IL233 hybrid cytokine can prevent and reverse lupus GN by enhancing 
Tregs and bears therapeutic potential.
Funding: Private Foundation Support
TH-OR073
Interleukin-27 Has Potential Predictive Role in the Onset of Post-Transplant 
Malignancies  Paola Pontrelli,1 F. Rascio,2 Giovanni Stallone,2 Matteo 
Accetturo,1 Margherita Gigante,1 Giuseppe Castellano,1 Barbara Infante,2 
Gianluigi Zaza,3 Loreto Gesualdo,1 Giuseppe Grandaliano.2  1Dept of Emergency 
and Organ Transplantation, Univ of Bari, Italy; 2Dept of Medical and Surgical 
Sciences, Univ of Foggia, Italy; 3Dept of Medicine, Univ of Verona, Italy.
Background: Malignancies are the third leading cause of mortality among transplant 
recipients and their incidence is increasing. Although the role of the immune system in the 
development of malignancies is known, the mechanisms of tumor escape remain unclear. 
Aim of the study was to evaluate the differences in transcriptomic profiles of peripheral 
blood mononuclear cells (PBMC) in subjects who developed post-transplant malignancies 
(PTM, n=8) compared to transplanted patients without malignancies (ctrl-Tx, n=8).
Methods: The two patients’ groups were comparable for the main clinical/demographic 
features and all patients were receiving calcineurin inhibitors (CNI), mycophenolate 
and steroids. Transcriptomic profiles of PBMC were assessed by microarray (Agilent 
technologies), analyzed by statistical and functional pathway analysis and validated by 
qPCR in an independent set of patients (PTM n=9; ctrl-Tx n=13).
Results: The comparison between PTM and ctrl-Tx (Fold-change>1.5), revealed that 
4,363 genes were differentially expressed. Among them, the most down-regulated gene was 
interleukin (IL)-27 (fold-change (FC):-10.88), a cytokine produced by antigen presenting 
cells, which regulates anti-tumor immunity promoting the cytotoxic T lymphocytes activity 
and the natural killer cells activation. qPCR confirmed a significant reduction of IL-27 
expression level in PTM patient compared to ctrl-Tx (p<.05). Since the treatment with 
mTOR inhibitors (mTORi) is associated to a reduce cancer risk in transplant recipients, we 
investigated whether mTORi may influence IL-27 expression in vivo. Interestingly, IL-27 
gene expression was significantly higher in transplant recipients receiving an mTORi (n=8) 
compared to those with a CNI-based therapy (p=.009).
Conclusions: Our data stress the role of the immune system in the onset of cancer 
and suggest that IL-27 might represent a useful marker in order to stratify patients at risk 
of developing post-transplant malignancies.
TH-OR074
Translation of Anti-Fibrotic MicroRNA Strategies into a Mouse Model 
of Chronic Allograft Dysfunction  Celina Schauerte,1 Song Rong,2 Michael 
Mengel,3 Hermann G. Haller,2 Thomas Thum,1 Johan Lorenzen.1,2  1Inst of 
Molecular and Translational Therapeutic Strategies (IMTTS), Hannover 
Medical School, Germany; 2Div of Nephrology & Hypertension, Hannover 
Medical School, Germany; 3Dept of Laboratory Medicine & Pathology, Univ 
of Alberta, Canada.
Background: Chronic allograft dysfunction (CAD) is characterized by fibrotic 
remodeling, renal injury and chronic inflammation. Pro-fibrotic microRNA-21 (miR-21) 
was shown to be upregulated in CAD. This study investigates miR-21-inhibition in an 
evaluated murine model of CAD.
Methods: Allogenic kidney transplantation (NTx) was performed from male C57BL/6 
into female Balb/c mice. Recipient mice were treated at day -1 and day 7 either with 
LNA-21 (miR-21 inhibitor) or LNA-SCR (control) (20mg/kg BW, i.p.). Six weeks after 
NTx, kidneys were harvested and analyzed e.g. by qRT-PCR, PAS and Sirius Red staining. 
Potential signal mechanisms were validated in vitro using renal fibroblast cell line NRK49F 
and macrophage-like cell line RAW264.7.
Results: We determined increased expression levels of markers for fibrosis (aSMA, 
Col1a2, Col3, FSP-1), inflammation (IL-6, MIP-1, IL-1β) and injury (NGAL, KIM-1) 
in transplanted kidneys which were rescued by miR-21 inhibition. Moreover, Sirius Red 
staining revealed significantly less fibrosis development due to miR-21 inhibition. Besides, 
BANFF chronic rejection score was decreased in allografts of LNA-21 treated mice. The 
miR-21 promoter region harbors a putative binding site of transcription factor STAT3, 
which is activated by IL-6. We identified upregulated IL-6 expression and secretion in 
LPS activated RAW264.7 and hypothesized, that infiltrating immune cells produce and 
secrete cytokines that might affect resident renal cells causing fibrosis and injury. Co-culture 
assays confirmed a crosstalk between RAW264.7 and NRK49F with increased expression 
levels of IL-6, CTGF and miR-21 in NRK49F. Similar results were observed due to IL-6 
treatment of NRK49F.
Conclusions: In our murine model of CAD allograft rejection is preserved by inhibition 
of miR-21 due to less inflammation and fibrosis thereby suggesting a new and essentially 
needed anti-fibrotic treatment strategy against CAD.
TH-OR075
Regulation of the Apical Cotransporter NKCC2 by a Novel Kinase: TNIK 
Paulo S. Caceres,1,2 Pablo A. Ortiz.1,2  1Hypertension & Vascular Research, 
Henry Ford Hospital, Detroit, MI; 2Physiology, Wayne State Univ, Detroit, MI.
Background: The apical cotransporter NKCC2 mediates NaCl absorption by the 
thick ascending ascending limb (TAL), maintaining blood pressure. Abnormally enhanced 
NKCC2 activity contributes to salt-sensitive hypertension. Phosphorylation of NKCC2 at 
amino terminal (NH2) threonines 96,101 (Thr-96,101) increases its activity. Trafficking of 
NKCC2 to the apical surface also regulate TAL NaCl absorption. Only the kinases SPAK 
and OSR1 have been shown to target Thr-96,101. Identifying additional kinases that target 
NKCC2 will help understand the role of Thr-96,101 in the regulation of NKCC2. To identify 
additional kinases, we performed a targeted proteomics screen using a GST-NH2-NKCC2 
fusion protein as bait in pull down assays from TAL protein lysates. We found that the 
Traf2 and NCK interacting kinase (TNIK) binds the NH2terminus of NKCC2. The role of 
TNIK in renal function and NKCC2 regulation is unknown. We hypothesized that TNIK 
phosphorylates NKCC2 at Thr-96,101 and stimulates surface NKCC2 expression in TALs.
Methods: We measured NKCC2-TNIK interaction by co-immunoprecipitation in rat 
TAL lysates. To determine whether TNIK directly phosphorylates NKCC2, we incubated the 
NH2 terminus of NKCC2 with recombinant TNIK and measured NKCC2 phosphorylation 
at Thr-96,101. We generated TNIK knockout mice (TNIK-/-), obtained TALs and measured 
total NKCC2, phosphorylation at Thr-96,101 and surface NKCC2 by surface biotinylation.
Results: We observed TNIK expression in isolated perfused TALs. NKCC2 and TNIK 
co-immunoprecipitate in TAL lysates and TNIK directly phosphorylates NKCC2 at Thr-
96,101 in vitro. In TALs from TNIK-/- mice on a normal diet, total NKCC2 expression was 
decreased by 32±9% (p<0.05) and phospho/total NKCC2 was decreased by 23±6% (p<0.05). 
In TNIK-/- mice fed a low Na diet, phospho/total NKCC2 was decreased by 51±9% (p<0.05). 
The surface/intracelluar NKCC2 ratio was decreased by 58±4% (p<0.01) in TNIK-/- mice.
Conclusions: TNIK is a new kinase that interacts with NKCC2 in TALs, it 
phosphorylates NKCC2 at Thr-96,101 and mediates total and surface NKCC2 expression 
in vivo. This represent a novel pathway in the field of renal ion transport.
Funding: Private Foundation Support
TH-OR076
Golgi Alpha1,2-Mannosidase IA Promotes the Efficient Degradation of 
NKCC2 and Its Disease Causing Mutants  Kamel Laghmani, Sylvie Demaretz, 
Nadia Defontaine, Elie Seaayfan.  Centre de Recherche des Cordeliers, INSERM/
UPMC/CNRS - U1138, ERL8228, Equipe 3, Paris, France.
Background: Mutations in the apically located Na-K-2Cl cotransporter, NKCC2, lead 
to type I Bartter syndrome, and inherited kidney disorder associated with salt wasting, 
hypokalemia, and metabolic alkalosis. We have previously shown that wild type (WT) 
NKCC2 protein and its mutants are subject to regulation by the endoplasmic reticulum-
associated degradation (ERAD). The aim of the present study was to identify the protein 
partners involved in ERAD of NKCC2.
Methods: To identify novel NKCC2-interacting proteins, we screened a kidney 
cDNA library through yeast two-hybrid using NKCC2 C-terminus as bait. NKCC2 protein 
expression was monitored in transiently transfected OKP and HEK cells, using immunoblot 
and confocal imaging. NKCC2 stability was assessed by cycloheximide chase assay.
Results: We identified Golgi alpha1, 2-mannosidase IA (MANIA) as a specific 
binding partner of NKCC2. In addition to ER mannosidases, recent reports revealed that 
Golgi-situated α-1, 2-mannosidases may also contribute to the ERAD of glycoproteins. Co-
immunoprecipitation and co-immunolocalization experiments confirmed NKCC2-MANIA 
interaction in renal cells. They also showed that MANIA association involves mainly the 
immature form of NKCC2. MANIA co-expression decreased total cellular WT NKCC2 
protein in a dose dependent manner. Cycloheximide chase assay showed that in cells over 
expressing MANIA, NKCC2 maturation is impaired. Importantly, MANIA co-expression 
had a more profound effect on the disease-associated NKCC2 folding mutants, A508T and 
Y998X (>90%). The MANIA induced reductions in NKCC2 expression were offset by the 
proteasome inhibitor MG132. Finally, kifunensine and 1-deoxymannojirimycin, two potent 
inhibitors of alpha1, 2-mannosidases, reproduced MG132 effect on NKCC2 regulation.
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Conclusions: Our data demonstrate the presence of a MANIA mediated ERAD pathway 
in renal cells promoting retention and/or degradation of misfolded NKCC2 proteins. They 
suggest a model whereby, Golgi MANIA contributes to ERAD of NKCC2, by promoting 
the retention, recycling, and ERAD of misfolded proteins that initially escape protein 
quality control surveillance within the ER.
Funding: Government Support - Non-U.S.
TH-OR077
Inhibition of Mitochondrial Complex-1 Prevents the Downregulation of 
NKCC2 and ENaCα in Obstructive Nephropathy  Zhanjun Jia,1,2 Yue Zhang,1 
Ying Sun,1 Guixia Ding,1 Songming Huang,1 Aihua Zhang.1  1Nephrology, 
Nanjing Children Hospital, Nanjing Medical Univ, Nanjing, Jiangsu, China; 
2Nanjing Key Laboratory of  Pediatrics.
Background: Ureteral obstruction with subsequent hydronephrosis is a common 
clinical complication. Downregulation of renal sodium transporters in obstructed kidneys 
could contribute to impaired urine concentrating capability and salt waste following the 
release of a ureteral obstruction. This study was undertaken to investigate the role of 
mitochondrial complex-1 inhibition in modulating sodium transporters in obstructive 
nephrophthy.
Methods: C57BL/6 mice were subjected to the sham surgery or unilateral ureteral 
obstruction (UUO) for 7 days. Then kidney tissues were harvested for the analyses.
Results: Following UUO, sodium transporters including NHE3, α-Na-K-ATPase, 
NCC, NKCC2, p-NKCC2, ENaCα, and ENaCγ were remarkably reduced by 60-90% 
contrasting to unaltered expression of ENaCβ, as determined by qRT-PCR, Western 
blotting, and immunohistochemistry. This global downregulation of sodium transporters 
was accompanied by striking reduction of mitochondrial DNA copy number (mtDNA), 
mitochondrial transcription factor (mTFAM), and mitochondria-encoded NADH 
dehydrogenase 1 (mtNd1) indicating a mitochondrial abnormality. Strikingly, specific 
inhibition of mitochondrial complex-1 by rotenone (500ppm in diet) completely abolished 
the downregulation of NKCC2, p-NKCC2, and ENaCα without affecting other sodium 
transporters. To study the potential mechanisms mediating the rotenoen effects on sodium 
transporters, we examined a number of known sodium modulators, including PGE2, ET1, 
Ang II, natriuretic peptides (ANP, BNP, and CNP), and nitric oxide synthases (iNOS, nNOS, 
and eNOS) and found that all of them were strikingly elevated by 3 to 80 folds except for 
nNOS in obstructed kidneys. However, after rotenone administration, only BNP with a 
80-fold increase and iNOS with a 4-fold increase but not others were significantly reduced 
by 62% and 96%, respectively.
Conclusions: These findings demonstrated a substantial role of mitochondrial 
dysfunction in mediating the downregulation of NKCC2 and ENaCα in obstructive 
nephropathy, possibly via iNOS-derived nitric oxide and BNP.
Funding: Government Support - Non-U.S.
TH-OR078
NLRP3 Inflammasome Activation Confers the Resistance to Loop Diuretics 
in Proteinuric Kidney Disease  Aihua Zhang,1,2 Yibo Zhuang,1 Guixia Ding,1 
Songming Huang,1 Zhanjun Jia.1,2  1Nephrology Dept, Nanjing Children Hospital, 
Nanjing Medical Univ, Nanjing, Jiangsu, China; 2Nanjing Key Laboratory of 
Pediatrics.
Background: The resistance to loop diuretics is a known phenomenon in proteinuric 
patients, particularly in the patients with nephrotic syndrome. However, the pathogenic 
mechanisms remain elusive.
Methods: Kidney biopsy specimens of proteinuric patients and mouse kidney tissues 
from albumin overloaded mice (daily i.p injection of albumin for 12 days) were analyzed.
Results: In the present study, we analyzed Na-K-Cl cotransporter (NKCC2, target 
of loop diuretics) expression in proteinuric patient kidneys via immunohistochemistry 
(IHC) and found a significant NKCC2 downregulation which was negatively correlated 
with proteinuria severity. Interestingly, in NKCC2 positive tubules (thick ascending limb, 
TAL), NLRP3 inflammasome was strikingly elevated and showed a positive correlation 
with proteinuria severity. These findings suggested a possibility that proteinuria may 
suppress NKCC2 expression via a NLRP3 inflammasome-mediated mechanism. To 
validate this hypothesis, NLRP3 WT and KO mice were subjected to albumin overload. 
Strikingly, albumin overload in WT mice resulted in a robust reduction of NKCC2 by 80% 
as determined by Western blotting, qRT-PCR, and IHC in accord with a specific induction 
of NLRP3 in TAL. Meanwhile, the downstream components of NLRP3 inflammasome 
including caspase-1, IL-1β, and IL-18 were remarkably activated. Importantly, such a 
reduction of NKCC2 was entirely abolished in NLRP3 KO mice. In primary cultures of renal 
tubular cells, albumin markedly reduced NKCC2, indicating a direct effect of albumin on 
NKCC2 dysregulation. In addition, WT mice with albumin overload displayed a remarkable 
resistance to loop diuretic furosemide (NKCC2 inhibitor), which was completely reversed 
by NLRP3 invalidation.
Conclusions: These novel findings demonstrated that albuminuria-stimulated 
NLRP3 inflammasome is highly responsible for the impaired response to loop diuretics 
via suppressing NKCC2 expression in proteinuric kidney diseases. This may also offer 
novel, effective therapeutic targets for dealing with the resistance to loop diuretics in 
proteinuric patients.
Funding: Government Support - Non-U.S.
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Targeted Knockin of Constitutively Active SPAK (CA-SPAK) in the Early 
Distal Convoluted Tubule (DCT) Causes Hyperkalemic Hypertension 
P. Richard Grimm,1 Richard A. Coleman,1 Eric J. Delpire,2 Paul A. Welling.1 
1Physiology, Univ of Maryland SOM, Baltimore, MD; 2Anesthesiology, 
Vanderbilt Univ SOM, Nashville, TN.
Background: Familial Hyperkalemic Hypertension (FHHt) is caused by aberrant gain 
in WNK function, leading to hyperactivation of the thiazide-sensitive sodium chloride 
co-transporter, NCC, and alterations in other salt transport pathways. SPAK is thought 
to be the key arbiter of WNK-NCC signaling in the DCT; upon activation by WNK1/4-
phosphorylation (S383 and T243), SPAK phosphorylates NCC to stimulate salt reabsorption. 
Here, we explore if constitutive activation of SPAK in the DCT is sufficient to produce FHHt.
Methods: Knockin-CA-SPAK lox/lox mice were created by inserting a SPAK 
phosphomimetic mutant (T243E and S383D) between Lox-P sites in the first exon of the 
SPAK gene, using homologous recombination. Upon Cre-Lox recombination, these mice 
express CA-SPAK under the control of the endogenous SPAK promoter. To drive DCT1-
specific expression of CA-SPAK in the kidney, mice expressing Cre-recombinase under 
the parvalbumin promoter (Parv-Cre+) were crossed with the CA-SPAK lox/lox mice. 
The phenotypes of DCT-specific CA-SPAK knockin (CA-SPAK KI) were compared to 
matched wild-type (WT) controls.
Results: As observed by immunofluoresent-confocal microscopy, CA-SPAK was 
specifically targeted to parvalbumin positive tubules in CA-SPAK KI mice, consistent with 
DCT1-specific expression. CA-SPAK KI mice displayed significantly greater amounts of 
phosphorylated NCC than WT even though the abundance of CA-SPAK and WT-SPAK 
were comparable, verifying the constitutively active nature of the knockin. Telemetric 
measurements of blood-pressure (BP) revealed the CA-SPAK KI mice are hypertensive 
despite low renin and aldosterone levels. Elevated BP was further exacerbated by high 
salt diet and ameliorated by hydrochlorothiazide (HCTZ). CA-SPAK KI also displayed 
HCTZ-remediable metabolic acidosis, and elevated plasma potassium levels, comparable 
to mouse models of WNK FFHT.
Conclusions: Targeted expression of CA-SPAK in the DCT1 phenocopies FHHt, 
underscoring the chief role of SPAK-dependent activation of NCC in early distal tubule 
in the pathogenesis of the disease.
Funding: NIDDK Support
TH-OR080
Generation and Analysis of Knock-In Mice Carrying Pseudohypoaldo-
steronism Type II-Causing Mutations in the Cullin 3 Gene  Yuya Araki, 
Tatemitsu Rai, Eisei Sohara, Takayasu Mori, Yuichi Inoue, Eriko Kikuchi, 
Shinichi Uchida.  Dept of Nephrology, Tokyo Medical and Dental Univ, 1-5-45 
Yushima, Bunkyo, Tokyo, Japan.
Background: Pseudohypoaldosteronism type II (PHAII) is a hereditary hypertensive 
disease caused by mutations in four different genes: WNK1 and 4, KLHL3, and cullin 3 
(Cul3). Cul3 and KLHL3 form an E3 ligase complex that ubiquitinates and reduces WNK4 
protein. However, the molecular pathogenesis of PHAII caused by mainly intronic Cul3 
mutations is unclear. In cultured cells and human leukocytes, PHAII-causing Cul3 mutations 
result in the skipping of exon 9, producing a mutant Cul3 protein lacking 57 amino acids 
(∆403–459). However, whether this phenomenon occurs in the kidneys and is responsible 
for the pathogenesis of PHAII in vivo is unknown.
Methods: We generated knock-in mice carrying a mutation in the C terminus of 
intron 8 of Cul3, c.1207 -1G>A, which corresponds to a PHAII-causing mutation in the 
human Cul3 gene.
Results: Heterozygous Cul3G(-1)A/+ knock-in mice did not exhibit PHAII phenotypes, 
and the skipping of exon 9 was not observed in their kidneys. However, the level of Cul3 
mRNA expression in the kidneys of heterozygous knock-in mice was approximately 
half that of wild-type mice. Furthermore, homozygous knock-in mice were nonviable, 
similar to Cul3 knockout mice, suggesting that the mutant allele does not produce Cul3 
mRNA lacking exon 9, but behaves like a knockout allele in this mouse model. These 
data suggest that the production of the mutant Cul3 may be necessary and important for 
the pathogenesis of PHAII.
Conclusions: Our findings highlight the pathogenic role of mutant Cul3 protein 
and provide insight to explain why intronic PHAII-causing mutations in Cul3, which 
has numerous binding partners in addition to KLHL3, cause only kidney-specific PHAII 
phenotypes.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-OR081
Disruption of SPAK/OSR1 Reveal Their Critical Roles in Potassium 
Homeostasis  Mohammed Zubaerul Ferdaus, Andrew Terker, James A. 
McCormick.  Dept of Medicine, Div of Nephrology & Hypertension, Oregon 
Health & Science Univ, Portland, OR.
Background: The WNK-SPAK/OSR1 pathway has been shown to play a key role 
in ion homeostasis, regulation of extracellular fluid volume, and blood pressure (BP). 
STE20 (sterile20)/SPS1-related proline/alanine-rich kinase (SPAK) and oxidative stress-
responsive kinase-1 (OSR1) activate the renal cotransporters NKCC2 and NCC by 
phosphorylation. SPAK knockout mice (SPAK-KO) and OSR1 knockout mice display mild 
renal phenotypes, and may compensate for each other. We therefore generated SPAK-KO/
inducible renal OSR1-KO mice (DKO) to compare the effects of deleting both kinases 
with SPAK deletion alone.
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Methods: To examine the effects of disrupting both SPAK and OSR1, we manipulated 
dietary sodium (Na) and potassium (K), and analyzed levels of phospho-NCC (pNCC) and 
phospho-NKCC2 (pNKCC2) and other relevant proteins. We also measured plasma and 
urine electrolytes, and the BP of SPAK-KO and DKO mice on different diets using telemetry.
Results: We found that DKO had lower pNCC (48% on low Na, p=0.02 & 40% on 
low K diet, p=5X10-7) and pNKCC2 (56% on low Na, p=0.04 & 57% on low K diet, 
p=0.002) than SPAK-KO (100%). On normal diet we found lower pNCC in DKO (40%, 
p=0.01) than in SPAK-KO but surprisingly no difference in pNKCC2. Total-NKCC2 and 
total-NCC levels did not differ between the strains on any diet except on low K diet where 
total-NCC was lower in DKO (74%, p=0.003) than in SPAK-KO. Surprisingly, levels of 
pS126-NKCC2, a non-SPAK/OSR1 target site, were lower in DKO (52%, p=0.0003) on 
normal diet. DKO displayed lower plasma potassium than SPAK-KO mice on normal (3.35 
vs 3.71 mmol/L, p=0.05), low Na (2.83 vs 3.44 mmol/L, p=0.00001) and low K (2.08 vs 
3.11 mmol/L, p=6X10-8) diet. Unexpectedly, urinary Na did not differ between strains, and 
DKO did not show lower BP than SPAK-KO.
Conclusions: Our data suggest that SPAK/OSR1 play more important roles in K 
homeostasis than in Na and BP homeostasis. Even after disrupting SPAK/OSR1, there 
was NKCC2 phosphorylation at sites reported to be SPAK/OSR1-dependent, suggesting 
alternative pathways for phosphorylation at these sites. Finally, disruption of SPAK/OSR1 
reduced levels of pS126-NKCC2.
TH-OR082
Inducible Kidney-Specific KCNJ10 Knockout Mice Show a Salt Losing 
Phenotype  Catherina A. Cuevas,1 James A. McCormick,1 Andrew Terker,1 
Chao-Ling Yang,1 WenHui Wang,3 David H. Ellison.1  1Dept of Medicine, Oregon 
Health & Science Univ, Portland, OR; 2Portland VA Medical Center, Oregon 
Health & Science Univ, Portland, OR; 3Pharmacology, New York Medical 
College, Valhalla, NY.
Background: Missense mutations of KCNJ10 cause EAST/SeSAME syndrome, which 
is characterized by epilepsy, ataxia, sensorineural deafness and a salt-wasting tubulopathy 
resembling Gitelman syndrome. KCNJ10 encodes the Kir4.1 potassium channel, which 
resides in the basolateral membrane of the distal nephron. KCNJ10-/- mice have a severe 
phenotype and die during the first two weeks of life, limiting the useful of this model. 
Results obtained in young mice show reduced basolateral K+ conductance, sodium chloride 
transporter (NCC) and SPAK (Ste20-related proline alanine rich kinase) abundances. Here, 
we determine the renal phenotype of kidney-specific KCNJ10-/- adult mice.
Methods: Doxycycline-inducible kidney-specific KCNJ10-/- mice were generated 
using the TetOn/CreLoxP system under the control of Pax8 promoter. Doxycycline was 
administered for two weeks in the drinking water (0.2 mg/ml in 5% sucrose) of 2 month 
old mice. Biochemical parameters were assayed in urine, blood or renal tissue in KS-
KCNJ10-/- mice after two weeks of the end of doxycycline treatment.
Results: Kir4.1 was absent in the KS-KCNJ10-/- mice, which displayed hypokalemia, 
hypochloremia with metabolic alkalosis, hypocalciuria, polyuria, and renal loss of sodium 
and potassium (P<0.05). At protein level, we observed that disruption of KCNJ10 decreased 
the expression of NCC and pNKCC2 (Na+-K+-Cl- cotransporter) without affecting the levels 
of WNK4 (with no lysine kinase 4) and SPAK.
Conclusions: In conclusion, disruption of KCNJ10 in adult mice induces a severe 
renal phenotype highlighted by hypokalemic metabolic alkalosis and renal loss of sodium 
with hypocalciuria. In contrast to constitutive KCNJ10-/- mice in which decreased of NCC 
and SPAK abundance may be explained by a reduction in DCT mass, the disruption of 
KCNJ10 in adult mice causes a sodium wasting phenotype accompanied by decreased 
NCC and NKCC2 abundances. suggesting a more widespread tubulopathy involving both 
DCT and TAL in our model.
Funding: NIDDK Support
TH-OR083
HIV Vpr Antagonizes Mineralocorticoid Receptor Activity, Explaining Salt 
Wasting  Koji Okamoto, Hewang Lee, Jeffrey B. Kopp, Shashi Shrivastav. 
Kidney Section, NIDDK, NIH, Bethesda, MD.
Background: Patients with HIV-associated-nephropathy (HIVAN) present with 
proteinuria but often lack edema, suggesting renal Na wasting. We have shown that the 
HIV accessory protein Vpr binds transcriptional regulators including the glucocorticoid-
receptor and PPAR-g and b/d. We investigated whether Vpr regulates mineralocorticoid-
receptor (MR) activity.
Methods: We have developed transgenic mice that express Vpr in proximal tubules 
(PEPCK/rtTA-X-TetOp/Vpr). Wild type and transgenic mice were fed a high protein diet 
for 2 weeks to induce transgene expression. After 6 days on a Na deficient diet, urine and 
kidneys were obtained. A human distal cortical tubular (DCT) cell line was exposed to 
soluble Vpr (100 ng/mL) and aldosterone (10-8 mM).
Results: On low salt diet, Vpr transgenic mice, compared to wild-type mice, manifested 
renal Na wasting (28±3 vs 15±2 mmol/g body weight/d) and an increased fractional Na 
excretion (2.0% vs 0.7%). We examined renal RNAexpression of the thiazide-sensitive 
cotransporter (TSC), NHE, ATP1A1, NKCC2, NaPi-2A and only TSC was decreased in 
Vpr mice. As TSC expression is regulated by MR, we focused the effect of Vpr on MR 
function. In a promoter reporter assay in CV1 cells, Vpr reduced aldosterone-stimulated 
MMTV and TSC promoter activity. We hypothesized that Vpr binds MR and inhibits its 
transcriptional activity. Using immunoprecipitation, we found that Vpr, but not Vpr with 
LXXLL motif mutations, bound recombinant MR. We reasoned that the interaction between 
Vpr and MR might interfere with the folding of the MR signal peptide, preventing nuclear 
entry, or might prevent MR from binding to promoter sequences. We performed WB using 
nuclear extracts from DCT cells and IHC, following exposure to Vpr and/or aldosterone. Vpr 
inhibited nuclear entry of MR. Using genome-wide ChIP sequencing with MR antibody in 
distal tubules cell line with aldosterone±Vpr, we found that the peak signal of TSC promoter 
was disappeared after treatment with Vpr.
Conclusions: Vpr binds MR and inhibits MR transcriptional activity, providing a 
molecular mechanism for renal salt wasting in HIVAN.
Funding: NIDDK Support
TH-OR084
The Sodium/Proton Exchanger NHA2 Is a Novel Regulator of Sodium, 
Calcium and Blood Pressure Homeostasis in the Distal Convoluted Tubule 
of the Kidney  Manuel Andreas Anderegg,1,2 Giuseppe Albano,1,2 Ganesh 
Pathare,1,2 Daniel G. Fuster.1,2  1Divison of Nephrology, Hypertension and 
Clinical Pharmacology, Univ of Bern, Bern, Switzerland; 2Dept of Clinical 
Research, Univ of Bern, Bern, Switzerland; 3Dept of Anatomy, Univ of Zürich, 
Zürich, Switzerland.
Background: NHA2 (also known as SLC9B2) is a sodium/proton exchanger expressed 
in the kidney, but its function there remains unknown.
Methods: We performed in vitro and in vivo experiments to elucidate the physiological 
role of NHA2 in the kidney.
Results: We found NHA2 expression restricted to distal convoluted tubules in both 
murine and human kidney. By confocal imaging, NHA2 had an apical to subapical tubular 
localization. Blood pressure, measured by invasive telemetry, was significantly lower in 
NHA2 KO mice compared to WT mice on low, normal and high sodium diets. In addition, 
NHA2 KO mice exhibited normocalcemic hypocalciuria with reduced plasma PTH but 
unaltered 1,25-OH Vitamin D3 levels. Interestingly, immunoblotting of kidney lysates 
revealed reduced phosphorylation of the sodium/chloride co-transporter (NCC) in NHA2 
KO mice. Similarly, phosphorylation of SPAK, as well as the abundance of WNK4, kinases 
regulating NCC phosphorylation, was reduced in kidney lysates of KO mice, compared 
with those of WT mice. In line with these findings, NHA2 KO mice exhibited a reduced 
natriuretic response to hydrochlorothiazide compared to WT mice. In the DCT cell line 
mpkDCT4, stimulation of NCC phosphorylation was reduced upon siRNA mediated 
knockdown of NHA2 compared with control siRNA treated cells. In addition, knockdown 
of NHA2 led to a decreased WNK4 abundance and an increase of WNK4 ubiquitylation.
Conclusions: These results indicate that the renal phenotype observed in vivo upon 
loss of NHA2 is a result of increased degradation and therefore reduced abundance of 
WNK4 in the kidney. 
Together, our data reveal the sodium/proton exchanger NHA2 as a novel regulator 
of calcium, sodium and blood pressure homeostasis in the distal convoluted tubule of 
the kidney.
Funding: Government Support - Non-U.S.
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Transgenic Mice Expressing APOL1-G0 or APOL1-G2 in Podocytes Do Not 
Develop Kidney Disease  Leslie A. Bruggeman,1 Zhenzhen Wu,1 Liping Luo,1 
Sethu M. Madhavan,1 Martha Konieczkowski,1 Paul E. Drawz,2 L. Barisoni,3 
John R. Sedor,1 John F. O’Toole.1  1Medicine, MetroHealth Medical Center, 
Case Western Reserve Univ, Cleveland, OH; 2Medicine, Univ of Minnesota, 
Minneapolis, MN; 3Pathology, Univ of Miami, Miami, FL.
Background: Variants in Apolipoprotein L1 (APOL1) associate with non-diabetic 
kidney diseases in African Americans, however, the mechanism of renal injury associated 
with APOL1 risk variants remains unknown.
Methods: Since APOL1 is present only in humans and some other primates, we created 
transgenic mice (FVB/N strain) expressing the reference allele of APOL1 (G0) and a risk 
variant (G2) in podocytes using the Nephrin promoter. Mice were phenotyped for APOL1 
expression, podocyte injury, and renal disease.
Results: Numerous founders for both G0 (n=29) and G2 (n=8) were obtained and 
progeny transmitted the transgenes consistent with Mendelian expectations. Founders 
and offspring expressed variable levels of APOL1 in podocytes, but even in the highest 
expressing G0 and G2 mice, markers for necrosis, apoptosis, or autophagic cell death 
were not identified in podocytes. Aged (~300days) G0 and G2 mice did not develop 
spontaneous kidney pathology, proteinuria, or azotemia. An unexpected phenotype in 
G0 and G2 founders and their offspring was sporadic seizures and sudden death during 
pregnancy. Pregnant mice from both G0 and G2 models exhibited hallmarks of preeclampsia 
including hypertension, proteinuria, glomerular endothelial damage, and elevated sFlt-1 
levels. APOL1 was expressed in placental tissues, confirming prior reports of placental 
expression of Nephrin and APOL1.
Conclusions: Constitutive expression of the APOL1 G0 and G2 protein in vivo was 
not cytotoxic to podocytes regardless of expression level, mimicking the observations in 
humans that APOL1 risk genotypes are insufficient to cause kidney disease in the absence 
of an additional stressor. The preeclampsia phenotype was not variant-dependent and may 
represent placental injury related to ectopic transgene expression, however, a role for 
APOL1 in placental function may warrant further investigation.
Funding: NIDDK Support
J Am Soc Nephrol 26: 2015 Podocytes and Beyond: New Targets and Mechanisms of Injury Oral Abstract/Thursday
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
22A
TH-OR086
Kidney Disease Associated Variants of Apolipoprotein L1 Changes 
Conformational Dynamics of the C-Terminal Domain  Sethu M. Madhavan,1 
John F. O’Toole,1 Martha Konieczkowski,1 Zhenzhen Wu,1 Yaping Gu,1 Leslie 
A. Bruggeman,1 Matthias Buck,2 John R. Sedor.1,2  1Medicine, MetroHealth 
System; 2Physiology and Biophysics, Case Western Reserve Univ, Cleveland, OH.
Background: APOL1 risk variants associate with non-diabetic kidney diseases in 
African Americans; however, the mechanisms of variant APOL1-mediated kidney injury 
remain unknown. We have shown a SNARE protein VAMP8 interacts with the C-terminus 
of APOL1; APOL1 variants change the C-terminal amino acid sequence and attenuate this 
interaction. Given this, we hypothesize that the structures of variant APOL1s are altered 
and disrupt protein interactions.
Methods: We modeled the 3D structure of the APOL1 C-terminus (residues 305-398) 
with the threading program ITASSER. We expressed the C-terminus of APOL1 with and 
without variants, (G0: reference, G1: S342G & I384M, and G2: del388-389NY) and used 
circular dichroism (CD) spectroscopy to experimentally verify the predicted secondary 
structure. Molecular Dynamics (MD) simulations assessed conformational behavior over 
time of G0, G1 and G2. PyMOL software modeled the APOL1:VAMP8 interaction.
Results: The computationally modeled structures of G0, G1, and G2 (residues 305-
398) initially overlapped as three α-helices folded into a bundle, linked by short loops, and 
CD spectroscopy confirmed the predicted alpha helical content. APOL1-G0 adopted an 
“open” conformation in MD simulations (over 40 ns) while the G1 and G2 variants both 
remained in a “closed” conformation, assessed as Cα deviation from starting structure. 
Fluctuations of the Cas over the last 10 ns and principal component analysis of protein 
motion also demonstrated increased mobility of the G0 C-terminus compared to G1 and 
G2. De novo formation of intramolecular H-bonds mediated the structural stability of G1 
and G2. The APOL1-G0:VAMP8 interaction is most stable with a 3:1 stoichiometry and 
does not involve the G1 and G2 residues.
Conclusions: APOL1-G0 adopts an “open” conformation but G1 and G2 both generate 
a “closed” C-terminal conformation, which limits protein interactions and explains 
attenuation of the APOL1:VAMP8 interaction. Kidney disease induced by G1 and G2 may 
result from protein conformational changes that limit interactions with SNARE proteins.
TH-OR087
SS-31, a Peptide Targeting Mitochondria, Restores Podocytes in Diabetic 
Nephropathy (DN) in BTBR ob/ob Mice  Minseob Eom,1 Anna Batorsky,1 
Hazel H. Szeto,2 Dao-fu Dai,1 Kelly L. Hudkins,1 Charles E. Alpers.1  1Pathology, 
Univ of Washington School of Medicine, Seattle, WA; 2Pharmacology, Weill 
Cornell Medical College, New York, NY.
Background: SS-31 is a novel peptide that selectively binds to cardiolipin in the 
inner mitochondrial membrane, where it prevents cardiolipin peroxidation and protects 
mitochondrial structure. We investigated the renoprotective effects of SS-31 in the BTBR 
ob/ob mice with advanced DN.
Methods: 18 week male diabetic BTBR ob/ob and wild type (WT) mice were randomly 
assigned to 5 groups:ob/ob with infusion of SS-31 via osmotic pump for 6 weeks, ob/ob 
with saline infusion, untreated ob/ob, WT, and WT with SS-31 infusion. Podocyte density, 
mesangial matrix (% tuft area occupied by collagen IV matrix), and glomerular macrophages 
were quantified by morphometry and immunohistochemistry.
Results: Podocyte density, diminished in ob/ob mice, was significantly restored in ob/
ob with SS-31 infusion (147.2 ± 6.33 podocytes/106µm3) compared with saline treated ob/
ob mice (107.6 ± 4.78) or untreated mice (100.5 ± 6.14) (p=0.0026 & 0.0002).
Mesangial matrix was reduced in the ob/ob with SS-31 treatment (30.9 ± 0.61 %) 
compared to ob/ob with saline treated (45.2 ± 2.15) and untreated mice (46.5 ± 1.29) 
(p<0.0001). Macrophage infiltration was lower in ob/ob treated with SS-31 (1.3 ± 0.36 
cells/glomerulus) than untreated ob/ob (1.9 ± 0.36) (p=0.02). Albumin-creatinine ratio was 
decreased in ob/ob with SS-31 (276.8 ± 60.14 mg/mg), compared with the untreated ob/
ob (671.8 ± 250.60), but results were not statistically significant.
Conclusions: Podocyte density was restored and mesangial matrix decreased in SS-
31 treated diabetic ob/ob mice, compared to saline treated and untreated controls. SS-31, 
currently in human clinical trials for other diseases, may be useful in treatment of DN and 
potentially other glomerular diseases in which podocytes are lost.
Funding: NIDDK Support
TH-OR088
Genetic and Pharmaceutical Targeting of GSK3β in Podocytes Reinforces 
the Nrf2 Antioxidant Response and Ameliorates Podocytopathy and 
Proteinuria  Sijie Zhou,1 Yan Ge,1 Zhangsuo Liu,2 Rujun Gong.1  1Nephrology, 
Brown Medical School; 2Nephrology, The First Affiliated Hospital of Zhengzhou 
Univ, China.
Background: Evidence suggests that the GSK3β dictated Nrf2 nuclear exclusion and 
degradation is pivotal for switching off the self-protective antioxidant response following 
injury. This study aimed to examine the role of the GSK3β regulated Nrf2 antioxidant 
response in podocyte pathobiology.
Methods: The regulatory effect of GSK3β on Nrf2 response was examined in cultured 
podocytes and in a murine model of adriamycin nephropathy by genetic targeting of GSK3β 
or by using SB216763, a selective small molecule inhibitor of GSK3.
Results: In cultured podocytes, adriamycin injury caused cell death, concomitant 
with GSK3 hyperactivity and minimal Nrf2 activation. Inhibition of GSK3 by SB216763 
exerted a prosurvival effect, which was dependent on the enhanced Nrf2 antioxidant 
response, marked by increased expression and nuclear accumulation of Nrf2 and elevated 
production of the Nrf2-target hemoxygenase-1. Ectopic expression of the kinase-dead 
mutant of GSK3β, the isoform of GSK3 predominantly expressed in glomerular podocytes, 
reinforced the Nrf2 antioxidant response upon adriamycin injury and prevented cellular 
death. Conversely, GSK3β overactivity induced by a constitutively active mutant resulted 
in a blunted Nrf2 response and exacerbated podocyte death following adriamycin injury, 
which could be abolished by SB216763. In adriamycin injured mice, genetic targeting 
of GSK3β by the doxycycline inducible podocyte specific knockout or pharmaceutical 
targeting by SB216763 attenuated albuminuria and ameliorated podocytopathic lesions, 
including glomerulosclerosis, loss of podocyte markers, de novo expression of podocyte 
injury marker desmin and ultrastructural changes of podocytes, like foot process effacement. 
This beneficial outcome was likely attributable to the enhanced Nrf2 response in podocytes, 
because trigonelline, a selective antagonist of Nrf2, largely abrogated the proteinuria 
reducing and podoprotective effect.
Conclusions: The GSK3β regulated Nrf2 antioxidant response might represent a novel 
therapeutic target to protect podocytes and treat proteinuric glomerulopathies.
Funding: NIDDK Support, Government Support - Non-U.S.
TH-OR089
Ablation of Podocyte-Derived Wnts Aggravates Proteinuria and Kidney 
Injury  Dong Zhou,1 Haiyan Fu,1 Roderick J. Tan,2 Youhua Liu.1  1Dept of 
Pathology, Univ of Pittsburgh, Pittsburgh, PA; 2Dept of Medicine, Univ of 
Pittsburgh, Pittsburgh, PA.
Background: Activation of canonical Wnt signaling has been implicated in podocyte 
injury and proteinuria. However, as Wnts are secreted extracellular signal proteins, whether 
podocyte-derived Wnts are obligatory for developing proteinuria remains elusive. Wntless 
(Wl), a cargo receptor protein, is required for the secretion of Wnt proteins.
Methods: We generated conditional knockout mice in which Wl was specifically 
deleted in podocytes by using the Cre-LoxP system. The mice were subjected to adriamycin 
administration, and urine and kidney were analyed at 7 days and 21 days, respectively. 
We utilized another proteinuric kidney disease model by chronic infusion of angiotensin 
II for 4 weeks.
Results: Mice with podocyte-specific ablation of Wl (podo-Wl-/-) developed normally. 
No albuminuria or overt pathologic lesions was observed up to 6 months of age, suggesting 
that Wl is dispensable for podocyte maturation, survival, and function under normal 
physiologic conditions. However, after adriamycin treatment for 7 days, podo-Wl-/- mice 
developed more severe podocyte injury and albuminuria than their control littermates. 
Surprisingly, ablation of Wl resulted in even more profound upregulation of β-catenin, 
accompanied by reduction and aberrant distribution of nephrin, Wilms tumor 1 (WT1), 
synaptopodin, and podocalyxin. In chronic injury induced by adriamycin or Ang II infusion, 
increased albuminuria, aggravated podocyte lesions and extracellular matrix deposition 
were evident in Podo-Wl-/- mice. Mechanistically, specific ablation of Wl in podocyte 
caused significant down-regulation of Dickkopf-3 expression. Meanwhile, NFAT1, a key 
downstream mediator in non-canonical Wnt signaling, was largely inhibited in Podo-Wl-/- 
mice after ADR injection.
Conclusions: These results indicate that podocyte-derived Wnts may play an important 
role in protecting podocytes from injury by repressing canonical Wnt/β-catenin signaling 
via promoting Dickkopf-3 expression and activating non-canonical pathway.
Funding: NIDDK Support
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Blockade of Wnt/β-Catenin Signaling Exhibits Superior Therapeutic 
Efficacy Than RAS Inhibition in CKD  Zhen Li,1 Lili Zhou,1 Xue Hong,1 
Youhua Liu.1,2  1Div of  Nephrology, Nanfang Hospital, Southern Medical 
Univ, Guangzhou, Guangdong, China; 2Dept of  Patholgy, Univ of Pittsburgh, 
Pittsburgh, PA.
Background: CKD has become a public health problem worldwide. Treatment options 
for CKD are limited and ineffective, underscoring enormous unmet medical need. The 
mainstay of clinical therapy for CKD is inhibition of renin-angiotensin system (RAS), using 
angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II type 1 receptor (AT1) 
blocker (ARB). However, current therapy with RAS inhibition is insufficient, partially 
because of compensatory upregulation of renin expression. Thus it is paramount to develop 
new therapeutic strategy with better outcomes.
Methods: Using two mouse models of CKD induced by adriamycin (ADR) or unilateral 
ischemic/reperfusion injury (UIRI), we directly compared the therapeutic efficacy of 
small-molecule Wnt/β-catenin inhibitor ICG-001 with trandolapril (ACEI) alone, or the 
combination of trandolapril and losartan (ARB). The effect of renin on fibroblast activation 
was also assessed in vitro.
Results: Compared to ACEI, or ACEI plus ARB, ICG-001 displayed superior 
therapeutic efficacy in both models. ICG-001 almost completely abolished proteinuria, 
ameliorated glomerular injury and fibrotic lesions and reduced serum creatinine in ADR 
nephropathy, whereas trandolapril, or trandolapril plus losartan only displayed as 50% 
efficacy as ICG-001. Similar results were obtained in UIRI model. We found that ICG-001 
completely abolished renal expression of all RAS components including angiotensinogen, 
renin, ACE and AT1 in both models. However, trandolapril or trandolapril plus losartan 
actually induced angiotensinogen and renin expression in the kidneys. In vitro, incubation of 
kidney interstitial fibroblasts (NRK-49F) with renin protein induced fibronectin expression, 
and this effect was dependent on ERK-1/2 activation. Losartan did not block renin-
induced fibronectin expression, suggesting that renin elicited its effect by an angiotensin 
II-independent mechanism.
Conclusions: Our studies demonstrate that blockade of Wnt/β-catenin, the master 
upstream regulator of all RAS genes, has superior therapeutic efficacy for the treatment 
of CKD than RAS inhibition.
Funding: Government Support - Non-U.S.
TH-OR091
Distinct Populations of FOXD1-Derived Renal Interstitial Cells Regulate 
Erythropoietin Production  Hanako Kobayashi, Volker H. Haase.  Medicine, 
Vanderbilt Univ, Nashville, TN.
Background: In adults, the kidney is the main physiologic production site of 
erythropoietin (EPO), a hypoxia-inducible factor (HIF)-2-regulated hormone that is 
essential for normal erythropoiesis. However, renal EPO producing cells (REPCs) are 
poorly characterized and their histogenetic origin is ill-defined.
Methods: To investigate the hypoxic regulation of renal EPO, we targeted the EPO/
HIF-2/prolyl-4-hydroxylase domain (PHD) oxygen-sensing pathway in renal interstitial 
cells using Foxd1-Cre transgenic mice and simultaneously labeled REPCs with green 
fluorescent protein (GFP). FOXD1 is expressed in embryonic stromal cells that give rise 
to renal pericytes and peritubular interstitial fibroblasts.
Results: In order to determine to what degree FOXD1-lineage cells contribute to EPO 
homeostasis, Epo or Hif2a were deleted (Foxd1-Epo-/- or Foxd1-Hif2a-/-). As expected, 
Foxd1-Epo-/- and Foxd1-Hif2a-/- mice developed anemia. While pharmacologic PHD 
inhibition and hypoxia exposure (10% O2 for 2 days) increased renal Epo mRNA and serum 
EPO (sEPO) levels in control mice, the renal EPO response was completely abrogated in 
both mutants, demonstrating that REPCs are exclusively derived from FOXD1-expressing 
stroma. To investigate the role of individual PHDs, we inactivated PHD1, PHD2 and/or 
PHD3 in FOXD1-lineage cells and used multi-color fluorescent in situ hybridization for a 
detailed characterization of the REPC pool. Deletion of PHD2 alone (Foxd1-Phd2-/-), but 
not of PHD1 or PHD3, was sufficient to induce Epo in a subpopulation of GFP+ interstitial 
cells (0.8 ± 0.5% in control vs. 39.0 ± 5.5% in Foxd1-Phd2-/- mutants). However, EPO 
synthesis was induced in additional GFP+ Phd2-/- cells following hypoxia exposure or PHD3 
deletion (73.0 ± 4.1% and 64.1 ± 8.4% respectively).
Conclusions: Our genetic studies demonstrate that REPCs consist of at least two 
distinct subpopulations, a) a PHD2-sensitive cell population and b) a subpopulation, in 
which in addition to PHD2 inactivation, hypoxia and/or PHD3 inactivation are required 
for EPO induction. In summary our data suggest that REPCs are entirely FOXD1 stroma-
derived and are heterogeneous with regard to HIF-2-dependent oxygen sensing and their 
ability to synthesize EPO.
Funding: NIDDK Support, Veterans Administration Support
TH-OR092
microRNA-21 in Human Glomerular Aging  Christopher Lund O’Connor, 
Yifan Wu, Harkamal Singh Jhajj, Jeffrey B. Hodgin, Markus Bitzer.  Internal 
Medicine, Univ of Michigan, Ann Arbor, MI.
Background: Loss of podocytes is sufficient to cause progressive glomerulosclerosis 
(the podocyte depletion hypothesis). We have recently shown that podocytes loss and 
glomerular hypertrophy are critical phenotypes of normal human aging (Hodgin, Bitzer, 
et al. JASN 2015) and that lack of miR-21 accelerates podocyte loss in murine models 
of glomerular injury. We now explore the role of miR-21 in aging of human and mouse 
glomeruli.
Methods: Kidney tissue samples were collected from 41 patients who underwent 
unilateral nephrectomy at the University of Michigan. 10 computer-assisted glomerular 
morphometric parameters were assessed in formalin fixed paraffin embedded sections by 
standard chemical and immunohistochemical stains. Gene expression profiles (Affymetrix 
human ST 2.1) and small RNA expression (Illumina tru-seq) were generated from RNA 
isolated from micro-dissected glomeruli and corresponding tubulointerstitium of the same 
individuals. Associations between gene expression and quantitative phenotypes were then 
determined. In addition miR-21 deficient mice and wild type littermates (C57BL/6J and 
DBA/2J; n≥6 for each genotype) were aged to in excess of two years and assessed for the 
same morphometric parameters.
Results: In human kidneys podocyte density declined with age and was significantly 
associated with increases in mesangial index (p=0.003), podocyte cytoplasmic size 
(p=<0.001) and focal global glomerulosclerosis (FGGS) (p=0.009). FGGS was significantly 
associated with interstitial fibrosis (p=0.006). miR-21 expression in glomeruli is positively 
correlated with podocyte density (p=0.041) and inversely correlated with mesangial index 
(p=0.02) and podocyte size (p=0.01). miR-21 expression increases with age in murine 
kidneys and miR-21-null mice exhibited decreased podocyte density (p=<0.001) and 
increased mesangial index (p=0.001) compared to wildtype littermates.
Conclusions: Both humans and mice experience an age-associated loss of loss of 
podocytes, and a concomitant increase in podocyte size and mesangial index. In mice 
miR-21 ameliorates phenotypes of glomerular aging. Candidate transcripts targeted by 
miR-21 that may mediate the observed phenotypes are being explored.
Funding: NIDDK Support, Other NIH Support - NIA
TH-OR093
Murine Double Minute-2 Inhibition Ameliorates Established Crescentic 
Glomerulonephritis  Dana Thomasova, Shrikant R. Mulay, Simone Romoli, 
Santhosh Kumar Vr, Jyaysi Desai, Hans J. Anders.  Nephrologisches Zentrum, 
Medizinische Klinik und Poliklinik IV, Klinikum der Univ München, Munich, 
Germany.
Background: Rapidly progressive glomerulonephritis (RPGN) is characterized by 
glomerular necroinflammation and crescent formation. The E3-ubiquitin ligase murine 
double minute (MDM)-2 is a non-redundant element of NF-κB signalling and the negative 
regulator of p53-mediated cell cycle arrest. We hypothesized that the MDM2 would drive 
crescentic GN via NF-κB-dependent glomerular inflammation and via p53-dependent 
parietal epithelial cell (PEC) hyperproliferation.
Methods: We used injection of 75 µl of sheep anti-rat anti-GBM serum in C57BL/6 
wild type and p53-deficient mice to induce crescentic GN and injection of MDM2 inhibitor 
nutlin-3a or vehicle every alternate day starting on day –1 for pre-emptive or day +1 for 
therapeutic intervention. Evaluation was performed 7 days after antiserum injection. For in 
vitro studies murine glomerular endothelial cells and PECs were transfected with MDM2 
or p53 siRNA and anlysed with qPCR or proliferation assay.
Results: The pre-emptive MDM2 blockade with nutlin-3a ameliorated all aspects of 
crescentic GN such as vascular necrosis, podocyte loss, glomerular crescent formation, 
albuminuria, as well as inflammation, preventing cytokine induction, and recruitment of 
glomerular leukocytes and macrophages. MDM2 inhibition with nutlin-3a had identical 
protective effects in p53 knockout mice, with the exception of crescent formation. In vitro 
experiments confirmed the MDM2 requirement for induction of NFκB-dependent cytokines 
in murine glomerular endothelial cells as well as the p53-dependency of MDM2-mediated 
PEC proliferation. To evaluate MDM2 blockade as a  therapeutic intervention in RPGN, we 
treated mice with established GN with nutlin-3a. Delayed onset of nutlin-3a treatment was 
equally protective as the pre-emptive treatment in abrogating crescentic GN.
Conclusions: The pathogenic effects of MDM2 are mostly p53-independent, associated 
with NFκB activation and increased intraglomerular inflammation, but the p53-dependent 
function of MDM2 regulates the PEC proliferation and crescent formation.We therefore 
propose MDM2 blockade as a potential novel therapy in RPGN.
TH-OR094
The Bone Marrow Initiates and Propagates suPAR-Mediated Kidney 
Disease  Eunsil Hahm,1 Changli Wei,1 Isabel Fernandez,1 Jing Li,1 Nicholas J. 
Tardi,1 Shikha Wadhwani,1 Vineet Gupta,1 Sanja Sever,2 Jochen Reiser.1  1Dept of 
Internal Medicine, Rush Univ Medical Center, Chicago, IL; 2Div of Nephrology, 
Massachusetts General Hospital, Charlestown, MA.
Background: Proteinuria is a hallmark of glomerular kidney dysfunction, seen in both, 
native and post-transplant focal segmental glomerulosclerosis (FSGS). Systemic soluble 
urokinase plasminogen activator receptor (suPAR) is implicated in FSGS, yet the origin 
of suPAR in FSGS remains unclear.
Methods: Humanization techniques, adoptive transfer, cell depletion, ELISA, flow 
cytometry, histology, and electron microscopy were performed.
Results: Here we report that bone marrow (BM) myeloid progenitor cells (MPCs) 
are responsible for the production of suPAR, resulting in kidney damage and proteinuria. 
Using a xenograft mouse model, we found that engraftment of CD34+ peripheral blood 
mononuclear cells (PBMCs), but not CD34- PBMCs, from patients with recurrent FSGS 
into immunocompromised mice resulted in an expansion of Gr-1lo murine BM myeloid 
cells, leading to proteinuria and FSGS-like glomerulopathy. Furthermore, adoptive 
transfer experiments demonstrated that Gr-1lo BM myeloid cells are capable of causing 
suPAR-mediated proteinuria and therefore transmitting disease in healthy mice. We 
immunophenotypically characterized uPAR+Sca-1+Gr-1lo cells as “diseased” BM myeloid 
progenitor cells (MPCs), which are responsible for the production of suPAR competent to 
investigate kidney damage and proteinuria.
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Conclusions: Collectively, these results reveal a novel connection between bone 
marrow and kidney, and implicate myeloid progenitor cells as initiators of glomerular 
dysfunction with particular relevance to post-transplant FSGS.
Funding: NIDDK Support
TH-OR095
C-Reactive Protein and Myeloid Derived Suppressor Cells in Acute Kidney 
Injury  Alexander J. Szalai, Melissa A. Pegues.  Dept of Medicine, The Univ 
of Alabama at Birmingham, Birmingham, AL.
Background: Myeloid derived suppressor cells (MDSCs) are best known for their 
anti-proliferative effects on immune cells. Their contribution in renal cell carcinoma and 
chronic kidney disease has been investigated and their association with kidney transplant 
survival documented, but their role in acute kidney injury (AKI) has not been studied. 
Renal ischemia reperfusion injury (IRI) is a frequent cause of AKI: the former triggering 
a systemic inflammatory response that leads to increased blood levels of C-reactive protein 
(CRP), a biomarker of worsened outcomes. Recently, using a CRP transgenic mouse 
(CRPtg) model of renal IRI, we provided direct evidence that CRP is causal in AKI, i.e. 
its expression exacerbates renal IRI. The purpose of the present study was to determine if 
this harmful effect of CRP was propelled by increased infiltration of inflammatory cells 
into the injured kidneys.
Methods: We compared myeloid cell populations in the kidneys of wild type (WT), 
human CRP transgenic (CRPtg), and CRP deficient (CRP-/-) mice subjected to bilateral 
renal IRI.
Results: In CRP-/-, which were nearly refractory to renal IRI, there was almost complete 
absence of MDSCs of the granulocytic subtype (g-MDSC; Gr-1+CD11b+Ly6ghighLy6clow 
cells identified by flow cytometry of kidney digest cells) in the injured kidneys. In stark 
contrast in CRPtg, wherein renal IRI was exaggerated, there was an abundance of g-MDSCs 
in the injured kidneys. Using in vitro T-cell proliferation assays we confirmed that these 
renal g-MDSCs were suppressive and in vivo in CRPtg, depletion of g-MDSCs prior to 
renal IRI (using anti-Gr-1 antibody) reduced serum/urine biomarkers of AKI. Importantly, 
CRPtg treated with an antisense oligonucleotide that specifically lowered human CRP levels, 
showed both dramatic improvement in renal biomarkers of AKI and dramatic reduction in 
renal infiltration of g-MDSCs after AKI.
Conclusions: To our knowledge these are the first data showing that (i) g-MDSCs 
contribute to the renal response to IRI and that (ii) CRP amplifies this contribution. By 
reducing g-MDSC infiltration into the injured kidney, CRP lowering therapy might be an 
effective treatment option for AKI.
Funding: NIDDK Support, Private Foundation Support
TH-OR096
C-Reactive Protein Promotes AKI by Impairing TEC Regeneration via the 
CD32-Smad3-P27 Dependent Inhibition of CKD2/Cyclin E Mechanism 
Xiao Ru Huang,1 Weiyan Lai,2 Ying Tang,3 Tan-qi Lou,2 Hui Y. Lan.1  1Dept of 
Medicine & Therapeutics, Li Ka Shing Inst of Health Sciences, and Shenzhen 
Research Inst, The Chinese Univ of Hong Kong, Hong Kong, China; 2Dept of 
Nephrology, The Third affiliated Hospital of Sun Yat-Sen Univ, Guangzhou, 
China; 3Dept of Nephrology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen 
Univ, Guangzhou, China.
Background: We have previous shown that C-reactive protein (CRP) plays a pathogenic 
role in acute kidney injury (AKI) by inhibiting tubular epithelial cell (TEC) regeneration. 
The present study tested a hypothesis that CRP may promote AKI via Smad3-p27 dependent 
inhibition of CKD2/cylin E-mediated TEC regeneration in vivo and in vitro.
Methods: The hypothesis was examined in a mouse model of AKI induced in human 
CRP transgenic/Smad3 knockout (CRP-Tg/Smad3-KO), CRP-Tg/Smad3-WT, CRP-WT/
Smad3-KO, and CRP-WT/Smad3-WT mice by clamping bilateral renal arteries for 40 
minutes and in cultured HK-2 TEC line.
Results: After 24 hours of AKI, CRP-WT/Smad3-WT showed a significant increase 
in serum levels of creatinine and severe tubular necrosis, which was further enhanced 
in CRP-Tg/Smad3-WT mice but blunted in CRP-Tg/Smad3-KO and CRP-WT/Smad3-
KO mice. Further studies revealed that enhanced AKI in CRP-Tg/Smad3-WT mice was 
associated with a marked activation of TGF-b/Smad3, upregulation of p27, and inactivation 
of CKD2 kinase, thereby reducing cyclin E expression and impairing TEC proliferation as 
determined by BrdU incorporation and PCNA. In contrast, deletion of Smad3 in CRP-Tg 
mice prevented the development of AKI as demonstrated by normalizing serum levels 
of creatinine and suppressing the Smad3-p27 pathway, thereby promoting CKD2/cyclin 
E-dependent TEC proliferation. In vitro studies confirmed these findings that CRP acted 
through its receptor CD32b to activate Smad3 signaling via both TGF-b-dependent and 
ERK/MAPK crosstalk pathway. Furthermore, we also found that activated Smad3 then 
bound directly to p27 to suppress CKD2/cyclin E-dependent TEC proliferation, which was 
inhibited by a Smad3 inhibitor (SIS3).
Conclusions: CRP promotes AKI by impairing the TEC regeneration via the CD32-
Smad3-p27 mediated inhibition of CKD2/cyclin E mechanism.
Funding: Other NIH Support - RGC GRF 468711, CUHK3/CRF/12R, 973 program 
(2012CB517705), CUHK FIS-A program.
TH-OR097
Peptidyl Arginine Deiminase-4 Exacerbates Ischemic Acute Kidney Injury 
by Finding NEMO  May M. Rabadi, Mihwa Kim, Kevin M. Brown, H. Thomas 
Lee.  Anesthesiology, Columbia Univ, New York, NY.
Background: Ischemic acute kidney injury (AKI) is a devastating clinical problem 
without effective therapy. We recently showed that peptidylarginine deiminase-4 (PAD4) 
that converts peptidylarginine to peptidylcitrulline plays a critical role in ischemic AKI 
by promoting renal tubular inflammation. We hypothesized that PAD4 induces renal 
inflammation and exacerbates AKI by citrullinating IKKγ (also known as NFkB Essential 
MOdulator or NEMO) and promoting renal tubular pro-inflammatory NFkB signaling. 
Furthermore, we tested whether targeted NEMO inhibition attenuates renal inflammation 
and protects against ischemic AKI.
Methods: We first tested whether recombinant human PAD4 (1-10 mg/ml) directly 
citrullinates human recombinant NEMO or NEMO in human proximal tubule (HK-2) 
cells. We also tested whether NEMO neutralization with NEMO binding peptide (NBP, 
10 µM) attenuates rPAD4-mediated nuclear NFkB translocation and induction of pro-
inflammatory mRNAs in HK-2 cells. Finally, after Columbia IACUC approval, we tested 
whether NEMO neutralization (5 mg/kg) in mice attenuates rPAD4-mediated exacerbation 
of 20 min ischemic AKI and renal inflammation.
Results: rPAD4 directly citrullinated NEMO in a cell free system as well as in HK-2 
cells. In addition, rPAD4 directly caused nuclear NFkB-p65 subunit translocation which 
was attenuated by NEMO neutralization. Furthermore, NEMO neutralization significantly 
attenuated rPAD4-mediated induction of pro-inflammatory genes (MCP-1 by 59±11%, 
MIP-2 by 43±10%, TNF-α by 59±12% and IL-8 by 83±3%) in HK-2 cells (P<0.05, N=5-
8). Finally, NEMO neutralization significantly attenuated rPAD4-mediated exacerbation of 
ischemic AKI (rPAD+veh Cr(mg/dL)=2.4±0.4 vs. rPAD+NBP Cr=1.2±0.1, N=6, P<0.01) 
and renal inflammation (assessed with pro-inflammatory gene expression, neutrophil 
infiltration) in mice.
Conclusions: Our studies show that PAD4 exacerbates ischemic AKI and inflammation 
by promoting renal tubular NFkB activity via NEMO citrullination. Furthermore, we show 
that NEMO inhibition attenuates kidney injury and reduces the inflammatory response after 
renal IR injury. Selective NEMO neutralization may serve as a potential therapy for this 
devastating clinical problem.
Funding: NIDDK Support, Other NIH Support - NIGMS
TH-OR098
Severity, Frequency and Prevalence of Proximal Tubule Injury Determines 
Renal Prognosis  Koji Takaori,1 Jin Nakamura,1 Tadashi Yamamoto,2 Kumar 
Sharma,3 Motoko Yanagita.1  1Nephrology, Kyoto Univ, Kyoto, Japan; 2Structural 
Pathology, Niigata Univ, Niigata, Japan; 3Center for Renal Translational 
Medicine and Inst of Metabolomic Medicine, Univ of California San Diego, 
Sandiego, CA.
Background: Acute kidney injury (AKI) increases the risk to develop chronic kidney 
disease (CKD) and end-stage renal disease, whereas the mechanisms linking AKI to CKD 
remain unclear. Because proximal tubule injury is the mainstay of AKI, we postulated that 
proximal tubule injury triggers several features of CKD.
Methods: We generated a novel mouse model to induce selective proximal tubule-
specific adjustable injury by inducing the expression of diphtheria toxin receptor (DTR) 
in proximal tubules with variable prevalence (Ndrg1CreERT2:iDTR mice). For in vitro 
analysis, we utilized co-culture of renal fibroblasts and tubular epithelial cells.
Results: Administration of high-dose diphtheria toxin (DT) faithfully causes severe 
proximal tubule-specific injury, associated with interstitial fibrosis and reduction of 
erythropoietin production. Mild proximal tubule injury from a single hit triggers reversible 
fibrosis, whereas repeated mild injuries cause sustained interstitial fibrosis, inflammation, 
glomerulosclerosis and atubular glomeruli. Fibroblasts co-cultured with damaged tubular 
cells exhibited the induction of extracellular matrix and inflammatory genes, supporting 
the crosstalk between these two cell types. Proximal tubule-specific injury also triggers 
distal tubule injury, implying the proximal-distal tubule crosstalk.
Conclusions: Our data provide new evidence that proximal tubule injury triggers 
several features of CKD, and that the severity, frequency and prevalence of proximal tubule 
injury determine the progression to CKD. Our results indicate that fibrosis after AKI is 
secondary to tubular injury, and that treatment of fibrosis itself might not be enough to halt 
AKI-to-CKD progression. There is an urgent need to develop therapeutic strategies to protect 
proximal tubules from repeated injury and to restore healthy proximal tubular function.
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TH-OR099
Proximal Tubule Necroptosis Is Mediated by Mixed Lineage Kinase 
Domain Like (MLKL) In Vivo and Ex Vivo  Andreas Linkermann,1 Nina 
Himmerkus,2 Ina Maria Schiessl,3 Hans J. Anders,4 Joel M. Weinberg,5 Alberto 
Ortiz,6 James M. Murphy,7 Ulrich Kunzendorf,1 Jan H. Braesen,8 Markus 
Bleich,2 Stefan Krautwald.1  1Clinic for Nephrology and Hypertension, Univ of 
Kiel, Kiel, Germany; 2Dept of Physiology, Univ of Kiel, Kiel, Germany; 3Inst 
for Physiology, Univ of Regensburg, Regensburg, Germany; 4Medizinische 
Klinik und Poliklinik IV, LMU Munich, Munich, Germany; 5Dept of Internal 
Medicine, Univ of Michigan, Ann Arbor, MI; 6Unidad de Dialisis, Fundacion 
Jimenez Diaz, Madrid, Spain; 7Div of Cell Signalling and Death, Walter and 
Eliza Hall Insitute of Medical Research, Parkville, Australia; 8Dept of Pathology, 
Unversity of Hanover, Hanover, Germany.
Background: RIPK3-dependent necroptosis is of critical relevance for many diseases 
including hypoxic organ damage in AKI (Linkermann and Green, NEJM 2014). However, 
the putative downstream mediators, such as mixed lineage kinase domain like (MLKL) have 
not been investigated in detail, but may trigger local tissue Inflammation in a process referred 
to as necroinflammation (Linkermann et al, NRI 2014). Ferroptosis, an iron dependent cell 
death, is thought not to be affected by MLKL.
Methods: We employed video-monitoring of microperfused freshly isolated renal 
tubules, intravital microscopy, biochemistry, and diverse in vivo models of AKI and SIRS in 
wild type, MLKL-deficient- and RIPK3-deficient mice in the presence of newly developed 
necrostatins and ferrostatins.
Results: MLKL-deficient mice exhibit stronger protection against all investigated 
models of AKI in direct comparison to RIPK3-deficient mice. In SIRS models, RIPK3 and 
MLKL-ko mice are protected compared to wild type littermates, but there is no statistically 
significant difference between these two. In intravital microscopy, MLKL-ko, unlike RIPK3-
ko, do not exhibit wider peritubular capillaries compared to wild type, but the perfusion 
is increased due to increased flow. In isolated renal tubules, erastin-induced synchronized 
renal tubular necrosis was significantly attenuated in MLKL-ko mice.
Conclusions: We identify MLKL as a master regulator of AKI and SIRS. In contrast 
to RIPK3, which exclusively functions in necroptosis, MLKL might affect ferroptosis.
TH-OR100
NMN, a NAD+ Precursor, Can Rescue the Age-Associated Susceptibility 
to Cisplatin Induced Acute Kidney Injury in a SIRT1-Dependent Manner 
Yi Guan, Chuanming Hao.  Dept of Nephrology, Huashan Hospital, Shanghai, 
China.
Background: AKI is a common critical condition, the incidence of which increases 
with age. SIRT1, a NAD+-dependent deacetylase, has been shown to have beneficial effect 
on both life span and renal health. NMN is a NAD+ precursor involved in NAD+ recycle 
and SIRT1 activity. This study explores the role of SIRT1 and NMN in age-associated AKI, 
and mechanism by which SIRT1 deficiency aggravates AKI.
Methods: Age-associated susceptibility to AKI was investigated using 3 month-
old and 20 month-old 129 mice. The role of SIRT1 in AKI was examined using SIRT1 
heterozygotes. AKI was induced by cisplatin(20mg/kg). Kidney damage was assessed 
by BUN, kidney histology and Tunel assay. Mitochondria was examined by electronic 
microscope. The signaling pathway involved was explored by microarray and validated 
by Q-PCR, western blot and co-IP.
Results: After exposed to cisplatin, the 20-month-old mice had a more severe acute 
kidney injury than 3-month-old. In the aged mice, the kidney NAD+ level was only 30% of 
that in the young (5.9±2.5vs19.9±5.9 pmol/mg protein), accompanied by reduced SIRT1 
expression. SIRT1 deficiency(SIRT1+/-) also significantly aggravated cisplatin-induced 
AKI compared to SIRT1 intact littermates. Severe mitochondrial dysfunction and cell 
damage was observed in proximal tubules of the AKI aged mice and SIRT1 knockouts. 
NMN, provided from the same day as cisplatin for 4days, markedly attenuated renal 
damage(BUN 78.31±18.16vs148.7±9.136, P<0.001). The effect of exogenous NMN was 
substantially reduced in SIRT1 deficient mice, suggesting that the protective effect of 
NMN was dependent on SIRT1 activity. Microarray suggests that JNK pathway is a critical 
signaling pathway associated with SIRT1 deficiency. Activation of JNK was validated by 
Q-PCR and Western blot. Co-IP experiment revealed DUSP16, a JNK dephosphorylase, 
might be regulated by SIRT1.
Conclusions: (1)In aged kidney, NAD+ level and SIRT1 expression is reduced, resulting 
in increased age-associated susceptibility to AKI;(2)Supplementation of NMN, a NAD+ 
precursor and a metabolite of a lipid lowering drug Niacin, rescued cisplatin-induced 
AKI;(3)JNK activation is associated with increased renal injury in SIRT1 deficient animals.
Funding: Government Support - Non-U.S.
TH-OR101
Therapeutic Effects of BB3, a Small Molecule Hepatocyte Growth Factor 
Mimetic, in Kidney Reperfusion Injury  Prakash Narayan, Bin Duan, Xingxi 
Peng, Kai Jiang, Latha Paka, Michael A. Yamin, Itzhak D. Goldberg.  Angion 
Biomedica Corp.
Background: Activation of the hepatocyte growth factor (HGF)/cMet pathway is 
therapeutic in ischemia-reperfusion (IR)-related acute kidney injury (AKI). However 
poor half-life makes clinical use of recombinant protein therapy in settings such as AKI or 
kidney transplantation (Tx) challenging. We investigated the effects of a unique and novel 
small molecule with HGF-like activities, BB3, in models of AKI and Tx. BB3 selectively 
phosphorylates cMet and triggers the HGF/cMet pathway in multiple in vitro assays.
Methods: IR: Adult male rats had 60 min normothermic renal artery occlusion. At 
reperfusion, the contralateral kidney was excised. BB3 (2 mg/kg) was administered QD 
starting at 24 hour into reperfusion. Tx: Kidneys from adult male Lewis rats were cold-
preserved (~4οC) for 4 hr and transplanted into syngeneic recipients whose native kidneys 
were excised. BB3 (2.0 mg/kg, QD) was administered until sacrifice on Day 14.
Results: IR: Treatment with BB3, starting 24 hr after reperfusion, increased tubular 
cMet phosphorylation in vivo 3.5-fold (p<0.01). BB3 decreased tubular expression of kidney 
injury marker-1 (KIM-1), decreased tubular apoptosis, enhanced preservation of tubular 
integrity, improved urine output and reduced serum creatinine (figure1) Tx: BB3 improved 
recipient survival (60% vs 30% for control) and mitigated renal dysfunction (e.g., Day 7 
SCr: 0.84 mg/dL vs 2.72 mg/dL for control; p<0.05).
Conclusions: Starting as late at 24 hour after AKI, activation of the HGF/cMet pathway 
with BB3 mitigates renal injury and improves renal function. These data together with the 
expanded window for therapeutic intervention support the use of BB3 in Angion’s Phase 2 
GUARD study in AKI patients and Phase 3 GIFT study in kidney Tx recipients presenting 
with delayed graft function. Funded by DK-062592, -066654, -079399.
Funding: NIDDK Support
TH-OR102
CRP Exacerbates Ischemia-Reperfusion Injury in the Kidney by Down-
Regulating Autophagy  Ao Bian,1 Mingjun Shi,1 Brianna Flores,1 Nancy 
Gillings,1 Orson W. Moe,1,2,3 Ming Chang Hu.1,2  1Charles and Jane Center for 
Mineral Metabolism and Clinical Research, UT Southwestern Medical Center; 
2Dept of Internal Medicine, UT Southwestern Medical Center; 3Physiology, UT 
Southwestern Medical Center, Dallas, TX.
Background: C-reactive protein (CRP), an acute biomarker, was recently reported to 
be closely associated with poor renal function in patients with acute kidney injury (AKI), 
but its pathogenic role in ischemic kidney injury remains unclear.
Methods: To examine the in vivo effect of CRP on autophagy in AKI induced by renal 
ischemia-reperfusion injury (IRI), we mated transgenic CRP overexpressing mice (CRP) 
with a autophagy reporter mouse (LC-3-GFP) to generate the combination mouse line 
(CRP;LC-3-GFP). In vivo: Mice were studied 2 days after IRI. Ex vivo: Renal tubules were 
isolated from LC-3-GFP mice at baseline for primary culture. In vitro: OK cells transfected 
with LC-3-GFP were used. The ex vivo and in vitro studies complement the in vivo study 
to define the direct effect of CRP on the kidney.
Results: Compared with LC-3-GFP mice, CRP;LC-3-GFP mice had higher serum 
creatinine (P<0.05), more tubular necrosis, and higher NGAL expression in the kidney after 
IRI. CRP addition exacerbated H2O2-increased LDH release from both primary cultured 
renal tubules and OK cells (P<0.01 respectively). Immunoblots showed lower LC-3 II/I ratio 
and higher p62, markers of autophagic flux, in the kidneys of CRP;LC-3-GFP compared 
to LC-3-GFP mice after IRI, and in primary culture of renal tubules and OK cells treated 
with CRP + H2O2 compared to H2O2 alone. Immunohistochemistry showed much fewer 
LC-3-GFP puncta in kidneys of CRP;LC3-GFP compared to LC-3-GFP mice after IRI. 
Similarly, CRP addition reduced LC-3-GFP puncta induced by H2O2 in primary cultured 
renal tubules and in OK cells transfected with LC-3-GFP plasmid. Autophagy inducers 
(rapamycin and LiCl) rescued the impaired autophagy and blunted the LDH release from 
OK cells treated with CRP + H2O2 (P<0.05).
Conclusions: CRP renders the kidney more susceptible to ischemic/oxidative injury by 
down-regulation of autophagy flux. Autophagy inducer repairs down-regulated autophagy 
triggered by CRP and protects the kidney against ischemia reperfusion injury.
Funding: NIDDK Support
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TH-OR103
Signal Inhibitory Regulatory Protein-α Regulates Pathologic Reactive 
Oxygen Species Generation in Acute Kidney injury  Natasha M. Rogers,1,2 
Daniel N. Meijles,1 Patrick J. Pagano,1 Jeffrey S. Isenberg.1  1Vascular Medicine 
Inst, Univ of Pittsburgh, Pittsburgh, PA; 2Starzl Transplant Inst, Univ of 
Pittsburgh, Pittsburgh, PA.
Background: Ischemia reperfusion injury (IRI) is a major cause of acute kidney 
injury mediated by oxidative stress. We recently reported that signal regulatory inhibitory 
protein (SIRP)-α is expressed by renal tubular epithelial cells (TEC), that the protein 
thrombospondin-1 (TSP1) is increased following renal IRI, and TSP1 binds to SIRPα. 
However, it is unclear how TSP1-SIRPα signaling contributes to IRI pathophysiology.
Methods: Wild-type (WT) mice, and SIRPα mutant (SIRPamut) mice lacking 
cytoplasmic recruitment domains, underwent bilateral renal IRI followed by assessment of 
renal function and biomolecular analysis after 24 h reperfusion. Murine WT and SIRPamut 
TEC were studied in vitro. Mice were also irradiated and rescued with WT or SIRPamut 
bone marrow.
Results: IRI resulted in elevated serum creatinine in WT mice which was mitigated 
in SIRPamut animals (2.3±0.5 versus 0.98±0.4 mg/dl, p<0.01). Changes in renal function 
reflected improvements in renal histology, including tubular necrosis and inflammatory 
infiltrate. TSP1 was expressed to a similar degree in all mice post-IRI. Measurement of 
reactive oxygen species (ROS) in kidney demonstrated a 3-fold increase in superoxide in 
WT mice post-IRI (p<0.001) but no increase in SIRPamutmice when compared to sham. 
Expression of 3-nitrotyrosine protein modification was reduced in SIRPamut compared to 
WT mice, although total renal expression of NADPH oxidase 1 and 2 were unchanged. In 
vitro, WT TEC displayed upregulation of ROS in response to TSP1 (p<0.01), which was 
not reflected in SIRPamut cells. SIRPα is expressed by all renal cells, and chimeric mice were 
generated to explore differences in cell compartment contribution to IRI. SIRPamut mice, 
regardless of hematopoietic reconstitution, were fully protected against renal dysfunction, 
tubular damage and ROS generation following IRI.
Conclusions: These data provide evidence for a role for SIRPα promoting renal IRI 
through generation of pathologic ROS, and blockade of SIRPα may provide a therapeutic 
target to modify IR-mediated damage.
Funding: NIDDK Support
TH-OR104
“Urine Sediment” the Ignored Treasure Chest in the Search for Biomarkers 
in Acute Kidney Injury  Nithin Karakala,1 Juan Carlos Q. Velez,1 Michael G. 
Janech,1 Joseph Alge,1 John M. Arthur.2  1Div.of Nephrology, MUSC, Charleston, 
SC; 2Div Nephrology, UAMS, Little Rock, AR.
Background: In the last decade novel urine biomarkers have been identified in urine 
supernatant. Urine sediment is extensively used in clinical practice for microscopy but has 
not been used for AKI biomarker discovery. We examined whether urine sediment from 
can be used to identify biomarkers and determine the proportion of sediment proteins that 
originate from brush border (BB), and mitochondria (MX).
Methods: Urine samples from patients admitted to the medical ICU at the Medical 
University of South Carolina were collected from 8 patients (4 without AKI and 4 with 
AKIN stage 3 AKI at the time of collection). The urine was centrifuged to separate sediment 
from supernatant. We performed liquid chromatography, tandem mass spectrometry (LC 
MS/MS) on each sediment and supernatant sample. We estimated the relative abundance of 
brush border, and mitochondrial proteins using Exponentially Modified Protein Abundance 
Index (emPAI). Database of BB, and MX proteins were used to identify BB and MX 
proteins from our experiment. The molar fraction of each protein in the sample relative to 
the total moles of all proteins in the sample was calculated for each protein. We used this 
to determine the percent of moles of protein for BB, and MX proteins in the sediment.
Results: We identified 479 proteins in sediment (396 from the AKI 3 and 430 in No 
AKI). We identified 556 proteins from the no AKI samples, 239 proteins were present only in 
the sediment and 126 were identified only in the supernatant. In AKI 3 samples we identified 
570 proteins, 169 proteins were unique to the sediment and 174 to the supernatant. The 
molar abundance percentage of BB proteins in the AKI 3 sediment and no AKI 3 sediment 
was 3.7 and 27.6% and MX proteins was 2.7 and 14.6% respectively.
Conclusions: We have developed an LC MS/MS technique for proteomic analysis of 
urine sediment. Urine sediment from no AKI and AKI 3 have proteins that are not found 
in supernatant. These proteins are potential biomarkers. As a percent of the molar amount 
of protein BB and MX is markedly less in AKI sediment. This finding has implication for 
the pathophysiology of shedding of renal tubular material in AKI.
TH-OR105
FGF23 Drives Progression of Chronic Kidney Disease in Mice 
Olena Andrukhova,1 Svetlana Slavic,1 Sathish Kumar Murali,1 William G. 
Richards,2 Reinhold Erben.1  1Dept of Biomedical Sciences, Univ of Veterinary 
Medicine, Vienna, Austria; 2Dept of Metabolic Disorders, Amgen Thousand 
Oaks, Thousand Oaks, CA.
Background: Circulating fibroblast growth factor 23 (FGF23) is associated with 
disease progression in patients with chronic kidney disease (CKD).
Methods: Here, we elucidate the role of Fgf23 and its co-receptor Klotho in 
pathogenesis of CKD in mice by a dual approach, using genetic loss-of-function together 
with pharmacological inhibition models. CKD was induced by 5/6 nephrectomy in 
3-month-old wild-type (WT) mice, vitamin D receptor (VDR) mutant mice, Fgf23-/-/
VDR∆/∆, and Klotho-/-/VDR∆/∆ compound mutant mice. All mice were kept on a rescue diet 
to prevent secondary hyperparathyroidism in VDR mutant mice. Sham-operated (SHAM) 
mice served as controls. In addition, SHAM and CKD WT, VDR, and Klotho/VDR mice 
were treated with low dose anti-FGF23 antibody (anti-FGF23Ab, 50 µg/mouse, 2 times/
week) over 8 weeks.
Results: Genetic ablation of Fgf23 in Fgf23/VDR compound mutant or treatment of 
WT and VDR CKD mice with anti-FGF23Ab partially or completely protected against 
the CKD-induced weight loss, increase in mortality, reduction in glomerular filtration 
rate, albuminuria, volume expansion, hypernatremia, hypercalcemia, hypertension, and 
left ventricular functional impairment observed in untreated and vehicle-treated WT and 
VDR mice. Anti-FGF23Ab treatment of Klotho/VDR CKD mice, which were characterized 
by the highest circulating Fgf23 concentrations among all CKD groups, reduced mortality 
and slowed disease progression in these mice to levels found in Fgf23/VDR mutants, 
demonstrating that Fgf23 also has Klotho independent effects at high circulating levels. 
Genetic or pharmacological ablation of Fgf23 prevented hypercalcemia and volume overload 
in CKD mice by down-regulating renal sodium-transporting molecules, and increasing 
urinary excretion of sodium and calcium.
Conclusions: Collectively, our data suggest that elevated Fgf23 contributes to the 
pathogenesis of CKD in a vitamin D hormone- and partially Klotho-independent manner. 
Hence, our study may provide a mechanistic explanation for the association between 
circulating FGF23 and disease progression in CKD patients.
TH-OR106
In Vivo Role of Klotho in the Renal Proximal Tubules  Noriko Ide,1 Hannes 
Olauson,3 Tadatoshi Sato,1 Junichi Hanai,2 Tobias E. Larsson,3 Beate Lanske.1 
1Dept of Oral Medicine, Infection, and Immunity, Harvard School of Dental 
Medicine, Boston, MA; 2Dept of Medicine, Div of Nephrology, Interdisciplinary 
Medicine and Biotechnology, Medicine, Boston, MA; 3Div of Renal Medicine, 
CLINTEC, Karolinska Inst, Stockholm, Sweden.
Background: Klotho is predominantly expressed in the distal tubules, but also in 
proximal tubules to regulate calcium and phosphate reabsorption, respectively. Global and 
total-nephron specific Klotho deletion both cause mineral disorder and premature aging. 
Klotho ablation from only distal tubules resulted in a mild phenotype indicating a key role 
for Klotho in proximal tubules.
Methods: No single Cre strain provided effective Klotho deletion in all proximal tubular 
segments. Therefore, three proximal tubule-specific Klotho knock-out mouse models were 
generated and compared by crossing PEPCK (phosphoenolpyruvate carboxykinase)-, KAP 
(Kidney androgen-regulated protein)-, or SLC34a1 (sodium phosphate cotransporter-2a1)-
cre with Klothofl/fl(KL) mice.
Results: Klotho deletion was confirmed by qPCR, Western, and IHC. FGF23-Klotho 
signaling regulates phosphate homeostasis, so mineral parameters and regulatory factors 
were measured. In PEPCK-KL and SLC34a1-KL mice, urine phosphate excretion 
significantly decreased. This was not clearly detected in KAP-KL mice, despite increased 
renal NaPi2a mRNA and protein levels. Challenge of KL-KAP mice with high phosphate 
diet resulted in a significant decrease of urine phosphate excretion compared with WT. 
Serum phosphate level remained normal in all mouse lines. In summary, Klotho deletion 
in renal proximal tubules leads to a slightly decreased phosphate excretion with no changes 
in serum phosphate levels.
Conclusions: We demonstrate a role for Klotho in renal proximal tubules. Importantly, 
while global and total-nephron deletion of Klotho result in a severe phenotype, deletion 
in either distal or proximal renal tubules alone results in only minor changes in mineral 
homeostasis. This suggests a more integrated and organized cooperation between these 
two loci. These results are the first to show an interdependent relationship of Klotho in the 
distal and proximal tubules.
Funding: Other U.S. Government Support
TH-OR107
The Increased Bone Fibroblast Growth Factor 23 Expression Is Mediated 
by the Fibroblast Growth Factor Receptor in Experimental Uremia 
Ronen Levi, Alia Hassan, Karina Durlacher, Justin Silver, Tally Naveh-Many. 
Minerva Center for Calcium and Bone Metabolism, Nephrology, Hadassah 
Hebrew Univ Medical Center, Jerusalem, Israel.
Background: Serum FGF23 is markedly elevated in CKD and has been associated 
with poor long-term outcomes. FGF23 expression is increased by activation of the FGF 
receptor 1 (FGFR1) in rats with normal renal function and in vitro in UMR106 osteoblast-
like cells. We now demonstrate a role for FGFR in the regulation of FGF23 in a mouse 
model of acute kidney injury (AKI) due to high dose folic acid (FA), in rats with adenine 
high phosphorus induced CKD and in UMR106 osteoblast like cells.
Methods: Mice were injected with 250 mg/kg folic acid ip to induce AKI and sacrificed 
at 3 and 6 h. The FGFR inhibitor PD173074 was given to the mice 1 h before FA. Rats 
were fed an adenine high phosphorus diet for 14 d and PD173074 given for the last 2 d of 
the diet. Serum biochemistry, FGF23 and PTH levels were analyzed and calvaria FGF23 
mRNA measured by qRT-PCR.  FGF2 and PD173074 were added to UMR106 cells for 
24 and 48 h and FGF23 mRNA levels measured.
Results: FA increased serum BUN and phosphate levels as expected from 3 h. Calvaria 
FGF23 mRNA and serum FGF23 levels were increased 2-3-fold at 6 h. PTH levels increased 
6-fold from 3 h after FA. The FGFR inhibitor PD173074 prevented the FA induced increase 
in both FGF23 mRNA and serum levels but had no effect on serum PTH levels. A more 
prolonged uremia due to an adenine high phosphorus diet for 14 d resulted in high levels 
of serum PTH (30-fold increase) and FGF23 (3.5-fold increase). PD173074 decreased 
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serum FGF23 and mRNA levels with no effect on PTH in the adenine high phosphorus 
induced uremic rats. Addition of FGF2 to UMR106 cells increased FGF23 expression that 
was also prevented by PD173074.
Conclusions: A derangement in FGF-23 regulation starts early in the course of AKI, 
is in part independent of the increase in serum PTH and involves activation of FGFR. This 
is the first demonstration that activation of FGFR is important to the high levels of FGF23 
in both acute and chronic experimental uremia. FGFR in the osteocyte may be activated 
by locally produced canonical FGFs such as FGF2.
TH-OR108
Acute and Chronic Inflammation Raises the Blood Levels of FGF23 
in Normal Mice  Shweta Bansal,1,2 William E. Friedrichs,1 Chakradhar 
Velagapudi,1 Sherry L. Werner,1,2 Paolo Fanti.1,2  1Medicine/Renal, Univ of Texas 
Health Sciences Center at San Antonio, San Antonio, TX; 2Renal Section, South 
Texas Veterans Healthcare System, San Antonio, TX.
Background: High levels of FGF23 are not fully explained by abnormal mineral 
metabolism in CKD. We and others found association of FGF23 with inflammation in CKD 
patients, but knowledge about the role of inflammation in FGF23 regulation is limited.
Methods: Inflammation was induced in FBV mice as follows (n=5 each Gr): Gr1-acute 
inflammation: single IP injection of 3.3 µg/kg of LPS (E.Coli 0111:B4) or vehicle control 
(Vh); Gr2-chronic pulsatile inflammation: daily IP injections of 3.3 µg/kg of LPS x 2 
weeks; Gr3-chronic persistent inflammation: SQ insertion of pellets releasing 2 mg/kg/
day of LPS plus Vh daily injection x 2 weeks; and Gr4-acute on chronic inflammation: 
SQ LPS pellets x 2 weeks and single IP LPS injection before sacrifice. Plasma FGF23 
(c-term) and TNFα levels and spleen weight measured at sacrifice.
Results: In Gr1, FGF23 levels were 0.5±0.1 ng/ml 5 hours after LPS injection vs. 
0.2±0.04 ng/ml in Vh (p=0.001). In Gr2, FGF23 was 0.2±0.02 ng/ml after 2-week daily 
LPS injections vs. 0.14±0.04 in Vh (p=0.02). In Gr3, FGF23 was 0.8±0.6 after 2-weeks 
LPS pellet vs. 0.14±0.04 ng/ml in Vh (p=0.04). In Gr4, FGF23 was the highest i.e.,1.3±0.7 
after 2-week LPS pellets and single LPS injection, vs. 0.14±0.04 in Vh (p=0.006). TNFα 
levels rose significantly in Gr3 and Gr4 vs. Vh (respectively 11±0.8, 14±0.8, and 8.0±0.8 
pg/ml). Spleen weights were significantly higher in Gr3 and Gr4 as further indication of 
presence of inflammation. Summary: Both acute and chronic exposure to LPS caused 
inflammation and stimulated the synthesis of FGF23. The effects of acute and chronic LPS 
exposure seemed to be synergistic.
Conclusions: Inflammation raises the FGF23 levels in FVB mice. The inflammation 
experienced by the Gr4 mice mimics events in CKD, where low-grade chronic inflammation 
is often aggravated by sporadic acute inflammation, e.g., caused by infections or 
translocation of inflammatory agents across the gut barrier. More studies are needed to 
delineate the role of inflammation in the regulation of FGF23 in the context of CKD.
Funding: NIDDK Support
TH-OR109
FGF23 Directly Targets Hepatocytes to Promote Inflammation in CKD 
Saurav Singh,1 Alexander Grabner,1 Karla J. Schramm,1 Christopher Yanucil,1 
Alexis J. Sloan,1 Ansel P. Amaral,1,2 Myles S. Wolf,2 Christian Faul.1  1Dept 
of Medicine, Univ of Miami Miller School of Medicine, Miami, FL; 2Dept of 
Medicine, Northwestern Univ Feinberg School of Medicine, Chicago, IL.
Background: Chronic inflammation is a hallmark of chronic kidney disease (CKD), 
and biomarkers of inflammation are strong predictors of poor clinical outcome. The 
molecular mechanisms underlying the interrelationship between deterioration of renal 
function and amplification of the inflammatory state are unknown. CKD patients develop 
marked elevations in circulating levels of the phosphorus-regulating hormone, fibroblast 
growth factor (FGF) 23. Our recent data indicates that FGF23 directly induces cardiac 
injury by activating FGF receptor (FGFR) 4 in cardiac myocytes, independent of α-klotho. 
Since hepatocytes express high levels of FGFR4, we postulate that FGF23 can directly 
target the liver.
Methods: Using HepG2 cells, a hepatocellular carcinoma cell line, and primary mouse 
hepatocytes, we analyzed signal transduction and expression of inflammatory cytokines, 
including C-reactive protein (CRP) and interleukin-6 (IL-6) upon FGF23 treatment. FGF23 
was injected intravenously into wild-type mice for 5 days, and FGFR4 knockout mice were 
fed a 2% phosphorus diet for 12 weeks. 5/6 nephrectomized rats were administered with 
an FGFR4-specific blocking antibody.
Results: FGF23 induces expression of inflammatory cytokines in hepatocytes by 
activating calcineurin/NFAT signaling in an FGFR4-dependent and α-klotho-independent 
manner. Elevation of serum FGF23 in wild-type mice via injections of recombinant FGF23 
or administration of a high phosphate diet increases CRP levels in liver and blood. High 
phosphate diet does not elevate CRP expression in FGFR4 knockout mice. Pharmacological 
FGFR4 blockade reduces the expression of CRP in rats with CKD.
Conclusions: We provide a causative link between FGF23 elevations and the induction 
of an inflammatory response in the liver, and suggest a novel mechanism to explain the 
development of chronic inflammation in patients with CKD. Pharmacologic FGFR4 
blockade might have anti-inflammatory effects in CKD.
TH-OR110
Differential Effects of Calcitriol on FGF23/Klotho System and LVH 
in Experimental Uremia  Maren Leifheit-Nestler,1 Laura Hermann,1 
Dagmar-Christiane Fischer,2 Dieter Haffner.1  1Dept of Pediatric Kidney, Liver 
and Metabolic Diseases, Hannover Medical School, Hannover, Germany; 2Dept 
of Pediatrics, Univ Hospital Rostock, Rostock, Germany.
Background: Vitamin D (vitD) deficiency and excess of circulating FGF23 are 
significant contributors to cardiovascular (CV) mortality in CKD patients. In vivo, vitD 
metabolites downregulate genes involved in the development of left ventricular hypetrophy 
(LVH). However, vitD is a known stimulator of FGF23 synthesis in the bone, and thus, 
may have paradoxical effects on the CV phenotype in CKD. Here, we investigated the 
effects of vitD on the FGF23 signaling cascade mediated LVH in experimental uremia.
Methods: 5/6 nephrectomized rats (Nx) were treated with vitD for 4 and 10 weeks, 
and compared with controls. Heart tissue was determined for gene/protein expression of 
the FGF23 signaling pathway, pathological cardiac remodeling, and LVH. Cardiomyocyte 
cross-sectional area was quantified by immunofluorescence microscopy. Renal Klotho 
expression was investigated by quantitative real-time PCR.
Results: Cardiac Fgf23 levels, Fgfr1 and Fgfr4 mRNA, and LVH were increased 
significantly in 5/6Nx rats compared with controls. The calcineurin-NFAT signaling 
pathway was activated in uremia demonstrated by enhanced calcineurin accompanied by 
a strong reduction of phosphorylated NFAT protein. Pro-hypertrophic genes were increased 
in myocardial tissue of 5/6Nx rats. In general, vitD treatment of 5/6Nx rats resulted in 
reduced cardiomyocyte cross-sectional area. Although, cardiac Fgf23 levels, and Fgfr1 
and Fgfr4 mRNA were further stimulated by vitD, vitD treated 5/6Nx rats showed reduced 
activation of NFAT ameliorating cardiac remodeling processes and LVH. Interestingly, 
renal Klotho expression was markedly reduced in uremic animals, and almost normalized 
after vitD treatment.
Conclusions: Cardiac FGF23 levels are enhanced in experimental uremia, and 
associated with LVH. VitD enhances NFAT phosphorylation and thereby blocks pathological 
remodeling processes induced by FGF23. In addition, vitD restores renal Klotho expression, 
and consequently enhances soluble Klotho, which may further be cardioprotective via 
binding to and neutralizing FGF23 in the heart.
TH-OR111
FGFR4 Activation Is Sufficient to Induce LVH in Mice  Alexander Grabner,1 
Karla J. Schramm,1 Saurav Singh,1 Christopher Yanucil,1 Alexis J. Sloan,1 
Ansel P. Amaral,1,2 Christian Faul.1  1Medicine, Univ of Miami Miller School 
of Medicine, Miami, FL; 2Medicine, Northwestern Univ Feinberg School of 
Medicine, Chicago, IL.
Background: Previously, we demonstrated that fibroblast growth factor (FGF) 23 is 
a causal factor in the pathogenesis of left ventricular hypertrophy (LVH). FGF23 directly 
targets cardiac myocytes via FGF receptors (FGFR) and activates calcineurin/NFAT 
signaling. Mammals express four FGFR isoforms (FGFR1-4). Using two loss-of-function 
approaches (delivery of a blocking antibody in a rat model of chronic kidney disease (CKD) 
and gene deletion in mice), we could show that FGFR4 is required for the development of 
LVH in rodents with high FGF23. To confirm this finding in a gain-of-function approach, 
we studied a genetic knock-in mouse model carrying a FGFR4 mutation (G385R) that 
causes constitutive and ligand-independent activation of FGFR4.
Methods: We studied 6 months old homozygous FGFR4-G385R knock-in mice and 
wild type littermates. LVH was assessed by echocardiography, H&E staining of cardiac 
cross sections, and cross sectional area of individual myocytes. We analyzed cardiac fibrosis 
by Picrosirius Red staining and qPCR. Activation of calcineurin/NFAT signaling in cardiac 
tissue was studied by qPCR and Western blot analysis, and serum levels of cleaved FGF23 
were determined by ELISA.
Results: Compared to wild type littermates, FGFR4-G385R mice develop LVH as 
evident by significantly increased LV wall thickness, cross sectional myocyte area and 
ejection fraction. FGFR4-G385R hearts are not fibrotic, and show a significant elevation 
of NFAT target gene expression. Although serum FGF23 levels were increased in FGFR4-
G385R mice, the elevation did not correlate with the cardiac phenotype.
Conclusions: Activation of FGFR4 per se is sufficient to induce LVH in mice 
independently of serum FGF23 levels. We postulate that FGFR4 is part of a novel 
pro-hypertrophic signaling pathway in the heart that could be activated in patients with 
cardiomyopathies. FGFR4 blockade might not only serve as a novel pharmacological 
intervention for LVH in CKD patients with elevated FGF23, but also in patients with 
primary cardiac disease and increased FGFR4 activity in the heart.
Funding: NIDDK Support, Private Foundation Support
TH-OR112
Downregulation of Thrombomodulin Expression in Endothelial Cells by 
Fibroblast Growth Factor-23 and Klotho  Kenji Tanaka,1 Yoko Oyama,2 
Tancharoen Salunya.3  1Internal Medicine, Suiyukai, Kashihara, Nara, Japan; 
2Dept of Laboratory and Vascular Medicine, Kagoshima Univ Graduate School 
of Medical and Dental Sciences, Kagoshima, Japan; 3Dept of Pharmacology, 
Faculty of Dentistry, Mahidol Univ, Bangkok, Thailand.
Background: Chronic kidney disease (CKD) is regarded as a state of excessive 
fibroblast growth factor-23 (FGF-23) and a Klotho (KL) deficiency. Moreover, the 
increased mortality risk in CKD patients associated with cardiovascular disease and 
endothelial dysfunction. Increasing evidence demonstrates that thrombomodulin (TM) 
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plays an important role in endothelial barrier. The mechanism responsible for the linkage 
of FGF-23 underlying endothelial damage in these patients is unclear. Here we report a 
downregulation of membrane TM in human umbilical vein endothelial cells (HUVEC) 
after FGF-23/ KL stimulation.
Methods: HUVECs were cultured in endothelial basal medium with supplement. 
SDS-PAGE analysis was performed to confirm the dose dependent effect of FGF-23 on TM 
expression in HUVECs, and to confirm the effect of KL. Next, membrane TM expression 
was performed by flow cytometry to confirm the effect of FGF-23 in HUVEC cell surface. 
Finally, immunofluorescence (IF) staining for TM expression on HUVECs was performed. 
Cells were visualized by double staining for TM expression and nucleus.
Results: SDS-PAGE and flow cytometry analysis shows that TM expression was 
markedly decreased when HUVECs were stimulated with 10 ng/ml FGF-23/ KL whereas 
this effect was less pronounced upon 1 ng/ml FGF-23/ KL treatment and that KL stimulation 
for 12 and 16 hours induced TM production significantly as compared to the controls and 
FGF-23 and FGF-23/ Klotho -treated cells. IF staining shows that TM is expressed on 
the cell surface in control cells while this number was dramatically increased after KL 
stimulation and that TM expression was reduced after FGF-23 and FGF-23/ KL stimulation.
Conclusions: TM is constitutively expressed in HUVEC and is suppressed by FGF-23 
and FGF-23/ KL dose-dependently. Our results imply that TM response by FGF-23/ KL is 
a possible mechanism that leads to vascular complications in CKD patients.
Funding: Private Foundation Support
TH-OR113
Iron Status Affects FGF23 Production and Metabolism in Mice with 
Chronic Kidney Disease  Mark Hanudel,1 Kristine Joy Chua,2 Katherine 
Wesseling-Perry,1 Elizabeta Nemeth,2 Tomas Ganz,2 Isidro B. Salusky.1 
1Pediatrics, UCLA, Los Angeles, CA; 2Center for Iron Disorders, UCLA, Los 
Angeles, CA.
Background: Iron deficiency anemia and elevated FGF23 levels occur early in CKD. 
In mice with normal renal function, iron deficiency upregulates FGF23 expression, resulting 
in higher circulating FGF23 levels. However, the impact of iron status on FGF23 production 
and metabolism in CKD is unknown.
Methods: Wild type (WT) and hepcidin knockout (HKO) C57BL/6 mice were fed 
diets that did or did not contain adenine (which induces CKD), with low iron (4 ppm), 
standard iron (335 ppm), or high iron (10,000 ppm) concentrations. The standard iron diet 
was sufficient to iron load the HKO mice. Mice were on the diets for 8 weeks post-weaning, 
then sacrificed (n=8-15 mice/group). We measured plasma C-terminal FGF23 (cFGF23) 
and intact FGF23 (iFGF23); BUN, phosphorus, CBC; liver iron; and bone FGF23 mRNA 
expression. Multiple linear regression modeling was performed to assess the independent 
effects of iron and phosphorus on FGF23 in CKD.
Results: In both the Control and CKD cohorts, the low iron groups had the highest 
FGF23 mRNA expression and highest cFGF23 levels. Among the WT CKD mice, the high 
iron group had the lowest serum phosphorus levels, lowest cFGF23 levels, and a lower 
percentage iFGF23, possibly secondary to iron sufficiency and/or normophosphatemia. 
The HKO CKD standard iron group had higher liver iron content, lower FGF23 mRNA 
expression, and lower cFGF23 levels than the WT CKD standard iron group. In the CKD 
mice (n=57), serum phosphorus was independently associated with higher cFGF23 levels 
and higher percentage iFGF23; and liver iron was independently associated with lower 
cFGF23 levels and higher percentage iFGF23.
Conclusions: In mice with CKD, iron status affects FGF23 production and metabolism, 
independent of the effects of serum phosphorus.
Funding: Other NIH Support - UCLA K12 Child Health Research Career Develop-
ment Award (NIH 5K12HD034610-18)
TH-OR114
Tenapanor, an NHE3 Inhibitor, Reduces Serum Phosphate in Patients 
with CKD Stage 5D and Hyperphosphatemia  Geoffrey A. Block,1 David 
P. Rosenbaum,2 Maria Leonsson Zachrisson,3 Magnus Åstrand,3 Susanne 
Johansson,3 Mikael Knutsson,3 Anna Maria Langkilde.3  1Denver Nephrology, 
Denver, CO; 2Ardelyx Inc., Fremont, CA; 3AstraZeneca R&D, Mölndal, Sweden.
Background: Tenapanor (AZD1722), a first-in-class small molecule with minimal 
systemic availability, is an inhibitor of the Na+/H+ exchanger NHE3. Healthy volunteer 
studies show that tenapanor treatment increases stool sodium and phosphate and 
concomitantly reduces urinary sodium and phosphate. This double-blind, dose-finding 
study (NCT02081534) examined the effect of tenapanor on serum phosphate in patients 
with CKD stage 5D (hemodialysis).
Methods: After a 1–3-week washout of phosphate binders, 162 patients with baseline 
serum phosphate 6.0–<10.0 mg/dL and ³1.5 mg/dL increase from pre-washout levels were 
randomized to placebo or one of six tenapanor groups (1, 3, 10 or 30 mg bid, or 3 or 30 mg 
qd) for 4 weeks. Blood samples were collected weekly. The primary endpoint was change 
in serum phosphate from baseline. Dose–response analysis was a secondary endpoint.
Results: Tenapanor treatment resulted in dose-dependent reductions in serum phosphate 
(Table), with a significant difference between the treatment groups (p=0.012, ANCOVA). 
Gastrointestinal AEs were more common with tenapanor than with placebo, with higher 
doses associated with higher rates of diarrhea.
Conclusions: Tenapanor provided clinically and statistically significant reductions in 
serum phosphate. Higher doses of tenapanor were associated with higher rates of diarrhea, 
as expected based on its additional pharmacodynamic effect on stool sodium. Once- or 
twice-daily administration of tenapanor may offer a new treatment mechanism to reduce 
serum phosphate in patients with CKD.
Funding: Pharmaceutical Company Support - AstraZeneca
TH-OR115
Racial Differences in Association of Serum Calcium with Mortality and 
Incident Cardio- and Cerebrovascular Events  Jun Ling Lu,1 Miklos Zsolt 
Molnar,1 Jennie Z. Ma,2 Lekha K. George,1 Kamyar Kalantar-Zadeh,3 Csaba P. 
Kovesdy.1,4  1Univ of Tennessee Health Science Center, Memphis, TN; 2Univ 
of Virginia, Charlottesville, VA; 3Univ of California, Irvine, CA; 4VA Medical 
Center, Memphis, TN.
Background: In CKD patients, both high and low serum calcium (CA) is associated 
with higher mortality. Calcium metabolism is different in African American (AA) vs. white 
individuals. It is unclear if CA is associated with mortality and vascular events in patients 
with normal kidney function and if such association differs by race.
Methods: We examined racial differences in associations between corrected CA and 
mortality or incident coronary disease (CHD) and stroke in a national cohort of 1,967,685 
US veterans with eGFR >60ml/min/1.73m2. We used multivariable Cox proportional hazards 
models with interaction terms for CA and race, adjusted for age, BMI, social-economics, 
eGFR, BP, comorbidities, and medications.
Results: The mean age (SD) was 60.6(13.5), and the mean eGFR (SD) was 83.3 (15.4) 
ml/min/1.73m2. 15.5% of patients were AA, with a mean baseline CA of 9.5±0.4 mg/dl. 
Over a median follow-up of 8.2-years, there were 47,790 (15.7%) deaths, 8,129 (2.7%) 
strokes, and 6,175 (2.0%) CHD events in AA, compared to 299,137 (21.1%), 30,300(2.1%) 
and 34,304(2.4%) events in whites. A U-shaped association between CA and mortality was 
present in both races, but AA patients experienced lower risk relative to white patients with 
CA>8.8mg/dl (Figure, p<0.01 for interaction). No associations were found between CA 
and CHD/stroke in either race.
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Conclusions: Both higher and lower CA are associated with higher mortality in patients 
with normal kidney function. AA patients appear to experience relatively lower risk of 
death compared to white patients when CCA≥8.8 mg/dl, but this could not be attributed 
to differences in incident occlusive vascular events.
Funding: NIDDK Support, Veterans Administration Support
TH-OR116
Relevance of LDL Cholesterol and C-Reactive Protein to Cardiovascular 
Risk Among Patients with Chronic Kidney Disease – Results from the 
Study of Heart and Renal Protection  Ben Storey.  On behalf of the SHARP 
Collaboration Group, Univ of Oxford.
Background: Previous observational studies have found J-shaped relationships 
between LDL-C and cardiovascular risk among patients with CKD and suggested 
this association may be modified by inflammation: that it is positive in the absence of 
inflammation but negative in its presence. Conversely, other studies suggest that statins 
may be most effective in people with inflammation.
Methods: SHARP was a randomised controlled trial of LDL-C lowering with ezetimibe/
simvastatin (E/S) in 9270 patients with CKD. Hazard ratios (HR) for all atherosclerotic 
vascular events (AVE) over 4.9 years were estimated with Cox regression. The effect of 
E/S on major atherosclerotic events (MAE) was estimated in the presence and absence of 
inflammation; defined as CRP ³3mg/L (the study median) or in a sensitivity analysis as 
CRP >10 mg/L and/or albumin <36 g/L (90th & 10th centiles in 3rd NHANES respectively).
Results: Among all patients, usual LDL-C was positively, and approximately log-
linearly, associated with risk of AVE (HR per 1 mmol/L [39 mg/dL] higher LDL-C 1.38 [95% 
CI 1.22-1.56]). Compared to patients with low CRP, patients with high CRP were at higher 
risk, but the relationship between LDL-C and AVE risk was similar in both groups (HR per 
mmol/L 1.29 [1.07-1.54] and 1.43 [1.21-1.69] respectively, p for interaction=0.58). E/S was 
similarly effective at reducing MAE in patients with low and high CRP. (Rate Ratio 0.84 
and 0.83 respectively, p for heterogeneity=0.96). Sensitivity analyses gave similar results. 
Conclusions: LDL-C was positively associated with risk of AVE irrespective of 
baseline inflammation. Furthermore, lowering LDL-C with E/S was similarly effective in 
the presence or absence of inflammation. While CRP is associated with vascular risk, it does 
not modify the association between LDL-C and risk nor the efficacy of lowering LDL-C.
Funding: Pharmaceutical Company Support - Study of Heart and Renal Protection 
(SHARP) was initiated, conducted and interpreted independently of the principal study 
funder (Merck & Co. and by Schering Plough Corporation, who merged in 2009)
TH-OR117
Utilization of Statin Medications in Non-Dialysis Dependent Chronic 
Kidney Disease (CKD) Patients  Holly J. Kramer,1 Talar Markossian,1 Nicholas 
Burge,2 Benjamin Ling,1 Julia Koval,1 David J. Leehey,2 Kevin Stroupe.2  1Loyola 
Univ Chicago; 2Hines VA Medical Center.
Background: KDIGO and KDOQI guidelines recommend statin medications for 
adults age ≥ 50 years with non-dialysis dependent chronic kidney disease (CKD) due to 
demonstrated benefits of statins in reducing the risk for cardiovascular events and mortality 
for these patients. Results from few empirical studies suggest that statins are underused 
for CKD patients.
Methods: Retrospective analysis of U.S. Department of Veterans Affairs Healthcare 
System (VA) national databases to determine statin use in patients with non-dialysis 
dependent CKD. Patients with non-dialysis dependent CKD stages 3-5 with no history 
of kidney transplantation were included in the analysis. Statin use was ascertained from 
pharmacy dispensing records in 2012 and 2013.
Results: Approximately sixty percent of patients with non-dialysis dependent CKD 
were prescribed statins. Among patients prescribed statins in 2012, 11.0% lacked statin 
prescriptions during 2013. Statin use varied by age (33.9% ≤50, 53.0% 50-59, 64.6% 60-
74, 58.0% ≥ 75 years). Table 1 shows the frequency of statin use by CKD stage and by 
presence of comorbidities. 
Characteristics 
(%)
CKD Stage 
undetermined 
(n=147, 508)
CKD Stage 
3A (n=457, 
528)
CKD Stage 
3B (n=194, 
470)
CKD Stage 
4 (n=51, 
299)
CKD Stage 
5 (n=13, 
999)
% Using 
statin
% Using 
statin
% Using 
statin
% Using 
statin
% Using 
statin 
62.6 57.8 61.6 61.3 53.6
Comorbidities
% using statin
by comorbid-
ity
% using 
statin
by comor-
bidity
% using 
statin
by comor-
bidity
% using 
statin
by comor-
bidity
% using 
statin 
by comor-
bidity
Coronary artery 
disease 80.6 82.9 83.2 82.5 76.5
Diabetes 75.1 70.5 71.2 70.4 61.8
Heart Failure 75.5 71.7 71.2 71.4 65.6
Myocardial 
infarction 82.8 77.6 77.5 77.2 73.0
Peripheral artery 
disease 77.5 72.9 73.1 72.5 66.3
Stroke 74.9 71.2 71.4 71.2 64.9
Conclusions: Despite KDIGO and KDOQI guidelines recommending statins for adults 
with non-dialysis dependent CKD, statin use is suboptimal in adults with CKD receiving 
care in the VA health system. Interventions are needed to increase knowledge regarding the 
clinical importance of statin use in adults with non-dialysis dependent CKD.
Funding: Veterans Administration Support
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Associations of Conventional Echocardiographic Measures with Incident 
Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort 
Study  Ruth F. Dubin,1 Amanda Hyre Anderson,2 Wei Yang,2 Alan S. Go,3 
Martin Keane,4 Rajat Deo,2 Nisha Bansal,5 Raymond R. Townsend,2 Michael 
Shlipak.1  1Univ of California, San Francisco/SF VAMC; 2Univ of Pennsylvania 
School of Medicine; 3Kaiser Permanente, California; 4Temple Univ School of 
Medicine; 5Univ of Washington.
Background: Heart failure (HF) is the most common cardiac complication for patients 
with chronic kidney disease (CKD). Left ventricular hypertrophy (LVH) develops early 
in CKD, but studies have not adequately evaluated the association of left ventricular mass 
index (LVMI) with HF incidence among men and women with CKD.
Methods: We evaluated two-dimensional echocardiograms among 2964 participants 
of the Chronic Renal Insufficiency (CRIC) Study without cardiovascular disease (CVD). 
LVMI was calculated using the linear method, indexed to height and analyzed using 
gender-specific quartiles. The primary outcomes of incident HF and all-cause mortality 
were adjudicated;HF analyses were censored for death.
Results: Among 2964 participants, 45% were women, 54% were non-white race, 
mean(SD) age was 59±11years, mean(SD) eGFR was 44±17ml/min/1.73m2 at baseline. 
Over a median[IQR] follow up of 6.6 [5.7-7.6] years, 262 participants developed incident 
HF, and 470 participants died. In both men and women, LVMI was a strong, independent 
predictor of incident HF and mortality, even after adjustment for BNP and troponin T. 
Hazard Ratio (95% CI)*
Q1* Q2 Q3 Q4
Heart Failure
Men Ref 1.9(0.68-5.4) 3.1(1.2-8.3) 3.5(1.3-9.5)
Women Ref 1.2(0.43-3.4) 2.5 (0.9-6.7) 5.1(1.8-14)
Death
Men Ref 1.3(0.8-2.2) 1.7(1.0-2.9) 1.7(1.0-3.0)
Women Ref 1.3(0.7-2.5) 2.2(1.1-4.4) 3.1(1.5-6.4)
* Model adjusted for: age, race, site, comorbidities, medications, proteinuria, eGFR, hemoglobin, PTH, 
FGF-23, BNP, Troponin T
There was no significant interaction for gender in this association, but the LVMI-HF 
association was stronger in persons without diabetes: per SD LVMI, HR[95%CI] 1.3[1.1-
1.6] with diabetes and 2.2[1.6-2.8] without diabetes (p for interaction:0.01).
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Conclusions: Among persons with CKD and without history of CVD, LVMI is a 
strong predictor of incident HF and death, even after adjustment for major cardiovascular 
biomarkers.
Funding: NIDDK Support
TH-OR119
Prevalence and Prognostic Significance of Apparent Treatment Resistant 
Hypertension in Chronic Kidney Disease: A Report from the CRIC Study 
George Thomas,1 Dawei Xie,2 Hsiang-Yu Chen,2 Amanda Hyre Anderson,2 
Lawrence J. Appel,2 Carolyn S. Brecklin,2 Paul E. Drawz,2 John M. Flack,2 
Edgar R. Miller,2 Susan P. Steigerwalt,2 Raymond R. Townsend,2 Matthew R. 
Weir,2 Jackson T. Wright,2 Mahboob Rahman.2  1Cleveland Clinic, Cleveland, 
OH; 2CRIC Investigators.
Background: While hypertension is common in patients with chronic kidney disease 
(CKD), the association between apparent treatment resistant hypertension (ATRH) and 
clinical outcomes is not well studied in this population.
Methods: We analyzed data on 3367 hypertensive participants in the Chronic Renal 
Insufficiency Cohort (CRIC) to determine prevalence, associations, and clinical outcomes 
of ATRH in non-dialysis CKD patients. ATRH was defined as blood pressure ³140/90 mm 
Hg on ³3 antihypertensives, or use of ≥4 antihypertensives with BP at goal at baseline.
Results: The prevalence of ATRH was 40.4%. Older age, male gender, black race, 
diabetes, and higher BMI were independently associated with significantly higher odds 
of having ATRH. Compared to participants without ATRH, after adjustment for common 
covariates, participants with ATRH had a higher risk of clinical events (composite of 
myocardial infarction (MI), stroke, peripheral arterial disease (PAD), congestive heart failure 
(CHF), and all-cause mortality) (HR [95% CI]): (1.38 [1.22,1.56]); renal events (ESRD or 
50% decline in GFR) (1.28 [1.11,1.46]); CHF (1.77 [1.44,2.16)]; and all-cause mortality 
(1.24 [1.06,1.45]). The subset of participants with ATRH and BP at goal on ≥ 4 medications 
also had significantly higher risk of composite of MI, stroke, PAD, CHF, and all-cause 
mortality (HR [95% CI]) (1.30 [1.12, 1.51]) and CHF (1.68 [1.32, 2.12]) compared to those 
without ATRH. The association between ATRH and CHF and renal outcomes differed 
depending on baseline GFR (interaction (p<0.05); ATRH was associated with significantly 
higher risk for CHF and renal events only among those with GFR ³30 ml/min/1.73 m2.
Conclusions: Our findings show that ATRH is common, and associated with high risk 
of adverse outcomes in a cohort of patients with CKD.
Funding: NIDDK Support, Other NIH Support - Perelman School of Medicine at 
the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS 
UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland 
GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, 
UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) 
component of the National Institutes of Health and NIH roadmap for Medical Research, 
Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University 
of Illinois at Chicago CTSA UL1RR029879, Tulane University Translational Research in 
Hypertension and Renal Biology P30GM103337, Kaiser Permanente NIH/NCRR UCSF-
CTSI UL1 RR-024131
TH-OR120
Aryl Hydrocarbon Receptor Is Activated during Chronic Kidney Disease 
and Is Associated with Mortality  Stephane Burtey,1,2 Laetitia Dou,1 Marion 
Sallée,1,2 Claire Cerini,1 Noemie Jourde-chiche,1,2 Bertrand Gondouin,1,2 Michael 
S. Denison,3 Philippe Brunet.1,2  1Aix-Marseille Univ; 2AP-HM; 3UC Davis.
Background: Aryl hydrocarbon receptor (AhR) is a transcription factor activated 
by numerous pollutants, like dioxin. Its activation is associated with cardiovascular risk. 
Indoxyl sulfate (IS) and indole-3 acetic acid (IAA) are uremic toxins associated with 
mortality in chronic kidney disease (CKD). They are agonists of AhR. Our goal was to study 
the activation of AhR in patients with CKD and its association with mortality.
Methods: We included 96 non-diabetic patients with CKD (50 patients with stage 3-5 
CKD and 46 patients with stage 5D) and 32 controls without CKD matched for age and 
gender. The median follow up was 966 days. Activation of AhR by serum was evaluated 
by a Chemical Activated LUciferase gene eXpression assay (CALUX) and was expressed 
in arbitrary units (AU). In a subset of 20 patients with CKD stage 5D and 17 controls 
we performed RT-qPCR to study whole blood expression of AhR target genes (CYP1A1, 
CYP1B1 and AHRR).
Results: The sera of patients with CKD stage 5D and CKD stage 3-5 activated AhR 
(means: 53.6 and 45.6 AU; 95% CI [45.6-61.6] and [32.6-58.7] respectively) compared to 
sera from controls (mean: 2.1 AU; 95% CI [0.5-3.8]). The activating effect of CKD serum 
was reduced by the addition of an AhR antagonist (CH-223191) in the CALUX assay. The 
expression of AhR target genes was increased in patients with CKD stage 5D compared 
to controls. In stage 3-5 CKD patients, AhR serum activity was inversely correlated with 
eGFR (r=-0.59, p<0.0001). All-cause mortality (log-Rank p=0.01) and cardiovascular 
mortality (log-Rank p=0.047) were increased in patients with an AhR serum activity above 
the median (44 AU) compared to patients with value below.
Conclusions: Serum from patients with CKD activates AhR, this ability is associated 
with mortality. Furthermore, AhR is activated in vivo in patients with CKD. Serum AhR 
activation is a new biomarker to predict the cardiovascular risk of patient with CKD. It is 
also an attractive target to develop new therapy.
Funding: Government Support - Non-U.S.
TH-OR121
Associations of Urine Kidney Injury Biomarkers and All-Cause Mortality 
in the CRIC Study  Meyeon Park,1 Chi-yuan Hsu,1 Alan S. Go,2 Dawei 
Xie,3 Xiaoming Zhang,3 Sushrut S. Waikar,4 Joseph V. Bonventre,4 Josef 
Coresh,5 Robert G. Nelson,6 Harold I. Feldman,3 Paul L. Kimmel,6 Vasan S. 
Ramachandran,7 Kathleen D. Liu.1  1UCSF; 2Kaiser Permanente of Northern 
California; 3U. of Pennsylvania; 4Harvard; 5Welch Center for Prevention; 
6NIH; 7Boston Univ.
Background: Among individuals with CKD, we hypothesized that ongoing kidney 
injury would associate with an increased risk of death. We tested this hypothesis in the 
Chronic Renal Insufficiency Cohort (CRIC) study.
Methods: Urine kidney injury molecule-1 (KIM-1), neutrophil gelatinase associated 
lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), and liver fatty acid-binding 
protein (LFABP) were measured in 2466 CRIC subjects. Cox proportional hazards models 
were used to examine the association between biomarker concentrations indexed to urinary 
creatinine and death.
Results: Mean age of study participants was 59.5 (± 10.8) years; 46% were women, 43% 
were white, 38% were black. 50% had diabetes mellitus and 34% had cardiovascular (CV) 
disease. After adjustment for baseline eGFR, albuminuria, age, sex, race, CV comorbidities, 
and medications, those in the highest quintile (Q5, >2290.3 pg/g) of KIM-1/Cr levels and 
in the highest two quintiles of NGAL/Cr (Q5, > 64 ng/g, Q4, >20.2 ng/g) relative to the 
lowest (Q1 KIM-1/Cr <661.3 pg/g, Q1 NGAL/Cr <2.6 ng/g) had an increased risk of death 
[KIM-1/Cr Q5 v. Q1, hazard ratio (HR) 1.6 (1.1-2.3); NGAL/Cr Q5 v. Q1 HR 1.8 (1.2-2.8); 
Q4 v. Q1 HR 1.5 (1-2.2)]. Both analytes were also associated with death when levels were 
expressed as a continuous variable [HR per log SD increase of KIM-1/Cr=1.21 (1.06-1.39); 
HR per log SD increase of NGAL/Cr=1.22 (1.07, 1.39)]. NAG/Cr was associated with 
death in the continuous analysis only [HR per log SD increase of NAG/Cr=1.2 (1.04-1.37)]. 
LFABP/Cr was not associated with death.
Conclusions: Urine KIM-1/Cr, NGAL/Cr, and NAG/Cr are independently associated 
with increased risk of death in individuals with CKD. Kidney tubular injury may mark 
processes related to mortality risk in individuals with CKD.
Funding: NIDDK Support
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Endogenous Klotho Is Expressed in Human Heart and May Associated 
with Fibrosis  Qinghua Liu,1,2 Tzongshi Lu,1 Qiying Dai,1 David M. Charytan,1 
Daniel Zehnder,3 Li-Li Hsiao.1  1Renal Div, Brigham and Women’s Hospital, 
Harvard Medical School, Boston, MA; 2Dept of Nephrology, The First Affiliated 
Hospital, Sun Yat-sen Univ, Guangzhou, China; 3Univ Hospital Coventry and 
Warwickshire NHS Trust, Coventry, UK.
Background: Cardiovascular disease is the major risk factor for patients with CKD. 
Emerging evidence suggests that fibroblast growth factor 23 (FGF23) is associated with 
left ventricular hypertrophy and cardiovascular events in ESRD patients. Klotho and 
fibroblast growth factor receptor (FGFR) serve as co-receptors for FGF23. We previously 
showed that endogenous Klotho is expressed in human arteries, and that CKD is a state of 
Klotho deficiency, but whether human heart expresses Klotho and whether Klotho levels is 
correlated with kidney function or cardiac fibrosis in CKD patients is unknown.
Methods: Human atrial appendage specimens were collected during cardiac surgery 
from individuals with and without CKD. Estimated glomerular filtration rate (eGFR) was 
calculated using the Modification of Diet in Renal Disease equation. CKD was defined 
as eGFR<60 ml/min/1.73 m2. Fibrosis was quantified digitally using trichrome stained 
sections. Paraffin embedded cardiac tissue was obtained commercially. Western blot and 
immunohistochemical assay were used to detect protein expressions of Klotho, FGF23 and 
FGFR3. Klotho mRNA expression was assessed with RT-PCR.
Results: We confirmed that FGF23 is expressed in human heart. Our results show that 
endogenous Klotho and its co-receptor FGFR3 are expressed in human atrial appendage 
and left ventricle both in protein and mRNA levels. Our results also showed that cardiac 
fibrosis is negatively correlated with eGFR. And the endogenous Klotho levels in the heart 
is significantly suppressed with decreasing eGFR and increasing cardiac fibrosis.
Conclusions: We show for the first time that endogenous Klotho expressed in human 
heart and that Klotho suppression is associated with the degree of cardiac fibrosis and 
kidney function, suggesting the endogenous Klotho may have an association with cardiac 
fibrosis with possible involvement of FGF23.
TH-OR123
Circulating TNF Receptors Predicts Cardiovascular Disease in CKD 
Patients  Eunjin Bae,1 Jung Nam An,2 Jin Ho Hwang,3 Dong Ki Kim,1 Chun 
Soo Lim,2 Jung Tak Park,4 Shin-Wook Kang,4 Yon Su Kim,1 Jung Pyo Lee.2 
1Internal Medicine, Seoul National Univ College of Medicine, Seoul, Republic 
of Korea; 2Internal Medicine, Seoul National Univ Boramae Medical Center, 
Seoul, Republic of Korea; 3Internal Medicine, Chung-Ang Univ Hospital, Seoul, 
Republic of Korea; 4Internal Medicine, Yonsei Univ College of Medicine, Seoul, 
Republic of Korea.
Background: Cardiovascular disease (CVD) is the main public health problem in 
patients with CKD. However, there is no definite biomarker for predicting CVD morbidity 
and mortality in CKD. The aim of this study is to evaluate the role of circulating tumor 
necrosis factor receptors (cTNFRs) as a predictor of CVD risk in CKD patients.
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Methods: We recruited 1,078 patients with CKD from 11 centers prospectively between 
2006 and 2012. The levels of cTNFR1 and cTNFR2 were determined by performing enzyme-
linked immunosorbent assay (ELISA). The correlation coefficient between cTNFRs and 
various values was measured using a Pearson’s correlation test. Cox regression analysis 
was used to calculate the hazard ratio (HR) of CVD.
Results: Among a total of 1,078 patients, 57.2% was men and mean age was 50.4±15.7 
years. 261 participants (24.2%) had DM. The mean serum creatinine was 1.9±1.0 mg/dL, 
UPCR was 2.2±2.7 g/g creatinine, hs-CRP was 0.6±2.4 mg/dL, cTNFR1 was 271±917 and 
cTNFR2 was 5687±3878 pg/ml. Serum cTNFR2 was correlated with the cTNFR1 (r=0.827), 
each other. In addition, age, BMI, UPCR, and eGFR were significantly correlated with 
cTNFR1 (r=0.43 for age, r=0.15 for BMI, r=0.20 for UPCR, r=–0.63 for eGFR; p<0.001 
for all). Similar correlations were observed with the cTNFR1. For the mean follow-up 
duration of 4 years, 51 patients experienced CVD event. Participants with CVD were older 
and had lower eGFR level, higher SBP, higher cTNFRs level than those without CVD. In 
cox proportional hazard analyses, cTNFR1 (HR 1.907, 95% CI 1.025-3.550, p=0.0042) 
and cTNFR2 (HR 2.271, 95% CI 1.269-4.065, p value=0.006) predicted risk for CVD even 
after adjustment for clinical covariates, such as UPCR, eGFR, hs-CRP.
Conclusions: cTNFR1 and 2 associate with CVD and other risk factors in CKD, 
independent of eGFR and UPCR. Furthermore, cTNFRs could be relevant predictors for 
CVD in CKD patients.
TH-OR124
Fibroblast Growth Factor 23 and Risk of Atrial Fibrillation in Chronic 
Kidney Disease: The CRIC Study  Rupal Mehta,1 Xuan Cai,1 Jungwha Lee,1 
Nisha Bansal,2 Julia J. Scialla,2 James H. Sondheimer,2 Rajat Deo,2 Jing Chen,2 L. 
Lee Hamm,2 Ana C. Ricardo,2 Mahboob Rahman,2 Sankar D. Navaneethan,2 Alan 
S. Go,2 Harold I. Feldman,2 Tamara Isakova,1 Myles S. Wolf.1  1Northwestern 
Univ; 2CRIC Study.
Background: Levels of fibroblast growth factor 23 (FGF23) are elevated in chronic 
kidney disease (CKD) and are strongly associated with cardiovascular disease and mortality. 
Atrial fibrillation (AF) is a common complication in CKD that is associated with poor 
outcomes, but whether FGF23 is an independent risk factor for AF in CKD is unknown.
Methods: We tested the associations of FGF23 with AF in cross-sectional and 
longitudinal analyses of 3879 participants in the Chronic Renal Insufficiency Cohort Study 
who had baseline FGF23 measurements. For longitudinal time-to-incident AF analyses, 
we excluded the 660 individuals with AF at baseline. Incident AF was adjudicated based 
on review of hospital records and yearly electrocardiograms.
Results: Mean estimated glomerular filtration rate (eGFR) was 44.3 ± 15.0 ml/
min/1.73m2 and median C-terminal FGF23 was 146 RU/ml (interquartile range 96, 239 
RU/ml). In multivariable logistic regression models, higher FGF23 expressed continuously 
and in quartiles was associated with greater prevalence of AF (Table 1). Over a median 
follow up of 7 years, 248 incident AF events occurred. In multivariable-adjusted Cox 
proportional hazards models, elevated baseline FGF23 was a risk factor for incident AF 
(Table 2). These associations remained significant across strata of sex, race, prior heart 
failure, and eGFR. When FGF23 was expressed in quartiles or in models that censored 
individuals at end-stage renal disease onset (loss of 55 incident AF events), FGF23 was 
no longer associated with incident AF. 
Conclusions: Among individuals with moderate to severe CKD, an elevated FGF23 
level was independently associated with prevalent AF and may be associated with incident 
AF.
Funding: NIDDK Support
FR-OR001
Effects of Cyclosporine on Renal Handling of Divalent Cations in 
Claudin 16-Deficient Mice  Hoora Drewell,1 Tilman Breiderhoff,2 Dominik 
Müller,3 Michael Fähling,4 Sebastian Bachmann,1 Kerim Mutig.1  1Anatomy, 
Charité-Universitätsmedizin, Berlin, Germany; 2Physiology, Charité-
Universitätsmedizin, Berlin, Germany; 3Pediatric Nephrology, Charité-
Universitätsmedizin, Berlin, Germany; 4Vegetative Physiology, Charité-
Universitätsmedizin, Berlin, Germany.
Background: Calcineurin inhibitors tacrolimus and cyclosporine are instrumental 
for immunosuppression after organ transplantation but cause substantial renal side effects 
including hypomagnesemia and hypercalciuria. The tight junctions protein Claudin 16 
(Cldn16) mediates paracellular reabsorption of divalent cations along the cortical thick 
ascending limb and has been implicated in the adverse effects of cyclosporine. We have 
compared effects of cyclosporine in wild-type (WT) and Cldn16-deficient (Cldn16-/-) mice.
Methods: Mice received cyclosporine (25 mg/kg) for 7 days and their kidney 
performance was analysed in metabolic cages. Expression of distal transport proteins has 
been studied by quantitative PCR and immunoblotting.
Results: Physiological analysis revealed baseline hypomagnesemia and hypercalciuria 
in Cldn16-/- mice. Administration of cyclosporine induced marked hypomagnesemia in 
WT mice but did not significantly alter plasma magnesium levels in Cldn16-/- mice. In 
contrast, cyclosporine-induced increase in urinary calcium was significantly stronger in 
Cldn16-/- mice compared to WT controls alongside more pronounced decrease of plasma 
calcium levels in Cldn16-/- mice. Cyclosporine stimulated distal sodium transporters leading 
to sodium retention in both genotypes.
Conclusions: In sum, our data corroborate the pivotal role of Cldn16 in the renal 
magnesium and calcium handling and suggest that Cldn16 may be involved in the 
cyclosporine-induced renal magnesium loss and hypomagnesemia, since genetic deletion 
of Cldn16 prevented these effects. In contrast, the strong manifestation of cyclosporine-
induced hypercalciuria in Cldn16-/- mice suggests that cyclosporine may affect transcellular 
calcium reabsorption pathways rather than the Cldn16-mediated paracellular transport.
FR-OR002
Ogr1 and Acid-Induced Hypercalcuria  Pedro Henrique Imenez Silva,1 
Kessara Chan,1 Marie-Gabrielle Ludwig,2 Jürg Andreas Gasser,2 Timothy R. 
Arnett,3 Olivier Bonny,4 Klaus Seuwen,2 Carsten A. Wagner.1  1Inst of Physiology, 
Univ of Zurich, Zurich, Switzerland; 2Novartis Insts for Biomedical Research, 
Basel, United Kingdom; 3Dept of Cell and Developmental Biology, Univ College 
London, London, United Kingdom; 4Dept of Pharmacology and Toxicology, 
Univ of Lausanne, Lausanne, Switzerland.
Background: The Ovarian cancer G-protein coupled Receptor 1 OGR1 (GPR68) is an 
extracellular proton activated GPCR that stimulates inositol triphosphate (IP3) production 
and increases intracellular Ca2+ levels. However, the physiological roles of OGR1 are not 
well established. In this work we aimed to identify the roles of OGR1 in acid-base and 
mineral balance.
Methods: Wild type (OGR1+/+) and an OGR1 mice-deficient model (OGR1-/-) were 
subjected to metabolic acidosis (280 mM NH4Cl) or non-acidotic control condition for 
1 and 7 days and basic physiological parameters were collected from blood and urine. 
Several organs were isolated such as kidneys, intestine, brain, heart, etc. in order to extract 
RNA and perform RT-PCR/real time PCR. Kidneys were also used for protein extraction/
western blotting.
Results: OGR1 mRNA was found in many organs including kidney where mRNA was 
detected in all nephron segments. No acid-base modifications were observed in OGR1-/- 
mice, except for a higher plasma pH in the 1 day metabolic acidosis group (7.20 ± 0.04 vs 
7.12 ± 0.03, p<0.05). As was expected, metabolic acidosis caused an increase in calcium 
and magnesium excretion in OGR1+/+, but this was not observed in OGR1-/-. The mRNA 
levels of proteins involved in Ca2+ and Mg2+ reabsorption like Calbindin D28k, TRPV5/6, 
TRPM6/7 and Claudins 16 and 19 were not altered in OGR1-/-. The protein expression of 
TRPV5, the main apical distal convoluted tubule route for calcium, was 2.4 - fold increased 
(p<0.001) in OGR1-/- under metabolic acidosis which may explain the diminished Ca2+ 
excretion in these mice.
Conclusions: OGR1 is involved in the hypermagnesuria and hypercalciuria developed 
during metabolic acidosis, by a mechanism involving the Ca2+ channel, TRPV5.
Funding: Government Support - Non-U.S.
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Conditional NFAT5 Knockout Causes Impaired Urinary Concentrating 
Ability with Renal Diabetes Insipidus and Hypernatremia without Renal 
Medullary Injury  Christoph Kueper,1 Franz Xaver Beck,1 Zoran Popovic,2 
Hermann-Josef Groene,2 Bernhard K. Krämer,3 Wolfgang Neuhofer.3  1Cellular 
Physiology, Univ of Munich, Munich, Germany; 2Molecular Pathology, German 
Cancer Research Inst, Heidelberg, Germany; 3Div of Nephrology, Univ Hospital 
Mannheim, Mannheim, Germany.
Background: This study addressed the effects of inducible deletion of NFAT5 in adult 
mice on the expression of components of urinary concentration, i.e. AQP-2, ClC-K1, barttin, 
and UT-A1. In parallel, NFAT5-dependent osmoprotective genes AR, HSP70, and others 
were determined along with renal functional, morphological, and systemic parameters.
Methods: Mice with tamoxifen-inducible deletion of NFAT5 were established. At the 
age of 3-4 weeks, conditional NFAT5 KO mice or control animals were fed with a diet 
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containing tamoxifen for further 3-4 weeks. Subsequently, the expression of NFAT5 target 
genes was determined by qRT-PCR, Western blot analysis, and immunohistochemistry 
in different kidney zones in animals with free access to water or in mice that were water 
deprived for 24 h. Urine and blood electrolyte and urea concentrations were determined 
by standard methods.
Results: Adult mice with conditional deletion of NFAT5 showed 80-90% reduced 
expression of NFAT5 in all tissues tested, particularly in renal medullary regions. 
Accordingly, the NFAT5 target genes AQP-2, ClC-K1, barttin, UT-A1, AR, and HSP70 were 
substantially downregulated. Consistently, these NFAT5-deficient mice had renal diabetes 
insipidus with reduced urinary concentrating ability, dehydration, and hypernatremia, 
particularly following water deprivation. In contrast to constitutive NFAT5 knockout 
animals, inducible deletion in adult mice was not associated with renal medullary injury 
or hydronephrosis.
Conclusions: Deletion of NFAT5 causes renal diabetes insipidus-like phenotype 
by diminished expression of genes essential for urinary concentration. Despite reduced 
expression of osmoprotective genes in the renal medulla, histological evidence of medullary 
cellular injury was not detectable. The lack of damage might be a consequence of diminished 
medullary interstitial sodium chloride and urea concentrations, and hence reduced osmotic 
stress in this kidney region.
FR-OR004
Effect of Concurrent P2Y2 Receptor Deletion and P2Y12 Receptor Blockade 
on Lithium-Induced Nephrogenic Diabetes Insipidus in Mice  Yue Zhang, 
Kristina M. Heiney, Bellamkonda K. Kishore.  Internal Medicine, Univ of Utah 
& VA Med Ctr, Salt Lake City, UT.
Background: Chronic lithium (Li) administration for bipolar disorder causes 
nephrogenic diabetes insipidus (NDI), characterized by polyuria, natriuresis and kaliuresis, 
resulting in a debilitating condition. Previously we reported that mice lacking ATP/UTP-
activated P2Y2 receptor are significantly, but not completely resistant to Li-induced polyuria. 
Recently in a mouse model we observed that pharmacological blockade of ADP-activated 
P2Y12 receptor offers near complete amelioration of Li-induced polyuria. However, there 
were differences between these two approaches in terms of natriuresis, kaliuresis and blood 
Li levels. Hence, we tested the concurrent effect of both in mice.
Methods: Groups (n = 5 to 7) of age-matched adult wild type B6D2 (WT) and 
syngeneic P2Y2-R knockout (KO) mice were fed Li-added diet (40 mmol LiCl/kg food) 
ad libitum, with or without administration of clopidogrel bisulfate (CLPD; 80 mg/kg bw/
day) in drinking water for 14 days and euthanized. Twenty-four hour urine samples were 
collected prior to and toward the end of the experimental period. Blood samples were 
collected at euthanasia.
Results: Compared to Li-fed WT mice: (i) Li-fed KO mice had ~50% less polyuria 
associated with significant amelioration of Li-induced natriuresis and kaliuresis; and (ii) 
Li-fed WT mice treated with CLPD had near complete amelioration of polyuria, but had no 
effect on Li-induced natriuresis and kaliuresis. Interestingly, Li-fed KO mice concurrently 
treated with CLPD showed significant amelioration of natriuresis and kaliuresis, in addition 
to almost complete suppression of polyuria. P2Y2-R deletion had no effect on blood Li 
levels, whereas P2Y12-R blockade caused modest, but significant increase in blood Li 
levels. However, the concurrent approach neutralized the effect of P2Y12-R blockade 
on blood Li levels.
Conclusions: Our results demonstrate that concurrent blockade of P2Y2 and P2Y12 
receptors has the potential for better outcomes in amelioration of Li-induced NDI without 
causing a rise in blood Li levels. By proper optimization of CLPD dose, it should be possible 
to achieve better control of all parameters of NDI.
Funding: Veterans Administration Support
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The V-ATPase B1 Subunit Polymorphism p.E161K Is Associated 
with Impaired Urinary Acidification in Recurrent Stone Formers 
Daniel G. Fuster,1,3 Nasser Dhayat,1,3 Giuseppe Albano,1,3 Andreas Pasch,1,3 
Bruno Vogt,1,3 Orson W. Moe.2  1Nephrology, Hypertension and Clinical 
Pharmacology, Univ Hospital of Bern, Bern, Switzerland; 2Div of Nephrology, 
UT Southwestern Medical Center, Dallas, TX; 3Dept of Clinical Research, Univ 
of Bern, Bern, Switzerland.
Background: Mutations in the V-ATPase B1 subunit gene ATP6V1B1 cause autosomal-
recessive distal renal tubular acidosis. We previously identified a single nucleotide 
polymorphism (SNP) in the human V-ATPase B1 subunit (c.481G>A; p.E161K) that 
displayed greatly diminished pump function in vitro.
Methods: To investigate the impact of this p.E161K SNP on urinary acidification in 
vivo, we conducted a genotype-phenotype analysis of recurrent stone formers in the Dallas 
and Bern kidney stone registries.
Results: 32 of 555 (5.77 %) of the patients examined were heterozygous for the 
p.E161K SNP, the remaining 523 patients (94.23%) carried two wild-type alleles. Adjusted 
for sex, age, BMI and dietary acid and alkali intake, p.E161K SNP carriers had a tendency 
to higher urinary pH under a random diet (6.31 versus 6.09; p=0.089). Under an instructed 
low calcium and sodium diet, urinary pH was higher in p.E161K SNP carriers (6.555 versus 
6.005; p<0.005). Kidney stones of p.E161K carriers were significantly more likely to 
contain calcium phosphate than stones of wild-type patients. In acute ammonium chloride 
loading, p.E161K carriers displayed a higher trough urinary pH(5.34 vs 4.89; p=0.01) than 
wild-type patients. 14.58 % of wild-type patients and 52.38% of p.E161K carriers were 
unable to acidify their urine below 5.3 and thus had incomplete distal renal tubular acidosis.
Conclusions: In summary, our data indicate that recurrent stone formers with 
the V-ATPase B1 subunit p.E161K SNP exhibit a urinary acidification deficit with an 
increased prevalence of calcium phosphate containing kidney stones. The burden of E161K 
heterozygosity may be a forme fruste of distal RTA.
Funding: Government Support - Non-U.S.
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Proximal Tubule-Specific Glutamine Synthetase Deletion Alters Basal and 
Acidosis-Stimulated Renal Ammonia Excretion  Hyun-Wook Lee,1 Gunars 
Osis,1 Mary E. Handlogten,1 Jill W. Verlander,1 I. David Weiner.1,2  1Renal Div, 
Univ of Florida, Gainesville, FL; 2Nephrology and Hypertension, NF/SGVHS, 
Gainesville, FL.
Background: Glutamine synthetase (GS) mediates the recycling of NH4+ and glutamate 
back to glutamine. In the kidney, the majority of GS is expressed in the proximal tubule 
where it may decrease net ammoniagenesis and limit ammonia available for net acid 
excretion. This study’s purpose was to determine the role of proximal tubule (PT) GS in 
normal acid-base homeostasis and in the renal response to metabolic acidosis.
Methods: We generated mice with proximal tubule-specific glutamine synthetase 
deletion (PT-GS-KO) by using Cre-loxP techniques. PT-GS-KO mice had loxP sites 
flanking exons 1 and 7 (GSfl/fl) and expressed Cre-recombinase under control of the 
phosphoenollpyruvate carboxykinase (PEPCK) promoter (PEPCK-Cre). Control (C) mice 
were GSfl/fl but PEPCK-Cre negative.
Results: Immunoblot analysis showed PT-GS-KO decreased GS protein expression 
by 47 ± 4% in the cortex and 89 ± 1% in the outer stripe of the outer medulla; 
immunohistochemistry showed efficient and specific PT GS deletion with occasional 
residual GS-positive cells. Under basal conditions, proximal tubule GS deletion increased 
urinary ammonia excretion: 102 ± 10 vs 75 ± 8 mmol/day in PT-GS-KO and C mice, 
respectively, consistent with our hypothesis that GS deletion increases net ammoniagenesis 
and thereby increases ammonia excretion. However, ammonia excretion after acid loading 
for 7 days increased similarly in PT-GS-KO and C mice during the first 4 days of acid 
loading but on days 5-7 was significantly less, by ~33%, in PT-GS-KO as compared to C 
mice. In acid-loaded mice, adaptive responses to PT-GS-KO included increased expression 
of cortical phosphate-dependent glutaminase (PDG), PEPCK, and the glutamine transporter, 
SN1, compared to C.
Conclusions: We conclude: 1) proximal tubule GS expression contributes to both basal 
and acidosis-stimulated renal ammonia excretion; and, 2) elimination of the contribution 
of proximal tubule GS downregulation to enhance ammoniagenesis during acid-loading 
is partially compensated for by adaptive increases in PDG, PEPCK and SN1 expression.
Funding: NIDDK Support, Veterans Administration Support
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The B1 H+-ATPase (Atp6v1b1) Subunit Is Required for Non-Type A 
Intercalated Cell Function and Defense against Alkalosis  Soline Bourgeois, 
Jana Kovacikova, Carsten A. Wagner.  Inst of Physiology, Univ of Zurich, 
Zurich, Switzerland.
Background: The final urine pH is fine-tuned by type A and non-type A intercalated 
cells (IC) along the connecting tubule (CNT) and collecting duct (CCD) involving the 
action of vacuolar H-ATPases. Mutations in the B1 subunit of H-ATPase (ATP6V1B1) 
in man cause distal renal tubular acidosis due to its importance in acid secretion by type 
A-ICs. Non-type A-IC also express the vacuolar H+-ATPases containing the B1 subunit 
isoform at their luminal and/or basolateral plasma membrane together with the luminal 
Cl-/HCO3- exchanger pendrin. The main function of non-type A-ICs is the excretion of 
bicarbonate during metabolic alkalosis. However, the function of the B1 isoform in non-
type A-ICs has remained elusive.
Methods: We studied the metabolic behaviour of B1 deficient mice during an alkali load 
induced by a 4-day desoxycorticosterone (DOCA, 2 mg/mouse s.c) and 0.28M NaHCO3 
treatment in the drinking water.
Results: Induction of metabolic alkalosis resulted in a more pronounced alkalosis 
in B1 deficient mice associated with increased blood bicarbonate, hypokalemia, and 
hypochloremia. Furthermore, while, pendrin localization was preserved, total pendrin 
expression was reduced and pendrin activity was altered in B1 deficient mice whereas 
the relative abundance of pendrin expressing cells was increased. In parallel, H+-ATPase 
activity in non-type A-IC from ex vivo microperfused cortical collecting duct was strongly 
reduced. Finally, the E and A subunits of H-ATPase did not associate with the basolateral 
domain of B1 deficient non-type A-ICs leading to the non-association of V1 domain while 
basolateral expression of a4 subunit, part of the V0 domain, was not disrupted.
Conclusions: Thus, the B1 subunit is required for the formation of a complete and 
functional basolateral H+-ATPases complexes and is critical for normal non-type A-IC 
function cells during alkalosis.
Funding: Government Support - Non-U.S.
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FR-OR008
Comparing the Effect of Combination of Acetazolamide and 
Hydrochlorothiazide Followed by Furosemide versus Combination of 
Hydrochlorothiazide and Furosemide Followed by Furosemide in Treating 
Refractory Edema Associated with Nephrotic Syndrome: A Randomized, 
Double-Blind Trial  Mohammad Kazem Fallahzadeh,1 Mohammad Amin 
Fallahzadeh,2 Banafshe Dormanesh,3 Jamshid Roozbeh,2 Mohammad Hossein 
Fallahzadeh,2 Mohammad Mahdi Sagheb.2  1Baylor Univ Medical Center, Dallas, 
TX; 2Shiraz Univ of Medical Sciences, Shiraz, Islamic Republic of Iran; 3AJA 
Univ of Medical Sciecnes, Tehran, Islamic Republic of Iran.
Background: The Cl/HCO3 exchanger pendrin and Na/Cl cotransporter (NCC) 
play important role in distal tubule salt reabsorption. A recent animal study has shown 
simultaneous inhibition of pendrin and NCC by acetazolamide and hydrochlorothiazide, 
respectively results in significant diuresis. The aim of this study was to evaluate the efficacy 
of combination of acetazolamide and hydrochlorothiazide followed by furosemide in 
treatment of refractory edema associated with nephrotic syndrome.
Methods: In this randomized, double-blind trial we enrolled 20 patients with nephrotic 
syndrome who had refractory edema despite receiving maximum furosemide dose. All 
patients had GFR>60 ml/min/1.73m2. After a 2-week washout period when patients received 
no diuretics, they were randomly assigned to 2 equal groups. Group 1 received 250-mg oral 
acetazolamide and 50-mg oral hydrochlorothiazide daily for 1 week. Group 2 received 40 
mg oral furosemide and 50-mg oral hydrochlorothiazide daily for 1 week. Then patients in 
both groups received 40-mg oral furosemide daily for 2 weeks. The primary outcome was 
the amount of change in weight from baseline to the end of the treatment phase.
Results: Although weight reduction occurred in both groups, it was significantly 
higher in group 1 as compared to group 2 at the end of first week (-1.4±0.52 vs. -0.65±0.41 
kg, p=0.004) and of third week of treatment phase (-3±0.94 vs. -1.15±0.47 kg, p=0.001). 
Increase in 24-hour urine volume was also significantly higher in group 1 at the end of 
treatment phase. Serum Na and K levels were in reference range in all the patients during 
the treatment phase.
Conclusions: Combination of acetazolamide and hydrochlorothiazide followed by 
furosemide may be a novel and safe diuretic therapy in refractory edema associated with 
nephrotic syndrome.
FR-OR009
Tissue Na+ in Chronic Kidney Disease and Effect of Renal Transplantation 
on Na+ Stores  Christoph Kopp,1 Jonathan Jantsch,5 Anke Dahlmann,1 Peter 
Linz,2 Daniela Amslinger,2 Matthias Hammon,3 Kai-Uwe Eckardt,1 Friedrich 
C. Luft,6 Jens Titze.2,4  1Nephrology and Hypertension, Univ Hospital Erlangen, 
Germany; 2Junior Research Group II, Interdisciplinary Center for Clinical 
Research, Erlangen, Germany; 3Radiology, Univ Hospital Erlangen, Germany; 
4Clinical Pharmacology, Vanderbilt Univ, Nashville; 5Clinical Microbiology 
and Hygiene, Univ Hospital Regensburg, Germany; 6Experimental and Clinical 
Research Center, Max-Delbrück Center, Berlin, Germany.
Background: Diminished kidney function as occurs in Chronic Kidney Disease (CKD) 
causes salt sensitive hypertension. By using 23Na-Magnetic Resonance Imaging (23Na-MRI) 
technology we recently could detect Na+ storage in humans, which was associated with 
hypertension. Whether impaired Na+ excretion in CKD results in tissue Na+ accumulation 
and if kidney transplantation affects tissue Na+ stores is not known.
Methods: We recruited 32 patients with CKD Stage 4 and 5 prior to preemptive 
living donor transplantation or dialysis treatment and 30 age- and gender-matched control 
subjects. 23Na-MRI at 3Tesla was used to quantify muscle and skin Na+ of the lower 
leg before kidney transplantation/dialysis as well as 3 and 6 months after living donor 
transplantation. Additionally, clinical parameters including blood pressure as well as blood 
and urine samples were assessed.
Results: Compared to healthy control subjects, CKD-patients showed increased muscle 
and skin Na+ content (skin 15.8 ± 3.6 vs. 23.1 ± 8.2, p<0.001; muscle 15.8 ± 1.8 vs. 21.0 ± 
3.9, p<0.001). Despite these differences in tissue Na+, serum Na+ concentration did not vary 
between both groups. Restoration of kidney function by successful renal transplantation in 
15 CKD patients was accompanied by reduced blood pressure (mean arterial pressure 104 
± 12 vs. 94 ± 11, p <0.01) and mobilization of tissue Na+ from muscle (21.4 ± 3.1 vs. 18.4 
± 2.9, p<0.01) and skin (24.4 ± 6.2 vs. 19.2 ± 4.5, p<0.01) 6 months post-transplantation.
Conclusions: Accelerated sodium storage occurs in pre-dialysis patients with CKD 
that could be reversed by successful kidney transplantation. Reduction of tissue Na+ after 
kidney transplantation was associated with better blood pressure control.
FR-OR010
Small-Molecule Inhibitors of Pendrin (SLC26a4) Augment the Diuretic 
Action of Furosemide  Onur Cil, Cristina Esteva-Font, Joseph-Anthony Tapia 
Tan, Puay Wah Phuan, Peter Michael Haggie, Alan S. Verkman.  Depts of 
Medicine and Physiology, Univ of California San Francisco, San Francisco, CA.
Background: Pendrin (Slc26a4) is a chloride/bicarbonate exchanger expressed in 
type-B and non-A, non-B intercalated cells of connecting tubule and cortical collecting 
duct, where it mediates Cl- absorption and modulates ENaC function by changing luminal 
HCO3- concentration. Under normal conditions, pendrin has a minimal role in renal salt 
metabolism; pendrin knock-out mice and patients with Pendred Syndrome (caused by loss-
of-function Slc26a4 mutations) do not manifest salt wasting. Previous studies demonstrated 
that double knock-out of pendrin with other renal salt transporters causes increased urine 
output, volume depletion and salt wasting. It has been hypothesized that pendrin may 
attenuate diuretic-induced salt loss.
Methods: A cell-based high-throughput screen was established to identify pendrin 
inhibitors involving fluorescence plate reader measurement of chloride influx in epithelial 
cells stably coexpressing human pendrin and a chloride-sensing fluorescent protein. 
Screening of ~30,000 drug-like small molecules produced three chemical classes of pendrin 
inhibitors with IC50 down to 1 µM. The pendrin inhibitors were administered to mice 
intraperitoneally (10 mg/kg) either alone or with low (5 mg/kg), intermediate (10 mg/kg) 
or high (20 mg/kg) dose furosemide. Urine was collected in metabolic cages for 3 hours 
after injection, and blood was collected afterwards.
Results: In furosemide-treated mice pendrin inhibitors of two chemically different 
classes produced an approximate 40% increase in urine output and osmolar clearance, 
without changing urine osmolality. The compounds had no effect in mice when administered 
alone. LC/MS analysis showed predicted therapeutic inhibitor concentrations in blood 
and urine.
Conclusions: Our findings suggest pendrin inhibition as a novel approach to amplify 
the diuretic action of loop diuretics. Such combination therapy might enhance diuresis and 
salt excretion for treatment of hypertension and edema, including diuretic-resistant edema.
Funding: NIDDK Support
FR-OR011
Increased Synthesis of Liver Erythropoietin in Patients with Chronic 
Kidney Disease  Sophie M. De Seigneux,1 Stine Lundby,2 Patrick Saudan,1 
Pierre-Yves F. Martin,1 Carsten Lundby.2  1Service of Nephrology, Univ of 
Geneva; 2Inst of Physiology, Univ of Zurich.
Background: Anemia of chronic kidney disease (CKD) is thought to be related to 
impaired renal erythropoietin (Epo) production. Epo may be synthetized by the kidney 
but also by the liver in humans. Epo glycosylation pattern is dependent on its synthesizing 
cell, thereby indicating its origin. Here we tested the hypothesis that synthesis of Epo from 
non-kidney cells increases to compensate for insufficient renal Epo production in patients 
with moderate CKD.
Methods: We determined plasma [Epo] levels and Epo glycosylation patterns in 19 
moderate non-dialyzed CKD patients (stage III-IV) and compared these to values obtained 
in healthy volunteers, rhEPO and umbilical cord plasma (liver derived Epo mainly).
Results: Despite higher Epo levels (15.75 (11.3 - 24.2) IU/L) compared to healthy 
controls (8.4 (7.56 - 8.98) IU/L, p<0.01), CKD patients were moderately anemic ([Hb]: 
113 ± 11 g/dl). Half of the patients presented higher Epo levels than expected from the 
calculated values corrected for anemia. Glycosylation was increased in CKD patients (34 
± 12 %; measured as percent migrated isoform, PMI,open bars ) when compared to healthy 
controls (8.6 ± 1 %; p<0.01, black bars) and rhEpo samples (1.4± 1.4 p<0.01, hatched bars), 
whereas the pattern did not differ from umbilical cord plasma (55 ± 10 %, p >0.05, lined 
filled bars) which is known to contain mainly liver derived Epo. 
Renal function correlated strongly to glycosylation pattern assessed by PMI ( R=-0.8, 
p<0.01), with patients having lowest eGFR diplaying higher Epo PMI values, indicating 
a larger part of liver derived Epo.
Conclusions: These results suggest that 1) moderate CKD patients exhibit preserved 
Epo levels despite declining renal function 2) this may be achieved by increasing liver Epo 
synthesis and 3) Epo originating from liver seems less erythropoietic.
Funding: Government Support - Non-U.S.
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FR-OR012
Associations Among Erythroferrone and Biomarkers of Erythropoiesis and 
Iron Metabolism, and Treatment of Long-Term Erythropoiesis-Stimulating 
Agents in Patients on Hemodialysis  Hirokazu Honda,1 Yasuna Kobayashi,2 
Shoko Onuma,3 Keigo Shibagaki,4 Toshitaka Yuza,4 Keiichi Hirao,5 Toshinori 
Yamamoto,2 Naohisa Tomosugi,6 Takanori Shibata.3  1Div of Nephrology, Dept 
of Medicine, Showa Univ Koto Toyusu Hospital, Tokyo, Japan; 2Div of Clinical 
Pharmacy, Dept of Pharmacotherapeutics, Showa Univ, School of Pharmacy, 
Tokyo, Japan; 3Dept of Preventive Medicine, Showa Univ, School of Medicine; 
4Shibagaki Dialysis Clinic Jiyugaoka, Tokyo, Japan; 5Shibagaki Dialysis Clinic 
Togoshi, Tokyo, Japan; 6Kanazawa Medical Univ, Kanazawa, Japan.
Background: The present study aimed to identify associations between erythroferrone 
(ERFE), a regulator of hepcidin 25, and biomarkers of erythropoiesis and iron metabolism. 
We also investigated the effects of the erythropoiesis-stimulating agents (ESA), continuous 
erythropoietin receptor activator (CERA) and darbepoetin-α (DA), on ERFE production 
in patients on hemodialysis (HD).
Methods: Blood samples were obtained from 59 patients before HD sessions on 
day 0 (baseline) for baseline cross-sectional analysis. Twenty patients who were injected 
with either CERA (N = 10) or DA (N = 10) at the end of the dialysis week (day 0), who 
were not iron-deficient (ferritin < 100 ng/mL and transferrin saturation < 20%) and had 
hemoglobin levels > 9 g/dL were selected from among the 59 patients. Blood was sampled 
serially before HD sessions on days 3, 5, 7 from patients on DA and on the same days and 
day 14 from those on CERA to assess impact of ESA on iron metabolism including ERFE.
Results: Levels of ERFE correlated inversely with those of hepcidin 25 and ferritin, 
and positively with soluble transferrin receptor. The hepcidin 25: ERFE ratio and hepcidin 
25 levels positively correlated with ferritin levels. Levels of ERFE significantly increased 
from day 3 of treatment with DA and CERA and decreased by days 7 and 14, respectively. 
Levels of hepcidin 25 were decreased by ESA in accordance as those of ERFE increased.
Conclusions: Erythroferrone might be associated with iron metabolism in patients on 
HD. Both DA and CERA increased levels of ERFE that regulated hepcidin 25 and led to 
iron mobilization from body stores during erythropoiesis.
FR-OR013
Dynamics of ESA Resistance Index in Incident Hemodiafiltration and High-
Flux Hemodialysis Patients  Daniele Marcelli, Inga Bayh, Aileen Grassmann, 
Laura Scatizzi, Katharina Brand, Bernard J. Canaud.  Fresenius Medical Care, 
Bad Homburg, Germany.
Background: Hemodiafiltration (HDF), combining diffusion and convection, provides 
efficient blood detoxification over a wide molecular weight range that may include 
erythropoiesis inhibiting agents. Study aim: to compare ESA resistance index (ERI) in 
incident HDF and high-flux hemodialysis (HD) patients. ERI is the weekly weight-adjusted 
ESA dose (U/kg/week) divided by hemoglobin level (g/dl).
Methods: 20,694 incident patients (7,674 HDF; 13,020 HD,) from 436 NephroCare 
clinics in 20 countries with ≥6 mths follow-up were studied between January 1 2007 and 
December 31 2013. Baseline (BL) was 6 mths after dialysis initiation; follow-up was 
1.35±0.69 yrs. Exclusion criteria: BL presence of metastatic tumors, malnourishment (BMI 
<18.5 kg/m2), treatment via catheter, age <18 years, less/more than thrice weekly dialysis, 
modality switch in month before BL, and missing ESA dose after BL. After propensity score 
matching to reduce bias by indication, a total of 6,568 patients (3,284 in each arm) remained.
Results: At BL, HDF patients had a non-significant higher ERI than HD patients 
(7.79 vs 7.48 IU/kg/(g/dl)) (p=0.06). ERI decreased by 0.087 IU/kg/(g/dl) per mth in HDF 
patients and significantly less in HD patients (0.050 IU/kg/(g/dl) per mth). The difference 
between both groups increased by 0.036 IU/kg/(g/dl) per mth. At 8.4 mths of follow-up, 
ERI was lower in HDF patients compared to HD patients. The delta ERI for each time 
interval versus BL also reveals ERI change dynamics (Figure).
Conclusions: ERI progressively decreased during the first 24 months on dialysis, 
but more sharply and to a great extent in the HDF group compared to the HD group. The 
dynamics of ERI change over the first year on dialysis may explain why previous studies 
encountered difficulties in recognizing ERI trends when various dialysis vintages are 
grouped together.
FR-OR014
Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients 
Tae Hee Kim,1 Joline L.T. Chen,1,2 Elani Streja,1 Connie Rhee,1 Yoshitsugu 
Obi,1 Csaba P. Kovesdy,3 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2VA Long 
Beach; 3UTHSC.
Background: Previous studies on maintenance hemodialysis (MHD) patients have 
shown that higher serum ferritin may be associated with inflammation and higher mortality. 
Additional studies have shown that serum ferritin increase sharply in the first year of MHD 
and gradually increase over time. However, associations between changes in serum ferritin 
levels over the first 6 months of dialysis and mortality are unknown. We hypothesized that 
a rapid rise in serum ferritin is associated with higher risk of mortality.
Methods: In a cohort of 93,996 incident MHD patients receiving treatment from 
a large dialysis organization during 2007-2011, we examined mortality associations of 
change in serum ferritin from baseline patient quarter (first 91 days from dialysis start) 
to subsequent quarters using Cox proportional hazard models. Models were adjusted for 
demographics, comorbidities, markers of the malnutrition and inflammation complex 
(MICS) and intravenous iron dose. Serum ferritin change was divided into five strata: 
(<-400, -400 to <-100, -100 to <100, 100 to <400, and ≥400 ng/ml over 3 months). 
Associations were examined across strata of baseline serum ferritin (<200, 200 to <500, 
500 to <800 and ≥800 ng/ml).
Results: Patients were 63±15 years old, 44% female, 32% African-American, and 60% 
diabetic. In patients with baseline serum ferritin ³200 ng/ml, a rise in serum ferritin ≥400 
ng/ml/quarter was associated with higher all-cause mortality during the 5-year follow-up 
compared with no change in serum ferritin (-100 to <100 ng/ml).
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Conclusions: Rapid rise in serum ferritin levels >400 ng/ml/quarter during the first 
6-months after MHD initiation is associated with higher 5-year mortality in patients with 
elevated baseline serum ferritin. Studies evaluating the conditions influencing these serum 
ferritin changes and their associations with mortality are needed.
Funding: NIDDK Support
FR-OR015
Decreasing ESA Dosage Can Be a Factor of the Increase in Ferritin Under 
the Administration of Ferric Citrate with Improving ESA Resistance Index 
Keitaro Yokoyama,1 Takashi Akiba,2 Masafumi Fukagawa,3 Masaaki Nakayama,4 
Hideki N. Hirakata.5  1Div of Nephrology and Hypertension, Jikei Univ School 
of Medicine, Tokyo, Japan; 2Dept of Blood Purification, Kidney Center, Tokyo 
Women’s Medical Univ, Tokyo, Japan; 3Div of Nephrology, Endocrinology 
and Metabolism, Tokai Univ School of Medicine, Isehara, Japan; 4Dept of 
Nephrology, Hypertension, Diabetology, Endocrinology, and Metabolism, 
Fukushima Medical Univ School of Medicine, Fukushima, Japan; 5Japanese 
Red Cross, Fukuoka Hospital, Fukuoka, Japan.
Background: Ferric citrate (an iron based phosphate binder) controlled serum 
phosphorus with lower concentrations and reduced the doses for ESA and intravenous iron 
in HD patients. Also, serum ferritin concentrations had a tendency to increase (Phase 3 trial).
Methods: To explore potential factors associated with an increase in ferritin values, data 
from the 52-week phase3 clinical study in Japanese HD patients were analyzed by a mixed 
model for repeated measurement (MMRM) including variables that were selected based 
on the results of correlation, simple linear regression, and multiple regression analyses. In 
addition, ESA resistance index (ERI) was analyzed to determine factors which contribute 
to it based on the result from the MMRM.
Results: The factor of the increase in ferritin was associated with not only the dosage 
of ferric citrate but also the degree of decrease in ESA dosage (Q1>: dosage was decreased 
in the course of study. Q1≤ to £Q3: dosage was not changed. Q3<: dosage was increased.). 
In subjects whose ESA dosage was decreased in the course of the study, the ERI went 
lower by the administration of ferric citrate in spite of that initial dosage of ESA and ERI 
were higher than other subjects group.
Conclusions: Decreasing ESA dosage might increase serum ferritin level under the 
administration of ferric citrate with improving ERI.
Funding: Pharmaceutical Company Support - TORII PHARMACEUTICAL CO.
FR-OR016
Triferic Maintains Hemoglobin and Iron Balance Long Term: Open-Label 
Phase III Extension Studies  Carrie D. Guss, Raymond D. Pratt, Ajay Gupta, 
Vivian H. Lin.  R&D, Rockwell Medical Inc., Wixom, MI.
Background: The objective of the Phase 3 extension studies was to confirm the 
safety of Triferic administered via dialysate for up to 18 months of treatment and to assess 
hemoglobin and iron status.
Methods: Patients who completed the Phase 3 randomized controlled treatment studies 
(RCT) could continue in the open-label (OL) extension studies for up to 18 months of 
combined participation. In the OL extensions, patients received ESA according to their site 
protocol and IV iron could be administered for presumed development of iron deficiency.
Results: Approximately 70% of patients completed the pivotal RCT and enrolled in 
the OL extension, providing a total of 412 patient-years of exposure to Triferic. Triferic 
reliably administered iron with each hemodialysis treatment. The average pre-HD to 
post-HD increment in serum total iron concentration was 96.2 ± 44.20 mg/dL. Chronic 
administration of Triferic maintained Hgb levels within the target range of 9.5 to 11.5 g/
dL during the study. ESA requirements and CHr also remained stable from study baseline 
throughout the study. Pre-dialysis serum iron values were maintained at baseline levels. 
Serum ferritin concentrations declined from 372.8 ± 236.78 mg/L at OL study entry to 
305.2 ± 219.36 mg/L at End of Treatment (EoT). Fewer patients who had received Triferic 
in the RCT studies required supplemental IV iron (48%) than patients who had received 
placebo (58%). OL long term safety was similar to the RCT results. The most frequent AE 
was procedural hypotension, occurring in 34.8% of patients. When adjusted for exposure, 
the rates of adverse events in the OL study were similar to those observed in the RCT.
Conclusions: Triferic administered long term (up to 18 months) reliably delivered 
iron with every treatment. Triferic administered via dialysate maintained Hgb while not 
increasing iron stores or increasing ESA doses. The safety profile was similar to that 
observed in the pivotal Phase 3 RCT studies. No anaphylaxis was observed in over 45,000 
individual doses administered in this program.
Funding: Pharmaceutical Company Support - Rockwell Medical Inc.
FR-OR017
Longer Sustained Reduction of Serum Hepcidin Level (Hep) During the 
Treatment of Anemia with Epoetin Beta Pegol (CERA) as Compared to 
Epoetin Beta (rEPO) in Predialysis Stage-5 CKD Patients  Yusuke Kuroki,1 
Koji Mitsuiki,1 Yuko Yoshida,1 Hokuto Arase,1 Kaneyasu Nakagawa,1 Hideki 
Yotsueda,1 Hideki N. Hirakata,1 Naohisa Tomosugi.2  1Nephrology & Dialysis 
Center, Fukuoka Red Cross Hospital, Fukuoka, Japan; 2Kanazawa Medical Univ.
Background: Efficient iron utilization is required in ESA-induced erythropoiesis in 
CKD patients, Hep being a key factor to modulate iron turn-over in this situation. In the 
present study, changes in Hep and the related iron markers were examined before and 
after CERA administration in comparison with rEPO in pre-dialysis ESA-naïve stage 5 
CKD patients.
Methods: Twenty-three patients were subjected to the study; age 70±13 [SD] y/o, 
m/f=15/8, DM/nonDM=10/13, eGFR 14±5 ml/min/1.73m2, Hb 9.7±1.1 g/dl. They were 
assigned randomly to 2 groups, being treated with either rEPO (n=13) or CERA (n=10). 
Their baseline data were as follows; Hb 9.8 ± 0.9 (rEPO) vs. 9.6 ± 1.3 (CERA) g/dl, serum 
iron (SFe) 75 ± 25 vs. 77 ± 17 mg/dl, TSAT 28 ± 8 vs. 31 ± 9 %, ferritin 129 ± 117 vs. 
173 ± 91 ng/ml, albumin 3.7 ± 0.5 vs. 3.6 ± 0.6 g/dl, IL-6 3.2 ± 2.8 vs. 3.8 ± 2.3 pg/ml, hs 
CRP 1038 ± 2539 vs. 1730 ± 4191ng/ml, and Hep 34 ± 19 vs. 52 ± 29 ng/ml, respectively.
ESA was given in the morning, SFe and Hep were measured before and on the 2nd, 4th, 
7th, 14th and 28th day. On the first day, circadian variation of SFe and Hep was evaluated. 
Hematological parameters, TSAT and ferritin were measured before and on the 28th day.
Results: Hep level was highest at 3 pm on the first day. Hb rose significantly in both 
group in associated with steep decrease in Hep in rEPO, being 34±19 to 7.7±8.5, and 
was returned to the baseline in 14 days. In CERA, Hep reduction was also observed but 
the trend was mild from 52±29 to 27±17 ng/ml on the 14th days. The decrease in Hep 
correlated significantly with the increase in reticulocyte production index, a marker of 
erythropoietic output, in all patients (r=0.66, p<0.01). These changes were associated with 
the significant decrease in SFe.
Conclusions: CERA has a sustained suppressive effect on Hep, which might contribute 
to its longer erythropoietic activity via enhancing iron utilization.
FR-OR018
Clinical Pharmacology, Efficacy, and Safety of the Anti-Hepcidin Spiegelmer 
Lexaptepid Pegol  Iain C. Macdougall,1 Enric Vilar,2 Helmut Reichel,3 Joachim 
H. Beige,4 Leela Goldstein,1 Frank Schwöbel,5 Luciana Summo,5 Kai Riecke.5 
1Dpt. of Renal Medicine, King’s College Hospital, London, United Kingdom; 
2Lister Hospital, Stevenage, United Kingdom; 3Nephrological Center Villingen 
Schwenningen, Germany; 4Hospital St. Georg, Leipzig, Germany; 5NOXXON 
Pharma AG, Berlin, Germany.
Background: Elevated hepcidin is frequent in hemodialysis patients and contributes to 
ESA-resistant anemia. Inhibiting hepcidin may therefore reduce resistance to ESA therapy 
and improve anemia. The anti-hepcidin L-RNA-Aptamer (Spiegelmer®) lexaptepid pegol 
binds and inactivates hepcidin and is in development for treatment of anemia.
Methods: We studied the pharmacological effects on iron metabolism, on anemia, 
and the safety of lexaptepid in 109 healthy subjects and patients with myeloma/lymphoma 
or on hemodialysis. A trial in dialysis patients with functional iron deficiency is ongoing.
Results: Lexaptepid increased iron concentrations and prevented the serum iron 
decrease after endotoxin challenge in healthy subjects. In patients with myeloma / 
lymphoma and functional iron deficiency, 2 doses/week of lexaptepid over 1 month 
increased hemoglobin by ³1 g/dL in patients with low reticulocyte Hb and high soluble 
transferrin receptor. In ESA-hyporesponsive dialysis patients, cross-over comparison with 
placebo showed increases in serum iron concentrations following lexaptepid administration, 
consistent with its anti-hepcidin action.
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The recruitment of hemodialysis patients for twice weekly treatment with lexaptepid 
for one month is ongoing in a randomized controlled trial. Lexaptepid was well tolerated 
by healthy subjects and patients.
Conclusions: Lexaptepid was safe and well tolerated and showed pharmacodynamic 
activity in healthy subjects and ESA-hyporesponsive dialysis patients as well as signs of 
efficacy in anemic cancer patients with functional iron deficiency.
FR-OR019
Neutrophil Gelatinase-Associated Lipocalin (NGAL) Is Associated with Iron 
Status in Anemic Patients with Chronic Kidney Disease  Min Jung Kim,1 
Il Young Kim,1 Soo Bong Lee,1 Joo Hui Kim,1 Dong Won Lee,1 Su Min Park,2 
Jong Man Park,2 Woo Jin Jung,2 Sang Heon Song,2 Eun Young Seong,2 Harin 
Rhee,2 Ihm Soo Kwak.2  1Internal Medicine, Pusan National Univ Yangsan 
Hospital, Yangsan, Republic of Korea; 2Internal Medicine, Pusan National 
Univ Hospital, Busan, Republic of Korea.
Background: Iron deficiency anemia is common in patients with chronic kidney disease 
(CKD). Neutrophil gelatinase-associated lipocalin (NGAL) is known as a biomarker of 
acute kidney injury and predictor of the progression of CKD. In addition, recent studies 
have shown that NGAL is associated with iron metabolism by binding siderophores, small 
molecules containing iron. We investigated whether serum NGAL levels is associated with 
iron status in CKD patients with anemia.
Methods: This study included 257 CKD patients [estimated glomerular filtration rate 
(eGFR) < 60 ml/min/1.73m2] who had anemia at the time of study enroll (hemoglobin 
levels < 13.0 g/dl in males and < 12.0 g/dl in females). The associations between serum 
NGAL and iron status [iron, total iron binding capacity, ferritin, transferrin saturation 
(TSAT)], eGFR, albumin, uric acid, lipid profile, calcium, phosphate, and C-reactive 
protein (CRP) were assessed.
Results: The CKD patients with TSAT ≤ 30 % had lower serum NGAL values than 
those with TSAT > 30% (274.9 ± 228.3 vs. 394.7 ± 232.2 ng/ml). In univariate analysis, 
serum NGAL correlated with eGFR (r = -0.367, P < 0.001), CRP (r = 0.253, P < 0.001), 
TSAT (r = 0.296, P < 0.001), and ferritin (r = 0.259, P < 0.001). In multivariate regression 
analysis, TSAT (β = 0.370, P < 0.001) was independently associated with serum NGAL 
in addition to CRP (β = 0.268, P < 0.001) and eGFR (β = -0.365, P < 0.001). However, 
ferritin lost its association with serum NGAL (β = 0.093, P = 0.132).
Conclusions: This study suggests serum NGAL is associated with iron status in anemic 
patients with CKD. Further studies are needed to demonstrate the role of NGAL in the 
assessment of iron deficiency and in the management of iron therapy for CKD patients.
FR-OR020
Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously 
and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis 
Subjects: Interim Analysis of a Phase 2 Study  Frank Dellanna,1 Francisco 
Maduell,2 Joan Fort,3 Xavier Warling,4 Hem N. Singh,5 William T. Smith.5 
1DaVita Nephrology, Duesseldorf, Germany; 2Hospital Clinic of Barcelona, 
Barcelona, Spain; 3Vall d’Hebron Univ Hospital, Barcelona, Spain; 4Citadelle 
Regional Hospital Center, Liege, Belgium; 5Celgene Corporation, Warren, NJ.
Background: An ongoing randomized study is evaluating intravenous (IV) and 
subcutaneous (SC) sotatercept, an ActRIIA-IgG1 fusion protein ligand trap, for maintenance 
of hemoglobin (Hb) after switching from a prior erythropoietin-stimulating agent (ESA) 
in end-stage kidney disease (ESKD) subjects on hemodialysis (HD).
Methods: In part 1 of a 2-part phase 2 study, ESA-responsive ESKD/HD subjects 
with Hb between 10 and 12 g/dL were switched from ESA and randomized to open-label 
sotatercept (IV: 0.1 and 0.2 mg/kg; SC: 0.13 and 0.26 mg/kg) given every 14 days for up 
to 8 doses; a third dose group level of IV and SC is enrolling. Pharmacokinetic, safety, 
tolerability, and Hb effect were assessed. Intrasubject dose escalation was not permitted. 
Treatment failures (Hb <9 g/dL) were rescued with ESA or transfusion.
Results: Among subjects receiving sotatercept (N=30; IV: 0.1 mg/kg [n=7], 0.2 mg/
kg [n=8]; SC: 0.13 mg/kg [n=7], 0.26 mg/kg [n=8]), ³1 adverse event (AE) occurred in 
100%, 67%, 57%, and 57%, respectively. Serious AEs occurred only in the IV 0.1 mg/kg 
group (29%). AEs were mostly mild/moderate, unrelated to study drug, relatively similar 
between groups, and generally consistent with subject medical histories. No dose- or 
route-dependent changes were seen in home blood pressure (BP); no injection site or 
hypersensitivity reactions were observed. At the end of the 99-day treatment phase, mean 
change from baseline Hb was -0.5 g/dL (IV 0.1 mg/kg), 0.3 g/dL (IV 0.2 mg/kg), -0.3 g/dL 
(SC 0.13 mg/kg), and -0.3 g/dL (SC 0.26 mg/kg); 57%, 13%, 43%, and 13% experienced 
treatment failure requiring rescue, respectively. In the IV 0.2 mg/kg group, 3 subjects 
discontinued after the first dose.
Conclusions: IV and SC sotatercept demonstrated acceptable safety in ESKD/HD, 
with no dose- or route-dependent effects on home BP. Enrollment in the highest dose 
group is ongoing.
Funding: Pharmaceutical Company Support - Study was sponsored by Celgene 
Corporation.
FR-OR021
The Role of Activin in the CKD-MBD  Keith A. Hruska,1 Toshifumi Sugatani,1 
Olga A. Agapova,1 Yifu Fang,1 Hartmut H. Malluche.2  1Pediatrics, Nephrology, 
Washington Univ School of Medicine, Saint Louis, MO; 2Medicine, Nephrology, 
Univ of Kentucky, Lexington, KY.
Background: At its inception, the CKD-MBD consists of vascular calcification, an 
osteodystrophy, decreased aklotho and stimulation of skeletal osteocyte FGF23 secretion. 
We have shown that inhibition of activin signaling through the activin type 2A receptor 
(ActRIIA), induced by CKD inhibits vascular calcification. Here, the other components 
of the CKD-MBD are analyzed.
Methods: CKD with hyperphosphatemia and 60% reduction in GFR (CKD-3) was 
induced at 14 weeks of age in our ldlr-/- high fat fed model of vascular calcification. Some 
CKD mice were treated with RAP-011 (a type 2 activin receptor, ActRIIA, ligand trap). 
Skeletal histomorphometry and microCT imaging, renal klotho levels, serum chemistries and 
FGF23 and PTH levels were measured. Activin klotho and ActRIIA levels were measured 
by elisa, RT-PCR, westerns and IHC.
Results: Activin levels in the circulation were 10 fold elevated. The ldlr-/- high fat 
fed model harbors a low turnover osteopenic osteodystrophy that was converted by CKD-
3 to a high turnover state characterized by PTH levels of 430pg/ml (7 fold elevated), 
hyperphosphatemia, increased osteoblast numbers,and surfaces, increased osteoclast 
numbers and eroded surfaces, increased bone formation rates (BFR) but a significant 
decrease in BFR/osteoblast. CKD-3 decreased renal tubular klotho levels and produced 
marked (10 fold) elevations in FGF23 levels. Inhibiting activin by an ActRIIA ligand 
trap surprisingly reduced osteoblast number and surfaces, decreased BFR but increased 
BFR/osteoblast thereby preserving MAR. RAP-011 decreased osteoclast numbers 
and eroded surfaces. MicroCT imaging showed that RAP-011 increased cortical bone 
thickness and cortical bone area compared to CKD-3. RAP-011 treatment did not affect 
hyperphosphatemia, PTH levels or FGF23 levels. Inhibiting activin signaling increased 
renal tubular klotho levels.
Conclusions: Activin is a critical factor in the pathogenesis of the CKD-MBD causing 
aklotho deficiency, vascular and skeletal disease, and surprisingly playing a key role in the 
osteoblast dysfunction of CKD heretofore attributed solely to PTH and FGF23.
Funding: NIDDK Support, Pharmaceutical Company Support - Celgene
FR-OR022
Increase in Trabecular Bone Volume by Inhibition of GSK-3β in Uremic 
Mice  Narihito Tatsumoto,1,2 Masaki Arioka,2 Shunsuke Yamada,1 Masanori 
Tokumoto,4 Kazuhiko Tsuruya,1,3 Takanari Kitazono,1 Toshiyuki Sasaguri.2 
1Dept of Medicine and Clinical Science, Graduate School of Medical Sciences, 
Kyushu Univ, Fukuoka, Japan; 2Dept of Clinical Pharmacology, Faculty of 
Medical Sciences, Kyushu Univ, Fukuoka, Japan; 3Dept of Integrated Therapy 
for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu Univ, 
Fukuoka, Japan; 4Dept of Medicine, Fukuoka Dental College, Fukuoka, Japan.
Background: Bone fracture increases the risk of hospitalization and mortality in 
patients with chronic kidney disease (CKD). Bone volume is closely related to the risk of 
fracture in CKD. Studies have shown that inhibition of glycogen synthase kinase (GSK)-3β, 
a critical component of Wnt/β-catenin signaling pathway, increases bone volume through 
accumulation of β-catenin. However, it remains unknown whether inhibition of GSK-3β 
increases bone volume in uremia.
Methods: The present in vivo study was performed to determine whether inhibition 
of GSK-3β could increase bone volume in adenine-induced CKD mice. Wild type mice 
were divided into three groups. One group was fed a control diet (CNT) and the other two 
groups were fed a diet containing 0.2% adenine with or without lithium chloride (LiCl), 
a GSK-3 inhibitor; CKD and CKD-LiCl group. GSK-3β heterozygous knockout mice 
were also fed a diet containing 0.2% adenine (CKD-GSK-3β+/-). Bone and blood samples 
were collected after 6 weeks and trabecular (Tb) and cortical (Ct) bone were analyzed by 
micro-computed tomography.
Results: CKD mice developed azotemia, hyperphosphatemia, and secondary 
hyperparathyroidism, followed by a decrease in Ct bone thickness and no change in Tb 
bone volume after 6 weeks. Treatment with LiCl increased Tb bone volume, accompanied 
by polyuria and polydipsia. Tb bone volume increased in CKD-GSK-3β+/- mice compared 
with CNT and CKD mice. There were no significant differences in kidney function, 
hyperphosphatemia, hyperparathyroidism, and Ct bone thickness among three CKD groups.
Conclusions: Inhibition of GSK-3β increased Tb bone volume in adenine-induced 
uremic mice.
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FR-OR023
Sclerostin Knock-Out Protects from Uremia-Induced Cortical Bone Loss 
in a Murine Model of Chronic Renal Failure  Daniel Cejka,1 Diego Michael 
Parada Rodriguez,1 Stefanie Pichler,1 Rodrig Marculescu,5 Ina Kramer,2 Michaela 
Kneissel,2 Thomas Gross,3 Andreas G. Reisinger,3 Dieter Pahr,3 Marie-Claude M. 
Faugere,4 Martin Haas,1 Hartmut H. Malluche.4  1Div of Nephrology & Dialysis, 
Dept of Medicine III, Medical Univ Vienna, Vienna, Austria; 2Musculoskeletal 
Disease Area, Novartis Insts for BioMedical Research, Basel, Switzerland; 3Inst 
of Lightweight Design and Structural Biomechanics, Vienna Univ of Technology, 
Vienna, Austria; 4Div of Nephrology, Bone and Mineral Metabolism, Dept of 
Internal Medicine, Univ of Kentucky, Lexington, KY; 5Dept of Laboratory 
Medicine, Medical Univ Vienna, Vienna, Austria.
Background: Renal osteodystrophy (ROD) affects the majority of patients with 
advanced chronic kidney disease (CKD) and is characterized by progressive bone loss. 
This study evaluates the effects of sclerostin-knock-out on bone in a murine model of CKD.
Methods: Severe CKD was surgically induced in sclerostin-knock-out-mice (SOST-
KO-CKD) and wild-type (WT-CKD). Mice with normal kidney function serve as controls 
(SOST-KO-CTRL, WT-CTRL). After 3 months of CKD, blood was drawn and vertebrae 
and tibia were collected for histomorphometric and µCT analyses.
Results: Cortical thickness (Ct.Th) of the tibia was significantly higher in sost-ko-CKD 
mice compared to wt-CKD mice (p<0.001). WT-CKD mice had lower Ct.Th compared 
to WT-CTRL (p<0.05), whereas no significant differences in Ct.Th were found between 
SOST-KO-CKD and SOST-KO-CTRL groups. Compared to WT-CKD mice, SOST-KO-
CKD animals had higher trabecular number (p<0.001) and trabecular thickness (p<0.001) 
and lower trabecular separation (p<0.001). Mineral density of trabecular bone was 
higher (p<0.001) in SOST-KO-CKD mice compared to WT-CKD animals. In the lumbar 
vertebrae, bone volume/tissue volume was higher in SOST-KO-CKD mice compared to 
the WT-CKD group (p<0.001). Osteoid maturation time and mineralization lag time were 
not influenced by SOST-KO.
Conclusions: Sclerostin knock-out leads to increased bone mass and improved 
microarchitecture but does not alter osteoid mineralization in a murine model of CKD. 
Inhibition of sclerostin may be a promising approach to prevent bone loss in CKD.
Funding: Clinical Revenue Support
FR-OR024
Bone Health in Incident Renal Transplant Recipients: A Prospective Bone 
Biopsy Study  Pieter Evenepoel,1 Geert J. Behets,2 Liesbeth Viaene,1 Patrick 
C. D’Haese.2  1Immunology and Microbiology, Catholic Univ Leuven, Leuven, 
Belgium; 2Pathophysiology, Univ of Antwerp, Antwerp, Belgium.
Background: Renal transplant recipients are at increased risk of fracture especially 
in the early post-transplant period. A better knowledge of the pathophysiology of post-
transplant bone disease may open perspectives for targeted therapy. More specifically 
the role of immunosuppressive drugs, persistent hyperparathyroidism and inflammation 
needs to be elucidated. Bone histomorphometry is the gold standard to assess bone health.
Methods: Patients with paired bone biopsies at time of transplantation and 1 year, 
enrolled in an ongoing study that aims to unravel the natural history of CKD-MBD after 
transplantation (NCT01886950), were included in the present interim analysis (n=36, 29 
males, age 54 ± 13 yrs). Maintenance immunosuppression consisted of steroids, a calcineurin 
inhibitor and mycophenolate mofetil. Mean cumulative methylprednisolone dose was 1.7 
± 0.7 g/d. None of the subjects had current or prior exposure to anti-resorptive agents.
Results: Histomorphometric parameters determined at baseline did not (or at best 
poorly) correlate with parameters determined  at 1 year. Static parameters of bone formation 
(Ob.Pm/T.Pm (%): 0.6 [0.0 -3.7] vs 1.9 [0.0 – 4.0]) and resorption (EPm/B.Pm (%) 2.1 [0.1- 
4.3] vs 4.7 [3.3 – 8.1]; Oc.Pm/T.Pm (%): 0.0 [0.0 - 0.6] vs 0.9 [0.0 – 1.4]) decreased after 
transplantation. Inter-individual variation, however, was substantial, and significance was 
reached for bone resorption and osteoclast perimeter only. Circulating levels of TRAP5b, 
a biomarker of osteoclast activity, changed accordingly (3.0 [2.0 -4.8] vs 4.7 [3.0- 7.1] 
U/L, p=0.003). Correlation statistics showed a significant correlation between change of 
EPm/B.Pm and TRAP5b over time. Trabecular bone loss during the study period was 
minimal. Cumulative steroid dose, but not PTH level was identified as a significant correlate.
Conclusions: Our data confirm a reduction of bone activity early after transplantation. 
Additional studies are required to further define underlying pathophysiological mechanisms. 
Trabecular bone loss in contemporaneous transplantation is minimal, most probably as a 
consequence of steroid minimization.
FR-OR025
Chronic Kidney Disease Is Associated with Progressive Increase in 
Arterial Stiffness and Bone Loss Over 1 Year  Rathika Krishnasamy,1,2,3 
Nicole M. Isbel,1,2 David W. Johnson,1,2 Tony Stanton,4 David Mudge,1,2 Scott 
B. Campbell,1,2 Sven-Jean Tan,5 Nigel David Toussaint,5 Carmel M. Hawley.1,2 
1School of Medicine, The Univ of Queensland, Brisbane, Australia; 2Dept 
of Nephrology, Princess Alexandra Hospital, Brisbane, Australia; 3Dept of 
Nephrology, Nambour General Hospital, Brisbane, Australia; 4Cardiovascular 
Imaging Research Group, The Univ of Queensland, Brisbane, Australia; 5Dept 
of Nephrology, The Royal Melbourne Hospital, Melbourne, Australia.
Background: To assess changes in arterial stiffness, bone structure and markers in 
stage 4/5 chronic kidney disease (CKD) compared with healthy controls.
Methods: In this prospective, single-centre, observational study, bone indices using 
peripheral quantitative computed tomography (pQCT) [cortical bone mineral density 
(cBMD), trabecular bone mineral density (tBMD), strength-strain index (SSI), bone mineral 
content (BMC) and cortical cross-sectional area (cCSA)], arterial stiffness [pulse wave 
velocity (PWV)] and bone markers including plasma intact fibroblast growth factor-23 
(FGF23) and soluble α-klotho (sKl)were compared between CKD stage 4/5 and controls 
at baseline and 12 months (12m).
Results: Forty CKD [mean estimated glomerular filtration rate (eGFR):19.5±6.7mL/
min/1.73m2] and 42 controls (eGFR:88.6±12.9mL/min/1.73m2) completed follow-up. 
At baseline, CKD subjects had lower cBMD (p=0.04), higher aortic PWV (p=0.047) 
and FGF23 (p=0.001) compared to controls. Lower baseline cBMD independently 
correlated with higher PWV (β=-0.51,p<0.001) in the CKD group. At 12m, CKD subjects 
had a significant decline in cBMD (-0.87%,p=0.01), tBMD (-1.70%,p=0.03), BMC 
(-2.60%,p<0.001), cCSA (-1.62%,p=0.01) and SSI (-3.79%,p=0.02) and an increase in 
PWV by 1.3m/s (16.7%,p<0.001). Serum phosphate, calcium, parathyroid hormone and 
sKl did not significantly change over 12m. FGF23 levels increased [240.6(141.9-1129.8) 
to 396.8(160.3-997.7),p=0.001] and was independently associated with changes in cBMD 
and PWV. Bone and vascular parameters remained unchanged in controls.
Conclusions: CKD was associated with significant losses of bone structure and greater 
increases in arterial stiffness and FGF23 levels over 12 months.
Funding: Pharmaceutical Company Support - Shire Australia, Private Foundation 
Support, Clinical Revenue Support
FR-OR026
Vascular Calcification Is Mediated by ERK-Dependent Upregulation of Pit1 
via Rac1/NADPH/MR Activity  Victor Manuel Barrientos,1 Néstor Abarzúa,1 
Diego Varela,1 Rodrigo Alzamora, Luis F. Michea.1,2  1ICBM, Univ de Chile, 
Chile; 2Millenium Inst on Immunology and Immunotherapy, Chile.
Background: Vascular calcification (VC) is a mayor mortality risk factor in patients 
with chronic kidney disease. During VC, vascular smooth muscle cells (VSMC) of the 
tunica media transdifferentiate into osteoblast-like cells. High extracellular phosphate (HP) 
promotes VC through the induction of the sodium-dependent phosphate cotransporter (Pit1) 
activity, increased NADPH oxidase activity (Nox1) and the expression of osteochondrogenic 
factors (OCF). Recent studies indicate that antagonists of the mineralocorticoid receptor 
(MR) ameliorate/prevent experimental VC and arteriosclerosis in mice. The small GTPase 
Rac1 modulates MR and Nox activity in VSMC. However, the role of Rac1 on vascular 
calcification remains unknown. We hypothesize that in VSMC, HP activates MR via Rac1 
leading to induction of Nox and ERK1/2 activity, promoting VC.
Methods: Effects of HP on VC (Alizarin red staining) and OCF gene induction (RT-
qPCR) were evaluated in rat aortic VSMC (A7r5). Inhibitors of Rac1 (NSC23766), MR 
(spironolactone) and Nox1 (apocynin) were used to determine signaling pathways involved 
in the activation of ERK caused by HP. Nox activity was determined using the Hyper 
H2O2 Biosensor. A7r5 cells were stimulated with HP, HP+NCS23766 or HP+apocynin 
to determine the role of Rac1 and MR on HP-induced H2O2 production. n=4-5 per group.
Results: HP increased Pit1 mRNA, OCF mRNA (cbfa1 and Sox9) and Nox1 mRNA 
(p<0.05 vs. normal phosphate (NP)) and caused mineralization. Aldosterone (100nM) 
potentiated the effect of HP on mineralization and gene expression (p<0.05). Incubation in 
the presence of spironolactone (10uM) prevented all the effects of aldosterone. Inhibition 
of Rac1 and NADPH oxidase activity prevented HP-induced H2O2 production (2.6% NP; 
25% HP; 1.8 % HP+NSC at 20 min of stimuli;p<0.05 vs. HP). The presence of Rac1 or 
MR antagonists in culture medium suppressed HP-induced activation of ERK (2.7 times 
at 10 min;p<0.05 vs. 0 min).
Conclusions: We conclude that high phosphate-dependent calcification is mediated by 
ERK-dependent upregulation of Pit1 via Rac1/NADPH/MR activity. Funding: FONDECYT 
1130550, IMII P09-016-F.
Funding: Government Support - Non-U.S.
FR-OR027
Inhibition of Wnt Signaling and Matrix Metalloproteinases Attenuates 
Calcium and Phosphate Induced Calcifications in Vascular Smooth 
Muscle Cells  Uwe Querfeld,1,2 Veronika Bobb,2 Christian Freise.2  1Pediatric 
Nephrology, Charité, Berlin, Germany; 2Center for Cardiovascular Research, 
Charité, Berlin, Germany.
Background: The trans-differentiation of vascular smooth muscle cells (VSMC) into an 
osteoblast-like phenotype and matrix remodeling are essential in the pathognesis of vascular 
calcifications in patients with chronic kidney disease (CKD). We have previously shown 
that the matrix metalloproteinases (MMP)-2 and -9 facilitate VSMC calcifications and, 
vice versa, their inhibition attenuates this process [1]. We studied the effects of calcifying 
conditions, recombinant MMPs and MMP-inhibitors on signal transduction in VSMC.
Methods: Mimicking the disturbed mineral balance during CKD, the trans-
differentiation/calcification of murine VSMC was induced by a calcification medium (CM) 
containing elevated concentrations of calcium and phosphorus (Ca/P). MMP activities were 
modulated by recombinant MMP-2 or -9 and selective MMP inhibitors. Wnt activation was 
induced by a recombinant Wnt agonist and assessed in reporter plasmid (pGL4.49[luc2P/
TCF-LEF RE/Hygro]) transfected VSMC. MMP-secretions and mRNA expressions were 
determined by substrate assays and qPCR, respectively.
Results: CM-induced calcifications in VSMC were accompanied by enhanced 
Wnt-signaling. Even under normal culture conditions, Wnt activation with a Wnt agonist 
induced VSMC calcifications associated with enhanced mRNA expression and secretion of 
MMP-2/-9. These Wnt-mediated effects were inhibited by MMP-2/-9 inhibitors. Treatment 
of VSMC with recombinant MMP-2/-9 induced a time-delayed Wnt-activation after 72h.
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Conclusions: Enhanced levels of Ca/P induce Wnt-activation in VSMC, resulting in 
enhanced production of MMP-2/-9 which further promotes VSMC calcification. These 
results confirm clinical studies showing upregulations of MMP-2/-9 in experimental uremia 
[1] and in arteries of patients with CKD [2]. The therapeutic potential of MMP- or Wnt-
inhibitors in the prevention of vascular calcification should be further explored in animal 
models of CKD-associated arteriosclerosis. [1] JASN 25: 2014 (SA-OR062, p.95A; TH-
PO555, p.233A; FR-PO833, p.562A) [2] Chung A. et al, Circulation 120, 792-801 (2009).
FR-OR028
Calciphylaxis Is Characterized by Vitamin K Deficiency and Impaired 
Matrix Gla Protein Carboxylation  Sagar U. Nigwekar,1 Rajeev Malhotra,1 
Julia Beth Wenger,1 Sarah Booth,2 Ravi I. Thadhani.1  1Massachusetts General 
Hospital; 2Tufts Univ.
Background: Calciphylaxis, a dermal arteriolar calcification disorder linked with 
high mortality, has unclear pathogenesis. We investigated vitamin K metabolism and its 
effects on vitamin K dependent carboxylation of calcification inhibitor, Matrix Gla Protein 
(MGP), in calciphylaxis patients.
Methods: We prospectively recruited 20 ESRD patients with biopsy-confirmed 
calciphylaxis and obtained plasma samples and clinical information at the time of 
calciphylaxis diagnosis. Plasma samples and clinical information were also obtained from 
20 controls (ESRD patients without calciphylaxis) matched to cases by age, sex, race, and 
warfarin status. Plasma levels of Proteins Induced by Vitamin K Absence (PIVKA-II) a 
sensitive measure of vitamin K deficiency, carboxylated MGP (c-MGP), and uncarboxylated 
MGP (uc-MGP) were measured using ELISA assays. MGP carboxylation status was derived 
by calculating c-MGP/uc-MGP ratio (MGP ratio). Prevalence of vitamin K deficiency 
(defined by PIVKA-II level ³2 ng/mL) was compared between cases and controls using 
Chi-square analysis. MGP ratios were compared between cases and controls using a Mann 
Whitney U test and multivariable linear regression.
Results: Prevalence of vitamin K deficiency was higher in cases compared to controls 
(90% vs. 50%, P=0.006) including in patients not on warfarin/vitamin K antagonist therapy 
(83% vs. 35%, P=0.014). Median MGP ratio was lower in cases compared to controls 
(1.29 vs. 2.42, p=0.001) including in patients not on warfarin (1.64 vs. 2.98, p <0.001).
In multivariable analyses adjusted for clinical characteristics, vitamin K deficiency 
was associated with a 48% reduced MGP ratio (P=0.004).
Conclusions: High prevalence of vitamin K deficiency and its potential impact on MGP 
carboxylation in calciphylaxis call for a therapeutic trial of vitamin K supplementation in 
calciphylaxis.
Funding: Private Foundation Support
FR-OR029
Dialysis with Medium Cut-Off (MCO) Filters Reduces In Vitro Calcification 
of Human VSMC: Lessons from a Randomized Clinical Trial  Daniel Zickler,1 
Markus Storr,3 Matthias Girndt,2 Roman Fiedler,2 Kevin Willy,1 Ralf Schindler.1 
1Dept of Nephrology and Internal Intensive Care Medicine, Charité Univ 
Medicine, Berlin; 2Dept of Internal Medicine II, Martin-Luther-Univ, Halle; 
3Research & Development, Gambro Dialysatoren GmbH, Hechingen.
Background: Vascular calcification is increased in CKD patients, partly caused 
by insufficient removal of inflammatory proteins with conventional dialysis filters. We 
assessed whether dialysis with MCO filters, which allow elimination of middle-sized 
inflammatory proteins with only limited permeability for albumine, influences vascular 
calcification in vitro.
Methods: 50 patients were dialysed in a randomized controlled clinical “first-in-man” 
trial with a MCO and a Highfluxfilter for four weeks in a randomized order. To test for 
longterm effects the patients were continued on their filter for eight more weeks. After each 
phase serum samples were drawn. In human VSMC calcification was induced and serum 
samples were added. After 7-12 days in vitro calcification was assessed via Alizarin red 
and Alkaline phosphatase assays and normalized to WST-8.
Results: Calcification in VSMC incubated with serum drawn after MCO dialysis was 
reduced compared to Highflux serum. Serum from patients, who started on a Highflux 
membrane showed a 35 % reduction (p<0,0001) of alizarin red staining after 4 weeks and 
a 49% (p<0,0001)reduction after 12 weeks of MCO dialysis. Alkaline phosphatase showed 
a 23% reduction after 4 weeks and a 32% reduction after 12 weeks MCO. Accordingly, 
serum from patients, who started on MCO showed an increase of calcification after switch 
to highflux dialysis. 
Conclusions: Dialysis of with MCO filter reduces in vitro vascular calcification. Our 
results encourage further investigation of the use of MCO filters in chronic dialysis patients 
with assessment of radiologic signs of vascular calcification and hard clinical end points.
Funding: Pharmaceutical Company Support - Gambro GmbH, Government Support– 
Non-U.S.
FR-OR030
First Experience with a Novel Inhibitor of Vascular Calcification (SNF472) 
in Healthy Volunteers and ESRD Patients on Hemodialysis  Joan Perelló, 
Carolina Salcedo, Pieter H. Joubert, Ana-Zeralda Canals, Miquel D. Ferrer. 
Sanifit, Palma, Spain.
Background: SNF472, an intravenous (i.v.) formulation of myo-inositol 
hexaphosphate, is being developed for treating calciphylaxis and for preventing vascular 
calcification progression in patients with end-stage renal disease on hemodialysis. It 
selectively inhibits the final common pathway in the etiology of vascular calcification, the 
formation and growth of hydroxyapatite (HAP) crystals. Non-clinical investigations showed 
adequate evidence of efficacy and safety to warrant a first study in humans.
Methods: A double-blind, randomized, phase 1 clinical trial was performed in two 
cohorts of 8 male healthy volunteers (HV) and one cohort of 8 hemodialysis (HD) patients. 
Single ascending doses of 0.5, 5, 9 and 12.5 mg/kg of SNF472 were administered through 
4-hour i.v. infusion to HV into a forearm vein. HD patients received a single i.v. dose of 
9 mg/kg through the dialysis tubing before the filter during the 4 hours of dialysis. Safety 
parameters, including extensive ECG monitoring, were recorded. Blood samples were 
obtained up to 24h for safety and pharmacokinetics. A PD (pharmacodynamics) assay was 
used to assess the potential of ex vivo formation of HAP crystals.
Results: SNF472 was well tolerated and no systemic adverse events were observed. 
Several HV reported irritation at the infusion site. This effect was concentration-dependent 
(not dose-dependent). In HD patients SNF 472 is diluted >500-fold in the dialysis system 
before reaching the patient and no local irritation occurred. No effects were seen in 
safety parameters, including ECG. Ionized calcium was slightly below the lower limit of 
normal in HV at 12.5 mg/kg. The 5, 9 and 12.5 mg/kg doses produced measurable plasma 
concentrations above the anticipated EC50 (5µM) and showed a 70-80% reduction in 
the ex vivo HAP crystal formation PD assay. HD patients had similar SNF472 plasma 
concentrations (suggesting low SNF472 clearance through the dialysis membrane) and 
PD effects to HV. Plasma ionized calcium levels were stable.
Conclusions: The data available suggests a favourable benefit/risk ratio of SNF472 and 
supports further studies in the target population. Supported by RETOS COLABORACIÓN 
RTC-2014-2460-1.
Funding: Pharmaceutical Company Support - Laboratoris Sanifit, Government 
Support - Non-U.S.
FR-OR031
Use of Peritoneal Dialysis (PD) Before and After the Bundled Prospective 
Payment System (PPS)  Richard Hirth,1 Tammie A. Nahra,1 Adam S. Wilk,1 
Marc Turenne,2 Jonathan H. Segal,1 John Wheeler,1 Kathryn Sleeman,1 Wei 
Zhang.1  1UM-KECC, Univ of Michigan, Ann Arbor, MI; 2Arbor Research 
Collaborative for Health, Ann Arbor, MI.
Background: PD rates steadily eroded prior to the PPS. Because the PPS bundles 
injectable drugs, which are used less in PD relative to hemodialysis (HD) while paying the 
same rate for PD and HD, the PPS increases the incentive to provide PD. PD rates began 
to rise in anticipation of the PPS and continued to rise after its implementation. This study 
extends these early observations to include 4 years under the PPS and examines whether 
the PD supply shortages of 2014 impacted the growth of PD.
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Methods: We used Medicare claims to examine trends in % of patient-months with 
PD during 2007-2014, for patients incident during the current year, prior year and ³2 years 
prior. The study period includes 3 pre-PPS years (2007-09), a transition year when the PPS 
was anticipated but not yet implemented (2010) and the first 4 years of the PPS (2011-14).
Results: PD continued to increase as a % of patient-months through the transition and 
post-bundle period. Initial increases occurred in the current and prior year cohorts with a 
trailing increase in the ³2 year cohort, reaching 10.7%, 11.9% and 7.4%, respectively by 
2014 (vs. 6.0%, 7.1% and 6.1% in 2007). Growth stalled in the current year cohort during 
2014, coincident with PD supply shortages.
Conclusions: PD use continued to increase under the PPS and is now reflected in 
increases among patients incident ³2 years prior, suggesting that the initial increases among 
newer patients are translating into longer-term modality tenure. PD fluid shortages are 
coincident with a stalling of growth among patients incident in 2014. Monitoring modality 
trends among the 2014 incident cohort will help determine whether those patients eventually 
started PD after shortages eased or if their rates never catch up.
Funding: Other U.S. Government Support
FR-OR032
The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): 
Preliminary Findings from the First Year  Jeffrey Perl,1 Junhui Zhao,2 Brian 
Bieber,2 Yun Li,3 Simon J. Davies,4 David W. Johnson,5 James A. Sloand,6 
Hideki Kawanishi,7 Bruce M. Robinson,2 Francesca Tentori.2,8  1St. Michael’s 
Hospital, Univ of Toronto, Toronto, ON, Canada; 2Arbor Research Collaborative 
for Health, Ann Arbor, MI; 3Univ of Michigan, Ann Arbor, MI; 4Univ Hospital 
of North Midlands, Stoke-on-Trent, United Kingdom; 5Princess Alexandra 
Hospital, Brisbane, Queensland, Australia; 6Baxter Healthcare Corporation, 
Deerfield, IL; 7Tsuchiya General Hospital, Hiroshima, Japan; 8Vanderbilt Univ, 
Nashville, TN.
Background: The PDOPPS is a prospective cohort study underway in the United 
States (US), Australia, Canada, Japan, and the United Kingdom, in collaboration with the 
International Society for Peritoneal Dialysis. PDOPPS aims to understand the impact of 
clinical practices on patient outcomes, including patient and technique survival. Here, we 
present results from the first year of data collection.
Methods: 170 randomly selected facilities and 6000 patients will participate in the 
initial study. A stratified random selection of facilities has yielded national samples of 
facilities and patients, with 20-45 patients per site. Clinical, demographic, biochemical, 
and treatment data are collected at 4-month intervals. Follow up is 3-years or until death, 
kidney transplantation, or 120-days after a change in permanent dialysis modality. Early 
descriptive data are presented for the three countries.
Results: To date, 99 facilities and 2211 patients have been recruited. Selected patient 
and treatment characteristics vary widely across countries (Table 1).
Conclusions: PDOPPS is the largest international study of PD patients and outcomes. 
Early findings demonstrate variability in PD practices (e.g. schedule, adequacy) across 
countries. PDOPPS will be a valuable resource to identify optimal practices and improve 
outcomes for patients on PD.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
FR-OR033
Risk Factors and Sequelae of Hyponatremia in a National Peritoneal 
Dialysis Cohort  Vanessa A. Ravel,1 Rajnish Mehrotra,2 John J. Sim,3 Kevin T. 
Harley,1 Alpesh Amin,1 Juan Carlos Ayus,4 Steven M. Brunelli,5 Elani Streja,1 
Csaba P. Kovesdy,6 Kamyar Kalantar-Zadeh,1 Connie Rhee.1  1UC Irvine; 
2UWashington; 3Kaiser Perm SC; 4Renal Consultants Houston; 5DaVita Clin 
Research; 6UTHSC.
Background: Hyponatremia is common in hemodialysis patients and has been linked 
with higher mortality risk. In peritoneal dialysis (PD) patients, few studies have examined 
the association of hyponatremia with mortality which have shown mixed findings. We 
sought to examine predictors of hyponatremia in a national PD cohort, and hypothesized 
that lower serum sodium (Na) is associated with higher death risk.
Methods: We examined a 5-year (1/2007-5/2011) cohort of 4687 incident PD patients 
from a large US dialysis organization with one or more serum Na measures within the 1st 91-
days of dialysis. We examined predictors of baseline hyponatremia (Na<140mEq/L) using 
case-mix+laboratory adjusted logistic regression models. We then examined the association 
of Na with all-cause mortality. Baseline and time-dependent Na as a proxy of long- and 
short-term exposure—mortality associations, respectively, were estimated using Cox 
models with 3 adjustment levels: Unadjusted, case-mix, and case-mix+laboratory adjusted.
Results: Having diabetes; lower residual kidney function, albumin, PTH; and higher 
glucose, calcium, and ferritin were associated with higher risk of hyponatremia. Baseline 
Na levels <140mEq/L were associated with higher mortality across all 3 models (ref: Na 
140-<142mEq/L). In time-dependent analyses, Na levels <140mEq/L were also associated 
with incrementally higher death risk in case-mix models. After further adjustment for 
laboratory covariates, Na—mortality associations persisted for levels <134mEq/L.
J Am Soc Nephrol 26: 2015 Clinical and Basic Issues in Peritoneal Dialysis Oral Abstract/Friday
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral Abstract PO - Poster; PUB - Publication Only
Underline represents presenting author.
40A
Conclusions: In PD patients, lower serum Na levels are associated with higher 
mortality. Further studies are needed to determine if correction of hyponatremia improves 
outcomes in this population.
Funding: NIDDK Support, Private Foundation Support
FR-OR034
Center-Specific Factors Associated with Peritonitis Risk - A Multi-Center 
Registry Analysis  Annie-Claire Nadeau-Fredette,1,2,3 David W. Johnson,1,2 
Carmel M. Hawley,1,2 Elaine M. Pascoe,1 Yeoung Jee Cho,1 Philip A. Clayton,2 
Sunil V. Badve,1 Kamal Sud,1 Monique Renee Borlace,1,2 Neil Boudville,2 
Stephen P. McDonald.2  1Princess Alexandra Hospital, Australia; 2Australia 
and New Zealand Dialysis and Transplant Registry; 3Maisonneuve-Rosemont 
Hospital, Canada.
Background: Previous studies have reported significant variation in peritonitis rates 
across dialysis centers. Limited evidence is available to explain this variability. This 
study aimed to assess the center-level predictors of peritonitis and their relationship with 
peritonitis rate variation.
Methods: This registry study included all incident peritoneal dialysis (PD) patients 
treated in Australia between October 2003 and December 2013. The primary outcome was 
peritonitis rate, evaluated in a mixed effects negative binomial regression model including 
patient and center-level characteristics. Peritonitis-free survival was assessed as a secondary 
outcome in a Cox proportional hazards model.
Results: Overall, 8711 incident PD patients from 51 dialysis centers were included. 
Center-level predictors of lower peritonitis rates included small center size (HR 0.78, 95% 
CI 0.69-0.90), high proportion of PD (HR 0.87, 95% CI 0.77-0.99), low performance of 
peritoneal equilibration test at dialysis start (HR 0.78, 95% CI 0.66-0.93), and low proportion 
of hospitalisation for peritonitis (HR 0.88, 95% CI 0.75-0.96). In contrast, low proportion 
of automated PD exposure (HR 1.24, 95% CI 1.10-1.39), large icodextrin exposure (1.26, 
95% CI 1.10-1.44) and low (HR 1.25, 95% CI 1.11-1.41) or high (HR 1.14, 95% CI 1.01-
1.30) use of antifungal prophylaxis at the time of peritonitis were associated with a higher 
peritonitis rate. Similar results were obtained for peritonitis-free survival. Accounting for 
center-level characteristics appreciably decreased peritonitis variability among dialysis 
centers (p=0.02).
Conclusions: This study identified specific center-level characteristics associated with 
variation in peritonitis risk. Whether or not these factors are directly related to peritonitis 
risk or surrogate markers of other characteristics is uncertain and should be validated in 
further studies.
FR-OR035
Successful Reduction in Peritonitis Rates in U.S. Pediatric Dialysis Units: 
Results of the SCOPE Collaborative  Alicia Neu,1 Troy Richardson,2 John 
P. Lawlor,2 Jayne Stuart,2 Nancy McAfee,3 Jason Newland,4 Bradley Warady.4 
1JHMI; 2CHA; 3Seattle Children’s; 4Children’s Mercy.
Background: The Children’s Hospital Association’s Standardizing Care to Improve 
Outcomes in Pediatric ESRD (SCOPE) Collaborative seeks to minimize peritonitis in 
children on chronic peritoneal dialysis (PD) by increasing compliance with standardized 
PD catheter care practices.
Methods: Peritonitis rates and compliance with care bundles focused on PD catheter 
insertion, pt/caregiver training and follow-up care were collected monthly. Center-specific 
monthly peritonitis rates were calculated as (#infections/#pt-mos). Changes in peritonitis 
rates and compliance were modeled using Generalized Linear Mixed Model techniques 
assuming a negative binomial distribution with a natural log link function and a binomial 
distribution with a logit link function, respectively. Models included random effects to 
accommodate PD center-specific variability.
Results: Data from 24 SCOPE sites that provided peritonitis rates for the 12 mos prior 
to Collaborative launch were included in the analysis. In the first 36 mos, 751 catheter 
insertions in 644 pts, 644 training sessions and 7,977 follow up encounters were captured. 
Compliance with the follow up bundle increased from 11% to 88% (p<0.001) over the 36 
mos, but neither insertion (22% to 36%, p=0.064) nor training compliance (75% to 71%, 
p=0.105) increased significantly. The peritonitis rate decreased significantly (p=0.026) 
from an average monthly rate of 0.052 (95% CI 0.036, 0.076) pre-launch to 0.035 (95% 
CI 0.026, 0.047)at 36 mos, figure 1. 
Conclusions: Using quality improvement methodology pediatric dialysis units 
participating in SCOPE significantly increased implementation of standardized follow up 
care practices and significantly reduced peritonitis rates. Efforts to increase compliance with 
insertion and training bundles and further reduce infection rates are ongoing.
FR-OR036
Diuretic Prescription and Outcomes Among Peritoneal Dialysis Patients 
in the BRAZPD Study  Jennifer L. Bragg-Gresham,1 Ludimila Guedim de 
Campos,2 Thyago Proença de Moraes,2 Ana Elizabeth Figueiredo,3 Pasqual 
Barretti,4 Rajiv Saran,1 Roberto Pecoits-Filho.2  1KECC, Univ of Michigan, Ann 
Arbor, MI; 2Pontifícia Univ Católica do Paraná, Curitiba, Brazil; 3Pontifícia 
Univ Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; 4Univ 
Estadual do Estado de São Paulo - UNESP, Botucatu, Brazil.
Background: Diuretics are prescribed to individuals with reduced renal function (RRF), 
but can continue to play a role in dialysis patients, to manage extracellular fluid volume 
and hypertension. We assess the prescription (Rx) of diuretics and their association with 
survival in a representative sample of PD patients.
Methods: We examined diuretic Rx among 9,905 patients from the BRAZPD study, 
a prospective cohort study launched in Dec 2004. Cox regression was used to estimate 
associations between baseline diuretic use and mortality, adjusting for age, sex, hypertension, 
diabetes, Davies score, pre-dialysis care, prior HD, and prior kidney Tx; interaction used 
to assess Rx by 90-day incident status.
Results: At baseline, 33.9% of patients had diuretic Rx. Patients with Rx were older, 
had higher BMI, more comorbidities, but longer pre-dialysis care (p<0.0001). A higher 
proportion of patients with Rx were incident to PD, male, diabetic, hypertensive, taking 
other anti-hypertensive medications and had received pre-dialysis care; while a smaller 
proportion of patients with Rx had received a prior Tx or HD (p£0.01). Accounting for 
these differences, patients with Rx had a lower risk of mortality (HR=0.87, p=0.005). The 
association was seen among both incident and non-incident patients.
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Conclusions: Despite being older and sicker, patients with diuretic Rx had lower 
mortality. While more striking in incident patients, association was also seen in non-incident 
patients. If diuretic Rx is a marker of RRF or independently associated with better outcomes 
remains to be elucidated.
FR-OR037
In-Hospital Mortality Outcome of Cirrhotic Patients with End Stage Renal 
Disease on Hemodialysis versus Peritoneal Dialysis  Mark Abi Nader,1 
Fernando Rodrigo Aguilar,1 Michael S. Lipkowitz,1 Parasuram Krishnamoorthy,2 
Ping Li,1 Serban A. Dragoi,1 Alex Montero,1 Wen Shen,1 Chanigan Nilubol,1 
Judit Gordon.1  1Nephrology and Hypertension, Georgetown Univ Hospital, 
Washington, DC; 2Internal Medicine, Mount Sinai School of Medicine.
Background: Renal disease is a common complication in cirrhotic patients related 
to electrolyte and acid-base alterations, inadequate response to diuretic drugs, and 
hemodynamic instability, often leading to end stage renal disease (ESRD) with need for 
dialysis. Little is known about the preferred dialysis modality in these patients. We aimed 
to compare the mortality outcomes between cirrhotic patients on either Hemodialysis (HD) 
or peritoneal dialysis (PD).
Methods: Nationwide Inpatient Sample database between 2005 and 2012 was 
queried. Patients with ESRD (ICD9 585.6) and liver cirrhosis (ICD9 571.2; 571.5; 571.6; 
572.3; 572.4) were included in the study. Patients having hepatocellular carcinoma were 
excluded (ICD9 155.0). Both groups were matched, undergoing propensity matching 
score, for chronic conditions including anemia, diabetes mellitus, hypertension, hepatic 
encephalopathy, esophageal variceal bleeding, gastrointestinal bleeding (GIB), paracentesis, 
hepatitis C as well as sex, race, Charlson Comorbidity Index and age. Logistic regression 
was used for multivariable analysis.
Results: 28,622 cirrhotic patients with incident ESRD were identified. 1.7% of them 
were on PD. After propensity score matching and multivariable regression analysis, cirrhotic 
on HD had higher mortality compared to PD patients [4.79% vs 2.70% P = 0.024]. Age>65 
and female gender were significant predictors of mortality in both HD and PD groups. 
Anemia was associated with less mortality rate.
Conclusions: Cirrhotic patients admitted to the hospital for dialysis have higher 
mortality  when started on HD compared to PD.
FR-OR038
AQP1 in Peritoneal Dialysate as Predictive Biomarker of Integrity of the 
Peritoneal Barrier and Ultrafiltration Efficiency  Simone Corciulo,1 Maria 
Celeste Nicoletti,2 Roberto Corciulo,3 Roberto Russo,3 Giuseppe Grandaliano,1 
Maria Svelto,2 Giuseppe Procino,2 Loreto Gesualdo.3  1Dept of Emergency and 
Organ Transplantation, Univ of Foggia, Foggia, Italy; 2Dept of Biosciences, 
Biotechnologies and Biopharmaceutics, Univ of Bari, Bari, Italy; 3Dept of 
Emergency and Organ Transplantation, Univ of Bari, Bari, Italy.
Background: The water channel Aquaporin 1 (AQP1) plays a pivotal role in the 
mechanism of free water ultrafiltration during peritoneal dialysis (PD). Wether or not is 
AQP1 exclusively expressed in peritoneal capillaries or also in the mesothelial cells (MC) is 
still debated. It has been hypothesized that decreased expression or function of AQP1 may 
be responsible for some cases of ultrafiltration failure (UFF). Plasma membrane proteins 
are released in biological fluids through the exosome pathway to an extent proportional to 
their abundance at the plasma membrane.
Methods: In this work we investigated the localization of AQP1 in human peritoneum 
and its presence in exosomes isolated from PD effluent.
Results: Proteomic analysis of peritoneal-derived exosomes showed a significant 
expression of AQP1. Interestingly, the same samples were devoid of the endothelial 
marker CD31 but were positive for the mesothelial marker mesothelin, thus suggesting a 
mesothelial, rather than endothelial origin for these vesicles. 
In human omental biopsies, AQP1 was localized in peritoneal capillaries and at the 
plasma membrane of MC, where it co-localized with mesothelin.
Conclusions: Our results suggest that AQP1 is expressed in MC and released in the 
peritoneal cavity through the exosome pathway. This evidence opens the debate on the role 
of MC in regulating the efficiency of PD and suggests that AQP1 released in the PD effluent 
may represent a potential non-invasive biomarker of integrity of the peritoneal barrier.
FR-OR039
Vascular Endothelial Cell Damage Is an Important Factor in the 
Development of Encapsulating Peritoneal Sclerosis  Mitsuhiro Tawada,1 
Yasuhiko Ito,1 Chieko Hamada,2 Kazuho Honda,3 Masashi Mizuno,1 Yasuhiro 
Suzuki,1 Fumiko Sakata,1 Shoichi Maruyama,1 Yoshifumi Takei,4 Seiichi 
Matsuo.1  1Nephrology, Nagoya Univ, Nagoya, Japan; 2Nephrology, Juntendo 
Univ, Tokyo, Japan; 3Pathology, Tokyo Women’s Medical Univ, Tokyo, Japan; 
4Biochemistry, Nagoya Univ, Nagoya, Japan.
Background: Encapsulating peritoneal sclerosis (EPS) is a rare, but serious and life-
threatening complication of peritoneal dialysis (PD); however, the precise pathogenesis 
remains unclear and predictors have not yet been established. The present study aimed to 
determine predictors of EPS in peritoneal membrane tissues obtained at catheter removal.
Methods: Eighty-three biopsy samples (10 EPS, 73 non-EPS) were assessed by 
pathological and immunopathological techniques to identify predictors of EPS. Tissue 
samples obtained at the time of catheter removal for reasons of peritonitis and a peritonitis 
episode within the past one month were not included. Furthermore, based on these analyses, 
the effects of PD solution on human umbilical vein endothelial cells (HUVEC) were studied.
Results: Univariate analysis of the pathological findings associated a thickened 
peritoneal membrane (P = 0.045), new membrane formation scores (P = 0.006), decreased 
ratio of lumen diameter to vessel diameter (L/V ratio, P < 0.001), CD31-negative vessels (P 
= 0.021) and fibrin deposition (P < 0.001) with the development of EPS. Stepwise Firth’s 
multivariate logistic regression analysis identified glucose exposure scores (odds ratio 2.03, 
P = 0.011) among clinical factors, the L/V ratio (AUC, 0.899; OR, 0.50; P = 0.002) and fibrin 
deposition (OR, 8.50; P = 0.023) among the pathological factors as independent predictors 
of EPS. Multivariate logistic regression analysis of the 10 patients with EPS and 20 controls 
matched for PD treatment period, diabetes and PD solution (acidic or neutral pH) identified 
decreased L/V ratio as an independent predictor. In cultured HUVEC, acidic condition and 
high glucose concentration of PD solution induced necrosis and apoptosis, respectively.
Conclusions: Vascular endothelial cells that become damaged mainly by 
bioincompatible PD solution might induce vascular leakage leading to EPS, and could 
serve as a predictor of EPS.
Funding: Government Support - Non-U.S.
FR-OR040
Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass 
Spectrometry Accelerates Pathogen Identification and May Confer Outcome 
Benefit in Peritoneal Dialysis-Related Peritonitis  Ming-cheng Wang,1 
Wei-hung Lin,2 Te-hui Kuo.1  1Div of Nephrology, Dept of Internal Medicine, 
National Cheng Kung Univ Hospital, Tainan, Taiwan; 2Dept of Internal 
Medicine, National Cheng Kung Univ Hospital, Tainan, Taiwan.
Background: Peritonitis is one of the major complications of peritoneal dialysis (PD) 
and contributes to technique failure and mortality in PD patients. The aim of this study 
was to evaluate the effects of matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF MS) on pathogen identification and clinical outcomes 
in PD-related peritonitis.
Methods: Ninety-eight causative microorganisms of monomicrobial PD-related 
peritonitis were identified using conventional standard methods, and 57 were identified using 
MALDI-TOF MS method. The time to pathogen identification using different identification 
methods was evaluated and compared. The outcome characteristics were time to dialysate 
effluent white blood cell <100/mm3, length of hospital stay, catheter removal/transfer to 
hemodialysis, and in-hospital mortality.
Results: MALDI-TOF MS allowed the direct pathogen identification from positive 
blood cultures accounting for 94.9% of all cases. MALDI-TOF MS method could identify 
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the causative microorganisms of PD-related peritonitis earlier than the conventional standard 
method. The average time saved is 64 hours for all pathogens, 52 hours for Gram-positive 
bacteria, 65 hours for Gram-negative bacteria, 37 hours for Staphylococcus species, 68 
hours for Streptococcus species, and 67 hours for E. coli and Klebsiella species. MALDI-
TOF MS method group had a shorter length of hospital stay than the conventional standard 
group (5.2 ± 4.8 days versus 8.2 ± 4.5 days, P = 0.001).
Conclusions: We demonstrate the clinical effects of pathogen identification using 
MALDI-TOF MS in PD-related peritonitis. Integration of MALDI-TOF MS with blood 
culture system can promote early pathogen identification and timely pathogen-directed 
antibiotic therapy, and may confer outcome benefit. We propose that it is time to speed up 
the pathogen identification in PD-related peritonitis.
Funding: Government Support - Non-U.S.
FR-OR041
Higher Systolic Blood Pressure Variability Is Associated with Increased 
Mortality, Coronary Heart Disease, Stroke, and End Stage Renal Disease 
Margit K. Mikkelsen,1 Miklos Zsolt Molnar,2 Jun Ling Lu,2 Lenar T. Yessayan,3 
Elvira Gosmanova,2 Kamyar Kalantar-Zadeh,4 Csaba P. Kovesdy.1,2  1VA Medical 
Center, Memphis, TN; 2Univ of Tennessee Health Science Center, Memphis, TN; 
3Henry Ford Hospital, Detroit, MI; 4Univ of California, Irvine, CA.
Background: Blood pressure does not remain constant, but instead fluctuates 
dynamically. The implications of this variability in blood pressure are not yet fully 
understood.
Methods: From among 3,285,684 US veterans with normal eGFR during 2005-
2006, we identified 2,865,157 patients who had more than 7 outpatient blood pressure 
measurements. Systolic blood pressure variability (SBPV) was measured using the standard 
deviation (SD) of all SBP values (normally distributed) in one individual. Associations of 
SD quartiles (<10.28, 10.28-12.68, 12.69-15.60, ³15.61 mmHg) with all-cause mortality, 
coronary heart disease (CHD), stroke, and end stage renal disease (ESRD) was examined 
using Cox models adjusted for age, gender, race, and baseline eGFR, comorbidities, BMI, 
SBP, DBP, and antihypertensive medication use.
Results: Higher SBPV was associated with significantly higher risk of all-cause 
mortality, CHD, stroke, and ESRD. In fully adjusted models SD quartiles 2 through 4 
(compared to the first quartile) were associated with mortality hazard ratios of 1.10, 1.32, 
and 1.79; CHD hazard ratios (95%CI) of 2.12, 3.60, and 6.01; stroke hazard ratios of 2.05, 
3.64, and 6.72; and ESRD hazard ratios of 0.88, 1.32, and 4.48.
Conclusions: Higher SBPV is associated with increased risk for mortality, CHD, and 
stroke independent of confounders. The highest SD quartile was associated with increased 
risk for ESRD. The effect of interventions that lower SBPV on mortality will need to be 
examined in clinical trials.
Funding: NIDDK Support, Veterans Administration Support
FR-OR042
Left Ventricular Mass in Early Autosomal Dominant Polycystic Kidney 
Disease  Vicente E. Torres,6 Ronald D. Perrone,1 Kaleab Z. Abebe,2 Kyongtae 
Ty Bae,2 Peter G. Czarnecki,3 Robert W. Schrier,4 Theodore I. Steinman,5 Susan 
Spillane,2 Charity G. Moore.2  1Tufts; 2U of Pittsburgh; 3Brigham and Womens; 
4U of Colorado; 5BIDMC; 6Mayo Clinic, for the HALT PKD Investigators.
Background: Autosomal dominant PKD (ADPKD) associates with hypertension and 
left ventricular hypertrophy (LVH). HALT PKD study A was designed to assess the effect 
of intensive BP control and dual renin angiotensin blockade on progression of total kidney 
volume (TKV) and left ventricular mass (LVM).
Methods: 543 subjects with eGFR >60 ml/min aged 15-50 were randomized to 
lisinopril (L) and placebo (P) vs L and telmisartan (T) with two levels of BP control: 
standard (SBP) (120-130/70-80 mmHg) vs low (LBP) (95-110/65-75 mm Hg). Cardiac 
magnetic resonance measurement of LVM was done at baseline, 24, 48, and 60 months. 
LVM adjusted for body surface area was expressed as LVM index (LVMI; g/m2).
Results: The prevalence of LVH at baseline was <1%. LBP reduced LVMI compared 
to SBP (p<0.001) but there was no effect of dual blockade (p=NS). There was no impact of 
baseline parameters (eGFR, age, systolic BP, TKV, serum K, urine Na or K, albuminuria, 
urine aldosterone, sex) on the BP effect on LVMI. Higher baseline TKV and systolic BP 
had significant associations with more rapid LVMI decline (p<0.0001); a trend of lower 
baseline eGFR also associated with LVMI decline (p=0.07); females had significantly 
reduced LVMI decline vs males (p<0.0001) irrespective of BP group.
Conclusions: LVMI decreased significantly after intensive vs standard BP control. 
Larger TKV, higher systolic BP, male sex, and possibly decreased eGFR were associated 
with a greater reduction in LVMI, irrespective of the level of BP control. Patient factors 
associated with a worse kidney outcome predicted improvement in LVMI after a long 
period of carefully controlled BP. BP reduction in ADPKD shows cardiac benefit and 
should be a focus of treatment.
Funding: NIDDK Support, Private Foundation Support
FR-OR043
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve 
Traffic After Renal Denervation in Patients with Resistant Hypertension: 
A Longitudinal Study  Carmine Zoccali,1 Gino Seravalle,2 Fosca Quarti 
Trevano,3 Domenico Spaziani,4 Filippo Scalise,5 Carla Auguadro,5 Patrizia 
Pizzini,1 Giovanni Tripepi,1 Graziella D’arrigo,1 Giuseppe Mancia,2 Guido 
Grassi,3,6 Francesca Mallamaci.1  1Clinical Epidemiology and Physiopathology 
of Renal Diseases and Hypertension, CNR-IFC, Reggio Calabria, Italy; 
2Istituto Auxologico Italiano, Milano, Italy; 3Clinica Medica, Dipartimento di 
Scienze della Salute, Univ Milano-Bicocca, Milano, Italy; 4Unità Operativa di 
Cardiologia, Ospedale Magenta, Milano, Italy; 5Cardiologia Interventistica, 
Policlinico di Monza, Monza, Italy; 6IRCCS Multimedica, Sesto San Giovanni-
Milano, Italy.
Background: The plasma concentration of the endogenous inhibitor of nitric oxide 
synthase asymmetric dimethyl arginine (ADMA) associates with sympathetic activity in 
patients (pts) with chronic kidney disease but the driver of this association is unknown.
Methods: In this longitudinal study (followup:2 weeks-6 months) we performed 
repeated measurements over time of muscle sympathetic nerve activity (MSNAC), plasma 
levels of ADMA and symmetric dimethyl arginine (SDMA) and blood pressure (BP) and 
heart rate (HR) in 14 pts with drug-resistant hypertension who underwent bilateral renal 
denervation. Stability of ADMA, SDMA, BPs and MSNAC over time (6 months) was 
assessed in 2 historical control groups of patients maintained on stable anti-hypertensive 
treatment.
Results: Time integrated changes in MSNAC following renal denervation ranged from 
-40.6% to +10% (average -15.1%) and these changes were strongly associated with the 
corresponding changes in plasma ADMA (r= 0.62, P=0.02) and SDMA (r=0.72, P=0.004). 
Changes in MSNAC went along with simultaneous changes in standardized systolic (r=0.65, 
P=0.01) and diastolic BP (r=0.61, P=0.02). In the historical control groups, no change in 
ADMA, SDMA, BPs and MSNAC levels was recorded during a 6-months follow up.
Conclusions: In pts with resistant hypertension changes in sympathetic activity 
after renal denervation associate with simultaneous changes in plasma levels of ADMA 
and SDMA. These observations are compatible with the hypothesis that the sympathetic 
nervous system exerts an important role in modulating circulating levels of ADMA and 
SDMA in this condition.
Funding: Government Support - Non-U.S.
FR-OR044
Intensive Blood Pressure Lowering and Kidney Function Decline 
Among Persons with prior Lacunar Stroke: The SPS3 Randomized Trial 
Carmen A. Peralta,1 Leslie Mcclure,2 Rebecca Scherzer,1 Michael Shlipak,1 
Carole White,3 Oscar Benavente,5 Pablo E. Pergola.3  1UCSF; 2UAB; 3UTHSC; 
4UCSF; 5UBC.
Background: The effect of intensive blood pressure (BP) lowering on kidney function 
among persons with vascular disease and preserved glomerular filtration rate (eGFR) is 
not known.
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Methods: SPS3 was a multi-center trial to test effectiveness of two BP targets on 
secondary prevention of stroke. In a post-hoc analysis of 2611 participants randomized to 
lower SBP (<130 mmHg) vs. higher (130-149 mmHg) with yearly creatinine measures, we 
evaluated differences in annualized eGFR decline and rapid decline (>30% ml/min/1.73m2) 
using linear mixed models and logistic regression, respectively.
Results: Mean age was 63±11; 949(36%) were diabetic, mean eGFR was 80±19,and 
410(16%) had eGFR <60 ml/min/1.73m2 at randomization. At 9 months, achieved SBP 
was 137±15 mmHg in higher vs. 127±14 mmHg in the lower BP group, and differences 
persisted throughout follow-up (mean 3.2 years). Relative to higher BP arm, use of ACE/
ARB, diuretic and calcium channel blocker were all increased by 20% among persons in the 
lower BP arm. Compared with higher, lower BP target had faster eGFR decline. Differences 
were most pronounced during the first year, whereas rates of eGFR decline did not differ 
between assigned BP groups after year 1.
A total of 313(24%) persons in the lower BP group had rapid kidney function decline, 
compared with 247(19%) in higher (OR 1.4 (95%CI 1.1 to 1.6)). Differences were apparent 
in the first year (OR 1.4, 1.1-1.8), but were not statistically significant after year 1 (OR 
1.0, 0.73-1.4).
Conclusions: In persons with prior lacunar stroke and relatively preserved kidney 
function, intensive BP lowering was associated with faster renal function decline. 
Differences were primarily observed during the first year of anti-hypertensive treatment 
with no evidence of renal protection during follow up.
Funding: NIDDK Support, Other NIH Support - NHLBI, NIA
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Hypertension Does Not Accelerate Age-Related GFR Decline in the General 
Middle-Aged Population  Bjorn Odvar Eriksen,1 Vidar T. N. Stefansson,1 
Trond G. Jenssen,1 Ulla Dorte Mathisen,1 Jørgen Schei,1 Marit D. Solbu,1 Tom 
Wilsgaard,2 Toralf Melsom.1  1Meatabolic and Renal Research Group, UiT the 
Arctic Univ of Norway, Tromsø, Norway; 2Dept of Community Medicine, UiT 
the Arctic Univ of Norway, Tromsø, Norway.
Background: Although hypertension is a risk-factor for ESRD, this complication 
only develops in a minority of hypertensive patients. Evidence is lacking to support non-
malignant hypertension as a sufficient cause of reduced kidney function. This is partly 
due to the difficulty of assessing normal-range GFR accurately with estimated GFR. In 
epidemiological studies, estimated GFR has been used almost exclusively because actual 
measurements of GFR are costly and complicated. We aimed to investigate whether 
hypertension accelerates GFR decline in the general population using measured rather 
than estimated GFR.
Methods: We included a representative sample of the general population (age 50 to 
62 years) without kidney disease, cardiovascular disease or diabetes at baseline. Baseline 
GFR was measured by iohexol-clearance in 1594 subjects, and 1299 (81%) had a second 
measurement in the RENIS Follow-Up Study (RENIS-FU) after a median observation period 
of 5.6 years. The effect of office blood pressure on the GFR change rate was analyzed.
Results: The mean GFR change rate was -0.95 mL/min/year. The negative sign signifies 
a decline. In multivariable adjusted linear mixed regression models with random intercept 
and slope, the increases in the change rate in mL/min/year/10 mmHg (95% confidence 
intervals) were 0.08 (0.03 to 0.14), 0.18 (0.07 to 0.28), 0.05 (-0.03 to 0.13) and 0.15 (0.07 
to 0.24) for increasing systolic, diastolic, pulse pressure and mean arterial blood pressure 
respectively, indicating that GFR declined more slowly with higher blood pressure within 
the study time-frame. The regression analyses used time-varying measurements of blood 
pressure, individual classes of antihypertensive medication and all adjustment variables.
Conclusions: Hypertension is not a direct sufficient cause of accelerated GFR decline 
in the general middle-aged population. Additional genetic and environmental causal factors 
are probably necessary for primary hypertension to cause clinically manifest chronic 
kidney disease.
Funding: Pharmaceutical Company Support - Boehringer-Ingelheim, Government 
Support - Non-U.S.
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Effect of Uric Acid Lowering on Ambulatory Blood Pressure: A Randomized, 
Double-Blind, Placebo-Controlled Clinical Trial  Ciaran Joseph McMullan,1 
Lea Borgi,1 Gary C. Curhan,1 Naomi D.L. Fisher,2 John P. Forman.1  1Renal Div, 
Brigham and Women’s Hopsital, Boston, MA; 2Endocrine Div, Brigham and 
Women’s Hospital, Boston, MA.
Background: Higher levels of uric acid are associated with higher blood pressure 
(BP) an increased risk of hypertension in many cohort studies, suggesting that uric acid 
may be a target for prevention of hypertension. However, the effect of lowering serum 
uric acid on BP is unclear.
Methods: We performed a randomized, double-blind, placebo-controlled trial of 
normotensive individuals with body mass index (BMI) ³25 and uric acid level ≥ 5.0 mg/dL; 
subjects were randomized to receive either allopurinol 300/600mg, probenecid 500/1000mg 
or placebo daily for 8 weeks. Mean 24 hour systolic BP(24hSBP) was measured using 24 
hour ambulatory blood pressure monitoring at baseline and 8 weeks.
Results: By the end of the trial, 22, 24 and 26 participants assigned to receive 
probenecid, allopurinol and placebo, respectively, had adequate 24 hour BP measurements 
at baseline and 8 weeks.  Uric acid levels changed over 8 weeks from means of 5.9, 5.6 and 
5.6 mg/dL to 3.5, 2.9 and 5.8 mg/dL in the probenecid, allopurinol and placebo groups, 
respectively. 24hSBP was not reduced after 8 weeks of uric acid lowering: from 127±10 
mmHg to 124±8 mmHg (p-value=0.25) in the probenecid group; 125±9 to 124±10 mmHg 
(p-value= 0.71) in the allopurinol group; and 121±9 to 122±10 mmHg (p-value=0.61) in 
the placebo group. Similarly, treatment had no effect on 24 hour diastolic BP.
Conclusions: In contrast to observational studies, this randomized, double-blind, 
placebo-controlled trial found that uric acid lowering does not improve mean 24 hour BP 
in normotensive individuals with high uric acid levels, suggesting that uric acid may not 
be a modifiable target for prevention of hypertension.
Funding: NIDDK Support
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Central Role for Altered Arginine Methylation in Salt-Sensitive 
Hypertension in CKD: A Metabolomic Profiling Study  Anna V. Mathew,1 
Adil Jadoon,1 Jaeman Byun,1 Robin L. Padilla,1 Peter Kotanko,2 Scott L. 
Hummel,1 Brenda W. Gillespie,1 Rajiv Saran,1 Subramaniam Pennathur.1  1Univ 
of Michigan, Ann Arbor; 2RRI, New York.
Background: As the nitrogen donor in nitric oxide (NO) synthesis by NO synthase 
(NOS), arginine and its metabolic products are integrally linked to blood pressure (BP) 
regulation, however their role in chronic kidney disease (CKD), salt sensitivity and BP 
response has not been systematically studied. We explored if arginine metabolites alter 
with sodium restriction and predict favorable blood pressure in response to dietary sodium 
restriction (DSR).
Methods: Samples from 34 subjects enrolled in the LoSalt trial, a randomized 
crossover trial of CKD 3-4 patients who underwent DSR (<2g/day) were utilized. Targeted 
metabolomic analysis of arginine metabolome in pre and post DSR plasma and urine was 
performed by isotope dilution liquid chromatography mass spectrometry including NG NG 
dimethylarginine (ADMA), NGN’G dimethylarginine (SDMA), NGmonomethyl-L-arginine 
(NMMA), arginine and citrulline. Salt sensitivity was determined by salutary changes to 
volume status and BP as measured by bioelectrical impedance spectroscopy (whole-body, 
segmental and calf) and 24-hour ambulatory blood pressure monitoring (ABPM). Pearson 
correlation assessed the associations between the metabolites and clinical parameters.
Results: After 4 weeks of DSR, mean urine sodium decreased by 73 ± 71 mmol/24hr 
and 24-hour systolic BP reduced by 10.8 ± 13.8 mmHg. Higher urine ADMA/ creatinine 
ratio correlated with lower total body water at baseline (r=-0.57; p<0.01). Changes in urine 
ADMA/ creatinine ratio (r=-0.46) and urine NOS inhibition index (NII, ADMA+NMMA/
SDMA, r=-0.46) negatively correlated with changes in mean arterial ABPM (p<0.05). Urine 
Total Arginine Methylation Index (TAMI, (ADMA+SDMA+NMMA)/arginine, r=-0.47, 
p<0.05) negatively correlated with change in extracellular volume.
Conclusions: Our results strongly implicate altered arginine methylation and NOS 
inhibition with BP response following DSR. Further research should examine whether 
urinary markers of altered arginine methylation (ADMA, NII and TAMI) can consistently 
serve as markers of salt sensitivity in both CKD and non-CKD subjects following DSR.
Funding: Private Foundation Support
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Mutations in TBX18 Cause Dominant Urinary Tract Malformations via 
Transcriptional Dysregulation of Ureter Development  Asaf Vivante,1 
Marc-Jens Kleppa,2 Julian Jakob Schulz,1 Stefan Kohl,1 Amita Sharma,3 Jing 
Chen,1 Shirlee Shril,1 Daw-yang Hwang,1 Anna-Carina Weiss,2 Elijah O. 
Kehinde,4 Erika J. Mancini,5 Richard P. Lifton,6,7 Velibor Tasic,8 Soeren S. 
Lienkamp,9 Harald Jüppner,3 Andreas Kispert,2 Friedhelm Hildebrandt.1,7  1Dept 
of Medicine, Boston Children’s Hospital, HMS, Boston, MA, USA; 2Inst für 
Molekularbiologie, Med Hochschule Hannover, Germany; 3Ped Nephrology, 
MGH, Boston, MA, USA; 4Div of Urology, Kuwait Univ, Safat, Kuwait; 5Div 
of Structural Bio, Univ of Oxford, UK; 6Dept of Human Genetics, Yale Univ, 
New Haven, CT, USA; 7Howard Hughes Medical Inst, Chevy Chase, MD; 8Univ 
Children’s Hospital, Skopje, Macedonia; 9Dept of Med, Renal Div Freiburg 
Med Center, Germany.
Background: Congenital anomalies of the kidneys and urinary tract (CAKUT) are the 
leading cause of CKD in children. Identification of monogenic causes of CAKUT permits 
the first insights into disease mechanisms.
Methods: We performed whole exome sequencing in a large kindred followed by 
high-throughput sequencing in individuals with CAKUT. Furthermore, we performed a 
transcriptional reporter assay, protein-protein and protein-DNA interaction studies, as well 
as in vivo studies in Xenopus laevis.
Results: We identified a heterozygous truncating mutation (p.G337Vfs*19) of the 
T-Box transcription factor 18 gene (TBX18) in all 7 affected members of a large kindred. 
We also detected 2 mutations (p.H524Y and p.K163E) in 3 of 1,295 unrelated families 
with CAKUT. TBX18 is essential for development of the ureteric mesenchyme and ureteric 
smooth muscle cells. We found that all 3 TBX18 mutant proteins still dimerize with the wild 
type protein, but had prolonged half-life, and exhibited reduced transcriptional repression. 
The mutation p.K163E altered a residue critical for TBX18-DNA interaction, resulting in 
impaired TBX18-DNA binding. In vivo overexpression in Xenopus laevis revealed decreased 
biological activity on pronephric kidney development for p.G337Vfs*19 and p.K163E.
Conclusions: We discovered dominant negative TBX18 mutations as a novel cause of 
human CAKUT that act via lack of repression of TBX18 transcriptional activity. Our studies 
implicate ureter smooth muscle cell development in the pathogenesis of human CAKUT.
FR-OR049
ACTN4 Mutations Lead to Increased Contractility of Human Podocytes in 
Response to Injurious Stimuli and Matrix Stiffening  Di Feng,1 Ramaswamy 
Krishnan,2 Gabriel Birrane,4 Julia M. Steinke,3 Jiayue Zhang,1 Martin R. Pollak.1 
1Nephrology, Beth Israel Deaconess Medical Center, Boston, MA; 2Emergency 
Medicine, Beth Israel Deaconess Medical Center, Boston, MA; 3Pediatric Kidney 
Transplant Program, Helen DeVos Children’s Hospital, Grand Rapids, MI; 
4Experimental Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
Background: Alpha-actinin-4 gene (ACTN4) mutations cause a rare form of familial 
focal segmental glomerulosclerosis (FSGS) in humans. Individuals with kidney disease-
causing ACTN4 mutations tend to have mild to moderate proteinuria, with many developing 
a progressive decline in kidney function, and eventual end stage kidney disease. All of the 
disease-causing ACTN4 mutations identified to date are located within the actin-binding 
domain (ABD) of the encoded protein, increasing its binding affinity to F-actin and leading 
to abnormal cellular aggregates. The mechanism by which the mutations give rise to FSGS 
is not well understood.
Methods: We used traction force microscopy to quantify contractile forces exerted by 
immortalized human podocytes on their underlying substrate. Immunofluorescence staining 
was used to examine the localization of ACTN4 and actin.
Results: We found that human podocytes transfected with mutant ACTN4 are more 
contractile in response to the injurious stimulus TGF-beta compared to podocytes transfected 
with WT ACTN4. We also found that podocytes seeded on a stiff substrate (26 kilopascal) 
and transfected with mutant ACTN4 are more contractile than podocytes transfected with 
WT ACTN4. This difference in contractile force between WT and mutant was blunted when 
podocytes are seeded on a softer substrate (1 kilopascal). Additionally, mutant ACTN4 
transfected podocytes show much more prominent actin stress fibers, which are largely 
absent from WT ACTN4 transfected podocyte.
Conclusions: We demonstrated that mutations in the ACTN4 ABD resulted in increased 
podocyte contractility in response to injurious circulating stimuli and increased matrix 
stiffness. These observations raise the hypothesis that reducing the contractility of podocytes 
by pharmaceutical agents in vivo might mitigate podocyte disease due to ACTN4 mutation.
Funding: NIDDK Support
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Assessing Two Novel Steroid-Resistant Nephrotic Syndrome Candidate 
Genes Using the Drosophila Model  Sara Gonçalves,1,2 Noëlle Lachaussée,1 
Christelle Arrondel,1 Martin Helmstaedter,3 Oliver Kretz,3 Olivia Boyer,1,4 
Olivier Gribouval,1 Christine Bole-feysot,1 Patrick Nitschke,1 Marie-Claire 
Gubler,1 Tobias B. Huber,3,5 Geraldine Mollet,1 Matias Simons,1,3,6 Corinne 
Antignac.1,7  1Inserm U1163 Inst Imagine, Paris Descartes Univ, Paris, France; 
2Renal Div, St. Maria Univ Hosp, Lisbon, Portugal; 3Renal Div, Univ Hosp 
Freiburg, Germany; 4Ped Nephrol, Hosp Necker, Paris, France; 5BIOSS Albert-
Ludwigs Univ, Freiburg, Germany; 6ZBSA, Freiburg, Germany; 7Genetics, Hosp 
Necker, Paris, France.
Background: Steroid-resistant nephrotic syndrome (SRNS) is a genetically 
heterogeneous disease. Using exome sequencing we previously identified two homozygous, 
potentially damaging, missense variants in ADD3 and KAT2B in the affected members of 
a consanguineous family presenting syndromic SRNS. The first gene encodes adducin, an 
important regulator of the actin cytoskeleton, and the second the lysine acetyltransferase 
KAT2B responsible for histone acetylation.
Methods: To address the importance of ADD3 and KAT2B on podocyte function and 
the impact of the mutations we used the Drosophila model. KD and rescue experiments with 
the WT and mutated genes were performed using the GAL4:UAS system in Drosophila 
nephrocytes, the fly counterparts of podocytes. Defects at a molecular and ultrastructural 
level were assessed using immunostaining and electron microscopy and functional assays 
were used to assess the filtration/endocytic functions of nephrocytes.
Results: In 3rd instar nephrocytes, adducin KD, but not KAT2B KD, disrupted the 
actin cytoskeleton, delocalized the slit diaphragm protein Kirre and led to decreased 
filtration/endocytosis. At the ultrastructural level ADD3 KD led to decreased number of slit 
diaphragms and foot process effacement. At the adult stage, both adducin and KAT2B KD 
induced a reduction of nephrocytes. While KAT2B rescue experiments are still pending, 
the WT but not the mutated form of ADD3 rescued the ADD3 KD phenotypes, namely the 
actin cytoskeleton defects and Kirre mislocalization.
Conclusions: These findings suggest that ADD3 plays a major role on podocyte 
morphology and function and that ADD3 mutations maybe causative to some forms of 
SRNS. However the impact of the KAT2B mutation in the patient phenotype cannot be 
excluded.
Funding: Government Support - Non-U.S.
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A Novel Mutation in CLCN5 Gene Associated with Silent Clinical 
Manifestations of Dent Disease and the Histologic Picture of FSGS 
Milos N. Budisavljevic, Michael G. Janech, Peifeng Deng, Robert Wilson, 
Thomas Morinelli, John M. Arthur.  Nephrology, MUSC, Charleston, SC.
Background: It is increasingly recognized that focal segmental (FSGS) and focal 
global glomerulosclerosis (FGGS) may be seen as a dominant feature in some patients 
with Dent disease and lead to an erroneous diagnosis of primary FSGS.
Methods: We identified two brothers, 37 and 32 years old, who presented with 
low grade proteinuria and renal failure. Kidney biopsies of both revealed FSGS and no 
nephrocalcinosis. Four additional male family members had kidney disease without an 
established diagnosis.
Results: Pedigree analysis suggested an X-linked mode of inheritance. Extensive 
evaluation of the medical history from affected individuals revealed no rickets, 
nephrocalcinosis or nephrolithiasis. We performed whole exome DNA sequencing on 7 
family members and identified a variant of the intracellular chloride channel 5 (CLCN5) 
gene which had not previously been described. The mutation resulted in a substitution 
of leucine for phenylalanine at position 521 (L521F). We constructed expression vectors 
(pCMV6-AC-GFP) that encode for wild-type and mutant L521F CLC5, respectively, and 
transfected HK2 cells. Transfection of HK2 cells with wild-type CLC5 revealed protein 
localization to both on the cell surface and throughout the cytoplasm. Cells transfected 
with the mutant construct displayed only intracellular perinuclear localization. CLCN5 
encodes the chloride hydrogen exchanger and is important for endocytosis in the proximal 
tubule. Recent evidence suggested that CLC5 also resides in the podocytes and may play 
an important role in proper function of the slit diaphragm. Thus, CLCN5 mutations may 
affect podocyte integrity and lead to FSGS or FGGS. We have identified a novel variant 
of CLCN5 associated with histologic FSGS. Whether glomerular or tubular expression of 
the variant is responsible for the kidney disease is not yet clear.
Conclusions: We identified a new mutation in the CLCN5 gene in adult patients who 
presented with a histologic diagnosis of FSGS but without clinical manifestations of Dent 
disease. In cell culture, the mutation results in aberrant localization that may underlie 
pathogenic significance.
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Defects of the Nuclear Pore Proteins NUP93, NUP205, or Exportin-5 Link 
Nephrotic Syndrome to Disrupted SMAD Signaling  Daniela A. Braun,1 
Carolin Sadowski,1 Stefan Kohl,1 Svjetlana Lovric,1 Susanne Astrinidis,2 Shazia 
Ashraf,1 Werner Lukas Pabst,1 Weizhen Tan,1 Jennifer A. Lawson,1 Merlin 
Airik,1 Richard P. Lifton,3,4 Heon Yung Gee,1 Wolfram Antonin,2 Friedhelm 
Hildebrandt.1,4  1Nephrology, Boston Children’s Hospital, Boston, MA; 2Friedrich 
Miescher Laboratory, Max Planck Society, Tübingen, Germany; 3Dep. of 
Genetics, Yale Univ School of Medicine, New Haven, CT; 4Howard Hughes 
Medical Inst, Chevy Chase, MD.
Background: Steroid resistant nephrotic syndrome (SRNS) is a frequent cause of 
end-stage renal disease in the first decades of life. Identification of single-gene causes of 
SRNS has furthered the understanding of its pathogenesis. However, additional genes and 
disease mechanisms remain unknown.
Methods: We combined homozygosity mapping with whole exome sequencing 
(WES) in 100 individuals with SRNS. To identify additional mutations, we screened our 
cohort of ~800 individuals with SRNS by microfluidic multiplex PCR (Fluidigm Access 
Array™) and next generation sequencing. We examined nuclear translocation of SMAD4, 
utilized a luciferase reporter construct under the control of a SMAD responsive element, 
and performed co-immunoprecipitation to test the pathogenicity of the identified human 
disease alleles.
Results: By WES and multiplex PCR, we identified mutations in the genes NUP93, 
NUP205, and XPO5 (encoding for nucleoporin 93, 205 and exportin-5) in 8 unrelated 
families with SRNS. All individuals had early onset SRNS with rapid disease progression. 
We show that all three proteins localize to WT1 positive podocyte precursor cells in 
developing rat kidney. Human mutations in NUP93 disrupt the assembly and integrity of 
the nuclear pore complex (NPC). A human mutation in NUP205 abrogates the interaction 
with NUP93 within the NPC. We demonstrate that NUP93 and exportin-5 interact with the 
transcription factor SMAD4, and that human mutations of NUP93 abrogate this interaction. 
Furthermore, human mutations of NUP93 interfere with SMAD dependent transcription 
downstream of BMP7.
Conclusions: We identify mutations of NUP93, NUP205, or XPO5 as novel monogenic 
causes of steroid-resistant nephrotic syndrome in humans, and implicate disrupted SMAD 
signaling in its pathogenesis.
Funding: Other NIH Support - DK076683
FR-OR053
A Heterozygous Rare Variant in IL-XR Contributes to Autosomal 
Dominant FSGS in an African American Kindred  Gentzon Hall,1,3,4 Jose 
A. Gomez,1 Peter J. Lavin,5 Eugene C. Kovalik,1,3 Peter J. Conlon,6 Rasheed 
A. Gbadegesin.2,3,4  1Internal Medicine, Duke Univ; 2Pediatrics, Duke Univ; 
3Nephrology, Duke Univ; 4Duke Molecular Physiology Inst, Duke Univ; 5Trinity 
College, Ireland; 6Beaumont Hospital, Ireland.
Background: FSGS is a disorder characterized by podocyte injury, focal glomerular 
scarring, nephrotic syndrome and rapid progression to ESKD. Although FSGS 
disproportionately affects African Americans (AA), there is no report of a causal FSGS 
gene identified in an AA index kindred. Here we report the discovery of a rare heterozygous 
missense variant in the interleukin-X receptor (IL-XR) as contributory to autosomal dominant 
(AD) FSGS in a AA kindred from the US.
Methods: We identified an AA kindred with six affected individuals spread over 
three generations. We performed whole-exome sequencing on three affected members 
of the family. We confirmed all pathogenic variants by direct sequencing and performed 
segregation analysis on the family. Complementary molecular genetic analyses were 
performed in conditionally immortalized human podocytes to evaluate the effects of the 
segregating variant on JAK/STAT signaling and cell proliferation.
Results: We identified a segregating heterozygous rare variant (K47R) within the 
ligand binding domain of IL-XR in the kindred. The variant was absent from 8,600 
Caucasian chromosomes and has a minor allele frequency of 0.003 in the AA population 
in EVS. The change is conserved in evolution and is considered damaging by in silico 
prediction. We confirmed the expression of IL-XR in kidney and podocytes by RT-PCR, 
immunohistochemistry, and immunoblot analyses. Because IL-XR is known to signal 
through the JAK/STAT pathway, we examined the effect of IL-XRK47R expression on 
STAT3 activation and proliferation in podocytes. We determined that IL-XRK47R expression 
enhanced basal STAT3 activation and induced hyperproliferation.
Conclusions: We report the identification of a heterozygous rare variant in IL-XR 
as a contributor to AD FSGS in an AA kindred. IL-XR is expressed in the kidney and 
podocytes and overexpression of IL-XRK47R significantly enhanced basal STAT3 activation 
and podocyte proliferation in vitro.
Funding: NIDDK Support
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Genetic Investigation and Phenotypic Characterization of Uromodulin 
Associated Kidney Disease  Christine Gast,1,2 Monica Arenas Hernandez,3 
Anthony Marinaki,3 Gopalakrishnan Venkat-Raman.1,2  1Wessex Kidney Centre, 
Portsmouth Hospitals Trust, Portsmouth, United Kingdom; 2Genetic and 
Genomic Medicine, Univ of Southampton, Southampton, United Kingdom; 
3Purine Research Laboratory, St. Thomas’ Hospital, London, United Kingdom.
Background: Uromodulin associated kidney disease (UAKD) is a difficult to diagnose, 
rare autosomal dominant genetic disorder caused by mutations in the UMOD gene. We 
aimed to determine the frequency and distribution of pathogenic UMOD mutations in 
a familial kidney disease cohort and to investigate any distinguishing clinical features.
Methods: CKD patients with a family history (FHx) of renal disease were ascertained 
from a large tertiary renal center through a questionnaire study and database search. 
Patients with a FHx suggesting an unknown genetic diagnosis or UAKD were recruited. 
DNA was extracted from blood or saliva and sequenced for UMOD exons 3-5. Phenotypic 
characteristics were compared between patients with and without UMOD mutations, with 
significance testing in SPSS.
Results: Of 3,760 patients in CKD stages 3-5, 131 patients with a compatible FHx 
were identified and recruited. Of these, 30 patients (23%) from 17 families had 11 distinct 
pathogenic UMOD mutations. In 12 patients (9%) from 7 families this was previously 
unsuspected. UAKD patients had significantly lower protein creatinine ratios (median 
28, versus median 222, Mann-Whitney-U p=0.001), less hematuria (c2 p=0.0003), more 
electrolyte abnormalities (c2 p=0.02) and less severe anaemia (c2 p=0.049) pre renal 
replacement therapy (RRT). There were no statistically significant differences in uric acid, 
gout, allopurinol use, hypertension, renal cysts, renal size, and age at presentation or RRT.
Conclusions: UAKD is common amongst familial nephropathy patients, and is poorly 
predicted by clinical features. Hyperuricaemia or gout, both typical of early UAKD, did 
not distinguish from prevalent familial nephropathies, but less proteinuria and haematuria 
did. More electrolyte abnormalities in UAKD could be due to an alteration in tubular 
water permeability; the reason for less anaemia is unclear. Having demonstrated a high 
prevalence of UAKD, we advise UMOD testing guided by family history regardless of 
typical phenotype.
Funding: Private Foundation Support
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Chaperone Therapy in Stem Cells Derived from Fibroblasts with Missense 
Mutations in X-Linked Alport Syndrome  Dongmao Wang,1 Sharon D. 
Ricardo,2 Judith A. Savige.1  1Medicine, The Univ of Melbourne (Melbourne 
Health), Melbourne, VIC, Australia; 2Anatomy and Developmental Cell Biology, 
Monash Univ, Clayton, VIC, Australia.
Background: Forty % of mutations in X-linked Alport syndrome are caused by 
missense changes, often where Gly is substituted with another amino acid. Chaperone 
treatment has been useful in other diseases due to missense mutations. The aim of this 
study was to produce iPS from fibroblasts from a male with X-linked Alport syndrome and 
determine the effects of the chemical chaperone, 4 phenyl butyric acid.
Methods: Stem cells were made by the Ricardo laboratory from skin fibroblasts from 
a male with X-linked Alport syndrome due to p.G624D. He had developed renal failure 
at the age of 54, and had hearing loss, but no lenticonus or central retinopathy. Stem cells 
were induced to become podocytes, and examined for collagen IV a1 – a6 expression, and 
for markers of ER stress (ATF6, HSPA5, DDIT3), autophagy (ATG5, BECN1, ATG7) and 
apoptosis (CASP3, BAD, BCL2) using qRT-PCR (Applied Biosystems 7500). Levels of 
collagen IV a5 chain were quantitated in an in-house inhibition ELISA.  These measurements 
were repeated after incubation with the chemical chaperone, 10 mM 4-phenyl  butyric acid.
Results: The iPS expressed collagen IV a3 and a4 mRNA consistent with a podocyte 
phenotype. Levels of collagen IV a5 mRNA and protein were not different from those in 
normal male fibroblasts. However levels of both intra and extracellular collagen IV a5 were 
reduced suggesting degradation.  The Alport iPS had increased transcripts for HSPA5, and 
apoptosis (CASP3 and BCL2) compared with normal. Incubation with 4 phenyl butyric 
acid, resulted in a reduction in all markers of autophagy and of CASP3.
Conclusions: iPS derived from Alport fibroblasts represent a model system in which 
to examine novel treatments. Chemical chaperone therapy has beneficial effects on cells 
derived from individuals with Alport syndrome due to missense mutations.
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Massively Parallel Sequencing (MPS) in Diagnostically Refractory Genetic 
Renal Disease (GRD)  Andrew John Mallett,1,2,4 Chirag Patel,2,3,4 Joanna 
Crawford,4 Bruce Bennetts,5 Melissa H. Little,4,7,8 Helen G. Healy,1,2 Stephen 
I. Alexander,5 Valentine Hyland,6 Cas Simons.4  1Kidney Health Service & 
Conjoint Kidney Research Laboratory, Royal Brisbane and Women’s Hospital, 
Australia; 2School of Medicine, The Univ of Queensland, Australia; 3Genetic 
Health Queensland, RBWH, Australia; 4Inst for Molecular Bioscience, UQ, 
Australia; 5Depts of Molecular Genetics and Nephrology, Children’s Hospital 
at Westmead, NSW, Australia; 6Molecular Genetics Laboratory, Pathology 
Queensland, Australia; 7Murdoch Children’s Research Inst, Melbourne, VIC, 
Australia.
Background: GRD accounts for 10% of adults and 50% of children with end stage 
kidney disease. An unknown proportion of cases remain refractory to current clinical genetic 
tests. Advances in MPS enable attempts to address this in a research setting. We aimed to 
utilize MPS with pedigree analysis in unresolved cases of GRD.
Methods: Families with clinically diagnosed GRD were recruited in whom clinical 
genetic testing was either negative or not available. Whole exome sequencing was 
undertaken and analyzed with custom in house bioinformatics assessment tools accounting 
for all inheritance patterns. Identified variants of interest were confirmed using Sanger 
sequencing in clinical laboratories.
Results: 14 families (62 participants) were recruited with a variety of GRD diagnoses 
and modes of inheritance. A molecular genetic diagnosis has been resolved in 5 families. 
These include mutations in RMND1 (compound heterozygous), IFT140 (compound 
heterozygous), HNF4A (heterozygous), COL4A5 (hemizygous) and tRNA(Phe) (mtDNA) 
genes. All have been confirmed in a clinical diagnostic laboratory and reported back to 
the participants with further genetic counseling. Research continues in the remaining 9 
families, including application of whole genome sequencing. No reportable incidental 
genetic findings were identified.
Conclusions: MPS confirmed and clarified a clinical genetic diagnosis in 5/14 families 
with previously and diagnostically refractory GRD. These results were integrated into 
clinical practice and demonstrate an emerging role for MPS in the delivery of clinical care. 
Further studies are required to resolve the remaining families.
Funding: Private Foundation Support
FR-OR057
Development and Validation of Targeted Genomic Enrichment and 
Massively Parallel Sequencing as a Diagnostic Test for Genetic Renal 
Diseases  Christie P. Thomas,1,3 M. Adela Mansilla,2 Ramakrishna Sompallae,2 
Sara Mason,2 Anne E. Kwitek,2 Colleen Ann Campbell,2 Richard J. Smith.1,2 
1Internal Medicine, Univ of Iowa, Iowa City, IA; 2Inst of Human Genetics, 
Univ of Iowa, Iowa City, IA; 3Vetarans Affairs Medical Center, Iowa City, IA.
Background: Many renal diseases have a genetic basis, although definite genetic 
confirmation of precise etiology is rarely sought, in spite of the value of genetic screening 
in patients with ESRD both to confirm a diagnosis and to guide the evaluation of living 
related kidney donors, who may be at increased risk of ESRD.
Methods: To enable comprehensive screening for genetic diseases, we developed a 
panel that combines targeted genomic enrichment with massively parallel sequencing to 
simultaneously interrogate 120 genes implicated in 75 renal diseases. To validate this panel, 
we studied 20 controls and 20 patients with presumed genetic renal disease, four of whom 
were transplant candidates. We also evaluated six siblings or children who were considering 
living donation. Samples were sequenced on the Illumina MiSeq®.
Results: On average, we identified 500 variants per sample at a mean depth-of-coverage 
of 390x. After filtering to remove low quality/common variants, rare/novel variants were 
annotated using the Human Gene Mutation Database (HGMD®). Pathogenicity of novel 
variants was predicted in silico using algorithms to score variants based on conservation 
and function. As a measure of specificity and sensitivity, we Sanger validated 876 variants, 
confirming all. To optimize relevance of generated data, variants were discussed in the 
context of clinical data and observed genetic results. We identified causal variants in six 
of 20 patients (30%) with presumed genetic disease, thus enabling us to counsel these 
patients and alter their care. We were able to confirm a genetic renal diagnosis in 3 of 4 
transplant candidates and offer asymptomatic family members mutation-specific screening 
to determine if they carried the disease genotype.
Conclusions: This genetic renal disease panel provides a rapid, efficient, unbiased 
and cost-effective way to diagnose monogenic renal diseases and evaluate living donors 
at risk for genetic renal disease.
FR-OR058
The B Cell Survival Cytokine BAFF Promotes Murine Lupus Nephritis via 
Activation of TACI, Not BAFF Receptor  Shaun W. Jackson,1,2 Holly Jacobs,1 
Christopher Thouvenel,1 Tanvi Arkatkar,1 Genita Metzler,1 Nicole Scharping,1 
David Rawlings.1,2  1Seattle Children’s Research Inst, Seattle, WA; 2Dept of 
Pediatrics, Univ of Washington, Seattle, WA.
Background: Transgenic (Tg) over-expression of the B cell survival cytokine BAFF 
(also known as BLyS) promotes immune-complex glomerulonephritis in mice. Consistent 
with this, lupus nephritis patients have increased serum BAFF levels and the BAFF-targeted 
monoclonal Belimumab is an approved SLE therapy. BAFF binds two B cell receptors, 
BAFF-R and TACI. Since BAFF-R is required for mature B cell survival, this receptor 
is predicted to explain BAFF-Tg autoimmunity. However, potential important roles for 
TACI have not been addressed.
Methods: To test the impact of TACI on BAFF-driven autoimmunity, we crossed 
BAFF-Tg and Taci-/- mice. Autoantibodies and urine albumin were measured by ELISA, 
and B cell phenotyping was performed by FACS.
Results: Despite marked splenic B cell hyperplasia, deletion of TACI abrogated 
serum anti-nuclear autoantibodies (ANA) in BAFF-Tg mice. In addition, lack of TACI 
prevented autoantibodies targeting RNA- and DNA-associated self-antigens, including 
Sm/RNP and dsDNA, across all immunoglobulin isotypes and subtypes, including IgM, 
IgG, IgA, IgG2b, IgG2c, IgG3. Aged BAFF-Tg mice develop prominent immune-complex 
glomerulonephritis, characterized by mesangial expansion, glomerular basement membrane 
thickening and capillary occlusion. Consistent with the lack of serum autoantibodies, Taci-
/-.BAFF-Tg were completely protected from murine lupus nephritis, as evidenced by lack 
of albuminuria and restoration of renal histology.
Conclusions: We report the novel observation that TACI, not BAFF-R, is the 
predominant B cell receptor promoting BAFF-mediated murine lupus nephritis. These 
findings suggest that TACI may be an important therapeutic target in SLE, particularly in 
patients with high serum BAFF levels.
Funding: Other NIH Support - K08 Career Development Award (NIAID), Private 
Foundation Support
FR-OR059
B Cell-Intrinsic Interferon Gamma (IFNγ) Signals Promote B Cell 
Activation and the Development of Lupus Nephritis  Shaun W. Jackson,1,2 
Nicole Scharping,1 Holly Jacobs,1 Tanvi Arkatkar,1 David Rawlings.1,2  1Seattle 
Children’s Research Inst, Seattle, WA; 2Dept of Pediatrics, Univ of Washington, 
Seattle, WA.
Background: The TH1 cytokine interferon gamma (IFNγ) has been implicated in lupus 
pathogenesis via direct activation of autoreactive T cells. Whether IFN-γ also exerts cell-
intrinsic impacts on autoantibody-producing B cells has not been studied. We developed 
a chimeric lupus model in which Wiskott-Aldrich syndrome protein (WAS)-deficient B 
cells promote spontaneous humoral autoimmunity (Jackson, et al. J Immunol 2014). An 
important advantage of the WAS chimera model is that dysregulated immune responses 
are limited to the B cell compartment, allowing genetic manipulation in a B cell-intrinsic 
fashion. In the current study, we contrast the impact of global, T cell- and B cell-intrinsic 
deletion of the IFNγ receptor (IFNgR) on development of lupus nephritis.
Methods: We established lupus-prone WAS chimeras in which IFN-γR was deleted 
on all immune cells (global IFN-γR-null) or specifically on B or T cells. Chimeras were 
analyzed for autoantibodies, immune activation and immune-complex glomerulonephritis 
(IC GN) by ELISA, flow cytometry and immunohistochemistry.
Results: Global IFNgR deletion prevented autoantibody (Ab) production and systemic 
inflammation in WAS chimeras. Strikingly, cell-intrinsic deletion of IFN-γR on either T cells 
or B cells recapitulated the phenotype of global IFNgR deficiency. Mechanistically, deletion 
of IFNgR on B cells prevented the formation of spontaneous germinal centers (GCs), 
required for class-switched Ab formation. Consistent with lack of serum autoantibodies, 
IC GN was abrogated in B cell IFNgR-null chimeras. Interestingly, B cell-intrinsic deletion 
of the TH1 transcription factor T-bet prevented pathogenic IgG2c subclass Ab, but did not 
impact spontaneous GCs or systemic inflammation.
Conclusions: We report a novel T-bet-independent mechanism whereby IFNγ promotes 
lupus nephritis via direct actions on B cells. This study is the first to directly address the 
impact of B cell IFN-γ activation in murine lupus, of relevance to both the understanding 
of disease pathogenesis and to efforts to target IFNγ therapeutically in SLE.
Funding: Other NIH Support - K08 Career Development Award (NIAID), Private 
Foundation Support
FR-OR060
Mechanisms of Anti-CD20 B Cell Treatment of Experimental Autoimmune 
MPO-ANCA Glomerulonephritis  Poh-Yi Gan,1 Joshua D. Ooi,1 A. Richard 
Kitching,1,2 Stephen R. Holdsworth.1,2  1Dept of Medicine, Monash Univ, 
Clayton, Victoria, Australia; 2Dept of Nephrology, Monash Health, Clayton, 
Victoria, Australia.
Background: Depletion of B cells with anti-CD20 monoclonal antibody (mAb), 
rituximab, is an effective therapeutic for human MPO-ANCA GN. Its capacity to attenuate 
established disease suggests that CD20+ B cells are important in maintaining anti-MPO 
autoimmunity. Whilst B cells are clearly important in maintaining ANCA production, their 
role in maintaining established nephritogenic anti-MPO CD4 T cell driven autoimmunity is 
unknown. This study assesses this role and its importance in this disease model.
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Methods: Experimental anti-MPO autoimmunity was induced by immunizing C57BL/6 
(WT) mice with MPO in Freund’s adjuvant and GN triggered using a subnephritogenic 
dose of anti-GBM globulin. Mouse anti-CD20 mAb (or control mouse anti-IgG2a mAb) 
was administered to mice with established anti-MPO autoimmunity (day 14) and continued 
through the development of GN (terminated on day 32).
Results: Administration of anti-CD20 mAb induced profound and continued B 
cell depletion and protected mice from the development of renal injury, compared to 
controls (segmental glomerular necrosis: 16±4 vs 44±4%, albuminuria: 221.0±81.6 vs 
898.8±330.3mg/24hrs and glomerular CD4+ T cell influx: 0.4±0.07 vs 0.9±0.1, all P<0.05). 
Systemic anti-MPO autoimmunity was also reduced; serum anti-MPO IgG (ANCA) titres 
(0.21±0.02 vs 0.34±0.07 OD450nm, P<0.05) and dermal MPO induced DTH swelling 
(0.07±0.02 vs 0.2±0.03 Dmm, P<0.01). Anti-CD20 mAb treatment decreased MPO specific 
recall proliferation in draining lymph node cells (104.5±12.7 vs 217.7±55.3 counts per 
minute, P<0.05) with reduced frequency of IFN-γ and IL-17A producing cells (ELISPOT: 
22±6 vs 115±27 cells, P<0.01 and 6±3 vs 40±18 cells, P<0.05, respectively). Furthermore 
anti-CD20 treatment increased the proportion of proliferating Foxp3+ T regulatory cells 
(2.9±0.1 vs 1.7±0.1 %, P<0.001; 15% of proliferating Foxp3+ T cells in both groups 
produced IL-10).
Conclusions: In addition to its known capacity to reduce humoral autoimmunity, this 
study shows that anti-CD20 mAb induced B cell depletion significantly reduces anti-MPO 
CD4 T cell effectors and enhances T regulatory cells.
Funding: Government Support - Non-U.S.
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Novel Anti-Peroxidasin Antibodies Are Part of the Autoimmune Milieu 
in Preclinical and Clinical Goodpasture’s Disease  Abraham Scott Mccall,1 
Gautam B. Bhave,1 Vadim Pedchenko,1 Agnes B. Fogo,3 Dustin J. Little,2 
Thomas P. Baker,2 Stephen W. Olson,2 Billy G. Hudson.1  1Nephrology and 
Hypertension, Vanderbilt Univ Medical Center, Nashville, TN; 2Nephrology, 
Walter Reed Army Medical Center, Bethesda, MD; 3Pathology, Vanderbilt Univ 
Medical Center, Nashville, TN.
Background: Goodpasture’s disease (GP) is an autoimmune disorder characterized 
by autoantibodies directed against the NC1 domains of the a3/α5 chains of collagen IV in 
the glomerular and alveolar basement membranes. Epidemiologically, anti-MPO positivity 
often occurs with GP diagnosis. The normally cross-linked collagen IV scaffold forms 
through the action of the heme peroxidase, peroxidasin, via its HOBr production to from a 
sulfilimine (S=N) crosslink in the NC1 domain, however loss of the S=N crosslink changes 
recognition of the NC1 domain by GP antibodies.
Methods: A Vanderbilt GP patient cohort and a retrospective case-control Department 
of Defense Serum Repository (DoDSR) cohort were tested for recognition of peroxidasin, 
MPO, a3 and α5(IV) NC1 domains by ELISA with 3:1 age, sex, race, and age of serum 
matched controls from the DoDSR. Competition binding ELISA was performed to determine 
antigen specificity and immunofluorescence was performed on GP biopsies for peroxidasin 
levels. Peroxidasin HOBr production in vitro was fluorometrically tested in the presence 
of purified antibodies.
Results: Anti-peroxidasin autoantibodies are present in GP patient sera 33%(8/24) 
at diagnosis, and in 66%(4/6) of pre-diagnosis GP patients. Unexpectedly, the anti-
peroxidasin specific antibodies cross-react with coated, but not native MPO, accounting 
for a subset of the currently defined dual-positive patients. We also found significantly 
elevated focal peroxidasin staining in crescentic glomeruli of GP patients. Importantly, 
patient IgG containing anti-peroxidasin antibodies significantly inhibited of peroxidasin’s 
HOBr production rate.
Conclusions: Peroxidasin is a novel autoantigen in a subset of GP patients validated 
in two independent cohorts. Anti-peroxidasin antibodies potentially contribute to disease 
pathogenesis in GP with possible implications to be explored in other anti-MPO associated 
disease.
Funding: NIDDK Support, Other U.S. Government Support
FR-OR062
Autoantibodies against Thrombospondin Type-1 Domain-Containing 
7A Induce Membranous Nephropathy in Mice  Nicola M. Tomas,1 Elion 
Hoxha,1 Lars Fester,1 Udo Martin Helmchen,1 Gerth H. Jens,3 Friederike 
Bachmann,2 Klemens Budde,2 Friedrich Koch-nolte,1 Gunther Zahner,1 
Gabriele M. Rune,1 Gerard J. Lambeau,4 Catherine Meyer-Schwesinger,1 Rolf 
A. Stahl.1  1Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 
2Charité- Universitätsmedizin Berlin, Berlin, Germany; 3Heinrich Braun 
Klinikum, Zwickau, Germany; 4Inst de Pharmacologie Moléculaire et Cellulaire, 
Valbonne, France.
Background: Membranous nephropathy (MN) is an autoimmune disease and a 
frequent cause of nephrotic syndrome in adults. Autoantibodies against the podocyte 
proteins phospholipase A2 receptor 1 and thrombospondin type-1 domain-containing 7A 
(THSD7A) have been identified in about 75% of patients with MN. However, it is unclear 
whether these autoantibodies are causative for the development of MN.
Methods: Sera from two patients with anti-THSD7A autoantibody positive MN and 
control serum were injected into male BALB/c mice. We then analyzed the morphological 
and clinical development of MN in these mice.
Results: Mice that received anti-THSD7A positive serum developed subepithelial 
immune deposits containing human IgG (huIgG), which colocalized with THSD7A, 
suggesting antigen specificitiy of bound huIgG. Supporting, IgG eluted from frozen kidney 
sections of these mice was specific for THSD7A in Western blot analysis. All mice that 
were exposed to human serum were found to have circulating mouse anti-huIgG, but only 
mice that received anti-THSD7A positive serum had subepithelial deposits containing 
mouse IgG. Moreover, histological analyses revealed granular subepithelial staining 
for complement C3, suggesting local activation of the complement system. Electron 
microscopy demonstrated electron-dense deposits in a strictly subepithelial localization and 
focal podocyte foot process effacement. Mice injected with anti-THSD7A positive serum 
developed albuminuria starting day 3, while urinary albumin excretion of mice injected 
with control serum remained unchanged.
Conclusions: We conclude that anti-THSD7A autoantibodies are pathogenic and can 
induce MN in mice.
FR-OR063
Epitope Spreading in PLA2R1 Is Associated with Bad Prognosis in 
Membranous Nephropathy  Barbara Seitz-Polski,1,2,3 Guillaume Dolla,2 
Christine Payre,2 Sylvia Benzaken,1 Ghislaine Bernard,1 Vincent L.M. Esnault,3 
Gerard J. Lambeau.2  1Immunology, Nice Univ Hospital, Nice, France; 2Inst de 
Pharmacologie Moléculaire et Cellulaire, CNRS and Univ of Nice, Valbonne, 
France; 3Nephrology, Nice Univ Hospital, Nice, France.
Background: The phospholipase A2 receptor (PLA2R1) is the major autoantigen in 
idiopathic membranous nephropathy, with two recently identified epitopes of unknown 
clinical significance.
Methods: Fifty PLA2R1-positive patients’ sera were screened by western blot on a 
series of PLA2R1 deletion mutants covering the ten extracellular domains. We identified 
epitopes in the CysR, CTLD1 and CTLD7 domains and confirmed the reactivity against 
these three domains with soluble forms of each domain using a new ELISA in 69 PLA2R1-
positive patients.
Results: Domain-specific ELISAs allowed stratifying 69 PLA2R1-positive patients 
into three subgroups: 23 CysR, 14 CTLD1 + CysR and 32 CysR + CTLD1 + CTLD7. 
Median ELISA titers measured using the full-length PLA2R1 antigen were not statistically 
different between patients’ subgroups. The 23 patients with anti-CysR restricted activity 
were younger (p=0.008), had less nephrotic range proteinuria (p=0.018) and exhibited 
more spontaneous remission (p=0.03), lower rate of renal failure progression (p=0.0025) 
and less end-stage kidney disease (p=0.01) during follow-up. Indeed, 31/69 patients had 
poor renal prognosis according to KDIGO (urinary protein/creatinine ratio over 4 g/g or 
eGFR<45 ml/min/1.73m2 at end of follow-up). High anti-PLA2R1 activity and epitope 
spreading beyond CysR epitope were independent risk factors of poor renal prognosis in 
multivariable cox regression analysis. Epitope spreading during follow-up was associated 
with disease worsening (n=3), whereas reverse spreading from CTLD7 profile back to 
CysR was associated with favorable outcome (n=1).
Conclusions: We conclude that analysis of the PLA2R1 epitope profile and spreading 
during follow-up is a powerful tool to monitor disease severity and stratify patients into 
subgroups with different renal prognosis.
Funding: Government Support - Non-U.S.
FR-OR064
Intravascular Extensions Allow Renal DC to Capture Bloodborne Antigens 
and Mediate T Cell Migration into the Kidney  Karim Yatim, Martin H. 
Oberbarnscheidt.  Thomas E. Starzl Transplantation Inst, Univ of Pittsburgh, 
Pittsburgh, PA.
Background: We have previously shown that the kidney, a non-barrier, highly 
vascularized organ possesses an extensive monocyte-derived DC network with around 25% 
of DC sampling intravascular antigen (Ag) by extending projections into the lumina of 
cortical postcapillary venules. Here, we hypothesized that renal DC have an active role in 
immune surveillance via (1) capturing intravascular antigens such as bacteria and immune 
complexes (IC) and (2) mediate Ag-specific T cell migration into the kidney.
Methods: 2-Photon Intravital Microscopy (2PIM) and flow cytometry was performed 
on CX3CR1 GFP/+ (DC express GFP) mouse kidneys. Ovalbumin immune complexes 
(OVA-IC) conjugated to PE-TxRed or E.coli expressing Ovalbumin (OVA) and CFP were 
i.v. injected. For migration experiments, CD8+DsRed+ OT-I effector T cells were injected i.v.
Results: After systemic administration of fluorescent E. coli we observed (1) DC 
uptake of bacteria from the intravascular space immediately after injection (2PIM and 
flow cytometry) and (2) a 41% increase of DCs with intravascular processes after E.coli 
injection(2PIM). DC also took up i.v. OVA-IC, (2PIM). Furthermore, in the setting of a 
systemic CFP-OVA E.coli infection, OT-I T cells migrated into the kidney (2PIM and flow) 
with 2PIM showing stable DC-T cell interactions and DC (green)-mediated T cell (red) 
migration into the kidney (figure 1) (blood=cyan). 
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OT-I migration was significantly higher (2-fold) when CFP-OVA E.coli was used as 
opposed to non-OVA expressing WT E.coli.
Conclusions: We have shown in two different models that renal DC are actively 
surveilling the blood for Ag. In the case of infection, we demonstrated that DC mediate 
Ag-specific T cell migration into the kidney. These findings may shed light on the role 
of DC in infection and the pathogenesis of immune-complex mediated renal diseases.
Funding: Private Foundation Support
FR-OR065
The C5a Receptor Mediates Anti-Myeloperoxidase Auto-Immunity and 
Glomerulonephritis  Jonathan Dick, Poh-Yi Gan, Sharon Lee Ford, Maliha A. 
Alikhan, A. Richard Kitching, Stephen R. Holdsworth.  Centre For Inflammatory 
Diseases, Monash Univ, Melbourne, Australia.
Background: C5aR inhibition is currently the subject of a clinical trial for treatment of 
ANCA associated vasculitis. C5a is known to play an important role in neutrophil behaviour, 
however whether complement acting through the C5aR influences anti-myeloperoxidase 
(MPO) autoimmunity itself is unknown.
Methods: MPO autoimmunity was induced by injecting C57BL/6 (WT) or C5aR-/- 
mice with MPO in Freund’s adjuvant. In separate experiments WT mice were injected with 
1x106 WT or C5aR-/- MPO-pulsed bone marrow derived dendritic cells (DCs). Anti-MPO 
glomerulonephritis was triggered by a sub-nephritogenic dose of anti-GBM globulin.
Results: Autoimmunity at 10 days measured by anti-MPO IgG ELISA was significantly 
reduced in C5aR-/- mice (0.64±0.05 vs 0.20±.0.02)OD450nm p<0.001). This was associated 
with a lower proportion of splenocytes that were B220+ B cells (58±2 vs 32±2% p<0.001) 
and a higher serum BAFF(11.4±0.5 vs16.6±1.4 ng/ml p=0.01) compared to WT. T cell 
immunity to MPO was significantly attenuated in C5aR-/- mice measured by proliferation 
of recombinant MPO stimulated lymph node culture ([3H]-Thymidine 1302±253 vs 
574±123 counts per minute, p=0.01). Th1 response was reduced measured by IFN-γ 
ELISPOT (55±11 vs 26±6cells p=0.03) and footpad DTH (0.16±0.02 vs 0.04±0.01Dmm 
p=0.001). There was no difference in Th17 response:IL17A ELISPOT (32±7 vs 31±8 cells). 
The proportion of CD4+CD25+Foxp3+ T regulatory cells was significantly increased in 
C5aR-/- mice (11.8±0.2 vs 13.5±0.4% p<0.001). To determine whether C5aR expression 
on DCs promotes T cell mediated anti-MPO glomerulonephritis, autoimmunity was 
induced by injection of MPO-pulsed C5aR-/- or WT bone marrow derived DCs into WT 
mice. Anti-MPO glomerulonephritis was induced 10 days after DC transfer resulting in 
reduced renal injury (segmental glomerular necrosis 30.9±5% vs 9.9±2%p=0.005) in the 
group receiving C5aR-/-DCs.
Conclusions: Complement acting through the C5aR plays an important role in 
modulating both humoral and cellular anti-MPO autoimmunity in mice. This suggests an 
additional mechanism by which C5aR inhibition in ANCA associated vasculitis may be 
an effective treatment strategy.
Funding: Government Support - Non-U.S.
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Intestinal TH17 Cells Drive Renal Tissue Injury in Crescentic 
Glomerulonephritis  Christian F. Krebs,1 Jan-Eric Turner,1 Hans-Joachim 
Paust,1 Tobias Koyro,1 Jan-Hendrik Riedel,1 Sonja Krohn,1 Anna Kaffke,1 
Rolf A. Stahl,1 Samuel Huber,2 Ulf Panzer.1  1III. Medizinische Klinik, Univ 
Hospital Hamburg-Eppendorf, Hamburg, Germany; 2I. Medizinische Klinik, 
Univ Hospital Hamburg-Eppendorf, Hamburg, Germany.
Background: TH17 immune responses play a critical role in inflammatory disorders 
and autoimmune diseases. Recent studies indicate that development of TH17 cell depends 
on microbial colonization of the gut. However, the impact of gut microbiota induced 
TH17 cells for pathogenic TH17 response in autoimmune diseases, such as crescentic 
glomerulonephritis (GN), remains unclear.
Methods: To characterize the CD4+ T cell response in the kidney of patients with 
ANCA-associated GN we established flow cytometry of human renal biopsies. In 
addition we traced lymphocytes in mice expressing the photoconvertible Kaede protein 
after induction of experimental glomerulonephritis by using the model of nephrotoxic 
nephritis (NTN).
Results: Using flow cytometry of renal biopsies we were able to demonstrate the 
presence of CD4+Rorgt+ TH17 cells in the inflamed kidney of patients with ANCA-GN. 
Interestingly, TH17 cells in the kidney displayed a gut homing phenotype (CCR6+, CCR9+, 
ICOS+, IL-7Ralpha+, CD103+), indicating that renal TH17 cells have been primed in the 
intestine. Tracing intestinal cells by photoconversion in Kaede mice, we could demonstrate 
that a significant proportion of the TH17 cell in the nephritic kidney originated from the 
small intestine. In line, using germ free mice, we were able to show that renal TH17 response 
and consecutive tissue injury in crescentic GN depends on intestinal TH17 cells. Finally, 
we demonstrated that treatment of nephritic mice with intestinal microbiota depleting 
broad-spectrum antibiotics reduced renal TH17 response and attenuated kidney damage.
Conclusions: These data indicate that pathogenic TH17 cells in glomerulonephritis, 
originate from the intestine, migrate into the kidney and induce injury of the renal tissue. This 
finding might have significant implications for the treatment of renal autoimmune disorders.
Funding: Government Support - Non-U.S.
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T-Bet Activation in Regulatory T Cells Is Required for General Fitness, 
Antibody Production and Control of Th1 Responses in Crescentic 
Glomerulonephritis  Anna Nosko,1 Malte A. Kluger,1 Paul Diefenhardt,1 Simon 
Melderis,1 Claudia Wegscheid,2 Gisa Tiegs,2 Rolf A. Stahl,1 Ulf Panzer,1 Oliver 
M. Steinmetz.1  1Nephrology, Hamburg Univ Medical Center; 2Experimental 
Immunology, Hamburg Univ Medical Center.
Background: Mechanisms responsible for down regulation of pathogenic Th1 
immunity remain widely unknown. Recently, it was proposed that activation of the Th1 
characteristic transcription factor T-bet optimizes Foxp3+ regulatory T cell (Treg) function 
to counteract Th1 responses.
Methods: Nothing is known about the role of T-bet+ Treg1 cells in inflammatory disease. 
We studied their function in the NTN model of acute crescentic glomerulonephritis (GN).
Results: Kidneys of nephritic wild type mice showed increasing percentages of Treg1 
cells during the course of NTN, indicating their functional importance. Naïve Foxp3CrexT-
betfl/fl mice (Treg1-/-), lacking Treg1 cells, showed spontaneous skewing towards Th1 
immunity. In the absence of Treg1 cells, NTN was aggravated in terms of renal function, 
histology and inflammatory cell infiltration with selectively elevated renal and systemic 
Th1 responses. Analyses of Tregs from Treg1-/- mice revealed unaltered systemic numbers, 
activation, cytokine production and in vitro suppressive function. However, expression of 
the Th1 characteristic trafficking receptor CXCR3 was absent on T-bet deficient Tregs, 
resulting in significantly reduced renal Treg infiltration. In addition to diminished renal 
trafficking, overall fitness of Tregs from Treg1-/- mice was greatly impaired. In competitive 
co-transfer experiments into lymphopenic hosts, T-bet deficient Tregs were outcompeted 
by wildtype Tregs in terms of proliferation and expression levels of Foxp3. Furthermore, 
T cell dependent humoral immunity was impaired in Treg1-/- mice, indicating that T-bet 
activation in Tregs plays a hitherto unrecognized role for antibody production.
Conclusions: Our data indicate the presence of a new subtype of regulatory T cells in 
crescentic GN. These Treg1 cells are characterized by activation of the transcription factor 
T-bet, which enhances their overall fitness, directs antibody responses and optimizes their 
capacity to down-regulate Th1 responses by inducing CXCR3 expression.
FR-OR068
Predicting the Lifetime Risk of End-Stage Renal Disease in Kidney Donor 
Candidates  Morgan Grams, Yingying Sang, Andrew S. Levey, Kunihiro 
Matsushita, Shoshana Ballew, Alex R. Chang, Bertram L. Kasiske, Csaba P. 
Kovesdy, Girish N. Nadkarni, Varda Shalev, Dorry L. Segev, Josef Coresh, 
Krista L. Lentine, Amit X. Garg.  CKD Prognosis Consortium.
Background: A tool to comprehensively evaluate the lifetime risk of ESRD in potential 
living kidney donors could help standardize transplant center acceptance criteria.
Methods: We developed statistical equations to predict the lifetime incidence of ESRD 
according to a person’s baseline demographic and health characteristics before kidney 
donation. Data sources included prevalence estimates from NHANES, ESRD incidence 
from USRDS, and ESRD risk associations in low-risk subgroups of 7 general population 
cohorts (N=4,580,454). Developed equations were applied to the general population (using 
NHANES) and the recent US donor population (using the OPTN registry) and made 
available in an online risk calculator (www.transplantmodels.com/lifetime).
Results: For the “base-case” potential donor (eGFR 90 ml/min/1.73 m2, urine ACR 
10 mg/g, systolic blood pressure 120 mmHg, and no adverse health characteristics), the 
predicted pre-donation lifetime incidence of ESRD varied by age, race, and sex: 2.7%, 1.1%, 
0.9%, and 0.6% in 20-year-old black men, black women, white men, and white women, 
respectively, and 0.6%, 0.3%, 0.3%, and 0.2% in the corresponding 60-year-old candidates. 
The lifetime incidence of ESRD was higher with additional risk factors, particularly low 
eGFR or high ACR in young persons (Figure). The predicted lifetime incidence of ESRD 
before donation was <1% in 88% of recent US donors.
Conclusions: We suggest consideration of pre-donation lifetime ESRD risk in the 
evaluation and counseling of potential living kidney donors. Our equations estimate a 
person’s lifetime incidence of ESRD in the absence of donation according to multiple 
demographic and clinical characteristics. 
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Post Donation Hypertension and Risk of Death and ESRD  Hassan N. Ibrahim, 
Robert N. Foley, Scott Reule, Danielle M. Berglund, Arthur J. Matas, Aleksandra 
Kukla, Naim S. Issa, Richard S. Spong.  Univ of Minnesota, Mpls, MN.
Background: Prevalence of de novo hypertension after kidney donation appears to be 
similar to that in the general population. Factors associated with it development, however, 
have not been studied. Goals: 1) ascertain donors’ risk of developing HTN, 2) describe the 
impact of its development on death and renal function and 3) develop a HTN risk prediction 
model using pre-donation parameters.
Methods: Our donors are followed indefinitely through surveys inquiring about HTN, 
renal disease and also serial laboratory testing. Risk factors for post donation new onset 
hypertension were determined using stepwise proportional hazards regression.
Results: HTN status was ascertained in 3638 donors with a mean follow-up of 13±11 
years. In total, 972 (27%) developed new onset hypertension. Pre-donation risk factors for 
development included older age, higher BMI, SBP, and serum glucose at donation (Table 
1a). White donors were 40% less likely to develop hypertension, p<0.001 for all. HTN 
following donation was associated with a nearly 4 fold increased risk of death, proteinuria, 
and eGFR < 30 ml/min or ESRD (Table 1b). Coefficients from the regression model were 
then used to create a HTN risk calculator (C-statistic 0.65). A sample output for a 40 year 
old donor is shown in figure 1. 
Variable Hazard Ratio p-value
1a) Pre-donation risk factors for HTN
Age 1.03 (1.03-1.04) < 0.001
BMI 1.06 (1.04-1.07) < 0.001
SBP 1.03 (1.02-1.04) < 0.001
Serum glucose 1.01 (1-1.01) < 0.001
White race 0.6 (0.45-0.79) < 0.001
1b) Post donation HTN and hard outcomes
Death 3.69 (2.88-4.73) <0.0001
Proteinuria 3.99 (2.62-6.07) <0.0001
eGFR <30 or RRT 2.48 (1.38-4.46) 0.002
Figure 1. Cumulative risk of HTN for a typical White donor
Conclusions: Hypertension can be reasonably predicted in kidney donors using baseline 
data. Hypertension is a significant contributor to reduced GFR, ESRD and also death.
Funding: Other NIH Support - NIH(5P01 DK013083)
FR-OR070
Effect of Changing African American Race to Apolipoprotein L1 Genotype 
on Kidney Donor Risk Index  Bruce A. Julian,1 Robert S. Gaston,1 Barry I. 
Freedman,2 William Mark Brown,2 Amber M. Reeves-Daniel,2 Ajay K. Israni,3,4 
David P. Schladt,3 Stephen O. Pastan,5 Sumit Mohan,6 Jasmin Divers.2  1Univ of 
Alabama at Birmingham; 2Wake Forest Univ School of Medicine; 3Minneapolis 
Medical Research Foundation; 4Hennepin County Medical Center, Univ of 
Minnesota; 5Emory Univ School of Medicine; 6Columbia Univ.
Background: Renal allografts from deceased African Americans (AAs) with 2 renal-
risk variants in apolipoprotein L1 gene (APOL1) are lost sooner than kidneys from AAs 
with 0 or 1 variant. For the latter, allograft survival is similar to that for kidneys from 
European Americans. Kidney Donor Risk Index (KDRI) was developed recently, before 
APOL1 effect was described, to quantitatively estimate quality of deceased-donor kidneys; 
it assigns higher risk for all AA donors. We postulated that replacing AA race with APOL1 
genotype in KDRI improves risk prediction for kidneys from deceased AA donors.
Methods: Using the effect size in retrospective studies, we calculated KDRI wherein 
only AAs with 2 APOL1 renal-risk variants received higher KDRI scoring. Weight of 
APOL1 risk variants was defined by 10-fold cross validation: 9/10 of available data was 
used to estimate parameter associated with APOL1 in Cox proportional hazard regression 
with other 9 KDRI variables as covariates. Revised KDRI scores were computed and tested 
on the last subset; predictive ability was measured by c-index. Cross-validation was done 
100x for comparison with original KDRI.
Results: Retrospective analyses of 1,149 kidney transplantations from deceased AA 
donors (979 APOL1=0/1; 170 APOL1=2 renal-risk variants) showed mean donor age, serum 
creatinine, and KDRI of 35.4 yr, 1.25 mg/dL, and 1.45. Observed c-index with original KDRI 
tested with full data was 0.89; distribution of observed APOL1-revised KDRI c-indices 
had minimum 0.55 and maximum 0.98, median 0.87. APOL1-revised KDRI c-index was 
higher than observed KDRI c-index in 44% of cases.
Conclusions: For the 13% of general AA population with 2 APOL1 risk variants, 
KDRI did not change. However, for the other 87% of AAs, the revised KDRI improved 
by deleting AA race as a risk factor and better reflects the quality of these kidneys relative 
to current system.
Funding: NIDDK Support
FR-OR071
Racial Disparities in Perioperative Complications After Live Kidney 
Donation  Krista L. Lentine,1 Ngan Lam,2 David A. Axelrod,3 Mark Schnitzler,1 
Amit X. Garg,3 Jesse D. Schold,4 Daniel C. Brennan,5 Dorry L. Segev.6  1Saint 
Louis Univ; 2Western Univ; 3Dartmouth; 4Cleveland Clinic; 5Washington Univ; 
6Johns Hopkins.
Background: The frequency and severity of perioperative complications after 
contemporary live kidney donation are not well-described.
Methods: We integrated national U.S. donor registry data with administrative records 
from an academic hospital consortium (98 centers, 2008-2012) to identify predonation 
comorbidity and perioperative complications captured in diagnostic, procedure and registry 
sources. Complication severity was graded by Clavien scoring. Correlates (adjusted odds 
ratio, aOR) of complications were examined with multivariate logistic regression.
Results: Among 14,964 donors, 11.6% were African American (AA) and 72.6% 
Caucasian; 93.8% of nephrectomies began as laparoscopic, 2.4% as robotic, and 3.7% 
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as open procedures. Compared with Caucasians, AA donors experienced higher rates of 
any complication (18.2% vs 15.5%, P=0.005), and those exceeding progressive severity 
thresholds including Clavien >=4 (3.7% vs 2.2%, P=0.0002) (Figure). 
After adjustment for demographic, clinical (including comorbidity diagnoses), 
procedure and center factors, AA race was associated with increased risk of any complication 
(aOR 1.26, P=0.001), and Clavien >=2 (aOR 1.39, P=0.0002), Clavien >=3 (aOR 1.56, 
P<0.0001), and Clavien >=4 (aOR 1.56, P=0.004) events. Other significant correlates of 
Clavien >=4 events included obesity (aOR 1.55), predonation hematologic (aOR 2.78) 
and psychiatric (aOR 1.45) conditions, and robotic nephrectomy (aOR 2.07), while annual 
center volume >50 (aOR 0.45) predicted lower risk.
Conclusions: AA race is independently associated with increased frequency and 
severity of perioperative complications after live donor nephrectomy. Future work should 
seek to identify underlying mechanisms and approaches to reducing outcome disparities.
Funding: NIDDK Support
FR-OR072
Risk Prediction of End-Stage Renal Disease in Living Kidney Donors 
Allan Massie, Dorry L. Segev, Eric Chow.  Johns Hopkins.
Background: Recent studies have shown increased risk of end-stage renal disease 
(ESRD) in living kidney donors compared with healthy nondonors. Accurate risk prediction 
is paramount for informed consent for donation, but individual ESRD risk is unknown.
Methods: Using national donor registry data, we modeled ESRD in 122,773 donors 
via Cox regression, censoring for mortality. We performed multiple imputation with 50 
repetitions to impute body mass index (BMI), unavailable prior to 1999. We used baseline 
hazard and hazard ratios to calculate individual risk of ESRD at 5, 10, 15, and 20 years 
post-donation.
Results: Male sex, African-American (AA) race, and higher BMI were associated 
with greater ESRD risk (all p<0.01, Table 1). Older age was associated with increased risk 
in non-AA donors (HR per 10y = 1.22 1.40 1.60, p<0.001), but decreased risk in AA donors 
(HR = 0.60 0.76 0.95, p=0.02).
Risk factor HR (*p<0.05; **p<0.01; ***p<0.001)
Male gender 1.51 1.95 2.51***
AA race (at age 40) 2.23 3.06 4.21***
Age per 10y (non-AA donors) 1.22 1.40 1.60***
Age per 10y (AA donors) 0.60 0.76 0.95*
BMI per 5 units 1.16 1.48 1.89**
Overall cumulative incidence of ESRD at 5, 10, 15, and 20 years was 3.0, 11.6, 27,7, 
and 56.9 events per 10,000 donors, respectively (Figure 1). Predicted individual 20-year risk 
ranged from 6.9 per 10,000 (0.07% chance) to 1240.4 per 10,000 (12.4% chance) of ESRD. 
Median (IQR) individual 20-year risk of ESRD was 49.8 (31.2-83.8) per 10,000 (Figure 1).
A web calculator of individual risk can be found at transplantmodels.com/donesrd
Conclusions: Male gender and higher BMI are associated with greater ESRD risk 
in kidney donors. Old age is associated with greater ESRD risk among non-AA donors, 
but younger age is associated with greater risk among AA donors, likely due to donor 
selection. Greater permissiveness may be warranted for older AA donor candidates; younger 
AA candidates should be evaluated carefully and counseled about long-term ESRD risk.
Funding: NIDDK Support
FR-OR073
Factors Influencing Decision About Kidney Transplant: A Survey of Dialysis 
Patients  Fareeha Khalil, Ming Wang, Naman Trivedi, Eric Chang, Nasrollah 
Ghahramani.  Pennsylvania State Univ College of Medicine, Hershey, PA.
Background: Kidney transplant (KT) is the treatment of choice for end stage renal 
disease (ESRD). The decision to pursue KT involves a complex interplay of disease-
related, socioeconomic and ethnic factors. We explored factors influencing patients’ 
decision about KT.
Methods: We sent flyers to 1,283 dialysis units. Of 2536 interested participants 
who fulfilled inclusion criteria, we randomly selected and invited 1400 to complete the 
questionnaire. Independent variables were demographic factors, distance to dialysis unit, 
and modes of education about options. In multivariate analysis, we calculated odds ratios 
(OR) and 95% confidence intervals (CI) for the probability of pursuing KT.
Results: Of 673 participants, 401 had been referred and 201 were listed for KT. Positive 
predictors of pursuing KT (n=268) included: ‘received 3 or more modes of education about 
KT (OR:3.08;CI:1.62 to 5.87); ‘nephrologist discussed the option of KT at least twice in 
previous year’ (OR:2.49;CI:1.43 to 4.32). The 2 most common reasons for not pursuing KT 
included satisfaction with current treatment (18%) and inadequate finances (14%). Urban 
residence (OR: 2.64;CI: 1.33 to 5.23) and > 5 years on dialysis (OR: 1.75;CI: 1.09 to 2.81) 
were associated with likelihood of indicating satisfaction with current treatment as a reason 
not to pursue KT. Age >60 (OR: 2.18;CI: 1.21 to 3.94) and proximity to dialysis unit (OR: 
2.30;CI: 1.27 to 4.17) were associated with higher likelihood of indicating inadequate 
finances as reason not to pursue KT. Of those pursuing KT, 36% would not consider 
LDKT, most commonly citing unavailability of potential donor (28%). Positive predictors 
of pursuing LDKT were: ‘nephrologist discussed the option of transplant at least twice 
in last year’; and married status. Negative predictors of considering LDKT were regular 
attendance at religious service, age >60, being on dialysis >5 years.
Conclusions: Nephrologist-related factors (delivering diverse education) and patient 
characterisitcs (age, gender, race, health status perception, marital/socioeconomic status, 
duration/comfort with dialysis) are important drivers of the decision making process for 
choice of KT.
Funding: NIDDK Support
FR-OR074
A Propensity-Matched Analysis Comparing Rates of Post-Transplant 
Diabetes Mellitus (PTDM) in South Asian and Caucasian Renal Transplant 
Recipients  Javeria Peracha, Krishan Parekh, Charles Ferro, Richard Borrows, 
Adnan Sharif.  Queen Elizabeth Hospital, Birmingham, United Kingdom.
Background: South Asians have increased risk for type 2 diabetes but the risk of 
post-transplantation diabetes mellitus (PTDM) is unknown. The aim of this study was 
to compare PTDM risk in South Asian versus Caucasian kidney allograft recipients in a 
propensity matched analysis.
Methods: In this retrospective analysis, data was extracted from electronic patient 
records at a single-centre (2004-2014). 354 Caucasian and 121 South Asians met the 
inclusion/exclusion criteria for this study. Caucasians were more likely to be older, male 
and have higher BMI compared to South Asians. Propensity score matching was therefore 
undertaken to remove their bias effect.
Results: Propensity matching resulted in 102 pairs of kidney allograft recipients. 
Median follow up was 51 months (range 3-130 months). Both groups had similar baseline 
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characteristics, although South Asians compared to Caucasians received more deceased-
donor kidneys (74% vs. 43% respectively, p<0.001) and were more likely to be CMV 
positive (77% vs. 43% respectively, p<0.001). Five-year PTDM was higher in South Asians 
versus Caucasians (34% vs. 11% respectively, hazard ratio 4.3 [95% CI: 2.0–9.4, p<0.001]). 
Donor type had significant interaction with ethnicity. While no difference in PTDM 
was observed in recipients of live kidneys, 5-year PTDM risk was 42% versus 5% for 
South Asian versus Caucasian deceased kidney recipients respectively (p<0.001). No 
difference was observed in allograft function, rejection episodes, adverse cardiovascular 
events or patient/graft survival.
Conclusions: South Asian kidney allograft recipients have increased risk of PTDM, 
especially in the context of deceased kidney donation. It is important to recognize South 
Asians as high risk for PTDM to allow targeted screening and management strategies.
FR-OR075
Increased Circulating T-Lymphocytes Expressing HLA-DR in Kidney 
Transplant Recipients with Microcirculation Inflammation  Hee-Yeon Jung,1 
Chan-Duck Kim,1 Sukyung Lee,1 Ji-Young Choi,1 Se-Hee Yoon,2 Jang-Hee Cho,1 
Sun-Hee Park,1 Yong-Lim Kim.1  1Internal Medicine, Kyungpook National Univ 
School of Medicine, Daegu, Republic of Korea; 2Internal Medicine, Konyang 
Univ, Republic of Korea.
Background: Despite the clinical impact of microcirculation inflammation (MI) and 
T-lymphocyte on antibody-mediated rejection in kidney transplant recipients (KTRs), the 
association between MI in allograft biopsy and activity of T-lymphocyte in the peripheral 
blood is not known. This study aimed to compare the histologic grading of renal allograft 
according to the Banff score with activity of serum T-lymphocyte subsets and HLA-DR 
positive monocytes in KTRs.
Methods: A total of 137 indication biopsies from renal allografts were performed 
from 117 KTRs. Among them, 24 biopsy specimens from KTRs who have data of serum 
T-lymphocyte subsets and HLA-DR positive monocytes at the time of biopsy were included 
in this study. The frequencies of serum HLA-DR+, CD4+, CD8+, and CD25+ T cells, and 
HLA-DR positive monocytes were determined by flow cytometry. The histologic grading 
of renal allograft was classified according to the sum score of g+ptc (MI), i+t, ci+ct, and 
cv+ah based on Banff 2013 classification.
Results: The frequencies of CD4+HLA-DR+/T cells, CD8+HLA-DR+/T cells, 
CD4+HLA-DR+/CD4+ T cells, and CD8+HLA-DR+/CD8+ T cells were significantly increased 
in KTRs with MI sum score ³1 (n=13) compared to KTRs with MI sum score=0 (n=11) 
(all P <0.05). Among four subsets, CD4+HLA-DR+/CD4+ T cells were positively correlated 
with MI sum score (P=0.013). However, no significant differences were observed between 
two groups categorized based on the sum score of i+t, ci+ct, and cv+ah. Analysis using 
the receiver-operating-characteristic curve showed that antibody-mediated rejection could 
be predicted with a sensitivity of 83.3% and a specificity of 58.3% using a cutoff value of 
12.25% frequency of CD4+HLA-DR+/CD4+ T cells.
Conclusions: MI was significantly associated with increased frequency of activated 
T-lymphocyte expressing HLA-DR in KTRs. Further large-scale studies are needed to 
confirm circulating CD4+HLA-DR+/CD4+ T cells as a useful noninvasive immunologic 
monitoring tool for prediction of antibody-mediated rejection.
FR-OR076
Monitoring of Calcineurin Inhibitors by NFAT-Regulated Gene Expression 
in De Novo Renal Allograft Recipients  Claudia Sommerer,1 Martin G. Zeier,1 
Stefan Meuer,2 Thomas Giese.2  1Nephrology, Univ Hospital, Heidelberg, 
Germany; 2Immunology, Univ Hospital, Heidelberg, Germany.
Background: Calcineurin inhibitors are critical-dose drugs with a narrow therapeutic 
range and the optimal monitoring strategies are discussed in terms of safety and efficacy. 
A new pharmacodynamic monitoring tool – assessing the expression of nuclear factor of 
activated T cells (NFAT)-regulated genes – has been established to measure directly the 
functional effect of ciclosporin A (CsA) in an individual patient. Until now, only sparse data 
on NFAT-regulated gene expression within the early post-transplant period are available.
Methods: Altogether 80 de novo renal transplant patients were enrolled in this 
prospective observational trial. The immunosuppression consisted of IL-2 receptor 
antagonist induction, CsA, mycophenolic acid and steroids. The expression of the 
NFAT-regulated genes (interleukin 2, granulocyte-macrophage colony stimulating-factor, 
Interferon γ) was determined by qRT-PCR at CsA C0 and C2 at regular follow-up visits 
within 6 months after transplantation.
Results: The median age of all patients was 47.9±13.7 years (54 male). Residual 
NFAT-regulated gene expression showed a high interindividual variability. Inversely to 
reduction of CsA doses expression of NFAT-regulated genes increased from 1.78±1.33% to 
8.04±7.36% in month 1 to month 6. Despite of comparable CsA C0 levels NFAT-regulated 
gene expression was significantly less inhibited in patients with treated biopsy-proven acute 
rejections(2.9±2.2% vs. 2.0±1.7%, p=0.047). Patients with very low residual expression 
on NFAT-regulated genes were on increased risk of early infectious episodes. Residual 
expression of IFNγ and GM-CSF genes correlated most significantly with clinical outcome.
Conclusions: NFAT-regulated gene expression is highly inhibited in the early 
post-transplant period in renal allograft recipients on CsA treatment. High residual 
NFAT-regulated gene expression was related to acute rejection episodes but low residual 
expression with infectious complications. Thus, NFAT monitoring has the potential to 
support pharmacokinetic monitoring in the early post-transplant period.
Funding: Pharmaceutical Company Support - Novartis Germany
FR-OR077
Proteomics of Urinary Exosomes to Identify Biomarkers of BK Virus 
Infection and Acute Rejection  Luuk Hilbrands, Mathijs van de Vrie, Jeroen 
Deegens, Johan Van der vlag.  Nephrology, Radboud Univ Medical Center, 
Nijmegen, Netherlands.
Background: Acute cellular rejection (ACR) and BK virus associated nephropathy 
(BKVAN) are frequent causes of graft dysfunction after renal transplantation with similar 
symptoms but requiring different treatments. We investigated whether patients with an ACR 
episode or BKVAN could be distinguished based on proteins present in urinary exosomes.
Methods: Urine samples (50 mL) were collected from renal transplant patients 
with ACR, BKVAN or stable graft function. Urinary exosomes were isolated by 
ultracentrifugation (110’ at 200.000×g). For each group (ACR, BKVAN, controls) we 
pooled equivalent amounts of exosome proteins of 4 patients (first set) and repeated this 
with 4 different patients in each group (second set). Subsequently, exosomes were lysed 
and 40 microgram of protein was resolved by a 4-12% SDS-PAGE. After electrophoresis, 
gel lanes were cut into 5 pieces according to molecular mass. Proteins were in-gel digested 
with trypsin, and peptide mixtures were analysed using LC-MS/MS. Proteins were identified 
using the NCBI database. Partial least squares enhanced discriminant analysis was used to 
classify the patient groups based on exosomal protein content.
Results: A total of 340 individual proteins was detected in the first set of samples 
and 385 proteins in the second set, with 204 proteins overlapping between both sets. Our 
preliminary findings show a number of proteins for which the exosome content differed 
between ACR and BKVAN. Specific candidate proteins that can serve as urinary biomarkers 
include acid ceramidase, low density lipoprotein-related protein 2, copine VIII, alpha-1-acid 
glycoprotein 1 syndecan 4, and lactate dehydrogenase.
Conclusions: In this study we show that profiling of urinary exosomes is a promising 
tool to identify urinary proteins which allow differentiation between ACR and BKVAN 
in renal transplant patients.
FR-OR078
Identification of Signature Long Non-Coding RNAs in the Development of 
Diabetic Nephropathy  Jianyin Long, Shawn S. Badal, Zengchun Ye, Bernard 
A. Ayanga, Farhad R. Danesh.  Dept of Emergency Medicine, The  Univ of Texas 
MD Anderson Cancer Center, Houston, TX.
Background: Long noncoding RNA (lncRNAs) have emerged as potent regulators 
of multiple cellular processes relevant to cellular homeostasis and differentiation. More 
recently, lncRNAs have also been implicated in the pathogenesis of a myriad of diseases, 
including cancer and heart diseases. However, the role of lncRNAs in diabetic nephropathy 
(DN) is unknown.
Methods: Total RNA-Seq analysis was performed on glomeruli from Type 2 diabetic, 
db/db mice to explore differentially expressed lncRNAs. Following identification of 
a candidate lncRNA, Tug1 (Taurine-upregulated gene-1) we employed CRISPR/Cas9 
genome editing to deplete Tug1 in cultured podocytes. Tug1 overexpression in podocytes 
was used for gain of function analysis. To understand the functional role of Tug1 in vivo 
and because Tug1 is reduced in diabetic podocytes, we generated podocyte-specific, Tug1 
transgenic, db/db mice.
Results: RNA-Seq analysis revealed that expression of Tug1, a predicted antioxidant-
responsive gene, is significantly reduced in the podocytes of db/db mice. Analysis of in vivo 
isolated podocytes from db/db mice demonstrated that downregulation of Tug1 over time is 
correlated with the progression of DN. To interrogate the functional relevance of Tug1, we 
performed transcriptome analysis on RNA from CRISPR/Cas9 Tug1 depleted podocytes, 
and found expression of a number of nuclear encoded, mitochondrial genes, including 
the master mitochondrial regulator, Pgc1α to be significantly decreased. Gain of function 
experiments revealed Tug1 mediated activation of Pgc1α and associated mitochondrial 
phenotypes. To assess the therapeutic potential of Tug1 overexpression in vivo, we generated 
podocyte-specific, Tug1 transgenic mice on the db/db background. Importantly, we observed 
significant and sustained improvement in ACR and histology up to 24 weeks.
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Conclusions: We have found a number of differentially regulated lncRNAs within DN 
and demonstrated that Tug1 is a mediator of the transcriptional response to high glucose. 
We demonstrate that Tug1 overexpression in a mouse model of DN exerts a renoprotective 
phenotype, in part, by rescuing expression of Pgc1α.
Funding: NIDDK Support
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Epigenetic Abnormalities Underlie Increased Expression of Nuclear 
Receptor PXR in Diabetic Kidney Disease  Atsushi Watanabe,1 Takeshi 
Marumo,2 Wakako Kawarazaki,2 Mitsuhiro Nishimoto,2 Nobuhiro Ayuzawa,2 
Daigoro Hirohama,2 Kohei Ueda,2 Hiroo Kumagai,1 Toshiro Fujita.2  1Dept of 
Nephrology and Endocrinology, National Defense Medical College, Tokorozawa, 
Japan; 2Div of Clinical Epigenetics, RCAST, Univ of Tokyo, Tokyo, Japan.
Background: Epigenetic abnormalities have been suggested to mediate the 
phenomenon of metabolic memory observed in diabetic complications. Because kidney 
is composed with various cell types, we investigated the epigenetic alterations in a cell 
type-specific manner and showed that epigenetic changes may induce persistent phenotypic 
changes of the proximal tubules in the diabetic kidney (JASN 2015 in press). PXR, a 
xenobiotic nuclear receptor, has recently been shown to play a critical role in metabolic 
changes in obesity and diabetes. In this study, we investigated the expression of PXR in 
normal and diabetic kidneys and explored the underlying epigenetic mechanisms and 
possible function.
Results: Immunohistochemistry and quantitative RT-PCR analysis demonstrated that 
PXR is selectively expressed in the proximal tubules. Combined bisulfite restriction analysis 
and bisulfite sequencing revealed that the promoter region of Pxr of normal proximal 
tubules is significantly demethylated as compared to that of non-proximal tubular cells. 
In diabetic mice, significant increase in Pxr mRNA, demethylation of DNA and increased 
H3K4me3 in the promoter were also observed. Epigenetic changes are likely to play a 
causative role in PXR induction because DMNT inhibitor and HDAC inhibitor increased 
mRNA expression of Pxr in cultured human proximal tubular cells. To identify specific 
functions of PXR in proximal tubules, we treated mice with PXR agonist (PCN 100mg/kg 
once i.p.), and analyzed transcriptome of the kidney by microarray analysis. Significant 
increase of Rgc32, a molecule known to exert fibrotic effects in the kidney, was observed 
in the PCN-treated kidney.
Conclusions: We revealed that PXR, expressed selectively in the proximal tubules, 
is increased in the diabetic kidney. Aberrant expression of PXR may be maintained by 
epigenetic mechanisms and contribute to the progression of diabetic kidney disease through 
the novel PXR-RGC32 pathway.
FR-OR080
Metabolic Control of Chromatin Remodeling by miR-93 in Diabetic 
Nephropathy  Shawn S. Badal,1 Yin Wang,1 Jianyin Long,1 Farhad R. Danesh.1 
1Section of Nephrology, The Univ of Texas MD Anderson Cancer Center, 
Houston, TX; 2Molecular and Cellular Biology, Baylor College of Medicine, 
Houston, TX.
Background: How podocytes respond to metabolic cues in their environment remains 
a central question in kidney research. This is relevant in the pathogenesis of diabetic 
nephropathy (DN), where recent evidence suggests that metabolic events in podocytes may 
play important roles in regulating chromatin structure. However, the molecular connection 
linking metabolic states in the cytoplasm to chromatin dynamics remains poorly understood.
Methods: We employed a combined in vivo and in vitro approach to understand the 
impact and mechanism of miR-93 overexpression in podocytes within the diabetic millieu. 
We generated triple transgenic, podocyte-specific, tamoxifen-inducible miR-93 transgenic 
mice on the Leprdb background (db/db).  We restored miR-93 expression in kidneys using 
systemically administered miR-93 mimics. Mechanistically, we employed RNA-Seq and 
DNase Hypersensitivity-Seq analysis to define novel targets of miR-93 in podocytes.
Results: Diabetic mice with forced expression of Pod-miR-93 exhibited a significant 
reduction in ACR and total albumin excretion whencompared to non-induced, diabetic 
controls. Tamoxifen induced mice exhibited a significant reduction in mesangial expansion 
measured by PAS and podocyte injury measured by Desmin staining, compared to controls. 
Ultrastructure analysis revealed reduced podocyte effacement, and improved glomerular 
basement membrane thickness in miR-93 induced mice compared to controls. Restoring 
miR-93 expression via miR-93 mimics delivery in diabetic mice rescued the DN phenotype 
in a similar fashion. RNA-Seq and DNase-Seq analysis revealed a previously unrecognized 
role for miR-93 as regulator of chromatin dynamics through a novel target in DN, Msk2.
Conclusions: Our data suggest that miR-93 is a critical metabolic/epigenetic switch 
in the diabetic environment linking the metabolic state to chromatin remodeling through 
its modulatory effect on Msk2/H3S10 phosphorylation signaling pathway. We propose that 
low levels of miR-93, via chromatin remodeling, results in global changes to DN-related 
chromatin signature and transcriptome.
Funding: NIDDK Support
FR-OR081
C-Reactive Protein Promotes Renal Fibrosis in Type 2 Diabetes via CD32-
Smad3-mTOR Signaling Pathway In Vivo and In Vitro  Hui Y. Lan, Yong-ke 
You, Xiao Ru Huang.  Dept of Medicine & Therapeutics, Li Ka Shing Inst of 
Health Sciences, and Shenzhen Research Inst, The Chinese Univ of Hong Kong, 
Hong Kong, China.
Background: Increasing evidence shows that patients with type-2 diabetic nephropathy 
(T2DN) is associated with elevated serum levels of C-reactive protein (CRP). In this study, 
we tested a hypothesis that CRP may promote T2DN by impairing the mTOR pathway via 
the Smad3-depenent mechanism.
Methods: Human CRPtg-db/db mice and their littermate controls including db/db, 
db/m and CRPtg-db/m mice were generated by crossing db/m mice with CRPtg mice that 
overexpress human CRP. Blood fasting glucose, intraperitoneal glucose tolerance test 
(IPGTT), intraperitoneal insulin tolerance test (IPITT), 24-hour urinary microalbumin levels 
were measured every 4 weeks in groups of 8 mice over the 36-week period. To study the 
signaling mechanism, intrarenal TGF-beta/Smad3 and mTOR signaling were also studied 
in vivo and in vitro in HK-2 tubular epithelial cells.
Results: Compared with littermate db/db mice, CRPtg-db/db mice developed higher 
levels of blood fasting glucose and enhanced insulin resistance. These was associated with 
a marked increase in microalbuminuria and the development of more severe renal fibrosis 
including an increase in collagen I and IV within the diabetic kidney. Enhance renal fibrosis 
in CRPtg-db/db mice was associated with a maked activation of TGF-beta/Smad3 and 
mTOR signaling. Further studies in cultured HK-2 TEC revealed that CRP acted through its 
receptor CD32b to promote high glucose-induced activation of Smad3 via both TGF-beta-
dependent and ERK/p38/MAP kinases-crosstalk pathways, which was confirmed by the 
finding that addition of an neutralizing antibody against CD32 or TGF-beta1 and an inhibitor 
to ERK or p38 was capable of inhibiting CRP-induced Smad3 signaling. Furthermore, we 
also found that activated Smad3 then bound directly to mTOR as determined by a ChiP 
assay and stimulated fibrosis in response to CRP and high glucose, which was blocked by 
a Smad3 inhibitor (SIS3) and a mTOR inhibitor (rapamycin).
Conclusions: CRP promotes renal fibrosis in T2DN via the CD32b-Smad3-mTOR 
signaling pathway.
Funding: Other NIH Support - RGC TRS-T12-402/13N, GRF-468711, CRF-
CUHK3/CRF/12R,  973 program-2012CB517705, CUHK FIS-A program.
FR-OR082
NLRC4 Knockout Ameliorates the Development of Diabetic Nephropathy 
in Mice  Fang Yuan,1 Yinghong Liu,1 Ryan Kolb,2 Fu-You Liu,1 Weizhou 
Zhang.2  1Dept of Nephrology, the Second Xiangya Hospital, Central South 
Univ, Changsha, China; 2Dept of Pathology,  Univ of Iowa, USA.
Background: Diabetic nephropathy is a growing health concern with characteristic 
sterile inflammation. An association of diabetic nephropathy with inflammasome activation 
has recently been shown, but the pathophysiological relevance of this finding remains 
unknown.In the current study, we aimed to study the role of NLRC4 inflammasome in the 
development of diabetic nephropathy in mice.
Methods: The expression of NLRC4 inflammasome and macrophage infiltration 
in renal tissues of patients with DN were detected by immunohistochemistry. Then,we 
used NLRC4-/-mice to test the hypothesis that diabetic nephropathy is associated with 
renal NLRC4 inflammasome activation.We used the STZ-induced diabetes model, and 
followed the mice for up to 8 weeks. The mice were randomly divided into 3 groups: 
the normal control group; the wild-type diabetic group; NLRC4-/- diabetic group.After 8 
weeks, serum biochemistry and urine albumin were measured.The kidneys were collected 
to test the macrophage by flow cytometric analysis and the renal pathologic changes were 
observed by light microcopy.We also detected the level of IL-1β by ELISA,and NLRC4 
inflammasome activation by western blot. NF-κB,JNK signal transduction pathways and 
inflammatory cytokines in wild-type and NLRC4-/-mice were determined by western blot 
and real-time PCR .
Results: There were significantly increased NLRC4 expression and macrophage 
infiltration in the renal tubules and interstitium of DN patients compared with that of control 
patients,and the expression of NLRC4 was positive correlated with glomerular sclerosis.
Inflammasome activation( caspase-1 and IL-1β) were detected in wild-type diabetic mice. 
Conversely, NLRC4 deficient mice were protected against diabetic nephropathy.Furthermore 
,inhibition of NLRC4 also suppressed NF-κB,JNK signal transduction pathways and 
decreased TNF-α,TGF-β and CTGF expression in STZ-diabetic mice.
Conclusions: Our study suggests that inhibition of NLRC4 inflammasome ameliorates 
the development of diabetic nephropathy in mice.Targeting the inflammasome may be a 
potential therapeutic approach to diabetic nephropathy.
Funding: Government Support - Non-U.S.
FR-OR083
Mitochondrial Lipid Overload in the Proximal Tubules Leads to Fibrosis 
Krisztian Stadler, Claudia Kruger.  Oxidative Stress and Disease Lab, Pennington 
Biomedical Research Center, Baton Rouge, LA.
Background: While there is ample evidence for defective lipid metabolism in diabetes 
and insulin sensitive tissues, the role of lipid metabolism in renal disease is underappreciated. 
Mitochondrial lipid overload – overburdening β oxidation – is an important phenomenon 
in metabolic flexibility. This metabolic disturbance in the kidney has not been studied. 
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Proximal tubules almost exclusively use fat as their energy source, therefore it is important 
to understand what happens when they are overloaded with lipids. Tubular fibrosis seems 
to be a common pathway where all chronic kidney diseases culminate.
Methods: To test the relationship between mitochondrial lipid overload and tubular 
damage, we have developed a proximal tubule specific (Ggt CRE) mouse strain lacking 
carnitine-acetyl transferase - crAT (CrATGgt-/-). CrAT is responsible for the removal 
of excess fatty acid products from mitochondria. In its absence, incompletely oxidized 
fatty acids accumulate, pyruvate oxidation is compromised and a reducing environment 
conducive to superoxide formation created. This can lead to hydroxyl radical production 
which then will induce lipid peroxidation. By deleting CrAT an ideal system can be created 
to specifically model lipid radical formation due to metabolic sources.
Results: Knockout mice developed fibrosis, protein casts and tubular injury as they aged 
when compared to fl/fl controls. This was accompanied with increased TGFβ expression, 
an increase in serum creatinine levels, increased expression of vimentin, collagen IV, 
Bax, and caspase-3. Similarly to other mice models of kidney disease, CrATGgt-/- mice 
displayed phenotypic variations from minor to more severe injury. Kim-1 expression in 
CrATGgt-/- mice correlated with the severity of fibrosis. Interestingly, mice also developed 
glomerular injury and FSGS-like lesions, suggesting tubulo-glomerular interactions when 
tubular mitochondria are overloaded. Challenging mice with high fat diet or uninephrectomy 
accelerated this phenotype.
Conclusions: Our studies suggest that mitochondrial lipid overload (deletion of CrAT) 
in the proximal tubules may lead to metabolic/redox disturbances and tubular apoptosis 
and fibrosis.
Funding: NIDDK Support
FR-OR084
Role of Neuropilin-1 in Glomerular Function and Disease  Christina S. Bartlett,1 
Monika Lucyna Wnuk,2 Vera Eremina,3 Chengjin Li,3 Yashpal S. Kanwar,1 Jeffrey 
H. Miner,4 Maria Pia Rastaldi,5 Susan E. Quaggin.1  1Feinberg Cardiovascular 
Research Inst and Div of Nephrology, Northwestern Univ, Chicago, IL; 2Univ 
of Bern, Switzerland; 3Mount Sinai Hospital, Toronto, Canada; 4Washington 
Univ, St. Louis, MO; 5Fondazione IRCCS Ca’Granda Ospedale Maggiore 
Policlinico, Milano, Italy.
Background: Neuropilin-1 (NP-1), a co-receptor for a variety of growth factors (e.g. 
VEGF, PDGF, and TGF-b), is critical for development and patterning of vascular and 
nervous systems. Mesangial cells strongly express NP-1 yet the physiological relevance 
of this is unclear. To date, onset of proteinuria in humans following antibody blockade of 
NP-1 hints at the importance of NP-1 in glomerular function.
Methods: NP-1 expression was assessed by immunofluorescence in biopsy samples 
from diabetic (DN) and IgA nephropathy (IgAN) patients. To further investigate the in vivo 
function of NP-1, we analyzed mice with perivascular cell specific deletion of NP-1. Intrinsic 
cell behaviors affected by NP-1 were examined in primary human mesangial cultures.
Results: DN and IgAN biopsies have notably elevated mesangial expression of NP-1 
indicating that NP-1 may have a role in glomerular dysfunction. In mice, deletion of NP-1 
in the mesangium restricts glomerular maturation and causes dramatic mesangial expansion, 
marked GBM thickening and tubular dilatation. NP-1-deficient mutants develop severe 
proteinuria and succumb to renal insufficiency. In mutant glomeruli lacking NP-1 in the 
mesangium, VEGFR2 phosphorylation is increased while podocyte ERK signaling is 
hyperactivated. In vitro, we showed that NP-1 mediates directed migration of mesangial 
cells towards PDGFB. Inducible gene targeting of NP-1 is currently underway to delineate 
developmental versus maintenance functions of NP-1 in the glomerulus particularly within 
the context of DN.
Conclusions: NP-1 expression in the mesangium is needed for glomerular development. 
NP-1 regulates matrix production and its absence compromises glomerular filtration. 
Increased expression of NP-1 in DN and IgAN further suggests that glomerular function 
relies on a finely tuned level of NP-1 signaling. Accordingly, NP-1 may be suitable as target 
to ameliorate glomerular disease.
Funding: Other NIH Support - 5T32 DK007169
FR-OR085
Protein S Protects Podocyte from Injury in Early Diabetic Nephropathy 
Fang Zhong,1,2 Kim Lee,1 John C. He.1  1Dept of Medicine/Nephrology, Icahn 
School of Medicine at Mount Sinai, New York, NY; 2Dept of Nephrology, Hang 
Zhou Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical 
Univ, Hang Zhou, Zhejiang, China.
Background: Elucidating mechanisms that mediate the early stage of diabetic 
nephrology (DN) may help us identify novel preventive and therapeutic measures for 
patients with DN. Protein S (PS), a vitamin K-dependent protein, functions mainly as 
a cofactor for the formation of activated protein C (APC). APC is known to have podo-
protective effects in DN. However, the role of PS in DN has not been studied.
Methods: Proteomic analysis was performed in glomeruli isolated from STZ and 
control rats. The podocytes cell-specific Pros1 homozygous knockout mice (KO) were 
developed to determine the role of PS in DN. Immortalized human podocytes (HPC) were 
used for in vitro studies. The expression of TMA receptors and podocyte-specific genes 
were examined by western blot and RT-PCR. The Protein S expression was examined in 
human kidney biopsies by immunostaining.
Results: Proteomic analysis of glomeruli revealed higher expression of PS in diabetic 
glomeruli. Then, we confirmed an increase of PS expression in the glomeruli of diabetic 
rats by RT-PCR and immunostaining. Interestingly, PS expression also increased in human 
kidneys with early DN but decreased in those with advanced DN. As a control, plasma 
concentrations of PS were not significantly different between diabetic and non-diabetic 
rats or humans. Since the staining of PS was more prominent in podocytes of human 
diabetic kidney, we determined the role of PS in cultured human podocytes. We found 
that Knockdown of Pros1 enhanced high glucose-induced apoptosis while overexpression 
of Pros1 inhibited TNF-α-induced pro-inflammatory gene expression in podocytes likely 
through activation of tyro3, one of the TMA receptors. To further determine the role of PS 
in DN, we developed podocyte-specific Pros1 knockout mice (KO) and found that diabetic 
KO mice (KO-STZ) developed more proteinuria, mesangial expansion, and foot process 
effacement than diabetic wide-type mice (WT-STZ).
Conclusions: Our data support a protective role of PS against podocyte injury in 
early DN.
Funding: Other NIH Support - NIH 1R01DK078897, NIH 1R01DK088541, NIH 
P01-DK-56492
FR-OR086
Deletion of SHP-1 in Podocytes Prevents Diabetic Nephropathy 
Farah Lizotte, Benoit Denhez, Andréanne Guay, Pedro Miguel Geraldes. 
Medecine, Univ of Sherbrooke, Sherbrooke, QC, Canada.
Background: Both clinical and experimental data suggest that podocyte injury is 
involved in the onset and progression of diabetic nephropathy (DN) in the patients with 
type 1 diabetes. Although the mechanisms underlying the development of podocyte loss are 
not completely understood, insulin and nephrin actions have been shown to play a major 
role in the podocyte survival and function. We have reported that SHP-1, a protein tyrosine 
phosphatase, is increased in podocytes of diabetic mice and inhibited insulin and nephrin 
actions. However, the precise role of SHP-1 in the development of diabetic nephropathy 
remains to be investigated.
Methods: We have generated a non-diabetic (NDM) and diabetic Akita (DM; Ins2+/C96Y) 
conditional podocyte specific SHP-1 knockout (podo-SHP-1KO) mice using the TetON-
Cre lox system. Mice received or not doxycycline at 4 weeks of age and renal function 
(albuminuria and GFR) and pathology were examined at 7 months of age.
Results: Elevated albumin/creatinine ratio and GFR showed in DM mice are prevented 
by 86% and 100%, respectively in DM mice that lack SHP-1 gene specifically in podocytes. 
Mesangial cell expansion and glomerular hypertrophy is increased by 1.8 and 4.9 fold in DM 
mice and reduced by 78% and 72%, respectively in DM podo-SHP-1KO mice. Moreover, 
the expression of collagen type IV and TGF-ß that is enhanced in DM mice compared to 
NDM was not increased in DM podo-SHP-1KO mice. Transmission electron microscopy 
analysis demonstrated podocyte foot process effacement in DM mice that is not observed 
in DM podo-SHP-1KO mice. Furthermore, inhibition of insulin-induced Akt and ERK 
phosphorylation showed in DM mice is completely prevented in DM podo-SHP-1KO 
mice. Similar to insulin, nephrin phosphorylation is restored in DM podo-SHP-1KO mice 
compared to DM mice.
Conclusions: Our data indicate that the deletion of SHP-1 specifically in podocytes 
restored insulin and nephrin actions and prevented renal pathology and dysfunction in 
diabetic mice.
Funding: Government Support - Non-U.S.
FR-OR087
Targeted Proximal Tubule Injury Promotes Progression of Diabetic 
Kidney Disease in Akita Mice  Jae Hyung Chang, Takaharu Ichimura, Venkata 
Sabbisetti, Joseph V. Bonventre.  Renal Div, Dept of Medicine, Brigham and 
Women’s Hospital, Boston, MA.
Background: Increasing evidence suggests that the kidney tubulointerstitial injury 
plays an important primary role in the pathophysiology of diabetes.
Methods: In the present studies, a mouse containing the renal epithelial cell-specific 
Six2Cre allele was crossed with a mouse transgenic for a Cre-inducible simian diphtheria 
toxin receptor (DTR). The bigenic mouse was then bred with Akita mice as a genetic model 
of type 1 diabetes. Targeted tubule injury was induced in these animals (Akita DTRrenal 
epithelial cell (DTRrec)) with injection of diphtheria toxin (DT).
Results: Male Akita mice developed sustained hyperglycemia. A single sublethal 
dose of DT in Akita DTRrec mice resulted in an acute two-fold rise in urinary albumin 
excretion and progression of albuminuria over the study period. By 19 weeks after DT 
injection, Akita DTRrec mice developed an almost five-fold increase in albuminuria, 40% 
increase in serum creatinine level, almost two-fold increase in blood urea nitrogen (BUN) 
level, and reduced kidney size when compared with Akita controls. Moderate glomerular 
mesangial expansion, and increased interstitial fibrosis and tubular atrophy (IFTA) and 
glomerulosclerosis were observed in Akita DTRrec mice 20 weeks after DT injection. 
These pathologic changes were accompanied by increased levels of the molecular marker 
of proximal tubule injury, kidney injury molecule (KIM)-1, in both kidneys and urines of 
Akita DTRrec animals. Increased proximal tubule DNA damage response (DDR) activation, 
pro-inflammatory and pro-fibrotic cells infiltration, and peritubular capillary rarefaction 
were observed in kidneys of DT-treated Akita DTRrec mice.
Conclusions: In diabetes, proximal tubule injury, perhaps from glycotoxins, can drive 
interstitial inflammation and fibrosis, capillary rarefaction, and secondary glomerular injury 
leading to progression of diabetic nephropathy. Our findings suggest novel therapeutic 
targets for the prevention and treatment of diabetic kidney disease.
Funding: Private Foundation Support
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Wnt11 Signals from the Ureteric Bud Direct Organization of the Nephron 
Progenitor Niche Determining Nephron Endowment  Lori L. O’Brien,1 
Alexander N. Combes,3 Kieran M. Short,2 Peter H. Whitney,1 Odyssé Michos,1 
Ali Ju,3 Luise A. Cullen-McEwen,2 John F. Bertram,2 Melissa H. Little,3 
Andrew P. McMahon.1  1USC, Los Angeles, CA; 2Monash Univ, Melbourne, 
VIC, Australia; 3Murdoch Childrens Research Inst, Melbourne, VIC, Australia.
Background: Normal nephron endowment requires a balance of nephron progenitor 
(NP) self-renewal and differentiation during kidney development. Wnt11, a non-canonical 
Wnt signal produced by ureteric tip (UT), has been shown to positively regulate the Gdnf-
Ret signaling axis and branching morphogenesis. Our current data identifies a new role 
for Wnt11 in organization of the NP niche.
Results: Six2+ NPs are normally tightly associated with the UT, separating adjacent 
Foxd1+ interstitial progenitors from the UT. In Wnt11 mutants, inter-niche boundaries 
become less distinct and Six2+ and Foxd1+ cells intermix. RNA-seq of whole kidneys 
revealed minimal transcriptional changes within NPs suggesting Wnt11 primarily regulates 
cell behavior, as expected for a non-canonical Wnt. Single cell analysis of NPs in vivo and 
live imaging of kidney organ cultures shows that NPs normally make extensive membranous 
contacts with UTs. Long membrane projections extend to the UT from NPs that form layers 
above the UT. In contrast, NPs in Wnt11 mutants fail to exhibit elongated UT-directed 
membrane extensions. Wnts signal through Frizzled (Fzd) receptors: Fzd2 and Fzd7 are 
co-expressed within NPs. Fzd2-/-;Fzd7-/+mutants display a similar disorganization of the 
NPs, suggesting these two receptors likely mediate the non-canonical Wnt11 response. 
Quantitative analyses of the Wnt11 phenotype revealed a 30% reduction in UTs and 20% 
reduction in kidney size by E15.5. At birth, UT numbers were further reduced by 40% 
and mutant kidneys were 38% smaller. Further, NP niches were significantly depleted and 
prematurely lost. As a consequence, adult nephron number was reduced by 50%.
Conclusions: Taken together, these data highlight the importance of non-canonical 
Wnt11 signals in maintaining NP behavior, and appropriate stratification and organization of 
distinct mesenchymal progenitor compartments in the UT niche, a prerequisite for generating 
a normal nephron complement in the developing mammalian kidney.
Funding: NIDDK Support, Private Foundation Support
FR-OR089
Bim Gene Dosage Is Critical in Modulating Nephron Progenitor 
Survival in the Absence of Dicer Activity During Kidney Development 
Debora Malta Cerqueira, Andrew J. Bodnar, Yu Leng Phua, Kenneth A. 
Walker, Jacqueline Ho.  Dept of Pediatrics, Children’s Hospital of Pittsburgh, 
Pittsburgh, PA.
Background: We have previously demonstrated that conditional depletion of the 
miRNA-processing enzyme, Dicer, in nephron progenitors results in increased apoptosis and 
premature depletion of this cell population during kidney development. This is accompanied 
by increased expression of the pro-apoptotic protein, Bim.
Methods: To determine the functional significance of increased Bim, we generated 
a mouse model with depletion of both Dicer and Bim from nephron progenitors in 
the developing kidney. To this end, Six2-TGCTg/+; Dicerflx/flx mice were crossed with a 
conditionally floxed Bim allele generating the following genotypes: Six2-TGC+/+; Bimflx/+; 
Dicerflx/+ (control), Six2-TGCTg/+; Dicerflx/flx; Bim+/+ (mutant), Six2-TGCTg/+; Dicerflx/flx; Bimflx/+ 
(heterozygous rescue) and Six2-TGCTg/+; Dicerflx/flx; Bimflx/flx (homozygous rescue).
Results: The depletion of Bim partially restored the number of nephron progenitors 
and improved nephron formation in Dicer-deficient kidneys. At the molecular level, the 
expression of the most abundant isoform of Bim (BimEL) was increased, while the levels 
of the pro-survival protein Bcl-2 were reduced in mutant compared to control kidneys. 
In contrast, the loss of Bim restored Bcl-2 expression and reduced BimEL levels in a 
dose-dependent manner in the homozygous and heterozygous rescue kidneys. Finally, we 
analyzed the survival and proliferation of nephron progenitors. The loss of Bim decreased 
apoptosis of nephron progenitors in kidneys that were Dicer-deficient in the progenitors, 
with no significant effect on cell proliferation.
Conclusions: Together these data provide evidence for a model in which miRNA-
mediated regulation of Bim controls the balance between apoptosis and survival during 
nephrogenesis, as one potential means of regulating nephron number.
Funding: NIDDK Support
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DGCR8-Dependent MicroRNA Biogenesis Is Essential to the Function of 
Pax8-Positive Epithelial Organs  Roman-Ulrich Mueller,1 Malte P. Bartram,1 
Elena Amendola,2 Gabriella De vita,2 Bernhard Schermer,1 Thomas Benzing.1 
1Dept II of Internal Medicine and Center for Molecular Medicine, Univ Hospital 
Cologne, Cologne, Germany; 2Dipartimento di Biologia e Patologia Cellulare 
e Molecolare, Univ degli Studi di Napoli ‘Federico II’, Naples, Italy.
Background: MiRNAs are small regulatory RNA molecules that have been shown 
to play an important role in physiology, development and disease of many organs. As to 
most organs our knowledge on the role of miRNAs depends on the use of Dicer-knockout 
models with this enzyme being a key component of the miRNA biogenesis machinery. 
However, Dicer has been shown to fulfil a number of other functions beyond the maturation 
of miRNAs. Furthermore a number of these small RNAs does not depend on Dicer in 
its maturation. Consequently, the phenotypes observed might well be due to miRNA-
independent functions of Dicer. For most organs examined - including renal disease models 
- we still lack confirmation that the phenotype observed is truly due to miRNA deficiency.
Methods: We examined mice harboring a conditional knockout allele of Dgcr8. Dgcr8 
- together with its interaction Partner Drosha - is essential to the nuclear steps of miRNA 
biogenesis. This mouse line was crossed to a Pax8Cre line to examine and confirm the role 
of miRNAs in Pax8-positive epithelial organs.
Results: The knockout mice develop a cystic kidney disease and hydronephrosis. End-
stage renal disease occurs by the age of 4-8 weeks. On the cellular level this phenotype is 
accompanied by a strong increase in both cellular proliferation and apoptosis. Furthermore 
severe hypoplasia of the thyroid gland and consecutive hypothyroidism were observed. 
The hypoplasia does not appear to depend on a block in differentiation but may rather be 
due to impaired cell polarization.
Conclusions: This study shows the importance of DGCR8-dependent miRNA 
biogenesis for both renal and thyroid function and can thus be the basis to future experiments 
addressing the role of specific miRNA sequences. Nonetheless, some aspects of the 
phenotype differ from the Dicer knockout model pointing towards miRNA-independent 
contributions of Dicer and Dgcr8 regarding the pathogenesis of these two organs in our 
mouse model.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Oxygenation and Von Hippel-Lindau Regulate Nephron Progenitor 
Differentiation  Elina Mukherjee, Jacqueline Ho, Sunder Sims-Lucas.  Univ 
of Pittsburgh, Pittsburgh, PA.
Background: During development, oxygenation plays a crucial role in kidney 
formation. Nephron progenitor (NP) differentiation is highly dependent on appropriate 
vascularization and subsequently oxygen concentration. Alterations in nephron 
differentiation lead to kidney malformations. The unperfused NP are hypoxic, which 
activates the hypoxia inducible factors (HIFs). The HIF genes are potent factors involved in 
tissue differentiation. Upon oxygenation the Von Hippel-Lindau gene (VHL), degrades the 
HIFs and allows for tissue differentiation. We previously showed in vitro that oxygenation 
drives NP differentiation. Thus, we hypothesize that stabilization of HIFs in the NP will 
cause congenital kidney defects.
Methods: To determine the role of VHL in the NP we utilized VHL floxed mice bred 
with the Six2EGFPcre line, to generate Six2creVHLlox/lox mutant mice. We performed a 
thorough histological assessment from early kidney development through to post natal 
ages. We coupled this with immunofluorescence (IF) of the various kidney compartments 
as well as immunohistochemistry (IHC) and western blot analysis to analyze VHL and 
HIF expression.
Results: Histology revealed that Six2creVHLlox/lox mutant mice were underdeveloped 
from E15.5, with fewer differentiated NP derived structures. Postnatal mutant kidneys 
displayed significant pathology containing fewer nephrons, cystic tubules and proteinaceous 
casts. The mutant kidneys contained fewer proximal tubules, and remaining tubules were 
dilated. The mutant animals failed to thrive and were significantly smaller at weaning. IHC 
staining revealed a down regulation of VHL in the mutants coupled with an up regulation 
of HIF1a in the NP, which was confirmed via western blot analysis. IF staining of mutant 
embryonic kidneys showed a delay in NP differentiation with ectopic Six2 remaining highly 
expressed in NCAM positive epithelialized structures of mutants.
Conclusions: In conclusion, VHL is critical in the NP to regulate the expression of 
HIFs. Inappropriate up regulation of HIFs causes alterations in NP differentiation, leading 
to kidney malformations.
FR-OR092
Interplay Between the Tbx2 Transcription Factors and Notch Signaling 
Directs Nephron Segmentation  Bridgette Drummond, Yue Li, Amanda N. 
Marra, Christina N. Cheng, Rebecca A. Wingert.  Biological Sciences, Univ of 
Notre Dame, Notre Dame, IN.
Background: Nephron segment patterning remains an enigmatic process. The 
conservation of nephron segments across vertebrates enables insights through work with 
animal models, and among these the zebrafish provides a simple system for developmental 
genetic studies of nephrogenesis. Zebrafish nephrons contain proximal and distal tubule 
segments, and endocrine cells called the corpuscle of Stannius (CS) also arise from the 
intermediate mesoderm (IM) and are situated between the distal nephron segments.
Methods: Here, we show that the T-box 2a/b (tbx2a/b) orthologs are spatially restricted 
to the distal IM. tbx2a and tbx2b single and doubly deficient embryos, as well as tbx2bfby 
mutants, exhibited a modest expansion in the proximal segments accompanied by a reduction 
in the distal nephron, indicating that these genes have redundant roles in segment patterning.
Results: Abrogation of tbx2a/b expression was also associated with significantly 
expanded CS structures, coincident with increased expression of sim1a, a transcription 
factor that was recently demonstrated to be necessary and sufficient for CS formation. 
Further, we identified expression of the Notch pathway component her9 in the developing 
CS. In exploring the link between tbx2 genes and Notch, DAPT treatment was found to 
cause a moderate CS expansion in wildtypes, while DAPT induced further enlarged CS 
clusters in tbx2 deficient embryos. Ectopic activation of Notch signaling in Tg(hsp70::Gal4; 
UAS::NICD) led to a reduced CS in wildtypes but not tbx2 deficient embryos, suggesting 
the tbx2 genes function downstream of Notch to inhibit the CS. In addition, ectopic Notch 
expanded proximal tubule segments at the expense of distal, reducing tbx2 expression 
domains and therefore suggesting that Notch promotes proximal segments in part by 
inhibiting tbx2 expression.
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Conclusions: Taken together, these data suggest a model in which Tbx2a/b are essential 
for patterning of the distal IM from which the distal nephron segments and CS arise, and 
thus provide novel insights into the regulatory networks that influence renal ontogeny.
Funding: NIDDK Support, Other NIH Support - Office of the Director
FR-OR093
Dot1l Deficiency Leads to Increased Intercalated Cells and Up-Regulation 
of V-ATPase B1 in Mice  Zhou Xiao,1 Lihe Chen,2 Qiaoling Zhou,1 Wenzheng 
Zhang.3  1Internal Medicine, Xiangya Hospital, Central South Univ, Changsha, 
Hunan, China; 2Graduate School of Biological Sciences, Univ of Texas Health 
Science Center at Houston, Houston, TX; 3Internal Medicine, Univ of Texas 
Medical School at Houston, Houston, TX.
Background: The collecting duct in the mammalian kidney consists of principal cells 
(PCs) and intercalated cells (ICs), which regulate electrolyte/fluid and acid/base balance, 
respectively. The epigenetic regulators of PC and IC differentiation remain obscure. Using 
Aqp2 and V-ATPase B1B2 to label PCs and ICs, respectively, we previously reported that 
mice with histone H3 K79 methyltransferase Dot1l disrupted in Aqp2-expressing cells 
(Dot1lAC) vs. Dot1lf/f possessed ~20% more ICs and a similar decrease in PCs.
Methods: In this study, we performed multiple double immunofluorescence staining 
using various PC and IC markers to assess the relative abundance of PC and IC in Dot1lAC 
and Dot1lf/f. Real-time RT-qPCR, luciferase assay, and chromatin immunopreciptation 
assays were conducted to determine if Dot1l regulates the transcription of Atp6v1b1 in 
vivo in mousre kidney and in vitro in IMCD3 cells.
Results:    Dot1lAC vs. Dot1lf/f had more IC and less PC, with expanded both a-IC and 
b-IC populations. These changes were associated with significantly upregulated V-ATPase 
B1 and B2, but not Aqp2, AE1, and Pendrin. Decreased V-ATPase B1 mRNA expression 
was coupled with a significant reduction of Dot1l and H3K79 di-methylation bound at the 
Atp6v1b1 5’ flanking region. Overexpression of WT Dot1a, but not the methyltransferase-
dead mutant Dot1a significantly downregulated a stably-transfected luciferase reporter 
driven by the Atp6v1b1 promoter in IMCD3 cells. 
Conclusions: Dot1l is a new epigenetic regulator of PC and IC differentiation and 
Atp6v1b1 is a new transcriptional target of Dot1l.
Funding: NIDDK Support
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DNp63 Progenitor Cells Pattern the Ureteric Bud Stem Cell Niche and 
Give Rise to β-Intercalated Cells  Yuwen Li, Jiao Liu, Altaf-M Khan, Zubaida 
R. Saifudeen, Samir S. El-Dahr.  Pediatrics, Tulane Univ School of Medicine, 
New Orleans, LA.
Background: 1. Ureteric Bud (UB) tip cells constitute a stem/progenitor cell niche 
with bipotential properties enabling them to self-renew or differentiate, giving rise to all cell 
types in the collecting duct. Understanding how the UB tip cell commits to the Principal 
Cell (PC) or Intercalated Cell (IC) fate is essential for the design of strategies to re-build 
a kidney from stem cells and for hastening epithelial cell regeneration after injury. 2. The 
N-terminus-truncated p63 isoform, DNp63, is a master transcriptional regulator of epithelial 
stem cells in skin. 3. Here, we document expression of DNp63 in the UB tip and assess the 
progenitor cell identity, fate and regenerative potential of DNp63 cells.
Methods: 1. Ret-GFPTg mice were used to demonstrate expression of DNp63 in Ret 
tip cells. 2. DNp63GFP/+ knockin mice were used to define the spatiotemporal pattern of 
DNp63. 3. DNp63Cre:Rosa26mT/mG or EYFP mice were used to trace the fate of DNp63 cells 
from embryonic to adult life. 4. DNp63GFP/GFP mice were used to define the effect of DNp63 
deletion on UB tip cell differentiation. 5. Adult DNp63Cre:Rosa26tdTomato were subjected to 
unilateral ureteral obstruction (UUO) for 7 days to determine the response of fate-restricted 
DNp63 cells to injury. Cell proliferation was determined by BrdU incorporation.
Results: 1. DNp63 expression is restricted to cell clusters in UB tip until PN day 5 
when expression is permanently silenced. 2. In vivo lineage analysis identified DNp63 
as a marker of UB progenitor cells dedicated to generating H-ATPase+/Pendrin+ cells in 
cortical nephrons. 3. A fraction of cortical H-ATPase+/AE1+ cells are also DNp63-lineage+, 
supporting the notion that at least some cortical α-IC are derived from β-IC. 4. DNp63null 
UB tip cells are maintained. In contrast, progeny of DNp63null collecting duct cells lack 
H+-ATPase/carbonic anhydrase II. 5. In response to UUO, DNp63-lineage+ cells proliferate 
and contribute to collecting duct cells expressing PC and IC markers.
Conclusions: 1. UB tip DNp63 cells are unipotent progenitors of β-ICs. 2. In response 
to injury, fate-restricted DNp63 lineage cells regenerate damaged collecting ducts.
Funding: NIDDK Support
FR-OR095
Critical Role of Talin in Cell-Cell Adhesion and Kidney Development 
Sijo Mathew,1,4 Riya Jose Palamuttam,1 Glenda Mernaugh,1 Ambra Pozzi,1,2 
Charles R. Sanders,3,4 Roy Zent.1,2  1Div of Nephrology and Hypertension, Dept 
of Medicine, Vanderbilt Univ Medical Center, Nashville, TN; 2Veteran Affairs 
Hospital Nashville, Nashville, TN; 3Dept Biochemistry, Vanderbilt Univ Medical 
Center, Nashville, TN; 4Center for Structure Biology, Vanderbilt Univ Medical 
Center, Nashville, TN.
Background: Interactions between cells and basement membranes are required for 
normal kidney development and function. These interactions are primarily mediated by 
the major cell surface adhesion receptor proteins integrins. Integrins are composed by α 
and β subunits and have two important functions: ligand binding and regulation of the 
cytoskeleton. The cytoskeletal protein, talin, is a key regulator of integrin function. Talin 
has two isoforms talin 1 and 2. Both talins isoforms bind to the membrane proximal NPxY 
motif of integrin b1 cytoplasmic tail. Talin binding is proposed to promote integrin activation 
and link integrins to the actin cytoskeleton.
Results: In this study we investigated the role of talin in kidney development by 
generating mice lacking both isoforms in the developing ureteric bud. These mice die 
immediately after birth due to renal agenesis. Talin-null collecting ducts cells showed a 
severe adhesion defect on ECM proteins and were unable to undergo tubule formation 
in collagen matrigel matrix. In addition they had altered expression of cell-cell adhesion 
proteins claudin and E-cadherin. To better define the role of talin binding to the integrin 
b1 cytoplasmic tail in the collecting system development, we generated mice expressing a 
Y-to-A mutation in the membrane proximal NPxY motif of integrin b1 tail. Surprisingly, 
these mice only had a moderate developmental phenotype, characterized by a hypoplastic 
and dysplastic collecting system. Near complete abolition of talin binding with integrin b1 
was observed in the mutant when in vitro binding was studied using NMR spectroscopy 
in isotropic bicelles.
Conclusions: Thus, we conclude that talin is essential for ureteric bud development 
and that some of its most important effects are likely mediated by integrin-independent 
processes.
Funding: NIDDK Support, Veterans Administration Support
FR-OR096
Loss of Frs2α in Peri-Wolffian Duct Stroma Leads to Abnormal Ureteric 
Bud Induction and Vesicoureteral Reflux  Deepti Narla,1 Kenneth A. Walker,1 
Stacey B. Slagle,2 Caitlin M. Schaefer,1 Carlton M. Bates.1  1Div of Nephrology, 
Univ of Pittsburgh; 2Div of Neonatal Medicine, Univ of Pittsburgh School of 
Medicine, PA.
Background: Deletion of fibroblast growth factor receptor 2 (Fgfr2) from peri-Wolffian 
duct stroma (ST) in mice results in aberrant ureteric bud induction, abnormal ureteral 
insertion into the bladder, and high rates of vesicoureteral reflux (VUR). It is unclear 
which receptor docking protein(s) is/are responsible for these actions of Fgfr2. Thus, we 
investigated whether the Fgfr docking protein, fibroblast receptor substrate 2α (Frs2α), had 
roles in peri-Wolffian duct stroma similar to Fgfr2.
Methods: We conditionally deleted Frs2α in per-Wolffian duct stroma with a Tbx18cre 
mouse line (Frs2aST-/-). We assessed embryos for ureteric induction defects and for alterations 
in candidate downstream targets mediating induction defects. We assessed postnatal mice 
for VUR with euthanized cystograms and ureter insertions into the bladder via three 
dimensional (3D) reconstruction.
Results: Embryonic day (E) 11.5 Frs2α ST-/- embryos exhibit nearly random ureteric 
bud induction sites (several cranially or caudally displaced sites along the Wolffian duct) 
versus controls; moreover, apoptosis and proliferation rates were unchanged in Frs2aST-/-
Wolffian duct segments between the ureteric bud base and cloaca (common nephric ducts) 
versus control littermates. E11.5 Frs2α ST-/- embryos had significant decreased Bmp4 mRNA 
stromal expression, which is known to cause abnormal ureteric bud induction. Postnatal day 
1 (P1) and P30 Frs2aST-/- mice had significantly higher rates (worsening with age) and grades 
of VUR verses age-matched controls. Refluxing ureters in Frs2aST-/- mice had improper 
ureteral insertion locations into the bladder and significantly shortened intravesicular 
tunnel lengths versus controls.
Conclusions: Deletion of Frs2α in peri-Wolffian duct stroma leads to aberrant ureteric 
induction sites resulting in improper ureteral insertion and shortened intravesicular length 
and lifelong VUR. Mechanistically, the induction site defects appear secondary to decreased 
Bmp4 expression in mutant stroma. Finally, it is likely that Frs2α mediates Fgfr2 signaling 
in peri-Wolffian duct stroma.
Funding: Other NIH Support - T32 DK091202
FR-OR097
HCN3 Positive Urinary Pacemaker Cells Arise from the Neural Crest 
Norman D. Rosenblum,1,2,3 Meghan M. Feeney.1,2  1Dev and Stem Cell Biology, 
Hosp Sick Children; 2Dept Lab Medicine and Pathobiology, U Toronto; 3Div 
Nephrology, Dept Paediatrics, Hosp Sick Children, Toronto, Canada.
Background: Coordinated proximal to distal ureteric peristalsis is mediated by 
HCN3(+) pacemaker cells (PMCs) in the pelvis-kidney junction (PKJ). Perturbations in 
HCN3 expression and function are associated with congenital hydronephrosis and loss of 
Hedgehog signaling in in mice. Yet, identification of the specific perturbations in PMC 
function has been precluded by lack of knowledge of how PMCs develop. The objective 
of this study is to determine the developmental lineage of HCN3(+) PMCs and identify a 
molecular signature of these cells during development.
Methods: To determine the lineage of origin of the HCN3(+) PMCs, we genetically 
labeled five distinct lineages of the urogenital system via Cre-mediated expression of ROSA-
tdTomato (tdTom) fluorescent protein and analyzed for co-localization with HCN3, using 
antibodies, in mouse embryonic kidney tissue. To investigate the molecular signature of 
the PMCs, HCN3(+) cells were isolated using HCN3 antibodies and fluorescence activated 
cell sorting (FACS). RNA was prepared from sorted samples and gene expression was 
analyzed in isolated HCN3(+) PMCs via qRT-PCR and genome-wide RNA sequencing.
Results: TdTom expressed downstream of promoters specific for metanephric or tailbud 
mesenchyme, ureteric bud or renal stroma failed to co-localize with HCN3-marked PMCs. 
In contrast, tdTom, expressed downstream of the neural crest (NC) specific Wnt1 promoter, 
co-localized with HCN3 in the PKJ, demonstrating that HCN3(+) PMCs arise from the 
NC. HCN3(+) PMCs were FACS isolated from mouse embryonic kidneys with >94% 
purity and >8,000 HCN3(+) cells were collected per litter. Genetic analysis of HCN3(+) 
PMCs via qRT-PCR demonstrated enrichment of both Hcn3 and Sox10, a NC marker, 
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further outlining the NC origin of these cells. Analysis of isolated PMCs, compared to 
adjacent cells in the PKJ, via RNA sequencing, revealed a 3-7-fold upregulation of genes 
associated with neuronal function.
Conclusions: We conclude that HCN3(+) urinary PMCs arise from the NC and express 
genes associated with neuronal function. These results provide a basis to identify molecular 
mechanisms that control PMC development.
Funding: Government Support - Non-U.S.
FR-OR098
Sox9 Activation Highlights a Cellular Pathway of Renal Repair in the 
Acutely Injured Mammalian Kidney  Sanjeev Kumar,1 Jing Liu,1 Paul D. 
Pang,1 A. Michaela Krautzberger,1 Antoine Reginensi,2 Jill A. Mcmahon,1 
Andreas Schedl,2 Benjamin D. Humphreys,3 Andrew P. McMahon.1  1Dept of 
Stem Cell Biology and Regenerative Medicine, Univ of Southern California, 
Los Angeles, CA; 2Centre de Biochimie, Univ de Nice-Sophia Anitpolis, Nice, 
France; 3Renal Div, Brigham and Women’s Hospital, Boston.
Background: Surviving tubular epithelial cells repair the epithelium after acute 
kidney injury (AKI), but the molecular driver of such a reparative response is not known.
Methods: Mice and injury models: Sox9IRES-CreERT2/+, R26RtdTomato/tdTomato, Slc34a1CreERT2/+, 
TCF/Lef:H2B-GFP mice, Sox9fl/fl and Pax2Cre:Sox8/9 double knock-out mutants 
mice. AKI was induced via renal ischemia reperfusion injury and unilateral ureteral 
obstruction. Lineage tracing: for induction of CreERT2 protein, mice were injected with 
low and high-dose tamoxifen pre-and post-ischemic AKI, and during nephrogenesis. 
Immunofluorescence, histology, in situ hybridization, confocal microscopy, nephron 
microdissection. RNA-sequencing and Fluidigm PCR based quantification of transcript 
levels in the kidney.
Results: We identify Sox9 as an acute epithelial stress response that drives epithelial 
regeneration after injury. Translating ribosome affinity purification of mRNAs from 
nephron compartment revealed Sox9 as one of the most upregulated transcription factors 
early after injury. Sox9+ cells demarcated injured, proliferating proximal tubular epithelial 
(PTE) cells early after ischemic and obstructive AKI. Sox9-descendent cells regenerate a 
functional PT epithelium and PT-specific pre-injury deletion of Sox9 impairs renal function 
recovery and PT repair with increased fibrosis. Four weeks after injury, persistent Sox9 
expression demarcates injured PTE cells with unresolved injury-repair responses. During 
nephrogenesis, Sox9-descendent cells give rise to nearly the entire epithelial component 
of the nephron, including PT, and removal of Sox9 activity in Sox8/9 conditional mutant 
mice resulted in striking deficiency of the nephron epithelia.
Conclusions: These findings provide a direct, intrinsic molecular link between 
regeneration of an injured tubular epithelium and its formation during development.
FR-OR099
AKI Up-Regulates the Transcriptional Activator Etv4 Specifically 
in Dedifferentiated Proximal Tubule Where It Drives Epithelial Cell 
Proliferation and Migration  Susanne V. Fleig,1 Fengfeng Xu,1 Flavia G. 
Machado,1 Chia-Chun Wu,1 Rafael Kramann,1 Motoko Yanagita,2 Benjamin 
D. Humphreys.1  1Brigham and Women’s Hospital, Boston; 2Kyoto Univ, Japan.
Background: The transcriptional activator etv4 is required during nephrogenesis 
but roles in adult kidney are undefined. Proximal tubule repair after AKI occurs by 
dedifferentiation, but the transcriptional circuitry regulating this process is unknown. We 
characterized the expression pattern and function of Etv4 in repair after AKI.
Methods: For in vitro studies, we used lentiviral transduction of RPTEC for ETV4 
overexpression or inhibition with a dominant-negative Etv4 (DN-Etv4) cDNA. We used 
an Etv4-nLacZ reporter strain to localize expression, and also generated a novel genetic 
mouse model for tamoxifen-dependent expression of DN-Etv4 specifically in full proximal 
tubule (NDRG1-CreERt2;R26-LoxP-DN-Etv4). These mice and cre-negative littermate 
controls were subject to severe bilateral ischemia/reperfusion surgery.
Results: Cultured RPTEC express Etv4 but DN-Etv4 transduction strongly inhibited 
proliferation (9.44 ± 3.44% KI67+ cells vs. 57.38 ±6.63% in control, p<0.001). By 
contrast, Etv4 overexpression increased proliferation after starvation (67.14 ±8.93% vs. 
34.75 ±18.03% KI67+ cells, p<0.05.) In a wound healing assay, Etv4 inhibition reduced 
migration and increased RPTEC apoptosis while etv4 overexpression increased migration. 
Etv4-nLacZ reporter mice showed almost no expression in healthy kidney, but after IRI, 
Etv4 was specifically expressed in dedifferentiated proximal tubule cells (Kim-1+, Ki67+). 
In moderate or severe IRI timecourse, Etv4 mRNA was strongly upregulated with a 72hr 
maximum at 30- and 70-fold over baseline. Mice with PT-specific expression of DN-Etv4 
showed increased tubular damage at 72h post-IRI compared to controls (Kim1 mRNA 2x, 
Kim1 protein expression 4x higher, p<0.01) with reduced tubular epithelial proliferation 
(14.2±9% vs. 32.9±2.8% KI67+ tubule cells, p<0.05).
Conclusions:    Etv4 is specifically induced in dedifferentiated proximal tubule epithelia 
after AKI. It is a novel positive regulator of epithelial cell proliferation and migration 
during kidney repair after AKI.
Funding: NIDDK Support
FR-OR100
Tubular Regeneration After Acute Kidney Injury Is Limited and Only 
Driven by Tubular Progenitors  Elena Lazzeri, Anna Julie Peired, Maria 
Lucia Angelotti, Francesca Becherucci, Duccio Lombardi, Laura Lasagni, Paola 
Romagnani.  Excellence Centre DENOTHE, Univ of Florence, Italy.
Background: Traditionally, AKI was considered as reversible because of the high 
regenerative capacity of the tubule. Despite this, AKI is associated with increased risk to 
develop CKD, suggesting an incomplete repair of the tubules. In addition, it is debated 
whether regeneration is mediated by differentiated tubular cells or a population of tubular 
progenitors.
Methods: We developed inducible transgenic Pax8-rtTA/tetO-cre/ROSA26-Confetti 
(Pax8/Confetti) mice to track all tubular cells and the PAX2.rtTA;tetO.cre;R26.Confetti 
mouse model (Pax2/Confetti) to track putative tubular progenitors. Administration of 
doxycyline at the 5th week of age drove the stochastic expression at single cell level of CFP, 
GFP, RFP, YFP, allowing to track Pax2+ or Pax8+ cells and their progeny. After 1 week of 
washout, mice underwent 30 min of unilateral ischemia followed by a 30 day reperfusion 
period. Inducible PAX8.rtTA;tetO.cre;R26.Fucci2 (Pax8/Fucci2) and PAX2.rtTA;tetO.
cre;R26.Fucci2 (Pax2/Fucci2) mouse models were used to study cell-cycle (mCherry in 
G1cells and mVenus in S/G2/M cells).
Results: Comparison of clonal analysis in confetti mice demonstrated that Pax2+ 
progenitors is the only population that undergoes clonal expansion after tubular injury, 
excluding involvement of other tubular cells. However, regeneration was limited, and the 
majority of lost tubular cells was not replaced. In addition, confocal microscopy and DNA 
content analysis by flow cytometry in Pax8 and Pax2/Fucci2 mouse models demonstrated 
that only Pax2+ progenitors complete mitosis, while other tubular cells that entered the cell 
cycle do not complete cytokinesis and undergo death or growth arrest.
Conclusions: In summary: 1. The tubule displays limited regenerative capacity; 2. 
Differentiated tubular cells enter the cycle but do not complete mitosis; 3. Only tubular 
progenitors undergo a complete cell division providing regeneration after injury. Taken 
together, these results provide an innovative explanation of the mechanisms of tubular repair 
and a suggestive hypothesis to explain the occurrence of CKD after AKI.
FR-OR101
Mitochondria-Targeting Peptide (SS-31, Bendavia®) Prevents Progression 
of Chronic Kidney Injury After Acute Ischemia  Hazel H. Szeto, Shaoyi 
Liu, Yi Soong, Surya V. Seshan.  Pharmacology and Pathology, Weill Cornell 
Medical College, New York, NY.
Background: It has been estimated that about 15% of patients who survive acute 
kidney injury (AKI) will advance to chronic kidney disease (CKD) characterized by 
tubulointerstitial fibrosis and glomerulosclerosis. We recently reported that mitochondria 
protection by SS-31 during ischemia mitigates microvascular rarefaction, inflammation 
and fibrosis (Am J Physiol 306:F970-F980, 2014). Here we report that delayed treatment 
with SS-31 can halt the progression of CKD.
Methods: Sprague-Dawley rats (n=40) were subjected to bilateral renal ischemia for 45 
min followed by 4 weeks of reperfusion. Surviving animals (n=27) were then randomized 
to SS-31 (2 mg/kg/day) or saline by osmotic pump for 6 weeks. Kidneys were harvested 
for histopathology. Sham animals did not undergo ischemia.
Results: Despite recovery of renal function within 1 week after ischemia, pronounced 
tubular dilation, interstitial inflammation, glomerulosclerosis, and tubulointerstitial fibrosis 
was seen at 4 weeks. Further increase in inflammation and fibrosis, accompanied by increase 
in TGFβ and TNFα, were observed by 10 weeks in saline-treated rats. Pronounced changes 
were observed in glomeruli, with extensive fibrosis and peri-glomerular infiltration of 
inflammatory cells. Glomerular endothelial injury is suggested by the large increase in vWF 
expression. Electron microscopy revealed stressed vacuoles in podocytes and flattened foot 
processes. Rats that were treated with SS-31 from 4 weeks did not show any progression of 
glomerular or tubular injury, and prevented the upregulation of TGFβ and TNFα. 
Conclusions: These results show that SS-31 can halt the progression of chronic kidney 
disease even when administered 4 weeks after the acute ischemic injury. SS-31 (Bendavia®) 
represents a novel paradigm for the treatment of CKD beyond approaches targeted at TGFβ.
Funding: Private Foundation Support
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Early Activation of Fibroblasts Is Required for Renal Protection and 
Regeneration After Acute Kidney Injury  Dong Zhou,1 Haiyan Fu,1 Roderick 
J. Tan,2 Youhua Liu.1  1Dept of Pathology, Univ of Pittsburgh, Pittsburgh, PA; 
2Dept of Medicine, Univ of Pittsburgh, Pittsburgh, PA.
Background: Acute kidney injury (AKI) is responsible for about 2 million deaths 
each year worldwide, and its incidence is rising. While the role of vascular, tubular and 
inflammatory injury in the pathogenesis of AKI is well established, whether interstitial 
fibroblasts play any role in this process is poorly characterized.
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Methods: To address this issue, we established moderate (20 min) and severe (30 
min) renal ischemia/reperfusion injury (IRI) models. Sonic hedgehog (Shh) signaling was 
inhibited by cyclopamine. Conditional knockout mice in which Shh was ablated in tubular 
epithelial cells were generated and mice were subjected to IRI.
Results: In both moderate and severe IRI, interstitial fibroblasts became activated, as 
illustrated by vimentin expression, as early as 1 hour after AKI. Fibroblast proliferation 
as assessed by Ki67 staining was detected in renal interstitium at 4 hours and reached the 
peak at 12 hours. This early activation of fibroblasts was mediated by Shh signaling, as Shh 
protein was rapidly induced at 1 hour after IRI and Shh induced fibroblast activation and 
proliferation in vivo. To investigate the role of tubule-derived Shh in mediating fibroblast 
activation and injury repair, we generated tubule-specific Shh conditional knockout mice 
(Ksp-Shh-/-) by mating Shh-floxed mice with Ksp-Cre mice. Mice with ablation of Shh in 
renal tubules exhibited normal phenotype under physiologic conditions, but displayed an 
increased level of serum creatinine and morphological injury at 1 day after IRI, compared 
with controls. This aggravated AKI in Ksp-Shh-/- mice was associated with a decreased 
vimentin and desmin expression, suggesting a beneficial role of fibroblast activation in 
this setting. Similarly, pharmacological blockade of Shh signaling by cyclopamine also 
aggravated serum creatinine and histological damages through inhibiting fibroblasts 
proliferation.
Conclusions: These studies suggest that fibroblast activation is an early event mediated 
by Shh signaling and plays an essential role in conferring reno-protection and injury repair 
in the setting of AKI.
Funding: NIDDK Support
FR-OR103
Endothelial Sphingosine 1-Phosphate Receptor 1 (S1P1) Is Necessary 
for Recovery from Ischemia-Reperfusion Injury (IRI) and Prevention 
of Fibrosis  Heather M. Perry,1 Amandeep Bajwa,1 Liping Huang,1 Hong 
Ye,1 Kevin Lynch,2 Mark D. Okusa.2  1Medicine, UVA, Charlottesville, VA; 
2Pharmacology, UVA.
Background: Progression to fibrosis after AKI may result from maladaptive repair 
processes and can potentiate kidney dysfunction. The endothelium is the keystone of 
vascular homeostasis and vascular insufficiency after AKI may result in progressive 
fibrosis. S1P1, a G-protein coupled receptor, is important for endothelial function and 
we hypothesize that endothelial cell (EC) S1P1 is necessary for recovery from AKI and 
prevention of fibrosis.
Methods: Tamoxifen inducible, EC specific, S1P1 knockout mice (iTie2CreERT2S1pr1fl/
fl; S1P1 ECKO) or control (iTie2CreERT2S1pr1wt/wt) mice were subject to unilateral IRI or 
sham operation for 24’ and mice were allowed to recover for 3 days. Tamoxifen was then 
administered i.p. daily for 5d followed by a nephrectomy of the un-operated kidney and 
mice were euthanized on day 9. Plasma was collected for creatinine (PCr) measurement 
and kidneys were prepared for histology to assess renal injury, fibrosis by picro-sirius red, 
detection of aSMA+PDGFRβ+ myofibroblasts by IF, and neutrophils and macrophages by 
flow cytometry. Total kidney tissue mRNA was measured by RT-qPCR.
Results: S1P1 ECKO mice had higher PCr levels compared to control mice (1.24 vs. 
0.38 mg/dL; p < 0.001 n = 5-6) on day 9 post IRI. S1P1 ECKO mice had increased tubular 
atrophy, a higher proportion of fibrotic area in the medulla and cortex (1.57 vs. 0.68 %; p 
< 0.05 n = 4-5), and increased density of interstitial myofibroblasts expressing COL1 and 
COL3 in IRI kidneys compared to controls. Leukocyte adhesion molecules Pecam-1, Icam1, 
E-selectin, and Vcam1 expression and the number of neutrophils and Ly6Clo macrophages 
were increased in IRI kidneys of S1P1 ECKO mice compared to control mice.
Conclusions: During recovery from IRI, S1P1 suppresses endothelial cell activation of 
leukocyte adhesion molecules and subsequent inflammation to prevent maladaptive repair 
and tubular atrophy in protection against fibrosis. This data suggests that pharmacological 
activation of EC S1P1 as a novel therapeutic strategy for preserving EC function during a 
critical period of recovery after AKI may prevent the progression to fibrosis.
Funding: NIDDK Support
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IL-4/13-Mediated Polarization and Proliferation of Renal Macrophages Are 
Essential for Recovery from Acute Kidney Injury  Bing Yao, Yinqiu Wang, 
Ming-Zhi Zhang, Raymond C. Harris.  Medicine, Vanderbilt Univ, Nashville, TN.
Background: Cytokines IL-4 and IL-13 play important roles in polarization of 
macrophages/dendritic cells to an M2 phenotype, which is important in the recovery 
process following acute kidney injury (AKI). Both IL-4 and IL-13 can activate JAK3/
STAT6 signaling.
Methods: Mice with selective DTR expression in proximal tubule (“DTR mice”) 
with or without IL-4 deletion were used for diphtheria toxin-induced AKI via a single DT 
injection. DTR mice with or without inducible deletion of both IL-4 and IL-13 (DTR:IL-
4/13flox/flox mice and DTR: UBC-Cre-ERT2: IL4/IL13flox/flox mice, tamoxifen treatment 2 
weeks before experiment) were also used. A selective JAK3 inhibitor, CP-690550, was 
given via mini-pump at a dose of 15 mg/kg/day.
Results: The effectiveness of CP-690550 was confirmed by decreased p-STAT6 levels 6 
days after DT injection. JAK3 inhibition led to more severe kidney injury, delayed recovery 
from AKI and development of more severe renal fibrosis, in association with increased 
levels of M1 markers (iNOS and CCL3) and decreased levels of M2 markers (arginase-1 
and CD206) in macrophages/dendritic cells. In DTR mice with inducible IL-4/13, both renal 
IL-4 and IL-13 levels were reduced after tamoxifen injection. Similar to JAK3 inhibition, 
with IL-4 and IL-13 deletion, macrophages/dendritic cells expressed increased M1 markers 
and decreased M2 markers. Although IL-4 deletion alone only led to moderately delayed 
recovery from AKI, deletion of both IL-4 and IL-13 led to more severe kidney injury and 
delayed recovery, persistent kidney injury (increased KIM-1 expression), and development 
of more severe renal fibrosis (Sirius red and Masson’s trichrome staining and increased 
expression of α-SMA and collagen I and IV).
Conclusions: These studies demonstrate that both IL-4 and IL-13 are required to 
effectively polarize macrophages/dendritic cells to an M2 phenotype and to promote 
recovery from acute kidney injury.
Funding: NIDDK Support
FR-OR105
Select ADAM17 Substrates Released from Proximal Tubular Cells Promote 
Progressive Fibrotic Kidney Disease  Eirini Kefalogianni, Muthu lakshmi 
Muthu, Venkata Sabbisetti, Benjamin D. Humphreys, Joseph V. Bonventre, 
Andreas Herrlich.  Renal Div, Brigham and Women’s Hospital, Boston, MA.
Background: The metalloprotease ADAM17 activates epidermal-growth-factor (EGF) 
ligands, tumor-necrosis-factor-alpha (TNFα) and other substrates by ectodomain cleavage 
of their pro-forms. Sustained EGF receptor (EGFR) activation in tubular cells is linked to 
injury-induced kidney fibrosis. We showed previously that ADAM17 hypomorph mice and 
mice with inducible proximal tubular- ADAM17 deletion are strongly protected against 
ischemia-reperfusion-injury (IRI)-induced fibrosis. We hypothesized that ADAM17’s role 
extends to other fibrotic kidney injuries and that only select ADAM17 substrates mediate its 
effect by sustaining EGFR activation and by potentiating its pro-fibrotic downstream effects.
Methods: We used ADAM17 hypomorph mice (A17ex/ex) and SLC34a1-Cre-ERt2/
ADAM17fl/fl mice (ADAM17 PTC-KO). Mice were subjected to severe bilateral IRI and 
unilateral ureteral obstruction (UUO). Human AKI and CKD urine samples were tested 
by ELISA. ADAM17 substrates were studied in primary tubular cells and tubular cell 
lines in vitro.
Results: ADAM17ex/ex and ADAM17 PTC-KO mice are also protected against 
UUO-induced fibrosis. This effect can be mimicked with a specific ADAM17 inhibitor 
which blocks its catalytic site (A17 pro-domain). Select EGFR ligands are significantly 
upregulated by IRI and UUO in mice, and also in urine samples of AKI and CKD patients. 
These specific EGF ligands have particularly pro-fibrotic and pro-inflammatory effects 
in primary tubular cells by sustaining EGFR and downstream pathway activation, as 
compared to other pro-repair EGF ligands. In vivo knockdown of specific pro-fibrotic 
ADAM17 substrates in tubular cells protects against injury-induced fibrosis. Finally, we 
detect evidence of activation of ADAM17-dependent pathways in human kidney biopsies 
of AKI and CKD patients.
Conclusions: Specific proximal tubule released ADAM17 substrates promote sustained 
pro-fibrotic EGFR activation and progressive kidney disease in mice and possibly humans. 
Mechanistic differences of molecular action explain why certain EGF ligands are pro-
fibrotic and others are pro-repair.
Funding: NIDDK Support
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Pericyte Ablation Leads to Acute Kidney Failure  Dario R. Lemos,1 Gabriela 
Campanholle,2 Ivan G. Gomez,1 Jeremy Stuart Duffield.1  1Molecular Discovery, 
Biogen; 2Pfizer.
Background: Pericytes (PCs) are tissue-resident mesenchymal progenitor cells 
embedded within the basement membrane of blood vessels. We recently showed that 
during nephrogenesis pericytes are critical in both vascular and epithelial maturation 
and patterning. Those data indicate that PCs are important for the maintenance of kidney 
homeostasis postnatally.
Methods: Diphtheria toxin was delivered in vivo, via intraperitoneal injection. Kidneys 
were collected and preserved for histology. Urine albumin was measured using Albuwell 
M kit (Exocell Philadelphia, PA). Urine and plasma creatinine levels were measured using 
creatinine Liquid reagents Assay (DIAZYME, San Diego, CA). Plasma albumin was 
measured using an Olympus au640 Chemistry Analyzer. Gene expression was measured 
by Taqman PCR, using pre-made assays (Life Technologies, Palo Alto, CA).
Results: PDGFRβ+ pericytes present in the adult kidney derive from FoxD1+ 
mesenchymal progenitor cells. Here we created a FoxD1-Cre; Rs26-iDTR mouse to study 
the effect of pericyte ablation in kidney homeostasis. We observed virtually complete 
depletion of PDGFRβ+ cells in the kidney, compared to the control group, after two 
days of daily intraperitoneal diphtheria toxin (DT) delivery without detectable variations 
in podocyte numbers or glomerular capillary structure. Significant decrease in vascular 
density, increased vascular cell proliferation and endothelial swelling was detected. This 
was associated with aberrant vacuolization, lipid accumulation, and injury of the proximal 
tubules, indicative of epithelial cell dysfunction. These observations were supported by 
finding elevated levels of plasma creatinine, blood urine nitrogen and albuminuria, markers 
of organ failure. Mice lacking pericytes progressed to rapid health deterioration and death by 
three days. Importantly, neither the number of macrophages nor the levels of inflammatory 
cytokines changed significantly during the treatment, ruling out a role for inflammation-
induced damage as the cause for progressive loss of kidney integrity.
Conclusions: Our data show that by supporting homeostasis, pericytes are essential 
for proper kidney function.
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Preferential Proliferation in Response to Injury by an Interstitial-Derived 
Collecting Duct Subpopulation  Joan Li,1 Jinjin Guo,5 Jill A. Mcmahon,2 
Andrew P. McMahon,2 Melissa H. Little.1,3,4  1Univ of Queensland, Brisbane, 
QLD, Australia; 2Keck School of Medicine of the Univ of Southern California, 
Los Angeles, CA; 3Murdoch Childrens Research Inst, Melbourne, VIC, Australia; 
4Univ of Melbourne, Melbourne, VIC, Australia; 5Univ of Southern California 
Keck School of Medicine, Los Angeles, CA.
Background: We have reported the incorporation of Wnt4-expressing interstitial cells 
into the developing collecting duct (CD) during early postnatal development. These cells, 
representing a distinct CD subpopulation, may play a specific role in CD repair.
Methods: Time-mated Wnt4GCE/+: R26tdTomato/+ females received Tamoxifen injection 
(25mg/kg bw) at E17.5. Male offspring (8-12 wks) were subjected to Unilateral Ureteral 
Obstruction (UUO) for 3 or 7 days. Mice were euthanized 3 or 7 days after UUO. Kidneys 
were collected and processed for immunofluorescence studies. Confocal images were 
analyzed and quantified using Imaris software.
Results: At 7 days after UUO the cortical CDs were severely dilated. This was 
accompanied by down-regulation and misdistribution of Aqp2 protein as well as up-
regulation of Wnt4 expression. Flattening of the CD epithelial cells and up-regulation of 
aSMA expression suggested epithelial-to-mesenchymal transition (EMT). Tdtomato+ cells 
within the CD represent a subpopulation derived from the interstitial Wnt4-expressing 
cells present at E17.5. At 7 days after UUO the percentage of Tdtomato+ cells within the 
CD increased significantly compared to control (37% vs 14%, p= 0.00001), while pHH3 
positivity was significantly higher in these cells at 7 days after UUO compared to control 
(4.6% vs 0.2%, p=0.03). The number of Tdtomato+ cells within the CD and the proliferation 
rate were not significantly different at 3 days after UUO compared to control.
Conclusions: In response to UUO damage, CD epithelium underwent EMT 
accompanied by up-regulation of Wnt4 expression. An interstitial-derived, Wnt4 expressing 
CD subpopulation showed preferential proliferation capacity compared to ureteric bud-
derived CD epithelial cells. These observations support previous work suggesting the 
presence of possible stem/progenitor cells within this compartment and CD plasticity 
and imply a distinct repair mechanism from that documented for nephron epithelial cells.
FR-OR108
Net Acid Excretion and Progression of CKD: Results from the Chronic 
Renal Insufficiency Cohort Study  Julia J. Scialla,1 John R. Asplin,2 Mirela A. 
Dobre,3 Alex R. Chang,4 James P. Lash,5 Chi-yuan Hsu,6 Radhakrishna Reddy 
Kallem,7 L. Lee Hamm,8 Harold I. Feldman,7 Jing Chen,8 Lawrence J. Appel,9 
Cheryl A. Anderson,10 Myles S. Wolf.11  1Duke Univ; 2Litholink Corp; 3Case 
Western Reserve; 4Geisinger Health System; 5Univ of Illinois Chicago; 6Univ of 
California San Francisco; 7Univ of Pennsylvania; 8Tulane Univ; 9Johns Hopkins 
Univ; 10Univ of California San Diego; 11Northwestern Univ.
Background: Higher diet-dependent acid load has been associated with faster CKD 
progression, but not using gold-standard measurements [net acid excretion (NAE)].
Methods: We measured NAE in 24h urines from 1000 CKD participants as urinary 
ammonia + titratable acidity (calculated from urinary phosphorus, creatinine and pH). 
Urinary bicarbonate (HCO3) was negligible. 19 samples with urine pH ≥7.4 were excluded. 
Urinary biomarkers (UUN and K) were used to calculate net endogenous acid production 
(NEAP), as previously published. We modeled risk of ESRD or 50% reduction in eGFR 
(n=290 events) over a median of 5y using Cox models with stratification by diabetes (DM).
Results: Higher NAE associated with greater intake of meat/fish/poultry and calories 
by questionnaire (each p<0.01) and independently with higher eGFR (p=0.01) and lower 
serum HCO3 (p<0.01). Higher NEAP associated with lower fruits and vegetables (p<0.01), 
but not meat/fish/poultry (p=0.7) or calories (p=0.2). Higher NEAP independently associated 
with lower HCO3 (p<0.01), but not eGFR (p=0.8). Unexpectedly, higher NAE associated 
with lower risk of renal events after adjustment (HR 0.91 per 10mEq higher NAE; p=0.04). 
The HR associated with NAE differed by DM. NEAP was not associated with higher risk 
in either group.
Conclusions: Higher NAE, but not NEAP, associated with lower risk of renal events 
in DM. This may be due to changes in renal ammoniagenesis, particularly in diabetic CKD.
Funding: NIDDK Support
FR-OR109
Meat Intake and Risk of End Stage Renal Disease in the Singapore Chinese 
Health Study  Quan Lan J. Lew,1 Tazeen H. Jafar,4 Hiromi Wai Ling Koh,2 
Jin Ai Zhen,3 Khuan yew Chow,3 Woon-puay Koh.4  1Singhealth Polyclinics, 
Singapore; 2National Univ of Singapore, Singapore; 3Health Promotion Board, 
Singapore; 4Duke NUS Graduate Medical School Singapore, Singapore.
Background: Although protein restriction is recommended as part of the management 
for chronic kidney disease, the evidence remains controversial. In addition, few studies have 
investigated the effects of different sources of protein on kidney disease.
Methods: We used data from the Singapore Chinese Health Study, a prospective cohort 
with 60, 198 Chinese adults aged 45-74 years at recruitment (1993-1998). Habitual diet 
information, including frequency and number of servings, was collected via a validated 
semi-quantitative 165-item food frequency questionnaire. Incident end stage renal disease 
(ESRD) was identified via record linkage with the nationwide Singapore Renal Registry 
up to 31 December 2012. Multivariable Cox proportional hazards models were used, 
with adjustments for total caloric intake, and other lifestyle factors and co-morbidities 
associated with ESRD.
Results: There were 951 participants with ESRD after a mean of 15.5 years of follow-
up. Total protein intake was weakly associated with increased risk of ESRD. Compared to 
the lowest quartile intake, the adjusted hazard ratio (HR) for those in the upper 3 quartiles 
combined was 1.23 [95% confidence interval (CI): 0.99-1.53]. Among the different sources 
of protein, red meat intake was associated with increased risk of ESRD in a dose-dependent 
manner; the HR (95% CI) for the fourth quartile compared to the lowest quartile was 1.45 
(1.19-1.77) (p<0.001 for trend). No statistically significant associations were found with 
intakes of other protein sources (poultry, fish, eggs, dairy products or legumes). Substituting 
one daily serving of red meat with the other protein sources significantly reduced the risk 
of ESRD by 51.9% to 66.3% (all P<0.01).
Conclusions: Red meat intake is associated with an increased risk of ESRD in the 
general population of Chinese origin. Replacing red meat intake with other sources of 
protein may reduce ESRD risk.
Funding: Government Support - Non-U.S.
FR-OR110
The Course of Acid Retention without Metabolic Acidosi as GFR Declines 
in CKD: Ten Year Follow Up  Nimrit Goraya,1,2 Jessica Pruszynski,4 Jan 
Simoni,3 Donald E. Wesson.1,2  1Internal Medicine, Baylor Scott and White 
Health, Temple, TX; 2Internal Medicine, Texas A and M, Temple, TX; 3Surgery, 
Texas Tech Health Sciences Center, Lubbock, TX; 4Biostatistics, Baylor Scott 
and White Health, Temple, TX.
Background: Patients with CKD 2 (eGFR 60-89 ml/min/1.73 m2) compared to CKD 1 
(eGFR < 90 ml/min/1.73 m2) due to macroalbuminuric hypertension-associated nephropathy 
have acid retention despite no metabolic acidosis but the contribution of reduced eGFR 
to acid retention is unknown.
Methods: We explored the role of reduced GFR in acid retention by re-assessing it 
after further GFR decline. Acid retention was determined by comparing observed to the 
expected increase in plasma [HCO3] in response to retained HCO3 (dose - urine excretion) 
eight hours after an oral NaHCO3 bolus (0.5 meq/Kg bw), assuming 50% body weight 
HCO3 space of distribution. Specifically, acid retention = [(retained HCO3/0.5 x body 
weight) – observed increase in plasma [HCO3] ] x (0.5 x body weight). CKD 2 (n=40) 
and CKD 1 (n=26) patients had blood pressure controlled with regimens including ACE 
inhibition and followed ten years.
Results: Although eGFR declined in both groups, eGFR was less preserved in CKD 
2 (73.5±6.1 to 51.4±4.4 ml/min/1.73 m2, p < 0.01) than CKD 1 (97.4±7.7 to 84.2±9.1 
ml/min/1.73 m2, p < 0.01). Neither group had or developed metabolic acidosis. Potential 
renal acid load (PRAL), a measure of dietary acid, was not different between CKD 2 vs. 
CKD 1 at baseline (60.4±19.4 vs. 62.9±14.5 mmol/day, respectively, p=0.56) or ten years 
(64.3±17.7 vs. 61.1±12.1 mmol/day, respectively, p=0.54) and ten year vs. baseline PRAL 
was not different for CKD 2 (p=0.19) or CKD 1 (p=0.76). Acid retention was higher in 
CKD 2 vs. CKD 1 at baseline (29.8±14.9 vs. 5.3±15.1 mmol, respectively, p < 0.01) and 
ten years (37.6±9.6 vs. 7.1±16.9 mmol, respectively, p < 0.01). Acid retention was higher 
at ten years in CKD 2 (p<0.02) but not in CKD 1 (p=0.44).
Conclusions: The data show that GFR reduction exacerbates acid retention in CKD 2 
patients with less well preserved eGFR but not in CKD 1 patients whose eGFR was better 
preserved, supporting the importance of reduced eGFR in mediating the acid retention 
of CKD.
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Urinary Sodium and Potassium Excretion and Risk of Developing Chronic 
Kidney Disease  Lyanne M. Kieneker,1 Ron T. Gansevoort,1 Rudolf A. de Boer,2 
Gerjan Navis,1 Stephan J.L. Bakker,1 Michel M. Joosten.1  1Internal Medicine, 
Nephrology, UMC Groningen, Netherlands; 2Cardiology, UMC Groningen, 
Netherlands.
Background: It is unclear whether dietary sodium and potassium intake are relevant 
to the development of chronic kidney disease (CKD) in the general population. Our aim 
was to examine the associations of urinary sodium and potassium excretion (UNaV and 
UKV resp.), as estimates of intake, with risk of developing CKD in the general population.
Methods: We studied 5,315 subjects free of CKD at baseline of the Prevention of Renal 
and Vascular End-Stage Disease (PREVEND) study, a prospective, population-based cohort 
of Dutch men and women aged 28-75 years. UNaV and UKV were measured in two 24-
hour urine specimens at baseline (1997-1998) and midway during follow-up (2001-2003). 
Incident CKD was defined as de novo development of creatinine+cystatin C-based estimated 
glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 and/or albuminuria >30 mg/24h.
Results: Baseline UNaV and UKV were 135 mmol/24h (interquartile range [IQR]: 
106-169 mmol/24h) and 70 mmol/24h (IQR: 57-85 mmol/24h), respectively. During a 
median follow-up of 10.3 years (IQR: 6.2-11.4 years), 872 subjects developed CKD. After 
multivariable adjustment for important covariables, no association was observed between 
UNaV and risk of CKD (hazard ratio per 50 mmol/24h decrement [1 standard deviation], 
1.03; 95% confidence interval, 0.93-1.13). Each 21 mmol/24h (1 standard deviation) 
decrement in UKV was significantly associated with a 16% higher risk of developing CKD 
(multivariable adjusted hazard ratio, 1.16; 95% confidence interval, 1.05-1.29; Figure 1). 
Sensitivity analyses in which CKD was defined by either eGFR or albuminuria alone, 
rendered essentially similar results.
Conclusions: Low potassium intake and not high sodium intake was associated with 
an increased risk of developing CKD in the general population.
Funding: Private Foundation Support
FR-OR112
Sedentary Behavior as a Risk Factor for CKD  Dominique Ferranti,1 Kate 
Lyden,3 Xiaorui Chen,1 Robert E. Boucher,1 G. Wei,1 Srini Beddhu.1,2  1U of 
Utah; 2VA SLC; 3UC Denver.
Background: Sedentary behavior (engaging in activities in the seated or lying position 
that barely raise the energy expenditure above resting level) is commonly confused with 
physical inactivity (lack of moderate/ vigorous physical activity (MVPA)). Sedentary 
behavior is an important risk factor for DM, HTN and obesity. It is unclear whether 
sedentary behavior is an independent risk factor for CKD. Therefore, we examined this 
in 5873 participants in whom intensity and duration of physical activities were measured 
objectively with an Actigraph accelerometer in the 2003-2006 National Health & Nutrition 
Examination Survey (NHANES) data.
Methods: Based on the number of counts/min recorded, sedentary (<100/min) and 
moderate/vigorous (≥ 2020/min) activity durations were defined and normalized to 60 
min. Logistic regression models adjusted for age, gender, race, education, smoking, 
alcohol use, lung disease and mobility limitations were used to examine the associations 
of sedentary and MVPA durations with the presence of CKD (defined as CKD-EPI eGFR 
< 60 ml/min/1.73 m2).
Results: The mean age was 49 ± 13 yrs. 52% were women and 9.5% were black. 7.4% 
had CKD. The mean sedentary duration was 34.0 ± 5.6 min/hr. MVPA duration was highly 
skewed with median (25th - 75th percentile) of 1.2 (0.5 – 2.3) min/hr. Prevalence of CKD 
by sedentary and MVPA durations are summarized in the figure. 
Adjusted for MVPA duration, demographics, CAD, CHF, lung disease and mobility 
limitations, each 5 min/hr ↑ in sedentary duration was associated with ↑ odds of CKD (OR 
1.20, 95% CI 1.09 -1.33) in a logistic regression model. This persisted even after adjusting 
for DM, HTN and obesity (OR 1.18, 95% CI 1.07 -1.31).
Conclusions: These results suggest that sedentary behavior is likely an independent 
risk factor for CKD and interventions that target sedentary behavior might slow the 
progression of CKD.
Funding: NIDDK Support
FR-OR113
The Metabolically Healthy Obesity Phenotype and Risk of Incident Kidney 
Failure  Alex R. Chang,1 Morgan Grams,2 Amanda Young,1 Holly J. Kramer,3 
H. Lester Kirchner.1  1Geisinger Health System; 2Johns Hopkins Bloomberg 
School of Public Health; 3Loyola Univ Medical Center.
Background: Little data exist on the association between obesity in the absence of 
metabolic abnormalities (metabolically healthy obesity) and renal outcomes.
Methods: Using data from 86,004 patients in the Geisinger Health System from 
2004-2014, we examined the risk of kidney failure (dialysis, transplant, or eGFR < 15 
ml/min/1.73m2) and eGFR decline >= 30% by categories of body mass index (normal 
18.5-24.9, overweight 25-29.9, obesity >= 30) and metabolic health (<2 of the following : 
triglycerides >=150, HDL cholesterol <40 in men, <50 in women, blood pressure >=130/85, 
and glucose >=100). Cox regression analyses were adjusted for demographics, smoking 
status, history of cardiovascular disease, and baseline eGFR.
Results: Only 10.6% of patients had normal BMI with 30.0% overweight, and 54.3% 
obese. Proportions of metabolically healthy individuals in normal, overweight, and obesity 
groups were 67.9%, 30.0%, and 20.0%, respectively. Over a median follow-up time of 6.0 
years, 1,376 patients developed kidney failure and 17,668 developed eGFR decline >= 
30%. Compared to metabolically healthy persons of normal BMI, metabolically healthy 
overweight and obese individuals had similar or lower risk for ESRD (overweight HR 
0.75, 95% 0.47-1.19;obese HR 0.77, 95% CI: 0.48-1.25). When examining eGFR decline 
>= 30% as the outcome, metabolically healthy overweight and obese individuals were at 
increased risk (overweight HR 1.08, 95% CI: 0.98-1.19; obese HR 1.45, 95% CI: 1.32-
1.59). Metabolically unhealthy persons had higher risk for ESRD and eGFR decline >= 
30%, with a similar risk regardless of BMI. (Figure) Relationships were similar using a 
competing risks model accounting for risk of death.
Conclusions: Metabolically healthy obesity is associated with eGFR decline >= 30% 
but not kidney failure.
Funding: Private Foundation Support
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The Metabolomic Signature of Diabetic Kidney Disease Predicts Diabetic 
Renal Disease Progression  Manjula Darshi,1,2 Loki Natarajan,2,3 Minya Pu,2,3 
Rintaro Saito,1,2 Kumar Sharma.1,2,4  1Center for Renal Translational Medicine, 
Univ of California, San Diego, La Jolla, CA; 2Inst of Metabolomic Medicine, 
Univ of California, San Diego, La Jolla, CA; 3Moores Cancer Center, Univ of 
California, San Diego, La Jolla, CA; 4Veteranls Administration, San Diego 
Healthcare System, La Jolla, CA.
Background: We recently published a metabolomic signature of diabetic kidney 
disease (MSDKD), indicative of mitochondrial dysfunction. Presently we determined 
the prognostic value for chronic kidney disease progression in diabetic patients from the 
longitudinal FinnDiane cohort.
Methods: 60 patients with mean 55 years (SD=9.6) age and mean diabetes duration 
27 years (SD = 11 years) were analyzed to predict eGFR. Predictors included baseline 
(BL) metabolites and clinicalvariables, BL eGFR, HbA1c, UACR, and diabetes duration. 
Principal component weights obtained from the MSDKD were designated as PCA score1 
and PCA score2. Linear (for continuous eGFR) and logistic (for dichotomous eGFR: > vs 
<= 3ml/min/1.73m2 per year) regression models were examined to determine associations 
between the PCA scores and eGFR outcomes.
Results: Baseline mean eGFR levels were 86.23 (26.67) mL/min/1.73m2, HbA1c were 
8.3% (SD 1.1), and UACR were 11 (SD 34.1) and follow up was 6.6 (SD 3.5) yrs. eGFR 
levels at follow up were 81.96 (SD 24.69) mL/min/1.73m2, and 25% (N=15) declined 
more than 3 mL/min/1.73m2 per year. Statistical modeling revealed that, after adjustment 
for baseline eGFR and follow-up interval, the PCA Score 2 (mean =0.4, SD=0.64) was 
a significant predictor of worse (i.e. lower) eGFR (coef.=-12.4, p=0). For dichotomized 
eGFR (> vs <3 mL/min/1.73m2 per year decline), the PCA score2 was the only independent 
predictor that was selected (odds ratio per SD increase =7.4, 95% CI 1.78-45.73, p=0.01) 
by the LASSO model. A model to predict follow-up eGFR using clinical variables alone 
had an AUC of 0.73 (95% CI 0.58-0.88); when score 2 was included, AUC increased to 
0.88 (95% CI 0.79-0.97).
Conclusions: We demonstrate that MSDKD is a strong independent predictor for 
kidney disease progression in type I and type II diabetes patients, and hence may serve as 
prognostic biomarker for CKD.
Funding: NIDDK Support, Veterans Administration Support
SA-OR001
FMO3 Allelic Variant 158K Affects Trimethylamine Metabolism, 
Disease Progression, and All-Cause Mortality in Patients with CKD 
Catherine K. Yeung,1,2 Cassianne Robinson-Cohen,1 Richard Newitt,1 Danny D. 
Shen,2 Allan E. Rettie,3 Bryan R. Kestenbaum,1 Jonathan Himmelfarb.1  1Kidney 
Research Inst, Div. of Nephrology, Univ of Washington, Seattle, WA; 2Dept of 
Pharmacy, School of Pharmacy, Univ of Washington, Seattle, WA; 3Dept of 
Medicinal Chemistry, School of Pharmacy, Univ of Washington, Seattle, WA.
Background: Elevated levels of circulating pro-atherogenic uremic toxins are 
implicated in the development of cardiovascular disease in chronic kidney disease (CKD) 
patients. Trimethylamine N-oxide (TMAO) is generated from diet and catabolized by 
intestinal flora to betaine and then to trimethylamine (TMA). TMA is rapidly metabolized 
by the hepatic enzyme flavin-containing monooxygenase 3 (FMO3) to TMAO, which 
accumulates in CKD. The FMO3 gene is highly polymorphic; up to 40% of individuals 
possess a non-synonymous variant.
Methods: We tested the association of FMO3 158K, the most common allelic variant, 
with plasma TMAO concentration and the TMAO/betaine ratio, CKD progression, and 
all-cause mortality in 339 participants from the Seattle Kidney Study (SKS), an ongoing 
clinic-based cohort study of CKD.
Results: Each additional minor allele at the 158K locus was associated with a 0.35 µg/
mL higher serum TMAO concentration (1.42, 1.97, 2.10 µg/mL for 0, 1, 2 minor alleles, 
respectively; p=0.02) and a 0.20 unit higher TMAO/betaine ratio (p=0.05). A greater 
number of minor alleles at the 158K locus was associated with faster rates of eGFR decline. 
Participants who had 0, 1 and 2 minor alleles at the 158K locus experienced average eGFR 
losses of 8%/year, 12%/year, and 14%/year, respectively (p for trend= 0.05). Compared 
to participants with the homozygous dominant genotype (G/G), heterozygous (G/A) and 
homozygous recessive (A/A) participants had a 1.94-fold and 2.24-fold higher risk of 
mortality (p for trend 0.04).
Conclusions: In summary, we demonstrate that common genetic variation within the 
metabolizing enzyme FMO3 is associated with altered TMA substrate catabolism, CKD 
progression, and mortality among CKD patients. Further elucidation of these relationships 
could have implications for personalized recommendations for diet modification in patients 
with CKD.
Funding: Other NIH Support - NCATS 1KL2RR025015-01, Private Foundation 
Support
SA-OR002
Association Between Mitochondria DNA Copy Number and Incident 
Chronic Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) 
Study  Adrienne Tin, Morgan Grams, A. Rosenberg, Foram N. Ashar, Josef 
Coresh, Dan Arking.  John Hopkins Univ, Baltimore, MD.
Background: Mitochondria play a key role in cellular energy production. Higher 
mitochondrial DNA copy number (mtDNA-CN) in peripheral blood has been associated 
with lower risk of diabetes and lower prevalence of microalbuminuria, both risk factors 
of chronic kidney disease (CKD). It is unknown whether mtDNA-CN is associated with 
incident CKD.
Methods: We estimated mtDNA-CN from 119 mtDNA single nucleotide 
polymorphisms (SNPs) genotyped using the Affymetrix 6.0 microarray. Incident CKD 
was defined as a composite outcome of (a) baseline estimated glomerular filtration rate 
(eGFR) ≥ 60mL/min/1.73m2 with a 25% drop to < 60mL/min/1.73m2, (b) CKD-related 
hospitalization, or (c) end-stage renal disease (ESRD) based on linkage to the US Renal 
Data System (USRDS). The association between quartiles of mtDNA-CN and incident 
CKD was evaluated using Cox regression.
Results: Among 9060 participants, those with higher mtDNA-CN had significantly 
lower prevalence of coronary heart disease and diabetes, and lower levels of C-reactive 
protein and white blood cell count. Baseline eGFR did not differ significantly by mtDNA-
CN quartiles. Over a median follow-up period of 19 years, 1459 participants developed 
CKD. Higher mtDNA-CN was associated with lower risk of incident CKD adjusted for 
age, gender, and race (quartile 4 vs. 1: hazard ratio [HR] 0.76, 95% confidence interval 
[CI]: 0.66-0.87, p for trend < 0.0001). This association persisted with some attenuation 
after further adjustment for risk factors of CKD, including prevalent diabetes, hypertension, 
and coronary heart disease, smoking, high sensitive C-reactive protein and white blood cell 
count (quartile 4 vs. 1: HR 0.89, 95% CI: 0.76-1.03, p for trend 0.03).
Conclusions: Higher mtDNA-CN is associated with lower risk of incident CKD 
independent of known risk factors of CKD and inflammation biomarker levels. Further 
research on modifiable factors influencing mtDNA-CN may lead to insight on the 
pathogenesis and prevention of CKD.
Funding: NIDDK Support, Other NIH Support - NHLBI
SA-OR003
Urinary EGF Predicts Composite Endpoints in Three Independent Chronic 
Kidney Disease Cohorts  Viji Nair,1 Li Zhu,2 Peter X.K. Song,3 Laura H. 
Mariani,1,4 Susan P. Steigerwalt,6 Jicheng Lv,2 Jennifer Joyce Hawkins,1 Hong 
Zhang,2 Matthias Kretzler,1 Wenjun Ju.1  1Medicine, Univ of Michigan, Ann 
Arbor, MI; 2Medicine, Peking Univ First Hospital, PKU Inst of Nephrology, 
Peking, China; 3Biostatistics, Univ of Michigan, Ann Arbor, MI; 4Arbor Research 
Collaborative for Health, Ann Arbor, MI; 5St. John Hospital and Medical 
Center, Detroit, MI.
Background: The nephrology community is in need of non-invasive biomarkers 
that can predict CKD progression and identify patients for targeted treatment better than 
estimated glomerular filtration rate (eGFR) and proteinuria. Our previously identified and 
validated epidermal growth factor (EGF) as an intrarenal marker for eGFR. The significant 
correlation of urinary EGF protein (uEGF) with intrarenal EGF mRNA and eGFR suggested 
that it can be a non-invasive biomarker for kidney function.
Methods: We used Cox proportional hazards models to evaluate the predictive value 
of uEGF on CKD outcome, defined as a composite of end stage kidney disease or 40% 
reduction of baseline eGFR, in the Clinical Phenotyping Resource and Biobank Core 
(C-PROBE), the Nephrotic Syndrome Study Network (NEPTUNE), and the Peking 
University First Hospital IgA Nephropathy (PKU-IgAN) cohorts with average of follow-
up period of 1.8-3.6 years. The goodness of fit and improved prediction ability of markers 
were assessed by likelihood ratio tests, C-statistics, and Akaike information criterion (AIC).
Results: Lower uEGF was associated with higher risk of reaching composite endpoints: 
multivariable-adjusted associations of uEGF with the hazard of progression to composite 
endpoints are 0.27, 0.29 and 0.53 in C-PROBE, NEPTUNE and PKU-IgAN cohort, 
respectively. Prediction of renal survival by eGFR and albuminuria was significantly 
improved by addition of uEGF to the model, with an increase of c-statistic from 0.75 to 
0.87, 0.74 to 0.80 and 0.71 to 0.75, in these cohorts.
Conclusions: uEGF shows promise as an independent risk predictor of CKD 
progression. Inclusion of uEGF significantly improved prediction of composite end points 
by eGFR and proteinuria in diverse populations worldwide with a wide range of CKD.
Funding: NIDDK Support, Pharmaceutical Company Support - Hoffmann-La Roche
SA-OR004
Normalization of Biomarkers to Urine Creatinine: Impact on CRIC Study 
Findings  Kathleen D. Liu, Dawei Xie, Sushrut S. Waikar, Xiaoming Zhang, 
Venkata Sabbisetti, Joseph V. Bonventre, Theodore E. Mifflin, Josef Coresh, 
Robert G. Nelson, Clarissa Jonas Diamantidis, Claudia M. Lora, Francis Perry 
Wilson, Edgar R. Miller, Jiang He, Jeffrey R. Schelling, Mahboob Rahman, 
Akinlolu O. Ojo, Paul L. Kimmel, Harold I. Feldman, Vasan S. Ramachandran, 
Chi-yuan Hsu.  For the NIDDK CKD Biomarkers Consortium.
Background: There is no standard approach to the reporting of urine biomarkers; some 
studies normalize to urine creatinine (UCr) concentration and others do not. Whether this 
influences findings is not well understood.
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Methods: Urine kidney injury molecule-1 [KIM-1], neutrophil gelatinase associated 
lipocalin [NGAL], N-acetyl-beta-D-glucosaminidase [NAG], and liver fatty acid-binding 
protein [LFABP] were measured in 2466 Chronic Renal Insufficiency Cohort participants. 
Cox models were used to examine the association between biomarkers and CKD 
progression, defined as halving of eGFR or incident ESRD. We compared results with and 
without normalization of biomarkers to UCr.
Results: Baseline mean eGFR was 44±18 mL/min/1.73 m2; median albuminuria was 53 
mg/g UCr (6-503). After adjustment for eGFR, albuminuria, as well as socio-demographic 
and clinical covariates, non-normalized KIM-1 and NAG were independently associated 
with CKD progression by quintile (Table) and continuous biomarker value analysis [HR 
per SD 1.16(1.05-1.28) and 1.14(1.04-1.25), respectively] but KIM-1/Cr and NAG/Cr were 
not. There were no independent associations between NGAL or LFABP and outcomes 
regardless of normalization. 
KIM-1 quintiles (pg/mL) Adjusted HR NAG quintiles (mU/mL) Adjusted HR
≤253 Referent ≤0.8 Referent
>253-522 0.93(0.66-1.31) >0.8-1.5 1.07(0.72-1.57)
>522-918 1.39(1.01-1.92) >1.5-2.5 0.93(0.64-1.36)
>918-1675 1.59(1.16-2.18) >2.5-4.7 1.48(1.02-2.14)
>1675 1.39(1.01-1.93) >4.7 1.48(1.01-2.15)
Conclusions: Normalization for UCr influences the associations of biomarkers with 
CKD outcomes. In theory, normalization controls for differences in urine concentration, but 
more studies are needed to better understand the impact on a variety of clinical outcomes. 
At minimum, researchers should state their approach a priori, measure UCr, and perform 
sensitivity analyses where the alternate approach is tested.
Funding: NIDDK Support
SA-OR005
Proton Pump Inhibitor Use Is Associated with Incident Chronic Kidney 
Disease  Benjamin Lazarus,1,2 Yuan Chen,1 Francis Perry Wilson,3 Josef Coresh,1 
Morgan Grams.1  1Johns Hopkins Univ, Baltimore, MD; 2Royal Brisbane and 
Women’s Hospital, Queensland, Australia; 3Yale Univ School of Medicine, 
New Haven, CT.
Background: Proton pump inhibitors (PPIs) are one of the most commonly used 
drugs worldwide, and have been linked to acute kidney injury and interstitial nephritis. 
We hypothesized that PPI use may also be associated with chronic kidney disease (CKD).
Methods: We followed 10,482 participants in the Atherosclerosis Risk in Communities 
study with an eGFR of ≥60mL/min/1.73m2 from a baseline visit (1996-1999) to December 
31, 2011. In primary analysis, we evaluated the association between baseline PPI use and 
incident CKD, using a validated definition of hospitalization and death related diagnostic 
codes. In sensitivity analysis, we assessed 1) PPI use as a time varying exposure, 2) an 
alternative outcome of reduced eGFR at follow-up (2011-2013), and 3) the risk of incident 
CKD in a cohort of respondents in 2006, stratified by PPI use in 2006 and at baseline. We 
evaluated histamine-2 receptor (H2) antagonist use as a negative control.
Results: Compared to non-users, PPI-users at baseline were more often white, obese, 
and taking antihypertensive medication. Baseline PPI use was associated with incident CKD 
in unadjusted (hazard ratio [HR], 1.45, 95% CI, 1.11, 1.90; P=0.006) and fully adjusted 
analyses (HR, 1.50, 95% CI, 1.14, 1.96; P=0.003). The association persisted when PPI 
use was modeled as a time-varying variable, and when reduced eGFR was used as the 
outcome. In the 2006 cohort, participants who reported PPI use at both baseline and 2006 
had the highest risk, followed by those who reported use at only one time point, followed by 
never-users (Figure). There was no significant association between baseline H2-antagonist 
use and incident CKD (P=0.2).
Conclusions: PPI use is an independent risk factor for CKD. Caution against 
unnecessary use is warranted.
SA-OR006
Underuse of Renin Angiotensin System Inhibitors and Other Medications 
in U.S. Patients with Advanced Chronic Kidney Disease Receiving 
Nephrologist Care: Results from the International CKDopps  Elodie Speyer,1 
Laura H. Mariani,1 Charlotte Tu,1 Lindsay Zepel,1 Celine Lange,2 Brian 
Bieber,1 Christian Combe,3 Antonio Alberto Lopes,4 Ziad Massy,5,8 Roberto 
Pecoits-Filho,6 Ronald L. Pisoni,1 Helmut Reichel,7 Benedicte Stengel,8 Bruce 
M. Robinson.1  1Arbor Research Collaborative for Health, USA; 2Biomedicine 
Agency, France; 3CHU Bordeaux, Univ de Bordeaux, France; 4Federal Univ of 
Bahia, Brazil; 5Ambroise Pare Univ Hospital, UVSQ, France; 6Pontificia Univ 
Catolica do Parana, Brazil; 7Nephrological Center Villingen Schwenningen, 
Germany; 8Inserm UMR1018, France.
Background: In the US, ~86% of incident ESRD cases are attributable to hypertension 
or diabetes. Guideline-directed medication use may help to slow CKD progression and 
lower ESRD incidence. We report early findings on use of key medication classes by CKD 
stage in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps).
Methods: CKDopps is a prospective cohort study of patients with eGFR<60 in random 
national samples of nephrology clinics in Brazil, France, Germany, and the US. Early 
data from CKDopps (excluding Brazil and Germany for now) were used to characterize 
medication usage.
Results: 2,621 patients were included from 39 French, and 17 US clinics. The median 
number of prescriptions ranged from 7-9. Statin use was 52% and aspirin use was 31-48%. 
RASi (ACEI or ARB) use for CKD Stage 3 and 4 patients was 72 and 77% in France, and 
51 and 35% in the US, respectively. Aldosterone blockade use was 3-6. Among diabetics, 
insulin use was lower in US (32%) than in France (48 and 57% for stage 3 and 4 patients, 
respectively), as was metformin use which was 30 and 7%, and 10 and 1%. For stage 4 
patients, sulfonylurea use was higher in the US (21%) than in France (8%).
Conclusions: These early results show large international differences in medication 
usage for diabetes and cardiovascular disease amongst CKD patients. Patients in US 
were much less likely to use RASi, metformin or insulin than in France. Early data from 
Germany and Brazil will be available by mid 2015. Further investigation should determine 
the reasons for these practice variations and their impact on CKD progression, survival, 
and other outcomes.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
SA-OR007
Albuminuria Changes and Subsequent Risk of End-Stage Renal Disease and 
Mortality  Juan Jesus Carrero,1 Yingying Sang,2 Alessandro Gasparini,1 Abdul 
Rashid Tony Qureshi,1 Kunihiro Matsushita,2 Johan Arnlov,3 Marie Evans,1 
Peter F. Barany,2 Bengt Lindholm,1 Morgan Grams,2 Shoshana Ballew,2 Carl 
Gustaf Elinder,1 Josef Coresh.2  1Renal Medicine and Baxter Novum, Karolinska 
Inst, Sweden; 2Johns Hopkins Bloomberg School of Public Health, Baltimore; 
3Medical Sciences, Uppsala Univ, Sweden.
Background: Albuminuria is used to stage chronic kidney disease (CKD). Changes in 
albuminuria during the course of disease may serve as early indicators of CKD progression 
and complications beyond eGFR, but the risk implications are not well understood in large 
clinical studies.
Methods: Observational study from the Stockholm CREAtinine Measurements 
(SCREAM) project, a laboratory data extraction of all citizens from the region of 
Stockholm, Sweden, with at least one serum creatinine during 2006-2011; 39802 individuals 
with repeated albumin to creatinine ratio (ACR) measurements were followed up until 
12/31/2012. ESRD risk after baseline (908 events) was related to fold-change in ACR during 
a baseline window of 1, 2 or 3 years. The secondary outcome was death (3890 events). 
Adjustment variables included demographics, comorbid history, laboratory assessments 
and medication, as well as first eGFR and ACR.
Results: The association between ACR changes and ESRD risk was strong and 
showed a largely linear dose-response relationship (Figure for 2-y baseline period). For 
example, 8-fold increase in ACR (e.g., from normal of 5 mg/g to microalbuminuria of 40 
mg/g) conferred ~5 fold higher risk of ESRD compared to stable ACR. The association 
was weaker for mortality but significant for ACR increases. The observed risk estimates 
were similar and consistent at 1-, 2- and 3-y time-window. 
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Conclusions: Increases in albuminuria were strongly and consistently associated with 
the risk of ESRD and mortality, suggesting their usefulness as a kidney outcome in clinical 
studies of CKD progression.
SA-OR008
Prevalence of Chronic Kidney Disease, Diabetes and Hypertension in 
Rural Tanzania Based of Different Methodologies  David W. Ploth,1 Virginia 
Fonner,2 Bruce Horowitz,3 Philip Zager,3 Francis Fredrick,4 Caroline M. West,2 
Michael D. Sweat.2  1Medicine, MUSC, Charleston, SC; 2Div of Family Services 
Research, MUSC, Charleston, SC; 3Medicine, Univ of New Mexico School of 
Medicine, Albuquerque, NM; 4Nephrology, Muhimbili Univ of Health and Allied 
Sciences, Dar es Salaam, Tanzania, United Republic of.
Background: Studies were conducted to explore the hypothesis that there are previously 
underappreciated and interrelated epidemics of chronic kidney disease (CKD), diabetes 
(DM), and hypertension (HTN) in rural Tanzania.
Methods: We initially assessed prevalence in a probability-based sample of 740 
subjects randomly sampled from households in Kisarawe District, TZ. Prevalence of DM 
was obtained by measuring HbA1c. Blood pressure was measured by AHA guidelines, 
and kidney function by serum creatinine in blood samples obtained at home interview. 
Estimation of glomerular filtration rate (eGFR) was computed with the CKD-EPI equation.
Results: 
NCD Diabetes Pre-Diabetes CKD Stage 3-5 Pre-HTN HTN 
Criteria HBA1C >6.5%
HBA1C > 5.9 
to < 6.5
eGFR < 60 ml/
min/1.73 M2
BP 120-
130/80-89 
mmHg
BP > 
140/90 
Prevalence 14.7% 30.5% 12.6% 40.0% 17.5%
Following the probability based screening of households, we assessed the same 
NCD’s in individuals who voluntarily presented for healthcare assessment in a community 
prevention center we established. We measured BP and assessed urine for glycosuria 
and proteinuria with dipsticks in 685 subjects self-selected from the community. We 
observed glycosuria in 3.6%, proteinuria in 8.1% and proteinuria and glycosuria in 1.8%. 
Hypertension was observed in 23.6 % and pre-hypertension in 34.9%. We observed a 
significant, direct relationship between increasing levels of BP and the prevalence of 
glycosuria and proteinuria (p < 0.05).
Conclusions: In summary we observed unexpectedly high and similar prevalence 
estimates for CKD, HTN and DM in a probability-based sample in rural Tanzania and from 
observations in a walk-in community clinic. The higher than expected prevalence of these 
NCD’s will likely contribute to rapidly accelerating rates of cardiovascular morbidity and 
mortality in these areas. Additional studies are desperately needed to address this problem.
Funding: Pharmaceutical Company Support - Dialysis Clinics Inc, Nashville, TN
SA-OR009
Race and the Association of Blood Pressure with Clinical Outcomes in U.S. 
Veterans with Chronic Kidney Disease  Csaba P. Kovesdy,1,2 Miklos Zsolt 
Molnar,1 Praveen Kumar Potukuchi,1 Elvira Gosmanova,1 Fridtjof Thomas,1 
Jun Ling Lu,1 L. Ebony Boulware,3 Keith C. Norris,4 Kamyar Kalantar-Zadeh.5 
1Univ of Tennessee Health Science Center, Memphis, TN; 2VA Medical Center, 
Memphis, TN; 3Duke Univ School of Medicine, Durham, NC; 4UCLA, CA; 
5UC, Irvine, CA.
Background: African American (AA) patients with CKD have poorer BP control, but 
it is unclear if the association of BP with outcomes is different in AA vs. white patients 
with CKD.
Methods: We examined the association of baseline SBP with mortality, slopes of eGFR, 
ESRD, incident coronary heart disease (CHD) and incident stroke in 308,920 US veterans 
(54,852 AA and 254,068 white) with CKD over a median follow-up of 4.9 years. We used 
Cox models and logistic regressions with interaction terms to explore race differences in 
associations of SBP categories (relative to SBP 130-139 mmHg in white patients) with 
outcomes, adjusted for demographic and socioeconomic characteristics, comorbidities, 
baseline eGFR, and medications.
Results: Compared to whites, AA patients were younger, less likely to be married, 
had lower income, more diabetes, but less CVD. Mean baseline SBP (SD) was 133 (17) in 
AA and 130 (16) mmHg in whites. Elevated SBP was associated with linearly higher risk 
of all outcomes in both race groups. Race and elevated SBP showed no interaction for the 
risk of mortality, ESRD, strokes, and CHD. The association of elevated SBP with steeper 
eGFR slopes was, however, 1.6 fold more pronounced in AA patients. 
Adjusted hazard/odds ratios 
(95%CI)
AA with SBP≥170 vs. 
white with SBP 130-
139 mmHg
White with 
SBP≥170 vs. white 
with SBP 130-139 
mmHg
P for 
interaction 
All-cause mortality 1.40 (1.27-1.55) 1.44 (1.36-1.54) 0.6
Incident ESRD 10.69 (8.94-12.78) 6.09 (5.07-7.30) 0.6 
Steeper slopes of eGFR (<-5 
ml/min/1.73m2/yr) 3.51 (3.13-3.93) 2.20 (2.04-2.38) 0.003 
Incident ischemic stroke 1.96 (1.62-2.36) 1.86 (1.62-2.15) 0.7 
Incident CHD 1.46 (1.11-1.91) 1.81 (1.48-2.20) 0.8 
Conclusions: Hypertension is associated with higher incidence of mortality, vascular 
events and ESRD in both AA and white patients with CKD. Elevated SBP may affect the 
progression of CKD more in AA patients.
Funding: NIDDK Support, Veterans Administration Support
SA-OR010
Association of eGFR Decline with Post Dialysis Mortality in Late-Stage CKD 
Patients Who Transitioned to ESRD  Keiichi Sumida,1 Miklos Zsolt Molnar,1 
Praveen Kumar Potukuchi,1 Fridtjof Thomas,1 Jun Ling Lu,1 Jennie Jing,2 
Vanessa A. Ravel,2 Melissa Soohoo,2 Connie Rhee,2 Elani Streja,2 Lawrence 
Agodoa,3 Kevin C. Abbott,3 Paul W. Eggers,3 Kamyar Kalantar-Zadeh,2 Csaba 
P. Kovesdy.1,4  1Univ of Tennessee Health Science Center, Memphis, TN; 2Univ of 
California, Irvine, CA; 3NIH, Bethesda, MD; 4VA Medical Center, Memphis, TN.
Background: The rate of eGFR decline is an independent risk factor for mortality in 
CKD. However,it is not known if pre-dialysis eGFR slopes are associated with outcomes 
after dialysis initiation.
Methods: We examined the association of pre-dialysis eGFR slopes with all-cause, 
cardiovascular (CV), and infectious mortality during two years after dialysis start in 
19,254 U.S. veterans who transitioned to ESRD between October 1, 2007-September 30, 
2011. eGFR slopes were categorized into four groups (<-10, -10-<-5, -5-<0, and 0+ mL/
min/1.73m2/year). Associations were examined in Cox models with adjustment for age, 
gender, race, comorbidities, and last pre-dialysis eGFR.
Results: Patients were 68.7±11.4 years old, 98% male, 29% black, and 72% diabetic. 
There were 5,226 all-cause, 2,751 CV, and 613 infectious deaths. Compared to eGFR 
slope of -5-<0 (42% of the total cohort), the adjusted hazard ratios [95%CI] for those with 
eGFR slopes of <-10, -10-<-5, and 0+ were 1.26 [1.17-1.35], 1.09 [1.03-1.15], and 1.04 
[0.93-1.16], respectively (Table). Similar trends were observed for the associations of eGFR 
slopes with CV and infectious mortality.
eGFR slopes
(mL/min/ 
1.73m2/
year)
Unadjusted
HR
(95% CI)
P
Value
Age, sex, 
race-Adjusted
HR
(95% CI)
P
Value
Fully 
Adjusted
HR
(95% CI)
P
Value
<-10 0.67 (0.63-0.72) <0.001
1.17 (1.09-
1.25) <0.001
1.26 (1.17-
1.35) <0.001
-10 – <-5 0.80 (0.76-0.85) <0.001
1.03 (0.98-
1.10) 0.24
1.09 (1.03-
1.15) 0.005
-5 – <0 1.00 (reference) N/A
1.00 
(reference) N/A
1.00 
(reference) N/A
0+ 1.42 (1.29-1.57) <0.001
1.53 (1.39-
1.69) <0.001
1.04 (0.93-
1.16) 0.47
Conclusions: Patients with rapid pre-dialysis eGFR decline have higher mortality risk 
in the first two years after dialysis start. The rate of eGFR decline in late CKD stages can 
be an additional predictor of mortality in incident dialysis patients.
Funding: NIDDK Support, Veterans Administration Support
SA-OR011
A Randomized Controlled Trial of Rituximab for Severe Idiopathic 
Membranous Nephropathy (IMN)  Pierre M. Ronco,1,2,8 Karine Dahan,1 
Hanna Debiec,2,8 Emmanuelle M. Plaisier,1,2,8 Marine Cachanado,3 Alexandra 
Rousseau,3 Laura Wakselman,3 Pierre-Antoine Michel,1 Fabrice Mihout,1 
Bertrand Dussol,4 Marie Matignon,5 Christiane I. Mousson,6 Tabassome 
Simon.3,7,8  1Nephrology and Dialysis, AP-HP, Hôpital Tenon, Paris, France; 
2UMR_S 1155, INSERM, Paris, France; 3Clinical Pharmacology and Unité de 
Recherche Clinique (URCEST), AP-HP, Hôpital Saint Antoine, Paris, France; 
4Nephrology and Transplantation, AP-HM, Hôpital de la Timone, Marseille, 
France; 5Nephrology and Transplantation, AP-HP, Hôpital Henri Mondor, 
Créteil, France; 6Nephrology and Transplantation, Centre Hospitalier Univ, 
Dijon, France; 7UMR_S1148, INSERM, Paris, France; 8UPMC, Sorbonne 
Univs, UPMC Univ Paris 06, Paris, France.
Background: IMN is a common cause of nephrotic syndrome. Anti-PLA2R antibodies 
occur in 70% of patients. No randomized controlled trial has evaluated rituximab efficacy 
and safety.
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Methods: Patients with biopsy proven IMN and persistent nephrotic syndrome after 6 
months despite Non Immunosuppressive Antiproteinuric Treatment (NIAT) were randomly 
assigned to 6-month therapy with NIAT and 375 mg/m2 of rituximab on days 1 and 8, or 
NIAT alone. At month 6, the primary end point was the rate of remission; the composite end 
point was defined as reduction of proteinuria > 50% and increase of serum albumin > 30%; 
secondary end points were proteinuria, serum albumin, serum creatinine, and PLA2R-Ab.
Results: 37 and 38 patients received NIAT with rituximab and NIAT alone. At month 3, 
rituximab decreased PLA2R-Ab rate and titer (P<0.001), and induced PLA2R-Ab depletion 
in 56 % of patients (P<0.001). At month 6, 13 (35 %) patients in the NIAT-rituximab group 
and 8 (21 %) in the NIAT group reached the primary end point (P=0.17); 15 (41 %) patients 
in the NIAT-rituximab group and 5 (13 %) in the NIAT group reached the composite end 
point (OR=0.22, 95% CI= [0.07; 0.70]; P=0.007). Serum albumin increased more with 
rituximab (P=0.029), without difference in proteinuria. Number of SAEs was comparable 
in both groups.
Conclusions: Rituximab induced immunological and clinical remission defined by a 
composite end point with a high safety profile (GEMRITUX ClinicalTrials.gov number).
Funding: Pharmaceutical Company Support - Hoffmann–La Roche, Private 
Foundation Support, Government Support - Non-U.S.
SA-OR012
Two-Year Outcomes of Patients with Idiopathic Membranous Nephropathy, 
Previously Randomized to Either Modified Ponticelli Regimen or to 
a Combination of Tacrolimus and Steroids  Krishan L. Gupta, Raja 
Ramachandran, Harbir Singh Kohli, Vivekanand Jha.  Nephrology, Postgraduate 
Insitute of Medical Education and Research, Chandigarh, India.
Background: The patients with idiopathic membranous nephropathy (IMN followed 
for 1 year are known to relapse more often with Tacrolimus than with cyclophosphamide 
either given with oral steroids. The present study aimed at finding the clinical outcome 
in patients randomized to a combination of Tacrolimus and oral prednisolone (TAC*) or 
Modified Ponticelli regimen (MPR) (cyclical cyclophosphamide and steroids) at 2 years.
Methods: IMN patients (n=70) with persisting nephrotic syndrome after at least 6 
months of ACEIs or ARBs or with complications of nephrotic syndrome were randomized 
to receive TAC* or MPR. The outcome of the study was remission at the end of 18 and 24 
months of initiating therapy. Definition: Complete remission (CR): 24-hour urine protein < 
500 mg/day with normal serum albumin (³3.5 gm/dl) and serum creatinine. Partial remission 
(PR): 24 hour urine protein ≥500 mg/day but <2 gm/day or <50% of baseline with normal 
serum albumin (³3.5 gm/dl) and serum creatinine.
Results: Of the 70 randomized patients followed for 18 months, 54 had follow-up 
for 24 months. Intention-to-treat analysis and remission at the end of 12 (n-70), 18 (n-70) 
and 24 (n-54) months are mentioned in Table. At the end of 18 and 24 months response 
rate with TAC* was lower compared to subjects treated with MPR (p-0.05). The adverse 
events were comparable in both the groups. PLA2R antibodies titer rose in all patients with 
relapse of nephrotic range proteinuria. 
12m
(TAC*)
(n-35)
12m
(MPR)
(n-35)
18m
(TAC*)
(n-35)
18m
(MPR)
(n-35)
24m
(TAC*)
(n-28)
24m
(MPR)
(n-26)
Remission 71.4 77.1 62.8 85.7 64.2 88.4
CR 54.2 51.4 54.2 65.7 42.8 69.2
PR 17.2 25.7 8.6 20 21.4 19.2
Resistant 28.6 22.8 37.2 14.3 35.7 11.6
Conclusions: Preliminary analysis suggests that at 2 years post randomization, TAC* 
is inferior to MPR in maintaining remission of NS (The total follow-up of 70 cases will 
be presented at ASN).
SA-OR013
Antibody Guided Therapy with Cyclophosphamide and Prednisone in 
Patients with Idiopathic Membranous Nephropathy  Anne-Els van de Logt, 
Julia M. Hofstra, Jack F. Wetzels.  Nephrology, Radboud Univ Medical Center, 
Radboud Inst for Health Sciences, Nijmegen, Netherlands.
Background: The discovery of anti-PLA2R antibodies provides options for 
individualized therapy in patients with idiopathic membranous nephropathy (iMN). We 
previously showed that the level of anti-PLA2R antibodies (aPLA2R) after 6-12 months 
of cyclophosphamide (CP) therapy predicted long-term outcomes (Bech, CJASN 2014). 
We present the first data of antibody guided therapy.
Methods: CP-therapy (combined with steroids) is started in patients with aPLA2R 
positive iMN and high risk of progression. aPLA2R are repeatedly monitored (IFT test) at 
8, 16, and 24 weeks after start of treatment. If antibodies become negative, CP is stopped 
and prednisone is tapered. Otherwise, therapy is continued after 24 weeks with MMF 
and prednisone.
Results: We treated 22 patients (characteristics in table 1). aPLA2R were negative 
in respectively 15/22 (68%) after 8 weeks, 17/21 (81%) after 16 weeks and 17/20 (85%) 
patients after 24 weeks of treatment. A partial remission of proteinuria (PCR < 3.0 gram/10 
mmol creatinine) was observed in 23 % (5/22), 44 % (8/18) and 67 % (10/15) of patients 
after 8, 16 and 24 weeks respectively. Thus far, 4 of the 17 patients (24%) developed an 
immunological relapse after 3.4 (1.6-6.7) months. All 4 patients have persistent or recurrent 
proteinuria. Thus far, 6 of 22 patients (27%) needed additional treatment; 1 because of 
renal failure, 3 because of persisting positive aPLA2R at 24 weeks and 2 patients because 
of an immunological and clinical relapse . At the end of follow-up 14 of the 22 patients 
(64%) were in clinical remission.
Conclusions: Monitoring of aPLA2R could allow individualized therapy in patients 
with iMN, thus shortening overall duration of CP therapy. Longer follow-up is needed to 
establish that the overall relapse rate is acceptable.
Gender (male/female) 16/6
Age (years) 58 (±14)
Serum creatinine (µmol/l) 117 (96-141)
Serum albumin (g/l) 21 (16-23)
Protein-creatinine ratio (g/10 mmol/Cr) 8.7 (5.5-13.3)
Previous immunosuppressive treatment 1/22 (5%)
Follow-up duration (months) 8.0 (4.9-11.3)
Values are expressed as number (percent), means ± SD and median [interquartile ranges].
SA-OR014
Is Serum PLA2R Monitoring Clinically Relevant in Idiopathic Membranous 
Nephropathy?  Harbir Singh Kohli, Raja Ramachandran, Vinod Sharma, 
Vivekanand Jha, Krishan L. Gupta.  Nephrology, PGIMER, Chandigarh, India.
Background: In this prospective study, we evaluated glomerular staining for PLA2R, 
serum anti-PLA2R antibodies, and its association with clinical response to therapy.
Methods: Adult IMN on immunosuppressive therapy were enrolled during Sept 2011 
to Nov 2014. PLA2R in glomerular deposits was assessed in fresh frozen tissue (Abcam 
ab80054) by confocal microscopy. Anti- PLA2R was estimated in serum before,6 and 12 
months after therapy (ELISA and IIF, EUROIMMUN, Germany). The patients were treated 
with either alternating monthly cycles of cyclophosphamide and steroids or tacrolimus with 
steroids. Definitions: complete remission: 24 hr urine protein <0.5gm on 3 occasions with 
normal serum albumin. Partial remission: urine protein >0.5 gm to 2 gm/day or <50% of 
baseline with normal serum albumin.
Results: A total of 86 patient, 52 males, 34 females, mean age 42.6 yrs were studied. 
Sixty three (73.25%) had glomerular PLA2R staining. Sixty (69.76%) showed elevated 
serum anti- PLA2R by ELISA and 56 (65.11%) by IIF. Fifty-two (60.45%) had both serum 
and glomerular positivity, 11 (12.79%) had isolated glomerular positivity, 8 (9.3%) had 
only serum antibodies and 15 (17.44%) had no detectable PLAR in serum or glomeruli. 
Of 86 who completed 12 months of follow-up, 58 (67%) responded to therapy: 38 (44%) 
had complete and 20 (23%) partial remission. Of 60 serum PLA2R Ab positive cases, 
40(67%) had remission and 20 (33%) were resistant to therapy. Thirty-seven (92.5%) with 
remission had negative PLA2R Ab at end of therapy and 18 (90%) resistant patients had 
elevated PLA2R Ab titer (p<0.001). There was parallel reduction in mean PLA2R Ab titre 
and 24 hr urine protein, 5 cases had clinico-serological discordance; 3 patients showed 
elevated 12-month anti-PLA2R levels but were in clinical remission - all of them relapsed 
over the next 2 months. On the other hand, 2 cases who tested negative for anti-PLA2R but 
continued to have nephrotic syndrome at 12 months, achieved remission by 14 months.
Conclusions: PLA2R antibodies and glomerular deposits are present in over two-thirds 
of IMN. PLA2R antibodies have an association with clinical response and the immunological 
recovery may precede clinical recovery.
SA-OR015
An Indirect Immunofluorescence Test (IFT) to Measure Thrombospondin 
Type-1 Domain-Containing 7A Antibodies (THSD7A-Ab) in Patients with 
Membranous Nephropathy (MN)  Elion Hoxha,1 Laurence H. Beck,2 Nicola 
M. Tomas,1 Christian Probst,3 David J. Salant,2 Rolf A. Stahl.1  1III. Medizinische 
Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 2Boston 
Univ School of Medicine, Boston Univ, Boston, MA; 3EUROIMMUN AG, 
Lübeck, Germany.
Background: THSD7A is a target antigen in MN. Measurement of THSD7A-Ab might 
be helpful for the diagnosis of MN and when making treatment decisions in these patients.
Methods: In this study we validated an IFT to detect THSD7A-Ab in 2 cohorts of 
patients with biopsy-proven MN. The presence of THSD7A-Ab was correlated with clinical 
parameters reflective of disease activity.
Results: Using the western blot (WB) technique, we identified 35 patients positive 
for THSD7A-Ab, 24 in the Hamburg cohort and 11 in the Boston cohort. 34 out of the 
35 cases resulted THSD7A-Ab positive in the IFT analysis. All 35 THSD7A-Ab positive 
patients were negative for PLA2R-Ab in both analyses. They were 56.5±17.0years old and 
14 (40%) were male. Proteinuria was 6.9±4.3g/day, serum creatinine 1.3±0.7mg/dl. In 22 
patients the time between serum collection and renal biopsy was less than 6 months and 
18 had no immunosuppression prior to serum collection. The control group consisted of 
671 patients, 555 with MN (120 of them PLA2R-Ab positive) and 116 with renal diseases 
other than MN (all of them PLA2R-Ab negative). All these patients were negative for 
THSD7A-Ab when measured with the IFT. In 30 randomly selected PLA2R-Ab positive 
patients sera were analyzed and resulted negative for THSD7A-Ab and positive for PLA2R-
Ab in IFT and WB analyses.For 4 THSD7A-Ab positive patients follow-up data of at least 
12 months could be analyzed. In 1 patient THSD7A-Ab disappeared and he experienced 
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remission of proteinuria. In 3 patients THSD7A-Ab persisted. 2 of them achieved remission 
of proteinuria, 1 had a relapse 3 months afterwards. The third patient had no remission of 
proteinuria during follow-up.
Conclusions: In this cohort of patients with MN the new IFT showed 97% sensitivity 
and 100% specificity for the detection of THSD7A-Ab compared to WB. A larger cohort 
of patients and their clinical follow up will be necessary to test its usefulness in patients 
with MN.
Funding: Government Support - Non-U.S.
SA-OR016
Melanocortin 1 Receptor (MC1R) Is Dispensable for the Proteinuria 
Reducing and Glomerular Protective Effect of Melanocortin Therapy 
Yingjin Qiao,1 Anna-lena Berg,2 Yan Ge,1 Zhangsuo Liu,1 Rujun Gong.1  1Brown 
Medical School; 2Lund Univ, Sweden.
Background: Evidence suggests that melanocortin therapy by using ACTH or non-
steroidogenic melanocortin peptides attenuates proteinuria and podocyte injury in animal 
models of glomerular diseases and induces remission of nephrotic syndrome in patients 
with a variety of proteinuric glomerulopathies, even those resistant to steroids. The 
underlying mechanism, however, remains elusive. This study aimed to validate the role of 
MC1R in mediating the beneficial effects of melanocortin therapy in glomerular diseases, 
as suggested by recent research.
Methods: The recessive yellow MC1R-mutant (MC1Re/e) and wild type (WT) mice 
were injured by lipopolysaccharide (LPS) or adriamycin (ADR) to develop podocytopathy 
and the effect of NDP-MSH, a non-steroidogenic melanocorin pan agonist, was tested. In 
patients with steroid-resistant nephrotic syndrome and nonfunctional MC1R mutations, 
the effect of ACTH therapy was evaluated.
Results: Following LPS or ADR insult, NDP-MSH attenuated proteinuria in WT 
and MC1Re/e mice to the same extent and ameliorated signs of glomerular injury and 
podocytopathy, including loss of podocyte markers, de novo expression of podocyte damage 
markers, and podocyte foot process effacement. In vitro in primarily cultured podocytes, 
LPS or ADR elicited apoptosis and podocyte hypermotility, and impaired the filtration 
barrier function of podocyte monolayers. These injurious effects were mitigated by NDP-
MSH to a similar degree in podocytes derived from WT and MC1Re/e mice. Moreover, two 
patients with congenital red hair and nephrotic syndrome due to idiopathic membranous 
nephropathy were enrolled and confirmed by gene sequencing to bear nonfunctional MC1R 
mutations. After failing multiple immunosuppressive regimens, including glucocorticoids, 
the patients were converted to synthetic ACTH monotherapy for 21 months and 8.5 months 
respectively (escalation and de-escalation included) and both achieved complete remission 
of proteinuria, denoting a steroid independent effect.
Conclusions: Melanocortin therapy confers a proteinuria reducing and podoprotective 
effect in proteinuric glomerulopathies via a mechanism independent of MC1R.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
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Clinical Genetic Testing for the C3 Glomerulopathies and Thrombotic 
Microangiopathies Using a High-Throughput Panel  Fengxiao Bu, Nicolo 
Ghiringhelli Borsa, Michael Jones, Erika Takanami, Carla Nishimura, Jill 
Johanna Hauer, Hela Azaiez, Elizabeth Ann Black-Ziegelbein, Nicole Meyer, 
Diana Kolbe, Yingyue Li, Kathy Frees, Michael J. Schnieders, Christie P. 
Thomas, Carla M. Nester, Richard J. Smith.  Univ of Iowa, Iowa City, IA.
Background: C3 glomerulonephritis (C3GN), dense deposit disease (DDD), atypical 
hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP) 
are rare diseases with phenotypic similarities and genetic commonalities. Variants in the 
CFH, CFI, CFB, C3, CFHR5, CD46, DGKE, ADAMTS13, THBD and PLG genes, and 
copy number variation of CFHR3-CFHR1 contribute to their pathogenesis and inform 
diagnosis and treatment options. To improve patient care, we developed a comprehensive 
genetic complement panel (GCP) to screen these genes. Herein we present our one-year 
experience using this panel in the clinical care of these patients.
Methods: 184 patients (37 with C3G and 147 with TMA) were studied using the 
GCP panel.
Results: Positive genetic diagnoses were provided in 43% of C3G patients and in 
41% of TMA patients. 
17 novel and 71 rare variants (minor allele frequency <1%) were identified, which 
we classified as pathogenic (11), likely pathogenic (12), or of uncertain significance (65). 
In C3G patients, the novel/rare variant load was increased in both C3 convertase (C3 and 
CFB) and complement regulator (CFH, CFI, CFHR5, and CD46) genes, consistent with a 
multifactorial genetic contribution to this disease. In TMA patients, the novel/rare variant 
load was increased only in complement regulator genes, consistent with an abnormality 
in regulation of the alternative complement pathway as a driving factor in this disease.
Conclusions: GCP panel provides a comprehensive and efficient genetic screen of 
complement genes. The observed differences in variant aggregation in patients with C3G 
and TMA refine our understanding of these diseases.
Funding: Private Foundation Support
SA-OR018
Amelioration of the Adverse Effects of Prednisolone by Rituximab 
Treatment in Adults with Steroid-Dependent Minimal-Change Nephrotic 
Syndrome  Yoei Miyabe, Takashi Takei, Yuko Iwabuchi, Takahito Moriyama, 
Kosaku Nitta.  Tokyo Women’s Medical Univ, Japan.
Background: We previously demonstrated the efficacy of single-dose 6-monthly 
rituximab infusions in 25 adults with steroid-dependent minimal-change nephrotic 
syndrome. Herein, we assessed the safety of rituximab treatment and its effect in 
ameliorating the adverse effects of prednisolone (PRED) in a larger study sample.
Methods: We treated 54 adult patients with four a single-dose 6-monthly infusions 
of rituximab (375 mg/m2 BSA per dose). We compared the adverse effects of PRED 
(osteoporosis, hypertension and diabetes mellitus) between the first rituximab infusion 
(baseline) and the end of the 24-month observation period. In addition, we examined the 
adverse effects of rituximab during the same period.
Results: The PRED dose was significantly lower at 24 months than at the baseline. 
The bone density was significantly higher at 24 months as compared to the baseline value 
(Z-score: -1.8 vs. -1.1; p < 0.05). Blood pressure at 24 months was significantly lower 
than that at the baseline (120.9/74.4 vs. 111.8/70.3 mmHg; p < 0.05). Eight patients with 
diabetes mellitus showed improved glycemic control at 24 months as compared to that at 
the baseline. There were no severe adverse effects of rituximab. However, mild infusion 
reactions occurred in 31 patients (57%). The frequency of the infusion reactions decreased 
significantly with every successive infusion.
Conclusions: Rituximab treatment was effective and safe in patients with steroid-
dependent nephrotic syndrome, allowed reduction of the PRED dose, and ameliorated the 
adverse effects of PRED. It may be preferentially used in patients at a risk of the adverse 
effect of PRED.
SA-OR019
Determining eGFR Trajectory Clusters in the NEPhrtoic Syndrome STUdy 
Network (NEPTUNE)  Laura H. Mariani,1,2 Jarcy Zee,2 Tony Wang,2 Viji Nair,1 
Wenjun Ju,1 Jonathan P. Troost,1 Debbie S. Gipson,1 Peter X.K. Song,1 Brenda 
W. Gillespie.1  1Univ of Michigan; 2Arbor Research Collaborative for Health.
Background: Non-linear changes in eGFR over time are common in nephrotic 
syndrome. Traditional outcomes (e.g. 50% eGFR decline) may not capture these changes. 
We identified patient clusters via eGFR longitudinal trajectory and associated clinical 
characteristics with the groups.
Methods: NEPTUNE is a multi-center, prospective cohort study of children and 
adults with >500mg/day of proteinuria, enrolled at the time of renal biopsy. eGFR was 
calculated using the CKD-Epi formula for participants ³18 yo and modified CKiD-Schwartz 
formula for those <18 yo. 367 patients with ³3 eGFR measurements were included. Each 
patient’s eGFR trajectory was estimated using Bayesian smoothing and a probability of 
non-linearity was calculated (Li, AJKD, 2012;59(4)). Quadratic regression coefficients 
from each trajectory were used in a clustering algorithm to identify distinct groups by 
minimizing within-cluster variance.
Results: Mean follow-up time was 26 mo. 25% (n=92) of the cohort had a trajectory 
with >50% probability of being non-linear and 10% (n=35) had a non-linearity probability 
>83%. The clustering algorithm produced five trajectory groups. Baseline mean eGFR 
(p<0.001) and median upcr (p<0.001) differed by cluster. Mean age was lowest in clusters 
1 and 5 (28 and 25 vs. 39, 39, 31; p=0.002). Race and sex did not vary by cluster. MN 
composed 13-20% of each cluster whereas FSGS composed 40 and 35% of clusters 2 and 
3, respectively (p=0.005). 
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Conclusions: This unique statistical approach identified clusters which describe 
individual eGFR trajectories. Non-linear trajectory groups had more young patients, 
higher eGFR and upcr. Further work is needed to determine whether trajectory clusters 
represent different underlying disease pathophysiology and to identify cluster predictors 
at the time of biopsy.
Funding: NIDDK Support, Other NIH Support - NCATS, ORDR
SA-OR020
The Role of Calcineurin Inhibitors in Early Treatment of Primary FSGS 
Louis-Philippe Laurin,1 Bethany J. Foster,4 A. Gasim,2 Caroline J. Poulton,3 J. 
Charles Jennette,2 Ronald J. Falk,3 Patrick H. Nachman.3  1Div of Nephrology, 
Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; 2Dept of Pathology 
and Laboratory Medicine, Univ of North Carolina at Chapel Hill, Chapel 
Hill, NC; 3Div of Nephrology and Hypertension, Univ of North Carolina at 
Chapel Hill, Chapel Hill, NC; 4Div of Nephrology, McGill Univ Health Center, 
Montreal, QC, Canada.
Background: In primary focal segmental glomerulosclerosis (FSGS), calcineurin 
inhibitors (CNIs) have primarily been studied in patients deemed resistant to glucocorticoid 
(GC) therapy. Little data is available about their use early in the treatment of FSGS. We 
sought to estimate the association between choice of therapy and end-stage kidney disease 
(ESKD) in idiopathic FSGS.
Methods: An inception cohort of patients with biopsy-proven primary FSGS diagnosed 
between 1980 and 2012. Time to ESKD between different early therapies was reported 
with time-dependent Cox regression hazard ratio (HR) with 95% confidence interval (CI).
Results: 458 patients were studied (332 NOS, 64 Tip, 62 Collapsing): age 40.7±20.8 
years; 45.6% Black; 48.7% female; follow-up time 92±94 months. 183 patients received 
no immunosuppression, 173 received GC alone, 90 were treated with CNIs ± GC and 12 
received other immunosuppressive agents. 
Multivariate determinants of ESKD HR (95% CI)
Immunosuppression
None
CNIs and/or GC
1
0.49 (0.28-0.86)
Age 1.00 (0.99-1.01)
Male sex 1.15 (0.76-1.73)
FSGS variant
NOS
Tip
Collapsing
1
0.21 (0.09-0.48)
1.71 (0.99-2.95)
Baseline eGFR <30 mL/min/1.73m2 4.28 (2.81-6.48)
Baseline proteinuria ≥3.5 g/d 1.25 (0.68-2.29)
Baseline serum albumin (per g/dL higher) 0.69 (0.53-0.90)
Baseline hypertension 1.33 (0.81-2.20)
Although not statistically significant, CNIs ± GC were associated with a lower 
likelihood of ESKD compared to GC alone [HR 0.42 (95% CI 0.15, 1.18)].
Conclusions: The use of CNIs as part of the early immunosuppressive regimen in 
primary FSGS may be associated with improved outcome, but their superiority over GC 
alone remains unproven.
SA-OR021
Living Donation Has a Greater Impact on Allograft Survival Than HLA 
Matching in Pediatric Renal Transplant Recipients  Matko Marlais,1 Alex 
J. Hudson,2 Laura Anne Pankhurst,2 Susan V. Fuggle,2 Stephen D. Marks.3 
1Univ College London, United Kingdom; 2NHS Blood and Transplant, United 
Kingdom; 3Great Ormond Street Hospital NHS Foundation Trust, United 
Kingdom.
Background: Living donor kidney transplantation accounts for around half of all 
paediatric (<18 years) renal transplant recipients (PRTR) and results in improved renal 
allograft survival, although there are no data comparing the effect of HLA-mismatching 
on outcomes. The UK 2006 Kidney Allocation Scheme prioritises children with good 
HLA mismatching (Level 1/2: 000 A,B,DR or [0 DR & £1 B]). The aim of this study was 
to determine the effect of HLA mismatching on deceased and living donor renal allograft 
outcomes in paediatric recipients.
Methods: Data were obtained from the UK Transplant Registry on all PRTR who 
received a donation after brain death (DBD) or living donor (LD) kidney-only transplant 
between 2000 and 2011. HLA A, B and DR mismatch were categorised into four levels and 
two groups. Data were fully anonymised and ethical principles adhered to.
Results: 1,389 paediatric renal transplant recipients were analysed; 807 (58%) received 
a DBD donor kidney. Using Cox proportional hazard regression modelling of renal allograft 
survival, the risk of graft failure is 1.55 times as likely in children who receive a well 
HLA-matched DBD kidney compared to those that receive a poorly HLA-mismatched LD 
kidney (p=0.01, 95% CI 1.11-2.18). This analysis accounts for survival improvements across 
transplant years. In both DBD and LD grafts, there was no difference in renal allograft 
survival in children who received a good or poorer HLA-mismatched transplant (p=0.16 
for DBD graft, p=0.55 for LD graft).
Conclusions: In children, well HLA-matched DBD renal transplants have inferior graft 
outcomes when compared with poorly HLA-matched LD grafts. It is difficult to justify 
preferentially waiting for an improved HLA-matched DBD kidney even when a poorer 
HLA-mismatched LD kidney transplant is available.
Funding: Government Support - Non-U.S.
SA-OR022
UK National Registry Study of Kidney Donation After Circulatory Death for 
Pediatric Recipients  Matko Marlais,1 Laura Anne Pankhurst,2 Alex J. Hudson,2 
Khalid Sharif,3 Stephen D. Marks.4  1Univ College London, United Kingdom; 
2NHS Blood and Transplant, United Kingdom; 3Birmingham Children’s Hospital, 
United Kingdom; 4Great Ormond Street Hospital, United Kingdom.
Background: Donation after circulatory death (DCD) is an important source of organs 
for kidney transplantation and evidence in adults suggests that similar graft outcomes 
are achieved to donation after brain death (DBD) kidney transplantation. There is very 
little evidence reporting the use of DCD kidneys in children. The aim of this study was 
to determine graft outcomes for children in the UK who have received a DCD kidney and 
compare these to outcomes for all renal transplants.
Methods: Data was collected on all kidney transplants performed for paediatric 
recipients (age <18 years) in the UK from the NHS Blood and Transplant registry from 
2000-2014 and separated into DCD, DBD and living donor kidney transplants. Data obtained 
included donor and recipient characteristics with 3-year graft survival and overall patient 
survival. All data were fully anonymised and ethical principles adhered to.
Results: 1773 kidney transplants were performed in children in the UK from 2000-
2014. 22 (1.2%) of these were from DCD donors, 955 (53.9%) were from DBD donors and 
796 (44.9%) were from living donors. 3-year graft survival was 95.5% in the DCD group, 
87.1% in the DBD group and 92.9% in the living donor group. Overall patient survival is 
100% in the DBD group, 98.7% in the DBD group and 98.8% in the living donor group. 
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In the DCD group the median time to asystole was 12.5 minutes and the median standard 
warm ischaemia time was 13 minutes. In the DCD group there was 1 case of primary non-
function and 5 cases of delayed graft function.
Conclusions: This is one of the largest studies reporting outcomes in children who 
receive DCD kidney transplants. In the post-2000 era children receiving a DCD kidney 
transplant have good graft survival at 3-year follow up, comparable to those receiving a 
kidney from a DBD donor or a living donor. This limited evidence encourages the use of 
selected DCD kidneys in paediatric transplantation as favourable graft outcomes can be 
achieved, and national DCD allocation algorithms may need to be amended in view of this.
Funding: Government Support - Non-U.S.
SA-OR023
Longitudinal Change in Neurocognitive Functioning in Pediatric Chronic 
Kidney Disease  Stephen R. Hooper,1 Matthew Matheson,2 Rebecca J. Johnson,2 
Arlene C. Gerson,2 Marc Lande,2 Susan R. Mendley,2 S. Shinnar,2 Debbie S. 
Gipson,2 Susan L. Furth,2 Bradley Warady.2  1UNC; 2CKiD Study Group.
Background: Few longitudinal data exist on the cognitive functioning of children 
with mild to moderate chronic kidney disease (CKD). We report longitudinal findings for 
the neurocognitive functioning of participants with mild to moderate CKD from the 48-
site CKiD Study, with a particular focus on identifying CKD-related variables predictive 
of change in cognition over time and progression to renal replacement therapy (RRT).
Methods: The sample comprised 2,009 assessments over a span of approximately 12 
years. Measures of IQ, attention, and parent ratings of executive functions were obtained. 
Joint longitudinal mixed models and time-to-event models with a shared random effect were 
used to examine the predictive value of CKD-related variables at study entry (glomerular 
diagnosis, age of CKD onset, iGFR, nephrotic proteinuria, elevated blood pressure, 
anemia) and over time (duration of disease, iGFR annual percent change) adjusting for 
baseline covariates (e.g., gender, maternal education), while simultaneously examining the 
association of neurocognitive decline with RRT.
Results: Median chronological age at study entry was 11.3 yrs; 56% Caucasian; 62% 
male. 33% had maternal education of a college degree. The median duration of CKD was 
7.9 yrs., with 62% of children having disease onset at birth. 21% had a glomerular diagnosis; 
average iohexol-based GFR was 52.3 ml/min/1.73m2. After adjusting, lower iGFR and 
elevated blood pressure at study entry were associated with declining Performance IQ. 
Lower iGFR and annual percent change in iGFR were associated with worse parent ratings of 
executive functioning. The shared parameter associating declining neurocognitive abilities 
with RRT showed Attention Variability to be related to progression to RRT.
Conclusions: Findings suggest that selected disease-related variables should 
trigger referral for neurocognitive assessment as children with lower iGFR and elevated 
blood pressure, and those with larger annual iGFR change may be at greatest risk for 
neurocognitive declines. Attention variability also was significantly associated with CKD 
disease progression to RRT.
Funding: NIDDK Support
SA-OR024
Biomarkers and Urinary Tract Infection in Infants  Sindri Valdimarsson, 
Sverker Hansson, Ulf I. Jodal.  Pediatric Uronephrologic Center, The Queen 
Silvia Children’s Hospital, Sahlgrenska Academy, Univ of Gothenburg, 
Göteborg, Sweden.
Background: Urine culture is needed to diagnose infants with urinary tract infection 
(UTI). Symptoms are nonspecific and urine biomarkers are a possible tool to improve the 
diagnostic accuracy minimizing the need for investigations and invasive procedures. The 
aim was to evaluate if urine biomarkers can aid in the diagnosis of UTI.
Methods: This is a prospective study of infants with first UTI. Urine biomarkers were 
measured in infants with UTI and in a control group of children with fever from other 
causes. Measured urine biomarkers were Kidney injury molecule 1, Clara cell protein, 
Retinol binding protein, Neutrophil gelatinase associated lipocalin, high sensitive C-reactive 
protein, Interleukin-1b, Interleukin-6 and Interleukin-8 (IL-8); all were adjusted for urine 
creatinine(cr).The area under the ROC curve (AUC) for each biomarker was compared 
for children with UTI versus children with fever without UTI; the optimal cutoff level for 
equal weight on sensitivity and specificity was determined.
Results: 108 infants with UTI, 59 boys (mean age 2.7 months) and 49 girls (mean age 
4.0 months) and a control group of 64 patients with fever without UTI (23 girls and 41 
boys) were included. The biomarkers NGAL/cr and IL-8/cr were superior in differentiating 
between children with and without UTI. AUC for NGAL/cr was 0.98 and a cutoff value 
of 233 had 96.3% sensitivity and 100% specificity. AUC for IL-8/cr was 0.97 and a cutoff 
value of 486 had 91.7 % sensitivity and 95.3% specificity. 
Conclusions: This prospective study shows that the urine biomarkers NGAL and IL-8 
had high sensitivity and specificity for the diagnosis of UTI in infants. Infants with fever 
and a low NGAL/cr value were highly unlikely to have a UTI.
Funding: Government Support - Non-U.S.
SA-OR025
Phospholipase A2 Receptor Autoantibodies in Pediatric Membranous 
Nephropathy  Rebecca Kirkwood-Wlison,1 Maryline Fresquet,1 Nicholas 
J. Webb,2 Paul E. Brenchley,3 Rachel Lennon.1,2  1Wellcome Trust Centre 
for Cell-Matrix Research, Univ of Manchester, United Kingdom; 2Dept of 
Paediatric Nephrology, Royal Manchester Children’s Hospital, United Kingdom; 
3Manchester Inst of Nephrology and Transplantation, United Kingdom.
Background: Membranous nephropathy (MN) is the commonest cause of nephrotic 
syndrome in adults, with most cases being primary, or autoimmune in nature. Understanding 
of MN advanced with the discovery of phospholipase A2 receptor (PLA2R) as the target 
autoantigen and with the detection of circulating autoantibodies in the sera of adult patients. 
In the pediatric population, MN is rare and often presents with persistent, steroid-resistant, 
proteinuria and is diagnosed by typical histological features on renal biopsy. In this study, 
we describe the clinical phenotype, renal histological analysis, anti-PLA2R status, and 
autoantibody binding in 6 children with biopsy-proven PMN treated at the Royal Manchester 
Children’s Hospital over the past 7 years.
Methods: We carried out phenotypic characterisation of patients, determination of anti-
PLA2R status by ELISA, anti-PLA2R Ig subclass analysis and histological characterisation 
of renal biopsies. Anti-PLA2R binding was determined by comparing autoantibody 
reactivity to recombinant fragments of the PLA2R under denatured and native conditions.
Results: Determination of anti-PLA2R status revealed 50% of children were 
seropositive. Seropositivity was associated with a severe clinical phenotype with nephrotic 
syndrome with renal impairment and IgG4 was the predominant subclass. Seronegative 
patients presented with asymptomatic proteinuria. Autoantibody reactivity patterns to 
recombinant fragments of the PLA2R, differed with clinical phenotype at presentation.
Conclusions: Here we report, for the first time, a series of 6 children with biopsy-
proven MN. We demonstrate a correlation between clinical phenotype and anti-PLA2R 
status and evaluate autoantibody-PLA2R binding in the paediatric MN population. Our 
results suggest that minor, or alternative, epitopes exist within the PLA2R which may be 
responsible for autoantibody binding in paediatric MN.
SA-OR026
APOL1-Associated Glomerular Disease in African-American Children in 
the CKiD and NEPTUNE Cohorts  Derek Ng,1 C. Robertson,2 C. Gillies,2 
Sophie Limou,3 Robert Woroniecki,4 Kimberly J. Reidy,5 Sangeeta R. Hingorani,6 
Keisha L. Gibson,7 Christine B. Sethna,8 Cheryl Ann Winkler,3 Jeffrey B. Kopp,9 
Susan L. Furth,10 Bradley Warady,11 John R. Sedor,12 Frederick J. Kaskel,5 
M. Sampson.2  1Johns Hopkins; 2U of Michigan; 3NCI; 4Stony Brook Univ; 
5Montefiore Med. Center; 6U of Washington; 7U of North Carolina; 8Cohen 
Children’s Med Center; 9NIDDK; 10Children’s Hosp of Philadelphia; 11Children’s 
Mercy Hosp; 12Case Western Reserve.
Background: Little is known about APOL1 associated nephropathy in children. This 
study aimed to describe characteristics and longitudinal outcomes in African-American 
children with glomerular disease, stratified by APOL1 risk genotype in the Chronic Kidney 
Disease in Children cohort (CKiD) & the Nephrotic Syndrome Study Network (NEPTUNE).
Methods: Enrollment criteria for CKiD was age 1-16, diagnosis of CKD, & estimated 
glomerular filtration rate (GFR) of 30-90 mL/min. NEPTUNE subjects were enrolled with 
suspected primary nephrotic syndrome, proteinuria, >0.5g/day, & clinically indicated 
biopsy. 56 CKiD subjects with glomerular disease & 48 NEPTUNE pediatric subjects were 
included here (all African-American). APOL1 was directly genotyped and subjects were 
classified as low risk (LR, 0 or 1 risk alleles) or high risk (HR, 2 risk alleles). All analyses 
were performed under the recessive model; LR vs HR subjects. By APOL1 genotype, odds 
of prematurity and eGFR & proteinuria over time were modeled.
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Results: All subjects were of similar age (12 to 15 yrs). HR subjects in both cohorts 
had a lower baseline GFR by about 20 ml/min. The combined cohort demonstrated a 
significantly increased odds of prematurity in HR subjects (OR: 4.57; 1.4-15.5). NEPTUNE 
HR subjects had 15% decline in GFR per year, comparable to that seen in all CKiD subjects, 
independent of genotype. LR NEPTUNE subjects had no eGFR decline (3% per year).
Conclusions: HR genotype was associated with higher odds of prematurity, suggesting 
an interaction between the APOL1 HR genotype and prematurity in the development of 
pediatric glomerular disease and subsequent CKD. NEPTUNE children with the HR 
genotype had a similar decline in eGFR as CKiD subjects.
Funding: NIDDK Support
SA-OR027
Comprehensive Approach to Understand Human Renal Development Based 
on the Identification of Responsible Genes for CAKUT  Akemi Shono, Naoya 
Morisada, Kandai Nozu, Kazumoto Iijima.  Pediatrics, Kobe Univ Graduate 
School of Medicine, Kobe, Hyogo, Japan.
Background: Although regenerative medicine using the pluripotent stem cells holds 
promise of the treatment for the renal failure, the complexity of the structure composed of 
diverse cell types makes the difficulty in the establishment of the differentiation protocol 
into renal nephron. Towards the comprehensive understanding of the molecular network 
underlying human renal development, this study aims to identify responsible genes for 
congenital anomalies and the kidney and urinary tract (CAKUT) and reveal the molecular 
mechanism of pathogenesis.
Methods: Two hundred six CAKUT cases including 115 cases from 105 families of 
syndromic CAKUT and 91 cases from 82 families of non-syndromic CAKUT together with 
some indistinguishable cases from CAKUT, were collected in agreement with participants, 
which was approved by the ethical committee at Kobe University. Genomic DNA samples 
were analyzed by the next-generation sequencing (Illumina exome and Agilent custom 
panels) in combination with the conventional Sanger sequencing and/or the DNA microarray 
subsequent to the phenotype classification based on the clinical manifestation.
Results: Responsible genes in 62 cases from 44 families were identified. The phenotype 
classification assisted to detect the reported responsible genes including PAX2, EYA1, 
HNF1B, UMOD, OFD1, SALL1 and CHD7 by Sanger sequencing, and the next-generation 
sequencing powerfully enabled us to identify responsible/candidate genes including PAX2, 
UPK3A, RET, FRAS1 and EP300 which were unpredictable from the clinical phenotype. 
To clarify the molecular mechanisms of candidate genes, further experiments including in 
vitro and in silico assays would be required.
Conclusions: These results would be significant to understand the network of disease-
associated genes and the molecular mechanism underlying the human renal development, 
and might give us a future perspective for the regenerative medicine.
Funding: Government Support - Non-U.S.
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A Randomized Study of Cholecalciferol Supplementation in Incident 
Hemodialysis Patients – Preliminary Evaluation After 2 Years 
Cristina Jorge,1,2,5 Patrícia Matias,1,2,5 Pedro Bravo,3 Clara Mil-homens,4 
Cecília Silva,4 Pedro M. Ponce,4 Carlos M.P.C. Oliveira,3 Célia Gil,1,2,5 Manuel 
A. Ferreira.1,2,5  1Nephrocare Vila Franca de Xira, Portugal; 2Dialverca, 
Portugal; 3Nephrocare Almada, Portugal; 4Nephrocare Lumiar, Portugal; 
5NIDAN, Portugal.
Background: Studies have shown that vitamin D deficiency is associated with 
cardiovascular (CV) risk factors, morbidity and mortality in uremic patients (pts). Our 
aim is to prospectively assess the safety and efficacy of vitamin D (cholecalciferol) 
supplementation in incident HD pts and to compare the clinical results with a control group 
supplemented with placebo.
Methods: We evaluated 108 (66% M) pts in group A (GA) under VIT D 20 000 U/wk, 
and 95 (67% M) pts in Group B (GB) on placebo, matched in age, (mean 66 and 65 years), 
BMI (mean 25,7 and 26,3 kg/m2) respectively, etiology of renal disease and the presence 
of comorbidities such as HTN, arrhythmia, peripheral vascular disease and cancer. The 
prevalence of DM (42 vs 57%), ischemic heart disease (18 vs 32%) and cerebrovascular 
disease (16 vs 27%) was higher in GB. A follow-up of 12 and 24 months (m) was attained 
respectively in 67 and 18 pts in GA vs 60 and 21 pts in GB.
Results: The basal levels of 25(OH)VitD3 were similar in the two groups (median 11 
ng/mL) and significantly increased at 12m in GA (30 vs 11 ng/ml in GB; p<0,001) and at 
24m (38 in GA vs 15 ng/ml in GB; p<0,001). Laboratory evolution (Ca, P, PTH, bAP, Hb, 
CRP or albumin), was similar in both groups. There was difference in the Erythropoiesis 
Resistance Index (ERI) (mcg/kg/wk/g/dl) at T0 (GA=0,034 > GB=0,023, p=0,03) and at 
24M (GA=0,010 < GB=0,022, p=0,01). No differences in the evolution of pulse pressure, 
left ventricular mass index or vascular calcifications were observed. The leading causes 
of hospitalization were CV and infectious, similar in both groups. There were 18 (16.7%) 
deaths in GA and 12 (12.6%) in GB (Log rank=0,752; p=NS, Kaplan-Meier). Treatment 
with antihypertensive drugs, phosphate binders, active vitamin D, or cinacalcet was similar 
in both groups.
Conclusions: Cholecalciferol administration at a dose of 20 000 U/week was safe 
and permitted a significant increase of vitamin D levels and a decrease of ERI in the 
supplemented group at 24M.
SA-OR029
Levocarnitine Improves Cardiac Function in Hemodialysis Patients with 
Left Ventricular Hypertrophy  Masanori Abe, Noriaki Maruyama, Tetsuya 
Furukawa, Kazuyoshi Okada.  Nephrology, Hypertension and Endocrinology, 
Nihon Univ School of Medicine, Tokyo, Japan.
Background: Levocarnitine deficiency in hemodialysis (HD) patients is common. 
This may contribute to clinical disorders, including cachexia, erythropoiesis stimulating 
agent resistant anemia,and glucose intolerance, muscle weakness, and myopathy as well 
as to intradialytic symptoms such as muscle cramps, hypotension, and cardiac arrhythmia. 
Although the effect of levocarnitine therapy on uremic anemia has been studied in small 
trials, its effects on cardiac function remain unclear.
Methods: This prospective, open-label, randomized, parallel, controlled, multi-center 
trial examined 222 HD patients who were randomly assigned to an oral levocarnitine therapy 
group (n = 110) or a control (no levocarnitine therapy) group (n = 112). Patients were 
monitored for 12 months during levocarnitine treatment (administered orally 20 mg/kg/
day) or control. The primary endpoint was cardiac function measured by echocardiography. 
The secondary endpoints were clinical parameters and identification of factors that predict a 
favorable response to levocarnitine therapy. Echocardiographic parameters were measured 
at baseline and after 6 and 12 months of therapy.
Results: A total of222 patients were randomly assigned, of whom 148 patients 
(levocarnitine group, n = 75; control group, n = 73) were analyzed. The ejection fraction 
values increased from 54.0±5.8% at baseline to 56.0 ± 6.1% after 6 months (p<0.001) to 
58.1±5.6% after 12 months (p<0.0001) in the levocarnitine group, while no significant 
changes in ejection fraction were observed in the control group. Furthermore, left ventricular 
mass index (LVMI) and N-terminal probrain natriuretic peptide levels were significantly 
decreased throughout the study in the levocarnitine group. Multivariate analysis revealed 
that LVMI was an independent predictor of improvement in ejection fraction following 
levocarnitine therapy. Subgroup analysis revealed that responders to levocarnitine were 
patients with left ventricular hypertrophy (LVH).
Conclusions: Levocarnitine therapy is useful for hemodialysis patients with LVH; 
these patients may benefit from such therapy, with amelioration of cardiac function and 
mitigation of LVMI.
SA-OR030
Predictive Ability of Self-Rated Health and Symptom Burden for Mortality 
in Hemodialysis  Donal J. Sexton,1 Aoife C. Lowney,2 Conall M. O’Seaghdha,3 
Sinead Kinsella,4 Peter J. Conlon.3  1Medicine, HRB Clinical Research Facility, 
NUIGalway, Galway, Ireland; 2Palliative Medicine, Marymount Hospice, Cork, 
Ireland; 3Nephrology, Beaumont Hospital, Dublin, Ireland; 4Renal Medicine, 
Cork Univ Hospital, Cork, Ireland.
Background: Little is known about the ability of self-rated health to predict mortality 
in hemodialysis.
Methods: A prospective cohort study in hemodialysis (N=362). The Euro Quality of 
Life Questionnaire (EQ5D), the Palliative Care Outcome Scale Renal (POS-S Renal) and 
the participant self-rated health (EQ visual analogue scale: EQVAS) were used to assess 
HRQOL, symptom burden and self-rated health. Participants were followed from instrument 
completion to death or study end.
Results: Over a median (25th-75th centile) of 2.6 (1.41-3.38) years, 32% (N=116) of 
participants died. With competing risks survival analysis factors most notably associated 
with mortality adjusted hazard ratio (95%CI) included: higher symptom burden 2.4 (1.3, 
4.3) P=0.004 (highest tertile), lower HRQOL 2.6 (1.3, 5.3) P=0.01 (lowest tertile), lower 
self-rated health 2.7 (1.4, 5.2) P=0.004 (lowest tertile). Answering ‘Yes’ to the questions: 
“problems with mobility?” 2 (1.1, 3.3) P=0.01, or “problems with usual activities?” 2.1 
(1.4, 3.3), P<0.001. 55% of those aged > 60 years reporting problems with either self care, 
mobility or daily activities in this study died over a mean (SD) of 2.1 (1.1) years, compared 
to 18% over 2.5 (1) years in those reporting ‘no’ to these questions, P<0.001. After age 
adjustment area under the receiver operating curves (AUC) (95%CI) for mortality were: 
0.71 (0.63, 0.80) for symptom burden, 0.76 (0.68, 0.84) for HRQOL and 0.71 (0.62, 0.79) 
for self-rated health.
Conclusions: Age adjusted participant-rated health and predictive models based 
on combinations of individual elements from the POS S Renal and EQ5D instruments 
could possibly aid in mortality discrimination and subsequent advance care planning in 
hemodialysis.
SA-OR031
Isonatric Dialysis Biofeedback in Hemodiafiltration with Online 
Regeneration of Ultrafiltrate in Hypertensive Hemodialysis Patients: A 
Randomized Controlled Study  Lucile Mercadal,1 Frederic Debelle,2 Christine 
Fumeron,3 Lise Mandart,4 Isabelle Simon,5 Yahsou Delmas,6 Sophie Tezenas 
du montcel.7  1AP-HP, Paris; 2RHMS Baudour, Belgium; 3AURA Paris; 4CH 
Vannes; 5CH Erasme Bruxelles; 6CHU Bordeaux; 7Biostatistics, AP-HP, France.
Background: Biofeedback in hemodiafiltration with online regeneration of ultrafiltrate 
(HFR) could improve arterial hypertension by using an isonatric mode maintaining a 
natremia equal between start and end of the dialysis session. We evaluated the impact of 
Isonatric HFR (HFRiso) on hypertension compared to Conventionnal HFR.
Methods: 47hemodialysis patients having an arterial pressure > 140/90 mmHg were 
randomized (ratio 2/1) HFR iso versus HFR during 24 dialysis sessions. The course from 
S1 to S24 of the predialytic systolic (SBP) and diastolic (DBP) blood pressure, the defined 
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daily dose (DDD) of antihypertensive treatment and of the dry weight were compared 
by t-test and by mixed model for repeated measurements adjusted for treatment x time 
interaction. The impact of age, diabetes and cardiovascular co-morbidities on response to 
treatment was evaluated. Tolerance was evaluated by the number of sessions complicated 
by symptomatic hypotension.
Results: In the Isonatric HFR group (N=32), the predialysis SBP decreased from S1 
to S4 of 9 ± 20 mmHg (-0.12 ± 0.08 mmHg /day) and increased of 5 ± 24mmHg (+0.13 ± 
0.05 mmHg /day) in the HFR group (N=15), variation that differed between the 2 groups 
(DS1-S24, p = 0.035; interaction treatment*time, p=0.012). The DBP (HFRiso -3 ± 14 
mmHg vs HFR 5 ± 13 mmHg; p=0.088), the DDD of antihypertensive treatment (HFR iso 
-0,1 ± 0,9 vs HFR -0,3 ± 1,1, p=0.7) and the dry weight (HFRiso 0,2 ± 1 vs HFR 0,2 ± 1,5kg, 
p=0.9) did not vary during the study. Age influenced the PAS course independently of the 
treatment group (interaction age*time, p=0.05). The number of symptomatic hypotension 
was similar in the 2 groups.
Conclusions: Isonatric HFR improved blood pressure control without increasing 
dialysis hypotension episodes.
Funding: Pharmaceutical Company Support - Bellco
SA-OR032
Relevance of B-Lines on Lung Ultrasound in Volume Overload and 
Pulmonary Congestion: Clinical and Therapeutic Correlations in 
Hemodialysis Patients  Marc M. Saad, Jeanne Kamal, Wissam Mansour, 
Boutros Karam, Elias Moussaly, Emad Gobran, Devjani Das, Morton J. Kleiner, 
Elie El-Charabaty, Suzanne E. El Sayegh.  Internal Medicine/Emergency Dept/
Nephrology, Staten Island Univ Hospital, Staten Island, NY.
Background: Volume overload in patients on hemodialysis (HD) is an independent 
risk factor for death from cardiovascular events. The imminent role of B-Lines (BL) on 
ultrasound (US) in predicting physical performance, morbidity and mortality, raises interest 
in its utility for assessing volume status in patients on HD.
Methods: ESRD patients on HD at Island Rehab center older than 18 were screened. 
Those who have lung disease and pregnant women were excluded. Patients achieving their 
dry weight(DW) had a lung US in a supine position. Residents were trained to visualize 
BL and recorded scores in real time. Clips were reviewed by blinded certified physicians. 
Scores were classified as mild (0-14), moderate (15-30) and severe (>30) for pulmonary 
congestion, as validated by Zoccali et al.
Results: 81 patients on HD were recruited. 58 were males, mean age 59.7 years, 
hemoglobin 10.6 g/dL. 44 had NYHA Class 1, 24 had class 2, and 13 had class 3. In 
univariate analysis, NYHA class had significant correlation with BL scores and classes 
(<0.001), and diastolic dysfunction (0.002). In multivariate analysis, NYHA grade strongly 
correlates with B-Lines classification (0.01) but not with heart function (0.95). The mean 
difference between physicians and residents scoring was 3.77 (0.048). However this 
difference was not significant after classification and scores were in agreement (Kappa 
= 0.56).
Conclusions: At DW, NYHA grading tightly corresponded to BL classification 
irrespective of cardiac function. Pulmonary congestion is common among patients on HD; 
NYHA score is mainly driven by the extravascular water and not by heart dysfunction. 
These results render fluid overload estimated by BL a better predictor for ESRD patient’s 
performance and a reliable indicator for their volume status assessment. Moreover, moderate 
lung congestion noted in patients with NYHA class 1 outline the importance of lung US in 
identifying subtle lung congestion opening a new concept for achieving DW.
SA-OR033
Combined Target Ranges for Blood Pressure and Fluid Overload 
Ulrich Moissl,1 Peter Wabel,1 Paul William Chamney,1 Bernard J. Canaud,2 
Stefano Stuard.3  1GRD, Fresenius Medical Care, Bad Homburg, Germany; 
2Medical Board, FMC, Bad Homburg, Germany; 3NephroCare Coordination, 
FMC, Bad Homburg, Germany.
Background: Recent research has revealed areas of increased mortality risk in the 
combination of systolic blood pressure (BPsys) and fluid overload (FO) (Fig 1a). It was 
the aim of this retrospective analysis to assess whether classifying patients according to a 
dedicated flow chart taking into account BP, FO and antihypertensive therapy (AHT) may 
indicate improved survival compared with a BP target range alone.
Methods: Pre-dialysis FO and BPsys were measured monthly in 31,349 patients from 
the Fresenius NephroCare Clinic Network. Patients were classified as being on/off target 
in January 2013 according to the flow chart in Figure 1b, which combines a BPsys target 
range of 130 to 160mmHg with information about AHT and FO [L] (Target1). FO was 
measured by bioimpedance spectroscopy. Normohydration was defined as FO normalized 
by extracellular volume <13% (females) and <15% (males). Target1 was compared with 
only a BPsys target range of 130 to 160 (Target2). All-cause mortality hazard ratios (HR) 
were calculated over 2 yrs follow-up time using COX analysis adjusting for 31 different 
co-morbidities and laboratory parameters.
Results: Unadjusted Kaplan Meier curves revealed a 2yr survival of 82% for patients 
on Target1, and 75% for being not on Target1 (p<0.0001), Fig 1c. Adjusted HR for patients 
being on Target1 was 0.74 [95% CI: 0.70 - 0.78]; the adjusted HR for being on Target2 
was 0.84 [0.79 – 0.88]. At time of classification 66% of patients were on Target1, while 
61% were on Target2.
Conclusions: Combining information on BPsys, AHT and FO indicates survival 
advantages compared with using only a BP target.
Fig 1. (a) Mortality risk of BPsys and FO. (b) Classification tree based on BPsys, 
AHT and FO. (c) Kaplan Meier curves for 31,349 patients being on/off target according 
to classification in Figure 1b.
SA-OR034
Volume Status Assessed by Bioimpedance in Hemodialysis Predicts 
Mortality  Janice P. Lea, Laura Plantinga, Rebecca H. Zhang, Nancy G. Kutner. 
Medicine, Emory Univ, Atlanta, GA.
Background: Mortality rates average over 20% in the End-Stage Renal Disease 
(ESRD) US population with cardiovascular disease being the leading cause of death. 
Accurate intravascular volume assessment is critical in the treatment of patients who receive 
chronic hemodialysis (HD) therapy due to its deleterious effects on the heart and blood 
pressure (BP). Clinically assessed dry weight and interdialytic weight gain (IDWG) are 
often used as surrogates of volume status. Bioimpedance has emerged as an effective tool 
for volume management but is not readily available in clinical practice. Thus we examined 
the association of volume status determined by bioimpedance with mortality, compared to 
the association of IDWG and BP with mortality in ESRD patients.
Methods: ACTIVE/ADIPOSE (A Cohort Study to Investigate the Value of Exercise in 
ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival) was a multi-
center study of prevalent HD patients coordinated by the United States Renal Data System 
in 2009-2011. The data collection sites were 14 outpatient dialysis clinics in Atlanta and 
San Francisco. Volume status by bioimpedance defined by calculation of extracellular fluid 
(ECF): total body water (TBW) ratio. Associations by quartiles of ECF:TBW, IDWG, and 
BP with 1-year mortality were estimated using Cox proportional hazards regression models.
Results: 660 patients were included in this analysis, with 36 total deaths at 1 year. 
After adjustments, each increase of 0.01 in ECF:TBW (range, 0.39-0.57) in quartiles was 
associated with a >30% increased risk of mortality, (HR- 1.32, 95% CI, 1.15-1.52) p<.001. 
In comparison, quartiles of IDWG (HR- 0.96, 95% CI, 0.78-1.17) and BP (per 10 mmHg, 
systolic, HR=.99, 95% CI, 0.82-1.19; diastolic (HR=0.90, 95% CI, 0.64-1.25), were not 
associated with mortality. Further, the associations of ECF:TBW with mortality were 
independent of BP, IDWG, and BMI.
Conclusions: Volume status by bioimpedance, but not IDWG or BP, was significantly 
and independently associated with greater mortality in this HD cohort. These findings 
question the common clinical practice of using IDWG as a surrogate of volume status in 
the HD population as it may not correlate with clinical outcomes.
Funding: NIDDK Support
SA-OR035
Abnormal Global Longitudinal Strain Is Associated with All-Cause 
Mortality in Hemodialysis Patients  Diana Chiu, Darren Green, Nik Abidin, 
Philip A. Kalra.  Univ of Manchester, MAHSC, UK.
Background: Cardiovascular mortality is high in hemodialysis (HD) patients.Early 
detection of cardiac dysfunction is important.Left ventricular global longitudinal strain 
(GLS) measures the maximal shortening of myocardial longitudinal length during systole 
compared to the resting length in diastole.Reduced GLS may reflect abnormal systolic 
function before loss of ejection fraction (EF) becomes apparent.We aimed to determine the 
prevalence, clinical correlates and prognostic value of abnormal GLS in stable HD patients.
Methods: Clinical and echocardiographic data were obtained in a prospective study of 
HD patients at one centre.Survival analysis for GLS was performed using Cox regression 
adjusted for age, co-morbidities, dialysis chronicity, laboratory data, left ventricular mass 
index adjusted for height (LVMIHt2.7) and Teicholz EF.
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Results: The mean age was 62±14years, 69% were male, 39% had diabetes, 29% 
heart failure, 17% coronary artery disease.The mean GLS was -13.4±3.5%, LV ejection 
fraction(LVEF) 63.8±12.9% and LVMIHt2.7  53.6±17.2g/m2.7. 98% of patients had 
abnormal GLS (>-20%), compared with 14% with reduced LVEF(<50%) and 55% with 
LV hypertrophy.Factors associated with an abnormal GLS included LVMIHt2.7 (OR 1.06, 
95%CI 1.04-1.09, P<0.01), LVEF (OR 0.96, 95%CI 0.94-0.99, P<0.01) and diabetes (OR 
2.04, 95%CI 1.08-3.9, p=0.03).Median follow-up was 24 (17-30) months, during which 
there were 41 deaths (21%).After adjustment for age, diabetes, coronary artery disease, 
LVEF, LVMIHt 2.7, 3 month-averaged serum potassium and albumin, a less negative GLS 
remained an independent predictor of all-cause mortality (HR 1.18 for each 1% worsening 
change in GLS, 95% CI 1.03-1.35, P=0.02).
Conclusions: Abnormal GLS is highly prevalent amongst HD patients, and appears 
to be a better marker of all-cause mortality in stable HD patients than the “standard” 
echocardiographic parameters LVEF and LVMIHt2.7.
SA-OR036
Trimethylamine-N-Oxide (TMAO) and Cardiovascular Events in 
Hemodialysis Patients: The Retained Organic Solutes and Clinical 
Outcomes (ROSCO) Study  Tariq Shafi,1 Thomas H. Hostetter,2 Timothy 
W. Meyer,3 Seungyoung Hwang,1 Michal L. Melamed,4 Tanushree Banerjee,2 
Josef Coresh,1 Neil R. Powe.5  1Johns Hopkins Univ; 2Univ of California 
San Francisco; 3Stanford Univ; 4Albert Einstein College of Medicine; 5Case 
Western Univ.
Background: Uremic toxins that contribute to cardiovascular (CV) disease and 
observed higher mortality in whites vs. blacks remain undefined. TMAO, a highly dialyzable 
metabolite, is associated with accelerated atherosclerosis and CV events in non-dialysis 
patients but previous studies in dialysis patients have been equivocal.
Methods: We measured TMAO in 1232 patients of the Hemodialysis (HEMO) Trial, 
3-6 months after randomization and analyzed its association with CV mortality, sudden 
cardiac death (SCD) and first CV event, using Cox models adjusted for demographics, 
clinical characteristics, comorbidities, albumin and residual urea clearance.
Results: Mean age of the patients was 58 years, 34% white and 42% male. Median 
TMAO level was 88 µM (IQR, 62 to 124) and did not differ by race (p=0.9). The association 
of TMAO with outcomes differed by race (Figure) and was associated with outcomes only 
in whites. In whites, each 2-fold increase in TMAO was associated with a 45% higher risk 
of CV mortality, 70% higher risk of SCD and 15% higher risk of CV events (Table). TMAO 
levels decreased in the higher Kt/VUREA group but did not have an effect on outcomes (p>0.1).
Adjusted HR* (95% CI) of the Association between TMAO and Outcomes
Events Overall White Black P-interaction
CV Mortality 220 1.09 (0.96-1.24)
1.45 (1.24-
1.69)
0.90 (0.77-
1.06) <0.001
Sudden Cardiac 
Death 126
1.18 (1.02-
1.37)
1.70 (1.34-
2.16)
0.92 (0.78-
1.08) <0.001
First CV Event 644 1.05 (0.97-1.13)
1.15 (1.01-
1.32)
1.01 (0.92-
1.10) 0.09
* Per 2-fold increase
Conclusions: The association between TMAO and CV events differs among white 
and black hemodialysis patients.
Funding: NIDDK Support
SA-OR037
Serum Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginine 
and Morbidity and Mortality in Hemodialysis Patients: The Retained 
Organic Solutes and Clinical Outcomes (ROSCO) Study  Tariq Shafi,1 Neil 
R. Powe,2 Timothy W. Meyer,3 Seungyoung Hwang,1 Michal L. Melamed,4 
Tanushree Banerjee,2 Josef Coresh,1 Thomas H. Hostetter.5  1Johns Hopkins 
Univ; 2Univ of California, San Francisco; 3Stanford Univ; 4Albert Einstein 
College of Medicine; 5Case Western Univ.
Background: ADMA, an endogenous nitric oxide synthase inhibitor, and SDMA, 
a promoter of oxidative stress, accumulate in dialysis patients and may contribute to 
uremic toxicity.
Methods: We measured predialysis levels of ADMA and SDMA in 1276 patients of the 
Hemodialysis (HEMO) Trial, 3-6 months after randomization and analyzed its association 
with all-cause and cardiovascular (CV) mortality, sudden cardiac death (SCD) and first 
CV event, using Cox model adjusted for potential confounders (demographics, clinical 
characteristics, comorbidities, albumin, residual urea clearance).
Results: Mean age of the patients was 58 years, 63% black and 42% male. Median 
(interquartile range) for ADMA was 0.9 µM (0.8, 1.0) and SDMA was 4.1 µM (3.3, 5.0). 
In fully adjusted models, ADMA was associated with all outcomes whereas SDMA was 
only associated with CV mortality (Table). Subgroup analyses did not show significant 
interactions with race or HEMO interventions.
Fully Adjusted Model for the Association of ADMA and SDMA with Outcomes in the HEMO 
Study
Events IR* ADMA SDMA
HR** (95% 
CI) p
HR** (95% 
CI) p
All-Cause Mortality 565 172 1.44 (1.13-1.83) 0.003 
1.21 (1.00-
1.47) 0.05
Cardiovascular 
Mortality 220 67
1.83 (1.29-
2.58) <0.001 
1.40 (1.03-
1.92) 0.03
Sudden Cardiac Death 126 38 1.79 (1.19-2.69) 0.006
1.40 (0.96-
2.06) 0.08
First Cardiovascular 
Event 644 274
1.50 (1.20-
1.87) <0.001 
0.98 (0.83-
1.16) 0.83
* IR, Incidence Rate; **HR per 2-fold increase in solute
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Conclusions: ADMA and SDMA are uremic solutes associated with morbidity and 
mortality in hemodialysis patients.
Funding: NIDDK Support
SA-OR038
Glomerulus on-a-Chip as a Model to Study the Glomerular Filtration 
Barrier In Vitro  Stefano Da Sacco,1 Jos Joore,2 Paul Vulto,2 Roger E. De 
Filippo,1 Laura Perin.1  1Urology, Children’s Hospital Los Angeles, Los Angeles, 
CA; 2MIMETAS.
Background: The glomerular filtration barrier (GFB) has three major components: 
the podocyte with the “slit diaphragms”, the glomerular basement membrane and the 
fenestrated glomerular endothelial cell (hGEC): each of them is essential for the correct 
blood filtration. Damage to any of these components often leads to a severe, irreversible 
GFB disruption with onset of chronic damage requiring drug treatment and eventually 
dialysis and transplantation. Development of alternative therapeutic approaches is limited 
by our poor understanding of the complex cell-matrix interactions and cellular cross-talk 
in vivo and the absence of in vitro GFB models. Therefore, an in vitro system that mimics 
the complex GFB architecture and that can be used to better study glomerular (patho)-
physiology is urgently needed.
Methods: We have generated a population of renal progenitors from human amniotic 
fluid (hAKPC-P) that can differentiate into podocyte-like cells. Taking advantage of the 
peculiar characteristics of available microfluidic systems, we have developed an innovative 
Glomerulus-on-a-Chip system by co-culturing hAKPC-P and hGEC cells in OrganoplateTM 
microfluidic plates. Evaluation of culture conditions, immunostainings and qPCR were 
performed to characterize the 3D culture.
Results: We have successfully established the conditions for in vitro co-culture of 
hAKPC-P/hGEC in a microfluidic plate for up to 21 days. Apoptosis and proliferation were 
assessed by TUNEL and PCNA. Vessel formation by hGEC was confirmed along with 
expression of endothelial marker VE-Cadherin while hAKPC-P-derived podocytes were 
positive for nephrin and podocin. De-novo deposition of collagen IV in the 3D microfluidic 
plates was confirmed by immunostaining.
Conclusions: Our preliminary results suggest the feasibility of Organoplates for co-
culture of podocytes and hGEC in a 3D environment that more closely mimics the structure 
of the GFB. If successful this system might prove useful for the assessment of several aspects 
of cell-cell and cell-matrix interaction, thus helping to understand podocytes/endothelial 
crosstalk (or its perturbations) and how this might affects glomerular homeostasis.
Funding: Private Foundation Support
SA-OR039
Pharmacokinetic Model for Screening Nephrotoxicity Using Kidney on 
a Chip  Sejoong Kim,1,2 Sasha Cai Lesher-Perez,1 Byoung Choul C. Kim,1 
Cameron Yamanishi,1 Joseph M. Labuz,1 Shuichi Takayama.1  1Univ of Michigan 
College of Engineering, Ann Arbor, MI; 2Internal Medicine, Seoul National Univ 
Bundang Hospital, Seongnam, Korea.
Background: Animal renal clearance is usually higher than human renal clearance, 
which may underestimate nephrotoxicity. We developed a microfluidic device lined 
by kidney epithelial cells to mimic in vivo-like microenvironment. We evaluated the 
nephrotoxicity of two different gentamicin regimens using this kidney on-a-chip and 
human pharmacokinetic data.
Methods: The microfluidic device had top channels like luminal spaces and bottom 
channels like interstitial spaces. MDCK cells on the porous membranes between the two 
channels were exposed with a fluid shear stress (1.0 dyne/cm2). D1 regimen was 19.2 mM 
of gentamicin for initial dosage and reduction by half every 2 hours to mimic human renal 
clearance, and D2 regimen was continuous infusion of gentamicin (3 mM for 24 hours) 
in the top channels.
Results: After 6-hour shear stress, fluorescences of ZO-1 and occludin were increased 
and transmembrane permeability was decreased, compared to the static condition. For the 
next 24 hours, D1 and D2 regimens were applied under shear-stress condition. Although 
the junctional protein immunoreactivity was decreased in the both regimens, ZO-1 and 
occludin fluorescences showed higher in the D1 regimen than in the D2 regimen (P < 0.05).
D1 regimen sustained the permeability, while D2 leaded to increase in the permeability 
(P < 0.05). In addition, D1 regimen indicated less cytotoxic than D2 (Dead cell 1.43 ± 0.30 
% vs. 4.9 ± 0.20%, respectively, P < 0.05).
Conclusions: These data suggest that gentamicin may interrupt junctional protein 
complex and membrane permeability, and that single daily dose alleviate the nephrotoxicity, 
compared to the continuous infused regimen. Microfluidic devices can be one of novel 
pharmacokinetic models for evaluating nephrotoxicity.
Funding: Other NIH Support - NIH GM096040, Government Support - Non-U.S.
SA-OR040
Computational Prediction and Experimental Analyses of Proteins 
That Bridge Metabolite Markers of Human Diabetic Nephropathy 
Rintaro Saito,1,2,3 Anaïs Rocanin-Arjo,4 Minya Pu,1,5 Simone Romoli,4 Loki 
Natarajan,1,5 Wenjun Ju,6 Matthias Kretzler,6 Robert G. Nelson,7 Dana 
Thomasova,4 Shrikant R. Mulay,4 Hans J. Anders,4 Kumar Sharma.1,2,3,8  1Inst 
Metabol Med; 2Center Renal Transl Med; 3Dept Med, UCSD, CA; 4Medizinische 
Klinik und Poliklinik IV, Klinikum der Univ München, Munich, Germany; 
5Dept Family Med Epidem, UCSD; 6Dept Internal Med, Nephrology & Dept 
Comput Med & Bioinfo, Univ of Michigan, MI; 7NIDDK, AZ; 8VA Health 
Systems, SD, CA.
Background: We have previously shown that thirteen metabolites are shown to 
be characteristic of human diabetic kidney disease (DKD) and linked to mitochondrial 
dysfunction. However, novel bioinformatic tools could indicate novel connections among 
these metabolites to identify new relevant protein targets for human disease.
Methods: We integrated publicly available human protein-protein interaction (PPI) 
networks with global metabolic networks onto a software (Cytoscape) to enhance the 
interpretation of metabolomic data. Validation was performed with gene expression data 
from Nephromine and experimental studies in mice.
Results: We found that all thirteen metabolites can be connected through a single 
subnetwork of PPIs. We focused on bridge proteins, which were predicted to potentially 
connect these metabolites through their associated enzymes and found that several 
proteins had a significant number of connections regulating the original 13 metabolites. 
These included MDM2 (BH corrected p < 0.005, 14 connections) and PEX5 (p < 0.005, 
9 connections). Of these, MDM2 had the strongest regulation in its gene expression in 
glomeruli (p <0.01) and tubulointersitium (p <0.01) from two different cohorts of diabetic 
kidney biopsies. In vivo studies with Nutlin3a, an inhibitor of MDM2 binding site, in both 
healthy C57B6/JL mice and db/db type 2 diabetic mice resulted in a reduction podocytes, an 
increase in proteinuria and higher levels of plasma urea levels in healthy and diabetic mice.
Conclusions: Our bioinformatics approach has been demonstrated to make biologically 
relevant interpretation of dysregulated metabolites, highlighting the significance of MDM2 
dysregulation in DKD both in experimental models and in patients with DKD.
Funding: NIDDK Support
SA-OR041
Mechanical Properties of Renal Tubules Measured Using Glass 
Microcantilevers  Nicholas J. Ferrell.  Nephrology, Vanderbilt Univ Medical 
Center, Nashville, TN.
Background: The mechanical properties of tissues play an important role in maintaining 
tissue function, and altered biophysical properties affect disease progression. Measuring 
the mechanical properties of isolated biological structures, including renal tubules can be 
challenging, especially in tension. We have developed a new method to measure the elastic 
modulus of renal tubules using glass micropipettes as force measurement cantilevers.
Methods: Cortical tubules were manually dissected from normal mice. Elastic 
modulus was measured by clamping each tubule between a measurement microcantilever 
with pre-determined stiffness and a holding micropipette. The holding micropipette was 
translated using a micromanipulator and images were acquired at fixed displacements. 
Tubule strain and applied force were determined my measuring the change in the tubule 
length and deflection of the measurement cantilever. Tubule stress was estimated assuming 
the resistance to deformation was imparted primarily by the tubular basement membrane. 
The cross-sectional area of each tubular basement membrane was calculated based on a 
basement membrane thickness of 0.24 µm. Elastic modulus was calculated from the slope 
of the stress-strain curve at a given strain.
Results: Stress-strain curves indicated a strain dependent increase in elastic modulus 
suggesting significant strain stiffening of renal tubules. At low strain (0-15%) elastic 
modulus was measured at 555±98 kPa. At higher strain (15-30%) elastic modulus was 
1113±150 kPa and at even higher stain (30-50%) elastic modulus was 2161±173 kPa. Strain 
stiffening behavior was observed throughout the range of measurable strain.
Conclusions: These results indicate that renal tubules are highly deformable structures 
that exhibit increased stiffness as strain increases, a response typical of extracellular matrices 
such as collagen gels. This method provides a relatively simple means of determining 
renal tubular biophysical properties and may be a useful tool for evaluating renal tubule 
mechanical properties in a variety of kidney diseases.
Funding: NIDDK Support
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SA-OR042
Non-Invasive Measurement of Renal Blood Flow (RBF) in Rat by Magnetic 
Resonance Images (MRI)  Cesar A. Romero,1 Robert Knight,2 Oscar A. 
Carretero.1  1Hypertension and Vascular Research Div, Henry Ford Hospital; 
2Henry Ford Hospital; 3Henry Ford Hospital; 4Henry Ford Hospital.
Background: Quantitative measurement of RBF provides important information on 
renal physiology, nephropathies and kidney viability in different animal models. Arterial 
Spin Labelling–MRI (ASL-MRI) is a non-invasive method to measure blood flow without 
exogenous contrast media, using arterial water protons labeled by radiofrequency as an 
endogenous tracer. However, the low signal/noise ratio and the motion artifacts pose a 
challenge when acquiring RBF in small animals. Our objective is to evaluate the feasibility 
and reproducibility of the RBF measurement by ASL-MRI under basal conditions and in 
a high RBF state in rats.
Methods: ASL-MRI images were obtained in seven males Sprague-dawley rats 
(200-300g) under the inhalatory anesthesia (isofluorane 2%). Rectal temperature probe 
was used to control the body temperature. After 4 days the MRI studies were repeated in 
3 rats (6 kidneys) to evaluate reproducibility, using paired sample T-test and the test-retest 
reliability (TR) by the equation TR=(1-SDn/Mn)x100 were M and SD are the mean and 
standard deviation of the RBF in “n” different sessions. RBF was also measured in a set of 
animals that underwent unilateral nephrectomy 24 hours before and after the surgery. MRI 
was acquired using a 7 Tesla Varian MRI system with a spin echo imaging sequence using 
respiratory triggering and navigator correction to reduce motion artifacts. The sequence 
was averaged 16 times and the total scan time for the entire series of ~20 minutes. In house 
software was used to analyze the postprocessing imaging.
Results: The mean cortical RBF was 305±59 and 271.8±39 ml/min/100g tissue in 
right and left kidney, respectively. Re-test analysis showed no differences, with the means 
of differences 9.4±35ml/min/100g tissue (p=0.58). The TR was 92.4±6%. The RBF before 
and after the nephrectomy was 270±30 and 456.6±34 ml/min/100g tissue (p=0.004), 
respectively, showing a relative increase of 69.1%.
Conclusions: ASL-MRI performed with navigator correction and respiratory gating 
is feasible and reliable non-invasive method to measure RBF in rats.
SA-OR043
Intravoxel Incoherent Motion Analysis of Diffusion Weighted Imaging 
to Measure Glomerular Filtration Fraction – Proof of Concept 
René van der Bel,1 Oliver J. Gurney-Champion,2 Wouter V. Potters,2 Hein J. 
Verberne,3 Liffert Vogt,1 Erik Stroes,1 Aart J. Nederveen,2 C.T.P.  (Paul) Krediet.1 
1Internal Medicine, AMC, Univ of Amsterdam, Netherlands; 2Radiology, AMC, 
Univ of Amsterdam, Netherlands; 3Nuclear Medicine, AMC, Univ of Amsterdam, 
Netherlands.
Background: Glomerular filtration fraction (FF) can be calculated from the 
125I-thalamate clearance (glomerular filtration rate (GFR)) and 131I-hippuran clearance 
(effective renal plasma flow (ERPF)). This technique is costly and time consuming. 
Intravoxel Incoherent Motion (IVIM) analysis provides an assessment of diffusion weighted 
imaging (DWI) for fractions of blood and (pre-)urine within kidney tissue. This could serve 
as a surrogate for filtration fraction. With this study we a proof of concept for an MRI 
derived kidney function measurement.
Methods: After a baseline phase, 6 healthy volunteers (age 18-24 yrs) were subjected 
to continuous Angiotensin II (Ang-II) infusion at 3.0 ng/kg/min. Blood and (pre-)urine 
fractions and renal blood flow (RBF) were assessed using DWI and phase contrast MRI 
(Ingenia 3.0T, Philips Healthcare). Fractions were calculated via tri-exponential IVIM 
model fit to the DWI data (TE 45ms; TR 1344 ms; matrix: 112x68, FOV 336x204 mm2; 
voxel size 3.0x3.0x3.0 mm, b-values: 0, 2, 4, 8, 12, 18, 24, 32, 40, 50, 70, 110, 200, 300, 
450, 600 s/mm2; gradient directions: 15). RBF was calculated in the proximal renal artery 
after manual vessel segmentation. During a second visit, gold standard GFR, ERPF and 
FF were measured during a similar infusion protocol.
Results: Ang-II decreased both GFR and ERPF (10±7.1%, p=0.016; 24±4.5%, 
p<0.001), resulting in an increase in FF of 19±3.1% (p<0.001). RBF decreased from 
11.1±2.07 to 8.05±1.02 ml/s (by 27%, p=0.001). Renal IVIM imaging showed an increase 
in the urine fraction of 24.6±14% (p=0.002) and a decrease of the perfusion fraction by 
12±21.8% (p=0.096). Renal IVIM measures (pre-)urine fractions and FF were correlated 
(R=0.44, p=0.033). RBF correlated to the gold standard ERPF (R=0.75, p<0.001).
Conclusions: These data suggest that a combination of IVIM and phase contrast 
kidney imaging could provide reliable and fast noninvasive FF and ERPF measurement.
SA-OR044
Visualization of Kidney Fibrosis in Diabetic Nephropathy by DTI MRI 
Jun-Ya Kaimori,1 Yoshitaka Isaka,2 Masaki Hatanaka,2 Satoko Yamamoto,2 
Hiroshi Shibata,4 Akira Fujimori,4 Akihiko Fujikawa,4 Sosuke Miyoshi,4 
Naotsugu Ichimaru,1 Toshiki Moriyama,3 Hiromi Rakugi,2 Shiro Takahara.1 
1Dept of Advanced Technology of Transplantation, Osaka Univ Graduate School 
of Medicine, Suita, Osaka, Japan; 2Dept of Geriatrics & Nephrology, Osaka 
Univ Graduate School of Medicine, Suita, Osaka, Japan; 3Osaka Univ Health 
Care Center, Osaka Univ, Toyonaka, Osaka, Japan; 4Drug Discovery Research 
Inst, Astellas Pharma Inc, Tsukuba, Ibaraki, Japan.
Background: Renal fibrosis (RF) is a well-known marker for chronic kidney disease 
(CKD) progression. However, an available examination for evaluation of RF is invasive 
biopsy. Diffusion MRI was once recognized as a promising option for RF. But now it is 
controversial and it could not be applied to diabetic nephropathy (DN).
Methods: To seek an optimal imaging method applicable even for fibrosis in DN, we 
tried series of MR imaging methods,including proton density weighted imaging (PDWI), T1 
weighted imaging (T1WI), T2 weighted imaging (T2WI), T2* weighted imaging (T2*WI), 
diffusion weighted imaging (DWI), and diffusion tensor imaging (DTI).
Results: We identified DTI MRI by spin echo sequence plus a special kidney attachment 
as the best option for evaluation of UUO fibrosis, compared with normal kidney in the 
opposite side. To confirm these results, we applied this technique to rat UUO therapeutic 
model with anti-fibrotic reagent, Fasudil. FA values calculated form DTI MRI showed 
statistically significant linear correlation with RF area measured by Sirius Red or Masson 
trichrome staining positive area. Next, by using SHR/NDmcr-cp(cp/cp) rat with or without 
telumisartan as a RF model of DN, we finally succeeded in visualization and evaluation of 
fibrosis accumulated in outer stripe of outer medulla region by FA map. 
Conclusions: By DTI MRI with spin echo sequence, it may be possible to accurately 
evaluate RF in CKD including even DN.
Funding: Pharmaceutical Company Support - Astellas.Co.LTD, Government 
Support- Non-U.S.
SA-OR045
Super-Resolution Microscopy Reveals the Formation of a Mat of Contractile 
Fibers as Part of the Podocyte Foot Process Effacement Phenomenon 
Hani Suleiman,1 Jeffrey H. Miner,3 Andrey S. Shaw.2  1Pathology and 
Immunology, Washington Univ in Saint Louis, Saint Louis, MO; 2Pathology 
and Immunology, Washington Univ in Saint Louis, Saint Louis, MO; 3Renal 
Devision, Washington Univ in Saint Louis, Saint Louis, MO.
Background: The ~200 nm resolution of traditional microscopes is limited by the wave-
length of light. Imaging structures smaller than 200 nm, such as podocyte foot processes 
and slit diaphragms, has required electron microscopy (EM). New super-resolution imaging 
techniques can break the diffraction barrier of light, thus allowing us to easily image and 
resolve the molecular composition of structures in a nanometer range.
Methods: We used an array of antibodies for Stochastic Optical Resolution Microscopy 
(STORM) to study the spatial distribution of key molecules of the podocyte cytoskeleton 
and slit diaphragm in healthy and injured glomeruli. We also developed a novel technique 
that allows us to image podocyte actin cables by EM.
Results: In healthy glomeruli, synaptopodin is localized to the center of each foot 
process, while nephrin is at the slit diaphragm. As foot processes efface, nephrin redistributes 
apically away from the base of foot processes. We confirmed this in 3 different injury 
models. After podocyte injury the positions of synaptopodin and α-actinin-4 clusters did 
not change, but there was robust recruitment of myosin IIa, normally only in primary 
processes, to the bases of foot processes. The pattern of myosin IIa staining, in alternating 
stripes with synaptopodin and α-actinin-4, indicates the formation of contractile actin 
fibers during effacement. Using our new EM method, we observed a dramatic change in 
the morphology of actin fibers during effacement.
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Conclusions: We demonstrate the utility of super-resolution microscopy to visualize 
podocyte foot processes. Our data show that in the normal podocyte, contractile actin cables 
are in primary processes, while only non-contractile actin filaments are in foot processes. 
After foot process effacement, the contractile cables fall to the bottom of the podocyte and 
form a sarcomere-like contractile network adjacent to the GBM.
Funding: NIDDK Support, Private Foundation Support
SA-OR046
Intravital and Organ Slice Imaging of Podocyte Membrane Dynamics 
Sebastian Braehler,1 Haiyang Yu,1 Gokul Murali Krishnan,1 Hani Suleiman,1 
Jeffrey H. Miner,2 Bernd H. Zinselmeyer,1 Andrey S. Shaw.1  1Dept of Pathology 
and Immunology, Washington Univ School of Medicine, St. Louis, MO; 2Renal 
Div, Washington Univ School of Medicine, St. Louis, MO.
Background: The elaborate network of podocyte foot processes, which is stabilized 
by the actin cytoskeleton, is one of the key components of the glomerular filtration barrier. 
The question of whether podocytes change their shape under physiological conditions or in 
response to injury has been vigorously debated. The Rho-family of small GTPases is at the 
center of this debate, as these molecular switches control assembly and disassembly of the 
actin cytoskeleton. Evidence as to whether and how small-GTPases change podocyte shape 
and dynamics is largely circumstantial, as all studies to date have been conducted in vitro.
Methods: Here we use intravital two-photon imaging of fluorescently labeled podocytes 
to answer these questions. Rosa26-confetti/Podo-Cre mice were used as reference and 
compared with mice expressing eGFP-labeled, constitutively active Rac1 (eGFP.CA-Rac1) 
in podocytes. To achieve a higher resolution we also imaged freshly isolated kidney slices 
in an organ bath.
Results: Podocytes in Rosa26-confetti/Podo-Cre mice showed a stable network of foot 
processes, with no significant membrane movement. eGFP.CA-Rac1 podocytes lost their 
characteristic shape and showed increased membrane dynamics and podocyte shedding. 
Shed podocytes seemed viable, as they were observed migrating in the tubular system. 
Organ slice imaging resembled the intravital results but yielded a higher temporal-spatial 
resolution, which validates this approach as a suitable technique to complement intravital 
imaging. With this approach, we were also able to show that increased membrane dynamics 
is a feature of injured podocytes in a glomerular disease model.
Conclusions: We show in vivo for the first time that Rac1 converts podocytes from 
a state of immobility to one with greatly increased membrane dynamics and blunted foot 
processes, which also occurs in a model of glomerular injury. This suggests that foot process 
effacement is the end result of a highly dynamic state, and that foot process instability could 
contribute to proteinuria itself.
Funding: NIDDK Support, Government Support - Non-U.S.
SA-OR047
Intravital Multiphoton Imaging of Podocyte Ca2+ Confirms the Important 
Role and Mechanism of TRPC6 in Glomerular Pathology  Kengo Kidokoro, 
Anne Riquier-brison, Janos Peti-Peterdi.  Physiology and Biophysics, and 
Medicine, Univ of Southern, Los Angeles, CA.
Background: TRPC6 channels in podocytes are important Ca2+ influx pathways 
involved in the modulation of the actin cytoskeleton and in the actions of angiotensin 
II (ANG II). TRPC6 overactivity by gain-of-function mutations and high ANGII leads 
to albuminuria and chronic kidney disease (CKD). However, the regulation of podocyte 
Ca2+ dynamics by TRPC6 and the mechanism of the resulting glomerular dysfunction in 
vivo and in response to injury have been elusive. We aimed to directly and quantitatively 
visualize and study the dynamic effects of TRPC6 on podocyte and glomerular function 
during the development of glomerular injury.
Methods: Serial multiphoton microscopy of the intact living kidney of the same wild 
type (WT), TRPC6 transgenic (TG), and TRPC6 knockout (KO) mice was performed over 
two weeks of high ANGII treatment (1000 ng/kg/min). All mice expressed the intensely 
green and calcium sensitive fluorescent protein GCaMP3 only in podocytes. Changes 
in single cell GCaMP3 fluorescence intensity were measured and served as readout for 
podocyte [Ca2+]i changes.
Results: Systolic blood pressure increased from baseline 106±4 to 145±5 mmHg after 
ANGII treatment for two weeks in weeks in WT mice, and similarly in TRPC6 TG and 
KO mice. In WT mice, normalized GCaMP3 fluorescence intensity in podocytes ([Ca2+i) 
increased >2.5-fold, glomerular diameter increased from 64±2 to 76±2 um, and single 
nephron glomerular filtration rate reduced from 9±1 to 3±1 nl/min, in response to ANGII. 
Podocyte GCaMP3 fluorescence intensity was increased >2-fold, but reduced by 20%, at 
baseline in TRPC6 TG and KO mice, respectively. Glomerular functional parameters after 
ANGII treatment were exacerbated in TRPC6 TG mice, while improved in TRPC6 KO mice. 
Podocytes with high GCaMP3 fluorescence appeared migrating to the parietal Bowman’s 
capsule after ANGII in WT and TPRC6 TG, but not in TRPC6KO mice.
Conclusions: This study demonstrated in vivo direct visual evidence of the critically 
important pathogenic role of TRPC6 in the development and progression of glomerular 
disease. Podocyte TRPC6 is a promising therapeutic target for the prevention of CKD.
Funding: NIDDK Support, Pharmaceutical Company Support - Amgen
SA-OR048
Mesangial Filopodial Invasion of Glomerular Capillaries in Alport 
Syndrome  Dominic E. Cosgrove, Daniel T. Meehan, Brianna M. Dufek, Duane 
C. Delimont.  Genetics, Boys Town National Research Hospital, Omaha, NE.
Background: Recent work shows mesangial cell filopodia invade the glomerular 
capillaries in Alport mice and humans. Filopodia progressively deposit laminin 211 and 
likely other mesangial matrix proteins in the GBM. Laminin 211 activates focal adhesion 
kinase in podocytes, which results in up-regulation of metalloproteinases and pro-
inflammatory cytokines. These novel observations, which are key to glomerular disease 
initiation, have been met with some skepticism, which incentivized the current study.
Methods: Three color structured illumination microscopy (SIM, an ultra-high 
resolution methodology) was used to label mesangial processes, glomerular endothelial 
cells, and the GBM. A mesangial cell culture bioassay was developed that allows induction 
of mesangial filopodia. RNAseq analysis of preproteinuric glomeruli identified novel 
candidates likely involved CDC42 activation in mesangial cells. These candidates were 
tested in the bioassay.
Results: SIM analysis showed that integrin α8-immunopositive mesangial processes 
extend, contiguous with the mesangial angles, into the sub-endothelial spaces of the GBM. 
These processes are exclusive of CD31 immunopositive glomerular endothelium and the 
laminin α5 immunopositive GBM. Endothelin-1 (ET-1) activates CDC42 in mesangial 
cells and results in the formation of drebrin-immunopositive actin microspikes (filopodia). 
Of the six candidate proteins identified that may regulate endothelin A receptor (ETAR) 
mediated activation of CDC42, two have been tested by SiRNA knockdown. MAL2 
knockdown blocked ET-1 activation of filopodia, while BMP-7 knockdown had no effect. 
ETAR knockdown (a positive control) also prevented formation of actin microspikes.
Conclusions: SIM analysis unequivocally proves mesangial filopodial invasion of the 
glomerular capillaries in Alport mice. The bioassay shows ET-1 mediated activation of 
CDC42 promotes filopodia formation. RNAseq identified one novel regulator of CDC42 
activation, MAL2 which is critical mediator of CDC42 activation. This bioassay can thus 
be exploited to identify new therapeutic targets with the potential to prevent mesangial 
filopodial invasion of the glomerular capillaries.
Funding: NIDDK Support
SA-OR049
The DREADD Concept: A Novel In Vivo Tool for Kidney Research 
Questioning the Role of Ca2+ on Actin Dynamics in Podocytes  Sybille Köhler,1,2 
Sebastian Braehler,4 Julia Binz,1,2 Matthias Hackl,1,2 Frank Schweda,3 Thomas 
Benzing,1,2 Bernhard Schermer,1,2 Paul T. Brinkkoetter.1,2  1Dept II of Internal 
Medicine and Center for Molecular Medicine, Univ Hospital Cologne, Germany; 
2Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated 
Diseases (CECAD), Univ of Cologne, Germany; 3Dept of Physiology, Univ of 
Regensburg, Germany; 4Dept of Pathology and Immunology, Washington Univ 
School of Medicine.
Background: The close homology between the slit diaphragm of the kidney glomerulus 
and the mechanosensor in C. elegans led to the hypothesis that the slit diaphragm is part of 
a conserved mechanosensor that is closely linked to an actin-based, contractile cytoskeleton 
regulated by Ca2+.
Methods: We generated a transgenic mouse line with specific expression of a mutated 
(Y149C/A239G) G protein-coupled human muscarinic type 3 receptor transgene (hM3D) 
in the ROSA26 locus. This receptor is exclusively activated by the synthetic compound 
clozapine-N-oxide (CNO) and not by the endogenous M3-ligand acetylcholine. We mated 
the hM3D-STOPflox/flox-mouse with the podocin:cre mouse to achieve podocyte specific 
expression. We validated receptor expression and function both, in vitro and in vivo using 
immunofluorescence stainings, western blotting and live Ca2+-imaging using 2-photon 
microscopy.
Results: Here, we applied the DREADD (designer receptor exclusively activated by a 
designer drug, Conklin et al. 1998) concept to further test this hypothesis and to investigate 
the effects of an intracellular Ca2+ increase on the podocyte actin cytoskeleton. Even though 
we observed a strong Ca2+ increase in podocytes after CNO-administration no effects 
on the actin based cytoskeleton, glomerular perfusion or filtration were observed. Even 
administration of CNO over a prolonged period (4 wks) did not induce glomerular disease.
Conclusions: In conclusion, increasing Ca2+ levels in podocytes alone are not sufficient 
to induce cytoskeletal rearrangements and to affect glomerular perfusion and filtration. 
Hence, these results challenge our current view on actin dynamics in podocytes and their 
role in glomerular perfusion and filtration.
Funding: Government Support - Non-U.S.
SA-OR050
Loss of Epithelial Membrane Protein 2 Aggravates Podocyte Injury via 
Upregulation of Caveolin-1  Weibin Zhou,1 Xiaoyang Wan,1 Zhao-hong 
Chen,1,2 Won- Il Choi,3 Heon Yung Gee,3 Friedhelm Hildebrandt.3,4  1Pediatrics 
and Communicable Diseases, Univ of Michigan, Ann Arbor, MI; 2Research Inst 
of Nephrology, Jinling Hospital, Nanjing, China; 3Boston Children’s Hospital, 
Boston, MA; 4Howard Hughes Medical Inst.
Background: Nephrotic syndrome is a chronic kidney disease defined by proteinuria 
with subsequent hypoalbuminemia, hyperlipidemia and edema, due to impaired renal 
glomerular filtration barrier function. Glomerular podocytes haven been proposed to play 
a critical role in the maintenance of glomerular filtration barrier and the pathogenesis of 
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nephrotic syndrome. We have previously identified mutations in EMP2 (epithelial membrane 
protein 2) as a novel monogenic cause of this disease. Detrimental mutations in EMP2 
have been found in patients with steroid-sensitive and steroid-resistant nephrotic syndrome.
Methods: To understand the pathogenic mechanism underlying EMP2 mutations, 
we have generated a zebrafish knockout model of emp2 using TALEN and transgenic 
zebrafish overexpressing caveolin-1 in podocytes. We have also characterized cultured 
human podocytes with shRNA-mediated EMP2 knockdown.
Results: We found that loss of emp2 in zebrafish up-regulated caveolin-1 (cav1), a 
major component of caveolae, in embryos and mesonephric glomeruli, and exacerbated 
podocyte injury. This phenotype could be partially rescued by glucocorticoids. We showed 
that overexpression of cav1 in zebrafish podocytes was sufficient to induce the same 
phenotypes seen in emp2 homozygous mutants, which were treatable by glucocorticoids. 
Consistently, knockdown of EMP2 in cultured human podocytes resulted in an increase of 
CAV1 and a decrease of podocyte survival in the presence of puromycin aminonucleoside, 
while glucocorticoid treatment ameliorated these phenotypes.
Conclusions: Taken together, we have established excessive CAV1 as a mediator of 
the predisposition to podocyte injury due to loss of EMP2, suggesting CAV1 could serve 
a novel therapeutic target of nephrotic syndrome and podocyte injury.
Funding: NIDDK Support, Private Foundation Support
SA-OR051
GLEPP1 Deficiency Defines a Novel Glomerular Disease  Eva Koenigshausen,1 
Christian Weigel,1 Philip Schüppler,1 Laura Lennartz,1 Thorsten Wiech,2 
Catherine Meyer-Schwesinger,2 Roger C. Wiggins,3 Sophie C. Collinson,4 Rachel 
Lennon,4 Magdalena Woznowski,1 Ivo Quack,1 Lars C. Rump,1 Lorenz Sellin.1 
1Univ Hospital Duesseldorf, Germany; 2Univ Hospital Hamburg Eppendorf, 
Germany; 3Univ of Michigan; 4Royal Manchester Children’s Hospital, United 
Kingdom.
Background: Albuminuria is the early clinical marker for glomerular disease. 
Mutations in GLEPP1 were linked with podocytic diseases in children (MCD/FSGS). 
GLEPP1 is a receptor tyrosine phosphatase present in the podocyte foot processes. Its 
precise function is not fully understood.
Methods: GLEPP1 KO and WT mice were examined at 4 and 10 months. Mouse plasma 
and urine were analyzed for cystatin C, albumin and creatinine. qPCR was performed for 
collagen IV (col IV) a1-5, laminin (lam) a1, 5 and b1, 2. Western blot (WB) was stained for 
col IV a1 and lam a1. PAS staining was performed. Cryosections of kidneys were stained 
for col IV a1 and a2. In EM sections GLEPP1 was labeled with immunogold. GBM defects 
were imaged by serial block-face scanning EM to generate 3-D models.
Results: GLEPP1 KO mice display a significantly higher urinary ACR and cystatin 
C compared to WT mice at 10 months. This correlated significantly with focal thickening 
of the GBM in KO mice, resembling GBM humps in light microscopy and TEM. At 
the sights of humps, beginning foot process effacement was observed. qPCR revealed 
significant upregulation of col IV a1, a2 and lam a1, b1 expression while a3 expression was 
significantly down regulated. WB confirmed qPCR results. Immunofluorescence microscopy 
of KO glomeruli revealed enhanced expression of col IV a1, a2 in the GBM. The EM 3D 
models of the GBM confirmed the cone shaped humps and a significant podocyte foot 
process effacement in KO mice. Two albuminuric patients with similar GBM phenotype 
and without signs of MCD or FSGS were identified.
Conclusions: GLEPP1 deficiency mediates the formation of GBM humps in mice and 
potentially in humans. GLEPP1 deficiency mediates GBM composition from a mature to 
an immature state. This switch can only be seen in aging mice and results functionally in 
albuminuria and renal disease. GLEPP1 deficiency defines a novel glomerular disease.
SA-OR052
The Role of Podocyte Associated Angiotensin II Type 1a Receptor in 
Nephrosis  Kazunori Inoue, Xuefei Tian, Shuta Ishibe.  Internal Medicine, Yale 
Univ School of Medicine, New Haven, CT.
Background: Inhibition of the renin-angiotensin system has demonstrated to reduce 
both proteinuria and the decline in GFR. This beneficial effect has been postulated to go 
beyond blood pressure control. Controversies remain on the direct effect of angiotensin 
II (Ang II) on podocytes. Dynamin plays an important role in angiotensin II receptor type 
1a (AT1aR) internalization and we have previously demonstrated that podocyte specific 
Dynamin 1 and 2 knockout (Dnm KO) mice display severe proteinuria and glomerular 
sclerosis. Our objective is to determine whether podocyte specific persistant AT1aR signaling 
in Dnm KO mice results in podocyte injury in–vivo.
Methods: Live cell imaging of fluorescently tagged clathrin and AT1aR in primary 
podocytes from Wild type (WT) and Dnm KO was performed. WT, Dnm KO, Pod-Cre 
Agtr1a fl/- Dnm1 fl/fl Dnm2 fl/fl (Pod Agtr1a KO Dnm KO), and Agtr1a -/- Pod-Cre Dnm1 
fl/fl Dnm2 fl/fl (Agtr1a KO Dnm KO) mice were generated and characterized to unearth 
the role of AT1aR in podocytes.
Results: Clathrin mediated AT1aR internalization was observed after Ang II treatment 
in WT podocytes, but was arrested at the plasma membrane in Dnm KO podocytes. ERK, 
a downstream target of AT1aR, was continuously activated in Dnm KO podocytes after 
Ang II stimulation. Compared with Dnm KO mice, both Pod Agtr1a KO Dnm KO, and 
Agtr1a KO Dnm KO mice showed a decrease in proteinuria (urine albumin creatinine ratio 
were 3708.7 (ug/mg) (Dnm KO) vs 3089.7 (Pod Agtr1a KO Dnm KO) vs 2166.2 (Agtr1a 
KO Dnm KO) at 6 weeks old age respectively) and an advantage in survival. Histological 
examination demonstrated that Pod Agtr1a KO Dnm KO mice showed modest reduction in 
the progression of glomeruloscrelosis, proteinaceous casts compared with Dnm KO mice. 
Agtr1a KO Dnm KO mice showed lower mean arterial blood pressure than Dnm KO mice, 
but there was no difference between the Dnm KO and Pod Agtr1a KO Dnm KO mice.
Conclusions: Our results demonstrate that deletion of Dynamin 1, 2 in podocytes 
results in sustained AT1aR signaling. Inhibition of AT1aR signaling in podocytes plays a 
fundamental role in retarding the progression of podocyte injury when compared to total 
deletion of Agtr1a in Dnm 1, 2 KO podocytes.
SA-OR053
The Spectrum of Nephrotic Syndrome from Minimal Change Disease to 
FSGS Correlates with Rac1 Activation  Richard Robins, Cindy Baldwin, 
Lamine Aoudjit, Indra R. Gupta, Tomoko Takano.  Nephrology, McGill Univ, 
Montreal, QC, Canada.
Background: Within podocytes, cytoskeletal organization is regulated by Rho-family 
GTPases including Rac1. Clinical and animal studies suggest that Rac1 activation within 
podocytes contributes to the pathogenesis of nephrotic syndrome (NS). We hypothesize 
that Rac1 activity is increased in clinical NS and podocyte-specific activation of Rac1 
will result in NS in mice.
Methods: Kidney biopsies from patients with minimal change disease (MCD) and 
idiopathic focal segmental glomerulosclerosis (FSGS) were immunostained for active Rac1. 
Sera from FSGS patients were used for Rac1 activity assays in cultured podocytes. Mice 
carrying the tetracycline-inducible constitutively active Rac1 mutant (L61, CA-Rac1, Flag-
tagged) were bred with mice with the podocin-driven reverse tetracycline trans-activator 
to generate double transgenic mice (DTG). Proteinuria was assessed by the albumin/
creatinine ratio (ACR). Renal histology was evaluated by light, immunofluorescence (IF) 
and electron microscopy.
Results: By IF, active Rac1 staining was increased in glomeruli (co-localized with 
nephrin) in patients with NS. FSGS patient sera activated Rac1 in cultured podocytes. DTG 
mice had 1 or 2 copies of the CA-Rac1 transgene; mice with 2 copies had significantly 
higher proteinuria upon 5 days Dox treatment (high responders), compared with those with 
1 copy (low responders). Foot process effacement was more diffuse and pronounced in 
high responders compared to low responders. When Dox was withdrawn after 5 days, low 
responders returned to baseline proteinuria after 2 weeks while high responders returned 
to near baseline levels after 4 weeks. When Dox was withdrawn after 2 weeks in high 
responders, proteinuria did not resolve. After 1 month, high responders displayed severe 
glomerulosclerosis.
Conclusions: Active Rac1 staining is increased in patients with NS. FSGS sera 
promote Rac1 activation in cultured podocytes. In mice, the amount of Rac1 activation 
within podocytes determines severity of foot process effacement, proteinuria, and degree 
of reversibility upon Dox withdrawal. The amount of Rac1 activation may be a critical 
factor determining whether MCD or FSGS arises within the NS spectrum.
Funding: Government Support - Non-U.S.
SA-OR054
Glomerular TNFα Expression Causes Free Cholesterol Mediated Podocyte 
Apoptosis in DKD and FSGS  Christopher E. Pedigo,1 Farah Leclercq,1 Mayrin 
Correa-Medina,1 Gloria Michelle Ducasa,1 Judith T. Molina David,1 Matthias 
Kretzler,2 Sebastian Martini,2 Robert G. Nelson,3 Alla Mitrofanova,1,4 Armando 
Mendez,5 George William Burke,4 Sandra M. Merscher,1 Alessia Fornoni.1  1Katz 
Drug Discovery Center, Nephrology, U of Miami; 2U of Michigan; 3NIDDK; 
4Surgery, U of Miami; 5Diabetes Research Inst, U of Miami.
Background: Tumor Necrosis Factor alpha (TNFα) levels predict the development of 
Diabetic Kidney Disease (DKD). TNFα inhibition may be efficacious in some patients with 
Focal Segmental Glomerulosclerosis (FSGS). Podocyte injury is observed in both diseases 
and glomerular cholesterol accumulation was associated with albuminuria and reduced 
ATP-Binding Cassette A1 (ABCA1) expression in experimental DKD. We hypothesized 
that TNFα causes lipid dependent podocyte injury in FSGS and DKD.
Methods: Caspase 3 activity and cholesterol efflux was determined in human podocytes 
treated with TNFα. Cyclodextrin (CD) was used for cholesterol depletion.
Results: DKD and FSGS sera treated podocytes showed increased TNFα expression. 
Glomerular TNFα expression correlated with reduced ABCA1 expression in FSGS. 
Podocytes treated with sera from patients with progressive DKD showed reduced ABCA1 
expression compared to non progressive DKD. TNFα treatment increased apoptosis and 
cholesterol content, reduced ABCA1 mediated cholesterol efflux, esterified cholesterol and 
Sterol-O-Acyltransferase (SOAT1) activity. ABCA1 overexpression or CD prevented TNFα 
induced apoptosis. ABCA1 knockdown increased esterified cholesterol content. Treatment 
of ABCA1 knockdown cells with SOAT inhibitors caused apoptosis that was prevented 
by CD. TNFα treated mice showed albuminuria and kidney cholesterol accumulation, the 
former was prevented by CD.
Conclusions: Podocytes treated with FSGS or DKD sera show increased TNFα 
expression. Increased glomerular TNFα expression correlates with reduced ABCA1 
expression in patients with FSGS and reduced ABCA1 expression correlates with DKD 
progression. TNFα attenuates ABCA1 mediated efflux and reduces cholesterol esterification 
leading to free cholesterol mediated apoptosis. Our data suggest that targeting the TNFα-
ABCA1-cholesterol axis may represent a new strategy to treat DKD or FSGS.
Funding: NIDDK Support, Pharmaceutical Company Support - Hoffman La Roche
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SA-OR055
Novel Score to Predict Post-Transplant Outcomes  Miklos Zsolt Molnar,1 
Danh V. Nguyen,2 Vanessa A. Ravel,2 Elani Streja,2 Mahesh Krishnan,3 Yanjun 
Chen,2 Csaba P. Kovesdy,1 Kamyar Kalantar-Zadeh.2  1Univ of Tennessee 
Health Science Center, Memphis, TN; 2Univ of California, Irvine, CA; 3DaVita 
Healthcare Partners, VA.
Background: Several previous studies have developed scoring tools to predict the 
allograft and patients’ survival in kidney transplant patients using information, which was 
not available at the time of transplantation. We developed a score to predict post-transplant 
outcomes using pre-transplant information including routine laboratory data available at 
the time of transplantation.
Methods: Linking the 5-year patient data of a large dialysis organization to the SRTR, 
we identified 15,125 hemodialysis patients who underwent first kidney transplantation. 
Prediction models were developed using Cox models for (a)mortality, (b)transplant 
failure(death censored) and (c)combined death or transplant failure. The cohort was divided 
into a two-thirds development set and a one-third validation set. We used backward-selection 
based on Akaike’s information criterion to avoid arbitrary and ineffective selection rules 
based on p-values. We used the bootstrap method to assess model overfitting and calibration 
using the development dataset. Model predictive discrimination was assessed using the 
index of concordance, or C statistic, which accounts for censoring in time-to-event(a-c).
Results: Patients were 50±13 years old and included 39% women, 15% African-
American and 36% diabetics. For prediction of post-transplant mortality and graft loss 
10-10 predictors were used (recipients’ age, cause and length of ESRD, hgb, albumin, 
comorbidities, race and type of insurance as well as donor characteristics such as donor age, 
diabetes, number of HLA mismatches). The new model showed the overall best C-statistics 
comparing to the currently used EPTS score.
Current model Model based on EPTS predictors
Discrimination C (95%CI) Discrimination C (95%CI)
Combined 0.63 (0.62-0.65) 0.57 (0.56-0.58)
Mortality 0.70 (0.69-0.71) 0.66 (0.65-0.67) 
Allograft failure 0.63 (0.62-0.65) 0.59 (0.58-0.61) 
Conclusions: The new prediction tool, using exclusively data available prior to the 
time of transplantation, performs better to predict outcomes than currently used tool such 
as EPTS.
Funding: Other NIH Support - R21AG047306 and R01DK95668
SA-OR056
Long-Term Deceased Donor Kidney Graft Survival Has Improved in the 
Last Decade  Douglas Scott Keith, Gayle M. Vranic, Angie G. Nishio-Lucar. 
Medicine, UVA, Charlottesville, VA.
Background: Long-term graft survival did not improve significantly in the 1990s. We 
sought to determine if long-term graft survival is improving in the last decade.
Methods: All adults deceased donor renal transplant recipients in the SRTR database 
between 2000 and 2010 were included in the study. K-M survival analysis was carried out 
based on year of transplantation in all recipients who had at least 6 months of graft survival. 
Graft survival, death censored graft survival and death with graft function were analyzed. 
Cox modeling was carried out to determine if the year of transplant affected the outcomes.
Results: 92,616 deceased donor kidney transplants survived at least six months. The 
rate of graft failure has improved over the last decade.
This occurred in spite of the decreasing quality of kidneys based on KDPI. The 
improvement in graft survival was exclusively due to improved death censored graft 
survival. The rate of death with graft function did not change. This steady improvement 
in graft survival occurred during a transition in maintenance immunosuppression from 
cyclosporine based regimens to tacrolimus. Cox analysis confirmed the improvement in 
graft survival and death censored graft survival but also showed that the rate of death with 
graft function was decreasing when adjusted for the covariates.
Transplant Year 
Reference: 2000 H.R of Graft Failure (C.I.)
2001 0.97 (0.93-1.03)
2002 0.94 (0.89-0.98)
2003 0.91 (0.87-0.96)
2004 0.88 (0.84-0.93)
2005 0.85 (0.81-0.89)
2006 0.82 (0.78-0.87)
2007 0.79 (0.75-0.83)
2008 0.71 (0.67-0.75)
2009 0.73 (0.68-0.78)
2010 0.70 (0.65-0.75)
Covariates: Age, Race, Gender, Acute Rejection, DGF, 
KDPI, HLA mismatch, Dialysis Duration, PRA, and Retransplant
Conclusions: Long-term graft survival has improved in the last decade in spite of 
declining donor quality. This improvement was associated with a shift in maintenance 
immunosuppression to tacrolimus.
SA-OR057
Characteristics Associated with Greater Than 5 Year Kidney Graft Survival 
Among HIV+ Recipients  Laura Panarey, Alden Michael Doyle, Karthik M. 
Ranganna.  Nephrology and Hypertension, Drexel Univ Hahnemann Hospital, 
Philadelphia, PA.
Background: We have previously reported that donor factors have direct influence 
on the incidence of peri-operative delayed graft function (DGF), decreased time to acute 
cell-mediated rejection (ACR), and affect graft outcomes.
Methods: Our aim was to identify donor and recipient risk factors associated with 
> 5 year kidney allograft survival among HIV+ recipients by conducting a retrospective 
chart analysis of all HIV + transplants performed at our center with at least 5 years of 
follow up (N=94).
Results: In our HIV + kidney transplant cohort, greater than 5 year allograft survival 
was significantly associated with modifiable risk factors including: living donor allografts 
(LRT), minimizing cold ischemia time, and pre-transplant diagnosis of HCV. Non-
modifiable demographics not associated with at least 5 year survival included: Age, Sex, 
BMI, and the history of CAD or DM. Implicated elsewhere; neither ethnicity nor gender 
mismatch of allograft appeared to significantly affect our HIV + transplant outcomes at 
5years. While cellular and humoral rejection are known to affect the HIV + transplant cohort; 
time to ACR was significantly different, inferior graft survival experienced an earlier first 
ACR (188 ± 258 days vs. 458 ± 444 days, p = 0.02). Reflected in graft outcomes; inferior 
graft survival best GFR 50.58 mL/min ± 25 vs. 65.49 mL/min ± 23, p = 0.02.
Conclusions: Our data suggest that optimization of HIV+ kidney transplant outcomes 
is associated with modifiable factors such as HCV (encouraging data for new treatment); 
addendum of donor quality (LRT preferable) and avoidance of DGF. 
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Identifying the Two Specific Types of Antibody-Mediated Rejection and 
Their Outcomes in Kidney Recipients  Olivier Aubert,1 Alexandre Loupy,1 
Luis G. Hidalgo,2 Jeff Reeve,2 Denis Glotz,1 Christophe M. Legendre,1 Carmen 
Lefaucheur,1 Philip F. Halloran.2  1INSERM; 2ATAGC.
Background: Antibody-mediated rejection (ABMR) can be related to preformed/
recurrent anti-HLA DSA or de novo anti-HLA DSA.
Methods: We included 965 kidney biopsies taken from two North American and 
five European centers and assessed patients with ABMR. We compared patients with 
preformed/recurrent DSA (Type-1 ABMR) to patients with de novo DSA (Type-2 ABMR). 
Microarray-based gene expression was assessed in biopsies. Patients with type-1 were 
managed in two centers with aggressive standardized treatment protocols; type-2 ABMR 
was managed as standard-of-care.
Results: We identified 278 patients with ABMR: 153 (55%) type-1 and 125 (45%) 
type-2. The mean time from transplantation to rejection was 10.1±18.8 vs 84.9±71.1 
months for the type-1 and 2 ABMR. The mean eGFR at the time of biopsy was lower in 
type-1 ABMR (38±18) vs type-2 (46±20 mL/min/1.73m2) (p=0.0012). Kidney biopsies 
with type-1 ABMR presented with higher microcirculation injury (g+ptc score: 3.3±1.4 
vs 2.4±1.5) and less transplant glomerulopathy score (0.5±0.9 vs. 1.6±1.1) (p<0.0001). 
C4d PTC deposition was similar (32% vs 34%). Using the gene expression assessment, 
type-1 ABMR exhibited a higher expression of global disturbance transcripts, injury-repair 
response associated transcripts (IRRATS), endothelial cell associated transcripts (ENDAT), 
injury-induced transcripts (IRIT3) (p<0.0001) but a lower expression of NK cell transcript 
burden (NKB) (p=0.0147). Type-1 and Type-2 ABMR exhibited similar high expression 
of transcripts reflecting γ-IFN response (GRIT1), T cell transcript burden (TCB) and 
macrophage-associated transcripts (QCMAT). Kidney allograft survival at 4 and 8 years 
after rejection was superior in type-1 ABMR (72% and 58%) compared to type-2 (51% 
and 35%) (p<0.0001).
Conclusions: Type-1 and type-2 ABMR present with distinct phenotypes and outcomes. 
The fact that type-1 ABMR is treated with aggressive defined protocols and has superior 
outcomes despite lower GFRs and more molecular injury at the time of biopsy suggests that 
trials of structured aggressive therapy protocols in type 2 ABMR deserve study.
SA-OR059
Serum Dickkopf-1, Renal Allograft Fibrosis and the Risk of Graft Failure 
After Kidney Transplantation  Martin H. De Borst,1 Charlotte A. Keyzer,1 
Jelmer K. Humalda,1 Thomas Vanhove,2 Gerjan Navis,1 Dirk R. Kuypers,2 
Stephan J.L. Bakker.1  1Dept of Nephrology, Univ Medical Center Groningen, 
Netherlands; 2Dept of Nephrology and Renal Transplantation, Univ Hospitals 
Leuven, Belgium.
Background: Renal fibrosis is a final common pathway contributing to graft failure after 
kidney transplantation (KTx). Aberrant Wnt/β-catenin signaling contributes to progressive 
renal fibrosis. Dickkopf-related protein 1 (Dkk-1) is a soluble endogenous inhibitor of the 
Wnt signaling pathway, and is induced in response to tissue injury in animal studies. We 
investigated whether serum Dkk-1 is associated with renal interstitial fibrosis and graft 
failure in renal transplant recipients (RTR).
Methods: Serum Dkk-1 was measured by ELISA (R&D) in two cohorts of outpatient 
RTR. In a cross-sectional cohort we analyzed the relationship between Dkk-1 and prevalent 
renal fibrosis using logistic regression. In a longitudinal cohort we studied the association 
with graft failure using Cox regression.
Results: In the cross-sectional cohort (n=225, 60% male, age 54±13 years) serum 
Dkk-1 was associated with renal fibrosis at two years post-KTx independent of age, sex, 
proteinuria and eGFR (odds ratio 2.10 [95% CI 1.11-3.95], P=0.02). In the longitudinal 
cohort (n=700, 57% male, age 53±13 years, 5.4 [1.9-12.0] years after KTx) 45 (6%) patients 
developed graft failure during 3.1 [2.6-3.8] years of follow-up. Serum Dkk-1 was inversely 
associated with graft failure (HR 0.45 [95% CI 0.27-0.76], P=0.003 per doubling of Dkk-1), 
independent of known risk factors for graft failure or Dkk-1 correlates. The association 
persisted in sensitivity analyses restricted to patients with interstitial fibrosis/tubular atrophy.
Conclusions: We present the first human data connecting serum Dkk-1, an endogenous 
inhibitor of the pro-fibrotic Wnt/β-catenin signaling, with prevalent renal allograft fibrosis, 
and with long-term protection against graft failure in RTR. These findings are in line with 
preclinical studies suggesting that Dkk-1 is induced upon tissue injury and serves as an 
endogenous anti-fibrotic factor, and position Dkk-1 as a potential target for anti-fibrotic 
therapy after KTx.
Funding: Pharmaceutical Company Support - The generation of the cohort was made 
possible by a grant from the Dutch Top Institute Food and Nutrition. M.H.d.B. and C.A.K. 
are supported by a consortium grant from the Dutch Kidney Foundation (NIGRAM 
consortium, grant no. CP10.11). This study was funded by a grant from De Cock-Hadders 
Foundation (grant no. 2015-44).
SA-OR060
Longitudinal Assessment of Cardiac Morphology and Function following 
Kidney Transplantation  Clark David Kensinger,1 Antonio Hernandez,2 
Meagan Fairchild,4 Guanhua Chen,3 Loren Lipworth,4 Talat Alp Ikizler,4 
Kelly A. Birdwell.4  1Dept of Surgery, Vanderbilt Univ Medical Center; 2Dept 
of Anesthesiology, Vanderbilt Univ Medical Center; 3Dept of Biostatistics, 
Vanderbilt Univ Medical Center; 4Dept of Medicine, Vanderbilt Univ Medical 
Center.
Background: Despite improvement in traditional cardiovascular (CV) risk factors 
following renal transplantation, the death rate from CV disease remains high. Our aim 
was to evaluate the longitudinal change of cardiac morphology and function in a cohort 
of patients following renal transplantation, as well as to evaluate the association between 
Fibroblast Growth Factor 23 (FGF-23) concentrations and the evolution of cardiac 
morphology following transplant.
Methods: We performed a longitudinal prospective cohort study of 145 kidney 
transplant recipients, measuring left ventricular mass index (LVMI), left atrial volume 
index (LAVI) and ejection fraction (EF) by echocardiography at months 1 (baseline), 12, 
and 24 post-transplant. FGF-23 levels were measured at months 1 and 24 post-transplant. 
A linear mixed effects model was used to assess each outcome adjusting for age, race, 
gender, time on dialysis, CV disease, mean arterial pressure, glomerular filtration rate, 
diabetes, and body mass index.
Results: The cohort (mean age 49±13 years) was 74% male and 75% white. LVMI 
(P=<0.001), LAVI (P=<0.001), and EF (P=0.009) decreased significantly over time 
following transplant. Results from the multivariate models can be reviewed in Table 1. 
A one-unit decrease in FGF-23 was significantly associated with a 5.83 grams/meter2 
decrease in LVMI (P=0.04).
Conclusions: LVMI, LAVI and EF improved significantly over 12 and 24 months 
post-transplant. There was also a significant association between FGF-23 and LVMI 
following transplant.
Outcome 12 month effect 95% CI P Value
24 month 
effect 95% CI P Value
LVMI -10.95 -16.34, -5.56 <0.001 -14.77
-22.02, 
-7.52 <0.001
LAVI -3.31 -5.13, -1.49 <0.001 -4.95 -7.38, -2.52 <0.001
Ejection 
fraction 1.5 0.09, 2.91 0.04 2.75 0.87, 4.63 0.005
Table 1: Adjusted change in echocardiogram morphology and function following renal 
transplantation
Funding: NIDDK Support, Other NIH Support - UL1TR000445 from the National 
Center for Advancing Translational Sciences
S10RR027033 from the National Center for Research Resources
K24 DK62849 (Ikizler) and P30 DK079341 from the National Institute of Diabetes, 
Digestive and Kidney Diseases; R01 HL070938 (Ikizler)
K23 GM100183 (Birdwell) from the National Institute of General Medical
SA-OR061
Tolerance Induction versus Conventional Immunosuppression in HLA-
Matched Kidney Transplantation: Comparison at Two Years Post-
Transplant  John D. Scandling, Stephan Busque, Judith A. Shizuru, Asha 
Shori, Robert Lowsky, Kent Phillip Jensen, Richard T. Hoppe, Samuel Strober. 
Stanford Univ.
Background: Over 10 years we have studied the safety and efficacy of tolerance 
induction using hematopoietic cell transplantation in combination with kidney 
transplantation.
Methods: Twenty-two patients underwent HLA-matched living donor kidney 
transplantation followed by a conditioning regimen of 10 fractions of total lymphoid 
irradiation (12 Gy total) and 5 doses of ATG. Infusion of purified donor CD34+ 
hematopoietic progenitor cells and T cells was on day 11 post-kidney transplant. Fifty-three 
patients contemporaneously underwent HLA-matched living donor kidney transplantation 
under conventional immunosuppression.
Results: Seventeen patients developed mixed chimerism of 6 months duration or longer 
and have now been off immunosuppression from 1 to 7 years. Their outcomes at two years 
post-transplant are compared to those of the 52 (one graft was lost to thrombosis on day 
1) conventionally treated patients.
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Conventionally 
Treated, 2000-13 Tolerance Induction, 2005-13
Number 52 17
ImmunoRx (mono/dual/triple) 2 / 34 / 16 Off drug 4 to 18 mo (of 24 mo)
Age at transplant (years) 38 +/- 11.2 40 +/- 10.5
Sex (M/F) 26/26 9/8
Cause of ESRD (DM/GN/other) 4 / 17 / 31 1 / 6 / 10
Infection (N of episodes) 8 (1 CMV, 2 v. zoster) 6 (1 CMV, 4 v. zoster)
Cancer 0 1 (breast, at 23 mo)
Acute rejection (N of patients) 3 (5.9%) 0
Creatinine (mg/dL) 1.2 +/- 0.35 1.2 +/- 0.26
Weight gain (kg) 5.2 +/- 7.36 7.4 +/- 8.39
Hypertension 27 (52%) 9 (53%)
Antihypertensive drugs (1/2/3) 15 / 9 / 36 6 / 3 / 0
Hyperlipidemia 20 (39%) 3 (18%)
Post-transplant diabetes mellitus 4 (7.8%) 0
Death-censored graft survival is shown (p=0.10). 
Conclusions: Transplantation under this protocol is safe, achieves tolerance eliminating 
risk of acute rejection, and offers a better metabolic profile and better graft survival with time.
Funding: Other NIH Support - NHLBI, Private Foundation Support
SA-OR062
Better Renal Function Preservation with Early Conversion to Everolimus 
in De Novo Renal Transplant Recipients: 24-Month Results from the 
ELEVATE Study  Johan W. De Fijter,1 Hallvard Holdaas,1 Patricia M. Lopez,2 
Cesar Escrig,2 Zailong Wang,3 Josep M. Cruzado,1 Markus van der Giet.1  1For 
the ELEVATE Study; 2Novartis, Basel, Switzerland; 3Novartis Corporation, 
East Hanover, NJ, USA.
Background: Long-term exposure to calcineurin inhibitors (CNIs) is one of the key 
factors contributing to progressive deterioration of renal function and graft loss. We present 
the 24 month (M) renal outcomes from the ELEVATE study which determined whether 
early CNI to everolimus (EVR) conversion in renal transplant recipients (RTxRs) provides 
better preserved renal function compared to continuation of standard CNIs.
Methods: ELEVATE (NCT01114529) was a 24M, multicenter, open-label study, in 
which de novo RTxRs were randomized (RND) at 10–14 weeks post-transplant to convert 
from CNI to EVR (n=360; C0 6–10 ng/mL) or continue standard CNI (n=357; C0 tacrolimus: 
5–10 ng/mL, cyclosporine: 100–250 ng/mL); all received enteric-coated mycophenolate 
sodium + steroids. The primary end point was change in estimated glomerular filtration 
rate (eGFR; MDRD-4) from RND to M12.
Results: A total of 717 patients were RND; 229 (65%) and 283 (79%) patients 
completed on study drug in EVR and CNI groups, respectively. The least squares (LS) 
mean change in eGFR for EVR vs CNI from RND to M12 was 0.25 vs -1.45 (diff: 1.70, 
p=0.134) and 0.74 vs -1.07 (diff: 1.80, p=0.117) mL/min/1.73 m2 for intent-to-treat (ITT) 
and on-treatment (OT) analysis, respectively. Up to M24, mean eGFR was significantly 
higher at all time-points after RND in EVR vs CNI group for OT analysis. At M24, mean 
eGFR in EVR vs CNI groups was 62.5 vs 57.4 mL/min/1.73 m2 (ITT: p=0.006) and 66.1 vs 
59 mL/min/1.73 m2 (OT: p=0.001), respectively. The difference in eGFR at M24 between 
EVR and CNI groups was 5.1 (ITT) and 7.1 mL/min/1.73 m2 (OT), respectively, in favor 
of EVR. Proteinuria (³3 g/day) was reported in three patients in the EVR group and two 
in the CNI group.
Conclusions: Early conversion to EVR therapy 3M post-transplant vs continued CNI 
resulted in better preserved renal function up to 2-years of follow-up.
Funding: Pharmaceutical Company Support - Novartis
SA-OR063
Month 48 Follow-Up Results of the HERAKLES Study: Superior Renal 
Function After Early Conversion to an Everolimus-Based Calcineurin 
Inhibitor Free Regimen  Klemens Budde,1 Oliver Witzke,1 Thomas Rath,1 Peter 
Weithofer,1 Johannes Jacobi,1 Bruno Vogt,2 Ingeborg A. Hauser,1 Rolf A. Stahl,1 
Petra Reinke,1 Martina Porstner,3 Martin G. Zeier,1 Frank Lehner,1 Wolfgang 
Arns,1 Claudia Sommerer.1  1HERAKLES Study Group, Germany; 2HERAKLES 
Study Group, Switzerland; 3Novartis Pharma, Germany.
Background: To follow up on renal function (GFR) at month (mo) 48 after kidney 
transplantation (Tx) in patients (pts) on immunosuppressive regimen with different 
calcineurin inhibitor (CNI) exposures.
Methods: 802 pts were included in this prospective, open-label, randomized multi-
center study. After induction with basiliximab all pts received cyclosporine A (CsA), 
enteric-coated mycophenolate sodium (EC-MPS) and steroids. 3 mo post Tx 499 pts 
were randomized 1:1:1 to either a) continue standard (STD) CsA (100-180ng/ml) with 
EC-MPS (n=166), b) convert to a CNI-free regimen with everolimus (EVR;5-10ng/ml) + 
EC-MPS (n=171) or c) convert to CNI-reduced regimen CsA (50-75ng/ml) with EVR(3-
8ng/ml) (n=162).
Results: GFR (Nankivell, ITT) was similar at randomization 3 mo post Tx and had 
significantly improved at mo 12 by +5.6mL/min (95%CI:[+2.9;+8.3]; p<0.001) and 
remained significantly improved by +6.8mL/min in favor of CNI-free regimen at mo 
48(p=0.02). 54% of CNI-free, 36% of CNI-reduced and 44% of STD pts had an improvement 
in GFR at mo 48 (p=0.09 CNI-free vs STD). All 3 groups had similar rejection rate since 
randomization (13% STD, 16% CNI-free, 16% CNI-reduced) and overall comparable 
safety profile. Mean trough levels at mo 48 were for CsA 111ng/ml in STD and 86ng/ml 
in CNI-reduced pts and for EVR 5.5ng/ml in CNI-free and 5.5ng/ml in CNI-reduced pts.
Conclusions: CNI-free as well as reduced CNI in combination with EVR represent both 
efficacious and safe regimen. CNI-reduced group had higher CsA levels than anticipated. 
The fact that CNI reduction was not fully accomplished might have prevented GFR 
differences compared to STD in this randomized treatment group. However, CNI-free 
regimen was associated with better GFR maintained for 4 years post Tx. The results of 
this large trial confirm previous reports of improved GFR after CsA withdrawal with EVR 
in combination with EC-MPS.
Funding: Pharmaceutical Company Support - Novartis Pharma
SA-OR064
Belatacept pts Had Superior Graft Survival versus CsA pts: Final 
Results from BENEFIT  Flavio Vincenti,1 J. Grinyo,2 R. Bray,3 L. Rostaing,4 
B. Bresnahan,5 K. Rice,6 S.M. Steinberg,7 H. Gebel,3 M. Polinsky,8 U. 
Meier-Kriesche,8 S. Munier,8 R. Townsend,8 C.P. Larsen.3  1Univ of California, 
San Francisco; 2Univ Hospital Bellvitge, Barcelona, Spain; 3Emory Univ, 
Atlanta; 4Univ Hospital and INSERM U563, IFR-BMT, Toulouse, France; 
5Medical College of Wisconsin, Milwaukee; 6Baylor Univ Medical Center, 
Dallas; 7Sharp Memorial Hospital, San Diego; 8BMS, Lawrenceville.
Background: At 3 and 5 yrs post-transplant in BENEFIT, renal function was improved 
in kidney transplant recipients administered belatacept (bela) vs CsA. We report final 
7-yr results.
Methods: Pts were randomized to more (MI) or less intensive (LI) bela or CsA 
regimens. Outcomes were assessed for all randomized, transplanted pts at yr 7. In a 
prospective analysis, time to death or death-censored graft loss was compared using Cox 
regression. Presence of DSAs was established centrally (FlowPRA®). Kaplan–Meier 
estimates for the cumulative rate of de novo (DN) DSAs were derived. Mean calculated 
GFR (cGFR) was estimated from mos 1–84 using a repeated measures model with an 
unstructured covariance matrix. Differences in cGFR at each time point were also estimated.
Results: In total, 153/219 of bela MI, 163/226 of bela LI, and 131/221 of CsA pts 
were evaluable. HRs comparing time to death/graft loss were 0.573 for bela MI vs CsA 
(P=.02)and 0.570 for bela LI vs CsA (P=.02)—a 43% risk reduction in death/graft loss 
for bela (MI or LI) vs CsA. Cumulative event rates of DN DSAs at yr 7 for bela MI, bela 
LI, and CsA were 1.86, 4.64, and 17.81, respectively. Serious AE rate was similar (71%, 
bela MI; 69%, bela LI; 76%, CsA). Mean cGFR increased slightly over 7 yrs for both bela 
regimens but declined for CsA. Differences in mean cGFR at yr 7 were 25.6 mL/min/1.73 
m2 for bela MI vs CsA and 27.3 mL/min/1.73 m2 for bela LI vs CsA differences favored 
each bela regimen vs CsA at all time points (P<.0001).
Conclusions: In this 7-yr analysis, bela conferred statistically better graft survival and 
renal function vs CsA, with a reduced incidence of DN DSAs. The bela safety profile was 
consistent with previous reports. 
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SA-OR065
Differential Expression of MicroRNA in Urinary Exosomes of Preeclampsia 
Patients  Belinda Bun Jim,1 Alison P. Sanders,3 Daniel Flores,2 Rajeev 
Rohatgi.2  1Medicine/Nephrology, Jacobi Medical Center, Bronx, NY; 2Medicine/
Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY; 3Preventive 
Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Urinary exosomes are low density membrane vesicles originating from 
the multivesicular bodies of upstream renal epithelial cells. The exosomes contain molecules, 
such as microRNA (miRNA), which may serve as potential biomarkers for kidney disease, 
and, in particular, preeclampsia, a systemic disease with renal manifestations that affects 
5-8% of pregnant women in the world.
Methods: We recruited 10 preeclamptic pregnant women and 9 healthy pregnant 
controls; each submitted a 50 mL spot urine sample for exosome isolation. Exosomes were 
isolated by sequential centrifugation and ultracentrifugation, and the exosomal miRNAs 
purified using miRNeasy kit (Qiagen).After isolation of miRNA from urinary exosomes, 
we used the Nanostring nCounter system to assess miRNA expression. Analysis of Variance 
(ANOVA) was performed to test for differences in exosomal miRNA expression (log2) 
between cases (n=10) and controls (n=9). Statistical significance was defined at p<0.05 
and Storey’s false discovery rate q-values were calculated.
Results: After adjusting for maternal age and experimental batch, two miRNAs 
remained statistically significant. miR-544a was upregulated among cases compared to 
controls, whereas and miR-495 was downregulated. Enrichment analysis of the 624 and 
913 highly predicted downstream mRNA targets showed that miR-544a targets were 
enriched for cardiovascular system diseases including arterial pressure (p<4.6x10-4) and 
vasculogenesis (p<1.2x10-3); whereas the targets of miR-495 were associated with renal 
and urological system development (p<2.8x10-6).
Conclusions: We believe that these pilot results demonstrate the potential to identify 
a biomarker for preeclampsia that may be mechanistically plausible. Larger studies are 
presently being conducted.
SA-OR066
Functional Testing of Human Epithelial Na+ Channel Missense Variants 
Identified in the GenSalt Study  Evan C. Ray,1 Jingxin Chen,1 Tanika Kelly,2 
Jiang He,2 D.C. Rao,3 James E. Hixson,4 Dongfeng Gu,5 Shaohu Sheng,1 Thomas 
R. Kleyman.1  1Univ of Pittsburgh; 2Tulane Univ; 3Washington Univ; 4Univ of 
Texas; 5Peking Union Medical College.
Background: In Liddle syndrome, epithelial Na+ channel (ENaC) mutations that 
result in increased cell-surface expression are associated with early on-set hypertension, 
underscoring the importance of this channel in modulating blood pressure. Whether genetic 
variants that result in subtler increases in channel function contribute to salt-sensitive 
hypertension remains unclear.
Methods: A number of human ENaC variants were identified in 300 Genetic 
Epidemiology Network of Salt Sensitivity (GenSalt) participants with salt-sensitive 
hypertension and 300 with salt-independent hypertension. We used the Xenopus oocyte 
expression system to examine the functional properties of missense ENaC variants identified 
in the GenSalt study.
Results: Among 6 SCNN1A (encoding the ENaC α subunit) variants, 3 (aS115N, 
aR476W and aV481M) showed significantly greater, and one (αA334T) showed significantly 
lower ENaC currents than wild type. Among 3 SCNN1B (ENaC β subunit) variants, βD31N 
showed a significant reduction in ENaC currents; bS635N showed a significant increase 
in ENaC currents. Both β subunit variants substitute amino acids in intracellular domains. 
Among 5 SCNN1G (ENaC γ subunit) variants, one (γL438Q) had significantly greater 
ENaC currents than wild type. Each of the variants located in ENaC’s extracellular domain 
that altered channel activity also altered Na+ self-inhibition, a process wherein extracellular 
Na+ suppresses channel open-probability.
Conclusions: Some missense ENaC variants identified in the GenSalt study alter ENaC 
function and may influence salt-sensitivity of blood pressure.
Funding: NIDDK Support, Other NIH Support - NHLBI
SA-OR067
Nephron Specific Deletion of the Prorenin Receptor Modulates Blood 
Pressure and Urinary Na Excretion  Nirupama Ramkumar,1 Deborah Stuart,1 
Elena V. Mironova,2 Vladislav V. Bugay,2 Mykola Mamenko,3 Shuping No 
Wang,1 Oleh Pochynyuk,3 James D. Stockand,2 Donald E. Kohan.1  1Medicine, 
Univ of Utah; 2Medicine, Univ of Texas Health Sciences Center - San Antonio; 
3Medicine, Univ of Texas Health Sciences Center - Houston.
Background: The nephron prorenin receptor (PRR) may modulate blood pressure 
(BP) and Na balance.
Methods: Since previous models of PRR knockout (KO) mice had early lethality 
and/or structural defects, we developed an inducible nephron-wide PRR KO using the 
Pax8/LC1 transgenes.
Results: Disruption of nephron PRR at 1 month of age caused no renal histological 
abnormalities. On a normal Na diet, wild-type (WT) and PRR KO mice had similar BP and 
Na excretion. However, PRR KO mice had elevated PRC (KO- 377 ± 77 vs WT- 127 ± 19 ng 
Ang-I/ml/hr) and a 50% decrease in renal ENaC-α protein. Protein levels of NHE3, NKCC2, 
NCC and ENaC-β/γ were similar between the two groups. Treatment with mouse prorenin 
(10 nM for 30 min) increased ENaC channel number by 2-fold, but not open probability, in 
isolated split-open cortical collecting ducts (CCD) from WT mice; this was prevented by 
PRR inhibition (PRO20) and Akt inhibition (A6730) but unaffected by blockade of AT-1 
(losartan), ERK1/2 (U0126) or p38 MAPK (SB203580). Addition of prorenin (10 nM) did 
not change isolated CCD [Ca2+]i as assessed by Fura-2 loading (10 min exposure). On a 
low Na diet, PRR KO mice had increased Na excretion (Day 2: KO - 66 ± 11 vs WT- 42 ± 
6 mmol/day; Day 6: KO - 39 ± 4 vs ET- 23 ± 4 mmol/day) however, no differences in BP 
were observed. PRC remained elevated in PRR KO mice on a low Na diet. PRR KO mice 
had an attenuated hypertensive response to Angiotensin-II (Ang-II) infusion at 600 ng/Kg/
min for 2 weeks (MAP: KO - 117 ± 4 vs WT - 133 ± 4 mm Hg over 2 weeks). Urinary Na 
excretion was elevated in Ang-II treated PRR KO mice as compared to WT mice (KO-344 
± 14 vs WT-268 ±30 mmol/day).
Conclusions: Taken together, these data indicate that nephron PRR, likely via direct 
prorenin/renin stimulation of an Akt-dependent pathway, stimulates CCD ENaC activity. 
Absence of nephron PRR promotes Na wasting and reduces the hypertensive response 
to Ang-II.
SA-OR068
Pendrin Localizes to the Adrenal Medulla and Modulates Catecholamine 
Release  Annie Y. Park,1 Truyen D Pham,1 William H. Beierwaltes,3 Roy L. 
Sutliff,1 Jill W. Verlander,2 Carla L. Ellis,1 Brandi M. Wynne,1 Robert S. Hoover,1 
Susan M. Wall,1 Yoskaly Lazo-Fernandez.1  1Medicine and Pathology, Emory 
Univ, Atlanta, GA; 2Medicine, Univ of Florida, Gainesville, FL; 3Hypertension 
and Vascular Research, Henry Ford Hospital, Detroit, MI.
Background: Pendrin (Slc26a4) is a Cl-/HCO3- exchanger expressed in renal 
intercalated cells that mediates renal Cl- absorption. Pendrin gene ablation reduces 
blood pressure and vascular volume. While pendrin gene ablation increases plasma renin 
concentration, serum aldosterone is not increased, suggesting that pendrin regulates 
aldosterone production in the adrenal cortex. The purpose of this study was to determine 
if pendrin is expressed in the rodent adrenal gland and if it modulates adrenal function.
Methods: Pendrin mRNA and protein abundance were explored by PCR, immunoblots 
and immunohistochemistry. Mean arterial pressure (MAP) was measured by telemetry. 
Catecholamines were measured by HPLC in plasma samples from mice bearing chronic 
indwelling jugular catheters.
Results: Pendrin localizes to the rodent adrenal gland in epinephrine- and 
norepinephrine-producing chromaffin cells of the adrenal medulla rather than in adrenal 
cortical cells. We examined the effect the pendrin gene ablation on adrenal medullary 
function by measuring stress-induced catecholamine release. While basal levels of 
epinephrine (E) and norepinephrine (NE) were similar, E and NE levels were ~25-50% 
higher pendrin null than in wild type mice after 20 min of immobilization stress. 30 min 
following relief of stress, NE levels were 50% higher in pendrin null than in wild type 
mice. MAP rose in both wild type and pendrin null mice following immobilization stress, 
but MAP in pendrin null mice was 16 mm Hg lower than in wild type mice under basal 
conditions and 12 mm Hg lower following 20 min of immobilization stress (P<0.05). 
However, 30 min after relief of stress, MAP was the same in both groups (Wild type 121± 
1.33 versus 117 ± 3.5 mm Hg, pendrin null mice).
Conclusions: Pendrin is expressed in mouse adrenal medulla where it plays a role 
in restraining catecholamine release during stress, which probably modulates pendrin-
dependent changes in blood pressure.
Funding: NIDDK Support, Other NIH Support - DK46493, DK085097, T32 
DK07656
SA-OR069
Renal-Selective Silencing of Adrenomedullin Gene Causes Hypertension 
in Mice  Xiaoyan Wang, Donghai Zhou, Laureano D. Asico, Hai Lin, John 
Edward Jones, Pedro A. Jose.  Medicine, Univ of Maryland Medical School, 
Baltimore, MD.
Background: Adrenomedullin (ADM) is a potent hypotensive and natriuretic peptide 
whose gene variants are associated with human essential hypertension. Although the 
kidney is one of the ADM producing organs, the mechanism by which ADM induces a 
natriuresis is not clear.
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Methods: To determine the role of renal ADM on blood pressure in C57BL6/J mice 
(3.5 months old, male) fed a 0.6% NaCl diet, we silenced the ADM gene by the renal 
subcapsular infusion of Adm siRNA (3 mg/day), via osmotic minipump, into the remnant 
kidney one week after unilateral nephrectomy. Mock siRNA (3 mg/day) was used as control. 
The mice were placed in metabolic cages for 24 hr urine collection before blood pressure 
was measured under anesthesia, via the femoral artery on day 7.
Results: Body weight, water/food intake, and serum Na+, K+, & Cl- were similar in the 
two groups. Systolic blood pressure was elevated in Adm siRNA group (129.3±5.1, mm 
Hg) relative to Mock group (96.2±1.4n=5/group). The two groups of mice excreted similar 
amounts of sodium and water but the sodium excretion and blood pressure plot in Adm 
mice was shifted to the right of Mock mice. Immunofluorescence confocal microscopy in 
normal mice revealed that ADM was mainly located in the cortex, especially in the apical 
membrane of renal proximal convoluted tubules (RPCT). ADM colocalized with NHE3 
but not with NKCC2 and NCC. ADM also coimmunoprecipitated with NHE3 in whole 
kidney homogenates. In mouse RPCT cells, Adm siRNA decreased ADM protein to 48 
±4% of Mock group (n=4/group) and doubled the protein abundance of NHE3 (192±21) 
but did not alter aNKA. In polarized human PPCT cells, human ADM (1 hr, n=5-6/group) 
inhibited apical sodium transport at 10 nM (84±4 % of vehicle) and 100 nM (81±3%), 
similar to that achieved with the NHE3 inhibitor EIPA (81±6%, 100 nM).
Conclusions: Our data suggest that a renal-selective silencing of ADM gene increases 
blood pressure and impairs sodium excretion that is related, in part, to an increase in NHE3 
abundance and function in the RPCT.
Funding: NIDDK Support
SA-OR070
Vascular AT1 Angiotensin Receptors Regulate Sodium Transporter 
Abundance in Kidney Epithelium  Matthew A. Sparks,1 Susan B. Gurley,1 
Alicia A. McDonough,2 Thomas M. Coffman.1  1Duke; 2USC.
Background: Vasoconstriction is a signature physiological action of angiotensin II 
(AngII) acting via AT1 receptors (AT1R).
Methods: In order to define the contribution of AT1R in vascular smooth muscle cells 
(VSMCs) to BP control, we generated mice with cell-specific deletion of AT1AR from 
VSMCs (SMKOs) using Cre-loxp technology.
Results: Baseline BP was reduced by ~7 mmHg and responses to AngII-induced 
hypertension were blunted by in SMKO mice compared to controls (16 vs. 30 mm Hg ∆ 
BP from baseline after 4 wks AngII, P<0.02). Baseline renal blood flow (RBF) was higher, 
and renal vasoconstriction to AngII was impaired in SMKOs. Moreover, SMKO mice 
displayed Na+ sensitivity and exaggerated natriuresis during chronic AngII. To investigate 
the mechanism of the lower baseline BP and the enhanced natriuresis during AngII infusion 
(1000ng/kg/min for 5 days), we measured a panel of key Na+ transporters in the kidney 
by immunoblot. Baseline measurements in SMKO vs. controls detected reductions in 
NKCC2 in both cortex (0.8±0.03 vs. 1±0.03; P=0.0002) and medulla (0.6±0.02 vs. 1±0.05; 
P<0.0001); medullary NHE3 was similarly reduced (0.6±0.07 vs. 1±0.07; P=0.002). In 
controls, AngII infusion was associated with reduced cortical and medullary NHE3 and 
medullary NKCC, consistent with the pressure-natriuresis response, whereas cortical 
NKCC, NCC and ENaC were all significantly activated. By contrast, in SMKOs, there 
was no AngII infusion dependent depression in cortical or medullary NHE3, nor medullary 
NKCC. However, the extent of increase in activated (cleaved) αENaC was significantly less 
than controls (cortex: 1.46±0.16 vs. 2.58±0.17, P=0.002; medulla: 1.49±0.09 vs. 2.22±0.31, 
P=0.01). Yet, 24 hr urinary aldosterone excretion was not different between the groups 
(18.6±2.7 vs. 15.8±4.5 ng/24hrs).
Conclusions: Our studies indicate that the lower baseline BP in SMKO mice is 
associated with reduced Na+ transporter abundance along the loop of Henle, and that 
attenuated hypertension and improved natriuresis during AngII infusion are associated with 
diminished ENaC activation. We suggest that vascular-epithelial cross-talk modulates renal 
Na+ handling and thereby contributes to BP control at baseline and during hypertension.
Funding: NIDDK Support, Veterans Administration Support
SA-OR071
Chronic Inhibition of Renal Outer Medullary Potassium Channel Not Only 
Prevented but also Reversed Hypertension Development and End Organ 
Damage in Dahl Salt Sensitive Rats  Xiaoyan Zhou,1 Wanda Sharif-Rodriguez,2 
Gail M. Forrest,1 Daphne Szeto,1 Olga Price,1 Yonghua Zhu,1 Andra S. 
Stevenson,1 Yuchen Zhou,1 Sloan Stribling,1 Maya Dajee,1 Shawn P. Walsh,1 
Alexander Pasternak,1 Kathleen A. Sullivan.1  1Merck & Co., NJ; 2Regeneron 
Pharmaceuticals, NY.
Background: The renal outer medullary potassium (ROMK) channel mediates 
potassium recycling and facilitates sodium reabsorption through the Na+/K+/2Cl- 
cotransporter in the loop of Henle and potassium secretion at the cortical collecting duct. 
Evidence from the phenotype of humans and rodents with functional ROMK deficiency 
supports the contention that selective ROMK inhibitors (ROMKi) will represent a novel 
diuretic with potential of therapeutic benefit for hypertension. ROMKi have been recently 
synthesized by Merck & Co. The present studies were designed to examine effects of 
ROMKi A on systemic hemodynamic, renal function and structure, and vascular function 
in Dahl salt-sensitive (SS) rats.
Methods: Four experimental groups: control, high salt diet alone; ROMKi A 3 mg•kg-
1d-1; ROMKi A 10 mg•kg-1d-1; and hydrochlorothiazide (HCTZ) 25 mg•kg-1d-1 were included 
in the prophylactic (from week 1 to week 9 on high salt diet) and therapeutic study (from 
week 5 to week 9 on high salt diet), respectively. The compounds were administrated in feed. 
Blood pressure was measured by radiotelemetry. Renal function was assessed in metabolic 
cage studies. Vascular function was assessed by vascular relaxation assay.
Results: ROMKi A produced sustained blood pressure reduction and improved renal 
and vascular function and histological alterations induced by a high salt diet. ROMKi A was 
superior to HCTZ at reducing blood pressure. Furthermore, ROMKi A provided beneficial 
effects on both lipid profile and bone mineral density.
Conclusions: Chronic ROMK inhibition not only prevented but also reversed 
hypertension development and end organ damage in Dahl SS rats. Our findings may suggest 
a great potential of ROMKi as novel antihypertensive agents, particularly in treating salt 
sensitive hypertension patient population.
Funding: Pharmaceutical Company Support - Merck & Co.
SA-OR072
Analysis of Children with Hypercalciuria and Kidney Stones Identified 
a Mutation in a 5’ Upstream Regulatory Element of Claudin-14 That 
Increases Gene Expression  R. Todd Alexander, Megan E. Ure, Wanling Pan, 
Emmanuelle Cordat.  Univ of Alberta, Edmonton, AL, Canada.
Background: Kidney stones are prevalent and painful. The greatest risk factor for 
kidney stones is hypercalciuria for which the etiology is largely unknown. A recent GWAS 
study linked hypercalciuria to claudin-14, however it failed to identify the molecular 
mechanism mediating disease. We recently determined a role for claudin-14 in inducing 
calcium excretion when plasma calcium levels are elevated. We postulated therefore that 
children with kidney stones may have a mutation in CLDN14 increasing its expression.
Methods: To assess this hypothesis, we collected DNA from 16 children with idiopathic 
hypercalciuria and sequenced the target gene, including introns. To assess for a functional 
effect of the identified SNP we performed dual luciferase assays. We also engineered the 
identified mutant region in front of the SV40 promoter and the CLDN14 coding sequence and 
created stable cell lines. In silico studies were used to identify potential novel transcritpion 
factor binding sites introduced by identified SNPs and gel electrophoretic mobility shift 
assays to asses the binding of a transcription factor to the sequences.
Results: We found an intronic SNP in CLDN14 that occurred with greater frequency 
in children with hypercalciuria and kidney stones relative to ethnically matched controls 
(from the 1000 genome project). Dual luciferase assays found the mutant sequence doubled 
expression while the wild type had no effect (relative to empty vector). Despite similar 
numbers of the engineered constructs being incorporated into genomic DNA of the stable 
cell lines, the mutant sequence doubled mRNA and protein expression. In silico studies 
predicted the SNP introduced a novel INSM1 transcription factor binding site. To asses 
this, we expressed the WT and mutant luciferase constructs in the presence and absence 
of INSM1 and found a further increase in expression. Finally, gel electrophoretic mobility 
shift assays confirmed preferential binding of INSM1 to the mutant sequence.
Conclusions: Some children with hypercalciuria and kidney stones have a intronic 
mutation in CLDN14 that introduces a novel INMS1 binding site.
Funding: Government Support - Non-U.S.
SA-OR073
Oxalobacter-Derived Bioactive Factors Reduce Urinary Oxalate Excretion 
in a Mouse Model of Primary Hyperoxaluria  Hatim A. Hassan,1 Donna 
L. Arvans,1 Yong-chul Jung,1 Dionysios A. Antonopoulos,1,3 John R. Asplin,2 
Ignacio Granja,2 Jason C. Koval,3 Mark W. Musch,1 Eugene B. Chang.1  1Univ 
of Chicago; 2Litholink Corporation; 3Argone National Laboratory.
Background: Hyperoxaluria is a major risk factor for calcium oxalate kidney stones 
(COKS) and has no therapy. The probiotic bacterium Oxalobacter formigenes (Of) plays a 
critical role in preventing recurrent COKS by metabolizing its host dietary oxalate, leading to 
reduced intestinal absorption and urinary excretion. Of also interacts with colonic epithelium 
by inducing colonic oxalate secretion, leading to reduced urinary excretion, via an unknown 
secretagogue. Sustaining Of colonization in animals and humans in the absence of high 
exogenous oxalate remains problematic, underscoring the need for identifying Of-derived 
factors exerting effects similar to live Of.
Methods: We previously found that small molecular weight protein(s) and/or peptide(s) 
in Of culture conditioned medium (CM) significantly stimulate oxalate transport (>2-fold) 
by human intestinal Caco2-BBE cells. To evaluate the CM in vivo effects, CM or OM 
(control medium) was given rectally as enemas (100 µl twice daily x 23 days) to PH1 mice 
(a mouse model of primary hyperoxaluria type 1).
Results: The CM significantly reduced urinary oxalate excretion by 32.5% while 
OM has no effect (µM/mg creatinine: OM = 51.50±3.33; 46.08±2.04; CM = 47.27±3.43; 
31.91±4.81; before and after treatment, respectively). To test our hypothesis that the 
observed reduction in urinary oxalate is due to CM-induced enhanced colonic oxalate 
secretion, colonic tissues were isolated and mounted in Ussing chambers. While a small 
net oxalate secretory flux (-1.54) is observed in distal colonic tissues from OM-treated 
mice, a >10-fold higher net oxalate secretory flux (-16.34) is seen in distal colonic tissues 
from CM-treated mice(pmol/cm2/h: OM: JMS (absorptive flux) = 39.99±5.29, JSM (secretory 
flux) = 41.53±4.59; CM: JMS = 42.62±3.67, JSM = 58.96±3.02), which is due to significantly 
increased JSM.
Conclusions: We conclude that Of-derived bioactive factor(s) retain(s) its/their 
biological activity in vivo and significantly reduce(s) urinary oxalate excretion in PH1 
mice by stimulating distal colonic oxalate secretion.
Funding: NIDDK Support, Other NIH Support - Digestive Disease Research Center 
of the University of Chicago(NIDDK P30 DK42086), Private Foundation Support
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SA-OR074
Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and 
Kidney Stone Disease  Jonathan Nicodemos Eberhard, Shrikant R. Mulay, 
Jyaysi Desai, Julian A. Marschner, Santhosh Kumar Vr, Hans J. Anders.  Ludwig 
Maximillians Univ, Germany.
Background: Nephro- or urolithiasis involves intratubular mineral hypersaturation 
as well as lack of crystallization inhibitors to form crystal plugs obstructing renal 
tubules. Recently, NLRP3 inflammasome-related renal inflammation was added as a 
pathomechanism of acute oxalosis (Mulay et al, JCI 2013) as well as nephro-/urolithiasis 
(Knauf et al, KI 2013). As TNF receptor (TNF-R) signaling is a major mediator of 
inflammation in several chronic kidney diseases (CKD), we speculated that TNF-Rs would 
also drive the progression of nephrolithiasis-related CKD.
Methods: All in vivo experiments were approved by the local government authorities. 
Immunohistochemistry, WB, RT-PCR and atomic force microscopy (AFM) were used for 
data analysis.
Results: We observed that kidney immunostaining of humans and mice with 
hyperoxaluria-related CKD displayed strong tubular positivity for TNF-α, TNF-R1 and 
TNF-R2, which was absent in healthy kidneys. WB and mRNA expression analyses were 
consistent in mice kidneys. To test our hypothesis we fed an oxalate-rich diet to wild 
type (WT) mice or mice deficient for Tnfr1, Tnfr2 or Tnfr1/2. Oxalate feeding induced 
CaOx nephrolithiasis and progressive CKD in WT mice. Surprisingly, KO mice showed 
absolutely no intrarenal CaOx crystal deposits, as revealed by computed tomography as 
well as kidney immunostainings for CaOx, despite comparable hyperoxaluria and urinary 
calcium concentrations to WT mice. Further, we measured the adhesion forces between 
tubular epithelial cells and CaOx crystals by atomic force microscopy. We observed that lack 
of TNFR1/2 impairs CaOx crystal adhesion to the tubular epithelial cell surface. However, 
in an independent experiment we did not see any direct binding of CaOx crystals to the 
soluble TNF-R1-IgG fusion protein. Instead, we observed that TNF-R signaling is indeed 
required for inducing the expression of known crystal adhesion molecules viz. osteopontin, 
CD44, annexin II on tubular epithelial cells in vitro and in vivo.
Conclusions: We conclude that TNF-Rs are essential mediators of CaOx crystal 
adhesion at the luminal membrane of renal tubules as a fundamental mechanism of oxalate 
nephropathy.
SA-OR075
Critical Role of Toll-Like Receptor 4 in Crystal-Induced Inflammation 
and Renal Failure  Venkata Surya Narayana Murty Darisipudi,1 Christoph 
Daniel,2 John R. Asplin,3 Ignacio Granja,3 Kerstin U. Amann,2 Kai-Uwe Eckardt,1 
Peter S. Aronson,4 Felix Knauf.1,4  1Dept of Nephrology und Hypertension, 
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany; 2Dept of 
Nephropathology, Univ Erlangen, Erlangen, Bavaria, Germany; 3Litholink 
Corporation, Chicago, IL; 4Dept of Internal Medicine, Yale Univ School of 
Medicine, New Haven, CT.
Background: Crystal-induced inflammation is a serious condition associated with 
chronic kidney disease. We have recently demonstrated that progressive renal failure in 
oxalate crystal nephropathy results from NLRP3-mediated inflammation. Since interactions 
between NLRP3 and Toll-like receptors (TLRs) have been described, we examined the role 
of TLRs to identify early molecular mechanisms initiating crystal-induced renal failure.
Methods: We evaluated the expression of TLRs in renal sections of mice and humans 
with crystal-induced renal failure. Age- and gender-matched wild-type and Tlr4-null 
mice were placed on a high soluble oxalate diet and monitored for progression of renal 
failure longitudinally by measuring plasma creatinine via retroorbital blood collections, 
and animals were monitored for mortality. Urine oxalate levels were measured and renal 
histology examined for crystal deposition, tubular damage and macrophage infiltration 
using F4/80 staining.
Results: Crystal-induced renal damage was observed to upregulate TLR4 expression in 
renal tubule epithelial cells and interstitium in mice and humans with oxalate nephropathy. 
Tlr4-null mice demonstrated reduced crystal deposition, tubular damage and inflammation 
on renal histology despite identical urinary oxalate excretion as compared to wild-type mice. 
Moreover, Tlr4-null mice were completely protected from the progressive renal failure that 
was associated with 100% mortality in wild-type mice.
Conclusions: Taken together, these findings highlight the importance of TLR4 as a 
critical mediator of crystal-induced inflammation and progressive renal failure. Blocking 
TLR4 with neutralizing antibodies/inhibitors may represent a therapeutic approach to treat 
patients suffering from crystal-induced inflammatory kidney disease.
SA-OR076
ALLN-177 Oral Enzyme Therapy Reduces Urinary Oxalate in Patients with 
Secondary Hyperoxaluria (20 HO) and Recurrent Kidney Stones: Results of 
a Phase 2 Study  Gyan Pareek,1 James E. Lingeman,2 Zeph Okeke,3 Linda H. 
Easter,4 Danica Grujic,5 Craig B. Langman,6 Jennifer Nezzer,7 Lee Brettman.5 
1Miriam Hospital, Brown Univ; 2IU Health Methodist; 3North Shore LIJ; 4Allena 
Conslt; 5Allena; 6NWU; 7PRG.
Background: (20HO) can lead to kidney stones (KS) and oxalate nephropathy which 
can result from excess absorption of dietery oxalate of an unknown cause idiopathic 
hyperoxaluria (IH), or in patients with enteric hyperoxaluria (EH). Presently there are no 
pharmacological therapies (Rx) to reduce 20HO. ALLN-177 is an orally-administered, 
oxalate-degrading enzyme Rx that significantly reduced oxalate excretion shown in a 
previous Phase 1 study. Objective: To test the efficacy and safety of ALLN-177 in patients 
with 20HO and a history of recurrent calcium oxalate KS.
Methods: 16 male and female patients with KS within the last 2y (5 EH and 11 IH), 
were enrolled in a multi-center, open-label, single arm study. Patients continued their regular 
diets and medical Rx (8/16 subjects had thiazides, K-citrate, or calcium supplements). The 
study had a 35d screening period, a 3d baseline, a 4d ALLN-177 Rx (7,500 u/meal TID) 
and a 4d follow up. 8x24h urines were collected. Safety assessments and 24h dietary recalls 
(DR) were performed. The 10 endpoint was the per subject change in mean 24h urinary 
oxalate (Uox) from baseline to ALLN-177 Rx.
Results: Mean baseline Uox (SD) for all subjects was 77.7 (55.9) mg/d and during 4 
days of ALLN-177 Rx, it was reduced 14mg to 63.7 (40.2) mg/d, p=0.0084. Mean daily 
dietary oxalate, calcium and fluid intakes based on DR were 200, 199, 840 mg and 3.4 L, 
respectively and did not differ by study period. Mean baseline Uox for EH and IH were 
110.5(82.9) vs. 62.7(33.8) mg/d, while the reduction on ALLN-177 Rx was 22.0 (26.6) 
vs 10.2 (13.3) mg/d, respectively. The CaOx relative urinary supersaturation index was 
reduced from 11.6 to 8.8, with 95% CI of [-4.9, -0.78]. This difference was driven by 
oxalate reduction, but not any other urinary parameters. ALLN-177 was well tolerated, 
and no safety issues were noted.
Conclusions: In this Phase 2 study, ALLN-177 significantly reduced urinary oxalate 
excretion and supersaturation index.
Funding: Pharmaceutical Company Support - Allena
SA-OR077
Diet-Dependent Net Acid Load, Protein Intake, and Risk of Incident 
Kidney Stones  Pietro Manuel Ferraro,1,2 Ernest I. Mandel,2 Gary C. Curhan,2 
Giovanni Gambaro,1 Eric N. Taylor.2  1Div of Nephrology, Catholic Univ of 
the Sacred Heart, Rome, Italy; 2Channing Div of Network Medicine, Harvard 
Medical School, Boston.
Background: Higher dietary acid load and protein intake may increase risk of 
kidney stones (KS). However, associations between net acid load and stone risk have not 
been explored in population-based studies, and it is not known whether stone risk varies 
according to protein type.
Methods: We prospectively examined the association between estimated net 
endogenous acid production (NEAP), protein intake (vegetable [VP], dairy [DP] and 
animal non-dairy [AP]) and risk of incident KS in three large ongoing cohorts, the Health 
Professionals Follow-up Study (n=42,919 men), Nurses’ Health Study I (n=60,128 older 
women), and Nurses’ Health Study II (n=90,629 younger women). We used Cox hazards 
regression models to generate hazard ratios (HRs) adjusted for age, BMI, dietary, lifestyle, 
and medical factors. We also analyzed multivariable associations between NEAP and 24-h 
urine composition in >6,000 study participants.
Results: During 3,133,014 person-years of follow-up, there were 6,347 incident KS. 
There was a significant association between NEAP and KS risk in all cohorts (pooled HR 
for highest vs lowest quintile 1.41, 95% CI 1.16, 1.72; p-value for trend < 0.001). There 
was no association between VP intake and risk of KS. There was a significant association 
between AP intake and risk of KS in HPFS (HR 1.14, 95% CI 0.97, 1.35; p-value for trend 
= 0.04) and NHS I (HR 1.23, 95% CI 1.01, 1.49; p-value trend = 0.05) but not in NHS II. 
There was no association between DP and risk except in NHS II, where the HR was 0.83, 
95% CI 0.72, 0.95; p-value trend =0.003. After multivariable adjustment, participants in 
the highest compared with lowest quintile of NEAP had 85 mg/d less urine citrate, 0.18 
lower urine pH, 177 mL/d less urine volume, and higher urine supersaturations with respect 
to calcium oxalate and uric acid (all p-values ≤ 0.001).
Conclusions: In 3 large cohorts, higher NEAP is associated with higher risk of KS, 
as well as lower urine citrate and pH. In contrast with AP, VP and DP are not associated 
with higher risk of KS.
Funding: Other NIH Support - NIH grants DK094910, DK91417, CA186107, 
CA176726 and CA167552
SA-OR078
Urologic Interventions for Urolithiasis and Risk of Incident Hypertension 
and Chronic Kidney Disease: A Population-Based Cohort Study 
Michelle Denburg,1,2 Thomas Jemielita,2 Gregory Edward Tasian,1,2 Kevin 
Haynes,2 Phillip Mucksavage,2 Justine Shults,1,2 Lawrence A. Copelovitch.1,2 
1The Children’s Hospital of Philadelphia; 2Perelman School of Medicine, Univ 
of Pennsylvania.
Background: We sought to determine if among individuals with urolithiasis, 
extracorporeal shock wave lithotripsy (ESWL) and ureteroscopy (URS) are associated 
with a higher risk of incident hypertension (HTN) and/or chronic kidney disease (CKD).
Methods: A population-based retrospective cohort study using The Health 
Improvement Network comprised 11,570 participants (pts) with incident urolithiasis and 
127,464 pts without urolithiasis; pre-existing HTN and CKD were excluded. 1319 and 
919 of urolithiasis pts had ³1 ESWL or URS procedure, respectively. Median year for the 
start of follow-up was 2006. Cox regression, adjusted for age, gender, diabetes, gout, and 
calendar time, was used to estimate the hazard ratio (HR) for incident HTN and CKD 
stage 3-5 in separate analyses.
Results: Over a median of 3.7 and 4.1 years, 1423 (12.3%) and 595 (5.1%) of 
urolithiasis pts developed HTN and CKD, respectively. Urolithiasis was associated with a 
HR for HTN of 1.42 (95% CI: 1.35, 1.51; p<0.001) and for CKD of 1.82 (95% CI: 1.67, 
1.98; p <0.001). ESWL was associated with an increased risk of HTN with a HR of 1.34 
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(95% CI: 1.15, 1.57; p <0.001), while URS was not. When further stratified as ESWL to 
the kidney or ureter, only ESWL to the kidney was independently associated with HTN 
(HR 1.40, 95% CI: 1.19, 1.66; p <0.001). 
Neither ESWL nor URS was associated with incident CKD.
Conclusions: Given that urolithiasis itself was associated with a HR of 1.42 for 
HTN, an individual who undergoes ESWL to the kidney can be expected to have a HR of 
1.96 (95% CI: 1.67, 2.29; p <0.001) compared to an individual without urolithiasis. We 
recommend judicious use of ESWL if a calculus is asymptomatic or URS is a viable option.
Funding: NIDDK Support
SA-OR079
Anti-MicroRNA-21 Oligonucleotides Prevent Renal Fibrosis Progression 
by Blocking the Auto-Regulatory Loop of miR-21/PDCD4/AP-1 During 
Myofibroblasts Activation  Qi Sun, Junwei Yang.  Center for Kidney Disease, 
Second Affiliated Hospital, Nanjing Medical Univ, Nanjing, Jiangsu, China.
Background: Renal fibrosis is a final common pathway of chronic kidney injury. During 
the injury, the resident fibroblasts are stimulated and trans-differentiated into myofibroblasts, 
which produce a large amount of extracellular matrix (ECM) components and ultimately lead 
to the loss of kidney function. Sustained activation of myofibroblasts is considered to play 
a key role in perpetuating renal fibrosis, but the driving force of myofibroblasts activation 
is only partially understood. Aberrant expression of miRNAs is associated with numerous 
pathologic processes including renal injury. To date, some investigations have identified 
specific overexpression of miR-21 in the progression of kidney fibrosis. Nevertheless, the 
precise role of miR-21 in myofibroblasts activation remains largely unknown.
Methods: To understand the role of miR-21 in the progression of kidney fibrosis, 
microarray and quantitative real-time PCR analysis were performed to examine the 
expression level of miR-21 in unilateral ureteral obstruction (UUO)-injured mice. Then, 
mice were administered with control or antagomir-21 before or during surgery by tail 
vein injection, to determine whether blocking miR-21 in kidneys affects UUO-induced 
renal fibrosis.
Results: In this study, we identified miR-21 was instantly up-regulated after TGF-b1 
stimulation, and maintained itself at constant high levels by employing a microRNA-21/
programmed cell death protein 4/activation protein-1 (miR-21/ PDCD4/ AP-1) auto-
regulatory loop during myofibroblasts activation. The persistent up-regulated miR-21 
depressed Smad7 and PTEN expression and eventually enhanced TGF-b1/Smad pathway 
to promote fibrosis progression. More importantly, we found miR-21 sequestration in mouse 
kidneys attenuated UUO-induced renal fibrosis.
Conclusions: Altogether, these data suggest that miR-21 is a main driving force of 
myofibroblasts activation and keeps its high expression level by an auto-regulatory loop 
of miR-21/PDCD4/AP-1. Targeting this aberrantly activated feedback loop may provide 
new therapeutic strategy in treating fibrotic kidneys.
Funding: Government Support - Non-U.S.
SA-OR080
Silencing of MicroRNA-132 Reduces Renal Fibrosis by Selectively 
Inhibiting Myofibroblast Proliferation  Roel Bijkerk,1,2 Ruben de Bruin,1 
Coen van Solingen,1 Janine van Gils,1 Jacques Duijs,1 Eric P. van der Veer,1 Ton 
J. Rabelink,1 Benjamin D. Humphreys,2 Anton Jan Van Zonneveld.1  1Dept of 
Nephrology and Einthoven Laboratory for Experimental Vascular Medicine, 
Leiden Univ Medical Center, Leiden, Netherlands; 2Renal Div, Brigham & 
Women’s Hospital and Harvard Medical School, Boston.
Background: Chronic kidney disease is associated with progressive renal fibrosis. 
Lineage analysis has shown that FoxD1-derivative perivascular cells give rise to the majority 
of α-SMA positive myofibroblasts during renal fibrosis. We sought to identify pericytic 
microRNAs that could serve as a target to decrease myofibroblast formation.
Methods: To that end, we induced kidney fibrosis in FoxD1-GC;Z/Red-mice by 
unilateral ureteral obstruction (UUO) followed by FACS sorting of dsRed-positive FoxD1-
derivative cells and profiled for differentially expressed miRNAs.
Results: MiR-132 expression selectively increased 21-fold during pericyte-to-
myofibroblast formation whereas miR-132 was only 2.5-fold upregulated in total kidney 
lysates (both in UUO and ischemia-reperfusion injury). Antagomir-induced miR-132 
silencing in the UUO model resulted in 35% decreased collagen deposition and decreased 
tubular apoptosis. Immunohistochemistry, Western blot and qRT-PCR analyses confirmed a 
similar decrease in α-SMA positive cells. Pathway analysis of differential gene expression 
in myofibroblasts identified a rate-limiting role for miR-132 in myofibroblast proliferation 
that was confirmed by in vitro studies with cultured fibroblasts. Indeed, UUO kidneys 
of antagomir-132 treated mice displayed a significant reduction in proliferating, ki67+ 
myofibroblasts. Interestingly, this reduction in proliferation was selective for the interstitial 
compartment and did not impair the reparative proliferation of tubular epithelial cells, as 
evidenced by increased numbers of ki67+ epithelial cells, as well as increased (p-)RB1 and 
Cyclin-A and decreased RASA1 and p21 levels in total kidney lysates.
Conclusions: Taken together, silencing miR-132 counteracts the progression of renal 
fibrosis by selectively decreasing myofibroblast proliferation and could potentially serve 
as a novel antifibrotic therapy.
SA-OR081
Characterizing the Molecular Identity of Pathogenic Fibroblasts Using 
Single Cell RNAseq  Yongen Chang,1 Kai-Hui Sun,1 Ian Driver,2 Andrew J. 
King,3 Meagan Fricano,3 Jason Rock,2 Nilgun Reed,1 Dean Sheppard.1  1Dept 
of Medicine, Univ of California San Francisco, San Francisco, CA; 2Dept of 
Anatomy, Univ of California San Francisco, San Francisco, CA; 3Abbvie Inc., 
Chicago, IL.
Background: Fibroblasts are the main effectors of organ fibrosis but their molecular 
identity is poorly understood. Using Col1a1-GFP mice, we isolated pathogenic fibroblasts 
from 3 fibrotic organs and performed single cell RNAseq analysis.
Methods: We induced fibrosis in the kidney (unilateral ureteral obstruction), lung 
(intratracheal bleomycin) and liver (carbon tetrachloride injections). With fluorescence-
activated cell sorting, we isolated collagen-expressing GFP positive cells from each organ. 
Single cell cDNA was obtained via a fluidic system and libraries generated and sequenced. 
We performed hierarchical clustering (HC) analysis, principal component analysis (PCA) 
and targeted correlation assays on RNAseq data.
Results: We analyzed 130 kidney cells, 160 lung cells and 177 liver cells. HC and PCA 
analysis revealed 3 distinct groups of fibroblasts in fibrotic kidney and lung. Group 1 express 
high levels of collagen 1 and a set of fibroblast-related genes. Group 2 express low levels 
of collagen 1 and leukocyte markers. Group 3 express intermediate levels of collagen 1 as 
well as fibroblast-related genes and leukocyte markers. This group may represent circulated 
fibrocytes. In contrast, collagen-expressing cells in the liver are a mostly homogeneous 
population that differs substantially in gene expression from those of the lung and kidney. 
By correlation assays, we found 63 genes that highly correlate with col1a1 in renal, lung 
and liver fibroblasts. Some of these are known fibroblast-related genes but many are novel.
Conclusions: We characterized the molecular diversity of fibroblasts in 3 fibrotic 
organs. While pathogenic fibroblasts from the kidney, lung and, less so, liver share a core 
identity, they also each express a unique set of genes. This study may yield new biomarkers 
and therapeutic targets for treating fibrosis.
Funding: Pharmaceutical Company Support - Abbvie Inc., Private Foundation 
Support
SA-OR082
Persistent Activation of Autophagy in Kidney Tubular Cells Promotes 
Renal Interstitial Fibrosis During Unilateral Ureteral Obstruction 
Man J. Livingston,1,2 Zheng Dong.1,2  1Georgia Regents Univ; 2Charlie Norwood 
VA Medical Center, Augusta, GA.
Background: Renal fibrosis is the final, common pathway of end stage renal disease. 
Whether and how autophagy contributes to renal fibrosis remains largely unknown.
Methods: Using pharmacological and genetic inhibitory approaches, our study has 
determined the regulation of renal interstitial fibrosis by autophagy in a mouse model 
of unilateral ureteral obstruction (UUO) and in TGF-b1-treated proximal tubular cells.
Results: UUO led to renal interstitial fibrosis, which was associated with persistent 
autophagy in kidney proximal tubules, as indicated by punctuate LC3 staining, LC3-II 
accumulation, P62 degradation as well as autophagosome formation and maturation. 
Pharmacological inhibitors of autophagy (chloroquine and 3-methyladenine) partially 
suppressed interstitial fibrosis during UUO. The inhibitors also suppressed apoptosis in 
renal tubules. Moreover, knockout of Atg7 specifically from kidney proximal tubules 
(PT-Atg7 KO) not only blocked autophagy but also attenuated renal fibrosis. Proliferation 
and activation of fibroblasts, as indicated by the expression of α-SMA and vimentin, was 
inhibited in these mice, so was the accumulation of extracellular matrix components 
including fibronectin and collagen fibrils. UUO induced 8.4% interstitial fibrosis in 
wild-type kidneys after 4 days of obstruction, which was further increased to 13.5% by 1 
week and 25% after 2 weeks. The fibrotic lesions were significantly reduced in PT-Atg7 
KO kidneys at all three time points, with 4.5% for 4-day, 7.9% for 1-week and 15.2% 
for 2-week respectively. UUO led to FGF2 expression in wild-type kidneys, which was 
markedly reduced in PT-Atg7 KO mice. PT-Atg7 KO mice also showed significantly less 
interstitial macrophage infiltration and tubular apoptosis. In cultured proximal tubular 
cells, TGF-b1 induced autophagy and the accumulation of fibronectin and, inhibition of 
autophagy suppressed fibronectin accumulation.
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Conclusions: Together, the results suggest that persistent activation of autophagy in 
kidney proximal tubules promotes renal interstitial fibrosis by regulating tubular cell death, 
interstitial inflammation, and the production of profibrotic cytokines.
Funding: NIDDK Support, Veterans Administration Support
SA-OR083
Macrophage Migration Inhibitory Factor Promotes Kidney Fibrosis in 
ADPKD  Xia Zhou,1,2 Li Chen,1,2 Dorien J.M. Peters,3 Mihaela Gadjeva,4 
Xiaogang Li.1,2  1Internal Medicine; 2Kidney Inst, Univ of Kansas Medical 
Center, Kansas City, KS; 3Leiden Univ Medical Center, Leiden, Netherlands; 
4Harvard Medical School, Boston, MA.
Background: Macrophage migration inhibitory factor (MIF) is a pleotropic cytokine 
that functions to induce cell proliferation, inhibit apoptosis and regulate the inflammation. 
We found that MIF promoted renal cyst growth in different ADPKD mouse models (Chen 
et al., JCI, 2015). Renal cyst progression is accompanied by tubulointerstitial fibrosis which 
is associated with the renal function decline. However, whether MIF regulates fibrosis in 
ADPKD remains unknown.
Methods: To understand the role of MIF in regulating renal fibrosis in vivo, we 
generated Pkd1nl/nl:MIF-/- mice.To explore the pathways mediated by MIF in regulating this 
process, we treated renal epithelial cells and fibroblasts with MIF or MIF inhibitor, ISO-1.
Results: We found that knockout of MIF or inhibition of MIF with ISO-1 not only 
delayed cyst growth but also decreased renal interstitial fibrosis as examinedby Trichrome 
Masson staining, and decreased the expression of TGFβ, Col1A1 and Col3A1 mRNA as 
analyzed by qRT-PCR in postnatal day 28 Pkd1nl/nl mice compared with age matched control 
mice. We further found that knockout of MIF or inhibition of MIF with ISO-1 decreased 
the phosphorylation and activation of ERK, Akt, S6 and Rb, which were associated with 
the fibroblast activation and fibrosis development in human diseases, in kidneys of Pkd1 
mutant mice whereas fibroblasts treated with MIF induced the phosphorylation of ERK, 
Akt, S6 and Rb. In addition, MIF treatment induced the expression of 1) TGFβ in mouse 
IMCD3 cells, 2) COL1A1 and COL3A1 in mouse fibroblasts (NIH3T3), and 3) TGFβ, 
COL3A1 and fibronectin in rat kidney interstitial fibroblasts (NRF-49F). The expression 
of TGFβ, COL1A1, COL3A1 and fibronectin induced with or without MIF in the above 
cells could be inhibited or decreased by the treatment with ISO-1.
Conclusions: MIF activates the renal fibroblasts and promotes renal interstitial fibrosis 
in ADPKD, which may be mediated by TGFβ, ERK, mTOR and Rb signaling pathways. 
Targeting MIF may be a viable new therapy for ADPKD.
Funding: NIDDK Support
SA-OR084
HGF/c-met Signaling in Macrophages Attenuates Kidney Fibrosis by 
Regulating Matrix Remodeling and Turnover  Haiyan Fu,1 Dong Zhou,1 
Liangxiang Xiao,1 Roderick J. Tan,2 Youhua Liu.1  1Dept of Pathology, Univ of 
Pittsburgh, Pittsburgh, PA; 2Dept of Medicine, Univ of Pittsburgh, Pittsburgh, 
PA.
Background: Kidney fibrosis results from an excessive accumulation and deposition of 
extracellular matrix (ECM). This is mainly due to an imbalance between matrix synthesis 
and degradation. While significant progress has been made recently on identifying the 
matrix-producing cells and elucidating how they are regulated, relatively little is known 
about the mechanism controlling matrix degradation and turnover.
Methods: We generated hepatocyte growth factor (HGF) receptor c-met conditional 
knockout mice in which c-met was deleted specifically in myeloid cells including 
macrophages (Mac-c-met-/-). MIce were then subjected to renal unilateral ischemia/
reperfusion injury (UIRI) or unilateral ureteral obstruction (UUO), respectively. Cultured 
bone-marrow-derived macrophages were also used.
Results: Mice with macrophage-specific ablation of c-met were phenotypically normal. 
We found that at different time points (3, 7 and 14 days) after UUO, there was no difference 
in the mRNA levels of major fibrosis-related genes such as α-SMA, collagen I, collagen 
III and fibronectin in the kidneys between Mac-c-met-/- and control mice, suggesting that 
HGF signaling in macrophages does not affect matrix synthesis. However, kidney fibrotic 
lesions as assessed by Masson’s-Trichrome staining were more profound in Mac-c-met-/- 
mice than controls. Comparable results were obtained after analysis of matrix proteins by 
Western blot. Similarly, in UIRI model, loss of c-met in macrophage significantly aggravated 
renal lesions at 10 days, with elevated serum creatinine and increased deposition of matrix 
proteins, whereas renal mRNA expression of major matrix genes was not changed. In vivo, 
increased deposition of ECM was closely associated with the down-regulation of tissue-type 
plasminogen activator (tPA) in Mac-c-met-/- kidneys. In vitro, HGF induced tPA, uPA and 
MMP-12 expression in cultured bone marrow-derived macrophages.
Conclusions: These results suggested that HGF/c-met signaling in macrophages plays 
a critical role in reducing kidney fibrosis by promoting matrix degradation and turnover.
Funding: NIDDK Support
SA-OR085
The Hippo-Salvador Signaling Pathway Regulates Renal Tubulointerstitial 
Fibrosis  Yong kyun Kim,1 Sun-ah Nam,2 Wan-Young Kim,2 Arum Choi,2 Yumi 
Kim,2 Jin Kim.2  1Dept of Internal Medicine, Medical College, The Catholic Univ 
of Korea, Seoul, Korea; 2Dept of Anatomy and Cell Death Disease Research 
Center, College of Medicine, The Catholic Univ of Korea, Seoul, Korea.
Background: Renal tubulointerstitial fibrosis (TIF) is the final common pathway 
of various renal injuries. The mammalian Hippo-Salvador signaling pathway is a highly 
conserved kinase cascade that regulates contact inhibition, cell proliferation, organ size 
control, tissue regeneration and tumorinogenesis. The expression pattern and the role of 
Hippo-Salvador signaling pathway on development of renal TIF remain unknown. Here, 
we reported that activation of Hippo-Salvador pathway in tubular epithelial cell (TEC) in 
patients and in mouse model of TIF plays a role in TIF development.
Methods: The expression of Hippo-Salvador pathway including WW45, Mst1/2, 
Lats1/2, YAP/TAZ were examined . TEC-specific WW45 knockout mice (WW45flox/
flox;Ksp-Cre+) were generated for in vivo experiments and Hippo-Salvador pathway were 
knock-downed or overexpressed in HK2 cells. Unilateral ureteral obstruction (UUO) was 
used for in vivo model and TGF- β treatment was used for in vitro model of renal fibrosis.
Results: Expression of WW45 (a homolog of Drosophilia Salvador and adaptor 
for the Hippo kinase) and TAZ (transcriptional coactivator with PDZ binding motif, a 
WW-domain transcriptional regulator) were increased after UUO in mice and in TEC in 
patients with CKD. In vivo, TEC-specific WW45 deletion enhanced renal TIF after UUO. 
TEC-specific WW45 deletion enhanced apoptosis and proliferation of TECs after UUO. 
The expression of TAZ was increased in the kidneys of WW45-deficeint mice after UUO.
In Vitro,WW45 deletion induced EMT by TGF-β treatment. WW45 deficiency enhances 
TGF-β signaling by the interaction of TAZ with Smads.WW45 deficiency also increases 
activated β-catenin dependent on TAZ.
Conclusions: Our data showed that Hippo-Salvador pathway regulate renal TIF and 
EMT through TGF-β/Smad and Wnt/β-catenin signaling. Our experiments suggest that 
Hippo-Salvador pathway is a new mechanism in the pathogenesis of TIF development and 
indicate that regulation of Hippo signaling pathway may be a therapeutic target to reduce TIF.
SA-OR086
Cytosine Methylation Levels Determine Regeneration versus Fibrosis After 
Injury  Kriti Gaur, Ae Seo Deok Park, Frank S. Chinga, Katalin Susztak.  Renal 
Electrolyte and Hypertension Div, Univ of Pennsylvania.
Background: Cytosine methylation is an epigenetic mark that regulates gene 
expression, whereby increased methylation of promoter regions inhibits gene transcription 
by interfering with transcription factor binding. We previously showed that human CKD and 
DKD samples have differences in cytosine methylation levels. We hypothesize that these 
cytosine methylation differences are functionally important in the pathophysiology of CKD. 
The ten-eleven translocation (TET) family of proteins, regulate DNA methylation status 
by oxidizing 5-methylcytosine (mC) to 5-hydroxymethylcytosine (5hmC). In the absence 
of TET2, there is increased cytosine methylation and decreased hydroxymethylation. Here 
we examined the functional role of tubular epithelial cell (TEC) methylation levels in vivo 
by deleting TET2 in TECs.
Methods: TET2flox/flox and Cadherin 16 Cre mice were crossed to generate animals with 
renal tubular epithelial cell deletion of TET2. Kidney injury was induced by administering 
folic acid intraperitoneally at 6 weeks of age, at a dose of 250mg/kg of body weight and 
sacrificed 1 or 12 weeks later. Mouse kidneys and primary epithelial cells were analyzed 
by quantitative RT-PCR, and immunohistochemistry to examine fibrotic changes.
Results: Mice with TEC specific deletion of TET2 appeared histologically normal. 
We hypothesize that this may be due to the low turnover rate of tubule cells in the kidney. 
Acute kidney injury and regeneration was induced through administration of folic-acid. 
Twelve weeks after folate administration control animals almost recovered, while fibrosis 
appeared more even severe in mice with TEC specific deletion of TET2. These TET2 null 
mice also had increased expression of  collagen, activated myofibroblast and inflammatory 
markers. We believe that fibrosis developed as a secondary consequence of impaired 
epithelial cell differentiation, as TET2-deficient TECs remained undifferentiated and yet 
continued to proliferate.
Conclusions: TET2 is an epigenetic director of renal epithelial repair following injury. 
Increased TEC cytosine methylation levels interfere with epithelial cell differentiation and 
directs cells into a profibrotic phenotype.
Funding: NIDDK Support
SA-OR087
Roles of CCN2 and Caspase Activities in Tubular Epithelial Cells Involved 
in AKI Transition to CKD  Takeru Kusano, Tsutomu Inoue, Hirokazu Okada. 
Saitama Medical Univ, Iruma-gun, Saitama, Japan.
Background: In AKI, severely injured tubular epithelial cells (TEC) are destined to be 
removed by apoptosis while a small part of them survive and transform, which then facilitate 
interstitial fibrosis (IF).(Nat Med 16;535, 2010) We previously reported that CCN2 and 
caspase activities in TEC are important for IF in CKD models.(JASN 16;133, 2005, Clin 
Exp Nephrol (in press)) In this study, we investigate possible linkages between AKI and 
CKD, focusing especially on roles of CCN2 and caspase activities in TEC.
Methods: CCN2-haploinsufficiency mice (CCN2fx/-), mice transgenic for baculovirus 
pan-caspase inhibitor p35 gene in a nonexpression state (p35), and mice carrying Cre 
recombinase under the control of proximal tubule-specific g-glutamyltransferase promoter 
(g-GT.Cre) are used for generation of following mice; g-GT.Cre:p35, p35 is expressed in 
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TEC; g-GT.Cre:CCN2fx/-, CCN2 expression is defected in TEC; g-GT.Cre:p35:CCN2fx/-, 
defective CCN2 with p35 expression in TEC; and CCN2fx/- as the control. We performed 1 
hour ischemia and reperfusion injury (IRI) on these 4 groups of mice and evaluated renal 
fibrosis on day 14.
Results: The mRNA levels of collagen I (ColI),fibronectin EIIIA (FN) and TGF-b1 
were significantly lower in g-GT.Cre:CCN2fx/- mice than the control mice (ColI: 7.26±0.62 
vs. 63.5±16.7, FN: 1.29±0.18 vs. 9.96±2.83, TGF-b1: 0.83±0.12 vs. 4.35±0.98)(p<0.05). 
The fibrosis area% in Masson trichrome stain was significantly narrower in g-GT.
Cre:CCN2fx/- mice than the control mice (7.46±1.36% vs. 34.8±3.16%)(p<0.05). In the 
comparison between g-GT.Cre:p35CCN2fx/- and g-GT.Cre:CCN2fx/- mice, the fibrosis 
area% was significantly wider in g-GT.Cre:p35CCN2fx/- mice (16.4±2.12 vs. 7.26±0.62)
(p<0.05). We also revealed that the number of phosphorylated histone H3-positive TEC 
were significantly higher in g-GT.Cre:p35CCN2fx/- mice.
Conclusions: In conclusion, CCN2 expressed in TEC promotes IF, a typical feature 
of CKD, following IRI in the post-AKI kidney. Furthermore, it appears that TEC escaped 
from caspase activities after IRI exacerbate IF irrespectively of CCN2. Thus, caspase 
activities and CCN2 in TEC are likely involved in AKI transition to CKD in the opposite 
direction, at least after IRI.
SA-OR088
Repeated Minor AKI Accelerates Renal Fibrosis and Dysfunction in 
Klotho Deficit Mice  Ken Tsuchiya, Hidekazu Sugiura, Miki Nishida, Kenichi 
Akiyama, Kosaku Nitta.  Dept of Medicine IV, Tokyo Women’s Medical Univ, 
Shinjuku-ku, Tokyo, Japan.
Background: It has been recognized that AKI and CKD are not independent disease 
but integrated syndrome in which there is bidirectional nature of the relationship between 
them. Especially, frequent occurrence of minor AKI induces acceleration to advancing to 
the CKD. On the other hand, Klotho protein is one of the key modulator in the preceding 
the CKD, during which expression of Klotho is markedly suppressed in CKD. Acceleration 
of renal fibrosis is a basic pathophysiology for progression of CKD, and previously, we 
showed that the renal interstitial fibrosis was severer in the kl (+/-) mice than those in the 
wild-type mice by ureteral obstruction procedure. So, we hypothesized that kidney with 
reduced Kltoho expression was more vulnerable to minor or repeated stress during the 
progression of CKD pathophysiology.
Methods: We explored the effects of repeated minor AKI on the kidney in the rodent 
model of reduce Klotho expression. Minor AKI was induced by short time clamping of 
renal artery, once a week for 3 weeks in kl (-/+) and wild type mice. Serum creatinine 
level was measured and the expression levels of fibrosis related marker, such alpha SMA, 
MCP-1etc., by immunostining and RT-PCR was assessed. Internal expression of Klotho 
was modified by gene delivery.
Results: Frequent AKI reduced the renal function much more (70% higher in Cr) in kl 
(-/+) mice than wild type mice. Klotho expression quickly diminished after each ischemic 
maneuver. The expression of fibrotic markers increased (2.2 folds) in the kidney comparing 
with wild type kidney. The reduction of renal function and tissue damage was attenuated 
by Klotho gene delivery. Preliminary, gene screening suggested more down regulation of 
heat shock protein and ATF by AKI accumulation in kl (-/+) mouse kidney.
Conclusions: It is likely that reduction of Klotho levels in the kidney, such as in aging 
or CKD, is a risk factor for accelerating the progression of CKD, resulting in sensitive 
status to various kinds and frequency of renal damage, and upregulation of the Klotho may 
attenuate advancing the kidney dysfunction, which is one possible strategies for preventing 
the final pathway to the ESRD.
Funding: Government Support - Non-U.S.
SA-OR089
Global Prevalence of Protein-Energy Wasting (PEW) in Kidney Disease: 
Systematic Review and Meta-Analysis of Contemporary Cohort Studies 
by the International Society of Renal Nutrition and Metabolism (ISRNM) 
Juan Jesus Carrero,1 Csaba P. Kovesdy,2 Miklos Zsolt Molnar.2  1Karolinska Inst, 
Stockholm, Sweden; 2Univ of Tennessee Health Science Center, Memphis, TN.
Background: PEW is a common complication in kidney disease, but its prevalence is 
poorly defined. To increase awareness on the commonness of PEW, we performed a meta-
analysis of its global prevalence throughout the kidney disease spectrum.
Methods: We performed a systematic review and meta-analysis of contemporary 
cohort studies including >50 patients with kidney disease and reporting on PEW prevalence 
by either subjective global assessment (SGA) or malnutrition-inflammation score (MIS). 
Searches were restricted to Jan 2000-Nov 2014. Data was reviewed throughout different 
kidney disease strata (acute kidney injury [AKI], pediatric chronic kidney disease [CKD], 
non-dialyzed CKD 3-5, dialysis and renal transplant [Tx]). Because PEW may reflect 
underlying country-specific malnutrition, studies including dialysis patients were analyzed 
after clustering by their countries’ Gross National Income (GNI).
Results: No studies including pediatric patients fulfilled the inclusion criteria for meta-
analysis. The PEW meta-prevalence of the rest of kidney disease strata is summarized in 
the table, along with number of patients and studies. In studies including dialysis patients, 
PEW prevalence increased considerably across worsening GNI clusters, being consistently 
higher in peritoneal dialysis (PD) as compared to hemodialysis (HD) patients.
Stratum N
o of 
studies N
o of patients PEW Prevalence (95% CI)
AKI 4 387 63% (58-67)
non-dialyzed CKD 3-5 12 2682 21% (19-22)
Tx patients 2 1067 30% (28-33)
Dialysis, 
high-income countries 64
5920
3339 in HD
2581 in PD
35% (34-46)
41% (40-43)
Dialysis, 
upper middle-income countries 53
8923
5844 in HD
3079 in PD
42% (41-44)
50% (49-52)
Dialysis, 
low-income countries 8
887
588 in HD
299 in PD
62% (58-66)
74% (69-78)
Conclusions: PEW is common across the entire spectrum of kidney diseases, but it 
exhibits the highest prevalence among dialysis and AKI patients. Its commonness, together 
with its well-documented impact on patient outcomes, deserves increased medical attention.
SA-OR090
A Novel Deleterious Role for Dietary Salt-Sugar Interplay in Metabolic 
Syndrome and Elevated Blood Pressure in Mice  Miguel A. Lanaspa, 
Christina Cicerchi, Ana Andres-hernando, Carlos Alberto Roncal-jimenez, 
Takuji Ishimoto, Richard J. Johnson.  Univ of Colorado Denver, Aurora, CO.
Background: High amounts and chronic salt intake are important risk factors for the 
development and progression of hypertension. Our group has described that also sugars, 
and in particular fructose, contribute to the pathogenesis of elevated blood pressure thus 
suggesting a potential interplay between both dietary components in hypertension and 
metabolic syndrome. Consistently, increased sodium excretion is observed in obese 
people. Here, we aim to determine whether dietary salt can play a deleterious role in the 
pathogenesis of other features of metabolic syndrome besides hypertension and if it is 
related to sugar metabolism.
Methods: Wild type and fructokinase deficient mice –that cannot metabolize sugar and 
fructose- were exposed to 1% salt in drinking water for 30 weeks and features of metabolic 
syndrome including elevated blood pressure, fatty liver, insulin resistance, leptin resistance 
and weight gain were determined.
Results: Exposure of mice to salt induced the hypertonic activation of aldose reductase 
and the endogenous production of fructose in liver, pancreas and fat. Consistent with 
increased fructose production and metabolism in these tissues, wild type but not fructokinase 
deficient mice demonstrated significantly higher fat deposition, fatty liver and blood pressure 
compared to controls. Furthermore, salt intake in wild type mice induced a significant 
increase in insulin resistance as determined by oral glucose and insulin tolerance test, 
hyperleptinemia, hypothalamic leptin resistance, increased food intake and body weight 
gain compared to fructokinase deficient mice.
Conclusions: Our study indicates that dietary salt can induce multiple features of 
metabolic syndrome besides high blood pressure. It also suggests interplay between salt 
and sugar in which salt will induce the endogenous production of fructose . The metabolism 
of endogenous fructose by fructokinase would be the underlying factor for salt-induced 
metabolic syndrome in mice. Thus, blockade of fructokinase could be a novel therapeutic 
approach for the prevention and treatment of hypertension and metabolic syndrome.
Funding: NIDDK Support
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Sodium Chloride Promotes Tissue Inflammation via Osmotic Stimuli in 
Subtotal Nephrectomized Mice  Fumiko Sakata,1 Yasuhiko Ito,1 Masashi 
Mizuno,1 Yasuhiro Suzuki,1 Takeshi Terabayashi,1 Takako Tomita,1 Mitsuhiro 
Tawada,1 Shoichi Maruyama,1 Enyu Imai,2 Yoshifumi Takei,1 Seiichi Matsuo.1 
1Nephrology and Biochemistry, Nagoya Univ, Nagoya, Japan; 2Nephrology, 
Nakayamadera Imai Clinic, Takarazuka, Japan.
Background: Chronic inflammation is prevalent in patients with end-stage renal 
disease, but the precise mechanisms remain unclear. Sodium that is reportedly stored in 
tissues after high salt intake induces lymphangiogenesis and autoimmune diseases via 
osmotic stimuli. We studied the effects and mechanisms of high salt loading on tissues and 
systemic inflammation (with a focus on macrophage infiltration) in sub-total nephrectomized 
(5/6Nx) mice and in cultured cells.
Methods: Mice underwent 5/6Nx or sham surgery (Sham), and were provided with 
either tap water (Water) or 1% NaCl (NaCl) for four weeks. Inflammatory changes in 
peritoneal wall, heart and paraaortic tissues were evaluated by immunohistochemistry, 
Western blot, ELISA and quantitative PCR. Inhibition studies were performed in vivo 
and in vitro.
Results: Significantly more macrophages infiltrated the peritoneal wall (p < 0.001), 
heart (p < 0.05) and paraaortic tissues (p < 0.001) of sub-total nephrectomized mice with 
salt loading (5/6Nx/NaCl) compared with 5/6Nx/Water. Tissue levels of IL-6, monocyte 
chemotactic protein-1 (MCP-1) and tonicity-responsive enhancer binding protein (TonEBP) 
were significantly increased in the peritoneal wall and heart of 5/6Nx/NaCl compared with 
5/6Nx/Water. The administration of furosemide or tap water after NaCl for four weeks, 
indicating reverse NaCl loading, reduced local macrophage infiltration associated with the 
suppression of MCP-1 (p < 0.05) and TonEBP mRNA (p < 0.01). A high NaCl concentration 
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in the culture media of mesothelial cells and cardiomyocytes induced MCP-1 protein, MCP-1 
mRNA, serum- and glucocorticoid-inducible kinase 1 (Sgk1), and TonEBP mRNA, all of 
which were suppressed by TonEBP siRNA and upregulated in 5/6Nx/NaCl. The induction 
of MCP-1 by high salt did not involve Rac1.
Conclusions: High salt intake enhances macrophage infiltration via the TonEBP-
MCP-1 pathway in association with inflammation, oxidative stress and Sgk1 activation 
during renal failure.
Funding: Government Support - Non-U.S.
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The Relationship of Chronic Kidney Disease Severity with Urine Sodium 
Excretion  Cheryl A. Anderson,1 Amanda K. Leonberg-Yoo,2 Joachim H. Ix,1 
Mark J. Sarnak,2 Lawrence J. Appel.3  1Univ of California San Diego; 2Tufts 
Medical Center; 3Johns Hopkins Medical Insts.
Background: In healthy individuals, the gold standard measurement for sodium intake 
is 24-hour urine excretion. It is unknown whether chronic kidney disease (CKD) severity 
affects this measurement. We aimed to evaluate whether sodium excretion differs by level of 
glomerular filtration rate (GFR). We hypothesized that with increased CKD severity, 24-hr 
urine excretion is reduced, possibly as a result of a greater fraction of sodium being excreted 
by non-renal pathways (e.g. sweat or lower intestinal absorption) as kidney function declines.
Methods: Baseline data from the African American Study of Kidney Disease and 
Hypertension (AASK) and the Modification of Diet in Renal Disease (MDRD) Study 
were used to separately examine the relationship between GFR measured by iothalamate 
clearance and 24-hour urine sodium excretion. Both studies recruited individuals with 
reduced GFR. Urine sodium excretion was measured using a single 24-hour urine collection. 
Linear regression models were adjusted for age, race, sex, and BMI.
Results: In AASK (n=1093) and MDRD (n=814), baseline mean(SD) age was 
54.5(10.7) and 51.4 (12.4) years; mean(SD) for GFR (mL/min/1.73m2) was 46.8(14.1) and 
33.5(12); and mean(SD) for sodium (g/day) was 3.7(2.0) and 3.5 (1.5); respectively. After 
adjustment, each SD reduction in GFR was associated with a 0.24 g/day (p=0.002) lower 
sodium excretion in AASK; and a 0.15 g/day (p=0.001) lower sodium excretion in MDRD.
Conclusions: Our findings challenge the existing paradigm that the amount of sodium 
excreted in a 24-hour urine collection is roughly equivalent to intake in all persons. Further, 
the association of reduced urine sodium excretion with advanced CKD may help explain 
paradoxical risk relationships in studies that did not take into account concurrent kidney 
function. Controlled balance studies in CKD patients are needed to confirm our findings.
Funding: NIDDK Support
SA-OR093
Lower Risk of ESRD Associated with DASH Diet in Adults with Moderate 
CKD and Hypertension  Tanushree Banerjee,1 Deidra C. Crews,2 Meda E. 
Pavkov,3 Nilka Rios Burrows,3 Jennifer L. Bragg-Gresham,4 Rajiv Saran,4 Neil 
R. Powe.1  1UCSF; 2JHU; 3CDC; 4U Michigan, Ann Arbor.
Background: Although the Dietary Approaches to Stop Hypertension (DASH) diet, rich 
in fruits, vegetables, and plant derived protein, has been shown to reduce blood pressure in 
individuals with normal and mildly impaired kidney function, it is not known whether the 
DASH diet impacts CKD progression among patients with moderate CKD.
Methods: We determined a baseline diet adherence score (higher score=greater 
adherence), consistent with DASH diet recommendations, using a 24-hour dietary recall 
questionnaire in a cohort of 1,110 adults with moderate CKD (eGFR 30-59ml/min/1.73m2) 
and hypertension from the National Health and Nutrition Examination Survey III (1988-
1994).We related this score to the development of ESRD ascertained over a median of 
14.2 years of follow-up via linkage with the Medicare ESRD Registry. We examined 
the association of baseline level of DASH diet adherence with ESRD after adjusting for 
demographics, diabetes, eGFR, and albuminuria, while accounting for intervening mortality 
events using the Fine-Gray competing risks method.
Results: A total of 267 (24.1%) participants developed ESRD. Baseline level of 
adherence to the DASH diet was greater among older vs younger adults (57.9% vs 42.1%), 
females vs males (60.4% vs 39.6%), and whites vs blacks (61.4% vs 18.3%); v p<0.05. 
Compared to quintile 5 (greatest DASH diet adherence score) there was a greater risk of 
ESRD with lower adherence scores --for quintile 4: Relative Hazard [95% CI] = 1.1[0.8-
1.6], for quintile 3: 1.5[0.9-2.8], for quintile 2: 2.7[1.8-3.3] and for quintile 1 (lowest 
adherence): 1.9[1.4-2.7] (p for trend =0.001). There was effect modification by the DASH 
score quintiles and diabetes (p-interaction=0.03). The higher risk of ESRD with lower 
adherence was present among participants with diabetes (2.5[1.4-4.6]) but not among 
participants with no diabetes (0.7[0.4-1.4]).
Conclusions: Adherence to the DASH diet may lower the risk of progression to 
ESRD in adults with moderate CKD and hypertension, particularly among persons with 
diabetes. Our results provide evidence that the DASH diet may be beneficial for adults 
with moderate CKD.
Funding: Other U.S. Government Support
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Normal Weight with Central Obesity Is Associated with the Highest Risk 
of Coronary Artery Calcification in Chronic Kidney Disease Patients 
Mi Jung Lee,1 Shin-Wook Kang,1 Curie Ahn,2 Tae-Hyun Yoo.1  1Dept of Internal 
Medicine, Yonsei Univ College of Medicine, Seoul, Korea; 2Dept of Internal 
Medicine, Seoul National Univ, Seoul, Korea.
Background: In chronic kidney disease (CKD), body mass index (BMI) showed a 
U-shaped association with cardiovascular (CV) risk. In contrast, central obesity was directly 
associated with increased CV risk. This bi-directional relationship prompted us to evaluate 
the CV risk assessed by coronary artery calcification (CAC) based on a combination of 
BMI and waist-to-hip ratio (WHR) in CKD patients.
Methods: We included 1,217 CKD stage 1 to 5 patients who enrolled in the KoreaN 
cohort study for Outcome in patients With Chronic Kidney Disease. Patients were divided 
into 3 groups by BMI (normal, 18.5≤ to <23.0; overweight, £23.0 to <27.5; obese, >27.5 
kg/m2) and were dichotomized by sex-specific median of WHR (0.92 in male; 0.88 in 
female). CAC was defined as >10 Agatston using a multi-slice computed tomography. 
Logistic regression analysis was used to assess the independent association of CAC with 
BMI, WHR, and cross-categorization of BMI and WHR, respectively.
Results: CAC was observed in 500 patients (41.4%). Multivariate logistic regression 
analysis indicated that BMI was not independently associated with CAC (per 1 kg/m2 
increase, odds ratio [OR]=1.03, 95% confidence interval [CI]=0.98-1.08, P=0.24). However, 
WHR showed an independent linear association with CAC (per 0.01 increase, OR=1.04, 
95% CI=1.02-1.07, P<0.001). Furthermore, when patients were categorized into 6 groups 
according to combination of BMI and WHR, normal BMI but increased WHR (OR=1.91, 
95% CI=1.05-3.48, P=0.03) had the highest risk of CAC compared to others (normal BMI 
with lower WHR, as reference; overweight with lower WHR, OR=1.46, 95% CI=0.93-
2.30, P=0.10; obese with lower WHR, OR=1.51, 95% CI=0.68-3.40, P=0.31; overweight 
with increased WHR, OR=1.45, 95% CI=0.95-2.22, P=0.06; obese with increased WHR, 
OR=1.49, 95% CI=0.88-2.53, P=0.14).
Conclusions: In CKD patients, normal weight with central obesity was associated 
with the highest risk of CAC, suggesting that combining BMI and WHR could be more 
helpful to stratify CV risk than BMI alone.
Funding: Government Support - Non-U.S.
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MicroRNA-27a Is Decreased in Skeletal Muscle During Atrophy and Is 
Regulated by Calcineurin/NFAT Signaling: A Regulatory Mechanism for 
Myostatin Expression  Xiaonan H. Wang,1 Russ Price,1,2 Jill A. Rahnert,1 
Matthew B. Hudson.1  1Medicine/Nephrology, Emory Univ, Atlanta, GA; 2Atlanta 
VAMC, Atlanta, GA.
Background: Muscle atrophy occurs in chronic conditions like chronic kidney disease 
and diabetes. Production of myostatin by muscle plays a central role in the pathogenesis of 
atrophy during these conditions and research has recently focused on understanding how 
myostatin (MSTN) is controlled in muscle. MicroRNA-27a (miR-27a) can target MSTN 
mRNA and decrease MSTN protein in muscle; however, the mechanism(s) that control the 
level of miR-27a under atrophy-inducing conditions are unknown. The objective of our 
study was to investigate how miR-27a is regulated during muscle atrophy.
Methods: Diabetes was induced in rats by a single IV injection of 125/mg streptozotocin 
(STZ). Muscles were harvested 3 days later. Since glucocorticoids mediate many atrophy-
inducing effects of diabetes and CKD, some studies were conducted with C2C12 muscle 
cells incubated with dexamethasone (DEX; 100 nM, 48 h). miR-27a was measured by 
quantitative RT-PCR using U6 as a control miR.
Results: In hindlimb muscles of STZ rats, miR-27a was decreased 40±3% 
(mean±SEM), a finding consistent with the reported elevation in MSTN during diabetes. 
Similarly, treatment of C2C12 myotubes with DEX reduced miR-27a 68±3% within 0.5 
h and this suppression was sustained at >51% for at least 48 h. The miR-23a/miR24-2/
miR-27a cluster has been reported to be regulated by Calcineurin(CnA)/NFAT signaling 
and earlier, we found that CnA activity is reduced in skeletal muscle during CKD and STZ 
and in muscle cells following DEX treatment. Therefore, we investigated the relationship 
between CnA and miR-27a by measuring miR-27a following alteration in CnA activity. 
Infection of muscle cells with an adenovirus to overexpress constitutively active CnA 
increased miR-27a by 35±3%.
Conclusions: These results are consistent with a model in which atrophy-inducing 
conditions regulate MSTN production in skeletal muscle in part by reducing the level of 
miR-27a via a mechanism that involves decreased CnA/NFAT signaling. The resulting 
increase in MSTN will exacerbate muscle loss by accelerating proteolysis.
Funding: NIDDK Support, Veterans Administration Support
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Systemic Inflammation Affects Skeletal Muscle Protein Homeostasis in 
Maintenance Hemodialysis (MHD) Patients  Serpil Muge Deger,1,2 Adriana 
Hung,1,2 Edward D. Siew,1,2 Cindy Booker,1,2 Talat Alp Ikizler.1,2  1Vanderbilt 
Univ, TN; 2VA, Nashville, TN.
Background: Systemic inflammation is closely associated with protein energy wasting 
(PEW) in MHD. In order to understand its metabolic effects on skeletal muscle metabolism, 
we examined whole body and skeletal muscle protein turnover in MHD patients with 
varying degrees of inflammation.
J Am Soc Nephrol 26: 2015 Patient-Oriented Research in AKI Oral Abstract/Saturday
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral Abstract PO - Poster; PUB - Publication Only
Underline represents presenting author.
84A
Methods: 129 MHD patients participating in metabolic studies between 1998 and 
2011 were included in this analysis. Whole body and forearm skeletal muscle protein 
turnover was examined using primed infusions of L- (1-(13) C) leucine and L-(ring-(2)
H(5)) phenylalanine.
Results: Mean age was 45 ±13 years, 73% were male, 26% were white and 22% 
had DM. BMI was 28.8 ±7.5 kg/m2, median (IQR) hs-CRP was 13(0.8, 33.8) mg/dL and 
HOMA-IR 1.53 (0.74, 2.87). Forearm muscle protein synthesis (FAPS), breakdown (FAPB) 
and net balance (FANB) were [median (IQR)] 57 (14, 94), 69 (32, 118) and -21 (-58, 22) 
ug/100ml/min, respectively. Whole body PS, PB and NB were 4.7 (3.8, 5.4), 3.75 (3.2, 4.3) 
and 0.43 (-0.36, 0.77) mg/kgffm/min, respectively. There was a strong positive correlation 
between hs-CRP and FAPB (r=0,544 p<0.001) and strong inverse correlation with FAPS 
(r=-0.525; p<0.001) and FANB (r= -0.957, p<0.001).The FAPB was significantly higher 
and FAPS and FANB were lower in subjects in the highest quartile of hs-CRP versus all 
other quartiles (p<0.01 for all).
After adjustment for age, sex, HOMA-IR, and serum HCO3, hs-CRP remained 
statistically significant predictor of all components of FA protein homeostasis. There 
were no significant associations between whole-body protein turnover and hs-CRP levels.
Conclusions: Hs-CRP levels independently predict skeletal muscle protein homeostasis 
in MHD patients. These data suggest that systemic inflammation is an appropriate target 
for treatment of PEW in MHD patients.
Funding: NIDDK Support, Veterans Administration Support, Private Foundation 
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IL-1 Blockade Improves Adiponectin (ADPN) Levels in Patients with CKD 
Stages 3 and 4  Adriana Hung,1,2 Kristen L. Nowak,3 Talat Alp Ikizler,1,2 Natjalie 
Salas,2 Heather Farmer,3 Rafia I. Chaudhry,2 Michel Chonchol.3  1Nashville VA, 
TN; 2Vanderbilt Univ, TN; 3Univ of Colorado Denver, CO.
Background: Adiponectin (ADPN), an adipose tissue-derived hormone, is known to 
have insulin sensitizing, anti-inflammatory, and anti-atherogenic properties in the general 
population. ADPN secretion is suppressed by systemic inflammation, a highly prevalent 
condition in chronic kidney disease (CKD), and may have cardiovascular health implications 
in this population. In this study, we evaluated whether short-term administration of a 
interleukin-1 (IL-1) blocker, improves ADPN levels and insulin sensitivity in patients 
with CKD stages 3&4.
Methods: This study was a pilot randomized placebo-controlled double-blind trial of 
administration of IL-1 blockade in patients with CKD stages 3&4. Forty-two patients were 
randomly assigned (1:1) to receive 160 mg of an IL-1 blocker (rilonacept) or placebo for 
12 weeks; 37 completed the trial. The primary outcomes for this analysis were the effect 
of the intervention on the serum levels of ADPN, leptin, leptin adiponectin ratio (LAR) 
and HOMA IR. Mixed effect models were used for all analysis.
Results: Mean age was 63±11 years, the median eGFR 37.9 (IQR 29.1, 46.7) ml/
min, 76% were males and 24% were African Americans. The values for ADPN, leptin, 
LAR and HOMA IR at baseline were 17.8±17.42 µg/mL, 27.7±22.8 ng/mL, 2.63±2.76 
and 5.6±5.35, respectively. IL-1 blockade resulted in an increase in serum ADPN in the 
intervention group compared to placebo (p=0.03). Leptin, LAR or HOMA IR levels did 
not change significantly [table 1].
Conclusions: Short-term administration of an IL-1 blocker significantly increased 
ADPN levels among patients with CKD stages 3&4. The intervention did not impact other 
insulin sensitivity parameters, including HOMA-IR, leptin and LAR. Results are consistent 
with those observed in dialysis patients.
Funding: Veterans Administration Support, Private Foundation Support
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Effects of Chronic Intradialytic Resistance Physical Exercises in Nrf2 and 
NF-κB Expression and Antioxidant Enzymes in Hemodialysis Patients 
Denise Mafra, Cinthia Da costa Abreu, Milena Barcza Stockler-Pinto, Ludmila 
Fmf Cardozo.  Post-Graduate Program in Cardiovascular Sciences, Fluminense 
Federal Univ (UFF), Niterói, Rio de Janeiro, Brazil.
Background: Oxidative stress and inflammation are cardiovascular risk factors in 
patients with chronic kidney disease (CKD) on hemodialysis (HD). Nuclear factor Kappa 
B (NF-κB) play roles in the coordinated expression of inflammatory genes and Nuclear 
factor erythroid 2-related factor 2 (Nrf2) increases the transcription of genes encoding 
enzymes of phase II detoxifying and antioxidant enzymes. Several studies have shown 
that Nrf2 expression can be modulated by some factors, such physical exercise. The aim 
of this study was to evaluate the effects of resistance exercise program on the Nrf2 and 
NF-κB expression and antioxidant enzymes HD in patients.
Methods: This study included 44 patients on regular HD program, 25 patients (14 men, 
46.1 ± 16.3 years and 71.2 ± 42.2 months HD) composed the exercise group and 19 patients 
(7 men, 46.8 ± 12.5 years and 67.4 ± 51,7months HD) the control group. Strength exercise 
program was performed during HD sessions, 3 times a week (36 exercises sessions). The 
Nrf2 and NF-κB expressions were analysed by quantitative real time PCR. Superoxide 
dismutase (SOD)activity and glutathione peroxidase (GPX) levels were measured using 
ELISA commercial kits.
Results: The Nrf2 mRNA expressionincreased significantly after intervention in 
exercises group (0.8 ± 0.4 to 1.7 ± 0.8, p<0.01). In both groupsthere were no changes in 
NF-κB mRNA expression after intervention. The SOD levels reduced in exercise group 
(from 44.5±3.5U/mL to 28.4±3.3U/ml, p<0.05) and in control group (from 45.1±6.1U/
mL to 31.9±4.6U/mL, p<0.05). However,GPX levels increased in exercise group (from 
24.7±12.4nmol/mL/min to 53.4±20.04nmol/mL/min, p<0.0001) and in the control group 
there was tendency to decrease (from 26.0±5,314nmol/mL/mi to 20.6±7,74nmol/mL/min, 
p=0.06). A negative correlation was found between the differences of NF-κB and GPX 
plasma levels (before and after 3 months) (R=-0.76, p=0.007).
Conclusions: Chronic intradialytic resistance exercises during 3 months seem to be 
able to modulate the Nrf2 activation and increase the antioxidant protection in HD patients.
SA-OR099
Evaluation of Novel Urine Biomarkers for Diagnosis of Subclinical Acute 
Tubular Necrosis  Dennis G. Moledina, Isaac E. Hall, Mona D. Doshi, Peter P. 
Reese, Francis L. Weng, Bernd Schroppel, Heather Thiessen Philbrook, Joseph 
Ficek, Chirag R. Parikh.  TRIBE-AKI.
Background: Rise in serum creatinine (SCr) is currently accepted as the “gold-
standard” for clinical diagnosis of acute kidney injury (AKI). However, acute tubular 
necrosis (ATN) may occur without evidence of AKI, a condition known as “sub-clinical 
AKI.” We evaluated the performance of SCr and urinary biomarkers of kidney injury for 
diagnosis of ATN on kidney biopsy.
Methods: This is a substudy of a multicenter prospective cohort of deceased donors 
and associated kidney transplants. A diagnosis of ATN was assigned if the kidney biopsy 
report (read at organ procurement) indicated acute injury in ³25% of tubules. AKI was 
defined by AKIN criteria based on admission and terminal SCr. Urine biomarkers were 
measured from stored samples collected at procurement.
Results: Of 581 donors with at least one kidney biopsied, 220(38%) had AKI (Stage 1 or 
higher). Of the 57 donors with ATN on biopsy, 28 (49%) did not have AKI. SCr had an area 
under the ROC curve (AUC) for diagnosing ATN of 0.58(95% CI 0.49, 0.67). Sensitivity 
and specificity for ATN were 51% and 64% using the AKIN stage 1 SCr cut-off; 26% and 
83%, respectively, using the AKIN stage 2 cut-off. In the 361(62%) donors without AKI, 
median NGAL was higher if ATN was noted [79.5(IQR: 22.7-209.5) vs. 30.1(10.2-87.6) 
ng/mL for those without ATN, P=0.03]. Median L-FABP and YKL-40 were higher (though 
not significantly) in ATN compared to no ATN [L-FABP 25.6(6.4, 64.0) vs. 10.4(3.4, 41.0) 
ng/mL, P=0.08; YKL-40 4.3(0.6, 13.6) vs. 1.6(0.5, 5.2) ng/mL, P=0.11]. IL-18, KIM-1 and 
MCP-1 concentrations were similar regardless of ATN. Adding NGAL to SCr correctly 
reclassified 26% of donors for ATN events. We noted a trend for lower 6-month recipient 
estimated glomerular filtration rate (eGFR) [-2.6(95CI -5.4, 0.2) ml/min] for worsening 
degrees of ATN, but 6-month eGFR was paradoxically better [+3.6(95CI 1.7, 5.4) ml/min] 
for each higher stage of SCr-defined donor AKI.
Conclusions: SCr lacks sensitivity and specificity for diagnosing ATN. Urinary 
biomarkers like NGAL, L-FABP and YKL-40 may help distinguish “subclinical AKI,” if 
not improve clinical prediction of biopsy-proven ATN over that of SCr alone.
Funding: NIDDK Support, Private Foundation Support
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The Epidemiology and Outcome of Worldwide Acute Kidney Injury in 
Critically Ill Children: A Prospective Multinational Study  Ahmad Kaddourah,2 
Rajit K. Basu,2 Stuart Goldstein.2  1On behalf of the “Assessment of Worldwide 
Acute Kidney Injury, Renal Angina and Epidemiology in Critically ill Children 
(AWARE)” investigators; 2Cincinnati Children’s Hospital Medical Center.
Background: Epidemiologic data for pediatric acute kidney injury (AKI) is limited 
to retrospective single-center studies. We conducted a prospective observational study of 
critically ill children to provide an international epidemiological description of pediatric 
AKI and associated outcomes.
Methods: 32 centers from 5 continents collected data for 3 consecutive months in 
2014 from children (aged 3 months to 25 years) admitted to a pediatric intensive care 
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unit. AKI was defined and classified by serum creatinine and urine output KDIGO criteria 
within the first 7 days of admission (Stage 2-3 = severe). Outcomes were assessed at 28 
days. Children with end-stage kidney disease (ESKD) or kidney transplant in the last 90 
days were excluded.
Results: 5,237 children (55% males) were studied. Median age was 64.6 months (IQR 
19,149). Day to day ranges of severe AKI prevalence and incidence during the first 7 days 
were 6.5-10.3% and 1.1–7.0%, respectively. Severe AKI incidence peaked at 7% on day 
3 (127/1816). On multivariate analysis, shock on admission (OR 2.4, p=0.007), history 
of transplantation (OR 4.0, p<0.001) and urinary system comorbidity (OR 2.0, p<0.001) 
were independent predictors of Day 3 severe AKI. Table 1 depicts the univariate outcome 
associations with AKI.
No/ stage 1 
AKI
n=4142
Severe AKI
n=541 p
Mortality (%) 2.6 11.3
<0.001 (all)
Length of stay, mean (SD) 3.9 (6.1) 6.6 (6.9)
ECMO use (%) 0.39 1.85
Dialysis (%) 0.31 11.1
Duration of mechanical ventilation, 
mean (SD) 5.2 (6.3) 7.7 (7.3)
Severe AKI independently predicted mortality after adjustment for illness severity (OR 
5.1, p<0.001). In a multivariate regression model, a 1-unit change in stage of AKI was 
associated with 1.28 days increase in illness-severity-adjusted length of stay (p<0.001).
Conclusions: AWARE represents the largest epidemiologic assessment of AKI in 
critically ill children. We demonstrate AKI is independently associated with multiple 
deleterious outcomes. Our data will help guide future research to develop accurate and 
early diagnostic models of AKI.
SA-OR101
Derivation and Validation of Risk Models for Chronic Kidney Disease 
following Hospitalization with Acute Kidney Injury  Matthew T. James,1 
Neesh I. Pannu,2 Amit X. Garg,3 Marcello Tonelli,1 Braden J. Manns,1 Zhi 
Tan,1 Eric Mcarthur,3 Ron Wald,4 Pietro Ravani,1 Robert R. Quinn,1 Brenda 
Hemmelgarn.1  1Univ of Calgary, AB, Canada; 2Univ of Alberta, AB, Canada; 
3Western Univ, ON, Canada; 4Univ of Toronto, ON, Canada.
Background: Some, but not all patients, will develop chronic kidney disease (CKD) 
after a hospitalization with acute kidney injury (AKI). We developed and validated predictive 
models for progression of AKI to CKD.
Methods: We studied patients with baseline eGFR>45 mL/min/1.73m2 who survived >3 
months following a hospitalization with AKI. We identified those with a sustained reduction 
in eGFR<30 mL/min/1.73m2 for >3 months. Data from 11,437 patients hospitalized with 
AKI in Alberta, Canada were used to develop the risk models. External validation was 
performed in a cohort of 9,387 similar patients from Ontario, Canada. Models were derived 
using logistic regression and evaluated based on discrimination, calibration, integrated 
discrimination improvement (IDI), and net reclassification improvement (NRI).
Results: Seven variables were associated with a higher risk of progression to CKD: 
older age, female sex, higher baseline serum creatinine, higher urine albumin, greater AKI 
severity (KDIGO Stage), lesser recovery of kidney function by the time of discharge, and 
heart failure. The full model showed good discrimination in the derivation and validation 
cohorts (c-statistics of 0.85 and 0.82, respectively). A reduced model that included age, 
sex, baseline serum creatinine, AKI severity, and recovery of kidney function at discharge 
performed similarly to the full model, but better than a base model that included age, sex, 
and AKI severity alone (IDI 3.3%; 95%CI 2.3-4.4%, NRI 26.4%;95%CI 18.8-33.9%).
Conclusions: These prediction models can stratify patients for risk of CKD following 
hospitalization with AKI. The impact of these models for guiding CKD follow-up in the 
community should be prospectively evaluated.
Funding: Government Support - Non-U.S.
SA-OR102
Long-Term Outcomes After Rhabdomyolysis  Ian J. Stewart,1 Tarra Ischele 
Faulk,1 Jonathan Sosnov,2 Kevin Chung.3  1David Grant Medical Center, Travis 
AFB, CA; 2San Antonio Military Medical Center, JBSA Fort Sam Houston, TX; 
3US Army Inst of Surgical Research, JBSA Fort Sam Houston, TX.
Background: There are few data regarding long term outcomes after rhabdomyolysis. 
We examined the relation of rhabdomyolysis with mortality, renal function and the 
development of hypertension (HTN) in a US military population injured in combat.
Methods: We queried military databases for US military personnel critically injured 
in combat between 1 Feb 2002 and 1 Feb 2011. Patients that died within 90 days of injury, 
had pre-existing HTN or chronic kidney disease, or had missing data were excluded. 
Demographic variables, creatinine, creatine kinase (CK), mean arterial pressure (MAP), 
Injury Severity Score (ISS), and burn injury were extracted. Acute kidney injury (AKI) 
was determined by KDIGO criteria, rhabdomyolysis was defined as a CK>5000 unit/L 
and MAP was categorized into high (>106mmHg), normal (65-106mmHg) and low 
(<65mmHg). Outcomes were mortality, eGFR (by CKD-EPI) and a new diagnosis of HTN. 
Cox proportional hazard regression models were used to test associations.
Results: The analysis included 1962 patients. Patients with rhabdomyolysis (30.3%) 
were more severely injured as evidenced by higher ISS (median 24 vs 18, p<0.01), more 
AKI (23.8% vs 12.3% p<0.01), and more patients in the low MAP category (24.0% vs 
8.9%, p<0.01). Despite a longer median follow up time for patients with rhabdomyolysis 
compared to those without (1.3 years vs 1.0 years, respectively), eGFR was higher in 
rhabdomyolysis patients (118 ± 21 vs 111 ± 20, p<0.001). The follow up period for 
assessing death and HTN was longer and not significantly different for those with and 
without rhabdomyolysis (3.7 vs 4.0 years, respectively). While rhabdomyolysis was not 
associated with long-term mortality, it was associated with HTN (HR 1.32, 95% confidence 
interval 1.05-1.66, p=0.02) after adjustment.
Conclusions: Rhabdomyolysis was not associated with a decline in eGFR or mortality 
after a median follow up of approximately 1 and 4 years, respectively. Rhabdomyolysis was 
independently associated with a new diagnosis of HTN. Long term follow-up of patients 
with rhabdomyolysis may be needed to understand their true risk.
Funding: Other U.S. Government Support
SA-OR103
Podocyte Injury Is a Potential Contributor to Kidney Damage and 
Its Irreversibility During Acute Decompensated Heart Failure with 
Cardiorenal Syndrome  Parta Hatamizadeh, Todd Koelling, Mahboob A. 
Chowdhury, Su Qing Wang, Judith Grossi, Roger C. Wiggins.  Dept of Internal 
Medicine, Univ of Michigan, Ann Arbor, MI.
Background: Deterioration of kidney function in association with acute decompensate 
heart failure (ADHF) is common and may or may not be reversible. Podocytes are vital 
for glomerular integrity and their injury can lead to glomerular sclerosis and permanent 
kidney damage. Hemodynamic dysregulations and activation of inflammatory and oxidative 
pathways are elements of cardiorenal syndrome while both can damage podocytes. We 
hypothesized that podocyte injury can occur in the context of ADHF.
Methods: We examined urine pellet podocin and nephrin mRNA in 39 ADHF patients 
during hospitalization and post-discharge as well as 172 adult healthy controls by reverse 
transcription-polymerase chain reaction. Urine podocin mRNA:creatinine ratio (uPODCr) 
and urine nephrin mRNA:creatinine ratio (uNephCr) were considered as indices of podocyte 
stress and podocyte injury, respectively.
Results: Mean age of the patients was 58.9±10.9 years and 31 were male. uPODCr and 
uNephCr were 5 (P<0.001) and 1.9 (P=0.009) times greater in ADHF patients compared to 
healthy controls respectively. Post-hospital discharge uPODCr was not different from that 
of ADHF phase, whether it was measured within a month of discharge or after 3 months 
of hospital discharge. However, post-hospital discharge uNephCr was not different from 
ADHF phase when it was measured within a month of discharge; but it was 14 times smaller 
when it was measured after 3 months of hospital discharge (P=0.03).
Conclusions: In ADHF, podocytes might be under greater stress compared to healthy 
individuals and may become injured. Podocyte stress level remains markedly elevated 
several weeks after clinical stabilization of ADHF; but then drops remarkably. Podocyte 
injury, however, continues to progress even after 3 months of clinical stabilization. 
Measurement of uPODCr and uNephCr during ADHF may help with risk stratification for 
permanent kidney damage. Potential interventions to prevent advancement of podocyte 
stress to podocyte injury in the setting of ADHF, may help prevent permanent kidney injury.
SA-OR104
Micronutrient Loss in Renal Replacement Therapy for Acute Kidney Injury 
Weng Oh,1 David S. Gardner,2 Mark A.J. Devonald.1  1Renal and Transplant 
Unit, NUH NHS Trust, Nottingham, United Kingdom; 2Faculty of Medicine and 
Science, Univ of Nottingham, Nottingham, United Kingdom.
Background: Malnutrition is common in acute kidney injury (AKI) patients receiving 
renal replacement therapy (RRT). No clinical study has quantified and contrasted 
micronutrient losses between types of RRT that use differing methods to remove solutes 
(e.g. IHD, by diffusion; SLED-F, by convection; CVVH, by a combination of both).
Methods: Using a prospective, observational design patients (n=24/modality) were 
consented to the study before their first treatment session. Blood and RRT effluent (dialysate 
or filtrate) were sampled at baseline (pre-RRT), mid and end-RRT. Amino acids were 
measured by HPLC, trace elements by ICP-MS and B-vitamins (B1, B3, B6, B9, B12) 
by LC-MS. Plasma concentrations and dialysate losses (gms) were corrected for dose of 
RRT (urea reduction ratio or solute removal index, as appropriate). Data were analysed by 
mixed effect models (Genstat v16).
Results: Patients receiving CVVH had significantly higher plasma amino acids, but not 
trace elements, at baseline (amino acids: CVVH, 3762 ± 357; IHD, 2039 ± 337; SLED-f, 
2505 ± 423 µmol/L; trace elements: IHD, 4156 ± 465; SLED-f 3732 ± 521; CVVH 3982 
± 465 µg/L). At RRT end, plasma amino acids and trace elements had significantly reduced 
(by 429 ± 223 µmol/L; 600 ± 400 µg/L, respectively). Loss of all trace elements was similar 
between types of RRT, but SLED-F cleared many (>10) individual amino acids to a greater 
extent (e.g. lysine loss, -64 ± 23 µmol/L vs. HD) than other types of RRT. Micronutrient loss 
was largely through effluent but also dialyser adsorption, the latter contributing <1g amino 
acids. Additional effluent losses were upto 25g with CVVH, 5-6g for IHD and 8-10g for 
SLED-F (P<.001). Effluent losses of individual trace elements varied significantly, but in 
all cases were greater for CVVH (e.g. loss of copper, +850 ± 475 µg vs. HD or SLED-F).
Conclusions: RRT results in significant loss of all water-soluble micronutrients. 
This loss is not equal between type of RRT; SLED-F clears certain amino acids, whereas 
CVVH clears certain trace elements, highly effectively. This has implications for nutritional 
management of RRT patients.
Funding: Government Support - Non-U.S.
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SA-OR105
Renal Replacement Therapy Intensity for Acute Kidney Injury and 
Recovery to Dialysis Independence  Ying Wang,1 Serigne N. Lo,1 Martin P. 
Gallagher,1 Qiang Li,1 Alan Cass,1 John A. Myburgh,1 Robert Faulhaber-Walter,2 
John A. Kellum,3 Paul M. Palevsky,3 Claudio Ronco,4 Patrick Saudan,5 Ashita J. 
Tolwani,6 Rinaldo Bellomo.1  1George Inst for Global Health; 2Hanover Medical 
School; 3Univ of Pittsburgh School; 4Bortolo Hospital; 5Univ Hospital; 6The 
Univ of Alabama.
Background: In acute kidney injury, randomized controlled trials (RCTs) have not 
found differences in survival with higher intensities of renal replacement therapy (RRT), 
but trials have not been powered for renal outcomes such as recovery of renal function.
Methods: Through an individual patient data meta-analysis we merged individual 
patient data from RCTs comparing high with standard intensity RRT. We assessed mortality 
at 28, 60 & 90 days and renal recovery at 7, 14, 28, 60 & 90 days post randomisation. 
Renal recovery was assessed two ways; by the proportion of patients RRT dependent and 
by time to RRT independence at these time points.
Results: Of the eight prospective RCTs assessing different RRT intensities, seven 
contributed individual patient data (n=3688) to the analysis. Mortality was not different 
between the high and standard intensity groups across these 7 studies at 28 days (775/1890 
and 744/1798 respectively, 41% vs 41.4%, p = 0.24) after randomization, nor at any of the 
other time points. The proportion of patients RRT dependent at the 14 day point was greater 
in patients receiving high compared to standard intensity RRT (RR 1.36, 95%CI 1.12-1.65, p 
= 0.0016), but not at any other time point. Analysis by time to RRT independence suggested 
that patients receiving higher intensity therapy had less time independent of RRT (Day 28: 
HR 0.87, 95% CI 0.78 to 0.97, p=0.014, Day 60: HR 0.87, 95%CI 0.78 to 0.97, p=0.012, 
Day 90: HR 0.84, 95%CI 0.76 to 0.94, P=0.0022). This effect was more pronounced in trials 
that allowed the use of intermittent hemodialysis (IHD) to deliver higher intensity RRT. 
The robustness of these effects was confirmed in multiple sensitivity analyses.
Conclusions: Higher intensity RRT does not affect mortality but does appear to delay 
recipient’s recovery to RRT independence. This effect appears to relate to the use of IHD 
to delivery higher intensity RRT.
Funding: Government Support - Non-U.S.
SA-OR106
Outcomes of In-Hospital Cardiopulmonary Resuscitation (CPR) in Patients 
with Acute Kidney Injury  Fahad Saeed,1 Jean L. Holley,2 Sevag Demirjian.1 
1Cleveland Clinic; 2Univ of Illinois at Urbana-Champaign.
Background: There is paucity of data on the CPR-related outcomes in patients with 
AKI. Herein, we have analyzed the impact of AKI on the outcomes of in-hospital CPR.
Methods: We extracted data from the Nationwide Inpatient Sample (NIS, 2005- 2011) 
including patients with and without AKI who had undergone in-hospital CPR. Baseline 
characteristics, in-hospital complications and discharge outcomes were compared between 
the two groups. We determined the effect of AKI on length of hospital stay, discharge 
destination, and hospital mortality in patients who underwent in-hospital CPR.
Results: 180,970 patients with primary or secondary diagnosis of AKI underwent in-
hospital CPR compared to 323,620 patients without AKI. Unadjusted in-hospital mortality 
rates were higher in the AKI group (78.2 % vs. 71.8% , p=<.0001 ). After adjusting for age, 
sex, and potential confounders, patients in the AKI group had higher odds of mortality with 
odds ratio 1.3, 95 % confidence interval 1.2-1.4, p=<.0001. Survivors in the AKI group were 
more likely to be discharged to nursing homes; odds ratio 1.4, 95 % confidence interval 
1.3-1.5, p=<.0001. Mean length of stay was significantly higher in patients with AKI; 11 
±34 days versus 7 ±26 days, p=<0.0001.
Conclusions: AKI independently increases the odds of in-hospital mortality and 
nursing home placement after in-hospital CPR.These data may facilitate CPR discussions 
and decision-making.
SA-OR107
Acute Kidney Injury After Surgical Aortic Valve Replacement and Long-
Term Risk of Death and End-Stage Renal Disease  Linda C. Ryden,1 Ulrik 
Sartipy,2 Martin Holzmann.1  1Dept of Internal Medicine, Solna, Karolinska 
Inst, Stockholm, Sweden; 2Dept of Molecular Medicine and Surgery, Karolinska 
Inst, Stockholm, Sweden.
Background: Acute kidney injury (AKI) is a common complication after cardiac 
surgery that is associated with adverse outcomes. The incidence of AKI after surgical aortic 
valve replacement (SAVR) and its association with long-term mortality and end-stage renal 
disease (ESRD) is not known.The aim of this study was to determine the incidence of AKI 
and its relationship to mortality and long-term renal outcomes in a large cohort of patients 
who underwent a first isolated SAVR from 1999 to 2013 in Sweden.
Methods: We included all 9,047 patients from the SWEDEHEART register who 
underwent primary isolated SAVR between 1999 and 2013 in Sweden. AKI was classified 
according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria: stage 
1: serum Creatinine (sCr) concentration ≥ 0.3 mg/dL (³26.5 mmol/L) or 1.5- to 1.9-fold 
increase in sCr; stage 2: 2.0- to 2.9-fold increase in sCr; Stage 3: 3.0-fold increase in 
postoperative sCr compared to baseline value, or initiation of renal replacement therapy.
Results: In total, 17% of patients developed AKI postoperatively, of whom 13% 
were AKI stage 1 and 3.7% AKI stages 2–3. During a mean follow-up of 5.6 (standard 
deviation [SD] 3.7) years, 2,109 patients (23%) died and 29 (0.3%) developed ESRD. 
After multivariable adjustment, the hazard ratio (HR) with 95% confidence interval (CI) 
for death in AKI stage 1 was 1.27 (1.12–1.44) and in AKI stages 2–3 was 2.47 (2.03–3.00). 
The subdistribution HR for ESRD in AKI stage 1 was 4.4 (1.7–12), and in stage 2 to 3 
was 5.3 (1.6–18).
Conclusions: AKI is common after a first isolated SAVR and is associated with an 
increased long-term risk of both death and ESRD, independent of preoperative renal 
function.
SA-OR108
Incidence and Predictors of Acute Kidney Injury After Total Hip 
Replacement  Kamel A. Gharaibeh, Abdurrahman M. Hamadah, Nelson Leung, 
Ziad El-Zoghby.  Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Background: Total hip replacement (THR) is a common procedure that has increased 
in number with the improvement in life expectancy. Nonsteroidal antiinflammatory drugs 
(NSAID) are commonly used pre and post THR but their risk of causing acute kidney injury 
(AKI) in this setting is not well quantified.
Methods: Between 2004 and 2014, 10,327 patients underwent THR. We retrospectively 
collected demographic and co-morbidities data on those who developed AKI (defined 
by AKIN criteria) after THR. A control group without AKI was matched by age, gender 
and year of surgery. Variables associated with AKI were determined by univariate and 
multivariate logistic regressions.
Results: Mean age was 64.6 ± 13.8 years, 48.6% were male and 114 patients (1.1%) 
developed AKI (79% stage 1, 18.4% stage 2, 2.6% stage 3). Older age (RR 1.8, per decade, 
p<0.001) and male gender (RR 1.8, p=0.0016) were associated with AKI. Characteristics of 
those with and without AKI are shown in table-1. Several variables were associated with AKI 
(table-1) on univariate analysis but on multivariate analysis only CHF (OR 27.7, p<0.001); 
HTN (OR 2.8, p<0.001); CKD (OR 2.9, p<0.001) and transfusion (OR 3.5, p<0.001) 
remained significant. Diabetes (OR 2, p = 0.064); NSAID (OR 0.9, p=0.9); ACEi/ARB 
(OR 1.5, p=0.23) and diuretics exposure (OR 0.8, p=0.6) were not associated with AKI. 
Table-1
Variables AKI(n=114) Control(n=114) P-value
Age±SD 73.4±11.3 73.4±11.5
Gender (male) 63.2% 63.2 %
BMI 34.2±11 31.3±7.6 0.02
CKD 49% 21% <0.001
eGFR(CKD-EPI) 64±1.7 77±1.7 <0.001
CHF 28.1% 0.9% <0.001
Diabetes 34.2% 16.7% 0.002
HTN 87.7% 64% <0.001
ACEi/ARB use 67.5% 44.7% <0.001
Diuretics use 64% 42.1% <0.001
NSAID use 51.8% 67.5% 0.015
NSAID+ACEi/
ARB+Diuretics 36.8% 28.1% 0.16
Hemglobin (pre-op) 12.8±1.7 (8.7-17.1) 13.5±1.4 (8.4-16.4) 0.0016
Hemoglobin (post-op) 9.9±1.3 (6.5-14.5) 10.6±1.3 (7-13.5) <0.001
transfusion 61(53.5%) 23(20.2%) <0.001
Conclusions: The incidence of AKI after THR is low. Several known risk factors were 
independently associated with AKI after THR; however, ACEi/ARB, diuretics and NSAID 
exposure were not. A prospective study is needed to confirm these results.
SA-OR109
Discovery and Testing in Rat Models of UT-A1 Urea Transporter Inhibitors 
Cristina Esteva-Font,1 Onur Cil,1 Tao Su,1 Sujin Lee,1 Marc O. Anderson,2 Alan 
S. Verkman,1 Puay Wah Phuan.1  1Medicine and Physiology, Univ of California, 
San Francisco, San Francisco, CA; 2Chemistry and Biochemistry, San Francisco 
State Univ, San Francisco, CA.
Background: Inhibitors of urea transport function have potential clinical applications 
as first-in-class salt-sparing diuretics for treatment of edema and hyponatremia (Nat Rev 
Nephrol 11, 113-123, 2015). Our goal is to develop small-molecule, UT-A1-selective 
inhibitors and demonstrate their diuretic efficacy in clinically relevant animal models.
Methods: Screening of >250,000 drugs and synthetic small molecules was done using 
a cell-based fluorescence assay involving osmotic volume response to an urea gradient 
(Chem Biol 20, 1235-1244, 2013). Pharmacokinetics (PK) was measured in rats by liquid 
chromatography and mass spectrometry; diuretic efficacy was studied using metabolic 
cages and in a model of SIADH produced by chronic minipump infusion of dDAVP (5 
ng/h) with liquid diet administration.
Results: 22 distinct chemical classes of UT-A1 inhibitors were identified and optimized 
by structure-activity studies on > 3,000 analogs. Compounds with high UT-A1 vs. UT-B 
selectivity were identified, some with nanomolar inhibition potency. In addition, analog 
and natural-product screening identified dimethylthiourea (DMTU) as a non-selective UT 
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inhibitor. Several classes of compounds gave good PK in rats with predicted therapeutic 
concentrations in blood and urine. Salt-sparing diuretic action was demonstrated in control, 
hydrated rats and rats administered dDAVP acutely. Up to a 2.5-fold increase in hourly urine 
volume and 2-fold reduction in urine osmolality was found. Compounds also prevented 
hyponatremia in rats chronically treated with dDAVP.
Conclusions: UT-A1 inhibitors show salt-sparing diuretic action in rats, and efficacy 
in a clinically relevant model of hyponatremia. In contrast to existing diuretics that target 
renal tubule salt transporters, UT-A1 inhibitors have a novel diuretic mechanism of action 
involving disruption of urinary concentration by renal countercurrent multiplication.
Funding: NIDDK Support
SA-OR110
Pathways for Urea Transport Across the Rat Inner Medullary Thin Limbs 
of Henle’s Loops  Kristen K. Evans,1 William H. Dantzler,1 Alan S.L. Yu,2 
Thomas L. Pannabecker.1  1Physiology, The Univ of Arizona, Tucson, AZ; 2The 
Kidney Inst, Univ of Kansas, Kansas City, KS.
Background: Transepithelial solute flows in thin limbs of Henle’s loops play critical 
roles in countercurrent exchange and the urinary concentrating mechanism; our goal is to 
identify the urea transport pathways in these segments. The rat inner medullary long-loop 
descending thin limbs (DTLs) consist of water permeable upper and water impermeable 
lower segments, positioned in the upper and lower 50% of the inner medulla, respectively. 
Mean transepithelial urea permeabilities of upper DTL are approximately 60 E-5 cm/sec 
and permeabilities of lower DTL and ascending thin limb (ATL) are approximately 350 to 
450 E-5 cm/sec. A urea transporter, UT-A2, has been identified by immunohistochemistry 
only in a very limited region of the upper DTL, near the outer medullary-inner medullary 
border and only in the presence of vasopressin.
Methods: Tubules were isolated without enzyme digestion and perfused with concentric 
glass micropipettes by the method of Burg. The lumen-to-bath transepithelial urea flux was 
determined and permeabilities were calculated.
Results: Urea transport in isolated perfused upper and lower DTL is not inhibited 
by peritubular 0.25 mM phloretin and urea transport in lower DTL is not inhibited by 10 
mM ouabain and is unaffected by a 125 mM lumen Na+ and 0 mM bath Na+ concentration 
gradient. The urea flux in upper and lower DTLs is almost completely and reversibly 
inhibited by peritubular 5 mM lanthanum. Activation energy for transepithelial urea 
permeability measured at 37° and 16° C in isolated perfused lower DTLs and ATLs is 
approximately 13 kJ/mol, a value that is consistent with channel-like activity.
Conclusions: The data suggest that a substantial fraction of the transepithelial urea 
flux occurs independently of known facilitated urea transporters such as UT-A1-3, is 
unlikely to be coupled to Na+ flux and occurs, in large part, by way of a plasma membrane 
or paracellular channel-like pathway.
Funding: NIDDK Support, Other U.S. Government Support
SA-OR111
Comparative Analysis of Vasopressin V1a and V2 Receptors Distribution 
in the Mammalian Kidney  Torsten Giesecke,1 Taka-aki Koshimizu,2 
Katsumasa Kawahara,3 Sebastian Bachmann,1 Kerim Mutig.1  1Dept of Anatomy, 
Charité Universitätsmedizin Berlin, Berlin, Germany; 2Dept of Molecular 
Pharmacology, Jichi Medical Univ, Shimotsuke-shi, Tochigi-ken, Japan; 3Dept 
of Physiology, Kitasato Univ School of Medicine, Kitasato, Japan.
Background: Vasopressin (AVP) promotes urinary concentration by activating the 
vasopressin V2 receptor (V2R). Parallel activation of the vasopressin V1a receptor (V1aR) 
may affect renal acid-base balance and stimulate the renin-angiotensin-aldosterone axis. 
Analysis of the renal distribution of these receptor subtypes has been difficult owing to the 
lack of suitable, specific antisera. Here we have extended available data on their distribution 
and function using subtype-specific antibodies. Subtype-selective agonists were used for 
functional analysis.
Methods: Antibodies to V1aR- and V2R-specific peptides were generated. Segmental 
and cellular distribution of the subtypes along mouse and rat nephron were characterized by 
immunofluorescence and high-resolution immunocytochemistry. Functional studies were 
performed in AVP-deficient Brattleboro rats using subtype-specific agonists; AO-4-67 was 
used for V1aR, and desmopressin for V2R activation at short term.
Results: The V2R was localized basolaterally in mouse and rat kidney thick ascending 
limb (TAL), distal convoluted tubule (DCT), connecting tubule (CNT) and collecting 
duct (CD) epithelia; macula densa (MD) and intercalated cells were negative. Conversely, 
application of the anti-V1aR antibody produced basolateral signal exclusively in MD 
cells and intercalated CNT/CD cells. Staining was controlled using V2R- and V1aR-
deficient mouse kidneys, respectively. In line with the localization data, administration of 
desmopressin in Brattleboro rats induced the activation and trafficking of distal tubular 
NaCl transporters and of aquaporin 2 in the CNT/CD principal cells, whereas application 
of AO-4-67 resulted in luminal trafficking of V-ATPase in intercalated cells of CNT/CD.
Conclusions: These data provide morphological support for the distinct epithelial 
effects of AVP mediated by V2R or V1aR and may improve our understanding of the 
pathophysiology of nephrogenic diabetes insipidus.
SA-OR112
Role of Nedd4-2 Underlying V2R Activation of ENaC  Alan C. Pao,1,2 Yu 
Chen,1 Sheela V. Thomas,1 Mollie E. Jacobs,1 Sindhu Chandran,1 Mariana 
Labarca,1 Vivek Bhalla.1  1Div of Nephrology, Stanford Univ School of Medicine, 
Stanford, CA; 2Veterans Affairs Palo Alto Health Care System, Palo Alto, CA.
Background: Arginine vasopressin (AVP) can increase renal sodium (Na+) 
reabsorption in the cortical collecting duct (CCD) by stimulating the epithelial Na+ channel 
(ENaC). One presumed mechanism by which AVP stimulates ENaC is through activation 
of vasopressin-2 receptor (V2R) and inhibition of the E3 ubiquitin ligase Nedd4-2. Snyder 
and colleagues first demonstrated that cAMP/PKA signaling reverses Nedd4-2 inhibition 
of ENaC. However, how V2R signals through Nedd4-2 to regulate ENaC is not fully 
understood.
Methods: We therefore tested mechanisms by which V2R inhibits Nedd4-2 and 
increases ENaC cell surface expression in transfected HEK293T kidney cells, an established 
model for the study of Nedd4-2 function.
Results: We found that V2R, similar to cAMP, relieved Nedd4-2 inhibition of ENaC cell 
surface expression, but surprisingly V2R did not decrease the interaction between Nedd4-2 
and ENaC. Instead, V2R increased expression of Nedd4-2, which in turn increased the pool 
of Nedd4-2 that interacted with ENaC. The V2R-dependent increase in Nedd4-2 expression 
was blocked with introduction of mutations that eliminate phosphorylation of Ser-444 of 
Nedd4-2. While V2R increased Nedd4-2 expression, V2R still relieved Nedd4-2 inhibition 
of ENaC cell surface expression if Ser-338, Thr-363, and Ser-444 remained intact. If all 
three residues were disrupted, V2R-mediated stimulation of ENaC was attenuated but not 
fully prevented, suggesting that V2R signals through additional residues on Nedd4-2 or 
independent of Nedd4-2.
Conclusions: Our findings provide a molecular basis for how AVP signals through 
Nedd4-2 to increase ENaC activity and demonstrate how the level of Nedd4-2 expression 
or interaction with ENaC is not necessarily an accurate surrogate for Nedd4-2 function.
Funding: NIDDK Support
SA-OR113
Vasopressin Lowers Renal Epoxyeicosatrienoic Acid Levels by Activating 
Soluble Epoxide Hydrolase  Alexander Paliege,1 Allein Plain,2 Markus Bleich,2 
Sebastian Bachmann,1 Nina Himmerkus.2  1Anatomy, Charité, Berlin, Germany; 
2Physiology, CAU, Kiel, Germany.
Background: Activation of the thick ascending limb (TAL) Na(+)-K(+)-2Cl(-) 
cotransporter (NKCC2) by vasopressin (AVP) is an essential mechanism of volume 
homeostasis and may also contribute to the development of arterial hypertension and chronic 
kidney disease. AVP effects in the kidney are counteracted by locally produced eicosanoids 
including epoxyeicosatrienoic acids (EETs). The effects of AVP on the renal expression of 
EETs and their metabolizing enzymes have not been determined.
Methods: Adult AVP-deficient Brattleboro rats were treated with the AVP receptor 
agonist desmopressin (dDAVP, 5ng/h; 3d) via osmotic minipump. Renal EET-levels were 
measured by mass spectrometry. Regulation of EET-metabolizing enzymes was determined 
by Affymetrix microarray analysis. Microarray results were confirmed by real-time PCR, 
immunohistochemistry and Western blot. EET effects on TAL transport activity were studied 
using the isolated perfused tubule setup.
Results: dDAVP treatment significantly lowered renal EET levels (-56±3% for 5,6-
EET, -50±3.4% for 11,12-EET and -60±3.7% for 14,15-EET relative to controls; p<.05). 
Microarray analysis revealed elevated mRNA levels for the principal EET-degrading enzyme 
soluble epoxide hydrolase (sEH) and unchanged mRNA-levels for the EET-synthesizing 
epoxygenases. Regulation of sEH was confirmed by real time PCR (+160±37%, p<.05) and 
Western blot (+120±26%; p<.05). Immunohistochemistry in control animals demonstrated 
abundant expression in the macula densa, connecting tubule (CNT), and in the cortical 
(CCD), outer (OMCD) and inner (IMCD) medullary collecting duct. dDAVP treatment 
increased protein levels in CNT, CCD, and OMCD with close proximity to TAL profiles. 
Preincubation of TAL segments with 5,6-EET (1µM; 30 min) significantly reduced 
furosemide inhibitable short circuit current (-45±5%; p<.05) thus confirming inhibitory 
effects of EETs on NKCC2 transport activity.
Conclusions: We have shown that activation of AVP signaling causes upregulation of 
renal sEH biosynthesis and enzyme activity. The resulting reduction of EET tissue levels may 
be instrumental for increased NKCC2 transport activity during AVP-induced antidiuresis.
Funding: Government Support - Non-U.S.
SA-OR114
MicroRNA-132 Regulates Diuresis by Mediating Vasopressin Production 
Roel Bijkerk,1,2 Ruben de Bruin,1 Coen van Solingen,1 Ton J. Rabelink,1 
Benjamin D. Humphreys,2 Peter M.T. Deen,3 Anton Jan Van Zonneveld.1 
1Dept of Nephrology and the Einthoven Laboratory for Experimental Vascular 
Medicine, Leiden Univ Medical Center, Netherlands; 2Renal Divison, Brigham 
& Women’s Hospital and Harvard Medical School, Boston; 3Dept of Physiology, 
Radboud Univ Nijmegen Medical Centre, Netherlands.
Background: The collecting duct (CD) principal cells of our kidneys are critical in the 
maintenance of blood water levels, as binding of vasopressin (AVP) to its V2-receptor and 
the subsequent translocation of aquaporin-2 (AQP2) water channels to the apical membrane 
fine-tunes water balance. AVP dependent regulation of water homeostasis can be modulated 
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by renal prostaglandin E2 (PGE2), a metabolite of the cyclooxygenase (Cox) pathway, by 
inducing the internalization and lysosomal degradation of AQP2. A role for microRNAs 
(miRNAs) in the regulation of water and electrolyte balance remains virtually unexplored.
Methods: We generated antagomirs to silence miR-132 function. Synthetic AVP 
(ddAVP) was administered with osmotic minipumps. Mice were housed in metabolic cages 
and sacrificed 1 day after i.v. or i.c.v. injection of the antagomirs or scrambled controls.
Results: Silencing of miR-132 caused severe weight loss as a result of acute diuresis 
characterized by increased plasma osmolality and decreased urine osmolality. In addition, 
urinary PGE2 levels were elevated and hypothalamic AVP mRNA expression and blood AVP 
levels were decreased, resulting in less translocation of AQP2 in CD cells. We identified 
Cox2 as a direct target of miR-132, but administration of Cox2-inhibitor Celecoxib did not 
affect antagomir-132 induced diuresis, suggesting a PGE2 independent pathway. In contrast, 
infusion of synthetic AVP (ddAVP) reversed antagomir-132 induced diuresis, suggesting 
an effect on hypothalamic AVP production. Confirming this hypothesis, i.c.v. injection 
of antagomiR-132 similarly resulted in acute diuresis and decreased AVP production and 
we found miR-132 to target and increase hypothalamic MeCP2, which is known to block 
AVP transcription.
Conclusions: Taken together, silencing of miR-132 causes acute diuresis. Our data 
indicate that this is the result of a MeCP2 mediated decrease in hypothalamic AVP synthesis.
SA-OR115
Dephosphorylation at Ser-261 Is a Determinant for the Regulated AQP2 
Apical Accumulation  Naofumi Yui, Sei Sasaki, Shinichi Uchida.  Nephrology, 
Tokyo Medical and Dental Univ, Bunkyo-ku, Tokyo, Japan.
Background: AQP2 apical plasma membrane accumulation is crucial for vasopressin 
(VP)-regulated urine concentration.It is well known that VP induces post-translational 
modification on AQP2 phosphorylation at several serine (S) sites in its C-terminus, however, 
how these complicated phosphorylation and dephosphorylation regulate AQP2 apical 
accumulation is unknown. Recently, we identified that 1) pS261-AQP2 is continuously 
targeting to the apical plasma membrane, then internalized into the cytoplasm without any 
stimulations, 2) pS269-AQP2 is observed intracellularly at 1 min in the initial phase of 
forskolin (FK) stimulation, 3) S269 phosphorylation preceded S261 dephosphorylation in 
polarized MDCK cells. Therefore, we hypothesized that dephosphorylation at S261 is crucial 
for regulated AQP2 apical accumulation at the downstream step during the stimulation.
Methods: To test this hypothesis, we expressed mutated AQP2 and analyzed them in 
MDCK cells focusing on phosphorylation status at S261 and S269.
Results: In P262L-AQP2, a recessive NDI causing mutant, pS269 was greatly increased 
with continuous S256 phosphorylation after forskolin (FK) stimulation (20 µM, 10 min) 
as well as wild-type AQP2 (WT-AQP2), whereas, pS261 was increased after FK treatment 
contrary to WT-AQP2 (20 µM, 10 min). Surprisingly, pS269-AQP2 was accumulated in 
the basolateral membrane after FK treatment (20 µM, 10 min). S269A-AQP2, a S269-
dephosphorylation mimic, accumulates in the apical membrane after FK treatment (20 
µM, 30 min) with a striking reduction of phosphorylation at S261. Interestingly, it took 
longer time (20 min) to dephophorylate S261 in S269A-AQP2 compared to WT-AQP2 
(within 5 min).
Conclusions: These results demonstrated that FK-mediated subcellular translocation 
of pS269-AQP2 is greatly affected by phosphorylation status at S261 and that FK-mediated 
AQP2 apical accumulation might be determined by S261 dephosphorylation, which is 
likely to be facilitated by precedent phosphorylation at S269. Further investigation how 
VP-mediated S269 phosphorylation catalyzes dephosphorylation at Ser-261 would be 
important to draw a complete picture of AQP2 translocation mechanism.
Funding: Other U.S. Government Support
SA-OR116
ILK Is Important for Recycling of AQP2 and Its Subsequent Entry into 
the Exocytotic Pathway  Fahmy Mamuya,1 Jose Luis Cano-Peñalver,2 Dennis 
Brown,1 Hua Ann Jenny Lu.1  1Dept of Medicine, Massachusetts General 
Hospital, Boston, MA; 2Inst Reina Sofia de Investigación Renal and Red de 
Investigación Renal (REDinREN), Inst de Salud Carlos III, Madrid, Spain.
Background: Within the past decade tremendous efforts have been made to understand 
the mechanism behind aquaporin-2 (AQP2) water channel trafficking and recycling, in order 
to open a path towards effective diabetes insipidus therapeutics. A recent study has shown 
that Integrin Linked Kinase (ILK) conditional-knockdown (cKD-ILK) mice developed 
polyuria along with decreased expression of AQP2.
Methods: To better understand the role of ILK in this process, we performed in vitro 
analysis using LLCPK1 cells stably expressing rat AQP2 (W2 cells).
Results: Upon treatment of W2 cells with ILK-SiRNA and the ILK inhibitor, 
Calbiochem-cpd22, we observed a accumulation of AQP2 in the perinuclear region, 
without accumulation of AQP2 in the plasma membrane.We next examined the effect 
of ILK inhibition on endocytosis using a fluid phase marker, FITC-dextran (10 KDa). 
There was no significant difference in endocytosis of FITC-dextran in W2 cells after ILK 
inhibition. When we examined the clathrin mediated endocytotic pathway using rhodamine 
conjugated transferrin, a perinuclear accumulation of rhodamine transferrin was detected in 
the presence of ILK inhibition, which colocalized with AQP2. To further test whether we 
could “rescue” AQP2 accumulated in the perinuclear patch, lysine vasopressin (LVP) was 
added in conjunction with ILK-SiRNA or ILK inhibitor. Interestingly, the canonical LVP 
induced AQP2 membrane accumulation was prevented. To examine whether these effects 
were due to an alteration of AQP2 phosphorylation, we performed western blotting of AQP2 
phosphorylation, targeting the S256, 261, 269 and 264 sites. Our data did not reveal any 
significant effects on AQP2 phosphorylation patterns after ILK inhibition.
Conclusions: Therefore, while our data suggest that the ILK signaling pathway 
modulates AQP2 trafficking, this is not through affecting endocytosis of AQP2 nor 
modulating the phosphorylation of AQP2. Because ILK inhibition results in the formation 
of a perinuclear patch in which cellular AQP2 is concentrated we hypothesize that ILK 
is important for recycling of AQP2 and its subsequent entry into the exocytotic pathway.
SA-OR117
GI Regulation of Vesicle Osmotic Swelling Is Required for Nonsecretory 
Vesicle Fusion: Aquaporin 2 Water Channel as a Paradigm  Giovanna Valenti,1 
Maria De santo,2 Mariangela Centrone,1 Maria Grazia Mola,1 Marianna Ranieri,1 
Vincenzo Formoso,2 Grazia Tamma.1  1Dept of Biosciences, Biotechnologies and 
Biopharmaceutics, Univ of Bari, Italy; 2Dept of Physics, Univ of Calabria, Italy.
Background: We have previously shown that the heterotrimeric G protein Gai3, 
associated with AQP2 vesicles, is required for the water channel fusion to the plasma 
membrane. On the other hand, swelling of secretory vesicles has been implicated in 
exocytosis. Here we address the question of whether vesicle swelling is also a prerequisite 
for fusion of nonsecretory vesicles. The role of Gai3 in this process is investigated. AQP2 
vesicles are chosen as paradigm of nonsecretory vesicles.
Methods: AQP2 vesicles isolated from rat kidney were analyzed by high resolution 
dynamic imaging using the atomic force microscope (AFM), allowing analysis of unfixed 
vesicles in a hydrated environment at nanoscale resolution. In parallel, a rapid fluorescence-
based assay of vesicle or cell volume changes in a multiwell format was applied to analyze 
real time fluorescence kinetic data.
Results: α subunits of PTX-sensitive G proteins, Gai3, was found associated to isolated 
AQP2 vesicles. Treatment of renal AQP2-transfected MCD4 cells with pertussis toxin 
(PTX), which inhibits G proteins of the Gi family, inhibited cAMP-triggered increase in 
osmotic water permeability implicating a critical role of Gai3. Dynamic imaging of isolated 
AQP2 vesicles by AFM revealed that mastoparan, known to stimulate Gi proteins, caused 
a significant increase in vesicle swelling. This effect was confirmed by fluorescence-based 
assay of vesicle volume changes. Of note, mastoparan-induced vesicle swelling was 
abolished by anti- Gai3 antibodies or by anti-AQP2 antibodies.
Conclusions: Our results demonstrate that Gai3 localized in AQP2 vesicles mediates 
vesicle swelling regulating rapid water entry though AQP2, a potentially important 
prerequisite for vesicle fusion to the plasma membrane. We conclude that vesicle swelling is 
required also for nonsecretory vesicle fusion committed to insert a channel into the plasma 
membrane and depicts a general mechanism for vesicle fusion.
Funding: Government Support - Non-U.S.
SA-OR118
An Enzyme Immunoassay for Urinary Extracellular Vesicles  Mahdi Salih,1 
Robert A. Fenton,2 Robert Zietse,1 Ewout J. Hoorn.1  1Internal Medicine, Erasmus 
MC, Rotterdam, Netherlands; 2Biomedicine, Aarhus Univ, Denmark.
Background: Urinary extracellular vesicles (uEVs) are derived from epithelial cells of 
the kidney and urinary tract. uEVs (also called exosomes) contain disease-related proteins 
and also transfer information to target cells. As such uEVs offer exciting opportunities for 
nephrology, but current isolation techniques rely on time-consuming ultracentrifugation 
hindering high-throughput clinical application.
Methods: To navigate this problem, we designed an enzyme-linked immunosorbent 
assay (ELISA) that isolates uEVs using a biotinylated CD9 antibody. uEVs are then lysed 
with a detergent and treated with an antibody targeting the protein of interest. The use of 
two conjugated antibodies allows quantification of the protein of interest and CD9. We 
tested the set-up using aquaporin-2 (AQP2) and the sodium chloride cotransporter (NCC). 
Results: CD9 but not CD63 coated immunobeads isolated AQP2+ and NCC+ uEVs. 
Urinary creatinine and CD9 correlated strongly (n=20, r=0.9, P<0.001); thus CD9 can 
also be used for normalization in spot urines. Our uEV-ELISA sensitively detected AQP2 
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and NCC (coefficients of variance 5.6 and 3.3%). To verify whether expected effects of 
vasopressin on AQP2 and NCC were captured by our uEV-ELISA, we performed overnight 
thirsting followed by water loading in 4 volunteers. After water loading, similar 2-3 fold 
decreases in AQP2 and NCC were observed using either uEV-ELISA or immunoblotting 
after isolating uEVs with ultracentrifugation. The results by uEV-ELISA showed good 
correlations with immunoblot (r=0.8 for AQP2, r=0.6 for NCC, both P<0.001).
Conclusions: We successfully developed an ELISA to capture and quantify uEV-
proteins and validated this technique for AQP2 and NCC. Our uEV-ELISA set-up does 
not require ultracentrifugation or measurement of urinary creatinine and may be used as a 
platform to examine other uEV proteins of interest in nephrology.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
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TH-PO001
The Long Non-Coding RNA Landscape in Hypoxic and Inflammatory 
Renal Epithelial Injury  Jennie Lin, Xuan Zhang, Chenyi Xue, Sager Jayesh 
Gosai, Hanrui Zhang, Michael G. Shashaty, Nuala J. Meyer, Alison Grazioli, 
Katalin Susztak, Mingyao Li, Muredach Reilly.  Medicine, Univ of Pennsylvania, 
Philadelphia, PA.
Background: Long non-coding RNAs (lncRNAs) are emerging as key regulators 
of disease processes. To identify lncRNAs involved in acute renal epithelial injury, we 
performed whole transcriptome profiling of human proximal tubular epithelial cells (PTECs) 
in hypoxic and inflammatory conditions.
Methods: Strand-specific RNA-seq (50 million paired-end reads per library) was 
performed on poly-adenylated RNA fraction of control PTECs and PTECs subjected to 
12 hours of hypoxia or cytokine (IL6, TNF-α, and IFN-γ cocktail) stimulation. A transcript 
was considered differentially expressed (DE) between control and stimulation at > 1.5 fold 
change with FDR-adjusted p < 0.05.
Results: 3,728 mRNAs and 69 lncRNAs were DE between cytokine-stimulated and 
control PTECs, while 2730 mRNAs and 70 lncRNAs were DE between hypoxic and 
control cells. Three lncRNAs were prioritized for further study based on abundance. 
Linc-ATP13A4-8 was specifically upregulated (8.1-fold at 12 hours, FDR p < 0.001) in 
PTEC hypoxia, peaked its expression 15-fold at 24 hours, is located in the nucleus and 
cytoplasm, and has both synteny and 80.6% conservation of a 206 bp sequence with the 
mouse genome. Linc-KIAA1737-2 was specifically upregulated after cytokine treatment 
(4.6-fold at 12 hours, FDR p < 0.001), was over 50-fold upregulated at 48 hours, is located 
primarily in the nucleus with an enhancer region (high H3K4me1/H3K4me3 overlying 
H3K27ac mark for adult kidney on NIH Epigenomics Roadmap), and is syntenic with 
mouse with no sequence conservation. Linc-POU5F1-1 increased in expression (2 to 4 
fold, FDR p < 0.001) in both stimulations, declined in expression after 12 hours, is located 
in the nucleus with a canonical promoter region shared with protein-coding POU5F1, and 
is human-specific. All three lncRNAs are expressed in human PTECs from healthy donor 
nephrectomy kidneys previously micro-dissected and sequenced.
Conclusions: Transcriptome profiling of stimulated renal epithelial cells reveals 
different lncRNAs that may regulate the cellular response to distinct stressors relevant to 
acute kidney injury.
Funding: NIDDK Support, Other NIH Support - NHLBI
TH-PO002
Cortical Consequences of Ischemia-Reperfusion Injury: Computational 
Studies of the Renal Microvasculature  Gunnar Schley,1 Bernd Klanke,1 
Kai-Uwe Eckardt,1 Seymour Rosen,2 Carsten Willam.1  1Nephrology and 
Hypertension, Univ of Erlangen-Nuremberg, Erlangen, Germany; 2Pathology, 
Beth Israel Deaconess Medical Center, Boston, MA.
Background: The acute injury of the ischemia-reperfusion (I/R) kidney model affects 
mainly the outer stripe (OS) of the outer medulla, but its long-term consequence is extensive 
cortical involvement. We were therefore interested in the long-term effects of such ischemic 
injury on the cortical capillary network.
Methods: Male C57BL/6 mice (n=11) were subjected to bilateral renal I/R for 25 min 
and sacrificed 2 weeks later. Untreated mice (n=5) served as controls. Kidney sections 
were stained for MECA-32 to visualize the renal microvasculature. Vessel geometry was 
selectively quantified in damaged tissue regions by computer-assisted morphometric 
analysis.
Results: In the normal subcapsular cortex peritubular capillaries appeared elongated 
and formed an organized network. Although I/R initially affects the OS, 2 weeks after 
I/R, marked chronic tubular atrophy occurred in the cortex. Adjacent microvessels’ shape 
remarkably changed: capillaries were significantly smaller (perimeter, diameter decreased) 
and rounder (circularity and roundness increased, see Figure, aspect ratio decreased) 
compared to control vessels. 
These alterations resulted in an abnormal structural organization. We validated our 
technique by comparing geometric parameters of vasa recta and the capillary plexus in 
the inner stripe of the outer medulla in controls kidneys.
Conclusions: Long-term effects of renal I/R involved cortical tubules and microvessels. 
Semiautomated morphometric analysis of cortical capillaries showed a remarkable shift 
from organized and elongated towards disorganized, smaller and rounder forms. Thus the 
late consequences of I/R, a primary medullary insult, are those of profound changes in the 
cortical microvasculature.
TH-PO003
Glomerular Injury Induces a Calcium Signal in Proximal Tubular Cells – A 
Mutliphoton In Vivo Study  Julia Binz, Matthias Hackl, Bernhard Schermer, 
Thomas Benzing.  Dept II of Internal Medicine and Cologne Center for 
Molecular Medicine, Univ of Cologne, Cologne, Germany.
Background: Recently it has been demonstrated that renal tubular cells undergo 
synchronized necrosis after ischemic injury, implying that the death of a single cell can 
induce a disastrous chain reaction. An early event in damage signaling is a massive increase 
in intracellular calcium levels. Therefore we investigated if a localized damage to glomerular 
cells can influence tubular calcium levels downstream of the damage site.
Methods: 4 weeks old mice expressing the calcium indicator GCaMP3 in proximal 
tubular cells (Pax8:cre) were anaesthetized, an arterial catheter was placed into the right 
carotid artery and the left kidney was exteriorized for in vivo multiphoton microscopy. 
Blood vessels were labelled by injection of 70 kDa Texas Red dextrane. Acute glomerular 
injury was induced by focusing the laser beam on a podocyte to cause a localized injury. 
The resulting calcium response in tubular cells was recorded with in a time series of the 
glomerulus and the originating proximal tubulus.
Results: Upon laser induced injury of a podocyte, a strong calcium signal can be 
observed within seconds in the continuous stretch of proximal tubular cells downstream 
of the glomerulus. The signal lasts for a few seconds and then the calcium signal returns to 
baseline. The calcium response in proximal tubular cells is faster than the known calcium 
wave in podocytes after injury.
Conclusions: Glomerular injury induces a calcium signal in proximal tubular cells 
in vivo, linking glomerular injury to tubular damage signaling. The almost instantaneous 
calcium increase in tubular cells suggest that the release of podocyte cell content and most 
probably damage-associated molecular pattern molecules (DAMPs) affects tubular cells, 
uninjured by the initial damage.
TH-PO004
Inhibition of Oxygen-Sensing Prolylhydroxylases 1 (PHD1) Protects from 
Acute Kidney Injury  Almut Grenz,1 Raechel Peralta,2 Uladzimir Shabeka,1 
Sue Murray,2 Shuling Guo,2 Gene Hung.2  1Dept of Anesthesiology, UC Denver, 
Denver, CO; 2ISIS Pharmaceuticals, ISIS Pharmaceuticals, Carlsbad, CA.
Background: Acute kidney injury (AKI) due to ischemia is associated with dramatic 
increases of morbidity and mortality. Conditions of ischemia with limited oxygen availability 
inhibit oxygen-sensing prolyl hydroxylases (PHD1-3) with subsequent stabilization of 
hypoxia-inducible factors (HIFs) resulting in a transcriptionally regulated response towards 
hypoxia adaptation. Thus, we hypothesize that a new pharmacological approach to inhibit 
PHDs on a transcript level via specific antisense treatment before the onset of ischemic 
injury mediates protection.
Methods: Mice were studied in two ischemic models of AKI. With a hanging weight 
system we only compress the renal artery whereby we clamp the whole pedicle by using 
micro vessel clamps. Renal function was determined by inulin clearance, serum creatinine, 
BUN, renal NGAL and KIM-1.
Results: Our previous studies in gene-target mice (PHD1-3 KO mice) has shown that 
renal protection from ischemia was associated with PHD1. To pursue our hypothesis, we first 
treated wild type mice with PHD1 specific antisense inhibitors (ASO1 and ASO2). We tested 
the compounds over 2 to 6 week treatment periods in different doses. The optimal treatment 
length was 2 weeks before renal ischemia (30min ischemia and 24 hours reperfusion by 
utilizing the hanging weight system) in a dose of 100mg/kg per week. Treatment reduces 
renal PHD1 RNA by 90% and 60%, respectively and improved the glomerular filtration 
rate (GFR) by almost 300% in both treatment groups compared to untreated mice following 
30min of renal ischemia. In a next step we used the clamp model to induce kidney ischemia. 
PHD1 specific antisense inhibitor treatment showed comparable kidney protection as in 
the hanging weight model demonstrated in GFR improvement, serum creatinine and renal 
tubular injury markers (NGAL, KIM1).
Conclusions: In conclusion, PHD1 oligo treatment before renal ischemia in two 
different ischemia models shows a tremendous attenuation from renal injury due to ischemia. 
If translatable from mice to human, these data have important therapeutic implications.
Funding: Pharmaceutical Company Support - ISIS Pharmaceuticals, Private 
Foundation Support
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TH-PO005
Role of Thioredoxin-Interacting Protein (TXNIP) in Mitochondrial 
Function of Renal Tubular Cells in Ischemia Reperfusion Injury AKI Model 
Natsuki Maeda, Tatsuki Matsumoto, Kazu Hamada-Ode, Yoshiko Shimamura, 
Koji Ogata, Kosuke Inoue, Yoshinori Taniguchi, Taro Horino, Shimpei Fujimoto, 
Yoshio Terada.  Kochi Univ, Japan.
Background: Thioredoxin-interacting protein (TXNIP) has been found to regulate 
the cellular reduction-oxidation (redox) state by binding to and inhibiting thioredoxin in 
a redox-dependent fashion. However, little is known about the role of TXNIP in acute 
kidney injury (AKI) pathogenesis.
Methods: We evaluated the role of TXNIP in renal function in bilateral renal ischemia/
reperfusion injury (IRI) model using TXNIP knock-out (KO) and wild type (WT) mice. 
cultured renal tubular cells (NRK-52E cells) as an in vitro model. To elucidate the functional 
roles of TXNIP, we evaluated mitochondrial enzymes, morphology, and apoptotic change 
by transfection of siRNA for TXNIP in cultured renal tubular cells.
Results: TXNIP KO mice had significantly higher SCr (0.78+0.28 versus 0.45 + 0.20 
mg/dl) and significantly higher BUN (152.5+32.5 versus 75.3+18.2 mg/dl) at 24h post 
ischemia compared to WT mice. Immunohistological examination showed severer tubular 
injury in cortex and outer medulla in TXNIP KO mice compared to WT mice. The number 
of TUNEL positive tubular cells was increased in in TXNIP KO mice compared to WT 
mice. The protein expressions of mitochondrial enzymes (ATP5a, UCP2 and complex IV) 
were decreased in TXNIP KO mice at 24h post ischemia. In vitro experiments, protein 
and mRNA levels of ATP5a, complex IV, UCP2, PGC-1a were significantly decreased by 
H2O2, and siRNA for TXNIP amplify the reduction of these enzymes in NRK-52E cells.
Conclusions: These data demonstrate that TXNIP protects from IRI induced AKI. 
TXNIP changes mitochondrial function in oxidative conditions. These results indicate that 
TXNIP plays a key role in the pathophysiology of AKI.
TH-PO006
TWEAK Decreases PGC-1α Expression in Renal Injury and Promotes 
Mitochondrial Dysfunction in Tubular Cells  Olga Ruiz Andrés, Beatriz 
SuarezAlvarez-, Cristina Sánchez-Ramos, Maria Monsalve, Maria D. 
Sanchez-niño, Marta Ruiz-Ortega, Jesus Egido, Alberto Ortiz, Ana Belen 
Sanz.  Nephrology, Inst de Investigacion Sanitaria - Fundación Jimenez Diaz 
(IIS-FJD), Madrid, Spain; Dept of Metabolism and Cellular Signalling, Inst de 
Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Madrid, Spain.
Background: There is currently no satisfactory therapy for acute kidney injury (AKI). 
Successful testing of mitochondria-targeted nephroprotective agents suggests a key role 
of mitochondrial injury in AKI. We hypothesized that an improved understanding of the 
regulation of factors responsible for mitochondrial biogenesis may provide clues to novel 
therapeutic approaches to AKI. Thus, we explored the interaction between inflammation 
and mitochondrial biogenesis regulators.
Methods: Transcriptomics databases from cultured murine tubular epithelial cells 
and folic acid-induced AKI in mice identified downregulation of PGC-1α and target genes 
regulated by the inflammatory cytokine TWEAK. Functional studies in vivo ad cell culture 
studies characterized the TWEAK- PGC-1α relationship.
Results: Transcriptomics identified decreased expression of PGC-1α mRNA and 
PGC-1α-dependent genes encoding mitochondrial proteins (Ndufs1, Sdha and Tfam) as a 
shared feature between AKI and TWEAK-stimulated cultured tubular cells. Neutralizing 
anti-TWEAK antibodies prevented the decrease in kidney PGC-1α and its targets during 
AKI. TWEAK stimulation decreased kidney PGC-1α expression in healthy mice. TWEAK 
also decreased the expression of PGC-1α and its targets as well as mitochondrial membrane 
potential in cultured tubular cells. Adenoviral-mediated PGC-1α overexpression prevented 
TWEAK-induced downregulation of PGC-1α-dependent genes and the decrease in 
mitochondrial membrane potential. TWEAK promoted histone H3 deacetylation at the 
murine PGC-1α promoter. TWEAK-induced downregulation of PGC-1α was prevented 
by histone deacetylase (HDAC) or NFκB inhibitors.
Conclusions: TWEAK decreases PGC-1α and target gene expression in tubular cells 
through NFκB activation and histone deacetylation. This information may be used to 
design therapeutic approaches that preserve mitochondrial function during kidney injury.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-PO007
miR-21 Targets Prolyl Hydroxylase Domain Protein 2 in Renal Ischemia/
reperfusion  Xiaoyan Jiao,1,2,3 Xialian Xu,1,2,3 Jie Teng,1,2,3 Yi Fang,1,2,3 Mingyu 
Liang,4 Xiaoqiang Ding.1,2,3  1Div of Nephrology, Zhongshan Hospital, Fudan 
Univ, Shanghai, China; 2Shanghai Inst of Kidney Disease and Dialysis, 
Shanghai, China; 3Kidney and Blood Purification Laboratory of Shanghai, 
Shanghai, China; 4Dept of Physiology and Center of Systems Molecular 
Medicine, Medical College of Wisconsin, Milwaukee, WI.
Background: We previously reported that up-regulation of miR-21 attenuated renal 
ischemia-reperfusion injury, which was associated with increased hypoxia inducible factor 
(HIF)-1α expression. HIF-1α is mediated by prolyl hydroxylase domain protein 2 (PHD2) 
.We hypothesized that miR-21 regulated HIF-1α by targeting PHD2 in the renal ischemic 
preconditioning (IPC).
Methods: Luciferase reporter assay was performed to examine if miR-21 could target 
the 3’-untranslated region of PHD2. In vitro, hypoxia (1% O2) for 6h was followed by 
reoxygenation for 0.5h in HK-2 cell. In vivo, bilateral kidneys of mice were clamped for 
15min to induce IPC, followed by 35min ischemia 4 days later in the IPC/IR group. The 
mice for Sham/IR group were subjected to 35min ischemia without IPC. Locked nucleic 
acid (LNA) modified anti-miR-21 or scrambled anti-miR was transfected into cells or 
delivered into the mice via tail vein injection less than 1 hour prior to IPC.
Results: miR-21 targeting of PHD2 was confirmed by 3’-untranslated region reporter 
assay. miR-21 was significantly up-regulated by hypoxia/reoxygenation in HK-2 cell, 
while PHD2 protein decreased significantly. LNA anti-miR-21 significantly decreased 
miR-21 levels and increased the abundance of PHD2. In vivo, IPC up-regulated miR-21 
expression 24h after the second ischemia. PHD2 expression decreased significantly with 
up-regulation of HIF-1α protein and VEGF mRNA in the IPC/IR group. miR-21 induced 
by delayed IPC was effectively inhibited by the LNA anti-miR-21. With down-regulation 
of miR-21, the protection of delayed IPC was attenuated and PHD2 protein was increased. 
Furthermore, up-regulation of HIF-1α and VEGF were abolished in the IPC/IR mice after 
the LNA anti-miR-21 treatment.
Conclusions: miR-21 could protect kidney against IRI via HIF-1α by inhibiting 
PHD2. The study suggested a new mechanism mediating the effect of miR-21 on HIF-1α 
and renal IRI.
Funding: Government Support - Non-U.S.
TH-PO008
Mir-668 Is Induced via HIF-1 to Prevent Mitochondrial Fragmentation 
and Protect Kidneys from Ischemia-Reperfusion Injury  Qingqing Wei,1 
Yong Liu,2 Mingyu Liang,2 Zheng Dong.1,3  1Dept of Cellular Biology and 
Anatomy, Medical College of Georgia, Georgia Regents Univ, Augusta, GA; 
2Dept of Physiology, Center of Systems Molecular Medicine, Medical College of 
Wisconsin, Milwaukee, WI; 3Charlie Norwood VA Medical Center, Augusta, GA.
Background: MicroRNAs are important regulators in various pathophysiological 
condition including ischemic acute kidney injury(AKI). We identified mir-668 that was 
significantly up-regulated in ischemic AKI. mir-668 induction was attenuated in kidney 
proximal tubule-HIF-1-knockout mice, suggesting a role of HIF-1 in the inductive response.
Methods: Analysis of the sequence of the potential promoter region of mir-668 
predicted two HIF-1 binding sites. The binding of HIF-1 to one of the sites was verified 
by Chromatin immunoprecipitation (CHIP) assay, suggesting that HIF-1 may directly 
regulate mir-668 transcription.
Results: Functionally, inhibition of mir-668 exacerbated kidney injury, supporting a 
protective role of this microRNA. Consistently, inhibition of mir-668 led to apoptosis in 
cultured rat proximal tubular cells (RPTC) and overexpress mir-668 reduced ATP-depletion 
mediated RPTC apoptosis. Interestingly, mir-668 inhibition also induced significant 
mitochondrial fragmentation, a pathogenic event in renal tubular cell death in ischemic 
AKI. To further examine the regulation mechanism of mitochondrial morphology by 
mir-668, we identified a list of potential mir-668 targets by Ago2 immunoprecipitation 
and RNA deep sequencing.
Conclusions: In summary, mir-668 is up-regulated via HIF-1 during ischemic AKI. 
Following the induction, mir-668 may play a role in the preservation of mitochondrial 
dynamics and morphology for the protection of kidney cells and tissues. n also induced 
significant mitochondrial fragmentation, a pathogenic event in renal tubular cell death in 
ischemic AKI. To further examine the regulation mechanism of mitochondrial morphology 
by mir-668, we identified a list of potential mir-668 targets by Ago2 immunoprecipitation 
and RNA deep sequencing.
Funding: NIDDK Support, Veterans Administration Support, Private Foundation 
Support
TH-PO009
Implication of AMPK Activation in Experimental Aristolochic Acid 
Nephropathy: Use of a Targeted Metabolomic Analysis  Anne-Emilie Decleves,1 
Inès Jadot,3 Vanessa Colombaro,3 Kefeng Li,2 Nathalie Caron,3 Joelle L. Nortier,1 
Robert K. Naviaux.2  1Free Univ of Brussels; 2Univ of California, San Diego; 
3Univ of Namur.
Background: Experimental aristolochic acid nephropathy (AAN) is a progressive 
tubulointerstitial injury, characterized by early and transient acute tubular necrosis. In order 
to better explore the pathogenesis of AAN, a targeted metabolomic analysis was performed 
in plasma of AA-intoxicated mice. In addition, the effect of AMP-activated Protein Kinase 
(AMPK) activation with AICAR was also investigated.
Methods: C57BL/6J male mice were randomly subjected to i.p. injection of either 
sterile saline solution, AA, AA+AICAR, the specific AMPK activator for 4 days. Mice were 
then euthanized at day 5. Targeted metabolites were detected in plasma using an AB SCIEX 
QTRAP 5500 triple quadrupole mass spectrometer equipped with a Turbo V electrospray 
ionization (ESI) source, and Shimadzu LC-20A UHPLC system.
Results: Thirty metabolites were dysregulated in this acute phase of the experimental 
AAN model. Among them, 23 metabolites were significantly increased in AA-treated mice 
and 7 were significantly decreased. AICAR treatment ameliorated the change of 15 of these 
metabolites. Among the observed changes, several metabolic pathways were affected, 
in particular gut microbiome metabolism, liver and bile acid metabolism, tryptophan 
metabolism, purine and pyrimidine metabolism and mitochondrial metabolism. Tryptophan-
derived metabolites considered as uremic toxin such as xanthurenic acid, kynurenic acid 
were increased in AA-treated mice and reduced with AICAR.
Conclusions: These metabolomic approach provided novel findings regarding early 
perturbations occurring in metabolic pathways in AAN. Moreover, our results suggest 1) 
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a crosstalk between gut microbiome and kidney, especially in relation with tryptophan 
metabolism and accumulation of uremic toxins; 2) a beneficial role of AMPK in reducing 
the level of uremic toxins.
Funding: Private Foundation Support
TH-PO010
Suppressed Renal Mitochondrial Biogenesis After Liver Transplantation 
in Rats  Zhi Zhong,1 Qinlong Liu,1,2 Yasodha Krishnasamy,1 Hasibur Rehman,1 
Peifeng Deng,1 John J. Lemasters,1 Rick G. Schnellmann.1,3  1Medical Univ of 
South Carloina, Charleston, SC; 2Darlian Medical Univ, nd Affiliated Hospital, 
Darlian, China; 3Ralph H. Johnson VA Medical Center, Charleston, SC.
Background: Suppressed mitochondrial biogenesis (MB) contributes to acute kidney 
injury (AKI) after renal ischemia-reperfusion and sepsis. AKI occurs frequently after 
liver transplantation (LT), which substantially increases mortality. This study investigated 
whether suppressed MB plays a role in AKI after LT.
Methods: Livers were explanted from Lewis rats and implanted after 18 h cold storage. 
Liver, kidney and blood were collected 18 h after LT or survival was determined at 7 days.
Results: Seven-day survival after LT decreased to 25%. Focal necrosis, apoptosis and 
leukocyte infiltration occurred in liver grafts, and serum ALT and total bilirubin increased 
markedly after LT. In the kidney, nuclear DNA-encoded oxidative phosphorylation 
(OXPHOS) protein ATP synthase-β and mitochondrial DNA (mtDNA)-encoded OXPHOS 
protein NADH oxidase-3 decreased 44% and 81%, respectively, and their associated mRNAs 
decreased 72% and 46%, respectively, indicating suppressed OXPHOS protein synthesis. 
Renal PGC-1α, the master regulator of MB, decreased 57% after LT and mitochondrial 
transcription factor-A (TFAM), which controls mtDNA replication and transcription, 
decreased 66%. PGC-1α and TFAM mRNAs also decreased. mtDNA was reduced by 60%. 
Together, these data indicate marked MB suppression in the kidney after LT. Inhibited MB 
was associated with 17- and 13-fold increases in NGAL and cleaved caspase-3 in the renal 
tissue. Mild to moderate histological changes were observed in the kidney, including loss 
of brush border, vacuolization of tubular cells in the cortex, cast formation and necrosis in 
some proximal tubular cells. Myeloperoxidase and ED-1 also increased in the kidney after 
LT, indicating inflammation. Serum creatinine increased >2 fold.
Conclusions: MB is disrupted in the kidneys of recipients of liver grafts after long cold 
storage, which may contribute to the occurrence of AKI and increased mortality after LT.
Funding: NIDDK Support
TH-PO011
TXNIP Is Involved in the Mitochondrial ROS Mediated NLRP3 
Inflammasome Activation in Ischemia/Reperfusion Induced AKI  Liu Yiran, 
Wen Yi, Tang Taotao, Bi-Cheng Liu.  Inst of Nephrology, Southeast Univ, 
Nanjing, Jiangsu Province, China.
Background: Renal ischemia reperfusion is a leading cause of acute kidney injury 
(AKI). Previews studies suggest that mitochondrial dysfunction and NLRP3 inflammasome 
activation are important events of AKI. TXNIP, an endogenous inhibitor of the antioxidant 
thioredoxin and ROS sensor, may have a role in NLRP3 inflammasome activation. In this 
study, we explored the relationship between TXNIP on NLRP3 inflammasome activation 
in ischemia/reperfusion induced AKI.
Methods: Ischemic mice models were built as previewsly reported. MitoTEMPO, a 
mitochondria-targeted antioxidant, was used to attentuate ROS production. Also, HK-2 
cells were cultured for 8h with hypoxia-hypoglycemic plus 2 h normoxia/normal glucose 
incubation. SiRNA of NLRP3 and TXNIP were applied to interupt the signaling.
Results: In this study, we established an ischemia reperfusion induced-AKI model 
characterized by tubular necrosis and excessive mROS production.The renal expression 
of NLRP3 inflammasome, IL-1β and IL-18 were significantly increased in this animal 
model. However, kidney dysfunction and mitochondrial damage were attenuated obviously 
in NLRP3-/- mice compared with WT mice with ischemia AKI. In vitro study,oxygen–
glucose deprivation injury time dependently increased the expression levels of NLRP3 
inflammasome axis and TXNIP. The mitochondrial injury in damaged HK2 cells was 
suppressed by silence of NLRP3. Furthermore, MitoTEMPO could restore mitochondrial 
function and dissociate TXNIP from NLRP3 to inhibit NLRP3 inflammasome activation. 
TXNIP siRNA significantly abrogated the mROS and NLRP3 inflammasome activation. 
Conclusions: NLRP3 inflammasome activation induced by excessive ROS production 
in ischemic AKI is mediated by TXNIP. And the mROS-TXNIP-NLRP3 inflammasome 
pathway can be a potential target for AKI therapy.
Funding: Other NIH Support - National Natural Science Foundation of China
TH-PO012
PPAR Activation in Regulatory T Cells Enhances Protection from Kidney 
Ischemia Reperfusion Injury  Gilbert R. Kinsey, Didier Portilla, Liping Huang, 
Mana Yang, Michael N. Pham, Brian K. Stevens.  Medicine, Univ of Virginia, 
Charlottesville, VA.
Background: Regulatory T cells (Tregs) are anti-inflammatory lymphocytes that 
protect the kidney from multiple types of injury.  Our recent studies suggest that Tregs 
must express the surface receptor programmed death 1 (PD-1) to mediate protection.  A 
metabolic program favoring mitochondrial oxidative phosphorylation (OxPhos) over 
glycolysis in Tregs is critical for Treg development and function in other models.  PD-1 
and peroxisome proliferator-activated receptors (PPARs) promote OxPhos in several cell 
types, but their role in Treg-mediated renal protection is not known.
Methods: Mitochondrial membrane potential (TMRE) and mass (Mitotracker) were 
assessed using flow cytometry. Tregs isolated from WT or PD-1 KO mice were adoptively 
transferred to naïve WT recipients 1 hr prior to ischemia reperfusion injury (IRI).  WT and 
PD-1 KO Tregs were exposed to the pan PPAR activator bezafibrate (BEZA) or vehicle 
(DMSO) overnight, then washed, prior to adoptive transfer in the IRI model.
Results: PD-1 KO Tregs had significantly lower mitochondrial mass and mitochondrial 
membrane potential (TMRE mean fluorescence intensity: 45±10% of WT Tregs, p<0.05). 
In contrast to WT Tregs, untreated PD-1 KO Tregs offered no protection from kidney IRI 
in terms of plasma creatinine levels, ATN scores and kidney neutrophil accumulation at 24 
hr of reperfusion.  Treatment of WT Tregs with bezafibrate overnight significantly enhanced 
the ability of a sub-optimal number of Tregs to protect the kidney from IRI (24 hr plasma 
creatinine (mg/dl): Sham 0.4±0.1; IRI + saline 1.8±0.1; IRI+ WT Tregs (DMSO) 1.1±0.3; 
IRI + WT Tregs (BEZA) 0.6±0.1*, N=7 per group, *P<0.01 vs. DMSO). Bezafibrate 
treatment endowed PD-1 KO Tregs with modest, but statistically significant, protective 
ability in the kidney IRI model.
Conclusions: These results demonstrate that PD-1 must be expressed on Tregs in order 
for them suppress kidney IRI and that PPAR activation ex vivo enhances subsequent Treg 
activity in this model.  Our findings suggest that enhanced OxPhos in Tregs promotes their 
ability to protect the kidney.
Funding: NIDDK Support
TH-PO013
Effects of Short Chain Fatty Acids on Inflammatory Process in Acute Kidney 
Injury  Sung Yoon Lim,1 Young Ju Na,1 Myung-gyu Kim,1 So-young Lee,2 
Sang-Kyung Jo,1 Won-Yong Cho.1  1Dept of Nephrology, Korea Univ Hospital, 
Seoul, Korea; 2Dept of Nephrology, Eulji Univ Hospital, Korea.
Background: Short chain fatty acids (SCFAs) are the metabolic end products of normal 
bacterial fermentation of fibers in the large intestine. Emerging evidence suggest the role of 
gut-kidney crosstalk in regulating inflammatory processes. Purpose of the present study was 
to elucidate the role of SCFAs in an acute kidney injury (AKI) in which the inflammatory 
process has a major role.
Methods: Bilateral ischemia reperfusion injury (IRI) was induced in C57BL/6 mice. 
Sodium acetate were given to mice 30 minutes before ischemia and at the moment of 
reperfusion. Biochemical values, histological kidney damage and tissue inflammation were 
assessed. In in vitro analysis, immune cells harvested from mice spleen were stimulated 
with LPS and the effect of sodium acetate on cytokine production was measured. Effects 
of SCFAs on T cell proliferation was also determined.
Results: Treatment with SCFAs attenuated IRI and reduced inflammation. Tubular cell 
apoptosis, determined by TUNEL stain also was decreased by SCFAs. The anti-inflammatory 
effects of SCFAs persisted until IRI day 14, thereby attenuating renal fibrosis after injury. 
Significantly lower level of pro-inflammatory cytokines was observed in the supernatant 
of cells from spleen co-treated with LPS and SCFAs, compared with those treated with 
LPS alone. Especially, IL-12p70, major inflammatory cytokine of dendritic cells was also 
reduced, suggesting that SCFAs might modulate the function of dendritic subset. In addition, 
administration of SCFAs can dose dependently inhibit normal T cell proliferation induced 
by anti-CD3 Ab stimulation.
Conclusions: Thus, our findings provide evidence that the SCFAs have renoprotective 
effect in AKI and also that this might be partially mediated by its immune modulatory effect.
TH-PO014
The Renoprotective Effect of Abatacept in Ischemia/Reperfusion Injury in 
Mice  Masaki Saito, Shinya Kaname, Hideki Shimizu, Yoshinori Komagata, 
Yoshihiro Arimura.  Kyorin Univ School of Medicine, 6-20-2 Shinkawa, Mitaka, 
Tokyo, Japan.
Background: Although AKI is still an important complication in hospitalized patients, 
its prognosis remains poor, thus elucidation of the pathogenic mechanism and its effective 
treatment is urgently needed. Recently, a role for T cells in the renal ischemia/reperfusion 
injury (IRI) and also the renoprotective effect of abatacept, an inhibitor for CD28-CD80 T 
cell costimulatory signals, in the IRI have been reported, while its precise mechanisms are 
not fully understood. The purpose of this study is to determine the effect and mechanism 
of abatacept in the IRI model in mice.
Methods: Heminephrectomized mice were divided into three groups; the mice treated 
with ischemia/reperfusion (22 min) with normal saline or abatacept, and those treated with 
sham operation without renal ischemia as a control. Renal function (serum urea nitrogen 
and Cr, urine albumin excretion), pathology including T cell infiltration, expression of 
mRNA and protein for various parameters in the kidney were evaluated at 1 day after 
ischemia/reperfusion procedures.
Results: Compared with normal saline-treated mice, renal injury in the abatacept-treated 
mice were markedly attenuated both functionally and pathologically, with serum parameters 
improved to almost control levels. In addition, in abatacept-treated mice, apoptosis and 
expression of KIM-1 and PAI-1 were significantly suppressed as compared with normal 
saline-treated mice. Although the number of inflammatory cells and expressions of MCP-
1 reduced by abatacept, the number of CD3-positive T cells, which was increased after 
ischemia/reperfusion, was not altered by abatacept.
Conclusions: We here showed that abatacept dramatically ameliorate IRI in mice, 
suggesting that it might be a new therapeutic option. It may be that abatacept, by blocking 
CD80-mediated signal in some cells responsible for the pathogenesis, exhibit anti-
inflammatory effects, resulting in improvement of IRI, independently of T-cell-mediated 
acquired immune mechanisms.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
93A
J Am Soc Nephrol 26: 2015 AKI: Basic - I Poster/Thursday
TH-PO015
Autophagy Is Activated to Protect against Kidney Injury following in 
Lipopolysaccharide Treatment  Shuqin Mei,1,2 Man J. Livingston,2 Changlin 
Mei,1 Zheng Dong.2  1Nephrology, Shanghai Changzheng Hospital, Shanghai, 
China; 2Cellular Biology and Anatomy, Georgia Regents Univ, Augusta, GA.
Background: Sepsis, characterized by systemic inflammation, is a major cause of 
acute kidney injury (AKI) in hospitalized patients, especially in intensive care unit. The 
pathogenesis of septic AKI is poorly understood. Autophagy is a conserved, cellular 
catabolic pathway that plays crucial roles in cellular homeostasis including the maintenance 
of cellular function and viability. The regulation and role of autophagy in septic AKI 
remains unclear.
Methods: Lipopolysaccharide (LPS), an endotoxin, was injected in C57BL/6 mice 
to induce endotoxic/septic AKI. Autophagy reporter (CAG-RFP-(GFP-LC) mice were 
used to monitor the dynamic changes of autophagy following LPS treatment. To determine 
the pathological role of autophagy, autophagy was inhibited pharmacologically with 
chloroquine or genetically by using proximal tubule-specific Atg7 (Autophagy gene-7) 
ablated mice. Blood urea nitrogen (BUN) and serum creatinine were measured to evaluate 
renal function. HE staining and TUNEL staining were used to detect kidney injury. For 
in vitro study, cultured proximal tubular cells were treated with LPS in the absence or 
presence of chloroquine.
Results: LPS induced AKI in mice as indicate by increased in BUN and serum 
creatinine, and tubular injury, which was accompanied by an increase in LC3II expression. 
In CAG-RFP-(GFP-LC mice, LPS induced mRFP and EGFP-labeled autophagic puncta 
in renal tubular cells, further verifying the activation of autophagy. Chloroquine enhanced 
kidney injury during LPS treatment. For in vitro study, we detected LC3II expression 
accumulation and P62 degradation after LPS treatment for 12 hours, which was consistent 
with the mRFP, EGFP-labeled autophagic puncta results showed in proximal tubular cells.
Conclusions: Autophagy is activated in LPS-induced AKI and plays a renoprotective 
role.
Funding: NIDDK Support, Veterans Administration Support, Government Support 
- Non-U.S.
TH-PO016
Vascular Endothelial Growth Factor (VEGF) Contributes to Sepsis-Induced 
Acute Kidney Injury  Arnaldo F. Lopez-Ruiz, Andrea P. Soljancic, Kiran B. 
Chandrashekar, Luis A. Juncos.  Nephrology, Univ of Mississippi Medical 
Center, Jackson, MS.
Background: Sepsis is the most common cause of acute kidney injury (AKI) in the 
ICU. However, we still have an incomplete understanding of the mechanisms that cause it, 
and consequently our therapies provide only suboptimal protection at best. Previous studies 
have shown that VEGF is upregulated in sepsis and plays a role in its associated morbidity 
and mortality. We recently found that sFlt-1, an endogenous VEGF inhibitor is upregulated 
in both sepsis and AKI; however not sufficiently to normalize VEGF levels or neutralize 
its deleterious effects. We tested whether administering additional sFlt-1 protects against 
AKI and improves the balance between deleterious and protective cytokines and factors.
Methods: We used the cecal ligation and puncture technique (CLP) to induce sepsis. 
Male Sprague-Dawley rats were randomized into 4 groups: 1) Sham. 2) Sham + sFlt-1, 
3) CLP, 4) CLP + sFlt-1. We administered sFlt-1 (12 µg/kg SQ) 6 hs after the CLP or 
sham procedure. At 24hs the rats were euthanized after collecting blood and kidneys for 
determination renal function and injury.
Results: 
VEGF 
pg/ml
Sflt-1 
pg/ml
Creat 
mg/dl
uKIM-1 
pg/ml
TNF 
pg/ml
i-NOS 
pg/ml
HO-1 
ng/ml
SHAM 370± 10 30± 5 0.5± 0.07 135± 5 20± 0.8 1.8± 0.3
0.53± 
0.01
CLP 780± 15 *
330± 
10 *
2.2± 
0.09 *
1900± 
50 *
265± 
10 *
13± 
0.5 *
3.0± 
0.1*
CLP+Sflt-1 530± 10 * #
500± 
15 * #
1.4± 0.1 
* #
1100± 45 
* #
130± 6 
* #
6± 0.4 
* #
7.5± 0.2 
* #
Data: Mean ± SEM * p< 0.05 vs Sham #p<0.05 vs CLP
Conclusions: CLP causes AKI within 24hs and is associated with increased intra-renal 
expression of VEGF, i-NOS, TNF and only a modest increase in renal HO-1. Administering 
Sflt-1 during sepsis attenuated the severity of AKI and blunted the increase in i-NOS, VEGF 
and TNFα, while paradoxically causing a large increase in HO-1. Our data demonstrate 
a protective effect of sFlt-1 in sepsis-induced AKI, suggesting that excessive VEGF is 
deleterious in this condition, and that sFlt-1 associated induction of HO-1 may play a role 
in its beneficial actions.
Funding: NIDDK Support, Private Foundation Support
TH-PO017
Up-Regulation of miR-98 in the Kidney with Ischemia Reperfusion Injury 
Protects Endothelial Cells against Apoptosis by Targeting Caspase-3 
Guang Yu, Xueli Lai.  Dept of Nephrology, Changhai Hospital, the Second 
Military Medical Univ, Shanghai, China.
Background: Endothelial dysfunction is one of the main pathophysiological processes 
involved in renal ischemia reperfusion injury. In our previous study, we screened the 
aberrantly expressed miRNAs in the kidney with ischemia reperfusion injury (IRI) by 
microarray assay, among which miR-98 was predicted to target caspase-3. The present 
study was performed to whether miR-98 was involved in the regulation of endothelial 
apoptosis under hypoxia and re-oxygenation (HR) conditions.
Methods: The level of miR-98 in IRI kidney and HR HUVECs was determined by 
real-time PCR. HUVECs were treated with HIF-1α siRNA to investigate the role of HIF-
1α on miR-98 regulation. HUVECs were transfected with miR-98 mimics or antisense 
oligonucleotides against miR-98 to identify the effect of miR-98 on the expression of 
caspase-3, as well as the hypoxia-induced apoptosis. Finally, the relationship between 
miR-98 and caspase-3 was confirmed by dual-luciferase reporter assay.
Results: Both of IRI and HR induced significantly up-regulation of miR-98 in 
the ischemic kidney and hypoxic HUVECs, respectively (Figure 1A). HIF-1α siRNA 
remarkably down-regulated the expression of miR-98 in both normal and hypoxic HUVECs 
(Figure 1B). MiR-98 mimics significantly inhibit caspase-3 expression in HUVECs, while 
anti-miR-98 significantly up-regulated it (Figure 1C). Furthermore, miR-98 protected 
HUVECs against apoptosis induced by hypoxia, while anti-miR-98 had the reverse effect 
(Figure 1D). The dual-luciferase reporter assay showed that miR-98 decreased the luciferase 
activity when transfected with wild-type caspase-3 sequence, but not mutant sequence at 
the predicted binding site (Figure 1E).
Conclusions: Renal IRI induces up-regulation of miR-98 potentially dependent on 
HIF-1α, which protects endothelial cells against apoptosis by targeting caspase-3.
Funding: Government Support - Non-U.S.
TH-PO018
Endothelial Caspase-8 Is a Key Mediator of Sepsis-induced Acute Kidney 
Injury  Bradley K. Hack, Lihua Bao, Chang Xu, Patrick Cunningham.  Section 
of Nephrology, Univ of Chicago, Chicago, IL.
Background: Acute kidney injury (AKI) is a frequent complication of gram negative 
sepsis. Prior work has demonstrated the importance of tumor necrosis factor (TNF) in 
endotoxin (LPS)-induced AKI. Caspase-8 is a key downstream effector of TNF, leading to 
apoptosis, and possibly facilitating inflammation. Mice genetically deficient in caspase-8 
die in utero due to abnormal cardiovascular development.
Methods: To define the importance of caspase-8 activation in the endothelium in sepsis, 
we generated mice deficient in endothelial cell caspase-8 (EC-Casp8-/-), using Cre expressed 
in the endothelium under inducible control of the VE-cadherin promoter, activated after 
tamoxifen administration. After one week of tamoxifen followed by a washout period, mice 
were injected with 0.25 mg/g E. coli LPS i.p. At baseline, EC-Casp8-/- mice showed an 
absence of caspase-8 staining in endothelium after tamoxifen. Mice were sacrificed at 24 
h and blood collected for cytokines, BUN, and creatinine. Kidney tissue was analyzed for 
light microscopic and immunohistochemistry. A subset of mice underwent renal cortical 
blood flow measurement by laser Doppler.
Results: As expected, wildtype mice developed significant AKI with elevation of BUN 
and subtle pathologic injury. In contrast, EC-Casp8-/- mice had significantly less AKI (24 
h BUN of 45.3 +± 11.2 v. 114.9 ± 9.9 mg/dl, p < 0.01). LPS induced a decrease in renal 
cortical blood flow that was restored in EC-Casp8-/- mice (24 h renal blood flow of 1472 ± 
61 perfusion units (BPU) in saline injected controls, 614 ± 89 BPU in LPS injected wildtype 
mice, and 1320 ± 159 BPU in LPS injected EC-Casp8-/- mice, p < 0.01). EC-Casp8-/- mice 
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also had reduced evidence of pathologic injury on light microscopy (cortical injury score 0.9 
± 0.20 in LPS injected EC-Casp8-/- mice v. 1.7 ± 0.15 in wildtype, p < 0.05), and evidence 
of less vascular and tubular apoptosis on TUNEL staining.
Conclusions: These findings point to a key role of endothelial caspase-8 in sepsis-
induced AKI. Further work will determine the relative role of caspase-8 in affecting renal 
microvascular perfusion, inflammation, and apoptosis in sepsis-induced AKI.
Funding: NIDDK Support
TH-PO019
Sepsis Reduces Kidney Function in Mice Before Hemodynamic Alterations 
or Clinical Symptoms Become Apparent  Jonathan Street, Yuning George 
Huang, Peter S.T. Yuen, Robert A. Star.  NIDDK, Bethesda, MD.
Background: Acute kidney injury (AKI) increases the mortality and morbidity of 
sepsis. A rise in serum creatinine is used to detect AKI clinically and experimentally, but 
the slow kinetics prevents early detection of injury. To expand our understanding of the 
onset of AKI following sepsis we used a novel transcutaneous measurement of the plasma 
clearance of a fluorescent marker to directly measure GFR in near real-time.
Methods: Sepsis was induced in male CD-1 mice by cecal ligation and puncture (CLP). 
Blood pressure, heart rate, and activity/locomotion were simultaneously monitored by an 
implanted telemetry device. FITC-Sinistrin was injected at 0 and 90 min after surgery 
enabling GFR to be monitored for 5 hours via transcutaneous fluorescence, measured by 
a miniaturized fluorimeter attached to the mouse back.
Results: Log transformation of FITC-Sinistrin fluorescence decay allowed easy 
identification of when single pool kinetics applied, permitting calculation of GFR. GFR 
following CLP was similar to baseline during the first hour. During the second hour GFR 
fell by 30%, and dropped to 20% of baseline by 5 hours (p<0.01). In contrast, mean arterial 
pressure, and heart rate were stable immediately following CLP, but then began to decrease, 
and were statistically significantly different from sham 3, and 4 hours later, respectively 
(p<0.01). Activity/locomotion began to decline in the second hour, and was significantly 
different from sham 4 hours after CLP (p<0.01).
Conclusions: Transcutaneous fluorescence measurement of plasma clearance 
longitudinally enables greater temporal resolution in measured GFR than prior approaches, 
revealing novel pathophysiology during early AKI. GFR was initially stable after sepsis 
surgery, then fell rapidly 2 hours later. The fall in GFR preceded hemodynamic alterations 
and the appearance of clinical symptoms such as reduced activity.
Funding: NIDDK Support
TH-PO020
Urinary AIM/CD5 Interacts with Kidney Injury Molecule-1 (KIM-1) and 
Promotes Recovery from Acute Kidney Injury via Enhancing Intraluminal 
Debris Clearance  Toru Miyazaki, Kento Kitada, Satoko Arai.  Molecular 
Biomedicine for Pathogenesis, Faculty of Medicine, The Univ of Tokyo, Tokyo, 
Japan.
Background: Acute kidney injury (AKI) is associated with prolonged hospitalization 
and high mortality, and may predispose patients to chronic kidney disease. To date, no 
effective treatments have been established for AKI. The apoptosis inhibitor of macrophage 
(AIM; also called CD5L) protein is a circulating protein that associates with IgM pentamers 
in blood, which protects AIM from renal excretion and maintains high levels of AIM 
(approximately 5 mg/mL in humans and mice) in blood.
Methods: By in vivo studies using AKI mouse models on a wild-type and AIM-deficient 
background, as well as in vitro experiments including phagocytosis assay focusing on the 
functional relationship between AIM and kidney injury molecule-1 (KIM-1), we here 
present that AIM is a ligand of KIM-1 and promotes potent clearance of pathogenic dead 
cell debris by tubular epithelial cells, which is crucial for overall recovery from AKI.
Results: The blood AIM dissociates from IgM upon AKI attack and excreted in urine 
in AKI patients and mice. The urinary AIM accumulates on intratubular dead cell debris. 
The accumulated AIM binds to KIM-1 on injured tubular epithelial cells and induces the 
phagocytic removal of the debris by epithelial cells, facilitating kidney tissue repair. When 
subjected to ischemia/reperfusion-induced AKI, AIM-deficient mice exhibit abrogated 
debris clearance and markedly higher mortality due to progressive renal dysfunction than 
wild-type mice. AIM administration promotes the rapid removal of the debris, thereby 
ameliorating AKI in both AIM-deficient and wild-type mice.
Conclusions: Our study demonstrates that the AIM/KIM-1 cooperation efficiently 
promotes recovery from acute kidney injury through rapid clearance of intraluminal debris. 
These findings could be the basis for novel AKI therapies.
Funding: Government Support - Non-U.S.
TH-PO021
Renal Handling of Circulating and Renal Synthesized Hepcidin and 
Its Protective Effects against Hemoglobin-Mediated Kidney Injury 
Rachel Van Swelm, Jack F. Wetzels, Vivienne G.M Verweij, Coby M.M. 
Laarakkers, Jeanne C.L.M. Pertijs, Rosalinde Masereeuw, Dorine W. Swinkels. 
Radboudumc, Nijmegen, Netherlands.
Background: In multiple clinical observational studies it has been demonstrated that 
increased urinary hepcidin levels are associated with reduced risk of developing acute 
kidney injury (AKI) due to hemolysis in cardiac surgery patients. This study aimed to 
get more insight in renal hepcidin handling and its potential protective effects against 
heme-mediated AKI.
Methods: C57Bl/6 mice were treated with i) a single i.p. dose of 10 µg human 
hepcidin-25 (hhep25) to study renal handling of systemic hepcidin, ii) a single i.v. dose of 
5 mg hemoglobin (Hb) to induce AKI, and iii) Hb combined with hhep25 to evaluate the 
protective effects of hhep25 on Hb-mediated kidney injury.
Results: Systemic hhep25 was rapidly cleared from plasma and excreted to urine. 
In addition to hhep25, we also detected the smaller isoforms hhep22 and hhep20 in 
urine, but not in plasma, showing that hhep25 is degraded in the tubular lumen. Urine 
hhep25 was 20-fold increased in megalin deficient mice compared to control (p<0.05) 
and immunofluorescence staining showed that hepcidin was present in tubules expressing 
megalin, but NOT in megalin-deficient tubules, demonstrating that megalin is responsible 
for hhep25 uptake in the proximal tubules. Administration of hhep25 simultaneously or 4h 
after Hb injection in wildtype mice significantly attenuated the Hb-induced rise in urinary 
NGAL and KIM1 levels, and renal IL6 and NGAL mRNA expression. Interestingly, 
simultaneous administration of Hb and hhep25, but not Hb or hhep25 alone, resulted 
in an increase in renal Hamp1 mRNA expression (15 fold, p<0.05). Administration of 
hhep25 to Hb-treated mice reduced renal mRNA expression of HO-1, DMT1, H-ferritin 
and L-ferritin (all p<0.05), possibly reflecting the mechanisms by which hepcidin exerts 
its protective effects.
Conclusions: Systemic hepcidin is filtered to the urine, partly reabsorbed via megalin 
in the proximal tubules and degraded in the tubular lumen. Moreover, our data suggest that 
both systemically delivered hepcidin and locally produced hepcidin are involved in renal 
protection against heme-induced AKI.
TH-PO022
The Lungs in Mice with Acute Kidney Injury Have an Exuberant 
Inflammatory Response to Endotoxin  Hyo-Wook Gil, Chris Altmann, Ana 
Andres-hernando, Danielle Soranno, Sarah Faubel.  Internal Medicine Renal, 
Univ of Colorado, Denver, CO.
Background: Sepsis occurs in 40% of patients after the diagnosis of acute kidney 
injury (AKI) that may be related to impaired immune function. We sought to determine 
immune function specifically in the lungs in mice with AKI.
Methods: AKI was induced by bilateral renal pedical clamping. Lung immune function 
was assessed by intratracheal instillation of either endotoxin (LPS) or Pseudomonas bacteria 
to induce pneumonia.
Results: Intratracheal LPS was administered 4 hours or 7 days after Sham or AKI. 4 
hours after intratracheal LPS, lung inflammation as judged by bronchoalveolar fluid TNF, 
lung myeloperoxidase (MPO) activity (a marker of lung neutrophils), and lung CXCL1 
(a neutrophil chemokine) was greater after AKI+IT LPS versus Sham+IT LPS in both the 
4 hour and 7 day group (P<0.05 for all endpoints n=4). To determine the role of alveolar 
macrophages, alveolar macrophages were recovered by bronchoalveolar lavage 4 hours after 
Sham or AKI, placed in culture, and exposed to endotoxin. Media TNF-α was significantly 
higher in alveolar macrophages from AKI. Since the response to endotoxin was excessive, 
we tested the response to pneumonia. AKI or Sham was performed and pneumonia was 
induced at 2 different time points post procedure: 1) 5 minutes and 2) 7 days. 24 hours 
after induction of pneumonia, blood cultures were 0 colony forming units (CFU) in Sham 
and 61 CFU in AKI (n=10); notably, 0% of Sham were bacteremic (n=0 of 10) and 60% of 
AKI were bacteremic (n=6 of 10) in the 5 minute group; in the 7 day group, blood cultures 
were higher in AKI and were 31% positive in sham (4 out of 13), and 70% positive in 
AKI (7 out of 10). Inflammation (as judged by lung MPO activity) was greater in AKI + 
pneumonia versus Sham + pneumonia in both 5 min and 7 d groups. Lung cultures were 
similar in Sham and AKI in both time groups indicating similar infection fighting ability 
between Sham and AKI.
Conclusions: In mice with AKI, the lung immune response to bacteria or gram 
negative bacteria is characterized by an exuberant inflammatory response which leads to 
bacteremia during pneumonia .
Funding: Other NIH Support - NHLBI
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TH-PO023
Inhibition of MEK/ERK by Trametinib Attenuates Sepsis-Induced Systemic 
Inflammation and Multi-Organ Injury in Mice  Joshua Andrew Smith,1 
Philip R. Mayeux,2 Rick G. Schnellmann.1  1Drug Discovery and Biomedical 
Sciences, Medical Univ of South Carolina, Charleston, SC; 2Pharmacology and 
Toxicology, Univ of Arkansas for Medical Sciences, Little Rock, AR.
Background: MEK/ERK signaling is an essential component of the innate immune 
response in sepsis. We previously demonstrated that a potent and specific inhibitor of 
MEK1/2, trametinib, prevents endotoxin-induced renal injury in mice. Our goal was to 
further assess the efficacy of trametinib in a more clinically relevant model of sepsis induced 
by cecal ligation and puncture (CLP) in mice.
Methods: Male C57BL/6 mice (40 weeks of age) were subjected to CLP, and trametinib 
(1 mg/kg, i.p.) was administered at 6 h post-CLP. Serum cytokine levels were determined 
using a Luminex-based multiplex assay. Standard assays were used to measure clinical 
markers of organ/cellular injury including serum creatinine (SCr), blood urea nitrogen 
(BUN), alanine aminotransferase (ALT), creatine kinase (CK), and lactate dehydrogenase 
(LDH) in the serum. Renal microvascular perfusion was evaluated by intravital microscopy. 
Transcript levels of tubular injury markers and pro-inflammatory cytokines in the renal 
cortex were determined by qPCR.
Results: Delayed trametinib administration partially attenuated increases in circulating 
pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, GM-CSF) and development of 
hypothermia at 18 h post-CLP. In addition, MEK/ERK inhibition restored SCr to baseline 
levels and reduced other markers of organ/cellular injury (serum ALT, CK, LDH) in CLP 
animals. In the kidney, trametinib completely reversed the early deficits in peritubular 
capillary perfusion and decreased mRNA expression of tubular injury markers including 
KIM-1, NGAL, and HO-1. MEK/ERK blockade also attenuated CLP-mediated up-
regulation of cytokines (TNF-α, IL-1β, IL-6) in the renal cortex.
Conclusions: These data reveal that the MEK/ERK inhibitor trametinib attenuates 
systemic inflammation, AKI, and other organ injury in a clinically relevant model of sepsis, 
even with delayed administration. Since trametinib is FDA approved, this drug may represent 
a readily translatable approach to limit organ injury in sepsis.
Funding: Other NIH Support - NIGMS Support, Veterans Administration Support
TH-PO024
Chemokine Receptor 5 Blockade Modulates Inflammation and Immunity 
in Renal Ischemic Reperfusion Injury  Kyung Don Yoo,1 Hajeong Lee,1 
Ran-hui Cha,2 Jung Pyo Lee,1 Yon Su Kim,1 Seung Hee Yang.3  1Seoul National 
Univ College of Medicine; 2National Medical Center; 3Seoul National Univ 
Kidney Research Inst.
Background: The CC chemokine receptor (CCR5) is an important regulator of 
macrophage trafficking in the kidney in response to inflammation and immunity. Therefore, 
we investigated a role of CCR5 in the pathogenesis of experimental ischemic reperfusion 
injury (IRI).
Methods: Bilateral renal artery pedicles clamping for 30 min followed by reperfusion 
was performed on B6 wild type and CCR5 KO mice. We performed adoptive transfer of LPS 
treated RAW cells following depletion of macrophage by liposome clodronate (LC) in mice.
Results: CCR5 KO mice showed less aggravated IRI in terms of the apoptosis of 
tubular epithelial cells and creatinine compare to B6 wild type. CCR5 deficiency decreased 
mRNA expressions of proinflammatory cytokines but increased mRNA expressions of Th2 
cytokines. CXCR3 positivity in CD11b+ cells and iNOS were attenuated in CCR5 KO 
mice compared to that in B6 wild type mice. On the contrary, the CCR5 KO mice showed 
increased numbers of Arg1- or CD206-expressing macrophages. LC-treated wild type 
mice showed severe injury compared to CCR5 KO mice aftertransfer of M1 macrophage.
Adoptive transfer of LPS-treated RAW cells, which constitutively express iNOS, reverses 
the functional protection against IRI only in wild-type, not CCR5 KO mice. When CCR5 
was knocked out in macrophages, bone marrow-derived macrophages showed M2 
macrophage activation.The migration of Bone marrow-derived macrophage fromwild type 
mice towardprimary tubular epithelial cell with rCCR5 was increased. Moreover, blockade 
of CCR5 inhibited migration of macrophages. Renal tissue of patients with delayed graft 
function frequently contained CCR5 cells, and the number of these cells tended to positively 
correlate with acute tubular necrosis severity.
Conclusions: These findings show that CCR5 deficiency favors M2 macrophages 
activation and provide a potential strategy for treating acute kidney injury through 
blocking CCR5.
TH-PO025
Early Activation of Inflammasome in Acute Kidney Injury After Renal 
Sympathetic Denervation in Pig  Il Young Kim,1 Min Jung Kim,1 Joo Hui Kim,1 
Dong Won Lee,1 Soo Bong Lee,1 Su Min Park,2 Jong Man Park,2 Woo Jin Jung,2 
Harin Rhee,2 Sang Heon Song,2 Eun Young Seong,2 Ihm Soo Kwak.2  1Internal 
Medicine, Pusan National Univ Yangsan Hospital, Yangsan, Republic of Korea; 
2Internal Medicine, Pusan National Univ Hospital, Busan, Republic of Korea.
Background: Renal sympathetic denervation (RDN) is available and implemented as 
a strategy for the treatment of resistant hypertension. In the aspect of chronic safety, renal 
function, as assessed by serum creatinine, eGFR(MDRD), and cystatin C was reported to 
be unchanged from baseline at 6 months. We investigated whether RDN might cause subtle 
inflammation and subclinical damage in the early phase of acute kidney injury (AKI).
Methods: Female pigs were divided into 6 groups; normal control (group A), Sham-
operated control (group B), contrast media control (group C), and renal sympathetic 
denervation groups subdivided into 3 groups according to the time of sacrifice; immediately 
(group D), 1 week later (group E), and 2 weeks later (group F) after RDN. We checked 
IL-1α, 1β, 18, 6, 10, TNF-α, cystatin C, caspase-1, ASC, and NLRP3 as early biomarkers 
of inflammation and AKI.
Results: There were no significant changes in group B and C compared to group A. Hb, 
BUN, serum Na, K, Cl, CRP, urine protein/creatinine ratio, and urine albumin/creatinine 
ratio showed no significant changes between groups. Serum creatinine and cystatin C were 
increased from 1st week after RDN. Serum LDH was increasedimmediately after RDN, and 
then decreased at 2nd week.IL-1α, -1β and -18 were increased immediately after RDN, and 
showed a tendency to be decreased at 2nd week after RDN. IL-6 was increased immediately 
after RDN, and also increased in contrast media control group. TNF-α was increased from 1st 
week after RDN. IL-10 was increased immediately after RDN, and decreased at 2nd week. 
Casapse-1 and ASC expression were increased from 1st week, and decreased at 2nd week 
after RDN. However NLRP3 expression showed no significant changes between groups.
Conclusions: RDN did not cause clinically significant damages on kidneys. However, 
RDN can induce the activation of pro-inflammatory cytokines, caspase-1 and then cause 
transientand self-limited acute kidney injury.
TH-PO026
The Orphan Nuclear Receptor ROR Alpha Exerts a Protective Potential 
in Acute Kidney Injury via Transcriptional Activation of HIF-1  Jieru Cai,1 
Rende Xu,2 Xiaofang Yu,1 Xiaoqiang Ding.1  1Dept of Nephrology, Zhongshan 
Hospital, Fudan Univ, Shanghai, China; 2Dept of Cardiology, Zhongshan 
Hospital, Fudan Univ, Shanghai, China.
Background: Emerging evidence indicates that retinoid-related orphan receptor alpha 
(RORalpha), a member of the ROR subfamily of nuclear receptors, mediates key cellular 
adaptions to hypoxia and contribute to pathophysiology of many disease states. However, 
the potential renal functions of RORalpha in response to ischemia/reperfusion (I/R) injury 
remain unclear. Here, we investigated the renal expression and biological function of 
RORalpha in acute kidney injury (AKI).
Methods: I/R injury was induced by 35min bilateral clamping of the renal pedicle and 
24h reperfusion in wild-type and staggerer (RORalpha(sg/sg)) mice,a natural mutant strain 
lacking RORalpha expression. Renal injury and RORalpha abundance were analyzed. In 
addition, human proximal tubular cell line (HK-2) was used to investigate the expression 
of RORalpha under hypoxia.
Results: RORalpha was detected in both mouse renal endothelial and tubular 
epithelial cells.Significant up-regulation of RORalpha was found after renal I/R injury. 
Compared with wild-type, RORalpha(sg/sg) mice displayed significantly increased levels 
of serum creatinine (2.30±0.21 vs. 1.18±0.35mg/dl, p<0.01), renal tissue damage, and 
pro-inflammatory cytokine production after ischemic kidney injury.
Further mechanistic studies indicated that RORalpha agonists enhanced transcriptional 
activity of hypoxia-inducible factor 1alpha (HIF-1alpha) in HK-2 cells, which was abolished 
by siRNA-mediated silencing of endogenous RORalpha.
Conclusions: These results suggest that RORalpha protects kidney from I/R damage 
through transcriptional activation of HIF-1 and represents a potential therapeutic target 
for AKI.
Funding: Government Support - Non-U.S.
TH-PO027
Immunosuppressive Double Negative aβ T Cells Protect Mice from Ischemic 
Acute Kidney Injury  Maria Noel Martina,1 Sanjeev Noel,2 Ankit Saxena,1 
Richa S. Majithia,1 Samatha Bandapalle,2 Abdel Hamad,1 Hamid Rabb.2  1Dept 
of Pathology; 2Dept of Medicine, Johns Hopkins Univ, Baltimore, MD.
Background: TCRaβ+CD4-CD8- double negative (DN) T cells are one of the least 
understood T cells, partly due to their rarity. We recently found them at high frequency 
in both murine and human kidney and demonstrated that they secrete large amounts 
of the anti-inflammatory cytokine IL-10. We tested the hypothesis that DNT cells are 
immunosuppressive in a mouse model of ischemic AKI and in vitro.
Methods: Immunosuppressive functions of kidney DNT cell were assessed by their 
ability to inhibit CD4 T cell proliferation using a standard T cell suppression assay. DNT 
cells isolated from the periphery of FasL-deficient gld mice (which accumulate large 
numbers of DN T cells in lymph nodes) were adoptively transferred in to wild type 
(WT) mice in the presence or absence of anti-IL-10 antibody and assessed their ability to 
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modulated ischemic AKI. Serum creatinine (SCr) was measured to assess kidney function 
and histology was studied. DNT cells from human peripheral blood was studied to lay the 
foundation for translational studies.
Results: Murine kidney DNT cell significantly (p£0.001) inhibited proliferation of CD4 
T cells in vitro, using CD4+CD25- T cells as controls. Transfer of DNT cells significantly 
(p£0.01) improved kidney function in WT mice (SCr= 0.5±0.1) following IR-induced 
AKI compared to WT mice that either received no cells (SCr=1.3±0.4) or conventional T 
cells (SCr=1.4±0.4). Histological evaluation showed significantly reduced tubular necrosis 
(p=0.03) in mice that received DNT cells. This protection was lost in mice that received 
DNT cells with anti-IL-10 Ab (p£0.01). DNT cells were found in normal subjects-n=3 
(n=3, 1.6±0.4 %) and higher in renal cell carcinoma patients (n=3, 3.5±0.1%, p£0.001).
Conclusions: Kidney resident DNT cells suppress CD4 T cell proliferation in vitro 
and protect WT mice from IR-induced AKI via IL-10. Furthermore, DNT cells are found 
in human peripheral blood and increase with kidney cancer. Future studies are warranted to 
better understand immunosuppressive properties of DNT cells and their clinical significance 
in AKI and other kidney diseases.
Funding: NIDDK Support
TH-PO028
Interleukin-37 Diminishes the Inflammatory Response of Ischemia/
Reperfusion-Susceptible Renal Tubular Epithelial Cells  Luuk Hilbrands,1 
Wilco P. Pulskens,1 Sandrine Florquin,2 Leo Ab Joosten,3 Janin A. Bublitz,1 
Johan Van der vlag.1  1Nephrology, Radboud Univ Medical Center, Nijmegen, 
Netherlands; 2Pathology, Academic Medical Center, Amsterdam, Netherlands; 
3Internal Medicine, Radboud Univ Medical Center, Nijmegen, Netherlands.
Background: Renal ischemia and subsequent reperfusion (IR) induces excessive local 
inflammation that results in tubular injury and renal dysfunction. Therapeutic strategies 
aiming to dampen inflammation might therefore provide new opportunities to diminish 
renal IR injury. The human cytokine Interleukin (IL)-37 inhibits inflammation via nuclear 
as well as cell-surface receptors. IL37 is expressed by different cell types, including renal 
epithelium and circulating monocytes. Cell type-specific effects of IL37 in renal IR remain 
however unknown.
Methods: Primary tubular epithelial cells (PTECs) and bone marrow-derived 
macrophages (BMDMs) were isolated from WT and transgenic mice expressing human 
IL37 (hIL37tg) and cultured. In vitro, cells were pretreated with different concentrations 
of recombinant human IL37 protein (rhIL37) or vehicle and subsequently stimulated with 
LPS for 4 or 24hrs. Cytokine release (ELISA) and mRNA expression (quantitative RT-
PCR) were determined.
Results: After 24hrs of LPS stimulation, the release of both CXCL1 and IL6 was 
reduced in hIL37tg PTECs as compared to WT PTECs. This was preceded by diminished 
CXCL1 and IL6 mRNA levels after 4hrs of LPS stimulation. rhIL37 pretreatment of WT 
PTECs reduced CXCL1 mRNA, but not IL6 mRNA expression after 4hrs. In hIL37tg 
BMDMs CXCL1 mRNA levels and protein release were both reduced after 4 and 24hrs of 
LPS stimulation, as compared to WT BMDMs. IL6 release was only diminished after 24hrs, 
whereas IL6 mRNA levels did not significantly differ. In contrast, rhIL37 pretreatment of 
WT BMDMs reduced IL6 mRNA expression after 24hrs of LPS stimulation, but neither 
affected CXCL1 nor IL6 release.
Conclusions: Our data indicate that both endogenous and exogenous IL37 diminishes 
inflammatory responses of renal epithelial cells and macrophages, both central players in 
the pathophysiology of renal IR injury.
TH-PO029
Compensatory Induction of IL-17 Producing NKT Cells in Post Ischemic 
T Cell Deficient Rats Fed High Salt Diet  Purvi Mehrotra, Carlie M. Ivancic, 
Jason Andrieu Collett, Seth D. Mckinney, David P. Basile.  Dept of Cellular and 
Intergrative Physiology, Indiana Univ of Medicine, Indianapolis, IN.
Background: Surviving AKI patients have a higher risk for developing chronic kidney 
disease (CKD) but the mechanism of AKI to CKD transition is unclear. Previous studies 
have shown inhibition of T-cell activity by mycophenolate blocked the proteinuria, fibrosis 
and hypertension in post ischemic rats fed a high dietary salt and that Th17 helper cells are 
dramatically increased in post ischemic rats on high salt diet. Therefore, we hypothesized 
that T-cell deficient athymic rats would manifest an attenuated salt sensitive progression 
of CKD following AKI.
Methods: Athymic rats (Foxn1rnu-/rnu-) or heterozygote control euthymic rats (Foxn1rnu-/+) 
were subjected to a model of AKI-to-CKD in which rats are allowed to recover from 
unilateral I/R (40 min ischemia) for 5 weeks on standard salt diet (0.4% NaCl) and then 
subjected to contralateral UNX and 4% NaCl diet for 4 additional weeks.
Results: As expected we observed that MMF treatment in control-euthymic rats (day 
35-63) lead to significant reduction in renal CD4+ infiltration (35%±4.8, p³0.05), Th-17 cells 
(78%±5.2, p³0.05%) and reduced fibrosis by 50% vs vehicle.  T cell deficient athymic rats 
showed an unexpected and similar level of renal fibrosis as compared to euthymic rats and 
MMF treatment did not have any effect. The increased fibrosis could not be explained by 
enhanced initial injury in athymic vs euthymic rats, which was similar 24 hours following 
bilateral I/R, indicating that athymic rats may operate an alternative pro-inflammatory 
pathway in the absence of T cells.  Interestingly, athymic rats showed an increase population 
of IL-17+ Natural Killer T cells (NKT) (126018±7507) as compared to euthymic rats 
(63892±12656), which was not sensitive to MMF treatment.
Conclusions: Taken together these data suggest that in the absence of T cells, 
compensatory NKT cell activity may mediate cytokine production and participate in salt 
diet induced fibrosis post AKI.
Funding: NIDDK Support
TH-PO030
Chronic Kidney Disease and the Chromogranin A Pathway: From 
Pathogenic Molecule to Disease  Sucheta M. Vaingankar, Saiful A. Mir, Wai 
W. Cheung, Kuixing Zhang.  Medicine, Univ of California at San Diego.
Background: The human chromogranin A gene (CHGA) variants are associated with 
autonomic blood pressure regulation and hypertension in the majority population, as well 
as hypertensive renal disease in African Americans. CHGA proprotein is the master switch 
for nucleation of catecholamine granules in neuroendocrine tissue. In this study we address 
the effect of CHGA in acute kidney injury.
Methods: Experimental chronic kidney disease (5/6 th nephrectomized) mouse models 
were used to study susceptibility of mouse strains (wild type and Chga -/-) to kidney injury. 
Kidney tissues of sham and nephrectomized mice were examined by histology and also 
profiled for genome-wide expression using NimbleGen microarray. The murine glomerular 
function was measured by LC-mass spectrometry based assay for creatinine. Array data was 
analyzed for differentially expressed genes using Bioconductor. The differentially regulated 
genes were analyzed by GO enrichment analysis using DAVID Bioinformatics Resources. 
The molecular function and biological process terminologies in the PANTHER database 
were considered during the GO analysis; the P-value cutoff was set at 0.01. The human study 
involved twin data set of European ancestry 129 monozygotic and 58 dizygotic twin pairs.
Results: A significantly greater loss of eGFR function was observed in nephrectomized 
mice expressing CHGA as compared to Chga knock out mice. Kidney injury resulted in 
far greater response of increased plasma CHGA, azotemia, catecholamine and systolic 
blood pressure in Chga+/+ mice. Kidney biopsy also showed greater pathology and 
interstitial fibrosis associated with nephrectomized Chga+/+ mice. In nephrectomized 
mice, the differentially up regulated genes in the Chga+/+ strain include panoply of 
mitochondrial genes, oxidoreductases and extracellular matrix proteins, wound healing 
genes and transcription factors. In humans the plasma CHGA concentration has an inverse 
relationship to plasma creatinine levels.
Conclusions: CHGA expression is inversely correlated to glomerular function and is 
detrimental to kidney injury outcomes.
Funding: NIDDK Support, Other NIH Support - NHLBI
TH-PO031
Inhibition of avβ5 Integrin Protects against Renal Ischemia-Reperfusion 
Injury  Amy T. Mccurley,1 Robert W. Dunstan,1 Taylor L. Reynolds,1 Silvia B. 
Campos-bilderback,2 Ruben M. Sandoval,2 Bruce A. Molitoris,2 Shelia Violette,1 
Michael Crackower.1  1Biogen, Cambridge, MA; 2Div of Nephrology, Indiana 
Univ School of Medicine, Indianapolis, IN.
Background: Ischemia-reperfusion injury is a leading cause of acute kidney injury 
(AKI), which is a common clinical complication that lacks effective therapies and can lead 
to the development and progression of chronic kidney disease. The avβ5 integrin, a receptor 
for RGD-containing extracellular matrix proteins, has been suggested to be important in 
acute injury settings including septic shock and acute lung injury. To examine the in vivo 
function of this receptor in AKI we tested the impact of inhibiting avβ5 in a rat model of 
renal ischemia reperfusion injury (IRI).
Methods: IRI was induced by removing the right kidney and clamping the renal artery 
of the left kidney for 30 minutes. Rats were administered avβ5-blocking antibody or an 
isotype control antibody subcutaneously at various doses and times prior to ischemia.
Results: avβ5 antibody-treatment significantly reduced serum creatinine levels with a 
single administration 6 hours prior to ischemia. avβ5 inhibition led to significantly reduced 
renal damage by 3 days after ischemia as assessed by histopathological scoring of fixed 
kidneys. Antibody blockade of avβ5 also resulted in significantly fewer apoptotic tubular 
cells, and significant reductions in urinary KIM-1 and serum MCP-1 levels in IRI rats. 
Global gene expression profiling of kidneys identified several established injury markers 
that were impacted by avβ5 inhibition including reduced levels of havcr1 (KIM-1), lcn2 
(NGAL), and adamts1 transcripts after ischemia. Finally, a single dose of avβ5 antibody 8 
hours post-ischemia was shown to significantly reduce serum creatinine levels at 24 hours, 
suggesting protection from injury with therapeutic dosing is possible.
Conclusions: This study identifies a novel role for avβ5 integrin biology in the 
pathogenesis of renal ischemia-reperfusion injury. Inhibition of avβ5 integrin with antibody 
administration may hold therapeutic promise for the treatment of acute kidney injury.
Funding: Pharmaceutical Company Support - Biogen
TH-PO032
Blocking avβ6 Integrin Provides Protection in Renal Ischemia-Reperfusion 
Injury  Shelia Violette,1 Amy T. Mccurley,1 Paul H. Weinreb,1 Silvia B. 
Campos-bilderback,2 Ruben M. Sandoval,2 Bradley J. Maroni,1 Michael 
Crackower,1 Bruce A. Molitoris.2  1Biogen, Cambridge, MA; 2Indiana Univ 
School of Medicine, Indianapolis, IN.
Background: The avβ6 integrin is a key mediator of TGF-β activation and plays an 
important role in promoting tissue injury and fibrosis. avβ6 is expressed at low levels in 
normal tissue and upregulated on epithelial cells in disease, providing a target for localized 
suppression of TGF-β. Function-blocking avβ6 antibodies are protective in models of 
kidney, lung, and liver fibrosis and a humanized avβ6 antibody (BG00011) is in clinical 
development in patients with idiopathic pulmonary fibrosis. We evaluated the role of 
avβ6 in renal ischemia reperfusion injury (IRI), a model in which avβ6 is upregulated in 
tubular epithelium.
Methods: IRI was induced in rats by removing the right kidney and clamping the renal 
artery of the left kidney for 30 minutes. A single 3 mg/kg dose of avβ6 antibody (3G9) 
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or an isotype control was administered 6, 12 or 18 hours pre-ischemia or 4, 8 or 12 hours 
post-ischemia. Serum creatinine (SCr) was evaluated 24, 48 and 72 hours post-injury and 
gene expression and histology in kidneys evaluated at 72 hours.
Results: 3G9 treatment significantly reduced SCr levels at all time points evaluated 
whether administered pre- or post-induction of ischemia. Equivalent effects were detected 
when 3G9 was administered 6, 12 or 18 hours pre-ischemia and maximal effects observed 
when administered 4 to 8 hours post-ischemia. 3G9 reduced kidney damage as assessed by 
histopathological scoring of tubular necrosis, dilation and casts. Gene expression profiling 
of kidneys identified transcripts impacted by avβ6 inhibition suggesting promotion of repair. 
This included reduced levels of cell death and necroptosis markers such as GADD45, ATF3, 
and RIPK3, and an upregulated cell growth signature including cyclins, cyclin-dependent 
kinases, and epidermal growth factor.
Conclusions: The combined role of avβ6 in regulating IRI and fibrosis highlight the 
potential for therapeutic intervention with BG00011 in acute kidney injury, a common 
clinical complication that lacks effective therapies and can lead to the development and 
progression of chronic kidney disease.
Funding: Pharmaceutical Company Support - Biogen Idec
TH-PO033
Suramin Protects from Cisplatin-Induced Acute Kidney Injury  Tess Dupre,1 
Mark A. Doll,1 Parag P. Shah,1 Michael T. Scherzer,1 Cierra Sharp,1 Judit 
Megyesi,4 Lavona Casson,1 Levi J. Beverly,1 Rick G. Schnellmann,3 Leah J. 
Siskind.1  1Pharmacology/Toxicology, Univ of Louisville, Louisville, KY; 2Univ 
of Arkansas for Medical Sciences; 3Medical Univ of South Carolina.
Background: Acute kidney injury (AKI) resulting from cisplatin administration 
remains an obstacle in chemotherapeutic treatments. Suramin, an FDA approved drug 
for the treatment of trypanosomiasis, has been previously shown to speed recovery from 
multiple models of AKI and chronic kidney disease and is currently in clinical trails for 
combination therapy with cisplatin for the treatment of lung cancer.
Methods: In this study we examined the efficacy of the prophylactic use of suramin 
in a murine model of cisplatin-induced AKI. Nine-week old C57Bl/6 male mice were pre-
treated with 10mg/kg suramin via tail vein injection 72h prior to cisplatin administration 
(20mg/kg, i.p) and sacrificed 72h after cisplatin treatment.
Results: Our data indicate that pre-treatment with suramin protects the kidney from 
cisplatin injury according to markers of kidney function (BUN, Serum Creatinine), 
kidney injury (urinary Kim-1, and NGAL). Assessment of renal histology also indicated 
that suramin pre-treatment significantly protects mice from cisplatin-induced injury. The 
expression of many pro-inflammatory chemokines and cytokines (TNF-α, IL-1β, IL-6, 
MCP-1, and CXCL-1) involved in the response of cisplatin-induce AKI were examined 
via qRT-PCR. Mice pretreated with suramin had significantly reduced expression of all 
the above inflammatory markers. Western blot analysis indicated that mice pre-treated 
with suramin were protected from death receptor-mediated apoptosis. We also utilized the 
same experimental design using 10-month old FVB mice expressing mutant KRAS driven 
lung tumors. The assessment of both renal and pulmonary histology and markers of kidney 
function (BUN and Serum Creatinine) indicate that suramin protects mice from cisplatin-
induced kidney injury and more importantly does not inhibit cisplatin’s anti-tumor efficacy.
Conclusions: Thus, data presented suggest that suramin shows great potential as a 
renoprotective agent for the treatment and prevention of cisplatin-induced AKI.
Funding: NIDDK Support
TH-PO034
ATIII Attenuates Acute Kidney Injury following Acute Severe Pancreatitis 
Feng Wang,1 Zeyuan Lu,1 Guangyuan Zhang,1 Jianyong Yin,1 Niansong Wang,1 
Mingyu Liang.2  1Nephrology, Shanghai Jiao Tong Univ Affiliated People¶s 
Hospital, Shanghai, China; 2Physiology, Medical College of Wisconsin, 
Milwaukee, WI.
Background: Antithrombin III (ATIII) is the major anti-coagulation molecule in vivo 
and has anti-inflammatory effects. Acute kidney injury (AKI) is the most common organ 
failure following acute severe pancreatitis (ASP), which often results in death. Herein, we 
hypothesized that ATIII could protect against AKI following ASP.
Methods: Acute severe pancreatitis was induced in rats by retrograde pancreatic 
duct infusion of 3.5% sodium taurocholate. Intravenous injection of ATIII (500mg/kg) 
was carried out 30 min before induction of ASP. Animals were sacrificed 24 hours later. 
Renal tubular injury and renal function were assessed. Serum amylase, glutamic-pyruvic 
transaminase (ALT), and serum Ca2+ were also measured.
Results: Renal tubular injury scores were increased from 0.5±0.2 in control rats to 
4.2±0.5 in the ASP group and to 2.7±0.3 in the ASP+ATIII group 24 hours after ASP 
induction (P<0.05,one-way ANOVA, n=6). Serum creatinine was increased from 23.2±1.6 
mmol/L to 92.3±8.6 mmol/L in the ASP group and to 34.8±3.2 mmol/L in the ASP+ATIII 
group (P<0.05, n=6). Blood urea nitrogen was increased from 5.2±0.3 mmol/L to 47.0±1.3 
mmol/L in the ASP group and to 30.0±1.9 mmol/L in the ASP+ATIII group (P<0.05, n=6). 
There were no significant differences between ASP group and ASP+ATIII group in serum 
amylase, ALT, serum Ca2+ and pancreatic injury.
Conclusions: ATIII attenuates AKI following ASP.
Funding: Government Support - Non-U.S.
TH-PO035
TRPM7 in Renal Ischemia Reperfusion Injury and Renoprotecion of 
Erythropoietin Derived Cyclic Helix B Peptide  Aifen Liu,1 Jing Wu,2 Cheng 
Yang,3 Yuanyuan Wu,4 Yufang Zhang,1 Yaqiu Long,5 Tongyu Zhu,3 Yaping Fan,2 
Bin Yang.1,2,6  1Basic Medical Research Centre, Medical School of Nantong 
Univ; 2Nephrology, Affiliated Hospital of Nantong Univ; 3Urology, Zhongshan 
Hospital, Fudan Univ; 4Pathology, Medical School of Nantong Univ; 5CAS Key 
Laboratory of Receptor Research, Shanghai Inst of Materia Medica, Chinese 
Academy of Sciences; 6Infection, Immunity and Inflammation, Univ of Leicester, 
Univ Hospitals of Leicester.
Background: Transient receptor potential melastatin 7 (TRPM7) is multi-function ion 
channel and kinase. The novel cyclic helix B peptide (CHBP), erythropoietin derivadive, 
improves renal ischemia reperfusion injury (IRI). Here, the role and mechanism of TRPM7 
in IRI and CHBP renoprotection were investigated.
Methods: TRPM7 mRNA and protein, apoptosis, inflammation, renal function and 
structure were measured in TCMK1 cells and mouse kidneys subjected to 12-h hypoxia 
(H)/30-min ischemia followed by reoxygenation (R) at different time points. 2-APB 
(TRPM7 inhibitor) and CHBP were also applied in HR cells and/or IRI kidneys. The 
correlations between TRPM7 and other injury parameters were analysed.
Results: TRPM7 mRNA and protein were increased in the TCMK1 cells exposed to 
12 and 24-h R, while TRPM7 protein was also increased by 42%, 35% and 30% in IRI 
kidneys at 12 and 24 h, and 7 d. Increased apoptotic cells were reduced 65% by 2-APB in 
TCMK1 cells post HR, while LDH in supernant and HMGB1 in TCMK1 cells were also 
increased. Further more, CHBP reduced TRPM7 in HR TCMK1 cells, as well as IRI kidneys.
TRPM7 was significantly correlated with LDH and HMGB1; and serum creatinine, 
blood urea nitrogen, inflammation, apoptosis and tubulointerstitial damage in these in 
vitro and/or in vivo models.
Conclusions: TRPM7 is involved in renal IR-related injuries and CHBP renoprotection, 
which might be a biomarker for diagnosis and intervention.
Funding: Government Support - Non-U.S.
TH-PO036
Caspase-3 siRNA and CHBP Ameliorate Renal Ischemia Reperfusion Injury 
in Mice  Weiwei Chen,1 Cheng Yang,4 Yuanyuan Wu,3 Yufang Zhang,2 Aifen Liu,2 
Jing Wu,1 Yaqiu Long,5 Tongyu Zhu,4 Yaping Fan,1 Bin Yang.1,2,6  1Nephrology, 
Affiliated Hospital of Nantong Univ; 2Basic Medical Research Centre, Medical 
School of Nantong Univ; 3Pathology, Medical School of Nantong Univ; 4Urology, 
Zhongshan Hospital of Fudan Univ; 5CAS Key Lab of Receptor Research, 
Shanghai Inst of Materia Medica, Chinese Academy of Sciences; 6Infection, 
Immunity and Inflammation, Univ of Leicester, Univ Hospitals of Leicester.
Background: Ischemia/reperfusion (IR) is a main cause of acute kidney injury (AKI). 
Up-regulated caspase-3, a key enzyme involved in inflammation and apoptosis, was revealed 
in renal IR injury and reversed by a novel cyclic helix B peptide (CHBP), derived from 
erythropoietin. Here, caspase-3 small interfering RNA (C3siRNA) and/or CHBP were 
applied in a mouse model to further explore underlying mechanisms.
Methods: Bilateral renal occlusion for 30 min was performed in male C57BL/6 mice 
and followed by 48 h reperfusion. 0.03 mg/kg C3siRNA or its negative control (NC) was 
injected intravenously 2 h before ischemia. 24 nmol/kg CHBP was injected intraperitoneally 
post reperfusion. Serum and kidney samples were collected for renal function, histology 
and molecular biology analyses.
Results: Serum creatinine and tubulointerstitial damage (TID) score were increased by 
IR injury, but decreased by C3siRNA and/or CHBP (all P<0.01). In addition, the expression 
of 17 kD active caspase-3, active caspase-3+ cells and apoptotic cells were raised by IR 
injury, but reduced by C3siRNA and/or CHBP (P<0.01). More interestingly, there was a 
significant reduction in TID in the kidneys treated with both C3siRNA and CHBP compared 
with its sole treatment.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
98A
J Am Soc Nephrol 26: 2015 AKI: Basic - I Poster/Thursday
Conclusions: C3siRNA and CHBP ameliorated IR injury, both of which might have 
certain synergetic effects. CHBP might reduce active caspase-3, subsequently affect 
apoptosis, and improve renal function and structure.
Funding: Government Support - Non-U.S.
TH-PO037
Resveratrol Ameliorates Contrast-Induced Nephropathy Through 
Activation of SIRT1-PGC-1α-FoxO1 Signaling in Murine Model 
Gang Jee Ko,1 Yu ah Hong,2 So yeon Bae,1 Heui-jung Pyo,1 Young-Joo Kwon.1 
1Div of Nephrology, Dept of Internal Medicine, Korea Univ School of Medicine, 
Seoul, Republic of Korea; 2Div of Nephrology, Dept of Internal Medicine, 
Catholic Univ College of Medicine, Daejeon St. Mary¶s Hospital, Daejeon, 
Republic of Korea.
Background: Contrast-induced nephropathy (CIN) is a common cause of acute kidney 
injury among impatient, but the pathogenesis has not been clearly defined. We aimed to 
investigate whether upregulation of situin 1 (SIRT1)-dependent signaling by resveratrol 
could attenuate CIN through modulation of renal oxidative stress and tubular apoptosis.
Methods: CIN were established in vivo and vitro model by administration of iohexol 
in male C57BL/6J mice and rat tubular cells (NRK-52E). Resveratrol (30mg/kg in vivo/ 
10 and 50µM in vitro) was treated with iohexol or saline as an activator of SIRT1. SIRT1 
expression was reduced by siRNA treatment in vitro study. Tubular cell injury caused by 
iohexol was examined.
Results: Increase of serum creatinine and tubular injury measured by histologic 
examinations after iohexol administration was significantly attenuated by resveratrol 
treatment (creatinine 1.79±0.48 vs 0.72±0.59 mg/dL, p<0.001). It resulted in reduction of 
oxidative stress which were demonstrated by reduced malondialdehyde (MDA) levels and 
increased Mn superoxide dismutase (SOD). Increased apoptosis in CIN was also reduced by 
resveratrol treatment examined with caspase 3 expression and TUNEL staining. Attenuation 
of CIN with resveratrol treatment was accompanied with the increase of SIRT1 expression, 
activation of PPARγ co-activator 1α (PGC-1α) and dephosphorylation of forkhead box 
O(FoxO1). Resveratrol treatment also reduced inflammatory cell infiltration induced by 
iohexol into kidney. On the other hand, SIRT1 inhibition by siRNA treatment accentuated 
cytotoxicity by iohexol.
Conclusions: Our results suggest that resveratrol attenuates CIN by modulation of renal 
oxidative stress and apoptosis through the activation of SIRT1-PGC-1α-FoxO1 signaling, 
and SIRT1 provides a potential therapeutic target to minimize CIN.
TH-PO038
Loss of Alpha(E)-Catenin-Fscn2 Signaling Increases Cisplatin-Induced 
Apoptosis in Aged Kidney  Xinhui Wang, LaNita A. Nichols, Elizabeth A. 
Borgmann, Alan R. Parrish.  Medical Pharmacology and Physiology, Univ of 
Missouri School of Medicine, Columbia, MO.
Background: Aging patients are highly susceptible to acute kidney injury. Previous 
studies in our laboratory demonstrated a dramatic decrease of α(E)-catenin expression in 
proximal tubular epithelium in the aged kidney.
Methods: We created stable α(E)-catenin knock-down NRK-52E (C2) cells (NT3 is the 
non-targeted control) and observed a significant loss of viability in C2 cells as compared 
with NT3 cells after cisplatin challenge. In this study, we aimed to delineate the pathway 
by which loss of α(E)-catenin increases cisplatin injury.
Results: Increased caspase-8 and -9 activation, BID cleavage and cytochrome C release 
were observed in C2 cells after cisplatin treatment. Blocking apoptosis, using caspase-8 or 
-9 inhibitors, completely abolishes the increased susceptibility of C2 cells. Interestingly, 
the expression of fascin actin bundling protein 2 (Fscn2) is decreased in α(E)-catenin 
knock-down cells. Re-expression of Fscn2 in C2 cells attenuates the increased apoptosis 
following cisplatin challenge.  Furthermore, our in vivo study showed a significant increase 
in serum creatinine, KIM-1 and in situ apoptosis levels at 72 hr after a single dose of 
cisplatin in 24-month-old rats, but not in 4-month-old rats. The expression of Fscn2 was 
also decreased in aged kidney.
Conclusions: Taken together, these results suggest that loss of α(E)-catenin-Fscn2 
signaling increases cisplatin-induced apoptosis in aged kidney.
Funding: Other NIH Support - Research reported in this publication was supported 
by the National Institute of Aging of the National Institutes of Health under award number 
RO1AG034154.
TH-PO039
Adenosine A1 Receptors Alleviate Cisplatin-Mediated Acute Kidney Injury 
Yuan Liu, Dongli Tian, Xuemei Li, Limeng Chen.  Dept of Nephrology, Peking 
Union Medical College Hospital, Beijing, China.
Background: We have observed the incidence of acute kidney injury (AKI) in 479 
lung cancer patients using platinum is 10.39% and AKI is the independent risk factor of 
in-hospital mortality. The results of previous studies about adenosine A1 receptors (A1ARs) 
in cisplatin-mediated AKI are controversial. In this study, we aimed to investigate the role 
of A1ARs in AKI induced by cisplatin and the involvement of mitochondria-mediated 
cell apoptosis.
Methods: 8- to 10-week-old male C57BL/6J wild type (WT) and A1AR-/- mice were 
given a single intraperitoneal injection of either vehicle (saline) or cisplatin (25mg/kg, 
1mg/ml). Weight, blood pressure and heart rate were monitored. Mice were euthanized 
24h/72h after cisplatin. Blood samples were collected to measure serum creatinine and 
urea. Acute tubular necrosis assessments were done through PAS staining. Western Blot 
and RT-PCR were used to study the expression change of CD73, A1AR and mitochondria-
mediated apoptosis markers.
Results: 1) 72h after cisplatin injection, serum creatinine and urea were substantially 
elevated (85.9±65.59 vs 8.5±1.16mmol/L, 63.3±33.84 vs 6.7±1.24mmol/L, p<0.05) in WT 
mice which suggested AKI happened. The systolic blood pressure, heart rate and body 
weight remarkably declined (64±4 mmHg vs 105±2 mmHg , 412±16 bpm vs 721±48 bpm, 
p<0.05) compared with control mice. 2) 24h after cisplatin, the expression of A1AR in 
WT mice was significantly higher than control mice. Cisplatin also induced the expression 
of A2bAR and Bax, targets of mitochondria-mediated apoptosis. 3) Compared with WT 
mice, serum creatinine elevation and tubular injury were more obvious in A1AR-/- mice 
(25.8±19.28 vs 11.4±0.43mmol/L, p<0.05). But contrast to WT mice, A2bAR and Bax 
expression were not elevated in A1AR-/- mice. The expression of CD73 was up-regulated 
significantly.
Conclusions: A1AR may be involved in cisplatin-mediated AKI and could alleviate 
the cisplatin nephrotoxicity. But it doesn’t work through mitochondria-mediated apoptosis 
pathway. A1AR agonists are potential to protect the kidney in cisplatin-mediated AKI.
Funding: Government Support - Non-U.S.
TH-PO040
Testosterone Upregulates Heme-Oxygenase-1 – A Potential Mechanism 
to Protect against Acute Kidney Injury  Andrea P. Soljancic, Arnaldo F. 
Lopez-Ruiz, Kiran B. Chandrashekar, Luis A. Juncos.  Medicine-Nephrology, 
Univ of Mississippi Medical Center, Jackson, MS.
Background: Sex hormones modulate renal injury during ischemia-reperfusion-
induced acute kidney injury (I/R-AKI). We reported that testosterone is reduced during 
I/R-AKI and that supplementing this hormone ameliorates the renal injury. This protective 
effect is dependent on the chronicity of therapy and dose (chronic exposure and high doses 
may exacerbate injury). In this study, we investigated a possible mechanism by which acute 
administration of low-dose testosterone propionate (A-LD-TP) can protect against I/R-AKI. 
Because we found that A-LD-TP increased hypoxia inducible factor-1α (HIF-1α), which 
in turn induces heme oxygenase-1 (HO-1), we hypothesized that the protective effect of 
A-LD-TP during I/R-AKI is mediated by HIF-1α dependent upregulation of HO-1.
Methods: SD rats were randomized into 4 groups; 1) Sham, 2) I/R-AKI, 3) I/R-AKI+TP, 
4) I/R-AKI+A-LD-TP+2-ME. I/R-AKI was induced by 40 min bilateral renal pedicle 
clamping. A-LD-TP was given 3 h after releasing the clamps, and a HIF-1α antagonist, 
2-Methoxystradiol [2-ME] was given 1 day before inducing AKI. Rats were followed for 
48hs. Blood, urine and tissue were collected to evaluate renal function, injury, and expression 
of pro-inflammatory cytokines and the HIF-1α - HO-1 cascade.
Results:
Creat(mg/
dl)
KIM-1(pg/
ml)
TNFα(pg/
ml)
HIF-1α (pg/
ml)
HO-1 (ug/
ml)
Sham 0.51±0.06 450±120 30±8 0.45±0.05 0.55±0.1
I/R-AKI 2.4±0.07* 4500±190* 190±15* 5.6±0.3* 5.8±0.3*
I/R-AKI+TP 1.4±0.08# 1700±200# 115±6# 10.6±0.8# 11.7±0.6# 
I/R-AKI+TP+2-
ME 2.2±0.1 4400±350 175±12 3.95±0.4 6.2±0.4
Conclusions: A-LD-TP supplementation ameliorated I/R-AKI-induced renal 
dysfunction, inflammation and tubular injury. These beneficial changes were associated 
with further upregulation of HO-1. Blocking HIF-1α attenuates the cytoprotective effects 
conferred by A-LD-TP. This data supports the hypothesis that A-LD-TP supplementation 
activates the renal HIF-1α pathway and its downstream cytoprotective factor (HO-1), which 
protects against I/R-AKI, thus providing a potential therapeutic target.
Funding: Private Foundation Support
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Endotoxin Preconditioning Induces an Effective Immune Response That 
Avoids Collateral Tissue Damage  Takashi Hato, Pierre C. Dagher.  Medicine, 
Indiana Univ, Indianapolis, IN.
Background: Endotoxin preconditioning is a powerful model of renoprotection against 
a variety of insults. Harnessing these protective pathways has important therapeutic potential 
in sepsis. However, the protective molecular pathways remain unknown. Here we examined 
the metabolic profiles of endotoxin preconditioning.
Methods: Mice were divided into 3 groups: control, endotoxin injury (LPS 5 mg/kg ip) 
and preconditioning (0.25 mg/kg followed by 5 mg/kg LPS). Renal injury was assessed by 
serum creatinine and tissue KIM1. Cecal ligation and puncture (CLP) was used to evaluate 
mortality and bacterial load. Tissues and sera were examined using cytokine assays, 2DIGE 
proteomics and metabolomics.
Results: Preconditioning improved survival after CLP (75% vs. 25% in non-
preconditioned mice). This protection was accompanied by reduced bacterial load in solid 
organs including kidneys (320 vs. 1,200 cfu/gram tissue). Macrophages harvested from 
preconditioned mice exhibited robust phagocytic activity. Preconditioning also resulted 
in renal protection after toxic dose LPS (mean serum creatinine 0.08 mg/dL vs. 0.40 mg/
dL in non-preconditioned mice; tissue KIM1 mRNA fold changes 110 vs. 2,960). 2DIGE 
proteomics analyses revealed upregulation of molecules required for the activation and 
maintenance of phagocytosis in the preconditioned group. These molecules include clusterin, 
serum amyloid P-component, neutrophil gelatinase-associated lipocalin, and complement 
factor B. Despite the activation of these efficient bacterial clearing pathways, serum and 
tissue proinflammatory cytokine levels were broadly downregulated in preconditioned 
animals. Tissue metabolomic analysis revealed that preconditioning increased metabolites 
involved in tissue repair (proline and spermidine), antimicrobial activity (itaconate) and 
antioxidant pathways (ergothioneine), while uremic toxin levels were reduced (p-cresol 
sulfate, 3-indoxil sulfate, pseudouridine).
Conclusions: Preconditioning confers tissue protection and increases survival through 
an organized upregulation of a modified innate immune response characterized by enhanced 
bacterial clearing and yet lacking the proinflammatory tissue damage frequently observed 
with ordinary innate immunity.
Funding: NIDDK Support
TH-PO042
Myeloid Cell Specific Nrf2 Activation Protects Elderly Mice from Acute 
Kidney Injury  Sanjeev Noel,1 Samatha Bandapalle,1 Sekhar P. Reddy,2 Hamid 
Rabb.1  1Dept of Medicine, Johns Hopkins Univ, Baltimore, MD; 2Dept of 
Pediatrics, Univ of Illinois, Chicago, IL.
Background: Transcription factor Nrf2 confers protection against ischemia-
reperfusion (IR)-induced acute kidney injury (AKI) in mice by upregulating antioxidant 
and cytoprotective genes, but the specific cell types where Nrf2 is working is unknown. We 
recently demonstrated that T cell Nrf2 activity is a major modulator of IR-induced AKI in 
mice with increased T cell Nrf2 (J Am Soc Nephrol, in press). In this study we tested the 
hypothesis that Nrf2 activation in myeloid cells (neutrophils, macrophages) is protective 
against IR-induced AKI. We tested our hypothesis in young and elderly mice with genetic 
deletion of Nrf2 inhibitor, keap1 in myeloid cells (Lysm keap1-/-).
Methods: Young (7-8wks) and old (32-48wks) male Lysm keap1-/- and keap1f/f 
(control) mice underwent 30 minute bilateral kidney ischemia. Serum creatinine (SCr) 
was measured at 0, 24, 48 and 72h post ischemia. Histological and inflammatory changes 
in kidney were examined at 72h.
Results: We observed significantly reduced SCr levels in young (0.6±0.1 vs 1.3±0.2, 
p£0.02, 24h) and elderly (0.4±0.2 vs 1.3±0.3, p£0.02, 48h and 0.2±0.03 vs 0.9±0.2, 
p£0.02, 72h) Lysm keap1-/- mice as compared to age matched keap1f/f mice. Histological 
examination of corticomedullary region of kidney tissue revealed a significantly lower 
necrotic debris (24±8.7 vs 54±3.8, p£0.01), regeneration (22.1±7.0 vs 41.1±4.0, p=0.04) and 
higher percent of normal tissue (53.8±15.7 vs 5.0±0.6, p£0.01) in elderly Lysm keap1-/- mice. 
Young Lysm keap1-/- mice did not show any significant difference in kidney histology post 
AKI compared to young keap1f/f mice. Cytokine analysis showed significantly (p£0.04) 
higher levels of TGF-β, IL-1β, IL-2, IL-6, IL-10, IL-13, IL-17 and TNF-α in elderly Lysm 
keap1-/- kidneys. These cytokines were comparable in young Lysm keap1-/- and keap1f/f 
kidneys post AKI.
Conclusions: These data demonstrate that enhancing Nrf2 activity in myeloid cells 
can provide protection against IR-induced AKI, which is markedly enhanced in elderly 
mice. These findings reveal that myeloid cell oxidative stress responses are a mechanism 
by which elderly are more susceptible to AKI.
Funding: NIDDK Support
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Sphingosine-1-Phosphate-3 Deficient Dendritic Cells Modulate Splenic 
Responses to Ischemia-Reperfusion Injury  Amandeep Bajwa,1 Elvira 
Kurmaeva,1 Liping Huang,1 Joseph C. Gigliotti,1 Hong Ye,1 Diane L. Rosin,2 
Peter I. Lobo,1 Mark D. Okusa.1  1Medicine-CIIR, UVA, Charlottesville, VA; 
2Pharmacology, UVA, Charlottesville, VA.
Background: The plasticity of dendritic cells (DCs) permits phenotypic modulation 
ex-vivo by gene expression or pharmacological agents, and these DCs can exert therapeutic 
immunosuppressive effects in-vivo through direct interactions with T-cells by either inducing 
T regulatory (Treg) cells or causing anergy. Sphingosine 1-phosphate (S1P), a sphingolipid 
that is the natural ligand for five G-protein coupled receptors (S1P1-5Rs), and S1PR agonists 
reduced kidney ischemia-reperfusion injury (IRI) in mice. S1pr3-/- mice are protected 
from kidney IRI due to the inability of dendritic cells to mature. We tested the therapeutic 
advantage of S1pr3-deficient bone marrow-derived DC (BMDC) transfers in kidney IRI.
Methods: Renal injury was assessed by plasma creatinine (PCr; mg/dl). 8-wk old 
CBL/ :T and Spr-/- male mice were used for generating highly pure BMDCs from 
whole BM precursors.
Results: IRI produced a rise in plasma creatinine (PCr) in naïve mice, no cell (NC) 
and in mice pretreated with WT BMDCs. However, S1pr3-/- BMDC-pretreated mice were 
significantly protected from kidney IRI. S1pr3-/- BMDC-pretreated mice had significantly 
higher numbers of splenic Tregs compared to NC and WT BMDC-pretreated mice. S1pr3-
/- BMDC-induced protection of the recipient kidney required an intact spleen, B/T cells, 
and CD11c+ DCs, as S1pr3-/-BMDCs were ineffective in attenuating IRI in splenectomized, 
Rag-1-/- or CD11c+ DC-depleted mice. Additionally, S1pr3-/- BMDC dependent protection 
requires CD169+-marginal zone (MZ) macrophage dependent CCL22/macrophage-derived-
chemokine (MDC) signaling to increase Treg.
Conclusions: We conclude that genetically induced deficiency or pharmacological 
blockade of S1pr3 on allogenic BMDCs could serve as a useful therapeutic approach to 
prevent IRI-induced acute kidney injury or delayed graft function associated with transplant.
Funding: NIDDK Support
TH-PO044
Spleen Plays a Critical Role in Hepcidin-Mediated Protection against 
Renal Ischemia-Reperfusion Injury  Sundararaman Swaminathan,1 Yogesh 
M. Scindia,1 Mark D. Okusa,1 Diane L. Rosin,1,2 Liping Huang,1 Paromita 
Dey.1  1Medicine, Univ of Virginia, Charlottesville, VA; 2Pharmacology, Univ 
of Virginia, Charlottesville, VA.
Background: We showed previously that pretreatment with hepcidin mitigates kidney 
IRI by acting on hepato-splenic iron compartments. In these studies we observed that 
changes in the splenic iron content and ferroportin expression far exceeded that in the 
kidney and liver. We therefore hypothesized that hepcidin-mediated protection is through 
its iron-retaining effect on the spleen, and that splenocytes are necessary in preventing 
renal injury following kidney IRI.
Methods: Mice (C57Bl/6, n=6-8) were splenectomized 1 week prior to treatment with 
saline or 50 mg of hepcidin and 24 hours later were subjected to bilateral renal IRI (26 
min). In some experiments, splenocytes (1e6-1e7) from 24 hour saline or hepcidin treated 
animals were adoptively transferred and the recipient mice were subjected to similar IRI 
regimen. Outcomes (renal function, injury markers, histopathology and inflammation) were 
examined after 24 hours of reperfusion.
Results: Splenectomy worsened IR-induced kidney injury (PCr: IRI; 1.9 Vs 
Splenectomy+IRI; 2.4, p < 0.005). Importantly, hepcidin was not able to rescue 
splenectomized mice from renal IRI (PCr: Hepcidin+Splenectomy+IRI; 2.1). Acute tubular 
necrosis and immune cell infiltration in splenectomized mice treated with or without 
hepcidin were comparable to untreated mice subjected to IRI. Adoptive transfer of 1e7 
splenocytes from hepcidin-treated (but not PBS) mice to naïve mice was sufficient to 
completely protect kidneys of recipient mice from IRI (PCr: PBS treated splenocytes; 2.3 
Vs Hepcidin-treated splenocytes; 0.25, p < 0.001).
Conclusions:    Our results demonstrate that protection afforded by hepcidin 
during episode of renal IRI, is dominantly mediated through its action on the spleen. 
Moreover,splenocytes of hepcidin-treated mice by themselves are capable of mitigating IRI 
in vivo, supporting our ongoing hypothesis that manipulation of splenic iron metabolism 
has therapeutic potential for AKI.
TH-PO045
Endothelial Krüppel-Like Factor 4 Mediates the Protective Effect of Statins 
against Ischemic Acute Kidney Injury  Tadashi Yoshida, Maho Yamashita, 
Matsuhiko Hayashi.  Apheresis and Dialysis Center, Keio Univ School of 
Medicine, Shinjuku-ku, Tokyo, Japan.
Background: Endothelial cells participate in the pathophysiology of ischemic acute 
kidney injury (AKI) by increasing the expression of cell adhesion molecules and by 
recruiting inflammatory cells. Results of our previous studies showed that endothelial 
Krüppel-like factor 4 (Klf4) regulated Vcam1 expression and neointimal formation 
following carotid injury. The aim of the present study was to determine if endothelial Klf4 
is involved in ischemic AKI.
Methods: Endothelial Klf4 conditional knockout (Klf4 cKO) mice were generated 
by breeding Tek-Cre mice and Klf4 floxed mice, and their phenotype was analyzed after 
bilateral renal ischemia.
Results: Klf4 cKO mice were phenotypically normal before the surgery. However, 
endothelial Klf4 deletion exacerbated renal ischemia-reperfusion injury, as indicated by 
elevated serum levels of urea nitrogen and creatinine and aggravated renal histology. 
Moreover, Klf4 cKO mice exhibited the enhanced accumulation of neutrophils and the 
elevated expression of cell adhesion molecules including Vcam1 and Icam1 in injured 
kidneys. Interestingly, statins ameliorated renal ischemia-reperfusion injury in control mice, 
but not in Klf4 cKO mice, suggesting that the protective effect of statins against ischemic 
AKI is mediated by endothelial Klf4. Mechanistic analyses in cultured endothelial cells 
revealed that statins increased Klf4 expression, and that Klf4 mediated the suppressive 
effect of statins on tumor necrosis factor-α-induced Vcam1 expression through reducing 
the binding of NF-κB to the Vcam1 promoter.
Conclusions: These results provide evidence that endothelial Klf4 is a mediator of 
statins and plays a protective role in ischemic AKI by regulating the expression of cell 
adhesion molecules with concomitant recruitment of neutrophils.
Funding: Government Support - Non-U.S.
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Kidney Endothelial Progenitors Play a Critical Role in Susceptibility to 
Acute Kidney Injury  Katherine V. Maringer, Natasha M. Rogers, Jeffrey S. 
Isenberg, Sunder Sims-Lucas.  Univ of Pittsburgh, Pittsburgh, PA.
Background:    Acute Kidney Injury (AKI) is characterized by an abrupt decrease in 
renal function leading to renal failure, and contributing to high percentages of morbidity 
and mortality. Kidney formation involves the production of nephrons each with a rich 
vascular supply surrounding it. This complex and high vascularization makes the kidney 
especially susceptible to ischemic injury. We hypothesize that malformations of the vascular 
system during kidney development compromise its ability to cope and recover from AKI.
Methods:    We generated mice with a conditional deletion of Vegfr2 (floxed) in the 
Foxd1cre positive renal stroma (Vegfr2ST-/-), and evaluated the formation of the vasculature 
via histology, immunohistochemistry and fluorescent microangiography. Furthermore we 
performed ischemia reperfusion injury (IRI) on control and mutant mice and determined 
their ability to recover 1 (injury phase) and 7 days (repair phase) post injury. Lastly, we 
performed a lineage tracing study where Foxd1cre mice were bred with a TdTomato reporter 
(permanently labeling all Foxd1 derived cells) and performed IRI and interrogated the 
percentage of Foxd1 derived endothelial cells that were present in the IRI and contralateral 
control kidneys.
Results:    We determined that the Vegfr2ST-/- mice had dilated microvasculature 
embryonically and post-nataly. Furthermore, when we stressed the Vegfr2ST-/- animals with 
IRI they had an increased injury compared to controls (both histologically and inflammatory 
markers). This increased susceptibility in the mutants continued to be observed 7 days 
following the injury. Lineage tracing experiments showed the Foxd1 derived endothelial 
cells are highly plastic during the repair phase of IRI and their deletion in the Vegfr2ST-/- is 
likely the reason for the increased susceptibility to injury.
Conclusions:    From this we determined that Foxd1 derived endothelial cells are highly 
pertinent to normal formation of the renal vasculature and their risk of AKI. Patients that 
have an underlying perturbation of the renal microvasculature are likely at higher risk of 
suffering long term renal damage following AKI.
TH-PO047
Diadenosine Pentaphosphate Reduces Glomerular Filtration Rate 
Vera Jankowski,1 Andreas Patzak,2 Joachim Jankowski.1  1Inst of Molecular 
Cardiovascular Research, Univ Hospital RWTH, Aachen, NRW, Germany; 
2Inst of Vegetative Physiology, Charité-Universitätsmedizin, Berlin, Germany.
Background: Mechanisms and participating substances responsible for the reduction 
of glomerular filtration (GFR) rate in contrast induced acute kidney injury (CI-AKI) are 
still matter of debate. Here we hypothesize that diadenosine polyphosphates are released by 
the action of contrast media and may act on glomerular arterioles thereby reducing GFR.
Methods: Rat tubules were freshly isolated using a modified iron oxide sieve technique 
and treated with iodixanol (47 mg iodine/ml) at 37°C for 20 min. The supernatant was 
analyzed regarding the content of ApnA (n=3-5) by using reversed phase chromatography, 
affinity chromatography and Maldi-MS. Concentration response curves for ApnA (n=3-5, 
10-12-10-5 mol/l) were measured in isolated perfused glomerular arterioles. The GFR was 
obtained in conscious mice by inulin clearance.
Results: Treatment of tubules with iodixanol increased the concentration of ApnA 
(n=3-5) significantly in the supernatant. ApnA (n=3-5) reduced afferent arteriolar diameters 
dose dependent, but did not influence efferent arterioles. Ap5A acted strongest; its effect 
weakened with time. Suramin blocked the Ap5A effect. Further, application of Ap5A in 
conscious mice significantly reduced the GFR.
Conclusions: The data indicate that contrast media induced release of Ap5A act 
differentially on glomerular arterioles resulting in the reduction of the GFR. This mechanism 
may add to the reduced GFR in CI-AKI.
TH-PO048
Effect of Anakinra on Inflammasome Markers in Hepatorenal Syndrome 
Type 1  Sindhura Bobba, Siddhartha S. Ghosh, Todd W. Gehr, Daniel E. Carl. 
Dept of Internal Medicine-Div of Nephrology, Virginia Commonwealth Univ 
Health System, Richmond, VA.
Background: Hepatorenal syndrome (HRS) type 1 is a life threatening complication 
of cirrhosis with limited therapeutic options. We hypothesize that Inflammasome plays a 
major role in HRS type 1 and we investigated this in a mouse model by blocking IL-1β, 
an end product of inflammasome pathway by Anakinra, so that it could serve as a potential 
therapeutic agent in patients at risk for HRS type 1.
Methods: C57BL/6 mice received 1mL/kg of carbon tetrachloride (CCl4) biweekly 
for 12 weeks induce liver cirrhosis. A 6 mg/Kg of Lipopolysaccharide (LPS) was given 
intraperitoneally to mice to induce acute kidney injury by simulating the inflammatory 
stressor caused by acute infection. A 30 mg/ kg of Anakinra was given intraperitoneally 3 
hours before and 1 hour after LPS to CCl4 and LPS treated mice. Four mouse populations 
were studied. (1) control mice (2) CCl4 treated mice (3) CCl4 treated mice with LPS 
(4) CCl4 treated mice with LPS and Anakinra (N=6 per group). Renal function was 
monitored by measuring urine output, urinary sodium, and serum creatinine measured 
10 hrs after administration of Anakinra. The mouse kidneys were then harvested and 
analyzed by western blot for the presence of inflammasomal markers: IL-1β, caspase 1, 
and apoptosis- associated speck like protein (ASC) and the therapeutic effect of Anakinra 
on these inflammatory markers.
Results: Control and CCl4 treated mice showed no change in renal function. The 
CCl4+LPS treated mice had a significant decrease in urine volume (p<0.05) and urinary 
Na (p<0.05) and marked increase in serum creatinine (p<0.05) compared to the other 3 
mice groups. In CCl4+LPS+Anakinra treated mice IL-1β, caspase 1, and ASC expression 
significantly decreased (p<0.05) compared with CCl4+LPS treated mice.
Conclusions: In the CCl4-induced cirrhotic mouse model, simulating HRS type 1 by 
administration of LPS, accompanied by an increase in the expression of IL-1β, caspase-1, 
and ASC in mouse kidney. Anakinra resulted in down regulation of these markers and 
improvement in renal function. This suggests that agents like Anakinra could be a potential 
therapeutic option for patients at risk of HRS type 1.
TH-PO049
Matrix Metalloproteinase-7 Protects against Acute Kidney Injury in Mice 
Haiyan Fu,1 Dong Zhou,1 Liangxiang Xiao,1 Roderick J. Tan,2 Youhua Liu.1 
1Dept of Pathology, Univ of Pittsburgh, Pittsburgh, PA; 2Dept of Medicine, Univ 
of Pittsburgh, Pittsburgh, PA.
Background: Matrix metalloproteinase-7 (MMP-7), a secreted and zinc-dependent 
endopeptidase that proteolytically degrades a broad range of extracellular matrix and 
other substrates, is a direct downstream target of the canonical Wnt/beta-catenin signaling. 
MMP-7 is specifically induced in the tubular epithelium of the kidneys in a variety of 
chronic kidney diseases. However, whether MMP-7 plays a role in acute kidney injury 
(AKI) is still ambiguous.
Methods: MMP-7 expression in the kidneys after AKI was assessed. MMP-7 knockout 
and wild-type control mice were subjected to renal ischemia/reperfusion injury (IRI) and 
cisplatin administration, respectively. Cultured proximal tubular epithelial cells (HKC-8) 
were used an in vitro model.
Results: MMP-7 was markedly induced in renal tubular epithelial cells at 12 hours after 
IRI. To investigate the role of MMP-7 in AKI, we utilized MMP-7 knockout mice (MMP-7-
/-). Mice with global ablation of MMP-7 were phenotypically normal with no appreciable 
defects in kidney morphology and function. In AKI induced by either IRI or cisplatin, 
loss of MMP-7 substantially aggravated renal lesions, compared with wild-type controls. 
MMP-7-/- mice displayed higher mortality rate, elevated serum creatinine, and more severe 
morphologic injury, which was accompanied by an increased expression of FasL, Caspase 
7 and FADD, while little change with Bax. In MMP-7-/- kidneys, more prevalent apoptotic 
cells were detected in renal tubular epithelial cells after injuries. Moreover, deficiency of 
MMP-7 also promoted the expression of pro-inflammatory cytokines and chemokines, such 
as TNF-α, MCP-1 and RANTES, and caused an increased inflammatory cell infiltration as 
illustrated by immunostaining for CD3+, CD45+ and F4/80+ antigens. In vitro, recombinant 
MMP-7 protein protected human kidney proximal tubular cells (HKC-8) against apoptosis 
through inhibiting FasL/Caspase-7/FADD axis.
Conclusions: MMP-7 plays a protective role in the setting of AKI through inhibiting 
FasL-mediated apoptotic pathway and reducing renal inflammation.
Funding: NIDDK Support
TH-PO050
Metformin Protects against Cisplatin-Induced Acute Kidney Injury via an 
AMPK-Dependent Manner  Jianzhong Li, Chunsun Dai.  Nanjing Medical 
Univ.
Background: Metformin, one of the most common prescriptions for the therapy of type 
2 diabetes, is beneficial for early diabetic nephropathy. However, the role and mechanisms 
for metformin in treating acute kidney injury remain to be established.
Methods: Adult male CD1 mice were injected with cisplatin intraperitoneally to 
induce AKI. Rat Kidney tubular epithelial cells (NRK-52E) were incubated with cisplatin 
to induce cell death.
Results: Here, we found that mice exhibited severe kidney injury at day 2 after 
cisplatin injection. Metformin treatment could markedly ameliorate kidney dysfunction 
and kidney morphologic abnormality. Cell apoptosis in kidney tissue presented as TUNEL 
and anti-cleaved caspase 3 staining was much less in metformin-treated mice compared 
with the diseased control. Anti-Ly6b and anti-F4/80 staining demonstrated that the 
inflammatory cells infiltration in the kidneys was also diminished in metformin-treated 
mice. In addition, LC3-II, an autophagy biomarker, was induced at 1h and peaked at 12h 
in the kidneys after cisplatin injection, whereas autophagy induction as well as p-Ampk 
abundance were largely enhanced in metformin-treated mice. In cultured NRK-52E cells, 
cell apoptosis was markedly induced at 12h after cisplatin treatment and metformin could 
largely attenuate it. Furthermore, cells pretreated with metformin dramatically increased 
the abundance of phosphorylated Ampk. LC3-II protein level was also significantly induced 
after metformin treatment. Knocking down Ampk expression with small interfering RNA 
or using 3-methyladenine to block metformin-induced autophagy could largely diminish 
the protective effect of metformin on cell apoptosis.
Conclusions: In summary, metformin may protect against cisplatin-induced AKI 
through promoting tubular cell survival by inducing AMPK activation and tubular cell 
autophagy.
Funding: Government Support - Non-U.S.
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TH-PO051
A Comparison of Three Prediction Models for Acute Kidney Injury 
Requiring Renal Replacement Therapy After Coronary Artery Bypass 
Graft Surgery  Ailene Ramos Buelva-Martin, Aina Bautista-Duque, Oscar D. 
Naidas.  Dept of Medicine, Section of Nephrology, St. Luke¶s Medical Center, 
Quezon City, Metro Manila, Philippines.
Background: Acute kidney injury (AKI) following cardiac surgery is associated with 
increased post-operative morbidity and mortality. Scoring systems to predict acute kidney 
injury requiring renal replacement therapy (RRT) among patients undergoing cardiac surgery 
have been developed to assess risk pre-operatively and give necessary prophylactic agents 
and also assist clinicians on the management post-operatively.
Methods: Cross sectional analytic study of 427 patients who underwent coronary 
artery bypass graft from January 2009-October 2014. The following were excluded: a) on 
hemodialysis b) with missing data. Primary outcome: acute kidney injury requiring RRT 
after CABG. Risks were calculated using the three models: Cleveland scoring by Thakar, 
Simplified Renal Index by Wijeysundera, and the Bedside Tool for Predicting Risk of 
Postoperative Dialysis by Mehta. The area under the receiver operating curve (AUROC) 
was determined for each model.
Results: AKI was documented in 25.5% (n=109), 13.3% (n=57) underwent post-
operative RRT. Discrimination for the prediction of RRT was good for the three scoring 
models using AUROCs: Mehta: 0.94 (95% CI, 0.916 to 0.963); Thakar: 0.92 (95% CI, 0.890 
to 0.944), and SRI: 0.90 (95% CI, 0.867 to 0.926). Mehta showed the highest predictive 
value, with significant difference with SRI (P = 0.0053). However, it was not signficantly 
different with Thakar (p=0.23).
Conclusions: The Bedside Tool for Predicting Risk of Postoperative Dialysis by Mehta 
showed the highest predictive value but with no significant difference with the predictive 
value of the Cleveland scoring system. The advantages of the Cleveland scoring over Mehta 
are the applicability in cardiac surgeries other than CABG and the less number of variables.
TH-PO052
Effect of Off-Pump and On-Pump Coronary Artery Bypass Graft Surgery 
on Acute Kidney Injury  Ailene Ramos Buelva-Martin, Oscar D. Naidas.  Dept 
of Medicine, Section of Nephrology, St. Luke¶s Medical Center, 4uezon City, 
Metro Manila, Philippines.
Background: Acute Kidney Injury (AKI) is one of the serious complications of 
cardiac surgery. AKI is associated with increased mortality and morbidity. Coronary 
artery bypass graft (CABG) surgery can be done with a beating-heart (off-pump) or with 
a cardiopulmonary bypass machine (on-pump). There are conflicting studies regarding 
reduction of acute kidney injury with the use of the Off-pump CABG vs. On-Pump CABG.
Methods: Adult patients who underwent CABG using Off-pump and the On-pump 
technique from January 2005 to October 2014 were included in this retrospective cohort 
study. The following patients were excluded: a)chronic hemodialysis b)baseline eGFR 
<15ml/min/1.73m2 c)missing data. The outcomes were: AKI defined as absolute increase 
in the serum creatinine concentration of ³0.3 mg/dL from baseline within 48 hours after 
CABG and AKI requiring renal replacement therapy. Odds ratio were calculated between 
the use of Off-pump and On-pump CABG with the respective outcomes.
Results: Postoperative Acute Kidney Injury The incidence of acute kidney injury 
with off-pump group was lower (4/28 [14.3%]) vs on-pump group (109/427 [25.5%]) with 
OR 2.05 [95% CI, 0.69 to 6.59]); however, it was not significantly different at p-value 0.19. 
Postoperative Acute Kidney Injury with Renal Replacement Therapy Out of the 109 
patients who had acute kidney injury after On-pump CABG, 53 (48.6%) patients underwent 
hemodialysis. While in the Off-pump CABG group, no one underwent hemodialysis out 
of the 4 patients who had acute kidney injury postoperatively (OR 8.8 [95% CI 0.5327 to 
146.9], P=0.1283). [table1]
Conclusions: There was a lower incidence of AKI and AKI requiring renal replacement 
therapy in the Off-pump CABG group, however, it was not statistically significant with the 
On-pump CABG group. There is still insufficient evidence to say that the use of Off-pump 
CABG technique reduces incidence of AKI. Limitations of this study are: small sample 
size, confounding variables since this study is a retrospective study, off-pump CABG 
population may not have been represented accurately. A multi-center study to increase 
sample size is recommended.
TH-PO053
Renal Dysfunction Detected by an Automatic Alert System: DETECT-H 
Proyect  Pedro J. Labrador, Silvia Gonzalez S, Santiago Polanco Candelario, 
Elena Davin carrero, Jesús P. Marin, Ines Castellano, Juan R. Gomez-Martino. 
Nephrology, San Pedro de Alcantara Hospital, Caceres, Spain.
Background: The aim was to analyse the prevalence of chronic kidney disease (CKD) 
and acute kidney injury (AKI), length of stay (LOS) and in-hospital mortality.
Methods: To evaluate renal dysfunction in admissions we developed a fully automated 
electronic alert system which identifies all adult patients with reduced glomerular filtration 
rate according to CKD-EPI. Two alert levels were established, <60 and <30 mL/min/1.73m2 
in patients over 80. Patients admitted to nephrology unit and on dialysis were excluded. 
Detected patients were retrospectively analysed. CKD and AKI was defined according to 
KDIGO guidelines. Baseline serum creatinine was the lowest between 0.5-6 months before 
admission. LOS and in-hospital mortality was recorded.
Results: Between January and June 2014, issued alerts were 1.241 from 11.022 adult 
admissions (11.3%), from 1.079 patients (13.1% multiple admissions). Median age 77 
years (interquartile range (IQR) 70-81), and 53.9% were men. Previous renal function 
was present in 1.042 patients (84%). Stage 1 9.6%, stage 2 37.7%, stage 3a 25%, stage 3b 
17.7%, and stages 4-5 10%. Previous CKD was only registered in 31.9%. AKI was present 
in 846 admission episodes (69.9% of alerts and 7.7% of overall admissions). AKI stage 1, 
2 and 3, respectively was 421 (49.7%), 207 (24.5%) and 218 (25.8%). AKI episode was 
specified to be suffered in 33.2% patients at discharge. In patients with CKD not AKI 7.5%, 
in overall AKI patients 45.3%, in AKI 1 30.4%, in AKI 2 47.8% and in AKI 3 71.6%; 
p<0.001. LOS in overall admissions in the same period was 5.31 days, for overall detected 
patients median LOS was 8 days (IQR 4-13 days). Median LOS for CKD not AKI, or AKI 
stage 1, 2 and 3 was 6 (3-10), 8 (5-13), 8 (6-14) and 10 (5-19) days; p<0.001. Mortality for 
all detected patients was 14.9% (185 patients). In-hospital mortality for CKD not AKI, or 
AKI stage 1, 2 and 3 was 4.3%, 10.9%, 22.7% and 33.9%. Mortality in patients with AKI 
stage 3 requiring dialysis was 57.1%, p<0.001.
Conclusions: Electronic alerts could be a useful tool to detect in-hospital renal 
dysfunction patients to improve CDK and AKI hospital outcomes.
Funding: Private Foundation Support
TH-PO054
Identification of a Pediatric Inpatient Cohort at Risk for Developing Acute 
Kidney Injury Using Machine Learning Methods  Michael G. Semanik, 
Sangeeta R. Hingorani.  Pediatric Nephrology, Seattle Children¶s Hospital, 
Seattle, WA.
Background: Acute kidney injury (AKI) is prevalent amongst pediatric inpatients, 
and its prevention requires rapid detection of those at risk. A rise in creatinine often 
comes too late for prevention to be effective. Therefore, this study seeks to apply machine 
learning methods to routine clinical data in order to identify patients at risk for AKI before 
creatinine levels rise.
Methods: A cohort of pediatric inpatients with at least one creatinine value was created, 
then split into AKI and non-AKI groups. AKI was defined using KDIGO creatinine-based 
criteria. Information on demographics, vital signs, lab values, procedures, and medications 
were collected for each patient. For the AKI group, only data collected 24 hours before each 
patient’s peak creatinine value were used. Simple logistic regression was used to identify 
features that predicted the development of AKI, and these features were used to produce 
two algorithms: a logistic regression-based algorithm and a Bayes Net probability-based 
algorithm. Both algorithims used 10-fold cross validation to create a training and test set.
Results: 4064 patients were included in the cohort, of whom 370 (9.1%) developed 
AKI. Sixty features were significantly associated with AKI. The logistic regression 
algorithim created from these features identified 144/370 AKI patients and 3653/3694 
non-AKI patients (giving it a sensitivity of 39% and specificity of 99%). The Bayes Net 
algorithm’s sensitivity was 48% (identifying 176/370 AKI patients) and its specifity was 
91% (identifying 3347/3694 non-AKI patients). The ROC areas for the algorithms were 
0.84 and 0.81, respectively.
Conclusions: Machine learning methods can be used to identify a cohort of pediatric 
inpatients that are at increased risk of developing AKI before serum creatinine rises. 
Identification of this population allows for both additional testing (such as urinary 
biomarkers) and preventative treatment (such as removal of nephrotoxic drugs). Acute 
kidney injury predictive algorithms have the potential to improve patient care, and, if 
correctly implemented, will become more accurate as more data is collected.
Funding: Other NIH Support - NIH T32 Training Grant
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TH-PO055
The Jelliffe Method for GFR Estimation with Non Steady State Creatinine 
Performs Better for Subjects with Higher Weight and Baseline Chronic 
Kidney Disease  Reejis Stephen, Sevag Demirjian, Steve Campbell. 
Nephrology, Cleveland Clinic, Cleveland, OH.
Background: The Jelliffe method is used to estimate the glomerular filtration rate(GFR) 
when creatinine is in a non-steady state, such as in patients with acute kidney injury 
(AKI). We explored the agreement between iothalamate-measured renal function (iGFR) 
and estimated GFR by the Jelliffe method (eGFR) in subjects with AKI after undergoing 
partial nephrectomy.
Methods: iGFR was measured within a week of partial nephrectomy in subjects who 
sustained AKI (>0.3 mg/dl rise in serum creatinine from baseline) after partial nephrectomy. 
iGFR and eGFR based on creatinine drawn at the time of iGFR measurement, were compared 
using Pearson’s correlation (r) in subjects grouped by weight (above and below median 
weight; 86 Kg) and baseline chronic kidney disease status (CKD; GFR<60ml/min/1.73m2).
Results: 69 of 90 subjects undergoing partial nephrectomy sustained AKI. Mean age 
was 61±11 years, and 55 were male. eGFR had a high correlation with iGFR (r=0.75, 
p<0.001). Correlation of eGFR with iGFR is shown and was significant except in the group 
with both CKD and lower weight (Table). Subgroup analysis showed that subjects with 
lower body weight and no CKD had lower correlation (r=0.54) than those with both CKD 
and the higher weight (r=0.96). The group with no CKD but higher weight had a strength 
of correlation in between these extremes. 
Group; Mean±SD (Kg) No CKD CKD
Low Weight; 74 ± 9 0.54 (p 0.003) 0.40 (ns)
High Weight; 105 ± 15 0.79 (p < 0.001) 0.96 (p < 0.001)
Conclusions: GFR estimated by the Jelliffe equation correlates well with measured 
GFR in the AKI setting. Higher body weight and CKD at baseline are associated with 
higher creatinine levels, which may account for the better performance of the Jelliffe 
method in these states.
TH-PO056
Development of a Multicenter Ward-Based Acute Kidney Injury (AKI) 
Prediction Model  Jay L. Koyner, Richa Adhikari, Dana P. Edelson, Matthew 
M. Churpek.  Dept of Medicine, Univ of Chicago.
Background: Early identification of those at risk for the development of AKI on 
the general wards prior to increases in serum creatinine (SCR) would enable preemptive 
evaluation and intervention to minimize the risk and severity of AKI. We aimed to develop an 
AKI risk prediction algorithm using electronic health record (EHR) data in non-ICU patients.
Methods: All hospitalized ward patients who had SCr measured in 5 hospitals were 
included. Patients with a first measured SCr>3.0mg/dl or who developed inpatient AKI 
outside the general ward were excluded. Using a discrete-time survival model, demographics 
(age, sex), continuous variables (respiratory rate, pulse, temperature, pulse pressure index, 
oxygen saturation, systolic and diastolic blood pressure, complete blood count, hepatic 
panel and blood chemistries) were modeled as restricted cubic splines with 4 knots. The 
algorithm was derived in 60% of the data and prospectively validated in the remaining 
40%. Area under the curve (AUC) was calculated for the prediction of SCr-based KDIGO 
AKI within 12 or 24 hours. Subgroup analyses were conducted across baseline glomerular 
filtration rate (eGFR) groups and severity of AKI stage.
Results: Among the 206,192 included patients, 17,522 (8.5%) developed KDIGO AKI 
on the wards, with 792 progressing to stage 2 and 257 to stage 3 during their hospital stay. 
The AUC(95%CI) of the model was 0.74(0.74-0.74) for predicting AKI within 24 hours 
and 0.76(0.76-0.76) for within 12 hours. Accuracy was highest for predicting AKI stage 3 
in the next 12 hours (AUC 0.90(0.89-0.92)).
Subgroup AUC(95%CI)
12hr outcome 24hr outcome
Baseline GFR
GFR ≥90 0.71(0.69-0.70) 0.69(0.68-0.70)
GFR 60-89 0.76(0.75-0.76) 0.74(0.73-0.74)
GFR 30-59 0.75(0.74-0.76) 0.73(0.72-0.73)
AKI Stage
Stage 1 0.76(0.76-0.76) 0.74(0.74-0.74)
Stage 2 0.77(0.76-0.78) 0.73(0.73-0.74)
Stage 3 0.90(0.89-0.92) 0.87(0.86-0.89)
Conclusions: Readily available EHR data can be used to predict impending AKI 
on the general wards with good to excellent accuracy across different patient subgroups. 
Real-time use of this model, prior to changes in SCr, would allow early diagnostic and 
therapeutic interventions for those at high risk of AKI and may improve cost and outcomes.
TH-PO057
Survivor Bias: Utilization of Multiple Admissions for Evaluation Risk of 
Inpatient Mortality Associated with Hospital-Acquired (HA) Acute Kidney 
Injury (AKI)  David G. Warnock, T. Clark Powell, John P. Donnelly.  Univ of 
Alabama at Birmingham, Birmingham, AL.
Background: Inpatient deaths censored the cohort at risk, introducing survivor bias 
favoring those with >1 admission. Analysis of first admissions avoids this bias, but also 
loses information about those who survive multiple admissions. We evaluated inpatient 
mortality associated with AKI for adult admissions to UAB Hospital for FY2010-FY2013.
Methods: We used ICD9 codes and all inpatient serum creatinine (sCr) values for 
109,456 adult patients with 5,452 inpatient deaths. We excluded patients with patients with 
<2 sCr values, ESRD, post-renal transplant, eGFR (<5 or >500 ml/min.1.73 m2), length 
of stay <1 and >28 days, and patients with community-acquired AKI. Minimum sCr for 
each admission was used as baseline, and HA-AKI was defined by peak sCr > (0.3 mg/dL 
+ minimal sCr) and date-time for minimal sCr < dateBtime peak sCr. No-AKI was defined 
as (peak Scr - minimal sCr) <0.3 mg/dL. Survivor functions included HA-AKI, median 
age, black race, male gender, DeyoBCharlson comorbidity score, and median admissions 
for each patient (Med#).
Results: For 40,471 patients with 1 admission, there were 7,594 cases of HA-AKI 
(19%) with 1,290 deaths (17%), For 14,860 patients with 23,633 admission, there were 
6,633 cases of HA-AKI (22%) with 732 deaths (11%). Figure shows survival curves for 
1 versus >1 admissions (A); 1 versus >1 admissions adjusted for Med# (B), 1 versus 
selected >1 random selected admission (C), and 1 versus >1 random selected admission 
adjusted for Med# (D). 
Conclusions: Survivor curves for multiple admissions (dashed lines) fell above the 
curve for single admissions, demonstrating survivor bias. Combining random selection 
and adjustment for Med# resolved the survivor bias, permitting inclusion of patients with 
multiple admissions in risk models for inpatient mortality.
Funding: NIDDK Support, Other NIH Support - P30 DK079337
T32-HS013852
R01-NR012726
TH-PO058
Validation of the Acute Renal Failure Trial Network (ATN) Study Risk 
Model for Predicting Mortality in Critically Ill Adults with Acute Kidney 
Injury  Ridhmi P. Rajapakse,1 Christopher M. Keener,2 Paul M. Palevsky,1,3 
John A. Kellum,2 Emily Foldes.2  1Medicine, Univ of Pittsburgh, Pittsburgh, PA; 
2Critical Care Medicine, Univ of Pittsburgh, Pittsburgh, PA; 3Renal Section, VA 
Pittsburgh HCS, Pittsburgh, PA.
Background: Disease specific severity of illness scoring systems have been developed 
to predict survival of patients with acute kidney injury. Performance of these scoring systems 
outside of the population in which they have been generated has been poor. We therefore 
evaluated the performance of the recently developed ATN Study risk model predicting 
60 day all-cause mortality in intensive care unit (ICU) patients at initiation of dialysis for 
acute kidney injury (AKI).
Methods: We evaluated the performance of the ATN Study risk model using the High 
Density Intensive Care (HiDenIC) Database which contains data on all adult patients 
admitted to any of the eight ICUs at UPMC between July 2000 and October 2008. Clinical 
data and physiologic variables were closely matched with the original study model; missing 
data were imputed by either assuming clinical normality or viewing these data elements 
following similar rules used to build the original model. Model discrimination was assessed 
via area under the receiver operating characteristic curve (AUROC). Calibration was 
assessed using the Hosmer-Lemeshow goodness-of-fit test.
Results: 1747 patients were initiated on renal replacement therapy (RRT) for AKI 
during this interval; full data for model testing were available for 1300 patients (74%). The 
AUROC for the model was 0.78 (95% CI: 0.75-0.80) with a Hosmer-Lemeshow goodness-
of-fit test p-value of 0.59 (Figure). 
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Conclusions: The ATN score demonstrated good discrimination and calibration 
for predicting 60-day all-cause mortality in in ICU patients initiating RRT for AKI in a 
population separate for the population in which it was developed.
TH-PO059
A Multifaceted Quality Improvement Programme for Tackling Acute 
Kidney Injury in a Large Teaching Hospital  Leonard Ebah, Prasanna 
Hanumapura subbegowda, Deryn Jennifer Waring, Rachael Challiner, Robert 
Henney, Alastair J. Hutchison.  Manchester Acute Kidney Injury Strategy, Dept 
of Renal Medicine, Central Manchester Univ Hospitals, Manchester, United 
Kingdom.
Background: Acute kidney injury (AKI) is now widely recognised as a serious health 
care issue. Up to 25% of hospital patients have been reported to develop it, often with 
worse outcomes compared to those without AKI. AKI care in hospitals has been shown 
to be substandard. This study aimed to use quality improvement methodology to improve 
AKI care and outcomes in a large teaching hospital.
Methods: Several areas of documented poor AKI care were identified and specific 
improvement activities implemented through sequential Plan-Do-Study-Act (PDSA) cycles. 
An electronic alert system for AKI was developed, a ten point Priority Care Checklist 
(AKI PCC) was tested with the aid of specialist nurses and pharmacists whilst targeted 
education activities were carried out. Impact on key AKI care processes and patient 
outcomes was studied.
Results: The electronic alert had a sensitivity of 99% for the detection of new cases 
of AKI.  Nine aspects of the PCC saw significant improvements in their attainment: 
Baseline creatinine 66% to 84%, identification of a cause for AKI 62% to 77%, fluid 
balance assessment 77% to 92%, appropriate investigations 61% to 77% catheterisation 
92% to 99% ultrasound scans 79% to 95% renal or intensive care referrals 80% to 100%, 
fluid charts 64% to 71% after, and appropriate drugs review 57% to 87%. The intervention 
led to a significant reduction in variability of delivered AKI care. AKI incidence showed 
a trend towards reduction; 9.9% of all hospitalisations before any intervention to 7.8% 
towards the end of the intervention period. AKI related length of stay dropped from 20.2% 
to 15.5% and AKI deaths also showed a trend towards reduction, from 44 deaths averagely 
per month to 31 deaths. The number of cases of hospital acquired AKI were down from 
107 to 90 per month.
Conclusions: This study demonstrates the success of an AKI care checklist 
implemented with the aid of a nurse/pharmacist in improving key processes of care and 
showing an early improvement in key patient outcomes.
TH-PO060
The Quality of Hospital Discharge Communications About AKI 
Raquel C. Greer,1 Yang Liu,1 Deidra C. Crews,1 Bernard G. Jaar,1 Hamid Rabb,1 
L. Ebony Boulware.2  1Johns Hopkins Univ; 2Duke Univ.
Background: Post-hospital discharge (DC) care for patients hospitalized with AKI 
could influence patients’ subsequent risks of CKD and related morbidity. High-quality 
written hospital DC communications (DC summaries to outpatient providers and patient 
DC instructions) about AKI may help facilitate adequate follow-up and patient self-care.
Methods: We reviewed electronic health records of patients hospitalized with 
community and hospital-acquired AKI in 2012 at a single hospital in Baltimore MD to 
characterize the quality of written hospital DC communications about AKI. We assessed 
patient and system characteristics independently associated with higher quality DC 
communications (greater number of quality elements out of 10 possible) in a multivariable 
model.
Results: Among 75 randomly selected hospitalized patients with AKI stratified by 
KDIGO stage 1 to 3 (n=25 per stage), mean age was 56 years, 48% were African American, 
15% had known CKD, median length of stay was 9 days and 65% were discharged from 
medical (vs. surgical) services. Less than half of DC communications included key 
elements about AKI.
Presence of 10 Quality Elements about AKI in Discharge Communications (n=75)
Presence of Quality Element
N (%)
Type of Quality Element
Quality 
Elements 
Possible
Physician 
Discharge 
Summary
Patient 
Discharge 
Instructions
Mention of AKI occurence 2 33 (44) 10 (14)
Mention of AKI cause 2 32 (43) 1 (1)
Description of AKI course 1 23 (31) NA
Recommended/scheduled follow-up 
appointments 2 60 (80) 67 (94)
Recommendations for care specific 
to AKI 2 11 (15) 6 (8)
Named outpatient provider to receive 
the discharge summary 1 58 (77) NA
NA:Not applicable
Communications featured a median of 4 quality elements. Quality elements were 
greater in communications for patients with more severe AKI (number of additional quality 
elements (β) [95% CI]: 2.0 [0.6-3.4] for Stage 3 vs. Stage 1) and those discharged from 
medical (vs. surgical) services (β [95% CI]: 1.2 [0.1-2.3]).
Conclusions: Few hospital DC communications provided information or 
recommendations for AKI care in sufficient detail to facilitate adequate follow-up. 
Improvements in this important aspect of care for patients with AKI are urgently needed.
Funding: NIDDK Support, Other NIH Support - National Center for Research 
Resources, a component of the NIH and the NIH Roadmap for Medical Research
TH-PO061
Prognosis of Contrast Induced Nephropathy After Outpatient Computed 
Tomography in Chronic Kidney Disease Patients  Sehoon Park, Seokwoo 
Park, Eunjeong Kang, Hajeong Lee, Jung Pyo Lee, Kwon Wook Joo, Yon Su 
Kim, Dong Ki Kim.  Dept of Internal Medicine, Seoul National Univ Hospital.
Background: Most studies regarding contrast induced nephropathy (CIN) were done in 
angiography era but computed tomography (CT) is more common cause of contrast exposure 
in general populaton. There were few prognosis data concerning CIN after outpatient CT.
Methods: Patients with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 
m2 underwent outpatient CIN prophylaxis program for contrast CT from 2008 to 2014 in 
Seoul National University Hospital. Patients received intravenous isotonic saline and oral 
N-acetylcysteine. Baseline blood sample was done within 2 weeks before CT. Basic data was 
colleted retrospectively by medical chart review. Prognosis was surveyed from death registry 
of National Statics Korea and dialysis registry of The Korean Society of Nephrology. CIN 
was defined by ³0.5mg/dl or ³25% increase of serum creatinine (sCr) from baseline within 
48-96 hours after CT. Primary outcome was event of renal replacement therapy (RRT), 
duration from CT to RRT and survival period after CT. Results: 12179 cases of CT were 
performed with CIN prophylaxis protocol and 2816 cases of CT had baseline eGFR<60 
without RRT history and follow up sCr 48-96 hours after CT. 84 (3%) cases of CIN were 
found and 99 (3.5%) cases went RRT, 551 death reported after CT. Prognosis was analyzed 
after adjustment with age, sex, baseline eGFR, history of diabetes and hypertension. No 
relationship between death, RRT incidence, doubling of sCr and CIN was shown. However, 
we found shorter period from CT to RRT in CIN cases. So we performed analysis with RRT 
within 6 months as outcome with subgroup devided by eGFR. CIN was risk factor for RRT 
within 6 months in cases with baseline eGFR<30 (aRR 4.70, 95% CI 1.39-15.90, P=0.013). 
However, in cases with eGFR³30, start of RRT in acute period was not increased by CIN.
Conclusions: CIN due to CT contrast after appropriate prophylaxis was not related to 
long term renal prognosis. CIN was a risk factor for start of RRT within 6 months after CT 
in cases with baseline eGFR<30, but even this relationship was not seen in patients with 
relatively preserved renal function.
TH-PO062
Outcomes following Intra Arterial Contrast in Chronic Kidney Disease 
Louise Goodall,2 Thomas Hugh Douglas Patterson,2 Jane Elizabeth Cross,1 
William E. James,1 Venkataraman Manickavasagam.1  1Nephrology, Lismore 
Base Hospital, Lismore, NS:, Australia; 2Medicine, Univ of Western Sydney, 
Sydney, NSW, Australia.
Background: Contrast Induced Nephropathy (CIN) is a recognised complication of 
angiography. Risk factors include chronic kidney disease (CKD), advanced age, diabetes 
and cardiac insufficiency. Although incidence in the general population is 2-5%, reported 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
104A
J Am Soc Nephrol 26: 2015 AKI: Clinical Poster/Thursday
incidence of CIN in CKD is 15-27%. The risk of CIN may have been over-estimated in 
CKD.We hypothesise that pre-procedure optimisation decreases incidence and improves 
outcome of CIN. The aim of this study is to determine the incidence and outcome of CIN 
in CKD patients in our centre.
Methods: Consecutive patients with stage III-V CKD, undergoing peripheral (group 
1) or cardiac (group 2) angiography, at a regional Australian hospital between 2005-2015 
were included. Pre procedure optimisation included oral N-AcetylCysteine,intravenous 
hydration with Normal Saline and withholding Metformin and Frusemide. Low osmolality 
contrast diluted to 1/3 strength (group 1) or half strength (group 2) was used. CIN was 
defined as serum creatinine rise of >25% from baseline within 72 hours. Primary outcome 
was incidence of CIN. Secondary outcomes were mortality at 6 months, progression to 
dialysis and progression of CKD. follow up ranged from 2-73 months.
Results: 537 patients with CKD stage III-V underwent angiography. 222 patients 
concurrently dialysing were excluded. Median ages were similar in both groups (75years 
in group 1, 76years in group 2, P=0.25); diabetes was more prevalent in group 1 (70.5% 
versus 48.4%, P=0.001) and ischaemic heart disease more prevalent in group 2 (60.0% 
versus 44.3%, P=0.02). Median volume of contrast used was significantly lower for group 
1 (35mls, range 2.5-350mls) than group 2 (75mls, range 20-357mls) (P<0.001). The 
incidence of CIN was 3.7%. Incidence of CIN did not differ between groups (group 1= 
4.1%, group 2 = 3.2%, P=0.74). No patient with CIN died within 6 months or progressed 
to higher CKD stage or dialysis.
Conclusions: Pre procedure optimisation of CKD patients may reduce incidence of 
CIN. In our study,incidence of CIN in CKD patients was low and did not lead to death or 
progression of chronic kidney disease.
TH-PO063
AKI Risk Scores in Acute Admissions: Selecting the High-Risk or Missing 
the Vulnerable?  Amy Jeanne Riddell, Christopher J. Mulgrew.  Renal Unit, 
Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom.
Background: AKI commonly complicates acute illness. 2014 UK NICE AKI guidelines 
stress early identification of those at high risk. In patients with many co-morbidities, while 
risk scores in select groups have been studied, there remains debate as to the effective use 
of AKI risk scoring in 1y and 2y care populations (currently being investigated by the UK 
National AKI Programme). If correctly identified, steps could be taken to minimise risk and 
manage AKI earlier. Alternatively, should we not treat all acutely ill patients as ‘at risk’?
Methods: Review of acute admissions to the AMU on 4 weekdays between 
Mar’14&Mar’15. 158 cases were reviewed and risk scored based on NICE/KDIGO 
published risk factors. Any AKI, demographic data, specialist nephrology input, length of 
stay and overall outcomes were recorded.
Results: Of 158 patients, 35 (22%) had AKI during their hospital stay. Most had AKI1 
(24/35), vs AKI2 (7/35) and AKI3 (4/35). 28 had AKI on admission vs 7 after admission. 
Patients with AKI (at any time) had higher median scores (4, (0-9)) than non-AKI (2, (0-7)).
 The 7 post-admission AKI cases had a median score of 4 (2-5). Length of stay (LoS) 
was greater in AKI group (9.2d v 5.8d). AKI was due to sepsis/volume depletion in 68%, 
alongside other risk factors. There was one death in the AKI group (AKI3).
Conclusions: 2y care AKI risk scoring aims to identify those at high risk to prevent 
deterioration, but a greater challenge seems to be in 1y care than acute settings. Our data 
would suggest that while patients developing AKI post-admission may have a range of 
risk scores on arrival, with high scores correlating with AKI and LoS, the majority with 
AKI arrive from primary care with high scores. A validated risk score for use in 1y care, 
aiming to prevent admission, may be more more useful than stratifying all acute hospital 
admissions - are they not all ‘high risk’ anyway?
TH-PO064
Acute Kidney Injury Care Bundle Compliance in a Large District General 
Hospital in UK  Preetham Boddana, Shiva Sreenivasan, Israr Baig, Nerys 
Conway.  Renal Unit, Gloucestershire NHS Foundation Hospitals, Gloucester, 
Gloucestershire, United Kingdom.
Background: AKI is a common and harmful condition, which is often treatable and 
avoidable. The incidence of AKI in patients admitted to a hospital is approximately 3 – 7%. 
Gloucestershire Hospitals NHS Foundation Trust sees about 500 cases of acute kidney 
injury (AKI) monthly from a catchment population of 612,000.
Methods: An audit of patients with AKI showed deficiencies in care. We created an 
AKI care bundle (senior review, medication review, fluid balance, and repeat creatnine 
within 24 hours) for those patients with AKI, prompted by an AKI sticker for the case notes.
Results: For patients receiving an AKI flag, case notes were audited for appropriate 
use of the care bundle. We reviewed audit results over a 2-year period to see if the AKI 
bundles were being used appropriately and if patient care had improved. There has been 
improvement in AKI care bundle compliance. Figures up to August 2014 show that 
compliance for AKI care bundle use is 87%.
The compliance since its launch has generally exceeded the Commissioning for Quality 
and Innovation (CQuIN ) targets set in place by the project.
Conclusions: We have shown an improved care in patients with acute kidney injury by 
using an electronic alert system prompting early management. AKI can easily be identified 
and managed early and appropriately by frontline staff by frontline staff using an ALERT 
system. On going study is being taken place in our department to assess if this has reduced 
patient mortality, morbidity and length of stay in hospital.
TH-PO065
Reducing Post-CABG Acute Kidney Injury by Multipronged Preventive 
Interventions  Wisit Cheungpasitporn, Michael A. Mao, Charat Thongprayoon, 
Qi Qian.  Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Background: Acute kidney injury (AKI) post cardiac surgery is frequently a 
multifactorial event, associated with an increased morbidity and mortality. As AKI has no 
specific treatment, prevention is critical. This study aims to apply multipronged preventive 
measures to reduce AKI after coronary artery bypass grafting (CABG).
Methods: Prospective randomized interventional study. Non-dialysis and non-kidney 
transplant adults (³18 years old) undergoing elective CABG in March 2014-Feburary 2015 
were randomized (1:1 ratio) to control and intervention groups. The intervention group 
was intervened to minimize potential nephrotoxic conditions perioperatively (48 hours 
prior to the operation to 5 days postoperation). Outcome measures included the incidence 
and severity of post-CABG AKI using the AKIN criteria, length of hospital stay, discharge 
disposition and hospital mortality. Data from a similar cohort in March 2013-Feburary 
2014 were extracted and compared with the results from the control group to assess the 
spillover effects.
Results: Post-CABG AKI occurred in 19% (n=33) of the 174 patients in the intervention 
group; 30% (n=51) of the 172 in the control group, p=0.02, consistent with a 36% AKI 
risk reduction with the interventions [RR = 0.64 (95% CI: 0.44-0.94)]. Number needed 
to prevent one AKI was 10. The AKI severity was mostly mild and similar between the 
two groups; 98% and 94% were in stage 1 AKI in the control and intervention groups, 
respectively. Compared to non-AKI, AKI patients in both groups had a longer length of 
hospital stay and higher risk of being discharged to a care facility. No hospital mortality 
was noted in both groups. The AKI occurrence in the year prior to the study was similar 
to that in the control group.
Conclusions: Multipronged preventive measures can significantly reduce post-CABG 
AKI. The implementation of the preventive measures is uncomplicated. This approach can 
potentially be adopted in most hospital settings. These results should encourage initiatives 
towards developing AKI prevention protocols.
TH-PO066
Outcomes of Early Initiation of Continuous Renal Replacement Therapy 
in Elderly Patients with Acute Kidney Injury: A Multicenter Prospective 
Cohort Study  Jae Yoon Park,1 Dong Ki Kim,1 Hyung Jung Oh,2 Kwon Wook 
Joo,1 Yun Kyu Oh,1 Chun Soo Lim,1 Shin-Wook Kang,2 Yon Su Kim,1 Jung Tak 
Park,2 Jung Pyo Lee.1  1Seoul National Univ College of Medicine, Seoul, Korea; 
2Yonsei Univ College of Medicine, Seoul, Korea.
Background: Continuous renal replacement therapy (CRRT) is essential in the 
management of critically ill patients with acute kidney injury (AKI). However the optimal 
timing for initiating CRRT remains controversial, especially in elderly patients. Therefore 
we investigated outcomes of early initiation of CRRT in elderly patients with AKI.
Methods: A total of 616 patients aged equal or over 65 years who started CRRT due 
to AKI from August 2009 to December 2013 were enrolled prospectively at three centers. 
They were divided into 2 groups based on the median 6-hours urine output immediately 
before CRRT was applied.
Results: The mean age of both group was 74.3 years. The median 6-hours urine output 
was 80 mL. 186 patients (60.0%) were male in early initiation group and 179 patients 
(60.3%) in late initiation group. The most common cause of AKI was sepsis (45.9% versus 
46.0%). Mean arterial pressure was higher in early initiation group (79.8 mmHg versus 
76.8 mmHg). Prothrombin time-international normalized ratio, total bilirubin, aspartate 
aminotransferase and alanine aminotransferase were lower in early initiation group (P<0.05). 
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Overall cumulative survival and 28-days survival rates were higher in early initiation group 
(Log-rank P<0.001 for both). Furthermore, early CRRT treatment was associated with lower 
mortality rate after adjustment for age, sex, mean arterial pressure, Charlson comorbidity 
index, Sequential Organ Failure Assessment score, hemoglobin, serum C-reactive protein, 
serum albumin level and prothrombin time (hazard ratio, 0.752; 95% confidence interval 
0.595-0.951, P=0.008).
Conclusions: Early initiation of CRRT was associated with a better prognosis in 
critically ill elderly patients with AKI.
TH-PO067
Outcomes in Patients with Persistent Dialysis-Dependent AKI  Aedan Olaso, 
Daniel Tseytlin, Hope Kincaid, Sharon E. Maynard.  Lehigh 9alley Health 
Network, Allentown, PA.
Background: We sought to describe clinical characteristics & outcomes in patients 
with persistent dialysis-dependent AKI at the time of hospital discharge.
Methods: We performed a retrospective descriptive study of patients requiring dialysis 
for AKI at the time of hospital discharge in Lehigh Valley Health Network Subacute Dialysis 
Program between October 2012 & July 2014.
Results: Of 55 patients enrolled in the program, 26(47.3%) recovered renal function 
& 29(52.7%) developed ESRD. Clinical characteristics of these patients are shown below. 
The median duration of dialysis in the renal recovery group was 3.5 weeks. Although 75% 
of patients who recovered renal function did so by 5.1 weeks, 2/26(7.7%) recovered >3 
months after dialysis initiation. 
Clinical Characteristics Renal Recovery (n=26) No renal recovery (n=29)
Age 64 74
Comorbidities - n(%)
HTN
CHF
CAD
DM
Cerebrovascular ds
PVD
18 (69.2) 
5(19.2)
6(23.1)
16 (61)
3 (11.5)
4 (15.4)
25 (86.2)
10 (34.5)
10 (34.5)
10 (34.5)
1 (3.4)
3 (10.3)
Baseline creatinine (mg/dl) 1.3 2.0
Creatinine on hospital admission (mg/dl) 2.5 3.9
Creatinine on dialysis initiation (mg/dl) 5.2 5.5
Change in creatinine between week 3 & 4
after dialysis initiation -0.86* +0.13
Etiology - n (%)
ATN
Multiple myeloma
CIN
AIN
ANCA
CRS 
Acute renal allograft rejection
Other
15 (57)
0 (0)
2 (7.7)
1 (3.8)
1 (3.8)
3 (11.5)
1 (3.8)
2(7.7)
7 (24.1)
5 (17.2)
2 (6.9)
1 (3.4)
1 (3.4)
3 (10.3)
2 (6.9)
5 (17.2)
* Among those who recovered renal function but were still dialysis dependent at 4 weeks. 
Conclusions: This study indicates that patients who did not recover renal function 
were older & had higher creatinine levels at each time point than those who recovered renal 
function. While there was a decrease in serum creatinine from week 3 to week 4 in patients 
with renal recovery, there was an increase for those who did not recover. More patients 
who did not recover renal function had HTN, HF & CAD. Additionally, more patients 
who had ATN recovered renal function, while all patients with multiple myeloma did not. 
Hypothesis-testing studies are needed to explore whether or not these clinical characteristics 
may be used to predict which patients are likely to recover renal function and which are not.
TH-PO068
Acute Kidney Injury Episodes Accelerates Rate of Loss of Renal Function 
in Diabetes Mellitus  Charuhas V. Thakar,1,2 Anthony C. Leonard,1,3 Karthikeyan 
Meganathan,1,3 V. Shane Pankratz.4  1Internal Medicine, Univ of Cincinnati, 
Cincinnati, OH; 2Medicine, Cincinnati VAMC, Cincinnati, OH; 3Family 
Medicine, Univ of Cincinnati, Cincinnati, OH; 4Internal Medicine, Univ of New 
Mexico, Albuquerque, NM.
Background: Although acute kidney injury (AKI) is a risk factor for chronic kidney 
disease (CKD), whether it accelerates the rate of loss of estimated glomerular filtration 
rate (eGFR) is not known.
Methods: In a de-identified cohort of 3,678 type 2 diabetes patients we studied the 
impact of AKI on the rate of decline in eGFR. Patients with an entry eGFR of > 30 ml/min 
and at least two creatinine (Cr) values at least one month apart were followed until their 
eGFR was < 15 ml/min, death, or the end of the study. Cr measurements spanned over an 
average of 65 months. Estimated rates of linear eGFR decline were compared between those 
with and without AKI. We assessed the effect of AKI on the outcome of a rapid decline in 
eGFR (defined as > 5 ml/min/year) adjusting for demographics, proteinuria, and baseline 
CKD status (initial eGFR greater or less than 60) in a multivariable logistic model, and 
expressed this as odds ratios (OR) and 95% confidence limits (95% CI).
Results: Patients’ mean (standard deviation) age was 62 (11) years at study entry with 
an average eGFR of 79.7 (22.5). In 3,055 non-AKI patients the mean eGFR decline was 
2.7 vs 4.2 ml/min/yr in the 623 AKI patients (p < .0001). For 499 AKI patients with both 
pre and post-AKI eGFR slopes, the mean decline pre-AKI was 2.7 ml/min/yr versus 6.3 
ml/min/yr post-AKI (p = .03; paired t-test). In the non-AKI group 23.4% met the rapid 
decline outcome, compared with 36.0% in AKI group (p < .0001); within AKI patients, 
rapid decline occurred in 37% of patients pre-AKI and 46% post-AKI (paired OR = 1.4; 
95% CI, 1.1-1.8, McNemar p = .008). AKI was associated with rapid decline (OR 1.8; 
95% CI, 1.5-2.2; p < .0001), adjusted for age, gender, race, proteinuria, and CKD status.
Conclusions: Compared to no-AKI, diabetic patients with AKI experience an 
accelerated rate of decline in eGFR; and it occurs at twice the pace in the post- vs pre-AKI 
periods. Biological and process of care factors may be responsible for this effect.
Funding: Veterans Administration Support, Clinical Revenue Support
TH-PO069
Impact of Transient or Persistent Acute Kidney Injury on Chronic Kidney 
Disease Progression and Mortality After Gastric Surgery for Gastric Cancer 
Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim.  Dept of 
Internal Medicine, Chonnam National Univ Hospital, Gwangju, Republic of 
Korea.
Background: Acute kidney injury (AKI) was common after gastric surgery for gastric 
cancer and associated with adverse outcomes. However, impact of transient or persistent 
AKI on clinical outcomes after gastric surgery for gastric cancer has not been described. 
The objective of this study was to determine the incidence, factors, and clinical outcomes 
associated with transient or persistent AKI after gastric surgery.
Methods: We performed a retrospective study of 4,886 patients with normal renal 
function who underwent partial or total gastrectomy for gastric cancer between June 2002 
and December 2012. Transient AKI was defined as return of serum creatinine to the no-AKI 
range at discharge after gastric surgery. Our outcomes included occurrence of new-onset 
chronic kidney disease (CKD), and long-term kidney function and mortality.
Results: AKI occurred in 638 (13.1%) after gastric surgery. Of these, transient AKI 
was documented in 556 (87.1%). Length of intensive care unit (ICU) and hospital stay, 
and ICU admission rate (5.8% versus 1.0%) were higher in patients with transient AKI 
than in those without AKI. Male, use of diuretics and postoperative vasopressor, and lower 
baseline creatinine were common risk factors for persistent and transient AKI after gastric 
surgery. After adjusting for confounding factors, patient with transient and persistent AKI 
had a significantly higher new-onset CKD (odds ratio [OR], 1.62; 95% CI, 1.16–2.26, P 
=0.005; OR, 3.60; 95% CI, 1.77–7.34, P <0.001, respectively) and 1-year mortality (OR, 
1.75; 95% CI, 1.15–2.66, P = 0.009; OR, 12.70; 95% CI, 7.57–21.31, P <0.001, respectively) 
compared with no-AKI.
Conclusions: Not only persistent AKI but Transient AKI is associated with increased 
of hospital complications and a significantly higher risk of CKD progression and long-term 
mortality than patients without AKI after gastric surgery.
TH-PO070
Use of Non-Tunneled Versus Tunneled Catheters for Renal Replacement 
Therapy in Acute Kidney Injury  Mallika L. Mendu, Sushrut S. Waikar.  Div 
of Renal Medicine, Brigham and :omen¶s Hospital, Harvard Medical School, 
Boston, MA.
Background: Treatment of severe acute kidney injury requiring renal replacement 
therapy (AKI-RRT) requires vascular access, with either temporary, non-tunneled dialysis 
catheters (NTDC), or tunneled dialysis catheters (TDC). The relative risks and benefits of 
these two vascular access options have not been well studied.
Methods: We conducted a 1-year prospective cohort study in an academic medical 
center to compare outcomes between TDC and NTDC for AKI-RRT. We collected 
information about catheter placement including reasons for type of catheter used, number 
of insertion attempts, duration of use, and infectious and mechanical complications.
Results: Over one year we collected information on 140 NTDC and 80 TDC placement 
procedures on 154 patients with AKI-RRT. Compared to NTDCs, TDCs required fewer 
insertion attempts (1.0 vs. 1.5), had longer median duration of use (58.5 vs. 6.5 days), and 
had fewer infectious and mechanical complications (6% vs. 25%) (all p<0.001). The most 
common reasons for NTDC over TDC placement were immediate need for use (74%) and 
suspicion of systemic infection (21%). Tunneled line conversion (22%), infection (11%) and 
catheter not working (7%) were the most common reasons for NTDC removal. Infection 
(4%) was the most common reason for TDC removal.
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AKI Causes NTDC (N=140, N (%)) TDC (N=80, N (%))
Acute Tubular Necrosis 42 (30) 36 (45)
Hypotension 15 (11) 5 (6)
Ischemia 12 (9) 5 (6)
Prerenal 12 (9) 5 (6)
Hospital location 
Intensive care unit 133 (95) 39 (49)
Floor 7 (5) 41 (51)
Mean Insertion Attempts p-value
1.5 1.0 <0.001
Total Number of Complications 
(mechanical and infectious)
35 (25) 5 (6) <0.001
Median Days Duration of Use (IQR)
6.5 (4,10) 58.5 (12, 267) <0.001
Catheter Placement Characteristics 
Conclusions: Compared to NTDCs, the placement of TDCs was associated with fewer 
complications and longer duration of use in patients with AKI-RRT. In appropriate patients, 
TDCs should be the first choice for vascular access in AKI-RRT.
TH-PO071
Nonapnea Sleep Disorders and the Risk of Acute Kidney Injury: A 
Population-Based Retrospective Cohort Study  Hugo You-Hsien Lin,1,2,3 
Yu-Han Chang,1 Chi-chih Hung,1 Shang-Jyh Hwang,1 Hung-Chun Chen.1  1Dept 
of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, 
Taiwan; 2Div of Nephrology, Dept of Internal Medicine, Kaohsiung Medical 
Univ Hospital, Kaohsiung, Taiwan; 3Graduate Inst of Medicine, College of 
Medicine, Kaohsiung Medical Univ, Kaoshiung, Taiwan.
Background: Nonapnea sleep disorders (NASD) and sleep-related problems, which are 
high prevalent in patients with kidney diseases,are associated with cardiovascular disease, 
type 2 diabetes mellitus (DM) and chronic kidney disease (CKD). However, whether 
NASD is associated with acute kidney injury (AKI) development and prognosishave not 
been thoroughly investigated. The aim of this study is to determine whether NASD is an 
independent risk factor of AKI by using the database of National Health Insurance Research 
Database (NHIRD), which is one of the largest medical databases of the world.
Methods: The retrospective study used an 11-year nationwide database, which random 
sampled of 1,000,000 individuals covered by the National Health Insurance in Taiwan, 
to analyze the incidence.The patients with NASD were identified through diagnostic and 
medication codes. Kaplan-Meier and Cox regression analyses were performed.
Results: From 2000 to 2010, 9,316newly diagnosed NASD cases compared with 27,948 
control participants without sleep disorders randomly selected, frequency matched by age, 
sex, index year from the general population. We demonstrated that the NASD cohort had an 
adjusted hazard ratio (HR; 95% confidence interval [CI] = 1.16-1.71) of subsequent AKI 
1.44-foldhigher than that of the cohort without sleep disorders. Elder age, lower monthly 
income, hypertension, DM, cerebrovascular disease, CKD status, depression and higher 
Charlson comorbidity index were significant factors associated with the increased risk of 
AKI (p<0.05). Male and younger (age< 65 year-old) female increased significant risk of 
AKI development with NASD (HR=2.23; 95% CI = 1.57-3.16, p<0.001 ).
Conclusions: This nationwide population-based cohort study provides evidence that 
patients with NASD are at higher risk of developing AKI than people without NASD.
Funding: Clinical Revenue Support
TH-PO072
Subarachnoid Hemorrhage Induces Transient Renal Dysfunction 
Naoki Ikegaya,1 Kiyoshi Mori,5 Yasuhiro Yamamura,4 Mamoru Tomida,4 Seiya 
Takehara,4 Takuya Yoshida,6 Hiromichi Kumagai,6 George Seki,2 Akira Hishida.2 
1Dept of Medicine, Yaizu Cityl Hospital, Yaizu, Japan; 2Dept of Nephrology, 
Yaizu City Hospital, Yaizu, Japan; 3Dept of Neurology, Yaizu City Hospital, 
Yaizu, Japan; 4Dept of Neurosurgery, Yaizu City Hospital, Yaizu, Japan; 5Medical 
Innovation Center, Kyoto Univ Graduate School of Medicine, Kyoto, Japan; 
6Dept of Clinical Nutrition, Univ of Shizuoka, Shizuoka, Japan.
Background: Subarachnoid hemorrhage (SAH) is known to induce acute 
cardiovascular stress as reflected by ECG changes, and renal dysfunction is associated 
with poor prognosis in SAH. However, the precise effect of SAH on renal function and 
the possible mechanisms of renal dysfunction in SAH have not been fully understood.
Methods: First, we retrospectively analyzed renal function by serum creatinine (Scr) 
on day 1, 2, 3, 7, 14, and 28 in 317 patients with stroke including SAH, cerebral infarction 
(CI) and cerebral hemorrhage (CH). The relationship between renal dysfunction and ECG 
abnormalities including ST elevation, depression, negative T-wave was evaluated. Next, 
we prospectively analyzed urinary albumin, NGAL, and L-FABP and serum Cr and NT-
proBNP in 22 SAH patients on day 1, 2, and 14.
Results: The retrospective study showed that there was a significant transient increase 
(+40.7%) in Scr in patients with SAH in the first three days of the acute phase. However, 
no significant changes in Scr were observed during the course in patients with CI and CH. 
ECG abnormalities were observed in 57% of patients with SAH. In the prospective study, 
SAH patients showed increased levels of albuminuria and NT-proBNP on day 0, 1 and 14 
and NGAL on day1and 14. Eleven SAH patients with increased levels of NT-proBNP (more 
than 400 pg/ml) on day 2 showed significantly higher albuminuria (108 ±147 vs.21±11.8 
mg/gCr, p< 0.005 ) and urinary NGAL (67.5±101.7 vs. 17.5±15.0 ng/ml, p< 0.05) than 
eleven patients with lower NT-proBNP (less than 400 pg/ml).
Conclusions: Significant renal dysfunction was induced in the acute phase of SAH but 
not in CI and CH. Renal dysfunction was associated with NT-proBNP elevation, suggesting 
some interactions between heart, brain and kidneys.
TH-PO073
Acute Kidney Injury Post Nephrectomy in Living Donors?  Marilina Antonelou, 
Andrew Davenport.  Royal Free London NHS Foundation Trust.
Background: In 2014, the NHS UK introduced an AKI screening algorithm that was 
integrated into all UK biochemistry laboratories to report cases with AKI with 50% increase 
in serum creatinine. We aimed to measure the incidence of AKI in healthy living kidney 
donors post laparoscopic nephrectomy and determine whether this leads to reduction in 
renal function in the short term.
Methods: Retrospective data collection from 71 living kidney donors presenting 
between 2006-2011. We calculated serum creatinine (sCr) changes defined as stage 1 AKI 
as per the KDIGO guidelines (sCr increase by 26.5 umol/L within 48 hours or 1.5-1.9 times 
baseline increase) and stage 2 AKI (2.0-2.9 times baseline increase).
Results: 54.9% of patients developed AKI: 52.1% AKI stage 1 and 2.8% AKI stage 
2. The median age was 53 years (IQR 21-66 years) in the group of patients that developed 
AKI and 52 years (IQR 27-71 years) in the non-AKI group. 39.7% were males (26.8% 
with AKI) and 60.6% females (28.2% with AKI) (p 0.07). The AKI group had a lower 
mean sCr at baseline: 71±22.3 umol/L vs 84±18.0 umol/L (p =0.01). However, there was 
no difference in the CKDepi at baseline (91.6±18.6 ml/min in the AKI group vs 89±17.3 
ml/min, p=0.14) as well as the raw and adjusted for surface area isotopic EDTA-GFR at 
baseline (101±38.2 ml/min in the AKI group vs 96±22.9 ml/min (p= 0.31) and 89±20.2 
ml/min in the AKI group vs 86±16.2 ml/min (p=0.41) respectively). Post nephrectomy 
there was no difference in absolute renal function (CKDepi in the AKI group 62.8±15.4 
ml/min vs 60.2±10.7 ml/min, p=0.06) or change in renal function (33.4±16.5% decrease 
in CKDepi in the AKI group vs 35.4±14.0%, p=0.25) at 6 months.
Conclusions: Although 54.9% of patients fulfilled the diagnostic criteria for AKI as 
reported by the laboratory AKI screening algorithm this might not reflect actual kidney 
injury, and there were no differences in renal function measured after 6 months.
TH-PO074
Fluid Overload and Mortality in Neonatal Intensive Care Unit Patients 
Requiring Continuous Renal Replacement Therapy  Heeyeon Cho,1 Sang 
Taek Lee,1 Hye Won Park.2  1Dept of Pediatrics, Samsung Medical Center, 
Sungkyunkwan Univ School of Medicine, Seoul, Korea; 2Dept of Pediatrics, 
Seoul National Univ Bundang Hospital, Sungnam, Korea.
Background: Continuous renal replacement therapy (CRRT) has emerged as a 
favored modality in the management of the high risk neonates with acute kidney injury 
(AKI) and with inborn errors of metabolism. Recently, there are some reports that lesser 
degrees of fluid overload (FO) at CRRT initiation was associated with improved outcomes 
in children in pediatric intensive care unit (PICU). However, there has been little data that 
have analyzed the fluid status, risk factors, and outcome of neonates who receiving CRRT. 
The aim of this study is to evaluate the factors including FO associated with the outcome 
of neonates with CRRT.
Methods: A retrospective medical record review was performed 34 hemodynamic 
unstable neonates with AKI who underwent at least 48 hours of CRRT in neonatal intensive 
care unit (NICU) at Samsung Medical Center between January 2007 and December 2014. 
We divided into two groups with survivor (N=15) and non-survivor (N=19). Data were 
collected regarding demographic characteristics, fluid overload, CRRT parameters, and 
mean circuit time. Fluid overload from NICU admission to CRRT initiation, defined as a 
percentage equal to ^(CRRT initiation weight [kg]–NICU admission weight [kg])/NICU 
admission weight [kg]`x 100%. CRRT was initiated without anticoagulation, and decided 
to use the anticoagulation if the initial circuit lifespan was less than 12 hours.
Results: Survivors were more likely to have longer gestational age, fewer days in NICU 
prior to CRRT, lower percent FO at CRRT initiation, and higher urine output at the end of 
CRRT. There was no significant difference in mean daily effluent volume between survivors 
and non-survivors. Adjusted regression analysis revealed that FO at CRRT initiation was 
associated with mortality, duration of CRRT, and hospitalization period.
Conclusions: Fluid overload might cause mortality, prolonged hospitalization period, 
and duration of CRRT in neonates. Early initiation of CRRT before severe fluid overload 
might improve the outcome of neonates requiring CRRT.
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TH-PO075
Survival and Renal Outcomes following Transjugular Intrahepatic 
Portosystemic Shunt Placement in Hepatorenal Syndrome: A Case Series 
Guillermo Ortiz,1 Andrew S. Allegretti,1 Jie Cui,1 Julia Beth Wenger,1 Ishir 
Bhan,1 Raymond T. Chung,2 Ravi I. Thadhani,1 Zubin Irani.  1Nephrology Div, 
MGH, Boston, MA; 2Gastrointestinal, MGH, Boston, MA; 3Radiology, MGH, 
Boston, MA.
Background: Few effective treatment options are available for hepatorenal syndrome 
(HRS). There may be a role for the placement of a transjugular intrahepatic portosystemic 
shunt (TIPS) in reversing the pathophysiologic changes in HRS.
Methods: We performed a multicenter, retrospective review of patients who underwent 
TIPS placement concurrent to having HRS from 1995 to 2014 using a centralized clinical 
data warehouse. Two clinicians adjudicated HRS diagnosis and classified cases as Type 1 
(T1-HRS) or Type 2 (T2-HRS) based on review of medical records. Estimated glomerular 
filtration rate (eGFR), survival, and other parameters were assessed immediately before 
and after TIPS, and 90 days pre- and post-procedure.
Results: We identified 17 cases. Mean age was 54±12 years, 12 (71%) were male, 7 
(41%) had T1-HRS and 10 (59%) had T2-HRS. Median MELD score at time of procedure 
was 21 (quartile 1, quartile 3: 14, 33). TIPS significantly reduced portal pressure gradient 
from16 (14, 20) to 7 (5, 8) mmHg (p<0.001). Median eGFR 90 days pre TIPS was 50 
(37-77) mL/min; TIPS significantly improved eGFR from 32 (28, 35) pre-TIPS to 47 (38, 
55) mL/min post-TIPS (p=0.003) and 69 (63,97) mL/min at 90-days post TIPS (p=0.006).
Ninety-day survival was 53%; 1 subject (6%) received a liver transplant during 
follow-up.
Conclusions: TIPS improves eGFR in HRS post-procedure and at 90 days follow-up. 
Further study is needed to identify those who would benefit from the procedure.
TH-PO076
Evolution of the Management of Multiple Myeloma and Impact on Survival 
and Dialysis Independence  Manon Laforet, Noemie Jourde-chiche, Stephane 
Burtey, Bertrand Gondouin.  Centre de Nephrologie et Transplantation Rénale, 
Assitance Publique Hopitaux de Marseille, Marseille, France.
Background: During the past decade, the management of myeloma has evolved. 
Several studies found an improved disease-free survival since the late 2000s with the 
advent of new molecules in first line chemotherapy (Bortezomib and / or IMiDs (Revlimid, 
Thalidomide). Nevertheless, this benefit is mostly seen in patients of less than 65 years old 
and survival and renal outcomes are not well studied in elder patients. Our study aimed to 
compare two cohorts of patients according to the period of treatment: before or after 2008 
focussing on global and renal outcomes.
Methods: We retrospectively collected clinical and biological data of 135 patients 
admitted to the University Hospital of Marseille from 1999 to 2014 with a diagnosis of 
multiple myeloma and acute renal injury (as defined by an increase in serum creatinine 
above 120 mcmol/L). We separated this cohort based on the year of admission (<or> to 
2008, respectively group 1 and group 2). The parameters studied were: overall survival 
and dialysis independence 2 years after initial chemotherapy.
Results: 88 patients were included in group 1 and 47 in group 2. No differences were 
seen in terms of baseline characteristics between groups: median age (67.1 vs 70.2), sex ratio, 
conventional biological parameters. A higher proportion of relapsing patients was found 
in group 2 (10/47 (22%) in group 2 versus 9/88 (10%) in group 1). A higher proportion of 
dialysis dependent patients at diagnosis was found in group 2 (26/47, (55.3%) in group 2 
versus 36/88 (40%) in group 1). No difference was seen in terms of overall survival or 
dialysis independence 2 years after diagnosis of AKI when group 2 was compared to 
group 1 (OR 1.9 (0.8-4.1) and HR 0.7 (0.4-1.2) respectively).
Conclusions: In our cohort, we did not observe any benefit on overall survival or 
dialysis independence at 2 years according to the treatment period. Our results are not in 
accordance with previous papers. Our patients were older with a high proportion of dialysis 
dependance at diagnosis. More studies are needed to clarify the benefit of the use of novel 
agents in older patients with severe AKI.
TH-PO077
Effect of Genes Involved in Endogenous Ouabain Synthesis on the 
Development of AKI After Cardiac Surgery  Marco Simonini, Simona 
Pozzoli, Elena Frati, Elena Bignami, Lorena Citterio, Chiara Lanzani, Nunzia 
Casamassima, Guido Gatti, Paolo Manunta.  San Raffaele Scientific Inst, Italy.
Background: Acute kidney Injury (AKI) is an important complication of cardiac 
surgery. Elevated levels of Endogenous Ouabain (EO), an adrenal stress hormone with 
haemodynamic and renal effects, have been associated with worse renal outcome after 
surgery. Polymorphisms in candidate genes related to EO synthesis, as LSS (lanosterol 
synthase) and HSD3B1 (steroid dehydrogenase), have been described to be involved in 
determination of EO activity. Aim of this work is to investigate the relationship between 
these genes and the development of AKI.
Methods: 700 consecutive patients, undergoing cardiac surgery at our Hospital, were 
genotyped. The primary outcome was AKI according to Acute Kidney Injury Network. 
Secondary outcomes were length of ICU stay and total in-hospital mortality. Total AKI 
incidence was 25.1%.
Results: No difference in basal EO plasmatic levels was observed according to LSS 
or HSD3B1. Patients carrying the derived alleles of the LSS studied polymorphism had 
a more severe clinical presentation (EuroSCORE: 5.17±4.81 vs 4.88±5.74 vs 3.54±3.49; 
p=0.05). Likewise, AKI incidence according to LSS polymorphism was greater (34.9% 
vs 27.5% vs 21%; p=0.029). Even after adjustment for the main covariates (sex, age, 
eGFR, EF, hypertension, DM, type of surgery and EuroSCORE) results remain significant 
(AKI logistic regression: Exp(B) 1.97, IC95% 1.05-3.70; p=0.038). Finally, in a higher 
percentage of the same patients (25.5% vs 17.0% vs 12.6%) i.v. furosemide was used in 
the immediate post-operative time to maintain adequate diuresis. No other effects of LSS 
or HSD3B1 were observed.
Conclusions: Patients with at least one derived allele of LSS polymorphism 
investigation have a greater chance of developing AKI after cardiac surgery, despite on 
clinical presentation. Moreover, in a higher percent of the same patients, i.v. furosemide 
was needed to maintain adequate diuresis. These effects appear to be independent on EO 
plasmatic levels. We believe that these preliminary findings could be interesting for the 
identification of new cellular mechanisms undergoing the development of post-surgical AKI.
TH-PO078
Obstructive Nephropathy in Ovarian Hyperstimulation Syndrome and 
Successful Delivery  Katherine M. Wang, Syed S. Haqqie, Arif Asif.  Albany 
Medical Center, Albany, NY.
Background: Ovarian hyperstimulation syndrome (OHSS) is a well-described 
iatrogenic complication of exogenous gonadotropin administration preceding in vitro 
fertilization (IVF). Underlying pathophysiology stems from influx of reproductive 
hormones and inflammatory vasoactive mediators that increase capillary permeability and 
cause intravascular volume depletion due to large fluid shifts into the interstitial space. 
Most cases are mild and can be managed on an outpatient basis with close monitoring. We 
present an intriguing and rare case of severe OHSS with acute renal failure secondary to 
obstructive nephropathy. Our patient is a nulliparous 38 year old black female stimulated 
with beta-human chorionic gonadotropin (β-hCG) prior to transfer of fresh embryos 
resulting in a diamniotic dichorionic twin gestation. She presented to the OB-GYN service 
with progressive ascites, gaining 17 kg in 1 week, and also acute renal failure due to 
mechanical obstruction of both ureters from bilaterally enlarged fluid-filled ovaries. Initial 
ultrasonography estimated the dimension of the left ovary at 22 cm, containing 1.7 L of 
fluid volume. Her baseline creatinine of 0.8 mg/dL peaked at 5.8 mg/dL prior to placement 
of bilateral nephrostomy tubes, which led to rapid and effective relief of obstruction and 
normalization of kidney function within days.At follow-up, patient had spontaneous 
intrauterine demise of one fetus at 9 weeks; however, she successfully delivered the other 
fetus preterm at 35 weeks gestational age via C-section. The nephrostomy tubes remained 
in place for the duration of her pregnancy. This case highlights a rare presentation of a 
well-known, but potentially life-threatening complication of ovarian induction, which has 
become an increasingly popular treatment for infertility.
Methods: Cinical couorse of the patient during the entire pregnancy and the outcome.
Results: Successful fetal outcome.
Conclusions: Patient presented with severe obstructive uropathy from very large 
kidneys from hyperstimulation resulting in acute renal failure and bilateral nephrostomy 
tube placements.  This resulted in release of obstruction, normalization of renal function, 
and a successful delivery.
TH-PO079
Analysis of the VA/NIH Acute Renal Failure Trial Network Data: 
Comparison of Outcomes in Nutrition Delivery in Acutely Dialyzed Patients 
Youngho Kim, V. Shane Pankratz, Eduardo A. Alas, Christos Argyropoulos, 
Mark L. Unruh.  Div of Nephrology, Univ of New Mexico School of Medicine, 
Albuquerque, NM.
Background: The optimal nutrition management for acute kidney injury (AKI) is not 
well defined and recommendations for nutritional support in acutely ill patients who undergo 
renal replacement therapy (RRT) are largely based on expert opinion.
Methods: In order to better understand associations between nutrition and outcomes 
of critically ill patients with AKI requiring RRT, we analyzed data available from the ATN 
study. Patients were classified by nutritional support provided at the time of enrollment 
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into the following groups: NPO, Tube feed (TF), Total parenteral nutrition (TPN), and 
Oral (PO). Two competing outcomes were considered: mortality and continued dialysis 
dependency among survivors.
Results: Characteristics among groups were similar. ICU predictive scoring systems 
and disease etiology were strongly associated with mode of nutrition delivery. High ICU 
predictive score and a surgical primary treating service were associated with a higher 
percentage of patients treated with TPN. There were significant differences in 60-day 
outcomes among nutrition groups (p=0.011) [Figure 1]. Notably, PO group had better 
survival and RRT independency. After adjustment for patient characteristics, the strength 
of association between mode of nutrition delivery and outcomes weakened and was not 
statistically significant (p=0.106), although the patterns of association were similar to the 
unadjusted analyses with TPN having the highest and PO the lowest adjusted risks of death 
and continued dialysis dependency.
Conclusions: There was no significant global association between baseline nutrition 
modalities and 60-day mortality or 60-day dialysis dependence. Further investigation could 
be performed to prospectively elucidate the benefit of enteral vs. TPN feeding in AKI.
TH-PO080
Pilot Trial of Dietary Restriction for Protection from Acute Kidney Injury 
in Cardiac Surgery  Franziska Grundmann, Torsten Kubacki, Roman-Ulrich 
Mueller, Maximilian Scherner, Michael Faust, Ingrid Becker, Martin Späth, 
Marc Johnsen, Thomas Benzing, Volker Rolf Burst.  Univ of Cologne, Cologne, 
Germany.
Background: Even small acute changes in kidney function as a result of acute kidney 
injury (AKI) can result in short-term and long-term complications including chronic kidney 
disease, end-stage renal disease and death. However, despite an increasing incidence of 
AKI few preventive and therapeutic options exist. Short-term reduction of calorie intake 
has been shown to provide effective protection from ischemic AKI in mice.
Methods: In this single-center randomized controlled trial (ClinicalTrials.gov Identifier: 
NCT01534364) 82 patients with at least one risk factor for postsurgical AKI scheduled for 
cardiac surgery (CABG, valve replacement) were randomly assigned in a 1:1 ratio into a 
diet group (DG: 60% of calculated energy expenditure for 7 days prior to surgery) or an ad 
libitum food intake control group (CG). The intention-to-treat population encompassed 76 
patients. The primary endpoint was defined as the change in serum creatinine from baseline 
to 24 hours after surgery, secondary endpoints included incidence of AKI (KDIGO criteria).
Results: Demographic and surgery associated characteristics were similar in both 
groups (DG 80% male vs. CG 77.5% male; age: DG 72y[63-76] vs. CG 75y[70-77], body 
weight: DG 84.6kg[72.-91.7] vs. CG 79.1kg[75.0- 72.7], crossclamp time: DG 59min[52-
82] vs. CG 59min[44-82]). Average calorie intake in the DG was 1323 kcal and a 3 kg[-
4.0 to -2.2] weight loss was observed (no weight change in the CG). With respect to the 
primary outcome measure there was no difference between the groups. Overall incidence 
of AKI was similar in both groups with considerably less patients with stage 1 AKI in the 
DG (n.s.). Length of stay, need for renal replacement therapy and mortality did not differ.
Diet Group Control Group
no AKI 21(58.3%) 21(52.5%)
KDIGO 1 7(19.4%) 13(32.5%)
KDIGO 2 6(16.7%) 5(12.5%)
KDIGO 3 2(5.6%) 1(2.5%)
Conclusions: Dietary restriction is safe and feasible in patients awaiting cardiac 
surgery. Despite its beneficial effect in animal studies restriction of calorie intake did not 
alter serum creatinine dynamics or AKI incidence after cardiac surgery.
Funding: Pharmaceutical Company Support - Fresenius Kabi
TH-PO081
Minute Ventilation-Targeted Adaptive Servo Ventilation Reduces 
Kidney Injury in Patients with Acute Decompensated Heart Failure 
Matt Kawahara,3 Boris Arbit,1 Elizabeth Lee,3 Trenton Gluck,3 Kathleen 
Sarmiento,2 Atul Malhotra,2 Alan S. Maisel.1  1Div of Cardiovascular Medicine, 
Univ of California, San Diego, La Jolla, CA; 2Div of Pulmonary and Critical 
Care Medicine, Univ of California, San Diego, La Jolla, CA; 3Cardiac Research, 
9A San Diego Healthcare System, La Jolla, CA.
Background: Acute kidney injury (AKI) is a frequent comorbidity in patients admitted 
for acute decompensated heart failure (ADHF). Minute ventilation targeted adaptive servo 
ventilation (MV-ASV) relieves apneas, pulmonary congestion, and renal hypoxia. Kidney 
injury molecule (KIM-1) is a marker of AKI and could be used to detect early injury and 
the improvement of kidney function. MV-ASV may mitigate AKI in patients admitted of 
ADHF compared to standard care.
Methods: This is a pilot study in which twenty-one consecutive patients with ADHF 
were randomized to receive either MV-ASV therapy (S9 VPAP Adapt, ResMed Corp.) with 
standard care, or standard care alone. MV-ASV therapy was administered for a minimum 
of six hours per day for up to 5 days, or until discharge. Daily measurements of plasma 
KIM-1 were obtained with SMC™ technology (Singulex). Daily serum creatinine levels 
were measured and used to calculate eGFR.
Results: Median baseline KIM-1 levels in the MV-ASV and standard groups were 
312pg/mL and 361pg/mL, respectively. In the control group KIM-1 increased 18 % to 
426pg/mL while the group with MV-ASV demonstrated a mitigation of kidney injury 
with a 7% decrease to 290pg/mL. These changes correlated with subsequent changes in 
serum creatinine and eGFR.
Conclusions: The use of MV-ASV therapy resulted in mitigation of kidney injury 
typically seen in patients with ADHF during hospitalization.
Funding: Pharmaceutical Company Support - Resmed
TH-PO082
Early Volume Expansion Improves the Outcome of Shigatoxin-Associated 
Hemolytic Uremic Syndrome – Data from the North Italian HUS Network 
Gianluigi Ardissino,1 Francesca Tel,1 Ilaria Possenti,1 Sara Testa,1 Dario 
Consonni,2 Stefania Salardi,1 Rosaria Colombo,3 Erminio Torresani.3  1Center 
for HUS Prevention, Control and Management, Fondazione IRCCS Ca¶ 
Granda, Ospedale Policlinico, Milan, Italy; 2Unit of Epidemiology, Fondazione 
IRCCS Ca¶ Granda, 2spedale Policlinico, Milan, Italy; 3Unit of Microbiology, 
Fondazione IRCCS Ca¶ Granda, 2spedale Policlinico, Milan, Italy.
Background: Shigatoxin-associated hemolytic uremic syndrome (STEC-HUS) 
is a severe disease which has no specific treatment and among supportive care, fluid 
management is concentrated on preventing fluid overload because of oligo/anuric AKI. 
Hemoconcentration is associated with more severe disease, but it is unknown whether 
volume expansion (VE) can improve disease outcome. A network of pediatric hospitals 
has been operating in Northern Italy with the aim of early diagnosis and referral of STEC 
infections and to investigate the efficacy of VE to minimize disease severity.
Methods: All children with STEC-HUS referred to our centre in 2012-2014 received 
intravenous saline targeted at inducing a moderate VE (+10% of working weight) on the 
basis of the hypothesis that prompt restoration of circulating volume can limit thrombi 
formation and ischemic tissue damage. Their short- and long-term outcomes were compared 
with those of 38 patients (pts) referred to our centre during the years immediately before 
the network was established, when their fluid intake was routinely restricted.
Results: The pts undergoing VE showed a mean increase in body weight of 12.5%vs0% 
in their predecessors and had significantly better short-term outcomes with a reduced rate 
neurological involvement (7.9%vs23.7%,p 0.059), less need for dialysis (26.3%vs57.9%,p 
0.005) or intensive care support (median 8.5,IR 3.5-15.5vs2.0,IR 1-4.5 days,p 0.022), and 
required fewer days of hospitalisation (median 12.0, IR 7.0-18.0vs9.0,IR 7.0-12.0 days,p 
0.025). Long-term outcomes were also significantly better in terms of renal and extra-renal 
sequels (13.2%vs39.5%,p 0.009).
Conclusions: Pts with STEC-HUS benefit greatly from VE. Early and generous fluid 
infusions can reduce thrombi formation and ischemic organ damage, and thus have positive 
effects on both short- and long-term disease outcomes.
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TH-PO083
Role of Statins on Contrast-Induced Nephropathy in Patients Undergoing 
Percutaneous Coronary Intervention  Ricardo M. Heguilen, Amelia R. 
Heguilen, Martin J. Ortemberg, Amador A. Liste.  Nephrology, Hospital Juan 
A Fernandez, Buenos Aires, Argentina.
Background: The occurrence of contrast-induced kidney injury (CIAKI) increased 
and is responsible for ~10% episodes of hospital-acquired AKI. The mechanism of renal 
dysfunction is incompletely understood; vasoconstriction, hyperosmolarity, free radicals 
and direct toxicity may play additive roles. Statins reduce O2 stress, increase renal NO and 
may prevent AKI. The aim of this retrospective study was to analyse the association between 
statin and the development of RCIN, defined by an increase in SCr >25 % 48–72 h after 
the administration of low osmolar contrast agents, in high risk patients (Ps) undergoing 
percutaneous coronary intervention (PCI).
Methods: Data from 165 consecutive adults with SCr >1.25 mg/dl,undergoing non-
emergent PCI during a 24- mo period were assessed. All had received prophylaxis for 
RCIN (volume expansion + NAC). 31 Pts were removed due to absence of follow up SCr 
data or lacked information on statin use. Continuous variables are expressed as mean (sd) 
and categorical variables as frequency. Unpaired t-test, chi2 or Fischer’s exact test were 
used as appropriate. Those variables resulting significantly related to RCIN on univariate 
analysis, were included in a multivariate logistic regression model. P-values <0.05 were 
considered significant.
Results: 134 Pts met the admission criteria; 67 were on statins prior PCI. Both groups 
had similar clinical, and laboratory baseline conditions. 18Pts (13.4%) developed RCIN. 
There was a lower incidence of RCIN among Pts on statins (4.47%) vs. those not on statins 
(22.4%) (OR: 0.16; 95% CI: 0.04–0.59; P = 0.004). Multivariate logistic regression revealed 
that, after adjusting for covariates with significant association with RCIN in the univariate 
analysis (diabetes, hiponatremia, etc),statins demonstrated to be an independent predictor 
of decreased risk for RCIN.
OR 95% CI p value 
Statin 0.14 0.037 - 0.5653 0.005
DBT 3.67 1.168 - 11.540 0.026
HypoNa 2.45 0.728 - 8.262 0.148
Conclusions: Our data suggest that statin use before PCI reduces the risk of RCIN. 
Further prospective, well designed, randomized clinical trials in a larger number of 
individuals are necessary to confirm these findings.
TH-PO084
Statin Use and Survival After Acute Kidney Injury  Sandeep Brar, Neesh I. 
Pannu.  Dept of Medicine, Univ of Alberta, Edmonton, AB, Canada.
Background: The incidence of acute kidney injury (AKI) in hospitalized patients is 
rising, and there is a lack of effective therapies for treatment. Recent studies suggest that 
nephrology follow-up may reduce long term mortality after AKI; however, the processes of 
care that underlie this finding remain unknown. The objective of this study was to determine 
if statins which are of known benefit in chronic kidney disease (CKD) are also associated 
with improved mortality in survivors of AKI with CKD.
Methods: Retrospective cohort study of adults 65 years of age or older, residing in 
Alberta, who were admitted to hospital between 2002 and 2011, developed AKI during 
the index hospitalization and progressed to CKD (n= 27,470 mean age 78.7 years, mean 
post-discharge eGFR 49.6 mL/min/1.73m2).
Results: Within two years of discharge, only 39.1% of the participants received 
a statin. Over a subsequent two-year follow up period, the adjusted hazard ratio (HR) 
(95% confidence interval [95% CI]) for mortality associated with use of a statin was 0.64 
(0.59, 0.69). Patients who received a statin also had a lower risk of cardiovascular events 
(adjusted HR, 0.87; 95% CI, 0.80, 0.94) and all cause re-hospitalization (adjusted HR, 
0.81; 95% CI, 0.77, 0.84).
Conclusions: Among AKI survivors with CKD, statin use was associated with 
decreased mortality, cardiovascular events and re-hospitalization rates.
TH-PO085
Effect of Rosuvastatin on Acute Kidney Injury (AKI) in Sepsis-Associated 
Acute Respiratory Distress Syndrome (ARDS)  Raymond K. Hsu,1 Jonathon 
Truwit,2 Michael Matthay,1 Joseph Levitt,3 Boyd Taylor Thompson,4 Kathleen 
D. Liu.1  1UCSF; 2Medical College of Wisconsin; 3Stanford; 4MGH-Harvard.
Background: While statins may be protective in animal models of sepsis-induced 
AKI, few human studies have addressed this question.
Methods: We analyzed data from the NHLBI ARDS Network Statins for Acutely 
Injured Lungs in Sepsis (SAILS), a multicenter randomized controlled trial. 745 patients 
with sepsis-associated ARDS were randomized to receive rosuvastatin or placebo. Subjects 
who had AKI at enrollment and subjects with new or worsening AKI were defined by 
KDIGO creatinine-based AKI criteria. In a secondary analysis, we corrected serum 
creatinine (SCr) for cumulative fluid balance. The association between statin and AKI was 
modeled using logistic regression.
Results: 644 subjects did not have ESRD and had available SCr data. Age, sex, race, 
baseline SCr, and severity of illness were similar in the 2 treatment arms. Among the 511 
without AKI at enrollment, AKI incidence was similar in the two groups (38% statin vs 
40%, P=0.66). The association remained non-significant after adjustment for demographics 
and severity of illness, and after correcting SCr for fluid balance. Among 93 subjects with 
stage 1 AKI at enrollment, the statin arm had a higher incidence of worsening AKI (61% 
vs 41% placebo, P=0.06). The association was strengthened after adjustment (OR 3.06, 
P=0.03). However, in the secondary analysis using fluid-corrected SCr, rosuvastatin was 
not associated with worsening AKI.
Risk of new AKI in patients without AKI at 
enrollment (n=511)
OR (Rosuvastatin vs 
Placebo) P
Crude 0.92 (0.65-1.32) 0.66
Adjusted 0.99 (0.67-1.44) 0.94
Crude + SCr corrected for fluid balance 0.84 (0.59-1.21) 0.35
Adjusted + SCr corrected for fluid balance 0.91 (0.63-1.34) 0.64
Risk of worsening AKI in patients with stage 1 AKI 
at enrollment (n=93)
Crude 2.26 (0.97-5.24) 0.06
Adjusted 3.06 (1.14-8.22) 0.03
Crude + SCr corrected for fluid balance 1.41 (0.61-3.27) 0.42
Adjusted + SCr corrected for fluid balance 1.85 (0.70-4.84) 0.21
Conclusions: Rosuvastatin did not prevent de novo AKI, and may have led to worsening 
of pre-existing AKI in patients with sepsis-associated ARDS.
Funding: NIDDK Support, Other NIH Support - NHLBI
TH-PO086
Potential Nephroprotective Effects of Carnitine and Phosphodiesterase-5 
Inhibitor Therapy in Contrast-Induced Nephropathy  Zaher Anis Armaly,1 
Suheil Artul,2 Adel Rafik Jabbour,3 Raymond Farah,4 Amir Abd Elkadir,1 
Bishara Bisharat.1  1Dept of Nephrology, E.M.M.S. Hospital, Bar Ilan Univ, 
Nazareth, Israel; 2Dept of Radiology, E.M.M.S. Hospital, Nazareth, Israel; 
3Dept of Biochemical Laboratory, (.M.M.S. Hospital, Nazareth, Israel; 
4Internal Medicine “B”, Ziv Medical Center, Faculty of Medicine, Bar Ilan 
Univ, Safed, Israel.
Background: Contrast induced nephropathy (CIN) is connected with , prolonged 
hospitalization, need for dialysis and increased morbidity and mortality. The current 
available prophylactic measures are not sufficient to protect against CIN. Therefore, 
there is unmet need for novel therapeutic agents to prevent the development of CIN. This 
study examines whether phosphodiesterase type 5 (PDE-5) inhibitor or carnitine exert 
nephroprotective effects in individuals undergoing imaging that involves radiocontrast 
media (CM) administration as compared with N- acetyl Cysteine.
Methods: The study included 3 arms of patients with CKD (stage 3-4) as follows:1- 
Control group (n=14 ), who were treated with Acetylcysteine of 600 mg twice daily, day 
before and on the day of CM administration; 2- Carnitine group (n=10), where the patients 
were infused with 20 mg/kg carnitine over 10 minutes 2 h prior to the CM administration 
and 24 hours post CT; 3- Phosphodiesterase type 5 inhibitor group (n= 12), where patients 
were given orally 20 mg tablets of PDE5 inhibitor-Tadalafil 2 h prior to the administration 
of the CM and in the subsequent day. Urine and blood samples were collected before and 
at the following time sequence: 2, 6, 12, 24, 48, 120 hours after the contrast administration, 
for creatinine and NGAL determination.
Results: Administration of CM to CKD patients who were pretreated with Acetyl 
cysteine caused a significant increase in urinary NGAL, but not of plasma NGAL and 
SCr. In contrast, pretreatment with carnitine prior to CM prevented the increase in urinary 
NGAL throughout the follow up period and reduced SCr below basal levels. Similarly, 
tadalafil administration attenuated the elevation in CM-induced urinary NGAL, but did 
not affect neither plasma NGAL nor Scr.
Conclusions: These results suggest that carnitine and PDE-5 inhibition may comprise 
novel nephroprotective approaches aganist CIN.
TH-PO087
Acute Interstitial Nephritis: Case Series, 1998-2015  Xuemei Li.  Nephrology, 
Peking Union Medical College Hospital, Beijing, China.
Background: Acute interstitial nephritis (AIN) is an important cause of acute kidney 
injury. The time and effectiveness of steroids for treatment of AIN is debated.
Methods: Study Design: Case series. Study population: 40 cases with acute interstitial 
nephritis(secondary AIN was excluded) conformed by renal biopsy in PUMC hospital 
between 1998 and 2015 years were analysed. Outcomes: The complete recovery was 
defined as improvement in serum creatinine level to 124umol/L; partial recovery as a 50% 
decrease in serum creatinine level from its peak value, but not reaching to 124umol/L; and 
no recovery as failure to meet criteria for complete or partial recovery or remaining on 
renal replacement therapy.
Results: The causes were not available in most cases (63%), 15% were identified 
due to drugs. Infectious causes were 13%. Idiopathic AIN were 10%. 68% patients had 
no records of baseline serum creatinine levels, which were available for 13 patients only 
(106±14.7umol/l), and 5(38%) patients had CKD as defined by baseline eGFR <60 mL/
min/1.73 m2. 30% patients had hematuria. 33% patients had glycosuria. Some degree 
of proteinuria (less than 1g/L) was present in 75% of patients. 60% patient had aneamia 
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(105±14.8). Most of the patients had normal urine output. 5 patients (12.5%) had larger 
kidney in ultrasound. 33 patients (83%) used steroids treatment.The periods of steroid 
treatment were 12±4.7months. The time which began to use steroids was 33±15.2days from 
SCr increased. The doses of steroid were 49±10.1mg/d. The SCr level was 210±83.8umol/l 
when started steroid treatment. Only 5 patients (13%) added immune inhibits. Of the 
40 patients, 48%, 38%, and 10% had complete, partial, and no recovery respectively in 
discharge. 65% had normal renal function and 30% had CKD by 15±9.7 months. Of the 
6 patients who required dialysis or CRRT, no patients were still on dialysis therapy in 
discharge, all of whom had drug-induced AIN. No patients had ESRD, with no difference 
by cause of AIN.
Conclusions: The cause of AIN may be different. Steroid treatment may be effective 
in recovery of kidney function of AIN.
TH-PO088
Causality Assessment in Determining Drug-Induced Renal Injury 
Celina D. Cepeda, Linda Awdishu, Etienne Macedo, Ravindra L. Mehta. 
Nephrology, Univ of California San Diego, San Diego, CA.
Background: Drug induced renal injury (DIRI) accounts for 18-27% of cases of 
acute kidney injury (AKI) and is usually recognized based on the timing and duration of 
drug exposure.The Naranjo (NJ) and Liverpool (LP) causality assessment tools (CAT) are 
validated for identifying adverse drug reactions and serious skin reactions, respectively. 
We hypothesized that inter-rater and inter-tool agreement using the two CAT would not 
be specific to identify DIRI.
Methods: Thedrug induced renal injury (DIRECT) study is an ongoing prospective 
multicenter study evaluating genetic determinants of DIRI. Each enrolled case was 
adjudicated for causality by two independent nephrologists. We analyzed the first consecutive 
86 adult (n= 69) and pediatric (n=17) AKI cases. Two nephrologists adjudicated each case 
and used both CAT to determine likelihood of AKI due to a particular medication(s). We 
determined inter-rater and inter-tool agreement using percent agreement and kappa scores.
Results: Adjudicators agreed 87.2% (n=75) had DIRI. A single drug was involved in 
54.7% (n=47), 2 drugs in 37.2% (n=32), and 3 drugs in 8.1% (n=7) of cases. The inter-
rater agreement was better with the NJ  vs LP tool (61.6% vs 48.8%) and was significant 
for adults (p=<0.038) however the inter-tool kappa score was slight (0.181) and was fair 
(kappa 0.325) for pediatric patients (p=0.006).
Table 1. Percent Agreement and Kappa Values for Drug 1
Inter-rater Inter-tool
Categories Naranjo Liverpool
All Cases
% Agreement
Kappa
61.6
0.251 (p=0.01)*
48.8
0.140 (p=0.04)*
50
0.181 (p=0.001)*
DIRI 58.70.206 (p=0.052)
52
0.049 (p=0.557)
49.3
0.109 (p=0.074)
No DIRI 81.80 (p=1)
27.3
0.064 (p=0.489)
54.5
0.16 (p=0.147)
1 Drug 57.40.199 (p=0.126)
57.5
0.250 (p=0.011)*
58.5
0.312 (p<0.001)*
Adult 59.40.224 (p=0.038)*
49.3
0.154 (p=0.026)*
47.8
0.142 (p=0.017)*
Pediatric 70.60.351 (p=0.116)
47.1
0.131 (p=0.441)
58.8
0.325 (p=0.006)*
*, denotes significant p-value <0.05
Conclusions: For most categories, inter-rater percent agreement and kappa scores were 
superior using the NJ tool. Neither tool had better than moderate inter-rater agreement. 
Agreement between the tools was at best fair in determining likelihood of DIRI.  Better 
causality assessment tools need to be developed for DIRI.
Funding: Private Foundation Support
TH-PO089
Gadolinium Nephrotoxicity  Kamlesh Reddy Kurre, Ashraf El-Meanawy, 
Sameer Gupta.  Nephrology, Zablocki VA Medical Center, Milwaukee, WI.
Background: Gadolinium-based contrast (GBC) agents are widely used as contrast 
agents for magnetic resonance imaging (MRI) and have generally been considered to be 
safe. Early on, phase III trials and small studies in low-risk patients suggested a benign renal 
profile; however, more recent studies raised the possibility of nephrotoxicity. In the US, 
approximately 34.9 million MRI scans were performed in 2014 and in 45% of these cases 
a gadolinium chelate was administered. As with iodinated radiocontrast agents, concern 
for contrast-induced nephropathy existed with gadolinium-contrast as it possessed many 
similar qualities (hyperosmolar, renal excretion via glomerular filtration). Gadolinium-
based contrast agents have recently been reported to induce a usually reversible decrease of 
glomerular filtration rate in a high-risk population group, especially in patients with altered 
baseline renal function The lethal dose of gadolinium in animals is increased by 100 folds 
when gadolinium is in the form of a chelate. This raise a concern that the leaching of free 
metal from the chelate can pose health risk.
Methods: We present a prospective study involving 122 patients ( 48 male and 74 
female) who had an elective MRI performed. Subjects have been fasting for at least 8 hrs 
prior to the imaging . We collected a blood sample 1 hr prior to the imaging and followed 
up with a repeat blood sample collection 48 hrs after completion of the imaging procedure.
Results: These samples were analyzed for serum creatinine and BUN levels . 
Preliminary data shows that 46.43 % ( 52 out of 112) of the study subjects exhibited 
worsening of renal function while 53.57 % ( 60 out of 112) had normal or slightly improved 
renal function .
Conclusions: Preliminary data analysis suggests gadolinium induces nephrotoxicity 
in general population including patients with normal kidney function and with chronic 
kidney disease . We appreciate the limitation of the study which are mainly the number of 
subjects and the fasting status of subjects. Since there was no exclusions, patient who are 
on diuretics and ACEI inhibitors could display a higher base line creatinine which might 
explain the improvement of renal function post study in some subjects .
TH-PO090
Risk of Pediatric Acute Kidney Injury Is Increased with Vancomycin and 
Piperacillin-Tazobactam Combination Therapy  Joseph Michael Rusnak,1 
Cristin Kaspar,1 Timothy E. Bunchman,1 Nianzhou Xiao,1 Megan M. Lo,1 Jeremy 
S. Stultz.2  1Pediatric Nephrology, Children¶s Hospital of Richmond at 9irginia 
Commonwealth Univ, Richmond, VA; 2Pharmacotherapy and Outcomes Science, 
Virginia Commonwealth Univ, Richmond, VA.
Background: Hospitalized pediatric patients at risk for infection are often treated with 
vancomycin (vanc) and piperacillin-tazobactam (PT). Risk of nephrotoxicity from vanc 
and other antimicrobials (e.g. aminoglycosides, beta-lactams) is well-described. Recently, 
an increased risk of acute kidney injury (AKI) resulting from combination therapy of vanc 
with PT has been reported in the adult literature, but not in the pediatric literature.
Methods: Retrospective single center study of hospitalized pediatric patients £20 
years who received vanc, PT, or the combination for 48 hours or more. Data collection 
included creatinine levels, medication and demographic characteristics. Patients on ECMO 
or dialysis were excluded.
Results: 164 patients identified, 30 (18.3%) developed AKI (definition: ≥ 50% above 
baseline creatinine) after beginning treatment with the antimicrobials. Eight patients in 
the vanc alone and PT alone groups (8%) versus 22 patients in the combination group 
(34.4%) developed AKI (p<0.0001). The median percent creatinine change from baseline 
was significant (p=0.03) between the combination and single therapy groups of 104% and 
52.3%, respectively. 
AKI Non-AKI
Total Number (%) 30 (18.3%) 134 (81.7%)
Median Age, years (range) 9.5 (3 months - 20 years) 9 (1 month - 19 years)
Vanc Only 4 (8.2%) 45 (91.2%)
PT Only 4 (7.8%) 47 (92.2%)
Combination Vanc & PT 22 (34.4%) 42 (65.6%)
Conclusions: Results of this study suggest a higher risk of AKI in pediatric patients 
receiving the combination therapy of vanc and PT compared to single drug therapy with 
either. Further studies are needed to determine if other confounding factors (e.g. dehydration, 
medical diagnosis, or additional nephrotoxins) contribute to the risk of AKI with this 
particular combination, or if there is a safer alternative for broad-spectrum antimicrobial 
coverage in the pediatric population.
TH-PO091
Associations Between Vancomycin, Other Antibiotics, Acute Kidney Injury 
and Mortality in Hospitalized Patients  Victoria Gutgarts,1,2 Christian Suarez,1,2 
Ladan Golestaneh,1,2 Michal L. Melamed.1,2  1Nephrology, Montefiore Medical 
Center, Bronx, NY; 2Nephrology, Albert Einstein College of Medicine, Bronx, NY.
Background: Vancomycin is a commonly prescribed antibiotic. Animal and human 
studies suggest that vancomycin can cause acute kidney injury (AKI). We hypothesized 
that exposure to vancomycin with other nephrotoxic antibiotics (aminoglycosides) will 
be associated with AKI compared to vancomycin use with non-nephrotoxic antibiotics 
in hospitalized patients.
Methods: We performed a retrospective observational study, including patients 18 
years or older admitted from 2008 and 2010 at Montefiore Medical Center. All patients 
had at least two serum creatinine values during their admission and a baseline creatinine 
within 6 months prior to admission. AKI was defined as a 50% increase in baseline serum 
creatinine. One year mortality data was from the Social Security Death Index.
Results: Of 46,580 admissions, 2,104 developed AKI (4.7%). 7,889 patients (17%) 
had exposure to vancomycin, 1,172 patients (2.5%) had exposure to aminoglycosides and 
vancomycin, 3,700 patients (7.9%) had exposure to fluoroquinolones and vancomycin and 
3,994 patients (8.6%) had exposure to cephalosporins and vancomycin. Those developing 
AKI were more likely female (70% vs 63% p<0.001), had GFR < 60 (37% vs 22% p< 
0.001) and vancomycin exposure (31% vs 16% p< 0.001). The AKI risk associated with 
vancomycin alone was 1.55 (1.37, 1.76), combining vancomycin and gentamicin the risk 
was 1.95 (1.56, 2.45) while vancomycin with fluoroquinolones was 1.38 (1.17, 1.63) and 
vancomycin with cephalosporins was 1.37 (1.16, 1.62). The risk of mortality associated 
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with vancomycin alone was 2.27 (2.06, 2.49), combining vancomycin and gentamicin the 
risk was 3.87 (3.26, 4.58), combining vancomycin with fluoroquinolones the risk was 3.42 
(3.05, 3.84), and combining vancomycin with cephalosporins the risk was 2.62 (2.34, 2.95).
Conclusions: Our data suggests that vancomycin exposure is associated with a high 
risk of AKI and mortality, especially in combination with aminoglycosides. Further studies 
should be conducted to evaluate whether aminoglycosides should not be used in combination 
with vancomycin in order to prevent AKI.
TH-PO092
Adverse Renal Effects of Targeted Anti-Cancer Therapies: A Systematic 
Review of Data from the FDA Adverse Event Reporting System 
Kenar D. Jhaveri, Rimda Wanchoo, Daniel W. Ross, Vipulbhai Sakhiya, Steven 
Fishbane.  Nephrology, Hofstra NSLIJ, NY.
Background: Novel molecular targeted anti-cancer therapies have shown improvement 
in patient survival compared to standard chemotherapy. Renal toxicities of novel targeted 
therapies are limited to case reports.
Methods: We reviewed the FDA Adverse Event Reporting System’s (FAERS) 
quarterly legacy data file (2011-2014). We queried the database for medications listed 
below. The adverse events queried were: hypokalemia, hypomagnesemia, hyponatremia, 
hypophosphatemia,proteinuria, renal failure acute. To compare what has been published, 
we searched PubMed for each medication plus each adverse event.
Results: Total number of adverse events reported were 1,657. Ipilimumab had the 
highest number of events (341) and these were mostly acute renal failure (126) and 
hyponatremia (112). In PubMed review all case reports were diagnosis of renal failure. 
The second highest number of events occurred in cetuximab and most of the events were 
impaired renal function (128). For all targeted therapies listed below in figure, the most 
common adverse event was acute renal failure (549). The most common electrolyte 
abnormality was hypokalemia (367). More males developed renal failure at mean age of 
65y as opposed to females with mean age of 61y( <0.01). More females got electrolytes 
disorders at mean age of 59y compared to males at 61y(<0.01). For all medications, renal 
adverse events were more common in males mean age 63y compared to females mean age 
59y( <0.01). Hypokalemia was more common in females ( <0.01) and hyponatremia more 
common in males (<0.01). Figure below compares all agents searched.
Conclusions: Our data elucidate previously unknown adverse renal events in targeted 
therapies. Older males are at higher risk for renal failure and females are at higher risk for 
electrolytes disorders from certain targeted anti-cancer therapies.
TH-PO093
Vemurafenib and Dabrafenib Related Renal Toxicities  Kenar D. Jhaveri, 
Rimda Wanchoo, Vipulbhai Sakhiya, Steven Fishbane.  Nephrology, Hofstra 
NSLIJ School of Medicine, NY.
Background: Vemurafenib and dabrafenib, selective BRAF inhibitors has shown 
significant improvement in patient survival compared to standard therapy in V600 mutant 
metastatic melanoma. No cases of AKI have been reported with dabrafenib use. AKI has 
been recently reported in few case series with vemurafenib use. One case series included 
a patient who had a kidney biopsy demonstrating acute tubular necrosis as a potential 
mechanism of renal injury.
Methods: We reviewed the FDA Adverse Event Reporting System’s (FAERS) quarterly 
legacy data file from 3rd quarter of 2011 to 2nd quarter of 2014 for vemurafenib and 2nd 
quarter of 2013 to 2nd quarter of 2014 for dabrafenib. Vemurafenib and dabrafenib related 
renal adverse event data were extracted through formation of a query using FAERS assigned 
unique case identifiers. Search terms utilized were “renal insufficiency, elevated creatinine, 
renal failure, renal injury, proteinuria, renal impairment, blood creatinine increase, renal 
failure acute, low phosphorus, hypophosphatemia, hypercreatinemia, hyponatremia, 
hypokalemia, renal damage”.
Results: 132 cases of AKI were reported secondary to vemurafenib to the FAERS in the 
time frame reviewed. Eighty five patients were men and 47 women ( p= 0.01). Average age 
of the men was 65 years and 59 years for the women ( p=0.03). The cases are reported from 
around the world with France, USA and Germany having most of the cases. Fourteen cases 
of electrolyte disorders were reported ( hypokalemia-6 cases and hyponatremia-8 cases). 
A total of 13 cases were reported of AKI from dabrafenib to the FAERS in the time frame 
stated above. Twelve patients were men. Average age of the men were 55 and 75 years for 
women ( p=0.0022). Eight cases of electrolyte disorders were reported ( hypokalemia-2 
cases and hyponatremia-6 cases).
Conclusions: While the FAERS reporting system is a crude database with scant 
demographic information, the number of cases reported of AKI is still alarming with the 
BRAF inhibitors. Vemurafenib appears to be more nephrotoxic than dabrafenib. This renal 
toxicity seems to be more prominent among male patients with melanoma. Dermatologists, 
oncologist and nephrologists need to be made aware of this important toxicity.
TH-PO094
Protective Effects of Oral L-Arginine Supplement in Patients with Chronic 
Kidney Disease After Intravenous Contrast Media Injection: A Randomized 
Controlled Trial  Theerasak Tangwonglert.  Medicine, Phramongkutklao 
Hospital.
Background: Contrast-induced acute kidney injury (CI-AKI) is a common 
complication in hospitalized patients. Nitric oxide-signal transduction plays an important 
role in prevention of CI-AKI. L-Arginine is an amino acid involved in ammonia 
detoxification, and is well known as a precursor to nitric oxide, a key component of 
endothelial-derived relaxing factor.
Methods: A randomized, double blind, placebo controlled trial was done in CKD 
stage 3-4 patients undergoing computer tomography. Eligible patients were randomly 
assigned into two groups: arginine 3 g in 6 gelatin capsules orally per day, and placebo 6 
capsules as the same manner for 3 days before contrast media injection. Serum cystatin C, 
creatinine, electrolyte, estimated GFR and urinary nitric oxide were measured at baseline 
and 48 hours after procedure.
Results: A total of 84 patients were screened. Sixty percent were male with mean age 
of 74 years. 27 patients in arginine group and 34 patients in placebo group were analyzed. 
There were no significant differences between the arginine and placebo groups regarding 
baseline demographic and biochemical characteristics, including baseline GFR (48.8 ± 8.8 
mL/min/1.73 m2 versus 48.8 ± 7.5 mL/min/1.73 m2). The incidence of CI-AKI was 3.7% 
(1 patient) in the arginine group and 23.53% (8 patients) in the placebo (p = 0.036). No 
serious adverse event was detected in the both groups. There is a trend toward an increase 
in urinary nitric oxide difference in patients with CI-AKI.
Conclusions: This study indicated that oral L-arginine supplement before intravenous 
contrast media injection plus the standard hydration regimen can prevent CI-AKI in 
hospitalized patients with CKD stage 3-4.
TH-PO095
Decline in Estimated Glomerular Filtration Rate After Acute Kidney 
Injury: A Surrogate Endpoint?  Morgan Grams,1 Yingying Sang,1 Josef 
Coresh,1 Shoshana Ballew,1 Kunihiro Matsushita,1 Tom Greene,2 Andrew S. 
Levey,3 Miklos Zsolt Molnar,4 Zoltan Szabo,5 Kamyar Kalantar-Zadeh,6 Csaba 
P. Kovesdy.4,7  1JHU; 2Utah; 3Tufts; 4UTHSC; 5Linköping Univ; 6UC Irvine; 
7Memphis VA Medical Center.
Background: Often a transient condition, acute kidney injury (AKI) is not currently 
accepted as an endpoint for drug registration trials by the US FDA. We sought to determine 
whether an intermediate-term change in eGFR after AKI has a sufficiently strong relationship 
with subsequent ESRD to serve as an alternative endpoint in clinical trials of AKI prevention 
and/or treatment.
Methods: We evaluated 161,185 US veterans who underwent major surgery between 
2004-2011. Post-surgical AKI was defined by the KDIGO creatinine criteria;decline in eGFR 
was calculated from pre-hospitalization value to two time-points post-discharge (60-days, 
90-days) and related to ESRD and mortality using Cox proportional hazards regression.
Results: In-hospital mortality varied by AKI status, ranging from 1% for patients 
without AKI to 35% for those with dialysis-requiring AKI. An eGFR decline of ³30% at 
60-days was relatively frequent: 2.5%, 9.7%, 17.2%, and 28.6% in those with no AKI, Stage 
1 AKI, Stage 2 AKI, and Stage 3 AKI, respectively. There was a graded relationship between 
eGFR decline at 60-days and risk of ESRD in persons both with and without AKI (Figure). 
Compared to stable eGFR/no in-hospital AKI, the adjusted hazard ratio (HR) of ESRD 
associated with a 30% decline at 60-days after AKI was 6.42 (95% CI: 4.8-8.7). Risks for 
mortality associated with eGFR decline were smaller: the HR for 30% decline 60-days after 
in-hospital AKI was 1.59 (95% CI: 1.46-1.73). Risk relationships were similar at 90-days.
Conclusions: A 30% decline in eGFR from pre-hospitalization baseline to 60-days or 
90-days after an episode of AKI may be an acceptable surrogate endpoint in trials of AKI 
prevention and/or treatment.
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TH-PO096
Creatinine Changes After Contrast: Chloride Poor versus Chloride Rich 
Solutions  Asish Thakkar, Rima Kang, Salem Almaani, Udayan Y. Bhatt. 
Nephrology, The Ohio State Univ Wexner Medical Center, Columbus, OH.
Background: There has been recent emphasis on utilization of chloride poor solutions 
for the prevention of acute kidney injury (AKI). The purported mechanism is the potential for 
chloride rich fluids to possibly impair renal blood flow. Similarly, exposure to intravenous 
radiographic contrast is known to induce renal vasoconstriction. Given these findings, 
the objective of this project was to examine the effect of chloride rich versus chloride 
poor intravenous (IV) fluids on the change in serum creatinine occurring after IV contrast 
administration.
Methods: This project was performed under an IRB-approved Honest Broker 
Protocol. Retrospective data was obtained from patients receiving IV contrast over a 4 
week period. Variables collected included: age, race, gender, type of contrast procedure, 
baseline creatinine, creatinine at days 1 and 2, and all intravenous medications. Chloride 
rich solutions (normal saline) and chloride poor solutions (sodium bicarbonate, Plasmalyte, 
and Lactated Ringers) were identified. Multivariate linear modelling was used to examine 
the primary endpoint of change in creatinine at day 2 relative to baseline (delta creatinine).
Results: 
Cl Poor(N=22) Saline(N=220) p-value
Age 62.4±11.6 58.7±16.8 NS
Male 6(27.3%) 120(54.5%) 0.021
Caucasian 18(81.8%) 172(78.2%) NS
Heart Catheterization 2(9.1%) 10(4.5%) NS
Baseline Creatinine 1.38±0.88 0.94±0.49 0.003
Delta Creatinine 0.09±1.00 -0.06±0.37 NS
Multivariate analysis Delta Creatinine Chloride rich verse Cl poor p-value
Saline -0.370 0.000
The change in creatinine after IV contrast in the chloride rich group, after adjusting 
for all variables including baseline creatinine, was 0.37±0.09 lower than in the chloride 
poor group (p=0.000).
Conclusions: Patients receiving chloride rich IV solutions appeared to have a 
significantly lower change in serum creatinine after administration of IV contrast compared 
to patients receiving chloride poor solutions. On this basis, more investigation is needed 
on chloride poor solutions to fully define the most appropriate utilization.
TH-PO097
Clinical Characteristics in Patients with Alcoholic Ketoacidosis and Acute 
Kidney Injury  Hyeon-Cheol Park, Shinhan Song, Jae seok Kim, Jae Won 
Yang, Byoung Geun Han, Seung-Ok Choi.  Internal Medicine, Yonsei Wonju 
College of Medicine, Korea.
Background: Alcoholic ketoacidosis (AKA) is a serious disorder that has a high 
mortality. Acute kidney injury (AKI) is a typical complication of AKA, which is known to be 
associated with increased mortality. This study aimed to investigate clinical characteristics 
and risk factors for AKI in patients with AKA.
Methods: We retrospectively reviewed records of 357 patients who had been diagnosed 
with AKA in Wonju Severance Christian Hospital from January 2004 to March 2014. We 
investigated clinical history and characteristics, laboratory data, progress and mortality. 
In addition, we estimated Acute Physiology and Chronic Health Evaluation (APACHE) 
II score and Sequential Organ Failure Assessment (SOFA) score for assessing severity of 
patients. Lastly, we investigated the risk factors for AKI.
Results: A total of 357 patients were included in the study. Among them, 293 patients 
(82.1%) were diagnosed with AKI by AKIN (Acute Kidney Injury Network) criteria; stage 
I (n=80, 22.4%), stage II (n=70, 19.6%), stage III (n=143, 40.1%). Mortality was reported 
in 84 patients (23.6%), and mean interval from initial visit to mortality was 6.0 ± 10.7 days. 
As the AKI stage advanced (non-AKI vs. stage I vs. stage II vs. stage III), the mortality rate 
increased (3.1 vs. 7.5 vs. 25.7 vs. 40.6 %), and APACHE II / SOFA scores were elevated 
as well (11.1 vs. 13.2 vs. 19.4 vs. 22.5 / 3.6 vs. 4.5 vs. 7.3 vs. 9.5). In addition, clinical 
history of liver cirrhosis, complications of rhabdomyolysis, pancreatitis, infection, and 
in hospital cardiac-arrest showed the more occurrence frequencies in the advanced AKI 
stages. However, alcohol histories including duration of total alcohol intake, last drinking 
day before the visit, and alcohol amounts to intake were not associated with AKI stages. 
Lastly, our study demonstrated that independent risk factors for AKI in the patients with 
AKA included rhabdomyolysis (odds ratio, 7.1, 95% confidence interval, 2.3-22.2) and 
pancreatitis (3.7, 1.1-11.8).
Conclusions: This study indicates that AKI in the patients with AKA is associated with 
higher mortality, and the major risk factors for AKI include complications of rhabdomyolysis 
and pancreatitis.
TH-PO098
Renal Cortical Necrosis following Postpartum Hemorrhage: A Case 
Series  Marie Frimat,1 Mélanie Decambron,1 Celine Lebas,2 Viviane Gnemmi,3 
Benedicte Sautenet,4 Francois Glowacki,1 Eric Rondeau,5 Christian Noel,1 
Francois Provot,1 Alexandre Hertig.5  1Nephrology, CHRU Lille, Lille, France; 
2Nephrology, CH Valenciennes, Valenciennes, France; 3Anatomopathology, 
CHRU Lille, Lille, France; 4Nephrology, CHRU Tours, Tours, France; 
5Nephrology, APHP, Tenon Hospital, Paris.
Background: Pregnancy-related renal cortical necrosis induces severe kidney damage 
and may thus result in end stage renal disease. Although this obstetrical complication had 
virtually disappeared in high-income countries, we noted new cases in France during the 
past few years, all in the aftermath of a postpartum hemorrhage.
Methods: We retrospectively identified 18 patients from 5 French departments of 
Nephrology who developed renal cortical necrosis following postpartum hemorrhage 
between 2009 and 2013. Obstetrical and renal features, therapeutic measures, and renal 
outcome were studied. In order to identify prognostic factors for renal outcome, we stratified 
the analysis according to the estimated glomerular filtration rate at 6 months postpartum: 
£15ml/min or dialysis-dependent (Gp1) versus > 15ml/min (Gp2).
Results: All patients had a severe postpartum hemorrhage (mean blood loss: 2.6±1.1L). 
Hemodynamic instability and disseminated intravascular coagulation were reported in 5 
and 11 patients, respectively. All had a rapid onset of acute kidney injury and required 
hemodialysis. Diagnosis of renal cortical necrosis was performed 4 to 33 days following 
delivery. At 6 months post-partum, 8 patients remained dialysis-dependent and none 
recovered normal renal function. Retrospectively, the severity of the initial presentation was 
comparable between the Gp1 (n=9) and Gp2 (n=9) groups. Only the maintenance dose of 
tranexamic acid treatment was significantly more prolonged in the Gp1 patients (7.1±4.8 
hours versus 2.9±2.4 hours, p=0.031).
Conclusions: The pejorative outcome of pregnancy-related renal cortical necrosis 
seems darkened by a prolonged use of tranexamic acid. In a setting of gravid endothelium, 
disseminated intravascular coagulation and concomitant use of fibrinogen, we speculate 
that the accumulation of this antifibrinolytic drug due to acute kidney injury might facilitate 
the uncontrolled clotting in renal cortex.
TH-PO099
Intermittent Hemodialysis (IHD) versus Sustained Low Efficiency Dialysis 
(SLED) for Lithium Toxicity: A Case Series  Justine Bunka, Alejandro 
Quiroga.  Dept of Pediatric Nephrology, Dialysis, and Kidney Transplant, Helen 
De9os Children¶s Hospital, Grand Rapids, MI.
Background: Severe lithium toxicity is a medical emergency requiring hemodialysis 
when patients present with toxic levels (above 2.5mmol/L) and/or are symptomatic. This 
case series describes two pediatric patients who presented with severe lithium toxicity, 
one who was treated with intermittent hemodialysis (IHD) and the other who was treated 
with sustained low efficiency hemodialysis (SLED). We report a successful single use of 
SLED in a pediatric patient with lithium toxicity without the need for further dialysis.
Methods: A 16 year old female with history of depression was admitted to the Pediatric 
ICU after ingestion of multiple medications as a suicide attempt including lithium carbonate 
extended release 300 mg tabs. The patient was started on continuous CVVHDF due to 
hemodynamic instability requiring multiple vasopressor agents. CVVHDF was initiated 
when the patient’s lithium level was 0.62mmol/L and it was continued for 12 hours. 
Eighteen hours after cessation of CVVHDF, the lithium level rebounded to 2.5mmol/L and 
conventional intermittent hemodialysis (IHD) was required for 2 consecutive days. After 
IHD, lithium level decreased to below 1mmol/L when dialysis was discontinued. A 12 year 
old male with history of bipolar depression on chronic lithium therapy presented to the 
Pediatric ICU with altered mental status and tremors with a lithium level of 4.0. Sustained 
low efficiency dialysis (SLED) was done for 8 hours until lithium level was below 1.0. 
After SLED was discontinued the rebound lithium level peaked at 1.4 and the neurologic 
symptoms resolved, indicating no further dialysis was needed.
Conclusions: SLED is an effective modality for lithium clearance and may reduce the 
total duration needed for IHD due to less rebound of lithium level.
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TH-PO100
Demographic Characteristics of Acute Kidney Injury and Utilization of 
Continuous Renal Replacement Therapy with Extracorporeal Life Support 
in Adult Patients  Christopher Hebert, Brain Lima, Britton Blough, Avery Smith, 
Omar Hernandez.  Dept of Internal Medicine, Div of Nephrology, Baylor Scott 
and White Health Care System, Dallas, TX.
Background: Extracorporeal life support (ECLS), also known as extracorporeal 
membrane oxygenation (ECMO) has been used over the last 40 years to help manage patients 
with severe cardiovascular or respiratory illnesses. Acute kidney injury is a very common 
complication in this particular patient population as is the need for renal replacement therapy. 
Much of the success and experience related to extracorporeal therapies has been limited to 
neonatal and pediatric populations. More recent data suggests that centers who perform a 
higher volume of ECMO cases have better outcomes. This study presents a demographic 
assessment of the first 199 cases of ECMO utilization over the last 36 months along with 
outcomes, specifically related to acute kidney injury.
Methods: We collected data for review of the first 199 cases of patients treated with 
ECLS at Baylor Scott and White Health Care System since July of 2012. We examined the 
patient demographics, type of ECLS, indication, location, comorbidities, incidence of acute 
kidney injury by RIFLE criteria and need for renal replacement therapy. Specific outcome 
measurements we looked at were overall survival, ability to wean from ECLS or bridge to 
transplant, withdraw of care, need for long term dialysis, and death.
Results: In our ECMO program, 144 patients were male (72%) and 56 were female 
(28%). Regarding the types of ECLS, 136 were VA ECMO, 61 were VV ECMO and there 
were 2 RVADs. The main indications for ECLS were Cardiac in 129 cases, pulmonary in 
63 cases, and 8 were ECPR. There were 61 patients who required CRRT. The majority of 
these were VA ECMO (41 patients) and the rest were VV ECMO (20 patients). A total of 
129 patients were weaned from ECLS, 92 of which survived to discharge. Survival was 
worse in patients with AKI, overall survival on ECMO was 64.5% versus 36% for those 
on CRRT with AKI.
Conclusions: Our data set is fairly consistent with ELSO registry numbers. AKI appears 
to impact mortality in similar fashion. We hope to gain insight into more prospective research 
regarding this unique patient population.
TH-PO101
Performance of Renal Replacement Therapy for Acute Kidney Injury in 
Adult Patients on Extracorporeal Life Support  Christopher Hebert.  Dept 
of Internal Medicine, Div of Nephrology, Baylor Scott and White Health Care 
System, Dallas, TX.
Background: Extracorporeal life support is being used more commonly in adult patients 
with severe cardiovascular and respiratory illnesses. Acute kidney injury requiring renal 
replacement therapy is a very common complication in this patient population. Much of 
the data regarding the technical aspect of these concurrent procedures has been limited to 
neonatal and pediatric patient populations. We sought to examine the most efficient and 
effective ways to deliver renal replacement therapy in conjunction with extra corporeal 
life support.
Methods: Between July 2012 and March 2015, our institution performed 200 cases 
of extracorporeal life support. Of these cases, 61 required renal replacement therapy. 
Individual decisions regarding timing of initiation of renal replacement therapy and specific 
modality were based on physician discretion regarding other patient comorbidities, type 
of ECMO, and overall goals of care. Data was then collected on isolated cases that faced 
specific complications with respect to the technical aspect of performing renal replacement 
therapy. Our institution utilized the NXStage System One dialysis machine, and the Macquet 
Rotaflow or Cardiohelp ECMO machine.
Results: The most common and effective way to perform continuous renal replacement 
therapy was to place the arterial line after the pump in the circuit, and return the blood before 
the oxygenator in the circuit. This minimized the risk of potential thrombosis to the patient 
and circuit clotting. Machine alarms would have to be interpreted in light of circuit position, 
and often had to be overridden. These included positive arterial pressures, high venous 
pressures, arterial blood flow during ECMO “chattering”, and high chamber pressures.
Conclusions: Continuous renal replacement therapy can easily be safely and effectively 
implemented into almost any extracorporeal life support system circuit. There are technical 
challenges with each type of machine, that can be circumvented through a thorough 
understanding of each circuit. A good understanding of ECLS and CRRT allows teams 
to troubleshoot a different set of challenges than traditional CRRT.  We hope to evaluate 
this patient population in a more standardized fashion with respect to interventions and 
outcomes in future studies.
TH-PO102
Prescribed versus Delivered Dose of Continuous Veno-Venous Hemodialysis 
in a Non-Study Population  Aqsa F. Rahman, Majid A. Khan, Akshar N. Patel, 
Krystal Hunter, Lawrence S. Weisberg, William D. Sirover, Christopher B. 
McFadden.  Nephrology, Cooper Univ Hospital, Camden, NJ.
Background: Critically ill patients requiring continuous renal replacement therapy 
(CRRT) experience high mortality rates. In randomized studies, intensification of CRRT 
by increasing effluent volumes from 20 to 35 ml/kg/hr did not improve survival. These 
studies ensured achievement of prescribed dose. We evaluated how often a subject achieves 
the prescribed dose in a non-study population.
Methods: We conducted a retrospective, observational cross sectional study and 
examined the electronic medical records (EMR) of subjects receiving CRRT. An automated, 
real time wireless link from the dialysis machines to EMR, contained data on the CRRT 
settings and hourly effluent volumes. With this data we calculated percentages of prescribed 
dosages achieved and compared subjects who did or did not achieve the prescribed dose. 
Access problems, procedures, electrolyte disturbance or no clear reason documented were 
investigated as variables in subjects not achieving prescribed doses. Pearson Chi Square 
or Fisher exact tests were used to compare dichotomous, and Independent T test or Mann 
Whitney U tests were used to compare continuous variables.
Results: This study represents an analysis of 73 of a planned 90 subjects.  We found 
that 14% subjects achieved 100% of prescribed dose, 53% achieved 80-99% and 33% 
achieved < 80%. Mean prescribed dose was 25 ml/kg/hr and achieved dose was 20 ml/kh/
hr.  Access/Filter problems were present in 63.4%, imaging/procedure 12% , electrolyte 
imbalance 2% and no clear reason documented in 19.2% when goal dose was not achieved. 
Subjects in whom CVVHD was not interrupted achieved > 96% of prescribed dose which 
was statistically significant (P<0.001) compared to 76.5% achieved in subjects that had 
interruptions.
Conclusions: In a non-study population the proportion of patients who do not achieve 
prescribed CRRT dose is very large. In order to achieve a dose of 20 ml/kg/hr effluent volume 
the prescribed dose may need to be significantly higher in a non-study population. Timely 
correction of access/filter problems is another area of focus which may need attention for 
better dose achievement.
TH-PO103
A Predictive Model for Successful Conversion of Continuous Renal 
Replacement Therapy to Intermittent Hemodialysis for Acute Kidney 
Injury in Critical Ill Patients  Ji Hyeon Park, Jee Eun Park, Subin Hwang, 
Hye Ryoun Jang, Wooseong Huh, Dae Joong Kim, Yoon-Goo Kim, Ha Young 
Oh, Jung eun Lee.  Nephrology, Samsung Medical Center, Seoul, Korea.
Background: Continuous renal replacement therapy (CRRT) is preferred modality 
of renal replacement therapy (RRT) in critical ill patients with acute kidney injury 
(AKI). However, it has several disadvantage such as high cost and risk of continuous 
anticoagulation. Therefore, initial application of CRRT and subsequent conversion to 
intermittent hemodialysis (IHD) could be practical. However, there has been no standard 
criteria for optimal timing of conversion to IHD in pateints receiving CRRT. The aim of 
this study was to develop a predictive model for successful conversion of CRRT to IHD.
Methods: This case-control study was conducted by retrospective chart review. We 
identified 513 adult patients who received CRRT at least 24 hours and and then IHD 
subsequently in ICU between April 2009 and February 2014. Failure in conversion to IHD 
was defined when CRRT was re-applied within 72 hours after CRRT stop, and 83 out of 
513 patients corresponded failure criteria: failure group. Equal number of patients were 
selected randomly from remaining 430 patients: success group.
Results: Cardiovascular (CV) SOFA score and neurologic (NR) SOFA score at CRRT 
stop day were only two independent predictors of conversion failure. The risk of failure 
was discriminated between score 0,1 and score 2-4 for both CV and NR SOFA. CV SOFA 
score 2-4 was associated with 13 fold increased Odds ratio for failure (95% C.I. 4.6 - 38.3, 
Ref 0-1) and NR SOFA score 2-4 was associated with 5.4 fold increased Odds ratio for 
failure (95% C.I. 2.6 - 11.4, Ref 0-1). Final prediction model included CV SOFA and NR 
SOFA weighting CV SOFA (≥ 2) as 2 points and NR SOFA (≥ 2) as 1 point. Risk score 
ranged from 0 to 3 points (0; 47%, 1; 29%, 2; 13%, 3; 11%). The performance of this 
model was acceptable with area under the receiver operating characteristic curve of 0.79 
(95% C.I. 0.77–0.86).
Conclusions: The prediction model might provide an objective criteria for conversion 
to IHD in patients receiving CRRT and contribute to establish cost-effective protocol of 
RRT for AKI in critical ill patients.
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TH-PO104
Mortality Factors in Septic Shock Patients Requiring Continuous 
Renal Replacement Therapy and Timing Effect Based in Urine Output 
Xose Luis L. Perez-Fernandez,1 Florentina E. Sileanu,2 Joan Sabater Riera,1 
Kathleen D. Liu,3 John A. Kellum.2  1Servei de Medicina Intensiva, Hospital 
Univ de Bellvitge, L¶Hospitalet de Llobregat, Barcelona, Spain; 2Critical Care, 
Univ Pittsburgh Medical Center, Pittsburgh, PA; 3Nephrology & Critical Care, 
Univ California San Francisco Parnassus MC, San Francisco, CA.
Background: Our primary objective was to identify factors associated with mortality 
in patients with septic shock and severe acute kidney injury (AKI) in order to design future 
interventional trials.
Methods: Observational retrospective study conducted in two tertiary care hospitals 
with more than 100 intensive care unit (ICU) beds each. Data were from 2000-2008 at 
UPMC (Pittsburgh, USA) and 2006-2012 at HUB (Barcelona, Spain). The final cohort 
included 938 patients who received CRRT and presented with septic shock. Cox models 
were used to identify variables associated with 90 day mortality. Timing analyses were 
performed in patients with severe AKI at ICU admission who were started on RRT within 
the first 5 days of ICU stay.
Results: Overall 90day mortality was 62.9%. Independent risk factors for death 
included: age, SOFA score at ICU admission, days from hospital admission to ICU 
admission, days from ICU admission to CRRT initiation, and medical (vs surgical)
admission. Both lower creatinine at CRRT start and lower urine output in the 24 hours 
before start of CRRT were associated with lower survival. ROC curve analysis identified 
urine output less than 500 ml in the 24 hours prior to CRRT initiation as the best variable 
to discriminate between survivors and non-survivors.
Conclusions: In patients with septic shock and advanced AKI (KDIGO stage 3), 
survival is lower when CRRT is started in the setting of low urine output. However, whether 
this finding represents differences in severity of illness betweenstudy subjects or is a useful 
tool to time CRRT initiation needs to be evaluated in a future randomized controlled trial.
Funding: Government Support - Non-U.S.
TH-PO105
Outcomes in Acute Kidney Injury Patients Undergoing Continuous 
Venovenous Hemodiafiltration and Regional Citrate-Based Anticoagulation: 
A Comparison Between Individuals with and without Liver Dysfunction 
Thais OC Santos,1 Marisa S. Oliveira,1 Henrique Pinheiro Konigsfeld,1 Virgilio 
Gonçalves Pereira,2 Marcelo Costa Batista,1,2 Oscar Santos,1,2 Bento C. Santos,1,2 
Julio M. Monte,1,2 Marcelino Souza Durao.1,2  1Univ Federal de São Paulo, 
Brazil; 2Hospital Israelita Albert Einstein, Brazil.
Background: Regional citrate-based anticoagulation (RCA) has been widely used in 
intensive care unit (ICU) to treat subjects with acute kidney injury (AKI). Patients with liver 
failure (LF) have citrate metabolism impairment and are likely to experience citrate toxicity.
Methods: A prospective observational study was performed in a private hospital ICU, 
comparing clinical and laboratory data including citrate (Ci) plasma concentration from 
patients with and without LF. LF was defined as an International Normalized Ratio (INR) 
³2.5. Trisodium-citrate 4% was infused in the dialysis system to keep post-filter ionized 
calcium between 0.25-0.35mmol/L. Patients with LF had a Ci fixed-set infusion of 17mmol/h 
(120 ml/h) regardless of the post-filter ionized calcium value.
Results: Two hundred patients were evaluated. LF group patients showed a higher 
mortality rate (70,5% vs 51,8%, p=0.014). Ci was significantly higher in the LF group 
(median 3.497vs2.786mg/dL, p£0,03) in all evaluated days.LF group showed higher INR 
(median 2.68vs1.42, p<0,001), lactate levels (median 34vs16mEq/L, p<0,001) and lower 
serum bicarbonate (median 15.8vs19.4mEq/L, p<0,001) at baseline, as well as throughout 
the study period. There was no significant difference regarding systemic ionic calcium 
levels.LF group patients also underwent more red blood cell transfusions (median 3 vs 1, 
p<0.001). There were no differences in relation to delivered dose (33ml/kg/h), number of 
filters used and total dialysis time. Analyzing the relationship between serum levels of citrate 
and total calcium/ionic calcium ratio (CaT/Cai), we found a weak positive correlation, with 
the highest correlation coefficient of 0.354.
Conclusions: LF group showed higher mortality.Despite the LF group have presented 
higher citrate levels, there were no signs of toxicity, especially ionic hypocalcemia. There 
was a poor correlation between CaT/Cai ratio, a predictor of citrate toxicity, and Ci levels.
Funding: Government Support - Non-U.S.
TH-PO106
Outcomes in a Cohort of Patients with Acute Kidney Injury Submitted 
to Continuous Venovenous Hemodiafiltration: The Role of Negative 
Fluid Balance and Early Dialysis  Thais O.C. Santos,1 Marisa S. Oliveira,1 
Henrique Pinheiro Konigsfeld,1 Marcelo Costa Batista,1,2 Oscar Santos,1,2 Bento 
C. Santos,1,2 Virgilio Gonçalves Pereira,2 Julio M. Monte,1,2 Marcelino Souza 
Durao.1,2  1Univ Federal de São Paulo, Sao Paulo, Brazil; 2Hospital Israelita 
Albert Einstein, Sao Paulo, Brazil.
Background: Several factors are associated with adverse outcomes in acute kidney 
injury (AKI). These include some comorbidities, sepsis, high prognosis scores, positive 
fluid balance, and delay in beginning dialysis.
Methods: In a prospective and observational study, we evaluated risk factors for death 
in 183 patients with AKI requiring continuous venovenous hemodiafiltration (CVVHDF).
Results: Sepsis was the main cause of AKI (57%). Overall mortality was 58%. The 
median cumulative fluid balance (FB) during dialysis was -4127mL among non-survivors 
and +646mL among the survivors. There were 114 oliguric individuals. Independent risk 
factors for death in multivariate analysis were chronic obstructive pulmonary disease 
(COPD) (OR 3.07, 95% CI 1.01 to 9.32, p = 0.047), liver cirrhosis (OR 4.47, 95% CI 1, 
77 to 11.3, p = 0.002), hematologic malignancy (OR 6.19, 95% CI 1.83 to 20.93, p=0.003), 
oliguria (OR 3.01, 95% CI 1.43 -6.32, p=0.004), positive cumulative FB during dialysis 
(OR 1.13, 95% CI 1.06 to 1.20, p<0.001) and time between ICU admission and beginning 
of CVVHDF (OR 1.13, 95% CI 1.01 to 1.25, p=0.039). Among survivors, nearly 30% were 
discharged dependent on dialysis and, among those who were discharged out of dialysis, 
there was a statistically significant reduction in glomerular filtration rate in relation to 
admission (81 vs 50mL/min/1,73m2, p<0,001). The SAPS 3 score at ICU admission showed 
unsatisfactory performance as a predictor of death in patients with AKI (AUC=0.637, 
95%CI, 0.557 to 0.717).
Conclusions: We found an association between positive FB during dialysis, oliguria, 
late starting dialysis and death in patients with AKI submitted to CVVDHF. Others factors 
related to death were COPD, hematologic malignancy and liver cirrhosis.
Funding: Government Support - Non-U.S.
TH-PO107
The Impact of Dialysis-Dependent Acute Kidney Injury on Mortality 
in Myeloma: Findings from England Hospital Episode Statistics Data 
Punit Yadav,1,2 Felicity K. Evison,1 Jason Sangha,3 Daniel Ian Ray,1,2 Adnan 
Sharif,1 Jennifer H. Pinney,1 Mark Trehane Drayson,1,2 Mark Cook,1,2 Paul 
Cockwell.1,2  1Univ Hospital Birmingham, UK; 2Univ of Birmingham, UK; 3St. 
James Univ Hospital, UK.
Background: In patients with myeloma, severe acute kidney injury requiring in-hospital 
dialysis treatment is a life-threatening complication. However the current incidence and 
mortality risk associated with dialysis is unknown. We aimed to examine the incidence and 
impact of dialysis on the survival of patients with first diagnosis of myeloma.
Methods: We utilised hospital episode statistics to analyse data from 36,348 patients 
with a first diagnosis of myeloma in England from April 2006 to March 2014. We examined 
the incidence and impact of in-hospital dialysis on overall survival, by year of presentation. 
Cox proportional outcome models were used to adjust for age, gender, area socio-economic 
deprivation, ethnicity and comorbidity.
Results: We identified 1240 (3.4%) patients who received dialysis treatment within 
28 days of a diagnosis of myeloma. In Kaplan-Meier analysis patients who did not receive 
dialysis had better median overall survival (3.0 years; interquartile range [IQR] 0.7-8.1) than 
patients who received dialysis [1.4 years; IQR 0.2-4.6]. From 2006/7 to 2010/11 survival 
improved from 2.6 years [IQR 0.6-7.7] to 3.3 years [IQR 1.0-not reached] for patients who 
did not receive dialysis and 0.6 [IQR 0.1-2.7] to 1.2 years [IQR 0.4–4.0] for those who 
received dialysis respectively. Compared to patients who did not receive dialysis, those who 
received dialysis were more likely to be older, male, and less socio-economically deprived.
Conclusions: Dialysis is a major independent risk factor for increased mortality in 
patients with myeloma; the overall survival of patients with myeloma requiring dialysis 
is improving.
TH-PO108
Predictors of Survival in the ICU Patient on Continuous Veno-Venous 
Hemofiltration (CVVH)  Amina Saqib, Jwalant R. Modi, Gautam Kishore 
Valecha, Abdul H. Siddiqui, Suzanne E. El Sayegh.  Medicine, Staten Island 
Univ Hospital.
Background: In the ICU setting, Acute Renal Failure is a part of multiple organ 
dysfunction syndrome with mortality in these patients ranging from 28%-90%. Continuous 
Venovenous hemofiltration (CVVH) is most commonly used for renal replacement therapy 
in ICU’s. The objective of this study is to describe demographic characteristics and to 
establish an association between these characteristics and variables that define the severity 
of illness and in-hospital mortality outcomes of patients undergoing CVVH.
Methods: Medical records of patients who underwent CVVH from January 2007 to 
December 2013 in the intensive care at our institution were analyzed. Chi Square test was 
done for categorical variables. Descriptive analysis was used to identify demographic data.
Results: 233 patients underwent CVVH from January 2007 to December 2013. The 
overall mortality was 75.22%. 49.3% of patients required ventilatory support. Acute 
respiratory failure requiring mechanical ventilation was associated with significantly 
increased mortality, 76.74% vs 40.0 % (p=0.04) in patients who did not require mechanical 
ventilation. Septic Shock was the most common reason for ICU admission, 71.2% followed 
by post-operative admissions at 18.8%. The most common indication for CVVH was ATN 
(63.9%) followed by hyperkalemia (57.0%). However, CVVH for metabolic acidosis was 
associated with highest mortality at 81.06 % vs. 67.02 % in patients who underwent CVVH 
for other indications. Poor APACHE II scores were associated with higher mortality. Scores 
ranging from 0-24 were associated with an overall mortality of 69.9% whereas scores 
between 25-50 were associated with an overall mortality of 80.53%.
Conclusions: This observational study in patients undergoing CVVH in an ICU setting 
revealed that patients presenting with worse baseline APACHE II scores had poor in-hospital 
outcomes. CVVH initiation for metabolic acidosis and use of mechanical ventilation was 
associated with higher mortality. There are no established guidelines for use of CVVH. 
This study may aid in delineating the group of patients who may benefit the most from use 
of CVVH and help us in more judicious use of health care resources. .
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TH-PO109
Clinical Effectiveness of Diuretics following Continuous Renal 
Replacement Therapy  Do Hee Kim, Subin Hwang, Jin Hae Kim, Jee Eun 
Park, Ji Hyeon Park, Jung Eun Lee, Wooseong Huh, Yoon-Goo Kim, Dae Joong 
Kim, Ha Young Oh, Hye Ryoun Jang.  Div of Nephrology, Dept of Medicine, 
Samsung Medical Center, Sungkyunkwan Univ School of Medicine, Seoul, 
Republic of Korea.
Background: There is no consensus regarding diuretics administration in acute kidney 
injury (AKI) in patients weaning from continuous renal replacement therapy (CRRT). The 
effect of diuretics on the clinical course of critically ill patients with AKI was analyzed 
focusing on urine output and renal recovery following CRRT. In addition, we tried to 
identify the most optimal administration method of diuretics.
Methods: A total of 1213 adult patients who survived more than 3 days after 
discontinuing CRRT between September 2009 and December 2014 were included. Changes 
in renal function and urine output as well as the prescription of diuretics during the 3 days 
after discontinuation of CRRT were retrospectively analyzed. Patients were categorized 
depending on re-initiation of RRT within 3 days.
Results: There was no difference in baseline characteristics among all groups. CRRT 
cessation group had greater urine output after discontinuation of CRRT compared with other 
groups. Overall, patients who were treated with diuretics (diuretics subgroup) showed greater 
urine output than patients without diuretics (control subgroup) after cessation of CRRT and 
there was no difference in the degrees of serum creatinine elevation between control and 
diuretics subgroups. In CRRT cessation group, continuous infusion of furosemide showed 
greater urine output compared to other administration methods. However, serum creatinine 
increased significantly compared to other methods when the infusion was continued for 
more than 1 day.
Conclusions: Diuretic therapy following CRRT increases urine output significantly 
without causing significant deterioration of renal function. Compared with other methods 
using diuretics, continuous infusion of furosemide increases urine output significantly, 
but also increases serum creatinine further when continued for more than 1 day. Our 
study suggests that diuretics in patients who had received CRRT may be clinically useful.
TH-PO110
The Prognostic Value of Volume Status Assessment by Bioelectrical 
Impedance Analysis and Lung Ultrasound on Mortality in Septic Acute 
Kidney Injury Patients Undergoing Continuous Renal Replacement 
Therapy  Sul A Lee, Shin-Wook Kang, Tae-Hyun Yoo.  Dept of Internal 
Medicine, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Volume overload affects clinical outcome in patients with acute kidney 
injury (AKI). However, the significance of various methods to evaluate volume status has not 
been fully evaluated. Therefore, the prognostic value of volume status assessment measured 
by bioelectrical impedance analysis (BIA) and lung ultrasound (US) on mortality was 
investigated in septic AKI patients requiring continuous renal replacement therapy (CRRT).
Methods: Septic AKI patients requiring CRRT between April 2014 and February 
2015 at Yonsei University Health System were included. Surrogates of volume status 
were 1) percent of body weight change between CRRT initiation and admission day, 2) 
over-hydration (OH)/extracellular water (ECW) measured by BIA, and 3) B-lines measured 
by lung US. Prognostic values of surrogates of volume status for 28-day mortality were 
evaluated.
Results: Among the 36 enrolled patients, 19 (52.8%) patients died during the follow-
up duration. The mean percentage of weight change and OH/ECW measured by BIA was 
5.3±20.7 % and 0.3±0.1 L/L. The median number of B-lines counted by lung US was 6 
(interquartile range, 4-10). OH/ECW was significantly correlated (r=0.39, P=0.02) with 
48-hour fluid balance before CRRT initiation, while the number of B-lines was not. Kaplan-
Meier analysis showed that 28-day mortality was higher in patients with the highest OH/
ECW tertile compared to patients with lower OH/ECW values (P=0.02). Percent of weight 
change and the number of B-lines were not significantly associated with 28-day mortality 
(P=0.44 and P=0.45, respectively). Multivariate Cox proportional hazard regression analysis 
showed that higher OH/ECW was an independent risk factor for 28-day mortality after 
adjustment of confounding factors (HR=3.83, 95% CI=1.04-14.03, P=0.04).
Conclusions: Higher OH/ECW measured by BIA was an independent risk factor for 
28-day mortality in septic AKI patients undergoing CRRT. Determining fluid status by BIA 
could be a useful method to stratify mortality risk in this patient group.
TH-PO111
Effect of Fluid Overload on the Outcome Among Acute Kidney Injury 
Patients Receiving Renal Replacement Therapy After Cardiac Surgery 
Zhouping Zou,1,2 Jiarui Xu,1,2 Wenlv Lv,1,2 Bo Shen,1,2 Yi Fang,1,2 Jianzhou Zou,1,2 
Jie Teng,1,2 Xiaoqiang Ding.1,2  1Dept of Nephrology, Zhongshan Hospital, Fudan 
Univ, Shanghai, China; 2Shanghai Inst for Kidney and Dialysis, Zhongshan 
Hospital, Fudan Univ, Shanghai, China.
Background: We explored the effect of fluid overload in different periods on the 
outcome among acute kidney injury (AKI) patients receiving renal replacement therapy 
(RRT) after cardiac surgery in order to guide the fluid manegement strategy.
Methods: Clinical data of patients who developed AKI requiring RRT after cardiac 
surgery from January 2009 to April 2014 in our hospital were prospectively analyzed. 
Demographic characteristics were recored. The absolute fluid overload (FO) = fluid in (L) 
– fluid out (L). Percent fluid overload (%FO)=[(fluid in-fluid out)/admission weight×100]. 
%FO³10% baseline weight was defined as fluid overload.
Results: A total of 297 patients were enrolled, the hospital mortality was 64.7%(n=192). 
The %FO at RRT initiation and at the end of RRT in death group was significantly higher 
than in survival group [5.0 (2.4, 9.3) vs. 2.5 (0.2,5.8)%; 8.4(3.6,14.2) vs. 3.9(0.4,9.2)%; 
P<0.05]. Even though the fluid overload before RRT was corrected at the end of RRT, 
the overall mortality and rate of renal completely recovery was not improved (P>0.05). 
Compared with patients without fluid overload during the whole ICU stay, patients without 
fluid overload before RRT but had fluid overload at the end of RRT had significantly higher 
mortality(P<0.05)and lower renal complete recovery(P<0.05).Among AKI-RRT patients, 
the incidence of low cardiac output syndrome (LCOS) in death group was significantly 
higher than in survival group (p<0.001). The hospital mortality in LCOS group was 
significantly higher than non-LCOS(P<0.001). The %FO at RRT initiation and at the end 
of RRT in LCOS group was higher than in non-LCOS group [4.7(1.7,7.9) vs. 3.1(1.1,5.2), 
P<0.05; 8.9(4.4,15.3) vs. 4.8 (1.4,11.3), P<0.05].
Conclusions: Among patients with AKI-RRT after cardiac surgery, absolute FO and 
%FO in death group were higher than in survivor group. Fluid overload and LCOS increased 
the risk of mortality in AKI-RRT patients after cardiac surgery.
Funding: Government Support - Non-U.S.
TH-PO112
Carnitine Deficiency in Children Receiving Continuous Renal Replacement 
Therapy  Kristen Sgambat, Asha Moudgil. Children¶s National, :ashington DC.
Background: Carnitine deficiency is known to occur in chronic hemodialysis, however 
the effect of continuous renal replacement therapy (CRRT) on carnitine homeostasis has not 
been studied. The purpose of this study was to investigate carnitine deficiency in critically 
ill patients with acute kidney injury undergoing CRRT in the pediatric intensive care unit. 
We hypothesized that patients receiving CRRT are at risk for deficiency due to continuous 
removal, absent intake, and comorbidities related to critical illness.
Methods: Records of patients with acute kidney injury receiving CRRT at Children’s 
National between 2011 and 2015 were reviewed for total carnitine (TC), free carnitine (FC), 
Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score indicators, and survival outcome. 
PELOD-2 score was calculated to measure of severity of illness on a scale from 0 to 33 
(maximum severity of illness). The proportion of carnitine deficient patients at baseline, 
1, 2, and ≥ 3 weeks on CRRT were compared by Chi square, and relationships with other 
variables assessed by Pearson’s correlation and linear regression.
Results: The study group included 44 CRRT patients, age 8.1± 1.1 years. Severity of 
illness of the population determined by PELOD-2 score ranged from 2 to 19 (mean 11.2 + 
0.43). Of 44 patients, only 14 (31.8%) survived. The prevalence of total and free carnitine 
deficiency, according to age-and-sex- specific reference values, significantly increased with 
time on CRRT. At baseline, 26.6% and 40% of patients were TC and FC deficient. Within 
1 week, 65.6% (p=0.01) and 71% (p=0.04) were TC and FC deficient, and prevalence of 
deficiency increased to 80% (p=0.008) and 90% (p=0.01) by 2 weeks; 100% of patients 
were deficient ³3 weeks (p=0.002 and p=0.01, respectively, vs. baseline). TC and FC 
negatively correlated with days on CRRT (r=-0.4, p=0.001 and r=-0.37, p=0.003). Lower 
TC and FC levels significantly associated with higher mortality (β-10.1, p=0.03 and β-8.1, 
p=0.02 respectively).
Conclusions: Carnitine is significantly and rapidly depleted with longer time on CRRT, 
and carnitine deficiency is associated with increased mortality. Consequences of deficiency 
and benefits of supplementation in the pediatric CRRT population should be investigated.
TH-PO113
The Relationship Between Hypophosphatemia and Outcomes During 
Two Different Intensities of Continuous Renal Replacement Therapy 
Soo Young Kim,1 Joung Wook Yang,1 Ye Na Kim,1 Ho Sik Shin,1 Ji-hwan Kim,2 
Yeon Soon Jung,1 Hark Rim,1 Bong Geon Chun,3 Hyun Yul Rhew.4  1Internal 
Medicine, Kosin Univ College of Medicine; 2Internal Medicine, Good GangAn 
Hospital; 3Pathology, Kosin Univ College of Medicine; 4Urology, Kosin Univ 
College of Medicine.
Background: To identify risk factors for development of hypophosphatemia in patients 
treated with two different intensities of continuous renal replacement therapy (CRRT) and 
to assess the independent association of hypophosphatemia with major clinical outcomes.
Methods: We performed retrospective analysis of data collected from 620 patients. 
We allocated patients to two different intensities of CRRT (more than or less than 40 mL/
kg/hour of effluent generation) and obtained daily measurement of serum phosphate levels.
Results: We obtained total 1800 phosphate measurements in day 0, 1 and 2 and identified 
49 patients (8%), 93 patients (15%) and 142 patients (23%) with hypophosphatemia, With 
lower intensity CRRT, there were 23 episodes of hypophosphatemia/1000 patient days, 
compared with 83 episodes/1000 patient days with higher intensity CRRT(P < 0.01).
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
116A
J Am Soc Nephrol 26: 2015 Dialysis for AKI: Hemodialysis, CRRT, SLED, Others Poster/Thursday
On multivariable logistic regression analysis, higher intensity CRRT and hypokalemia 
were independently associated with an increased odds ratio (OR) for hypophosphatemia. 
On multivariable models, when analysis was confined to patients alive at 48 hours, 
hypophosphataemia was not independently associated with clinical outcomes.
Conclusions: Hypophosphatemia is common during CRRT and its incidence increases 
with greater CRRT intensity. Hypophosphatemia may be not a independent predictor of 
mortality.
TH-PO114
Determinants of Filter Clotting in Acute Kidney Injury (AKI) Cancer 
Patients in the Intensive Care Unit (ICU) Submitted to Regional Citrate 
Anticoagulation (RCA) for Continuous Venovenous Hemodialysis (CVVHD) 
Veronica T. Costa E Silva, Renato Antunes Caires, Juliana Silva Bezerra, Elerson 
Costalonga, Ludhmila Abrahão Hajjar, Ana paula Leandro Oliveira, Luciane 
Oikawa, Cilene Muniz Soares, Luis Yu, Emmanuel A. Burdmann.  Sao Paulo 
State Cancer Inst, Univ of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Background: Determinants of filter clotting in AKI cancer ICU pacients submitted 
to RCA have not been studied.
Methods: We prospectively analyzed all CVVHD performed in AKI adult cancer 
pcts in the Sao Paulo State Cancer Institute ICU from January 2010 to December 2011. 
RCA for CVVHD was utilized according to an adapted protocol published by Mehta et al. 
CVVHD was performed with a Diapact machine (BBraun) with polysulphone hemofilter.
Results: A total of 7,198 hours of CVVHD therapy (250 filters) were performed in 122 
AKI pcts. They were 61 ± 16 years-old, 61.5% male, 75.4% on vasopressors and 41.8% 
on mechanical ventilation. Most (78%) patients had solid cancer, 37.7% with metastatic 
disease (MD) and 48.4% with previous chemotherapy (CT). Sepsis was the most important 
AKI etiology factor (71.1%). Hospital mortality was 78.7%. Venous access was temporary 
triple lumen catheter (11 Fr) in 97% (70% femoral and 27% internal jugular veins). Blood 
flow was 150 (120 – 150) ml/min and citrate dose was 20.4 (16.3 – 24.5) mmol/hr. Dialysis 
dose was 28.2 (22.3 – 30.2) ml/Kg/hr and achieved ultrafiltration was 1042 (573 – 1712) 
ml/24hrs. Median filter patency was 24.8 (11 – 43) hrs and post-filter ionized calcium level 
was 1.60 (1.40 – 1.80) mg/dL.The independent factors related with clotting on logistic 
regression model are depicted.
Logistic regression model for clotting during CVVHD
Variable P OR (95% CI)
Cancer status: no tumor evidence 0.050 0.44 (0.18 - 0.99)
Genitourinary cancer 0.006 1.83 (1.18 - 2.81)
Platelet count (each 10,000/mm3) 0.005 1.02 (1.00 - 1.04)
INR 0.005 0.59 (0.41 - 0.85)
Citrate flow (each 10mL/hour) 0.002 0.88 (0.82 - 0.95)
Conclusions: Filter clotting in AKI ICU cancer patients submitted to RCA is related 
to lower citrate dose, higher INR (international normalized ratio), higher platelet level, 
genitourinary cancer and uncontrolled cancer disease.
TH-PO115
Pre-Dilution Haemodiafiltration Improves Outcomes in Acute Haemodialysis 
Caburn Chamberlain, Preetham Boddana.  Renal Dept, Gloucestershire NHS 
Foundation Hospitals, Gloucester, Gloucestershire, United Kingdom.
Background: Haemodialysis is an extracorporeal blood treatment for Renal Failure 
that requires effective anti-coagulation in order to prevent loss of the blood circuit due to 
clotting. A haemodialysis blood circuit contains approximately 250ml of blood, equivalent 
to 1 unit of packed cells. In routine Haemodialysis, this is achieved by the administration 
of Heparin, or its equivalent, during the treatment, which may be up to four hours duration. 
In the Acute setting, the administration of Heparin may be contra-indicated for a number 
of reasons – pre or post surgery, post-stroke, Gastro intestinal bleeds, deranged clotting 
factors, and so on. Care must then be taken to avoid loss of blood in the dialysis circuit.
Methods: Observational study looking at the effectiveness of traditional anti 
coagulation strategies such as saline flushes in acute haemodialysis had shown increased 
frequency of blood circuits lost on dialysis. Over a period of 4 weeks, we used pre-dilution 
haemodiafiltration instead of conventional post dilution haemodialfiltration. This modality 
dilutes the blood just before it passes through the dialysis filter. As the majority of the 
clotting starts as the blood passes along the filter membranes, diluting the blood at this 
point would theoretically reduce the amount of clotting occurring.
Results: By using this technique, we were able to reduce the number of clotted circuits 
from 100% down to just 30%, with only 10% leading to loss of the entire blood circuit. 
There was no significant change in the effectiveness of the treatment, and no significant 
increase in the cost of the treatment provided.
Conclusions: Over the next few months, we were able to improve on these outcomes 
still further, by optimizing the variables, and in some cases, adding saline flushes in addition 
to the pre-dilution HDF. Having used this technique now for some hundreds of treatments, 
we have reduced the number of blood circuits lost to all but zero. Hence this has become a 
highly effective technique which has drastically improved patient outcomes, reduced the 
need for blood transfusions, and saved money without cost implications.
TH-PO116
Nationwide Use of Hemodialysis and Other Extracorporeal Therapies 
in Poisoned Patients, 2006-2013  Joshua D. King,1,2 Priyanka Vakkalanka,1 
Diana M. Robinson,3 Christopher Holstege.1  1Div of Medical Toxicology, 
Univ of Virginia, Charlottesville, VA; 2Div of Nephrology, Univ of Virginia, 
Charlottesville, VA; 3Dept of Psychiatry, Univ of Virginia, Charlottesville, VA.
Background: Nationwide use of extracorporeal therapies (ECT) in poisoned patients 
has not been characterized since 2005. The purpose of this study was to review the use of 
hemodialysis (HD), hemoperfusion (HP), and other ECT in poisoned patients throughout 
the United States from 2006 until 2013.
Methods: The National Poison Data System (NPDS) was queried for all poisoning cases 
reported to U.S. poison centers between 2006 and 2013 where HD, HP, or other ECT was 
performed. Data analyzed included demographics and geography, clinical characteristics, 
exposure chronicity, and reported substances used by patients. The annual prevalence of 
each therapy per 1,000,000 human exposures was evaluated. The top 30 substances reported 
among all deaths were characterized among patients receiving HD.
Results: There were 18,252 patients who received ECT, of which 17,900 (98.0%) 
received HD, 257 received HP, and 214 received some other ECT. The patient population 
was predominantly 40-59 years of age (45.0%). Poisonings were acute in 56.7% of patients. 
The prevalence of ECT (per million human exposures) was 865 in 2006 versus 1,140 in 
2013. The substances most frequently identified among patients receiving HD included 
ethylene glycol (n=3,828), lithium (n=3,385), sedatives (n=2,711), salicylates (n=2,352), 
and opioids (n=1,783). Overall, 9.4% of patients receiving ECT for poisoning died. The 
three leading substances reported among all deaths included acetaminophen (22.1%), 
opioids (18.3%), and sedatives (15.3%).
Conclusions: The use of HD in the management of poisoning has continued to increase. 
While ethylene glycol, lithium, and salicylates remain frequent indications for dialysis, HD 
seems to be used more often in a supportive role as well given the number of patients treated 
for opioid and sedative poisoning. We were not able to distinguish the use of intermittent 
HD versus continuous renal replacement due to database limitations. Hemoperfusion has 
continued to be rarely used.
TH-PO117
Dialysis Treatment Options for Acute Kidney Injury in the Canadian 
Intensive Care Unit: A Systematic Review and Cost-Utility Analysis 
Danielle Marie Nash,1,2 Ron Wald,4 Michel Louis Grignon,1 Sebastian Przech,3 
Daria O’Reilly.1  1Clinical Epidemiology and Biostatistics, McMaster Univ, 
Hamilton, ON, Canada; 2Kidney, Dialysis and Transplantation Program, Inst 
for Clinical Evaluative Sciences, ON, Canada; 3Epidemiology and Biostatistics, 
Univ of :estern 2ntario, London, 2N, Canada; 4Medicine, Univ of Toronto, 
Toronto, ON, Canada.
Background: Up to 67% of all patients admitted to the intensive care unit (ICU) 
will develop acute kidney injury (AKI). Treatment for these patients is very expensive. 
For example, in the United States, the incremental health care costs attributed to AKI are 
upwards of 10 billion USD per year. In this health economic analysis, we simulate the 
cost per quality-adjusted life year (QALY) gained comparing three dialysis treatments 
for patients with AKI in a Canadian ICU setting: continuous renal replacement therapy 
(CRRT), intermittent hemodialysis (IHD), and sustained low efficiency dialysis (SLED).
Methods: A decision analytic model, with a 1-year time horizon, was developed to 
compare the incremental cost per QALY gained for the three dialysis modalities. The model 
used a public payer perspective, with Canadian costs and relevant utility values obtained 
from targeted searches of the literature. A systematic review of randomized controlled trials 
was performed to determine the clinical parameters for the model, including the probability 
of in-hospital death, dialysis dependence and death at one year post-discharge. One-way 
sensitivity analyses were performed by varying all parameters by +/- 10%.
Results: The incremental cost per QALY gained for SLED compared to IHD was 
68,501. Compared to IHD and SLED, CRRT was extendedly dominated (i.e. it is more 
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cost-effective to provide SLED to some of the eligible patients and IHD to the remaining 
patients than to provide CRRT). The sensitivity analyses showed that the results are generally 
robust across a wide-range of parameter values.
Conclusions: Similar to previous economic evaluations, these results suggest that 
CRRT is not cost-effective compared to IHD. A novel finding is that SLED may be cost-
effective depending on the willingness-to-pay threshold.
TH-PO118
Efficacy of Acute Peritoneal Dialysis (PD) Over Sustained Low Efficiency 
Dialysis (SLED) in Critically Ill ICU Patients with Acute Kidney Injury – A 
Comparative Study  Mitul Bora.  Nephrology, Ayur Sundra Super Speciality 
Hospital, Guwahati, Assam, India.
Background: Acute peritoneal dialysis (PD) has largely been replaced by continuous 
renal replacement therapies (CRRT) and sustained low efficiency dialysis (SLED) in 
critically ill ICU patient.
Methods: Patient admitted in the ICU with acute kidney injury and multiple organ 
dysfunction were included in the study irrespective of the etiology of renal failure. Patients 
were randomly divided in to two group. Group A patients received acute PD and group B 
patients received SLED. Primary outcomes were correction of uremia, metabolic acidosis, 
fluid overload, dyselectrolytemia, and mortality. Secondary outcomes were improvement 
in sensorium, hemodynamic stability, ICU length of stay, cost of treatment and duration 
of mechanical ventilation.
Results: 116 were enrolled in this study. The mean age was 41.23±11.56 years in group 
A where it was 45.87± 13.45 years in group B. Average duration of dialysis was 72.80± 
67.90 and 19.07 ± 11.08 hours in PD and SLED group respectively. Correction of uremia 
[Urea 24.78± 10.31 ml/min vs 26.23 ± 9.34 ml/min, creatinine 8.89 ± 3.78 ml/min vs 9.98± 
7.09 ml/min, p value <0.001) were similar. Significant acidosis was present in 36 patients 
in Group A (92%) and in 23 patients (28%) in Group B. SLED had a better correction of 
acidosis in comparison to PD. Correction of fluid overload was faster in SLED and net 
ultrafiltration was significantly higher in group B (22.21±21.67 L vs 4.87±5.09 L in group 
A, P<0.001). No significant differences were seen in correction of hyperkalemia, altered 
sensorium. PD group had a better hemodynamic stability. Mortality was almost similar in 
both the groups (81% v 76%). Renal function recovery (21% vs 24%) were also similar. 
Acute Physiology and Chronic Health Evaluation II score was similar (25.8±5.4 versus 
23.9±7.9) and also the duration of ventilatory support (11.9 ±7.3 vs 13.5± 8.7 days). Cost 
of treatment was much cheaper in the PD group.
Conclusions: Acute PD still remains as a viable alternative to SLED in critically ill 
patients in low cost setting. Advantages are its low cost, ease of administration, needs less 
expertisation and its metabolic and clinical outcomes are not inferior to SLED.
TH-PO119
Measurement of Adequacy of Intermittent Hemodialysis in Acute Kidney 
Injury: Is There a Simpler Approach?  Kelly V. Liang,1 Jane Hongyuan 
Zhang,2 Paul M. Palevsky.3  1Renal-Electrolyte Div, Univ of Pittsburgh, 
Pittsburgh, PA; 2Cooperative Studies Program Coordinating Center, VA 
Connecticut Healthcare System, West Haven, CT; 3Renal Section, VA Pittsburgh 
Healthcare System, Pittsburgh, PA.
Background: The KDIGO Guideline for Acute Kidney Injury (AKI) recommends a 
minimum single pool Kt/Vurea of 1.3 when intermittent hemodialysis (IHD) is delivered 
thrice weekly. However, Kt/V in AKI is complicated by uncertainty regarding volume of 
distribution of urea and non-steady state rates of urea generation. In the Acute Renal Failure 
Trial Network (ATN) Study, adequacy of IHD was assessed using Kt/V. Using data from 
the ATN Study, we assessed whether the simpler urea reduction ratio (URR), which does 
not require assessment of volume status, would provide sufficient correlation with Kt/V 
to provide a reliable assessment of adequacy of hemodialysis in AKI.
Methods: Using data from IHD in the ATN Study, values of URR were plotted against 
Kt/V. We determined URR thresholds corresponding to Kt/V values ≥ 1.2, 1.3, and 1.4 and 
generated receiver operating characteristic (ROC) curves at each level of Kt/V to identify 
optimal URR thresholds.
Results: There was tight correlation between URR and Kt/V (figure).
The area under the ROC curves were 0.99 for all three Kt/V thresholds. The sensitivity 
and specificity of URR³0.67 for corresponding values of Kt/V³1.2 were 0.769 (95% CI 
0.745 to 0.793) and 0.999 (95% CI 0.997 to 1.000), and for corresponding values of Kt/
V³1.4 were 0.998 (95% CI 0.995 to 1.000) and 0.791 (95% CI 0.771 to 0.811), respectively.
Conclusions: A URR ³0.67 provides a specificity of 0.999 that the corresponding 
value for Kt/V is ³1.2 and a sensitivity of 0.998 that the corresponding value of Kt/V is 
³1.4. Therefore, this URR threshold provides a simplified means of assessing adequacy of 
IHD provided for management of AKI in the acute care setting.
Funding: NIDDK Support, Veterans Administration Support
TH-PO120
A Novel Treatment for Edema and Fluid Overload: Transdermal Removal 
of Interstitial Fluid  Leonard Ebah,1,2,3 Paul E. Brenchley,1,2,3 Sandip Mitra,1,2,3 
Idalia Dawidowska.3  1Renal Medicine and Research, Manchester Royal 
Infirmary, Manchester, United Kingdom; 2Inst of Cardiovascular Sciences, Univ 
of Manchester, Manchester, United Kingdom; 3Renephra Limited, Manchester, 
United Kingdom.
Background: Fluid overload is highly prevalent in kidney and heart failure, contributing 
to worse outcomes. Diuretics are the mainstay of treatment; they sometimes become 
ineffective requiring intravenous treatment and/or invasive approaches to fluid removal 
such as dialysis. Transdermal fluid removal from interstitial fluid (ISF), the main fluid 
reservoir in these overloaded patients presents a potentially attractive elegant solution to 
fluid removal in these patients.
Methods: Plastic solid microneedle arrays and standard hypodermic needles were 
tested as methods of accessing epidermal ISF whilst vacuum pressure and superabsorbent 
wound dressings were investigated as fluid flow enhancers.
Results: 144 interventions were performed, with 71 (49%) resulting in the extraction 
of at least 1ml of ISF and 36 (25%) at least 5ml. Microneedle access was superior with 
spontaneous significant flow of ISF in 56% of cases compared to 10% for hypodermic 
needles (p<0.0001). Vacuum pressure correlated with extracted ISF volume; r=0.42, 
p=0.03. ISF volume also increased linearly with time (r=0.24, p=0.008) by the equation 
volume(ml)=5.7t(hrs)-4.5. Of the patient characteristics, edema grade (r=0.46, p=0.003), 
edema refill time (r=0.28, p=0.01) and serum albumin (r=-0.33, p=0.004) were significantly 
related to ISF volume extracted. ECFV/TBW was the strongest correlate of ISF volume 
extraction (r=0.40, p=0.0001). With a Bio-ratio of 0.50 or higher, the OR for extracting 
5ml of more was 10.4 [3.4-31]. Microneedle access with suction and a high Bioratio could 
achieve ISF extraction rates of 2ml/cm2/hr which equates to 800ml over 4 hours using a 
10by 10cm skin surface. The microneedle interventions were safe, painless and bloodless.
Conclusions: Microneedle access with vacuum pressure seems promising as a potential 
safe, minimally invasive transdermal treatment of significant fluid overload. Further 
evaluation to refine device characteristics and clarify patient stratification may lead to a 
potential clinical utility of such a device.
TH-PO121
Comprehensive Program to Treat Acute Kidney Injury (AKI) Using 
Peritoneal Dialysis (PD) in Developing Countries  John Callegari,1,2 Grzegorz 
Wystrychowski,3 Nathan W. Levin,1,2 Ewa Zukowska-szczechowska,3 Mary 
Carter.1,2  1Renal Research Inst, New York, NY; 2Sustainable Kidney Care 
Foundation, New York, NY; 3Dept of Internal Medicine, Diabetology and 
Nephrology, Medical Univ of Silesia, Zabrze, Poland.
Background: HD as a therapy for acute kidney injury (AKI) is unavailable in most 
developing countries due to lack of trained staff, equipment, electricity, water treatment, 
and funding. However, peritoneal dialysis (PD) can be established in almost any setting as a 
cheaper modality that requires few resources. A team of pediatric & adult nephrologists with 
nurses, a functional laboratory, and delivery of PD catheters and supplies. Nephrologists 
shoudl be trained to place single cuff Tenckhoff catheters.
Methods: In compliance with these prerequisites, AKI PD programs have been started 
in Benin, Ghana, Tanzania, Cameroon, Ivory Coast, Ethiopia, Uganda and Cambodia with 
support provided by the Sustainable Kidney Care Foundation (SKCF) and the Saving Young 
Lives consortium comprised additionally by the International Society of Nephrology (ISN), 
International Society for Peritoneal Dialysis (ISPD), International Pediatric Nephrology 
Association (IPNA).
Results: So far, 129 AKI patients were treated with PD in these countries. Aproximately 
55% recovered kidney function and were discharged with no need of further dialysis; nearly 
20% were diagnosed with end-stage renal disease and referred to hemodialysis where 
available or given palliative care; 1 in 4 patients died during hospitalization (table 1). 
Peritonitis rates were 12.3% and were not a factor in outcomes (logistic regression analyses).
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Conclusions: PD is a viable treatment modality in low-resource settings and decreases 
mortality rates in the course of AKI to the levels seen in developed countries. The frequency 
of PD-related peritonitis is low and does not affect treatment outcomes.
Funding: Private Foundation Support
TH-PO122
Pulse High Volume Hemofiltration versus Coupled Plasma Filtration 
Adsorption in Septic Shock – A Pilot Randomized Study  Paolo Lentini,1 
Luca Zanoli,2 Massimo de Cal,1 Stefania Rastelli,2 Andrea Contestabile,1 Antonio 
Granata,3 Roberto Dell’Aquila.1  1Nephrology, St. Bassiano Hospital, Bassano 
Del Grappa, Italy; 2Univ of Catania, Italy; 3St. Giovanni di Dio, Italy.
Background: Acute kidney Injury(AKI),a frequent complication in critically ill 
septic patients is an independent risk factor for increased mortality, particularly when 
patients require renal replacement therapy(RRT).High Volume Hemofiltration (HVHF)
and Coupled Plasma Filtration Adsorption(CPFA)have shown potential improvement in 
hemodynamics:however, no studies have compared these two methods.Our aim was to 
compare the hemodynamic effects of HVHF and CPFA in septic shock patients undergoing 
Continuous Renal Replacement Therapy (CRRT).
Methods: A cross-over study enrolling pts with septic shock undergoing CRRT. 
Pts were treated with pHVHF+CVVH on Day 1 and CPFA+CVVH on Day 2. HVHF 
was performed for 8-10 hrs with a replacement fluid rate (Qr) of 85 ml/kg/hr. CPFA was 
performed for 8-10 hrs using Mediasorb (Bellco®Italy) with a maximum plasma flow rate 
of 15%. CVVH was performed for the rest of the day with a Qr of 35 ml/kg/hr. Both HVHF 
and CVVH used polysulfone filters. The primary endpoints were changes in vasopressor 
requirement (expressed as vasopressor score, VS), in noradrenaline (NA) dose (mg/kg/
min), and in mean arterial pressure (MAP) before and after pHVHF and CPFA. These 
values were compared using nonparametric paired tests.
Results: 8 pts(5M/3F,70.5 yr,SOFA 12.5,SAPS II 69.5).VS and NA dose were 
significantly decreased after CPFA(p=0.04).These endpoints were not significantly different 
after pHVHF(p=0.13).When CPFA and pHVHF are compared between each other,the 
change in VS and NA dose becomes NS (p=0.22).There was no significant change in MAP 
with either pHVHF or CPFA.
Conclusions: The data provide no evidence for a difference in hemodynamic effects 
between pHVHF and CPFA in patients with septic shock undergoing CRRT.
TH-PO123
Polymyxin B Hemoperfusion and Renal Outcomes in Septic Shock: A 
Propensity-Matched Analysis  Dinna Cruz,1 Jing Zhang,1 Tsukasa Nakamura.2 
1Univ of California San Diego; 2Shinmatsudo Hospital, Japan.
Background: Septic acute kidney injury (AKI) is a common ICU complication with 
high mortality. Only supportive management is available at this time. Hemoperfusion 
with Polymyxin B fiber column (PMX) reduces blood endotoxin levels & vasopressor 
requirement, & increases blood pressure. These may improve renal perfusion & decrease 
renal tubular cell apoptosis. We hypothesized that PMX may improve renal outcomes in 
sepsis.
Methods: Single center retrospective study of 697 septic shock patients. Patients were 
treated with PMX (n=337) if they met all criteria: SIRS, documented/suspected infection, 
vasopressors despite adequate fluid resuscitation, ³1 organ failure, Gram(-) organism &/or 
elevated endotoxin levels; 360 pts were treated with standard medical therapy (SMT) alone. 
PMX patients were matched 1:1 with SMT patients, based on a propensity score for the 
likelihood of receiving PMX. Groups were compared using survival curve analysis & Cox 
regression for: 1) death or need for RRT at 28-days, and 2) Major Adverse Kidney Events 
(MAKE28): death, need for RRT, or ³1 point increase in renal SOFA score.
Results: Propensity score matching created a matched cohort of 426 patients. The PMX 
& SMT groups were well-matched in terms of baseline characteristics, including initial 
ICU Cr, endotoxin levels, type of organism, & APACHE score. The risk of death/RRT and 
MAKE28 was significantly lower among PMX patients (Figure). On multivariable analysis, 
PMX was associated with lower risk for death/RRT (adj HR 0.48, 95%CI 0.36,0.65) and 
MAKE28 (adj HR 0.48, 95%CI 0.37,0.61). Peak & nadir Cr, ICU & hospital length of 
stay were also lower in PMX group.
Conclusions: In this retrospective study, PMX, when added to SMT, was associated 
with better renal outcomes in septic shock. These results warrant further exploration with 
prospective trials.
TH-PO124
Effect of Polymyxin B Hemoperfusion on Septic AKI: A Systematic Review 
Dinna Cruz, Deepti Mundkur, Ravindra L. Mehta.  UCSD, San Diego.
Background: Septic acute kidney injury(AKI) is common in the ICU, and associated 
with high mortality. Polymyxin B fiber column(PMX) is a medical device that reduces 
blood endotoxin levels in sepsis. In a prior metaanalysis, PMX hemoperfusion was shown 
to improve blood pressure and reduce vasopressor requirement, which could help renal 
perfusion. PMX possibly reduces proapoptotic activity of septic plasma on renal tubular 
cells. A systematic review was performed to assess renal outcomes when PMX is used 
in sepsis.
Methods: We searched MEDLINE, PubMed to identify studies on PMX hemoperfusion 
in sepsis. Full-text articles were screened for renal-related outcomes. The primary endpoint 
was need for acute RRT after enrollment. Secondary endpoints included development of 
AKI, change in Cr, BUN, urine output, urine protein and biomarkers after PMX.
Results: A total of 18 studies (n=591 pts) with renal outcomes were identified. In 6 
RCTs & 1 non-RCT, patients were treated with either PMX+standard medical therapy(SMT) 
(n=188) or SMT alone (n=136). In 10 cohort studies 267 pts were treated with PMX+SMT. 
The following renal outcomes were reported: need for RRT (n=4 studies), serum Cr &/or 
CrCl (n=10), BUN (n=4), urine output (n=5), urine protein/biomarkers (n=6). One study 
reported severe AKI (Failure) in 0/8 PMX and 1/8 SMT patients at 72h. Pooled analysis 
showed a non-significant trend for reduced need for RRT with PMX (OR 0.44, 95%CI 
0.19,1.04). Figure 1 shows Cr and urine output before and after PMX. Weighted mean 
difference for Cr after PMX was not significant but there was an increase in urine output 
by 45 ml/hr (95%CI 15,74) after PMX.
Conclusions: Based on published studies, PMX has no significant effect on RRT need 
or Cr in patients with septic shock when added to SMT, although urine output appeared to 
improve post-PMX. These data provide evidence for scientific equipoise for a randomized 
clinical trial to address this question.
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TH-PO125
Four Hour Infusion Piperacillin-Tazobactam in CRRT Patients Is 
Associated with Improved Target Attainment Compared to 30 Minute 
Infusion  Matthew S. Shotwell,1 Ed Gould,2 Phillip Madonia,2 Ross Marshall 
Nesbit,2 Charbel A. Salem,3 Milen Amde,3 Olufemi Aduroja,3 Seth R. Bauer,4 
Michael J. Connor,3 Joseph J. Groszek,2 Maria E. Taylor,5 Peilin Wei,5 Ashita J. 
Tolwani,5 William Henry Fissell.2  1Biostatistics, Vanderbilt Univ, Nashville, TN; 
2Nephrology and Hypertension, Vanderbilt Univ, Nashville, TN; 3Nephrology and 
Hypertension, Cleveland Clinic, Cleveland, OH; 4Pharmacy, Cleveland Clinic, 
Cleveland, OH; 5Nephrology, Univ of Alabama, Birmingham, Birmingham, AL.
Background: Sepsis is the leading cause of death in acute kidney injury. Dose 
adjustments to account for kidney failure and continuous renal replacement therapy 
(CRRT) may result in poor target attainment. Four hour infusion (EI) of beta lactams may 
result in improved target attainment compared to 30 minute infusion (SI). We conducted 
a multicenter observational study of piperacillin pharmacokinetics in patients receiving 
CRRT and compared predicted target attainment in a typical patient receiving EI or SI.
Methods: Piperacillin concentrations were measured in subjects at Cleveland Clinic (3 
gm q6h, q8h, or q12h SI; n=29) University of Alabama Birmingham (2 gm q6h or q8h, 3g 
q6h SI, n=25) and Vanderbilt University (3 gm q8h or q12h, EI; n=14). A two-compartment 
pharmacokinetic model was fitted simultaneously to all data using nonlinear mixed effects 
regression in R. Target attainment was quantified as the fraction of the dosing cycle wherein 
piperacillin concentration was greater than 64 µg/mL. Target attainment for a typical patient 
was estimated using the population mean (fixed-effect) for each pharmacokinetic parameter.
Results: For EI versus SI in the two most common dosing patterns, 2g q6h and 3g 
q8h, target attainment was improved by 27% (95% CI: 19, 35) and 23% (95% CI: 18, 
28), respectively.
Conclusions: Limits of the study include that it is solely observational, and that subjects 
in Cleveland and Birmingham were enrolled earlier than subjects in Nashville. These 
results characterize the typical patient in this population. Additional analysis is warranted 
to examine the sensitivity of our findings to population pharmacokinetic heterogeneity.
Funding: NIDDK Support, Pharmaceutical Company Support - Gambro Renal 
Systems
TH-PO126
Effects of Complement Factor H and Factor I Deficiency on Anti-MPO 
Induced Crescentic Glomerulonephritis in Mice  Hong Xiao,1 Peiqi Hu,1 
Cheng Wan,1 Matthew C. Pickering,2 Ronald J. Falk,1 J. Charles Jennette.1 
1Pathology and Laboratory Medicine, Univ of North Carolina, Chapel Hill, NC; 
2Molecular Genetics, Imperial College, London, United Kingdom.
Background: Complement alternative pathway (AP) activation plays a critical role 
in the pathogenesis of anti-neutrophil cytoplasmic autoantibodies (ANCA) crescentic 
glomerulonephritis (CGN). AP is negatively regulated by complement factor H (CFH) and 
factor I (CFI). Deficiency of either of these regulators results in uncontrolled C3 activation 
with secondary depletion of C3, factor B and properdin. In this study, we investigate the 
effects of CFH and CFI deficiency in anti-MPO induced CGN in mice.
Methods: 9-11 wk-old CFH and CFI KO and WT B6 mice were injected with anti-MPO 
IgG and were sacrificed at day 6 and kidney tissue was obtained for pathologic examination 
and IF staining with anti-C3 antibodies. Circulating C3 levels were determined by ELISA. 
In vitro neutrophil function was assayed.
Results: At day 6 of anti-MPO treatment, all CFH-/- mice (n=5) developed much 
more severe CGN (mean 85% glomeruli with crescents) compared to the WT control mice 
(n=8, 11% crescents). In contrast, no CGN developed in CHI-/- mice (n=8). Glomerular 
C3 staining shown strong (score 4+) linear capillary wall staining in CFH-/- mice, whereas 
CHI-/- mice had weak (1.5+) mesangial staining. On day 0 and day 6 after anti-MPO 
treatment, the circulating C3 level had no significant differences in WT and CFI-/- mice 
(p>0.05) and substantially reduced in CFH-/- mice (p<0.001). In vitro neutrophil function 
assay showed that anti-MPO IgG caused similar activation of neutrophils from CFH-/-, 
CHI-/- and WT mice.
Conclusions: 1) Absence of the CFH causes more severe anti-MPO induced CGN. 
This is probably because they have uncontrolled alternative pathway activation and 
sufficient glomerular capillary wall deposition of complement activation fragments to 
synergistically attract and amplify anti-MPO activated neutrophils. 2) CHI deficiency 
protects from anti-MPO CGN. This might be because of no glomerular capillary wall C3 
deposits and consumption of circulating AP components, such as factor B and properdin, 
as a consequence of uncontrolled AP activation.
Funding: NIDDK Support
TH-PO127
Can a Bacterial Protein Rescue Disease-Linked Mutations in Complement 
Factor H?  Heather Kerr,1 Edwin K.S. Wong,3 Andrew P. Herbert,2 Anna 
Richards,1 David Kavanagh,3 Paul N. Barlow.2  1Centre for Inflammation 
Research, Univ of Edinburgh, Edinburgh, United Kingdom; 2School of 
Chemistry, Univ of Edinburgh, Edinburgh, United Kingdom; 3Inst of Genetic 
Medicine, Newcastle Univ, Newcastle, United Kingdom.
Background: Factor H (FH) regulates the complement system. Mutations and 
polymorphisms in FH are implicated in atypical haemolytic uraemic syndrome and C3 
glomerulopathies. Studies using short FH fragments suggested detrimental functional 
consequences of many disease-linked amino acid substitutions. The protein PspC from 
Streptococcus pneumoniae hijacks host-derived FH in a complement-evasion strategy. 
Binding of PspCN (N-terminal region of PspC) to wild-type (WT) FH was shown to enhance 
complement regulation implying that PspCN might restore useful levels of regulatory 
activity to disease-related variants of FH.
Methods: Overcoming technical hurdles to recombinant full-length FH production, 
two mutant versions, R53H and S1191A V1197L, were prepared in Pichia pastoris. Using 
surface plasmon resonance (SPR), binding of mutants to C3b, and their C3bBb decay-
accelerating activities (DAA), were compared with WT FH. Mutants were also compared 
to WT FH in erythrocyte DAA and co-factor lysis assays. Measurements were repeated 
in the presence of PspCN.
Results: R53H decreased FH affinity for C3b and impacted negatively on both assays 
used to measure DAA as well as the haemolysis-based assay of co-factor activity. The double 
mutant had WT-like abilities to bind C3b and decay C3b convertase on an SPR chip, but 
was deficient in cell-based assays, and especially in co-factor activity. PspCN enhanced 
both C3b binding and DAA on the SPR chip by both mutants and WT. The effects of PspCN 
on cell-based assays were less clear.
Conclusions: These studies with full-length FH imply that disease-linked substitutions 
in its C-terminal surface-recognition region (unlike those in the functionally critical 
N-terminal region) have little effect on SPR-based assays performed on a non-native and 
hence, in effect, foreign surface. Whether the enhancing effects of PspCN in SPR-based 
assays can be replicated on host-cell surfaces has therapeutic implications and will be 
discussed in the light of ongoing measurements.
TH-PO128
Recombinant Complement Factor H in a Model of C3 Glomerulopathy 
Heather Kerr,1 Andrew P. Herbert,2 Talat H. Malik,3 Anna Richards,1 Paul 
N. Barlow,2 Matthew C. Pickering.3  1Centre for Inflammation Research, 
Univ of Edinburgh, Edinburgh, United Kingdom; 2School of Chemistry, Univ 
of Edinburgh, Edinburgh, United Kingdom; 3Centre for Complement and 
Inflammation Research, Imperial College, London, United Kingdom.
Background: C3 glomerulopathy (C3G) is an inflammatory renal disorder that is 
associated with abnormal complement alternative pathway activation. This includes 
deficiency of complement factor H (FH), the negative regulator of the alternative pathway. 
FH gene-targeted (FH-/-) mice are a model of C3G and spontaneously develop reduced 
plasma C3 levels and abnormal deposition of C3 within the glomerulus. We tested the 
efficacy of recombinant murine FH (mrFH) to restore C3 regulation in FH-/- mice.
Methods: MrFH was produced in Pichia pastoris. Plasma-purified mFH or hrFH 
(human) was used as a control. In experiment 1, mice received an injection of mrFH or 
mFH and were culled at 24 hours. In experiment 2, mice received a daily injection of mrFH 
or hrFH for 10 days and were culled at 11 days.
Results: A single injection of mrFH resulted in increased plasma FH and C3 levels 
peaking at 6 hours. In mice receiving mFH, plasma FH and C3 levels remain elevated at 
24 hours. Glomerular histology at 24 hours showed a decrease in glomerular C3 staining 
both for mice receiving mFH and mrFH. In experiment 2, mice receiving daily injections 
of either mrFH or hrFH exhibited elevated levels of both plasma FH and C3 at 24 hours, 
but these decreased to baseline within five days. All mice showed reduced C3 glomerular 
staining at 11 days. Mice receiving hrFH showed strong glomerular IgG staining at 11 days.
Conclusions: Restoration of complement regulation is the goal of treatment for C3G. 
In our experiments mrFH increased plasma C3 and FH levels and reduced glomerular 
C3 deposition. The rapid reduction in FH and C3 levels (relative to a slower decline in 
mice treated with plasma-purified FH) may be due to glycosylation differences between 
plasma-purified and recombinant protein. Administration of recombinant FH is a rational 
treatment choice for patients with C3G associated with deficiency or dysfunction of FH. 
However, the challenges of this approach include plasma half-life, immunogenicity and 
large scale production.
TH-PO129
Reduced Renal Infiltration of Inflammatory Cells following Selective 
Endothelial Injury in Mice Deficient for C3, C3aR or C5aR  Jan Sradnick, 
Anika Luedemann, Vladimir T. Todorov, Christian Hugo, Bernd Hohenstein. 
Div of Nephrology, Dept of Internal Medicine III, Univ Hospital CGC, Dresden, 
Germany.
Background: Complement dysregulation leads to kidney specific diseases such as C3 
glomerulopathy and thrombotic microangiopathy. However, data on the specific role of the 
complement system for local inflammation after endothelial cell injury (ECI) is limited. 
We here investigated the inflammatory response following site selective renal ECI in mice 
deficient (-/-) for C3, C3ar or C5ar.
Methods: Renal ECI was induced by intra-arterial injection of Concanavalin(ConA)/
anti-ConA in C3-/- (day (d) 2:n=5; d4: n=4), C3ar-/- (d2:n=5; d4: n=4), C5ar -/- (d2:n=4; 
d4: n=3) deficient and C57Bl/6 wildt-type (wt) mice (n=5; n=4). Six wt mice served as 
sham control (ctrl). Kidneys were harvested on day 2 or day 4. Multicolor FACS analysis 
was used to count macrophages (M), neutrophils (N) and T-cells (T). Cells were stained 
with the following antibodies:  CD11b+ F4/80+ GR1- CD11c- (M), GR1+ CD11b+ (N) 
and CD4+ CD8+ (T). Histology was used to analyze macrophages (MAC2, F4/80) and 
the ECI  (CD31).
Results: Inflammatory cells were increased in C57Bl/6 mice 2 days after ECI (C57Bl/6: 
M=1.3%±0.4; N=2.9%±1.0; T=0.8±0.3 vs. sham:  M=0.1%±0.04; N=0.15%±0.09; 
T=0.2%±0.2; p<0.01). Compared to C57Bl/6 wt mice a reduced influx of macrophages (C3-
/-: 0.3%±0.05; C3ar-/-: 0.4%±0.2; C5ar-/-: 0.5%±0.3) and neutrophils (C3-/-: 0.9%±0.74; 
C3ar-/-: 0.9%±0.9; C5ar-/-: 0.7%±0.5; ctrl: 0.15%±0.09) was observed in C3, C3ar and 
C5ar deficient mice (p<0.01). CD8+ cells were reduced in C3 -/- mice (C3-/-:0.3%±0.03 
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d2: wt:0.8%±0.33). Histological analysis using MAC2 and F4/80 support these findings. 
While histology demonstrated enhanced ECI, no differences in ECI were detected between 
C3, C3ar and C5ar and wt mice.
Conclusions: The recruitment of inflammatory cells into the kidney after selective ECI 
depends on the presence and function of C3, C3ar and C5ar. However, C3, C3ar and C5ar 
deficiency did not modulate the extent of ECI in this disease model.
TH-PO130
Investigating a Pathogenic Role of C5a-C5aR1 Signaling in Diabetic 
Nephropathy  Sih Min Tan,1,2 Vicki Thallas,1 Alison Skene,3 Richard J. 
MacIsaac,4,5 David A. Power,3,4 Mark E. Cooper,1,2 Elif Ekinci,3,4 Trent M. 
Woodruff,6 Melinda T. Coughlan.1,2  1Diabetic Complication, Baker IDI Heart 
& Diabetes Inst, Melbourne, VIC, Australia; 2Central Clinical School, Monash 
Univ, Melbourne, VIC, Australia; 3Endocrine Centre, Austin Health, Melbourne, 
VIC, Australia; 4Dept of Medicine, The Univ of Melbourne, VIC, Australia; 5Dept 
of (ndocrinology 	 Diabetes, St. 9incent¶s Hospital, Melbourne, 9IC, Australia; 
6School of Biomedical Sciences, Univ of Queensland, Brisbane, Australia.
Background: Complement 5a is a potent pro-inflammatory effector molecule. Although 
previous studies indicate a link between activation of the complement pathway and diabetic 
nephropathy (DN), the role of C5a and its receptor C5aR1 in DN has yet to be determined.
Methods: Complement signaling was characterized in type 1 diabetic (T1D) human, 
rat and mouse kidneys. C5a-C5aR1 signaling axis was inhibited by using the highly 
selective and potent C5aR1 antagonist, AcF-[OPdChaWR] (PMX53), in streptozotocin 
(STZ)-induced diabetic mice (2mg/kg/day, drinking water, 24 weeks, n=6-15 mice/group). 
C5 and C5aR1 were measured by qRT-PCR and immunohistochemistry. Urinary C5a and 
albumin were measured by ELISA.
Results: The expression of C5aR1 was increased in renal biopsies from patients with 
DN compared to healthy donor kidneys (4.2±1.3 vs 15.7±1.8%; p<0.001, n=9-23). C5aR1 
expression was upregulated in the renal cortex of STZ-induced diabetic rats (1.0±0.1 
vs 1.5±0.2 fold change; p<0.05) and spontaneously diabetic Ins2-Akita mice (1.0±0.1 
vs 1.4±0.1 fold change; p=0.05) compared to controls. Urinary C5a was increased in 
the diabetic rats (181±56 vs 1153±297 ng/24hr; p<0.05) and Ins2-Akita mice (50±9 vs 
151±32pg/24hr, p<0.01) after 16 and 26 weeks of diabetes, respectively and was associated 
with albuminuria (p<0.05). Blockade of C5aR1 signaling with PMX53 attenuated 
albuminuria in STZ-induced diabetic mice when compared to vehicle-treated diabetic 
controls (247±30 vs 74±28 µg/24hr; p<0.001).
Conclusions: The C5a-C5aR1 signaling is activated in human and experimental 
DN. A pilot study using PMX53 indicates that pharmacological blockade of C5aR1 is 
renoprotective in DN. Further studies are required to validate C5aR as a therapeutic 
target in DN.
Funding: Private Foundation Support
TH-PO131
Identif ication of Glycosaminoglycans That Inhibit  Specific 
Complement Pathways  Ditmer Talsma,1 Romain Vives,2 Marc Maj Seelen,1 
Coen A. Stegeman,1 Jacob van den Born.1  1Nephrology, UMCG, Groningen, 
Netherlands; 2Inst. for Struct. Biol., Univ of Grenoble, Grenoble, France.
Background: Complement has been shown to play a role in renal diseases, such 
as hemolytic uremic syndrome, C3 glomerulopathy and renal transplantation. It is well 
known that heparin and other glycosaminoglycans (GAGs) reduce complement activation. 
However, no studies have yet compared  the complement pathway specific inhibitory 
properties of a library of GAGs. We have tested over 70 different GAGs for their complement 
inhibiting potential and their specificity for either of the complement pathways.
Methods: 72 GAG-based polysaccharides were tested for their complement inhibiting 
potential in the Wieslab complement screening assay. To pinpoint the inhibitory effect of 
GAGs on the lectin pathway (LP), the interference of GAGs on the binding of MBL to 
mannan and further C4 activation was tested. GAGs were also tested in the Wieslab ficolin 
3 screening kit to evaluate their  effect on ficolin based LP activation. Direct binding of 
LP components to heparin was assessed by detecting MBL and MASP 1 & 2 after serum 
incubation to immobilized heparin-albumin.
Results: Unfractionated regular and partially desulfated heparin exhibit dose-dependent 
inhibitory potential of all three complement pathways, while small heparin and heparan 
sulfate (HS)-derived oligosaccharides show specific LP inhibition. These small heparin/
HS derivatives do not interfere with the binding of MBL to mannan, but do inhibit the 
MASP-based activation of C4 and ficolin-3 mediated LP activation. We also find a dose-
dependent binding of the MBL/MASP 1&2 complex to immobilized heparin-albumin, 
but not to albumin.
Conclusions: A large number of heparin(oids)block all three pathways of complement, 
however small heparin/HS oligosaccharides inhibit the LP of complement specifically, 
according to our data via the inhibition of the MASP enzymes. Our data also suggest that 
HS on cell surfaces and in basement membranes might act as a docking platform for the 
MBL-MASP complex. We speculate that GAG-derived polysaccharides may be useful as 
MASP specific LP inhibitors.
TH-PO132
Anti-GBM Antibody-Mediated Glomerular Injury Depends on Neutrophil 
Degranulation  Dawn J. Caster,1,2 Erik Korte,1 Liliane Hobeika,1 David W. 
Powell,1 Kenneth R. McLeish.1,2  1Medicine, Univ of Louisville, Louisville, KY; 
2Dept of 9eterans Affairs, Louisville, KY.
Background: Acute proliferative glomerulonephritis (GN) induced by ANCA or 
by anti-GBM antibodies is neutrophil (PMN) dependent. In vitro studies suggested that 
endothelial injury induced by ANCA was dependent on PMN granule enzymes, not release 
of reactive oxygen species. To test the hypothesis that PMN degranulation is responsible 
for acute GN, degranulation was inhibited in an in vivo model of heterologous anti-GBM 
disease in mice.
Methods: After collection of urine for baseline protein excretion, two groups of 10 
C57BL/6 mice received an intravenous injection of sheep anti-rat GBM (1.5 mg/ 25 g body 
weight) at time 0. One group also received an intravenous injection of a TAT-fusion protein, 
TAT-SNAP-23 (0.5 mg/kg body weight) at time 0 and 6 hr later. We showed previously 
that TAT-SNAP-23 inhibited PMN degranulation in vitro and in vivo. At 24 hr urine was 
collected for protein excretion, and then mice were sacrificed and kidney tissue prepared 
for histology. Urine protein was measured as the protein:creatinine (ug/mg). Glomerular 
proliferation and mesangial expansion were graded on a 0 to 4+ scale.
Results: Baseline urine protein:creatinine did not differ between groups (18 + 3.3 vs 
22 + 3.5, untreated vs TAT-SNAP-23 treated). Anti-GBM induced a significant increase in 
proteinuria, and that increase was significantly inhibited by TAT-SNAP-23 treatment (376 
+ 108 vs 73 + 15, untreated vs TAT-SNAP-23 treated). By light microscopy there was no 
difference in proliferation (2.2 + 0.2 vs 2.0 + 0.2) or mesangial expansion 1.2 + 0.3 vs 1.2 
+ 0.2) between the two groups. By electron microscopy the degree of podocyte foot process 
effacement was reduced by TAT-SNAP-23 treatment.
Conclusions: We conclude that PMN degranulation plays a critical role in acute 
glomerular injury induced by anti-GBM antibody deposition. We postulate that proteinuria 
may result from direct podocyte damage by PMN granule enzymes.
Funding: Other NIH Support - NIAID, Veterans Administration Support
TH-PO133
Shared and End Organ Specific Transcriptional Networks in Skin versus 
Kidney Biopsies in Systemic Lupus  Celine C. Berthier, Jasmine N. Stannard, 
Emily M. Myers, Lori Lowe, Tamra J. Reed, Sean Eddy, Matthias Kretzler, J. 
Michelle Kahlenberg.  Univ of Michigan.
Background: Patients with subacute cutaneous (sCLE) lesions have higher risk of 
lupus nephritis (LN) compared to those with discoid (DLE) lesions. We hypothesized that 
renal flares may be triggered via a crosstalk between skin and kidneys. To determine the 
potential factors contributing to this increased risk, we used systems biology approaches 
to integrate the regulatory events occurring specifically in sCLE and DLE and compared 
with those in LN.
Methods: Formalin-fixed paraffin-embedded tissue from 8 normal, 22 DLE and 24 
sCLE rash biopsies were analyzed via microarrays. Gene expression profiles from 22 class 
III + IV LN and 14 healthy microdissected human renal biopsies (ERCB) were compared.
Results: Analyses using Genomatix and Ingenuity softwares highlighted a strong 
upregulation of IFNg associated pathways unique to DLE, and IL-4 a likely prominent 
DLE-specific regulator. Type I IFN signaling predominated in sCLE, with unique CD14, 
CCL-2,-20 chemokine expression. Respectively 415 and 435 genes were regulated in 
the same direction in the glomeruli of LN patients vs controls and in DLE and sCLE vs 
normal (q-value <0.01). The 85 genes regulated only in the LN glomeruli and DLE rashes 
represented a mainly down-regulated network highlighting MEP1B, CDH1 and CD8a as 
main nodes. Top pathways were epithelial adherens junction signaling. The 105 genes 
specific to LN glomeruli and sCLE showed a mainly up-regulated network with ITGB2, 
CD40, SYK, TIMP1 as major nodes. Ingenuity top pathway was crosstalk between 
dendritic cells and natural killer cells, both of which may play a role in cutaneous and 
renal lupus pathogenesis.
Conclusions: DLE and sCLE have overlapping and unique transcriptional expression 
signatures which may guide therapeutic decisions and predict renal involvement. Further 
analysis of these specific profiles may identify the molecular crosstalk mechanism between 
skin and kidneys, as well as targets for novel therapy of cutaneous lupus lesions which could 
help to prevent or delay the renal disease. Our data suggest an inflammatory cell crosstalk 
between skin and kidneys in sCLE, which may not happen in DLE.
Funding: Other NIH Support - NIAMS R03-AR-066337
TH-PO134
Molecular Determinants of Myeloperoxidase-ANCA Glomerulonephritis: 
Transcriptomic Analysis Across Three Species  Maja Lindenmeyer,1 Hamad Al 
nuaimi,2 Peter W. Hewett,2 Viji Nair,3 Caroline O.S. Savage,2 Matthias Kretzler,3 
Mark Alan Little.5  1Klinikum Harlaching, Germany; 2Univ of Birmingham, 
United Kingdom; 3Univ of Michigan; 4UMC Groningen, Netherlands; 5TCD, 
Ireland.
Background: Human myeloperoxidase (MPO)-ANCA vasculitis causes crescentic 
GN that results in glomerular destruction. This has been modelled in rats (EAV) and mice 
(MEV), although it tends to resolve spontaneously in these models with little glomerular 
scarring. To investigate conserved and divergent molecular pathways involved in glomerular 
injury we analysed the glomerular transcriptome in EAV, MEV and humans with MPO-
ANCA vasculitis.
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Methods: Glomeruli were microdissected from WKY rats immunised with MPO 
(EAV) or human albumin (control), from mice receiving anti-MPO (MEV) or BSA (control) 
antibodies raised in MPO-/- mice (n=5/group), and from patients with MPO-ANCA GN 
(n=7) and healthy controls (n=18). RNA expression was analysed on Affymetrix arrays. 
Differential regulation was assessed by ChipInspector and rodent/human orthologs identified 
using HomoloGene. After restriction of gene lists using co-citation at sentence level, the 
human network was used to overlap with mouse and rat networks using TALE. In 74 
selected genes, regulation was confirmed by rtPCR.
Results: 3512, 1725 and 783 glomerular genes were significantly associated with GN 
in humans, mice and rats respectively. We observed overlap between human and mouse in 
675 (12.9%), human and rat in 134 (3.1%) and across all 3 species in 179 (2.9%) genes. 
Of these 179 genes, 135 (75.4%) were differentially regulated in the same direction and 
44 (24.6%) in opposite directions. We identified 12 canonical pathways (p value <0.001) 
conserved between human and mouse, and 5 between human and rat.
Conclusions: The transcriptomic profile in MEV was more similar to human disease 
than EAV. 2.9% of differentially regulated genes were conserved across all 3 species, 
with a quarter of these regulated in opposite directions between rodent and human. These 
data provide insights into both shared pathophysiology and mechanisms underpinning the 
divergent clinical phenotype between rodent and human MPO-ANCA GN.
Funding: Government Support - Non-U.S.
TH-PO135
PRTN3 and MPO Expression Correlates with Disease Activity in a Large 
Inception Cohort with Longitudinal and Serial Measurements Among 
Patients with ANCA Disease  Jia Jin Yang,1 JulieAnne G. McGregor,1 
Elizabeth J. Brant,1 Caroline J. Poulton,1 Candace Henderson,1 Britta E. Jones,2 
J. Charles Jennette,2,1 Dominic J. Ciavatta,3 Ronald J. Falk,1,2 William Franklin 
Pendergraft.1  1Medicine, UNC-CH; 2Pathology, UNC-CH; 3Genectics, UNC-
CH, Chapel Hill, NC.
Background: We demonstrated aberrant up-regulation of autoantigen genes, PRTN3 
and MPO, in mature neutrophils and monocytes from patients with ANCA disease (J Am 
Soc Nephrol 2004, 15:2103-14). Here, we performed a longitudinal and serial analysis of 
PRTN3 and MPO expression following their disease course.
Methods: A total of 1063 leukocyte samples were collected from 152 ANCA-patients 
during various stages of disease activity and compared to 152 healthy controls. These 
patients were followed serially every 3 months over the past 5 years. Q-PCR was used to 
measure mRNA levels.
Results: PRTN3 (155±506, p<0.0001) and MPO (384±940, p<0.0001) mRNA levels 
were significantly up-regulated in leukocytes from patients with ANCA disease compared 
to healthy controls (PRTN3:16±34; MPO:56±54). PRTN3 and MPO gene transcription 
correlated closely with disease activity. In the majority of patients with systemic vasculitis, 
their disease course was characterized by elevated expression in active disease and reduced 
expression in remission. The duration of increased PRTN3 and MPO expression was variable 
from several days to several months. Increased PRTN3 and MPO mRNA levels returned 
to normal in all patients with stable remission. 
However, low PRTN3 and MPO mRNA levels were also observed in some active 
patients, particularly in those with limited organ involvement.
Conclusions: Our longitudinal and serial analysis of PRTN3 and MPO expression in 
patients with ANCA disease indicates that regulation of PRTN3 and MPO genes strongly 
tracks with disease activity suggesting that expression of these ANCA autoantigens is 
involved in disease pathogenesis.
Funding: NIDDK Support
TH-PO136
Galactose-Deficient IgA1-Containing Immune Complexes Induce 
Proliferation of Human Mesangial Cells and Activate PDGF/PDGFR 
Signaling Pathway  Zhi qiang Huang,1 Xianwen Zhang,1,2 Qi Bian,1,3 Joshua 
Charles Anderson,1 Stacy D. Hall,1 Christopher D. Willey,1 Bruce A. Julian,1 
Jan Novak.1  1Univ of Alabama at Birmingham, Birmingham, AL; 2Medicine, 
Longhua Hospital, Shanghai Univ of Traditional Chinese Medicine, Shanghai, 
China; 3Medicine, Changhai Hospital, Second Military Medical Univ, Shanghai, 
China.
Background: Our prior kinomic profiling showed that circulating immune complexes 
(CIC) and engineered immune complexes (EIC) consisting of galactose-deficient IgA1 
(Gd-IgA1) bound by anti-Gd-IgA1 autoantibodies activated multiple tyrosine kinases in 
cultured human mesangial cells (hMCs) and induced cellular proliferation. Activation of 
PDGF signaling and an anti-apoptotic processes were two major processes detected. In 
this study, we assessed the mechanisms involving PDGF/PDGFR and ERK1/2 signaling 
in hMC stimulated with CIC from sera of patients with IgAN and EIC.
Methods: CIC were isolated from sera of IgAN patients using size-exclusion 
chromatography. EIC were prepared using Gd-IgA1, anti-Gd-IgA1 recombinant IgG1, and 
human serum and then isolated using size-exclusion chromatography. hMC proliferation 
was determined using bromodeoxyuridine (BrdU) uptake. Gene expression of PDGF A, 
PDGF B, PDGF receptor-α (PDGFR-α) and PDGFR-β was determined using RealTime 
RT-PCR. Signaling induced by CIC or EIC was assessed by analyzing cell lysates using 
SDS-PAGE and Western blotting.
Results: Twenty-four hour incubation of hMC with CIC increased cellular proliferation 
by 30-50%; incubation with EIC increased cellular proliferation by 30-40%. Incubation with 
CIC and EIC for 15 min and 24 h enhanced phosphorylation of PDGFR-β and ERK1/2. 
Incubation of hMC with CIC for 24 h enhanced expression of mRNA of PDGF A, PDGF 
B, and PDGFR-α. Incubation with EIC for 24 h enhanced expression of PDGFR-α and 
PDGFR-β.
Conclusions: CIC and EIC stimulated proliferation of hMC and activated PDGFR 
and ERK1/2 signaling. Understanding how CIC and EIC mediate signaling in hMC may 
lead to future therapeutic approaches for IgAN.
Funding: NIDDK Support, Private Foundation Support
TH-PO137
The Pathogenic Role of NLRP3 Inflammasome in IgA Nephropathy and 
Establishment of a Therapeutic Strategy  Shuk-Man Ka,1 Yu-Juei Hsu.2 
1School of Medicine, Graduate Inst of Aerospace and Undersea Medicine, 
National Defense Medical Center, Taipei, Taiwan; 2Div of Nephrology, Dept 
of Internal Medicine, Tri-Service General Hospital, National Defense Medical 
Center, Taipei, Taiwan.
Background: IgA nephropathy (IgAN) is the most common cause of primary 
glomerular disorders induced by IgA immune complex. Inflammatory responses have been 
shown to correlate with the progression of IgAN. NLRP3 inflammasome, a multiprotein 
complex, positively regulates caspase-1 activity and the maturation and release of IL-1β. 
NLRP3 inflammasome plays an important role in inflammatory response and controls the 
pathogenesis of various inflammatory diseases. However, the potential pathogenic role of 
NLRP3 inflammasome on IgAN is unclear.
Methods: The pathogenic role of NLRP3 inflammasome and molecular mechanisms 
on IgAN pathogenesis using NLRP3 deficient mice and NLRP3 in kidney were specific 
knockdown by an ultrasound-mediated microbubble shRNA gene transfer method.
Results: NLRP3 deficient and blockage resulted in attenuation of albuminuria, 
improved renal function, and blocking of renal progressive lesions, including glomerular 
proliferation, and periglomerular mononuclear leukocyte infiltration. These findings were 
associated with (1) inhibiting ROS production and NF-κB activation in the kidney, (2) 
reducing NLRP3 inflammasome activation in the kidney, (3) inhibiting effect/memory 
T-cell activation and IL-17 expression, and (4) inhibiting maturation and activation of 
dendritic cells.
Conclusions: These results indicate that activation NLRP3 inflammasome is involved 
in the development of IgAN, and a kidney-specific knockdown of NLRP3 may have 
therapeutic potential for IgAN.
Funding: Government Support - Non-U.S.
TH-PO138
Effects of DPPIV Inhibitor on Renal Function in Mice Model of Adriamycin 
Induced Nephropathy  Hye Sook Min,1 Jin Joo Cha,1 Kitae Kim,1 Jungyeon 
Ghee,1 Jung Eun Kim,1 Ji Eun Lee,2 Hyunwook Kim,2 Jee Young Han,3 Dae 
R. Cha,1 Young Sun Kang.1  1Internal Medicine, Korea Univ Medical College 
Ansan Hospital, Republic of Korea; 2Internal Medicine, Wonkwang Univ Sanbon 
Hospital, Republic of Korea; 3Pathology, Inha Univ College of Medicine, 
Republic of Korea.
Background: The murine model of adriamycin(ADR) induced nephropathy is 
characterized by severe proteinuria, development of podocyte injury and glomerulosclerosis. 
The aim of our study was to investigate the mechanism and preventive effect of fibrosis 
in glomerular, tubular and interstitial tissue associated with DA1229 treatment in ADR-
induced nephropathy.
Methods: 6-week-old balb/c mice were divided into 4 groups as follows: 1) untreated 
after injection of ADR(control of group 2), 2) immediately treated with DA1229 for 
3 weeks after injection of ADR(preventive protocol), 3) untreated after injection of 
ADR(control of group 4), 4) treated with DA1229 for 2 weeks after 3 weeks from injection 
of ADR(therapeutic protocol).
Results: Treatment with DA1229 showed preventive effect on weight gain and renal 
hypertrophy after 5 weeks of injection of ADR. Plasma DPPIV activity was significantly 
decreased in treatment with DA1229. DPPIV activity in kidney was significantly increased 
after injection of ADR and was decreased with DA1229. Notably, both preventive and 
therapeutic protocol significantly decreased proteinuria and albuminuria induced by ADR 
injection. Urinary excretion of nephrin was significantly decreased and inflammatory and 
fibrotic molecules in kidney tissue were significantly inhibited with DA1229 treatment. 
Additionally, infiltration of macrophages and fibrosis in the kidney were attenuated with 
DA1229 treatment in ADR groups.
Conclusions: Our data suggest that DA1229 might protect renal injury from podocyte 
injury in ADR-induced nephropathy, via antiinflammatory and antifibrotic effects. DA 1229 
might be a potential therapeutic agent in a variety of glomerular disease inducing proteinuria.
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TH-PO139
Effects of Highly Selective Adenosine 3 Receptor Antagonist on 
Renal Function in Mice Model of Adriamycin Induced Nephropathy 
Hye Sook Min,1 Jin Joo Cha,1 Kitae Kim,1 Jung Eun Kim,1 Jungyeon Ghee,1 
Ji Eun Lee,2 Hyunwook Kim,2 Jee young Han,3 Sung Jin Kim,4 Young Sun 
Kang,1 Dae R. Cha.1  1Internal Medicine, Korea Univ Medical College Ansan 
Hospital, Republic of Korea; 2Internal Medicine, Wonkwang Univ Medical 
College Sanbon Hospital, Republic of Korea; 3Pathology, Inha Univ College 
of Medicine, Republic of Korea; 4Internal Medicine, Anyang Sam Hospital.
Background: Concentration of adenosine in normal kidney increases markedly 
during renal hypoxia and ischemia. Previous studies have reported that mice lacking renal 
A3 adenosine receptor(A3AR) show significant protection against acute kidney injury, 
such as ischemia-reperfusion injury and myoglobinuira-induced injury. Moreover, A3AR 
antagonist blocked the development and attenuated the progression of renal fibrosis. The 
aim of this study was to investigate the effects of highly selective adenosine 3 receptor 
antagonist(LJ1888) treatment in ADR-induced nephropathy.
Methods: We designed three animal groups as following: 1) 6-week-old balb/c 
mice(control), 2) untreated with LJ1888 after injection of ADR(11mg/kg), 3) treated with 
LJ1888(10mg/kg) for 2 weeks after 5 weeks of injection of ADR.
Results: Body weight was significantly decreased in both ADR injection groups. ADR 
injection significantly induced proteinuria and albuminuria, which were notably reduced 
after treatment of LJ1888. Urine 8-isoprostane and kidney lipid peroxidase level were also 
decreased with LJ1888. Urinary excretion of nephrin was significantly reduced and kidney 
nephrin stain showed increased nephrin expressions in the glomeruli of LJ1888 group. Less 
glomerular injury and macrophage infiltration were observed in LJ1888 treated kidney. 
Immunoreactions with profibrotic molecule were significantly decreased with LJ1888. 
Additionally, protein expressions of Nox4, TGF-b1, NF-κB were attenuated with LJ 1888.
Conclusions: These renoprotective effects of LJ1888 on ADR-induced nephropathy 
may be associated with protective effect on podocyte injury. LJ1888 might be a potential 
therapeutic agent for glomerulonephropathy inducing proteinuria.
TH-PO140
Innate Immunity Is Activated Early in Adriamycin Nephropathy and Is 
Strongly Associated with Lymphocyte Infiltration  Viviane D. Faustino, 
Simone CA Arias, Flavia P. Albuquerque, Camilla Fanelli, Victor F. Avila, 
Lisienny CT Rempel, Orestes Foresto-Neto, Gizely CS Moreira, Claudia R. 
Sena, Vivian L. Viana, Denise M. Malheiros, Niels OS Camara, Roberto Zatz, 
Clarice K. Fujihara.  Univ of Sao Paulo, Brazil.
Background: Protein overload promotes interstitial injury by unclear mechanisms 
that may involve innate immunity (INIM). Here we investigated the time course of INIM 
activation in adriamycin nephropathy (AN), and the participation of lymphocytes (LY) 
in this process.
Methods: AN (5 mg/kg iv) was induced in 30 Munich-Wistar rats. Control rats (C, 
N=10) received saline only. At 2 (AN2wk), 4 (AN4wk) and 20 (AN20wk) wks, albuminuria 
(ALB, mg/day), interstitial macrophages (Mĭ) and LY (cells/mm2), α-SMA and collagen 
(COL). Renal INIM was assessed by gene expression (NLRP3 and IL-6, 2-∆∆Ct) and protein 
content (IL-1β, Casp1, TLR4). Four additional AN rats received mycophenolate mofetil 
(MMF, 10 mg/Kg/day, vo), and their ALB, LY, α-SMA, COL and renal content of IL-1β, 
Casp1 and TLR4 were assessed at 30 days.
Results: 
C AN2wk AN4wk AN20wk
ALB 4±2 336±34a 356±49a 505±34abc
Mĭ 10±2 213±50a 188±29a 272±49abc
LY 19±5 149±23a 188±18a 234±22abc 
%α-SMA 2±1 9±2a 12±2a 19±3abc
%COL 3±1 10±3a 13±2a 27±2abc
IL-1β 0.5±0.1 1.3±0.4 1.8±0.4a 4.4±0.9abc
NLRP3 1.0±0.1 1.8±0.3a 2.4±0.3a 2.1±0.2a
Casp1 1.0±0.2 1.6±0.3 1.5±0.5 4.0±0.6abc
TLR4 1.0±0.2 3.4±0.9a 3.4±1.0a 8.5±1.4abc
IL-6 1.0±0.1 8.1±2.7a 8.5±2.3a 12.0±1.9a
Mean±SE, ap<0.05 vs C, bp<0.05 vs. AD2wk , cp<0.05 vs. AD4wk
Massive ALB promoted early and intense Mĭ/LY infiltration and % α-SMA/COL, 
and activated renal INIM. Ly correlated strongly with INIM parameters. All parameters 
increased with time. MMF treatment significantly reduced LY (81±12), α-SMA (4±1) and 
COL (6±1), without changing ALB.
Conclusions: In AN, INIM is activated in concomitance with the early development 
of renal injury, and relates strongly with lymphocyte infiltration. Both inflammation and 
INIM activation parallel the progression of renal injury in tis model. FAPESP/CNPq.
TH-PO141
Inhibition of NF-κB Signaling in Podocytes Ameliorates Albuminuria 
in Adriamycin-induced Nephropathy  Tadashi Yoshida, Maho Yamashita, 
Matsuhiko Hayashi.  Apheresis and Dialysis Center, Keio Univ School of 
Medicine, Shinjuku, Tokyo, Japan.
Background: Inflammation involving the activation of the NF-κB signaling has been 
shown to contribute to proteinuria in chronic kidney disease. NF-κB is expressed not only 
in inflammatory cells, such as lymphocytes and macrophages, but also in podocytes. We 
herein examined the role of NF-κB in podocytes in adriamycin-induced nephropathy.
Methods: Podocyte-specific truncated IκB expressing (Pod-IκBDN) mice, in which 
the NF-κB signaling was inhibited selectively in podocytes, were generated and analyzed 
their phenotype following the intravenous injection of adriamycin. Expression of nephrin 
and podocin was examined by immunostaining.
Results: Pod-IκBDN mice did not exhibit any abnormalities in body weight, blood 
pressure, and the heart rate before the treatment. Following the administration of adriamycin, 
albuminuria was observed in both Pod-IκBDN mice and control mice. However, of 
importance, the amount of albuminuria in Pod-IκBDN mice (373 ± 122 mg/g creatinine) was 
significantly lower than control mice (992 ±305 mg/g creatinine) 14 days after adriamycin 
injection. Serum concentrations of urea nitrogen were not different between these mice. 
Expression of nephrin and podocin in the glomeruli was decreased in adriamycin-treated 
control mice, but not in Pod-IκBDN mice.
Conclusions: Results suggest that NF-κB in podocytes plays an important role in 
proteinuric renal disease by regulating the expression of podocyte-specific proteins.
Funding: Government Support - Non-U.S.
TH-PO142
Apoptosis Signal Regulating Kinase 1/p38 Signalling Promotes Renal 
Inflammation in a Rat Model of Crescentic Glomerulonephritis 
Liv A. Amos,1,2 Yingjie Han,1,2 John T. Liles,3 David J. Nikolic-Paterson.1,2 
1Dept of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia; 
2Dept of Medicine, Southern Clinical School, Monash Univ, Clayton, Victoria, 
Australia; 3Gilead Sciences Inc, Foster City, CA.
Background: Apoptosis signal-regulating kinase 1 (ASK1) is required for p38 mitogen-
activated protein kinase (MAPK) signalling in tubular cells in response to angiotensin II 
and oxidative stress, but not to IL-1 or LPS. However, it is not known whether ASK1 
is required for p38-dependent glomerular injury. The aim of the study was todetermine 
whether blockade of apoptosis signal-regulating kinase 1 (ASK1) can suppress renal injury 
in rapidly progressive glomerulonephritis.
Methods: Accelerated anti-glomerular basement membrane (GBM) disease was 
induced in groups of 6-8 rats. Treatment with ASK1 inhibitor GS-444217 (30mg/kg/po/
bid) or vehicle began 1hr before anti-GBM serum injection and continued until animals 
were killed on day 1 or 14.
Results: Compared to normal controls, anti-GBM disease showed a 3-fold increase 
in phosphorylated (activated) p38 in glomeruli on day 1 which was prevented by ASK1 
inhibition. In addition, the 20-fold increase in urine protein/creatinine ratio at day 1 was 
prevented by ASK1 inhibitor treatment. In a separate study, vehicle treated anti-GBM disease 
exhibited 30±3% (mean±SD) crescents on day 14, which was reduced to 10±2% by ASK1 
inhibitor (P<0.001). ASK1 inhibitor treatment reduced proteinuria by 50% compared to the 
vehicle group (P<0.01), and prevented an increase in serum creatinine (40±9umol/L vs. 
27±9umol/L; P<0.05). Glomerular macrophage and T cell infiltration was also reduced by 
the ASK1 inhibitor (P<0.05), with an associated reduction in macrophage M1/M2 markers 
(iNOS, CD206). Finally, immunostaining and PCR analysis showed a reduction in renal 
fibrosis with ASK1 inhibitor treatment.
Conclusions: This study suggests that ASK1 is involved in activating p38 MAPK 
signalling in glomerular inflammation. In addition, treatment with GS-444217 decreased 
glomerular inflammation and crescent development. Further studies are required to 
investigate potential effects of therapeutic intervention in established anti-GBM disease.
Funding: Government Support - Non-U.S.
TH-PO143
Transforming Growth Factor β-Activated Kinase 1(TAK1) Attenuates 
Experimental Glomerulonephritis  Liv A. Amos,1,2 Elyce Ozols,1,2 Yingjie 
Han,1,2 David J. Nikolic-Paterson.1,2  1Nephrology, Monash Medical Centre, 
Clayton, Victoria, Australia; 2Medicine, Southern Clinical School, Monash 
Univ, Clayton, Victoria, Australia.
Background: Activation of p38/JNK signalling promotes glomerular inflammation. 
TAK1 is an upstream kinase in the p38/JNK pathway. TAK1 regulates the response to a 
range of stimuli which promote glomerular inflammation (TNF-a, IL-1 and TLR ligands). 
Therefore, we investigated whether TAK1 activates p38/JNK signalling in acute glomerular 
inflammation.
Methods: Global Tak1 gene deletion was induced in Tak1f/fERCre mice via tamoxifen, 
while Tak1f/fPodCre mice have conditional Tak1 deletion in podocytes. Accelerated anti-
glomerular basement membrane (GBM) disease was induced in Tak1f/fERCre and Tak1f/f 
littermate controls (n=8-11) and killed after 3hr or 24hr. Disease was also induced in Tak1f/
fPodCre and Tak1f/f littermate controls (n=5) and killed at 24hr.
Results: Compared to controls, global deletion of TAK1 had no effect upon the initial 
inflammatory response at 3hr in terms of neutrophil and macrophage infiltration and 
platelet deposition. However, at 24hr TAK1 deletion caused exacerbation of glomerular 
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injury compared to littermate controls in terms of: proteinuria (11.9±5 vs 5.4±0.5 mg/
mmol; P=0.03); thrombosis (59±11% vs 8±3% glomeruli; P=0.001); renal function (1.4-
fold increase in serum cystatin c; P<0.01); p38 and JNK activation (p-p38+ cells/gcs 
20.81±0.45 vs 9.8±0.611; P<0.001; p-c-Jun+ cells/gcs 14.62±1.35 vs 8.171±1.12; P<0.05). 
The neutrophil infiltrate had largely subsided in control mice at 24hr; however, prominent 
neutrophil infiltration and platelet deposition was evident in mice with global TAK1 deletion 
at 24hr (neutrophils/gcs 3.27±0.29 vs 0.42±0.06; P<0.05; platelet clumps/gcs 29.88±3.37 
vs 16.69±1.75; P<0.05). This exacerbation of glomerular damage was not due to a direct 
effect upon podocytes since Tak1f/fPodCre mice showed no difference compared to controls 
in proteinuria, p38/JNK activation or thrombosis at 24hr.
Conclusions: TAK1 is a negative regulator of glomerular p38/JNK signalling and acute 
renal inflammation, which may operate via limiting neutrophil-mediated glomerular injury.
Funding: Government Support - Non-U.S.
TH-PO144
Absence of Osteopontin Accelerates Oxidative Stress-Induced Fibrosis 
in Glomerulonephritis  Gabriela E. Garcia,1 Jessica Helen Trostel,1 Luan D. 
Truong,2,3 Richard J. Johnson.1  1Medicine, Univ of Colorado Denver, Aurora, 
CO; 2Pathology, Baylor College of Medicine, Houston, TX; 3Pathology, The 
Methodist Hospital, Houston, TX.
Background: Osteopontin (OPN) is a pro-and anti-inflammatory and profibrotic 
molecule that simultaneously attenuates oxidative stress in the inflammatory milieu. 
Evidence suggests that oxidative stress plays a significant role in the progressive fibrosis by 
upregulating fibrosis related genes. Moreover, elevation of biomarkers of increased oxidative 
stress has been demonstrated in patients with chronic kidney disease. OPN is highly induced 
in nephritic kidney and inactivation of macrophages (Mĭ) by an A2AR agonist, attenuated 
OPN expression and protected from progressive kidney injury.
Methods: To further characterize the role of OPN in kidney injury we use OPN-
/- mice in anti-glomerular basement membrane glomerulonephritis (anti-GBM GN), an 
inflammatory and progressive model of kidney disease.
Results: Wild type and OPN-/- mice did not show histological differences in the 
glomeruli and the tubulointerstitium. However, nephritic kidneys from OPN -/- mice 
showed severe kidney damage compared with those in WT mice. Fibrinoid necrosis, 
crescent formation, and tubulointerstitial injury were significantly higher in OPN-/- mice 
compared to WT mice. In addition, collagen (Col) I, Col III, and Col IV deposition were 
increased in nephritic kidneys from OPN-/- mice compared with WT mice. Mĭ and T 
cell infiltration in nephritic kidneys was not different between WT mice and OPN-/- mice. 
Elevated expression of the reactive oxygen species (ROS)-generating enzyme Nox 4 
was observed in nephritic kidneys from OPN-/- mice. In contrast, Mĭ isolated from WT 
mice and OPN-/- mice did not show difference in the expression of Nox4. Importantly, 
the antigen-specific humoral immune response and the glomerular immunoglobulin G 
deposition were not affected in OPN-/- mice.
Conclusions: These findings suggest that in global OPN -/- mice elevated Nox4 creates 
a redox imbalance with increased oxidative stress induced-fibrosis. Targeting Mĭ OPN 
could be protective to attenuate inflammation and inflammation-associated fibrosis without 
affecting the anti-oxidative stress of OPN.
Funding: NIDDK Support
TH-PO145
Investigating Connective Tissue Growth Factor as a Critical Mediator 
of Cryoglobulinaemia  Gayathri K. Rajakaruna,1 Charles E. Alpers,2 Alan 
D. Salama.1  1UCL Centre for Nephrology, Univ College London, Royal Free 
Campus, London, United Kingdom; 2Dept of Pathology, Univ of Washington, 
Seattle.
Background: Cryoglobulins are immunoglobulins that precipitate at temperatures 
below 37 0 C. Cryoglobulinaemic vasculitis (CV) is commonly associated with hepatitis C 
(HCV) infection and causes a membrano proliferative glomerulonephritis (MPGN) in the 
kidney. Through a serendipitous finding we have previously established the development of 
CV in Connective tissue growth factor (CTGF) over expressing transgenic mice. CTGF, a 
matricellular protein involved in cell proliferation and key regulatory pathways, is elevated 
in patients with HCV-induced CV. Thymic stromal lymphopoetin (TSLP) transgenic mice 
also develop CV and have high serum CTGF levels. Higher TSLP levels have been shown 
in patients with HCV-induced CV. We hypothesized that CTGF overexpression is the key 
driver for cryoglobulin formation, and represents and potential therapeutic target.
Methods: TSLP Tg animals were used for this pilot study. We investigated whether 
CTGF anti sense oligonucleotides (ASO) attenuated CV, in comparison to control ASO. 
14 TG and 12 WT animals were studied over a 10 week period.
Results: There were no deaths amongst CTGF ASO group whist one control animal 
died. The incidence of ulcerative ear and neck lesions was 50% lower in the CTGF ASO 
group compared to the controls.(p=0.0549). The CTGF ASO cohort had lower proteinuria 
compared to the controls; this was significant between treatment arms and the duration of 
treatment (p=0.0092 and p=0.0034 respectively).
There was less severe histological injury in the CTGF ASO cohort (mean mesangial 
expansion score 1.485±SD 0.2824 vs. 2.247± SD 1.116, p=0.0458).
Conclusions: This preliminary pilot study suggests that antagonism of CTGF 
ASOs may attenuate CV in TSLP Tg animals. Larger studies are required to confirm this 
observation.
TH-PO146
The Toll-Like Receptor Signaling Pathway Is Activated Before the 
Development of Renal Injury in the 5/6 Nephrectomy Model  Camilla Fanelli, 
Jessica K. Okuma, Simone CA Arias, Flavia G. Machado, Victor F. Avila, Viviane 
D. Faustino, Gizely CS Moreira, Orestes Foresto-Neto, Lisienny CT Rempel, 
Claudia R. Sena, Vivian L. Viana, Hatylas Azevedo, Denise M. Malheiros, Niels 
OS Camara, Clarice K. Fujihara, Roberto Zatz.  Univ of Sao Paulo.
Background: Mechanisms of activation of inflammation in Chronic Kidney 
Disease (CKD) are unclear. We examined the participation of innate immunity in the 5/6 
nephrectomy model (Nx) from its beginning to advanced phases.
Methods: Munich-Wistar rats underwent Nx (N=40) or Sham (S, N=10) operation. 
Tail-cuff pressure (TCP, mmHg), albuminuria (ALB, mg/24h) glomerulosclerosis index 
(GSI) and cortical interstitium (%INT) were assessed 7, 15, 60 and 120 days after Nx. 
Gene and protein content of Tlr4, Casp1, Il1b and Nlrp3 were also evaluated. PCR-Array 
and gene enrichment analysis (GEA) by z-score evaluated gene expression of innate and 
adaptive immunity components.
Results: 
S Nx7 Nx15 Nx60 Nx120
TCP 142±1 168±5a 188±5ab 209±3abc 216±4abc
ALB 8±2 44±11a 108±15ab 112±18ab 177±11abcd
GSI 0±0 0±0 0±0 29±8abc 105±17abcd
%INT 0±0 1±0 1±0 4±1abc 5±1abc
Cytokine Cytokine-
Receptor Interaction -2.1a -2.0a -2.0a -2.1a
Hematopoietic Cell 
Lineage -1.8a -0.2a -1.7a -1.8a
Type I Diabetes Mellitus -1.6a -1.8a
Jak Stat Signaling 
Pathway -0.2a
Toll Like Receptor 
Signaling Pathway -1.8a -1.8a -1.9a -1.7a
Natural Killer Cell 
Mediated Cytotoxicity -1.7a
Fc Epsilon Ri Signaling 
Pathway -1.7a
Cell Adhesion 
Molecules -1.6a -1.7a -1.7a -1.4
Mean±SE: ap<0.05 vs S, bp<0.05 vs Nx7, cp<0.05 vs Nx15, dp<0.05 vs Nx60 
In addition, Tlr4, Tlr9, Nlrp3, Lbp2 and Irf7 genes were twice as high in Nx7 vs S. 
The same was seen for Casp1, Il1b, Tlr2 and Tlr5 after 15d. Tlr4, Casp1 and Il1b protein 
content increased following gene expression. GEA showed heightening of the Tlr Signaling 
Pathway (TlrSP) at all times in Nx.
Conclusions: The TlrSP, among other immune-related signaling pathways, is activated 
in the Nx model since its earliest stages until advanced phases, suggesting that they may 
contribute to initiate and maintain renal injury in this model.
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TH-PO147
TLR2/TLR4-MyD88-NF-κB Pathway Is Involved in Tubulointerstitial 
Inflammation Caused by Proteinuria  Lihong Ding, Dan Liu, Hong Liu, Kun 
ling Ma, Bi-Cheng Liu.  Inst of Nephrology, Zhong Da Hospital, Southeast Univ, 
Nanjing, Jiangsu, China.
Background: Proteinuria, an independent risk factor for progression of chronic 
kidney diseases (CKD), has been suggested to initiate or aggravate thetubulointerstitial 
inflammation (TI). While the potential mechanism is still to be clarified. In this study, we 
hypothesized that activation of the TLR2/TLR4-MyD88-NF-κB pathway might be involved 
in proteinuria induced TI.
Methods: We established an albumin-overload nephropathy rat model, and the 
expression of TLR2, TLR4, MyD88, NF-κB as well as TNF-α and IL-6 were detected by 
immunohistostaining, real-time PCR and Western blot.  In vitro, we investigated the impact 
of albumin stimulation on these parameters in HK-2 cells.  Furthermore, siRNA for TLR2, 
TLR4 and BAY 11-7082, the inhibitor of NF-κB, was applied to study their influence on 
the expression of TNF-α and IL-6 caused by albumin stimulation.
Results: Rats treated withalbumin-overload induced a significant increase of 
proteinuria, proteinaceous casts and tubulointerstitial inflammation. The expression of 
TLR2, TLR4, MyD88 andNF-κB in the proximal tubular cells were significantly increased 
as well as TNF-α and IL-6 expression. In addition, the expression of TNF-α and IL-6 was 
significantly correlated with proteinuria.  Albumin-overload induced TNF-α and IL-6 
expression by TLR2/TLR4-MyD88-NF-κB pathway activation, which could be attenuated 
by the siRNA for TLR2, TLR4 or NF-κB inhibitor BAY 11-7082 in HK-2 cells.
Conclusions: This study demonstrated that proteinuria might play as an endogenous 
danger-associated molecular pattern (DAMP) that induced renal TI via the TLR2/TLR4-
MyD88-NF-κB pathway.
Funding: Government Support - Non-U.S.
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Targeting Integrin CD11b/CD18 Reduces Inflammation and TLR-Mediated 
IFN Responses Implicated in Lupus Nephritis  Samia Khan,1 Shehryar J. 
Khaliqdina,1 Mohd Hafeez Faridi,1 David J. Cimbaluk,1 Mariana Kaplam,2 
Vineet Gupta.1  1Internal Medicine, Rush Univ Medical Center, Chicago, IL; 
2Systemic Autoimmunity Branch, National Insts of Health (NIH), Bethesda, MD.
Background: GWAS studies show strong associations between SNPs in the ITGAM 
locus, which encodes for the α-subunit (CD11b) of the b2 integrin CD11b/CD18 and 
susceptibility to lupus nephritis. CD11b/CD18 is a leukocytic adhesion receptor that 
modulates their biological functions and negatively regulates TLR-mediated pro-
inflammatory signaling. Insufficient activity of CD11b/CD18 drives disease pathogenesis, 
hence making it a promising therapeutic target.
Methods: We tested whether activation of CD11b/CD18 with small molecule agonist, 
leukadherin-1 (LA1), suppresses pro-inflammatory TLR and IFN signaling pathways in vitro 
and in vivo. Since stimulation of TLR-induced overproduction of inflammatory cytokines 
drives lupus nephritis, we also tested whether dampening of these pathways with LA1 
treatment reduces kidney injury in lupus prone MLR/lpr mice.
Results: Treatment of macrophages or neutrophils with LA1 and TLR4 agonist LPS 
or TLR7/8 agonist R848 induced a significant decrease in IL-6, TNFα and MCP-1, as well 
as type I IFN pathways, as compared to controls. In a murine model of severe sepsis, LA1 
treatment significantly prolonged survival and reduced serum IL-6 and IL-1β levels as 
compared to controls. In a murine model of lupus nephritis (MRL/lpr), renal pathology of 
kidneys from LA1 treated mice revealed significantly reduced kidney damage as compared 
to controls. LA1 treatment also reduced proteinurea and IgG levels in the kidney, while 
protecting glomerular expression of WT1, SYNPO and activated b1 indicating enhanced 
kidney function. Renal tissue from LA1 treated mice displayed normal foot process width 
as compared to controls.
Conclusions: LA1-mediated CD11b/CD18 activation suppresses TLR-induced 
production of pro-inflammatory cytokines and IFN pathways. LA1 treatment also dampens 
TLR-stimulated overproduction of cytokines in vivo, which drives lupus nephritis. These 
findings indicate a crucial role for CD11b/CD18 in suppressing inflammation and identify 
LA1 as a promising therapeutic agent for human autoimmune diseases.
Funding: NIDDK Support
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Allopurinol Attenuates Innate Immunity Activation and Renal Injury in 
the Nx Model, Despite Low Uric Acid Levels  Orestes Foresto-Neto, Victor 
F. Avila, Simone CA Arias, Camilla Fanelli, Lisienny CT Rempel, Denise M. 
Malheiros, Hugo Abensur, Niels OS Camara, Roberto Zatz, Clarice K. Fujihara. 
Univ of Sao Paulo, Brazil.
Background: Allopurinol (Allo) attenuates renal damage in experimental CKD. It is 
unknown whether this protection is due to inhibition of uric acid (UA) synthesis or to a 
direct action on oxidative stress and innate immunity (INIM). We studied the effect of Allo 
in the 5/6 nephrectomy model (Nx) in rats, in which UA degradation by uricase allows its 
effect on renal injury and INIM to be studied without its confounding action on UA levels.
Methods: Munich-Wistar rats (N=33) underwent Nx or sham operation (S, N=16). Nx 
rats were divided in: Nx, untreated; and Nx+Allo, given Allo 36 mg/kg/day vo. Tail-cuff 
pressure (TCP, mmHg), albuminuria (ALB, mg/24h), glomerulosclerosis (GS), urinary 
NGAL (uNGAL, mg/24h), interstitial collagen 1 (COL) and macrophages (Mĭ, cells/mm2), 
renal xanthine oxidase activity (rXO, mU/mg), plasma UA (pUA, mg/dL) and renal content 
of IL-1β (pg/g) and TLR4 (fold increase vs C) were assessed on Day 60.
Results: 
S Nx Nx+Allo
TCP 134±2 212±8a 191±6ab
ALB 3±1 111±15a 89±10a
% GS 0±0 15±4a 10±3a
%COL 2±1 9±1a 5±1ab
uNGAL 29±4 48±5a 32±3b
MØ 22±2 187±26a 130±20ab
rXO 70±5 116±7a 69±5b
pUA 1.3±0.2 2.1±0.2a 0.8±0.2b
IL-1β 1.5±0.2 4.7±0.6a 2.4±0.3b
TLR4 1.0±0.1 3.3±0.4a 2.3±0.2ab
Mean ± SE , ap <0.05 vs S; bp<0.05 vs Nx 
As expected, pUA was only slightly (though significantly) elevated in Nx, remaining 
far lower than previously seen with uricase inhibition. Allo normalized rXO activity and 
cancelled the slight increase of pUA observed in Nx. Despite the low pUA, Allo attenuated 
hypertension and promoted selective tubulointerstitial protection, reducing uNGAL, COL 
and Mĭ. In addition, Allo lowered the renal content of TLR4 and IL-1β, which correlated 
positively with both TCP and ALB.
Conclusions: In the Nx model, Allo exerts a renoprotective effect even in the context 
of low UA levels, which is associated, at least in part, with inhibition of innate immunity. 
FAPESP/CNPq.
TH-PO150
Megalin/Cubulin-Lysosome-Mediated Albumin Reabsorption Is Involved in 
the Tubular Cell Activation of NLRP3 Inflammasome and Tubulointerstitial 
Inflammation  Dan Liu, Bi-Cheng Liu.  Inst of Nephrology, Zhong Da Hospital, 
Southeast Univ School of Medicine, Nanjing, Jiangsu, China.
Background: Albuminuria contributes to the development and progression of chronic 
kidney disease (CKD) by inducing tubulointerstitial inflammation (TI) and fibrosis. 
However, the exact mechanisms of TI in response to albuminuria are unresolved. We 
previously demonstrated that NLRP3 and inflammasomes mediate albumin-induced lesions 
in tubular cells. Here, we further investigated the role of endocytic receptors and lysosome 
rupture in NLRP3 inflammasome activation.
Methods: We established an albumin-overload induced rat nephropathy model. The 
adult male Wistar rats that were uninephrectomized or sham operated under anesthesia 5 
days before starting BSA injection. In vitro, tubular epithelial cell line (HK-2) was cultured 
with or without megalin/cubilin gene siRNA transfection and then stimulated with BSA for 
different time durations (6h, 12h, 24h, 48h) and concentrations (5, 10, 20,40 mg/ml). Cell 
lysates and supernatants were collected and determined by western blotting and ELISA. 
Cathepsin B and Cathepsin D with or without their inhibitors were detected by western 
blotting and immunofluorescence staining.
Results: The priming and activation signals for inflammasome complex formation were 
evoked simultaneously by albumin excess in tubular epithelial cells. The former signal was 
dependent on albumin-triggered NF-κB pathway activation. This process is mediated by 
the endocytic receptor, megalin and cubilin. However, the silencing of megalin or cubilin 
inhibited the albumin-induced NLRP3 signal. Notably, subsequent lysosome rupture and 
the corresponding release of lysosomal hydrolases, especially Cathepsin B, were observed 
in TECs exposed to albumin. Cathepsin B release and distribution is essential for NLRP3 
signal activation, and inhibitors of Cathepsin B suppressed the NLRP3 signal in TECs.
Conclusions: Taken together, our findings suggest that megalin/cubilin and lysosome 
rupture are involved in albumin-triggered tubular injury and TI.
TH-PO151
Targeted Inhibition of Protein Kinase C-a Ameliorates Nephrotoxic 
Nephritis  Nino Kvirkvelia,1 Maggie McMenamin,1 Vanessa Iris Gutierrez,1 
Istvan Czikora,2 Rudolf Lucas,2 Michael P. Madaio.1  1Medicine, Georgia 
Regents Univ, Augusta, GA; 2Pharmacology and Toxicology, Georgia Regents 
Univ, Augusta, GA.
Background: Protein kinase C (PKC) is a ubiquitous phospholipid-dependent 
enzyme, with multiple isozymes that differ in their structure, biochemical properties, tissue 
distribution, subcellular localization, and substrate specificity. Since PKC-a expression was 
shown to be increased in patients with chronic kidney disease and in podocytes in renal 
biopsies of patients with diabetic nephropathy, we investigated the effect of specific PKC-a 
inhibition on renal injury in a murine model of acute kidney inflammation.
Methods: Mice were divided into four groups: 1) controls, 2) NTN, 3) NTN + PKC-a 
inhibitor Ro-32-0432 given i.p. after induction of nephritis on day 2, and 4) NTN group + 
PKC-a inhibitor conjugated to glomerular specific antibodies (i.e. a well-defined, human 
mAb (F1.1) directed against a3(IV) collagen) on day 2 to achieve kidney targeted drug 
delivery.
Results: On day 7, all NTN mice had severe nephritis, as evidenced by increased 
BUN, proteinuria and histology, whereas mice that received PKC-a inhibitors in either form 
had minimal evidence of kidney injury. BUN levels were reduced from 99.84±0.33mg/
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dL in NTN mice to 32.29±1.70mg/dL in mice receiving free PKC-α inhibitor and to 
36.07±4.51mg/dL in mice injected with F1.1 conjugated-PKC-a inhibitor. Serum levels 
of cytokines, assessed in multiplex analysis (MagPix) further confirmed reduction of 
inflammation.
Conclusions: These results suggest that PKC-a is an important mediator of antibody-
mediated glomerulonephritis, and that glomerular targeted inhibition of this enzyme is 
feasible. This methodology, has the advantage of diminishing systemic side effects while 
limiting and/or reversing ongoing damage associated with severe inflammation. This 
approach has potential therapeutic implications for the treatment of human kidney diseases.
Funding: NIDDK Support
TH-PO152
Renal Sympathetic Nerve Activity Controlled by Renal Afferent 
Sympathoexcitatory or Inhibitory Nerves?  Tilmann Ditting,1 Kristina 
Rodionova,1 Sonja Heinlein,1 Karl F. Hilgers,1 Christian Ott,1 Roland E. 
Schmieder,1 Martin Hindermann,1 Kerstin U. Amann,2 Roland Veelken.1 
1Nephrology & Hypertension, Friedrich Alexander Univ Erlangen, Erlangen, 
Bavaria, Germany; 2Pathology, Friedrich Alexander Univ Erlangen, Erlangen, 
Bavaria, Germany.
Background: Renal sympathetic nerve activity (RSNA) is important in hypertension, 
volume disorders or renal disease. It is unclear if increases of RSNA in disease are due to 
sympathoexcitatory or impaired sympathoinhibitory renal afferent nerves. We present data 
from nephritic rats suggesting the latter.
Methods: Nephritis due to OX7-antibodies in male Sprague-Dawley-rats. Methohexital 
anesthetized nephritic rats & controls were instrumented to stimulate renal afferent 
nerve activity (ARNA) in order to influence RSNA: ipsilateral renal arterial catheter 
for intrarenal administration (IRA) of the TRPV1 agonist capsaicin to stimulate ARNA 
(CAP 6.6*10-7M) and induce the release of the tachykinin receptor agonist SP from renal 
afferents; contralateral stainless steel electrode for RSNA recording; before and after IRA 
CAP the tachykinin-receptor blocker RP67580 was given. Baseline RSNA & ARNA were 
assessed. Some nephritic rats were pretreated with tachykinin receptor antagonists to prove 
increased SP effects.
Results: IRA CAP decreased RSNA from 67.5±12.0 mV*sec to 14.8±4.2 mV*sec 
(p<0.05) over 60 minutes while in nephritis RSNA suppression was abolished. 
Suppressed RSNA in controls was transiently reversed by the tachykinin inhibitor. 
Under resting conditions RSNA was higher, ARNA lower in nephritis as compared to 
controls. Tachykinreceptor antagonism ameliorated damage in renal nephritis suggesting 
increased SP release from renal afferent nerves despite lack of the tachykinin dependant 
sympathoinhibition seen in controls.
Conclusions: Our data suggest that a tachykinin dependant reno-sympathetic reflex 
mechanism exerts sympathoinhibitory effects being impaired under pathophysiological 
circumstances.
Funding: Government Support - Non-U.S.
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Fan1-/- Mice Develop Karyomegalic Interstitial Nephritis  Rannar Airik,1 
Markus Schueler,1 Merlin Airik,1 Jonathan Porath,1 Friedhelm Hildebrandt.1,2 
1Divison of Nephology, Dept of Medicine, Boston Children¶s Hospital, Boston, 
MA; 2Howard Hughes Medical Inst, Chevy Chase, MD.
Background: Karyomegalic interstitial nephritis (KIN) is a chronic interstitial 
nephropathy, characterized by tubulointerstitial nephritis and formation of enlarged nuclei 
in kidneys and other tissues (1). We recently reported that recessive mutations in the gene 
encoding FANCD2/FANCI-Associated Nuclease 1 (FAN1) cause KIN in humans (2). In 
order to study the function of Fan1 in kidneys we generated a Fan1 knock-out mouse model.
Methods: Targeted Fan1tm1a/+ ES cells were obtained from EUCOMM and injected into 
blastocysts to generate Fan1-mice. Abrogation of Fan1 expression in the mutant mice was 
confirmed by qRT-PCR. Renal histology was studied using hematoxylin/eosin, PAS and 
Masson’s trichrome staining. Tubular damage was induced with intraperitoneal cisplatin 
injection. Cell culture experiments were performed using mouse embryonic fibroblasts or 
mesenchymal stem cells isolated from Fan1-/- and wild type animals.
Results: Fan1-/- mice were born at Mendelian ratio and appeared healthy with no gross 
abnormality in kidney. Treatment of Fan1-/- and wild type mice with 10 or 20 mg/kg cisplatin 
caused severe tubular injury with cast formation and tubular dilation in Fan1-/- animals 
(n=5), accompanied with dramatic weight loss and lethality. Chronic injection of cisplatin 
at 2 mg/kg induced karyomegalic interstitial nephritis that lead to renal failure within 5 
weeks in Fan1-/- animals, but not in wild type mice. Cell culture studies demonstrated 
decreased survival and reduced colony formation of Fan1-/- cells in response to treatment 
with genotoxic agents.
Conclusions: Fan1-/- mice provide a new model to study the pathomechanisms of 
chronic kidney disease. We demonstrate that Fan1-/- mice are highly sensitive to genotoxic 
insults that lead to kidney failure. Our data indicate that Fan1 is involved in the physiological 
response of the kidney cells to DNA damage, which has been recently acknowledged to 
contribute to the pathophysiology of the chronic kidney disease (2, 3).
Funding: NIDDK Support, Private Foundation Support
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Down Regulation of Vitamin D Receptor (VDR) Expression Determines 
Initiation and Progression of HIV-Associated Nephropathy (HIVAN) with 
Variable Angiotensinogen (Agt) Copies  Xiqian Lan, Hongxiu Wen, Anjali 
Maheshwari, Gauri P. Patil, Ramachandra prasanna Bongu, Ashwani Malhotra, 
Pravin C. Singhal.  Medicine, Hofstra North Shore LIJ Medical School, Great 
Neck, NY.
Background: Agt transgenic mice have accelerated renin angiotensin system (RAS). 
On that account, we hypothesized that mice with enhanced expression of Agt would display 
accelerated progression of HIVAN. We evaluated the effect of different copies of Agt in 
the initiation and progression of HIVAN in genetically engineered HIVAN mice (Tg26).
Methods: Control and Tg26 mice with 2 (Tg26/Agt-2) and 4 (Tg26/Agt-4) copies 
of Agt were evaluated for severity of renal lesions, arteriosclerosis and hypertension at 8 
weeks and 16 weeks. Renal cortical sections were stained with sirus red and PAS. RNA 
was extracted from renal tissues and probed for AT1, AT2, VDR and molecules involved 
in profibtotic and epithelial mesenchymal transition (EMT) pathways.
Results: Tg26/Agt-4/8wks showed lower blood pressure (P<0.01) vs. Tg26/Agt-2/8 
wks, while Tg26/Agt-4/16wks displayed higher blood pressure vs. Tg26/Agt-2/16wks. 
Tg26/Agt-4/8wks displayed attenuated expression of PAI-1 vs. Tg26/Agt-2/8wks; however, 
Tg26/Agt-4/16wks showed 3-fold greater PAI-1 expression than to Tg26/Agt-2/16wks. 
Tg26/Agt-2/8wks displayed attenuated expression VDR and enhanced production of Ang II 
vs. Tg26/Agt-4/8wks, however this pattern reversed at 16 wks. Tg26/Agt-4/8wks displayed 
attenuated expression of AT1 and AT2 and down regulation of Tert, TGF-β, Snail, and 
vimentin when compared to Tg26/Agt-2/8wks. However, all these markers were comparable 
between these groups at 16 wks of age. Tg26/Agt-2/8wks developed renal lesions which 
were more advanced than Tg26/Agt-4/8wks. Conversely, Tg26/Agt-4/16wks displayed 
more advanced renal lesions vs. Tg26/Agt-2/16wks.
Conclusions: Tg26/Agt-4 displayed slower progression of HIVAN initially at 8 
weeks associated with enhanced renal tissue VDR expression and attenuated expression 
of AT1, TGB-β, PAI-1, Tert and EMT markers. However, Tg26/Agt-4 at 16 wks displayed 
accelerated growth due to attenuated VDR expression leading to high blood pressure, 
upregulation of EMT and profibrotic molecules.
TH-PO155
Egr1 Deficiency Abolishes Inflammatory and Fibrotic Responses of Renal 
Tubular Cells  Li-chun Ho,1 Junne-Ming Sung,2 Yau-Sheng Tsai.1  1Inst of 
Clinical Medicine, National Cheng Kung Univ, Tainan, Taiwan; 2Internal 
Medicine, National Cheng Kung Univ Hospital, Tainan, Taiwan.
Background: Early growth response-1 (Egr-1) is a transcription factor that has been 
found to regulate inflammation and fibrosis in non-kidney tissues, but its role in renal 
failure has not been well established.
Methods: Wild type and Egr1-/- mice were fed with adenine-enriched diet to induce 
tubulointerstitial nephritis (TIN), and primary tubular epithelial cells (PTECs) were 
treated with pro-inflammatory and pro-fibrotic cytokines. In addition, human kidney 
tissues were obtained from diabetic patients with renal failure and from non-diabetic 
patients without renal failure. The cell-type in which Egr-1 was activated was assessed 
using immunofluorescence and immunohistochemical stain. The levels of inflammatory 
and fibrotic markers were analyzed using RT-PCR and Western blotting. Kidney sections 
were also stained with H&E and Masson’s trichrome to assess immune cell infiltration 
and fibrotic area.
Results: In mouse kidneys with TIN as well as in human kidneys with renal failure, 
tubular epithelial cell is the primary site for Egr-1 activation and undergoing nuclear 
translocation. Egr1-/- mice were protected from renal failure, reflected by lower levels 
of serum urea and creatinine. This is consistent with Egr-1 deficiency-related reductions 
of immune cell infiltration, NF-κB activity, and expression of cytokines and chemokines 
in the kidneys. In addition, Egr1-/- mice with TIN had less fibrotic area and attenuated 
TGFβ signaling than wild-type mice with TIN. Egr-1 deficiency also abolished the ordinary 
responses of PTECs to TNFα and TGFβ.
Conclusions: Egr-1 activation in the renal tubular cell plays an integrative role for 
renal inflammation, fibrosis and the subsequent renal failure. Thus, Egr-1 may serve as a 
therapeutic target for human kidney diseases.
TH-PO156
Angiopoietin-1 Overexpression Attenuates Renal Fibrosis Through 
Decreasing Inflammation  Fan-Chi Chang,12 Ming-Hsuan Tsai,2 Yu-hsiang 
Chou,2 Shuei-Liong Lin.23  1Internal Medicine, Taipei Medical Univ Hospital, 
Taipei, Taiwan; 2Graduate Inst of Physiology, College of Medicine, National 
Taiwan Univ, Taipei, Taiwan; 3Renal Div, Dept of Internal Medicine, National 
Taiwan Univ Hospital, Taipei, Taiwan.
Background: Our previous studies have found dysregulated angiogenic growth factors 
in fibrotic kidney. We thus hypothesized that dysregulated angiopoietin-Tie system is related 
to microvascular destabilization and inflammation in the injured kidney.
Methods: We use unilateral ureteral obstruction (UUO) and 5 to 6 subtotal nephrectomy 
(5/6Nx) as animal models of progressive renal fibrosis. Specific overexpression of 
angiopoietin-1 (Angpt1) is induced with cross-breed between Pax8-rtTA (with C57BL/6 
background) and pTRE-hAngpt1 (with ICR genetic background). Under the control of 
mouse Pax8 promoter, doxycycline administration directs high levels of expression of the 
reverse tertracycline-dependent transactivator (rtTA) to all proximal, distal tubules and 
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the entire collecting duct system of both embryonic and adult kidneys. Double transgenic 
mice inherit both Pax8/rtTA and pTRE-hAngpt1 responder. Littermates that inherited one 
or no transgenes serve as experimental controls.
Results: In animal model of UUO and 5/6Nx, Angpt1 decreases whereas Angpt2 
and Angpt2/Angpt1 ratio increase as renal fibrosis progresses. Cross-breed of pTRE-
hAngpt1 (with ICR genetic background) and Pax8-rtTA (with C57BL/6 background) 
lines is conducted for conditional overexpression. Overexpression of Angpt1 by tubule 
cells, include all proximal, distal tubules and the entire collecting duct system is induced 
after doxycycline administration in offspring with two transgenes. Compared to littermate 
control, transgenic mice with Angpt1 overexpression attenuate interstitial fibrosis in UUO 
kidney demonstrated by picrosirius red staining. Further analyses demonstrate decrease 
of inflammatory cell infiltration in UUO kidney of mice with Angpt1 overexpression.
Conclusions: These studies indicate that Angpt1 supplement may provide a novel 
therapy to attenuate renal fibrosis through reduction of inflammatory cell infiltration in 
UUO kidney.
Funding: Government Support - Non-U.S.
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Benidipine Targets Leukocyte Kv1.3-Channels and Slows the Progression of 
Renal Fibrosis in Rats with Advanced Chronic Renal Failure  Itsuro Kazama. 
Physiology I, Tohoku Univ Graduate School of Medicine, Sendai, Miyagi, Japan.
Background: Leukocytes, such as lymphocytes and macrophages, predominantly 
express delayed rectifier K+-channels (Kv1.3) in their plasma membranes. In our previous 
study, the overexpression of these channels in leukocytes was strongly associated with 
their proliferation in kidneys and the progression of renal fibrosis in the advanced stage 
chronic renal failure (CRF). Since benidipine, a long-acting 1,4-dihydropyridine Ca2+ 
channel blocker, is also highly potent as a Kv1.3-channel inhibitor, it could exert therapeutic 
efficacy in advanced CRF.
Methods: Male Sprague-Dawley rats that underwent 5/6 nephrectomy followed by a 14-
week recovery period were used as the model of advanced CRF. Benidipine hydrochloride 
(5mg/kg) was started at 8 weeks after nephrectomy and orally administered daily for 6 
weeks. The histopathological features of the kidneys were examined in vehicle-treated and 
benidipine-treated CRF rat kidneys. Cellular proliferation of leukocytes and the cortical 
expression of pro-inflammatory cytokines were also examined.
Results: In CRF rat kidneys, Kv1.3-channels began to be overexpressed in leukocytes 
as early as 8 weeks after nephrectomy. In the cortical interstitium of benidipine-treated 
CRF rat kidneys, both immunohistochemistry and real-time PCR demonstrated decreased 
expression of fibrotic markers. Benidipine treatment significantly reduced the number of 
proliferating leukocytes within the cortical interstitium and decreased the expression of 
cell cycle markers and pro-inflammatory cytokines.
Conclusions: This study demonstrated for the first time that benidipine slowed 
the progression of renal fibrosis in rat kidneys with advanced CRF. Kv1.3-channels 
overexpressed in leukocytes were thought to be the most likely therapeutic targets of 
benidipine in decreasing the number of proliferating leukocytes and repressing the 
production of inflammatory cytokines.
Funding: Government Support - Non-U.S.
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Renoprotection by Treatment with CXA10, an Endogenous Nitro-Fatty 
Acid  Cynthia M. Arbeeny,1 Hong Ling,1 Mandy M. Smith,1 Stephen OBrien,1 
Stefan Wawersik,1 Steven R. Ledbetter,1 Diane K. Jorkasky.2  1Genzyme, a Sanofi 
Company, Framingham, MA; 2Complexa, Inc., Pittsburgh, PA.
Background: CXA10 is an electrophilic nitro-fatty acid that modulates anti-oxidant 
and anti-inflammatory pathways through activation of NRF2 and reduction of NFkB 
activity. Here, we examine the potential therapeutic benefit of CXA10 in a mouse model of 
hypertension-induced chronic renal injury that mimics human Focal Segmental Glomerular 
Sclerosis (FSGS).
Methods: Uninephrectomized male mice (129/sv) were implanted with a DOCA 
salt pellet (or placebo) at 2 and 5 weeks post-surgery, maintained on 1% NaCl (drinking 
water), and supplemented with 24% fat diet. Animals (n=8-10/group) were treated for 4 
weeks with CXA10 (2.5mg/kg, p.o.); or with enalapril (20mg/kg; in drinking water) as 
the positive control.
Results: Body weight was slightly decreased and blood pressure was increased with 
DOCA treatment, and neither parameter was significantly altered by intervention. Kidney- 
and heart-to-body weight ratios were increased with DOCA and were significantly reduced 
in the CXA10 but not in the enalapril group, whereas plasma cholesterol levels were reduced 
in both groups. CXA10 and enalapril significantly reduced albuminuria and nephrinuria but 
did not significantly improve the reduction in GFR following DOCA. Histologic evaluation 
revealed that both treatments improved interstitial lesions and fibrosis, whereas only CXA10 
reduced glomerular sclerosis and hypertrophy. Molecular markers of glomerular injury 
and podocyte number were unchanged in all groups, suggesting that structural glomerular 
injury was modest. Even so, markers of inflammation and fibrosis were elevated in tissue 
and urine samples in this model. CXA10 reduced urinary MCP-1 as well as mRNA levels 
encoding MCP-1, osteopontin, collagen III, fibronectin, and PAI-1. Enalapril treatment did 
not significantly alter this expression profile.
Conclusions: These results provide in vivo evidence that CXA10 is renoprotective in a 
kidney disease model by affecting anti-inflammatory, anti-oxidant and anti-fibrotic pathways 
and that the beneficial effects of CXA10 were differentiated from enalapril in this model.
TH-PO159
Selective Knock-Out of Glycogen Synthase Kinase 3-β in Proximal Renal 
Tubular Epithelial Cells (RTE) Attenuates Inflammation and Tubular 
Injury After Unilateral Ureteral Obstruction (UUO)  Josef Bautista, Eman 
Mohammad Shaban, Evelyn Tolbert, Rujun Gong, Lance D. Dworkin.  Medicine, 
Brown Univ, Providence, RI.
Background: Glycogen synthase kinase 3-beta (GSK-3β) is a ubiquitous serine/
threonine protein kinase that regulates a large number of processes in diverse cell types 
including RTE. Systemic administration of small molecule inhibitors of GSK-3B reduces 
inflammation and fibrosis and lessens acute and chronic kidney injury. However, the extent 
to which the beneficial effects of GSK-3β inhibition depend on blocking the enzyme 
specifically in kidney cells is unknown. We investigated whether gene deletion of GSK3β 
in RTEs alone would reduce inflammation and progression of CKD.
Methods: The GSK-3β gene was selectively deleted in the renal tubular cells by 
crossing mice in which exon 2 of the GSK3b gene was “floxed” with mice expressing 
CRE recombinase under a ڜGT promoter expressed only in adult proximal RTE (KO). 
Injury was induced by UUO in wild type (WT), KO, and WT mice given low-dose (1 mg/
kg) thiadiazolidinone (TDZD), a specific GSK3β inhibitor. After 7 days, kidneys were 
weighed and examined for tubular and glomerular injury, interstitial edema, and macrophage 
infiltration. Groups were compared by ANOVA.
Results: 
Group Kidney Wt(gm/100g body wt)
Injured Tubules
(%)
Glomerular 
Injury Score
Interstitial 
edema score
KO (n=7) 0.74 + 0.09 35% ± 0.15 * 2.14 ± 0.94 1.47 ± 0.32
WT (n=11) 0.79 + 0.16 57% ± 0.09 1.54 ± 0.66 1.59 ± 0.35
TDZD (n=11) 0.69 + 0.12 46% ± 0.12 1.52 ± 0.82 1.77 ± 0.28
*P<0.01 KO vs. WT 
Macrophage infiltration assessed by immunohistochemistry also declined by about 
40% in KO mice
Conclusions: Selective deletion of GSK-3β in RTE attenuated macrophage infiltration 
and reduced tubulo-interstitial, but not glomerular injury after UUO. Elimination of GSK-
3β signaling in RTE was more effective than systemic, low dose GSK-3β inhibition. Our 
data suggest that GSK-3β dependent pathways in RTEs play a critical role in promoting 
interstitial inflammation and tubular injury in CKD.
Funding: NIDDK Support, Clinical Revenue Support
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TIMP-1 Up-Regulates the Expression of MCP-1 Through NF-κB Pathway in 
Rat Mesangial Cells  Xiang-Mei Chen, Xizhao Chen, Qing-gang Li, Guangyan 
Cai.  Chinese PLA General Hospital, Chinese PLA Inst of Nephrology, State 
Key Laboratory of Kidney Diseases, National Clinical Research Center for 
Kidney Diseases.
Background: In mesangial proliferative glomerulonephritis (MesPGN), tissue 
inhibitors of metalloproteinases (TIMPs) can regulate transcription factors and cytokines 
and participate in immune and inflammation reactions in an MMP-independent way.We 
found that in the anti-Thy-1 nephritis model, TIMP-1 andmonocyte chemotactic protein 
1 (MCP-1) were significantly increased at the mesangial dissolved phase and peaked at 
the mesangial proliferative phase, finally backed to normal at the recovery phase. Our 
hypothesis is that TIMP-1 can regulate MCP-1 expression through NF-κB in mesangial cells.
Methods: (1) We established the anti-Thy-1 nephritis model. Animals were sacrificed 
at day 0, 1, 2, 3, 5 and 7, mRNA levels of TIMP-1 and MCP-1 were detected at separate 
time points by Taqman probe technique. (2) TIMP-1 over-/low-expression rat mesangial cell 
model were established by GFP-TIMP-1 lentivirus transfection and siRNA interference. (3) 
The cells of TIMP-1 over-expression were harvested at day 5, 6, 7, and low-expression cells 
at 48h. Then we detected the mRNA and protein levels of TIMP-1, MMP2, MMP9, NF-κB 
and MCP-1 by Taqman probe technique and Western blot. (4) TIMP-1 over-expression cells 
were treated with NF-κB inhibitor BAY 11-7082 (5mmol/L) at 4th day. After 48h-culture, 
mRNA level were detected.
Results: (1) In rat anti-Thy-1 nephritis, the expression levels of TIMP-1 and MCP-1 
was increased gradually and peaked at day 5, then began to decrease. MCP-1 followed 
the same trend but peaked at day 2. (2)We established the TIMP-1 over-/low-expression 
model successfully. (3)When TIMP-1 presented over-expression, MMP9, NF-κB and 
MCP-1 were up-regulated (P<0.05); When TIMP-1 presented low-expression, these were 
down-regulated. (P<0.001) The change in expression of MMP2 was not obvious. (4) At 
48h after inhibition with NF-κB inhibitor, the expression level of MCP-1 in the TIMP-1 
over-expression cells was down-regulated(P<0.01).
Conclusions: TIMP-1 could participate in the immune and inflammation reactions of 
MesPGN by up-regulating the expression of MCP-1 through NF-κB in rat mesangial cells.
Funding: Government Support - Non-U.S.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
127A
J Am Soc Nephrol 26: 2015 Basic/Experimental Inflammation Poster/Thursday
TH-PO161
Calcitriol Protects against Renal Tubular Cell Apoptosis by Promoting M2 
Macrophage Polarization in Diabetic Nephropathy Rats  Yinfeng Guo, Zhixia 
Song, Min Zhou, Ying Yang, Xiaoliang Zhang.  Zhong Da Hospital, Southeast 
Univ, School of Medicine.
Background: Renal tubular apoptosis is a key event in initiating kidney damage in DN. 
Heterogeneity of macrophage phenotype and function ultimately determines the outcome 
of DN. Therefore, we sought to investigate whether calcitriol, known as an important 
renal-protective drug, is sufficient to protect against tubular cell apoptosis by promoting 
M2 macrophage in DN rats.
Methods: DN model rats were established by intraperitoneal injection with streptozocin 
(STZ). The rats were subsequently receiving either calcitriol (0.1mg/kg/d) or vehicle by 
gavage. Rats were sacrificed at 18w for histological and molecular analysis. In addition, 
we performed in vitro study using Raw264.7 cells cultured with either high glucose or high 
glucose followed by 1,25-dihydroxyvitamin D3 medium to assess macrophage phenotype.
Results: Calcitriol significantly improved renal function and ameliorated renal 
histology in DN rats. The increased tubular cell apoptosis in DN rats was alleviated by 
calcitriol. Calcitriol up-regulated the expression of anti-apoptotic protein Bcl-2, down-
regulated the expression of pro-apoptotic protein such as Bax and caspase-3. Interestingly, 
calcitriol significantly enhanced M2 macrophage polarization in interstitium with elevated 
expressions of M2 markers, including CD163, Arg-1 and MR. Moreover, the ratio of 
CD163/CD68 considered as the proportion of M2 macrophage was about 2.9 fold highly 
after calcitriol treatment. In vitro, 1,25-dihydroxyvitamin D3 also promote high glucose-
induced pro-inflammatory M1 macrophage toward anti-inflammatory M2 polarization.
Conclusions: Calcitriol protects against renal tubular cell apoptosis by promoting M2 
macrophage polarization in STZ-induced DN rats.
Funding: Government Support - Non-U.S.
TH-PO162
APOL1 Risk Variants Induce Aberrant THP-1 Monocyte Differentiation 
and Increased Eicosanoid Production  Hewang Lee, Jeffrey B. Kopp.  Kidney 
Diseases Section, NIDDK, National Insts of Health, Bethesda, MD.
Background: Apolipoprotein L1 (APOL1) is an innate immune protein and its risk 
variants are strongly associated with kidney disease. We investigated the effects of APOL1 
variants on monocyte differentiation and eicosanoid production in macrophages, as activated 
tissue macrophages in kidney might contribute to injury.
Methods: THP-1 cells, a human monocytic cell line, were transiently transfected with 
APOL1-A isoform G0 (ancestral allele) or the renal risk variants G1 and G2 and cultured 
for 36 hr before RNA was obtained for gene expression studies.
Results: APOL1-transfected THP-1 cells manifested a 6-8 fold increase in CD14 
and CD68 gene expression, similar for all three variants, and similar to that seen with 
phorbol-12-myristate acetate treatment. Furthermore, APOL1 risk variants induced activated 
monocytes into atypical M1 macrophages with increased RNA encoding M1 markers 
CD80, TNF, IL1β, and IL6 (all vs EV p <0.05, G1 vs G2 p>0.05), modest increase in M2 
markers CD163, CD206, and TGFb1 with G1 transfection (all RNAs vs EV p <0.05) and 
CD204 and TGFb1 with G2 transfection (both RNAs vs EV p <0.05). Gene expression 
for eicosanoid generating enzymes was increased as well: cyclo-oxygenase-2, G0, 1.3±0.9 
fold over empty vector (EV), G1, 4.1±0.5 and G2, 4.5±0.5 (both G1 and G2 vs G0 p<0.01) 
and thromboxane synthase, G0, 2.1±0.8 fold over EV, G1, 5.2±0.9 and G2, 4.5±0.5 (both 
G1 and G2 vs G0 p<0.05). Thromboxane A2 receptor (TXA2R) gene expression was 
unchanged with G0, 1.8±0.4 fold over EV (p>0.05), and increased with G1, 6.1±1.0, and 
G2, 4.1±0.5 (G1 vs G0 p<0.001, G2 vs G0 p<0.01). Higher levels of thromboxane B2, a 
stable metabolite of thromboxane A2, were present in the supernatant of cultured THP-1 
cells transfected with G1 (10.0±1.3 pg/mL/105cells, p<0.05 vs G0) and G2 (15.1±3.0 pg/
mL/105cells, p<0.01 vs G0) compared to G0 (6.0±1.0 pg/mL/105cells), which was similar 
to EV (6.7±1.0 pg/mL/105cells, p>0.05 vs EV).
Conclusions: These results demonstrate a novel role of APOL1 variants in the 
regulation of monocyte differentiation and eicosanoid metabolism, which could modify the 
immune response and promote inflammatory signaling within the kidney and elsewhere.
Funding: NIDDK Support
TH-PO163
Purification and Analysis of Exosomes Derived from Primary Human 
Proximal Epithelial Cells (PTEC)  Helen G. Healy,1 Xiangju Wang,2 Andrew J. 
Kassianos,2,3 Ray Wilkinson.1,2,3,4  1Renal Medicine, Royal Brisbane and :omen¶s 
Hospital, Brisbane, Queensland, Australia; 2Conjoint Kidney Laboratory, 
Pathology Queensland, Brisbane, Queensland, Australia; 3School Biomedical 
Sciences, Queensland Univ of Technology, Brisbane, Queensland, Australia; 
4Medical School, Univ of Queensland, Brisbane, Queensland, Australia.
Background: Exosomes are extracellular vesicles secreted by multiple cell types 
in the body which contain a tissue-type signature courtesy of their incorporated RNA 
and protein cargo. Exosomes have crucial roles in extracellular communication and are 
implicated in kidney inflammation and disease progression. Human PTEC play a central 
role in renal disease yet their exosome expression remains virtually unknown. Here we 
characterize exosomes from primary human PTEC cultured under normal, hypoxic and 
inflammatory conditions.
Methods: Exosomes were purified from normal, hypoxic (1% O2) and inflammatory 
(IFN-γ/TNF-α treated) PTEC cultures using ultracentrifugation and density gradients 
and analyzed for morphology (electron microscopy), size/concentration (qNano) and 
CD9/63/81 expression (Western blot). Protein and microRNA content were analyzed by 
mass spectroscopy (MS) and sequencing respectively.
Results: Exosomes from all three culture conditions displayed the same size range 
(50-120nM) and morphology (spherical doughnut shape) with a similar expression of CD9 
(high), CD63 (medium) and CD81 (low). However, concentrations of exosomes from 
both hypoxic and inflammatory conditions increased by more than two fold compared to 
normal culture conditions. MS analysis demonstrated exosomes from hypoxic cultures 
contained 134 proteins not expressed in those from normal cultures, whilst inflammatory 
exosomes contained 152 unique proteins. A number of these proteins have been implicated 
in development of chronic kidney disease.
Conclusions: Collectively, our data indicate that exosome secretion is increased under 
“diseased” conditions, and importantly, there is condition specific differential protein 
expression. Further investigation of exosome protein/microRNA cargo will identify novel 
targets whose utility in therapies and disease biomarkers warrant analysis.
Funding: Government Support - Non-U.S.
TH-PO164
HIF-2α in Dendritic Cells in Renal Injury Soeren Schwuchow,1 Joanna 
Kalucka,2 Gunnar Schley,1 Bernd Klanke,1 Kai-Uwe Eckardt,1 Alexander 
Weidemann.1  1Nephrology and Hypertension, Univ of Erlangen-Nuremberg, 
Erlangen, Germany; 2Laboratory of Angiogenesis 	 Neurovascular Link, Univ 
of Leuven, Leuven, Belgium.
Background: Hypoxia-inducible transcription factors, HIF-1α and -2α play key 
roles in cellular adaptation to hypoxia and have been linked to innate immune responses. 
In macrophages they are non-redundant and are expressed depending on polarization. 
However, in other innate immune cells, such as dendritic cells (DCs), the differential role 
of HIFα isoforms is less clear. DCs are abundant in the kidney and have been implicated 
in renal (patho)physiology. As shown previously, HIF-1α in DCs affects maturation and T 
cell stimulation, but whether HIF-2α plays a specific role is elusive. The aim of our study 
was therefore to elucidate the functional properties of HIF-2α in DCs in vitro and in vivo 
during renal injury.
Methods: Murine primary DCs (BMDC) were generated from bone marrow of 
tissue specific conditional knock-out mice (CD11c Cre-HIF-2alox/lox). BMDCs were then 
stimulated with hypoxia and LPS followed by mRNA, FACS and protein analysis. Bilateral 
renal ischemia and reperfusion injury (IRI) was used as a model of acute renal injury. To 
induce chronic kidney injury, mice were subjected to either a 3 week adenine rich diet 
or to unilateral ureteral obstruction (UUO), followed by the above mentioned analyses.
Results: HIF-2α protein is detected in BMDC after LPS treatment and with hypoxic 
stimulation. Loss of HIF-2α does not affect expression of maturation markers such as CD86 
or MHCII after LPS and the ability of T cell activation. In vivo during acute or chronic renal 
injury, loss of dendritic HIF-2α does not affect renal function, inflammatory cell responses 
or the expression of fibrotic or inflammatory markers.
Conclusions: Taken together, our data indicates that loss of HIF-2α in DCs does not 
affect maturation in vitro and leukocyte infiltration or renal function in models of acute 
and chronic renal injury in vivo. Thus, in contrast to macrophages, HIFα isoforms in DCs 
do not seem to play functional opposing roles. This might have important implications 
for the development of pharmacologic agents targeting HIFα in DCs to modulate immune 
responses during renal injury.
Funding: Government Support - Non-U.S.
TH-PO165
Fecal Transplantation from Uremic Mice Aggravates Kidney Fibrosis 
Myung-gyu Kim, Young Ju Na, Sung Yoon Lim, Sang-Kyung Jo, Won-Yong 
Cho.  Dept of Internal Medicine, Korea Univ Anam Hospital, Seoul, Republic 
of Korea.
Background: Emerging evidence showed the important role of kidney-gut crosstalk 
in diverse pathological processes. Alterations in intestinal barrier or microbiota has 
been demonstrated in chronic kidney disease (CKD) and thought to be associated with 
increased cardiovascular risks or progression of CKD. The purpose of this study was to 
investigate the effect of gut microbiota in the animal model of kidney fibrosis with using 
fecal transplantation.
Methods: Unilateral ischemia/reperfusion injury (IRI) for 45min was performed in C57/
BL6 mice for fibrosis model. Supernatants of centrifuged feces from 5/6 nephrectomized 
mice (8wks) or age matched control mice were administered 3 times per wk for 3 wks after 
gut decontamination and degree of fibrosis was compared (CKD feces vs control feces).
Results: Compared to mice with fecal transplantation from control mice, mice who 
were transplanted with CKD feces showed aggravated fibrosis at 2 wks after unilateral 
ischemia in the analysis of the Masson’s trichrome staining and Western blot for type 4 
collagen. Ex vivo analysis of immune cells showed increased number of mature CD80+ 
CD11c+ cells in mesenteric lymph node whereas percentage of splenic Tregs increased in 
mice transplanted from uremic mice. Immune cells from these mice showed significantly 
suppressed cytokine release upon LPS stimulation compared mice with WT feces.
Conclusions: This study showed the possible effect of kidney-gut crosstalk on 
the progression of CKD and this effect is thought to be partially mediated by immune 
modulatory effect.
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TH-PO166
A Novel Mineralocorticoid Receptor Blocker Protects the Remnant Kidney 
Better Than Eplerenone as an Add-On to Late Losartan  Clarice K. Fujihara,1 
Mark Kowala,2 Matthew D. Breyer,2 Claudia R. Sena,1 Mariliza V. Rodrigues,1 
Simone CA Arias,1 Camilla Fanelli,1 Denise M. Malheiros,1 Jose E. Krieger,1 
Roberto Zatz.1  1Univ of São Paulo, Brazil; 2(li Lilly.
Background: Aldosterone (Ald) worsens, whereas MR blockers, e.g. eplerenone (E), 
slow CKD, but cause hyperkalemia, especially with RAS inhibitors, e.g. Losartan (L). 
LY2180176 (LY) is a novel, nonsteroidal, high-affinity MR blocker (Ki 1.6 nM vs 124 for 
E). We tested LY as an add-on to L in 5/6 ablation (Nx) rats.
Methods: Male Munich-Wistar rats underwent Nx (N=89) or sham (S, N=24) surgery, 
being divided in (all drugs in mg/kg/d, from Day 60 to 150 post Nx): Nx, untreated; Nx+L, 
given L, 50; Nx+L+E, L 50 + E 150; Nx+L+LY, L 50 + Ly 20. ALB, albuminuria, mg/d; 
TCP, tail-cuff pressure, mmHg; PR, plasma renin, ng/mL/h; plasma Ald, pg/mL; Serum 
K+, mmol/L; GS, Glomerulosclerosis; COL, cortical collagen; interstitial AngII+, cells/
mm2. Genes (italic): RT-PCR (x increase).
Results: 
S Nx Nx+L Nx+L+E Nx+L+LY
ALB 5±1 162±12a 79±18ab 35±5abc 5±1bcd
TCP 125±2 216±5a 168±5ab 155±4abc 124±3bcd
PR 3±1 1±1a 16±12a 112±78abc 147±48abcd
Ald 175±23 394±83a 132±30b 775±117abc 2478±290abcd
K+ 4.3±0.2 5.2±0.2a 5.5±0.2a 5.8±0.2a 5.3±0.2a
%GS 0.1±0.1 30.2±4.0a 19.2±4.0ab 10.5±2.1abc 6.7±1.4abc
%COL 4±1 29±3a 20±3a 18±4a 12±2abc
AngII+ 0.8±0.2 6.9±1.0a 6.3±1.7a 4.8±0.8a 2.9±0.6ab
Renin 1.0±0.1 0.6±0.1a 1.4±0.4b 2.7±0.6abc 11.7±1.3abcd
SGK1 1.2±0.3 1.3±0.2 0.8±0.2 0.5±0.1ab 0.7±0.1
NHE3 1.1±0.1 0.6±0.1a 0.6±0.1a 0.7±0.1 0.8±0.1bcd
NKCC2 1.0±0.1 0.6±0.1a 0.6±0.1a 0.9±0.1 1.2±0.1bc
WNK1 1.0±0.1 0.7±0.1 0.9±0.1 0.9±0.1 1.1±0.1b
SGLT1 1.0±0.1 0.7±0.1a 0.7±0.1a 0.8±0.1 1.1±0.1bcd
LY normalized TCP and ALB and slowed CKD better then E. LY strongly raised PR 
and Ald, and restored transporter expression, suggesting volume loss. Despite strong MR 
blockade, LY did not raise K+.
Conclusions: LY may become a new asset in the therapy of CKD.
TH-PO167
Role of Innate Immunity in a Model of CKD following Brief Dietary Adenine 
Overload  Gizely CS Moreira, Ricardo P. Mazzonetto, Lisienny CT Rempel, 
Orestes Foresto-Neto, Camilla Fanelli, Simone CA Arias, Viviane D. Faustino, 
Claudia R. Sena, Victor F. Avila, Vivian L. Viana, Denise M. Malheiros, Niels 
OS Camara, Clarice K. Fujihara, Roberto Zatz.  Univ of São Paulo, Brazil.
Background: Adenine (ADE) excess leads to accumulation of crystals (Crys) at the 
renal interstitium (INT) through NF-κB activation (AJPRenal:F155,2013). After ADE 
cessation, INT nephritis progresses even as Crys disappear. Here we verified whether AngII 
and innate immunity (INIM) are activated in the acute and/or chronic phases of this model.
Methods: Adult male Munich-Wistar rats (n=76) received no treatment (C) or 
0.5% ADE in chow for 1 wk, after which Crys/mm2, tail-cuff pressure (TCP, mmHg), 
glomerulosclerosis (GS, %), INT collagen (COL, %), INT macrophage (M݊) and AngII+ 
(cells/mm²), renal IL1β (pg/mg), and renal IL6, NLRP3 (2-∆∆Ct) and TLR4 (WB, fold) were 
assessed. Measurements were repeated 4 and 24 wk after ADE cessation.
Results: 
1 wk ADE+ 4 wk ADE- 24 wk ADE-
C ADE C ADE C ADE
Crys - 1.3±0.2a - 0.6±0.2a - 0.2±0.1ab
TCP 130±2 157±4a 134±2 141±3b 137±3 150±4a
GS 0±0 0±0 0±0 0±0 0.4±0.2 2.1±1.0ab
COL 5±1 5±1 4±1 9±2 4±1 12±2ab
Mĭ 16±2 90±8a 24±6 65±6ab 20±1 64±7ab
AngII+ 1±0.3 4±0.6a 1±0.4 4±0.6a 1±1 7±2ab
IL1β 0.9±0.1 6.7±1.1a 1.1±0.3 3.0±0.6b 1.6±0.6 1.4±0.4b
IL6 1.2±0.3 4.9±0.9a 1.2±0.3 1.8±0.3b 1.2±0.3 1.1±0.2b
NLRP3 1.0±0.1 2.0±0.1a 1.0±0.1 1.5±0.1ab 1.0±0.1 1.2±0.1b
TLR4 1.0±0.4 3.6±0.8a 1.0±0.4 1.0±0.1b 1.0±0.2 1.2±0.2b
(Mean ± SE, ap <0.05 vs C, bp <0.05 vs 1 wk) 
Innate immunity activation was seen at 1 week. However, only M݊ and AngII+ 
remained elevated as chronic renal injury settled in, despite disappearance of Crys.
Conclusions: INIM may participate, along with renal AngII production and M݊ 
infiltration, in the acute phase of this model. However, INIM seems not to influence the 
late progression to chronic glomerular and interstitial injury, which may depend on as yet 
unidentified mechanisms. FAPESP/CNPq.
Funding: Government Support - Non-U.S.
TH-PO168
Assessing the Role of B7.1 in Diabetic Nephropathy  Marcela Herrera,1 
Magnus Soderberg,2 Johan C. Molne,3 Beatriz Santamaria pérez,4 Angela M. 
Valverde,4,5 Stephanie C. Heasman,1 Lutz Jermutus,1 David J. Baker,1 Carol 
Patricia Moreno Quinn.1  1Cardiovascular & Metabolic Diseases, Medimmune, 
Cambridge, United Kingdom; 2AstraZeneca, Molndal, Sweden; 3Pathology, 
Sahlgrenska Univ, Gothenburg, Sweden; 4Inst for Biom Res Alberto Sols, CSIC.
UAM, Madrid, Spain; 5Centro de Investigación Biomédica en Red de Diabetes 
y Enfermedades Metabólicas Asociadas (ISCIII), Madrid, Spain.
Background: Upregulation of podocyte B7.1 has been reported in kidney biopsies of 
Diabetic Nephropathy (DN) patients and in stressed cultured human podocytes. Blocking 
B7.1 with a CTLA4-Fc fusion (Abatacept) protects the injured podocyte in vitro and 
improves DN pre-clinically. B7.1 is found in antigen presenting cells and binding of 
CTLA4-Fc to B7.1 prevents T-cell activation. Since inflammation is an important feature 
of diabetes, we hypothesized that Abatacept protects the kidneys during DN primarily by 
blocking T-cell activation.
Results: We investigated B7.1 expression in 42 DN kidney biopsies using 
immunohistochemistry. B7.1 expression was not detected in podocytes but predominantly 
localized in a limited number of macrophages, with no differences found between control 
and DN patients (0.15±0.23 vs. 0.19±0.22cells/mm2). In situ hybridization confirmed 
these results. In cultured human podocytes, B7.1 was found at relatively low levels when 
assessed by qPCR, and treatment with high-glucose (30mM for 3, 5, 10 and 14 days) 
or LPS (20 and 50ug/uL for 24 hrs) did not enhance B7.1 expression. Western blotting 
analysis confirmed these results. LPS-induced F-actin re-organization was not prevented 
by Abatacept (10-100ng/mL). We then tested Abatacept in the STZ-induced DN model 
(high fat-diet-C57Bl6). After 3 weeks of diabetes induction, Abatacept was dosed s.c. at 
50mg/kg every 2 days for 12 weeks. At 3 weeks of dosing, urinary albumin:creatinine ratio 
increased from 3.6±0.8 to 8.3±0.9ug/umoles in the diabetic animals (p<0.05) while in the 
Abatacept group UAC was 4.0±0.6ug/umol (p<0.05 vs. DN group). Glucose or HbA1c 
were unaffected across groups and throughout the study.
Conclusions: B7.1 is a valid target for DN where the mechanism of action is more 
likely inhibition of T-cell activation rather than podocyte protection.
Funding: Pharmaceutical Company Support - Medimmune
AstraZeneca
TH-PO169
Systemic Overexpression of Endogenous Secretory RAGE Attenuates 
Diabetic Kidney Injury Through TLR4 Not TLR2 Signaling  Xiaochen Chen,1 
Jin Ma,1 Elisabeth G.D. Stribos,1 A. Lianne Messchendorp,1 Moumita Paul,1 
Eithne Cunningham,1 Alexandra Sharland,1 Steven J. Chadban,1,2 Huiling Wu.1,2 
1Kidney Node Laboratory, Charles Perkins Centre, Univ of Sydney, Australia; 
2Royal Prince Alfred Hospital, Australia.
Background: Endogenous secretory RAGE (esRAGE) is a soluble decoy receptor 
that can competitively bind ligands for TLRs/RAGE, including HMGB1. Here we test 
whether: 1) esRAGE after the induction of diabetes can prevent the development of diabetic 
nephropathy(DN) in mice with streptozotocin-induced diabetes; 2) the protective effects 
of esRAGE are attributable to interruption of signaling via the HMGB1 receptors(TLR2, 
TLR4 and RAGE).
Methods: DN was induced in WT, TLR4-/- and TLR2-/- mice by intraperitoneal injection 
of streptozotocin. At 2 weeks after STZ injection, mice received an IP injection of 5x1011 
vector genome copies rAAV encoding either esRAGE or HSA, or saline-control. Samples 
were collected at week 12 post-induction of diabetes.
Results: Diabetic mice that received rAAV-esRAGE, rAAV-HSA or saline developed 
equivalent degrees of hyperglycaemia. Diabetic WT-mice given rAAV-HSA or saline 
developed significant albuminuria versus non-diabetic WT-mice(ACR309±213 & 
313±215 versus 55±10, p<0.05-0.01), whilst rAAV-esRAGE treated-diabetic-mice were 
protected(118±42, p<0.05). WT diabetic-mice developed histological damage including 
glomerular hypertrophy, podocyte injury, macrophage accumulation and interstitial fibrosis. 
These changes were significantly attenuated in diabetic mice given rAAV-esRAGE versus 
rAAV-HSA(p<0.05-0.01).While both TLR2-/- mice and TLR4-/-mice were partially protected 
against DN, esRAGE treatment provided additional protection to TLR2-/- mice, but not 
TLR4-/-mice. A further study of esRAGE treatment in RAGE-/- mice is underway.
Conclusions: High-level expression of serum esRAGE after the induction of diabetes 
provided partial protection against the development of DN in STZ-induced diabetic mice, 
which may operate through the TLR4 pathway.
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Calcitriol Inhibits Advanced Glycation End Product (AGE)-Elicited 
Mesangial Cell Damage by Sequestrated RAGE-NF-κB Signaling 
Ao Cheng, Yanlin Zhang.  Dept of Nephrology, The First Affiliated Hospital of 
Xiamen Univ, Xiamen, Fujian, China.
Background: Actived vitamin D3 (Calcitriol) can effectively slow the progression 
of chronic kidney disease and its mechanism is not very clear. The advanced glycation 
products (AGEs) accumulate in the kidney disease through RAGE receptors. The aim of 
this experiment was to explore the effect and mechanism of Calcitriol on the inflammatory 
of mesangial cells caused by AGEs, and to further expand the clinical application of 
actived vitamin D3.
Methods: AGE-HSA was prepared and human glomerular mesangial cells were 
cultured in vitro. the purpose of the present study was to investigate the efficacy of calcitriol 
on AGEs-induced inflammatory in human mesangial cell. Pretreatment or not with calcitriol, 
the human mesangial cell was treatment with various concentrations and time period of 
AGEs. IL-6 and MCP-1 were measured by real-time PCR and ELISA. The expression of 
vitamin D receptor (VDR), receptor of advanced glycation end products (RAGE), NF-κB 
p65 and phosphorylated p65 was measured by Western-blot. NF-κB p65 translation was 
determined by immunofluorescence. Cellular oxidative stress was measured by reactive 
oxygen species (ROS) production.
Results: (1) AGE-HSA induces IL-6 and MCP-1 expressing in human mesangial cells, 
and calcitriol inhibits this effect. (2) Not AGE-HSA but calcitriol induces Vitamin D receptor 
(VDR) expression in human mesangial cells. And calcitriol inhibits this effect through VDR. 
(3) AGE-HSA induced Receptor for advanced glycation end products (RAGE) expression, 
and effects was blocked by calcitriol. (4) Effect of calcitriol on ROS production induced by 
AGE-HSA in mesangial cells. (5) NF-κB activation in renal mesangial cells was induced 
by AGE-HSA, and the effect was inhibited by calcitriol.
Conclusions: Calcitriol could attenuate the AGE-induced up-regulation of IL-6 and 
MCP-1 though VDR by suppressing RAGE expression and subsequent ROS generation 
and reducing NF-κB activation.
Funding: Government Support - Non-U.S.
TH-PO171
GLP-1 Receptor Agonist Exendin-4 Ameliorates Renal Injury by Reducing 
Cholesterol Deposition and Inflammation in Glomerular Endothelial Cell 
via ABCA1-JAK2/STAT3 Pathway in Diabetic apoE-/- Mice  Qinghua Yin, 
Ping Fu, Fang Liu.  Div of Nephrology, West China Hospital of Sichuan Univ, 
Chengdu, Sichuan, China.
Background: Lipid accumulation in glomerular endothelial cells has been found a 
unique feature, which may contribute to the renal inflammation in diabetic kidney disease. 
The ATP-Binding Cassette Transporter (ABCA1) is an important transporter responsible 
for cholesterol efflux. This study was performed to examine the effect of GLP-1R agonist 
exendin-4 on cholesterol deposition and inflammation in diabetic kidney disease and to 
explore the possible mechanism.
Methods: The human renal biopsy specimens with diabetic kidney disease were 
examined by electron microscope to determine lipid droplets. Oil Red O staining and CD31 
double staining was also performed. In vivo, the double immunofluorescent staining of 
CD31 with GLP-1R, ABCA1, p-JAK2 and p-STAT3 was detected in the kidney tissues of 
exendin-4 treatment diabetic apoE-/- mice. The expression of proinflammatory cytokine 
(e.g. IL-6, TNF-α), CaMKK, CaMKIV, ABCA1, p-JAK2 and p-STAT3 were examined 
in the isolation of glomeruli from diabetic apoE-/- mice and exendin-4 treatment diabetic 
apoE-/- mice and in human renal glomerular endothelial cells (HRGECs) were cultured 
in high glucose and with cholesterol, exendin-4, STO-609 (CaMKK inhibitor), ABCA1 
siRNA and AG 490 (JAK2 Inhibitor).
Results: Extensive lipid accumulation in glomerular endothelial cells of kidney biopsies 
from DKD patients. Double-labeling of GLP-1R, ABCA1, p-JAK2, pSTAT3 and CD31 
was detected in the glomerulus of the renal tissues. Exendin-4 treatment upregulated the 
expression of CaMKK, CaMKIV, ABCA1, p-JAK2 and p-STAT3 and downregulated IL-6 
and TNF-α, as well as ameliorated lipid accumulation compared with diabetic mice. In vitro, 
exendin-4 decreased the expression of IL-6,TNF-α ,whereas, STO-609(CaMKK inhibitor) 
, ABCA1 siRNA and AG 490 (JAK2 Inhibitor) all increased IL-6 and TNF-α in HRGECs.
Conclusions: GLP-1R agonist exendin-4 reduced cholesterol deposition and regulated 
ABCA1 via CaMKK/CaMKIV pathway in glomerular endothelial cells, and then activated 
ABCA1-JAK2/STAT3 pathway, which may ameliorat renal inflammation in diabetic 
apoE-/- mice.
Funding: Clinical Revenue Support
TH-PO172
Renal Consequences of Coxsackievirus Infection in Non-Obese Diabetic 
Mice  Debra L. Walter,1,2 Frank L. Schwartz,3,5 Kelly D. Mccall,1,3,5 Karen T. 
Coschigano.1,4,5  1Molecular & Cellular Biology Program, College of Arts & 
Sciences; 2Dept Biological Sciences, College of Arts & Sciences; 3Dept Specialty 
Medicine, Heritage College of Osteopathic Medicine; 4Dept Biomedical 
Sciences, Heritage College of Osteopathic Medicine; 5Diabetes Inst, Ohio 
Univ, Athens, OH.
Background: Diabetes is the leading cause of end stage renal disease in the United 
States, however, it is difficult to predict which diabetic patients will go on to develop 
diabetic nephropathy. Recently, viruses have been found to mediate many autoimmune 
diseases, such as type 1 diabetes (T1D), that result in kidney damage. While research on 
viral induction of T1D has been brought into focus, effects of viral infection in the kidneys 
of T1D patients has remained undefined. Characterizing the consequences of viral infection 
in the kidney will allow for a better understanding of kidney disease progression in patients 
with virus-mediated T1D.
Methods: The non-obese diabetic (NOD) mouse is genetically predisposed to develop 
T1D over time. Disease onset can be accelerated by viral infection, making it a novel model 
to study virus-mediated kidney damage. In the current study, NOD mice were infected with 
coxsackievirus at 8-10 weeks of age and euthanized 3, 7, 10 and 14 days and 3, 7, 12 and 
17 weeks post infection. Gene expression was measured by real-time PCR.
Results: Coxsackievirus expression in NOD mouse kidneys was upregulated acutely 
(3 days post infection) along with genes involved in glomerular and tubular damage and 
the inflammatory response (Lcn2, TLR3, MCP-1, IL-6, TNFα, etc.).
Conclusions: This study characterizes both acute and chronic virus-mediated alterations 
in the kidneys of NOD mice predisposed to develop T1D. Results will provide information 
regarding acute and chronic effects of coxsackievirus after a one-time infection, identifying 
functional changes occurring in the kidney and the immunological responses associated 
with these changes. These results will provide a better understanding of virus-mediated 
kidney injury in NOD mice genetically predisposed to develop T1D as a step towards 
understanding mechanisms of diabetic nephropathy in humans. Funding: OHF, JOW-ECDR 
and OU BF, SEA and GSS-OWG.
Funding: Private Foundation Support
TH-PO173
Renal Protection by Atorvastatin in Sickle Cell Nephropathy  Rima S. Zahr,1 
Vanesa Bijol,2 Kenneth I. Ataga,3 David Archer.1  1Pediatrics, Emory SOM, 
Atlanta, GA; 2Pathology, Brigham and Womens Hospital, Boston, MA; 
3Hematology, UNC, Chapel Hill, NC.
Background: Sickle Cell Disease (SCD) affects approximately 100,000 people in 
the USA. Renal involvement begins early commonly manifested as hyposthenuria with 
microalbuminuria occurring ~20% of SCD patients <18 years. Current treatment options 
for sickle cell nephropathy include ACE inhibitors or ARBs to prevent progressive 
proteinuria. Statins have pleiotropic effects in addition to their lipid lowering properties. 
Here we investigated the functional effects of Atorvastatin treatment on the development 
of nephropathy in a murine model of sickle cell disease.
Methods: Cohorts (n=10) of 8-12 week homozygous sickle cell mice were treated 
with atorvastatin (10mg/kg) or vehicle daily for 8 weeks by oral gavage. We assessed 
effects of atorvastatin on albuminuria, maximum urine concentrating ability and GFR at 
baseline and week 8. Urine was collected in metabolic cages for 24hrs and albuminuria 
quantified by ELISA. GFR was measured by plasma clearance of FITC-Inulin. Mice were 
water deprived for 12hrs and spot urine for maximum urine concentrating ability. Kidneys 
were prepared appropriately for light microscopic analysis and glomerular morphometry.
Results: After 8 weeks of daily treatment mice receiving atorvastatin were found to 
have statistically significant improvement in urine concentrating abilities and improvement 
in GFR ( p < 0.01 and p < 0.001 respectively). Urine protein excretion was unchanged 
by treatment with atorvastatin. Under light microscopy there were no gross changes in 
appearance of glomeruli or glomerular vasculature. In addition we did not find significant 
statistical changes in glomerular tuft size.
Conclusions: We assessed the pleiotropic effects of statins in SCD. While we did 
not find differences in urine albumin excretion and glomerular tuft size we found that 
atorvastatin increased the low baseline GFR and improved urine concentrating abilities in 
sickle cell mice These complications of are found both in animal and human models. Further 
studies will examine microscopic examination of podocyte and endothelial structures and 
look at biomarkers of renal injury.
Funding: Other NIH Support - R01HL111659
TH-PO174
Endothelin Receptor Antagonism Protects from Sickle Cell Nephropathy 
Olivia Lenoir, Carole Hénique-Gréciet, Pierre-Louis Tharaux.  Paris 
Cardiovascular Center - PARCC, INSERM, Paris, France.
Background: Sickle-cell disease (SCD) is characterized by chronic hemolysis and 
recurrent episodes of vaso-occlusive events that affect the microcirculation and lead to 
ischemic tissue injury with multi-organ dysfunction. Sickle cell nephropathy (SCN), a 
major mortality risk factor in SCD, is characterized by an early increase in glomerular 
filtration rate with subsequent progressive decline of renal function.Focal and segmental 
glomerulosclerosis (FSGS) and hypertrophied glomeruli with distended capillaries are the 
major hallmarks of glomerular lesions. We investigated the effects of chronic mixed ET 
receptor antagonism in a model of SCD-mediated FSGS.
Methods: We used SAD Hbbsingle/single hemizygous mice on the C57BL/6J 
background. At 3 months of age SAD mice displayed little evidence of chronic renal damage 
but significant glomerulomegaly compared to controls. Glomerulomegaly persisted, and 
was worse, at 6 months of age (average glomerular section area: 2372±207 vs. 1519±180 
µm2, p<0.001). In addition, SAD mice had significant glomerulosclerosis. Based on these 
data we treated SAD mice and controls aged 3 months with the dual ET receptor antagonist 
bosentan for 9 months in a preventative study, and 6 months old SAD mice for 6 months 
in a therapeutic study. We assessed blood pressure, kidney structure and function after 6 
and 9 months of continuous treatment.
Results: In the preventative study, 6 months of bosentan therapy was associated with ~4-
fold less glomerulosclerosis compared to untreated SAD mice (22±8 vs. 86±4%, p<0.001). 
Additionally, there was an 80% reduction in mean glomerular surface area (p<0.05). In 
the therapeutic study, there was a significant reduction in glomerulosclerosis (p<0.01) and 
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glomerulomegaly (p<0.01) compared to untreated mice but this was less effective than in 
the preventative study (p<0.05). Furthermore, chronic ET-1 receptor antagonism alleviated 
the development of tubulointerstital fibrosis in both groups and limited the rise of blood 
urea nitrogen levels that characterized untreated aged SAD mice.
Conclusions: ET receptor antagonism is a potentially useful preventative or therapeutic 
approach in SCN. Based on these data clinical trials are warranted.
TH-PO175
Erythropoietin and Its Carboxylated Derivative Protected aganist Chronic 
Cyclosporine Nephropathy  Wenhan Peng, Jianghua Chen.  Kidney Disease 
Center, The First Affiliated Hospital, College of Medicine, Zhejiang Univ, 
Hangzhou, Zhejiang, China.
Background: Erythropoietin (EPO) is known to raise hemoglobin and protect tissues 
and its carboxylated derivative (CEPO) has no effect on hemoglobin but could induce 
tissue protection. The aim of this study is to determine the effect of EPO and CEPO on the 
animal model of chronic cyclosporine nephropathy.
Methods: We evaluated therapeutic effects of EPO and CEPO using a rat model of 
chronic cyclosporine nephropathy. Rats were randomly divided into five groups: (1) the 
saline treatment group (control group, n=12); (2) EPO treatment group at low dose (low 
EPO group, 100U/kg, n=12); (3) CEPO treatment group at low dose (low CEPO group, 
100U/kg, n=12); (4) EPO treatment group at high dose (high EPO group, 500U/kg, n=12); 
(3) CEPO treatment group at high dose (high CEPO group, 500U/kg, n=12).
Results: In control group, the levels of sodium, protein and NAG enzyme of urine, 
the values of serum creatinine and urea nitrogen, the concentration of MDA and GSH-PX 
of kidney tissue were significantly increased. Those of EPO and CEPO treatment groups 
were significantly lower than those of control group. EPO and CEPO could promote to 
produce new endothelial cells and promote microvascular formation by analysis of CD31 
+ / CD 34+ cell number of blood and kidney tissue. EPO and CEPO decreased collagen 
fibers, tubular apoptosis and expression of TGF-b1, Caspase-3 and α-SMA in kidney tissue. 
The higher doses of EPO and CEPO showed more protection effects. But EPO treatment 
increased hemoglobin concentration and induced infarction.
Conclusions: EPO and CEPO could effectively antagonize cyclosporine nephrotoxicity 
through anti-fibrosis,anti-inflammatory cell infiltration, anti-apoptotic, anti-oxidant, 
promotion new growth of renal tubular epithelial and endothelial cells, and the promotion 
of release and proliferation of endothelial progenitor cells.
Funding: Government Support - Non-U.S.
TH-PO176
Glucose Promotes Secretion-Dependent Renal Cyst Growth  Andre Kraus,1 
Gunnar Schley,1 Karl Kunzelmann,2 Rainer Schreiber,2 Kai-Uwe Eckardt,1 
Bjoern Buchholz.1  1Dept of Nephrology, Univ Erlangen-Nuernberg, Erlangen, 
Germany; 2Dept of Physiology, Univ Regensburg, Regensburg, Germany.
Background: ADPKD is characterized by continuous cyst growth which is highly based 
on transepithelial Cl- secretion into the cyst lumen. Since ADPKD is a long-lasting, chronic 
disease, there is a significant number of patients suffering from both, ADPKD and type 2 
diabetes mellitus. Recently, ADPKD patients with type 2 diabetes mellitus were shown to 
have kidneys with almost double the volume compared to non-diabetic ADPKD patients. 
Therefore, we wanted to test for the impact of glucose on renal cyst growth.
Methods: We examined the effect of different glucose concentrations ranging from 5.6 
mmol/l up to a maximum of 25.0 mmol/l on cyst growth of MDCK cells within a collagen 
matrix as well as in ex vivo cultured embryonic mouse kidneys treated with forskolin. 
In addition, we analysed changes in expression of potentially relevant ion channels and 
transporters at different glucose levels. Furthermore, we performed Ussing chamber 
experiments with MDCK cells in order to detect alterations of transepithelial Cl- secretion 
upon changes in glucose concentration.
Results: Cyst expansion highly correlated with the levels of glucose in both cyst models, 
revealing already significant increase of cyst growth by elevating glucose concentration 
from 5.6 mmol/l to 11.1 mmol/l. These effects were neither referable to changes in pH or 
lactate, nor due to osmotic changes demonstrated by the use of equivalent doses of mannitol. 
However, elevated levels of glucose resulted in significantly increased transcription of 
the Ca2+-activated Cl- channel Anoctamin (ANO) 1 which we have previously shown is 
involved in renal cyst growth. In line with these data, CaCCInh-AO1, a specific inhibitor 
of ANO1, inhibited glucose-dependent cyst expansion in both models. In addition, Ussing 
chamber experiments revealed a significant increase of Ca2+-dependent Cl- secretion at 
elevated glucose levels which could be inhibited by the use of CaCCInh-AO1.
Conclusions: Increased glucose levels could augment secretion-dependent cyst growth 
in ADPKD. Therefore, tight glucose control might be beneficial in ADPKD to reduce cyst 
growth and preserve renal function.
Funding: Government Support - Non-U.S.
TH-PO177
Kidney Stones Provide a “Third Hit in Autosomal Dominant Polycystic 
Kidney Disease”  Jacob A. Torres,1 Mina Rezaei,1 Saeed R. Khan,2 Thomas 
Weimbs.1  1Molecular Celluluar and Developmental Biology, Univ California 
Santa Barbara, Santa Barbara, CA; 2Dept of Pathology, Univ of Florida, 
Gainesville, FL.
Background: The progression of autosomal-dominant polycystic kidney disease 
(ADPKD) exhibits high inter- and intrafamilial variability suggesting the possibility that 
unknown environmental factors may play an important role. Work on mouse models has 
led to the idea that renal injury is required as a so-called “third-hit trigger” for the initiation 
of renal cysts. We hypothesized that a much more frequent and prevalent form of renal 
insult may determine the speed of progression in ADPKD. We report here that chronic or 
acute hyperoxaluria leads to very rapid dilation of renal tubule diameters in response to 
CaOx crystal deposition.
Methods: Mice and rats were challenged with intraperitoneally administered oxalate 
to rapidly produce calcium oxalate crystals or were fed oxalate producing compounds to 
form oxalate stones inside the kidney. To test the effect of the mTOR pathway, mTOR was 
inhibited with the administration of rapamycin prior to oxalate administration.
Results: The mTOR and STAT3 signaling pathways are rapidly activated in dilated 
tubule cells. Fast tubule dilation can be prevented by mTOR inhibition. Once crystals 
are cleared, mTOR and STAT3 signaling is inhibited and tubule diameters return back to 
normal. Our results suggest that tubule diameter dilation is an active mechanism employed 
by the kidney to clear lodged crystals. Both, mTOR and STAT3 have previously been 
shown to be aberrantly activated in cyst-lining cells in ADPKD and drive cyst growth. 
We find that challenging pre-conditioned mice lacking primary cilia with oxalate leads to 
persistent tubule dilation.
Conclusions: These results suggest that cilia are required for reestablishing normal 
tubule diameters after crystal clearing. Furthermore, these results suggest that renal crystal 
deposition may be a clinically relevant, environmentally controlled “third-hit trigger” that 
affects disease progression in ADPKD. This suggests that dietary changes or treatments to 
reduce renal crystal burden may be effective in slowing ADPKD progression.
Funding: Private Foundation Support
TH-PO178
Soluble RAGE Alleviates Disease Progression in Autosomal Dominant 
Polycystic Kidney Disease by Down-Regulation of Cell Proliferation 
Jong Hoon Park, Eunji Lee, Hyowon Mun, Je Yeong Ko, Do Yeon Kim.  Dept 
of Biological Science, Sookmyung :omen¶s Univ, Seoul, Republic of Korea.
Background: Autosomal polycystic kidney disease (ADPKD) is a one of the common 
genetic renal diseases in which epithelial-lining fluid-filled cysts appear in kidneys. It is 
accompanied by hyper-activation of cell proliferation, interstitial inflammation and fibrosis 
around the cyst lining cells, finally reaching end-stage renal disease (ESRD). Previously, 
we found high expression of ligands stimulating the receptor for advanced glycation 
endproducts (RAGE) in ADPKD mice. Furthermore, gene silencing of RAGE was revealed 
to reduce cystogenesis via down-regulation of cell proliferation in vitro, while intravenous 
administration of anti-RAGE adenovirus in vivo also displayed alleviation of the disease.
Methods: Using either mice primary cells or human ADPKD cell line WT9-12, both 
sRAGE treatment and over-expression of sRAGE with cloned construct we established 
herein were tested in vitro. In addition, in vivo test via intraperitoneal injection using 
ADPKD mice model jck, and confirmed the in vitro results in in vivo systems.
Results: Here, we attempted to identify the role of soluble RAGE (sRAGE) in inhibiting 
the progression of ADPKD, in vivo. sRAGE is an endogenously expressed form of RAGE 
which has no membrane-anchoring domain, thereby being able to neutralize the ligands 
that stimulate RAGE signals. Both over-expression of sRAGE and sRAGE treatment 
blocked RAGE-mediated cell proliferation in vitro. In addition, sRAGE-injected ADPKD 
mice showed reduced cysts accompanied by enhanced renal function, inhibition of cell 
proliferation, inflammation and fibrosis.
Conclusions: These positive therapeutic effects of sRAGE displayed little liver 
toxicity, suggesting it as a new potential therapeutic target of ADPKD with low side effects.
Funding: Government Support - Non-U.S.
TH-PO179
Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystic 
Kidney Disease  Ming-Yang Chang.  Kidney Research Center and Dept of 
Nephrology, Chang Gung Memorial Hospital, Chang Gung Univ College of 
Medicine, Kueishan, Taoyuan, Taiwan.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is 
characterized by enhanced fluid secretion and abnormal cell proliferation in renal tubular 
epithelial cells. Recent research has proposed that activation of AMP-activated kinase 
(AMPK) is a novel treatment strategy for ADPKD. We examined the effects of metformin 
on the initiation of pronephric cysts in a PKD2 zebrafish model.
Methods: Morpholino-mediated knockdown of pkd2 was performed in wt-1b 
pronephric-specific GFP-expressing zebrafish embryos to induce visible pronephric cysts 
for observation. Pkd2 morphants were incubated with metformin (2.5 to 10 mM) in the 
embryo medium until 48 hours post fertilization.
Results: Metformin significantly reduces the frequency of cyst formation and 
pronephric tubular cell proliferation in pkd2 morphant embryos. Whole mount in situ 
hybridization for L-plastin mRNA showed significantly reduced macrophage infiltration 
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in metformin-treated pkd2 morphants. RT-PCR showed that P2X7, IL-1β and IL-10 
mRNA expression were significantly inhibited by metformin. Simultaneously morpholino 
knockdown of AMPK a1 prevents the rescue effects of metformin on cystogenesis.
Conclusions: We showed that metformin decreases cyst formation through inhibiting 
cell proliferation and macrophage accumulation in a pkd2 zebrafish model. These results 
indicate that metformin reduces the earliest cyst formation in polycystic kidney disease, 
although its effect on progression of disease remained to be investigated.
Funding: Government Support - Non-U.S.
TH-PO180
Cardiac Hypertrophy and Cardiac mTORC1/2 Signaling in Rodent Models 
of PKD  Kameswaran Ravichandran, Qian Wang, Charles L. Edelstein.  Univ 
Colorado Denver.
Background: Cardiac disease is the commonest cause of death in ADPKD patients. 
Young normotensive ADPKD adults and children have higher LVMI compared to controls. 
Aim of study was to determine in rodent PKD models: 1) whether there is cardiac 
hypertrophy and increased mTORC1/2 signaling in the heart 2) the effect of mTOR kinase 
inhibition on cardiac hypertrophy.
Methods: Heart weight was determined in Pkd1 -/- mice, Pkd2WS25/- (Pkd2 -/- mice) 
and Han:SPRD (Cy/+) rats. pS6 and p4E-BP1, markers of mTORC1 and pAktSer473, 
marker of mTORC2, were determined by immunoblot analysis of 3 separate experiments. 
Pkd2 -/- mice were treated with an mTOR antisense oligonucleotide (ASO) that inhibits 
mTORC1/2 and PKD from 4-16 wks of age. Cy/+ rats were treated with the mTOR kinase 
inhibitor, PP242, that inhibits mTORC1/2 and PKD from 3-8 wks of age.
Results: There was increased heart weight in 150 d old Pkd1 -/- mice, 16 wk old Pkd2 
-/- mice, 8 wk old normotensive Cy/+ rats and Pkd2+/- mice that are haplo-insufficient 
for Pkd2 and do not have hypertension. There was increased pS6, p4E-BP1 and pAkt in 
Pkd1 -/- hearts and increased p4E-BP1 and pAkt in Pkd2 -/- and Pkd2+/- hearts. mTOR 
ASO resulted in less p4E-BP1 and pAkt and less cardiac hypertrophy in Pkd 2-/- mice. 
mTOR kinase inhibitor, PP242, resulted in less cardiac hypertrophy in normotensive Cy/+ 
rats HW/TBW(%) was 0.4 in +/+, 0.52 in Cy/+ (P<0.05 vs +/+) and 0.44 in Cy/+PP242 
(P<0.05 vs. Cy/+).
++ Pkd1 -/- ++ Pkd2 -/-
Pkd2 -/- 
ASO +/+
Pkd2 
+/- 
HW/TBW 
(%) 0.46 0.61* 0.52 0.66* 0.56** 0.52 0.69*
p/tS6 + +++ + + + + +
p/t 4E-
BP1 + +++ + ++ + + ++
p/t 4E-
BP1 + ++ + ++ + + ++
*P<0.05 
vs +/+
**P<0.05 
vs Pkd2-/-
HW=heart 
weight
p/t= 
phospho/
total
Conclusions: There was increased heart weight in normotensive Cy/+ rats and Pkd2+/- 
mice. There was increased mTORC1 and 2 signaling in Pkd1 -/-, Pkd2 +/- (without PKD) 
and Pkd2 -/- hearts. mTOR kinase inhibition, that blocks both mTORC1 and 2, resulted 
in less cardiac hypertrophy. Discovery of an agent e.g. mTOR kinase or 4E-BP1 inhibitor 
that decreases early cardiac hypertrophy in PKD in addition to decreasing PKD would be a 
significant finding and would increase the enthusiasm to use these agents in ADPKD patients.
Funding: Veterans Administration Support
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Polycystic Kidney Disease – A Case of Suppressed Autophagy? 
Kameswaran Ravichandran,1 Charles L. Edelstein.1  1Univ of Colorado Denver; 
2Univ of Colorado Denver.
Background: Autophagy is a normal physiological process that involves the 
degradation of damaged cellular components. Autophagy in general promotes cell survival 
while apoptosis that promotes cell death. We have reported (Edelstein et al, AJP, 2011) 
that there are features of autophagy like autophagosomes, mitophagy and autolysosomes 
in normal tubules and tubular cells lining cysts in Cy/+ rats with PKD and that there is 
suppression of autophagic flux in cpk mice with PKD.
Methods: 150 day old mice with PKD due to a kidney specific Pkd1 knockout were 
studied. MDCK cells with a stable knockdown of PC1 was achieved by lentiviral-mediated 
delivery of a specific SiRNA for PKD1 were studied. MDCK cells that form tubules were 
used as controls. LC3-II, a marker of autophagic flux and cleaved caspase-3, a marker of 
apoptosis, were measured by immunoblot analysis of at least 3 separate experiments. Pkd1 
-/- mice were treated with bafilomycin-A1 (5 mg/kg//d IP), a lysosomal inhibitor, for 3 
days. MDCK cells were treated with bafilomycin 100 nm.
Results: In Pkd1 -/- mouse kidneys there was an increase in LC3 –II compared to 
wild type. The increase in LC3-II in Pkd1-/- versus wild type kidneys suggests increased 
autophagosome synthesis or decreased degradation in the lysosome. To investigate these 
possibilities, Pkd1 -/- mice were treated with bafilomycin-A1. Bafilomycin-A1 had no 
effect on LC3-II in PKD kidneys of Pkd1 -/- mice. To determine the direct effect of PC-1 
knockout on autophagy, PC-1 -/- MDCK cells were studied. In PC-1 -/- cells, there was a 
decrease in LC3-II compared to control MDCK. In PC1 -/- cells treated with bafilomycin, 
there was a further suppression of LC3-II, indicating decreased autophagic flux. Increased 
apoptosis is a feature of PKD kidneys. In the PC-1 -/- cells there was a 2-fold increase in 
cleaved caspase-3, a marker of apoptosis, associated with the decrease in autophagic flux.
Conclusions: The lack of effect of the lysosomal inhibitor bafilomycin-A1 to increase 
LC3-II in Pkd1-/- kidneys and in PC-1 -/- cells suggests a defect in autophagy resulting 
from a block of autophagosome-lysosome fusion and degradation. There was an association 
between suppressed autophagy and increased apoptosis in PC-1 -/- cells.
Funding: Veterans Administration Support
TH-PO182
Retinoid X Receptor Pathway: A Novel Signaling Cascade Responsible 
for Cystogenesis in Three Rodent Models of Polycystic Kidney Disease 
Daisuke Yoshihara,1 Masanori Kugita,1 Harold M. Aukema,2 Tamio Yamaguchi,2 
Shizuko Nagao.1  1Education and Research Center of Animal Models for Human 
Diseases, Fujita Health Univ, Toyoake, Aichi, Japan; 2Dept of Human Nutritional 
Sciences, Univ of Manitoba, Winnipeg, MB, Canada.
Background: Polycystic kidney disease (PKD) is the most common inherited renal 
disorder and is characterized by innumerable cysts and tubular epithelial cell proliferation. 
We previously speculated that retinoid X receptor (RXR) may be related to cystogenesis in 
the Han:SPRD-Cy (Cy/+) rat, since VDR/RXR activation, LPS/IL-1-mediated inhibition 
of RXR function, and LXR/RXR activation were altered in diseased kidneys. RXR is 
known to induce cellular proliferation and is normally degraded by ubiquitin after binding 
to its cognate ligand. In human hepatocellular carcinoma, the degradation rate of RXR is 
abnormally reduced, and treatment with a RXR agonist suppressed its proliferative activity 
(Adachi, Hepatology 2002). We therefore determined the expression and distribution of 
renal RXR, and the effect of a RXR agonist in polycystic kidneys.
Methods: Kidneys were obtained from three rodent models: Cy/+ rats, jck and pcy 
mice. Expression of RXR was confirmed by western blot analyses. Co-localization of 
RXR with PCNA, an index for cell proliferation, was detected by standard procedures. In 
addition, Cy/+ rats were orally treated with 30mg/kg bexaroten (BEX), a RXR agonist, 
from 4 to 10 weeks of age.
Results: In all three models, renal RXR levels were increased compared with age-
matched rats/mice with normal kidneys. Total RXR was detected in the nuclear extract of 
cystic kidneys, and increased RXR was co-localized with PCNA in cystic epithelia nuclei. 
In Cy/+ rats, BEX treatment significantly decreased RXR expression and kidney weight 
adjusted to body weight.
Conclusions: RXR was related to aberrant cell proliferation in PKD progression in 
three different animal models, and a RXR agonist suppressed disease progression in Cy/+ 
rats. These findings suggest that RXR signaling may have an important role in cystogenesis 
and that RXR ligands may have therapeutic potential.
Funding: Government Support - Non-U.S.
TH-PO183
Integrin Linked Kinase Promotes Cyst Growth and Fibrosis in ADPKD 
Archana Raman, Gail Reif, Yuqiao Dai, Darren P. Wallace.  Depts of Medicine 
and Physiology, KU Kidney Inst, Univ of Kansas Medical Center, Kansas 
City, KS.
Background: Aberrant expression of extracellular matrix (ECM) molecules and 
secreted factors contribute to renal cyst growth and fibrosis in ADPKD. Periostin, a 
matricellular protein involved in tissue development and repair, is overexpressed in kidneys 
of ADPKD patients and murine models of PKD. Gene knockout of periostin reduced renal 
cyst growth and interstitial fibrosis, and prolonged the survival of PKD mice. Periostin binds 
to av-integrins (avb3, avβ5) and induces cell proliferation via integrin linked kinase (ILK) 
activation of Akt/ mTOR, a key signaling pathway involved in PKD. We have determined 
if knockdown/knockout of ILK prevents periostin-induced proliferation of human ADPKD 
cells and reduces cyst growth and fibrosis in an ADPKD mouse.
Methods: We knocked down ILK expression in ADPKD cells using lentiviral shRNA. 
Activation of the Akt/ mTOR pathway was determined by measuring phosphorylation of 
Akt and S6 kinase (S6K), a downstream target of mTOR. To determine if ILK may be a 
potential therapeutic target, we knocked out ILK in collecting ducts of Pkd1flox/flox: Pkhd1-
Cre mice, an orthologous model of ADPKD, by breeding these mice with ILKflox/flox mice. 
At postnatal day 25, mice were euthanized and kidney weight/body weight (%KW/BW), 
cystic index, interstitial fibrosis and cell proliferation were measured.
Results: We found that ILK knockdown blocked periostin-induced phosphorylation 
of Akt and S6K and proliferation of human ADPKD cells. CPD-22, an ILK inhibitor, also 
blocked the effect of periostin on the Akt/ mTOR pathway and ADPKD cell proliferation. 
Gene knockout of one ILK allele (Pkd1flox/flox ILKflox/+: Pkhd1-Cre) or both alleles (Pkd1flox/
flox ILKflox/flox: Pkhd1-Cre) significantly decreased %KW/BW, renal cystic index and cell 
proliferation. Furthermore, ILK knockdown reduced renal interstitial edema and fibrosis 
in PKD mice, suggesting that blockade of the ILK signaling pathway may reduce both 
cyst growth and fibrosis in ADPKD.
Conclusions: Aberrant expression of periostin stimulates ILK activation of signaling 
pathways that contribute to renal cyst growth and fibrosis, suggesting that ILK may be a 
therapeutic target for ADPKD.
Funding: NIDDK Support
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TH-PO184
Periostin Regulates Polycystic Kidney Cell Proliferation and Cyst 
Formation via CFTR and JAK2/STAT3 Signaling Pathway  Sun Ae Han,1 
Hayne C. Park,2 Hyunsuk Kim,3 Hyunjin Ryu,3 Kook-Hwan Oh,3 Young-Hwan 
Hwang,4 Curie Ahn.3  1Transplanatation Research institute, Seoul National Univ 
Medical Research Center, Seoul, Korea; 2Dept of Internal Medicine, Armed 
Forces Capital Hospital, Sungnam-si, Gyunggi-do, Korea; 3Dept of Internal 
Medicine, Seoul National Univ Hospital, Seoul, Korea; 4Dept of Internal 
Medicine, Eulji General Hospital, Seoul, Korea.
Background: Renal cyst formation and fibrosis are the hallmark of autosomal 
dominant polycystic kidney disease (ADPKD). ADPKD cyst-lining cells have an increased 
proliferation rate and are surrounded by an abnormal extracellular matrix (ECM). The 
matricellular protein periostin was shown to be activated in cyst-lining cells in ADPKD 
and PKD mouse models and may drive renal cyst growth, but the mechanism of periostin-
induced cyst formation is still unclear. We examined the effect of periostin expression on 
cystic fibrosis transmembrane conductance regulator (CFTR) and phosphorylated levels 
of Janus kinase 2 (JAK2) /signal transducers and activators of transcription 3 (STAT3) 
signaling pathway.
Methods: Periostin expression was analyzed using immunohistochemistry and western 
blot analysis in ADPKD cells and normal human kidney (NHK) cells. Cell growth and 
western blot analysis for related molecular levels were assayed after suppression of periostin 
by small interfering RNA (siRNA). Finally, a three-dimensional culture was performed to 
understand how periostin affected cyst formation, in vitro.
Results: The periostin expression was highly increased in ADPKD cells compared 
to NHK cells. Transfection of ADPKD cells with periostin siRNA decreased cell growth 
and reduced the expression of CFTR and phosphorylated levels of JAK2/STAT3. In three-
dimensional culture, addition of recombinant periostin enhanced cyst formation, whereas 
periostin depleted cells showed lower level of cystogenesis.
Conclusions: Periostin stimulated cyst formation via CFTR and JAK2/STAT3 signaling 
pathway in ADPKD.
TH-PO185
The Possible Role of mTORC1 and TCA Cycle in Renal Cyst Formation 
and Transformation  Luca Drusian,1,2 Monika Pema,1 Valeria Mannella,1 
Isaline Rowe,1 Marco Chiaravalli,1 Musco Giovanna,1 Alessandra Boletta.1 
1Div Genetics and Cell Biology, San Raffaele Scientific Inst, Milan, MI, Italy; 
2Univ 9ita-Salute San Raffaele, San Raffaele Scientific Inst, Milan, MI, Italy.
Background: We have recently shown that PKD is characterized by an increased use 
of glycolysis in a process resembling the Warburg effect. This feature of PKD is in part 
dependent on mTORC1. However, mTORC1 upregulation, increased proliferation and 
the Warburg effect are hallmarks of cancer. In contrast, ADPKD patients do not have a 
propensity to increased rates of cancer as compared to the normal population. We aimed 
at investigating this conundrum.
Methods: We generated a mouse model carrying kidney-specific inactivation of the 
Tsc1 gene (Tsc1kKO), which survives for up to three months and displays cyst formation, 
followed by cystadenomas and transformation into carcinomas.
Results: This phenotype is fully penetrant and the lesions manifest progressively within 
a reproducible window of time (P20 to P80). We performed metabolomic profiling both 
by NMR spectroscopy and by mass spectrometry on these kidneys collected at different 
time points (P20, P50 and P80). The analysis revealed the presence of major changes at 
the level of the TCA cycle and a strong accumulation of fumarate, which is completely 
non-detectable in normal kidneys at any stage. We are currently investigating if these 
metabolic changes can account for the progressive transformation of cysts into carcinomas. 
Notably, a preliminary study of metabolic profiling in kidneys derived from mice carrying a 
kidney-specific inactivation of the Pkd1 gene, revealed that fumarate does not accumulate 
in these mutants. We hypothesize that ADPKD kidneys display a mild metabolic change 
affecting glycolysis, but not the TCA cycle, while cancerous lesions have a more profound 
metabolic alteration.
Conclusions: These studies will hopefully help identifying metabolic changes specific 
for PKD and likely good targets for therapy.
TH-PO186
Aberrant Expression of Rad9 in ADPKD  Wei Wang, Michel Chonchol, 
Berenice Y. Gitomer.  Dept of Medicine, Univ of Colorado, Aurora, CO.
Background: The pathogenesis of ADPKD is still not fully understood, however, 
increased proliferation of renal tubular epithelial cells is a key factor in cyst growth. 
There are similarities between cyst growth in ADPKD and the characteristics of benign 
tumor. Dysregulated expression of genes involved in cell cycle gene regulation as a result 
of epigenetic modification by DNA methylation has been associated with oncogenesis. 
We thus hypothesized that aberrant methylation of cell cycle related genes might be an 
underlying mechanism in ADPKD.
Methods: Genomic DNA was extracted from normal (HK-2) and ADPKD (WT9-12) 
tubular epithelial cells using a DNeasy blood and tissue kit (Qiagen). A cell-cycle DNA 
methylation PCR array (Qiagen) was used to examine gene methylation. RNA was extracted 
from normal and ADPKD kidneys using RNaqueous-4-PCR kit (Ambion). mRNA levels 
were examined using real-time RT-PCR.
Results: Among the 22 cell cycle genes examined,Rad9 was significantly different 
between the control HK-2 and cystic WT 9-12 cells. 62.2% of the gene was methylated 
in HK-2 cells as compared to only 1.4% in WT 9-12 cells. Rad9 mRNA levels were 
significantly higher in human ADPKD (0.024±0.008; n=7) kidneys than in normal kidney 
tissues (0.0166±0.006; n=4).
Conclusions: Aberrant expression of Rad9 occurs in ADPKD kidneys. This is at 
least partly due to the decreased methylation of the gene. Expression of Rad9 part of 
the 9-1-1 (Rad9-Hus1-Rad1) complex is increased and has been associated with DNA 
damage and with tumor growth. Increased susceptibility for genomic DNA damage has 
been demonstrated in ADPKD which may affect cyst development or growth. While the 
role of Rad9 in ADPKD merits further study it is intriguing to postulate that Rad9 may 
play a role in cyst growth.
Funding: NIDDK Support
TH-PO187
Effect of Simvastatin on Cell Adhesion in ADPKD  Wei Wang, Michel 
Chonchol, Melissa A. Cadnapaphornchai, Berenice Y. Gitomer.  Dept of 
Medicine, Univ of Colorado, aurora, CO.
Background: We have previously shown that statin treatment reduced the rate of cyst 
growth in children and young adults with autosomal dominant polycystic kidney disease 
(ADPKD) suggesting that this may be an effective intervention to slow progression of renal 
disease in ADPKD, however the mechanisms are unclear. Treatment of cultured cystic 
renal tubular cells with simvastatin significantly reduces cell viability in cystic epithelial 
cells (WT 9-12) in a time and dose dependent manner but had minimal effect on normal 
tubular epithelial cultures (HK-2). We hypothesized that loss of viability was associated 
with reduced cell adhesion due to reduced expression of cell adhesion proteins.
Methods: Cystic tubular epithelia cells and normal renal tubular epithelial cells were 
treated with 1µM simvastatin for 24 hours and mRNA expression of integrin β-1 and 
E-cadherin assessed by quantitative PCR.
Results: In normal tubular cells simvastatin significantly increased integrin β-1 
expression while a significant decrease in expression was observed in the cystic tubular cells.
In untreated cystic tubular epithelial cells E-cadherin expression was significantly 
lower compared to normal control cells. Expression of E-cadherin was slightly reduced 
in the cystic cells after treatment with simvastatin. This cytoxic effect on cystic cells was 
increased with simvastatin compared to pravastatin.
Conclusions: Simvastatin may have pleiotropic effects on cystic epithelial cells 
including an effect on cell adhesion. The lack of effect on normal tubular epithelial cells 
indicates that simvastatin may have specific therapeutic benefits in human ADPKD. Future 
clinical trials will be necessary to test the benefits of simvastatin on slowing cyst growth.
Funding: NIDDK Support
TH-PO188
Identification of a Renal Pkd1/Pc1 Self-Amplification Mechanism via c-Myc 
in Polycystic Kidney Disease  Marie Trudel, Almira Kurbegovic, Delphine 
Cotteverte, Jennifer Lake.  Molecular Genetics and Development, Inst de 
Recherches Cliniques de Montréal, Montréal, QC, Canada.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the 
most common monogenic disorder associated mainly with Pkd1 mutations. One of the 
most extensively studied dominant polycystic kidney disease (PKD) mouse model is the 
transgenic SBM mice produced by specific targeting of c-Myc expression in the kidneys. 
All mice reproducibly developed tubular and glomerular cysts leading to renal insufficiency 
with high similarities to the orthologous Pkd1 dosage-increased and -reduced mouse models.
Methods: The cystogenic mechanisms of SBM and Pkd1 orthologous models were 
investigated concomitantly by molecular and cellular analyses.
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Results: We first determined that Pkd1 dosage-increased and -reduced mouse models 
lead to stimulation of renal c-Myc expression (5-10-fold) as in ADPKD renal tissues, 
identifying a key downstream effector and the high relevance of SBM mice. This prompted 
analysis of SBM mice that showed enhanced protein expression of c-Myc full length and 
nick-Myc in tubular epithelial cells. C-Myc immunostaining determined intense nuclear 
sub-localization mainly in cell clusters of cystic tubules. Renal SBM proliferation index 
was increased 10-fold over non-transgenic controls. Analysis of c-Myc downstream target, 
the cystogenic hypoxia inducible factor 1 alpha (Hif1α) in SBM kidneys showed intense 
stimulation as observed in ADPKD, particularly in epithelial cells of cystic tubules and 
glomeruli. SBM kidneys also displayed a marked activation of β-catenin in renal epithelium 
that was stimulated as well in both Pc1 dosage-increased and reduced mouse models. 
Importantly, SBM caused striking upregulation of polycystin-1/Pc1 and Pkd1 ~6-17-fold 
over endogenous levels in kidneys. SBM and Pkd1 mouse models uncovered a reciprocal 
cystogenic targeting and an inter-regulatory network of c-Myc and Pc1 in PKD.
Conclusions: Together our data support a regulatory positive Pkd1/Pc1 self-
amplification loop via c-Myc that governs ADPKD.
Funding: Government Support - Non-U.S.
TH-PO189
DNMT1 Promotes Renal Cyst Growth in Autosomal Dominant Polycystic 
Kidney Disease  Xia Zhou,1,2 Xiaoyan Li,1,2 Yijian Chen,1,2 Senta K. Georgia,3 
Xiaogang Li.1,2  1Internal Medicine; 2Kidney Inst, Univ of Kansas Medical 
Center, Kansas City, KS; 3Children¶s Hospital Los Angeles, Los Angeles, CA.
Background: DNA methylation was the first epigenetic modification to be identified. 
Aberrant expression of DNA methyltransferases (DNMTs) and disruption of DNA 
methylation patterns are closely associated with human disease. However, the roles and 
underlying mechanisms of DNMTs in polycystic kidney disease remain unknown. In 
this study, we investigated the direct involvement of DNMT1 in regulating cystogenesis.
Methods: To understand the role of DNMT1 in cyst growth in vivo, we generated 
Pkd1 and DNMT1 double conditional knockout Pkd1flox/flox:DNMT1flox/flox:Pkhd1-Cre mice. 
To identify the novel DNMT1 target genes involving in cystogenesis, we performed ChIP-
seq, MBD-seq and RNA-seq analysis.
Results: We found that knockout of DNMT1 delayed cyst growth characterized by 
decrease of 1) cyst index; 2) the kidney weight (KW)/body weight (BW) ratios; and 3) 
the blood urea nitrogen (BUN) levels (p < 0.01); as well as the 1) the phosphorylation 
of ERK, Rb, S6 and STAT3; and 2) the expression of cyclin D1, which were upregulated 
and contributesd to cyst growth in ADPKD. Further, we identified 8 novel DNMT1 target 
genes which were found within the intersection of the DNMT1 binding genes identified by 
ChIP-seq and the CpG islands hypermethylated genes identified by MBD-seq, and were 
downregulated in cystic renal epithelial cells as analyzed by RNA-seq. The downregulation 
of these candidate genes were validated by qRT-PCR. One of these genes named Ptprm 
(protein tyrosine phosphatase receptor type M) is a tumor suppressor gene which regulates 
the tyrosine phosphorylation of proteins and is hypermethylated in cancers. Inhibition of 
DNMT1 with 5-azacytidine increased the expression of Ptprm mRNA but decreased the 
phosphorylation of ERK, Rb, S6 and STAT3 as well as the expression of cyclin D1 as that 
in Pkd1 and DNMT1 knockout kidneys.
Conclusions: DNMT1 promotes renal cyst growth in ADPKD through methylation of 
Ptprm gene to inhibit its expression, leading to increase the phosphorylation and activation 
of PKD associated pathways.
Funding: NIDDK Support
TH-PO190
Triptolide Retarded Disease Progression in Polycystic Kidney Disease 
Through Reducing Polycystin-2 Over-Expression and Suppressing JAK2/
STAT3 Pathway  Ming Wu, Changlin Mei.  Kidney Inst, Dept of Nephrology, 
Shanghai Changzheng Hospital, Shanghai, China.
Background: The beneficial effect of triptolide in polycystic kidney disease (PKD) 
has been shown in several animal models and also in a clinical trial. It is suggested that 
triptolide inhibits cell proliferation in PKD by activating endoplasmic reticulum bounded 
calcium channel polycystin-2 (PC2) and thereby enhancing intracellular calcium level. 
The aim of current study was to prove a new working mechanism of triptolide in PKD 
that triptolide directly inhibit PC2 mediated mitogenic signaling pathways which is 
independent of calcium.
Results: Triptolide inhibited ADPKD cell proliferation which was correlated with 
decreased PC2 protein level and reduced JAK2/STAT3 activation. Over-expression of PC2 
restored triptolide suppressed cell proliferation and JAK2/STAT3 activity. Blockage of PC2 
by siRNA abolished triptolide mediated inhibition on cell proliferation and JAK2/STAT3 
activity. Twelve weeks triptolide treatment reduced BUN and creatinine level by 22% and 
25% respectively in cystic Cy/+ Han:SPRD rats. Administration of triptolide decreased the 
two kidney weight/total body weight ratio and cystic volume density in Cy/+ rats by 18.6% 
and 12.7% respectively. Western blot analysis showed that tiptolide decreased polycystin-2 
protein level and reduced JAK2/STAT3 activation in vivo.
Conclusions: Our study revealed a novel triptolide’s mechanism of action in PKD. 
Reducing PC2 over-expressed could be a new strategy for PKD treatment in the future.
Funding: Government Support - Non-U.S.
TH-PO191
Resveratrol Delayed Disease Progression in Polycystic Kidney Disease 
Through Attenuating P50/p65 Induced Inflammation  Ming Wu, Changlin 
Mei.  Kidney Inst, Dept of Nephrology, Shanghai Changzheng Hospital, 
Shanghai, China.
Background: The natural anti-inflammatory compound resveratrol displayed beneficial 
effects in a variety of diseases. The current study aimed to study the efficacy of resveratrol 
in polycystic kidney disease (PKD) and reveal it’s underline mechanism.
Results: Five weeks resveratrol treatment reduced BUN and creatinine level by 20% and 
24% respectively in cystic Cy/+ Han:SPRD rats. Administration of resveratrol decreased the 
two kidney weight/total body weight ratio and cystic volume density in Cy/+ rats by 15% 
and 24% respectively. The proliferation index and the macrophage infiltration index were 
reduced by 40/% and 43% respectively in resveratrol treated cystic kidneys in comparison 
to vehicle treated cystic kidneys. Resveratrol reduced protein levels of pro-inflammatory 
factors such as MCP-1, TNF-ܤ and CFB in Cy/+ kidneys, which was correlated with 
decreased activity of NF-κB (p50/p65). Resveratrol and NF-κB specific inhibitor QNZ 
inhibited the expression of MCP-1, TNF-ܤ and CFB and reduced NF-κB activity in ADPKD 
cells. Moreover NF-κB blockage minimized the reduction but not completely abolish the 
inhibition of inflammatory factor production by resveratrol treatment.
Conclusions: NF-κB signaling pathway is activated in PKD and partly responsible for 
PKD inflammation. Targeting inflammation through resveratrol could be a new strategy 
for PKD treatment in the future.
Funding: Government Support - Non-U.S.
TH-PO192
Increased Hedgehog Signaling in jck Mice and in Human ADPKD 
Luciane M. Silva, Bailey A. Allard, Damon T. Jacobs, Gail Reif, Archana 
Raman, Darren P. Wallace, Pamela Vivian Tran.  Anatomy and Cell Biology, 
Kidney Inst, Univ of Kansas Medical Center, Kansas City, KS.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused 
by disruption of Polycystin-1 and Polycystin-2, which localize to primary cilia of renal 
epithelial cells. Activation of the Hedgehog (Hh) pathway relies on primary cilia. Previously, 
we showed that renal cystic disease in mice caused by deletion of Thm1, a ciliary gene 
and negative regulator of Hh signaling, was attenuated by genetically downregulating the 
Hh pathway, suggesting a role for enhanced Hh activity in renal cystogenesis. We aim to 
determine whether a role for dysregulated Hh signaling extends to cystic disease in jck 
mice and in human ADPKD.
Methods: We determined whether Hh activity correlated with disease progression in 
jck mutants. Hh signaling was downregulated in jck mice by deleting Gli2, the primary 
transcriptional activator of the Hh pathway, using a ubiquitous, tamoxifen-inducible 
Cre recombinase. To examine Hh status in human ADPKD, we compared Hh levels 
in normal human kidney (NHK) and ADPKD tissue and primary cells using Q-PCR, 
immunohistochemistry and immunofluorescence.
Results: In jck mice, expression of Hh target genes, Gli1, Gli3 and Ptch2, were elevated 
at seven weeks of age and increased further at 18 weeks of age. Immunohistochemistry for 
GLI1 revealed increased expression in renal epithelial and interstitial cells, suggesting both 
paracrine and autocrine signaling mechanisms. Further, jck,Gli2 double mutants showed 
decreased renal cystogenesis compared to single mutant littermates, suggesting a causative 
role for increased Hh signaling in jck cystic disease. In human ADPKD cells and tissues, 
Hh target gene expression was elevated and GLI1 protein expression was increased in both 
cystic epithelial cells and interstitial cells. Additionally, even in the absence of a Hh agonist, 
ADPKD cells showed localization of the Smoothened signal transducer to primary cilia, 
reflecting increased basal pathway activity.
Conclusions: Increased Hh signaling appears to play a role in renal cystogenesis and 
could represent a novel therapeutic target for ADPKD.
Funding: Other NIH Support - NIGMS
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The Development of a Clinically Relevant Mouse Model for Autosomal 
Dominant Polycystic Kidney Disease  Wouter N. Leonhard,1 Hester Happé,1 
Emile De Heer,2 Dorien J.M. Peters.1  1Human Genetics; 2Pathology, Leiden 
Univ Medical Center, Netherlands.
Background: To perform pre-clinical studies for Autosomal Dominant Polycystic 
Kidney Disease (ADPKD), it is desirable that the models have an adult onset of PKD 
with cysts derived from all tubular segments, but within a time-window that is suitable 
for therapeutic testing. As described previously, Pkd1 deletion in neonatal mice leads to 
rapid PKD and Pkd1 deletion in adult mice leads to slow PKD. The differences in rate of 
PKD progression are largely explained by a rather sharp developmental switch that occurs 
around P13 (Piontek et. al. 2007). This suggests that there is limited flexibility in generating 
models with intermediate phenotypes. Surprisingly, in this study, Pkd1 inactivation at 
different ages in tamoxifen inducible Pkd1 knockout mice led to multiple models for PKD 
with different characteristics.
Methods: To inactivate Pkd1, tamoxifen administration was done on three consecutive 
days at P10, P16, P18 or P40. Disease progression was monitored by measuring Blood 
Urea concentration. The cystic burden and segmental origin of the cysts was studied using 
PAS staining and IHC for segment specific markers.
Results: P10 mice developed PKD within 3 to 4 weeks, with large distal and collecting 
duct cysts and few proximal tubular cysts. The progression rate in P16 mice was highly 
variable. By contrast, P18 mice developed end-stage PKD at an age of 14-17 weeks, with 
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cysts derived from all tubular segments that contributed equally to the phenotype. P40 
mice developed end-stage PKD at an age of approximately 22 weeks with predominantly 
proximal cysts.
Conclusions: Despite a sharp developmental switch at P13 that has been proposed 
previously (Piontek et. al. 2007) it is possible to generate multiple models with different 
progression rates and different origins of cyst. Notably, Pkd1 deletion at P18 reproducibly 
led to adult onset PKD within a time-window that is highly suitable for therapeutic testing. 
In addition, since cysts were derived from all tubular segments, this model will contribute 
to finding a clinically relevant therapy for ADPKD patients.
TH-PO194
Identification of New Signaling Pathways Related to Polycytic Kidney 
Disease: From Animal Models to Treatment  Olaya Lamas-Gonzalez,1 
Susana Bravo,1 Ana Belen Sanz,2 Ana Barcia de la Iglesia,1 Alberto Ortiz,2 
Terry J. Watnick,3 Gregory G. Germino,4 Candido Diaz rodriguez,1 Miguel A. 
Garcia-Gonzalez.1  1Health Research Inst of Santiago de Compostela, Spain; 
2Fundación Jiménez Díaz, Spain; 3Univ of Maryland School of Medicine; 
4National Inst of Diabetes and Digestive and Kidney Disease National Inst 
of Health.
Background: Pathogenesis of Polycystic Kidney Disease (PKD) has been related 
to a number of different mechanisms that make it very complex and there is no therapy 
for complete inhibition of cystogenesis, although there are advances in controlling cyst 
volume and cyst progression.
Methods: Taking advantage of the identified developmental window in PKD using the 
Pkd1 conditional KO mouse, we have identified the differential proteome of the cystic and 
non-cystic Pkd1 mutant kidneys. We identify TWEAK as a window dependent modulator of 
cystogenesis, inhibiting cystic progression in the cystic window, and promoting cystogenesis 
in the non-cystic window. We perform an exhaustive proteomics analysis of each cyst 
developmental stage by MALDI-TOF/TOF analysis of peptides and proteins separated 
either by LC or 2D-PAGE.
Results: We stablish the proteomics fingerprint of each physiopathologic condition 
and refine new therapeutic targets to a very short list of 12 candidate targets. During 
cystogenesis, cytoskeleton interactions with the extracellular matrix (focal adhesions) 
seemed to be altered and, thus their downstream signaling and regulatory pathways. Cell 
polarity, endocytosis and trafficking of proteins to nucleus are altered as well. Processes 
such as acyl-CoA, free fatty acid metabolism and their transport are downregulated. Fructose 
metabolism is also downregulated. We have targeted the identify pathways both inhibiting 
complete cystogenesis deriving from distal nephron segment, as well as, reducing/delaying 
global cystic progression.
Conclusions: Here, we first describe the proteome related to the developmental cystic 
window as well those pathways associated to the cystic progression under inflammatory 
respond, triggering new possible targeting pathways for both controlling origin and 
progression of cystogenesis.
TH-PO195
Cytokine Tweak as an Intermediary in Autosomal Dominant Polycystic 
Kidney Disease (ADPKD)  Olaya Lamas-Gonzalez,1 Ana Belen Sanz,2 Maria 
D. Sanchez-Niño,2 Ana Barcia de la Iglesia,1 Adrian Cordido-Eijo,1 Alberto 
Ortiz,2 Miguel A. Garcia-Gonzalez.1  1Health Research Inst of Santiago de 
Compostela, Spain; 2Fundación Jiménez Díaz, Spain.
Background: The pathogenesis of Polycystic Kidney Disease (PKD) remains unclear, 
but appears to involve altered tubular cell proliferation, cell death, differentiation and 
polarity as well as inflammatory and pro-fibrotic factors. It has been reported that acute 
kidney injury (AKI) and inflammation accelerate cystogenesis. TWEAK is a TNF-like 
cytokine that has a key role in AKI since anti-TWEAK antibodies prevented experimental 
loss of kidney function and renal inflammation, cell death and proliferation.
Methods: We hypothesize that response to treatment and cyst progression depend on 
a particular developmental window, so the correct dose and timing of a drug may prevent 
cystogenesis and make chronic treatment unnecessary. Here, we use a mouse model in 
which conditional inactivation of the PKD1 gene by Cre-mediated recombination results 
in cystogenesis at different ages depending on when PKD1 is inactivated.
Results: PKD1 inactivation at day 12 resulted in massive cyst growth by day 30. Under 
these conditions systemic TWEAK administration for 10 days significatively decreased 
kidney cystogenesis. By contrast, PKD1 inactivation at day 14 did not result in cyst 
growth by day 30. Under these conditions systemic TWEAK administration for 10 days 
significatively promoted kidney cystogenesis. Inflammation background, tissue remodeling 
and immune response to kidney injure could be playing a key role in the development and 
progression of ADPKD. Interestingly, liver appeared to present a different developmental 
pattern than kidney since TWEAK had mild effects in its cystogenesis.
Conclusions: These results demonstrate a developmental impact of PKD1 inactivation 
and TWEAK in cystogenesis and are pointing out the antagonic effects of the same molecule 
in different cyst developmental stages. Under the conditions of early PKD1 inactivation 
of the human condition, TWEAK may protect from cystogenesis if administered early in 
the disease course. However, detailed time course are needed before human extrapolation 
given that TWEAK induce cystogenesis in some settings.
TH-PO196
Defects in Epithelial Morphogenesis of Fibrocystin-Deficient Cells Are 
Associated with Disturbed Cell Adhesion  Wolfgang H. Ziegler, Birga Soetje, 
Lisa P. Marten, Dieter Haffner.  Dept of Pediatric Kidney, Liver and Metabolic 
Diseases, Hannover Medical School, Hannover, Germany.
Background:    Mutations of the Pkhd1 gene cause autosomal recessive polycystic 
kidney disease (ARPKD).  Pkhd1 encodes fibrocystin (FPC), a type I transmembrane 
protein of largely unknown function, which has been suggested to affect adhesion signaling 
of cells. Contributions of epithelial cell adhesion and contractility to the disease process 
of ARPKD remain to be defined. Having established a link between loss of FPC function 
and epithelial morphogenesis in 3D cell culture, we now aim to determine FPC-mediated 
parameters of (i) cell contact formation and (ii) the function / orientation of the actin 
cytoskeletal and microtubular networks.
Methods:    We analyze FPC function in Madin-Darby canine renal collecting duct 
epithelial cells (MDCK) based on Pkhd1 silencing. Cells are being studied on micro-
pattered chips in 3D cell culture conditions, which induce formation of epithelial spheroids. 
To determine critical differences in cell adhesion parameters, MDCK cells are analyzed 
in their one and 2(4)-cell stages after seeding on chips using fluorescence microscopy.
Results:    Based on defined adhesion conditions, we quantified the impact of FPC-
deficiency on size / density of adhesion sites, cell shape characteristics and initiation of 
an apical surface. In cells deficient for FPC, cell culture conditions supporting correct 
epithelial morphogenesis induced significantly reduced cell area and number of cell adhesion 
sites per cell, with differences originating from defects in cytoskeletal organization rather 
than reduced cell size. Further insight is expected from ongoing analysis of centrosome 
positioning. Analysis of quantitative parameters in FPC-deficient cells provides a set 
of cell characteristics that correlate with and are expected to reveal causes of defective 
epithelial morphogenesis.
Conclusions:    FPC silencing in MDCK cells disturbs adhesion signaling and cell-
cell interaction resulting in impaired epithelial morphogenesis. Using a cell-based model 
system, we can address molecular consequences of and analyze rescue strategies for FPC 
deficiency in collecting duct epithelia.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-PO197
Identification of FUBP1 as a PKD2 mRNA 3’UTR Binding Protein That 
Suppresses Its Translation  Wang Zheng, Xing-Zhen Chen.  Dept of Physiology, 
Univ of Alberta, Edmonton, AB, Canada.
Background: PKD2, also called polycystin-2, a Ca2+-permeable non-selective cation 
channel that is mutated in around 15% autosomal dominant polycystic kidney disease 
(ADPKD). Increasing evidence indicates that the PKD2 protein level is important for 
embryo development, cell response to ischemic renal injuries, and cyst formation, but there 
are limited studies so far about how PKD2 protein level is regulated.
Methods: Here, with dual luciferase assays, western blotting, biotin-RNA pull down, 
gene knockdown in zebrafish, co-immunoprecipitation and GST-pull down, we studied how 
PKD2 mRNA translation is regulated by its 3’ untranslated region (3’UTR).
Results: First, by dual luciferase assays, we identified a fragment in PKD2 3’UTR, 
named 3FI (3’ fragment inhibitory), that negatively regulates luciferease activity. Western 
blotting with a luciferase antibody confirmed the data obtained from the luciferase assays. 
By biotin-RNA pull down and mass spectrometry, we identified a 3FI-binding protein, 
called far upstream element binding protein 1 (FUBP1) that was originally found to promote 
transcription of oncogene c-Myc. Over-expression and knockdown of FUBP1 decreased 
and increased the PKD2 protein level, respectively, without altering the mRNA level. 
More interestingly, tail curvature induced by PKD2 morpholino (MO) knockdown in larval 
zebrafish was rescued by FUBP1 MO co-injection. Further, by co-IP and GST pull-down, 
we showed that FUBP1 directly binds with 4EBP1, a translational repressor that binds with 
eIF4E. Interestingly, 3FI RNA was shown to strengthen this binding.
Conclusions: Therefore, our data indicate that FUBP1 inhibits PKD2 translation 
through anchoring to PKD2 mRNA 3FI and interacting with 4EBP1.
Funding: Government Support - Non-U.S.
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Towards Understanding the Structure-Function Relationships of 
Polycystin-1  Robin L. Maser,1 Brenda S. Magenheimer,1 Aaron Matthew 
Smalter Hall.2  1Univ of Kansas Med Ctr, Kansas City, KS; 2Univ of Kansas, 
LaZrence, KS.
Background: Appropriate levels of functional polycystin-1 (PC1), product of the 
PKD1 gene, are the key determinant preventing the development of renal cysts in ADPKD. 
Recent work revealed the existence of hypomorphic missense mutations of PKD1 and the 
importance of the proper biogenesis and trafficking of PC1, and suggested that mutation-
specific therapies could potentially be designed to correct the biogenesis of mutant PC1. 
These advances underscore our lack of knowledge regarding PC1 structure and emphasize 
the importance of understanding PC-1 structure-function relationships. As such, we seek 
to generate a plausible tertiary structure model of human PC1.
Methods: A combination of comparative protein structure modeling along with 
validation by biochemical analyses is being used to predict and refine a human PC1 structure 
model. Our initial goal is to generate a 3D model of the arrangement of the 11 transmembrane 
(TM) segments and their connecting intra- and extracellular loops. Methodology involves 
secondary structure prediction and homology modeling between PC1 and known TM 
domains (using overlapping partitions of PC1 sequence), biophysical parameter-based 
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prediction of transmembrane domain bundling, and experimental biochemical analyses to 
validate predicted models. Use of the predicted secondary structure or template-modeled 
tertiary structure of loops is used to constrain and refine TM segment arrangement.
Results: Initial work has focused on TM segments connected by shorter loops. Thus 
far, N-linked glycosylation scanning experiments have confirmed the de novo modeling 
results for TM segments 9 and 11. Glycosylation analyses for TM segment 10 are not entirely 
consistent with the predicted model, due to an extension of the length of the domain. Such 
discrepancy may result from the inherent membrane-associating property of this loop region 
of PC1, as described in earlier published work.
Conclusions: Preliminary, proof-of-concept work has resulted in a coarse model of 
the last 3 TM segments of PC1. These analyses will provide important knowledge for 
understanding structure-function relationships of PC1 and for the development of new 
ADPKD treatments.
Funding: Other NIH Support - KU-NIH Center of Biomedical Research Excellence 
in Protein Structure and Function
TH-PO199
A Sorting Nexin 3 Retromer Complex Regulates the Surface Localisation 
and Activity of Wnt-Activated Polycystin-1 Regulated Polycystin-2 
Channels  Andrew J. Streets,1 Shuang Feng,1 Vasyl Nesin,2 Leonidas Tsiokas,2 
Albert C. Ong.1  1Kidney Genetics Group, Academic Nephrology Unit, Univ of 
Sheffield Medical School, Sheffield, United Kingdom; 2Dept of Cell Biology, 
Univ of Oklahoma Health Sciences Center, Oklahoma City, OK.
Background: Autosomal dominant polycystic kidney disease (ADPKD), is caused by 
inactivating mutations in PKD1 (85%) or PKD2 (15%). The ADPKD proteins, polycystin-1 
(PC1) and polycystin-2 (PC2) form a plasma membrane receptor-ion channel complex. 
PC2 is a member of the transient receptor potential (TRP) superfamily and functions as a 
non-selective calcium channel. PC2 has been localised to multiple cell compartments in 
renal epithelial cells including the endoplasmic reticulum, plasma membrane and primary 
cilia. However the mechanisms controlling the subcellular localization of PC2 are complex 
and not well understood.
Methods: Y2H, Co-immunoprecipitation and GST pulldown assays were used to 
identify protein interactions. IF, siRNA knockdown and surface biotinylation was used to 
monitor protein trafficking and siRNA knockdown and electrophysiology used to monitor 
PC2 dependent Ca2+ channels.
Results: Here, we identify a new isoform of sorting nexin 3 (SNX3-102, isoform 5) as 
a novel interacting partner of PC2. Compared to the classical SNX3 isoform (SNX3-162, 
isoform 1), SNX3-102 cannot bind PtdIns(3)P but instead binds directly to the C-terminus 
of PC2. SNX3-162 binds indirectly to the N-terminus of PC2 via the retromer cargo-
specific adaptor protein VPS35. SNX3-102 is expressed mainly in clathrin-coated vesicles 
whereas SNX3-162 is expressed in early endosomes. Knockdown of SNX3 or VPS35 in 
LLCPK-1 cells results in increased expression of PC2 and PC1 in the plasma membrane 
and upregulated Wnt-activated PC2 dependent Ca2+ channel activity.
Conclusions: Our results support a sequential model where SNX3-102 regulates 
PC2 endocytosis by directly binding PC2 and clathrin to cluster PC2 in clathrin-coated 
vesicles before relaying it to early endosomes where SNX3-162 and VPS35 regulate its 
sorting and fate. Molecular targeting of endosomal sorting of PC1 and PC2 could lead to 
new therapeutic approaches in this major human disease.
TH-PO200
Leucine Stimulates the Proliferation of Pkd1-Null Renal Epithelial Cells 
via ERK/MAPK and Mtor Pathway  Junya Yamamoto, Saori Nishio, Tasuku 
Nakagaki, Tatsuya Atsumi.  Dept of Medicine II, Hokkaido Univ Graduate 
School of Medicine, Sapporo, Japan.
Background: Mammalian target of rapamycin (mTOR) cascade is one of the important 
pathways regulating cyst growth in ADPKD and branched-chain amino acids (BCAA) 
modulate various physiological effects through activating mTOR cascade. We have recently 
reported that BCAA supplementation accelerates cyst development and disease progression 
in Pkd1 conditional knockout mice (Pkd1flox/flox: Mx1-Cre mice).
Methods: To elucidate the effects of BCAA in ADPKD, Pkd1-/-(PN) and Pkd1+/-(PH) 
renal epithelial cell lines were utilized and cultured in a medium with or without leucine. We 
evaluated cell proliferation by cell count. 3x105 cells were plated on a 10-cm dish, 3 days 
later the total number of cells was counted. We also performed Ki-67 stains and western 
blotting of signaling pathway of proliferation.
Results: PN cells treated with leucine significantly increased the rate of proliferation 
compared to without leucine, but not in PH cells. Ki-67 positive ratio increased only in PN 
cells treated with leucine. In western blotting analysis, leucine promoted phosphorylation 
of p70S6 kinase in dose-related manner both in PN cells and PH cells, but leucine activated 
phosphorylation of ERK only in PN cells. PD98059 (MEK1 inhibitor), U0126 (MEK1 
and MEK2 inhibitor) and rapamycin (mTOR inhibitor) attenuated leucine-induced cell 
proliferation by inhibiting ERK/MAPK pathway and mTOR pathway respectively.
Conclusions: Our findings suggest that leucine accelerates cyst development in ADPKD 
by promoting cystic epithelial cell proliferation via ERK/MAPK and mTOR pathways.
TH-PO201
Activation of the Polycystin Complex by WNT Ligands  Seokho Kim,1 
Hongguang Nie,1 Vasyl Nesin,1 Uyen Tran,2 Patricia Outeda,3 Chang-Xi Bai,1 
Jacob Keeling,1 Dipak Maskey,1 Terry J. Watnick,3 Oliver Wessely,2 Leonidas 
Tsiokas.1  1Cell Biology, Univ of Oklahoma HSC, Oklahoma City, OK; 2Cellualr 
and Molecular Medicine, Cleveland Clinic, Cleveland, OH; 3Medicine/
Nephrology, Univ of Maryland School of Medicine, Baltimore, MD.
Background: PKD1 (Polycystin 1) is considered an orphan, atypical G protein coupled 
receptor complexed with TRPP2 (Polycystin 2 or PKD2), a Ca2+-permeable ion channel. 
Inactivating mutations in their genes cause autosomal dominant polycystic kidney disease 
(ADPKD), one of the most common genetic diseases. However, the molecular identity 
of the extarcellular ligands activating the Polycystin complex is unknown. WNT ligands 
induce Ca2+ signaling on target cells. Here, we tested whether WNTs can bind and activate 
the Polycystin complex.
Methods: Experimental approaches include electrophysiology, protein-protein-
interactions using co-immunoprecipitations, directed cell migration assays, and 
embryological experiments in Xenopus laevis.
Results: Our data show that secreted WNTs bind to the extracellular domain of PKD1 
and induce large whole cell currents and Ca2+ influx dependent on TRPP2, but independent 
of Frizzled (FZD) receptors. Pathogenic PKD1 or PKD2 mutations that abrogate complex 
formation, compromise cell surface expression of PKD1, or diminish TRPP2 channel 
activity suppress activation by a WNT protein. Pkd2-/- fibroblasts lack WNT-induced Ca2+ 
currents and are unable to polarize during directed cell migration. In Xenopus embryos, 
PKD1 acts independently of FZD8, but within the same pathway with Disheveled 2 to 
preserve normal kidney tubulogenesis.
Conclusions: These data define PKD1 as a new class of WNT (co)receptors and 
implicate defective WNT/Ca2+ signaling as one of the causes of ADPKD.
Funding: NIDDK Support
TH-PO202
Caffeine Consumption Contributes to Cyst/Kidney Enlargement and 
Progression of Polycystic Kidney Disease in a Pkd1-Deficient Mouse Model 
Renata Meca,1 Bruno E. Balbo,2 Milene Subtil Ormanji,1 Luiz F. Onuchic,2 Ita 
Pfeferman Heilberg.1  1Nephrology Div, Federal Univ of Sao Paulo, Sao Paulo, 
SP, Brazil; 2Nephrology Div, Univ of Sao Paulo, Sao Paulo, SP, Brazil.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common monogenic renal disease, characterized by progressive cyst formation and growth, 
leading to kidney failure. In cultured cells from ADPKD patients, caffeine increased the 
levels of cyclic AMP and induced apoptosis and proliferation. We aimed to examine the 
in vivo effects of Caffeine on cyst growth and progression of renal disease using a murine 
model orthologous to human ADPKD1.
Methods: Male and female Pkd1cond/condNestincre(cystic - CysCaf) and Pkd1cond/cond 
(NonCystic - NonCysCaf) mice consumed caffeine (3mg/day, in drinking water), from 
conception to 12 weeks of life. Caffeine was orally administered to the mother until puppy 
weaning (5 weeks) and thereafter directly supplemented in drinking water.Cistic control 
animals consumed water (CysCtrl) for the same period.
Results: 
CysCaf CysCtrl NonCysCaf
Global Renal Cystic Index(%)
38.5
(15.3-54.3)*
n=21
9.4
(2.1-15.2)
n=16
NA
Total kidney volume/Body Weight(mm3/g)
25.5
(22.1-34.4)*
n=21
17.4
(15.6-19.5)
n=16
NA
sCystatin(pg/ml)
5.95±
1.14*
n=13
2.07
0.57
n=4
3.36
0.71
n=4
sUrea(mg/dl)
83.7
21.5*
n=22
48.1
16.6
n=17
64.5
11.4
n=11
Renal Fibrosis Index(%)
0.84
(0.38-1.18)* 
n=18
0.37
(0.06-0.47)
n=6
0.30
(0.19-0.63)
n=13
Cell Proliferation Index - Ki67(%)
5.34
1.66
n=8
2.52
1.34
n=5
0.57
0.23
n=6
* p<0,01 vs CysCtrl, p<0,05 vs NonCysCaf
Data are mean±SD or median(interquartile range);NA-not applicable
Ultrasonographic analysis showed higher global renal cyst index and total kidney 
volume in the CysCaf group versus CysCtrl. CysCaf group presented higher serum 
Urea (sUrea) and Cystatin C (sCystatin) and lower maximum urine osmolality (data 
not shown) when compared to the NonCysCaf and CysCtrl groups. Renal fibrosis was 
higher in CysCaf than in the other groups and cell proliferation was higher in CysCaf than 
NonCysCaf kidneys.
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Conclusions: Present findings demonstrate that caffeine induced an increase in renal 
volume and accelerated the progression of polycystic kidney disease in Pkd1-deficient mice.
Funding: Government Support - Non-U.S.
TH-PO203
Changes in Urine Metabolites in PCK Rat Induced by dDAVP 
Administration  Maria V. Irazabal, Ivan Vuckovic, Song Zhang, Fouad T. 
Chebib, Xiaofang Wang, Hong Ye, Petras P. Dzeja, Slobodan Macura, Vicente 
E. Torres.  Mayo Clinic.
Background: V2 receptor agonist 1-deamino-8-D-arginine vasopressin (dDAVP) 
aggravates the cystic disease of PCK rats by increasing renal cAMP without inducing cystic 
changes in wild-type rats (WT). We aimed to investigate the urinary metabolic changes in 
1) PCK vs WT, and 2) response to dDAVP in PCK and WT rats.
Methods: PCK and WT rats were treated with 20 ng sc of dDAVP b.i.d. from p7 to 
p21, increasing to 40 ng sc b.i.d. from p22 to p35 inclusive or sc injections of isotonic (0.15 
M) saline (S) at identical intervals. Abdominal MRI was performed at p10, p21 and p35 
for kidney volume (KV). 1H-NMR-based metabolomics analysis was performed from 24h 
urine collections at p30. The urine spectra were normalized to creatinine.
Results: Administration of dDAVP significantly aggravated the disease in PCK rats as 
evidenced by KV at p10, p21 and p35 (p=0.04, <0.001 and <0.001), but did not increase 
significantly KV or generate a cystic phenotype in WT rats (Fig1A-B). BUN levels were 
not different between groups at p35. Thirty seven urinary metabolites were identified. 
Thirteen metabolites were significantly different between PCK (S) and WT (S) (Fig1C). 
dDAVP induced significant changes in 5 metabolites in PCK but only 1 in WT rats. For 
example, urinary concentration of betaine, an important osmoregulatory compound, was 
significantly increased in PCK (S) compared to WT (S) and increased even further with 
dDAVP only in PCK rats. 
Conclusions: 1H-NMR-based metabolomics analysis identified 13 significantly 
different metabolites between PCK(S) and WT(S) rats. dDAVP aggravated the cystic disease 
and induced significant changes of urinary metabolites in PCK rats. Measurements of kidney 
tissue and plasma metabolites, in progress, will assist in the interpretation of these findings.
Funding: NIDDK Support
TH-PO204
Localized Changes in MicroRNAs Are Critical to the Development of 
Fibrosis in PKD  Ameya P. Patil, William E. Sweeney, Ellis D. Avner.  Pediatric 
Nephrology, Dept of Pediatrics, Medical College of Wisconsin, Wauwatosa, WI.
Background: ADPKD is characterized by proliferation and growth of tubular cysts and 
development of progressive interstitial fibrosis. These phases are consistently reproduced 
in the Pkd1(nl/mcw) mouse, an orthologous model of Pkd1. In this mouse model, as in human 
ADPKD, the progression of fibrosis, rather than cyst size, leads to ESRD. MicroRNA’s 
(miRNA’s) are small noncoding RNA’s that act as potent regulators of gene expression. In 
ADPKD, the progression of interstitial fibrosis in distinct patterns suggests that crosstalk 
between cystic epithelia and interstitial cells create a “pro-fibrotic” microenvironment. 
We hypothesize that changes in miRNA expression are critical to development of fibrosis 
in ADPKD.
Methods: Laser capture micro-dissection (LCM) of trichrome positive interstitium 
and, adjacent cystic tubular epithelia were profiled seperately for local miRNA expression 
with Qiagen miScript 384 HC miRNA PCR arrays at four distinct time points during which 
fibrosis is initiated and progresses. The miRNA profile was compared to age-matched whole 
kidney miRNA profiles, correlated with fibrosis pathway arrays, and immunohistochemical 
analysis.
Results: From PN21 to 28, interstitium and adjacent cystic epithelia demonstrated 
significant changes in miRNA expression (20 upregulated, 15 downregulated). These 
changes correlated with: a shift in the site of proliferation; a change in macrophage subtypes 
and number; significant increase in Tgf-B1,2,& 3, p-Smad2 and col3a1 and significantly 
decreased BMP7 expression. 9 miRNA’s exhibited a variable expression with initiation 
and then progression of the disease.
Conclusions: 1. Compartmental changes in miRNA expression seen with LCM were 
not seen in the whole kidney analysis, demonstrating the value of the approach. 2. Pro-
fibrotic and ADPKD specific miRNA’s(predicted to regulate TGFR1, 2 and 3, collagen 
3a1, 4a1, 4a4 and 4a5 and most interestingly EGFR, and STAT3) are significantly altered 
in peri-cystic interstitium. 3. We speculate that such compartment specific changes in 
miRNA expression are critical to development of fibrosis in ADPKD and may provide 
future therapeutic targets to halt the progression of ADPKD.
Funding: Pharmaceutical Company Support - Taisho pharmaceutical ltd., Private 
Foundation Support
TH-PO205
miR-21 Promotes Cyst Growth in Polycystic Kidney Disease  Ronak Lakhia,1 
Sachin S. Hajarnis,1 Darren Williams,1 Karam S. Aboudehen,2 Matanel Yheskel,1 
Vishal Patel.1  1Internal Medicine, UT Southwestern, Dallas, TX; 2Internal 
Medicine, Univ of Minnesota, Minneapolis, MN.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is 
characterized by the presence of numerous fluid-filled cysts in the kidney. MicroRNAs 
(miRNAs), short noncoding RNAs that regulate gene expression, have emerged as promising 
new therapeutic targets for many common diseases.  The goal of this study was to identify 
miRNAs that represent new drug targets for ADPKD.
Methods: Microarrays, Q-PCR, and ISH were performed to determine miR-21 
expression in PKD.  ChIP and promoter luciferase reporter assays were performed to 
understand the mechanisms that underlie miR-21 regulation in cystic kidneys.  To study 
the role of miR-21 in ADPKD, miR-21 was inactivated in Pkhd1/Cre; Pkd2F/F (Pkd2-KO) 
mice, an orthologous mouse model of ADPKD.  RNA-Seq was performed to elucidate 
the differential gene expression pattern between Pkd2-KO and Pkd2-miR-21-/- KO mouse 
kidneys.
Results: miR-21 expression was increased in multiple mouse models of PKD, including 
two orthologous models of PKD.  Upregulation of miR-21 was primarily localized to mouse 
kidney cyst epithelial cells.  Increased miR-21 expression was also seen in cysts of human 
ADPKD tissue samples.  cAMP-CREB signaling transactivated the miR-21 promoter in 
kidney cells.  Inactivation of miR-21 in Pkd2-KO mice reduced kidney size, cyst number, 
and prolonged survival.  RNA-Seq and subsequent pathway analysis identified cell death 
as the main biological effect of miR-21 deletion.  Accordingly, compared to Pkd2-KO 
mice, Pkd2-miR-21-/- KO mice exhibited increased apoptosis of cyst epithelial cells 
without any change in proliferation.  Expression of Pdcd4, a pro-apoptotic miR-21 target, 
was increased in cysts of Pkd2-miR-21-/- double knockout mice, indicating that miR-21 
inhibits Pdcd4 in cystic kidneys.
Conclusions: Upregulation of miR-21 is a common feature of mouse and human forms 
of PKD.  Deletion of miR-21 attenuates cyst burden and prolongs survival.  miR-21 may 
promote cyst growth in ADPKD by preventing apoptosis of cyst epithelial cells through 
direct suppression of Pdcd4. Our studies suggest that inhibiting miR-21 may be a useful 
therapeutic strategy for ADPKD.
Funding: NIDDK Support, Other NIH Support - NIH institutional T32 grant, Private 
Foundation Support
TH-PO206
Macrophages Programmed by Polycystic Kidney Disease Cyst Cells 
Produce Soluble CXCR2 Ligands That Promote Cyst Cell Proliferation 
Sally M. Salah, Darren P. Wallace, Timothy A. Fields, Katherine Swenson-Fields. 
The Kidney Inst, Univ of Kansas Medical Center, Kansas City, KS.
Background: The presence of renal macrophages in animal models of PKD has been 
shown to promote disease progression. The mechanisms underlying this phenomenon are 
incompletely understood but are likely due to reciprocal interactions between infiltrating 
macrophages and cyst epithelial cells: cyst cells stimulate macrophage differentiation to an 
M2-like, pro-proliferative phenotype and, in turn, these now “programmed” macrophages 
secrete unknown factors that promote cyst cell proliferation.
Methods: To identify macrophage-secreted factors that promote disease progression, 
macrophages were incubated for 48 h with conditioned media from primary human ADPKD 
cyst cells. These programmed macrophages were either collected and analyzed by RNAseq 
or were washed extensively and incubated for a further 24 h to allow production of secreted 
pro-proliferative factors, which were subjected to protein/proteome analysis and antibody 
array. Similar analyses of resting macrophages were carried out in parallel for comparison.
Results: Co-culture of ADPKD cyst cell conditioned media with macrophages 
enhances macrophage production of protease-sensitive, pro-proliferative activity. RNAseq 
and cytokine array analysis revealed up-regulation of multiple candidate pro-proliferative 
factors in programmed macrophages, including several ligands of the CXCR2 receptor. 
The addition of a CXCR2 receptor antagonist (SB225002) to ADPKD cells significantly 
reduced proliferation stimulated by programmed macrophage conditioned media.
Conclusions:   Efforts are underway to identify the specific CXCR2 ligands produced 
by programmed macrophages that are responsible for this pro-proliferative effect. These 
factors and their signaling pathways could provide new targets for the development of 
therapies to slow PKD progression.
Funding: Other NIH Support - NCATS and NIGMS
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TH-PO207
PKD2-Related Autosomal-Dominant Polycystic Kidney Disease 
(ADPKD): Mutation Spectrum, Clinical Presentation, and Prognosis 
Emilie Cornec-Le Gall,1,2 Marie-Pierre Audrezet,1,2 Christophe Charasse,5 Cecile 
M. Vigneau,6 Lise Mandart,7 Claude Ferec,1,2 Yannick Le Meur.1  1CHRU Brest, 
France; 2INSERM 1078; 3CH Saint Malo; 4CHRU Nantes; 5CH Saint Brieuc; 
6CHRU Rennes; 7CH Vannes.
Background: The milder severity of PKD2 related ADPKD (˜15% of the pedigrees) as 
compared to PKD1 is well acknowledged, but population-based studies, enabling to depict 
the exact burden of the disease, are currently lacking. In this study, we aimed to describe 
the clinical presentation and the mutation spectrum in a large cohort of PKD2 patients.
Methods: Genkyst is a cross-sectional cohort which aims to include all consenting 
ADPKD patients followed in 23 Nephrology centers from the western part of France. 
Clinical data were collected and a comprehensive molecular analysis of PKD1 and PKD2 
genes was undertaken.
Results: A total of 70 different PKD2 mutations were identified in 248 patients from 
172 pedigrees (i.e. 20.2% of the mutation-positive pedigrees from Genkyst). A recurrent 
28-kb deletion involving exons 10-15 was identified in 45 patients from 23 pedigrees 
confined in an area of ~3500 km², which represents to our knowledge the first case of 
founder mutation in ADPKD. Median age at diagnosis in the total cohort was 41.5 yrs. At 
age 70, cumulative probability of ESRD obtained by Kaplan Meier analysis was 37.4%, 
whereas probabilities for hypertension, pains related to cysts and gross hematuria were 
respectively of 93.3%, 46.6% and 23.3%. Although there was no gender influence on renal 
survival, multiple linear regression demonstrated that men had significantly lower kidney 
function than women. Disease variability was observed in some patients harbouring the 
same mutation, suggesting that additional genetic or environmental factors may modulate 
the disease severity in PKD2 patients. In line with this hypothesis, familial study led to 
the identification of PKD1 hypomorphic alleles possibly acting as disease modifiers in 2 
PKD2 pedigrees with marked intra-familial variability.
Conclusions: This large cohort confirms that PKD2 patients typically present with 
a mild disease and therefore a vast majority of them may not require emerging targeted 
therapies.
Funding: Government Support - Non-U.S.
TH-PO208
Transcriptome Analysis Identifies A Novel Candidate Therapy for Polycystic 
Kidney Disease  Robert L. Bacallao,1,2 Sherry G. Clendenon,3 James A. 
Glazier,3 Rita M.c. De almeida.4  1Medicine, Indiana Univ School of Medicine, 
Indianapolis, IN; 2Medicine, Richard Roudebush VAMC, Indianapolis, IN; 
3Physics, Biocomplexity Inst, Indiana Univ, Bloomington, IN; 4Physics, Instituo 
Nacional de Ciencia e Techologic, Univ Federal do Reio Grande do Sul, Porto 
Alegre, R.S., Brazil.
Background: ADPKD is a genetic disorder characterized by accumulation of renal 
cysts culminating in renal failure. A critical need exists ameliorate ADPKD. Transcriptogram 
analysis is a new method for whole genome gene expression data analysis that more 
sensitively identifies affected molecular networks and pathways.
Methods: Genes are ordered into a list using a Monte Carlo simulation that minimized 
distance between associated gene products, such that proximity on the list correlates with 
co-participation in biological processes. Transcriptogram profiles are then produced by 
calculating the average transcription level for genes within a moving window. The resulting 
transcriptogram reveals which pathways are differentially expressed.
Results: Using this approach, gene chip analysis revealed cystic epithelial have 
significant over expression of cGMP phosphodiesterases, components of inflammasome 
pathway (IL6, IL1B, NFKB1A, CCL2, BIRC3, TNFAIP3, IL18, PYCARD, MAPK13), 
and potassium ion transport (KCNJ12, KCNK3, KCNC4, KCNMB4, KCNQ1, KCNS1). 
Conversely many genes participating in oxidative phosphorylation are expressed 
at significantly lower levels in cystic epithelia. To test the significance of cGMP 
phosphodiesterases; human cystic epithelial cells were grown in 3D collagen culture with 
forskolin plus or minus sildenafil. Strikingly the cGMP phosphodiesterase inhibitor inhibited 
cyst growth at all doses (4 ug/ml, 2 ug/ml and 1 ug/ml). Average cyst size was decreased 
compared to controls (p<1 E-6 for 4 ug/ml dose, p<0.01 for 2 ug/ml dose, and p<0.01 for 
the 1 ug/ml dose). Also frequency analysis of cyst sizes we found that large cysts were 
absent from sildenafil treated cultures.
Conclusions: Transcriptogram analysis of gene chip data provides a powerful new way 
to analyze changes in the gene expression profile in ADPKD. Secondly, sildenafil blocks 
kidney epithelial cyst growth in 3D culture.
Funding: Private Foundation Support
TH-PO209
Gene Discovery for Autosomal Dominant Polycystic Liver Disease (ADPLD) 
Whitney E. Besse,1 Yiqiang Cai,1 Ali G. Gharavi,2 Simone Sanna-Cherchi,2 Terry 
J. Watnick,3 York P. Pei,4 Vicente E. Torres,5 Stefan Somlo.1  1Internal Medicine, 
Section of Nephrology/Genetics, Yale School of Medicine, New Haven, CT; 2Div 
of Nephrology, Columbia Univ Dept of Medicine, NY; 3Div of Nephrology, Univ 
of Maryland School of Medicine, Baltimore, MD; 4Div of Nephrology, Univ 
Health Network, Toronto, ON, Canada; 5Nephrology and Hypertension, Mayo 
Clinic, Rochester, MN.
Background: ADPLD involves identical polycystic liver disease to that seen in 
ADPKD, but without clinically relevant kidney cysts. While mutations in PKD1 lead 
to ADPKD, mutations in genes that indirectly affect Polycystin 1 (PC1) expression or 
function cause ADPLD. Study of two identified ADPLD genes, SEC63 and PRKCSH, has 
shown the importance of co/post-translational modifications in the ER for PC1 function, 
and demonstrated the critical role of PC1 dosage in cyst pathogenesis. We hypothesize 
that discovery of additional ADPLD genes in patients will identify other functional 
modulators of PC1.
Methods: We have established a cohort of 161 unrelated individuals and families with 
ADPLD. Those without known mutations (Discovery Cohort) underwent whole exome 
sequencing together with linkage analysis where sufficient family material existed. Initial 
evaluation focused on candidate genes with rare heterozygous loss of function mutations. We 
established an in vitro bioassay to test a subset of candidates by evaluating PC1 expression 
and cilia trafficking following knockout of the candidate gene by CRISPR in cell culture.
Results: We found that 65/161 (40%) of ADPLD probands have mutations in SEC63 
(18%) or PRKCSH (22%). Initial analysis of exome sequencing of our Discovery Cohort 
identified three candidate genes that function in ER biogenesis pathways related to the 
known genes and explain a total of 10 unrelated cases. We have generated cell knockout 
of one of these new candidate genes and shown a decrease in PC1 expression and as well 
activation of XBP1s, similar to our earlier findings in Sec63 knockouts.
Conclusions: ADPLD gene discovery using whole exome sequencing coupled with in 
vitro assays of PC1 function is an unbiased and achievable approach to identify necessary 
proteins and pathways for PC1 function, and thus help to better define cyst pathogenesis 
in ADPLD and ADPKD.
Funding: NIDDK Support
TH-PO210
Morpholino and Mutant Studies of Pde3A and Pde1a in Renal Cystogenesis 
Using Zebrafish  Caroline R. Sussman, Raad B. Chowdhury, Matthew Durant, 
Peter C. Harris, Vicente E. Torres.  Nephrology & Hypertension, Mayo Clinic, 
Rochester, MN.
Background: Numerous studies demonstrate the role of cAMP in cyst development 
and Polycystic Kidney Disease (PKD) progression. Studies in zebrafish using morpholinos 
show that Phosphodiesterase (Pde) 1A modulates renal cyst development and associated 
phenotypes, consistent with its hydrolysis of cAMP.
Methods: MOs were used to assess effects of Pde3A on renal cyst development and 
associated phenotypes, hydrocephalus and otolith defects. Additionally, we have generated 
3 Pde1a mutant zebrafish lines using TALENs. Phenotypes were evaluated blinded, and 
data were analyzed using chi-square on embryos summed within treatments from 3-4 
experiments.
Results:    Depletion of Pde3A using two splice-blocking MOs increased the incidence 
of renal cysts at 2 days post-fertilization (dpf).  Both MOs targeted exon 12 of pde3a, the 
first exon of the hydrolytic domain, encoding the conserved HD required for hydrolysis. 
Splice acceptor MO induced cysts with dose dependence at 5 ng (13%) and 10 ng (33%) 
vs. control MO (p<0.002, n>57 embryos / treatment). Splice donor MO induced cysts with 
dose dependence at 1 ng (13%), 2.5 ng (22%), and 5 ng (59%) vs. 5 ng of control MO (0%) 
(p<0.003, n≥40 embryos/treatment). The splice-donor MO also induced hydrocephalus at 
2.5 ng (25%) and 5 ng (60%), and otolith defects at 2.5 ng (38%) and 5 ng (79%) vs. 5 ng 
of control MO (0%) (p<0.001, n≥60 embryos/treatment). Injection of 1 ng caused a non-
significant trend toward induction of hydrocephalus (3%, p=0.3) and otolith defects (8%, 
p=0.06) (n≥40 embryos / treatment). Sequencing of cystic embryos showed altered splicing 
at the targeted exon. Similar to MOs, Pde1a TALENs were generated targeting the exon 
encoding the conserved HD. We have obtained 3 unique mutant lines which disrupt the 
HD. In initial studies, Pde1a+/- fish are found at expected frequencies in adult populations, 
indicating survival equivalent to that of Pde1a+/+ fish.
Conclusions: MO studies of Pde3A suggest its involvement in renal cystogenesis and 
associated phenotypes, similar to previous studies using Pde1A MOs. TALENs effectively 
induced function-blocking mutations in Pde1a, which will allow studies of Pde1a-/- fish.
Funding: NIDDK Support, Private Foundation Support
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TH-PO211
Transcriptional Repression of PKD1 by Gene-Body Hypermethylation 
Induces Renal Cyst Development in ADPKD  Yu mi Woo, Yu bin Shin, Jong 
Hoon Park.  Dept of Life Systems, Sookmyung :omen¶s Univ, Seoul, Republic 
of Korea.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a 
common human genetic disease characterized by the formation of multiple fluid-filled 
cysts in bilateral kidneys. Although mutations in polycystic kidney disease 1 (PKD1) are 
predominantly responsible for ADPKD, the focal and sporadic property of individual 
cystogenesis suggests another molecular mechanism such as epigenetic alterations.
Methods: To determine the epigenomic alterations in ADPKD and their functional 
relevance, ADPKD and non-ADPKD individuals were analyzed by unbiased methylation 
profiling genome-wide and compared with their expression data.
Results: Intriguingly, PKD1 was hypermethylated in gene-body regions, and its 
expression was downregulated in ADPKD. Hypermethylation of PKD1 gene-body was 
associated with recruitment of methyl-CpG-binding domain 2 (MBD2) proteins. Moreover, 
treatment with DNA methylation inhibitors retarded in vitro cyst formation, accompanied 
with the upregulation of Pkd1 expression.
Conclusions: These results are consistent with previous studies that knock-down 
of PKD1 was sufficient for cystogenesis. Therefore, our results reveal a critical role for 
hypermethylation of PKD1 and cystogenesis-related regulatory genes in cyst development, 
suggesting epigenetic therapy as a potential treatment for ADPKD.
Funding: Government Support - Non-U.S.
TH-PO212
Age- and Sex-Dependent Salt Sensitivity in Pkhd1pck Rats  Chunhua Jin, 
Michal Mrug, Bradley K. Yoder, Robert A. Kesterson, Edward W. Inscho, David 
M. Pollock.  Univ of Alabama at Birmingham, Birmingham, AL.
Background: Most forms of hypertension are influenced by gender and salt sensitivity. 
However, interplay of these two factors and their functional consequences in PKD-associated 
hypertension are incompletely understood. Thus, we tested the hypothesis that age and 
male sex would pre-dispose animals with PKD to hypertension and risk of renal injury.
Methods: We used Pkhd1pck rat model of autosomal recessive PKD to study sex 
difference in blood pressure in response to high salt (HS) diet. Two month- and eight month-
old male and female Pkhd1pck rats were surgically implanted with telemetry transmitters and 
allowed to recover for at least one week before obtaining baseline mean arterial pressure 
(MAP). Rats were then fed a high salt (HS; 4% NaCl) diet for 3 weeks. At the end of the 
study, rats were placed in metabolic cages and a 24 hr urine sample was collected before 
taking a terminal blood sample and kidneys removed.
Results: In the 2-month old Pkhd1pck rats, blood pressures were in a normal range and 
there were no differences between male and female animals. Furthermore, 3 weeks on a high 
salt diet had no effect on 24 hr MAP. In 8-month old rats, again there were no sex differences 
between animals on normal rat chow. MAP was progressively increased in both male and 
female rats after 3 weeks of HS diet treatment. MAP increased from 127±6 to 171±6 mmHg 
in male and from 112±3 to 127±3 mmHg in female rats, both p<0.05. However, the MAP 
increase was significantly greater in male (∆44±6 mmHg) versus female (D15±5 mmHg, 
p<0.05) rats. The blood pressure increase in male rats was associated with higher urinary 
protein excretion compared to female rats (1015±134 vs. 478±45 mg/day, p<0.05). These 
male rats had also higher kidney weight to body weight (bwt) ratio compared to female 
rats (1.0±0.2 vs. 0.5±0.1 g/100 g bwt, p<0.05).
Conclusions: Our studies demonstrate that male Pkhd1pck rats with advanced cystic 
kidney disease are more vulnerable to salt sensitive hypertension and renal injury than 
age-matched females.
Funding: Other NIH Support - NHLBI
TH-PO213
Sodium Intake versus Disease Progression in Experimental Polycystic 
Kidney Disease  Maatje D.A. van Gastel,1 Laura R. Harskamp,1 Debbie Zittema,1 
Dorien J.M. Peters,2 Ron T. Gansevoort,1 Esther Meijer.1  1Nephrology, UMC 
Groningen; 2Human Genetics, Leiden UMC.
Background: Vasopressin, a known determinant of disease severity and progression in 
ADPKD, increases in response to an increase in plasma osmolarity, of which sodium is the 
most important osmol. We hypothesized that lowering sodium intake reduces vasopressin 
concentration and thereby may improve disease progression in ADPKD.
Methods: We used a tamoxifen-inducible kidney epithelium-specific Pkd1-deletion 
mouse model. All mice were treated for 3 weeks with either a low sodium (LS: 0.39 g/
kg) or high sodium (HS: 15.2 g/kg) diet, after which physiological effects were studied 
and mice were sacrificed.
Results: The attached table summarizes the results after the dietary intervention. A 
higher water intake was seen in Pkd1-mice in comparison with healthy controls (HC), in 
line with the impaired urine concentrating capacity occurring in PKD. For both HC and 
Pkd1-mice water intake was higher in HS groups, in line with the physiological effects of 
sodium intake. In contrast to our hypothesis, a LS diet did not result in improved disease 
progression as total kidney weight (TKW), TKW per body weight (TKW/BW), cyst ratio 
and renal function (creatinine) were similar in all Pkd1-mice, regardless of the diet. 
HC LS HC HS Pkd1 LS Pkd1 HS
N 15 15 23 25
Weight (g) 16.6 (16.4-18.2) 15.8 (14.2-17.3)
17.2 (14.8-
18.0)îî
14.6 (13.6-
16.0)
TKW (mg) 235 (204-247)** 227 (206-271)** 415 (361-448)î 356 (320-399)
TKW/BW (%) 1.3 (1.3-1.4)**îî 1.5 (1.4-1.6)** 2.5 (2.0-2.8) 2.5 (2.1-2.9)
Cyst ratio (%) 5.0 (2.6-7.3)** 6.4 (4.3-9.4)** 27.4 (17.3-30.3) 29.6 (20.8-34.5)
PCreatinine (mol/L) 7.0 (7.0-9.0)** 6.0 (6.0-8.0)** 11.0 (9.0-13.0) 9.0 (7.0-12.0)
PNa+ (mmol/L) 147 (146-148) 146 (145-148) 147 (143-150) 147 (145-149)
Water intake (g) 2.8 (2.6-2.9)*îî 3.2 (3.0-3.8)** 3.7 (2.9-4.1)îî 4.1 (3.8-5.3)
Na+ excr 
(mol/24h) 161 (89-169)îî 556 (372-1210) 45 (39-57)îî 488 (276-676)
Variables are given as median (IQR). *p<0.05, **p<0.01: HC vs Pkd1 îp<0.05, ×îp<0.01: LS vs 
HS, same group.
Conclusions: A low sodium diet results in less water intake, but does not improve 
disease progression in Pkd1-mice.
TH-PO214
Tuba, a CDC42-Specific Guanine Nucleotide Exchange Factor (GEF), Is 
Necessary for Ciliogenesis and Kidney Development  Jeong-in Baek,1 Soo 
Young Choi,1 Xiaofeng Zuo,1 Joshua H. Lipschutz.1,2  1Div of Nephrology, 
Medical Univ of South Carolina, Charleston, SC; 2Renal Section, Ralph H. 
Johnson VAMC, Charleston, SC.
Background: Polycystic kidney disease (PKD) is associated with perturbations in 
renal primary cilia structure and/or function. The exocyst, a highly conserved eight-protein 
membrane trafficking complex, is essential for ciliogenesis, and is regulated by Cdc42. Our 
previous studies showed that Cdc42 deficiency disrupts renal ciliogenesis and causes PKD in 
zebrafish and mice, and that Tuba is also necessary for ciliogenesis in cultured MDCK cells.
Methods: Tuba knockdown MDCK cells were grown on Transwell filters and in three 
dimensional (3D) collagen gels, and zebrafish embryos were generated in which tuba was 
knocked down using antisense morpholinos. Ciliary and kidney defects caused by tuba 
deficiency were analyzed at molecular, histological and phenotypic levels.
Results: Tuba depletion resulted in an absence of cilia with impaired apical polarization 
of MDCK cell cysts. In hepatocyte growth factor-induced tubulogenesis, we found that 
Tuba knockdown significantly inhibited tubule formation. In zebrafish, tuba was expressed 
in ciliated organs, including the brain, eye, neuromast cells, and kidney. Tuba morphants 
phenocopied cdc42 morphants, with ciliary mutant phenotypes that included: a curly tail, 
hydrocephalus, and abdominal fluid accumulation. In tuba morphant kidneys, pronephric 
cilia were short and disordered, and glomeruli were disorganized. Moreover, tuba morphants 
showed defects in cardiac laterality, consistent with ciliary dysfunction. Following co-
injection of small amounts of tuba and cdc42 morpholinos, that alone had no effect, a 
severe phenotype was observed, suggesting that tuba and cdc42 act in the same pathway.
Conclusions: Our study showed that Tuba plays a critical role in ciliogenesis and 
kidney development in MDCK cells and zebrafish. We are generating tuba knockout 
zebrafish and Tuba kidney-specific knockout mice,using CRISPR and the Cre-lox binary 
mouse system, respectively.These animal models will allow us to better understand the 
pathogenic mechanisms of PKD, and could lead to novel treatments.
Funding: Veterans Administration Support
TH-PO215
Kidney-Specific Inactivation of the Exocyst Gene Sec10 in Mice Leads 
to Primary Cilia Defects and a Cystic Kidney Phenotype  Noemi Polgar, 
Amanda J. Lee, Vanessa H. Lui, Kadee-Kalia Tamashiro, Josephine Andrea 
Napoli, Ben Fogelgren.  Dept of Anatomy, Biochemistry and Physiology, Univ 
of Hawaii, Honolulu, HI.
Background: The primary cilium is a sensory organelle that projects from the apical 
surface of renal epithelial cells, and has been implicated in the pathogenesis of polycystic 
kidney disease. The exocyst complex is responsible for guiding the polarized exocytosis 
of subsets of secretory vesicles. Previous studies in cultured epithelial cells implicated 
exocyst activity, and particularly its Sec10 subunit, in primary cilia assembly. Our previous 
inhibition of Sec10 in a zebrafish model resulted in defective ciliary signaling, but no 
measurable defects in cilia structure.
Methods: To allow in vivo studies of the exocyst complex in mammalian kidney 
development and disease, we have generated a novel transgenic mouse to conditionally 
knockout the Sec10 gene using the Cre-loxP system. Here, we used the Ksp-Cre mice to 
specifically delete Sec10 in ureteric bud-derived epithelial tissues, which include distal renal 
tubules. We analyzed the renal phenotype and primary cilia in the Sec10-mutant kidneys.
Results: Conditional deletion of Sec10 showed a surprising neonatal lethal phenotype 
of prenatal ureter obstructions, although a small percentage of mice were non-obstructed 
and survived until at least 3 weeks of age. Histological analysis revealed the 20-day old 
Sec10FL/FL;Ksp-Cre mice had a polycystic kidney phenotype not seen in control littermates. 
Using immunostaining and confocal microscopy, we visualized primary cilia in renal 
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tubules of Sec10 mutant and control mice. Sec10-knockout tubules showed a 38.5% 
average ciliation ratio compared to 84.5% in control kidneys (p<0.0001). The primary cilia 
that were detected in Sec10-knockout tubules were much shorter than those in the control 
littermates (p<0.0001). Furthermore, significantly elevated blood urea nitrogen levels in 
knockout animals compared to controls suggested impaired kidney function.
Conclusions: Findings from our mouse model provide the first in vivo evidence of 
the exocyst’s involvement in mammalian primary cilia assembly and links Sec10 and the 
exocyst to the pathogenesis of polycystic kidney disease.
Funding: NIDDK Support, Other NIH Support - NIGMS, Private Foundation Support
TH-PO216
Whole Exome Sequencing (WES) Resolves ARPKD-Like and Meckel 
Syndrome (MKS)-Like Pedigrees Unresolved by Sanger/Ciliopathy Panel 
Screening  Katharina Hopp, Sarah J. Koon, Christina M. Heyer, Vicente E. 
Torres, Peter C. Harris.  Mayo Clinic.
Background: ARPKD and MKS have phenotypic and genetic overlap with other 
ciliopathies, with many unresolved pedigrees after Sanger sequencing of commonly 
mutated genes (ARPKD: ~10% of severe and ~50% of mild cases; MKS: ~45% of cases).
Methods: We performed WES (Agilent SureSelect, Illumina HiSeq 2000) of 18 Sanger 
screened, unresolved pedigrees, of which 13 were also assessed by targeted next-generation 
sequencing (NGS, 258 ciliopathy/cilia genes). Identified variants were filtered/scored based 
on quality, population frequency, segregation and substitution/gene significance.
Results: Screening for homozygous, compound heterozygous, and de novo variants 
identified disease-alleles in 4 pedigrees. Ped 1, ARPKD diagnosis at 4y, was homozygous 
for a novel BBS9 mutation (c.437B438insA), although the proband lacked key Bardet-Biedel 
Syndrome (BBS) features (retinal dystrophy, obesity, polydactyly, learning disability). The 
variant was missed by the targeted NGS panel due to preferential WT allele enrichment. 
Ped 2, two MKS diagnosed fetuses with PKD, polydactyly, hepatic fibrosis, but no CNS 
abnormalities, inherited two novel BBS7 variants (c.1405B1406delCA and p.V266E [scored 
as pathogenic]). Of note, BBS rarely causes embryonic lethality. Ped 3, a 15w MKS-like 
fetus with occipital encephalocele, sloping forehead and bifid tongue, inherited two C2CD3 
mutations (p.C1114=, caused ex18 skipping, and p.V899M [scored as pathogenic]). This 
verified findings of the targeted NGS panel and excluded additional genetic disease causes. 
C2CD3 is linked to oral-facial-digital syndrome 14 but the fetus lacked key associated 
features (polydactyly, microcephaly). Ped 4, a 16w MKS fetus with PKD, was initially 
diagnosed with a single CC2D2A variant (c.2182-2A>G). WES identified a second variant 
(c.3289-1delG) missed by Sanger sequencing.
Conclusions: We show here the value of WES for resolving Sanger/NGS panel 
unresolved ciliopathy pedigrees, although with low detection rates. In addition, we show 
BBS genes associated with a broad ciliopathy disease spectrum, reporting for the first time 
BBS9 mutations in an ARPKD-like case and BBS7 mutations in a MKS-like pedigree.
Funding: NIDDK Support, Private Foundation Support
TH-PO217
IFT81, Encoding an Intraflagellar Transport Protein, as a Rare Cause of 
a Ciliopathy Phenotype  Jan Halbritter,1 Isabelle Perrault,2 Jonathan Porath,1 
Xavier Gerard,2 Daniela A. Braun,1 Heon Yung Gee,1 Hanan Fathy,3 Richard 
P. Lifton,4 Jean-michel Rozet,2 Friedhelm Hildebrandt.1  1Medicine, Boston 
Children´s Hospital, Boston, MA; 2Imagine Inst, Paris Descartes, Paris, France; 
3Pediatric Nephrology, Univ of Alexandria, Alexandria, Egypt; 4Genetics, Yale 
Univ, New Haven, CT.
Background: Bidirectional intraflagellar transport (IFT) consists of two major 
protein complexes, IFT-A and IFT-B. In contrast to the IFT-B complex, all components 
of IFT-A have recently been linked to human ciliopathies when defective. We therefore 
hypothesized that mutations in additional IFT-B encoding genes can be found in patients 
with multisystemic ciliopathies.
Methods: We screened 1,628 individuals with reno-ocular ciliopathies by targeted 
next-generation sequencing, including all IFT-B encoding genes.
Results: Consequently, we identified a homozygous mutation in IFT81 affecting an 
obligatory donor splice site in an individual with nephronophthisis and polydactyly. Further, 
we detected a loss-of-stop mutation with extension of the deduced protein by 10 amino 
acids in an individual with neuronal ceroid lipofuscinosis-1 (CLN1). This proband presented 
with retinal dystrophy and brain lesions including cerebellar atrophy, a phenotype to which 
the IFT81 variant might contribute. Cultured fibroblasts of this latter affected individual 
showed a significant decrease in ciliated cell abundance compared to controls and increased 
expression of the transcription factor GLI2 suggesting deranged sonic hedgehog signaling.
Conclusions: This work describes identification of mutations of IFT81 in individuals 
with symptoms consistent with the clinical spectrum of ciliopathies. It might represent the 
rare case of a core IFT-B complex protein found associated with human disease. Our data 
further suggest that defects in the IFT-B core are an exceedingly rare finding, probably due 
to its indispensable role for ciliary assembly in development.
TH-PO218
Loss of Aatf in Murine Tubular Cells Leads to a Nephronophthisis-Like 
Phenotype  Manaswita Jain,1 Heide Irene Heinen,1 Heike Goebel,2 Bernhard 
Schermer,1 Thomas Benzing,1 Katja Hoepker.1  1Internal Medicine II, Univ 
Hospital Cologne, Cologne, Germany; 2Dept of Pathology, Univ Hospital 
Cologne, Cologne, Germany.
Background: Genomic integrity is continously being challenged by DNA damage 
of endogenous or exogenous sources. Aatf is a key regulator of the tumor suppressor 
p53 in the DNA-damage response signaling cascade. Aatf inhibits the ability of p53 to 
transactivate pro-apoptotic target genes. The conventional knockout of Aatf in mice is 
pre-implanationally lethal. A central role of DNA-damage signaling in tubular cells and 
cystic kidney diseases has been suggested. Here we show that deletion of Aatf in developing 
distal tubular and collecting duct cells leads to a degenerative, cystic phenotype, much 
alike juvenile nephronophthisis.
Methods: Conditional knockout mice, histology, phenotypic analysis.
Results: Aatf was knocked out using the Ksp:Cre mouse line in a floxed Aatf genetic 
background. The homozygous Aatf deletion results in weight loss and kidney failure at the 
age of 6-10 weeks. The mice show polyuria, polydipsia and have a reduced urine osmolarity. 
Their kidneys are small, pale and show small cysts predominantly at the cortico-medullary 
border. Histological examination shows tubular and glomerular cysts and interstitial fibrosis 
as well as an increased rate of apoptotic cell death.
Conclusions: Alterating the outcome of the p53-driven DNA-damage response in the 
Ksp:Cre;Aatf knockout leads to clinical and histological signs of juvenile nephronophtisis 
that links DNA damage response signaling close to cystic kidney disease.
Funding: Government Support - Non-U.S.
TH-PO219
Role for the Primary Cilium in Regulation Interstitial Macrophage 
Proliferation and Polarization During Kidney Maturation and Injury 
Cheng ’Jack’ Song,1 Kurt Zimmerman,1 Michal Mrug,2 Bradley K. Yoder.1 
1Dept of Cell Developmental and Integrative Biology, Univ of Alabama 
at Birmingham, Birmingham, AL; 2Dept of Medicine, Univ of Alabama at 
Birmingham, Birmingham, AL.
Background: Induction of cilia loss in juvenile mice results in rapid cyst development 
while induction of cilia loss in adult mice causes a much slower rate of cyst progression.
Rapid cyst formation can be initiated in the adult-induced IFT mutants by ischemic 
reperfusion (IR) injury suggesting a possible role for inflammation in cyst development.
This was recently confirmed by liposome clodronate (LC) mediated depletion of phagocytic 
macrophages that reduced cyst severity and improved renal function. However, the crosstalk 
between primary cilia located on epithelial cells and the interstitial macrophages during 
cyst progression is unknown. Here, we investigate potential connections between primary 
cilia associated cystogenesis and changes in macrophage populations.
Results: Our preliminary data suggest the presence of a kidney resident macrophage 
population, likely derived from the yolk sac, which are present in juvenile mice and re-
immerge in adult-induced cilia mutants following IR injury. Renal Resident macrophage 
demonstrates rapid proliferation following IR injury in adult-induced IFT88 mutant mice 
as early as 3 days following injury and persists for at least day 21. In contrast, resident 
macrophages from control mice show peak proliferation 3 days following IR injury that 
then abates at days 7-21.
Conclusions: This work suggests communication between the cilia on epithelial cells 
and the resident macrophages is important for kidney maturation and repair after injury. Our 
prediction is that defects in this communication will result in persistent resident macrophage 
proliferation that contributes to the rate of cyst formation. This work will provide possible 
targets for therapeutic intervention.
Funding: NIDDK Support
TH-PO220
Ciliary Trafficking of Polycystin-1 and Polycystin-2 Is Interdependent 
Chong Luo, Maoqing Wu, Wassim El-jouni, Jing Zhou.  Harvard Center for 
Polycystic Kidney Disease Research and Renal Div, Dept of Medicine, Brigham 
and :omen¶s Hospital, Harvard Medical School, Boston, MA.
Background: Mutations in PKD1 account for over 85% cases of autosomal dominant 
polycystic kidney disease (ADPKD). About 30% of the PKD1 mutations are missense 
mutations which likely produce full-length proteins that are defective in trafficking to the 
primary cilia. We have recently shown that multiple sequences including a coiled-coil (CC) 
motif in the C-terminal tail of PC1 regulate full-length PC1 trafficking to primary cilia. PC1 
remains to traffic to the primary cilia in cells depleted of PC2. The proteolytic cleavage at 
the GPS site of PC1 is not required for its ciliary trafficking.
Methods: A set of deletion/mutation constructs in mouse PC1 including those 
corresponding to ADPKD patient-derived mutations, as well as chimeric constructs 
with different mPC1 C-terminal motifs were developed. Transient transfection and 
immonostaining methods were used.
Results: We found that all pathogenic mutations we tested are defective in ciliary 
trafficking.Ciliary localization of full-length PC1 or its mutants is completely abolished 
in PC2 knockout cells. However, this defect can be rescued by co-expression of PC2 in a 
dose dependent manner. Overexpression of PC2 even drives the C-tail-less PC1 mutant to 
the primary cilia in IMCD-3 cells. This promotion doesn’t rely on the previously identified 
ciliary targeting VxPx motif at the N-terminus of PC2. The ciliary targeting of PC2 is also 
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regulated by the dose of PC1. Analyses of the C-tail of PC1 also led to the identification 
of a potential ciliary targeting sequence within the C-terminal tail of PC1 in addition to the 
previously identified VxPx motif. This sequence is sufficient to drive a chimeric construct 
to the cilia in IMCD-3 cells and is independent of the presence of PC2.
Conclusions: Ineffective ciliary trafficking of PC1 may represent a pathogenic 
mechanism of ADPKD. The mechanisms of polycystins trafficking to the primary cilia are 
complex involving multiple motifs and factors. Ciliary trafficking of full-length PC1 and 
PC2 are interdependent, they mutually promote each other to traffic to the primary cilia.
Funding: NIDDK Support
TH-PO221
Anoctamin 6 Is Localized in the Primary Cilium of Renal Tubular 
Cells and Is Involved in Apoptosis-Dependent Cyst Lumen Formation 
Bjoern Buchholz,1 Victoria Forschbach,1 Margarete Goppelt-struebe,1 Karl 
Kunzelmann,2 Rainer Schreiber,2 Andre Kraus,1 Kai-Uwe Eckardt.1  1Dept 
of Nephrology, Univ Erlangen-Nuernberg, Erlangen, Germany; 2Dept of 
Physiology, Univ Regensburg, Regensburg, Germany.
Background: Anoctamin (ANO) 6 is a member of a novel family of Ca2+-activated 
Cl- channels. Although ANO6 is the most widely expressed paralogue, only little is known 
about its subcellular localization. Recently, we could show that ANO6 together with ANO1 
is expressed in renal cyst-lining cells. Unlike ANO1, which was involved in cyst expansion, 
the role of ANO6 remained elusive. Therefore, we analyzed the localization of ANO6 in 
renal tubular cells and tested for a role in cyst formation.
Methods: We stained polarized MDCK cells for ANO6 in comparison to stably ANO6-
deficient cells. In addition, we analyzed human collecting duct (HCD) cells and primary 
human tubular cells to test for species- and segment-specific expression. We also examined 
the effect of ANO6 deficiency on MDCK cyst formation and performed Ussing chamber 
experiments to test for changes in transepithelial Cl- secretion. Additionally, we stained 
kidney sections comprising healthy and cystic tissues from ADPKD patients for ANO6.
Results: ANO6 was localized in the primary cilium of all tubular cells irrespective 
of species or tubular origin. In addition, ciliary localization of ANO6 could be detected 
in human kidneys. ANO6 knockdown resulted in loss of ciliary ANO6 signals but had no 
effect on ciliogenesis or MDCK cyst growth. In line with these data, ANO6-deficient MDCK 
cells revealed no alteration in Ca2+-dependent Cl- secretion. However, lumen formation 
was markedly disturbed in ANO6-deficient cysts which could be referred to an increased 
number of cells situated within the cyst lumen which normally would get removed by 
apoptosis. However, ANO6-deficient cells showed a strong reduction of Ca2+-dependent 
phospholipid scrambling as well as TUNEL- and Caspase3 signals. In addition, apoptotic 
cyst cells in human ADPKD were characterized by strong co-expression of ANO6.
Conclusions: ANO6 is a ciliary protein and involved in apoptosis-dependent cyst 
lumen formation.
Funding: Government Support - Non-U.S.
TH-PO222
Regulation of Cilia Function by Protein Palmitoylation  Kasturi Roy, 
Levente Jozsef, Ethan P. Marin.  Internal Medicine / Nephrology, Yale School 
of Medicine, New Haven, CT.
Background: Cilia are microtubule based protrusions of the plasma membrane 
which serve sensory and signaling functions. Abnormalities in cilia cause diseases 
known as ciliopathies, which include autosomal dominant polycystic kidney disease and 
nephronophthsis. Many ciliopathies involve abnormal trafficking of proteins to cilia. 
Trafficking of proteins may be affected by cysteine palmitoylation, the reversible post-
translational attachment of the lipid palmitate to proteins. Since numerous cilia proteins 
are palmitoylated, here we have explored the role of palmitoylation in cilia function and 
protein trafficking. As a model, we have used Arl13b, a palmitoylated monomeric G protein 
that localizes to cilia and that causes a ciliopathy in humans when mutated.
Methods: Mouse inner medullary collecting duct cells (IMCD3) were used as a 
model system to studie cilia structure and function. A combination of genetic engineering, 
biochemical, and microscopic approaches were used to determine Arl13b palmitoylation 
status, localization, and effects on cilia formation.
Results: IMCD3 cells engineered using CRISPR/Cas9 to have mutations disrupting 
the Arl13b gene did not form cilia unlike the WT parent cells. Preventing palmitoylation of 
Arl13b by mutagenesis or by chemical inhibitors blocked trafficking to the cilia. Introduction 
of a myristoylation site restored proper localization of palmitoylation-deficient Arl13b. In 
order to identify enzymes involved in Arl13b palmitoylation, we characterized localization 
and activity of all 24 ZDHHC family protein acyl transferases. Five were found to increase 
Arl13b palmitoylation at least 3-fold. Further, several were found to be expressed in a 
compartment proximal to the cilia.
Conclusions: These data collectively show that Arl13b is necessary for cilia formation 
in IMCD3 cells, and that palmitoylation is as a key regulator of Arl13b localization. Further, 
these studies identify acyl transferase enzymes that may be novel regulators of Arl13b and 
thus cilia function. Given the large number of palmitoylproteins in cilia, palmitoylation 
may be a general mechanism regulating localization of cilia proteins and thus controlling 
cilia function.
Funding: NIDDK Support, Other NIH Support - NHLBI, Private Foundation Support
TH-PO223
Cell Cycle-Dependent Ubiquitylation and Destruction of NDE1 by CDK5-
FBW7 Regulates Cilium Biogenesis  Dipak Maskey, Leonidas Tsiokas.  Cell 
Biology, Univ of Oklahoma Health Sciences Center, Oklahoma City, OK.
Background: The primary cilium is an antenna-like organelle housing numerous 
signaling pathways. Loss of primary cilia can have opposing effects on cystogenesis: 
in general, it induces cystogenesis, but it suppresses cyst formation in mouse models of 
autosomal dominant polycystic kidney disease (ADPKD). Therefore, inhibiting ciliogenic 
pathways can be beneficial in treating ADPKD. Cilia are formed when cells exit the cell 
cycle and disassemble when cells re-enter the cell cycle. We have previously identified 
NDE1 as a suppressor of ciliogenesis and showed that its expression is markedly reduced 
when cells exit the cell cycle. However, the mechanisms controlling its downregulation 
upon cell cycle exit are unknown.
Methods: Methods used in the study included Western blotting and co-
immunoprecipitations, sire-directed mutagenesis, ubiquitylation assays, and indirect 
immunofluorescence.
Results: Focusing on the mechanisms mediating its downregulation, we have now 
discovered a pathway involving the CDK5 kinase and the FBW7 E3 ubiquitin ligase that 
controls ciliary formation. Specifically, CDK5, which is active only in quiescent cells, 
phosphorylates NDE1 at a specific site, which is in turn recognized by the FBW7 E3 ligase 
and targets NDE1 for degradation through the Skp1, Cullin 1, FBW7 (SCFFBW7) ubiquitin 
ligase. The destruction of NDE1 by SCFFBW7 allows ciliogenesis to proceed normally, cilia 
to reach their appropriate length and function properly. However, when this pathway is 
inhibited by depletion of FBW7, CDK5, or chemical inhibition of CDK5, NDE1 levels 
rise causing a reduction in ciliary length and function.
Conclusions: Our study furthers our knowledge on the mechanisms of ciliary formation 
and function and helps develop new approaches to treat cystic diseases.
Funding: NIDDK Support, Other NIH Support - Oklahoma Center for the 
Advancement of Science and Technology
TH-PO224
Platelet-Derived PAI-1 Accelerates Podocyte Detachment in FSGS 
Namiko Kobayashi,1,2 Yukina Takahashi,1 Taiji Matsusaka,3 Michio Nagata.1 
1Renal Pathology, Univ of Tsukuba, Tsukuba, Japan; 2Nephrology, Tsuchiura 
Kyodo General Hospital, Tsuchiura, Japan; 3Depts of Molecular Life Science 
and Inst of Medical Science, Tokai Univ School of Medicine, Isehara, Japan.
Background: Platelet activation has been shown to be involved in glomerular diseases 
by releasing cytokines and pro-coagulant factors. In FSGS mice, we have previously shown 
that PAI-1 is upregulated within the glomerular capillary, which accelerates detachment 
of remnant podocytes through uPAR-mediated b1 integrin endocytosis. Endothelial cells 
and platelets are the possible producers of intracapillary PAI-1. Although endothelial cells 
were involved in the early stage in our study, the role of platelet-derived PAI-1 in FSGS 
is unknown. Here we tested whether platelet-derived PAI-1 is involved in podocyte loss 
in FSGS mice.
Methods: We used an immunotoxin inducible FSGS model, NEP25 mice. NEP25 
mice were injected with immunotoxin (LMB2, 4 ng/g body weight) on day 0 and treated 
with 2 mg of anti-mouse platelet antibody (Ab group, n=10) or PBS (C group, n=10) on 
day-1,4,9. Proteinuria, histology, and PAI-1 localization were examined on day 1 and 12. 
The WT-1-positive cell number was counted on day -1 and 12.
Results: Platelet depletion decreased proteinuria (P < 0.05) with the protection of 
podocyte number on day 12 (3.15 ± 0.21 in Ab group vs. 1.55 ± 0.27 in C group, P < 0.05). 
Glomerular PAI-1 mRNA expression was increased on day 1 in both groups, but it was 
decreased on day 12 in Ab group (0.14 ± 0.02 in Ab group vs. 1.0 ± 0.23 in C group, P < 
0.05). Immunostaining showed glomerular PAI-1 was colocalized with CD31 (endothelial 
cell marker), but not with CD41 (platelets marker) on day 1 in both groups. PAI-1 was 
colocalized with CD41, and occasionally with synaptopodin, but not with CD31, on day 
12 in C group.
Conclusions: In podocyte injury, PAI-1 was initially induced in the endothelial cells 
and shifted to the platelets later. Since intracapillary PAI-1 has been shown to promote 
additional podocyte detachment via integrin endocytosis, inhibition of platelets is a plausible 
strategy to slow progression of FSGS.
TH-PO225
Podocyte Knockdown of Plasminogen Activator Inhibitor-1 (PAI-1) Is 
Insufficient to Replicate Protective Effect of Systemic PAI-1-/- in Chronic 
Kidney Disease  Tareq M. Altuhaifi,1 Jae Won Yang,1 Taiji Matsusaka,2 Haichun 
Yang,1 Agnes B. Fogo.1  1Dept of Pathology, Microbiology, and Immunology, 
Vanderbilt Univ, Nashville, TN; 2Dept of Molecular Life Science, Tokai Univ 
School of Medicine, Isehara-shi, Kanagawa, Japan.
Background: Podocyte injury is a major trigger for glomerulosclerosis. PAI-1 is 
upregulated in injured podocytes and sclerosing glomeruli. We assessed the role of podocyte 
vs. systemic PAI-1 in a primary podocyte injury model.
Methods: We generated a podocyte injury model with intact (PAI-1+/+/Nep25, n=8) 
or systemic PAI-1 deficiency (PAI-1-/-/Nep25, n=8) by crossing wild type or PAI-1-/- with 
Nep25 mice, which express human CD25 receptor on podocyte and develop sclerosis after 
immunotoxin (LMB2) injection. We also generated podocyte PAI-1 knock down mice 
(PAI-1floxed/Podocin Cre/Nep25, n=7) and its control (PAI-1floxed/Nep25, n=7) by mating 
PAI-1loxp/loxp/teTO-Cre+/Podocin-rtTA+ with PAI-1loxp/loxp/Nep25 mice. Doxycycline was given 
from day -7 till day 10. All mice received LMB2 at day 0, and were sacrificed at day10.
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Results: Nep25 mice with systemic PAI-1 deficiency had less body weight increase, 
an index of edema, but similar proteinuria, when compared to those with intact PAI-1, 
and also had more preserved podocytes, as shown by higher synaptopodin expression and 
glomerular WT-1+ density (PAI-1-/-/Nep25 5.07±0.17 vs. PAI-1+/+/Nep25 2.59±0.22x10-3/
um2, p<0.05). Total glomerular CD44 positivity, a marker for activated parietal epithelial 
cells (PEC), was increased in PAI-1-/-/Nep25 vs PAI-1-/-/Nep25 (5.06±0.35 vs 3.84±0.36/
glom, p<0.05). In contrast, Nep25 mice with podocyte specific PAI-1 knockdown had 
similar edema and proteinuria as its control, and WT1+ density and glomerular CD44 
positivity were not different between PAI-1floxed/Podocin Cre/Nep25 and PAI-1floxed/Nep25. 
However, synaptopodin was higher in mice with podocyte PIA-1 knockdown vs its control 
(3.82±0.87 vs 1.98±0.23%, p<0.05).
Conclusions: We conclude that podocyte PAI-1 knockdown was insufficient to produce 
a similar protective effect as seen in systemic PAI-1 knockout in a podocyte-specific kidney 
injury model.  We speculate that this may partially relate to PEC to podocyte transition.
Funding: NIDDK Support
TH-PO226
Reversal of Podocyte Loss in Mice with Membranoproliferative 
Glomerulonephritis (MPGN) by Imatinib  Noppanit Pattanachaiwit, Masayuki 
Iyoda, Tomasz A. Wietecha, Kelly L. Hudkins, Charles E. Alpers.  Univ of 
Washington, Seattle, WA.
Background: Mice transgenic for thymic stromal lymphopoietin (TSLP-Tg) develop 
cryoglobulinemia and MPGN. Platelet-derived growth factor (PDGF)-D, expressed by 
podocytes in humans, with its receptor (PDGFR-β) are likely mediators of mesangial 
expansion in MPGN. Inhibition of PDGFR-β by imatinib, a tyrosine kinase inhibitor, 
reduces mesangial proliferation in TSLP-Tg mice. The importance of podocyte loss and 
PDGF-D expression in MPGN are currently unknown. This study sought to identify possible 
podocyte loss and investigate the effect of imatinib on podocyte density in mice with MPGN.
Methods: Three-week old female mice were assigned to three groups: TSLP-Tg mice 
treated with imatinib (50 mg/kg) daily by intraperitoneal injection for eight weeks; control 
TSLP-Tg mice treated with sterile water; and wild type (WT) control mice. Podocytes were 
identified by immunohistochemical stain (IHC) for p57, and their density morphometrically 
quantitated. Expression of PDGF-D and PDGFR-β was detected by IHC. Albuminuria was 
measured from timed urine samples.
Results: Podocyte density in TSLP-Tg mice was significantly less than WT controls 
(182.67 ± 21.15 vs 278 ± 6.19 podocytes/106 µm3, p = 0.005), and was markedly increased by 
imatinib (249.17 ± 14.49, p = 0.029). TSLP-Tg mice had significantly increased mesangial 
(but not podocyte) expression of PDGF-D (248.23 ± 40.75 µm2) and slightly increased 
PDGFR-β expression (192.91 ± 17.31) compared to WT controls (124.17 ± 10.46, p = 
0.028 and 175.55 ± 6.61, p = 0.388 respectively). The overexpression of PDGF-D was 
significantly reduced (129.02 ± 10.95, p = 0.025) whereas the expression of PDGFR-β was 
increased after imatinib treatment (260.51 ± 18.62, p = 0.024). Albuminuria in TSLP-Tg 
mice was higher than WT controls (16.6 ± 4.66 vs 4.23 ± 0.76 µg/24 h, p = 0.036), and 
was decreased by imatinib (4.97 ± 1.64, p = 0.049).
Conclusions: This study demonstrates podocyte loss in MPGN. Restoring podocyte 
number may be a key to reversal of MPGN. Imatinib largely reversed podocyte loss and 
reduced mesangial injury, PDGF-D overexpression and albuminuria in TSLP-Tg mice. 
Unlike humans, mesangial cells rather than podocytes express PDGF-D in mice.
Funding: NIDDK Support
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Role of Epithelial Membrane Protein 2 in Nephrotic Syndrome 
Michael D. Donnan, Rizaldy P. Scott, Tuncer Onay, Anna Woo, Susan E. 
Quaggin.  Feinberg Cardiovascular Research Inst and Div of Nephrology and 
Hypertension, NorthZestern Univ, Chicago, IL.
Background: Mutations in the human gene EMP2 (Epithelial Membrane Protein 
2) have recently been linked to childhood-onset nephrotic syndrome. Its gene product, a 
tetraspan integral membrane protein, affects various cell behaviors including regulation 
of cell adhesion, migration, proliferation, apoptosis and tumorigenesis. EMP2 protein 
modulates the expression of GPI-anchored proteins, caveolin-1, integrin, and the growth 
factor VEGFA. EMP2 is also necessary for embryo implantation and chlamydial infectivity. 
We studied the renal expression pattern of EMP2 and generated a conditional Emp2 
knockout (KO) mouse as first steps towards understanding its role in glomerular disease.
Methods: We created a floxed Emp2 (Emp2flox/flox) mouse containing a LacZ reporter 
gene controlled by the endogenous Emp2 promoter. We assessed Emp2 expression in kidneys 
using whole-mount β-galactosidase (β-gal) histochemistry. To complement this analysis, 
we used an antibody against EMP2 to assess its localization by immunofluorescence (IF). 
Podocyte-specific KO mice (Emp2Pod/Pod) were generated by breeding Emp2flox/flox mice to 
the Nphs1-Cre driver strain and were assessed for proteinuria.
Results: β-gal staining reveals that Emp2 is prominently expressed within major 
vascular bundles and a distinct band of cells within the cortex and renal papillae. Double-
label IF using an EMP2 antibody and Lotus lectin suggests that the Emp2 expression 
within the renal cortex is in proximal tubules. The EMP2 antibody did not stain the renal 
papilla or renal vasculature. Whether this disparity is due to cell-specific post-translational 
modification (e.g. glycosylation) remains to be addressed. However, in both β-gal and IF 
assays Emp2 within the glomerulus was not seen. By 3 months of age, Emp2Pod/Pod do not 
have proteinuria.
Conclusions: In contrast to a previous report, we did not observe Emp2 expression in 
podocytes while Emp2Pod/Pod mice do not develop overt kidney disease. Genetic deletion of 
Emp2 in tubular and endothelial compartments will provide additional insights regarding 
the etiology of renal dysfunction in patients with EMP2 mutations.
TH-PO228
Discovery of Mesencephalic Astrocyte-Derived Neurotrophic Factor as 
a Urine Biomarker for Endoplasmic Reticulum Stress-Related Kidney 
Diseases  Yeawon Kim,1 Heedoo Lee,1 Scott R. Manson,2 Jeffrey H. Miner,1 
Fumihiko Urano,3 Ying Maggie Chen.1  1Renal Div, :ashington Univ, St. Louis, 
MO; 2Div of Urology, :ashington Univ, St. Louis, M2; 3Div of Endocrinology, 
Metabolism and Lipid Research, :ashington Univ, St. Louis, M2.
Background: Accumulating evidence has highlighted the important role of endoplasmic 
reticulum (ER) stress in the pathogenesis of a variety of kidney diseases. Thus, it is 
imperative to develop non-invasive biomarkers for detecting ER stress in podocytes or 
tubular cells in the incipient stage of disease, when clinically a kidney biopsy is not yet 
indicated. Moreover, restoration of ER homeostasis before irreversible kidney cell injury 
may hold significant promise as an attractive therapeutic strategy. Here for the first time 
we discovered mesencephalic astrocyte-derived neurotrophic factor(MANF) as a potential 
urine biomarker for detecting ER stress in associated kidney diseases.
Methods: We used mouse models of human nephrotic syndrome (NS) caused 
by podocyte ER stress and of acute kidney injury (AKI) triggered by the ER stressor 
tunicamycin or ischemia/reperfusion (I/R)-induced tubular ER stress.
Results: In our NS mouse model carrying the C321R laminin β2 (LAMB2) mutation 
in podocytes, podocyte ER stress was induced. The mutants exhibited MANF induction 
in podocytes at P24, when proteinuria was minimal, compared with controls. In vitro, 
secretion of MANF by mutant primary podocytes was increased as compared to that by 
control podocytes. Most importantly, MANF was easily detected in the crude urines of 
C321R mutants in the incipient stage of disease as compared to the controls. Meanwhile, in 
tunicamycin or I/R-induced AKI mouse models, urinary MANF excretion concurrent with 
tubular cell ER stress preceded clinical or histological manifestations of acute tubular injury.
Conclusions: MANF can potentially serve as a urine biomarker to help stratify disease 
risk and predict disease progression in the ER stress-related kidney diseases. In addition, 
MANF can help identify subgroups of patients who can be treated with ER stress modulators 
and monitor treatment response in a highly-targeted manner.
Funding: NIDDK Support, Other NIH Support - UL1TR000448, Private Foundation 
Support
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Identification of Differentially Expressed Genes in Rat Puromycin 
Aminonucleoside (PAN) Nephropathy, a Mimic of MCNS with Next-
Generation Sequencing  Yoshiyasu Fukusumi, Hiroshi Kawachi.  Dept of 
Cell Biology, Inst of Nephrology, Niigata Univ Graduate School of Medical 
and Dental Sciences, Niigata, Japan.
Background: To explore the novel therapeutic targets of nephrotic syndrome resulted 
from podocyte dysfunction, we intend to identify the molecules of which gene expression 
is changed in rat nephrotic models by the Next-Generation Sequencing analysis.
Methods: The profile of gene expression of PAN nephropathy was analyzed by next 
generation high-throughput RNA sequencing (RNA-Seq) with Solid system 5500. 581 
molecules, whose mRNA was clearly altered (more than 5 times increase or less than 20% 
decreased to normal level), were identified. 20 molecules, which were expected to play a role 
in maintaining podocyte function, were selected, and the kinetic of the mRNA expression of 
these molecules were precisely analyzed in several nephrotic models including anti-nephrin 
antibody (ANA)-induced nephropathy, a proteinuric model caused by the disarrangement of 
the SD molecules, and in ADR nephropathy, a mimic of FSGS, as well as PAN nephropathy.
Results: In PAN nephropathy, mRNA expression of 153 genes were increased (> 5 
times) at 1 h when abnormal proteinuria was not detected yet. mRNA expressions of 121 
genes were increased on day 10 when proteinuria peaked. mRNA expressions of 37 genes 
were increased both time points. 297 genes, whose mRNA expression was lowered to less 
than 20%, were identified. mRNA expressions of 186 genes were decreased similarly on 
day 10, and those of 121 genes were decreased at both 1h and day 10. For further analyses 
Phospholipase A2, group IID (Pla2g2d) and proto cadherin alpha 5 (Pcdha5) were focused. 
mRNA expression of Pla2g2d was decreased to 11% at 1h and 13 % on day 10 of PAN 
nephropathy. mRNA expression of Pcdha5 was decreased to 2.7% at 1h and 1.5% on day 
10 of PAN nephropathy and 15% on day 5 of ANA nephropathy, whereas the mRNA 
expression was clearly increased on day 5 of ADR nephropathy.
Conclusions: RNA-Seq is a powerful tool for profiling gene expression and the 
detection of differentially expressed gene in proteinuric state. It is assumed that the 
decrease in the mRNA expression of Pla2g2d and Pcdha5 is involved in the development 
of proteinuria.
Funding: Government Support - Non-U.S.
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Comprehensive Polysome Analysis in Injured Podocytes  Masahiro Okabe,1,2 
Yoichi Miyazaki,2 Takashi Yokoo,2 Masafumi Fukagawa,1 Taiji Matsusaka.1 
1Tokai Univ School of Medicine, Isehara, Japan; 2Jikei Univ School of Medicine, 
Tokyo, Japan.
Background: Podocyte injury is the key event for progressive renal failure. It is difficult 
to isolate the RNA of podocytes from the kidney, which is made up with multiple-type cells.
Methods: To solve this problem, we used Ribotag transgenic mouse line (established 
by Dr. Amieux PS), in which HA-tag is inserted into the C-terminus of Rpl22, a component 
of the ribosomal protein, in the presence of Cre recombinase. Ribotag line was mated with 
nephrin-Cre and NEP25, an immunotoxin-inducible podocyte-selective injury model. 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
142A
J Am Soc Nephrol 26: 2015 Glomerular Epithelial Cell Injury and Rescue Poster/Thursday
Glomeruli were isolated before or after induction of podocyte injury. Podocyte-specific 
polysome was yielded by immunoprecipitation with anti-HA antibody and analyzed by 
Agilent’s 8X66K microarray (n=12) and qRT-PCR (n=8).
Results: In a basal condition, microarray analysis revealed 5070 (9.1%) probes were 
significantly and more than 2-fold enriched in podocytes within the glomerulus, which 
include most known podocyte genes. qRT-PCR confirmed that Nphs1 and Nphs2 RNAs 
were concentrated in podocytes (15 and 8.6-fold), while mesangial and endothelial RNAs 
were diluted. Seven days after immunotoxin injection, 3130 (5.6%)/1938 (3.5%) probes 
were significantly and more than 2-fold up/down-regulated in podocytes from the basal 
condition. Nphs1, Podxl, Synpo and Wt1 were decreased (0.37, 0.39, 0.28 and 0.49-fold), 
and Des, Relb, Gadd45b and Cxcl1 were markedly upregulated (8.1, 6.9, 20 and 160-fold), 
which were confirmed by qRT-PCR. These changes were significantly correlated with 
those in Actn4 KO podocytes reported in TRAP study (R=0.520, p<0.001), suggesting that 
these represent common pathogenic responses. Separately, reviewing 84 published CKD 
candidate genes identified by GWAS, thirteen, including Vegfa, were found concentrated 
in normal podocytes whereas Dach1 and Aff3 decreased after podocyte injury (0.42, 0.64-
fold) similarly to Vegfa (0.28-fold), suggesting their important functional role in podocytes.
Conclusions: Thus, these comprehensive data provide potentially important insights 
for understanding podocyte pathophysiology.
Funding: Government Support - Non-U.S.
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Expression of Mouse uPAR Alternative Isoform 2 Produces a Dimeric 
Protein and Severe Renal Disease  Changli Wei,1 Brian D. Adair,2 Jing Li,1 
Liu Shuangxin,1 Nicholas J. Tardi,1 Jochen Reiser.1  1Rush Univ Medical Center; 
2Massachusetts General Hosptial, Harvard Medical School.
Background: Soluble urokinase receptor (suPAR) has been proposed as a circulating 
factor in focal segmental glomerulosclerosis (FSGS) by direct activation of podocyte 
aVb3 integrin. Mouse secretive uPAR isoform 2 (msuPAR) is an alternatively spliced 
uPAR variant. This study was aimed to evaluate the ability of this isoform to function as 
a circulating factor.
Methods: For structural study, msuPAR was cloned from podocytes, and expressed 
in HEK cells with a Flag tag. The recombinant msuPAR protein was purified with Flag 
beads and analyzed by electron microscopy (EM). For functional study, a transgenic mouse 
model was created that drives msuPAR expression from adipocytes with consequent 
release into circulation.
Results: Negative-stain EM and single particle image analysis reveal that msuPAR 
protein forms a compact, well-defined structure in solution, which is formed by a dimer 
of two globular domains. The three-dimentional reconstruction shows one of the domains, 
which provides a good fit for domain 1, connected to the other globular domain in an open 
conformation, in contrast with the tight closed conformation seen in crystal structures of 
the intact protein (isoform 1). msuPAR transgenic mice are fertile and they start to develop 
proteinuria 1 month after birth. With rising serum msuPAR level, progressive proteinuria 
develops in most animals. By 7 to 8 months old, about 20% of msuPAR transgenic mice 
developed FSGS-type lesions, while 80% of mice showed mild glomerular damages. 
Transmission EM analysis showed variant degree of podocyte foot process effacement that 
correlated to the proteinuria and the light microscopy changes. Analysis of serum level of 
the inflammatory marker, CRP or IL-6 did not distinguish msuPAR transgenic mice from 
littermate control. Glomerular b3 integrin activity however was significantly increased in 
msuPAR transgenic mice.
Conclusions: The mouse secretive isoform uPAR 2 forms a dimeric protein with 
globular domains. Its expression in transgenic mice results in increased podocyte integrin 
activation and progressive renal disease with a spectrum from minimal change to FSGS 
type kidney lesion.
Funding: NIDDK Support, Pharmaceutical Company Support - Therumo BCT
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Sildenafil-Dependent Reduction of TRPC6 Expression, Podocyte Injury 
and Proteinuria Is Mediated via PPARγ  Ramon Sonneveld,1 Joost 
Hoenderop,2 Carole Hénique,3 Jo H.M. Berden,1 Pierre-Louis Tharaux,3 Johan 
Van der vlag,1 Tom Nijenhuis.1  1Nephrology, Radboud Univ Medical Center, 
Nijmegen, Netherlands; 2Physiology, Radboud Univ Medical Center, Nijmegen, 
Netherlands; 3Cardiovascular Research Centre, INSERM, Paris, France.
Background: Increased transient receptor potential channel C6 (TRPC6) activity in 
the podocyte leads to glomerular injury and proteinuria. Sildenafil (Viagra®) is used to 
treat erectile dysfunction and pulmonary arterial hypertension where it reduces TRPC6 
activity and expression. The nuclear receptor PPARγ is a downstream target of sildenafil 
via the cGMP-activated protein kinase G (PKG) axis. PPARγ agonists likePioglitazone 
(Pio) may be antiproteinuric. We hypothesized that sildenafil has renoprotective effects, 
with PPARγ as central mediator modulating TRPC6 expression and activity in podocytes.
Methods: Using pharmacological compounds in cultured podocytes, rat and mouse 
models, the role of the PPARγ-PKG in mediating TRPC6 expression/activity was tested.
Results: TRPC6 expression was upregulated in adriamycin-injured podocytes, which 
was dose-dependently downregulated by sildenafil, the cGMP derivative 8-Br-cGMP or 
the PPARγ agonist Pio. The PKG blocker KT5823 or the PPARγ antagonist GW9662 
enhanced TRPC6 expression. The effects of sildenafil and 8-Br-cGMP were counteracted by 
inhibition of PKG by KT5823 and PPARγ by GW9662. The effect of Pio was negated only 
by GW9662. Similar results were shown for TRPC6 promoter activity and calcium influx. 
Chromatin immunoprecipitation showed binding of PPARγ to the TRPC6 promoter. Healthy 
rats treated with GW9662 showed proteinuria and upregulation of TRPC6 expression in the 
podocytes, which was also observed in podocyte-specific PPARγ knock-out mice. Renal 
injury and increased TRPC6 expression in adriamycin induced nephropathy rats could be 
prevented by sildenafil and Pio treatment.
Conclusions: Amelioration of podocyte injury by sildenafil involves cGMP- and PKG-
dependent binding of PPARγ to the TRPC6 promoter, thereby inhibiting TRPC6 promoter 
activity, expression and activity. Our data identify sildenafil as a novel antiproteinuric agent, 
which acts by inhibiting deleterious TRPC6-mediated intracellular podocyte signaling.
TH-PO233
APOL1 Risk Variants Enhance Initiation but Retard the Terminal Part of 
Autophagy in Podocytes  Xiqian Lan,1 Hongxiu Wen,1 Ashwani Malhotra,1 
Karl Leon Skorecki,2 Pravin C. Singhal.1  1Medicine, Hofstra North Shore LIJ 
Medical School, Great Neck, NY; 2Medicine, Rambam Health Care Campus, 
Haifa, Israel.
Background: Patients with APOL1 Variants carry 10 fold higher chance for the 
development of HIVAN if not on antiviral therapy. HIV is known to hijack autophagy in 
the host cells-enhancement of autophagosome formation (the site of viral replication) but 
inhibits the delivery of autophagosomal cargo (AC) to the lysosomes and thus, prevents viral 
degradation. Since podocytes are terminally differentiated cells their protein homeostasis is 
tightly regulated by autophagy. We hypothesized that APOL1 risk variants would also have 
potential for augmenting the initial phase but would inhibit the terminal phase of autophagy.
Methods: We used human podocytes (HPs) stably expressing APOL1G0, G1, or G2 
(Vec/HPs, G0/HPs, G1/HPs, and G2/HPs). Pseudo type HIV or empty vector (control) 
virus was transduced into Vec/HPs, G0/HPs, G1/HPs and G2/HPs. After 48 h, cells were 
harvested and assayed for vacuolar density (number of autophagosomes) by staining with 
acridine orange or monodansylcadaverine (MDC). Protein blots of HPs (Vec, G0, G1, and 
G2) were probed for mTOR (pathway modulating autophagy), beclin-1 and LC3-II (markers 
of early steps of autophagy), p62 (marker of degradation of AC) and reprobed for actin. HPs 
were co-labeled for APOL1 and endosomal/lysomal markers to delineate route of APOL1.
Results: G0/HPs, G1/HPs and G2/HPs displayed greater number of autophagosomes 
when compared to Vec/HPs. Protein blots of G1/HPs and G2/HPs demonstrated enhanced 
expression of LC3II and beclin-1 and thus indicating enhancement of initiation of 
autophagy. Protein blots of G1 and G2/HPs also displayed enhanced expressin of p62, which 
indicated that AC did not reach to lysosomes. Additionally, G1/HPs and G2/HPs showe 
attenuated mTOR expression. HIV expression by G1/HPs and G2/HPs further enhanced 
early markers of autophagy but displayed further attenuation of lack AC at lysosomal 
compartment. Co-labeling studies of APOL1 revealed decreased presence of APOL1 in 
lysosomal compartment.
Conclusions: APOL1 risk variants enhance initiation but inhibit terminal phase of 
autophagy both in control and HIV stimulated states.
TH-PO234
Disparate APOL1 Expression in HIV-Associated Nephropathy Reflects 
Podocyte Injury  Xiqian Lan,1 Hongxiu Wen,1 Ashwani Malhotra,1 Karl Leon 
Skorecki,2 Pravin C. Singhal.1  1Medicine, Hofstra North Shore LIJ Medical 
School, Great Neck, NY; 2Medicine, Rambam Health Care Campus, Haifa, Israel.
Background: ApolipoproteinL1 (APOL1) variants G1 and G2 contribute to the higher 
percent of kidney diseases in African Americans. Renal biopsy specimens in patients of 
focal segmental glomerulosclerosis (FSGS) and HIV-associated Nephropathy (HIVAN) 
revealed lower expression of APOL1 by podocytes but higher expression by vascular smooth 
muscle cells (VSMC). The involved mechanisms for disparate expression of APOL1 by two 
different cell types in the affected population is not clear. We hypothesized that modulation 
of APOL1 expression is a marker of ongoing podocyte injury.
Methods: Human odocytes (HPs) and VSMCs were transduced with equal amounts 
of lentivirus (vector, G0, G1, and G2) and cultured for 48 hours. Subsequently, cells were 
evaluated for reactive oxygen species (ROS) generation (DCFDA loading and co-labeling 
with mitotracker green and Red CC1), viability (MTT/Trypan blue assays), apoptosis, 
and necrosis (morphologic assay by staining with H33342 and propidium iodide). VSMC 
proliferation was determined by cell counting and labeling for PCNA. In parallel sets of 
experiments, APOL1 expression in these cells was quantified by Western blotting analysis.
Results: Compared to Vector and G0, HPs expressing G1 and G2 displayed higher 
rates of ROS generation, enhanced loss of cell viability, greater number of apoptosed and 
necrosed cells. HPs transduced with G1 and G2 displayed lower expression of APOL1 
when compared to G0. VSMCs transduced with G0, G1, and G2 displayed comparable 
expression of APOL1 expression. VSMCs transduced with either G0 or G1/G2 displayed 
minimal loss of viability, number of apoptosed or necrosed cells, but they displayed greater 
number of proliferating cells when compared to Vector transdueced HPs.
Conclusions: APOL1 variants expressing podocytes experience higher degree of 
oxidative stress but display lower APOL1 expression. On the other hand, VSMCs expressing 
G1 and G2 experience lesser degree of injury when compared to vector transduced 
VSMCs.These findings suggest that APOL1 expression by podocytes may be a marker 
of ongoing stress.
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A Soluble Guanylate Cyclase Activator Is Superior to a Phosphodiesterase 
Type 5 Inhibitor and a Soluble Guanylate Cyclase Stimulator in Protecting 
from Diabetic Nephropathy in the ZSF1 Rat  Kathleen A. Lincoln, Paul 
Harrison, Hongxing Chen, Hong Wang, Holly Clifford, Hu Sheng Qian, 
Diane Wong, Christopher Sarko, Ryan M. Fryer, Jeremy G. Richman, Glenn 
A. Reinhart, Steven S. Pullen, Carine Boustany.  Cardiometabolic Disease 
Research, Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT.
Background: Therapies which restore cyclic GMP (cGMP) levels within the kidney 
are hypothesized to slow disease progression. We evaluated the effects of BI703704, a 
soluble guanylate cyclase (sGC) activator, EX76637; a sGC stimulator, and EX77619; 
a phosphodiesterase type 5 (PDE5) inhibitor, on the progression of diabetic nephropathy 
in obese ZSF1 rats.
Methods: Male ZSF1 rats, implanted with telemetry devices, were treated with either 
BI703704 at 2 mg/kg, EX76637 at 1 or 3 mg/kg , EX77619 at 5 or 15 mg/kg for 10 weeks, 
during which mean arterial pressure (MAP) and urinary protein excretion (UPE) were 
determined. At study end, glomerular and renal interstitial lesions were assessed. Alpha 
smooth muscle actin (α-SMA, a marker of myofibroblast activation) and p-57 (a marker 
of podocyte health) were determined by immunohistochemistry. Renal cGMP levels were 
quantified as a measure of target engagement.
Results: By Week 10, similar reductions in MAP were achieved (~8mmHg) across 
treatment groups vs. vehicle. In parallel, sGC activation resulted in significant reductions 
in UPE (-31% vs veh), while there was no significant effect of EX76637 (+4% at 1 mg/
kg ; -16 % at 3 mg/kg vs veh), or EX77619 (-15% at 5 mg/kg; -9% at 15 mg/kg vs veh). 
Importantly, BI703704’s effects on UPE were accompanied by reductions in the incidence 
of glomerulosclerosis (-21% vs veh), while neither EX76637 nor EX77619 were effective. 
In addition, interstitial lesions were modestly reduced by BI703704 (-13 % vs veh) and 
EX77619 (-18% vs veh). α-SMA was reduced by BI703704 (-27% vs veh) and EX76637 
(-8% vs veh), while P57 was significantly increased by BI703704 (+11% vs veh) but not 
by EX76637 or EX77619. Importantly, target engagement was confirmed for EX77619.
Conclusions: Despite similar effects on MAP, BI703704 was superior to EX76637 or 
EX77619 in reducing proteinuria and preventing renal damage in kidneys of ZSF1 rats.
Funding: Pharmaceutical Company Support - Boehringer-Ingelheim Pharmaceuticals
TH-PO236
Localization of Phosphodiesterase 4 Isoforms in the Renal Cortex 
Xianzhong Lau, Yuan Zhang, Darren J. Kelly, Robyn G. Langham.  Dept of 
Medicine St 9incent¶s, Univ of Melbourne, Melbourne, 9ictoria, Australia.
Background: There are limited therapeutic options for the treatment of chronic kidney 
disease (CKD). Our recent studies have found that Phosphodiesterase 4 (PDE4) inhibitor 
roflumilast (RFL) was effective in attenuating renal decline in subtotal nephrectomized 
(STNx) rats, a model of CKD, indicating that PDE4 inhibition is may be effective in 
treating CKD. There have been studies on the contribution of cAMP hydrolysis by PDE4 
in nephron segments and the mRNA expression distribution of PDE4 isoforms in several 
cultured renal cells. However, the localization of PDE4 isoforms in the kidney has yet to 
be explored. Hence, we sought to investigate the distribution of PDE4 isoforms in the renal 
cortex, as it may also elucidate the renal cell types that RFL targets.
Methods: Sprague-Dawley rats underwent either STNx or sham surgery, further 
randomized after 2 weeks to receive an oral dose of either RFL (1 mg/kg/day) or vehicle, 
and sacrificed at 12 weeks. PDE4 isoforms (PDE4A, PDE4B, PDE4C) were localized 
with immunohistochemistry. Immunofluorescence was used to co-localize PDE4 isoforms 
with podocytes.
Results: The distribution pattern for each PDE4 isoform was distinct. However, 
positive staining was mainly localized on the podocytes in the glomerulus (for PDE4A, 
PDE4B and PDE4C) and distal tubules and in tubulointerstitium (for PDE4A and PDE4C). 
In the STNx group, positive staining on the podocytes was significantly more intense than 
the sham group. RFL treatment significantly reduced the elevated expression of PDE4 
isoforms in the podocytes. 
PDE4 Isoform Sham Sham+RFL STNx STNx+RFL
PDE4A 3.22±0.49 2.84±0.64 11.38±0.88**** 8.44±1.30***
PDE4B 0.38±0.18 0.50±0.17 8.75±1.50**** 5.49±1.21** 
PDE4C 2.17±0.31 2.63±0.25 12.44±1.86**** 8.01±0.87**
Conclusions: PDE4 isoforms are distributed throughout the renal cortex, especially 
in the podocytes and distal tubules. During CKD, the expression of PDE4 isoforms in 
the podocytes increases. As the reduction in PDE4 expression with RFL treatment was 
associated with the attenuation of renal decline, PDE4 inhibition may be especially relevant 
in preserving podocyte health.
Funding: Government Support - Non-U.S.
TH-PO237
The Glomerular Parietal Epithelial Cell Phenotype Depends on SPARC 
Levels  Shokichi Naito.  Nephrology, Kitasato Univ School of Medical Sciences, 
Sagamihara, Kanagawa, Japan.
Background: Parietal epithelial cell (PECs) might play a critical role in a glomerular 
repair through their progenitor function. Conversely, PECs might paradoxically contribute 
to the deterioration of glomerular function by augmentation of scarring and crescent 
formation under certain conditions. The factors governing these PEC functions are not 
well understood. We have previously shown that SPARC (secreted protein acidic and 
rich in cysteine) plays a causal role in mediating podocyte detachment and accelerating 
glomerulosclerosis in experimental crescentic glomerulonephritis. However, the effect of 
SPARC levels on PECs is unknown.
Methods: Experimental glomerular disease was induced in aged-matched SPARC+/+ 
and SPARC-/- mice by intraperitoneal injection of a sheep anti-rabbit glomerular antibody. 
Immunostaining methods were then employed on days 0 and 7 of disease.
Results: The number of PEC transition cells, defined as cells co-expressing a PEC 
marker (PAX2), and podocyte marker (Synaptopodin) was higher in diseased SPARC-/- 
mice compared with SPARC+/+ mice  (1.35 ± 0.18 vs. 0.46 ± 0.14, P < 0.01 vs. SPARC+/+ 
mice). WT1 staining along Bowman’s capsule was higher in diseased SPARC-/- mice (2.57 
± 0.30 vs. 1.37 ± 0.30, P < 0.01 vs. SPARC+/+ mice). This observation was accompanied 
by increased PEC proliferation (measured by Ki-67 staining, (4.56 ± 0.46 vs. 2.66 ± 4.99; 
P < 0.01) and an increase in immunostaining for a progenitor marker, neural cell adhesion 
molecule (1.35 ± 0.05 vs. 1.21 ± 0.05, P < 0.05 vs. SPARC+/+ mice), in a subpopulation of 
PECs in diseased SPRAC-/- mice.
Conclusions: PECs have the potential to become glomerular epithelial transition 
cells. SPARC expression in PECs favors a decrease in the number of PEC transition cells.
TH-PO238
Low Dose Hydralazine Augments Losartan Mediated Reversal of Epigenetic 
Alterations in Diabetic Nephropathy (DN)  Himanshu Vashistha,1 Nirupama 
Chandel,2 Xiqian Lan,2 Anjali Maheshwari,2 Nairuti H. Shah,2 Ashwani 
Malhotra,2 Leonard G. Meggs,1 Pravin C. Singhal.2  1Medicine, Ochsner Health 
System, NeZ 2rleans, LA; 2Medicine, Hofstra North Shore LIJ Medical School, 
Great Neck, NY.
Background: Epigenetics has been demonstrated to play a role in the development 
and progression of DN. Recently, we observed that losartan reverses high glucose-induced 
podocyte epigenetic alterations. We now hypothesized that low (non-hypertensive) 
dose hydralazine (HYDZ) will further augment losartan-induced reversal of epigenetic 
alterations in DN.
Methods: Protein blots of renal tissues/renal cortical sections of 2, 4, and 6 month 
old control and Akita mice (n=3) were probed for methylation at histone (H)3 lysine (K)4 
residue, acetylation at H3 lysine (K)9 residue, SNAIL, vitamin D receptor (VDR), and 
nephrin. In vitro studies, protein blots of control and high glucose (30 mM, HG) treated 
human podocytes (HPs) were probed for SNAIL, VDR, nephrin, H3K4me3, H3K9ac and 
actin. Podocyte VDR and nephrin gene methylation status (pyrosequencing)and SNAIL 
binding at VDR and nephrin promoter (ChIP assay) were determined. Control and Akita 
mice (n=4) were treated with losartan with/without HYDZ (10 mg/kg/day, 4 weeks) followed 
by evaluation of proteinuria and renal epigenetic alterations.
Results: Protein blots of renal tissues of Akita mice displayed enhanced expression 
of SNAIL and H3K4me3 but down regulation of VDR and nephrin. Podocytes in renal 
cortical sections also displayed similar profile; losartan not only decreased proteinuria but 
also partially reversed epigenetic alterations and associated SNAIL, VDR and nephrin 
expressions; HYDZ alone has similar effects on proteinuria and epigenetic markers and 
further augmented these effects when combined with losartan. HG/HPs displayed enhanced 
expression of SNAIL and H3K4me3 and attenuated expression of VDR, nephrin, and 
H3K9ac. Both nephrin and VDR displayed more than 70% cytosine methylation. HG/HP 
displayed deacetylation of nephrin and degradation via ubiquitation. ChIP assay revealed 
binding of SNAIL at VDR and nephrin promoter.
Conclusions: Optimal reversal of epigenetic alterations can be used as a therapeutic 
strategy in DN.
TH-PO239
Klotho Ameliorates Proteinuria by Targeting TRPC6 Channels in Podocytes 
Jian Xie,2 Ji-Hee Kim,1 Kyu-Hee Hwang,1 Yueh-lin Wu,2 Noelynn Oliver,3 
Chou-Long Huang,2 Seung-Kuy Cha.1  1Wonju College of Medicine, Yonsei Univ, 
Wonju, Korea; 2Dept of Medicine, UT Southwestern Medical Center, Dallas, 
TX; 3Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.
Background: Klotho is a type-1 membrane protein mainly produced in the kidney 
tubules. The extracellular domain of klotho is secreted into extracellular space. Whether 
klotho is expressed in podocytes and whether and how it may protect the glomerular filter 
are unknown.
Methods: TRPC6-mediated Ca2+ influx, cytoskeletal remodeling, and transepithelial 
albumin flux were studied in cultured mouse podocytes. Klotho expression in cultured 
podocytes and the kidney was examined by immunostaining, in situ hybridization, and 
RNA sequencing. Effects of klotho on albuminuria were studied using mouse models with 
genetically altered expression of TRPC6 and klotho.
Results: Recombinant secreted soluble klotho suppressed ATP-stimulated, TRPC6-
mediated Ca2+ influx in cultured mouse podocytes. Cytoprotection by klotho on cultured 
podocytes is supported by the reduction in ATP-stimulated actin cytoskeletal remodeling 
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and transepithelial albumin leakage. Overexpression of TRPC6 by gene delivery in mice 
induced albuminuria, and exogenous administration of soluble klotho ameliorated the 
albuminuria. Heterozygous klotho-deficient sham-operated mice had no basal albuminuria 
vs WT sham mice, but het-klotho chronic kidney disease (CKD) mice had aggravated 
albuminuria compared to that in WT CKD mice with a similar degree of hypertension and 
reduced clearance function. Klotho is expressed in podocytes of mouse and human kidney. 
Disrupting the integrity of glomerular filter increased urinary excretion of soluble klotho.
Conclusions: Klotho protects podocytes from injury by suppressing TRPC6-mediated 
Ca2+ entry. Cytoprotection of podocytes in the native state may be through membranous 
klotho present on podocyte cell surface or soluble klotho present in Bowman’s space. 
Soluble klotho may be a treatment for proteinuria.
Funding: NIDDK Support, Government Support - Non-U.S.
TH-PO240
Aminopeptidase A Is Up-Regulated in the Intact Areas of Segmentally 
Sclerotic Glomeruli in Advanced Focal Segmental Glomerulosclerosis 
Juan Carlos Q. Velez, Michael G. Janech, Wayne R. Fitzgibbon.  Div of 
Nephrology, Medical Univ of South Carolina, Charleston, SC.
Background: Angiotensin (Ang) II is involved in the pathogenesis of focal segmental 
glomerulosclerosis (FSGS). We hypothesized that FSGS may be associated with adaptive 
changes in glomerular expression of Ang-metabolizing peptidases.
Methods: Using fawn-hooded hypertensive (FHH) rats as a model of FSGS, we 
examined the pattern of glomerular expression of Ang converting enzyme (ACE) and 
the robust Ang II-cleaving enzyme aminopeptidase A (APA) by Western blot (WB) and 
immunohistochemistry (IHC).
Results: ACE was absent in glomeruli by both WB and IHC. Overall expression of APA 
in glomerular extracts was found to gradually decrease over time, with 87% reduction at 60 
weeks compared to 6 weeks of age (p<0.0001). Glomerular extracts from 30 week-old FHH 
rats had lower APA expression and lower APA activity compared to age-matched Wistar rats 
(p<0.05). By IHC, 60-week kidneys showed loss of glomerular APA in globally sclerotic 
glomeruli as well as on the sclerosed area of the segmentally sclerotic glomeruli. On the 
other hand, the “surviving” intact areas within the segmentally sclerotic glomeruli as well 
as some normal-appearing glomeruli exhibited a markedly accentuated APA expression. In 
contrast, the podocyte marker GLEPP1 was not only absent in all sclerotic areas but also 
attenuated in the intact areas within the segmentally sclerotic glomeruli and in normal-
appearing glomeruli, suggesting that APA increases during the late response phase to 
podocyte injury. To determine whether the APA augmentation corresponded to a feedback 
response to Ang II, cultured mouse podocytes were incubated with Ang II (100 nM) for 
24-72 hours. No change in APA abundance was observed, nor could APA abundance be 
induced by infusing Ang II in 8-week FHH rats for 4 weeks.
Conclusions: In conclusion, podocyte-localized APA is up-regulated in the “surviving” 
non-sclerosed segmental areas in glomeruli of FHH rats. However, the mechanism of 
up-regulation does not appear to be directly mediated by Ang II. Understanding the 
mechanism of APA up-regulation may provide tools to enhance the actions of a potentially 
renoprotective peptidase.
Funding: Private Foundation Support
TH-PO241
Anti-VEGF Treatment by Transfection of the Natural Inhibitor sFlt-1 
Increases Albuminuria in Type 1 Diabetic Mice  Pascal Bus, Jan A. Bruijn, 
Hans J. Baelde.  Dept of Pathology, Leiden Univ Medical Center, Leiden, Zuid-
Holland, Netherlands.
Background: It has been shown that VEGF-A is involved in diabetic nephropathy (DN). 
In diabetic mice, treatment with anti-VEGF antibodies reduced glomerular hypertrophy. 
On the other hand, women with pre-eclampsia develop proteinuria due to increased levels 
of soluble Flt-1 (sFlt-1) – a natural inhibitor of VEGF-A. In this study we investigated 
the effects of systemic VEGF-A inhibition by sFlt-1 transfection in type 1 diabetic mice.
Methods: Diabetic mice were transfected with an sFlt-1 construct at the onset of 
diabetes. After five weeks of treatment mice were sacrificed. Collection of urine and blood 
was performed at baseline, and week 1, 3, and 5. Albuminuria was measured using Rocket 
Electrophoresis. Kidneys were sectioned and stained for PAS, FA-11 (macrophages) and 
WT1 (podocytes). Glomerular hypertrophy was measured using Philips Digital Pathology 
Solutions. One-way ANOVA was performed to measure differences between the groups. 
Differences with a probability level (P) < 0.05 were considered statistically significant.
Results: Diabetic mice transfected with sFlt-1 had higher albuminuria levels than mice 
with diabetes alone (p<0.05). However, glomerular hypertrophy as well as the number of 
glomerular macrophages were reduced in the treated group (p<0.05). No effect on podocyte 
numbers was observed.
Conclusions: In contrast to other studies investigating VEGF-A, we reduced VEGF 
levels with the use of a natural inhibitor. In line with previous findings we showed that sFlt-1 
treatment reduced glomerular hypertrophy in diabetic mice. In addition, sFlt-1 treatment 
resulted in higher albumin levels in diabetic mice. These results show that treatment for 
reducing VEGF-A levels has to be performed with care since treatment has both beneficial 
and detrimental effects.
TH-PO242
Apolipoprotein C1 Transgenic Mice Develop Gomerulosclerosis: A Potential 
Role for Macrophages  Pascal Bus,1 Rosalie Bor,1 Jimmy F. P. Berbée,2 Jan 
A. Bruijn,1 Emile De Heer,1 Hans J. Baelde.1  1Dept of Pathology, Leiden Univ 
Medical Center, Leiden, Zuid-Holland, Netherlands; 2Dept of Medicine, Div of 
(ndocrinology, Leiden Univ Medical Center, Leiden, Zuid-Holland, Netherlands.
Background: Associations between an APOC1 polymorphism and the development 
of diabetic nephropathy (DN) have been identified and confirmed in several meta-analyses. 
In addition, patients with type 1 and type 2 diabetes have higher serum levels of APOC1 
compared to healthy control subjects. APOC1 transgenic (APOC1tg) mice develop 
albuminuria and glomerulosclerosis at 15 months of age. In this study we investigated the 
role of macrophages in APOC1 induced glomerulosclerosis in APOC1tg mice.
Methods: APOC1tg and wild-type (WT) mice were sacrificed at various ages. Kidneys 
were sectioned and stained for APOC1, F4/80 (macrophages), CD11b (M1 macrophages), 
CD163 (M2 Macrophages) and TNF-alpha. RT-PCR was performed to measure APOC1 
mRNA levels. To confirm data from APOC1tg mice, human autopsied kidneys with DN 
and healthy controls were included, sectioned and stained for APOC1. Correlations were 
assessed using the Pearson’s correlation test.
Results: In APOC1tg mice, the number of glomerular macrophages were already 
increased at 15 weeks of age, long before the development of glomerular damage, and 
increased even further in time. A strong linear correlation was found between the number 
of glomerular macrophages and glomerular damage (p<0.001). These macrophages were 
found to be of the M1 type and expressed high amounts of APOC1 and TNF-alpha. In 
patients with DN, glomerular APOC1 expression was significantly increased compared to 
healthy control subjects.
Conclusions: Both our mice and our human autopsied data indicate that APOC1 
could play a crucial role in the development of glomerular damage. We hypothesize that 
APOC1-expression by macrophages causes glomerular damage, potentially by increasing 
the inflammatory state of these macrophages.
TH-PO243
Decreased Renal α-Klotho Expression Is Associated with Urinary Calcium 
Excretion in Early Diabetic Nephropathy in db/db Mice  Kyung don Ju, 
Tsogbadrakh Bodokhsuren Bodokhsuren, Hyo Jin Kim, Seungmi Lee, Miseon 
Park, Curie Ahn, Kook-Hwan Oh.  Div of Nephrology, Dept of Internal Medicine, 
Seoul National Univ Hospital, Seoul, Republic of Korea.
Background: Hypercalciuria is one of the early manifestations of diabetic nephropathy 
(DN). We surveyed the role of α-Klotho, a protein expressed predominantly in the distal 
tubules (DTs). α-Klotho is known to up-regulate transient receptor potential vanilloid type 
5 (TRPV5) expression, involved in tubular calcium reabsorption.
Methods: We used db/db mice, a type II diabetes mellitus (DM) model. We employed 
puromycin aminonucleoside (PAN)-induced nephrotic mice and db/m mice for control. 
PAN mice was induced by injecting 150 mg/kg PAN intraperitoneally for every 2 weeks.
Results: Animals were sacrificed at the age of 15th week. At 15th week, db/db mice 
and PAN mice developed albuminuria (218 ± 33 mg/day and 68 ± 9 mg/day, respectively), 
while db/m mice were normoalbuminuric (14 ± 3 mg/day). Urinary calcium excretion 
(UCa/UCr) significantly increased in db/db mice (0.91 ± 0.09 mg/mg Cr), compared to 
PAN (0.30 ± 0.02 mg/mg Cr) or db/m mice (0.29 ± 0.03 mg/mg Cr). mRNA and protein 
expression levels of α-Klotho in the distal tubule were markedly ameliorated. Urinary klotho 
concentration (UKL/UCr) was significantly decreased in db/db mice (1.45 ± 0.02 fM/mg 
Cr) compared to PAN (10.77 ± 3.01 fM/mg Cr) or db/m mice (6.39 ± 0.40 fM/mg Cr). By 
immunohistochemistry and immunofluorescence staining, we also confirmed reductions 
of renal α-Klotho, FGF receptor type 1 (FGFR1) and TRPV5 expressions in db/db mice.
Conclusions: Thus, renal loss of α-Klotho may affect urinary calcium excretion via 
inhibition of TRPV5 expression in DTs in early diabetic nephropathy.
TH-PO244
NF-κB System Inhibition Attenuates Renal Injury in Diabetic Nephropathy 
Orestes Foresto-Neto, Amanda H. Albino, Simone CA Arias, Lisienny CT 
Rempel, Gizely CS Moreira, Victor F. Avila, Viviane D. Faustino, Camilla 
Fanelli, Claudia R. Sena, Vivian L. Viana, Denise M. Malheiros, Niels OS 
Camara, Clarice K. Fujihara, Roberto Zatz.  Univ of Sao Paulo, Brazil.
Background: The NF-κB system may be involved in the pathogenesis of 
diabetic nephropathy (DN). We investigated whether NF-κB inhibition with 
pyrrolidinedithiocarbamate (PDTC) exerts renoprotection in experimental DN.
Methods: Diabetes was induced in 27 adult male Munich-Wistar rats through 
streptozotocin injection (65 mg/kg, iv) and maintained moderately hyperglycemic with 
daily insulin. Rats were divided in untreated (DM) and PDTC-treated, 60 mg/kg/day vo 
(DM+PDTC). Untreated nondiabetic rats (C, n=12) were also followed. Body weight 
(BW, g), blood glucose (BG, mg/dL), tail-cuff pressure (TCP, mmHg), urinary albumin/
creatinine ratio (Ualb/Ucr), kidney/body weight ratio (KW/BW), % glomerular sclerosis 
(%GS), interstitial and glomerular macrophage infiltration (intMØ and glomMØ, cells/mm2) 
and % glomerular zonula occludens (ZO-1, %) were assessed after 12 months of follow-up.
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Results: 
C DM+V DM+PDTC
BW 408±9 335±5a 335±3a
BG 98±2 378±24a 386±7a
TCP 135±3 134±2 131±2
Ualb/Ucr 1.5±0.2 5.1±1.2a 1.3±0.3b
KW/BW 0.49±0.01 0.72±0.01a 0.64±0.02ab
%GS 2.6±0.4 7.9±1.9a 2.1±0.7b
intMØ 57±6 85±8a 45±5b
glomM 16±3 54±15a 33±10b
ZO-1 77±1 61±2a 75±2b
Mean±SE. ap<0.05 vs C; bp<0.05 vs DM+V.
After 12 mo, untreated DM rats exhibited high Ualb/Ucr, renal hypertrophy, high %GS, 
intMØ and glomMØ, and loss of %ZO-1, without changes in TCP. Treatment with PDTC 
attenuated renal hypertrophy and prevented the increase in Ualb/Ucr, %GS, intMØ and 
glomMØ, and the loss of ZO-1, without interfering with BG or TCP.
Conclusions: PDTC exerts a renoprotective effect on the progress of DN in diabetic 
rats, suggesting the involvement of the NF-κB system in the pathogenesis of the disease 
and the possibility that this system becomes a therapeutic target. The beneficial effects of 
PDTC may also be the result of an antioxidant effect of the drug. FAPESP/CNPq.
TH-PO245
Renin Accelerates Progression of HIVAN-Associated Nephropathy (HIVAN) 
Through Kidney Cell HIV Gene Expression  Partab Rai, Rivka Lederman, 
Shabirul Haque, Ashwani Malhotra, Pravin C. Singhal.  Medicine, Hofstra North 
Shore LIJ Medical School, Great Neck, NY.
Background: The activation of renin -angiotensin system has been demonstrated 
to play an important role for the development and the progression of HIVAN. However, 
the progression of HIVAN attributed predominantly to Ang II generation by kidney cells. 
Recently, HIV has been demonstrated to stimulate renin generation by kidney cells in 
vitro studies. We hypothesized that HIV-induced kidney cell renin production might also 
be enhancing kidney cell HIV gene expression, which may accelerate progression of renal 
lesions, independent of the effects of Ang II.
Methods: Human podocytes (HPs) were trandudced with either empty vector (EV/
HP) or HIV (NL4-3, HIV/HP). To increase endogenous renin production, EV/HPs and 
HIV/HPs were transfected with siRNA vitamin D receptor (siRNA-VDR/HIV/HPs) or 
scrambled (Scr-siRNA/HIV/HP) siRNA; protein blots were probed for renin and actin. To 
evaluate the effect of renin in vivo, mRNA expressions of HIV genes from renal tissues 
of HIVAN (Tg26) mice with high endogenous renin (Tg26 mice either with 2, 3 and 4 
copies of angiotensinogen [Agt] or lacking VDR) were quantified by qPCR. To down 
regulate renal tissue renin expression, Tg26 mice were treated with either vehicle or a VDR 
agonist (VDA) for 2 weeks and then renal tissues were evaluated for HIV gene expression. 
Additionally, gene expression and progression of renal lesions were compared in Tg26 
mice and Tg26 mice lacking renin.
Results: HIV enhanced renin expression in HPs. Silencing of VDR in HIV/HPs further 
enhanced expression of Nef, Tat, and Vif. On the other hand, treatment of HIV/HPs with 
VDA downregulated HIV gene expression. Renal tissues of Tg26-Agt-4 displayed 2-4 fold 
increase in mRNA expression of gp120, Vpr, Tat, Nef and Vpu vs. Tg26-Agt-2. Similarly, 
Tg26 mice lacking VDR displayed greater HIV gene expression when compared with Tg26 
mice with intact VDR. VDA treatment of Tg26 also down regulated renal tissue expressions 
of renin as well of HIV genes. Tg26 mice lacking renin, displayed attenuated renal tissue 
HIV gene expression and slowed progression of renal lesions.
Conclusions: Renin enhances progression of HIVAN through HIV gene expression.
TH-PO246
Podocyte and Tubule Injury Have Different Effects on Renal Handling of 
Apolipoprotein A-I (ApoA-I) and Its Receptors  Jianyong Zhong,1,2 Haichun 
Yang,2 Yohei Tsuchida,1 Taiji Matsusaka,3 Agnes B. Fogo,2 Valentina Kon.1 
1Pediatric Nephrology, Vanderbilt; 2Pathology, Microbiology and Immunology, 
Vanderbilt Univ, Nashville, TN; 3Dept of Molecular Life Science, Tokai Univ 
School, Isehara-shi, Kanagawa, Japan.
Background: CKD disrupts HDL composition and function. ApoA-I, the major 
lipoprotein of HDL, modulates many of its beneficial effects. To determine how injury 
affects renal handling of ApoA-I, we studied tubule- and podocyte-specific injury models.
Methods: Diphtheria toxin transgenic mice (DT) express human DT receptor in 
proximal tubular epithelial cells and DT injection causes acute tubule necrosis. Folic acid 
injury induces crystal formation in distal nephron and distal tubule necrosis. Nphs1-hCD25 
transgenic mice (NEP25) express human CD25 in podocytes which can be injured by 
injection of immunotoxin, LMB2.
Results: Compared to baseline (W0), DT increased urinary KIM-1 and doubled ApoA-I 
at week 2 (W2 18580±1543 vs. W0 10319±2641 ng/mg, p<0.05). Folic acid caused greater 
increase in Ngal than KIM-1, consistent with distal but not proximal injury with no change 
in urinary apoA-I or albuminuria. Low dose LMB2 induced edema and albuminuria. 
Urinary apoA-I increased >10-fold at W2 and remained elevated at W6 (>7-fold) although 
albuminuria normalized. High dose LMB2 reduced GFR, caused glomerulosclerosis, and 
increased apoA-I excretion 1400-fold.
In DT, proximal tubule expression of cubilin was reduced and ApoA-I localized 
to the apical side. By contrast, low-dose LMB2 stimulated cubilin expression without 
changing ApoA-I localization. Neither injury affected abundance or localization of ApoA-I 
transporters. High dose LMB2 not only increased cubilin expression but translocated 
ApoA-I to the cytoplasm of tubular cells and to peritubular capillaries. ABCA1, but not 
G1 or SRBI, translocated from the apical membrane to cytoplasm of parietal and proximal 
tubule epithelial cells.
Conclusions: Renal handling of ApoA-I is determined by the glomerular filtration 
barrier and proximal, but not distal, tubules through mechanisms that involve cubilin and 
ABCA1. Podocyte injury increases ApoA-I in glomerular filtrate and may be a sensitive 
marker of injury to the glomerular filtration barrier.
Funding: Other NIH Support - NHLBI
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Increased Toxicity of APOL1 Kidney Risk Variants Is Not due to Decreased 
VAMP8 Binding  Patrick D. Dummer,1 Alison Hickman,1 Jurgen Heymann,1 
Michael Kruhlak,2 Katalin Susztak,3 Cheryl Ann Winkler,2 Jeffrey B. Kopp.1 
1NIDDK, Bethesda, MD; 2NCI, Bethesda, MD; 3Univ of Pennsylvania, 
Philadelphia, PA.
Background: Developing effective therapies for APOL1 nephropathies will require 
insights into the mechanisms of APOL1-associated cell damage. Disease-associated G1 and 
G2 mutations in the C-terminus of APOL1 increase toxicity through lysosomal membrane 
permeability (LMP). Vesicle-associated membrane protein (VAMP) 8, a lysosomal soluble 
NSF attachment protein receptor (SNARE), has been proposed to inhibit APOL1 function 
by binding the C terminus, with the G1 and G2 mutations decreasing affinity compared 
to the ancestral G0 variant.
Methods: GFP-LC3 (autophagosome marker), GFP-SNAREs (to monitor vesicle 
trafficking), and His6-, GFP-, and mCherry-tagged APOL1-A isoform were expressed by 
transient co-transfection of HeLa and HEK293 cells. Autophagy was assessed by microscopy 
using GFP-LC3. Endoplasmic reticulum (ER) stress was measured by Western blot for BiP 
and phospho-PERK. Toxicity was measured by SyTox Blue staining.
Results: APOL1-A G1 and G2 variants increased ER stress and autophagy compared 
to the ancestral G0 variant. All APOL1 variants traffic to Rab7-, LBPA-, and VAMP8-
positive late endosomes and lysosomes. Deletion of the APOL1 C terminus abolished 
APOL1-induced autophagy and toxicity, but not trafficking to lysosomes. APOL1 bound 
all R-SNAREs, with greatest affinity for lysosomal VAMP7 and VAMP8. There were no 
differences in affinity to VAMP8 among the APOL1 variants, and truncation of the APOL1 
C terminus did not abolish the interaction. Co-expression of VAMP8 increased APOL1 
toxicity. A non-toxic APOL1-A protein lacking the N-terminal signal peptide exhibited 
the greatest affinity to VAMP8.
Conclusions: APOL1 G1 and G2 toxicity may not be due to decreased VAMP8 
affinity, as previously proposed. The APOL1 C terminus is required for toxicity but not for 
lysosomal trafficking, suggesting the increased toxicity of APOL1 risk variants is not due 
to altered APOL1 trafficking to lysosomes. Cellular stress pathways beyond LMP, such as 
autophagy and ER stress, may contribute to the increased toxicity of APOL1 risk variants.
Funding: NIDDK Support, Other NIH Support - NCI
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N-Acetylmannosamine Mitigates Neuraminidase-Induced Podocyte Injury 
in Mice  Marjan Huizing,1 Obiageri Okafor,1 Patricia M. Zerfas,2 Steven 
Bodine,1 Matthew F. Starost,2 A. Rosenberg,3 William A. Gahl,1 Jeffrey B. 
Kopp,3 May christine V. Malicdan.1  1Medical Genetics Branch, NHGRI, NIH; 
22ffice of Research Services, 2D, NIH; 3Kidney Disease Section, NIDDK, NIH, 
Bethesda, MD.
Background: Podocyte injury is present in many glomerular diseases. Current therapies 
do not achieve sustained remissions and often have adverse events. Recent findings suggest 
that a subset of patients with glomerular disease may have ongoing desialylation or impaired 
resialylation of certain renal glycans (glycoproteins and glycolipids), as detected by lectin 
histochemistry.
Methods: We induced podocyte injury in mice by a single intraperitoneal injection 
of Vibrio cholera neuraminidase (NA), an enzyme that removes a2,6 linked sialic acid 
end-groups from glycans. The sialic acid precursor N-acetylmannosamine (ManNAc) 
was administered in drinking water at a ~1 g/kg/d dose, either prophylactic (starting 10 
days prior to NA and continued for 5 days), or therapeutic (starting 12 hours after NA and 
continued for 4.5 days).
Results: NA-injected wild type mice developed proteinuria and renal insufficiency in 
a dose-dependent manner. Podocalyxin and other glomerular glycans were hyposialylated. 
Histopathology showed acute renal injury predominantly in the cortical region, swollen 
podocytes, and glomerular mesangial cell hyperplasia and hypertrophy. Ultrastructural 
studies showed podocyte foot process effacement. Importantly, both prophylactic and 
therapeutic ManNAc treatments increased renal glycan sialylation and markedly reduced 
urine albumin/creatinine ratio (ACR) and podocyte injury at Day 5 (N=14 per group). 
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Neuraminidase Treatment ACR Day 0.5 ACR Day 5
- None 41 ± 26 72 ± 36
+ None 1860 ± 840 485 ± 90
+ Prophylactic ManNAc 2087 ± 1840 85 ± 66*
+ Therapeutic ManNAc 3078 ± 2510 150 ± 72*
* P<0.05 compared to NA with no treatment 
Conclusions: ManNAc holds promise to mitigate hyposialylation-related disease 
mechanisms of glomerular diseases; ManNAc has minimal toxicity and is orally 
administered. ManNAc is currently tested in a Phase 2 clinical trial for the rare 
hyposialylation disorder GNE myopathy. We plan a Phase 1 clinical trial of ManNAc in 
patients with glomerular diseases.
Funding: NIDDK Support, Other NIH Support - NHGRI
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A Mismatch Between Glomerular Volume and Podocyte Mass Is Associated 
with Albuminuria and Accelerated Podocyte Hypertrophic Injury in Leptin-
Deficient Zucker Rats  Akihiro Fukuda,1 Yuji Sato,1 Takashi Iwakiri,1 Kazuo 
Kitamura,1 Roger C. Wiggins,2 Shouichi Fujimoto.1  1First Dept of Internal 
Medicine, Univ of Miyazaki, Miyazaki, Japan; 2Nephrology Div, Dept of Internal 
Medicine, Univ of Michigan, Ann Arbor, MI.
Background: Glomerular hypertrophy is a well-established component of diabetic 
nephropathy. We previously reported that failure of podocytes to match glomerular tuft 
enlargement (in response to growth signaling through the mTORC1 pathway) can trigger 
proteinuria, glomerulosclerosis and progression to end stage renal disease in dominant 
negative AA-4E-BP1 Tg rat model. We therefore tested the hypothesis that a mismatch 
between glomerular volume and podocyte mass causes progression of diabetic nephropathy.
Methods: We used the leptin-deficient Zucker Diabetic Fatty (ZDF-fatty) rat model 
of type 2 diabetes compared with heterozygous ZDF rats as a control. Glomerular volume 
and podocyte number per tuft, density (podocyte number per glomerular tuft volume), mass 
(Glepp1 positive volume) and the urine podocin:aquaporin2 mRNA ratio were measured. 
Rats were evaluated over a 45 week time-course.
Results: ZDF-fatty rats gained weight much faster than control rats over the first 15 
weeks, but did not become hypertensive over the study period. ZDF-fatty rats became 
diabetic with increased blood glucose and glycosuria by 10 weeks. Albuminuria and urine 
podocin:aquaporin2 mRNA ratio were also significantly increased by 10 weeks. Sequential 
kidney biopsies at 15, 30, and 45 weeks revealed that by 15 weeks glomerular volume 
was already significantly increased above control (1.5-fold, P<0.01) and podocyte density 
was significantly reduced (P<0.01), although podocyte number per tuft was not detectably 
decreased. By 45 weeks glomerulosclerosis was present and the Glepp1 peroxidase positive 
podocyte tuft area was significantly reduced in the ZDF-fatty rats but not in controls.
Conclusions: These data indicate that a mismatch between glomerular volume and 
podocyte mass (reduced podocyte density) is associated with development of albuminuria 
and accelerated podocyte hypertrophic stress in this model of type 2 diabetes, compatible 
with data previously reported in Pima Indians.
TH-PO250
An ER Stress-Regulated Transcript Hosting a MicroRNA Megacluster as 
Therapeutic Target in the Early Stage of Diabetic Nephropathy  Mitsuo Kato, 
Mei Wang, Zhuo Chen, Supriya Deshpande, Kirti Bhatt, Hyung Jung Oh, Linda 
L. Lanting, Rama Natarajan.  Beckman Research Inst, City of Hope, Duarte, CA.
Background: microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have 
important roles in the pathogenesis of diabetic nephropathy (DN). We observed that the 
miR-379 megacluster (MGC, ~40 miRNAs) and its host transcript lncRNA (lncMGC) 
were upregulated in glomeruli of streptozotocin (STZ)-injected diabetic mice through the 
ER-stress induced transcription factor, CHOP.  Targets of the MGC miRNAs had functions 
related to DN. We hypothesized that lncMGC may be a therapeutic target in early DN to 
prevent progression.
Methods: The expression of cluster miRNAs, lncMGC, miRNA targets and profibrotic 
genes, and early features of DN [glomerular hypertrophy, extracellular matrix (ECM) 
accumulation] were examined in STZ-injected diabetic CHOP knockout (KO) mice, and 
also in diabetic mice injected with GapmeRs (LNA–modified antisense oligonucleotides) 
targeting lncMGC. These parameters were also examined in human mesangial cells (HMC) 
transfected with GapmeR targeting human lncMGC.
Results: Key miR-379 cluster miRNAs, lncMGC and profibrotic genes were decreased, 
whereas targets of miR-379 cluster miRNAs were increased in glomeruli of diabetic CHOP 
KO mice compared to wild type. Glomerular hypertrophy and ECM accumulation were 
ameliorated in diabetic CHOP KO mice. GapmeR targeting lncMGC decreased lncMGC, 
cluster miRNAs and profibrotic genes, and also attenuated glomerular hypertrophy and 
ECM accumulation, but reciprocally upregulated targets of the cluster miRNAs in diabetic 
mice. GapmeR targeting human lncMGC inhibited lncMGC, miR-379 cluster miRNAs and 
profibrotic genes, but upregulated cluster miRNA targets in HMC.
Conclusions: These results demonstrate that a unique ER stress-regulated lncRNA 
and component cluster of miRNAs co-ordinately regulate the expression of several genes 
involved in glomerular hypertrophy and ECM accumulation associated with early DN. 
Furthermore, a single oligonucleotide targeting the host lncRNA was effective in preventing 
these early features of DN, highlighting the GapmeR approach for targeting lncRNAs as 
a novel therapy for DN.
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No Difference in Cytotoxicity of APOL1-G0 or Risk Variants G1 and G2 
John F. O’Toole,1 Sethu M. Madhavan,1 Martha Konieczkowski,1 Yaping Gu,1 
Liping Luo,1 Zhenzhen Wu,1 William P. Schilling,2 Leslie A. Bruggeman,1 
John R. Sedor.1,2  1Medicine, MetroHealth Medical Center, Cleveland, OH; 
2Physiology and Biophysics, Case Western Reserve Univ, Cleveland, OH.
Background: The genetic evidence linking variation in the APOL1 gene to kidney 
disease in ancestral African populations is strong; however, the biological mechanisms that 
underlie the association remain uncertain. Autophagy and cell death has been observed 
after the expression of APOL1 and variant dependent cell death has been reported with 
the transient expression of APOL1. Therefore we sought to examine autophagy and cell 
death for variant dependent effects in stable expression systems.
Methods: Stable tetracycline inducible HEK293 cells were generated for the expression 
of APOL1-G0 (reference), the -G1, and -G2 risk variants. Murine podocytes were isolated 
from transgenic animals expressing human APOL1-G0 or APOL1-G2 under the Nephrin 
promoter and control animals. Autophagy was monitored with biochemical methods and 
three assays of cell death were used; a fluorescent assay, an MTT assay and a clonogenic 
assay.
Results: Three stable HEK293 clones of each genotype were assayed for autophagy 
and cell death after induction of APOL1 with tetracycline. We noted significant variability 
in the kinetics of APOL1 induction between clones, which was not dependent upon APOL1 
genotype. Stable expression of APOL1-G0, -G1, and –G2, all increased autophagic flux 
to a similar degree. The stable expression of all APOL1 genotypes (G0, G1 and G2) 
resulted in cell death in all three assays, without variant dependent differences. Inhibitors 
of autophagy or autosis did not reduce APOL1-G0, -G1, or -G2 induced cell death and 
none of the APOL1s activated the apoptosis effector caspase 3. The expression of APOL1 
in differentiated mouse podocytes did not induce autophagy or cell death.
Conclusions: Stable expression of APOL1 in cell culture leads to cell death and 
autophagy induction in a variant independent manner, but the regulated expression of 
APOL1 in differentiated podocytes does not. The absence of variant dependence of 
autophagy induction or cell death suggest that alternative mechanisms underlie the genetic 
association of APOL1 with kidney disease.
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NGAL Regulates TH17 Immunity in ANCA Vasculitis  Adrian Schreiber,1 
Erik M. Disteldorf,2 Ulf Panzer,2 Ralph Kettritz.1  1Dept of Nephrology and 
Intensive Care Medicine, CVK Charité, Berlin, Germany; 2III. Medizinische 
Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Background: ANCA activate neutrophils and thereby participate in necrotizing 
crescentic glomerulonephritis (NCGN). NGAL is a marker of intrinsic kidney injury 
and is expressed by neutrophils and renal tubular cells. Whether or not NGAL is merely 
a diagnostic marker or participates mechanistically in renal damage is not known. We 
hypothesized that neutrophil NGAL plays a pathogenic role in ANCA NCGN.
Results: Patients with active ANCA disease demonstrated increased NGAL serum 
levels by western blot analysis (47.3±13.1OD) compared to patients in remission (19.4±8.1) 
and healthy controls (2.1±0.4). We then assessed ANCA-activated neutrophils as a potential 
source for upregulated serum NGAL. By ELISA, both PR3-ANCA and MPO-ANCA 
stimulated NGAL release from human neutrophils (887±72 and 961±70ng/ml), whereas 
control IgG induced much lower levels (105±21ng/ml). Mice with anti-MPO-induced 
NCGN demonstrated upregulated NGAL serum levels by ELISA (data not shown).To 
assess the role of neutrophil NGAL in vivo, we used a murine model of anti-MPO induced 
NCGN, where MPO-KO mice were immunized with mMPO and subsequently transplanted 
with either WT- or NGAL-KO bone marrow (BM). NCGN was significantly aggravated in 
mice that received NGAL-KO BM (34.8±6.1% crescents in NGAL-KO versus 13.4±2.8% 
in WT mice). With respect to intrinsic neutrophil function, migration, ROS generation, 
degranulation and apoptosis were similar in NGAL-KO and WT neutrophils. In addition, 
humoral immunity did not differ. In contrast, FACS demonstrated increased T cell immunity 
in NGAL-KO mice: CD4 cells were 28.7±6.1% of renal CD45 cells in NGAL-KO versus 
13.9±0.6% in WT mice, TH17 cells were 21.7±7.6% of renal CD4 cells versus 5.7±1.0%, 
whereas TH1 cells did not differ (14.4±3.8% versus 14.9±1.2% CD4 cells). Furthermore, 
splenocytes from NGAL-KO BM transplanted mice showed increased IL-17 production. 
When WT and NGAL-KO mice were immunized with mMPO, we observed an increased 
percentage of TH1 and TH17 cells in the latter.
Conclusions: Our findings indicate that neutrophil NGAL down-regulates inflammation 
in ANCA-induced NCGN by inhibiting TH17 immunity.
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TH-PO253
Streptococcus mutans Strains with Collagen-Binding Protein May Cause 
IgA-Like Glomerulonephritis in Rats  Taro Misaki,1 Shuhei Naka,2 Ryota 
Nomura,2 Taisuke Isozaki,1 Kazuhiko Nakano.2  1Div of Nephrology, Seirei 
Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan; 2Dept of Pediatric 
Dentistry, Osaka Univ Graduate School of Dentistry, Suita, Osaka, Japan.
Background: The precise pathological mechanisms of IgA nephropathy (IgAN) remain 
unclear. It is known that 10-20% of healthy subjects harbor strains of Streptococcus mutans,a 
known pathogen of dental caries, that possess Cnm, a cell surface collagen-binding protein 
encoded by the cnm gene. Furthermore, it is widely accepted that an association between 
S. mutans with Cnm protein and systemic diseases exists. We previously found that the 
rate of cnm-positive S. mutans organisms isolated in saliva specimens was significantly 
higher in an IgAN group as compared to the controls, and reported those findings atASN 
Kidney Week 2014 and in Clinical and Experimental Nephrology in 2014. The aim of this 
study was to investigate whether nephritis is induced by Cnm-positive S. mutans strains 
inoculated into the oral cavity of a rat model of dental caries.
Methods: Cnm-positive S. mutans strains (JD-17R, JD-52R, JD-74R) were isolated 
from the oral cavities of 3 IgAN patients. Those along with MT8148, a standard oral 
isolate, were inoculated into the oral cavities of 2-week-old Sprague-Dawley rats fed a 
56% sucrose-containing diet and then we confirmed that the strains were harbored in the 
oral cavity of each rat 1 week later. From 10 weeks of age, findings of severe dental caries 
were confirmed in all rats. They were euthanized at 24 weeks of age, then kidney tissues 
were extirpated and stained with PAS, and immunohistochemistry with the IgA antibody 
was performed for histopathological analysis.
Results: Dental caries in nearly all of the rats were found extending to the pulp space, 
which contains nerves and blood vessels. In rats harboring Cnm-positive strains in the 
oral cavity, mesangial cell proliferation was observed and immunochemical staining of 
the IgA antibody was seen in the para-mesangial area. However, no abnormal findings 
were observed in extirpated kidney tissues from rats harboring MT8148 in the oral cavity.
Conclusions: Our results indicate that Cnm-positive S. mutans strains harbored in the 
oral cavity may cause IgA-like glomerulonephritis.
TH-PO254
Prevention of Lupus Nephritis in the BXSB-Yaa Mouse by Metabolic 
Inhibitors  Byron P. Croker,1,2 Derry C. Roopenian,3 Laurence Morel.1 
1Pathology, Immunology and Laboratory Medicine, Univ of Florida, Gainesville, 
FL; 2Pathology and Laboratory Medicine Service, NF/SG 9HS, Gainesville, 
FL; 3The Jackson Laboratory, Bar Harbor, M(.
Background: In a heavily Type II gamma interferon activated model of lupus nephritis 
( LN ) we showed metabolic inhibition by chronic oral combination of 2 deoxyglucose 
(2DG) and metformin (Met) reversed LN. We now show 2DG + Met prevents LN in the 
heavily Type I alpha interferon driven BXSB-Yaa LN.
Methods: Mice were treated chronically with test medications in drinking water. At 
sacrifice blood and tissues were taken for analysis and correlation of renal histopathology 
with a LN classification modeled on the ISN-RPS classification of LN. For clarity of 
presentation, % animals with global proliferative glomerulonephritis (Pg) will be given for 
each treatment group in results. Other animals were classified as normal to mesangiopathic 
LN (data not shown).
Results: 2DG (Pg 0.0%), 2DG + Met (Pg 0.0%) and rapamycin (Pg 0.0%) all showed 
marked reduction in LN. Dichloroacetic acid (Pg 20.0%) and Met (single agent, Pg 40.0%) 
showed moderate but significant reduction of LN compared to disease controls (Pg 76.5%). 
Untreated C57Bl/6 mice were used as a normal (disease free) control (Pg 0.0%). Target 
organ preservation is supported by in vivo and in vitro determination of immunologic and 
metabolic parameters.
Conclusions: This study presents a second model of LN that responds favorably 
to metabolic inhibition and normalization by existing drugs utilized for other clinical 
indications.
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Successful Treatment of a Mesangial Proliferative Glomerulonephritis by 
Foxd1+ Metanephric Mesenchymal Cells  Li Zhang,1 Meiling Jin,1,2 Qing-gang 
Li,1 Guangyan Cai,1 Xiang-Mei Chen.1  1Dept of Nephrology, Chinese PLA 
General Hospital, Chinese PLA Inst of Nephrology, State Key Laboratory of 
Kidney Diseases, National Clinical Research Center for Kidney Diseases; 
2Medical College, NanKai Univ.
Background: This study is aiming to observe the effect of Foxd1+ metanephric 
mesenchymal cells on MsPGN.
Methods: 1.We use Foxd1cre/GFP transgenic mice and Rosa-DTRflox transgenic mice to 
screen target embryonic kidney cells, and isolate Foxd1+ metanephric mesenchymal cells 
by adding diphtheria toxin; 2.We detect Foxd1+ cell proliferation, cell surface markers, and 
osteogenic adipogenic differentiation potential. 3. 24h after establishment of anti-Thy1 
mesangial proliferative glomerulonephritis, Foxd1+ cells were injected vie intravenous, 
and this group was set as group of treatment. We detect renal pathology and renal function 
at different time points on control, model and treatment group. 4.Mesangial cells were 
stimulated by PDGF-BB, we detect the influence of Foxd1+ cells on the proliferation and 
migration of activated mesangial cells.
Results: 1. The results showed that CD90 positive rate was 0.96.05, CD 44 91.11%, 
CD106 96.69, CD34 0.53, CD34 0.53%, CD45 0.35%. After the induction, we found 
that Foxd1+ cells had good osteogenic and adipogenic differentiation capacity. 2.After 
intravenous injection of Foxd1+ cells could improve the pathological changes in the kidney 
and could reduce urinary protein significantly. 3.CCK-8 results showed that Foxd1+ cells 
condition medium could antagonize proliferation of mesangial cells actived by PDGF-
BB from 48 hours. Transwell migration assay results showed that Foxd1+ cells could 
significantly inhibit actived mesangial cell migration.
Conclusions: 1.Foxd1+ metanephric mesenchymal cells could be isolated using 
transgenic mice, and also are proved that they have the characteristics of stem cells. 2.Foxd1+ 
metanephric mesenchymal cells could improve the renal pathological changes in anti-Thy1 
mesangial proliferative glomerulonephritis, and inhibit the activation of mesangial cells.
Funding: Government Support - Non-U.S.
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Beyond HIF1α - Regulatory Genomic Insights into Renal Cell Carcinoma 
Revealed by DNaseI-seq  Shreeram Akilesh.  Pathology, Univ of Washington, 
Seattle, WA.
Background: Clear cell renal cell carcinoma (RCC) is the most common sporadic 
malignancy affecting the kidney. Inactivation of the 9HL tumor suppressor gene and 
subsequent stabilization of the HIF1α transcription factor (TF) is very common in RCC. 
However, it is unclear how HIF1α and the closely related HIF2α (EPAS1) interact with 
each other and other TFs to produce and maintain the RCC phenotype. Here, we delineate 
the regulatory genomic landscape of RCC using DNaseI-seq and define the transcriptional 
regulatory network of RCC.
Methods: Fresh normal human kidney tissue and RCC were disaggregated and cultured 
to generate primary tubular and renal cell carcinoma cultures. These were subjected to 
DNaseI-seq and RNASeq according to established protocols. DNaseI hypersensitivity 
profiling (DNaseI-seq) allows for comprehensive mapping of regulatory DNA at a genomic 
scale and with single nucleotide resolution. Examination of footprinting depth DNaseI-seq 
data identifies DNaseI-protected transcription factor (TF) motifs within the promoter of 
other TFs. Mapping these TF footprints across all TFs with known motifs results in a TF 
interaction network (Cell. 150: 1274-1286). 
Results: Even though HIF1α plays an important role in RCC biogenesis, it does not 
prominently feature in the TF interaction network of RCC. Instead, several other TFs (e.g. 
FOX, CEBP, SMADs nuclear receptors, etc.) interact to control the regulatory network of 
RCC with a relatively minor contribution from HIF2α (EPAS1).
Conclusions: While the HIF transcription factors play an important role in RCC 
oncogenesis, DNaseI-seq reveals that other TFs are responsible for maintaining the RCC 
phenotype. Systematically testing this regulatory circuitry promises to identify novel 
pathways to intervene in the growth of this deadly cancer. These techniques/approaches are 
also being applied to other primary kidney cells such as endothelial cells and podocytes.
Funding: Other NIH Support - NHGRI - 5U54HG007010-03, Private Foundation 
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Uneven Reinnervation After Unilateral Renal Denervation: Afferents 
Dominate Efferents  Kristina Rodionova,1 Franziska Günther,2 Eric 
Grouzmann,5 Michael J.m. Fischer,2 Sonja Heinlein,1 Winfried Neuhuber,3 
Christian Ott,1 Roland E. Schmieder,1 Kerstin U. Amann,4 Roland Veelken,1 
Tilmann Ditting.1  1Nephrology & Hypertension, Friedrich Alexander Univ 
Erlangen, Erlangen, Bavaria, Germany; 2Physiolgy 1, Friedrich Alexander 
Univ Erlangen, Erlangen, Bavaria, Germany; 3Anatomy 1, Friedrich Alexander 
Univ Erlangen, Erlangen, Bavaria, Germany; 4Pathology, Friedrich Alexander 
Univ Erlangen, Erlangen, Bavaria, Germany; 5Pharmacologie et Toxicologie, 
CHU9 Lausanne, Lausanne, SZitzerland.
Background: Renal nerve ablation is a beneficial, but controversial treatment for 
resistant hypertension. We found morphological evidence that intrarenal perivascular 
afferents reinnervate more thoroughly than efferent sympathetic nerves. We now measured 
the tissue content of the afferent and efferent neurotransmitters, calcitonine gene relatated 
peptide (CGRP) and norepinephrine (NE) within 12 weeks after denervation.
Methods: Tissue levels of CGRP and NE from 24 male SD rats (ELISA-test, mass-
spectrometry) were measrurd in denervated left (L) and non-denervated right kidneys (R) 
1, 4 and 12 weeks after renal denervation±phenol.
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Results: CGRP decreased by 72% in denervated (L) kidneys compared to (R) kidneys in 
week 1 [W1BR: 3.20±0.33 vs. W1BL: 0.97±0.25; p<0.05 (ng/g kidney)]. In week 12 CGRP 
content in (L) kidneys did not differ from (R) kidneys. We observed a 78% decrease of NA 
tissue levels [pmol/mg kidney] in week 1 due to surgical denervation [W1BR: 1.09±0.16 
vs. W1BL: 0.24±0.06; p<0.05]. In contrast to the CGRP tissue levels there was no complete 
recovery of NA in week 12. The commonly used addition phenol to the surgical denervation 
procedure did not influence these results significantly. All data are given as mean±SEM.
Conclusions: We could show that there is a complete reinnervation of CGRP positive 
perivascular nerves within 12 weeks after renal denervation. However, NA tissue content did 
not recover completely inspite of complete morphological regrowth of sympathetic nerve 
fibers. This might potentially result in a net surplus of afferent sympatho-inhibitory influence, 
adding to the beneficial effect of renal denervation in some cases of resistant hypertension.
Funding: Government Support - Non-U.S.
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An Aristolochic Acid-Induced Nephropathy (AAN) Model for Stable CKD 
in Mice  Hiroshi Kojima, Xuzhen Hu, Yuning George Huang, Ana C. Souza, 
Jonathan Street, Peter S.T. Yuen, Robert A. Star.  Renal Diagnostics and 
Therapeutics Unit, NIDDK, NIH, Bethesda, MD.
Background: ACEi/ARB are standard therapy for progressive CKD but do not slow 
progression in ~50% of patients. To obtain novel therapies of CKD in humans, better 
preclinical models are needed. A few mouse models for CKD have been developed, 
each with strengths and weaknesses. In humans, Aristolochic Acid (AA) causes Balkan 
nephropathy, with chronic interstitial fibrosis and slow progression to ESRD. However, 
published AAN mouse models have poorly characterized CKD outcomes.
Methods: CD-1 or C57BL/6 mice were injected i.p. with AA dissolved in DMSO using 
two regimens: R1: AA I i.p. (3 mg/kg) every 3 d for 6 wk, then 6 wk of disease development; 
R2: AA i.p. (2.5 mg/kg) every 7 d for 3 wk, then 1 wk of disease development. Spot urine 
samples and non-invasive GFR by plasma disappearance of FITC-Sinistrin were obtained 
weekly: serum and kidney were collected at euthanasia. Using aged animals, or addition 
of salt-loading, uninephrectomy (UNx), or an adenine-rich diet were tested to increase the 
severity of the model.
Results: CD-1 mice (R1) had severe body weight (BW) loss at 3 wk and was 
discontinued. Both CD-1 and C57BL/6 (R2) showed moderate loss of BW. All R2 mice 
survived. Both CD-1 and C56BL/7 mice had elevated BUN, and developed severe 
tubulointerstitial injury. CD-1 mice showed higher injury score and fibrosis (%) than 
C57BL/6 mice. There was no elevation of blood pressure in CD-1 (R2). Neither regimen 
nor strain developed progressive CKD model as urinary albumin transiently peaked then 
fell, and GFR dropped by 60%, but plateaued within two weeks. Aging, salt-loading, UNx, 
or an adenine-rich diet did not increase injury or lead to progressive CKD.
Conclusions: AA caused a strain- and regimen-dependent severity of tubulointerstitial 
injury, with moderate but stable decreases in kidney function (~ human CKD stage 3). AAN 
may still be a foundation of a progressive CKD model, but additional renal insults might 
be needed to achieve a progressive CKD model.
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The Polymeric Immunoglobulin Receptor Is Expressed in Scattered 
Cells of Human Kidney and Increase in Expression following Kidney 
Injury  Krzysztof Krawczyk,1 Helén Nilsson,1 Jenny C. Nystrom,2 Martin E. 
Johansson.1  1Dept of Translational Medicine, Lund Univ, Malmö, Sweden; 
2Dept of Physiology, Inst of Neuroscience and Physiology, Univ of Gothenburg, 
Gothenburg, Sweden.
Background: We have previously shown that the proximal tubules of human kidney 
contain a scattered cell (SC) population of importance for kidney regeneration, where the 
markers for SC are identical to those of the pariethal epithelium of Bowmans’ capsule. 
Using gene expression analysis of the SC we found that these may express the Polymeric 
immunoglobulin receptor (PIGR), a transporter classically attributed to export of secretory 
IgA and IgM to the mucosal side of the respiratory and gastrointestinal tracts.
Methods: Biopsy material was procured from normal and diseased kidneys. 
Nephrotic and nephritic diseases were included along with cases of diabetes nephropathy. 
Immunofluoresence was used for colocalization of PIGR to the SC and immunohisto-
chemistry was performed to assess the distribution of PIGR in the various disease states. 
Sandwich ELISA was used to measure secretory IgA levels in urine and blood samples 
from the same disease categories. Primary culture of renal tubular epithelium on permeable 
supports was used to establish an in-vitro system for functional studies of IgA transcytosis.
Results: Colocalization studies showed that PIGR indeed localizes to the SC of human 
kidney. Furthermore, the tubular PIGR expression increases as an early response to both 
acute and chronic renal injury. ELISA measurements of secretory IgA levels in serum and 
urine samples from patients suffering from various kidney diseases show and increased 
urinary content of secretory IgA. In vitro, we show that primary renal epithelial cells perform 
vectorial transport of secretory IgA towards the apical compartment.
Conclusions: The human kidney uses PIGR to export secretory IgA into the tubular 
luminal contents, a function similar to the established secretion of dimeric IgA onto the 
mucosal surfaces of the respiratory and gastrointestinal tracts. The levels of urinary secretory 
IgA increase prominently in response to renal injury.
Funding: Government Support - Non-U.S.
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Establishment of Canine Remnant Kidney Model in Beagle Dogs 
Hajeong Lee,1 Jun gu Kang,2 Seung Hee Yang,2 Dong Ki Kim,1,2 Kwon Wook 
Joo,1,2 Yon Su Kim.1,2  1Internal Medicine, Seoul National Univ Hospital; 2Kidney 
Research Inst, Seoul National Univ College of Medicine.
Background: The remnant kidney model has been well established in the rodents, 
whereas it has not been fully understood in higher and bigger animals. Canine remnant 
kidney model is important for better medical applications. We aimed to establish 1/16 
canine remnant kidney model.
Methods: Remnant kidney model was induced in beagle dogs by a two-step subtotal 
nephrectomy. First, left kidney was exposed by flank incision. Among a total of eight 
branches of left renal arteries, seven-eighths of left renal arteries were ligated. Ischemia 
induction was confirmed by visual identification of topical cyanosis.
After 1 week, right kidney was removed and consequently 1/16 remnant kidney model 
was completed. A total of 20-weeks of subtotal nephrectomy, we sacrificed the animals and 
their renal histopathologic changes were examined.
Results: During 20 weeks, CKD dogs (n=12) and sham-operated dogs (n=2) were 
monitored. Blood pressure of CKD dogs had been maintained highly at 2 weeks. In spite 
of anti-hypertensive medication, 3 CKD dogs died from uremia and hypertension. After 
surgery, body weights were declined in both CKD and sham-operated dogs in first 2 weeks. 
Sham-operated dogs had recovered their body weight within 3 weeks, however, CKD dogs 
had recovered slowly until 3-months after surgery. Blood urea nitrogen, serum creatinine 
and proteinuria amount were significantly higher than those of sham-operated dogs during 
overall period. Renal function decline were accentuated during first 3 weeks after subtotal 
nephrectomy and last 2 weeks before sacrifice. Intra-renal infiltration of inflammatory cells, 
apoptosis of renal tubular cells, and renal fibrosis were prominent in CKD dog than in sham.
Conclusions: We successfully established 1/16 remnant kidney model by renal artery 
ligation in beagle dogs.
TH-PO261
Molecular Score of Acute Kidney Injury Identifies Discarded Kidneys That 
Are Potentially Transplantable  Konrad S. Famulski,1 Silke V. Niederhaus,2 Jeff 
Reeve,1 Jonathan Bromberg,2 Philip F. Halloran.1  1Univ of Alberta, Edmonton, 
AB, Canada; 2Univ of Marlyland, Baltimore, MD.
Background: Many kidneys from older deceased donors are discarded due to 
uncertainty based on conventional features (clinical or histology). We previously showed 
that the molecular AKI score in implantation biopsies (Bx) predicts future graft function 
better than histology. Now we hypothesize that AKI scores in kidneys accepted for 
transplantation will be similar to some discarded kidneys when decision to transplant is 
based on conventional features.
Methods: Pre-implantation Bx from accepted and discarded kidneys were obtained 
from brain dead >50 years donors. Decision to discard was based on MAPI scores of 
wedge Bx in 20/28 discards. Molecular AKI scores and global gene expression were 
analyzed by microarrays.
Results: The molecular AKI scores in all kidneys were compared by principal 
component analysis (PCA). 
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PCA defined two sets of kidneys. Group 1 had low AKI scores and included 14 discarded 
kidneys and 5 accepted kidneys. Thus many discarded kidneys had low AKI scores similarly 
to accepted kidneys and were potentially transplantable. Group 2 contained 14 discarded 
kidneys and 2 transplanted kidney, all with high AKI scores. 1852 transcripts associated 
with PC1 of the AKI scores. Pathway analysis demonstrated that Group 2 kidneys had 
decreased expression of genes related to oxidative phosphorylation suggestive of activation 
of MTORC2 pathway, and had increased expression of genes related to antigen presentation 
driven by IFNG and to response to wounding. Thus Group 2 kidneys with high AKI scores 
were more stressed than other potentially acceptable kidneys.
Conclusions: Addition of molecular features to the evaluation of biopsies may lead 
to improved kidney utilization from older donors and offers mechanistic insights into why 
such kidneys have impaired performance.
TH-PO262
Characterization of Injury in Renal Proximal Tubules During Cold 
Incubation and Rewarming  Anja H. Bienholz,1 Gesine Pless-Petig,2 Andreas 
Kribben,1 Ursula Rauen.2  1Nephrology, Univ Duisburg-Essen, Essen, Germany; 
2Physiological Chemistry, Univ Duisburg-Essen, Essen, Germany.
Background: Cold incubation and rewarming induce an essential component of 
preservation injury which is iron-dependent in many cell types. In rat hepatocytes a 
chloride-dependent component of injury has been described, while chloride-poor solutions 
accentuated damage in endothelial cells. This work examines the injury induced by cold 
incubation and rewarming in isolated renal proximal tubules.
Methods: Rat renal proximal tubules were isolated by collagenase digestion and 
Percoll gradient centrifugation. The vascular storage solution TiProtect® and a chloride-
poor modification +/- iron chelators (IC; deferoxamine 0.5mM, LK614 20µM) were used 
for cold incubation. Incubation of 5ml tubular suspension respectively was performed 
in closed flasks at 4°C, followed by rewarming in an extracellular buffer (3h at 37°C). 
LDH release, ATP content and resazurin reduction were measured as indicators of cellular 
integrity, energy content and metabolic activity.
Results: No differences in LDH release were detected after 24h of cold incubation. 
After rewarming LDH release was less in solutions with IC (23+6% vs 39+10%; p<0.05 
chloride-rich and 25+6% vs 50+7%; p<0.001 chloride-poor; n=3). After 48, 120 and 168h 
of cold incubation LDH release was less in solutions with IC. Without IC LDH release 
showed a tendency to be higher in chloride-poor solutions (53+4% vs 30+7% after 48h of 
cold incubation; p<0.001; n=8). Following rewarming metabolic activity was tendentially 
better conserved in tubules stored with IC (109+35% vs 47+17%; ns; n=4, chloride-rich). 
After 48h of cold incubation ATP content was better conserved in chloride-rich than in 
chloride-poor solutions (51+20% (chlorid-rich, without IC) and 67+12% (with IC) vs 18+6% 
(chloride-poor, without IC) and 27+6% (with IC); p min. <0.05; n=8). These results were 
confirmed after 120h of cold incubation.
Conclusions: The results confirm an iron-dependent component of injury in proximal 
tubules during prolonged cold incubation and rewarming. This data for the first time shows 
a benefit of chloride-rich solutions for preservation of energy content in renal proximal 
tubules during cold incubation.
Funding: Private Foundation Support
TH-PO263
Apoptosis During Extreme Cold Ischemia and Rewarming Involves a 
Caspase Independent Pathway  Swati Jain, Charles L. Edelstein, Alkesh Jani. 
Renal, Univ of Colorado, Aurora, CO.
Background: Cold ischemia (CS) followed by warm reperfusion (REW) during 
hibernation is a natural model we have used to understand Delayed graft function (DGF). We 
have shown that hibernating ground squirrel kidneys and tubular cells (RTEC) survive CS 
for several days in torpor followed by REW in Arousal without RTEC apoptosis. In contrast 
mouse & human kidneys demonstrate significant tubular apoptosis after CS/REW. We have 
previously shown that apoptosis during CS/REW in mouse RTECs is mediated in part by 
a caspase dependent pathway. Here we explore whether a caspase independent pathway 
of apoptosis is activated during CS/REW. We hypothesized that increased mitochondrial 
injury during CS/REW in mouse RTECs would result in release of mitochondrial AIF, 
thus activating caspase independent apoptosis. Furthermore, we hypothesized that squirrel 
RTECs would be protected from apoptosis and not release AIF during CS/REW.
Methods: Squirrel and mouse RTECs were subjected to cold storage (CS) in UW 
solution followed by rewarming (REW) in normal media as previously described (Jain, 
S. Transpl Int, 2015). Apoptosis was quantified by TUNEL assay. AIF was examined in 
mitochondrial and cytosolic fractions.
Results: Mouse RTECs exposed to CS/REW had significantly increased apoptosis 
vs. squirrel RTECs. Furthermore, mouse RTECs subjected to CS/REW had significantly 
increased mitochondrial AIF translocation to the cytosolic fraction vs. squirrel RTECs.
Squirrel RTECs Mouse RTECs
Cont CS/REW Cont CS/REW
TUNEL +ve cells 0.25±0.2 2.0±0.4 2.7±0.4 26±2.2*
AIF - - - ++++
n = 3; * p <0.05 vs squirrel RTECs 
Conclusions: The data provide evidence of mitochondrial disruption in mouse RTECs 
during CS/REW, resulting in caspase independent apoptosis mediated by AIF. One potential 
reason for the remarkable ability of hibernators to survive prolonged CS/REW far in 
excess tolerable by nonhibernators is mitochondrial preservation that prevents release of 
AIF. Understanding caspase independent pathways during CS/REW may lead to improved 
organ preservation, and novel therapies for DGF.
Funding: Other NIH Support - R03 DK96151-01 to Alkesh Jani
TH-PO264
Phenotype of Renal Tubular Cell Death During Delayed Graft Function 
Swati Jain, Robert J. Plenter, Danica Galesic Ljubanovic, Chelsea M. Ruller, 
Trevor L. Nydam, Alkesh Jani.  Renal, Univ of Colorado, Aurora, CO.
Background: Delayed graft function (DGF) independently predicts reduced 5 yr kidney 
transplant survival. Treatments of DGF are lacking. Cold ischemia (CI) is a significant risk 
factor for DGF but the mechanism by which CI leads to DGF is unknown. The aim of this 
study was to determine the effects of CI on donor kidneys alone versus CI followed by 
warm reperfusion after kidney transplant (CI+Txp). We hypothesized that CI alone would 
produce a different injury phenotype to CI+Txp.
Methods: Male C57BL6 mice aged 8-12 weeks, were subjected to mouse kidney 
transplant. Donor kidneys were subjected to 3 hours CI in UW solution, and processed 
immediately or subjected to syngeneic mouse kidney transplant. Renal function was assessed 
by serum creatinine (SCr). Renal tubular cell (RTC) apoptosis and necrosis were quantified 
by an independent nephropathologist. TLR4, RIP3, cleaved BID, Bax, cleaved caspase-8 
(CC8) and cleaved caspase-3 (CC3) were examined by immunoblot.
Results: CI+ Txp resulted in a significantly increased SCr (1.9±0.15) vs. transplant 
without CI (0.3± 0.05). CI alone results in increased RTC apoptosis and CC3 but did not 
result in necrosis. In contrast, CI +Txp led to; (1) increased CC8, cleaved BID, Bax and 
CC3, and thus increased RTC apoptosis and also increased programmed necrosis; (2) 
increased RTC necrosis that was associated with increased RIP3 and TLR4.
Conclusions: CI results in RTC apoptosis alone without necrosis.  In contrast CI +Txp 
results in a distinct injury phenotype of RTC apoptosis, and also programmed necrosis that 
is associated with: (1) increased RIP3 and TLR4; (2) CC8 activation of BID, which may 
further promote bax activation and thus programmed necrosis. Understanding the phenotype 
of injury following prolonged CI and kidney transplant may lead to novel therapies for DGF.
Funding: Other NIH Support - R03 DK96151-01 to Alkesh Jani
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Abstract Withdrawn
TH-PO266
Swine Leukocyte Antigens and Orthotopic Kidney Transplantation in 
Yorkshire Piglets and Yucatan Miniature Swine  Todd D. Merchen,1 Victor 
Monterroso,2 Daniel Moralejo,2 Andrea Saucedo,2 Daniel Kleven,3 Chak-Sum 
Ho,4 N. Stanley Nahman.5  1Surgery, Georgia Regents Univ; 2Laboratory Animal 
Sciences, Georgia Regents Univ; 3Pathology, Georgia Regents Univ; 4Gift of 
Life Michigan, Ann Arbor, MI; 5Medicine, Georgia Regents Univ.
Background: PCR with sequence-specific primers (PCR-SSP) is a rapid and 
inexpensive approach to low-resolution (Lr) swine leukocyte antigen (SLA) genotyping. 
PCR-SSP may be used in Yorkshire pigs (Yorks), cheaper than expensive Yucatan miniature 
swine (YMS), for kidney transplantation (KT). We performed dual exchange allogeneic 
KT (DEAK) in both Yorks and YMS, and correlated outcome with SLAs.
Methods: Orthotopic DEAK (30 kg sows) was performed in 2 YMS (Pig #9, SLA 
haplotype Lr-4.5/6.7, blood type A; and Pig #10, SLA Lr-4.5/4.5, A) and 2 Yorks (Pig 
#7, SLA Lr-6.12/22.15b, non-A; and Pig #8, SLA Lr-4.4/40.12, A). Species couples were 
operated simultaneously. For YMS Pig #9, the left kidney (LK9) was resected, ex vivo 
perfused on ice, and stored in an ice bath. LK10 was then removed, perfused and stored 
while LK9 was transplanted into #10. Then LK10 was transplanted into #9. Both R kidneys 
were removed. The same procedure was performed in Yorks. No immunosuppression was 
used; animals were sacrificed (sac) on POD 2-10.
Results: Mean pre-op creatinine (Cr) was 1.05 mg/dl. For YMS, Pig #10 rejected 
LK9 and died on POD-6 (Cr 19.6). Pig #9 accepted LK10 with Cr 2.4 at sac on POD-9. 
For Yorks, Pig #7 showed hyperacute rejection (RJX) of LK8 (POD-2, Cr 12.1) and Pig 
#8 had vascular RJX of LK7 (POD-2, Cr 4.4). All KT organs were well perfused at sac. 
For YMS, one SLA haplotype mismatch (Lr-6.7) led to RJX of LK9 by Pig #10, whereas 
complete SLA match in the other direction allowed graft acceptance of LK10 by Pig #9; 
both animals were blood type A. For Yorks, hyperacute RJX occurred in Pig #7 due to 
blood type incompatibility. Vascular RJX in Pig #8 resulted from a two class I haplotype-
one class II haplotype mismatch.
Conclusions: Orthotopic DEAK and SLA typing with PCR-SSP are equally effective 
in Yorks and YMS, allowing for predictable patterns of RJX/acceptance.  Yorks may offer 
a reasonable alternative to YMS for the study of experimental KT.
Funding: Private Foundation Support
TH-PO267
Development of Experimental Model of Renal Thrombotic Microangiopathy 
in Rat Allogeneic Bone Marrow Transplantation  Takafumi Kanemitsu, Go 
Kanzaki, Yusuke Okabayashi, Michiko Aoki, Kiyotaka Nagahama, Akira 
Shimizu.  Dept of Analytic Human Pathology, Nippon Medical School, Bunkyo-
ku, Tokyo, Japan.
Background: Renal thrombotic microangiopathy (TMA) after clinical hematopoietic 
stem cell transplantation (HSCT) is a well-recognized complication that carries a high 
risk of death. In TMA after HSCT, total body irradiation, use of immunosuppressants for 
prophylaxis against graft versus host disease (GVHD), viral infection, and GVHD have 
been proposed as risk factors. However, so far, experimental model of renal TMA after 
HSCT or bone marrow transplantation (BMT) has not been reported.
Methods: In order to develop the experimental rat model of renal TMA after allogeneic 
BMT, we performed BMT from Lewis (RT1l) bone marrow cells (6.0x107 cells) to DA 
(RT1a) rats after 10G irradiation without immunosuppression. We examined the clinical 
and pathological characteristics of several organs, including the skin, liver, gut and kidney 
during 9 months after BMT.
Results: In syngeneic BMT and non-BMT control DA rats, acute or chronic GVHD 
and renal TMA did not develop by 9 months. In DA rats after Lewis BM cell transplantation 
without immunosuppression, renal TMA in the kidney developed in 3 out of 6 rats 9 
months after BMT with GVHD in the skin, gut, and liver. Renal dysfunction including 
the increased levels of the serum creatinine (0.33±0.1mg/dL) and urinary protein (0.4±0.1 
g/day) developed at 9 months with skin rush, alopecia, decreased body weight, and liver 
dysfunction (AST: 231 mg/dl; ALT: 112 mg/dl; LDH: 987 mg/dl). Renal pathology showed 
collapsed and sclerotic glomeruli with endothelial cell injuries in all animals. Renal TMA 
findings were characterized by the glomeruli with mesangiolysis, duplication of the GBM, 
and fibrin thrombi formation. Exudative lesions in small arteries were also seen. These renal 
findings were quite similar findings as renal TMA after HSCT in humans.
Conclusions: In 50% of animals, renal TMA associated with GVHD developed with 
renal dysfunction after Lewis to DA rat allogeneic BMT. Further studies are needed to 
assess the mechanism of renal TMA after BMT.
TH-PO268
Beneficial Effect of Exendin-4 on Autophagy Dysfunction During 
Tacrolimus-Induced Pancreatic Islet Injury  Sun Woo Lim, Long Jin, Jian 
Jin, Chul Woo Yang.  Transplant Research Center & Div of Nephrology, Dept 
of Internal Medicine, Seoul, St Mary¶s Hospital, The Catholic Univ of Korea, 
Seoul, Korea.
Background: Autophagy is a cellular degradation-recycling system for aggregated 
proteins and damaged organelles. Previously, we reported that chronic calcineurin inhibitors 
(CNIs)-induced nephropathy is characterized by excessive autophagosome formation 
and decreased autophagic degradation rate. We suggested that lysosomal dysfunction 
may associate in the process of autophagic degradation. In this study, we evaluated the 
autophagic function in CNI-induced pancreatic beta cell injury, and combined treatment 
of exendin-4 (Exd), anti-diabetic agent has therapeutic effect by improving CNI-induced 
lysosomal dysfunction.
Methods: Rats were treated with tacrolimus (TAC, 1.5 mg/kg, s.c.) and Exd, (1 ug/
kg, i.p.) for 4 weeks. The effects of Exd on TAC-induced pancreatic beta cell dysfunction 
were evaluated by IPGTT, serum insulin level, HOMA-IR index, and islet size. Using an 
INS-1 cells, we examined the effect of Exd on TAC-induced lysosomal dysfunctions such 
as pH increase, reduced cathepsin B activity and LAMP-2A. Autophagosome formation 
and autophagic protein aggregates were confirmed by the expression of LC3-II and p62, 
respectively. Oxidative stress was measured by the concentration of 8-OHdG, MnSOD, 
catalase, and H2DCF-DA. The influence on apoptosis was examined by TUNEL assay, 
Annexin V, and active caspase-3.
Results: Four weeks of TAC treatment increased blood glucose levels and HOMA-
IR index, and decreased serum insulin level and islet size. But co treatment with Exd-4 
attenuated TAC-induced pancreatic beta cell dysfunction and islet size. Exd treatment 
improved TAC-induced pH increase, cathepsin B activity, and LAMP-2A expression in 
INS-1 cells. These were accompanied by restored expression of LC3-II and p62 which is 
markers for autophagic degradation rate. The markers for oxidative stress and apoptosis 
were also recovered by cotreatment of Exd.
Conclusions: The results of our in vivo and in vitro studies demonstrate that Exd 
has an effective antidiabetic agent that exerted antioxidative and antiapoptotic effects via 
restoring TAC-induced autophagic dysfunction.
Funding: Government Support - Non-U.S.
TH-PO269
Klotho Deficiency Is Associated with Chronic Tacrolimus-Induced Oxidative 
Injury  Sun Woo Lim, Jian Jin, Long Jin, Byung ha Chung, Chul Woo Yang. 
Transplant Research Center & Div of Nephrology, Dept of Internal Medicine, 
Seoul, St Mary¶s Hospital, The Catholic Univ of Korea, Seoul, Korea.
Background: We previously demonstrated that experimental animal model of chronic 
calcineurin inhibitors (CNIs)-induced nephropathy showed down regulated Klotho in renal 
tissues. We suggested that Klotho deficiency is highly associated with prolonged treatment 
of CNI-induced oxidative injury and resultant apoptosis and renal dysfunction. To determine 
whether Klotho deficiency is closely associated with CNI-induced renal injury via oxidative 
stress, Klotho heterozygote mice were compared with wild type control.
Methods: Mice of wild type (+/+) and Klotho heterozygote (Kl/+) were daily treated 
TAC (0.25, 0.5 ,1 mg/kg, s.c.) for 4 weeks under the 0.01% sodium diet. The effects of 
various dose of TAC and Klotho deficiency on renal function, fibrosis, and apoptosis. 
The expression of Klotho was measured in renal tissue and serum. Oxidative stress was 
evaluated with measuring 8-OHdG and MnSOD. Using a HK-2 cells, we examined the 
protective effect of recombinant Klotho under TAC treatment by measuring oxygen 
consumption rate (OCR), ATP production, amount of ROS, mitochondrial membrane 
potential (MMP), and apoptosis.
Results: Four weeks of TAC treatment induced renal dyfunction, renal fibrosis, and 
apoptosis in a dose-dependently in +/+ mice. These changes were aggravated in Kl/+ mice 
receiving TAC. Reduced Klotho level in urine, serum, and renal tissue was accompanied 
increased renal injury by TAC treatment. Moreover, 8-OHdG was increased in +/+ mice 
treated with TAC, and Kl/+ mice showed further increased 8-OHdG. The expression of 
MnSOD was reversely responded. Based on the in vivo results, in vitro test using HK-2 
cells also performed by treatment of recombinant Klotho and/or TAC. Klotho treatment 
reversed the mitochondrial function such as OCR, ATP production, MMP as well as ROS 
production and apoptosis.
Conclusions: The results of our in vivo and in vitro studies demonstrate that Klotho 
has a renoprotective role against TAC-induced renal dysfunction and cellular injury by 
reducing oxidative stress. These results suggest that Klotho has therapeutic potential in 
CNI-induced nephrotoxicity.
Funding: Government Support - Non-U.S.
TH-PO270
Discrepant Effect of Metformin on Hyperglycemia in Rats with Tacrolimus- 
or Sirolimus-Induced Diabetes Mellitus  Jian Jin, Long Jin, Ji Hyun Yu, Sun 
Woo Lim, Byung ha Chung, Chul Woo Yang.  Transplant Research Center & 
Div of Nephrology, Dept of Internal Medicine, Seoul, St Mary¶s Hospital, The 
Catholic Univ of Korea, Seoul, Korea.
Background: Metformin is the first choice used drug in the treatment of diabetes 
mellitus. However, the effect of metformin on immunosuppressant-induced hyperglycemia 
is still controversy. In this study, we aimed to investigate the effects of metformin in 
tacrolimus-or sirolimus-induced diabetes mellitus.
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Methods: Six groups of Sprague-Dawley rats were studied: animals received tacrolimus 
(1.5 mg/kg) or sirolimus (0.3 mg/kg) and metformin (200 mg/kg) or vehicle for 4 weeks. 
Body weight, water intake, and urine volume were measured before sacrifice. The effect of 
metformin on tacrolimus or sirolimus- induced hyperglycemia was evaluated by assessing 
intraperitoneal glucose tolerance test (IPGTT), islet size, and insulin level. For further 
analysis, isolated rat islets from normal rats were treated with tacrolimus (30 ng/ml) or 
sirolimus (90 ng/ml) and metformin (165 ng/ml) for 12hr, then glucose stimulated insulin 
secretion (GSIS) were performed.
Results: After four weeks, tacrolimus or sirolimus-treated animals showed decreased 
body weight and increased water intake and urine volume compared with vehicle group. 
Treatment with tacrolimus or sirolimus caused elevated blood glucose level and reduced 
serum insulin level. Islet size by measuring insulin-positive area was significantly decreased 
in tacrolimus or sirolimus-treated group. Combined treatment of metformin did not improved 
tacrolimus-induced blood glucose level. On the other hand, metformin recovered these 
value compared with the sirolimus alone. In vitro study of GSIS, combined treatment 
with metformin and tacrolimus showed a reduction in insulin secretion ability compared 
with tacrolimus alone. But, sirolimus and metformin-treated group showed higher level 
of insulin secretion than sirolimus alone.
Conclusions: In this study, we found that metformin confers to the insulin secretion 
capacity during sirolimus treatment, but not in tacrolimus. Therefore, use of metformin 
should be considered in transplant recipients receiving tacrolimus.
Funding: Government Support - Non-U.S.
TH-PO271
Effect of Vitamin D on Th17 Related Immune Responses in Tacrolimus-
Based Immune Suppression  Byung Ha Chung, Hyunseon Kim, Chul Woo 
Yang.  Internal Medicine, Seoul St. Mary¶s Hospital, Seoul, Korea.
Background: The aim of this study is to investigate the effect of vitamin D on Th17 
allo-immune responses in tacrolimus (Tac)-based immune suppression.
Methods: First, we investigated the clinical significance of 25-hydroxyvitamin D 
(25(OH)D) level on the development of acute rejection orserum Th17 associated cytokine 
levels in kidney transplant recipients (KTRs). Second, we determined the suppressive effect 
of 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3)on T cell proliferation upon T-cell specific 
stimulation or on inflammation of human primary tubular epithelial cells (HPRTEpiC) 
induced by interleukin-17 (IL-17) or TNF-α. Third, we investigated the pathway of the 
protective action of 1,25(OH)2D3 on T cell or HPRTEpiC.
Results: In renal transplant recipients under Tac based immunosuppression, 25(OH)
D level at KT was significantly associated with the development of acute rejection and 
the level was inversely correlated with Th17 related cytokines such as IL-17, IL-22, IL-23 
and IL-1beta in another KTR patients group. In T cell experiment, Tac suppressed Th1, 
Th2 and regulatory T cells in a concentration-dependent manner, but did not suppress 
Th17 cells even at high concentration. In contrast, addition of 1,25(OH)2D3 significantly 
suppressed Th17 proliferation. Next, IL-17 and TNF-α significantly induced the secretion 
of IL-6 and IL-8 from HPRTEpiC, however, addition of 1,25(OH)2D3 significantly reduces 
the secretion of those cytokines.
Conclusions: This study suggests that addition of 1,25(OH)2D3 to Tac is beneficial by 
suppression of Th17 alloimmune responses and hence it could be proposed as therapeutic 
strategy to improve allograft outcome.
TH-PO272
Use of D-Lactate for Therapeutic Immunosuppression  Ulf H. Beier,1 
Zhonglin Wang,2 Wayne W. Hancock,1 Matthew H. Levine.2  1Children¶s Hospital 
of Philadelphia, Philadelphia, PA; 2Univ of Pennsylvania, Philadelphia, PA.
Background: Current immunosuppressive therapies are limited by non-specificity and 
toxicity. Lactic acid is a carboxylic acid present as L- and D- optical isomers. In mammals 
including humans, lactate is present almost entirely as L-lactate. L-lactate can accumulate 
in the contexts of ischemia and/or Warburg metabolism, and suppress T cell function.
Methods: We hypothesized that since D-lactate is more slowly eliminated than 
L-lactate, it may have immune modulatory effects similar to L-lactate that maybe exploited 
for therapeutic immunosuppression, and tested both optical isomers in vitro and in vivo.
Results: We observed that while both D- and L-lactate (5-40 mM) markedly impaired 
murine and human CD4 and CD8 T cell proliferation in vitro, D-lactate had stronger effects 
than L-lactate. Neither D- nor L-lactate affected cell viability and apoptosis (7AAD, annexin 
V), and IL-2 and IFN-γ cytokine production by CD4 and CD8 T cells were unaffected. 
However, adding 20 mM D-lactate to CD+CD25-Foxp3- T-effector cells (Teff) under 
polarizing conditions increased Foxp3+ Treg formation by 46.2 ± 31.5% (P<0.03, n=4), 
whereas the effects of L-lactate were not statistically significant (22.8 ± 22.7%, p=0.09). 
To test effects of D-lactate in vivo, we adoptively transferred 1 × 106 Teff with or without 
1.25 × 105 Tregs into Rag1–/– mice, and treated each group with 90 mmol/kg/d D-lactate 
or control NaCl for 5 days, and assessed T cell proliferation. D-lactate reduced Teff cell 
proliferation (P<0.001, n=5), and de-novo Foxp3+ Treg formation was increased in D-lactate 
(21.2 ± 7.4%) vs. NaCl (11.9 ± 3.4%) treated animals (P<0.01, n=5).
Conclusions: Together, these results show that sodium D-lactate can impair T cell 
proliferation and promote Foxp3+ Treg induction. Our data suggest that use of specific, 
defined metabolites may have important therapeutic value as novel immunosuppressive 
agents.
Funding: Other NIH Support - NIAID
TH-PO273
Environment and Graft Interaction Impact on Endothelium After 
Experimental Kidney Transplantation  Diana A. Papazova, Nynke R. 
Oosterhuis, Jaap A. Joles, Marianne C. Verhaar.  Nephrology & Hypertension, 
Univ Medical Center Utrecht, Netherlands.
Background: At transplantation (TX) into a CKD recipient, the donor’s endothelium 
is exposed to uremic and oxidative stress that may negatively influence graft function and 
structure. We hypothesized that in CKD milieu, graft endothelial damage is determined 
by both donor quality and exposition to uremic and oxidative stress. We also investigated 
whether healthy environment halts progressive endothelial loss in expanded criteria donor 
(ECD) graft.
Methods: Male inbred Lewis rats were used as donors and recipients. CKD developed 
in 24 rats after bilateral ablation of 2/3 of kidney mass. Control rats (n=24) were age-
matched. Orthotopic TX was performed: healthy kidney to healthy rat (HD-HR); CKD 
kidney to healthy rat (CD-HR); healthy kidney to CKD rat (HD-CR); CKD kidney to 
CKD rat (CD-CR). Right donor kidney served as reference for left kidney (graft) injury 
at TX. Contralateral kidney of recipient was removed 10-14 days after TX. At wk 6, we 
evaluated graft function and morphology, and systemic oxidative (TBARS) and vascular 
damage (aorta calcification).
Results: Graft function (inulin& PAH clearance) at wk 6 after TX confirmed marked 
impairment after ablation and was not affected by environment (CD-HR vs. CD-CR and 
HD-CR vs. HD-HR, all NS). TX of healthy vs. CKD graft did not influence oxidative and 
vascular damage at wk 6 postTX (CD-HR vs. HD-HR and HD-CR vs. CD-CR, both NS). 
Grafts from healthy donors developed more glomerulosclerosis (GS) and tubulointerstitial 
injury (TI) and a reduction in glomerular and interstitial endothelium (JG12 stain) compared 
to reference kidneys after TX in a CKD donor (all P<0.05). However, despite similar 
ischemia-reperfusion, TI and GS did not worsen in ECD grafts and TX of ECD grafts in 
healthy recipients did preserve glomerular and interstitial endothelium.
Conclusions: TX to CKD environment was less detrimental for ECD graft as shown 
by preserved endothelium compared to healthy graft, possibly due to preconditioning. In 
the reverse model, healthy environment halted progression of endothelial damage in ECD 
grafts. Thus, depending on environment, ECD grafts appear to maintain their structure.
TH-PO274
Heparan Sulfate in the Glycocalyx of Donor Renal Allografts Modulates 
Transplant Rejection  William L. Clapp, Sriram Ambadapadi, Dara N. 
Wakefield.  Univ of Florida; Univ of Florida; Univ of Florida.
Background: The molecular mechanisms underlying transplant allograft vasculopathy 
and chronic rejection are not fully elucidated. Glycosaminoglycans (GAGs) modulate 
inflammatory cell responses and Heparan sulfate (HS) is the predominant GAG in the 
endothelial glycocalyx. Binding to GAGs plays an important role in the function of 
chemokines. The role of donor allograft GAGs in renal transplant rejection is not well 
defined. In these studies, we investigated the effects of selective HS deficiency and 
interference with HS-chemokine interaction on renal allograft rejection in the mouse.
Methods: Donor renal allografts from mice with conditional deletion of the 
N-deacetylase-N-sulfotransferase-1 gene (Ndst1) in endothelial and myeloid/lymphoid 
precursors leading to HS deficiency were examined. M-T7, a viral-derived secreted 
glycoprotein was used to block HS-chemokine interaction. Donor renal allografts from 
C57B1/6 (WT) or Ndst1-/- mice were transplanted into Balb/C mice and then treated with 
either saline (control) or M-T7.
Results: Compared to the WT, the Ndst1-/- donor renal allografts had significantly 
reduced scores for lesions induced by rejection including infiltrates, tubulitis, peritubular 
capillaritis, glomerulitis, vasculitis and mesangial matrix. M-T7 treatment of WT donor 
renal allografts significantly reduced the histologic markers of rejection. However, the 
M-T7 mediated decrease in rejection was not observed in the Ndst1-/- donor allografts.
Conclusions: Donor renal allografts, deficient in endothelial glycocalyx HS, reduces 
renal rejection. Although M-T7 reduces rejection in WT donor renal allografts, M-T7 
treatment in Ndst1-/- donor renal allografts is inactive, and negates the reduction of rejection 
mediated by the Ndst1-/- donors. Donor kidney HS and HS/chemokine interactions may 
have a major role in reducing allograft rejection.
TH-PO275
Identification of Key Meta-Signatures Associated with Acute Rejection 
Post Kidney Transplant  Weijia Zhang,1 Zhengzi Yi,1 Karen Lok yee Keung,1 
Li Li,2 Madhav C. Menon,1 Barbara T. Murphy.1  1Renal Div, Medicine, Icahn 
School of Medicine at Mount Sinai; 2Dept of Genetics and Genomics, Icahn 
School of Medicine at Mount Sinai.
Background: Acute rejection (AR) is a major contributor to chronic allograft 
dysfunction and graft failure in kidney transplantation. Molecular expression profiling of 
kidney biopsies has been performed by several independent studies in recent years,but the 
AR-associated signatures identified from these studies vary.
Methods: Meta-analysis and Bayesian network analysis were performed on 6 kidney 
biopsy expression datasets to identify key meta-signatures associated with acute rejection 
and the key drivers were validated in independent expression datasets of kidney transplant 
and kidney diseases.
Results: Using 733 biopsy samples (239 AR episodes) from 6 expression datasets as 
discovery cohort, we identified 982 meta genes with differential expression in AR vs noAR 
patients at FDR<0.05. Gene Ontology enrichment analysis indicated that genes involved in 
immune response, T/B cell activation and proliferation, antigen processing and presentation, 
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protein kinase cascade and NFKB signaling pathways were upregulated, while genes 
involved in metabolism were downregulated.The expression data of metagenes was used 
to build a meta-coexpression network from which functional submodules were identified. 
14 key driver genes were subsequently derived from these network submodules that had 
differential connectivity in AR compared to noAR patients. The differential modules and 
key drivers also themselves significantly correlated with HLA antibody and graft survival. 
Finally, the differential expression of key drivers was validated in independent expression 
datasets from kidney transplants ( N=839) as well as other kidney diseases (IgA and Diabetic 
nephropathy and Lupusnephritis).
Conclusions: We identified a set of AR-associated key drivers that may play a common 
and pivotal role for driving the inflammatory responses in acute rejection in kidney 
transplantation as well as other kidney diseases, which will help the better understanding 
of molecular mechanism of acute rejection post transplant and therefore improve the early 
diagnosis/treatment of acute rejection to prevent renal failure.
Funding: NIDDK Support
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SNPs of Solute Carrier Family Genes Associated with Acute Renal Allograft 
Rejection in Korean Population  Byeongwoo Kim,1 Yeong Hoon Kim,1 Sang 
ho Lee,2 Sunwoo Kang.1  1Dept of Nephrology, Inje Univ, Busan Paik Hospital, 
Busan, Korea; 2Dept of Nephrology, College of Medicine, Kyung Hee Univ, 
Seoul, Korea.
Background: Solute carrier family has been reported to be associated with various 
kinds of renal diseases. Thus, we hypothesized that single nucleotide polymorphisms 
(SNPs) of the solute carrier family genes might have association with acute rejection of 
kidney transplantation(KT) in Korean population. This study sought to investigate whether 
polymorphisms of solute carrier family genes are involved in the development of acute 
renal allograft rejection.
Methods: We firstly selected 349 solute carrier family genes in NCBI gene database 
and searched the nonsynonymous SNPs on coding region in each genes. Finally we selected 
4200 exonic SNPs. The genotypes of these SNPs were performed using AxiomTM genome-
wide human assay. SNPStats and SPSS 18.0 were used for the analysis of genetic data. 
Logistic regression models were performed to determine odds ratio (OR), 95% confidence 
interval (CI), and P value.
Results: A total of 90 renal allograft recipients transplanted in Pusan Paik hospital. 
Acute rejection developed in 49 patients among them. Among 4200 SNPs of 349 solute 
carrier family genes, three SNPs (rs5036 in SLC4A1, rs11643718 in SLC12A3, and 
rs1047099 in SLCO4A1) only showed significant association with acute rejection (p<0.05).
Conclusions: These results suggest that these significant SNPs (rs5036 in SLC4A1, 
rs11643718 in SLC12A3, and rs1047099 in SLCO4A1) may be associated with the 
susceptibility to the acute rejection in the KT patients of Korean population.
Funding: Clinical Revenue Support
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The Expression and Role of Human Cytomegalovirus-Induced Viral 
Chemokine Receptor US28 in Smooth Muscle Cells of Renal Allografts 
Wouter Lollinga,1 Raymond H. De Wit,2 Gwenda F. Vasse,1 Afsar Rahbar,3 
Annelies Riezebos-brilman,4 Cecilia Söderberg-naucler,3 Willem Van Son,1 
Johannes S. Sanders,1 Martine J. Smit,2 Jacob van den Born.1  1Nephrology, UMC 
Groningen, Groningen, Netherlands; 2Medicinal Chemistry, VU, Amsterdam, 
Netherlands; 3Medicine, Karolinska Inst, Stockholm, Sweden; 4Medical 
Microbiology, UMC Groningen, Groningen, Netherlands.
Background: Renal transplantation is the preferred treatment for end-stage renal 
disease. Human cytomegalovirus (HCMV) infection is associated with decreased renal 
graft function and survival. HCMV expresses US28, a chemokine receptor that enables 
HCMV to escape immune surveillance and affect microenvironment in the graft. Our aim 
was to localize the expression of US28 in renal biopsies and determine its effect on viral 
dissemination in vitro.
Methods: US28 and immediate early antigen (IEA) expression was semi-quantitatively 
scored in recipient renal transplant biopsies (n=49) from HCMV-seropositive donors 
using immunohistochemistry. Expression in glomeruli, endothelium, smooth muscle cells, 
epithelium and inflammatory infiltrates was analyzed. Primary vascular smooth muscle cells 
were infected (MOI 0.01) with HCMV WT and US28-deficient HCMV (dUS28) carrying 
a GFP-tag, to follow viral dissemination in vitro.
Results: IEA was uniformly distributed over the renal compartments. US28 was 
expressed during active infection and latency. It was expressed in all compartments, but 
prevalent (Kruskal-Wallis; P<0.001) in vascular smooth muscle (42% cells positive) and 
tubular epithelial cells (30%). It was also expressed in the neointima. Smooth muscle cells 
were permissive to HCMV and underwent lytic infection in vitro, but dissemination was 
delayed for US28-deficient HCMV.
Conclusions: In short, HCMV-induced US28 is expressed in smooth muscle cells 
of renal allografts. US28 expression here suggests a role in vascular disease following 
viral infection, especially given its presence in the neointima. Absence of US28 decreased 
HCMV dissemination in smooth muscle cells in vitro, yielding it an interesting target for 
intervention. The observation that HCMV may interfere with vascular function through the 
expression of chemokine receptor US28 is an intriguing finding worth further exploring.
TH-PO278
Multiple Domains of CTGF Amplify Pericyte Activation to Become 
Pathological Matrix Producing Cells  Shuyu Ren, Bryce Gordon Johnson, 
Gamze Karaca, Ivan G. Gomez, Jeremy Stuart Duffield.  Research & 
Development, Biogen, Cambridge, MA.
Background: Connective tissue growth factor (CTGF), a member of the CCN gene 
family, is an extracellular matrix (ECM)-associated heparin-binding protein involved in 
matrix production. CTGF has been shown to contribute to progression of fi bro-proliferative 
diseases and scarring by modifying of proliferation, migration, and adhesion of fibroblasts. 
CTGF has also been shown to play a role in ECM remodeling in normal physiological 
processes including embryogenesis, implantation, and wound healing. However recent new 
insights into the pathogenesis of fibrosing kidney diseases lead us to re-evaluate CTGF 
in this context at a cellular level. We therefore generated a mouse model which facilitates 
tissue specific, conditional over-expression of CTGF using homologous recombination.
Methods: We generated mice conditionally over expressing CTGF in pericytes only. 
We cloned domains of CTGF and the WNT inhibitor DKK1 and tested their function on 
primary pericyte cultures.
Results: Overexpression of CTGF in pericytes has no impact on nephrogenesis or 
adult homeostasis but amplifies fibrogenic and inflammatory responses to kidney disease. 
CTGF domain IV activates WNT/b-catenin signaling in pericytes, which is inhibited by 
recombinant DKK-1. CTGF Dom-IV rapidly phosphorylates the co-receptor of WNT/b-
catenin signaling - LRP6. DKK-1 blocks CTGF domain IV mediated fibrotic responses 
in culture including fibrotic gene activation, pericyte morphology changes and migration 
in JNK MAP kinase dependent, WNT partially dependent pathway. CTGF Dom-I also 
activates pericyte migration which is also inhibited by DKK-1, JNK inhibition or Wnt 
ligand secretion.
Conclusions: CTGF over expression restricted to kidney stroma in vivo is sufficient
to amplify cell activation and myofibroblast transition. Multiple domains of CTGF drive 
fibrogenic responses in pericytes through WNT and JNK signaling pathways.
Funding: Pharmaceutical Company Support - Biogen
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Sphingosine Kinase 2 Mediates Kidney Fibrosis Through Epigenetic Change 
Tsuyoshi Inoue,1 Amandeep Bajwa,1 Heather M. Perry,1 Liping Huang,1 Hong 
Ye,1 Youichiro Wada,2 Diane L. Rosin,1 Mark D. Okusa.1  1Univ of Virginia; 
2The Univ of Tokyo.
Background: In numerous forms of organ injury, interstitial fibrosis is a final common 
pathway. Despite recent epidemiological studies, therapies to focus on fibrosis and to delay 
progressive renal failure are limited. We recently found that sphingosine kinase 2 deficient-
mice (SphK2KO) develop less fibrosis after folic acid (FA)- or ischemia-reperfusion-induced 
kidney injury. Sphingosine 1-phosphate (S1P) is produced by two sphingosine kinase 
isoforms (SphK1 and SphK2). S1P is involved in diverse functions, but the role of S1P 
produced by SphK2 is gathering attention as treatments focused on epigenetics have been 
developed. SphK2 is primarily located in the nucleus, SphK1 is cytoplasmic. S1P produced 
by SphK2 inhibits histone deacetylase (HDAC) and change in histone acetylation status, 
which can lead to an altered target gene expression. The aim of this study is to elucidate 
new mechanisms of kidney fibrosis through epigenetic changes.
Methods: Transcriptome analysis and ChIP-seq of H3K9ac and H3K27ac using primary 
renal fibroblasts from WT, Sphk1KO and Sphk2KO mice were applied to find new target 
genes that regulate fibrosis through histone acetylation.
Results: Microarray analysis identified 135 down-regulated (<1/4) genes and 245 
up-regulated (>4) genes in Sphk2 KO compared to Sphk1KO mice. ChIP-seq (QuEST) 
revealed that 258 genes have H3K27ac and 589 genes have H3K9ac only in SphK1KO 
and not in SphK2KO. The combination of microarray and ChIP-seq analysis yielded 21 
candidate genes. To determine the in vivo relevance of gene expression was evaluated using 
an in vivo fibrosis model (FA model and unilateral IRI). We further applied SphK2 knock 
down to WT fibroblasts and overexpression to fibroblasts from SphK2KO to determine 
if the selected genes are regulated by SphK2. Based on these strategies, candidate genes 
were identified that are regulated by SphK2 through the change of histone acetylation.
Conclusions: The combination of microarray and ChIP-seq of H3K9ac and H3K27ac 
identified 21 candidate genes. A more detailed investigation is needed, but some genes 
regulated by SphK2 appear to modulate kidney fibrosis through epigenetic changes.
TH-PO280
MCP-1 Directly Induces Renal Tubulointerstitial Fibrosis Independently 
of Monocytes/Macrophages Infiltration  Meiyan Wu, Hye-Young Kang, Mi 
Jung Lee, Shin-Wook Kang.  Severance Biomedical Science Inst, Brain Korea 
 PLUS, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Previous studies have demonstrated the importance of monocyte 
chemoattractant protein-1 (MCP-1) and its receptor, C-C chemokine receptor 2 (CCR2), 
in the pathogenesis of tubulointerstitial fibrosis via the recruitment and activation of 
monocytes/macrophages. However, recent in vitro evidence has suggested that MCP-1 
per se may act directly on renal cells via CCR2. Therefore, the results of a number of 
former studies showing the impacts of MCP-1/CCR2 blockade on renal injury may be 
partly attributed to a direct inhibitory effect of MCP-1 on renal cells, but this has not been 
clarified in vivo to date.
Methods: Monocyte/macrophage-deficient mice were induced by either liposome-
clodronate or diphtheria toxin. These mice were treated with MCP-1-expressing lentivirus 
(LV) and/or RS102895, a specific inhibitor of CCR2. NRK-52E cells were treated with 
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recombinant MCP-1 with or without RS102895, or CCR2 siRNA. The mRNA and protein 
expression of fibronectin and type I collagen in cultured NRK-52E cells and the whole 
kidney were evaluated by Western blot and real-time PCR.
Results: Fibronectin and type I collagen expressions were increased in NRK-52E 
cells exposed to MCP-1, which was then significantly abrogated by co-administration with 
RS102895 or CCR2 siRNA. LV-MCP-1 transfection in mice (n=6) resulted in significant 
increases in infiltrated macrophages, fibronectin, and type I collagen mRNA and protein 
expression in the kidney. However, LV-MCP-1 transfection in monocyte/macrophage-
deficient mice (n=6) resulted in increases in fibronectin and type I collagen in spite of an 
absence of increased macrophage infiltration. This up-regulation of fibronectin and type 
I collagen protein and mRNA expression in monocyte/macrophage-depleted mice were 
significantly ameliorated by RS102895 treatment (n=8).
Conclusions: The MCP-1/CCR2 system is directly involved in MCP-1-induced renal 
fibrosis and blockade of the MCP-1/CCR2 system can be a promising approach to treat 
various kidney diseases such as diabetic nephropathy, of which MCP-1-induced renal 
fibrosis is involved in the pathogenesis.
TH-PO281
T-Type Calcium Channel Blocker Attenuates Unilateral Ureteral 
Obstruction-Induced Renal Interstitial Fibrosis via Activation of the Nrf2 
Antioxidant Pathway  Soojeong Kim, Eun Sil Koh, Cheol Whee Park, Seok 
Joon Shin, Sungjin Chung.  Internal Medicine of Nephrology, The Catholic 
Univ of Korea, Seoul, Republic of Korea.
Background: Besides the effect on high blood pressure, T-type calcium channel 
blocker has been reported to exert a renoprotective effect in experimental models with 
renal fibrosis. However, the exact mechanism of T-type calcium channel blocker on 
tubulointerstitial fibrosis has not been elucidated. In the present study, we investigated 
whether the renoprotective effect of T-type calcium channel blocker is associated with 
modulation of the signaling of oxidative stress-induced renal fibrosis.
Methods: Treatment with a nonhypotensive dose of efonidipine, a T-type calcium 
channel blocker, or nifedipine, an L-type channel blocker, was initiated one day before 
unilateral ureteral obstruction (UUO) in C57BL6/J mice, and was continued until 3 and 
7 days after UUO. Markers of renal fibrosis, inflammation, apoptosis and oxidative stress 
were evaluated.
Results: In the obstructed kidneys of UUO mice, treatment with efonidipine 
significantly attenuated interstitial fibrosis, collagen deposition and inflammation increased 
by UUO creation compared with treatment with nifedipine. Efonidipine significantly 
increased the expression of antioxidant enzymes such as HO-1, NQO1, catalase and 
SOD1. Increased apoptotic cell death and decreased Bcl-2 expression in the obstructed 
kidneys were also significantly ameliorated by treatment with efonidipine. The expression 
of the histone acyltransferase p300/CBP-associated factor, which is known as a regulator 
of inflammatory molecules, was significantly inhibited by efonidipine. These beneficial 
effects of efonipidine were attributed to the increased nuclear expression of Nrf2 on UUO 
day 3 and the increased expressions of both total and nuclear Nrf2 with elevated Keap1 
on UUO day 7, suggesting that efonidipine would promote activation of Nrf2 differently 
depending time course after UUO. Nifedipine had little effect on antioxidant enzymes, 
anti-apoptosis and Nrf2 signaling.
Conclusions: These results suggest that T-type calcium channel blocker exerts 
beneficial effects in renal interstitial fibrosis by activating Nrf2 and subsequent antioxidant 
enzymes.
TH-PO282
Fimasartan, the Novel Angiotensin Receptor Antagonist, Protects against 
Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral 
Obstruction: A Possible Role of Nrf2  Soojeong Kim, Sungjin Chung, Hye Eun 
Yoon, Ji hee Lim, Bum soon Choi, Cheol Whee Park, Seok Joon Shin.  Internal 
Medicine of Nephrology, The Catholic Univ of Korea, Seoul, Republic of Korea.
Background: A newly developed angiotensin II receptor blocker, fimasartan, has 
effective blood pressure lowering effect via blocking renin-angiotensin system. Renal 
interstitial fibrosis is a final pathological process in the progression of chronic kidney disease, 
which is believed to be due to oxidative injury. Transcription factor nuclear factor-erythroid 
2-related factor 2 (Nrf2) is known to regulate cellular oxidative stress and induce antioxidant 
genes. This study investigated the role of Nrf2 in fimasartan-mediated antioxidant effects 
in mice with renal fibrosis induced by unilateral ureteral obstruction (UUO).
Methods: Fimasartan was administered intraperitoneally (3mg/kg/day) from the day 
of UUO surgery in C57BL/6 mice and was continued for 7 days after operation.
Results: UUO-operated mice revealed renal inflammation and fibrosis as evidenced by 
the degree of fibrosis and inflammatory cell infiltration in histopathological findings, total 
collagen content in kidney tissues and the expression of fibrotic markers in immunoblot 
analysis, which were reversed in the obstructed kidneys of fimasartan-treated mice. 
Fimasartan treatment upregulated renal expression of Nrf2 and its downstream signaling 
molecules, such as NQO1, HO-1, Nox 1, 2 and 4, GSTm2 and GSTm3 in both protein and 
mRNA levels. Furthermore, fimasartan increased the expression of antioxidant enzymes 
including CuSOD, MnSOD and catalase. Significantly less apoptosis in TUNEL staining, 
decreased pro-apoptotic protein, along with increased anti-apoptotic protein were observed 
in fimasartan-treated mice.
Conclusions: In conclusion, these results demonstrate that fimasartan has beneficial 
effects on renal oxidative stress, inflammation and fibrosis, which may be via upregulating 
of Nrf2 signaling, subsequently the induction of antioxidant pathways.
TH-PO283
The Na/K-ATPase Signaling and Oxidative Stress Contribute to PNx-
Mediated Cardiac and Renal Fibrosis in Mice  Muhammad A. Chaudhry,1 
Kyle D. Maxwell,1 Xiaoliang Wang,2 Yanling Yan,1 Preeya Tushar Shah,1 Zi-jian 
Xie,2 Jiang Liu,1 Joseph I. Shapiro.1  1Pharmacology, Physiology and Toxicology, 
Marshall Univ JCE School of Medicine, Huntington, WV; 2Marshall Inst for 
Interdisciplinary Research, MIIR at Marshall Univ, Huntington, WV.
Background: We have shown that the Na/K-ATPase signaling regulates cardiac 
and renal fibrosis both in vivo and in vitro. We have also demonstrated that increases in 
oxidative stress activate Na/K-ATPase signaling. Here we report that administration of 
CoPP (an inducer of heme oxygenase-1, HO-1) and pNaKtide (a Na/K-ATPase signaling 
antagonist) attenuate 5/6 renal partial nephrectomy (PNx) mediated fibrosis in heart and 
kidney in C57BL/6 mice.
Methods: The C57BL/6 mice were randomly divided into six experimental groups. 
(1) Sham surgery (Sham), (2) PNx surgery (PNx), (3) Sham+CoPP, (4) PNx+CoPP, (5) 
Sham + pNaKtide, and (6) PNx+pNaKtide. CoPP (5mg/KG BW, ip) was given 5 day and 
one day before surgery as well as every 5 day after PNx surgery. pNaKtide (25mg/KG BW, 
ip) was given weekly 7days after surgery. All experimental mice were sacrificed 4 weeks 
after PNx surgery. Expression of collagen-1, HO-1, and protein carbonylation of heart and 
kidney was determined by western blot.
Results: Comparing with sham, PNx surgery significantly stimulates type 1 collagen 
expression both in heart and kidney assayed by western blot and histology analyses. 
Induction of HO-1 by CoPP significantly attenuates PNx-mediated collagen production 
and protein carbonylation. Administration of pNaKtide, which blocks Na/K-ATPase-
mediated c-Src activation, also attenuates PNx-mediated collagen production. Transthoracic 
Echocardiography analysis demonstrates that treatment with CoPP and pNaKtide restores 
PNx-induced changes in relatively wall thickness (RWT) and myocardial performance 
index (MPI).
Conclusions: Attenuating oxidative stress and blocking Na/K-ATPase signaling is 
capable of restoring PNx-mediated cardiac and renal fibrosis as well as cardiac function.
TH-PO284
Wnt4 Induces Renal Fibrosis by Activating p38 Mitogen-Activated Protein 
Kinase Pathway  Jae Eun Um, Seonghun Kim, Bo Young Nam, Hye-Young 
Kang, Meiyan Wu, Jimin Park, Tae-Hyun Yoo, Shin-Wook Kang.  Severance 
Biomedical Science Inst, Brain Korea  PLUS, Yonsei Univ College of 
Medicine, Seoul, Korea.
Background: Previous studies demonstrated that Wnt signaling pathway plays a key 
role in the pathogenesis of renal fibrosis and is related to various kidney diseases. However, 
although Wnt4 is abundantly expressed in renal tubule cells, the roles of these specific Wnt 
subfamilies in the pathogenesis of renal fibrosis have not been fully explored. Therefore, 
the effect of Wnt4 on renal tubulointerstitial fibrosis via p38 mitogen-activated protein 
kinase (MAPK) pathway was examined in unilateral ureteral obstruction (UUO) animals 
and tumor growth factor-b1 (TGF-b1)-stimulated renal tubular cells.
Methods: In vivo, UUO was performed in C57BL/6 mice (n=12). The kidneys were 
harvested after 6 days of UUO. Immunohistochemistry was conducted with renal tissues. 
In vitro, renal proximal tubular cells (NRK-52E) and inner medullary collecting duct 
cells (IMCD) were each treated with recombinant TGF-b1 with or without Wnt4 siRNA 
transfection. The effect of recombinant Wnt4 protein treatment was also examined in 
NRK-52E and IMCD cells. Real-time PCR and Western blot analysis were performed to 
evaluate Wnt4, fibronectin (FN), collagen type 1 (Col I), α-SMA, phospo-p38 and p38.
Results: Immunohistochemistry revealed a significant up-regulation in kidney Wnt4 
expression in UUO mice compared to control mice. The mRNA and protein expression of 
Wnt4 were significantly higher in recombinant TGF-b1-stimulated NRK-52E and IMCD 
cells compared to control cells. Protein expression of fibrosis-related proteins such as FN, 
Col I and α-SMA as well as phospho-p38 MAPK were significantly increased in cells treated 
with recombinant TGF-b1. Increased fibrosis-related proteins and phosphorylation of p38 
MAPK were significantly ameliorated by Wnt4 siRNA transfection in TGF-b1 treated 
cells. Furthermore, recombinant Wnt4 treatment also led to increase in protein expression 
of fibrosis-related proteins and phospho-p38 in NRK-52E and IMCD cells.
Conclusions: These findings suggest that Wnt4 may play a role in renal tubulointerstitial 
fibrosis by activating the p38 MAPK pathway.
TH-PO285
Peroxiredoxin 5 Protects TGF-β Induced Renal Fibrosis by Modulating 
Stat3 Activation  Hoon In Choi,1 Jung Sun Park,1 Seong Kwon Ma,2 Eun Hui 
Bae,2 Jong un Lee,1 Soo Wan Kim.2  1Dept of Physiology, Chonnam National 
Univ Medical School, Gwangju, Korea; 2Dept of Internal Medicine, Chonnam 
National Univ  Medical School, Gwangju, Korea.
Background: Renal fibrosis is common final pathway of end-stage kidney diseases 
which is induced by aberrant accumulation of myofibroblasts. This process is triggered by 
reactive oxygen species (ROS) and proinflammatory cytokines generated by various source 
of injured kidney cells. Peroxiredoxin 5 (Prdx5) is a thiol-dependent peroxidase that reduces 
oxidative stress by catalyzing intramolecular disulfide bonds. Along with its antioxidant 
effects, expression level of Prdx5 also was involved in inflammatory regulation by immune 
stimuli. However, the physiological effects of Prdx5 in renal fibrosis have not been fully 
characterized and the underlying mechanisms remain poorly understood.
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Methods: As in vivo and in vitro model of renal fibrosis, Sprague-Dawley rats were 
subjected to unilateral ureteral obstruction (UUO) for 1 or 7 days. Fibroblast-like rat 
proximal tubule cells (NRK49F) were treated with transforming growth factor β (TGF-β) 
for 0, 1, 3, or 5 days. To access the involvement of its peroxidase activity in TGF-β induced 
renal fibrosis, wild type Prdx5 (WT) and double mutant Prdx5 (DM), converted two 
active site cysteines at Cys 48 and Cys 152 residue to serine, were transiently expressed 
in NRK49F cells.
Results: The protein expression of Prdx5 was reduced in UUO kidneys. Upregulation 
of fibrotic markers, such as fibronectin, vimentin, and alpha-smooth muscle actin (α-SMA), 
were declined at 5 days in time point of higher Prdx5 expression in TGF-β treated NRK49F 
cells. The overexpression of wild type Prdx5 by transient transfection in NRK49F cells 
attenuated the TGF-β induced upregulation of fibronectin and α-SMA. On the other hand, 
the transient transfection of double mutant Prdx5 did not prevent the activation of fibrotic 
markers. Overexpression of Prdx5 also suppressed the TGF-β induced upregulation of Stat3 
phosphorylation, while phosphorylation of Smad2/3 was unchanged.
Conclusions: Prdx5 protects TGF-β induced renal fibrosis in NRK49F cells by 
modulating Stat3 activation in a peroxidase activity dependent manner.
TH-PO286
Fucoidanreduces Pressure-Induced Fibrotic Responses in Renal Tubular 
Cells Through Down-Regulating β-Catenin  Tso Hsiao Chen, Cheng-hsien 
Chen.  Div of Nephrology, Wan Fang Hospital, Taipei Medical Univ, Taipei, 
Taiwan.
Background: Fucoidan is a kind of natural fucose-enriched sulfated polysaccharides 
found mainly in various species of brown algae and brown seaweed. In recent years, 
many studies show fucoidan reduces hypoxia nephropathy, and also inhibits liver fibrosis. 
However, the influence of fucoidan on renal fibrosis is not clear yet.
Methods: Rat renal tubular cells (NRK-52E) are applied in this study. We study the 
influence of low-molecular-weight fucoidan (500 Da) on renal fibrosis in a pressure-stressed 
cell model. Sixty mmHg of pressure will be applied on NRK-52E cells for different 
periods to induce EMT. The expression of EMT markers and β-catenin will be monitored 
by Western blotting.
Results: NRK-52E cells were subjected to 60 mmHg of pressure for the indicated 
periods. Cellular E-cadherin, TGF-β, CTGF, fibronectin, α-SMA and Snail were detected 
by Western blotting. We found sixty mmHg of pressure induces EMT markers expression in 
NRK-52E cells. Fucoidan (0.1 – 1 mg/ml ) reduced pressure-induced α-SMA and fibronectin 
in NRK-52E cells. Fucoidan reduced pressure-induced CD44 and β-catenin, which may 
be a critical mechanism of anti-fibrosis effect of fucoidan. NRK-52E cells were pretreated 
with fucoidan for 30 min and then treated with TGF-β for 24 h. We found fucoidan could 
reduced TGFβ-induced α-SMA and fibronectin in NRK-52E cells.
Conclusions: In summary, fucoidan at adequate doses inhibits pressure-induced fibrotic 
responses in rat renal tubular cells. The investigation of the protective effect of fucoidan 
against renal fibrosis may provide a new therapeutic agent for CKD patients.
Funding: Government Support - Non-U.S.
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Indoxyl Sulfate Exacerbates Oxidative Stress and Impairs NF-κB/Nrf2 
Levels in RAW Macrophages  Denise Mafra,1 Milena Barcza Stockler-Pinto,1 
Juliana Saldanha,2 Christophe O. Soulage,3 Denis Fouque.4  1Post-Graduate 
Program in Cardiovascular Sciences, Fluminense Federal Univ (UFF), 
Niterói, Rio de Janeiro, Brazil; 2Post-Graduate Program in Medical Sciences, 
Fluminense Federal Univ (UFF), Niterói, Rio de Janeiro, Brazil; 3INSA de 
Lyon, CarMeN, INS(RM U, Univ de Lyon, 9illeurbanne, France; 4Dept 
of Nephrology, Centre Hopitalier Lyon Sud, INS(RM , C(NS, Univ de 
Lyon, Pierre Bénite, France.
Background: Indoxyl sulfate (IS), a uremic toxin produced by intestinal bacterias, is 
accumulated in Chronic Kidney Disease (CKD) patients and exhibits potent inflammatory 
effects. However, no informed scientific evidence has evaluated the effects of this toxin 
on nuclear E2-related factor 2 (Nrf2) and nuclear factor-kB (NFkB) expression, which 
regulate the expression of many detoxifying enzymes and the transcription of pro-
inflammatory cytokines genes, respectively, in CKD. Thus the aim of the study was to 
evaluate the influence of IS in Nrf2, NF-κB and malondialdehyde (MDA) levels in RAW 
macrophage cells.
Methods: Mouse RAW 264.7 macrophage cells were incubated overnight with IS (250, 
500, 1000 or 4000mM) according to the recommendations of the European Uremic Toxin 
Work Group. Nucleus and cytoplasm were separated using a specific Kit. Quantitative Real-
Time PCR analysis and Western Blotting were performed to evaluate the Nrf2 and NF-κB 
levels. MDA levels were measured by High Performance Liquid Chromatographywith 
visible detection.
Results: In macrophages culture Nrf2 nuclear translocation and NF-κB protein were 
not activated by IS, however, NF-κB mRNA expression was stimulated by IS at the 
concentration of 1000 mM, 4 fold higher than detected in CKD patients i.e.
MDA levels were increased by IS in the cells (Figure 2).
Conclusions: IS exacerbates oxidative stress and could activate NF-κB mRNA 
expression especially for the highest concentrations in RAW macrophages culture.
TH-PO288
Association of Intraglomerular Cytokine Environment with Distinctive 
Infiltrating Myeloid Cell Populations in Lupus Nephritis  Sun-sang J. Sung,1,4 
Yan Ge,1 Chao Dai,1,4 Hongyang Wang,1,4 Shu Man Fu,1 Thu H. Le,1,4 Jing Yu,2,4 
Rahul Sharma,1,4 Mark D. Okusa,1,4 Kline Bolton,1,4 Young Hahn,3 Jessica R. 
Lawler.1,4  1Medicine, U. of Virginia, Charlottesville, VA; 2Cell Biology, U. of 
Virginia, Charlottesville, VA; 3Microbiology, U. of Virginia, Charlottesville, 
VA; 4Center for Immunity, Inflammation, and Regenerative Medicine, U. of 
Virginia, Charlottesville, VA.
Background: Glomerular infiltrating myeloid cells are important in mediating 
intraglomerular tissue damage, cellular dysfunction, and functional obliteration in lupus 
nephritis.
Methods: A spontaneous chronic lupus model using NZM2328 mice and an anti-GBM-
induced GN model were used to assess glomerular cytokine environment and myeloid cell 
infiltration in SLE by confocal microscopy. Glomeruli were isolated by magnetic bead 
trapping and single cell suspensions were analyzed by flow cytometry.
Results: In NZM2328 mice with severe proteinuria, increased CD11b+ dendritic 
cells (DC), CD103+ DC, and MHCII+ and MHCII- macrophages were found infiltrating 
the kidney interstitium. However, glomerular infiltrating cells in these sick mice consisted 
mostly of MHC-CD11b+ M2-like macrophages but not MHCII+ cells. Microarray analysis 
of FACS-purified mesangial cells followed by confocal microscopy analysis of cytokine 
staining showed that mesangial cells mainly produced IL-6, M-CSF, stem cell factor, KC, 
and MIP2. Immunofluorescence also showed that endothelial cells produced IP-10 whereas 
podocytes produced IL-1b. These cytokines likely determine the differences in cellular 
distribution between the interstitium and glomerulus and mediate GN. Anti-GBM-induced 
GN showed disproportionately high glomerular infiltration of PMN and Ly6C+ macrophages 
compared to NZM2328 mice with chronic GN, which suggest significant differences in 
pathogenesis between the 2 SLE models.
Conclusions: The secretion of selected cytokine and chemokines by glomerular 
parenchymal cells support a pathway for mediating the infiltration of Ly6C+ monocytes 
and PMN by CXCR2 and CXCR4 chemokines and the development of monocytes into 
CD11b+MHC-low macrophages. These infiltrating cells are likely to interact with other 
cells to cause the pathological conditions in GN.
Funding: Other NIH Support - NIAID
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Mono-Sodium Urate (MSU) Activates PKR and NLRP3 Inflammasome in 
Human Renal Proximal Tubular Cells (HRPTCs)  Shabirul Haque, Nairuti 
H. Shah, Rabani Bharara, Ramachandra prasanna Bongu, Gauri P. Patil, Amrita 
Kaur Chawla, Ashwani Malhotra, Pravin C. Singhal.  Medicine, Hofstra North 
Shore LIJ Medical School, Great Neck, NY.
Background: Protein kinase R (PKR) is triggered by double stranded RNA (ds-
RNA) which directly interacts with NLRP3 and activates NLRP3 infalammasomes. 
Infalammasome is a multiprotein complex consists of caspasse-1, ASC, and NLRPs 
proteins. Inflammasome activation and maturation augments secretion of proinflammatory 
cytokines interleukin (IL)-1β and IL-18. High serum uric acid levels have also been 
reported to promote both acute and chronic tubulointerstitial disease. However, the role of 
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PKR in MSU mediated tubular cell infalammasome complex has not been investigated. 
We hypothesized that MSU triggers PKR pathway to activate NLRP3 inflammasomes in 
tubulointerstitial fibrosis.
Methods: Human renal proximal tubular cells (HRPTCs) were incubated with MSU 
(100 µg/ml) for either 24 or 48 hours and assayed for pyroptosis by a morphologic assay 
(through staining with H3342 and propidium iodide). To determine the involved mechanism, 
protein blots of HRPTCs treated with MSU (100 mg/ml) for 48 hrs were probed for PKR and 
actin. Total RNA was extracted from HRPTCs treated under similar conditions and cDNAs 
were amplified with specific primers. To establish causal relationship between caspase-1 
activation and pyroptosis, HRPTCs were pulsed with MSU in the presence or absence 
of caspase-1 inhibitor and then assayed for pyroptosis. To establish a causal relationship 
between NLRP3 mediated induction of K-efflux and inflammasome formation, HRPTCs 
were treated with MSU with/without glyburide.
Results: MSU exposure enhanced tubular cell pyroptosis. MSU promoted transcription 
of NLPR3, caspase-1, and IL-1β. MSU exposure augmented protein expression of PKR, 
NLRP3, IL-1β and caspase-1. MSU-induced pyroptosis was attenuated by caspase-1 
inhibitor. Glyburide treatment showed downregulation of NLRP3, caspase-1 and IL-1β 
expressions in MSU treated HRPTCs.
Conclusions: MSU activates PKR which leads to NLRP3 inflammasome activation 
and pyroptosis in HRPTCs.
TH-PO290
Hyperglycemia-Induced NLRP3 Inflammasome Formation Contributes 
to Podocyte Dedifferentiation via IL-1β and p53  Shabirul Haque, Gauri P. 
Patil, Amrita Kaur Chawla, Anjali Maheshwari, Ramachandra prasanna Bongu, 
Rabani Bharara, Rivka Lederman, Ashwani Malhotra, Pravin C. Singhal. 
Medicine, Hofstra North Shore LIJ Medical School, Great Neck, NY.
Background: NLRP3 inflammasomes have been reported to play a role in 
hyperglycemia associated morbidities including diabetic nephropathy. Functionally active 
inflammasome pathway promotes the maturation of proinflammatory cytokines such as 
IL-1β and IL-18. We hypothesize that hyperglycemia-induced NLRP3 inflammasome 
complexes would down regulate p53 pathway through the generation of IL-1β. These 
interactions would lead to dedifferentiation of podocytes in high glucose milieu.
Methods: Human podocytes (HPs) were incubated in media containing either buffer 
(C/HP) or high glucose (35 mM, HG/HP) for variable time periods. High glucose (HG) and 
normal glucose (NG) conditioned media (CM) were collected. Total RNA was extracted 
from cellular lysates and cDNAs were amplified with specific primers for inflammasome 
molecular markers (IMMs, NLRP3, ASC, caspase-1, IL-1β, and IL-18). Protein blots of 
C/HPs and HG/HPs were probed for NLRP3 and reprobed for protein expression of IMMs 
and actin. To establish a causal relationship between HG and IMMs, HPs were incubated 
in media with/without HG in the presence or absence of casapse-1 inhibitor/glyburide 
(K-efflux inhibitor) for 48 hours followed by mRNA and protein analysis for IMMs. 
Effects of IL-1 β alone and HG-CM were evaluated on podocyte dedifferentiation (loss of 
podocyte markers- nephrin and syanptopodin by Western blot analysis and immunolabeling).
Results: HG upregulated mRNA and protein expressions of NLRP3, casapse-1, 
ASC, IL-1β in HPs. Both caspasse-1 inhibitor and glyburide inhibited mRNA and protein 
expression of IMMs in HG/HPs. HG-CM not only downregulated p53 mRNA transcription 
but also induced dedifferentiation in HPs in the form of attenuated expression of nephrin 
and synaptopodin. IL-1β down regulated p53, nephrin and synaptopodin expressions in HPs.
Conclusions: Hyperglycemia induces dedifferentiation of HPs through inflammasome 
formation and down regulation of p53.
Funding: NIDDK Support
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Human Renal Proximal Tubular Epithelial Cells: Effects of Primary 
Cilia Loss on Epithelial Phenotype and Function  Michael Higgins, Tara 
McMorrow.  School of Biomolecular and Biomedical Science, Conway Inst, 
Univ College Dublin, Dublin, Ireland.
Background: The primary cilium is a hair-like microtubule based structure, protruding 
from nearly all mammalian cells. Originally thought to be a vestigial organelle, it is now 
well established as a crucial signalling hub. The importance of the primary cilium in cell 
signalling has become clear with a range of diseases associated with its loss (ciliopathies). 
Recently there has been increased interest in the link between the primary cilium and the 
development and progression of cancer, with several cilia associated genes dysregulated in 
numerous cancers. The primary cilium has been found to be absent in renal cell carcinomas, 
breast and pancreatic cancers. The aim of this study was to investigate the functional and 
mechanistic link between cilia and important epithelial characteristics including epithelial 
marker expression and barrier function. This involved assessing the effects of cilia loss in 
a human renal proximal tubular epithelial cell line (RPTEC/TERT1).
Methods: Deciliating agents were used to induce loss of the primary cilium. 
Immunofluorescent labelling of the ciliary marker acetylated α-tubulin was used to detect 
the primary cilium in the RPTEC/TERT1 cells. Western blotting was used to assess epithelial 
marker expression and tight junction protein expression. Trans-epithelial electrical resistance 
(TEER) was measured to assess epithelial barrier function following cilia loss.
Results: Removal of cilia from RPTEC/TERT1 cells by deciliating agents was 
confirmed by acetylated α-tubulin staining. Deciliation was found to cause alteration of 
tight junction protein expression, in particular claudin family members. Cilia loss caused 
an increase in TEER, suggesting a decrease in tight junction permeability and a change in 
epithelial barrier function following deciliation.
Conclusions: Results suggest an altering of epithelial cell junctions and barrier function 
following deciliation. Further analysis is being carried out to understand the relationship 
between the primary cilium and the maintenance of an epithelial phenotype and function.
TH-PO292
Development of a Novel Human Renal Proximal Tubule Epithelial Cell 
Culture Model That Retains Robust Mitochondrial Respiratory Capacity, 
and Critical In Vivo Renal Functional Attributes  Diana Zepeda-Orozco,1 
Kathryn S. Brown,1 Arpit Sharma,2 Ian M. Thornell,3 Eric Taylor.2  1Pediatrics, 
Univ of Iowa, Iowa City, IA; 2Biochemistry, Univ of Iowa, Iowa City, IA; 3Internal 
Medicine, Univ of Iowa, Iowa City, IA.
Background: Renal mitochondrial dysfunction and oxidative stress are implicated in 
diabetic kidney disease, acute kidney injury, and the progression of chronic kidney disease. 
The renal proximal tubule is a mitochondria-rich nephron segment that relies on oxidative 
phosphorylation to carry out its multiple, metabolically demanding absorptive and buffering 
functions. However, mechanistic investigation of proximal tubule mitochondrial biology 
with cell culture systems in vitro is challenging because available immortal proximal 
tubule epithelial cells exhibit a transformed, glycolytic metabolism concomitant with loss 
of key functional parameters.
Methods: In this study, primary human renal proximal tubule epithelial cells (PTECs) 
were immortalized (iPTEC) by retroviral transduction with hTERT and papilloma virus. 
To test their utility as a cell culture model of in vivo kidney function, we evaluated iPTECs 
for retention of mitochondrial respiratory capacity and key proximal tubule cell functional 
attributes.
Results: iPTECs maintained capacity for mitochondrial respiration and oxidative 
phosphorylation utilizing several substrates including pyruvate and glutamine. Furthermore, 
iPTECs retained critical proximal tubule functional characteristics, including monolayer 
formation with expression of E-cadherin, expression of proximal tubule cell transporters, 
and the ability to perform gluconeogenesis and ammoniagenesis. iPTECs plated on millicell 
cell culture inserts developed transepithelial potential that was maximal on day 20 and 
mediated in part by polarized Na/K-ATPase expression in the basolateral membrane.
Conclusions: The development of an immortalized PTEC line with broad retention of 
in vivo functional attributes, including robust oxidative phosphorylation, will enable the 
study of mitochondria biology in kidney health and disease.
TH-PO293
Pangenomic Analyses of Hypoxia Inducible Factor (HIF) Pathway 
Activation in Human Primary Renal Tubular Cells  Steffen Grampp,1 
Franziska Bertelshofer,2 Margarete Goppelt-Struebe,1 Kai-Uwe Eckardt,1 
Johannes Schödel.1  1Dept of Nephrology and Hypertension, Friedrich-
Alexander-Univ Erlangen Nürnberg, Erlangen, Germany; 2Computer Graphics 
Group, Friedrich-Alexander-Univ Erlangen Nürnberg, Erlangen, Germany.
Background: In the kidney, epithelial integrity is crucial for organ function. Ischemic or 
toxic damage of tubular cells can cause acute kidney injury. Preconditional stabilization of 
hypoxia inducible factor 1 alpha (HIF-1α) in tubular cells is beneficial in animal models of 
acute kidney injury. The precise protective mechanisms and the relevance of the HIF system 
in human kidneys remain unknown. Therefore, the aim of this study was to characterize 
the hypoxic response and to investigate direct HIF effects in primary human tubular cells.
Methods: Healthy human kidney tissue from patients undergoing tumour nephrectomy 
was used for tissue studies and isolation of primary tubular cells. HIFs were stabilized using 
hypoxia (1%) or the hypoxia-mimetic dimethyl oxallylglycine. We used genome-wide 
analyses of open chromatin (FAIRE-seq) and HIF DNA-binding (ChIP-seq) in freshly 
isolated primary human tubular cells from several individuals to define conserved regulatory 
DNA elements and HIF-binding sites.
Results: Immunohistochemistry experiments using human kidney tissue revealed 
the presence of HIF-1α protein in tubular cells. Co-staining with 11β-hydroxy steroid 
dehydrogenase localized HIF-1α signals predominantly in the distal convoluted tubule and 
the collecting duct. Using ChIP-seq we identified over 500 high-stringency HIF-1 binding 
sites. HIF DNA-binding was strongly enriched in regions of open chromatin and regulatory 
regions. Patterns of HIF-DNA interactions were conserved across several individuals. 
Functional clustering of HIF-binding genes showed strong enrichment for protective 
pathways and included novel binding sites at renoprotective genes such as HO-1 and MUC1.
Conclusions: The importance of the HIF system for cell survival and integrity is well 
documented for rodent kidneys. We expand analyses of the renal HIF response to human 
kidneys and identify important mechanisms to potentially preserve tubular function in 
human kidney disease.
Funding: Government Support - Non-U.S.
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The Na-H Exchanger Regulatory Factor Isoform 1 Is a Critical Determinant 
of Renal Proximal Tubule Brush Border Composition  Rebecca Murray,1,2 
Corey James Ketchem,1 Amanda R. Sherwood,1 Michael Merchant,1 Lauren 
D. Grant,1 Barbara Clark,1,3 Syed J. Khundmiri,1,2,4 Eleanor D. Lederer.1,2,4 
1Medicine, Univ of Louisville, Louisville, KY; 2Medical Services, Robley Rex 
9A Medical Center, Louisville, KY; 3Biochemistry and Molecular Biology, Univ 
of Louisville, Louisville, KY; 4Physiology, Univ of Louisville, Louisville, KY.
Background: The Na-H Exchanger Regulatory Factor Isoform 1 (NHERF1), a 
multifunctional scaffolding protein, is required for regulated forward trafficking and brush 
border membrane (BBM) anchoring of the type IIa sodium phosphate cotransporter, Npt2a. 
We have shown that OK cells, a model of proximal tubule, lacking NHERF1 (OKH) have 
decreased BBM expression of Npt2a, SGLT1, ezrin, GGTase and Munc18. OKH cells 
also show a 50% decrease in total RNA levels and a near absence of Npt2a mRNA. We 
hypothesize that NHERF1 plays a defining role in BBM protein expression.
Methods: To test this hypothesis, we performed proteomic analysis of BBM proteins 
from WT and NHERF1 deficient (KO) mice and measured mRNA expression of selected 
transport proteins from WT and OKH cells.
Results: We identified 148 proteins whose expression was downregulated at least 
two fold and 78 proteins whose expression was upregulated at least three fold in KO 
mouse BBM. 14 proteins were absent in KO. Integrity Pathway Analysis demonstrated 
that 113 of the downregulated proteins were involved in cellular organization, assembly, 
function, or maintenance, specifically, microvilli and actin cytoskeleton structure (Shroom4, 
Fascin), protein trafficking (CLIC1 and 4), signaling (taperin, FGFR2), and repair. 
Immunohistochemistry of KO kidneys and scanning electron microscopy of OKH cells 
show no obvious defects in cell structure/polarity. The mRNA levels of Npt2a, SGLT1, 
and NHE3 in OKH were less than 50% of WT but promoter activity of SGLT1 was similar.
Conclusions: We conclude that the presence of NHERF1 defines renal BBM protein 
expression through post-transcriptional, trafficking, and anchoring mechanisms.
Funding: Other NIH Support - NIA, Veterans Administration Support, Clinical 
Revenue Support
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Tamm-Horsfall Protein (Uromodulin) Regulates IL-23 Expression in S3 
Segments by Inhibiting the Rac-1-NOX2 Signaling Pathway of Oxidative 
Stress  Radmila Micanovic, Shehnaz Khan, Frank Witzmann, Tarek M. 
El-Achkar.  Indiana Univ School of medicine.
Background: We recently showed that Tamm-Horsfall protein regulates granulopoiesis 
by inhibiting the expression of IL-23 in S3 segments and the resultant activation of the 
IL-23/IL-17 axis. The molecular mechanism of this observation is unclear.
Methods: We performed laser micro-dissection (LMD) of S3 segments from THP-/- 
and THP+/+ kidney sections followed by 2 Dimensional –Differential Gel Electrophoresis 
(2D-DIGE) to identify pathways that are modulated by THP in vivo. We also used an 
unbiased, label free proteomics approach to understand the signaling of THP on human 
proximal HK-2 cells. Additional experimental methodology is described in Results.
Results: Bioinformatics analysis of differentially expressed proteins in S3 segments 
dissected from THP-/- compared to THP+/+ kidneys revealed that the free radical scavenging 
network had the highest score of clustering, suggesting that THP regulates redox balance 
in S3 segments. Using in vivo reporter dyes and by measuring enzymatic markers of 
oxidative stress (OS), we found increased OS in S3 segments from THP-/-compared to 
THP+/+ kidneys. Label-free proteomic analysis of HK-2 cells revealed that incubation of 
these cells with THP inhibited multiple pathways that converge on Rac-1 signaling. Since 
Rac-1 signaling is essential to the activation of NADPH oxidase (NOX), a major source 
of reactive oxygen species in cells, we verified that THP-/- mice had increased expression 
of Rac-1 and Nox-2 but not Nox-4. Treatment of HK-2 cells with THP directly decreased 
IL-23 expression. In addition, oxidative insult using H2O2, but not LPS, stimulated IL-23 
mRNA expression in these cells, suggesting that oxidative stress but not classical endotoxin 
signaling, is needed for IL-23 induction in epithelial cells.
Conclusions: Taken together, our data support that THP inhibits Rac-1/NOX-2 
oxidative stress in S3 segments, which in turn regulates the production of IL-23 and 
activation of the IL-23/IL-17 axis. These findings significantly enhance our understanding 
of how THP shapes the function and reactivity of S3 segments, which could have both renal 
and systemic implications, through the regulation of granulopoiesis.
Funding: Veterans Administration Support
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Hydrophobic Motif Site Phosphorylation of Protein Kinase CbetaII 
by mTORC2 Regulates High Glucose (HG)-Induced Mesangial Cell 
Hypertrophy  Falguni Das, Nandini Ghosh-choudhury, Meenalakshmi M. 
Mariappan, Balakuntalam S. Kasinath, Goutam Ghosh-Choudhury.  Univ of 
Texas Health Science Center at San Antonio, San Antonio, TX.
Background: Protein kinase C beta II (PKCbII) has been implicated in diabetic 
nephropathy (DN). Mesangial cell (MC) hypertrophy is a pathologic feature of DN. PKCbII 
undergoes phosphorylation at the hydrophobic motif site Ser-660 for its activity. We have 
shown that mTOR complex 1 (C1) regulates MC hypertrophy. How activation of PKCbII by 
Ser-660 phosphorylation fits into mTOR signaling to control MC hypertrophy is not known.
Methods: Human MCs, immunoblotting, siRNA and shRNA transfections, protein 
synthesis assays were used.
Results: HG significantly increased phosphorylation of PKCbII at Ser-660 in a PI 
3 kinase-dependent manner. siRNAs against PKCbII, dominant negative PKCbII and 
nonphosphorylatable mutant of PKCbII, PKCbIIS660A, blocked mTORC1 activity due 
to lack of PRAS40 phosphorylation, resulting in significant inhibition of HG-induced 
MC protein synthesis and hypertrophy. Also, PKCbIIS660A attenuated phosphorylation 
of Akt at Ser-473, a putative mTOR complex 2 (C2) site. Specific inhibition of mTORC2 
by shRNAs against rictor or Sin1, two exclusive and required components for its activity, 
suppressed HG-induced phosphorylation of PKCbII Ser-660, PRAS40 and Akt Ser-473, 
resulting in attenuation of mTORC1 activity leading to inhibition of MC hypertrophy. 
Constitutively active (CA) Akt or CA mTORC1 reversed shRictor- or shSin1-mediated 
inhibition of HG-induced MC hypertrophy. Furthermore, CA PKCbII reversed the shRictor- 
or shSin1-induced inhibition of HG-stimulated Akt Ser-473 phosphorylation and MC 
hypertrophy. Finally, we show increased phosphorylation of PKCbII Ser660, PRAS40 
and Akt Ser-473 in association with activation of mTORC1 in renal cortices of OVE26 
mice with type 1 diabetes.
Conclusions: These results provide the first evidence that HG-induced activation of 
mTORC2 phosphorylates and activates PKCbII to increase the phosphorylation of Akt 
at Ser-473 to finally activate mTORC1 to induce MC hypertrophy. Thus, we uncover a 
specific role of mTORC2 for Akt/mTORC1 activation via PKCbII Ser-660 phosphorylation.
Funding: NIDDK Support, Veterans Administration Support
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Hyaluronan Mediated Motility Receptor Regulates Cell Motility 
in Glomerular Endothelial Cells in Response to Shear Stress 
Hesham e hussien Elhegni, Gavin Iain Welsh, Simon C. Satchell.  Academic 
Renal Unit, Univ of Bristol, Bristol, United Kingdom.
Background: Laminar shear stress (LSS) is an important determinant of vascular 
health. The glycocalyx is a carbohydrate-rich layer that covers the endothelial cell surface. 
Glycocalyx translates shear forces into intracellular signals. Hyaluronan (HA) motility 
mediated receptor (HMMR) promotes cell motility and invasion through interactions with 
HA on the cell surface in non-renal cells.
Methods: Human conditionally immortalized glomerular endothelial cells (GEnC) 
were exposed to LSS (10 dyn/cm2) using an orbital rotator for 0, 24, 48 and 72h. Effects 
on expression of glycocalyx-related genes were analysed using a custom designed focused 
Taqman qPCR array. HMMR and CD44 (another hyaluronan receptor) and production of HA 
itself by radiolabelling were also assessed. Motility assays (scratch assay, 2D chemotaxis and 
Electric Cell-Substrate Impedance Sensing) were performed on GEnC and siRNA HMMR 
knockdown GEnC with and without HA fragments. HMMR expression was assessed on 
freshly isolated and cultured glomeruli.
Results: There was a significant increase in versican expression, peaking at 24h. 
Thrombomodulin expression significantly increased and reached a plateau within 24h. 
CD44 expression peaked at 72h of LSS. There was a dramatic decline in HMMR expression 
by 24h of LSS (10-fold decrease p<0.0001) and levels remained suppressed over 72h. 
Furthermore, HMMR recovered to nearly pre-LSS level after a period without LSS for 24h. 
LSS increased release of HA into culture medium. What is more, HA fragments increased 
cell motility where LSS for 24h reduced it. HA fragments did not increase cell motility on 
siRNA HMMR knockdown GEnC. HMMR expression was increased in isolated glomeruli 
after 24h in culture.
Conclusions: HMMR is exquisitely shear-sensitive in vivo and ex vivo and acts as 
a marker for LSS exposure in endothelial cells. Chronic LSS reduces cell motility. Our 
data suggest this is due to HMMR expression changes and that HMMR is likely to play 
important roles in glomerular physiology and disease.
Funding: Government Support - Non-U.S.
TH-PO299
Cell Surface Expression of TRPC6 in Podocytes Depends on Synaptopodin 
Stability  Hao Yu,1 Andreas D. Kistler,2 James Otto Meyer,3 Jochen Reiser.1 
1Internal Medicine, Rush Univ, Chicago, IL; 2Internal Medicine, Cantonal 
Hospital Frauenfeld, Frauenfeld, Switzerland; 3Neuroscience, Univ College 
London, London, United Kingdom.
Background: TRPC6 gain-of-function mutations and increased TRPC6 expression 
in podocytes were found in familial FSGS and acquired glomerular diseases. TRPC6 is 
expressed in synaptopodin (synpo) rich podocyte yet only a fraction is located on plasma 
membrane. Modulation of localization and function of TRPC6 harbors potential for 
treatments.
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Methods: Immunogold and co-IP were performed to examine co-localization and 
interaction of TRPC6 and synpo. Cell surface biotinylation and high throughput analysis 
were used for quantitative analysis of cell surface levels of TRPC6. Calcium imaging 
was performed to measure calcium influx mediated by TRPC6. Glomerular isolation, 
biotinylation and podocyte enrichment were performed to determine podocyte membrane 
TRPC6 levels in vivo.
Results: Co-localization of TRPC6 and synpo was observed in podocyte foot processes 
by immunogold double labeling in mouse kidney. Interaction of the two proteins was 
observed by co-IP in cultured podocytes and mouse glomeruli. TRPC6 levels on cell surface 
increased in synpo knockdown podocytes and decreased in synpo overexpressing podocytes. 
Consistent with the changes in expression levels, calcium influx mediated by TRPC6 was 
enhanced in synpo knockdown podocytes and reduced in synpo overexpressing podocytes. 
Mechanistically, we found both actin and microtubule cytoskeletons were involved in 
regulating membrane TRPC6 expression affected by synpo. Membrane TRPC6 expression 
in podocytes was elevated upon LPS treatment and was restored by cyclosporine A (CsA) 
in WT mice. Functionally, CsA treatment significantly reduced LPS proteinuria in WT 
mice (71%) and to a lesser extent in TRPC6-/- mice (45%).
Conclusions: Synaptopodin limits expression of TRPC6 on podocyte plasma 
membrane. CsA, a drug that stabilizes synpo, is shown to lower podocyte surface TRPC6 
levels upon LPS treatment. The partial benefit of CsA in reducing LPS proteinuria in 
TRPC6-/- mice suggests that CsA protects podocytes partially by lowering cell surface 
expression of TRPC6 through stabilization of synpo.
Funding: NIDDK Support
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APOL1 Risk Variants Enhance Podocyte Oxidative Stress  Xiqian Lan, 
Hongxiu Wen, Ashwani Malhotra, Karl Leon Skorecki, Pravin C. Singhal. 
Medicine, Hofstra North Shore LIJ Medical School, Great Neck, NY.
Background: APOL1 variants have been implicated for increased prevalence and 
acceleration in the rate of progression of kidney diseases amongst African Americans. 
Since oxidative stress has been demonstrated to play a role for loss of podocytes in both 
experimental animal and human kidney disease models, we hypothesized that APOL1 
variants could be inducing podocyte injury through augmentation of oxidative stress.
Methods: Human podocytes (HPs) stably expressing Vector, APOL1G0, APOL1G1, 
or APOL1G2 were used. Pseudo type HIV or empty vector (control) virus was transduced 
into Vector/HPs, G0/HPs, G1/HPs, and G2/HPs. After 48 h, cells were loaded with DCFDA 
and ROS generation was assayed every 10 min for 60 min by a fluorometer. Three sets 
of experiments were carried out in triplicate. Protein blots of HPs expressing Vector, 
APOL1G0, APOL1G1 and APL1G2 were probed for molecular markers for oxidative 
stress and associated down stream signaling (phospho-p53, phospho-Foxo3A, p27, BAD, 
RIP3, MnSOD, and catalase). To evaluate the status of apoptotic pathway, protein blots of 
HPs expressing Vector, APOL1G0, APOL1G1, and APOL1G2 were probed for caspase-3 
and then reprobed for actin. To determine the role the activation of Ang II type I (AT1R) 
and II (AT2R), protein blots of HPs expressing APOL1 and variants were probed for 
AT1R and AT2R.
Results: Both HP/G1 and HP/G2 displayed increased ROS generation when compared 
to Vec/HPs and G0/HPs. G1/HPs and G2/HPs displayed higher expression of pro-oxidant 
molecules, including RIP3, P27, BAD, phospho-FOXO3A, phospho-P53; HP/G1 and HP/
G2 also enhanced expression of cleaved caspase-3 when compared with vector/HPs and G0/
HPs. However, both G1/HPs and G2/HPs displayed lower expression of MnSOD and AT2R. 
Both G1/HPs and G2/HPs displayed greater ROS generation and enhanced expression of 
pro-oxidant molecules in HIV milieu when compared to vector/HPs and G0/HPs.
Conclusions: These results indicate that APOL1 risk variants have potential to augment 
oxidative stress in podocytes and this effect is further exacerbated in HIV milieu.
TH-PO301
The SMAD2/3 Ratio Is Controlled by PLCe in Podocytes  Carl J. May,1 
Gavin Iain Welsh,1 Moin Saleem.1,2  1Academic Renal Unit, Univ of Bristol, 
Bristol, United Kingdom; 2Children¶s Renal Unit, Bristol Children¶s Hospital, 
Bristol, United Kingdom.
Background: Podocytes are thought to be the target cell in nephrotic syndrome 
pathogenesis. Mutations in PLCE1: which encodes a lipid signalling enzyme, have been 
reported in patients with early onset nephrotic syndrome. However, the effects of mutations 
in PLCE1 in the mature podocyte are not clear.
Methods: A conditionally immortalised human podocyte cell line was established 
from a patient, with a SNP at nucleotide 321 of PLCE1 that leads to a stop codon. This 
mutation severely truncates the protein such that no protein expression was detected. This 
cell line was characterised in order to investigate the deleterious effect of this mutation on 
podocyte phenotype and function.
Results: The PLCE1 mutant podocytes express lower levels of both epithelial and 
podocyte markers than wild-type cells. Morphologically they appear more mesenchymal. 
They demostrate a diminished response to TGF-B1 compared to the wild-type. Interestingly 
the PLCE1 mutant podocytes show no SMAD2 phosphorylation but a robust SMAD3 
phosphorylation. Whereas, the wild-type podocytes which show marked SMAD2 
phosphorylation and only low level SMAD3 phosphorylation. It is thought that the SMAD2 
pathway is anti-fibrotic while the SMAD3 pathway is pro-fibrotic. The PLCE1 mutant 
podocytes had equal levels of SMAD2 and SMAD3 while the wild-type podocytes had 
twice the amount of SMAD2 compared to SMAD3. This biases TGF-B1 signaling along 
the anti-fibrotic SMAD2 pathway in the wild type. Despite the 1:1 ratio between SMAD2 
and SMAD3 the lack of SMAD2 phosphorylation shows that the PLCE1 mutant podocytes 
are biased towards the pro-fibrotic SMAD3 signaling. Most interestingly, however, PLCE1 
knockdown by siRNA in the Wild-type pdoocytes increased the expression of SMAD3 
relative to SMAD2. This changes the SMAD bias of the podocyte.
Conclusions: This work suggests that by altering the SMAD2/3 ratio within the 
podocyte, the PLCE1 mutant enhances the pro-fibrotic response to TGF-B1. This provides 
a novel therapeutic target to modulate the podocyte’s response to TGF-B1 and may prove 
to be protective against the development of fibrosis.
TH-PO302
Dynamin Oligomerization Plays a Catalytic and Structural Role with 
Regard to Actin Dynamics During Actin-Dependent Clathrin Mediated 
Endocytosis  Changkyu Gu, Sanja Sever.  Nephrology, Massachusetts General 
Hospital, Charlestown, MA.
Background: The GTPase dynamin is essential for podocyte structure and function 
as it plays a role in regulating endocytosis and the actin cytoskeleton. Recently, using a 
combination of different dynamin mutants and Bis-T-23, we showed that it is possible 
to directly target actin cytoskeleton dynamics by targeting the dynamin oligomerization 
cycle in the whole organism. It has been shown that direct dynamin-actin interactions 
are required for the scission of the clathrin-coated pits in yeast. While actin is critical for 
endocytosis in yeast cells, data suggest that it plays a cell type specific role in endocytosis 
in mammalian cell. In this study, we aim to investigate the functional role for dynamin 
oligomerization in endocytosis.
Methods: Actin polymerization assay was performed to investigate dynamin 
oligomerization-driven actin polymerization using purified proteins or cytosolic extracts. 
Electron microscopy was used to explore the effects of dynamin on actin structures. Tfn 
uptake assay and Transmission electron microscopy were used to examine endocytosis 
and Clathrin coated pits profiles respectively.  Total internal reflection fluorescence 
microscopy was used to monitor clathrin medicated endocytosis.
Results: Here we show, using a combination of diverse dynamin mutants and a small 
molecule that specifically promotes actin-dependent dynamin oligomerization named 
Bis-T-23, that dynamin provides a physiological link between gelsolin and Arp2/3 complex 
driven actin polymerization. Dynaminpromoted Arp2/3 complex driven nucleation by 
providing free barbed ends via gelsolin displacement in vitro, in cell extracts and in the 
cell.In addition, dynamin oligomers exhibited a structural role with regard to the actin 
cytoskeleton by crosslinking microfilaments. This dual role of dynamin oligomerization 
with regard to the actin cytoskeleton (kinetic and structural) regulated actin dynamics 
at distinct stages of clathrin-coated vesicle formation, including coated pit formation, 
constriction and fission.
Conclusions: Dynamin oligomerization plays a catalytic and structural role with regard 
to actin dynamics during actin-dependent clathrin mediated endocytosis.
Funding: NIDDK Support
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Functional Characterization of β-Catenin in Podocyte Damage 
Michelle Duong, Beina Teng, Hermann G. Haller, Mario Schiffer.  Nephrology, 
Medical School Hanover.
Background: β-Catenin plays a crucial role in the Wnt signaling pathway as well 
as in cell adhesion. In the kidney β-Catenin is critically involved in the development of 
proteinuria and podocyte damage. Here we investigated if the injury is associated with a 
certain subcellular localization of β-Catenin and/or is mediated via its binding partner: 
α-Catenin is an essential binding partner of β-Catenin, which leads to a proper adhesion 
between cells while the function of β-Catenin as a gene transcription regulator is linked 
with TCF (T cell-lymphoid factor).
Methods: We used the zebrafish model to express human β-Catenin mutants lacking 
the ability to bind α-Catenin or TCF. To examine the impact of β-Catenin acting in only 
one of its subcellular localization, we expressed β-Catenin either in the membrane or in 
the nucleus. Knockdown of endogenous β-Catenin was conducted by morpholino injection 
and co-expression of the mutants by injection of mRNA. After that the integrity of the 
glomerular filtration barrier was analyzed.
Results: Our analysis revealed that β-Catenin tethered to the membrane only seems 
to be able to partially retain the glomerular filtration barrier, whereas nuclear β-Catenin 
alone cannot abrogate the impact of the β-Catenin knockdown and leads to loss of high 
molecular weight proteins from the circulation. Further, zebrafish with β-Catenin missing the 
function of binding TCF have a normal glomerular filtration function, while the expression 
of β-Catenin unable to bind to α-Catenin leads to proteinuria.
Conclusions: These results suggest that the cell-cell adhesion function of β-Catenin 
is of greater importance for the maintenance of the glomerular filtration barrier than its 
role as a transcription factor.
Funding: Government Support - Non-U.S.
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Vitamin D (VD) Upregulates Nephrin in HIV-Induced Dedifferentiated 
Podocytes Through Down Regulation of SNAIL  Nirupama Chandel, Rivka 
Lederman, Ashwani Malhotra, Pravin C. Singhal.  Medicine, Hofstra North 
Shore LIJ Medical School, Great Neck, NY.
Background: HIV infection of kidney cells plays a key role in the development of HIV-
associated nephropathy (HIVAN). We recently observed that HIV-induced dedifferentiations 
of podocytes regulated through SNAIL. We hypothesize that VD has potential to prevent 
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the Nephrin downregulation through modulation of SNAIL expression. VD may be down 
regulating SNAIL either through demethylating the signature of active transcritption (H3K4 
trimethylatione) at snail promoter or at Nephrine promoter (H3 K27 trimethyllation) or 
either through reversal of HIV-induced stabilization of SNAIL.
Methods: Renal tissues were harvested from (FVB/N) and HIV-transgenic (Tg26) 
mice, and VD (EB1089) receiving FVBN and Tg26 mice for two weeks (n=3, 4 wk old). 
In vitro studies, human podocytes (HPs) were transduced with either empty vector (EV) 
or NL4-3(HIV). EV/HPs and HIV/HPs were treated with EB1089 for 48 hours. Protein 
blots of renal tissues, EV/HPs and HIV/HPs with/without VD were probed for SNAIL, p62 
(marker of endosomal cargo degradation), and histone trimethylation. Immunoprecipitation 
(IP) studies were carried in cellular lysates of EV/HPs and HIV/HPs with SNAIL antibody. 
Binding of SNAIL at VDR promoter was evaluated by ChIP assay. Additionally, we 
evaluated the effect VD on disruption of SNAIL repressor complex at nephrin promoter.
Results: Renal tissues from Tg26 mice (n=3) displayed enhanced SNAIL transcription 
as well as translation but downregulation of nephrin. VD not only down regulated SNAIL 
but also uptegulated nephrin expression in renal tissues of Tg26 mice as well as in HIV/
HPs. Chip assay revealed enhanced trimethylation at SNAIL promoter and binding of 
SNAIL at Nephrin promoter in HIV/HPs. VD also enhanced nephrin expression through 
disruption of SNAIL repressor complex at nephrin promoter in HIV/HPs. HIV/HP displayed 
decreased levels of p62 which signifies increased HIV induced autophagy in in vitro system.
Conclusions: VD has potential to upregulate nephrin expression in HIV-induced 
dedifferentiated podocytes through multiple ways including modulation of HIV-induced 
epigenetic alterations, autophagy, and disruption of SNAIL repressor complexes.
TH-PO305
Krüppel-Like Factor 15 Mediates Glucocorticoid-Induced Podocyte 
Differentiation  Sandeep K. Mallipattu,1 Lucia Roa,1 Timothy W. Miller,1 Jason 
Ling,1 Victoria Ly,1 Monica Patricia Revelo Penafiel,3 John C. He.2  1Medicine/
Nephrology, Stony Brook Medicine; 2Medicine/Nephrology, Mount Sinai School 
of Medicine; 3Pathology, Univ of Utah.
Background: Glucocorticoids (GCs) are the initial and often, the primary, treatment for 
primary glomerulopathies such as MCD and FSGS. The mechanism by which GCs restores 
podocyte differentiation and improves cell survival is unclear. We previously demonstrated 
that Krüppel-Like Factor 15 (KLF15), a kidney-enriched zinc-finger transcription factor, 
was required for podocyte differentiation. Here, we hypothesize that KLF15 mediates 
GC-induced podocyte differentiation.
Methods: Human podocytes (HP) and primary mouse podocytes (MP) were treated with 
and without dexamethasone (DEX) (1µM, 10µM) for 3, 6, 12, and 24 hours. Initially, we 
generated podocyte-specific knockout mice, Podocin-Cre Klf15flox/flox (Klf15-/-). Proteinuria 
was induced in Klf15-/- and wildtype mice with LPS (10mg/g) and subsequently treated with 
or without DEX (1mg/kg). HP with stable overexpression of KLF15 (Lenti2RF-KLF) 
were generated. Immunostaining for KLF15 was performed on kidney biopsies from patients 
with healthy donor nephrectomies (n=16), GC-responsive (n=20), and GC-nonresponsive 
(n=15) FSGS and MCD.
Results: KLF expression was induced in HP and primary MP within 3 hours 
of DEX treatment. TRANSFAC promoter analysis revealed that KLF15 binding sites 
occupy genes involved in GC signaling. LPS-treated Klf15-/- mice exhibited less podocyte 
recovery (albuminuria, podocyte effacement, nephrin, and synaptopodin expression) after 
DEX administration as compared to LPS-treated wildtype mice. The pattern of Tnfα, Il-6, 
Il-1β, and Infγ were unchanged in the serum and glomerular extracts between both groups 
of mice treated with DEX. Furthermore, actin stress fiber formation was preserved with 
G1/S cell cycle arrest in HP with Lenti2RF-KLF as compared to Lenti2RF-RFP with 
LPS treatment. Finally, reduced expression of KLF15 in the glomeruli correlated with 
non-responsiveness to GCs in patients with MCD and FSGS.
Conclusions: These findings suggest that KLF15 is essential for GC-mediated 
restoration of differentiation markers, ultrastructure, and cell survival in the setting of 
podocyte injury.
Funding: NIDDK Support
TH-PO306
CXCR4 Plays a Crucial Role in Mediating Oxidative Stress-Induced 
Podocyte Injury  Hongyan Mo,1 Xue Hong,1 Lili Zhou,1 Youhua Liu.1,2 
1Div of Nephrology, Nanfang Hospital, Southern Medical Univ, Guangzhou, 
Guangdong, China; 2Dept of Pathology, Univ of Pittsburgh, Pittsburgh, PA.
Background: Oxidative stress is key mediator to podocyte damage and proteinuria. 
However, the underlying mechanism remains to be elucidated. In this study, we investigated 
the potential role of CXCR4, the chemokine receptor for SDF-1α, in mediating oxidative 
stress-induced podocyte injury.
Methods: In a mouse model of adriamycin nephropathy (ADR), CXCR4 mRNA and 
protein expression, as well as oxidative stress was examined. AOPPs, advanced oxidation 
protein products, were utilized to trigger oxidative stress, and their effects on podocyte 
dysfunction and CXCR4 expression were assessed. AMD3100, a specific inhibitor of 
CXCR4, was used to block CXCR4 action both in vitro and in vivo.
Results: CXCR4 expression was significantly induced in podocytes as early as 3 
days after injection of adriamycin. This was accompanied by an increased upregulation of 
oxidative stress in podocyte, as detected by MDA assay of kidney homogenate, nitrotyrosin 
staining in podocyte, and induction of NOX2, a major subunit of NADPH oxidase. Similar 
results were obtained when we stained for CXCR4 in human kidney biopsies from patients 
with proteinuric kidney diseases including IgAN, crescent and FSGS. Using immortal 
podocyte cell line MPC5 and mouse models of podocyte injury induced by ADR or 
AOPPs, we found that AOPPs induced significant loss of podocyte marker WT1, nephrin 
and podocalyxin, accompanied by upregulation of mesenchymal marker desmin both in 
vitro and vivo. Furthermore, AOPPs worsen proteinuria, aggravated glomerulosclerosis and 
renal fibrotic lesions. Concomitantly, SDF-1α/CXCR4 signaling was remarkably induced in 
podocytes by AOPPs. Administration of AMD3100, a specific inhibitor of CXCR4, reduced 
proteinuria, ameliorated podocyte dysfunction and renal fibrotic lesions triggered by AOPPs.
Conclusions: These results suggest that chemokine receptor CXCR4 may play a 
crucial role in mediating oxidative stress-induced podocyte injury, proteinuria and renal 
fibrotic lesions.
Funding: Government Support - Non-U.S.
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PKCİ Is Identified as a Novel Binding Partner of β-Catenin in Podocytes 
Xuejiao Yu,1 Beina Teng,1 Michelle Duong,1 Mario Schiffer.1  1Medical School 
Hannover.
Background: PKCα, one conventional isoform of PKC, is a binding partner of 
β-catenin. However, a link between PKCİ, a novel isoform, and β-catenin remains unclear. 
PKC഍ regulates the cytoskeleton by phosphorylating IQGAP1, a protein involved in the 
regulation of b-Catenin in the cell-cell adhesion complex. So, we investigated the association 
between PKC഍ and β-catenin.
Methods: Staining was performed on murine kidney sections and podocytes to examine 
the β-catenin expression. Time courses were performed in murine wild type and PKC഍-
/- podocytes. 7 promising phospho-motifs in β-catenin were selected and site-specific 
mutations were produced. The interaction between the β-catenin mutants and PKC഍ were 
verified by immunoprecipitation. The mutants were overexpressed in murine podocytes 
using adenovirus. Zebrafish larvae were injected with mutant β-catenin RNA.
Results: During the development of mice β-catenin showed increasing expression 
level in the glomeruli. However, the upregulation of β-catenin in wild type mice was 
much higher than those of PKCİ-/- mice. While in wild type podocytes,β-catenin showed a 
translocation from the perinuclear areas to the nuclei during differentiation, the distribution 
of β-catenin switched the reverse way in PKC഍-/- podocytes from the nuclei to the 
perinuclear areas. During the time course, the expression of active β-catenin was increased 
and total β-catenin decreased in the wild type podocytes under the stimulation of PMA. 
However, in the PKC഍-/- podocytes, both active β-catenin and total β-catenin displayed 
decreased expression level. 3 of 7 mutant β-catenin exhibited decreased interaction with 
PKC഍ in immunoprecipitation, indicating these phospho-motifs as importantbinding sites. 
Overexpression of these 3 mutants in wild type podocytes, showed no changes in the time 
course. These 3 mutant β-catenin were unable to rescue the β-catenin knockdown zebrafish.
Conclusions: It is the first time to indicate that PKC഍ binds β-catenin directly and 
they are involved in the process of glomerular disease and podocytes differentiation. 3 
phospho-motifs in β-catenin are proved as binding sites for PKC഍.
TH-PO308
Reactive Lipids Affect Podocyte Homeostasis Through the Redox Sensitive 
RhoA-Slit Diaphragm Protein-Akt Axis  Krisztian Stadler, Claudia Kruger. 
2xidative Stress and Disease Lab, Pennington Biomedical Research Center, 
Baton Rouge, LA.
Background: Podocyte loss is a characteristic early feature of obesity and diabetes 
related glomerular disease. Despite much attention on reactive lipids in diabetic kidney 
disease, surprisingly little is really known regarding their biological role in podocytes.
Methods: Here we developed a quantitative lipid radical generating system using 
the donor AAPH, and conditionally immortalized podocytes to test the effects of reactive 
lipids on podocyte homeostasis.
Results: Surprisingly, low levels of reactive lipids led to improved motility, dynamic 
rearrangements of F-actin filaments, increased basal Akt phosphorylation, and increased 
levels of slit diaphragm proteins nephrin and WT-1. As nephrin directly activates Akt, these 
observations can be interpreted as beneficial adaptation, adjusting podocyte physiology 
to an initial stress. Only higher levels of reactive lipids led to motility decline, F-actin 
aggregates and low levels of pAkt. Since motility and F-actin filaments were affected, we 
hypothesized that lipid radicals may be sensed through the redox active master regulator 
protein RhoA, modulating GTP-bound RhoA levels. RhoA has two redox sensitive cysteine 
residues that may serve as redox switches, resulting in GDP/GTP exchange and modulation 
of RhoA activity. When tested with a novel G-LISA assay, exposure of podocytes to low 
levels of reactive lipids indeed rapidly activated RhoA. Next, we have generated constructs 
to mutate Cys16, Cys20 or both residues on RhoA to ultimately test if RhoA activation is 
key in the redox sensing mechanism.
Conclusions: In contrast to the traditional view, our results suggest that lipid radicals 
may act on an adaptive to maladaptive scale to control redox sensitive mechanisms and 
podocyte physiology. Lipid radicals may affect important signaling elements of podocyte 
homeostasis in a tightly regulated fashion, through the RhoA-slit diaphragm proteins-
Akt axis. Therefore, modulating their levels can be a novel basis for redox-targeted drug 
development in diabetic complications, such as nephropathy.
Funding: NIDDK Support
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TH-PO309
The Redox Sensitive Glycogen Synthase Kinase (GSK) 3β Suppresses 
the Self-Protective Antioxidant Response in Podocytes upon Oxidative 
Glomerular Injury  Changbin Li,1 Yan Ge,1 Ai Peng,2 Rujun Gong.1 
1Nephrology, Brown Medical School, Providence, RI; 2Dept of Nephrology, 
Tongji Univ, Shanghai, China.
Background: GSK3 has been recently implicated in the pathogenesis of kidney 
diseases, including proteinuric glomerulopathy. However, prior studies were less 
conclusive because they relied solely on chemical inhibitors of GSK3, which provide poor 
discrimination between the isoforms of GSK3 apart from potential off target activities. This 
study aimed to examine the effect of podocyte specific ablation of GSK3β on glomerular 
pathophysiology.
Methods: GSK3β was selectively knocked out (KO) in mature glomerular podocytes 
in adult mice by employing the tetracycline-inducible Cre-loxP site specific gene targeting 
system. KO mice and control littermates were subjected to intraperitoneal protein overload 
followed by examination of proteinuria and glomerular histology.
Results: In murine kidneys, the β rather than the α isoform of the redox sensitive 
GSK3 was found to be predominantly expressed in glomeruli and distributed intensely 
in podocytes. Podocyte specific ablation of GSK3β resulted in a phenotype no different 
from control littermates with normal kidney function. Electron microscopy demonstrated 
more glycogen accumulation in podocytes but otherwise normal glomerular ultrastructures 
in KO mice. Upon oxidative glomerular injury induced by protein overload, KO 
mice excreted significantly less albuminuria and had much attenuated podocytopathy, 
characterized by glomerulosclerosis, the loss of podocyte specific marker synaptopodin 
and by de novo expression of podocyte injury marker desmin, as shown by fluorescent 
immunohistochemistry staining and by immunoblot analysis of isolated glomeruli. The 
antiproteinuric and glomerular protective effect observed in KO mice was concomitant 
with diminished accumulation of reactive oxygen species and attenuated oxidative injuries 
in glomeruli, which was likely secondary to a reinforced Nrf2 antioxidant response in 
glomerular podocytes.
Conclusions: Collectively, our data suggests that GSK3β is dispensable for glomerular 
function and histology under normal circumstances but may serve as a therapeutic target 
for protecting from oxidative glomerular injuries.
Funding: NIDDK Support, Government Support - Non-U.S.
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Vitamin D Receptor (VDR) Inversely Modulates Renin Angiotensin System 
(RAS) Through MDM2 and p53 in Kidney Cells  Hongxiu Wen, Shabirul 
Haque, Xiqian Lan, Ashwani Malhotra, Pravin C. Singhal.  Medicine, Hofstra 
North Shore LIJ Medical School, Great Neck, NY.
Background: Vitamin D has been reported to be a negative regulator of renin 
transcription. However, this concept is not able to provide a logical explanation for activation 
of the RAS in VDR knockout (KO) mice. We hypothesized that VDR inversely modulates 
the RAS through modulation of MDM2 and P53 expression. Since MDM2 is a negative 
regulator of p53 (MDM2 induces transcriptional repression and proteosomal degradation), 
VDR would also negatively regulate p53 via MDM2. p53 is known to activate the via 
transcription of angiotensinogen (Agt) and AT1R. On that account we further hypothesize 
that vitamin D down regulates the RAS through upregulation of VDR/MDM2 and down 
regulation of p53.
Methods: Protein blots of control and VDRKO mice were probed for MDM2. The 
same blots were reprobed for p53, angiotensinogen (Agt), renin, AT1R, and actin. RNAs 
were extracted from renal tissues of control and VDRKO mice. cDNAs were probed with 
specific primers for MDM2, p53, Agt, and renin. Human podocytes (HP) and tubular 
cells (HPTC) were silenced for VDR. Protein blots of control and siRNA-VDR/ HP and 
siRNA/HPTC were probed for MDM2, p53 Agt, and AT1R. To evaluate the role p53, cells 
were transfected with either p53 plasmid or siRNAp53. To evaluate relationships amongst 
VDR, MDM2, and p53, protein blots of VDR agonist treated-p53/HP and p53/HPTCs and 
si-RNAp53/HP and HPTCs were evaluated for MDM2 and p53 expressions.
Results: Renal tissues of VDRKO mice displayed attenuated protein and mRNA 
expression of MDM2 but enhanced expression of p53, Agt, renin, and AT1R. Both poodcytes 
and tubular cells lacking VDR also displayed attenuated expression of MDM2 but enhanced 
expression of p53, Agt, renin, and AT1R. HPs and HPTCs displaying enhanced expression 
of p53 also displayed down regulation of VDR but activation of RAS; on the other hand, 
HPs and HPTCs silenced for p53 displayed upregulation of VDR but down regulation of 
RAS. VDR agonist enhanced expression of VDR and MDM2 but down regulated expression 
of p53 and the RAS.
Conclusions: VDR determines the status of the RAS through modulation of MDM2 
and p53 expression in kidney cells.
TH-PO311
The Role of CD133 Molecule in Renal Papillary Cells and Its Possible 
Involvement in Wnt Signaling and Cellular Senescence Prevention 
Elli Papadimitriou, Alessia Brossa, Benedetta Bussolati.  Dept of Molecular 
Biotechnology and Health Sciences, Univ of Turin, Turin, Italy.
Background: The nature of cells involved in homeostasis/repair of adult human kidney 
is unclear. In human tissue, using the AC133 antibody, recognizing a stem cell-specific 
glycosylation-dependent epitope of prominin (CD133), CD133+ cells with phenotypic and 
functional progenitor-like properties were detected in all nephron segments as scattered 
distinct cells with a dedifferentiated phenotype that survive and proliferate after damage. 
However, the role of the CD133 in the progenitor phenotype and its possible modulation is 
unknown. In the present study we aim to evaluate the role of the CD133 in the maintenance 
of cellular stem-like phenotype and its involvement in cellular senescence.
Methods: CD133+ progenitor cells were isolated from the inner medullary of human 
kidney biopsies. We generated CD133 knock-down (kd) cell lines by infecting them with 
lentiviruses carrying GFP-shPROM plasmids. Cytotoxicity was evaluated by BrdU uptake 
or MTT assay. Spheroid formation was evaluated by sphere counting and MTT assay after 
48h of hypoxia. The senescence was evaluated by β-galactocydase expression and telomere 
length measurement by real time PCR. The activity of the Wnt pathway was investigated 
using a Wnt-reporter luciferase assay.
Results: Preliminary data showed CD133 kd cells downregulated the stem-related 
gene Oct4A and acquired the differentiation marker AQP1. The activity of Wnt pathway 
seemed to be reduced in CD133 silenced cells both in basal culture conditions as well as 
after damage, as shown by a Wnt-reporter assay. Functionally, CD133 kd cells did not 
modify their response to cisplatin, cyclosporine or hydrogen peroxide, suggesting that 
CD133 may not be involved in resistance to damage. At variance, in CD133 kd cells the 
sphere formation was slightly reduced, both in number and size. Interestingly CD133 kd 
cells showed an increased expression of β-galactocydase, a marker of senescence, compared 
to CD133+ cells, along with a telomere length shortening.
Conclusions: Our preliminary data suggest that CD133 may be involved in the 
maintenance of a stem-like phenotype in renal cells along with a delay of senescence.
Funding: Government Support - Non-U.S.
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The Effect of Wnt5a/Ca2+ Pathway on High-Glucose Induced Fibrosis of 
Human Peritoneal Mesothelial Cells  Jin Liu, Jianfei Ma, Ye Hu, Linshan 
Jiao, Yichen Chen.  Nephrology, The First Affiliated Hospital of China Medical 
Univ, Shenyang, Liaoning, China.
Background: Fibrosis is the main reason of ultrafiltration failure. Human Peritoneal 
Mesothelial Cells (HPMC) expresses wnt5a,which induces noncanonical wnt signaling 
pathway, Increase cytosolic free [Ca2+] ,then dephosphorylation of nuclear factor of activated 
T-cells 2(NFAT2) translocate to nuclear.The wnt5a/Ca2+/NFAT2 signaling pathway may be 
activated and necessary for the fibrosis of HPMC.
Methods: HPMC were cultured under normal glucose, high glucose(HG126mM)
or BAPTA-AM (calcium chelator,BA for short) /HG for 24h,or BA for 2h,or different 
concentrations of HG (60 mM, 126 mM, 220 mM) for 24h,or HG126 mM for 0h,6h,12h,24h.
Western Blot technique detects Wnt5a expression in cells and NFAT2 expression in nuclears, 
Nuclear translocation was observed by immunofluorescence microscopy.The Wnt5a mRNA 
was detected by RT-PCR.The expression of connective tissue growth factor(CTGF) was 
detected by Elisa.
Results: Western blot shows the expression of Wnt5a elevated in HG groups, 
which depended on concentration and action time.Wnt5a mRNA elevated in HG group 
in early stage, and in 48h it decreased.According to the results of Western blot and 
immunofluorescence in HPMC after HG treatment,NFAT2 translocated from cytoplasm to 
nucleus,NFAT2 increased in the nuclei by the dependence of action time and concentration 
of HG.Interestingly, in BA/HG group the expression of NFAT2 decreased in the nucleus,and 
in BA group there was no statistical significance controlled with normal glucose.The 
stimulation of HG increased CTGF, which depends on action time and concentration,and 
after join BA in HPMCS the expression of CTGF reduced.
Conclusions: The noncanonical wnt5a/Ca2+/NFAT2 signaling pathway is activated 
by high glucose induced fibrosis of Human Peritoneal Mesothelial Cells,and inhibition 
of this pathway may contributed to the anti-fibrogenesis of HPMC,prolong the period of 
peritoneal dialysis.
Funding: Government Support - Non-U.S.
TH-PO313
The Serine Protease Hepsin Mediates Urinary Secretion and Polymerisation 
of Zona Pellucida Domain Protein Uromodulin  Martina Brunati,1 Simone 
Perucca,1 Ling Han,2 Celine Schaeffer,1 Sara Santambrogio,1 Eric Olinger,3 
Romain Perrier,4 Marcel Bokhove,2 Angela Bachi,5 Edith Hummler,4 Olivier 
Devuyst,3 Qingyu Wu,6 Luca Jovine,2 Luca Rampoldi.1  1San Raffaele Scientific 
Inst, Milan, Italy; 2Karolinska Inst, Stockholm, Sweden; 3Univ of Zurich, Zurich, 
Switzerland; 4Univ of Lausanne, Lausanne, SZitzerland; 5FIRC Inst of Molecular 
Oncology, Milan, Italy; 6Lerner Research Inst, Cleveland.
Background: Uromodulin is the most abundant protein in the urine. Genetic and 
functional evidence demonstrated that this protein, exclusively produced by renal epithelial 
cells, plays key roles in kidney function and disease. Uromodulin mainly exerts its function 
as an extracellular filamentous matrix whose assembly depends on a conserved, specific 
proteolytic cleavage leading to conformational activation of a Zona Pellucida (ZP) 
polymerisation domain. In this work we aimed at understanding the nature of such cleavage.
Methods: We used a comprehensive approach, ranging from biochemistry, molecular 
and cell biology in cells stably expressing uromodulin and in urine and kidney samples 
of relevant knock-out mice.
Results: Starting from the observation that uromodulin is uniquely cleaved at the 
urinary site and assembled into polymeric filaments in MDCK cells we demonstrate that 
physiological cleavage of uromodulin depends on a serine protease, and that this enzyme is 
likely membrane bound. Differential expression analysis in different cell models identified 
two candidate enzymes, hepsin and prostasin. Both interact with uromodulin, and could 
induce its specific cleavage in transfected cells and in vitro. Through gene silencing in 
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MDCK cells and extensive analysis of urinary uromodulin processing in vivo in hepsin 
and prostasin knock-out mice, we demonstrate that hepsin is the enzyme responsible for 
the physiological cleavage releasing urinary uromodulin.
Conclusions: Our findings define a key aspect of the biology of uromodulin that could 
pave the way for future studies on the regulation of its secretion. Given the similar function 
of the ZP domain and the high conservation of cleavage site in ZP domain proteins, our 
results are likely relevant for other members of this protein family.
Funding: Private Foundation Support
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The Favorable Effect of AdipoRon on Diabetic Nephropathy through 
Improvement of Endothelial Dysfunction in db/db Mice  Yaeni Kim, Ji Hee 
Lim, Min Young Kim, Hyung Wook Kim, Cheol Whee Park.  Div of Nephrology, 
Dept of Internal Medicine, College of Medicine, The Catholic Univ of Korea, 
Seoul, Republic of Korea.
Background: Adiponectin is one of the numerous adipocyte-derived adipokines that 
interplays with others to exert the milieu of metabolic syndrome. It binds to adiponectin 
receptors (AdipoR), AdipoR1 and AdipoR2 and exhibits antidiabetic effects via activation 
of AMPK and PPAR-α. Orally active synthetic small-molecule AdipoR agonist, AdipoRon 
binds to both AdipoR and ameliorates obesity-related disease. Therefore, we investigated the 
possible role of AdipoRon in renal physiology in the view of prevention and development 
of diabetic nephropathy in diabetic mouse model.
Methods: Male db/db mice were fed a diet containing AdipoRon (30 mg/kg/day p.o. 
for 4 weeks from 17 to 20 weeks of age). Serum, urine and renal tissue were obtained to 
analyze for changes in metabolic parameters, molecular levels and renal structure.
Results: AdipoRon treatment showed decreased amount of albuminuria with no 
significant changes in the levels of serum adiponectin, glucose and creatinine and it 
seems to be weight neutral. Increased expressions of AdipoR1 in the renal cortex and 
consistent up-regulations of phosphorylated AMPK and PPAR-α level were associated with 
AdipoRon treatment. AdipoRon treatment showed favorable effects on diabetes-induced 
GBM thickening, foot process widening and slit diaphragm space narrowing and further 
decreased glomerular matrix expansions and inflammation.
Conclusions: Increased expressions of renal AdipoR1, not AdipoR2, indicates that 
renal injury may cause a compensatory up-regulation of relevant receptors in kidneys to 
mitigate further renal injury. AdipoRon may control oxidative stress in glomerulus through 
AMPK and PPAR-α activated pathways and further contribute to prevent deterioration of 
renal function. The protective role of AdipoRon against the development of albuminuria 
seems to occur through a direct action on podocytes independently of systemic effects of 
adiponectin. Its reduction of oxidative stress provides protection against albuminuria and 
podocyte damage thereby ameliorating endothelial dysfunction in diabetic nephropathy.
TH-PO315
Diabetes-Induced Impairments in Slit-Robo Signaling Augment Glomerular 
Angiogenesis  Darren A. Yuen,1 Stephen G. Szeto,1,2 Mingliang Lu,1 Lauren 
Yuk-sum Chan,1 Krystale A. De freitas,1 Lisa Robinson,3 Ahmad Mohammad 
Omar Sidiqi.1,2  1St. Michael¶s Hospital Keenan Research Centre for Biomedical 
Science, Toronto, ON, Canada; 2Faculty of Medicine, Univ of Toronto, Toronto, 
ON, Canada; 3The Hospital for Sick Children, Toronto, ON, Canada.
Background: Diabetic nephropathy is characterized by glomerular endothelial cell 
(GEC) injury. One of the earliest manifestations of this injury is glomerular angiogenesis, 
a process that classically is thought of as being driven by increased glomerular VEGF 
production. Slit2 is a regulator of endothelial function, eliciting either pro- or anti-angiogenic 
effects through its Robo1 and Robo4 receptors, respectively. We have shown previously 
that glomerular endothelial Robo4 expression is downregulated by high glucose exposure, 
whereas Robo1 expression is unchanged. Objectives: To determine whether high glucose-
induced alterations in Robo1 and Robo4 expression regulate VEGF-induced angiogenesis 
in the diabetic kidney.
Methods: GEC responsiveness to VEGF in angiogenesis assays was examined in both 
normal glucose (NG) and high glucose (HG) conditions, and following Robo1 knockdown. 
Using Robo4 knockout (KO) mice, the effect of Robo4 deficiency on diabetic glomerular 
angiogenesis was also analyzed using fluorescence microangiography (FMA) and PECAM-1 
immunohistochemistry.
Results: As compared to GEC grown in NG medium, GEC grown in HG medium 
expressed lower levels of the anti-angiogenic Robo4 receptor, but not the pro-angiogenic 
Robo1 receptor, and exhibited greater VEGF responsiveness. Loss of Robo1 eliminated 
VEGF-induced GEC network formation and migration in both normal and high glucose 
conditions. In contrast, Robo4 deficiency was associated with enhanced PECAM-1 density 
and glomerular capillary length in Robo4 KO mice (compared to their WT littermates) 
after 4 weeks of STZ-induced diabetes.
Conclusions: Our observations suggest that diabetic glomerular angiogenesis is driven 
not only by enhanced VEGF production, but also by enhanced glomerular endothelial VEGF 
responsiveness. Our data also suggest that this increased responsiveness is promoted by 
a shift in glomerular endothelial Slit2-Robo signalling, favouring more pro-angiogenic 
Robo1, and less anti-angiogenic Robo4 activity.
Funding: Government Support - Non-U.S.
TH-PO316
Dynamic Regulation of Endothelial Specific Molecule 1 in Diabetic Mouse 
Kidney  Xiaoyi Zheng,1 Fariborz Soroush,2 Sanchita Bhattacharya,3 Mohammad 
F. Kiani,2 Vivek Bhalla.1  1Div of Nephrology, School of Medicine, Stanford 
Univ, Stanford, CA; 2Dept of Mechanical Engineering, College of Engineering, 
Temple Univ, Philadelphia, PA; 3Dept of Pediatrics, School of Medicine, UC 
San Francisco, San Francisco, CA.
Background: Performing glomerular gene expression profiling in diabetic mouse 
models with differential susceptibility to nephropathy (DN), we identify endothelial specific 
molecule 1 (Esm-1), as a novel candidate gene in the development of DN.
Methods: We studied Esm-1 function using a bioinspired microfluidic assay (bMFA) 
and Esm-1 expression by qPCR and ELISA in diabetic and non-diabetic mice.
Results: Esm-1 is proposed to disrupt LFA-1: ICAM-1 interactions at the leukocyte: 
endothelial cell interface, and leukocyte infiltration into glomeruli is a known risk factor for 
DN. In a bMFA, pre-treatment of leukocytes with Esm-1 inhibits rolling and transmigration 
in a dose-dependent manner. Consistent with the diminution of leukocyte infiltration, 4 
weeks after induction of diabetes, Esm-1 mRNA is markedly attenuated in glomeruli from 
DN-susceptible, DBA/2J, compared to DN-resistant, C57BL/6J, mice (relative fold: 0.085 
± 0.012, p<0.05). Secretion of Esm-1 is also lower from glomeruli of DN-susceptible mice 
(132.6 ± 41.6 vs 226.4 ± 79.3 pg/mL, p<0.05). These changes occurred in the background 
of a dynamic response of kidney Esm-1 to diabetes. Urine Esm-1 excretion increases in 
diabetic vs. non-diabetic mice (307.7 ± 51.6 vs 102.3 ± 29.7 pg/mg creatinine, p<0.05), 
despite no increase in urine albumin and a ~50% decrease in circulating Esm-1 in diabetic 
mice. Further in vitro studies in cultured glomeruli show that hyperglycemia significantly 
increases Esm-1 mRNA and protein and suggest that urine Esm-1 reflects increased 
production by glomeruli.
Conclusions: These results demonstrate that diabetes induces Esm-1 in glomeruli, 
and this induction is attenuated in DN-susceptible mice. These data suggest that increased 
production of glomerular Esm-1 would be sufficient to attenuate leukocyte infiltration 
and consequently, DN. Furthermore, we propose urine Esm-1 as a non-invasive candidate 
biomarker for resistance to DN.
Funding: NIDDK Support, Private Foundation Support
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Activation of Rho/Rho-Kinase Pathway in Proximal Tubules as a Culprit 
in Obesity-Related Nephropathy  Makiko Naitoh, Hirobumi Tokuyama, Koji 
Futatsugi, Shu Wakino, Hiroshi Itoh.  Keio Univ, Tokyo, Japan.
Background: A small GTP-binding protein, Rho, and its effector, Rho-kinase, have 
several pathological functions. We previously demonstrated that in obesity adipocyte 
cellular hypertrophy activates Rho/Rho-kinase signaling through mechanical stretch, 
leading to inflammatory changes(Science signaling, 2011).We have also documented 
enlarged and vacuolated proximal tubules (PT) in obesity-related kidney damage ( Int J 
Obesity, 2012). We examined whether Rho/Rho-kinase was activated in enlarged PT that 
were supposed to be under the mechanical stress and contributed to the pathophysiology 
of obesity-induced kidney damages.
Methods: We created mice that overexpressed dominant negative RhoA genes 
specifically in PT under the control of promoter of sodium-phosphate co-transporter (PT-
DN-RhoA TG). PT-DN-RhoA TG mice (DN) and their wild-type littermates (WT) were 
fed a high fat (HFD) or low fat diet (LFD) for 12 weeks and compared in phenotypes.
Results: WT on HFD not only developed obesity but also manifested histological 
changes, including the enlargement in PT as well as in glomeruli, vacuolation of PT, the 
infiltration of inflammatory cells and the overexpression of stress fibers, which paralleled 
the increase in urinary albumin and NGAL of tubular injury markers. Enhanced Rho-
kinase activity was noted particularly in PT. Inflammatory cytokines were subsequently 
overexpressed in WT on HFD as compared with those in WT on LFD. In DN, the activation 
of Rho kinase was attenuated in PT region leading to the decrease in the size, vacuolation 
and stress fiber formation in PT cell, the decrease in inflammatory cells infiltration and 
cytokine expressions, and the reduction in albuminuria and PT impairment.
Conclusions: Excess fat intake causes obesity-induced renal injury, which are 
mediated by an Rho/Rho-kinase activation in PT and inflammatory process. It is surmised 
that hypertrophic process in PT during obesity formation affects Rho-kinase activation 
presumably through mechanical stress. This process subsequently induces inflammation 
and accelerates the histological changes of PT. The intervention of Rho/Rho-kinase may 
constitute a novel strategy blocking the progression of obesity-induced renal damages.
TH-PO318
SUL121: A Novel Compound Preserving Endothelial Function and 
Inhibiting Progression of Kidney Damage in Type 2 Diabetes Mellitus 
in Mice  Leo E. Deelman, Sebastiaan Lambooy, Arash Bidadkosh, Hendrik 
Buikema, Robert H. Henning.  Clinical Pharmacy and Pharmacology, Univ 
Medical Center Groningen, Univ of Groningen, Groningen, Netherlands.
Background: Diabetic nephropathy is a common complication of Type 2 Diabetes 
mellitus (T2DM), a chronic metabolic disorder with increasing incidence worldwide. 
To stop the progression of diabetic kidney disease, new strategies are urgently needed. 
Endothelial dysfunction (ED) and reactive oxygen species (ROS) are important targets 
for novel therapies to stop diabetic nephropathy. To improve ED and inhibit ROS, we 
recently developed the compound SUL121, a putative hydrogen sulfide (H2S) inducer 
and inhibitor of ROS.
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Methods: To test the therapeutic effects of SUL121 in diabetic and normal mice, db/
db mice and lean control mice were subcutaneously implanted with osmotic mini pumps 
delivering SUL121 or vehicle from age 10 to 18 weeks. Mice were placed in metabolic 
cages every two weeks until termination at which time endothelial mediated relaxation in 
aortic rings was assessed. ROS status and H2S levels were measured in plasma, and renal 
expression of H2S producing enzymes was determined.
Results: While treatment with SUL121 did not alter the glycemic state in db/db, it 
prevented albuminuria and diabetic kidney damage, as evidenced by an inhibition of the 
progression of albumin excretion rate, lower albumin creatinine ratio, decreased focal 
glomerular sclerosis score and normalization of kidney weight. In addition, SUL121 
normalized systemic ROS formation, increased renal expression of the H2S producing 
enzymes, cystathionine gamma lyase and cystathionine beta synthase (CSE and CBS), 
and prevented the development of endothelial dysfunction in db/db. SUL121 treatment 
in lean control mice demonstrated no observable side-effects, indicating that SUL121 is 
well tolerated.
Conclusions: Thus, SUL121 represents a novel compound inhibiting the progression 
of experimental diabetic kidney damage via a mechanism that inhibits both oxidative stress 
and preserves vasorelaxation.
Funding: Pharmaceutical Company Support - This study was patially financed by 
Sulfateq B.V., a company that owns patents on SUL121, and produces and markets 
similar compounds., Government Support - Non-U.S.
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Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Targets 
for Treating Diabetic Nephropathy  Yuji Oe,1 Emiko Sato,1,2 Hiroshi Sato,1,2 
Sadayoshi Ito,1 Nobuyuki Takahashi.1,2  1Div of Nephrology, Endocrinology, and 
Vascular Medicine, Tohoku Univ Graduate School of Medicine, Sendai, Japan; 
2Div of Clinical Pharmacology and Therapeutics, Tohoku Univ Graduate School 
of Pharmaceutical Sciences, Sendai, Japan.
Background: Role of hypercoagulability in pathogenesis of diabetic nephropathy 
(DN) remains elusive. We have recently demonstrated that elevated coagulation factor 
III (tissue factor) exacerbates DN (J Thromb Haemost 2010, PNAS 2011). Tissue factor 
activates factor X (FXa), which in turn stimulates protease-activated receptor 2 (PAR2). 
PAR2 causes inflammation and fibrosis. Accordingly, we hypothesized that activation of 
FXa- PAR2 signaling exacerbates DN.
Methods: To test this hypothesis, we used diabetic mice with reduced expression of 
endothelial NO synthase (Nos3) as a model of DN. We first tested whether inhibiting FXa 
ameliorates DN by administering an oral FXa inhibitor Edoxaban (50 mg/kg/day) for 3 
months to diabetic mice lacking eNOS (Ins2Akita/+; Nos3-/-). We next tested whether lack 
of PAR2 ameliorates DN using diabetic mice lacking PAR2 (F2rl1-/-; Ins2Akita/+; Nos3+/-). 
Finally, the effects of FXa or PAR2 agonist (SLIGKV) on human endothelial cells (EA. 
hy926) and conditionally immortalized murine podocytes were evaluated.
Results: Renal expression of FX and PAR2 was up-regulated in DN, together 
with elevation of FXa activity in the urine. Edoxaban and lack of PAR2 both reduced 
renal expression of inflammatory and profibrotic genes, and ameliorated diabetic 
glomerulosclerosis and urinary albumin excretion. FXa or a PAR2 agonist (SLIGKV) 
increased IL-8 secretion and gene expression of MCP1 and PAI1 in human endothelial cells. 
These treatments also increased Mcp1 mRNA level in murine podocytes.
Conclusions: We conclude that FXa - PAR2 signaling exacerbates DN possibly 
through up-regulating inflammatory response. FXa - PAR2 signaling is a promising target 
for treating or preventing DN.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Herniation of the Mesangium Together with Sprouting of Blood Vessels Out 
of the Glomerular Entrance Is a frequent Feature of Diabetic Nephropathy 
Wilhelm Kriz, Jana Loewen.  Anatomy, Univ of Heidelberg, Medical Faculty 
Mannheim, Mannheim, Germany.
Background: In contrast to diabetic retinopathy, where neovascularizations have a 
central pathogenetic impact, in diabetic nephropathy (DN) angio-proliferative processes 
are generally not considered as a major factor underlying disease progression. The studies 
by Osterby and Nyberg (J Diab Compl 1987, 1:122) and Min and Yamanaka (Virchows 
Arch A Pathol Anat 1993, 423:201) have shown neovascularizations in DN but have found 
little attention.
Methods: Re-evaluation of biopsies of DN (archive: Dep. of Molecular Pathology, 
German Cancer Research Center, Heidelberg) has revealed that the proliferation of newly 
formed blood vessels out of the glomerular entrance into the surroundings of the glomerulus 
is a frequent feature in DN.
Results: In a total of 437 biopsies (so far evaluated) 60.2% contained aberrant vessels 
at the vascular pole or in periglomerular position. 13% of these cases were associated 
with diffuse mesangial sclerosis (DMS), 35% with transitional stages from DMS to 
nodular sclerosis (NS) and 52% with NS. The outgrowth is based on extensive widening 
of the glomerular entrance accompanied by herniation of the expanded mesangium with 
displacement of the extraglomerular mesangium and the macula densa. The aberrant vessels 
spread into glomerular surroundings, preferentially along the outer aspect of Bowman’s 
capsule finally draining into peritubular capillaries. These vessels mostly have the structure 
of small arterioles. Frequently, almost regularly, accumulations of exudative material are 
encountered beneath the endothelium or within the layer of smooth muscle cells.
Conclusions: It is suggested that the exposure of mesangial areas to environmental 
stimuli accounts for the angio-proliferations. As derivatives from glomerular capillaries 
the aberrant vessels are likely perfused under high pressure accounting for the exudative 
lesions. The periglomerular matrix and fibrotic envelopes frequently seen in DN (in 69.6% 
in our material) seem to emerge in response to exudations and possibly other stimuli from 
the aberrant vessel. The encroachment of these processes along the transition to the tubule 
likely contributes to the tubulo-interstitial disease.
TH-PO321
Exploiting Angiopoietin-Tie Signaling for Treatment of Diabetic 
Nephropathy  Tomokazu Souma,1 Isabel Anna Carota,1 Benjamin R. Thomson,1 
Jing Jin,1 Susan E. Quaggin.1  1Div of Nephrology/Hypertension, Feinberg 
Cardiovascular Research Inst, Feinberg School of Medicine, Northwestern 
Univ, Chicago, IL; 2Aerpio  Therapeutics, Cincinnati, OH.
Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal 
disease in the US, and is characterized by microvascular dysfunction. The Angiopoietin-
Tie signaling pathway plays a key role in endothelial health and survival. The endothelial 
Tie2 receptor tyrosine kinase becomes activated upon binding its endogenous ligand 
Angiopoietin1 (ANGPT1). This activity elicits a cascade of intracellular signaling events, 
leading to junctional reinforcement and vasculo-protection. VE-PTP is a Tie2 selective 
phosphatase, which negatively modulates Tie2 signaling intensity. Here we tested whether 
augmentation of Tie2 signaling by VE-PTP inhibition protects against DN.
Methods: To test the therapeutic potential of Tie2 activation, we treated Ins2Akita DBA/2J 
Mice with a VE-PTP inhibitor (AKB-9785, Aerpio) or vehicle control (n=8 in each group). 
In parallel, cell-based analyses were performed to elucidate ANGPT-Tie signaling events. 
The role of VE-PTP on the phosphorylation status of Tie2 expressed in HEK293 cells was 
determined by LC-tandem mass spectrometry (LC-MS/MS).
Results: 17-week treatment of AKB-9785 improved the general status of Ins2Akita mice 
(body weight change from baseline; vehicle +15%, AKB-9785 +35%, P<0.01). Further, 
AKB-9785 preserved mGFR of Ins2Akita mice (vehicle 560 ml/min, AKB-9785 945 ml/min 
with 6-week daily treatment, P<0.067). LC-MS/MS identified 13 phospho-tyrosine residues 
in Tie2; all sites were dephosphporylated by VE-PTP co-expression. Treatment with either 
recombinant Angpt1 or AKB-9785 rapidly induced Tie2 phosphorylation, suggesting Tie2 
can be activated in a ligand-independent fashion. Administration of AKB-9785 to Angpt1 
KO mice confirmed ligand-independent Tie2 activation occurs in vivo.
Conclusions: Our data suggest that the small molecule inhibitor, AKB-9785 is a potent 
activator of Tie2 phosphorylation, has positive effects in a preclinical rodent model of Type 
I diabetes and is an attractive therapeutic candidate for DN.
Funding: Other NIH Support - National Heart, Lung, and Blood Institute (NHLBI)
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Berberine Ameliorate High Glucose and Advanced Glycation End Products 
Induced Glomerular Endothelial Cell Hyperpermeability  Nanmei Liu. 
Jimin Hospital of Shanghai.
Background: Glomerular endothelial cells (GEnC) are important part of the glomerular 
filtration barrier. The dysfunction of glomerular endothelial cells (GEnCs) could be a 
characteristic of early stage diabetic nephropathy (DN). Accumulating evidence indicate 
that advanced glycation end products (AGEs) play a pivotal role in the progressive of 
glomerulosclerosis or thickening of the glomerular basement membrane in DN. Berbine, 
an extracts from some Chinese plant medicine such as Huanglian Letasiova S(Rhizoma 
coptidis); Huangbai (cortex phellodendri), Gold Seal ( hydrastis canadensis), was reported 
lower blood sugar and attenuated diabetic nephropathy, but the mechanism still need verified. 
This study was to investigate the changes of monolayer permeability in GEnCs caused by 
high concentration glucose and AGEs, and the effects of Berbine.
Methods: GEnCs were cultured in growth medium causing cell proliferation, then seed 
in a Transwell chamber culture system to form confluent monolayer. The cell was treated 
with ordinary glucose (5.5mM), or high glucose (25mM), AGE 100mg / mL, berberine 
(3uM) inspectively. The GENC permeability was evaluated by measuring the diffusion of 
biotin-conjugated bovine serum albumin (biotin-BSA) across a cell monolayer. The changes 
of cytoskeleton was obsearved under Confocal laser scanning fluorescence microscopy 
after double staining of F-actin and G-actin.
Results: The protein leakage rate was increased slightly after treated with high glucose 
(25mM), but increased significantly in high glucose plus AGE 100mg/mL compared with 
low glucose control group. High glucose and AGE strongly affected orientation of F-actin 
fibers, induced rearrangement of F-actin fibers. While berberine intervention can reduce 
protein leakage rate (P <0.05), improved the F-actin cytoskeletal actin disorder significantly.
Conclusions: High glucose and AGE increased permeability of the GEnC monolayer 
and leads to long-term alterations of F-actin structures. Berberine has a protective effect. 
The mechanism may be related to inhibit endoplasmic reticulum stress and reduce the 
cytoskeleton injury.
Funding: Government Support - Non-U.S.
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Arginase Inhibition: A New Treatment for Preventing Progression of 
Established Diabetic Nephropathy  Hanning You,1 Ting Gao,1 Timothy K. 
Cooper,2 Sidney M. Morris,3 Alaa S. Awad.1  1Medicine, Penn State Univ College 
of Medicine, Hershey, PA; 2Comparative Medicine, Penn State Univ College 
of Medicine, Hershey, PA; 3Microbiology and Molecular Genetics, Univ of 
Pittsburgh, Pittsburgh, PA.
Background: Our previous publication showed that inhibition of arginase prevents 
the development of diabetic nephropathy (DN). However, identification of targets that 
retard the progression of established DN--which is more clinically relevant--is lacking. 
Therefore, we tested the hypothesis that arginase inhibition would prevent the progression 
of established DN. Effects of arginase inhibition were compared to treatment with the ACE 
inhibitor captopril, a current standard of care in DN.
Methods: Experiments were conducted in Ins2Akita mice treated with the arginase 
inhibitor S-(2-boronoethyl)-L-cysteine (BEC) or captopril starting at 6 wks of age for 12 
wks (early treatment) or starting at 12 wks of age for 6 wks (late treatment).
Results: Early and late treatment with BEC resulted in protection from DN as 
indicated by reduced albuminuria, histological changes, kidney macrophage infiltration, 
urinary TBARS, and restored nephrin expression, kidney nitrate/nitrite, kidney eNOS 
phosphorylation, and renal medullary blood flow compared with vehicle-treated Ins2Akita 
mice at 18 wks of age. Interestingly, early treatment with captopril reduced albuminuria, 
histological changes, and kidney macrophage infiltration without affecting the other 
parameters, but late treatment with captopril was ineffective.
Conclusions: These findings highlight the importance of arginase inhibition as a new 
potential therapeutic intervention in both early and late stages of diabetic renal injury.
Funding: NIDDK Support
TH-PO324
Transgenic TGF-β1 Receptor Type II (TbRII) Overexpression in Podocytes 
Promotes STZ Induced Diabetic Nephropathy in Rats  Sigrid C. Hoffmann, 
Stamatia Matina Papagiannarou, Wilhelm Kriz, Tamara Micakovic.  Medical 
Faculty Mannheim, Univ Heidelberg, Mannheim, Germany.
Background: Glomerular TGF-β1 is increased early in the course of diabetic 
nephropathy. The podocytes are sources and targets of TGF-β1. This study addresses the 
hypothesis that increased TGF-β1 in diabetic rats stimulates the development of diabetic 
nephropathy via selective signalling in podocytes.
Methods: Transgenic rats carrying the TGRTβRII driven by the podocin promoter were 
generated. Transgene expression was verified by Northern blotting, in-situ hybridization 
and Western blotting. Glomerular expression profiling was performed by real time RT-PCR, 
Western blotting and immunohistochemistry. Podocyte density was determined by counting 
WT-1 stained podocytes per glomerular area, which was determined morphometrically 
in 200 glomeruli per rat. At 2 months of age rats received STZ (40mg/kg i.v.) or diluent, 
respectively. Body weight and kidney function were evaluated by urinary albumin excretion 
in the 24h-urine and by creatinine clearance at monthly intervals.
Results: TGR expressed the transgenic receptor specifically in podocytes. Glomerular 
TbRII protein levels were almost twice that of WT. At 5 months of age 40 % of TGR 
exhibited moderately increased albumin excretion up to 2.2 mg/24hr vs. 0.11 mg/24hr in 
WT. 3 months after STZ, albumin excretion was significantly increased in 80% of TGR 
with an average of 4 mg/24hr (max: 7.3) but only slightly elevated in 40% of the WT with 
in average 0.7mg/24hr (max: 2.2). Expression profiling in isolated glomeruli revealed that 
in TGR PAI-1 was significantly upregulated and the survival marker blc-2 and podocyte 
differentiation marker synaptopodin, podocin and nephrin were significantly down-regulated 
relative to WT. Podocyte number per glomerulus was significantly decreased in diabetic 
TGR vs. diabetic WT.
Conclusions: Podocyte-selective TbRII-overexpression contributes to the leakage 
of the glomerular filter in the course of STZ induced diabetic nephropathy which might 
be mediated by podocyte loss due to podocyte dedifferentiation, downregulation of bcl-2 
and PAI-1 upregulation.
Funding: Government Support - Non-U.S.
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Comparison of Glomerular and Podocyte mRNA Profiles in eNOS-/- Diabetic 
Mice Induced by Streptozotocin  Jia Fu,1,2 Chengguo Wei,2 Kim Lee,2 Weijia 
Zhang,2 Peter Y. Chuang,2 Zhihong Liu,1 John C. He.2,3  1National Clinical 
Research Center of Kidney Diseases, Jinling Hospital; Nanjing Univ School 
of Medicine, Nan Jing, Jiangsu, China; 2Div of Nephrology, Dept of Medicine, 
Icahn School of Medicine at Mount Sinai, New York, NY; 3Renal Program, James 
J Peters VA Medical Center at Bronx, New York, NY.
Background: Gene expression profiles have never been reported in primary podocytes 
isolated from the diabetic kidney. Here, we compared mRNA profiles in both isolated 
glomeruli and sorted podocytes between diabetic and control mice.
Methods: IRG mice carrying a two-color fluorescent reporter gene were first crossed 
with eNOS-/- mice and then with podocin-rTTA and TetON-Cre mice allowing us to 
permanently label podocytes. Then, mice were injected with either streptozotocin (STZ-
eNOS-/-) or vehicle (CL-eNOS-/-). STZ-eNOS-/- mice developed typical findings of diabetic 
nephropathy at 10 weeks after STZ injection. mRNA sequencing was performed in both 
isolated glomeruli and sorted podocytes from STZ-eNOS-/- and CL-eNOS-/- mice.
Results: Consistent with the previous reports, expression of podocyte-specific 
markers in the glomeruli were down-regulated in the STZ-eNOS-/- mice compared to CL-
eNOS-/- mice. However, these differences disappeared when mRNA levels were corrected 
for podocyte number/glomerulus. Interestingly, expression of these markers in sorted 
podocytes did not differ between diabetic and non-diabetic mice. These data suggest that 
reduced expression of podocyte markers in isolated glomeruli is likely secondary to reduced 
podocyte number/glomerulus, rather than loss of differentiation markers. Analysis of the 
differentially expressed genes (DEGs) between diabetic and non-diabetic mice revealed 
distinct pathways between glomeruli and podocytes. The up-regulated DEGs in isolated 
glomeruli were involved mostly in the regulation of mitochondrial function and oxidative 
stress pathway, while the up-regulated DEGs in sorted podocytes were heavily involved 
in the actin organization.
Conclusions: In conclusion, our data suggest that podocyte-specific gene expression 
in transcriptome obtained from glomeruli may not represent those of podocytes in diabetic 
kidney.
Funding: Other NIH Support - JCH is supported by NIH 1R01DK078897, NIH 
1R01DK088541, and NIH P01-DK-56492;
PYC is supported by NIH 1R01DK098126-01A1., Veterans Administration Support, 
Government Support - Non-U.S.
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SS-31, a Mitochondrial Therapeutic, Prevents High Fat Diet-Induced 
Podocyte Injury  Hazel H. Szeto, Shaoyi Liu, Yi Soong, Nazia Alam, Glen T. 
Prusky, Surya V. Seshan.  Pharmacology, Physiology, Pathology, Weill Cornell 
Medical College, New York, NY.
Background: High fat diet (HFD) leads to rapid onset of microalbuminuria and 
podocyte injury that precedes the onset of insulin resistance and hyperglycemia in 
mice. It was recently suggested that glomerular injury is triggered by palmitate-induced 
mitochondrial dysfunction in podocytes (Sun et al., Kidney Int, 2015). We investigated the 
protective effects of SS-31, a mitochondrial therapeutic, against HFD-induced podocyte 
injury in mice.
Methods: 4 week-old C57BL/6 mice were fed normal diet (ND) or HFD for 28 weeks. 
4 weeks later, HFD mice received streptozotocin (40 mg/kg, qd x 5d). Body weight (BW), 
blood glucose (BG) and glucose tolerance tests (GTT) were determined after 8 and 24 weeks 
of HFD. SS-31 (2 mg/kg, sc) or saline was administered to HFD mice daily starting at 8 
weeks. Kidneys were harvested at 28 weeks for histopathology.
Results: GTT was abnormal at 8 weeks despite no change in BW or BG. BW and BG 
were significantly increased at 28 weeks. Histological examination revealed mesangial 
expansion, thickening of the glomerular basement membrane, elevated collagen-IV, and loss 
of podocyte markers (podocin and synaptopodin). Electron microscopy revealed extensive 
vacuolization and swelling in podocytes, with swollen mitochondria, autophagic vacuoles, 
and loss of foot processes. TGFβ, TNFα and MCP-1 were all significantly increased. 
Treatment with SS-31 significantly prevented these HFD-induced pathological changes 
in the glomeruli without affecting BW, BG or GTT. 
Conclusions: These results suggest that SS-31 can protect podocytes against HFD-
induced mitochondrial toxicity without changing BW, insulin resistance or hyperglycemia. 
SS-31 (BendaviaTM), currently in clinical trials for acute kidney injury, may be useful in 
the treatment of diabetic nephropathy.
Funding: Private Foundation Support
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Tristetraprolin Overexpression Ameliorated Inflammation in db/db Mice 
and Mouse Podocytes  Guo Jia, Zhangsuo Liu.  The First Affiliated Hospital 
of Zhengzhou Univ, Zhengzhou, Henan, China.
Background: Tristetraprolin(TTP)isawell-characterized,zincfinger-containing,  RNA-
binding protein.,which plays a role in the regulation of  inflammatory factors expression 
by targeting the 3’untranslated region (3’UTR).We investigated whether TTP modulates 
inflammation in high glucose induced-podocytes and in db/db mice kidneys.
Methods: Differentiated mouse podocytes were treated by high glucose,and TTP 
expression and inflammatory factors was measured by quantitative real-time PCR, western 
blot or ELISA. TTP siRNA or lentiviral vectors containing TTP sequences were transfected 
into podocytes to down-regulate or up-regulate TTP expression.Db/db mice  were used 
as the diabetic model in the in vivo experiment. At the age of 10 weeks,db/db mice were 
injected via tail vein with lentiviral vectors containing TTP sequences.At the age of 14 
weeks,the lentivirus injection was repeated.Inflammatory factors and podocyte makers 
were examined in both podocytes and mice kidneys.Urine albumin to creatinine ratio and 
serum creatinine was also detected.
Results: TTP was down-regulated while IL-6,IL-18,TNF-awere up-regulated in high 
glucose-induced mouse podocytes.Silencing TTP by siRNA induced  inflammatory factors 
expression.Overexpression of TTP reduced the expression of inflammatory factors in high 
glucose-induced podocytes.TTP expression was significantly decreased in db/db mice 
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kidneys compared with db/m mice.Overexpession of  TTP by lentivirus injection ameliorated 
inflammation in db/db mice.Urine albumin to creatinine ratio and urine inflammatory factors 
was also decreased in db/db mice overexpressing TTP.
Conclusions: TTP is involved in the regulation of inflammation in diabetic conditions.
Targeting TTP might be effective in diabetic kidney disease.
Funding: Government Support - Non-U.S.
TH-PO328
CIN85 Deficiency Prevents Nephrin Endocytosis in Podocytes Under 
Diabetic Conditions  Beina Teng, Hermann G. Haller, Mario Schiffer.  Medical 
School Hannover, Hannover, Germany.
Background: Podocytes are important for the maintenance of the glomerular filter 
in the kidney. Podocyte damage is associated with ultrastructural changes and decreased 
expression of components of the slit diaphragm in many glomerular diseases. Nephrin, a 
podocyte specific protein is crucial for the intact filtration barrier. Loss of nephrin has been 
observed in rodent models of experimental diabetes as well as in human diabetic kidney 
disease. CIN85, a homologue of CD2AP, was identified as a binding partner of nephrin 
and mediates the nephrin endocytosis via ubiquitination in podocytes.
Methods: Using STZ injection, we induced a type I diabetes in BLC57/N wild type 
and CIN85Dex2 mice to examine diabetes induced dysregulation of glomerular filtration 
barrier and alteration of extracellular matrix. We then generated immortalized cell lines of 
podocytes for the CIN85Dex2 and the CD2AP-/- to examine nephrin endocytosis in both cell 
types on the molecular level. To inquire the impact of CIN85 and CD2AP on filtration barrier 
integrity in zebrafish, we examined proteinuria in zebrafish injected with capped mRNAs.
Results: We can demonstrate that the loss of nephrin expression and onset of the 
proteinuria in diabetic mice correlates with an increased accumulation of ubiquitinated 
proteins and expression of CIN85 in podocytes. The CIN85Dex2 deficiency leads to 
preserved nephrin surface expression, reduced proteinuria and Collagen-IV deposition 
in glomeruli under diabetic conditions. High glucose levels induced an increased CIN85 
expression in contrast to a significantly reduced expression of CD2AP and nephrin in both 
murine and human podocytes. Furthermore, by high glucose stimulation, the CD2AP-/- 
podocytes, which express more full-length CIN85, showed an increased nephrin endocytosis 
compared to the CIN85 knockout podocytes. In addition, injection of capped CIN85 mRNA 
induced a servere edema and proteinuria in zebrafish embryos which could be rescued by 
co-injection of CD2AP mRNA.
Conclusions: Our findings suggest that CIN85 is involved in the endocytosis of nephrin 
in podocytes under diabetic conditions promoting the development of glomerulopathy. 
Therefore CIN85 might be a novel treatment target to preventdiabetic nephropathy.
Funding: Government Support - Non-U.S.
TH-PO329
Atrasentan Ameliorates Diabetic Nephropathy and Restores Podocyte 
Number in BTBRob/ob Mice  Kelly L. Hudkins, Tomasz A. Wietecha, Floortje 
Steegh, Kristina M. Sorg, Noppanit Pattanachaiwit, Minseob Eom, Julia K. 
Shankland, Charles E. Alpers.  Pathology, Univ of Washington, Seattle, WA.
Background: Leptin deficient BTBRob/ob mice develop type 2 diabetes and DN that 
closely mimics human DN, including mesangial expansion, podocyte loss, and proteinuria. 
This study tested the effect of atrasentan (A), an endothelin-1 receptor antagonist, with or 
without concurrent RAAS inhibition by losartan (L) on DN and whether this can restore 
podocyte number.
Methods: Cohorts of 18 week old BTBRob/ob mice and BTBR WT littermates were 
treated via drinking water with A (5 mg/kg/day), A plus L (25 mg/kg/day) or normal 
water for 6 weeks. Mice were analyzed for body weight, blood glucose, serum creatinine, 
proteinuria and morphometric measures of numbers of p57 expressing podocytes, collagen 
IV staining mesangial matrix.
Results: Treatment with A alone had no effect on body weight or blood glucose. 
Combined treatment with A and L also had no effect on body weight, but significantly 
decreased blood glucose levels in both BTBR WT (243 + 14.8 vs 160 + 5.6, p<0.005) and 
BTBRob/ob (595 + 5.3 vs 382 + 51.5, p<0.01) mice. Treatment with A and combined A 
and L decreased proteinuria in BTBRob/ob mice, although this did not reach statistical 
significance due to wide variations within the groups. Serum creatinine was elevated in 
BTBRob/ob compared to WT mice, and was decreased by treatment with A plus L (p<0.05). 
Mesangial collagen IV was reduced in both the A and A plus L treated mice (p<0.05). There 
were decreased podocytes (p57 expressing cells) in BTBRob/ob (149.7 + 6.7) compared 
to WT mice (188.7 + 9, p<0.05). Podocytes increased in BTBRob/ob mice receiving A 
(167.0 + 7, ns, p=0.093) and were restored to WT numbers in mice receiving A plus L 
(190.4 + 5.7, p< 0.001).
Conclusions: Treatment with A plus L significantly increased podocyte number in 
diabetic BTBRob/ob mice. A treatment alone increased podocyte number, but to a lesser 
degree. Podocyte restoration correlated with decreased blood glucose, serum creatinine, 
and mesangial matrix with A plus L treatment. The benefit of combined A and L treatment 
in patients with DN may occur in part through a previously unrecognized restoration of 
podocytes.
Funding: Pharmaceutical Company Support - Abbvie Pharmaceuticals
TH-PO330
Insulin Signaling in Glomeruli and Podocytes from Insulin Resistant db/
db DBA/2J Mice  Mette Viberg Østergaard,1,2 Jesper Worm,1 Lisbeth N. Fink,1 
Richard Coward.2  1Global Research, Novo Nordisk A/S, Maaloev, Denmark; 
2Academic Renal Unit, Univ of Bristol, Bristol, United Kingdom.
Background: Impaired insulin signalling in the podocyte may contribute to the 
glomerular pathology in systemic insulin resistance and type 2 diabetes (T2D). We 
hypothesize that insulin signalling in the podocyte is altered early during development of 
insulin resistance and T2D due to altered insulin receptor (IR), IGF-1 receptor (IGF-1R) 
or insulin/IGF-1 hybrid receptor (HR) expression levels.
Methods: The development of insulin resistance, T2D, albuminuria, and renal 
pathology was characterised in db/db DBA/2J mice and wild-type (wt) littermates from 
6 weeks of age. Insulin-induced phospho-Akt, phospho-ERK1/2 signalling, and IR, IGF-
1R and HR expression levels were investigated in the glomeruli of insulin resistant db/db 
DBA/2J mice. The PodCre,ROSAmT/mG reporter strain enriched in the DBA/2J background 
is crossed with the db/db DBA/2J strain to enable isolation of insulin resistant GFP+ 
podocytes by FACS and characterisation of podocyte IR, IGF-1R and HR expression levels.
Results: The body weight was >50% higher in db/db vs. wt mice (P<0.001) from 8 
weeks. From week 9, db/db males were hyperglycaemic with non-fasting blood glucose 
ranging from 23.4-30.7 mM (wt range 6.3-7.7 mM; P<0.05). Insulin tolerance tests showed 
development of whole-body insulin resistance by 8 weeks in male and female db/db vs. 
wt mice (P<0.05). The urinary albumin-to-creatinine ratio was elevated in db/db vs. wt 
mice from 7-12 weeks of ages (range of means 2451-9597 vs. 75-479 µg/mg; P<0.01). 
GFP+ podocytes were successfully isolated from glomerular single cell suspensions from 
PodCre,ROSAmT/mG mice and their purity validated by qPCR analysis of Nphs2, Pecam1, 
and Pdgfrb. Podocytes are currently being isolated from 9-week-old insulin resistant db/
db PodCre,ROSAmT/mG DBA/2J mice to characterise IR, IGF-1R and HR expression levels.
Conclusions: The db/db mouse in the DBA/2J background show early signs of systemic 
insulin resistance and glomerular disease. Isolating podocytes from this model will allow 
us to further clarify the roles of IR, IGF-1R and HR in podocytes during the development 
of insulin resistance and diabetic nephropathy.
Funding: Pharmaceutical Company Support - Novo Nordisk A/S
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PKC-α Triggers EGFR Ubiquitination, Endocytosis and MAPK/ERK 
Activation in Podocytes with High Glucose Stimulation  Hua Su, Yanhong 
Wei, Chun Zhang.  Nephrology, Huazhong Univ of Science and Technology, 
Wuhan, Hubei, China.
Background: PKCα and EGFR are both involved in diabetic kidney disease, however 
the association between these two proteins during high glucose induced podocyte injury 
is unclear.
Methods: Diabetes was induced in SD rats by a single intra-peritoneal injection of 
STZ at a dose of 55 mg/kg body weight in sodium citrate buffer. 14 days later the rats 
were sacrificed and the cortex of kidney was removed and subjected to plasma membrane 
isolation and lipid raft fraction. In vitro study human podocyte cell line was employed, 
and after differentiation it was treated with high glucose or osmotic control for 24 h. 
The membranous protein expression and endocytosis were assessed by biotinylation and 
MesNa treatment. Gö6976 and PYR-41 were used as an inhibitor for PKCα and ubiquitin 
activating E1 enzyme respectively.
Results: By plasma membrane isolation and lipid raft separation we identified that 
in diabetic rat the abundance of PKCα in membranous fraction and lipid raft domain was 
elevated, whereas EGFR level was reduced in abovementioned compartments. Consistently, 
in vitro high glucose treated podocyte the membranous EGFR was downregulated 
accompanying with the increased membranous PKCα expression which was examined 
by biotinylation and plasma membrane isolation. Furthermore by immunoprecipitation, 
biotinylation and MesNa treatment experiments it showed that the ubiquitination and 
endocytosis of EGFR were enhanced in podocyte under high glucose stimulation which 
accompanied with MAPK/ERK signaling activation and the injury of podocyte which was 
proved by the reorganization of F-actin fibers and increased desmin level. However above 
processes could be ameliorated by either PKCα or ubiquitin activating E1 enzyme inhibitor.
Conclusions: Our observations demonstrate that in high glucose treated podocyte PKCα 
mediates EGFR ubiquitination, endocytosis from cell plasma membrane and eventually 
leads to the activation of MAPK/ERK signaling pathway which partially attributes to 
podocyte injury in diabetic kidney disease.
Funding: Government Support - Non-U.S.
TH-PO332
Activation of Protein Kinase C-β in the Podocyte by Diabetes-Associated 
Inflammatory Mediators  Brad Dieter,1 Rick L. Meek,1 Robert J. Anderberg,1 
Sheryl K. Cooney,1 Katherine R. Tuttle.1,2  1Providence Health Care, Spokane, 
WA; 2School of Medicine, Univ of Washington, Seattle, WA.
Background: Activation of protein kinase C-beta (PKC-β) is a key signal transduction 
mediator strongly implicated in development and progression of diabetic kidney disease 
(DKD). However, the potential role of PKC-b in podocyte mechanisms of DKD has not 
been previously studied. The aim of this study was to determine whether advanced glycation 
end-products (AGE) or serum amyloid A (SAA), inflammatory mediators in DKD, activate 
PKC-β and downstream consequences of inflammation and apoptosis in podocytes.
Methods: Podocytes were exposed to AGE (300 mg/ml) or exogenous SAA (10 mg/
ml) for 1 hour. PKC-β activity was measured as the phosphorylated form and by membrane 
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fraction (Western blot). Immunostaining with imaging by confocal microscopy was used for 
PKC-β localization. PKC-β was inhibited by LY379196 (100 nm) in podocytes exposed to 
SAA and AGE for 20 hours. Outcomes included mRNA (qRT-PCR) for pro-inflammatory 
proteins: C-X-C motif chemokine ligand 5 (CXCL5), C-C motif chemokine ligand 5 
(CCL5), monocyte chemoattractant protein-1 (MCP-1), inducible nitric oxide synthase 
(iNOS), SAA, and TUNEL assay (apoptosis).
Results: AGE and SAA exposure increased PKC-β activation in podocytes as evidenced 
by increased phosphorylation (1.3-fold, p=0.007 and 1.4-fold, p=0.001, respectively) and 
increased PKC-β in the membrane fraction (2.1-fold, p<0.001 and 1.6-fold, p=0.002, 
respectively). Immunostaining for PKC-β revealed greater membrane localization. AGE and 
SAA exposure also increased podocyte TUNEL staining (2.1-fold, p=0.002 and 3.4-fold, 
p<0.001, respectively). PKC-β inhibition reduced expression of CXCL5, CCL5, MCP-1, 
iNOS, SAA, and TUNEL staining.
Conclusions: PKC-β activity is increased in podocytes after exposure to diabetes-
related inflammatory mediators. Consequent podocyte inflammatory and apoptotic responses 
are mediated by the PKC-β pathway.
Funding: Private Foundation Support
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Podocyte SIRT1 Deficiency Contributes to Albuminuria and Renal Fibrosis 
in Diabetic Kidney Damage in Mice  Yi Guan, Chuanming Hao.  Dept of 
Nephrology, Huashan Hospital, Shanghai, China.
Background: SIRT1 has been shown to play an important role in stress response, 
metabolic disorder and aging process, and is suggested to be involved in the pathogenesis 
of diabetic kidney damage. The study examines whether and how SIRT1 deficiency is 
involved in diabetic nephropathy.
Methods: High fat diet plus 5-day-low-dose STZ was used to model type 2 diabetes. 
The role of SIRT1 in diabetic kidney is examined using SIRT1 heterozygotes (C57BL/J6). 
Urinary albumin excretion, kidney histology and extracellular matrix protein accumulation 
were used to assess diabetic kidney damage. Blood pressure was determined by tail-cuff 
method. Endothelium selective SIRT1 knockout was generated by crossing floxed SIRT1 
mice with SCLCreER, and recombination was induced by tamoxifen. Podocyte selective 
SIRT1 knockout were generated by crossing floxed SIRT1 mice with PodocinCre. Deletion 
of SIRT1 in endothelium and podocytes was confirmed by immunohistochemistry.
Results: In diabetic kidney, SIRT1 expression was significantly reduced. Urinary 
albumin excretion of diabetic SIRT1 heterozygote was markedly increased by 4 fold 
compared with littlemates. Renal histology showed mesangial expansion, Sirius red 
staining revealed more fibrosis and qPCR indicated higher expression of PAI-1, aSMA, Col 
18aI, Loxl gene, in diabetic SIRT1 knockout than wild type. Losing one allele of SIRT1 
did not alter blood pressure in diabetic mice, suggesting that the diabetic kidney damage 
in the SIRT1 deficient mice is not caused by blood pressure change. To further examine 
the mechanism by which SIRT1 deficiency increased diabetic damage, endothelium and 
podocyte SIRT1 was selectively deleted respectively. Following STZ challenge, podocyte 
SIRT1 deficient mice showed higher albuminuria and developed diabetic kidney damage, 
compared with wild type. Podocyte SIRT1 deficiency did not alter blood pressure. In 
contrast, endothelium SIRT1 deletion did not cause significant change in albuminuria and 
kidney damage in diabetic mice .
Conclusions: SIRT1 deficiency, especially in podocyte is responsible for the 
development of albuminuria and renal fibrosis. The mechanism by which podocyte SIRT1 
protects the kidney from diabetic kidney damage remains to be explored.
Funding: Government Support - Non-U.S.
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β-Arrestins Promote Podocyte Injury in Diabetic Nephropathy  Fan Yi. 
Pharmacology, Shandong Univ School of Medicine, Jinan, Shandong, China.
Background: Although autophagy has been implicated in the pathogenesis of diabetic 
nephropathy (DN), the precise roles and regulatory mechanisms of autophagy are largely 
unknown. β-arrestins are multifunctional proteins originally identified as negative adaptors 
of G protein-coupled receptors (GPCRs). Emerging evidence has also indicated that 
β-arrestins can activate signaling pathways independent of GPCR activation.
Methods: Ten-week-old male β-arrestin-1 and β-arrestin-2 deficient mice (β-arrestin-1-/- 
and β-arrestin-2-/-, 18-20g) were induced by tail-vein injection of streptozotocin (STZ) and 
were maintained for 12 weeks.
Results: We found that both β-arrestin-1 and β-arrestin-2 were up-regulated in the 
kidney from streptozotocin-induced diabetic mice, diabetic db/db mice and kidney biopsies 
from diabetic patients. We further revealed that either β-arrestin-1 or β-arrestin-2 deficiency 
ameliorated renal injury in diabetic mice. In vitro, we observed that podocytes increased 
both β-arrestin-1 and β-arrestin-2 expressions under hyperglycemia condition, which were 
associated with suppressing autophagy by negative regulation of ATG12-ATG5 conjugation 
and the activation of Wnt/β-catenin signaling pathways. Finally, we evaluated the genetic 
therapeutic efficiency targeting to β-arrestin-1 or β-arrestin-2 in DN showing that in vivo 
gene silencing of β-arrestin-1, β-arrestin-2 or both by intrarenal lentiviral gene delivery 
ameliorated diabetic renal injury in mice.
Conclusions: This study for the first time demonstrate that β-arrestin-1 and β-arrestin-2 
share common mechanisms to mediate podocyte autophagic process (Figure 1), indicating 
that β-arrestins are critical components of multiple signal transduction pathways that 
link renal injury to reduced autophagy in DN. Modulation of these pathways may be an 
innovative therapeutic strategy for treating patients with DN.
Funding: Government Support - Non-U.S.
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Myo-Inositol Oxygenase (MIOX) Contributes to Renal Tubular Injury 
via Endoplasmic Reticulum (ER) Stress and a Hyaluronic Acid (HA) 
Production  Tatsuya Tominaga,2 Toshio Doi,2 Yashpal S. Kanwar.1  1Pathology, 
NorthZestern Univ, Chicago, IL; 2Nephrology, Tokushima Univ, Tokushima, 
Japan.
Background: MIOX is a renal tubular enzyme which channels myo-inositol into 
xylulose-pentose pathway. We previously indicated its increased expression in diabetic 
nephropathy and its transcriptional regulation by high glucose, osmotic agents and 
oxidant stress. Both ER stress and a macrophage accumulation are contributing factors 
for progression of the renal tubular injury. In this study, we examined the role of MIOX 
for the ER stress and chemokine induction.
Methods: MIOX knockout mice were fed with high fat diet (HFD) or treated with 
tunicamycin (Tm). We crossbred MIOX transgenic mice with PEPCK Cre mice for 
generating mice with predominant tubular expression of MIOX. HK2 cells were subjected 
to Tm treatment and transfected with MIOX siRNA. ER stress was gauged by examining the 
expression of C/EBP homologous protein (CHOP), sXBP1 (transcriptional factor), GRP78 
and GRP94 (ER molecular chaperons) in kidney tissues or HK2 cells.
Results: sXBP1, CHOP, GRP78 and GRP94 increased in mice receiving HFD or 
Tm treatment. These expressions decreased in the MIOX KO mice compared with wild 
type mice. While, the expressions of GRP78, GADD153 in kidneys increased in MIOX 
transgenic mice. Also, tubular injury observed following Tm treatment was alleviated in 
MIOX KO mice and but worsened in MIOX transgenic mice. MIOX expression increased 
with Tm treatment in a dose-dependent (0.3 - 10 mg/mL) and time-dependent (0.5 - 24 hr) 
manner in HK2 cells. The sXBP1 and GRP78 expressions also increased following Tm 
treatment in HK-2 cells. Simultaneously, Tm treatment increased HA synthesis in HK2 
cells. The transfection of MIOX siRNA decreased the expression of sXBP1, MCP1, IL6 
and hyaluronan synthase 2 (HAS2) under the Tm treatment. Overexpression of MIOX 
increased sXBP1, CHOP, GRP78 and GRP94, as well as induction of MCP1, IL6 and HAS2.
Conclusions: These findings indicate that MIOX contributes to ER stress and HA 
synthesis and chemokine induction possibly initiated by macrophage accumulation.
Funding: NIDDK Support
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Mitochondrial-Targeted MitoQ Attenuated Renal Tubular Damage 
in Diabetic Nephropathy by Regulation of Mitochondrial Quality and 
Modulating Mitophagy  Li Xiao,1 Dang Tang,1 Jiahui Wang,1 Xiaoxuan Xu,1 
Yashpal S. Kanwar,2 Lin Sun,1 Fuyou Liu.1  1Dept of Nephrology, 2nd Xiangya 
Hospital, Central South Univ, Changsha, China; 2Depts of Pathology and 
Medicine, NorthZestern Univ, Chicago, IL.
Background: The protection of Mitochondria-targeted ubiquinone (mitoQ) on 
mitochondrial oxidative damage in various diseases including diabetic kidney disease 
(DKD) has been reported. However, the mechanism by which Mito Q reverses renal 
injury in DKD is unclear.
Methods: 15 of renal biopsy samples from patients with DKD were obtained, 20 db/
db mice and HK-2 cells, a proximal tubular cells line were used for this study. Patients with 
MCD and db/m mice used as control. db/db mice were intravenously injection of MitoQ with 
5 mg/kg twice/week for 12 weeks. The pathological change of renal tissues was observed 
by HE, PAS, Mass staining. Mitophagy, mitochondrial fragmentation, mitochondrial ROS 
production, and mitophagy-related mRNA and protein were detected by EM, mitoSOX 
staining, immunofluorescence, cofocal, Real-time PCR and western blot.
Results: Compared to MCD patients and db/m mice, defective mitophagy was 
observed in the kidney tubular of DKD patients and db/db mice, which associated with 
increased mitochondrial fragmentation, oxidative stress, caspase-3 activity and apoptosis. 
Furthermore, down-regulated expression of mitophagy-related genes and proteins, such 
as Pink/parkin, Atg7, NIX and Tom20 were observed, while VDAC is upregulated. These 
changes above were partially reversed in that of treated with mito Q, and consistent with 
attenuated tubular damage and urine protein excretion. In vitro study, high glucose (HG) 
reduced mitophagy with downregulated mitophagy-related proteins as well as LC3 and P62 
accumulation. It also increased mitochondrial fragmentation, oxidative stress, caspase-3 
activity and apoptosis. However, mito Q abolished these effects. In addition, parkin-siRNA 
and NIX-siRNA inhibited the benefical effect of mitoQ.
Conclusions: These results indicating that MitoQ could improve mitochondrial quality 
and attenuate oxidative damage through regulation of mitophagy under DKD condition. 
MitoQ may be as a potential therapeutic agent for amelioration of DKD.
TH-PO337
Evaluation of iNOS Inhibition on Kidney Functions in High-Fat Diet-
Induced Obesity  Anne-Emilie Decleves,1,2 Blanche Martin,2 Vanessa 
Colombaro,2 Inès Jadot,2 Isabelle Habsch,2 Joelle L. Nortier,1 Nathalie Caron.2 
1Laboratory of (xperimental Nephrology, Faculty of Medicine, Univ Libre de 
Bruxelles ULB; 2Molecular Physiology Research Unit-URPHYM, Univ of 
Namur (UNamur).
Background: Central obesity is related to caloric excess promoting deleterious cellular 
responses in targeted organs. Nitric oxide (NO) has been determined as playing a critical role 
in the pathogenesis of metabolic diseases. Here, we investigated the implication of iNOS in 
the development of progressive renal dysfunction leading to obesity-induced kidney disease.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
165A
J Am Soc Nephrol 26: 2015 Diabetes Mellitus and Obesity: Basic-Experimental - I Poster/Thursday
Methods: C57Bl/6 male mice were randomized to a low fat diet (LFD - 10% of total 
calories from fat) or a high-fat diet (HFD - 60% of total calories from fat) and treated with 
L-NIL, a specific iNOS inhibitor (0.1 % in drinking water) for 16 weeks.
Results: Mice fed a HFD exhibited a significant increase in body weight, fasting 
blood glucose, plasma levels of NEFA,triglyceride and insulin. iNOS inhibition with 
L-NIL prevented these changes in mice fed a HFD. Interestingly, the significant increase 
in albuminuria and mesangial matrix expansion was not ameliorated with L-NIL while 
there was a significant amelioration in glucosuria and proteinuria, suggesting that iNOS 
inhibition is more suitable for tubular function than glomerular function. Moreover, the 
urinary hydrogen peroxide level, a stable product of ROS production, significantly higher 
in mice fed a HFD, was reduced with L-NIL. In order to better determine the beneficial 
effect of L-NIL in the development of obesity, peri-renal white adipose tissue were also 
investigated. The histological analysis revealed an increasing size of adipocytes in mice 
fed a HFD. This change was significantly reduced with L-NIL treatment. Inflammation, 
as attested by macrophage infiltration and enhanced MCP-1 level, was also prevented by 
L-NIL in the adipose tissue.
Conclusions: These results suggest that inhibition of iNOS leads to beneficial effects in 
kidney and adipose tissue in mice fed a HFD. This study opens new area of investigations 
on the involvement of iNOS in obesity-induced organ injury.
Funding: Government Support - Non-U.S.
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The Impact of Diabetes on Total Glomerular Number and Size in Kidney 
Estimated by Synchrotron Radiation Micro-CT in SPring-8  Yumi Takiyama,1 
Toshihiro Sera,2 Masanori Nakamura,3 Ryoichi Bessho,1 Kentaro Uesugi,4 Naoto 
Yagi,4 Masakazu Haneda.1  1Dept of Medicine, Asahikawa Medical Univ, 
Hokkaido, Japan; 2Dept of Mechanical Engineering, Kyushu Univ, Fukuoaka, 
Japan; 3Graduate School of Science and Engineering, Saitama Univ, Saitama, 
Japan; 4Research & Utilization Div, Japan Synchrotron Radiation Research 
Inst, Hyogo, Japan.
Background: To investigate the impact of diabetes on the number and volume of 
glomeruli in the whole kidney, we explored CT imaging of male type 2 diabetic db/db mice 
and of nondiabetic db/m mice at 22 week of age using synchrotron radiation.
Methods: Perfused kidneys with contrast medium were removed and visualized 
using the synchrotron radiation micro-CT in SPring-8. X-ray image was detected on the 
fluorescent screen lens coupling sCMOS camera detector with 15.5mm in the pixel size. 
A segmentation algorithm was conducted to identify and count all glomeruli within the 
whole kidney, using image analyzing Amira™ software.
Results: Db/m mice had larger kidney volume and more glomerular number in right 
kidney than left kidney. Intriguingly, diabetes abolished this laterality in db/m mice. Db/db 
mice had larger glomerular volume than db/m mice. Especially, the cortical glomerular size 
was remarkably increased. On the other hand, diabetes failed to affect the total glomerular 
number in kidneys. The mean glomerular volume was strongly correlated with fasting blood 
glucose, kidney volume, urinary volume and glomerular number in all mice, and urinary 
volume was a significant independent determinant of the mean glomerular volume, whereas 
the mean glomerular volume was associated with glomerular number.
Conclusions: Our study, for the first time, showed the impact of diabetes on total 
glomerular number and glomerular volume of the whole kidney by developing new imaging 
analyzing system, providing the possibility of glomerular hypertrophy in subjects before 
diabetes onset.
TH-PO339
NADPH Oxidase-Nox5 Plays a Deleterious Role in Diabetic Nephropathy 
Jay Chandra Jha,1 Stephen P. Gray,1 Claudine Banal,1 Harald H. Schmidt,2 
Mark E. Cooper,1 Rhian Touyz,3 Chris R. Kennedy,4 Karin Jandeleit-Dahm.1 
1Diabetes Complications Div, Baker IDI Heart and Diabetes Inst, Melbourne, 
Australia; 2Dept of Pharmacology, Maastricht Univ, Maastricht, Netherlands; 
3Inst of Cardiovascular and Medical Sciences, Univ of Glasgow, Glasgow, United 
Kingdom; 4Dept of Medicine, Ottawa Hospital Research Inst, Ottawa, Canada.
Background: Diabetic nephropathy (DN) is the leading cause of end stage renal 
disease. It has been indicated that recently discovered NADPH oxidase, Nox5 could play 
a role in DN. Nox5 is present in humans but not in mice or rats. Thus, there is a paucity of 
information about Nox5 in animal models of DN. We examined the role of Nox5 in a model 
of human inducible Nox5 transgenic mice expressing Nox5 selectively in either endothelial 
cells (VEcadNox5+) or vascular smooth muscle cells (SM22Nox5+) in the setting of diabetes.
Methods: VEcadNox5+or SM22Nox5+ mice were rendered diabetic via streptozotocin 
injections. At week 10 urine samples were collected for the assessment of albuminuria. 
Animals were culled and kidneys were removed for the assessment of structural damage 
as well as gene and protein expression of markers of inflammation and fibrosis.
Results: Both VEcadNox5+ and SM22Nox5+ mice demonstrated a further increase in 
albuminuria (ug/24hrs) compared to their respective Nox5 deficient mice in the presence 
of diabetes (control & diabetic VEcadNox5- : 209±33 & 4139±714; control & diabetic 
VEcadNox5+ : 184±21 & 5888±771; control & diabetic SM22Nox5- : 177±19 & 3036±394; 
control & diabetic SM22Nox5+ : 147±14 & 4273±537). In addition, both diabetic Nox5 
transgenic mouse groups appeared to have increased glomerulosclerosis and mesangial 
area as well as increased gene and protein expression of fibronectin and MCP-1 in the 
renal cortex when compared to Nox5 negative diabetic mice.
Conclusions: Our findings of an additional increase in albuminuria and 
glomerulosclerosis as well as increased expression of pro-fibrotic and pro-inflammatory 
markers in Nox5 transgenic diabetic mice suggest a deleterious effect of Nox5 in the context 
of diabetic nephropathy and emphasize its role as a target for new renoprotective agents.
Funding: Government Support - Non-U.S.
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Resveratrol Exhibits Protective Effects on Early-Stage Diabetic 
Nephropathy by Restoring Mitochondrial Function of Renal Tubular Cells 
Hao Ding, Junwei Yang.  Center for Kidney Disease, Second Affiliated Hospital, 
Nanjing Medical Univ, Nanjing, Jiangsu, China.
Background: Diabetic nephropathy (DN) is a progressive and irreversible renal disease. 
Mitochondrion plays an important role in the pathogenesis of DN. Resveratrol (RSV), a 
naturally occurring sirtuin-1 (SIRT1) activator, has been shown to promote mitochondrial 
function. The aim of the present study is to investigate the renoprotective effects of RSV 
and delineate its underlying mechanism in early-stage DN.
Methods: Diabetes was induced by streptozotocin (STZ) injection in male CD-1 mice. 
Two weeks after the onset of DM, the DM mice were further divided into three subgroups 
concomitantly treated with placebo, RSV 50mg/kg or RSV 100mg/kg for 28 consecutive 
days. At the end of RSV treatment course, the mice were sacrificed. Primary kidney proximal 
tubular cells (PTCs) were cultured in high glucose with indicated concentrations of RSV.
Results: In diabetic mice, RSV treatment postponed the progression of DN, as 
demonstrated by ameliorating the increases of urine albumin excretion, mean artery 
pressure level, plasma blood glucose level and plasma triglyceride level. Meanwhile, the 
increases of plasma creatinine level, plasma BUN level, glomerular diameter, mesangial 
accumulation and renal fibrosis in diabetic mice were also reduced by RSV treatment. 
Moreover, orally administration of RSV partly restored the distribution and expression of 
nephrin, WT1 and podocin. We demonstrated that hyperglycemia increased mitochondrial 
mass and mitochondrial DNA content, upregulated mRNA and protein expression of 
oxidative phosphorylation enzyme complexes in early-stage DN but led to mitochondrial 
dysfunction both in vitro and in vivo.RSV acted as a phosphodiesterase 4B inhibitor and 
SIRT1 activator, attenuated high glucose-induced mitochondrial network fragmentation 
and impaired oxidative phosphorylation capacity both in vitro and in vivo. Furthermore, 
it was shown that the protective role of RSV on early-stage DN was probably through 
AMPK-ACC pathway.
Conclusions: These findings suggested that RSV exhibited a strong ability to inhibit 
highglucose-induced PTCs damage and may serve as a promising new therapeutic approach 
for treating early-stage DN.
Funding: Government Support - Non-U.S.
TH-PO341
Possible Implication of Xanthine Oxidase Activation on the Pathogenesis 
Diabetic Nephropathy  Seiji Itano, Minoru Satoh, Atsushi Uchida, Hiroyuki 
Kadoya, Hajime Nagasu, Tamaki Sasaki, Naoki Kashihara.  Dept of Nephrology 
and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Background: Endothelial dysfunction represents a predominant early feature of 
diabetes and makes diabetic patients prone to renal complications. Recent evidence 
has indicated possible role of xanthine oxidase (XO) in the pathogenesis of vascular 
dysfunction associated with diabetes. However, it is not clear whether XO activity is 
involved in pathogenesis of diabetic nephropathy (DN). We investigated the contribution 
of XO activation on the progression of mouse DN by selective XO inhibitors, Topiroxostat 
(Top) and Febuxostat (Feb).
Methods: Male Ins2Akita heterozygote (Akita; 10 weeks old) mice were used. Wild-
type (WT) mice were used for control. Akita mice were treated with Top (3mg/kg/day), 
Feb (1mg/kg/day) or Vehicle (Vehi) for 4weeks. Serum uric acid and urinary albumin 
excretion (UAE) were measured. Glomerular pathological changes were also examined 
by light microscope andelectron microscope. Glomerular permeability was assessed using 
2 photon microscopy and fluorescent labeling albumin.
Results: Serum uric acid levels showed no significant difference between all groups. 
Akita+Top or Akita+Feb groups showed significant reduction of UAE in comparison with 
Akita+Vehi group. Mesangial expansion, glomerular collagen IV deposition, and glomerular 
endothelial injury (examined by lectin stain and transmission electron microscope) 
were ameliorated in Akita+Top or Akita+Feb group compared with Akita+Vehi group. 
Furthermore, glomerular permeability was deteriorated in Akita+Vehi group compared with 
WT group. These changes were ameliorated with addition of Top or Feb.
Conclusions: XO inhibitors preserved glomerular endothelial function and improved 
deteriorated glomerular permeability, indicating that XO activation is involved in 
pathogenesis of DN.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
166A
J Am Soc Nephrol 26: 2015 Diabetes Mellitus and Obesity: Basic-Experimental - I Poster/Thursday
TH-PO342
Effect of Mitochondria-Targeted Ubiquinone Q in Tubular Oxidative 
Injury of Diabetic Nephropathy Modulate by Mitochondrial ROS/NLRP3/
IL-1β Biological Axis  Xiaoxuan Xu,1 Li Xiao,2 Chun Hu,3 Yachun Han,4 
Yashpal S. Kanwar,5 Fuyou Liu,6 Lin Sun.7  1The Second Xiangya Hospital of 
Central South Univ; 2The Second Xiangya Hospital of Central South Univ; 
3The Second Xiangya Hospital of Central South Univ; 4The Second Xiangya 
Hospital of Central South Univ; 5Northwestern Univ, Chicago; 6The Second 
Xiangya Hospital of Central South Univ; 7The Second Xiangya Hospital of 
Central South Univ.
Background: To understand the underlying mechanism by MitoQ attenuate the 
progression of DN.
Methods: 18 patients with DN or primary minimal changes disease were enrolle. 
Renal pathological changes were observed. MitoQ was intraperitoneally injected to the 
db/db mice twice a week for 12 week(5mg/kg). The injury of kidney and expression of 
NLRP3,IL-1β, Caspase-1 were tested. HK-2 cells were incubated with D-glucose treated 
by MitoQ and NLRP3 siRNA. The expression of NLRP3, Caspase-1, IL-1β, FN, Collagen 
I,Mitochondrial membrane potential(MMP), mt ROS and the mitochondrial translocation 
of NLRP3 were observed.
Results: The expression of NLRP3, IL-1β, IL-18 increased in kidney of DN patients. 
which were positively associated with the renal pathological change, oxidative injury in 
db/db mice. MitoQ ameliorated proteinuria, renal damage, mitochondrial dysfunction, 
oxidative stress, and apoptosis in the kidney of db/db mice, which was accompanied with 
decreased NLRP3/IL-1β biological axis related protein and Caspase-1, FN, Col-I. MitoQ 
also decreased the expression of NLRP3, IL-1β, Caspase-1, FN, Col-I and attenuated 
mtROS and apoptosis in HK-2 cells. It also recovered MMP and decreased mitochondrial 
translocation of NLRP3 induced by high glucose. These effect was blocking partially in 
transfection with lentiviral vectors expressing NLRP3 plasmid , while this effect was 
abolished by treated with NLRP3 siRNA .
Conclusions: This data indicated that MitoQ ameliorate injury of renal tubular of DN 
through mtROS/NLRP3/IL-1β axis.
TH-PO343
Inhibition of Enhanced Xanthine Oxidoreductase Activity Prevents the 
Progression of Diabetic Nephropathy by Attenuating Oxidative Stress 
Goshi Nagao,1 Takayo Murase,1 Ryusuke Sakamoto,1 Takashi Iwanaga,2 Naoki 
Ashizawa,2 Takashi Nakamura.1  1SanZa Kagaku Kenkyusho, Co., Ltd., Japan; 
2Fuji Yakuhin, Co., Ltd., Japan.
Background: Topiroxostat, a xanthine oxidoreductase (XOR) inhibitor, has been 
approved as a medicine for hyperuricemia and gout in Japan, and showed a decrease of 
urinary albumin excretion (UAE) in hyperuricemic stage 3 chronic kidney disease patients 
in clinical trial. Meanwhile, the induction of oxidative stress and morphological changes 
known as the representative evidences of diabetic nephropathy (DN) has been reported. 
We aimed to test the hypothesis that XOR-induced oxidative stress was associated with 
progression of DN.
Methods: Nine-week-old male diabetic db/db mice were fed with diet containing 
topiroxostat (0.1-10 mg/kg) for 4-8 weeks. The levels of plasma uric acid, UAE 
concentration for 24 hours, and XOR activity of kidney were determined. PAS staining was 
performed in paraffin section of renal tissue, and then glomerular tuft area, diameter and 
cell height of proximal tubules were measured with image analysis software. In addition, 
immunohistochemical staining for nitrotyrosine was performed.
Results: Treatment with topiroxostat decreased the levels of plasma uric acid and UAE. 
XOR activity of kidney in db/db was significantly elevated compared with that in db/m, 
which was inhibited by treatment with topiroxostat (db/m: 47.1±12.6, db/db: 87.2±19.7, and 
3 mg/kg: 16.6±4.6 pmol/min/mg protein; P<0.01, mean±SD). In morphometric analysis, 
glomerular hypertrophy in db/db control was significantly attenuated by treatment with 
topiroxostat 3 mg/kg (db/m: 2952±302, db/db: 4028±301, and 3 mg/kg: 3692±270 mm2; 
P<0.05). The diameter and cell height of proximal tubules in topiroxostat 3 mg/kg group 
were significantly smaller than those in db/db control (db/m: 38.6±2.7, 15.9±1.2, db/db: 
43.8±2.0, 18.5±0.9, and 3 mg/kg: 41.7±1.8; P<0.01, 16.8±0.7 mm; P<0.05, respectively). 
As compared to db/m, glomerular nitrotyrosine positive area in db/db was increased 7.4-
fold, which was reduced by 46% by treatment with topiroxostat.
Conclusions: Topiroxostat decreased UAE and attenuated renal morphological changes, 
at least in part, by inhibition of enhanced XOR-induced oxidative stress in DN.
TH-PO344
Knockout of Matrix Metalloproteinase 2 Attenuates the Progression of 
Renal Disease in Streptozotocin-Induced Diabetic Dahl Salt Sensitive 
Rats  Takashi Hirata,1,2 Fan Fan,1 Naoki Kojima,2 Teisuke Takahashi,2 
Noriyuki Miyata,3 Richard J. Roman.1  1Pharmacology and Toxicology, Univ of 
Mississippi Medical Center, Jackson, MS; 2Pharmacology Laboratories, Taisho 
Pharmaceutical Co., Ltd., Saitama, Japan; 3Pharmaceutical Business Planning, 
Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.
Background: We have found that chronic blockade of MMPs with a broad spectrum 
inhibitor, XL784, reduced renal injury in type 2 diabetic nephropathy rats. However, the 
isoforms involved in the development of diabetic nephropathy are unclear.
Methods: The present study examined the role of MMP2 in the development of diabetic 
nephropathy using a MMP2 knockout (KO) rat in the Dahl salt sensitive (SS) genetic 
background that we created. Nine week old SS and MMP2 KO rats (n=10) were treated 
with intravenous injection of streptozotocin (STZ, 50 mg/kg) to induce diabetes and given 
an insulin implant (2 U/day) to maintain blood glucose around 400 mg/dL. Blood pressure 
and proteinuria were followed for 12 weeks. Age-matched SS rats (n=5) were studied to 
serve as a non-diabetic control for the assessment of renal hemodynamics and injury.
Results: Blood glucose and HbA1c levels increased to the same extent in STZ-treated 
SS (SS-STZ) and MMP2 KO (MMP2 KO-STZ) rats. Systolic blood pressure rose to 195 
± 3 in SS-STZ rats versus 163 ± 3 mmHg in MMP2 KO-STZ rats. Proteinuria increased 
to 5-fold to 557 ± 33 in SS-STZ rats versus 94 ± 8 mg/day in MMP2 KO-STZ rats. The 
urinary excretion of MMP2 increased from 45 ± 10 to 2496 ± 365 ng/day in SS-STZ rats 
but it was absent in MMP2 KO-STZ rats. The kidneys of SS-STZ rats developed more 
severe glomerulosclerosis, mesangial expansion, and renal fibrosis than MMP2 KO-STZ 
rats. Glomerular filtration rate (GFR) in SS-STZ rats fell by 33% in comparison to time 
control SS rats, but GFR only fell by 12% in MMP2 KO-STZ rats.
Conclusions: These data indicate that activation of MMP2 may contribute to the 
development of diabetes induced renal injury and suggest that a MMP2 selective inhibitor 
may be useful to prevent the progression of renal disease in diabetic patients.
TH-PO345
Role of DUPS4 in Diabetic Nephropathy  Benoit Denhez,1 Farah Lizotte,1 
Mannix Auger-Messier,2 Pedro Miguel Geraldes.1  1Dept of Medicine, Div 
of Endocrinology, Univ of Sherbrooke, Sherbrooke, QC, Canada; 2Dept of 
Medicine, Div of Cardiology, Univ of Sherbrooke, Sherbrooke, QC, Canada.
Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal 
disease and is characterized by dedifferentiation and apoptosis of podocytes, which are 
highly specialized epithelial cells involved in the glomerular filtration process. Podocyte 
apoptosis is a strong predictor of DN progression. It has been shown that the activation of 
p38 MAPK induced by hyperglycemia plays an important role in podocytes dysfunction 
and apoptosis. However, the precise mechanisms leading to the sustained activation of p38 
MAPK remain unresolved. DUSP4, a dual specificity phosphatase, is known to bind directly 
to p38 MAPK and inhibits its activity. Our goal is to evaluate the role of DUSP4 in p38 
MAPK activation induced by hyperglycemia, which contributes to podocyte dysfunction 
and apoptosis in diabetic nephropathy.
Methods: Type 1 diabetic (DM) mice with deletion of DUSP4 (DM-DUSP4KO) was 
generated and studied during 7 months to evaluate renal function and pathology. Glomerular 
filtration rate (GFR) and 24h albumin excretion levels were measured in DM mice with 
or without deletion of DUSP4. Activation of p38 MAPK and expression levels of DUSP4 
in podocytes exposed to high glucose (HG) concentrations for 96 hours were evaluated 
by qPCR and immunoblot.
Results: The mRNA expression of DUSP4 is reduced by 50% in the renal cortex of 
DM mice. Although elevated GFR in DM mice was similar in DM-DUSP4KO (0,34 vs 
0,35 ml/min), albumin excretion was further exacerbated by 3.4 fold in DM-DUSP4KO 
compared to DM mice. In vitro, immunoblot analysis showed that HG level exposure 
reduced the expression of DUSP4 by 40%, which correlated with an increase of p38 MAPK 
phosphorylation by 70% in podocytes.
Conclusions: Our results suggest that decrease of DUSP4 expression in podocytes and 
renal cortex of diabetic mice contributes to podocyte dysfunction in diabetic nephropathy.
Funding: Government Support - Non-U.S.
TH-PO346
Telomerase Deficiency-Dependent Senescence Promotes Diabetic 
Nephropathy (DN) Progression  Huifang Cheng,1 Xiaofeng Fan,1 Paisit 
Paueksakon,2 Raymond C. Harris.1  1Medicine, Vanderbilt Univ Medical School, 
Nashville, TN; 2Pathology, Microbiology and Immunology, Vanderbilt Univ 
Medical School, Nashville, TN.
Background: Diabetes is a common disease in the elderly, and a link with telomere 
shortening has been reported, although whether it is Diabetes is a common disease in the 
elderly, and a link with telomere shortening has been reported, although whether it is a 
cause or a consequence of the disease has not been determined. Both telomerase reverse 
transcriptase (TerT) and telomerase RNA (TerC) are essential to maintain telomere length.
Methods: To investigate the role of telomerase in DN, we measured telomerase 
expression in kidneys from mice with streptozotocin (STZ)-induced (type I) and db/db 
(type II) diabetes. We also studied DN in wild type (Wt) and fourth generation (G4) mice 
with TerC or TerT deletion. In vitro studies were performed in primary cultured glomerular 
endothelial cells (GEnCs).
Results: Renal telomerase expression decreased in both type I and type II diabetic 
mice, compared with age-matched controls. 26 weeks after STZ injection, TerC and TerT 
KO mice had more albuminuria than Wt, and EM indicated increased GBM thickness, 
although mesangial expansion was similar. β-galactosidase, a marker of cell senescence, was 
mildly elevated in non-diabetic TerC and TerT KO mice. Diabetes accelerated senescence, 
especially in TerC and TerT KO. In glomeruli, senescence was predominately detected in 
endothelial cells. GEnCs from TerC deletion mice proliferated much slower than Wt in 
normal glucose medium (glucose 5.5 mM). After incubation for 96 hours in high glucose 
(30 mM) medium, GEnCs exhibited cellular senescence, with a marked increase in cells 
with TerC deletion. There was minimal senescence with incubation with the mannitol 
osmolality control.
Conclusions: These results indicate that telomerase deficiency promotes DN 
progression and accelerates glomerular endothelial senescence, implicating a role for the 
telomere shortening of aging as a predisposing factor for development of DN.
Funding: NIDDK Support, Veterans Administration Support
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TH-PO347
Interaction of the EGF Receptor and the Hippo Pathway in Diabetic 
Nephropathy  Jianchun Chen, Raymond C. Harris.  Medicine, Vanderbilt Univ 
Medical Center, Nashville, TN.
Background: Activation of both EGFR and the Hippo signaling pathway can control 
cell proliferation, apoptosis and differentiation, and their dysregulation can contribute to 
tumorigenesis. Previous studies have shown that activation of EGFR signaling in renal 
epithelial cells can exacerbate diabetic kidney injury. YAP is a transcriptional regulator 
that is regulated by the Hippo signaling pathway, which is a kinase cascade in which 
Mst1/2 kinases and Sav1 form a complex to phosphorylate and activate LATS1/2, which 
phosphorylate and inhibit the downstream effector, YAP.
Methods: We induced type I diabetes in proximal tubule EGFR deletion mice 
(EGFRptKO) and their wild type littermates (WT) by daily low dose streptozotocin injections 
for 5 consecutive days. A subset of wild type diabetic mice were administrated the EGFR 
kinase inhibitor, erlotinib. Cell signaling studies were performed in a proximal tubule 
epithelial-like cell (LLCPKCl4).
Results: STZ injection induced similar levels of hyperglycemia in EGFRptKO and 
WT mice. Both total and phosphorylated YAP (at Ser127) increased in diabetic WT mice, 
primarily in proximal tubule cells, and these increases were inhibited in EGFRptKO mice 
or by administration of erlotinib. Further studies demonstrated that EGFR-PI3K-Akt 
signaling pathway activation mediated YAP gene expression, YAP nuclear translocation and 
interaction with the TEAD transcription complex, which led to up-regulation of expression 
of TEAD-dependent genes, CTGF and AREG (amphiregulin). In a renal proximal tubule 
cell line, either pharmacologic or genetic inhibition of EGFR or Akt blunted YAP expression 
in response to high glucose treatment. In addition, knocking down YAP expression by 
specific siRNA inhibited cell proliferation in response to high glucose or exogenous EGF.
Conclusions: This is the first study to demonstrate that the Hippo pathway downstream 
effector YAP activation is a mediator of EGFR-mediated renal epithelial injury in diabetes.
Funding: NIDDK Support, Veterans Administration Support
TH-PO348
Role of Histone Modification in 12-Lipoxygenase Related P21 Gene 
Regulation  Hang Yuan,1 Nian Liu,2 Weixia Sun,1 Fu-zhe Ma,1 Tao Sun,1 Mindan 
Sun,1 Zhong-gao Xu.1  1Nephrology, The First Hospital of Jilin Univ, Changchun, 
Jilin, China; 2Urology, The First Hospital of Jilin Univ, Changchun, Jilin, China.
Background: Glomeruli hypertrophy is characteristic pathological changes of 
diabetic nephropathy, which is associated with p21 protein overexpression under diabetic 
condition. It has been demonstrated epigenetic histone modifications like acetylation (Ac) 
and methylation (Me) are involved in gene transcriptional regulation. We have certified 
12-Lipoxygenase (12-LO) and its metabolic product 12(S)-HETE can active p21 expression, 
but the mechanism details are still unclear.
Methods: Mesangial cells (MC) from Rat were used for this study. Chromatin 
immunoprecipitation assay, QRT-PCR and Luciferase assay were used to detect 
transcriptional activity, enrichment of H3K Ac as well as Me in the p21 promoter (P) and 
transcribe (T) regions induced by 12(S)-HETE; transfection was used to overexpression 
of p300 to see changes of 12(S)-HETE related p21 regulation as well as epigenetic 
modifications.
Results: 12(S)-HETE enhanced p21 transcriptional activity and mRNA expression; in 
the promoter regions of P1, P2 and T1 transcribe region, 12(S)-HETE induced significant 
H3K9Ac as well as H3K4Me1 epigenetic modifications, but no changes were seen in T2 
region; on the contrary, 12(S)-HETE treatment prevented H3K9Me3 at p21 promoter 
obviously, suggest complex Me involved in 12(S)-HETE associated p21 regulation; 
furthermore, overexpression of p300 obviously enhanced basal as well as 12(S)-HETE 
associated p21 transcriptional regulation in MC. At same time, 12(S)-HETE treatment also 
induced histone acetyltransferase p300 occupancy at p21 promoter, reduced demethylase 
LSD1 nuclear expression and occupancy at p21 promoter.
Conclusions: 12(S)-HETE can induce p300 occupancy at p21 promoter, reduced 
LSD1 nuclear expression and occupancy at p21 promoter, therefore enhanced H3K9Ac 
as well as H3K4Me1 at p21 promoter and transcribe regions, decreased H3K9Me3 at p21 
promoter, increased p21 expression.
Funding: Government Support - Non-U.S.
TH-PO349
E-Box CpG Hypomethylation of NMN-Producing Enzyme Nampt in 
Proximal Tubules Enables a Constant Supply of NMN from Tubules to 
Glomeruli, which Is Disrupted in Diabetic Nephropathy  Hirokazu Muraoka, 
Kazuhiro Hasegawa, Shu Wakino, Hiroshi Itoh.  Keio Univ.
Background: Nicotinamide mononucleotide (NMN)-producing enzyme nicotinamide 
phosphoribosyltransferase (Nampt) cooperates with a longevity gene, Sirt1, to exert the 
stress resistance. We previously reported that high expression levels of Nampt lead to 
NMN production in the proximal tubules (PTs), which contributes to the sufficient supply 
of NMN to glomeruli (Nat Med 2013). Downregulation of Nampt and NMN in PTs in 
diabetic nephropathy (DN) leads to glomerular damage. However, the underlying molecular 
mechanisms by which Nampt is regulated remain unknown. Here, we investigated how 
Nampt expression is consistently retained at high levels in PTs under normal conditions 
and decreased in DN.
Methods: Expression levels of Sirt1, TGF-β, and Nampt were measured in PTs 
of mice with DN. A promoter analysis was performed, and luciferase reporter and gel 
electrophoresis mobility shift assays were used to examine promoter binding. Methylation 
levels were investigated with methylation-specific PCR and bisulfite sequencing using 
laser-microdissected PT regions.
Results: Sirt1 expression in mouse PTs was decreased 8 weeks after DN onset. At 
24 weeks, TGF-β production increased, which directly lowered Nampt expression in PT. 
Human renal biopsy samples showed the same patterns seen in mice. CpG islands at -323 
to -456 bp in human and at -510 to -28 bp in mice were found to contain four enhancer 
(E) boxes (E1–E4). The basal transcription of Nampt depended on AhR/ARNT binding 
to E3 and E4, identifying this as a core promoter. We found that TGF-β activated Dnmt1, 
leading to the hypermethylation of CpGs in E3 and E4. This hypermethylation blocked 
AhR/ARNT binding and decreased Nampt expression. The methylation levels of E3 and 
E4 were significantly higher in DN mice than in non-DN mice.
Conclusions: Although E-boxes are generally enhancer regions, Nampt’s E-box is a 
core promoter with low CpG methylation and is easily bound by AhR/ARNT. This binding 
results in the regularly high protein expression of Nampt providing sufficient NMN under 
normal conditions. DN-induced PT TGF-β production and its concomitant hypermethylation 
of the E-box disrupt this balance.
TH-PO350
MicroRNA-21 Silencing as Novel Therapeutic Strategy in Diabetic 
Nephropathy  Malte Kölling,1 Tamás Kaucsár,2 Celina Schauerte,1 Joon-Keun 
Park,1 Martin Busch,3 Claudia Bang,1 Peter Hamar,2 Hermann G. Haller,1 Thomas 
Thum,1 Johan Lorenzen.1  1Hanover Medical School, Germany; 2Semmelweis 
Univ, Hungary; 3Jena Univ Hospital, Germany.
Background: Diabetic nephropathy (DN) is the main cause of end-stage renal disease. 
We therapeutically inhibited microRNA-21 (miR-21) in mice with DN.
Methods: We used miRNAome analysis, qPCR, in situ PCR, Western Blot, 
electrophoretic mobility shift assay and bioinformatic algorithms. Furthermore, we fused 
the 3’UTR of cell division cycle 25a (Cdc25a) and cyclin-dependent kinase 6 (Cdk6) to a 
Luciferase reporter gene. Luciferase activity was measured after overexpression of miR-
21. 28 patients and 20 controls were included. Mesangial cells (MC) and renal fibroblasts 
were treated with TGF-β. F-Actin staining, Cell Cycle FACS, scratch migration and BrdU 
incorporation revealed functional changes. In vitro and in streptozotocin-induced diabetic 
mice, miR-21 was silenced by locked nucleic acid. Immuno-, PAS- and Sirius red stainings 
were performed.
Results: MiR-21 was among the most up-regulated miRs in kidneys of diabetic mice 
and was mainly increased in the glomerular and interstitial compartement. In kidney biopsies 
of patients, miR-21 correlated with the tubulointerstitial injury. Moreover, miR-21 was 
tightly associated with albuminuria, hypertension and inflammation. Activator Protein-1 
regulated miR-21 expression. Cdc25a and Cdk6 were identified as novel targets of miR-21 
in MC. MiR-21 mediated repression of Cdc25a and Cdk6 resulted in G1-phase arrest and 
subsequent MC hypertrophy. In renal fibroblasts, we identified dual specificity phosphatase 8 
(Dusp8) as novel target of miR-21, in association with extracellular-signal-regulated kinase 
signaling activation, increasing renal fibroblast proliferation, migration and extracellular 
matrix production. MiR-21 silencing in diabetic mice ameliorated various functional 
parameters including mesangial expansion, tubulointerstitial fibrosis, inflammatory cell 
infiltration, albuminuria and podocyte loss.
Conclusions: MiR-21 antagonism might thus be a viable therapeutic option in future 
clinical trials involving patients with DN.
TH-PO351
The NMDA Receptor Antagonist MK-801 Reduces Progression of 
Nephropathy in Two Mouse Models of Type-1 Diabetes  Hila Roshanravan, 
Eunyoung Kim, Stuart E. Dryer.  Biology and Biochemistry, Univ of Houston, 
Houston, TX.
Background: Podocytes express ionotropic NMDA receptors that can be activated by 
endogenous circulating agonists such as L-homocysteic acid and quinolinic acid. Sustained 
activation of NMDA receptors causes cytotoxicity and oxidative stress in podocytes. Here 
we examined if the prototypical antagonist MK-801 can reduce nephropathy in mouse 
type-1 diabetes.
Methods: We examined two mouse models: the Akita mice on a DBA/2J background 
(with DBA/2J mice as controls), and the low-dose streptozotocin (STZ) protocol in DBA/2J 
mice. MK-801 or saline were administered by surgically implanting subcutaneous Alzet 
osmotic minipumps (protocol approved by local IACUC). Nephropathy was monitored by 
periodic analysis of 24-hr urine samples, and by histology and electron microscopy at the end 
of the protocol. NMDA subunit expression in renal cortex was examined by immunoblot.
Results: MK-801 treatment was initiated in 7-week Akita mice. Urine albumin secretion 
is already slightly elevated at that age. Over the next 28 days, albumin excretion increased 
3-4 fold in saline-treated mice, but did now show a significant increase in the MK-801 
group. At the time of sacrifice there was less foot process effacement in MK-801-treated 
animals compared to controls. The STZ protocol was carried out at 10 weeks of age, and 
MK-801 or saline treatment was initiated 15 weeks later. With this model, albuminuria 
was more severe at the time that drug treatment was initiated. In saline-treated controls 
albuminuria continued to increase over the next 28 days but did not worsen in the MK-801 
group. Foot process effacement, glomerulosclerosis, tubular atrophy and interstitial fibrosis 
were reduced in MK-801-treated animals. Akita and STZ-treated mice are smaller than 
their controls. MK-801 did not alleviate this. We observed markedly increased expression 
of NMDA receptor NR1 and NR2C subunits in renal cortex of Akita and STZ-treated 
mice compared to controls.
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Conclusions: These data support the hypothesis that sustained NMDA receptor 
expression and/or activation contribute to the progression of diabetic nephropathy, and 
suggest that targeting these receptors might be a useful therapeutic strategy.
Funding: Private Foundation Support
TH-PO352
Role of the N-Type Calcium Channel in a Mouse Model of Diabetic 
Nephropathy  Shoko Ohno,1 Hideki Yokoi,1 Kiyoshi Mori,2 Masato Kasahara,3 
Takashige Kuwabara,1,4 Moin Saleem,5 Kazuwa Nakao,2 Motoko Yanagita,1 
Masashi Mukoyama.1,4  1Dept of Nephrology, Kyoto Univ Graduate School of 
Medicine, Kyoto, Japan; 2Medical Innovation Center, Kyoto Univ Graduate 
School of Medicine, Kyoto, Japan; 3Inst for Advancement of Clinical and 
Translational Science, Kyoto Univ Graduate School of Medicine, Kyoto, Japan; 
4Dept of Nephrology, Graduate School of Medical Sciences, Kumamoto Univ, 
Kumamoto, Japan; 5Academic Renal Unit, Univ of Bristol, Bristol Children¶s 
Hospital, Bristol, United Kingdom.
Background: Recent clinical studies have shown that an L-/N-type calcium channel 
blocker cilnidipine reduces urinary protein in hypertensive patients with proteinuria. In 
the present study, to explore the functional role of N-type calcium channel (Cav2.2) in 
diabetic nephropathy, we investigated renal injury in Cav2.2-deficient diabetic db/db mice.
Methods: We employed mice lacking the N-type calcium channel a1 subunit gene 
(Cav2.2-/-) to generate db/db (diabetic), Cav2.2-/- double mutant mice. Because the genetic 
background plays an important role in developing diabetic nephropathy, in this study, we 
backcrossed Cav2.2 knockout mice on the C57BL/6J background to those on the C57BLKS 
background.
Results: Cav2.2 was localized in glomeruli, including podocytes, and vascular walls. 
Diabetic Cav2.2-/- mice showed lower BP than diabetic WT mice by ~20 mmHg, and 
exhibited ~50% reduction in urinary catecholamines. Compared with diabetic WT mice, 
both diabetic Cav2.2+/- and Cav2.2-/- mice revealed a significant reduction (by ~70%) in 
UAE. The increase in mesangial matrix and downregulation of nephrin in diabetic WT mice 
were alleviated in diabetic Cav2.2-/- mice. There was an improvement in glycemic control in 
diabetic Cav2.2-/- mice but not in diabetic Cav2.2+/- mice. Furthermore,db/db mice receiving 
cilnidipine showed a significant reduction in UAE. In vitro, depolarization-dependent 
calcium entry was abolished by Ȧ-conotoxin, a Cav2.2-specific inhibitor. The reduction of 
nephrin expression by TGF-β was abolished with Ȧ-conotoxin and cilnidipine in podocytes.
Conclusions: The inhibition of Cav2.2 exerts renoprotective effects against the 
progression of diabetic nephropathy.
TH-PO353
D-Carnosine Prevents Diabetic Nephropathy in db/db Mice 
Giuseppe Pugliese, Carla Iacobini, Stefano Menini.  Dept of Clinical and 
Molecular Medicine, La Sapienza Univ, Rome, Italy.
Background: The endogenous dipeptide L-carnosine was shown to act as a quencher 
of reactive carbonyl precursors of advanced glycation end products (AGEs). However, in 
humans, it is rapidly inactivated by carnosinase. This study was aimed at evaluating the 
efficacy of the carnosinase-resistant compound D-carnosine (DC) in preventing diabetic 
nephropathy in db/db mice.
Methods: Adults male db/db mice and the corresponding db/m controls were treated 
with a DC derivative (60 mg/kg body weight in the drinking water) or vehicle for 14 weeks. 
Glomerular sclerosis index (GSI), mean glomerular area (mGA), fractional mesangial 
area (fMA), and mean glomerular volume (mGV) were assessed morphometrically. 
Renal expression of inflammatory and disease progression markers were assessed by 
immunohistochemistry and/or RT-PCR. Serum AGEs and isoprostane-8-epi-PGF2awere 
measured by ELISA, pentosidine by HPLC and total carbonylated proteins (PCOs) by 
slot blot immunoassay.
Results: DC treatment induced a significant attenuation of renal disease in db/db 
mice, whereas it did not influence renal structure in db/m control mice. Proteinuria (-35%), 
GSI (-31%), mGA (3.22 ± 0.27 vs. 3.52 ± 0.21 mm 2x103), mGV (137.5 ± 10.1 vs. 157.2 
± 13.7 mm 3x103), mMA (428.0 ± 82.5 vs. 588.5 ± 48.7 µm2) and fMA (13.2 ± 1.8 vs. 
16.8 ± 1.7%) decreased significantly (P<0.001) in DC-treated db/db mice, as compared 
with untreated animals. Glomerular staining for HNE adducts (5.6 ± 2.7 vs. 13.5 ± 2.8 % 
glom area), fibronectin (11.7 ± 2.6 vs. 19.7 ± 1.8 % glom area) and collagen IV (13.2 ± 
3.4 vs. 24.6 ± 3.1 % glom area) were also significantly reduced (P<0.001) in DC-treated 
vs. untreated db/db mice. The mRNA levels of F4/80, CXCR3, MCP-1, TNF-α, CHOP, 
RAGE, galectin-3 and CD36 were also significantly lower in db/db mice treated with DC. 
Finally, serum AGE, pentosidine, PCOs, and isoprostane-8-epi-PGF2alevels were lower in 
DC-treated vs. untreated db/db mice.
Conclusions: DC is effective in reducing carbonyl reactive species and preventing 
renal injury in db/db mice, thus suggesting that carbonyl stress plays a major role in diabetic 
nephropathy and that DC derivatives might be useful for treatment of this complication.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-PO354
Effect of an Oral Adsorbent AST-120 on Type 2 Diabetes Rats and Mice 
Rieko Aoki, Yusuke Yamashita, Sumie Goto, Hiroko Iijima, Fujio Sekine, 
Shigeaki Miyazaki, Yoshiharu Itoh.  Pharmaceuticals Div, Kureha Corporation, 
Tokyo, Japan.
Background: Diabetic nephropathy is a major complication of diabetes and the leading 
cause of end-stage renal disease. An oral adsorbent AST-120 has been used clinically as 
a medicine for patients with chronic kidney disease (CKD) to slow down the progression 
of CKD. However, there is little evidence to support therapeutic efficacy of AST-120 for 
early stage overt diabetic nephropathy. Our previous study showed that the administration 
of AST-120 reduced the urinary protein and albumin excretion on SHR/NDmcr-cp (SHR/
ND) rats, model rats of metabolic syndrome/ type 2 diabetes. In this study, we aimed to 
assess the effect of AST-120 on the pathological changes in renal tissues of SHR/ND rats 
and on other type 2 diabetic model animals, KK-Ay mice.
Methods: Male SHR/ND rats, aged 7 weeks, were administered 8% AST-120 for 
12 weeks in their diets. WKY rats were used as a normal. At every 4 weeks, serum and 
24-hour urine samples were collected for biomedical studies. The podocyte foot process 
width (FPW) was measured by Transmission Electron Microscopy as foot process 
effacement. Pathological changes in renal tissues stained with periodic acid-Schiff (PAS) 
and Hematoxylin-Eosin (HE) were investigated by light microscopy. Monocyte/macrophage 
infiltration in renal tissues and tubular injury was investigated by ED-1 staining and kidney 
injury molecule-1 (KIM-1) staining. Male KK-Ay mice, aged 7 weeks, were administered 
8% AST-120 for 8 weeks in their diets. C57BL/6J mice were used as non-diabetic animals. 
At every 4 weeks, serum and 24-hour urine samples were collected for biomedical studies.
Results: AST-120-administered SHR/ND rats showed significantly lower levels of 
urinary protein excretion, urinary albumin excretion, and the FPW as compared with SHR/
ND rats. The renal histological damage, the number of ED-1 positive cells and KIM-1 
positive area were reduced by the administration of AST-120. AST-120-administered KK-Ay 
mice also showed lower levels of urinary protein and albumin excretion.
Conclusions: These results indicate that the administration of AST-120 at an early stage 
of diabetic nephropathy has a protective effect on the disease progression.
TH-PO355
Blockade of KCa3.1 Attenuated Diabetic Nephropathy Through Induction 
of Autophgy  Chunling Huang, Xinming Chen, Carol A. Pollock.  Renal Lab, 
Kolling Inst of Medical Research, Univ of Sydney, Sydney, New South Wales, 
Australia.
Background: Autophagy is emerging as an important pathway in many biological 
processes and diseases including diabetic nephropathy. It was reported that oxidative stress 
plays a critical role in diabetic nephropathy, and blockade of KCa3.1 ameliorates renal 
fibrotic responses in diabetic nephropathy through inhibition of the TGF-b1 pathway. The 
aim of the study is to identify the role of KCa3.1 on dysfunctional tubular autophagy in 
diabetic nephropathy.
Methods: Human proximal tubular cells (HK2 cells) transfected with scramble siRNA 
or KCa3.1 siRNA were exposed to TGF-b1 for 48h. The formation of autophagosomes was 
examined using transmission electron microscopy (TEM). The autophagy marker LC3-II 
was measured by western blotting and immunofluorescence staining. The activation of 
oxidative stress was measured by nitrotyrosine using immunofluorescence staining. The 
signaling pathways of PI3K, Akt and mTOR were assessed with western blotting. In 
vivo, the expression of LC3-II and nitrotyrosine were examined by imunofluorescence or 
immunohistochemistry staining in kidneys from diabetic KCa3.1+/+ and KCa3.1-/- mice.
Results: TEM results demonstrated that several autophagic vacuoles appeared in 
HK2 cells transfected with scramble siRNA exposed to TGF-b1 but decreased autophagic 
vacuoles were observed in HK2 cells transfected with KCa3.1 siRNA. Western blotting 
and immunofluorescence staining results showed TGF-b1 significantly increased LC3-II in 
scramble siRNA-transfected HK2 cells which was reduced in KCa3.1 siRNA transfected-
HK2 cells. Blockade of KCa3.1 with transfected siRNA reversed TGF-b1 induced-activation 
of PI3K, Akt and mTOR signaling pathways. In vivo, diabetic induced upregulation of 
LC3-II and nitrotyrosine were dramatically attenuated in the kidneys of diabetic KCa3.1-
/- mice compared to diabetic KCa3.1+/+ mice.
Conclusions: Blockade of KCa3.1 attenuated diabetic nephropathy through induction 
of autophgy.
TH-PO356
PBI-4050 Protects against Renal Fibrosis and Improves Pancreatic Function 
in the Type II Diabetes db/db Mouse Model  Lyne Gagnon, Kathy Hince, 
Lilianne Geerts, François Sarra-Bournet, Alexandra Felton, Liette Gervais, 
Alexandre Laverdure, William Gagnon, Martin Leduc, Mikaël Tremblay, 
Marie-Pier Cloutier, John Moran, Frank Cesari, Pierre Laurin, Brigitte Grouix. 
ProMetic BioSciences Inc., Laval, 4C, Canada.
Background: PBI-4050, a novel first-in-class orally active compound which is currently 
in clinical phase Ib/II in metabolic syndrome associated with diabetes, displays antifibrotic 
activities via a novel mechanism of action. In a double-blind single ascending dose (400 to 
2400 mg) in healthy volunteers, PBI-4050 was found to be safe and well tolerated up to 2400 
mg without any significant adverse effects (SAEs). Similarly, PBI-4050 was well tolerated 
in CKD patients with no SAEs observed at 800 mg for 10 consecutive days. In the present 
study, we examined whether PBI-4050 affected hyperglycemia, insulin resistance and the 
development of renal fibrosis as well as biomarkers in obese db/db mice.
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Methods: db/db mice were uninephrectomized at week 6 and received vehicle (water) 
or PBI-4050 (100 or 200 mg/kg/day) by daily gastric gavage from 6 to 24 weeks of age.
Results: PBI-4050 treatment ameliorated the fasting hyperglycemia and abnormal 
glucose tolerance tests seen in vehicle-treated db/db mice. In addition, PBI-4050 led to 
higher serum insulin, C-peptide and GIP levels which correlates with the improvement 
of β-cells function observed by immunohistochemistry analysis. Kidney function was 
also improved by PBI-4050 treatment as shown by significant decrease in hyperfiltration, 
proteinuria and mesangial expansion lesions. Furthermore, expression of IL-6, Collagen 
I, MMP2 and Timp1 in kidney were downregulated by PBI-4050 treatment. Moreover, 
using a mouse cytokines multiplex panel, serum IL-6 and IL-9 levels were significantly 
reduced in PBI-4050-treated mice.
Conclusions: These studies suggest that PBI-4050 improves hyperglycemia, preserves 
insulin production and β-cells function and survival, and prevents renal fibrosis in association 
with regulation of pro-fibrotic and fibrotic biomarkers.
TH-PO357
Kallistatin Protects against Diabetic Nephropathy in db/db Mice by 
Suppressing AGE-RAGE-Induced Oxidative Stress  Wai Han Yiu,1 Dickson 
WL Wong,1 Hao-Jia Wu,1 Ruixi Li,1 Loretta Y.Y. Chan,1 Joseph C K Leung,1 
Hui Y. Lan,2 Kar Neng Lai,1 Sydney C.W. Tang.1  1Dept of Medicine, The Univ 
of Hong Kong, Hong Kong, Hong Kong; 2Dept of Medicine and Therapeutics, 
and Li Ka Shing Inst of Health Sciences, The Chinese Univ of Hong Kong, 
Hong Kong.
Background: Kallistatin is a serine protease inhibitor that exerts anti-inflammatory, 
anti-apoptotic and anti-oxidative effects in regulating cellular dysfunction. As oxidative 
stress plays a critical role in the pathogenesis of diabetic nephropathy, we aim to investigate 
the effect and mechanisms of kallistatin gene transfer on diabetic renal injury in the db/db 
mouse model of type 2 diabetes.
Methods: Plasmid with kallistatin gene was injected into the kidney of db/db mice 
using ultrasound-mediated microbubble-inducible gene transfer. The therapeutic potential 
of kallistatin in diabetic kidney was evaluated by histopathology, renal function, oxidative 
and fibrotic pathways.
Results: Kallistatin expression was induced in tubules of kidney after gene 
transfer compared with mice treated with empty plasmid. In db/db mice, kallistatin 
overexpression reduced serum creatinine and BUN levels, ameliorated glomerulosclerosis 
and tubulointerstitial injury and attenuated renal fibrosis by inhibiting TGF-β signaling 
and the downstream plasminogen activator inhibitor-1 and type IV collagen expression. 
Furthermore, kallistatin gene transfer significantly attenuated elevated oxidative stress in 
db/db mice as evidenced by suppressed levels of Nox4 and the oxidative marker (8-OHdG 
and MDA) in diabetic renal tissue. Finally, kallistatin inhibited expression of RAGE in both 
diabetic kidney and AGE-stimulated cultured proximal tubular epithelial cells, reflecting 
an anti-oxidative mechanism via AGE/RAGE axis.
Conclusions: Our results suggest a renoprotective role of kallistatin against progression 
of diabetic nephropathy via anti-oxidative properties. Kallistatin reduced AGE-RAGE-
induced Nox4 expression, leading to suppression of oxidative stress and TGF-β-mediated 
renal fibrosis. 
Funding: Research Grants Council of Hong Kong (GRF grant number 7796/11M) 
and the National Basic Research Program of China 973 program no. 2012CB517600 (no 
2012CB517606).
TH-PO358
Kidney pSMAD2 in Type 1 and Type 2 Diabetic Nephropathy Patients 
and in Mouse Models of Diabetic Nephropathy  Lise Thomsen,1,2 Troels 
Krarup Hansen,2 Morten Tonnesen,1 Emile De Heer,3 Peter Dijke,4 Alexander 
Rosendahl.1  1Diabetes Complications Biology and Pharmacology, Novo Nordisk 
A/S, Måløv, Denmark; 2Dept of Clinical Medicine – Dept of Endocrinology and 
Internal Medicine, Aarhus Univ Hospital, Aarhus, Dominican Republic; 3Depts 
of Pathology, Leiden Univ Medical Center, Netherlands; 4Depts of Molecular 
Cell Biology, Leiden Univ Medical Center, Leiden, Netherlands.
Background: Fibrosis is a hallmark of diabetic nephropathy (DN) leading to chronic 
kidney disease. However, we lack good animal models resembling kidney pathology of 
human DN. Renal fibrogenesis has been suggested to be caused by dysregulation of SMAD 
signalling by members of the TGFβ superfamily. The purpose of this study was to evaluate 
these events in kidneys from patients and compare to DN mouse models.
Methods: Human (type 1 and type 2 diabetes patient; T1D and T2D) and murine (db/
db and streptozotocin (STZ) treated mice) kidneys were stained for pSMAD2. Kidney 
transcriptional signature of 44 genes including TGFβ/BMP target-genes, BMP modulators, 
TGFb-superfamily ligands and EMT markers was evaluated in the mouse models.
Results: Nuclear as well as cytoplasmic pSMAD2 expression was increased in tubules 
of diabetes patients. T1D patients displayed elevated staining in proximal tubuli, whereas 
T2D patients showed elevated staining in distal tubuli. Increase in SMAD2 activation in 
distal tubules was also observed in STZ-treated mice, while db/db mice showed noSMAD2 
activation. Genetic profiling showed increased expression of BMP antagonists and other 
genes (CTGF, Gremlin, KCP, USAG1) promoting increased TGFβ activity in both models 
of DN.
Conclusions:  Early experimental DN displays little fibrogenesis, but studying the 
nuclear pSMAD2 expression suggests that the TGFβ/activin A pathway is upregulated 
in diabetes patients and mouse DN models. The tubular compartment showed increased 
pSMAD2 activity in both mouse and man but expression pattern differed between T1D 
and T2D patients and translated poorly into the mouse models of DN tested in this study. 
Genetic profiling of murine tissue indicates local blockade of BMP pathways suggesting 
dampening of the renoprotective BMP7 pathway in both T1D and T2D models.
TH-PO359
Role of Liver X Receptors in Diabetic Nephropathy and Obesity Related 
Glomerulopathy  Michal Herman-Edelstein,1 Ana Tobar,1 Talia R. Weinstein,1 
Uzi Gafter,1 Avry Chagnac,1 Vivette D. D’Agati,3 Moshe Levi.2  1Rabin Medical 
Center-Felsenstein ,Tel Aviv Univ, Israel; 2Univ of Colorado; 3Columbia Univ.
Background: Our recent human and rodent studies have associated ectopic lipid 
accumulation and abnormal lipid metabolism in the kidney with diabetic nephropathy 
(DN) and obesity-related glomerulopathy (ORG). Liver X receptors (LXR) α and β are 
nuclear receptors that are master regulators of cholesterol metabolism and also inhibit 
inflammation. Next-generation RNA sequencing data show downregulation of LXR 
pathways in DN. To obtain insight into the pathophysiology of obesity- induced renal 
lipotoxicity, we investigated the expression of LXRs and their target genes in human DN 
and ORG kidney biopsies.
Methods: Renal lipid contents, inflammation ,genes involved in cholesterol and fatty 
acid metabolism, and LXRs target genes, were studied on amplified mRNA of laser capture 
microdissection (LCM) isolated glomeruli and tubules from kidney biopsies of patients 
with established DN (n=16), ORG (N=16), and normal kidneys (n=16).
Results: LXRα and LXRβ mRNA were higher in the glomerular compared to the 
tubular fraction.LXRα and β mRNA and protein were significantly decreased in DN 
and ORG kidneys.We found a significant relationship between LXRs mRNA, eGFR 
,glomerulosclerosis, and inflammation. Furthermore, we studied the anti inflammatory 
effect of different LXR agonists including DMHCA, TO-901317and GW3965 against 
oxLDL and palmitate-induced lipotoxicity in culture podocytes. Our results indicate that 
all LXR agonists induce cholesterol efflux while DMHCA exhibited limited effect on 
SREBP1c. Furthermore treatment of diabetic db-db mice with the LXR agonist resulted 
in significant decreases in albuminuria and expression of the proinflammatory cytokines 
IL-6 and TNFα in the kidney.
Conclusions: Our results suggest that decreased glomerular and tubular expression 
of LXRs seems to have a role in DN and ORG. Consequently, decreased activity of LXR 
and related downstream pathway mediators may contribute to lipotoxicity, inflammation 
and GFR decline. We suggest that modulation of LXR receptors in the kidney may serve 
as a novel therapeutic target in DN and ORG.
Funding: NIDDK Support
TH-PO360
Dual Activation of FXR and TGR5 by INT-767 Mediates Protection 
from Diabetic Nephropathy and Retinopathy  Xiaoxin Wang,1 Michal 
Herman-Edelstein,2 Jonathan Levi,3 Uzi Gafter,2 A. Rosenberg,3 Jeffrey B. Kopp,3 
Luciano Adorini,4 Maria B. Grant,5 Moshe Levi.1  1Univ of Colorado Denver; 
2Rabin Medical Center; 3NIDDK; 4Intercept; 5Indiana Univ, Indianapolis, IN.
Background: Bile acids are agonists for the nuclear hormone receptor, farnesoid X 
receptor (FXR) and the G protein-coupled receptor TGR5. We have found that FXR and 
TGR5 expression are decreased in human diabetic nephropathy.
Methods: We examined the effect of their combined activation by the dual FXR/
TGR5 agonist INT-767 on diabetic nephropathy in DBA/2J mice fed a Western diet and 
streptozotocin (STZ) induced hyperglycemia.
Results: Diabetic mice developed marked albuminuria, increased glomerular area and 
mesangial expansion, decreased podocyte (WT-1) density. Diabetic mice also had increased 
renal triglyceride and cholesterol accumulation, increased NF-κB activity, and increased 
oxidized protein accumulation. Treatment with 30 mg/kg BW/day INT-767 for 8 weeks 
normalized albuminuria (ACR), glomerular area and mesangial expansion, podocyte density 
(WT-1), kidney cholesterol (CHOL), NF-κB transcriptional activity, oxidized proteins, and 
profibrotic growth factors TGF-β and CTGF and significantly decreased kidney triglycerides 
(TG). In addition, in the retina INT-767 also reduced the number of acellular capillaries, 
decreased the inflammatory infiltration into the retina, and corrected the diabetes-associated 
endothelial progenitor cell dysfunction, restoring cell migration to nondiabetic levels.
Control STZ STZ + INT-767
ACR: mg/g 88±11 603±113* 50±18**
Podocyte Density 42±2 30±2* 38±1**
Kidney TG: µmol/g 7.5±1.3 33.6±2.7* 20.5±2.3**
Kidney CHOL: µg/g 6.6±0.5 9.4±0.7* 6.3±0.7**
NF-κB Activity 1.0±0.1 1.4±0.1* 1.2±0.1**
Oxidized Proteins 0.7±0.1 1.2±0.1* 0.8±0.1**
Conclusions: Our studies therefore indicate that dual activation of FXR and TGR5 
protects from diabetic nephropathy and retinopathy by decreasing inflammation, oxidative 
stress, lipid accumulation, and fibrosis.
Funding: NIDDK Support
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TH-PO361
High Fat Diet and BCL2-Modifying Factor (Bmf) Overexpression Together 
Promote Tubular Apoptosis in BMF-Transgenic Mice via Reactive Oxygen 
Species Generation  Anindya Ghosh,1 Hasna Maachi,1 Shaaban Abdo,1 Yixuan 
Shi,1 Chao-Sheng Lo,1 Isabelle Chenier,1 Janos G. Filep,2 Julie R. Ingelfinger,3 
Shao-Ling Zhang,1 John S.D. Chan.1  1CRCHUM, Univ de Montreal, Montreal, 
QC, Canada; 2Research Centre, Maisonneuve-Rosemont Hospital, Montreal, 
QC, Canada; 3Pediatric Nephrology Unit, Mass Gen Hosp, Boston, MA.
Background: We previously reported that the pro-apoptotic gene Bmf is up-regulated 
in renal proximal tubular cells (RPTCs) of diabetic obese mice (db/db) compared to normal 
lean mice (db/m+). We investigated whether high-fat diet (HFD) regulates Bmf expression 
and RPTC apoptosis and studied its underlying molecular mechanism(s) in RPTCs.
Methods: Non-transgenic (non-Tg) mice, catalase-Tg (Cat-Tg) and Bmf-Tg mice 
overexpressing rat Cat and human Bmf in RPTCs, respectively, were fed normal chow 
or HFD from 4 to 20 weeks of age. All animals were euthanized at 20 weeks. Blood 
glucose (BG), systolic blood pressure (SBP) and urinary albumin creatinine ratio (ACR) 
were monitored bi-weekly. Renal oxidative stress and ROS generation were quantified by 
dihydroethidium staining and lucigenin assay, respectively. RPTC apoptosis was evaluated 
by TUNEL assay, immunostaining for active caspase-3 and Bax expression. Pro-apoptotic 
protein and gene expression were assessed by Western blotting and quantitative-PCR. Rat 
RPTCs stably transfected with the plasmid pGL4.20 containing rat Bmf gene promoter 
were also studied.
Results: Non-Tg mice fed HFD had increases in BG, ACR, acetylated p53, renal 
oxidative stress and pro-apoptotic genes (Bax, Bmf) expression and RPTC apoptosis. 
Catalase overexpression prevented HFD-induced RPTC apoptosis and pro-apoptotic gene 
expression in Cat-Tg mice. In contrast, overexpression of Bmf gene in RPTCs with or 
without HFD aggravated RPTC apoptosis , pro-apoptotic genes expression and ACR. In 
vitro, high glucose and palmitate attenuated SIRT1 expression, enhanced acetylated p53 
expression and stimulated Bmf gene transcription.
Conclusions: We conclude that HFD and Bmf may act in concert to induce ROS-
mediated tubular apoptosis, suggesting an important role for Bmf in tubular atrophy in 
diabetes.
Funding: Government Support - Non-U.S.
TH-PO362
Prevention of Diabetic Nephropathy and Other End Organ Damage 
by Stem Cell-Based Cure of Type I Diabetes Mellitus in Mice and Rats 
Christof Westenfelder,1,2,3 Anna Gooch,3 Jon D. Ahlstrom,3 Zhuma Hu,3 Evan 
Hurlow,1,3 Ping Zhang.3  1Medicine, U of Utah and 9AMC, Salt Lake City, UT; 
2Physiology, U of Utah, Salt Lake City, UT; 3SymbioCellTech, Salt Lake City, UT.
Background: Endogenous insulin replacement by pancreas or islet transplants is 
currently the optimal treatment to achieve insulin-independence and end organ protection 
in patients with T1DM. However, the limited availability of cadaveric pancreas donors, and 
both the need for permanent antirejection therapy and repeated islet transplants continue 
to prevent the wide spread use of these therapies. Auto- and allo-immune isolation of 
transplanted islet cells is currently tested with encapsulation technologies, several of which 
have failed early. Because β-Cells cannot be adequately expanded ex vivo, Embryonic or 
induced Pluripotent Stem Cells are evaluated instead. In our present studies, we succeeded 
to cure T1DM in mice and rats by achieving both adequate culture expansion of islet cells 
and dual immune isolation by exploiting the robust immune modulating and other trophic 
activities of Mesenchymal Stem Cells (MSCs).
Methods: Immune isolation of islet cells was accomplished by two methods: either by 
fusing islet cells and MSCs, creating heterokaryons (β-MSCs), or by generating islet-sized 
cell clusters (Pseudo islets) composed of islet cells and MSCs. Islet cell expansion was 
accomplished via reversible epithelial-mesenchymal transition.
Results: Streptozotocin (STZ) diabetic rats and mice and spontaneously diabetic female 
NOD mice were infused i.p. with either β-MSCs or Pseudo islets. STZ-diabetic NOD/SCID 
mice were identically treated with canine Pseudo islets. Long-term euglycemia and normal 
i.p. Glucose Tolerance Tests were obtained in all treated animals. No antibody responses 
were detected in allogeneic groups, no adverse events were observed and no evidence of 
diabetic nephropathy or other end organ damage was detected. Retrieval of administered 
cells resulted in prompt return of hyperglycemia.
Conclusions: We conclude that our pre-clinical data have significant translational utility 
for clinical T1DM. In further preparation for clinical trials, we are currently conducting a 
Phase I/II Trial in dogs with T1DM.
Funding: Veterans Administration Support
TH-PO363
High Glucose Modulates Hedgehog Interacting Protein (Hhip) Gene 
Expression in Diabetic Related Proximal Tubular Cell Damage 
Shiao-Ying Chang,1 Xin-Ping Zhao,1 Min-Chun Liao,1 Isabelle Chenier,1 Julie 
R. Ingelfinger,2 John S.D. Chan,1 Shao-Ling Zhang.1  1CRCHUM, Univ of 
Montreal, Montreal, QC, Canada; 2Pediatric Nephrology Unit, Massachusetts 
General Hospital, Boston, MA.
Background: Hedgehog Interacting Protein (Hhip) is a putative antagonist of hedgehog 
(Hh) signaling, since both the full length Hhip and its soluble form (sHhip) bind Hh 
ligands with nanomolar affinity to attenuate the Hh signaling. We previously reported that 
high glucose (HG) modulates Hhip gene expression and then, targets TGFb1 signaling in 
embryonic renal cells, resulting in impaired kidney formation. Given our prior findings we 
hypothesized that Hhip might be involved in the evolution of kidney damage in diabetic 
conditions, such as proximal tubular injury during the development of diabetic nephropathy.
Methods: Two diabetic animal models-- the spontaneously diabetic Akita (T1DM) 
and db/db (T2DM) mouse models were used for in vivo studies. Renal morphology, 
immunohistochemistry (IHC), promoter activity analysis and gene expression were 
assessed by standard methods. Rat immortalized renal proximal tubular cells (IRPTCs) 
were used in vitro studies.
Results: As compared to non-diabetic Akita littermates and lean db/db animal (db/m), 
renal Hhip expression/urinary sHhip levels were significantly increased in adult Akita and 
db/db mice at 20 weeks of age. There was strong Hhip-and TGFb1-IHC expression in 
diabetic kidneys, mostly localized to glomerular endothelial cells and renal proximal tubular 
cells. In vitro, high glucose significantly stimulated the activity of the plasmid containing 
mouse Hhip gene promoter in dose-dependent manner. HG stimulated intracellular Hhip and 
inhibited sHhip level protein expression in time-dependent manner. Hhip siRNA attenuated 
the stimulatory effect of HG on intracellular Hhip and TGFb1 gene expression in IRPTCs.
Conclusions: Our data suggest that high glucose increases both Hhip and TGFb1 
gene expression acting in a paracrine fashion to promote renal tubulointerstitial fibrosis 
in DN, both in vivo and in vitro.
Funding: Government Support - Non-U.S.
TH-PO364
Development of Diabetic Nephropathy in Streptozotocin-Treated ID1 
Knockout Mice  Matthew D. Plotkin.  Univ of Arkansas for Medical Sciences, 
Little Rock, AR.
Background: Cell injury induces expression of Id1, a bHLH transcription factor 
inhibitor that regulates cell cycle and differentiation. Id1 knockout results in increased tissue 
fibrosis in injury models. Since Id1 may have an important role in maintaining vascular 
stability during hyperglycemia and oxidative stress associated with diabetes, preliminary 
studies were done to determine if Id1 knockout would result in kidney pathology in a 
diabetic nephropathy resistant strain of mice.
Methods: Id1 -/- mice in a B6;129 background and WT littermates were treated with 
streptozotocin (STZ) 125 mg/kg I.P. for 2 doses to induce type I diabetes (DM). Mice 
with persistent blood glucose levels > 300 mg/dL (n = 10/genotype) were sacrificed at 3 
months. Endothelial and perivascular cells from WT and KO mice were cultured in 2% 
FBS and used at passages 1 and 2.
Results: In WT B6;129 mice, Id1 levels were increased 15-fold at 3 months in response 
to STZ induced DM with increased expression detected in glomerular capillary endothelial 
cells compared with normal mice. WT mice had no pathological changes despite severe 
hyperglycemia. In contrast, Id1 -/- mice developed mesangial expansion and matrix 
deposition, focal capillary aneurysms and glomerular arteriolar hypertrophy and increased 
proteinuria (albumin/cr: 0.61±0.26 mg/mg vs. 0.30±0.14 mg/mg, p = .05). KO mice showed 
a 5-fold increase in glomerular endothelial and tubular epithelial cell proliferation by Ki67 
immunohistochemistry. These changes occurred despite no significant difference in average 
glucose between WT and KO mice. Comparison of primary co-cultures of WT and KO 
endothelial and perivascular cells demonstrated 10-fold decreased angiopoietin-1 expression 
by qPCR and decreased autophagy in response to TGFβ in KO cells. These results correlated 
with marked p62 accumulation in glomerular arterioles in normal and diabetic KO mice.
Conclusions: Glomerular endothelial Id1 expression is increased with type I DM. 
KO mice develop diabetic nephropathy suggesting a protective effect of endothelial Id1.
Funding: Veterans Administration Support
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Heterogeneous Nuclear Ribonucleoprotein F Stimulates Sirtuin 1 
Expression and Attenuates Renal Proximal Tubular Cell Apoptosis in Mice 
with Type 2 Diabetes  Chao-Sheng Lo,1 Yixuan Shi,1 Isabelle Chenier,1 Janos G. 
Filep,2 Julie R. Ingelfinger,3 Shao-Ling Zhang,1 John S.D. Chan.1  1CRCHUM, 
Univ de Montreal, Montreal, QC, Canada; 2Research Centre, Maisonneuve-
Rosemont Hospital, Montreal, QC, Canada; 3Pediatric Nephrology Unit, Mass. 
Gen. Hosp., Boston, MA.
Background: We hypothesized that overexpression of the transcription factor 
heterogeneous nuclear ribonucleoprotein F (hnRNP F) can stimulate sirtuin 1 (SIRT1, a 
NAD+-dependent deacetylase) expression and signaling in renal proximal tubular cells 
(RPTCs), subsequently attenuating RPTC apoptosis in type 2 diabetic db/db mice.
Methods: We made and studies db/db (BKS strain) transgenic (Tg) mice specifically 
overexpressing hnRNP F in their RPTCs. Blood glucose (BG), systolic blood pressure (SBP) 
and albuminuria were monitored bi-weekly in adult male non-diabetic db/m+ littermates, 
db/db and db/db hnRNP F-Tg mice from 10 to 20 weeks of age. Kidneys were processed for 
histology and apoptosis studies. Renal oxidative stress and reactive oxygen species (ROS) 
generation were quantified by dihydroethidium staining and lucigenin assay, respectively. 
Renal proximal tubular (RPT) gene expression was evaluated by respective real time-qPCR 
and Western blotting.Rat immortalized RPTCs stably transfected with hnRNP F cDNA or 
SIRT 1 gene promoter were also studied.
Results: Db/db mice developed higher BG, SBP, renal hypertrophy and albuminuria 
at week 20 as compared to db/m+ littermates; db/db hnRNP F-Tg mice did not have 
elevated SBP, renal hypertrophy or albuminuria. ROS generation, apoptosis, acetylated 
p53, Bax and active caspase-3expression were significantly increased in RPT of db/db 
mice but not in db/db hnRNP F-Tg mice. In contrast, SIRT 1 and catalase expression 
were significantly decreased in RPT of db/db mice but not in db/db hnRNP F-Tg mice. 
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Finally, overexpression of hnRNP F stimulates SIRT1 protein, mRNA and gene promoter 
activity and reverses high glucose (35 mM D-glucose) and palmitate inhibition of SIRT1 
expression in rat RPTCs in vitro.
Conclusions: Overexpression of hnRNP F attenuated RPTC apoptosis in type 2 diabetic 
mice via up-regulation of SIRT1 gene expression and signaling.
Funding: Government Support - Non-U.S.
TH-PO366
Lack of CD2AP Disrupts Glucose Transporter 4 Trafficking and Attenuates 
Glucose Uptake  Sanna H. Lehtonen, Surjya Narayan Dash, Zydrune 
Polianskyte-prause, Vincent Dumont, Tuomas Aleksi Tolvanen.  Dept of 
Pathology, Univ of Helsinki, Finland.
Background: Recent data indicate that adapter protein CD2AP is downregulated in 
diabetic conditions via PI3K/Akt signaling in podocytes. In this study we investigated 
the role of CD2AP in insulin-dependent glucose transporter 4 (Glut4) trafficking and 
glucose uptake.
Methods: Glucose uptake was measured using tritium-labeled 2-deoxyglucose. 
CD2AP-/- and wildtype (WT) podocytes expressing HA-Glut4-GFP were utilized to 
quantify the amount of Glut4 on the plasma membrane and to study the trafficking of 
Glut4 by live cell imaging. Protein complexes were analyzed by coimmunoprecipitation 
and Duolink proximity ligation assay (PLA).
Results: The level of glucose uptake was 32% lower in CD2AP-/- podocytes compared 
to WT podocytes in the basal state. After insulin stimulation, glucose uptake in WT cells 
increased 19%, whereas CD2AP-/- podocytes failed to respond. Knockdown of Cd2ap in 
L6 myoblasts with siRNA lowered glucose uptake by 20% in the basal state and blunted 
insulin-induced glucose uptake. In line with this, insulin stimulation increased HA-Glut4-
GFP on the plasma membrane by 50% in WT podocytes, whereas no difference was observed 
in cells lacking CD2AP. Live cell imaging revealed dynamic trafficking of HA-Glut4-GFP 
in response to insulin in WT cells, whereas in CD2AP-/- podocytes HA-Glut4-GFP formed 
insulin unresponsive clusters in the perinuclear region. Subcellular fractionation indicated 
that CD2AP is found in intracellular membrane fractions together with Glut4, IRAP and 
sortilin, constituents of Glut4 storage vesicles (GSVs). Coimmunoprecipitation and PLA 
assays revealed that CD2AP forms a complex with GGA2, a clathrin adaptor which sorts 
Glut4 to GSVs. We further found that lack of CD2AP increases the interaction between 
GGA2 and clathrin. Insulin stimulation further increased GGA2-clathrin interaction and 
led to perinuclear accumulation of the complex in CD2AP-/- podocytes.
Conclusions: Our results indicate that CD2AP facilitates glucose uptake into podocytes 
and muscle cells. Interaction of CD2AP with GGA2 suggests a role for CD2AP in sorting 
of Glut4 to GSVs and insulin-responsive trafficking of Glut4 to the plasma membrane in 
podocytes.
Funding: Private Foundation Support
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Tauroursodeoxycholic Acid (TUDCA) Ameliorates Both Tubular and 
Glomerular Injury in Diabetic Nephropathy, Thus Providing an Added 
Value to ACE-Inhibition  Moh’d Mohanad Ahmad Al-Dabet,1 Andi Marquardt,1 
Fabian Bock,1,2 Khurrum Shahzad,1,3 Madhusudhan Thati,1 Berend Heinrich 
Isermann.1  1Inst of Clinical Chemistry and Pathobiochemistry, Otto-von-
Guericke-Univ, Magdeburg, Germany; 2Dept of Internal Medicine I and Clinical 
Chemistry, Univ of Heidelberg, Heidelberg, Germany; 3Univ of Health Sciences, 
Khayaban-e-Jamia Punjab, Lahore, Pakistan.
Background: Therapeutic inhibition ofthe Renin-Angiotensin Aldosterone System 
(RAAS) is firmly established in diabetic nephropathy (dNP). Despite efficient RAAS 
inhibition dNP frequently progresses to end-stage renal disease, necessitating the need 
of additional and mechanistically distinct therapeutic approaches. We have recently 
demonstrated that amelioration of endoplasmic reticulum stress using TUDCA protects 
mice from dNP (Madhusudhan et. al., Nat Commun 2015). To foster clinical evaluation 
of TUDCA, which is approved for other medical indications, we determined the efficacy 
of TUDCA in db/db mice in addition to ACE-inhibition (Enalapril).
Methods: 16 weeks old db/db mice with established albuminuria were randomly 
assigned to control (PBS), Enalapril (50mg/L, drinking water), TUDCA (150mg/Kg, i.p. 
daily), or combined Enalapril and TUDCA treatment. Mice were analyzed after 6 weeks of 
treatment. Albuminuria, glomerular and tubular damage (PAS-staining, electron microscopy, 
marker proteins), and markers of ER-stress were analyzed.
Results: Both agents (Enalapril and TUDCA) resulted in a significant reduction of 
UACR, glomerular hypertrophy, and FMA (fractional mesangial area). The combined 
treatment was more efficient with regard to UACR reduction, but similarly protective 
against glomerular sclerosis. Unlike Enalapril, TUDCA conveyed additional tubular 
protection, which was associated with reduced ER-stress (e.g. nuclear ATF6) in the tubular 
compartment.
Conclusions: A combined therapy of TUDCA and Enalapril is more efficient than 
Enalapril alone in preventing the progression of dNP in db/db mice. These results should 
foster translational efforts evaluating TUDCA in patients with dNP.
Funding: Government Support - Non-U.S.
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Fatty Acid Binding Protein 3 Might Mediate Diabetic Nephropathy in 
Mouse Lacking eNOS Gene  Shota Ozawa,1,2 Shuko Ueda,1 Kiyoshi Mori,1 
Katsuhiko Asanuma,1 Motoko Yanagita,1,3 Takahiko Nakagawa.1  1TMK 
Project, Medical Innovation Center, Kyoto Univ Graduate School of Medicine, 
Japan; 2Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma 
Corporation, Japan; 3Dept of Nephrology, Kyoto Univ Graduate School of 
Medicine, Japan.
Background: Insulin deficiency leads to an increase in serum free fatty acid 
concentration. Diabetic glomerular nodules often contain lipid droplet, suggesting that 
abnormal fatty acid metabolism might contribute to the development of diabetic glomerular 
injury. However, its precise mechanism remains unclear. Fatty acid binding proteins (FABPs) 
are currently considered as key molecules for lipid metabolism.
Methods: Since diabetic eNOS knockout (KO) mouse is considered to be a good 
model for human diabetic nephropathy, we here investigated whether FABP could mediate 
glomerular and tubular injury in this model.
Results: First of all, oil red O staining demonstrated that lipid droplets were accumulated 
in the injured glomeruli in diabetic eNOSKO mice, suggesting that lipid abnormality was 
involved in the injured process. Microarray assay with isolated glomeruli revealed that 
among 10 isoforms in FABP family, FABP3 mRNA was most highly expressed in diabetic 
eNOSKO mice compared to non-diabetic eNOSKO mice. We found that FABP3 protein 
was predominantly located in the mesangial cells while glomerular injuries were associated 
with inflammatory processes, such as macrophage infiltration and MCP-1 induction in 
the diabetic eNOSKO mice. Overexpression of FABP3 resulted in a greater response to 
palmitate, a satulated FA, to induce MCP-1 in the rat mesangial cells. Furthermore, tubular 
FABP3 was likely exclusively translocated from cytoplasm to basolateral membrane in 
proximal tubular epithelial cells under diabetic condition. In turn, the heart, a major organ for 
FABP3 protein in normal condition, did not show any significant changes in its expression 
level under diabetic condition in either wild type or eNOSKO mice.
Conclusions: FABP3 likely mediates diabetic glomerular and tubular injury.
Funding: Pharmaceutical Company Support - Mitsubishi Tanabe Pharma
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Cinacalcet Ameliorates Diabetic Nephropathy Through Intracellular Ca++ 
-CaMKKβ-LKB1-AMPK Activation  Ji Hee Lim, Min Young Kim, Yaeni 
Kim, Eun Nim Kim, Soojeong Kim, Hyung Wook Kim, Cheol Whee Park. 
College of Medicine, Dept of Internal Medicine, The Catholic Univ of Korea, 
Seoul, Republic of Korea.
Background: In cardiovascular system, the Calcium-sensing receptor(CaSR) 
simulates the production of NO in the endothelial cells. A decrement in NO bioavailability 
associated with AMPK inactivation and increased generation of reactive oxygen species 
are critical to the pathogenesis of diabetic vascular complications. Therefore, we evaluated 
the renoprotective effect of cinacalcet on glucotoxicity through AMP-protein kinase 
(AMPK)-eNOS-NO pathway in diabetic nephropathy in db/db mice and human glomerular 
endothelial cells (HGECs).
Methods: Male C57/BLKS db/db mice and db/m controls at 8 weeks of age were 
divided to receive either a regular diet chow or a diet containing cinacalcet (10 mg/kg; n=8, 
respectively). Mice were followed for 12 weeks and were evaluated for renal functions, 
pathologic phenotypes, and AMPK-eNOS-NO pathway.
Results: Cinacalcet ameliorated albuminuria in db/db mice without influencing the 
changes in blood glucose and Ca++ concentrations. The mesangial area expansion and 
inflammatory cell infiltration in the glomerulus were observed in db/db mice, which were all 
restored by cinacalcet treatment. Cinacalcet increased expression of CaSR, phosphorylation 
of CaMMKβ and LKB1 and subsequent AMPK activation, which in turn activated PGC-1α 
and phospho-Ser1177 eNOS-NO. As a result, an increase in the ratio of Bcl-2/Bax in renal 
cortex and decrease in urinary 8-hydroxy-deoxyguanosin and isoprostane concentrations 
enhanced the expression of superoxide dismutase; SOD1 and SOD2. In cultured HGECs, 
cinacalcet decreased oxidative stress and apoptosis by increasing intracellular Ca++ and by 
enhancing phosphorylation of CaMMKβ, LKB1 and AMPK, which were associated with 
an increase in the phosphorylation of eNOS-NO as well.
Conclusions: In conclusion, the results suggest that cinacalcet improves glucotoxicity 
through an increase in intracellular Ca++ and subsequent activation of the CaMKKβ-LKB1-
AMPK signaling in the kidney, especially GECs, and may be a potential therapeutic modality 
for type 2 diabetic nephropathy.
TH-PO370
Ectopic Expression of TIMP-1 and LTBP-2 in Proximal Tubule-Specific 
Nampt Conditional Knockout Mice Aggravates Bridging Fibrosis in 
Diabetic Nephropathy  Kazuhiro Hasegawa, Hirokazu Muraoka, Shu Wakino, 
Hiroshi Itoh.  Keio Univ.
Background: Nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting 
enzyme for nicotinamide adenine dinucleotide (NAD) synthesis, and Sirt1, an NAD-
dependent histone deacetylase, exert protective effects in various tissues, leading to 
enhanced stress resistance and extended longevity. We previously reported that proximal 
tubule (PT)-specific Sirt1 transgenic mice are protected against diabetic nephropathy (DN), 
and that PT-conditional knockout (CKO) aggravates DN (Nat Med 2013). However, the role 
of Nampt in DN remains unknown. In this study, we established PT-specific conditional 
Nampt-deficient mice to investigate the role of Nampt in DN initiation and progression.
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Methods: We generated PT-specific, Nampt-deficient mice by crossing Namptflox/
flox mice with γ-GT-Cre mice. Wild-type (WT) and CKO mice were injected with saline 
(Sal; control) or streptozotocin (STZ) to induce DN. The phenotypes of four groups of 
mice, WT+Sal, CKO+Sal, WT+STZ, and CKO+STZ, were analyzed at 8 and 24 weeks 
after treatment.
Results: At 24 weeks in WT+STZ mice, Nampt expression was reduced in PTs in 
parallel to renal fibrosis progression. PAM, Masson trichrome, and EVG staining revealed 
thickening of the tubular basement membrane and basement membrane of Bowman’s 
capsule. Peritubular and periglomerular fibrosis in the cortex and perivascular fibrosis 
surrounding interlobular arteries and veins in the medulla were clearly detected in CKO+Sal 
mice. These fibroses were bridging fibrosis connecting the tubule and glomerulus. DNA 
microarray, real-time PCR, and immunoelectron microscopic findings clearly showed 
that expression of tubular tissue inhibitor of metalloproteinase 1 (TIMP-1) and latent 
transforming growth factor beta binding protein 2 (LTBP-2) was elevated in CKO+Sal 
ectopically in PTs. Such expression caused basement membrane thickening and fibrosis. 
All changes were further enhanced in CKO+STZ mice.
Conclusions: Nampt deficiency in PTs induces bridging fibrosis and overproduction 
of TIMP-1 and LTBP-2. Disruption of Nampt in PTs causes the initiation and progression 
of DN-induced fibrosis through the novel mechanism of PT-periglomerular-perivascular 
fibrotic interplay.
TH-PO371
The Presence of the Anti-Fibrotic MicroRNA Crosstalk in the Effect of 
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Kidney Fibrosis in Diabetes 
Keizo Kanasaki,1,2 Swayam Prakash Srivastava,1 Shi Sen,1 Daisuke Koya.1,2 
1Diabetology and Endocrinology, Kanazawa Medical Univ, Kahoku, Japan; 2Div 
of Anticipatory Molecular Food Science and Technology, Kanazawa Medical 
Univ, Kahoku, Ishikawa, Japan.
Background: N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous 
peptide with anti-fibrotic activity. We have shown that restoration of fibroblast growth factor 
receptor1 (FGFR1) and concomitant induction of microRNA (miR)-let-7s were involved in 
the anti-fibrotic action of AcSDKP. Endothelial-mesenchymal transtion (EndMT) could be 
the importnat source of matrix producing mesenchymal cells in fibrotic kidney. Interferon 
(IFN)γ is potential inhibitor of FGFR1; miR-29 targets IFNγ 3’UTR.
Methods: Streptozotocin-induced diabetic CD-1 mice were used for all animal 
experiments. Mice were sacrificed at 6 months after the induction of diabetes; either 
AcSDKP or PBS was given by osmotic mini-pump for 1 month from 5 months after diabetic 
induction. In vitro experiments were performed using Human Dermal Microvascular 
Endothelial Cells (HMVEC).
Results: Diabetic CD-1 mice with fibrotic kidneys exhibited suppressed levels 
of AcSDKP in urine, anti-fibrotic miRs, such as miR-29s and miR-let-7s, as well as 
the prominent induction of IFNγ and EndMT; these alterations were all reversed by 
AcSDKP treatment. Transfection studies in HMVEC revealed that miR-29s and miR-let-
7s demonstrated crosstalk regulation against the mesenchymal cell activation program. 
Antagomirs for miR-29 induced IFNγ and suppressed both FGFR1 and miR-let-7s; 
neutralising antibody for IFNγ restored the levels of both FGFR1 and miR-let-7s.
Conclusions: The present study provides insight into the physiologically relevant 
anti-fibrotic actions of AcSDKP via anti-fibrotic miRs crosstalk mechanisms. IFNγ is the 
significant regulator of the miR crosstalk between miR-29s and miR-let-7s. Restoring 
such anti-fibrotic programs (mediated by AcSDKP) could demonstrate potential utility in 
combating kidney fibrosis in diabetes.
TH-PO372
Novel Drug-Inducible Megalin Knockout Mice Reveal Marked Increase 
of Both Total Nephron Glomerular Filtration and Tubular Reabsorption 
of Albumin in Early Diabetic Nephropathy  Keita P. Mori,1 Hideki Yokoi,1 
Masato Kasahara,2 Takashige Kuwabara,3 Hirotaka Imamaki,1 Akira Ishii,1 
Kazuwa Nakao,4 Tomomi Endo,1 Motoko Yanagita,1,4 Masashi Mukoyama,3 
Kiyoshi Mori.4  1Dept of Nephrology, Kyoto Univ Graduate School of Medicine, 
Kyoto, Japan; 2Inst for Advancement of Clinical and Translational Science, 
Kyoto Univ Hospital, Kyoto, Japan; 3Dept of Nephrology, Kumamoto Univ 
Graduate School of Medical Sciences, Kumamoto, Japan; 4Medical Innovation 
Center, Kyoto Univ Graduate School of Medicine, Kyoto, Japan.
Background: The early phase of Diabetic nephropathy (DN) is characterized with 
hyperfiltration (or increased clearance) of creatinine or inulin. On the other hand, recent 
reports using micropuncture technique or multi-photon microscopy for superficial nephrons 
indicated that glomerular filtration of albumin is not increased and tubular reabsorption is 
decreased in rodent models of early DN.
Methods: Tamoxifen (Tam)-inducible megalin knockout mice (iMegKO) were 
generated by crossbreeding megalin floxed mice (from Professor T. Willnow, Max Delbrück 
Center) with Ndrg1-CreERT2 mice (from Professor Yanagita), which enable efficient gene 
disruption in proximal tubules of adult mice. For analysis of DN, iMegKO mice were given 
low-dose Tam at 8 weeks after streptozotocin (STZ) treatment.
Results: Low or high-dose Tam-treated, non-diabetic iMegKO exhibited 15-fold 
increase of urinary albumin excretion (UAE), which should represent total nephron 
glomerular filtration of albumin in normal mice. Megalin protein elimination was almost 
complete by high dose Tam, but some expression remained in S3 by low dose.By comparing 
STZ;iMegKO and non-STZ;iMegKO mice, total filtration of albumin was estimated to be 
elevated by 1.7-fold with STZ. Importantly, total reabsorption of albumin, calculated by 
subtraction of UAE before Tam from that after Tam, was also elevated by 1.6-fold with 
STZ. These changes were normalized by insulin treatment.
Conclusions: By use of iMegKO, which allows overall quantitation of albumin 
handling in the whole kidney including juxtamedullary nephrons, total filtration and total 
reabsorption of albumin was markedly increased in STZ diabetic mice.
TH-PO373
Erythropoiesis Stimulating Agents Cannot Improves Circulating 
Endothelial Progenitor Cell Counts in Patients with End-Stage Renal 
Disease on Maintenance Hemodialysis Because of Erythropoietin 
Resistance  Hong Joo Lee,1 Ju-Young Moon,2 Sang Ho Lee,2 Chun-Gyoo Ihm,2 
Tae Won Lee,2 Kyung-hwan Jeong.2  1Dept of Nephrology, Seoul Red Cross 
Hospital, Seoul, Republic of Korea; 2Dept of Nephrology, Kyung Hee Univ 
School of Medicine, Seoul, Republic of Korea.
Background: Decreased circulating endothelial progenitor cells (EPCs) associate 
with occurrence of cardiovascular disease and all cause mortality in end stage renal 
disease(ESRD) patients on hemodialysis. It is known that erythropoiesis stimulating 
agents(ESA) connect to vasculoprotective effects such as enhanced nitric oxide production 
in endothelial cells and mobilization of EPCs. Patients with ESRD on hemodialysis have 
markedly decreased EPC counts although they are often treated with ESA. We investigated 
that ESA can improve EPC levels in hamodialysis patients. Or not, we hypothesized that 
erythropoietin resistance index(ERI) may associate with decreased effect of ESA on EPC.
Methods: We quantified ESA dose and EPCs in blood samples from 86 patients with 
ESRD on hemodialysis. The ERI was calculated by dividing the weekly erythropoietin dose 
per kilogram of weight (µg/wk.kg) by the Hb level (g/dL). Participants were divided into 4 
groups based on the lowest, median, highest ERI and no use of ESA group.
Results: The number of circulating EPCs at baseline ranged from 1 to 350cells/200ml, 
with a mean ± SD of 26.0± 48.2 cells/200µL. There was no significant association with ESA 
dose and EPC counts. However, the EPCs counts of lowest ERI group were significantly 
higher than the medium, highest EPI and no use of ESA group. There was no different 
occurrence of cardiovascular events among the groups.
Conclusions: Administration of EPO may not always increase the number of circulating 
EPCs in ESRD patients on HD. The resistance to erythropoietin may associate with 
decreased circulation EPC counts.
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Dialysis with Medium Cut-Off Membranes (MCO) Modulates Endothelial 
Function In Vitro: Findings from a Randomized Controlled “First in 
Man” – Trial  Daniel Zickler,5 Kevin Willy,5 Ralf Schindler,5 Matthias Girndt,1 
Roman Fiedler,1 Markus Storr,4 Christian Luecht,5 Duska Dragun,5 Rusan Catar.5 
1Dept of Internal Medicine II, Martin-Luther-Univ, Halle, Germany; 2Inst for 
Epidemiology and Applied Biometry, Eberhard-Karls-Univ Tübingen, Tübingen, 
Germany; 3NMI Technology Transfer GmbH, Reutlingen, Germany; 4Research 
& Development, Gambro Dialysatoren GmbH, Hechingen, Germany; 5Dept 
of Nephrology and Internal Intensive Care Medicine, Charité Univ Medicine, 
Berlin, Germany; 6Inst for Chemistry / Food Chemistry, Martin-Luther-Univ, 
Halle, Germany.
Background: Cardiovascular mortality in dialysis patients is in part caused by 
insufficient removal of proinflammatory interleukins. We examined the influence of serum 
samples from an RCT on markers of EC function. MCO membranes that allow elimination 
of 45 kd molecules were used for the first time.
Methods: 50 patients were dialyzed with a Highflux and a MCO membrane for 4 or 12 
weeks. Serum samples were drawn and tested in an endothelial cell model. Neoangiogenesis 
was assessed by the measurement of total segments length and KLF2 mRNA, a flow-
responsive endothelial transcription factor, was measured. VEGF expression and VEGF 
protein release was investigated.
Results: Highflux serum enhances neoangiogenesis in EC compared to healthy serum, 
with MCO filters a reduction was noted. This effect was enhanced after 12 weeks of dialysis 
(MCO 12 weeks 3206 ±340SEM, p<0,05 vs. highflux). The serum drawn from the patients 
started on MCO showed diametrically opposite results. Antiparallel to neoangiogenesis 
a significant reduction of KLF2 expression in EC was noted with Highflux serum, while 
MCO serum showed results comparable with healthy serum. Neither VEGF mRNA nor 
protein release was significantly altered in EC. 
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Conclusions: Our findings underline that dialysis with a higher cut-off influences 
endothelial cell function in vitro.
Funding: Pharmaceutical Company Support - Gambro GmbH, Government Support 
- Non-U.S.
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Pharmacological Inhibition of Prolyl-4-Hydroxylase Improves the 
Impaired Angiogenic Response to Ischemia in Chronic Kidney Disease 
Karl F. Hilgers,1 Julian Panesar,1 Nada Cordasic,1 Johannes Jacobi,1 Nicolai 
Burzlaff,2 Kai-Uwe Eckardt,1 Carsten Willam,1 Kerstin U. Amann.1  1Univ 
Hospital Erlangen; 2Univ of Erlangen-Nürnberg, Germany.
Background: Ischemia-induced angiogenesis is impaired in chronic kidney disease 
(CKD). Activation of hypoxia-inducible factors has been shown to improve angiogenesis. 
Here, we investigated whether activation of hypoxia-inducible factors can improve capillary 
supply in rats with CKD. Inhibition of proly-4-hydroxylase (PHD) was started a few hours 
after onset of hindlimb ischemia.
Methods: CKD was induced in rats by 5/6 nephrectomy; controls were sham operated. 
After 8 weeks, ischemia of the right limb was induced by ligation & resection of the 
femoral artery. Post-conditional activation of hypoxia-inducible factors was induced by 
2 intraperitoneal injections of the PHD inhibitor 2-(1-chloro-4-hydroxyisoquinoline-3-
carboxamido) acetate (ICA), 12.5 mg/kg, 2 and 6 hours after onset of ischemia. Further 
animals received placebo injections. Rats were sacrificed 24 h or two weeks after the onset 
of ischemia. Computer-assisted integration of capillary area normalized for the number 
of muscle fascicles was performed after double staining for CD31 and laminin of sections 
of the gastrocnemius muscle.
Results: In control rats, capillary area increased in the ischemic vs. non-ischemic 
hindlimb by 38±3 % after 2 weeks (p< 0.01, N=8). In contrast, there was no significant 
increase in the ischemic over the opposite limb in CKD (5±4%, N=8, p>0.1). ICA increased 
capillary supply of ischemic limbs of CKD rats by 45±5 % compared to CKD-placebo rats 
(n=8, p<0.01), and by 36±4 % (p<0.05) compared to non-ischemic limbs of CKD-ICA 
animals. After ICA treatment, capillary supply of ischemic limbs was no longer different 
between CKD and control rats. RT-PCR showed that the ischemia-induced stimulation of 
VEGF-A was doubled after 24 h by ICA in CKD. The short treatment with ICA did not 
affect hematocrit levels.
Conclusions: Transient PHD inhibition restores ischemia-induced angiogenesis in CKD 
rat hindlimb even if applied in a therapeutic approach after onset of ischemia.
Funding: Government Support - Non-U.S.
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Vascular Access Choice in Elderly ESRD Patients  Eunjin Bae, Hajeong Lee, 
Dong Ki Kim, Kook-Hwan Oh, Yon Su Kim, Kwon Wook Joo.  of Internal 
Medicine, Seoul National Univ College of Medicine, Seoul National Univ 
Hospital, Seoul, Republic of Korea.
Background: The number of elderly ESRD patients is rapidly increasing. Their high 
prevalence of comorbidity and short life expectancy result in substantial challenges for 
choice of vascular access. The aim of this study is to suggest optimal choice of vascular 
access in elderly ESRD patients who require hemodialysis(HD).
Methods: We included outpatients visiting vascular access clinic between january 
2008 and March 2014, retrospectively. We divided these patients into 3 groups by age as 
follows: younger (<65yrs), elderly (65–79yrs) and very elderly (≥80yrs). Various clinical 
and vascular access associated characteristics were compared among these groups. Cox 
proportional model was used to analyze the effect of vascular access type on maturation 
failure, access failure and all-cause mortality.
Results: Among a total of 1,109 patients, 59.1% was men and the mean age was 61±14 
years. At the time of HD initiation, 56.4% of patients used central catheters, 38.9% used 
AVFs and 4.7% used AVGs. Of these, 87.4% (n=973) were chosen AVFs as their permanent 
vascular access and the proportion of AVF was decreased with age. Compared with AVG, 
AVF was associated with better survival rate, require less intervention to maintain patency 
and have lower access failure. Very elderly patients had higher proportion of proximal 
vascular access and also required more preoperative surveillance and interventions. In total 
patients, the rate of mortality, access failure, maturation failure was 15.7%, 7.1% and 32%. 
The mortality benefit with RC AVF was superior to that with both BC AVF and AVG for 
all age. In elderly group, BC AVF has lowest access failure and highest 1yr patency rate 
compared with RC AVF or AVG. However, in very elderly group, there was no significant 
associations between access type and access failure or 2ndary outcomes when adjusted 
for confounding factors.
Conclusions: We concluded that AVF is the preferred form of vascular access for 
long term outcome in elderly patients. Nevertheless, BC AVF could be considered by 
individual characteristics in elderly patients who has complicated radiocephalic site and 
a short life expectancy.
TH-PO377
Evaluation of Renal Perfusion in CKD Patients Using Arterial Spin 
Labelling (ASL) Magnetic Resonance Imaging (MRI)  Tsutomu Inoue,1 
Eito Kozawa,2 Masahiro Ishikawa,3 Kei Sugiyama,1 Takeru Kusano,4 Naoki 
Kobayashi,3 Hirokazu Okada.1  1Nephrology, Saitama Medical Univ, Iruma, 
Saitama, Japan; 2Dept of Imaging Diagnosis, Saitama Medical Univ 
International Medical Center, Hidaka, Saitama, Japan; 3School of Biomedical 
Engineering, Faculty of Health and Medical Care, Saitama Medical Univ, 
Hidaka, Saitama, Japan; 4Dept of General Internal Medicine, Saitama Medical 
Univ, Iruma, Saitama, Japan.
Background: The evaluation of renal blood flow in chronic kidney disease (CKD) 
is beneficial for the determination of drug efficacy and prognostic expectations of CKD. 
At present, radionuclide scanning or contrast agents are required for this purpose. In this 
study, we employed arterial spin labeling (ASL) MRI, which is a non-invasive method of 
measuring tissue perfusion using magnetized blood as an endogenous contrast agent, for 
the evaluation of CKD patients.
Methods: A total of consequtive 50 CKD patients (33 males and 17 females, 57.1±16.1 
years old) were subjected to MRI, including T1-weighted images, ASL and blood oxygen 
level-dependent (BOLD)-MRI. MRI was performed using a 3.0-T Imager (Skyra; Siemens, 
Erlangen, Germany). MATLAB, a technical computing language for data analysis, was 
used for the production of a perfusion map; while OsiriX, image-processing software for 
digital imaging and communications in medicine (DICOM), was used for measuring the 
signal intensity on each map.
Results: The perfusion map showed that the signal intensity of the renal cortex is 
higher than that of the medulla. Similarly, T2* map obtained by BOLD MRI showed the 
same tendency. These findings appear to reflect the differences in the volume of blood flow 
and tissue oxygenation in each area. Mean cortical blood flow was 134.1±43.8 in G4-5 
and 180.0±48.6 in G3a/b (ml/min/100g tissue weight, p<0.05), with significant differences 
observed between the two groups.
Conclusions: A reliable, non-invasive and repeatable system for monitoring renal 
blood flow is currently clinically unavailable. ASL MRI at 3.0 Tesla provides a method of 
measuring renal perfusion in CKD patients as well as healthy subjects without the need 
for the administration of exogenous compounds.
Funding: Government Support - Non-U.S.
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In-Vivo Studies of the Microcirculation in Experimental Uremia 
Uwe Querfeld,1,3 Hans-Ulrich Prommer,2 Johannes Maurer,2 Karoline Websky,3 
Dorothea Burghardt,1 Rudi Sampati,2 Kerstin Sommer,3 Axel Pries.2  1Pediatric 
Nephrology, Charité, Berlin, Germany; 2Physiology, Charité, Berlin, Germany; 
3Center for Cardiovascular Research, Charite, Berlin, Germany.
Background: Endothelial dysfunction is a clinical hallmark of cardiovascular disease 
in patients with CKD. We analyzed morphology and function of the microcirculation in-
vivo in mice with experimental uremia.
Methods: In-vivo microscopy of the musculus cremaster capillary bed was performed 
in BALB/c mice with moderate to severe uremia due to 5/6 nephrectomy or adenine feeding 
(n=18), and in healthy controls (n=5). Morphological measurements included capillary 
length, capillary density, and the non-vascularized area. Functional parameters included 
the arterio-venous difference in oxygen saturation (avΔO2) and the change in diameter 
(∆D/D) before and after application of acetylcholine, sodium-nitroprusside, papaverine 
and adenosine.
Results: Capillary length was inversely associated with the degree of experimental 
uremia, with a reduction of 15% per 100 mg/dL increase of serum urea. Overall, there was 
a heterogeneous pattern of capillary rarefaction, with areas of normal capillary density and 
capillary-free areas. The mean non-vascularized area in severely uremic animals (urea > 400 
mg/dL) was 19.8x103 mm² ± 50.5x103 mm², and 3.1x103 mm² ±3.7x103 mm² in controls. The 
∆D/D after pharmacological vasodilatation was 15.4% ± 3.7% in controls, 12.4% ± 4.2% 
in moderately uremic animals and 7.0% ± 3.5% in severely uremic mice. The avΔO2 was 
13.1% ± 2.6% in controls, 11.8% ± 3.3% in moderately uremic and 9.8,% ± 2.9% in severely 
uremic mice, indicating an arteriovenous shunt effect and a diminished oxygen delivery.
Conclusions: These in-vivo studies show a loss of microcirculation in the musculus 
cremaster of mice with experimental uremia, occurring in a heterogeneous “wipe-out” 
pattern. Morphological changes (capillary rarefaction) and functional changes (∆D/D, 
avΔO2) were associated with the degree of experimental uremia. These data suggest that a 
diseased microcirculation (uremic microangiopathy) contributes to endothelial dysfunction 
and precedes macrovascular disease in uremia.
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TH-PO379
Arterial Biopsies of Children with CKD Show Altered Morphology, 
Calcium Content and Gene Expression  Uwe Querfeld,1,2 Betti Schaefer,3 
Aysun Bayazit,4 Ursula Schulz,2 Kerstin Sommer,2 Markus J. Kemper,5 Guido 
Laube,6 Francesca Mencarelli,7 Sandra Habbig,8 Franz S. Schaefer,3 Rainer 
Büscher,10 Claus Peter Schmitt,3 Christian Freise.2  1Pediatric Nephrology, 
Charité, Berlin, Germany; 2Center for Cardiovascular Research, Charité, 
Berlin, Germany; 3Pediatric Nephrology, Univ of Heidelberg, Heidelberg, 
Germany; 4Pediatric Nephrology, Cukurova Univ, Adana, Turkey; 5Pediatric 
Nephrology, UKE, Hamburg, Germany; 6Pediatric Nephrology, Univ of Zurich, 
Zurich, Switzerland; 7Pediatric Nephrology, Policlinico S. Ursula Malphigi, 
Bologna, Italy; 8Pediatric Nephrology, Univ of Cologne, Cologne, Germany; 
9Pediatric Nephrology, AKH, Wien, Austria; 10Pediatric Nephrology, Univ of 
Esssen, Essen, Germany.
Background: The prospective 4C study investigates cardiovascular comorbidity in 
children with CKD. We have studied arterial biopsies of 4C-patients and age-matched 
controls.
Methods: Arterial biopsies were performed at the time of renal transplantation of 
patients aged 15.4 (8-21) years (n=21). Age-matched healthy control biopsies were obtained 
from a biobank (Deutsches Herzzentrum Berlin) collecting arterial biopsies from children 
undergoing elective cardiac surgery. Calcium concentrations were determined by the OCPC 
method. Intima-media thickness (IMT) was measured manually (Image J software) in H&E 
stained sections. Gene expressions were analyzed by a Custom RT² Profiler PCR Array. 
Statistical significances were determined using the Holm-Sidak method, with α=5.000%.
Results: IMT was correlated with the calcium content of biopsies (r=0.41; P<0.05). 
Marked transcriptomic alterations were detected in the arteries of the CKD patients: 
Amongst 34 significantly regulated genes (P<0.05-0.0001), SP7 (osterix; ratio 4C/
control: 247.5), NOS2 (35.8), RUNX2 (24.8), IL-10 (11.3), TNF (8.3) and TRPV6 (7.7) 
were upregulated, whereas COL1A2 (0.07), TIMP2 (0.26) and ENPP1 (0.31) were 
downregulated.
Conclusions: Arterial biospsies from children with stage 5 CKD show an increased 
calcium content and an upregulation of osteogenic proteins (VSMC and matrix), calcium-
transporting proteins, inflammatory cytokines, and downregulation of calcification 
inhibitors. These findings most likely reflect an early stage of a CKD-specific calcifying 
arteriopathy.
TH-PO380
Capillary Rarefaction in Omental Biopsies of Children with CKD 
Uwe Querfeld,1 Dorothea Burghardt,1 Betti Schaefer,2 Maria Bartosova,2 
Hamoud Nasser,1 Bernd Lahrmann,3 Joan Nyarangi-Dix,6 Anja Lingnau,4 Claus 
Peter Schmitt.2  1Pediatric Nephrology, Charité, Berlin, Germany; 2Pediatric 
Nephrology, Univ of Heidelberg, Heidelberg, Germany; 3BioQuant TIGA Center, 
Univ of Heidelberg, Heidelberg, Germany; 4Pediatric Urology, Charite, Berlin, 
Germany; 5Pediatric  Surgery, Charite, Berlin, Germany; 6Pediatric Urology, 
Univ of Heidelberg, Heidelberg, Germany.
Background: Endothelial dysfunction in CKD could be related to a damaged 
microcirculation. We studied microvascular density in omental biopsies of children with 
CKD (stage 5) and in healthy age-matched controls.
Methods: Omental tissue was collected from 34 healthy children (0-18 years) 
undergoing elective abdominal surgery. In a case-control study, we selected 24 age-matched 
cases with stage 5 CKD from the biobank of the International Peritoneal Dialysis Network 
with stored omental tissue taken at the time of PD catheter insertion. Biopsies were 
analyzed by immunohistochemistry for capillary density (CD-31 antibody, Ab), autophagy 
(LC3A/B (D3U4C) XP® Rabbit mAb), apoptosis (Caspase-3-AK), VEGF-1 (Abcam, 
Rabbit) and VEGF-R-II expression (VEG Fr-2 (Flk-1). Capillary density was measured 
by 2 trained observers with a digital microscope (BZ-9000 and Analyzer Software®) and 
fully automated with Nanozoomer Digital Pathology System and NDP Viewer Software 
(Hamamatsu Photonics, Japan).
Results: Capillary density was significantly reduced in CKD (median surface area 
0.53% vs. 0.95%, p<0.001 in controls). This was confirmed by automatic imaging (0.89% 
vs. 1.17% p=0.01). Capillary density was inversely associated with age in uremic (r=-0.88, 
p<0.0001) and healthy children (r=-0.63, p<0.0001). There was an inverse correlation 
between capillary density and serum BUN (r=-0.53, p£0.05), serum creatinine (r=-0.58, 
p£0.05), and hemoglobin (r=-0.59, p£0.05). VEGF-1 was reduced by 50% (p<0.05), 
but VEGF-R-II-was not different (p=0.89). There were no differences in autophagy and 
apoptosis between groups.
Conclusions: Capillary density was significantly reduced in omental biopsies of 
children with stage 5 CKD and associated with diminished VEGF signaling. Capillary 
rarefaction could be an essential part of the cardiovascular pathology induced by CKD.
Funding: Clinical Revenue Support
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CD40 Silencing Reduces NF-ȀB Activation and the Progression of 
Atherosclerotic Lesions in the ApoE-/- Murine Model  Miguel Hueso,1 Laura 
De ramon,3 Estanislao Navarro,2 Josep M. Cruzado,1 J. Grinyo,1 Joan Torras.1 
1Nephrology, Hospital BellvitgeBIDIB(LL; 2Laboratori d¶2ncología Molecular, 
IDIB(LL; 3Laboratori de Nefrología (xperimental, IDIB(LL.
Background: Chronic kidney disease (CKD) and inflammation are risk factors for 
atherosclerosis. In inflammatory states NF-κB is frequently activated and the CD40/CD40L 
axis may be a link between inflammation, atherosclerosis and thrombosis. The goal of this 
work is to study the evolution of atherosclerotic lesions, inflammation and mRNA profiling 
in an animal model of hypercholesterolemia after CD40 silencing.
Methods: 35 APOE-/- mice of 8 weeks old were sequentially euthanasied (at 8, 10, 14 
and 24 weeks of age). We compared a group treated with a siRNA against CD40 with a 
control group treated with a scrambled siRNA. Atherosclerotic lesions (red-oil, HE), number 
of macrophages (F4/80) and degree of NFKb activation, in the aorta, were quantified. 
Furthermore, a mRNA profiling by microarray hybridization was performed.
Results: Silencing CD40 reduced the number (Control-14w:13.7±3%, siRNA-
14w:7.7±4%, Control-24w:13.7±7%, siRNA-24w:8.8±5%, p=0.015) and the progression 
of lesions (Control-10w:0.10±0.09mm2, siRNA-10w:0.01±0.02mm2, Control-
14w:0.27±0.21mm2, siRNA-10w:0.18±0.12mm2, Control-24w:0.68±0.061mm2, siRNA-
24w:0.33±0.16mm2, p=0.002). SiRNA group displayed lower numbers of infiltrating 
macrophages (p=0.04) and a lower NF-κB activation than controls (p=0.026). mRNA 
profiling detected 1996 genes up-regulated and 1285 genes down-regulated associated 
with the progression of lesions. CD40 silencing showed 190 genes up-regulated and 403 
genes down-regulated. The analysis of these genes detected the enrichment of biological 
processes related with tissular remodelation, macrophage differentiation and apoptosis. 
CD40 silencing was associated with IFN-gamma production, chronic inflammation, 
endothelial cell migration and apoptosis.
Conclusions: CD40 and NF-κB were associated with the progression of atherosclerotic 
lesions in the APOE-/- model.
Funding: Government Support - Non-U.S.
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Diabetic Cardiomyopathy Is Associated with Loss of Endothelial Glycocalyx 
in Coronary Microvessels  Yan Qiu,1 Kenton P. Arkill,2 Gavin Iain Welsh,1 
Andy Salmon,1 Rebecca R. Foster,1 Paolo Madeddu,3 Simon C. Satchell.1 
1Academic Renal Unit; 2School of Biochemistry; 3Bristol Heart Inst, Univ of 
Bristol, United Kingdom.
Background: Endothelial glycocalyx (Glx) contributes to the microvascular 
permeability barrier and its dysfunction correlates with diabetic nephropathy. 
Microalbuminuria represents a major risk factor for cardiovascular disease in diabetes. 
We hypothesised the albuminuria associated with glomerular endothelial Glx damage in 
diabetes would be accompanied by coronary microvacscular Glx dysfuction in diabetic 
cardiomyopathy (DCP).
Methods: CD1 and FVB mice were rendered diabetic with low doses of streptozocin 
(STZ) i.p. daily for 5 days. Echocardiography was applied to assess DCP by E/A ratio. A 
group of diabetic CD1 mice were treated with vitamin B1 analogue Benfotiamine (BFT, 
70mg/kg/d) after DCP development.
Results: Microvessels from diabetic CD1 heart had decreased MOA lectin binding at 
16 weeks after the development of DCP. Recovered MOA intensity was associated with 
BFT’s beneficial effect on DCP (Ctrl: 17.78±3.48; DCP: 2.53±1.24; DCP+BFT: 30.85±3.80, 
p<0.05, one-way ANOVA). 
FVB mice showed increased albuminuria (7 fold) at six weeks after STZ injection 
(p<0.001, two-way ANOVA); developed DCP at 7 weeks after STZ injection (p<0.01, 
two-way ANOVA). Reduced MAL I lectin binding was noted in microvessels from diabetic 
FVB heart (DCP: 1.64±0.27; ctrl: 2.70±0.27, p<0.05, t test), but not MOA or SNA lectins. 
Electronic microscopy (EM) of 4%PFA-fixed paraffin-embedded heart sections stained with 
biotinylated MAL I and streptavidin-conjugated quantum dots indicated MAL I binding 
molecules localised on endothelial GLx. EM of capillaries from diabetic heart perfusion 
fixed with alcian blue and glutaraldehyde showed reduced Glx depth (DCP: 14.54±0.79; 
ctrl: 27.88±5.82 nm, p<0.05, t test).
Conclusions: These evidence suggest Glx damage is associated with DCP development. 
Recovered heart function with BFT treatment parallels with reversed Glx intensity. 
Identification of Glx with simpler technique is possible, i.e. specific lectins staining. Thus, 
correction of disarranged Glx may have therapeutic potential for DCP and other diabetic 
vascular complications, e.g. diabetic nephropathy.
Funding: Private Foundation Support
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Monocyte Subpopulations of Hemodialysis Patients Exhibit Distinct 
Changes of Cold Shock Y-Box Protein-1 Expression  Lara Ewert, Florian 
Gunnar Scurt, Christos D. Chatzikyrkou, Sabine Brandt, Peter R. Mertens. 
Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke 
Univ Magdeburg.
Background: The cold-shock protein YB-1 is a ubiquitously-expressed RNA/DNA 
binding protein involved in proliferation, signal transduction, and inflammation. In 
monocytes YB-1 expression is regulated as part of the cellular differentiation process. 
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Upon acetylation YB-1 is secreted via a non-classical pathway, influencing inflammatory 
processes by acting as mitogen and chemokine. In dialysis patients prone to inflammations 
we investigated monocyte populations and their YB-1 content and degree of acetylation.
Methods: The monocytic phenotypes Mo1/Mo2/Mo3 were differentiated by flow 
cytometry with the surface marker CD14 and CD16. After permeabilisation and antibody 
staining intracellular content of acetylated and non-acetylated YB-1 was measured.
Results: In dialysis patients (n=63; 63+/-17 years; m 41; f 22) leukocyte numbers 
varied markedly (6,500 +/- 2,000/µl) while monocyte fractions were equal among control 
(n=100; 43+/-11 years, m: 59; f: 41) and patient cohorts. An analysis of the monocytic YB-1 
content revealed that non-acetylated YB-1was significantly lower in the dialysis cohort 
(healthy control: MFI 18000; dialysis cohort: MFI 12000, p<0,001), whereas the amount 
of acetylated YB-1 was increased in all three monocytic subpopulations in comparison 
with healthy controls (healthy control: MFI 4850; dialysis cohort: MFI 6700; p<0,001). 
Amongst the CD14 positive monocytes two distinct subpopulations could be assigned 
according to their YB-1acetyl content (CD14++YB-1acetyl +;CD14++YB-1acetyl ++). In dialysis 
patients monocytes belonging to the CD14++YB-1acetyl ++ population were significantly 
more abundant. Notably, challenge with LPS (5 ng/ml for 2h) resulted in a major shift with 
loss of the CD14++YB-1acetyl ++ population.
Conclusions: Monocyte subpopulations and their YB-1 content are highly regulated 
and differ significantly between healthy controls and dialysis patients. The cold shock 
protein YB-1 undergoes acetylation in dialysis patients, which may causally linked to the 
pro-inflammatory state.
TH-PO384
Epoetin Beta Pegol Improves Endothelial Function in Diabetic Nephropathy 
Rats Even After Onset of Endothelial Dysfunction  Ken-ichi Serizawa, 
Kenji Yogo, Yoshihito Tashiro, Ryohei Kawasaki, Michinori Hirata, Koichi 
Endo, Yasushi Shimonaka.  Product Research Dept, Chugai Pharmaceutical 
Co., Ltd., Japan.
Background: Endothelial dysfunction is a powerful surrogate marker of cardiovascular 
events in nephropathy patients, and flow-mediated dilation (FMD) is a useful indicator of 
endothelial function in clinical settings. Epoetin beta pegol (continuous erythropoietin 
receptor activator, C.E.R.A.) is a drug for the treatment of renal anemia. In this study, we 
examined the ameliorating effect of C.E.R.A. on vascular endothelial function as evaluated 
by FMD in diabetic nephropathy rats.
Methods: Male Spontaneously Diabetic Torii rats (SDT, 22 wks old) were used as 
type-2 diabetic rats. Male Sprague-Dawley rats (SD) were used as age-matched control. 
C.E.R.A. (0.6, 1.2 µg/kg) was administered subcutaneously once every 2 wks for 8 wks. 
At 1 wk after last administration (31 wks old), we assessed endothelial function by FMD 
in the femoral arteries of anesthetized rats.
Results: Blood glucose level was over 500 mg/dL in SDT rats. FMD was significantly 
decreased in SDT rats before the start of C.E.R.A. treatment (22 wks old; SD, 16.2 ± 1.3%; 
SDT, 10.0 ± 1.3%; n = 8), and persisted to 31 wks old (SD, 17.8 ± 1.7%; SDT, 10.4 ± 1.8%; 
n = 7–8). C.E.R.A. dose-dependently improved FMD in SDT rats (31 wks old; C.E.R.A. 0.6 
µg/kg, 17.0 ± 2.0%; C.E.R.A. 1.2 µg/kg, 19.2 ± 2.1%; n = 7–10) without lowering blood 
glucose. Endothelium-independent vasodilation by nitroglycerin and kidney function were 
not changed by C.E.R.A. treatment. Because long-term treatment with C.E.R.A. increased 
hemoglobin (Hb), we also examined the relationship between Hb up-regulation and FMD 
improvement in a separate experiment. We found FMD was not significantly improved 1 
wk after single administration of C.E.R.A. (SD, 15.5 ± 1.6%; SDT, 10.8 ± 0.5%; C.E.R.A. 
5 µg/kg, 12.5 ± 2.1%; n = 6–8), whereas Hb levels were comparable with those in long-
term C.E.R.A. treatment.
Conclusions: These results demonstrated that C.E.R.A. improved endothelial function 
as evaluated by FMD in type-2 diabetic rats, even after onset of endothelial dysfunction, 
and these effects were exerted independently of the increasing shear stress induced by 
hematopoiesis.
Funding: Pharmaceutical Company Support - Chugai Pharmaceutical Co., Ltd.
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Determinants and Progression of Intimal and Medial Arterial Changes 
in Children with CKD  Frida Dangardt, Devina Bhowruth, Daniela 
Thurn-Valsassina, Alicja Rapala, Marietta Charakida, Franz S. Schaefer, John 
Eric- Deanfield, Rukshana Shroff.  9ascular Physiology, UCL, London, United 
Kingdom.
Background: I In CKD, both intimal and medial arterial disease occur, and may 
have different risk factors. A novel imaging technique, very high resolution ultrasound 
(VHRUS) enables visualization of vessel wall layers separately. We hypothesize that 
vascular remodeling begins pre-dialysis, progresses on dialysis, and may be reversible 
after kidney transplantation, and these changes are due to modifiable pathophysiology.
Methods: Intimal (IT) and medial (MT) thickness of the carotid (CA), radial (RA) 
and dorsal pedal (DPA) arteries were measured by VHRUS (40-50MHz) in 54 children (19 
pre-dialysis CKD, 20 on dialysis and 15 post-transplant) at baseline. One year follow up 
measurements were performed in 24 children (11 pre-dialysis CKD and 15 post-transplant). 
Conventional ultrasound (CUS) for CA IMT was measured.
Results: Children on dialysis for >1 year had greater CA and DPA MT compared to 
those on dialysis for <1 year (p = 0.007). In the CKD and dialysis cohort (n=39), higher CA 
MT at baseline was associated with increased serum phosphate (p<0.001, r=0.42) and PTH 
levels (p=0.03, r=0.27). No vascular measures were correlated to 25(OH)D, FGF23 or BMI. 
Renal transplant patients had better GFR and lower serum phosphate and PTH levels, but 
higher BP, BMI and lipid levels compared to the CKD or dialysis cohort (p<0.01 for all). 
Transplanted patients had higher CA and RA IT associated with higher lipid levels (p=0.02, 
r=0.31). At 1-year follow-up transplanted children had a decrease in CA MT (p = 0.01) 
but not IT. Increased DPA IT in transplanted patients was associated with a higher systolic 
BP z- score (p = 0.2, r = 0.22). CA IMT by CUS did not reveal any significant changes.
Conclusions: VHRUS assessment of arterial morphology in CKD patients identified 
potentially modifiable risk factors for intimal and medial vascular disease that were not 
detected by conventional US. Differential thickening in media and intima in dialysis vs 
transplant patients suggests vascular remodelling in response to a changing cardiovascular 
risk factor profile after renal transplantation.
Funding: Private Foundation Support, Clinical Revenue Support, Government 
Support - Non-U.S.
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Is Polymorphonuclear Leukocytes’ Priming a Prerequisite for Monocyte 
Activation and Transmigration, Initiating the Atherosclerotic Process? 
Batya Kristal,2 Eynav Kliger,1 Galina Shapiro,1 Ronit Geron,2 Shifra Sela.1 
1(liachar Research Laboratory, Galilee Medical Center, Nahariya, Israel; 
2Nephrology Dept, Galilee Medical Center, Nahariya, Israel.
Background: Endothelial dysfunction and monocytes transmigration underlie 
the development of atherosclerosis. Increased counts and priming of peripheral 
polymorphonuclear leukocytes (PMNLs) are associated with future or ongoing 
atherosclerosis, however, the role of PMNLs in the accelerated atherosclerotic procces 
of hemodylasis (HD) patients is still unclear. We hypothesize that atherosclerosis is a 
circulatory disease, where circulating primed PMNLs activate monocytes and the endothelial 
layer, at the circulaton. Our aims are to examine endothelial dysfunction, monocytes 
transmigration, post-transmigration activation and differentiation, induced ex-vivo by 
primed PMNLs (HD).
Methods: A unique ex-vivo co-cultivation system of 3 cells types was developed, 
enabling interaction among: primary endothelial cells (HUVEC), in-vivo primed PMNLs 
and monocytes (THP-1), mimicking the initiation of the atherosclerotic process. The 
interactions among these cells was examined at the cellular, protein and gene expression 
levels.
Results: THP-1 transmigration through pre-treated HUVEC with HD PMNLs showed 
a significant increase in: transmigration 
A, post-transmigration activation, B compared to transmigration through HUVEC 
pre-treated with PMNLs from healthy subjects (HC). THP-1 transmigration correlates with 
the PMNLs counts and priming state. Pre-treatment with primed PMNLs induced higher 
MCP-1 expression (2-folds) in HUVEC.
Conclusions: The higher levels of monocytes transmigration, post-transmigration 
activation and endothelial MCP-1 expression mediated by primed PMNLs suggest a novel 
mechanism for the initiation of the atherosclerotic process, emphasizing the pivotal role of 
PMNLs in the initiation of the atherosclerotic process.
TH-PO387
The Effect of End-Stage Renal Disease (ESRD) on Differentiation of 
Circulating T Cell Subsets  Eun hye Seo,1 Chae ho Lim,1 Seunghyun Lee,2 
Young-Il Jo.1  1Nephrology, Konkuk Univ Medical Center,Konkuk Univ School 
of Medicine; 2Dept of Microbiology, Konkuk Univ School of Medicine.
Background: Progressive loss of renal function is associated with a dysregulation of 
circulating T cells that may underlie their impaired T-cell immunity. However, it is not known 
how dysregulation of circulating T cells contribute to the ESRD-related immune deficiency. 
In this study, we investigated the ESRD-related changes in subsets and differentiation of 
circulating T cells in ESRD patients.
Methods: Adult ESRD patients on HD and healthy subjects were recruited. Peripheral 
blood mononuclear cells were collected and staining CD4, CD8, CD45RO, CCR7 and 
CD95(FAS). The frequency of apoptotic cells was calculated by scoring annexin-V binding 
cells after back-gating of CD4/CD8 T cells. CD95(FAS) protein levels were confirmed by 
Western blot analysis and Flow    cytometry    .
Results: A total of 20 adult ESRD patients on HD (male:female 12:8, DM 65%) and 
17 healthy subjects (male:female 6:11) were enrolled. The ESRD patients revealed an 
increased frequency of CD4+CD25+ Treg and CD14+ cell compared with healthy subjects. 
However, the frequency of CD4+ and CD8+ T cells decreased in ESRD patients. (Figure. 
1-A). Circulating of naïve, central-memory(CM), effector-memory(EM), and terminal 
effector-memory(TEM) subsets of CD4+ and CD8+ T cells. The CD4+ and CD8+ TEM 
cell subsets showed a statistically significant decreased in ESRD patients (Figure. 1-B). 
In ESRD patients, the differentiation of effector memory CD8+ T cells increased  (Figure 
1), showing a significantly higher percentages of CD4+ TEM (8.7–12.3%, P<0.05) and 
CD8+ TEM cells (26.8–34.2%, P<0.05). The FAS and apoptosis level showed a statistically 
significant decreased in ESRD patients  (Figure 2).
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Conclusions: These results suggested that the T cell dysregulation may play a role in 
ESRD-related immune deficiency.
TH-PO388
CB1 Cannabinoid Receptor Antagonist Attenuates Cardiac Hypertrophy 
and Fibrosis in Experimental Chronic Kidney Disease  Yu-Juei Hsu, 
Sung-Sen Yang, Shih-Hua P. Lin.  Div of Nephrology, Dept of Medicine, Tri-
Service General Hospital, Taipei, Taiwan.
Background: Cannabinoid receptor type 1 (CB1R) has been shown to participate in 
the development of myocardial hypertrophy and fibrosis—two main pathological features 
of uremic cardiomyopathy. However, it remains unknown whether CB1R is involved in the 
pathogenesis of uremic cardiomyopathy. Here, we aimed to elucidate the role of CB1R in 
the development of uremic cardiomyopathy via modulation of Akt signalling.
Methods: The myocardial hypertrophy and fibrosis were evaluated by echocardiography 
and immunohistochemical staining, respectively, in 5/6 nephrectomy chronic kidney disease 
(CKD) mice treated with a CB1R antagonist. CB1R and fibrosis marker expression levels 
were determined by immunoblotting in cardiac tissue obtained from CKD mice and in H9c2 
cells exposed to the uremic toxin indoxyl sulfate (IS), with an organic anion transporter 
1 inhibitor or a CB1R antagonist or agonist. Akt phosphorylation was also assessed to 
examine the signaling pathways downstream of CB1R activation in both in vitro and in 
vivo models of uremic cardiomyopathy.
Results: CKD mice exhibited marked left ventricular hypertrophy and myocardial 
fibrosis, which were reversed by treatment with the CB1R antagonist. CB1R, collagen 
I, transforming growth factor (TGF)-β, and α-smooth muscle actin (SMA) expression 
showed time- and dose-dependent upregulation in H9c2 cells treated with IS. The inhibition 
of CB1R by either CB1R antagonist or small interfering RNA-mediated knockdown 
attenuated the expression of collagen I, TGF-β, and α-SMA in IS-treated H9c2 cells, while 
Akt phosphorylation was enhanced by CB1R agonist and abrogated by CB1R antagonist 
in these cells.
Conclusions: CB1R blockade attenuates LVH and Akt-mediated cardiac fibrosis in 
a CKD mouse model. Uremic toxin IS stimulates the expression of CB1R and fibrotic 
markers and CB1R inhibition exerts anti-fibrotic effects via modulation of Akt signaling 
in H9c2 myofibroblasts. Therefore, the development of drugs targeting CB1R may have 
therapeutic potential in the treatment of uremic cardiomyopathy.
TH-PO389
The CD4 T-Cell Response to Cytomegalovirus Targets the Endothelium 
and Is Linked to Increased Arterial Stiffness in ANCA Associated Vasculitis 
Dimitrios Chanouzas, Matthew David Morgan, Lovesh Dyall, Jessica Anne 
Dale, Paul Moss, Lorraine Harper.  Univ of Birmingham, United Kingdom.
Background: Cytotoxic CD4+CD28- cells have been linked to cardiovascular disease 
(CVD) but their origin remains unclear. We previously showed that in ANCA associated 
vasculitis (AAV) these cells are only present in CMV seropositive patients and are 
independently linked with mortality. CVD is a leading cause of mortality in AAV. Here we 
have characterised CD4+CD28- cells in AAV and examined their relationship to central 
pulse pressure (cPP), a marker of arterial stiffness and CVD risk.
Methods: We phenotyped CD4+CD28- cells after overnight stimulation with CMV 
lysate via flow cytometry and measured cPP using the Vicorder device in 43 CMV+ 
AAV patients in remission. We stained for CX3CR1, the fractalkine receptor implicated 
in endothelial damage, and Tbet as Th1 cells are linked to atherogenesis. We used Mann 
Whitney U for between group comparisons, Spearman rank for correlations and multivariate 
regression to adjust for confounders.
Results: CD4+CD28- cells expressed Tbet and CX3CR1 and secreted large amounts of 
IFNγ after CMV lysate stimulation compared to CD4+CD28+ cells (15.7 vs. 0.5%,p<0.001).
The CD4+CD28- % correlated with IFNγ secretion after CMV lysate stimulation 
(r=0.614,p<0.001). The CMV specific CD4+CD28-IFNγ+ percentage as well as absolute 
count correlated with cPP (r=0.501,p=0.001) and this persisted after controlling for age, 
gender, mean arterial pressure, urinary ACR and GFR (R square=0.58,B=0.13(95%CI 
0.05-0.21),p=0.003).
Conclusions: CD4+CD28- cells in AAV are proinflammatory, Th1, CMV specific 
cells, able to target the endothelium through expression of CX3CR1 and are independently 
associated with higher arterial stiffness, a risk factor for CVD. This opens therapeutic 
possibilities not only in AAV but also in CKD where CD4+CD28- cells are prevalent and 
linked to CVD.
Funding: Other NIH Support - This study was funded by the Wellcome Trust as part 
of a Research Training Fellowship awarded to Dimitrios Chanouzas.
TH-PO390
A Novel Interacting Molecule with AT1 Receptor, ATRAP, Inhibits Ang 
II-Induced Proliferative Activity and Oxidative Stress in Vascular Smooth 
Muscle Cells  Koichi Azuma,1 Kouichi Tamura,2 Takayasu Taira.1  1Dept of 
Medical Science and Cardiorenal Medicine, Zenjinkai Group, Yokohama, 
Kanagawa, Japan; 2Dept Medical Science and Cardiorenal Medicine, Yokohama 
City Univ Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Background: Ang II influenses the structure and function of vascular smooth muscle 
cells, and plays an important role in reactive oxygen species production. Superoxide 
anions are recognized as mediators of intracellular signaling cascades and are known to 
participate in cardiovascular diseases such as arteriosclerosis and hypertension. Previous 
studies reported that the production of superoxide is modulated by many factors including 
Ang II - AT1 receptor signaling. One of the major sources of superoxide in the aorta is 
NADPH oxidase located in the smooth muscle cells.
Methods: We cloned a novel molecule interacting with carboxy-terminal domain of AT1 
receptor, which we named ATRAP (for AT1 receptor-associated protein), using the yeast 
two-hybrid strategy. In this study, we tested the hypothesis that vascular smooth muscle 
cells express ATRAP and that ATRAP attenuates Ang II-induced proliferative activity and 
oxidative stress in vascular smooth muscle cells. We used rat smooth muscle cells and used 
adenoviral gene transfer for ATRAP overexpression. We used real time PCR,ELISA of 
TGF-β,p22phox,Rac1,Nox1 and BrdU incorporation assay for cell proliferation.
Results: We identified that the ATRAP mRNA and protein were endogeneously 
expressed in VSMC, and found a colocalization of ATRAP and AT1 receptor in Ang 
II-stimulated VSMC. The results of gain-of-function studies by adenoviral gene transfer 
demonstrated that overexpression of ATRAP significantly inhibited Ang II-mediated 
increases in c-fos gene transcription, BrdU incorpoaration, and mRNAs expression of 
NADPH oxidase complex .
Conclusions: These results indicate that ATRAP significantly attenuates Ang II-
mediated proliferative activity and oxidative stress in vascular smooth muscle cells, and 
suggests a novel strategy to inhibit cardiovascular disease such as arteriosclerosis and 
hypertension.
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Myostatin: A Playmaker in Chronic Kidney Disease and Vascular Damage 
Daniela Verzola,1 Giacomo Garibotto,1 Maria bianca Bertolotto,2 Samantha 
Milanesi,1 Barbara Villaggio,1 Jan Lindeman,3 Giorgio Ghigliotti,5 Claudio 
Brunelli,5 Pietro Ameri,5 Domenico Palombo,4 Chiara Barisione.5  1Div 
Nephrology, Genoa Univ; 21st Clinic of Internal Medicine, Univ of Genoa 
-IRCCS AUO San Martino-IST; 3Dept 9ascular Surgery, LUMC, Leiden, the 
Netherlands; 4Unit of Vascular and Endovascular Surgery Univ of Genoa; 
5Research Centre of Cardiovascular Biology Univ of Genoa, Italy.
Background: Patients with abdominal aortic aneurysms (AAA) have higher prevalence 
of chronic kidney disease (CKD), that may contribute to arterial deterioration in a mutual 
detrimental feedback. Myostatin (Mstn), a TGF-β family member with cell-cycle inhibitory 
effects, is up regulated by CKD, but its role in vascular remodeling is unexplored. We 
hypothesized that Mstn may play a role in the progression of vascular damage.
Methods: In human AAA(N=8), non aneurysmatic atherosclerotic lesions (NAAL) 
samples(N=7) and normal abdominal aortas (N=3): Rt-PCR for Mstn and Smoothelin, 
a protein with contractile function (Smtn), immunostaining for Mstn, Smtn, CD45 and 
aSMA. In vitro studies: A7R5 vascular smooth muscle cells (VSMC) and human monocytes 
exposed to normal sera (NS), sera from patients with AAA (AAAS) or Mstn (500 ng/ml) 
for 48 hours. VSMC: proliferation, rt-PCR for Mstn and Smtn. Human monocytes: rt-PCR 
for Mstn, α-SMA and MCP-1 dependent chemotaxis.
Results: Mstn mRNA was overexpressed (by 8 folds, p<0.05) in AAA. Mstn 
immunostaining was also higher in AAA and NAAL and associated with downregulated 
Smtn (p<0.05). Mstn colocalized with VSMC (aSMA) and leukocytes (CD45). In A7R5, 
AAAS upregulated Mstn and downregulated Smtn (p<0.05); Mstn exposure decreased 
Smtn and cell proliferation. In monocytes, AAAS upergulated Mstn and α-SMA and Mstn 
increased aSMA and chemotaxis (p<0.01).
Conclusions: Our data suggest that Mstn is overexpressed in atherosclerotic lesions 
at sites of leukocyte infiltration and de-differentiated VSMCs. Unrecognized circulating 
factors in AAA patients enhance Mstn expression in VSMCs and monocytes. In turn, Mstn 
leads to VSMCs dedifferentiation, blunting their contractile function. In addition, Mstn 
activates monocytes, contributing to the inflammatory milieu in the aortic wall.
TH-PO392
Carbamylation of Plasma Proteins in Children with Chronic Kidney 
Disease  Christine Pietrement,1 Anja Christine Sander,3 Stephane Jaisson,2 
Laetitia Gorisse,2 Philippe Gillery,2 Uwe Querfeld, Franz S. Schaefer.3  1Pediatric 
Dept, Nephrology Unit, Univ Hospital of Reims, Reims, France; 2Laboratory 
of Pediatric Biology and Research, Univ Hospital of Reims, Reims, France; 
3Div of Paediatric Nephrology, Center for Pediatric and Adolescent Medicine, 
Heidelberg, Germany.
Background: In adults with ESRD, Hcit concentration predicts increased CV risk 
and mortality. In adults with CKD and ESRD, CV morbidity and mortality are affected by 
traditional risk factors which tend to override effects of uremia such as carbamylation due 
to enhanced post-translational carbamylation of lysine and homocitrullin formation. Such 
mechanisms may be sensitively studied in children with CKD. Here, we analyzed plasma 
Hcit levels in a large cohort of children with CKD followed as they progressed to RRT.
Methods: Plasma Hcit concentrations were analysed, by mass spect, in 114 6 to 17 yo 
children from the 4C (Cardiovascular Comorbidity in Children with CKD) Study cohort 
with CKD stages 3-5 both cross-sectionally and longitudinally when treatment modality 
changed to dialysis (n=55) or transplantation (n=59). Factors predicting the change in Hcit 
were analyzed by multivariate linear modeling.
Results: Hcit concentrations were independent of age but correlated with eGFR (r=-
0.56, p<0.0001) urea (r=0.61, p<0.0001) and albumin (r=0.36, p=0.0001) successively 
increasing from 277±86 mmol/mol Lys in CKD3 to 634±527 in CKD5. Hcit levels declined 
by an average of 14.6 % after initiation of dialysis, and by 58.1% after transplantation 
(p<0.0001). When adjusting for baseline levels, Hcit concentrations decreased significantly 
more markedly in patients starting peritoneal dialysis (PD) than in those starting 
hemodialysis (HD) (-106±226 vs. -52±169 mmol/mol Lys, p<0.05).
Conclusions: Hcit is strongly inversely correlated to eGFR and urea. Dialysis only 
partially compensates for the continued carbamylation process, although continuous PD 
appears to lower Hcit more efficiently than intermittent HD. After transplantation Hcit 
concentrations rapidly decrease to the range observed in CKD stage 3. Further studies 
are underway to analyze the role of protein carbamylation for the early occurrence of 
intermediate CV endpoints in this pediatric population.
Funding: Government Support - Non-U.S.
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Effect of Far Infrared Radiation on Platelet Adhesion to Human Umbilical 
Vein Endothelial Cells  Wen-Yi Chen,1 Daw-yang Hwang,2 Ke-Li Tsai,1 
Shang-Jyh Hwang.2,3  1Dept of Physiology, Kaohsiung Medical Univ, Kaohsiung, 
Taiwan; 2Divsion of Nephrology, Kaohsiung Medical Univ Hospital, Kaohsiung, 
Taiwan; 3Faculty of Renal Care, Kaohsiung Medical Univ, Kaohsiung, Taiwan.
Background: Far-infrared Radiation (FIR) is an invisible electromagnetic waves with 
wavelength between 3-1000mm. FIR has multiple effects on the cardiovascular system, 
including increasing eNOS and heme oxygenase-1 (HO-1) expression in the endothelial 
cells. FIR improves dialysis fistulas function in hemodialysis patients with impaired 
endothelial function. Activation of thromboxane A2 receptor (TBXA2R) increses von 
Willebrand factor (vWF) expression and release, which lead to increased platelet adhesion 
to endothelial cells and vascular thrombosis. We hypothesis that FIR may reduce TBXA2R 
expression and decrease platelet adhesion to endothelial cells.
Methods: Cultured HUVECs were treated with or without FIR radiation for 30 minutes. 
Cells were harvested and total RNA was extracted for RNA-Seq. Total protein expressions 
of TBXA2R were assessed by western blot. To examine platelet-HUVEC interactions, we 
labeled platelet with calcein AM and co-culturedcalcein AM-labeled platelet with FIR-
treated or controlled HUVECs followed by fluorescence microscopy analysis.
Results: The RNA-Seq results showed increased RNA expression in 665 genes and 
decreased RNA expression in 1,428 genes. There were 34 pathways of genetic expressions 
were significant different. Nineteen genes were involved in platelet aggregation (including 
GNA12, F2RL2, TBXA2R) after FIR radiation. Significant decreases in TBXA2R protein 
levels were observed after FIR radiation. The platelet binding to HUVEC cells was 
significantly less in the FIR-treated versus control.
Conclusions: These data suggest that FIR irradiation reduced TBXA2R RNA and 
protein expressions with decreased platelet adhesion to HUVECs. Our result may provide 
further mechinisms of FIR in the prevention of thrombus formation.
Funding: Clinical Revenue Support
TH-PO394
Vitamin D Analogs-Induced Ectodomain Shedding of Tumor Necrosis 
Factor Receptor 1 as an Anti-Inflammatory Action  Su-Kil Park, Won 
Seok Yang.  Div of Nephrology, Univ of Ulsan, Asan Medical Center, Seoul, 
Republic of Korea.
Background: 1,25-Dihydroxyvitamin D3 (1,25D3), causes a disintegrin and 
metalloprotease 10 (ADAM10)-mediated ectodomain shedding of tumor necrosis factor 
receptor 1 (TNFR1) in human aortic smooth muscle cells (HASMCs) and thereby decreases 
responsiveness of the cells to TNF-α. In this study, we examined the potencies of other 
vitamin D3 and D2 analogs to induce ectodomain shedding of TNFR1 in HASMCs.
Methods: TNFR1 was measured by Western blot. Intracellular Ca2+ was measured 
using Fluo-4 AM. ADAM10 was localized by immunofluorescence staining.
Results: 25-Hydroxyvitamin D3 (25D3) and elocalcitol (an analog of 1,25D3) 
caused ectodomain shedding of TNFR1 at 30 min in a dose-dependent manner, whereas 
1,25-dihydroxyvitamin D2 (1,25D2) and paricalcitol (a derivative of 1,25D2) did not. Both 
25D3 and elocalcitol rapidly induced extracellular Ca2+ influx and caused a marked increase 
in intracellular Ca2+, which was blocked by verapamil, an L-type Ca2+ channel inhibitor. In 
contrast, 1,25D2 and paricalcitol caused only small increases in intracellular Ca2+. 25D3- 
and elocalcitol-induced TNFR1 ectodomain sheddings were abolished by verapamil and 
in Ca2+-free media. Both 25D3 and elocalcitol caused the translocation of ADAM10 to 
the cell surface, which was inhibited by verapamil, while 1,25D2 and paricalcitol did not 
cause ADAM10 translocation. Depletion of ADAM10 by ADAM10-siRNA prevented 
25D3- and elocalcitol-induced ectodomain shedding of TNFR1. 1,25D2 and paricalcitol 
did not antagonize, but rather increased 1,25D3-induced ectodomain shedding of TNFR1.
Conclusions: In summary, both 25D3 and elocalcitol caused ADAM10-dependent 
ectodomain shedding of TNFR1, whereas 1,25D2 and paricalcitol did not. This was due 
to the differences in the potency to induce extracellular Ca2+ influx. By causing TNFR1 
ectodomain shedding and thereby decreasing responsiveness to TNF-α, vitamin D3 analogs 
may regulate inflammatory response of vascular smooth muscle cells.
TH-PO395
Effect of Mycophenolate Mofetil on Cytokine Release and Cholesterol 
Transport in Different Subsets of Polarized Macrophages  Joseph Mattana, 
Nobuyuki (Bill) Miyawaki, Isaac Teboul, Iryna Voloshyna, Allison B. Reiss. 
Medicine, Winthrop-Univ Hospital, Mineola, NY.
Background: Patients withsystemic lupus erythematosus (SLE) have a 5-9 fold 
increased incidence of cardiovascular disease (CVD). Lupus nephritis is commonly treated 
with mycophenolate mofetil (MPA). We examined the effect of MPA on cytokine release 
and expression of the proteins involved in cholesterol transport in M0, M1 and M2 human 
macrophages (Mĭ).
Methods: THP-1 human monocytes were differentiated to a non-polarized phenotype 
(M0) (100nM PMA) and then incubated ± MPA (0.5, 1, 5, 10 and 20mg/ml). Supernatants 
were collected and level of Il-10, IFN-γ and TNF-α were analyzed. M0 were then incubated 
with 20 ng/ml interferon-γ+100 ng/ml LPS to obtain M1 or 20 ng/ml IL-4 to obtain M2 
subsets. M0, M1 and M2 Mĭ were incubated ± MPA (0.5, 1, 5mg/ml). Total RNA and protein 
were isolated. Expression of the major proteins involved in cholesterol transport, ABCA1, 
CD36 and SRA1, were evaluated by real-time PCR and confirmed with Western blot. Foam 
cell formation (FCF) was assessed by incubating ±50 mg/ml oxLDL and Oil-red-O staining.
Results: MPA decreased release of IFN-γ and TNF-α at 1mg/ml. At 5mg/ml level of 
cytokines was as in untreated cells and higher concentrations (10 and 20mg/ml) increased 
cytokine release up to 1.5 and 1.6 fold. In M0 Mĭ MPA increased expression of ABCA1 
(reaching 1.83±0.07at 5mg/ml) and decreased expression of CD36 and SR-A1 to 0.75±0.03, 
0.6±0.08, respectively (n=3, P<0.05). FCF was decreased 0.75 times at 1mg/ml but returned 
to the level of untreated cells at 5mg/ml. In M2 Mĭ MPA displayed a significant effect 
only on SR-A1 decreasing its expression to 0.7±0.04 at 5mg/ml. Effect of MPA on M1 Mĭ 
was contradictory to other subtypes, reducing ABCA1 (0.71±0.04) and augmenting CD36 
and SR-A1 expression (2.4±0.1 and 1.9±0.08 at 5mg/ml, respectively). Accordingly, FCF 
was enhanced 1.5 times at 5mg/ml.
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Conclusions: MPA has effects on Mĭ cytokine release and cholesterol handling 
which are dependent on Mĭ subtype and concentration. These effects may be important 
in modifying atherogenesis in patients with SLE and may have relevance in kidney 
transplantation as well.
Funding: Other NIH Support - 5
NCCAM R21 AT007032 02 Allison B. Reiss
TH-PO396
Mitochondria Derived Reactive Oxygen Species and Microvascular 
Dysfunction in Chronic Kidney Disease  Danielle L. Kirkman,1 Meghan 
G. Ramick,1 Bryce J. Muth,1 Raymond R. Townsend,2 David G. Edwards.1 
1Kinesiology and Applied Physiology, Univ of Delaware; 2Clinical and 
Translational Research Center, Univ of Pennsylvania.
Background: Endothelial dysfunction in chronic kidney disease (CKD) is characterized 
by reduced nitric oxide bioavailability as a consequence of oxidative stress. Damaged and 
dysfunctional mitochondria as a result of CKD are likely a large contributor to reactive 
oxygen species. The aim of this study was to determine if mitochondria derived reactive 
oxygen species contribute to impairments in nitric oxide mediated microvascular function 
in CKD.
Methods: Cutaneous vasodilation in response to local heating was assessed in 8 CKD 
patients (age:67±7 years; eGFR:48±11 ml/kg/1.73m2) and 8 matched healthy individuals 
(age:60±6 years; eGFR:91±11 ml/kg/1.73m2). Participants were instrumented with 2 
intradermal microdialysis fibers for the infusion of 1) Ringers solution and 2) mitochondria 
specific superoxide scavenger mitoTempo. Skin blood flow in response to local heating 
(42°C) was assessed at the microdialysis sites by laser-Doppler flowmetry. Cutaneous 
vascular conductance (CVC) was calculated as a percentage of the maximum CVC achieved 
during sodium nitroprusside infusion at 43°C.
Results: CVC was attenuated in CKD patients compared to healthy controls (86±5 vs 
95 ±3 %; p<0.01). MitoTempo significantly improved CVC in CKD patients (CKD Ringers 
vs CKD MitoTempo: 86±5 vs 93±6; p<0.05) to levels similar to that of healthy controls 
(CKD MitoTempo vs Healthy Ringers: 93±6 vs 95± 3; p=0.67).
Conclusions: MitoTempo improved cutaneous microvascular function in CKD patients 
suggesting that mitochondria derived reactive oxygen species play a role in microvascular 
dysfunction in CKD. Improving mitochondria health and reducing mitochondria derived 
oxidative stress may be a potential therapeutic target for improving endothelial function 
in CKD.
Funding: Other NIH Support - National Heart Lung and Blood Institute R01HL113514
TH-PO397
Indolic Uremic Solutes-Aryl Hydrocarbon Receptor-Tissue Factor: A Novel 
Uremic Thrombosis Axis and Aryl Hydrocarbon Receptor as an Emerging 
Antithrombotic Target  Moshe Shashar, Laith Al-Rabadi, Mostafa Belghasem, 
Lawrence Prince-Wright, Jamaica Siwak, Jean M. Francis, Vipul C. Chitalia. 
Renal Section, Boston Medical Center, Boston, MA.
Background: Thrombosis, a highly prevalent complication in CKD patients, remains 
an area of high unmet clinical need with poorly defined pathogenesis. While recent work 
has implicated indolic uremic solutes as potent prothrombotic toxins acting through Tissue 
Factor (TF), a procoagulant protein, it also uncovered Aryl Hydrocarbon Receptor(AHR) 
as a key mediator of this regulation and a druggable target for thrombosis. Since AHR 
blockers (AHRBs) inhibited thrombosis in uremic milieu. we hypothesized that inhibition 
of AHR activity destabilizes TF through its ubiquitination.
Methods: Sera from 25 ESRD patients on hemodialysis matched with controls were 
used. RNA silencing oligos to carboxy terminus of hsc70-interacting protein (CHIP), full-
length and a truncation of TF and full-length CHIP were expressed in various cell lines.
Tissue factor expression and activity were examined using western blotting and a surface 
procoagulant activity assay, respectively.
Results: Our data showed that TF ubiquitination is inhibited in uremic milieu, a 
process substantially restored by AHRBs. The kinetic profile of this regulation suggested 
a post-translational mechanism. AHR is known to interact with CHIP, a RING-finger 
E3 ubiquitin ligase, and thus we posited that CHIP regulates TF ubiquitination. Binding 
and immunofluroesence studies supported an interaction of CHIP and TF in the cytosol. 
Deletion of the intracelllular domain of TF substantilly abrogated the interaction with CHIP 
suggesting that CHIP binds at the intracytosolic tail of TF. CHIP knock-out and silenced 
cells showed both significantly elevated TF expression and activity and prolonged TF 
half-life in uremic mileu supporting CHIP’s role as an E3 ligase of TF.
Conclusions: Our data suggest CHIP as a candidate E3 ligase of TF and raise a 
tantalizing possibility of AHRBs regulating TF ubiquitination and thrombosis through CHIP. 
While supporting a novel post-translational regulation of TF, this work in future will unveil 
a potential mechanism of action of AHRBs, an emerging class of anti-thrombotics in CKD.
Funding: Private Foundation Support
TH-PO398
APOL1-B3 G2 Risk Variant Perturbs Cholesterol Homeostasis in THP-1 
Macrophages  Alex Dinh,1 Hidefumi Wakashiu,1 Jurgen Heymann,1 Alessia 
Fornoni,2 Jeffrey B. Kopp.1  1NIDDK, NIH, Bethesda, MD; 2Dept of Medicine, 
Univ of Miami, Miami, FL.
Background: Apolipoprotein L1 (APOL1) circulates in human plasma bound to high-
density lipoprotein (HDL). AP2L G1 and G2 variants increase the risk of developing 
chronic kidney disease. We examined differences in cholesterol homeostasis in THP-1 
macrophages stably expressing G0 and G2 variants of the APOL1-B3 (intracellular) isoform.
Methods: THP-1 cells were stably transfected with the G0 or G2 APOL1-B3 variants 
or an empty vector, and activated with phorbol myristate acetate (PMA) for 3 days. For 
cholesterol efflux assays, cells were incubated with 1 µCi/mL [3H]-cholesterol for 24 h. 
Efflux ligands were added to the media for 4 h, after which [3H]-cholesterol in media and 
cells was quantified. For amphotericin B lysis, cells were exposed to amphotericin B for 
5 h. Cell viability was assessed using the CellTiter-Glo luminescent assay. To generate 
foam cells, THP-1 cells were stimulated with PMA for 2-3 d and incubated with 20 mg/
ml oxidized LDL for 18 h. Cells were stained with Oil Red O.
Results: THP-1 macrophages expressing the APOL1-B3 G2 variant exhibited increased 
survival compared to cells expressing the APOL1-B3 G0 variant at amphotericin B 
concentrations of 10 mg/ml (93.2%±2.6% vs 79.4%±2.6%), 100 mg/ml (52.4%±0.3% vs 
30.8%±0.5%), and 250 mg/ml (11.0%±0.8% vs 8.0%±1.1%), all p<0.01. Cells expressing 
the APOL1-B3 G2 variant had increased cholesterol efflux compared to cells expressing 
the APOL1-B3 G0 variant (25.2%±3.5% vs 11.6%±5.6%, p<0.05). Following incubation 
with oxidized LDL, APOL1-B3 G2 expressing cells had qualitatively less Oil Red O 
staining compared to APOL1-B3 G0 expressing cells, indicating a relative decrease in 
neutral lipid uptake.
Conclusions: Stable expression of the APOL1-B3 G2 risk variant in THP-1 
macrophages increased cholesterol efflux and decreased neutral lipid content compared 
to APOL1 G0 cells, which could lead to cellular cholesterol depletion. This finding may 
explain the observed protective effect of APOL1 risk variants on cardiovascular mortality 
in African Americans with type 2 diabetes, a disease characterized by decreased cholesterol 
efflux and increased propensity to form foam cells.
Funding: NIDDK Support, Private Foundation Support
TH-PO399
Indoxyl Sulfate-Induced Endothelial Microparticles Stimulate Vascular 
SMC Proliferation and Neointimal Hyperplasia Formation Through TGF-β 
Induction  Jung-hwa Ryu, Shina Lee, Dong-Ryeol Ryu, Duk-Hee Kang, Kyu 
Bok Choi, Seung-Jung Kim.  Internal Medicine, College of Medicine, Ewha 
Womans Univ, Seoul, Republic of Korea.
Background: Vascular access stenosis occurs frequently and predominantly as a 
result of neointimal hyperplasia formation caused by vascular smooth muscle cell(SMC) 
proliferation. Previous reports showed that endothelial microparticle(EMP) is closely 
associated with vascular dysfunction and atherosclerosis. In this study, we investigated 
the effects of EMP on TGF-β signaling and its association with proliferation of vascular 
SMC and neointimal hyperplasia formation.
Methods: To produce EMPs, HUVECs were stimulated by indoxyl sulfate (IS). IS-
induced EMPs were collected by ultracentrifugation of culture media and sorted by flow 
cytometry. Human aortic SMCs(1.0x106) were treated by EMPs of 2x106 particles Western 
blot analysis was done for Akt, ERK1/2, p38 MAPK, and Smad3. SMC proliferation was 
measured by BrdU cell proliferation assay. TGF-β production was measured by PCR and 
ELISA. Porcine internal jugular veins were cultured ex vivo in the presence of EMPs for 
12 days, and immunohistochemistry for TGF-β and phospho-specific TGF-β signalings 
was done.
Results: EMPs stimulated the proliferation of aortic SMCs in a dose-dependent 
manner. EMPs induced TGF-β secretion from aortic SMCs as well as the phosphorylation 
of its down-stream signaling molecules including Akt, ERK1/2, p38 MAPK, and Smad3. 
The proliferation of aortic SMCs and the phosphorylation of the signaling molecules were 
significantly reduced by anti-TGF-β neutralizing antibody. In ex vivo culture of porcine 
internal jugular veins, neointimal hyperplasia was significantly developed in EMP-treated 
venous tissues. The expression of TGF-β and the phosphorylated signaling molecules were 
significantly up-regulated in the area of neointimal hyperplasia.
Conclusions: IS-induced EMPs stimulated the proliferation of vascular SMCs and the 
production of TGF-β by vascular SMCs, and the proliferation of these cells was mediated 
by TGF-β. Accordingly, EMPs induced neointimal hyperplasia formation and TGF-β 
expression in cultured venous tissue. Further investigation is needed to demonstrate the 
role of EMPs on vascular access stenosis.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
179A
J Am Soc Nephrol 26: 2015 Vascular Biology: Atherosclerosis, Inflammation, Endothelium Poster/Thursday
TH-PO400
Inflammation, Apoptosis, Fibrosis and Vascular Calcification in a Model 
of Balloon Injury in Rats with Chronic Kidney Disease  Artur P. Mendes. 
ISNI, CHL2, Lisboa, Portugal.
Background: Cardiovascular disease (CVD) is more prevalent and has a worse 
prognosis in chronic kidney disease (CKD) patients than in the general population and is 
the leading cause of morbimortality in those patients. Not only traditional risk factors of 
CVD but also uremia-related ones like inflammation, fibrosis and mineral disorder may 
contribute to the poor CVD prognosis.
Methods: We developed a model of accelerated vasculopathy in rats with CKD to study 
the vascular damage in CKD: inflammation, apoptosis, fibrosis and vascular calcification. 
The animal model consisted of inducing a balloon injury (BI) with angioplasty in the 
carotid arteries (CA) of 5/6 nephrectomy rats and compare the lesion with non-CKD rats 
(NR). We used 24 Wistar rats.
Results: We analyzed the normal and injured CA of NR and CKD rats with histology, 
immunohistochemistry (IH) and RT-PCR, 1 week after the BI. With HE, we saw similar 
intimal hyperplasia in the CA with BI in both groups. With Masson trichrome and sirius 
red we observed connective tissue mainly in adventitia layer. With IH for fibronectin we 
saw abundant expression in hyperplasia areas of the intima of the CA submitted to BI. The 
expression in the media layer was higher in CKD than NR. In cellular proliferation studies 
with Mib1 Ab we also appreciated a higher expression of the Ab in the neointima of CKD 
rats. In IH for activated caspase 3 no expression was noticed in both groups. In the anti-
CD68 Ab study we could see macrophages mainly in the adventitia layer of injured CA of 
the CKD rats than on the NR. We didn’t observe tissue calcification with Von Kossa staining 
in any group. In the RT-PCR studies there were more type 1 collagen and fibronectin in 
the injured CA than in the non injured CA of the NR, as expected, but also more type 1 
collagen and fibronectin in the non injured CA of the CKD rats than in the NR and much 
more in the injured CA of CKD rats.
Conclusions: In a model of accelerated vasculopathy we have shown a more intense 
activation of the inflammation and fibrosis pathways in the CKD rats than in NR.
TH-PO401
Post-Transcriptional Guidance of Monocyte to Macrophage Differentiation 
by the RNA-Binding Protein Quaking  Jurrien Prins, Ruben de Bruin, Janine 
van Gils, Ton J. Rabelink, Anton Jan Van Zonneveld, Eric P. van der Veer. 
Nephrology, Leiden Univ Medical Center, Leiden, Zuid-Holland, Netherlands.
Background: Kidney injury is associated with excessive recruitment and influx of 
monocytes to sites of tissue damage and their ensuing differentiation into macrophages. 
This differentiation is associated with a striking increase in protein expression levels of 
the RNA-binding protein Quaking (QKI). We therefore set out to investigate the role of 
QKI in monocyte and macrophage function.
Methods: Monocytes expressing an shRNA against QKI were studied for their capacity 
to adhere, migrate and differentiate into macrophages. RNA-seq and microarray analysis 
of human monocytes and macrophages, including those of a unique QKI haploinsufficient 
patient, was performed to identify QKI-mediated splicing events. Identified splice variants 
of the actin capping protein y-Adducin were validated using a splicing reporter construct 
and were ectopically expressed in monocytes to study migration using a transwell migration 
assay. Unilateral ureteral obstruction (UUO) on mice hypomorphic for QKI (QKv) was 
performed and analysed.
Results: Specific depletion of QKI protein significantly impaired monocyte adhesion, 
migration and differentiation into macrophages in vitro. RNA-seq and microarray analysis 
revealed 571 and 629 splicing events in monocytes and macrophages, respectively. One 
such event was the inclusion of a cassette exon in y-Adducin, which occurred after depletion 
of QKI protein, and was found to reduce monocyte migration when ectopically expressed. 
UUO in hypomorphic QKv mice revealed a two-fold reduction in macrophage markers 
(F4/80 and CD115) and decreased interstitial collagen deposition compared to controls.
Conclusions: We show that QKI post-transcriptionally guides monocyte and 
macrophage function in vitro and in vivo, partially by mediating alternative splicing of 
pre-mRNA targets of QKI such as y-Adducin. The reduced infiltration of monocytes and 
ensuing differentiation into macrophages, and deposition of interstitial collagen observed 
in a UUO model in QKv mice identifies QKI as a novel target for therapeutic intervention 
in renal and inflammatory disease.
TH-PO402
Induction of Autophagy and Its Role in Endothelial Cell Injury in Response 
to Carbamylated Low-Density Lipoprotein (cLDL)  Chhanda Bose,1,2 Sudhir 
V. Shah,1,2 Oleg K. Karaduta,1,2 Alexei G. Basnakian,1,2 Gur P. Kaushal.1,2  1Dept 
of Internal Medicine, Div of Nephrology, Univ of Arkansas for Medical Sciences, 
Little Rock, AR; 2Medicine Service, Renal Section, Central Arkansas Veterans 
Healthcare System, Little Rock, AR.
Background: We and others have demonstrated that plasma levels of carbamylated 
proteins are elevated in CKD patients and that they are significant predictors of 
cardiovascular events and all-cause mortality. Autophagy is a highly conserved process 
of protein and organelle degradation and is involved in regulation of cellular injury. Its 
induction and role in endothelial cell injury in response to cLDL has not been examined.
Methods: A time course (for up to 24 hours) and concentration dependence of cLDL 
(0 µM to 500 µM) was performed for autophagy measurements. The effect of cLDL 
on autophagy was evaluated by increased formation of punctate immunofluorescence 
staining of GFP-LC3-II from GFPLC3-I following transfection with GFP-LC3 plasmid 
and conversion of LC3-I to LC3-II as determined by western blot. The effect of inhibition 
of cLDL-induced autophagy on cell death and DNA fragmentation was determined using 
5mM 3-methyladenine (3-MA) and chloroquine. DNA fragmentation will be measured 
by a TUNEL assay.
Results: Carbamylated LDL treatment of human coronary artery endothelial cells 
(HCAECs) increased LC3-II punctate dots in a dose- and time-dependent manner. 
Autophagy induction in response to cLDL was observed by conversion of LC3-I to LC3-II 
by western blot. The formation of cLDL-induced LC3-II vesicles were markedly inhibited 
by 3-MA. These studies provide the first evidence that cLDL increases LC3-II protein and 
autophagosome formation in endothelial cells. The autophagy inhibitor 3-MA suppressed 
cLDL-induced LDH release, EndoG activation, and DNA fragmentation, suggesting that 
inhibition of cLDL-induced autophagy provides a cytoprotective role against EndoG 
activation and cell death in HCAECs.
Conclusions: HCAECs respond to cLDL by induction of autophagy in a dose- and 
time- dependent manner, and inhibition of cLDL-induced autophagy is cytoprotective 
against cLDL-induced cell death, DNA fragmentation, and EndoG activation.
Funding: Veterans Administration Support
TH-PO403
Fractalkine Receptor CX3CR1 on Bone Marrow Derived Cells Is 
Required for Excess Atherosclerotic Inflammation in Renal Impairment 
Shuwang Ge, Johannes Nordlohne, Barbara Hertel, Hermann G. Haller, Sibylle 
Von Vietinghoff.  Nephrology and Hypertension, Hannover Medical School, 
Hannover, Germany.
Background: Reduced kidney function is an important risk factor of aggravated 
atherosclerosis. Inflammatory leukocytes are attracted to the lesion and regulate lesion 
growth and composition. Fractalkine receptor CX3CR1 is highly expressed on peripheral 
blood leukocytes, but also resident vascular cells such as smooth muscle cells. This study 
investigated the role of CX3CR1 in atherosclerotic inflammation a mouse model with 
moderate renal impairment.
Methods: Apolipoprotein E (Apoe-/-) and LDL receptor (LDLr-/-) deficinet mice 
underwent unilateral nephrectomy or sham surgery and were maintained on high-fat diet. 
Bone marrow transplantation was conducted after lethal irradiation. Aortic lesion size was 
quantified macroscopically and histologically in the aortic root and leukocyte infiltration 
determined by microscopy and flow cytometry.
Results: Apoe-/- mice without CX3CR1 were protected from increased aortic 
atherosclerotic lesion size and macrophage accumulation in renal impairment. LDLr-
/- mice were similarly protected. Renal impairment increased CX3CR1 expression on 
aortic macrophages. Conversely, in renal impairment, aortic macrophage numbers were 
significantly decreased in the absence of CX3CR1. In mixed chimeric mice, absence of 
CX3CR1 on bone marrow cells only sufficed to decrease atherosclerotic macrophage 
numbers and aortic root lesion size in renal impairment.
Conclusions: CX3CR1 was instrumental in enhanced atherosclerosis in renal 
impairment. This effect was beyond the CX3CR1 effect observed in normal renal function 
suggesting that CX3CR1 inhibition should be investigated as a targeted treatment approach 
in this high-risk group.
TH-PO404
Afferent Arteriolar Endothelial-Dependent Dysfunction Precedes 
Radiation-Induced Nephropathy and Hypertension  John D. Imig,1 Eric P. 
Cohen.1  1Medical College of Wisconsin; 2Univ of Texas Southwestern.
Background: Chronic kidney disease (CKD) occurs in 15% of hematopoietic stem 
cell transplant (HSCT) patients, and has been clearly linked to irradiation at the time of 
the HSCT. Radiation nephropathy is expressed in rats and in humans as azotemia and 
hypertension. There is a latent period of 6-8 weeks after irradiation to the development 
of proteinuria, azotemia, and hypertension in rats. We tested the hypothesis that afferent 
arteriolar responses to the endothelial-dependent dilator acetylcholine are impaired prior to 
the development of azotemia and hypertension in rats exposed to total body irradiation (TBI).
Methods: Male WAG/RijCmcr rats were subjected to TBI (11 Gy) and afferent 
arteriolar responses to acetylcholine using the juxtamedullary nephron technique were 
determined at one, three, and six weeks.
Results: Systolic blood pressure (117 ± 6 vs. 119 ± 4 mmHg) and BUN (15.6 ± 1.4 vs. 
15.8 ± 0.8 mg/dl) were not different between control and TBI groups at 6 weeks. Afferent 
arteriolar diameters averaged 22.5 ± 0.8 mm (n=30) in controls and 21.7 ± 0.7 mm (n=27) 
in TBI rats and were not different between control and TBI groups at 1, 3, or 6 weeks. 
Acetylcholine dilator responses were progressively attenuated from one to six weeks in TBI 
compared to control rats. During exposure to acetylcholine (0.01, 0.1, 1, and 10 mmol/L), 
afferent diameter increased by 8 ± 2%, 18 ± 3%, 27 ± 2% and 31 ± 3% in control rats 
(n=6), and 3 ± 2%, 9 ± 3%, 12 ± 3%, and 16 ± 3% in kidneys of 3 week TBI rats (n=8, 
p<0.05). However, TBI did not change the nitroprusside vasodilator responses at 1, 3, or 
6 weeks. Renal microvessels were isolated from control and TBI groups at 3 and 6 weeks 
for protein expression assessment of endothelial enzymatic pathways Cyp2C, COX, and 
NOS. We found that epoxygenase Cyp2C protein expression was significantly lower 3 and 
6 weeks following TBI compared to control rats.
Conclusions: Taken together, these results indicate that the impaired afferent arteriolar 
endothelial-dependent acetylcholine responses and decreased epoxygenase enzymes precede 
the development of proteinuria, azotemia, and hypertension in irradiated rats.
Funding: Veterans Administration Support
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TH-PO405
Elevated Lp-PLA2 Plasma Activity Is an Independent Predictor of 
Subclinical Atherosclerosis in CKD5-D Patients – No Correlation with 
Lp-PLA2 mRNA Expression in Isolated Monocyte Subsets  Christof Ulrich, 
Bogusz Trojanowicz, Roman Fiedler, Felix Kohler, Anna-Franziska Wolf, Eric 
Seibert, Matthias Girndt.  Internal Medicine II, Martin-Luther-Univ Halle-
Wittenberg, Germany.
Background: The continued search for biomarkers indicating future cardiovascular 
events among patient on renal replacement therapy is well-founded by the extraordinarily 
high cardiovascular mortality rate in these patients. The combination of inflammatory cells 
capable of expressing atherogenic molecules within the plaque makes the monocyte-/ Lp-
PLA2-axis an interesting subject to study in patients on maintenance dialysis (CKD5-D).
Methods: CKD5-D were stratified upon the presence (A+) or absence (A-) of 
subclinical atherosclerosis by carotid artery ultrasound. Lp-PLA2 plasma activity was 
measured by an enzymatic kinetic test and leucocytic Lp-PLA2 mRNA expression by 
real time PCR. Monocyte subsets were analyzed flow-cytometrically and defined as 
classical CD14++CD16- (Mo1), intermediate CD14++CD16+ (Mo2) and non-classical 
CD14+CD16++ (Mo3). mRNA expression analysis of these subsets (N=24) was done after 
sorting of cells using ARIA II FACS-sorter.
Results: 60 CKD5-D (62.3±15.5 years) patients and 39 healthy control subjects 
(54.0±8.4 years) were enrolled in a cross-sectional study. Lp-PLA2 mRNA expression in 
leucocytes and plasma Lp-PLA2 activity were significantly higher in CKD5-D. CKD5-D 
patients diagnosed with subclinical atherosclerosis (A+) had the most prominent Lp-PLA2 
activity values, which even remained significantly different compared to A- after adjustment 
for age and HbA1c. Among different monocyte subsets Mo1 and Mo2 had the highest 
Lp-PLA2 mRNA level, but it was Lp-PLA2 mRNA expression on “patrolling” Mo3 cells 
which was significantly elevated in A+ versus A-.
Conclusions: We conclude that Lp-PLA2 activity is an independent predictor of 
subclinical atherosclerosis in CKD5-D patients. Among monocyte subsets Mo3 cells appear 
to have an exceptional position within the setting of atherosclerosis. These vessel patrolling 
cells may reflect a physiological response to vascular inflammation in CKD5-D patients.
Funding: Private Foundation Support
TH-PO406
Hypoxanthine, a Uremic Small Solute, Induces Cholesterol Accumulation 
in Hepatocytes and Incites Atherosclerosis in APO E Deficiency Status 
Yong-Lim Kim,1,2 Hye-Myung Ryu,1 Sukyung Lee,1 Hee-Yeon Jung,1 Se-Hee 
Yoon,3 Ji-Young Choi,1 Chan-Duck Kim,1 Sun-Hee Park,1 Jang-Hee Cho.1 
1Div of Nephrology and Dept of Internal Medicine, Kyungpook National Univ 
Hospital, Daegu, Korea; 2BK21 Plus KNU Biomedical Convergence Program, 
Dept of Biomedical Science, Kyungpook National Univ, Daegu, Korea; 3Dept 
of Internal Medicine, Konyang Univ, Daejeon, Korea.
Background: Hypoxanthine which originates from purine metabolism is a small free 
water-soluble uremic toxin. Its biological functions remain unknown. In this study, we 
investigated the role of hypoxanthine on chronic kidney disease (CKD) and cholesterol 
synthesis with atherosclerosis development, particularly in apolipoprotein E (APOE)-
deficient mice.
Methods: The effect of hypoxanthine on the regulation of cholesterol synthesis and 
atherosclerosis were evaluated in cultured HepG2 cells and Apoe knockout (KO) mice.
Results: Hypoxanthine had no effect on the renal interstitial fibrosis in CKD mouse. 
The effect of hypoxanthine on the regulation of cholesterol synthesis and atherosclerosis 
were evaluated in cultured HepG2 cells and Apoe knockout (KO) mice. In HepG2 cells, 
hypoxanthine increased intracellular ROS production. Hypoxanthineincreased cholesterol 
accumulation and decreased APOE and ATP-binding cassette transporter A1 (ABCA1) 
mRNA and protein expression in HepG2 cells. Furthermore, H2O2 also increased cholesterol 
accumulation and decreased APOE and ABCA1 expression. This effect was partially 
reversible by pre-treatment with the antioxidant N-acetyl cysteine. Hypoxanthine and 
APOE knockdown using APOE-siRNA synergistically induced cholesterol accumulation 
and reduced APOE and ABCA1 expression. Hypoxanthinemarkedly increased serum 
cholesterol levels and the atherosclerotic plaque area inApoe KO mice.
Conclusions: Hypoxanthine induces cholesterol accumulation in hepatic cells through 
alterations in enzymes that control lipid transport and induces atherosclerosis in APOE-
deficient cells and mice. These effects are partially mediated through ROS produced in 
response to hypoxanthine.
Funding: Government Support - Non-U.S.
TH-PO407
Atherosclerosis following Renal Injury Is Ameliorated by Pioglitazone 
and Losartan via Macrophage Phenotype  Suguru Yamamoto,1,2 Jianyong 
Zhong,1,3 Haichun Yang,3 Yiqin Zuo,3 Ichiei Narita,2 Valentina Kon.1  1Dept of 
Pediatrics, Vanderbilt Univ Medical Center, Nashville, TN; 2Div of Clinical 
Nephrology and Rheumatology, Niigata Univ Graduate School of Medical and 
Dental Science, Niigata, Japan; 3Dept of Pathology, Vanderbilt Univ Medical 
Center, Nashville, TN.
Background: Chronic kidney disease (CKD) amplifies atherosclerosis which involves 
renin-angiotensin system (RAS) regulation of macrophages. RAS influences peroxisome 
proliferator-activated receptor-γ (PPARγ), a modulator of atherogenic functions of 
macrophages, however, little is known about its effects in CKD related vasculopathy.
Methods: Apolipoprotein E knockout mice were uninephrectomized (UNx) and 
treated with pioglitazone, losartan, or both (UNx+Pio/Los) for 10 weeks. Extent and 
characteristics of atherosclerotic lesions and macrophage phenotypes were assessed. 
Peritoneal macrophages and RAW264.7 cells were used to examine pioglitazone and 
losartan effects on macrophage phenotype and inflammatory response.
Results: UNx significantly increased atherosclerosis. Pioglitazone and losartan each 
significantly reduced the atherosclerotic burden by 29.6% and 33.5%, respectively; however 
the benefit was dramatically augmented by combination treatment (55.7%). Assessment of 
plaques revealed significantly greater macrophage area in UNx+Pio/Los with more apoptotic 
cells. The expanded macrophage-rich lesions of UNx+Pio/Los had more alternatively 
activated, Ym-1 and arginine 1-positive M2 phenotypes. There was no difference in plaque 
collagen content or calcifications. In vitro, pioglitazone alone and together with losartan 
was more effective than losartan alone in dampening lipopolysaccharide-induced cytokine 
production, suppressing M1 phenotypic change while enhancing M2 phenotypic change.
Conclusions: Combination of pioglitazone and losartan is more effective in reducing 
renal injury-induced atherosclerosis than either treatment alone. This benefit reflects 
mitigation in macrophage cytokine production, enhanced apoptosis, and a shift toward an 
anti-inflammatory phenotype.
Funding: NIDDK Support
TH-PO408
Differential Activation of Monocyte and Neutrophil Genomics following 
Fistula Placement  Christopher S. Kuppler,1,2 Lyle L. Moldawer,2 Scott A. 
Berceli,1,2 The HFM Study Group.3  1Div of Vascular Surgery and Endovascular 
Therapy, Univ of Florida, Gainesville, FL; 2Dept of Surgery, Univ of Florida, 
Gainesville, FL; 3NIDDK, NIH.
Background: Systemic inflammation is as an important regulator of flow mediated 
vascular adaptation. We evaluated the genomic response of circulating leukocytes after 
fistula (AVF) placement, hypothesizing that this severe flow environment induces unique 
monocyte (mono) and neutrophil (PMN) expression patterns.
Methods: Blood samples were collected pre-op, 2 weeks, and 6 weeks following 
AVF creation (n=74). Mono and PMN mRNA was isolated and analyzed for 44,699 genes 
using the HTA 2.0 microarray. BRB ArrayTools and Ingenity Pathway Analysis was used 
to identify leukocyte genome changes, relevant ontologies, and upstream regulators.
Results: Compared to pre-op levels, 1,014 mono and 1,594 PMN genes were found to be 
differentially expressed 2 weeks after AVF placement (p<0.001), but returned to baseline by 
6 weeks post-op [91 (mono) and 1 (PMN); p<0.001]. Mono and PMN showed a divergent, 
inversely correlated expression pattern (A, p<0.001), with 892 genes upregulated in mono/
downregulated in PMN (Group 1) and 1189 genes upregulated in PMN/downregulated in 
mono (Group 2). Group 1 genes were mostly associated with intracellular translational 
control and cell survival; Group 2 genes were associated with the extrinsic stimulation of 
non-inflammatory systems (B). Upstream regulator analysis revealed enhanced interferon 
signaling in monocytes as the driver of these divergent expression patterns (C).
Conclusions: Following AVF creation and exposure to this new flow environment, there 
is a significant but divergent shift in the genomic profile of leukocytes. We hypothesize that 
this unique activation pattern has important implications in early AVF adaptation. Integration 
with the anatomic, physiologic and outcome data sets from the parent HFM study is ongoing. 
Funding: NIDDK Support
TH-PO409
Identification of Angiotensin Peptides Modulating the Harmful Effects of 
Ang II Inchronic Renal Failure  Joachim Jankowski, Vera Jankowski.  Inst 
of Molecular Cardiovascular Research, Univ Hospital RWTH, Aachen, NRW, 
Germany.
Background: Angiotensin II (Ang II) is essential in the physiology and pathology of 
vascular regulation. Ang II is the principal vasoactive substance of the renin-angiotensin 
system (RAS), having a variety of physiological actions. In the past few years, the classical 
concept of the RAS system has experienced substantial conceptual changes. Angiotensin 
peptides such as Ang 1-7, Ang III and Ang IV were identified as mediators involved in 
vascular regulation. Progress of mass-spectrometric techniques affords the opportunity 
for identification of unknown angiotensin peptides. When screening the molecular mass 
range of Ang II for novel peptides, we observed two signals which could represent further 
angiotensin peptides.
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Methods: In order to identify novel angiotensin peptides, we isolated these peptides 
from human plasma. Chromatographic purification and structural analysis by mass-
spectrometry revealed Ang II like octapeptides Pro-Glu-Val-Tyr-Ile-His-Pro-Phe and 
Ala-Arg-Val-Tyr-Ile-His-Pro-Phe,. We named these peptides Angioprotectin and Ala-
Angiotensin (Ala-Ang).
Results: Angioprotectin antagonises the contractile actions of Ang II. These 
physiological antagonism of vasoconstrictor actions of Ang II by Angioprotectin is 
mediated by theMas receptor. Angioprotectin has a stronger affinity to the Mas receptor 
than Ang-1-7. Plasma concentrations in healthy human volunteers were about 15 % and in 
CKD patients up to 50 % of plasma Ang II concentrations. Ang A has the same affinity to 
the AT1 receptor as Ang II, but a higher affinity to the AT2 receptor. Ang A revealed a less 
vasoconstrictive effect than Ang II in-vitro, which is not modified in the presence of the 
AT2 receptor antagonist PD 123319, suggesting a lower intrinsic activity at the AT1 receptor. 
In healthy subjects, Ang A concentrations are less than 20% of the Ang II concentrations, 
but the ratio Ang A / Ang II is higher in CKD.
Conclusions: In conclusion, Angioprotectin and Ang A are novel human, 
vasoconstrictive angiotensin-derived peptides. Due to stronger agonism at the MAS and 
AT2 receptor, respectively, and -furthermore- their increased plasma concentration in CKD. 
Ang A may modulate the harmful effects of Ang II.
TH-PO410
Phosphate (Pi)-Induced Endothelial Microparticles Express Histone H2B 
which Supports Thrombin Generation  Nima Abbasian,1 Karl Herbert,2 
James O. Burton,1,3 Nigel J. Brunskill,1,3 Alan Bevington.1  1Dept of Infection, 
Immunity, 	 Inflammation, Univ of Leicester, Leicester, United Kingdom; 2Dept 
of Cardiovascular Sciences, Univ of Leicester, Leicester, United Kingdom; 
3John :alls Renal Unit, Univ Hospitals of Leicester, Leicester, United Kingdom.
Background: Cardiovascular disease is common in patients with chronic kidney 
disease. Hyperphosphatemia is a well-known cardiovascular risk factor which we have 
recently shown can induce the formation of pro-coagulant endothelial microparticles (EMPs) 
through an elevation of intracellular Pi concentration, and that EMPs express VE-cadherin 
and superficial phosphatidylserine (PSer) on their surface; however, a comprehensive 
characterization of the antigenic composition of Pi-induced EMP has been poorly defined.
Methods: EAhy926 endothelial cells were treated with control 1mM vs. high 2.5mM 
Pi. EMPs were separated from the cultured medium by centrifugation. EMPs were subjected 
to ‘shotgun proteomics’ using LC MS/MS analysis. The presence of H2B in EMPs was 
probed by immunoblotting using anti-H2B antibody. The presence of DNA and RNA in 
EMPs was determined by Burton DNA Assay and using an Agilent RNA 6000 Pico Kit.
Results: MS analysis demonstrated that high Pi-induced EMPs contain nucleosome 
components (H2B, H2A, H2A.x, H3.2, and H4), enzymes, proteins involved in vesiculation 
& signalling, chaperones, and cytoskeleton associated proteins. Immunoblotting using 
anti-H2B antibody confirmed Pi-induced EMPs are enriched in H2B. DNA and RNA 
measurements showed EMPs contain both DNA and RNA.
Conclusions: These data for the first time show that Pi-induced EMPs are enriched 
in H2B, along with DNA, and RNA. H2B promotes activation of the contact pathway 
and inhibition of fibrinolysis and hence supports coagulation in vivo. In conclusion, Pi-
induced EMPs influence thrombosis through expressing PSer, inhibition of fibrinolysis 
and activation of the contact pathway by expressing H2B. Further studies are needed to 
confirm the exact mechanistic role of these molecules expressed on Pi-induced EMPs in 
the pathogenesis of thrombosis in vivo.
Funding: Private Foundation Support
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Identification of the “Vasoconstriction Inhibiting Factor” (VIF) – A Potent 
Endogenous Cofactor of Angiotensin II Acting on the AT2 Receptor 
Joachim Jankowski, Vera Jankowski.  Inst of Molecular Cardiovascular 
Research, Univ Hospital RWTH, Aachen.
Background: The renin-angiotensin-system and especially the angiotensin peptides 
play a central role in blood pressure regulation. Here, we hypothesize that a yet unknown 
peptide is involved in the action of Ang-II modulating the vasoregulatory effects as a 
cofactor.
Methods: The peptide with vasodilatory properties was isolated from adrenal glands 
chromatographically.The effects of this peptidewere evaluated in-vitro and, in-vivo and 
the receptor affinity was analysed.
Results: The plasma concentration in humans was quantified in chronic kidney disease 
patients, heart failure patients and healthy controls. The amino acid sequence of the peptide 
from bovine adrenal glands was HSSYEDELSEVLEKPNDQAEPKEVTEEVSSKDAAE, 
which is a degradation product of Chromogranin-A. The sequence of the peptide isolated 
from human plasma was HSGFEDELSEVLENQSSQAELKEAVEEPSSKDVME. Both 
peptides diminished significantly the vasoconstrictive effect of Ang-II in-vitro. Therefore, 
we named the peptide “vasoconstriction inhibiting factor” (VIF). The vasoregulatory effects 
of VIF are mediated by the AT2-receptor. VIF impairs Ang-II-induced phosphorylation of the 
p38MAPK-pathway but not of ERK1/2. The vasodilatory effects were confirmed in-vivo. 
The plasma concentration was significantly increased in renal and hear failure patients.
Conclusions: VIF is a vasoregulatory peptide which modulates the vasoconstrictive 
effects of Ang-II by acting on the AT2-receptor. It is likely that the increase in VIF may 
serve as a counter-regulatory effect to defend against hypertension. The identification of 
this target may help us to understand the pathophysiology of renal and heart failure and 
may form a basis for the development of new strategies for the prevention and treatment 
of cardiovascular disease.
TH-PO412
A Novel Microfluidic System for Studying Human Microvascular 
Integrity  Graham Marsh, Angela Huang, Jeremy Stuart Duffield.  Research 
& Development, Biogen, Cambridge, MA.
Background: The microvasculature of the kidney plays a critical role in kidney 
physiology, injury, and disease. Proper hemodynamic and biochemical signals are pivotal 
for sustaining normal functions in kidney microvasculature, which are greatly altered during 
kidney injury. Traditional 2D cultures in vitro fail to reconstruct the microenvironment 
of the kidney capillary network and cannot accurately examine the microvasculature in 
injury conditions. To bridge the gap between in vitro and in vivo models, we developed a 
novel platform to study kidney microvasculature by building a 3D capillary using a Nortis 
microfluidic system.
Methods: We seeded primary kidney endothelial cells from a human fetal donor into 
a 120 mm tube in a collagen matrix.  We then flowed media though the device with a 
controlled shear stress to mimic in vivo conditions.  The system allows for cells to be grown 
in co-culture by embedding supporting cells, such as pericytes, in the collagen matrix.  In 
this engineered microenvironment, we are able to deliver growth factors or stimulants in 
controlled doses to observe changes in microvessel function and morphology.  This platform 
has allowed us to visualize the microvessel with a high resolution by confocal microscopy, 
to observe cell-cell interactions, study the basement membrane composition, and measure 
vessel integrity.  We evaluated the barrier function of the capillary network by examining 
vascular leak under normal conditions and in an injury model with TNFα activation.
Conclusions: There was a significant increase in the permeability of the vessels when 
they are activated with TNFα compared to resting condition, and microvessels co-cultured 
with pericytes had significantly enhanced microvascular integrity and lowered vascular 
leak.  The microfluidic platform has enormous potential to study the human kidney 
microvasculature in vitro while maintaining the structure and morphology observed in vivo.
Funding: Pharmaceutical Company Support - Biogen
TH-PO413
The Circadian Clock Provides Beneficial Effects against the Endothelial 
Dysfunction to Promote Atherogenesis by Regulating Plasminogen Activator 
Inhibitor-1 and Cellular Adhesion Molecules Generation  Hideyuki Negoro. 
Medicine, Harvard Medical School, Boston.
Background: The circadian clock is a molecular mechanism that confers 24 hour 
variations in gene expression and function to regulate number of physiological functions in 
humans. Disruption of the clock is associated with pathological remodeling in the arterial 
structure and vascular stiffness. Chronic circadian clock disruption is also associated with 
dysfunction in endothelial signaling and responses. In this study, we observed if the deletion 
of Bmal1, a critical component of the circadian clock, can influence plasminogen activator 
inhibitor-1 (PAI-1) and cellular adhesion molecules, such as monocyte chemotactic protein-1 
(MCP-1) and intracellular adhesion molecule-1 (ICAM-1) which play an important part in 
the progression of vascular diseases.
Methods: Congenic 12- to 16-week-old male, wild-type and Bmal1-KO littermate 
mice were generated from heterozygote breedings to be used for these studies. We also 
knocked down Bmal1 to evaluate the protein levels of PAI-1, MCP-1 and ICAM-1 in the 
knocked down cells.
Results: Endothelial function was reduced in aorta from Bmal1-KO mice. In aorta 
from Bmal1 KO mice, there was an increase in MCP-1 and ICAM-1 expression in mice 
with a dysfunctional circadian rhythm. Moreover, Bmal1 KO mice display pre-mature 
aging to have a dramatic prothrombotic phenotype. This phenotype is linked to changes 
in the regulation of key risk factors for cardiovascular disease. These include circulating 
fibrinogen and PAI-1, which are significantly elevated in Bmal1KO mice.We confirmed 
that PAI-1 levels follow a circadian pattern and this pattern was absent in Bmal1 KOmice.
Conclusions: These findings indicate that circadian clock provides beneficial effects 
against the endothelial dysfunction to promote atherogenesis by regulating PAI-1and cellular 
adhesion molecules generation.This study establishes a mechanistic connection between 
Bmal1 and cardiovascular phenotype.
Funding: Other U.S. Government Support
TH-PO414
TNF-Alpha Receptor 1 Is Associated with Mortality in Persons with 
Coronary Artery Disease  Meyeon Park, Daniela Maristany, Eric Vittinghoff, 
Mary Whooley, Michael Shlipak.  UCSF.
Background: Inflammation is a possible mechanism to explain the association between 
atherosclerosis and mortality. Chronic kidney disease is associated with high levels of 
inflammation. This study evaluated circulating tumor necrosis factor receptor type 1 
(TNFR1A), a marker of inflammation, as a risk factor for mortality.
Methods: In the Heart and Soul Study, a cohort with established coronary artery disease 
(CAD), we measured TNFR1A from baseline serum samples and defined elevated levels 
of TNFR1A by the highest quartile (Q4, > 3.4 ng/ml). Our outcomes were myocardial 
infarction, heart failure hospitalizations (HF), and death. We evaluated the associations of 
high TNFR1A with outcomes using Poisson regression and adjusting for age, race, smoking, 
hypertension, diabetes, cholesterol, albuminuria, and baseline estimated glomerular 
filtration rate (eGFR).
Results: Among 981 participants who had TNFR1A measurements at baseline, median 
TNFR1A was 2.47 ng/ml (1.9-3.4). Median TNFR1A in individuals with eGFR < 60 was 
2.9 (3.8–5) and 1.7 (2.1-2.7) in those with eGFR > 60. Median follow-up time was 8.9 
years. Higher levels of TNFR1A (Q4 v. Q1-3) were associated with a higher risk of MI in 
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unadjusted analyses [incident rate ratio (IRR) 2.56 (95% CI 1.73-3.81). This was attenuated 
by adjustment [IRR 1.59 (0.92-2.72)]. TNFR1A was strongly associated with HF in both 
unadjusted and adjusted analyses [adjusted IRR 1.79 (1.12-2.86)] as well as with death 
[adjusted IRR 1.6 (1.22-2.1)].
Conclusions: Levels of TNFR1A are elevated in CKD.  TNFR1A is independently 
associated with HF and mortality.  These findings implicate inflammation as a potential 
contributor to the elevated mortality risk in persons with CAD.
Funding: NIDDK Support
TH-PO415
Blood Monocyte Profiles and P2X7 Receptor Expression in Chronic Kidney 
Disease and End-Stage Renal Disease  Serika D. Naicker, Susan Logue, 
Deirdre Cotter, Matthew D. Griffin.  REMEDI, School of Medicine, National 
Univ of Ireland, Galway, Ireland.
Background: Monocytes are innate immune cells with 3 subsets [Classical 
(CD14++CD16-), Intermediate (CD14++CD16+) and Non-classical (CD14+CD16++)] which 
have distinct pathogenic roles in chronic inflammation and atherosclerosis. We quantified 
blood monocyte subsets in a cohort of patients with CKD and ESRD/chronic hemodialysis 
(cHD) and evaluated their expression of the inflammasome-activating ATP receptor P2X7.
Methods: CKD stage 1-5 was assigned based on MDRD eGFR. PBMCs from healthy 
adults (CTRL, n=25), patients with CKD stages 1-5 (n=100) or ESRD prior to and after 
HD (n=32) were analyzed by 8-colour flow cytometry to quantify monocyte subsets and 
their surface expression of P2X7 receptor. PBMC stimulation cultures were carried out 
using optimized concentrations of TLR ligands ± ATP.
Results: Total monocyte numbers progressively increased from CTRL through CKD 
stage 1-5 and ESRD/cHD. Among the subsets, Intermediate monocytes were most highly 
expanded in CKD in a stage-dependent manner. ESRD patients additionally demonstrated 
higher numbers of non-classical monocytes which diminished significantly following 
HD. Surface expression of P2X7 was readily detected on all monocyte subsets in CTRL, 
CKD Stages 1-5 and ESRD but was most highly expressed by Non-classical monocytes. 
Compared to CTRL, all stages of CKD were associated with higher monocyte expression 
of P2X7 but, in ESRD, this was further increased on Non-classical monocytes following 
HD. High-level interleukin (IL)-1-beta release by monocytes from CRTL and CKD/
ESRD patients was observed upon brief exposure to the P2X7 ligand ATP following 
priming with ligands for TLR4 (highly expressed by Classical monocytes) or TLR7/8 
(highly expressed by Non-classical monocytes) indicating active inflammasome response 
in multiple monocyte subsets.
Conclusions: CKD is associated with a stage-dependent increase in circulating 
monocytes that is greatest for the Intermediate subset. Non-classical monocytes are 
also expanded in ESRD and modulated by HD. The P2X7 receptor, which mediates 
inflammasome activation via extracellular ATP, is expressed by all monocyte subsets in 
CKD/ESRD but most highly by Non-classicals.
Funding: Government Support - Non-U.S.
TH-PO416
Activation of CXCL16/CXCR6 Pathway by Inflammation Accelerates the 
Progression of Atherosclerosis in ESRD Patients  Zebo Hu,1 Kun ling Ma,1 
Yang Zhang,1 Wu Yu,1 Bi-Cheng Liu.1  1Inst of Nephrology, Southeast Univ, 
Nanjing City, Jiang Su Province, China; 2Inst of Nephrology, Southeast Univ, 
Nanjing City, Jiang Su Province, China.
Background: Objective Chronic inflammation plays a crucial role in the progression 
of atherosclerosis (AS). The current study aimed to observe the effects of inflammation on 
lipid accumulation in the radial arteries of end-stage renal disease (ESRD) patients with 
arteriovenostomy and further investigate whether inflammation accelerates the progression 
of AS via the dysregulation of the CXCL16(CXC chemokine ligand 16, CXCL16)/
CXCR6(CXC chemokine receptor 6,CXCR6) pathway.
Methods: Fourty-seven ESRD patients were divided into control group (n=20) and 
inflamed group (n=27) according to plasma C-reactive protein (CRP) level. Biochemical 
index and lipid profile of patients were measured. Surgically removed tissues from the 
radial arteries of patients receiving arteriovenostomy were used in the experiments for 
preliminary evaluation of AS. Foam cell formation was observed by Hematoxylin-eosin 
(HE) and Filipin staining. CXCL16/CXCR6 pathway related protein expressions and the 
expressions of monocyte chmotactic protein 1 (MCP-1), tumor necrosis factor α (TNFα), and 
CD68 were detected by immunohistochemistry staining and immunofiuorescence staining.
Results: Immunohistochemical staining demonstrated that inflammation increased both 
protein expressions of MCP-1 and TNF-α in radial arteries of inflamed group accompanied 
with macrophage infiltration. Further analysis showed that there were significantly increased 
foam cell formation in continuous cross-sections of radial arteries of inflamed group 
compared to the controls, which were closely correlated with increased protein expressions 
of CXCL16, CXCR6, and decreased protein expression of ADAM10.
Conclusions: Inflammation contributed to foam cell formation in the radial arteries 
of ESRD patients via the activation of the CXCL16/CXCR6 pathway.
TH-PO417
Ablation of Pericytes Induces Capillary Rarefaction and Proximal Tubular 
Injury  Janewit Wongboonsin, Rafael Kramann, Susanne V. Fleig, Flavia 
G. Machado, Benjamin D. Humphreys.  Renal Div, Brigham and Women´s 
Hospital, Boston.
Background: We recently showed that Gli1+ cells in the pericyte niche are the 
predominant source of myofibroblasts in kidney fibrosis. One hypothesis for the mechanism 
of capillary rarefaction observed in fibrotic kidney disease is that injury induces pericyte 
detachment from endothelium, leading to capillary dropout and hypoxia. There is no direct 
evidence supporting this idea, however. In this study we measured pericyte detachment 
during injury, and asked whether ablation of pericytes in the absence of any other injury 
destabilizes capillaries and induces tubular injury.
Methods: We performed unilateral ischemia reperfusion injury (IRI) in bigenic 
Gli1CreER;tdTomato mice and performed fluorescence microangiography (FMA) at 2 
weeks after injury to delineate the renal microvasculature and quantify detachment of Gli1+ 
cells from capillaries. In a second set of experiments we ablated Gli1+ in Gli1CreER, iDTR 
mice by diphtheria toxin injection, performed FMA and analyzed peritubular capillary 
changes by automated software-based quantification over a time course of 56 days.
Results: After IRI, Gli1+ cells proliferate and detach from the renal microvasculature. 
Specific genetic ablation of Gli1+ cells triggers peritubular capillary rarefaction and induces 
mild focal cortical tubular injury. While peritubular capillary number decreased, peritubular 
capillary perimeter and area remain unchanged. Injured tubules were characterized by focal 
Kim1+ expression in cortical areas with decreased FMA+ perfused capillaries. Renal Kim1 
and Hif1a mRNA expression increased early after Gli1+ cell ablation. Interestingly, while 
aSMA and Collagen1a1 mRNA expression decreased early after ablation, confirming the 
role of Gli1+ cells as myofibroblasts progenitors, we detected increased expression of both 
fibrotic readouts at 56 days after ablation. Immunostaining for aSMA showed focal cortical 
areas with myofibroblast expansion and scar formation.
Conclusions: Ablation of Gli1+ pericytes in healthy kidney causes peritubular capillary 
rarefaction, focal tubular epithelial injury and focal fibrosis in the outer cortex most likely 
due to hypoxia.
Funding: NIDDK Support
TH-PO418
Activation of Tie2 by Deletion of VE-PTP Increases GFR in Mice 
Isabel Anna Carota,1,2 Chengjin Li,3 Vera Eremina,3 Tuncer Onay,1 Susan E. 
Quaggin.1  1Div. of Nephrology/Hypertension and Feinberg Cardiovascular 
Research Inst, Northwestern Univ, Chicago; 2(li Lilly and Company; 3Samuel 
Lunenfeld Research Inst, Mount Sinai Hospital, Toronto, Canada.
Background: With an increasing number of patients suffering from CKD, there is 
an urgent need for new therapeutic targets. The Angiopoietin-Tie2 signaling pathway has 
been implicated in the development of kidney disease. In CKD patients elevated levels of 
circulating Angpt-2, the antagonist of the tyrosine kinase receptor Tie2, correlate with a 
decrease in glomerular filtration rate (GFR). Additionally it has been shown that loss of 
Angpt-1, the Tie2 agonist, leads to enhanced glomerular scarring in diabetic Angpt-1 KO 
mice. These findings suggest that an imbalance of Tie2 ligands is associated with progression 
of renal disease. Here we investigate the impact of Tie2 activation on baseline renal function 
by genetic deletion of its negative regulator the endothelial specific phosphataseVE-PTP 
in an inducible KO mouse model.
Methods: To study the effect of Tie2 activation following loss of VE-PTP, we generated 
inducible VE-PTP KO mice. Kidneys were examined histologically and phosphorylation 
level of Tie2 was quantified by IP from lung lysates followed by Western blot analysis. GFRs 
were measured using the FITC-Sinistrin clearance method (n=7 KO, 6 contr. at 10 weeks).
Results: Knock-out of VE-PTP enhances Tie2 phosphorylation 2-fold resulting 
in enhanced Tie2 activity in a ligand-independent manner. Deletion of VE-PTP before 
embryonic day 13.5 leads to the formation of dilated glomerular capillaries, which are not 
observed in kidneys of mice when VE-PTP is deleted after E18.5. In contrast, mGFRs of 
VE-PTP iKO mice (deletion after E18.5) were increased from 298.6±28.0 in controls to 
458.1±27.9 ml/min in KO litter mates (p=0.016). Both groups showed no difference in 
blood pressure, albuminuria or renal histology.
Conclusions: Inhibition of VE-PTP leads to elevated Tie2 phosphorylation suggesting 
VE-PTP as a potential target to rescue the effects of increased Angpt-2 levels that occur in 
CKD patients. The increased GFR observed in VE-PTP iKO mice suggest that disrupting 
VE-PTP–Tie2 interactions may be a strategy to slow progression of CKD.
Funding: Other NIH Support - RC1HL124120, Pharmaceutical Company Support - 
Eli Lilly and Company
TH-PO419
Circulating VEGF-C Levels Are Associated with Insulin Sensitivity in End 
Stage Renal Disease Patients  Serpil Muge Deger,1,2 Adriana Hung,1,2 Edward D. 
Siew,1,2 Feng Sha,1 Charles D. Ellis,1 Jens Titze,1 Talat Alp Ikizler.1,2  1Vanderbilt 
Univ, Nashville, TN; 2VA, Nashville, TN.
Background: Insulin resistance (IR) is a common metabolic derangement in advanced 
kidney disease. We have previously demonstrated that inflammation is a key mediator of 
IR in end-stage renal disease (ESRD). Vascular Endothelial Growth Factor C (VEGF-C) 
is a key regulator of lymphangiogenesis that may contribute to IR. Recent experimental 
data suggest that the VEGF-C pathway may have important effects on adipose tissue IR by 
promoting macrophage recruitment. The relationship between VEGF-C and IR in humans 
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not been well characterized. We aimed to examine the relation between circulating VEGF-C 
and insulin sensitivity by the gold standard hyperinsulinemic euglycemic clamp (HEGC) 
in patients on chronic dialysis.
Methods: Fourteen HD and 10 PD patients who participated HEGC were included in 
this analysis. Serum VEGF-C values were measured by ELISA.
Results: Characteristics of study population are summarized in (table 1). 
HD PD p
Age (years) 55(38, 60) 48(35, 55) 0.21
Gender(M,%) 93 50 0.03
Race(AA, %) 79 60 0.29
BMI(kg/m2) 29(26, 33) 30(26, 35) 0.75
Diabetes(%) 21 10 0.43
GDR by HEGC(mg/kg/min) 5.4(3.5, 6.2) 6.4(6, 8.1) 0.07
hs-CRP(mg/L) 4.8(2.5, 11.3B 2.5(1.5, 14) 0.37
Median serum VEGF-C levels were 350 (270, 638) pg/mL in PD and 230 (184, 270) pg/
mL in HD patients (p=0.029). The median glucose disposal rate (GDR) derived by HEGC 
tend to lower in HD compared to PD patients. There was a significant positive correlation 
between serum VEGF-C and GDR by HEGC (r=0.495, p=0.016).
The association remained significant after adjusted by age, gender, and hs-CRP 
(p=0.026).
Conclusions: Our data suggest that the lymphangiogenic growth factor VEGF-C may 
be an important contributor to IR in the chronic uremia and a potential therapeutic target. 
Further studies are needed to delineate this relation.
Funding: Veterans Administration Support, Private Foundation Support
TH-PO420
Disruption of Angiopoietin-Tie2 Signaling Leads to Cystic Kidney Disease 
Yael Kenig-Kozlovsky,1 Rizaldy P. Scott,1,2 Benjamin R. Thomson,1,2 Shinji 
Yamaguchi,1 Christine Jiang Wu,1 Stefan Heinen,2 Susan E. Quaggin.1,2  1Div 
of Nephrology-Hypertension and Feinberg Cardiovascular Research Inst, 
NorthZestern Univ, Chicago, IL; 2Lunenfeld-Tanenbaum Research Inst, Toronto, 
Canada.
Background: Angiopoietin ligands Angpt1 and Angpt2 and their cognate receptor 
Tie2/Tek are essential for development of the heart and systemic blood vasculature. While 
investigating their function in the shaping of the complex renal vasculature, we uncovered 
that mid-gestational inactivation of the Angpt1/Angpt2-Tie2 signaling axis remarkably 
causes cystic kidney disease.
Methods: Using a tetracycline-inducible gene targeting approach we deleted both 
Angpt1 and Angpt2 or Tie2 at embryonic stage E16.5 in the mouse.
Results: Compound deletion of Angpt1 and Angpt2, or loss of Tie2 led to kidney 
cyst formation detectable as early as 2 weeks after birth. By 8 weeks of age, enlarged 
cysts had severely distorted the renal architecture and glomerular filtration rate dropped 
by ~40%. Surprisingly, mutants did not manifest proteinuria, urine concentrating defects 
or blood pressure differences relative to control littermates. Cyst formation was predated 
by a distinctive pattern of renal vascular rarefaction, most notably at the corticomedullary 
junction. Cysts were lined by flattened mesenchymal-like cells, which expressed vimentin 
and a-smooth muscle actin but not classic markers for tubular epithelium, blood or 
lymphatic endothelium.
Conclusions: Recently, we reported that inactivation of angiopoietin-Tie2 signaling 
impairs the development of lymphatic vasculature and specialized “hybrid” vessels 
(exhibiting features of both blood and lymphatic vessels) of the eyes resulting in abnormal 
drainage of aqueous humor, ocular hypertension and glaucoma. Based on these findings, 
including the renal vascular rarefaction in the absence of Angpt1/Angpt2-Tie2 signaling, 
we hypothesize that renal cystogenesis may be attributed, in part, to defective vascular 
and/or lymphatic drainage of interstitial fluid in the kidney. Our study highlights a hitherto 
unidentified role of angiopoietin-Tie2 signaling in the pathogenesis of renal cysts and 
suggests this pathway as a potential therapeutic target to alleviate cystic kidney disease.
Funding: Other NIH Support - Grant R01HL124120
TH-PO421
Role of Macrophage in Hyaluronic Acid-Induced Lymphangiogenesis in 
UUO Model  Won Kim, Jong-Hwan Jung, Yujin Jung, Kyung Pyo Kang, Sik 
Lee, Sung Kwang Park.  Chonbuk National Univ Medical School.
Background: Hyaluronic acid (HA) is one of important component of extracellular 
matrix proteoglycan, has many biologic and pathologic effects such as inflammation, 
angiogenensis, wound healing and tissue remodeling. Renal lymphangiogenesis has been 
demonstrated in a rat remnant kidney model and in mouse unilateral ureteral obstruction 
(UUO) model. However, there is few data about role of macrophage in HA-induced 
lymphangiogenesis in UUO. We investigated the effect of macrophage in HA-induced 
lymphangiogenesis in UUO.
Methods: RAW 264.7 cells (RAW cell, macrophage cell line) were incubated with 
TFG b1 and HA production was evaluated by ELISA. LYVE-1-positive lymphatics, HA, 
vascular endothelial growth factor (VEGF)-C were evaluated by immunofluorescence and 
ELISA in UUO-induced fibrotic kidney treatment with or without clodronate (macrophage 
depleting agent).
Results: To evaluate the changes in HA expression in macrophages, RAW cell 
were treated with TGF-b1. We found that TGF-beta1 (1, 5, and 10 ng/mL) increased 
hyaluronic acid synthase (HAS)1, HAS2 and HAS3 mRNA expression in the cells. ELISA 
data demonstrated that treatment of RAW cells with TGF-b1 (10 ng/mL) increased HA 
production in a time-dependent manner. In UUO model, renal HA level was higher in ureteral 
obstruction operated kidney than that of sham-operated kidney. Our immunofluorescence 
finding showed that HA is expressed on interstitial space in UUO kidney. HA accumulation is 
correlated with the number of LYVE-1-positive lymphatic vessels after ureteral obstruction. 
HA expression was also costained with F4/80-positive renal macrophages 7 days after 
ureteral obstruction. Depletion of macrophage with clodronate significantly decreased 
UUO-induced renal HA expression and UUO-induced increased density of LYVE-1-
positive lymphatic endothelial cells. We also found that VEGF-C expression in the kidney 
was significantly decreased in UUO kidney after treatment with clodronate compared to 
that after treatment with control buffer.
Conclusions: These results suggest that macrophage has a partial role in HA production 
and HA-induced renal lymphangiogenesis in UUO model.
TH-PO422
Nfat5/TonEBP Deficiency in B Cells Results in Reduced Antibody 
Formation, Hypoplastic Cutaneous Lymph Capillary Formation, and 
Salt-Sensitive Hypertension  Jens Titze,1,2 Ljiljana Rokvic,1 Patrick Neubert,1 
Kento Kitada,2 Wolfgang Schuh,3 Hans-Martin Jack,3 Friedrich C. Luft.2,4 
1Interdisciplinary Center for Clinical Research, UC Erlangen; 2Dept of Cin. 
Pharm., Vanderbilt Univ; 3Div. of Mol. Immun., UC Erlangen; 4MDC, Charite 
Berlin.
Background: Interstitial Na+ storage induces pro-inflammatory responses in 
macrophages (Mࢥ), which are mediated by the osmoprotective transcription factor Nfat5 
to promote host defense. However, Mࢥ also reduce salt concentration in the subcutaneous 
barrier by Nfat5/VEGF-C driven lymphatic clearance of electrolytes, protecting the 
organism from excess interstitial Na+ storage and hypertension. The role of Nfat5 in B 
cells is unknown. We hypothesized that Nfat5 in B cells boosts pro-inflammatory and 
homeostatic immune responses.
Methods: We fed 6 control (mb1wtNfat5flox/flox) and 5 mb1creNfat5flox/flox (genetic deletion 
of Nfat5 in B cells) mice a high-salt diet (4% NaCl chow/ 0.9% saline; HSD) for 8 weeks 
and studied their ability to produce antibody after vaccination with trinitrophenyl conjugated 
to keyhole limpet hemocyanin (TNP-KLH; 100µg i.p.), followed by a boost injection (50 
µg) after 6 weeks. We also studied the size of cutaneous lymph capillaries and mean arterial 
blood pressure (MAP) in these mice fed a HSD.
Results: On HSD, mb1creNfat5flox/flox mice showed a >30% reduction in total IgM / IgG 
(p<0.05), and TNP-KLH-specific IgM / IgG (p<0.05) antibody production versus control, 
indicating reduced pro-inflammatory immune function. Additionally, these mice showed 
reduced lymph capillary diameters (40±9µm vs. 25±8µm, p<0.05), accompanied with 
increased MAP (117±8mmHg vs. 129±8mmHg, p<0.05), indicating reduced homeostatic 
immune function.
Conclusions: Nfat5 in B cells is important for specific antibody formation, suggesting 
that Na+ storage and B cell osmoprotection is relevant for the T cell/Dendritic Cell (DC)-
mediated adoptive immune response in secondary lymphatic organs. We currently study 
Mࢥ, DC, or T-cell driven modulation of the cutaneous lymph capillary network to better 
understand hypoplastic cutaneous lymph vessel formation, extrarenal lymphatic electrolyte 
clearance, and the salt-sensitive hypertension in mb1cre Nfat5flox/flox mice.
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TH-PO423
Novel Mechanisms for Salt Sensitive Hypertension in Humans: 
Effects of Salt Loading on Skin Sodium, VEGF-C and Blood Pressure 
Viknesh Selvarajah,1 Kaisa Maki-Petaja,1 Liliana Domingues Pedro,2 Sylvaine 
Fa Bruggraber,2 Carmel M. McEniery,1 Ian Wilkinson.1  1Div of Experimental 
Medicine and Immunotherapeutics, Univ of Cambridge, Cambridge, United 
Kingdom; 2MRC Human Nutrition Research Unit, Fulbourn, Cambridge, 
United Kingdom.
Background: Dietary sodium is an important trigger for hypertension. Animal 
studies show that the skin buffers dietary salt and salt-loading induces lymphangiogenesis 
mediated by VEGF C from macrophages, helping to maintain BP in response to salt load. 
The relevance of these mechanisms in humans is unclear.
Methods: We conducted a double-blind randomised crossover trial examining the 
effects of dietary salt loading on skin sodium, systemic haemodynamics, ambulatory BP 
and plasma VEGF-C in 48 healthy participants. Participants were placed on a low salt 
diet (70mmol sodium/day). Dietary compliance was checked using 24hr urine collections. 
Skin biopsies were taken after placebo and slow-sodium treatment (200mmol daily for 
7 days). Skin Na and K concentrations (mg/g tissue) were analysed by ICPOES.Results 
were expressed as the ratio of Na:K to correct for variability in sample hydration. Plasma 
VEGF C was analysed by ELISA.
Results: Skin data was available for 47 individuals. Mean age was 29.9 ± 8.3 with mean 
baseline urinary sodium 98.8 ± 55.0 mmol/24 hours. 24hr urine sodium excretion increased 
from 71.4 ± 43.1 to 225.9 ± 89.0 mmol (p< 0.001) with salt loading. Ambulatory MAP 
showed a non-significant increase from 88 ± 7.0 to 89 ± 7 mmHg (p=0.10). Office MAP 
was unchanged. Skin Na:K increased from 2.91 ± 0.56 to 3.12 ± 0.62 (p=0.01). Percentage 
change in Na:K was negatively correlated with baseline Na:K (r=-0.40, p=0.007). Changes 
in ambulatory MAP correlated positively with baseline skin Na:K (r=0.30, p=0.048). Stroke 
volume correlated with skin Na:K post placebo (r =-0.42,p=0.002) and slow sodium (r 
= -0.53, p<0.0001) respectively. No significant change was noted in plasma VEGF C.
Conclusions: Skin sodium appears to increases with dietary salt loading and the degree 
of change correlates with baseline Na:K levels. Ambulatory blood pressure change with 
dietary salt loading correlates with baseline skin Na:K, supporting a possible role for for 
the skin as a buffer for dietary sodium.
TH-PO424
Albuminuria Downregulates NKCC2 via Stimulation of COX-2/mPGES-1/
PGE2 Cascade in Thick Ascending Limb  Zhanjun Jia,1,2 Yibo Zhuang,1 Guixia 
Ding,1 Yue Zhang,1 Songming Huang,1 Aihua Zhang.1,2  1Nephrology Dept, 
Nanjing Children Hospital, Nanjing Medical Univ, Nanjing, China; 2Nanjing 
Key Laboratory of  Pediatrics.
Background: Impaired response to loop diuretics is a common phenomenon in 
nephrotic syndrome patients. However, the pathogenic mechanisms remain elusive. Here 
we hypothesized that albuminuria itself may act as a key intrarenal factor leading to the 
dysregulation and dysfunction of NKCC2, as well as the subsequent resistance to loop 
diuretics.
Methods: C57BL/6 mice were subjected to albumin overload via i.p injection for 
12 days. The mouse kidney tissues and renal biopsy specimens from proteinuric patients 
were analyzed.
Results: After albumin overload, we found an 80% downregulation of Na-
K-Cl cotransporter (NKCC2) as determined by Western blotting, qRT-PCR and 
immunohistochemistry (IHC). Meanwhile, the COX-2 and mPGES-1 were strikingly 
elevated by 2.1 and 3.5 folds, respectively, as determined via Western blotting and qRT-
PCR. By IHC, stimulation of COX-2 and mPGES-1 were localized in the thick ascending 
limb (TAL, NKCC2 positive tubules). Accordingly, the urinary PGE2 excretion was 
significantly enhanced by 82% following albumin overload. Interestingly, inhibition of 
COX-2 via a specific COX-2 inhibitor Celebrex in albumin overloaded mice entirely 
reversed NKCC2 downregulation in line with normalized urinary PGE2 output. In 
addition, mice with albumin overload exhibited a remarkable resistance to loop diuretic 
furosemide (NKCC2 inhibitor), which was completely reversed by COX-2 inhibition. Next, 
we examined NKCC2 expression in kidney biopsy specimens of proteinuric patients via 
IHC and found a 50% downregulation of NKCC2 which was negatively correlated with 
proteinuria severity. Meanwhile, mPGES-1 was strikingly elevated in TAL in parallel with 
a remarkable increment of urinary PGE2, and both mPGES-1 and urinary PGE2 showed 
a positive correlation with proteinuria severity.
Conclusions: These novel findings highly suggest that albuminuria plays an important 
role in mediating the downregulation and dysfunction of NKCC2 via a stimulation of 
COX-2/mPGES-1/PGE2 cascade in TAL, which could contribute to the impaired response 
to loop diuretic in proteinuric kidney disease.
Funding: Government Support - Non-U.S.
TH-PO425
The Physiological Roles of Moesin, a Cytoskeletal-Associated Protein, in 
Renal Salt Reabsorption  Kotoku Kawaguchi, Ryo Hatano, Shinji Asano. 
Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan Univ, 
Kusatsu, Shiga, Japan.
Background: Tubular reabsorption of electrolytes in the kidney is an essential function 
in regulating fluid balance in the body. In the thick ascending limb of the loop of Henle 
(TAL), 20-40% Na+ filtered by the glomeruli are reabsorbed by Na+-K+-2Cl- cotransporter 
type 2 (NKCC2). In humans, mutations in the gene coding for NKCC2 were identified in 
patients of Bartter syndrome type I, which is characterized by severe salt losing tubulopathy. 
Despite of the physiological importance of NKCC2 in NaCl homeostasis, the molecular 
mechanisms for its membrane trafficking have not been fully elucidated. In 2012, Carmosino 
et al. (Biol. Cell. 104(11): 658-676) reported that moesin, which is a member of ERM 
(Ezrin-Radixin-Moesin) family, plays an important role in the apical membrane trafficking 
of NKCC2 by in vitro experiments.
Methods: We examined the physiological impact of Moesin in the regulation of renal 
function in vivo by using male moesin-null (Msn-/y) mice. Wild-type (Msn+/y) and Msn-/y mice 
were kept in metabolic cages and daily urinary volume and urinary contents of electrolytes 
were measured. Western blotting and immunostaining were performed to investigate the 
expressions and localizations of proteins in the medullary tubules.
Results: Fractional excretions of Na+, K+ and Cl- were significantly increased in Msn-/y 
mice compared to Msn+/y mice. On the other hand, GFR and blood pressure were decreased 
in Msn-/y mice possibly due to body fluid loss. Immunoblotting for apical surface membrane 
proteins of medullary tubules did not show a significant difference in NKCC2 expression 
level between Msn+/y and Msn-/y mice whereas the distribution of NKCC2 in the lipid raft 
was decreased in Msn-/y mice.
Conclusions: Our results suggest that urinary loss of electrolytes in Msn-/y mice 
would be due to the disturbed localization of NKCC2 in the apical membrane domain. 
Since phosphorylated moesin, which represents an active form, is concentrated in lipid 
raft fractions in Msn+/y mice, moesin might play a pivotal role in the regulation of lipid 
raft localization of NKCC2 rather than the regulation of membrane trafficking of NKCC2 
in TAL.
TH-PO426
Paracellular Cation Selectivity in the Thick Ascending Limb of Henle’s 
Loop Increases Under the Control of Vasopressin  Nina Himmerkus,1 Allein 
Plain,1 Rita D. Marques,2 Jens G. Leipziger,2 Markus Bleich.1  1Inst of Physiology, 
Christian-Albrecht-Univ, Kiel, Kiel, Germany; 2Dept of Biomedicine, Physiology 
and Biophysics, Aarhus Univ, Aarhus, Denmark.
Background: The thick ascending limb of Henle’s loop (TAL) has the highest 
paracellular cation selectivity along the nephron. Trans- and paracellular pathways are 
strongly interdepended. The transepithelial voltage as driving force for the paracellular 
reabsorption of cations can be generated either by transcellular transport properties or by 
paracellular cation diffusion. Arginine vasopressin (AVP) has been shown to stimulate active 
transcellular NaCl transport and we hypothesize that paracellular permeability properties 
are co-regulated to support the increase in NaCl reabsorption.
Methods: To measure long term regulation 8-10 week old mice were kept for 4 days 
on low (antidiuresis, AD, 0.26ml/gBM/d) or high (water diuresis WD, 0.78ml/gBM/d) 
water intake. Spot urine osmolality was determined as treatment indicator. For acute 
AVP experiments mice were kept at water ad libitum. mTAL were isolated perfused and 
transcellular electrophysiological properties (transepithelial resistance Rte, voltage Vte, 
equivalent short circuit current I’sc) were assessed as well as paracellular properties (NaCl 
dilution potential, ion permeabilities PNa and PCl).
Results: mTAL of AD mice showed a higher active transcellular transport compared 
to the WD group tubules, represented by a two-fold increase in I’sc. Urine osmolality was 
positively correlated to I’sc. NaCl dilution potential was increased in the AD group, indicating 
a higher PNa/PCl, and a higher PNa compared to WD. PNa/PCl as a measure of paracellular 
cation selectivity was also positively correlated to urine osmolality. mTAL from untreated 
mice were stimulated acutely ex vivo for 12 minutes by basolateral application of 10 nM 
AVP, (n=6), in paired experiments. I’sc increased while it decreased in a time control group. 
At the same time, AVP induced an increase in PNa/PCl compared to time controls.
Conclusions: Acute application of AVP as well as water restriction increase paracellular 
cation selectivity and permeablility in mTAL in parallel to the increase of active transcellular 
NaCl transport.
TH-PO427
Adult Nephron-Specific MR-Deficient Mice Develop a Severe Renal 
Pseudohypoaldosteronism Type 1 Phenotype  Jérémie Canonica,1,2 Chloe 
Sergi,1 Marc P. Maillard,3 Petra Klusonova,4 Alex Odermatt,4 Bernard C. 
Rossier,1,2 Simona Frateschi,1,2 Edith Hummler.1,2  1Dept of Pharmacology 
and Toxicology, Univ of Lausanne, Lausanne, SZitzerland; 2National Center 
of Competence in Research Kidney. CH, Switzerland; 3Service of Nephrology 
Dept, Univ Hospital of Lausanne CHU9, Lausanne, SZitzerland; 4Dept of 
Pharmaceutical Sciences, Univ of Basel, Basel, Switzerland.
Background: Aldosterone is the main mineralocorticoid hormone controlling sodium 
balance, fluid homeostasis and blood pressure by regulating sodium reabsorption in the 
Aldosterone Sensitive Distal Nephron (ASDN). Germline loss-of-function mutations of the 
mineralocorticoid receptor (MR) in humans and in mice lead to the “renal” form of type 1 
pseudohypoaldosteronism (PHA-1), a case of aldosterone resistance characterized by salt 
wasting, dehydration, failure to thrive, hyperkalemia and metabolic acidosis.
Methods: To investigate the importance of MR in adult epithelial cells, we generated 
nephron-specific MR knockout mice (MRPax8/LC1) using a doxycycline inducible system.
Results: Under standard diet, MRPax8/LC1 mice exhibit inability to gain weight and 
significant weight loss compared to control mice. Interestingly, despite failure to thrive, 
MRPax8/LC1 mice survive but develop a severe PHA-1 phenotype with higher urinary Na+ 
levels, decreased plasma Na+, hyperkalemia and higher levels of plasma aldosterone. This 
phenotype further worsens and becomes lethal under a sodium-deficient diet. NCC protein 
expression and its phosphorylated form are downregulated in the MRPax8/LC1 knockouts, as 
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well as αENaC protein level, whereas the expression of glucocorticoid receptor (GR) is 
increased. A diet rich in Na+ and low in K+ does not restore plasma aldosterone to control 
levels, but is sufficient to restore body weight, plasma and urinary electrolytes.
Conclusions: In conclusion, MR expression along the nephron and in the collecting 
duct system during adulthood is crucial for Na+ and K+ homeostasis, and its deletion cannot 
be compensated neither by sodium transporters including ENaC, nor by GR overexpression, 
but solely by a high Na+ and low K+ rescue diet.
Funding: Government Support - Non-U.S.
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The Succinate Receptor 1 Is a Physiological Regulator of the Renin-
Angiotensin Aldosterone System  Peter M.T. Deen,1 Claudia Carmone,1 
Ana Carolina Ariza,1 Steef Kurstjens,1 Olivier Devuyst,2 Joris Hubertus 
Robben.1  1Physiology, Radboud Univ Medical Centre, Nijmegen, Netherlands; 
2Physiology, Univ of Zürich, Zürich, Switzerland.
Background: It has been shown that oxidative cell stress in diabetes type I (T1DM) 
induces tubular release of mitochondrial succinate and that subsequent activation of the 
SUCNR1 in the juxta-glomerular apparatus is needed for renin release and T1DM-induced 
hypertension. Here, we tested whether the SUCNR1 also has a physiological role in renal 
water and electrolyte handling.
Methods: Wild-type (wt) and SUCNR1-/- mice 10 weeks old were placed in metabolic 
cages and 24h clinical parameters were analyzed in order to assess physiologically relevant 
differences. After sacrifice, kidneys were weighed and collected for further analysis.
Results: Blood and urine analysis of wt and SUCNR1-/- mice showed that loss of 
SUCNR1 increased sodium and urea excretion, reduced renal renin and plasma angiotensin 
II (AngII) and aldosterone levels. Immunoblotting revealed a downregulation of the most 
crucial sodium transporters (NHE3, NCC and ENAC) in SUCNR1-/- mice. Fractional 
excretion of urea and water were increased in absence of the receptor, coinciding with 
reduced AQP2 abundance. With an unchanged overall morphology, wet, but not dry, weights 
of kidneys of SUCNR1-/- mice were significantly increased than of wild-type littermates.
Conclusions: Our data reveal that the SUCNR1 is essential for the physiological 
maintenance of renin and AngII levels, and proper proximal tubule and collecting duct 
sodium reabsorption. The increased wet kidney mass is likely due to tubular dilation due 
to increased tubular pressure because of life-long diuresis. Our data thus indicate that 
the mammalian SUCNR1 is a physiological regulator of water and volume homeostasis.
Funding: Government Support - Non-U.S.
TH-PO429
Adult Nephron-Specific Beta- and Gamma-ENaC Knockout Mice Develop 
a Severe Pseudohypoaldosteronism Type 1 (PHA1)  Emilie Boscardin,1 
Romain Perrier,2 Chloe Sergi,1 Bernard C. Rossier,1 Edith Hummler.1  1Dept of 
Pharmacology and Toxicology, Univ of Lausanne, Lausanne, SZitzerland; 2Inst 
of Chemistry and Biology of Membranes and Nano-Objects, Univ of Bordeaux, 
Pessac, France.
Background: The epithelium sodium channel (ENaC) consists of three subunits (alpha, 
beta and gamma ENaC) that are expressed at the apical side in tight epithelia in the kidney, 
and is limiting for sodium reabsorption. Mutations in ENaC subunits is causative for the 
human pseudohypoaldosteronism type 1 (PHA-1), a salt-losing syndrome. Since mice 
with ubiquitous and constitutive gene inactivation of beta- and gamma-ENaC die soon 
after birth, the consequences of a kidney-specific deletion of either beta- or gamma-ENaC 
cannot studied in adulthood. Therefore, we aimed to unveil the specific role of these ENaC 
subunits in the adult kidney using an inducible and kidney-specific CreloxP-mediated 
recombination system.
Methods: We used 4-weeks old doxycycline inducible nephron-specific beta- and 
gamma-ENaC knockout mice obtained by crossing the double transgenic mouse (PAX8/
LC1), which express the reverse tetracycline transactivator under the control of a tetracycline 
response element (Traykova-Brauch et al., 2008) with the floxed Scnn1b and Scnn1g mice, 
respectively (Mérillat et al, 2009).
Results: Already following 3-4 days of doxycycline treatment, beta- and gamma-ENaC 
KO mice develop a severe and lethal PHA-1, characterized by severe body weight loss, 
severe hyperkalemia (beta-ENaC KO: 11mM, n= 7, Ctl: 5 mM, n= 21, p<0.001; gamma-
ENaC KO: 11mM, n=6:, Ctl: 5mM; n=7, p<0.001), and dehydration. Beta-ENaC KO 
additionally suffer from severe hyponatremia, while the gamma-ENaC KO present with 
significant decreased plasma sodium concentration.
Conclusions: Our data demonstrate that the single beta- and gamma-ENaC subunits 
are crucial for daily maintaining sodium and potassium balance in adulthood.
Funding: Government Support - Non-U.S.
TH-PO430
New Mechanistic Insights into the Regulation of ENaC by AMPK in Kidney 
Epithelial Cells  Hui Li,1,2 Kenneth R. Hallows.1,2  1Medicine, Univ of Pittsburgh 
School of Medicine, Pittsburgh, PA; 2Medicine, Univ of Southern California 
Keck School of Medicine, Los Angeles, CA.
Background: Renal collecting duct epithelial Na+ channels (ENaCs) play a key role 
in total body volume and blood pressure control. The metabolic sensor AMP-activated 
protein kinase (AMPK) inhibits ENaC currents in kidney and other epithelial cells, but 
the mechanisms involved are unclear. We hypothesized that AMPK regulation of ENaC 
could occur via modulation of ENaC degradation, ENaC subunit cleavage status, and/or 
ENaC protein synthesis.
Methods: Mouse polarized kidney cortical collecting duct (mpkCCDc14) cells were 
cultured on Transwells for immunoblot analysis and equivalent short-circuit current (Isc) 
measurements of ENaC following AMPK activity modulation and proteasomal or lysosomal 
inhibitor treatments. Apical domain biotinylation assays were performed to measure changes 
in ENaC apical membrane expression, and cycloheximide chase assays were performed 
to investigate ENaC stability.
Results: AMPK activation decreased cellular ENaC stability in cycloheximide chase 
assays. ENaC-dependent Isc was inhibited by the AMPK activators AICAR and A769662 
(Abbott), and these effects were blocked by the proteasomal inhibitor MG132, but not by 
the lysosomal inhibitor leupeptin. Western blot analyses revealed that AMPK activation 
decreased both mature and immature b-ENaC expression as well as cleaved g-ENaC 
expression, while increasing uncleaved g-ENaC expression. Moreover, treatment of 
mpkCCDc14 cells with AMPK activators decreased pP70S6K expression, suggesting 
decreased signaling of the mTOR pathway involved in protein synthesis and cell 
proliferation. Finally, AMPK activation decreased apical cell surface expression of both 
mature b- and cleaved g-ENaC, the active forms of ENaC, an effect that was blocked by 
MG132.
Conclusions: AMPK-dependent regulation of ENaC in mpkCCDc14 cells occurs by: 
1) increased targeting of ENaC for proteasomal degradation, thereby decreasing cellular 
ENaC stability; 2) inhibition of g-ENaC cleavage and g-ENaC surface expression; and 3) 
inhibition of ENaC protein synthesis along with mTOR pathway inhibition.
Funding: NIDDK Support
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Sodium Retention in Nephrotic Syndrome Occurrs Independly of 
Proteinuria  Alexey Larionov,1 Geraldine Mollet,2 Corinne Antignac,3 Franziska 
Theilig.1  1Medicine, Anatomy, Fribourg, Switzerland; 2Inserm U1163, Paris, 
France; 3Inserm U983, Paris, France.
Background: Patients with nephrotic syndrome often present symptoms of volume 
retention, such as edema formation or hypertension. The primary dysregulation was localized 
to the renal cortical collecting duct and involves an inappropriate activation of the epithelial 
sodium channel, ENaC. Plasma proteases passing the leaky glomerular filter were made 
responsible; however, clinical observation demonstrated signs of volume retention before 
the initiation of proteinuria.
Methods: To elucidate the relationship between sodium retention and proteinuria 
tamoxifen-inducible podocinCre; Nphs2fl/fl were used and metabolic cage experiments for 
4 weeks were performed and functional renal parameters were determined. Additionally, 
morphological and biochemical analysis were performed on kidneys harvested 9 days or 
21 days after the beginning of the treatment. Results: Compared to Nphs2fl/fl, podocinCre; 
Nphs2fl/fl demonstrated reduced sodium excretion on day 7 (Na+/creatinine: 246±10 vs. 220±8 
µmol/mg) while proteinuria occurred on day 11 (protein/creatinine: 13±1 vs. 6.85±0.8 mg/
mg). Blood pressure started to increase on day 10 (BP: 120±12 vs. 74±10 mmHg) and 
remained high till the end of the experiment. In mice with nephrotic syndrome western 
blot analysis of kidneys harvested on the day 9 of the experiment demonstrated no change 
in the full length ENaC subunit abundance and a 3-fold increase in the 30 kDa αENaC 
cleavage product. Nephrotic kidneys at the day 21 of the experiment demonstrate strongly 
increased abundance of full length and cleaved forms of α- and γENaC.
Conclusions: Our experiments demonstrate the occurrence of a possibly endogenous 
protease responsible for cleaving αENaC which may lead to increased sodium retention 
and hypertension in the early phase of the nephrotic syndrome.
Funding: Government Support - Non-U.S.
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Altered Renal Electrolyte Handling in Mice with Genetic Knockout of the 
Insulin-Like-Growth Factor-1 Receptor (IGF1R) from the Collecting Duct 
Principal Cell  Carolyn M. Ecelbarger, Marcus J. Byrd, Patrice Dixon, Lijun 
Li.  Dept of Medicine, Georgetown Univ, Washington, DC.
Background: IGF1, produced predominantly in liver, can be increased in the circulation 
during metabolic syndrome (MetS) due to hyperinsulinemia. In addition to anabolic effects, 
IGF1 has been shown to activate the epithelial sodium channel (ENaC) in the renal collecting 
duct (CD); however, the role of the IGF1R in these effects is uncertain, since the insulin 
receptor can also bind IGF1.
Methods: To address the role of IGF1R in the CD, we produced CD-principal-
cell-select knockout (KO) mice, by crossing mice with Cre-recombinase driven by an 
aquaporin-2 promoter with mice with loxP sites flanking IGF1R gene. Adult KO mice were 
of normal body weight and had no overt alterations in kidney structure/function. To test 
the impact of IGF1 infusion on urinary electrolytes, anesthetized male WT and KO mice 
were infused via the jugular vein with either saline vehicle (V) or a 290 µM solution of 
IGF1 (I) in saline at a rate of 15 µl/min for 60 minutes (n = 5/genotype/treatment). Urine 
was collected via a cannulated bladder.
Results: Urine volume was reduced by IGF1 and the reduction was blunted in the 
KO (µl/60 min): 142 ± 41 (WTV), 45 ± 9 (WTI), 86 ± 9 (KOV), 73 ± 8 (KOI), p < 0.018 
for treatment. In WT, IGF1 infusion led to a significant 42, 65, and 67% reduction in the 
concentration of Na+, K+, and Cl-, respectively in urine. Total urine Na+ in the WTI was 
20% of WTV. In contrast, the excretion of electrolytes was relatively maintained in KO, i.e., 
IGF1 led to a 19, 21, and 17% reduction in Na+, K+, and Cl- concentrations, respectively, 
and means (KOV verus KOI) were not significantly different. The ratio of Na+ to K+ in 
the urine was also affected by genotype, i.e., increased by 76% in the WT, but reduced 
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by 9% in the KO (p = 0.023 for interaction). A benzamil test (ENaC antagonist, 1.4 mg/
kg·bw, i.p.) revealed 23, 34, and 27% (all significant) reduced total Na+, K+ and Cl- in 
KO versus WT in 4-hour urine.
Conclusions: These results support a role for IGF1 via the IGF1R to increase Na+ 
and Cl- reabsorption in the CD, through activation of ENaC. Thus, IGF1 may play a role 
in sodium retention associated with MetS.
Funding: NIDDK Support
TH-PO433
ENaC Activity in the Cortical Collecting Duct of HKa1 H,K-ATPase 
knockout Mice Is Uncoupled from Na Intake  James D. Stockand,1 Elena 
V. Mironova,1 Vladislav V. Bugay,1 I. Jeanette Lynch,2,3 Michelle L. Gumz,2,3 
Charles S. Wingo.2,3  1Univ of Texas HSC, San Antonio, TX; 2NF/SG VHS, 
Gainesville, FL; 3Univ of Florida, Gainesville, FL.
Background: The renal H,K-ATPases are integral membrane proteins of the collecting 
duct (CD), a segment that mediates Na reabsorption via the mineralocorticoid regulated 
epithelial Na channel, ENaC. ENaC activity is inversely related to dietary Na intake, a 
relationship essential to blood pressure (BP) regulation, and its dysfunction contributes 
to salt-sensitive hypertension. Mineralocorticoids stimulate the activity and expression 
of renal H,K-ATPases. We hypothesized that HKa1 H,K-ATPase knockout (KO) would 
affect ENaC activity.
Methods: Na reabsorption was measured by in vitro microperfusion in CCD from KO 
and control mice fed a 0.2% Na diet. Single channel analysis of ENaC activity in split open 
CCD by cell-attached patch clamp and measurements of urinary ATP were performed on 
KO and control mice fed a 0, 0.2, or 2.0% Na diet.
Results: Na reabsorption in the KO was significantly less than in controls and was not 
significantly inhibited by benzamil. ENaC activity in the KO is uncoupled from Na intake. 
When fed a 2.0% Na diet ENaC activity is higher in the KO vs. controls; and is lower on 
a 0% Na diet in KO vs. controls with no difference in activity in the KO on any of the Na 
diets. Preliminary results suggest that purinergic regulation of ENaC by a local signaling 
system is abnormal in the KO contributing to inappropriate channel responses to changes in 
dietary Na. KO mice have lower urinary ATP than controls and show no dietary Na-effect 
on ATP in contrast to controls where ATP is proportionally related to dietary Na intake. 
The defect in the KO is likely upstream of the inhibitory purinergic receptor since ENaC 
in the KO responds normally to exogenous ATP.
Conclusions: These results implicate the HKa1 H,K-ATPase in the maintenance of 
Na homeostasis. The lack of response to Na intake implies that renal Na excretion and 
BP in the KO are expected to be abnormal particularly at extremes in dietary Na intake. 
Dysfunctional regulation of ENaC and compromised purinergic signaling in the CD are 
predicted to contribute to the expected BP phenotype.
Funding: Veterans Administration Support
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High Cholesterol Diet (HCD) Impairs K Secretion in the Rabbit Cortical 
Collecting Duct (CCD)  Rolando Carrisoza-Gaytan, Daniel Flores, Lisa M. 
Satlin.  Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The apical BK channel in the CCD mediates flow-induced K secretion 
(FIKS). BK channels possess multiple cholesterol recognition/interaction motifs in the 
α subunit and, in non-renal cells, are inhibited by enhanced cholesterol content in the 
lipid membrane and hypercholesterolemia. Cholesterol determines membrane fluidity, 
and changes in membrane cholesterol are expected during postnatal development and in 
response to HCD. We speculated that HCD, via enhanced incorporation of cholesterol into 
the plasma membrane (PM), inhibits BK channel-mediated FIKS in the CCD.
Methods: NZW rabbits were randomized after weaning to receive either a standard 
or a cholesterol enriched diet (HCD; 0.3%) for 4-5 wks, at which time the animals were 
sacrificed. Kidneys were dissected for (i) isolation of renal cortical membranes for 
immunoblotting of BKα, ROMK and ENaCβ, and (ii) microperfusion of isolated CCDs 
to measure net Na absorption (JNa) and net K secretion (JK).
Results: Rabbits fed HCD (n=5) vs. control (n=4) showed lower plasma [Na+] 
(130.7+0.7 vs. 137.1+0.7 mM; P<0.001), no difference in plasma [K+], and greater 
serum cholesterol (30,491.6+253.6 vs. 1413.2+231.1 mg/mL; P<0.01). Immunoblotting 
demonstrated a greater abundance of ROMK and ENaC in total membranes and lower 
abundance of BK and ENaC in cortical PMs of HCD vs. control (n=2 in each group). In 5 
HCD CCDs, JNa increased from 14.4+7.9 to 32.3+10.0 pmol/min.mm (P<0.02) in response 
to an increase in flow rate from 1 to 5 nl/min.mm; this flow-stimulated increase in JNa 
was less than observed in historical controls (13.2+2.1 to 72.2+10.3; n= 13; P<0.01). In 
HCD CCDs, JK increased from -4.8+1.6 to -12.4+2.5 pmol/min.mm (P<0.05) in response 
to a 5-fold increase in flow rate; these transport rates are half those observed in historical 
controls (-10.4+2.2 to -22.7+5.6; n= 13; P<0.04).
Conclusions: Our results suggest that HCD blunts flow-stimulated but not basal JNa, 
and inhibits basal JK and FIKS, which may be due to a reduced abundance of ENaC and 
BK channels in the CCD. Whether enhanced incorporation of cholesterol into the PM of 
the CCD underlies these changes in transport is currently under investigation.
Funding: NIDDK Support
TH-PO435
Net K Secretion in Thick Ascending Limb of Mice on Low Na High K Diet 
Bangchen Wang, Donghai Wen, Ryan J. Cornelius, Yang Yuan, Huaqing Li, Jun 
Wang-France, Steven C. Sansom.  Cellular and Integrative Physiology, Univ 
of Nebraska Medical Center, Omaha, NE.
Background: It has been long understood that thick ascending limb (TAL) reabsorbs 
Na+, Cl- and K+, and high K diet inhibits NaCl reabsorption in TAL. In the present study, 
however, we found a persistent NaCl reabsorption and a net K secretion in TAL of mice 
on a low Na high K diet (LNaHK) that is dependent on β4 subunit of large Ca-activated K 
channels (BK). We hypothesized that K secretion in the TAL was the result of K recycling 
via BK-α/β4 from the medullary collecting ducts (MCD).
Methods: Wild-type (WT) and mice with a knock-out of BKβ4 (KO) were fed either 
a control or LNaHK diet for 7-10 days. They received intraperitoneal (IP) injections of 
vehicle (veh), furosemide (furo), amiloride (ami), or furosemide + amiloride (furoami) 
and were placed in metabolic cages for 12 hours to collect urine. Urine and plasma [Na] 
and [K] were measured with flame photometry. Micropuncture was used to measure [K] 
in the early distal tubule (EDT) of mice before and after IP injection of furo. Fluorescent 
immunohistochemistry (FIHC) and western blotting were used to determine BK-α and 
Na-K-Cl cotransporter (NKCC2) expressions.
Results: In WT on a control diet, K clearance was higher in furo-treated mice 
compared to veh due to increased distal flow. However, in WT on LNaHK, K clearance 
was significantly lower in furo-treated mice despite increased distal flow, and furoami 
decreased K clearance more than either drug alone. In KO on LNaHK, K clearance was not 
different between furo and veh groups. Micropuncture studies showed that furo decreased 
[K] in EDT of WT on control diet but increased [K] in EDT of WT on LNaHK. In WT 
on LNaHK, Na clearance was higher and urine osmolality lower in furo-treated mice 
compared to veh, indicating NKCC2 was still active. NKCC2 expression in medullary 
TAL was higher in WT on LNaHK compared to control diet. FIHC showed that BK-α was 
expressed in the apical membranes of MCD of WT on LNaHK, but not KO, which may 
mediate K recycling in MCD.
Conclusions: These results suggest that there is a furosemide-sensitive BKβ4-
dependent net K secretion in the thick ascending limb of mice on LNaHK diet.
Funding: NIDDK Support
TH-PO436
A Decrease in ENaC and ROMK Activity in the Late Distal Convoluted 
Tubule/Connecting Tubule May Contribute Hyperkalemia in PHAII 
Mutant WNK4 Knockin Mice  WenHui Wang.  Pharmacology, New York 
Medical College, Valhalla, NY.
Background: Pseudohypoaldosteronism type II (PHAII) is caused by mutations in 
with-no-lysine kinase 1 (WNK1) and WNK4. Mice harboring PHAII WNK4 mutant  by 
genomic manipulation (TgWNK4PhAII) developed typical PHAII phenotypes characterized 
by hypertension and hyperkalemia. While the hypertension is caused by an excessive Na 
absorption through NCC in the distal convoluted tubule (DCT), hyperkalemia has been 
attributed to a low Na delivery to the distal nephron. However, the role of ENaC and ROMK 
in causing hyperkalemia is not explored.
Methods: In the present study, we used the whole-cell patch-clamp technique to 
examine the ROMK and ENaC activity in the late DCT (DCT2) and early connecting 
tubule (CNT). The tubule was split open to exposure the apical membrane and was bathed 
in a solution containing 135 K-gluconate and 10 KCl. The pipette contains a symmetrical 
K solution.
Results: Western blot confirmed that NCC expression is upregulated in TgWNK4PHAII 
mice in comparison to the WT and TgWNK4WT mice. The whole cell recording detected 
amiloride-sensitive Na currents and TPNQ-sensitive K currents (ROMK) in DCT2/CNT. 
However, both Na currents (40 pA/per cell) and ROMK currents  (350 pA per cell) in DCT2/
CNT of TgWNK4PHAII mice were significantly smaller than those in WT  (Na currents, 260 
pA per cell; ROMK 1190 pA per cell) and TgWNK4WT mice (Na currents, 230 pA per cell; 
ROMK, 960 pA per cell). We also measured the whole cell K currents in the DCT1 which 
lacks apical ROMK and ENaC channels. In contrast to Na and ROMK currents in the 
DCT2/CNT, the basolateral K currents in the DCT1 were similar among WT, TgWNK4WT 
and TgWNK4PHAII mice. This suggests that the upregulation of NCC in TgWNK4PHAII mice 
did not stimulate the basolateral Kcnj10 channels.
Conclusions: We conclude that ENaC and ROMK channel activity are inhibited in 
TgWNK4PHAII mice and that WNK4PHAII-induced inhibition of ENaC and ROMK may 
contribute to the suppression of K secretion in the DCT2/CNT in addition to a reduction 
of Na delivery.
Funding: NIDDK Support
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Gilz Regulates Sodium and Potassium Balance During Dietary Sodium 
Restriction  Priyanka Rashmi, Michael Ng, David Pearce.  Univ of California 
San Francisco, San Francisco, CA.
Background: The hormonal regulation of ion transport by the kidney tubules is 
critical for regulating sodium and potassium balance in blood, extracellular fluid volume 
and blood pressure. The renin-angiotensin-aldosterone (RAAS) system is the primary 
regulator of Na+ reabsorption and K+ secretion. RAAS regulates multiple transporters 
implicated in electrolyte homeostasis such as Na+Cl- cotransporter (NCC) and epithelial 
sodium channel (ENaC). While both ENaC and NCC mediate Na+ reabsorption, they affect 
K+ differently:Electrogenic Na+ reabsorption via ENaC stimulates K+ excretion, while 
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electroneutral reabsorption of Na+via NCC inhibits K+secretion by competing with ENaC 
for Na+ reabsorption. Glucocorticoid induced leucine zipper protein (Gilz) is an aldosterone-
regulated gene product reported to cause changes in ion balance but the mechanism has 
not been explored. In this study we use the Gilz knock out (Gilz-/-) mouse generated in 
our laboratory to show that during sodium deprivation Gilz-/- mice come into sodium 
balance more quickly, than do wild type (WT) and become significantly hyperkalemic. 
These observations raised the possibility that loss of Gilz results in hyperactivation of an 
electroneutral Na+ transporter, which does not stimulate K+ secretion. Indeed, Gilz knock 
out mice are more sensitive to thiazide diuretics suggesting increased NCC activity. 
Consistently, expression of phosphorylated NCC (pT53/58) at the plasma membrane is also 
higher in the kidneys of Gilz knock out mice than in the WT mice maintained on a sodium 
deficient diet. In HEK293T cells, overexpression of Gilz isoform 1 (Gilz1) inhibits NCC 
activation in response to hypotonic low-Cl conditions as assessed by its phosphorylation at 
T53 and T58. Gilz mediated NCC inhibition is lost in the presence of constitutively active 
SPAK suggesting that it is at least in part mediated by WNK1/4-SPAK pathway. Indeed, 
co-expression of Gilz1 inhibits SAPK phosphorylation at S373. Together, our results suggest 
that during sodium restriction, Gilz1 shifts sodium reabsorption from NCC to ENaC, thus 
favoring K+ excretion. This effect may be critical for the maintenance of eukalemia in the 
face of Na+ restriction.
Funding: Other NIH Support - T32
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Pharmacological Inhibition of the Circadian Regulatory Casein Kinases 
1¨/İ Prevents Aldosterone-Mediated Induction of Na-Cl Cotransporter 
Activity  Michelle L. Gumz,1,2 Kristen Solocinski,1,2 Robert S. Hoover,3,4 
Benjamin S. Ko.5  1Medicine/Nephrology, Univ of Florida, Gainesville, FL; 
2Biochemistry and Molecular Biology, Univ of Florida, Gainesville, FL; 
3Medicine/Nephrology, Emory Univ, Atlanta, GA; 4Research Service, Atlanta 
9eteran¶s Administration Medical Center, Atlanta, GA; 5Medicine, Univ of 
Chicago, Chicago, IL.
Background: The circadian clock protein Per1 transcriptionally regulates the Na-Cl 
co-transporter NCC and members of the WNK kinase cascade. Per1 must be phosphorylated 
by casein kinase 1∆/İ (CK1∆/İ) in order to enter the nucleus. Previously, we showed that 
inhibition of CK1∆/İ decreased Per1 nuclear protein levels and decreased NCC activity 
under basal conditions in mouse distal convoluted tubule cells (mDCT15).
Methods: mDCT15 cells were treated with a CK1∆/İ inhibitor prior to either 
aldosterone (100 nM for 24 hr) or Angiotensin II (AngII) (10-11M for 30 or 120 min) 
treatment. NCC activity was determined by measuring thiazide-sensitive, Cl-dependent 
22Na uptake.
Results: NCC activity was significantly increased following either aldosterone or AngII 
treatment, consistent with previously published data. In the presence of the CK1∆/İ inhibitor, 
however, the aldosterone-dependent increase in NCC activity was prevented. In contrast, 
the AngII-dependent increase in NCC activity was not affected by CK1∆/İ treatment.
Conclusions: Inhibition of Per1 nuclear entry via pharmacological blockade of CK1∆/İ 
appears to prevent the aldosterone-mediated but not AngII-mediated induction of NCC 
activity. These results suggest an important role for the circadian clock proteins Per1 and 
CK1∆/İ in aldosterone-dependent regulation of NCC with possible implications for the 
treatment of hypertension.
Funding: NIDDK Support, Veterans Administration Support, Private Foundation 
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Disruption of 14-3-3 γ Binding to NCC Altered the Aldosterone-Mediated 
Regulation of NCC Protein Expression  Xiuyan Feng,1,2 Zhizhi Zhuang,1 
Courtney Marie Caroti,1,2 Hui Cai.1,2  1Medicine, Emory Univ School of Medicine, 
Atlanta, GA; 2Section of Nephrology, Atlanta Veterans Administration Medical 
Center, Decatur, GA.
Background: 14-3-3 γ belongs to a family of multifunction regulatory proteins that 
mainly bind to phosphorylated Ser/Thr residues in the target proteins. Previous data have 
shown that 14-3-3 proteins regulate renal ion channel and transporter such as ENaC and 
UT-A1 by altering their ubiquitinations. We have previously shown that aldosterone 
increases both total and surface expressions of sodium chloride co-transporter (NCC) via 
reducing NCC ubiquitination. Thus, we investigated whether 14-3-3 γ is involved in the 
aldosterone-mediated regulation of NCC.
Methods: Cell culture, transfection, western blot analysis, immunostaining, confocal 
microscopy, co-immunoprecipitation and C57/B6 mice were used for this study.
Results: Co-immumoprecipitaion (co-IP) in Cos-7 cells showed that 14-3-3 γ is the 
strongest one binding to NCC among all isoforms of 14-3-3. Immunostaining and confocal 
microscopy also showed that 14-3-3 γ is localized in distal convoluted tubule in mice. Co-IP 
experiments in Cos-7 cells showed that wild-type (WT) 14-3-3 γ binds to NCC, whereas 
14-3-3 γ K50E mutant almost completely loses its binding to NCC. Western blot analysis 
showed that WT 14-3-3 γ significantly decreased total NCC expression by 63 % compared 
to the control group, whereas 14-3-3 γ K50E mutant did not change NCC protein expression. 
WT 14-3-3 γ increased NCC ubiquitination by 1.5 fold (1.5 ± 0.44 vs 1.00), whereas 14-3-3 
γ K50E mutant did not alter NCC ubiquitination compared to the control group. In addition, 
we implanted aldosterone osmotic mini-pump to WT mice for 14 days and then harvested 
the kidney tissues. Western blot analysis showed that aldosterone treatment increased total 
NCC expression by 1.68 folds (1 ± 0.28 vs 1.68 ± 0.15) and decreased the ubiquitinated 
NCC by 56 %. Co-IP also showed aldosterone decreased the 14-3-3 γ binding to NCC by 
57 % without changing total 14-3-3 γ expression.
Conclusions: These results suggested that aldosterone up-regulates NCC expression 
by disruption of 14-3-3 γ binding to NCC that leads to decreasing NCC ubiquitination.
Funding: Veterans Administration Support, Private Foundation Support
TH-PO440
Calcineurin Inhibitors Upregulate the Thiazide-Sensitive NaCl 
Cotransporter in Urinary Exosomes of Kidney Transplant Patients 
Omar Tutakhel,1 Mathijs van de Vrie,1 Marco Valdez Flores,1 Ewout J. Hoorn,2 
Luuk Hilbrands,1 Joost Hoenderop,1 Renp J. Bindels.1  1Physiology and 
Nephrology, Radboud Univ Medical Center, Nijmegen; 2Div of Nephrology & 
Transplantation, Erasmus Medical Center, Rotterdam, Netherlands.
Background: Calcineurin inhibitors (CNIs), including cyclosporine A (CsA) and 
tacrolimus (Tac), are the cornerstone of immunosuppression and superior in preventing 
acute allograft rejection. This benefit, however, comes at the cost of common adverse 
effects including hypertension. Recently several studies have shown that CNI-induced 
hypertension is largely mediated by activation of the thiazide-sensitive NaCl cotransporter 
(NCC). The aim of the present study was to further substantiate the role of NCC in CNI-
induced hypertension by assessing the abundance and activity of NCC in urinary exosomes 
of CNI-treated patients.
Methods: Kidney transplant patients were enrolled 6 months after transplantation and 
treated with CsA (n=14), Tac (n=18) or a CNI-free immunosuppressive regimen (n=13). 
Six healthy subjects were also included. Urinary exosomes were isolated from 10 ml 
midstream urine samples by ultracentrifugation and normalized by urinary creatinine. The 
corresponding immunoblots were probed with antibodies specifically recognizing NCC 
and pNCC-T58. To confirm equal loading of the samples the abundance of the exosomal 
marker CD9 was determined.
Results: NCC was detected in urinary exosomes by immunoblots as two bands of ~260 
and ~130 kDa representing the dimeric and monomeric forms, respectively. Abundance of 
both NCC and pNCC-T58 in urinary exosomes of CsA and Tac groups was significantly 
increased in comparison to patients treated with a CNI-free immunosuppressive regimen 
and healthy subjects. Moreover, both the NCC and pNCC-T58 abundance was 2.5-fold 
higher in CsA group compared to Tac group. CD9 abundance in urinary exosomes was 
similar between the various groups.
Conclusions: The present study demonstrates that: i) total and phosphorylated NCC 
abundance is increased in urinary exosomes of CNI-treated kidney transplant patients; ii) 
urinary exosomes can be used as a novel biomarker to assess NCC abundance and activity 
in CNI-treated kidney transplant patients.
Funding: Government Support - Non-U.S.
TH-PO441
Generation of Hypertension-Associated STK39 Polymorphism Knock-
in Cell Lines with the CRISPR/Cas9 System  Shintaro Mandai, Takayasu 
Mori, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida.  Dept of Nephrology, 
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental 
Univ, Tokyo, Japan.
Background: Previous genome-wide association studies identified STK39, encoding 
STE20/SPS1-related proline/alanine-rich kinase (SPAK), as one of a limited number of 
hypertension susceptibility genes. A recent meta-analysis confirmed the association of 
STK39 intronic polymorphism rs3754777 with essential hypertension, among previously 
reported hypertension-associated STK39 polymorphisms. However, the physiological 
function of this polymorphism is yet to be clarified.
Methods: To investigate whether SPAK and the downstream targets are modulated 
by this polymorphism, we generated STK39 rs3754777 G > A knock-in human embryonic 
kidney (HEK293T) cell lines with the clustered regularly interspaced short palindromic 
repeats (CRISPR/Cas9) system, using a double-nickase (Cas9-D10A), single guide 
RNAs targeting STK39 intron 5 around SNP, and a 100-bp donor single-stranded DNA 
oligonucleotide.
Results: Homozygous (A/A) and heterozygous (G/A) knock-in cell lines were 
generated. Reverse transcription-polymerase chain reaction (RT-PCR) with sequencing 
analyses revealed the identical STK39 transcripts among the wild-type and both knock-in cell 
lines. Quantitative RT-PCR showed increased STK39 mRNA expression, and immunoblot 
analysis revealed increases in total and phosphorylated SPAK with increased phosphorylated 
Na–K–Cl cotransporter isoform 1 (NKCC1) in both knock-in cell lines. The largest increases 
in these molecules were observed in the homozygous cell line.
Conclusions: STK39 intronic polymorphism rs3754777 increases STK39 transcription, 
leading to activation of the SPAK-solute carrier family 12 (SLC12A) signaling cascade. 
Activation of the target cation-chloride cotransporters may be responsible for hypertension 
susceptibility in individuals with this polymorphism.
Funding: Private Foundation Support, Government Support - Non-U.S.
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TH-PO442
The Major Contribution of WNK4 to the Pathogenesis of Pseudohypo-
aldosteronism Type II (PHAII) Caused by the KLHL3 Mutation R528H 
Koichiro Susa, Eisei Sohara, Daiei Takahashi, Tatemitsu Rai, Shinichi Uchida. 
Dept of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo 
Medical and Dental Univ, Tokyo, Japan.
Background: Recently, we reported that KLHL3R528H/+ knock-in mice, a PHAII model 
mouse, exhibit the activation of OSR1/SPAK-NCC signaling by the increased protein levels 
of both WNK1 and WNK4 due to impaired protein degradation by the mutant KLHL3. 
Previously we have demonstrated that the amount of phosphorylated and total NCC 
decreased to almost undetectable levels in the WNK4-/- mice, indicating that WNK4 plays 
the major role in NCC regulation and that other WNKs including WNK1 and WNK3 cannot 
compensate for the absence of WNK4. In this study, we sought to determine the contribution 
of WNK4 to the activated OSR1/SPAK-NCC signaling in the KLHL3R528H/+ knock-in mice.
Methods: We generated WNK4-/-KLHL3R528H/+ mice by crossing the WNK4-/- mice 
with the KLHL3R528H/+ mice. In addition, we also generated WNK4-/-KLHL3R528H/R528H 
mice. Thereafter, WNK-OSR1/SPAK-NCC phosphorylation signal cascade was examined 
in kidneys from these mice.
Results: As previously reported, compensatory increased WNK1 was observed in the 
WNK4-/- mouse kidney, compared to WNK4+/+. Expectedly, both WNK4-/-KLHL3R528H/+ 
mice and WNK4-/-KLHL3R528H/R528H mice showed further increases in WNK1 in the kidney, 
due to the KLHL3 mutation. However, although phosphorylated SPAK was increased in 
the whole kidney to the levels comparable with that in wild-type mouse, total NCC and 
NCC phosphorylated at S71 were almost completely absent even in WNK4-/-KLHL3R528H/
R528H mice.
Conclusions: As in the wild-type mice, WNK4 plays the major positive role in the 
regulation of NCC in the KLHL3R528H/+ PHAII model mice.
TH-PO443
Mechanism of Regulation of WNK Kinases  Elizabeth J. Goldsmith. 
Biophysics, Univ of Texas  Southwestern Med Center Dallas, Dallas, TX.
Background: WNK1 is a protein kinase on pathway for the regulation of cation-
choride cotransporters. We demonstrated that the kinase domain of WNK1 binds chloride 
ion and inhibits WNK1 autophosphorylation (Piala et al. Sci Signaling 7 ra41 2014). New 
crystallography improves our understanding of the mechanism of this regulation.
Methods: New crystals of the kinase domain of WNK1 (210-483)/S* (phosphorylated) 
were obtained using peg-ion screening, that yielded crystals diffracting to 2.1 Å. Data were 
collected at the APS Beamline 19, and data were processed in HKL2000; the structures was 
solved by molecular replacement. In addition, the structure of a chloride sensing mutant 
was solved in an unphosphorylated form of the same construct on diffraction to 2.5 Å.
Results: The structure of the phosphorylated form reveals conformational changes 
associated with dislodging the chloride from the active site of WNK1, and how a ATP 
analog, AMP-PNP, binds to the unique WNK1 active site. The structure adopted however, 
is not in a fully active configuration based on numerous structural cues. The structure of the 
mutant WNK1/L299F reveals aspects of the contacts of chloride with the protein structure.
Conclusions: The new structural data confirms the chloride regulation of WNK1, and 
strongly suggests that activation is a multistage process.
Funding: NIDDK Support, Private Foundation Support
TH-PO444
Characterisation of the Cullin-3 Mutation That Causes a Severe Form 
of Familial Hypertension and Hyperkalaemia  Keith Siew,1 Frances-Rose 
Schumacher,2 Thimo K. Kurz,2 Kevin O’Shaughnessy.1  1EMIT, Dept of 
Medicine, Univ of Cambridge, Cambridge, United Kingdom; 2MRC PPU, 
College of Life Sciences, Univ of Dundee, Dundee, United Kingdom.
Background: Deletion of exon-9 from Cullin-3 (CUL3, residues 403-459: CUL3∆403-
459) causes pseudohypoaldosteronism type IIE (PHA2E), a severe form of Familial 
Hyperkalaemia and Hypertension (FHHt). CUL3 bound to KLHL3 ubiquitylates WNK 
kinases, promoting their ubiquitin-mediated proteasomal degradation. Mutations in both 
KLHL3 and WNK kinases cause PHA2 by disrupting Cullin-RING-Ligase formation, 
and since WNKs activate Na-Cl co-transporters (NCC) to promote salt retention, CUL3 
regulates blood pressure. The aim of our study was to understand the pathophysiology of 
CUL3∆403-459 mutations which underlies PHA2E severity.
Methods: Blood pressure traces and in vivo pressor responses were obtained in 
CUL3WT/∆403-459 and CUL3WT mice by catheterisation of the right carotid artery and jugular 
vein under anaesthesia (isoflurane). After sacrifice by exsanguination, tissues were harvested 
for electrolyte and western blot analysis. All data are mean±SEM; student t-test statistical 
analysis (* P<0.01; ** P<0.001).
Results: CUL3WT/∆403-459 compared to CUL3WT have elevated blood pressure [93.9±1.2 
vs 81.0±0.7** MAP mmHg], hyperkalaemia [5.1±0.2 vs 4.3±0.1** K+ mmol/L] and 
hyperchloraemia [119.4±0.4 vs 115.6±0.6** Cl- mmol/L] due to renal WNK4 accumulation 
causing NCC hyperphosphoylation. CUL3WT/∆403-459 mice also have stiffened arteries 
[50.2±1.6 vs 42.6±1.8 Augmentation Index % ], increased phenylephrine maximal 
pressor response [183.9±2.5 vs 164.9±1.4* Systolic EMax mmHg] and a 1.7-fold higher 
phosphorylation of MYPT1 in aorta suggesting increased vasoconstriction.
Conclusions: We report here a novel knock-in mouse model of CUL3WT/∆403-459 that 
fully recapitulates the human PHA2E phenotype. The PHA2E mutant, CUL3∆403-459, is 
severely compromised in its ability to ubiquitylate WNKs, probably due to altered structural 
flexibility. Our discovery of a vascular phenotype suggests an explanation for the severity 
of PHA2E. It will be important to establish if this vascular phenotype exists in PHA2E 
patients and can be normalised by thiazide treatment.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-PO445
Paracellular Na+ Transport by Claudin-2 Enhances the Efficiency of Oxygen 
Usage by the Kidney and Protects against Ischemic Injury  Lei Pei,1 Glenn 
Solis,2 Lynn Magenheimer,1 Mien T.X. Nguyen,3 Nikhil Kamat,3 Min Zhuo,1 
Jiahua Li,1 Timothy A. Fields,1 William J. Welch,2 Alicia A. McDonough,3 Alan 
S.L. Yu.1  1Univ Kansas Medical Center; 2Georgetown Univ; 3Univ Southern 
California.
Background: Claudin-2 is a tight junction protein that mediates paracellular Na 
reabsorption in the proximal renal tubule (PT). We previously showed that claudin-2 
null mice (KO) were able to conserve Na normally by upregulating transcellular Na-
K-2Cl transport in the thick ascending limb. Paracellular transport exploits pre-existing 
electrochemical gradients to drive passive diffusion without consumption of additional 
ATP. We therefore hypothesized that the shifting of Na transport to transcellular pathways 
would lead to increased O2 consumption, intrarenal hypoxia, and increased susceptibility 
to ischemic injury.
Methods: The ratio between whole kidney Na reabsorption (TNa) and O2 consumption 
(QO2 = RBF X A-VO2) was determined in KO mice and WT littermates. Intrarenal PO2 
was measured by Clark-type O2 microelectrode. Mice were subjected to 23 min of bilateral 
renal ischemia and assessed for injury 48 h after reperfusion.
Results: TNa/QO2 (mol/mol) in KO mice (16.36±1.31) was significantly lower than in 
WT (10.34 ±1.33), indicating decreased efficiency of O2 utilization. The outer medullas of 
KO mice kidneys were relatively hypoxic, but after furosemide, KO exhibited a 2.7-fold 
greater increase in PO2 compared to WT mice. After ischemia-reperfusion injury, BUN 
(246.98± 12.46 mg/dl KO, 72.19± 21.04 mg/dl WT) and plasma creatinine (0.33±0.16 mg/dl 
KO, 1.45± 0.08mg/dl WT) were significantly higher in KO compared to WT mice. mRNA 
of the injury marker, KIM-1, was also higher in KO. KO kidneys exhibited markedly worse 
tubule injury by histology compared to WT.
Conclusions: Our results indicate that paracellular Na transport in the PT is required 
for efficient utilization of oxygen in the service of sodium transport. The cost of loss of 
paracellular transport is medullary hypoxia and increased susceptibility to ischemic injury. 
Our results suggest that paracellular permeability may have evolved as a general strategy 
in epithelia to maximize energy efficiency.
Funding: Other NIH Support - R01DK062283
TH-PO446
The Diuretic and Natriuretic Effect of the GLP-1 Receptor Agonist, 
Exendin-4, Is Independent of Tubular NHE3  Yiling Fu,1 Panai Song,1 Akira 
Onishi,1 Falk Bernhard Batz,1 Manoocher Soleimani,2 Meinrad Busslinger,3 
Volker Vallon.1  1Div of Nephrology, UC San Diego & VA San Diego Healthcare 
System, La Jolla, CA; 2Dept of Medicine, Univ of Cincinnati, Cincinnati, OH; 
3Research Inst of Molecular Pathology, Vienna, Austria.
Background: Exendin-4 (EX-4) activates the glucagon-like receptor GLP-1R and is 
used as an antidiabetic drug, but also induces natriuresis. The natriuretic effect of EX-4 
has been associated with phosphorylation and potential inhibition of Na-H-exchanger 3 in 
proximal tubules, but the quantitative contribution has not been defined.
Methods: Tubule-specific NHE3 knockdown mice were generated (Pax8-Cre/NHE3fl/
fl [tubNHE3-/-]) and compared with littermate controls (NHE3fl/fl [WT]). a) EX-4 (10 mg/
kg) or vehicle was applied i.p. in a cross-over design together with an oral NaCl load (30 
ml/g bw of 0.85% saline) and the urine quantitatively collected over 3 hours in metabolic 
cages. b) Terminal 3H-inulin clearance studies determined effects of EX4 on GFR, blood 
pressure (BP), and fractional fluid excretion (FE).
Results: Western blotting revealed non-detectable renal NHE3 in tubNHE3-/-. 
tubNHE3-/- and WT showed a) similar diuresis and natriuresis during vehicle application 
(not shown) and EX-4-induced increase in diuresis (50±14 vs 60±17 %) and natriuresis 
(103±34 vs 100±28 %)(each P<0.01 vs vehicle; n=9-10/group), and b) similar basal values 
(not shown) as well as EX4-induced changes in GFR (14±6 vs 13±9 %) and blood pressure 
(-3±3 vs -7±2 %); EX-4 induced similar increase in FE in tNHE3-/- (1.1±0.1 to 3.1±0.8%) 
and WT (1.1±0.4 to 2.5±0.5%)(each P<0.01 vs basal); n=7-8/group).
Conclusions: The acute EX-4-induced diuresis and natriuresis does not require tubular 
NHE3 in mice.
Funding: NIDDK Support, Pharmaceutical Company Support - Astra-Zeneca
TH-PO447
Protein Carbonylation of a Single Amino Acid Residue of Na/K-ATPase a1 
Subunit Dictates Na/K-ATPase Signaling and Sodium Transport in Renal 
Proximal Tubular Cells  Yanling Yan,1 Anna P. Shapiro,2 Jiang Tian,2 Deepak 
K. Malhotra,2 Zi-jian Xie,3 Joseph I. Shapiro,1,2 Jiang Liu.1,3  1Pharmacology, 
Marshall Univ JCE School of Medicine, Huntington, WV; 2MIIR at Marshall 
Univ, Huntington, WV; 3Medicine, Univ of Toledo, Toledo, OH.
Background: We have demonstrated that direct carbonylation modification of the 
Na/K-ATPase a1 subunit regulates Na/K-ATPase signaling and subsequent transepithelial 
sodium transport in renal proximal tubules.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
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Methods: Mutation of Pro224 of rat a1 subunit. Assays for protein carbonylation, 
c-Src and ERK1/2 activation, Na/K-ATPase activity, NHE3 activity, active transepithelial 
22Na+ transport, cellular redistribution of ion transporters, etc.
Results: Cardiotonic steroids (CTS, such as ouabain) signaling through Na/K-ATPase, 
regulate sodium reabsorption in renal proximal tubule (RPT). By direct carbonylation 
modification of the actuator (A) domain of the Na/K-ATPase a1 subunit, reactive oxygen 
species (ROS) are required to initiate ouabain-stimulated Na/K-ATPase/c-Src signaling 
and subsequent regulation of active transepithelial 22Na+ transport. A single mutation 
of Pro224 to Ala in rat a1 subunit was established into a stable cell line, and the mutant 
cells were compared to the wild-type RPT cells by characterization with Na/K-ATPase 
a1/b1 expression, [3H] ouabain binding and ouabain-sensitive 86Rb+ uptake assays. The 
mutation of Pro224 to Ala abolishes ouabain-stimulated Na/K-ATPase/c-Src signaling, 
protein tyrosine phosphorylation, protein carbonylation, redistribution of Na/K-ATPase 
and sodium/proton exchanger isoform 3 (NHE3), and inhibition of active transepithelial 
22Na+ transport. However, a mutation of Ala416 to Pro in rat a1 subunit, also characterized 
as aforementioned, does not affect ouabain-mediated Na/K-ATPase signaling and sodium 
handling. The data indicates that carbonylation modification of Pro224 in rat a1 subunit 
dictates ouabain-mediated RPT Na/K-ATPase signal transduction and subsequent sodium 
transport.
Conclusions: Direct carbonylation of a single amino acid dictates ouabain-mediated 
Na/K-ATPase signaling and related sodium handling in renal proximal tubules.
TH-PO448
The Mineralocorticoids Receptor Regulates the Expression of Na+-K+-
ATPase b3 Subunit in Kidney Collecting Duct Cells  Pablo Diaz, Cristian 
Degregorio, Luis F. Michea, Magdalena Gonzalez.  Univ de Chile, Chile.
Background: Aldosterone modulates the activity of the Na+-K+-ATPase (NKA) in 
principal cells (PC) of kidney collecting duct (CD) via activation of the mineralocorticoid 
receptor (MR). The NKA is a heterodimer with a catalytic α subunit and a regulatory β 
subunit. a1, b1 and b3 are the only subunit isoforms expressed in the kidney. The β subunit 
may be determinant of subcellular localization and trafficking of the α-β heterodimers, 
and also may have a role in the cell-cell adhesion that may be relevant in paracellular 
permeability. Previous studies addressed the modulation of a1 and b1 expression in response 
to aldosterone. However the role of aldosterone in the regulation of the b3 subunit has 
not been analyzed. We tested the hypothesis that the activation of the MR modulates the 
expression of NKA b3 subunit in CD.
Methods: C57BL/6 mice underwent adrenalectomy (ADX) or sham surgery 
(SHAM). The ADX mice received high salt diet or hormone replacement therapy with 
deoxycorticosterone (ADX+DOCA, 10mg/mL/day). In a second set of experiment mice 
received spironolactone (Spi, 50 mg/Kg/day) or vehicle (Control) treatment. After 3 days 
we obtained the kidneys (cortex and medulla) for the analysis of NKA a1, b1 and b3 subunits 
(mRNA and protein abundance by qRT-PCR and Western blot). Finally, we studied the 
effect of aldosterone (0.1-100 nM) in primary culture of inner medullary collecting ducts 
cells (IMCD, 24 hours).
Results: Adrenalectomy increased b3-subunit mRNA and protein abundance in mouse 
renal medulla but not in kidney cortex (200% vs control, P<0.05 n=4 for mRNA and 65% 
vs control, P<0.001, n=9 for protein). Similarly, Spi treatment increased the abundance 
of b3-subunit mRNA and protein in renal medulla only (250% vs control, P<0.01, n=8 
for mRNA and 100% vs control, P<0.05, n=5 for proteins). Both the ADX mice as the 
Spi-treated mice showed no-significant changes in the abundance of a1 or b1 transcripts 
and proteins. The treatment with Aldosterone decreased b3 mRNA in IMCD cells (50% 
vs control,P<0.01, n=5).
Conclusions: We conclude that the NKA b3 subunit expression is downregulated by 
the activation of the MR.
Funding: FONDECYT 1130550, IMII P09-016F, BECA CONICYT 21120658 .
TH-PO449
Purified Recombinant ApoL1 Forms Anion Channels in Phospholipid 
Bilayers  John C. Edwards.  Internal Medicine, Saint Louis Univ, Saint Louis, 
MO.
Background: Variants in the protein ApoL1 confer the increased risk of certain types 
of chronic kidney disease that is observed in people of African ancestry. ApoL1 has been 
reported to function as an ion channel but reports vary on the nature of this activity. We 
sought to characterize ApoL1 channels with anticipation that detailed properties of the 
channel activity of WT and variant ApoL1 may provide insight into the pathophysiology 
of ApoL1-associated kidney disease.
Methods: Recombinant ApoL1 was expressed in bacteria with a N-terminal GST tag 
replacing the signal sequence and separated from the ApoL1 coding region by a thrombin 
cleavage site, and with a C-terminal V5-6Histidine tag. N-octyl glucoside-solubilzed protein 
was bound to glutathione agarose. The bound fusion protein was cleaved with thrombin, 
releasing ApoL1-V5His which was further purified by Ni-affinity. Channel activity was 
assessed using vesicle-based voltage dependent Cl and K efflux assays employing ion 
selective electrodes. Single channel properties were investigated using the Tip-Dip lipid 
bilayer approach with ApoL1 added to the bath solution.
Results: The preparation yields highly purified soluble ApoL1. Introduction of ApoL1 
into phospholipid vesicles either by reconstitution via detergent dialysis, or by direct 
insertion into pre-formed vesicles yields a Cl selective permeability that supports voltage-
driven chloride transport. The Cl channel activity requires that the protein interacts with 
the lipids at low pH (5.0). We do not find potassium-selective permeability when assayed 
at either pH 5 or 7.5. In tip-dip bilayer, ApoL1 spontaneously inserts at low pH, generating 
transitions with single channel conductance of about 5 pS, and with a non-rectifying 
current-voltage relationship. We do not find enhanced channel activity if the bath solution 
is changed to pH 7.5.
Conclusions: Purified recombinant ApoL1 can insert directly into phospholipid 
membranes at low pH and function as an anion selective channel. A prominent difference 
between our preparation and that of others reported to function as a cation channel is that 
our method avoids denaturation and refolding. Whether the disease associated variants 
show altered channel properties remains to be determined.
Funding: Other NIH Support - NHLBI
TH-PO450
Using ChlopHensor to Measure Intracellular Cl- in a Transporting 
Renal Epithelium  Aylin R. Rodan,1 Qifei Sun,1 Drew Stenesen,2 Helmut 
Kramer.2  1Internal Medicine, UT Southwestern, Dallas, TX; 2Neuroscience, 
UT Southwestern.
Background: Drosophila melanogaster eat a K+-rich diet and secrete a KCl-rich 
fluid from the main segment of the renal tubule. We have previously shown that ~1/3 of 
transepithelial K+ flux through the cation-conducting principal cell is via the basolateral 
NKCC and is regulated by the WNK-SPAK/OSR1 kinase cascade. This pathway is activated 
under hypotonic conditions. Cl- is a key regulator of WNK activity. Here, we measured 
intracellular Cl- in the fly tubule using the transgenic Cl- sensor, ChlopHensor.
Methods: The GAL4-UAS system was used to drive tubule expression of ChlopHensor, 
a pH- and Cl--sensitive GFP linked to a pH- and Cl--insensitive dsRed. Fluorescence after 
excitation at 488 nm (green), 458 nm (cyan) and 543 nm (red) was quantified using ImageJ. 
Calibration curves of the green/cyan ratio (to measure pH) and cyan/red ratio (to measure 
Cl-) were generated at varying intracellular pH and Cl- by equilibrating in the presence of 5 
mM nigericin, CCCP, valinomycin and 10 mM tributyltinchloride. Fluorescence emission 
was then measured in the tubule principal cells under varying conditions.
Results: In standard bathing medium (SBM), intracellular Cl- concentration was 27±2 
mM (n=21 cells in 7 tubules), similar to previous measurements made with double-barrelled 
ion-specific electrodes. In hypotonic medium, Cl- decreased to 16±1 mM (p<0.0001, paired 
t-test). pHi was unchanged. In a timecourse experiment, initial Cl- was 30±4 mM in SBM, 
then decreased to 20±3, 16±2, and 15±2 mM at 10, 30 and 60 minutes of hypotonic exposure. 
The decrease in Cl- in hypotonic conditions was blunted by increasing [K+] in the hypotonic 
medium (∆, 8±1 mM) and increased by decreasing [K+] and [Cl-] in the hypotonic medium 
(∆, 17±2 mM, p<0.05 compared to usual hypotonic and p<0.001 compared to high-K+ 
hypotonic, one-way ANOVA with Bonferroni correction).
Conclusions: Activation of the WNK-SPAK/OSR1-NKCC pathway in the Drosophila 
renal tubule under hypotonic conditions correlates with decreased intracellular Cl- 
concentration. The decrease in Cl- is accentuated when bath K+ and Cl- are lowered, 
suggesting KCl efflux in hypotonic conditions, perhaps due to regulatory volume decrease 
mechanisms.
Funding: NIDDK Support, Private Foundation Support
TH-PO451
Potassium-Induced Dephosphorylation of Renal Sodium Chloride 
Cotransporter Is NOT Dependent on the Anions  Naohiro Nomura, Wakana 
Shoda, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida.  Dept of Nephrology, 
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental 
Univ, Tokyo, Japan.
Background: Dietary potassium intake is strongly associated with blood pressure and 
cardiovascular death. High-potassium diets decrease phosphorylation of sodium-chloride 
cotransporter (NCC) and induce lower blood pressure. In many experimental studies 
using high-potassium diets, potassium chloride was added to make high-potassium diets. 
On the other hand, there is a recent report that a high-potassium diet made of potassium 
citrate increased phosphorylation of NCC. It is also known that chloride itself affects NCC 
phosphorylation. Thus, the accompanying anion might modulate the NCC phosphorylation 
response to the high potassium diets, and aldosterone also might be involved in the 
discrepancy. In this study, we clarified the change of NCC phosphorylation with potassium 
compounds accompanying different anions, and confirmed the association between 
potassium intake and NCC phosphorylation with acute oral infusion.
Methods: Adult C57BL/6 mice were fed potassium chloride, potassium gluconate, and 
potassium citrate with oral gavage. Kidneys were collected after 15 min infusion, because 
plasma aldosterone level did not show significant difference at this time point. Western 
blotting was performed with anti-phospho-NCC antibody.
Results: All potassium compound infusion showed significant decrease of NCC 
phosphorylation. Sodium gluconate and calcium gluconate infusion showed very little and 
no reduction of NCC phosphorylation respectively.
Conclusions: Rapid potassium infusion decreases phosphorylation of NCC. It is not 
depend on the anions at least in acute potassium infusion.
Funding: Government Support - Non-U.S.
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Association of Birth History and BMI with APOL1 Risk Alleles in CKiD 
Rebecca C. Hjorten,1 Kimberly J. Reidy,1 Derek Ng,2 Robert Woroniecki,3 
Susan L. Furth,4 Bradley Warady,5 Craig S. Wong,6 Larry A. Greenbaum,7 
Marva M. Moxey-Mims,8 Jeffrey B. Kopp,8 Sophie Limou,8 Cheryl Ann 
Winkler,8 Frederick J. Kaskel.1  1Pediatrics/ Nephrology, Montefiore, Bronx, 
NY; 2Epidemiology, Johns Hopkins, Baltimore, MD; 3Pediatrics/ Nephrology, 
Stony Brook Univ, Stony Brook, NY; 4Pediatrics/Nephrology, Children¶s Hospital 
of Pennsylvania, Philadelphia, PA; 5Pediatric/ Nephrology, Children¶s Mercy, 
Kansas City, MO; 6Pediatrics/ Nephrology, Univ of New Mexico, Albuquerque, 
NM; 7Pediatrics/ Nephrology, Emory Univ, Atlanta, GA; 8NIH, Bethesda, MD.
Background: In the Chronic Kidney Disease in Children (CKiD), there is a high 
prevalence of abnormal birth history (BH) and poor growth. African Americans (AA) have 
increased rates of prematurity. AP2L risk alleles are associated with risk of glomerular 
CKD in AA patients, but the association with BH or growth is unknown.
Methods: Children of AA descent were genotyped for AP2L risk alleles (G1, G2). 
High risk (HR) was defined as 2 risk alleles (G1,G1; G1,G2 or G2,G2) Low risk (LR) was 
defined as no risk alleles or one G1/G2 allele. Demographics and growth parameters were 
compared between AP2L HR vs. LR groups.
Results: 28/84 AA children with glomerular disease had HR APOL1, 28 had LR APOL1 
and 28 did not have APOL1 measured. 26.9% (7/28) with HR APOL1 were premature, 
versus 3.7% (1/28) in AA LR APOL1 patients and 6.9% (13/191) in non-AA LR APOL1 
patients (p=0.010). Also in AA children with HR APOL1, 29.2% (7/28) were small for 
gestational age, vs. 36% (9/28) in AA LR APOL1 patients and 15.4% (27/191) in non-AA 
LR APOL1 patients (p=0.011). Overall, 48.1% (13/28) AA children with HR APOL1 had 
an abnormal BH, versus 35.7% (10/28) in AA LR APOL1 patients and 20.5% (39/191) in 
non-AA LR APOL1 patients (p=0.007). HR ApoL1 risk alleles were also associated with 
increased BMI in patients with FSGS (p<0.04).
Conclusions: HR APOL1 in CKiD is significantly associated with an abnormal BH 
and higher BMI. Further analysis of the interaction of APOL1 genotype with BH and BMI 
in CKD is warranted.
Funding: NIDDK Support
TH-PO453
Relationships of Serum Growth Hormone, Insulin-Like Growth Factor-1 
and IGF-1 Binding Proteins (BPs) in Children with CKD on Growth 
Hormone Therapy  Rose M. Ayoob,1 John D. Mahan,1 Larry A. Greenbaum,2 
Amira Al-Uzri,3 Frederick J. Kaskel,4 Susan L. Furth,5 Bradley Warady.6 
1Pediatrics, NationZide Children¶s/The 2hio State Univ, Columbus, 2H; 
2Pediatrics, Emory Univ, Atlanta, GA; 3Pediatrics, Oregon Health & Science 
Univ, Portland, OR; 4Pediatrics, Albert Einstein COM, New York, NY; 
5Pediatrics, Univ of Pennsylvania, Philadelphia, PA; 6Pediatrics, Children¶s 
Mercy Hospital, Kansas City, MO.
Background: We evaluated children with chronic kidney disease (CKD) enrolled in 
the Chronic Kidney Disease in Children (CKiD) study to determine relationships between 
Growth Hormone (GH), Insulin-Like Growth Factor-1 (IGF-1) and IGF-1 Binding Proteins 
(BP’s), with/without recombinant GH therapy, to assess values that might be useful to guide 
individual treatment decisions.
Methods: 266 CKiD children: 206 - normal height; 26 - short stature; 34 [18 short, 
16 normal height] on recombinant (r) GH therapy were selected for gender, age and GFR 
matching. Normal height = Height Standard Deviation Score (SDS) > -1.88. GH, IGF-1, 
and IGFBP-1 were measured by chemiluminometer and ELISA.
Results: Children with CKD on rGH display lower IGF-1/GH than normal height and 
short CKD children not on rGH therapy. 
IGF-1/GH* IGF-1/IGF-1 BP 1*
Children Height SDS < -1.88 356.7 [152.3-1017.2] 0.0056 [0.0012, 0.0161]
Children Height SDS > -1.88 811.8 [168.2, 2360.0] 0.0136 [0.0055, 0.0582]
Children on rGH Therapy 138.8 [66.1, 291.0] 0.0098 [0.0017, 0.0308]
p-value (Kruskal Wallis ANOVA) 0.0002 0.02
* = (median [IQR]) 
On rGH, IGF-1/IGF-1 BP1 is closer to that in normal height CKD children than in 
short CKD children. Height SDS correlates with serum IGF-1 in children on rGH better (r 
= 0.374) than normal height (r = 0.323) and short children (r = 0.048).
Conclusions: IGF-1/IGF-1 BP1 in children on rGH is closer to that in normal height 
then in short CKD children not on rGH, supporting importance of serum IGF-1 levels 
achieved in rGH treated children to drive statural growth. Further analyses in samples over 
time and in paired subjects may provide further insights into effective ‘therapeutic targets’ 
for rGH treatment in these children.
Funding: NIDDK Support, Private Foundation Support
TH-PO454
Two-Year Kidney Outcomes of Teen-LABS Participants  Edward Nehus,1 
Todd Jenkins,1 Nianzhou Xiao,2 Marc P. Michalsky,3 Anita Courcoulas,4 Thomas 
H. Inge,1 Mark Mitsnefes.1  1Cincinnati Children¶s Hospital Medical Center, 
Cincinnati, OH; 2Children¶s Hospital of Richmond at 9CU, Richmond, 9A; 
3NationZide Children¶s Hospital, Columbus, 2H; 4Univ of Pittsburgh Medical 
Center, Pittsburgh, PA.
Background: A significant amount of severely obese adolescents undergoing weight 
loss surgery have evidence of early kidney damage. The objective of this study was to 
determine if early kidney injury is reversible following weight loss surgery.
Methods: We analyzed data two years following bariatric surgery in the Teen 
Longitudinal Assessment of Bariatric Surgery (Teen-LABS) cohort, a prospective 
multicenter study of 242 severely obese adolescents undergoing bariatric surgery. Primary 
outcomes of albuminuria (urinary albumin to creatinine ratio > 30 mg/g) and cystatin 
C-estimated GFR (eGFR) were compared to baseline values to determine the effect of 
bariatric surgery on kidney injury.
Results: At surgery, the mean (± SD) age of the patients was 17 ± 1.6 years, 76% 
were female, and 72% were white race. Procedures included gastric bypass (67%), sleeve 
gastrectomy (28%), and adjustable gastric band (5%). Median BMI (IQR) at baseline was 
51 (45, 58) kg/m2, and this decreased to 35 (30, 43) kg/m2 at two years follow-up. Cystatin 
C-based eGFR was 108 ± 27 mL/min/1.73m2 at baseline and by two years post-operatively, 
eGFR had increased by 10% to 119 ± 27 mL/min/1.73m2 (p<0.01). Low eGFR (< 90 mL/
min/1.73m2) was observed in 25% at baseline, and this improved to 12% at two years 
follow-up (p<0.01); 71% with low baseline eGFR experienced normalization of eGFR at 
follow-up. Alternatively, 7% of subjects with normal baseline eGFR developed incident 
low eGFR at two years post-op. Albuminuria was observed in 17% at baseline and 12% at 
two years follow-up (p=0.03). Among those with baseline albuminuria, 69% experienced 
normalization of albuminuria at follow-up. In contrast, 7% of subjects were observed with 
incident albuminuria at two years post-op.
Conclusions: Two years following surgery, improvements in kidney function 
and albuminuria were observed in our cohort. Further study will permit assessment of 
durability of improvements and longer-term kidney outcomes of severely obese adolescents 
undergoing bariatric surgery.
Funding: NIDDK Support
TH-PO455
Genetic Variation Underlying Uric Acid Clearance in Hispanic Children: 
The Viva La Familia Study  Geetha Chittoor,1 Sandra L. Laston,2 Nitesh R. 
Mehta,3 Karin Haack,4 Shelley A. Cole,4 Anthony Gean Comuzzie,4 Nancy F. 
Butte,3 V. Saroja Voruganti.1  1Nutrition and Nutrition Research Inst, Univ of 
North Carolina at Chapel Hill, Kannapolis, NC; 2South Texas Diabetes and 
Obesity Inst and Regional Academic Health Center, UTHSC at San Antonio/
Univ of Texas Rio Grande Valley, Brownsville, TX; 3Pediatrics and USDA/ARS 
Children¶s Nutrition Research Center, Baylor College of Medicine, Houston, 
TX; 4Genetics, Texas Biomedical Research Inst, San Antonio, TX.
Background: Variation in renal excretion of uric acid is a key factor in the development 
of gout, hyperuricemia, and nephropathy. Hyperuricemia (increased serum uric acid 
concentrations) and hyperuricosuria (increased urinary uric acid concentrations) can lead 
to uric acid nephrolithiasis. These are two common multifactorial disorders that have been 
shown to be associated with progression to kidney disease and have a familial inheritance. 
The genetic determinants of renal handling of uric acid are poorly elucidated.
Methods: We investigated the genetic factors that influence the excretion of uric acid 
and its related indices in 769 Hispanic children of the Viva La Familia Study. We conducted 
a genome-wide association analysis for uric acid clearance after accounting for family 
kinships. All methods were implemented in SOLAR.
Results: All renal uric acid clearance measures were significantly heritable (p <2 x 
10-6). We observed a strong association of uric acid clearance with a single nucleotide 
polymorphism (SNP) in the zinc finger protein 446 (ZNF446) gene on 19q13 [p < 8 x 
10-8, rs2033711 (A/G), minor allele frequency (MAF) of 0.30]. The minor allele (G) was 
associated with increased uric acid clearance. We also found suggestive associations of 
uric acid clearance with SNPs in ZNF324, ZNF584, and ZNF132 (within 72kb region of 
19q13, p <1 x 10-6, MAFs between 0.28 and 0.31).
Conclusions: Our study indicates, for the first time, the importance of the chromosomal 
region 19q13 in the regulation of renal clearance of uric acid in Hispanic children.
Funding: Other NIH Support - DK080457; USDA/ARS [Cooperative Agreement 
6250-51000-053]
TH-PO456
Association Between Height and Clinical Outcomes in Children at Time of 
ESRD Onset  Elaine Ku,1 Richard N. Fine,2 Chi-yuan Hsu,1 David V. Glidden,1 
Barbara A. Grimes,1 Kirsten L. Johansen.1  1UCSF; 2Stony Brook Univ. 
Background: Short and tall stature are associated with adverse outcomes in the general 
adult population. The aim of this study was to examine risk of mortality and transplantation 
in children with short and tall stature at time of ESRD onset.
Methods: Using data from US Renal Data System, we performed a retrospective 
analysis of children ages 2-19 who began renal replacement therapy during 1995-2011. 
We used Cox models adjusted for demographic and socioeconomic factors, calendar year, 
and cause of ESRD to determine the association between short (<3rd percentile) and tall 
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(>97th percentile) stature and risk of transplantation and death. In sensitivity analysis, we 
also evaluated mortality and transplant risk in the subset of children with normal BMI 
(5th-95th percentile).
Results: Among 13,666 children, 26% of children were short and 3% were tall at 
time of ESRD onset. During a median follow-up of 7.1 years, 10,354 kidney transplants 
and 1,795 deaths occurred. Risk of death was higher in children with short and tall stature 
[table 1], and cause-specific mortality differed by height category. The higher risk of death 
in children with short stature persisted even when analysis was limited to children with 
normal BMI. Children with short stature were also less likely to receive a kidney transplant 
(HR 0.83, 95% CI 0.79-0.87).
Outcome
(N=13,666)
Short Stature 
(N=3576)
Tall Stature 
(N=397)
All-cause mortality HR* (95% CI) HR* (95% CI)
Adjusted model (primary analysis) 1.48 (1.33-1.65) 1.30 (1.01-1.67)
Adjusted model among persons with normal BMI 
(N=9,663) 1.56 (1.36-1.77) 0.98 (0.67-1.44)
Cause-specific mortality 
Adjusted model for cardiac death 1.45 (1.19-1.76) 1.19 (0.76-1.85)
Adjusted model for infectious death 1.77 (1.34-2.33) 1.23 (0.57-2.63)
Adjusted model for malignancy death 0.79 (0.44-1.41) 2.70 (1.11-6.60)
*Reference is children with normal stature 
Conclusions: Both extremes of height at ESRD onset were associated with higher risk 
of all-cause and cause-specific mortality, and short stature was also associated with lower 
risk of transplantation. Further studies are warranted to determine whether interventions 
can improve the risk associated with growth failure.
Funding: NIDDK Support
TH-PO457
Genital Organ Anomalies in Female Pediatric Patients with End-Stage 
Renal Disease  Shoichiro Kanda,1 Naoya Morisada,2 Yuji Tomii,1 Keiichi 
Takizawa,1 Naoto Kaneko,1 Tomoo Yabuuchi,1 Hirotaka Hama,1 Eiji Nakano,1 
Norimasa Tada,1 Kiyonobu Ishizuka,1 Yuko Akioka,1 Hiroko Chikamoto,1 
Kazumoto Iijima,2 Motoshi Hattori.1  1Pediatric Nephrology, Tokyo :omen¶s 
Medical Univ, Shinjuku-ku, Tokyo, Japan; 2Pediatrics, Kobe Univ Graduate 
School of Medicine, Kobe, Hyogo, Japan.
Background: In the general population, the rate of prevalence of genital organ 
anomalies in females is 1.3–4.0 per 1000 births. Although female pediatric patients with 
end-stage renal disease (ESRD) appear to occasionally have genital organ anomalies, the 
clinical features of them have not been examined.
Methods: We performed a retrospective analysis of female pediatric ESRD patients 
attending the Department of Pediatric Nephrology, Tokyo Women’s Medical University 
(TWMU) Hospital. The study was in accordance with the ethical guidelines of the Ministry 
of Health, Labour and Welfare, Japan. The study was also approved by the central ethics 
board of TWMU and Kobe University.
Results: Eighty-two patients were included in this study. Genital organ anomalies were 
found in eight (9.7%) patients and consisted of bicornuate uterus in three patients, double 
uteri with vaginal atresia in two, cicatricial tissue in two, and double uteri in one. Renal 
phenotypes were congenital anomalies of the kidney and urinary tract in six patients and 
FSGS in two patients. In seven (87.5%) patients, genital organ anomalies were diagnosed 
after the start of renal replacement therapy. Two patients complained of acute abdomen 
associated with their first menstrual period. Genetic and chromosome analyses revealed 
hypoparatyroidism, deafness, and renal dysplasia syndrome (GATA3, c.1013G>T) in one 
patient, Turner syndrome in one, Frasier syndrome (46XY, WT1, IVS9+5G>A) in one, 
and FSGS carrying a mutation of WT1 (c.745C>A) in one.
Conclusions: Our study showed that female pediatric ESRD patients had a frequency of 
genital organ anomalies of approximately 10%. Additionally, genetic disorders responsible 
for kidney and genital organ development were detected in four out of eight patients. 
Therefore, physicians need to be aware of the possibility of genitourinary syndrome and 
investigate genital organ anomalies in the medical care of female pediatric patients with 
ESRD.
TH-PO458
Intestinal Microbiota in Pediatric Patients with End Stage Renal Disease 
Janice Crespo-Salgado,1 Tyrus Stewart,1 Mike J. Ferris,1 Mahmoud Kallash,2 
Larry A. Greenbaum,3 V. Matti Vehaskari,1 Diego H. Aviles.1  1Pediatric 
Nephrology, LSUHSC, NeZ 2rleans, LA; 2Pediatric Nephrology, Women & 
Children¶s Hospital of Buffalo, Buffalo, NY; 3Pediatric Nephrology, Emory 
Children¶s Center, Atlanta, GA.
Background: Cardiovascular mortality is increased in children with end stage renal 
disease (ESRD). Studies in adult population suggest that uremia increase intestinal 
permeability and alters the intestinal microbiota. These changes could facilitate the 
translocation of endotoxin and bacterial metabolites to the systemic circulation leading 
to inflammation. We hypothesized that children with ESRD have an altered intestinal 
microbiota that lead to increased bacterially derived uremic toxins, and renal transplantation 
will reverse those changes.
Methods: Subjects were divided into 4 groups: ESRD on peritoneal dialysis (PD), 
ESRD on hemodialysis (HD), post kidney transplant and healthy control. PCR and 
pyrosequencing analysis of 16S rRNA gene was used to assess stool bacterial composition. 
Serum levels of CRP, D-lactate, p-cresyl sulfate and indoxyl sulfate were detected.
Results: Children with ESRD showed significant decrease in Firmicutes (p=0.006). HD 
patients showed significant increase in Bacteroidetes (p=0.017) and PD patients showed 
significant increase in Proteobacteria (p=0.0006). Bacterial diversity was significantly 
decreased in ESRD and transplant patients. ESRD patients had significantly increased 
serum levels of p-cresyl sulfate and indoxyl sulfate (p<0.0002).
Conclusions: ESRD in children results in alteration of the intestinal microbiota favoring 
bacteria able to metabolize and produce more uremic toxins. Renal transplantation does not 
restore the decreased bacterial diversity, but results in normalization of bacterially derived 
uremic toxins. These findings may be associated with the increased cardiovascular mortality 
seen in children with ESRD.
TH-PO459
Cardiorenal Effects of Exposure to Environmental Chemicals in Children 
Anglina Kataria,1 Suzanne M. Vento,1 Leonardo Trasande,1 Dov Levine,1 Debra 
J. Morrison,2 Rachel Brody,2 Kurunthachalam Kannan,3 Jingchuan Xue,3 Howard 
Trachtman.1  1Pediatrics, NYU Langone Medical Center, NeZ York, NY; 22ffice 
of Collaborative Sciences, Human Specimen Resource Center, NYU Langone 
Medical Center, New York, NY; 3Environmental Health Sciences, School of 
Public Health, State Univ of New York at Albany, Albany, NY.
Background: Exposure to short-lived organic chemicals such as bisphenol A and S 
(BPA/BPS) and phthalates is ubiquitous in the US. Graded exposure to BPA and di-(2-
ethylhexyl) phthalate (DEHP), based on urinary excretion, is associated with an increased 
low-grade albuminuria. Oxidant stress is hypothesized as the mediator underlying these 
associations. We conducted the following study to assess (1) the mechanism of action of 
these compounds and (2) the impact of exposure on vascular function in children.
Methods: A cross-sectional study recruiting 10-13 year old children was conducted at 
Bellevue Medical Center. Demographic information was obtained and height, weight and 
BP were measured. A first morning and spot urine samples were collected for determination 
of BPA, BPS, phthalate, 8(OH)-deoxyguanosine, and F2-isprostane excretion (normalized 
to creatinine excretion). Pulse wave velocity (PWV) was measured non-invasively 
(SphygmoCor). Multivariate analysis was used to evaluate the relationship between 
exposures and the laboratory tests.
Results: There were 41 participants, 19 M:22 F, age 12±1 yr. 31 Hispanic, 7 Caucasian, 
and 3 Other. The mean BMI was 21.7±5.0 and albuminuria 11.4±23.6 mg/g. and 10 (25%) 
were pre-hypertensive (BP≥90th percentile). The degree of exposure to BPS, total bisphenols, 
DEHP, and high molecular weight (HMW) phthalates correlated with F2-isoprostane 
excretion (P<0.05). Multivariate regression also showed each unit of DEHP and HMW 
phthalate exposure was associated with an increase in PWV of 0.034 m/s (p=0.037) and 
0.024 m/s (p=0.041), respectively.
Conclusions: This is the first demonstration of oxidant stress and vascular dysfunction 
related to environmental chemicals in otherwise healthy children. The link with replacement 
compounds such as BPS suggests that the consequences of exposure to these chemicals 
will be a long-term public health problem.
Funding: NIDDK Support, Other NIH Support - NIEHS Pilot study Award
TH-PO460
Safety of Eculizumab in Pediatric Patients with Atypical Hemolytic Uremic 
Syndrome  Gema Ariceta,1 Larry A. Greenbaum,2 Jimmy Wang,3 John F. 
Kincaid,3 Christoph Licht.4  1Hospital Univ 9all d¶Hebron, Barcelona, Spain; 
2Emory Univ, Atlanta, GA; 3Alexion Pharmaceuticals, Inc, Cheshire, CT; 4The 
Hospital for Sick Children, ON, Canada.
Background: The safety of eculizumab, a terminal complement inhibitor approved 
for treatment of children and adults with aHUS, was characterized in 4 prospective trials. 
This post hoc analysis further evaluates its safety in pediatric participants in 3 of the trials.
Methods: Treatment-related adverse events (TRAEs) and serious AEs (SAEs) reported 
for patients (pts) (<18 y) after 1 year and by end of study (EOS) in studies C08-002, C08-
003, and C10-003 were pooled.
Results: Pediatric pts (N=28) received eculizumab for a mean (SD) of 67 (42) weeks. 
TRAEs occurred in 13 pts (46.4%) after 1 year (Table). SAEs are listed in the Table. 
Elevated levels of alanine transaminase and aspartate aminotransferase were noted in some 
pts before and after receiving eculizumab; levels generally were higher before treatment 
and normalized over time. By EOS after 433 cumulative months of treatment, there were 
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no deaths or meningococcal infections; 6 infection-related serious TRAEs occurred in 
4 pts: viral upper respiratory tract infection (n=2), influenza, peritonitis (patient was on 
peritoneal dialysis), respiratory syncytial virus infection, and pyelonephritis (n=1 each).
Conclusions: Eculizumab appears well tolerated in pediatric pts with aHUS. The 
safety profile of eculizumab in pediatric pts is similar to that in the broader pt population 
of these studies. Although more infection-related TRAEs were noted, most were mild to 
moderate in severity, none led to treatment discontinuation, and all pts recovered. Some 
TRAEs might have been manifestations of underlying aHUS disease. 
Medical writing support - Kristen W. Quinn, PhD, of Peloton Advantage, funded by 
Alexion 
Funding: Pharmaceutical Company Support - Alexion Pharmaceuticals, Inc.
TH-PO461
Early Renin-Angiotensin System Inhibition in Pediatric Chronic 
Kidney Disease Patients May Prevent Progression of Renal Failure 
Kazuya Matsumura, Midori Awazu.  Dept of Pediatrics, Keio Univ School of 
Medicine.
Background: While inhibitors of renin-angiotensin system (RASi) are known to slow 
CKD progression, the optimal timing of their introduction is not established. Some patients 
with chronic kidney disease (CKD) have nonprogressive GFR periods (stable or increasing 
GFR). We compared longitudinal GFR trajectories between patients in whom RASi was 
initiated during stable periods (early-treated) and those during decline periods (late-treated).
Methods: GFR was estimated by equation for Japanese children and adults. Stable 
GFR periods were defined as GFR slope = 0 or positive. Fifty-three pediatric CKD patients 
(stage ³2) were studied (26 males and 27 females, age 3 to 38 years, median 17). Blood 
pressure (BP) was evaluated as BP index (BP divided by the 95th percentile).
Results: Twenty-seven subjects (11 early-and 16 late-treated) were prescribed with 
RASi. All of the early-treated subjects showed stable GFR during the follow-up period of 
8.5 years (NS vs the late-treated 11.4 years), whereas GFR declined in all the late-treated 
subjects (P<0.05). Current age and the age at the time of follow up were significantly 
younger in the early-treated vs the late-treated (12.6 vs 20.6 and 4.1 vs 9.1 years). There was 
no difference in gender. In the early-treated, 8 of 11 had CAKUT, which was significantly 
more than the late-treated (4 of 16). The initial GFR tended to be lower in the early-treated 
than the late-treated (69 vs 92 ml/min/1.73 m2). There was no difference in BP index (0.88 
vs 0.86), but urine protein creatinine ratio was numerically lower in the early-treated 
(median 0.15 vs 0.27 g/gCr). The reason for the initiation of RASi in the early-treated 
was hypertension (6), albuminuria (4), or accompanying cardiac disease (3). Of all 53 
patients, 26 had stable GFR periods during the course. Ten patients with stable periods 
were not on RASi because of the absence of hypertension or albuminuria and only one of 
whom subsequently developed GFR decline, proteinuria, and hypertension requiring RASi.
Conclusions: In pediatric CKD patients, initiation of RASi during periods of stable 
GFR may prevent CKD progression although the influence of age and underlying disease 
cannot be ruled out.
TH-PO462
Novel Urinary Biomarkers for Detecting Renal Scar in Children with 
Febrile Urinary Tract Infection  Takahisa Kimata,1 Tetsuya Kitao,1 Sohsaku 
Yamanouchi,1 Jiro Kino,1 Hiroyuki Kurosawa,2 Yoshiaki Hirayama,2 Akihiko 
Saito,3 Kazunari Kaneko.1  1Pediatrics, Kansai Medical Univ, Osaka, Japan; 
2Denki Kagaku Kogyo K.K., Tokyo, Japan; 3Applied Molecular Medicine, 
Niigata Univ, Niigata, Japan.
Background: Recurrent febrile urinary tract infections (fUTI) during infancy cause 
renal scar. Renal scar can be diagnosed through renal scintigraphy while it seems impractical 
to perform it for all infants with fUTI. Therefore, exploring biomarkers that can identify 
the patients at high risk of developing renal scar is worthwhile. Urinary excretions of total 
proteins, beta-2 microglobulins (BMG), and N-acetyl-β-D-glucosaminidase (NAG) have 
been traditionally used for assessing kidney injury including interstitial damage. In addition, 
urinary excretions of neutrophil gelatinase-associated lipocalin (NGAL), liver-type fatty 
acid binding protein (L-FABP), full-length megalin (C-meg) and angiotensinogen (AGT) 
have recently been reported as sensitive biomarkers for various kidney injuries. This study 
was undertaken to explore sensitive urinary biomarkers to diagnose renal scar.
Methods: Thirty one infants who underwent renal scintigraphy during the chronic 
phase after fUTI were enrolled. The following measurements were performed using urine 
samples; total proteins, BMG, NAG, NGAL, L-FABP, C-meg and AGT. The values were 
corrected by creatinine and compared between the patients with renal scar (n=20) and 
these without renal scar (n=10).
Results: Among urinary biomarkers, AGT and C-meg in the group with scar (median 
value 14.4 mg/gCr and 6.7 pmol/gCr) demonstrated significantly higher levels than those in 
the group without scar (median value 4.5 mg/gCr and 1.9 pmol/gCr) (P = 0.021 and 0.0046). 
Among the area under the curves in receiver operating characteristic curve calculated for 
each urinary biomarker, C-meg yielded the highest value as following: C-meg (0.81)> AGT 
(0.76) > NAGL (0.60) > protein (0.58) > BMG (0.54) > NAG (0.50) > L-FABP (0.46). When 
using the point on the curve closest to the (0, 1) point, cut-off in the C-meg (AGT) was 3.06 
pmol/gCr (10.4 mg/gCr), the test had 80 % (70 %) sensitivity, 72.7 % (81.8%) specificity.
Conclusions: Urinary C-meg and AGT are useful for renal scar screening.
TH-PO463
Prevalence and Distribution of (Micro)Albuminuria in Toddlers: A Sign of 
Early Endothelial Dysfunction?  Sophie Van den Belt,1 Valentina Gracchi,2 
Eva Corpeleijn,3 Dick de Zeeuw,1 Hiddo Jan Lambers Heerspink.1  1Dept 
Clinical Pharmacy & Pharmacology, UMC Groningen, Netherlands; 2Dept 
Paediatric Nephrology, UMC Groningen, Netherlands; 3Dept Epidemiology, 
UMC Groningen, Netherlands.
Background: Microalbuminuria is common in the general population with a 
prevalence of 7% and is an independent indicator of renal/cardiovascular risk. Whether 
microalbuminuria is acquired during life (as a result of hypertension/diabetes) or 
is congenital and already present at birth is unknown. We studied the prevalence of 
microalbuminuria in toddlers and compared distributions of albuminuria with the general 
adult population. In addition, we looked for possible associations with antenatal, postnatal 
and maternal factors explaining albuminuria variations.
Methods: The urinary albumin (UAC) was measured in 1352 children (20-40 months 
old) from the GECKO Drenthe cohort. Albuminuria distribution was compared with the 
distribution in 40854 participants of the general adult cohort PREVEND. Difference in 
prevalence of increased albuminuria (UAC³20 mg/L) was tested with chi-square. Associations 
between logarithm of UAC and antenatal, postnatal and maternal factors were tested with 
linear regression analysis.
Results: The median UAC in GECKO was 2.3 mg/L[5-95th percentile: 2.1-25.5] and 
in PREVEND 6.0 mg/L[2.3-28.6] (P distribution comparison 0.053). Prevalence of UAC³20 
mg/L was 6.9% in GECKO and 7.8% in PREVEND(Figure; P=0.195). UAC was lower in 
boys and not associated with other factors.
Conclusions: The distributions of UAC and the prevalence of microalbuminuria 
in toddlers and general adult population are comparable. These findings suggest that 
microalbuminuria is a congenital condition which may predispose those affected at a higher 
renal/cardiovascular risk later in life. 
Figure: Prevalence of different UAC levels in toddlers (GECKO) vs adults (PREVEND).
Funding: Pharmaceutical Company Support - Hutchison Whampoa Ltd, Hong Kong, 
Government Support - Non-U.S.
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TH-PO464
Validation of a Novel Device to Collect Urine for Albuminuria Assessment 
in Young Children  Sophie Van den Belt,1 Valentina Gracchi,2 Dick de 
Zeeuw,1 Hiddo Jan Lambers Heerspink.1  1Dept of Clinical Pharmacy and 
Pharmacology, UMC Groningen, Netherlands; 2Dept of Paediatric Nephrology, 
UMC Groningen, Netherlands.
Background: Urine collection for albuminuria measurement in babies and toddlers is 
cumbersome. Taped plastic bags are complicated and may come loose. Old-fashioned cotton 
wool (pantyliner) or a felt (PeeSpotR) are used as collection devices in a regular disposable 
diaper. We compared the analytical performance of these two methods.
Methods: The pantyliner and urine collection felt were placed in the diaper; 81 different 
standard urines with a wide range of albuminuria were applied by hand (in duplicate); 
incubated for 3 hours at 37oC (simulating the baby), and 72 hours at room temp (simulating 
transport); extracted by centrifuging. Urinary Albumin Concentration was measured 
Analytical performance of two methods was tested according National Committee for 
Clinical Laboratory Standards (NCCLS) guidelines for method comparison, and compared 
with the standard urine. Performance measures assessed were bias, precision and accuracy.
Results: Median albumin concentration was: standard 66.0 mg/L [IQR 25.0–211.0 
mg/L]; pantyliner method 32.0 mg/L [4.7-165.0 mg/L], and PeeSpot method 61.0 mg/L 
[27.0-216.0 mg/L]. Bias and precision were higher in pantyliner (-34.2% and 32.4 mg/L) 
than in PeeSpot (3.3% and 5.0 mg/L) and accuracy was lower in pantyliner (48.1%) vs 
PeeSpot (96.3%). Passing-Bablok regression and Bland-Altman plot showed a systemic 
underestimation for pantyliner method, but not for PeeSpot method (Figure).
Conclusions: The PeeSpot method is a reliable method for the collection of urine in 
babies and toddlers albuminuria measurement. This technique should be used in future 
research into this subject. 
Figure: A; Passing-Bablok regression for pantyliner and PeeSpot. B; Bland-Altman 
plots for pantyliner and PeeSpot on logarithm of albuminuria. LoA = Limit of Agreement.
Funding: Government Support - Non-U.S.
TH-PO465
A Distinct Urinary Lipid Profile in Patients with FSGS  Elif Erkan, Xueheng 
Zhao, Prasad Devarajan.  Pediatrics, Children¶s Hospital of Cincinnati.
Background: Focal segmental glomerulosclerosis (FSGS) accounts for the majority 
of patients with end-stage renal disease (ESRD) during adolescence. Treatment of FSGS 
has been a great challenge for pediatric nephrologists due to intertwined molecular 
pathways underlining its complex pathophysiology. In FSGS patient kidney biopsy sections 
display increased tubular apoptosis a hallmark for tubular injury. We hypothesize that 
tubulointerstitial injury caused by the uptake of lipogenic mediators in glomerular filtrate 
contributes to the progressive nature of FSGS.
Methods: We explored urinary lipid profile of patients with FSGS, minimal change 
disease (MCD) and healthy controls by High Performance Liquid Chromatography. 
Normalized data from GC/MS and UPLC/MS analysis including 625 metabolites were 
thereby used for subsequent statistical analysis. A total of 29 metabolites met the significant 
threshold of p-value (student two samples t test) less than 0.05 and fold changes between 
FSGS and MCD urine samples bigger than 2.
Results: We discovered a unique signature characterized by increased concentration of 
fatty acid (FA) and lysophosphatidylcholines (LPC) and a decrease in urinary concentration 
of phosphotidylcholine (PC) in patients with FSGS. Patients with FSGS had lower urinary 
acylcarnitine levels. Patients with FSGS were divided into two groups (four patients in each 
group) based on their estimated GFR, to normal GFR (105.29 ± 4.11 ml/min/1.73m2) and 
low GFR group (69.25 ± 6.49 ml/min/1.73 m2). Low GFR group had higher urinary FA 
concentration and lower urinary acylcarnitine concentration (p<0.05).
Conclusions: We speculate that these findings indicate increased metabolism of 
membrane phospholipid PC by phospholipase A2 (PLA2) resulting in higher urinary 
concentrations of LPC and FA. We propose that decrease in urinary acylcarnitine levels in 
FSGS implicates an arrest at mitochondrial fatty acid oxidation despite high FA levels. e 
believe increased by products of PC metabolism further potentiate tubular and podocyte 
toxicity in FSGS. Validation of urinary lipids as a biomarker in predicting the diagnosis 
and progression of FSGS in a larger patient population is warranted.
Funding: NIDDK Support
TH-PO466
Steroid Dependency in Childhood Steroid-Sensitive Nephrotic Syndrome – 
Clinical Characterization of a Large Single Center Cohort  Anja K. Büscher, 
Mareen Sadau, Rainer Büscher, Peter F. Hoyer, Stefanie Weber.  Pediatric 
Nephrology, Univ of Duisburg-Essen, Pediatrics II, Essen, Germany.
Background: Steroid-sensitive nephrotic syndrome (SSNS) is characterized by 
preservation of renal function and recurrent disease. Clinical course depends on the number 
of relapses which is highly variable. A subset of patients presents with relapses during or 
shortly after steroid therapy (steroid-dependency, SDNS). Mostly, childhood SSNS is of 
idiopathic origin with minimal change glomerulopathy (MCN) in renal histology. Aim of 
our study was the characterization of SSNS patients with regard to differences between 
SDNS and non-SDNS.
Methods: We retrospectively analyzed 100 SSNS patients treated at our hospital. Data 
collection comprised age at onset, number/trigger of relapses, dose/duration of steroid 
therapy, time to response, further immunosuppressants, renal function, renal histology, 
and family history.
Results: 89% of patients experienced relapses (mean 9 (range 0-34)), 55% developed 
SDNS (after 15 (2-45) months from onset). In 80% of cases trivial infections triggered SSNS 
relapse. 60% of patients received further immunosuppressants (95% cyclophosphamide, 
58% ciclosporinA; sustained disease remission in 24/51%, respectively). Renal biopsy was 
performed in 70% (93% MCN, SDNS and non-SDNS). SDNS patients were significantly 
younger at disease onset (4.16ys (SDNS) vs. 5.34ys (non-SDNS), P=0.035; all patients 
4.7ys). Mean time to first relapse was significantly shorter in SDNS (6.3months vs. 
16.3months non-SDNS; P<0.001; all patients 9.8months). Response to steroids at disease 
onset was faster in non-SDNS (6.8days vs. 11.7days SDNS; P<0.001). SDNS patients 
developed secondary steroid resistance in 20% (2% non-SDNS; P<0.01; all patients 12%).
Conclusions: 55% of patients developed SDNS and differed from non-SDNS patients 
by a younger age at disease onset, a shorter time until first relapse and a slower therapy 
response. The clinical course in general was influenced by therapy regimen.
Funding: Clinical Revenue Support
TH-PO467
Dyslipidemia in Pediatric CKD Patients from KNOW-PedCKD Study 
Seong heon Kim,1 Yo Han Ahn,3 Eujin Park,3 Kyoung Hee Han,2 Heeyeon 
Cho,4 Joo Hoon Lee,6 Hee Gyung Kang,3 Young seo Park,6 Hae Il Cheong,3 
Curie Ahn,7 IL-Soo Ha.3  1Dept of Pediatrics, Pusan National Univ Children¶s 
Hospital, Yangsan, Republic of Korea; 2Dept of Pediatrics, Jeju National 
Univ School of Medicine, Jeju, Republic of Moldova; 3Dept of Pediatrics, 
Seoul National Univ Children¶s Hospital, Seoul, Republic of Korea; 4Dept of 
Pediatrics, Samsung Medical Center, Sungkyunkwan Univ School of Medicine, 
Seoul, Republic of Korea; 5Dept of Pediatrics, Yonsei Univ College of Medicine, 
Severance Children¶s Hospital, Seoul, Republic of Korea; 6Dept of Pediatrics, 
Medical Center, Univ of Ulsan College of Medicine, Seoul, Republic of Korea; 
7Dept of Internal Medicine, Seoul National Univ Hospital, Seoul, Republic of 
Korea; 8Dept of Pediatrics, Kyungpook National Univ School of Medicine, 
Daegu, Republic of Korea.
Background: Children with chronic kidney disease (CKD) exhibit various co-
morbidityes, including dyslipidemia. We investigated the prevalence and characteristics 
of dyslipidemia in pediatric CKD patients.
Methods: Seven major pediatric nephrology centers of Korea enrolled children 
younger than 20 years who had CKD. From July 2010 to December 2013, 322 children 
(M:F 218:104) were enrolled.
Results: Baseline lipid analysis found a high prevalence of dyslpidemia in 49%. 
Several factors were analyzed including age, gender, CKD stage, primary renal disease, 
height, weight, BMI, social economic status, hypertension, co-morbidity, z score of height, 
z score of weight, z score of BMI, gestational age at birth, birth weight, estimated GFR 
and duration of underlying diseases. Univariate logistic regression analysis demonstrated 
that several factors including BMI, co-morbidity, Z score of weight and Z score of BMI 
were associated with dyslipidemia. After multivariate adjustment, social economic status 
and Z score of BMI were significantly associated with dyslipidemia.
Conclusions: Among children with CKD, dyslipidemia is quite common and is 
associated with factors such as social economic status and Z score of BMI.
Funding: Government Support - Non-U.S.
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TH-PO468
Self-Management/Transition Readiness and Health Services Utilization 
Among Adolescents/Young Adults with Chronic Conditions in the Pediatric 
or Adult Settings from Across the USA  Maria E. Ferris,1 Keisha L. Gibson,1 
Hsiao Ling Lai,2 Susan F. Massengill,3 John D. Mahan,4 Randal K. Detwiler,1 
Gerald A. Hladik,1 Mara Medeiros.5  1UNC at Chapel Hill, NC; 2East Carolina 
Univ, NC; 3Carolinas Medical Center, NC; 4The Ohio State Univ, OH; 5Hospital 
Infantil de Mexico “Federico Gomez”, DF, Mexico.
Background: The performance in self-management and/or health care transition 
readiness measurements by adolescents or young adults with chronic conditions (AYA) 
needs to be correlated to clinical outcomes and health services utilization.
Methods: The 18-question STARx Questionnaire is a self-report survey of self-
management (adult-focused setting) and/or transition-readiness (pediatric setting) with 
6 factors: Medication Management, Provider Communication, Engagement during 
Appointments, Disease Knowledge, Adult Health Responsibilities, and Resource Utilization. 
The total raw score ranges from 0-90, with higher scores reflecting more intact skills (Ferris 
et al., 2015). Data presented is from 321 AYA with chronic health conditions (including 
chronic kidney disease, transplant, hypertension and lupus), seen in the pediatric- or 
adult-focused settings at 6 large health systems in the northeast, southeast, and midwest 
regions of USA, or who attended Victory Junction Camp (from several states in USA). 
The outcomes/health services utilization measures were adherence (Morisky et al., 1986) 
and number/length of hospitalizations in the last year.
Results: Higher STARx Questionnaire total score correlated with higher medication 
adherence (β = .301, p = .000, R2 = .070). Higher STARx Medication Management Subscale 
correlated with higher medication adherence (β = .499, p = .000, R2 = .224). Greater STARx 
Disease Knowledge Subscale correlated with higher medication adherence (β = .216, p 
= .001, R2 = .044), fewer number of hospitalizations (β = -.453, p = .000, R2 = .262) and 
inpatient days in the past year (β = -.432, p = .000, R2 = .187).
Conclusions: The strong reliability of the STARx Questionnaire in AYA with a variety 
of conditions treated in either the pediatric or adult-focused clinics, correlates with health 
outcomes and health services utilization.
Funding: Private Foundation Support
TH-PO469
Emotional-Behavioral Functioning of Children Enrolled in the Chronic 
Kidney Disease in Children (CKiD) Cohort Study  Rebecca J. Johnson,1,2 
Matthew Matheson,2 Arlene C. Gerson,2 Susan R. Mendley,2 S. Shinnar,2 
Marc Lande,2 Amy Kogon,2 Lyndsay Harshman,2 Debbie S. Gipson,2 Bradley 
Warady,1,2 Susan L. Furth,2 Stephen R. Hooper.2  1Children¶s Mercy; 2Chronic 
Kidney Disease in Children (CKiD) Study Group.
Background: CKiD is a longitudinal study examining medical, neurocognitive, and 
psychosocial outcomes for children with mild to moderate CKD ages 1-16 years at study 
entry. Little is known about how CKD affects emotional-behavioral functioning (EBF), 
although data from the CKiD study indicate that these children are at increased risk of 
attention and executive functioning deficits. In one of the largest studies to date, we report 
EBF of participants at baseline and over time.
Methods: Parents of participants completed the Behavior Assessment System for 
Children (BASC-2) at baseline and every 2 years. 835 participants had BASC-2 data, 
including 797 at baseline. Linear mixed models predicted participants’ scores on BASC-2 
summary measures (Internalizing, Externalizing, Behavioral Symptoms Index, Adaptive 
Skills) and selected clinical scales (Depression, Attention Problems). Analyses controlled 
for key demographic (age, sex, ethnicity, maternal education, household income, Full Scale 
IQ) and medical (GFR, hypertension [HTN], low birth weight, anemia, seizures, proteinuria, 
glomerular diagnosis, time since CKD onset) covariates.
Results: Children with mild to moderate CKD have EBF scores generally within normal 
limits at baseline and over time. At baseline, the proportion with scores at least 1 SD above 
the mean was 24% for internalizing problems and 27% for attention problems, higher 
than would be expected in a typical sample. In an adjusted linear mixed model, persistent 
hypertension was related to attention problems (β = 1.81, 95% CI = 0.40-3.21, p<.02).
Conclusions: Children with mild to moderate CKD have parent-reported EBF that 
is within normal limits, at baseline and over time. However, the proportion with scores 
more than one SD above the mean is higher than would be expected, suggesting that this 
population may be at slightly increased risk for internalizing symptoms and attention 
problems, particularly in the context of HTN, which was associated with increased risk of 
parent-reported attention problems.
Funding: NIDDK Support, Other NIH Support - National Institute of Neurological 
Disorders and Stroke (NINDS), National Institute of Child Health and Human 
Development (NICHD), and the National Heart, Lung, and Blood Institute (NHLBI)
TH-PO470
Echocardiographic Findings in Hypertensive Children with Kidney Disease 
or Essential Hypertension  Gabriel Paris,1 Wacharee Seeherunvong,2 Aura 
Jeannette Arenas morales,2 Marissa J. Defreitas,2 Carolyn L. Abitbol,2 Michael 
Freundlich,2 Sethuraman Swaminathan,1 Gaston E. Zilleruelo.2  1Pediatric 
Cardiology, Univ of Miami; 2Pediatric Nephrology, Univ of Miami, Miami, FL.
Background: Hypertension (HT) is a major risk factor causing left ventricular 
hypertrophy (LVH) and diastolic dysfunction. In children with chronic kidney disease 
(CKD), the cardiovascular morbidity exceeds that of peers without CKD.
Methods: Children with diagnosis of HT underwent echocardiography with concurrent 
tests of kidney disease were included. LV mass, systolic and diastolic function were 
reviewed. Diastolic transmitral early (E), late (A), septal E’, lateral-mitral E’ velocities 
measured. Calculated E/A<1 and/or E/E’ Z-score(Z) >2 defined diastolic dysfunction.
Results: 52 HT children (11±5yr), 29 had CKD (CKD-HT) and 23 essential HT (eHT). 
No differences in age, gender, body mass index (BMI), %obesity, degree HT between groups. 
Prevalence LVH (25% & 30%) and LVMI-Z were similar. LVMI-Z was strongly correlated 
with BMI-Z in both groups (each r +0.6,p<0.01) and to a lesser degree with SBP-Z (r 
+0.3,p 0.05). No correlation of LVMI-Z with GFR. Diastolic dysfunction was identified 
in both eHT and CKD-HT (24% vs. 25%) whereas systolic function was preserved in both 
groups. Changes of E/A and aortic root diameter were subtle but significantly different 
between eHT and CKD-HT (see figure). Additionally, a significant decline in E/A (p 0.01) 
and Septal E/E’-Z (p 0.03) was observed with worsening GFR. 
Conclusions: High prevalence of LVH and diastolic dysfunction noted in HT children 
with or without CKD. Severity of LVH associated with obesity and to a lesser extent to 
high BP. HT children with CKD had subtle but significantly lower E/A ratio and larger 
aortic root diameter which could be related to poor renal function.
TH-PO471
Glomerular Capillary Injuries in Thin Basement Membrane Disease 
Yusuke Kajimoto, Michiko Aoki, Go Kanzaki, Kiyotaka Nagahama, Akira 
Shimizu.  Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Background: Thin basement membrane disease (TBMD) is diagnosed by diffuse 
reduction of the thickness of glomerular basement membrane (GBM) in electron microscopy 
(EM), and characterized clinically by benign familial hematuria. However, some cases 
progress to end-stage renal disease. In the present study, we performed the clinico-
pathological analyses of TBMD, especially focusing on glomerular capillary injuries, 
including morphological and qualitative alterations of GBM and glomerular capillaries, 
and correlated with clinical findings.
Methods: In our department, 27 renal biopsy cases of TBMD (1.9%) was identified. We 
investigated clinical characteristics using clinical records. We also examined pathological 
characteristics using light and EM, immunostaining for CD34, which can detect glomerular 
capillaries, immunostaining for α5 (IV) chains of type IV collagen, which is one of the main 
component of GBM, and low-vacuum scanning electron microscopy (LV-SEM), which 
allows detailedthree-dimensional observation of GBM surface.
Results: The average age was 37.3±19.5 (5-64) years. 26 cases had hematuria and 
21 cases had proteinuria. 17 cases (63.0%) indicated hematuria or proteinuria under 
20 years of age. In 6 cases, the eGFR declined in G3a to G4 in clinical CKD stage. In 
immunofluorescence, α5 (IV) expression was significantly reduced in the GBM with partial 
enhancement of a2 (IV). In LV-SEM observations, thinning and flattering of GBM was 
noted with multiple small holes and manufactures in the surface of GBM. In CD34 and 
PAS staining, narrowed glomerular capillaries increased with accumulation of glomerular 
extracellular matrix (ECM), associated with glomerular endothelial cell injuries.
Conclusions: In TBMD, narrowing glomerular capillaries developed with increased 
glomerular ECM, in association with glomerular endothelial injuries. In addition, qualitative 
(reduced α5 (IV) expression) and ultrastructural alterations of GBM (small holes and 
manufactures) were noted. These glomerular capillary injuries might be associated with 
the clinical findings including urinary abnormalities and renal dysfunction.
TH-PO472
Clinical Significance of IgM Disposition in Kidney Biopsy of Paediatric 
Minimal Change Disease, Single-Centre Case-Control Study  Duaa Alromaili, 
Turki Abdullah Alshareef.  Pediatrics, King Faisal Specialist Hospital and 
Research Centre, Riyadh, Saudi Arabia.
Background: In many cases of Minimal change nephrotic syndrome, or Minimal 
change disease (MCD), immunoglobulin M (IgM) is occasionally deposited in the 
mesangium, and can be seen under the electron microscopy (EM) and immunofluorescence 
(IF). Based on many studies, the rule of IgM is controversial in minimal change disease 
MCD which is one of the histopathological types of INS The aim of this study is to explore 
the clinical significance of mesangial IgM deposits in paediatric MCD cases.
Methods: We reviewed a sample of 313 cases children with MCD who underwent 
a native kidney biopsy (NKB) at King Faisal Specialist Hospital and Research Centre in 
Riyadh, Saudi Arabia from 2003 to 2014. The sample is divided furtherly according to the 
presence of IgM deposits under EM and IF to IgM +IF and IgM-IF, which are labeled as 
case- control groups respectively. We reviewed the clinical course as per the response to 
the steroid treatment. Initial adjuvant therapies included: Cyclosporine, Tacrolimus and 
Cyclophosphamide.
Results: MCD IgM+IF has shown a significant association with the presence of 
hypertension at the time of diagnosis, where a p-value of 0.03. MCD IgM+IF showed 
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statistical significance in association of steroid dependence where p-value of 0.04 in the 
MCD IgM+IF steroid dependence group and p- value of 0.05 in the MCD IgM+IF steroid 
resistance cases. Chronic kidney disease is not associated statistically with the presence 
of IgM. In term of treatments, cyclosporine (CSA) has shown a significant association in 
the development of remission of the MCD IgM+IF with a p value of 0.04 for the subtype.
Conclusions: Our results indicate that IgM+IF may be a marker of the initial disease 
severity of MCD as it correlates with the outcome of steroid response. Cyclosporine 
shows a better outcome in achieving the remission in MCD IgM+IF. A prospective study 
is required to support our conclusion.
TH-PO473
Correlation Between Age-Dependent Expression of Oxidant Handling 
Genes and Sensitivity to Nicotine Exposure in the Mouse Kidney 
Istvan Arany, Samuel Hall, Mehul P. Dixit.  Pediatrics, Univ of Mississippi 
Medical Center, Jackson, MS.
Background: Studies have shown that childhood exposure to secondhand smoke 
may increase adulthood renal risk. Other studies also suggest that children may be more 
vulnerable to secondhand smoke exposure than adults, which may imply augmented 
sensitivity to renal oxidative stress. Accordingly, we tested the status of oxidant handling 
genes and extent of oxidative stress in the kidneys of adolescent mice exposed to active or 
passive smoking-equivalent nicotine and compared to the kidneys of adult mice.
Methods: 4– and 24-week-old male C57BL/6J mice -that are equivalent to early 
adolescence and early adulthood, respectively- had ad libitum access to NIC in their 
drinking water (200 or 5 µg/ml) for 4 weeks that results in either active (>150 µg/ml) or 
passive (<10 µg/ml) smoking-equivalent cotinine (stable metabolite of NIC) levels in their 
plasma. Renal oxidative stress (4HNE content), injury (KIM-1 expression) and function 
(plasma creatinine) were determined. Expression of select pro- and antioxidant genes were 
determined by Western blotting and microarray.
Results: Active smoking-equivalent NIC exposure resulted in 2.5 fold increase in 
renal 4HNE content in adolescent mice compared to vehicle, which is significantly higher 
(p<0.05) than in adult mice (1.7 fold). Similarly, renal KIM-1 expression increased 2.2 vs 
1.5 fold (p<0.05), respectively, while renal function was unchanged. In contrast, passive 
smoking-equivalent NIC exposure increased renal 4HNE content only in young (1.4x) but 
not in adult mice. Interestingly, baseline expression of select pro-oxidant genes (p66shc) 
was higher, while expression of some anti-oxidant genes (Nrf2, MnSOD) was lower in the 
young kidney compared to the adult kidney. In vitro experiments confirmed that high level 
of p66shc or low level of Nrf2 or MnSOD exacerbates NIC-mediated ROS production and 
consequent mitochondrial depolarization-dependent injury in renal proximal tubule cells.
Conclusions: Our results imply that the young kidney exhibits a more pro-oxidant 
environment than the adult kidney, which may explain their higher sensitivity to chronic 
NIC exposure-dependent oxidative stress.
TH-PO474
Maternal Nutrient Restriction Aggravates Renal Tubular Necrosis and 
Interstitial Fibrosis After Unilateral Ureteral Obstruction in Rat Offspring 
Mariko Hida,1 Tokiya Abe,2 Akinori Hashiguchi,2 Midori Awazu.1  1Dept of 
Pediatrics, Keio Univ School of Medicine, Tokyo, Japan; 2Dept of Pathology, 
Keio Univ School of Medicine, Tokyo, Japan.
Background: Maternal nutrient restriction not only reduces nephron number but may 
also affect tubules, interstitium, capillary density, endothelial function, and response to 
oxidant injury. These changes may become apparent only after a secondary injury to the 
kidney. We examined the response to unilateral ureteral obstruction (UUO) in the kidney 
of offspring from control and nutrient restricted rats.
Methods: Six-week old offspring from rats given food ad libitum (CON, n=3) and 
those subjected to 50% food restriction throughout pregnancy (NR, n=6) were subjected to 
left ureteral obstruction. After 7 days, blood pressure, serum creatinine, urea nitrogen, and 
urine from the left kidney were examined. Kidneys were stained with Masson trichrome, 
elastica van Gieson, or CD31. Collagen was quantified by analyzing the color distribution 
of whole-slide-images after color classification of the pixels. The expression of nitrotyrosine 
was assessed by immunoblot of kidney lysate.
Results: There was no difference between CON and NR in body weight, blood pressure, 
serum creatinine, and urine protein or osmolality. Blood urea nitrogen was significantly 
higher in NR than CON (20.8±0.8 vs 17.5±0.1 mg/dL, P<0.05). Macroscopically, pelvic 
dilation of similar degree was noted in the obstructed kidney of CON and NR. Tubular 
necrosis, however, was more extensively observed in NR. There was no difference in the 
collagen area ratio of the contralateral kidney between CON and NR. The collagen area 
ratio of the obstructed kidney was increased compared with the contralateral kidney, and 
the increase was significantly greater in NR compared with CON (6.8±3.8% vs 2.6±0.5%, 
P<0.05). There was no difference in immunohisotochemical expression of endothelial 
marker CD31 between CON and NR. The expression of nitrotyrosine, a marker of oxidative 
stress, was increased in the obstructed kidney in both CON and NR, and the extent was 
greater in NR.
Conclusions: NR kidneys are more susceptible to ischemia and fibrosis secondary to 
UUO, which may be due to increased oxidative stress.
Funding: Government Support - Non-U.S.
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Post-Weaning High-Fat Diet Accelerates Kidney Injury, but Not 
Hypertension Programmed by Maternal Diabetes  Min-Chun Liao,1 
Yessoufou Aliou,1 Xin-Ping Zhao,1 Shiao-Ying Chang,1 Isabelle Chenier,1 Julie 
R. Ingelfinger,2 Shao-Ling Zhang.1  1CRCHUM, Univ of Montreal, Montreal, 
QC, Canada; 2Pediatric Nephrology Unit, Massachusetts General Hospital, 
Boston, MA.
Background: Severe maternal diabetes results in offspring with intrauterine growth 
restriction (IUGR) phenotype. The long-term outcome of these affected IUGR diabetic 
offspring who experience overnutrition in early life is incompletely delineated. In the 
current study, we aimed to establish the underlying mechanisms by which a post-weaning 
high-fat diet (HFD) accelerates the perinatal programming of kidney injury occurring in 
the offspring of diabetic mothers.
Methods: Male offspring of non-diabetic and diabetic C57/BL6 dams were fed with 
standard chow (normal diet, ND) or HFD from 4 to 20 week-old. Biological parameters, 
renal morphology, and gene expression were assessed. Rat immortalized renal proximal 
tubular cells (IRPTCs) were used for in vitro studies.
Results: As compared to offspring from non-diabetic dams, on ND, the offspring of 
dams with severe maternal diabetes had IUGR phenotype and developed mild hypertension 
and evidence of kidney injury in adulthood. Exposing the IUGR offspring to HFD 
resulted in rapid weight gain, catch-up growth and later, to profound kidney injury with 
glomerulosclerosis and tubular apoptosis.  In adulthood these IUGR animals demonstrated 
activation of renal TGFb1 and collagen type IV expression, increased oxidative stress and 
enhanced renal lipid deposition, but not systemic hypertension. HFD or free fatty acid 
(FFA) in the diet appear to accelerate the process of perinatal programming of kidney 
injury, associated with increased CD36 and fatty acid binding protein 4 (Fabp4) expression 
in proximal tubular cells, which may target reactive oxygen species (ROS), NF-κB and 
TGFb1 signaling.
Conclusions: Early postnatal exposure to overnutrition with a HFD appears to increase 
the risk of development of kidney injury, but not hypertension, in IUGR offspring of dams 
with maternal diabetes.
Funding: Government Support - Non-U.S.
TH-PO476
Does Anemia Contribute to Growth Delay in Pediatric CKD? 
Implications from Adenine Mouse Model of CKD-Related Growth Failure 
Oleh M. Akchurin,1 Adele L. Boskey,2 Stefano Rivella.3  1Weill Cornell Medical 
College; 2Hospital for Special Surgery; 3Children¶s Hospital of Philadelphia.
Background: Growth delay remains common in children with CKD and it worsens 
their quality of life. The origin of CKD-related growth failure in children is thought to 
be muti-factorial but the contribution of anemia remains controversial based on the data 
from the major clinical studies. Experimental investigations of the role of anemia and iron 
homeostasis in growth and nutrition in juvenile CKD are lacking.
Methods: C57Bl6 mice and hepcidin gene (HAMP) knock-out (KO) pups were started 
on 0.2% adenine diet at weaning (3 weeks) and sacrificed in 8 weeks. Litter-mate controls 
were fed a regular diet. Weekly measurements of nose to tip of tail length were used for 
tracking linear growth.
Results: Adenine fed juvenile mice had statistically significant elevation of BUN, 
serum creatinine and phosphorus at sacrifice. Adenine fed mice had slower rate of weight 
gain compared with controls and by 3 weeks they stopped gaining and / or started to loose 
weight. Linear growth was also significantly slower in adenine fed mice. At sacrifice, 
adenine fed mice had approximately 40% deficit in body weight and 10-15% deficit in 
body length, as compared with controls (both differences were statistically significant). 
Bone histology revealed marrow adiposity in adenine fed mice. While wild type adenine 
fed mice developed anemia, hemoglobin and hematocrit levels remained unchanged in 
HAMP-KO mice throughout the experiment. However, no differences in linear growth 
or serum creatinine were observed between wild-type and HAMP-KO adenine-fed mice.
Conclusions: In this study we demonstrated that 0.2% adenine diet reliably induces 
CKD-related growth failure and anemia in juvenile mice, resembling those seen in children 
with CKD. Knocking out HAMP rescues the anemia phenotype but does not affect linear 
growth and renal function decline, thus providing new insights into the interplay between 
anemia and other CKD complications in children. Our ongoing experiments are directed 
towards further characterization of the mineral metabolism and erythropoiesis in this model 
and testing novel therapies that can improve growth in juvenile CKD.
Funding: Other NIH Support - R01 DK090554 05 (S. Rivella)
TH-PO477
Establishment of Urinary Tract Infections in the Absence of Umbrella Cells 
and Uroplakin Plaque  Ashley R. Jackson,1 Birong Li,2 Kirk M. McHugh,3 
Brian Becknell.4  1Biomedical Sciences Graduate Program, Ohio State Univ; 
2Center for Clinical and Translational Research, NationZide Children¶s 
Hospital; 3Div of Anatomy, Ohio State Univ; 4Nephrology Section, Nationwide 
Children¶s Hospital.
Background: Uropathogenic Escherichia coli (UPEC) accounts for 90% of human 
urinary tract infections (UTI). Urothelial umbrella cells elaborate uroplakin plaques that 
establish a permeability barrier to urine and pathogens. UPEC attach to Upk1a within 
uroplakin plaques, invade umbrella cells, and establish intracellular bacterial communities. 
We genetically ablated plaques and umbrella cells to test their role in UPEC invasion and 
establishment of experimental UTI.
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Methods: Six week old Upk1bRFP/RFP and wild type mice were intravesically inoculated 
with 108 cfu UPEC strain UTI89. Upk1a was localized by immunohistochemistry. Bacterial 
burden and histopathology were analyzed at baseline, 1 and 7 days post infection (dpi). 
Urothelial permeability was evaluated at baseline using 10,000 dalton FITC-Dextran.
Results: Deletion of Upk1b led to absent urothelial plaques and umbrella cells, as 
well as reduced expression and apical concentration of Upk1a protein. UPEC established 
intracellular bacterial communities in wild type but not Upk1bRFP/RFP urothelium 1 dpi. 
Upk1bRFP/RFP bladders demonstrated reduced urothelial neutrophil infiltrates 1 dpi. Whereas 
bacterial recovery from urine, bladder, ureters and kidneys was significantly reduced in 
Upk1bRFP/RFP versus wild type 1 dpi (p<0.05, Mann-Whitney), comparable burden was 
observed 7 dpi. Upk1bRFP/RFP but not wild type bladder urothelium was permeable to 
FITC-dextran.
Conclusions: Upk1b serves an essential role in plaque assembly and terminal 
differentiation of umbrella cells. Whereas umbrella cells and uroplakin plaques facilitate 
initial UPEC colonization of the bladder, these structures are dispensable for maintenance 
of infection. Comparable UPEC recovery from Upk1bRFP/RFP urinary tracts 7 dpi supports 
the existence of alternative UPEC reservoirs, potentially as a consequence of a disrupted 
urine permeability barrier. Thus, genetic ablation of umbrella cells provides the opportunity 
to define alternative pathways for UTI pathogenesis.
Funding: NIDDK Support
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3D Modeling of the Urinary Tract to Better Understand Urothelial 
Development and Pathogenesis  Leah D. Hunter,1,2 Claudia F. Mosley,1,2 
Ashley R. Jackson,2,3 Kirk M. McHugh.1,2  1Div of Anatomy, Ohio State Univ; 
2Center for Human and Molecular Genetics, NationZide Children¶s Hospital; 
3Biomedical Sciences Graduate Program, Ohio State Univ.
Background: Recent evidence implicates a role for urothelium in the pathogenesis 
of chronic kidney disease (CKD). To better understand these processes, we plan to three-
dimensionally (3D) reconstruct and electronically annotate the expression of urothelial 
markers during development.
Methods: Embryonic day (E)13.5 (undifferentiated), E14.5 (urothelial differentiation 
onset) FVB/N mice were 3D reconstructed electronically from 10mm serial sections labeled 
with urothelial antibodies. Molecular annotations were electronically generated using Stereo 
Investigator software and quantitated using Neurolucida Explorer.
Results: E13.5 urothelium displayed highly undifferentiated characteristics, lacking 
keratin (Krt) and uroplakin expression, while E14.5 exhibited significant urothelial identity 
expressing a wide range of markers. Bladder basal urothelial cells express sporadic Krt5, 
Krt14 and Ki67. Unexpectedly, Krt5 also localized to intermediate and select superficial 
cells at E14.5. Shh and p63 uniformly localized to basal and most intermediate urothelial 
cells. Shh and Ki67 localized to some superficial urothelial cells. Intermediate and superficial 
bladder urothelial cells expressed uroplakins. Interestingly, uroplakin expression was more 
prominent in the dorsal urinary tract, while Shh exhibited more ventral patterning, and 
Krt14 commonly localized to anterior portions of the caudal bladder urothelium. Krt20 
was only minimally expressed at E14.5. Overall, E14.5 bladder urothelial cells expressed 
13% Krt14, 57% uroplakin, 1% Krt20, 79% p63, 66% Shh, 21% Ki-67, and 34% Krt13, 
when normalized to E-cadherin.
Conclusions: Molecular annotation and 3D modeling of the entire embryonic urinary 
tract will provide novel insight into the expression pattern of urothelial-specific proteins 
temporally and spatially. Future studies will include 3D mapping of these tissues and 
markers throughout development and disease states. Our work will serve as a vital resource 
for developing diagnostic and therapeutic measures for CKD.
Funding: NIDDK Support
TH-PO479
Cardiac Hypertrophy Causes Elevation in Circulating c-FGF23 Levels in 
Mice  Isao Matsui,1 Akihiro Shimomura,2 Yasuo Kusunoki,1 Daisuke Mori,1 
Sayoko Yonemoto,2 Masamitsu Senda,2 Yusuke Sakaguchi,1 Takayuki Hamano,2 
Yoshitaka Isaka,1 Hiromi Rakugi.1  1Geriatric Medicine and Nephrology, Osaka 
Univ Graduate School of Medicine, Suita, Osaka, Japan; 2Comprehensive 
Kidney Disease Research, Osaka Univ Graduate School of Medicine, Suita, 
Osaka, Japan.
Background: Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that 
regulates phosphate homeostasis. Besides its phosphaturic effect, intact FGF23 induces 
left ventricular hypertrophy (LVH). However, it remains unclear whether ventricular 
hypertrophy affects circulating levels of FGF23.
Methods: The activation of the calcineurin/NFAT (nuclear factor of activated T-cells) 
pathway plays pivotal roles in the pathogenesis of LVH. Using cardiomyocyte-specific 
calcineurin A transgenic (CnA-TG) mice, we assessed whether ventricular hypertrophy 
affects circulating levels of FGF23.
Results: CnA-TG mice at age 6 weeks developed ventricular hypertrophy. Heart 
weight/body weight ratio was 0.0111 ± 0.0014 in CnA-TG mice and 0.0043 ± 0.0003 in 
wild type (WT) mice. Real time PCR analyses demonstrated that cardiac tissues of CnA-
TG mice had higher levels of atrial natriuretic peptide, brain natriuretic peptide, and β 
myosin heavy chain. Serum C-terminal FGF23 levels of CnA-TG mice was significantly 
higher than those of WT mice (214.7 ± 68.7 vs. 137.2 ± 19.8 pg/mL, P=0.032), whereas 
the levels of intact FGF23 were not different between the two groups (CnA-TG mice 27.6 
± 14.4 pg/mL vs. WT mice 24.7± 6.1 pg/mL, P=0.943). All parameters — body weight, 
food intake, water intake, urine volume, creatinine clearance, serum phosphate/calcium 
levels, urinary phosphate/calcium excretion, and fractional excretion of phosphate/calcium 
— were not different between the two groups. Although iron deficiency has been reported 
to be associated with high circulating c-FGF23, but not i-FGF23 levels, CnA-TG mice 
had higher transferrin saturation than WT mice (91.5 ± 6.3 vs. 71.7 ± 15.5%, P<0.001).
Conclusions: Cardiac hypertrophy causes elevation in circulating c-FGF23 levels 
through yet-unknown mechanisms.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Soluble Klotho and Cardiac FGF23 Modulate Left Ventricular Hypertrophy 
in CKD Patients  Maren Leifheit-Nestler,1 Christian Faul,2 Dieter Haffner.1 
1Dept of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical 
School, Hannover, Germany; 2Div of Nephrology and Hypertension, Dept of 
Medicine, Univ of Miami Miller School of Medicine, Miami, FL.
Background: Elevated levels of circulating fibroblast growth factor 23 (FGF23) are 
strongly associated with chronic kidney disease (CKD) mortality, and left ventricular 
hypertrophy (LVH), a major cause of cardiovascular death in CKD patients. Existence and 
role of a paracrine cardiac FGF23/Klotho system in the heart, however, remain elusive.
Methods: We conducted a retrospective case-control study in 25 deceased patients with 
end-stage renal disease, and 25 age and sex-matched healthy controls. At the time of death 
18 patients were on dialysis treatment, and 7 patients were transplanted. Myocardial autopsy 
samples of the left ventricle (LV) were evaluated for endogenous FGF23 expression, FGFR 
1-4, Klotho, calcineurin-NFAT signaling mediated LVH, and genes regulating pathological 
cardiac remodeling by immunohistochemistry and quantitative real-time PCR analysis. The 
expression of brain natriuretic peptide (BNP) served as a marker of LVH.
Results: Here, we find that FGF23 is expressed in human cardiomyocytes, and that 
myocardial expression of FGF23 in concert with Klotho deficiency strongly correlates with 
the presence of LVH in CKD patients. Enhanced cardiac FGF23 expression is associated 
with chronic phosphate load, up-regulation of FGFR4 expression, and activation of 
calcineurin-NFAT signaling, an established inducer of cardiac remodeling and LVH. Most 
important, these changes are reversed after renal transplantation. Using in vitro studies, we 
observe that cardiomyocytes express and release full-length biologically active FGF23, and 
that enhanced FGF23 secretion results in cardiomyocyte hypertrophy, which is blocked in 
the presence of soluble Klotho.
Conclusions: Our results indicate that enhanced levels of FGF23 induce LVH via a 
paracrine mechanism in settings of Klotho deficiency. In CKD patients, this process is 
reversed after renal transplantation.
TH-PO481
Role of FGF23 Mediating LVH in a Mouse Model of Klotho Deficiency 
Maren Leifheit-Nestler,1 Melis Basaran,1 Makoto Kuro-o,2 Ioana Alesutan,3 
Jakob Völkl,3 Florian C. Lang,3 Dieter Haffner.1  1Dept of Pediatric Kidney, 
Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany; 
2Center for Molecular Medicine, Jichi Medical Univ, Shimotsuke, Japan; 3Dept 
of Physiology, Univ of Tuebingen, Tuebingen, Germany.
Background: In patients with chronic kidney disease (CKD), high serum concentrations 
of the phosphaturic hormone fibroblast growth factor 23 (FGF23) result in high mortality 
rate and left ventricular hypertrophy (LVH). FGF23 signals via FGF receptors (FGFR) in 
the presence of its cofactor Klotho. Recent studies reveal a Klotho independent pathway 
of FGF23 in cardiomyocytes to promote cardiac remodeling and LVH. However, Klotho 
seems to be cardioprotective. The aim of our study was to investigate the role of cardiac 
FGF23/FGFR signaling in the activation of pathologic cardiac remodeling and LVH in the 
Klotho knockout (kl/kl) mouse.
Methods: Hearts of 8 weeks old kl/kl mice and wild-type (WT) mice were excised and 
weighted. The left ventricle was isolated and stained with wheat germ agglutinin (WGA) to 
quantify cross-sectional area of individual cardiomyocytes. Furthermore, cardiac tissue was 
homogenized and analyzed by quantitative real-time PCR for genes involved in pathological 
cardiac remodeling, and protein lysates were used to determine FGF23-mediated activation 
of calcineurin-NFAT pathway mediating LVH.
Results: Relative heart weight of kl/kl mice was significantly higher compared with 
WT, and cardiomyocyte cross-sectional area was increased in kl/kl mice indicating LVH. 
Cardiac Fgf23 gene and protein levels were induced significantly in kl/kl mice compared 
with WT. Interestingly, expression of Fgfr1, the physiological receptor for FGF23/Klotho 
signaling, was unaffected in kl/kl mice, but Fgfr4 was up-regulated significantly. The 
calcineurin-NFAT protein complex was activated in kl/kl mice inducing genes involved in 
pathological cardiac remodeling and the development of LVH.
Conclusions: Our data suggest that high levels of circulating and cardiac FGF23 
contribute to cardiac remodeling and LVH in Klotho deficient mice indicating a direct 
impact of FGF23 signaling via FGFR4 on cardiovascular disease beyond CKD.
TH-PO482
Cardiac FGF23 in Concert with Klotho Deficiency Affect Myocardial 
Fibrosis in Dialysis Patients  Maren Leifheit-Nestler, Felix Kirchhoff, Dieter 
Haffner.  Dept of Pediatric Kidney, Liver and Metabolic Diseases, Hannover 
Medical School, Hannover, Germany.
Background: Pathologic cardiac remodeling, i.e. left ventricular hypertrophy (LVH) 
and myocardial fibrosis, is a major cause of cardiovascular (CV) death in patients with 
chronic kidney disease (CKD). Increased circulating levels of fibroblast growth factor 23 
(FGF23) are associated with increased mortality in CKD coinciding with enhanced CV 
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disease risk factors and LVH. The impact of cardiac FGF23 on myocardial fibrosis in CKD is 
not known. Here we investigate the association of cardiac FGF23 and its coreceptor Klotho 
with myocardial fibrosis in autopsy samples of CKD patients on dialysis.
Methods: Myocardial autopsy samples of the left ventricle of 18 deceased CKD 
patients on dialysis treatment, and age and sex-matched controls were evaluated with human 
fibrosis RT2 ProfilerTM PCR Arrays including genes responsible for fibrotic remodeling. 
For histological investigation of cardiac fibrosis, samples were stained with picosirius red 
and quantified by brightfield and polarized light microscopy. Cardiac FGF23 and soluble 
Klotho in cardiac tissue were assessed by qPCR and immunohistochemistry, respectively.
Results: The degree of cardiac fibrosis was increased in dialysis patients compared 
with controls, and correlated positively with duration of ESRD, and dialysis treatment. 
The expression of cardiac FGF23 was enhanced in the dialysis group, and associated with 
fibrosis. The amount of circulating Klotho was reduced in myocardial tissue of our patient 
cohort, and correlated negatively with cardiac fibrosis. Human fibrosis gene array analyses 
identified 31 genes regulated significantly in dialysis patients. The TGFβ pathway, with 
TGFb1, TGFbRs and SMAD3, was up-regulated in patients on dialysis treatment, and 
TGFb1 correlated negatively with circulating Klotho. BMP7 and SMAD7, which attenuate 
fibrotic activity, were down-regulated in our patient cohort. In contrast, the pro-fibrotic 
target genes CTGF and collagen I and III were up-regulated.
Conclusions: Enhanced cardiac FGF23 expression in concert with Klotho deficiency 
is strongly associated with fibrotic cardiac remodeling processes in heart tissue of CKD 
patients on dialysis treatment.
TH-PO483
FGF23-Induced LVH Is Reversible in Rodents  Ansel P. Amaral,1,2 Alexander 
Grabner,1 Saurav Singh,1 Karla J. Schramm,1 Christopher Yanucil,1 Alexis J. 
Sloan,1 Christian Faul.1  1Medicine, Univ of Miami Miller School of Medicine, 
Miami, FL; 2Medicine, Northwestern Univ Feinberg School of Medicine, 
Chicago, IL.
Background: Left ventricular hypertrophy (LVH) contributes cardiovascular disease 
in chronic kidney disease (CKD). Serum levels of fibroblast growth factor (FGF) 23 rise 
as patients progress to renal failure. We have previously shown that FGF23 can activate 
FGF receptor (FGFR) 4 and calcineurin/NFAT signaling in cardiac myocytes and induces 
LVH in rodents. Administration of a pan-FGFR inhibitor in the 5/6 nephrectomy model of 
CKD immediately after surgery protects rats from developing LVH. Furthermore, LVH in 
rats 2 weeks after surgery is reversible by pan-FGFR inhibition.
Methods: To further study FGFR4-dependency and reversibility of FGF23-mediated 
LVH, we elevated serum FGF23 in FGFR4 knockout (-/-) mice and wild type littermates 
by administration of a high phosphate (2%) diet for 3 months. Furthermore, a group of 
wild type mice that received a high phosphate diet for 3 months was returned to normal 
chow for 3 months. LVH was assessed by histology and analysis of cross sectional area 
of individual myocytes. Serum levels of cleaved FGF23 were determined by ELISA and 
kidney function by BUN.
Results: Serum levels of phosphate and FGF23 were elevated in mice on high phosphate 
diet when compared to mice on normal chow. However, only wild type but not FGFR4-/- 
mice developed LVH after 3 months as evident by significantly increased LV wall thickness 
and cross sectional myocyte area. When wild type mice were switched from high phosphate 
to normal chow, the LVH phenotype resolved within 3 months and cardiac parameters were 
comparable to those of mice that constantly received a normal diet.
Conclusions: FGFR4 is required for the development of LVH in mice with high FGF23. 
LVH caused by 3 months of FGF23 elevation is reversed when serum FGF23 levels are 
normalized. We propose that FGF23-induced LVH in CKD is treatable, and that the FGF23/
FGFR4 signaling mechanism in the heart provides novel options for pharmacological 
interventions, including FGFR4 blockade. Progression and reversibility of cardiac injury 
might depend on the duration of FGF23/FGFR4 activation in the heart.
Funding: NIDDK Support, Private Foundation Support
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FGF23/FGFR4 Signaling Mediates LVH in Aging Mice  Alexander Grabner,1 
Karla J. Schramm,1 Saurav Singh,1 Christopher Yanucil,1 Alexis J. Sloan,1 
Ansel P. Amaral,1,2 Christian Faul.1  1Medicine, Univ of Miami Miller School 
of Medicine, Miami, FL; 2Medicine, Northwestern Univ Feinberg School of 
Medicine, Chicago, IL.
Background: Serum levels of fibroblast growth factor (FGF) 23 are elevated in patients 
with chronic kidney disease (CKD) and are independently associated with increased rates of 
left ventricular hypertrophy (LVH). A recent translational study from our group demonstrated 
that FGF23 is a causal factor in the pathogenesis of LVH and that FGF receptor (FGFR) 4 
mediates the cardiac effects of FGF23. We have shown that constitutive FGFR4 knockout 
(-/-) mice that were administered a high phosphate diet to elevate circulating FGF23 were 
protected from LVH. Human studies have shown that serum FGF23 levels increase with 
age and are associated with LVH in the elderly population. Therefore we wanted to test, if 
FGF23 is causatively involved in the development of age-related LVH.
Methods: We studied 6 and 18 months old FGFR4-/- mice and wild type littermates. 
LVH was assessed by H&E staining of cardiac cross sections and quantification of LV 
wall thickness, as well as analysis of cross sectional area of individual myocytes by WGA-
fluorochrome labeling. Serum levels of cleaved FGF23 were determined by ELISA and 
kidney function by BUN.
Results: Serum FGF23 levels continuously increase in wild type mice with age, whereas 
kidney function is not altered over time. Compared to 6 months old mice, 18 months old 
wild type mice develop LVH as evident by significantly increased LV wall thickness and 
cross sectional myocyte area. Although the increase in serum FGF23 levels in 18 months 
old FGFR4-/- mice is even higher than in wild type littermates, FGFR4-/- mice do not 
develop an LVH phenotype.
Conclusions: Aging wild type mice develop elevated serum FGF23 levels as well as 
LVH. Since aged FGFR4-/- mice are protected from LVH, we postulate that FGF23 mediates 
age-associated LVH via activation of cardiac FGFR4, similar to the mechanism that we have 
previously described in animal models of CKD. In our aging model, elevations of serum 
FGF23 and cardiac effects of FGF23 appear to be independent of reduced kidney function.
Funding: NIDDK Support, Private Foundation Support
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miR-29b and miR-30c in the Regulation of Cardiac Fibrosis by VDRAs 
Sara Panizo,1 Manuel Naves,1 Natalia Carrillo-Lopez,1 Adriana S. Dusso,1 Amalia 
Fernandez-Vazquez,2 Laura Martinez-Arias,1 Guillermo Solache-Berrocal,1 
Jorge B. Cannata-Andia,1 Isabel Rodriguez.1  1Bone and Mineral Research 
Unit, IRSIN, REDinREN, Hospital Univ Central de Asturias, Univ de Oviedo, 
Oviedo, Spain; 2Centro Medico de Asturias, Oviedo, Spain.
Background: Cardiac remodeling in chronic kidney disease is associated with 
increased myocardial fibrosis. miRNAs could have a regulatory role in this process. The 
aim of the study was to identify the role of some miRNAs in myocardial fibrosis and also 
their implication in the effect of the vitamin D receptor activation (VDRA) as well as their 
potencial use as biomarkers.
Methods: Male Wistar rats with chronic renal failure (CRF, by 7/8 nephrectomy) were 
treated intraperitoneally with equivalent doses of two VDRAs (10 ng calcitriol and 30 ng 
paricalcitol /kg/day, 5 days per week, during 4 weeks). A placebo group (CRF + vehicle) 
and a sham group with normal renal function served as controls. Biochemical parameters, 
cardiac fibrosis (Sirius red staining), miRNAs (miR-29b and miR-30c) levels in heart and 
serum, and the expression of target genes (collagen I [COL1A1], matrix metalloprotease 2 
[MMP2], and connective tissue growth factor [CTGF]) in heart were evaluated.
Results: All VDRAs prevented cardiac fibrosis, achieving statistically significant 
difference in the paricalcitol treated group. A reduced expression of miR-29b and miR-30c 
was observed in heart of CRF rats, which was prevented with all VDRAs, observing the 
better results in paricalcitol group. It is described that miR-29b regulates COL1A1 and 
MMP2 expression and miR-30c regulates CTGF expression. In the hearts of CRF rats, 
increases in RNA and protein levels of COL1A1, MMP2 and CTGF were observed, which 
were prevented with all VDRAs. In serum levels of miR-29b and miR-30c, a significant 
increase was observed, which was prevented by VDRAs use. In the heart and serum analyses, 
the more marked effects were observed with paricalcitol.
Conclusions: The VDRAs, particularly paricalcitol, reduced cardiac fibrosis acting 
on COL1A1, MMP2 and CTGF expression, probably through the regulation of miR-29b 
and miR-30c. These miRNAs could be useful serum biomarkers for cardiac fibrosis and 
also potential new therapeutic targets.
Funding: Government Support - Non-U.S.
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Inhibition of FGFR4 Reduces Changes in Cardiac Contraction Induced 
by FGF23, but Does Not Rescue Impaired Endothelium-Mediated 
Vasorelaxation  Neerupma Silswal,1 Chelsea Shapland,1 Matthew J. Hendrix,1 
Chad D. Touchberry,2 Alexander Grabner,3 Christian Faul,3 Michael J. Wacker.1 
1Univ of Missouri-Kansas City School of Medicine, Kansas City, MO; 2Health 
and Sport Sciences, Univ of Memphis, Memphis, TN; 3Univ of Miami Miller 
School of Medicine, Miami, FL.
Background: Fibroblast growth factor 23 (FGF23) is released by bone cells and is 
an important hormone in bone-kidney crosstalk in the regulation of phosphate. As kidney 
function declines, plasma FGF23 increases significantly and elevated FGF23 has been 
correlated with cardiac pathologies. Recently, our laboratory has shown that FGF23 
treatment increases intracellular calcium in primary cardiomyocytes, increases contractility 
of left ventricular muscle strips, and impairs endothelium-mediated relaxation of aortic rings 
by reducing nitric oxide bioavailability. While FGF receptors (FGFR) 1-4 are expressed 
in the heart and vasculature, it is currently unknown which FGFR mediates these direct 
effects of FGF23.
Methods: We tested the effects of FGF23 on adult mouse heart and aortic rings in 
the presence of an isoform specific FGFR4 blocking antibody (anti-FGFR4; U3 Pharma/
Daiichi-Sankyo).
Results: Acute treatment of FGF23 (9000 pg/ml) increased contraction of paced left 
ventricular muscle strips 1.6 ± 0.1 fold over vehicle (P<0.01; n=5). Additionally, FGF23 
treatment of paced Landendorff-perfused hearts acutely induced contraction abnormalities 
typically in the form of mechanical alternans. Both the increase in contractility as well 
as the alternans were eliminated by pretreatment with anti-FGFR4. Using isometric 
tension myography, preincubation with FGF23 (9000 pg/ml) caused a 35% inhibition 
of endothelium-dependent relaxation elicited by acetylcholine in PGF2α-precontracted 
aortic rings (n=3-5; P<0.05). However, pretreatment with anti-FGFR4 did not improve 
relaxation (n=5; P>0.05).
Conclusions: FGF23 can directly target cardiomyocytes via FGFR4 to alter cardiac 
excitation-contraction, but may work through different FGFR isoforms to alter endothelium-
mediated relaxation. Our findings have importance for targeting potential mechanisms of 
arrhythmias and cardiovascular changes directly induced by FGF23.
Funding: Private Foundation Support
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Differential Expression and Regulation in Uremia of FGF23 in Bone and 
Kidney  Maria Lerche Mace,1 Eva Gravesen,2 Jacob Hofman-Bang,2 Klaus 
Olgaard,2 Ewa Lewin.1,2  1Nephrology B, Herlev Hospital, Copenhagen, 
Denmark; 2Nephrology P, Rigshospitalet, Univ of Copenhagen, Copenhagen, 
Denmark.
Background: CKD is associated with increased plasma levels of FGF23 and 
contribution from extraskeletal sources has been proposed. Our aim was to study the 
regulation of FGF23 expression in bone and kidney tissues and the potential importance 
of kidney FGF23 for the increased plasma FGF23 in uremia.
Methods: The remnant kidney model of chronic uremia (8 weeks) in 5/6 
nephrectomized rats was used. Groups of uremic and age-matched normal rats (n= 6-9) 
were treated with a bolus of the FGF receptor (FGFR) inhibitor, PD173074 (PD) 50mg/
kg, or calcitriol 200ng or parathyroidectomy (PTX). Intact FGF23 levels in plasma, and 
FGF23 expression in bone and kidney were studied.
Results: FGF23 was not expressed in the normal kidney,  but was induced in injured 
kidney tissue. FGFR  inhibition significantly (p<0.01) decreased iFGF23 plasma levels 
in normal PD rats from 364±22 to 154±18pg/ml, and in uremic PD rats from 1590±229 
to 581±84pg/ml, whereas the plasma levels in the vehicle groups remained unchanged, 
normal 357±26 and uremic 1004±112pg/ml. In parallel, a decrease in FGF23 mRNA in 
bone tissue was demonstrated in both normal and uremic PD rats, as compared to their 
vehicle control (p<0.005); normal vehicle 1.54±0.23 vs normal PD 0.15±0.02, and uremic 
vehicle 2.38±0.52 vs uremic PD 0.12±0.2. In contrast, kidney FGF23 mRNA remained 
unchanged in the uremic PD rats 1.19±0.25 vs  vehicle 1.13±0.40 (ns). PTX at time of 
5/6 nephrectomy prevented the increase in plasma iFGF23 and bone FGF23 expression in 
uremia (normal 1.0, uremic 3.01±1.28 and uremic-PTX 0.42±0.09), while it had no influence 
on induction of kidney FGF23 expression in uremia (uremic 3.87±1.61 vs uremic-PTX 
3.06±2.27). Calcitriol further stimulated the increased iFGF23 plasma levels in uremia, 
whereas it had no impact on kidney FGF23 expression.
Conclusions: FGF23 is induced in the injured kidney. In contrast to bone tissue, 
the kidney expression of FGF23 in uremia is not regulated by FGFR , PTH or calcitriol 
signaling. The present results indicate that kidney FGF23  is not contributing to the high 
plasma levels of iFGF23 in uremia.
Funding: Government Support - Non-U.S.
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MEMO1 Deletion Abolishes Renal Responses to FGF23  Matthias B. Moor,1 
Barbara Haenzi,2 Nancy Hynes,3 Olivier Bonny.1,4  1Dept of Pharmacology & 
Toxicology, Univ of Lausanne, Lausanne, SZitzerland; 2Wolfson Centre for 
Age-Related Diseases, King¶s College London, London, United Kingdom; 
3Friedrich Miescher Inst for Biomedical Research, Basel, Switzerland; 4Service 
of Nephrology, Lausanne Univ Hospital, Lausanne, SZitzerland.
Background: Mediator of ErbB2-Driven Cell Motility 1 (Memo) modulates fibroblast 
growth factor (FGF) signaling in vitro, but its physiological role is unclear. Memo KO 
mice showed premature aging, insulin hypersensitivity and a deranged mineral metabolism 
similar to what is observed in FGF23 KO and Klotho mutant mice (Haenzi B, FASEB J 
2014). Here, we assessed Memo’s role in renal FGF23 effects. We attempted to rescue the 
Memo KO phenotype, and we established kidney-specific Memo KO mice.
Methods: Exon 2 of MEMO1 was deleted in the full body of Memofl/fl mice using 
a tamoxifen-inducible Cre recombinase to obtain cKO mice. Littermates without Cre 
served as controls. Twelve Memo cKO and 12 control mice were randomized to receive an 
intraperitoneal FGF23 or vehicle injection, and kidneys were studied by immunoblotting 
and qPCR. Memo cKO mice were put on 0.2% or 0.8% phosphate diets, and disease-free 
survival was assessed. Inducible kidney-specific Memo KO mice were established using 
the PAX8-LC1 Cre recombinase (Traykova-Brauch M, Nat.Med 2008).
Results: Memo cKO mice developed a phenotype of premature aging upon tamoxifen 
treatment. Reducing dietary phosphate content did not alter disease-free survival. Memo 
cKO mice lacked renal responses to FGF23. Moreover, the vitamin D inhibitory effect of 
FGF23 on the 24a-hydroxylase (CYP24A1) was absent in cKO mice. Kidney-specific Memo 
KO mice remained viable and had abolished Memo expression in the kidney but not in 
other organs upon KO induction. These mice showed renal calcium wasting.
Conclusions: Memo is involved in the mediation of renal FGF23 effects and in renal 
calcium handling. This explains many similarities that Memo cKO mice share with FGF23 
or Klotho KO mice. However, the three mouse models differ in phosphate dependence of 
the eventually lethal phenotype.
Funding: Government Support - Non-U.S.
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Exploring Bacterial Endotoxin as a Promoter of Fibroblast Growth Factor 
23 Production in Chronic Kidney Disease  Shiqin Zhang, Jason R. Stubbs. 
The Kidney Inst, The Univ of Kansas Medical Center, Kansas City, KS.
Background: Serum fibroblast growth factor 23 (FGF23) is elevated in chronic kidney 
disease (CKD) and correlates with circulating concentrations of inflammatory cytokines. 
Low levels of bacterial endotoxin have been detected in the bloodstream of CKD patients 
and may promote inflammation in this setting. We hypothesized that endotoxemia may 
stimulate FGF23 production in CKD.
Methods: We first utilized a mouse osteocyte cell line (IDG-SW3) to explore the 
direct effects of lipopolysaccharide (LPS) on FGF23 production. Next, we tested the in 
vivo effects of low-dose LPS injection on FGF23 production in both wild-type (WT) mice 
and mice lacking CD14, a primary LPS receptor. Lastly, we compared the progressive 
changes in FGF23 production in WT and CD14-/- mice in response to CKD induction by 
adenine ingestion.
Results: Treatment of IDG-SW3 cells with LPS (1ug/ml) resulted in an 11-fold 
increase in FGF23 mRNA expression compared to vehicle (p<0.05, triplicate experiments). 
Moreover, intraperitoneal injection of LPS (2mg/kg) in WT mice resulted in a 35-fold 
increase in calvarial FGF23 gene expression two hours post-treatment (p<0.001 compared 
to vehicle-treated WT mice), which was accompanied by a doubling of serum FGF23 (342.9 
± 124.2 pg/ml vs. 166.5 ± 25.9 pg/ml in vehicle-treated WT mice; p=0.001). Identical 
LPS dosing in CD14-/- mice blunted this response, resulting in only a 10-fold increase in 
calvarial FGF23 gene expression (p<0.01) and no obvious difference in serum FGF23 
(188.9 ± 75.8, p=NS) compared to vehicle-treated WT mice (n≥8 per group). Finally, CKD 
induction in WT mice led to a marked elevation of serum FGF23 (6862.0 ± 4829.1 pg/ml 
vs. 251.9 ± 133.3 pg/ml in WT mice fed a control diet). The absence of CD14 failed to 
mitigate FGF23 increments with CKD progression, as CD14-/- mice with CKD exhibited 
comparable serum FGF23 concentrations to WT mice with CKD (9958.7 ± 5047.6 pg/ml, 
p=NS; n≥9 per group).
Conclusions: Bacterial endotoxin stimulates FGF23 production by bone by a 
mechanism that is partially dependent on CD14 signaling; however, the deletion of CD14 in a 
CKD mouse model fails to attenuate the rise in serum FGF23 that accompanies kidney injury.
Funding: NIDDK Support
TH-PO490
I n f l a m m a t i o n  A f f e c t s  F G F 2 3  P r o d u c t i o n  i n  U r e m i a 
Maria Encarnacion Rodriguez Ortiz,1 Juan miguel Diaz-tocados,2 Juan 
R. Munoz-Castaneda,2 Carmen maria Herencia,2 Julio Manuel Martínez 
Moreno,2 Addy Rosa Montes de Oca Gonzalez,2 Alberto Ortiz,1 Escolastico 
Aguilera-tejero,3 Mariano Rodriguez,2 Yolanda Almaden peña.4  1IIS-Fundacion 
Jimenez Diaz, REDinREN, Madrid, Spain; 2IMIBIC. Reina Sofia Hospital. 
Un. of Cordoba, Cordoba, Spain; 3Dep. Animal Medicine and Surgery, Univ 
of Cordoba, Cordoba, Spain; 4Lipid and Atherosclerosis Unit, IMIBIC/Reina 
Sofia Hospital/Un. of Cordoba. CIB(R2bn, Cordoba, Spain.
Background: FGF23 increases since early stages of chronic kidney disease (CKD). 
In CKD, other factors as inflammation may affect the phosphaturic action of FGF23, and 
higher FGF23 may be required to control P. We aimed to determine if the production of 
FGF23 is affected by LPS-induced inflammation in experimental uremia.
Methods: 5/6Nx Wistar rats on diets with 0.2% or 0.4%P received LPS for 15 days. 
Sham rats also received LPS. Blood, urine, and kidney samples were collected.
Results: Nx rats on a 0.2%P diet had lower FGF23 compared to sham, whereas a 0.4%P 
diet increased FGF23 levels. LPS-treated groups had more than a 3-fold increase in plasma 
levels of FGF23 as compared with their respective controls. Fractional excretion of P in 
sham and Nx rats was not modified by the administration of LPS. No differences in renal 
Klotho expression were found between sham and rats on a 0.2%P diet. A 50% reduction 
in Klotho was seen in 5/6Nx rats on the diet containing 0.4%P. The administration of LPS 
to sham rats reduced Klotho expression by approximately 25%. In 5/6 Nx rats on 0.2% 
and 0.4%P, LPS reduced Klotho by 70% and 50%, respectively.
Sham 
0.6%P
Sham 
0.6%P+ 
LPS
Nx 
0.2%P
Nx 0.2%P+ 
LPS
Nx 
0.4%P
Nx 0.4%P+ 
LPS
Serum P (mg/dl) 4.86± 0.33 5.45± 0.94
2.41± 
0.31c 6.40± 1.81
5.74± 
0.61 6.44± 0.93
Serum PTH 
(pg/ml) 22± 0.6 21± 0.5 18± 0.4 29± 6 33± 10 24± 0.6
Serum 
1,25(OH)2D3 
(pg/ml)
57± 21 37± 7 55± 31 10± 2a,b 11.1± 1a,b 7± 1
a,b
Serum FGF23 
(pg/ml) 92± 12 245± 73
a 25± 6a 324± 32a 142± 19a 472± 95c
FEP (%) 8.1± 0.6 5.4± 1.4 4.2± 1.7 2.4± 2 16.1± 2.3a 14.9± 2.7
a
Conclusions: The prevention of the increase in FGF23 associated with CKD is not 
possible in the presence of inflammation.
TH-PO491
Dietary Sodium Bicarbonate Decreases Serum Fibroblast Growth Factor 
23 in Normal Rats  Nancy S. Krieger, Felix M. Ramos, Min Ho Kim, Kevin K. 
Frick, David A. Bushinsky.  Medicine, Univ of Rochester School of Medicine, 
Rochester, NY.
Background: Patients with CKD have a marked increase in serum fibroblast growth 
factor 23 (FGF23) which is associated with increased mortality. FGF23 is synthesized in 
osteoblasts and osteocytes; however, its specific regulators are not clear. During CKD there 
is a fall in renal net acid excretion leading to metabolic acidosis (MET). We have previously 
shown that MET directly stimulates FGF23 in mouse bone and in primary osteoblastic cells 
in vitro, suggesting that an in vivo increase in serum HCO3 might reduce serum FGF23 
levels. In this study we tested the hypothesis that oral NaHCO3 would decrease serum 
FGF23 levels in normal rats.
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Methods: Sprague Dawley rats (250 g) were acclimated to a powdered 1.2% Ca, 
0.65% P diet, 13 g/d, for 14d. Rats were either continued on this diet supplemented with 
3% NaCl (n=9) or 3% NaHCO3 (n=10) for an additional 8 d. Blood was then obtained by 
cardiac puncture for measurement of FGF23 by ELISA (intact FGF23, Immutopics) as 
well as standard metabolic parameters.
Results: Feeding rats NaHCO3 lead to a significant fall in serum FGF23 and an 
increase in serum HCO3 compared to feeding NaCl (Table; values are mean±SE; *, p< 
0.05; **, p<0.01). Serum PO4 fell with NaHCO3 as did both serum Cl and K. There were 
no differences in serum Ca, Na or creatinine with NaHCO3 compared to NaCl fed rats.
Treatment FGF23 (pg/ml)
HCO3 
(mmol/L)
Ca
(mg/dL)
PO4 
(mg/dL)
K
(mmol/L)
Cl
(mmol/L)
NaCl 391± 27 23.2± 0.68 9.41± 0.09 7.10± 0.21 4.51± 0.26 101.0± 0.67
NaHCO3
255± 
15**
27.0± 
1.49* 9.59± 0.10
6.16± 
0.22**
3.95± 
0.07*
98.6± 
0.40**
Conclusions: Provision of oral NaHCO3 sufficient to raise serum HCO3 led to a 
significant fall in FGF23 in normal rats supporting the hypothesis that pH (or HCO3) 
directly regulates FGF23; however, we cannot exclude that a NaHCO3 -induced change 
in PO4 contributed to the change in FGF23. If comparable acid-base regulation of FGF23, 
now demonstrated in vitro and in vivo, is confirmed in humans, it suggests that correction 
of acidosis in patients with CKD may lower their elevated FGF23 levels.
Funding: NIDDK Support
TH-PO492
Metabolic Acidosis Increases Osteoblastic MEPE Expression in Parallel 
to the Increase in Fibroblast Growth Factor 23  Nancy S. Krieger, Min Ho 
Kim, David A. Bushinsky.  Medicine, Univ of Rochester School of Medicine, 
Rochester, NY.
Background: Serum fibroblast growth factor 23 (FGF23) increases with the severity 
of chronic kidney disease (CKD), leading to decreased renal tubular phosphate (Pi) 
reabsorption and serum 1,25(OH)2D3. FGF23 is synthesized in osteoblasts and osteocytes; 
however, the primary factors regulating its production are not clear. Patients with CKD 
have decreased renal net acid excretion leading to metabolic acidosis (MET). During MET, 
acid is buffered by bone with release of mineral calcium and Pi. MET directly stimulates 
FGF23 in mouse bone and primary osteoblastic cells utilizing the same signaling pathways 
that lead to MET-induced bone resorption. To further characterize the regulation of FGF23 
by MET we utilized primary osteoblasts to study gene expression pathways upstream of 
FGF23 production, including the major extracellular phosphoglycoprotein, MEPE, and the 
phosphate-regulating endopeptidase, PHEX.
Methods: Confluent osteoblastic cells isolated from neonatal mouse calvariae were 
incubated in neutral (NTL, pH=7.50, Pco2=39 mmHg, [HCO3-]=30 mM) or acid (MET, 
pH=7.20, Pco2=39 mmHg, [HCO3-]=14 mM) medium. Specific RNA gene expression was 
analyzed by real time PCR with expression normalized to RPL13A and calculated relative 
to non-incubated cells.
Results: Maximal stimulation of FGF23 was found at 24h (MET=7.26±1.55 vs 
NTL=3.75± 0.64, p<0.05). MET significantly increased MEPE RNA expression as early 
as 6h compared to NTL (relative expression: MET=2.23±0.41, vs NTL=1.19±0.16, p<0.05) 
with a further increase at 24h. There were no significant differences in PHEX expression in 
response to MET compared to NTL, although there was a progressive decrease in PHEX 
expression in both groups over 24h.
Conclusions: Thus, MET stimulation of MEPE expression may be an initial step by 
which MET increases FGF23 production in mouse osteoblasts. By better understanding 
how MET stimulates FGF23, therapeutic interventions directed toward correction of 
MET, especially in CKD patients, can be devised to not only prevent bone resorption but 
also lower FGF23.
Funding: Private Foundation Support
TH-PO493
Effect of High-Dose and Flux Hemodialysis on Circulating Markers of 
Mineral Metabolism in the HEMO Study  Anna Jeanette Jovanovich,1,2 
Alfred K. Cheung,3,4 Tom Greene,4 Jian Ying,4 Michel Chonchol.2  1Denver VA 
Medical Center; 2Univ of Colorado Denver; 39A Salt Lake City; 4Univ of Utah.
Background: There are limited and somewhat contradictory data in the literature on 
the effects of high versus low dialysis clearance and high versus low flux on circulating 
markers of mineral metabolism.
Methods: The HEMO Study was a randomized multicenter study of the effects of high-
dose versus standard-dose and high-flux versus low-flux hemodialysis. Fibroblast growth 
factor 23 (iFGF23, pre-specified primary endpoint for these analyses), serum phosphorus, 
and 25-hydroxivitamin D (25(OH)D) were measured in stored serum samples. We used 
multi-state analyses to analyze the dose and flux effects on each mineral metabolism marker 
while accounting for mortality. We estimated the proportions of patients in 5 ordered states 
(S) for serum phosphorus, 25(OH)D and FGF23: S1= deceased (score=0); S2 = alive in 
highest quartile (score=1); S2 = alive in 3rd quartile (score =2); S4 = alive in 2nd quartile 
(score=3); and S5 = alive in lowest quartile (score=4). The average rank was computed 
over 3 years of follow-up and compared between the randomized groups.
Results: Randomized patients had high rates of coexisting conditions 45% had 
diabetes, and 80% had a history of cardiac disease. Characteristics of the patients in the 
two dose groups were similar, as were the characteristics of those in the two flux groups. 
The state distributions for FGF23 each year by dose (KTV) group and by flux group 
are shown in Figure 1. FGF23 differed significantly between dose groups (p=0.02) but 
not between flux groups (p=0.17). No significant differences were observed for serum 
phosphorus or 25(OH)D. 
Conclusions: Over 3 years, high-dose of dialysis appeared to reduce FGF23 compared 
to standard dialysis dose.
Funding: NIDDK Support, Veterans Administration Support
TH-PO494
Factors for Persistent Low or High FGF-23 Levels in Maintenance 
Hemodialysis Patients  Sonoo Mizuiri,1 Yoshiko Nishizawa,1 Kazuomi 
Yamashita,1 Kohji Usui,2 Shigehiro Doi,3 Takao Masaki,3 Kenichiro Shigemoto.1 
1Nephrology, Ichiyoukai Harada Hospital, Hiroshima, Japan; 2Nephrology, 
Ichiyokai Ichiyokai Clinic, Hiroshima; 3Nephrology, Hiroshima Univ, Hiroshima, 
Japan.
Background: The aim of this study was to assess the association between serum 
fibroblast growth factor-23 (FGF-23) and mortality, and to determine the factors for 
persistent low or high FGF-23 levels, in maintenance HD (MHD) patients.
Methods: We examined serum intact FGF-23, age, dialysis vintage, presence of 
diabetes, BMI, blood pressure, (Ccr+Curea)/2, Kt/Vurea, hs CRP, b2MG, serum albumin, 
nPCR, geriatric nutritional risk index (GNRI), serum phosphate, serum calcium, iPTH, 
active vitamin D dosage, and phosphate binders and/or cinacalcet in 332 MHD patients 
in September of 2012, 2013 and 2014. Coronary artery calcification score (CACS) was 
measured in a subgroup (n=173). According to quartile (Q) of FGF-23 in 2012, mortality 
was assessed by Kaplan-Meyer and adjusted Cox models. Patients with FGF-23 Q1-Q1-Q1 
were categorized in Group 1, patients with FGF-23 Q4-Q4-Q4 in Group 3, and the others 
in Group 2.
Results: Median age and dialysis vintage were 69 years and 66 months, respectively, 
at baseline. During the 2 years, 71 patients died and 24 patients left our hospital. Baseline 
FGF-23 levels (pg/ml) were <310 (Q1), 310-1489 (Q2), 1490-5294 (Q3) and >5294 (Q4) 
(P<0.05), with cumulative survival rates of 65.4%, 78.9%, 85.1% and 80.6%, respectively 
(P<0.01), and hazard ratios (HRs) for death of 1.0, 0.6, 0.4 and 0.5, respectively, in univariate 
model. However, there was no significant association between Q of FGF-23 level and 
mortality in multivariate model. HR for death of CACS was 1.1 (P<0.01), but there were 
no differences in CACS in patients based on FGF-23 level. Significant associations between 
Group 1 and diabetes (OR: 3.5), age (OR: 1.1), serum phosphate (OR:0.4) and vitamin D 
dosage (OR: 0.2), and between Group 3 and serum phosphate (OR: 2.0), iPTH (OR: 1.004) 
and vitamin D dosage (OR: 1.9), were observed (P<0.05).
Conclusions: FGF-23 in the lowest quartile showed the lowest 2-year cumulative 
survival rate in MHD patients, and factors for persistent low FGF-23 levels were diabetes, 
age, serum phosphate and active vitamin D dosage.
Funding: Private Foundation Support
TH-PO495
Maintenance of Residual Diuresis and Type of Dialysis Can Influence 
FGF23 Levels  Valentina Corradi,1,2 Sara Samoni,2 Francesca K. Martino,1,2 Elisa 
Scalzotto,2 Ilaria Santolin,3 Elisabetta Galloni,3 Carla Estremadoyro,2 Renhua 
Lu,2 Carlo Crepaldi,1,2 Monica Zanella,1,2 Alessandra Brendolan,1,2 Claudio 
Ronco.1,2  1Nephrology, San Bortolo Hospital, Vicenza, Italy; 2IRRIV, San Bortolo 
Hospital, Vicenza, Italy; 3Neurology, San Bortolo Hospital, Vicenza, Italy.
Background: Bone mineral disorders are common in patients (pts) with end stage renal 
disease (ESRD). In particular, hyperphosphatemia can be frequently seen in pts undergoing 
peritoneal dialysis (PD) and hemodialysis (HD). Recently, several studies investigated the 
role of fibroblast growth factor 23 (FGF23) in regulation of renal phosphate excretion in 
ESRD pts. However, patients with residual diuresis (RD) seem to better control serum 
phosphorus levels than those without RD. The aim of our study was to determine if the 
dialysis modality and the preservation of RD influence serum levels of FGF23.
Methods: We performed a cross-sectional study in two groups of pts: HD and PD. 
The variables analyzed were creatinine, urea, calcium, phosphate (Phosp), i parathormone 
(intact PTH) and cFGF23 (C-term). The urinary output collection refers to one week. All 
p value were two sides and statistical significance was set at p<0.05. Statistical analysis 
was performed by SPSS version 20.
Results: A total of 122 pts were enrolled (58HD,64PD).The mean age of HD pts 
was 64.45±14,25yrs and of PD pts 62,33±13,86 yrs. RD was present in 78 pts (65,46± 
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12,87yrs) and the median volume was 5600 (3412-9450 ml/week). The median cFGF23 
were significantly higher in HD compared to PD pts (2634 [1192-6880] vs 1395 [609-2660] 
RU/ml; p=0,012) and higher in pts without than in pts with preserved RD (2634 [970-8348] 
vs 1428 [1042-3047] RU/ml; p=0,030). We found a significant correlation between FGF23 
and age, Phosp, dialysis modality and RD. Univariable and multivariable adjusted analysis 
showed that Phosp, dialysis modality and RD are independent predictors of cFGF23 
respectively with OR=0,495 [p<0,001], OR=-0,184 [p=0,040] and OR=-0,189 [p=0,034].
Conclusions: In our study, serum cFGF23 levels were lower in patients with preserved 
RD and those undergoing PD compared to patients without RD and undergoing HD. The 
dialysis modality and the preservation of RD are independent predictors of cFGF23 levels.
TH-PO496
Iron Deficiency Is Associated with Elevated FGF23 Levels in Pediatric CKD 
Farah N. Ali,1 Bradley Warady,2 Susan L. Furth,3 Harald Jüppner,4 Isidro B. 
Salusky,5 Anthony A. Portale,6 Myles S. Wolf.1  1Northwestern Univ; 2Children¶s 
Mercy Hospital; 3Children¶s Hospital of Philadelphia; 4MGH; 5UCLA; 6UCSF.
Background: FGF23 excess contributes to CV disease and death in CKD. Mechanisms 
of elevated FGF23 levels in CKD are incompletely understood. Iron deficiency is a novel 
stimulus of FGF23 production. Given high rates of iron deficiency in CKD, we hypothesize 
that iron deficiency is related to higher FGF23 levels in pediatric CKD and that iron 
deficiency induced by proteinuria contributes to higher FGF23 levels in glomerular diseases.
Methods: We measured ferritin, TSAT, C-terminal (c) FGF23, CRP, and urine protein/
creatinine (pr/cr) in 551 children in the CKiD Study.
Results: Mean age was 10.2 ± 4.4 yrs; 62% were male; mean eGFR was 53 ± 19 
ml/min/1.73m2; mean TSAT was 26 ± 13%, median ferritin was 46 ng/mL (IQR 27-81); 
median urine pr/cr was 0.31 mg/mg (IQR 0.10-1.00); median cFGF23 was 114 RU/mL 
(IQR 80-185). cFGF23 correlated inversely with ferritin (p=0.055) and eGFR (p<0.001) and 
directly with CRP (p=0.049), proteinuria (p<0.001), and phosphate (p<0.001). Grouping 
proteinuria into low or high grade (pr/cr >3) revealed no differences in ferritin and TSAT, 
but TIBC was lower (288 vs 310 µg/dL, p=0.011) and cFGF23 was higher in the high vs 
low grade groups (362 vs 184, p=0.016). cFGF23 levels were significantly elevated in the 
lowest ferritin quartile, preferentially in early stages of CKD (Figure).
In multivariate analysis that included proteinuria and CRP, only lower eGFR, glomerular 
disease, higher phosphate, and lower ferritin were independent predictors of higher cFGF23 
levels (p<0.001 for all). The relationship between proteinuria and cFGF23 was mitigated 
when ferritin was added to the multivariable model.
Conclusions: Iron deficiency is associated with higher cFGF23 levels in pediatric CKD 
and may contribute to the relationship between proteinuria and higher FGF23.
Funding: NIDDK Support, Other NIH Support - NICHD
NHLBI
TH-PO497
The Ratio of C-Terminal to Intact Fibroblast Growth Factor 23 Was 
Elevated in Iron Deficient Patients with Chronic Kidney Disease 
Sayoko Yonemoto,1,3 Takayuki Hamano,2 Naohiko Fujii,1 Daisuke Mori,3 Yasuo 
Kusunoki,3 Akihiro Shimomura,2 Isao Matsui,3 Hiromi Rakugi,3 Yoshitaka 
Isaka.3  1Dept of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, 
Nishinomiya, Hyogo, Japan; 2Dept of Comprehensive Kidney Disease Research, 
Osaka Univ Graduate School of Medicine, Suita, Osaka, Japan; 3Dept of 
Geriatric Medicine and Nephrology, Osaka Univ Graduate School of Medicine, 
Suita, Osaka.
Background: A recent study showed iron deficiency was associated with elevated 
fibroblast growth factor 23 levels by c-terminal assay (cFGF23) but not with intact FGF23 
(iFGF23) levels in women without chronic kidney disease (CKD). It remains elusive if 
this holds true also in patients with CKD.In this cross-sectional study, we examined the 
associations between iron deficiency and FGF23 levels by the two assays in predialysis 
patients.
Methods: The study population consisted of 100 predialysis outpatients of the 
nephrology department in a hospital in Japan. We measured plasma cFGF23 (Immutopics) 
and serum iFGF23 (Kainos). Restricted cubic spine analysis was employed to estimate 
non-linear relationships between iron markers and ratio of cFGF23 to iFGF23 CI ratio. 
The CI ratio can be regarded as a FGF23 cleavage marker.
Results: The mean age and eGFR was 70.1±15.0 and 26.9±12.9 ml/min/1.73m2, and 
the proportions of female and patients with diabetes mellitus were 30 and 40%, respectively. 
Only 18 and 6.0% of patients were treated with ESA and oral iron therapy, respectively. 
The cFGF23 was elevated with the decrease in TSAT and ferritin levels, and the CI ratio 
was also elevated with the decrease in TSAT and ferritin levels.
Conclusions: In this study, we observed elevation of cFGF23 and CI ratio in iron 
deficiency patients with CKD. This might be because iron-deficiency stimulates FGF23 
transcription and its cleavage simultaneously just as reported in non CKD women.
TH-PO498
Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently 
of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency 
Akira Iguchi,1 Noriaki Iino,3 Ichiei Narita.2  1Div of Nephrology and 
Rheumatology, Saiseikai Niigata Daini Hospital, Niigata, Japan; 2Div of Clinical 
Nephrology and Rheumatology, Niigata Univ Medical and Dental Hospital, 
Niigata, Japan; 3Uonuma Inst of Community Medicine, Niigata Univ Medical 
and Dental Hospital, Minamiuonuma, Japan.
Background: Fibroblast growth factor 23 (FGF23) is regulated by dietary phosphate 
intake and vitamin D receptor activator (VDRA). Iron is another potential modulator for 
FGF23 metabolism.
Methods: This prospective study enrolled 27 maintenance hemodialysis patients with 
iron deficiency and hyperphosphatemia who had been treated with sevelamer-HCl. Their 
phosphate binder was changed to ferric citrate hydrate (FCH), so that their phosphate levels 
were maintained constant. VDRA, other phosphate binders, and cinacalcet hydrochloride 
were unchanged. Serum intact-FGF23, C-terminal FGF23, intact parathyroid hormone, 
1,25(OH)2D, and other parameters were prospectively monitored for 12 weeks.
Results: Serum levels of phosphate and 1,25(OH)2D were unchanged. Serum ferritin 
levels increased from 25.6 ± 24.3 ng/mL at baseline to 55.8 ± 33.5 ng/mL at 12 weeks with 
the administration of FCH. Serum intact-FGF23 and C-terminal FGF23 levels were 2000 
(1300.0 – 3471.4) pg/ml and 1608.7 (634.8 – 2308.7) RU/ml at baseline, respectively. At 12 
weeks, intact-FGF23 and C-terminal FGF23 significantly decreased to 1771.43 (1142.9 – 
2342.9) pg/ml (P = 0.0258) and 1165.2 (626.1 – 1547.8) RU/ml (P = 0.0298), respectively. 
Serum intact parathyroid hormone levels significantly increased from 96 (65 – 125) pg/ml 
at baseline to 173 (114 – 283) pg/ml after 12 weeks (P = 0.0006).
Conclusions: Oral administration of FCH decreased both serum intact- and C-terminal 
FGF23 levels and increased intact parathyroid hormone levels, without any change in 
phosphate and 1,25(OH)2D. Treatment of iron deficiency with oral FCH may be a useful 
strategy to reduce serum FGF23 levels independent of phosphate and VDRA.
TH-PO499
Intravenous Iron Leads to Fibroblast Growth Factor 23-Dependent 
Changes in Calcium-Phosphate Metabolism in Non-Dialysis Patients with 
Chronic Kidney Disease Stages 3-5  Katarzyna Muras-Szwedziak, Michal 
P. Nowicki.  Dept of Nephrology, Hypertension and Kidney Transplantation, 
Medical Univ of Lodz, Lodz, Poland.
Background: Iron deficiency is a common phenomenon among patients with chronic 
kidney disease (CKD) treated with erythropoiesis stimulationg agents. Intravenous iron 
may interfere with calcium-phosphate (Ca-P) metabolism in CKD. Iron infusion may 
reduce peripheral degradation and clearence of circulating iFGF23 after its secretion by 
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osteocytes but it is unclear whether it could also modulate FGF23 synthesis. Our research 
objective was to evaluate the effect of intravenous iron supplementation on the parameters 
of mineral metabolism in patients with CKD.
Methods: The study included 35 non-dialysis patients with CKD stages 3-5. Each 
patients received once-daily 100 mg iron solution (Ferric oxide saccharated complex; 
Vifor, France) for 5 consecutive days. Iron doses were administered in a slow 40-min. 
intravenous infusion. On day 1 and 3 at baseline and 2 hours after each dose administration, 
calcium (Ca), phosphorus (P), parathormone (PTH), intact-FGF23 (iFGF23), C-terminal-
FGF23 (cFGF23), bonealkaline phosphatase (BAP) were assessed. The measurements 
were repeated on day 6.
Results: Two hours after the first iron infusion and on day 6 a significant increase in 
serum iFGF23 was observed (from 257±446.5 to 326.3±529.9 on day 1; p=0.005 and to 
451.4±601 on day 6 pg/ml; p<0.05). The concentration of cFGF23 was reduced in parallel 
only on day 1 (from 654.3±441.3 to 473.6±414 RU/ml; p<0.05). Serum phosphorus 
concentration decreased significantly on day 1 two hours after iron infusion (from 1.75±0.6 
to 1.53±0.35 mmol/l; p=0.005). On following days the changes of cFGF23 and phosphorus 
concentration were not significant. The serum concentrations of Ca, BAP and PTH were 
unchangedthroughout the study.
Conclusions: Intravenous iron supplementation may interfere with the mechanisms 
governing both production and degradation of FGF23 thereby leading to transient 
hypophosphatemia at the beginning of iron therapy.
TH-PO500
The Increase of Fractional Excretion of Phosphorus Induces FGF23 
Resistance due to a Decrease in Renal Klotho  Juan R. Munoz-Castaneda,1 
Carmen maria Herencia,1 Maria Encarnacion Rodriguez Ortiz,3 Juan miguel 
Diaz-tocados,1 Julio Manuel Martínez Moreno,1 Addy Rosa Montes de 
Oca Gonzalez,1 Yolanda Almaden peña,2 Mariano Rodriguez.1  1Servicio 
de Nefrología, Inst Maimónides de Investigación Biomédica de Córdoba 
(IMIBIC), Hospital Univ Reina Sofía, Córdoba, Spain; 2Unidad de Lípidos y 
Aterosclerosis (CIBEROBN), IMIBIC, Hospital Univ Reina Sofía, Córdoba, 
Spain; 3Laboratorio de Nefrología, IIS-Fundación Jiménez Díaz, REDinREN, 
Madrid, España.
Background: The maintenance of serum phosphate (P) levels is critical in the context of 
renal diseases to prevent CKD-MBD, the progression of CKD and mortality mainly caused 
by cardiovascular events. As renal function declines P levels increases instead of the high 
FGF23. In these conditions an unsolved FGF23 resistance is produced. The mechanisms 
whereby FGF23 resistance is produced will be evaluated.
Methods: Renal FGFR1 and klotho were analyzed in normal rats receiving continuously 
infusion of rat recombinant FGF23 and 5/6 Nx rats with high or low levels of P in the 
diet. An additional group with anti-FGF23 antibody was also used in 5/6 Nx rats unsolved 
FGF23 resistance is produced.
Results: In normal rats, high levels of FGF23 increased fractional excretion of P (FePi) 
and renal FGFR1, whereas klotho was decreased. In 5/6Nx with normal FGF23 (0.6%P 
diet), the FePi was moderately increased and FGFR1 and klotho was decreased. In 5/6Nx 
rats with high FGF23 levels (1.2%P diet) there was a severe decrease of klotho and an 
increase of FGFR1. Anti-FGF23 was administered to check whether renal klotho decreases 
due to high FGF23 or by the increase of FePi. Anti-FGF23 increased serum P decreasing 
slightly phosphaturia. In addition we checked that in HEK293 cells high P activated the 
wnt/b-catenin pathway and decreased klotho expression. Dkk1 administration prevented 
the drop of klotho in presence of high P. Therefore renal FGFR1 levels results FGF23-
dependent, whereas the decrease of klotho is induced by the increase in FePi.
Conclusions: High FGF23 levels increase FGFR1, whereas higher phosphaturia 
decreases klotho expression through the activation of the canonical wnt/b-catenin pathway, 
which may induce the resistance to FGF23.
Funding: Government Support - Non-U.S.
TH-PO501
Regulation of α-Klotho Expression by Dietary Phosphate During Growth 
Periods  Shiori Fukuda,1 Hironori Yamamoto,2 Masashi Masuda,1 Mari Nakao,1 
Yutaka Taketani.1  1Dept of Clinical Nutrition and Food Management, Inst of 
Biomedical Sciences, Tokushima Univ Graduate School, Tokushima, Japan; 
2Dept of Health and Nutrition, Faculty of Human Life, Jin-ai Univ, (chizen 
City, Fukui, Japan.
Background: Phosphate is critically important for biological functions, particularly 
during growth periods. Phosphate deficiency causes bone diseases such as rickets and 
osteomalacia. On the other hand, excess intake of dietary phosphate increases secretion of 
fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) to maintain plasma 
phosphate level. FGF23, is a potent phosphaturic factor, binds to α-klotho / FGFR complex 
in the kidney to promote excretion of phosphate into urine. In addition, excess intake of 
dietary phosphate also decrease in renal α-klotho expression. Downregulation or lack 
of α-klotho induces a premature aging-like phenotype such as ectopic calcification and 
osteoporosis resulted from hyperphosphatemia. However, the effects of high phosphate 
diet on renal α-klotho expression just after weaning period are still unknown.
Methods: To investigate that, we used C57BL / 6J mice aged 3-4 week old under a 
rapid growth phase. Mice were fed 0.02, 0.3, 0.6, 0.9, 1.2, 1.5 or 1.8% phosphate diets for 
7 days beginning just after weaning at 3 week old.
Results: As a result, elevation of plasma phosphate and FGF23 levels, and decrease in 
renal α-klotho expression were observed as the content of dietary phosphate increased. In 
addition, renal calcification was clearly observed in mice fed 1.5 or 1.8% phosphate diets. 
The renal calcification did not observed when the 8 week-old mice were fed with 1.5 or 
1.8% phosphate diet for 7 days. These results suggest that the effects of high phosphate diet 
during growth periods have a much greater adverse effect on renal α-klotho expression and 
morphology of the kidney as compared to a similar investigation during maturation periods.
Conclusions: In conclusion, excessive dietary phosphate intake during growth 
periods such as just after weaning period decreases in renal α-klotho expression relating 
to premature aging-like lesions.
Funding: Government Support - Non-U.S.
TH-PO502
The Secreted Klotho mRNA Transcript Is Continuously Degraded by 
Nonsense-mediated mRNA Decay and Its Splicing Is Dysregulated After 
Kidney Damage  Rik Mencke, Geert Harms, Jan-luuk Hillebrands.  Pathology 
and Medical Biology, Univ Medical Center Groningen, Groningen, Netherlands.
Background: Klotho is an anti-aging gene of which two mRNA transcripts have been 
identified: one corresponds to the full 5-exon coding sequence and the other, alternatively 
spliced, consists of exons 1-3 and 50 downstream base pairs, forming a stop codon. The latter 
mRNA is thought to code for a secreted Klotho protein. While soluble Klotho proteins can 
be detected in blood, urine, and cerebrospinal fluid, a product of this alternative transcript 
has never been identified. Nonsense-mediated mRNA decay (NMD) research predicts that 
the premature stop codon induces continuous degradation during translation.
Methods: We first assessed the mRNA transcripts in human kidney and HK-2 cells by 
RT-PCR and DNA sequencing. We then blocked NMD in HK-2 cells using cycloheximide 
(CHX) (100 µg/ml) for 2, 4, or 6 h, or using XRN1 siRNA for mRNA degrading enzyme 
exoribonuclease 1, to assess possible accumulation of the alternative mRNA by RT-PCR and 
densitometry. Then, we assessed whether splicing was different in normal human kidneys 
(N=11) and in chronic rejection transplanted (CRT) kidneys (N=4).
Results: Expression of both Klotho mRNA transcripts was confirmed in human 
kidney and in HK-2 cells by RT-PCR and DNA sequencing. CHX-induced inhibition of 
translation increased the “secreted” / membrane-bound Klotho mRNA ratio from 0.14±0.02 
to 0.44±0.06 (p<0.001). Preliminary data show that silencing of XRN1 has the same effect. 
Furthermore, already in normal kidneys, there was a marked, reproducible variation in 
splicing ratios, ranging from 0.03±0.01 to 0.20±0.02. In CRT kidneys, Klotho mRNA 
was expectedly down-regulated and splicing was skewed towards the non-functional 
alternative splice variant.
Conclusions: The alternative Klotho mRNA contains a premature stop codon and is a 
likely NMD substrate. Soluble Klotho would therefore be cleaved Klotho only. Furthermore, 
in damaged kidneys, splicing of the Klotho gene is dysregulated, which constitutes a new 
mechanism of Klotho down-regulation.
Funding: Government Support - Non-U.S.
TH-PO503
Genetic Deletion of NaPi-2c Rescue Phenotype of Klotho Knockout Mice 
without Improving Severe Hyperphosphatemia  Ai Hanazaki, Hiroko Segawa, 
Kayo Ikuta, Toru Fujii, Ichiro Kaneko, Shihoko Yuki, Shiori Nishiguchi, 
Kejiro Notsu, Yuji Shiozaki, Sawako Tatsumi, Ken-ichi Miyamoto.  Molecular 
Nutrition, Inst of Biomedical Sciences, Tokushima Univ Graduate School, 
Tokushima, Japan.
Background: SLC34A3/NaPi-2c is one of the renal sodium dependent phosphate (Pi) 
transporters. Mutation of human NaPi-2c causes hereditary hypophosphatemic rickets with 
hypercalciuria (HHRH). Thus, NaPi-2c may have an important role on renal Pi reabsorption 
and bone mineralization in humans. The physiological role of NaPi-2c, however, has not 
been completely explained yet. NaPi-2c knockout (NaPi-2c-/-) mice showed hypercalciuria, 
but did not show any Pi abnormality. Recently, Hernand N. et al. reported that kidney specific 
NaPi-2c conditional knockout mice did not show any abnormality. These results suggested 
that NaPi-2c has minor role in the Pi homeostasis. To discover the role of NaPi-2c, we 
examined genetic inactivation of NaPi-2c in klotho knockout (klotho-/-) mice.
Methods: To obtain the klotho and NaPi-2c double knockout (klotho-/-/NaPi-2c-/-, 
KL2c DKO) mice, kloho+/- mice and Npt2c+/- mice were crossed. Total body weight of 
each of wild-type, klotho-/-, KL2c DKO and NaPi-2c-/- mice was taken every week. Urine 
and blood were obtained for biomedical measurements at the several ages of weeks. Tissues 
were obtained from each mice for histological and calcification analysis.
Results: Genetic disruption of NaPi-2c significantly increased body weight and 
extended the life span of klorho-/- mice. KL2c DKO mice were viable and larger in size than 
klotho-/- mice, but smaller than wild-type and NaPi-2c-/- mice. KL2c DKO mice showed 
slightly decreased plasma Pi levels at early hood, but not adult hood. Plasma FGF23 levels 
were extremely high in KL2c DKO mice as well as klotho-/- mice.
Conclusions: Our finding demonstrated that NaPi-2c genetic deletion rescued the 
phenotype of klotho-/- mice without improving severe hyperphosphatemia.
Funding: Government Support - Non-U.S.
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TH-PO504
Klotho/FGF23-Independent and ERα Mediated Direct Downregulation of 
NaPi-IIa by Estrogen in the Mouse Kidney Proximal Tubule  Hassane Amlal, 
Sulaiman Sheriff, Rose P. Webster.  Internal Medicine, Univ of Cincinnati, 
Cincinnati, OH.
Background: Estrogen treatment is associated with renal wasting of inorganic 
phosphate (Pi) and hypophosphatemia in rats and humans; however the molecular and 
signaling mechanisms mediating this effect are still not fully understood.
Methods: To determine the roles of estrogen receptor isoforms (ERα and ERβ) and 
Klotho/FGF23 pathway in these effects, we studied the effects of estrogen on renal Pi 
handling in the kidneys of mice with null mutations of ERα or ERβ or Klotho and their 
wild-type (WT) littermates. Accordingly, Females ERα Knockout (KO), ERβ KO and WT 
mice were placed in metabolic cages and had free access to food and distilled water. After 
adjustment, mice were injected daily with 17β-estradiol (estrogen) or vehicle for 3 days.
Results: The results indicate that estrogen-treated WT and ERβ KO mice exhibited a 
significant phosphaturia despite a reduction in food intake. The phosphaturic effect resulted 
from a significant downregulation of NaPi-IIa and NaPi-IIc protein abundance with no 
change in their mRNA expression levels. Interestingly, these effects were abolished in 
ERα KO mice. Further, the results showed that estrogen-treated Klotho KO mice exhibited 
hypophosphatemia and a significant downregulation of NaPi-IIa with no change in the 
abundance of NaPi-IIc. In vitro studies showed that estrogen treatment (24 hrs) of a cell 
line (U20S) stably co-expressing both ERα and ERβ caused a significant downregulation 
of NaPi-IIa protein, when cells are transiently transfected with a plasmid containing ORF-
3’UTR but not 5’UTR-ORF of the mouse NaPi-IIa transcript.
Conclusions: In conclusion, estrogen causes phosphaturia in mice despite a reduction 
in food intake. This effect results from the downregulation of NaPi-IIa and NaPi-IIc protein 
abundance with no change in their mRNA expression levels. This effect is independent of 
Klotho/FGF23 pathway and is mediated through the exclusive activation of ERα. A Cis-
acting element in the 3’UTR region of mNaPi-IIa mRNA likely plays an important role in 
the inhibition of its translation by estrogen.
Funding: NIDDK Support
TH-PO505
Effect of Calcitriol on Serum Hepcidin in Individuals with Chronic Kidney 
Disease  Bhupesh Panwar, Orlando M. Gutierrez.  Univ of Alabama.
Background: Anemia is highly prevalent in CKD. Elevated hepcidin levels are an 
important mediator of disordered iron metabolism, a key mechanism underlying anemia of 
CKD. Vitamin D was recently shown to reduce hepcidin levels in healthy individuals. We 
examined whether treatment with calcitriol reduces serum hepcidin in individuals with CKD.
Methods: 40 participants with stage 3/4 CKD (eGFR 15-60 ml/min) were randomized 
to placebo or oral calcitriol 0.5mcg daily for 6 weeks. Primary outcome variable was change 
in hepcidin levels. Secondary outcomes variables included change in iron parameters, 
calcium and hemoglobin. Samples were drawn at baseline, 3 days, 1 week and 6 weeks after 
randomization. Repeated measures analysis was used to examine differences in outcome 
variables over time in the 2 groups.
Results: At baseline, the only differences in the 2 groups were that hemoglobin and 
creatinine clearance were higher in the placebo vs. calcitriol arm (13.3±1.7 vs 12.2±1.9 
mg/dL; and 69.7±26.8 vs 50.9±23.7 ml/min, respectively). Over 6 weeks of follow-up 
there were no significant differences in serum hepcidin, iron parameters, or hemoglobin 
between the 2 groups. There was a significant increase in serum calcium at 6 weeks in the 
calcitriol arm compared to the placebo. 
Table 1. Median[IQR] or Mean±SD of outcome variables over a 6 week follow-up. 
Baseline 3 days 1 week 6 weeks
Hepcidin
Calcitriol 72[46,196] 79[39,146] 81[48,151] 91[39,180]
Placebo 76[46,124] 77[46,121] 73[40,112] 64[39,94]
Ferritin
Calcitriol 140[84,390] 177[91,339] 177[91,339] 177[88,277]
Placebo 176[73,296] 173[63,238] 173[63,238] 142[57,217]
Transferrin 
saturation
Calcitriol 25.3±12.5 24.1±7.9 24.9±15.8 23.5±10.5
Placebo 23.2±8.1 23.6±7.8 22.7±7.6 21.5±5.5
Hemoglobin
Calcitriol 12.3±1.7 12.2±1.7 12.2±1.9 12.1±1.8
Placebo 13.2±1.6 13.1±1.8 13.2±1.6 13.3±1.7
Calcium
Calcitriol 9.21±0.43 9.28±0.42 9.32±0.48 9.51±0.51*
Placebo 9.34±0.29 9.39±0.36 9.39±0.36 9.48±0.37
Conclusions: Calcitriol did not reduce serum hepcidin levels among individuals with 
stage 3/4 CKD. Future studies are needed to assess if nutritional forms of vitamin D affect 
hepcidin levels in CKD.
TH-PO506
A Double Blind Randomized Trial to Compare the Effect of High-Dose 
Cholecalciferol versus Placebo on Secondary Hyperparathyroidism in 
Chronic Kidney Disease Stage 3-4  Per-Anton Westerberg,1,3 Gunnar Sterner,2 
Osten Ljunggren,1 Torbjorn Linde.1  1Medical Sciences, Univ Hospital, Uppsala, 
Sweden; 2Nephrology, Skåne Univ Hospital, Malmö, Sweden; 3Internal Medicine, 
Ryhov County Hospital, Jönköping, Sweden.
Background: Suboptimal levels of calcidiol (25D) may accelerate secondary 
hyperparathyroidism (SHPT) in chronic kidney disease (CKD). The aim of this study is 
to determine if a substantial increase in 25D has beneficial effects on mineral metabolism, 
muscle strength or fatigue.
Methods: We conducted a double blind randomized trial (EudraCT 2011-002586-38) 
of cholecalciferol 8000IU/day versus placebo in 97 adult CKD3-4 patients with mild SHPT 
and a 25D level below 75 nmol/L. The primary endpoint was the difference in mean change, 
after 12 weeks, in intact PTH between those treated with cholecalciferol as compared to 
those recieving placebo. Other endpoints were the proportion of participants having a 
30% reduction in PTH, hand grip strength and fatigue, assessed by a questionnaire, and 
differences in calcium, phosphate, calcitriol and FGF23. The statistical test of treatment 
effect was based on ANCOVA, with baseline value as covariate.
Results: 95 subjects completed the study. Their median age was 66 years, 64 were 
males and mean GFR was 32 ml/min/1.73 m2. Baseline 25D were 57.5±23 and 56.8±22 
nmol/L, and PTH 10.9±5 and 13.1±9 pmol/L in the cholecalciferol and placebo groups 
respectively. 25D increased to 161.6±49 nmol/L and PTH decreased slightly to 10.5±5 
pmol/L in the treatment group, while 25D remained stable and PTH increased to 15.2±11 
pmol/L in the placebo group. A significant difference in the mean change in PTH between 
the groups at 12 weeks (P<0.01) was recorded. There was no significant difference in the 
proportion of subjects reaching a 30% decrease in PTH. Additionally, there was no effect 
on grip strength or fatigue. The calcium level was unchanged in the treatment group, 
calcitriol increased distinctly from 64.5±43 to 101.5±54 pmol/L, while there were no 
effects on phosphate or FGF23.
Conclusions: High dose cholecalciferol increases calcitriol and alleviates the 
development of SHPT in CKD, without causing hypercalcemia or influencing muscle 
strength or fatigue.
Funding: Pharmaceutical Company Support - Renapharma Ab, Government Support 
- Non-U.S.
TH-PO507
Comparison Between Paricalcitol and Non-Selective Vitamin D Receptor 
Activator for Secondary Hyperparathyroidism in Chronic Kidney Disease: 
A Systematic Review and Meta-Analysis  Panpan Cai, Zi Li, Wei Qin, 
Xiaohong Tang.  Nephrology, West China Hospital Sichuan Univ, Chengdu, 
Sichuan, China.
Background: Secondary hyperparathyroidism (SHPT) is a common complication of 
chronic kidney diseases (CKD). Paricalcitol is a tissue-selective vitamin D receptor activator 
(VDRA) with the promising effects of lower risks of hypercalcemia, hyperphosphatemia, 
and even calciphylaxis. We conducted a systematic review and meta-analysis to compare 
the efficacy and safety of paricalcitol and non-selective VDRA for the management of 
SHPT in CKD patients.
Methods: We comprehensively searched MEDLINE, Embase, the Cochrane takes 
Group’s Specialized Register and CENTRAL database,collected all randomized controlled 
trials (RCTs) on comparison paricalcitol and VDRA in adult CKD patients with SHPT. A 
quality evaluation to every enrolled RCT was conducted. Analysis was performed using 
the statistical software Review Manager 5.2.
Results: A total of 8 trials involving 674 patients were identified for this review. The 
quality of included trials was limited. Except for one trial that mentioned two deaths, all other 
trials did not report all-cause mortality and vascular calcification. Paricalcitol effectively 
lowered the level of PTH (MD: -11.27, 95% CI: -18.70 to -3.85, P=0.003) but no significant 
difference was observed in the proportion of patients that achieved the target reduction 
of PTH between paricalcitol and non-selective VDRA (OR: 2.22, 95% CI: 0.91 to 5.40, 
P=0.08). No statistical differences were found among patients in terms of serum calcium, 
episodes of hypercalcemia, serum phosphorus, calcium×phosphorus products and bone 
metabolism index. The low quality of enrolled studies, lack of hard outcome, and multiple 
definitions of target PTH reduction composed the limitation of our systematic review.
Conclusions: Current evidence provides some support for the use of this selective 
VDRA in lowering PTH. No sufficient evidence is available to prove that VDRA can 
reduce the burden of mineral loading. Further trials are required given the limitation of 
current research.
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TH-PO508
Paricalcitol and Calcitriol Exhibit Differential Effects on Gene Expression 
in Human Arteries  Tzongshi Lu,1 Li-lun Ho,2 Thomas F. Hiemstra,3 Daniel 
Zehnder,4 Li-Li Hsiao.1  1Renal Div, Brigham and :omen¶s Hospital, Harvard 
Medical School, Boston, MA; 2Chemical Engineering, Massachusetts Inst of 
Technology, Cambridge, MA; 3School of Clinical Medicine, Univ of Cambridge, 
Cambridge, United Kingdom; 4Univ Hospital Coventry and Warwickshire NHS 
Trust, Coventry, United Kingdom.
Background: Vitamin D deficiency is common in patients with CKD, and therapeutic 
use of vitamin D receptor activators (VDRAs) may improve cardiovascular outcomes. The 
molecular targets of the VDRAs calcitriol and paricalcitol are incompletely understood.
Methods: We studied gene expression in human arterial explants from healthy 
individuals and CKD patients after exposure to calcitriol, paricalcitol or vehicle. We 
selected the leading differentially expressed genes based on log 2 ratio fold changes (∆). 
Analysis utilized KEGG and DAVID.
Results: Calcitriol and paricalcitol exhibited differential effects on gene expression. 
Calcitriol induced expression of Toll-like receptor 4 (TLR4) (∆ 14369) and Nuclear Factor 
of Activated T-cells (NFAT) (∆ 3851) in healthy arteries. In CKD arteries, Calmodulin-
dependent KinaseIIβ (CamKIIβ) (∆7972) and HIF1β (ARNT) expressions were upregulated 
(∆ 235). Interestingly, TLR4 is involved in the HIF1 pathway, and NFAT is downstream 
of CamK in the non-canonical Wnt/calcium pathway. In contrast, paricalcitol significant 
upregulates Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) (∆ 8461) in 
healthy arteries and AXIN1 (∆ 1933) in CKD arteries. AXIN1 is also involved in the Wnt 
signaling pathway.
Conclusions: Our data demonstrate differential effects of calcitriol and paricalcitol on 
gene expression in human arterial explants. This finding may provide important mechanisms 
in developing therapeutic strategies for the roles of VDRAs. Further investigation is needed.
Funding: Private Foundation Support
TH-PO509
Paricalcitol and FGF23 Effects on the Progression of Cardiac Disease 
in Pediatric Hemodialysis  Wacharee Seeherunvong,1 Chryso P. Katsoufis,1 
Arpit Kumar Agarwal,2 Sethuraman Swaminathan,2 Phillip Ruiz,3 Gaston E. 
Zilleruelo,1 Carolyn L. Abitbol,1 Michael Freundlich.1  1Pediatric Nephrology, 
Univ of Miami; 2Pediatric Cardiology, Univ of Miami; 3Pathology, Univ of 
Miami, Miami, FL.
Background: FGF23 induces and Paricalcitol (Pc) attenuates left ventricular 
hypertrophy (LVH) in uremic animals. In adults CKD, Pc has not yet consistently improved 
LVH. We hypothesized that in young hemodialysis (HD) patients, Pc improves LVH and 
function despite ↑FGF23 levels.
Methods: Twenty patients (16±4 years) on HD (31±17 months) on Pc >6 months 
underwent longitudinal biochemical and echocardiography (Echo1 and Echo2) 
measurements. LV mass index (LVMI) reflects LV structure and shortening fraction (SF) 
systolic function. To assess LV diastolic function, early (E), late (A) diastolic trans-mitral 
(m), annular Em, septal Es, tricuspid annular Et velocities were measured with E/A, E/
Em and E/Et ratios calculated. Values >2 Z-scores defined diastolic dysfunction. Echo 
results were reported as height-age adjusted Z-scores. The ratio of the cumulative average 
weekly Pc dose to the prevalent logFGF23 level (Pc/logF) was used as a reflection of the 
opposing hormonal effects.
Results: Overall Z-LVMI (1.7±1.3 vs. 2.0±1.8) was unchanged; LVH prevalence Ļ 
from 55% to 45% (ĀZ-LVMI in 35%,p=0.01); SF was normal throughout. Abnormal E, 
Em and E/Em (in 30-61%) all improved by 25% on Echo2. Z-LVMI correlated with E/
Et (r 0.6, p<0.01) suggesting concurrent ↑ LV mass with diastolic dysfunction. Pc dose 
correlated with Echo2 LVMI & E/Et (both r -0.5, p<0.05), indicating improved LVMI & 
diastolic dysfunction. LogFGF23 changes correlated positively with the changes of weekly 
Pc dose (p<0.05) and serum P (p<0.05). Pc/logF ratio (4.0±3.2) correlated with LVMI, wall 
thickness and E/Et (all r -0.5, p<0.05).
Conclusions: Diastolic dysfunction observed in 2/3 of young HD patients and 
concurrent LVH improved with Pc despite ↑FGF23 levels. The Pc/logF ratio associated 
significantly with LV structure and diastolic dysfunction and may reflect the net mechanistic 
effects of these hormones on myocardial hypertrophy and function. Studies in larger cohorts 
with higher and longer dose regimens of Pc are warranted.
TH-PO510
A Phase 2A Pharmacokinetic Study of an Oral Vitamin D Compound 
(2MD) in Patients on Dialysis with Secondary Hyperparathyroidism 
Daniel W. Coyne,1 Richa A. Pandey,1 Hector F. Deluca,2,3 Julia B. Zella,2,3 Lori 
A. Plum,2,3 Margaret Clagett-Dame.2,3  1Renal Div, Washington Univ School 
of Medicine, Saint Louis, M2; 2Biochemistry, Univ of Wisconsin-Madison, 
Madison, WI; 3Deltanoid Pharmaceuticals, Inc., Madison, WI.
Background: Dialysis patients frequently receive a vitamin D receptor agonist such 
as the endogenous hormonal form of the vitamin, calcitriol, or an analog (e.g. paricalcitol) 
for treatment of secondary hyperparathyroidism. Although effective, these drugs can cause 
hypercalcemia. 2MD is a new vitamin D analogue that suppresses parathyroid hormone 
(PTH) at doses that do not adversely affect serum calcium and phosphorus.
Methods: We enrolled 11 hemodialysis patients with secondary hyperparathyroidism 
for a pharmacokinetic (PK) study of oral 2MD. After a 4-week screening period that 
included a 2-week washout of current pharmaceutical vitamin D therapy, patients received 
550ng of 2MD orally after each dialysis treatment for the next 4 weeks. PK studies were 
performed after the first and final dose.
Results: All eleven patients completed the study. At 4 weeks, the half-life (t1/2) of 
2MD was 50.8 ± 25.8h, time to maximum plasma concentration (tmax) was 4.0 ± 2.4h 
and concentration maximum (Cmax) was 3.44 ± 0.89pg/ml, while the area under the curve 
(AUC (0-96h)) was 148.0 ± 38.7pg*h/ml. Similar results were observed after a single dose. 
Mean PTH was suppressed 32% and calcium and phosphorus did not change significantly. 
Parameter (unit)a First dose n = 10b Week 4 n = 10
Cmax (pg/ml) 2.50 ± 1.16 3.44 ± 0.89
Tmax (hr) 2.1 ± 1.4 4.0 ± 2.4
AUC (0-t) (pg*hr/ml) 50.7 ± 18.5 148.0 ± 38.7
AUC (0-) (pg*hr/ml) 120.8 ± 59.5 204.3 ± 75.7
t1/2 (hr) 55.8 ± 36.8 50.8 ± 25.8
a all results are mean  SD.  
b One subject was excluded from the PPS because of a major protocol violation. 
Conclusions: In hemodialysis patients, 2MD has a much lower Cmax and AUC but a 
much longer t1/2 than calcitriol and paricalcitol. These characteristics are consistent with 
its high potency and effectiveness in suppressing PTH without significant perturbations 
of calcium and phosphorus.
Funding: Pharmaceutical Company Support - Deltanoid Pharmaceuticals
TH-PO511
Effect of a Novel Vitamin D Receptor Analog VS-105 on Chronic Kidney 
Disease-Mineral Bone Disorder  Hideki Fujii, Yuriko Yonekura, Kentaro Nakai, 
Keiji Kono, Shunsuke Goto, Shinichi Nishi.  Div of Nephrology and Kidney 
Center, Kobe Univ Graduate School of Medicine, Kobe, Japan.
Background: VS-105 is a novel vitamin D receptor (VDR) analog to suppress 
the progression of secondary hyperparathyroidism. Most important clinical problem is 
hypercalcemia, hyperphosphatemia and vascular calcification. In the present study, we 
compared the effect of VS-105 on chronic kidney disease-mineral bone disorder (CKD-
MBD) to that of paricalcitol (Pari) using CKD model rats.
Methods: We used male Sprague Dawley (SD) rats and CKD was induced by 5/6 
nephrectomy at 8 and 9 weeks. At 10 weeks, they were classified into six groups and were 
administered vehicle (V), low-dose paricalcitol (LP), high-dose paricalcitol (HP), low-
dose VS-105 (LV), and high-dose VS-105 (HV) three times a week, except in the sham 
operation group (C) (the C, V, LP, HP, LV, and HV group). At 20 weeks, the rats were 
sacrificed and urinary and blood biochemical analyses and calcium contents of the aorta 
were performed in all the groups.
Results: At 20 weeks, serum calcium levels showed overall comparable results at 
low doses. However, at higher doses, serum calcium levels were highest in the HP group 
followed by the HV group. Serum phosphate levels were higher in the Pari treated-group 
than in the VS-105 treated-group. The urinary excretion of phosphate was greater in the 
VS-105 treated-group than in the Pari treated-group. Serum parathyroid hormone (PTH) 
levels were decreased and serum fibroblast growth factor-23 (FGF23) levels were elevated 
after administering Pari and VS-105; however, despite comparable serum PTH levels, serum 
FGF23 levels were remarkably elevated in the Pari treated-group compared to the VS-105 
treated group. Calcium content of the aorta was higher in the Pari treated-group than in the 
VS-105 treated-group. The expressions of VDR and Klotho in the kidney were significantly 
higher in the VS-105 treated-group compared to Pari treated-group.
Conclusions: While serum PTH levels were similar, our data suggested that the effect 
of VS-105 on CKD-MBD was more favorable compared to paricalcitol. The mechanism 
appears to be associated with the difference in the expression of VDR and Klotho in the 
kidney.
TH-PO512
Vitamin D Receptor Modulators Suppress Vascular Remodeling in the 
Inflammatory State of Subtotally Nephrectomized Rats  Masahide Mizobuchi,1 
Keiichi Sumida,2 Takashi Inoue,1 Nozomu Hosaka,1 Hiroaki Ogata,3 Fumihiko 
Koiwa,4 Takanori Shibata.1  1Dept of Nephrology, Showa Univ School of 
Medicine, Tokyo, Japan; 2Nephrology Center, Toranomon Hospital Kajigaya, 
Kawasaki, Japan; 3Dept of Internal Medicine, Showa Univ Northern Yokohama 
Hospital, Yokohama, Japan; 4Dept of Medicine, Showa Univ Fujigaoka Hospital, 
Yokohama, Japan.
Background: Vitamin D receptor (VDR) modulators (VDRMs) have been shown to 
have pleiotropic effects. In this study we focused on this effect of a novel VDRM, VS-
105 on the vasculature in 5/6 nephrectomized rats in which inflammation was induced by 
lipopolysaccharide (LPS).
Methods: Male SD rats were 5/6 nephrectomized and fed a normal diet. Two weeks 
after the nephrectomy, an infusion mini pump was implanted through a catheter placed 
into the right jugular vein; saline was infused for 7 days and LPS was infused for another 
4 weeks. During the LPS infusion period, rats were treated (i.p. 3 times/week) with vehicle 
(propylene glycol; UC), calcitriol (0.015 µg/kg; CAL), or VS-105 (0.9 µg/kg; VS-105). 
Normal rats on the normal diet served as control (NC).
Results: The UC showed significant increase in serum TNFα levels (pg/ml) compared 
with NC (36.9 vs 11.0, P<0.05) suggesting the induction of systemic inflammation in 
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this model. Both VDRMs (CAL: 13.4, P<0.05 vs UC, and VS-105: 6.0, P<0.05 vs UC) 
significantly suppressed the increase in TNFα. Serum creatinine levels, significantly 
increased in the UC (P<0.05 vs NC), were not altered by the VDRMs. No statistical 
significance was observed in serum calcium and phosphorus among all 4 groups. The mRNA 
expression of PCNA in the aortic tissue was significantly increased in the UC (15.8-fold) 
compared with the NC (P<0.05), which was significantly suppressed by the VDRMs (CAL: 
9.2-fold, P<0.05 vs UC, and VS-105: 5.0-fold, P<0.05 vs UC). A similar observation was 
made in the Nox4 mRNA levels (7.2-fold in UC, 1.3-fold in CAL, and 1.8-fold in VS-105).
Conclusions: These results demonstrate that VS-105 has a suppressive effect on 
vascular remodeling in the inflammatory state of 5/6 nephrectomized rats in which oxidative 
stress is involved, suggesting that VS-105 exhibits anti-inflammatory pleiotropic effects.
Funding: Government Support - Non-U.S.
TH-PO513
Differential Effects of Ergocalciferol and Cholecalciferol Therapies in 
Chronic Kidney Disease  Cassandra A. Kimber,1 James B. Wetmore,2 Jason 
R. Stubbs.1  1The Kidney Inst, Univ of Kansas Medical Center, Kansas City, 
KS; 2Div of Nephrology, Hennepin County Medical Center, Minneapolis, MN.
Background: Nutritional vitamin D deficiency is common in patients with chronic 
kidney disease (CKD) and may contribute to a variety of comorbidities. Prospective studies 
assessing the comparative efficacy of cholecalciferol and ergocalciferol for correction of 
25(OH)D deficiency in CKD patients are lacking.
Methods:        We conducted a prospective, randomized, double-blinded trial to assess 
the relative efficacy of ergocalciferol versus cholecalciferol, 50,000 IU weekly for 12 weeks, 
to raise serum 25(OH)D levels in vitamin D-insufficient CKD patients (n = 41).  Serum 
25(OH)D concentrations were assessed at baseline, during therapy (week 6), immediately 
post-therapy (week 12), and six weeks following discontinuation of therapy (week 18). 
The primary outcome was the absolute change in 25(OH)D from baseline to 12 weeks. 
Secondary analyses included change in 25(OH)D from weeks 12 to 18, as well as changes 
in PTH and 1,25(OH)2D from baseline to 12 weeks.
Results: Mean baseline 25(OH)D concentrations were 20.5 ± 5.5 and 20.9 ± 6.3 ng/
mL in the ergocalciferol and cholecalciferol groups, respectively. Cholecalciferol therapy 
resulted in a greater absolute change in 25(OH)D (45.0 ± 16.5 ng/mL) versus ergocalciferol 
(30.7 ± 15.4 ng/mL) from baseline to week 12 (p<0.01). However, this superiority of 
cholecalciferol was transient, as the cholecalciferol group had a more pronounced decline in 
25(OH)D (-27.7 ± 19.5 ng/mL) compared to ergocalciferol (-13.2 ± 11.5 ng/mL) following 
the discontinuation of therapy (week 12 to 18; p<0.01). We observed no significant difference 
between these two therapies with regard to serum PTH or 1,25(OH)2D changes.
Conclusions: Therapy with cholecalciferol, compared to ergocalciferol, is more 
effective at raising serum 25(OH)D concentrations in CKD patients while active therapy 
is ongoing; however, this superiority is offset by a more pronounced decline in 25(OH)D 
concentrations with cholecalciferol following discontinuation of therapy. We observed no 
significant difference in serum PTH or 1,25(OH)2D changes between these two therapies.
TH-PO514
Effectiveness of High Dose Ergocalciferol versus Conventional Dose 
Ergocalciferol on 25-Hydroxyvitamin D Level in Chronic Kidney Disease 
Patients with Vitamin D Insufficiency  Bancha Satirapoj,1 Siwimon Areepong,1 
Panbubpa Choovichian,1 Ouppatham Supasyndh.1  1Medicine, Phramongkutklao 
Hospital and College of Medicine, Bangkok, Thailand; 2Phramongkutklao 
Hospital.
Background: Patients with chronic kidney disease (CKD) have an exceptionally high 
rate of 25-hydroxyvitamin D (25OHD) deficiency. Progression of CKD and the all cause 
mortality link to 25-OHD deficiency. The KDOQI guideline, modest supplementation 
with ergocalciferol to raise serum 25-OHD levels and might improve bone and mineral 
disorders in CKD. There was limitation of evidence for dosage of ergocalciferol supplement 
in CKD population.
Methods: This was an open labeled, randomized, controlled study in CKD patients with 
stage III-IV and serum 25-OHD<30 ng/mL. The patients were randomized into two groups: 
conventional-group treated with ergocalciferol as recommended by K/DOQI guidelines or 
high-dose-group treated with double dosage of ergocalciferol from the recommendation. 
Serum testing including 25-OHD, intact PTH, phosphate, and calcium were performed at 
baseline and 12th weeks.
Results: Sixty-three patients with average aged 69.23±11.62 years were included. 
Characteristics of the two groups were similar at baseline. At the end of the 12-week, the 
mean 25-OHD level significantly increased from 18.98±7.25 to 27.95±10.06 ng/mL in 
the conventional-group (p<0.001) and increased from 18.15±7.44 to 32.08±9.04 ng/mL 
in the high-dose-group (p<0.001). There was also a significantly increase 25-OHD levels 
in high-dose-group compared with conventional-group (13.64±9.87 vs. 8.52±6.77 ng/mL, 
p= 0.03). Moreover, there was a significantly greater decrease in serum PTH level in the 
high-dose-group than in the conventional-group(-16.75±26.42 vs. -0.25±26.76 pg/mL, p= 
0.03). Serum calcium and phosphate were not significantly different between the groups. 
There was no adverse effects associated with the treatment.
Conclusions: The studydemonstrated that oral high-dose ergocalciferol had higher 
efficacy for increasing 25-OHD and decreasing PTH level in patients with CKD than 
conventional-dose ergocalciferol after 12 weeks of treatment. The high-dose treatment might 
have potential effects on improved the bone and mineral disorders in patients with CKD.
TH-PO515
A Rapid Liquid Chromatography Tandem Mass Spectrometry (LC-MS/
MS) Method for Measurement of 24,25-Dihydroxyvitamin D for the 
Identification of Patients with CYP24A1 Mutations  Hemamalini Ketha, 
Ravinder Singh, Rajiv Kumar.  Dept of Laboratory Medicine and Pathology, 
Dept of Medicine, Mayo Clinic, Rochester, MN.
Background: Patients with inactivating CYP24A1 gene mutations exhibit elevated 
serum 1,25(OH)2D concentrations with resultant hypercalcemia, hypercalciuria and 
nephrolithiasis. The measurement of serum 25(OH)D to 24,25(OH)2D ratios permits 
the identification of patients with CYP24A1 mutations and is clinically valuable in the 
identification of patients who are candidates for subsequent CYP24A1 gene sequencing. The 
objective of our study was to validate a LC-MS/MS assay for 24,25(OH)2D (-D3 and –D2), 
to establish a range for normal serum 25(OH)D/24,25(OH)2D ratios and demonstrate the 
utility of such a ratio in patients with CYP24A1 mutations.
Methods: We validated a LC-MS/MS assay for serum 24,25(OH)2D3 and -D2. Inter- and 
intra-assay imprecision, limits of detection (LOD), limits of quantitation (LOQ), analytical 
measurement range (AMR) and recovery were determined. Interference, carry over, stability 
and ion suppression studies were performed. The serum 25(OH)D/24,25(OH)2D reference 
interval in 91 normal subjects was established and similar measurements were performed 
in 34 patients with clinically suspected CYP24A1 mediated hypercalcemia.
Results: The LOD and LOQ were 0.03 ng/mL and 0.1 ng/mL for 24,25(OH)2D3 and 
0.1 and 0.5 ng/mL for 24,25(OH)2D2, respectively. Intra- and inter-assay imprecision was 
4-15% across the AMR of 0.1-25 ng/mL. No interference was observed with 25(OH)D 
and 1,25(OH)2D. Intra- and inter-assay imprecision was 4-15% across the AMR of 0.1-25 
ng/mL. A 25(OH)D/24,25(OH)2D ratio of 7-35 was observed in normal subjects whereas 
in patients with CYP24A1 mutations 25(OH)D/24,25(OH)2D ratios were significantly 
increased (99-467; P<0.01). A 25(OH)D/24,25(OH)2D ratio of ≥99 identifies patients who 
are candidates for CYP24A1 genetic testing.
Conclusions: Elevated 25(OH)D/24,25(OH)2D ratios support the diagnosis of reduced 
CYP24A1 activity found in patients with mutations of the CYP24A1 gene. A 25(OH)
D/24,25(OH)2D ratio of ≥99 in a patient with hypercalcemia of unknown etiology warrants 
genetic confirmation by sequencing of the CYP24A1 gene.
Funding: NIDDK Support, Private Foundation Support
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Initiation of AMG 416 After Discontinuation of Cinacalcet  Kenneth Liss,1 
Geoffrey A. Block,2 Glenn Matthew Chertow,3 Bastian Dehmel,4 Yan Sun,4 
David M. Spiegel.4  1Hypertension and Nephrology Association, Eatontown, NJ; 
2Denver Nephrology, Denver, CO; 3Div of Nephrology, Stanford Univ School of 
Medicine, Palo Alto, CA; 4Amgen, Thousand Oaks, CA.
Background: AMG 416 is a novel intravenous calcimimetic agent that has been shown 
to significantly decrease parathyroid hormone (PTH) without increasing serum phosphate 
(P) or the albumin-adjusted serum calcium (cCa) in two 26-week placebo-controlled 
randomized clinical trials.
Methods: This 4-week, multiple-dose single-arm, open-label safety study was 
conducted to assess the incidence of hypocalcemia (< 7.5 mg/dL and < 8.3 mg/dL; primary 
and secondary endpoints respectively) in patients treated with the intravenous calcimimetic 
AMG 416 after discontinuation of daily oral cinacalcet. Subjects on a stable dose of daily 
oral cinacalcet (30, 60, or ≥ 90 mg) for a minimum of 4 weeks before and during the 4 weeks 
of screening were enrolled and underwent a cinacalcet washout period of a minimum of 7 
days. Subjects who had a serum cCa ≥ 8.3 mg/dL during the washout period were treated 
with AMG 416, 5 mg TIW after hemodialysis for 4 weeks followed by a safety observation 
period for 4 weeks. During the treatment period, the dose of AMG 416 could be restarted 
at 2.5 mg if a dose hold was required for low serum calcium or low PTH (two consecutive 
predialysis PTH < 100 pg/mL). Dose increases were not allowed.
Results: 158 subjects were enrolled and 148 completed the washout period and received 
AMG 416. 140 subjects completed the 4-week treatment period. The per-subject incidence 
(n, %) of low cCa during the 4 week treatment period was as follows: Prior cinacalcet dose 
cCa < 7.5 mg/dL cCa < 8.3 mg/dL 30 mg (N=63) 0 (0%) 18 (28.6%) 60 mg (N=47) 1 (2.1%) 
4 (8.5%) ≥90 mg (N=35) 0 (0%) 1 (2.9%) No subject had a post-baseline cCa < 7.0 mg/dL 
and no subject developed symptomatic hypocalcemia. Eight subjects discontinued AMG 
416: 4 due to subject request, 2 due to adverse events, 1 loss to follow up, and 1 due to death.
Conclusions: Treatment with AMG 416 at a starting dose of 5 mg can be safely initiated 
after a 7-day washout of cinacalcet therapy, provided that cCa is ≥ 8.3 mg/dL.
Funding: Pharmaceutical Company Support - Amgen
TH-PO517
Treatment with Cinacalcet Increases Plasma Sclerostin Concentration 
in Hemodialysed Patients with Chronic Kidney Disease and Secondary 
Hyperparathyroidism  Andrzej Wiecek, Piotr Kuczera, Marcin Adamczak. 
Dept of Nephrology, Transplantation and Internal Medicine, Medical Univ of 
Silesia, Katowice, Poland.
Background: Sclerostin (Scl) is a paracrine acting factor which is expressed in the 
osteocytes and articular chondrocytes. Results of recent clinical studies suggest that Scl 
may decrease the osteoblast-related bone formation through the inhibition of the Wnt/b-
catenin pathway. The aim of this prospective, single-arm, open-label clinical study was 
to assess the influence of six-month cinacalcet treatment on plasma Scl concentration in 
hemodialysed patients with secondary hyperparathyroidism (sHPT).
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Methods: In 45 hemodialysed patients with sHPT (PTH>300 pg/ml) plasma Scl as 
well as serum PTH, calcium and phosphate concentrations were assessed before the first 
dose of cinacalcet and after 3 and 6 months of treatment. Repeated measures ANOVA with 
Bonferroni correction was used in the statistical analyses. The results are shown as means 
and 95% confidence index.
Results: Serum PTH concentration decreased significantly after 3 and 6 month of 
treatment from 1173 (905-1441) pg/ml to 859 (584-1134) pg/ml and to 700 (432-767) pg/
ml; p for trend <0.0001, respectively. Mean serum calcium and phosphate concentrations 
remained stable during the treatment period. Plasma Scl concentration increased after 3 and 
6 months of treatment from 1.39 (1.20-1.58) ng/ml to 1.47 (1.27-1.67) ng/ml and to 1.55 
(1.32-1.79) ng/ml; p for trend = 0.04, respectively. There were no significant correlations 
between the magnitude of the plasma sclerostin increase and the decrease of serum PTH 
concentration after 3 or 6 months of treatment (r=-0.006;p=0.97 and r=0.004;p=0.98), 
respectively.
Conclusions: In hemodialysed patients with secondary hyperparathyroidism treatment 
with cinacalcet increases plasma sclerostin concentration which seems to be independent 
from the concomitant decrease of parathormone concentration.
Funding: Government Support - Non-U.S.
TH-PO518
The Effect of Cinacalcet Persistence on Risk of All-Cause Mortality and 
Heart Failure  Diane Reams,1 Paul Dluzniewski,3 Abhijit V. Kshirsagar,2 
Brian D. Bradbury,3 Liron Walsh,3 M. Alan Brookhart.1  1UNC Gillings School 
of Global Public Health, Chapel Hill, NC; 2UNC Kidney Center, Chapel Hill, 
NC; 3Amgen, Inc., Thousand Oaks, CA.
Background: Cinacalcet (Sensipar®) discontinuation occurs frequently for medical and 
non-medical reasons, such as parathyroid hormone levels below 150 pg/mL and medication 
cost. However, the clinical impact of discontinuing calcimimetic therapy is not well studied. 
We compared the risk of mortality and congestive heart failure (CHF) hospitalization 
between individuals with persistent cinacalcet use and patients who discontinued therapy 
for pre-defined non-medical indications.
Methods: Using data from a large dialysis provider merged with data from the 
USRDS, we identified new users of cinacalcet (2007-2011) from Part D prescription 
claims. Cinacalcet discontinuation was assessed in 30-day intervals and classified as 
either for medical or non-medical reasons. CHF hospitalizations were defined as ICD-9 
code 428.x in the primary position, with a broader definition used in a sensitivity analysis. 
Informative censoring was addressed using inverse probability of censoring weighted 
(IPCW) estimators. The risk differences (RD) and 95% CI’s for mortality and CHF 
hospitalizations were estimated at pre-specified follow-up times by comparing crude and 
IPCW cumulative risk functions.
Results: We identified 21,827 cinacalcet initiators who contributed 340,622 30-day 
follow-up intervals. At 12 months, 3,246 initiators (14.9%) had discontinued for medical 
indications and 12,077 initiators (55.3%) had discontinued for non-medical indications. 
We observed RDs for all-cause mortality at 12 months and 24 months, RD = -0.03 (95% 
CI -0.02, -0.03) and -0.04 (95% CI -0.03, -0.05), respectively. For CHF hospitalizations 
at 12 months and 24 months, RD = -0.00 (95% CI 0.00, -0.00) and -0.00 (95% CI 0.01, 
-0.01), respectively.
Conclusions: Our results find that approximately 3 extra deaths per 100 persons occur 
with discontinuation due to non-medical reasons during the first year of treatment. Reduction 
in risk for CHF hospitalization was evident when a broader definition of hospitalization 
was used, but no effect was seen with a more specific definition.
Funding: Pharmaceutical Company Support - Amgen, Inc.  Thousand Oaks, CA
TH-PO519
A Bayesian Meta-Analysis of Randomized and Observational Studies 
on Cinacalcet and Mortality in Secondary Hyperparathyroidism 
Mark E. Bensink,1 Greta Lozano-Ortega,2 Geoffrey A. Block,3 Glenn Matthew 
Chertow,4 Sarah Goring,2 Heather Bennett,2 Marie-Louise Trotman,1 Kerry 
Cooper,1 Adrian R. Levy,5 Vasily Belozeroff.1  1Amgen Inc., Thousand Oaks, 
CA; 2ICON plc, Vancouver, BC, Canada; 3Denver Nephrology, Denver, CO; 
4Stanford Univ, Palo Alto, CA; 5Dalhousie Univ, Halifax, NS, Canada.
Background: Conventional meta-analyses of therapeutic effects focus on randomized 
controlled trials (RCTs) and exclude valuable information captured in observational 
studies. We conducted a meta-analysis of the effect of cinacalcet in treating secondary 
hyperparathyroidism (sHPT) in patients with end stage renal disease (ESRD) using 
methodology that allows for incorporation of non-RCT evidence.
Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of 
Controlled Trials (2000-Februrary 2014) for RCTs and observational studies in which 
cinacalcet was compared to placebo or standard of care using all-cause mortality as an 
endpoint. A high Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) score was used as an entry criterion. We applied a Bayesian approach where 
evidence from observational studies was used as the informative prior for treatment effect 
for the meta-analysis of RCTs.
Results: A total of 616 abstracts were identified. High quality studies meeting inclusion 
criteria included 2 RCTs and 2 observational. There was insufficient data to estimate 
between-study variance under a random effects model. The fixed effect hazard ratio estimate 
(95% credible interval) for the effect of cinacalcet on mortality was 0.83 (0.78, 0.89).
Conclusions: This Bayesian meta-analysis of high quality studies indicates potential 
beneficial effects of cinacalcet on mortality in ESRD patients with sHPT.
TH-PO520
WELCOME – Web-Based Evaluation of Clinical Benefit of Cinacalcet in End-
Stage Renal Disease in Central and Eastern Europe  Jaroslav Rosenberger,1 
Piotr Mierzicki,2 Alexander Selyutin,3 Frantisek Svara,4 Kinga Jedynasty.5  1FMC, 
Kosice, Slovakia (Slovak Republic); 2SP Wojewodzki Szpital Specjalistyczny, 
Chelm, Poland; 3Regional Clinical Hospital Orenburg, Orenburg, Russian 
Federation; 4Dept of Medicine, Strahov General Univ Hospital, Prague, Czech 
Republic; 5C(( Headoffice, Amgen GmbH, 9ienna, Austria.
Background: Cinacalcet (MIM) is approved for treatment of secondary 
hyperparathyroidism (sHPT) in ESRD. Study objective: to describe KDOQI target 
achievement and treatment patterns before release of KDIGO guidelines (BGR; cut-off 
08/2009) and thereafter (AGR).
Methods: Design: multicenter, non-interventional, observational study from CEE. 
Dialysis patients (pts) starting MIM £1 month prior enrollment (BL) were eligible. Primary 
endpoint: % achieving PTH £300 pg/mL after 6 months. Secondary endpoints: % at KDOQI 
target for Ca or P at BL and 6 months; MIM dose; vitamin D sterol (VitD) and phosphate 
binder (PB) use; adverse drug reactions (ADR). The 2nd interim analysis is reported on 12 
cohorts enrolling between 01/2007-12/2012. 4 of 6 countries enrolled pts BGR (Figure).
Results: 2571 pts were enrolled, 2172 (84.5%) completed ³144 days of MIM.
BGR
N=824 
AGR
N=1747 
BL 6-mo BL 6-mo
PTH ≤300 pg/mL (%) 2.8 32.2 1.6 29.1
PTH (pg/mL), median (IQR) 683 (510-1011)
379 (261-
615)
739 (547-
1094)
430 (269-
738)
Ca 8.4-9.5 mg/dL (%) 46.4 58.9 49.5 49.8
P 3.5-5.5 mg/dL (%) 23.7 35.6 32.3 42.5
PB use (%) 82.5 61.7 84.6 61.7
VitD use (%) 59.0 40.5 59.0 43.2
Average median (IQR) MIM dose was 30 (30-42; BGR) and 30 (30-43) mg/day (AGR). 
Substantial differences in PTH were observed between countries. 
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110 patients (4.3%) reported ADR (gastrointestinal disorders, n=37; hypocalcemia, 
n=12); serious ADR: n=2 (cholecystitis, cholelithiasis) in 1 pt. All-cause mortality: 3.1%.
Conclusions: Overall, median PTH was not changed AGR. MIM substantially reduced 
PTH. Treatment practice varied by country.
Funding: Pharmaceutical Company Support - Amgen
TH-PO521
Persistent Hyperparathyrodism as a Risk Factor for Long Term Graft 
Dysfunction  Maria Julia C. L. N. Araujo, Melani Custodio, Janaina de 
Almeida Mota Ramalho, William C. Nahas, Rosilene M. Elias, Vanda Jorgetti, 
Elias David-Neto, Rosa M.A. Moyses.  Nephrology, Univ of Sao Paulo, Sao 
Paulo, Brazil.
Background: A successful kidney transplant (KTx) improves most of the mineral 
disturbances produced by CKD, but some disorders may persist for several years, such as 
hypercalcemia, elevated PTH and low phosphorus. Previous studies have shown the negative 
impact of persistent hyperparathyroidism (PHPT) on one year graft function. However, the 
long term effects of PHPT on renal function are poorly known. Based on that, we aimed 
to analyze the impact of PHPT on long term graft outcome.
Methods: Retrospective analysis of the isolated adult KTx that ocurred between 
01/2005 and 12/2014 at the Hospital das Clinicas - USP. Clinical and laboratory data 
were collected from the charts. Graft failure was defined as return to dialysis. PHPT was 
considered when, one-year after Ktx, ionized calcium was > 5,3 mg/dl or PTH >100 pg/ml.
Results: From the total of 1708 Ktx occurred in this period, we analyzed 1102 patients 
that, one year after KTx had an eGFR>30 ml/min and available data for analysis. Of those, 
28% (318) had hypercalcemia and 32% (356) had an elevated PTH. PHPT was present in 
47% of the patients. The mean follow up time was 1689 days. Graft failure was observed 
in 47 patients (33 in PHPT and 14 in non-PHPT group, HR = 1,5; p <0,05). Cox-regression 
analysis showed that graft failure was dependent on PHPT (β=2.3; 1.3-4.1; p= 0.007) even 
after adjustment for age at KTx, donor age, donor type, PTX and eGFR at 1 year after 
KTx, as shown in Figure.
Conclusions: Individuals with PHPT one year after KTx, even those with slightly 
elevated calcium or PTH, have an increased risk of long term graft failure. Our results 
call our attention for a better management of CKD-MBD before KTx and during the first 
year of follow-up.
TH-PO522
Epigenetic  Alterations in Secondary Hyperparathyroidism 
Gonzalo Bedia-Diaz,1 Agustin F. Fernandez,2 Jorge B. Cannata-Andia,1 
Adriana S. Dusso,1 Pablo Roman-Garcia.1  1Bone and Mineral Research Unit, 
Hospital Univ Central de Asturias, Univ de Oviedo, RedinRen, Oviedo, Spain; 
2Epigenetics, Hospital Univ Central de Asturias, Oviedo, Spain.
Background: Secondary hyperparathyroidism (sHPT) is a complication of CKD 
characterized by a decreased expression not only of genes such as the VDR, CaSR and 
Klotho, critical to control parathyroid growth and PTH secretion, but also of 80% of the 
parathyroid genome. Increased parathyroid DNA methylation in sHPT is an epigenetic 
change that could account for this widespread down-regulation of gene expression. This 
work examined the contribution of epigenetic alterations to the severity of sHPT.
Methods: To study methylation patterns in the promoter of the VDR, CaSR, Klotho 
and PTH genes, the methylation-prone areas in the promoter of each gene were identified 
and amplified using specific biotin-labelled primers. Parathyroid glands were collected 
from control and severely uremic rats
Parathyroid gDNA was extracted and treated with bisulphite to protect methylated 
cytosines. Specific PCRs were performed, purified and the PCR product, pyro-sequenced.
Results: Only the Klotho promoter was hyper-methylated (147.2% compared to 
controls-100%) supporting an epigenetic transcription blockage for this gene. In contrast, 
the VDR and CaSR promoters were robustly hypo-methylated in sHPT (46.7% and 67%, 
respectively), thus favouring rather than impairing gene transcription. Importantly, the 
PTH promoter was also significantly hypo-methylated (50.2%). Taken together, these 
results support an unrecognized contribution of epigenetic modifications to increase the 
PTH synthesis in sHPT, and to compensate for the marked reductions in VDR and CaSR 
expression.
Conclusions: Identification of the regulators of these distinct and gene specific 
epigenetic changes could provide novel targets for therapeutic interventions to improve 
outcomes in advanced sHPT.
Funding: Government Support - Non-U.S.
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Chronic Kidney Disease Caused Hypermethylations of CaSR and VDR 
Genes in Parathyroid Glands  Taketo Uchiyama,1,2 Norifumi Tatsumi,1 Ichiro 
Ohkido,2 Takashi Yokoo,2 Masataka Okabe.1  1Dept of Anatomy, The Jikei 
Univ School of Medicine, Minato-ku, Tokyo, Japan; 2Div of Nephrology and 
Hypertension, Dept of Internal Medicine, The Jikei Univ School of Medicine, 
Minato-ku, Tokyo, Japan.
Background: The stability of mineral homeostasis is the most important for the 
health of the organism. Secondary hyperparathyroidism (SHPT), a common disorder in 
patients with chronic kidney disease (CKD), occurs during early course of progressive 
renal insufficiency. It is well known that the reduction of calcium sensing receptor (CaSR) 
and vitamin D receptor (VDR) occur slowly and progressively, however the mechanism is 
largely unknown. Upstream transcription factors of CaSR and VDR are not clear except 
Glial cells missing 2 (Gcm2), it has affected the CaSR gene directly and transactivates by 
Gcm2 response elements in the CaSR promoters. In recent years there are reports about 
epigenetic studies in the field of various diseases including CKD. However, there are few 
reports related to mineral homeostasis. Here we investigated altered expressions of CaSR, 
VDR in CKD rats’ parathyroid glands. We then demonstrate that the pathogenomic change 
of SHPT, the reductions of CaSR and VDR expressions proceed from hypermethylations 
of CaSR and VDR genes.
Methods: Taqman probe (ABI) were used for quantitative real-time PCR. DNA 
methylation analysis was performed using a restriction digestion and quantitative PCR 
(qAMP), a combination of methyl-binding protein (MBP) and quantitative PCR (MBP-
qPCR). CKD was induced by two-step 5/6 nephrectomy.
Results: The expression level of Gcm2 was not significant both in CKD rats and 
controls. We then found hypermethylations of CaSR and VDR in CKD rats. 
Conclusions: These results suggest that CaSR reduction was independent to the Gcm2 
expressions in CKD rats, and chronic kidney disease caused hypermethylations of CaSR 
and VDR genes in parathyroid glands.
TH-PO524
Proteomic Comparative Analysis of Parathyroid Oxyphil Cell and 
Chief Cell Nodules of Uremic Secondary Hyperparathyroidism Patients 
Shensen Li, Qian Zhang, Minmin Zhang, Jing Chen.  Div of Nephrology, 
Huashan Hospital, Shanghai Medical College, Fudan Univ, Shanghai, China.
Background: Secondary hyperparathyroidism (SHPT) is the common abnormality in 
CKD patients. Hyperplasia of the parathyroid gland (PG) was considered to be an important 
processes in SHPT pathology. Physiologically, PG mainly composed of chief cells (CC, 
95-99%) and oxyphil cells (OC, 1-5%). Our previous study shown that OC in PG were 
significantly increased in uremic SHPT patients and closely related to oral calcitriol dose 
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and treatment duration. In order to investigate OC proliferation and vitamin D metabolism, 
we conducted proteomic analysis to compare differences between PG OC and CC nodules 
from SHPT patients.
Methods: Two pairs of PG OC and CC nodules were selected to conduct proteomic 
(liquid chromatography tandem mass spectrometry). The protein expression were quantified 
and filtered by more than 2-fold between two groups. By using bioinformatics analysis, 
the protein expression profiles were sorted to several terms (cellular component, molecular 
function and biological process). Vitamin D metabolism were further analyzed in both 
cell type groups.
Results: 14691 unique peptides were identified and 2675 proteins were quantified. 
A total of 174 proteins (6.5%) were more than 2-folds up/down expressed in OC nodules 
compared to CC nodules (40 increased and 134 decreased in OC nodules). Bioinformatics 
analysis showed that in cell components, membrane structure including mitochondrial 
(47.89%) were most significantly differences. In molecular function, protein with binding 
capacity (38.46%) were the major differences. In biological processes, protein and energy 
metabolism (33.92%), cell replication and cycle regulatory (10.14%) were significantly 
differences. Vitamin D transport and metabolic regulation proteins were less expressed in 
OC than CC nodules, among which, the decreasing of vitamin D binding protein in OC 
nodules were the most significantly (0.32 times of CC nodules).
Conclusions: Protein, energy metabolism, cell stress and cell cycle regulation are 
significant differences in the OC from CC nodules. Vitamin D transport and metabolic 
regulation proteins were less expressed in OC than CC nodules.
Funding: Government Support - Non-U.S.
TH-PO525
Clinical Outcomes in Japanese Chronic Kidney Disease Patients Aged 
Over 65 Years: A Report from the Gonryo Study  Tae Yamamoto,1 Mariko 
Miyazaki,1 Masaaki Nakayama,2 Gen Yamada,1 Hiroshi Sato,1 Sadayoshi Ito.1 
1Tohoku Univ, Sendai, Japan; 2Fukushima Medical Univ, Fukushima, Japan.
Background: Japan will become a full-fledged aged society. Aging is a risk factor for 
progression of chronic kidney disease (CKD) and CKD is common in elderly population. 
However the information of clinical feature of elder CKD is limited.
Methods: We prospectively followed up 1,750 elder outpatients over 65 years old under 
the care of nephrologists. Inclusion criteria was the basal age over 65 years, and estimated 
glomerular filtration rate < 90 mL/min and/or proteinuria. Survival, censored for RRT, was 
recorded for a follow-up time of 5 years. Patients were divided into 3 age groups, 65-74, 
75-85 and over 85 years old, and stratified by CKD stages. The effects on outcomes were 
evaluated, and assessed in association with body mass index (BMI).
Results: Among 1,750 patients, the median age 74 (min 65- max98) years and males 
49.8%, and 118 died and 200 patients started RRT during a median follow-up of 4.60 (qurtile 
1.84 – 5.00) years. The ESKD incidence did not differ among age groups. While the risk 
for survival increased in the higher aged groups (Log-Rank c2=62.93, P <0.0001), and the 
incidence rate was higher than that of ESKD in the over 85 years group (164.7 vs. ESKD 
126.9 per 1,000 persons per year). When patients were divided by CKD stages, patients 
with G5 progressed mainly ESKD in all groups, on the other hand, the context of all-cause 
mortality increased even in G3 and G4 in the higher aged groups compaerd to ESKD. In 
competing models, the survival risk before developing ESKD associated significantly with 
high age, smoking, low BMI, low palse pressure and history of cardiovascular disease, but 
did not with diabetes, renal function, proteinuria and hemoglobin level. A high BMI, which 
decreased significantly in the higher aged groups (P = 0.043), predicted a better survival in 
patients over 85 years old, but had no clear effects in patients under 75 years old.
Conclusions: The content of clinical outcomes were different among generations in 
elder CKD especially in CKD G3-4.In patients over 85 years increased the survival risk 
before developing ESKD, and the lower BMI associated the higher risk.
TH-PO526
Undocumented Immigrant and Uninsured Status Are Independent Risk 
Factors for Chronic Kidney Disease Progression  Orlando Nicholas Machado,1 
Ilay Rakhman,1 Jonathan M. Wyrick,2 Brittany Kalosza,2 George N. Coritsidis.1,2 
1Div. of Nephrology, Elmhurst Hospital Center, MSSM, Elmhurst, NY; 2Dept of 
Surgery, Elmhurst Hospital Center, MSSM, Elmhurst, NY.
Background: Being uninsured is a risk factor for chronic kidney disease (CKD) 
progression to end stage renal disease (ESRD). Undocumented immigrants (UI)belong 
to a vulnerable group in terms of healthcare. Little is known about the association of UI 
status and CKD progression.
Methods: Records of adult patients admitted to Elmhurst Hospital Center from 2009 
to 2014 with CKD stage 4 or 5 as diagnosis or comorbidity were analyzed. ESRD patients 
were excluded. Covariates analyzed included sex, age, documentation (Social Security 
Number) and insurance status. Data was analyzed using STATA; Pearson’s Chi Squared 
test was used for bivariate analyses.
Results: Of 703 patients analyzed: 81% had insurance (n=569), 19% were uninsured 
(n=134), 84% were documented (DOC, n=588), and 16% were UI (n=115). Of the DOC, 
89% had insurance (n= 525) vs. 38% (n=44) of UI (p<0.005) and were older than UI 
(71±15 vs. 59±15, p<0.005). 21% of CKD patients progressed to ESRD (n=151): 20% of 
DOC compared to 30% of UI (p<0.05). Analyzed by insurance status, 18% of the insured 
developed ESRD compared to 36% of the uninsured (p<0.0001). On bivariate level, UI 
was associated with ESRD progression (p<0.05). On multivariate level, documentation 
status lost significance, but insurance status remains significant for ESRD progression. 
Likelihood of Progression to ESRD
Model 1 OR(95% CI) Model 2 OR(95% CI)
Documentation Status
DOC 1.00 1.00
UI 1.18(0.74-1.89) 0.90(0.53-1.53)
Gender
Male 1.00 1.00
Female 0.82(0.56-1.20) 0.79(0.54-1.16)
Age
18-59 1.00 1.00
60-79 0.63(0.41-0.94)* 0.70(0.46-1.08)
80-99 0.18(0.10-0.33)** 0.21(0.11-0.39)**
Insurance Status
Insured 1.00
Uninsured 1.81(1.10-2.10)*
Model 1: Controlling for Documentation Status Gender and Age
Model 2: Controlling for above and Insurance Status
*p<0.05, **p<0.0005
Conclusions: Documentation and insurance status are associated with ESRD 
progression. Once controlling for demographic variables, documentation status is no longer 
significant, but insurance status remains significant for progression.
TH-PO527
The Impact of Medical Comorbidities on Renal Function following Radical 
or Partial Nephrectomy  Michael J. Vacchio, Andrew G. Winer, Emily C. Zabor, 
A. Ari Hakimi, Paul Russo, Jonathan A. Coleman, Edgar A. Jaimes.  Memorial 
Sloan-Kettering Cancer Center, New York, NY.
Background: Increasing utilization of nephron sparing surgery (NSS) for kidney tumors 
has led to superior renal functional outcomes while maintaining oncologic control. However, 
the impact of comorbidities on post-nephrectomy renal function is not well understood. 
Here, we aim to identify patient and disease characteristics which have an adverse impact 
on renal function following nephrectomy.
Methods: We conducted a retrospective review of data on 440 patients who underwent 
robotic partial (PN) or radical nephrectomy (RN) for renal tumors by a single surgeon 
between 2006 and 2014 at our institution. Loess plot was generated to visually assess 
renal function over time. Univariable and multivariable longitudinal regression analyses 
incorporated a random intercept and slope to evaluate the association between patient and 
disease characteristics with renal function following surgery.
Results: Advanced age at surgery, larger tumor size, male sex, history of smoking, 
hypertension and higher ASA score were significantly associated with lower preoperative 
estimated glomerular filtration rate (eGFR). On multivariate analysis, independent predictors 
of reduced renal function following surgery were advanced age, lower preoperative eGFR, 
and RN. Length of time from surgery was strongly associated with improvement in renal 
function among all patients.
Conclusions: Independent predictorsof post-operative decline in renal function include 
advanced age, lower pre-operative eGFR and RN. A significant number of subjects had 
recovery in renal function over time following surgery which continued past the 12 month 
mark. These findings suggest that patients undergoing nephrectomy can experience long-
term improvement in renal function. This improvement is greater among younger patients 
with higher pre-operative eGFR undergoing PN.
Funding: Private Foundation Support
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TH-PO528
A Longitudinal Analysis of Chronic Kidney Disease and Related 
Comorbidities Among Human Immunodeficiency Virus (HIV) Patients 
Grace Mccomsey,1 Nicole M. Meyer,2 Xue Song,2 Jonathan A. Winston.3  1Case 
School of Medicine, Cleveland, OH; 2Truven Health Analytics, Cambridge, MA; 
3Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Patients with HIV infection can present with or develop multiple 
comorbidities including risk factors for chronic kidney disease (CKD). This study examined 
CKD and comorbid conditions in HIV patients in the US.
Methods: Adults diagnosed with HIV (ICD-9 code: 042.xx, 795.71, V08) in 2007-2013 
were selected from MarketScan Commercial, Medicare, and Medicaid Databases. Patients 
were continuously enrolled for ≥ 365 days in 2007-2013 and stratified by the presence 
of CKD based on diagnosis codes. Comorbidities, prevalence (per 1,000 patients), and 
incidence (per 1,000 patient-years) of CKD in 2007-2013 were assessed.
Results: A total of 31,229 HIV patients (mean age: 42.8; male: 77.9%; mean Deyo-
Charlson comorbidity index (CCI): 6.0) were selected from Commercial data, 1,541 (mean 
age: 71.9; male: 62.7%; CCI: 7.9) from Medicare, and 10,190 (mean age: 42.9; male: 
44.1%; CCI: 7.0) from Medicaid. CKD prevalence and incidence were, respectively, 48.6 
and 13.1 in Commercial, 242.1 and 61.1 in Medicare, and 114.3 and 28.4 in Medicaid. 
Prevalence and incidence increased over time. During 2007-2013, end-stage renal disease 
(ESRD)/dialysis patients accounted for 1.8% of Commercial, 7.7% of Medicare and 4.8% 
of Medicaid patients. Common CKD risk factors included hypertension (Commercial: 
32.5%; Medicare: 77.0%; Medicaid: 55.5%), hyperlipidemia (30.6%, 52.7%, 33.8%), 
diabetes (11.2%, 36.9%, 25.1%), cardiovascular disease (6.4%, 34.4%, 15.5%), and 
obesity/overweight (7.0%, 7.5%, 16.9. Annual incremental healthcare costs in 2013 were 
higher in CKD patients than non-CKD patients (Commercial: 16,406; Medicare: 6,879; 
Medicaid: 5,663).
Conclusions: We observed an increase in CKD prevalence and incidence over time in 
HIV-infected person.  Because of the potential effects of ART treatment on CKD observed 
in published data, understanding CKD risk factors of HIV patients will help optimize care 
of patients, including choice of antiviral regimens and screening and treating of these 
risk factors.
Funding: Pharmaceutical Company Support - Gilead Sciences
TH-PO529
Association of Short Sleep Duration and Rapid Decline in Renal Function 
Ciaran Joseph McMullan, Gary C. Curhan, John P. Forman.  Renal Div, Brigham 
and :omen¶s Hospital, Boston, MA.
Background: The kidney, like all other organs in the human body, is influenced 
by circadian rhythms, allowing renal function to be entrained to the sleep-wake cycle. 
Coordination of this periodicity in the kidney permits anticipation of the metabolic and 
physiological demands of the kidney throughout a 24-hour cycle. Unsurprisingly, disruption 
of the sleep-wake cycle may lead to disruption of renal physiology. Although sleep disruption 
has been studied extensively in cardiovascular and metabolic disease, its association with 
chronic kidney disease has not been shown.
Methods: In a prospective cohort study of 4238 participants from the Nurses’ Health 
Study with renal function measured on at least two occasions, we analyzed the association 
of self-reported sleep duration with decline in renal function over an 11year period.
Results: Individuals who reported shorter sleep duration were more likely to experience 
a rapid decline in estimated glomerular filtration rate (≥ 25% decline from 1989 to 2000). 
Compared with sleeping 7-8 hours per night, the adjusted odds ratios for a rapid decline 
in renal function were 1.65 (95% CI, 1.06-2.55) for ≤5 hours sleep per night, 1.31 (95% 
CI, 1.06-1.61) for 6 hours sleep per night, and 0.78 (95% CI, 0.48-1.25) for ≥9 hours sleep 
per night. Similarly, adjusted annualized decline in estimated glomerular filtration rate 
was 1.2 ml/min/1.73m2/year, 0.9 ml/min/1.73m2/year, 0.8 ml/min/1.73m2/year, and 0.8ml/
min/1.73m2/year for individuals sleeping ≤5 hours per night, 6 hours per night, 7-8 hours 
per night, and ≥ 9 hours per night, respectively (p-trend = 0.02).
Conclusions: Shorter sleep duration is prospectively and independently associated 
with faster decline in renal function.
Funding: NIDDK Support
TH-PO530
Impairment of Endogenous Nighttime Melatonin Secretion Relates to 
Intrarenal Renin-Angiotensin System Activation and Renal Damage in 
Patients with Chronic Kidney Disease  Sayaka Ishigaki,1 Naro Ohashi,1 
Shinsuke Isobe,1 Takayuki Tsuji,1 Akihiko Kato,2 Hideo Yasuda.1  1Internal 
Medicine 1, Hamamatsu Univ School of Medicine, Hamamatsu, Shizuoka, 
Japan; 2Blood Purification Unit, Hamamatsu Univ School of Medicine, 
Hamamatsu, Shizuoka, Japan.
Background: Activation of the intrarenal renin-angiotensin system (RAS) plays a 
critical role in the pathophysiology of chronic kidney disease (CKD) and hypertension. 
Recently, we have demonstrated that the circadian rhythm of intrarenal RAS activation 
leads to renal damage and hypertension. Melatonin is considered as a major hormone 
regulating the circadian rhythm and nocturnal melatonin concentrations are reduced in 
patients with CKD. However, it has not known whether the impairment of endogenous 
melatonin secretion is related to BP, intrarenal RAS or renal damage in patients with CKD.
Methods: We recruited 53 patients with CKD stage 1-5 and 24-hour ambulatory BP 
monitoring (ABPM) and urine collection divided into daytime and nighttime were conducted. 
We investigated the relationship among urinary 6-sulphatoxymelatonin (U-aMT6s), that 
is the major melatonin metabolite, BP, renal function, urinary angiotensinogen (U-AGT), 
and urinary protein (U-P) in daytime and nighttime, respectively.
Results: The nighttime U-aMT6s levels were decreased according to the progression 
of CKD stage and those in CKD stage 5 was significantly decreased compared with those 
in other CKD stages. The U-aMT6s levels were significantly and negatively correlated 
with the clinical parameters such as renal function (serum creatinine), systolic BP, U-AGT 
and U-P in both daytime and nighttime. Multiple regression analyses for U-aMT6s levels 
were performed using age, sex, serum creatinine and each parameter (systolic BP, U-AGT 
or U-P) in daytime and nighttime, respectively. U-aMT6s levels tended to correlate with 
systolic BP (β=0.22, p=0.11), and were significantly associated with U-AGT (β=0.31, 
p=0.040) and U-P (β=0.26, p=0.041) in nighttime. On the other hand, U- aMT6s had no 
associations with the clinical parameters in daytime.
Conclusions: Impairment of nighttime melatonin secretion may be associated with 
nighttime intrarenal RAS activation and renal damage in patients with CKD.
TH-PO531
Climate Temperature Affects the Age of Onset of End Stage Renal Disease 
Michael E. Bleyer, Marwan M. Abbas, Elizabeth Swain, Kendrah O. Kidd, 
Anthony J. Bleyer.  Section on Nephrology, Wake Forest School of Medicine, 
Winston-Salem, NC.
Background: Increasing global temperatures is a rising concern. We were interested 
to see if there was a relationship between climate temperature and the age of onset of 
end-stage kidney disease.
Methods: We obtained demographic data and cause of ESRD on 1,332,402 individuals 
who had their first occurrence of ESRD between ages 30 and 90 between June 1971 and 
October 2012 from the United States Renal Data system (USRDS). We obtained the annual 
mean temperatures from 1990 to 2010 for weather stations throughout the US and linked 
a participant’s zip code to the nearest weather center. We performed multivariate linear 
regression for white individuals with age of onset of ESRD as the dependent variable, 
and independent variables being age, gender, mean income for the participant zip code, 
baseline estimated glomerular filtration rate at the start of dialysis, and mean temperatures 
according to participant zip code categorically from 40°F to 75°F in 5 degree intervals.
Results: Figure 1 shows the relationship between age of ESRD and temperature 
with race/gender combinations. Temperature affects white individuals more than African 
Americans. The U shaped relationship was similar for PKD, IgA nephropathy and Type 2 
diabetes. A multivariate model of whites showed the correlation between temperature and 
age of ESRD persisted after adjustment for other variables (p<0.0001).
Variable Type III SS F value p value
Gender 107334 760 <0.0001
Temperature 118355 838 <0.0001
Year starting dialysis 242949 1721 <0.0001
Median income by zip code 310045 2196 <0.0001
GFR at start of dialysis 1120868 7940 <0.0001
Conclusions: There is a U-shaped relationship between the age of ESRD and mean 
temperature for a given region in whites, but not in African Americans. This variation 
persisted after multivariate regression. Global warming could affect the age of onset of 
ESRD.
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Prognostic Implications of Anemia in Patients with Chronic Kidney Disease 
Undergoing Elective Percutaneous Coronary Intervention  Yuichiro Kitai,1 
Neiko Ozasa,2 Motoko Yanagita,1 Takeshi Kimura.2  1Dept of Nephrology, Kyoto 
Univ Graduate School of Medicine, Kyoto, Japan; 2Dept of Cardiovascular 
Medicine, Kyoto Univ Graduate School of Medicine, Kyoto, Japan.
Background: Little is known about the prognostic implications of anemia in patients 
undergoing elective percutaneous coronary intervention (PCI), especially when they have 
coexisting chronic kidney disease (CKD).
Methods: We identified 2792 patients with CKD who underwent elective PCI from 
the CREDO-Kyoto registry cohort-2. The primary outcome was 3-year major adverse 
cardiac events (MACE); composite of all cause death, heart failure hospitalization, and 
myocardial infarction.
Results: In total, 738 patients (26.4%) had mild anemia (hemoglobin = 11.0–11.9 g/dL 
for women and 11.0–12.9 g/dL for men), and 740 patients (17.9%) had moderate-to-severe 
anemia (hemoglobin < 11.0 g/dL both for women and for men). Compared to the no-anemia 
group, cumulative incidence of MACE was significantly higher in the mild and moderate-
to-severe anemia groups (12.2%, 23.5%, and 37.4%, respectively). The adjusted hazard 
ratios of mild and moderate-to-severe anemia versus no-anemia for MACE were 1.46 (95% 
confidence interval: 1.13–1.90) and 1.76 (95% confidence interval: 1.33–2.34), respectively. 
In addition, the risk for MACE showed an accretive increment with exacerbation in either 
the renal function or anemia (interaction p < 0.001).
Conclusions: Even mild anemia was associated with significantly worse 3-year clinical 
outcomes in CKD patients who underwent elective PCI. Anemia and reduced renal function 
independently and additively increased the risk for MACE in these patients.
TH-PO533
Pathologic Classification of Diabetic Kidney Disease in Prognosticating 
Time to End-Stage Renal Disease or Death  Askia K. Dunnon,1 A. Gasim,2 
Fernanda Payan Schober,1 Yichun Hu,1 J. Charles Jennette,2 Amy K. Mottl.1 
1UNC Kidney Center; 2Dept of Pathology, UNC School of Medicine, Chapel 
Hill, NC.
Background: We performed a retrospective, longitudinal study of patients with 
diabetic kidney disease (DKD) undergoing renal biopsy to ascertain the prognostic value 
of histopathologic features when combined with clinical information.
Methods: Specimen from clinical native kidney biopsies performed in 1998-2006 
containing diabetic glomerulosclerosis in the final diagnoses were analyzed according to 
the Renal Pathology Society classification system for DKD. Clinical data were extracted 
from medical records from time of biopsy until the composite outcome of ESRD or death. 
Multivariate cox proportional-hazards regression was used to estimate hazard ratios (HR) 
of the composite outcome according to glomerular class or severity of interstitial fibrosis. 
Covariates included age, gender, diabetes duration, blood pressure, eGFR and urine protein 
at the time of biopsy.
Results: Baseline characteristics according to glomerular class are displayed below. 
Covariates Class 2a/2bN = 44
Class 3
N = 67
Class 4
N = 19 p-value
Age, yrs 49±18 48±18 56±10 0.1
Female sex, % 43 47 32 0.5
Diabetes duration, yrs 11±6 15±7 13±7 0.07
HbA1c, % 7.7 ±2.4 8.3 ±2.6 6.7 ±1.1 0.2
Systolic blood pressure, mmHg 141±33 151±22 169±30 0.01
Urine protein*, gm/gm median (IQR) 2.8 (1.5-7.0)
5.2 (2.8-
8.7)
5.5 (2.4-
9.3) 0.2
estimated GFR, ml/min/1.73m2 23±24 21±18 12±12 0.07
Interstitial fibrosis severity, %:
0/1
2
3
36
34
30
12
55
33
0
16
84
Time to ESRD or death, months 23 ±23 18 ±26 6 ±7 0.01
The risk for ESRD/death for glomerular classes 2a/b and 3 versus class 4 was HR=0.12 
(0.04-0.42) and HR=0.17 (0.06-0.51), respectively. Analysis of interstitial fibrosis (IF) 
severity 0/1 versus 3 yielded a HR=0.19 (0.06, 0.63). The HR for IF 2 versus 3 was not 
significant (p=0.09). The only statistically significant clinical covariate in the analyses was 
eGFR: HR=0.96 (0.93, 0.99) and HR=0.94 (0.91, 0.97), respectively.
Conclusions: Kidney biopsy significantly improves the prognostication of ESRD or 
death in patients with diabetic glomerulosclerosis.
Funding: Private Foundation Support
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Progression of Chronic Kidney Disease Stage 3 Over 5 Years in a Prospective 
Primary Care Cohort Study  Adam Shardlow,1,2 Natasha Juliette Mcintyre,1 
Richard J. Fluck,1 Christopher W. McIntyre,3 Maarten W. Taal.1,2  1Renal 
Medicine, Royal Derby Hospital, Derby, United Kingdom; 2Faculty of Medicine 
and Health Sciences, Nottingham Univ, Nottingham, United Kingdom; 3London 
Health Sciences Centre, London, 2N, Canada.
Background: CKD stage 3 is commonly diagnosed in primary care. Previous studies 
indicate that it runs a variable course with only a minority progressing to ESRD. The Renal 
Risk in Derby study aims to evaluate progression of CKD in a cohort of people with CKD 
3 recruited prospectively from primary care in Derbyshire, UK.
Methods: 1741 participants were recruited from local primary care practices. All had 
eGFR 59-30ml/min on 2 occasions prior to recruitment. At baseline, year 1 and year 5 visits, 
participants underwent clinical assessment, urine and serum biochemistry. Progression of 
CKD was defined using KDIGO criteria (25% loss of GFR and an increase in GFR category, 
or an increase in albuminuria category).
Results: 299 (17.2%) participants died prior to the end of year 5 follow-up. Only 4 
participants (0.2%) progressed to ESRD. 1064 participants attended for year 5 visits or 
submitted blood and urine samples. Mean age was 71 years at baseline. Mean eGFR was 
55.3ml/min at baseline and 53.8ml/min at year 5 (p<0.001). Progression occurred in 263 
participants (24.6%). Binomial logistic regression identified male gender (HR1.55), baseline 
eGFR (HR0.97), logUACR (HR1.33), diabetes (HR1.57), haemoglobin (HR=0.81) and 
the change in GFR at year 1 (HR0.95) as independent determinants of progression at 5 
years. Progression in eGFR and albuminuria categories occurred largely independently. 
No Albuminuria Progression Albuminuria Progression
No eGFR Progression 804 (75.6%) 143 (13.5%)
eGFR Progression 86 (8.1%) 30 (2.8%)
Baseline eGFR and change in eGFR at year 1 were independent determinants of eGFR 
category progression. Albuminuria progression was independently associated with age, 
male gender, baseline eGFR, logUACR and diabetes.
Conclusions: Our data confirm that the 5-year risk of ESRD is low in CKD 3 but 
progression occurred in 24.6% of participants. Change in eGFR over 1 year was an 
independent predictor of progression over 5 years indicating that annual monitoring is 
beneficial for assessing prognosis.
Funding: Private Foundation Support
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Change in Albuminuria and Risk of ESRD in a Large Health System 
Josef Coresh,1 Yingying Sang,1 Morgan Grams,1 Kunihiro Matsushita,1 Shoshana 
Ballew,1 H. Lester Kirchner,2 Andrew S. Levey,3 Lesley Inker,3 Hiddo Jan 
Lambers Heerspink,4 Ron T. Gansevoort,4 Alex R. Chang.2  1JHU; 2Geisinger; 
3Tufts; 4UMCG.
Background: Albuminuria is used in chronic kidney disease (CKD) staging but it is 
uncertain how change in albuminuria is associated with ESRD risk in primary care and 
other generalizable settings.
Methods: We included Geisinger Health System participants with multiple albuminuria 
measurements within a 2-year baseline period, using Cox proportional hazards regression 
to estimate the association of ESRD with log change in albuminuria (per 2-fold rise in 
albumin to creatinine ratio, ACR). We tested risk for non-linearity and also analyzed 1- and 
3-year baseline periods.
Results: 27,121 participants (6.5% of all primary care patients; 75% of diabetics) had 
at least 2 ACR measurements during baseline. After the 2-year baseline, 296 ESRD events 
occurred over a median follow-up of 5.2 years. Change in ACR had a geometric mean (25th-
75th percentiles) of 1.1 fold rise (1.9 fold decrease - 2.1 fold rise). A two-fold rise in ACR 
over 2-years was associated with a subsequent HR (95% CI) of ESRD of 1.42 (1.33-1.51) 
adjusted for initial eGFR, ACR and 7 other risk factors. The HR was generally similar if 
the 2-fold ACR rise occurred over 1-year (1.48 (1.36-1.61)) or 3-year (1.42 (1.35-1.51)), as 
well as across the range of baseline ACR (<10, 10-99, 100+) and diabetes status. There was 
a suggestion toward non-linearity with 8-fold rise showing a stronger association than an 
8-fold fall (HR 3.2 vs. 0.4, reference: stable ACR). Limitations: ACR measurement follows 
clinical care standards and selection criteria. Replication across other settings will be useful.
Conclusions: In primary care, change in ACR is associated with risk of ESRD. The 
CKD Prognosis Consortium will expand this investigation to multiple settings to inform 
use of change in ACR as an outcome in clinical practice, research, and regulatory purposes.
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TH-PO536
Association Between Vascular Access Creation and Regression of eGFR 
Decline in Late-Stage CKD Patients Transitioning to ESRD  Keiichi Sumida,1 
Miklos Zsolt Molnar,1 Praveen Kumar Potukuchi,1 Fridtjof Thomas,1 Jun 
Ling Lu,1 Jennie Jing,2 Vanessa A. Ravel,2 Melissa Soohoo,2 Connie Rhee,2 
Elani Streja,2 Lawrence Agodoa,3 Kevin C. Abbott,3 Paul W. Eggers,3 Kamyar 
Kalantar-Zadeh,2 Csaba P. Kovesdy.1,4  1Univ of Tennessee Health Science 
Center, Memphis, TN; 2Univ of California, Irvine, CA; 3NIH, Bethesda, MD; 
4VA Medical Center, Memphis, TN.
Background: Arterio-venous dialysis access (AVF) creation may be associated with 
slowing of the decline in eGFR. It is unclear if this is due to physiological benefits of a 
mature access vs. other confounding factors in late CKD. We hypothesized that the beneficial 
change in the eGFR would only be seen with a mature AVF.
Methods: From 52,172 U.S. veterans who transitioned to dialysis between 2007-
2011, we identified 3,220 who had an AVF created prior to dialysis start, and had at least 3 
outpatient eGFR measurements both before the AVF creation and between AVF creation 
and the initiation of dialysis. We estimated crude and adjusted slopes of eGFR vs. time in 
multilevel mixed effects models with random intercepts and slopes. Pre- and post-AVF 
eGFR slopes were compared both overall, and in patients stratified by AVF maturation.
Results: Mean (SD) age was 66.3 (10.8) years, and patients were 98% male, 35% black, 
and 76% diabetic. Median (IQR) eGFR slope was -5.2 (-8.3 to -3.2) ml/min/1.73m2/year, 
and 71% had a mature AVF at dialysis start. Compared with the eGFR slopes before AVF, 
a significant improvement was observed post-AVF (-5.5 [-8.9 to -3.4] vs. -4.0 [-4.6 to -3.2], 
P<0.001). This association was present to a similar extent in both patients with matured 
and un-matured AVF (Figure). Results were unchanged in adjusted models.
Conclusions: Regardless of maturation, the creation of AVF is associated with improved 
eGFR slopes. Clarifying the mechanism behind this warrants additional studies.
Funding: NIDDK Support, Veterans Administration Support
TH-PO537
Presence of Periventricular Hyperintensity in Magnetic Resonance 
Imaging Is a Predictor for Future End Stage Renal Disease in Predialysis 
CKD Patients  Hideaki Shima,1 Tatsuhiko Mori,1 Toshihide Naganuma,2 Mika 
Sonoda,3 Tetsuo Shoji,3 Mikio Okamura,4 Eiji Ishimura,3 Masaaki Inaba.3 
1Nephrology, Osaka Medical College, Takatsuki, Osaka, Japan; 2Urology, 
Osaka City Univ Hospital, Osaka, Japan; 32nd Div of Internal Medicine, Osaka 
City Univ Hospital, Osaka, Japan; 4Nephrology, Ohno Memorial Hospital, 
Osaka, Japan.
Background: In the general population, periventricular hyperintensity (PVH) evaluated 
by brain magnetic resonance imaging (MRI), is a predictor of future stroke. CKD is a high 
risk condition of ESRD as well as cardiovascular disease (CVD). However, no longitudinal 
studies have been performed to determine the clinical significance of PVH in CKD. In 
the present study, we investigated the influence of PVH as a predictor of future CVD and 
ESRD in predialysis CKD.
Methods: This is a prospective cohort study. We examined the effect of the presence 
of PVH for CVD and renal outcome. CVD and renal outcome are defined as the new onset 
of stroke, ischemic heart disease, amputation as peripheral arterial disease and the doubling 
of serum creatinine levels or development of ESRD, respectively. We followed up 404 
CKD patients without renal replacement therapy, who underwent brain 1.5T-MRI, for 37 
months (median survival time, range: 19-56 months). Cox proportional hazard models were 
performed to each outcome adjusted by several atherosclerotic factors.
Results: At baseline, PVH were detected in 187 of the 404. During follow-up, 124 cases 
reached outcomes. In the 22 cases of stroke during follow up, the incidence of stroke was 
significantly higher in the group with PVH than that of without (p=0.0197, Log rank test). 
The presence of PVH was significantly associated with the increased risk for the future 
CVD and renal outcome in an unadjusted model. After adjustment, the power to predict 
CVD but not renal outcome by PVH was diminished (CVD: 1.44, 95%CI 0.66-3.46, renal 
outcome: HR 1.70, 95%CI 1.05-2.84).
Conclusions: This is the first report clearly showing that the presence of PVH is a 
strong predictor for future ESRD in predialysis CKD patients, but not CVD. Presence of 
PVH was a novel predictor for the progression of CKD. These results show one of the 
evidence of brain-kidney association.
TH-PO538
Telomerase Activity in Patients with Stage 2-5 Chronic Kidney Disease 
Mehmet Tugrul Sezer,1 Veysel Kidir,1 Ayse Aynali,2 Atila Altuntas,1 Salih Inal,1 
Buket Ar?dogan.2  1Dept of Internal Medicine, Div of Nephrology, Suleyman 
Demirel Univ, Medical Faculty, Isparta, Turkey; 2Dept of Medical Microbiology, 
Suleyman Demirel Univ, Medical Faculty, Isparta, Turkey.
Background: The relationship between telomerase activity and stages and progression 
of Chronic Kidney Disease (CKD) is unknown. The aim of this study is to investigate the 
association between telomerase activity and stages of CKD.
Methods: A total of 120 patients (30 patients from each stages of 2-5) and 30 healthy 
volunteers applying to the clinic for their routine examinations were enrolled in the study. 
The individuals from patient and control groups were matched in terms of age and gender. 
PBMC telomerase activity was measured by telomeric repeat amplification protocol.
Results: PBMC telomerase activity was significantly different between the groups 
(p < 0.001). Telomerase activity was found to be lowest in healthy controls (0.15 ± 0.02), 
and highest in patients with stage 5 CKD (0.23 ± 0.04). Telomerase activity was similar 
between patients with stage 2, 3, and 4 CKD (p > 0.05). There was positive correlation 
between telomerase activity and CKD stage (r = 0.412, p < 0.001), serum creatinine (r = 
0.404, p < 0.001), potassium (r = 0.207, p = 0.023), and intact parathyroid hormone (r = 
0.245, p = 0.007) levels and negative correlation between telomerase activity and estimated 
glomerular filtration rate (eGFR) (r = -0.407, p < 0.001), serum sodium (r = -0.179, p = 
0.05), calcium (r = -0.357, p < 0.001), LDL-cholesterol (r = -0.218, p = 0.017), hemoglobin 
( r = -0.186, p = 0.042), trombocyte (r = -0.252, p = 0.006), and body mass index (BMI) 
(r = -0.240, p = 0.008) values. In linear regression analyses, eGFR and BMI were found 
to be independent predictors of high telomerase activity in CKD group. (Model 1: R² = 
0.151, for eGFR β = -0.001, P < 0.001. Model 2: R² = 0.195, for eGFR β = -0.001, P = 
0.010; for BMI β = -0.002, p = 0.012).
Conclusions: PBMC telomerase activity is significantly higher in patients with CKD 
compared to healthy controls. Telomerase activity increases as the CKD stage proceeds, 
particularly in stage 5. The increase in PBMC telomerase activity is associated with eGFR 
and BMI.
TH-PO539
Congestive Heart Failure Increases Risk of Long Term Adverse Renal 
Outcomes  Lekha K. George,1 Santhosh K. Koshy,1 Miklos Zsolt Molnar,1 Jun 
Ling Lu,1 Kamyar Kalantar-Zadeh,2 Csaba P. Kovesdy.1,3  1Univ of Tennessee 
Health Science Center, Memphis, TN; 2Univ of California, Irvine, CA; 3VA 
Medical Center, Memphis, TN.
Background: Congestive heart failure (CHF) is associated with poor long term cardiac 
outcomes and mortality. Reduced cardiac output reduces renal perfusion. It is not known 
if CHF leads to poor renal outcome including progression to Chronic Kidney Disease 
(CKD). We hypothesized that a diagnosis of CHF would increase the risk of long-term 
adverse renal outcome.
Methods: Among 3,570,865 US veterans with eGFR >60ml/min/1.73m2 during 
2005-2006, we identified 156,743 patients with ICD-9 diagnosis of CHF. We examined 
the association of the presence of CHF with incident CKD, the composite of incident CKD 
and mortality, and rapid rate of eGFR decline (slopes steeper than -5 ml/min/1.73m2/year) 
using Cox proportional hazard analyses and logistic regression, as appropriate. Adjustments 
were made for age, gender, race, comorbidities, baseline BP, ACEI and statin use, eGFR 
and cholesterol.
Results: Mean±SD baseline age and eGFR were 68±11 years and 78±14 ml/min/1.73m2, 
in CHF patients vs. 59±14 and 84±16 respectively for patient without CHF. CHF patients 
had higher prevalence of hypertension, diabetes, cardiac, peripheral vascular and chronic 
lung diseases, stroke, and dementia. Incidence of CKD was 69/1000 patient years (PY) 
in CHF patients vs. 14.5/1000PY in patients without CHF, and 22% of patients with CHF 
had rapid decline in eGFR compared to 8.5% in patients without CHF. A diagnosis of CHF 
was associated with a two-fold higher risk of incident CKD, composite end point of CKD 
and mortality and rapid eGFR decline. 
Unadjusted Adjusted
Incident CKD 4.30 (4.26-4.35) 2.12 (2.10-2.14)
Incident CKD and Mortality 2.96 (3.94-3.99) 2.06 (2.05-2.08)
GFR decline >5ml/min/year 2.96 (2.92-3.00) 2.13 (2.10-2.17)
Conclusions: CHF is associated with significantly higher risk of incident CKD, 
incident CKD and mortality and more rapid GFR decline. Early diagnosis and management 
of CHF risk factors before it leads to CHF is warranted to reduce the risk of long-term 
renal complications.
Funding: NIDDK Support, Veterans Administration Support
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TH-PO540
Left Ventricular Global Longitudinal Strain as Early Detection of 
Subclinical Myocardial Dysfunction in Chronic Kidney Disease Patients 
Secundino Cigarran,1 Jose Lomban,3 Ana maria Sanjurjo amado,1 Diego 
Coronel,1 Sheila Casas,3 Juan Latorre,1 Mª milagros López hernández,1 Jesus 
Calvino.2  1Nephrology, Hospital Da Costa, Burela, Lugo, Spain; 2Nephrology, 
Hospital Lucus Augusti, Lugo, Spain; 3Cardiology, Hopsital Da Costa, Burela, 
Lugo, Spain.
Background: CV mortality is increased in patients with chronic kidney disease (CKD).
Little is known regarding the natural longitudinal changes in cardiac structure and function.
Global longitudinal strain (GLS) measures myocardial deformation in addition to left 
ventricular twist.The aim of our cross sectional study is to assess the grade of myocardial 
dysfunction in CKD stage 1-5ND without previous CV events & normal left ventricular 
ejection fraction (LVEF).
Methods: 161 pts.38% F,47% DM,Age 67.37±6.8yo,not previous CV events and 
LVEF >55%.All received ACEI/ARB,CCHB& diuretics.Echocardiogram was performed 
using Vivid 9 (GE Vigmed Ultrasound Horten, Norway).Parameters derived:GLS, left 
Atrial volume index (LAVI),E/e´,E/A & LVEF as recommendations of American Society 
of Echocardiography.Body composition analysis was performed by BIVA and serum 
biomarkers of inflammation,anaemia,mineral bone disease,renal function (GFR-EPI) and 
CV risk markers. AGEs mere measured by autofluorescence (AGE´s reader.Diagnostic, 
Kroningen ND).CKD (%) stage:1 &2 (20%);3(55.5%);4&5 (24.5%).Normal GLS (-20%) 
LAVI 24 ml/m2 were considered as published for general population Rev Esp Cardiología 
2014;67:651-8.
Results: Mean GLS -15.59 ± 4.4%,LVEF 61.5 ± 4.4%.LAVI 40.6±19.8 ml.GFR showed 
negative significantly correlation to GLS (r: -228, P<0.016).GLS progress with CKD 
progression CKD 1&2:-18.1±4.7%,CKD3:-15.96±4.1%;CKD4&5:-13.22± 5.6%(P adjusted 
0.008).LAVI:CKD 1&2:49.6±29.8 ml/m2 CKD3:96.36±42.4ml/m2,CKD 4&5:83.33± 51 ml/
m2(P adjusted =0.006).16% pts have GLS > 20% and 60% LAVI > 24 ml/m2.GLS correlates 
negative with cholesterol (r:-191, p= 0.50).No other correlation were met.
Conclusions: GLS&LAVI are two useful parameters to detect early subclinical 
myocardial damage(myocardial fibrosis & ischemia) in CKD with normal LVEF.We detect 
abnormal GLS in 16% pts and LAVI in 60% of CKD pts at early stages. Studies of larger 
CKD populations are required.
Funding: Other NIH Support - Sergas
TH-PO541
Aortic Stiffness and Change in GFR and Albuminuria in Older People 
Naya Huang,1 Lesley Inker,1 Andrew S. Levey,1 Meredith C. Foster,1 Gary 
F. Mitchell,2 Lenore J. Launer,5 Vilmundur Gudnason,3,4 Runolfur Palsson,3 
Gudny Eiriksdottir.4  1Deparement of Nephrology, Tufts Medical Center, MA; 
2Cardiovascular Engineering Inc., MA; 3Univ of Iceland; 4Icelandic Heart 
Association, Iceland; 5National Inst of Aging, MD.
Background: Higher aortic stiffness (AS) has a direct effect on microvascular structure 
and function, and may be an underlying mechanism for progression of CKD in older people.
Methods: Our study included community dwelling Icelandic elderly adults. Linear and 
logistic regression were used to assess the association between AS measures (carotid-femoral 
pulse wave velocity [CFPWV], carotid pulse pressure [CPP] and augmentation index [AI]) 
with the change in creatinine-cystatin C based estimated glomerular filtration rate (eGFR) 
and urine albumin to creatinine ratio (ACR) by two measurements 5 years apart. Rapid 
eGFR decline was defined as a decrease of ≥ 3 mL/min/1.73 m2/year.
Results: Of the 629 included, mean age was 75 years at baseline, mean eGFR was 
72 mL/min/1.73 m2 and median ACR was 2.9 mg/g. The table  shows associations of AS 
parameters to change in eGFR. No significant associations were observed between AS 
parameters and change in ACR.
Table. Associations of AS parameters with change in eGFR
Per SD change Models eGFR change (ml/min/1.73m2/year)
Rapid eGFR Decline 
Odds Ratio (95% CI)
CFPWV
Model 1 -0.2 (-0.4, -0.1) 1.5 (1.1,1.9)
Model 2 -0.2 (-0.4, -0.1) 1.7 (1.3,2.3)
Model 3 -0.1 (-0.3, 0.1) 1.5 (1.1,2.1)
CPP
Model 1 -0.3 (-0.4, -0.1) 1.4 (1.1,1.8)
Model 2 -0.3 (-0.4, -0.1) 1.4 (1.1,1.8)
Model 3 -0.1 (-0.3, 0.1) 1.3 (0.9,1.7)
AI
Model 1 -0.1 (-0.2, 0.1) 1.2 (1.0,1.5)
Model 2 -0.1 (-0.3, 0.1) 1.2 (0.9,1.5)
Model 3 -0.1 (-0.2, 0.1) 1.2 (0.9,1.5)
CFPWV was negatively inverse transformed. SD, standard deviation; Model 1: unadjusted; 
Model 2: adjusted by age, sex, heart rate, height and baseline eGFR; Model 3: model 2+mean 
arterial pressure, high dense lipoprotein, hemoglobin A1c and C-reactive protein. Bold indicates 
significance at p < 0.05.
Conclusions: AS is associated with rapid decline in kidney function in older age 
beyond traditional cardiovascular risks.
TH-PO542
Central Aortic Blood Pressure in Patients with Chronic Kidney Disease 
Rasmus Carlsen,1 Christian D. Peters,1 Dinah S. Khatir,1 Esben Laugesen,2,3,4 
Simon Winther,5 Niels Henrik Buus.6  1Dept of Renal Medicine, Aarhus Univ 
Hospital; 2Dept of Endocrinology, Aarhus Univ Hospital; 3Aarhus Univ; 
4Danish Diabetes Academy; 5Dept of Cardiology, Aarhus Univ Hospital; 6Dept 
of Nephrology, Aalborg Univ Hospital.
Background: Central blood pressure (BP) has been suggested as a better predictor 
cardiovascular outcome than the brachial BP. However, in patients with chronic kidney 
disease (CKD) the relationship between aortic BP and brachial BP remains to be elucidated. 
This study compared invasive measurements of central aortic BP with brachial artery BP 
and the accuracy of estimated central BP obtained non-invasively by radial artery tonometry.
Methods: 83 with stage 3-5 CKD and 41 patients without signs of renal disease 
undergoing planned coronary angiography for evaluation of ischemic heart disease were 
included. BP was sequentially measured at the brachial artery with an oscillometric BP 
device; in the ascending aorta using an invasive catheter; and by radial artery tonometry 
using the SphygmoCor device for the estimation of the central BP. Arterial stiffness was 
assessed by pulse wave velocity (PWV).
Results: The difference between estimated central and invasive systolic BP increased 
with 3.6(95% CI 1.8;5.3) mmHg per level increase in CKD stage (P<0.001) and 0.1(95% 
CI 0.05;0.18) mmHg per decrease in eGFR (P=0.001) in unadjusted linear regression. The 
difference between brachial and invasive systolic BP increased with 3.1(95% CI 1.3;4.8) 
mmHg per level increase in CKD stage (P<0.001) and 0.1(95% CI 0.03;0.16) mmHg per 
decrease in eGFR (P=0.003) in unadjusted linear regression. Multivariate adjustment 
did not change the results. The difference between brachial and invasive systolic BP was 
significantly associated with PWV (P=0.01).
Conclusions: Our data shows, that central BP increases more than brachial BP with 
increasing CKD stage. The differences were significantly associated with increased arterial 
stiffness. As brachial BP is used for calibration of the tonometry based SphygmoCor device, 
central BP is increasingly underestimated as CKD stage increases. Thus, in advanced kidney 
disease the utility of non-invasively obtained central BP seems questionable.
TH-PO543
Correlation of Pulse Pressure to Renal Functional Parameters in a 
Cross Sectional Study of General Population – The Texas Kidney Study 
Sharma S. Prabhakar, Katherine Kam.  Medicine, Texas Tech Univ Medical 
Center, Lubbock, T;.
Background: Chronic kidney disease (CKD) presents an increasing economic burden. 
Diabetes and hypertension remain the major risk factors for development and cardiovascular 
complications the leading cause of mortality among patients with CKD. Pulse pressure has 
been noted to be an important and independent factor for cardiovascular mortality. Effect of 
pulse pressure (PP) on renal function in the general population has not been well studied. 
In this study, we examined the relation of pulse pressure to kidney function in a random, 
cross-sectional study of unselected population in Texas.
Methods: A cohort of 1606 subjects was recruited from the general population using 
random digit dialing. Detailed history and physical examination were performed and 
blood and urine samples were taken for renal function assessment. Estimated glomerular 
filtration rate (eGFR) was derived using both the 4 variable MDRD formula. Subjects 
were divided into normal PP group (PP≤45), wide PP group (PP>45) and were further 
subdivided in different age categories (age <50 and age ≥50) and those with and without 
systolic hypertension. Correlation of PP to eGFR and logarithmically transformed urine 
albumin to creatinine ratio (UACRlog) were analyzed.
Results: A total of 1576 subjects completed the study. There were 976 subjects with 
normal PP and 603 with wide PP. Among subjects with age ≥50, wide PP was associated 
with higher UACRlog (p<0.001), but not with eGFR (p=0.99). In subjects without systolic 
hypertension, the group with wide PP compared to normal PP, had a significantly lower 
eGFR (p<0.0011) and a greater UACRlog (p<0.05) . In patients with systolic hypertension, 
no significant differences in these parameters were seen between the PP groups (p=0.234).
Conclusions: In patients without systolic hypertension, wide PP is a predictor of worse 
kidney function in terms of eGFR and UACRlog. This could be attributed to underlying 
heart disease, severe anemia, thyroid disorders and other factors that lower diastolic blood 
pressure. Hemodynamic significance of wide pulse pressure on renal functional parameters 
needs further exploration.
Funding: Other U.S. Government Support
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TNFα Receptor Type 2 Is Not Associated with an Accelerated Age-Related 
GFR Decline in the General Middle-Aged Non-Diabetic Population 
Jørgen Schei,1 Vidar T. N. Stefansson,1 Bjorn Odvar Eriksen,1,3 Trond G. 
Jenssen,1,4 Marit D. Solbu,1,3 Tom Wilsgaard,2 Toralf Melsom.1,3  1Metabolic and 
Renal Research Group; 2Dept of Community Medicine, UiT the Arctic Univ of 
Norway; 3Section of Nephrology, Univ Hospital of Northern Norway, Tromsø; 
4Oslo Univ Hospital, Oslo, Norway.
Background: TNF-α is an inflammatory cytokine that mediates renal injury in animal 
studies. Soluble TNFα receptor type 2 (sTNFR2) is a reliable marker of TNFα activity 
and has emerged as an independent predictor for kidney function decline in persons 
with diabetes. However, few studies have investigated the effect of sTNFR2 on chronic 
kidney disease (CKD) risk in the general population. Previous studies have mainly used 
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estimated GFR which is inaccurate in the near normal range of GFR and biased by non-
GFR determinants. We investigated whether sTNFR2 is a risk-factor for GFR decline in 
the general population using measured GFR.
Methods: We measured GFR by iohexol clearance in a cohort of the general population 
aged 50-62 years without diabetes, kidney- or cardiovascular disease at baseline. Of the 
1594 subjects investigated at baseline, 1299 (81%) had a second measurement after a 
median observation of 5.6 years in the Renal Iohexol-clearance Survey Follow-Up study 
(RENIS-FU). Baseline sTNFR2 levels were measured by ELISA.
Results: In a linear mixed regression model adjusted for time-dependent variables 
including sex, weight, height, smoking, use of NSAIDs, HbA1c and albumin-creatinine-
ratio, one standard deviation (SD) increase in baseline sTNFR2 was associated with a slower 
GFR decline of 0.10 ml/min/year (95% CI: -0.01 to 0.19). There was a strong negative 
association between the baseline values of sTNFR2 and GFR; one SD increase in sTNFR2 
was associated with lower GFR (β= -5.63 ml/min, 95% CI: -6.87 to -4.40).
Conclusions: Increased sTNFR2 is not a risk-factor for accelerated decline in GFR in 
the general middle-aged population. The negative baseline association between sTNFR2 
and GFR is probably due to renal clearance of sTNFR2. A longer follow-up time may be 
necessary to fully evaluate whether sTNFR2 influences age-related GFR decline in the 
general population.
Funding: Pharmaceutical Company Support - Boehringer-Ingelheim
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Diagnosis of Non-Adherence and Renal, and Cardiovascular Outcomes 
in Newly Treated Hypertensive U.S. Veterans  Elvira Gosmanova,1 Miklos 
Zsolt Molnar,1 Ahmed Zeen Alabedeen Alrifai,1 Jun Ling Lu,1 Elani Streja,2 
William C. Cushman,3 Kamyar Kalantar-Zadeh,2 Csaba P. Kovesdy.1,3  1Univ 
of Tennessee, Memphis, TN; 2Univ of California, Irvine, CA; 3VA Medical 
Center, Memphis, TN.
Background: Adherence is paramount in treating hypertension, yet no gold standard 
method is available for non-adherence screening delineating high-risk patients. An ICD-9-
CM non-adherence diagnostic code (V15.81) has been available for many years; however, 
its utility is poorly studied.
Methods: We examined the association between V15.81 code assigned prior to HTN 
diagnosis, with renal (incident CKD and ESRD) and cardiovascular (incident coronary 
heart disease-CHD and stroke) outcomes in 312,489 incident hypertensive individuals 
identified from a historical prospective cohort. Baseline mean age was 53.8 years, patients 
were 91% males and 20% African Americans; 10,401 patients had a V15.81 code. We used 
crude and Cox models adjusted for baseline demographic characteristics, eGFR, BMI, 
blood pressure, and co-morbidities.
Results: During a median follow up of 7.9 years, event rates were: for incident 
CKD 7.1 (7.0-7.2)/1000 patient-years, for ESRD 0.15 (0.13-0.16)/1000 PY, for CHD 
4.6 (4.5-4.7)/1000 PY, and stroke 4.0 (3.6-4.5)/1000 PY. The presence of a V15.81 code 
was associated with a higher risk of all renal and cardiovascular outcomes in unadjusted 
and adjusted analyses including 2 fold higher risk of ESRD and 70% higher stroke risk. 
Conclusions: A diagnosis of non-adherence based on the assignment of a V15.81 code 
prior to the diagnosis and treatment of hypertension was associated with increased adverse 
renal and CV outcomes in incident hypertensive US veterans.Further research is warranted 
to examine interventions targeting modifiable patient characteristics linked to non-adherence 
with the aim to improve outcomes in hypertensive individuals.
Funding: NIDDK Support, Veterans Administration Support
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Soluble KLOTHO Negatively Correlates with Low-Grade Inflammation in 
Chronic Kidney Disease Patients  Marek Kuzniewski,1 Beata Kusnierz-cabala,2 
Danuta Fedak,2 Paulina Dumnicka,3 Magdalena Barbara Kaziuk.1  1Dept of 
Nephrology, Jagiellonian Univ Medical College, Krakow, Poland; 2Dept of 
Diagnostics, Chair of Clinical Biochemistry, Jagiellonian Univ Collegium 
Medicum, Krakow, Poland; 3Dept of Medical Diagnostics, Jagiellonian Univ 
Collegium Medicum, Krakow, Poland.
Background: Circulating soluble KLOTHO (sKLOTHO) is a multifunctional 
protein, possessing anti-aging properties, recently associated with beneficial modulation 
of phosphate metabolism, cardiovascular protection and lower oxidative stress. In chronic 
kidney disease (CKD), sKLOTHO concentrations decrease along with the decrease of 
kidney function. Our aim was to study the relationship of low-grade inflammation observed 
in CKD patients with sKLOTHO concentrations.
Methods: The studied group consisted of 90 predialysis CKD patients (13 stage 1, 
4 stage 2, 13 stage 3a, 19 stage 3b, 32 stage 4 and 9 stage 5), 52 male and 38 female, age 
60+/-17. Serum concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP) were 
measured to assess inflammation. Soluble KLOTHO concentrations were measured in sera 
of patients using ELISA method.
Results: Median sKLOTHO concentrations in the whole group of patients were 822 
(IQR: 475-1078) pg/ml and was highest in patients with stage 1-2 CKD [1078 (990-1832) 
vs 704 (469-1034) pg/ml; p=0.002]. Median CRP concentrations were 2.13 (IQR: 0.80-
4.97) mg/l. In the whole studied group, log(CRP) and log(IL-6) concentrations negatively 
correlated with log(sKLOTHO) (R=-0.33; p=0.002 and R=-0.25; p=0.014, respectively). 
Such correlations were observed throughout CKD stages, even in patients with CKD stage 
1-2 (R=-0.66; p=0.005 and R=-0.75; p=0.001). In the whole group, CRP above the median 
value was associated with significantly lower sKLOTHO [713 (412-1031) vs 979 (574-
1823) pg/ml; p=0.042]. In multiple analysis, log(CRP), but not log(IL-6) was a significant 
predictor of log(sKLOTHO) concentrations (beta=0.22+/-0.10; p=0.045), independently 
of age and CKD stage.
Conclusions: In CKD patients chronic low-grade inflammation may be one of the 
factors lowering sKLOTHO concentrations. It is important to carefully diagnose and treat 
any inflammatory states in those patients, starting at early stages of CKD.
Funding: Government Support - Non-U.S.
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Inflammasome Activation by Lipopolysaccharide (LPS) and Angiotensin II 
(Ang II) in CKD  Sindhura Bobba, Siddhartha S. Ghosh, Daniel E. Carl, Todd 
W. Gehr, Richard Krieg.  Nephrology, VCU, Richmond, VA.
Background: Inflammasome dependent cytokines, such as IL-1β play a role in CKD, 
but their regulation during renal injury is not clearly elucidated. In this study we analyzed 
the ontogeny of inflammasome markers during the development of CKD in rats. Earlier 
studies have shown that changes in gut microbiota releases LPS in the circulation of CKD 
animals. LPS plays a major role in inflammasome activation. In this study we explored if 
LPS plays a role to activate inflammasome in CKD.
Methods: CKD was generated in Sprague dawley rats by 5/6 nephrectomy (Nx). Rats 
were sacrificed at 2, 4, 8 and 12 weeks after Nx (n=5/group). The controls were sham 
operated rats sacrificed on the 12th week. A group of Nx rats received 10 mg/kg losartan 
from 4 to 8 weeks. Kidney cytosols were taken to measure inflammasome markers (NFκB, 
ASC, caspase 1 and 1L-1β) by western blots. Serum LPS was measured by LAL assay. 
Ang II levels in the kidney were measured by ELISA. Rat mesangial cells were treated 
with Ang II and LPS to investigate inflammasome activation.
Results: Serum creatinine and urea significantly went up from 2 weeks onwards and 
glomerulosclerosis was seen from 4 weeks onward. Kidney Ang II concentration increased 
longitudinally from 2 weeks and plateaued at 8 weeks. Significant increase in caspase 1 and 
IL-1β were seen only at 8 and 12 weeks, whereas ASC increased from 4 weeks. However, 
pNFκB was significantly activated from 2 weeks onward. Serum LPS significantly increased 
from 4 weeks onward. Losartan significantly decreased all the inflammasome markers. 
Mesangial cells were treated with LPS and/or Ang II to investigate inflammasome activation. 
50 ng/ml LPS and 10-9M and 10-6M Ang II did not affect inflammasome activation. When 50 
ng/ml LPS and Ang II (10-9M) were combined significant increase in all the inflammasome 
markers were observed and this was blocked by losartan.
Conclusions: Appearance of LPS at 4 weeks is probably due to increased intestinal 
permeability associated with CKD. Neither LPS or AngII alone could activate 
inflammasome. By blocking AT1 receptor we could reduce inflammasome activity. This 
suggest that Ang II is required for LPS mediated inflammasome activation in CKD.
TH-PO549
Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of 
Cardiovascular Events and All-Cause Mortality in Patients with Chronic 
Kidney Disease  Midori Hasegawa, Kazuo Takahashi, Hiroki Hayashi, Shigehisa 
Koide, Yukio Yuzawa.  Nephrology, Fujita Health Univ School of Medicine, 
Aichi, Japan.
Background: Elevated neutrophil gelatinase-associated lipocalin (NGAL) levels 
have recently been reported in patients withheart failure, coronary heart disease, or stroke. 
Here, we aimed to assess the usefulness of plasma NGAL (pNGAL) as a predictor of 
cardiovascular (CV) events and mortality in patients with chronic kidney disease (CKD).
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Methods: In this prospective cohort study, the pNGAL level was measured in 371 
ambulatory patients with CKD not on dialysis with an estimated glomerular filtration rate 
< 60 mL/min/1.73 m2. CV events were defined as CVdeath, acute coronary syndrome, 
hospitalization for worsening heart failure, stroke, or aortic dissection.
Results: During a median follow-up period of 58 months, 84 CV events (22.6%) and 32 
deaths (8.6%) occurred. On Cox stepwise multivariate analysis of all significant variables 
(p < 0.05) on univariate analysis, pNGAL, B-type natriuretic peptide (BNP), the urinary 
albumin creatinine ratio, and a history of previous CV diseases were significant predictors 
of CV events, while pNGAL, BNP, hemoglobin, and age were significant predictors of 
mortality. Considering both pNGAL and BNP, we stratified patients into four groups, with 
the median level of each marker as cutoff values (109.7 ng/mL for pNGAL and 42 pg/mL 
for BNP). Five-year CV event-free survival rates were 94.6%, 80.3%, 68.3%, and 59.4% 
in the four groups above, respectively (p < 0.0001).
Conclusions: Elevated pNGAL could predict future CV events and mortality in 
patients with CKD, while the combination analysis of pNGAL and BNP was useful in 
stratifying CV event risk.
TH-PO550
Clinical Significance of Urinary Liver-Type Fatty Acid Binding Protein 
as a Predictor of End Stage Renal Disease and Cardiovascular Disease in 
Patients with Chronic Kidney Disease  Katsuomi Matsui,1,2 Atsuko Ikemori,2 
Naohiko Imai,1,2 Takeshi Sugaya,2 Takashi Wada,3 Sayuri Shirai,1,2 Kenjiro 
Kimura,4 Yugo Shibagaki.2  1Dept of Nephrology and Hypertension, Internal 
Medicine, St. Marianna Univ School of Medicine Yokohama City Seibu Hospital, 
Yokohama, Kanagawa, Japan; 2Dept of Nephrology and Hypertension, Internal 
Medicine, St. Marianna Univ School of Medicine, Kawasaki, Kanagawa, Japan; 
3Div of Nephrology, Kanazawa Univ Hospital, Kanazawa, Kanazawa, Japan; 
4Dept of Internal Medicine, Tokyo Takanawa Hospital, Takanawa, Tokyo, Japan.
Background: To improve outcomes in patients with chronic kidney disease (CKD), 
it is important to identify prognostic factors for end-stage renal disease (ESRD) as well 
as cardiovascular disease (CVD). This study assessed urinary concentrations of albumin, 
N-acetyl-β-D-glucosaminidase (NAG), and liver-type fatty acid-binding protein (L-FABP), 
as predictors of ESRD and CVD.
Methods: A prospective, observational, multicenter study, comprising 244 Japanese 
outpatients with CKD who had a follow-up period of at least 3 months. The primary 
endpoint was the first onset of a nonfatal or fatal CVD event and progression to ESRD, 
defined as myocardial infarction, stroke, or artery revascularization (coronary, carotid or 
peripheral), and initiation of dialysis.
Results: During a median follow up of 3.8 years, the primary endpoint occurred in 
39 (15.8%) patients. Irrespective of diabetes, high urinary L-FABP correlated with the 
development of ESRD and CVD. The areas under the receiver operator characteristic 
curves (AUCs) for predicting the primary endpoint for urinary concentrations of L-FABP, 
albumin, and NAG were 0.825, 0.797, and 0.722, respectively. Cox regression analyses, 
which were adjusted for factors knownto influence the primary endpoint, including patient 
characteristics, and serum and urinary parameters, demonstrated that the primary outcome 
was associated with high urinary L-FABP and low eGFR (p = 0.049, hazard ratio = 1.341 
[95% CI, 1.005 -1.790]; and p < 0.000, hazard ratio = 0.953 [95% CI, 0.930 - 0.976], 
respectively).
Conclusions: Urinary L-FABP may be a useful prognostic marker of progression to 
ESRD and the onset of CVD in patients with CKD.
Funding: Government Support - Non-U.S.
TH-PO551
Elevated Serum Adiponectin Concentrations Might Predict End-Stage 
Renal Disease in Japanese Patients with Moderate to Severe Chronic Kidney 
Disease  Hitomi Tanimoto,1 Hirotake Kasuga,1 Ryo Takahashi,1 Keiko Kimura,1 
Chieko Matsubara,1 Mari Maseki,1 Yasuhiko Ito.2  1Dept of Nephrology, Nagoya 
Kyoritsu Hospital, Nagoya, Japan; 2Dept Nephrology, Nagoya Univ Graduate 
School of Medicine, Nagoya, Japan.
Background: Adiponectin (ADPN) is an adipocyte-derived, anti-inflammatory, anti-
atherogenic, insulin-sensitizing polypeptide. However, elevated serum ADPN levels are 
associated with high mortality rates and more cardiovascular events in patients with chronic 
kidney disease. In addition, ADPN reportedly helps to protect renal function, whereas others 
have found that high ADPN levels predict end-stage renal disease.
Methods: We monitored serum ADPN, Cr and eGFR in 215 outpatients during 2008 
and assigned 104 of them with eGFR ≤60 mL/min/1.73 m2 to groups based on ADPN 
values ≤ 12.3 (L) or > 12.3 (H) mg/mL. These patients were followed for five years or 
until they started dialysis.
Results: During the study period, 6 patients in the L group (n=55) and 21 patients 
in the H group (n=49) started dialysis (P < 0.0005). The dialysis-free survival rates at 
60 months in groups L and H were 87.4% and 52.2%, respectively (p < 0.0005). Cox 
multivariate analysis identified low ADPN (HR, 0.35; p < 0.05), age (HR, 0.9; p < 0.05) 
and eGFR 30 - 60 mL/min/1.73 m2 (HR, 0.07; p = 0.00005) as independent risk factors 
for end stage kidney disease.
Conclusions: High serum adiponectin levels might predict end stage kidney disease 
in Japanese patients with moderate-to-severe chronic kidney disease.
TH-PO552
The Association Between Direct Measures of Body Fat, Incident Chronic 
Kidney Disease and Kidney Function Decline: The Health Aging Body and 
Composition Study  Magdalena Madero,1 Ronit Katz,2 Linda F. Fried,5 Rachel 
A. Murphy,6 Michael Shlipak,4 Carmen A. Peralta,4 Joachim H. Ix,9 Anne B. 
Newman,8 Suzanne Satterfield,7 Kushang V. Patel,6 Mark J. Sarnak.3  1National 
Heart Inst Mexico; 2Washington U; 3Tufts; 4UCSF; 5VA; 6NIH; 7UTHSC; 
8Pittsburgh; 9UCSD.
Background: We evaluated and compared the association of CT and anthropometric 
measures of obesity with kidney outcomes in the Health ABC Study. We hypothesized that 
CT measures, particularly of visceral fat, would confer the highest risk for kidney outcomes 
in comparison with other measures.
Methods: CT measures included visceral abdominal fat (VAT) and subcutaneous 
adipose tissue (SAT), anthropometric measures included waist circumference (WC) and 
body mass index (BMI). Kidney outcomes included incident CKD (follow-up eGFRcysC less 
than 60 ml/min/1.73 m2 in individuals with baseline GFR>60 ml/min/1.73m2 ) and kidney 
function decline (30% decrease in eGFRcysC in follow up at either year 3 or 10). Multivariable 
logistic regression models were used to evaluate the association with outcomes.
Results: 2489 individuals were included. Mean age was 74±3 y, 49% were male, 39% 
were black and 15% were diabetic. In continuous models SAT, VAT, BMI and WC were 
associated with kidney function decline. VAT, BMI and WC were also all associated with 
incident CKD, but SAT did not reach statistical significance. 
Unadjusted Adjusted
KF Decline >30% OR (95% CI)
VAT (per SD=67) 1.30 (1.17-1.43) 1.19 (1.06-1,33)
SAT (per SD=121) 1.15 (1.04-1.27) 1.18 (1.04-1.34)
BMI (per SD= 4.6) 1.28 (1.15-1.41) 1.20 (1.07-1.34)
WC (per SD= 12.5) 1.32 (1.19-1.46) 1.22 (1.09-1.37)
Unadjusted Adjusted
Incident CKD (per SD) IRR (95% CI)
VAT 1.36 (1.25-1.47) 1.21 (1.09-1.33)
SAT 1.18 (1.08-1.29) 1.11 (0.99-1.23)
BMI 1.28 (1.18-1.41) 1.15 (1.04-1.27)
WC 1.28 (1.19-1.38) 1.18 (1.06-1.30)
Adjusted for age, gender, race, site, baseline GFR, DM, BP, HTN meds, albuminuria, smoking, LDL 
and HDL cholesterol, oral estrogen, prevalent CHD and prevalent HF 
Similar results were found in categorical analyses using quartiles of the exposure 
variable
Conclusions: Anthropometric measures of body fat appear to provide as reliable 
estimates of kidney decline risk as direct measures in elders.
Funding: NIDDK Support
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TH-PO553
Gender Dependent Association Between Metabolic Syndrome and Arterial 
Stiffness in Patients with Chronic Kidney Disease: Findings from the 
Korean Cohort Study for Outcome in Patients with Chronic Kidney 
Disease (KNOW-CKD) Study  Yong Un Kang,1 Eun Hui Bae,1 Seong Kwon 
Ma,1 Kook-Hwan Oh,2 Curie Ahn,2 Soo Wan Kim.1  1Dept of Internal Medicine, 
Chonnam National Univ Medical School, Gwangju, Korea; 2Dept of Internal 
Medicine, Seoul National Univ Hospital, Seoul, Korea.
Background: We investigated the relationships of metabolic syndrome (MS) to arterial 
stiffness in chronic kidney disease (CKD) patients across a wide range of renal function 
from early CKD to predialysis.
Methods: Risk factors for MS and brachial-ankle pulse wave velocity (baPWV) 
as measures of arterial stiffness were assessed in 1,256 CKD patients from the KNOW-
CKD study. MS was defined by modified National Cholesterol Education Program 
Adult Treatment Panel III guidelines. Multivariate logistic regressionwas used to test 
the association between MS and cardiovascular risk factors,measures of Chronic Kidney 
Disease-Mineral and Bone Disorder (CKD-MBD), and arterial stiffness.
Results: Higher arterial stiffness levels were associated with older age, lower estimate 
glomerular filtration rate, diabetes, and hypertension. Arterial stiffness was not associated 
with measures of CKD-MBD including total calcium, intact parathyroid hormone, alkaline 
phosphatase, and albumin. MS was an important determinant of arterial stiffness in CKD 
patients after adjustment for demographics, cardiovascular risk factors, and CKD-MBD 
measures, and medication. Systolic blood pressure (SBP) and fasting plasma glucose were 
the major determinant of arterial stiffness. In sub-analysis by gender, women had more 
stronger association between arterial stiffness and MS than men. SBP, waist circumference, 
and triglyceride were independent determinants of arterial stiffness in women, whereas 
only SBP predicted arterial stiffness in men.
Conclusions: The presence of MS and its risk factors were associated with increased 
arterial stiffness and that these relationships were independent of renal function, CKD-
MBD measures, and cardiovascular risk factors in CKD patients. Women had more stronger 
association between arterial stiffness and MS than men and the association between risk 
factors for MS and arterial stiffness may differ between men and women in CKD patients.
Funding: Government Support - Non-U.S.
TH-PO554
Body Mass Index (BMI) Has a U-Shaped Association with Chronic 
Kidney Disease (CKD) Progression in Children with Glomerular Diseases 
Robert H. Mak, Christopher B. Pierce, Nancy MacDonald Rodig, Craig S. 
Wong, George J. Schwartz, Marva M. Moxey-Mims, Susan L. Furth, Bradley 
Warady.  Pediatric Nephrology, Univ of California San Diego, La Jolla, CA.
Background: In adult patients, BMI has a U-shaped association with disease 
progression in CKD stages II to IV. Data in children have not been reported. We investigated 
BMI association with disease progression in the Children with CKD (CKiD) Cohort.
Methods: Children with CKD stages II to IV had annual measurements of glomerular 
filtration rate (GFR), either directly by iohexol clearance or estimated using a CKiD 
data-derived equation. Stratifying by CKD diagnosis, glomerular (G) and non-glomerular 
(NG) diseases, GFR decline rate during follow-up was modeled on baseline BMIz-score 
for height-age and sex using joint shared-parameter models to account for informative 
censoring associated with renal replacement therapy (RRT). GFR was log-transformed 
and change was estimated as %/yr.
Results: 866 children with median age 11 [8,15] yrs and median GFR 52 [38,71] ml/
min/1.73m2 at baseline were followed for a median of 4.6 [2.0,6.9] yrs; 131 children initiated 
RRT or died (n=2) during follow-up. In 276 children with G diagnoses, expected GFR 
decline rate exhibited a quadratic relationship with baseline BMIz modeled continuously; 
high and low ends of the baseline BMIz spectrum showed steeper relative declines in GFR 
rates compared with patients with slightly above average baseline BMIz. Specifically, G 
children with BMIs <= 25th %tile (10% of G) had expected GFR declines of 13.6%/yr 
or greater; G children with BMIs between 75th and 90th %tile (20%) had expected GFR 
declines of 8.5%/yr; G children with BMIs >=98th %tile (15%) had expected GFR declines of 
11.3%/yr. Adjusting for sex, age, black race and proteinuria did not change this relationship 
qualitatively. In contrast, in 590 children with NG diagnoses, BMIz was not associated 
with expected GFR decline rate, which was 4.5%/yr.
Conclusions: BMIz has a U-shaped associated with disease progression in children 
with CKD stages II to IV with G but not with NG diagnoses. Weight management in CKD 
children to avoid extremes in BMIz may improve CKD outcomes and await clinical trials 
confirmation.
Funding: NIDDK Support
TH-PO555
Combination of Low Body Mass Index and Serum Albumin Level 
Leads to Chronic Kidney Disease Progression: The Chronic Kidney 
Disease–Research of Outcomes in Treatment and Epidemiology Study 
Hiroaki Kikuchi,1 Eiichiro Kanda,2 Soichiro Iimori,1 Shotaro Naito,1 Sei 
Sasaki,1 Eisei Sohara,1 Tomokazu Okado,1 Tatemitsu Rai,1 Shinichi Uchida.1 
1Nephrology, Tokyo Medical and Dental Univ; 2Nephrology, Tokyo Kyosai 
Hospital.
Background: The relationship between nutritional deficiency and chronic kidney 
disease (CKD) progression is unknown. In the present prospective cohort study, we 
evaluated the hypothesis that a combination of low body mass index (BMI) and serum 
albumin level leads to rapid CKD progression.
Methods: The study cohort comprised 728 predialysis patients with CKD (stages 2–5) 
enrolled from 2010 to 2011. Patients were categorized into 4 groups according to their 
serum albumin levels and BMI: group 1, low serum albumin level (<4 g/dL) and low BMI 
(<23.5 kg/m2); group 2, high serum albumin level (≥4 g/dL) and low BMI; group 3, low 
serum albumin level and high BMI (³23.5 kg/m2); and group 4, high serum albumin level 
and high BMI. The primary outcome was a 30% decline in estimated glomerular filtration 
rate (eGFR) or start of dialysis within 2 years. The secondary outcome was an annual GFR 
decline (mL/min/1.73 m2/year).
Results:  Logistic regression analysis adjusted for baseline characteristics (reference, 
group 4) showed that only group 1 was associated with a high risk of CKD progression; 
adjusted odds ratio (aOR) 3.07 [95% confidence interval (CI) (1.51, 6.24)]; group 2, aOR 
1.81 (95% CI 0.89, 3.70); group3, aOR 1.97 (95% CI 0.96, 4.03). A multivariate general 
linear regression analysis adjusted for baseline characteristics showed a significant 
difference in annual eGFR decline between groups 1 and 4 (β =-3.04, P ≤ 0.001).
Conclusions: This study suggests that combined effects of low body mass index and 
serum albumin level lead to CKD progression.
TH-PO556
Weight Reduction Has an Additive Effect on the Anti-Albuminuric Effect 
of Angiotensin II Type I Receptor Blocker in Hypertensive Patients with 
Chronic Kidney Disease  Ho Jun Chin,1,3 Chun Soo Lim.2,3  1Internal Medicine, 
Seoul National Univ Bundang Hospital; 2Seoul National Univ Boramae Medical 
Center; 3Seoul National Univ Hospital, Seoul.
Background: We searched the additive anti-proteinuric effect of weight reduction in 
addition to medication of an angiotensin II type I receptor blocker (ARB) for hypertensive 
chronic kidney disease (CKD) patients with mild overweight.
Methods: This study is a sub-analysis of data from an open-label, case-controlled, 
randomized clinical trial including 245 hypertensive CKD patients completed the trial 
(NCT01552954).We were able to calculate the ratios of estimated daily excretion of 
sodium (eUna), albumin (eUalb), and urea nitrogen (eUUN) in 227 participants during 16 
week-trial period with medication of Olmesartan 40 mg a day. The primary outcome of 
the study was a decrement of eUalb ≥ 25% during 16 weeks. We grouped the participants 
according to the ratio of weight (WtRatio) during 16 weeks.
Results: The baseline mean values of BMI, GFR, and eUalb were 25.4 ± 3.8 kg/m2 , 
67.0 ± 23.9 ml/min/1.73 m2 and 1.0 ± 0.7 g/day, respectively. The proportion of patients 
that achieved a decrement of eUalb ≥ 25% during 16 weeks with an ARB medication was 
93.0 % (53/57) in group 1 with a decrement of weight ≥ 1.5 %, 83.3 % (25/30) in group 2 
with WtRatio between -1.4 % and -0.1%, and 70.6 % (96/136) in group 3 with WtRatio ≥ 
0.0 % (p = 0.002). The probability of a decrease in albuminuria was 7.405-fold (95% CI: 
2.168-25.293, p=0.001) higher in group 1 compared to group 3, as observed in multiple 
logistic regression analysis as well. The decrement of eUalb was the highest in group 1 (-59.4 
± 47.1 %) compared to group 2 (-38.4 ± 70.1 %) or group 3 (-26.2 ± 160.4 %) (p=0.005). 
The additive anti-albuminuric effect of weight change in addition to the medication of an 
ARB was independent from the change in urinary excretion rate of sodium or urea nitrogen 
calculated using 24-hour urine collection.
Conclusions: The small change of body weight had an additive anti-albuminuric 
effect in hypertensive CKD patients with albuminuria using an ARB, independent from 
the change of sodium or protein intake.
Funding: Pharmaceutical Company Support - Daichi-Sancho Korea and Daewoong 
Pharm.
TH-PO557
Can Exercise-Induced Proteinuria Predict the Onset of Chronic Kidney 
Disease? A Systematic Review  Naushad Ali Junglee,1,2 Mahdi M. Jibani,1,2 
Andrew B. Lemmey,1 Jamie Hugo Macdonald.1  1Extremes Research Group, 
School of Sport Health and Exercise Sciences, Bangor Univ, Bangor, Gwynedd, 
United Kingdom; 2Renal Unit, Ysbyty Gwynedd, Bangor, Gwynedd, United 
Kingdom.
Background: Post-exercise proteinuria (PeP) shares characteristics with proteinuria 
of chronic kidney disease (CKD) including its cause (increased intraglomerular pressures) 
and its consequences (albuminuria and reduction in glomerular filtration rate). The aim of 
this study was to perform a systematic review to determine if PeP could predict the onset 
or progression of CKD.
Methods: A systematic review of articles published in Ovid Medline(R), Ovid Medline 
in process, AMED, EMBASE, Pubmed, Cochrane Library and Web of Science between 
1946 and 2014 was conducted. Eligible studies included randomized controlled trials 
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and prospective observational cohorts whose participants had or were at-risk of CKD 
and performed an exercise test to elicit PeP. Search terms included: exercise, proteinuria, 
albuminuria, chronic kidney disease and nephropathy. Primary outcomes examined were 
biomarkers of CKD (e.g. rise in blood creatinine) during a follow-up period of at least 
three months.
Results: Five studies (n=351) met inclusion criteria. Full meta-analysis was not possible 
interventions and PeP measurements varied markedly between studies. Therefore, narrative 
synthesis was performed. When combining results of the primary outcome in four similar 
studies (n=318), the presence of PeP was highly associated with elevated resting proteinuria 
at follow-up (c2 test, P < 0.0001) and significant odds ratios (OR) of developing CKD 
following a positive exercise test vs. not developing CKD were noted for each of these 
four studies (OR 2.3 to 52). However, interventions induced potential bias with notable 
differences in type of exercise routines between studies. Also, primary outcomes did not 
factor confounding variables (e.g. use of angiotensin-receptor antagonists). Finally, findings 
are only generalisable to a young type I diabetics at risk of CKD.
Conclusions: Despite the limited number of studies in the literature and their 
shortcomings, PeP shows promise as a predictor for CKD progression. However, there is 
a need to define the most appropriate exercise test for this purpose.
Funding: Private Foundation Support
TH-PO558
Ketoanalogs Supplementation Decreases Dialysis and Mortality Risk in 
Patients with Advanced Chronic Kidney Disease  Che-Hsiung Wu,1 Vincent 
Wu.2  1Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, 
Taiwan; 2National Taiwan Univ Hospital, Taipei, Taiwan.
Background: The benefit of alpha-ketoanalogs (KA) supplementation for advanced 
chronic kidney disease (CKD) patients that followed low-protein diet (LPD) remains 
undetermined.
Methods: We extracted longitudinal data for all advanced CKD patients in the Taiwan 
National Health Insurance from January 1, 2000 through December 31, 2010. A total of 
1483 patients with advanced CKD treated with LPD, who started KA supplementation, were 
enrolled in this study. We analyzed the risks of end stage renal disease and all-cause mortality 
using Cox proportional hazard models with influential drugs as time-dependent variables.
Results: A total of 1113 events of initiating long-term dialysis and 1228 events of 
composite outcome occurred in patients with advanced CKD after a mean follow-up of 1.57 
years. Data analysis using the Cox model suggests KA supplementation is associated with a 
lower risk for long-term dialysis (table 1) (HR, 0.54 [95% CI 0.47 - 0.62]) and the composite 
outcome of long-term dialysis or death (HR, 0.49 [95% CI 0.43 - 0.55]) when daily dosage 
is more than 5.5 tablets. The beneficial effect was consistent in subgroup analysis.
Variables Hazard Ratio (95% confidence interval) p value
Diabetes mellitus 1.80 ( 1.52 - 2.12 ) < 0.001
Hypertension 1.25 ( 1.10 - 1.42 ) < 0.001
Age, >60 vs. ≤60 years old 1.29( 1.14 - 1.45 ) < 0.001
CCI score, >3 versus ≤3 1.26 ( 1.05 - 1.52 ) 0.0124
Medicine Hospitalization 8.04 ( 7.02 - 9.20 ) < 0.001
Daily KA dosage ( expressed as tablets)
larger than 5.5 vs. Unsuitable dose 0.65 ( 0.43 - 1.00 ) 0.0492
ACEI use 0.63 ( 0.49 - 0.81 ) < 0.001
ARB use 0.65 ( 0.56 - 0.76 ) < 0.001
KA use 0.54 ( 0.47 - 0.62 ) < 0.001
Conclusions: Among advanced CKD patients that followed LPD, KA supplementation 
at an appropriate dosage may substantially reduce the risk of initiating long-term dialysis 
or of developing the composite outcome. KA supplementation represents an additional 
therapeutic strategy to slow the progression of CKD. The promising results in terms of 
mortality and commencing chronic dialysis need confirmation with different study designs.
TH-PO559
Serum Fibroblast Growth Factor 21 Is a Significant Predictor for Renal 
Outcomes in Patients with Chronic Kidney Disease  Masashi Kitagawa, 
Hitoshi Sugiyama, Hiroshi Morinaga, Ayu Akiyama, Toshio Yamanari, Akifumi 
Onishi, Keiko Tanaka, Yoko Kikumoto, Tatsuyuki Inoue, Jun Wada.  Medicine 
and Clinical Science, Okayama Univ Graduate School, Okayama, Japan.
Background: Fibroblast growth factor 21 (FGF21) is a metabolic hormone that plays 
a significant role in glucose and lipid homeostasis. FGF21 activity depends on its binding 
to FGF receptors and β-Klotho. Circulating FGF21 levels are independently associated 
with the renal function. The purpose of this study was to identify the relationship between 
the serum FGF21 levels and the renal function in patients with chronic kidney disease 
(CKD) and investigate whether the serum FGF21 levels can predict renal outcomes in 
patients with CKD.
Methods: We conducted a prospective cohort study. We enrolled 120 CKD patients 
and measured serum FGF21 levels by a sandwich ELISA. The endpoint was defined as an 
increase in serum creatinine of 50% or the initiation of renal replacement therapy (median 
age, 56 years; 62% male; 59% had glomerulonephritis).
Results: At enrollment, the median estimated glomerular filtration rate (eGFR) was 56 
(24-73) mL/min/1.73m2 and median proteinuria was 0.84 (0.31-2.49) g/gCr. The median 
serum FGF21 levels were 296 (90-560) pg/mL. The natural logarithm FGF21 concentrations 
negatively correlated with the eGFR (r=-0.4940, p<0.0001) and positively correlated with 
proteinuria (r=0.2583, p=0.0044). During two years, 29 patients reached the endpoint. The 
renal survival was significantly lower in patients with serum FGF21 ≥ 296 pg/mL than in 
those with serum FGF21 < 296 pg/mL (p<0.0001). A Cox regression analysis showed that 
serum FGF21 ≥ 296 pg/mL was significantly associated with an increased risk for the renal 
endpoint adjusted for age, gender, body mass index, current smoking, eGFR, proteinuria, 
pulse pressure, fasting plasma glucose, glycoalbumin, non HDL-cholesterol, phosphate, 
FGF23 and renin angiotensin system blockade.
Conclusions: The data indicate that the serum FGF21 level is significantly associated 
with the renal outcomes, suggesting that a higher serum FGF21 level may serve as a novel 
biomarker for CKD progression.
TH-PO560
Serum Phosphorus Independently Predicts Risk of ESRD in an Urban CKD 
Clinic  Jonathan W. Bazeley, Fei He, Sharon M. Moe, Ali Khalil, Ranjani N. 
Moorthi.  Indiana Univ.
Background: Serum phosphorus (PO4) levels have been positively associated with 
adverse outcomes in chronic kidney disease (CKD) populations, albeit in cross sectional 
studies of largely Caucasian cohorts. Given differences in vitamin D and PTH homeostasis 
in African-Americans (AA) and dietary fluctuation, we tested the hypothesis that PO4 
measured over time (as is done in clinical practice) will be associated with the risk of 
dialysis initiation in our urban, predominantly AA CKD population.
Methods: A retrospective cohort of 754 adult patients with CKD(eGFR <60ml/min 
at baseline) visiting the nephrology clinic at a large urban county hospital from 2007-10 
were followed until death or May 2012. A Cox proportional hazards model adjusted for 
demographics, comorbidities, medications, and laboratory values was used to study the 
association of time varying PO4 with the end point of time to dialysis initiation (days to 
event from index date). Death before dialysis was a censoring event(n=100;13.26%).
Results: Of 754 patients, 54% were female, 60% were AA and 57% had diabetes 
mellitus. The mean age was 58.6 ± 13.6 years (mean ± SD), mean eGFR at the start of 
follow-up period was 33.4 ± 14.9 ml/min/1.73m2.The median PO4 level was (3.9 mg/dl; 
IQR 3.3-4.3). PO4 was measured ≥ 2 times in 437 (58%) of patients. During a median follow 
up of 714 days, 117 (15.5%) patients were initiated on dialysis. When fully evaluated in 
a multivariable model, the time varying PO4 remained a significant in predicting time to 
dialysis initiation (HR 1.44, 95%CI 1.07-1.93).
Conclusions: An increase in serum PO4 over time was associated with faster progression 
to dialysis initiation in an AA urban population of CKD patients, even when adjusted 
for eGFR. The results suggest PO4 may have independent negative consequences on 
CKD progression; testing this would require trials that evaluate lowering serum PO4 on 
progression to dialysis.
Funding: Pharmaceutical Company Support - Dialysis Clinic, Inc.
TH-PO561
Serum Phosphorus Is Associated with Increased Risk of Kidney Failure 
Alex R. Chang,1 H. Lester Kirchner,1 Amanda Young,1 Morgan Grams.2 
1Geisinger Health System; 2Johns Hopkins Bloomberg School of Public Health.
Background: Limited data exists on the association between serum phosphorus and 
progression to kidney failure.
Methods: Using data from 28,542 outpatients at Geisinger Health System, we examined 
the association between serum phosphorus and incident kidney failure (dialysis, transplant, 
eGFR < 15 ml/min/1.73m2). Cox regression analyses were adjusted for demographics, 
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history of cardiovascular disease, eGFR, fasting status, phosphorus-altering medications 
(estrogen, testosterone, calcium supplements, and other phosphorus-binding medications), 
time of day (morning, afternoon, evening), and renal risk factors.
Results: Overall, 25% were fasting lab values and 70% were drawn in the morning 
(8-12am). Elevated serum phosphorus was associated with increased risk of kidney failure. 
The highest quartile of serum phosphorus (>=3.8 mg/dL) was associated an adjusted hazard 
ratio of 1.99 (95% CI: 1.65-2.41) compared to the lowest quartile of serum phosphorus. The 
relationship between serum phosphorus and risk of kidney failure was similar by gender, 
baseline eGFR, and time of day of measurement. Associations between serum phosphorus 
and eGFR decline >= 30% were similar.
Conclusions: Elevated serum phosphorus is associated with increased risk of kidney 
failure. Future studies are needed to determine whether lowering phosphorus levels can 
delay progression to ESRD.
Funding: Private Foundation Support
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Serum Calcification Propensity Signifies Myocardial Injury and Myocardial 
Structural and Functional Abnormalities in Chronic Kidney Disease 
Angela Yee Moon Wang,1 Qizhe Cai,1,4 Matthias Bachtler,2 Xiuzhang Lu,4 
Andreas Pasch.3  1Medicine, Univ of Hong Kong, Queen Mary Hospital, Hong 
Kong, Hong Kong; 2Clinical Research, Univ of Bern, Bern, Switzerland; 
3Chemistry, Univ Hospital Bern and Univ of Bern, Bern, Switzerland; 
4Echocardiography, Heart Center, Beijing Chao-Yang Hospital, Capital Medical 
Univ, Beijing, China.
Background: A recent novel blood test measuring the maturation time of calciprotein 
particles or serum calcification propensity (T50) has been shown to predict all-cause 
mortality in CKD subjects. This study aims to elucidate the mechanisms that explain this 
association.
Methods: We prospectively recruited 300 stages 3–5 non-dialysis CKD patients 
(age:60±10yrs, 56%men) & 100 healthy control subjects. Echocardiography with tissue 
Doppler Imaging & plain cardiac multislice computed tomography were done to evaluate 
cardiac dimensions, function & coronary artery calcium scores. Their associations with 
T50 were investigated.
Results: T50 was significantly lower in CKD patients vs control subjects (P<0.001). 
A significant increase in age (P=0.05), serum phosphate (P<0.001), intact parathyroid 
hormone (P=0.001), C-reactive protein (P=0.031), spot urine protein to creatinine ratio 
(P=0.001) as well as a decrease in serum albumin (P<0.001) & eGFR (P<0.001) were 
observed across the three tertiles of decreasing T50 in CKD. Adjusting for age & gender, 
T50 showed significant inverse associations with left ventricular (LV) mass index (P<0.001), 
left atrial volume index (P=0.012), early diastolic mitral annular velocity (Em) (P=0.004) & 
the ratio of early transmitral flow velocity (E) to Em (P=0.001) but not systolic functional 
parameters. Serum T50 retained significant association with cardiac troponin T (P=0.027) 
in the model adjusting for age, gender, eGFR & LV mass index. T50 however showed no 
direct association with baseline coronary artery calcium score.
Conclusions: Low T50 may predict adverse outcomes in CKD via its close associations 
with myocardial injury, myocardial structural & diastolic functional abnormalities. These 
data suggest T50 may more be a biomarker reflecting myocardial disease rather than 
calcification of the coronary arteries.
Funding: Pharmaceutical Company Support - Sanofi
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Loss of AT-1 Receptor Regulation in CKD: Role of β-Arrestin2 
Siddhartha S. Ghosh, Sindhura Bobba, Daniel E. Carl, Richard Krieg, Todd W. 
Gehr.  VCU, Nephrology, Richmond, VA.
Background: Angiotensin II (A-II) is known to play a major role in renal failure. 
Studies have proven that A-II down regulates AT-1 receptors via β-arrestin2. In CKD 
A-II levels increase significantly and mediates it action via ERK signaling. Increased A-II 
will down-regulate AT-1 receptors in CKD and ERK signaling will decrease. However, 
regulation of the AT-1 receptor in CKD kidney has not been clearly evaluated. This study 
was conducted to understand AT-1 receptor regulation in CKD.
Methods: CKD was generated in Sprague dawley rats by 5/6 nephrectomy (Nx). Nx 
rats were sacrificed at 2, 4, 8 and 12 weeks after Nx (n=5/group). The sham control rats 
were sacrificed on the 12th week. A group of Nx rats received 10 mg/kg losartan from 4 
to 8 weeks. Expression of kidney AT-1 receptor, β-arrestin2, pERK/ERK was measured 
by western blots. A- II was measured by RIA. Serum from these rats was analyzed for 
creatinine and urea.
Results: Serum creatinine and urea went up gradually and peaked at 8 weeks. The mean 
kidney A-II concentration of the control animals was 303±25 fmol/gm. The results shown 
in the table are expressed as fold change. A-II levels peaked at 8 weeks. AT-1 receptor and 
ERK signaling went down but was restored by 8weeks. β-arrestin2 expression decreased 
at 2 weeks and never recovered. Losartan effectively reduced ERK signaling. 
Control 2 weeks 4 weeks 8 weeks 12weeks Losartan
A-II 1.00± 0.08
1.56+ 
0.12*
2.68± 
0.25*
3.29± 
0.27*
3.31± 
0.26* 3.15± 0.38
AT-1 1.00± 0.08
0.13± 
0.02*
0.45± 
0.05* 0.81± 0.14 0.76± 0.05 0.86+ 0.13
pERK/ERK 1.00± 0.14
0.18± 
0.06*
0.53± 
0.06* 0.99± 0.12 0.91± 0.19
0.15± 
0.05*,
β- arrestin2 1.00± 0.17
0.25± 
0.11*
0.37± 
0.08*
0.20± 
0.06*
0.33± 
0.10*
0.38± 
0.20*
*p<0.05 compared to control p<0.05 compared to 8 weeks 
Conclusions: β-arrestin2 is known to internalize AT-1 receptor. Our study shows that 
normal regulation of AT-1 receptor by A-II is lost as CKD progressed which is likely due 
to the loss of β arrestin2 . Losartan neither affected AT-1 receptor expression or β-arrestin2 
levels but by blocking ERK signaling it could abate A-II mediated deleterious effect on CKD.
TH-PO564
Sphingosine 1-Phosphate Changes in Patients with Chronic Kidney 
Disease on Hemodialysis and Peritoneal Dialysis  Daria Salata,1 Malgorzata 
Marchelek-Mysliwiec,2 Marta Budkowska,1 Wojciech Brzoska,2 Barbara 
Dolegowska.1  1Medical Analytics, Pomeranian Medical Univ, Szczecin, Poland; 
2Dept of Nephrology, Transplantology and Internal Medicine, Pomeranian 
Medical Univ, Szczecin, Poland.
Background: Sphingosine-1-phosphate is involved in the development and 
pathogenesis of renal function and physiology of many renal diseases including chronic 
kidney disease. Changes in concentrations of sphingosine-1-phosphate may affect the renal 
function and appear to be potential indicators of renal damage and renal graft function. 
The aim of this study was the evaluation of the biochemical parameters and quantitative 
analysis of the concentrations of sphingosine-1-phosphate in patients with chronic renal 
failure undergoing peritoneal dialysis, hemodialysis, or pre-dialysis.
Methods: The study included 120 patients with CKD:, on peritoneal dialysis (n=30) 
and hemodialyzed (n=30), in predialysis state (n=60). The concentrations of biochemical 
parameters in serum were determined by colorimetric methods. The concentrations of 
S1P in the plasma were measured using the RP-HPLC. Obtained results were statistically 
analysed using STATISTICA PL v.10.1.
Results: The highest average concentration of S1P has been obtained in patients on 
peritoneal dialysis (83.83 ± 18.99 mg/dL), and the lowest in patients with pre-dialyis therapy 
(58.06 ± 20.38 mg/dL). The average concentration of S1P in patients before hemodialysis 
(71.52 ± 19.86 mg / dL) and after treatment (77.83 ±26.48 mg/dL) were similar. Significant 
differences in concentration of S1P were found between patients with peritoneal dialysis 
and pre-dialysis patients (p = 0.0002) and between patients after hemodialysis and pre-
dialysis (p = 0.003).
Conclusions: Observed higher concentrations of S1P in hemodialysis patients and 
peritoneal dialysis in comparison to patients treated conservatively. Indicate that activation 
of cellular lipid sources may be caused by the activation of the coagulation system and 
increased oxidative stress
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TH-PO565
Renal Elasticity of Patients with Chronic Kidney Disease Evaluated with 
Real-Time Ultrasound Elastography  Hugo You-Hsien Lin,1,2,3 Shang-Jyh 
Hwang,1 Hung-Chun Chen,1 Chi-chih Hung.1  1Div of Nephrology, Dept of 
Internal Medicine, Kaohsiung Medical Univ Hospital, Kaohsiung, Taiwan; 
2Dept of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, 
Taiwan; 3Graduate Inst of Medicine, College of Medicine, Kaohsiung Medical 
Univ, Kaohsiung, Taiwan.
Background: Ultrasound real-time elastography is a new imaging technique, which 
provides information about the elasticity of soft tissue. It is widely applied in patients 
with liver diseases. In patients with chronic kidney disease (CKD), glomerulosclerosis 
and tubulointerstitial fibrosis could be associated with lower renal parenchymal elasticity. 
However, little is known about the elasticity of the kidney. We designed a study to evaluate 
renal elasticity in patients with CKD stage 3-5.
Methods: There were 148 healthy volunteers and 227 patients with CKD in this cohort 
from Southern Taiwan. Renal sonography was performed on the Hitachi EUB 7500 and 
HIVISION PREVIUS sonographer with elastrography and the EUP-C715 (1-5MHz) probe.
Results: There were 143 (63.0%) male, 166 (73.1%) diabetes, with a mean estimated 
glomerular filtration rate (eGFR) of 33.9±15.8 ml/min/1.73 m2 and a median urinary 
protein-to-creatinine ratio (UPCR) 502 (122-1491) mg/g in the CKD group. Patients with 
later CKD stages had lower value of renal elasticity, which means more stiff (p<0.001), and 
smaller kidney long length (p<0.001). We demonstrated that renal elasticity only correlated 
with log-transformed UPCR (β = -7.544, P< 0.001). Renal long length correlated with 
age (β = -0.231, P< 0.001), sex (β = -3.730, P< 0.001), serum albumin level (β = -3.024, 
P= 0.001), body mass index (β = 0.390, P= 0.009) and eGFR (β = 0.146, P< 0.001). In 
fully-adjusted logistic regression model, the odds ratio (OR) per 10 unit change of renal 
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elasticity for rapid renal progression was 0.928 (95% CI, 0.864-0.997; P = 0.042). The 
OR per 1mm change of renal long length for rapid renal progression was 1.022 (95% CI, 
0.994-1.050; P = 0.125).
Conclusions: Renal elasticity is associated with proteinuria and rapid renal progression 
in patients with CKD. It may be a useful tool for early detecting renal function change in 
patients with CKD.
Funding: Clinical Revenue Support
TH-PO566
The Availability of Proteinuria/Urinary Beta2-Microglobulin Combination 
as a Complementary Marker to Predict Early Progress in Chronic Kidney 
Disease  Chang Hwa Lee, Il hwan Oh, Joon-sung Park.  Internal Medicine, 
Hanyang Univ College of Medicine, Seoul, Korea.
Background: Proteinuria as a marker of glomerular damage is of pathogenic 
importance to the progression of chronic kidney disease (CKD). However, renal 
tubulointerstitial damage can serve a common pathway of CKD progression. Urinary b2-
microglobulin excretion, a marker of proximal tubular damage, may reflect the presence of 
tubulointerstitial damage. We hypothesized that the combination of proteinruia and urinary 
b2-microglobulin may be useful predictor of renal outcome.
Methods: Proteinuria and urinary b2-microglobulin excretion were measured in 104 
patients with CKD. Based on the value of urine protein-to-creatinine ratio (PCR) or urinary 
b2-microglobulin-to-creatinine ratio (UBCR), a total of 104 patients were divided into four 
groups: group I (n = 39), PCR < 0.5 mg/g and UBCR £300 ug/g: group II (n = 16), PCR < 
0.5 mg/g and UBCR> 300 ug/g: group III (n = 24), PCR ³0.5 mg/g and UBCR £300 ug/g: 
group IV (n =25), PCR ³0.5 mg/g and UBCR> 300 ug/g. Logistic regression analysis was 
used to compute odds ratio to examine the relationship of proteinuria or increased UBCR 
with deterioration of renal function (DRF), and Kaplan-Meier analysis was used to compare 
cumulative renal survivals among the groups.
Results: During a mean follow-up of 71 ± 21 months, renal function deteriorated in 
28 of the 104 patients with CKD. Among four groups, there was statistically significant 
difference in gender (P < 0.0198), serum glucose (P < 0.0147), serum uric acid (P < 
0.0279), and eGFR at 12 months (P < 0.0158). Logistic regression analysis identified the 
only combination of proteinuria and high UBCR (OR 7.396; 95% CI, 1.235 to 44.284; P 
= 0.028) as risk factors for DRF. In Kaplan-Meier analyses, group IV had most inferior 
cumulative renal survival rate and there were statistically significant difference among 
the groups (P < 0.008).
Conclusions: The combination of protein and b2-microglobulin in urine of CKD may 
be useful predictors of long-term renal survival. Proteinuria and urinary b2-microglobulin 
should not be discretely but simultaneously considered to early detect and delay DRF.
TH-PO567
Renal Hyperfiltration Predicts Increased Urinary Albumin Excretion in the 
General Non-Diabetic Population  Toralf Melsom,1,2 Vidar T. N. Stefansson,1 
Jørgen Schei,1,2 Marit D. Solbu,1,2 Trond G. Jenssen,1,4 Tom Wilsgaard,3 Bjorn 
Odvar Eriksen.1,2  1Metabolic and Renal Research Group, UiT the Arctic Univ 
of Norway; 2Dep. of Nephrology, Univ Hospital of North Norway; 3Dep. of 
Community Medicine, UiT the Arctic Univ of Norway; 4Dep. of Nephrology, 
Oslo Univ Hospital, Norway.
Background: In cohort studies, both low and high estimated glomerular filtration 
rate (eGFR) have predicted cardiovascular disease (CVD) and death. The increased risk 
associated with high eGFR has been explained by confounding due to a low serum creatinine 
in persons with chronic illness. However, abnormally high GFR, renal hyperfiltration, has 
been hypothesized to cause elevated urinary albumin excretion, a known risk factor for 
CVD and death. We investigated this hypothesis in the non-diabetic general population 
using measurements of GFR instead of eGFR.
Methods: In 2007-2009 we measured GFR by iohexol clearance in 1552 persons aged 
50-62 years from the general population without diabetes or high albumin-creatinine ratio 
(ACR) (ACR >3mg/mmol). 1274 (82%) had a follow-up measurement of GFR in 2013-
2015. 36 persons with diabetes at follow-up were excluded. Hyperfiltration was defined as 
an increase in absolute GFR (positive ∆GFR) within the same individual between baseline 
and follow-up. Since nephron number does not increase with age, this will be a proxy for 
increased single nephron GFR.
Results: ∆GFR was positively associated with a change in log(ACR) in multiple linear 
regression. The ratio ACRFU /ACRBASELINE increased 7% (95% CI: 0.4 to 13%) per standard 
deviation (SD) increase in ∆GFR. The top ∆GFR quartile was associated with a 34% (95% 
CI: 8 – 68%) increased ACRFU /ACRBASELINE ratio in women, but not in men, p<0.05 for the 
interaction. The odds ratio (95% CI) of high ACR at follow-up was 2.0 (1.3 – 2.9) per SD 
increase in ∆GFR. We adjusted for baseline CVD risk factors and change in body weight 
and use of anti-hypertensive medication.
Conclusions: Hyperfiltration predicts high ACR in the general population without 
diabetes. Although this may represent a link between hyperfiltration and an increased risk of 
CVD and mortality, it is unknown whether hyperfiltration is associated with these outcomes.
Funding: Pharmaceutical Company Support - Boehringer-Ingelheim, Government 
Support - Non-U.S.
TH-PO568
Elevated Urinary Excretion of Cysteine-Rich Protein 61 Is Associated with 
Rapid Renal Function Decline in Patients with Chronic Kidney Disease 
Chun-Fu Lai, Shuei-Liong Lin, Wen-Chih Chiang, Yung-Ming Chen.  Dept of 
Internal Medicine, National Taiwan Univ Hospital, Taipei City, Taiwan.
Background: Cysteine-rich protein 61 (Cyr61) has been identified as a proinflammatory 
factor in animal models of obstructive kidney fibrosis and ischemic kidney injury. We 
hypothesized that Cyr61 participates to the inflammatory process in injured kidneys and 
leads to progressive renal failure. The present clinical study aimed to examine urinary 
Cyr61 excretion in patients with chronic kidney disease (CKD).
Methods: Adult patients with stages 1-5 CKD were recruited from outpatient clinic. 
Urinary levels of Cyr61 were measured by sandwich enzyme-linked immunosorbent assay. 
The clinical factors associated with urinary Cyr61 excretion were explored using regression 
analysis. Rapid renal function decline was defined as estimated glomerular filtration rate 
(eGFR) decline rate higher than 4 cc/min/year during the follow-up period.
Results: A total of 154 patients were included (n= 29, 31, 34, 31, and 29 in stage 1, 
2, 3, 4, 5 CKD, respectively). Their age were 60.9 ± 13.4 years, and there were 57 women 
(37%). Urinary Cyr61 to creatinine ratio (UCry61CR) was markedly elevated in patients 
with stage 4 and 5 CKD (Figure 1A). UCry61CR was negatively correlated with eGFR 
(Figure 1B) and positively correlated with urinary protein to creatinine ratio. Furthermore, 
eGFR was independently associated with UCry61CR after adjusting age, gender, body 
weight, body high, and urinary protein to creatinine ratio (β= -0.026, P<0.001). Among 
patients with stage 3-5 CKD, UCyr61CR was significantly higher in those with rapid renal 
function decline in the following 3 months (P=0.02). 
Conclusions: Urinary Cyr61 excretion increases significantly in patients with 
advanced CKD. Higher UCyr61CR may be associated with following rapid renal function 
deterioration.
Funding: Government Support - Non-U.S.
TH-PO569
Hyperuricemia Can Be a Risk Factor for the Development of Hypertension 
and CKD – An 8-Year Follow-Up Study  Shinichiro Nishio, Satoru Kuriyama, 
Naoki Sugano, Takashi Yokoo.  Div of Nephrology and Hypertension, Dept of 
Internal Medicine, The Jikei Univ School of Medicine.
Background: Uric acid (UA) levels correlate positively with the prevalence of 
CKD and/or hypertension, suggesting that UA can be a progression factor. We tested the 
hypothesis that UA may also have a link to a new incidence of chronic kidney disease 
(CKD) and hypertension.
Methods: Study design is a cohort study and the predictor is UA levels. Of the 14,360 
screened cases, 7,536 participants without CKD were eligible for the analysis of the 
incidence of CKD. Among these CKD candidates, 6,475 participants were eligible for the 
analysis of the new development of hypertension. The observation period was 8 years. UA 
levels were dicided into 4 groups (Group 1:UA<5mg/dL, Group 2:5.0-5.9mg/dL, Group 
3:6.0-6.9mg/dL, Group 4:UA≥7mg/dL).
Results: Higher UA levels had a closer association with the new development of 
CKD at year 8; 1.6% (Group 1), 2.3% (Group 2), 3.1% (Group 3), and 4.9% (Group 4), 
respectively.  Cox proportional hazard analysis showed that the estimates of the CKD 
development were age, UA levels (Hazard Ratio (HR) 1.372,95% confidence interval 
(CI) 1.214-1.550), HbA1c and gender, indicating that UA levels can be predictors. The 
logistic analysis showed that the odds ratio (OR) to estimate CKD incidence in the high 
UA group (Group 4; OR 3.41, 95% CI, 95%CI 1.99-5.84) was greater than that in the low 
UA group (Group 1). On the other hand, higher UA levels had a closer association with 
the new development of hypertension; 6.9% (Group 1), 10.5% (Group 2), 13.0% (Group 
3), and 17.0% (Group 4), respectively. Cox proportional hazard analysis showed that the 
estimates of the hypertension development were BMI, age, HDL-cholesterol, male gender, 
UA level (HR 1.112, 95% CI, 1.024 to 1.207), and eGFR. The logistic analysis showed that 
the odds ratio (OR) to estimate hypertension in the high UA group (Group 4; OR 1.33, 95% 
CI, 1.01 to 1.80) was greater than that in the low UA group (Group 1).
Conclusions: High UA levels are associated with the incidence of CKD and the 
development of hypertension.
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TH-PO570
Associations Between Uric Acid, Adiponectin and Urinary Biomarkers in 
Persons with and without the Metabolic Syndrome  Marit D. Solbu,1,2 Jon 
viljar Norvik,2 Jens Kronborg,2,3 Bjorn Odvar Eriksen,1,2 Toralf Melsom,1,2 Trond 
G. Jenssen.2,4  1Section of Nephrology, Univ Hospital of North Norway, Tromsø, 
Norway; 2Metabolic and Renal Research Group, UiT the Arctic Univ of North 
Norway, Tromsø, Norway; 3Innlandet Hospital Trust, Lillehammer, NorZay; 
4Oslo Univ Hospital, Oslo, Norway.
Background: In the metabolic syndrome (MetS), serum uric acid (UA) is often 
increased, and adiponectin is low; UA may cause renal damage, whereas adiponectin may 
be renoprotective. It is not known whether UA and adiponectin interact in development of 
renal damage. We assessed the cross-sectional association between UA, adiponectin and 
two urinary biomarkers (albumin creatinine ratio (ACR) and orosomucoid creatinine ratio 
(oroCR)) in persons with or without the MetS (NCEP-ATPIII definition).
Methods: From the Tromsø Study 2007-08, 7047 persons were included. Three urine 
specimens were collected and median values of ACR and oroCR used. The associations 
between UA, adiponectin and the upper vs. three lower quartiles of each biomarker were 
assessed by logistic regression analysis adjusted for cardiovascular risk factors, medication 
use and eGFR in persons with and without the MetS.
Results: Mean age was 63.5 (±SD 9.2) years, 57% were women and 27% had the MetS. 
UA was associated positively with the upper ACR quartile and negatively with the upper 
oroCR quartile. The association with ACR was stronger in persons with the MetS than 
in those without (OR 1.18; 95% CI 1.07–1.31; P=0.002 vs. OR 1.08; 95% CI 1.01–1.16; 
p=0.04 per 1 mg/dL increase in UA.) Adiponectin was positively associated with ACR 
and oroCR, but only in persons without the MetS (OR 1.08 (95% CI 1.04-1.13); OR 1.07 
(95% CI 1.03-1.12), both P<0.001, per µg/mL). There were no interactions between UA 
and adiponectin in their associations with the urinary biomarkers.
Conclusions: UA and adiponectin did not interact in their associations with biomarkers 
of renal damage. Contrary to what we expected, adiponectin was positively associated 
with ACR and oroCR, but only in persons without the MetS. UA was positively associated 
with ACR only. The findings should be studied longitudinally before firm conclusions 
could be made.
Funding: Government Support - Non-U.S.
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The Longitudinal Association Between Uric Acid Level and Progression 
of Chronic Kidney Disease in Chinese Population  Ching-Wei Tsai, Shih-yi 
Lin, Chin-Chi Kuo, Chiu-Ching Huang.  Div of Nephrology and Kidney Inst, 
China Medical Univ and Hospitals, Taichung, Taiwan.
Background: Hyperuricemia is commonly observed in patients with chronic 
kidney disease (CKD). Although increasing evidence supports the association between 
hyperuricemia and incident CKD, there are conflicting data about the role of hyperuricemia 
in the progression of CKD. The main aim of current study was to add empirical evidence 
to the debate on the direction of the relationship among uric acid levels, allopurinol, and 
CKD progression in Chinese population.
Methods: We conducted a retrospective cohort study in central Taiwan. Patients 
who had documented hyperuricemia (defined by uric acid greater than 7 mg/dL) and/or 
receiving uric acid-lowering agents between 2003 and 2005 were included in the study. 
They were followed till December 31, 2011. Only patients with at least three available 
renal function profiles were analyzed. CKD progression was evaluated by the change in 
eGFR using linear mixed models.
Results: Longitudinal analyses showed patients with a baseline uric acid level greater 
than 7 mg/dl had faster decline in eGFR, comparing to those with uric acid level less 
than 7 mg/dl. After adjustment for demographics, comorbidities, proteinuria, allopurinol 
and ACEI/ARB use, three categories of hyperuricemia (uric acid 7-9, 9-11, >11 mg/dl) 
remained strongly associated with faster decline in eGFR over the follow-up. In multivariate 
longitudinal analysis, those receiving allopurinol was associated with a significantly faster 
decline in eGFR than non-allopurinol users during the follow-up.
beta p value
uric acid<7 mg/dl Ref
uric acid 7-9 mg/dl -6.7 0.002
uric acid 9-11 mg/dl -7.2 0.006
uric acid >11 mg/dl -10.7 0.001
age at exam -0.6 <0.0011
sex 1.8 0.9
DM -2.2 0.2
CAD -0.5 0.8
SBP -0.03 0.4
Baseline creatinine -6.4 <0.001
proteinuria -10.6 <0.001
Allopurinol -9.6 <0.001
Conclusions: Our study showed higher uric acid level is strongly associated with an 
accelerated decline in renal function in Chinese population. However, uric acid-lowering 
therapy with allopurinol was associated with even faster progression of CKD in this study.
TH-PO572
Revisiting Medullary Tophi: A Link Between Uric Acid and Progressive 
Chronic Kidney Disease?  Salem Almaani,1 Isabelle Ayoub,1 Sergey V. 
Brodsky,2 Tibor Nadasdy,2 Jason Prosek,1 Lee A. Hebert,1 Brad H. Rovin.1  1Div 
of Nephrology, The Ohio State Univ, Columbus, OH; 2Dept of Pathology, The 
Ohio State Univ, Columbus, OH.
Background: It is well-established from autopsy studiesthat gouty tophi can form in 
the kidney, particularly in the renal medulla. Recently hyperuricemia has been identified 
as a risk factor for progression of chronic kidney disease (CKD). Because each collecting 
duct serves more than 2000 nephrons, we postulated that obstruction or disruption of 
collecting ducts by medullary tophi may explain, at least in part, the association between 
hyperuricemia and progressive CKD. This work was done to determine the prevalence of 
medullary tophi in CKD patients.
Methods: We queried our nephropathology database over the last ten years for native 
kidney biopsiesthat had medullary tophi. The presence or absence of CKD and uric acid 
levelsaround the time of biopsy were determined by chart review.
Results: Predominant medullary tissue was reported in 796 of 7409 total biopsies, and 
572 of these were from patients with established CKD. Medullary tophi were seen in36 
patients, 35 of whom had CKD, suggesting a minimum prevalence of tophi in CKD and 
no-CKD of 6.11% and 0.45%, respectively. Medullary tophi occurred with and without 
hyperuricemia or a history of gout.
ID Age1 Race2 Gout Nephroli-thiasis
Serum Creatinine 
Concentration/eGFR4
Serum Uric 
Acid Concen-
tration5
1 42 CAU Yes No 2.8/26 9.1
2 47 CAU No No 1.6/46 7.9
3 37 CAU No No 1.5/39 8.7
4 69 CAU No Yes 2.9/21 9.1
5 54 CAU No No 4.0/19 9.8
6 65 CAU Yes No 6.5/6 6.3
7 52 CAU No No 2.5/28 7.5
8 60 CAU No No 4.2/11.5 Normal6
9 36 CAU No No 10.7/5.8 8.8
10 22 H Yes NA 13.5/4.9 Normal
11 37 NA No No 26/NA 6.0
12 65 CAU Yes No 2.5/20.5 5.8
13 67 CAU Yes NA 2.2/41 6.8
14 22 H No No 2.8/35 10.1
15 51 CAU Yes Na 14/NA 17.4
16 40 CAU No No 1.5/40 13.5
Conclusions: Medullary tophi appear to be far more likely to occur in CKD compared 
to no-CKD patients. This cross-sectional study cannot determine whether medullary tophi 
are a cause or consequence of CKD. However, given their strategic location and bulk, it 
is possible that medullary tophi contribute toprogression of established CKD by causing 
upstream nephron damage.
TH-PO573
Serum Uric Acid Over 7 mg/dL Is an Independent Risk of Incident 
End Stage Kidney Disease – A 6-Year Population-Based Cohort Study 
Ouppatham Supasyndh, Puvanant Wiputhanuphong, Bancha Satirapoj. 
Nephrology Div, Dept of Internal Medicine, Phramongkutklao Hospital and 
College of Medicine, Thailand.
Background: Uric acid deteriorates kidney function via crystal and non-crystal 
dependent mechanisms. However epidemiological evidence for the significance of serum 
uric acid levels on the risk for developing end-stage kidney disease (ESKD) is scarce in a 
setting of population-based screening especially in Asian population. The purpose of the 
study was to evaluate the effect of serum uric acid level on incidence of impaired kidney 
function and ESKD.
Methods: A total of 23,712 individuals from an integrated health care delivery system 
in the Thai army who participated for health checkups between July 1, 2006, and December 
31, 2012 were screened. Only 18,390 participants (14,686 men, 3,704 women) older than 
20 years for whom available for body weight, serum uric acid, and creatinine data with 
estimated glomerular filtration rate (eGFR) over 60 ml/min/1.73m2 were enrolled in the 
study. The cumulative incidence of chronic kidney disease (CKD, eGFR<60 mL/min per 
1.73 m2) and ESKD (eGFR<15 mL/min per 1.73 m2) was calculated according to quartiles 
of baseline serum uric acid levels and significant high serum uric acid levels (≥7.0 mg/dL).
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Results: The mean age of participants was 47.69±6.69 years and body mass index 
was 24.71 ±3.47 kg/m2. Fourteen percent (n=2,648) was diabetes and 65.2% (n=11,998) 
had high blood pressure. Average serum uric acid and eGFR were 6.29 ± 1.55 mg/dL and 
87.84 ± 13.27 mL/min per 1.73 m2, respectively. The incidence of CKD at 6 years follow 
up was 3.64/1000 person-year. A total of 11 patients (0.06%) of ESKD were observed. 
Participants with highest serum uric acid quartile (>7.3 mg/dL) had a 3.42-fold increase in 
adjusted hazard ratio (HR) (95%CI; 2.19 to 5.32), compared to those with the lowest serum 
uric acid quartile (<5.2 mg/dL). Moreover, serum uric acid ≥ 7 mg/dL were significantly 
increased risk of ESKD (adjusted HR 5.74 with 95%CI; 1.58 to 20.8, P =0.008). Finally, 
every 1 mg/dL increasing of serum uric acid, eGFR would decline 2.2 mL/min per 1.73 m2.
Conclusions: Serum uric acid level is an independent risk of CKD and ESKD in 
Thai population.
TH-PO574
Proton Pump Inhibitors Are Associated with Increased Risk of Development 
of Chronic Kidney Disease  Pradeep Arora,1,2 Mojgan Golzy,3 Anu Gupta,2 
Rajiv Ranjan,1,2 Randy L. Carter,3 James W. Lohr.1,2  1Nephrology, VA Medical 
Center, Buffalo, NY; 2Medicine, SUNY, Buffalo, NY; 3Dept of Biostatistics, UB, 
Buffalo, NY.
Background: Proton pump inhibitors (PPI) are one of the common cause of acute 
interstitial nephritis in the United States. This frequently goes undiagnosed due to its 
subacute clinical presentation, which may later present as chronic kidney disease (CKD). 
We investigated the association of PPI use with the development of CKD and death.
Methods: The population included 99,351 patients who were seen in primary care 
VISN2 clinics from 4/2001 until 4/2008. For evaluation of CKD outcome, 27,835 patients 
with baseline CKD were excluded. Study data was obtained from Veterans Affairs Health 
Care Upstate New York (VISN2) network. Data obtained included use of PPI (Yes/No), 
age, gender, race, retrospective observation time , laboratory data including eGFR, pre-PPI 
comorbidity variables: vascular disease, chronic obstructive pulmonary disease (COPD), 
cancer, diabetes, and hypertension. A prospective logistic analysis of case-control data 
(Prentice and Pyke) was used to investigate the association of treatment (exposure to PPI) 
with onset of CKD with propensity score in the model.
Results: A total of 24,149/71,516 patients developed CKD. Of those who developed 
CKD 25.7% were treated with PPI. Patients receiving PPI were more likely to have 
vascular disease, COPD, cancer and hypertension. Of the total of 99,251 patients analyzed 
for mortality outcome, 36,290 died. Propensity score analysis showed higher odds for 
development of CKD ( OR 1.29 95% CI 1.24-1.34) and mortality (OR 1.97, 95% CI 1.88-
2.06) among patients taking PPIs versus those not on PPIs. Sensitivity analyses showed a 
significant effect of the interaction of age and PPI use in models with CKD.
variables contrast Odds ratio with 95% CI
PPI Yes vs No 1.29 (1.24-1.35)
Age 1 Year Increase 1.06 (1.05-1.07)
Race Black vs white 0.92 (0.87-0.98)
Gender Female vs Male 0.91 (0.84-0.99)
Time one quater increase 0.9 (0.89-0.91)
Propensity score 0.1 unit increase 0.45 (0.3-0.66
Conclusions: Use of proton pump inhibitors are associated with increased risk of 
development of CKD.
TH-PO575
Influence of Statin on Iron Utilization and Metabolism in Patients with 
Chronic Kidney Disease Stage 3-4  Anna Masajtis-zagajewska, Michal P. 
Nowicki.  Dept of Nephrology, Hypertension and Kidney Transplantation, 
Medical Univ of Lodz, Lodz, Poland.
Background: Hepcidin, an acute phase reactant protein is a key regulator of iron 
homeostasis. Elevated hepcidin levels are expected in the face of decreased glomerular 
filtration and inflammation. Hepcidin is a potentially modifiable mediator of anemia in 
patients with chronic kidney disease (CKD). Statins have had potent anti-inflammatory 
effects in experimental and clinical CKD and may thereby modulate erythropoiesis.
Methods: Thirty-six patients (17 M, 19 F, mean age 58±13 years) with stage 3 and 
4 CKD and LDL cholesterol ³100 mg/dl not on statin therapy were studied. In a double 
blind, crossover study all subjects received in a random order either atorvastatin 20 mg/
day or placebo for two 6-month periods with 3-month wash-out. Basic biochemistry, serum 
inflammatory markers such as hsCRP, IL-6, parameters of iron metabolism including iron, 
serum hepcidin, Total Iron Binding Capacity (TIBC), Unsaturated IronBinding Capacity 
(UIBC) and hemojuvelin were measured both before and after each treatment period.
Results: TIBC and UIBC did not change during placebo phase but significantly 
increased after 6 months statin therapy from 255±43 to 267±45ug/dl (p=0.006) and 
from 186±48 to 196±50µg/dl (p=0.03), respectively. Serum iron tended to increase from 
68.8±19.1µg/dl to 72.4±17.8µg/dl (p=0.08) only during statin treatment. Hemoglobin 
increased after 6 months statin therapy from 11.6±1.6 to 11.8±1.5g/dl (p=0.001) while 
after placebo period hemoglobin did not change. Hepcidin levels significantly decreased 
during statin treatment from 241±337 to 160±210pg/ml (p=0.01), while no effect was found 
during placebo phase. Hemojuvelin levels did not change after both statin and placebo. IL-6 
and hsCRP tended to decrease after 6 months only after statin therapy (from 11.5±11.1 to 
11.1±15.2pg/ml; p=0.06 and from 52.2±28.9 to 46.2±28.1mg/dl; p=0.06, respectively. Total 
and LDL-cholesterol decreased significantly only during statin treatment.
Conclusions: The treatment of CKD patients with statin may reduce inflammation 
and improve iron utilization through decreased serum hepcidin.
Funding: NIDDK Support
TH-PO576
CKD Prevalence and Iron Status: Are They Linked to the Etiology and 
Ejection Fraction in Chronic Heart Failure  Jacek S. Malyszko,1 Hanna 
Gajewska,2 Slawomir Dobrzycki,2 Jolanta Malyszko.3  11st Nephrology, Medical 
Univ, Poland; 2Invasive Cardiology, Medical Univ, Poland; 32nd Nephrology, 
Medical Univ, Poland.
Background: Kidney disease and cardiovascular disease are tightly associated and 
there is a mounting evidence of inter-organ cross-talk. Anemia and iron deficiency are 
frequent in CKD. We performed the cross-sectional study on 273 prevalent patients and 
investigated a) the prevalence of chronic kidney disease in patients with heart failure due 
to coronary artery disease, cardiomyopathy or valvular disease undergoing percutaneous 
coronary interventions-PCI; b) iron status (additionally assessed using circulating soluble 
transferrin receptor-sTfR, hepcidin, hemojuvelin, GDF-15) in these 3 subpopulations in 
regard to kidney function.
Methods: GFR was estimated by MDRD formula. sTfR, hepcidin, hemojuvelin, 
GDF-15 were studied using commercially available kits.
Results: Prevalence of CKD (stage 3 or more) was the highest in in valvular disease 
(34%), the lowest in coronary artery disease (23%). According to the WHO definition, the 
prevalence of anemia in the studied cohort was 23.1%. We observed a progressive decline in 
GFR and hemoglobin concentration together with a rise in NYHA class in the whole cohort. 
Iron deficiency and anemia were the most often found in patients with heart failure due to 
coronary artery disease, with the highest hepcidin and GDF15 levels, and highest eGFR. 
Anemic patients had worse kidney function, except valvular disease subgroup relative to 
non- anemics. In the latter serum hepcidin was the lowest. Iron status in heart failure was 
related to the etiology of this clinical setting, but not to kidney function. However, when 
divided into groups with preserved or reduced ejection fraction-EF, CKD, anemia and 
iron deficiency was more prevalent in patients with worse ejection fraction. Significant 
correlations were observed between eGFR and age, NYHA class, hepcidin, GDF-15.
Conclusions: The prevalence of anemia and chronic kidney disease is high and depends 
on the etiology of heart failure and EF in patients undergoing PCI. Hemodynamic changes 
and subclinical inflammation seems to play a major role in altered iron status and impaired 
kidney function in heart failure.
Funding: Government Support - Non-U.S.
TH-PO577
Hormone Replacement Therapy in Post-Menopausal Women Is Associated 
with Better Kidney Function  Andrea G. Kattah,1 Bradley R. Lewis,2 Stephen 
T. Turner,1 Vesna D. Garovic.1  1Div of Nephrology and Hypertension, Mayo 
Clinic; 2Health Sciences Research, Mayo Clinic, Rochester, MN.
Background: The effect of hormone replacement therapy (HRT) on renal function 
in post-menopausal women is unclear. Experimental models suggest estrogen has a 
renoprotective effect, but human studies have had variable results.
Methods: We performed a cross-sectional study on 2217 post-menopausal women 
who participated in the Family Blood Pressure Program, a mutli-network study aimed at 
studying the genetics of hypertension. We compared markers of renal function, including 
urine albumin/creatinine ratio (UACR) and estimated glomerular filtration (eGFR) using 
the CKD-EPI equation, between women who were using HRT (n=673, median age 60.2) 
and those who were not (n=1544, median age 62.9). Clinical characteristics, including body 
mass index (BMI), medical history, medications, family history and blood and urine tests 
were measured at a single study visit conducted between 2000-2004.
Results: UACR was significantly lower in those on HRT versus those who were not 
(3.5 vs. 5.2 mg/g Cr, p<0.001), as was the number of women with eGFR < 60 ml/min/1.73 
m2 (7% vs. 10%, p=0.003). We performed linear and logistic regression models using 
generalized estimating equations for log(UACR), UACR > 25 mg/g Cr and eGFR < 60 ml/
min/1.73 m2 and adjusted for age, race, network, education, smoking, diabetes, hypertension, 
family history of hypertension, log(BMI), log(HDL), log(LDL) and log(triglycerides). After 
adjusting for these factors, we found that the use of HRT was still significantly associated 
with lower log(UACR )(-0.307, p<0.001) and women not on HRT had an odds of 1.6 (95% 
CI 1.2-2.3) times that of those on HRT of having UACR > 25 mg/g Cr. The association 
between HRT and eGFR < 60 ml/min/1.73m2 was no longer significant after adjustment.
Conclusions: The use of HRT in post-menopausal women was associated with lower 
UACR after adjusting for known risk factors for renal and cardiovascular disease. Strengths 
of our study include a large sample size and a comprehensive medical history of subjects. 
Limitations include that subjects were recruited on the basis of hypertension and that we 
had limited information on the length of time on HRT.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
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TH-PO578
Tobacco Smoking and Progression of Chronic Kidney Disease: A Role for 
Reactive Aldehydes?  Gabriel Rezonzew,1 Phillip H. Chumley,1 Wenguang 
Feng,1 Ping Hua,1 Huma Fatima,1 Edgar A. Jaimes.2  1Univ of Alabama at 
Birmingham; 2Memorial Sloan Kettering Cancer Center.
Background: Clinical and experimental evidence supports the role of tobacco 
smoking as a risk factor in the progression of chronic kidney disease (CKD) of different 
etiologies. Cigarette smoke (CS) contains numerous compounds that could be responsible 
for the deleterious effects of tobacco smoking. Among these compounds are included large 
concentrations of reactive aldehydes such as acrolein that react with thiol groups and active 
NADPH oxidase as we have previously shown (ATVB’04). In these studies we postulated 
the hypothesis that acrolein (Acr) accelerates the progression of CKD and that these effects 
are linked to increased oxidative stress.
Methods: Sprague-Dawley rats (n=6-8) rats were divided in the following groups: 
Sham, Sham+Acr (0.5 mg/kg/day via osmotic minipump),5/6Nx and 5/6Nx+Acr. Rats 
were euthanized after 12 weeks and kidneys saved for glomerular injury score (GIS) and 
tubular injury score (TIS). Urine was collected every two weeks for proteinuria (Bio-Rad). 
Urinary isoprostanes and TGF-β were measured by Elisa and adjusted for urinary creatinine.
Results: Sham rats on Acr had a significant increase in proteinuria, urinary excretion 
of isoprostanes and TGF-β, TIS but not GIS. Rats with 5/6Nx had a significant increase 
in proteinuria, TIS and GIS and a modest increase in TGF-β. The administration of Acr 
to 5/6Nx resulted in further increases in proteinuria, isoprostanes and TIS but not GIS. 
The urinary excretion of TGF-β in these rats was also increased and similar to Sham+Acr. 
Sham Sham+Acr 5/6Nx 5/6Nx+Acr
Proteinuria (mg/24 hours) 51.1± 9.8 122.4± 10.2* 122.7± 13.6* 420.5± 98.5*,#
Isoprostanes (pg/mg creatinine) 61.4± 10 164.5± 32.4* 51.5± 20 336.5± 126.7*,#
TIS 2.9± 0.6 6.5± 1.2* 8.26± 2.1* 15.1± 2.5*,#
GIS 0 0.1± 0.1 36± 22* 36± 20*
TGF-β (pg/mg creatinine) 5.3± 1.8 50.1± 16.7* 10.7± 4. 51.5± 28.1*,#
* P <0.05 vs Sham, # P<0.05 vs 5/6NX (N=6-8) 
Conclusions: These studies suggest that the reactive aldehyde acrolein plays a role 
as mediator of the deleterious effects of tobacco smoking in the progression of CKD.
Funding: Other NIH Support - National Institute of Environmental Health Sciences
TH-PO579
Intermittent Smoking Associates with Chronic Kidney Disease in U.S. 
Hispanics: The Hispanic Community Health Study/ the Study of Latinos 
(HCHS/SOL)  Nora Franceschini.  Epidemiology, Univ of North Carolina, 
Chapel Hill, NC.
Background: Cumulative smoking exposure is associated with chronic kidney disease 
(CKD). However, the patterns of exposure, such as the effect of intermittent smoking, 
on CKD risk are unknown. These patterns may be important given the recent increase in 
alternative smoking exposures such as e-cigarettes.
Methods: Cross-sectional study of 15,664 participants of a population-based cohort 
of Hispanic/Latinos aged 18-74 years recruited from four U.S. field centers from 2008 to 
2011. Data on current, past and never smoking, and smoking pack-years were obtained 
through a questionnaire. The association between smoking exposure and CKD (estimated 
glomerular filtration rate <60 ml/min/1.73 m2 or urine albumin to creatinine ratio ≥ 30 
mg/g) was estimated using logistic regression models. We tested the interaction between 
smoking status and cumulative pack-years at the significance level of 0.05.
Results: Approximately 62% individuals were non-smokers, 17% were past smokers 
and 22% were current smokers, of which 14% were daily smokers and 8% were intermittent 
smokers. The adjusted prevalence estimates of CKD were 10% for non-smokers, 11% 
for past smokers, 8% for daily smokers and 12% for intermittent smokers.There was a 
significant interaction between smoking status with pack-years of exposure (p=0.0002). 
In adjusted models accounting for this interaction, there were increased odds of CKD 
among current daily, intermittent, and past smokers by pack-years compared to never 
smokers. The association of intermittent smokers with CKD was significant at 10 pack-
years of smoking, whereas for daily smokers, it was observed only at 40 pack-years of 
smoking. Past smokers had a 20% increased odds of CKD compared with non-smokers 
across pack-years of smoking.
Conclusions: This study demonstrates significant effects of current daily and 
intermittent smoking on prevalent CKD among Hispanic/Latinos, which was significant 
at lower pack-years of exposure among intermittent smokers. Our research support efforts 
to aggressively eliminate smoking exposure through public health interventions and extend 
these current recommendations to prevention of CKD.
Funding: Other NIH Support - R21HL123677, R01ES021367, 1R01HL118305-
01A1
TH-PO580
Incidence of Chronic Kidney Disease in Patients with COPD: Systematic 
Review and Meta-Analysis  Swarna Gouddam,1 Sameer K. Gunukula,1 James 
W. Lohr,2 Nader Nader,3 Pradeep Arora.2  1Medicine, SUNY at Buffalo, Buffalo, 
NY; 2Medicine, VAMC, Buffalo, NY; 3Anesthesiology, VAMC, Buffalo, NY.
Background: Chronic obstructive pulmonary disease (COPD) is common disease 
especially in elderly population, and is a important cause of mortality world-wide. 
Several studies have identified COPD as part of a systemic inflammatory syndrome and 
reported on the association of comorbidities like lung cancer, osteoporosis, progression of 
atherosclerosis. However, the relationship between COPD and incidence of chronic kidney 
disease (CKD) has not been clearly demonstrated in the literature. The focus of our study 
was to systematically review the medical literature reporting the incidence of renal function 
disturbances specifically incidence of CKD in patients with COPD.
Methods: We conducted a systematic review using the Cochrane Collaboration 
Methodology. We searched Medline via Ovid, Pubmed, Embase and ISI web of Science 
databases from 1950 through 2015. We rated the quality of evidence for each outcome using 
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
methodology. Meta-analysis was done using Review Manager Version 5.0.20.
Results: Our search resulted in 8 eligible studies. COPD was found to be associated 
with a significantly increased incidence of CKD (Odds Ratio [OR]=2.10; 95% Confidence 
Interval [CI] 2.04, 2.16. 
Conclusions: COPD patients are at increased risk of developing chronic kidney disease. 
The exact reasons for the increase in the incidence of CKD are unclear. Clinical research 
and practice guidelines usually target disease conditions in isolation. Research into COPD 
and CKD is scant and there is a need for further studies to delve into the pathophysiological 
mechanisms and clinical implications of incidence of CKD in patients with COPD.
TH-PO581
Effects of Nicotine on the Severity of Diabetic Nephropathy: Role of 
α7-Nicotine Receptor  Mohammed Siddiqui,1 Wenguang Feng,1 Gabriel 
Rezonzew,1 Lawrence P. Wennogle,2 Edgar A. Jaimes.3  1Univ of Alabama at 
Birmingham; 2Intra-cellular Therapies; 3Memorial Sloan Kettering Cancer 
Center.
Background: Tobacco smoking plays a major role in progression of chronic kidney 
disease (CKD) of different etiologies including diabetes mellitus (DM). In previous studies 
we demonstrated that nicotine is responsible for deleterious effects of smoking in the 
progression of CKD and pharmacologic blockade of the α7 nicotine receptor subunit (α7-
nAchR) reduces the effects of nicotine in a CKD rat model. Whether this receptor also plays 
a role in the progression of other models of CKD such as diabetic nephropathy is not known.
Methods: DM was induced with streptozotocin (STZ) in eNOS-/- and eNOS-/-/α7-
nAchR-/- (DKO) mice. A separate group of eNOS-/- mice also received a α7-nAchR blocker 
(IC200610, 2 mg/kg IP, 5 days a week for 10 weeks). Mice were given nicotine (100mg/
ml in drinking water) or tap water for 10 weeks. Blood pressure (BP) was measured by 
tail-cuff method and urine collected every 2 weeks for albuminuria.
Results: All mice became diabetic after STZ and had no significant differences in weight 
or blood glucose at sacrifice. All animals were also hypertensive and nicotine had no effect 
on BP in any of the groups. Diabetic mice receiving nicotine (DN) had higher albumin 
excretion as compared to diabetic mice on tap water (DT). Diabetic mice on nicotine lacking 
the α7-nAchR (DN-/-) or with pharmacologic blockade (DN+B) had urinary excretions of 
albumin similar to diabetics on tap water (DT). Neither absence of the α7-nAchR (DT-/-) 
nor pharmacologic blockade (DT+B) had any effect on mice on tap water.
DN 
(n=13)
DT 
(n=10)
DN-/- 
(n=9)
DT-/-) 
(n=12)
DN+B 
(n=8)
DT+B 
(n=7)
Body Weight (gm) 26± 1.0 22± 0.9 25±  1.9 23± 0.5 25± 0.5 26± 1.1
Blood Glucose (mg/dL) 442± 48 542± 17 479± 41 516± 26 441± 43 354± 51
Albuminuria (ng/24 hr) 103± 25* 71± 8 42± 14 46± 7 35± 6 50± 13
Systolic BP (mm Hg) 153± 6 147± 6 153± 5 147± 4 142± 13 150± 11
* p<0.05 vs other groups.
Conclusions: These studies demonstrate that α7-nAchR is a critical mediator of the 
deleterious effects of nicotine in the severity of diabetic nephropathy.
Funding: Other NIH Support - National Institute of Environmental Health Sciences
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TH-PO582
Lithium Nephropathy: A Long-Term Complication of Chronic Lithium 
Therapy  Aleksander Hercegovac.  Nephrology, Maasstad Hospital Rotterdam, 
Rotterdam, Zuid-Holland, Netherlands.
Background: Lithium is the treatment of choice for bipolar disorder. Lithium-induced 
nephropathy is a known complication limiting its use. The aim of this study is to establish 
the prevalence of renal failure in our population. We sought to quantify the contribution 
of lithium therapy to the risk of developing renal failure.
Methods: We selected 1751 patients on lithium therapy from the laboratory database of 
the Delta Center for Mental Health Care, Rotterdam. The database contains measurements of 
lithium and creatinine concentration over a period from 2000 to 2011. eGFR was calculated 
using the 4-variable MDRD formula. Renal failure was defined as having GFR<60mL/min 
on at least 2 measurements 6 weeks apart. A comparison was made between patients with 
and without renal insufficiency regarding gender, mean lithium concentration in serum, 
lithium intoxication, duration of therapy, age at initiation of therapy, cardiovascular disease, 
hypertension and diabetes mellitus.
Results: 305 out of 1751 (17.4%) patients were classified as having renal failure. 
Occurrence of renal failure was positively correlated with female sex, age at initiation of 
therapy and duration of lithium therapy (p<0.001). Significant correlation was also observed 
between renal failure and cardiovascular risk factors. Mean lithium serum concentration 
was 0.68 mmol/l and did not differ between patients with and without renal failure. In 251 
patients follow up data was available for a period of more than 10 years. In these patients 
history of lithium intoxication did not predict occurrence of renal failure.
Conclusions: Prevalence of renal failure in our cohort is similar to other reports. 
Longer duration of lithium therapy was found to be associated with an increased risk of 
renal failure. Contrary to our expectation, lithium intoxication was not correlated with renal 
failure. Although therapy duration was a significant predictor, one should not forget the 
importance of cardiovascular risk factors in development of renal failure.
TH-PO583
Study of Organochlorine Pesticides in Patients with Chronic Kidney Disease 
of Unknown Etiology  Om Prakash Kalra,1 Chetna Gothwaal,1 Alpana Raizada,1 
Ashok Kumar Tripathi,2 Sunil Agarwal.1  1Medicine, UCMS and GTB Hospital, 
Delhi, India; 2Biochemistry, UCMS and GTB Hospital, Delhi, India.
Background: An apparently new form of CKD not attributable to diabetes, 
hypertension or other known causes, i.e. CKD of unknown etiology (CKDu) has emerged 
in south Asia, especially Sri Lanka, and Sub-Saharan Africa in the last one decade. CKDu 
affects younger individuals and is asymptomatic until advanced stages. Organochlorine 
pesticides (OCPs) are implicated in the etiopathogenesis of CKDu. This study aimed at 
estimating the serum level of various OCPs (α-HCH, β-HCH, g-HCH, total HCH, Aldrin, 
Dieldrin, α-endosulfan, β-endosulfan, p,p’-DDT, p,p’-DDE) and total pesticide load (TPL) 
in patients with CKDu in comparison with patients with CKD of known etiology (CKDk) 
and to assess their role in etiopathogenesis of CKDu.
Methods: This was a case-control, cross-sectional study conducted in east Delhi. 
Subjects in the age group 18-60 years of either sex were recruited under 3 groups: Group 
I: Healthy controls (n=30), Group II: Patients with CKDu (n=30) and Group III: Patients 
with CKDk (n=30). Detailed history, physical examination, routine investigations and 
urinary protein excretion estimation were done. Serum OCP levels were estimated by high 
performance liquid chromatography.
Results: The median serum levels of all OCPs were higher in patients of group II as 
compared to other study groups and this difference was statistically significant for α-HCH, 
β-HCH, total HCH, α-endosulfan, p,p’-DDE and TPL. For the same CKD stage, CKDu 
patients had higher levels of TPL as compared to CKDk patients. Mean blood urea and 
serum creatinine levels were higher in patients of group II. Significantly greater proportion 
(66.34%) of CKDu patients had stage V CKD as compared to CKDk patients. CKDu 
patients had higher urinary protein excretion as compared to CKDk patients though this 
was statistically insignificant.
Conclusions: Despite some limitations of the study, the presence of higher serum OCPs 
in individuals with CKDu in comparison to CKDk at corresponding CKD stages suggests 
their possible role in the etiopathogenesis of CKDu.
Funding: Government Support - Non-U.S.
TH-PO584
Chronic Kidney Disease After Intravenous Colistin Use in Survivors of 
Severe Infections  Alejandro Y. Meraz-Munoz, Juan Carlos Ramirez-Sandoval, 
Ricardo Correa-Rotter.  Nephrology and Mineral Metabolism, Inst Nacional de 
Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
Background: The resurgence of colistin use for multidrug-resistant (MDR) infections 
has led to an increase of colistin-associated acute kidney injury (AKI). Nevertheless, long-
term renal prognosis information is scarce.
Methods: A retrospective cohort study was performed from January 2011 to March 
2015. Patients who received colistin for >5 days were included. We excluded cases with 
CKD, history of kidney transplant, and non-survivors to MDR infection. The primary 
outcome was the development of CKD after colistin treatment. CKD was defined as eGFR 
<60mL/1.73m2 and/or proteinuria during ³3 months.
Results: In all, 132 patients received colistin, of them, 50 (40%) died due to MDR 
infection. During a median follow-up of 2.1 years (interquartile range [IQR]: 1.2-3.1) in 
82 survivors, 28 (35%) progressed to CKD (stage 3: 25, stage 4: 2, and stage 5: 1). Mild 
AKI occurred in 29 patients during colistin treatment, one patient needed dialysis and 22 
progressed to CKD. Independent predictors of colistin-associated progression to CKD in 
a logistic regression analysis were AKI (odds ratio [OR]: 32.0; 95% confidence interval 
[CI]: 6.0-87.0), colistin cumulative dose >5 g (OR: 16.0, 95% CI: 2.6-95.0), and age (OR: 
1.1, 95% CI: 1.0-1.05).
Conclusions: Patients treated with intravenous colistin had a substantial risk for 
CKD.  Therefore, they should be tightly monitored when cumulative dose is >5 g and 
AKI is identified.
Table1. Bivariate analyses on factors associated with progression to CKD
Characteristic 
Patients without 
progression to CKD 
(n=54) 
Patients with progression 
to CKD 
(n=28)
p value 
Age, y (IQR) 38 (25-54) 59 (25-72) 0.024 
Male gender, n (%) 25 (47) 15 (53) 0.580
Baseline SCr, mg/dL 
(IQR) 0.6 (0.5-0.7) 0.7 (0.5-0.9) 0.200
SOFA, score (IQR) 4 (2-5) 4 (3-5) 0.420
Colistin dose, mg/kg 4 (4-5) 4 (3-5) 0.290
Diabetes, n (%) 3 (6) 6 (21) 0.058
AKI, n (%)* 7 (13) 22 (78) 0.001
Colistin cumulative 
dose, g (IQR) 3.8 (2.1-4.9) 6 (3.9-8.4) 0.001
Final eGFR, mL/
min/1.73m2 (IQR) 101 (72-130) 55 (37-64) 0.001
*According to KDIGO
TH-PO585
High-Density Lipoprotein Subfractions and Their Oxidized Subfraction 
Particles in Patients with Chronic Kidney Disease  Hirokazu Honda,1 Tsutomu 
Hirano,2 Masashi Ueda,3 Shiho Kojima,3 Shinichi Mashiba,3 Yasuyuki Hayase,3 
Tetsuo Michihata,4 Takanori Shibata.5  1Div of Nephrology, Dept of Medicine, 
Showa Univ Koto Toyosu Hospital, Tokyo, Japan; 2Div of Diabetes, Metabolism, 
and Endocrinology, Dept of Medicine, Showa Univ School of Medicine, Tokyo, 
Japan; 3Ikagaku Co. Ltd., Kyoto, Japan; 4Ebara Clinic, Tokyo, Japan; 5Div of 
Nephrology, Dept of Medicine, Showa Univ school of Medicine, Tokyo, Japan.
Background: Chronic kidney disease (CKD) may lead to reduced concentrations of 
high-density lipoprotein (HDL) and its subfractions (HDL2 and HDL3), and damage them 
via inflammation and oxidative stress. The present study aimed to determine the contribution 
of such changes to cardiovascular disease (CVD) in patients with CKD.
Methods: Levels of total cholesterol, low-density lipoprotein cholesterol, HDL-C, 
HDL2, HDL3, apolipoproteins, malondialdehyde-modified LDL (MDA-LDL), oxidized 
(ox) HDL, oxHDL2 and oxHDL3 were measured in blood samples from patients with CKD 
(stages 2 – 5, n = 86) who were not on dialysis and from patients undergoing hemodialysis 
(CKD stage 5D, n = 25). The patients were followed up for 28 ± 9 months after baseline 
examinations and CVD events were recorded.
Results: Levels of HDL3 and ApoA1 in HDL3 fraction decreased according to CKD 
severity, whereas those of HDL2 and ApoA1 in HDL2 fraction did not differ. Levels 
of oxHDL were similar across CKD stages. Levels of oxHDL3 and MDA-LDL were 
decreased, whereas those of oxHDL2 increased according to CKD severity. Multivariate 
analyses using the Cox proportional hazards model selected high levels of oxHDL and its 
subfractions, and those adjusted with HDL-C and HDL subfractions or ApoA1 in HDL 
fractions respectively, compared with HDL-C and HDL subfractions or ApoA1 in HDL 
fractions alone as independent risk factors for CVD events.
Conclusions: Levels of HDL subfractions and their oxidized subfraction particles 
differed among patients with CKD. Increasing levels of oxHDL subfractions might cause 
a high frequency of CVD events in those patients.
TH-PO586
The Relevance of Systolic Blood Pressure to Vascular Disease in Chronic 
Kidney Disease Patients with and without Vascular Disease: Observations 
from the Study of Heart and Renal Protection (SHARP)  Parminder K. Judge, 
William G. Herrington.  On behalf of the SHARP Collaborative Group. CTSU, 
Univ of Oxford.
Background: Confounding by prior disease may distort associations between systolic 
blood pressure (SBP) and disease outcomes in people with chronic kidney disease (CKD), 
causing uncertainty about the effect of low SBP on vascular risk in advanced CKD. 
Measurement of troponin may allow confounding by subclinical cardiac disease to be 
reduced.
Methods: SHARP randomized 9270 people with CKD. Over 5 years, SBP and clinical 
outcomes were recorded at baseline and at 6 monthly intervals. Cox regression, adjusted for 
relevant confounders, was used to assess the relevance of usual SBP to vascular outcomes. 
Analyses were stratified by baseline vascular disease (defined as self-reported vascular 
disease or troponin-I >0.01 ng/mL).
Results: Overall, there was a “U”-shaped association between usual SBP and vascular 
risk. Among the 4075 participants without baseline vascular disease, there was a log-linear 
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association: each 20 mmHg higher usual SBP was associated with an average 65% increase 
in risk of vascular events (adjusted hazard ratio [HR] 1.65, 95% confidence interval 1.29-
2.12) and 2-fold increased risk of vascular death (HR 2.03,1.20-3.42). By contrast, among 
the 4603 participants with baseline vascular disease, the associations between usual SBP 
and vascular events (HR 1.15,1.00-1.32; p for heterogeneity=0.01) and vascular death (HR 
1.07,0.85-1.35; p for heterogeneity=0.03) were significantly weaker. There was no clear 
association between usual SBP and non-vascular mortality (HR 0.96,0.82-1.13), irrespective 
of history of prior vascular disease.
Conclusions: In CKD, the “U”-shaped relationship between usual SBP and vascular 
risk appears to be explained by confounding by vascular disease. Trials to assess the effect 
of lower than currently recommended SBP targets are indicated.
Funding: Pharmaceutical Company Support - Merck/Schering-Plough 
Pharmaceuticals(North Wales,PA,USA), Government Support - Non-U.S.
TH-PO587
Serum Triglyceride Levels during Progression to ESRD and Early 
Dialysis Mortality among U.S. Veterans: A Transition of Care in CKD 
Study  Elani Streja,1 Melissa Soohoo,1 Connie Rhee,1 Yoshitsugu Obi,1 Jennie 
Jing,1 Danh V. Nguyen,1 Moti L. Kashyap,1,2 Csaba P. Kovesdy,3 Kamyar 
Kalantar-Zadeh.1  1UC Irvine; 2UTHSC; 39A Long Beach.
Background: High triglyceride (TG) levels are an established cardiovascular risk factor 
in the general population. In a study of non-dialysis dependent chronic kidney disease, 
higher TG levels (<200 mg/dL) were associated with higher mortality risk, whereas other 
data show that patients with low TG levels (<115 mg/dL) have even higher mortality risk. 
The impact of TG levels in the prelude period immediately preceding transition to dialysis 
on early post-transition outcomes is not known.
Methods: In a cohort of 52,172 US veterans who transitioned to dialysis between 
October 2007 and September 2011, we identified 15,345 patients with available TG 
measurements within the last 6 month prelude period (preceding dialysis transition). We 
examined the association of TG (averaged over 6 months) as a continuous predictor of 
early all-cause mortality (within the first 3 months post-transition), using restricted cubic 
spline analysis and Cox models adjusted for age, sex, race, ethnicity, cause of ESRD, and 
region of residence.
Results: The mean±SD age was 69±11 years, among whom 27% were African-
American, 7% were of Hispanic, and 51% had diabetes listed as their primary cause of 
ESRD. The 6-month averaged prelude TG showed an inverse linear association with post 
ESRD mortality risk, in which patients with TG<115mg/dL had a higher risk of mortality 
and patients with TG³115mg/dL had comparatively better survival.
Conclusions: Among veterans transitioning to dialysis, higher TG levels were 
associated with lower risk of early post-ESRD mortality. Further studies are needed to 
investigate underlying mechanisms and to determine how lipid-modulating treatments 
influence these associations.
Funding: NIDDK Support
TH-PO588
Initiation of Statins for Chronic Kidney Disease Patients in the Veterans 
Affairs Health System  Sai Hurrish Dharmarajan,1 Rajesh Balkrishnan,4 Kara 
Zivin,1 Tanushree Banerjee,2 Neil R. Powe,2 Nilka Rios Burrows,3 Rajiv Saran,1 
Sundar Shrestha.3  1Univ of Michigan, Ann Arbor, MI; 2Univ of California, San 
Francisco, CA; 3Centers for Disease Control and Prevention, Atlanta, GA; 
4Univ of Virginia, Charlottesville, VA.
Background: The 2013 Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines recommend cholesterol-lowering treatment with statins for Chronic Kidney 
Disease (CKD) patients aged 50 years or older, and those aged 30-49 years with elevated 
risk of cardiovascular disease (CVD). We investigated the predictors of statin initiation in 
a cohort of CKD patients in the Veterans Affairs Health System between 2010 and 2012.
Methods: Our sample included patients with at least one outpatient visit with a serum 
creatinine value in 2010 or 2011. Patients were categorized into five stages of increasing 
severity based on estimated glomerular filtration rate (eGFR). A cohort of these patients 
not using statins in the baseline year (2010 or 2011) were identified and followed in the 
subsequent year (2011 or 2012) to determine statin initiation. A multivariate logistic 
regression model was used to examine the socio-demographic and comorbidity related 
predictors of statin initiation.
Results: Our sample included 1,676,215 patients in 2010 and 1,778,655 patients in 
2011. Of these, 8.77 % in 2010 and 9.48 % in 2011 initiated statins in the subsequent year. 
The most significant predictors of statin initiation were diagnosis of CVD in the prior year 
(adjusted Odds Ratio-aOR: 2.46, 95% CI: 2.43 – 2.49) and diabetes mellitus (aOR: 1.94, CI: 
1.92 – 1.95). Using patients with eGFR>90ml/min/1.73m2 (Stage 1) as reference, CKD Stage 
3 patients had a higher odds (aOR: 1.24, CI: 1.23 – 1.26) of statin initiation, in comparison 
to stage 4 (aOR: 0.87, CI: 0.83 – 0.91) and stage 5 (aOR: 0.33; CI: 0.29 – 0.38) patients.
Conclusions: CVD and diabetes were the most influential predictors of statin initiation 
in CKD patients in a large cohort of U.S. Veterans. Statin initiation appeared to be lowest 
in patients with CKD Stage 4 and 5. Future research will consider adherence to statin 
prescription and its association with CKD progression.
Funding: Other U.S. Government Support
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Association of Urine Kidney Injury Biomarkers with Risk of Cardiovascular 
Events in CRIC  Meyeon Park,1 Chi-yuan Hsu,1 Alan S. Go,2 Dawei 
Xie,3 Xiaoming Zhang,3 Sushrut S. Waikar,4 Joseph V. Bonventre,4 Josef 
Coresh,5 Robert G. Nelson,6 Harold I. Feldman,3 Paul L. Kimmel,6 Vasan 
S. Ramachandran,7 Kathleen D. Liu.1  1UCSF; 2Kaiser Permanente; 3U. of 
Pennsylvania; 4Brigham and :omen¶s Hospital; 5Johns Hopkins Univ; 6NIH 
NIDDK; 7Boston Univ.
Background: Chronic kidney disease (CKD) is an important risk factor for 
cardiovascular disease (CVD). We investigated whether kidney injury biomarkers were 
associated with increased risk of atherosclerotic and non-atherosclerotic CVD events in 
the Chronic Renal Insufficiency Cohort (CRIC) study.
Methods: Urine kidney injury molecule-1 (KIM-1), neutrophil gelatinase associated 
lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), and liver fatty acid-binding 
protein (LFABP) were measured in 2466 CRIC subjects in CRIC. Cox proportional hazards 
models were used to examine the associations between biomarkers indexed to urinary 
creatinine and heart failure (HF) or a composite of CVD events (myocardial infarction, 
ischemic stroke, or peripheral artery disease).
Results: Mean age of study subjects was 59.5 (± 10.8) years; 46% were women, 50% 
had diabetes mellitus, and 34% had history of cardiovascular disease. NGAL/Cr, NAG/
Cr and LFABP/Cr were associated with HF and CV events in unadjusted models, but not 
in multivariable adjusted models (accounting for baseline eGFR, albuminuria, age, sex, 
race, comorbidities, and medications). Those in the highest two quintiles [Q5 (>2990.3 
pg/g) and Q4 (>1830.9 pg/g)] of KIM-1/Cr levels had an increased risk of HF relative to 
the lowest quintile (Q1, <661.3 pg/g) [Q5 v. Q1 hazard ratio (HR) 1.7 (1.1-2.9); Q4 v. Q1 
HR 1.6 (1.0-2.6)]. KIM-1/Cr was not independently associated with HF in the continuous 
analysis [HR per log SD increase 1.14 (0.98-1.33)]. Higher KIM-1/Cr was independently 
associated with CVD events in the continuous analysis [HR per log SD increase 1.21 
(1.02-1.41)] after adjustment for confounders.
Conclusions: Select urine biomarkers of kidney injury were independently associated 
with increased risk of HF and CVD events.
Funding: NIDDK Support
TH-PO590
Cystatin C as a Predictor for Mortality in Elderly Patients with Chronic 
Kidney Disease  Sebastjan Bevc,1 Nina Hojs,1 Masa Knehtl,1 Robert Ekart,2 
Radovan Hojs.1  1Clinic for Internal Medicine, Dept of Nephrology, Univ Clinical 
Centre Maribor, Slovenia; 2Clinic for Internal Medicine, Dept of Dialysis, Univ 
Clinical Centre Maribor, Slovenia.
Background: The prevalence of chronic kidney disease (CKD) in the elderly is 
high. Serum cystatin C, an accurate marker of estimation of kidney function have also 
prognostic utility in CKD patients.The aim of our study was to determine the prediction 
for mortality of different markers for estimation of kidney function on long-term survival 
in elderly CKD patients.
Methods: 103 adult Caucasian patients, older than 65 years (56 women, 47 
men; mean age 72.5 years; range from 65 to 86 years), were included. In each patient 
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51CrEDTA clearance, serum creatinine (IDMS traceable method), serum cystatin C 
(immunonephelometric method) and eGFR using the CKD-EPI creatinine formula were 
determined on the same day and then followed for 10 years or until patient’s death.
Results: The mean 51CrEDTA clearance was 52.2±15.9 ml/min/1.73m2, mean serum 
creatinine 142.1±41.9 µmol/l, mean serum cystatin C 1.79±0.6 mg/l, CKD-EPI creatinine 
formula 39.7±12.9 ml/min/1.73m2, respectively. In the follow up period of 10 years 60 
(61.2%) of our elderly CKD patients (32 men and 28 women) died. Cox regression analysis 
showed different hazard ratios (HR): for 51CrEDTA clearance HR 0.963 (95% CI 0.592-
0.778; P=0.015), serum creatinine HR 1.012 (95% CI 1.007-1.018; P=0.0001), serum 
cystatin C HR 1.611 (95% CI 1.234-2.105; P=0.0001), CKD-EPI creatinine formula HR 
0.957 (95% CI 0.933-0.981; P=0.0001).
Conclusions: Our results indicate that serum cystatin C values at the beginning of 
follow-up are better in predicting the outcome of elderly CKD patients than other markers 
for estimation of kidney function.
TH-PO591
The Relationship Between Neutrophil to Lymphocyte Ratio and 
Cardiovascular Disease in Patients with Chronic Kidney Disease  Dede Sit, 
Hasan Kayabasi, Emel Gokmen, Zehra Sucuoglu, Serhat Sigirci, Suleyman 
Yildirim, Bennur Esen, Saadet Pilten guzel.  Bagcilar Training & Research 
Hospital, Istanbul, Turkey.
Background: Neutrophil to lymphocyte ratio (NLR) is a new, widely-easily available, 
inexpensive marker calculated from complete blood count is a new addition to the 
inflammatory markers. In many studies it has been established that NLR is associated 
with CVD. In this study we evaluated the relationship between NLR and CVD in patients 
with predialysis CKD.
Methods: In total 172 predialysis CKD patients who were undergone coronary 
angiography for CAD where studied. GFR of all patients were calculated using MDRD 
formula, and according to eGFR, the patients were divided into stage 1-5 CKD via K/DOQI 
guidelines. The patients were divided into two groups as angiography positive and negative 
group for coronary artery disease. Demographic, biochemical, hematological parametrs 
and NLR of pateints were compared.
Results: The mean age of patients was 65.06±10.53 years, 119 were male, and 53 
were female. Accorgding to eGFR 16 were stage 1, 75 were stage 2, 46 were stage 3, 17 
were stage 4 and 18 were stage 5. There was a statistically significant difference in NLR 
between twoo groups. In patients with CAD NLR was higher than in patients without CAD 
(p<0.01). All parameters of patients were detailed in table 1.
Table 1: Comparison of the parameters of patients according to CAD 
CAD
No Yes p 
Calcium 9,09±0,73 8,6±0,65 0,002
Phosphorus 3,93±1,39 3,79±1,42 0,415
CaxP 35,63±12,37 32,69±12,14 0,195
PTH 156,45±144,7 328,87±476,18 0,238
Albumin 4,05±0,63 3,66±0,5 0,002
CRP 32,26±40,16 42,49±48,58 0,348
Spot Protein/ Creatinin 815,57±1644,7 1501,05±2284,78 0,043
Neutrophil/ Lymphocyte 4,14±4,49 8,46±11,4 0,001
Conclusions: In many studies, NLR is reported as an independent predictor of outcome 
in coronary artery disease, as well as a predictor of short- and long-term mortality in 
patients with CVD. We found that NLR is significantly higher among CKD patients with 
CAD, thus we suggest that it may be used as a new marker to investigate CAD and its 
results in CKD population.
Funding: NIDDK Support
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Change in Skin Autoflourescence Over One Year Predicts Mortality at Five 
Years in a Prospective Cohort of People with Chronic Kidney Disease Stage 
3  Adam Shardlow,1,2 Natasha Juliette Mcintyre,1 Richard J. Fluck,1 Christopher 
W. McIntyre,3 Maarten W. Taal.1,2  1Renal Medicine, Royal Derby Hospital, 
Derby, United Kingdom; 2Faculty of Medicine and Health Sciences, Univ of 
Nottingham, Nottingham, United Kingdom; 3London Health Sciences Centre, 
London, 2N, Canada.
Background: Tissue advanced glycation end product (AGE) accumulation is a marker 
of cumulative metabolic stress assessed by a simple non-invasive measurement of skin 
autofluoresence (SAF). This has been shown to predict mortality in haemodialysis patients 
and in earlier CKD in some studies, but the impact of change in SAF over time has not 
previously been reported. In this study we sought to investigate the associations of SAF 
and change in SAF over time with mortality in people with CKD stage 3.
Methods: 1741 people with CKD 3 (confirmed by two eGFR values) were recruited 
from primary care. Participants attended for baseline, year 1 and year 5 study visits and 
underwent clinical assessment, blood and serum biochemistry. SAF was recorded at each 
visit. Dates of death were collected from hospital and national records.
Results: At baseline mean eGFR was 53.5 ml/min/1.73m2, mean age 73 years and 
mean SAF 2.7 arbitrary units. There was a small decrease in mean SAF after 1 year (-0.1 
arbitrary units; p<0.001) but 310 (20.1%) participants evidenced an increase of >10%. 299 
(17.2%) participants died prior to the year 5 study visit. Cox proportional hazards showed 
that both baseline SAF (HR 1.38) and change in SAF (HR 1.53) over the first year were 
independent determinants of mortality at 5 years in addition to age (HR 1.77), male gender 
(HR 1.53), baseline eGFR (HR 0.98) and previous cardiovascular disease (HR=1.56). In a 
sensitivity analysis of participants without diabetes, change in SAF at 1 year remained an 
independent determinant of mortality (HR 1.5), adjusted for age, gender, baseline eGFR, 
previous cardiovascular disease and baseline SAF.
Conclusions: Our data show for the first time that an increase in SAF over 1 year is 
an independent predictor of mortality in CKD stage 3 in addition to baseline SAF. Serial 
measures of SAF may therefore be useful in predicting risk and monitoring interventions 
for reducing AGE accumulation.
Funding: Private Foundation Support
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Fibroblast Growth Factor 21 Plasma Levels and Future Cardiovascular 
Outcome Among Non-Dialysis Chronic Kidney Disease Patients 
Lucie Bauer,1 Kyrill S. Rogacev,1 Adam M. Zawada,1 Sarah Seiler,1 Insa E. 
Emrich,1 Kevin L. Duffin,2 James R. Voelker,2 Matthew D. Breyer,2 Danilo 
Fliser,1 Gunnar H. Heine.1  1Internal Medicine IV - Nephrology and Hypertension, 
Saarland Univ Medical Center and Saarland Univ Faculty of Medicine, 
Homburg, Saarland, Germany; 2(li Lilly and Company, Indianapolis, IN.
Background: Patients with chronic kidney disease have substantial metabolic 
alterations, which comprise insulin resistance, hypertriglyceridemia and low HDL-
cholesterolemia. Fibroblast Growth Factor 21 (FGF-21) is a recently discovered hormone 
which is a central regulator of glucose and lipid metabolism. We examined the effects 
of chronic kidney disease (CKD) on circulating plasma FGF-21 concentration, and the 
association of plasma FGF-21 with incident cardiovascular disease.
Methods: We analyzed plasma FGF-21, along with traditional cardiovascular and 
renal risk factors, in 441 CKD G2 – G4 patients who were recruited into the prospective 
CARE FOR HOMe cohort. Plasma adiponectin (total and subfractions) were measured 
in 339 patients. All patients were followed for the occurrence of cardiovascular events; 
defined either as atherosclerotic (acute myocardial infarction, stroke, amputation above 
the ankle, any surgical or interventional coronary/cerebrovascular or peripheral-arterial 
revascularization, or death of any cause) or as cardiac events (admission for heart failure, 
or death of any cause).
Results: Baseline plasma FGF-21 correlated with higher age (r=0.114), body mass 
index (r=0.116), waist-hip-ratio (r=0.113), triglycerides (r=0.292) and CRP (r=0.149), as 
well as with lower eGFR (r=-0.272) and HDL (r=-0.134, all p<0.001), but not with total 
adiponectin or adiponectin subfractions. In univariate Kaplan-Meier-analyses, higher 
quartiles of baseline FGF-21 were associated with future atherosclerotic (p=0.001) and 
cardiac (p<0.001) events. However this association lost statistical significance after 
adjustment for eGFR.
Conclusions: Our study results demonstrate an increase of plasma FGF-21 levels in 
CKD patients. Despite its role in glucose and lipid metabolism, plasma FGF-21 does not 
independently predict adverse cardiovascular outcome among CKD patients.
TH-PO594
Graded Increases in Cardiac Biomarkers Across Advancing CKD Stages 
Elizabeth K. Batchelor, Gates Colbert, Nishank Jain, Beverley Adams-Huet, 
Xilong Li, James Delemos, Susan Hedayati.  UT Southwestern and VA North 
Texas Medical Centers, Dallas, TX.
Background: Elevated cardiac troponin T (cTnT) ³10 ng/L is reported in 80% of 
ESRD patients and associated with poor outcomes. There are less data on whether cardiac 
biomarkers are elevated in non-dialysis CKD patients.
Methods: We investigated whether cTnT, high sensitivity cTnT (hs-cTnT), brain 
natriuretic peptide (BNP), and N-terminal-pro-BNP (NT-pro-BNP) levels increase with 
worsening CKD in 3,298 asymptomatic, multi-ethnic participants of the Dallas Heart Study.
Results: Mean age was 44±10 years. 55% were female, 50% Black, 31% Caucasian, 
17% Hispanic, and 2% other races. 288 had CKD, defined as eGFR<60 mL/min/1.73 m2 
or albumin-to-creatinine ratio ³17 mg/g in men or ³25 in women. Of those with CKD, 37% 
had diabetes mellitus and 66% hypertension vs. 10% and 33% if without CKD, p<0.05. A 
higher proportion of CKD vs. non-CKD individuals, 8.0 vs. 0.43%, had elevated cTnT ³10 
ng/L and hsTnT ³3 ng/L, 58.3 vs. 24.2%, p<0.0001 for both. Mean BNP was 55.5±314.8 in 
CKD vs. 10.9±32.5 pg/mL in non-CKD, and NT-pro-BNP was 319.7±1225.7 in CKD vs. 
53.4±117.5 pg/mL in non–CKD (p<0.0001 for both). There were graded increases in the 
proportion with elevated troponins as CKD severity increased across stages. 
Group N (Total=288) cTnT hs-cTnT
% ≥10 ng/L % ≥3 ng/L 
CKD 1 143 3.5 47.6
CKD 2 76 5.3 61.8
CKD 3 59 15.3 74.6
CKD 4/5 10 50.0 90.0
P <0.0001 <0.0001
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The same was seen with BNP and NT-pro-BNP levels, with the highest increases in 
those with eGFR<30. 
Conclusions: A higher proportion of CKD vs. non-CKD individuals had elevated 
cardiac biomarkers, even at early CKD stages. Graded increases in biomarkers were 
observed across advancing stages. Further research should determine if higher cardiac 
biomarker cutoffs are warranted to improve diagnostic and prognostic utility in CKD 
patients.
Funding: Other NIH Support - UL1TR001105 from the National Center for 
Advancing Translational Sciences, National Institutes of Health.  M01-RR00633 from 
NIH/NCRR-CR., Veterans Administration Support, Private Foundation Support
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Circulating Endothelial Cells and Cardiovascular Risk in Chronic Kidney 
Disease and Hemodialysis Patients  Yasser Ahmed Nienaa,1 Nahla Mohamed 
gamal Farahat,2 Iman Ezzat Elgohary,1 Marwa Fathy Oraby.1  1Internal Medicine- 
Nephrology Unit, Faculty of Medicine, Alexandria, Egypt; 2Clinical and 
Chemical Pathology, Faculty of Medicine, Alexandria, Egypt.
Background:  This work was conducted with the aim to study circulating endothelial 
cells in CKD patients and correlate this with some cardiovascular risk factors.cardiovascular 
disease remains the leading cause of morbidity and mortality in patients with CKD and 
may account for 50% of all deaths. Endothelial dysfunction is commonly observed along 
the CKD spectrum. Endothelial dysfunction is a well-documented early phenomenon in 
atherosclerosis that precedes structural changes and clinical manifestations. The chronic 
micro inflammation state present in uremia has been proposed as one of the mechanisms 
causing endothelial dysfunction. Inflammatory circulating endothelial cells (CECs) are 
thought to be mature cells that have detached from the intimal mono layer in response 
to endothelial injury. In humans, elevated levels were reported in various cardiovascular 
disorders, as a result of mechanical injury, ischemic injury or hypertension.
Methods: This study included 50 subjects classified as follows:Group I 20 patients with 
CKD not yet on dialysis, group II 20 patients on maintenance hemodialysis and 10 age and 
sex matched individual used as a control (groupIII). All included individual were subjected to 
complete blood count, renal function tests, estimation of GFR by MDRD formula, complete 
lipid profile, high sensitive CRP, ESR and detection of CEC count using flow cytometry.
Results: The study showed increased count of CEC and hs CRP in both CKD groups 
than the control and it was higher in patients on dialysis than those on conservative treatment. 
There was a statistically positive correlation between ESR, hs CRP,TG and CECs in the 
three groups, there was also a statistically negative correlation between estimated GFR 
and CECs in the three groups.
Conclusions: Measurement of CECs count might offer a mean for recognizing CKD 
patients at risk of cardiovascular events.
TH-PO596
The Association Between Soluble Klotho and Cardiac Parameters in 
Chronic Kidney Disease: Korean CKD Patients  Hyo Jin Kim,1 Kyung 
don Ju,1 Tsogbadrakh Bodokhsuren Bodokhsuren,1 Seungmi Lee,1 Aram Lee,1 
Shin-Young Ahn,2 Dong-Wan Chae,2 Ho Jun Chin,2 Curie Ahn,1 Kook-Hwan 
Oh.1  1Internal Medicine, Seoul National Univ College of Medicine, Seoul, 
Korea; 2Internal Medicine, Seoul National Univ Bundang Hospital, Seongnamsi, 
Gyeonggi-do, Korea.
Background: Klotho is one of mineral metabolism regulator in chronic kidney 
disease (CKD). Bone mineral metabolism is important in CKD and it is associated with 
cardiovascular (CV) complications. We investigated factors determining soluble klotho 
concentration and the association between klotho and cardiac parameters from Korean 
CKD patients.
Methods: We analyzed 1,443 CKD patients with soluble klotho at baseline from the 
prospective KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease 
(KNOW-CKD) study. Left ventricular hypertrophy (LVH) and arterial stiffness were 
explored as CV parameters. LV mass index (LVMi) was used as a maker of LVH (male > 
115 g/m3, female > 95 g/m3). Brachial-to-ankle pulse wave velocity (baPWV) was used 
as a marker of arterial stiffness. Renal outcome (initiation of renal replacement therapy or 
decline of estimated glomerular filtration rate ≥50% or doubling of creatinine) or composite 
outcome (renal outcome or death) were analyzed for association soluble klotho level.
Results: Patients were 53.5 ± 12.4 years old and 61.5% were male. In a multivariable 
linear regression analysis, uric acid and log CRP were positively and hemoglobin was 
inversely associated with klotho. LVH (OR 0.46; 95% CI, 0.25 to 0.85; P = 0.014) and 
baPWV (Pearson correlation, -0.099; P = 0.001) were associated with klotho in univariate 
analysis. However, in multivariable analysis, klotho was not independently associated with 
LVH and baPWV. 887 (61.5%) patients were investigated for association between klotho 
and outcomes (23.3+4.7 months follow-up). Analyzed by Cox proportional hazard model, 
klotho was not associated with renal or composite outcomes.
Conclusions: Soluble klotho was not an independent determining factor for LVH, 
arterial stiffness, and renal outcomes. Further studies are warranted to elucidate the clinico-
pathogenic significance of klotho in Korean CKD patients.
Funding: Government Support - Non-U.S.
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Elevated C-Reactive Protein, and Albuminuria Increase Mortality Risk in 
Metabolic Syndrome Patients  Satyesh K. Sinha,1 Magda Shaheen,1 Deyu Pan,1 
Keith C. Norris,2 Susanne B. Nicholas.2  1Charles R DreZ Univ, Los Angeles, 
CA; 2David Geffen School of Medicine, UCLA, Los Angeles, CA.
Background: Metabolic syndrome (MetS) is a serious health condition affecting 
nearly 25% of adults in the United States and places them at higher risk of cardiovascular 
disease (CVD), chronic kidney disease, and mortality.Studies have shown that the MetS is 
associated with albuminuria (urinary albumin excretion [UAE] >30ug/ml). Inflammation 
has been posited as an important link between the MetS and UAE. However, little is known 
about the added value of UAE and C-reactive protein (CRP) in predicting mortality in 
patients with the MetS. Therefore, the study objective was to determine the relationship 
between mortality and the MetS, after adding both CRP & UAE as additional components.
Methods: We analyzed data from the National Health and Nutrition Examination 
Surveys 1999-2004 of 5,930 adults aged ³20 years with and without MetS (=>3 components 
of the MetS according to the definition of National Cholesterol Education Program’s Adult 
Treatment Panel III). We added elevated CRP and UAE as a 6th and 7th criteria, respectively 
for the MetS. We analyzed data using Cox regression to estimate the hazard ratio (HR) for 
mortality, controlling for demographics, smoking, and CVD. Data are presented as HR, 
and 95% confidence interval (CI); p<0.05 was statistically significant.
Results: In the adjusted model, the MetS was not associated with mortality. However, 
HR for mortality was high with elevated CRP (>0.5 mg/dl; HR=1.84, 95% CI 1.45-2.35, 
p<0.001) and albuminuria (HR=1.89, 95% CI 1.36-2.63, p<0.001) compared to low CRP 
(<0.5 mg/dl) and no albuminuria (UAE<30 ug/ml). With addition of elevated CRP to the 
MetS, HR for mortality was high (HR=1.36, 95% CI 1.05-1.77, p<0.02) vs. low CRP 
and no MetS. HR for mortality was high when albuminuria was also added to MetS with 
elevated CRP (HR=1.52, 95% CI 1.12-2.06, p<0.01).
Conclusions: We conclude that elevated CRP and UAE may predict the group at high 
risk for mortality in MetS patients.
Funding: Other NIH Support - NIH grant U54MD007598, UL1TR000124, and S21-
MD-000103.
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Longitudinal Change in Low-Grade Albuminuria Is a Better Predictor of 
Cardiovascular Disease Than Change in Serum Uric Acid: The Tromsø 
Study  Marit D. Solbu,1,2 Bjorn Odvar Eriksen,1,2 Toralf Melsom,1,2 Hilde Merete 
Storhaug,2 Jon viljar Norvik,2 Trond G. Jenssen.2,3  1Section of Nephrology, Univ 
Hospital of North Norway, Tromsø, Norway; 2Metabolic and Renal Research 
Group, UiT the Arctic Univ of North Norway, Tromsø, Norway; 3Oslo Univ 
Hospital, Oslo, Norway.
Background: Serum uric acid (SUA) and albuminuria are independent risk factors 
for cardiovascular disease (CVD), but the joint impact of longitudinal changes in SUA and 
albuminuria on clinical events is unknown. We assessed the associations between change 
in SUA and urinary albumin-creatinine ratio (ACR) over 7 years and the occurrence of 
incident myocardial infarction, ischemic stroke and all-cause mortality.
Methods: We included 3931 participants without CVD from the population-based the 
Tromsø Study; Tromsø 4 (1994/95) and Tromsø 5 (2001/02). SUA change was categorized 
into four groups according to upper (high) versus the three lower (low) gender specific 
quartiles of SUA in Tromsø 4 and 5; persistently high, decreasing , increasing, and 
persistently low SUA. ACR change was categorized the same way. Percentage of change 
from baseline in SUA and ACR was calculated.
Results: During follow-up (median 9.3 years for CVD; 11.3 years for mortality) there 
were 379 myocardial infarctions, 223 strokes and 869 deaths. In multivariable analyses 
increasing ACR predicted mortality (HR 1.65; 95% CI 1.38-1.96). Persistently high ACR 
predicted myocardial infarction (HR 1.34; 95% CI 1.03-1.75) and stroke (HR 1.79; 95% 
CI 1.28-2.51). Increasing and persistently high SUA did not predict any endpoint. A ≥50% 
increase in ACR from baseline predicted myocardial infarction and death, whereas ³15% 
increase in SUA did not. Change in SUA and ACR did not interact in their association with 
CVD. Baseline SUA significantly predicted stroke and mortality.
Conclusions: Longitudinally increasing ACR predicted CVD independently from SUA 
change. Baseline, but not changes in SUA predicted stroke and mortality. This may have 
implication for the use of change patterns in risk assessment.
Funding: Government Support - Non-U.S.
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TH-PO599
Transient Dipstick-Proteinuria Could Be a Risk of Cardio-Vascular 
Diseases  Kei Nagai,1 Kunihiro Yamagata,1 Toshiaki Usui,1 Koichi Asahi,2 
Kenjiro Kimura,2 Kunitoshi Iseki,2 Toshiki Moriyama,2 Ichiei Narita,2 
Shouichi Fujimoto,2 Kazuhiko Tsuruya,2 Tsuneo Konta,2 Masahide Kondo,2 
Tsuyoshi Watanabe.2  1Univ of Tsukuba; 2Steering Committee for ‘Design of 
the Comprehensive Health Care System for CKD Based on the Individual Risk 
Assessment by Specific Health Checkups.
Background: Dipstick-proteinuria is the major method to detect high-risk participants 
for cardiovascular diseases (CVD). A large part of positive dipstick-proteinuria has gone 
to negative in the next year, which means transient proteinuria. The aim of this study is to 
clarify whether transient proteinuria is a risk of CVD comparing to sequentially negative 
proteinuria with one-year interval measurement.
Methods: By using a population-based 339,172 persons longitudinal cohort receiving 
annual health checkups sequentially twice or more, we examined presence of dipstick-
proteinuria both at baseline year and in the next year. Medical history of CVD was obtained 
via a self-reported questionnaire. The incidence of CVD event in this study was defined as a 
negative history at the baseline year and a positive history in the follow-up year. Proteinuria 
was defined as (+) or more.
Results: Forty-five percent of subjects with positive proteinuria at baseline year in male 
and 58% of those in female have gone to negative proteinuria in the next year. 
Proteinuria in the next year Subtotal
At baseline year Negative Positive % per Total
119,020 95.7% 5,317 4.3% 94.0%
3,571 45.3% 4,301 54.7% 6.0%
195,925 97.5% 4,986 2.5% 97.1%
3,538 58.5% 2,514 41.5% 2.9%
Subjects with proteinuria have higher risk of CVD than those with sequentially negative 
proteinuria as reference (hazard ratio [HR] and 95% confidential intervals [CI], 1.58 [1.38-
1.81] in male and 1.55 [1.32-1.81] in female). 
Conclusions: Transient proteinuria could be a risk of the incidence of CVD.
TH-PO600
Urinary Phosphate Excretion Modifies the Association Between Serum 
Osteoprotegerin and Coronary Calcification in CKD: KNOW-CKD Study 
Young Youl Hyun,1 Kyu-Beck Lee,1 Hyang Kim,1 Kook-Hwan Oh,2 Curie Ahn,2 
Dong-Wan Chae,3 Yong-Soo Kim,4 Wookyung Chung,5 Young-Hwan Hwang,6 
Soo Wan Kim,7 Yeong Hoon Kim.8  1Sungkyunkwan Univ School of Medicine, 
Kangbuk Samsung Hospital; 2Seoul National Univ Hospital; 3Seoul National 
Univ Bundang Hospital; 4The Catholic Univ of Korea, Seoul St. Mary¶s Hospital; 
5Gachon Univ, Gil Hospital; 6Eulji General Hospital; 7Chonnam National Univ 
Medical School; 8Inje Univ, Pusan Paik Hospital.
Background: High serum osteoprotegerin (OPG) is closely related to coronary 
calcification, but the exact mechanism is not known well. To understand the underlying 
pathophysiology, we explored whether this association between OPG and coronary 
calcification is modified by 24-hr urinary phosphate excretion (UPi) in CKD patients.
Methods: This cross-sectional study analyzed 871 participants from the KNOW-CKD 
cohort who underwent a coronary MDCT, serum OPG measurement and 24-hr urine 
collection as baseline examinations between 2011~2013. We evaluated the association 
between serum OPG and coronary artery calcium scores (CACS) in each group with low and 
high UPi. Effect modification was evaluated by an interaction term and tested by Wald test.
Results: Percentages of participants with CACS > 0 were different between OPG 
quartiles (23.4%, 41.1%, 52.5% and 78.8% for the lowest to highest quartiles of OPG, 
P<0.001). In multivariate-adjusted Tobit models, the CACS ratio (95% confidence intervals) 
comparing the highest quartile of OPG to the lowest quartile was 19.74 (4.14-94.10) in 
the low UPi group, whereas the ratio was 1.86 (0.48-7.20) in the high UPi group (P for 
interaction = 0.003). In multivariate logistic model, the odds ratio of highest quartile for 
CACS > 0 compared with lowest quartile was 6.56 (2.52-17.11) in the low UPi group, 
whereas the odds ratio was 1.65 (0.68-3.99) in the high UPi group (P for interaction = 0.006).
Conclusions: Serum OPG was associated with coronary calcification only in CKD 
patients with low UPi, but not in those with high UPi. Further studies are warranted to 
verify the role of phosphate excretion in OPG-related coronary calcification.
Funding: Government Support - Non-U.S.
TH-PO601
The Relationship of LV Mass Index and FGF-23/25(OH)D Modulating 
Phosphaturia  Shin-Young Ahn,1 Ho Jun Chin,1 Kook-Hwan Oh,2 Curie Ahn,2 
Dong-Wan Chae.1  1Internal Medicine, Seoul National Univ Bundang Hospital, 
Seongnam, Republic of Korea; 2Internal Medicine, Seoul National Univ Hospital, 
Seoul, Republic of Korea.
Background: As renal function declines, level of fibroblast growth factor-23 (FGF-
23) rise and 25-hydroxyvitamind D (25(OH)D) decrease. We evaluate the relationship 
among 25(OH)D and FGF-23 on cardiovascular risk factors such as LV mass index and 
vascular calcification (VC).
Methods: KNOW-CKD is an on-going, prospective, university hospital based 
observational cohort study under the sponsorship of Korean Center for Disease Control 
and Prevention. Cross-sectional analysis of echocardiography data and other clinical data 
was performed in 1529 participants of KNOW-CKD. The study participants were divided 
into 4 groups by FGF-23 and 25(OH)D values below and above the median.
Results: Among the 1529 study participants, the mean of age and estimated GFR were 
53.6 ± 12.4 years and 50.9 ± 31.7 ml/min/1.73m2. The median FGF-23 concentration was 
17.85 RU/ml (interquartile range [IQR] = 0.42, 31.28), and median level of 25(OH)D was 
16.52 ng/ml (interquartile range [IQR] = 13.31, 21.04). The patients who had FGF-23 
above the median but 25(OH)D below the median had highest level of serum P, iPTH, 
mean of pulse wave velocity(PWV), and LV mass index. They also had lowest level of 
hemoglobin, serum albumin, eGFR, corrected Ca, and bone mineral density of femur neck. 
After multivariate analysis, the result showed significant correlation between LV mass 
index and FGF-23/25(OH)D ratio (std β=0.176, p=0.021). Decreasing level of 25(OH)
D reduced phosphaturia caused by FGF-23. Finally vascular calcification measured by 
abdominal aorta calcification showed significant negative relationship with phosphaturia 
after multivariate analysis (stdβ=-0.095, p=0.031).
Conclusions: We observed the significant association between FGF-23/25(OH)D and 
LV mass index and FGF-23/25(OH)D and degree of phosphaturia which was correlated 
with vascular calcification. We suggest that FGF-23/25(OH)D may increase LVMI through 
modification of phosphaturia and vascular calcification.
Funding: Government Support - Non-U.S.
TH-PO602
Fractional Excretion of Phosphorus Is Independently Associated with 
Left Ventricular Hypertrophy in Chronic Kidney Disease Patients 
Xiaoyan Zhang.  Nephrology, Zhongshan Hospital, Fudan Univ, Shanghai, 
China.
Background: Left ventricular hypertrophy (LVH) is an important mechanism of 
cardiovascular disease in chronic kidney disease (CKD). Elevated Fibroblast growth 
factor-23 (FGF23) levels are independently associated with LVH. The aim of this study is 
to investigate whether elevated fractional excretion of phosphorus, as one major action of 
FGF23, is independently associated with LVH in CKD patients.
Methods: LVH was defined as LVMI (Left ventricular mass index) ≥ 50 g m–2.7 in men 
or ≥ 47 g m–2.7 in women. The fractional excretion of phosphorus (FePi [%]) was calculated 
as [urine phosphorus (mg/dl)/serum phosphorus (mg/dl)]/[serum creatinine (mg/dl)/urine 
creatinine (mg/dl)]×100.
Results: We measured FePi levels in 1,389 individuals who underwent echocardiography 
within 3 months. The median FePi level was 13.44%. The mean (± SEM) left ventricular 
ejection fraction was 67% ± 17%, left ventricular mass indexed to height2.7(LVMI) was 
42 ± 14 g m–2.7 , and LVH was present in 24% of participants. The left ventricular ejection 
fraction was lower in the highest versus the lower quartiles of FePi levels, while the LVMI 
increased with increasing FePi quartiles. Each ten percent increase in FePi was associated 
with a 2.406 g m–2.7 greater LVMI (95% CI, 2.022–2.789; P < 0.001). Each ten percent 
increase in FePi was associated with a 1.363-fold greater relative risk (RR) of eccentric 
hypertrophy and concentric hypertrophy (95% CI, 1.275–1.456; P < 0.001) compared with 
normal ventricular geometry. Multivariable analyses that adjusted for age, sex, weight, 
hypertension, diabetes, GFR, total cholesterol, total triglyceride, hemoglobin, proteinuria, 
parathyroid hormone (PTH), and serum phosphate demonstrated that elevated FePi was 
independently associated with increased LVMI (0.745 g m–2.7 greater LVMI per ten percent 
increase in FePi , 95% CI, 0.264–1.226; P < 0.01) and conferred greater risk of eccentric and 
concentric LVH (RR 1.102 per ten percent increase in FePi ; 95% CI, 1.000–1.214; P < 0.05).
Conclusions: FePi is independently associated with left ventricular hypertrophy in 
patients with CKD across a broad range of kidney function.
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TH-PO603
Clinical Significance of Vascular Calcification and Retinopathy on Renal 
and Cardiovascular Outcomes in Patients with Chronic Kidney Disease 
Hyeon Seok Hwang, Hye Eun Yoon, Yu ah Hong, Suk young Kim.  Div of 
Nephrology, Dept of Internal Medicine, College of Medicine, The Catholic 
Univ of Korea, Korea.
Background: Vascular calcification and retinopathy is the representative marker of 
macrovascular and microvascular dysfunction in patients with chronic kidney disease 
(CKD). While both of them share common pathophysiology, their relationship and combined 
effects on clinical outcome remained undetermined.
Methods: We included 523 nondialysis-dependent CKD stage 3–5 patients, who had 
been examined with fundoscopy for diabetic or hypertensive retinopathy. Simple X-ray 
images of the pelvis and the abdomen were analyzed for the presence of intimal or medial 
arterial calcifications. The clinical significance of intimal calcification and retinopathy was 
evaluated in terms of the rate of renal function decline and composite of any cardiovascular 
event or death.
Results: Intimal calcification was observed in 81 (15.5%) CKD patients, medial 
calcification in 50 (9.6%) CKD patients, and retinopathy in 258 (49.3%) CKD patients. 
The presence of retinopathy was independently associated with intimal (odds ratio 1.72, 
95% CI 1.03-2.89) and medial calcification (OR 3.41, 95% CI 1.68-6.90). The renal 
function decline rate was significantly steeper in patients with than in those without intimal 
calcification (–8.1 ± 9.4 mL/min/1.73 m2/yr vs. –4.6 ± 10.4 mL/min/1.73 m2/yr; P = 0.005). 
However, medial calcification was not associated with rapid renal function decline (P = 
0.153) In multivariate analysis, patients with both intimal calcification and retinopathy were 
independently associated with a rapid decline in renal function (β = –4.21; P < 0.001). The 
combined status of retinopathy with intimal or medial calcification independently increased 
the risk of composite events (hazard ratio 3.34, 95% CI 1.41-4.43 for intimal calcification; 
hazard ratio 3.19, 95% CI 1.62-6.28 for medial calcification).
Conclusions: Coexistence of intimal calcification and retinopathy were independently 
associated with CKD progression, and the combined status of retinopathy with intimal or 
medial calcification was an independent predictor for composite cardiovascular event/death.
TH-PO604
Abdominal Aortic Calcification in Patients with Chronic Kidney Disease 
Mieke J. Peeters,1 Jan A.J.G. van den Brand,1 Arjan D. Van Zuilen,2 Marc 
G. Vervloet,3 Peter J. Blankestijn,2 Jack F. Wetzels.1  1Nephrology, Radboud 
Univ Medical Center, Nijmegen, Netherlands; 2Nephrology, Univ Medical 
Center Utrecht, Utrecht, Netherlands; 3Nephrology, VU Univ Medical Center, 
Amsterdam, Netherlands.
Background: Abdominal aortic calcification (AAC) is independently associated with 
cardiovascular events in dialysis patients and in the general population. However, data in 
non-dialysis chronic kidney disease (CKD) patients are limited. We studied determinants 
and prognostic value of AAC in non-dialysis CKD patients.
Methods: We included patients with CKD not receiving renal replacement therapy who 
participated in the MASTERPLAN study, a randomized controlled trial that started in 2004. 
In the period 2008-2009 an X-ray to evaluate AAC was performed in a subgroup of patients. 
We studied AAC using a semi quantitative scoring system by lateral lumbar X-ray. We used 
baseline and two year data to find determinants of AAC. We used a composite cardiovascular 
endpoint and propensity score matching to evaluate the prognostic value of AAC.
Results: In 280 patients an X-ray was performed. In 79 patients (28%) the X-ray 
showed no calcification, in 62 patients (22%) calcification was minor (<4), 139 patients 
(50%) had moderate or heavy calcification (≥4). Older age, prior cardiovascular disease, 
higher triglyceride levels, and higher phosphate levels were independent determinants of 
a calcification score ≥4. AAC score ≥4 was independently associated with cardiovascular 
events, with a hazard ratio of 5.5 (95% confidence interval 1.2-24.8).
Conclusions: Assessment of AAC can identify patients at higher cardiovascular risk, 
and may provide important information for personalized treatment. Whether this approach 
will ultimately translate into better outcomes, remains to be answered.
TH-PO605
Association of Serum Chloride Level with Mortality and Cardiovascular 
Events in Chronic Kidney Disease: The CKD-ROUTE Study 
Shintaro Mandai,1 Eiichiro Kanda,2 Soichiro Iimori,1 Shotaro Naito,1 Eisei 
Sohara,1 Tomokazu Okado,1 Sei Sasaki,1 Tatemitsu Rai,1 Shinichi Uchida.1 
1Dept of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo 
Medical and Dental Univ, Tokyo, Japan; 2Dept of Nephrology, Tokyo Kyosai 
Hospital, Tokyo, Japan.
Background: Electrolyte abnormalities, particularly dysnatremias, are increasingly 
recognized as independent predictors of adverse outcomes in individuals with and without 
renal failure. However, the association of serum chloride level (Cl-) with mortality or risk 
of cardiovascular (CV) events in patients with chronic kidney disease (CKD) has yet to 
be clarified.
Methods: This prospective cohort study included 1134 pre-dialysis CKD G2-G5 
patients among the participants of the CKD Research of Outcomes in Treatment and 
Epidemiology (CKD-ROUTE) study, who newly visited 16 nephrology centers. The primary 
outcome was a composite of death of any cause and CV events, and the secondary outcome 
was death of any cause. Data were analyzed with Cox hazards model with adjustment for 
potential cofounders including serum sodium. Patients were followed up until end-stage 
renal disease, death, transfer, or the end of 3-year follow-up.
Results: Median Cl- was 106.0 mEq/L at enrollment [quartile (Q) 1: £103.9, n = 
257; Q2: 104.0–105.9, n = 258; Q3: 106.0-108.0, n = 352; Q4: ³108.1, n = 267]. During 
33 months’ median follow-up, there were 115 CV events, 78 deaths, and 180 composite 
outcomes. The hazard ratio (HR) for the composite outcome was higher for Q1 than Q3 
(unadjusted HR, 1.74; 95% confidence interval (CI), 1.16–2.61; p = 0.007; and adjusted 
HR, 1.63; 95% CI, 1.05–2.52; p = 0.029). Examined as a continuous variable in a subset of 
patients whose Cl- was £106.0, higher Cl- was associated with lower risk of the composite 
outcome (unadjusted HR, 0.88; 95% CI, 0.84–0.93; p <0.001; and adjusted HR, 0.94; 95% 
CI, 0.88–1.00; p = 0.038). The HR for all-cause mortality was also higher for Q1 than Q3 
(unadjusted HR, 2.90; 95% CI, 1.56–5.41; p = 0.001; and adjusted HR, 2.56; 95% CI, 
1.30–5.05; p = 0.007).
Conclusions: Low Cl- was associated with greater mortality and risk of CV events 
in pre-dialysis CKD patients. Low Cl- may be an additive predictor of adverse outcomes 
in CKD.
TH-PO606
Association of Urine Potassium with ESRD, Cardiovascular (CVD) 
Death, and All-Cause Mortality in Chronic Kidney Disease (CKD) 
Amanda K. Leonberg-Yoo,1 Hocine Tighiouart,2 Andrew S. Levey,1 Mark J. 
Sarnak.1  1Div of Nephrology, Tufts Medical Center, Boston, MA; 2Research 
Design Center / Biostatistics Research Center, Tufts CTSI and Inst for Clinical 
Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Background: Low urine potassium excretion is associated with a higher risk of 
developing hypertension and CVD in the general population. There are few data on the 
relationship of urine potassium with clinically important outcomes in CKD.
Methods: The association of urine potassium with ESRD (defined as the need for 
dialysis or transplantation), CVD mortality and all-cause mortality was evaluated in 812 
participants enrolled in the MDRD Study. 24-hour urine potassium was measured at the 
first screening visit (before randomization) and in an average of 22 subsequent visits. 
Cox-proportional hazards models were adjusted for demographics, CVD risk factors, GFR, 
proteinuria, randomization assignment, and urine sodium. Interactions were performed 
with baseline GFR, proteinuria and urine sodium as well as blood pressure randomization.
Results: Mean age at baseline was 52±12 years; 60% were men and 85% were white. 
Mean 24-hour urine potassium excretion was 61.2±22.7 mEq/day. Median follow up for 
ESRD and mortality were 6.1(IQR 3.5, 11.7) and 19.2 (10.8, 20.6) years, respectively. Higher 
urine potassium levels were associated with a lower hazard of CVD mortality and all-cause 
mortality, but were not associated with ESRD (Table). No significant interactions were noted. 
Conclusions: Higher urine potassium is associated with lower risk of CVD mortality 
and all- cause mortality. It remains to be determined whether higher dietary potassium 
intake results in improved outcomes in CKD.
Funding: NIDDK Support
TH-PO607
Association Between Serum Bicarbonate and Heart Rate Variability in 
Hypertensive Adults: The Systolic Blood Pressure Intervention Trial 
Kalani L. Raphael,1 Elsayed Z. Soliman,2 William C. Cushman,3 Matthew J. 
Diamond,4 Jeff Whittle,6 Anthony Alexander Killeen,7 Laura Lovato,2 Joachim H. 
Ix,5 Srini Beddhu.1  1Univ of Utah; 2Wake Forest School of Medicine; 3Memphis 
VA Medical Center; 4Georgia Regents Univ; 5UC San Diego; 6Clement J Zablocki 
VA Medical Center; 7Univ of Minnesota.
Background: Reduced heart rate variability (HRV), a measure of cardiac autonomic 
dysfunction, has been associated with lower serum [HCO3-] in advanced CKD and ESRD. 
The purpose of this study is to determine if [HCO3-] is associated with HRV in hypertensive 
adults with more preserved eGFR.
Methods: We examined the cross-sectional association between baseline [HCO3-] and 
HRV in 9,265 participants from the Systolic Blood Pressure Intervention Trial (SPRINT). 
Three sequential 10-second 12-lead ECGs were used to calculate two time domain measures 
of HRV (standard deviation of all normal RR intervals [SDNN] and root mean square of 
the successive differences in normal RR intervals [RMSSD]) from the individual durations 
between normal RR intervals. Linear regression models (adjusted for demographics, 
smoking, eGFR, ACR, CVD, and SBP) were performed using [HCO3-] as the independent 
variable and log-transformed SDNN and RMSSD as dependent variables. These models 
were repeated using [HCO3-] as a categorical variable: < 22, 22.0-24.9, 25.0-29.9 (referent), 
and ≥ 30 mEq/L.
Results: Mean age was 67.9 (9.4) years, 28.4% had CKD, mean eGFR was 71.8 (20.6) 
ml/min/1.73m2, mean [HCO3-] was 26.3 (2.6) mEq/L, mean SDNN was 21.2 (17.6), and 
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mean RMSSD was 25.2 (24.6). There was no significant association between [HCO3-] 
and SDNN (beta coefficient -0.01, p=0.94) or RMSSD (beta coefficient 0.04, p=0.71) 
in adjusted linear regression models. Results were similar in models using [HCO3-] as a 
categorical variable. There was no interaction of these relationships by CKD status (p>0.40 
for SDNN and RMSSD).
Conclusions: In this large study of trial participants with normal kidney function 
to moderate CKD, there was no association between [HCO3-] and HRV. The association 
between lower [HCO3-] and reduced HRV may only exist in more advanced CKD.
Funding: NIDDK Support, Other NIH Support - NHLBI, NIA, Veterans 
Administration Support, Private Foundation Support
TH-PO608
Serum Alkaline Phosphatase Negatively Affects Endothelium Dependent 
Vasodilatation in Naïve Hypertensive Patients  Carmine Zoccali,1 Maria 
Perticone,2 Raffaele Maio,2 Angela Sciacqua,2 Michele Andreucci,2 Giovanni 
Tripepi,1 Salvatore Corrao,3 Francesca Mallamaci,1 Giorgio Sesti,1 Franco 
Perticone.2  1National Research Council-Inst of Clinical Phisiology, Reggio 
Calabria, Italy; 2Univ Magna Græcia of Catanzaro, Catanzaro, Italy; 
3Biomedical Dept of Internal Medicine and Subspecialties Univ of Palermo, 
Palermo, Italy.
Background: Tissue non-specific Alkaline Phosphatase (Alk-Phos) promotes arterial 
calcification in experimental models and, independently of other risk factors, high Alk-Phos 
is a powerful predictor of total  and cardiovascular (CV) mortality in the general population 
and in patients  with   heart  diseases.
Methods: To investigate the relationship  between Alk-Phos  and atherosclerosis at  an 
early disease stage we tested the association between serum Alk-Phos and the  endothelium 
dependent maximal vasodilatory response  to acetycholine   in 500 untreated  individuals 
with uncomplicated essential hypertension  without liver disease  and with Alk-Phos levels 
well  within the normal range of activity of this  enzyme.
Results: The maximal response  to acetylcholine was inversely related to Alk-Phos 
(r=-0.55, P<0.001) and this  association was unmodified (r=-0.61, P<0.001) in adjusted 
analyses  including demographic and classical risk factors, the BMI, the eGFR, serum 
phosphate and calcium as  well as serum C reactive protein (CRP) and albuminuria. The 
steepness of the Ach-max/Alk.Phos relationship  was substantially attenuated (P<0.001)  in 
patients  with serum phosphate  above the median value than in those   below the median 
( -5.0% per Alk-Phos Unit vs -10.0% per Alk-Phos Unit) and this interaction remained 
highly significant (P<0.001) in adjusted  analyses.
Conclusions: Our findings offer  a novel interpretative  clue   to explain the  association 
between serum Alk-Phos  and phosphate  and all cause and CV mortality in previous 
observational studies  in  the general population and in patients  with heart disease and 
suggest that  the endothelium   may be an   early target of raised  Alk-Phos.
TH-PO609
Alkaline Phosphatase Lowering by Selective BET Inhibition, a Novel 
Mechanism for MACE Reduction in High Risk CVD, Diabetes and 
CKD Patients – A Post-Hoc Analysis of Phase 2b Studies with RVX-208 
Kamyar Kalantar-Zadeh,1 Jan O. Johansson,2 Michael Sweeney,2 Kenneth E. 
Lebioda,2 Ewelina Kulikowski,2 Christopher Halliday,2 Norman Cw Wong.2 
1Div of Nephrology and Hypertension, 1Univ of California Irvine School of 
Medicine, Irvine, CA; 2Reseerch and Development, Resverlogix Corp, Calgary, 
AB, Canada.
Background: RVX-208 development is focused on reducing major adverse 
cardiovascular events (MACE) in high risk CVD, diabetes and CKD patients. RVX-208 
is a first in class select BET inhibitor small molecule that interacts with the second ligand 
domain found in bromodomain and extra-terminal proteins (BET). It is characterized by 
reductions in alkaline phosphatase (ALP) and anti-inflammatory effects.
Methods: In the SUSTAIN and ASSURE phase 2b clinical studies, high risk CVD 
patients were treated with 200 mg b.i.d RVX-208 or placebo for up to 26 weeks duration. 
Patients with a history of diabetes were analysed as a subgroup.
Results: A significant reduction in MACE in all the RVX-208 treated patients (n=331) 
compared to placebo (n=168) was observed (p=0.02) as well as in those with diabetes (RVX-
208 n=127/placebo n=65) (p<0.01). MACE included death, non-fatal myocardial infarct, 
and hospital admittance for cardiac reasons. In all patients (n=499), MACE compared to 
non-MACE patients had higher baseline ALP; 77.0 U/L vs. 72.0 U/L (p<0.05). Similar 
trends were observed in diabetes patients, 81.0 U/L vs. 75.5 U/L. RVX-208 treatment 
significantly lowered ALP vs. placebo in all patients (p<0.0001) and especially in those 
with diabetes (p<0.0001). In addition, in the RVX-208 treated group, patients who did not 
experience a MACE had greater reductions of ALP compared to those who experienced a 
MACE (-8.0 U/L vs. +3.0 U/L) (p<0.05).
Conclusions: In phase 2b studies in high risk CVD and diabetes patients treated with 
RVX-208, a select BET-inhibitor, baseline ALP levels were significantly different between 
the MACE and non-MACE patients. Furthermore, RVX-208 significantly lowered serum 
ALP. A prospective phase 3 study currently planned, called BETonMACE, will need to 
further examine RVX-208’s potential in reducing MACE in high risk CVD, diabetes and 
CKD patients.
TH-PO610
Serum Electrolyte Levels and Risk of Sudden Death in Patients with 
Moderate CKD  Patrick H. Pun, Benjamin A. Goldstein, John Gallis, Sarah H. 
Timberlake, Midori L. Mccarty, John Paul Middleton, Laura P. Svetkey.  Duke 
Unversity, Durham, NC.
Background: Abnormalities in the serum potassium(K), calcium(Ca) and 
magnesium(Mg) are known to disturb cardiac conduction and are rare causes of sudden 
death (SD). However, CKD patients are at higher risk for both electrolyte disturbances 
and SD; the extent to which these processes are related has not been well described. We 
examined the role of disordered serum electrolyte levels in SD risk among a large cohort 
of patients with coronary artery disease (CAD) and moderate CKD.
Methods: Retrospective longitudinal cohort study of 38,576 patients undergoing 
cardiac catheterization at a single institution from 1989 to 2014. Patients with significant 
CAD were included. Baseline laboratory measures were extracted within 60 days of the 
time of cardiac catheterization. GFR was estimated using the CKD-EPI equation. The main 
outcome measures were all-cause death and SD, which was determined by chart review, 
query of the national death index and information from surviving family members. Cox 
proportional hazards models were used to determine associations with predictors.
Results: 28% of patients had stage 3-4 CKD (eGFR 15-60). This group had a higher 
risk of death (HR=2.53, P<0.001), SD (HR 1.80, P<0.001), hyperkalemia (RR=3.5), 
hypercalcemia (RR=1.7), and hyper- and hypomagnesemia (RR=1.4, RR=1.2) compared 
to patients without CKD. Elevated K, Ca, and Mg were associated with increased risk of 
all-cause death among patients with moderate CKD, but not with SD. Hyperkalemia was 
associated with SD in the absence of CKD. 
Conclusions: Abnormalities in K, Ca and Mg are common among CKD patients and 
are associated with heightened risk of all-cause death, but are not associated with SD. 
Targeted management of serum electrolyte abnormalities could reduce overall mortality 
risk in CKD patients, but other strategies may be needed to protect from sudden death.
Funding: NIDDK Support
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Circulating ACE2 as a Biomarker of Chronic Kidney Disease Progression 
Lidia Anguiano,1 Marta Riera,1 Julio Pascual,1 Angels Betriu,2 Jose M. 
Valdivielso,2 Clara Barrios,1 Elvira Fernandez,2 Maria Jose Soler.1  1Nephrology, 
Hospital del Mar-Inst Hospital del Mar d¶Investigacions Mèdiques, Barcelona, 
Spain; 2Nephrology, Hospital Arnau de 9ilanova, Lleida, Spain.
Background: In a CKD population without previous history of CV disease, ACE2 
activity from human EDTA-plasma samples directly correlated with the classical CV 
risk factors namely older age, diabetes and male gender. Objective: To study circulating 
ACE2 as a biomarker of renal progression and atheromatous disease(AD) in CKD stages 
3-5(CKD3-5) patients.
Methods: Prospective study from 930 CKD3-5 patients without history of 
CVD. Circulating ACE2 activity was analyzed. We evaluated renal function(serum 
creatinine, glomerular filtrate MDRD-4), carotid/femoral echography, mortality, renal 
replacement therapy and AD at baseline and 24 months. ACE2 activity was divided in 
tertiles(£27.64;27.65-46.34;≥46.35RFU/µL/h). Univariate and multivariate(dependent 
variable ACE2 natural logarithm) were performed.
Results: Patients with ACE2 in the higher tertile doubled creatinine more 
frequently(61% higher tertile vs 28% lowest tertile,p=0.013). Patients that showed 
plaques appearance at 24month had a higher ACE2 activity in comparison to patients 
without(42.0±2.4 vs 34.2±1.2,p=0.009). Patients that presented plaques at baseline had 
higher ACE2 than those that have never had (48.2±1.7 vs 34.2±1.2,p<0.001). Femoral 
plaques: ACE2 increased in patients with baseline plaques(48.9±1.9) or with de novo plaques 
at 24months(46.6±3.2) respect to patients without plaques(35.9±1.5,p=0.002/p<0.001). 
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Carotid plaques: ACE2 increased in patients with baseline plaques respect to patients without 
plaques (49.0±2.1 vs 38.5±1.3, p<0.001). Patients with AD2-3 at 24months showed an ACE2 
increase as compared to AD0-1 at 24months(47.6±1.6 vs 35.7±1.6,p<0.001). Multivariate 
analysis demonstrated circulating ACE2 in CKD3-5 as a predictor of doubling creatinine 
(β=0.069,p=0.034), de novo appearance of femoral plaques at 24months (β=0.087,p=0.016) 
and presence of femoral plaques at basal and 24months(β=0.199,p<0.001).
Conclusions: In CKD3-5 patients without history of CVD, circulating ACE2 may 
become a biomarker of CKD progression and AD appearance at 24months of follow-up.
TH-PO612
Blood Pressure and Risk of Cardiovascular Events at Advanced CKD: The 
CRIC Study  Nisha Bansal,1 Charles E. McCulloch,2 Feng Lin,2 Cassianne 
Robinson-Cohen,1 Mahboob Rahman,3 John W. Kusek,4 Amanda Hyre 
Anderson,5 Raymond R. Townsend,5 Jackson T. Wright,6 Alan S. Go,7 Arnold 
B. Alper,8 Radhakrishna Reddy Kallem,5 Chi-yuan Hsu.2  1UW; 2UCSF; 3UH; 
4UPenn; 5NIDDK; 6Case Western; 7KPNC; 8Tulane.
Background: The association of SBP with cardiovascular events (CVD) among 
patients with advanced CKD is not known and may be an important modifiable risk factor.
Methods: Participants of the Chronic Renal Insufficiency Cohort (CRIC) Study with 
advanced CKD (defined as eGFR <30 ml/min/1.73 m2) had SBP measured by standardized 
methods at yearly in-person visits. We studied the association of SBP with time to physician-
adjudicated atherosclerotic CVD (defined as myocardial infarction, stroke, peripheral 
vascular disease) and heart failure (HF) using Cox models.
Results: Among 1,795 participants with eGFR<30 ml/min/1.73 m2, mean age was 
60±11 years, 46% were women and 46% were African American. Mean eGFR was 26±5 
ml/min/1.73 m2 and mean BP was 131 (±24)/69 (±13) mm Hg. In models adjusted for 
demographics, clinical site, tobacco use, body mass index, diabetes, urine proteinuria, statin 
use and number of classes of anti-hypertensive medications, higher SBP was associated 
with greater risk of incident atherosclerotic disease and HF. Results were similar when 
participants with prevalent atherosclerotic CVD and HF were excluded.
Conclusions: Among this diverse multi-center cohort of advanced CKD patients, higher 
SBP was associated with greater risk of atherosclerotic CVD and HF. This is similar to what 
has been reported in the general population and suggests that treatment guidelines developed 
for non-CKD populations can be extended to those with eGFR <30 ml/min/1.73 m2.
Funding: NIDDK Support
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CKD Does Not Impact Risk and Appropriateness of Device Therapies in 
Adults with Primary Prevention Implantable Cardioverter Defibrillators 
Nisha Bansal,1 Adam Szpiro,1 Frederick A. Masoudi,2 Robert Greenlee,3 Jerry 
H. Gurwitz,4 Kristi Reynolds,5 Grace Hsu Tabada,6 Sue hee Sung,6 Ashveena 
Dighe,1 Andrea E. Cassidy-Bushrow,7 Romel J. Garcia-Montilla,3 Stephen 
Hammill,8 Alan Kadish,9 Param Sharma,3 Humberto Vidaillet,3 Alan S. Go.6 
1UW; 2UC; 3MCRC; 4MPCI; 5KPSC; 6KPNC; 7HFH; 8MC; 9TC.
Background: Implantable cardioverter defibrillators (ICD) reduce the risk of sudden 
cardiac death (SCD). CKD patients are at high-risk for SCD, but whether CKD is associated 
with greater risk of delivered shocks/anti-tachycardia pacing (ATP) therapies among those 
with an ICD remains unclear.
Methods: We studied participants in the Cardiovascular Research Network 
Longitudinal Study of Implantable Cardioverter Defibrillators (CVRN LS-ICD). CKD 
was defined as eGFR<60 ml/min/1.73 m2 at the time of ICD implantat. Outcomes included 
number and type of shock/ATP (inappropriate or appropriate, determined by physician 
adjudication) within 3 years after implant. We evaluated the associations between kidney 
function and time to first device therapy, burden of device therapy, and inappropriate vs. 
appropriate device therapy.
Results: Among 2,161 participants, 49.3% had CKD at the time of ICD implantat. 
During mean follow-up of 2.3±0.9 years, 9.8% and 18.5% of participants had at least 1 
inappropriate and appropriate shock/ATP, respectively. CKD was not associated with time 
to first shock/ATP of any type. 
CKD was not associated with greater overall burden of shock/ATPs (adjusted relative 
rate 0.93, 95% CI: 0.74-1.17) or inappropriate vs. appropriate shock/ATP (adjusted relative 
risk 0.88, 95% CI: 0.68-1.14).
Conclusions: In adults receiving a primary prevention ICD, CKD was not associated 
with the timing, burden or appropriateness of delivered ICD therapies. Concern for more 
frequent or inappropriate ICD therapies should not preclude ICD implantation among 
eligible CKD patients.
Funding: Other NIH Support - 1R56HL121069-01A1
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Diagnostic and Prognostic Characteristics of Amino-Terminal Pro 
B-Type Natriuretic Peptide in Patients with Diminished Renal Function: 
A Systematic Review and Meta-Analysis  Jennifer A. Schaub,1 Steven G. 
Coca,2 Dennis G. Moledina,1 Jeffrey M. Testani,1 Chirag R. Parikh,1 Mark 
Gentry.1  1Yale Univ School of Medicine, New Haven, CT; 2Nephrology, Mount 
Sinai, New York, NY.
Background: Patients with renal dysfunction have higher plasma Amino-terminal pro 
B-type Natriuretic Peptide (NT-proBNP), which may complicate interpretation for diagnosis 
of acute decompensated heart failure (ADHF) or prognosis. We sought to systematically 
review studies on NT-proBNP testing in patients with and without renal dysfunction.
Methods: We searched MEDLINE, EMBASE and Web of Science through August 
2014 and selected studies with sub-group analysis by renal function of the diagnostic or 
prognostic ability of NT-proBNP.
Results: For diagnosis, nine studies were included with 4,287 patients and 1,325 ADHF 
events. Patients were mostly divided into sub-groups with and without renal dysfunction 
by an estimated glomerular filtration rate of 60 ml/min/1.73m2. In patients with renal 
dysfunction, the area under the curve (AUC) for NT-proBNP ranged from 0.66 to 0.89 with 
a median cut-point of 1980 pg/ml while the AUC ranged from 0.72 to 0.95 with a cut-point 
of 450 pg/ml in patients with preserved renal function. For prognosis, 30 studies with 32,203 
patients were included, and mortality in patients with renal dysfunction (25.4%) was twice 
that of patients with preserved renal function (12.2%). The unadjusted pooled risk ratio 
(RR) for NT-proBNP and mortality was 3.01 (95% CI, 2.53-3.58) in patients with preserved 
renal function and was similar in patients with renal dysfunction (3.25 [CI, 2.44-4.32]). 
There was significant heterogeneity, which was partially explained with meta-regression, 
if patients with heart failure or coronary artery disease were enrolled.
Conclusions: NT-proBNP retains utility for diagnosis of ADHF in patients with 
diminished renal function with higher cut-points. Elevated NT-proBNP confers a worse 
prognosis regardless of renal function.
Funding: Other NIH Support - T32DK007276-36
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Changes in Urinary L-FABP as a Biomarker for Cardiovascular Events 
Atsuko Ikemori,1,2 Takeshi Sugaya,1 Katsuomi Matsui,1 Mikako Hisamichi,1 
Kenjiro Kimura,3 Yugo Shibagaki.1  1Dept of Nephrology and Hypertension, 
Internal Medicine, St. Marianna Univ School of Medicine, Kawasaki, Japan; 
2Dept of Anatomy, St. Marianna Univ School of Medicine, Kawasaki, Japan; 
3Internal Medicine, Tokyo Takanawa Hospital, Tokyo, Japan.
Background: Contrast medium (CM) induces tubular hypoxia via endothelial damage 
due to direct cytotoxicity or viscosity.  Urinary liver-type fatty acid binding protein 
(L-FABP) is a tubular biomarker which increases along with tubular hypoxia and may be 
useful as a detector of systemic circulation injury. The aim of this study wasto evaluate the 
clinical usefulness of increase in urinary L-FABP levels due to administration of CM as 
a prognostic biomarker for cardiovascular disease in patients without occurrence of CM-
induced nephropathy undergoing cardiac catheterization procedure (CCP).
Methods: Cross-sectional and retrospective longitudinal analyses of the relationship 
between urinary L-FABP levels and occurrence of cardiovascular events were performed. 
Urinary L-FABP was measured by ELISA before, and at 6, 12, 24 and 48 h after CCP.
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Results: Urinary L-FABP levels were significantly higher at 12h and 24h after CCP 
compared with before CCP only in the patients with occurrence of cardiovascular events. 
The difference in urinary L-FABP levels (∆L-FABP) between before and at 24h after CCP 
was a risk factor for the occurrence of cardiovascular events.
Conclusions: Measurement of urinary L-FABP before and at 24h after CCP in patients 
with mild to moderate renal dysfunction may be an important indicator for risk stratification 
of onset of cardiovascular events in clinical practice.
TH-PO616
Suggested Role of Adiponectin in Reciprocal Relationships Between Pulse 
Wave Velocity and Bone Mineral Density in CKD Patients  Seon Ha Baek,1 
Sung Woo Lee,1 Shin-Young Ahn,1 Sejoong Kim,1 Ho Jun Chin,1 Ki Young 
Na,1 Dong-Wan Chae,1 Curie Ahn.2  1Internal Medicine, Seoul National Univ 
Bundang Hospital, Gyeonggi-do, Republic of Korea; 2Internal Medicine, Seoul 
National Univ Hospital, Seoul, Republic of Korea.
Background: Although adiponectin plays a beneficial role in the regulation of 
insulin action and atherosclerosis in various populations, the role of adiponectin remains 
a controversy in patients with chronic kidney disease (CKD).
Methods: A total of 1310 patients (male/female = 794/516) with CKD stage 1 to 5 who 
enrolled in the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease 
(KNOW-CKD) from June 2011 to December 2013. We measured serum total adiponectin 
and examined the association between adiponectin, bone mineral density (BMD) measured 
by dual energy X-ray absorptiometry, and pulse wave velocity (PWV) calculated by mean 
value of both brachial-ankle (ba) PWV.
Results: Increasing quintiles of serum adiponectin levels were associated with female 
gender; lower body mass indices, estimated glomerular filtration rate, triglycerides, BMD 
and albumin; higher urinary protein creatinine ratios, PWV, phosphorous, intact PTH. 
T-scores at LS spine (LS), total hip (TH), and femur neck (FN) inversely correlated with 
ba PWV (LS: r = -0.075, P = 0.010; TH: r = -0.097, P = 0.001; FN: r = -0.111, P <0.001) 
in male CKD, however, this association was not significant for female CKD (LS: r = 
0.019, P = 0.607; TH: r = -0.046, P = 0.223; FN: r = -0.043, P = 0.277). Adiponectin was 
inversely associated with T-scores at all sites for both male and female CKD patients (LS: 
r = -0.133, P <0.001; TH: r = -0.135, P <0.001; FN: r = -0.099, P <0.001). Adiponectin 
was positively associated with ba PWV for male CKD (r = 0.074, P = 0.016), but not for 
female CKD (r = -0.021, P=0.567).
Conclusions: Adiponectin, BMD, and PWV were associated with each other in 
male CKD patients. The findings suggested that adiponectin have the role in reciprocal 
relationships between PWV and BMD in not female but male CKD patients.
TH-PO617
The Association of High-Sensitivity Troponin I and N-Terminal Pro-Brain 
Natriuretic Peptide with Plasma Galectin-3 in Chronic Kidney Disease 
Patients  Gek Cher Chan,1 Rui shian Ao,2 Jialiang Li,2 Boon Wee Teo.1,3 
1Nephrology, National Univ Hospital, Singapore; 2Statistics and Applied 
Probability, National Univ of Singapore, Singapore; 3Yong Loo Lin School of 
Medicine, National Univ of Singapore, Singapore.
Background: Plasma galectin-3 (pG3), a beta-galactoside-binding lectin, regulates 
inflammation and fibrosis. N-terminal pro-brain natriuretic peptide (NTproBNP), high-
sensitivity Troponin I (hsTnI), and pG3 concentrations are elevated in chronic kidney 
disease (CKD) patients with heart failure. Between hsTnI and NTproBNP, it is unknown 
which has a better association with pG3. We assessed the relationship of NTproBNP and 
hsTnI with pG3 in Asian CKD patients and healthy controls.
Methods: We retrieved prospectively collected frozen plasma samples from 163 
stable CKD patients and 105 healthy controls. NTproBNP, hsTnI and pG3 were assayed. 
By univariate analysis, we assessed pG3 for associations with age, gender, ethnicity, 
systolic (SBP) and diastolic (DBP) blood pressures (mmHg); height, weight, body mass 
index (BMI, kg/m2), previously diagnosed CKD, diabetes, hypertension, coronary artery 
disease, estimated glomerular filtration rate (eGFR, mL/min/1.73m2); C-reactive protein 
(CRP), beta-trace protein (BTP), 24-hr urine protein (TUP), serum albumin, uric acid 
and cystatin C. We created 2 models predicting pG3 using multiple linear regression by 
backwards elimination to include hsTnI and NTproBNP. Akaike Information Criterion 
(AIC) was used for comparison. Significance was taken at P<0.05.
Results: Population averages: Age=52.7±15.3 years; BMI=26.9±5.2, eGFR=75 
(IQR:36-102); pG3=19.4 (IQR:14.9-29.9)ng/mL, NTproBNP=27 (IQR:11-71) pg/mL, 
hsTnI=3.1 (IQR:1.6-6.0) ng/L. Age, SBP, DBP, height, BMI, previous disease diagnoses, 
Ln CRP, Ln BTP, Ln TUP, Ln albumin, Ln uric acid, Ln creatinine, Ln cystatin C, Ln 
eGFR, Ln hsTnI, Ln NTproBNP were associated with pG3. The best model included Ln 
hsTnI, diagnosis of CKD, Ln albumin, Ln cystatin C, Ln uric acid, and height. (AIC: 83.3).
Conclusions: NTproBNP and hsTnI are associated with pG3 in CKD patients. The 
model including hsTnI is a better predictor of pG3.
TH-PO618
ACE/ARB Use in Patients with Severe Kidney Disease and Heart Failure 
Is Not Associated with Worsening Renal Function, Acute Kidney Injury 
and Hyperkalaemia  Gowrie Balasubramaniam, Sebastian Vandermolen, Sarah 
Mapplebeck, Michael K. Almond.  Dept of Medicine, Southend Univ Hospital, 
Southend, Essex, United Kingdom.
Background: The role of ACE/ARB in patients with severe kidney disease and heart 
failure needs clarification. This includes patients with preserved systolic function. ACE/
ARB use is associated with better cardiac prognosis but there is a risk of worsening renal 
function, especially in older and frail people.
Methods: We undertook a retrospective analysis of patients who were diagnosed with 
heart failure in primary care with BNP testing and Echocardiogram. Our centre serves a 
population of 350,000, details of hospital admissions, drug information and blood results 
were obtained from our electronic patient records. A BNP>450 and clinical features of heart 
failure is the criteria used by general practitioners for diagnosis, an eGFR < 30 was used 
to identify patients with severe kidney disease. We looked at rates of worsening kidney 
function, AKI and hyperkalaemia.
Results: 159 patients with raised BNP and eGFR <30 were identified on electronic 
search from 01/12 to 01/14. Mean age was 81.7year (range 41-96), M:F was (79:80). 
Average follow-up was 17 months. 27 patients with transient rise in serum creatinine (Cr) 
or on dialysis were excluded. 87 of the remaining 132 patients had echocardiograms; 13 
had ejection fraction (EF) <40%, 7 EF had 40-50% and 67 had preserved ejection fraction 
(>50%). Comparing with EF<50% vs. EF>50%; mortality was 55% (11/20) vs. 10% (7/67), 
mean BNP was 12,037 vs. 3645, mean Cr was 235 vs. 201 and 1/20 vs. 1/67 reached ESRD, 
respectively. 84 patients had drug information available.
On ACE/ARB
(n=62)
Not on ACE/ARB
(n=22)
Mortality 21% 23%
Episode of AKI 58% 45%
Worsening CKD at follow-up 53% 45%
Mean potassium 4.2 4.7
Conclusions: Impaired EF was associated with worse mortality. ACE/ARB use was not 
associated with more adverse events with regards to episodes of AKI, worsening egfr and 
mean potassium. We feel that ACE/ARB treatment for heart failure should be maintained 
even in the setting of severe renal disease to reduce cardiovascular mortality.
TH-PO619
Protein-Fiber Intake Ratio and Cardiovascular Risk in Older Men with 
Chronic Kidney Disease  Hong Xu,1 Megan Rossi,2 Katrina L. Campbell,2,3 
Gloria Lissete Sencion martinez,1 Johan Arnlov,4 Tommy Cederholm,5 Per 
Sjogren,5 Bengt Lindholm,1 Juan Jesus Carrero.1  1Renal Medicine & Baxter 
Novum, Karolinska Inst, Stockholm, Sweden; 2Princess Alexandra Hosp, 
Brisbane, Australia; 3Health Sciences & Medicine, Bond Univ, Robina, 
Australia; 4Medical Sciences, Uppsala Univ, Uppsala, Sweden; 5Public Health 
and Caring Sciences, Uppsala Univ, Uppsala, Sweden.
Background: The elevated cardiovascular (CVD) risk in chronic kidney disease 
(CKD) may be partially alleviated through a healthy diet. While protein intake has been 
linked to CVD events in CKD patients, dietary fiber may be cardioprotective. Nutrients 
are not consumed in isolation; we hypothesize that CVD incidence associates with dietary 
patterns aligned with excess of dietary protein relative to fiber.
Methods: Prospective cohort study from Uppsala Longitudinal Study of Adult Men 
of 390 elderly men aged 70–71 years with manifest CKD (eGFR<60 mL/min/1.73m2 and 
albuminuria³20 µg/min) and no clinical history of CVD. Protein and fiber intake and its 
ratio, were calculated from 7-day dietary records. Cardiovascular structure and function 
was estimated from echocardiographic examination. Fatal and non-fatal cardiovascular 
events were registered prospectively during median follow-up of 9.1 (IQR 4.5-10.7) years.
Results: The median of protein-fiber ratio was 4.0 (3.5-4.7); dietary protein was 
66.7 (60.7-71.1) and dietary fiber was 16.6 (14.5-19.1) grams/day. Protein-fiber intake 
ratio, rather than separate components, remained strongly associated to left ventricular 
cardiovascular structure and diastolic function after multivariable adjustment.During follow-
up, 164 first-time CVD events occurred (incidence rate 54.5/1,000 py). Protein-fiber intake 
ratio was an independent risk factor for CVD incidence [adjusted HR per SD increase (95% 
confidence interval, CI) 1.29 (1.05, 1.57)]. Although in opposing directions, neither dietary 
protein [1.10 (0.92, 1.33)] nor dietary fiber [0.83 (0.68, 1.02)] associated with this outcome.
Conclusions: An excess of dietary protein relative to fiber intake associated with 
cardiovascular structural dysfunction and with incidence of cardiovascular events in a 
homogeneous population of older men with CKD.
Funding: Pharmaceutical Company Support - Baxter Healthcare Corporation
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TH-PO620
Impact of Percutaneous Transluminal Renal Angioplasty (PTRA) on 
Long-Term Prognosis in Patients with Severe Atherosclerotic Renal Artery 
Stenosis (RAS)  Yasuhiro Mochida, Takayasu Ohtake, Kunihiro Ishioka, 
Machiko Oka, Hidekazu Moriya, Sumi Hidaka, Shuzo Kobayashi.  Nephrology, 
Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
Background: PTRA for the patients(Pt’s) with RAS was concluded to be not superior 
to medical therapy in terms of preserving renal function, renal events, and cardiovascular 
events in multicenter randomized trial in ASTRAL and CORAL. However, in these studies, 
approximately 40% of all Pt’s had only mild to moderate RAS (50~70%). Therefore, we 
studied whether PTRA for the Pt’s with more severe RAS would be beneficial or not.
Methods: Eligibility of the study included the Pt’s with RAS in stenosis more than 
75%, who underwent PTRA in our hospital from September 2004 to December 2007. 
Mean follow-up period was 81±34 months (median 7 years). We investigated the changes 
of renal function as primary endpoint, and renal event (doubling of serum creatinine(=Scr) 
or dialysis initiation) and cardiovascular death as secondary endpoint.
Results: Among 80 RAS patients with PTRA treatment, 74 Pt’s were followed by 
April 2015. There were 24 Pt’s with 75-89% (moderate group), 38 Pt’s with 90-95% 
(severe group), and 12 Pt’s with more than 95% (more severe group) in stenosis. At the 
time of PTRA, 92% of all the Pt’s had ischemic heart disease . The changes of Scr from 
baseline to the final hospital visit (mean±SD) were from 1.21±0.59 to 1.47±0.91 mg/dl in 
moderate, from 1.10±0.34 to 1.89±1.84 mg/dl in severe, and from 1.95±1.14 to 1.76±0.80 
mg/dl in more severe group, respectively. During the follow-up period, totally four renal 
events (5.4%) occurred (1 in moderate , 3 in severe). However, none of the more severe 
group presented renal event, nor renal function worsening in this group (P=0.002). Fourteen 
Pt’s died (19%), of which cardiac death occurred in 6 Pt’s (8.1% among all Pt’s) during 
the follow-up period.
Conclusions: In comparison with 5-year cumulative rate of 22% renal events and 
11.4% cardiovascular death in medical group in ASTRAL study, the results in our study 
clearly demonstrated the effectiveness of PTRA in more severe RAS patients in preserving 
renal function and protecting from cardiac deaths. PTRA is a useful treatment for the Pt’s 
with more severe RAS .
TH-PO621
Changes in Renal Function After LVAD Placement – A Meta-Analysis 
Reejis Stephen,1 Chandrashekar Kashyap,2 Minesh Rajpal,1 Sankar D. 
Navaneethan.1  1Nephrology, Cleveland Clinic, Cleveland; 2Medicine, 
MetroHealth Medical Center, Cleveland.
Background: Renal function after Left Ventricular Assist Device (LVAD) placement 
predicts survival, irrespective of baseline Creatinine Clearance (CrCl). Continuous flow 
devices have been reported to have better renal outcomes than pulsatile devices. We 
compared the change in renal function in recipients of both continuous and pulsatile-flow 
devices at various time points following LVAD placement.
Methods: We searched MEDLINE for all publications with prospective cohorts and 
trials of LVAD recipients. Studies documenting renal-function at various time points after 
LVAD placement were included. CrCl at suitable time points after LVAD placement was 
pooled using an inverse of variance method and analyzed using random-effects models. 
Changes in CrCl after continuous and pulsatile flow LVAD placement was compared for 
cohorts with at least 10 subjects.
Results: 33 studies with 23 cohorts including continuous flow devices (n=1262) and 
18 including pulsatile flow (n = 678) were included. Baseline CrCl for continuous and 
pulsatile-device recipients were similar. Continuous flow LVAD recipients showed higher 
CrCl at 1 month, compared to baseline and pulsatile-flow device recipients. There was a 
non-significant trend towards improved renal function after LVAD placement (Figure).
Conclusions: In this pooled analysis, we noted a pattern of an initial improvement in 
renal function followed by later decline with continuous-flow devices. While CrCl appears 
to improve after LVAD placement, the long-term effect remains unclear. Further studies 
focused on renal function and risk factors are needed to better understand the phenomenon 
in LVAD recipients.
TH-PO622
Impact of Kidney Function on Intima-Media Thickness in Patients with 
Type 2 Diabetes  Yusuke Nakade,1,3 Tadashi Toyama,2 Shinji Kitajima,2 Yasuyuki 
Shinozaki,2 Akinori Hara,2 Miho Shimizu,2 Yasunori Iwata,2 Norihiko Sakai,2 
Kengo Furuichi,2 Takashi Wada.1,2,3  1Clinical Laboratory, KanazaZa Univ 
Hospital, Kanazawa, Ishikawa, Japan; 2Div of Nephrology, Kanazawa Univ 
Hospital, Kanazawa, Ishikawa, Japan; 3Dept of Laboratory Medicine, KanazaZa 
Univ Hospital, Kanazawa, Ishikawa, Japan.
Background: Carotid echo indexes [intima–media thickness (IMT)] are commonly 
used surrogate markers for cardiovascular disease; However, the impacts of chronic kidney 
disease (CKD) on changes in IMT are unclear. We examined associations between CKD 
and IMT in participants with and without type 2 diabetes through longitudinal analysis.
Methods: In total, 424 subjects were enrolled in this study. IMT was measured as per 
carotid echo indexes. Relationships between IMT and risk factors were analyzed using 
multiple linear regression analysis, in which we defined IMT as the dependent variable 
and atherosclerosis-related factors (age, sex, systolic pressure, total cholesterol, body mass 
index, estimated glomerular filtration rate (eGFR), uric acid, smoking index, number of 
antihypertensive drugs, statin use, urinary protein levels, past cardiovascular event, glycated 
hemoglobin, and diabetes duration) as independent variables.
Results: The study population was composed of 70.3 % male subjects. Participants 
with diabetes accounted for 64.4 % of the total population. The mean follow-up duration 
was 2.2 ± 1.5 years. Alterations in IMT tended to be associated with systolic blood pressure 
(+10 mmHg) (β = -0.0084, p = 0.09) and eGFR (+10 mL/min/1.73 m2) (β = -0.0049, p = 
0.06) in all participants. In participants without diabetes, alterations in IMT were associated 
with eGFR (+10 mL/min/1.73 m2) (β =-0.0104, p = 0.03) and tended to be associated with 
systolic blood pressure (+10 mmHg) (β = 0.0094, p = 0.06). No significant relationships 
were found in participants with diabetes.
Conclusions: Low eGFR was associated with progression of carotid thickness 
independent of common cardiovascular risk factors in non-diabetic participants.
TH-PO623
The Number of Arterial Territories with Atheroma Plaque Predicts 
Cardiovascular Event-Free Survival in Chronic Kidney Disease. Analysis 
of the NEFRONA Study after 36 Months of Follow-up  Jose M. Valdivielso,1 
Montserrat Martinez-alonso,3 Marta Gracia,1 Angels Betriu,1 David Arroyo,2 
Maria Abajo,1 Mercedes Salgueira lazo,4 Jose L. Gorriz,5 Elvira Fernandez.2 
1(xperimental Nephrology, IRBLleida, Lleida, Spain; 2UDETMA, Arnau de 
9ilanova Univ Hospital, Lleida, Spain; 3Statistics Unit, IRBLleida, Lleida, Spain; 
4Unidad Mixta, Hospitales Virgen Macarena y Virgen del Rocio, Sevilla, Spain; 
5Nephrology, Hospital Dr Peset, Valencia, Spain.
Background: Cardiovascular disease remains the leading cause of morbidity and 
mortality in patients with chronic kidney disease (CKD).
Methods: The NEFRONA study enrolled 2445 patients in different stages of CKD to 
assess the value of detection of subclinical atherosclerosis by ultrasound in the prediction 
of cardiovascular risk. This study shows the data on cardiovascular events (CVE) with a 
minimum follow-up time of three years, and the COX regression analysis of predicting 
factors .
Results: There have been 67 fatal and 152 nonfatal CVE and 113 deaths from other 
causes. The number of missings is 648 (593 renal transplants, 1 non renal transplant and 67 
changes of center). The cumulative incidence of CVE is of 8.96% (median follow-up=42.09 
months); stage 3: 6.95% (48 months), stage 4-5: 9.29% (42.8 months), stage 5D: 11.34% 
(23.1 months). Kaplan Meier curves of survival free from CVE show that the survival time 
is inversely proportional to the number of territories with plaque. 
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The COX regression analysis shows that the factors significantly predicting event-
free survival time are the number of territories with plaque, being on dialysis, smoking, 
diabetes, high levels of phosphorus, low albumin and 25OH vitamin D as well as having 
1,25(OH)2 vitamin D below 14 pg/dl.
Conclusions: The severity of arterial atheromatosis estimated by ultrasound predicts the 
time free from CVE in CKD. Arterial ultrasound is a useful tool to predict cardiovascular 
risk in CKD patients.
Funding: Pharmaceutical Company Support - ABBVIE, Government Support - Non-
U.S.
TH-PO624
The Effects of Diuretics on the Progression of CKD and Incidence of 
Cardiovascular Events: Results from the CKD-ROUTE Study – A 
Prospective Cohort Study of Newly Visiting CKD Patients in Japan 
Shotaro Naito, Soichiro Iimori, Eisei Sohara, Tomokazu Okado, Sei Sasaki, 
Shinichi Uchida, Tatemitsu Rai.  Dept of Nephrology, Tokyo Medical and Dental 
Univ, Tokyo, Japan.
Background: Anti-hypertensive agents are requisite for control of blood pressure 
in CKD patients. Although diuretics seem to be associated with progression of CKD or 
incidence of cardiovascular (CV) events, this hypothesis has not been adequately elucidated. 
To evaluate the association of anti-hypertensive agents prescription and outcomes, we 
analyzed a cohort study of newly visiting pre-dialysis CKD patients in Japan.
Methods: We recruited 937 newly visiting CKD patients followed for the next 3 years. 
At 6 months visit, use of RAAS inhibitors (RAASi), calcium channel blockers (CCB), 
and diuretics was assessed, and the association between these medications and outcomes 
was evaluated. The outcomes were composite kidney endpoint of ESKD or 50% decline 
of eGFR from baseline, incidence of CV events and CV related death during three years 
after first visit to nephrologists. We used multivariate Cox proportional hazards regression 
adjusted by age, sex, albumin, hemoglobin, eGFR, systolic blood pressure, presence of 
proteinuria and diabetes, and past history of CV events.
Results: At first visit, mean age was 67 years old, 70.2% was male, mean eGFR 
was 33.7 ml/min/1.73m2, and mean systolic blood pressure was 139 mmHg. During the 
follow-up period of 3 years, 114 CV events occurred, 24 patients died of CV events, and 
220 patients reached the composite kidney endpoint. In multivariable analysis, risk of 
CV events and CV related death during the 3-year period was higher in the patients using 
diuretics at six months visit (adjusted hazard ratio 1.55 [95%CI 1.23-2.33] for CV events, 
3.09 [95%CI 1.19-8.02] for CV related death.) The patients taking both diuretics and 
RAASi had comparable risk of CV events with those taking diuretics only (adjusted HR 
1.09 [95%CI 0.54-2.2].) However, none of the three kinds of anti-hypertensive agents had 
associations with CKD progression.
Conclusions: CKD patients using diuretics were more likely to have CV events and 
CV related death. RAASi might contribute to reduce the risk of CV events by diuretics.
TH-PO625
Rapid Increase in Aortic Stiffness in Patients on Hemodialysis and 
Peritoneal Dialysis Compared with Non-Dialysis-Dependent Chronic 
Kidney Disease Patients: A Longitudinal Study Using MRI-Based Pulse 
Wave Velocity  Kazuhiko Tsuruya,1 Hisako Yoshida,1 Takanari Kitazono.2 
1Dept of Integrated Therapy for Chronic Kidney Disease, Graduate School 
of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 2Dept of Medicine and 
Clinical Sciences, Graduate School of Medical Sciences, Kyushu Univ, Japan.
Background: Pulse wave velocity (PWV) is a well-established technique for 
obtaining a measure of arterial stiffness that has the potential to provide information on 
early atherosclerotic disease. MRI-based PWV measurements have been well validated in 
comparison with invasive pressure recordings (Grotenhuis et al. J Magn Reson Imaging, 
2009). To date, very few studies have reported on MRI-based PWV in patients with chronic 
kidney disease (CKD), especially in patients with end-stage kidney disease on hemodialysis 
(HD) and peritoneal dialysis (PD). In the present study, we examined the annual changes 
in MRI-based PWV from baseline to 2 years and compared them among non-dialysis 
dependent-CKD (ND), HD, and PD patients.
Methods: A total of 172 CKD patients (ND, n=89; HD, n=47; PD, n=36) were recruited 
and underwent cardiovascular MRI at baseline and 2 years after. Using cine and phase 
contrast sequences, the cross-sectional area for distensibility and average blood flow were 
measured between the ascending and the proximal descending aorta. Annual change in 
MRI-based PWV was calculated as (MRI-based PWV after 2 years–baseline MRI-based 
PWV) × 365/interval days between the first and second MRI. Multivariable linear regression 
was used to evaluate differences in the changes among the 3 patient groups.
Results: The annual changes in MRI-PWV were significantly increased in patients on 
HD and PD compared with ND patients, even after adjusting various confounding factors 
including age, sex, and blood pressure (least square means were -0.18, 0.35, and 0.49 in 
ND, HD, and PD patients, respectively; p <0.001). Meanwhile, there was no difference in 
the changes between HD and PD patients (p = 0.736).
Conclusions: Progression of aortic stiffness is more rapid in patients on HD and PD 
compared with ND patients independent of age and blood pressure, while comparable 
between those on HD and PD.
TH-PO626
The Recent ADQI Proposal for a Functional Classification System of 
Heart Failure in Patients with End-Stage Renal Disease Will Substantially 
Overdiagnose Cardiac Disease Among Chronic Kidney Disease Patients 
Kathrin Untersteller,1 Francesca Mallamaci,2 Danilo Fliser,1 Gerard M. London,3 
Carmine Zoccali,2 Gunnar H. Heine.1  1Saarland Univ Medical Center, Homburg, 
Germany; 2CNR-Inst of Clinical Physiology, Reggio Calabria, Italy; 3Manhès 
Hospital, Fleury-Mérogis, France.
Background: The Acute Dialysis Quality Initiative (ADQI) XI Workgroup has recently 
proposed a novel classification for HF stages in advanced CKD, which is based upon a broad 
spectrum of echocardiographic criteria. We hypothesize that these criteria will substantially 
overdiagnose HF across the whole spectrum of CKD, as echocardiographic changes are a 
very frequent finding even among patients with mild to moderate CKD.
Methods: Within the ongoing CARE FOR HOMe study, we echocardiographically 
examined 317 patients in GFR categories G2 – G4, following American Society of 
Echocardiography guidelines. According to ADQI criteria, HF is defined by moderate to 
severe changes in any of the following criteria: valve function, left atrial volume index 
(LAVI), left ventricular (LV) or right ventricular systolic function, LV mass index, LV 
diastolic function, LV diameter, or regional LV wall contractility. Patients were followed 
for a mean of 3.6 ± 1.5 years until the first admission for decompensated HF.
Results: Among the 317 CKD patients, 209 (66%) fulfilled ADQI criteria. HF was 
detected more often in advanced CKD (G3b/G4: 114/146; 78%) than in milder CKD (G2/
G3a: 95/171; 56%). An increased LAVI (158/317; 50%) and diastolic dysfunction (101/317; 
32%) were the most frequent findings within the subcategories of echocardiographic 
changes. Among all 209 patients with ADQI HF, only 24 patients (11%) suffered 
decompensated HF during follow-up, and event-free four year survival was 89%.
Conclusions: The proposed ADQI criteria will substantially overdiagnose HF 
among patients with mild to moderate CKD. We suggest defining more conservative 
echocardiographic criteria for HF prior to introduction of this new classification in daily 
clinical practice. The validity and reliability of such revised criteria should subsequently 
be analyzed across the whole spectrum of CKD.
TH-PO627
Prognostic Value of Pulmonary Hypertension in Combination with Heart 
Valvular Calcification on Cardiovascular Outcome in Maintenance 
Hemodialysis Patients  Zhilian Li, Zhonglin Feng, Wei Dong, Sijia Li, Wei 
Shi.  Nephrology, Nephrology Dept of Guangdong General Hospital, Guangdong 
Academy of Medical Sciences, Guangzhou, Guangdong, China.
Background: Our previous study had revealed pulmonary hypertension (PH) as a 
predictor of all-cause mortality, cardiovascular mortality and new onset cardiovascular 
events in maintenance hemodialysis (MHD) patients. We hypothesize that patients 
complicated with both PH and heart valvular calcification (HVC) may take higher 
cardiovascular risk than those suffer from PH or HVC only.
Methods: 304 Chinese MHD patients were enrolled  and followed up for 24 months. 
Each patient underwent Doppler echocardiographic evaluation before entry. A value of 
Systolic PAP (SPAP) ³35 mmHg was defined as PH. HVC was defined as the presence of 
bright echoes of >1mm on one or more cusps of the aortic valve, mitral valve or mitral 
annulus. Patients were divided into 3 groups: No risk group (with neither PH nor HVC, 
n=140), One Risk Factor Group (with PH or HVC, n=121) and Two Risk Factors Group 
(with PH and HVC, n=43). The endpoints were all-cause mortality, CV mortality and 
CV events.
Results: A total of 63 (20.7%) patients died during follow-up from all causes; 18 
(12.9%) in Group 1, 29 (24.0%) in Group 2, and 16(37.2) in Group 3. 36 died of CV 
events (57.1% of the causes of death); 7(5.0%) in Group 1, 16(13.2) in Group 2, and 13 
(30.2%) in Group 3. All-cause and CV mortality increased significantly in both Group 2 
and 3. 101(33.2%) had new-onset CV during the follow-up period; 29(20.7%) in Group 
1, 43(35.5%) in Group 2, and 29 (67.4%) in the non-PH group, which was a significant 
difference (p<0.05).PH in combination with HVC increased risk for all-cause, CV mortality 
and new onset CV even[HR:4.32(2.01-8.90) versus 1.93(1.03-3.63) for all-mortality, 
6.49(2.57-16.39) versus 2.60(1.05-6.44) for CV mortality and 3.51(2.03-6.07) versus 
1.40(0.86-2.30) for new onset CV event].
Conclusions: PH in combination with HVC predicts worse outcome than those with 
either PH or HVC in MHD patients. Echocardiography can easily identify both PH and 
HVC, and is helpful to stratify risk in this population.
Funding: Government Support - Non-U.S.
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Survival of ESRD Patients Diagnosed with Idiopathic Heart Failure 
prior to Dialysis  Frances M. Yang,1 Chen chun Chen,1 Shuang Li,4 Adam E. 
Berman,2 Lu Y. Huber,2,3 Matthew J. Diamond,2,3 Mufaddal F. Kheda,2 Jusmin 
Patel,2 N. Stanley Nahman.2,3  1Biostatistics, Georgia Regents Univ, Augusta, 
GA; 2Medicine, Georgia Regents Univ; 3Medicine, Norwood VAMC, Augusta, 
GA; 4Statistics, UTMB, Galavaston, TX.
Background: Cardio-renal syndrome type 2 (CRS-2) is defined as chronic 
abnormalities in heart function leading to kidney injury or dysfunction, and may occur 
in over 60% of patients admitted for heart failure (HF) (Ronco, Eur Hrt J 31:703, 2010). 
Idiopathic HF (IHF) may clinically manifest as CRS-2 and progress to ESRD. The prognosis 
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of patients with pre-dialysis IHF after the institution of dialysis is unknown. We used the 
USRDS to compare survival between IHF patients diagnosed prior to ESRD (PRE) with 
patients developing IHF after the institution of dialysis (POST).
Methods: All incident adult ESRD cases from the USRDS from 1967-2012 were 
queried for a diagnosis of IHF before or after the incident date of dialysis. IHF was defined by 
the presence of any ICD-9 HF code (428.0 - 428.9), and the absence of other cardiovascular 
diagnoses. Descriptive statistics and co-morbidities by group were calculated, and survival 
analysis performed using Cox regression.
Results: 50,052 patients were identified with IHF. 46% and 54% were diagnosed with 
IHF PRE or POST the incident date of dialysis, respectively. When compared to POST, 
PRE were older (73% > age 65 vs. 33%), White (61% vs. 59%), diabetic (45% vs. 6%), and 
female (52% vs. 47%, all p < 0.001), and with a hazard ratio (HR) for death of 1.82 (95% 
CL 1.773-1.861, p < 0.001). Diabetes prior to dialysis and age > 44 years also exhibited 
increased HR for death (1.11 and 1.62, respectively). Non-white race was protective for 
death in all patients with IHF.
Conclusions: In ESRD, a diagnosis of IHF is common either before or after the incident 
date of dialysis. PRE is associated with decreased survival, perhaps due to pre-existing heart 
disease in an older, diabetic population. IHF in POST included younger patients likely with 
volume overload and an intact ejection fraction; thus with more readily reversible conditions. 
IHF before and after the incident date of dialysis may be two distinct entities, and suggests 
unique management strategies for each syndrome may be indicated.
TH-PO629
Association of Sleep Apnea with Mortality in Chronic and End Stage Kidney 
Disease Patients  Manisha Jhamb,1 Herbert T. Davis,2 Mark L. Unruh.2  1Univ 
of Pittsburgh; 2Univ of New Mexico.
Background: Presence of sleep apnea and its severity has been associated with 
increased mortality in the general population. In the dialysis population, limited evidence 
suggests an association of nocturnal hypoxemia with mortality. We sought to determine the 
association of sleep apnea and mortality in patients with advanced chronic kidney disease 
(CKD) and end-stage kidney disease (ESKD).
Methods: 180 patients (87 CKD stage 4-5, 93 ESKD), underwent 1 night home 
polysomnography. Sleep apnea severity was measured as number of apneas and 
hypopneas per hour (apnea-hypopnea index, AHI). Information on patients’ demographics, 
comorbidities and laboratory values was obtained from patient interviews and chart review. 
Mortality data was obtained from National Death Index. Chi-square and ANOVA were 
used to test between group differences and Cox proportional hazard model was employed 
to test association with mortality.
Results: 71% of the patients had sleep apnea (AHI≥5) and 23% had severe sleep apnea 
(AHI>30). There was no difference in age, race, hypertension, body mass index, smoking 
status, renal function status (CKD vs ESRD), depression, hemoglobin or albumin levels 
among patients with no or varying severity of sleep apnea. Males were more likely to have 
more severe sleep apnea. In both males and females, sleep apnea severity increased with 
age. Over a mean (SD) follow-up period of 9.0 (3.7) years, there were a total of 31 deaths 
and 57 patients received kidney transplant. We found no association between sleep apnea 
severity and all-cause mortality.However, in unadjusted analysis, more percentage of time 
with SpO2 < 90% was associated with higher mortality [HR 1.03 (1.01-1.06), p <0.001].
Conclusions: In patients with advanced CKD and ESRD, sleep apnea is common 
and increases in severity with age. Sleep apnea, as measured by AHI was not associated 
with all-cause mortality.
Funding: NIDDK Support, Private Foundation Support
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CKD Measures and Segment-Specific Arterial Stiffness: The Atherosclerosis 
Risk in Communities (ARIC) Study  Kunihiro Matsushita,1 Yuanjie Pang,1 
Yingying Sang,1 Shoshana Ballew,1 Hirofumi Tanaka,2 Gerardo Nmn Heiss,3 
Josef Coresh.1  1Johns Hopkins Univ; 2Univ of Texas; 3Univ of North Carolina.
Background: Several studies have reported an association of CKD with arterial 
stiffness but generally focus on either, but not both, of eGFR or albuminuria, assess pulse 
wave velocity (PWV) at limited segments, or investigate clinical populations.
Methods: We studied 3,687 ARIC participants aged 66-90 (mean 75) years during 2011-
13 after excluding those with missing variables and clinical conditions potentially biasing 
PWVs (e.g., morbid obesity). Four PWV parameters were assessed: carotid-femoral (cf, 
the indicator of central arterial stiffness), heart- and brachial-ankle (ha and ba, respectively, 
reflecting both central and peripheral stiffness), and femoral-ankle (fa, the indicator of 
peripheral stiffness). Multiple logistic regression was used to quantify the associations of 
eGFR and albuminuria with elevated PWV (highest 25% value) at each segment.
Results: There were 57.9% of women and 23.2% of blacks. After accounting for 
potential confounders, cfPWV was the only PWV parameter consistently and monotonically 
associated with both low eGFR and high ACR (Table). haPWV also demonstrated positive 
association with all high ACR categories. baPWV and faPWV were only significantly 
associated with high normal ACR (10-29 mg/g). None of haPWV, baPWV, and faPWV 
was significantly associated with low eGFR.
Conclusions: Both low eGFR and high ACR were independently associated with 
central arterial stiffness, with more robust results for ACR than for eGFR. In contrast, 
peripheral arterial stiffness tended to relate to high normal ACR but not necessarily to 
clinical ACR categories or low eGFR. These results suggest central artery stiffness as a 
pathophysiologic link in the cardiorenal interaction and potentially unique pathophysiology 
of elevated ACR within normal range. 
Funding: Other NIH Support - NHLBI
TH-PO631
Impact of Kidney Failure on Management and Outcome of Patients 
Admitted with Heart Failure  Debasish Banerjee, Juan Carlos Kaski, Lisa 
J. Anderson.  Renal and Transplantation Unit, St. Georges Hospital, United 
Kingdom.
Background: Data from epidemiological studies and intervention trials suggest poor 
prognosis in heart failure patients with kidney disease. However no study has investigated 
the impact of severe kidney failure on management and outcome of in-hospital heart 
failure patients.
Methods: We analysed data on clinical, laboratory, management and in-hospital 
mortality on 990 patients admitted between 01/03/2013 and 17/03/2013.
Results: Severe kidney failure (eGFR<30 ml/min/1.73m2) was present in 19% of 
patients and moderate kidney failure (eGFR 30-60 ml/min/1.73m2) was present in 43%. 
Patients with severe kidney failure, compared to the rest were older (79±11vs.75±13 
years; p<0.001), with lower haemoglobin (10.5±1.9 vs. 12±1.8 g/dL; p<0.001), higher 
potassium (4.8±0.8 vs. 4.2±0.6 mmol/L; P<0.05) and higher NT-pro BNP (17915±12911 
vs.9240±9577; p<0.001). Diuretics use in severe kidney failure patients was less (85% vs. 
90%, p<0.005); however β blocker use was similar (74% vs. 75%). Furosemide dose was 
high in severe kidney failure (101±62 vs. 79±43 mg; p<0.001) but dose of bumetanide 
was similar (3.9±2.3 vs. 4.1±1.9 mg, p=0.5). In the presence of echocardiographic LV 
dysfunction severe kidney failure patients were less likely to be on ACEi or ARB (24% 
vs. 74%; p<0.001). 98 patients who died during admission were older (78±10 vs. 76±13 
years; p<0.05), with lower haemoglobin (11.1±2.2 vs. 11.8±1.9 g/dL, p<0.01), higher 
creatinine (191±123 vs. 135±93 µmol/L; p<0.001), higher NT-pro BNP (16536±12727 
vs. 10174±10346, p<0.001) and higher potassium (4.7±0.9 vs. 4.2±0.6 mmol/L, p<0.001). 
In-hospital mortality was 6% in patients with eGFR>60, 8% with moderate kidney failure 
and 22% with severe kidney failure. Adjusted for age, haemoglobin, potassium and NT-pro 
BNP, presence of severe kidney failure was an independent predictor of mortality (p<0.01).
Conclusions: Among hospital admissions for heart failure, patients with severe kidney 
failure had low haemoglobin, high potassium, high BNP; were less often on ACEi/ARB and 
diuretics; suffered higher in-hospital mortality. Severe kidney failure is common, adversely 
affects management and outcomes in admitted heart failure patients.
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TH-PO632
Pulse Wave Velocity in Children with Chronic Kidney Disease 
Jonathan D. Savant,1 Aisha Betoko,2 Kevin E.C. Meyers,1,3 Mark Mitsnefes,2 
Joseph T. Flynn,2 Raymond R. Townsend,2 Larry A. Greenbaum,2 Allison Dart,2 
Bradley Warady,2 Susan L. Furth.1,2,3  1Dept of Pediatrics, The Children¶s Hospital 
of Philadelphia, Philadelphia, PA; 2Chronic Kidney Disease in Children (CKiD) 
Study Investigators; 3Perelman School of Medicine at the Univ of Pennsylvania, 
Philadelphia, PA.
Background: Pulse wave velocity (PWV) is a measure of arterial stiffness associated 
with CV events in the general population and adults with CKD. However, few data exist 
regarding PWV in children with CKD. We compared observed PWV to normative data 
in healthy children and examined risk factors associated with elevated PWV in children 
enrolled in the CKiD cohort study.
Methods: PWV was assessed via carotid/femoral tonometry using the SphygmoCor 
device (AtCor, Australia). PWV Z-score for height/gender was calculated from and 
compared to published pediatric norms (Reusz et al., 2010). Multivariate linear regression 
was used to assess the relationship between PWV and level of proteinuria (UP/C) adjusted 
for age, gender, race, height, waist circumference, mean arterial pressure (MAP), and GFR.
Results: 249 PWV studies were performed on 90 participants. 63% were male, 20% 
African American, 49% had glomerular CKD, 9% UP/C >2mg/mg; median age was 16 
years, median MAP was 82mmHg, and median GFR was 67 ml/min. Average PWV was 
5.1±0.9 m/s, Z-score= -0.01(1.2). As expected, PWV was significantly associated with 
age and MAP in multivariate analysis (Table 1). Additionally, the point estimate for UP/C 
was large but non-significant.
Conclusions: In this pediatric cohort with mild kidney dysfunction, arterial stiffness 
was comparable to that of normal children. Data collection is ongoing to further assess the 
effects of BP and proteinuria on arterial stiffness in children with CKD. 
Table 1. PWV multivariate analysis.
Variable Estimate  SE P-value
Age (years) 0.09 ± 0.04 0.02
Male -0.05 ± 0.17 0.79
African American 0.12 ± 0.20 0.55
Height (cm) -0.01 ± 0.01 0.41
Waist circumference (cm) 0.00 ± 0.01 0.47
MAP (mmHg) 0.03 ± 0.01 0.02
ieGFR (per 10 ml/min/1.73m2) -0.02 ± 0.04 0.56
UP/C (mg/mg) - -
<0.5 Ref. -
0.5-2.0 0.03 ± 0.22 0.88
>2.0 0.34 ± 0.32 0.29
Funding: NIDDK Support, Other NIH Support - NICHD, NHLBI
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The Cardiovascular Comorbidity in Children with Chronic Kidney Disease 
(4C) Study: Baseline Data of a Multicentre Prospective Observational 
Study  Uwe Querfeld,1 Anke Doyon,2 Elke Wuehl,2 Daniela Thurn-Valsassina,3 
Mieczys?aw P. Litwin,4 Aysun Bayazit,5 Ali Duzova,6 Mahmut Civilibal,7 
Betul Bs Sozeri,8 Franz S. Schaefer.2  1Pediatric Nephrology, Charité, Berlin, 
Germany; 2Pediatric Nephrology, Univ of Heidelberg, Heidelberg, Germany; 
3Pediatric Nephrology, MHH Hannover, Hannover, Germany; 4Pediatric 
Nephrology, Children¶s Memorial Health Inst, :arsaZ, Poland; 5Pediatric 
Nephrology, Cukurova Univ, Adana, Turkey; 6Pediatric Nephrology, Hacettepe 
Univ, Ankara, Turkey; 7Pediatric Nephrology, Haseki Hospital, Istanbul, Turkey; 
8Pediatric Nephrology, Ege Univ, Izmir, Turkey; 9Pediatric Nephrology, Univ 
Hospital Essen, Essen, Germany.
Background: The role of CKD-specific factors in the initiation and progression of 
cardiovascular disease (CVD) are likely to be characterized with increased sensitivity in 
the pediatric age group. The Cardiovascular Comorbidity in Children with CKD (4C) 
Study is a multicentre, prospective, observational study in children with CKD aged 6 to 
17 years, initial glomerular filtration rate 10-60 ml/min/1.73m² . The prevalence, degree 
and progression of cardiovascular comorbidity and its association with CKD progression 
is explored through longitudinal follow-up.
Methods: The morphology and function of the heart and large arteries is monitored by 
non-invasive methods and compared with aged-matched healthy controls.
Results: A total of 705 patients were enrolled in 55 participating centers from 
12 European countries. At baseline examination, 30% of children were hypertensive 
(ambulatory blood pressure monitoring), 40% had left ventricular hypertrophy 
(echocardiography), 40% showed an increased initima-media thickness of the carotid artery 
(cIMT; ultrasound), and 23% an increase in aortic pulse-wave velocity (PWV; oscillometry). 
By multivariate analysis, systolic blood pressure and serum levels of 25-hydroxyvitamin 
D, parathyroid hormone, and serum calcium- and phosphorus levels showed significant 
associations with age-corrected IMT and PWV, respectively.
Conclusions: Children aged 6-17 years with CKD stage 3-5 have significant sublinical 
CVD. At initial examination, surrogate endpoints of CVD were associated with systolic 
blood pressure and disturbances of mineral metabolism.
TH-PO634
Impaired Systolic and Diastolic Left Ventricular Function in Children with 
Chronic Didney Disease: Results from the Cardiovascular Comorbidity 
in Children with Chronic Kidney Disease (4C) Study  Anke Doyon,1 Pascal 
Haas,1 Maria chiara Matteucci,2 Francesca Mencarelli,3 Uwe Querfeld,4 Franz 
S. Schaefer.1  1Univ Children¶s Hospital, Heidelberg, Germany; 2Ospedale 
Bambino Gesu, Rome, Italy; 3Univ Children¶s Hospital, Bologna, Italy; 4Charité 
Children¶s Hospital, Berlin, Germany.
Background: Tissue doppler (TD) velocities are sensitive markers of left ventricular 
function. The aim of this work was to describe TD velocities in a large cohort of children 
with chronic kidney disease and to assess risk factors for ventricular dysfunction.
Methods: A standardized echocardiographic exam was performed in 128 patients of 
the 4C Study aged 6 -18 years with eGFR 10-60 ml/min/1.73 m2. TD measurements of the 
left ventricle included early (E’) and late (A’) diastolic and systolic (S’) velocity. Diastolic 
function was described by E’/A’ ratio and left ventricular compliance by early diastolic 
conventional to tissue doppler (E/E’) ratio. Measured values were normalized to z scores 
using reference data from 325 healthy children.
Results: TD diastolic E’ velocity was reduced and A’ increased at the mitral and septal 
anulus, resulting in a reduced E’ to A’ ratio (z-score -0.14, p<.0001) indicating diastolic 
dysfunction. Diastolic function (E’/A’) was positively correlated with midwall fractional 
shortening (r=0.23, p<0.01). Reduced diastolic function was independently associated with 
declining renal function (β=0.006, p=0.005), increased systolic blood pressure (β=-0.04, 
p=0.045) and pulse wave velocity (β=-0.03, p=0.07). Left ventricular compliance was 
increased (z-score 0.65, p<.0001), possibly as a result of increased preload. Systolic TD 
velocities were significantly decreased (z-score -0.24, p=0.001). Reduced systolic velocities 
in TD imaging were inversely correlated to left ventricular compliance (r=-0.4, p<.0001). 
The LVMI was not associated to systolic or diastolic TD velocities.
Conclusions: TD evaluation showed alterations of both systolic and diastolic function 
in children with chronic kidney disease. Renal function and systolic blood pressure are 
significant predictors for diastolic function. TD velocities are independent of LV mass and 
provide early information about ventricular dysfunction.
Funding: Private Foundation Support
TH-PO635
Rapid Early Postnatal Growth Increases Blood Pressure Level in 5-Year-
Old Children Born with Low Birthweight  Benedicte Stengel,1 Marion 
Taine,2 Marie-Aline Charles,2 Barbara Heude.2  1Epidemiology of Renal and 
Cardiovascular Disease Team, Inserm UMR1018, Villejuif, France; 2ORCHAD 
Team, Inserm UMR1153, Villejuif, France.
Background: Low birth weight (BW) is associated with hypertension and excess ESRD 
risk in adults, but whether postnatal growth may modify its impact on blood pressure (BP) 
and albuminuria in children is unknown. We studied the relationship of BW, gestational age 
(GA), and postnatal growth with BP and albuminuria in 5-year-old children.
Methods: We used data from the EDEN mother-child cohort of 1,119 children 
followed from birth to age 5. A mean of 17 weights were collected over this period which 
enabled to predict weights and weight growth velocities at any age. Three standard BP and 
albumin-to-creatinin ratio were measured at age 5. In order to avoid the reverse paradox 
phenomenon due to confounding by 5-year corpulence in the analysis of the relationship 
with BW, we studied BP SD-score preadjusted for age, gender, 5-year BMI and height. 
BW was also analyzed using age- and gender- specific z-score. We systematically tested 
interactions between BW categories and weight growth velocities in the relation with BP 
SD-score at different ages.
Results: Mean BW was 3,285±10 g. At 5 years of age, mean systolic BP was 101.5±0.3 
mmHg in boys, and 102.7±0.3 in girls. After adjusting for mothers’ pre-pregnancy BMI and 
hypertension status during pregnancy, the lower the BW z-score the higher the systolic BP 
SD score (beta=-0.06 ± 0.03, p=0.03), without gender interaction. In children born small 
for GA, faster weight growth in the first 4 months of life was associated with higher SBP 
SD-score at 5 years (p for interactions : 0.002 to 0.08 from 1 to 4 months), but not at older 
ages (p>0.20). Only boys born prematurely had elevated albuminuria level (>1mg/mmol) 
at age 5 : OR = 2.5[1.2-5.5].
Conclusions: Rapid early postnatal growth associates with higher blood pressure level 
in 5-year-old children born with low birthweight.They may deserve early monitoring for 
cardiovascular risk.
Funding: Government Support - Non-U.S.
TH-PO636
Kidney Function and Risk of Subclinical and Clinical Heart Failure in 
African Americans: The Jackson Heart Study  Ronit Katz, Nisha Bansal, Ian 
H. De Boer, Jonathan Himmelfarb, Maryam Afkarian, Bryan R. Kestenbaum, 
Bessie A. Young.  Kidney Research Inst, Univ of Washington, Seattle, WA.
Background: African-Americans (AA) and those with chronic kidney disease (CKD) 
have high risk for heart failure (HF). We determined in an AA cohort the association of 
kidney function with left ventricular disease (LVD) and risk of incident HF accounting 
for baseline LVD.
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Methods: We studied Jackson Heart Study participants and calculated eGFR from 
baseline serum creatinine (CKD-EPI equation) and urine albumin-to-creatinine ratio (ACR) 
from urine samples. We tested association of eGFR and urine ACR with left ventricular 
mass (LVM), left ventricular ejection fraction (LVEF) and incident HF.
Results: In 3332 participants, 5% had eGFR<60ml/min/1.73m2 and 12% had urine 
ACR>30mg/g. Mean LVM was higher in those with eGFR<60 (175g vs 147g) and urine 
ACR³30 (169g vs 143g). Mean LVEF was similar across eGFR and ACR levels. The 
association of eGFR with LVM was significant adjusting for age, sex, education, blood 
pressure, BMI, smoking, hypertension, statins, diabetes and cardiovascular disease 
(β-coefficient 13g[95% CI:7,19]), while association with LVEF was not (β-coefficient 
-0.9%[95% CI:-1.9,0.1]). Urine ACR³30mg/g was associated with higher LVM in adjusted 
models (β-coefficient 6g[0.7,11]); however, was not associated with LVEF (adjusted 
β-coefficient -0.4[95%CI:-1.2,0.4]). Rate of HF events was greater in those with CKD 
(Table). Higher urine ACR was strongly linked with incident HF after adjusting for LVM 
and LVEF (Table). 
Conclusions: LVM was higher in AA with lower eGFR and higher ACR. Higher 
urine ACR was linked with incident HF and not entirely explained by LVD. We show 
the importance of mild/early kidney dysfunction with risk of HF among AA. More study 
is needed to characterize the mechanisms by which kidney disease contributes to worse 
outcomes in HF in this group.
Funding: NIDDK Support
TH-PO637
Racial Differences in Risk of Chronic Kidney Disease in Patients with 
Congestive Heart Failure  Lekha K. George,1 Santhosh K. Koshy,1 Miklos 
Zsolt Molnar,1 Jun Ling Lu,1 L. Ebony Boulware,2 Keith C. Norris,3 Kamyar 
Kalantar-Zadeh,4 Csaba P. Kovesdy.1,5  1Univ of Tennessee Health Science Center, 
Memphis, TN; 2Duke Univ School of Medicine, Durham, NC; 3UCLA, CA; 4Univ 
of California, Irvine, CA; 5VA Medical Center, Memphis, TN.
Background: While CKD is more common in African Americans (AA), the prevalence 
of CV disease is lower in AA patients with CKD. It is unclear if the higher risk of incident 
CKD associated with AA race is modified by the presence of CHF.
Methods: Among 3,065,749 AA or white US veterans with eGFR>60ml/min/1.73m2, 
we identified 143,229 with a diagnosis of CHF (17% AA), and 2,922,520 with no CHF 
(18% AA). We examined the interaction of race with CHF for the risk of incident CKD and 
rapid rate of decline in eGFR (slopes <-5 ml/min/1.73m2/yr) during a median follow up 
of 7.8 yrs. We examined outcomes in Cox models (for CKD) and logistic regression (for 
slopes), including interaction terms for race-CHF, and adjusting for baseline age, gender, 
race, comorbidities, BMI, BP, eGFR and medication use.
Results: Mean±SD baseline age and eGFR were 68±11 yrs and 79±14 ml/min/1.73m2 
for patients with CHF, vs. 59±14 yrs and 84±16 ml/min/1.73m2 for those without CHF. 
327,548 (11%) patients developed incident CKD and 253,081 (9%) experienced rapid 
eGFR decline. AA race showed a significant interaction with HF for both CKD incidence 
(p=0.009) and loss of kidney function (p<0.001). Compared to white patients with no CHF, 
AA patients with CHF experienced a >2-fold higher risk of incident CKD and more rapid 
eGFR loss after multivariable adjustments (Figure). 
Conclusions: The increased risk of renal complications associated with AA vs. white 
race is higher in patients with CHF compared to those with no CHF. Interventions aimed at 
improving renal outcomes in AA patients with CHF should be further examined.
Funding: NIDDK Support, Veterans Administration Support
TH-PO638
Incidence of Congestive Heart Failure in African-American versus White 
Patients with and without Chronic Kidney Disease  Csaba P. Kovesdy,1,2 
Miklos Zsolt Molnar,2 Praveen Kumar Potukuchi,2 Jun Ling Lu,2 Kamyar 
Kalantar-Zadeh.3  1Memphis VA Medical Center; 2Univ of Tennessee Health 
Science Center; 3Univ of California Irvine.
Background: African Americans (AA) are at higher risk of cardiovascular disease 
and its complications, such as congestive heart failure (CHF). CKD is also more common 
in AA, yet the prevalence of coronary artery disease is lower in AA patients with CKD. 
It is unclear if the risk of CHF is also lower in AA with CKD, given its more complex 
pathophysiology in patients with kidney disease.
Methods: Among 2,929,736 AA (N=523,181) or white (N=2,406,555) US veterans 
with eGFR≥60 ml/min/1.73m2 and no CHF at baseline, we examined the association of 
AA race with incident CHF (hospitalization-based ICD9 codes) during a median follow up 
of 6.7 yrs. We examined outcomes separately in patients who maintained an eGFR≥60 ml/
min/1.73m2 (non-CKD group; N=2,632,034), and those who developed 2 eGFR values <60 
with >90 days in-between (CKD group; N=286,597). We used Cox proportional hazards 
models, without adjustments (Model 1) and with sequential adjustments for baseline 
demographics and eGFR (Model 2), comorbidities (Model 3), BMI and BP (Model 4), 
and medications and socioeconomic indicators (Model 5).
Results: 71,137 (event rate: 4.8/1000 patient-years, 95%CI: 4.8-4.9) and 42,067 
(26.4/1000PY, 26.2-26.7) patients developed CHF in the non-CKD and CKD groups, 
respectively. Compared to whites, AA race was associated with similar unadjusted risk of 
CHF in non-CKD (hazard ratio, 95%CI: 0.97, 0.95-0.99), but with higher unadjusted risk 
among CKD (1.23, 1.20-1.26). After adjustments, the risk of CHF in AA was minimally 
lower in both non-CKD and CKD patients (Figure1). 
Conclusions: The risk of incident CHF is slightly lower in AA US veterans with and 
without CKD. These qualitatively different associations compared to the non-veteran 
population warrant additional studies.
Funding: NIDDK Support, Veterans Administration Support
TH-PO639
Continued Underrepresentation of Patients with Kidney Disease in 
Cardiovascular Trials: An Updated Systematic Review After a Decade 
Ioannis Konstantinidis,1 Aparna Saha,1 Priti R. Poojary,1 Priya Simoes,1 Rabi 
Yacoub,1 Chirag R. Parikh,2 Girish N. Nadkarni,1 Steven G. Coca.1  1Mount 
Sinai Medicine; 2Yale Univ.
Background: Cardiovascular disease (CVD) is a major cause of morbidity/mortality in 
kidney disease (KD). Two systematic reviews showed that KD patients are underrepresented 
in CVD randomized controlled trials (RCTs) using data from 1985-2005 and 1998-2005. 
We aimed to update estimates of KD patient representation in major CVD RCTs over the 
past decade.
Methods: We searched MEDLINE for congestive heart failure/acute coronary 
syndrome RCTs in major journals between 2006-2014. We excluded RCTs not reporting 
mortality outcomes, with <100 participants, or were subgroup, follow-up, or post-hoc 
analyses.
Results: We included 371 trials randomizing 590,040 participants. KD patients were 
excluded in 212 (57.1%) RCTs and were more likely to be excluded from North American 
(p=0.02) or industry-funded (p=0.01) trials. They were more likely to be excluded in RCTs 
of anticoagulants, antiplatelet agents, statins or RAAS antagonists compared to trials of 
PCI (p£0.01).
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Of 212 RCTs excluding KD patients, 111 (52.4%) used serum creatinine, 25 (11.8%) 
used eGFR cut-offs, 23 (10.8%) used creatinine clearance, 60 (28.3%) excluded if on renal 
replacement and 36 (17.0%) had non-specific kidney-related exclusions. Only 156 (42.0%) 
trials reported baseline kidney function and only 84 (22.6%) trials reported the proportion 
of KD patients in each randomization arm. While 197 (53.1%) reported subgroup analyses 
of >1 non-renal baseline characteristics, only 60 (16.2%) reported subgroup analyses by 
renal parameters.
Conclusions: Most CVD RCTs continue to exclude KD patients. They neither 
adequately report nor analyze outcomes by participants’ baseline kidney function.
Funding: NIDDK Support
TH-PO640
Effect of Niacin on Markers of Mineral Metabolism in CKD: The AIM-
HIGH Trial  Joachim H. Ix,1 Ronit Katz,2 Andrew N. Hoofnagle,2 Dena E. 
Rifkin,1 Andrew Bostom,3 Jeffrey L. Probstfield,2 Geoffrey A. Block.4  1UCSD; 
2U Washington; 3Brown Univ; 4Denver Nephrology.
Background: Niacin blocks intestinal phosphate (P) transport in vitro. Short-term 
human studies suggest niacin lowers P in CKD patients. Longer-term effects on P, and on 
other mineral markers are uncertain. Fibroblast growth factor (FGF) 23 is a phosphaturic 
hormone that induces left ventricular hypertrophy in vitro and higher levels are associated 
with heart failure and death in CKD patients. Higher serum P may stimulate higher FGF23. 
We hypothesized that 3-year treatment with niacin would induce lower plasma P (1° aim) 
and FGF23 (2° aim) in CKD patients.
Methods: AIM-HIGH randomized 3,414 patients with cardiovascular disease (CVD) 
and dyslipidemia to sustained-release niacin 1500-2000mg vs. placebo (pbo) for prevention 
of recurrent CVD events (1° endpoint). Both groups were on a background of statin therapy. 
Exclusions included serum Cr ≥ 2.7mg/dL. The trial was stopped after 3 yrs mean follow-
up due to futility. In 352 patients with eGFR<60 ml/min/1.73 m2, we measured plasma P, 
calcium (Ca), intact (i) FGF23 (Kainos), intact parathyroid hormone (iPTH), and calcitriol 
(LC/MS) at baseline, yr 1, and yr 3. Mean levels were compared between arms, and linear 
mixed models provided summary estimates of the effect of niacin on each.
Results: Demographics, CVD history, and CVD risk factors were well balanced in 
the pbo (n=174) and niacin (n=178) arms at baseline. Mean eGFR was 47±8 and 45±9 ml/
min/1.73 m2, respectively. At 3 yrs, P was 0.25mg/dL lower in the niacin vs. pbo arm. No 
significant differences were noted in iFGF23, Ca, iPTH, or calcitriol between arms at 3 yrs.
Conclusions: Niacin lowers serum P in CKD patients, an effect that extends for 3 
yrs. We observed no significant effect of niacin on other mineral measures. Regulation of 
FGF23 may be more complex than simply reflecting changes in serum P.
Funding: NIDDK Support, Veterans Administration Support
TH-PO641
Efficacy and Safety of Modified-Release Calcifediol in Stage 3-4 CKD 
Patients with Secondary Hyperparathyroidism and Vitamin D Insufficiency 
Stuart M. Sprague,1 Stephen A. Strugnell,2 Joel Z. Melnick,2 Jay A. White,2 
Martin P. Petkovich,3 Charles W. Bishop.2  1Medicine, NorthShore Univ 
HealthSystem-Univ of Chicago, (vanston, IL; 22PK2 Health, Miami, FL; 
3Queens Univ, Kingston, ON, Canada.
Background: Current approaches to correct vitamin D insufficiency (VDI) in 
stage 3 or 4 CKD are poorly defined and generally ineffective in controlling secondary 
hyperparathyroidism (SHPT). The effectiveness of modified-release calcifediol (MRC) at 
correcting VDI and controlling SHPT was evaluated.
Methods: Two identical, randomized, double-blind, placebo-controlled trials were 
conducted in patients with SHPT (>85 pg/mL), stage 3 or 4 CKD and VDI (serum 25OHD 
of 10-29 ng/mL). The trials enrolled a total of 429 subjects from 77 US sites, randomized 
2:1 to receive MRC or placebo for 26 weeks. MRC dosing started at 30 mg/d and increased, 
as needed to lower iPTH, to 60 mg/d after 12 weeks. Subjects were stratified based upon 
their 25OHD levels (0-20, 20-40, 40-60, 60-80 or > 80 ng/mL) at the end of treatment 
(EOT). The mean EOT plasma iPTH, serum total 1,25-dihydroxyvitamin D (1,25D), serum 
Ca and Phos in each group were calculated and compared.
Results: A total of 364 (85%) subjects completed the trials. Serum 1,25D levels 
progressively increased with increasing 25OHD concentrations, with mean levels 41% 
higher in the highest quintile compared to the lowest (p < 0.001). Conversely, plasma 
iPTH progressively decreased with increasing 25OHD concentrations, with mean iPTH 
levels 40% lower in the subjects with the highest- 25OHD concentrations compared to 
the lowest concentrations (Figure; p < 0.001). No changes were observed in serum Ca and 
Phos concentrations independent of 25OHD concentration. 
Conclusions: MRC increased serum total 25OHD levels and total 1,25D, while 
reducing plasma iPTH, without significantly increasing serum Ca or Phos in CKD patients 
with SHPT and VDI.
Funding: Pharmaceutical Company Support - OPKO Health
TH-PO642
CKD-MBD Indices After 52 Weeks of Sucroferric Oxyhydroxide, an 
Iron-Based Phosphate Binder, in African American Dialysis Patients 
Stuart M. Sprague,1 Anjay Rastogi,2 Markus Ketteler,3 Adrian C. Covic,4 Jürgen 
Floege,5 Viatcheslav Rakov,6 Llera Armando Samuels.7  1NorthShore Univ Health 
System, Chicago; 2Univ of California; 3Coburg Clinic and KfH-Dialysis Center, 
Germany; 4¶Gr.T. Popa¶ Univ of Medicine and Pharmacy, Romania; 5RWTH 
Univ Hospital Aachen, Germany; 6Vifor Pharma; 7Temple Univ, Philadelphia.
Background: A post hoc analysis of data from a randomized, open-label, Phase 3 study 
and its extension investigated the effects of the iron-based phosphate binder sucroferric 
oxyhydroxide (SFOH; VELPHORO®) vs sevelamer carbonate (SEV; Renvela®) on chronic 
kidney disease-mineral bone disorder (CKD-MBD) indices in African American dialysis 
patients.
Methods: Overall, 1059 patients were randomized to SFOH (1.0–3.0 g/day; n=710) 
or SEV (2.4–14.4 g/day; n=349) for 12 weeks’ dose titration then 12 weeks’ maintenance. 
Eligible patients enrolled in a 28-week extension study.
Results: Of the 549 patients who completed the extension study, 100 were African 
American patients, (n=48, SFOH; n=52, SEV). Serum phosphorus control was maintained 
over 1 year; both SFOH and SEV were associated with significant decreases in serum 
phosphorus from baseline to Week 52 (Table), as well as significant reductions in mean 
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serum fibroblast growth factor-23 (FGF-23). Decreases in mean serum intact parathyroid 
hormone (iPTH) were seen with both treatments over 52 weeks, but were not significant 
with SFOH. There were small but statistically significant increases in total calcium levels 
in both groups over 52 weeks. No significant differences between treatment groups were 
observed for any of the indices reported here.
Conclusions: SFOH and SEV led to reductions in serum phosphorus, FGF-23 and 
iPTH over 1-year of treatment in African American dialysis patients. Post hoc results so 
far reflect those from the overall study population. 
Funding: Pharmaceutical Company Support - Vifor Pharma
TH-PO643
Concomitant IV Iron Use Drives Changes in Iron Indices in African 
American Dialysis Patients Over 52 Weeks of Sucroferric Oxyhydroxide 
Treatment  Stuart M. Sprague,1 Anjay Rastogi,2 Markus Ketteler,3 Adrian 
C. Covic,4 Jürgen Floege,5 Viatcheslav Rakov,6 Llera Armando Samuels.7 
1NorthShore Univ Health System, Chicago; 2Univ of California; 3Coburg 
Clinic and KfH-Dialysis Center, Germany; 4Gr.T. Popa¶ Univ of Medicine and 
Pharmacy, Romania; 5RWTH Univ Hospital Aachen, Germany; 6Vifor Pharma; 
7Temple Univ, Philadelphia.
Background: A post hoc analysis of data from a randomized, open-label, Phase 3 study 
and its extension investigated iron indices after treatment with the iron-based phosphate 
binder sucroferric oxyhydroxide (VELPHORO®; SFOH) vs sevelamer carbonate (SEV) in 
African American dialysis patients who received IV iron vs those who did not.
Methods: Overall, 1059 patients were randomized to SFOH (1.0–3.0 g/day; n=710) 
or SEV (2.4–14.4 g/day; n=349) for 12 weeks’ dose titration then 12 weeks’ maintenance. 
Eligible patients enrolled in a 28-week extension study.
Results: Of the 549 patients who completed the extension study, 100 were African 
American (n=48, SFOH; n=52, SEV). A high proportion of patients in the SFOH and 
SEV groups received IV iron (95.8 and 92.3%) and erythropoietin-stimulating agents 
(95.8 and 98.1%) during the 1-year study. Baseline levels of ferritin appeared elevated in 
both treatment groups with higher levels in the SEV group (Table). Significant increases 
in ferritin were observed in SFOH ‘IV iron’ subgroup. Ferritin and TSAT levels increased 
only in patients receiving IV iron. Hemoglobin was relatively stable over 1 year.
Conclusions: Changes in iron indices in both treatment groups were mainly attributable 
to concomitant IV iron use. Differences between groups may be due to baseline differences 
and minimal iron uptake from SFOH, although no signs of iron accumulation were observed 
over 1 year. Post hoc results, in terms of changes in iron indices, reflect those from the 
overall study population.
Funding: Pharmaceutical Company Support - Vifor Pharma
TH-PO644
The Effectiveness and Safety of Cinacalcet: Randomized, Open Label 
Study in Chronic Hemodialysis Patients with Severe Secondary 
Hyperparathyroidism  Paweena Susantitaphong,1 Teerada Susomboon,2 
Wanchana Singhan,2 Somratai Vadcharavivad,2 Kearkiat Praditpornsilpa.1  1Dept 
of Medicine, Chulalongkorn Univ, Bangkok, Thailand; 2Dept of Pharmacy 
Practice, Chulalongkorn Univ, Bangkok, Thailand.
Background: Secondary hyperparathyroidism (HPT) results in high incidence 
of cardiovascular disease, bone fracture, and mortality. This study was conducted to 
demonstrate the efficacy of treatment with cinacalcet compared to control group for 
controlling plasma parathyroid hormone (iPTH) levels among hemodialysis (HD) subjects 
with severe secondary HPT.
Methods: 60 adult HD patients with iPTH> 800 pg/mL and serum calcium> 9 mg/dL 
was randomized 1:1 for treatment (cinacalcet 25-100 mg/day) and control group for 12 
weeks follow up. The patients who previously received cinacalcet and parathyroidectomy 
were excluded. Achievement of>30% reduction of iPTH from baseline was set up as 
primary end-point.
Results: The mean baseline iPTH of both groups were comparable (1,435±506 pg/mL 
in control group and 1,535±965 pg/mL in treatment group). Following 12-week treatment 
in 30 HD patients, the percentage reductions of iPTH was significantly different (-67% in 
treatment group and -13% in control group, P=0.02). Regarding the ethic issue, we switched 
the patients in control group to treatment group and follow up as prospective cohort study 
to further explore the optimal cinacalcet dose on baseline iPTH. The mean cinacalcet dose 
was 50±23 mg/day. The mean serum calcium and phosphate were significantly decreased 
from baseline. On contrary, the dialysate calcium was significantly increased from baseline. 
Subgroup analysis by baseline iPTH on efficacy of cinacalcet showed that higher iPTH 
level associated with less reduction of iPTH to achieve primary end-point.
Subgroup by baseline PTH level in cinacalcet 
group
Equal or greater 30% reduction of PTH from 
baseline at 12-wk follow up
PTH 801-1600 pg/mL 22/26 (85%)
PTH 1601-2400 pg/mL 8/14 (57%)
PTH 2401-3200 pg/mL 1/2 (50%)
PTH >3,200 pg/mL 1/3 (33%)
P-Value (Linear by linear association) 0.018
Conclusions: The high efficacy of cinacalcet was still demonstrated even in case of 
severe secondary HPT. However, higher iPTH reduced the efficacy outcome of cinacalcet.
TH-PO645
A Double-Blind, Randomized, Placebo-Controlled Trial of Ergocalciferol 
with/without Calcitriol in Chronic Kidney Disease with Proteinuria 
Paweena Susantitaphong, Siriwan Nakwan, Khajohn Tiranathanagul, Pisut 
Katavetin, Kearkiat Praditpornsilpa, Somchai Eiam-ong.  Dept of Medicine, 
Chulalongkorn Univ, Bangkok, Thailand.
Background: These are no available data regarding the role of natural vitamin D with/
without active vitamin D on proteinuria and renal function in CKD patients with vitamin 
D insufficiency/deficiency.This study was conducted to explore the additional effect of 
both active vitamin D (calcitriol) and natural vitamin D (ergocalciferol) on proteinuria and 
kidney function in CKD with vitamin D insufficiency/deficiency.
Methods: The first double-blind, randomized placebo-controlled trial was performed to 
answer this question. Sixty eight patients with eGFR 15-60 mL/min/1.73m2, UPCR greater 
than 1 g/g,and vitamin D insufficiency/deficiency were enrolled. Patients were randomly 
assigned to receive 12-week treatment with oral ergocalciferol plus placebo (n=36) or 
ergocalciferol plus oral calcitriol (n=32).
Results: The mean baselines UPCR of both groups were comparable (3.6 ± 3.8 g/g in 
combined group and 3.5±3.0 g/g in ergocalciferol group). Following 12 -week treatment, 
there were significant reductions in UPCR of both groups from baseline (2.3± 2.1 g/g in 
combined group and 2.4± 2.0 g/g in ergocalciferol group). The percentage reductions in 
UPCR of both groups were not significantly different (-25.5% in combined group and -23.7% 
in ergocalciferol group). These effects were demonstrated in all range of proteinuria, diabetic 
nephropathy, non-diabetic nephropathy, receiving RAAS blockade and non-receiving 
RAAS blockade. The mean eGFR and blood pressure did not differ between baseline and 
12-week follow up and between both groups. No severe hypercalcemia or serious side 
effects were noted in both groups.
Conclusions: This is the first RCT which illustrates the lowering proteinuria effect of 
ergocalciferol in CKD patients with vitamin D deficiency. However, additional calcitriol did 
not have more effects on proteinuria. Therefore, ergocalciferol should be added for more 
decreasing proteinuria in CKD patients with proteinuria that cannot tolerate or increase 
the dosage of RAS blockage due to any side effects.A longer study is required to examine 
the renal function retardation effects.
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TH-PO646
Anemia Correction with Roxadustat Lowers Hepcidin in Chronic Kidney 
Disease (CKD) Patients  Lynda Szczech, Anatole Besarab, Khalil Georges 
Saikali, Stefan Hemmerich, Lona Poole, Gopal Saha, Kin-Hung Peony Yu, 
Frank H. Valone, Thomas B. Neff.  FibroGen, San Francisco, CA.
Background: The hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat 
(FG-4592) is being developed for treatment of CKD anemia. Hepcidin regulates iron 
metabolism and higher levels are associated with greater mortality. This analysis of phase 
2 studies was undertaken to explore the consistency of the suppressive effect of roxadustat 
on hepcidin.
Methods: Among CKD-NDD (017 and 041) & CKD-DD (040 and 053) studies, 
roxadustat doses, study duration, and comparator (placebo or epoetin) varied. Studies 
restricted IV iron in general but allowed oral iron. Baseline (BL) hepcidin and change from 
BL (CFB) are summarized (mean±SD) overall and by BL tertile. Significant differences 
(p<0.05 vs BL) based on within-group comparisons (A).
Results: Mean BL hepcidin in CKD-NDD roxadustat subjects was 292.8±179.8 
and 120.3±107.0 ng/mL (studies 017 & 041). Hepcidin fell with roxadustat treatment 
by 158.4±179.2 & 45.6±87.7. Mean BL hepcidin in CKD-DD roxadustat subjects was 
303.9±172.9 & 91.1±90.0 (040 and 053). Hepcidin fell with roxadustat treatment by 
26.7±192.0 & 57.4±68.5. For both groups, the greatest declines were in the highest BL 
tertiles.
Study Treatment Hepcidin at BL
CFB during 
treatment 
(4 wks, 8 wks 
for 041)
CFB: 
highest 
tertile BL 
hepcidin
CFB: 
middle 
tertile BL 
hepcidin
CFB: 
lowest 
tertile BL 
hepcidin
017
Roxadustat 
(N=38)
292.8± 
179.8
-158.4± 
179.2A
-290.7± 
211.2A
-132.3± 
67.7
-52.2± 
106.5A
Placebo 
(N=15)
288.7± 
176.3 -29.0 ± 70.6
041 Roxadustat (N=139)
120.3± 
107.0 -45.6 ± 87.7A
-108.3± 
120.7A
-22.2± 
63.6A
-14.2± 
23.1A
040
Roxadustat 
(N=100)
303.9± 
172.9 -26.7± 192.0
-90.3± 
247.6
-32.6± 
166.7
27.7± 
151.8
Epoetin alfa 
(N=34)
283.6± 
135.2 25.5± 147.9
053 Roxadustat (N=57) 91.1± 90.0 -57.4±  68.5A
-112.6± 
93.1A
-45.2± 
26.5A
-16.7± 
17.7A
Conclusions: Roxadustat consistently lowered hepcidin in phase 2 studies. The 
decrement in hepcidin is greatest among those with the highest BL levels. The roxadustat 
phase 3 trials will include measurements of hepcidin to further define this effect.
Funding: Pharmaceutical Company Support - FibroGen
TH-PO647
Anemia Correction with Roxadustat Increases Soluble Transferrin Receptor 
(sTfR) in Chronic Kidney Disease (CKD) Patients  Lynda Szczech, Anatole 
Besarab, Khalil Georges Saikali, Stefan Hemmerich, Lona Poole, Kin-Hung 
Peony Yu, Frank H. Valone, Thomas B. Neff.  FibroGen, San Francisco, CA.
Background: The hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat 
corrected anemia in phase 2 trials without IV iron.This analysis of 4 phase 2 studies explores 
roxadustat’s effect on sTfR levels.
Methods: In phase 2 studies CKD-NDD 017 & 047 and CKD-DD 040 & 048, subjects 
were randomized to roxadustat at different doses with comparator arms of placebo or 
epoetin-alfa. Studies restricted IV iron use in general but allowed oral iron. sTfR at baseline 
(BL) and % change from BL were summarized by treatment.
Results: Among CKD-NDD subjects (n=125), BL sTfR mean±SD was 1.35±0.56 and 
3.58±1.69 mg/L (studies 017 & 047 respectively) in roxadustat groups. sTfR rose with 
roxadustat treatment in both studies by 86.5% and 101.5%. These increases were greater 
than the placebo arm (15.3% & 2.6%, p=0.0081 & <0.0001 respectively). Among subjects 
with CKD-DD (n=199), BL sTfR mean±SD was 3.57±1.41 and 3.33±1.47 mg/L (studies 
048 & 040 respectively) in the roxadustat group. In 040, the increase in the roxadustat group 
was greater than in the epoetin arm (31.1% vs -0.7% respectively, p=0.0013). However, in 
048, the changes in sTFR were comparable to epoetin arm (32.1 vs 39.9% respectively).
Study
Population 
(N)
Control 
(N)
Baseline sTfR mg/L
Mean (SD) EOT
% Change from BL
Mean (SD)
Roxadustat Control Roxadustat Control
017 CKD-
NDD (24)
Placebo 
(10) 1.35 (0.56)
1.37 
(0.43)
Day 
26-29 86.5 (92.9)
15.3 
(42.7)
047 CKD-
NDD (61)
Placebo 
(30) 3.58 (1.69)
3.47 
(1.20) Week 8 101.5 (72.2) 2.6 (17.8)
040 CKD-
DD (78)
Epoetin 
(26) 3.33 (1.47)
3.52 
(1.04) Day 43 31.1 (60.1)
-0.7 
(21.3)
048 CKD-
DD (73)
Epoetin 
(22) 3.57 (1.41)
2.92 
(1.21) Week 7 32.1 (54.6)
39.9 
(61.8)
Conclusions: Roxadustat consistently increased sTfR in phase 2 studies with oral 
iron supplementation. Placebo had little effect on sTfr, and epoetin results varied. The 
consistent increase in sTfR supports sufficient iron delivery for erythropoiesis during 
the time periods studied. The coordinated erythropoiesis induced by roxadustat is being 
evaluated in phase 3 trials.
TH-PO648
Anemia Correction with Roxadustat Lowers Cholesterol in Chronic Kidney 
Disease (CKD) Patients  Lynda Szczech, Anatole Besarab, Khalil Georges 
Saikali, Stefan Hemmerich, Brian K. Roberts, Lona Poole, Kin-Hung Peony Yu, 
Frank H. Valone, Thomas B. Neff.  FibroGen, San Francisco, CA.
Background: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor roxadustat 
is being developed for CKD anemia.The HIF pathway affects cholesterol metabolism & 
ascension to altitude reduces total cholesterol (TC).This analysis of phase 2 studies explores 
roxadustat’s effect on TC in non-dialysis (NDD) and dialysis (DD) CKD.
Methods: In Phase 2 studies 41&47 in NDD & 40,48&53 in DD, roxadustat dose, 
study duration and comparator (placebo, epoetin) varied. Studies restricted IV iron but 
allowed oral iron. Baseline (BL) TC and change from BL (∆) were summarized overall 
and by BL tertile. Data are mean±SD.
Results: Among roxadustat NDD subjects (n=206), mean BL TC was 170.9±45.2 and 
166.8±39.1 mg/dL (studies 41&47). TC fell with roxadustat by 25.8±29.7 and 33.7±31.8. 
Among roxadustat DD subjects (n=238), mean BL TC was 171.1±35.1, 174.3±57.3, and 
171.0±56.7 (studies 48, 53&40). TC fell with roxadustat treatment by 14.2±36.4, 44.4±45.9 
and 36.7±37.0. The greatest declines were among the highest BL tertile in both populations.
Study Treatment (N) BL TC
CFB during 
treatment
CFB in 
highest 
tertile of 
BL TC
CFB in 
middle 
tertile of 
BL TC
CFB in 
lowest 
tertile of 
BL TC
041 Roxa (145) 170.9± 45.2 -25.8± 29.7*
-33.5± 
37.1*
-28.7± 
26.8*
-15.9± 
21.5*
047
Roxa (61) 166.8± 39.1 -33.7± 31.8*
-48.1± 
38.1*
-33.8± 
14.3*
-16.4± 
31.0
Placebo (30) 182.6± 52.0 +8.0± 30.0
048
Roxa (74) 171.1± 35.1 -14.2± 36.4*
-21.9± 
39.4*
-14.3± 
34.5 -7.0± 35.2
Epoetin alfa 
(22)
158.4± 
28.4
+18.3± 
24.3*
053 Roxa (56) 174.3± 57.3 -44.4± 45.9*
-66.3± 
29.2*
-58.0± 
36.9* -11.3± 48.9
040
Roxa (108) 171.0± 56.7 -36.7± 37.0*
-59.3± 
48.6*
-35.4± 
21.8*
-16.6± 
19.8*
Epoetin alfa 
(36)
168.9± 
40.5 +4.1± 27.4
*p<0.05 two-sided;within-group comparisons; ∆ at wk 9 for 041 and wk 5 for 053.
Conclusions: Roxadustat consistently lowered TC in phase 2 studies.The decrement in 
TC is greatest among those with highest BL levels. Roxadustat phase 3 trials will include 
tests to further define this effect and significance.
Funding: Pharmaceutical Company Support - FibroGen
TH-PO649
AKB-6548 Demonstrates Controlled Hemoglobin (HGB) Response in a 
Phase 2b Study for the Treatment of Anemia in Patients with Chronic 
Kidney Disease Not on Dialysis (ND-CKD)  Volker H. Haase,1 Bruce S. 
Spinowitz,2 Pablo E. Pergola,3 Tasha Farmer,4 Bradley J. Maroni,4 Charlotte 
S. Hartman.4  1Vanderbilt Univ, Nashville, TN; 2New York Hospital Queens, 
Flushing, NY; 3Renal Associates PA and Univ of Texas Health Sciences Center, 
San Antonio, TX; 4Akebia Therapeutics, Inc., Cambridge, MA.
Background: AKB-6548 is a novel, once daily, oral hypoxia-inducible factor prolyl-
hydroxylase inhibitor (HIF-PHI) that preferentially stabilizes HIF-2α. Current standard 
of care for anemia in ND-CKD with recombinant ESAs often results in overshoots and 
oscillations of HGB levels. It has been suggested that fluctuations in HGB concentrations, 
rapidly increasing HGB levels, and overshoots of the HGB target are associated with 
increased risk of cardiovascular events. Presented here are data assessing the control and 
predictability of HGB response from a Phase 2b study.
Methods: A randomized, double-blind, placebo-controlled study was conducted to 
assess the HGB response of AKB-6548 over 20 weeks of dosing in ND-CKD subjects 
with anemia. 210 subjects were randomized 2:1 (138 AKB-6548, 72 placebo) to once daily 
AKB-6548 (450mg) or placebo. HGB was monitored at each study visit and a protocol-
defined dose adjustment algorithm was used to raise and maintain HGB and to minimize 
excursions ³13 g/dL.
Results: The starting dose of 450 mg once daily was validated by the final average dose 
of 450 mg/day in the AKB-6548-treated subjects. Only 15 subjects (11%) had a confirmed 
HGB ³12 g/dL and only 2 subjects (1%) had a confirmed HGB ³13 g/dL. From Weeks 12 
to 20, 74% and 81% of all HGB measurements were between 10-12 g/dL and 10-13 g/dL, 
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respectively. The majority of subjects (120 of 135, 89%) achieved and maintained a stable 
HGB level with 2 or fewer dose adjustments throughout the 20-week treatment period and 
24% (33 of 135) of subjects required no dose adjustment.
Conclusions: AKB-6548 increased and maintained HGB levels in ND-CKD patients 
in a controlled and predictable manner with minimal dose adjustments. The study provides 
support that targeting the HIF oxygen sensing pathway is likely to represent a more 
physiologic and potentially safer approach to treating anemia than currently available 
therapy.
TH-PO650
Randomized Controlled Trial of Darbepoetin Alfa and Continuous 
Erythropoietin Receptor Activator Once Every 4 Weeks in Patients with 
Chronic Kidney Disease at the Pre-Dialysis Stage  Tetsuya Furukawa, 
Kazuyoshi Okada, Ritsukou Tei, Masanori Abe, Noriaki Maruyama.  Div of 
Nephrology, Hypertension and Endocrinology, Dept of Medicine, Nihon Univ 
School of Medicine, Tokyo, Japan.
Background: Subcutaneous injection of Continuous Erythropoietin Receptor Activator 
(CERA) seems to maintain a stable Hb level than darbepoetin alfa (DA) in CKD patients 
who are not on dialysisbecause of its longer half-life. We therefore conducted a randomized 
controlled trial.
Methods: The cohort consisted of 20 CKD patients at the pre-dialysis stage who were 
receiving a fixed dose of DA with a Hb level >9.5 g/dL and ferritin level >80 ng/mL in the 
12 weeks prior to the study. Patients were randomly assigned to receive subcutaneous CERA 
or DA once every 4 weeks. The study consisted of a 48-week evaluation period. The target 
Hb range was from 11.0 g/dL to 12.5 g/dL. Primary endpoints were rate of achievement 
of target Hb and change of eGFR, and the secondary endpoints were change in Hb level 
after start of the study and change in dose of DA and CERA.
Results: In both groups, the rate of achievement of target Hb level at week 0 was 
70%, which rose to 100% in the interval between weeks 4 to 48, with no significant 
difference between the groups. Despite the absence of a significant difference in Hb level, 
it was significantly increased from week 24 and from week 8 relative to those at week 0 
in the DA continuation group and CERA changeover group, respectively. In addition, the 
reticulocyte count was significantly increased at weeks 4, 8 and 12 in the CERA changeover 
group compared with the DA continuation group. The doses of DA and CERA during the 
evaluation period were not significantly changed. Because the total administered doses of 
DA and CERA over 48 weeks were 0.998±0.106 mg/kg/4 weeks and 0.956±0.204 mg/
kg/4 weeks, the dose conversion ratio was 1.05:1 mg. There was no significant difference 
in the levels of eGFR and iron state between both groups.
Conclusions: The present study demonstrated that subcutaneous administration of DA 
and CERA once every 4 weeks to predialysis patients have similar effects on achievement 
of target Hb levels but longer acting CERA can increase the Hb level earlier than DA.
TH-PO651
QW or Q2W Darbepoetin Alfa in Pediatric Subjects with Chronic 
Kidney Disease  Bradley Warady,1 John P. Barcia,2 Nadine M. Benador,3 
Augustina Jankauskiene,4 Kurt Olson,5 Ludmila Podracka,6 Aleksey Shavkin,7 
Poyyapakkam Srivaths,8 Cynthia Wong,9 Jeffrey Petersen.5  1Children¶s Mercy; 
2UVA Med; 3UCSD; 4Vilniaus U; 5Amgen; 6UPJS; 7Children¶s City; 8TX 
Children¶s; 9Stanford Med.
Background: Minimal data are available on the initiation of erythropoiesis stimulating 
agents (ESA) for the correction of anemia in ESA-naive pediatric patients with CKD. 
Additionally, the optimal dosing frequency with darbepoetin alfa (DA) in this setting has 
not been previously evaluated. This study assessed the ability of DA administered either 
once weekly (QW) or once every 2 weeks (Q2W) to correct anemia in pediatric patients.
Methods: Multicenter, double-blind, randomized study in pediatric subjects (age 1 to 
18 years) with CKD and anemia (hemoglobin; Hb < 10.0 g/dL) on or not on dialysis and not 
treated with an ESA. The primary endpoint was Hb ≥ 10.0 g/dL at any time after the first 
dose without receiving a RBC transfusion within 90 days prior to initial Hb measurement 
or after randomization. Subjects were randomized to DA QW or Q2W at an initial dose of 
0.45mg/kg or 0.75mg/kg, respectively. For both treatment groups, subsequent DA doses 
were titrated to achieve Hb 10.0 g/dL to 12.0 g/dL, inclusive over a 25 week period of 
observation.
Results: 116 subjects were enrolled: 59 were randomized to DA QW and 57 to Q2W. 
114 subjects (58 QW; 56 Q2W) were included in the analyses. Mean (SD) Hb for the QW 
group increased from 8.6 (0.84) g/dL at baseline to 11.3 (1.33) g/dL at week 10 and remained 
relatively stable (range: 10.9 [1.10] to 11.7 [1.19] g/dL) through week 25. Mean Hb for 
the Q2W group increased from 8.7 (0.84) g/dL at baseline to 10.9 (1.38) g/dL at week 12 
and remained relatively stable between 10.4 (0.97) and 11.1 (1.00) g/dL through end of 
study. Hb concentrations were corrected to ≥ 10 g/dL in 98% and 84% of pediatric subjects 
administered DA QW or Q2W, respectively. 4 (7%) QW and 5 (9%) Q2W subjects received 
RBC transfusions. Safety results were consistent with the known safety profile for DA.
Conclusions: Hb concentrations were corrected to ≥ 10 g/dL in > 80% of pediatric 
subjects administered DA QW or Q2W. No new safety signals were identified in this 
pediatric subject population.
Funding: Pharmaceutical Company Support - Amgen Inc.
TH-PO652
Intravenous (IV) Ferric Carboxymaltose (FCM) versus Oral Iron in the 
Randomized FIND-CKD Trial of Patients with Non-Dialysis Dependent 
CKD (ND-CKD): A Safety Analysis  Simon D. Roger,1 Andreas H. Bock,2 
Fernando Carrera,3 Kai-Uwe Eckardt,4 Carlo A. Gaillard,5 David B. Van wyck,6 
Bernard Roubert,7 Maureen Cronin,7 Iain C. Macdougall.8  1Renal Research, 
Gosford, NSW, Australia; 2Kantonsspital, Aarau, Switzerland; 3Eurodial, 
Leiria, Portugal; 4Uni. of Erlangen-Nuremberg, Erlangen, Germany; 5Uni. 
Groningen, Groningen, Netherlands; 6Davita Healthcare Partners, Denver, 
CO; 79ifor Pharma Ltd, Glattbrugg, SZitzerland; 8King¶s College Hospital, 
London, United Kingdom.
Background: There are safety concerns, including hypersensitivity reactions, iron 
overload, increased risk of infection, oxidative stress and mortality risk, in patients with 
CKD receiving IV iron.
Methods: In the 56-week, open-label, multicenter, prospective, randomized FIND-
CKD study, 626 anemic patients with ND-CKD and iron deficiency not receiving ESA 
therapy were randomized (1:1:2) to IV ferric carboxymaltose (FCM), targeting higher 
(400–600µg/L) or lower (100–200µg/L) ferritin, or oral iron.
Results: In the IV iron arms, two patients had mild hypersensitivity reactions, neither 
requiring treatment nor hospitalization. Desired target ferritin levels were achieved and 
transferrin saturation (TSAT) levels were maintained within KDIGO guidelines (mean TSAT 
31% in the high ferritin FCM group). The rate of infections was equivalent within all three 
groups (33.1%, 34.0% and 30.4% in the high ferritin FCM, low ferritin FCM and oral iron 
groups, respectively), as was the rate of serious infections (3.9%, 3.3%, 3.8%). As a measure 
of oxidative stress, estimated GFR values were unchanged during the study. Overall, 4.1% 
of patients died (4.5%, 2.0% and 4.8% in the high ferritin FCM, low ferritin FCM and oral 
iron groups, respectively). No death was assessed by the investigator as related to study 
drug. Most frequent causes of death were cardiovascular events and respiratory infections.
Conclusions: Despite this being the longest RCT of oral vs IV iron in ND-CKD patients, 
the follow-up was still only 12 months and there was no placebo group. Nevertheless, 
there was no obvious signal of excess harm in patients targeting a higher ferritin range 
with IV FCM.
Funding: Pharmaceutical Company Support - Vifor Pharma, Glattbrugg, Switzerland
TH-PO653
Recruitment for Clinical Trials of Interventions to Prevent ESRD in T2D 
Patients  Adam Smiles,1 Melissa Major,1 Masayuki Yamanouchi,1 Natalia Z. 
Nowak,1 Monika A. Niewczas,1 Jan Skupien,1 Marcus G. Pezzolesi,1 Fergus 
Fleming,2 James Warram,1 Matthew D. Breyer,3 Kevin L. Duffin,3 Nick Pullen,4 
Andrzej S. Krolewski.1  1Joslin Diabetes Center, Boston; 2EKF Diagnostics, 
London, United Kingdom; 3(li Lilly, Indianapolis; 4Pfizer Global R&D, 
Cambridge, MA.
Background: The current dependence of clinical trials of measures to prevent ESRD, on 
recruitment of patients with T2D and proteinuria is problematic. The eligible pool, shrunken 
due to ACE inhibitor treatment, largely consists of non-progressors (due to depletion of 
rapid progressors) whose participation may be less informative.
Methods: In search of alternatives, we recruited T2D patients attending Joslin 
Clinic from 2003 to 2009 by screening those age 35-69 (and CKD stage 1-3) for onset 
of albuminuria (ALB), micro or macro, and identified for each a similar patient in the 3x 
larger pool with normo ALB. 2/3 granted participation consent. Mean baseline eGFR was 
95 for Normo and Micro ALB groups and 68 mL/min/1.73 m2 for Macro-ALB group. 
Patients were examined at baseline and followed to 2013 to ascertain onset of ESRD or 
death unrelated to ESRD. Baseline and follow-up blood and urine were assayed for serum 
creatinine and other characteristics.
Results: After 4-6 year follow-up for 1335 patients (excluding 82 incomplete follow-
ups) are summarized according to ALB category: 
Outcome Normo-ALBn=695 [2085]*
Micro-ALB
n=484
Macro-ALB
n=156
All
n=1335 [2725]
ESRD onset 2/0.3% [6]* 7/1.4% 32/21% 41 [45]
Loss>40% eGFR 24/3.5% [72]* 54/11% 49/31% 127 [177]
Death 16/2.3% [48]* 23/4.8% 19/12% 58 [90]
Composite 42/6.0% [126]* 84/17% 100/64% 226 [310]
* expected number if all normo-ALB patients were followed
Unfavorable outcomes occurred in an estimated 310 of 2725 patients (including all 
normo ALB patients). Although incidence was highest in Macro-ALB group, 2/3 occurred 
in Normo and Micro ALB groups and 1/3 occurred in patients with baseline eGFR >90 ml/
min/1.73 m2. Circulating levels of TNFR1 and KIM-1 and urinary levels of MCP-1 and 
KIM-1 at baseline are associated with risk of these outcomes.
Conclusions: In summary increased clinical trial enrollment of patients with outcomes 
can be achieved by including patients with normal renal function and Micro or Normo ALB.
Funding: NIDDK Support, Pharmaceutical Company Support - Pfizer 
Pharmaceuticals, Eli Lilly and Company, EKF Diagnostics
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TH-PO654
Post Hoc Analyses of the EPPIC Trials to Assess the Effect of AST-120 in 
Chronic Kidney Disease Patients  Gerald Schulman,1 Tomas Berl,2 Gerald 
J. Beck,3 Giuseppe Remuzzi,4 Eberhard Ritz,5 Miho Shimizu,6 Yuko Shobu,7 
Mami Kikuchi.7  1Vanderbilt U., Nashville, TN; 2U. Colorado, Denver, CO; 
3Cleveland Clinic, Cleveland, OH; 4Mario Negri Inst, Bergamo, Italy; 5U. 
Heidelberg, Heidelberg, Germany; 6Mitsubishi Tanabe Pharma Co, Tokyo, 
Japan; 7Kureha Co, Tokyo, Japan.
Background: The orally administered spherical carbon adsorbent AST-120 is 
approved in Asian countries for delaying the initiation of dialysis and ameliorating 
symptoms of uremia in patients with progressive CKD. Two randomized, double-blind, 
placebo-controlled trials (EPPIC trials) investigated the efficacy and the safety of AST-
120 in adults with CKD. The benefit of adding AST-120 was not supported by the results 
of the primary analysis as reported previously. In order to further assess the efficacy of 
AST-120, we examined clinical and geographic factors by post hoc analyses using pooled 
populations of 2 trials.
Methods: The primary endpoint was a composite of dialysis initiation, kidney 
transplantation and serum creatinine doubling. The same statistical methods for the efficacy 
endpoint analysis were applied for these post hoc analyses.
Results: In a multivariable analysis using baseline parameters, positive hematuria and 
elevated UP/UCr were found to be an independent risk factor for the primary endpoint. 
In the ITT population with positive hematuria, elevated UP/UCr (³1.0) and ACEI/ARB 
use, a difference between the AST-120 and the placebo treatment groups was observed 
in primary endpoint occurrence (HR 0.74, 95% CI 0.56-0.96). In subgroup analysis by 
country, a higher event rate was observed in the USA population than outside the USA. 
In the ITT population from the USA with ACEI/ARB use, a difference between the AST-
120 and the placebo treatment groups was observed in primary endpoint occurrence (HR 
0.74, 95% CI 0.56-0.98).
Conclusions: These results suggest that there may be a beneficial effect of adding 
AST-120 to standard therapy regimens in high risk populations such as patients with 
hematuria and elevated UP/UCr and in the patients similar to those enrolled in the USA 
EPPIC trials. Due to its post hoc nature of the analysis, further prospective studies are 
needed to confirm the results.
Funding: Pharmaceutical Company Support - Mitsubishi Tanabe Pharma Co
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A Phase 2 Study on the Effect of Tenapanor on Albuminuria in Patients 
with T2DM and CKD  Bergur V. Stefansson,1 David P. Rosenbaum,2 Peter J. 
Greasley,1 Maria Leonsson Zachrisson,1 Anna Maria Langkilde.1  1AstraZeneca 
R&D, Mölndal, Sweden; 2Ardelyx Inc., Fremont, CA.
Background: Patients with type 2 diabetes mellitus (T2DM) and CKD are treated 
with renin–angiotensin–aldosterone system (RAAS) inhibitors to slow the decline in renal 
function. The effectiveness of RAAS inhibition is limited by high sodium (Na) intake. 
Tenapanor (AZD1722), an inhibitor of the Na+/H+ exchanger NHE3, reduces absorption of 
Na and phosphate from the gut. This trial evaluated the effects of tenapanor on albuminuria 
levels, which may be associated with renal function decline, in patients with T2DM and 
CKD stage 3 receiving RAAS inhibitors.
Methods: This was a randomized, placebo-controlled, 12-week study (NCT01847092) 
in patients with urine albumin-to-creatinine ratio (UACR) 200–3500 mg/g. The starting 
dose of tenapanor hydrochloride was 15 mg bid: there was a 4-week titration period 
(dose escalation up to 60 mg bid followed by reduction down to 5 mg bid), based on 
gastrointestinal tolerability, before fixed-dose treatment with 5–60 mg bid for 8 weeks.
Results: Patients were randomized to tenapanor (n=77; mean±SD urinary Na, 182±81 
mmol/day; completed, n=51) or placebo (n=77; mean±SD urinary Na, 189±85 mmol/day; 
completed, n=66). Reductions from baseline to week 12 in UACR were 16% for tenapanor 
and 11% for placebo (p=0.36). Tenapanor had no observed effect on systolic or diastolic BP 
or eGFR. Changes (tenapanor vs placebo) in urinary Na were (LS mean±SE) -9.6±9.7 vs 
-1.5±9.1 mmol/day (p=0.54) and in urinary phosphorus were (mean±SD) -3.8±14 vs 1.7±9.7 
mmol/day. Tenapanor treatment resulted in a softer consistency and increased frequency 
of stool compared with placebo. The tolerability profile of tenapanor was consistent with 
that seen in other studies, with diarrhea reported more frequently with tenapanor use.
Conclusions: In patients with T2DM and CKD stage 3, the pharmacodynamic effects 
of tenapanor were confirmed, as shown by softer consistency and increased frequency of 
stool, and reduced urinary phosphorus excretion following tenapanor treatment. However, 
these observations did not translate into effects on albuminuria.
Funding: Pharmaceutical Company Support - AstraZeneca
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Effect of Fluvastatin Treatment on Proteinuria in Diabetic Patients with 
Chronic Kidney Disease  Jin Joo Cha,1 Kitae Kim,1 Hye sook Min,1 Jungyeon 
Ghee,1 Yeo-Joo Kim,2 Eun-Young Lee,2 Shin-Wook Kang,3 Tae-Hyun Yoo,3 Jung 
Tak Park,3 Yaeni Kim,4 Cheol Whee Park,4 Ho Jun Chin,5 Young Sun Kang,1 Dae 
R. Cha.1  1Internal Medicine, Korea Univ, Republic of Korea; 2Internal Medicine, 
Soonchunhyang Univ Cheonan Hospital, Republic of Korea; 3Internal Medicine, 
Yonsei Univ College of Medicine, Republic of Korea; 4Internal Medicine, The 
Catholic Univ of Korea Seoul St. Mary, Republic of Korea; 5Internal Medicine, 
Seoul National Univ Bundang Hospital.
Background: Correction of dyslipidemia with statin has shown to be protective and 
therapeutic in the progression of cardiovascular events. However its association with 
progression of kidney disease has not been established. In this study, we investigated the 
efficacy of fluvastatin (Lescol XR) on the progression of diabetic nephropathy in patients 
with renal insufficiency.
Methods: A total of 75 diabetic patients with CKD (stage 2 to 4) completed this 
multicenter, randomized 12 month controlled trial. All patients were treated with 20mg 
fluvastatin for 6 months. At month 6, patients were randomized to either continue or to 
discontinue fluvastatin for additional 6months. Primary endpoint was the difference in 
urinary protein to creatinine ratio between the groups at 12months.
Results: Baseline characteristics showed no differences between the groups in HbA1c, 
HOMA-IR, diabetes duration and estimated glomerular filtration rate (GFR).Majority of 
patients (81%) were using RAS blockers. After 6months of fluvastatin treatment, there was 
no significant decrease in urinary protein excretion or microalbumin excretion. Estimated 
GFR significantly declined at 6months in both groups and continued to decline after 
discontinuation of fluvastatin, whereas the change was not significant with fluvastatin 
treatment. Interestingly, HOMA-IR significantly improved in continuation group. Significant 
decrease in total and low density cholesterol was observed after 6, 12months in patients 
treated with fluvastatin.
Conclusions: In conclusion, there was no significant reduction in proteinuria with 
fluvastatin treatment in diabetic patients with chronic kidney disease. However, our study 
suggests that there might be a role in statin to slow the progression of kidney disease.
Funding: Pharmaceutical Company Support - Norvatis Pharmaeuticals
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Hyperkalemia in the HALT PKD Trial  Ronald D. Perrone,1 Kaleab Z. Abebe,2 
Peter G. Czarnecki,3 Marie C. Hogan,4 Theodore I. Steinman,5 Susan Spillane,2 
Charity G. Moore.2  1Tufts; 2U Pittsburgh; 3Brigham and Womens; 4Mayo Clinic; 
5BIDMC, for the HALT PKD Investigators.
Background: HALT-PKD was a prospective, randomized trial designed to determine 
the effects of dual renin-angiotensin system (RAAS) blockade and blood pressure (BP) 
reduction on ADPKD progression. In view of prior reports of hyperkalemia (HK) with dual 
RAAS blockade, we describe the frequency and severity of HK in HALT-PKD.
Methods: Study A subjects with eGFR >60 ml/min aged 15-50 were randomized to 
lisinopril (L) and placebo (P) vs L and telmisartan (T) with two levels of BP control: standard 
(SBP) (120-130/70-80 mmHg) vs low (LBP) (95-110/65-75 mm Hg). Study B subjects with 
eGFR 25-60 ml/min aged 18-65 were randomized to L and P vs L and T with SBP only. 
Serum K was measured every 6 months at study visits, within 1-2 weeks after an increase 
in L or T dose, and every 3 months when eGFR was less than 30. All elevated serum K 
values were reviewed on a monthly basis by a quality control committee.
Results: HK was infrequent in Study A; mild, but not moderate or severe HK, was 
more common in Study B. 
Hyperkalemia STUDY A : STUDY B
(N) L/T (273)
L/P 
(285)
SBP 
(284)
LBP 
(274) : L/T (244) L/P (242)
Mild >5.5 - 6 7,7 (3%) 5,4 (1%) 8,7 (3%) 4,4 (2%) :
61,42 
(17%)
60,38 
(16%)
Moderate >6 
- 6.5
5,4 
(2%)
1,1 
(0.4%) 3,3 (1%) 3,2 (1%) : 9,9 (4%) 4,4 (12%)
Severe >6.5 1,1 (.4%) 0,0 (0%) 0,0 (0%)
1,1 
(.4%) : 0,0 (0%) 1,1 (0.4%)
# events, # participants, (% participants); L/T: lisinopril/telmisartan; L/P: lisinopril/placebo; SBP: 
standard BP; LBP: low BP. There were no significant differences in HK due to L/T or LBP
Intervention with dietary K reduction, furosemide, or Kayexalate was succesful in 
reducing serum K in all participants. There was no relationship between HK and serious 
adverse events (SAEs) and there were no SAEs within 21 days after detection of HK.
Conclusions: HK was infrequent with eGFR>60, despite dual RAAS blockade or 
intensive BP control. Mild HK was more common with eGFR 25-60, but easily managed. 
Severe HK was rare. With careful management, dual RAAS blockade and intensive BP 
control were safe in the HALT PKD trial. Clinical use of dual RAAS blockade or intensive 
BP control should only be done with close monitoring.
Funding: NIDDK Support, Private Foundation Support
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TH-PO658
Chronic Diuretic Therapy Does Not Impair the Effectiveness of Patiromer 
in Hyperkalemic Patients with CKD  Matthew R. Weir,1 Martha Mayo,2 Dahlia 
Garza,2 Yuri Stasiv,2 Susan Arthur,2 Lance Berman,2 David A. Bushinsky,3 
Daniel J. Wilson,2 Murray Epstein.4  1Univ of Maryland; 2Relypsa, Inc.; 3Univ 
of Rochester; 4Univ of Miami.
Background: Loop diuretics control volume in advanced CKD and may reduce elevated 
serum K+, but can induce intravascular volume depletion or gout and may not be ideal for 
long-term hyperkalemia (HK) management. Thus, the efficacy of investigational serum 
K+ binders in HK pts on chronic diuretics is of interest. We compared patiromer’s effects 
in RAASi-treated CKD pts with HK on diuretics to those not on diuretics in the treatment 
phase of the 2-part OPAL-HK study.
Methods: Pts (n=243) with baseline (BL) s-K+ 5.1 to 6.5 mEq/L on RAASi received 
patiromer (4.2 or 8.4 g BID to start) for 4 wks. For this post hoc analysis, Ds-K+ from 
BL to wk 4 was assessed in pts stratified by diuretic use and type. Pts (n=22) receiving 
aldosterone antagonists were excluded.
Results: Mean (SD) age was 64 (10.5) yr; 58% were male. Mean s-K+ decreased from 
BL at wk 4 in all subgroups (Table). Reductions in s-K+ did not differ in pts receiving 
any diuretic vs those not on diuretics. Patiromer was well tolerated; mild–moderate GI 
constipation was the most common AE. Hypokalemia (s-K+<3.5 mEq/L) was infrequent.
Conclusions: The s-K+-lowering efficacy of patiromer in HK pts was unaffected by 
concomitant diuretics. 
Table: Efficacy, safety, and disease characteristics in pts on patiromer   diureticsa
Loop 
(n=51)
Thiazide/ 
T-like (n=51)
Combina-
tion Loop/
thiazide 
(n=15)
Any diuretic
(n=117)
No diuretic 
(n=104)
BL
HF, % 49.0 25.5 66.7 41.0 32.7
S-Creatinine
Mean± SD 
(mg/dl)
2.4± 0.9 2.0± 0.8 2.0± 0.7 2.2± 0.8 2.1± 1.2
Mean± SE BL 
s-K+, mEq/L 5.61± 0.06 5.58± 0.07 5.67± 0.13 5.58± 0.04 5.57± 0.05
Wk 4
Mean± SE 
Δ s-K+ BL to 
wk 4 (95% 
CI), mEq/L 
[p-value]
í1.02± 0.06
(í1.14, 
í0.89)
[<0.001]
í0.97± 0.06
(í1.09, 
í0.86)
[<0.001]
í0.69± 0.19
(í1.11, 
í0.28)
[0.0037]
í0.95± 0.05
(í1.04, 
í0.86)
[<0.001]
í1.03± 0.05
(í1.13, 
í0.93)
[<0.001]
Hypokale-
mia, % 2.0 0 6.7 1.7 3.9
a6 pts without a s-K+ value at a weekly visit after day 3 were excluded.
Funding: Pharmaceutical Company Support - Relypsa, Inc.
TH-PO659
Add-On HCTZ Administration to ARB Can Achieve Lower Sodium Balance 
in CKD Patients  Daisuke Fuwa,1 Michio Fukuda,1 Toshiyuki Miura,1 Yoshiaki 
Ogiyama,1 Sumiko Abe-Dohmae,1 Hiroyuki Kobori,2 Nobuyuki Ohte.1  1Nagoya 
City Univ; 2International Univ of Health and Welfare.
Background: Recently, we have reported that angiotensin receptor blocker (ARB) can 
attain lower sodium balance and resultant restoration of nondipper circadian BP rhythm in 
patients with augmented intrarenal renin angiotensin system (RAS). It has been established 
that ARB can enhance renal sodium excretion in subjects with sodium deprivation. We 
tested whether add-on administration of hydrochlorothiazide (HCTZ) can further achieve 
a lower sodium balance in patients with CKD under ARB treatment.
Methods: CKD patients (n=20) with previous treatment with valsartan (80mg/day) 
for 2 months or more, office BP >130/80 on at least one occasion were eligible. Filtered 
tubular sodium load was defined as PNa x GFR. Ambulatory BP and sodium balance were 
studied before and 8-week administration with HCTZ (12.5mg/day).
Results: Add-on HCTZ to ARB could attain lower sodium balance: tubular sodium 
load (13200±930011800±7800 mmol/day, p=0.04), and tubular sodium reabsorption 
(13000±930011700±7800 mmol/day, p=0.04) were both decreased, while urinary sodium 
excretion did not change (160±80161±60 mmol/day, p=0.9). Decrease in tubular sodium 
load correlated directly with baseline urinary angiotensinogen excretion (uATG) (r2=0.10), 
and the decrease in night/day SBP ratio (r2=0.16). uATG was significantly decreased 
(150±10ĺ80±20 mg/gCre, p=0.02).
Conclusions: Add-on administration with HCTZ to ARB can attain the lower 
sodium balance and resultant restoration of non-dipper BP rhythm with no acceleration 
of intrarenal RAS.
TH-PO660
Association of Serum Adiponectin Level with Albuminuria in Chronic 
Kidney Disease Patients  Ha yeon Kim,1 Eun Hui Bae,1 Seong Kwon Ma,1 
Kook-Hwan Oh,2 Curie Ahn,2 Soo Wan Kim.1  1Internal Medicine, Chonnam 
National Univ Medical School, Gwangju, Korea; 2Internal Medicine, Seoul 
National Univ Hospital, Seoul, Korea.
Background: Adiponectin, peptide hormone secreted in an adipocytes, has been known 
to exert anti-diabetic, anti-atherogenic and anti-inflammatory properties. We aimed at 
determining the relationship between serum adiponectin levels and albuminuria and evaluate 
determinant factors for serum adiponectin in patients with chronic kidney disease (CKD).
Methods: A total of 1,474 CKD patients were included and divided into three groups 
according to their albumin-to-creatinine ratio: patients with normoalbuminuria (N = 232), 
microalbuminuria (N = 459), macroalbuminuria (N = 783). The serum adiponectin was 
specifically assayed with a commercially available enzyme-linked immunosorbent assay kit.
Results: Serum adiponectin was significantly higher in patients with macroalbuminuria 
than those without macroabluminuria. (9.7±6.06 mg/ml in patients with normoalbuminuria, 
12.4±9.07 mg/ml in patients with microalbuminuria, 14.9±11.09 mg/ml in patients with 
macroabluminuria). Univariate linear regression analysis showed that the serum adiponectin 
concentrations correlated with age, albumin-to-creatinine ratio, total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, whereas negatively correlated 
with body mass index, estimated glomerular filtration rate, serum albumin and triglyceride. 
Multiple backward regression analysis revealed that sex, diabetes mellitus, estimated 
glomerular filtration rate, body mass index, total cholesterol, high-density lipoprotein 
cholesterol, triglyceride, logarithm of albumin-to-creatinine ratio were independently 
associated with logarithm of serum adiponectin levels (r = 0.55, p < 0.001).
Conclusions: The serum adiponectin concentrations are higher in patients with 
increasing albuminuria and these levels are also associated with renal insufficiency and 
lipid profiles.
TH-PO661
Effects of Candesartan on Clinical Remission in IgA nephropathy Treated 
with Steroid Pulse Therapy and Tonsilectomy (CAST IgA Study) – A 
Randomized Control Study  Kentaro Kohagura,1,2 Hisatomi Arima,3 Hitoshi 
Miyasato,5 Tung-Huei Chang,6 Hiroyuki Kobori,4 Kunitoshi Iseki,7 Yusuke 
Ohya.1  1Dialysis Unit, Univ Hospital of the Ryukyus, Nishihara-cho, Okinawa, 
Japan; 2Cardiovascular Medicine, Nephrology and Neurology, Univ of the 
Ryukyus, Nishihara-cho, Okinawa, Japan; 3Center for Epidemiologic Research 
in Asia, Shiga Univ of Medical Science, Shiga, Japan; 4Pharmacology, Kagawa 
Univ, Kagawa, Japan; 5Internal Medicine, Okinawa Chubu Hospital, Okinawa, 
Japan; 6Internal Medicine, Okinawa Heartlife Hospital, Okinawa, Japan; 
7Clinical Research Center, Tomishiro Central Hospital, Okinawa, Japan.
Background: Angiotensin receptor blockade (ARB) may have additional benefit on 
the conventional therapy with steroid pulse and tonsillectomy among Japanese patients 
with IgA nephropathy.
Methods: Seventy seven patients with IgA nephropathy were randomly assigned to 
regular regimen consists of steroid pulse followed by oral prednisolone for 6 months and 
tonsillectomy (control groupor, n=37) regular regimen combined with ARB (candesartan) 
for 6 months (ARB group, n=40). Among all patients in both groups who did not achieve 
remission of proteinuria at 12 M, candesartan was initiated and titrated until the 24 M 
visit. The primary endpoint was the remission of proteinuria (<0.2g/gCr) and hematuria.
Results: Baseline proteinuria (g/gCr, interquartile range) were comparable between the 
groups (0.90, 0.70-1.20 vs. 0.95, 0.60-1.50, P=0.97). Cumulative remission rate in control 
group and ARB group at 6, 12 and 24 M were comparable (10.8% vs. 15% [P=0.58], 29.7% 
vs. 30.0% [P=0.98], 45.9% vs. 42.5% [P=0.76]). The hazard ratio for remission was 1.01 
(95% confidence interval, 0.51-1.99; p=0.98). Proteinuria was slightly heavier in control 
group than ARB group (0.11 vs. 0.21g/gCr, p=0.002) at 6 M, but comparable afterwards 
(0.20 vs. 0.23 g/gCr at 12 M, 0.12 vs. 0.13 g/gCr at 24 M). Although remission rate of 
hematuria was comparable until 12M, it was higher in control group than ARB group at 
24M (85% vs. 64%, P=0.008).
Conclusions: Early use of ARB regardless of the level of blood pressure combined 
with steroid pulse and tonsillectomy may not provide benefit for clinical remission among 
IgA nephropathy.
TH-PO662
Tacrolimus Monotherapy Follows Intravenous Methylprednisolone in 
Adults with Minimal Change Nephrotic Syndrome: A Prospective, Multi-
Centered, Open, Randomized, Controlled Trial  Xiayu Li, Jianghua Chen. 
Kidney Disease Center, The First Affiliated Hospital, College of Medicine, 
Zhejiang Univ, Hangzhou, Zhejiang Province, China.
Background: Adults with minimal change nephritic syndrome (MCNS) show excellent 
responses to glucocorticoid (GC).However, responding patients may suffer relapses and GC 
related frequent side effects. Tacrolimus(TAC) may serve as an alternative to GC therapy 
for adult-onset MCNS with less-frequent side effects.
Methods: This randomized, multicentre, controlled study was undertaken in 8 renal 
units across the China. 119 adult-onset patients were randomly allocated to receive the 
conventional GC therapy (GC group) or tacrolimus monotherapy (trough blood level of 
4 to 8 ng/mL) follows intravenous methylprednisolone for 10 days (TAC group). The 
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primary outcome variables was remission. The secondary outcome variables included 
relapse, time to remission, time to relapse, change of serum creatinine (Scr) and eGFR, 
and adverse events (AEs).
Results: Remission (either complete or partial remission) was attained by 51 of 53 
patients (96.2%) in GC group and 55 of 56 (98.3%) of patients in TAC group (p=0.611).51 
of 53 patients (96.2%) in GC group and 52 of 56 patients (92.9%) in TAC group experienced 
complete remission, respectively (p=0.679). The mean time to remission in GC group 
(2.7±2.3 weeks) was similar (p=0.548) to TAC group (2.6±2.6 weeks), respectively. Relapse 
occurred in 25 (49.0%) of GC group versus 25 (45.5%) of TAC group (p=0.847), and 7 
patients with GC therapy and 4 patient with TAC therapy suffered frequent relapse. The 
mean time to relapse in GC group (27.6±16.9 weeks) was similar (p=0.617) to TAC group 
(25.2±16.9 weeks), respectively. There was no significant difference of SCr and eGFR 
between two groups during therapy and follow-up periods. Adverse events were more 
frequent in GC group than in TAC group (128 events versus 81 events), of which 9(7 in 
GC group and 2 in TAC group) were deemed serious AEs.
Conclusions: The regimen with tacrolimus monotherapy follows short-term 
intravenous methylprednisolonewas noninferior to conventionalGC treatment in adult-
onset MCNS, and could replace steroids as the initial therapy for such patients due to 
less-frequent side effects.
TH-PO663
Changes in Concentrations of Chemokine Ligands for CCR2 and CCR5 
Receptors in Response to Administration of PF-04634817  Karen M. Page, 
Julie M. Lee, Amira Quazi, Lori Fitz, Weidong Zhang, Steven A. Gilbert, Nick 
Pullen, Robert Webster, Jeremy D. Gale.  Worldwide Research and Development, 
Pfizer, Cambridge, MA.
Background: PF-04634817 is a competitive dual inhibitor of CCR2 and CCR5 
receptors. In early clinical studies, administration of this compound to healthy volunteers has 
been found to elevate circulating levels of the primary CCR2 ligand, CCL2 (MCP-1). The 
ability of PF-04634817 to reduce albuminuria, compared with placebo, after administration 
for 12 weeks was tested in a phase 2 study in subjects with diabetic nephropathy and 
macroalbuminuria. In this study, samples were collected to confirm the previously observed 
pharmacological effect on CCL2 in this population and to examine the impact on other 
ligands known to bind to CCR2 or CCR5 receptors.
Methods: CCL2 in serum and urine was measured by ELISA from 226 subjects at 
Eurofins (The Netherlands) at baseline and during treatment at weeks 4, 8, and 12. CCL5 
(RANTES) was measured in plasma and urine as part of a multi-analyte panel at Myriad 
Rules Based Medicine (Austin, TX) and CCL8 (MCP-2), CCL3 (MIP-1a), and CCL4 
(MIP-1b) were measured in plasma using two Luminex assays (Bio-Rad, Berkeley, CA) 
from 158 subjects at baseline and weeks 8 and 12.
Results: At week 12, serum levels of CCL2 and plasma levels of CCL4 were elevated 
9.25 fold (p < 0.0001) and 2.11 fold (p < 0.0001) respectively following administration 
of PF-04634817, but not placebo. Elevation of both chemokines was also observed at the 
earlier time points. Levels of CCL8, CCL5 and CCL3 in circulation and CCL2 and CCL5 
in urine did not change in either group.
Conclusions: This study confirms elevation of the CCR2 ligand, CCL2, following 
treatment with PF-04634817 in diabetic nephropathy subjects. It also identifies the CCR5 
ligand, CCL4, as another potential pharmacodynamic marker. The observed lack of apparent 
change in CCL5 warrants further follow up analysis.
Funding: Pharmaceutical Company Support - Pfizer
TH-PO664
Circulating Tumor Necrosis Factor Receptor Expression in a Phase 2 Study 
to Evaluate the Efficacy and Safety of PF-04634817 in Adults with Type 2 
Diabetes and Overt Nephropathy  Karen M. Page, Lori Fitz, Weidong Zhang, 
Steven A. Gilbert, George Bashirians, Nick Pullen, Robert Webster, Jeremy D. 
Gale.  :orldZide Research and Development, Pfizer, Cambridge, MA.
Background: PF-04634817 is a small molecule dual inhibitor of CCR2 and CCR5, 
chemokine receptors found on the surface of monocytes and T cells that are involved in 
the development and progression of diabetic nephropathy (DN). Identifying patients with 
accelerated renal function decline is an important area of research. Circulating TNFRs have 
been identified as biomarkers with potential to predict accelerated decline. In the current 
study, we investigated changes in soluble TNFR-1 and TNFR-2 following 12 weeks of 
treatment with PF-04634817 or placebo in subjects with DN.
Methods: Soluble TNFR-1 and TNFR-2 were measured from 161 subjects in serum 
by ELISA at baseline, weeks 8 and 12. Urinary albumin and creatinine concentrations 
were averaged from 3 consecutive first morning voids immediately prior to each visit. 
Estimated glomerular filtration rate (eGFR) was measured using the abbreviated (4 variable) 
Modification of Diet in Renal Disease (MDRD) formula. Study subjects were defined at 
baseline by a mean UACR of 180.78 ± 160.53 mg/mmol Cr and a mean eGFR of 41.46 
± 12.64 mL/min/1.73 m2.
Results: Mean concentrations at baseline of soluble TNFR-1 and TNFR-2 were 4.25 
± 1.37 ng/mL and 8.27 ± 2.99 ng/mL respectively. Baseline concentrations were strongly 
correlated between the receptors (Corrs = 0.90, p < 0.0001). Soluble TNFRs were weakly 
correlated with UACR at baseline (Corrs = 0.35, p < 0.0001 and =0.34, p < 0.0001), in 
contrast to a stronger inverse correlation with eGFR (Corrs = -0.69, p < 0.0001 and = -0.61, 
p < 0.0001). The concentration of neither TNFR was changed from baseline following 
treatment with PF-04634817 and baseline TNFR concentrations were not able to predict 
changes observed at week 12 in UACR.
Conclusions: At baseline, TNFR-1 and TNFR-2 in subjects with DN were well 
correlated to each other and more strongly correlated with eGFR than UACR. Our 
observations do not support either TNFR-1 or TNFR-2 as pharmacodynamic biomarkers 
or as predictive biomarkers of clinical response as measured by UACR.
Funding: Pharmaceutical Company Support - Pfizer
TH-PO665
Effects of Intensified Vasodilatory Antihypertensive Treatment on Renal 
Function, Bloodsupply and Oxygenation in Chronic Kidney Disease 
Dinah S. Khatir,1 Michael Pedersen,2 Per R. Ivarsen,1 Kent L. Christensen,3 
Bente Jespersen,1 Niels Henrik Buus.4  1Renal Medicine, Aarhus Univ Hospital, 
Aarhus N, Denmark; 2Comparative Medicine Lab, Aarhus Univ Hospital, Aarhus 
N, Denmark; 3Cardiology, Aarhus Univ Hospital, Denmark; 4Renal Medicine, 
Aalborg Univ Hospital, Denmark.
Background: Progression of Chronic kidney disease (CKD) may result from tissue 
hypoxia induced by small artery structural narrowing, with increased renal vascular 
resistance (RVR) and impaired blood supply. We investigated whether vasodilating therapy 
(VT) is superior to non-vasodilating therapy (nonVT) for improvement of RVR, tissue 
oxygenation, and preservation of kidney function.
Methods: Eighty-two hypertensive grade 3-4 CKD patients (glomerular filtration 
rate (GFR) 36±15 ml/min/1.73 m2) were randomised to renin-angiotensin inhibition 
combined with either VT (amlodipine) or nonVT (beta-blocker metoprolol). At baseline 
and following 18 months of therapy we determined forearm resistance by venous occlusion 
plethysmography. Using magnetic resonance imaging (MRI) renal artery blood flow was 
measured for calculation of RVR, and blood oxygen level dependent (BOLD) MRI was 
used as a marker of renal oxygenation (R2*). GFR was measured as 51Cr-EDTA clearance.
Results: The VT and nonVT arms had similar blood pressure levels throughout 
the study. At follow-up, in the VT group forearm resting resistance had decreased by 
7% (P<0.05) and RVR by 12% (P<0.05), while in the nonVT group forearm resistance 
increased by 39% (P<0.01) while RVR remained unchanged. Cortical and medullary R2* 
values were not affected by VT and nonVT. After 18 months GFR decline was similar in 
the two groups (3.0 vs. 3.3 ml/min/1.73 m2).
Conclusions: In CKD, long-term VT reduced both peripheral and RVR, but was not 
associated with improved renal oxygenation and did not influence loss of kidney function 
compared to nonVT.
Funding: Government Support - Non-U.S.
TH-PO666
The Epigenetic BET-Inhibitor RVX-208/Apabetalone Shows Favorable 
Effects on ALP and eGFR in Chronic Kidney Disease (CKD) Patients – A 
Post-Hoc Analysis of Phase 2 Clinical Trials  Kamyar Kalantar-Zadeh,1 Jan 
O. Johansson,2 Michael Sweeney,2 Kenneth E. Lebioda,2 Ewelina Kulikowski,2 
Christopher Halliday,2 Norman Cw Wong.2  1Div of Nephrology & Hypertension, 
1Univ of California Irvine School of Medicine, Irvine, CA; 2Research and 
Development, Resverlogix Corporation, Calgary, AB, Canada.
Background: The epigenetic BET inhibitor RVX-208 is a small molecule with anti-
inflammatory and apolipoprotein A-I (apoA-I) enhancing effects. It exerts its’ actions by 
inhibiting bromodomain extra-terminal proteins (BET) thus inhibiting acetylated lysine, 
present in histones, from binding to the same site. In this process chromatin structure is 
altered and activity of select genes inhibited. A subpopulation analysis from the double-
blind placebo controlled phase 2b program in cardiovascular disease (CVD) identified 81 
subjects with CKD based on eGFR < 60 ml/min/1.73m2.
Methods: The effect of selective BET inhibition on key renal parameters in 81 CKD 
subjects (RVX-208 n=58/Placebo n=23) that were treated with either RVX-208 100mg/
day or 150 mg b.i.d or matching placebo for 3 to 6 months were studied. A pooled analysis 
was performed to assess the changes from baseline for eGFR, ALP and creatinine at 3 
and 6 months.
Results: ALP changes for RVX-208 and placebo were -14.2% and -0.34% at 3 months 
(p<0.05 vs. placebo) and -13.9% vs. -6.28% (p<0.05 vs. placebo) at 6 months. Following 6 
months of RVX-208 treatment, eGFR showed an increase of +3.4% (p=0.04 vs. baseline) 
in the RVX-208 group compared to a decrease of -5.9% in the placebo group. After 6 
months treatment serum creatinine was decreased (-2.82%, p<0.10 vs. baseline) compared 
to increases in the placebo group of +3.0% and +4.85% at 3 and 6 months, respectively. No 
significant change in eGFR and serum creatinine were observed after 3 months RVX-208 
treatment, albeit nominal numbers went in the normalization directions.
Conclusions: Six months treatment with RVX-208, a selective BD2 selective BET-
inhibitor significantly lowers serum ALP, and shows trends for eGFR and serum creatinine 
improvements. A phase 3 study BETonMACE is being planned in which these effects 
will be assessed in the prospective setting in diabetic CVD patients with or without CKD.
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TH-PO667
Impact of Grazoprevir plus Elbasvir on Health-Related Quality of Life in 
Patients with Hepatitis C Virus Genotype 1 Infection and Chronic Kidney 
Disease Stages 4 and 5  Jean Marie Arduino,1 Boshao Zhang,1 Beth Jackson,1 
David Roth,2 Annette Bruchfeld,3 Shazia Khawaja,1 Elisa Martinez,1 Chizoba 
Nwankwo,1 Chris Mast,1 Wayne L. Greaves.1  1Merck & Co., Inc.; 2Univ of 
Miami Miller School of Medicine; 3Karolinska Univ Hospital.
Background: Health-related quality of life (HRQOL) is diminished in patients with 
hepatitis C virus (HCV) infection and chronic kidney disease stages 4 and 5 (CKD4/5).A 
randomized, double-blind, placebo-controlled trial of Grazoprevir 100 mg + Elbasvir 50 mg 
(GZR+EBR) once daily for 12 weeks was conducted among patients with HCV genotype 
1 infection and CKD4/5. GZR+EBR was highly effective, with a sustained viral response 
rate at follow-up week 12 (FW12) of 99.1%(95% Confidence Interval (CI):95.3%-100.0%).
GZR+EBR was well-tolerated, with a safety profile that was comparable to placebo.The 
aim was to assess whether HCV treatment with GZR+EBR altered the HRQOL profile.
Methods: 224 patients were randomized and received at least one dose of study drug 
(GZR+EBR:n=111,Placebo:n=113). Patients completed the SF-36v2® Health Survey at 
baseline, treatment week 12 (TW12), and FW12 (GZR+EBR arm).Mean change from 
baseline in health domain, mental component summary (MCS) and physical component 
summary (PCS) scores, with 95% CIs, were estimated.Differences in mean change scores, 
with 95% CIs, were estimated between treatment groups.
Results: At baseline, mean scores were balanced between treatment groups.At TW12, 
GZR+EBR had more favorable changes from baseline in PCS and health domain scores 
(except for SF, RE, MCS) than placebo. 
At FW12 for GZR+EBR, GH improved from baseline (mean change score:4.5(95% 
CI:1.2-7.9)).
Conclusions: Treatment with GZR+EBR had a positive impact on HRQOL as 
compared to placebo. In addition, changes in HRQOL were substantially more favorable 
than the large declines in HRQOL historically associated with interferon and ribavirin-
containing regimens.
Funding: Pharmaceutical Company Support - Merck & Co., Inc.
TH-PO668
Bortezomib Before, in and After Autologous Hematopoietic Stem Cell 
Transplantation in Patients with Newly Diagnosed AL Amyloidosis 
Xiang-hua Huang, Qingwen Wang, Wencui Chen, Dehua Gong, Caihong Zeng, 
Zhihong Liu.  National Clinical Research Center of Kidney Diseases, Research 
Inst of Nephrology, Jinling Hospital, Nanjing, Jiangsu, China.
Background: In previous study, we have demonstrated that the outcome of treating 
AL amyloidosis with bortezomib with dexamethasone (BD) induction followed by 
autologous hematopoietic stem cell transplantation (ASCT) was superior to the outcome 
of the ASCT treatment alone. To further improve the hematologic response rate, we 
conducted a prospective trial of bortezomib before, in and after ASCT in newly diagnosed 
AL amyloidosis.
Methods: Newly diagnosed AL amyloidosis patients who met the criteria of ASCT 
could be included in this trial. Treatment schedule consisted of two cycles of BD induction 
therapy (bortezomib 1.3mg/m2 and dexamethasone 40 mg/d on days 1, 4, 8 and 11 followed 
by 10 days rest), ASCT treatment (the conditioning regimen consisted of melphalan and 
bortezomib, the dose of bortezomib was 1mg/m2 in day -6, -3, +1, +4), and four additional 
21-day cycles of bortezomib treatment (with a dose of 1.6mg/m2 on day 1 and 8 of the cycle) 
will be conducted as consolidation therapy after ASCT. The objectives were hematologic 
response, tolerability and survival.
Results: 18 patients were enrolled in the study. 9 patients had cardiac involvement. The 
overall hematologic response rate was 94.4% (17/18), including 13 patients (72.2%) with 
complete response, 4 patients (22.2%) with very good partial response. The organ response 
rate was 72.2%. The organ response was reached in 13 patients of the 18 patients with renal 
involvement and 7 of the 9 patients with cardiac involvement. Peripheral neuropathy and 
infection were the common adverse events during the treatment, and 4 patients have been 
discontinued bortezomib for neuropathy. No death occurred in this study. After a median 
follow up of 24 months, the overall survival was 100%, and the estimated progression free 
survival was 91% at 48 months.
Conclusions: In conclusion, our preliminary data suggest that incorporating bortezomib 
into induction, conditioning and consolidation with ASCT yielded a high rate of hematologic 
response with tolerable toxicity. (ClinicalTrial.gov Id: NCT01273844).
Funding: Pharmaceutical Company Support - Xi’an Janssen Pharmaceutic Ltd: 
Research Funding.
TH-PO669
Phase 1 and 1b Studies of PBI-4050, a Novel Anti-fibrotic Agent for Chronic 
Kidney Disease  John E. Moran,1,2 Lyne Gagnon,1 Pierre Laurin,1 Vincent 
Pichette.3  1ProMetic Life Sciences, Laval, 4C, Canada; 2Nephrology, Stanford 
Univ School of Medicine, Palo Alto, CA; 3Univ de Montréal, Montréal, QC, 
Canada.
Background: PBI-4050 is an orally administered new chemical entity with a MW < 
300 showing remarkable anti-fibrotic efficacy in multiple pre-clinical models of fibrosis 
in kidney, liver, lung, and heart. Phase 1 studies in normal volunteers and Phase 1b 
studies in patients with advanced nephropathy associated with Type 2 diabetes have been 
successfully completed.
Methods: Single ascending dose (SAD) phase 1 studies were performed in 5 cohorts 
of healthy volunteers, 6 subjects in each cohort receiving PBI-4050 and 2 receiving 
identical placebo, at doses of 400 to 2,400 mg po. The 800 mg cohort had studies in both 
the fasting and fed state. Phase 1b studies were performed in 8 subjects with Stage 3b and 
4 nephropathy associated with Type 2 diabetes (eGFR 15-45 mL/min), 2 of whom received 
placebo; after a single dose of 800 mg po and a washout period, the same patients received 
800 mg po daily for 10 days.
Results: In the SAD study all doses were well-tolerated; there were no dose-related 
adverse events (AE) and no serious AE’s. The half-life (T1/2) mean was 3.3-5.0 hours, 
dependent on dose (See Figure). There was a 34% decrease in the area under the curve 
(AUC0-inf) after a fat meal. Protein binding in plasma was > 99%. 
In the patients with CKD the T1/2 mean and AUC0-inf were unchanged and there was 
no change in plasma protein binding. In the 10 day study there was no significant drug 
accumulation. One subject experienced diarrhea listed as mild to moderate and possibly 
related. There were no other significant AE’s.
Conclusions: PBI-4050 was found to be safe in normal volunteers and in advanced 
CKD. The pharmacokinetics and protein binding were unchanged in CKD. Phase 2 studies 
are underway in patients with CKD associated with Type 2 diabetes.
Funding: Pharmaceutical Company Support - ProMetic Life Sciences
TH-PO670
Immunogenicity and Safety of Quadrivalent Human Papillomavirus 
(HPV) Types 6/11/16/18 Recombinant Vaccine in CKD Stage IV-V-VD 
Kearkiat Praditpornsilpa, Paweena Susantitaphong, Somchai Eiam-ong.  Dept 
of Medicine, Chulalongkorn Univ, Bangkok, Thailand.
Background: Up to 70% of sexually active adults will become infected withHPV during 
their lifetime. HPV infection can result in anogenital cancer and genital warts. Studies have 
demonstrated the efficacy of HPV-6/11/16/18 vaccination(GARDASIL®) 3 doses at day1, 
month2, and month6 to lower the occurrence of high-grade cervical intraepithelial neoplasia. 
HPVvaccination has been integrated in health care in nonCKD. However,immunogenicity 
and safety of the HPV vaccine have not been proven in CKD. This study investigated the 
immunogenicity and safety of quadrivalentHPV-6/11/16/18vaccination by the current 
recommended dose/schedule in CKD stage IV-V-VD.
Methods: This is a prospective, open-label study. CKD stage IV-V-VD patients 
were enrolled. Vaccine was given as a 0.5mL intramuscular injection at day1,month2,and 
month6. Each dose contains 20gHPV6L1 virus-like-particle(VLP), 40gHPV11L1VLP, 
40gHPV16L1VLP, and 20gHPV18 L1VLP. HPV type-specific Ab response was performed 
by multiplexed, competitive Luminex immunoassay(cLIA) to neutralizing epitopes on 
HPV6/11/16/18 at day1 and month7.
Results: Sixty CKD cases(male/female:28/32 ) received vaccination. Pre-dialysis/
HD/CAPD cases were 2/44/14 cases. Mean age was 25.0±4.7years. Average Cr and eGFR 
were 10.3±4.5mg/dL and 14.3±12.8mL/min/1.73m2respectively. Five patients underwent 
kidney transplanation before completing 3 doses of vaccination. At baseline, anti-HPV 
seropositivity was3.3-8.3% forHPV genotype6/11/16/18.
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Day1 Month7
HPV genotype %Seropositivity MeancLIA (mMu/ml) %Seropositivity
MeancLIA (mMu/
ml)
Anti-HPV6 8.3 49.8 100 928.5
Anti-HPV11 8.3 19.4 100 1,136.1
Anti-HPV16 6.6 69.2 100 6,951.0
Anti-HPV18 3.3 12 100 2,196.3
Patients received 3 doses of vaccine had 100% seropositivity for all genotypes. The 
average cLIA for genotype6/11//16/18 were 928.4±231.1,1,136±264.6, 6,951.0±1872.3 
and2,196.3±761.2mMu/ml respectively. No serious vaccine related adverse events were 
observed.
Conclusions: Standard dose/schedule of quadrivalent HPV vaccine provided excellent 
immunogenicity and safety inCKD stageIV-V-VD. HPV vaccination for CKD should be 
integrated in public health policy.
Funding: Pharmaceutical Company Support - MSD provided vaccine doses, 
Government Support - Non-U.S.
TH-PO671
Minocycline-EDTA: Good Performance for Catheter Patency Maintenance 
Marcus Vinicius de Souza Joao Luiz,1 Cristoforo Scavone,1 Carmen B. 
Tzanno-Martins.2  1Pharmacology, Inst of Biomedical Sciences, Sao Paulo, 
Brazil; 2Nephrology, Integrated Centre of Nephrology, Guarulhos, Sao Paulo, 
Brazil.
Background: Poor flow (PF) and catheter-related blood stream infections (CRBSI) are 
highly prevalent among CKD 5D patients with long-term central venous catheters. Heparin 
(H) catheter lock solutions are commonly used to maintain catheter patency, however PF 
and CRBSI incidence remains high. The purpose of this study was to evaluate two lock 
solutions on reduction of PF and CRBSI: one, a lock solution combining of the tetracycline 
antibiotic minocycline with the anticoagulant/chelation agent EDTA (M-EDTA) versus H; 
and other, trisodium citrate (C) versus H. M-EDTA and C were also evaluated as to their 
safety versus H.
Methods: Thirty CKD 5D patients on high-efficiency hemodialysis (blood flow rate = 
350 ml/min) at the Integrated Centre of Nephrology (Guarulhos, Brazil) were randomized 
1:1:1 to receive M-EDTA, C or H locks for 15 weeks. Lock solutions concentrations were 
M-EDTA 30 mg/ml/3 mg/ml, C 30% (C) and H 1,000 U/ml and both investigators and 
patients were blinded to treatment allocation. The primary end-point was a 10% reduction 
in HD blood flow rates (35ml). The frequency of CRBSI was recorded. Bleeding and lock 
solution-related adverse events were the primary safety end points. Logistic Regression 
was performed to evaluate differences in PF rates among the treatments (SPSS version 
13.0, IBM, USA).
Results: PF was significantly higher among patients on H (7/10) compared to C (3 
/10) and M-EDTA (1/10) locks, according to results of Logistic Regression comparison: 
H vs C (p=0.082); H vs M-EDTA (p=0.016). Heparin was associated with the highest rate 
of PF. M and C lock solutions had similar PF rates. Only one CRBSI was identified in a 
patient on receiving a C lock. No bleeding or adverse events were identified. There was 
no difference in CRBSI prevention.
Conclusions: M-EDTA and C seem may preserve catheter patency. A larger clinical trial 
is being conducted in order to confirm these findings and to further evaluate CRBSI rates.
Funding: Government Support - Non-U.S.
TH-PO672
Long-Term Outcomes After Renal Artery Stenting Among Diabetic and 
Non-Diabetic Patients with Renal Artery Stenosis  Happy Farouk Sadiek, 
Amol Mittal, Shraddha Narechania, Bassel Akbik, Gaurav Kistangari, Arash 
Rashidi.  1Internal Medicine, Cleveland Clinic-Fairview Hospital, Cleveland, 
OH; 2Internal Medicine, Cleveland Clinic-Fairview Hospital, Cleveland, 
OH; 3Internal Medicine/Nephrologist, Cleveland Clinic-Fairview Hospital, 
Cleveland, OH.
Background: The current study aims to determine if renal-artery stenting affects 
mortality and/or delays the onset of Renal Replacement Therapy over a 10 year period in 
diabetic and non-diabetic patients with renal artery stenosis (RAS).
Methods: Using electronic medical records of Cleveland Clinic Health System, 168 
patients with a diagnosis of RAS were identified from 01/01/2000 to 12/31/2004. Patients 
were categorized into two groups - “stented” for those who underwent renal artery stenting 
and “medical” for those who were treated with medical therapy alone. The primary outcome 
was time to death. The secondary outcome was a composite end point of death or the need 
for renal replacement therapy.
Results: Out of 168 patients, 67 were in ‘stented’ group and 101 in ‘medical’ therapy 
group; diabetic patients represented 24% in the stented group and 38% in the medical group. 
Overall, a higher percentage of deaths were seen in ‘stented’ group (64% vs. 42%, p 0.02). 
Multivariable analysis revealed CKD stage=>3 as the only variable significantly associated 
with death (HR 2.45, 1.32-4.85, p 0.003). In another analysis - bilateral renal artery stenosis, 
CKD stage =>3 and DM were found to be significantly associated with the occurrence 
of composite end point of RRT and/or death. On subgroup analysis among diabetics, 
multivariable analysis revealed mortality benefit among patients who underwent renal 
artery stenting (HR 0.15, 0.03-0.55, p 0.006) when compared to ‘medical’ therapy alone; 
and a trend towards delaying the onset of composite end point (HR 0.28, 0.06-1.11, p 0.07).
Conclusions: Renal-artery stenting in RAS did not confer any benefit in terms of 
survival or delaying the onset of RRT; however stenting of renal arteries in diabetics showed 
a survival benefit and may have some benefit in delaying the onset of RRT. Further research 
is warranted to confirm these findings.
TH-PO673
Oral versus Intravenous Hydration to Prevent Contrast Induced 
Nephropathy  Corinne E.A. Balemans,1 Yvonne R.P. de Waal,1 Jan A.J.G. van 
den Brand,1 Marc A.G.J. Ten Dam,2 Louis J.M. Reichert,3 Jack F. Wetzels.1 
1Nephrology, Radboud Univ Nijmegen Medical Center, Nijmegen, Gelderland, 
Netherlands; 2Nephrology, Canisius-Wilhelmina Hospital, Nijmegen, 
Gelderland, Netherlands; 3Nephrology, Rijnstate Hospital, Arnhem, Gelderland, 
Netherlands.
Background: Contrast Induced Nephropathy (CIN) complicates the use of iodinated 
contrast media. Guidelines advise identification of high risk patients and intravenous 
hydration as preventive measure. We conducted a multicenter randomized controlled trial 
to compare oral (home) hydration versus standard therapy (NCT01654328). The trial was 
stopped prematurely because of a low recruitment rate.
Methods: Patients with an eGFR<60ml/min/1.73m2 were stratified for risk of CIN 
based on eGFR and the presence of risk factors (diabetes, peripheral arterial disease, heart 
failure, age, anemia, use of diuretics or NSAID’s) Exclusion criteria were: overhydration, 
use of ³2 diuretics, severe heart failure, CKD stage V. High risk patients were randomized. 
Arm A: sodiumchloride 1g/10kg of body weight/day per os on day -2 and -1 before contrast 
exposure. Maximum 10g sodiumchloride/day. Arm B: NaCl 0.9% 1000ml in 4 hrs or (in 
case of heart failure or severe renal failure) 12 hrs before and after contrast administration. 
We evaluated the incidence of CIN (defined as a rise in serum creatinine ³25% or ≥44umol/L 
48-96hrs after contrast) and adverse events.
Results: From Aug 2012 until Nov 2014 there were 1593 radiological procedures in 
high risk patients. In 1116 the inclusion criteria were met. Only 255 patients gave informed 
consent. We evaluated 233 procedures (11 missing data, 7 intercurrent hospitalisation, 4 
severe nausea and vomiting.) (table 1) provides clinical characteristics and outcome data. 
Nausea was a frequent complaint during oral hydration. One SAE (overhydration) was 
related to IV hydration.
Oral
N=154
IV
N=79 P
Female 48(31%) 28(35%) 0.56
Age(yrs) 71±9 67±14 0.02
eGFR(ml/min/1.73m2) 47±16 44±9 0.05
CIN 3(1.9%) 1(1.3%) 1.00
SAE 5 2 1.00
Conclusions: Oral hydration is as effective as intravenous hydration in preventing CIN. 
Oral hydration obviates the need for hospital admission, and thus reduces costs. Adaptation 
to the protocol is needed to prevent nausea and vomiting.
TH-PO674
Obstructive Sleep Apnea and Blood Pressure and in Patients with 
Hypertension and Chronic Kidney Disease, Stage 2  Bodil Gade Hornstrup,1,2 
Jeppe B. Rosenbaek,1,2 Nikolai Hoffmann-petersen,1,2 Pia Holland Gjørup,2 Jost 
Wessels,2 Erling B. Pedersen,1,2 Jesper N. Bech.1,2  1Univ Clinic of Nephrology 
and Hypertension, Regional Hospital West Jutland and Aarhus Univ; 2Dept 
of Internal Medicine, Regional Hospital West Jutland, Holstebro, Denmark.
Background: High nocturnal blood pressure (BP) and non-dipping are important 
prognostic factors in the evaluation of the risk of cardiovascular disease in patients with 
hypertension (HT). Many patients with chronic kidney disease (CKD) suffer from high 
nocturnal BP and non-dipping. The mechanism behind this phenomenon is unknown, but 
might be related to the presence of obstructive sleep apnea (OSA). In general population, 
OSA is observed in 10-15% of men and 5-8% of women, only symptomatic in 2-4%.
Methods: From a population study in Holstebro County, 238 subjects diagnosed with 
HT and CKD stage 2 were invited to participate. 70 subjects were included and underwent 
conventional 24-h ambulatory BP monitoring (ABPM) and applanation tonometry to 
monitor central BP (HealthSTATS BPro), 24 h urine collection for microalbuminuria, blood 
samples for creatinine, and cardiorespiratory monitoring to determine apnea hypopnea 
index (AHI). HT, nocturnal HT, resistant HT and non-dipping were defined according to 
current guidelines. OSA was diagnosed when AHI > 5.
Results: Of the 70 subjects, 27 (39%) were diagnosed with OSA (average AHI 16,5). 
The subjects suffering from OSA were more obese, had lower mean oxygen saturation 
and longer snoring time during sleep. There were no difference between subjects with 
and subjects without OSA in regard to age, gender, eGFR, u-albumine, number of 
antihypertensive agents, weekly alcohol intake, Epworth score, and lung function. Subjects 
with OSA tended to have higher clinic BP, average 24 h BP, nocturnal BP, central BP both 
24 h, day and nocturnal. In addition a tendency was measured towards higher frequency 
of resistant HT and non-dipping in OSA.
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Conclusions: The occurrence of OSA in a population with hypertension and CKD 
stage 2 was larger than expected in general population. In subjects with OSA, there was a 
tendency towards higher central and brachial BP. It is suggested, that OSA is the cause of 
high BP in patients with CKD stage 2.
Funding: Government Support - Non-U.S.
TH-PO675
Structured Exercise in Obese Diabetic Patients with Chronic Kidney 
Disease: A Randomized Controlled Trial (NCT01036490)  David J. Leehey,1,2 
Eileen Collins,1 Holly J. Kramer,1,2 Cheryl Cooper,1 Jolene Butler,1 Conor 
Mcburney,1 Christine Jelinek,1 Susan Oconnell.1  1Research, Hines VA Hospital, 
Hines, IL; 2Medicine, Loyola Univ Medical Center, MayZood, IL.
Background: Patients with type 2 diabetes, obesity, and chronic kidney disease (CKD) 
are generally physically inactive and may benefit from an exercise program. However, 
there have been few randomized controlled trials to determine the benefits of exercise 
training in this population.
Methods: We hypothesized that exercise training in obese diabetic patients with CKD 
will improve physical fitness and stabilize renal function. This was a 52-week randomized 
controlled study. Inclusion criteria were type 2 diabetes, obesity (body mass index > 30 
kg/m2), CKD (stage 2-4), and persistent proteinuria (> 200 mg/day for at least 3 months). 
Subjects were randomized to a control group consisting of dietary management alone 
(CON) vs. dietary management plus 12 weeks of exercise training followed by 40 weeks 
of supervised home exercise (EX).
Results: 46 subjects were enrolled, of whom 36 (n=18 in each group) completed at 
least the 12-week evaluation. At baseline, mean values (± SD) were as follows: age 70.0 
± 8.0 years, body mass index (BMI) 36.9 ± 4.5 kg/m2, body fat 41.3 ± 6.6%, glycated 
hemoglobin (HbA1c) 8.0 ± 1.8%, eGFR 39.9 ± 19.0 mL/min/1.73m2, and urinary albumin 
excretion rate (UAE) 1118 ± 1236 mg/24h. Average symptom-limited treadmill time was 
7.8 ± 3.8 minutes and peak oxygen consumption (VO2 peak) was 13.2 ± 3.4 mL/kg/min. 
Treadmill time was increased from baseline at both 12 weeks and 52 weeks in EX but not 
in CON (p < 0.05). Change from baseline in eGFR was somewhat less in the EX than in 
the CON group at both 12 weeks (0.2 ± 4.7 vs. -3.4 ± 8.9 mL/min/1.73m2) and 52 weeks 
(-2.0 ± 5.8 vs. -3.1 ± 6.0 mL/min/1.73m2), though this did not reach statistical significance. 
No changes were seen between the groups in the other parameters.
Conclusions: Obese diabetic subjects with CKD have markedly impaired physical 
fitness. A structured exercise program improved exercise capacity but did not affect renal 
function.
Funding: Veterans Administration Support
TH-PO676
Strength Training Intervention in Patients with Advanced Chronic Kidney 
Disease: A 20 Week Pilot Study  Jordana B. Cohen,1 Erica D. Palmer,1 Angela 
M. Sheridan,1 Brenden David Connor,1 Mary B. Leonard,2 Kathryn H. Schmitz,1 
Francis Perry Wilson.3  1Univ of Pennsylvania, Philadelphia, PA; 2Stanford Univ, 
Stanford, CA; 3Yale Univ, New Haven, CT.
Background: Although chronic kidney disease (CKD) is highly associated with 
sarcopenia and poor functional status, the feasibility and impact of longitudinal strength 
training in subjects with advanced CKD is not well understood.
Methods: Patients took part in a predominantly home-based 20 week program with 
60 minutes of resistance training three times per week. We measured dual-energy X-ray 
absorptiometry (DXA) assessment of appendicular lean mass (ALM), bio-electrical 
impedance analysis (BIA) of fat free mass (FFM), 1 repetition-maximum (1RM) assessment 
of maximum quadriceps strength, short-physical performance battery (SPPB) assessment of 
functional status, 24-hr urine creatinine collection (UCr), and Kidney Disease and Quality 
of Life Short Form (KDQOL-SF) in individuals >=45 and <80 years of age with baseline 
eGFR  >=15 and <=45 mL/min/1.73m2. We used paired t-testing and Wilcoxon sign-rank 
to assess for changes in within-subject measurements before and after the intervention 
period as well as change-on-change analyses.
Results: 22 subjects completed the training program. The median age was 71 years, 
63% were male, median eGFR was 27.9 mL/min/1.73m2, and median BMI was 29.2 kg/m2. 
There was a significant improvement in 1RM (mean difference 15.9 kg +/- 6.5, p=0.03), 
but no significant change was appreciated in ALM (p=0.99), FFM (p=0.99), SPPB score 
(p=0.67), 24-hr urine creatinine (p=0.22), eGFR (p=0.26) or KDQOL-SF score (p=0.78). 
There was a significant decrease in AST (p=0.01), ALT (p=0.01), and total bilirubin (p<0.01). 
There was also a significant association between within-subject improvement in 1RM and 
improvement in FFM (p=0.02).
Conclusions: In this small study of patients with advanced CKD, we successfully 
developed a predominantly participant-driven strength training program. The significant 
improvement in 1RM indicates that patients were adherent with the protocol, however 
larger studies are needed to assess for the effect of strength training on anthropomorphic 
measures, serologic measures, and quality of life.
Funding: NIDDK Support
TH-PO677
Effect of a Medication Management Intervention on Acute Care Utilization 
After Hospitalization in CKD  Katherine R. Tuttle,1,2,3 Radica Z. Alicic,1,3 
Robert Short,1,2 Joshua J. Neumiller,2 Kenn B. Daratha,2,3 Brian J. Gates,2 
Cynthia F. Corbett.2  1Providence Health Care; 2Washington State Univ; 3Univ 
of Washington.
Background: People with chronic kidney disease (CKD) are hospitalized often and 
incur high risk of readmission.The study objective was to test the effect of a medication 
management intervention during the hospital-to-home transition on subsequent acute care 
utilization.
Methods: A single-center, randomized, controlled clinical trial of an intervention 
to improve medication information transfer (MIT) was conducted by pharmacists in 
participants’ homes within the first week of hospital discharge and compared to usual 
care. Hospitalized participants with CKD stages 3-5 (not treated by dialysis or transplant) 
were enrolled. The primary outcome was a composite of hospital readmissions and visits 
to emergency departments or urgent care centers within 90 days of discharge.
Results: Enrollee (n=182) characteristics included: age 69±11 (mean±SD) years; 
women 48%; diabetes 56%; hypertension 83%; eGFR (CKD-EPI creatinine) 41±14 ml/
min/1.73m2; albuminuria 43 (4,521; median, IQ range) mg/g creatinine. The 3 top categories 
of primary diagnoses for hospitalization were cardiovascular disease (30 %), infection (19 
%), and kidney disease (14 %). Enrollees lost before the baseline visit (n=41, mainly due 
to severe illness) were not included as active study participants. In intent-to-treat analysis 
(n=141), the primary outcome occurred in 32/72 (44 %) of the MIT group and 28/69 (41 
%) of those in usual care (Kaplan Meier, log-rank p=0.72). At 90 days post-discharge, 
achievement of guideline-based CKD goals did not differ significantly between MIT 
and usual care groups: blood pressure <140/90/<130/80 mm Hg in those without/with 
albuminuria, respectively (43 % vs 50 %); hemoglobin A1c <7.5 % in diabetic participants 
(69 % vs 76 %); hemoglobin >11 g/dl (81 % vs 83 %); and phosphorous <5 mg/dl (97 
% vs 96 %).
Conclusions: A medication management intervention conducted during the hospital-
to-home transition did not reduce subsequent acute care utilization for hospitalized people 
with CKD. This high-risk population may require more comprehensive interventions to 
improve outcomes after hospitalization.
Funding: NIDDK Support
TH-PO678
Impact of Decision Making Tools Use at the Time of Modality Choice and 
PD Take on in a Multicentre-Multinational Setting  Belen Marron,1 Janusz 
Ostrowski,2 Delia Timofte,3 Marietta Torok,4 Jose C. Divino-Filho.1  1Diaverum 
Home Therapies. Medical 2ffice, Diaverum, Munich, Germany; 2Wloclawek 
Diaverum Clinic, Diaverum, Wloclawek, Poland; 3Sema Diaverum Clinic, 
Diaverum, Bucharest, Romania.
Background: Different factors have been attributed to low PD take on such as late 
referral, unplanned start, physician bias towards PD, large HD availability and lack of 
patient´s choice. Some references apply for 50% of PD if a good modality information is 
provided. Objectives: To analyze the impact of a structured modality information program 
with the use of decision making tools (DMTs) on type of modality choice and start.
Methods: Observational, prospective, multicentre and multinational experience. All 
patients under ESRD 4-5 and/or after an unplanned dialysis start if non-informed before 
were recruited to undergo a DMT process for RRT choice. Process included: personal 
values evaluation, RRTs information with different tools, deliberation and patient´s 
modality election.
Results: 444 patients, mean age 61,5 y. from 31 clinics in Poland, Hungary and Romania 
underwent a DMTs evaluation between August-December 2014.Staff considered PD as 
contraindicated in 45% of Polish patients, 32% in RO and 24% in HU. Reasons behind 
were mix causes and “other” than abdominal or mental. Home orientation was stated for 
30% (PL), 40% (RO) and 54% (HU). Written information was largely used for 71 to 97% 
of patients; DVD in 9-21% and in centre HD/PD touring visits in 31-75%. PD as elected 
modality varied among countries: 10% (RO), 21% (PL) and 35% (HU). For patients who 
started dialysis (n= 163), PD was used in 10% (RO), 14% (PL) and 36% (HU).
Conclusions: Use of DMTs at the time of RRT modality choice is encouraging and 
complies with patient´s empowerment. An increase in PD take-on has been observed in our 
institution after DMTs use.  However, when compared with other references, our patient´s 
PD election is still low and factors behind this fact needs to be elucidated with a larger 
recruitment pool (in process).
TH-PO679
Thrombotic Microangiopathy And Complement Factor C4d Predict Poor 
Prognosis in IgA Nephropathy and Henoch-Schönlein Purpura Nephritis 
Jamie S. Chua,1 Malu Zandbergen,1 Johan W. De Fijter,2 Ron Wolterbeek,3 Jan 
A. Bruijn,1 Ingeborg M. Bajema.1  1Pathology, LUMC, Leiden, Netherlands; 
2Nephrology, LUMC, Leiden, Netherlands; 3Medical Statistics, LUMC, Leiden, 
Netherlands.
Background: Thrombotic microangiopathy (TMA) was previously reported to be 
clinically relevant and underdiagnosed in IgA nephropathy (IgAN). Complement factor 
C4d is a common denominator of TMA. Aim: to validate the prevalence of TMA and 
to determine the clinical significance of TMA and C4d in IgAN and Henoch-Schönlein 
Purpura Nephritis (HSN).
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Methods: We included 129 native renal biopsies from 2003-2013; IgAN in 82% 
and HSN in 18%. Biopsies were classified according to Oxford MEST-scores, scored for 
vascular lesions including TMA, arterial intimal sclerosis and arteriolar hyalinosis, and 
immunostained for C4d. Retrospectively collected clinical data included hypertension and 
renal function. Three groups were distinguished: absence of both TMA and C4d; presence of 
both TMA and C4d; and presence of either TMA or C4d. Changes in eGFR over time were 
compared using a linear mixed model. Renal survival was analyzed with Cox regression. 
Prognostic values of C4d, TMA and hypertension for renal survival were analyzed with 
multivariable Cox regression.
Results: The prevalence of TMA in this cohort was 20% (n=26). TMA was mainly 
chronic (65%; 17/26) and was localized in arterioles (81% of TMA cases), glomeruli (15%) 
or both (4%). TMA was associated with interstitial fibrosis and tubular atrophy, arterial 
intimal sclerosis, hyalinosis and hypertension (p-values<0.05). TMA was strongly associated 
with the presence of C4d deposits (p<0.001). Linear Mixed Model analysis: patients with 
hypertension and both C4d and TMA had significantly lower eGFR (mean decrease 24 and 
40 ml/min/1.73m2 respectively). Patients with both TMA and C4d had significantly worse 
renal survival than the two groups without both C4d and TMA (HR 6.33 and 3.38 resp.) 
corrected for hypertension (HR 4.52 and 3.30 resp.).
Conclusions: The prevalence of TMA in IgAN and HSN is substantial (20%) but 
lower than previously reported. TMA was mainly chronic, arteriolar and associated with 
C4d, hypertension and chronic lesions. TMA and C4d mark poor renal function and poor 
renal survival in IgAN and HSN.
TH-PO680
Glomerular Complement Factor C4d Marks Glomerular Basement 
Membrane Duplications: C4d Beyond Antibody Induced Injury 
Jamie S. Chua,1,2 A. Gasim,2 Ron Wolterbeek,1 Harsharan Kaur Singh,2 Volker 
Nickeleit.2  1LUMC, Leiden, Netherlands; 2UNC, Chapel Hill, NC.
Background: C4d deposits along peritubular capillaries (ptc) mark antibody mediated 
rejection (ABMR) in renal allografts. The diagnostic significance of linear C4d deposits 
along glomerular basement membranes (GBM-C4d), which can occur as isolated event, 
is poorly understood. Hypothesis: GBM-C4d, especially when isolated, is not a sign of 
ABMR but rather a marker of structural GBM changes and duplications in native kidneys 
and renal transplants.
Methods: We analyzed 319 renal allograft biopsies from 219 patients. GBM remodeling 
was analyzed by light (Banff cg-score) and by electron microscopy. Linear C4d staining by 
immunohistochemistry (IHC) and immunofluorescence (IF) was scored along the GBM and 
ptcs. Controls: native kidneys with minimal change disease (n=10) and chronic thrombotic 
microangiopathy with GBM duplications (n=26).
Results: Transplants: GBM duplications/transplant glomerulopathy (TG) occurred 
in 52/319 biopsies (16%). By IF, 49/52 (94%) TG cases had GBM-C4d; 36/49 (73%) had 
isolated GBM-C4d lacking ptc-C4d deposits. By IHC, 74% of TG cases had GBM-C4d; 60% 
of which as isolated event. GBM-C4d staining intensity correlated with Banff cg-scores (IF: 
rs=0.453, p<0.01; IHC: rs=0.478, p<0.01). 80% of cases (24/30) with GBM duplications 
present only by electron microscopy revealed GBM-C4d. Association GBM-C4d with 
TG/GBM duplications: p<0.001. Statistical significance between GBM-C4d staining and 
structural GBM duplications remained after omitting cases with presumed or definitive 
ABMR (DSA-positivity, C4d positivity in ptcs,transplant glomerulitis). Multivariate logistic 
regression: GBM duplication/TG was an independent predictor of GBM-C4d positivity. 
Native kidneys: GBM-C4d occurred in 24/26 (92%) cases with thrombotic microangiopathy 
and GBM duplications; no staining was seen in minimal change disease.
Conclusions: The diagnostic significance of linear C4d deposits along ptc versus GBM 
differs. C4d along ptc marks ABMR while linear GBM-C4d is associated with structural 
GBM duplications in native and transplanted kidneys, independent of the etiology or 
antibody induced injury. In transplants GBM-C4d serves as marker for TG.
TH-PO681
Predicting Outcome in Patients with Anti-GBM Glomerulonephritis Using 
the Histopathological Classification for ANCA-Associated Vasculitis: 
Preliminary Results  Emma Elisabeth Van Daalen,1 J. Charles Jennette,2 Jan A. 
Bruijn,1 Ingeborg M. Bajema.1  1Pathology, Leiden Univ Medical Center, Leiden, 
Netherlands; 2Pathology and Laboratory Medicine, Univ of North Carolina at 
Chapel Hill, Chapel Hill, NC.
Background: The renal biopsy in anti-glomerular basement membrane 
glomerulonephritis (anti-GBM GN) is characterized by crescent formation. No 
histopathological classification has been implemented for the disease. We have applied 
the histopathological classification for ANCA-associated vasculitis (AAV) to see whether 
this classification can distinguish patients regarding renal outcome.
Methods: We analyzed biopsies of 20 patients, diagnosed with anti-GBM GN between 
1984 and 2014 at a university hospital in the Netherlands. We classified these biopsies 
according to the histopathological classification for AAV: sclerotic (≥50% sclerotic 
glomeruli), focal (≥50% normal glomeruli), crescentic (≥50% cellular crescents) or mixed 
(no dominant lesion) class. We collected data on serology, renal function and end-stage 
renal disease (ESRD) during 5-year follow-up.
Results: Fourteen biopsies (70%) were categorized as crescentic, three (15%) as 
focal, two (10%) as mixed and one (5%) as sclerotic. Mean age was 47.4 years (SD: 17.1, 
range: 17.0-74.9) and differed between classes (P=0.039), with the focal class having 
the youngest patients with a mean age of 25.4 years. Estimated glomerular filtration rate 
(eGFR) at time of biopsy differed between classes (P<0.001), focal class having a mean 
of 80.2 ml/min/1.73m2, crescentic 6.9 and mixed 8.7 (no available data for sclerotic class). 
Mean eGFR at 1 year was 107.6 in the focal, 10.1 in the crescentic, and 21.8 in the mixed 
class (P<0.001).The occurrence of ESRD differed between groups (P=0.016), with no 
occurrence in the focal group .
Conclusions: These preliminary results show that the histopathological classification 
for AAV is useful for anti-GBM GN, predicting outcome in terms of eGFR at time of biopsy 
and at 1 year after biopsy. The focal group had more favorable outcomes regarding renal 
function and development of ESRD.
TH-PO682
The Role of C4d Immunohistochemistry to Highlight Immune Complex 
Deposition in IgA Nephropathy  Umer Sheikh,1 Hong Qu,2 Alton Brad Farris,1 
Thomas E. Rogers,1 Carla L. Ellis.1  1Pathology, Emory Univ Hospital and 
School of Medicine, Atlanta, GA; 2Pathology, St. John Hospital and Medical 
Center, Detroit, MI.
Background: IgA glomerulonephropathy (IgAN) is one of the most common 
immune complex associated nephropathies worldwide. It may develop de novo or recur 
in an allograft. Recently, C4d immunohistochemistry has been show to highlight immune 
complex deposits in a variety of glomerular diseases. Limited conclusive data is available 
regarding the utility of C4d immunohistochemistry to highlight mesangial deposits in 
IgAN despite some authors claim to the contrary. The presence of this finding would be 
beneficial in cases where immunofluorescence studies are unavailable. Our study seeks to 
determine the ability of C4d immunohistochemistry to highlight mesangial, IgA dominant 
immune complex deposition.
Methods: A retrospective study from two institutions is performed. 24 cases (19 native 
and 5 allografts) from one and 36 native cases from the other of IgAN diagnosed between 
the years of 2005 and 2012 were selected (n=60). All cases were confirmed IgAN by 
immunofluorescence and electron microscopy. Paraffin-embedded tissue sections from all 
biopsies were then stained for C4d immunohistochemistry by each respective institutional 
protocol. Cases from each institution were reviewed by the respective senior author for the 
presence, intensity and location of glomerular staining by the C4d antibody.
Results: All native and allograft cases of IgAN from both institutions showed complete 
absence of mesangial C4d immunoreactivity with some non-specific tubular epithelial 
staining in some cases and some low intensity, segmental capillary wall staining in others. 
Control tissue reacted appropriately.
Conclusions: Our results suggest that at least in our small cohort spanning two 
academic medical centers, the utility of C4d immunohistochemistry to support a diagnosis 
of IgAN in the native or allograft population is limited despite recent evidence of C4d 
deposition in immune complex associated disease. Although complement deposition with 
C3 is typically seen in IgAN, C4d deposits are not identified, suggesting the lack of this 
specific complement factor in IgAN.
TH-PO683
DNA Methylation as a Biomarker of Disease Status in Patients with ANCA-
Associated Vasculitis  Britta E. Jones, Jia Jin Yang, Akhil Muthigi, Susan L. 
Hogan, Joshua Starmer, Candace Henderson, Elizabeth J. Brant, JulieAnne G. 
McGregor, William Franklin Pendergraft, Ronald J. Falk, Dominic J. Ciavatta. 
Univ of North Carolina at Chapel Hill-Kidney Center.
Background: ANCA-associated vasculitis (AAV) is associated with environmental 
exposures and age, both of which are linked to changes in DNA methylation. We tested 
whether DNA methylation changes in patients compared to healthy controls and if DNA 
methylation may be used as a biomarker of disease status.
Methods: AAV patients (67) were followed longitudinally through disease activity and 
remission (143 leukocyte samples), including 21 patients in long-term remission off therapy 
and 32 healthy individuals. DNA methylation was measured using mass spectrometry and 
bisulfite sequencing at myeloperoxidase (MPO) and proteinase 3 (PRTN3). Expression was 
measured for MPO, PRTN3 and DNA methyltransferase 1 (DNMT1).
Results: Patients with active AAV were hypomethylated compared to healthy 
individuals. Within paired active and remitting patients, MPO-ANCA and half of PR3-
ANCA patients showed increased DNA methylation. In PR3-ANCA patients with increased 
methylation in remission, DNA methylation correlated with expression of MPO and PRTN3, 
and stable remission. DNMT1 expression in leukocytes from active and remitting patients 
was 0.6 fold and 0.8 fold, respectively, of healthy individuals. At MPO and PRTN3 there 
is a positive correlation between DNA methylation and DNMT1 expression.
Conclusions: AAV patients are characterized by dynamic changes in DNA methylation; 
differences in methylation during disease remission suggest these fates have an epigenetic 
basis. 
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MPO-ANCA patients restore DNA methylation in remission, while chronically 
relapsing PR3-ANCA patients may benefit from therapies that increase DNA methylation. 
These data suggest that DNA methylation in leukocytes may function as a biomarker of 
disease status in AAV.
Funding: NIDDK Support, Private Foundation Support
TH-PO684
Epidemiologic Features of Anti-Glomerular Basement Membrane Disease 
Nicole K. Andeen,1 Anthony Chang,2 Shreeram Akilesh.1  1Pathology, Univ of 
Washington; 2Pathology, Univ of Chicago.
Background: Anti-glomerular basement membrane (anti-GBM) disease is a rapidly 
progressive glomerulonephritis mediated by autoantibodies to the noncollagenous domain of 
the alpha-3 chain of type IV collagen. Previous reports demonstrated an association with a 
seasonal or environmental exposures in some cases (PMID: 4604010, 3256901). We sought 
to understand epidemiologic factors associated with anti-GBM disease.
Methods: Reports from consecutive cases of anti-GBM diagnosed at the University 
of Washington were retrospectively reviewed, with specific attention to epidemiologic 
parameters. Statistical analysis was performed on Graphpad Prism using Fisher’s exact 
and Mann-Whitney tests.
Results: Seventy three (M=31; F=42) cases of anti-GBM disease were identified, with 
a median age of 56 years. Overall, 2 to 11 cases were seen per year (median = 6); a high 
incidence year was defined as > median number of cases. 60% of cases were diagnosed 
in winter or spring (95% CI: 48-72%), and 40% in summer or fall (95% CI 28 – 52%). 
The M:F ratio was 1:2 in high incidence years, but nearly 1:1 with a male predominance 
in low incidence years (p=0.07). Of variables studied, concurrent deposition of IgA in the 
mesangium was associated with younger age at diagnosis (p=0.01); 6 of 7 of these were seen 
in a high-incidence year (p=0.07). No associations among ANCA-positivity vs. respiratory 
symptoms, age, sex, and/or season of presentation were identified.
Conclusions: There were quantitative and qualitative differences in epidemiologic 
parameters in anti-GBM disease. Unlike low incidence years, cases diagnosed in high 
incidence years showed a trend for increased likelihood of concurrent mesangial IgA 
deposition, and male gender. The findings suggest potential differences in the environmental 
and/or gender-based triggers in the development of anti-GBM.
TH-PO685
The Lumped System Utilized in the Japanese Histological Grade 
Classification of IgA Nephropathy May Produce a Score with a Broader 
Applicability Compared to the Split System of Oxford Classification 
Kensuke Joh,1 Akinori Hashiguchi,2 Akira Shimizu,3 Ritsuko Katafuchi,4 Tetsuya 
Kawamura.5  1Dept of Pathology, Tohoku Graduate School of Medicine, Sendai-
City, Miyagi-ken, Japan; 2Dept of Pathology, Keio Univ School of Medicine, 
Tokyo, Japan; 3Dept of Pathology, Nihon Medical School, Tokyo, Japan; 4Div 
of Internal Medicine, Fukuoka Higashi Medical Center, Fukuoka, Japan; 5Div 
of Kidney and Hypertension, Jikei Univ School of Medicine, Tokyo, Japan.
Background: Japanese Histological Grade Classification (JHGC; HG1-HG4) (J 
Nephrol, 2013) and Oxford classification (Oxford) were compared with a focus on their 
ability to predict renal functional decline (RFD) and proteinuric remission (PUR).
Methods: 411 Japanese with IgAN (male 49%) were collected from 32 centres in 
Japan. The patients, whose median age was 36.2 years old, were prospectively followed 
for a median of 36 months. The average amount of initial proteinuria (PU) was 0.8 g/day. 
Mean eGFR was 77.9±29.6 ml/min/1.73m2 and median rate of decline in eGFR was -0.7 
ml/min/1.73m2.
Results: 24 % and 55% of patients received steroid and RAS blockade, respectively. The 
ICC among 5 observers on M, E, S, T, and HG scores were fair or good. In multivariate Cox 
analysis, hazard ratio (HR) of MEST in Oxford for 1.5 time’s increase of serum creatinine 
(sCr) was not significant, whereas HG3 and HG4 in JHGC were significant (HR of 13 
and 42, respectively) even after adjustment by steroid, RAS blockade, initial PU, initial 
eGFR, and initial MAP (p<0.05). When comparing HG, M, E, S and T, HG score was the 
only independent predictor in isolation or in comparison to varied combinations of MEST 
parameters. The HR for PUR (an endpoint of proteinuria as 0.3 g/day) was not significant 
in Oxford, whereas HG3, initial MAP and steroid were independent predictors with HR 
as 0.4, 0.9, and 1.7, respectively (p<0.05).
Conclusions: HG score was more effective than Oxford in predicting both RFD and 
PUR in the Japanese cohort consisting of earlier stage of IgAN. The inherent flexibility in 
a lumped approach (JHGC) as opposed to a split system (Oxford) may make the HG score 
more robust when being applied to diverse cohorts allowing a wider application of scoring.
Funding: Government Support - Non-U.S.
TH-PO686
Prospective Cross-Sectional and Longitudinal Observational Study of 
Urinary Podocyte Markers and Urinary Megalin in Kidney Disease of 
ANCA-Associated Vasculitis  Hiroshi Kajiyama,1 Keiju Hiromura,2 Daisuke 
Ikuma,1 Junya Suwa,2 Hidekazu Ikeuchi,2 Hiroyuki Kurosawa,3 Yoshiaki 
Hirayama,3 Masanori Hara,4 Akihiko Saito,5 Yoshihisa Nojima,2 Toshihide 
Mimura.1  1Dept of Rheumatology and Applied Immunology, Saitama Medical 
Univ, Iruma, Saitama, Japan; 2Dept of Medicine and Clinical Science, Gunma 
Univ Graduate School of Medicine, Maebashi, Gunma, Japan; 3Diagnositcs 
Research Dept, Denki Kagaku Kogyo K.K., Machida, Tokyo, Japan; 4Dept 
of Pediatrics, Yoshida Hospital, Tsubame, Niigata, Japan; 5Dept of Applied 
Molecular Medicine, Niigata Univ Graduate School of Medicine and Dental 
Sciences, Niigata, Japan.
Background: The purpose of this study is to clarify the significance of urinary podocyte 
markers (urinary podocyte number (U-Pod/Cr) and urine podocalyxin (PCX) (U-PCX/Cr)) 
and urinary megalin (A-Meg/Cr, megalin’s extracellular domain; C-Meg/Cr, full-length of 
megalin) in ANCA-associated vasculitis (AAV).
Methods: AAV patients (30 cases) were recruited from August 2009 to April 2014. 
Presence of proteinuria and/or reduced eGFR or histological renal diagnosis was defined 
as kidney disease (KD)(+). U-Pod/Cr, U-PCX/Cr, A-Meg/Cr and C-meg/Cr were measured 
around the treatment start (M0), and at 1 (M1), 3 (M3), 6 (M6) and 12 months (M12) 
after treatment.
Results: At M0, urinary protein creatinine ratio (U-PCR) was significantly higher, 
and eGFR was significantly lower in KD(+). CRP was not different between KD(+) and 
KD(-) at M0. U-Pod/Cr was significantly higher in KD(+), and U-PCX/Cr, A-Meg/Cr and 
C-Meg/Cr were not different at M0, although there was a trend of high C-Meg/Cr in KD(+), 
compared with KD(-). After treatment in KD(+), CRP (from M1 on), U-PCR, urinary-NAG 
(U-NAG)/Cr (from M3 on) significantly improved. U-Pod/Cr and C-Meg/Cr (from M6 on) 
were significantly improved after treatment in KD(+), and U-PCX/Cr and A-Meg/Cr were 
not significantly changed. Only the correlation of C-Meg/Cr with U-NAG/Cr (p=0.028, 
Spearman r:0.46, 95%CI 0.04-0.74) was significant between laboratory data and urinary 
markers measured at M0.
Conclusions: U-Pod/Cr and C-Meg/Cr are elevated in AAV kidney disease and 
improve after treatment. U-Pod/Cr and C-Meg/Cr may reflect podocyte and proximal 
tubular injuries, respectively, in AAV.
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TH-PO687
Clinical and Histological Determinants of Renal Outcome in Lupus 
Nephritis  Emilie Rijnink,1 Suzanne Wilhelmus,1 Mathilde M.M. Almekinders,1 
Ron Wolterbeek,2 Jan A. Bruijn,1 Ingeborg M. Bajema.1  1Pathology, Leiden 
Univ Medical Center; 2Statistics, Leiden Univ Medical Center.
Background: The ISN/RPS 2003 histopathological classification of lupus nephritis 
(LN) is based on lesions historically thought to be relevant for prognosis, but for some 
lesions the evidence base is lacking. Without preconceptions, we tested a wide range 
of histologic and clinical features to objectively identify prognostic indicators of renal 
outcome in patients with LN.
Methods: 42 histological and 7 clinical parameters were determined as candidate 
predictors of renal outcome. A cohort of patients was identified from the pathology archives 
of our center, diagnosed with any class of LN between 1990-2011. Renal biopsies were 
rescored for 42 histologic parameters. eGFR and proteinuria were recorded at time of 
renal biopsy, as well as during 1, 5, and 10 years of follow-up. For preliminary analyses, 
variables were tested using univariate mixed models, in which p<0.05 for fixed effects was 
considered statistically significant.
Results: Interim analysis was performed on 29 patients, of whom none developed 
end-stage renal disease. Significant associations with eGFR were found for age (p=0.03) 
and eGFR (p<0.001) at time of renal biopsy, percentage of normal glomeruli (p<0.01), 
percentages of glomeruli with mesangial hypercellularity (p=0.05), endocapillary 
hypercellularity (p=0.03), endothelial swelling (p=0.03), endocapillary mononuclear cells 
(p=0.01), wire loops (p=0.02), and cellular crescents (p<0.05), as well as the presence of 
an interstitial infiltrate (p=0.04). Significant associations with proteinuria were found for 
eGFR at time of biopsy (p=0.02), percentage of glomeruli with mesangial global sclerosis 
(p=0.02), presence of cellular and fibrocellular crescents (p=0.01), as well as the presence 
of an interstitial infiltrate (p<0.01) and tubular atrophy (p=0.02).
Conclusions: Besides histological parameters characteristic of the previously 
established classes of LN, also interstitial and clinical parameters may have prognostic 
significance. These and other features will be studied in an extended dataset in multivariate 
analyses of which the outcome may be relevant for future modifications of the LN 
classification.
TH-PO688
Specificity of Full House Immunofluorescence for Systemic Lupus 
Erythematosus  Emilie Rijnink,1 Yoe Kie Onno Teng,2 Tineke Kraaij,2 Jan 
A. Bruijn,1 Ingeborg M. Bajema.1  1Pathology, Leiden Univ Medical Center, 
Netherlands; 2Nephrology, Leiden Univ Medical Center, Netherlands.
Background: The finding of full house immunofluorescence (IF) in combination 
with various histological lesions in renal biopsies of patients without overt systemic lupus 
erythematosus (SLE) poses a diagnostic challenge. We studied the clinical course of these 
patients as compared to patients who did have SLE at the time of biopsy.
Methods: Patients with full house IF on renal biopsy between 1968-2014 were 
identified from the pathology archives at our center. Clinical records were reviewed for 
the presence of ACR or SLICC criteria for the classification of SLE at the time of renal 
biopsy and during follow-up.
Results: 149 patients with full house IF on renal biopsy were identified. At time of 
biopsy, 112 had SLE according to >4 ACR criteria (SLEACR), 7 according to SLICC criteria 
(SLESLICC), and 30 did not fulfill criteria for SLE. Of the latter 30, one was classified 
as SLESLICC during follow-up. Survival without end-stage renal disease regardless of 
immunosuppressive therapy was better in the group of patients with SLEACR/SLICC than 
in those without SLE (p<0.01). No difference was noted between patients with SLESLICC 
or SLEACR (p=0.16). Compared to patients with SLEACR/SLICC, patients without SLE were 
significantly more often male, had significantly higher serum creatinine, CH50, and C3, 
and had significantly less frequent anti-ENA, anti-SS-A, anti-RNP70, and anti-C1q. All 
SLE criteria were significantly more frequent in patients classified as SLEACR/SLICC, except 
for chronic cutaneous lupus, and oral/nasal ulcers.
Conclusions: This study demonstrates that the presence of full house IF in renal biopsies 
as a marker of biopsy-confirmed LN, has limited specificity for SLE. This contrasts with the 
SLICC classification, where biopsy-confirmed LN was seen as a highly specific feature of 
SLE. Our results show that patients with full house IF without SLE are clinically distinct 
from SLE patients. Consequently, for clinical and study purposes, a separate classification 
for these patients is warranted.
TH-PO689
Novel Urinary Tubular Biomarkers for Diagnosis and Predictive Active 
Lupus Nephritis  Bancha Satirapoj, Panbubpa Choovichian, Ouppatham 
Supasyndh, Kulachon Leelasiri.  Medicine, Phramongkutklao Hospital and 
College of Medicine, Bangkok, Thailand.
Background: Tubulointerstitial damage is important in the prediction and progression 
of lupus nephritis (LN). Novel urinary tubular biomarkers included neutrophil gelatinase-
associated lipocalin NGAL, kidney injury molecule- KIM- and periostin have been 
reported to increase in progressive kidney injury. Therefore, these urinary biomarkers may 
relate and predict renal activity in systemic lupus erythematosus (SLE) patients.
Methods: We performed a diagnostic and prospective study in SLE patients with 
biopsy-proven active LN and with inactive LN. All patients were collected urine for NGAL, 
KIM-1 and periostin measurement by ELISA. After standard treatment in active LN patients, 
urinary biomarkers were repeated.
Results: A total of 67 patients with SLE including 35 patients with active LN and 32 
patients without active LN were included. Urinary levels of KIM-1 was higher in active 
LN compared to inactive LN (median 2.17 (IQR; 0.92, 5.18) vs.0.29 (IQR; 0.13, 1.11) 
µg/g creatinine, P<0.001), while no significant difference was found in urinary NGAL 
and periostin levels. Urinary KIM-1, NGAL and periostin correlated positively with 
proteinuria, and only KIM-1 and NGAL correlated negatively with renal function. On 
ROC analysis, urinary KIM-1 (AUC; 0.80, 95%CI 0.69-0.92) outperformed conventional 
biomarkers (serum creatinine, urine protein, serum complements and anti-dsDNA antibody) 
in differentiating active LN from non-LN group. On follow-up after treatment in active 
LN patients (n = 19), there was no significant difference in all urinary tubular biomarkers 
between response and nonresponse LN patients.
Conclusions: Levels of urinary KIM-1, but not of urinary NGAL and periostin may 
be potentially useful markers of LN activity and urine KIM-1 is better performance than 
conventional markers of active LN. However, these novel tubular biomarkers are not 
predictive for a clinical response to treatment of active LN.
Funding: Government Support - Non-U.S.
TH-PO690
Revisiting of Anti-Phospholipase A2 Receptor Antibodies and Its Antigen 
as Specific Biomarkers in Membranous Nephropathy  Li Lin, Jing Xu, 
Xiaoxia Pan, Wen Zhang, Weiming Wang, Jingyuan Xie, Nan Chen.  Dept of 
Nephrology, Rui Jin Hospital, Shanghai Jiao Tong Univ, School of Medicine, 
Shanghai, China.
Background: M-type phospholipase A2 receptor (PLA2R) as antigen in idiopathic 
membranous nephropathy (IMN) is a success model of fast-speed translational medicine. 
The objective of this study was to assess the prevalence and clinical value of serum 
antoantibodies against the M-type phospholipase A2 receptor (anti-PLA2R) in Chinese 
MN patients.
Methods: In this prospective study, 195 patients with MN including 37 MN patients 
with coexisting diseasesand 70 patients with other glomerular diseases were enrolled. Anti-
PLA2R antibodies in serum were assessed by direct immunofluorescence assay (IFA). The 
staining of PLA2R in glomeruli was evaluated by standard immunofluorescence microscopy.
Results: Anti-PLA2R was only found in MN patients. PLA2R-related MN rate in MN 
was 87.23%, the positive rate of the serum anti-PLA2R and glomeruli PLA2R were 68.09% 
and 83.21%, respectively. PLA2R-unrelated MN patients had more coexisting diseases 
compared with PLA2R -related MN patients (61.11%vs 21.13%, p=0.01),but in MN patients 
with coexisting diseases, the rate of PLA2R-related MN is 72.97%, thus we regard that 
PLA2R in glomeruli or anti- PLA2R in circulation is not suitable for discrimination of IMN 
and SMN. In 54 MN patients who have received treatment the positive rate for Anti-PLA2R 
was 8.33%, 31.58% and 69.57% in Complete remission (CR), Partial remission (PR), and 
disease active patients, respectively (p=0.001). More Anti-PLA2R positive patients at the 
start of the study developed nephrotic-range proteinuria(70.31%)compared to Anti-PLA2R 
negative PLA-related MN (53.85%) (p=0.004), but there was no statistical difference in 
remission rate during follow-up (p=0.406).
Conclusions: We confirm that anti-PLA2R antibody measured by IFA is specific 
detected in serum of MN patients but it is controversy as used in the differential diagnosis 
of IMN and as a biomarker to predict outcome of disease. the absence of predictive value 
may be due to the fact that you have not looked at quantitative data (would need ELISA 
or quantitative expression of IF data).
TH-PO691
Endoplasmic Reticulum Stress Marker Glucose-Regulated Protein 
78 Instead of Calcineurin Expression within Kidney Is Predictive of 
Poor Response to Cyclosporine Treatment in Idiopathic Membranous 
Nephropathy  Wei Zhang, Yu-bing Wen, Baobao Wang, Liangyan Zhang, 
Weifeng Lin, Jianling Tao, Limeng Chen, Hang Li, Mingxi Li, Xuewang Li, 
Xuemei Li.  Div of Nephrology, Peking Union Medical College Hospital, Peking 
Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Background: Cyclosporine (CsA) is effective to achieve 60-70% remission rate in 
treatment of idiopathic membranous nephropathy (IMN). Little is known if Endoplasmic 
Reticulum stress marker glucose-regulated protein 78(GRP78) within kidney before CsA 
treatment could predict post treatment outcome.
Methods: Seventy-six adult biopsy-confirmed IMN patients treated by CsA for at 
least six months from Peking Union Medical College Hospital from 1996 to 2014 were 
retrospectively reviewed. They were grouped into non-remission (NR) (n=12), partial 
remission (PR) (n=12), or complete remission(CR) (n=52) at the end of six month treatment 
of CsA with an initial CsA dosage (2.8±0.7 Mg/Kg/d). GRP78 in kidney and Calcineurin 
(CAL) expression in the kidney and serum were assayed by immunohistochemistry and 
ELISA, and their expressions were correlated with clinical outcome.
Results: Serum CAL and kidney CAL expression in IMN patients are significantly 
increased compared to healthy controls, although there is no difference in either serum or 
kidney CAL among NR, PR or CR groups. There is a negative correlation between serum 
CAL activity and renal CAL expression (p=0.034). However, glomerular GRP78 expression 
in NR group is significantly higher than CR group (Bonferroni correction p<0.0083). There 
is a positive correlation between kidney CAL expression and GRP 78 expression (p<0.05).
Conclusions: ER stress marker GRP78 expression in glomerular section of kidney 
instead of serum or kidney CAL expression could be an additional marker, which negatively 
predicts the clinical response to CsA treatment in IMN patients. New drugs targeting to 
alleviate ER stress in IMN could be developed to treat those non-responders to CsA. 
(Supported by National Natural Science Foundation of China 81170665 to Dr. Jianling Tao).
Funding: Government Support - Non-U.S.
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TH-PO692
Selected Reaction Monitoring for Quantification of Angiotensin-II Signature 
Proteins in Urine  Ana Konvalinka,1 Andrei Drabovich,2 Xuewen Song,1 
York P. Pei,1 James W. Scholey,1 Eleftherios P. Diamandis.2  1Medicine, Div. 
of Nephrology, Toronto General Hospital, Toronto, ON, Canada; 2Laboratory 
Medicine and Pathobiology, Lunenfeld Research Inst, Toronto, 2N, Canada.
Background: Angiotensin-II (AngII) mediates polycystic kidney disease progression. 
However, there are no specific markers of kidney AngII activity. We previously defined 83 
AngII-regulated proteins in vitro, which reflected kidney AngII activity in vivo. We aim 
to quantify these proteins in urine using a mass spectrometry technique called selected 
reaction monitoring (SRM), and establish their role as markers of kidney AngII activity 
in patients with ADPKD.
Methods: We demonstrated that 47 of 83 AngII-regulated genes were differentially 
expressed in cystic vs normal kidney tissue. We then selected 18 AngII-regulated proteins 
upregulated in cystic tissue and/or present in urine. We developed SRM assays for 37 
peptides corresponding to 18 AngII-regulated proteins. To assess reproducibility and 
recovery, we spiked in bovine serum albumin (BSA), and the corresponding heavy-labeled 
peptides. We determined an optimal method for detection of AngII-regulated peptides. 
Heavy peptides corresponding to 13 identified AngII-regulated peptides were purchased and 
spiked into urine. Ultimately, 20ug of total protein/sample was concentrated and analyzed 
on triple-quadrupole mass spectrometer. We quantified AngII-regulated peptides in urine 
samples of 9 ADPKD and 2 healthy subjects.
Results: Technical replicate CVs were <6% for BSA peptides, and recovery was ~100%. 
Calibration curves demonstrated linearity (R2>0.99) and CVs<20% in the concentration 
range of 7/13 peptides in normal and ADPKD urines. Deamidated peptides accounted 
for 1-40% of total concentration. Peptides were quantified in all urine samples. Peptides 
corresponding to proteins TSP1, BST1, and LAMB2 had the highest excretion rate in urine 
of the only ADPKD patient with impaired GFR.
Conclusions: We have developed a protocol for SRM quantification of AngII-regulated 
proteins in urine. Seven AngII-regulated peptides were quantified in urine samples. Future 
studies will examine if urine excretion rate of AngII signature proteins is associated with 
cyst size and GFR in larger cohorts of ADPKD patients.
TH-PO693
Establishment of Proteomic Profiles of Normal Glomeruli Using Laser 
Microdissection and Mass Spectrometry  Ying Sun,1 Mingxi Li,1 Yubing Wen,1 
Wei Sun,2 Jian Sun,3 Xuemei Li.1  1Dept of Nephrology, Peking Union Medical 
College Hospital, Beijing, China; 2Dept of Core Instrument Facility, Inst of Basic 
Medical Sciences, Inst of Basic Medical Sciences, Chinese Academy of Medical 
Sciences, Peking Union Medical College, Beijing, China; 3Dept of Pathology, 
Peking Union Medical College Hospital, Beijing, China.
Background: Laser microdissection combined with mass spectrometry (LMD/MS) 
has become an powerful tool in proteomics study. There is little data of normal glomeruli 
proteomic profiles which are fundamental in the study of differential proteomics of kidney 
diseases. Our study aimed on establishing proteomic profiles of normal glomeruli from 
formalin-fixed paraffin-embedded (FFPE) specimen through LMD/MS.
Methods: Normal kidney cortices were obtained from four patients underwent 
nephrectomy due to renal carcinoma. 10-mm FFPE sections were prepared for laser 
microdissection, 4-6 glomeruli were cut out each case and collected for digestion. Peptides 
were quantified using Thermo Scientific LTQ Orbitrap Velos mass spectrometer. MASCOT 
software was used for identification of proteins, with tandem mass spectrometry data 
searching against UniProt. Scaffold 4 software was used to integrate results, taking proteins 
with credibility of ≥95% and identified peptides number > 1 into statistics.
Results: 67 proteins were identified in normal glomeruli from four cases with LMD/
MS analysis. High abundance glomerular structural proteins and blood-related proteins 
are shown below. 
MS/MS View Accession Number Molecular Weight
Alpha-actinin-4 O43707 105 kDa
Zinc-alpha-2-glycoprotein P25311 34 kDa
Na(+)/H(+) exchange regulatory cofactor Q15599 37 kDa
Uromodulin P07911 70 kDa
Synaptonemalcomplex protein 2 Q5T4T6 94 kDa
Basement membrane-specific proteoglycan P98160 469 kDa
Osteopontin P10451 35 kDa
Peroxiredoxin-2 P32119 22 kDa
Lamininsubunit alpha-5 O15230 400 kDa
Tubulinbeta chain P07437 50 kDa
Conclusions: This study obtained proteomic profile of normal glomerular from FFPE 
samples, which can provide comparison data for differential proteomic study of glomerular 
diseases. Further study is needed to analyse the function and location of glomeruli proteins 
identified with LMD/MS.
Funding: Government Support - Non-U.S.
TH-PO694
Systemic Lupus Erythematosus/ANCA-Associated Vasculitis Overlap 
Syndrome in Patients with Biopsy-Proven Glomerulonephritis 
Noemie Jourde-chiche,1 Pierre-André Jarrot,2 Laurent Chiche,3 Laurent Daniel,4 
Bertrand Gondouin,1 Bertrand Dussol,1 Stephane Burtey.1  1Nephrology, Aix-
Marseille Univ, Marseille, France; 2Internal Medicine, Aix-Marseille Univ, 
Marseille, France; 3Internal Medicine, Hopital Europeen, Marseille, France; 
4Pathology, Aix-Marseille Univ, Marseille, France.
Background: SLE and AAV are distinct auto-immune diseases with possible renal 
involvement. Some patients fulfil both SLE and AAV classification criteria, defining the 
SLE/AAV overlap syndrome. We aimed: 1) to report clinical, biological and pathological 
characteristics of patients with SLE/AAV overlap syndrome and a biopsy-proven 
glomerulonephritis (GN), 2) to evaluate the incidence of overlapping auto-antibodies and 
of the overlap syndrome in a cohort of patients with lupus nephritis (LN) or crecentic 
GN (CGN).
Methods: A nationwide survey was conducted to identify cases of SLE/AAV overlap 
syndrome. Data were collected from SLE and AAV French research groups. Inclusion 
criteria were diagnosis of both SLE and AAV and biopsy-proven GN between 1995 
and 2014. An independent cohort of LN and CGN was used to study the prevalence of 
overlapping antibodies and/or overlap syndrome. Additional cases were identified through 
a systematic literature review.
Results: The national survey identified 8 cases of SLE/AAV overlap syndrome. All 
patients were female, median age was 40 years. AAV preceded (n=3), followed (n=3) or 
occurred concomitantly (n=2) to SLE. Six patients had rapidly progressive GN, and 3 
had alveolar hemorrhage. All patients had antinuclear antibodies (ANA), 7 had p-ANCA 
anti-myeloperoxidase (MPO) antibodies. Renal biopsy showed LN or CGN. Remission 
was obtained in 6 patients. Literature review identified 31 additional cases with similar 
profile. Cohort analysis revealed ANCA positivity in 24% of LN, ANA positivity in 55% 
of CGN, with no correlation with pathological findings, and a prevalence of 2/110 (1.8%) 
for SLE/AAV overlap syndrome.
Conclusions: In patients with GN, SLE/AAV overlap syndrome may occur but its 
prevalence seems low. Most patients have an aggressive renal presentation, with usually both 
ANA and anti-MPO antibodies. Further studies are needed to assess shared pathogenesis 
and therapeutic options.
TH-PO695
The Effect of Chronic Kidney Disease on Plasma Cell-Free DNA Levels 
and Apoptosis  Alessandra Brocca, Grazia Maria Virzì, Sabrina Milan manani, 
Massimo de Cal, Claudio Ronco.  S Bortolo Hospital, Vicenza, Italy.
Background: Cell-free plasma DNA (cfDNA) is composed of circulating extracellular 
DNA fragment that originates from necrotic and apoptotic cells reflecting inflammation. 
cfDNA has been found in many conditions, in which apoptosis or necrosis was involved 
suggesting that such events are the main source for its presence. CfDNA quantification is 
a possible method to determine cell damage in vivo. Caspase-3 is an effector caspase, it 
is responsible for progression to apoptosis. We focused on plasma cfDNA and Caspase-3 
detection in patients with different stages of Chronic Kidney Disease (CKD), as index of 
inflammation, apoptosis and tissue damage in this population.
Methods: We enrolled 25 CKD patients who came to our center for routine visit and 
we divided them according to CKD stage (1-5). In addition, 8 healthy volunteers (CTR) 
were enrolled as control group. cfDNA was extracted from plasma and quantified by Real 
Time PCR for the β-globin gene. Quantitative plasma level of Caspase-3 was performed 
by ELISA.
Results: Quantitative analysis of plasma cfDNA and Caspase-3 showed significantly 
higher levels in CKD patients compared with CTR (both p<0.05). Furthermore, cfDNA 
and Caspase-3 levels were significantly different comparing CKD stages (both p<0.05). 
A significant positive correlation was observed between cfDNA and Caspase-3 levels 
(Sperman’s rho=0.66 p<0.001) and Caspase-3 levels were significantly different between 
CKD stages (p=0.002). Positive correlations were observed between urea/cfDNA 
(Sperman’s rho=0.57 p=0.01) and urea/Caspase-3 (Sperman’s rho=0.53 both p=0.02).
Conclusions: In conclusion, our data suggest that cfDNA is increased in the plasma 
of CKD patients and cell apoptosis is one of the potential source of cfDNA. Plasma levels 
of cfDNA could be a potential biomarker of cytotoxicity due to uremic status of CKD 
patients. cfDNA can be considered as a direct marker of cell apoptosis which plays a pivotal 
role in the pathophysiology of CKD. Its levels increase in case of CKD progression AKI 
and are correlated to urea and cytotoxicity. Plasma levels of cfDNA could be a potential 
biomarker of cytotoxicity due to uremic status and progression of CKD in these patients.
Funding: Private Foundation Support
TH-PO696
Correlation of the Quantification Methods of Proteinuriain Glomerular 
Disease Patients  Gabriela Miranda Mu?oz, Carmen Vozmediano Poyatos, 
Maria Dolores Sanchez de la Nieta Garcia, Francisco Rivera Hernandez, Isabel 
Ferreras Garcia.  Nephrology, Ciudad Real Univ General  Hospital, Ciudad 
Real, Ciudad Real, Spain.
Background: This study evaluate the correlation between the measurements of 24-
hour proteinuria(P24H) versus protein/creatinine ratio(P/Cr) from patients with glomerular 
disease(GD) diagnosed histologically in Nephrology’s Service in HGUCR. Assess whether 
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this correlation varies with the GD, age, sex, blood pressure control(BP), body mass 
index(BMI), glomerular filtration rate(GFR) by MDRD, proteinuria degrees mg/24h(PD), 
urine output(UO) and ACEi/ARBs treatment.
Methods: Observational cross-sectional study of renal biopsies performed 2010-2014. 
Spearman´s coefficient and multiple linear regression was used to identify the correlation 
of the two proteinuria determinations.
Results: 148 biopsies collected; 96 were GD. Mean age 54±18 years; 66% male; BMI 
27.71±5.75. The GD was: glomerulonephritis(GN) IgA 21%, membranous(MGN)19%, 
vasculitis17%, focal segmental(FSGS)13%, minimal change(MCGN)10%, lupus10%, 
and others10%. The GFR was categorized >60 mL/min 37.5%; 30-60mL/min 22.9% and 
<30mL/min 39% and PD was categorized <300mg 8.3%; 300-3500mg 47.9%; >3500mg 
43.8%. The BP was controlled in 60.4%. Median P24H 3.01g/24h(1.18-4.79) and P/Cr 
2.72(1.16-5.0). P24H and P/Cr showed significant correlations(r=0.71;P<0.001). An 
1g increase in ratio P/Cr resulted in an increased in P24H of 0.7g/24h(95% CI 0.59-
0.87;P<0.001). There was no correlation seen in subgroup analysis of UO<1liter/day and 
vasculitis(r=0.39;P=0.13). The correlation was higher in women than men(r=0.81vs r=0.64), 
if aged ≤65 than >65(r=0.85vs r=0.50), in controlled BP(r=0.79vs r=0.57), in GFR>60 
ml/min(r=0.90) and in PD <300 mg(r=0.71). In group of ACEi/ARBs(r=0.75vs r=0.66) 
and in BMI group(r=0.83 r=0.59 r=0.76). IgAGN(r=0.67), MGN(r=0.77), FSGS(r=0.78), 
MCGN(r=0.93) and lupus(r=0.90).
Conclusions: Excellent correlation was observed P/Cr and P24H. The P/Cr is useful 
in IgAGN, MGN, FSGS, MCGN and lupus, regardless of sex, age, BP, ACEi/ARBs and 
BMI. The correlation was greater with higher GFR and with lower PD. Perform proteinuria 
determinations in 24-hour urine in patients with UO<1liter/day and vasculitis.
TH-PO697
Renal Functional Reserve and Electron Microscopy in the Evaluation of 
Subclinical Lupus Nephritis  Renato V. Almeida.  Nephrology, Federal Univ 
of Paraná, Curitiba, Brazil.
Background: The aim of this research was to study the renal functional reserve (RFR) 
and electron microscopy (EM) in patients with subclinical lupus nephritis, and to evaluate the 
changes in the urinary excretion of albumin, retinol-binding protein and electrolytes induced 
by amino-acids (AAs) infusion; and their relationship with the renal morphology data.
Methods: In 25 lupus patients (SLE group) and in 15 controls, on the 24-hour urine 
collection and on urine specimens taken after both an oral water load and an AAs infusion, 
glomerular filtration rate (GFR: creatinine clearance - ml/min/1.73m2),microalbuminuria 
(uALB) and sodium excretion (FENa+/Nau) were evaluated. The urinary retinol-binding 
protein (RBP) was evaluated only in the SLE group which was also divided in subgroups 
according to the classification of lupus nephritis (ISN/RPS 2003). Biopsies were also 
analized in order to characterize the renal ultrastructural abnormalities (EM).
Results: Both in the SLE group and controls there was a significant increase in GFR, 
uALB, FeNa+ and Nau after the AAs infusion. The SLE group showed significantly higher 
stimulated GFR than controls; and higher basal and stimulated values for uALB (ug/min) 
and uALB (um/mg creatinine), respectively, Urinary RBP showed no basal value above 0.4 
ug/ml and after stimulation it resulted significantly decreased. When we compared these 
data to the renal biopsy findings, we found that class II patients showed higher basal GFR 
than class I patients. Ultrastructural abnormalities in EM were present in 40% of the cases.
Conclusions: The results suggest that in patients with subclinical lupus nephritis, AAs 
infusion elicits an increase in GFR which indicates the presence of RFR. Although RFR 
was not a parameter of disease severity in the SLE group, the presence of higher mean-
values for uALB - both basal and stimulated - suggests altered glomerular permselectivity 
in these patients. Higher basal GFR in class II patients might suggest that compensatory 
hyperfiltration precedes the decline of renal reserve in patients with more severe forms 
of lupus nephritis. Electron microscopy findings showed low sensivity to predict the 
severity of disease.
Funding: Government Support - Non-U.S.
TH-PO698
Course of PR3 Titers versus MPO Titers in ANCA Vasculitis Patients After 
Rituximab Therapy  Vega Goedecke, Marcus Hiss, Hermann G. Haller, Annette 
D. Wagner.  Dept of Nephrology and Hypertension, Medical School Hannover, 
Hannover, Germany.
Background: Rituximab has been proven to be an effective therapeutical agent 
in moderate to severe cases of ANCA vasculitis. B cell depletion plays a major role in 
suppressing inflammatory processes mediated by granulocytes in ANCA vasculitis. PR3 
antibodies are specific for cANCA vasculitis, whereas MPO antibodies are detectable in 
pANCA vasculitis.
Methods: We compared the time course of anti-PR3 titers in 25 cANCA patients 
with the course of anti-MPO titers in 11 pANCA patients receiving rituximab induction 
therapy. We compared anti-PR3 and anti-MPO titers before initiation of rituximab therapy 
and approximately 3 months, 6 months, 12 months and 24 months after starting therapy. 
The mean age of both groups was comparable (51,6 in cANCA patients vs. 58,1 years in 
pANCA patients). The female to male gender ratio was 13/12 in cANCA patients and 6/5 
in pANCA patients.
Results: Our results show that rituximab therapy significantly lowers anti-PR3 titers 
in cANCA vasulitis patients after 3, 6, 12 and 24 months. In contrast, anti-MPO titers are 
not lowered significantly in pANCA vasculitis patients after rituximab therapy. 
female/
male age
average 
titer before 
treatment
average 
titer after 
3 months 
average 
titer after 
6 months 
average 
titer 
after 12 
months 
average 
titer 
after 24 
months 
cANCA 
patients 13/12 51,6
anti-PR3 
32,4 IU/ml
anti-PR3 
15,7 IU/
ml
anti-PR3 
9,2 IU/ml
anti-PR3 
5,1 IU/ml
anti-PR3 
3,1 IU/ml
pANCA 
patients 5/6 58,1
anti-MPO
51,8 IU/ml
anti-MPO
37,3 IU/
ml
anti-MPO
40,1 IU/
ml
anti-MPO
45,5 IU/
ml
anti-MPO
63,1 IU/
ml
Conclusions: Clinical experience shows that anti-MPO titers correlate less well with 
clinical disease activity than anti-PR3 titers. Detailed further analysis of our data will show 
whether MPO titers correlate with long term clinical patient outcome and FACS analysis 
data will elucidate involved cell types in pANCA vasculitis.
TH-PO699
Comparison of Urinary Microvesicle Isolation Methods for miRNA Profiling 
in Nephrotic Syndrome  Ilse M. Rood,1 Thomas Laufer,2 Thomas Brefort,2 
Hannah Schroers,2 Johan Van der vlag,1 Jack F. Wetzels,1 Jeroen Deegens.1 
1Nephrology, RadboudUMC, Nijmegen, Netherlands; 2Comprehensive 
Biomarker Center GmbH, Heidelberg, Germany.
Background: Urinary microvesicles (uMV) are a promising source for biomarker 
discovery, including miRNAs (small noncoding single stranded RNAs, which regulate gene 
expression). UMV can be isolated by different techniques. In healthy subjects, an exosome 
precipitation protocol yielded the highest quantities of miRNA in uMV. The optimal isolation 
method of uMV for miRNA profiling in proteinuria is unknown.
Methods: Urine samples were collected from 1 normal control (NC) and 4 patients with 
nephrotic syndrome (NS1-4). UMV were isolated by 6 different protocols: exoquick(B), 
Qiagen’s exoRNeasy(C), exoquick after additional 17.000g centrifugation step (D), 
Qiagen’s exoRNeasy after additional 17.000g centrifugation step (E), ultracentrifugation 
(UC) (F), UC followed by size exclusion chromatography(G). The miRNA-profiles were 
compared with the profile of raw urine (A) to correct for contamination. We determined 
the expression profiles of all miRBase release v20 human miRNAs using CBC’s custom 
Agilent SurePrintG3 Human miRNA (8x60K) microarrays.
Results: Results are shown in the table. miRNA-analysis was unsuccessful in 5/35 
samples (method B/D/G) due to insufficient amount of RNA. Method C and E resulted in 
highest amount of total miRNAs and in highest percentage miRNAs that were not detected 
in A. In method F, despite lower amount of total miRNAs, 9-56 additional miRNAs that 
were not present in A/C/E, were detected. 
Method ( of miRNAs / % not present in A /  of miRNAs in C not present in 
A/E/F, in E compared to A/C/F and in F compared to A/C/E)
Sample A B C D E F G
NC 271 294/34 614/56/53 284/35 554/51/0 312/34/51 156/21
NS1 179 - 477/63/7 134* 480/63/4 324/51/56 214/37
NS2 188 181/25 434/57/7 229/29 441/58/27 305/41/35 -
NS3 130* - 420 217 341 367 243
NS4 154 208/39 346/58/30 - 400/62/74 236/42/9 -
*analysis is ongoing
Conclusions: Method C, E and F are the most consistent methods. Method C and E 
had the highest yield of miRNAs that were not detected in raw urine. Method F may be of 
additional value to detect miRNAs not present in A/C/E.
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Gross Hematuria of Glomerular Origin in Adults  Sami Safadi,1 Samih H. 
Nasr.2  1Nephrology and Hypertension, Mayo Clinic, Rochester, MN; 2Anatomic 
Pathology, Mayo Clinic, Rochester, MN.
Background: Gross hematuria is a relatively uncommon presentation of 
glomerulonephritis. Glomerular gross hematuria (GGH) is more frequent in children 
than adults. IgA nephropathy and Alport syndrome are the most common causes of 
GGH in children. The clinicopathologic characteristics of GGH in adults have not been 
systematically evaluated. We investigated the etiology and clinicopathologic characteristics 
of GGH in a large single-center cohort of adults.
Methods: Adult patients (³18) with native kidney biopsy were identified from the 
pathology database. The electronic medical record (EMR) was searched for the symptom of 
gross hematuria in these patients. The EMR was then examined manually to select patients 
with GGH. Patients with a urological cause of hematuria were excluded. Univariate logistic 
regression was used to test association between age, gender, and diagnosis.
Results: Between 1993 and 2015, 101 patients with GGH were identified. 51% were 
male and 88% were white. Median age at biopsy was 52 yrs. (18-89). The clinicopathologic 
causes of GGH were heterogeneous as shown in table 1. The most common causes were: 
IgA nephropathy/HSP nephritis (IgA/HSP) (36%), thin basement membrane disease 
(TBMD) (14%), pauci-immune crescentic GN (PICGN) (13%), and monoclonal protein 
related glomerular disease (amyloidosis, MIDD, PGNMID) (13%). Younger adults were 
more likely to have IgA/HSP (OR 3.2, p<0.01), and less likely to have PICGN (OR 0.05, 
p<0.01). Male patients were more likely to be older on presentation (dif 8 years, p<0.05). 
Female patients were slightly more likely to have loin pain hematuria syndrome (LPHS) 
and TBMD. Only 30% of patients with IgA/HSP with GGH had crescents on biopsy.
Conclusions: This is the first study to analyze GGH in adults. We show that causes 
of GGH in adults are very heterogeneous, but most cases are due to IgA/HSP or TBMD 
disease in younger adults, and PICGN in older adults. 
Diagnosis N
IgA/HSP 36
TBMD 14
PICGN 13
LPHS 5
MIDD 5
Infection-related GN 3
Proliferative Lupus Nephritis 3
Amyloidosis 3
MPGN, immune complex (IC) type 3
Fibrillary GN 3
PGNMID 3
MGN with Renal Vein Thrombosis 3
Anti-GBM Disease 2
C3 GN 2
Proliferative GN, IgG4 related 1
Mesangioproliferative GN, IC type 1
Fabry Disease 1
101
TH-PO701
IgM Staining in Immunofluorescence Is a Risk Factor for Relapsing in 
Focal Segmental Glomerulosclerosis  Daiane Silva, Gisele Vajgel Fernandes, 
Luis H.B.C. Sette, Renata Silva, Denise Maria do nascimento Costa, Maria 
Alina G.M. Cavalcante, Lucila Maria Valente.  Nephrology, Univ Federal de 
Pernambuco, Recife, Pernambuco, Brazil.
Background: Glomerular IgM and C3 deposits are frequently found in idiopathic focal 
segmental glomerulosclerosis (iFSGS). Some experimental studies have suggested that IgM 
deposits may play a role in activation of the complement system in the glomeruli. However, 
the clinical meaning of the IgM deposits is unclear in iFSGS patients. In this study we 
analyzed outcomes regarding the presence of IgM deposits in biopsies of iFSGS patients.
Methods: We collected data from single center retrospective cohort of patients with 
histologic diagnosis of iFSGS between 2002-2014 that had a minimum follow-up period 
of 6 mo. Secondary FSGS, collapsing glomerulopathy (CG), childhood onset of iFSGS 
and patients with baseline Scr>3.0mg/dL where excluded. Relapsing was defined as new 
onset of nephrotic proteinuria after remission.
Results: We reviewed data from 96 patients, however 38 were excluded: secondary 
FSGS (14), CG (20) and patients with baseline Scr>3.0mg/dL (2), leaving 58 patients to 
analysis. The mean age was 31.3±14.3y, 58.6% were female and 46.5% were self-identified 
as white. Labs showed: mean Scr 1.2±0.6mg/dL; proteinuria 8.1±4.95 g/d; Salb 1.9±0.9 mg/
dL; GFR (MDRD) 81 ±41ml/min. The median follow up period was 34.5 mo. Interstitial 
fibrosis was moderate to severe in 26%, IgM and C3 deposits were present in 31% and in 
12% of the biopsies, respectively. ACEI/ARB was used in 81%, prednisone in 96.6% and 
cyclosporine in 46.6% of the cases. Complete or partial remission was achieved in 79.3% of 
the patients during follow-up. Relapsing was seen in 17 of 41 cases (41.5%). IgM staining 
in the glomeruli was the only significant risk factor for relapsing in the multivariate analysis 
(OR 6.1 [CI 1.02-36.4]; P=0.047). Nevertheless, C3 deposits showed some association but 
lost strength in the multivariate analysis (OR 8.3 [CI 0.79-87.7] P=0.077).
Conclusions: In a single center retrospective cohort we found that IgM staining in 
immunofluorescence was a risk factor for relapsing in idiopathic FSGS.
TH-PO702
Targeted Metabolomics Reveals Reduction in TCA Cycle Metabolites in 
Non-Diabetic Hypertensive Chronic Kidney Disease  Stein I. Hallan,1 Maryam 
Afkarian,2 Leila R. Zelnick,2 Bryan R. Kestenbaum,2 Shoba Sharma,3 Rintaro 
Saito,1 Kumar Sharma,1 Ian H. De Boer.2  1Center for Renal Translational 
Medicine, UCSD, San Diego, CA; 2Kidney Research Inst and Div of Nephrology, 
Univ of Washington, Seattle, WA; 3Clinical Metabolomics Inc, La Jolla, CA.
Background: Interesting metabolic disturbances have recently been described in 
DKD using metabolomic analysis. Non-diabetic hypertensive CKD is common and needs 
to be better characterized.
Methods: Using a targeted quantitative panel of 66 organic acids, we compared plasma 
concentrations and urine excretion/24h in 22 adults with stage 3-4 non-diabetic hypertensive 
CKD to those of 10 healthy controls.
Results: After correcting for multiple testing, urinary excretion of 27 metabolites and 
plasma concentration of 33 metabolites differed significantly (range -68% to +113%). All 
27 altered urine metabolites was reduced in CKD, while 27 of 33 altered plasma metabolites 
were higher in CKD. Pathway analysis based on significantly altered metabolites identified 
seven metabolic pathways significantly altered in CKD, most strikingly the TCA cycle (6 
of 20 measured metabolites significantly different, q<0.001). 
Urinary excretion of citrate, cis-aconitate, isocitrate, oxoglutarate and succinate was 
reduced 40-68%. Based on data from Nephromine, expression of genes for four TCA cycle 
enzymes was reduced in human kidney tissues with nephrosclerosis. One transcription 
factor (TFAP2C) regulating TCA genes was also significantly reduced in nephrosclerosis.
Conclusions: In conclusion, in non-diabetic CKD, targeted metabolomics identified 
differences in the urinary excretion and plasma concentrations of small molecules that 
are consistent with both reduced renal excretion and impaired metabolism. Reductions in 
TCA cycle metabolites and gene expression were also identified and suggested suppressed 
mitochondrial function in CKD.
Funding: NIDDK Support, Other U.S. Government Support, Pharmaceutical 
Company Support - Abbvie
TH-PO703
The Application of Laser Microdissection and Liquid Chromatography – 
Mass Spectrometry in the Diagnosis of Renal Amyloidosis  Michiko Aoki, 
Dedong Kang, Yusuke Kajimoto, Takafumi Kanemitsu, Kiyotaka Nagahama, 
Akira Shimizu.  Analytic Human Pathology, Nippon Medical School, Tokyo, 
Japan.
Background: In our department, renal amyloidosis of kidney biopsies have been 
diagnosed by congo-red stain, immunofluorescence (IF) for immunoglobulin light (L) and 
heavy (H) chains, and immunostaining for amyloid A, transthyretin, and b2-microglobulin. 
Recently, it has been reported that liquid chromatography tandem mass spectrometry 
(LCMS/MS) is helpful for detection of the amyloid precursor proteins.
Methods: We retrospectively investigated 30 cases of renal amyloidosis, 11 cases 
(36.7%) of AA and 19 cases (63.3%) of AL amyloidosis, from a series of renal biopsies 
in our department from 1999 to 2014. We examined the component proteins in deposited 
amyloid in formalin fixed paraffin embedded tissues using laser microdissection of glomeruli 
and LCMS/MS. These results were compared with the results of serum immunofixation 
electrophoresis (IEP) and findings of IF.
Results: We retrospectively investigated 30 cases of renal amyloidosis, 11 cases 
(36.7%) of AA and 19 cases (63.3%) of AL amyloidosis, from a series of renal biopsies 
in our department from 1999 to 2014. We examined the component proteins in deposited 
amyloid in formalin fixed paraffin embedded tissues using laser microdissection of glomeruli 
and LCMS/MS. These results were compared with the results of serum immunofixation 
electrophoresis (IEP) and findings of IF.
Conclusions: LCMS/MS could detect the component proteins in amyloid depositions 
in all cases, even in the cases that had less than 5% area of amyloid deposition in glomeruli. 
Furthermore, among AL amyloidosis, which was diagnosed previously, we found 2 cases of 
AH amyloidosis and 2 cases of AHL amyloidosis. LCMS/MS is very helpful for diagnosis 
of amyloidosis, especially AHL and AH amyloidosis.
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TH-PO704
THSD7A Staining of Membranous Glomerulopathy in Clinical Practice 
Reveals Cases with Dual Autoantibody Positivity  Christopher Patrick Larsen,1 
Larry N. Cossey,1 Laurence H. Beck.2  1Nephropath, Little Rock, AR; 2Boston 
Univ Medical Center, Boston, MA.
Background: The majority of primary membranous glomerulopathy (MG) cases are 
due to antibodies directed against the podocyte phospholipase A2 receptor (PLA2R) antigen. 
Recently, thrombospondin type-1 domain containing 7A (THSD7A) was described as a 
second antigenic target leading to MG. We sought to validate an immunohistochemical 
stain for the diagnosis of THSD7A-associated MG on renal biopsy material.
Methods: Immunohistochemical staining for THSD7A (Sigma) and PLA2R (Sigma) 
was performed in all cases of non-SLE associated MG diagnosed in our laboratory 
between December 2014 and April 2015. This included a total of 258 cases. Both stains 
were performed on formalin fixed paraffin embedded tissue. PLA2R was performed by 
immunofluorescence while THSD7A was performed by immunoperoxidase. Serologic 
testing for PLA2R (ELISA, WB) and THSD7A (WB) antibodies was performed in a 
subset of cases to determine the specificity of positive THSD7A staining for the diagnosis 
of THSD7A MG.
Results: MG stained positive for THSD7A-only in 7 (2.7%) cases, PLA2R-only in 
141 (54.7%) cases, and showed dual positivity for THSD7A and PLA2R in 2 (0.8%) cases. 
Staining was negative for both in 108 (41.8%) cases. Serologic testing was performed for 
antibodies to PLA2R and THSD7A in 9 cases with both serum and biopsy material available 
and the results are shown in Table 1.
Biopsy result Serum Anti-PLA2R +
Serum Anti-
THSD7A +
MG with PLA2R only (n=3) 3/3 0/3
MG with THSD7A only (n=2) 0/2 2/2
MG with dual PLA2R and THSD7A (n=2) 2/2 2/2
MG negative for PLA2R and THSD7A (n=1) 0/1 0/1
Non-membranous glomerulopathy (n=1) 0/1 0/1
Conclusions: Based on these findings we believe it is possible to specifically diagnose 
THSD7A-associated MG based on renal biopsy staining. Additionally, we confirm that 
only a minority (3.5%) of MG cases reflect THSD7A-associated disease. Interestingly, 
2 (22%) THSD7A-positive cases showed dual positivity for PLA2R and THSD7A with 
serologic studies showing evidence of antibodies to both THSD7A and PLA2R antigens 
in these patients. These cases demonstrate the importance of using a panel based approach 
to subtyping MG.
Funding: NIDDK Support
TH-PO705
Clinical Characteristics Associate Differently with Single Nephron GFR 
Than Total GFR in Normal Adults  Aleksandar Denic,1 Lilach O. Lerman,1 
John C. Lieske,1 Mariam P. Alexander,2 Harini A. Chakkera,3 Emilio D. Poggio,4 
Richard J. Glassock,5 Andrew D. Rule.1  1Div of Nephrology, Mayo Clinic, MN; 
2Dept of Pathology, Mayo Clinic, MN; 3Div of Nephrology, Mayo Clinic, AZ; 
4Dept of Nephrology, Cleveland Clinic, OH; 5Dept of Medicine, Geffen School 
of Medicine, CA.
Background: Total GFR (GFR) is the product of mean single nephron GFR (snGFR) 
and the number of nephrons. Thus, associations with GFR may be attributable to associations 
with snGFR, nephron number, or both.
Methods: We identified 1,520 living kidney donors at Mayo Clinic and Cleveland 
Clinic with pre-donation contrast-enhanced CT scans and iothalamate clearance (GFR), and 
with kidney biopsies at the time of donation. snGFR was estimated from GFR divided by 
nephron number (CT bilateral cortical volume x biopsy non-sclerotic glomerular density). 
GFR, snGFR, and nephron number were associated with clinical and biopsy characteristics 
(age and sex-adjusted).
Results: Donors were 58% women, mean±SD age of 43±12 y, GFR of 103±20ml/
min/1.73m2, nephron number of 872,280±390,668 per kidney, and snGFR of 0.073±0.042 
ml/min/1.73m2. There was a strong decline in nephron number and modest rise in snGFR 
with age such that the net effect was an age-dependent decline in GFR.
*p<0.05; **p<0.001; NS p>0.05 Total GFR = snGFR × Nephron number
Characteristics % diff.
p 
value
% 
diff.
p 
value % diff. p value
Age, per y -0.6 ** 0.3 * -1 **
Female sex 1.5 NS 10.9 ** -8.5 **
Family history of ESRD 1.6 NS 12.3 ** -10 **
Glomerular volume, per SD 0.6 NS 26 ** -20.3 **
Tubular area, per SD 0.8 NS 14 ** -11.4 **
Glomerulosclerosis >5% 0.4 NS 14 ** -12 **
Intimal thickening >50% 2.7 NS 13 ** -7.7 **
Female gender, family history or ESRD, larger glomerular volume, larger tubular area, 
glomerulosclerosis, and intimal thickening all associated with fewer nephrons and higher 
snGFR, with the net effect that none associated with GFR.
Conclusions: Among normal adults, the age-dependent fall in GFR underrepresents the 
loss of nephrons because of a concurrent increase in snGFR. Total GFR did not associate 
with many risk factors because of the counterbalancing association of these risk factor with 
both lower nephron number and increased (likely compensatory) snGFR.
Funding: NIDDK Support
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Clinical and Histological Features of Lupus Nephritis in Japan: An 
Analysis of the Japan Renal Biopsy Registry (J-RBR)  Keiju Hiromura,1 
Ken Kayakabe,1 Hidekazu Ikeuchi,1 Hitoshi Sugiyama,2 Michio Nagata,3 
Hiroshi Sato,4 Hitoshi Yokoyama,5 Yoshihisa Nojima.1  1Dept of Medicine and 
Clinical Science, Gunma Univ, Maebashi, Japan; 2Dept of Medicine and Clinical 
Science, Okayama Univ, Okayama, Japan; 3Kidney and Vascular Pathology, 
Faculty of Medicine, Univ of Tsukuba, Tsukuba, Japan; 4Clinical Pharmacology 
and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku Univ, 
Sendai, Japan; 5Div of Nephrology, Kanazawa Medical Univ, Uchinada, Japan.
Background: A cross-sectional study was conducted to examine clinical and 
histological features of lupus nephritis (LN) in Japan.
Methods: Using the database of J-RBR, a nationwide prospective registry conducted 
by Japanese Society of Nephrology, we examined 372 LN patients whose ISN/RPS Class 
was available, out of total 18,463 registered patients who received renal biopsy between 
2007 and 2012.
Results: Median age was 37 years old (IQR 27-48); 9.4% of patients were less than 20 
years old and 81.2% of patients were female. The frequency of each ISN/RPS Class was 
as follows; I, 1.3%; II, 7.5%; III±V, 25.3%; IV-S±V, 13.4%; IV-G±V, 30.4%; V 21.2%; 
VI, 0.8%. Among Class III to V, patients with IV-G±V had lower eGFR, higher urine RBC 
score and higher incidence of nephrotic syndrome (Figure). In addition, the frequency of 
mixed proliferative and membranous type (III/IV+V) and chronic lesion (A/C or C) was 
significantly higher at the second or later biopsy compared to the first biopsy (mixed type, 
21.5% vs 43.9%, p=0.003; chronic lesion 51.1% vs 82.1%, P=0.002).
Conclusions: In Japan, patients with IV-G±V LN were significantly associated with 
decreased renal function and nephrotic syndrome. In addition, the frequency of mixed 
proliferative and membranous type and chronic lesions was higher at the repeat biopsy, 
suggesting that these histological features reflect progression of the disease or refractory 
nature to treatment.
Funding: Government Support - Non-U.S.
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MicroRNA Signatures in Renal Disease: A Meta-Analysis of Tissue and 
Urine Datasets  Christos Argyropoulos, Mark L. Unruh, V. Shane Pankratz. 
Internal Medicine, Univ of New Mexico, Albuquerque, NM.
Background: MicroRNA (miRNA) are negative regulators of gene translation and 
an emerging biomarker in a wide variety of diseases. Little is known about the ability of 
miRNA to classify patients with renal pathology.
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Methods: We undertook a meta-analysis of normalized miRNA profiles from clinical 
samples in Gene Expression Omnibus. miRNAs in miRBasev20 were scored for kidney 
relevance according to their experimentally or computationally ability to bind to proteins 
in the kidney proteome (http://www.proteinatlas.org). Elastic Net (EN) regression was then 
used to select short miRNA signatures according to their ability to classify diseased from 
healthy samples using 10-fold cross-validation.
Results: Using our systems biology approach we identified 739 miRNAs as potential 
kidney biomarkers out of 1689 candidates. A total of 8 studies with 178 samples were 
identified. Of those, 2 studies in patients were lupus (N=30) were excluded due to the 
incompatibility of the normalization strategy with the other samples. miRNAs profiles from 
31 urine samples and 117 biopsy samples were available for analyses.
Dataset Platform Source Normal Abnormal
GSE53771 Microarray (ȝA)
Renal Bx 
(Bx) 28 8 (Transplant, TxP AKI)
GSE30282 ȝA Bx 10
30 (TxP Cell Rejection). 
11 (TxP AB Rejection), 
14 (DGF)
GSE28283 ȝA Bx: Cortex 3 5 (Hypertension, HTN)
GSE28344 ȝA Bx: Medulla 3 5 (HTN)
GSE48318 qPCR Urine exosomes
2 (Normoalbumin-
uria, NA)
2 (Microalbuminuria, 
MA)
doi: 10.1371/
journal.
pone.0054662
qPCR Whole urine 10 NA 17 (MA within 2 years)
The median (IQR) AUC for individual miRNAs to classify diseased samples was 
0.59(0.46-068) for unselected miRNAs but increased to 0.64(0.54-0.69) in the preselected 
ones. A short signature of 19 miRNAs achieved a superior classification performance for 
renal pathology (cross-validated AUC 0.96).
Conclusions: This is the first study to date examining the performance of a panel of 
miRNAs in classifying patients with kidney disease. A panel of miRNAs may classify 
patients with native and allograft renal disease aiding the interpretation of elevated 
creatinine in clinical practice.
TH-PO708
Study into the Effect of Aquaporin-2 on the Efficcacy and Predicted Effect 
of Tolvaptan in Patients of Nephrotic Syndrome  Eiichi Sato,1 Tsukasa 
Nakamura,2 Mayuko Amaha,2 Mayumi Nomura,2 Daisuke Matsumura,2 Akiko 
Fujii,1 Yuko Ono,1 Yoshihiko Ueda.1  1Dept of Pathology, Dokkyo Medical Univ, 
Koshigaya Hospital, Koshigaya, Saitama prefecture, Japan; 2Div of Nephrology, 
Dept of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, 
Chiba Prefecture, Japan.
Background: A retrospective investigation was conducted into the efficacy and adverse 
drug reactions of tolvaptan in the treatment of diabetic nephropathy and MCNS (Minimal 
Change Nephrotic Syndrome) with heart failure.
Methods: The subjects of this study were 56 patients with chronic kidney disease (due 
to diabetic nephropathy) and MCNS with heart failure who over the last 2 years and who 
were treated with tolvaptan. We defined effective cases as those showing a 2-fold increase 
in urinary volume compared to pre-administration levels or a clear improvement in edema 
or heart failure symptoms.Immunohistochemistry was also used to examine aquaporin-2 
expression in the epithelial cells of the collecting duct (the site of tolvaptan action) based on 
renal biopsy findings. A score of (-) is assigned when the collecting duct shows no staining; 
a score of (+) is assigned when less than 50% is stained; a score of (++) is assigned when 
at least 50% of the biopsy specimens is stained.
Results: Of the 56 cases, 49 were tolvaptan responders. No problematic side effects 
were observed. Comparison of tolvaptan responders and non-responders indicated that 
serum Cre levels were significantly lower in responders. We conducted immunostaining 
for aquaporin 2 in the collecting duct. In diabetic cases. findings were positive for the 
responder but negative for the non-responder. In MCNS cases findings were positive for 
the responder but weak positive for the non-responder.
Conclusions: Diabetic nephropathy and nephrotic syndrome responders exhibited 
aquaporin 2 expression in collecting duct epithelial cells. No expression or weak positive 
expression was observed in diabetic nephropathy and in MCNS non-responders.
TH-PO709
Subclinical Anti-Smith and Anti-Ribonucleoprotein Antibodies Precede 
Proliferative Lupus Nephritis Diagnosis  Stephen W. Olson,1 Lisa K. Prince,1 
Dustin J. Little,1 Kevin C. Abbott.3  1Nephrology, Walter Reed National Military 
Medical Center, Bethesda, MD; 2Nephrology, Naval Medical Center San Diego, 
San Diego, CA; 3NIDDK, National Inst of Health (NIH), Bethesda, MD.
Background: Lupus Nephritis (LN) manifests in approximately 50% of Systemic 
Lupus Erythematosus cases. Anti-Smith (SM) and Anti-Ribonucleoprotein (RNP) antibodies 
are associated with proliferative lupus nephritis (PLN) at diagnosis. We hypothesized that 
prediagnostic anti-SM and anti-RNP antibodies were more common in PLN than SLE 
without LN.
Methods: This case-control Department of Defense Serum Repository study compared 
3 longitudinal prediagnostic quantitative anti-SM and anti-RNP antibody levels in 23 
patients with biopsy-proven PLN from the Walter Reed National Military Medical Center 
with 21 age, sex, race, and age of serum matched SLE without LN disease controls. 
Immunoassays were performed at Quest Diagnostics.
Results: More PLN patients had an anti-SM antibody level ≥4 AI than matched disease 
controls at any time (52% vs. 5%; p<0.001) and <2 years (47% vs. 6%, p=0.01) before 
diagnosis, but not >2years before diagnosis (22% vs. 0%, p=0.11). More PLN patients 
had an anti-RNP antibody ≥4 AI than matched disease controls at any time (57% vs. 14%, 
p=0.005), < 2years (53% vs. 19%, p=0.04), and >2 years (39% vs. 0%, p=0.008) prior to 
diagnosis. Only an anti-SM antibody absolute rise over time of >4 AI prior to diagnosis 
was specific for PLN (30% vs. 0%; p=0.02). But, anti-RNP antibody more often preceded 
anti-SM antibody when there was a clear antecedent antibody (89% vs. 11%, p=0.003).
Conclusions: In a large subgroup of PLN patients, anti-RNP antibodies were 
consistently elevated prior to anti-SM antibodies, but not rising, years prior to diagnosis. 
Anti-SM antibodies predominantly elevate in the last two years prior to PLN diagnosis 
which supports a possible direct contribution to PLN pathogenicity. Our data suggests that 
SLE patients with baseline RNP antibody along with a rising anti-SM antibody levels may 
benefit from increased surveillance for early signs of PLN. A more prompt biopsy diagnosis 
would allow for proactive therapeutic intervention to preserve maximal renal function.
Funding: Other U.S. Government Support
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The Relationship Between Phospholipase A2 Receptor Autoantibody and 
Idiopathic Membranous Nephropathy  Weifeng Lin,1,2,3 Hang Li,1,2,3 Xuemei 
Li,1,2,3 Yan Qin,1,2,3 Ying Su,1,2,3 Yang Yu,1,2,3 Yin Guan,1,2,3 Yubing Wen,1,2,3 
Xuewang Li.1,2,3  1Dept of Nephrology, Peking Union Medical College Hospital; 
2Peking Union Medical College; 3Chinese Academy of Medical Sciences.
Background: The value of PLA2R autoantibody is still controversial in diagnosis, 
activity monitoring and prognosis estimation in idiopathic membranous nephropathy (IMN). 
The test method is non-uniform.
Methods: A total of 233 patients with biopsy-proven IMN at Peking Union Medical 
College Hospital from 2012 January to 2014 March were enrolled. A control group was 
set up. The serum antibody titer collected at the time of renal biopsy was measured by 
quantitative ELISA. 14 IMN patients with detectable antibody at biopsy were followed 
up to retest antibody 6 months later. Besides, the diagnostic accuracy between ELISA and 
immunofluorescence (IF) method for IMN was compared. The consistency and difference 
in antibody detection between two methods were also performed.
Results: The total sensitivity of antibody was 60.0% in IMN. However, it increased to 
71.3% if patients didn’t receive immuno-suppression therapy before testing. The antibody 
specificity was 100.0%. Hypoalbuminemia became severe (P<0.05) and the proportion of 
nephrotic arrange proteinuria rose gradually (P<0.05) as antibody levels increased. The 
antibody changes were consistent with clinical outcomes. The antibody AUC-ROC for 
IMN diagnosis was 0.800 by ELISA. There was no significant difference in AUC-ROC 
between ELISA and IF in IMN diagnosis (P>0.05). The kappa value of antibody detection 
consistency between ELISA and IF was 0.941±0.033. The positive rate of antibody detection 
wasn’t significantly different between ELISA and IF (P<0.05).
Conclusions: PLA2R autoantibody has high sensitivity, notable specificity and good 
diagnostic accuracy for IMN. The antibody positive rate is affected by immunosuppression 
therapy and disease activity. The antibody could reflect disease activity and predict 
outcomes. Moreover, There is no significant difference in diagnostic accuracy and antibody 
detection difference between ELISA and IF. The antibody detection consistency is good 
between ELISA and IF.
TH-PO711
Factors Related to the Glomerular Volume in Different Cortical Zones of 
the Human Kidney  Yusuke Okabayashi, Go Kanzaki, Nobuo Tsuboi, Kotaro 
Haruhara, Kentaro Koike, Yoichi Miyazaki, Tetsuya Kawamura, Makoto Ogura, 
Takashi Yokoo.  Div of Nephrology and Hypertension, The Jikei Univ School 
of Medicine, Tokyo, Japan.
Background: Recent studies have shown that glomerular enlargement is a surrogate 
marker of low nephron number in primary hypertension and in people with lower birth 
weight. To date, however, information is limited regarding the diversity in the distribution 
of glomerular size within the same kidney of relatively healthy human adults.
Methods: A total of 89 autopsy kidneys without apparent renal diseases were analyzed 
to measure the glomerular volume (GV) in different parts of the renal cortex. The mean 
GV was calculated from the measured each glomerular area. Relationships between the 
GV and the other clinicopathological features were investigated.
Results: The GV showed wide variations between the individuals and showed maximal 
7-fold and 4-fold variations in superficial and juxtamedullary cortex, respectively. The 
GV showed close inverse correlations with the glomerular density in each cortical area. 
Multivariate analysis revealed that independent factors associated with the mean GV were 
low glomerular density in the superficial cortex, and hypertension in the juxtamedullary 
cortex.
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As a whole, compared to the GV in the superficial cortex (2.7±1.0 x 106mm3), the 
averaged GV in the juxtamedullary cortex (3.1±0.8 x 106mm3) was significantly larger. Of 
note, in 27 cases (30%), the mean GV in the superficial cortex was larger than that of the 
juxtamedullary cortex. Such individuals with glomerular enlargement in the superficial 
cortex were characterized by a low glomerular density and/or large body size.
Conclusions: In each individual kidney, there are considerable variations in the 
distribution of the GV. Nephron number/body size and hypertension underlie the 
enlargement of glomeruli in superficial and juxtamedullary cortex, respectively.
TH-PO712
Highly Sensitive Method for Quantification of Iohexol  Vera Jankowski, 
Joachim Jankowski.  Inst of Molecular Cardiovascular Research, Univ Hospital 
RWTH, Aachen, Germany.
Background: Iohexol  is used for accurate determination of the GFR in CKD 
patients. However, high iohexol amounts might lead to adverse effects in organism. In 
order to minimize the iohexol dosage required for the GFR determination in humans,the 
development of a sensitive quantification method is essential.Therefore, the objective of 
our preclinical study was to establish and validate a simple and robust LC-ESI-MRM 
method for iohexol quantification.
Methods: In order to test whether a significantly decreased amount of iohexol is 
sufficient for reliable quantification, a LC-ESI-MRM mass-spectrometric approach was 
assessed. We analyzed the kinetic of iohexol in rats after application of different amounts of 
iohexol (15 mg-150 µg/rat). Blood sampling was conducted at four time points. Iohexol and 
the internal standard (iothalamic acid) were separated from serum proteins using centrifugal 
filtration device with a cut-off of 3 kDa. The chromatographic separation was achieved on 
an analytical Zorbax SB C18 column. The detection and quantification were performed by 
ESI-MRM operating in a positive ion mode. Furthermore, the effect of iohexol on early 
regulated gene expression in thyroid and renal cortex was tested to determine a threshold 
of physiological active iohexol concentrations.
Results: A linear correlation of the iohexol amount and mass-signal (MS) intensity 
was found in the range of 50 pg-40 ng (r2 = 0.998). The lowest limit of quantification 
(LLOQ) was 50 pg. The intra- and inter-day accuracies were between 91.2 % and 98.7 
%. The intra- and inter-day precisions were between 2.7 % and 9.2 %. The recovery rate 
of iohexol was determined in the range of 100.8 % ± 10.9 %. The gene expressions test 
revealed that iohexol dosages exceeding 0.5 mg/kg induce a group of genes in thyroidal 
tissue that comprises transcription factors and genes of cellular stress response.
Conclusions: This mass-spectrometric based method has been proved to be sensitive, 
selective and suitable for the quantification of iohexol in serum. Due to high sensitivity of 
this novel method the iohexol application dose as well as the sampling time in the clinical 
routine could be reduced in the future in order to further minimize side effects in humans.
TH-PO713
Proliferative Lupus Nephritis: Are Three Years Enough for Histological 
Remission?  Marcelo Alejandro De Rosa, Federico Fuentes, Gabriel Pedro 
Alvarez, Graciela Elena De Rosa, Jorge E. Toblli.  Univ of Buenos Aires, 
Argentina.
Background: The duration of the treatment in Proliferative Lupus Nephritis (PNL) has 
not been determined. Almost 30 percent of patients will relapse during or after treatment, 
in the first 5 years. Furthermore, the factors associated to renal relapses remain unclear. 
Hence, a prospective histological control study (re-biopsy) performed before the end of the 
third year of treatment in patients with complete renal remission for a year may contribute 
to a better understanding on the relapses in PNL.
Methods: A total of 24 patients with PLN were included in this pilot study. All patients 
presented focal or diffuse PLN in the first renal biopsy, and received induction with 
cyclophosphamide and corticosteroids by six months. The maintenance therapy was based 
on mycophenolic acid and low doses of corticosteroids for at least 2 years and 6 months. 
On those patients who presented total remission during a year (proteinuria £0.5g/24h, 
inactive urinary sediment, and stable creatinine), a second renal biopsy was performed 
before reduction of treatment. Renal biopsies were classified according to ISN/RPS 2003.
Results: After a media of a 34 (30-42) months of treatment and in complete remission 
for a year, 70,8% of patients had mesangial or proliferative lupus activity.
Table 1
Baseline results
N: 24 mean median range
Age (years) 35.5 31 21-64
Gender (M/F) 5/19
Time of treatment (months) 34 34.2 30-42
Proteinuria g/day 0.2 0.2 0.05-0.43
Creatinine (mg/dl) 0.7 0.73 0.6-1.04
2nd.Biopsy
Histological class n 24 IF: IgG, C1q
Class I 3 -
Class II 5 +
Class III (A, A-C) 11 +
Class III (C) 3 -
Class IV (A, A-C) -
Class IV (C) 1 -
Class III/V 1 +
Activity index mean 2 (1-3)
Chronicity index mean 3 (2-4)
Histological activity 17 + 70.8 %
No Histological activity 7 - 29.2 %
Total 24 100 %
Conclusions: This study showed that after a satisfactory treatment, most patients 
with PLN, still presented mesangial or focal proliferative changes with positive IF for 
IgG and C1q in their second renal biopsy. While data in the present study suggest silent 
lupus activity, the association of these histological findings with potential relapses in PNL 
invites to an open discussion.
Funding: Government Support - Non-U.S.
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The Clinical and Renal Pathological Features and Presence of Anti-PLA2R 
Antibody in 9 Patients with Both Membranous Nephropathy and IgA 
Nephropathy  Xin Zhang, Weifeng Lin, Jianing Li, Yubing Wen, Jianfang Cai, 
Hang Li, Xuemei Li, Xuewang Li.  Nephrology Dept, Peking Union Medical 
College Hosptial, Beijing, China.
Background: Both membranous nephropathy (MN) and IgA nephropathy (IgAN) rank 
top among the primary glomerulonephropathy but they rarely coexist in the same patient.
Whether they are accidentally concurrent remains controversial. Here we reported the 
clinical and pathological features of 9 cases with concomitant biopsy-proved MN and IgAN.
Methods: The 9 patients were admitted to our hospital for renal biopsy between 2009 
and 2014, none having apparent secondary causes of renal diseases. 36 age-, sex-, and 
biopsy-year- matched controls with isolated IgAN or isolated primary MN, respectively, 
were randomly selected. Clinical features were compared across these groups. Anti-PLA2R 
antibody was assayed with ELISA test by using the -80°preserved serum samples in 9 cases 
and 36 controls with isolated MN.
Results: The clinical and pathological features of cases and controls were summarized 
in table 1. Table 1 the clinical and pathological features among patients with combined 
IgAN and MN, isolated primary MN, and isolated IgAN.
Group Combined IgAN and MN Isolated primary MN Isolated IgAN
Cases 9 36 36
Male 6 27 26
Age, yrs 40.2±8.4 40.9±7.6 38.6±9.8
24h-Upr, g/24h 5.9±3.7 6.7±5.5 1.6±1.9*
Serum creatinine, mmol/L 74.4±20.2 75.4±17.6 116.5±110.9*
Serum albumin, g/L 29.1±6.9 27.4±7.2 38.8±8.4*
Mesangial proliferation None None All
Lee’s grading of IgAN
Grade I
Grade II
Grade III
Grade IV
3
0
6
0
N/A
0 
0
11 
25
MN Classification
Grade I
Grade II
Grade III or IV
3
6
0
5
29
2
N/A
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
254A
J Am Soc Nephrol 26: 2015 Clinical/Diagnostic Renal Pathology and Lab Medicine Poster/Thursday
* p<0.05 vs concomitant group. A positive anti-PLA2R was detected in 2 patients 
among the cases and 18 patients among the isolated MN controls. The presence of anti-
PLA2R antibody did not differ significantly between the two groups (p>0.05),neither did 
the grading of MN (p>0.05). However, the pathological lesions in the 9 cases was less 
severe as compared with the controls with isolated IgAN (p<0.05).
Conclusions: The clinical features and presence of anti-PLA2R of patients with 
combined MN and IgAN are more likely to mimic isolated primary MN.
TH-PO715
MiRNA Profiling in Urine Exosomes Indicates Renal Tubulointerstitial 
Fibrosis in CKD Patients  Yang Zhou, Junwei Yang.  Center for Kidney Disease, 
Second Affiliated Hospital, Nanjing Medical Univ, Nanjing, Jiangsu, China.
Background: Renal fibrosis is an inevitable outcome of chronic kidney disease (CKD). 
It was reported that various microRNAs regulated the progression of tubulointerstitial 
fibrosis. However, whether fibrosis-related miRNAs are excreted in urine exosomes, as 
well as the changes of miRNA profiles in urine exosomes of CKD patients were unknown.
Methods: Morning urine specimens were collected from 10 healthy donor and 16 
CKD patients, whose renal biopsy showed mild to moderate tubulointerstitial fibrosis. 
Urine exosomes were isolated from 2ml samples using urinary exosome isolation kit and 
observed by transmission electron microscopy. Quantification of miRNA levels in urine 
exosomes were determined using stem-loop qRT-PCR followed by real-time PCR. CD63 
levels in exosomes were analysis by western blot.
Results: Urinary exosomes appeared as clusters of vesicles of 30-200nm in diameter 
under electron microscope, surrounded by a double-layer membrane. CD63, a major 
exosome marker associated with membranes of cellular vesicles, in exosomes isolated 
from same volume of urine indicated that the excretion of exosomes varied among different 
people. Moreover, the markedly increased CD63 levels in CKD patients suggested that the 
excretion rate of exosomes was probably upregulated in CKD patients with renal interstitial 
fibrosis. Most of preciously reported fibrosis-related miRNAs, including miR-21, miR-29 
family, miR-30e, miR-192 and miR-200 family were detectable in urine exosomes. However, 
their contents varied significantly from fmol/L to nmol/L. Furthermore, miRNA levels 
in urine exosomes were not associated with their levels in kidney. MiR-21 and miR-29c 
levels in urine exosomes were markedly increased and decreased as their upregulation and 
downregulation in kidney, respectively. MiR-29b, miR-30e and miR-200b levels in urine 
exosomes were markedly increased despite their downregulation in kidney. Although miR-
192 level in urine exosomes was as large as ~10-4mmol/L, its excretion was not significantly 
changed in CKD patients as compared with healthy control.
Conclusions: Profiling of miRNA in urine exosomes might indicate renal 
tubulointerstitial fibrosis in CKD patients.
Funding: Government Support - Non-U.S.
TH-PO716
Glucosuria in Normoglycemic Non-Diabetic Kidney Disease: Not Necessarily 
due to an Isolated Proximal Tubule Defect  Abdurrahman M. Hamadah, Kamel 
A. Gharaibeh, Samih H. Nasr, Nelson Leung.  Nephrology and Hypertension, 
Mayo Clinic, MN.
Background: In the absence of hyperglycemia, glucosuria has been classically 
attributed to either a global dysfunction of the proximal tubule known as the Fanconi 
syndrome, or familiar renal glucosuria which includes inherited defects in the genes 
that encode the glucose handling kidney transporters. We have investigated the clinical 
observation that glucosuria is common in other kidney disease entities.
Methods: We analyzed the data for adult patients with native kidney biopsy between 
January 2014 and January 2015 at our institution that had concurrent urinalysis. We identified 
the patients who had glucosuria on urinalysis, in the absence of concurrent hyperglycemia 
(serum glucose > 180 mg/dL) or diagnosis of diabetes mellitus.
Results: 186 adult patients with native kidney biopsy with concurrent urinalysis were 
identified. Sixty six patients (35%) had evidence of glucosuria on urinalysis. Twenty two 
(33 %) of these patients had either hyperglycemia (serum glucose > 180 mg/dL) or diabetes 
and were excluded from the analysis. The remaining sub-group of 44 (67 %) patients had 
a median age of 58 (19-81 years), 43 % were women, and 81 % were Caucasian. Median 
urinary glucose was 40 mg/dL (range 16-236). Concurrent serum glucose for this group 
showed a median of 101 mg/dL (range 54-149), with 66 % of patients having glucose 
less than 110 mg/dL. In this subgroup, biopsy findings included 32 (73 %) patients with 
glomerular disease (most commonly glomerular microangiopathy and pauci-immune 
crescentic glomerulonephritis), 10 (22 %) tubulointerstitial disease (most commonly acute 
tubular necrosis), and 2 (4%) arteriosclerosis as the predominant features on biopsy. No 
evidence of proximal tubulopathy was found amongst this group.
Conclusions: Glucosuria in the absence of hyperglycemia and diabetes, although 
classically associated with isolated proximal tubule dysfunction, is common in other kidney 
diseases and is a frequent occurrence in glomerular disease, which likely reflects a degree 
of secondary tubular injury. Future delineation of the pathophysiology of this observation 
may improve the understanding of tubular function in glomerular disease.
TH-PO717
Severe Renal Interstitial Fibrosis Can Be a Predictor of Renal Function in 
Patients with Lupus Nephritis, Especially in Cases With the International 
Society of Nephrology/Renal Pathology Society Class IV  Daisuke Honda, 
Kisara Onda-Tsueshita, Isao Ohsawa, Hiroyuki Inoshita, Satoshi Horikoshi, 
Yasuhiko Tomino.  Div of Nephrology, Dept of Internal Medicine, Juntendo 
Univ Faculty of Medicine, Tokyo, Japan.
Background: The ISN/RPS classification of lupus nephritis (LN) pays little attention 
to the interstitial injuries. We explored the association between irreversible interstitial 
fibrosis and renal function in patients with LN, especially class IV cases that have not been 
thoroughly examined in this aspect.
Methods: Forty-three patients of LN were enrolled in this study. All patients were 
classified using the ISN/RPS classification and were divided into 4 grades according to 
interstitial fibrosis extent (no, 0%; mild, 1-25%; moderate, 26-50%: and severe, more than 
50% fibrosis of the interstitial area, n = 8, 16, 11 and 8, respectively). All 8 patients with 
severe fibrosis were classified in class IV. Blood and urine analysis was evaluated at the 
time of renal biopsy and last follow-up period. We compared the data according to both 
categorizations in all patients, and in only class IV cases (n = 23).
Results: In each class categorized with the ISN/RPS classification, renal function 
showed no significant difference. When all patients were classified according to interstitial 
fibrosis severity, their renal function at the time of renal biopsy showed no significant 
difference. However, renal function with severe fibrosis at the last follow-up period was 
significantly worse than those in the other fibrosis grades (sUN, p < 0.01; sCre, p < 0.05; 
and eGFR, p < 0.05). Moreover, when we examined only class IV patients, renal function 
in patients with severe fibrosis at the last follow-up period was significantly worse than 
that in patients with non-severe fibrosis (sUN, p < 0.01; sCre, p < 0.05; and eGFR, p < 
0.01). On the other hand, the serological activities of systemic lupus erythematosus (SLE) 
significantly improved under all categorizations.
Conclusions: We conclude that severe renal interstitial fibrosis can be a predictor of 
renal function in patients with LN, independent of glomerular lesions and the serological 
activities of SLE, especially in cases with ISN/RPS class IV.
TH-PO718
Correlating Biophysical Structure Characteristics with Diagnosis 
and Phenotypic Severity in Complement-Mediated Renal Disease 
Jill Johanna Hauer, Fengxiao Bu, Nicolo Ghiringhelli Borsa, Michael Jones, 
Erika Takanami, Elizabeth Ann Black-Ziegelbein, Diana Kolbe, Yingyue Li, 
Carla Nishimura, Kathy Frees, Hela Azaiez, Christie P. Thomas, Carla M. 
Nester, Michael J. Schnieders, Richard J. Smith.  Univ of Iowa, Iowa City, IA.
Background: Rare genetic variations in the C3, CFH, and CFB genes may lead 
to dysregulation of the alternative pathway of the human complement system, altering 
the innate immune response associated with complement activation. The phenotypic 
consequence includes the thrombotic microangiopathies (TMA) and C3 glomerulopathies 
(C3G).
Methods: In this study, we compared variants identified in TMA patients to variants 
identified in C3G patients. Each variant was analyzed in a pipeline that included structural 
optimization of the wild type and mutant proteins based on molecular mechanics 
calculations. Initially, the wild type protein structure was optimized using the polarizable 
AMOEBA force field and dead-end elimination techniques. Each variant was then 
individually introduced to the wild type structure, which was then re-optimized. Both wild 
type and variant models were analyzed in molecular dynamics simulations and differences 
between wild type and variant free energies were calculated.
Results: Overall, for each variant we were able to obtain both: 1) qualitative data 
describing location and interactions; and 2) quantitative changes to protein conformation and 
stability relative to the wild type baseline. From these data, we were able to create a spectrum 
of free energy changes correlating to disease severity and enhance our interpretation of rare 
and novel variants, as well as identify biophysical characteristics specific to TMA and C3G.
Conclusions: These methods allow us to understand the biophysical consequences 
of every variant, predict the phenotypic severity of novel variants, and ultimately inform 
patient diagnosis.
TH-PO719
Urinary EGF Is Associated with Interstitial Fibrosis and Tubular Atrophy 
in Proteinuric Patients  Wenjun Ju,1 Viji Nair,1 Michelle R. Smith,1 S.M. 
Bagnasco,2 L. Barisoni,3 Matthias Kretzler.1  1Medicine, Univ of Michigan, Ann 
Arbor, MI; 2Pathology, The Johns Hopkins School of Medicine, Baltimore, MD; 
3Pathology, Univ of Miami, Miami, FL.
Background: Interstitial fibrosis (IF) and tubular atrophy (TA) are key morphologic 
determinants of progression and strong predictors for renal outcome. However, their 
broader clinical application is limited by the invasiveness of the kidney biopsy procedure. 
Non-invasive biomarkers predictive of IF/TA have not been reported. Our transcriptome–
driven approach identified EGF as a predictor of kidney function, and urinary EGF (uEGF) 
improved prediction of renal outcome by glomerular filtration rate (GFR) and albuminuria. 
EGF’s expression is limited to tubule epithelium and its role in epithelial cell regeneration 
suggested that the improved predictive value by uEGF may due to its potential association 
with chronic tubulointerstitial damage (c-TID).Here we aim to investigate the correlation 
between uEGF and TID, reflected by the % of cortex affected by IF/TA, and whether uEGF 
can predict c-TID in adult patients of the NEPTUNE cohort.
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Methods: Whole slide images of glass slides stained with Silver, Trichrome and PAS 
from 102 cases stored in the NEPTUNE digital pathology repository were assessed for 
% of cortex involved by IF/TA by 5 pathologists. The % of cortex involved by IF/TA was 
determined in each individual stain and averaged in an overall % value. We derived EGF 
mRNA levels in the tubulointerstitium using genome-wide expression data and measured 
uEGF using fully validated ELISA assay. uEGF was normalized by urine creatinine level. 
A regression model was utilized to predict c-TID using uEGF level.
Results: Both tubulointerstitial EGF mRNA and uEGF correlated significantly 
(p<0.0001) with IF/TA.
spearman rank correlation EGF mRNA uEGF
IF -0.55 -0.75
TA -0.53 -0.74
The correlations remain significant after adjusted for eGFR and proteinuria. uEGF 
predicted patients’ c-TID (%IF/TA) using a regression model in 102 adult NEPTUNE 
patients (r=0.77/0.74, p < 2.2e-16, predicted versus observed IF/TA).
Conclusions: uEGF shows promise as a non-invasive biomarker predictive of the 
biopsy dependent-IF/TA score in proteinuric patients.
Funding: NIDDK Support
TH-PO720
Considerations in the Use of Urine Protein: Creatinine Ratio (uPCR) and 
g/24h for Measuring Proteinuria in Nephrotic Patients in a Clinical Study 
Christine Barrett,1 Gengqian Cai,2 Caroline O.S. Savage.1  1GlaxoSmithKline 
plc, United Kingdom; 2GlaxoSmithKline plc.
Background: uPCR on spot urine samples is used as an alternative to measurement of 
g protein/day from 24h urine collections, due to its ease of use and the correlation between 
the two. Most studies on correlation have concentrated on patients with subnephrotic levels 
of proteinuria. In a clinical study (B(L to evaluate the mechanism of action of 
belimumab in idiopathic membranous nephropathy (IMN), uPCR and g protein/24h were 
assessed, correlation determined and variability in uPCR evaluated.
Methods: Samples from 14 patients with IMN and nephrotic proteinuria (>4g/10mmol 
uPCR at screening) were tested. On 2 occasions during screening, spot morning samples 
were tested for uPCR. At key timepoints, consecutive 24h urine collections, or a spot 
morning sample and post dose 24h collection were used to test uPCR, g protein/24h and 
g creatinine/24h.
Results: Median uPCR 8.31 mg/10mmol (range 3.21-12.20) or 11.70 g/24h (range 
3.99-20.40) at baseline was found in 11 M and 3 F aged 24 to 70y . High correlation 
(0.88–0.99) was observed between uPCR and g protein/24h within all groups with high, 
medium or low creatinine excretion. Different slopes were seen in each group: low- 0.93; 
medium– 1.34; high- 1.77. In individual samples, the ratio of g protein/24h to uPCR 
ranged from 0.66 to 2.97. In addition, with screening and prior to dosing data, a big range 
of within subject coefficient of variation for uPCR was observed: 8.5%-57.7%. Analysis 
of 6 mth history of proteinuria in the absence of immunosuppression prior to screening 
showed great variability and no specific pattern of worsening or improvement. Values for 
g protein/24h also varied considerably in consecutive samples.
Conclusions: uPCR values in patients with nephrotic syndrome are heavily influenced 
by creatinine excretion. This should be considered when setting eligibility criteria in clinical 
studies, or if basing dosing on levels of protein excretion. Variability in proteinuria in 
longitudinal samples from patients with nephrotic levels of proteinuria means that caution 
should be applied to values from single samples within clinical studies, whether using 
uPCR or g/24h.
Funding: Pharmaceutical Company Support - GlaxoSmithKline plc
TH-PO721
Increasing Incidence of Class V Membranous Lupus Nephritis: A Single 
Institution Biopsy Experience  Parker C. Wilson, Alison G. Obstler, Michael 
Kashgarian.  Dept of Pathology, Yale Univ School of Medicine, New Haven, CT.
Background: Lupus nephritis (LN) contributes significantly to morbidity and mortality 
in patients with systemic lupus erythematosus (SLE) and is categorized into classes based on 
the pattern of glomerular injury seen on kidney biopsy. We assessed the proportion of patients 
presenting with class V or III/IV+V since the advent of systemic immunotherapy for SLE.
Methods: The distribution of patients by LN class at initial presentation was assessed 
at 5-year intervals from 1998-2013 at our institution. 131 consecutively diagnosed cases of 
biopsy-proven LN and 54 repeat biopsies were classified using ISN/RPS criteria. Patient 
information was collected from the medical record. Chi-square test for trend was used to 
compare the incidence of class V or III/IV+V at 5-year intervals.
Results: The frequency of class V increased from 1998 to 2013 [p = 0.03: 1998 = 
9.7%, 2003 = 16.6%, 2008 = 13.0%, 2013 = 29.7%] and was associated with a decreasing 
incidence of class III/IV [p = 0.0003: 1998 = 78.0%, 2003 = 73.3%, 2008 = 69.5%, 2013 
= 37.8%]. Among the 54 patients with a repeat biopsy, 25 individuals who presented with 
class III/IV underwent a class switch to class V or III/IV+V. These findings showed a 
tendency for increased use of mycophenolate mofetil at the end of follow-up. Age, gender, 
race, and BMI were not statistically different over time.
Characteristics (*=Baseline, #=Follow-up) 1998 2003 2008 2013
* Patients (#female) 41 (32) 30 (24) 23 (22) 37 (25)
* with Class V 4 5 3 11
* with Class III/IV+V 1 0 1 7
* with Class III/IV 32 22 16 14
* Mean Age at First Biopsy 31.3 32.5 35.3 35.3
* Non-Hispanic White 17 (65%)
12 
(63%)
12 
(75%)
14 
(58%)
* BMI 29.1 30.3 31.2 29.0
# Mycophenolate Mofetil Use at End of Follow-up 
(2012-2015) 28.5% 29.4% 66.6% 42.8%
Conclusions: The incidence of class V lupus nephritis increased in the interval 1998-
2013. These findings were associated with a decreasing incidence of class III/IV and a 
tendency for these patients to switch to class V or III/IV+V on repeat biopsy. These changes 
occurred during a period of increased use of systemic immunotherapy, which may have 
altered the manifestation of lupus nephritis to a more indolent course.
TH-PO722
Serum Autoantibodies in Membranous Nephropathy Patients with Negative 
Anti-PLA2R Antibody  Jianing Li, Hang Li, Jianfang Cai, Weifeng Lin, Yubing 
Wen, Xin Zhang, Xuewang Li.  Div of Nephrology, Peking Union Medical 
College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Background: Anti-PLA2R antibodies are negative in up to 30% patients with idiopathic 
membranous nephropathy (iMN). Autoantibodies against Thrombospondin Type-1 Domain-
containing 7A (THSD7A), α-Enolase(αENO) or SOD2 have also been reported in iMN 
patients. We evaluated the clinical significance of these autoantibodies in iMN patients 
with negative serum anti-PLA2R-antibody.
Methods: In this prospective study, we consecutively recruited 97 iMN patients with 
negative anti-PLA2R antibody, 31 iMN patients with positive anti-PLA2R antibody, 
17 patients with secondary membranous nephropathy (sMN), 28 patients with primary 
glomerular diseases other than MN, and 40 healthy controls. ELISA kits were used to assay 
serum autoantibodies against THSD7A, SOD2 and αENO.
Results: A positive anti-THSD7A antibody was detected in 3 of 97 iMN patients with 
negative serum anti-PLA2R antibody, 1 of 31 iMN patients with positive serum anti-PLA2R 
antibody, but none of patients with sMN or other glomerular diseases or healthy controls. 
For titers of anti-SOD2 antibody, there was no statistical difference among anti-PLA2R 
antibody-negative iMN, anti-PLA2R antibody-positive iMN, sMN and other glomerular 
diseases.Result is the same for anti-αENO antibody. IMN patients with negative serum and 
absent of anti-PLA2R, anti-THSD7A , anti-SOD2, and anti-αENO antibodies had lighter 
proteinuria, higher eGFR, and higher serum albumin(all P<0.05) at baseline and shorter 
duration for remission(P<0.05) as compared with iMN patients with at least one positive 
above-mentioned antibodies.
Conclusions: In the present study, we found anti-THSD7A may have diagnostic 
significance for iMN, whereas iMN patients absent of anti-THSD7A , anti-SOD2, and 
anti-αENO antibodies may be associated with milder clinical manifestation and better 
response to treatment as compared with those with positive anti-THSD7A , anti-SOD2, 
or anti-αENO antibodies.
Funding: Government Support - Non-U.S.
TH-PO723
Interstitial Fibrosis Score by Whole Slide Imaging (WSI) Is a Predictor 
of Outcome in Proteinuric Renal Glomerulopathies  Laura H. Mariani,1 
Sebastian Martini,1 L. Barisoni,2 Pietro A. Canetta,3 Jonathan P. Troost,1 
Jeffrey B. Hodgin,1 Matthew Palmer,5 A. Rosenberg,7 Kevin V. Lemley,6 Chien 
Hui-Ping,4 Gerald B. Appel,3 Howard Trachtman,8 Stephen M. Hewitt,7 Matthias 
Kretzler,1 S.M. Bagnasco.4  1Univ of Michigan; 2Univ of Miami; 3Columbia 
Univ; 4Johns Hopkins Univ; 5Univ of Pennsylvania; 6Children¶s Hosp, Los 
Angeles; 7NIH; 8NYU.
Background: Interstitial fibrosis(IF), tubular atrophy(TA), and interstitial 
inflammation(II) are determinants of progression of renal disease. Standardized assessment 
could add value to current classification of glomerulopathies.
Methods: NEPTUNE is a multi-center, prospective study of children and adults with 
>500mg/day of proteinuria and clinically indicated renal biopsy. We studied 310 patients 
with minimal change disease (MCD n=88), focal segmental glomerulosclerosis (FSGS 
n=125), membranous nephropathy (MN n=58) and IgA nephropathy (IgAN n=39). IF, TA 
and II were quantified as % of interstitial space, on digitized whole slide biopsy images 
(WSI) by 2-5 pathologists (r>0.8 inter-reader agreement). Multivariable cox proportional 
hazards models were fit to assess hazard of complete remission (CR) and composite of 
reaching ESRD or 40% drop in eGFR.
Results: IF was highly correlated with TA (r2=0.98, P<0.001) and II (r2=0.66, P<0.001). 
Median(IQR) for IF was 7(2, 22) and varied by diagnosis [MN 7(4, 13), MCD 1(0, 3), FSGS 
17(5, 39), IgA 21(11, 35), P<0.001]. 57% of the cohort had no II. Median II was highest in 
IgAN (P<0.001). IF was strongly correlated with baseline eGFR (r=-0.71, P<0.001) and 
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UPCR (r=0.18, P=0.002). Adjusting for age, race, diagnosis, baseline eGFR and UPCR, 
each 10% increase in IF score had HR of 0.81 (95%CI 0.67, 0.96, P=0.018) for CR and 
1.55 (95%CI 1.3, 1.9, P<0.001) for ESRD/40% eGFR drop. 
Conclusions: IF has predictive value in assessing risk of progression and remission 
across different types of proteinuric glomerulopathy.
Funding: NIDDK Support, Other NIH Support - NCATS, ORDR
TH-PO724
Study of Relapse Patients with Steroid-Dependent Minimal Change 
Nephrotic Syndrome following Rituximab Treatment  Yuko Iwabuchi, 
Takashi Takei, Yoei Miyabe, Takahito Moriyama, Kosaku Nitta.  Dept of 
Medicine, Kidney center, Tokyo :omen¶s Medical Univ, Tokyo, Japan.
Background: In recent years, several clinical trials have shown the efficacy of rituximab 
(RTX) in patients with steroid-dependent minimal-change nephrotic syndrome (MCNS). 
We previously reported the efficacy and safety of a single dose of RTX infusions during 
24-months at an interval of 6 months for patients with steroid-dependent MCNS in adults 
(Medicine 93: e300, 2014). But there are few reports about the relapse, and we also had 
some patients with relapse after RTX treatment. Therefore, the objective of this study was 
to evaluate the case that relapsed in patients with RTX.
Methods: We conducted a prospective cohort study with a historical control to evaluate 
the effect of single-dose infusions of RTX at 375 mg/m2 BSA per dose at intervals of 6 
months during 24-months followed by continuous RTX treatment as a maintenance therapy. 
40 patients had RTX treatment, and 11 cases had a relapse during 24-months followed.
Results: In 11 cases with relapses, the patients with CD19 recovery (CD19>10/µL) 
at the time of the relapse were six, and mean CD19 at relapse was 56.4/µL, and the mean 
time to relapse from the RTX infusion was 178 days. On the other hand, three patients had 
relapse with CD19<10/µL, and mean CD19 at the time of the relapse was 2.63/µL, and the 
mean time to relapse from the RTX infusion was 77 days. Two patients were not measured 
CD19 revel at the time of relapse, and the time to relapses from the RTX infusion were 
128 days and 146 days each.
Conclusions: The cause of relapse after RTX treatment seemed to be the result of the 
recovery of CD19. However, we experienced two cases that relapsed without recovery of 
CD19, so we report it with clinical course.
TH-PO725
Long-Term Outcome in Glomerulonephritis with Organized Microtubular 
Monoclonal Deposits (Immunotactoid Glomerulonephritis): A Case Series 
of 25 Patients  Léa Dufour,1 Vincent Javaugue,1 Guy Touchard,1 Frank Bridoux.1 
1Nephrology, Hospital, Poitiers, France; 2Anatomopathology, Hospital, Poitiers, 
France; 3Hematology, hospital Saint Louis, Paris, France.
Background: Glomerulonephritis (GN) with organized microtubular monoclonal 
deposits (GOMMID), also referred to immunotactoid glomerulopathy, is a rare entity 
distinct from fibrillary GN and type 1 cryglobulinemic GN. Treatment and outcome in 
GOMMID remain poorly described.
Methods: Twenty-five adults (17 men, median age: 61 years) from 21 nephrology 
departments were retrospectively studied. Inclusion criteria were: Congo Red-negative, 
monotypic IgG glomerular deposits, with microtubular organization (10-60 nm in external 
diameter) by electron microscopy (EM), without pathological criteria for cryoglobulinemic 
GN.
Results: Renal manifestations included: constant proteinuria (median: 6.0 g/d), 
nephrotic syndrome (72%), microscopic hematuria (79%), hypertension (79%), median 
serum creatinine: 130 µmol/l. Biopsy proven extrarenal manifestations in 2 cases 
(mononeuritis, nodular hypodermitis). Eighteen patients had a serum and/or urinal 
monoclonal component, 12 had a lymphoproliferative disorder (chronic lymphocytic 
leukemia [CLL] n=9; lymphocytic B cell lymphoma n=3). Kidney biopsy showed atypical 
membranous GN (n=14) or membranoproliferative GN (n=11), with IgG deposits: IgG1 
(n=8/15), IgG2 (n=5/15), IgG3 (n=2/15), mostly kappa (n=15/25). By EM, microtubule 
mean diameter was 15.6 nm. Intracytoplasmic lymphocyte microtubular inclusions were 
observed in n=4/11 (CLL n=3, lymphocytic B cell lymphoma n=1). Twenty-one patients 
received chemotherapy based on alkylating agent (n=17) and/or Rituximab (n=6). Renal 
response occurred in 15 cases (71%), associated with hematological response in 9 evaluable 
cases. Eleven patients received a second line of chemotherapy. After a median follow-up 
of 45 months, 17 patients had a persistent renal response, 5 had reached end-stage renal 
disease and 5 had died.
Conclusions: GOMMID should be suspected in patients with glomerular disease in 
the context of CLL or lymphocytic B cell lymphoma. Early chemotherapy, adapted to the 
underlying B-cell clone, is associated with a favorable renal outcome in 68% of patients.
TH-PO726
PLA2R-Related Membranous Nephropathy in a Patient with Mannan-
Binding Lectin Deficiency  Stéphane Bally,1 Hanna Debiec,2 Chantal 
Dumestre-Perard,3 Frédérique Dijoud,4 John Rendu,5 Pierre M. Ronco,2 Denise 
Ponard.3  1Nephrology and Dialysis, CHU Chambéry, Chambéry, France; 
2UMR_S1155, INSERM, Paris, France; 3Immunology Laboratory, CHU 
Grenoble, Grenoble, France; 4Pathology Center, Hôpitaux de Lyon, Lyon, 
France; 5Biochemistry and Molecular Genetics laboratory, CHU Grenoble, 
Grenoble, France.
Background: About 75% of patients with primary membranous nephropathy (MN) 
have autoantibodies against phospholipase A2 receptor (PLA2R), predominantly of IgG4 
subclass. C3 and C5b-9 occur in glomerular immune deposits, implicating complement 
activation as a putative effector mechanism. It was also shown that purified anti-PLA2R 
IgG4 could activate the mannose binding lectin (MBL) pathway, but the respective role of 
the three pathways of complement activation remains elusive. Here we report the case of 
a patient with PLA2R related MN and MBL deficiency who developed MN.
Methods: Kidney biopsy specimens were evaluated for staining for PLA2R, IgG 
subclasses, and various complement components, including C3, C1q, C4d, factor B, 
properdin and C5b-9. MBL concentration was assayed by ELISA and its activity was 
measured from C4 cleavage. Polymorphisms in exon 1 and in the promoter region for 
MBL were detected by direct sequencing.
Results: Kidney biopsy showed MN with intense staining for PLA2R, IgG4, C3, factor 
B, properdin and C5b-9 and weak staining for C1q, IgG1 and C4d within the subepithelial 
deposits. Exploration of the lectin pathway revealed a severe MBL quantitative and 
functional deficiency (concentration 12 µg/l, normal range 30-3000 µg/l; and activity < 10% 
normal range 35-135%). Genotyping revealed a 57 (A/C) heterozygous polymorphism in 
codon 57 of exon 1 associated with homozygous and heterozygous variation at -550 (L/L) 
and -221 (X/Y) respectively in the promoter region, suggesting that the patient harbours 
the LXA/LYC haplotypes linked to MBL deficiency.
Conclusions: Due to MBL deficiency, binding of anti-PLA2R antibodies to PLA2R 
could not activate complement by lectin pathway. This is a first case of MN where 
complement was mainly activated by the antibody independent alternative pathway which 
does not exclude a direct role for the auto-antibody on receptor function with alteration 
of podocyte biology.
Funding: Government Support - Non-U.S.
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TH-PO727
Alternatively Activated CD163+ Macrophages Are a Common Feature in 
Progressive Interstitial Fibrosis  Yohei Ikezumi,1 Takeshi Yamada,1 Hiroya 
Hasegawa,1 David J. Nikolic-Paterson,2 Akihiko Saitoh.1  1Dept of Pediatrics, 
Niigata Univ Medical and Dental Hospital, Niigata, Japan; 2Monash Univ Dept 
of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.
Background: Recent studies have shown a disease-specific macrophage (MQ) 
phenotype in pathologies such as tumor metastasis, arteriosclerosis and diabetes. However, 
a kidney disease-specific MQ phenotype has not been described. This study examined 
whether alternatively activated CD68+CD163+ MQ are associated with interstitial fibrosis 
irrespective of the nature of the underlying disease.
Methods: Biopsies taken from children with IgA nephropathy (IgAN; n=81), purpura 
nephritis (HSPN; n=23), lupus nephritis (LN; n=16), minimal change nephrotic syndrome 
(MCNS) treated with cyclosporine (CyA) for >2 years (n=15), and chronic allograft injury 
(CAI; n=13, 28 biopsies) were immunostained for collagen I, pan macrophages (CD68) 
and CD163. Biopsies of thin basement membrane disease (n=9) or MCNS without CyA 
treatment (n=12) were used as controls. In vitro studies used monocyte-derived MQ from 
healthy human volunteers.
Results: Significant interstitial fibrosis and accumulation of CD68+ MQ was evident in 
all progressive disease groups. Most interstitial CD68+ MQ co-expressed CD163 (89-99%). 
By contrast, CD163 expression by glomerular CD68+ MQ varied from 20-93% across the 
progressive disease groups, indicating much greater heterogeneity of M1/M2 phenotypes in 
this compartment. Interstitial CD163+M2-type MQ correlated with the degree of interstitial 
fibrosis in each type of progressive renal disease (all p<0.01), with proteinuria in IgAN 
(p<0.001), HSPN, and LN (p<0.01), and with kidney function in CAI (p<0.001). In addition, 
CD163+ MQ co-localized in fibrotic lesions with excess type I collagen deposition. In 
vitro studies showed that dexamethasone (Dex) up-regulated CD163 expression by MQ, 
and that Dex plus oxidized LDL increased MQ production of pro-fibrotic factors (FGF-1, 
FGF-2, TGF-b1, CTGF).
Conclusions: Our study identifies CD163+ M2-type MQ as the main MQ population 
associated with interstitial fibrosis across a range of progressive forms of kidney disease, 
suggesting a functional role for this MQ subset in renal fibrosis.
Funding: Government Support - Non-U.S.
TH-PO728
Increased Urinary Angiotensinogen Is Associated with Crescent Formation 
in Initial Stage of Henöch Schönlein Purpura Nephritis  Yanjie Huang, 
Xiaoqing Yang.  Dept of Pediatrics, The First Affiliated Hospital of Henan Univ 
of Traditional Chinese Medicine, Zhengzhou, Henan, China.
Background: To investigate the relative factors of increased urinary angiotensinogen 
(uAGT) in children with Henöch Schönlein Purpura Nephritis (HSPN).
Methods: The severity of histopathological changes in HSPN is classified by the 
International Study of Kidney Disease in Children (ISKDC) into six categories: grade 
I-VI. 85 inpatient children with HSPN were underwent renal biopsy in our hospital from 
2014 June to 2015 march, and their histopathological changes included grade II (mesangial 
proliferation, n=21) and grade III ((a) focal or (b) diffuse mesangial proliferation or sclerosis 
with <50% crescents, n=64). The grade III was again divided into IIIa (n=39) and IIIb (n=25) 
groups, III£25% crescent (n=52) and III>25% crescent (n=12) groups. Morning urine and 
serum of HSPN patients were collected on the day before renal biopsy. The levels of AGT 
and collagen type IV (CL-IV) in urinary and serum were detected using ELISA method. 
The urinary microalbuminuria and IgG levels were measured using immunoturbidimetric 
method. All indexes mentioned above were corrected with urine creatinine ratio.
Results: The serum AGT and CL-IV concentration had no significant difference among 
different groups. The uAGT levels were higher in grade III (30.13±13.69ug/gCr) than gradeII 
group (12.09±4.87ug/gCr), and also higher in grade III>25% crescent (57.69±23.31ug/
gCr) than grade III£25% crescent group (28.26±12.02ug/gCr). The uAGT level had no 
significant difference between grade IIIa and IIIb group. The uAGT concentration was 
positively correlated with uCL-IV (r=0.505) and uIgG (r=0.512) respectively.
Conclusions: The increased uAGT level in initial stage of HSPN was related with the 
crescent formation. The enhanced uCL-IV suggested the glomerular basement membrane 
(GBM) may be cleavaged while the crescent formation. On the other hand, the increased 
uIgG concentration also showed the severe injury of GBM. Therefore, the combined 
detection of uAGT, uCL-IV and uIgG may contribute to judge the severity of pathological 
injury of HSPN.
TH-PO729
Ultrasound Microscopy Through a Fine Fiber for Renal Tissues  Takane Ito, 
Takahiro Kanai, Jun Odaka, Takanori Yamagata.  Pediatrics, Jichi Medical Univ, 
Shimotsuke, Tochigi, Japan.
Background: Renal pathology is a fundamental examination in observations of renal 
tissue conditions by light microscopy (LM), aiding in precise diagnoses. However, we 
cannot avoid a bleeding risk in renal biopsies. Additionally, we cannot sometimes make 
precise diagnoses in cases that the obtained renal tissue includes few glomeruli. Ultrasound 
(US) microscopy has been already developed, which enables histopathological observations 
by using the high frequency US. However, it has not been used clinically. We have been 
developing US microscopy through a fine quartz fiber (1mm in diameter). Our aim is to 
observe renal tissues in vivo using this method. As a result of this, we could perform safe 
and precise renal biopsy. For this purpose, we examined that the US microscopy through 
the fine fiber could obtain equivalent images of renal tissues with LM ex vivo.
Methods: We made the renal tissue slide specimens of patients with glomerulonephritis. 
Specifically, we made the unstained US microscopic slide specimens and the Periodic 
Acid-Schiff staining LM slide specimens from the paraffin blocks of renal biopsy tissues. 
Furthermore, we obtained their images of the US microscopy and LM.
Results: We could make discrimination between glomeruli and renal tubules by the 
US microscopy. In addition, mesangial cell proliferation and increased matrix, and fibro-
cellular crescent were detected by the US microscopy, which was enough to evaluate the 
conditions and lead to diagnoses.
Conclusions: We succeeded in obtaining the images of renal tissues using the US 
microscopy through a fine quartz fiber ex vivo. Furthermore these images were similar 
to them of LM. This preliminary study provides a first step toward clinical application of 
US pathological observation in renal diseases. These high-resolution images through a 
fine fiber could not only make live images of renal tissues possible, but prevent removing 
renal tissues which few glomeruli include in. This enables safe and precise renal biopsy, 
and we can thereby make precise diagnoses of renal diseases. This study provides an 
important contribution to future diagnoses and treatments of renal diseases, and further 
studies are warranted.
TH-PO730
Serum Levels of Antiglycan IgG Autoantibodies in Patients with 
IgA Nephropathy Predict the Oxford Classification Scores S and T 
Nicolas Maillard,1 Hitoshi Suzuki,2 Blandine Laurent,1 Bruce A. Julian,2 
Christopher R. Mariat,1 Jan Novak,2 Francois C. Berthoux.1  1Nephrology, 
Dialysis, Transplantation, CHU Saint Etienne, Saint Etienne, France; 2Dept 
of Microbiology, Univ of Alabama at Birmingham, Birmingham.
Background: IgA nephropathy (IgAN) is driven by mesangial deposition of 
immune complexes consisting of galactose-deficient IgA1 (Gd-IgA1) and IgG antiglycan 
autoantibodies, leading to glomerular injury and chronic kidney disease. As serum levels 
of Gd-IgA1 and IgG autoantibodies have prognostic significance, we evaluated in this 
study the relationship between these markers and renal histology according to the Oxford 
classification.
Methods: Ninety-seven biopsy-proven IgAN patients were selected from our to equally 
represent the absolute renal risk scores from 0 to 3. Gd-IgA1 and IgG autoantibody levels 
were assessed in the serum samples obtained at the time of diagnosis using ELISA. Oxford 
classification and global optical scores (GOS) were compiled based on the evaluation of 
stored kidney tissue sections. A logistic regression analysis and c statistics were performed.
Results: Eighty-six patients were included in the Oxford analysis (biopsies from 11 
patients did not have sufficient tissue) and GOS was calculated. IgG autoantibody levels 
predicted a T score of 1 or 2, using a logistic regression model (estimate 1.04, p=0.01), and 
an S score of 1 (estimate 1.10, p=0.006), but did not predict a positive M or E score. GOS 
was predicted by IgG autoantibody levels (linear regression, p<0.001). The ROC curve 
analysis revealed an areas under curve of 0.68 [0.55-0.81] and 0.68 [0.57-0.80] predicting 
positive T and S scores from IgG autoantibody levels. Gd-IgA1 levels were not associated 
with any histological pattern.
Conclusions: IgG autoantibody levels correlated with GOS and predicted positive S 
and T scores according to Oxford classification in IgAN.
TH-PO731
Comparison of Native and Transplant Percutaneous Renal Biopsy: Safety 
and Diagnostic Yield  William Luke Whittier, Samuel N. Saltzberg, Stephen 
M. Korbet.  Nephrology, Rush Univ, Chicago, IL.
Background: No prospective studies exist which directly compare the safety and 
adequacy of the percutaneous native (NRB) and transplant (TRB) renal biopsy. We report 
a large single-center prospective series comparing the success and complication rate of 
NRB and TRB over a twenty year period.
Methods: From 01/1995 to 04/2015, 1,705 adult pts underwent NRB (N= 767) or 
TRB (N=938) by a Nephrology attending or fellow. Data were collected prospectively in 
all biopsies. Real-time U/S guidance and automated needles were used for all biopsies. 
NRB was performed with either a 14 or 16 gauge needle while TRB was with a 16 gauge 
needle. All NRB pts were observed in the hospital for at least 24 hours and TRB pts for at 
least 3 hours. Complications were defined by the need for an intervention (i.e. transfusion, 
surgery or embolization), readmission, or death.
Results: At the time of biopsy, NRB pts were younger (47±17 vs. 50±14 years, 
p<0.0001) and more often female (62 vs. 48%, p<0.0001) compared to TRB. TRB pts had 
higher blood pressure (systolic BP: 140±22 vs. 133±18 mmHg, p<0.0001), higher serum 
creatinine (3.1±1.8 vs. 2.3±2.2 mg/dl, p<0.0001), increased aPTT (28±4.3 vs. 27±5 seconds, 
p<0.0001) as well as lower Hgb (11.2±1.8 vs. 11.7±2.1 g/dl, p<0.0001) compared to NRB. A 
fellow performed the biopsy in 91% of NRB compared to 63% of TRB (p<0.0001). Adequate 
tissue for diagnosis was obtained in 99% of NRB and TRB (p=0.71 ). Total number of 
glomeruli on light and immunofluorescent microscopy was 33±17 for TRB and 31±13 for 
NRB (p=0.11). The only factor predictive of a complication in the TRB was pre-TRB Hgb 
(no complication, 11.2±1.7 vs. complication, 10.1±1.7 g/dl, p<0.0001). Compared to TRB 
pts, NRB pts had a greater drop in Hgb post-PRB (0.97±1.1 vs. 0.73±1.3 g/dl, p<0.0001), 
had more complications (6.5 vs. 3.9%, p=0.02) and/or transfusions (5.2 vs. 3.3%, p=0.045). 
There was 1 death in each group attributed to the biopsy.
Conclusions: The NRB and TRB remain successful and safe procedures. There are 
more complications with NRB compared to TRB despite TRB pts having more risk factors. 
Differences in technique, operator (fellow or attending), or needle size may explain this 
variability.
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TH-PO732
Serum Immunoglobulin E Level Is Associated with Renal Progression in 
Immunoglobulin A Nephropathy  Shin yeong Lee, Jin sug Kim, Sang ho Lee, 
Se yun Kim, Yu ho Lee, Kyung-hwan Jeong, Tae won Lee, Ji hoon Lee, Yang 
gyun Kim, Ju-Young Moon, Chun-Gyoo Ihm.  Dept of Nephrology, Kyung Hee 
Univ Medical Center, Seoul, Korea.
Background: Previous studies reported that serum Immunoglobulin E(IgE) levels are 
elevated in Immunoglobulin A nephropathy(IgAN) and suggested IgE levels as a prognostic 
indicator in IgAN. The aim of this study is to explore the association between plasma IgE 
level of IgAN patients and renal outcome.
Methods: This study is an observational study of IgAN patients undergoing kidney 
biopsy between 1995 and 2012. We collected the data of patient’s demographics and 
serum IgE levels from routine laboratory examination. We retrospectively analyzed the 
correlation between serum IgE level and clinical parameters and pathologic findings. We 
defined renal progression if patient meets the following criteria; 1) negative value of delta 
estimated glomerular filtration rate(eGFR)(ml/min/1.73m2/months) and 2) a rise in serum 
creatinine(SCr) an absolute level ³1.3 mg/dl(male) or 1.2mg/dl(female).
Results: A total of 117 patients were included. The mean level of initial eGFR 
and serum IgE were 84.79±37ml/min/1.73m2 and 304±607IU/mL. The distribution in 
glomerular grades using the H. S. Lee grading was as follows; grade 1, 28 patients(23.9%); 
grade II, 62 patients(53%); grade III, 19 patients(16.2%); grade IV, 6 patients; grade V, 
1 patient. Of the 117 patients, twenty-two (22%) had renal progression. Serum IgE level 
was significantly high in renal progression group compared to nonprogressive group.
(590±1247 vs. 238±290, p=0.014). Gender(76% vs 50%, P=0.011) and history of gross 
hematuria (9% vs 29%, p=0.024) were significant difference between high and low IgE 
group. But no significant differences were seen for delta SCr,delta eGFR, delta proteinuria 
and pathologic findings. Linear regression analysis showed that male gender( β=0.308 ,p 
=0.028), initial proteinuria( β=0.617 ,p=0.008) and delta proteinuria ( β=0.404, p =0.028) 
were significant associated with IgE levels.
Conclusions: These results suggested that serum IgE level is probably associated 
with renal progression in IgAN patients. Further studies are needed to elucidate 
immunopathogenesis of the increased IgE level in IgAN.
TH-PO733
Podometric Changes in Perinatal Kidneys (127 to 471 Day Post-Conception) 
Masao Kikuchi, Larysa T. Wickman, Su Qing Wang, Mahboob A. Chowdhury, 
Roger C. Wiggins, Raja Rabah.  Div of Nephrology, Dept of Internal Medicine, 
Univ of Michigan, Ann Arbor, MI.
Background: We recently reported that glomerular volume increases and podocyte 
density decreases with age from 4 to 89 years in man. However the changes that occur 
before and immediately after 38 weeks gestation are not well defined.
Methods: Podometric parameters (including glomerular volume, podocyte number, 
density and cell size) were estimated from archival tissue sections with recently developed 
technology (Venkatareddy et al. JASN 2014 and Yang et al. JASN 2015) using autopsied 
kidney samples from newborn and infants without kidney disease as a proximate cause 
of death (n=25, age 0-240 day-old). Because premature kidneys were included, post-
conceptional age (range 127-471 day-old) was used instead of postnatal age.
Results: The younger post-conceptional age was, the greater the proportion of immature 
glomeruli present (R2=0.63, P<0.001). Compared to mature glomeruli, immature glomeruli 
were smaller (1.4×105 vs 4.9×105 µm3, P<0.001) and podocytes were smaller (140 vs 320 
µm3, P<0.001) and fewer per glomerular tuft (300 vs 520, P<0.001), and present at higher 
podocyte density (2,700 vs 1,400 /106 µm3, P<0.001). In mature glomeruli podocyte density 
decreased linearly with age (R2=0.54, P<0.001) due to a rapid increase in glomerular 
volume (+210% per year, R2=0.48, P<0.001). Podocyte number per glomerular tuft did 
not change with age (R2=0.008, P=0.68). Mean podocyte cell volume increased with age 
(+140% per year, R2=0.39, P<0.002). Glomerular volume correlated with kidney-to-body 
weight ratio (R2=0.49, P<0.001).
Conclusions: Prior to and after term there is a very rapid decrease in podocyte density 
(increase in glomerular volume and podocyte size without a change in podocyte number or 
proportion of the glomerulus that constitutes podocytes). These large perinatal adaptations 
could play a role in triggering glomerular syndromes prevalent early in life.
Funding: Other NIH Support - NIH U54-DK-083912
TH-PO734
Novel Monoclonal Antibody KM55 Specifically Detected Glomerular 
Galactose-Deficient IgA1 in Patients with IgA Nephropathy  Hitoshi Suzuki,1 
Junichi Yasutake,1,2 Yuki Tanbo,1,2 Yusuke Suzuki.1  1Nephrology, Juntendo Univ 
Faculty of Medicine, Tokyo, Japan; 2Nephrology Research Labs, KyoZa Hakko 
Kirin Co., Ltd., Tokyo, Japan.
Background: Galactose-deficient IgA1 (Gd-IgA1) has been proposed as an important 
effecter molecule in patients with IgA nephropathy (IgAN). Our previous study revealed that 
Gd-IgA1-specific monoclonal antibody KM55 could be a new tool for detecting circulatory 
Gd-IgA1 in patients with IgAN, which enabled us to study molecular roles of Gd-IgA1. In 
this study, we further examined pathophysiological significance of Gd-IgA1 in glomerular 
deposits of patients with IgA nephropathy by immunohistochemical analysis with KM55.
Methods: Immunostaining of Gd-IgA1 and immunoglobulins (IgA and IgG) was 
performed with KM55 and anti-immunogloblin polyclonal antibodies in paraffin embedded 
sections of renal biopsy specimens from patients with IgAN (n=16), and other renal 
diseases (n=19); such as lupus nephritis and membranous nephritis. Area of glomerular 
deposits of Gd-IgA1 and immunoglobulins were semi-quantitated by spectral imaging 
using Nuance software.
Results: Glomerular Gd-IgA1 was specifically detected in all patients with IgAN, 
but not in those with other renal diseases. Gd-IgA1 could not be detected even in 
patients with lupus nephritis whose glomerular IgA were positive. In patients with IgAN, 
immunofluorescence with KM55 revealed diffuse and global glomerular staining of Gd-
IgA1. Moreover, double staining of Gd-IgA1 and IgA showed that Gd-IgA1 was localized 
predominantly in the mesangial region; however the localization of IgA was similar to that 
of Gd-IgA1 but was more broadly observed.
Conclusions: This is the first observation to clearly reveal that Gd-IgA1 could be 
specifically deposited in glomeruli of IgAN, strongly suggesting the pathophysiological 
function of Gd-IgA1 in patients with IgAN. Further studies are necessary to clarify the 
underlying mechanisms of Gd-IgA1 deposition and induction of renal injuries in IgAN. 
Novel monoclonal antibody KM55 against galactose-deficient IgA1 could be a powerful 
tool to detect nephritogenic IgA in patients with IgAN.
Funding: Pharmaceutical Company Support - Kyowa Hakko Kirin Co., Ltd., 
Government Support - Non-U.S.
TH-PO735
Serum Levels of Galactose-Deficient IgA1 in Patients with IgA Nephropathy 
Correlate with Serum Levels of IgG Autoantibodies  William J. Placzek,1 
Yuko Makita,4 Matthew B. Renfrow,1 Bruce A. Julian,3 Yusuke Suzuki,4 Jan 
Novak,2 Hitoshi Suzuki.4  1Biochemistry and Molecular Genetics, The Univ 
of Alabama at Birmingham, Birmingham, AL; 2Microbiology, The Univ of 
Alabama at Birmingham, Birmingham, AL; 3Medicine, The Univ of Alabama at 
Birmingham, Birmingham, AL; 4Internal Medicine, Juntendo Univ, Tokyo, Japan.
Background: IgA nephropathy (IgAN) is an autoimmune disease in which IgA1 with 
some O-glycans deficient in galactose (Gd-IgA1) is recognized by anti-glycan IgG and/
or IgA autoantibodies to form pathogenic immune complexes. Some of these immune 
complexes deposit in the kidney and induce glomerular injury. In this study, we assessed 
possible associations between serum levels of Gd-IgA1 and IgA, and Gd-IgA1 and IgG 
or IgA autoantibodies.
Methods: Serum samples from 135 patients with biopsy-proven IgAN, 79 patients 
with other renal diseases, and 106 healthy controls at Juntendo University, Tokyo, Japan, 
were analyzed for levels of total IgA and IgG, Gd-IgA1, and Gd-IgA1-specific IgA and 
IgG autoantibodies and the data assessed for possible associations.
Results: Patients with IgAN had higher total IgA compared to healthy controls 
and exhibited a significantly stronger correlation between total IgA and Gd-IgA1 levels 
(r=0.639 vs. r=0.901, p<0.0001). Gd-IgA1 levels strongly correlated with levels of Gd-
IgA1-specific IgG autoantibodies in patients with IgAN (r=0.4909, p<0.0001), but not in 
healthy controls or disease controls. Levels of Gd-IgA1 did not correlate with the levels 
of IgA autoantibodies in any of the three groups. Furthermore, among IgAN patients with 
levels of Gd-IgA1-specific IgG higher than the mean + 2 SD level of healthy controls, only 
37% also had an elevated level of Gd-IgA1-specific IgA autoantibody.
Conclusions: Our data revealed a new association between the key autoantigen, Gd-
IgA1, and IgG autoantibodies in patients with IgAN, further supporting their key role in 
the pathogenesis of IgAN.
TH-PO736
Cryoglobulinemic Glomerulonephritis: A Single-Center Experience 
Insara Jaffer Sathick,1 Tyler V. Klobucher,2 Nelson Leung,1,3 Samih H. Nasr.4 
1Div of Nephrology, Mayo Clinic, Rochester, MN; 2Mayo Medical School, 
Rochester, MN; 3Div of Hematology, Mayo Clinic, Rochester, MN; 4Div of 
Anatomic Pathology, Mayo Clinic, Rochester, MN.
Background: Cryoglobulinemic glomerulonephritis(CryoGN) is a recognized form 
of glomerulonephritis. However,the clinical characteristics are not well-established due to 
lack of large studies with biopsy and serological confirmation. We present our experience 
with 42 cases of serologically and biopsy-proven CryoGN.
Methods: We conducted a retrospective search for patients with cryoglobulinemia and 
kidney biopsy and identified patients with CryoGN.
Results: From 2000 to 2014, we identified 569 patients with cryoglobulinemia. Of the 
71 patients who underwent kidney biopsy for kidney dysfunction,42(59%) had CryoGN, 
the remaining had other pathology, including interstitial nephritis, lupus nephritis, fibrillary 
GN and amyloidosis. Median age of CryoGN patients was 59 yrs;male/female ratio, 23:19. 
Median eGFR by MDRD equation was 41ml/min/1.73m2 at onset. 88% had nephritic 
syndrome and rest had nephrotic syndrome. 74% had Type II, 19%- Type I and 7%-Type III 
cryoglobulinemia. Hypocomplementemia was present in 83%. 76% had skin involvement, 
16% had joint symptoms, 14% had neuropathy and 1% had pulmonary involvement. 4 
patients required dialysis. Etiology of cryoglobulinemia was a hematological disorder in 
40%(of which 88% lymphoproliferative and 12% MGRS) and hepatitis C in 26% patients. 
Etiology of Cryo GN(% total) Type I(19%) Type II(74%) Type III(7%)
Hematological (40%) 23 71 6
Hepatitis C (26%) 9 82 9
Connective Tissue Disease (17%) 14 72 14
Idiopathic (17%) 34 66
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80% patients received immunosuppression for treatment, 54% receiving Rituximab. 
Median duration of follow up was 18 months. Median overall survival was 36.4 months. 
At 6 months, median eGFR improved to 48ml/min1.73m2.
Conclusions: Though CryoGN is the most common pathology in cryoglobulinemia, 
a wide array of other lesions is seen. Most patients with CryoGN have skin lesions while 
other systemic features of cryoglobulinemia are rare. In this study hematological disorders 
were the commonest etiology for CryoGN followed by hepatitis C infection.
TH-PO737
The Clinicopathological Impact of Medullary Ray Injury on Early Stage 
Renal Allografts  Takahito Niikura,1 Akimitsu Kobayashi,1 Yasuyuki Nakada,1 
Izumi Yamamoto,1 Yudo Tanno,1 Ichiro Ohkido,1 Masayoshi Okumi,2 Hideki 
Ishida,2 Kazunari Tanabe,2 Hiroyasu Yamamoto,1 Takashi Yokoo.1  1Nephrology 
and Hypertension, The Jikei Univ School of Medicine, Tokyo, Japan; 2Urology, 
Tokyo :omen¶s Medical Univ, Tokyo, Japan.
Background: Interstitial fibrosis and tubular atrophy (IF/TA) constitute an important 
cause of renal graft loss.Previously, we examined medullary ray injury (MRI) inducing IF/
TA via non-immunological mechanisms, classifying the etiology of MRI into calcineurin 
inhibitor (CNI) toxicity (32.8%), vesicoureteral reflux (50%), and urinary tract infection 
(8.6%) (Pathol Int. 2010;60:744–9). However, we did not examine the influence of the 
etiology on the long-term renal allograft prognosis, since the timing of the biopsies differed 
among the cases. Herein, we focused on MRI observed in protocol biopsies within 3 months, 
examining the influence on the renal allograft prognosis.
Methods: Retrospectively, we divided 53 protocol biopsies within 3 months into two 
groups with (n=34) and without (n=19) MRI. The MRI+ cases with isometric vacuolization 
and aah in the Banff classification were classified as CNI toxicity (MRI+CNI); the cases 
with Tamm-Horsfall protein casts in the interstitium and thyroid-like appearance were 
classified as urinary tract system abnormalities (MRI+UT); and the remaining cases as 
others. We compared the annual change in serum creatinine (sCr) levels over 3 years and 
the extent of fibrosis (ct+ci) at the 1-year biopsies. Cases with rejection were excluded.
Results: The sCr levels declined in both groups, but were significantly higher in the 
MRI+ group than the MRI– group at 3 years (p=0.024). Examining three MRI+ subgroups, 
only MRI+UT had significantly high sCr levels compared to the MRI– group (p=0.019). 
The observation of IF/TA in the base-line and 1-year biopsies in the MRI+ group indicated 
the significant development of IF/TA.
Conclusions: Cases developing MRI within 3 months after kidney transplantation were 
significantly more likely to develop IF/TA at the 1-year biopsies. These cases had higher 
sCr levels at 3 years. In the cases with MRI in the base-line biopsies, interventions might 
preserve kidney graft function over the long-term.
TH-PO738
Diagnostic Gene Signature from Urinary Extracellular Vesicles Can Be 
Used as Biomarker for Non-Invasive Diagnosis of Clear Cell Renal Cell 
Carcinoma  Giuseppe De Palma,1 Fabio Sallustio,1,2 Vanessa Galleggiante,3 
Monica Rutigliano,3 M. Battaglia,3 Francesco Paolo Schena.1  1C.A.R.S.O. 
Consortium, Univ of Bari, Valenzano, BA, Italy; 2Dept of Science, Biological 
and (nvironmental Sciences and Technologies, Univ of Salento, Lecce, L(, Italy; 
3Urology, Andrology and Kidney Transplantation Unit, Dept of Emergency and 
Organ Transplantation, Univ of Bari, Bari, BA, Italy.
Background: Clear cell renal cell carcinoma (ccRCC) is one of the most common 
malignancies and due to its intimate association with urine, it appears well suited for 
studies to identify non-invasive biomarker in this material. The extracellular vesicles 
(EV) can be isolated in urine. They transport proteins and nucleic acids that reflect the 
physiopathological status of renal cells. The purpose of this study has been to analyze the 
transcripts in the urinary EV from ccRCC patients and to specific transcripts for preventive 
diagnosis of ccRCC.
Methods: We enrolled 12 patients with a diagnosis of ccRCC undergoing unilateral 
nephrectomy. We collected pre-intervention urine. A group of healthy volunteers (n = 11) 
with negative urine analysis was used as control. The EV were isolated from the urine 
by differential centrifugation. Total RNA was extracted, quantified and qualitatively 
evaluated. Illumina HumanHT-12 v4 BeadChip was used for microarray analyses. Then, 
the dysregulated genes were validated by qRT-PCR in independent cohorts of 12 patients 
and 10 controls.
Results: We identified four genes (GSTA1, CEBPA, PCBD1, RCC2) differentially 
modulated in ccRCC patients and we investigated whether the functions of these genes 
could be related to ccRCC through the pathways analysis. The qRT-PCR validated a number 
of potential diagnostic biomarkers that could be used to distinguish ccRCC patients at an 
early stage from healthy individuals. Some potential biomarkers were already present 
in pathways involved in the pathogenesis of cancer as glutathione or arsenate mediated 
detoxification instead other biomarkers were new.
Conclusions: Using this approach, we have identified a signature of four transcripts 
that could be used as biomarkers for non-invasive diagnosis of ccRCC.
TH-PO739
Initial Clinical Trial Results of a Real-Time Point-of-Care Glomerular 
Filtration Rate Measurement Utilizing a Novel Fluorescent Tracer Agent 
Richard B. Dorshow,1 Martin Debreczeny,1 Jeffrey C. Fink,3 Thomas C. 
Dowling.2  1MediBeacon, LLC, St. Louis, M2; 2College of Pharmacy, Ferris 
State Univ, Grand Rapids, MI; 3Dept of Medicine, Univ of Maryland Medical 
System, Baltimore, MD.
Background: A first-in-human clinical study with MB-102, a fluorescent tracer agent 
engineered to have photophysical and clearance properties for use as a real-time point-of-
care measure of glomerular filtration rate (GFR) is reported. The clearance of this agent 
can be monitored noninvasively by transdermal fluorescence.
Methods: Blood samples were taken over a period of 12 hours post simultaneous 
administration of MB-102 and iohexol to assess pharmacokinetic parameters including 
clearance on 32 subjects recruited to have normal renal function. Urine samples were 
collected concurrently to assess percent injected dose recovered in the urine. A prototype 
noninvasive fluorescence detection device was employed to simultaneously measure 
the transdermal fluorescence from MB-102 to assess correlation with the plasma 
pharmacokinetics.
Results: The plasma pharmacokinetics displayed the expected 2 compartment model 
of a vascular-tissue equilibrium phase followed by renal excretion only. The GFR measured 
from the MB-102 plasma pharmacokinetics matched the GFR measured from iohexol. 
The % injected dose of MB-102 appearing in the urine (99+/-7%) matched that of 
iohexol. The MB-102 time-dependence of the transdermal fluorescence monitored by 
the prototype device matched that of the plasma (r2~0.98). No significant adverse events 
were reported.
Conclusions: MB-102 was shown to be a GFR tracer agent in humans from the 
plasma pharmacokinetic match and the % injected dose in urine match to iohexol. The 
transdermal fluorescence pharmacokinetics mirrored that of the plasma pharmacokinetics 
thus demonstrating that the validity of this noninvasive GFR measurement.
Funding: Pharmaceutical Company Support - MediBeacon, LLC
TH-PO740
Analysis of Exogenous Near Infrared Fluorescent Markers for the 
Transcutaneous Measurement of Glomerular Filtration Rate  Jiaguo Huang,1 
Stefanie Weinfurter,1 Johannes Pill,2 Norbert Gretz,1 Rossana Perciaccante,3 
Federica Rodeghiero,3 Lepoldo Della ciana.3  1Medical Faculty Mannheim, 
Univ of Heidelberg, Mannheim, Germany; 2Mannheim Pharma & Diagnostics 
GmbH, Mannheim, Germany; 3Cyanagen S.r.l., Bologna, Italy.
Background: Recently, we developed approaches for the transcutaneous measurement 
of GFR in lab animals. Using fluorescent markers allows GFR assessment without blood and/
or urine sampling. Therefore, there is considerable interest in the development of exogenous 
fluorescent markers for real-time and accurate measurement of GFR via transcutaneous 
fluorescent methods using new dye conjugates.
Methods: A near infrared (NIR) cyanine was synthesized by a five-step synthetic 
procedure. This dye was used to label (2-hydroxypropyl)-β cyclodextrin. The chemical 
structure was fully confirmed by 1H-NMR, 13C-NMR, and HRMS spectra. Optical properties 
were characterized by UV-2450 spectrophotometer and fluorescence spectrometer. The 
percent plasma protein binding (PPB) was determined by equilibrium dialysis of fluorescent 
marker solutions incubated with rat plasma using a two-chamber dialysis set-up. Elimination 
half-life was determined in combination with a miniaturized new electronic device for 
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the transcutaneous fluorescence detection in freely moving rats. Recovery rate in urine 
was measured in conscious rats after intravenous injection using metabolic cages. Mean 
± S.D are given.
Results: The NIR marker was synthesized in a high yield. It exhibits good water 
solubility with concentrations reaching more than 200 mg/mL with a molecular weight 
range from roughly 1200 up to 2700 D. In addition it shows a low plasma PPB, i.e. 3.7 %, 
which is clearly lower than that of iothalamate (9.5 %). The excitation and emission are 
705 nm and 790 nm respectively providing low background and high tissue penetration 
for in vivo application. The noninvasive real-time monitoring of clearance resulted in a 
half-life of 33.4 ± 4.6 min and 34.9 ± 6.8 min without and with probenecid treatment, 
respectively. A high urinary recovery of the marker with 99 ± 7.3% of the dose given was 
observed within 24 h.
Conclusions: We identified the marker with a high potential as exogenous fluorescent 
tracer for GFR measurement. A patent has been filed.
Funding: Government Support - Non-U.S.
TH-PO741
Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: 
Biopsy, Serum and Urine Findings  Aikaterini K. Nikolopoulou, Theresa H. 
Page, Gurjeet Bhangal, Janet Lee, Paul Brookes, Tom Cairns, Liz Lightstone, 
Megan Griffith, H. Terence Cook, Charles D. Pusey.  Renal and Transplant 
Centre, Imperial College London, London, United Kingdom.
Background: The major target antigen in Membranous Nephropathy (MN) is the 
phospholipase A2 receptor (PLA2R); its exact role is not yet fully understood. In this 
retrospective study we examined the presence of PLA2R in biopsy tissue, PLA2R antibodies 
in serum and urine of patients with MN, and aimed to identify associated clinical variables.
Methods: 120 MN patients were identified from 2008 - 2014: 74 with idiopathic 
MN (iMN); 12 secondary MN; 9 recurrent MN post transplantation; 25 class V lupus MN 
(LMN). 27 controls with other GN were also used. Immunofluorescence (IF) for PLA2R 
was performed on paraffin embedded biopsies and ELISA (EUROIMMUN) for the detection 
of PLA2R antibodies in serum and urine.
Results: In the iMN group 35/74 (47%) biopsies stained positive, 30 (40%) negative and 
9(12%) borderline. Circulating PLA2R antibodies were detected in sera from 30/74(40%) 
patients within 6 months from biopsy, all of whom had positive or borderline staining 
on biopsy. In the secondary MN group 5/12 stained positive; 1 had a detectable PLA2R 
antibody. In the transplant cohort 3/9 stained positive; 1 had a positive serum. Of 25 class 
V LMN, 3 stained positive and 1 had a positive serum antibody. There was no correlation 
between staining or the level of PLA2R antibody with proteinuria or creatinine at the time of 
biopsy. Urine from 5 iMN patients with active disease was positive for PLA2R antibodies; 
26 healthy controls and 6 iMN patients in remission tested negative.
Conclusions: Our data suggest that IF for PLA2R in biopsy tissue is more sensitive 
than serum testing for the presence of PLA2R antibodies. This cross sectional study did 
not demonstrate a correlation between PLA2R staining or antibody levels and proteinuria 
at the time of biopsy; however a longitudinal study to assess the variations of PLA2R Ab 
levels with clinical outcomes is in progress. The presence of PLA2R antibodies in urine of 
patients with active disease is interesting although further studies are required to determine 
whether this is due to nonspecific proteinuria.
TH-PO742
Belimumab in Idiopathic Membranous Nephropathy: An Interim Analysis 
of Exploratory Biomarkers Including Anti-PLA2R Autoantibodies 
Christine Barrett,1 Shaun Flint,1 Robert Brian Henderson,1 Tim Sebastian 
Schmidt,1 Sophie I. Gisbert,1 Gengqian Cai,2 Caroline O.S. Savage.1 
1GlaxoSmithKline plc, United Kingdom; 2GlaxoSmithKline plc.
Background: Belimumab, a B-lymphocyte stimulator (BLyS)-specific inhibitor 
has been shown to reduce anti-phospholipase A2 receptor (PLA2R) autoantibodies and 
proteinuria in a mechanistic study (BEL116472) in idiopathic (primary) membranous 
nephropathy (IMN). Here we report an interim analysis of individual patient responses 
and analysis of exploratory pharmacodynamic (PD) biomarkers.
Methods: 14 anti-PLA2R autoantibody positive IMN patients with nephrotic range 
proteinuria received 10mg/kg iv belimumab every 4 wks (or 2 wks if >10g/24h) for up to 
100 wks. 11 of these completed at least 28 wks treatment, with 3 withdrawals before wk 
16. Assessment of proteinuria, anti-PLA2R antibody levels, belimumab kinetics, BLyS 
levels and B cell immunophenotypes was performed.
Results: There was a significant reduction in anti-PLA2R antibodies by wk 12 (-46%, 
p=0.025) and in uPCR by wk 36 (-38%, p=0.022). 9 of 11 subjects showed a reduction of 
>50% in anti-PLA2R levels at the primary endpoint (wk 28). 6 of 11 achieved at least partial 
remission of proteinuria and negative or borderline anti-PLA2R levels by last follow-up to 
date (44-104 wks). Lack of remission was linked to a smaller fall in anti-PLA2R levels, or 
anti-PLA2R at wk 28 >100 RU/ml, or a shorter follow-up (≤ 36 wks). Week 2 belimumab 
trough levels showed strong negative correlation with baseline uPCR (rs=-0.94 p<0.0001). 
The correlation of baseline BLyS level with proteinuria response was weak. Exploratory 
belimumab PD effects included a reduction in naive B cells and expanded memory B cells.
Conclusions: This mechanistic trial of belimumab in IMN has enabled a novel analysis 
of PD and PK endpoints, confirming but also extending the PD effects previously reported 
in studies of SLE. Further analysis of anti-PLA2R antibody kinetics as a predictor of 
remission may also be informative.
Funding: Pharmaceutical Company Support - GlaxoSmithKline plc
TH-PO743
Diagnostic Performance of M-Type Phospholipase A2 Receptors 
Autoantibodies (Anti-PLA2R) for the Differentiation of Idiopathic 
Membranous Nephropathy (iMN) without Mesangial Immunocomplexes 
in Kidney Biopsy  Hugo Enrique Chavez,1 Juan Carlos Ramirez-Sandoval,1 
Magdalena Madero,2 Ricardo Correa-Rotter,1 Jose Antonio Nino-Cruz.1 
1Nephrology and Mineral Metabolism, Inst Nacional de Ciencias Medicas 
y Nutrición Salvador Zubiran, Distrito Federal, Mexico; 2Nephrology, Inst 
Nacional de Cardiología Ignacio Chávez, Distrito Federal, Mexico.
Background: The presence of mesangial immunocomplexes in membranous 
nephropathy without an apparent cause constitutes a controversial element and has been 
considered a potential indicator of an unidentified secondary cause. The value of anti-PLA2R 
for diagnosis of iMN and for this specific purpose has not been assessed. Objective: Assess 
the diagnostic performance of anti-PLA2R to differentiate iMN (without mesangial deposits) 
and MN with presence of mesangial deposits as well as from other glomerulonephritis (GM).
Methods: We prospectively enrolled 108 cases with biopsy proven GM: 40 iMN, 
33 systemic lupus erythematous (23 with proteinuria >1 g/day), and other. In 27 MN, we 
found proteinuria>1 g/day, of which 21 had typical granular deposition along the basement 
membrane (iMN cases); the 6 other had mesangial deposits without a diagnosed secondary 
cause of MN. Serum anti-PLA2R was assessed by ELISA (euroimmun, Germany).
Results: 21/108 patients had anti-PLA2R >9 RU/mL, all of them had iMN. Among 
patients with MN and proteinuria>1g/day, 19/27 had anti-PLA2R>9 RU/mL. The area 
under the ROC curve (AU-ROC) of anti-PLA2R was 0.87 (95% , CI: 78-0.96) when cases 
of MN and proteinuria>1 g/day were compared vs. other cases. At a cutoff of 9 RU/mL, 
sensitivity and specificity were 70% and 99% respectively. When we predefined cases of 
iMN and presence of mesangial deposits as probably not idiopathic, the AU-ROC was 
0.95 (95%. CI: 0.87-1.00). In this analysis, at the cutoff of 9 RU/mL, the sensitivity and 
specificity were 91% and 99% respectively. All clinically diagnosed MN that had mesangial 
immunocomplex deposition were negative for Anti-PLA2R.
Conclusions: Anti-PLA2R levels had an excellent diagnostic performance to detect 
iMN. Anti-PLA2R >9 RU/mL may be sufficient to diagnose iMN precluding the need of 
a renal biopsy.
TH-PO744
Declining Renal Function in Idiopathic Membranous Nephropathy: A 
Report from Two Tertiary London Renal Units  Sanjana Gupta,1 Kieran 
Mccafferty,2 Horia Stanescu,1 Stephen H. Powis,1 Alan D. Salama,1 John 
Connolly,1 Stephen B. Walsh,1 Robert Kleta,1 Muhammad M. Yaqoob,2 Neil 
Ashman.2  1UCL Centre for Nephrology; 2Royal London Hospital.
Background: Idiopathic Membranous Nephropathy (iMN) is a major cause of 
nephrotic syndrome in adults. Renal function may deteriorate (progressor) or be preserved 
(non-progressor patients).
Methods: We performed a retrospective analysis of patients with biopsy proven iMN 
between 2000-2015.
Results: We identified 188 patients with biopsy proven iMN. 
Median age 58 (44-71)
Male % 68
Ethnicity (White / Black / Asian / Unknown) % 48 / 17 / 24 / 11
Diagnosis Serum creatinine (sCr) (µmol/L) 86.5 (64 – 111)
Diagnosis Serum albumin (sAlb) (mmol/L) 25 ± 7
Diagnosis urine protein creatinine ratio (PCR) 900 (485 – 1255)
Spontaneous remission % 34
Renal replacement therapy % 34
Deceased % 12
20% of patients were progressors (increase in sCr >50%, no RRT). There was no 
statistical difference between sCr (101 ± 6 vs 92 ± 9 µmol/L, ns), sAlb (25.2 ± 1.3 vs 26.2 ± 
0.8 mmol/L, ns) or PCR (893 ± 87 vs 895 ± 94, ns) at diagnosis between progressors and non-
progressors, respectively. Progressors were more likely to be Asian (36% vs 21%, p=0.058) 
and non-progressors black (32% vs 20%, p=0.058). Of the 37 patients that spontaneously 
remitted, 5% relapsed. 65% of patients were treated with immunosuppressives. 60% 
received prednisolone, the most used first line agent was cyclophosphamide 35%, then 
anti-proliferatives 34% and calcineurin inhibitors (CNI) 23%. There was a significant 
difference between treatment between progressors and non-progressors; progressors were 
treated with CNI (38% vs 15%, p=0.04). Rituximab was used 3 times. The complication rate 
from immunosuppression was 25%. The most common was diabetes from steroid therapy at 
10%. Infection occurred in 2% and drug specific complications in 7%. Thromboembolism 
rate from nephrosis was low at 14%.
Conclusions: At diagnosis there was no significant difference in sCr, sAlb or PCR 
between progressors and non-progressors. Progressor patients with iMN may benefit from 
immunosuppression, but this is associated with risks. It is important to identify progressor 
patients; there is an unmet need for a biomarker to do this.
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TH-PO745
End-Stage Renal Disease from Membranous Nephropathy in the United 
States, 1995 to 2010  Robert N. Foley,1 Scott Reule,1 Donal J. Sexton.2  1Div 
of Nephrology, Univ of Minnesota; 2Div of Medicine, National Univ of Ireland, 
Galway.
Background: While management has evolved substantially, it is unknown whether the 
burden of end-stage renal disease from membranous nephropathy (end-stage membranous 
nephropathy, ESMN) has declined.
Methods: Here retrospective United States Renal Data System data were used to 
enumerate incidence trends and outcomes of ESMN in the US between 1995 and 2010 (n 
= 7035, overall rate 1.9 per million per year).
Results: When adjustment was made for demographic shifts, adjusted incidence ratios 
(AIR, compared to 1995-1996) rose to 1.15 in 1997-1998 and remained stable between 
1.09 and 1.14 in subsequent biennia. Other associations of ESMN included older age 
(AIR 4.08 for age 40-64 (Vs. < 20 yrs.), 9.55 for 64-79, and 8.09 for ≥ 80) male sex (AIR 
2.20) and Black/African American race (AIR 3.15 Vs. White). Incidence trends differed 
by age group: AIR fell for age 40-64 (0.84 in 2009-2010 [Vs. 1995-1996]) and rose for 
age ≥ 80 (AIR 2.63). ESMN patients were more likely than matched controls to be listed 
for transplant (9.8 vs. 7.5 per 100 person years [PHPY]) and to receive a transplant (7.4 
vs. 4.6 PHPY) and less likely to die (9.8 Vs. 15.9 PHPY). Among patients with ESMN, 
African American patients were as likely as whites to be listed for transplant (adjusted 
hazards ratio [AHR] 1.05), less likely to receive a transplant (AHR 0.61) and less likely 
to die prematurely (AHR 0.85).
Conclusions: While ESMN has not declined meaningfully in the last two decades, 
trends differ by age and racial disparities in outcomes on renal replacement therapy are 
apparent.
TH-PO746
42 Cases of Primary Sj|gren Syndrome with Membranous Nephropathy: 
Clinicopathologic Features and Ectopic Germinal Center Formation 
Mengyu Zhou, Yubing Wen, Jing Wang, Xiaoxiao Shi, Yang Yu, Hang Li, Mingxi 
Li, Xuemei Li, Xuewang Lee, Limeng Chen.  Dept of Nephrology, Peking Union 
Medical College Hospital, Beijing, China.
Background: To study the clinicopathologic features of primary Sjögren Syndrome 
(pSS) with membranous nephropathy (MN) from a single hospital center. Pathogenesis 
including the formation of ectopic germinal center (EGC) was explored.
Methods: From 1990 to 2014 in Peking Union Medical College Hospital, all pSS 
patients who underwent renal biopsy with a diagnosis of MN were reviewed. CD21 
immunohistochemistry study was used to characterize EGC formation.
Results: Among 154 pSS patients with a renal biopsy, 94 (61%) were diagnosed 
with glomerulonephritis, including 42 (45%) cases of MN. The majority were female 
(76.2%) with an age of 52.3±15.0 years. At the time of renal biopsy, the patients presented 
with microscopic hematuria (80.9%), proteinuria (4.57±3.11g/24h), hypoalbuminemia 
(26.5±7.3 g/L) with normal eGFR (92.8±26.3 ml/min). Hypergammaglobulinemia 
and hypocomplementemia were present in 26.8% and 20.5% patients respectively. 
Pathologically, 17 (40.5%) cases had atypical MN, featured by mesangial electron-dense 
deposit or C1q staining. On immunofluorescent study, C3 was positive in 43.9% cases 
and C1q positive in 34.1%. IgG subtype staining showed positivity of IgG4 (95%), 
IgG1 (55%), IgG3 (50%) but not IgG2. Most patients showed clinical improvement on 
prednisone (1mg/kg/d) and/or immunosuppressant (cyclophosphamide or cyclosporine), 
while 2 patients had progression of CKD with persistent or recurrent proteinuria. CD21 
staining on 36 available biopsy samples revealed the presence of EGC in 11 (31.4%) 
cases, and EGCs were notably abutting or surrounding the glomeruli in 7 cases. Grading of 
interstitial lymphocyte infiltration revealed the percentage of G0 (absent), G1 (scattered), 
G2 (focal) and G3 (EGC formation) to be 5.7%, 34.3%, 28.6% and 31.4%, respectively, 
which was negatively correlated with eGFR (p=0.008) and positively correlated with 
glomerulosclerosis index (p=0.001).
Conclusions: MN is the most common type of glomerulonephritis among pSS patients. 
Interstitial lymphocyte infiltration and EGC formation may be pathologically related to 
glomerular damage.
Funding: Government Support - Non-U.S.
TH-PO747
In Primary Membranous Nephropathy, Relapse After Partial Remission 
Is Predicted by Serum Albumin Level  Taewoo Lee,1 Vimal K. Derebail,1 
Daniel C. Cattran,2 Ronald J. Falk,1 Heather N. Reich,2 Patrick H. Nachman.1 
1UNC Kidney Center, Chapel Hill, NC; 2Toronto General Hospital, Toronto, 
ON, Canada.
Background: In primary membranous nephropathy (MN), partial remission (PR), 
defined as 50%reduction of proteinuria+attaining<3.5g/day with stable GFR, is associated 
with decreased risk of ESKD, compared to No remission. However, PR is associated 
with greater risk of relapse (46%,median 8 months) compared to complete remission 
(proteinuria<0.3g/day) (23%,median 25 months). Relapses are associated with increased 
risk of ESKD. We investigated risk factors of relapse among patients who achieve PR by 
18 months, thus simulating the setting of a clinical trial.
Methods: From the Glomerular Disease Collaborative Network cohort, we identified 
135 patients who had a minimum of 24 months of follow up from biopsy. Patients who 
reached a PR at 18 months were included for the analysis. Patients with a relapse (proteinuria 
>3.5g /day) were compared to those with no relapse. Risk factors for relapse were explored 
by logistic regression analysis. A threshold of serum albumin (salb) associated with risk of 
relapse was evaluated using a receiver operator curve (ROC).
Results: Among 86 patients who met inclusion criteria, 30(35%) relapsed over a 
median follow up of 33months. Patients with relapse were similar to those with no relapse 
with respect to baseline demographics, proteinuria, salb, eGFR and immunosuppressive 
treatment. Relapsers had significantly lower salb level at 18 months compared to non 
relapsers (3.47±0.68 vs 3.89±0.46 respectively; P=0.002). C-statistics from the ROC for 
salb as a predictor of relapse was 0.75. 22% of patients with salb>3.5 g/dl at 18 month 
relapsed (median time to relapse 174 months; 0.7/100 patient-month), compared to 72% of 
patients with salb£3.5 g/dl (median time 42months; 2.4/100 patient-month).
Conclusions: Attaining a PR and a salb> 3.5 g/dl at 18 months after biopsy is associated 
with a low risk of relapse. We suggest that a definition of PR should include attaining a 
salb> 3.5 g/dl in addition to the target decrease and level of proteinuria. This definition 
should be evaluated as a possible surrogate endpoint for clinical trials in MN.
TH-PO748
Clinical Significance and Risk Factor of Relapse in Proteinuria in Primary 
Membranous Nephropathy  Taewoo Lee,1 Vimal K. Derebail,1 Caroline J. 
Poulton,1 Ronald J. Falk,1 Daniel C. Cattran,2 Heather N. Reich,2 Patrick H. 
Nachman.1  1UNC Kidney Center, NC; 2Toronto General Hospital, ON, Canada.
Background: Achieving complete remission (CR) of proteinuria (<0.3 g/day) in 
primary membranous nephropathy (MN), is associated with excellent long-term renal 
outcome. Patients achieving partial remission (PR), defined as >50% reduction in proteinuria 
to <3.5 g/day with stable renal function, also show favorable prognosis compared to patients 
with no-remission (NR). Relapse in proteinuria is associated with a higher risk of ESKD. 
We investigated the risk factors of relapse in patients who have achieved a PR at any point.
Methods: To identify variables associated with relapse we studied 466 patients with 
primary MN registered in the Glomerular Disease Collaborative Network. 293 patients 
with at least 12 months of follow up were included. Time-to-event analysis from the time 
of PR to relapse was performed to evaluate risk factors for development of relapse. We 
incorporated various changes of remission status (PR, CR, and NR) during follow-up as 
time-dependent variable along with baseline patient characteristics.
Results: Of 293 patients, 213(83%) achieved PR and 80 (17%) had NR. Among 
patients with PR, 95 patients (45%) reached CR, and 118 (55%) remained in PR until the 
last follow-up or relapse. A total of 63 relapses were observed (48 from PR and 15 from 
CR). By univariate analysis, older age, male sex, higher baseline proteinuria, PR (vs CR) 
and lower serum albumin (sAlb) at PR were significantly associated with increased risk 
of relapse. Higher sAlb at PR was associated with a lower risk of relapse (HR, 0.49 [95% 
CI, 0.289-0.831]) adjusted for age, sex, proteinuria at baseline, and immunosuppressive 
therapy. 34% of patients with sAlb £3.5g/dl at PR had a relapse (median time to relapse 
7.4 months ) compared to 20% relapsers among patients with sAlb >3.5g/dl (median time 
21.8 months; P<0.001).
Conclusions: A serum albumin level > 3.5 g/dl when patient achieve first PR is 
associated with a low subsequent risk of relapse. We suggest that incorporating a normalized 
serum albumin level into the definition of PR would improve its predictive value of 
subsequent outcome.
TH-PO749
Clinical Implication of BAFF and APRIL in Membranous Nephropathy 
Seung Seok Han, Eunjin Bae, Kwon Wook Joo, Yon Su Kim, Dong Ki Kim. 
Internal Medicine, Seoul National Univ College of Medicine, Seoul, Korea.
Background: BAFF and APRIL have a role in B cell development. Additionally, 
these are related with several autoimmune diseases. However, the clinical implication of 
BAFF and APRIL remains unresolved in patients with membranous nephropathy (MN).
Methods: 84 patients with primary MN were recruited, and their plasma BAFF 
and APRIL levels at the time of diagnosis were compared with the data on patients with 
secondary MN (n=13) and healthy individuals (n=111). The time to complete remission 
was used as primary outcomes and the hazard ratios (HRs) by plasma BAFF and APRIL 
levels were calculated after adjustment of multiple variables.
Results: The plasma BAFF levels in primary MN (0.94 ± 0.26 ng/mL) were 
significantly higher than those of healthy individuals (0.54 ± 0.16 ng/mL) and lower than 
of secondary MN (1.59 ± 1.09 ng/mL). For the APRIL, a substantial number of primary MN 
patients (n=51) had undetectable plasma level. The APRIL levels of primary MN (0.73 ± 2.50 
ng/mL) were similar to the levels of healthy individuals (0.54 ± 0.16 ng/mL), but lower than 
those of secondary MN (8.07 ± 25.68 ng/mL). The BAFF levels were positively associated 
with the auto-PLA2 antibody titers, but the APRIL levels were not. The cumulative rates 
of complete remission were significantly different between APRIL groups (undetectable, 
low level, and high level) (Figure 1), in contrast to the similar remission rates between the 
BAFF tertile groups. Patients with high plasma APRIL attained the complete remission 
lower than patients with undetectable level: adjusted HR, 0.29 (0.089–0.921); P=0.036.
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Conclusions: The present study first demonstrates the plasma levels of BAFF and 
APRIL and their predictability for outcome in patients with membranous nephropathy.
TH-PO750
The Clinical and Prognostic Significance of Segmental Glomerulosclerosis 
Among Patients with Idiopathic Membranous Nephropathy  Hala M. KFoury, 
Sufia Husain, Abdulkareem Alsuwaida, Mohammed A. Al-Ghonaim, Saad S. 
Alobaili, Tariq Aljohani, Tameem Ashry, Jamal S. Al Wakeel.  College of 
Medicine, King Saud Univ, Riyadh, Saudi Arabia.
Background: Idiopathic membranous nephropathy (iMN) is a main cause of nephrotic 
syndrome in adults. In this study, we attempt to examine the relationship between segmental 
glomerular sclerosis in iMN and progression towards chronic kidney disease.
Methods: The study included 89 patients with iMN, followed over sixteen years, to 
evaluate the prognostic significance of glomerular segmental sclerosis in terms of renal 
survival. In the two groups (one with and one without segmental sclerosis), we analyze 
the various factors that are prognostic in iMN (eg. serum creatinine, proteinuria, etc.) and 
the histologic parameters.
Results: Segmental glomerulosclerosis was noted in 41 (46.1%) of 89 cases with 
iMN, representing cases from 57 (64.0%) males and 32 (36.0%) females. The prevalence 
of interstitial fibrosis and tubular atrophy did not contrast substantially between the two 
respective groups (3.38 ± 7.8 versus 1.22 ± 3.3, p=0.137). Only IgM positivity among the 
sclerosis group, compared to the non-sclerosis group was statistically significant (48.8% 
versus 25.0%, p=0.02). The median serum creatinine was significantly different among 
the two groups of 101 µmol/l in cases with sclerosis vs. 92 µmol/l among cases without 
sclerosis, p =0.059. The baseline proteinuria recorded was 2.2 gm and 2.9 gm per day in 
the two respective groups, p value=0.9. At last follow up, the median serum creatinine was 
similar among the two groups (median 90 µmol/l and 81 µmol/l, respectively).
Conclusions: Our study revealed that segmental glomerulosclerosis was not associated 
with the severity of interstitial fibrosis. Although baseline serum creatinine was higher in 
patients with glomerulosclerosis at the time of biopsy, there was no impact on longterm 
outcome of the patients. Further studies are needed to outline the therapeutic regimen in 
iMN with segmental glomerulosclerosis.
TH-PO751
Clinical Features and Outcomes of Membranous Nephropathy with 
Crescents  Jia Wang,1 Ping Zhu,2 Zhao Cui,1 Minghui Zhao.1  1Renal Div, Dept 
of Medicine, Peking Univ First Hospital, Beijing, Beijing, China; 2Renal Div, 
Dept of Medicine, The First College of Clinical Medical Science, China Three 
Gorges Univ, Yichang, Hubei, China.
Background: Cases of membranous nephropathy with crescents have been reported, 
in the absence of lupus, HBV-associated glomerulonephritis, anti-glomerular basement 
membrane nephritis, or antineutrophil cytoplasmic antibody. Disease presentation and 
outcomes of these patients are unclear.
Methods: All patients with biopsy-proven MN, diagnosed from 2008 to 2014 and 
followed up, were enrolled retrospectively. Patients with ANCA, anti-GBM antibodies, 
lupus, malignance or HBV infection were excluded. Clinical features and outcomes were 
compared between patients with crescentic MN and non-crescentic MN.
Results: In 401 consecutive patients with primary MN, 28 (6.9%) patients having 
crescent formation. All patients presented with proteinuria (6.5±4.8 g/24 h) and hematuria. 
21.4% of patients had declined eGFR (<60ml/min/1.73m2) on biopsy. Glomeruli showed 
on average 4.9% (range, 2.2-16.7%) involvement by crescents. Tubular atrophy was more 
common in these patients (96.3% vs. 78.6%, P=0.031). 12 (42.9%) patients received 
immunosuppressive therapy, similar to those with non-crescentic MN (41.33%). Fewer 
patients achieved remission in those with crescentic MN (67.9% vs. 86.7%. P=0.029). 
Crescent formation was a risk factor for no remission of treatments (RR=3.079, P=0.033). 
Higher percentage of crescents in glomeruli was also susceptible for no remission 
(RR=1.166, P=0.038). During follow-up, more patients with crescentic MN presented with 
eGFR decline (10.7% vs. 1.3%, P=0.031). Crescent formation was a risk factor for worse 
renal outcome (RR=10.24, P=0.046).
Conclusions: MN patients with crescent formation showed inferior response to 
treatments and worse renal outcome during follow-up, although the baseline clinical 
characters were similar on biopsy. The crescent was a risk factor for poor prognosis of 
MN patients.
Funding: Government Support - Non-U.S.
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Prevalence of Cancer in Membranous Nephropathy Patients 
Yasuyuki Nagasawa, Sayuri Kawada, Mana Yahiro, Yuki Morikami, Tomoko 
Kimura, Kiyoko Yamamoto, Aritoshi Kida, Masayoshi Nanami, Yukiko Hasuike, 
Takahiro Kuragano, Takeshi Nakanishi.  Dept of Internal Medicine, Div of 
Kidney and Dialysis, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Background: Membranous Nephropathy is one of major primary glomerulonephritis. 
This disease was known to have high prevalence of cancer. Recent meta-analysis reported 
that estimated prevalence of cancer in membranous nephropathy patients was 10%[95%CI, 
6.1-14.6] (Leeaphorn-N et al, Am J nephrol,2014). The aim of this study is to reveal the 
prevalence of cancer with image investigation information.
Methods: This study is retrospective cohort study. Among 720 cases who receive 
renal biopsy from 2000 to 2012 in Hyogo College of Medicine University Hospital, 73 
membranous nephropathy patients were enrolled sequentially in this study. Exclusion 
Criteria is secondary membranous nephropathy induced by collagen diseases, such as Lupus 
nephritis. Information about cancer and image scanning was collected from medical records.
Results: Mean age was 60.2±15.2 years old. Male was 49% and Female was 51%. 
Patients with smoking was 55% (Current 24%, Past 31%), and alcohol Drinking was 48%. 
Chest Xp and fecal occult blood examination were done for all patients. Gastroscope was 
done for 20 cases (27%), abdominal CT was done for 33 cases (45%), and chest CT was 
done for 31 cases (42%) according to the risk factors. At renal biopsy, 6 patients had past 
history of cancers; larynx, uterine body, renal, epipharynx, and colon cancers (2 cases). 3 
patients were diagnosed as cancer around renal biopsy; thyroid, gastric, and colon cancers. 
7 patients were suffering from cancers after renal biopsy; lung renal, cervical cancer, breast, 
tongue, and colon cancers. The prevalence of all cancers (both at renal biopsy and after 
diagnosis of membranous nephropathy) was 20.8%. Prevalence of cancer in membranous 
patients seemed to be higher than Caucasian membranous cohort. The previous review 
reported that only 20% cancers were found at renal biopsy, although our result suggested 
46% cancers were diagnosed at renal biopsy, probably because of high prevalence of 
advanced imaging check-up of cancers.
Conclusions: The prevalence of cancer in membranous patients was 20.8%.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
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Efficacy of Low-Dose Prednisone Treatment Combined with Mizoribine 
on Idiopathic Membranous Nephropathy and Nephrotic Syndrome 
Yoshihiro Matsumoto, Yasushi Shimada, Youichi Nojima, Kimitoshi Shiratori. 
Nephrology and Dialysis, Shizuoka City Hospital, Shizuoka, Japan.
Background: Idiopathic membranous nephropathy (IMN) patients with persistent 
high-grade proteinuria are at the highest risk for developing end-stage renal failure. 
We previously reported the effects of treatment with mizoribine followed by low-dose 
prednisone in 4 IMN patients. The purpose of the present study was to further assess the 
effects of this combined treatment in a larger study group.
Methods: Twenty-two patients with IMN and nephrotic-range proteinuria received 
combined treatment. Mizoribine was initiated at a dose of 150 mg/day, and 1–3 months 
later, 20 mg/day prednisone was added to mizoribine regimen. The dosage of prednisone 
and/or mizoribine was tapered according to the urinary protein-to-creatinine ratio (P/C). 
We evaluated patient responses for up to 36 months after initiation of combination therapy.
Results: Before treatment, patient urinary P/C ranged from 2.8 to 15.9 g/g. Although 
these values did not decrease during mizoribine monotherapy, all patients showed 
P/C decreases over the course of combination therapy. At 12, 24, and 36 months after 
combination therapy, 55% (12/22), 70% (14/20), and 79% (11/14) of patients attained 
complete remission, respectively. The 21 patients of 22 (95%) attained partial or complete 
remission at 12 months after combination therapy. Side effects including fracture were 
observed in 4 patients.
Conclusions: The addition of prednisone after mizoribine monotherapy can be 
beneficial for most of all IMN patients with nephrotic syndrome. The risks associated 
with immunotherapy can be decreased by initially prescribing mizoribine alone, which 
might act as a base for establishing therapy, followed by low-dose prednisone treatment.
TH-PO754
Response to Immunosuppressive Therapy in PLA2R-Associated IMN and 
Non-PLA2R-Associated IMN  Jia Wang, Qionghong Xie, Chuanming Hao. 
Div of Nephrology, Huashan Hospital, Shanghai, China.
Background: According to the renal PLA2R immunohistochemistry, iMN could 
be categorized into PLA2R-associated and non-PLA2R-associated iMN. We conducted 
a retrospective, multicenter cohort study of 99 patients to compare the effect of 
immunosuppressive therapy on PLA2R-associated and non-PLA2R-associated iMN patients.
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Methods: 99 biopsy-proven iMN patients were collected from Huashan hosipital 
and Peolple’s hosipital of Wuxi in past 5 years. The iMN with positive PLA2R 
immunohistochemistry in kidney biopsies were designated as PLA2R associated MN. 79 
of the 99 iMN patients were PLA2R-associated iMN and 13 were non-PLA2R-associated 
iMN. 49 patients were treated with prednisone plus CTX, and fifty with prednisone plus 
CNIs. 95% of the patients were on ACEI/ARB. The patients were followed for 15 months.
Results: The baseline characteristics between the PLA2R-associated and non-
PLA2R-associated iMN was demonstrated in Table 1 (left part). In patients with non-
PLA2R-associated MN, the remission rate at 3-month was significantly higher than that 
in PLA2R- associated group (table 1 right part). Relapses were observed in 8 patients of 
PLA2R-associated group and none of non-PLA2R-associated group.
PLA2R 
(+) 
(n=78)
PLA2R 
(-) (n=13) P
PLA2R 
(+) 
(n=78)
PLA2R   
(-) 
(n=13)
P
CTX% 47.4% (37/78)
61.5% 
(8/13) 0.346
3 month-
remission 44.9% 76.9% 0.032
gender (M:F) 52:26 5:8 0.102 3 months-CR 2.6% 30.8% 0.003
age 53.81± 14.64
53.54± 
17.52 0.953
6 month-
remission 64.1% 76.9% 0.557
urine protein 
(g/24h)
5.51 
(4.02, 
7.72)
5.23 
(2.34, 
12.51)
0.829 6 months-CR 11.5% 46.2% 0.007
albumin 
(g/L)
19.45± 
5.05
21.58± 
9.07 0.423
9 month-
remission 77.3% 91.7% 0.455
creatinine 
(ȝmmol/L)
78 
(61.65, 
93.75)
68.6 (60, 
132.5) 0.875
9 months-
CR 24.2% 50.0% 0.140
cholesterol 
(mmol/L)
7.86± 
2.69
6.93± 
1.88 0.238
12month-
remission 79.7% 100% 0.197
triglyceride 
(mmol/L)
2.1 (1.77, 
3.21)
1.82 
(1.57, 
2.98)
0.434 12month-CR 27.1% 50% 0.222
Conclusions: The non-PLA2R- associated IMN responded quicker to the 
immunosuppressive therapy compared with PLA2R-associated IMN, and relapses were 
more frequent in PLA2R-associated IMN. Non-PLA2R- associated IMN may have a better 
response to immunosuppressive therapy.
Funding: Government Support - Non-U.S.
TH-PO755
Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 
Domain-Containing 7A in Glomeruli in Japanese Patients with Idiopathic 
Membranous Nephropathy  Takamasa Iwakura,1 Naro Ohashi,1 Akihiko Kato,2 
Hideo Yasuda.1  1Internal Medicine 1, Hamamatsu Univ School of Medicine, 
Hamamatsu, Shizuoka, Japan; 2Blood Purification Unit, Hamamatsu Univ 
School of Medicine, Hamamatsu, Shizuoka, Japan.
Background: Membranous nephropathy (MN) is a leading cause of nephrotic 
syndrome in adults. Autoantibodies against M-type phospholipase A2 receptor (PLA2R) 
and thrombospondin type-1 domain-containing 7A (THSD7A) were reported as the 
primary causes of MN. Although PLA2R is a major pathogenic factor for idiopathic MN, 
the prevalence of MN patients seropositive for PLA2R in Japan is lower than in other 
countries. In this study, we conducted immunohistochemical analysis of the presence of 
THSD7A and PLA2R in renal specimens of MN patients to estimate the prevalence of 
THSD7A/PLA2R-related idiopathic MN in Japan.
Methods: All patients with the histologic diagnosis of MN in adults made in our 
institution between 1995 and 2015 were included in this study. Immunohistochemical 
analysis for THSD7A and PLA2R were performed to these patients, and samples showing 
enhanced granular staining along capillaries of glomeruli were recognized as histologically 
positive for THSD7A and/or PLA2R. We collected the clinical information and laboratory 
data at the time of biopsy in order to classify MN patients into primary and secondary, 
and in order to compare characteristics of patients with enhanced expression of THSD7A 
and that of PLA2R.
Results: Enhanced granular expression of THSD7A and PLA2R was detected in 9.1% 
and 52.7%, respectively, of the patients with idiopathic MN. Although none of patients 
with secondary MN displayed enhanced granular expression of THSD7A, 5.4% of them 
had enhanced granular expression of PLA2R.
Conclusions: The prevalence of enhanced granular expression of THSD7A in glomeruli 
in Japanese patients with idiopathic MN was higher than the prevalence of MN patients 
seropositive for THSD7A in USA and Europe. This higher prevalence of THSD7A-related 
MN is likely associated with the lower prevalence of PLA2R-related MN in Japan.
TH-PO756
PLA2R Autoantibodies and Glomerular PLA2R Deposit in Membranous 
Nephropathy: How to Evaluate the Roles They Played?  Huazhang Qin, 
Wei-bo Le, Ming-chao Zhang, Caihong Zeng, Hao Chen, Qiang Ren, Da cheng 
Chen, Ke Zuo, Feng Xu, Zhihong Liu.  National Clinical Research Center 
of Kidney Diseases, Research Inst of Nephrology, Jinling Hospital, Nanjing, 
Jiangsu, China.
Background: Higher Glomerular PLA2R-Antigen deposit (GAg) rates compared 
with the serum Phospholipase A2 receptor-Antibody (SAb) positive rates were reported. 
However, the exact roles played by this two biomarkers remained unknown.
Methods: A total of 572 patients diagnosed IMN were included. Both SAb and GAg 
were detected . Fifty-two IMN patients received repeat renal biopsy were also included.
Results: In the 572 patients, 401 (70.1%) were SAb positive (SAb+) while 171 (29.9%) 
were SAb negative (SAb-). In SAb+ patients, the glomerular PLA2R-Antigen deposition 
(GAg+) was observed in 99.1% (397/401). Interestingly, the GAg+ was observed in 68.4% 
(117/171) SAb- patients. Patients with SAb manifested more severe proteinuria (3.9 g/24h vs 
2.8 g/24h, P<0.001) and lower eGFR (104 ml/min.1.73m2 vs 110 ml/min.1.73m2, P=0.002) 
than patients without SAb. Further comparison between patients with SAb+/GAg+ and 
SAb-/GAg+ showed a similar profile (more severe clinical manifestation in patients with 
SAb). Patients with SAb+/GAg+ also showed lower chance of proteinuria remission and 
higher chance of renal function decline in the follow up when compared to patients with 
SAb-/GAg+. Changes of SAb and GAg were observed in patients with repeat renal biopsy, 
in 11 patients the SAb+ turned into SAb-, among them 1 patients failed to achieve remission, 
7 patients achieved remission and 4 remitted during the interval but relapsed at the time of 
repeat biopsy. While the GAg+ turned into GAg- in only 3 patients, all achieved remission 
at the repeat biopsy. The proportion of GAg disappearance was lower than SAb (P=0.016).
Conclusions: The GAg deposit can be detected in a large proportion of SAb negative 
patients, which can be explained by the lag of GAg disappearance in the follow up. The 
SAb was more tightly correlated to disease activity ,treatment response and prognosis than 
the GAg. We recommend adopting GAg deposit detection as a supplement to SAb in IMN 
diagnosing and keeping on monitoring SAb in the follow up.
Funding: Government Support - Non-U.S.
TH-PO757
Phospholipase A2 Receptor Autoantibody in Membranous Nephropathy 
Complicated with HIV Infection  Weifeng Lin,1,2 Xin Zhang,1 Jianing Li,1 Hang 
Li,1 Jianfang Cai,1 Xuemei Li,1 Yubing Wen,1 Xuewang Li.1  1Dept of Nephrology, 
Peking Union Medical College Hospital; 2Peking Union Medical College.
Background: When membranous nephropathy (MN) complicated with HIV-infection, 
it’s difficult to discriminate the relationship between them. MN is idiopathic or secondly to 
HIV-infection? The therapy should cover MN, HIV or both? Although PLA2R autoantibody 
is a potential biomarker for the differential diagnosis of idiopathic and secondly MN, its 
role in MN complicated with HIV-infection is unknown.
Methods: 6 patients with biopsy-proven MN complicated with HIV-infection admitted 
to Peking Union Medical College Hospital from 2011 January to 2015 March were recruited 
in this study. 5 HIV-infection patients without nephropathy were selected as control 
group. Serum PLA2R autoantibody in all patients were detected by ELISA method. The 
serum samples of MN group were collected at renal biopsy. The medical records were 
retrospectively reviewed.
Results: The antibody was found in most patients with MN complicated with HIV-
infection (5/6). However, the antibody in HIV-infection without nephropathy were all 
negative (5/5). The basic line of clinical data in 6 MN complicated with HIV-infection 
patients were as follows: all males, 24h-UP (12.62±6.65)g/d, serum albumin (19.16±5.49)
g/L, and serum creatinine (81.7±30.17)mmol/L. Table1 shows antibody test results, 
treatments and renal outcomes in 6 MN patients. Table1 6 patients with MN complicated 
with HIV-infection.
Patient NO.1a NO.2 NO.3 NO.4 NO.5 NO.6
Nephrotic 
Syndrome (+) (+) (+) (+) (+) (+)
PLA2R antibody (-) (+) (+) (+) (+) (+)
Treatment
HAARTb
ACEIc
GCSd
HAART
ACEI
GCS+ 
CsAe
HAART
ACEI 
GCS+ 
CTXf
HAART
ACEI ACEI
HAART
ACEI
Renal outcome PRg CRh CR PR PR SRi
a also had HBV infection. bhighly active antiretroviral therapy. c angiotensin converting enzyme 
inhibitors. d glucocorticoids. e Cyclosporine A. f cyclophosphamide. g partial remission. h complete 
remission. i spontaneous remission before HAART and ACEI therapy.
Conclusions: MN complicated with HIV-infection seems to be two independent 
diseases if PLA2R autoantibody is positive. First line immunosuppressive therapy is likely 
necessary for MN complicated with HIV-infection if antibody is positive.
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TH-PO758
Comparison of Outcomes Between Individuals with Pure and Mixed Lupus 
Nephritis: A Retrospective Study  Nosayaba Enofe,1 Anju A. Oommen,1 Jason 
Cobb,1 Jose E. Navarrete,1 Demilade Adedinsewo,2 Oluwatobiloba A. Osikoya,3 
Helene B. Fevrier,4 Alton Brad Farris,5 Laura Plantinga,1 Titilayo O. Ilori.1  1Dept 
of Nephrology, Emory Univ School of Medicine, Atlanta, GA; 2Morehouse School 
of Medicine, Atlanta, GA; 3Lee Univ, Cleveland, TN; 4Dept of Epidemiology, 
Rollins School of Public Health, Emory Univ, Atlanta, GA; 5Dept of Pathology 
and Laboratory Medicine, (mory Univ School of Medicine, Atlanta, GA.
Background: Lupus nephritis (LN) is divided into six classes (ISN/RPS Class I to VI) 
but can occur as a mixture of two classes. Pure proliferative LN (PPLN) comprises Class 
III or Class IV only while mixed proliferative and membranous LN (MPLN) comprises 
combinations of Class III & V or Class IV & V. Our aims were to compare individuals 
with biopsy-proven PPLN vs. MPLN in terms of clinical presentation and outcomes of 
complete or partial remission at 2 years and end-stage renal disease (ESRD)] and clinical 
predictors of outcomes.
Methods: A retrospective review of all adult (>18) LN patients (n=278; PPLN (n=60) 
and MPLN (n=96)) identified from a native renal biopsy registry at a hospital network 
performed January 2000-December 2011. We assessed associations of LN category 
(MPLN vs. PPLN) with: time to remission (define as ≥ 25% improvement in eGFR if 
baseline abnormal and urine protein creatinine ratio <0.5) and ESRD (defined using ICD-
9 diagnosis code - 585.6 or the onset of chronic renal dialysis) using multivariable Cox 
proportional hazards analysis.
Results: The population was predominantly female (84.0%) and African American 
(71.8%), with a mean age of 33.4. Over follow-up (median, 1.5 years), using the PPLN 
group as the reference group, we did not find any associations between MPLN and time 
to remission (HR=0.13, 95% CI = 0.01-1.36) or ESRD (HR=0.30, 95% CI = 0.07-1.26). 
Baseline eGFR was significantly associated with time to remission (HR = 0.90, 95% CI 
= 0.84 - 0.98).
Conclusions: We found no significant differences in remission or progression to ESRD 
between patients with PPLN and MPLN. We, however, demonstrated that higher baseline 
eGFR at presentation were important factors in achieving remission in individuals with LN.
TH-PO759
Pure Class V Lupus Nephritis: Towards a Better Understanding of Lupus 
Membranous Nephropathy Compared to Its Proliferative Counterparts 
Fernanda Payan Schober, Keisha L. Gibson, Taewoo Lee, Caroline J. Poulton, 
Mary Anne Dooley, William Franklin Pendergraft.  UNC Kidney Center, UNC 
Chapel Hill, Chapel Hill, NC.
Background: Class V lupus nephritis, also known as lupus membranous nephropathy, 
accounts for approximately 10-20% of patients with lupus nephritis. There is not a consensus 
on the best treatment for isolated class V lupus nephritis, so providers often turn to the 
proliferative lupus nephritis and idiopathic membranous nephropathy (IMN) literature to 
extrapolate treatment approaches and outcomes. Here we compare clinical data between 
patients with lupus membranous, proliferative lupus nephritis and IMN.
Methods: Clinical and treatment data for lupus membranous patients were extracted 
from electronic medical records starting at the time of diagnosis until date of chart review.
Results: Patients with lupus membranous resembled the lupus nephritis population 
more than the IMN population as they were more likely to be African American women 
in the fourth decade of life. At presentation, lupus membranous patients had preserved 
kidney function but significant proteinuria, much like patients with IMN. Almost all of these 
patients (94%) received immunosuppression. At mean follow up of 7.1 years, the mean 
serum creatinine remained 1.1 mg/dl, but proteinuria improved to a mean of 1.6 gram/day. 
Lupus Membranous 
(n=41)
Lupus Nephritis 
(n=601)
Idiopathic Membranous 
(n=558)
Female:Male (%) 37:4 (90:10) 510:90 (85:15) 216:342 (39:61)
Age (mean) 34 + 16 34 + 16 53+ 15
Ethnicity (%)
Caucasian
African American
Asian
American Indian
Other 
Unknown
3 (7)
35 (85)
1 (2)
1 (2)
1 (2)
0 (0)
200 (33)
297 (49)
8 (1)
9 (1)
25 (4)
62 (10)
412 (74)
92 (16)
1 (0.1)
1 (0.1)
12 (2)
38 (7)
Serum Creatinine 
(mg/dl) 1.1 + 0.6 1.56 + 2.3 1.4 + 1.3
Serum Albumin 
(mg/dl) 3.2 + 4 1.5 +1.8 2.6 +0.8
Proteinuria (gm) 8.4 + 13 4.3 + 26 8.2+16
Conclusions: Patients with lupus membranous make up a substantial portion of patients 
with lupus nephritis. They present with significantly more proteinuria than patients with 
proliferative lupus nephritis, but have less kidney impairment. There’s a clear need for more 
prospective multi-center randomized controlled studies to determine the most effective 
treatment in this population.
Funding: NIDDK Support
TH-PO760
Necrotizing Glomerular Lesions Portend a Worse Prognosis for Patients 
with Lupus Nephritis  Fernanda Payan Schober,1 Keisha L. Gibson,1 Mary 
Anne Dooley,1 Elizabeth R. Blyth,1 Caroline J. Poulton,1 Harsharan Kaur Singh,2 
Volker Nickeleit,2 William Franklin Pendergraft.1  1UNC Kidney Center, UNC 
Chapel Hill, Chapel Hill, NC; 2UNC Pathology, UNC Chapel Hill, Chapel 
Hill, NC.
Background: Necrotizing glomerular lesions on kidney biopsy are uncommonly 
found in patients with lupus nephritis (LN) and are similar in appearance to those lesions 
found in patients with ANCA glomerulonephritis. The presence of these lesions portends 
a worse prognosis and has been reported previously to be more common in patients of 
African descent. Here we describe the clinical and histologic features of 48 patients with 
lupus nephritis and necrotizing glomerular lesions on native kidney biopsy.
Methods: Patients with lupus nephritis who had necrotizing and crescentic lesions 
were identified from the UNC Division of Nephropathology database. Clinical, histologic, 
treatment, and long-term outcome data were obtained from the electronic medical record.
Results: Demographic and histologic data are shown in the following table. Most 
notably, these patients were predominantly African American women with class IV lupus 
nephritis high overall disease activity.
Tuft Necrosis
(n=48)
Female
Male
41 (87%)
7 (14%)
Ethnicity 
Caucasian
African American
Hispanic
Asian
American Indian
11 (23%)
32 (67%)
3 (6%)
1 (1%)
1 (1%)
Age 34 + 12
Serum creatinine (mg/dl) 1.64 +1.3
Proteinuria (gm) 3.71 + 3.1
LN Histologic class
II
III
IV
V
Mixed
2 (5%)
4 (5%)
24 (56%)
3 (7%)
10 (23%)
Activity Index 10.9 +3.6
Chronicity Index 3.5 + 2.8
£SLEDAI 11.1 + 9.6
Conclusions: This cohort represents one of the largest of its kind in the literature to 
date. Necrotizing lesions are more characteristic of pauci-immune ANCA vasculitis, but have 
been described in patients with lupus nephritis as well. This rare variant is an understudied 
glomerular disease that portends a poor prognosis with an increased risk of progression to 
ESKD.  There is a need for prospective multi-center treatment studies to determine durable 
therapeutic avenues. Korbett, et al.Severe lupus nephritis:Racial differences in presentation 
and outcome. JASN.18:244-254.2007.
Funding: NIDDK Support
TH-PO761
Membranous Lupus Nephritis: Immunoglobulin Deposits and Clinical 
Correlations  Eduardo J. D. de Sa Carneiro Filho, Alcino Gama, Leonardo 
Abreu Testagrossa, Denise M. Malheiros, Luis Yu, Cristiane B. Dias, Lectícia 
Jorge, Viktoria Woronik.  Nephrology Div, Univ of São Paulo, São Paulo, Brazil.
Background: Lupus nephritis histological hallmark, mostly in proliferative classes, 
is a “full house” (FH) pattern of immunoglobulin deposition and complement. However, 
Haas showed that membranous lupus nephritis (MLN) depicted this pattern only in 65% of 
the patients. The importance of FH deposition in MLN disease is still a matter of debate. 
It remains to be determined association between immunoglobulin deposition with clinical 
disease aggressiveness or transformation into proliferative forms.
Methods: All MLN patients submitted to kidney biopsies from July 1999 to 
August 2007 were included and biopsy tissue was studied by light microscopy and 
immunofluorescence. Patients were classified according to immunoglobulin glomerular 
capillary wall deposition in rich (rIF), with two or more deposited immunoglobulins, and 
poor (pIF) with a single and exclusive IgG deposition. Clinical and laboratorial data were 
collected at baseline, after one year and at the end of follow-up. Treatment was decided 
based on literature protocols.
Results: We included 15 patients in pIF group and 46 in rIF. At baseline, groups were 
similar regarding age, complement level, ANA, anti-DNA and proteinuria. Interestingly 
pIF was significantly associated with a lower eGFR at baseline that persisted after one year 
follow-up. At the end, the pIF showed a not significant tendency to lower eGFR.
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rIF pIF p
N 46 15
Age 33±10 34±12
MDRD Baseline 96±34 78±40 0.04
MDRD after 1 year 103±32 76±40 0.01
MDRD Final 80±39 63±33 ns
PTN Baseline (g/day) 4.6±3.6 4.4±5.7 ns
PTN Final (g/day) 1.2±1.8 2.1±3.8 ns
C3 (mg/dL) 85±32 96±52 ns
Hematuria Baseline 39% 46% ns
ACLIgG Baseline 54% 71% ns
ACLIgM Baseline 45% 64% ns
Mesangial Hypercellularity 76% 53% ns
Immunosuppression
Pred 22% 50% ns
Double 78% 50% ns
Conclusions: We found 25% of MLN patients with only one deposited immunoglobulin. 
The poor IF group compared to rich IF showed lower MDRD at baseline and even after 
one year. Studies are needed to elucidate the role of different patterns of deposits in the 
pathogenesis of MLN.
TH-PO762
Segmental versus Global Subclasses of Proliferative Lupus Nephritis: 
Clinical Correlations  Eduardo J. D. de Sa Carneiro Filho, Alcino Gama, 
Mariana Pin de Andrade, Beatriz Holanda, Leonardo Abreu Testagrossa, Denise 
M. Malheiros, Luis Yu, Cristiane B. Dias, Lectícia Jorge, Viktoria Woronik. 
Nephrology Div, Univ of São Paulo, São Paulo, Brazil.
Background: The International Society of Nephrologists and Renal Pathology 
Society classification of lupus nephritis proposes a subclassification of proliferative forms 
into segmental (S) and global (G). Data comparing renal outcomes between these two 
subclasses is controversial and pathogenesis also seems to differ (Bariéty J, 2005). We 
aimed to compare histopathology with clinical correlations.
Methods: Seventy-one biopsy-proven patients with proliferative (classes III or IV) 
lupus nephritis data were retrospectively analyzed. Twenty-nine of them were classified as 
global and 42 as segmental. All procedures were performed in one single center between 
2004 and 2014.
Results: All patients received induction therapy with steroids plus either intravenous 
cyclophosphamide monthly pulses or daily oral mycophenolate mofetil. Although there was 
no difference in age, eGFR and hemoglobin levels at baseline (see table), after a median 
follow-up of 3.6 years the global subgroup had worse renal outcome (final eGFR 59.6 ± 37.6 
vs 78.9 ± 28.4, p 0.02). During follow-up, there was also a tendency for faster eGFR recovery 
rate in segmental subgroup after treatment (5.2 vs 1.8 ml/min/year, p 0.2). Interestingly, 
the prevalence of males in global subgroup was significantly higher (20% vs 4%, p 0.03).
Global Segmental p
N 29 42
Baseline features
%Male 20% 4% 0.03 
Age (y) 31.8±12 31.5±9 ns 
Hb (mg/dL) 10.9±1.4 11±1.1 ns 
MDRD Baseline (ml/min/1.73m2) 55.2±26 63.9±27 ns 
Follow-up features
Follow-up (y) 3.63 3.62 ns 
MDRD Final (ml/min/1.73m2) 59.6±37.6 78.9±28.4 0.02 
MDRD Delta per year +1.8±2.3 +5.2±2.9 0.2 
Conclusions: In global compared to focal proliferative lupus nephritis patients: male 
sex prevailed and renal function decreased on 3.6 years follow-up in spite of similar MDRD 
on baseline. Prospective studies are necessary to determine if histological pattern is relevant 
to guide the clinician’s therapy choice.
TH-PO763
Renal Pathological Classification in Lupus Nephritis: What Else We Can 
Tell?  Yang Jing, Dandan Liang, Haitao Zhang, Zheng-zhao Liu, Wei-bo Le, 
Minlin Zhou, Weixin Hu, Caihong Zeng, Zhihong Liu.  National Clinical 
Research Center of Kidney Diseases, Research Inst of Nephrology, Jinling 
Hospital, Nanjing, Jiangsu, China.
Background: To observe the discrepancy between class III and class III+V, between 
class IV and class IV+V, and between subclass IV-S and IV-G on clinicopathological 
features and renal outcomes and explore the pathological lesions associated with poor 
renal outcomes in patients with different classes.
Methods: The records of all adult patients with biopsy-proven proliferative lupus 
nephritis followed for at least 1 year were reviewed. All patients were pathologically 
classified according to the 2003 ISN/RPS classification of lupus nephritis and each 
pathological lesion was semiquantatively scored.
Results: Patients with class III+V (class IV+V) presented with more severe proteinuria 
and chronic pathological lesions and milder acute pathological lesions than patients with 
class III (class IV); patients with subclass IV-G presented with more severe hypertension, 
proteinuria and hypocomplementemia, lower ANCA positivity rate, more severe glomerular 
cell proliferation and hyaline deposit, and milder fibrinoid necrosis and crescent than 
patients with subclass IV-S. The renal outcomes between patients with class III and class 
III+V, between class IV and class IV+V, and between subclass IV-S and subclass IV-G were 
not different respectively. Global glomerulosclerosis, cellular crescent, fibrous crescent, 
glomerular cell proliferation, tubular acute injury, interstitial inflammation and TMA were 
predictors for ESRD.
Conclusions: LN patients with proliferative lesions combined with membranous lesions 
presented with both clinicopathological characteristics of the two types of lesions, but their 
renal outcomes were not different from patients with pure proliferative lesions. Patients 
with subclass IV-S and subclass IV-G LN had their own clinicopathological characteristics 
respectively, but the division of class IV into the two subclasses was not meaningful for 
predicting renal outcomes. In addition to glomerular lesions, tubulointerstitial and vascular 
lesions were also predictors for poor renal outcomes.
Funding: Government Support - Non-U.S.
TH-PO764
Ability of Spot Urine Protein/Creatinine Ratio (Spot PCR) to Correctly 
Identify the Proteinuria Endpoints of Complete Remission (CR), Partial 
Remission (PR), and Treatment Failure (TF) as Determined by 24 Hour 
Urine PCR (24 PCR): Experience of the Abatacept and Cyclophosphamide 
Combination Efficacy and Safety Study (ACCESS)  Ganesh B. Shidham,1 
Daniel J. Birmingham,2 Brad H. Rovin,3 Lee A. Hebert.4  1Div of Nephrology, 
OSUWMC, Columbus, OH; 2Div of Nephrology, OSUWMC, Columbus, OH; 
3Div of Nephrology, OSUWMC, Columbus, OH; 4Div of Nephrology, OSUWMC, 
Columbus, OH.
Background: Spot PCR is an inherently highly variable estimate of 24 hour proteinuria 
magnitude, compared to 24 PCR (Ann Rheum Dis, 73, 475, 2014). So, it is likely that using 
spot PCR rather than 24 PCR to guide management increases the risk of management error. 
The present work is the first to rigorously test this hypothesis. ACCESS is a prospective 
randomized phase 2 trial of Abatacept or placebo added to the Euro-Lupus regimen of 
cyclophosphamide and prednisone followed by azathioprine and low dose prednisone. A 
unique feature of ACCESS was concurrent testing for spot PCR (monthly) and 24 PCR 
(each three months). ACCESS proteinuria endpoints were CR, PR, and TF assessed at 6 
months and 12 months of follow-up (Arth Rheum 66, 3096, 2014).
Methods: Evaluable data (spot PCR measured within one month of the 24 PCR) was 
present at six months in 100 patients, and at twelve months in 54 of the 100 patients. Spot 
PCR was deemed correct if it was concordant with the 24 PCR determination of whether CR, 
PR, or TF was present, and deemed incorrect if discordant with the 24 PCR determinations 
of whether CR, PR, or TF was present.
Results: At 6 month follow up, spot and 24 PCR were concordant in 36 CR, 25 PR, 
10 TF, and discordant in 10 CR, 11PR, and 8 TF. At 12 month follow up, spot and 24 PCR 
were concordant in 36 CR, 11 PR, and 2 TF, and discordant in 4 CR, 2 PR, 0 TF. Totals: 
Concordant 120, Discordant 35. P < 0.001 (null hypothesis that concordance is 95% is 
rejected).
Conclusions: The error rate of spot PCR in identifying ACCESS proteinuria endpoints 
(defined by 24 PCR) was 23%. Proteinuria endpoints in LN trials are broad targets and 
mainly involve low level proteinuria. This minimizes the impact of spot PCR variability.
Funding: NIDDK Support
TH-PO765
Induction Treatments for Proliferative Lupus Nephritis: A Network Meta-
Analysis  Suetonia Palmer,1 David J. Tunnicliffe,2 Allison Tong,2 Dimitris 
Mavridis,3 Jonathan C. Craig,2 Marcello Tonelli,4 David W. Johnson,5 Giovanni 
F.M. Strippoli.2,6  1Univ of Otago Christchurch; 2Univ of Sydney; 3Univ of 
Ioannina; 4Univ of Calgary; 5Univ of Queensland; 6Univ of Bari.
Background: Intravenous cyclophosphamide has been standard care for inducing 
remission among patients with proliferative lupus nephritis (class III and IV). More 
recently, several agents have been trialed, however, given the numerous treatment options 
and head-to-head trials, there is uncertainty about the comparative effectiveness of all 
available treatment options.
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Methods: Immunosuppressive treatments to induce remission of kidney disease among 
patients with proliferative lupus nephritis were all compared using network meta-analysis 
of parallel-group randomized controlled trials. Outcomes were complete disease remission, 
treatment failure, all-cause mortality, end-stage kidney disease, major infection, alopecia, 
ovarian failure and malignancy. Effect sizes for treatments were calculated using random-
effects network meta-analysis and compared to intravenous cyclophosphamide (referent). 
Trials were critically appraised using Cochrane risk of bias.
Results: 47 studies involving 3510 patients were eligible. Mycophenolate mofetil 
was superior to intravenous cyclophosphamide for inducing disease remission (network 
odds ratio 1.60, 95% CI 1.07-2.41), and resulted in lower risks of treatment failure (0.48, 
0.26-0.87), and alopecia (0.22, 0.13-0.39). Mycophenolate mofetil had uncertain risks of 
death (OR 1.14, 0.49-2.65), major infection (1.30, 0.88-1.92) and ovarian failure (0.48, 
0.11-2.08) versus intravenous cyclophosphamide. Comparative effects of other treatments 
including azathioprine and calcineurin inhibitors alone or in combination were uncertain. 
Information for end-stage kidney disease and malignancy endpoints for all treatments 
was sparse. Treatment effects were generally consistent within networks. Methodological 
reporting in trials was frequently unclear.
Conclusions: Mycophenolate mofetil is more effective than intravenous 
cyclophosphamide for induction treatment of proliferative lupus nephritis.
TH-PO766
A Systematic Review on Tacrolimus Treatment in Lupus Nephritis 
Tineke Kraaij,1 Edwin Bredewold,1 Tom Huizinga,2 Ton J. Rabelink,1 Yoe 
Kie Onno Teng.1  1Nephrology, LUMC, Leiden, Netherlands; 2Rheumatology, 
LUMC, Leiden, Netherlands.
Background: Recently, 2 large randomized controlled trials (RCTs) have been 
published on the efficacy of tacrolimus (TAC) in Asian LN patients. Both trials used 
different treatment regimens and efficacy was not consistent between the trials. Therefore, 
the role of TAC in the treatment of LN remains unclear. Thus, we performed a systematic 
review on TAC treatment for LN.
Methods: We searched multiple databases for all human studies investigating TAC 
treatment in LN. Then studies were selected on clinical relevance and results were analysed 
on renal response and adverse events.
Results: We found 26 clinical studies from which data were extracted from all 
controlled studies: 6 RCTs and 3 case-control studies involving a total of 888 patients. 
As induction treatment, TAC with steroids resulted in 82% responders of which 56% 
complete responders (CR). Induction with steroids, mycophenolate (MMF) and TAC 
resulted in 85% responders, of which 46% CR. Data from 1 RCT performed with TAC in 
combination with steroids as maintenance treatment, resulted in 100% responders of which 
56% CR. Generally, control patients receiving induction treatment with cyclophosphamide 
achieved 66% response of which 29% CR. Those receiving induction treatment with MMF 
achieved 76% response of which 53% CR. Overall infections were observed in 26% of 
TAC treated patients compared to 26% of control patients treated with cyclophosphamide 
and 29% in MMF treated control patients. A rise in serum creatinine was observed in 5% 
of all TAC treated patients compared to 2% in the cyclophosphamide control group and 
0% in the MMF control group.
Conclusions: This systematic review suggests that TAC-based treatments can achieve 
comparable renal responses in LN as conventional regimens. Currently, limitations of the 
available studies are the heterogeneity of TAC-based regimens, lack of studies in non-Asian 
LN patients and lack of long-term safety data. Altogether, these data warrant further RCTs 
on TAC-based regimens for LN. At this time, TAC can only be advised as consideration in 
difficult LN patients, such as therapy-refractory patients (especially if severe proteinuria 
is present) and in preparation or during pregnancy.
TH-PO767
Predicting Chronic Kidney Disease (CKD) in Lupus Nephritis (LN) 
Ana Malvar,1 Valeria Gabriela Alberton,1 Bruno Jorge Lococo,1 Haikady 
Nagaraja,2 Brad H. Rovin.3  1Hospital Fernandez, Buenos Aires, Argentina; 
2Ohio State Univ, Columbus, OH; 3Ohio State Univ Wexner Medical Center 
and the CKD Biomarker Consortium.
Background: Early identification of LN patients likely to develop CKD may permit 
therapy to be adjusted and CKD to be avoided. Clinical and histologic parameters measured 
after completing induction therapy were associated with long-term kidney outcomes in a 
cohort of LN patients to define predictors of new CKD.
Methods: Patients (n=69) with biopsy-proven class III/IV LN were induced with 
steroids and MMF (53%) or cyclophosphamide (44%) for 6 months, had repeat kidney 
biopsy (biopsy 2, 6.6±0.7 months), and were put on maintenance therapy. Long-term 
(median 73 months) follow-up was available on 87% of the cohort. Multivariate linear 
regression was used to develop a predictive model for future serum creatinine (SCr) based 
on clinical and histologic variables obtained after induction.
Results: No difference was seen in CKD at last follow-up among patients who did or did 
not achieve a complete clinical renal response after induction (19% vs 18.4%, respectively). 
Among patients with complete histologic renal remission after induction, 36% had a final 
SCr of 1.3-2.9 mg/dl. There was no relationship between the NIH activity index at biopsy 2 
and long-term kidney function. However, the median NIH chronicity index (CI) at biopsy 2 
of patients who developed CKD was 6 (range 2-8) compared to 4 (range 0-7) in patients who 
did not develop CKD (p<0.02). Regression analysis showed a significant linear correlation 
between CI ≥ 4 at biopsy 2 and log(SCr) at long-term follow-up (R2=0.36, p < 0.0001). 
In multivariate analysis CI and SCr at biopsy 2 were independent predictors of long-term 
SCr (R2=0.48, p < 0.0001). For a given level of SCr at biopsy 2, a 1 unit increase of CI in 
the range of 4-8 corresponded to a 20% increase in last SCr.
Conclusions: Neither clinical nor histologic remission after induction predicts long-
term renal function in LN. However, the combination of SCr and chronic damage on kidney 
biopsy after induction accounts for 48% of the long-term variability of renal function in 
those patients who reach a threshold level (CI=4) of chronic kidney damage.
Funding: NIDDK Support
TH-PO768
Clinical and Histologic Remission in Class IVG and IVS Lupus Nephritis 
(LN) After Induction Therapy  Ana Malvar,1 Bruno Jorge Lococo,1 Valeria 
Gabriela Alberton,1 Diego Morales,1 Brad H. Rovin.2  1Hospital Fernandez, 
Buenos Aires, Argentina; 2Ohio State Univ Wexner Medical Center, Columbus, 
OH.
Background: The ISN/RPS classification of LN distinguishes class IV with 
predominantly segmental lesions (IVS) from class IV with global (IVG) lesions. It has 
been suggested that IVS may have a lower remission rate than IVG, possibly because it is 
more like a vasculitis than IVG. However several studies found no significant difference in 
long-term kidney survival between these subclasses. We examined differences in histologic 
and clinical remissions between IVG and IVS in our LN cohort with serial kidney biopsies.
Methods: SLE patients (n=43) were biopsied at first presentation of kidney involvement 
(Bx1) and again at 6 months after completing induction therapy (Bx2). Class IVG and S 
patients were treated identically with steroids plus MMF or cyclophosphamide. NIH activity 
(AI) and chronicity (CI) indices, proteinuria and serum creatinine (SCr) were compared. 
Complete clinical response (CCR) was defined as normal SCr and proteinuria < 500 mg/d. 
Complete histologic remission was defined as an AI=0 at Bx2.
Results: Clinical outcomes and histologic data are shown in the Table. All patients 
were ANCA negative. Final SCr and proteinuria were determined after a mean follow-up 
of 54±7 months. Only 4 patients were lost to long-term follow-up.
Bx1 CRR Bx2
Final SCr 
≤1 (mg/dl)
Final 
Proteinuria 
(g/d)
AI Bx1 AI Bx2 
CI 
Bx1 
CI 
Bx2
IVG (n=33) 39% 87% 0.32± 0.24 10.3± 2.9 3.7± 2.8
3.5± 
1.9
4.9± 
1.9
IVS (n=10) 80% 89% 0.26± 0.19 8.5± 2.2 0.1± 0.3
2.6± 
1.8
4.4± 
0.7
P (IVG vs IVS) 0.034 1.00 0.43 >0.05 <0.05 >0.05 >0.05 
Conclusions: Class IVS LN has an excellent early clinical and histologic response 
to standard-of-care LN induction therapy. Class IVG takes longer to respond, but over 
time there are no differences in long-term renal outcomes between Class IVG and IVS 
LN as assessed by SCr and proteinuria. This suggests that these subclasses may be treated 
similarly. These results also raise the possibility that class IVS patients who have complete 
clinical and histologic remission after induction may do well with an abbreviated course 
of maintenance therapy.
Funding: NIDDK Support
TH-PO769
Complete Remission Rate and Outcome in Severe Lupus Nephritis: The 
Impact of Baseline Serum Creatinine  Stephen M. Korbet, William Luke 
Whittier, Edmund J. Lewis.  Rush Univ Medical Center, Chicago, IL.
Background: A complete remission (CR) in severe lupus nephritis (SLN) is associated 
with a favorable long-term outcome. Numerous factors including level of serum creatinine 
(SCr) at baseline have been shown to impact on CR rate and outcome. We assess the impact 
of baseline SCr on CR rate and outcome in SLN.
Methods: We evaluated the 86 adult patients in the prospective, controlled trial 
of plasmapheresis in SLN and compared them based on SCr level at baseline (£1.0, 
1.01-1.5, 1.51-2.0, 2.01-3.0 and >3.0 mg/dl; n= 22, 23, 16, 12, 13 respectively). The CR 
rate (defined by a serum creatinine (SCr) of ≤ 1.4 mg/dL and UPro of £0.33 g/day) and 
long-term outcomes (stable renal function, dialysis and death) were compared. Pts were 
followed for 121±64 mo.
Results: Baseline clinical features (age, gender, race and UPro) were similar among 
the groups. All pts had ISN/RPS class IV lesions and while the activity index was similar 
among the groups, the chronicity index (2 vs 3 vs 3 vs 5 vs 5, respectively, P 0.007) was 
significantly higher with increasing levels of SCr. At follow-up, CR rates (86% vs 52% 
vs 19% vs 25% vs 0, respectively, P <0.0001) were significantly higher and occurred in 
a shorter period of time (6 vs 12 vs 23 vs 18 mo, respectively, P 0.33) in pts with lower 
levels of SCr. Pts with a baseline SCr of £1.0 mg/dl were >16 times as likely (odds ratio, 
16.2; 95% confidence interval, 4.2-61.5) to attain a CR and >6 times as likely (odds ratio, 
6.1; 95% confidence interval, 1.9-18.6) to have stable renal function at last follow-up 
compared to pts with a SCr >1.0 mg/dl. The 15-yr renal survival (76% vs 57% vs 48% vs 
25% vs 10%, respectively, P <0.0001) and patient survival without ESRD (76% vs 40% 
vs 42% vs 25% vs 8%, respectively, P <0.0001) was greatest in the patients with a SCr of 
£1.0 mg/dl at baseline.
Conclusions: The CR rate and outcome in SLN are significantly affected by baseline 
serum creatinine. The CR rate is highest and long-term prognosis most favorable in pts 
with a baseline SCr £1.0 mg/dl; the group with the least amount of chronic disease on 
biopsy. This emphasizes the importance of early diagnosis and treatment in pts with SLN.
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TH-PO770
Urine Adiponectin Isoforms and Kidney Lesions in Lupus Nephritis (LN) 
Xiaolan Zhang,1 Divya Indrakanti,1 Anthony Alvarado,1 Sergey V. Brodsky,1 
Hermine Brunner,2 Brad H. Rovin.1,3  1Ohio State Univ Wexner Medical Center, 
Columbus, OH; 2Cincinnati Children¶s Hospital, Cincinnati, 2H; 3CKD 
Biomarker Consortium.
Background: Human adiponectin isoforms exert different effects on inflammation. 
Urine adiponectin is increased at LN flare, but the relationship between adiponectin isoforms 
and kidney lesions in LN has not been studied.
Methods: Urine and plasma total and high molecular weight (HMW) adiponectin 
isoforms were measured by specific ELISAs in samples from 39 normal controls and 
97 biopsy-diagnosed LN patients. Urine adiponectin levels were normalized and log-
transformed, and then examined for associations with histologic lesions on kidney biopsy 
by ANOVA, nonparametric Wilcoxon ranked-sum testing and multiple linear regression 
analysis.
Results: The HMW to total adiponectin ratio was increased in plasma (p=0.022) and 
urine (p=0.0004) of LN patients compared to controls. Total and HMW adiponectin levels 
were highly correlated within the plasma (R²=0.91, p < 0.0001) and urine (R²=0.64, p < 
0.0001) in LN, but between plasma and urine only HMW adiponectin showed a correlation, 
and this was minor (R²=0.21, p< 0.037). Urine adiponectin levels increased with the severity 
of ISN/PRS class. The highest total and HMW urine adiponectin levels were found in 
patients who had combined class III or IV + V LN. Using urine HMW adiponectin levels 
to differentiate between control and LN patients, and between single and combined LN 
classes, receiver-operating characteristic analysis showed areas under the curve of 0.96 and 
0.85, respectively. Urine HMW adiponectin was significantly increased when glomerular 
proliferation, cellular crescents or interstitial inflammation were present on the biopsy, and 
HMW adiponectin correlated with the biopsy activity index (R²=0.31, p < 0.0001), but not 
chronicity index. Using HMW adiponectin plus urine hemopexin plus serum creatinine, an 
equation to predict biopsy activity index was constructed with a R²=0.46.
Conclusions: Urine adiponectin isoforms increase with the severity of active kidney 
lesions in LN. The increase in urine adiponectin is not simply a reflection of changes in 
systemic adiponectin, and may be due to intra-renal processing.
Funding: NIDDK Support
TH-PO771
Significance of Serum Cystatin C as a Biomarker for Clinical Practice in 
Patients with Lupus Nephritis  Hua Zhou, Di Lu, Hairong Tang, Lizhi Li, 
Huimeng Qi, Lining Wang.  Nephrology Dept, 1st Hospital of China Medical 
Univ, Shenyang, China.
Background: Serum Cystatin C (sCysC) as a novel biomarker of renal function has 
been studied in many primary glomerular diseases. However, sCysC was barely reported in 
lupus nephritis (LN). We aim to compare the changes of sCysC and traditional biomarkers 
in LN patients.
Methods: 106 patients with LN proven by renal biopsy were studied. sCysC, serum 
creatinine (sCr), BUN, 24 hr total urinary protein (uTP), serum albumin (sAlb), systemic 
lupus erythematosus disease activity index (SLEDAI), C3, C4, IgG, ANA, DsDNA, 
C-reaction protein (CRP), and ESR were examined before and 1, 3, 6, 12, 24 months 
after treatment with steroid and immunosuppressants. estimated glomerular filtration rate 
(eGFR) was calculated by EPI-sCysC, EPI-sCr, and EPI-sCysC + sCr. The strength of 
correlation was compared between sCysC and sCr with uTP, sAlb, SLEDAI, and CRP 
before and after treatment.
Results: sCysC and eGFR (EPI-sCysC+sCr) showed stronger correlation with uTP, 
sAlb, SLEDAI, and CRP before the treatment (table). During treatment, a similar trend was 
seen in sCysC and eGFR (EPI-sCysC). sCysC also showed a better statistical p value than 
SCr/BUN in response to treatment with steroid plus either all kinds of immunosuppressants 
or cyclophosphamide.
Index sCysC sCr BUN eGFR (EPI-sCysC)
eGFR 
(EPI-sCr)
eGFR (EPI-
sCysC+ Scr)
uTP
r (p value)
0.25 
(p= 0.03)
0.16
(p= 
0.097)
0.24
(p= 0.012)
-0.23
(p= 0.06)
-0.11
(p= 0.29)
-0.31
(p= 0.014)
sAlb
r (p value)
-0.44
(p< 
0.0001)
-0.28 
(p= 
0.004)
-0.29
(p= 
0.0012)
0.40
(p= 0.0008)
0.17
(p= 0.08)
0.47
(p< 0.0001)
SLEDAI 
score
r (p value)
0.41
(p= 
0.0004)
0.29
(p= 
0.003)
0.36
(p= 
0.0001)
-0.42
(p= 0.0004)
-0.14
(p= 0.16)
-0.45
(P= 0.0001)
CRP
r (p value)
0.28
(p= 0.02)
0.25
(p= 
0.012)
0.10
(p= 0.31)
-0.25
(p=0 .046)
-0.14
(p= 0.19)
-0.26
P= 0.036
Conclusions: sCysC and eGFR based on sCysC might be useful early biomarkers 
to diagnose LN and better to monitor the treatment of LN. sCysC will likely help in 
clinical decision making for early intervention and the timing of reducing key treatments. 
Prospective study is needed to investigate the effect of early treatment based on sCysC 
increase (sCr normal) in large cohort of LN patients.
Funding: Government Support - Non-U.S.
TH-PO772
Neutrophil Modular Blood Transcriptional Signature Is Associated with 
Lupus Nephritis and Its Severity in SLE  Noemie Jourde-chiche,1 Bertrand 
Gondouin,1 Stephane Burtey,1 Laurent Daniel,2 Bertrand Dussol,1 Laurent 
Chiche.3  1Nephrology, Aix-Marseille Univ, Marseille, France; 2Pathology, 
Aix-Marseille Univ, Marseille, France; 3Internal Medicine, Hopital Europeen, 
Marseille, France.
Background: Lupus nephritis (LN) is a severe complication of SLE. . The aim of this 
study was to assess the link between blood transcriptional signatures and LN, comparatively 
with other pathological conditions associated with renal injury.
Methods: 102 patients were included: 62 SLE patients, 40 controls with various 
conditions (10 with crescentic GN due to ANCA-associated vasculitis (AAV), 15 with 
severe bacterial sepsis, 15 with non-proliferative glomerular diseases), and their matched 
healthy controls. SLE samples were split in those at the time of: a biopsy-proven active 
LN (group 1, n=24); an extra-renal flare (group 2, n=11); a clinically quiescent visit (group 
3, n=34). Microarray data were generated using Illumina beadchips and analyzed using 
modular repertoire analyses.
Results: Modular repertoire analysis in SLE patients revealed, in addition to the 
activation of IFN-related modules, a strong upregulation of M5.15, a module of 24 
transcripts annotated “neutrophil”. There was no correlation between M5.15 and SLEDAI, 
anti-dsDNA level or IFN modules activity. M5.15 was strongly associated with active LN 
(p=0.009), but not with non-renal manifestations. The neutrophil modular signature was 
present in 67%, 18% and 47% of patients from group 1, 2 and 3 respectively. In group 2 
and 3, its presence was associated with a past history of LN or the occurrence of LN during 
the follow-up. M5.15 was correlated with acute renal failure (p=0.03) and serum albumin 
(p=0.01). In group 1, the median value of M5.15 was higher in patients with proliferative 
than non proliferative LN (66.7 vs 18.8 %, p=0.04). AAV and sepsis patients shared the 
neutrophil signature observed in SLE, but displayed no IFN signature, while those with 
non-proliferative GN had none of these signatures.
Conclusions: Modular repertoire analysisdemonstrates that neutrophil signature is 
correlated with occurrence and severity of LN in SLE. This result could allow the design 
of new biomarkers in LN.
TH-PO773
Anticoagulation and Longterm Outcomes in Patients with Renal Artery 
Stenosis and Antiphospholipid Syndrome  Alina L. Casian, Shirish Sangle, 
Sotiria Manoustathopoulou, David D’Cruz.  Lupus Unit, Guy¶s Hospital, London, 
United Kingdom.
Background: Our previous data showed renal artery stenosis (RAS) is more 
prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive 
population(8%),and anticoagulation with INR>=3 was associated with initial reduction of 
chronic kidney disease(CKD) and hypertension.
Methods: We identified 37 patients with RAS and APS fulfilling Sapporo criteria: 
anticardiolipin IgG/IgM titer>40 units or >99th percentile (or +lupus anticoagulant) on >=2 
occasions >=6 weeks apart AND vascular thrombosis(or pregnancy morbidity). RAS was 
diagnosed by magnetic resonance angiography(MRA).
Results: 15 patients had APS alone and 22 APS associated with autoimmune conditions 
(13 lupus, 5 ANCA vasculitis, 4 mixed). Median age at RAS diagnosis was 48 years, 
31/37(83.8%) were female and median follow-up was 10.4 years. 25/37(67.6%) had 
previous thrombosis. 7/37(18.9%) had bilateral RAS, 3 artery occlusion. 6/37(16.2%) 
had coeliac stenosis. Recanalization of RAS occurred after hydroxychloroquine in 3/37 
and 9/37(24.3%) underwent angioplasty+/-stenting. MRA was repeated in 11/37(29.7%) 
after 2 years. 23/37(62.2%) were anticoagulated, with 9/37(24.3%) on antiplatelet therapy. 
13/37(35.1%) received hydroxychloroquine, 10/22(45.5%) immunosuppressives and 
18/37(48.6%) antihypertensives. 9/37(24.3%) died after a median of 10 years since RAS 
diagnosis. 21/37(56.8%) developed CKD: 6 endstage renal failure(ESRD) and 15 with 
median eGFR 39 mls/min.
Patient Group CKD ESRD Death
Anticoagulation(23) 15/23 4/23 5/23
No anticoagulation(14) 6/14 2/14 4/14
p value 0.3 1.0 0.7
APS(15) 7/15 3/15 1/15
APS+autoimmune disease(22) 14/22 3/22 5/22
p 0.3 0.7 0.4
Medical therapy(28) 13/28 3/28 7/28
Angioplasty (9) 8/9 3/9 2/9
p 0.05 0.14 1
Conclusions: The majority of patients with RAS and APS were female, developed CKD 
and did not benefit from angioplasty. Anticoagulation was not associated with longterm 
reduction of ESRD or death, suggesting a non-thrombotic pathogenic process underlying 
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RAS, e.g.intimal hyperplasia. Treatment of associated vascular risk factors and autoimmune 
disease is paramount. Anticardiolipin antibodies and renal MRA are useful for screening 
hypertensive lupus patients.
TH-PO774
A Prospective Study to Investigate Mycophenolic Acid Pharmacokinetics 
and Its Clinical Correlations in Lupus Nephritis Patients  Desmond Y.H. Yap,1 
Chun-Hay Tam,2 Sunny Sze ho Wong,2 Maggie Kam Man Ma,1 Susan Yung,1 
Daniel Tak Mao Chan.1  1Medicine, The Univ of Hong Kong, Hong Kong, 
Hong Kong; 2Medicine and Geriatrics, United Christian Hospital, Hong Kong, 
Hong Kong.
Background: The dosing regimen of mycophenolate mofetil (MMF) in the treatment 
of lupus nephritis (LN) is adopted from the kidney transplant experience. The role of 
therapeutic drug monitoring of mycophenolic acid (MPA) level in managing LN remains 
undefined.
Methods: We prospectively studied LN patients on maintenance treatment with 
prednisolone and MMF. Blood MPA level at 1, 2, 4, 8, 10 and 12 hours (i.e. C1, C2, C4, 
C8, C10 and C12) after MMF administration was measured with an enzymatic assay upon 
recruitment and repeated at 6-month intervals for 24 months, and at occurrence of clinically 
significant events, to investigate their clinical correlations.
Results: 51 patients were included, with prednisolone and MMF dose of 6.2±1.8mg/d 
and 1284±493mg/d respectively at baseline. C1, C2 and C12 MPA levels were 9.9±8.7mg/L, 
8.6±6.2mg/L, 1.9±1.4mg/L during disease remission. C1, C2 and C12 MPA levels correlated 
with AUC0-12 (r= 0.52, 0.85 and 0.77; p=0.004, <0.001 and <0.001 respectively). C12 
correlated inversely with hemoglobin, white cell and platelet counts (r= -0.359, -0.226, 
-0.20; p=0.001, 0.010 and 0.024 respectively). There was no association between C12 
and anti-dsDNA, serum creatinine or 24-hr urine protein excretion (p=0.53, 0.07 and 0.37 
respectively). C1 and C2 showed no association with clinical or serological parameters. 
Clinically significant events included infection in 2 patients, gastrointestinal upset in 3 
patients, and renal flare in 5 patients. C12 MPA level at the time of these events were 
1.7±1.6mg/L, 2.6±1.7mg/L and 1.5±0.9mg/L respectively.
Conclusions: C12 MPA level showed good correlation with drug exposure, and may 
be associated with renal flare and haematological side-effects but not infection.
Funding: Private Foundation Support
TH-PO775
Long-Term Prospective Study of Tacrolimus-Based Treatment in Lupus 
Nephritis Patients  Kazunori Karasawa, Keiko Uchida, Yukari Asamiya, 
Takahito Moriyama, Mitsuyo Itabashi, Takashi Takei, Kosaku Nitta.  Dept 
Medicine, Kidney Center, Tokyo :omen¶s Medical Univ, - KaZada-cho, 
Shinjyuku-ku, Tokyo, Japan.
Background: This study aimed to examine whether long-term maintenance treatment 
with tacrolimus for patients with lupus nephritis (LN) is effective and safe.
Methods: A total of 27 adult patients with LN after induction therapy were 
enrolled. Tacrolimus was initiated at a dose of 3 mg/day. Patients treated with other 
immunosuppressive agents were also switched to tacrolimus. Prednisolone doses were 
tapered throughout the period according to individual disease activity. Prospective data 
on renal response, lupus nephritis disease activity index (LNDAI) including hematuria, 
proteinuria, C3 and anti-ds DNA antibody (score range: 0-10), and prednisolone dose, 
were collected.
Results: Four patients discontinued tacrolimus treatment due to its ineffectiveness, 
complications including acute myeloblastic leukemia, or their personal intention to become 
pregnant or discontinue medication. A total of 23 patients (mean age 52.6 ± 11.8 years and 
mean duration of LN 15.6 ± 8.7 years) were treated with tacrolimus throughout a 5-year 
period and their data were analyzed. The mean urinary protein/creatinine ratio significantly 
decreased from a baseline of 1.12 ± 1.47 to 0.33 ± 0.78 at 1 year (p = 0.005) and 0.40 ± 
1.54 at 5 years (p = 0.016), while mean eGFR levels were unchanged throughout the 5 years 
of tacrolimus treatment. The mean LNDAI was significantly decreased from a baseline 
of 3.54 ± 2.53 to 1.96 ± 1.40 at 1 year (p = 0.021) and 2.08 ± 1.44 at 5 years (p = 0.022). 
Similarly, the mean prednisolone dose significantly decreased from a baseline of 0.35 ± 0.21 
mg/kg/day to 0.22 ± 0.15 mg/kg/day at 1 year (p = 0.022) and 0.17 ± 0.09 mg/kg/day at 5 
years (p = 0.001). The mean blood concentration of tacrolimus was 4.0 ± 2.3 ng/ml. Only 
one patient experienced a disease flare, and there were no deaths during the study period.
Conclusions: Our results suggest that tacrolimus can be potentially effective for the 
treatment of LN; moreover, the current dosage appeared to be generally well-tolerated for 
long-term maintenance treatment in patients with LN.
TH-PO776
Comparison of Kidney Function and Mortality of Mexican Children 
versus Adults with Lupus Nephritis  Luis Gerardo Gonzalez-Correa, Enrique 
Rojas-Campos, Benjamin Gomez-Navarro, Alfonso M. Cueto-Manzano, Petra 
Martínez.  Unidad de Investigación Médica en Enfermedades Renales, Inst 
Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico.
Background: Childhood-onset lupus nephritis (CLN; onset before 16 years of age) 
has been associated with a more aggressive disease course as compared to adulthood-onset 
lupus nephritis (ALN). Kidney factors such as LN Class and Activity and Chronicity Indexes 
are related to renal prognosis. No information is available in our setting. Aim: To compare 
kidney function and mortality of CLN vs ALN.
Methods: Retrospective cohort study. Medical records of patients with LN biopsy 
proven performed Jan/2005 – Dec/2012 were reviewed. Clinical, kidney function and 
sociodemographical variables were recorded. Kidney biopsy findings, LN class, Activity 
and Chronicity Indexes, and patient status (alive͞deceased) were also analyzed.
Results: There were 53 patients with CLN and 188 with ALN, with a follow–up 
of 24±23 vs 43±22 months, and age 12±2 vs 32±11 years, respectively.Main results are 
shown in the table. 
Variable CLN ALN
Baseline Final Baseline Final
Proteinuria g/day 2.0 (1.0-5.0) 0.5 (0.2-1.4)
2.1 (0.6-
4.3) 0.5 (0.2-1.5)
CrCl (ml/
min/1.73m2) 85±42 98±45 80±29 76 ±34*
Activity Index 10±4 4±3 8±3 7±4
Chronicity Index 2±1 5±2 3±2* 4±2
LN Class
Loss of Kidney 
function
Loss of Kidney 
function
N (%) N (%) N (%) N (%)
Class II 12 (23) 1 (8) 23 (12) 1 (4)
Class III 12 (23) 1 (8) 42 (22) 5 (12)
Class IV 22 (41) 8 (36) 54 (29) 10 (18)
Class V 4 (7) 0 48 (25) 1 (2)
Mixed Class 3 (6) 0 21 (12) 5 (24)
Death 10 (19%) 14 (7%)*
Death Sepsis 30% 36%
*p<0.05 vs CLN 
Conclusions: Patients with CLN had higher mortality and those with ALN had lower 
CrCl at the end of follow-up. Children died mainly due to infectious causes which might 
be related to the immunosuppression used because of the high prevalence of class IV LN.
TH-PO777
Determining Long-Term Outcomes in Lupus Nephritis Through Molecular 
Analysis of Serial Kidney Biopsies  Samir Parikh,1 Ana Malvar,2 Huijuan 
Song,1 Jianying Zhang,1 Lianbo Yu,1 Brad H. Rovin.1  1Div of Nephrology, The 
Ohio State Univ Wexner Medical Center, Columbus, OH; 2Nephrology, Hospital 
Fernandez, Buenos Aires, Argentina.
Background: Most patients with proliferative lupus nephritis (LN) achieve a partial 
remission (PR) after induction therapy. With time some patients will attain complete 
remission (CR) while others will not improve. We tested whether gene expression in 
serial kidney biopsies could identify markers of long-term kidney outcome in patients 
who achieved a PR after induction.
Methods: The expression of 511 immune response genes was evaluated for 9 pairs 
of proliferative LN biopsies. A kidney biopsy was done at flare (bx1) and after induction 
therapy was completed (bx2). All patients achieved a clinical PR prior to bx2. At 3 year 
follow-up 4 patients were in CR and 5 patients did not improve or worsened (NR). Gene 
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expression profiles were compared at bx1 and at bx2 between these CR and NR patients. 
Transcripts were considered differentially expressed only if they met both criteria of at 
least a 1.5-fold change (FC) and p-value < 0.01.
Results: At flare, 2 transcripts were differentially expressed between CR and NR. IL-
28a, a type 3 interferon gene was decreased 2.6-fold (p=0.006) and mannose-binding lectin 
serine peptidase 1 (MASP1), a member of the complement lectin-pathway, was decreased 
1.8-fold (p=0.009) in CR versus NR. From bx1 to bx2, 8 genes were differentially expressed 
in the CR group. Expression of adhesion molecule VCAM1 and macrophage regulator 
CEBPB was decreased while expression of TGF-β activator SMAD3, inhibitor of TLR 
signaling, TOLLIP, and inhibitor of NF-κB signaling, TRAF4 was increased. In NR, from 
bx1 to bx2, 9 genes were differentially expressed. Expression of the type 3 interferon, IL28b 
and the TNF-receptor TNFRSF13b (TACI) was decreased while expression of complement 
C2 and CFB and the TNF cytokine TNFSF8 was increased.
Conclusions: Molecular characterization of kidney biopsies at LN flare along with 
the change in expression after treatment identifies differentially-expressed genes among 
patients who eventually have or do not have a CR. Some of these genes may be candidate 
biomarkers of long-term renal outcomes in LN.
Funding: Other NIH Support - NIDDK U01: DK096927, Pharmaceutical Company 
Support - Mallinckrodt/Questcor Fellowship Grant: 00033990
TH-PO778
Evaluation of Healthcare Resource Utilization and Costs by 
Immunosuppressant Pattern of Use in Lupus Nephritis  Shih-Yin Chen, 
Ning Wu, Jie Ting, Fei Shih.  Biogen.
Background: US-based treatment guidelines recommend 6 months of 
immunosuppressant (IS) therapy before continuing or switching regimen for class III/IV 
lupus nephritis (LN) patients. Literature suggested that management of LN is costly, but 
published data on how costs and healthcare resource utilization (HRU) may vary by IS 
pattern of use are limited.
Methods: We identified LN patients initiating cyclophosphamide (CYC) or 
mycophenolate mofetil (MMF) in 2010-2013 from a US commercial/Medicaid claims 
database. All-cause costs and HRU during the year post-IS initiation were examined. 
Comparison was made between the following four groups based on their IS utilization 
during the first 6 months and 7-12 months post-IS initiation: 1) patients who used the same 
IS continuously for at least 7 or up to 12 months (reference group), 2) patients who switched/
added-on IS after 6 months, 3) patients who switched/added-on IS within 6 months, and 
4) patients who discontinued IS within 6 months.
Results: Final sample included 1,567 LN patients (mean age=37 years; 86% female) 
initiating CYC (16.1%) or MMF (83.9%). Patients who remained on the same IS throughout 
had significantly lower costs and HRU compared to other three groups.
Overall 
(N=1,567) Patient groups
Remained 
on the same 
treatment 
(reference 
group; 
N=833)
Switched/
added-on 
after 6 
months
(N=223)
Switched/
added-on 
before 6 
months
(N=206)
Discontin-
ued before 6 
months
(N=305)
Annual per 
patient costs 
(mean)
Total 37,636 25,261 44,308* 59,437* 51,832*
Inpatient 13,564 6,407 17,085* 23,442* 23,867*
Emergency room $1,771 1,407 2,238* 1,998* 2,272*
Outpatient 16,543 11,567 17,942* 28,080* 21,319*
Pharmacy 5,757 5,880 7,043* 5,916 4,374*
HRU (%)
Hospitalizations 26% 19% 35%* 39%* 30%*
*Significantly different from reference group at P <0.05
Conclusions: In LN patients, those who required additional IS or discontinued before 
6 months incurred more than twice the annual total costs compared to those who continued 
the same IS through 7-12 months. Identifying safe and efficacious therapies early for LN 
patients may have economic implications. Future study supplemented with clinical markers 
to understand the economic impact of achieving early renal response is warranted.
Funding: Pharmaceutical Company Support - Biogen
TH-PO779
Retrospective Analysis of 65 Pregnancies in Patients with Lupus Nephritis 
in France  Jean-charles Puthet,1 Noemie Jourde-chiche,2 Dominique Chauveau,3 
Eric Daugas,4 Laurent Juillard.1  1Hôpital Edouard Herriot - Hospices Civils 
de Lyon, France; 2Hôpital La Conception - CHU Marseille, France; 3Hôpital 
Rangueil - CHU Toulouse, France; 4Hôpital Bichat - APHP , on behalf of the 
French Cooperative Group on Lupus Nephritis, France.
Background: Lupus nephritis (LN) mostly affects women of childbearing age. Despite 
the improvement in care over the last decades, pregnant women with LN are still at high-
risk of maternal and foetal complications.
Methods: The aim of this study is to outline retrospectively the care and pregnancy 
prognosis carried out after 24 weeks of gestation between 2004 and 2014, in patients with 
LN diagnosed before or during pregnancy.
Results: Data was collected from 65 pregnancies in 44 patients across nine French 
hospitals centres. LN was revealed by pregnancy in five cases. A preparation phase preceded 
the pregnancy in 90% of the cases, and complete remission from the disease was obtained 
for more than 24 months in 74% of them. Corticosteroids and hydroxychloroquinine 
were generally continued (68% and 73% respectively). Azathioprine and aspirin were 
administered in 37% and 65% of pregnancies. Maternal complications occurred in 40% of 
pregnancies, mainly preeclampsia (18%) and LN flares (20%). The risk factors associated 
with LN flares during these pregnancies were: the presence of positive anti-native DNA 
antibodies (p <0.0001), low C4 (p = 0.004), the absence of complete remission of LN at 
conception (p < 0.001), or inactivity of LN inferior to 12 months (p = 0.003). Preeclampsia 
occurred more frequently with the degradation of kidney function or an increase in 
proteinuria at conception (p = 0.011 and p = 0.001). The perinatal death rate was calculated at 
6.8%. We observed 25% premature births and 15% intrauterine growth retardation (IUGR).
Conclusions: We found encouraging results. The incidence of maternal and foetal 
complications during pregnancy was reduced compared to previous European studies 
including lupus patients. Risk factors of major maternal complications are best characterized.
TH-PO780
Nephrotic Syndrome and Pregnancy  Iris C. De Castro,1 J. Ashley Jefferson,1 
Thomas R. Easterling.2  1Div of Nephrology, Dept of Medicine, Univ of 
Washington School of Medicine; 2Dept of Obstetrics and Gynecology, Univ of 
Washington School of Medicine, Seattle, WA.
Background: In the absence of hypertension or renal insufficiency, some consider the 
perinatal outcomes in pregnant women with nephrotic syndrome to be good. However, the 
diagnosis and management of both maternal and fetal well-being is challenging.
Methods: We describe the presentation, management, and maternal and fetal outcomes 
of 31 pregnancies in 24 women with biopsy proven nephrotic syndrome during pregnancy. 
We include hemodynamic data from UltraCOM cardiac output measurements. All patients 
had nephrotic-range proteinuria (>3.5g/24hr and or >3.5g/g on spot urine protein: creatinine 
ratio) during pregnancy, a kidney biopsy diagnosis, and serum creatinine <1.5mg/dL at 
presentation.
Results: There were 24 subjects (9 primiparas) with 31 pregnancies and 32 offspring. 
Mean age was 27.6 years (range 16- 39 years) and mean gestational age at presentation 
was 18.7 weeks (range 5- 40 weeks). Labs revealed a mean creatinine 0.85mg/dL (range 
0.4- 1.4mg/dL), mean serum albumin 1.97g/dL (range <1- 3.2g/dL), and mean proteinuria 
8.96g/24h (range 3.6- 32g). UltraCOM data was available for 18 pregnancies. Mean cardiac 
output at presentation was markedly elevated at 8.38L/min. 14 of 31 pregnancies were 
known to have kidney disease before pregnancy. Nephrotic syndrome was newly diagnosed 
in 16 patients. Biopsy was performed during pregnancy in 10 subjects (median age of 
gestation 20.5 weeks (range 2-27 weeks)) changing management in 70%. 6 were biopsied 
postpartum. Biopsy diagnoses were FSGS(11), IgAN(3), lupus nephritis(3), membranous 
nephropathy(3), and 1 case each of Fibrillary GN, MPGN, C3GN, and minimal change 
disease. Maternal complications included preeclampsia(10/31), acute kidney injury(3/31) 
and cellulitis(3/31). Mean age of gestation at delivery was 35.4 weeks (range 25-40 weeks). 
17 delivered via caesarean section. Fetal complications included birth weight <2,500g(18), 
IUGR(3), and 10 were admitted to NICU.
Conclusions: Pregnant women with nephrotic syndrome are at high risk for developing 
maternal and fetal complications despite the absence of significant hypertension or renal 
insufficiency.
TH-PO781
The Relationship Between Serum Cholinesterase, Number of Organ 
Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related 
Disease  Hirofumi Nishikawa, Yoshinori Taniguchi, Tatsuki Matsumoto, Kazu 
Hamada-Ode, Yoshiko Shimamura, Koji Ogata, Kosuke Inoue, Taro Horino, 
Shimpei Fujimoto, Yoshio Terada.  Kochi Univ, Japan.
Background: To evaluate the relationship between cholinesterase, number of organ 
involvement and serum fibrotic markers in Japanese patients with IgG4-related disease 
(IgG4-RD) including kidney involvement.
Methods: The clinical symptoms, laboratory, pathological and FDG-PET/CT findings 
of Japanese patients with IgG4-RD (n=20) were assessed. Several laboratory data of 
IgG4-RD with multiple organs’ involvements (IRDMOI) (n=10), IgG4-RD with limited 
organ’s involvement (IRDLOI) (n=10), ANCA-associated vasculitis (AAV) (n=10) and 
Sj|gren Syndrome (SjS) (n=10) were comparatively examined. Furthermore, we studied 
the relationship between the numbers of organ involvement (NOI) and several fibrotic 
markers (ELF score and serum Dkk-1) in IgG4-RD group.
Results: Serum cholinesterase (ChE) levels were significantly lower in IRDMOI group 
than IRDLOI, AAV and SjS groups. All cases did not show hepatic dysfunction in laboratory 
examinations. Serum albumin and IgG levels were significantly lower and CRP levels 
were significantly higher in AAV group, compared with IgG4-RD and SjS group. There 
were no significant differences in these levels between IRDMOI and SjS. In total IgG4-
RD cases, ChE levels inversely correlated with NOI and fibrotic score, and fibrotic score 
positively correlated with NOI. Finally, Dkk-1, one of Wnt inhibitors, levels in IRDMOI 
were significantly lower than IRDLOI and healthy subjects (p<0.05).
Conclusions: The ELF score and serum Dkk-1 level might be a clinically useful 
indicators of active fibrosis and the extent of disease in Japanese patients with IgG4-RD. 
Notably, serum ChE levels could predict these phenomena.
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TH-PO782
Crescentic IgA Nephropathy – A Prospective Study  Krishan L. Gupta,1 
Prabhakar Doddi,1 Ritambhra Nada,2 Raja Ramachandran.1  1Nephrology, 
PGIMER, Chandigarh, India; 2Pathology, PGIMER, Chandigarh, India.
Background: Crescentic IgA nephropathy (cIgAN) carries a very poor prognosis and 
the initial creatinine at presentation predicts long-term outcome. The present prospective 
study was carried out to evaluate the clinico-pathological correlation and outcome of cIgAN.
Methods: Patients ³12 yrs with Crescentic IgAN were included in the study. Patients 
with infection with evidence of systemic disease like HSP, SLE, hepatitis B surface antigen, 
anti hepatitis C antibody and HIV-I/II were excluded from the study. Patients were followed 
prospectively monthly for a period of 12 months or till end stage renal (ESRD) or death. 
Primary objective of the study was to evaluate percentage of patients achieving remission/
ESRD and the secondary outcome to see for histological correlation with clinical outcome.
Results: A total of 60 cases of crescentic IgAN were enrolled in the study. The mean 
age of the patients was 28.91±10.14 (12-60) years. The study included 46 (76.67%) males 
and 14 (23.33%) females. The mean 24 hour-urine protein (UP), serum creatinine and serum 
albumin were 2.22±1.33 gm, 6.37±4.13 mg/dl and 3.39±0.78 gm/dl respectively. Active 
sediments were present in 44 (74.57%) patients at presentation. The clinical presentation was 
RPRF in 34 (56.66%) cases, nephrotic syndrome in 04 (6.66%) and CKD in 20 (33.33%) 
and 2 (3.33%) cases presented with only subnephrotic proteinuria. Seventeen (28.33%) 
patients received combination of pulse cyclophosphamide and steroids, 29 (48.33%) 
received only steroids and 14 (23.34%) cases with tubular atrophy and interstitial fibrosis 
>70% were not treated with any immunosuppressive. At the end of 12 months 03 (5%) 
achieved CR, 08 (13.33%) had PR progressive CKD in 09 (15%) and 02 (3.33%) had 
persistent NS. Thirty-eight (63.33%) cases progressed to ESRD by the end of 12 months. 
Serum creatinine at presentation and IFTA> 50% and presence of fibrous crescent on 
biopsy was risk factor for ESRD.
Conclusions: Crescentic IgAN carries a very poor prognosis, with majority of the 
cases progressing to ESRD by 12 months. Serum creatinine at presentation and presence 
of diffuse IFTA and fibrous crescents on biopsy predicts development of ESRD.
TH-PO783
Comprehensive Microbiome Analysis of Tonsillar Crypts in IgA 
Nephropathy  Hirofumi Watanabe, Shin Goto, Masafumi Tsuchida, Ichiei 
Narita.  Div of Clinical Nephrology and Rheumatology, Niigata Univ Graduate 
School of Medical and Dental Sciences, Niigata, Japan.
Background: IgA nephropathy (IgAN) is the most prevalent primary chronic 
glomerular disease, in which the mucosal immune response, especially elicited in the tonsils 
or intestine, has been estimated to be involved with the development of the disease. To 
explore the relationship between IgAN and bacterial flora in the tonsils, we conducted a 
comprehensive microbiome analysis.
Methods: We enrolled 21 IgAN patients, 14 recurrent tonsillitis (RT) patients without 
urine abnormalities and 20 children with tonsillar hyperplasia (TH) who had been performed 
with tonsillectomy. Genomic DNA from tonsillar crypts of each patient was extracted, and 
V4 regions of the 16S ribosomal RNA (rRNA) gene were amplified and analyzed using a 
high-throughput multiplexed sequencing approach. Differences of the genus composition 
among three groups were statistically analyzed by PERMANOVA, and visualized by 
principal component analysis (PCA).
Results: In 16S rRNA analysis, substantial diversity of bacterial compositions was 
detected in each sample. Prevotella, Fusobacterium, Sphingomonas, and Treponema were 
dominated in IgAN. The proportion of the Haemophilus spp., Porphyromonas spp., and 
Treponema spp. of IgAN was different from that of TH. However, there was no bacterial 
genus that differs significantly in the frequency of between IgAN and RT. The PCA did not 
separate IgAN from RT, although it was discriminated from TH. In addition, we compared 
the bacterial composition between IgAN patients with higher and lower serum IgA levels; 
however, no difference in composition of microbiome between the two groups was observed.
Conclusions: Similar pattern of bacteria are present in tonsillar crypts of both IgAN 
and RT, suggesting that the host responsiveness to these bacteria is important in the 
development of IgAN.
TH-PO784
Urinary N-Acetyl-β-D-Glucosaminidase Level Is Associated with 
Tubulointerstitial Fibrosis and Therapeutic Response in Immunoglobulin 
A Nephropathy  Yosuke Yamada, Makoto Harada, Akinori Yamaguchi, Koji 
Hashimoto, Makoto Higuchi, Yuji Kamijo.  Dept of Nephrology, Shinshu Univ 
School of Medicine, Matsumoto, Nagano, Japan.
Background: Therapeutic response in Immunoglobulin A nephropathy (IgAN) 
patients has been shown to be affected by the severity of chronic renal lesion, such as 
tubulointerstitial fibrosis. Urinary N-acetyl-β-d-glucosaminidase (U-NAG) is a known 
biomarker of tubulointerstitial injury. The present study aimed to clarify if U-NAG level 
was associated with the severity of tubulointerstitial fibrosis and whether it could predict 
the effectiveness of combined steroid pulse and tonsillectomy therapy (ST), which is the 
primary treatment for IgAN in Japan.
Methods: Among the 81 IgAN patients who were diagnosed by kidney biopsy and 
treated with ST between March 2005 and April 2015 at Shinshu University Hospital, 
the U-NAG data of 77 patients were investigated for relationships between clinical and 
histological data. To search for associations between U-NAG level and clinical remission 
(CR) rate, we examined 39 of the above 77 patients who were observed for 3 years following 
ST. CR was defined as proteinuria of less than 0.3 g/gCre and urinary erythrocytes of less 
than 5 /high-power field.
Results: Multiple linear regression analysis adjusted by age and estimated glomerular 
filtration rate (eGFR) indicated that U-NAG level was significantly associated with 
tubulointerstitial fibrosis score (p<0.001) and the percentage of global sclerotic glomeruli 
(p=0.008). Multiple logistic regression analysis adjusted by age, sex and eGFR indicated 
that the CR rate 3 years after ST was significantly associated with tubulointerstitial fibrosis 
score (Odds Ratio [OR] 0.092, 95% Confidence Interval [CI] 0.009-0.914, p=0.042) and 
U-NAG level (OR 0.713, 95%CI 0.530-0.958, p=0.025).
Conclusions: U-NAG is a potentially useful biomarker of the severity of renal 
tubulointerstitial fibrosis and global glomerular sclerosis percentage in IgAN. U-NAG 
measurement may also aid in the prediction of therapeutic response to ST in IgAN.
TH-PO785
Beneficial Effect of Immunosuppressive Therapy for IgA Nephropathy with 
Moderately Impaired Renal Function  Kyung sun Park,1 Jongha Park,2 Jong 
Soo Lee,2 Hyun Chul Chung.2  1Div of Nephrology, Dept of Internal Medicine, 
Dongkang Medical Center, Ulsan, Korea; 2Div of Nephrology, Dept of Internal 
Medicine, Ulsan Univ Hospital, Ulsan, Korea.
Background: A variety of treatment has been attempt to slow progression of IgA 
nephropathy (IgAN) such as renin-angiotensin system inhibitors and adding corticosteroid 
for patients with impaired renal function. We compared clinical outcomes of IgAN patients 
who were treated with vs. without immunosuppressive therapy (IST), and explored identified 
risk factors associated with progression of renal dysfunction.
Methods: Patients who were diagnosed as IgAN between 2001 and 2014 were screened. 
Among them, patients who had initial estimated glomerular filtration rate (eGFR) of 30-60 
mL/min/1.73 m2 and had followed up for at least 12 months were included in this analysis.
Results: A total of 92 patients were analyzed. 39 patients received IST (Group 1) and 53 
did not (Group 2). Median follow-up (59 vs. 77 months) and mean age (46.6 vs. 47.4 years) 
were not different. In Group 1, mean arterial pressure (MAP, 99 vs. 93 mmHg, P=0.019), 
serum creatinine (1.66 vs. 1.45 mg/dL, P=0.003), and median amount of proteinuria (2033 
vs. 1115 mg/day, P<0.001) were significantly higher, but mean eGFR (43.7 vs. 50.1 mL/
min/1.73 m2, P<0.001) and serum albumin (3.5 vs. 4.0 g/dL, P=0.009) were lower than 
Group 2 at baseline. Three patient of Group 1 and 7 of Group 2 progressed to end-stage 
renal disease (ESRD). ESRD-free survival was comparable between two groups (P=0.639). 
For 1 year, the change of mean eGFR was significantly different between 2 groups (3.8 of 
Group 1 vs. -1.3 mL/min/1.73 m2 of Group 2, P=0.027).
Group 1 (n=39) Group 2 (n=53) P
Mean eGFR;ml/min/1.73m2
.baseline
.at 1 year
.change
43.7
47.5
3.8
50.1
48.8*
-1.3 0.027
P=0.069, *P=0.179 compared to baseline 
In multivariate linear regression, age at diagnosis (standardized beta, 0.212; P=0.041), 
MAP (standardized beta, -0.227; P=0.027), baseline eGFR (standardized beta, 0.566; 
P<0.001) and IST (standardized beta, 0.273; P=0.013) were independent predictors of 
last-visit eGFR.
Conclusions: IST may have a beneficial effect for slowing progression of IgAN with 
moderately impaired renal function.
TH-PO786
Longitudinal Study of a Kindred with Familial IgA Nephropathy Reveals 
Stable Serum Levels of Galactose-Deficient IgA1  Hiroyuki Ueda,1,2 Yoshimi 
Ueda,1,2 Zina Moldoveanu,1 Stacy D. Hall,1 Karen Hart,1 Krzysztof Kiryluk,3 
Ali G. Gharavi,3 Dana Rizk,1 Bruce A. Julian,1 Jan Novak.1  1Univ of Alabama 
at Birmingham, Birmingham, AL; 2The Jikei Univ School of Medicine, Tokyo, 
Japan; 3Columbia Univ College of Physicians and Surgeons, New York, NY.
Background: Patients with IgA nephropathy (IgAN) have elevated levels of circulatory 
galactose-deficient IgA1 (Gd-IgA1). Familial form of IgAN has been reported among people 
of all ancestries. Serum Gd-IgA1 levels are heritable in patients with familial and sporadic 
IgAN. Moreover, 50% of first-degree relatives of patients with familial IgAN have high 
serum Gd-IgA1 levels (≥95th percentile of healthy controls) without clinical signs of IgAN. 
This study is a longitudinal follow-up of a large kindred with familial IgAN.
Methods: Pedigree includes 4 men with biopsy-proven IgAN. Members recruited 
in 2005 and 2014 included 2 IgAN patients, 13 relatives, and 7 genetically unrelated 
individuals (marry-ins). Blood samples were drawn to determine for total IgA and Gd-IgA1 
levels. Gd-IgA1 was measured using lectin ELISA and expressed relative to a standard 
Gd-IgA1 in U/100 ng of serum IgA. Spot urine sample was obtained for urinalysis and 
protein/creatinine ratio. Abnormal urinalysis was defined by hematuria (³2+ blood) and/or 
protein/creatinine ratio ³0.5 g/g.
Results: Mean (± SD) ages of IgAN patients, blood relatives, and marry-ins were 48 
(±3), 43 (±16), 61 (±12) yr in 2014. Two patients had multiple kidney transplantations. 
Except for the 2 IgAN patients, no individual had an abnormal urinalysis. Serum Gd-IgA1 
levels for marry-ins were similar to other healthy controls. Serum Gd-IgA1 levels were 
higher in blood relatives and IgAN patients than in marry-ins at each sampling time (P 
= 0.03). Serum Gd-IgA1 levels demonstrated longitudinal stability in most individuals 
(Intraclass correlation coefficient = 0.812; 95% CI 0.604-0.917).
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Conclusions: Serum Gd-IgA1 levels in 22 individuals in this multiplex IgAN pedigree 
were stable over a 9-year period. No blood relative developed IgAN or exhibited a urinary 
abnormality during the 9-year follow-up.
Funding: NIDDK Support, Private Foundation Support
TH-PO787
Childhood IgA Nephropathy with Nephrotic Syndrome (NS-IgAN) at 
Onset  Yuko Shima,1 Koichi Nakanishi,1 Taketsugu Hama,1 Masashi Sato,1 
Hiroko Togawa,1 Hironobu Mukaiyama,1 Hiroshi Kaito,2 Kandai Nozu,2 Ryojiro 
Tanaka,3 Kazumoto Iijima,2 Norishige Yoshikawa.4  1Pediatrics, Wakayama 
Medical Univ, Wakayama, Japan; 2Pediatrics, Kobe Univ, Kobe, Japan; 
3Pediatric Nephrology, Hyogo Childrens¶ Hospital, Kobe, Japan; 4National 
Center for Child Health and Development, Tokyo, Japan.
Background: Clinical characteristics and long term outcomes of childhood NS-IgAN 
are not fully clarified.
Methods: We retrospectively analyzed 426 consecutive biopsy-proven samples of 
childhood IgAN from July 1976 to June 2013. There were 30 cases with NS-IgAN (7.0%) 
at onset. We compared clinical and pathological findings between NS- and other IgAN.
Results: Clinical findings showed significant differences (NS vs non-NS) in males 
(77 vs 53%, p=.008), gross hematuria (77 vs 51%, p=.006), and duration from onset to 
renal biopsy (1.5 vs 8.4 months, p<.001). Pathological findings had significant differences 
in mean mesangial hypercellularity score (M, 1.5 vs 0.8, p<.0001), median endocapillary 
hypercellularity (E, 27.3 vs 3.9%, p<.0001), and median crescents (C, 15.2 vs 3.6%, 
p=.0006). Logistic analyses showed a significant relation between M, an acute lesion, and 
NS-IgAN. Although Kaplan–Meier analysis showed significantly lower renal survival rate 
in cases with NS-IgAN than other cases (p=.02), the 10-year renal survival rate of NS-IgAN 
was 92.7% (95%CI=75.0–98.2). The prognostic factors for renal survival were proteinuria 
disappearance, M, E, tubular atrophy/interstitial fibrosis (T) and C, but not presence of 
NS at onset. Combination therapy including PSL and immunosuppressants was given to 
20/30 NS-IgAN patients, and 21 showed disappearance of proteinuria. Three cases (9.7%) 
developed chronic renal failure (eGFR<60) during the observation period (6.2±3.2 years). 
All three cases received combination therapy and showed heavy proteinuria after 2 years 
of treatment. The factor T, a chronic lesion unmodifiable by treatment, was identified in 
patients refractory to treatment.
Conclusions: Renal outcome of childhood NS-IgAN was good. Modifiable acute 
lesions are the dominant pathological findings in childhood NS-IgAN.
TH-PO788
Predictive Factors of Spontaneous Remission in Patients with 
Immunoglobulin A Nephropathy  Tae-Hyun Yoo,1 Kyoung Sook Park,1 Tae 
ik Chang,2 Shin-Wook Kang.1  1Dept of Internal Medicine, Yonsei Univ College 
of Medicine, Seoul, Korea; 2Dept of Internal Medicine, NHIC Ilsan Hospital, 
Gyeonggi-do, Korea.
Background: Although immunoglobulin A nephropathy (IgAN) is commonly 
considered as a lifelong disease, incidences of spontaneous remission (SR) have been 
occasionally reported. We investigate the incidence as well as the clinical predictors of 
SR in IgAN.
Methods: Medical records of biopsy-proven IgAN in Severance hospital from 2006 
to 2014 were reviewed. SR was defined as complete remission reached without any 
immunosuppressive therapy. Two different SR criteria were used to classify the patients into 
SR or non-SR (NR) group. A criteria proposed in previous reports was chosen as criteria 
I [urine red blood cell (RBC) count<5/HPF and random urine protein-to-creatinine ratio 
(UPCR)<0.3 g/g]. Criteria II was defined to better represent a normal renal function state 
[urine RBC<3/HPF, UPCR<0.2 g/g, and estimated glomerular filtration rate (eGFR)>60 
mL/min/1.73m2]. Cox proportional hazard analysis was performed to identify independent 
predictors of SR.
Results: A total of 488 patients were investigated. The mean age was 36.9±12.2 
years and 43.2% were male. Mean eGFR at the time of renal biopsy was 87.2±30.0 mL/
min/1.73m2. SR occurred in 95 patients (19.5%) by criteria I and in 61 patients (12.5%) by 
criteria II. According to the classification based on criteria II, SR group showed lower levels 
of UPCR (0.64±1.05 vs.1.44±1.52 g/g, P<0.001) and higher serum albumin concentrations 
(4.4±0.5 vs. 4.1±0.5 g/dL, P<0.001) compared with NR group. In multivariate Cox hazard 
models for prediction of SR, the levels of UPCR [per 1 g/g increase, criteria I, hazard ratio 
(HR)=0.58, 95% confidence interval (CI)=0.41-0.83, P=0.003; criteria II, HR=0.63, 95% 
CI=0.40-0.99, P=0.047] was an independent predictor of SR after adjustment for age, sex, 
diabetes, mean arterial pressure, eGFR, serum albumin concentrations, Haas subclass, and 
the use of renin-angiotensin-aldosterone system blockers.
Conclusions: The incidence of SR in IgAN was substantially frequent. UPCR levels 
may be an independent predictor of SR in patients with IgAN.
TH-PO789
Comparison of the Effect of Oral Steroid and Tonsillectomy Combined 
with Steroid Pulse Therapy for IgA Nephropathy  Yoshie Hoshino, Takahito 
Moriyama, Mitsuyo Itabashi, Takashi Takei, Ken Tsuchiya, Kosaku Nitta.  Dept 
of Medicine, Kidney Center, Tokyo :omen¶s Medical Univ, Tokyo, Japan.
Background: Recently, in Japan, IgA nephropathy (IgAN) has been often treated by 
tonsillectomy combined with steroid pulse therapy (TSP) instead of traditional oral steroid 
therapy (oPSL). However, there are few reports described about the comparison of them.
Methods: We identified the 68 IgAN patients who were diagnosed in our institution 
between 1991 and 2013, and met the following criteria: (1) age³16 years old; (2) proteinuria 
>1 g/day; (3) estimated glomerular filtration rate (eGFR) ³30 ml/min/1.73m2; (4) treated 
by TSP or oPSL with our standard protocol; (5) follow-up period >1 year; (6) interval from 
renal biopsy to initiation of therapy £3 years; (7) not combined with other renal disease. We 
compared the clinical findings at the time of renal biopsy, histological findings, renal function 
and urinary findings during the follow-up period between both groups. We defined complete 
remission (CR) as proteinuria <0.3 g/g•creatinine and urinary red blood cells <5 counts/HF.
Results: After adjusting clinical findings by propensity score, each 20 patients were 
selected in both groups. Almost of all clinical and histological findings at baseline between 
both groups did not differ (TSP vs. oPSL group; eGFR: 77.5 vs. 75.7 ml/min/1.73m2 and 
proteinuria: 1.9 vs. 2.2 g/day). The CR rate was increased significant earlier (mean duration: 
17.7±3.4 vs. 43.9±10.8 month, p<0.001) and higher (at 3 years: 61 % vs. 5 %, p<0.001) in 
TSP than oPSL group by Kaplan-Meier analysis. Renal function was decreased from baseline 
in both groups, however the ratio of patients with renal dysfunction (25% decreasing from 
baseline eGFR) was significantly lower in TSP than oPSL group during 3 years (at 3 years: 
7 vs. 50 %, p<0.001). TSP (HR 4.00, 95%CI 1.03-21.06, p=0.04, higher eGFR (HR 2.43, 
95%CI 1.10-5.80, p=0.03), lower triglyceride (HR 1.44, 95%CI 1.05-2.10, p=0.02) were 
the contributive factors to CR in multivariate analysis.
Conclusions: TSP therapy is useful for reaching CR and protecting renal function 
rather than oPSL therapy for IgAN with moderate to severe proteinuria.
TH-PO790
Evaluation of KDIGO Clinical Practice Guidelines for IgA Nephropathy 
by Japanese Multicenter Large Cohort Study  Kyoko Watanabe,1 Kentaro 
Koike,2 Akihiro Shimizu,2 Nobuo Tsuboi,2 Keita Hirano,1 Makoto Ogura,2 
Sayuri Shirai,3 Yoshinari Yasuda,4 Takashi Yasuda,5 Shoichi Maruyama,4 Tetsuya 
Kawamura,2 Seiichi Matsuo,4 Takashi Yokoo.2  1Ashikaga Red Cross Hospital, 
Ashikaga, Tochigi, Japan; 2Div of Nephrology and Hypertension, The Jikei Univ 
School of Medicine, Minato-Ku, Tokyo; 3Div of Hypertension and Nephrology, 
St. Mariana Univ, Kanagawa, Japan; 4Nephrology, Nagoya Univ, Nagoya, 
Japan; 5Nephrology, Kichijooji Asahi Hospital, Musashino-shi, Tokyo, Japan.
Background: Current KDIGO clinical practice guidelines for IgA nephropathy (IgAN) 
neither advocate tonsillectomy nor steroid therapy for patients with eGFR<50ml/min.
However,IgAN patients referred to nephrologists often have reduced eGFR at the time 
of referral.Therefore,we evaluated the KDIGO guidelines to assess,and further develop 
their clinical significance for treatment of IgAN with reduced eGFR by a large multicenter 
cohort study in Japan.
Methods: Of 1,174 patients registered for the multicenter cohort study led by the 
Progressive Kidney Disease Study Group funded by Japan Ministry of Health,Labor,and 
Welfare in 2012,cases with eGFR<50ml/min at the time of biopsy were selected.Primary 
outcome was defined as 1.5 times increase in creatinine concentration from baseline.
Results: Enrolled 201 patients showed 36.8 ml/min as mean eGFR and 1.15 g/day as 
median level of proteinuria. During the median follow up of 4 years,70 patients (34.8%) 
reached primary outcome. Like KDIGO recommendations,multivariate analysis adjusted 
with eGFR, proteinuria,and blood pressure at baseline revealed that steroid therapy alone 
did not significantly improve renal prognosis compared with no steroid therapy (hazard 
ratio [HR] 0.74; 95% confidence interval [CI] 0.43 to 1.25). By contrast,combining steroid 
therapy with tonsillectomy demonstrated significantly improved renal survival compared 
to no steroid therapy (HR 0.25; 95%CI 0.06 to 0.71).
Conclusions: In keeping with KDIGO recommendations, our results did not suggest 
improvement in renal prognosis by steroid therapy alone for IgAN with eGFR <50ml/
min.However,they indicated that combining steroid therapy with tonsillectomy could be 
associated with a significantly better renal outcome.
TH-PO791
The Effect of Renin-Angiotensin System Blockade on the Incidence of 
End-Stage Renal Disease in IgA Nephropathy  Shigeru Tanaka,1 Toshiharu 
Ninomiya,1,5 Ritsuko Katafuchi,2 Kosuke Masutani,1 Masaharu Nagata,1 Akihiro 
Tsuchimoto,1 Hideki N. Hirakata,3 Kazuhiko Tsuruya,1,4 Takanari Kitazono.1,5 
1Dept of Medicine and Clinical Science, Graduate School of Medical Sciences, 
Kyushu Univ, Fukuoka, Japan; 2Kidney Unit, National Fukuoka-Higashi Medical 
Center, Fukuoka, Japan; 3Nephrology and Dialysis Center, Japanese Red Cross 
Fukuoka Hospital, Fukuoka, Japan; 4Dept of Integrated Therapy for Chronic 
Kidney Disease, Graduate School of Medical Sciences, Kyushu Univ, Fukuoka, 
Japan; 5Div of Research Management, Center for Cohort Studies, Graduate 
School of Medical Sciences, Kyushu Univ, Fukuoka, Japan.
Background: The impact of renin-angiotensin system blockade (RASB) on the 
incidence of end-stage renal disease (ESRD) remains unclear in IgA nephropathy (IgAN). 
This study assessed associations between RASB treatment and the incidence of ESRD in 
IgAN using propensity score approaches.
Methods: We retrospectively analyzed 1267 patients with IgAN biopsied between 
1979 and 2010. Propensity scores were calculated using logistic regression. Associations 
between RASB and ESRD were examined using a Cox regression model adjusted by inverse 
probability of treatment weighted, regression, stratification and matching.
Results: During follow-up (median 5.1 years), 130 patients developed ESRD. With 
Cox regression adjusted by inverse probability of treatment weighted, RASB use was 
significantly associated with a lower risk of ESRD (hazard ratio, 0.57; 95% confidence 
interval, 0.41–0.79). Significant associations were observed for other propensity score-based 
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approaches. In stratified analysis, a beneficial association between RASB and ESRD was 
observed in patients ³35 years, with hypertension, reduced estimated glomerular filtration 
rate (<60 mL/min/1.73 m2), mesangial proliferation and segmental glomerulosclerosis 
(P for interaction <0.05), and tended to be greater in patients with proteinuria (³1.0 g/24 
h), extracapillary proliferation, and receiving methylprednisolone pulse therapy (P for 
interaction <0.10).
Conclusions: Treatment with RASB was associated with a lower incidence of ESRD 
in the real-world practice of IgAN.
TH-PO792
Long-Term Outcome in 56 Patients with Assumed Benign IgA Nephropathy 
Thomas Knoop, Bjorn Egil Vikse, Einar Svarstad, Sabine Leh, Rune 
Bjoerneklett.  Renal Research Group, Dept of Clinical Medicine, Univ of 
Bergen, Bergen, Norway.
Background: Patients with IgA nephropathy (IgAN) presenting with mild to moderate 
proteinuria and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m² are assumed 
to have excellent renal prognosis. There is however limited data on very long-term outcome 
(>15 years) in such patients.
Methods: Patients with biopsy proven IgAN were retrieved from the Norwegian 
Kidney Biopsy Registry when fulfilling the following criteria; biopsy taken at Haukeland 
University Hospital 1988-1999, eGFR ≥ 60 mL/min/1.73m² and proteinuria < 1 gram/24 
hours at presentation. Patients were invited for a medical examination and the following 
data were recorded: responsible physician during follow-up period (none/primary physician/
nephrologist), antihypertensive treatment (any/ angiotensin converting enzyme inhibitor 
(ACE-I)/angiotensin receptor blocker ARB)), blood pressure (BP), eGFR, urinary albumin 
creatinine ratio (UACR) (0-2.5 mg/mmol creatinine (negative) / 2.5–30 (microalbuminuria) 
/ 30-100 (manifest albuminuria) />100 mg/mmol creatinine) and hematuria.
Results: We report data for 56 patients with a median follow-up time of 22 years 
after diagnosis. Nine patients (16 %) had no medical follow-up, thirty-five patients (63 %) 
were followed by a primary physician on a regular basis, and twelve patients (21 %) were 
followed by a nephrologist. Thirteen patients (23 %) had eGFR < 60ml/min/1.73m2 (eight 
with eGFR 30-45 and five with eGFR 45-60). Fifteen patients (27 %) had microalbuminuria, 
six patients (11 %) had manifest albuminuria and three patients (5 %) had UACR > 100 mg/
mmol creatinine. Twenty-three patients (41 %) were treated with an ACE-I/ARB. Fifteen 
patients (27 %) had hypertension (BP >140/90 mmHg), nine of these had antihypertensive 
treatment and six were untreated. Nineteen patients (34%) had hematuria. Ten patients (18 
%) had no medication, normal BP, eGFR ≥60 ml/min/1.73m2 and normoalbuminuria. Of 
notice, several patients with no medical follow-up had microalbuminuria, hypertension 
and/or decreased eGFR < 60ml/min/1.73m2.
Conclusions: Prognosis in patients with assumed benign IgAN is not always favorable 
and adequate medical follow-up is needed.
Funding: Government Support - Non-U.S.
TH-PO793
J-Curve Effects of Uric Acid on the Progression of IgA Nephropathy 
Yuta Matsukuma,1 Shigeru Tanaka,1 Kosuke Masutani,1 Akihiro Tsuchimoto,1 
Ritsuko Katafuchi,2 Hideki N. Hirakata,3 Kazuhiko Tsuruya,1,4 Takanari 
Kitazono.1  1Dept of Medicine and Clinical Science, Kyushu Univ, Fukuoka, 
Japan; 2National Fukuoka Higashi Medical Center, Fukuoka, Japan; 3Japanese 
Red Cross Fukuoka Hospital, Fukuoka, Japan; 4Dept of Integrated Therapy for 
Chronic Kidney Disease, Kyushu Univ, Fukuoka, Japan.
Background: Recently, low uric acid (UA) as well as high UA has been emerged 
as a risk factor for cardiovascular disease (CVD).However the impact of low UA on the 
outcome of IgA nephropathy(IgA–N) remains unknown.
Methods: We retrospectively investigated 1226 patients with IgA-N diagnosed between 
1978 and 2010. Patients were divided into three groups by tertile of UA: low (T1), middle 
(T2), and high (T3) tertiles (<6.1, 6.1–7.1, and >7.1 mg/dL in men and <4.4, 4.4–5.4, and 
>5.4 mg/dL in women, respectively). The risk factors of developing end stage kidney 
disease (ESKD) were assessed using a Cox proportional hazards model.
Results: After an average of 5.2 years of follow–up, 145 patients (11.8%) developed 
ESKD. High UA was an independent risk factor for ESKD after adjusting for potential 
confounding factors, hazard ratio (HR) for men, 1.27; 95% confidence interval [CI], 1.07 
to 1.49, and HR for women, 1.41; 95% CI, 1.11 to 1.78, for every 1-mg/dL increase in 
UA), respectively. We also found that the HR showed a J-shaped trend with tertile of UA 
in both men (HR for T1, 1.24; 95% CI, 0.56 to 2.67, T2 [reference], HR for T3, 1.78; 95% 
CI, 1.03 to 3.21) and women (HR for T1, 2.64; 95% CI, 1.08 to 6.67, T2 [reference], HR 
for T3, 2.16; 95% CI, 1.06 to 4.86). Notably, low UA in women was significantly associated 
with the progression to ESKD.
Conclusions: UA showed a J–shaped trend with the progression of IgA–N. Not 
only high UA but also low UA is a risk factor for ESKD, and the trend was more clearly 
observed in women.
TH-PO794
Remission of Urinary Protein at 2 Years After Diagnosis with Normal 
Renal Function and Remission of Urinary Protein at 1 Year After Diagnosis 
with Decreased Renal Function as an Accurate Prognostic Marker in IgA 
Nephropathy  Takayuki Fujii,1 Junichi Hoshino,2 Joichi Usui,3 Satoshi Suzuki,1 
Yoshifumi Ubara,2 Kunihiro Yamagata.3  1Seirei Sakura Citizen Hospital, Sakura, 
Japan; 2Toranomon Hospital, Tokyo, Japan; 3Univ of Tsukuba, Tsukuba, Japan.
Background: Level of proteinuria (UP) has a strong association with poor renal 
prognosis in IgA nephropathy. Recent studies reported that the level of UP, especially, 
remission of UP (CR) defined as less than 0.3 g/d, during the follow-up was a more accurate 
prognostic factor than at diagnosis. In this multicenter study, we evaluated which post-
diagnosis measurement point achieving CR strongly associated with the renal prognosis.
Methods: 1,077 patients diagnosed with IgA nephropathy between March 1981 and 
December 2013, and could be followed-up for at least 3 years or reached end-stage kidney 
disease (ESKD) were enrolled. We performed a retrospective cohort study among 2 divided 
groups: 638 with eGFR≥60 mL/min/1.73m2 (A) and 439 with eGFR<60 mL/min/1.73m2 
(B). The endpoint of this study was a 50% decrease in eGFR or ESKD. The annual daily 
UP level until 3 years after diagnosis was categorized into 2 grades: <0.3 g/d and ³0.3 
g/d and its association with the renal prognosis was investigated. The hazard ratio of the 
endpoint adjusted with clinical and pathological findings and treatment was examined.
Results: Regarding CR as a reference, UP³0.3 g/d was not a significant poor prognostic 
factor at diagnosis, but at 1 year, especially at 2 years, it became a significant factor in 
group A. On the other hand, in group B, UP³0.3 g/d was already shown to be a significant 
factor at diagnosis and the strongest factor at 1 year.
eGFR≥60 ml/min/m2 eGFR<60 ml/min/m2
Measurement 
point
UP<0.3 
g/d
HR(95%CI) with 
UP≥0.3 g/d
UP<0.3 
g/d
HR(95%CI) with 
UP≥0.3 g/d
at diagnosis reference 1.97(0.96-4.58) reference 2.33(1.26-5.26)
after 1 year reference 4.91(2.03-14.64) reference 16.54(6.76-54.82)
after 2 years reference 10.84(3.68-48.33) reference 4.91(2.62-10.11)
Conclusions: CR within 2years after diagnosis with normal renal function and CR 
within 1year after diagnosis with decreased renal were the most accurate predictors for a 
favorable outcome in IgA nephropathy.
TH-PO795
Copeptin, a Surrogate Marker for AVP, Is Associated with Disease Severity 
and Progression in IgA Nephropathy Patients  Debbie Zittema,1 Jan A.J.G. 
van den Brand,2 Jack F. Wetzels,2 Ron T. Gansevoort.1  1Nephrology, Univ 
Medical Center Groningen, Groningen, Netherlands; 2Nephrology, Radboud 
Univ Medical Center, Nijmegen, Netherlands.
Background: The disease course of IgA Nephropathy (IgAN) is difficult to predict. 
Copeptin, a surrogate marker for AVP, has been described to cause kidney damage in 
various renal diseases. We investigated therefore the associations of copeptin with disease 
severity and progression in IgAN.
Methods: Included were 60 biopsy proven IgAN patients from the Radboud UMC 
Nijmegen, of whom urine and blood samples were available. Urinary excretion of a1M, 
b2M, KIM-1 and NGAL and plasma copeptin was measured at baseline. Survival analyses 
was performed for the composite outcome death, end stage renal disease (ESRD), doubling 
of serum creatinine, start of immunosuppressive therapy and the individual components.
Results: In IgAN patients (male: 72%, age: 42±13 year, eGFR: 48±21 mL/min/1.73m2, 
copeptin: 9.4 (5.5-18.1) pmol/L) copeptin was associated at baseline with proteinuria (St. 
β=0.34, p=0.05), a1M (St. β=0.41, p=0.003) and b2M (St. β=0.38, p=0.005), adjusted for 
age, sex and eGFR, and with NGAL when adjusted for age and sex (St. β=0.34, p=0.01). 
During a follow-up of 7±3 years, copeptin (divided in tertiles) was positively associated 
with the composite outcome (p=0.03) and with start of immunosuppressive therapy (p=0.04) 
using a log rank test. When patients who started immunosuppressive therapy during follow 
up (n=14) were excluded, copeptin (as continuous variable) was furthermore associated with 
the incidence of ESRD (p=0.01, HR=1.09; i.e. a 9% increase in risk of ESRD per 1 pmol/L 
increase in copeptin), doubling of serum creatinine (p=0.004, HR= 1.07) and the composite 
outcome (p=0.003, HR= 1.07) in Cox regression models, adjusting for proteinuria and sex. 
After additional adjustment for eGFR, which is debatable as eGFR decline could be part of 
the causal pathway between copeptin and outcomes, the survival analyses lost significance.
Conclusions: Copeptin is a promising disease severity marker in IgAN with additive 
predictive value for future kidney function loss over proteinuria, but not over eGFR, the 
strongest predictor of disease progression in this study.
Funding: Government Support - Non-U.S.
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TH-PO796
Clinical Outcomes of Nephrotic Syndrome in IgA Nephropathy 
Eu gene Jeong,1 Su mi Lee,1 Young ki Son,1 Dongyeol Lee,2 Hansae Kim,2 
Sung Hyun Son.3  1Dept of Internal Medicine, Dong-A Univ Hospital, Busan, 
Republic of Korea; 2Dept of Internal Medicine, Bong Seng Memorial Hospital, 
Busan, Republic of Korea; 3Dept of Internal Medicine, BHS Han Seo Hospital, 
Busan, Republic of Korea.
Background: Uncommonly, IgA nephropathy can be complicated by nephrotic 
syndrome. In such cases, although, corticosteroid therapy should be recommended, the 
response to steroid treatment has been variable, and spontaneous remission without steroid 
treatment can occur in some cases. Here, we report our experience of clinical outcomes of 
nephrotic syndrome in patients with IgA nephropathy.
Methods: Thirty-three patients with biopsy-proven IgA nephropathy with nephrotic 
syndrome were enrolled between March 1990 and March 2009 in Dong-A university 
hospital. We retrospectively analyzed the data, including demographic, clinical, and 
laboratory records.
Results: The mean follow-up duration were 62 ± 45 months (10-204) in 33 patients. 
Complete remission occurred in 10 patients with steroid therapy and 2 patients without 
steroid therapy. Partial remission occurred in 7 patients with steroid therapy and 8 patients 
without steroid therapy. There were 6 patients with progressive deterioration of kidney 
function during follow-up periods.
Conclusions: Of IgA nephropathy patients with nephrotic syndrome, 36% of patients 
have complete remission, 45% of patients have partial remission. Steroid treatment may 
effectively reduce proteinuria. However, spontaneous remission occurs in some cases. 
Large-scale studies may be necessary in the future.
TH-PO797
Comparative Outcomes in Primary Glomerulonephritis Among a Large 
Diverse United States Population  John J. Sim,1 Michael Batech,2 Teresa N. 
Harrison,2 Taurino N. Avelar,1 Aviv Hever.1  1Nephrology and Hypertension, 
Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA; 2Research and 
Evaluations, Kaiser Permanente Southern California, Pasadena, CA.
Background: Glomerulonephritis (GN) remains an important cause of end stage renal 
disease (ESRD) in the United States and the world. Within a large diverse population of 
an integrated health system, we sought to evaluate rates of primary GN and then compare 
ESRD and mortality outcomes within different GN’s.
Methods: Retrospective longitudinal cohort study in the period 1/1/2000 through 
12/31/2013 among patients within Kaiser Permanente Southern California. Patients who 
had biopsy proven primary GN were characterized and followed until they reached the 
outcome of ESRD or mortality. ESRD was defined as receiving dialysis or renal transplant.
Results: 2,849 patients were identified with biopsy proven GN. The mean age of the 
cohort was 47 yrs with 48% females, 37% Hispanics, 30% whites, 17% blacks, and 12% 
Asians. Focal segmental glomerulosclerosis (FSGS) was the most common GN among all 
race/ethnic groups (36% overall) followed by membranous GN (MGN) (12%), minimal 
change disease (MCD)(11%), IgA nephropathy (IgAN) (10%), and others (31%). The mean 
follow up was 3.8 yrs. ESRD occurred in 26% (704 required dialysis and 38 had a renal 
transplant). Mortality occurred in 18%. ESRD occurred among 35% of FSGS, 19% among 
IgAN, 12% among MGN, 10% among MCD, and 29% among other GN’s.
Conclusions: Among a large racially/ethnically diverse United States population, FSGS 
was the most prevalent GN and was associated with the highest rate of progression to ESRD 
among all race/ethnic groups. This diverse cohort may give insight into characterizing and 
risk stratifying different GN’s which may pave the way for more optimal management 
strategies.
Funding: Pharmaceutical Company Support - Questcor Pharmaceuticals
TH-PO798
A Specific Transcriptomic Profile Characterizes Peripheral Blood 
Mononuclear Cells (PBMCs) from Uremic Patients (pts) Treated with 
On Line Hemodiafiltration (OL-HDF) Compared to Those Treated with 
Bicarbonate Dialysis (BHD)  Simona Simone,1 Annarita Chieti,1 Matteo 
Accetturo,1 Roberto Corciulo,1 F. Rascio,2 Paola Pontrelli,1 Giovanni Stallone,2 
Loreto Gesualdo,1 Giuseppe Grandaliano,2 Giovanni B. Pertosa.1  1Dept of 
Emergency and Organ Transplantation, Univ of Bari, Italy; 2Dept of Medical 
and Surgical Sciences, Univ of Foggia, Italy.
Background: Recent studies suggest that OL-HDF can reduce the progression of 
dialysis-related cardiovascular diseases, but the molecular mechanisms underlying this 
improvement are not yet known. The aim of our study was to identify, through a high-
throughput approach, differences in gene expression profiles of PBMCs from pts undergoing 
OL-HDF compared to BHD.
Methods: The transcriptomic profile was evaluated in PBMCs isolated from 10 pts 
regularly dialyzed with OL-HDF (convective volume³22 L) and 10 pts treated with BHD 
using microarray analysis (Agilent Technologies). The results were evaluated by statistical 
(unpaired t test) and functional pathway analysis (Ingenuity Pathway Analysis).
Results: We observed that 868 genes were differentially expressed in the comparison 
between OL-HDF and BHD (fold change>1.5). Thirty-seven functional gene networks 
were identified and atherosclerosis signaling was the top canonical pathway associated 
with BHD (p=2.45x10-4). Among the downregulated genes in OL-HDF there were PDGF 
(FC -2.13) and Clusterin (FC -2.14), involved in vascular injury and Monoamine Oxidase 
A (MAO-A, FC=-2.43), an important source of oxidative stress and a major contributing 
factor to the development of ventricular hypertrophy and hearth failure. Interestingly, 
Apolipoprotein E (Apo-E) gene, an anti-oxidant/inflammatory protein, was upregulated 
(FC=+1.7) by OL-HDF. qPCR, performed in an independent testing-group [15 BHD, 15 
OL-HDF] confirmed that PDGF, Clusterin and MAO-A were down-expressed in OL-HDF 
(p=0.01), whereas APO-E resulted higher expressed (p<0.01).
Conclusions: The OL-HDF can contribute to cardiovascular risk reduction through 
the modulation of pathways involved in the progression of atherosclerotic disease. This 
observation could open new perspectives in the prevention of cardiovascular risk in 
dialysis pts.
TH-PO799
Twice-Weekly versus Thrice-Weekly Hemodialysis in Patients with or 
without Residual Kidney Function  Hyeon Seok Hwang,1 Suk young Kim,1 Su 
Hyun Kim,2 Yong-Lim Kim,3 Yon Su Kim,4 Shin-Wook Kang,5 Chul Woo Yang.1 
1College of Medicine, The Catholic Univ of Korea, Korea; 2Chung-Ang Univ 
College of Medicine, Korea; 3Kyungpook National Univ School of Medicine, 
Korea; 4Dept of Internal Medicine, Seoul National Univ College of Medicine, 
Korea; 5Yonsei Univ College of Medicine, Korea.
Background: Residual kidney function (RKF) accounts for large solute removal and 
significantly contributes to survival benefits in hemodialysis (HD) patients. However, there 
are no reliable outcome data suggesting that the frequency of HD might be safely reduced 
in patients with substantial RKF.
Methods: A total of 685 patients receiving more than 3 months HD therapy were 
included from the CRC registry for ESRD. The presence of RKF was defined as more than 
100 ml/day of urine volume, and patients were classified into twice-weekly HD with RKF (n 
= 113), thrice-weekly HD with RKF (n = 137) and thrice-weekly HD without RKF (n = 435).
Results: The baseline RKF was significantly higher in twice-weekly HD patients with 
RKF than in thrice-weekly HD patients with RKF, and it remained higher at 12 months 
follow-up. The sum of weekly renal Kt/V and delivered-standard Kt/V per week was similar 
pattern between twice-weekly and thrice-weekly HD patients with RKF. The thrice-weekly 
HD patients with RKF showed significantly higher survival rate than twice-weekly HD 
patients with RKF or thrice-weekly HD patients without RKF (P = 0.002). In multivariable 
analyses, compared with thrice-weekly HD patients without RKF, thrice-weekly HD 
patients with RKF were associated with lower risk for all-cause mortality (HR 0.11; 95% 
CI 0.02-0.53). However, twice-weekly HD treatment with RKF did not reduce the risk 
of mortality (HR 0.65; 95% CI 0.22-1.87). For hospitalization of cardiovascular events, 
thrice-weekly HD therapy with RKF was independently associated with lower risk, (HR 
0.40; 95% CI 0.16-0.98), but twice-weekly HD patients with RKF were not associated 
(HR 0.80; 95% CI 0.38-1.71).
Conclusions: Twice-weekly HD patients with RKF have similar outcome compared 
to thrice-weekly HD patients without RKF. However, thrice-weekly HD patients with RKF 
were more advantageous for mortality and CVE than those without RKF.
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TH-PO800
Comparison of Outcomes Between Incremental and Abrupt Initiation of 
Hemodialysis: A Propensity-Matched Analysis of a Prospective Cohort 
Study in Korea  Ji In Park,1,2 Yong-Lim Kim,2,3 Shin-Wook Kang,2,4 Chul Woo 
Yang,2,5 Yon Su Kim,2,6 Jung Pyo Lee.2,7  1Kangwon National Univ; 2Clinical 
Research Center of End Stage Renal Disease in Korea; 3Kyungpook National 
Univ; 4Yonsei Univ; 5The Catholic Univ of Korea; 6Seoul National Univ; 7Seoul 
National Univ Boramae Medical Center.
Background: When patients are diagnosed as end-stage renal disease (ESRD) and 
initiate hemodialysis (HD), thrice-weekly HD is a very common format. Recent report 
suggested possible benefit from beginning HD therapy less than three times weekly and 
incremental increase of dialysis dose, but there are not sufficient data. We compared 
outcomes of thrice-weekly and incremental HD.
Methods: A total of 1273 patients who were diagnosed as having ESRD and initiated 
hemodialysis from 2008 to 2014 were prospectively enrolled. The patients were classified 
into the abrupt initiation group (3 sessions/week) or the incremental initiation group (1-2 
sessions/week). We compared HRQOL evaluated by KDQOL-SF and Beck’s depression 
inventory (BDI) score at 3 months and 12 months after HD, and residual renal function 
by daily urine volume at 12 months after HD and all-cause mortality between the groups.
Results: Before propensity score matching, the abrupt group tends to be younger and 
showed smaller daily urine volume, higher modified Charlson comorbidity index (mCCI), 
and higher serum blood urea nitrogen and creatinine level compared to incremental group. 
A total of 432 patients (288 for abrupt and 144 for incremental group) were selected by 
propensity score matching. HRQOL tends to be better in incremental group for every domain 
of KDQOL-SF and BDI, but none of them showed significant difference at 3 months. At 
12 months after HD, only cognitive functioning domain was better in incremental group. 
Daily urine volume at 12 months after HD was similar in two groups. All-cause mortality 
was comparable between two groups before and after propensity score matching.
Conclusions: Incremental initiation of HD showed comparable results with abrupt 
group regarding HRQOL, residual renal function and all-cause mortality. Incremental 
HD might be considered as another format of initiating HD for selected ESRD patients.
TH-PO801
Predictors of Substantial Residual Kidney Function in the First Year of 
Hemodialysis Treatment  Yoshitsugu Obi,1 Elani Streja,1 Connie Rhee,1 Anna 
Mathew,2 Joline L.T. Chen,1 Wei Ling Lau,1 Steven M. Brunelli,3 Csaba P. 
Kovesdy,4 Rajnish Mehrotra,5 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2Hofstra 
North Shore-LIJ Health System; 3DaVita Clin Research; 4UTHSC; 5UW.
Background: Residual kidney function (RKF) plays a critical role in dialysis adequacy, 
quality of life, and survival in hemodialysis (HD) patients. Therefore, identifying predictors 
related to preservation of RKF may contribute to improving patient management and 
developing novel strategy for preserving RKF.
Methods: In a longitudinal cohort of 18,091 patients who initiated conventional HD 
over four years (1/2007-12/2010),we examined the association of baseline characteristics 
during the first 3 months of their dialysis treatment with RKF [renal urea clearance (KRU) 
and urinary volume (UV)] after one year. We employed multivariate logistic regression 
analyses using ³3 mL/min/1.73m2 of KRU or ≥600 mL/day of UV as outcomes with 
2-level adjustments for case-mix variables and laboratory measurements in addition to 
baseline RKF values.
Results: Patients were 62±14 years old, 37% female, 29% non-Hispanic Black, and 
67% diabetic. Median KRU and UV were 2.95 (IQR, 1.63-4.64) mL/min/1.73m2 and 800 
(IQR, 500-1,300) mL/day, respectively. High %lymphocyte, higher serum concentrations 
of albumin and calcium, and lower serum concentrations of creatinine and phosphorus were 
consistently associated with better preserved RKF indices irrespective of models. A history 
of congestive heart failure was an independent predictor for loss of RKF. 
Conclusions: Better nutritional and CKD-MBD indices were associated with preserved 
RKF while a history of congestive heart failure were associated with loss of RKF at 1 year 
of hemodialysis initiation in this large national cohort. Additional studies to preserve RKF 
in dialysis patients are warranted.
Funding: NIDDK Support
TH-PO802
Clinical Determinants of Ultrafiltration Rates in Hemodialysis 
Adam K. Horeish, Jeffrey M. Rimmer.  Univ of VT Med Ctr, Bulington, VT.
Background: High rates of ultrafiltration (UFR) are associated with adverse events. 
Approaches to reduce UFR other than fluid restriction alone are needed.
Methods: We examined characteristics associated with ultrafiltration rates (UFR) in 
patients dialyzed at UVMMC. Ultrafiltration rates (volume removed/pre-dialysis weight/
treatment time) are followed electronically. Charts of 233 patients treated in October 
2015 were examined with IRB approval. Patient characteristics and laboratory values 
were determined for 177 patients receiving three treatments during each of 4 consecutive 
weeks. These include average weight (PWt), treatment duration (RxT),and inter-dialytic 
weight gain (WtG); age, gender, dialysis vintage, sequence (TThS vs MWF), treating unit, 
diabetes, heart failure, prescribed diuretics, difference between serum and dialysate sodium 
(DifNa), percent urea reduction (PRU), absolute urea reduction, serum potassium, albumin, 
hemoglobin and pre and post dialysis blood pressure. The relation of weight, weight gain 
and treatment length were examined with descriptive statistics. Other potential explanatory 
variables were explored with multivariable regression models using both average UFR and 
average UFR for first weekly treatment as dependent variables.
Results: The range and median for PWt, RxT, and WtG respectively are 41.6 to 226, 
81 Kg, 3 to 5.5, 4 hrs; and 0.63 to 8.38, 2.69 kg. When the values of PWt, RxT and WtG 
are below the median, 48.4%, 44.8% and 19.1% of patients respectively have a UFR > 
10 ml/kg/hr and 15.6%, 23.9% and 48.9% if above the median. Variables significantly 
associated with UFR by regression are enumerated in table 1.
1st UFR AVG UFR
R Square 0.321 0.317
BETA P BETA P
Age -0.042 0.007 -.045 0.002
Vintage 0.014 0.025 NA NA
PreBP 0.022 0.037 0.020 0.042
DifNa 0.327 0.000 0.300 0.000
PRU 0.154 0.000 0.136 0.000
Sequence -1.452 0.000 -1.525 0.000
Unit 5 1.258 0.030 1.525 0.005
Potassium 0.502 0.000 0.596 0.000
On Lasix -0.765 0.117 -0.844 0.054
Variables not listed did not reach significance.
Conclusions: The large effect of low PWt requires long RxT to avoid high UFR with 
moderate WtG. Other prescribed variables that could be used to modify UFR include TThS 
vs MWF schedule, DifNa and possibly diuretic use.
TH-PO803
Study on Hemodialysis (HD) Time and Prognosis in Maintenance HD 
Patients: The Q-Cohort Study  Kiichiro Fujisaki,1 Shigeru Tanaka,1 Masatomo 
Taniguchi,1 Kazuhiko Tsuruya,1 Hideki N. Hirakata,2 Takanari Kitazono.1  1Dept 
of Medicine and Clinical Science, Kyushu Univ, Fukuoka, Japan; 2Div of 
Nephrology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Background: HD time has been recognized as an important factor of dialysis adequacy. 
However, there have been few reports on studying the associations between HD time and 
prognosis in maintenance HD patients. We present some findings from a prospective cohort 
study, the Q-cohort Study, which was set up to explore the risk factors for mortality in 
Japanese HD patients. In the present study, we examined the associations between HD time 
and mortality in Japanese HD patients.
Methods: A prospective multicenter cohort study (Q-Cohort Study) was conducted 
between December 2006 and December 2010. A total of 3,459 Japanese HD patients 
were prospectively followed for 4 years. We examined the association of HD time and 
prognosis using a Cox proportional hazards model. Propensity scores were calculated 
using logistic regression.
Results: During follow-up period, 566 patients died from any causes. Patients with 
HD of 5 hours or more (n = 2,144) showed significantly lower mortality risk for all cause 
death at hazard ratio = 0.82 (95% confidence interval: 0.68 to 0.99) compared with those 
with HD of less than 5 hours (n = 1,315) after adjusting for confounding risk factors. This 
association remained significant using a propensity score-based approach. We stratified 
the analysis by patient age in 10-year increments, this finding remained significant only in 
patients with older than 80 years.
Conclusions: Our results suggest that HD time of 5 hours or more improves all-cause 
mortality especially in older HD patients.
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TH-PO804
Salt Taste Sensitivity, Sodium Intake, and Fluid Status in Hemodialysis 
Panduranga S. Rao,1 Robin L. Padilla,1 Linton Cuff,1 Tanu P. Verma,1 Debra 
Peterman,1 Michael Heung,1 Scott L. Hummel,1 Peter Kotanko,2 Brenda W. 
Gillespie,1 Rajiv Saran.1  1Univ of MI; 2Renal Research Inst.
Background: Dietary Sodium intake (SI) contributes to volume status and blood 
pressure (BP) control in hemodialysis (HD) patients. Salt taste sensitivity (STS) may 
drive sodium intake, and has not been systematically studied in HD. We sought to assess 
the relationship between STS, SI, fluid status (as determined by bioelectrical impedance 
spectroscopy (BIS)) and pre-dialysis BP in HD patients.
Methods: As part of an ongoing randomized trial involving a low sodium diet, adults 
receiving outpatient HD were assessed for STS using commercial taste strips impregnated 
with 0-1.6% sodium chloride (NaCl); mean SI was estimated from 3-day food diary. Total 
Body Water (TBW) and Extracellular Volume (ECV) were estimated using whole-body 
and segmental (calf-resistivity) BIS, respectively.
Results: Baseline data on 33 enrolled patients (16 male, 17 black, 13 white, mean age 
52 ±15yr) were analyzed. Mean monthly pre-HD systolic BP was 151 ± 16 mmHg. Mean SI 
was 2.5 g/day (range: 1.1-5.2). Mean estimated SI was 0.8 g/day higher in patients without 
STS compared to those with STS £1.6% NaCl (p=0.06). Higher SI correlated with higher 
calf ECV (r=0.38, p=0.04), whole body-BIS TBW (r=0.65, p=0.0005) and ECV (r=0.34, 
p=0.09). Mean Calf ECV was significantly lower in those with STS vs those without STS 
at 1.6% (0.19 vs 0.23 L; p=0.04). There was no correlation between SI and pre-dialysis 
BP (in-center routine or standardized). 
Conclusions: Salt taste sensitivity and measures of hydration status by bioelectrical 
impedance spectroscopy are correlated with sodium intake in hemodialysis. These findings 
suggest that patients with low salt taste sensitivity may be particularly at risk for fluid 
excess. Future research should examine mechanisms of Salt taste sensitivity and its role 
in management of hemodialysis patients.
Funding: Private Foundation Support
TH-PO805
Arrhythmic Risk in Patients with Type II Diabetes on Hemodialysis: 
Preliminary Results from the Monitoring in Dialysis (MiD) Clinical Study 
Prabir Roy-Chaudhury,1 Don E. Williamson,2 James A. Tumlin,3 David M. 
Charytan,4 Kowdle chandrasekhar Prakash,5 Vijay K. Kher.6  1Univ of Cincinnati; 
2Nephrology Associates; 3Univ of Tennessee; 4Brigham and Womens Hospital, 
Boston; 5Apollo Hospitals-Chennai; 6Medanta-Medicity.
Background: 40% of the overall ESRD population has diabetes and these patients 
are considered to be at increased risk of cardiac events. The goal of this analysis was to 
describe the pattern of both clinically significant events and documented arrhythmias in 
a subset of patients with Type II diabetes from the Monitoring in Dialysis (MiD) study.
Methods: The MiD study is a prospective, multi-center, observational study designed 
to characterize the type and frequency of documented and adjudicated arrhythmias in 
hemodialysis patients during a 6-month period, using an implanted continuous cardiac 
monitoring device (Medtronic Reveal XT or Reveal LINQ). All documented arrhythmias 
and clinically significant arrhythmias (CSA) defined as bradycardia ≤40 bpm for ≥6 sec, 
asystole ³3 sec, sustained ventricular tachycardia ³130 bpm for ³30 sec and symptomatic 
arrhythmias during this period were then correlated temporally to the dialysis cycle (first, 
second or third dialysis session of the week; during or after hemodialysis; how long after 
hemodialysis).
Results: Type II Diabetes was present in 39/66 (59%) of the MiD patients. The mean 
age was 62 (36-76) years, 72% male, mean years on HD 2.8 (1-15), 36% with a history 
of cardiac arrhythmias with a mean follow-up of 8.6 months (range 0.6-13.9). Arrhythmic 
risk in the Type II diabetic patients was similar to the previously reported data on the entire 
study population, with the highest incidence of documented arrhythmias occurring in the 12 
hour period starting with each dialysis session (particularly in the 8 hours after the end of 
the session). The incidence then decreased, followed by a gradual rise during the rest of the 
interdialytic period. Interestingly, the incidence of CSA in the 12 hour period starting with 
the first dialysis session of the week was much greater than in the overall study population.
Conclusions: The increase in the incidence of CSA in diabetic ESRD patients suggests 
that these patients could be a target population for the use of the Reveal implant.
Funding: Pharmaceutical Company Support - Medtronic
TH-PO806
Individualising Fluid Restriction Based on Target Weight Can Prevent a 
High Ultrafiltration Rate  Emily See, John W. MacD. Agar.  Nephrology, Univ 
Hospital, Geelong, VIC, Australia.
Background: Fluid restriction (FR) in haemodialysis patients has traditionally been 
advised by residual urine output and an arbitrarily defined oral intake, commonly 750ml/
day. Surprisingly, little attention has been paid to individualising FR according to target 
post-dialysis weight (TW), despite the logical argument that smaller patients require less 
fluid. Excessive inter-dialytic weight gain (IDWG), when calculated as a percentage of 
TW (IDWG%), results in a high ultrafiltration rate (UFR) if session length (t) is constant 
[UFR(ml/kg/hr) = IDWG(ml) ÷ TW(kg) ÷ t(hr)]. Since a high UFR has been linked to a 
poor clinical outcome, these patients must be identified and targeted. We aim to determine 
if a high IDWG% can be predicted from TW and then be used to individualise FR.
Methods: Data were prospectively collected from 14,112 sessions in 139 patients 
undergoing in-centre thrice-weekly haemodialysis between Jan-Dec 2014. Mean age was 
68.9yr, 56% were male. Mean TW and IDWG% were calculated every 6 weeks. Results 
were divided into IDWG% cohorts, within each of which an average TW was calculated.
Results: Mean IDWG% was 2.30% (range 0.1-6.4). IDWG% was inversely 
proportional to TW (r2=0.78).
From this data, we devised a formula that calculates an individualised FR based on 
the desired UFR (dUFR), the session duration (t), TW, and interval days between sessions 
(n). As [IDWG = FR x n]; and [IDWG = dUFR x t x TW]; therefore [FR (ml) = dUFR x t 
x TW ÷ n + residual urine output].
Conclusions: Patients with low TW are most at risk of high IDWG% and, consequently, 
a high UFR. A high UFR leads to rapid intravascular volume contraction which triggers 
post-dialytic thirst and reinforces the inevitable cycle of further high IDWG%. As TW 
provides a readily accessible clinical end-point that predicts at-risk patients, we propose that 
FR be individualised according to TW to enable patients to remain below the desired UFR.
TH-PO807
Ultrafiltration Rate Should Be Independently Targeted as a Marker 
of Haemodialysis Adequacy  Emily See, John W. MacD. Agar.  Dept of 
Nephrology, Univ Hospital, Geelong, VIC, Australia.
Background: For 30 years, solute clearance has been the key determinant of dialysis 
adequacy. This emphasis has marginalised the critical contribution of safe rates of fluid 
removal to “adequate” dialysis. Ultrafiltration rate (UFR) has been proposed as an easily 
measurable marker of volume management (Agar 2015 HDI) and several studies have 
demonstrated a correlation between high UFR and poor clinical outcomes. Despite this 
association, UFR is not routinely targeted and the proportion of patients who meet percentage 
reduction in urea (PRU) but not UFR targets is unclear. While a “safe” UFRMAX is yet to be 
conclusively defined, current literature supports an escalating clinical risk beyond a UFR 
of 10ml/hr/kg and an absolute risk above 13ml/hr/kg.
Methods: Data were prospectively collected from patients undergoing in-centre 
thrice-weekly conventional haemodialysis over a 12-month study period (Jan-Dec 2014). 
PRU and mean UFR were calculated every 6 weeks. UFR <10ml/hr/kg was defined as 
“volume-adequate” and PRU >65% was considered “solute-adequate”.
Results: 720 episodes were collected from 115 patients. The mean age was 68.9yr 
and 56% were male. 73% of episodes met both adequacy targets (PRU+UFR+). 10% met 
the UFR but not the PRU target (PRU-UFR+). 16% met the PRU but not the UFR target 
(PRU+UFR-). 1% met neither (PRU-UFR-). In patients who met the PRU target 18% did 
not meet the UFR target. 
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Conclusions: Adequacy of solute removal does not equate to adequacy of volume 
removal. When a solute marker is used as the sole determinant of dialysis adequacy, a 
significant number of patients undergo “volume-inadequate” dialysis. These patients were 
more likely to be female and have a lower post-dialysis weight. Given the potentially 
substantial clinical implications, we propose that UFR be independently targeted allowing 
composite solute and volume markers to together define truly “adequate” dialysis.
TH-PO808
Fluid Management with Technology-Assisted Probing  Peter B. De Oreo,1 
Mary kay Deck,2 Anne M. Brumfield.2  1Medical Affairs, Centers for Dialysis 
Care 1, Shaker Heights, OH; 2Systems, Intelomed 2, Wexford, PA; 3Clinical 
Services, Intelomed 2, Wexford, PA.
Background: Intradialytic hypotension (IDH) is associated with mortality. Rapid fluid 
removal is associated with cardiovascular (CV) morbidity and mortality. Decreased pulse 
pressure during HD is associated with improved outcomes. A focused intervention approach 
assisted by monitoring technology was used to assess fluid management as defined by 1) 
achievement of post weight within 1 kg around dry weight, 2) avoidance of IDH [SBP<90], 
3) decrease in pulse pressure (PP) from pre-post dialysis.
Methods: 24 patients (16 controls, 8 intervention) were included. Control data: 18 
treatments (txs) with same staff, room, time interval. Intervention data: 36 baseline txs 
prior to protocol along with 18 txs during active monitoring and guided probing. The 
protocol required setting goal to .2 KG < dry weight OR < .2 KG last post weight with 
small goal changes early in treatment, set of defined actions based on CV physiologic 
monitoring via CVInsight™ (CVI) [Intelomed, Wexford, PA] and relative plasma volume 
(RPV) via Crit-Line III® [Fresenius, Kaysville, UT]. Interventions were employed based 
on monitoring data, with a goal to increase UF tolerance without increasing IDH events. 
BP was measured every 15 minutes.
Results: Intervention patients demonstrated significant improvement in all three fluid 
management parameters during the protocol compared to preceding txs. 
Intervention patients also demonstrated significant improvement in IDH compared to 
Control patients that dialyzed without guided probing.
Conclusions: A focused effort to improve fluid management through technology guided 
probing supported by CVI measures of cardiovascular stress and RPV, was successfully 
executed by chair-side staff. Optimizing fluid removal goals while simultaneously avoiding 
IDH events illustrates the benefit of patient monitorin.
Funding: Pharmaceutical Company Support - Intelomed
TH-PO809
Increased Mortality Associated with Higher Dialysate Sodium 
Concentrations Is Not due Solely to Higher Interdialytic Weight Gains 
and Blood Pressure  Ambreen Gul,1 Ronald Schrader,1 Susan Paine,1 Philip 
Zager.1,2  1DCI, Albuquerque, NM; 2UNM, Albuquerque, NM.
Background: There is ongoing controversy regarding the optimal DNa. Many 
investigators have urged the use of DNa of 134 to 138 mEq/L, to limit interdialytic weight 
gain (IDWG) and improve control of hypertension. In contrast, others have cautioned that 
low DNa may be associated with increased hospitalization and mortality.
Methods: We conducted a retrospective observational study of 26,000 chronic 
hemodialysis (HD) patients treated in facilities operated by Dialysis Clinic Inc. from 
2009-2013 to assess the relationships of DNa to IDWG and predialysis systolic BP (SBP) 
and their effect on mortality. We fit a time-varying Cox proportional hazards regression 
model for mortality, which included all incident and prevalent patients. There were over 
630,000 patient-months of follow-up. Multiple data values for each patient were aggregated 
by month. Predictor variables in addition to DNa included demographics, monthly lab 
values, and session-level data including IDWG and pre- and post-dialysis BP. Individual 
clinic effects were fit as random effects. Time-varying predictors were lagged by 2 months.
Results: Higher DNa concentrations were associated with only modest increases 
in IDWG and predialysis SBP [figure]. Moreover, neither predialysis SBP ≥ 150 mm 
Hg or IDWG < 4.2% of estimated dry weight were associated with increased mortality. 
Nevertheless, higher DNA concentrations were associated with increased mortality (HR 
[95%CI] = 1.09 [1.02, 1.16]) for DNa > 140 mEq/l (Referent DNa =140 mEq/L) after 
adjusting for all other variables including IDWG and BP.
Conclusions: Although reducing DNa to < 140 mEq/L may have only a modest impact 
on IDWG and predialysis SBP it has the potential to significantly decrease mortality.
TH-PO810
Comparison of Ordered versus Measured Dialysate Sodium Concentrations 
Ambreen Gul,1 Dana Miskulin,3 Leonard A. Arbeit,4 Sriram Narsipur,5 Susan 
Paine,1 Ronald Schrader,1 Philip Zager.1,2  1DCI, Albuquerque, NM; 2UNM, 
Albuquerque, NM; 3Tufts, Boston, MA; 4SUNY, Stony Brook, NY; 5SUNY, 
Syracuse, NY.
Background: There is controversy regarding the optimal dialysate sodium 
concentration (DNa). Many investigators have urged the use of DNa of 134 to 138 mEq/L, 
while others have cautioned that low DNa may be associated with increased hospitalization 
and mortality. Unfortunately, throughout this debate, little attention has been paid to how 
closely delivered DNa matches ordered DNa.
Methods: We studied 333 hemodialysis (HD) patients at 4 DCI facilities. We sampled 
dialysate from the arterial dialyzer port prior to the start of HD for measurement of DNa. 
Units 1 and 2 used Fresenius 2008 K and 2008 K2 machines and Fresenius Granuflo® Dry 
Acid and NaturaLyte®, mixed onsite from dry concentrates. Units 3 and 4 used Gambro 
Phoenix machines and pre-mixed acid concentrates obtained from Rockwell and bicarbonate 
cartridges from Baxter or Gambro. The online clearance feature was off.
Results: Measured DNa was usually higher than ordered DNa. The magnitude of 
difference varied by clinic (p <.0001). 
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Least squares mean differences (95% CI) were larger at Clinics 1 [-3.27 (-4.02, -2.53) 
mEq/L] and 2 [-3.77 (-4.49, -3.05) mEq/L] vs. with Clinics 3 [-1.44 (-2.10, -0.78) mEq/L] 
and 4 [-1.78 (-2.47, -1.10) mEq/L]. The percentages of measured DNa concentrations within 
± 2 mEq/L of the ordered DNa at Clinics 1, 2, 3 and 4 were 47, 25, 71 and 77%, respectively.
Conclusions: Measured DNa concentrations were often significantly higher than 
ordered DNa in facilities using Fresenius machines and dialysate concentrates mixed onsite. 
Routine measurement of DNa should be incorporated into facilities’ QAPI programs. Future 
studies looking at clinical outcomes associated with differences in prescribed DNa, should 
include measurements of delivered DNa concentrations .
Funding: Clinical Revenue Support
TH-PO811
Successful Use of Bivalirudin Protocol to Prevent Extracorporeal Thrombosis 
in Hemodialysis Patients with Heparin Induced Thrombocytopenia 
Abdullah Hamad, Fadwa S. Al-Ali, Hoda Tolba, Rania Abdelaziz Ibrahim, 
Mohamed Elsayed.  Nephrology, Fahd Bin Jasim Kidney Center, Hamad General 
Hospital, Doha, Qatar.
Background: Heparin Induced Thrombocytopenia (HIT) has been reported in 
hemodialysis (HD) patients with a variable prevalence of 1-13%. There have been few 
reports using Lepirudine, Argatroban and Danaparoid in the management of extracorporeal 
thrombosis (ECT) during dialysis in these patients as heparin is contraindicated. We are 
reporting use of Bivalirudin to prevent ECT.
Methods: Our Study was done in Fahad Bin Jassim Kidney Center in Doha, Qatar (a 
large outpatient HD clinic of 300 patients). All patients diagnosed with HIT were included. 
HIT was diagnosed by ELISA method.
Results: 8 patients had confirmed positive HIT AB, 2 were receiving warfarin for 
atrial fibrillation with no ECTevents and were excluded. One patient had a negative repeat 
test for HIT AB with no ECT events so he was excluded too. 5 patients with HIT AB 
and recurrent ECT events during dialysis were included. 3 patients had fistula and 2 had 
permanent catheter. A protocol was developed to start and adjust Bivalirudin based on 
activated partial thromboplastin time (aPTT) value. Table 1 summerize patients dosing 
and adjustment on protocol.
Patient Dialysis access type
Duration on 
Bivalirudin Starting dose Final dose
Adjustment of 
dose
1 fistula 5 months 1.8 mg/hour 3.4 mg/hour 6 times
2 fistula 4 months 1.6 mg/hour 2.1 mg/hour 2 times
3 permcath 2 months 2 mg/hour 4 mg/hour 4 times
4 fistula 4 months 1.5 mg/hour 1.8 mg/hour 1 time
5 permcath 8 months 1.7 mg/hour 3 mg/hour 3 times
Conclusions: We are reporting a successful use of Bivalirudin protocol to prevent 
ECT in HD patients with HIT. It provided a simple dosing initiation with easy adjustment 
based on weight, aPTT and ECT events. The protocol provided excellent safety where no 
bleeding complications occured in these patients thoughout the study.
TH-PO812
(13)-β-Glucans and Endotoxins in Hemodialysis  Jonathan P. Wong,1 
Yonglong Zhang,2 Enric Vilar,1 Malcolm A. Finkelman,2 Ken Farrington.1  1Lister 
Renal Unit, United Kingdom; 2Associates of Cape Cod.
Background: Endotoxemia is widely reported in dialysis patients and proposed to be 
related to systemic inflammation. Endotoxins are detected using the Limulus Amoebocyte 
Lysate (LAL) assay. However, the LAL assay is prone to interference and can be activated 
by (13)-β-glucans (BG), a component of fungal cell wall, through an alternative LAL 
enzymatic pathway leading to falsely high endotoxin signals. High endotoxin content 
reported in dialysis patients may be due, to an unknown extent, to BG-based activation 
of LAL.
Methods: Predialysis blood samples were collected from 10 hemodialysis (HD) 
patients with systemic inflammation and 10 HD patients without inflammation and tested 
for endotoxin using the kinetic turbidimetric LAL assay (KTA2, Charles Rivers). Endotoxin 
measurements were performed with and without a BG blocking buffer. The buffer prevents 
the activation of the LAL assay by BG, to ensure that LAL activation is endotoxin-specific. 
The same samples were also assayed for BG content using an FDA-cleared BG detection 
assay (Fungitell®, Associates of Cape Cod). Differences in endotoxin and BG content were 
compared between inflamed and non-inflamed patients. Differences in endotoxin content 
in samples assayed with and without a BG blocking buffer were compared.
Results: Blood endotoxin was higher in patients with systemic inflammation although 
this did not reach statistical significance (0.027 vs 0.013 EU/ml, p=0.579). Endotoxemia 
was detected in 55% of patients. On repeat measurement with a BG blocking buffer, 
no patients had detectable endotoxemia. Both inflamed and non-inflamed patients were 
found to have similarly significant elevated blood BG (60 vs 81.3 pg/ml, p=0.29). There 
was no significant correlation between levels of BG and endotoxin (r=0.435, p=0.055). 
No endotoxin and very low concentration of BG (3pg/ml) was detected in saline washout 
from the blood compartment of the dialyser.
Conclusions: Elevated blood endotoxin reported in HD patients may be due to BG 
interference. This suggests that endotoxin measurements should be carried out with BG 
blocking buffers. The source and clinical significance of elevated BG levels in HD patients 
is unknown and requires investigation.
Funding: Clinical Revenue Support
TH-PO813
The Correlation of BNP and hANP in Hemodialysis Patients and Their 
Prediction Ability of Life Prognosis  Koji Takemura, Fumitaka Fujino, 
Yoshihiro Miyauchi, Takashi Watanabe.  Nephrology, Asahi General Hospital, 
Asahi, Chiba, Japan.
Background: B-type natriuretic peptide (BNP) and human atrial natriuretic peptide 
(hANP) have been reported to be useful for assessment of the volume status, cardiovascular 
risk, or life prognosis in hemodialysis patients. However, correlation or superiority of the 
two parameters are not clear. The aims of this study were to assess whether BNP and hANP 
have correlation, and whether they are predictive.
Methods: Two hundred and twenty-eight hemodialysis patients at one hospital were 
assessed in March 2012. BNP and hANP were measured at the end of hemodialysis. And 
we observed the patients’ survival until May 2015.
Results: This study analyzed 228 patients. Results showed that BNP and hANP had 
strong correlation in patients without chronic heart failure (EF>40%): R2=0.70 in those 
with atrial fibrillation (Af), R2=0.57 without Af. 69 deaths occurred in about 3 years; in 
univariate analysis, BNP and hANP were significant predicting factors (p=0.004 and p=0.013 
for each) and in multivariate analysis, age and hANP were significant predicting factors in 
multivariate analysis (p=0.019 and 0.011).
Conclusions: BNP and hANP had strong correlation in hemodialysis patients without 
chronic heart failure. They also predicted life progonosis, and especially hANP had 
independent prediction ability. In hemodialysis paients, BNP and hANP are useful for 
assessment of life prognosis in spite of various known or unknown confounding factors.
TH-PO814
Intracranial Fluid Shifts During Hemodialysis Measured Using VIPS 
(Volumetric Integral Phase-Shift Spectroscopy) Is Influenced by Osmolarity, 
Sodium and Less So by Urea Nitrogen  Chethan P. Venkatasubba rao,1 
Sreedhar A. Mandayam,2 Eric Bershad,1 Eusebia Calvillo,1 Jose Ignacio Suarez.1 
1Neurology, Baylor College of Medicine, Houston, TX; 2Nephrology, Baylor 
College of Medicine, Houston, TX.
Background: End Stage Renal Disease (ESRD) patients undergoing hemodialysis(HD) 
experience a drop in serum osmolarity. This may result in cerebral edema. Cerebral edema 
has been measured by invasive monitors or imaging studies. We used Volumetric Integral 
Phase-shift Spectrocopy(VIPS), a non-invasive technology that detects fluid-induced phase 
shifts in low-energy radio waves transmitted through the brain.
Methods: The protocol was approved by the IRB of Baylor college of Medicine. 
ESRD on HD subjects without intracranial illnesses were enrolled. VIPS monitoring was 
performed pre, intra and post HD. Measured and calculated serum osmolarity(osm) and 
mini mental state examination was performed pre and post HD.
Results: 19 patients (12 males) were enrolled. Median age was 50 years. 1 patient 
withdrew. Of the 31 HD runs, 21 complete data sets were analyzed. There was a mean 
increase of 10.6% in the total Intracranial fluid(ICF) value from baseline corresponding to 
an average of 7 mOsm reduction. The ICF change measured by VIPS correlated with osm 
changes (r=0.31), best with change in Sodium change [Post HD – pre HD](r= 0.51), less 
so with the BUN change (r=0.14) and least with glucose (r=0.01). Subjects with sodium 
< 135 at baseline had a tendency to develop lower ICF change (3% n=5) as compared to 
eunatremic subjects (12%, n=16, p=0.22).
Conclusions: VIPS provides real-time non-invasive monitoring of intracranial fluid 
shifts. Subjects develop serum osmolar reductions during HD, which can potentially be a 
model for studying cerebral edema. Sodium shifts had a higher correlation to ICF change 
in our study. Further research to confirm our findings are warranted.
Funding: Pharmaceutical Company Support - Cerebrotech Medical Systems, Inc.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
278A
J Am Soc Nephrol 26: 2015 Standard Hemodialysis for ESRD - I Poster/Thursday
TH-PO815
Online Hemodiafiltration Using Citrasate® Dialysis Solution – An 
Alternative to Systemic Anticoagulation?  Pavlina Richtrova, Lukas 
Kielberger, Jan Mares, Tomas Reischig.  1st Medical Dept, Charles Univ Medical 
School and Teaching Hospital, Plzen, Czech Republic.
Background: Citrasate® is a dialysis solution using citrate (contrary to more common 
acetate) as the acidifying buffer compound. According to recently published data, its 
application could decrease or even obviate the need for systemic anticoagulation in 
hemodialysis (HD) patients. Particularly so during online hemodiafiltration (HDF) as in this 
setting predilution should provide yet higher in-dialyzer citrate concentrations resembling 
regional citrate anticoagulation (RCA).
Methods: In a prospective, randomized, cross-over study, 10 long-term HD patients 
were examined during 4h HDF procedure using Citrasate® (0.8 mmol/l citrate) in a 
predilution setting without additional systemic anticoagulation. Standard HDF procedure 
using acetate-buffered solution together with fractionated heparin was applied as a control. 
Along the session, blood and dialysate were sampled to enable analysis of thrombogenicity, 
acid base balance, calcium metabolism, and dialysis efficacy. Data are given as means±SD, 
statistical significance was calculated by ANOVA.
Results: No HDF session was terminated prematurely though the semiquantitative 
dialyzer clotting score showed increased clotting under citrate solution (p=0.001). At the 
same time, procedure efficacy assessed by spKt/V, as well as serum calcium, bicarbonate 
and pH did not differ significantly. While in controls the thrombin-antithrombin (TAT) 
levels remained unchanged, during citrate-buffered HDF a steady increase of TAT was 
demonstrated: from 3.6±2.36 and 5.6±3.85 µg/l at 0h to 7.8±7.65 and 38.9±23.25 µg/l at 
4h for acetate and citrate respectively (p<0.001).
Conclusions: From a clinical standpoint, HDF using Citrasate® excluding heparin 
may serve as a viable alternative to RCA where systemic anticoagulation is to be avoided. 
No issues were detected in terms of safety, tolerability, and dialyzer performance. Even 
then, increased laboratory markers of thrombogenicity suggest inferiority of such approach 
precluding its use for regular HD.
Funding: Government Support - Non-U.S.
TH-PO816
Hypertension in Hemodialysis Patients: Dialysis Techniques and Hormonal 
Regulation  Guido Gatti, Chiara Lanzani, Marco Simonini, Simona Pozzoli, 
Stefano Tentori, Elena Brioni, Lorena Citterio, Elisabetta Messaggio, Simona 
Delli carpini, Nunzia Casamassima, Teresa Arcidiacono, Maria Teresa Sciarrone 
Alibrandi, Rita Quartagno, Marco Melandri, Giorgio Slaviero, Donatella Spotti, 
Paolo Manunta.  Nephrology, Dialysis and Hypertension, IRCCS San Raffaele 
Scientific Inst, Milan, Italy.
Background: Hypertension in hemodialysis patients has a prevalence of 50-80% and 
is associated to increased cardiovascular mortality. Endogenous ouabain (EO), a digitalis-
like cardiotonic steroid produced by adrenal glands, in hemodialysis patients is associated 
to left ventricular mass, volume and eccentric hypertrophy remodeling. N-terminal pro 
B-type natriuretic peptide (NT-proBNP) is associated with heart failure and fluid overload. 
Hemodiafiltration (HDF) improves cardiovascular survival than bicarbonate hemodialysis 
(HD). The aim is to explore the relationship between BP values, hormonal regulation (EO 
and NT-proBNP) and hemodialysis techniques.
Methods: We enrolled 93 chronic hemodialysis patients; we performed ABPM of 
24 hours, blood and effluent dialysis fluid analysis. 42 patients were treated with HDF, 
51 with HD.
Results: NT-proBNP is directly associated with SBP of 24h and indirectly with EF of 
left ventricle; it is removed by HDF by convective clearance (decrease of 57%), as medium 
molecular weight compounds, and not by HD (increase of 21%). EO is directly associated 
with interdialytic weight gain and interventricular septum; it decreases with dialysis 
session independently of dialysis technique (decrease of 20%). Patients with cardiopathy 
have higher EO plasma levels than patients without cardiopathy. Beta-2 microglobulin is 
directly associated with NT-proBNP and SBP of 24h.
Conclusions: These data show that NT-proBNP is an index of hypertension and heart 
failure, while EO is linked to fluid overload and left ventricular hypertrophy. NT-proBNP 
is removed by convection, while EO decreases with dialysis independently of dialysis 
technique (may ultrafiltration determine the decrease?). Convective clearance, expressed 
indirectly by beta-2 microglobulin, may influence BP control through the modulation of 
NT-proBNP.
TH-PO817
NT-proBNP Is a Useful Biomarker to Identify Cardiac Dysfunction in 
Japanese Hemodialysis Patients  Minako Shimizu,1 Ayumu Nakashima,2 
Shigehiro Doi,3 Takao Masaki.4  1Dept of Nephrology, Hiroshima Univ Hospital, 
Hiroshima, Japan; 2Dept of Nephrology, Hiroshima Univ Hospital, Hiroshima, 
Japan; 3Dept of Nephrology, Hiroshima Univ Hospital, Hiroshima, Japan; 4Dept 
of Nephrology, Hiroshima Univ Hospital, Hiroshima, Japan.
Background: Serum N-terminal pro-brain natriuretic peptide (NT-proBNP) is a 
well-established diagnostic biomarker of heart failure in populations without kidney 
dysfunction. However, the clinical significance of NT-proBNP in hemodialysis (HD) 
patients remains unclear.
Methods: We enrolled 1428 HD patients from 14dialysis centers in Hiroshima, Japan 
and performed cross-sectional analysis. Blood samples for measurement of serum NT-
proBNP were collected at pre- and post-HD sessions. Among all participants, ultrasonic 
cardiography (UCG) was performed in 395 patients (27.7%). We evaluated whether 
serum NT-proBNP levels were associated with left ventricular hypertrophy (LVH) on the 
electrocardiogram (ECG), and LVH and ejection fraction (EF) on UCG. We also used 
multiple regression analysis to investigate the clinical factors that correlated with the 
reduction ratio of NT-proBNP levels due to HD.
Results: The mean pre- and post-HD NT-proBNP levels were 8789 ± 15311 and 5257 
± 8939 pg/mL, respectively. Multivariate regression analysis revealed that the post-HD 
NT-pro-BNP was significantly correlated with LVH on ECG as well as EF and LVH on 
UCG (P < 0.001). When both pre- and post-HD NT-proBNP were evaluated in the same 
patients, the odds ratios (ORs) for LVH on ECG, and LVH and EF on UCG were lower at 
pre- than post-HD (ORs: 1.36, 2.16, 3.47 versus 1.19, 1.54, 2.37,respectively). However, 
the sensitivity and specificity of pre- and post-HD NT-proBNP to predict LVH and EF 
were similar. In multiple linear regression analysis, the reduction ratio (%) of NT-proBNP 
due to HD was correlated with Kt/V (P < 0.001), membrane area (P < 0.001), membrane 
type (P < 0.001), modality (P < 0.001), % body weight gain (P < 0.001), treatment time (P 
< 0.001) and ultrafiltration rate (P = 0.003).
Conclusions: NT-proBNP is a useful biomarker to identify LVH and LV dysfunction 
in HD patients. Blood samples should be taken post-HD despite the NT-proBNP reduction 
due to HD.
Funding: Pharmaceutical Company Support - Roche
TH-PO818
Similar Complement Activation by Heparin-Coated Dialyzer Compared 
with Heparin-Free Dialysis Using Predilution  Susan J. Logtenberg,1,2 
Casper F.M. Franssen,1 Marc Maj Seelen.1  1Nephrology, Univ Medical Center, 
Groningen, Netherlands; 2Internal Medicine, Diakonessenhuis, Utrecht, 
Netherlands.
Background: Heparin-coated dialyzers have been shown to be an effective method for 
heparin-free hemodialysis and are increasingly used. Conflicting reports on complement 
activation by heparin have been published, however. Complement activation could 
therefore be potential harmful for patients that are scheduled for transplantation shortly 
after hemodialysis (HD). We investigated the difference in complement activation between 
heparin-coated dialyzers and heparin-free HD using conventional filters with predilution.
Methods: We measured C3 and C3d levels in 16 (5 F) consecutive patients that were 
treated with either a heparin coated filter (n=8 (Evodial®)) or a conventional filter (n=5 
cellulose triacetate, n=3 polyamide) with predilution 1-2l/h. C3 and C3d were measured 
before and at the end of a single HD treatment session. C3d to C3 ratios were calculated.
Results: Mean age was 58±16 years. The figure shows C3d/C3 ratios before and after 
HD for individual cases in the different filter groups. Mean C3d/C3 ratios increased during 
HD with all types of dialyzers. Mean C3d/C3 ratio in the heparin-coated dialyzer group 
increased from 9.7±7.6 before HD to 12.4±7.8 after HD (p=0.001). Mean C3d/C3 ratio in 
the conventional filter group increased from 8.0±2.1 to 11.8±5.4 (p=0.03). C3d/C3 ratio 
increased during HD with both the polyamide (from 7.5±1.8 to 10.0±1.2; p=0.09) and the 
cellulose triacetate dialyzer (from 8.3±2.4 to 12.9±6.9; p=0.02). There was no significant 
difference in the change of C3d/C3 ratio between the heparin coated filter group and the 
conventional filter group (2.7±1.4 vs. 3.7±3.7, respectively (p=0.5)). 
Conclusions: Heparin-coated dialyzers induce similar complement activation during 
HD when compared to conventional dialyzers.
TH-PO819
A Heparin-Grafted Membrane plus Citrate Containing Dialysate 
versus Regional Citrate Anticoagulation: Results of the CiTED Study 
Christoph Metalidis, Ruben Poesen, Annelore De winter, Dirk R. Kuypers, 
Pieter Evenepoel, Bjorn Meijers.  Nephrology, Univ Hospitals Leuven, Belgium.
Background: Heparin is the mainstay anticoagulant during dialysis. Alternative 
anticoagulant strategies include regional citrate anticoagulation (RCA), heparin-grafted 
dialyzers or saline flushes. Of these, RCA is the most efficacious, although technical 
complexity and labor intensiveness preclude widespread use. Heparin-grafted membranes 
are easy to use, but dialyzer patency is inferior to RCA. Whether combination of citrate-
containing dialysate plus heparin-grafted membranes is non-inferior to RCA is unknown.
Methods: The CiTrate plus EVodial in Dialysis (CiTED) study is a prospective, 
open-label randomized cross-over study comparing citrate-containing dialysate plus 
heparin-grafted membranes vs. RCA. In the study arm, we scheduled 750 dialysis sessions 
using combination of a heparin-grafted AN69ST dialyzer (Evodial 180®, BAXTER) and 
1 mmol/L citrate-containing dialysate (Selectbag Citrate®, BAXTER). In the control 
arm, 750 sessions of RCA were scheduled using Polyflux 170 (BAXTER) dialyzers and 
calcium-containing dialysate. In all sessions, scheduled treatment duration was 4 hours. 
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No systemic heparin was used. Primary endpoint was non-inferiority for clotting events of 
the combination of a heparin-grafted membrane plus citrate-containing dialysate vs. RCA, 
with a prespecified non-inferiority margin of 10%.
Results: We included 25 patients, receiving 1285 study dialysis sessions in total, 636 
in the study arm and 649 in the control arm. Both anticoagulation strategies were safe. 
Overall, clotting rates were low: 37/636 (5.82%) in the study arm and 42/649 (6.47%) in the 
control arm. The primary endpoint of non-inferiority was met (P < 0.0001). In secondary 
analysis, using Cox proportional hazard analysis, time to clotting did not differ between 
study arms (P 0.62).
Conclusions: Combination of a heparin-grafted dialyzer with citrate-containing 
dialysate is non-inferior to conventional RCA. The procedure is easy to perform without 
additional pumps or calcium measurements. Combination of a heparin-grafted dialyzer 
and citrate-containing dialysate is a valid alternative to RCA in patients requiring heparin-
free dialysis.
Funding: Pharmaceutical Company Support - Gambro - Baxter
TH-PO820
Effect of L-Carnitine on Markers of Mineral Bone Disease in the 
CARNIDIAL trial  Lucile Mercadal,1 Michel Chonchol,2 Messaoud Ouziala,4 
Christine Fumeron,5 Aude Servais,6 Sophie Tezenas du montcel.9  1Nephrology, 
AP-HP, Pitié-Salpêtrière, Paris, France; 2Nephrology, Univ of Colorado, 
Denver; 3CMC Pantin, Aubervilliers; 4AURA Paris; 5Nephrology, AP-HP, 
Necker; 8Statistics, AP-HP, Pitié-Salpêtrière, Paris.
Background: Previous studies suggested that L-carnitine in hemodialysis patients 
decreases intact parathyroid hormone levels (iPTH). We studied the effects of L-carnitine 
on markers of mineral bone disease (MBD), including fibroblast growth factor (FGF23) 
in a randomized, double-blind trial.
Methods: We evaluated the effects of 1 g of intravenous L-carnitine after each dialysis 
session for 1 year when compared to placebo in a randomized and double-blind trial. 
C-terminal FGF23 (cFGF23) were measured at baseline, every 3 months and end of study 
in 91 chronic hemodialysis patients. Serum calcium, phosphate and iPTH were available 
at similar time points. The effect of L-carnitine on serum calcium, phosphate, iPTH and 
plasma cFGF23 was studied by mixed linear models for repeated measurements in intent-
to-treat. We also examined the relation of cFGF23 with intravenous (IV) iron and EPO dose.
Results: Serum calcium and phosphate increased more in the L-carnitine than in the 
placebo group (calcium: β of L-carnitine x time 0.005 ± 0.002 mmol/L.month, p=0.03; 
phosphate: β of L-carnitine x time 0.02 ± 0.006 mmol/l.month, p=0.001). In both groups, 
serum iPTH was stable over time and plasma cFGF-23 increased (β log FGF23 0.05 ± 
0.01 rHu/mL.month, p<0.0001). In multivariable analyses on 166 measurements, cFGF23 
was positively correlated with serum calcium (β 1.5 ± 0.6, p=0.01), serum phosphate (β 
1.2 ± 0.2, p<0.0001) and negatively correlated with EPO dose (β -0.41± 0.17, p=0.02). No 
association was observed between cFGF23 and IV iron administration (p=0.13), serum 
ferritin (p=0.7) and iron saturation (p=0.7).
Conclusions: L carnitine treatment slightly increased serum calcium and phosphate 
without an effect on iPTH or cFGF23. FGF23 was inversely correlated with ESA dose 
but not with IV iron dose.
Funding: Government Support - Non-U.S.
TH-PO821
Clinicopathological Characteristics of Lanthanum Deposition in the 
Gastrointestinal Tract of Dialysis Patients  Shigeo Hara,1,2 Akira Fujimori,3 
Shinichi Nishi.4  1Dept of Diagnostic Pathology, Kobe Univ Graduate School 
of Medicine, Kobe, Hyogo, Japan; 2Div of Pathology, Ako City Hospital, Ako, 
Hyogo, Japan; 3Div of Nephrology, Konan Hospital, Kobe, Hyogo, Japan; 4Dept 
of Nephrology, Kobe Univ Graduate School of Medicine, Kobe, Hyogo, Japan.
Background: Lanthanum carbonate (LC) is a phosphate binder for dialysis patients with 
hyperphosphatemia. Recent studies have reported gastric lanthanum deposition in patients 
treated with LC (Haratake J et al. Am J Surg Pathol 2015; Makino M et al. Pathol Int 2015); 
however, clinicopathological features of LC deposition have not been fully evaluated. The 
present study was conducted to elucidate the clinicopathological characteristics of LC 
deposition in the gastrointestinal (GI) tract.
Methods: Pathological specimens of the GI tract (n = 60) obtained from the patients (n 
= 28) being administered LC were retrospectively reviewed. Prevalence, distribution, and 
duration from initiation of administration of LC to the detection of lanthanum deposition 
were evaluated.
Results: Among 28 patients (male:female = 17:11; mean age, 68.5 years), LC deposition 
was observed in 11 (39.3%). Pathological specimens were obtained from the pharynx (n = 
1), esophagus (n = 5), stomach (n = 40), duodenum (n = 1), colon (n = 12), and appendix 
(n = 1). LC deposition was confined to the stomach (n = 16) and the duodenum (n = 1). 
The duration from the initiation of administration to the first histological detection of LC 
ranged from 0.35 to 5.39 years (mean, 1.91±0.45 years). In 4 patients, follow-up biopsy 
revealed no improvement in the gastric LC deposition.
Conclusions: Lanthanum deposition occurs in approximately 40% of dialysis patients 
and is mostly confined to the stomach. Its deposition can be seen histologically within a 
couple of months from the commencement of LC administration.
TH-PO822
Comparative Effectiveness of Oral and Injectable Vitamin D Receptor 
Activator on Infectious Mortality in Hemodialysis Patients: The Q Cohort 
Study  Shigeru Tanaka,1 Toshiharu Ninomiya,2,5 Masatomo Taniguchi,2 Masanori 
Tokumoto,1 Hideki N. Hirakata,3 Hiroaki Ooboshi,1 Kazuhiko Tsuruya,2,3 
Takanari Kitazono.2,5  1Div of Internal Medicine, Fukuoka Dental College, 
Fukuoka, Japan; 2Dept of Medicine and Clinical Science, Graduate School 
of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 3Div of Nephrology and 
Dialysis Center, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan; 
4Dept of Integrated Therapy for Chronic Kidney Disease, Graduate School of 
Medical Sciences, Kyushu Univ, Fukuoka, Japan; 5Div of Research Management, 
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu Univ, 
Fukuoka, Japan.
Background: Vitamin D receptor activator (VDRA) has recently been reported to 
be associated with better survival after infection in hemodialysis patients. The optimal 
administration route of VDRA to prevent infection death remains unclear. The aim of this 
study is to investigate the comparative effectiveness of VDRA between oral route and 
injectable form on infectious mortality in hemodialysis patients registered in a prospective 
cohort study.
Methods: A total of 3,278 subjects were divided into 3 groups by the administration 
type of VDRA: oral group (n=1,835), injectable group (n=459) and non-user (n=984). 
Impacts of VDRA on infectious mortality were examined using a Cox regression model 
adjusted with propensity score-based approaches.
Results: During follow-up (median 3.9 years), 534 patients died and 115 patients 
developed infection death. The use of injectable VDRA was associated with a significant 
lower infectious mortality compared to non-user, while oral VDRA did not significantly 
reduce the risk of infection mortality compared to non-user (hazard ratio [HR] for injectable 
VDRA, 0.40; 95% confidence interval [CI], 0.18–0.91, and HR for oral VDRA, 0.78; 95% 
CI, 0.53–1.15, respectively). Direct comparison between oral and injectable VDRA revealed 
that the injectable group was also significantly associated with better survival than oral 
group (HR, 0.33, 95% CI, 0.13–0.83).
Conclusions: Treatment with injectable VDRA has a more favorable impact on the 
infectious mortality compared to oral VDRA in the real-world practice of hemodialysis 
patients.
TH-PO823
Aldosterone Levels in Patients on Hemodialysis/Relationship with the 
Metabolic Syndrome  Mar?a Jose Fernandez Reyes,1 Manuel M. Heras,1 Maria 
Gonzalez,2 Olaia Rodriguez fraga,2 Ramiro Callejas,1 Alvaro Molina,1 Vanesa 
Lopes-martin,1 Maria astrid Rodriguez gomez,1 Leonardo Calle.1  1Nephrology, 
Hospital General Segovia, Segovia, Spain; 2Biochemistry, Hospital Univ La 
Paz, Madrid, Spain.
Background: Recently it has been shown that serum aldosterone (SA) levels are 
correlated with several components of the metabolic syndrome (MSyn). OBJETIVE: to 
establish SA levels on hemodialysis (HD) patients and its possible association with insulin 
resistence (homeostasis model assessment of insulin resistance HOMA-IR), excess body 
fat and/or serum adypocitokines levels.
Methods: 44 stable patients on HD, not taking ACE inhibitors/angiotensin receptor 
blockers. Mean age: 72.5±12.5years; 52.3% men; 34.1% diabetics. Mean time on 
HD:43.2±49 months. 28 patients were anuric. All measurements were done prior to the 
midweek HD session.
Results: SA levels were above the normal range (1.17-23.6 ng/dl) in 63.6% of 
patients . Plasma Renin Activity (PRA) was above the normal range (0.23-3.32 ng/mL/
hour) in 27.3% of patients . SA median: 31.15 (p25: 5.6; p75: 411 ng/dl); PRA median: 
1.14 (p25: 0.04; p75: 20,9 ng/mL/hora). There were not statistically significant difference 
(Student´s-t) in SA levels between anuric and non-anuric; male and female; presence and 
absence of myocardiopathy or diabetes. There were no statistically significant correlations 
(Spearman) of SA levels or PRA with urine volume; residual renal function; dose or length 
of time on HD; age; or Charlson Comorbidity Index. SA levels were positively correlated 
(Spearman) with ARP (r= 0.72; p< 0.0001); body fat mass in kg/m2 (r=0.32; p=0.045); serum 
leptin levels (r=0.30; p= 0.05); HOMA-IR (r= 0.36; p=0.017) and negatively with serum 
adiponectin levels (r=- 0.31; p=0.041). Multivariate logitic regression analysis showed that 
SA levels above its median level were independently associated to PRA and HOMA-IR. 
Variables Independientes Odds ratio 95% CI Valor de p
HOMA-IR 1,236 1,025-1,452 0.01
Plasma renina Actividad 2,664 1,136-6,248 0,024
Conclusions: SA levels are elevated in a high percentage of HD patients and such 
elevation is associated with PRA and several components of MSyn (insulin resistance; 
body fat mass; and serum levels of adypocitokines).
Funding: Government Support - Non-U.S.
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TH-PO824
Dialysate Calcium Concentration Was Significantly Associated with 
Cardiovascular Diseases in Diabetics and Patients with High Body Mass 
Index among Hemodialysis Patients  Miho Tagawa,1 Takayuki Hamano,2 
Shinichi Sueta,3 Seiji Hashimoto,2 Satoshi Ogata.2  1Nara Medical Univ, Nara, 
Japan; 2Patient Registration Committee of Renal Data Registry, Japanese 
Society for Dialysis Therapy, Tokyo, Japan; 3Kyoto Univ, Kyoto, Japan.
Background: Previous studies showed that higher dialysate calcium (Ca) concentration 
was positively associated with cardiovascular (CV) diseases. Which patient characteristics 
modify this association has not been studied.
Methods: This was a longitudinal study based on the Japan Renal Data Registry (JRDR) 
from 2008 to 2009. Predictor variables were dialysate Ca concentration (³3.0 mEq/L vs 2.5 
mEq/L). Primary outcome was CV composite event (either myocardial infarction, stroke, 
amputation, or CV death). Statistical analyses were performed using multivariable logistic 
regression model, adjusted for potential confounders.
Results: Among 300,660 patients on JRDR database, data for 38,697 patients were 
available for analyses after excluding patients with missing data. Serum albumin corrected 
Ca was significantly higher (9.27±0.77 vs 9.18±0.79 mg/dL) and intact parathyroid hormone 
(iPTH) was significantly lower (135[65-236] vs 164 [85-274] pg/ml) among high dialysate 
Ca users compared with low dialysate Ca users. The odds ratio of CV composite outcome 
among high dialysate Ca users was higher among diabetics and patients with higher body 
mass index (BMI) (p for interaction 0.02 and 0.01, respectively). 
Additional adjustment for pre-dialysis serum albumin corrected Ca and iPTH did not 
change the effect size of high dialysate Ca among diabetics and patients with high BMI.
Conclusions: Diabetes and BMI, but not serum phosphate, Ca, or iPTH were effect 
modifiers for the association of high dialysate Ca and CV composite outcome. High 
dialysate Ca was significantly associated with CV composite outcome among diabetics 
and patients with high BMI.
TH-PO825
Association of Serum and Dialysate Electrolytes with Arrhythmic Risk in 
Incident Hemodialysis  Jacqueline Watt,1 Esther D. Kim,2 Larisa Tereshchenko,3 
Stephen M. Sozio,3 Bernard G. Jaar,3 Lucy A. Meoni,3 Michelle M. Estrella,3 
Rulan S. Parekh.2,3  1McMaster Univ; 2Univ of Toronto; 3Johns Hopkins Univ.
Background: Arrhythmias and sudden cardiac death (SCD) may occur during or shortly 
after receiving dialysis treatment. The extent to which serum and dialysate concentrations 
of potassium (K) and calcium (Ca) are associated with the risk of arrhythmias in incident 
hemodialysis is unclear.
Methods: In 402 patients from the Predictors of Arrhythmic and Cardiovascular Risk 
in End Stage Renal Disease (PACE) study, we analyzed the association of serum (ionized 
Ca[iCa], K, magnesium [Mg]) and dialysate (dCa and dK) electrolyte concentrations with 
prolonged QTc interval (Bazett’s formula) and heart rate variability (HRV). Outcomes were 
measured by a 5-minute signal-averaged ECG. Prolonged QTc was defined as >460ms in 
women and >440ms in men. Baseline associations were examined using linear and logistic 
regression, and repeated measures were analyzed using mixed-effects models.
Results: At baseline, 86.3% had QTc prolongation, of whom 68.5% had persistent 
QTc prolongation at the follow-up visit. In the baseline analysis, higher iCa was associated 
with a shorter QTc interval and lower odds of having QTc prolongation, independent of 
demographic and cardiovascular risk factors, CRP, and pH. 
Adjusted Associations
Baseline Repeated Measures
β or OR (95% CI) β or OR (95% CI)
QTc Interval -10.6(-17.7, -3.6)* -10.6(-17.5, -3.7)*
Heart Rate Variability 2.9(0.6, 5.1)* 2.9(0.7, 5.1)*
QTc Prolongation 0.1(0.0, 8.1)
*p<0.05
Higher iCa was also associated with higher HRV. The association of iCa with QTc 
interval and HRV remained significant in the repeated measures analysis. Associations with 
serum K, Mg, dCa, and dK were not significant at baseline or over follow-up. Serum-to-
dialysate Ca gradient, but not K gradient was associated with higher HRV at baseline and 
over follow-up (β=0.3(0.0, 0.6) and 0.3(0.0, 0.6) respectively).
Conclusions: Serum iCa, but not K and Mg, is consistently inversely associated with 
QTc prolongation and the serum to dialysate gradient is also associated with HRV. This 
suggests that the absolute serum level as well as the lower dCa concentration increases 
arrhythmic risk.
TH-PO826
Phosphorus Kinetics During Hemodialysis: Further Validation of a 
Pseudo-One Compartment Model  J. Ken Leypoldt,1 Baris U. Agar,2 Alfred K. 
Cheung,3 Angelito A. Bernardo.1  1Medical Products (Renal), Baxter Healthcare 
Corporation, Deerfield, IL; 2Medical Products (R&D), Baxter Healthcare 
Corporation, Round Lake, IL; 3Nephrology, Univ of Utah, Salt Lake City, UT.
Background: A pseudo-one compartment model has been proposed to describe 
phosphorus kinetics during hemodialysis (HD) and postdialysis rebound. This model 
suggests that phosphorus mobilization from tissues is proportional to the difference 
between the predialysis serum (Cpre) and instantaneous serum concentration. The current 
study evaluated the ability of a pseudo-one compartment model to describe the kinetics 
of phosphorus during two short HD treatments on the same day separated by a 1-hr inter-
treatment period without dialysis. The latter is the postdialysis rebound period for the 
first treatment.
Methods: Serum was collected frequently during both HD treatments and the inter-
treatment period to assess phosphorus kinetics in 21 chronic HD patients. Phosphorus 
mobilization clearance (KM) and predialysis central distribution volume (Vpre) were estimated 
for each patient during the first HD treatment and the inter-treatment period. Assuming 
those kinetic parameters remained constant for each patient, phosphorus concentrations 
during the second HD treatment were used to estimate the driving force concentration (Cdf) 
for phosphorus mobilization during that treatment.
Results: Treatment times (117±14 vs. 117±14 min), dialyzer phosphorus clearance 
(151±25 vs. 140±32 mL/min) and net fluid removal (1.44±0.74 vs. 1.47±0.76 L) were 
similar during both HD treatments. Phosphorus concentration at the start of the second 
HD treatment (3.3±0.9 mg/dL) was lower (P<0.001) than at the start of the first or Cpre 
(5.4±1.9 mg/dL). KM and Vpre were 98±44 mL/min and 11.0±4.2 L, respectively. Calculated 
Cdf was 4.9±2.0 mg/dL, not significantly different from Cpre (P=0.12). Cdf and Cpre were 
correlated (R=0.72, P<0.001).
Conclusions: The results from this study demonstrate that the driving force 
concentration for phosphorus mobilization during HD is constant and equal to that 
predialysis, consistent with a fundamental assumption of the pseudo-one compartment 
model.
Funding: Pharmaceutical Company Support - Baxter Healthcare Corporation
TH-PO827
Association of Sleep Apnea and Sleep Quality with Left Ventricular Mass 
in Hypertensive Hemodialysis Patients in the Blood Pressure in Dialysis– 
SLEEP study  Manisha Jhamb,1 Cynthia A. Kendrick,2 Dana Miskulin,3 
Lavinia A. Negrea,4 David W. Ploth,5 Jennifer J. Gassman,2 Mark L. Unruh,6 
Philip Zager.6,7  1Univ of Pittsburgh; 2Cleveland Clinic; 3Tufts; 4Case Western; 
5MUSC; 6UNM; 7DCI.
Background: Sleep apnea (SA), short and fragmented sleep may contribute to 
cardiovascular disease in hemodialysis (HD) patients. However, the relationship of sleep 
quality with left ventricular mass (LVM) is not well described.
Methods: Chronic HD patients joined an ancillary study during the baseline period of 
the Blood Pressure in Dialysis (BID) trial. SA was monitored for 1 night with a portable 
home monitor (ApneaLink with oximetry) and measured as Apnea Hypopnea Index 
(AHI). Sleep-wake behavior was assessed by actigraphy over a 5-day period. LVM was 
measured by MRI.
Results: We studied 42 patients. SA was present in 84% and was moderately severe 
(AHI >15) in 48%. 61% of patients slept <6 hrs/night and 89% had poor sleep efficiency. 
Patients with AHI£15 had longer dialysis vintage , lower hemoglobin, and lower Kt/V than 
those with AHI>15. BMI, systolic BP, diastolic BP, heart rate, number of antihypertensive 
medications, inter-dialytic weight gain, history of myocardial ischemia, and MRI 
characteristics did not differ between the two groups. LVM index was inversely correlated 
with sleep duration and efficiency (Pearson’s r= -0.35, p ≤ 0.04 for both, AHI (r= -0.01) 
and hypoxemic index (r= -0.04).
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No-mild SA (n=22) Mod-Severe SA (n=20)
Mean ± SD Mean ± SD
LV Mass (g) 154 ± 50.0 153 ± 57.4
LV Mass Index (g/m2) 78.2 ± 23.8 76.8 ±30.4 
LV End Diastolic Volume (ml) 195 ± 52.6 200 ± 69.1 
LV End Systolic Volume (ml) 89.6 ± 29.2 102 ± 51.7 
RV End Diastolic Volume (ml) 154 ± 45.2 156 ± 60.1 
RV End Systolic Volume (ml) 76.4 ± 26.1 82.2 ± 37.3 
LV Ejection Fraction (%) 53.3 ± 12.4 50.8 ± 11.1 
Inferior Vena Cava diameter (mm) 21.4 ± 8.2 23.3 ± 7.5 
Conclusions: SA and poor sleep quality were common among hypertensive HD 
patients. Short sleep duration and poor sleep efficiency, but not the severity of SA, were 
associated with higher LVM indices.
Funding: NIDDK Support, Clinical Revenue Support
TH-PO828
Role of Nicotinic Acid as Phosphate Lowering Agent in End Stage Renal 
Disease Patients on Maintenance Hemodialysis  Khalid Tahir,1 Hafiz 
I. Ahmad,1 Syed Rizwan Bokhari,1 Syed A. Khalid,1 Arif Asif.2  1Dept of 
Nephrology, Allama ITbal Medical College/ Jinnah Hospital, Lahore, Pakistan; 
2Div of Nephrology and Hypertension, Albany Medical College, Albany, NY.
Background: Hyperphosphatemia is associated with higher risk of mortality and 
morbidity in End Stage Renal Disease (ESRD) patients. Use of Nicotinic Acid as phosphorus 
lowering agent has been studied in many countries but available data is sparse and limited. 
We conducted a study to determine the mean decrease in serum Phosphorous level with 
Nicotinic acid use in our dialysis patients.
Methods: Nicotinic acid, in a dose of 250 mg twice a day with food for 4 weeks, was 
given to 45 ESRD patients with serum Phosphorous level more than 5.5 mg/dl. Serum 
phosphorus level was measured at the start and then at the end of study. Data was analyzed 
for decrease in serum phosphorus level with Nicotinic acid use.
Results: Mean age of 45 patients was 44.6 ± 13.9 years and 57.8% were male. Serum 
Phosphorus level before treatment was 5.6 - 10.8 mg/dl (mean 6.91 ± 1.33 ) and after 
treatment for one month it was 2.60 - 8.70 mg/dl (mean 5.82 ± 1.40). Mean decrease in 
phosphorus level with Nicotinic acid after one month of treatment was 1.08 ± 1.16 mg/
dl (p value < 0.001).
Conclusions: Nicotinic acid is an effective and cheaper phosphate lowering agent in 
dialysis patients. Further larger and Randomized Controlled Trials are needed to establish 
the role of this cheaper phosphate lowering agent.
Funding: Private Foundation Support
TH-PO829
Cerebral and Cognitive Effects of Short- and Long-Term Hemodialysis – A 
Pilot Study  Xiufeng Li,1 Yelena Slinin,2 Gregory J. Metzger,1 Lynn E. Eberly,1 
Donald R. Dengel,1 David Tupper,3 Anne M. Murray.3  1Univ of Minnesota, MN; 
2Veterans Affairs Medical Center, MN; 3Hennepin County Medical Center, MN.
Background: The short- (≤6 months) and long-term (³12 months) effects of 
conventional hemodialysis (HD) on brain structure, cerebral blood flow and cognitive 
function are not well understood.
Methods: We conducted a small longitudinal pilot study to investigate the effects of 
HD initiation on brain MRI and cognitive function in 4 HD patients by obtaining pre- and 
post- initiation brain MRIs and cognitive testing. The MRIs were obtained at 3-6 months 
before HD initiation (baseline), and at ~6 and ~12 months after HD initiation. The Modified 
Mini-Mental State Examination (3MSE) was performed within one month of the baseline 
and 12 month MRI examinations. MR diffusion tensor imaging (DTI) measured white 
matter (WM) fractional anisotropy (FA)(connectivity), and pseudo-continuous arterial spin 
labeling (PCASL) imaging was used to evaluate grey matter (GM) cerebral blood flow 
(CBF). A two-tailed paired t -test was used to compare pre- and post- initiation results. 
Patients provided written informed consent to participate in the IRB- approved protocol.
Results: Progressive and significant declines in frontal and temporal WM FA (Fig. 
1), prefrontal CBF (Fig. 2), and cognitive function (Fig. 3, left) were found following HD 
initiation (Table 1 for p values). The decline in frontal WM FA on MRI was correlated with 
the 3MSE decline (R= 0.42)(Fig. 3, right).
Table 1. P values from the comparisons between the baseline and follow-up sessions.
6 months 12 months
FA
Frontal 0.031 0.025
Temporal 0.048 0.044
CBF
Prefrontal 0.038 0.048
Anterior Hippocampus 0.042 0.013
Conclusions: Our results suggest that HD may adversely alter cerebral vascular function 
and progressively induce cerebral structural abnormalities and associated cognitive decline.
Funding: NIDDK Support
TH-PO830
Patient and Dialysate Temperature Characteristics in Incident Hemodialysis 
Patients: Results from a Large U.S. Population  Xiaoling Ye,1 Len A. Usvyat,2 
Yue Jiao,2 Peter Kotanko,1,3 Franklin W. Maddux.2  1Renal Research Inst, New 
York, NY; 2Fresenius Medical Care North America, Waltham, MA; 3Icahn School 
of Medicine at Mount Sinai, New York, NY.
Background: In chronic hemodialysis (HD) patients the use of dialysate at a 
temperature below the patient’s core temperature (“cool” dialysate) has been associated 
with improved outcomes in observational and prospective randomized studies [Odudu et 
al., CJASN 2015; Eldehni et al., JASN 2015; Selby, Sem. Dial 2008]. Little is known about 
temperature profiles in large US populations.
Methods: We include a subset of incident HD patients who were treated in Fresenius 
Medical Care North America facilities from 1/2010 to 12/2014 and who survived the first 
year of HD. Pre- and post-HD body temperatures were measured with thermometers. 
The dialysate temperature was measured by the HD machine. The dialysate-to-patient 
temperature gradient was computed as dialysate temperature minus patient temperature.
Results: We studied 20,360 incident HD patients (age 62.5 (SD 14.5) years; 57.6 % 
males; 68.1% White, 29.2 Black, 2.7% others). The vast majority (83.8 %) had a dialysate 
temperature above body temperature at the start; and at the end (80.6%) of HD. 
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The prescribed dialysate temperature was 36.87±0.31 °C. We observed a small yet 
significant rise in body temperature during HD.
Conclusions: Delivered dialysate temperature exceeds the body temperature in majority 
of patients. This may provide potential opportunities for dialysate temperature reduction 
to improve intradialytic stability and outcomes.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
TH-PO831
Effect of a Single Hemodialysis Session on Visual Evoked Potentials 
Savas Sipahi,1 Ahmed Bilal Genç,1 Yalcin Solak.1  1Nephrology, Sakarya Univ 
Research and Training Hospital, Sakarya, Turkey; 2Neurology, Sakarya Univ 
Research and Training Hospital, Sakarya, Turkey.
Background: Some studies have shown that visual evoked potentials (VEPs) may be 
a marker of dysfunction in visual pathways in uremic subjects. However, data are scarce 
regarding effect of hemodialysis procedure on VEPs. We aimed to compare VEPs of 
hemodialysis patients with healthy volunteers and in particular to assess the impact of a 
single hemodialysis session on VEPs.
Methods: Thirty hemodialysis patients were included in the study. We also recruited 
30 age and gender matched control subjects. Patients with diabetes mellitus, cataracts, 
glaucoma, and stroke were excluded . Demographic characteristics, midweek predialysis 
and postdialysis laboratory values, amount of ultrafiltration at that dialysis session were 
recorded. Patients underwent VEP measurement through which P100 latency values were 
determined just before hemodialysis session and 24 after hemodialysis session. We assessed 
the changes in P100 values with single hemodialysis session. We also investigated effect 
of ultrafiltration on VEPs in maintenance hemodialysis patients.
Results: There was no difference between the groups in terms of age and gender 
(mean age 49 ± 12 and 48 ±11 years, respectively). Median duration of hemodialysis 
was 78 months (range 12-192). At baseline there was no difference with respect to P100 
values between the groups (100.6 ± 8.8 vs 99 ± 5.8, p=0.4, for hemodialysis and controls 
respectively). Both right and left eye VEPs showed a significant decrease measured 24 hours 
after dialysis session compared with baseline values (right VEP; 100.6 ± 8.8 predialysis and 
97 ± 8.7 postdialysis, p<0.001, left VEP; 101.9 ± 9.2 predialysis and 97.3 ± 8.1, p<0.001). 
There was no correlation between baseline predialysis P100 values and age, serum urea, 
hemoglobin, and dialysis vintage. Amount of ultrafiltration was not significantly correlated 
with postdialysis P100 latency values.
Conclusions: Our results did not show a significant difference in P100 latency 
values between hemodialysis patients and healthy controls. A single hemodialysis session 
significantly shortened P100 latency values compared with baseline values.
TH-PO832
23NaMRI Detects Bound versus Soluble Tissue Sodium Content in 
Hemodialysis Patients  Anke Dahlmann,1 Carolin Maier,1 Christoph Kopp,1 
Peter Linz,2 Daniela Amslinger,2 Matthias Hammon,3 Kai-Uwe Eckardt,1 
Friedrich C. Luft,5 Jens Titze.4  1Nephrology and Hypertension, Univ Hospital 
Erlangen, Germany; 2Junior Research Group II, Interdisciplinary Center for 
Clinical Research, Erlangen, Germany; 3Radiology, Univ Hospital Erlangen, 
Germany; 4Clinical Pharmacology, Vanderbilt Univ, Nashville; 5Experimental 
and Clinical Research Center, MDC, Berlin, Germany.
Background: Tissue sodium content is elevated in patients with end-stage renal 
disease and can be corrected by hemodialysis treatment. Until now no data are available 
concerning the extent of water free sodium storage in muscle and skin tissue in humans. 
23Na magnetic resonance technique (MRI) can offer options to distinguish non-invasively 
between soluble and bound (water free) tissue sodium content.
Methods: We used 23Na magnetic resonance spectroscopy and imaging at 3Tesla (T) 
to quantify Na+ content in skeletal muscle and skin of the lower leg. Analysis of specific 
MRI echo times (2ms vs. 4ms during sodium signal decay) allowed determination of bound 
vs. total and soluble sodium content. 39 hemodialysis patients were measured before and 
after regular dialysis treatment with 23Na MRI.
Results: Initial bound sodium content of M. triceps surae in dialysis patients was 
1.58±0.78 mmol/l, which represents 7.5±4.1% of total detectable sodium signal in this 
tissue. While parts of soluble sodium content were removed during dialysis treatment, its 
bound fraction was unaffected by HD (1.63±0.54 mmol/l). Therefore the ratio of bound to 
total sodium significantly increased up to 10.0±4.1% (p<0.05) post dialysis. Initial bound 
sodium content in skin was 2.19±1.19 mmol/l, which represents 9.4±4.2% of total sodium 
signal in this tissue. This value was significantly higher compared to muscle tissue. During 
hemodialysis its content decreased significantly to 1.63±0.89 mmol/l (p<0.05). Due to the 
simultaneous reduction of soluble skin sodium, the ratio of bound to total sodium was 
unchanged by hemodialysis (9.3±5.0%).
Conclusions: Reduction of tissue sodium content by hemodialysis treatment differs 
in skin and muscle tissue: While bound sodium content in muscle was unaffected by 
hemodialysis, bound sodium content in skin tissue could be mobilized by HD.
TH-PO833
Blood Pressure in Hemodialysis Patients: Which Measurement Is More 
Reliable?  Jose Mora-Macia, Francesc J. Moreso, Jose Ignacio Merello, Rosa 
Ramos.  Hemodialysis, Fresenius Medical Care, Spain.
Background: The reliability of blood pressure (BP) measurements during the 
hemodialysis (HD) is controversial. The aim of this study was to evaluate which interval 
of intradialytic BP has less Bias in comparison with home BP monitoring (HBPM).
Methods: A cross-sectional study was done with interdialytic HBPM as reference 
standard and interdialytic BP measurement as test. Index BP recordings tested were 
predialysis (pre-HD), postdialysis (post-HD) and intradialysis (intra-HD). Dialysis unit 
BP recordings were averaged over 1 week: 2 pre-HD, 2 post-HD and 7 intra-HD (every 
30 min); and HBPM over 1 week (the same days): 3 morning and 3 evening readings. 
BP measurements during dialysis were measured by dialysis nurses using the validated 
oscillometric BP monitor OMRON M3 (HEM 7051 E, Omron Healthcare), and the same 
device was used for the patient at home. Patients were instructed to bring the device to 
the dialysis. Patients with symptomatic hypotension during dialysis were excluded. To 
measure Bias, average HBPM was subtracted from each of these three index BP intradialytic 
recordings. Bias was defined as the mean difference in BP (pre-HD, intra-HD, post-HD) 
compared with HBPM.
Results: 192 patients, mean age 63.8±14.8 y.o. (70% male), of 11 HD clinics of 
Fresenius Medical Care of Spain were included, 33% diabetic. All patients were on th ree 
times weekly HD. The mean time on HD was 46±57 months.
HBPM Pre-HD Intra-HD Post-HD
SBP 135±21.4 (80,194)
143.0±21.6 
(92,225)*
130.7±20.9 
(83,204)* 136.1±23.2 (84,207)
DBP 69.3±11.2 (44,97) 71.1±11.1 (46,117)*
68.4±10.4 
(49,105)** 70.2±10.4 (48,98)
Bias 
SBP reference
-7.97±12.1 
(-48,+22)&
4.35±13.16 
(-37,+44)&
-1.08±15.95 
(-52,+42)&
Bias 
DBP reference
-2.08±6.18 
(-35,+16)&
0.90±6.67 
(-23,+21)&
-0.92±7.44 
(-25,+21)&
Data are expressed as mean±SD (range). * p<0.001 vs HBPM. ** p=0.062 vs HBPM.  NS vs HBPM. 
& p<0.0001 ANOVA between HD 
Conclusions: BP at the end of the HD, in not hypotensive symptomatic patients, not 
differ from HBPM and have less Bias that predialysis or intradialysis BP measurements. 
So, the postdialysis BP measurements are the most reliable BP readings.
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TH-PO834
End-Dialysis Overweight and Chronic Inflammation: A Dangerous 
Association – A 36-Month Prospective Observational Study  Ezio Movilli. 
U.O. of Nephrology, Spedali Civili and Section of Nephrology Univ of Brescia, 
Brescia, Italy.
Background: Attaining dry body weight is paramount in dialysis practice, but this 
goal is not always reached. We hypothesized that the amount of end-dialysis overweight 
(edOW), could be associated to increased chronic inflammation and mortality. Aim of the 
study: to evaluate the effect of edOW on serum C-reattive protein(hsCRP) concentrations 
and on survival in a cohort of 182 prevalent HD patients (pts) followed for 36 months.
Methods: In 182 pts (117 men, age 65±12 years, vintage 48 months; range 6-336), 
edOW was present in 98/182 (54%) pts. Mean value was 0.4±0.2 Kg (range: 0.1-1.4). In 
the 98 pts with edOW (Group 1) and in the other 84 (Group 2) we evaluated: Ultrafiltration 
rate(UFR), hsCRPdry body weight (dBW), Kt/V, protein catabolic rate (PCRn), interdialytic 
weight gain (IDWG), mean arterial pressure (MAP). Unpaired Student’s t test was employed 
to compare groups, linear regression analysis to test correlations, log-rank test and Kaplan-
Meier curves to evaluate survival.
Results: Mean UFR was 11.7±2.8 ml/Kg/hour, dBW 64±12 Kg, hsCRP 6.6 (0.2-36) 
mg/L, Kt/V 1.27±0.09, PCRn 1.06±0.10 g/Kg/day, IDWG 2.8±0.4 Kg, MAP 97±6.5 
mmHg. edOW and hsCRP were directly and significantly correlated (r= 0.67; p<0.0001). 
Comparison between pts with (Group 1) and without (Group 2) edOW showed significant 
differences in: UFR (12.7±2.6 vs 10.9±2.6 ml/Kg/hour; p< 0.0001), hsCRP (13.0±8.1 vs 
5.2±5.3 mg/L; p< 0.0001), and PCRn (1.03±0.09 vs 1.08±0.10 g/Kg/day; p<0.004). 98 pts 
(54%) died during follow-up for cardiovascular complications in 69% of cases. Survival 
curves showed significantly greater mortality in Group 1 vs Group 2 in relation to the 
amount of edOW, and hsCRP (p<0.0001).
Conclusions: : edOW and chronic inflammation are directly correlated in HD pts, and 
both are associated to a greater long-term risk of mortality.
TH-PO835
Suicidal Erythrocyte Death in Hemodialysis Patients  Anna Clementi,1 Grazia 
Maria Virzì,2 Alessandra Brocca,2 Massimo de Cal,2 Antonio Granata,1 Claudio 
Ronco.2  1Nephrology, Agrigento; 2Nephrology-IRRIV, Vicenza.
Background: Even though anemia in ESRD results mainly from the lack of 
erythropoietin, compelling evidence points to the contribution of accelerated erythrocyte 
death/eryptosis, which is characterized by phosphatidylserine (PS) exposure at surface, 
cell shrinkage and cell membrane scrambling. Eryptosis may be stimulated both by uremic 
toxins and the mechanical stress induced by hemodialysis (HD). We investigated the 
possible difference in terms of eryptosis levels between healthy subjects and HD patients 
before and after HD session.
Methods: We enrolled 15 patients (4F, mean age 65±16yrs, 33% with diabetes) 
undergoing chronic HD and 15 healthy subjects (CTR). Blood samples were collected prior 
to and after 4h standard HD session. Measurements were made in isolated erythrocytes 
(RBCs). PS exposure was estimated from AnnexinV binding in flow cytometer.
Results: The percentage of AnnexinV reflecting the percentage of RBCs exposing PS 
at RBC surface was significantly higher (more than twice) in HD patients than CTR (2.2%; 
IQR 1.2-4.1 versus 0.8%; IQR 0.7-1.3; p<0.05). The average forward scatter reflecting cell 
volume was significantly higher in RBCs from HD patients than in CTR. There was no 
statistically significant relationship between urea levels and eryptosis in HD patients. The 
percentage of AnnexinV and cell volume were measured prior to and after 4h of HD: no 
significant differences were observed between pre and postdialytic eryptosis.
Conclusions: Our data suggest that HD may lead to a significant increase in eryptosis, 
but no differences in its level were observed before and after HD session. Although dialytic 
procedure is known to be responsible for cytokines and inflammatory mediators release, 
because of the interaction between blood and circuit lines and filters, it does not seem to 
induce eryptosis. Further studies are needed to compare different types of HD treatments.
TH-PO836
Deployment of a Dialysis Hospitalization Reduction Program Is Associated 
with Lower Hospitalization Rates  Hanjie Zhang,1 Dugan Maddux,2 Karen 
G. Butler,2 Len A. Usvyat,2 Yue Jiao,2 Brian Scott Ash,2 John W. Larkin,2 Terry 
Ketchersid,2 Peter Kotanko,1,3 Franklin W. Maddux.2  1Renal Research Inst, 
New York, NY; 2Fresenius Medical Care North America, Waltham, MA; 3Icahn 
School of Medicine at Mount Sinai, New York, NY.
Background: The aim of this study was to investigate the potential effect of a Dialysis 
Hospitalization Reduction Program (DHRP) on hospital admissions.
Methods: We deployed DHRP to 69 patients between 1/1/2014 and 5/5/2015 in a 
network of Fresenius Medical Care North America (FMCNA) dialysis clinics. These patients 
were identified as being at high risk for hospitalization based on FMCNA’s data driven 
predictive modeling efforts and clinical assessments. The DHRP encompasses multiple 
interventions, targeting malnutrition, non-compliance, mental status issues, fluid overload, 
and others. Each patient is identified to have one or more “clinical tags”; 88 tags were 
identified for 69 patients. Interdisciplinary teams were deployed to design and implement 
interventions. Hospitalization rates were measured 90 days before and after the program.
Results: DHRP was associated with a reduction of all-cause hospitalization from 7.5 
to 4.4 per patient year (ppy) (-42 %) (Figure 1A). Interventions targeting patients with 
“malnutrition” tag were associated with a reduction of hospitalizations from 9.3 to 4.1 
ppy (-56%) (Figure 1B). 
Conclusions: DHRP was associated with reductions in hospital admissions and days. 
Reductions in overall hospital admissions were even higher in patients specifically identified 
to have malnutrition issues.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
TH-PO837
The Long Inter-dialytic Period Is Not Associated with Inferior BP Control 
in Stable Hemodialysis Patients  Mohamed Shantier, Rajneet Singh, Paul 
Mcdermott, Sami Suleiman, Donal N. Reddan, Louise Giblin, David W. 
Lappin, Matthew D. Griffin.  Nephrology Dept, Saolta Univ Healthcare Group, 
Galway, Ireland.
Background: 3-day-a-week hemodialysis (HD) involves one long (72hr) and two short 
(48hr) inter-dialytic periods (IDP) with higher death risk after the long IDP. We investigated 
BP and CV biomarker patterns in clinically stable HD patients to determine whether BP 
control during the final 24 hrs of the long IDP is inferior to that of the short IDPs.
Methods: In an initial retrospective study, in-center BP readings over 1 month were 
analyzed for 81 adult HD patients with stable regimen and medical status for ³3 mths. 
Next, 23 patients completed a prospective study in which ambulatory BP monitoring was 
performed for the final 24hrs of the long and one short IDP in the same week. Blood was 
collected for CRP, Troponin T, BNP following each ABPM.
Results: In the retrospective study, mean pre-dialysis systolic and diastolic BP (SBP/
DBP) did not differ for the long and short IDPs despite greater weight gain during the long 
IDP. This observation was confirmed in the ABPM study and applied to both day- and 
night-time readings. Pre-dialysis CV biomarkers were not significantly higher following 
the long IDP. Inter-dialytic weight gain showed no correlation with BP indices.
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Index Long-IDP Short-IDP P value
24hr SBP (mmHg, mean± SD) 148.4±18 146.8±19.2 0.4
24hr DBP (mmHg, mean± SD) 80.8±10.3 80.5±11.2 0.5
24hr MAP (mmHg, mean± SD) 103.3±11.6 102.6±12.8 0.4
Day-time SBP(mmHg, mean± SD) 150.7±17 147.8±18.2 0.3
Night-time SBP (mmHg, mean± SD) 141.9±24.6 143.3±25.8 0.4
Inter-dialytic weight gain (kg, mean± SD) 2.7±1.4 1.8±0.8 0.002
Pre-dialysis Troponin T(ng/mL,mean± SD) 76±57 72±50 0.4
Pre-dialysis BNP (pg/mL, mean± SD) 9801±10805 8628±9822 0.1
Pre-dialysis CRP (mg/L, mean± SD) 9.5±12 6.6±9 0.2
Conclusions: In stable HD patients, BP control and CV biomarkers were similar during 
long compared to short IDP despite greater fluid gain. The adverse influence of excessive 
inter-dialytic fluid gain is unlikely to be mediated directly through a hypertensive effect.
TH-PO838
Notch Signaling in Bone Marrow-Derived FSP-1+ Cells Mediates a 
Phenotypic Change in Smooth Muscle Cells Leading to AVF Failure 
Ming Liang,1,2 Jinlong Luo,1 William E. Mitch,1 Jizhong Cheng.1  1Medicine, 
Baylor College of Medicine, Houston, TX; 2Nephrology, Guangzhou Medical 
Univ, Guangzhou, Guangdong, China.
Background: sociological and economic costs of failed arteriovenous fistulas (AVF) 
are well known but mechanisms of AVF losses are controversial. We have shown that 
smooth muscle cells (SMCs) from anastomosed artery compose of ~50% of neointima 
cells in AVF. Arterial anastomoses are also infiltrated by bone marrow (BM)-derived 
FSP-1+ cells, potentially linking FSP-1+ cells to SMC activation. However, whether 
Notch/RBP-JK signaling involves in BM-derived FSP-1+ cells activation has not been 
studied. We propose that Notch/RBP-JK activation in BM-derived FSP-1+ cells causes a 
phenotype-switch of SMCs, resulting in SMC translocation from the artery to the venous 
anastomosis, forming neointima.
Methods: we created CKD and AVFs in wild type and Notch knock out mice. The role 
of Notch signaling in activation and function of BM-derived FSP-1+ cells was explored. 
Activated SMCs were characterized by a loss of differentiation markers plus a gain in 
proliferation (PCNA+). Using BM transplantation, we examined if FSP-1+ cells lacking 
RBP-JK in CKD mice would suppress SMC phenotype switch and neointima formation 
in AVFs.
Results: BM-derived FSP-1+ inflammatory cells in AVFs from CKD mice were 
45% greater vs. results in pair-fed, control mice. In the artery anastomosis, increased 
infiltration of FSP-1+ cells led to loss of SMC differentiation markers, SMMHC, SM-22 
and SMA-α. Activation of Notch signaling (N1ICD+ and RBP-JK+) raised expression of 
cytokines (IL-1β, MCP-1) and growth factors (PDGF-BB, bFGF2 and TGF-b1) in FSP-1+ 
cells, The cytokines and growth factors caused a SMC phenotype switch (characterized 
by loss of SMC markers), resulting in SMC migration and proliferation. RBP-JK KO in 
BM-derived FSP-1+ cells significantly decreased the production of cytokines and growth 
factors, suppressed SMC activation of and neointima formation in AVFs.
Conclusions: Thus, Notch signaling in BM-derived FSP-1+ cells can induce a 
phenotypic switch in SMCs stimulating neointima growth. Targeting Notch signaling in 
FSP-1+ cells could improve AFV function.
Funding: NIDDK Support
TH-PO839
Cytoglobin Is Upregulated in Failed Arteriovenous Fistula from 
Hemodialysis Patients and Exerts Survival Functions in Medial Smooth 
Muscle and Neointimal Cells  David Jourd’heuil, Frances L. Jourd’heuil, 
Yongfeng Liu, Julia Steppich, Roman G. Ginnan, David J. Conti, Harold A. 
Singer, Arif Asif.  Center for Cardiovascular Sciences and Nephrology Group, 
Albany Medical Center, Albany, NY.
Background: Arteriovenous fistulae (AVFs) suffer significant problems with high 
incidence of both early and late failures. Interventions that may prolong access patency are 
still very limited and require strategies that may impair or regress neointimal hyperplasia. In 
the cardiovascular system, globins such as hemoglobin are thought exclusively to regulate 
O2 and nitric oxide (NO) levels. However, recent studies suggest that this model might be 
incomplete and that non-canonical mammalian globins including cytoglobin (CYGB) have 
survival functions independent of the regulation of O2 and NO. Our goal was to understand 
the function of CYGB in the hyperplastic response associated with AVF failure.
Methods: Histomorphometric, immunostaining, and protein analysis were performed 
on samples obtained from the venous segments of AVFs collected from patients undergoing 
surgical access creation/revision. The functional significance of CYGB was studied in vivo 
in rodent models of injury-induced neointimal formation and in sub-cultured human smooth 
muscle cells (SMCs) derived from primary placement and revision veins.
Results: CYGB was upregulated in revision compared to primary placement veins 
with significant expression in both medial smooth muscle and neointimal cells. Injury-
induced neointimal formation in vivo was attenuated by CYGB deficiency and associated 
with increase apoptosis and medial VSMCs loss. Human venous medial and neointimal 
SMCs derived from failed AVFs maintained high levels of CYGB in culture in contrast to 
medial SMCs from placement veins. Molecular strategies to modulate CYGB expression 
levels revealed that CYGB promotes SMC cell survival by inhibiting the mitochondrial 
pathway of apoptosis.
Conclusions: Our results challenge the current dogma on globin functions and 
demonstrate a role for CYGB in regulating venous VSMCs survival. Strategies aimed at 
regulating CYGB anti-apoptotic functions might represent important therapeutic options 
to control for AVF maturation and limit stenosis.
Funding: Pharmaceutical Company Support - DCI Paul Teschan Research Fund, 
Private Foundation Support
TH-PO840
Identification of Ca2+/CaM-Dependent Protein Kinase (CaMKII) Isoforms 
and Their Selective Regulation by NADPH Oxidases in Failed Arteriovenous 
Fistula from Hemodialysis Patients  Roman G. Ginnan,1 Ravi S. Shah,1 
David J. Conti,3 Arif Asif,2 David Jourd’heuil,1 Harold A. Singer.1  1Center 
for Cardiovascular Sciences, Albany Medical College, Albany, NY; 2Div of 
Nephrology and Hypertension, Albany Medical College, Albany, NY; 3AMC 
Surgery Group-Transplantation, Albany Medical College, Albany, NY.
Background: Placement of an arteriovenous fistula (AVF) provides vascular access for 
lifesaving hemodialysis to patients with severe and chronic kidney disease. A significant 
percentage of AVFs initially mature; serve as successful hemodialysis access points; but 
fail at some later time due to neointimal hyperplasia that occludes the vein. The causative 
underlying molecular, biochemical, and cellular factors that contribute to AVF failure are 
incompletely understood. CaMKII is a positive regulator of VSM cell proliferation and 
migration that results in occlusion of carotid arteries in both mice and rats. Currently, there 
is little known regarding the role of CaMKII in either physiological or pathophysiological 
venous function.
Methods: CephaIic veins from patients prior to AVF placement and after AVF failure 
were obtained. Immunohistochemical studies were performed on OCT embedded frozen 
sections. Molecular analyses were performed on RNA extracts from these venous segments 
and protein analyses were performed on protein extracts.
Results: Our results indicate that there is an increase in CaMKIId and CaMKIIg 
expression in failed AVFs as compared to cephalic vein prior to AVF placement. CaMKII 
activity is regulated by both phosphorylation and oxidation. NADPH oxidases (Noxs) 
generate reactive oxygen species (ROS) that increases CaMKII activity. Analysis of 
failed AVFs shows an upregulation of Nox4 and Nox5. Further studies show an increase 
in  CaMKII activity. Interestingly, our data indicates that only a subset CaMKII isoforms 
are oxidized under these conditions.
Conclusions: These findings lead us to conclude that increases in [Ca2+] and [ROS] 
after AVF placement may result in increases of CaMKII expression and sustained activity 
that contribute to AVF failure. They also identify CaMKII as a rational target for therapeutic 
manipulation to prevent AVF failure.
Funding: Pharmaceutical Company Support - DCI Paul Teschan Research Fund
TH-PO841
Combined RNA seq and gDNA Methylation Analysis for AVF Maturation 
Begoña Campos, Sonia Bhati, Nikhil Grandhi, Ashish Verma, Amanda B. 
Naciff-Campos, Gagan Deep Singh, Keith Louis Saum, Mario Medvedovic, 
Amy Pflum, Timmy C. Lee, Prabir Roy-Chaudhury.  Univ of Cincinnati.
Background: Early arteriovenous fistula (AVF) failure remains an important cause of 
hemodialysis vascular access dysfunction. In order to understand the cellular and molecular 
mechanisms involved in early AVF failure we evaluated the gene methylation profile 
(epigenetics) in conjunction with the gene expression profile (RNA Seq) from venous 
segment tissue samples obtained at the time of AVF creation. This approach allows us to 
identify genes that have altered expression (RNA Seq analysis) as a result of epigenetic 
changes (DNA methylation). The latter can be induced by different factors, including stress, 
inflammation, nutrition, metabolism, drugs and infection (all of which are prominent in the 
biological milieu of patients with CKD and ESRD).
Methods: Genomic DNA (gDNA) and RNA were isolated from venous segments 
collected at the time of AVF creation. We divided the samples into 2 groups, THICK 
(n=5) and THIN (n = 5), based on a histological evaluation of the amount of neointimal 
hyperplasia. Deep sequencing technologies were then used to identify differentially 
regulated levels of gene expression between the THICK and THIN groups, that also had 
significant differences in the degree of methylation. Standard bioinformatic techniques 
were used to identify/interrogate these changes.
Results: We were able to identify a number of genes that were differentially regulated, 
either at the level of the transcriptome or at the level of DNA methylation (epigenetics) 
between the THICK and THIN groups. However, we were not able to identify individual 
genes that had changes in both the RNA Seq and DNA methylation analyses, at a high 
level of statistical significance.
Conclusions: While we were unable to identify differences in both gene expression 
and the level of DNA methylation for individual genes, between our two groups (perhaps 
because of a small sample size), we do believe that these techniques and technologies could 
be used in larger studies, to dive deep into the mechanisms of AVF failure at a molecular 
and genetic level.
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TH-PO842
Computational Fluid Dynamic Analyses in a Uremic Mouse Model of AVF 
Stenosis: Of Surgery, Techniques and Computation  Begoña Campos,1 
Yang Wang,1 Yong He,2 John M. Pearce,3 Richard Scott Dunn,3 Keith Louis 
Saum,1 Janaka Wansapura,3 Charles L. Dumoulin,3 Scott A. Berceli,2 Prabir 
Roy-Chaudhury.1  1Univ of Cincinnati; 2Univ of Florida; 3CCHMC.
Background: Although arteriovenous fistulae (AVF) are the preferred form of 
vascular access for hemodialysis patients, over 50% of AVFs fail to mature (inability to 
increase blood flow and diameter adequately to support dialysis). Work performed in our 
laboratory suggests that AVF maturation failure is due to an interaction between “upstream 
hemodynamics” and “downstream vascular biology”. In order to better elucidate the 
mechanisms involved in both these processes, we herein describe the techniques needed 
to develop a shear stress profile within a uremic mouse AVF.
Methods: In order to create a uremic mouse model, C57Bl/6 animals underwent an 
initial cautery of the left kidney followed 2 weeks later by a contralateral nephrectomy. 
Four weeks later AVFs were created in the neck. In order to generate different shear stress 
profiles, we created AVFs between the carotid artery and jugular vein in the following 
surgical configurations (a) end of carotid artery to end of jugular vein (b) end of jugular 
vein to side of carotid artery and (c) end of carotid artery to side of jugular vein. Mice were 
then perfused with a silicone rubber casting agent (Microfil). Fistulae were harvested, stored 
in 4% paraformaldehyde, and treated with Lugol solution as a micro-CT contrast agent. 
Each AVF was then scanned using micro-CT imaging to create a 3D reconstruction of AVF 
geometry. In order to obtain blood flow parameters we have developed an MRI technique 
that allows us to quantify blood flow within the carotid artery. We then use software to 
develop a complete shear stress profile in the mouse AVF.
Results: We have described for the first time a hybrid surgery-fluid dynamics approach, 
which could allow us to identify the differential impacts of different surgical configurations, 
with or without the impact of uremia on AVF fistula functionality (with the promise of also 
being able to use genetically manipulated animals in the future).
Conclusions: We firmly believe that teasing out the relative roles of upstream 
hemodynamics and downstream uremic vascular biology will allow us to identify target(s) 
for future therapeutic interventions.
TH-PO843
Biodegradable Stents Improve Arteriovenous Fistula (AVF) Maturation 
Begoña Campos, Yang Wang, Zhangzhang Yin, Keith Louis Saum, Diego 
Celdran-Bonafonte, Mark J. Schulz, Vesselin Shanov, Prabir Roy-Chaudhury. 
Univ of Cincinnati.
Background: Arteriovenous fistula (AVF) maturation failure is currently a huge 
clinical problem with no effective therapies. At a pathogenetic level the three main causes 
of AVF maturation failure are (a) small veins (b) abnormal non-laminar flow profiles and 
(c) abnormal local endothelial function. We therefore, hypothesize, that the placement of 
a malleable, biodegradable magnesium based maturation enhancing stent (bMES) within 
the venous segment, at the time of surgical AVF creation would dilate small veins, optimize 
the anatomical configuration, and serve as a conduit for the future delivery of therapies to 
improve local vascular biology during the critical initial 4-8 week period with an absence 
of long term side effects (no stent after 4-8 weeks).
Methods: bMES were fabricated using pure Mg foil (125 mm) and Mg-Zn alloy 
wire. Bilateral AVFs were created between the femoral artery and vein of Yorkshire pigs. 
A bMES was inserted on one side and dilated to 8mm. A control AVF was created on the 
contralateral side. CT angiograms and ultrasounds were performed to document blood flow 
and diameter for the control and stented AVF.
Results: Preliminary data documents almost complete degradation of the bMES at 
4-8 weeks with an initial increase in diameter of the stented AVFs on CT angiograms at 2 
weeks (Figure). Histological examination performed on both the stented and control AVFs 
did not reveal any evidence of necrosis or inflammation.
Conclusions: These initial results clearly demonstrate technical feasibility and safety 
for the bMES, and also provide us with an efficacy signal based on our CT angiogram data 
(Figure). We believe that this technology could significantly reduce the huge morbidity and 
mortality associated with AVF maturation failure and also expand the patient population 
considered to be suitable for AVF placement in the future.
Funding: Other NIH Support - R21EB016150
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Abstract Withdrawn
TH-PO845
Association Between Clinical Outcomes and Type of Vascular Access 
in Elderly End-Stage Renal Disease Patients Initiating Hemodialysis 
Kyoung Sook Park, Mi Jung Lee, Tae-Hyun Yoo, Shin-Wook Kang.  Dept of 
Internal Medicine, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Although dialysis initiation via arteriovenous fistula (AVF) is the best 
strategy in incident hemodialysis (HD) patients. Elderly patients with HD are compelled 
to use HD catheter (HC) due to maturation failure after AVF operation. Therefore, we 
investigated the association of vascular access (VA) type and clinical outcomes in elderly 
incident HD patients.
Methods: A prospective cohort of incident HD patients from the Clinical Research 
Center for End-stage renal disease in Korea between 2009 and 2013 was used. Patients 
who were 65 years or older were defined as elderly. The patients were classified into three 
groups according to VA type at HD initiation. Since the hazard ratio (HR) according to 
type of VA was not proportional, time-dependent Cox regression analysis was performed 
to determine all-cause mortality.
Results: Among the 511 enrolled patients, 303 (59.3%) were male and the mean age 
was 72.3±5.4 years. HD was initiated with AVF, arteriovenous graft (AVG), or HC in 86 
(16.8%), 36 (7.0%), and 389 (76.1%) patients, respectively. During a median follow up of 
12 months, all-cause death was observed 12 (14.0%) in AVF, 13 (36.1%) in AVG, and 107 
(27.5%) in HC. Multivariate time-dependent Cox regression analysis demonstrated that AVG 
(AVF as reference, HR=1.719, 95% confidence interval [CI]=1.274-2.319, P <0.001) and 
HC (HR=1.304, 95% CI=1.036-1.640, P=0.023) were significant risk factors for all-cause 
mortality after adjustment of age, sex, diabetes mellitus, previous cardiovascular disease, 
timing of referral to nephrologist, hemoglobin, serum albumin, and C-reactive protein levels.
Conclusions: Patients with successful AVF were associated with better survival 
compared to those with AVG or HC. In addition, survival was comparable between elderly 
patients initiating HD with AVG and HC. Although vascular problems are common in elderly 
patients, AVF may be the best strategy to improve clinical outcomes in this population.
TH-PO846
International Variability in Arteriovenous Fistula Maturation and 
Placement: The Dialysis Outcomes and Practice Patterns Study 
Ronald L. Pisoni,1 Lindsay Zepel,1 Francesca Tentori,1,2 Yun Li,3 Jarcy Zee,1 
Richard J. Fluck,4 Loreto Gesualdo,5 Hideki Kawanishi,6 Gültekin Süleymanlar,7 
Bruce M. Robinson.1  1Arbor Research; 2Vanderbilt Univ; 3Univ of Mich.; 4Nat. 
Health Service England; 5Azienda Ospedaliero Univ Consorziale Policlinico; 
6Tsuchiya Gen. Hosp.; 7Akendiz Univ.
Background: Prior Dialysis Outcomes and Practice Patterns Study (DOPPS) findings 
demonstrate international variability in vascular access practices, and association with 
outcomes. Here we describe international practices in arteriovenous fistula (AVF) placement 
and predictors of AVF maturation.
Methods: We studied 2,230 patients with an AVF created during DOPPS phases 4-5 
(2009–2015) in North America, Europe/Australia-New Zealand (ANZ), and Japan. AVF 
maturation was defined as access use ≥ 30 days. Generalized estimating equations with a 
logit link were used to assess predictors of AVF maturation adjusting for country, phase, 
patient characteristics, and accounting for facility clustering.
Results: No significant association was found between many patient characteristics 
(e.g., age, diabetes, peripheral vascular disease) and AVF maturation. AVF maturation was 
more likely for males vs. females (OR = 1.49 [95% CI = 1.25-1.79]) and for AVFs placed in 
the upper vs. lower arm (OR = 1.40 [95% CI = 1.15-1.70]). Even though upper arm AVFs 
were more common in North America, AVF maturation was lowest in this region (Figure).
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Conclusions: There is large international variability in site of AVF placement and 
AVF maturation. Differences in blood flow used (much higher in the US vs. Europe and 
Japan) may lead to different interpretation of the term “maturation” internationally, and 
may influence maturation rates.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
TH-PO847
Vascular Access in Acute Kidney Injury: Results from the ATN Study 
Kavitha Ganta, Yue-Harn Ng, Herbert T. Davis, Mark L. Unruh.  Deapartment 
of Internal Medicine, Univ of New Mexico, Albuquerque, NM.
Background: Acute kidney injury requiring renal replacement therapy (RRT) portends 
a poor prognosis. Currently, the decision regarding catheter placement is based solely on 
physician discretion. Limited data exist to guide catheter placement. The Acute Renal Failure 
Trial Network (ATN) study was a multicenter, prospective, randomized trial on the effects of 
dialysis dose on mortality in critically ill patients. Using data from this study, we assessed 
the complications rates and the adequacy of dialysis based on different catheter locations.
Methods: Baseline characteristics were gathered. The outcomes of interest include 
catheter related infections, cardiac arrhythmias, excessive bleeding, local thrombosis 
and dialysis adequacy. Categorical variables were analyzed using Chi-square test while 
continuous variables were analyzed using the Student T test. The SAS software was used 
for analysis.
Results: There were 242 (11.7%) subclavian (SC), 951 (46.1%) internal jugular (IJ) 
and 861 (41.7%) femoral (FC) catheters inserted. The baseline characteristics based on 
catheter location is shown in Table.1.
Baseline Characteristics Catheter Location P
SC (%) IJ (%) FC (%)
Age 61.3 ± 14.3 61.3 ± 14.7 59.1 ± 15.8 <0.01
Gender (Male) 170 (70.3) 686 (72.1) 618 (71.8) 0.84
BMI 27.3 ± 6.0 28.6 ± 6.0 27.9 ± 5.6 <0.01
Platelet (000/mm3) 141 ± 138 144 ± 113 130 ± 114 0.04
INR 1.6 ± 0.8 1.7 ± 1.6 1.9 ± 1.8 <0.01
Diabetes 78 (32.2) 286 (30.1) 235 (27.3) 0.23
PVD 75 (31.0) 197 (20.7) 113 (13.1) <0.01
The rate of bacteremia was comparable between the 3 groups. (5.4% (SC) vs. 3.5% 
(IJ) vs. 3.5% (FC); p = 0.34) The IJ group experienced more cardiac arrhythmias (2%) 
compared to the SC (0.8%) and FC (0.5%) group [p = 0.01] while the FC group had more 
venous thrombosis (0.7%) compared to none in the SC and IJ group [p = 0.02]. Overall, 
complication rates were low. There was no clinically significant difference in the adequacy 
of dialysis between the 3 groups.
Conclusions: There was no significant differences in complication rates amongst 
the 3 catheter locations hence decision on catheter location should be based on operator 
experience and comfort level.
TH-PO848
Vascular Access at Dialysis Initiation in the United States Renal Data 
System (USRDS): Strong Agreement Between CMS 2728 Medical Evidence 
Form and CROWNWeb  Purna Mukhopadhyay,1 Jeffrey Pearson,1 Kenneth 
J. Woodside,2 Sarah Bell,2 Ronald L. Pisoni,1 Douglas E. Schaubel,2 Kaitlyn 
Ratkowiak,1 Rajiv Saran.2  1Arbor Research Collaborative for Health, Ann 
Arbor, MI; 2Univ of Michigan, Ann Arbor, MI.
Background: The USRDS has long reported vascular access (VA) at the start of 
hemodialysis (HD) using the CMS-2728 Form. In 2012, CMS rolled out the CROWNWeb 
(CW) system to collect clinical treatment and laboratory data monthly for all dialysis 
patients. As CW data are fully integrated into the USRDS database, it is critical to evaluate 
the level of completeness and consistency between these two data sources.
Methods: We compared VA used at the first HD session reported on the CMS-2728 
form for new ESRD patients in 2013 (n = 96,936) in USRDS database with VA used at the 
end of the 1st month of HD reported through CW. To evaluate the potential for data lag, we 
also compared to the 2nd month of HD reported through CW. Completeness and consistency 
was assessed at the patient level by 2x2 tables. The level of agreement was evaluated by 
kappa statistics. Logistic regression models were fit to identify patient characteristics 
associated with the level of agreement.
Results: 89% of patients had at least one monthly VA report in CW among which 0.23% 
was missing VA data from the CMS-2728 and 32.8% did not have a VA reported in CW 
for their 1st month of HD. However, completeness of CW data improved when either 1st 
or 2nd month of HD was considered as only 12.6% of patients did not have a VA reported. 
Among patients with VA reported from both data sources, kappa statistics was 0.88 using 
the 1st month of ESRD and 0.84 using first two months of ESRD. Agreement was highest 
for catheter (97-98%) and lowest for graft (78-81%). Age, sex, race were associated with 
the level of agreement; Hispanic ethnicity and cause of ESRD were not.
Conclusions: CW data has VA information for the vast majority of patients; however, 
coverage is not complete and may be lowest at start of ESRD. However, there is very strong 
agreement in VA reported on the CMS-2728 and in CW. This study also demonstrates near 
completeness of CMS Form 2728 with respect to VA information at start of HD.
Funding: NIDDK Support
TH-PO849
Vascular Access and Trends in Pediatric End-Stage Renal Disease: Results 
from the USRDS  Brett W. Plattner,1 Yee Lu,2 David T. Selewski,2 Xue Dietrich,4 
Nan Ji,4 Alissa Kapke,4 Douglas E. Schaubel,3 Debbie S. Gipson,2 Rajiv Saran.1 
1Internal Medicine, Univ of Michigan, Ann Arbor, MI; 2Pediatrics, Univ of 
Michigan, Ann Arbor, MI; 3Biostatistics, Univ of Michigan, Ann Arbor, MI; 
4Arbor Research Collaborative for Health, Ann Arbor, MI.
Background: Policy to improve outcomes for End-Stage Renal Disease (ESRD) 
patients (pts) may be less widely adopted in children. We describe vascular access (VA) in 
incident and prevalent pediatric ESRD pts and examine changes in the first year.
Methods: Pediatric ESRD was defined as 0-17 yrs at diagnosis of ESRD. Data was from 
the 2728 and CROWNWeb. For pts incident during 2006-2013, data on VA at hemodialysis 
(HD) initiation (n=2,851) was categorized as catheter only (CVC), AV Fistula (AVF), AV 
Graft (AVG), CVC with maturing fistula, or CVC with maturing graft. Pts initiating HD 
between 6/1/2012-12/31/2012 (N=197), were tracked over 12 months. For prevalent pts, 
AVF & AVG groups include CVC/maturing fistula and CVC/maturing graft,respectively.
Results: From ‘06-’12, incident pts began ESRD care using HD 39%, PD 36%, and 
transplant 25%. In 2013, in pts starting HD, 90% had a CVC, an increase from 84% in 
2006. CVC was lower for the older pts (<4yrs: 99% vs. 14-17yrs: 83%, p <.05). VA trends 
over a year in a 7-month incident cohort showed the proportion of CVC decreased from 
84% at 1 month to 31% at 1 year, while 16% were using or maturing an AVF. 1% were 
using or maturing an AVG. 13% of pts transitioned to PD and 35% received a TX by 1 year. 
Conclusions: Our analysis confirms the large CVC burden among pediatric HD pts. 
Conversion to AVF were observed over the first year in an incident cohort where nearly 50% 
of pts transitioned to PD or TX. Further study will assess the impact of CVC dependence 
among pediatric ESRD pts with respect to future VA options and patient outcomes.
Funding: NIDDK Support
TH-PO850
In Search of an Optimal Screening Program for Containing Graft 
Thrombosis  Nicola Tessitore,1 Giuseppina Pessolano,1 Valeria Bedogna,1 
Albino Poli,2 Antonio Lupo.1  1Emodialisi Borgo Roma, Verona, Italy; 2Dept 
Public Health, Verona, Italy.
Background: K/DOQI guidelines recommend regular screening for >50% stenosis (ST) 
in graft by surveillance (access blood flow (Qa) &/or static venous pressure ratio (sVPR) 
or Duplex Ultrasound to reduce the risk of thrombosis. Analysis of the literature suggests 
that the best predictor of thrombosis is sVPR>0.5, with an area under curve (AUC) of 
0.81[95%CI:0.75-0.85] significantly higher than that of Qa<600 ml/min (0.72[95%CI:0.68-
0.77]) & ST (0.49[95%CI:0.45-0.53]), but no study has compared vis-a-vis all of the tools.
Methods: To identify an optimal screening program, in 2013 we compared the 
diagnostic performance of the available tools for incipient thrombosis (within 3 mo) in the 
same population of 42 grafts (5 forearm loop & 37 straight upperarm), that underwent18 
thrombotic episodes.
Results: Qa by Ultrasound Dilution proved to be the best screening tool 
(AUC:0.81[0.69-0.93]):optimal thresholds between Qa<1000 ml/min(63% sensitivity[SE], 
18% false positives[FPR]) & Qa<1200 ml/min (83% SE, 27% FPR). Its AUC was higher 
than that of ST (0.69[95%CI:0.54-0.84]: 78% SE, 39% FPR), monitoring (0.62[95%CI 
0.45-0.79]: 33% SE, 9% FPR), & VAPR (0.58[95%CI:0.42-0.74]:VAPR>0.8:72% SE, 
58% FPR). At GLM analysis Qa was the only significant predictor of thrombosis, with 
18%[95%CI 7-29] lower risk for each 100 ml/min above a Qa 400 ml/min. From January 
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2014 onward we adopted a monthly Qa screening program using a Qa<1000 ml/min for 
stenosis repair & a drop inQa>25% for detecting & repairing restenosis. This led to a 
significant drop of thrombosis rate from 0.70[95%CI 0.41-1.11] (during the 2012-2013 
period in which screening was based on bimonthly VAPR and quarterly Qa measurements 
and stenosis repair triggered as per guidelines, by a VAPR>0.5 or a Qa<600 ml/min) to 
0.11[95%CI 0.01-0.40] event/graft-y (p=0.005), at a comparable elective angioplasty rate 
(0.71[95%CI 0.46-1.04] vs 0.77[95%CI 0.43-1.27] event/graft-y, p=ns).
Conclusions: Our comparative study suggests that Qa is the best predictor of graft 
patency & Qa surveillance using a Qa<1000 ml/min threshold allows for appropriate and 
timely stenosis repair & may contain the risk of thrombosis.
TH-PO851
The Impact of eGFR at Pre-HD Access Surgery on the Likelihood of Starting 
Hemodialysis with a Mature Vascular Access  Alian Albalas, Timmy C. Lee, 
Michael Allon.  Nephrology Dept, UAB, Birmingham, AL.
Background: The optimal timing of pre-dialysis vascular access surgery is uncertain. 
If the access is placed too late, it may not be ready for use; if it’s placed too early, it may not 
be needed. The optimal timing may differ for AVF vs AVG. We evaluated the association 
of eGFR at access placement with (1) likelihood of starting HD, and (2) likelihood of a 
mature access at HD initiation.
Methods: We retrospectively queried a prospective computerized access database 
to identify patients with pre-HD access surgery (301 AVF and 64 AVG placed between 
2006-12) with an eGFR recorded on the surgery date. Patients were stratified into 4 eGFR 
groups (<10; 10-14; 15-19; >20 ml/min). For each patient we determined:(1) whether 
dialysis was initiated within 2 years, and (2)whether the permanent access was used on 
the first HD session.
Results: Overall, 208 (or 69%) of pts with pre-HD AVF surgery initiated HD within 
2 years, but the proportion varied by eGFR at surgery (90, 81, 64, and 47% for eGFR <10, 
10-14, 15-19, and >20 ml/min).
Among the 208 pts with pre-HD AVF who started HD, 47% used the AVF on the first 
HD session, but the proportion varied by eGFR (30, 44, 59 and 45% for eGFR <10, 10-14, 
15-19, and >20 ml/min). Among pts with pre-HD AVG surgery, HD was initiated within 6 
months in 90, 62, and 50% for eGFR <10, 10-14, and 15-19 ml/min. The AVG was used 
for the HD session in 78, 89, and 88% of pts with eGFR of <10, 10-14, and 15-19 ml/min.
Conclusions: There are tradeoffs in the timing of pre-HD AVF surgery. A higher eGFR 
is associated with a lower likelihood of initiating HD in 2 years, but a higher likelihood 
that the AVF will be used on the first HD session. The optimal balance is achieved at an 
eGFR of 15-19 ml/min. In contrast, the optimal timing for pre-HD AVG surgery is an eGFR 
of 10-14 ml/min. Late placement of an AVG may be a catheter-sparing strategy.[figure]
TH-PO852
Economic Burden to Dialysis Providers of Central Venous Catheter (CVC)-
Related Blood Stream Infections (BSI) and Occlusions Among Incident 
Hemodialysis (HD) Patients  Steven M. Brunelli,1 Wendy Turenne,1 Scott 
Sibbel,1 John Alan Laich,1 Antony E. Pfaffle.2  1DaVita Clinical Research, 
Minneapolis, MN; 2CorMedix Inc, Bedminster, NJ.
Background: Complications of CVCs may have economic consequences for dialysis 
providers derived from opportunity costs for missed dialysis treatments and increased use 
of bundled medications. We sought to quantify this financial burden among incident patients 
at a large dialysis organization (LDO).
Methods: We considered patients who began HD via a CVC between Jan 2013 
and Dec 2014. In parallel analyses, patients who developed BSI (N=3269) or occlusion 
(N=676) during the first 6 months of dialysis were matched to control CVC-HD patients 
who did not. Missed HD treatment rates and medication utilization were considered from 
date of BSI/occlusion (or corresponding date for controls) for 180 days or until censoring 
for death, modality change or loss to follow up. Costs were derived using payor-specific 
remuneration rates (missed treatments), LDO acquisition costs (IV iron, ESA) and average 
wholesale prices (antibiotics, thrombolytics). Differences were estimated using linear mixed 
models including fixed effects for exposure status and month, adjusted for covariates that 
were imbalanced at baseline.
Results: CVC-related BSI was associated with significantly greater ESA utilization 
(59,339 vs 49,515 U/month, cases vs controls), IV antibiotic use (41.8% vs 6.0%) and 
missed HD treatment rate (1.95 vs 1.36 missed treatments/patient-month). This translated 
to a mean incremental cost of +397 per patient per month. CVC occlusion was associated 
with increased thrombolytic use (10.9% vs 4.2%) but no significant difference in costs.
Conclusions: CVC-related BSI is a potent cost driver for dialysis providers with 
incremental costs of ~400/month over a 6-month time horizon. No appreciable economic 
consequences of CVC occlusion were observed. 
Funding: Pharmaceutical Company Support - CorMedix Inc
TH-PO853
Obesity Related Decrease in Intraoperative Blood Flow Is Associated 
with Maturation Failure of Radiocephalic Arteriovenous Fistula 
Jwa-kyung Kim,1 Sun Ryoung Choi.2  1Internal Medicine, Dept of Internal 
Medicine, Kidney Research Inst, Anyang, Korea; 2Internal Medicine, Shamyook 
Medical Center, Seoul, Korea.
Background: Successful arteriovenous fistula (AVF) maturation is often challenging 
in obese patients. Optimal initial intraoperative blood flow (IOBF) is essential for adequate 
AVF maturation. This study was conducted to elucidate the effect of obesity on IOBF and 
radiocephalic AVF maturation.
Methods: Patients who newly created radiocephalic AVF were included (n=252). 
Obesity was defined as a baseline BMI³25 kg/m2, and primary maturation failure was defined 
as the failure to use AVF successfully by 3 months after its creation. IOBF was measured 
immediately after construction of AVF using a VeriQTM system.
Results: The mean BMI was 24.1±3.9 kg/m2, and the prevalence of obesity was 31.3%. 
Particularly, 8.3% (21 patients) were BMI ≥ 30 kg/m2. Primary maturation failure occurred 
in 100 (39.7%) patients and an IOBF< 190 mL/min was closely associated with the risk of 
maturation failure (relative risk,3.05; 95% CI,1.52–6.11). Compared to non-obese patients, 
obese subjects had a significantly higher prevalence of diabetes and elevated hs-CRP levels, 
whereas diameters of vessels were similar. When the patients were further divided into 3 
groups as the BMI <25, 25-29.9, and >30 kg/m2, patients in higher BMI group showed 
significantly lower IOBF and higher maturation failure rate. According to multivariate 
analysis, the statistically significant variables that determined maturation failure were 
obesity, previous vascular disease, increased hs-CRP levels, and IOBF < 190 mL/min.
Conclusions: Obese patients had a significantly lower IOBF, and both obesity and low 
IOBF contributed to the primary maturation failure of AVF. Obesity-associated inflammation 
and atherosclerosis might play roles in this association.
TH-PO854
The Impact of Vascular Access on Hemodialysis Patient Survival and 
Risk Analysis  Ping chin Lai,1 Le mei Yeh,1 Yueh hsia Chiu,2 Ling yin Chiu.1 
1Renal Dept, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 2Health Care 
Management, Chang Gung Univ, Taoyuan, Taiwan.
Background: Hemodialysis is the most common dialysis modality worldwide. 
However, the impact of different types of vascular access on hemodialysis patient survival 
has not been investigated in a large scale study. Therefore, we retrospectively reviewed the 
survival of hemodialysis patients in our center and analyzed the impact of vascular access 
on their survival. Other potential risk factors were also studied.
Methods: From 2001 to 2010, patients, who aged more than 40 years old and received 
regular hemodialysis in our center for at least 3 months, were included into this study. 
A total 916 patients were enrolled. The mean followed up interval were 4.4± 2.5 years. 
Among them, 51.1% were male, while 48.9% were female. These patients were divided 
into three groups according to their vascular access. Group A: patients used either native 
arteriovenous fistula or arteriovenous graft at the all time and dialysis catheter had never 
been used during the whole study period. Group B: patients used either native arteriovenous 
fistula or arteriovenous graft as their vascular access most of the time but they had used 
dialysis catheter at least once during study period. Group C: patients used dialysis catheter 
as their vascular access and arterioveonus shunt had never been established during the 
study period. Other survival associated factors were analyzed by using univariate and 
multivariate factor analysis.
Results: The results showed that group C patients had significantly worst survival rate 
(P<0.0001). The group B patients also had significantly worse survival rate when compare 
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with group A patients (P<0.0001). The hazard ratio was 1.71 (1.31-2.24) for group B and 
3.56 (2.08-6.08) for group C when compared to group A patients. Multivariate analysis 
showed that the associated risk factors for patient survival were male sex, diabetes mellitus, 
low albumin, high hsCRP, and abnormal AST level.
Conclusions: The use of dialysis catheter imposed high risk for patient mortality on 
top of other associated risk factors. Early establishment of vascular access can eliminate 
this risk factor and improve patient outcome.
TH-PO855
Early Experience with a Novel Device for Ultrasound-Guided Management 
and Cannulation of Hemodialysis Vascular Access  William D. Paulson,1 
Deborah J. Brouwer-Maier,2 Lillian A. Pryor,2 John Jason White,1 Laura L. 
Mulloy,1 Lu Y. Huber,1 Matthew J. Diamond.1  1Charlie Norwood VAMC & 
Georgia Regents Univ, Augusta, GA; 2Fresenius Medical Care, Waltham, MA.
Background: The vascular access continues to be the Achilles Heel of dialysis. Methods 
that facilitate easier management and cannulation of accesses are needed. We describe early 
experience with a novel ultrasound device.
Methods: The Sonic Window (Analogic Corp, Peabody, MA, USA) is designed to assist 
management of vessels in a variety of contexts. It differs from conventional ultrasound in 
that it provides a coronal view of vessels that yields determination of characteristics such 
as depth and luminal diameter, and assists in cannulation for dialysis. We have initiated 
a program in 4 FMC dialysis units which is designed to identify its role and limitations.
Results: Two experts in the use of the Sonic Window have trained dialysis staff in the 
4 FMC units. Staff have successfully cannulated 33 AV fistulas and synthetic grafts. Set 
up and use of the device generally adds an extra 1-3 minutes to cannulation time. Staff 
are able to easily visualize advancement of dialysis needles into the vessel lumen (figure).
We plan to evaluate the following potential uses of the device: 1. Assessing fistula 
maturation by measuring increase in luminal diameter over time; 2. Evaluating accesses 
that are difficult to cannulate; 3. Evaluating accesses with low blood flow, or high negative 
arterial or positive venous dialysis pressure; 4. Identifying alternative access sites for 
cannulation. Possible disadvantages to be addressed: potential staff & patient reluctance 
to accept new technology and additional cannulation time, to be assessed in surveys.
Conclusions: Our early experience supports the concept that Sonic Window is a 
significant advance in managing and cannulating accesses in both routine and difficult 
situations.
Funding: Pharmaceutical Company Support - Fresenius Medical Care
TH-PO856
Modifiable Risk Factors Affecting the Outcome Hemodialysis Graft 
Jee eun Park, Jin Hae Kim, Subin Hwang, Do Hee Kim, Hye Ryoun Jang, 
Jung eun Lee, Wooseong Huh, Yoon-Goo Kim, Ha Young Oh, Dae Joong Kim. 
Nephrology Div, Dept of Medicine, Samsung Medical Center, Sungkyunkwan 
Univ School of Medicine, Seoul, Korea.
Background: Arterio-venous graft (AVG) for hemodialysis has poorer outcome than 
arterio-venous fistula (AVF) with its frequent stenosis and thrombosis. We investigated 
modifiable risk factors affecting the outcome of AVG.
Methods: A single-center cohort of 254 patients (pts) receiving AVG for hemodialysis 
access from Sep 2010 to Oct 2014 were included. Demographics, laboratory data, 
comorbidities, and medications were collected from the medical records. Surgical factors 
related to AVG operation including the type and diameter of connected vessels, graft site, 
and type of operation (elective or emergent) were also recorded. End points was the interval 
from initial access formation to any intervention intended to restore patency (primary 
patency, days) and the total access survival duration (secondary patency, days).
Results: Data of 225 pts were analyzed. During the follow-up period, 139 (62%) pts 
received intervention and 45 (20%) pts underwent permanent failure. Survival analyses 
using Kaplan-Meier method was shown in the figure. In multivariate analysis, primary 
patency duration was associated with RAS inhibitor (hazard ratio [HR] 1.67, 95% 
confidence interval [CI] 1.13-2.46), and upper arm graft (HR 0.62, 95% CI 0.40-0.94). 
Secondary patency duration was associated with serum albumin level (HR 0.28, 95% CI 
0.13-0.61), diastolic blood pressure (BP) (HR 0.93, 95% CI 0.89-0.98) and warfarin (HR 
5.80, 95% CI 2.04-16.46). 
Conclusions: Patients’ nutritional status reflected by serum albumin levels and diastolic 
BP could be modified for favorable outcome of AVG.
TH-PO857
Effects of Diastolic Blood Pressure on the Patency of Brescia-Cimino 
Arteriovenous Fistula for Hemodialysis Access  Yan Yan.  Nephrology Dept, 
The First Affiliated Hospital of Nanchang Univ, Nan Chang, China.
Background: To evaluate the relationship of diastolic blood pressure (DBP) with the 
patency of the Brescia-Cimino arteriovenous fistula (AVF), and to determine DBP levels 
that predict the success of this procedure.
Methods: Data was collected from 986 patients with end-stage kidney disease (ESKD) 
who had Brescia-Cimino AVFs from March 2007 to December 2013. DBP was measured 
twice a day, at 6 AM and 5 PM, starting 3 days before surgery until 3 days post-procedure. 
A receiver operating characteristic (ROC) curve was constructed to determine the cutoff 
value of pre-operative DBP, which predicts an increased chance of AVF patency during 
the first 7 days after surgery.
Results: Only41 out of the 986 patients enrolled in this study developed AVF failure 
within the first 7 days following surgery, resulting in a 95.8% success rate in the procedure. 
This rate was increased by pre-operative DBP levels (P = 0.007). When the cutoff value 
was 77 mmHg, ROC analysis showed DBP was a pre-operative indicator for predicting 
AVF patency in the early postoperative period (P = 0.012; AUC = 0.607) with a sensitivity 
of 69.5% and specificity of 48.8%. 
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Conclusions: A DBP > 77 mmHg prior to surgery may be considered as a key prognostic 
indicator of the Brescia-Cimino procedure.
Funding: Government Support - Non-U.S.
TH-PO858
Vascular Access Outcomes following Peritoneal Dialysis to Hemodialysis 
Transition  Timmy C. Lee,1 Mae Thamer,2 Qian Zhang,2 Yi Zhang,2 Michael 
Allon.1  1Univ of Alabama at Birmingham; 2Medical Technology and Practice 
Patterns Inst.
Background: Few studies have evaluated vascular access (VA) use following transition 
from PD to HD. Our goal was to examine short-term VA utilization following PD to HD 
transition.
Methods: Using USRDS and Medicare claims data from July 2010-December 2012, 
we identified 3,565 incident Medicare-insured PD patients who were ³18yrs and initiated 
dialysis between July 2010-June 2011. Patients had at least one dialysis claim within 90 
days of dialysis initiation and were followed for 1 year until one of the following events: 
switched to HD, kidney transplant, death, or end of follow-up. We used Cox-regression 
models to examine the association of risk factors and switching to HD, with death and 
transplantation used as competing events.
Results: 991 (27.8%) patients switched from PD to HD during the 1 year follow-up. 
Of these, 46% switched to HD within 90 days of dialysis initiation and 66% by 6 months. 
The median switch time was 114 days (IQR: 32-226). Patients with cardiovascular disease 
(Adjusted Hazard Ratio (HR) 1.25, 95% CI 1.10-1.43), COPD (HR 1.29; 95% CI 1.01-
1.66), and without pre-dialysis nephrology care (HR 1.46; 95% CI 1.21-1.76 versus those 
with >12 months nephrologist care) were more likely to switch from PD to HD. After 
switching from PD to HD, 89% used a catheter, 6.6% AVF, and 1.9% AVG. 90 and 180 
days after switching to HD, 71% and 50% of patients, respectively, who remained on HD 
still used a catheter as their VA.
Type of VA 1st Switch 90 Days After 1st Switch*
180 Days After 1st 
Switch**
N pts Remaining on Hemodialysis 991 709 653
Catheter Only 868 (87.6) 476 (67.1) 299 (45.8)
Catheter with other VA 9 (0.9) 28 (3.9) 27 (4.1)
AVF only 65 (6.6) 130 (18.3) 224 (34.3)
AVG only 19 (1.9) 50 (7.1) 67 (10.3)
Missing 30 (3.0) 25 (3.5) 36 (5.5)
*Transplantation:41; death:127; switched back to PD:114
**Transplantation:50; death:160; switched back to PD:128
Conclusions: The majority of patients transitioning from PD to HD initiate HD with a 
catheter. 50% dialyze with a catheter at 6 months. This highlights the need for VA planning 
in patients with failed PD to ensure timely transition to permanent VA.
Funding: Private Foundation Support
TH-PO859
Temporal Trends in Pre-Hemodialysis Vascular Access Creation in Elderly 
Patients with CKD  Timmy C. Lee,1 Mae Thamer,2 Qian Zhang,2 Yi Zhang,2 
Michael Allon.1  1Univ of Alabama at Birmingham; 2Medical Technology and 
Practice Patterns Inst.
Background: Optimal timing of pre-dialysis vascular access (VA) creation remains 
unclear. Elderly CKD patients with high co-morbidity are more likely to die before starting 
HD, so deferring VA creation may be reasonable. We assessed whether nephrologists have 
started selecting healthier elderly patients for pre-HD VA surgery.
Methods: Using Medicare claims data we identified 3418 elderly patients (aged ≥70 
years) with CKD undergoing pre-HD VA creation in 2004 to 2009, and divided them into 
3 time cohorts (2004-05, 2006-07 and 2008-09). For each temporal cohort, we assessed the 
likelihood of initiating dialysis during 2 years of follow-up after VA surgery. We collected 
data on cardiovascular co-morbidities and cardiovascular events prior to VA surgery and 
after dialysis initiation to determine if there were significant changes in these variables 
during the 3 time cohorts.
Results: During the 3 consecutive time periods, the proportion of patients dying before 
initiating HD decreased by 28%, the proportion surviving without HD increased by 31%, 
whereas the proportion initiating HD remained constant (p<0.005).
Year of VA 
Insertion
N of 
Patients
Initiated HD within 2 
Years (%)
Died before 
HD (%)
Survived without 
HD(%)
2004-2005 1178 68.0 17.5 14.5
2006-2007 1222 66.0 14.8 19.2
2008-2009 1018 68.5 12.6 19.0
Concomitantly, during the 3 consecutive time periods there was a progressive decrease 
in patients with history of PVD (66.5 to 59.7%, p<0.005), CHF (47.0 to 35.8%, p<0.005), 
and prior MI (6.5 to 3.3%, p<0.001). Among patients who initiated dialysis, there was a 
progressive decrease in the proportion of patients with a CHF (38.8 to 26.0%, p<0.001) or 
MI (5.4 to 2.6%, p<0.01) event in the first year after dialysis.
Conclusions: From 2004-2009, there has been a progressive decrease in cardiovascular 
co-morbidities in elderly CKD patients undergoing pre-HD VA surgery, and this has been 
associated with a decrease in patients dying before HD and in patients with cardiovascular 
events after starting HD. Clinicians are becoming more selective in pre-HD placement of 
VA in this patient population.
Funding: Private Foundation Support
TH-PO860
Hemodynamic Changes in Arteriovenous Fistula During Dialysis 
Mary S. Hammes,1 Vikash Kumar Sinha,1 Tom Blicharski,1 Michael Boghosian,2 
Jane E. Hines,1 Sydeaka Watson,3 Kevin Cassel,2 S.M. Javid Mahmoudzadeh 
A.2  1Medicine/Nephrology, Univ of Chicago; 2Dept of Mechanical, Materials 
and Aerospace Engineering, Illinois Insitute of Technology; 3Dept of Public 
Health Sciences, Univ of Chicago.
Background: Optimal blood flow velocity (BFV) in arteriovenous fistulas (AVF) to 
prevent neointimal hyperplasia is yet to be determined. We have hypothesized that changes 
in BFV and diameter in a brachiocephalic fistula (BCF) are affected by fistula maturation 
and blood flow induced during hemodialysis.
Methods: Eight subjects with primary BCF participated. Doppler BFV was measured 
pre-dialysis and during dialysis at 250, 350 and 450 mL/min blood flow for up to 14 months. 
BFV was measured in the straight portion of the cephalic vein 10 cm proximal to the cephalic 
arch. The relationship between BFV and diameter was examined using a linear mixed effects 
model. Computational modeling using venography was performed at 3 and 12 months.
Results: The change in measured diameter and BFV showed an inverse relationship 
with a significant association at baseline (p<0.0074) and 350 mL/min dialysis blood flow 
(p<0.0092). The computational model of the cephalic arch in one subject showed a 4 fold 
increase in Reynolds number with a dramatic recirculation region shown by a swirling 
eddy at the upper elbow of the arch.
This region, present at baseline and 3 months is much deeper at 12 months and with 
increased dialysis blood flow rate of 450 mL/min.
Conclusions: In patients with BCF, as the AVF matures and with increased dialysis 
blood flow, an increase in diameter of the cephalic vein with subsequent decrease in BFV is 
observed. Increased blood flow during hemodialysis evokes recirculation eddy’s which may 
result in endothelial damage and subsequent intimal hyperplasia unless the arterilized vein is 
able to adapt and remodel to the pressures and flows that are generated during hemodialysis.
Funding: NIDDK Support
TH-PO861
Arteriovenous Fistula (AVF) Maturation Among Hemodialysis (HD) 
Patients: Results from the USRDS  Rajiv Saran,1 Sarah Bell,1 Brett W. 
Plattner,1 Douglas E. Schaubel,1 Sudipta Dasmunshi,1 Purna Mukhopadhyay,2 
Jeffrey Pearson,2 Ronald L. Pisoni,2 Kenneth J. Woodside.1  1Univ of Michigan; 
2Arbor Research Collaborative for Health.
Background: AVF are considered the gold standard for HD vascular access, but require 
time to mature and may not adequately develop, resulting in prolonged central venous 
catheter (CVC) use. We describe AVF survival from placement until time to first use for 
prevalent HD patients in the US.
Methods: We examined HD patients with new AVF placements during 2013 using 
Medicare claims. Failure of maturation was identified by non-use following placement using 
CROWNWeb (CW) where patient access use is reported monthly by the facility. Patients 
were followed until end 2014. We assessed the relationship between patient characteristics 
and time-to-first-use of AVF with a Cox model.
Results: In 2013, 51,561 AVF were placed among 42,160 HD patients followed 
through 2014. No subsequent evidence of use occurred in 44.3% of the placements. Of 
successfully used AVF, median time to first use was 113 days. Older age groups were 
incrementally associated with lower probability of using AVF. Pts in the 0-21 and 22-44yr 
groups (HRs=1.23 [95% CI=1.06-1.44], and 1.06 [1.03-1.11], respectively), were more 
likely to use AVFs compared to the 45-64yr group (ref.). Sex (Female; Fig. 1a), race (e.g., 
Black; Fig. 1b), comorbidity (cardiovascular disease, peripheral artery disease, diabetes, 
needing assistance or institutionalized status), vintage <1year, CVC and/or AV Graft use 
at incidence, were also associated with lower probability of AVF use.
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Conclusions: We have characterized AVF maturation in a national US sample and 
identified important associations with multiple patient-level factors. Research is urgently 
required into the importance of patient, region and practice factors that could improve AVF 
placement and maturation, decrease CVC use, to improve patient outcomes and experience. 
Funding: NIDDK Support
TH-PO862
Elderly Age Does Not Affect Long-Term Survival of Non-Transposed and 
Transposed Upper Extremity Arteriovenous Fistulae  Neville R. Dossabhoy,1,2 
Peter Van,1,2 Renu Gupta,1,2 Clifton Frilot.2  1Nephrology, Veterans Affairs 
Medical Center, Shreveport, LA; 2LSU Health, Shreveport, LA.
Background: The Fistula First initiative has successfully increased the placement of 
arteriovenous fistulae (AVF) for vascular access. Some authors have suggested that there is 
a higher failure rate of AVFs in elderly patients. The purpose of this study was to determine 
if elderly age influences the overall survival of transposed brachial-basilic fistulae (TBBF) 
and non-transposed AVFs (NT) placed in the upper extremity (UE).
Methods: Our prospective, computerized clinical database was queried retrospectively 
to identify the survival outcomes of all upper extremity (UE) fistulae placed in CKD and 
ESRD patients over a 6-year period at our VA hospital. All fistulae were placed by a single 
surgeon, hence eliminating inter-operator variability. Patient demographics and comorbid 
conditions were noted from the electronic record. The primary end point was permanent 
failure of the access. Kaplan Meier survival analysis was performed using SPSS.
Results: 230 UE fistulae were placed, which were categorized into two groups by 
patient age at the time of AVF placement: < 75 years and 75 years and older. The table 
shows the distribution by access type and age.
Age Type of AVF
TOTAL NUMBER OF 
AVFs
TOTAL NUMBER OF FAILED 
AVFs
< 75 years NT 124 40
< 75 years TBBF 72 19
> 75 years NT 15 6
> 75 years TBBF 19 5
The figure shows that there was no difference in the Kaplan-Meier survival curves for 
the two age groups when NT and TBBF were analyzed collectively (P=0.833). Furthermore, 
there was no statistical difference between the survival curves when each group above was 
analyzed separately (P=0.996). 
Conclusions: In conclusion, overall survival was similar for TBBF and NT AVF in our 
study and was not influenced by elderly age. This finding is contrary to popular opinion 
and some other reports.
TH-PO863
Peripherally Inserted Central Catheter (PICC) Placement in Hemodialysis 
Patients with Central Venous Catheters (CVC)  Rita L. McGill, Robin 
Ruthazer, Klemens B. Meyer, Dana Miskulin, Daniel E. Weiner.  Tufts Medical 
Center, Boston, MA.
Background: PICC insertion threatens opportunities for AVF creation and may reduce 
achievement of AVF. Accordingly, we evaluated the incidence of PICC placement in ESRD 
patients after starting dialysis and in the 2 years prior to starting dialysis, and recognizing 
that AVF rates are lower in women, whether PICC rates differed by sex.
Methods: After restricting to patients with pre-dialysis Medicare claims, we used 
CPT codes to ascertain all PICCs placed during the 2 years before HD initiation and up 
to 12/31/2012 in the subset of adult HD patients entering USRDS in 2010 or 2011 with 
CVC as sole vascular access. Accounting for censoring due to death and ESRD modality 
treatment change, and using Poisson regression to adjust for age, race, BMI, diabetes and 
peripheral vascular disease, we calculated sex-based incidence ratios (IRR) using PICC 
per 100,000 patient months.
Results: PICC were placed in 2437 (14.6%) of women and 2260 (12.2%) of men. 
Women Men
N 16686 18494
# PICC placed during the 2 years prior to HD 1983 1469
# PICC placed during first year of HD 1438 1330
# PICC placed after first year of HD 567 532
# PICC TOTAL 3988 3331
Compared to men, crude and adjusted IRR of PICC for female sex were 1.35 [1.28-
1.41] and 1.34 [1.27-1.41]. Multiple PICC (range= 2 to 14) were placed in 648/2260 (29%) 
men and 803/2437 (33%) women who had any PICC.
Conclusions: Despite persuasive indications for PICC avoidance, people dialyzing 
via CVC frequently receive one or more PICC before and even after starting dialysis. 
The PICC rate was 35% higher in women, a difference not attenuated by adjustment for 
demographic and clinical factors. More frequent PICC placement may explain some of the 
lower fistula rate in women. Eliminating frequent PICC placements in patients with CVC 
may improve achievement of AVF.
Funding: Other NIH Support - NIH/NIDDK
T32 DK007777 “Epidemiology, Clinical Trials and Outcomes Research In 
Nephrology”
Tufts CTSI Grant  [UL1 TR001064]
TH-PO864
Arteriovenous Fistula Outcomes in an Elderly UK Population 
Agnes Masengu,1,2 Jennifer B. Hanko,1 Alexander P. Maxwell.1,2  1Regional 
Nephrology Unit, Belfast City Hospital, Belfast, County Antrim, United 
Kingdom; 2Nephrology Research Group, 4ueen¶s Univ Belfast, Belfast, County 
Antrim, United Kingdom.
Background: The merit of placing arteriovenous fistulas (AVFs) in the elderly is 
debated in the literature. We sought to investigate AVF outcomes in the population aged 
≥ 65 years in our region.
Methods: The Northern Ireland Vascular Access Database incorporates vascular access 
data on patients with chronic kidney disease stage 4 and 5. The database includes information 
on all patients ≥ 65 years who had an AVF created during January 2009-December 2014 and 
had a functional outcome by the 1st March 2015. Functional AVF patency was defined as 
sustained 2-needle use on haemodialysis for at least 6 sessions. Failure to mature (FTM) was 
defined by either by clinical examination or failure to sustain 6 sessions of 2-needle dialysis.
Results: During the study period 344 patients ≥ 65 years had an AVF created. One 
AVF failed immediately, three AVFs were ligated due to steal, 56 patients had not started 
dialysis by the study end-point and records were incomplete for 30 patients. A total of 
254 patients (98% White) remained included for functional AVF patency analysis. Table 
1: Clinical Characteristics of Patients ≥ 65 years with AVF Patency Outcomes (n=254)
Clinical Characteristics Number (%)
Age (mean, median, range) 74, 74, 65-92
Male gender 170 (67)
Diabetes
Peripheral vascular disease
Ischamic heart disease
102 (40)
30 (12)
102 (40)
Lower arm AVF 134 (53)
A total of 150 AVFs (59%)achieved functional patency and 105 (41%)FTM. Binary 
logistic regression revealed that a lower arm AVF in this elderly population was associated 
with FTM (p < 0.001, 0R 0.23, CI 0.13- 0.40).
Conclusions: Given their shorter life-expectancy, the goal of vascular access creation 
in the elderly should be to create one functional AVF using the best vessels identified. The 
greater risk of FTM with lower arm AVFs may mean preferential creation of an upper arm 
AVF if these vessels are better on clinical and ultrasound assessment.
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TH-PO865
Type of Vascular Access and Mortality in Japan  Toshikazu Ozeki,1 Shun 
Minatoguchi,1 Yukako Ohyama,1 Hideaki Shimizu,1 Yoshiro Fujita,1 Daijo 
Inaguma.2  1Nephrology, Chubu Rosai Hospital, Nagoya, Japan; 2Nephrology, 
Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Background: The National Kidney Foundation (NKF) Kidney Disease Outcome 
Quality Initiative (KDOQI) guidelines have recommended the use of AVFs at dialysis 
initiation of dialysis. However, it has been reported that the dialysis environment has 
been significantly different between Japan and the United States, and there are few people 
who continue hemodialysis with CVCs in Japan. The aim of this study is to examine the 
association between type of vascular access at dialysis initiation and mortality in Japan.
Methods: This study is retrospective, multicenter, cohort study which data was 
collected by “Aichi Cohort study of Prognosis in Patients” (AICOPP) newly initiated 
into dialysis. 18 tertiary care centers in Japan participating in the “AICOPP”. This study 
enrolled 1,525 patients who started maintenance dialysis between October 1, 2011 and 
March 31, 2014. After exclusion of 129 patients who started peritoneal dialysis or without 
data, 1329 (87.1%) patients were enrolled. Cox regression was used to determine the effect 
of access type on total mortality. Type of vascular access was divided into four categories: 
AVFs, AVGs, CVCs changed to AVF during the course (CAVF), CVCs changed to AVG 
during the course (CAVG).
Results: This research showed prevalence of type of blood access in Japan.
Under multivariate analysis, CAVGs had a higher risk of mortality compared with AVFs 
group [hazard ratio (HR): 2.408, p value: 0.003]. No significant differences were observed 
compared AVFs with AVGs [hazard ratio (HR): 1.466, p value: 0.219] and CAVFs [hazard 
ratio (HR): 1.223, p value: 0.389].
Conclusions: As it is known, high AVF use was seen in japan. Compared with AVFs, 
using CVCs changed to AVG during the course is associated with higher risks of mortality.
TH-PO866
Comparison of Arteriovenous Fistula and Arteriovenous Graft on Patient 
Survival and Access Patency in Non-Elderly versus Elderly Population 
Hoon suk Park, Min Seok Choi, Woo Jeong Kim, Sung jun Kim, Hyung Wook 
Kim, Cheol Whee Park, Bum soon Choi, Byung ha Chung, Chul Woo Yang, 
Dong-Chan Jin.  Div of Nephrology, Dept of Internal Medicine, College of 
Medicine, The Catholic Univ, Korea.
Background: Arteriovenous fistula (AVF) is generally known to be the ideal option 
as a vascular access. However, this consensus can be challenging in elderly population.
Methods: From August in 2008 to April in 2014, 1452 adult incident hemodialysis 
patients were included from Clinical Research Center registry for ESRD prospective cohort, 
from 31 centers in the South Korea.
Results: In the whole population, AVF vs. AVG use was associated with the better 
patient survival only in male (p < 0.001) and DM (p = 0.004) patients. Multivariate Cox 
regression analysis showed AVG (vs. AVF; odds ratio [OR] 2.308, 95% confidence interval 
[CI]: 1.013–4.829; p = 0.026), catheter (vs. AVF; OR 10.658, 95% CI: 5.379–21.119; p < 
0.001) and age (OR 1.035, 95% CI: 1.012–1.058; p = 0.003) were significantly associated 
with poor patient survival. In the elderly patients (≥ 65 years old), the survival benefit 
by AVF use also existed in only male (p < 0.001) and DM (p = 0.009) patients, but AVF 
compared with AVG showed better access patency only in female (p < 0.001) and DM (p 
= 0.01) patients. Multivariate Cox regression analysis in the elderly population showed 
AVG (vs. AVF; OR 3.158, 95% CI: 1.080–9.238; p = 0.036), male (vs. female; OR 3.941, 
95% CI: 1.031–15.066; p = 0.045) and the presence of peripheral vessel disease (OR 4.659, 
95% CI: 1.389–15.626; p = 0.013) were significantly associated with poor patient survival. 
AVF showed the survival benefit compared with AVG in the even septuagenarian patients 
(≥ 70 years old), which is contrast to the previous reports about western population (p = 
0.01). However, the superior access patency of AVF in comparison with AVG began to 
decrease from septuagenarian population.
Conclusions: In the Korean septuagenarian patients, AVF placement can be considered 
because of its survival benefit. However, it seems appropriate that AVG is preferentially 
placed in the septuagenarian patients with multiple comorbidities.
TH-PO867
Abnormality of Fibrinolysis as well as Coagulation Were Associated 
with Second Patency Rates of Vascular Access in Hemodialyzed Patients 
Yukiko Hasuike,1 Naoto Kakita,2 Takeshi Nakanishi.1  1Div of Kidney and 
Dialysis, Dept of Internal Medicine, Hyogo College of Medicine, Nishinomiya, 
Hyogo, Japan; 2Vascular Access Center, Tanaka-Kitanoda, Japan.
Background: Vascular access (VA) is essential for the HD patients. However, VA 
is often occluded even after the percutaneous-transluminal angioplasty (PTA). There is 
increasing evidence indicating the importance of the fibrinolysis system (i.e., plasminogen 
activator inhibitor-1 (PAI–1) level) in the progression of vascular disease. We intended to 
clarify whether coagulation and fibrinolysis might be associated with VA failure after PTA.
Methods: Blood samples were taken from 262 HD patients at the PTA. Thrombin/
anti-thrombin (TAT) as a marker of coagulation, PAI–1, FDP, D-dimer as markers of 
fibrinolysis system, and laboratory data were measured. Blood flow volume of VA was 
evaluated by Doppler ultrasonography before PTA. The end point was the re-vascularization 
or re-operation of VA during the observational period after PTA. The results were analyzed 
using univariate (Kaplan-Meier methods) and Cox regression analyses.
Results: Age of patients was 70.6±9.7 years, and 121 patients (46.2%) have native 
arteriovenous fistula (AVF). During follow-up period, re-PTA was performed in 33 patients 
and re-operation in 28 patients. Native AVF, higher blood flow volume (≥500 ml/min), 
lower TAT (<3 ng/ml), and higher PAI–1 (≥7 ng/ml) were associated with good patency 
rates. The Kaplan–Meier analysis showed both higher TAT (p=0.0026) and lower PAI–1 
(Figure 1) were significantly associated with VA failure. Cox regression analysis revealed 
that higher TAT (HR 2.140, 95%CI 1.288-3.556, p=0.0033) and lower PAI–1 (HR 2.322, 
95%CI 1.390-3.880, p=0.0013) were related to VA failure event.
Conclusions: The present research indicates that VA failure after PTA might be 
associated with abnormality in the fibrinolysis system as well as activated coagulation.
TH-PO868
Early Hemodynamic and Geometric Changes in Brachiocephalic Fistula 
Access  Mary S. Hammes,1 Kevin Cassel,2 Michael Boghosian,2 Jane E. Hines,1 
Sydeaka Watson,3 S.M. Javid Mahmoudzadeh A.2  1Medicine/Nephrology, Univ 
of Chicago; 2Dept of Mechanical, Materials and Aerospace Engineering, Illinois 
Inst of Technology; 3Dept of Public Health Sciences, Biostatistics Laboratory, 
Univ of Chicago.
Background: An arteriovenous fistula is the optimal vascular access for hemodialysis. 
A brachiocephalic fistula (BCF) is often placed in the upper arm to provide effective 
dialysis, but unfortunately cephalic arch stenosis (CAS) commonly develops leading 
to access failure. We hypothesized that a contribution to fistula failure is low wall shear 
stress (WSS) resulting from changes that occur in the cephalic arch because of alteration 
in post-fistula creation hemodynamics.
Methods: Twenty-two subjects with advanced renal failure had BCF placed. The 
following procedures were performed at mapping (pre-operative) and  fistula maturation 
(8-32 weeks post-operative): venogram, Doppler to measure venous blood flow velocity, and 
whole blood viscosity. Geometric and computational modeling was performed to determine 
WSS and other parameters that represent the curve of the cephalic arch. The relationship 
between parameters was examined using univariate analysis and linear regression.
Results: Blood flow velocity, venous diameter, and regions of low WSS were shown 
to increase in subjects by the time of maturation (p < 0.05). The percent of low WSS 
was linearly related to an increase in blood flow velocity (p = 0.01). Although the mean 
global measures in curvature and asymmetry remained unchanged from baseline to time 
to maturation, the change fell for shorter time to maturation and rose for longer time to 
maturation (r = 0.52; p = 0.01), crossing the regression line at 15–16 weeks.
Conclusions: The maturation process of an AVF introduces geometric effects in arch 
curvature and asymmetry. Hemodynamic changes increase the percentage of low WSS 
regions within the cephalic arch by the time of fistula maturation. Low WSS may contribute 
to endothelial cell damage, subsequent intimal hyperplasia, and resultant CAS. If this 
hypothesis remains tenable with further studies, ways of protecting the arch through control 
of flow during maturation of the fistula, or alternatives to the BCF, may need to be developed.
Funding: NIDDK Support
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TH-PO869
Dilator-Assisted Banding and Beyond: Proposing an Algorithm for 
Managing Dialysis Access-Associated Steal Syndrome  Shouwen Wang. 
AKDHC Access Centers, Arizona Kidney Disease and Hypertension Center, 
Phoenix, AZ.
Background: Dialysis Access-associated Steal Syndrome (DASS) is a major 
complication of arteriovenous dialysis accesses and its proper management is of critical 
clinical importance. However, the reported approaches are diverse and general consensus is 
lacking. Recently, guided banding approaches have gained popularity, as they are minimally 
invasive. This report analyzes the clinical outcome of Dilator-assisted Banding (DAB), a 
simple technique initially described by the author for managing DASS.
Methods: This series included 30 patients that underwent DAB for DASS due to 
excessive dialysis access flow.
Results: Of the 30 patients: 29 had upper arm fistulas or grafts and 1 had a forearm 
fistula; 23 had arteriogram - 3 of which required angioplasty ± stent for feeding artery 
stenosis. The DAB procedures included: intraluminal DAB (12/30), extraluminal DAB 
(14/30) and open fistula reduction plus DAB (4/30). After DAB, the average severity scores 
of ischemic symptoms was reduced from 2.8 ± 0.4 to 0.2 ± 0.4 for the fistula group (n=24, 
p<0.001) and from 3.0 ± 0.0 to 1.2 ± 1.2 for the graft group (n=6, p=0.041). Of the 24 
patients with fistula, 19 had resolution of ischemic symptoms and 5 had minimal residual 
symptoms while 3 had finger necrosis that healed after DAB. Of the 6 patients with graft, 2 
had resolution, 2 had minimal residual and 2 had no change of ischemic symptoms. These 
two DAB-ineffective patients underwent proximalization of arterial inflow (PAI) revisions 
that resulted in resolution of ischemic symptoms. During follow-up of 18.7 ± 14.5 months 
(range 1-50), all dialysis accesses remained functional. At 24-month post-DAB, the primary 
patency, primary-assisted patency and secondary patency rates of the fistula group were 
72%, 91% and 100%, respectively.
Conclusions: DAB is a simple, effective and versatile approach for managing DASS 
due to excessive flow, especially in patients with fistula. In patients with failed banding, 
PAI can be effectively used for rescue. Based on the data in this series and the literature, 
an algorithm is proposed for managing DASS.
TH-PO870
Outcomes of Vascular Access Creation in Incident Hemodialysis Patients 
in Singapore  Nicholette Goh,1 Chieh-suai Tan,2 Shaam Achudan,1 Yi liang 
Tan,1 Kian Guan Lee,2 Hui-Lin Choong,2 Tze tec Chong.3  1National Univ of 
Singapore; 2Renal Medicine, Singapore General Hospital; 3Vascular Surgery, 
Singapore General Hospital.
Background: Hemodialysis is the main modality of renal replacement therapy for end-
stage renal disease (ESRD) patients in Singapore. Vascular access is critical for effective 
therapy. This study evaluates the impact of pre-operative vein mapping on vascular access 
creation in patients newly initiated on hemodialysis in Singapore General Hospital.
Methods: Data of ESRD patients initiated on hemodialysis from January 2010 to 
December 2012 were retrospectively collected from electronic medical records. 708 patients 
(mean 62.8 ± 12 years old, 61% male, 71.3% Chinese) who underwent surgical creation of 
their first vascular access were followed up for a mean of 2.3 ± 1.2 years.
Results: 694 (98%) arteriovenous fistulae (AVF) and 14 (2%) arteriovenous grafts 
(AVG) were created. Successful AVF cannulation was established in 543 patients (78.2%). 
After 1 year, 511 (73.6%) remained patent with 43.5% (302/694) primary and 30.1% 
(209/694) secondary patency. 216 upper arm and 478 forearm AVFs were created. Upper arm 
AVFs had significantly higher maturation rates (85.0% vs 76.4%, p = 0.011). Pre-operative 
vein mapping was performed in 42.5% (295/694) of patients. The mean vein diameter was 
2.44 ± 0.82mm. Maturation rates with and without vein mapping were 72.2% and 82.7% 
respectively (p = 0.001). Between vein diameters of <2 and ³2mm, there was no statistical 
difference in maturation rates (71.3% vs 72.6%; p = 0.887) or median maturation time (66.5 
vs 77 days; p = 0.280). There was no statistical difference in maturation rates between veins 
of <2 and ³2mm in both forearm (p = 0.076) and upper arm AVFs (p = 0.722). On univariate 
analysis, male gender (p = 0.001) and the presence of good post-operative thrill (p < 0.001) 
were associated with successful maturation in newly created AVF. AVFs created by trainees 
also had better maturation rates compared to consultants (83.5% vs 76.2%; p = 0.027).
Conclusions: In conclusion, successful vascular access creation can be accomplished 
in majority of ESRD patients. This is independent of vein size or the need for pre-operative 
vein mapping.
TH-PO871
Uremia Induced Gene Expression in a Mouse Model of Arteriovenous 
Fistula Stenosis  Keith Louis Saum, Begoña Campos, Neil Batra, Yang Wang, 
Prabir Roy-Chaudhury.  Univ of Cincinnati.
Background: Arteriovenous fistula (AVF) non-maturation remains a huge clinical 
problem resulting in significant morbidity and mortality. Unfortunately most animal models 
of AVF stenosis do not incorporate uremia. As a result, the molecular mechanisms by which 
uremia contributes to AVF dysfunction remain unknown. The aim of this study was to assess 
the impact of uremia on the expression of genes associated with the pathogenesis of AVF 
dysfunction using a uremic mouse model of AVF stenosis.
Methods: Mice were made uremic by cautery of one kidney, followed by contralateral 
nephrectomy. After 4 weeks, an end to side anastomosis was created between the jugular 
vein and carotid artery. Contralateral vessels served as controls. Vessels were harvested after 
14 days, and RNA isolated from the AVF venous segment. Gene expression of different 
mediators was measured with qPCR. Data was analyzed from control vein; uremic vein; 
veins of non-uremic AVFs; and veins of uremic AVFs.
Results: Significant upregulation in the expression of monocyte chemotactic protein-1 
(MCP1), NADPH Oxidase (NOX4), and E-Selectin were found within the veins of AVFs 
compared to wild-type control vessels (P<0.017 for each gene). Compared to normal vein, 
MCP1 expression was increased 4.4, 14.0, and 49.1 fold in uremic vein, the non-uremic 
AVFs, and uremic AVFs respectfully . Paradoxical increases in Krüppel-like factor-2 (KLF-
2) were also seen in uremic vessels compared to wild-type veins (P<0.017).
Conclusions: In summary, marked upregulation of the proteins MCP-1, NOX4, and 
E-Selectin were seen with uremia, and some of these (MCP-1) were further elevated 
within the AVF. Of note, the flow sensitive gene KLF2 was also elevated in uremia, but 
was attenuated in the setting of an AVF. These preliminary findings suggest key pathways 
by which uremia could exacerbate AVF dysfunction and future targets for the prevention 
and treatment of AVF maturation failure. 
TH-PO872
Chlorhexidine-Impregnated Transparent Dressing for Prevention of 
Catheter-Related Bacteremia in Hemodialysis Patients: A Quality 
Improvement Study  Vandana Niyyar,1 Ibironke W. Apata,1 John Hanfelt.2 
1Nephrology/ Internal Medicine, Emory Univ, Atlanta, GA; 2Rollins School of 
Public Health, Emory Univ, Atlanta, GA.
Background: CRBSI are a major cause of morbidity in HD patients dialyzing with a 
CVC. A major route of catheter contamination is introduction of organisms from the skin 
to the catheter. Tegaderm-CHG is a transparent catheter dressing with an integrated gel 
containing chlorhexidine, designed to combine the benefits of transparent dressings; and 
the bactericidal and bacteriostatic benefits of chlorhexidine. We conducted a QI project to 
assess the rates of catheter-related bloodstream infection (CRBSI) in three dialysis units 
following the introduction of chlorhexidine-impregnated transparent catheter dressings.
Methods: Our study was conducted in two phases. In the first phase (9/12 through 
10/13), we introduced the intervention, Tegaderm-CHG, to EDC, one of the three Emory 
hemodialysis units. EDGB and EDNS were the control sites where standard gauze catheter 
dressings were maintained. The rates of CRBSI at each dialysis units during the 12-month 
intervention were compared against the rates of CRBSI for the 12 month pre-intervention 
period. CRBSI rates were also compared between the dialysis units. The second phase of 
the study started in 11/ 2013, with the extension of Tegaderm-CHG dressing to EDGB and 
EDNS (the control sites in Phase 1). Tegaderm-CHG was maintained at EDC.
Results: The three dialysis units were comparable in terms of age, sex, and race of 
patients. In phase 1, the catheter infection rate (per 1,000 catheter days) in EDC decreased 
by 51% (pre: 1.69, post: 0.82). At EDGB, the infection rate increased by 12% (pre: 1.80; 
post: 2.02) while the infection rate increased by 35% (pre: 0.91; post: 1.23) at EDN. 
However, none of these increases in infection rates were significant (i.e., p > 0.05). The 
infection rates at EDGB and EDN decreased significantly in phase 2 by 86% (pre: 1.86, 
post: 0.26), and 53% (pre: 1.89, post: 0.88), respectively. At EDC, the catheter infection 
rate did not change significantly in phase 2.
Conclusions: The use of Tegaderm CHG dressing was associated with decreased rates 
of CRBSI at Emory outpatient dialysis units.
Funding: Other NIH Support - Partially supported by the National Center for 
Advancing Translational Sciences of the National Institutes of Health under Award 
Number UL1TR000454. The content is solely the responsibility of the authors and does 
not necessarily represent the official views of the National Institutes of Health.
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TH-PO873
In-Patient Permanent Access Is Associated with Reduced Catheter Time 
for Emergent Start Hemodialysis Patients  Catherine A. Moore,1 Richard 
E. Wing,1 Scott E. Liebman.1  1Medicine- Nephrology Div, Univ of Rochester, 
Rochester, NY; 2Aurora Medical Group, Marinette Menominee Clinic, Marinette, 
WI.
Background: Hemodialysis initiation with a tunneled catheter carries increased risk of 
morbidity and mortality. Conversion from a hemodialysis catheter to permanent access at 
any time is associated with improved outcomes. This study investigates whether a strategy 
of placing permanent dialysis access in incident HD patients without permanent access 
while still hospitalized is associated with reduced exposure to hemodialysis catheters.
Methods: We conducted a retrospective cohort study of ESRD patients initiating 
Hemodialysis with a catheter while hospitalized at a single University Hospital Medical 
Center from October 2010 through June 2013. Patients were divided into two groups: those 
with permanent access placed during the hospitalization (N = 22) vs. those discharged 
without permanent access (N = 67). Our primary endpoint was removal of the hemodialysis 
catheter.
Results: Subjects who underwent permanent access placement while still hospitalized 
had a median catheter exposure time of 114 days compared with 241 days for those 
who did not. The median time with HD catheter in place was shorter by 127 days in the 
Inpatient Access group. There was no significant difference in length of hospital stay or 
early access loss. 
Conclusions: The practice of placing permanent access while the patient is still admitted 
to the hospital is associated with greater likelihood of hemodialysis catheter removal.
TH-PO874
Factors Affecting Haemodialysis Arterio-Venous Fistula Maturation 
Hannah R. Wilson, Salman Ahmed, Joseph Russell, Nicola Ding, Maggi Steele, 
Ayesha Irtiza-Ali, David Makanjuola, Nihil Chitalia.  Renal Unit, St. Helier 
Hospital, Surrey, United Kingdom.
Background: Arterio-venous fistulae (AVF) are the preferred access for haemodialysis 
(HD). Many AVFs however, fail to mature. We investigated the factors affecting maturation 
of AVFs in order to identify any characteristics which were predictive of AVF maturation.
Methods: All AVFs created between 2006 and 2014 were reviewed. Data analysis 
was performed using GraphPad. AVFs were deemed to have failed to mature if by 90 days 
post-creation, it was not possible to use them for HD. The patients were divided into 2 
groups – those who had the AVF created pre-emptively (group 1) and those already on HD 
at the time of AVF creation (group 2). Characteristics reviewed were age, gender, ethnicity, 
co-morbidity score, diabetes status and site of AVF.
Results: There were 1876 AVFs created. 954 in group 1 and 922 in group 2. In group 
1, 597 patients started HD; 469 (79%) used their AVF for the 1st HD session. In group 2, 
330 (36%) used their AVF within 90 days from creation. Group 1 AVFs were more likely 
to mature than those in group 2. Co-morbidity scores, age, diabetes status and ethnicity 
had no impact on AVF maturation rates.
Variable Mature AVF(n=745)
Non-mature AVF
(n=833) p value
Pre-emptive 415 (55.7%) 241 (28.9%) *
Non pre-emptive 330 (44.3%) 592 (71.1%) *
Age in years >mean(SD)@ 63 ±15.6 64 ±15.6 ns
Gender 69% M, 31% F 59% M, 41% F 0.0002
Ethnicity
Caucasian
Asian
Afro-Caribbean
Not stated
56%
12%
8%
24%
55%
13%
9%
24%
ns
Upper arm AVF 54% 52% ns
Diabetic 35% 37% ns
Davies co-morbidity score
0 (no co-morbidities)
1 (1-2 co-morbidities)
2 (3 or more co-morbidities)
18%
68%
14%
15%
68%
17%
ns
*p<0.0001 for percentage of mature AVFs in pre-emptive vs non-pre-emptive groups.
Conclusions: Our data show that the timing of AVF creation is important; those formed 
pre-emptively are more likely to mature than those created when the patient is on dialysis. 
It is possible that the presence of a dialysis line might delay maturation, especially if it is 
ipsilateral to the AVF.
It highlights the importance of prompt referral to nephrology services so that AVFs 
can be created in a timely manner.
TH-PO875
Hand Held Ultrasound Device Solves Vascular Access (VA) Cannulation 
Problems  Beth Adams, Vivek Soi, Jerry Yee, Lalathaksha Murthy Kumbar. 
Henry Ford Hospital, Detroit, MI.
Background: The Fistula First Catheter Last workgroup coalition identifies VA 
cannulation as a fundamental “failure” point in optimizing arteriovenous fistula (AVF) 
usage. Infiltration from cannulation difficulties result in significant morbidity including loss 
of VA and cost. Cannulation success is reliant on cannulators’ skill and VA characteristics. 
Surface marking of VA to aid cannulation is frequently used but lacks real time information. 
Traditional ultrasound devices are expensive and need skilled operators rendering inapt 
for routine use in hemodialysis units. Sonic Window© (Analogic Ultrasound) is a coronal 
mode ultrasound device (CMUD) approved for VA cannulation. We present our early 
experience in using this novel hand held CMUD for real time guidance of AVF cannulation.
Methods: Three patients with cannulation failure defined as inability to achieve 3 
needle cannulations leading to tunnel cuffed catheter (TCC) removal were identified. AVF 
was evaluated initially for 1-2 dialysis sessions with CMUD for course, depth from skin, 
optimal site for cannulation, needle length and size. Infiltration rates, subsequent procedures 
and hospitalizations were noted before and after CMUD use and cannulation failure days 
(days from initial VA clearance for use to TCC removal).
Results: 
AVF Pre-events
Post-
events
Type
Cannula-
tion failure 
days
Infiltra-
tion
Interven-
tions
Hospital-
ization
Infiltra-
tion
Interven-
tions
Hospital-
ization
Brachio-
basilic 210 1 1 6 0 0 0
Brachio-
cephlaic 206 3 6 0 0 0 0
Radioce-
phalic 153 3 4 0 0 0 0
All 3 AVF were successfully cannulated leading to TCC removal within 21 days of 
CMUD guidance. CMUD usage resulted in no cannulation related complications and no 
subsequent revision procedures
Conclusions: CMUD guided cannulation of dialysis access is feasible and safe. Real 
time ultrasound guidance mitigates cannulation failure and catheter removal.
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TH-PO876
Reaching First Dialysis Quickly and Unassisted with Sirolimus 
Treated Fistulae – Serial Ultrasound Results and Clinical Outcomes 
Maria V. DeVita,1 Eric S. Chemla,2 Konstantine B. Kipiani,3 Nutsa K. Beridze,3 
Sriram Iyer.4  1Nephrology, Lenox Hill Hospital, NeZ York, NY; 2Vascular 
Surgery, St. George¶s NHS Foundation Trust, London, United Kingdom; 
3Vascular Surgery, Georgian Center of Angiology and Surgery, Tbilisi, Georgia; 
4Vascular Therapies Inc, Cresskill, NJ.
Background: Neointimal hyperplasia (NH) resulting in a flow limiting stenosis within 
the juxta-anastomotic segment (JAS) of an AV Fistula (AVF), impairs increase in upstream 
vein diameter (VD), often requires supplementary procedures and prolongs time to 1st 
cannulation for dialysis (D). Sirolimus delivered locally to the vessel wall can suppress 
NH and preserve lumen patency (“sirolimus effect”).
Methods: 30 pts (29 on D) undergoing AVF surgery [22 Radiocephalic (RCF), 8 
Brachiocephalic fistulae (BCF)] received a Sirolimus eluting collagen implant at and around 
the JAS. 1st cannulation was based on clinical evaluation.
Results: 18 males, mean age 50.8y, 20% diabetic. Analysis excludes 4/22 RCF that 
thrombosed £2 weeks; 18/22 RCF (88%) and all 8 BCF maintained Primary Patency (PP) 
prior to first cannulation (mean 49 days); 13 AVF were cannulated ≤6wks, 74% AVF 
maintained suitability for D with PP at 12mos. Table shows serial Ultrasound results. 
Characteristic Pre op 6-8 hours Post op 2 weeks 4 weeks 6 weeks 8 weeks
RCF (n=18)
VD Mean 
(±SD) 2.7 (0.5) 4.4 (0.5) 5.1 (0.8) 5.8 (0.7) 6.1 (0.4) 6.4 (0.4)
VD change 
from prior 
time point 
- 63% 16% 14% 5% 5%
VD ≥6mm n= 0 2 (11%) 8 (44%) 13 (72%) 18 (100%)
VD ≥4mm n= 14 (70%) 16 (89%) 17 (94%) 18 (100%)
BCF (n=08)
VD Mean 
(±SD) 3.9 (0.6) 5.4 (0.8) 6.8 (0.8) 7.5 (0.9) 7.9 (1.71)
8.45 
(1.38)
VD change 
from prior 
time point 
38% 26% 9% 5% 8%
VD ≥6mm n= 2 (25%) 6 (75%) 8 (100%)
VD ≥4mm n= 8 (100%)
Conclusions: 1.Maximum % increase in VD occurred within 8hrs of surgery with 
gradual continued increments thereafter. 2.At 4, 6 and 8wks, VD of 6mm was attained by 
62%, 81% and 100% of the AVF respectively. 3. 26/30 AVF(87%) maintained PP before 
first cannulation; time to first dialysis for 13 AVF(50%) was ≤6wks and at 12mos 75% 
were functional with PP. 4.Results signal a “sirolimus effect” and will be tested in an 
upcoming randomized trial.
Funding: Pharmaceutical Company Support - Vascular Therapies, Ic
TH-PO877
Economic Burden to Medicare of Central Venous Catheter (CVC)-
Related Blood Stream Infections (BSI) and Occlusions Among Incident 
Hemodialysis (HD) Patients  Scott Sibbel,1 Steven M. Brunelli,1 Abigail Hunt,1 
Wendy Turenne,1 Antony E. Pfaffle.2  1DaVita Clinical Research, Minneapolis, 
MN; 2CorMedix Inc, Bedminster, NJ.
Background: Episodes of CVC-related BSI and occlusion in HD patients result in 
hospitalizations and vascular access-related procedures, with attendant increases in costs. 
We sought to quantify this burden to the payor among Medicare-enrolled patients at a 
large dialysis organization.
Methods: Patients received HD via CVC during 2011 and were enrolled in Medicare 
Parts A and B. In parallel analyses, patients who developed BSI (N=1413) or occlusion 
(N=793) were matched with controls who did not, on the basis of entry month and 
incident/prevalent dialysis status. Outcomes were assessed from date of BSI/occlusion 
(or corresponding date for controls) for 6 months or until censoring for modality change, 
transfer of care, loss of Medicare benefits or death. Comparisons were made using linear 
mixed models including fixed effects for exposure status and month, adjusted for covariates 
that were imbalanced at baseline.
Results: CVC-related BSI was associated with greater rate of hospitalization (incidence 
rate difference [IRD], 1.07 events/patient [pt]-year) and vascular-related procedures (IRD, 
2.87 events/pt-year). Mean per patient per month (PPPM) costs were 2624 higher for BSI 
patients versus controls, driven primarily by increased inpatient costs. CVC occlusion 
was associated with modestly greater rate of hospitalization (IRD, 0.29 events/pt-year), 
but substantively greater rate of ambulatory procedures (IRD, 4.00 events/pt-year). Mean 
PPPM costs were 2354 greater for occlusion patients versus controls, driven by higher 
ancillary service and procedure costs.
Conclusions: CVC-related BSI and occlusion are potent cost drivers for Medicare. 
Risk mitigation strategies to prevent BSIs and occlusions should prove to reduce systemic 
health care costs. 
Funding: Pharmaceutical Company Support - CorMedix Inc
TH-PO878
Arteriovenous Fistula Maturation and Medial Collagen Organization 
Assessed by Second Harmonic Generation Microscopy  Yan-Ting E. Shiu,1 
Michael Allon,2 Daniel Pike,1 CS Jason Tey,1 Silvio H. Litovsky,2 Alfred K. 
Cheung.1,3  1U of Utah; 2U of Alabama; 39ASLCHCS.
Background: Arteriovenous fistula (AVF) maturation entails vascular dilation to allow 
increases in AVF blood flow. The required vascular wall distention is likely affected by 
its microstructure. We hypothesized that the organization of collagen fibers in the medial 
layer affects vascular dilation and hence AVF maturation. State-of-the-art second harmonic 
generation (SHG) microscopy and image-analysis algorithms were used to visualize and 
assess collagen-fiber organization.
Methods: Arteries and veins used for anastomosis were sampled during AVF creation 
from 128 participants with chronic kidney disease (CKD). Collagen SHG signals in 
unstained paraffin-embedded tissue sections were acquired under a two-photon microscope 
at 850 nm excitation, and analyzed for fiber pattern, anisotropy index (AI) and dominant 
angle (DA) by 3 independent observers blinded to AVF outcomes. AI ranged from 0 (random 
fiber network) to 1 (completely aligned fiber network). DA ranged from 0o (parallel to 
lumen) to 90o (perpendicular to lumen).
Results: Arterial and venous medial collagen fibers demonstrated a total of 5 patterns: 
parallel to lumen, perpendicular to lumen, track, web, or random (Fig. 1). The parallel and 
perpendicular patterns had a similar AI (~0.3) which was higher than the AI of the other 
patterns. However, the parallel pattern had a smaller DA than the perpendicular pattern 
in arteries (18o vs 70o, p=0.001). AVF non-maturation rate was lower in patients with a 
perpendicular vs parallel arterial fiber network (15 vs 40%, p=0.04). Likewise, AVF non-
maturation rate was lower in patients with venous DA >30o vs DA <30o (17 vs 36%, p=0.03).
Conclusions: We have characterized novel vascular medial collagen fiber organization 
in CKD patients. Moreover, these patterns appear to be associated with the likelihood of 
AVF maturation.
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TH-PO879
Polyurethane Prosthesis for Early Cannulation as an Alternative to Central 
Venous Catheter  Irena Glowinska,1 Jerzy Glowinski,2 Jolanta Malyszko.1  1II 
Dept of Nephrology and Hypertension, Medical Univ, Bialystok, Poland; 2Dept 
of Vascular Surgery and Transplantology, Medical Univ, Bialystok, Poland.
Background: Autologous arterio-venous fistulae is an optimal vascular access for 
haemodialysis. Arterio-venous fistula is not faultless and up to 40% of fistulae never 
mature. In patients with no possibilities to create effective native arterio-venous fistulae 
haemodialysis with using a proper prosthesis gives a chance to avoid a central venous 
catheter (CVC).
The aim of the study was to evaluate of usefulness polyurethane prosthesis as an 
emergency vascular access for haemodialysis.
Methods: The study involved 23 patients, 18 men and 5 women, at 29 – 83 years. Eight 
patients were in predialysis period , for 17 patients (2 in predialysis) it was a secondary 
procedure. All patients had implanted  AvFlo prosthesis (Nicast, Israel). There were 5 
loops in the forearm and 18 straight segments in the arm. Six patients underwent an urgent 
operation, because of lack of any vascular access. For others it was an elective operation.
Results: The longest observation period was over 36 months. Twenty one grafts were 
used for hemodialysis within 1-42 days, one prosthesis was removed due to infection, one 
patient died before initiation of dialysis. All grafts implanted for urgent indications were 
successfully cannulated within 24 hours. No differences were observed between diabetic 
and non-diabetic patients.
Conclusions: Implantation of polyurethane prosthesis provides an effective vascular 
access for dialysis and enables avoidance of CVC. Low infection rate improves the final 
outcome.
TH-PO880
Impact of DPP-4 Inhibitors on Hemodialysis Vascular Access Dysfunction 
Hiroki Ito, Yuki Nakamura, Satoru Sanada, Kozo Sato, Atsuhiro Kanno, Yasunori 
Miyasaka, Mitsuhiro Sato, Yoshio Taguma, Toshinobu Sato.  Nephrology, Japan 
Community Health Care Organization Sendai Hospital, Sendai, Miyagi, Japan.
Background: The maintenance of arteriovenous fistula (AVF) is crucial for 
hemodialysis patients and reduction of complications remains a challenge. Previous 
reports show that patients with diabetes mellitus are more likely to have AVF dysfunction 
than those with other underlying diseases. Also, elevated inflammatory cytokine such as 
IL-6 is known to be associated with AVF dysfunction. Recently, dipeptidyl peptidase 4 
inhibitors (DPP4-I) were known to have pleiotropic action including anti-inflammation 
that decrease IL-6. Thus, we hypothesized that DPP4-I could improve AVF outcome by 
decreasing inflammatory cytokines.
Methods: The study population included 157 consecutive patients newly starting 
hemodialysis between 2011 and 2012 with diabetic nephropathy. AVF dysfunction was 
tracked for 2 years; criteria of which include complete obstruction, insufficient inflow and 
uniform thrill. AVF survival between patients treated with DPP4-I (n=54) and without 
DPP4-I (n=103) was investigated using Kaplan Meier and Cox regression analysis. Serum 
IL-6 level was analyzed by ELISA.
Results: Baseline characteristics were identical between 2 groups in age, sex, blood 
pressure, body mass index, history of congestive heart failure and coronary artery disease. 
There was no difference in AVF survival between the groups (DPP4-I: 455±36 vs without 
DPP4-I: 464±28 days, p=0.81, Log-rank), although serum IL-6 levels were significantly 
lower in patients with DPP4-I (with DPP4-I: 5.0±1.9 vs without DPP4-I: 10.5±7.2 pg/ml, 
p=0.03). Among other drugs, no correlation was indicated between AVF dysfunction with 
insulin, RAS blocker, other antihypertensive drugs nor antiplatelet agents.
Conclusions: DPP4-I did not show any advantage in AVF outcome despite anti-
inflammatory effect of lowering serum IL-6 level.
TH-PO881
Drug-Eluting Balloon: New Endovascular Treatment for Haemodialysis 
Arteriovenous Fistula  Carmen Gonzalez corvillo, Alejandro A. Suarez 
benjumea, Alfonso Lara Ruiz, Mercedes Salgueira lazo.  Nephrology, Virgen 
Macarena-Rocio, Sevilla, Spain.
Background: The purpose of this article is to report our experience with drug-eluting 
balloon(DEB)for the treatment of failing Arteriovenous Fistula(AVF). Mean life expectancy 
of the vascular acces after the procedure,influence on adequate dialysis parameters 
postintervention and percentage of complications.
Methods: DEB procedures made in our hospital were evaluated. Main objective was to 
analyze: a)Reason of consulting and vascular lesion found. b)Hemodialytic arteriovenous 
shunt type. c)Kt/V, Qb, PV d)Survival of the vascular access at the end of the study e)
Complications related to the procedure.
Results: 9 angyioplastic were made by DEB. Mean age:74,6 years, 50% male. 5 left 
native radiocepahlic fistula and 1 humero-axillary prosthetic.Most of the patients had at 
least 4 previous interventions. Principal reasson of consultation was low flow,being the 
most frequent arterial stenosis. No complications were found related to any procedure. 
Every vascular access is permeable at the actual time, mean life since the intervention: 24 
months, being necessary only one reintervention in the target lesion. Blood flow, venous 
pressure and Kt/V improvement regarding to the basal was observed, after the procedure 
and at the end of the study.
Conclusions: There is limited experience with the use of drug-eluting balloon in 
haemodialysis arteriovenous fistula, an increase in average life expectancy of the vascular 
access with bad prognosis ( led to a new vascular access) was found, an improvement on 
adequate dialysis parameters was observed, preserving vascular system of the patient, 
decreasing costs and with no complications. More studies would be needed.
TH-PO882
Alteplase Infusion as Rescue Therapy for Central Venous Haemodialysis 
Catheter Dysfunction  Sanjana Gupta,1 Stephen B. Walsh,2 Karlene Thomas,1 
Ravindra Rajakariar.1  1Barts Health NHS Trust; 2UCL Centre for Nephrology.
Background: Central venous haemodialysis catheters (CVHC) can become occluded 
or have poor blood flow (Qb). CVHC complication estimates are 35% and result in 
hospitalisation and interventional procedures. This study aimed to review alteplase infusion 
success and patency rates.
Methods: We undertook a retrospective review of all patients that had an alteplase 
infusion at the Royal London Renal Unit over a 15-month period. Patients had failed an 
alteplase lock and 4mg alteplase was used in both lumens. Data was collected using the 
renal database.
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Results: There are 1002 haemodialysis patients; 412 dialyse via a CVHC.
Total uses / total patients (n) 94 / 74
Repeat Alteplase, same CVHC n (%) 20 (21)
Median age of CVHC (IQR) 147 days (77 - 300)
Indication (occlusion / Poor Qb) n 31 / 63
 CVHC age was statistically different depending on the indication; occluded CVHC age 
was 124 ± 22 vs 244 ± 27 days for low Qb (p=0.01). Rescued CVHC age was significantly 
lower than those in whom the alteplase was unsuccessful (147 ± 18.4 vs 269 ± 35.8, 
p=0.004). In 48% of patients with an occluded CVHC, flow was restored; the remaining 
52% required further intervention. Low Qb CVHC success rate was 60% compared to 38% 
requiring further intervention, 2% were removed (arteriovenous fistula or transplant). There 
was no significant difference between success rates depending on the indication (p=0.34). 
Alteplase infusion significantly increased litres processed in subsequent dialysis sessions, 
in whom the indication was low Qb (6.2 ± 1.16 litres, p < 0.0001). Overall of all infusions 
undertaken; 1 month patency was 56%, 3 months 45% and 6% removed. No patient had 
an adverse bleeding event as a result of the alteplase infusion.
Conclusions: Alteplase infusion use is common; approximately once a week in our 
centre. Interestingly, complete occlusion of CVHC occurs early, possibly suggesting rapid 
growth of fibrin following insertion. Total litres processed improves after an alteplase 
infusion in over half of patients. This study demonstrates the safety and success rates of 
an alteplase infusion, providing evidence for its role prior to replacing the CVHC and 
importance in saving resources.
TH-PO883
Temporal Evolution of Parameters Before and After Initiation of 
Hemodialysis  Jochen G. Raimann,1 John W. Larkin,2 Carly R. Van Zandt,2 Len 
A. Usvyat,2 Jeroen Kooman,3 Frank van der Sande,3 Barbara Cannon,2 Chad 
Sowers,2 Mark Stuart,2 Terry Ketchersid,2 Dugan Maddux,2 Peter Kotanko,1,4 
Franklin W. Maddux.2  1Renal Research Inst; 2Fresenius Medical Care North 
America; 3Maastricht Univ Medical Center; 4Icahn School of Medicine at 
Mount Sinai.
Background: Little is known about the dynamics of clinical and laboratory parameters 
during the transition between pre-dialysis chronic kidney disease and end stage kidney 
disease (ESKD). The goal of our research was to explore the temporal evolution of albumin 
(Alb), systolic blood pressure (SBP) and serum sodium (SNa) by analyzing monthly data 
before and after hemodialysis (HD) initiation.
Methods: We analyzed all available data from the de-identified Fresenius Medical 
Care CKD Data Registry to understand progression of clinical and laboratory markers 
before and after HD initiation. Average values of Alb, SBP and SNa were compared for 
12 months prior and after HD initiation using t-test. To estimate the trends of the average 
values, we fitted a linear regression function through monthly averages.
Results: We studied 136846 patients (64±14 years, 56% male) over 48 months. 
Average SBP increased prior to HD initiation (1.2 mmHg/year), immediately decreased 
following HD initiation, and remained lower for the following 12 months (142.4±22.8 vs. 
136.1±23.2 mmHg; P<0.05). Before starting HD, Alb was found to be relatively unchanged, 
but increased after HD initiation (average Alb increased by 0.14 g/dL per year; levels were 
slightly higher 12 months after HD initiation [3.7±0.5 vs. 3.8±0.4 g/dL; P<0.05]). Average 
SNa pre-ESKD had a declining trend (-0.5 mEq/L per year) and was lower compared to 
the HD period (139.0±3.4 vs. 138.4±3.5 mEq/L; P<0.05).
Conclusions: Our study demonstrates a trend toward improvement in SBP and Alb 
following HD initiation. The etiology of the SNa decrease after HD initiation requires 
further investigation.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
TH-PO884
Accelerated Arterial Stiffening in Vitamin-K-Antagonist Treated 
Hemodialysis Patients  Christian D. Peters, Krista D Kjaergaard, J. Dam 
Jensen, Bente Jespersen.  Dept of Renal Medicine, Aarhus Univ Hospital, 
Aarhus, Denmark.
Background: Many hemodialysis (HD) patients are treated with vitamin-K-antagonists 
(VKA) in order to prevent thromboembolic events. A potential side effect to VKA 
treatment is an increase in soft tissue calcification due to the inhibitory effect of VKAs on 
the central (liver) and peripheral (e.g. vascular) carboxylation cycle synthesis of several 
vitamin K-dependant calcification-inhibiting factors. The aim of the present study was to 
investigate the impact of VKA-treatment on arterial stiffness in a longitudinal, prospective 
comparative study.
Methods: Seventy-five HD patients from the SAFIR study with urine output >300 mL/
day and HD-vintage <1 year were divided into controls (n=67) and VKA-treated (n=8) and 
followed for one year. The groups were well matched according to age, sex, comorbidity, 
and intervention (placebo/irbesartan). Arterial stiffness was assessed with carotid-femoral 
pulse wave velocity (PWV) and pulse wave analysis using the SphygmoCor device.
Results: Blood pressure (BP), PWV, and glomerular filtration rate (GFR) were 
similar at baseline (controls/VKA-treated) systolic BP: 148±20/145±17 mmHg; PWV: 
11.6±3.2/11.0±3.9 m/s; GFR: 5±3/5±3 ml/min/1.73m2. Dialysis treatment and BP-
medication were also similar. During follow up, GFR decreased similarly in both groups 
(P=0.2). There was no significant difference in BP between the two groups over time 
although BP tended to decrease more in the controls. PWV decreased in the controls -0.9(-
1.4; -0.3) m/s; P=0.004 and increased in the VKA-treated 1.6(0.0; 3.2)m/s; P=0.05. Mean 
difference after 12 months between the groups (DPWV) was: 2.5(0.7; 4.2) m/s; P=0.006. 
DPWV remained significant after adjustment for ∆GFR, ∆MAP, age at baseline, and 
∆BP-medication: 2.2(0.4; 4.0) m/s; P=0.02. Mean differences after 12 months between the 
groups in heart rate adjusted augmentation index and time to pulse wave reflection were: 
7(-2; 15) %; P=0.11 (AIxHR75) and -14(-27; -2) ms; P=0.03 (TR).
Conclusions: Our findings indicate that VKA-treatment increases arterial stiffening 
significantly. We speculate that vitamin K-dependant calcification-inhibiting factors in HD 
patients may be inadvertently affected by VKA treatment.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-PO885
Associations of Kt/V with Mortality in Hemodialysis Patients by Heart 
Failure Status  Parta Hatamizadeh,1 Brian Bieber,2 Keith McCullough,2 Bruce 
M. Robinson.2  1Dept of Internal Medicine, Univ of Michigan, Ann Arbor, MI; 
2Arbor Research, Ann Arbor, MI.
Background: Kidney failure and heart failure (HF) frequently coexist, a condition 
called cardiorenal syndrome (CRS). Though HF patients on maintenance hemodialysis 
(mHD) have high risk of poor outcomes, there is a paucity of data to guide their care. Given 
the role of uremic toxins in the pathogenesis of CRS, we hypothesized that mortality for 
mHD patients is lower at higher Kt/V targets.
Methods: Cox regression was used to estimate associations of baseline Kt/V with all-
cause mortality (ACM) and cardiovascular mortality (CVM) in phases 1-4 of the Dialysis 
Outcome and Practice Patterns Study (DOPPS), an international prospective cohort study 
of mHD patients. Separate models for patients with and without HF (by clinical diagnosis) 
were stratified by country and DOPPS phase and adjusted for age, gender, race, diabetes 
and hypertension as comorbidities, dialysis vintage, serum albumin, pre-dialysis systolic 
blood pressure, and weight. SAS 9.4 was used for analyses.
Results: Among 51,678 mHD patients, mean age was 62.5±14.8 yrs, 41.5% female 
and 32% had HF. In non-HF patients, Kt/V was inversely associated with ACM and CVM, 
following a monotonic pattern. In HF patients, the association was similar for ACM but 
generally flat for CVM. A sensitivity analysis of Kt/V by sex showed a monotonic decline in 
mortality in women, but little decline at Kt/V >1.4 in men [consistent with prior literature]. 
HF did not clearly modify associations by sex. 
Conclusions: Contrary to our hypothesis, higher dialysis adequacy was not associated 
with longer survival in HF patients. Confounding by health status (patients with more 
advanced HF may achieve lower Kt/V because they tolerate dialysis poorly) may be 
an explanation for this finding. Additional study is needed to identify ways to improve 
outcomes for these high-risk patients.
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TH-PO886
Different Impact of Malnutrition-Inflammation and Metabolic Syndrome 
on Long-Term Mortality and Cardiovascular Events in Hemodialysis 
Patients  Naoki Nakagawa.  Renal Div, Dept of Internal Medicine, Asahikawa 
Medical Univ, Asahikawa, Hokkaido, Japan.
Background: Metabolic syndrome confers an increased risk of cardiovascular 
disease (CVD) in the general population. The relationship between adiponectins, and 
clinical outcomes in hemodialysis patients remains controversial. We investigated whether 
adiponectins, biomarkers of inflammation, nutrition status and clinical features predict the 
mortality of hemodialysis patients for 6 years.
Methods: We measured baseline plasma total and high-molecular-weight (HMW) 
adiponectins, tumor necrosis factor (TNF)-α, serum high sensitivity C-reactive protein 
(hsCRP), and clinical characteristics including visceral fat area (VFA) and the Geriatric 
Nutritional Risk Index (GNRI) in 133 hemodialysis patients.
Results: During the 6-year follow up period, 41 (30.9%) patients died (heart failure, 
n = 13; acute myocardial infarction, n = 11; stroke, n = 2; infection, n = 10; and malignant 
cancer, n = 5). The deceased patients were significantly older, had more prior CVD and 
diabetes, higher TNF-α and hsCRP levels but lower GNRI. VFA, and total and HMW 
adiponectin did not significantly differ between the two groups. TNF-α and hsCRP levels 
and GNRI score were significant for predicting all-cause and cardiovascular mortality in 
receiver operating curve analyses. The present ROC curve analysis for all-cause 6-year 
mortality found the predictive value of GNRI for mortality was 96. When stratified by a 
GNRI score of 96, Cox proportional hazards analyses identified TNF-α as a significant 
predictor of all-cause mortality (hazard ratio [HR] 1.23; P = 0.038) and hsCRP as a 
significant predictor of all-cause and cardiovascular mortality (HR, 2.32, P = 0.003; HR 
2.30, P = 0.012, respectively) after adjusting for age, sex, diabetes mellitus, and prior CVD, 
only in malnourished patients.
Conclusions: These results demonstrate that malnutrition and the inflammatory markers 
TNF-α and hsCRP, but not metabolic markers, including VFA and adiponectins have a 
significant impact on 6-year all-cause and cardiovascular mortality in hemodialysis patients.
Funding: Government Support - Non-U.S.
TH-PO887
Associations of the Malnutrition-Inflammation Complex Syndrome with 
Depression Symptoms, Kidney-Disease Targeted Quality of Life Measures 
and Mortality in a Hemodialysis Population of Predominantly African 
Descent  Marcelo Barreto Lopes,1 Raissa B. Peixoto,1 Priscila S. Carvalho,1 
Jean M. Monteiro,1 Jéssica S. Fernandes,1 Pedro Guimarães Silva,1 Luciana 
Ferreira Silva,2 Gildete Barreto Lopes,1 Antonio Alberto Lopes.1  1Univ Federal 
da Bahia; 2Univ do Estado da Bahia, Salvador, BA, Brazil.
Background: The malnutrition-inflammation score (MIS) has been used to assess 
protein-energy wasting (PEW), also named malnutrition-inflammation complex syndrome, 
in maintenance hemodialysis (MHD) patients. Higher MIS has been associated with poorer 
outcomes in MHD patients but remains unclear if MIS expands the predictive power for 
outcomes in relation to its ten components and if the published results may be generalized 
for populations not targeted by previous investigations. We assessed associations of MIS 
and its components with mortality and patient-reported outcomes, i.e., health-related 
quality of life (HRQOL) and depression symptoms in a MHD population predominantly 
of African descent.
Methods: Prospective cohort (PROHEMO) of 632 MHD patients (92% Black or mixed 
race) treated in Salvador, Brazil. The predictor was MIS (range: 0-30, higher worse) and 
its ten components. Outcomes were mortality, HRQOL by KDQOL-SF and depression 
symptoms by CES-D. Multivariable linear regression was used for differences in scores 
and Cox regression for mortality.
Results: After extensive adjustments for covariates, MIS≥6 was significantly 
(P<0.05) associated with higher mortality (hazard ratio=1.52; 95% CI=1.13, 2.05), higher 
depression symptoms and poorer HRQOL, including physical, mental and kidney-disease 
targeted HRQOL scales with differences > 4 points. Four of the 10 MIS components were 
independently associated with mortality, but not with patient-reported outcomes.
Conclusions: The consistent associations of MIS with mortality, HRQOL and 
depression symptoms despite the distinct association of MIS components with mortality 
and patient-reported outcomes support the importance of combining PEW components 
to assess health status and risks of outcomes in MHD patients. The observed results in a 
predominantly African descent population expand support to MIS as a valid predictor of 
outcomes in different MHD populations.
TH-PO888
Non-Traditional Risk Factors Predict Atherosclerotic Events in 
Haemodialysis Patients – Post-Hoc Analyses of the AURORA Trial 
Marit D. Solbu,1,2 Geir Mjøen,3 Patrick B. Mark,1,4 Hallvard Holdaas,5 Bengt C. 
Fellstrom,6 Alan G. Jardine.1,4  1Inst of Cardiovascular and Medical Sciences, 
Univ of Glasgow, Glasgow, United Kingdom; 2Section of Nephrology, Univ 
Hospital of North Norway, Tromsø, Norway; 3Dept of Nephrology Ullevål, Oslo 
Univ Hospital, Oslo, Norway; 4Renal and Transplant Unit, South Glasgow Univ 
Hospital, Glasgow, United Kingdom; 5Dept of Transplantation Medicine, Oslo 
Univ Hospital Rikshospitalet, Oslo, Norway; 6Div of Nephrology, Uppsala Univ 
Hospital, Uppsala, Sweden.
Background: Patients on haemodialysis are at high risk for cardiovascular events, but 
heart failure and sudden death dominate and atherosclerotic events are less common. The 
AURORA trial was designed to assess the effect of rosuvastatin on myocardial infarction 
and death from any cardiac cause in haemodialysis patients. We studied predictors of the 
atherosclerotic, and not all cardiovascular, events in AURORA.
Methods: We readjudicated all deaths and presumed myocardial infarctions according 
to stricter criteria to separate atherosclerotic from non-atherosclerotic cardiovascular events. 
The readjudicated atherosclerotic endpoint included non-fatal myocardial infarction, fatal 
coronary heart disease, non-fatal and fatal non-haemorrhagic stroke, revascularisation 
procedures and death from ischaemic limb disease. Baseline predictors were assessed for the 
2776 participants of the AURORA trial, and step-wise Cox regression analysis was applied.
Results: During a mean follow-up of 3.2 years, 716 patients experienced a readjudicated 
atherosclerotic event. Baseline phosphate (HR 1.33; 95% CI 1.16-1.53 per 1 mmol/L 
increase), albumin (HR 0.93; 95% CI 0.91-0.96 per 1g/L increase) and high sensitive CRP 
(HR 1.07; 95% CI 1.00-1.14 per mg/L increase) were significant predictors in addition to 
female sex, age, prevalent diabetes and cardiovascular disease. LDL cholesterol was not 
a significant risk factor.
Conclusions: Even with the use of strict criteria for endpoint definition, non-traditional 
risk factors, but not lipid disturbances, predicted atherosclerotic events in haemodialysis 
patients.
Funding: Pharmaceutical Company Support - AstraZeneca, Government Support - 
Non-U.S.
TH-PO889
Proteomic Studies of Blood Plasma Using 2DE and Mass Spectrometry 
for Deeper View into the Mechanisms Involved in Atherosclerosis in 
Chronic Kidney Disease  Maria Wanic-Kossowska,1 Dorota Formanowicz,2 
Elzbieta Pawliczak.1  1Dept of Nephrology, Transplantology and Internal 
Medicine, Poznan Univ of Medical Sciences, Poznan, Poland; 2Dept of Clinical 
Biochemistry, Poznan Univ of Medical Sciences, Poznan, Poland.
Background: The exact participation and association of particular risk factors and 
specific mechanisms that promote cardiovascular complications (CVD) in patients with 
chronic kidney disease (CKD) remain unclear. The close relationship between CVD and 
CKD is most likely due to the co-existence of both traditional and novel risk factors. To gain 
insight into better recognition of the mechanisms of CKD-related accelerated atherosclerosis, 
a comparative proteomic analyses have been performed.
Methods: Blood samples were taken from 90 patients (CKD1-2, CKD3-4, CKD5), 
30 patients with CVD, but without CKD and 30 healthy volunteers. Plasma samples were 
depleted using affinity chromatography and divided into three fractions: high-abundance 
protein, low-abundance protein and low molecular weight protein. The first two fractions 
were analyzed by two dimensional gel electrophoresis and mass spectrometry, the last 
one has been subjected to direct MS/MS analysis. Differential accumulated proteins were 
confirmed by selected reaction monitoring analysis.
Results: 49 proteins (13 high and 36 low molecular mass) showed differences in 
accumulation levels. The proteomic profiles in CKD5 and CVD patients differed in the 
accumulation of four LAPs the relative accumulations of alfa -2-macroglobulin, second 
isoform of alfa 1 microglobulin and were higher in CKD5 compared with CVD; fold changes 
1.77, 4.14, 2.68 and 1.79, respectively.  Moreover, the relative abundances of these proteins 
were up-regulated in CKD3-4 compared with CVD. CKD1-2 and CVD group differed in 
the accumulation of apolipoprotein A-4 and apolipoprotein A-1.
Conclusions: Our results definitely indicated similar proteomic profiles in CKD1-2 
and CVD patients, in contrast to CVD and CKD5 patients, suggesting that mechanisms of 
CVD acceleration may be different in initial and advanced stages of CKD. It seems that it 
is related to chronic inflammation and immune disturbances, typical for CKD.
TH-PO890
Hemodialysis-Induced Release of Microparticles  Liina Vassil,1 Inga Soveri,1 
Fariborz Mobarrez,2 Tora Almquist,3 Bengt C. Fellstrom.1  1Dept of Medical 
Sciences, Uppsala Univ, Uppsala, Sweden; 2Dept of Medicine, Karolinska Inst, 
Stockholm, Sweden; 3Dept of Clinical Sciences, Danderyd Hospital, Karolinska 
Inst, Stockholm, Sweden.
Background: Microparticles (MPs) are 0.1 -1.0 µm vesicles that are released from cells 
upon activation or during apoptosis. MPs are believed to be involved in the pathophysiology 
of atherosclerosis and thrombosis. Patients with cardiovascular risk factors have significant 
MP elevation. Measurements of MPs may uncover new insight into mechanisms behind 
the severely increased cardiovascular disease (CVD) risk in hemodialysis (HD) patients. 
The aim was to study whether a hemodialysis session affects MP formation and release.
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Methods: Plasma samples from 20 HD patients were drawn before and 1h after the start 
of a HD session. MPs derived from platelets (CD41+), monocytes (CD14+), endothelial 
cells (CD62E+), and their expression of phosphatidylserine (PS) and tissue factor (CD142) 
were analyzed using flow cytometry. P-selectin (CD62P) and CD40 ligand (CD154) were 
measured on platelet-MPs. In addition, Klotho and the receptor for advanced glycation end 
products (RAGE) expression were measured on MPs. Paired t-test was used.
Results: Mean age was 73.6 years (range 54-91), 5 patients were female, 14 had central 
dialysis catheter, 8 patients had diabetes and 14 had CVD.
Marker
(x106/L) Before HD 1h after start of HD P-value
Lactadherin (PS+MPs) 3645(1960-9784) 4388(1966-12672) 0.08
Lactadherin + CD41 464(153-2321) 774(169-3000) 0.04
Lactadherin+CD41+CD62P 186(50-1098) 550(70-1369) 0.01
Lactadherin+CD41+CD154 205(33-992) 365(52-1236) 0.05
Lactadherin+CD14 216(175-443) 337(205-584) 0.00
Lactadherin+CD62E a 713 (±233) 845 (±348) 0.03
CD41+CD142 a 467 (±262) 541 (±337) 0.30
CD62E+CD142 135(15-392) 171(26-900) 0.06
CD14+CD142 31(11-121) 58(17-193) 0.00
Klotho a 2260 (±276) 2612 (±414) 0.00
RAGE 154(122-1356) 252(178-1491) 0.00
Mean (± SD) a or Median (range)
Conclusions: The majority of MP levels increase significantly after the start of a HD 
session. Whether this is driven by patient or dialysis specific factors remains unclear. The 
clinical significance of MP release during HD needs to be evaluated.
Funding: Government Support - Non-U.S.
TH-PO891
The Monocyte Subset of CD14+CD16+ Cells Plays a Key Role of Promoting 
Atherosclerosis in Hemodialysis Patients  Miki Nishida,1 Minoru Ando,2 
Yusuke Iwamoto,3 Ken Tsuchiya,1 Kosaku Nitta.1  1Dept Medicine, Kidney 
Center, Tokyo :omen¶s Medical Univ, Tokyo, Japan; 2Tokyo Metropolitan 
Komagome Hospital, Tokyo, Japan; 3Saitou Memorial Hospital, Tokyo, Japan.
Background: Atherosclerosis is closely associated with morbidity and mortality in 
hemodialysis (HD) patients. The scavenger receptors (SR) in circulating monocytes play a 
key role in promoting foam cell formation by binding and internalizing oxidized low-density 
lipoprotein. In addition, heterogeneity of monocytes and macrophage-colony stimulating 
factor (M-CSF) may facilitate the atherosclerotic process by SR over-expression.
Methods: Subjects included 62 HD patients and 30 healthy controls. Peripheral 
monocytes were isolated using magnetically labeled Whole Blood CD14+ micro-beads. 
Transcriptional levels of CD16 and SR-A were measured in monocytes by quantitative 
real-time RT-PCR, using the comparative threshold (Ct) method. The gene expressions 
were compared between HD patients and controls, and between HD patients who had 
cardiovascular disease (CVD) and those who did not. Plasma concentration of M-CSF was 
measured with M-CSF ELISA kit. Additionally, CD16 protein expression was analyzed 
by a flow cytometry.
Results: SR-A gene expression was higher in monocytes from HD patients than in 
those from controls (2.35 vs 1.29, p=0.0006). Moreover, it was higher in HD patients with 
CVD than in those without (2.79 vs 1.64, p=0.0023). Plasma concentration of M-CSF was 
8-fold higher in HD patients than in controls (1173±517.3 vs 152±55.1 pg/ml, p<.0001). 
It was significantly correlated with the gene expression of SR-A (r2=0.129, p=0.0007). 
The CD16 gene expression was higher in CD14+ monocytes from HD patients than in 
those from controls(1.28 vs 1.07, p=0.0310), and was significantly correlated with the 
gene expression of SR-A (r2=0.051, p=0.0467). In a flow cytometry, the proportion of 
CD14+CD16+ cells was 2.2-fold higher in HD patients than in controls (34.60 vs 15.85, 
p=0.0034). In addition, this proportion was related with M-CSF (r2=0.354, p=0.0118) and 
SR-A gene expression (r2=0.540, p=0.0240).
Conclusions: The CD14+CD16+ cells are important subset of monocytes in HD patients, 
which may prime and increase SR expressions.
TH-PO892
Active Ghrelin Enhances the Association Between BMI and Clinical 
Outcome in Hemodialysis Patients Irrespective of Appetite  Ilia Beberashvili,1 
Inna Sinuani,2 Ada Azar,3 Leonid Feldman,1 Shai Efrati.1  1Nephrology, Assaf 
Harofeh Medical Center, Zerifin, Israel; 2Pathology, Assaf Harofeh Medical 
Center, Zerifin, Israel; 3Nutrition, Assaf Harofeh Medical Center, Zerifin, Israel.
Background: Ghrelin, a gastric orexigenic peptide, and BMI are known as inversely 
associated to each other and have both been linked to cardiovascular (CV) risk and mortality 
in hemodialysis (HD) patients. However, it is unclear whether ghrelin and BMI interact 
modifying risk of all-cause and CV death in this population.
Methods: We investigated the interactions between BMI and ghrelin as predictors of 
death over a 3 years of follow-up (median - 28 months, interquartile range - 17-34 months) 
in 261 maintenance HD patients (39% women, mean age of 68.6±13.6 years).
Results: A significant interaction effect of high ghrelin and high BMI (defined as 
their levels higher than median) on all-cause mortality was found: crude Cox hazard ratio 
(HR) for the product termed Ghrelin x BMI was 0.52, with a 95% confidence interval 
(CI): 0.29 to 0.95 (P=0.04). Across the four ghrelin-BMI categories, the group with high 
ghrelin and high BMI exhibited the better outcome in both all-cause and cardiovascular 
mortality (multivariable adjusted hazard ratios were 0.30, 95% CI 0.15 to 0.59, P<0.001, 
and 0.33, 95% CI 0.13 to 0.86, P=0.02, respectively). Compared to patients from other 
ghrelin-BMI categorized groups, patients in the high ghrelin-high BMI group were more 
surprisingly anorexic, were predominantly non-smokers, with lower incidence of diabetes 
and had higher Kt/V levels. These variables consequently were inserted in all multivariable 
models. Data analyses carried out by stratifying patients according to ghrelin-fat mass, but 
not to ghrelin-lean body mass categories, provided similar results.
Conclusions: We observed interactions between high ghrelin and BMI that were 
associated with decreased mortality risk in our cohort, especially those due to cardiovascular 
causes. Interestingly, the orexigenic effect of ghrelin does not seem involved in described 
interaction.
TH-PO893
Serum Procollagen Type I Carboxy-Terminal Propeptide Is Associated 
with Left Ventricular Hypertrophy and Dysfunction, and May Predict 
Cardiovascular Event in Incidental Dialysis Patient  Sung jun Kim,1 Hye 
Eun Yoon,1 Sungjin Chung,2 Seok Joon Shin.1  1Dept of Internal Medicine, 
College of Medicine, The Catholic Univ of Korea, Incheon, Korea; 2Dept of 
Internal Medicine, College of Medicine, The Catholic Univ of Korea, Korea.
Background: Serum procollagen type I carboxy-terminal propeptide(PICP) is a marker 
of myocardial fibrosis in hypertensive heart disease.However the clinical significance of 
this biomarkers is less determined in end-stage renal disease (ESRD) patients. This study 
was to evaluate the association of predialysis serum PICP levels with echocardiographic 
markers in ESRD patients.
Methods: Serum PICP, albumin, CRP, iPTH levels were obtained from predialysis 
blood samples of 123 incidental dialysis patients. Echocardiographic parameters included 
left ventricular mass index (LVMI) and ejection fraction, ratio of peak early transmitral 
flow velocity to peak early diastolic mitral annular velocity (E/E’ ratio), ratio of peak 
early transmitral flow velocity to peak late transmitral flow velocity (E/A ratio), and mitral 
valve-deceleration time (DT).
Results: A direct correlation was found between PICP and Left ventricular mass index 
(r=0.308, P=0.002), between PICP and E/E’ ratio (r=0.236, P = 0.009), between PICP and 
ratio of peak early transmitral flow velocity to peak late transmitral flow velocity (E/A) 
(r=0.285, P=0.002). A negative correlation was found between PICP and Left ventricular 
ejection fraction (r=-0.289, P=0.001), between PICP and mitral valve-deceleration 
time (r=-0.203, P=0.026). In the multivariate linear regression analysis, the PICP was 
independently positive associated with LVMI and E/e’ and negative associated with Left 
ventricular ejection fraction. In the multivariate cox regression analysis, previous CV event 
(HR 15.224, CI 3.26-71.04), and High PICP group (vs low PICP group) (HR 9.478, CI 
1.10-81.82) were the significant prognostic factors cardiovascular event.
Conclusions: Serum procollagen type I carboxy-terminal propeptide (PICP) is 
associated with left ventricular hypertrophy and dysfunction, and may predict cardiovascular 
event in incidental dialysis patient.
TH-PO894
Associations of Soluble Receptor for Advanced Glycation End Products 
(s-RAGE) and S100A12 (EN-RAGE) with Mortality in Long-Term 
Hemodialysis Patients  Ji Yong Jung,1 Eul Sik Jung,1 Byoungho Choi,1 Yun Jung 
Oh,2 Chungsik Lee,2 Ae jin Kim,1 Han Ro,1 Jae Hyun Chang,1 Hyun Hee Lee,1 
Wookyung Chung.1  1Div of Nephrology, Dept of Internal Medicine, Gachon 
Univ Gil Medical Center, Incheon, Republic of Korea; 2Div of Nephrology, Dept 
of Internal Medicine, Cheju Halla General Hospital, Jeju, Republic of Korea.
Background: Hemodialysis (HD) patients have been associated with vascular 
calcification and ultimately with high mortality rates. Formerly, we reported association 
of soluble receptor for advanced glycation end products (s-RAGE) and S100A12 (EN-
RAGE) with vascular calcification. We extended our observation whether those biomarkers 
could be proposed for predicting cardiovascular morbidity and mortality in these subjects.
Methods: This is a prospective observational cohort study in 199 HD patients from 
extended analyses of our previous study. Serum S-RAGE, S100A12, comorbidities, and 
other traditional risk factors were also investigated. The cumulative incidences for death 
using Cox proportional-hazards regression were evaluated in multivariable analyses. A 
mean observation period was 29 months.
Results: The patients were 57.1 ± 13.7 years of age; 54.3% were male, 49.2% were 
diabetic, and 36.2% had a history of cardiovascular disease. During the observation 
period, 27 patients (13.6%) were died. Univariate analysis demonstrated that S100A12 
was correlated with diabetes (P = 0.04) and hs-CRP (P = 0.01). In multivariable analyses, 
serum s-RAGE (HR [hazard ratio], 1.16; 95% CI [confidence interval], 0.61-2.19; P = 0.65) 
and S100A12 (HR 1.05; 95% CI, 0.62-1.77; P = 0.87) were not associated with mortality 
in hemodialysis patients, though traditional predictors for mortality including age, history 
of cardiovascular diseases, serum albumin and serum high-sensitivity C reactive protein 
(hs-CRP) were related to mortality. Powerful predictors for mortality were age, previous 
cardiovascular disease and serum albumin level.
Conclusions: Serum S-RAGE and S100A12 may be weak surrogate markers to predict 
all-cause mortality in patients receiving hemodialysis, even though S100A12 was partly 
related with diabetes and inflammation.
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TH-PO895
Impact of Sodium-Dependent Phosphate Co-Transport, Pit-1, in Peripheral 
Blood Mononuclear Cells on Cardiac Calcification in Maintenance 
Hemodialysis Patients  Minwen Ding, Mengjing Wang, Minmin Zhang, Jing 
Chen.  Huashan Hospital, Fudan Univ.
Background: Vascular calcification (VC) is an importance risk factor for cardiovascular 
disease in MHD patients, however, the mechanisms of which are still under investigation. 
The aims of this study were to explore the risk factors of VC in MHD patients, and to 
identify the expression of sodium-dependent phosphate co-transporter (Npt) in peripheral 
blood mononuclear cells (PBMCs) and assess its association with cardiac calcification and 
its possible impact factors.
Methods: This is a cross-sectional analysis of adult MHD patients who received at least 
6-month regular MHD in our dialysis center. The coronary artery calcification (CAC) was 
measured by cardiac MSCT. The gene expression of Npt in PBMCs was measured by Real-
time PCR and we tested serum TNF-α and IL-6 by ELISA. Multivariate logistic analysis 
was used to determine the risk factors of CAC. Correlation between the gene expression 
of Npt and other parameters was examined by Pearson relativity analysis.
Results: 1.68 eligible patients were enrolled. 2. Three kinds of Npts were detected 
in PBMCs of MHD patients. They were typeIINpt,Npt2b,type III Npt,Pit-1 and Pit-2, 
among which Pit-1 mRNA expression was significantly associated with extent of CAC. 3. 
The results of the logistic regression analysis were listed in Table 1. 4.Pearson relativity 
analysis showed Pit-1 mRNA expression of PBMCs was significantly correlated with serum 
phosphorus (r=0.43, P=0.002), CAC sore (r=0.63, P<0.001) and Pit-2 mRNA expression 
of PBMCs (r=0.53, P=0.001).
Conclusions: Our result showed that longer dialysis vintage, diabetes, higher 
concentration of serum TNF-α and Pit-1 mRNA expression of PBMCs are the risk factors 
of CAC in MHD patients. Pit-1 mRNA expression of PBMCs was significantly correlated 
with serum phosphorus, CAC sore and Pit-2 mRNA expression of PBMCs.
Funding: Government Support - Non-U.S.
TH-PO896
HDL Not as Predictive as apoA-1:apoB Ratio of Dialysis Patients in 
Predicting Death  Yuji Sato,1 Shouichi Fujimoto,2 Tatsunori Toida,2 Yasuhiro 
Yamashita,3 Takashi Iwakiri,3 Akihiro Fukuda.1  1Dialysis Div, Univ of Miyazaki 
Hospital, Miyazaki, Japan; 2epartment of Hemovascular Medicine and Artificial 
Organs, Faculty of Medicine, Univ of Miyazaki, Miyazaki, Japan; 3Dept of 
Internal Medicine, Div of Circulatory and Body Fluid Regulation, Faculty of 
Medicine, Univ of Miyazaki, Miyazaki, Japan.
Background: In dialysis patients, the risk extended by the apolipoprotein profile 
to all-cause or cardiovascular (CVD) mortality is obscure. Our aim was to investigate 
the association between the apolipoprotein profile and the incidence of death in chronic 
dialysis patients.
Methods: A prospective observational study of mortality incidence in dialysis patients 
was conducted.
Results: Prevalent dialysis patients (n=1088) were enrolled and followed for 4 years. 
Of the 194 deaths recorded, 82 were of CVD origin. For the regular lipid markers (HDL, 
non-HDL, and TG), +1 mg/dl of HDL was significantly associated with all-cause mortality 
[HR and 95% CI, 0.986 (0.974–0.999)] but not for CVD mortality by multivariable Cox 
analysis adjusted for sex, age, basal kidney disease, dialysis vintage, dry weight, and 
pre-dialysis systolic blood pressure. For apolipoprotein lipid markers (apoA-1:apoB 
ratio, apoCIII:apoE ratio, and apoB48:TG ratio), +1 digit of the apoA-1:apoB ratio was 
significant for all-cause [0.279 (0.102–0.765)] and CVD [0.165 (0.036–0.750)] mortality. 
When participants were divided into quartiles, the highest quartiles of the apoA-1:apoB 
ratio were significantly associated with both categories of death when compared with the 
lowest quartiles by multivariable Cox analysis.
Conclusions: Although controversies persist regarding whether lipids affect the 
prognosis of dialysis patients, our data revealed that the apoA-1:apoB ratio was significantly 
associated with all-cause and CVD mortality in dialysis patients.
Funding: Government Support - Non-U.S.
TH-PO897
HDL Subfractions in End-Stage Renal Disease (ESRD) Patients 
Anna Gluba-Brzozka, Beata Franczyk-Skora, Jacek Rysz.  Dept of Nephrology, 
Hypertension and Family Medicine, Medical Univ of Lodz, Poland.
Background: Chronic kidney disease is a common disease associated with high 
cardiovascular risk. Recent studies have suggested that HDL not LDL may play the more 
important role in the progression of atherosclerosis in CKD patients. HDL from CKD 
patients was shown to become dysfunctional, lose its vasoprotective properties and begin 
to promote endothelial dysfunction and inflammation.
Methods: The aim of this study was to analyze which HDL fractions were more 
abundant in ESRD patients and are associated with advanced atherosclerosis. This study 
included 50 ESRD patients (16 women, 34 men) on dialysis (WAM University Hospital, 
Lodz, Poland) and 20 healthy volunteers (14 women, 6 men). Blood samples were collected 
from all subjects and HDL subfractions were analyzed with the use of Lipoprint system. 
Moreover, all patients had IMT measured.
Results: This study revealed statistically significant differences in HDL subfractions 
between control and study group: HDL1 [5.6 (2.0-7.1) vs. 13.0 (8.2-15.8), p<0.0001], 
HDL2 [13.1 (7.8-14.9) vs.17.7 (15.2-21.0), p=0.009], HDL3 [5.5 (0.4-8.6) vs. 9.4 (7.8-
11.3), p<0.0001], HDL4 [8.5 (0-10.4) vs.10.6 (9.5-12.0), p=0.003], HDL5 [9.2 (3.3-10.5) 
vs. 11.4 (9.9-12.1), p=0.01], HDL7 [7.6 (7.2-8.4) vs. 5.3 (4.2-7.2), p<0.0001], HDL8 [8.7 
(8.0-9.5) vs. 4.8 (3.5-5.8), p<0.0001], HDL9 [7.0 (5.9-8.2) vs. 3.8 (3.0-4.8), [p<0.0001], 
HDL10 [15.9 (7.6-28.7) vs. 4.3 (2.6-7.1), p<0.0001] and large HDL [26.5 (17.5-29.2) 
vs. 40.3 (33.0-47.0), p<0.0001] and HDL Small [30.8 (22.3-43.2) vs. 12.8 (9.4-17.9), 
p<0.0001]. Significant differences were also observed in HDL1 [9.3 (6.6-12.9) vs. 13.4 
(8.7-16.9), p=0.014], HDL6 [20.2 (18.0-23.2) vs.17.6 (15.2-20.1), p=0.020], HDL Large 
[35.0 (23.7-40.0) vs. 41.4 (33.6-48.0), p=0.017 and HDL Intermediate [50.2 (45.8-51.7) 
vs.45.8 (40.0-49.1), p=0.017] between HD patients with IMT > 0.9 mm and <0.9 mm].
Conclusions: This study revealed that ESRD influences HDL subfractions. Subfractions 
of large HDL are more abundant in patients with ESRD while small HDL fraction is 
more frequent in healthy persons. It is possible that the shift in HDL subfractions may be 
responsible for the increased risk of atherosclerosis in CKD patients.
TH-PO898
High Non-HDL Cholesterol as an Independent Risk Factor for Coronary 
Restenosis in Hemodialysis Patients Undergoing Percutaneous Coronary 
Interventions  Shoko Hasegawa,1 Toshiaki Nakano,1 Yasushi Mukai,2 Yuta 
Matsukuma,1 Ryusuke Yotsueda,1 Akihiro Tsuchimoto,1 Kiichiro Fujisaki,1 
Kazuhiko Tsuruya,1,3 Takanari Kitazono.1  1Dept of Medicine and Clinical 
Science, Kyushu Univ Graduate School of Medical Sciences, Fukuoka, Japan; 
2Dept of Cardiovascular Medicine, Kyushu Univ Graduate School of Medical 
Sciences, Fukuoka, Japan; 3Dept of Integrated Therapy for Chronic Kidney 
Disease, Kyushu Univ Graduate School of Medical Sciences, Fukuoka, Japan.
Background: It has been reported that patients with end-stage kidney disease (ESKD) 
have a higher risk of restenosis after percutaneous coronary intervention (PCI). The aim 
of this study was to investigate the risk factors of restenosis after PCI in hemodialysis 
(HD) patients.
Methods: From January 2007 to December 2014, we enrolled 54 consecutive ESKD 
patients undergoing HD (mean age: 66.5 +/- 10.1 years; 15 women, 39 men; mean HD 
duration: 3.7 years), who received PCI and follow-up coronary angiography (CAG) after 
about 6 months. The coronary restenosis was defined by the patient having target lesion 
revascularization on follow-up CAG.
Results: Of 54 patients who had received PCI, restenosis occurred in 22 patients 
(40.7%) within 5-12 months after PCI. In the univariable logistic analysis, serum levels 
of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio, serum 
levels of non-high-density lipoprotein cholesterol (non-HDL-C), and history of major 
adverse cardiovascular events (MACE) were significantly associated with the occurrence of 
coronary restenosis; odds ratio (OR) [95% confidence interval (CI)] was 1.89 [1.02-3.50], 
1.22 [1.01-1.47], and 5.79 [1.59-20.99], respectively. In the multivariable logistic analysis, 
non-HDL-C and the history of MACE were significantly associated with the coronary 
restenosis; OR [95% CI] was 1.35 [1.08-1.69](per 10 mg/dL increase in non-HDL-C) and 
8.55 [1.88-38.85], respectively.
Conclusions: Non-HDL-C was an independent risk factor for the occurrence of 
coronary restenosis in HD patients undergoing PCI. This result suggests the significance 
and necessity of strict management of lipid metabolism after PCI in even HD patients.
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TH-PO899
Galectin-3 Does Not Correlate within Markers of Cardiac Structure 
and Function on Cardiac MRI: A Study in Haemodialysis Patients 
Lisa E. Crowley,1 Aghogho Odudu,1 Saoirse O’sullivan,2 Christopher W. 
McIntyre.3  1Dept of Renal Medicine, Royal Derby Hospital, United Kingdom; 
2Div of Medical Sciences, Univ of Nottingham, United Kingdom; 3Kidney 
Clinical Research Unit, London Health Sciences Centre, London, Canada.
Background: End-stage renal failure patients undergoing haemodialysis (HD) suffer 
disproportionate rates of death due to heart failure. Accurate tools to help predict those at 
highest risk are therefore desirable. Galectin-3 is a soluble β-galactoside binding protein 
secreted by activated macrophages that promotes cardiac fibroblast proliferation, collagen 
deposition and as a result ventricular dysfunction. Galectin-3 is the only FDA approved 
test for assessing prognosis in chronic heart failure. Our study explored the relationship 
between Galectin-3 and cardiac structure and function in a dialysis population.
Methods: We measured Galectin-3 (G3) levels in a multiplex assay (Merck Millipore) 
in HD patients enlisted in a clinical trial. Results were correlated with tagged cardiac 
magnetic resonance imaging to assess left ventricular structure and function.
Results: A total of 65 patients had G3 levels taken. The mean age of the cohort was 
60±24 years. The overall mean G3 level was 17.7ng/mL±0.07. The mean Left Ventricular 
Mass Index was 77.09g/m2±20.4, mean ejection fraction 57.47%±11.7 and mean End-
diastolic volume 143.4ml±39.4. In the whole cohort there was no significant correlation 
between G3 levels and any of the measure of left ventricular structure and function including 
LVMI (r=-0.22 p=0.24), LVEF (r=0.08 p=0.65) or LVEDV (r=0.012 p=0.94). The previously 
recommended upper limit of normal for G3 levels is 17.7ng/mL. 32 patients had a G3 level 
greater than this. In this group the mean G3 level was 23.2ng/mL, however there remained 
no significant correlations with age (r=0.10 p=0.38), LVEF (r=0.23 p=0.26), LVEDV 
(r=-0.01 p=0.95), LVMI (r=0.11 p=0.59) or global peak diastolic and systolic strain rates 
(r=0.3 p=0.14 and r=0.16 p=0.41).
Conclusions: In HD patients, Galectin-3 is not associated with structural and functional 
markers of systolic dysfunction seen on tagged cardiac MRI. Our results suggest that 
Galectin-3 does not have a role in risk stratification of this patient group.
Funding: Government Support - Non-U.S.
TH-PO900
Association of Klotho and FGF23 with Frailty in Patients Initiating 
Hemodialysis  Sahar Koubar,1 Esther D. Kim,2 Dorry L. Segev,1 Stephen M. 
Sozio,1 Larisa Tereshchenko,3 Lucy A. Meoni,1 Rulan S. Parekh,2 Michelle M. 
Estrella.1  1Johns Hopkins; 2Univ of Toronto; 3Univ of Oregon.
Background: Frailty at dialysis initiation is associated with higher mortality. Both 
FGF23 and its co-receptor, klotho, have been implicated in the development of frailty. We 
aimed to evaluate the independent association of FGF23 and soluble klotho (sKlotho) with 
frailty in hemodialysis (HD) patients.
Methods: We conducted a cross-sectional study of incident HD patients enrolled in the 
Predictors of Arrhythmic and Cardiovascular Events in ESRD (PACE) Study. Frailty was 
defined by ³3 of the following: unintentional weight loss ³10 lbs in prior year, self-reported 
exhaustion, weakness (by hand grip strength), slowness (by walking distance) and self-
reported low physical activity. Logistic regression was used to examine the associations 
of sKlotho and FGF23 with odds of frailty and frailty subcomponents.
Results: Of 336 individuals, 71% were black; 59% were male. Mean age was 55y. 
All had hypertension and 56% had diabetes, 38% CAD, and 37% obesity. Median sklotho 
level was 364.4 pg/ml (IQR 272.5-494.6); mean FGF23 level was 656.2 U/ml (SD: 498). 
40% of participants were frail. Adjusting for demographic factors, obesity, Charlson 
Comorbidity Index, hsCRP, serum albumin and Kt/V, higher sKlotho was associated with 
lower odds of frailty (Table). 
This remained robust after also adjusting for FGF23. Conversely, FGF23 was not 
associated with frailty. In adjusted analyses of the frailty subcomponents, higher sKlotho was 
only associated with self-reported exhaustion (OR=0.54, 95%CI: 0.30-0.95) while higher 
FGF23 was only associated with unintentional weight loss (OR=0.93; 95%CI: 0.88-0.98).
Conclusions: sKlotho, but not FGF23, was inversely associated with odds of frailty 
in incident HD patients, although both hormones appear to be associated with different 
individual subcomponents of the frailty phenotype.
Funding: NIDDK Support
TH-PO901
FGF23 Is Not Associated with Arterial Stiffness in Patients with CKD5D 
Kenneth Lim,1 Stephen M.S. Ting,2 Daniel Zehnder,3,4 Thomas F. Hiemstra.5  1Div 
of Nephrology, Massachusetts General Hospital, Boston, MA; 2Dept of Medicine, 
Heart of England NHS Foundation Trust, Birmingham, United Kingdom; 3Div 
of Nephrology, Univ Hospital Coventry and Warwickshire NHS Trust, Coventry, 
United Kingdom; 4Div of Metabolic and Vascular Health, Warwick Medical 
School, Coventry, United Kingdom; 5School of Clinical Medicine, Univ of 
Cambridge, Cambridge, United Kingdom.
Background: Arterial stiffening is thought to be a key determinant of excess 
Cardiovascular mortality in CKD patients. In CKD, the bone-derived phosphatonin 
fibroblast growth factor (FGF) 23 is elevated and has been implicated in the development of 
Cardiovascular disease. In this study, we sought to determine whether FGF23 is a predictor 
of arterial stiffness in dialysis-dependent CKD patients.
Methods: In this cross-sectional study, we enrolled 352 patients with advanced 
CKD and 150 healthy controls. Pulse wave velocity (PWV) was recorded by applanation 
tonometry, and blood pressure and biochemical parameters including plasma intact-FGF23 
concentrations determined.
Results: Patients with CKD were significantly younger than controls (46±14 versus 
49±11 years, p=0.02), had a higher blood pressure (MAP 97±14 vs 94±10 mmHg, p=0.003), 
and were more likely to be male (61% versus 49%, p=0.008). CKD patients had significantly 
higher FGF23 (3095 pg/ml, IQR 612-12726 versus 40 pg/ml, IQR 33-49, p<0.001) and 
parathyroid hormone (25 pmol/l, IQR 13-56 versus 3.8 pmol/l, IQR 3-5, p<0.001). PWV was 
elevated in patients with CKD (8 m/sec, IQR 6.9-9.6 vs 7.3m/sec, IQR 6.6-8.4, p=0.0002). 
In a regression model adjusted for known predictors of PWV, FGF23 did not predict PWV 
(β=-0.15, p=0.063), but was positively associated with the presence of CKD (p=0.009), age 
(p<0.001), mean arterial pressure (p<0.001) and heart rate (p=0.001).
Conclusions: In this prospective cohort study, FGF23 did not predict arterial stiffening 
beyond known risk factors of age, mean arterial pressure, heart rate and the presence of 
diabetes. Our findings suggest that the excess cardiovascular mortality observed with 
elevated FGF23 in CKD is not primarily driven by effects on arterial stiffening.
TH-PO902
Differential Association of Fibroblast Growth Factor-23 and Soluble Klotho 
with Left Ventricular Hypertrophy  Tanya S. Johns,1 Esther D. Kim,2 Tessa 
Kimberly Novick,3 Lucy A. Meoni,3 Stephen M. Sozio,3 Bernard G. Jaar,3 
Larisa Tereshchenko,4 Rulan S. Parekh,2 Michelle M. Estrella.3  1Albert Einstein 
College of Medicine; 2Univ of Toronto; 3Johns Hopkins Univ; 4Univ of Oregon.
Background: Fibroblast growth factor-23 (FGF23), a phosphaturic hormone, has been 
implicated in the pathogenesis of left ventricular hypertrophy (LVH) among patients with 
chronic kidney disease. Whether FGF23’s co-receptor, klotho, is independently associated 
with LVH is unclear.
Methods: To determine whether soluble klotho (sKlotho) is independently associated 
with LVH among incident hemodialysis patients, we conducted a cross-sectional study 
among participants who underwent baseline 2D echocardiograms in the Predictors of 
Arrhythmia and Cardiovascular Events (PACE) Study. Multivariable logistic regression 
models with FGF23, sKlotho, and both as primary predictors were constructed to estimate 
the odds of LVH (defined as LV mass index >116 g/m2 in men and >104 g/m2 in women).
Results: Of 391 participants who underwent echocardiogram, 371 and 387 had sKlotho 
and FGF23 levels available, respectively; 72% had LVH. Mean age was 54 years and 72% 
were black. All participants had hypertension with mean systolic BP 154 mm Hg. Median 
volume removed per HD session was 2.6L (IQR: 1.6 – 3.7). FGF23 was not associated 
with LVH after adjusting for age, race, gender, BMI, systolic BP, serum albumin level, and 
ultrafiltration volume. In contrast, higher sKlotho was independently associated with lower 
odds of LVH (OR=0.51 per 1 log higher; 95% CI: 0.29-0.96); this association remained 
robust with additional adjustment for FGF23 and Charlson Co-Morbidity Index.
Conclusions: sKlotho, not FGF23, is associated with a lower odds of LVH among 
incident hemodialysis patients.
Table. Association of FGF23 and sKlotho with LVH
OR 95% CI P-value
FGF23, per 100 rU/mL higher* 1.03 0.98 – 1.10 0.20 
sKlotho, per 1 log pg/mL higher* 0.51 0.28 – 0.96 0.04
sKlotho, per 1 log pg/mL higher¶ 0.51 0.27 – 0.95 0.03 
*Adjusted for age, race, gender, BMI, systolic BP, serum albumin level, ultrafiltration volume
Additionally adjusted for FGF23 and Charlson Co-Morbidity Index
Funding: NIDDK Support
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TH-PO903
Predictors of Arterial Stiffness in Incident Hemodialysis Patients 
Stephanie M. Toth-Manikowski,1 Esther D. Kim,2 Lucy A. Meoni,1 Bernard G. 
Jaar,1 Tariq Shafi,1 Michelle M. Estrella,1 Rulan S. Parekh,1,2 Stephen M. Sozio.1 
1Johns Hopkins Univ; 2Univ of Toronto.
Background: Premature vascular aging and arterial stiffening characterize CKD 
progression to ESRD and are associated with increased cardiovascular (CVD) morbidity 
and mortality. We identified predictors of arterial stiffness over time in HD patients.
Methods: In 339 incident HD patients in the Predictors of Arrhythmic and 
Cardiovascular Risk in ESRD (PACE) study, we examined the associations of baseline age, 
sex, race, comorbidities, CVD medications, and dialysis characteristics with longitudinal 
vascular stiffness measured by carotid-femoral pulse wave velocity (PWV) using 
generalized estimating equations. Annual change in PWV for up to 3 years was analyzed 
using linear regression.
Results: Mean age was 54, 58% male, 74% African-American, mean (SD) baseline 
PWV 10.7 (3.4) m/s, and annual PWV change 0.1 (2.6) m/s. Several factors were associated 
with higher PWV in univariate and multivariate longitudinal models. None were associated 
with PWV change.
Univariate Multivariate
β (95%CI) β (95%CI)
Demographics
Age (/10y) 1.03 (0.81-1.24)‡ 0.88 (0.66-1.09)‡
Female -0.35 (-1.03-0.32) -0.61 (-1.1--0.07)*
African-American -0.62 (-1.39-0.14) 0.34 (-0.29-0.98)
Comorbidities
Diabetes 2.62 (2.00-3.24)‡ 1.58 (0.99-2.16)‡
Coronary Disease 0.87 (0.17-1.56)* -0.24 (-0.87-0.39)
Congestive Heart Failure 0.93 (0.26-1.60) -0.14 (-0.72-0.45)
LV Mass Index -0.03 (-0.10-0.04) -
Tobacco Use -0.51 (-1.18-0.17) -
Medications
Renin-Angiotensin Inhibitor -0.01 (-0.70-0.67) -
Beta Blocker 0.83 (0.16-1.51)* 0.99 (-0.45-0.65)
Clinical Characteristics#
Pulse Pressure (/10mmHg) 1.12 (0.88-1.37)‡ 0.77 (0.54-1.00)‡
Phosphorus (/10mg/dL) -0.24 (-0.57-0.10) -
iPTH (/10mg/dL) -0.01 (-0.02-0.00)* 0.00 (-0.01-0.01)
Albumin (mg/dL) -0.38 (-1.11-0.34) -
P-value: 
*<0.05 
<0.01 
‡<0.001 
#1st 3 month average 
Conclusions: Although PWV did not change significantly over time in incident HD 
patients, age, male sex, diabetes, and pulse pressure were independently associated with 
higher PWV. It may be difficult to modify PWV after HD initiation and clinical factors 
should be optimized prior to starting HD.
TH-PO904
Differences in Risk Factors for Coronary Artery Calcification Between 
Nondiabetic and Diabetic Hemodialysis Patients  Yoshiko Nishizawa,1 
Sonoo Mizuiri,1 Kyoka Ono,1 Mariko Asai,1 Kazuomi Yamashita,1 Kenichiro 
Shigemoto,1 Kohji Usui,2 Michiko Arita,3 Kiyoshi Fujita,4 Takao Masaki.5  1Div 
of Nephrology, Ichiyokai Harada Hospital, Hiroshima city, Japan; 2Ichiyokai 
Ichiyokai Clinic, Hiroshima city, Japan; 3Ichiyokai East Clinic, Hiroshima city, 
Japan; 4Ichiyokai Yokogawa Clinic, Hiroshima city, Japan; 5Dept of Nephrology, 
Hiroshima Univ Hospital, Hiroshima city, Japan.
Background: The differences in risk factors for coronary artery calcification between 
nondiabetic and diabetic hemodialysis (HD) patients have not been fully explored.
Methods: We examined Agatston coronary artery calcium score (CACS) using MDCT, 
age, sex, presence of diabetes, dialysis vintage, smoking history, administration of phosphate 
binders, geriatric nutritional risk index (GNRI), HbA1c, serum calcium, phosphate, iPTH, 
CRP, b2MG, LDL-cholesterol and triglyceride (TG) in 355 HD patients: 242 nondiabetics 
and 113 diabetics. Factors related to CACS were assessed by multivariate regression analysis 
using all of the above independent variables. Differences in the above parameters according 
to quartile (Q) of CACS were also assessed.
Results: Mean age (years), dialysis vintage (months), CACS (H) and serum phosphate 
(mg/dl) were 63±14 vs. 66 ±12 (ns), 125±100 vs.71±50 months (P<0.01), 1651±2173 
vs. 2377±2513 (P<0.05), and 5.3±1.3 vs. 5.0±1.4 (ns) in nondiabetics and diabetics, 
respectively. Patients with CACS Q4 showed higher prevalence of diabetes (40 vs. 19%), 
age (68±12 vs. 58±14 years), and CRP (0.7±1.3 vs. 0.2±0.4 mg/dl), but lower iPTH 
(146±133 vs. 193±131 pg/ml) levels than patients with CACS Q1 (P<0.05), and other 
parameters were not significantly different except HbA1c. Significant associations were 
observed between CACS and age (P<0.001, β: 0.21), female(P<0.001, β: -0.21), dialysis 
vintage (P<0.001, β: 0.31), CRP (P<0.05, β: 0.16), TG (P<0.05, β: 0.15) in nondiabetics. 
However, CACS was significantly associated only with age (P<0.05, β: 0.30) and HbA1c 
(P<0.05, β:0.26 ) in diabetics.
Conclusions: Risk factors for coronary artery calcification differ between nondiabetic 
and diabetic HD patients, and poor glycemic control is the main factor in the latter.
TH-PO905
Hemodialysis and Hemodiafiltration Improve Serum Calcification 
Propensity  Marijke J.E. Dekker,2 Andreas Pasch,3 Frank van der Sande,1 
Constantijn Konings,2 Matthias Bachtler,4 Mauro Dionisi,4 Jeroen Kooman,1 
Bernard J. Canaud.6  1Maastricht Univ Medical Center; 2Catharina Hospital 
Eindhoven; 3Univ Hospital Bern; 4Calcisco AG; 5Fresenius Medical Care.
Background: Calciprotein particles (CPPs) may play an important role in the 
calcification process. The calcification propensity of serum (T50) is highly predictive 
of all-cause mortality in chronic kidney disease patients. Whether T50 is therapeutically 
improvable, by hemodialysis (HD) or even further by hemodiafiltration (HDF), has not 
been studied yet.
Methods: We designed a cross-sectional single center study, and included prevalent 
patients on HD or HDF. Patients were divided into two groups based on dialysis modality. 
We included patients on a thrice-weekly schedule, with a dialysis vintage of >3 months 
and vascular access providing a blood flow rate of >300 ml/min. Calcification propensity 
of serum was measured by the time of transformation from primary to secondary CPP (T50 
test), by time-resolved nephelometry.
Results: In total 64 patients were included and, T50 was measured in 376 pre- and post-
dialysis samples of all in-center dialysis sessions during one week. T50 levels improved in 
both the HD and HDF group with pre- and post-dialysis (mean (SD)) of 244(64)-301(57) 
and 253(55)-304(61) min respectively (P=0.43). The mean improvement of T50 was 26.29% 
in the HD group and 21.97% in the HDF group (P=0.61). The delta values (∆) of calcium, 
phosphate (P) and albumin were equal in both groups. The DT50 was mostly influenced by 
DP (r2 0.280; P=0.01 HD and r2-0.239; P=0.02 HDF). 
Conclusions: HD and HDF patients present with same baseline vascular calcification 
risk values pre-dialysis. Calcification propensity is significantly improved during both HD 
and HDF. T50 might be a useful guide to optimize renal replacement strategy to improve 
the individual calcification risk in dialysis patients.
Funding: Pharmaceutical Company Support - Unrestricted Grand from Fresenius 
Medical Care
TH-PO906
Association of Circulating Biomarkers with Vascular Stiffness and 
Coronary Artery Calcium in Incident Hemodialysis  Esther D. Kim,1 Stephen 
M. Sozio,2 Bernard G. Jaar,2 Lucy A. Meoni,2 Michelle M. Estrella,2 Rulan S. 
Parekh.1,2  1Univ of Toronto, Canada; 2Johns Hopkins Univ.
Background: Vascular calcification and stiffness are associated with higher mortality 
in hemodialysis. Studies examining the role of circulating biomarkers – specifically, FGF23, 
desphospho-uncarboxylated matrix Gla protein (dpucMGP), Fetuin A, osteoprotegerin 
(OPG), and C-reactive protein (CRP) – in vascular calcification have reported contradictory 
findings, and the independent association of the biomarkers remains inconclusive.
Methods: In 392 incident hemodialysis patients in the Predictors of Arrhythmic and 
Cardiovascular Risk End Stage Renal Disease (PACE) study, we examined the associations 
of baseline FGF23, dpucMGP, Fetuin A, OPG, and CRP with total coronary calcium score 
(Agatston) at baseline and vascular stiffness (pulse wave velocity [PWV]) at baseline and 
over 4 study visits. Baseline associations were determined using linear regression and 
repeated measures over visits were examined using mixed-effects models.
Results: At baseline, higher OPG was associated with increased odds of having a high 
coronary calcium score (>257), independent of other biomarkers (OR=1.11, 95%CI: 1.06, 
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1.16). The remaining biomarkers were not associated with high coronary calcium. Higher 
OPG was associated with higher PWV, and higher FGF23 was associated with lower PWV 
after adjusting for demographic factors, body mass index, comorbidity index, calcium 
phosphorus product, systolic blood pressure, and albumin.
Adjusted association with PWV β (95% CI)
OPG (1 pmol/l) 0.10 (0.02, 0.19)*†
FGF23 (100 RU/ml) -0.10 (-0.18, -0.02)*
dpucMGP (1-log pm) 0.07 (-0.38, 0.53)
Fetuin A (1 g/l) -0.79 (-2.77, 1.19)
CRP (1-log ȝg/ml) 0.02 (-0.27, 0.30)
*P<0.05
Adjusted for all biomarkers
OPG and FGF23 remained associated with PWV over follow-up and after additionally 
adjusting for all biomarkers (β=0.08, 95%CI: 0.01, 0.15 and β=-0.07, 95%CI: -0.13, -0.01).
Conclusions: Several vascular and phosphate biomarkers are associated with vascular 
calcification at baseline and/or stiffness longitudinally in incident dialysis patients. Further 
studies assessing interventions on these biomarkers are warranted.
Funding: NIDDK Support
TH-PO907
Association of Arterial Stiffness with Cognitive Impairment in Incident 
Hemodialysis  Esther D. Kim,1 Lucy A. Meoni,2 Bernard G. Jaar,2 Tariq Shafi,2 
Michelle M. Estrella,2 Rulan S. Parekh,1,2 Stephen M. Sozio.2  1Univ of Toronto, 
Canada; 2Johns Hopkins Univ.
Background: Cognitive impairment is common in hemodialysis and places a significant 
burden on patients and healthcare system. Though vascular stiffness is implicated in the 
pathogenesis of cerebral microvascular disease, few have examined the relationship between 
arterial stiffness and cognitive function in dialysis patients.
Methods: This study included 390 incident hemodialysis patients enrolled in the 
Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) 
study. Arterial stiffness was measured using aortic pulse wave velocity (PWV) and 
augmentation index (AIx). Cognitive function was measured using time to complete Trail 
making tests A and B (TMT A and TMT B) and the modified mini-mental state exam 
(3MS) score. Log-linear, Tobit, and logistic regression models were used to examine the 
baseline association of PWV with TMT A, TMT B, and 3MS, respectively. Changes in 
the scores over visits and mixed-effect models were used to examine association over 
time at 1 year follow-up.
Results: At baseline, higher PWV was associated with longer time to complete TMT A 
after adjusting for demographic factors, reading comprehension score, comorbidity index, 
systolic blood pressure, and atrial fibrillation (%TMT A=3.12, 95% CI: 0.37-5.87). In the 
repeated measures analysis, higher PWV was still associated with longer TMT A time 
(%TMT A=2.05, 95% CI: 0.00-4.11), and higher AIx was associated with longer TMT B 
time (β=0.80, 95% CI: 0.01-1.58).
Measures of arterial stiffness were not associated with 3MS.
Conclusions: Vascular stiffness isassociated with longer time to complete TMT A and 
TMT B suggesting that arterial stiffness may lead to subclinical cerebrovascular events and 
decline in executive function among incident hemodialysis patients.
Funding: NIDDK Support
TH-PO908
Close Relationship Between Vascular Endothelial Function and Serum 
Uric Acid Level in Hemodialysis Patients  Makoto Harada,1 Wataru Tsukada,2 
Yosuke Yamada,1 Akinori Yamaguchi,1 Koji Hashimoto,1 Makoto Higuchi,1 Yuji 
Kamijo.1  1Dept of Nephrology, Shinshu Univ School of Medicine, Matsumoto, 
Nagano, Japan; 2Dept of Nephrology and Urology, Ueda Kidney Clinic, Ueda, 
Nagano, Japan.
Background: Vascular endothelial function (VEF) impairment is often detected in 
hemodialysis (HD) patients and has been associated with atherosclerosis and cardiovascular 
disease (CVD). Although avoidance of VEF impairment is therefore desirable in preventing 
such complications, the precise factors that influence VEF remain unknown. The present 
study evaluated VEF for associating factors in HD patients.
Methods: We enrolled 48 patients undergoing maintenance HD at Ueda Kidney Clinic 
in Japan. No patient had a history of CVD. Reactive hyperemia index (RHI) as evaluated 
by Endo-PAT (Itamar Medical, Ltd., Caesarea, Israel) was used to asses VEF, whereby a 
higher RHI was indicative of better function. We also assessed for correlations between 
the natural logarithm of RHI (LnRHI) and clinical parameters.
Results: The median age of our patients was 67 years, the male-to-female ratio was 
approximately 2:1, and median LnRHI was low at 0.36. Analysis of Spearman’s rank 
correlation coefficient revealed a significant positive correlation between serum uric acid 
level (sUA) and LnRHI (rs=0.372, p=0.009). As sUA is influenced by dialysis efficiency 
and dietary intake, we also performed multivariable linear regression analysis adjusted by 
age, body mass index, dialysis efficiency by Kt/V, and normalized protein catabolic rate, 
and observed that sUA was significantly related to LnRHI (B=0.042, 95% CI: 0.007-0.078, 
β=0.396, p=0.021).
Conclusions: The current study suggests that VEF is closely associated with sUA in 
HD patients. Although the precise mechanism is unknown, a marked decrease in sUA might 
be correlated with VEF impairment and should be avoided in individuals undergoing HD.
TH-PO909
Ambulatory Arterial Stiffness Index: An Early Marker of Cardiovascular 
Disease in Young Hemodialysis Patients  Alcia D. Edwards- Richards, Chryso 
P. Katsoufis, Wacharee Seeherunvong, Nao Sasaki, Marissa J. Defreitas, Gaston 
E. Zilleruelo, Michael Freundlich, Carolyn L. Abitbol.  Pediatric Nephrology & 
Cardiology, Univ of Miami/ Holtz Children¶s Hospital, Miami, FL.
Background: Cardiovascular disease (CVD)is the leading cause of death in pediatric 
hemodialysis (HD) patients. Ambulatory arterial stiffness index (AASI) may be an earlier 
measure of vascular compliance in young patients than pulse pressure (PP). Our objective 
was to evaluate AASI as a marker of increased vascular stiffness in young HD patients and 
to compare it with other non-invasive indicators of CVD risk.
Methods: Retrospective review of 24-hour ambulatory blood pressure monitoring 
(ABPM) was performed in 11 pediatric patients on chronic HD(16±3.6yrs) and dialysis 
vintage of 32±18 months.AASI was calculated as 1-regression slope of the diastolic over 
systolic BP. Echocardiogram and bilateral carotid artery ultrasounds were performed to 
assess left ventricular mass index(LVMI)and carotid intimal medial thickness (cIMT).
Carotid artery stiffness indices included distensibility coefficient(DC), stiffness index-β 
(SI-β) and PP. These were compared with reference values for healthy pediatric controls.
Results: AASI was significantly increased in HD patients compared to controls 
(0.42±0.1 versus 0.20±0.2;p=0.01).When matched to controls with similar BP’s and PP’s, 
the AASI detected increased vascular stiffness independent of PP. cIMT,LVMI, and DC 
were also significantly increased in HD patients(p<0.01). 
Echocardiography & Carotid Ultrasound & 24-Hr ABPM 
Variable HD Controls p-Values 
cIMT (mm) 0.60±0.1 0.38±0.1 0.01 
LVMI (g/m2.7) 40±9 34±11 0.01 
DC (kPa-1103) 43±13 53±17 0.04
Stiffness Indexβ 4.2±10 5.3±3 0.13
PP (mmHg)
49±10 40±7 <0.05
24-hr PP (mmHg) 43±9 43±5 1.00 
AASI 0.42±0.1 0.20±0.2 0.01 
Conclusions: Young HD patients demonstrate early surrogate markers of CVD 
including increased LVMI, cIMT and decreased vascular compliance. Increased AASI 
detected vascular stiffness that was independent of BP’s and PP’s. AASI may be an early non-
invasive marker of vascular disease in young HD patients that merits further investigation.
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TH-PO910
Endovascular Renal Denervation Ameliorates Pathological Left Ventricular 
Dilatation in Dialysis Patients  Neil A. Hoye,1 J. Christopher Baldi,1 David L. 
Jardine,2 John B.W. Schollum,1 Gerard T. Wilkins,1 Luke C. Wilson,1 Robert J. 
Walker.1  1Dunedin School of Medicine, Univ of Otago; 2Christchurch School 
of Medicine and Health Sciences, Univ of Otago.
Background: Endovascular renal denervation (RDN) ameliorates left ventricular 
hypertrophy and improves contractile function in resistant hypertension. Its cardiac effects 
on a dialysis population are unknown. We hypothesized RDN would improve blood pressure 
(BP) control and sympathetic overload, resulting in improved ventricular function.
Methods: Nine dialysis patients with uncontrolled office BP (>140/90mmHg despite 
two or more agents at maximal tolerated dosages) were recruited into this feasibility 
study. Office and ambulatory BP monitoring (ABPM) were performed at baseline, one and 
three months post RDN, along with supine muscle sympathetic nerve activity (MSNA). 
Echocardiography was performed at baseline and three months. Bilateral RDN was 
undertaken with an EnligHTNTM catheter.
Results: 
Baseline 1 Month 3 Months P value
Office Systolic BP (mmHg) 179±28 156±24 152±25 <0.05
Office Diastolic BP (mmHg) 90±17 76±13 82±12 0.137
Mean Systolic ABPM (mmHg) 173±19 173±23 166±24 0.544
Mean Diastolic ABPM (mmHg) 92±11 89±13 88±11 0.906
MSNA Burst Frequency (bursts/
min) 59±12 59±15 59±13 0.872
LVIDd (mm) 54±6 50±7 <0.05
LV EDV (mL) 168±43 150±42 0.391
LV ESV (mL) 102±41 80±29 0.397
LV EF (%) 41±14 47±11 0.801
LVd mass/BSA (g/m2) 97±16 91±9 0.490
Diastolic Dysfunction Grade 2.0±0.7 1.1±0.4 0.063
Similar to previous, office systolic BP reduced and the effect on ABPM was attenuated. 
MSNA did not change, a novel finding. Despite lack of change in MSNA, LVIDd reduced 
with an improving trend in diastolic dysfunction, another novel finding. There was no 
correlation between change in office systolic BP and ventricular dilatation (R2=0.255) or 
dysfunction (R2=0.034), suggesting BP-independent effects.
Conclusions: RDN in dialysis patients improves office systolic BP and leads to a 
BP-independent improvement in ventricular dilatation and probably dysfunction. Further 
controlled studies are warranted in this population.
TH-PO911
Effects of Music and Exercise during Hemodialysis on the Cardiac 
Autonomic Nervous System Activity  Maria Mitsiou,1 Evangelia J. Kouidi,1 
Vassilios Liakopoulos,2 Asterios P. Deligiannis.1  1Laboratory of Sports Medicine, 
Aristotle Univ of Thessaloniki, Thessaloniki, Greece; 2Renal Unit, 1st Dept of 
Internal Medicine, Aristotle Univ of Thessaloniki, Thessaloniki, Greece.
Background: Cardiac autonomic nervous system (CANS) dysfunction is a common 
complication in Chronic Kidney Disease (CKD), linked with increased cardiovascular 
morbidity and mortality. It is known that exercise training during hemodialysis (HD) 
improves physical function and quality of life in HD patients. Exercise training can suppress 
the sympathetic over-excitation, restoring the sympathetic (SNS) to parasympathetic nervous 
system (PNS) balance. Music can positively affect CANS activity. The combination of music 
and physical training has never been used in CKD. The aim of this study was to investigate 
the effectiveness of a 6-month, music and physical training combined protocol during HD.
Methods: Heart rate variability (HRV) data were collected from 40 free of any systemic 
disease HD patients (age 50±14.7 yrs). Patients were randomly assigned to four equally 
numbered [n=10] groups, employing a joint music and exercise training program for Group 
A, a sole exercise training program for Group B, a sole music program for Group C and 
none of the above-mentioned interventions for Group D. At entry and at the end of the study 
all patients underwent a 6-minute walking test (6MWT) and ambulatory 24-hour Holter 
monitoring for time- and frequency- domain HRV calculation. The HRV indices obtained 
were: mean heart rate (HR); standard deviation of NN intervals (SDNN); root mean square 
of successive differences (RMSSD); proportion of NN50 divided by total number of NNs 
(pNN50) and very low frequency (VLF).
Results: All indices were significantly better for Group A: 6MWT [F(3,36)=13.095, 
p=0.000], HR[F(3,36)= 1.910, p=0.145]; SDNN [F(3,36)=11.671, p=0.000]; RMSSD 
[F(3,36)=12.395, p=0.000]; pNN50 [F(3,36)=45.752, p=0.000]; and VLF [F(3,36)=3.141, 
p=0.037].
Conclusions: Musical auditory stimulation when jointly used with exercise training 
during HD has the strongest influence on CANS activity, improving the dynamic interaction 
between the SNS and PNS. These favorable changes may positively affect cardiovascular 
morbidity and mortality.
TH-PO912
Temporal Loss of Bone Mineral Density Is Associated with Cardiovascular 
Diseases in Japanese Patients Starting Renal Replacement Therapy 
Sawako Kato,1 Shoichi Maruyama,1 Bengt Lindholm,2 Yukio Yuzawa,3 Yoshinari 
Tsuruta,4 Seiichi Matsuo.1  1Nephrology, Nagoya Univ Graduate School of 
Medicine, Nagoya, Japan; 2Baxter Novum & Renal Medicine Karolinska Inst, 
Stockholm, Sweden; 3Nephrology, Fujita Health Univ School of Medicine, 
Toyoake, Japan; 4Meiyo Clinic, Toyohashi, Japan.
Background: Atherosclerosis, vascular calcification and alterations of bone 
metabolism are common aging disorders, which may be biologically linked via bone-
vascular interactions. However, clinical studies on associations of temporal bone loss with 
cardiovascular disease (CVD) in dialysis patients are limited.
Methods: Seventy-six incident Japanese dialysis patients (46 males, age 60 ± 10 
years) were enrolled and followed for a median of 3.8 years (range 1-5.8 years). Bone 
mineral density (BMD) of the lumbar spine was measured by dual X-ray absorptiometry 
at baseline and after 1 year.
Results: Baseline BMD, median value 1.05 (0.67-1.56) g/cm2, negatively correlated 
to age (rho = -0.28, P = 0.015) and iPTH (rho = -0.14, P = 0.0002). When dividing patients 
into two groups according to delta BMD (defined as baseline - 1 year), those with high delta 
BMD had an increased mortality risk (Log rank 6.36, P = 0.012) and time from dialysis 
initiation to the first CVD event appeared, although not significant, shorter in patients 
with high delta BMD (Log rank 2.81, P = 0.094). Patients with high delta BMD had a 
significantly increased relative risk (RR; Cox hazard model) of mortality (10.9, 95% CI; 
1.34-250.6) even after adjustments for age, gender, diabetes and smoking,compared with 
those with low delta BMD. RR of the first CVD event was 5.52 (95% CI; 1.15-7.83) with 
adjustment for age and gender.
Conclusions: Progressive loss of BMD associated with an increasing risk of CVD and 
mortality. Whereas in end-stage renal disease patients, BMD may have limited value as 
predictor of a fracture risk, temporal changes of BMD, potentially reflecting bone-vascular 
interactions, may be useful as a marker of a CVD risk.
Funding: Government Support - Non-U.S.
TH-PO913
First in Man: Reduction of Inflammation with Medium Cut-Off (MCO) 
Membranes  Daniel Zickler,1 Ralf Schindler,1 Markus Storr,3 Kevin Willy,1 
Bogusz Trojanowicz,2 Peter Martus,4 Christof Ulrich,2 Kristin Liehr,5 Christian 
Henning,5 Torsten Böhler,3 Marcus A. Glomb,5 Roman Fiedler,2 Matthias 
Girndt.2  1Dept of Nephrology and Internal Intensive Care Medicine, Charité 
Univ Medicine, Berlin, Germany; 2Dept of Internal Medicine II, Martin-Luther-
Univ, Halle, Germany; 3Research & Development, Gambro Dialysatoren 
GmbH, Hechingen, Germany; 4Inst for Epidemiology and Applied Biometry, 
Eberhard-Karls-Univ, Tübingen; 5Inst for Chemistry / Food Chemistry, Martin-
Luther-Univ, Halle.
Background: High mortality in dialysis patients may be related to reduced clearance 
of cytokines with conventional dialysis membranes. Attempts to provide a better clearance 
with high cut-off membranes also leads to albumin loss. A new Medium-Cutoff membrane 
with better permeability for molecules up to 45 kDa but with limited permeability for 
albumin was tested clinically for the first time.
Methods: 50 patients were dialyzed with MCO and conventional high-flux (HF) 
membranes for four weeks following a randomized cross-over design. After the second 
phase, another 12-week-period was conducted to test for long-term effects. Serum samples 
were tested for inflammatory effects and cytokine concentrations. Support was granted by 
the German Federal Ministry of Education and Research (FKZ 13N11796-99).
Results: The primary end point mRNA content of TNF-alpha in leucocytes was 
reduced to a higher degree and significantly better after 4 weeks on MCO compared to HF 
membrane (p<0.001). Interleukin-6 mRNA was markedly reduced with MCO (p<0.001). 
After a significant drop after four weeks of MCO dialysis, albumin concentrations stabilized 
after 12 weeks.
Conclusions: MCO membranes modulate inflammation in dialysis patients. Albumin 
concentrations stabilize after an initial drop. These results encourage further investigations 
with longer treatment periods and clinically relevant endpoints.
Funding: Pharmaceutical Company Support - Gambro, Government Support - Non-
U.S.
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TH-PO914
Vitamin D and Cardiac Autonomic Tone in End-Stage Kidney Disease: A 
Blinded, Randomized Controlled Trial  Sofia B. Ahmed,1 Michelle C. Mann,1 
Brenda Hemmelgarn,1 David A. Hanley,1 Tanvir Chowdhury Turin,1 Jennifer 
M. MacRae,1 David C. Wheeler,2 Sharanya Ramesh,1 Darlene Y. Sola,1 Derek 
Exner.1  1Univ of Calgary, Canada; 2Univ College London, United Kingdom.
Background: Importance: End-stage kidney disease (ESKD) patients are at high 
cardiovascular (CV) risk. Vitamin D deficiency is associated depressed heart rate variability 
(HRV), a risk factor for CV death. Both vitamin D deficiency and depressed HRV are 
highly prevalent in ESKD.
Methods: Objective: To determine the effects of activated vitamin D (conventional) 
compared to activated and nutritional vitamin D (intensive) on HRV (low to high frequency 
spectral ratio; LF:HF) in patients with ESKD on hemodialysis (HD). Design: 2x2 crossover, 
blinded, randomized controlled trial in outpatient HD units. Fifty-six patients were 
randomized 1:1 to begin either conventional (0.25mcg alfacalcidiol and placebo 3 times/
week) or intensive vitamin D therapy (0.25mcg alfacalcidiol 3 times/week and 50000IU 
ergocalciferol weekly) for 6 weeks. Main Outcomes: HRV is a surrogate index of cardiac 
autonomic nerve function and independently predicts CV mortality. The primary outcome 
was the change in LF:HF from the 1st to 6th week HD session. Secondary endpoints 
included individual changes in LF and HF, parameters of mineral metabolism and renin 
angiotensin system (RAS) activity.
Results: There was no difference in LF:HF from baseline to 6 weeks for either vitamin 
D treatment (conventional p=0.9; intensive p=0.07). There were no significant changes in 
any other measure of HRV, mineral metabolism or RAS activity. On exploratory subgroup 
analysis, participants who remained vitamin D deficient (25-hydroxyvitamin D<50nmol/L) 
after treatment had a significant increase in LF:HF (conventional: n=13, p<0.001 vs. 
insufficient and sufficient groups; intensive: n=8, p<0.001 vs. sufficient group).
Conclusions: Six weeks of treatment with conventional or intensive vitamin D did not 
alter LF:HF in ESKD patients. However, improved LF:HF was observed in the vitamin 
D-deficient subgroup. This finding may translate into decreased CV risk and should be 
considered hypothesis-generating and deserving of further study. Trial Registration: 
ClinicalTrials.gov NCT01774812.
Funding: Private Foundation Support
TH-PO915
The Validity of Left Ventricular Mass as a Surrogate Endpoint for Mortality 
Outcomes in Chronic Kidney Disease  Sunil V. Badve,1,2 Suetonia Palmer,3 
Giovanni F.M. Strippoli,4 Matthew A. Roberts,5 Armando Teixeira-Pinto,11 Neil 
Boudville,6 Alan Cass,7 Carmel M. Hawley,1,2 Swapnil Hiremath,8 Elaine M. 
Pascoe,1 Vlado Perkovic,9 Gillian A. Whalley,10 Jonathan C. Craig,11 David W. 
Johnson.1,2  1Univ of Queensland; 2Princess Alexandra Hospital; 3Univ of Otago; 
4Univ of Bari; 5Monash Univ; 6Univ of Western Australia; 7Menzies School of 
Health Research; 8Univ of Ottawa; 9The George Inst for Global Health; 10Unitec 
Inst of Technology; 11Univ of Sydney.
Background: Left ventricular mass (LVM) is increasingly used as a surrogate endpoint 
in trials involving chronic kidney disease (CKD) patients, as intervention-induced reductions 
in LVM are assumed to lower cardiovascular (CV) risk.
Methods: The aim of this systematic review was to determine the validity of LVM 
as a surrogate endpoint for all-cause and CV mortality in CKD. Randomized controlled 
trials evaluating pharmacological and non-pharmacological interventions with follow-up 
³3 months were included. The outcomes of interest were LVM change from baseline to last 
measurement and all-cause and CV mortality. Standardized mean differences (SMD) in 
LVM change and relative risk of mortality were estimated using random-effects models. 
Correlations between LVM change and mortality endpoints were summerized across all 
interventions using a bivariate random-effects Bayesian model together with 95% credible 
intervals (CrI).
Results: Seventy trials (6420 participants) were eligible. Among 23 interventions, only 
3 significantly reduced LVM [erythropoiesis-stimulating agents (SMD -0.13, 95%CI -0.23 
to -0.03), renin-angiotensin-aldosterone-system inhibitors (SMD -0.28, 95%CI -0.44 to 
-0.11) and isosorbide mononitrate (SMD -0.43, 95%CI -0.72 to -0.14)]. There were weak 
and imprecise associations between LVM change and all-cause mortality (30 trials, 4749 
participants, correlation coefficient [r] 0.28, 95%CrI -0.15 to 0.60) and CV mortality (13 
trials, 2327 participants, r 0.22, 95%CrI -0.60 to 0.75).
Conclusions: In CKD, it is uncertain whether an intervention-induced LVM change 
correlates with reduced mortality. Evidence for LVM as a valid surrogate endpoint in CKD 
is currently lacking.
TH-PO916
Non-Invasive Left Ventricular End-Diastolic Pressure (LVEDP) 
Measurement in Hemodialysis Patients: A Pilot Study  Tariq Shafi, Bernard 
G. Jaar, Luis F. Gimenez, Alison G. Abraham, Chloe F. Knight, Naya El Hage, 
Paul J. Scheel, Josef Coresh, Harry A. Silber.  Johns Hopkins Univ.
Background: Optimal volume status in dialysis patients is difficult to assess. The 
Valsalva maneuver is recognized as an bedside marker of central volume overload. A novel 
handheld device that combines finger photoplethysmography with Valsalva maneuver can 
reliably estimate LVEDP (normal: <12mmHg). (Silber H. PMID: 22389389). The goal 
of our pilot study is to determine the role of this non-invasive LVEDP measurement in 
managing volume in hemodialysis patients.
Methods: The LVEDP-Guided Volume Management Study is being conducted at 2 
dialysis units in Baltimore. Baseline data collected includes demographics, medical history, 
KDQOL-36, NYHA dyspnea scale, intra/post dialysis symptoms, predialysis metrics 
[LVEDP, bioimpedance, blood pressure (BP)] and echocardiogram.  We assessed the 
cross-sectional association of predialysis LVEDP with dyspnea symptoms and intradialytic 
hypotension (IDH, defined as ³20mmHg drop in systolic BP + nursing interventions).
Results: In the first 28 participants (mean age 56 years, 71% male, 82% black), median 
(25th, 75th percentiles) for predialysis LVEDP was 14 mmHg (12, 19), interdialytic weight 
gain (IDWG) was 1.7 kg (0.9, 2.9) and systolic BP was 150 mmHg (133, 164). LVEDP 
was significantly higher in patients with dyspnea vs. those without. (Mean, 19.9 vs. 14.6; 
p=0.03). IDH occurred in 5 (18%) patients and all had LVEDP £14 mmHg (Table). The 
unadjusted odds ratio for IDH per SD decrease in LVEDP was 4.37 (p=0.08). There was 
no significant association between IDH and predialysis systolic BP or IDWG.
Table: Associations of IDH IDH
No
(n=23)
Yes
(n=5) p
Predialysis Factors Mean (SD) Mean (SD)
LVEDP 16.2 (4.7) 11.8 (2.8) 0.05
Systolic BP 153.8 (22.3) 135 (15.5) 0.10
Interdialytic weight gain 1.97 (1.5) 1.92 (0.8) 0.93
Conclusions: Non-invasive LVEDP measurements can identify hemodialysis patients 
with volume overload associated with symptoms (high LVEDP) and patients at risk for 
IDH (low LVEDP). Our ongoing study may help confirm these initial findings and define 
the role of this measurement for volume management in dialysis patients.
TH-PO917
E/e’ Calculated by Tissue Doppler Echocardiography and Cardiovascular 
Outcome in Incident Dialysis Patients  Jongha Park,1 Jongmin Lee,1 Kyung 
sun Park,2 Sung Hyun Son,3 Shin-Jae Kim,1 Jong Soo Lee,1 Hyun Chul Chung.1 
1Ulsan Univ Hospital, Ulsan, Republic of Korea; 2Dongkang Medical Center, 
Ulsan, Republic of Korea; 3BHS Han-Seo Hospital, Busan, Republic of Korea.
Background: The ratio of early diastolic peak mitral flow velocity (E) to early mitral 
annulus velocity (e¶), called (/e¶ is a less volume dependent, non-invasive index to estimate 
left ventricular (LV) filling pressure. However, the prognostic value of (/e¶ has not been 
evaluated sufficiently in patients with end-stage renal disease (ESRD).
Methods: The patients who newly started maintenance dialysis therapy between 
2009 and 2012, had survived for at least 3 months after dialysis initiation, and had (/e¶ 
data, were analyzed. (/e¶ was calculated by pulse and tissue Doppler echocardiography. 
Cardiovascular (CV) composite endpoint comprised hospitalization for heart failure (HF), 
acute coronary disease (ACD) requiring intervention, ventricular arrhythmia, cerebral 
infarction or hemorrhage, and CV death. The patients were followed up until 2013.
Results: A total of 206 patients were analyzed (mean age 55.0±13.7 years old, female 
51.5%). Median follow-up duration was 29.2 months (range 3.1-61.3). Forty-two CV events 
occurred during follow-up (15 HF, 17 ACD, 1 cerebral infarction, and 9 CV deaths). Mean 
(/e¶ was 13.6±5.4 (range 5-39). After adjusting age, sex, diabetes, mean arterial pressure, 
LV ejection fraction, hemoglobin, serum albumin, C-reactive protein and volume status, 
one unit increase in (/e¶ ratio was associated with 7% increase in the risk of CV composite 
endpoint (hazard ratio 1.07, 95% confidence interval 1.02-1.13, p=0.009). Adjusted hazard 
ratio linearly increased above 15 of (/e¶ in Cox regression with cubic splines. 
Conclusions: A higher (/e¶ ratio, reflecting high LV filling pressure which is the 
main physiological finding of diastolic HF, may be associated with a higher CV risk in 
patients with ESRD.
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TH-PO918
Tallium-201 Washout Rate of Single Photon Emission Computed 
Tomographic Myocardial Perfusion with Pharmacologic Stress as a 
Predictor of Mortality in CKD Patients Undergoing Hemodialysis: An 
Observational, Follow-Up Study  Toshihide Hayashi, Nobuhiko Joki, Masaki 
Iwasaki, Ai Matsukane, Takasuke Asakawa, Yuri Tanaka, Hiroki Hase.  Div of 
Nephrology, Toho Univ Ohashi Medical Center, Tokyo, Japan.
Background: Thallium-201 (201Tl) washout rate of single photon emission computed 
tomography (SPECT) has been reported to correlate with coronary flow reserve which is 
an index of myocardial microcirculation and be useful to detect coronary artery disease 
and evaluate the severity. However, the evidence for its use in chronic kidney disease 
(CKD) has been lacking, and the association between 201Tl washout rate and mortality is 
unknown. Therefore, a hospital-based, prospective, cohort study was conducted to evaluate 
the predictive ability of 201Tl washout rate for mortality in CKD patients undergoing 
hemodialysis.
Methods: A total of 156 patients who had been started on maintenance hemodialysis 
undergoing pharmacologic stress thallium-201 SPECT within 1 year, 107 men and 49 
women, with a median age of 67 years, were studied. The endpoint was defined as all-cause 
death. The Cox proportional hazards model was used to calculate hazard ratios (HR) and 
95 % confidence intervals (CI).
Results: During the mean follow-up period of 3.2 ± 2.4 years, 30 (19.2 %) deaths 
occurred. The median (interquartile range) of 201Tl washout rate was 45.1 (37.4 - 50.8) 
%. Cumulative survival rates at 5 years after starting dialysis, with 201Tl washout rate 
levels above and below the median, were 76.7 % and 63.8 % (p = 0.992, log-rank test), 
respectively. Overall, the multivariate Cox regression analysis revealed that 201Tl washout 
rate remained an independent predictor of death after adjusting by confounding variables 
(HR 0.95, 95 % CI 0.90 to 0.99). 
Conclusions: Among CKD patients undergoing hemodialysis, 201Tl washout rate seems 
to be useful for predicting death.
TH-PO919
Research Cardiac Magnetic Resonance Imaging in Chronic Kidney 
Disease – Incidence, Significance and Implications of Unexpected Incidental 
Findings  Elaine Rutherford,1 Jonathan Weir-mccall,1 Rajan K. Patel,2 John 
Graeme Houston,1 Giles Roditi,2 Allan Struthers,1 Alan G. Jardine,2 Patrick B. 
Mark.2  1Div of Cardiovascular & Diabetes Medicine, Univ of Dundee; 2Inst of 
Cardiovascular & Medical Sciences, Univ of Glasgow.
Background: Left ventricular (LV) mass on cardiac magnetic resonance imaging 
(CMR) is a common end point of clinical trials in nephrology. Incidental findings (IF) on 
research images have ethical & clinical implications. We retrospectively investigated the 
incidence of IF in research CMR & reviewed their impact on patient care.
Methods: 161 CKD5 patients underwent CMR for a 2002-2006 research study into 
transplant assessment. Images were used to assess LV mass & function. In our study a 
radiologist reviewed the scans for IF. Abnormalities in mass, perfusion or function were not 
considered IF. The clinical significance of every IF was determined by patient record review.
Results: There were 150 IF. 59% of patients had one or more IF. 68% were extra-
cardiac, 56% were new diagnoses.
Lung/Medi-
astinal
Pleural 
Effusion
GI 
Tract
Cysts (Not 
PKD) Other Total
Number of IF 11 15 19 50 7 102
New Diagnosis 9 4 12 18 7 50
Should have 
changed 
management but 
clinical course 
not altered
6 3 1 1 3 14
Identification 
may have altered 
clinical course
1 1 3 0 0 5
13% were gastrointestinal.
16 IF were suspicious of malignancy. 17 unidentified IF would have changed patient 
management if known, but a review of patient records showed these IF had no later clinical 
impact. In 6 cases earlier identification of an important IF may have improved quality of 
life or survival.
Conclusions: Without radiology support clinically important IF may be missed on 
CMR. A suitably trained radiologist should prospectively review all CKD CMR research 
studies & obtained images. Patients undergoing CMR in trials should be counselled about 
the frequency & implications of possible IF.
TH-PO920
A Significance of Cardiothoracic Ratio for Mortality in Hemodialysis 
Patients: The Q-Cohort Study  Ryusuke Yotsueda,1 Masahiro Eriguchi,1 
Shigeru Tanaka,1 Masatomo Taniguchi,1 Hideki N. Hirakata,3 Kazuhiko 
Tsuruya,1,2 Takanari Kitazono.1  1Dept of Medicine and Clinical Science, 
Graduate School of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 2Dept of 
Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical 
Sciences, Kyushu Univ, Fukuoka, Japan; 3Nephrology and Dialysis Center, 
Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Background: Cardiothoracic ratio (CTR) of chest X–ray is commonly used to 
determine the volume status in hemodialysis (HD) patients. Thus, the present study was 
conducted to evaluate the significance of CTR in terms of longitudinal prognosis of HD 
patients.
Methods: A total of 3,437 Japanese HD patients aged ³18 years were followed for 4 
years. Patients were divided into four groups according to quartiles of CTR levels by sex. 
Risk estimates were calculated by a Cox proportional hazards model, adjusting for potential 
confounders. We investigated stratified analysis by sex, age, etiology of end–stage kidney 
disease, history of major adverse cardiac events (MACE) and blood pressure for subanalysis.
Results: The median values (interquartile range) of CTR were 0.49 (0.46–0.53) in male 
and 0.52 (0.48–0.56) in female. During the follow–up period, 564 patients (16%) died from 
any causes and the 4 years survival rate decreased significantly with higher CTR levels (p for 
trend <0.001). Compared with the lowest CTR quartile, the multivariable–adjusted hazard 
ratios (HRs) for all–cause mortality were 0.89 (95% confidence intervals, 0.66–1.21), 1.41 
(1.07–1.86), and 1.52 (1.17–2.00) in subjects with low–intermediate, high–intermediate and 
highest quartile, respectively. Furthermore, the combination of higher CTR levels and history 
of MACE or lower blood pressure before HD (systolic blood pressure <140 mmHg and 
diastolic blood pressure <90 mmHg) synergistically increased the risk of all–cause mortality.
Conclusions: A higher CTR level is closely related to increased mortality in HD 
patients. This association is more remarkable in patients with history of MACE or without 
high blood pressure.
TH-PO921
High Convection Volumes in Postdilution Online Hemodiafiltration 
(HDF) Are Feasible in the Vast Majority of ESKD Patients 
Camiel LM de Roij van Zuijdewijn,1 Isabelle Chapdelaine,1 Menso Jan Nubé,1 
Peter J. Blankestijn,2 Constantijn Konings,3 Tonnis K. Kremer Hovinga,4 Neelke 
C. Van Der Weerd,5 Pieter M. Ter Wee,1 Muriel P. Grooteman.1  1Nephrology, 
VU Univ Medical Center, Amsterdam, Netherlands; 2Nephrology, Univ Medical 
Center Utrecht, Utrecht, Netherlands; 3Internal Medicine, Catharina Hospital, 
Eindhoven, Netherlands; 4Internal Medicine, Martini Hospital, Groningen, 
Netherlands; 5Nephrology, Academic Medical Center, Amsterdam, Netherlands.
Background: Available evidence suggests a survival benefit for patients treated with 
high volume postdilution HDF (hvHDF) when compared to HD. Since these studies are 
limited by an observational design, we investigated whether hvHDF (>22L/session) is 
feasible in the majority of patients (>75%).
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Methods: A prospective, multicenter study was performed (NCT01877499). HD(F) 
patients (³18y) were eligible if treated 3x/week for ≥6 weeks. Non-participating eligible 
patients formed a reference group to examine the representativeness of the study group. 
Treatment-related determinants of the convection volume were optimized in a stepwise 
fashion (treatment time [TT] up to 4 hours, blood flow rate [BFR] up to 400 mL/min and 
filtration fraction [FF] up to 33%). At the end of this protocol (T0) and 4 (T4) and 8 (T8) 
weeks thereafter, the convection volume was determined.
Results: Baseline characteristics were comparable in participants (n=86) and references 
(n=58). At T0 and at T4, 79/86 (92%) and 68/86 (79%) patients achieved hvHDF (mean 
26.9±3.56 and 26.3±3.36L/session, resp). Hereafter, 2 patients died and 1 was transplanted. 
83 patients remained; 66 (80%) reached hvHDF (mean 25.9±3.53L/session, fig 1). Study 
discontinuation (n=9), TT <4h (n=4) or BFR £300 mL/min (n=4) caused a convection 
volume <22L/session. 
Conclusions: hvHDF is feasible in the vast majority of ESKD patients. As TT remained 
virtually unaltered, these findings were mainly due to a higher BFR and FF.
Funding: Pharmaceutical Company Support - Fresenius Medical Care
TH-PO922
Physical Activity Among Patients with End-Stage Renal Disease: Use of 
the Exercise Vital Sign  Shayna L. Henry,1 Yi-Lin Wu,1 John J. Sim,2 Michael 
K. Gould.1  1Dept of Research & Evaluation, Kaiser Permanente Southern 
California, Pasadena, CA; 2Dept of Nephrology, Kaiser Permanente Southern 
California Los Angeles Medical Center, Los Angeles, CA.
Background: Exercise has been shown to improve physical functioning among ESRD 
patients. However, ESRD patients report exceedingly low levels of physical activity (PA) 
with only 13-34% engaging in recommended levels of PA. Although ESRD is characterized 
by substantial barriers to PA, low PA puts patients at risk for serious complications and higher 
mortality. Within Kaiser Permanente (KP), patients are administered the Exercise Vital Sign 
(EVS) – self-reported weekly minutes of PA – during each office encounter. The EVS has 
been validated in multiple KP regions, with roughly one-third each of the membership 
reporting no, insufficient, and sufficient PA, or ³150 minutes exercise/week. Although the 
relationship between EVS reports and cardiometabolic status has been examined, levels of 
PA reported by ESRD patients using the EVS have not yet been explored.
Methods: EVS reports of all KP patients with a diagnosis of ESRD between January 
2013 and July 2014 (N=8,187; Female=3,534, Mean Age=63.3 years) were assessed.
Results: Patients were 25% White, 38% Black, 23% Hispanic, 12% Asian, and the 
remainder Other, consistent with the regional patient catchment; just over 50% were 
married. The majority (88%) had comorbid HTN, 65% had comorbid DM, and 37% 
comorbid CHF. On average, patients had four other comorbid illnesses. During the study 
period, patients presented for 135,562 encounters. The mean reported PA frequency was 
1.4 times per week (SD=2.2), for a mean 12.3 minutes/bout (SD=22.4), or an average of 
49.0 minutes/week (SD=103.2) and a median zero minutes/week. The majority of ESRD 
patients did not achieve sufficient levels of PA during this period; 75% of the sample 
exercised for ≤60 minutes/week.
Conclusions: Self-reported rates of PA among ESRD patients at KP are critically low. 
Implications of low PA for cardiovascular and other outcomes as well as for interventions 
to improve rates of PA in this diverse population will be discussed.
TH-PO923
The Association of RAS Inhibition with Cardiovascular Events in Patients 
Undergoing Hemodialysis in Japan  Masahide Mizobuchi,1 Hiroaki Ogata,2 
Yoshihiro Onishi,4 Shingo Fukuma,3 Tadao Akizawa,1 Shunichi Fukuhara.3 
1Dept of Nephrology, Showa Univ School of Medicine, Tokyo, Japan; 2Dept of 
Internal Medicine, Showa Univ Northern Yokohama Hospital, Yokohama, Japan; 
3Dept of Epidemiology and Healthcare Research, Kyoto Univ Graduate School 
of Medicine, Kyoto, Japan; 4Inst for Health Outcomes & Process Evaluation 
Research (iHope International), Kyoto, Japan.
Background: Pharmacological inhibition of the renin-angiotensin system (RAS) 
contributes to cardiovascular protection in predialysis patients. However, definitive evidence 
of whether RAS inhibition is beneficial on cardiovascular event (CVE) among hemodialysis 
(HD) patients is lacking. The objective of this study was to investigate the association of 
RAS inhibitors usage with CVEs in patients enrolled in the Dialysis Outcomes Practice 
Pattern Study in Japan (J-DOPPS).
Methods: HD patients enrolled in J-DOPPS were eligible for analysis. Association 
of RAS inhibitors prescription with outcomes including all-cause death, death caused by 
CVE, and hospitalization due to cardiac failure was investigated by using a multivariable 
Cox proportional hazards model.
Results: Of the 3848 patients enrolled, 1784 (45 %) patients were treated by RAS 
inhibitors. The prevalence of male, diabetes, and other anti-hypertensive agent usage 
was higher in patients with RAS inhibitors compared to those without RAS inhibitors. 
Dialysis vintage was shorter and systolic blood pressure was higher in patients with RAS 
inhibitors. After adjusting for potential cofounders by Cox proportional hazards models, 
we did not find statistically significant associations of RAS inhibitors with all-cause death 
(HR: 1.19, 95%CI: 0.93-1.53, p=0.16), death caused by CVE (HR: 1.32, 95%CI: 0.80-2.18, 
p=0.28), and hospitalization due to cardiac failure (HR: 1.30, 95%CI: 0.89-1.89, p=0.18). 
A similar trend was observed when patients were stratified by the presence or absence of 
cardiovascular disease history.
Conclusions: RAS inhibition was not associated with CVEs suggesting that RAS 
inhibition alone is insufficient to reduce the risk of cardiovascular complications. Strategies 
in addition to RAS inhibition are needed to protect against CVEs in HD patients.
TH-PO924
Patient and Caregiver Priorities for Outcomes in Hemodialysis: A 
Multinational Nominal Group Technique Study  Allison Tong,1 Rachel 
Urquhart-Secord,1 Brenda Hemmelgarn,2 Braden J. Manns,2 Kevan 
Polkinghorne,3 David C. Harris,1 Peter G. Kerr,3 Helen Tam-Tham,2 Stephanie 
E. Thompson,4 Kara Schick-Makaroff,4 Martin Howell,1 Jonathan C. Craig.1 
1Univ of Sydney; 2Univ of Calgary; 3Monash Univ; 4Univ of Alberta.
Background: In the context of clinical trials, researchers have historically selected the 
outcomes they consider to be important. However, there is a growing awareness that they 
are often discordant with patient priorities. Efforts to define and report patient-centered 
outcomes are gaining momentum but have largely been outside of nephrology. We aimed 
to identify patient and caregiver priorities for outcomes in hemodialysis (HD).
Methods: Structured discussions using a nominal group technique were conducted 
with patients on HD and caregivers purposively sampled from 5 dialysis units in Australia 
(Sydney, Melbourne) and Canada (Calgary); who identified and ranked outcomes for HD. 
A mean rank score out of 10 was calculated for each outcome.
Results: 12 nominal groups involving 82 participants (patients n=58, caregivers n=24) 
aged 24–88 yrs (mean 58.3) identified 69 outcomes. The top 10 were: fatigue/energy (mean 
rank 4.4), ability to travel (3.7), survival (defined by patients as daily well-being and coping) 
(3.6), dialysis-free time (3.3), impact on family (3.1), ability to work (2.5), sleep (2.2), 
anxiety/stress (2.1), blood pressure (2.0), and knowledge (1.9). Mortality ranked 15th and 
participants distinguished this from survival. Caregivers ranked mortality, anxiety, and 
depression higher; patients ranked ability to work higher (P<0.05). 
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Conclusions: Patient prioritized outcomes are focused on maintaining a quality lifestyle 
above the usual outcomes in HD trials i.e. death, adverse events, and biological markers. 
Researchers need to consider interventions that could improve these outcomes, and measure 
and report patient-relevant outcomes in trials.
TH-PO925
Medicare Advantage (MA) Is Associated with Lower Rates of Mortality 
versus Medicare Fee-For-Service (MFFS) Among Incident End-Stage Renal 
Disease (ESRD) Patients  Steven M. Brunelli,1 Carey Colson,1 Scott Sibbel,1 
Abigail Hunt,1 Allen R. Nissenson,2 Mahesh Krishnan.2  1DaVita Clinical 
Research, Minneapolis, MN; 2DaVita HealthCare Partners Inc, Denver, CO.
Background: Patients with ESRD have a high burden of comorbid illness and are 
complex to manage and may therefore benefit from programs like MA that facilitate care 
coordination. Currently, ESRD patients are barred from enrolling in MA after onset of 
ESRD; however, those already enrolled at the time of ESRD onset may remain enrolled. 
To understand the potential impact of MA among ESRD patients, we compared mortality 
rates among patients who began dialysis enrolled with MA versus MFFS.
Methods: Adult patients initiating hemodialysis (HD) or peritoneal dialysis (PD) 
between 01 Jan 2009 and 30 Jun 2011 and who were enrolled with MA or MFFS as of 
ESRD onset were considered. MA patients were matched 1:1 to MFFS controls based on 
initial modality, access type, and propensity score (based on 26 demographic and clinical 
characteristics). Patients were followed from dialysis initiation until death, transplant, loss 
to follow up, change in benefits status, or end of study (31 Dec 2011). Mortality rates were 
compared using negative binomial models. Sensitivity analyses considering early and latent 
effects were performed using piecewise methods.
Results: Compared to MFFS, MA was associated with lower rates of mortality (64.3 
vs 70.7 deaths/100 patient-years; incidence rate ratio, 0.91). Mortality effects were limited 
to HD patients and were attenuated after the first 24 months of dialysis.
Conclusions: Enrollment in MA was associated with substantially lower rates of 
mortality during 2009-2011. 
Funding: Pharmaceutical Company Support - DaVita HealthCare Partners Inc
TH-PO926
Characteristics of Patients Receiving Dialysis at a Comprehensive 
Cancer Center and Outcomes  Ala Abudayyeh,1 Jai prakash babu Thippaiah 
Jadegondanahalli,2 Rima N. Pai,1 Maria del Pilar Fernandez,2 Alvin H. Moss.3 
1Section of Nephrology, UT MD Anderson Cancer Center; 2Nephrology and 
Hypertension, UT at Houston Medical School; 3Section of Nephrology, West 
Virginia Univ School of Medicine.
Background: With the increasing therapeutic options from the traditional cytotoxic 
therapies, small molecules for targeted therapies and more recently immunotherapies, 
cancer patients have been given a massive arsenal to tackle their cancer. With the associated 
renal toxicities from the chemotherapies, sepsis, infections, antibiotics, and obstruction 
we are often faced with decisions about the utility of dialysis. This is often the situation 
in the patients with advanced solid tumors that have failed multiple lines of treatment and 
are admitted with renal failure necessitating hemodialysis. Our hypothesis for this study 
is offering dialysis to advanced solid tumor patients will not improve overall survival and 
is not cost effective.
Methods: All patients diagnosed with Acute Kidney Injury in their last hospital 
admission with solid tumor and nephrology consult between 01/01/2005 through 12/31/2014 
were identified using billing data. Patient demographic data for those records was extracted: 
date of birth, gender, race, financial class, vital status and last contact date. Our final study 
cohort is a total of 2,268 unique patient records.
Results: Out of 2,268 patients, 392 patients (17.28%) received dialysis and 1876 
patients ( 82.72%) did not. A total of 1470 patients (64.81%) were discharged alive and 
798 patients (35.19%) resulted in a hospital death. The hospital deaths included 269 
patients (33.71%) that received dialysis and 529 patients (66.29%) that did not receive 
dialysis in the hospital.
Conclusions: Our preliminary data indicates that patients who survived their last 
hospitalization were less likely to have undergone dialysis (8.36%) when compared to 
patients that died during their last hospitalization (33.71% were dialyzed). Therefore, 
reaffirming that dialysis in advanced cancer patients would not likely add further benefit 
to their mortality.
TH-PO927
Emergency Room Utilization by Dialysis Patients: A Population Based 
Study  Claudio Rigatto,1,2 James M. Zacharias,1,3 Bing Hu,4 Brett M. Hiebert,1 
Navdeep Tangri,1,2 Paul Komenda.1,2  1Internal Medicine, Univ of Manitoba, 
Winnipeg, MB, Canada; 2Renal Health/Dialysis, Seven Oaks General Hospital, 
Winnipeg, MB, Canada; 3Renal Health/Dialysis, Winnipeg Health Sciences 
Centre, Winnipeg, MB, Canada; 4Manitoba Renal Program, Winnipeg Regional 
Health Authority, Winnipeg, MB, Canada.
Background: Patients with kidney failure are frail and have high rates of cardiovascular 
and infectious comorbidities. As a result, they are heavy users of non-dialysis acute health 
services such as the emergency department (ED). Despite this, accurate population based 
data on rates and patterns of ED visits by dialysis patients are lacking. The objective of 
the current study was to determine rates and patterns of ED utilization by adult dialysis 
patients vs. the adult general population.
Methods: We linked two large regional databases in Winnipeg, Manitoba, Canada 
(population 1.3 million), the Manitoba Renal Program Patient Registry and the Winnipeg 
Regional Emergency Program Admission Discharge Triage database. Data were analyzed 
for the years 2000-2010. Poisson Regression was used to compare rates.
Results: Over the study period, the linked dataset comprised >2.0 million visits in 1.2 
million non- dialysis patients, and 17,738 visits in 3260 dialysis patients. Our key findings 
were 1) Age and Sex adjusted rates of ER visits were 8.5X higher among dialysis patients 
[153 vs 18 visits per 100 patient-years, p<0.001), with negligible variation year to year 
over the study period; 2) Rate of ER visits were 25% higher on Mondays and Tuesdays 
overall; this “post-weekend” risk phenomenon was more pronounced in dialysis patients 
vs. the general population ( p<0.001for interaction); 3) among dialysis patients, ER visits 
were 8X higher during the two weeks before and after initiation of dialysis, reflecting a 
period of heightened vulnerability for patients with kidney disease.
Conclusions: Our population based rates of ED utilization will help health 
administrators predict the “collateral” impact of a typical dialysis unit on the health 
system. Strategies to mitigate the high risk of ED utilization “post weekend” and around 
the time of transition to dialysis are urgently needed and should be a focus of future health 
systems research.
Funding: Private Foundation Support
TH-PO928
Development of a Clinical Risk Prediction Tool for Six-Month Mortality 
After Dialysis Initiation Among Older Adults  James Wick, Tanvir Chowdhury 
Turin, Peter D. Faris, Jennifer M. MacRae, Robert G. Weaver, Brenda 
Hemmelgarn.  Univ of Calgary, Calgary, AB, Canada.
Background: Early mortality after dialysis initiation is common among older adults. 
We sought to develop a tool to predict mortality within 6 months of dialysis initiation in 
an older adult population.
Methods: We linked administrative and dialysis registry data to define a cohort of 
older adults (age 65+) in Alberta, Canada who initiated chronic dialysis between May 
2003 and March 2012. The outcome was all-cause mortality within 6 months of dialysis 
initiation. Potential predictors included demographics, comorbidities, health-system use, 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
308A
J Am Soc Nephrol 26: 2015 Dialysis: Epidemiology, Outcomes, and Clinical Trials: Noncardiovascular - I Poster/Thursday
laboratory measurements and dialysis-related information. We used logistic regression 
and 10-fold cross validation to identify and validate a model of significant predictors. 
Model discrimination and calibration were measured by c-statistic and Hosmer-Lemeshow 
goodness-of-fit respectively. A point system was created based on regression coefficients 
of predictors in the final model.
Results: 2,211 adults initiated dialysis, of whom 386 (17.4%) died within 6 months. 
Significant predictors of 6-month mortality were: age ≥80y, vascular access with central 
venous catheter, baseline eGFR 10-14.9 or >15mL/min/1.73m2, normal proteinuria, 
atrial fibrillation, lymphoma and congestive heart failure (CHF). Model discrimination 
(C-Statistic: 0.73) and calibration (Hosmer-Lemeshow c²: 6.09; p=0.64) were good. A 
40-point scale for 6-month mortality was created based on model coefficients with points 
assigned based on strength of each predictor as specified in Table 1. 
Category Points
Age
65-79.9 0
80+ 2
Vascular Access
Central Venous Catheter 10
Arteriovenous Fistula/Graft 0
PD Catheter 3
eGFR
<10 0
10-14.9 2
15+ 5
Proteinuria
Normal 6
Mild 4
Heavy 0
Unmeasured 5
Atrial Fibrillation 4
Lymphoma 9
CHF 4
TOTAL 0 - 40
Conclusions: We derived and internally validated a clinical risk prediction tool for 
6-month mortality for older adults initiating dialysis, using age, vascular access, eGFR, 
proteinuria, atrial fibrillation lymphoma and CHF as predictors. The results require external 
validation prior to use in clinical practice. A tool such as this can guide decision making 
for older adults with kidney failure.
TH-PO929
Coping Strategies and Outcomes Among Hemodialysis (HD) Patients 
in the DOPPS  Elodie Speyer,1 Hal Morgenstern,1,2 Peter G. Kerr,3 Antonio 
Alberto Lopes,4 Hugh C. Rayner,5 Bruce M. Robinson,1 Ronald L. Pisoni.1 
1Arbor Research, USA; 2Univ of Michigan, USA; 3Monash Health & Monash 
Univ, Australia; 4Federal Univ of Bahia, Brazil; 5Birmingham Heartlands 
Hospital, UK.
Background: Although HD presents numerous psychological and physical challenges 
for patients, how they cope with dialysis therapy and its impact on quality of life (QoL) 
and mortality is poorly understood.
Methods: Patients from 6 DOPPS countries completed the Coping Strategies Inventory-
Short Form (CSI-SF), which we found to be reliable and valid in those countries for 
measuring 4 coping strategies: problem-focused engagement (PFE) and disengagement 
(PFD), and emotion-focused engagement (EFE) and disengagement (EFD); and summary 
measures of engagement (actions to confront stressors) and disengagement (avoiding 
exposure to stressors). Outcomes were QoL (from SF-12 and KDQoL-SF), depression 
symptoms (from the CES-D), and all-cause mortality. Mixed linear and logistic models 
were used to estimate coping effects, adjusting for country and potential confounders.
Results: The sample included 2,262 HD patients from the US, UK, Australia/
New Zealand, Canada, and Sweden in DOPPS4 (2009-11). In general and whatever the 
instrument, both engagement coping strategies and the summary score were positively 
associated with better QoL scores and inversely associated with depression symptoms. In 
contrast, disengagement strategies were inversely associated with better QoL scores and 
positively associated with depression symptoms. The PFE score was inversely associated 
with mortality (HR =0.78 per 4 points higher score; 95% CI: 0.66-0.9).
Conclusions: Engagement strategies appear to be beneficial and disengagement 
detrimental for HD patients. A better understanding of the coping strategies used by 
patients may have prognostic implications and may help to improve disease management 
by providing tailored care for each patient.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
TH-PO930
Intradialytic Aerobic Cycling Exercise Improve Inflammation Status, 
Endothelial Progenitor Cells and Bone Density in Patients with End Stage 
Renal Disease on Maintenance Hemodialysis  Chia-chao Wu,1 Kuo-cheng Lu.2 
1Div of Nephrology, Dept of Medicine, Tri-Service General Hospital, National 
Defense Medical Center, Taipei, Taiwan; 2Dept of Medicine, Cardinal Tien 
Hospital, School of Medicine, Fu Jen Catholic Univ, New Taipei City, Taiwan.
Background: Inflammation, endothelial dysfunction and mineral bone disease play 
critical roles of morbidities and mortalities in the hemodialysis (HD) patients. Physical 
exercise can improve inflammatory status and bone density reverse protein-energy wasting 
(PEW) and bone loss. We investigate the effects of intradialytic aerobic cycling exercise 
(IACE) during HD.
Methods: Fourty end-stage renal disease patients undergoing HD will be randomly 
allocated into an exercise or control group for 3 months. The cycling session consisted 
of 5 minute warm-up, 20 minutes cycling at desired workload and 5 minutes cool-down 
during the three weekly dialysis sessions. Biochemical markers, inflammatory cytokines 
and nutritional status as well as serum endothelial progenitor cells (EPCs) count, bone 
mineral density and functional capacity were checked.
Results: There were no statistically differences in the baseline characteristics between 
groups. Biochemical and anthropometric parameters revealed improvement in serum 
albumin , body mass index and inflammatory cytokines in the exercise group. Statistically 
significant changes in numbers of CD133/CD34/KDR cells were observed in exercise 
group, whereas EPCs increased significantly during the study. The patients in exercise 
group showed a significantly greater 6-minute walk test than at baseline. Subjects who 
were able to walk faster showed greater increases in EPCs than other subjects. Bone loss at 
the femoral neck was significantly greater in the control group compared with the exercise 
group which essentially showed no change. The bone mineral density (BMD) change at 
the lumbar spine (L1 to L4) was not significantly different between the treatment groups.
Conclusions: In conclusion, an intradialytic aerobic cycling exercise program can 
decrease inflammation, increase nutritional status and bone mass index, improve 6-minute 
walk distance, and increase the number of EPCs in HD patients.
TH-PO931
Multicenter Trial of Aerobic Exercise in Maintenance Hemodialysis Patients 
Misa Miura,1 Aki Hirayama,1 Shigeru Owada,3 Yo Hirayama,4 Osamu Ito,2 
Masahiro Kohzuki.2  1Dept of Health, Tsukuba Univ of Technology, Tsukuba, 
Ibaraki, Japan; 2Dept of Internal Medicine and Rehabilitation Science, Tohoku 
Univ Graduate School of Medicine, Sendai, Miyagi, Japan; 3Asao Clinic, 
Kawasaki, Kanagawa, Japan.
Background: Hemodialysis patients show reduced physical function and greater risk of 
arteriosclerosis because of hypertension, metabolic disturbances, and vascular calcification. 
Meanwhile, exercise training in hemodialysis patients improves fitness, physical function, 
quality of life, and markers of cardiovascular disease such as arterial stiffness. This study 
aimed to determine whether aerobic training and electrical stimulation to skeletal muscles 
for 12 weeks could improve physical function and dialysis efficacy in patients with end-
stage renal disease (ESRD).
Methods: This was a multicenter trial. A total of 35 ESRD patients on three occasions 
(20 males, 15 females; age: 70.2±11.7 years) were randomized to receive 12 weeks of aerobic 
training exercise during hemodialysis session (Ex-group: n=19), electrical stimulation to 
the lower limbs (ES-group: n=6), or no specific intervention (Cont-group: n=10). The Borg 
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scale was used to control the intensity of training. At baseline and study completion, the 
primary outcome measures were grip strength, quad muscle torque, workout time, activities, 
dialysis efficacy, HDL, LDL, CRP, IL-6 and blood pressure.
Results: In the Ex-group, handgrip, quad torque, and workout time increased 
significantly (P<0.05). Dialysis efficacy, HDL-cholesterol, LDL-cholesterol, CRP, and 
blood pressure on the morning of the dialysis day also improved significantly (P<0.05). 
These effects were not observed in the Cont-group. In the ES-group, quad muscle torque 
and dialysis efficacy increased significantly (P<0.05), IL-6 decreased significantly (P<0.05), 
compared to the other two groups.
Conclusions: In this study, the safety and efficacy of training and electrical stimulation 
during hemodialysis were confirmed without sudden drop of blood pressure or any other 
side effects. Therefore, training during hemodialysis session for 12 weeks might improve 
physical function with specific whole-body effects as well as local effects in ESRD patients.
TH-PO932
Glycemic Markers and 2-Year Non-Diabetic Hemodialysis Outcomes from 
the Glycemic Indices in Dialysis Evaluation Study  Mark E. Williams,1 Neal 
Mittman,2 Lin Ma,3 Julia I. Brennan,4 Curtis D. Johnson,4 Franklin W. Maddux,3 
Eduardo K. Lacson.3,5  1Joslin Diabetes Center, Boston, MA; 2Kidney Care of 
Brooklyn and Queens, Brooklyn, NY; 3Fresenius Medical Care North America, 
Waltham, MA; 4Spectra Laboratories, Rockleigh, NJ; 5Physician, Lexington, MA.
Background: The ongoing GIDE (Glycemic Indices in Dialysis Evaluation) study 
includes data on nonDM hemodialysis (HD) patients (confirmed by HgbA1c <6.5%). 
Because nonglycemic factors may lower HgbA1c levels in ESRD, we previously reported 
their glycemic status/1-year outcomes using alternative glycemic markers [albumin-adjusted 
and unadjusted fructosamine (AlbF;F) and glycated albumin (GA) or percent GA (%GA)]. 
We now report 2-year study data.
Methods: 970 nonDM HD patients from 26 FMCNA facilities with glycemic markers 
from Jan-March 2013 were followed until April, 2015. Baseline AlbF, F, GA and %GA were 
used to classify patients as high or low glycemia using thresholds of AlbF≥974µmol/g, 
F>285µmol/L, %GA>15.7%, and GA>300µmol/L. Standard and Time-dependent (TD) Cox 
models with case-mix adjustment for age, sex, race, ethnicity, vintage, BMI, HD catheter 
and baseline comorbidity were used to determine associations between each glycemic 
index and hospitalization/death risk.
Results: While 1% had HgbA1c>7%, high glycemic status was more commonly 
detected using F (59%), AlbF (4%), GA (15%) and %GA (29%). Elevated AlbF was 
significantly associated with 2-year mortality [Standard Cox: Hazard Ratio (HR)=2.53, 
95% CI (1.31, 4.92), p=0.006; TD Cox: HR=3.55, 95% CI (1.97, 6.38), p<0.0001] and 
hospitalization [TD Cox: HR=2.49, 95% CI (1.70, 3.67), p<0.0001]. For all other glycemic 
markers, no such associations were evident at the proposed thresholds using adjusted 
analyses in the Cox model.
Conclusions: These data support our previous findings of an association between poor 
glycemic status (high AlbF) and hospitalization/mortality outcomes in nonDM HD patients. 
High AlbF-glycemic status may have prognostic implications in nonDM HD patients.
TH-PO933
Association of Change in Serum HDL Cholesterol with Mortality in 
Hemodialysis Patients: Role of Gender  Sheila Mazdyasni,1 Elani Streja,1 Tae 
Hee Kim,1 Connie Rhee,1 Steven M. Brunelli,2 Moti L. Kashyap,1,3 Nosratola D. 
Vaziri,1 Kamyar Kalantar-Zadeh,1 Hamid Moradi.1,3  1UC Irvine; 2DaVita Clin 
Research; 39A Long Beach.
Background: Elevated high-density lipoprotein cholesterol (HDL) levels, though 
protective in the general population, can be associated with higher mortality in hemodialysis 
(HD) patients. Association of HDL change over time with mortality has yet to be examined. 
Based on previous studies, we hypothesized that upward trends in HDL levels may be 
associated with higher mortality risk in HD patients.
Methods: We examined HDL change over time in 24,400 incident HD patients 
receiving care from a large dialysis organization in 2007-2011. Association of delta HDL 
(HDL change between the 1st and 2nd 91 day interval from dialysis start) and HDL trajectory 
with all-cause mortality were examined using mixed effect and Cox regression models and 
adjusted for demographics, comorbidities and baseline HDL. Delta HDL was treated both 
as a continuous variable using restricted cubic splines and in categories:<-6, -6 -<-2, -2 
-<2 (Ref), 2 -<6, and ≥6 mg/dL.
Results: Patients were 65±15 years old, 44% female, 31% black, 66% diabetic with 
a mean baseline HDL 40.5±13.9 mg/dL and HDL change 1.7±10.4 mg/dL. While male 
patients had no significant change in HDL over time, females had a significant decrease in 
HDL (mean -0.6mg/dL/year). A ≥6 mg/dL increase or decrease in delta HDL was associated 
with a 7% and 37%, respective increase in all-cause mortality compared to reference group. 
Delta HDL-mortality associations did not differ across gender.
Conclusions: Decreased HDL over time was associated with worse outcomes and 
increased HDL was paradoxically associated with higher mortality. While HD treatment 
can be associated with a decrease in HDL, this effect was magnified in younger females. 
The novel and intriguing role of age and gender in association of HDL and survival needs 
further evaluation.
Funding: NIDDK Support
TH-PO934
Differences in Perceived Kidney Disease Burden on Quality of Life by Race/
Ethnicity in a Diverse Cohort of Hemodialysis Patients  Anna C. Porter,1 Rani 
Gallardo,2 Linda A. Schiffer,3 Denise M. Hynes.2,3,4  1Dept of Medicine, Div of 
Nephrology, Univ of Illinois Hospital and Health Sciences System, Chicago, IL; 
2Dept of Medicine, Div of Academic General Internal Medicine and Geriatrics, 
Univ of Illinois at Chicago, Chicago, IL; 3Inst for Health Research and Policy, 
Univ of Illinois at Chicago, Chicago, IL; 4Center of Innovation for Complex 
Chronic Healthcare, (dZard Hines Jr., 9A Hospital, Hines, IL.
Background: Low health-related quality of life (HRQOL) has been well-documented 
in patients with end-stage renal disease on hemodialysis (ESRD). While African Americans 
and Hispanics remain at increased risk for ESRD, HRQOL has been less well-described in 
these individuals compared to non-Hispanic whites.
Methods: Baseline HRQOL data was analyzed for participants enrolled in the 
Patient-Centered Medical Home for Kidney Disease study (PCMH-KD), a trial of 
a multidisciplinary, patient-centered primary care intervention in a population of 
hemodialysis patients at two dialysis facilities in Chicago. The Kidney Disease Quality of 
Life (KDQOL-36) instrument was used to assess HRQOL at baseline, and the following 
subscale scores were obtained: Physical, Mental, Burden of Kidney Disease, Symptoms 
and Problems, and Effects of Kidney Disease.
Results: Baseline data were available for 95 patients. Approximately, 52% of patients 
were African-American, and 45% were Hispanic. Significant racial/ethnic differences were 
observed among subscales of self-reported HRQOL. 
KDQOL Subscale Mean Score for African American Participants
Mean Score for Hispanic 
Participants P value
Physical 35.8 34.5 >0.05
Mental 51.4 47.1 0.040
Burden 57.4 33.6 <0.001
Symptoms/Problems 76.6 76.0 >0.05
Effects 74.9 66.8 0.048
Conclusions: Hispanic patients with ESRD on HD report disproportionate burden 
and effects of kidney disease on HRQOL and worse mental HRQOL compared to African 
American patients with ESRD on HD. Further exploration of these disparities may lead to 
strategies for improvement of HRQOL in Hispanic patients.
Funding: Private Foundation Support
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TH-PO935
Relative Blood Volume and Mortality in Hemodialysis Patients 
Linda H. Ficociello,1 Paul Balter,1 Mark Costanzo,1 Patrice B. Taylor,1 Claudy 
Mullon,1 Robert J. Kossmann.1  1Fresenius Medical Care North America 
(FMCNA), Waltham, MA; 2Renal Research Inst (RRI), New York, NY.
Background: A quality improvement project on fluid management using Crit-Line® 
Monitors (CLM) was conducted across multiple RRI facilities. Percent change in relative 
blood volume (RBV) was measured during routine hemodialysis (HD). Previous analyses 
of the same cohort have shown associations between RBV reduction and reduced hospital 
admission rate; the current analysis assesses mortality.
Methods: A retrospective analysis of HD treatments with RBV measurements 
was conducted over 6 months. RBV was calculated using: RBV= [(Hematocrit(T0)/
Hematocrit(T)-1]X100. Average RBV at the end of HD was calculated for 1099 patients 
(22,579 treatments with RBV). Patient deaths were recorded as part of routine clinic 
procedures over the same 6 months. Mortality rate per patient month was calculated as 
#deaths/patient months. Time to death was modeled using Cox proportional hazards model.
Results: Patients were divided into RBV categories by 5% increments and compared 
on risk of death during the 6 months (Table). There was an increased risk of death with 
less reduction in RBV. For example, using patients with the greatest reduction in RBV (< 
-15%) as the reference, patients with the least reduction in RBV by the end of HD had 16 
times the risk of death. Modeling time to death, there is a 15% increase risk of mortality for 
each 1% increase in the end of HD blood volume (p< 0.0001). Similar results were obtained 
after controlling for age, gender, and race (11% increased risk, p=0.002).
% Relative 
Blood Volume Total # Patients Patient Months Mortality Rate Mortality Ratio
≤-15% 47 730 0.004 1 (Reference)
-14.9 to -10% 254 41821 0.006 1.34
- 9.9 to - 5% 507 80408 0.010 2.45
-4.9 to 0% 263 39098 0.017 3.96
> 0% 28 3081 0.068 15.97
Conclusions: In a large cohort of HD patients with relative blood volume measured, 
patients with less reduction in percent change in relative blood volume at the end of dialysis 
had higher risk of death over 6 months when compared to patients with greater reduction. 
These patients may represent a subset of patients at high risk for adverse outcomes and 
may benefit from fluid management programs.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
TH-PO936
The Effect of Altitude on Erythropoiesis-Stimulating Agent Dose, 
Hemoglobin Level, and Mortality in Hemodialysis Patients  Scott Sibbel,1 
Donna E. Jensen,1 John Alan Laich,1 Sarb Shergill,2 Bradley J. Maroni,2 
Steven M. Brunelli.1  1DaVita Clinical Research, Minneapolis, MN; 2Akebia 
Therapeutics, Cambridge, MA.
Background: Prior studies have shown that hemodialysis (HD) patients residing at 
high elevations have lower erythropoiesis-stimulating agent (ESA) utilization, possibly 
due to activation of hypoxia-regulated genes. We sought to better understand the impact 
of altitude on dosing of anemia medications and mortality following 2011 changes to the 
US epoetin alfa label and reimbursement policy.
Methods: We studied a cohort of prevalent nonveteran HD patients (vintage >6 months) 
treated at a large dialysis organization between 1 Jan 2012 and 31 Dec 2012. Patients were 
compared across categories of altitude for longitudinal hemoglobin (Hb) level, ESA and 
intravenous (IV) iron dose, and mortality risk using mixed linear models. Associations 
were adjusted for baseline demographic and clinical characteristics.
Results: Compared to altitude of 0-1499 ft, higher altitude was incrementally associated 
with higher mean Hb and lower mean ESA dose; mean IV iron utilization did not differ. 
Altitude >4500 ft (vs 0-1499 ft) was independently associated with lower mortality risk: 
incidence rate ratio (IRR) was 0.74 with 95% confidence interval (CI) 0.63-0.88. 
Conclusions: Among contemporary HD patients receiving treatment at altitude >1500 
ft, higher altitude was independently associated with greater Hb level despite lower ESA 
doses and comparable IV iron utilization. Altitude of >4500 ft was independently associated 
with a 26% lower mortality risk.
Funding: Pharmaceutical Company Support - Akebia Therapeutics
TH-PO937
Achieved Iron Stores and Clinical Efficacy in a Trial of Ferric Citrate as a 
Phosphate Binder  Kausik Umanath,1 Molly Mcfadden,2 Diana I. Jalal,3 Yoram 
Yagil,4 Erwin Antonio Aguilar,5 Anas Abou-Ismail,6 Mohammed Sika,6 Robert 
M. Niecestro,7 Mark Koury,6 Julia Lewis,6 Tom Greene,2 Barbara A. Greco,8 
Stephen Z. Fadem,9 Jamie P. Dwyer,6 The Collaborative study group.7  1Henry 
Ford Hosp; 2U of Utah; 3U of CO; 4Ben-Gurion U; 5LSU; 6Vanderbilt; 7CSG; 
8Baystate Med Ctr; 9Baylor College of Med.
Background: Adequate Fe stores are needed for hematopoiesis in ESRD pts on ESA, 
but optimal Fe stores assuring efficacy/safety are unknown. PO Fe preparations have been 
unable to do this. In a Ph3 RCT we showed ferric citrate (FC) as a Phos binder ↑Fe stores 
and ĻIV iron/ESA use. We studied IV iron/ESA use in the trial based on achieved Fe stores.
Methods: 441 pts randomized 2:1 to FC or non-Fe-containing active control (AC) 
were followed for 52 wks. IV iron use was at a site’s discretion while ferritin£1000ng/mL 
and TSAT£30%. Generalized estimating equations related ↑IV Iron/ESA dose to trailing 
4-mo means of ferritin/TSAT to IV iron by randomized group, adjusting for age, sex, black 
race, CHF and DKD, giving odds ratios (OR) for ESA use >75th %ile (10,611 Units/wk) 
or IV iron use >median for visits with nonzero dose (47.7 mg/wk) to compare middle and 
highest TSAT/ferritin tertiles to lowest.
Results: 398 subjects for ESA, 409 pts for IV iron were analyzable. In AC, ORs for 
↑ESA dose were 0.63 (0.42-0.95, p=0.03) for middle TSAT, 0.53 (0.31-0.93, p=0.03) for 
highest TSAT tertile. FC group was similar, Table 1. Ferritin did not predict ESA dose. In 
AC, ORs for ↑IV iron dose were 0.51 (0.34-0.78) for middle TSAT, 0.39 (0.20-0.76) for 
highest TSAT tertile; FC was similar, Table 2.  ferritin trended to ĻIV iron use, Table 2. 
Conclusions:  TSAT predicted ĻIV Iron/ESA, TSAT>37% showing lowest use. In these 
ranges no TSAT limit existed over which further ĻIV Iron/ESA did not occur.  ferritin levels 
predicted ĻIV Iron, not ĻESA use. TSAT may better predict ESA responsiveness in ESRD.
Funding: Other U.S. Government Support, Pharmaceutical Company Support - 
Keryx Biopharmaceuticals, Inc.
TH-PO938
Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in 
Patients with End-Stage Kidney Disease on Hemodialysis  John Havill,1 
Nelson P. Kopyt,2 Daniel W. Coyne,3 Michael Weiswasser,4 William T. Smith.4 
1Kidney Specialists of Southern Nevada, Las 9egas, N9; 2Lehigh 9alley 
Health Network, Allentown, PA; 3:ashington Univ, St. Louis, M2; 4Celgene 
Corporation, Warren, NJ.
Background: This ongoing, randomized, single-blind, placebo (PBO)-controlled study 
evaluated the pharmacokinetic (PK), safety, and hemoglobin (Hb) effect of sotatercept, an 
ActRIIA-IgG1 fusion protein ligand trap, in hemodialysis (HD) subjects and explored its 
effects on vascular calcification (VC) and bone mineral density (BMD) using quantitative 
computed tomography (QCT).
Methods: Subjects were washed out of erythropoietin-stimulating agent (ESA) effects 
until Hb was <10 g/dL and randomized to PBO or sotatercept given subcutaneously every 
28 days for up to 8 dose cycles. Treatment failures (Hb <9 g/dL) were rescued with ESA or 
transfusion; intrasubject dose escalation was not permitted. QCT scans of the hip, lumbar 
spine, and abdominal aorta were obtained at baseline and after the 225-day treatment phase. 
Interim results are reported for PK, safety, home BP, Hb, VC, and BMD effects in the 0.3, 
0.5, and 0.7 mg/kg dose groups.
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Results: Among subjects treated with PBO (n=9) or sotatercept 0.3 mg/kg (n=9), 0.5 
mg/kg (n=8), and 0.7 mg/kg (n=9), adverse events were mostly mild/moderate, unrelated 
to study drug, relatively similar in type/severity between groups, and generally consistent 
with subject medical histories. Two deaths occurred in the PBO group. There were no dose-
dependent changes in home BP. In the 225-day treatment phase, Hb was >10 g/dL in 33%, 
33%, 63%, and 78% of subjects treated with PBO or sotatercept 0.3, 0.5, or 0.7 mg/kg, 
respectively. Paired QCTs obtained in 4, 6, 5, and 6 subjects treated with PBO or sotatercept 
0.3, 0.5, or 0.7 mg/kg showed <15% progression of VC in 33%, 80%, 80%, and 100%, 
and >2% increase in femoral neck cortical BMD in 0%, 20%, 40%, and 75%, respectively.
Conclusions: Sotatercept appears to be well tolerated with an acceptable safety 
profile in HD, without increases in home BP. There are beneficial dose-related responses 
to sotatercept in Hb, VC, and BMD. A larger dataset, with an ongoing 14-day dose group, 
will further substantiate these results.
Funding: Pharmaceutical Company Support - Study was sponsored by Celgene 
Corporation.
TH-PO939
Impact of CKD-MBD Composite Score on Mortality and Hospitalization: 
Dialysis Outcomes and Practice Patterns Study (DOPPS)  Douglas S. Fuller,1 
Paul Dluzniewski,2 Kerry Cooper,2 Brian D. Bradbury,2 Mark D. Danese,3 Bruce 
M. Robinson,1,4 Francesca Tentori.1,5  1Arbor Research Collaborative for Health, 
Ann Arbor, MI; 2Amgen, Thousand Oaks, CA; 3Outcomes Insights, Inc., Westlake 
Village, CA; 4Univ of Michigan, Ann Arbor, MI; 5Vanderbilt Univ, Nashville, TN.
Background: The biochemistries associated with chronic kidney disease-mineral and 
bone disorder (CKD-MBD), parathyroid hormone (PTH), calcium (Ca), and phosphorus (P), 
are physiologically interrelated. We evaluated the impact of combinations of CKD-MBD 
parameters outside target ranges in HD patients (pts).
Methods: We identified DOPPS 3-5 (2005-2014) pts in the US, Canada, and Europe 
(France, Germany, Italy, Spain, Sweden, and the UK) with ³12 mos of follow-up. We 
assessed demographic and clinical covariates in study mos 9-12 and used Cox models to 
generate disease risk scores (DRS) by region based on pts with CKD-MBD parameters in 
target (MBD 0; P 3.5-5.5 mg/dL, Ca 8.4-10.2 mg/dL, PTH 150-600 pg/mL) and to compare 
event rates, adjusted for DRS, of mortality and a composite of death or hospitalization 
between MBD 0 and pts with 2-3 values outside target (MBD 2+).
Results: MBD 2+ prevalence, primarily due to high PTH and P, was 22.8%, 29.5%, 
and 26.9% in the US, Canada, and Europe, respectively. PTH above target was higher 
in the US (52%) compared to Canada (42%) and Europe (28%). Compared to MBD 0, 
MBD 2+ was associated with moderately higher mortality in the US and Canada but not 
Europe; MBD 2+ was weakly associated with higher composite rates in all three regions. 
We observed slightly stronger associations in pts with 2+ MBD labs above target only.
Conclusions: Distributions of CKD-MBD parameters varied by region, perhaps 
resulting in differential risk of adverse outcomes. Our findings in this international cohort 
highlight the importance of simultaneous, rather than independent, control of MBD 
parameters within clinical guidelines ranges.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Societa’ Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx, Private 
Foundation Support
TH-PO940
US DOPPS Practice Monitor: Comparisons with CMS ESRD Databases 
Douglas S. Fuller, Lindsay Zepel, Keith McCullough, Brian Bieber, Ronald L. 
Pisoni, Francesca Tentori, Bruce M. Robinson.  Arbor Research Collaborative 
for Health, Ann Arbor, MI.
Background: Since August 2010, the Dialysis Outcomes and Practice Patterns Practice 
Monitor (DPM; www.dopps.org/DPM) has leveraged its US hemodialysis (HD) sample 
(now >200 facilities) to provide timely and detailed (>750 data tables) updates on national 
trends in HD care. Here we compare DPM estimates to available results from end-stage 
renal disease (ESRD) data sources collected by the Centers for Medicare and Medicaid 
Services (CMS).
Methods: Pearson correlations (r) were used to compare contemporary trends since 
Aug 2010 between DPM and the 2014 US Renal Data System Annual Data Report (ADR, 
through Dec 2012) and the Nov 2014 CMS Claims-Based Monitoring Project (CBMP, 
through Jun 2014). We also compared monthly DPM estimates with cross-sectional estimates 
from 2014 CrownWEB (CW; Dec 2013).
Results: DPM trends in ESA use and dose, IV iron use, and hemoglobin levels were 
highly correlated (r’s: 0.89-0.98) with ADR and CBMP trends. Compared to CW, DPM 
showed slightly higher fistula use, but slightly lower percent of patients with adequate 
Kt/V and URR values.
Conclusions: DPM reports IV medications use as prescription at the end of the 
month (before Apr 2012) or anytime during the month (Apr 2012 and after), rather than 
administration. Thus, estimates for ESA and IV iron utilization each month may be 
somewhat different due to spontaneous or withheld dosing. Differences with CW cross-
sectional estimates may result from differences in calculation methods. DPM includes 
non-Medicare patients that are not necessarily present in claims-based sources. DPM now 
includes >4 years of monthly estimates for indicators of US HD care. Although differences 
in data sources and specifications may influence direct comparisons, DPM data remain an 
important resource for identifying important trends in HD care before confirmations from 
CMS ESRD databases are available.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Societa’ Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx, Private 
Foundation Support
TH-PO941
Reduced Free Triiodothyronine Is an Independent Predictor of Clinical 
Outcomes in Hemodialysis Patients with Low Albuminemia  Akihiko Kato,1 
Masafumi Ono,1 Takayuki Tsuji,2 Naro Ohashi,2 Hideo Yasuda.2  1Blood 
Purification Unit, Hamamatsu Univ Hospital, Hamamatsu, Shizuoka, Japan; 
2Internal Medicine 1, Hamammatsu Univ School of Medicine, Hamamatsu, 
Shizuoka, Japan.
Background: Low free triiodothyronine (fT3) and free thyroxine (fT4) are both related 
to malnutrition, inflammation and mortality in dialysis patients. Upper-normal thyrotropin 
(TSH) levels are also associated with a higher risk of total mortality in hemodialysis (HD) 
patients. However, it remains unclear which of thyroid-related hormones is most useful in 
predicting clinical outcomes. So, we aimed this study to compare the prognostic value of 
different hormones in prevalent HD patients.
Methods: We enrolled 339 HD patients (age: 64±13 years old, time on HD: 129±114 
months), and measured basal fT3, fT4 and TSH. We then followed the patients for the 
next 42 months, and assessed the impact of fT3, fT4 and TSH on all-cause mortality and 
cardiovascular (CV) events or hospitalization. Patients were divided into the 4 groups 
based on the quartiles of fT4, fT4 and TSH. The associations of basal levels with clinical 
outcomes were examined with Cox proportional hazards models adjusted for demographic 
and classical factors and comorbidities.
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Results: Mean serum fT3 and ft4 were 2.01±0.37 [0.95-3.73] pg/mL and 0.86±0.20 
[0.35-1.67] ng/dL. Serum levels of fT3 and fT4 were lower than those of reference ranges 
in 85.0% and 56.0% of the patients, respectively. In contrast, TSH levels were within the 
reference range in most patients (92.9%). Cox hazards analyses revealed that the lowest 
quartile of fT3 (<1.75 pg/mL) was an independent predictor of all-cause mortality (HR 
3.55 [95%CI: 1.17-4.09, p<0.01]), all-cause mortality plus CV events (HR 2.19 [95%CI: 
1.53-8.23,, p=0.01]), and all-cause mortality plus hospitalization (HR 2.16 [95%CI: 
1.28-3.67, p<0.01]) when compared with those with the top quartile (fT3³0.98 pg/mL). 
However, the significant impact of low fT3 on prognosis was observed only in patients 
with serum albumin lower than 3.8 g/dL (n=195). In contrast, serum fT4 and TSH levels 
did not relate to prognosis.
Conclusions: These findings suggest that low fT3 became an independent predictor 
of clinical outcomes in HD patients with low albuminemia.
TH-PO942
Low Socioeconomic Status and Co-Morbidity Are Associated with Limited 
Health Literacy in RRT Patients – Results from the ATTOM Study 
Dominic Taylor, The ATTOM investigators.  Southmead Hospital, Bristol, 
United Kingdom.
Background: Limited health literacy(LHL) is a risk factor for poor outcomes in chronic 
disease patients. Studies with limited patient numbers in RRT patients associate LHL with 
low socioeconomic status(SES), comorbidity and ethnicity.
Methods: This cross-sectional study used baseline data from the ‘Access to 
Transplantation and Transplant Outcome Measures’(ATTOM) cohort. ATTOM recruited 
incident dialysis and transplant patients aged 18-75 years in the UK during 2011-2013 and 
also wait-listed patients similar to those transplanted(matched controls). Health literacy 
was measured by the question ‘How often do you need someone’s help to read instructions, 
leaflets, or other written material from your doctor or pharmacy?’ answered on a scale from 
1-Never to 5-Always. LHL was defined as a score greater than 2. The three groups were 
analysed for associations between LHL and demographics, SES factors and comorbidity, 
using univariate and multivariate analysis, p<0.05.
Results: 6842 patients were recruited: 2621 incident dialysis (ID), 2262 incident 
transplant (IT) and 1959 matched controls (MC). 6373/6842(93%) completed the health 
literacy assessment. Prevalence of LHL was 20% in the ID, 12% in the IT and 15% in 
the MC group. In univariate analyses, in all groups, English not as first language, Asian 
ethnicity, low educational level, unemployment, absence of car or home ownership, 
increased comorbidity by modified Charlson index and mental illness were associated 
with LHL. In adjusted models, in all groups, the following factors were associated with 
LHL: English not as first language(OR>3), modified Charlson index (OR 1.2 for each 
point above zero), low level of education (OR>2 for no qualifications compared to any), 
unemployment (OR>3.0 compared to employed) and absence of car ownership (OR 1.7). 
Age and sex were not associated with LHL after adjustment.
Conclusions: In this large nationwide study, low SES and co-morbidity are associated 
with LHL in patients receiving dialysis or at the point of transplantation, independent of first 
language. LHL may impact upon patients’ ability to engage with shared decision making 
and their capacity to cope with the burden of disease and treatment.
Funding: Other NIH Support - NIHR(UK)
TH-PO943
Comparing Dialysis Facility Compare (DFC) Star Rating to QIP Payment 
Categories  Claudia Dahlerus,1 Christopher J. Harvey,1 Joseph M. Messana,1 
Richard Hirth,1 Cindy Liao,1 Natalie Scholz,1 Tempie H. Shearon,1 Zezhi (zac) 
Zhang,1 K. A. Wisniewski,1 Casey Parrotte,1 Ji Zhu,1 Elena K. Balovlenkov,2 
Joel S. Andress,2 Yi Li.1  1Biostatistics, Kidney Epidemiology and Cost Center, 
Univ of Michigan, Ann Arbor, MI; 2Centers for Medicare and Medicaid Services.
Background: CMS star ratings summarize DFC quality measures, giving each facility 
1 to 5 stars to help consumers compare facilities. The ESRD QIP, a value based purchasing 
program, applies performance-based payment reductions. We describe differences between 
the star rating and QIP payment reduction categories and how each distinguishes average 
facility performance.
Methods: We obtained the fixed percentile star rating (5-Star 10%, 4-Star 20% 3-Star 
40%, 2-Star 20%, 1-Star 10%) and QIP payment reduction for each facility from the Jan 
2015 DFC file. We calculated star rating mean final scores (MFS) for each tier and used 
t-tests to assess differences between adjacent tiers.
Results: Differences in MFS between adjacent star rating tiers are similar (~9 pts, 
p<.0001) (Table 1). In the QIP system, the difference between payment reduction tiers 0.5% 
to 2% is small (~1 to 3 pts) and not statistically significant and the difference between the 
0.5% and 0% categories is ~15 pts, p<.0001. 
Star Rating Facility N(%) MFS (SD)
QIP 
Payment 
Reduction
Facility 
N(%) MFS (SD)
1 563(10) 31.8 (0.2) 2.0% 37(0.6) 33.3 (2.1)
2 1127(20) 41.4* (0.1) 1.5% 23(0.4) 34.0 (1.6)
3 2255(40) 50.2* (0.1) 1.0% 41(0.7) 36.9 (1.4)
4 1127(20) 58.7* (0.1) 0.5% 242(3.9) 36.3 (0.6)
5 563(10) 67.7* (0.2) 0% 5795(94.4) 50.9* (0.1)
* p<.0001 vs. previous tier
Conclusions: Differences in MFS between adjacent DFC star tiers were larger and 
potentially clinically meaningful. QIP categories primarily distinguish between the top 
tier (0% reduction) and all lower tiers (.5% to 2% reduction). Programs evaluating facility 
performance have different goals, and methods for categorizing quality are informed by 
these goals. Further research and debate will help inform what is optimal.
Funding: Other U.S. Government Support
TH-PO944
Association of Socioeconomic Characteristics with Readmission Among 
Dialysis Patients  Claudia Dahlerus,1 John Wheeler,1 Deanna Chyn,1 Yanming 
Li,1 Richard Hirth,1 John Kalbfleisch,1 Jennifer Sardone,1 Zhi He,1 Tempie 
H. Shearon,1 Joel S. Andress,2 Elena K. Balovlenkov,2 Yi Li.1  1UM Kidney 
Epidemiology & Cost Center; 2Centers for Medicare & Medicaid Services.
Background: CMS recently developed hospital readmissions measures to reflect 
quality of care provided by nursing homes, long-term care hospitals, inpatient rehabilitation 
facilities, home health agencies and dialysis facilities. The intent is to encourage care 
coordination as patients transition between care providers. All measures adjust for patient 
characteristics. CMS has not adjusted quality measures for patient socioeconomic status 
(SES), so as not to condone disparities in care delivery. However, not including such 
adjustments may result in inappropriate assessments about quality of care. We present 
preliminary analyses assessing the association of SES and readmission among dialysis 
patients.
Methods: Using 2013 Medicare claims data, we model the probability of readmission, 
defined as an unplanned readmission within 30 days of a hospital discharge, adjusted for 
patient characteristics including age, sex, BMI, comorbidities, discharging hospital, and 
several measures of SES, plus measures reflecting SES of the patient’s area of residence.
Results: Patients with Medicare secondary payer (MSP) were less likely to experience 
a readmission (OR 0.92; CI 0.90-0.93); patients with dual Medicare and Medicaid coverage 
(OR 1.08; CI 1.08-1.09), unemployed at ESRD incidence (OR 1.07; CI 1.06-1.08) and 
living in ZIP codes with high unemployment, low education and income disparity were 
more likely to experience a readmission.
Conclusions: Insurance status and area of residence are strong proxies for SES and are 
associated with readmissions. MSP, largely reflective of private insurance coverage, can 
be an indicator of higher SES and perhaps better health. Dual eligibility for Medicare and 
Medicaid can be an indicator of lower SES, as can being unemployed at ESRD incidence. 
As interest in risk adjusting for indicators of SES has grown, the association between SES 
and readmission suggests further analysis may be appropriate. However, caution must be 
exercised in efforts to distinguish between SES factors that may or may not be related to 
quality of care.
Funding: Other U.S. Government Support
TH-PO945
Co-Morbidities (CM) Do Not Predict Adverse Outcomes in Peritoneal 
Dialysis (PD) versus Hemodialysis (HD) in a Multi-Ethnic Asian ESRD 
Cohort  Gek hsiang Lim,1 Khuan yew Chow,1 Vathsala Anantharaman.2  1Health 
Promotion Board, Singapore; 2National Univ Health System.
Background: There is conflicting data on outcomes following HD vs PD. USRDS 
data for ESRD in 2002-2004 suggested similar outcomes for HD and PD over 5 years of 
followup. This study evaluated outcomes for HD vs PD from a multi ethnic Asian ESRD 
population and evaluated the impact of CM on worse outcomes in either modality.
Methods: 3279 HD and 1330 PD patients who were included in the Singapore 
Renal Registry(SRR) in 2001-2007 and followed up till death or 31 Dec 2012 comprised 
the study population. Data on patients’ demographics, CM and survival were collected. 
Patients were stratified by age, presence of diabetes(DM) and occurrence of 1 or more 
vascular(V) vs non-vascular(NV) CM. 5-year survival was compared using Kaplan-Meier 
and regression analyses.
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Median Survival (Yrs)^
CM Age No. PD HD HR(95% CI)
0 All 999 - - 1.3(0.9–1.6)
Non-DM <65 1217 11.0 - 1.1(0.9-1.4)
Non-DM+No CM
<65
810 - - 1.0(0.7–1.4)
Non-DM+V 286 7.8 9.1 1.1(0.8–1.6)
Non-DM+NV 121 7.9 - 1.1(0.5-2.6)
Non-DM
≥65
496 3.4 4.9 1.5(1.2-1.9)
Non-DM+No CM 189 3.8 6.7 2.1(1.4–3.1)
Non-DM+V 265 3.3 3.9 1.3(1.0–1.8)
Non-DM+NV 42 7.2 3.6 0.6(0.2–1.9)
DM
<65
1838 3.2 5.6 1.8(1.6–2.0)
DM+No CM 545 4.8 6.8 1.7(1.3–2.1)
DM+V 1212 2.9 4.9 1.8(1.5–2.0)
DM+NV 81 3.8 7.2 2.1(1.1–2.3)
DM
>65
1058 2.2 3.3 1.7(1.5–2.0)
DM+No CM 224 2.4 4.3 1.7(1.2–2.3)
DM+V 802 2.2 3.0 1.7(1.4–2.0)
DM+NV 32 - 4.1 0.5(0.1–3.8)
^ -: Not reached
Results: Overall, survival was comparable for HD vs PD for ESRD patients with no 
CM(HR:1.3;95% CI:0.9-1.6). Likewise, for non-DM patients <65 years, neither V nor 
NV CM impacted on outcomes for PD vs HD. However, DM had worse survival on PD 
regardless of age or presence of V vs NV CM.
Conclusions: Median life expectancy for HD is superior in this Asian population 
relative to USRDS (SRR vs USRDS: 73.5 vs 38.4 months for HD; 42.8 vs 36.6 months for 
PD) Of note, outcomes for young, non-DM ESRD patients was comparable between HD 
and PD. CM did not confer additional risk for adverse outcomes for PD in any subgroup.
TH-PO946
Significance of the Decreased Risk of Dialysis-Related Amyloidosis Now 
Proven by Results from Japanese Nationwide Surveys in 1998 and 2010 
Junichi Hoshino,1,2 Kunihiro Yamagata,2 Shinichi Nishi,3 Kunitoshi Iseki,2 
Ikuto Masakane.2  1Nephrology Center, Toranomon Hospital, Tokyo, Japan; 
2Committee of Renal Data Registry, Japanese Society for Dialysis Therapy, 
Tokyo, Japan; 3Div of Nephrology, Kobe Univ, Kobe, Japan.
Background: Although dialysis technology greatly improved in recent years, it 
remained unclear whether those improvements helped decrease the incidence of dialysis-
related amyloidosis (DRA). Accordingly, we retrospectively compared the incidence 
of first-time carpal tunnel surgery (CTS)—as proxy for DRA onset—in two cohorts of 
hemodialysis patients, the second cohort studied after dialysis methods (especially dialysate 
quality) had greatly improved.
Methods: We used the 1998 and 2010 Japan Renal Data Registries to compare crude 
risk of first-time CTS the following year. After adjusting for patient background and 
laboratory data, odds ratios (ORs) for CTS in the whole cohorts and the populations matched 
by propensity score for hemodialysis and hemodiafiltration were calculated.
Results: 202,726 patients were analyzed. In the 1998 cohort, 1.77% experienced first-
time CTS compared with 1.30% of the 2010 cohort (p<0.001); with 2010 as referent, the 
adjusted 1998 OR was 2.22 (1.68-2.95). Both crude risks and adjusted ORs were analyzed 
by dialysis vintage, age, pre-dialysis b2-microglobulin (b2m) and b2m clearance, risk of 
CTS trending 1.5-2.0 higher in 1998 than 2010.
The reduction was most prominent in patients with longer dialysis vintage, patients 
who were younger, and those with lower pre-dialysis b2m levels. Similar results were 
obtained by propensity score-matched analysis. We also found that b2m clearance >80% 
may reduce risk of CTS.
Conclusions: The incidence of first-time CTS as proxy for DRA decreased significantly 
from 1998 to 2010. Several factors may have contributed to this decrease, including 
improved dialysis methods.
TH-PO947
Twice Weekly Hemodialysis and Clinical Outcomes in the China DOPPS 
Yucheng Yan,1 Mia Wang,2 Jia Qi Qian,1 Brian Bieber,2 Mei Wang,1 Nan 
Chen,3 Bruce M. Robinson,2 Shuchi Anand.4  1Shanghai Renji Hospital; 2Arbor 
Research; 3Shanghai Ruijin Hospital; 4Stanford Univ.
Background: Outcomes related to 2 times weekly hemodialysis (HD),substantially 
practiced in China, remain understudied. Small, single-center studies have indicated better 
preservation of residual kidney function (RKF) and similar survival for 2 vs. 3 times weekly 
HD. We used data from the China Dialysis Outcomes Practice Patterns study (DOPPS) to 
evaluate survival and hospitalizations by frequency of HD.
Methods: We studied 1433 patients from 45 HD unitsin China (2012-2015). Cox 
regression was used to model the association of 2 vs. 3 times weekly HD with clinical 
outcomes adjusting for patient and treatment characteristics.
Results: 270 patients (19%) were undergoing 2 times weekly HD in China. Compared 
with 3 times weekly HD, patients on 2 times weekly HD were more likely to be female and 
have shorter time on dialysis (4.3 vs. 2.6 yrs), more urine output, shorter dialysis session 
length (238 vs. 250 min) and longer travel times to facility. They were less likely to have 
diabetes or cardiovascular disease. Insurance coverage was similar in the two groups. During 
follow-up (median=1.7 years), 184 (13%) deaths and 516 (38%) hospitalizations occurred. 
No differences in mortality or hospitalization were found between the two frequency groups 
(Table). No interaction was observed with vintage (p=0.43). 
Conclusions: In this multi-center study with well-characterized patient and treatment 
data, outcomes of 2 vs. 3 times weekly HD were similar. Thus, it is possible that among 
carefully selected patients 2 times weekly HD may provide acceptable outcomes. An 
additional study is also need due to residual confounding, small sample size, and the 
changes in results with progressive adjustments.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
TH-PO948
Initiation of a Chronic Kidney Disease Case Manager Program Is Associated 
with Better Outcomes in Incident Hemodialysis Patients  Joseph A. Kuhn, 
Patrick Bridge, John W. Larkin, Hao Han, Sheetal Chaudhuri, Len A. Usvyat, 
Terry Ketchersid, Franklin W. Maddux.  Fresenius Medical Care North America, 
Waltham, MA.
Background: The Renal Care Coordinator (RCC) Program places chronic kidney 
disease (CKD) case managers in the Nephrology Practice to co-manage late stage CKD (4 
and 5) patients for an optimal outpatient start to Renal Replacement Therapy (RRT). This 
program is performed through both physical and virtual RCCs. We compared outcomes 
in patients starting hemodialysis (HD) who were previously enrolled in the RCC program 
to CKD patients cared for in the Nephrology practice, but were not in the RCC program.
Methods: All CKD 5 patients who transitioned to end stage renal disease (ESRD) 
requiring RRT between 1/1/2012 and 10/1/2014 at the nephrology practices that adopted 
the RCC were analyzed. We compared outcomes in patients enrolled into the RCC program 
versus patients considered to have a “Timely Referral” for dialysis (i.e. were followed in a 
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nephrology practice for >4 months before starting RRT), but received no RCC interaction. 
The access type, albumin (Alb), and hemoglobin (Hgb) was collected at the first outpatient 
HD treatment. We also computed the rates of hospital days and mortality in the first 120 
days of HD.
Results: 1,404 CKD 5 patients were identified for the analysis, where 51% of the 
population was enrolled in the RCC. Patients in the RCC had a lower % of catheters, higher 
% of Alb ≥4.0g/dL, and higher % of Hgb 10-11g/dL at the first HD treatment compared 
to patients with a “Timely Referral”, but no RCC care. During a 120 day follow up after 
initiating HD, patients in the RCC program had significantly lower hospitalization rates. 
Table 1. Comparison of parameters in incident HD patients
Patient 
group
Number 
of patients
120 Day 
hospital 
admissions 
(ppy)
120 Day 
hospital 
days 
(ppy)
Catheters 
at start of 
HD
Hgb 10-11 
at start of 
HD
Alb ≥4.0 
at start of 
HD
TIMELY, 
Non-RCC 685 1.9 13.7 52.2% 26.9% 21.5%
TIMELY, 
RCC 719 1.5* 9.3* 31.5%* 30.9%* 27.8%*
P<0.05 (*)
Conclusions: This analysis demonstrates that placement of CKD case managers is 
associated with better outcomes, including anemia, access type, nutritional status and 
hospitalizations in the first 120 days of HD.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
TH-PO949
Extracellular Overhydration Measured by Multifrequency Bioelectrical 
Analysis Is Associated with Increased Postdialysis Systolic Blood Pressure 
in Hemodialysis Patients  Hae Yeul Park,1 Seok-hyung Kim,1 Ah Ran Choi,1 
Jung eun Lee,2 Hyung Jong Kim,3 Hoon Young Choi,1 Sung-Kyu Ha,1 Hyeong 
cheon Park.1  1Nephrology, Gangnam Severance Hospital, Yonsei Univ College 
of Medicine, Seoul, Korea; 2Nephrology, Yongin Severance Hospital, Yonsei 
Univ College of Medicine, Seoul, Korea; 3Nephrology, Bundang CHA Hospital, 
Pochon CHA Univ College of Medicine, Seoul, Korea.
Background: Postdialytic hypertension is associated with increased morbidity and 
mortality for hemodialysis (HD) patients. Recent studies suggest that increased postdialysis 
extracellular volume may account for the rise in postdialysis systolic blood pressure 
(PDSBP). The aim of this study was to assess the relationship between volume status and 
PDSBP in HD patients.
Methods: Volume status assessments were performed after mid-week HD using 
multifrequency bioelectrical impedance (BIA, Inbody S10) in supine position. Demographic 
and routine biochemical data were collected and pre- and post-dialysis B-type natriuretic 
peptide (BNP) level was measured (Triage BNP test, Alere).
Results: We enrolled clinically stable 99 HD patients from 3 dialysis centers. Patients 
were divided into 3 groups based on a fall in SBP of 20mmHg or more (Hypotensive, 24.2%), 
an increased SBP of 10mmHg or more (Hypertensive, 32.3%), and a stable group (43.4%). 
The mean age was 55.1±13.3 years in hypotensive, 58.3±11.6 years in stable, and 65.2±7.2 
years in hypertensive group. Postdialysis BNP was 267.8±251.1 pg/mL in hypotensive, 
669.8±915.9 pg/mL in stable, 1124.2±1197.8 pg/mL in hypertensive group. There were no 
differences in gender, dialysis prescriptions, and subjective global assessment score among 
the patient groups. The ECW/TBW ratio was significantly higher in the hypertensive group 
and positively correlated with PDSBP and delta SBP. The only independent risk factor 
affecting PDSBP was ECW/TBW ratio after dialysis.
Conclusions: HD patients who demonstrate increase in PDSBP should have their 
volume status reassessed and target dry weights adjusted using BIA, with emphasis on 
increased the ECW/TBW ratio.
TH-PO950
Novel Phosphate Binder, Ferric Citrate Hydrate, Can Reduce Serum 
Phosphate Levels and Doses of Erythropoiesis Stimulating Agents in 
Japanese Patients on Hemodialysis  Hirotake Kasuga,1 Ryo Takahashi,1 Keiko 
Kimura,1 Chieko Matsubara,1 Hitomi Tanimoto,1 Mari Maseki,1 Yasuhiko Ito.2 
1Nephrology, Nagoya Kyoritsu Hospital, Nagoya, Japan; 2Nephrology, Nagoya 
Univ Graduate School of Medicine, Nagoya, Japan.
Background: Ferric citrate hydrate (FC) has been available in Japan as a phosphate 
binder for patients on dialysis (HD) since 2014 although its effects have not been evaluated 
in detail in such patients. The present study aimed to determine the effects of FC on serum 
phosphate levels and anemia control in patients on HD.
Methods: Thirty-eight outpatients (mean age, 62.5 y; male, n = 28 [73.7%]; mean 
HD vintage, 7.2 y; hypertension, n = 29 [76.3%]; diabetes, n =19 [50.0%]; secondary 
hyperparathyroidism, n = 15 [39.5%]) on maintenance HD were treated with FC for 
six months to control hyperphosphatemia. Serum concentrations of phosphate, calcium, 
hemoglobin, and ferritin levels, transferrin saturation (TSAT), and weekly epoetin (EPO) 
doses were evaluated.
Results: Mean phosphate levels were significantly decreased from 7.05 ± 1.11 to 6.19 
± 0.91 (p < 0.00001), 6.14 ± 1.16 (p < 0.005) and 6.01±1.11 (p < 0.005) mg/dL at one, three 
and six months, respectively. Calcium, hemoglobin and ferritin levels did not significantly 
differ during the same periods. Transferrin saturation was significantly increased (26.7 ± 
10.9% vs. 20.0 ± 9.5%, p < 0.05) and the weekly EPO dose was significantly decreased 
(2750 ± 2699 vs. 6801 ± 7406 IU/week, p < 0.05) after six months of FC therapy.
Conclusions: FC can decrease serum phosphate levels and the weekly EPO dose. 
Therefore, FC is useful for treating hyperphosphatemia and renal anemia in Japanese 
patients on HD.
TH-PO951
Geographic Variation of Potentially Avoidable Readmissions in 
Hemodialysis Patients  Daniel W. Ross,1 Kamyar Kalantar-Zadeh,2 Steven 
Fishbane,1 Anna Mathew.1  1Div of Nephrology, Hofstra North Shore ±LIJ 
School of Medicine, New York, NY; 2Harold Simmons Center for Kidney Disease 
Research and Epidemiology, Div of Nephrology, Univ of California, CA.
Background: In 2011 in the United States, 36.3% of prevalent hemodialysis patients 
were readmitted within 30 days of an index hospitalization. These rates are approximately 
twice that of the general U.S Medicare population.  While some readmissions to hospital 
are unavoidable, it is probable that a substantial number could be prevented. In the present 
study, we describe inter-state variability in 30-day potentially avoidable readmissions (PAR).
Methods: The United States Renal Data System (USRDS) was used to identify 
prevalent hemodialysis patients (vintage >90 days) with acute hospitalizations in 2008. 
Exclusion criteria were transfer to rehabilitation or skilled nursing facility, unknown dialysis 
start date, and renal function recovery.  PAR were identified using a validated, computerized 
algorithm (SQLape), and displayed geographically by state using Pitney Bowes MapInfo.
Results: 250,606 index hospitalizations were identified, with 37% readmissions 
within 30 days (n = 84,279). Nationwide, 24% of index hospitalizations were followed by 
a 30-day PAR (64.9% of all readmissions) (n= 59,803). PAR ranged from 12% to 31% by 
state. The figure shows the geographic distribution of potentially avoidable readmissions.
Conclusions: There is inter-state variability in PAR among chronic hemodialysis 
patients and that may be related to regional differences in practice patterns or patient 
demographics. Further characterization of risk factors associated with PAR is the focus 
of our ongoing research.
TH-PO952
Unravelling the Relationship Between Mortality, Hyponatremia, 
Inflammation and Malnutrition in Hemodialysis Patients: Results from the 
International MONDO Initiative  Marijke J.E. Dekker,1 Daniele Marcelli,3 
Bernard J. Canaud,3 Constantijn Konings,1 Karel M. Leunissen,2 Nathan W. 
Levin,4 Jochen G. Raimann,4 Frank van der Sande,2 Len A. Usvyat,3,4 Peter 
Kotanko,4 Jeroen Kooman.2  1Catharina Hospital Eindhoven; 2Maastricht Univ 
Medical Center; 3Fresenius Medical Care; 4Renal Research Inst.
Background: Hyponatremia is a risk factor for mortality in hemodialysis patients. 
However, it is not well known to which extent comorbidities, such as malnutrition, fluid 
overload and inflammation are related to hyponatremia and influence the association 
between hyponatremia and outcomes.
Methods: We studied 8892 patients from the European subset of the MONDO Initiative. 
Nutritional and fluid statuses were assessed by multifrequency bioimpedance spectroscopy. 
Based on pre-dialysis fluid status, fluid depletion was defined as an extracellular water 
volume < -1.0L and fluid overload > +2.5L. Malnutrition was defined as a lean tissue index 
below the 10th percentile of age- and gender matched healthy controls. Hyponatremia and 
inflammation were defined as serum sodium levels < 135 mEq/L and C-reactive protein 
levels >10 mg/L, respectively.
Results: Hyponatremia was predicted by the presence of malnutrition (odds ratio (OR) 
1.48 (95%CI 1.30-1.69) and inflammation (OR 1.44 (95%CI 1.26-1.64)), but not by fluid 
depletion (OR 1.38 (95%CI 0.98-1.93)) or fluid overload (OR 0.99 (95%CI 0.85-1.14)). 
Malnutrition (hazard ratio (HR) 1.39 (95%CI 1.23-1.58)), inflammation (HR 2.31 (95%CI 
2.04-2.62)), fluid overload (HR 2.17 (95%CI 1.90-2.47)) and hyponatremia (HR 1.63 
(95%CI 1.39-1.90)) were independent predictors for all-cause mortality.
Conclusions: In hemodialysis patients hyponatremia is associated with malnutrition and 
inflammation but not with deranged fluid status. Hyponatremia maintained predictive for all-
cause mortality after correction for malnutrition, inflammation and fluid status abnormalities. 
Hyponatremia may aid efforts to identify hemodialysis patients at increased risk of death.
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TH-PO953
Low Serum Sodium Concentration at the Induction of Maintenance 
Hemodialysis Predicts Higher Risk of Mortality  Yukako Ohyama,1 Hideaki 
Shimizu,1 Daijo Inaguma,2 Yoshiro Fujita.1  1Nephrology and Rheumatology, 
Chubu Rosai Hospital, Nagoya, Japan; 2Nephrology, Red Cross Nagoya Daini 
Hospital, Nagoya, Japan.
Background: Low serum sodium concentrations are associated with an increased risk 
of death in the general population because of underlying diseases such as congestive heart 
failure and cirrhosis. However some papers report hyponatremia itself further increases the 
mortality risk. The prevalence of hyponatremia and the mortality risk of hyponatremia at 
the induction of maintenance hemodialysis (HD) haven’t been reported before.
Methods: This study is a retrospective cohort study which date was collected from 
“Aichi Cohort study of Prognosis in Patients” (AICOPP) newly initiated dialysis. After the 
exclusion of peritoneal dialysis (PD) patients, this study enrolled 1395 patients (mean age; 
68 ± 13 years, mean eGFR level; 5.4 ± 2.2 ml/min/1.73m2) who started maintenance HD 
between 10/1/2011 and 11/30/2013. We divided the cohort to 4 groups by serum sodium 
concentration at the induction of HD adjusted by serum glucose concentration(Severe 
hypo:Na<130, Mild hypo:130£Na<136, Normal :136£Na£145, Hyper:Na>145 mEq/L). 
The proportional hazard model was used to examine the association between serum sodium 
level and mortality.
Results: The prevalence of hyponatremia, defined as Na<136 mEq/L and <130 was at 
23% and 5%, respectively. During 15.5 months’ mean follow up, 159 patients (11%) died. 
The lowest Na group was significantly associated with higher risk of mortality.(figure1) 
Patients with serum sodium levels of <130 mEq/L were more likely to have multivariable-
adjusted mortality hazard ratios (95% confidence interval) of 2.34 (1.31-4.15) compared 
to patients with serum sodium levels of 136-145 mEq/L.
Conclusions: Hyponatremia at the induction of HD is an independent predictor of 
higher risk for mortality.
TH-PO954
Frequency of Hyperkalemia Events in Dialysis Patients in a Large Dialysis 
Organization  Akeem Yusuf,1 Yan Hu,1 Bhupinder Singh,2 Alex Yang,2 James 
B. Wetmore.1  1Chronic Disease Research Group, MMRF, Minneapolis, MN; 
2ZS Pharma, Inc, Redwood City, CA.
Background: Hyperkalemia is a major problem in dialysis patients. It is associated with 
increased risk of cardiac arrhythmias and sudden cardiac death. However, few studies have 
examined frequency of hyperkalemia episodes in a large population of dialysis patients. 
We present a characterization of the magnitude of hyperkalemia prevalence in a large 
hemodialysis population and examine the role of interdialytic interval in its occurrence.
Methods: We derived annual cohorts of hemodialysis patients (2007-2010) from 
linked DaVita and USRDS databases. Included patients were those receiving thrice-weekly 
hemodialysis. On a monthly basis, hyperkalemia case was defined as a serum potassium 
level greater than or equal to 5.5 mEq/L. Hyperkalemia prevalence was calculated as 
the cumulative number of monthly episodes divided by cumulative follow-up time. 
Hyperkalemia prevalence was also reported separately by long and short interdialytic 
interval.
Results: Hyperkalemia prevalence in 2010 was 16.3 per 100 patient-months. 
Overall, hyperkalemia prevalence was stable between 2007 and 2010. The prevalence of 
hyperkalemia events occurring on day after the long interdialytic interval was about 2.0 
to 2.4 times as high as events occurring on the day after the short interdialytic interval. 
Number of events per 100 patient-months
Events on day after Events on day after
Cohort Cohort long interdialytic short interdialytic
Year Size interval interval
2007 28,769 58.74 28.84
2008 34,785 62.16 27.63
2009 34,567 62.94 26.26
2010 36,879 61.61 26.22
Conclusions: The findings from this study show that hyperkalemia is highly prevalent 
among hemodialysis patients, especially on the day after the long-interdialytic interval. 
Further studies are warranted.
Funding: Pharmaceutical Company Support - ZS Pharma, Inc.
TH-PO955
Serum Potassium Levels and Mortality in Hemodialysis Patients 
Akeem Yusuf,1 Yan Hu,1 Bhupinder Singh,2 Jose A. Menoyo,2 Alex Yang,2 James 
B. Wetmore.1  1CDRG/MMRF, Mpls, MN; 2ZS Pharma, Inc, Redwood City, CA.
Background: Hyperkalemia is common in patients receiving maintenance hemodialysis 
(HD) and is associated with sudden cardiac death. However, few studies have examined 
the association between serum potassium (K) level and death in a large population of 
dialysis patients.
Methods: A cohort of patients receiving thrice-weekly HD in 2010 was constructed 
using data linked between USRDS and a large dialysis organization (LDO). Patients were 
followed from first serum K measurement until death, transplant, change in dialysis modality, 
change in dialysate K concentration, loss of Medicare eligibility, loss to follow up, or 
Dec 31, 2010. Hyperkalemia was defined by serum K levels 5.5-6.0 mEq/L at 0.1 mEq/L 
intervals. Time-dependent Cox proportional hazards modeling was used to estimate the 
association between hyperkalemia occurrence and all-cause and cardiovascular mortality.
Results: Hyperkalemia defined as serum K ≥5.7 mEq/L was associated with all-cause 
mortality (adjusted hazard ratio [AHR] 1.1, 95% CI 1.01-1.28, P = 0.037, compared to 
K ≥5.0 mEq/L) after adjustment for demographic and clinical factors in time-dependent 
models; the AHRs increased progressively as the threshold for hyperkalemia rose (AHRs 
1.18, P = 0.014, for K=5.8 mEq/L; 1.29, P = 0.001, for K=5.9 mEq/L; 1.37, P = 0.0002, for 
K=6.0 mEq/L). The pattern of the point estimates was similar for cardiovascular mortality, 
although the results did not reach statistical significance (AHRs 1.09 for K=5.7 mEq/L, 
1.13 for K=5.8 mEq/L, 1.20 for K=5.9 mEq/L, 1.28 for K=6.0 mEq/L).
Conclusions: Hyperkalemia is associated with all-cause mortality beginning at 
K level ≥5.7 mEq/L, with mortality risk point estimates increasing in ordinal fashion 
through K level ≥6.0 mEq/L. A similar pattern was observed in the point estimates for 
cardiovascular mortality. This study may have identified a threshold at which point serum 
K becomes dangerous. 
Funding: Pharmaceutical Company Support - ZS Pharma, Inc
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TH-PO956
A Multicenter, Phase 2/3 Randomized, Double-Blind, Placebo-Controlled 
Trial of Nalbuphine ER Tablets for the Treatment of Uremic Pruritus: 
Baseline Population Characteristics  Vandana S. Mathur,1 Jayant Kumar,3 Paul 
W. Crawford,5 Howard Hait,4 Thomas Sciascia.2  1MathurConsulting, Woodside, 
CA; 2Trevi Therapeutics, New Haven, CT; 3Renal Medicine Associates, 
Albuquerque, NM; 4Biostatistics, Edenridge Consulting, Wilmington, DE; 
5Research by Design, (vergreen Park, IL.
Background: Uremic pruritus (UP) afflicts 30-40% of hemodialysis patients (HDP) and 
is associated with greater use of ESA and antibiotics. UP is hypothesized to be centrally-
mediated via the reduction in endogenous κ/µ opioid ligand ratio. Nalbuphine ER tablet 
(NAL), a κ-opioid agonist and µ-opioid antagonist, is being developed for treatment of UP.
Methods: 373 HDP with moderate or severe UP (Numerical Rating Scale, NRS itch 
intensity scores ≥4.5) were randomized to blinded placebo or NAL (60 or 120 mg BID) 
X 8-wks.
Results: Worsening itch intensity by baseline NRS quartile was monotonically 
associated with impaired QOL on all instruments as well as with sleep onset latency, anxiety, 
and depression, but not with age, gender, BMI, ethnicity, itch duration, iPTH, URR, or 
Kt/V. Black race appeared to be associated with higher NRS.
Itch Intensity Numerical Rating 
Scale (NRS) Quartile >N@
Q1 >97@ 
(4.5-5.6)
Q2 >97@
(5.7-6.8)
Q3 >104@
(6.9-8.0)
Q4 >75@
(>8.0)
NRS (0, no itch; 10, worst possible 
itch) 5.1 (0.4) 6.3 (0.3) 7.5 (0.4) 8.9 (0.6)
White/Black race 53/43% 49/47% 47/53% 44/55%
Self-Assessed Disease Severity 
Patient Type C [most severely 
affected]
20% 33% 46% 67%
Skindex-10 (0 - 60) [0 (least); 60 
(greatest) QOL impact of pruritus] 26.0 (11.1) 32.4 (13.1) 39.7 (12.4) 43.5 (13.3)
HADS - Depression 5.6 (3.6) 6.1 (3.6) 6.8 (4.0) 7.8 (4.5)
HADS - Anxiety 6.2 (3.9) 7.7 (4.1) 7.7 (4.4) 9.4 (4.6)
Time to fall asleep >60 minutes 20% 22% 36% 42%
iPTH (pg/mL) 492 (451) 336 (304) 433 (334) 463 (439)
Serum phosphate (mg/dL) 5.6 (1.7) 5.4 (1.7) 5.7 (2.0) 5.6 (1.8)
Urea Reduction Ratio (%) 74 (5) 74 (5) 73 (6) 74 (6)
spKt/V 1.6 (0.3) 1.6 (0.3) 1.5 (0.3) 1.7 (0.6)
Conclusions: In addition to the 1° endpoint hypothesis that NAL will reduce itch 
intensity, the apparent associations between itch intensity and QOL measures at baseline 
warrant examination by treatment. Unblinded results will be presented.
Funding: Pharmaceutical Company Support - Trevi Therapeutics
TH-PO957
International Variation of Characteristics of Health Literacy and Its 
Association with Mortality in Dialysis  Kerri L. Cavanaugh,1 Mia Wang,2 
Ken Wallston,1 Russell Rothman,1 Ali AlSahow,3 Patricia De Sequera,4 Takeshi 
Hasegawa,5 Brian Bieber,2 Bruce M. Robinson,2 Ronald L. Pisoni,2 Francesca 
Tentori.1,2  1Vanderbilt Univ; 2Arbor Research; 3Jahra Hospital; 4Hospital Infanta 
Leonor; 5Fukushima Medical Univ.
Background: In patients receiving hemodialysis (HD), low health literacy (LHL) 
has been associated with greater use of emergency care, more hospitalizations and higher 
mortality. Little is known about the characteristics of LHL in HD patients outside of the 
United States.
Methods: A total of 11,476 DOPPS participants completed the Brief Health Literacy 
Screen (BHLS) [0-12]. Descriptive statistics were performed overall and by country. 
Participant characteristics were examined between three health literacy categories using 
mixed, GEE, and multinomial logistic models. Cox models were applied to examine 
associations of LHL with mortality adjusting for the above variables and also potential 
effects of study phase, country, and facility clustering.
Results: LHL prevalence varied across countries (Figure). LHL was more likely in 
patients who were older, female, unemployed and in those who had fewer years on HD, 
lower education, and lower income (all P for trend<0.001). LHL was significantly associated 
with mortality when examined as a continuous score (HR=1.05; 95%CI=1.03-1.08 for 
each point decreased) or as a category (HR=1.65; 95%CI=1.28-2.12 Low vs. High), and 
no interaction with country was observed. 
Conclusions: LHL is common worldwide among HD patients. Variability in LHL 
prevalence across countries may be in part explained by cultural differences as well as health 
care systems. Vulnerable patients are at highest risk of LHL, and LHL is an independent 
predictor of mortality. Further examining by country the role of health system practices 
may help to overcome LHL-related barriers to patient engagement and improve outcomes 
in hemodialysis.
Funding: Pharmaceutical Company Support - The DOPPS Program is supported by 
Amgen, Kyowa Hakko Kirin, AbbVie Inc., Sanofi Renal, Baxter Healthcare, and Vifor 
Fresenius Medical Care Renal Pharma, Ltd. Additional support for specific projects and 
countries is also provided in Canada by Amgen, BHC Medical, Janssen, Takeda, Kidney 
Foundation of Canada (for logistics support); in Germany by Hexal, DGfN, Shire, WiNe 
Institute; for PDOPPS in Japan by the JSPD. All support is provided without restrictions 
on publications.
TH-PO958
Evaluation of a Vancomycin Weight-Based Dosing Protocol in Patients 
Undergoing High-Flux Hemodialysis  Katherine Desforges, Marieme N’Diaye, 
Robert Zoel Bell, Jean-Philippe Lafrance, Vincent Pichette, Michel Vallee. 
Nephrology, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada.
Background: Hemodialysis patients are frequently subject to Gram-positive 
infections including Staphylococcus aureus and Methicillin-resistant Staphylococcus 
aureus (MRSA).Vancomycin is an antibiotic of choice in this population to treat these 
infections.The objective of this project was to validate the performance of a pre formatted 
individual prescription protocol of vancomycin in its capacity to reach target vancomycin 
serum concentrations of 10 to 30 mg/L for Gram-positive infections and 15 to 20 mg/L 
for MRSA infections.
Methods: The records of 84 patients diagnosed with end-stage renal disease undergoing 
a 4-hour, three times weekly high-flux hemodialysis treatment were analyzed retrospectively.
All patients received vancomycin according to a weight-based dosing protocol between 
2011 and 2014.Patients < 70 kg received a 1000 mg loading dose followed by a 500 mg 
maintenance dose at each dialysis session.Patients between 70 and 100 kg received a 1500 
mg loading dose followed by a 750 mg maintenance dose.Patients > 100 kg received a 
1500 mg loading dose followed by a 1000 mg maintenance dose.
Results: We collected and analyzed 189 dosages of 84 patients.For all assays, 95.2% 
achieved levels between 10 and 30 mg/L and 50.3% achieved levels between 15 and 20 
mg/L.Stratified by weight categories, for the 10 to 30 mg/L target, 93.3% of patients < 70 
kg, 100 % of patients between 70 and 100 kg and 89.5% of patients > 100 kg achieved 
the target serum concentrations.For the 15 to 20 mg/L target, 49.3% of patients < 70 kg 
achieved the target serum concentrations (mainly below), 61.3% of patients between 70 and 
100 kg achieved the target serum concentrations and 31.6% of patients > 100 kg achieved 
the target serum concentrations (mainly higher, but below 30 mg/L).
Conclusions: The vancomycin weight-based dosing protocol achieved target serum 
concentrations of 10 to 30 mg/L in 95.2% of patients.However, because half the dosages of 
patients < 70 kg were below the target of 15 to 20 mg/L, vancomycin bolus and maintenance 
doses should be adjusted upward in this subgroup.No dose change is suggested in the 
other subgroups.
Funding: Private Foundation Support, Government Support - Non-U.S.
TH-PO959
Trends in Incident ESRD Counts Initiating Dialysis in Freestanding 
Facilities Have Regional Variation  David T. Gilbertson,1 Peer Kidney Care 
Initiative Investigators.2  1CDRG, MMRF, Minneapolis, MN; 2Peer Kidney 
Care Initiative.
Background: Overall rates of incident end-stage renal disease (ESRD) patients 
initiating dialysis in freestanding units have stabilized, and the growth in counts of incident 
ESRD patients begun to slow by the beginning of this decade. We assessed trends in incident 
ESRD counts from 2004–2011, overall and geographically by the 9 US Census Divisions.
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Methods: Data were ascertained from the Centers for Medicare & Medicaid Services 
ESRD database. For annual incident cohorts, we identified patients with their first outpatient 
dialysis within 3 months of initiating chronic dialysis in a freestanding facility.
Results: Yearly counts increased through 2010, with an average annual percent increase 
of 2.7% from 2004 to 2011. Between 2009 and 2011, this average percent increase was 
relatively unchanged (-0.1%). However, there were regional differences, with the New 
England Census Division experiencing the largest proportionate decrease in incident 
patients between 2009 and 2011, while the contiguous Middle Atlantic division averaged 
the highest increase during the same period by 2011.
Conclusions: Overall trends in dialysis incidence reveal substantial geographic 
variation that has not been explained, suggesting that an assessment based on overall U.S. 
counts may mask important regional differences. Whether these trends will continue in 
the face of increasing diabetes rates, an aging population and shifts in social demographic 
changes is uncertain and will require more detailed analysis.
Funding: Pharmaceutical Company Support - Financial support for Peer is provided 
by 13 participating dialysis provider organizations: American Renal Associates, 
Atlantic Dialysis Management Services, Centers for Dialysis Care, DaVita HealthCare 
Partners, Dialysis Clinic, Inc. (DCI), DSI Renal, Fresenius Medical Care, Independent 
Dialysis Foundation, Northwest Kidney Centers, Renal Ventures Management, Satellite 
Healthcare, The Rogosin Institute, and U.S. Renal Care. In collaboration with the Chief 
Medical Officers of these organizations, the Peer Kidney Care Initiative is operated by 
the Chronic Disease Research Group, a division of the Minneapolis Medical Research 
Foundation, in Minneapolis, Minnesota., Private Foundation Support
TH-PO960
Association of Intradialytic Hypoxemia with Hospitalization and Mortality: 
Results from a Large U.S. Hemodialysis Cohort  Anna Meyring-Wosten,1 
Hanjie Zhang,1 Xiaoling Ye,1 Doris H. Fuertinger,1 Franz Kappel,2 Mikhail 
Artemyev,1 Nancy Ginsberg,1 Yuedong Wang,3 Stephan Thijssen,1 Peter 
Kotanko.1,4  1Renal Research Inst, New York, NY; 2Univ of Graz, Austria; 3Univ 
of California - Santa Barbara, CA; 4Icahn School of Medicine at Mount Sinai, 
New York, NY.
Background: While intradialytic hypoxemia is recognized since the early days of 
hemodialysis (HD), its associations with hard clinical outcomes have not yet been assessed.
Methods: We analyzed arterial oxygen saturation (SaO2) data obtained by Crit-Line™ 
monitor (CLM) in chronic HD patients treated between 1/2012 and 1/2015. An individual 
6-month baseline with at least 10 CLM measurements preceded a 12-month follow-up. 
Prolonged intradialytic hypoxemia (PIH) was defined as SaO2 ≤ 90% for more than 
1/3 of treatment time. Patients were stratified based on the presence or absence of PIH. 
We conducted Cox proportional hazards analysis with adjustment for age, gender, race, 
vintage, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), 
diabetes, albumin, hemoglobin, erythropoietin (EPO) dose, neutrophil-to-lymphocyte 
ratio, interdialytic weight gain, post-HD systolic blood pressure, and ultrafiltration rate.
Results: We studied 983 patients (59% males; 53% whites) with 30.5±12.5 baseline 
SaO2 measurements. 100 patients (10.2%) had PIH. PIH patients showed a higher prevalence 
of CHF and COPD required significantly more EPO, and resembled an inflammatory 
phenotype. During the follow-up, 2.21 and 1.55 hospitalizations per patient-year were 
recorded in patients with and without PIH, respectively (P=0.009). Eighty-nine patients 
died during follow-up. The mortality rate was 24.1 per 100 patient years in the PIH group 
and 10.2 in the non-PIH group (P=0.0008). Cox proportional hazards analysis corroborated 
the increased probability of death in PIH patients (hazard ratio 1.98 [95% CI: 1.14 to 3.43]).
Conclusions: Prolonged intradialytic hypoxemia (PIH) is associated with increased 
risk for hospitalization and mortality. A better understanding of the pathophysiology of 
PIH, its clinical consequences and its medical management requires future basic and 
clinical research.
Funding: Pharmaceutical Company Support - Renal Research Institute
TH-PO961
A New Polymethyl Methacrylate Membrane (PMMA) Improves the 
Membrane Adhesion of Blood Components and Clinical Efficacy 
Ikuto Masakane.  Yabuki Hospital, Nephrology, Yamagata, Japan.
Background: Polymethyl methacrylate (PMMA) is a unique dialysis membrane 
which has protein adsorption property and it has been reported to effective to reduce the 
pruritus and maintain nutritional status on chronic dialysis patients. The newly launched 
PMMA membrane (NF) has been modified in order to improve hemo-compatibility as 
well as maintaining the protein adsorptive capacity. The aim of the current study is to 
evaluate the solute removal performance, peripheral circulation during dialysis session and 
clinical efficacy on patient’s subjective symptoms in the comparison with conventional 
PMMA (BG).
Methods: The six subjects were treated with NF and BG for 3 months each in a 
crossover design. We evaluated the solute removal properties by the clearance of urea, 
beta-2 microglobulin (B2MG) , removed amount of alpha-1 microglobulin (A1MG) and 
albumin loss in spent dialysate. The hemo-compatibility was evaluated by changes in 
platelet count. The peripheral circulation was estimated by the Skin Perfusion Pressure 
(SPP) by PAD-3000® (Kaneka Medix, Osaka, Japan) Dialysis-related complaints, including 
itching, distraction, malaise, headache, hypotension, fatigue after dialysis, and appetite, 
were compared.
Results: The total amount of removal in each urea, B2MG, A1MG and albumin leakage 
was not different in both NF and BG. During dialysis, the percent changes in platelet count 
were (for NF and BG, respectively) 97.1% and 86.1% after 15 min of dialysis, 96.5% 
and 85.1% after 30 min, 97.3% and 88.3% after 1 h, and 99.6% and 90.1% after 4 h. The 
changes in platelet count during dialysis were significantly smaller with the NF than with 
the BG. The SPP was well maintained in NF but time-dependently deteriorated in BG. 
There were no significant differences in any subjective symptoms, but the mean score of 
the seven items tended to be lower in NF.
Conclusions: The new PMMA (NF) membrane may improve the QOL of chronic 
dialysis patients by stabilizing the platelet and peripheral circulation.
TH-PO962
Outcomes of Infants Receiving Chronic Peritoneal Dialysis  Keia Sanderson,1 
Hongying Dai,2 Laurel K. Willig,1 Bradley Warady.1  1Nephrology, Children¶s 
Mercy Hospital, Kansas City, MO; 2Research Development and Clinical 
Investigation, Children¶s Mercy Hospital, Kansas City, M2.
Background: Outcome data for infants receiving chronic peritoneal dialysis (CPD) 
is limited and has been reported primarily by small voluntary registries. The impact of 
treatment era has also been poorly studied.
Methods: The USRDS database was reviewed for demographic features and outcomes 
of patients who initiated CPD at £12 months of age from 1990-2014.
Results: A total of 1,730 infants (575 £1 month and 1155 >1-12months ) who initiated 
CPD at £12 months from 1990-2014 were identified. Overall, 68% of the infants were male 
and the most common primary diagnoses were obstructive uropathy (31.8%) and congenital 
renal dsysplasia/hypoplasia (29.9%). Mean age at initiation of CPD was 0.4 months (+/-
0.3 months) in infants £1 month and 5.2 months (+/-3.1 months) in infants >1-12months. 
Overall, 1066 infants received at least one kidney transplant during the follow up (333 
infants £1 month and 733 infants >1-12months. Mean age at first kidney transplant was 2.9 
years (+/-1.6yrs) in infants £1 month and 2.5 years (+/-2.15yrs) in infants >1-12months . 
Crude all cause mortality rates were higher among infants who initiated CPD at £1 month 
(276 per 1000 persons at 3 years) versus infants who initiated CPD at >1-12 months of 
age (185 per 1000 persons at 3 years). Mortality rates at 5 years were 28.7% for infants 
initiated on CPD at £1 month and 20.7% for infants at >1-12 months of age. Multivariable 
Cox proportional hazards modeling of factors associated with mortality demonstrated 
a statistically significant adjusted HR of 4.027 (95% CI 3.274-4.952) for initiation era 
(1990-2000 vs 2001-2014) and an HR of 1.42 (95% CI 1.15-1.744) for age at initiation of 
dialysis (£1 month vs >1-12months). Patient sex, race, and primary ESRD diagnosis were 
not significantly associated with mortality in this model.
Conclusions: In the largest cohort of infants on CPD reviewed to date, the probability 
of mortality among infants initiating CPD in the first year of life appears to be greaterduring 
the prior initiation era (1990-2000) and greater among infants who initiated dialysis at £1 
month of age.
TH-PO963
ESRD from Scleroderma in the United States 1995-2010  Donal J. Sexton, 
Scott Reule, Robert N. Foley.  Medicine, Univ of Minnesota, Minneapolis, MN.
Background: Though the management of scleroderma continues to evolve it is 
unknown whether the burden of ESRD from scleroderma has changed.
Methods: We examined United States Renal Data System data (N = N = 1,557,117) for 
the years 1995-2010 to calculate incidence rates and outcomes of ESRD due to scleroderma 
treated with renal replacement therapy (RRT, N=2342).
Results: ESRD rates due to scleroderma in 1995-1996 were 0.6 per million per year 
in the overall population, with higher rates in age 40-64 (0.9) and ≥ 65 (1.4) years, females 
(0.8) and African Americans race (0.9). Standardized incidence ratios declined between 
1995-1996 and 2009-2010 in the overall population (ratio 0.55), in those aged 40-64 yrs 
(0.49), 65+ yrs (0.62), in male (0.56) and female sex (0.55), in white (0.6) and AA race 
(0.37). Characteristics of ESRD from scleroderma included age 40-64 (57.9% Vs. 41.3% 
yrs.), female sex (76.6% Vs. 45.1%) and white race (78.1% Vs. 65.2%). 74.3 % of patients 
with scleroderma died over a mean observation period of 3.3 years, while 16.9% were 
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listed for renal transplant and 10.1% received a renal transplant. With matching for age, 
sex and race, overall mortality rates were higher in scleroderma cases than controls (22.3 
Vs. 15.5 per 100 person-years, P < 0.001). Overall rates of listing for renal transplant (8.4 
Vs. 8.5 per 100 person-years, P = 0.92) and rates of transplantation (4.1 Vs. 4.3 per 100 
person-years, P = 0.66) were similar in scleroderma cases and controls.
Conclusions: The incidence of ESRD from scleroderma appears to have declined in 
the United States since 1995. Mortality rates on RRT are higher in scleroderma cases than 
controls taken from ESRD from other causes. However, listing for and receiving a renal 
transplant were as likely in scleroderma patients as matched controls.
TH-PO964
Prevalence and Mortality Associations of Protein- Energy Wasting 
Syndrome Criteria in Maintenance Hemodialysis Patients  Srini Beddhu,1,2 
G. Wei,1 Xiaorui Chen,1 Kalani L. Raphael,1,2 Robert E. Boucher,1 Dominique 
Ferranti,1 Tom Greene,1 Michel Chonchol.3  1U of Utah; 29A SLC; 3UC Denver.
Background: As the prevalence and mortality associations of protein-energy wasting 
(PEW) syndrome criteria in the MHD population are not well established, we examined 
these in 1480 MHD pts in the HEMO Study, a multi-center RCT to examine the effects of 
dialysis dose and dialyzer flux on mortality.
Methods: The prevalence of International Society of Renal Nutrition and Metabolism 
panel PEW criterion (listed in the table) at the 12 m follow-up visit were examined. 
Subsequent mortality associations were examined in Cox models adjusted for demographics, 
duration of ESRD, Kt/V and flux groups, smoking and alcohol use.
Results: There were 632 deaths / 3390 yrs of follow-up. The prevalence of PEW 
criterion varied widely: 0% for low body fat% to 64% for low DEI (figure). 
Low serum albumin and cholesterol, low BMI, weight loss and low mid-arm muscle 
circumference (MAMC) were strongly associated with higher risk of mortality (Table 1). 
However, dietary criteria were not associated with mortality. 
PEW Criterion* All cause mortalityHR* (95% CI)
Serum Alb < 3.5 (g/dl) 2.12 (1.68, 2.69)
Serum Chol < 100 (mg/dl) 3.68 (2.46, 5.50)
BMI < 23 (kg/m2) 1.51 (1.23, 1.86)
Wt loss >10% 1.95 (1.47, 2.58)
Muscle mass category
Low MAMC# 2.00 (1.60, 2.50)
Dietary protein intake (DPI)
< 0.60 (g/kg/day) 1.00 (0.80, 1.24)
Dietary energy intake (DEI) < 25 (kcal/kg/day) 0.87 (0.72, 1.05)
*as none had body fat% < 10%, this variable could not be examined, #10% or more lower than the 50th 
percentile of reference population
Conclusions: As there is a wide variability in the prevalence of PEW criteria, the 
thresholds used in their definition need to be further refined. Dietary variables were not 
associated with mortality and the validity of these variables as PEW criteria also needs 
further study.
Funding: NIDDK Support
TH-PO965
Primary Care Physician Involvement in the Care of Chronic Dialysis 
Patients in the U.S.  Vahakn B. Shahinian, Deanna Chyn, Yi Li, John Z. 
Ayanian, Richard Hirth, William H. Herman, Rajiv Saran.  Univ of Michigan.
Background: Current health reform efforts aimed at improving quality and value 
center around delivery of good primary care. However, national patterns of primary care 
physician (PCP) involvement along with a nephrologist in the care of chronic dialysis 
patients are unknown.
Methods: Patients on chronic dialysis during 2010-11 with Medicare as the primary 
insurer were identified using US Renal Data System (USRDS) data. PCP involvement was 
defined based on a claim for an outpatient (non-dialysis) visit with a physician specializing 
in family practice, general internal medicine or geriatrics. Patients were characterized with 
respect to two aspects of preventive care: influenza vaccination and diabetes care.
Results: The sample included 179,645 patients, 81,272 of whom were diabetic. In 2010, 
59% of patients had evidence of PCP involvement based on ³1 outpatient visit. Patients 
with PCP involvement were older and more likely to be female, white and with diabetes as 
cause of ESRD (Table). Rates of vaccination and diabetes care were higher in those with 
PCP involvement, even after adjustment (ORs: 1.48 [1.45-1.51] for vaccination and 1.53 
[1.48-1.58] for a composite of diabetes care). 
Patient Characteristics or Delivered Care PCP Involvement (1+ Visit in 2010)
No (n=73,597) Yes (n=106,048)
Mean age at ESRD (SD) 52.1 (17.0) 57.8 (16.0)
Sex
Female 40.2 48.7
Male 59.8 51.3
Race
White 48.6 55.3
Black 45.4 38.3
Other 6.0 6.4
Primary Disease Causing ESRD
Diabetes 35.8 45.7
Hypertension 31.0 27.7
Glomerulonephritis 15.7 12.0
Influenza Vaccination 59.2 68.4
Diabetes-related care (among diabetic patients) No (N=29,524) Yes (N=51,748)
1+ HbA1C test 75.9% 83.5%
1+ Lipid test 65.5% 74.3%
1+ Diabetic eye exam 36.3% 46.3%
All 3 tests 24.1% 33.6%
By a more restrictive definition of ³2 visits in 2010, 47% had PCP involvement; under 
a looser definition of ³1 visit over 2 years (2010-11), vs 70% had PCP involvement.
Conclusions: Even under the loosest definition of PCP involvement, over one quarter 
of dialysis patients have no evidence of PCP involvement. Patients with PCP involvement 
have higher rates of preventive care, but further study should examine the impact on 
outcomes and costs.
Funding: NIDDK Support
TH-PO966
Are We Choosing Wisely? A Study of Colon Cancer Screening Practices 
Among Dialysis Patients in the United States  Christopher A. Carlos,1 
Chi-yuan Hsu,1 Meda E. Pavkov,3 Nilka Rios Burrows,3 Vahakn B. Shahinian,2 
Rajiv Saran,2 Neil R. Powe,1 Kirsten L. Johansen.1  1Univ of California, San 
Francisco, San Francisco, CA; 2Univ of Michigan, Ann Arbor, MI; 3Centers for 
Disease Control and Prevention, Atlanta, GA.
Background: Because estimated net gains in life expectancy are very small, the 
American Society of Nephrology recommended against routine cancer screening in 
asymptomatic dialysis patients. We aimed to determine how often colon cancer screening 
is performed in the U.S. and whether colon cancer screening is targeted toward healthier 
dialysis patients. Methods: We performed a retrospective cohort study of patients aged 
≥50 years on dialysis between January 1, 2007 and September 30, 2012 using data from 
the United States Renal Data System (USRDS). Using multivariable Cox regression 
models, patients were divided into quartiles based on the risk of death and the likelihood of 
receiving a kidney transplant and, according to these quartiles of risk, we then assessed the 
likelihood of colon cancer screening (CCS) by fecal occult blood testing, sigmoidoscopy 
or colonoscopy from Medicare claims data.
Results: Of 391,616 patients, 13% received CCS over a median follow-up of 1.5 
years (interquartile range 0.7-2.9). Screening was most common in patients with the lowest 
mortality risk (16%), compared with 9% of those with the highest mortality risk (HR 1.33; 
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95% CI 1.30-1.37). Overall, 41% of CCS occurred in those whose risk of death was above 
the median. Patients least likely to receive a transplant were less often screened (10%) than 
those most likely to receive a transplant (HR 0.75; 95% CI 0.73-0.76). 
Conclusions: Our findings suggest that screening was appropriately targeted to dialysis 
patients with longer life expectancies and away from those with the lowest chances of 
receiving kidney transplantation.
Funding: NIDDK Support, Other U.S. Government Support
TH-PO967
Severe Sepsis Hospitalizations in Those on Maintenance Dialysis – National 
Trends and Outcomes  Ankit Sakhuja,1 Kianoush Banaei-Kashani,2 Hatem 
Amer,2 Robert C. Albright.2  1Nephrology, Univ of Michigan; 2Nephrology and 
Hypertension, Mayo Clinic.
Background: Severe sepsis (SS) is a life-threatening condition requiring early diagnosis 
and management. Incidence of SS is increasing in general population (GP) and mortality is 
declining; however, epidemiology and outcomes of SS have not been well studied in those 
on maintenance dialysis (MD). We designed this study to look at incidence and outcomes 
of SS in those on MD.
Methods: Using Nationwide Inpatient Sample database we included all hospitalizations 
(age ³20 yr) with SS based on ICD-9-CM codes of severe sepsis, septic shock or blood 
stream infection with organ dysfunction from 2005 to 2010. Those on MD were identified 
based on ICD-9-CM codes. Age adjusted incidence of SS and mortality in subgroups was 
calculated by direct standardization to 2000 standard US population. Linear regression 
was used to assess trends over time and logistic regression to assess independent effect 
of MD on mortality.
Results: Of estimated 5,000,152 (95% CI: 4,798,520-5,201,784) hospitalizations with 
SS, 6.4% were on MD. Unadjusted incidence of SS was 145.4/1000 in MD compared to 
3.5/1000 in GP with incidence rate ratio 40.9 (95% CI: 40.8-40.9). Age adjusted incidence of 
SS seems to be increasing in both subgroups though trend was not significant in MD (Fig 1). 
Unadjusted in-hospital mortality is higher in MD (30.3% vs 26.2%; p<0.001). Age-
adjusted mortality is decreasing in both subgroups though trend was not significant in MD. 
Age-adjusted mortality continues to be higher in MD (Fig 1). MD is an independent risk 
factor for mortality with OR 1.26 (95% CI: 1.23-1.29).
Conclusions: Hospitalizations with SS are over 40 times more common in MD. 
Mortality is higher in MD and being on MD is an independent predictor of mortality in 
those admitted with SS. Though incidence of SS seems to be increasing, there is a trend 
towards decrease in mortality even in MD.
TH-PO968
Trends in Colorectal Cancer Screening in U.S. End-Stage Renal Disease 
Population  Kevin C. Abbott,1 Chyng-Wen Fwu,2 Paul L. Kimmel,1 Paul 
W. Eggers.1  1Div of Kidney, Urologic Hematologic Diseases, NIDDK, NIH, 
Bethesda, MD; 2Social 	 Scientific Systems, Inc., Silver Spring, MD.
Background: Screening for colorectal cancer (CRC) has been recommended for 
those over 50 years old. Medicare coverage of CRC screening began in 2000. Dialysis 
patient care is shared by many practitioners, perhaps leading to therapeutic nihilism and 
insufficient screening. CDC data show almost 2/3 of patients at risk report CRC screening. 
We determined rates of CRC screening in ESRD hemodialysis (HD) patients, compared to 
a 5% Medicare sample, and to assess secular trends.
Methods: We used data from the 2001-2011 USRDS to describe trends in percentages 
of HD patients receiving CRC screening tests per year. We limited our study population 
to patients with Medicare Part A and B as primary payer to ensure complete Medicare 
claims data for CRC screening. Current Procedural Terminology /Healthcare Common 
Procedure Coding System (CPT/HCPCS) codes identified Medicare physician and supplier 
billing data for screening: colonoscopy (G0105 and G0121), sigmoidoscopy (G0104), and 
fecal-occult blood test (FOBT; G0107, G0328, and 82270). We compared HD data to a 
5% Medicare sample.
Results: Overall, the proportion of HD patients having CRC screening decreased from 
6.1% annually in 2001 to 3.5% in 2011 due to decreased use of FOBT. There was a persistent 
increase in the proportion of patients with colonoscopy or sigmoidoscopy for CRC screening 
in the 11-year study period, from 0.3% to 1.0% annually. In most years, male, black and 
age 50-75 patients were more likely to receive colonoscopy or sigmoidoscopy than female, 
white, and other age subgroups. In 2006, the most recent available comparable year, CRC 
screening in HD patients was less than that of the general Medicare population; 0.8% 
vs. 1.6% annually for colonoscopy and sigmoidoscopy, 6.0% vs. 8.1% including FOBT.
Conclusions: Screening for CRC in ESRD HD patients is less frequent than in 
the general Medicare population, and considerably less than CDC recommendations. 
Differences in ascertainment methods (CDC uses self-report) may account for most of the 
disparity from CDC estimates.
Funding: NIDDK Support
TH-PO969
Increasing Prevalence of Withdrawal from Dialysis: Trends from 2004-
2011  James B. Wetmore,1 Peer Kidney Care Initiative Investigators.2  1CDRG, 
MMRF; 2Peer Kidney Care Initiative.
Background: Voluntary withdrawal from dialysis, which frequently occurs when a 
patient perceives dialysis as having become unduly burdensome, is an area of increasing 
interest. How early withdrawal, defined as that occurring within 1 year of dialysis initiation, 
has changed over the past decade has not been fully explored.
Methods: Patients initiating dialysis between 2004 and 2011 were selected from the 
Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD) database. 
Information on withdrawal was ascertained from the ESRD Death Notification Form 
by the presence of code 104 (“withdrawal”) in the 1st or 2nd position. The unadjusted 
cause-specific monthly mortality rate (deaths per 100 pt-years) was calculated for patients 
initiating in each year.
Results: Annual incident counts ranged from 87,174 (2004) to 100,665 (2011). Overall, 
during the first year of dialysis, the withdrawal rate was highest soon after initiation, peaking 
at month 2 for all years except 2004. Rates then decreased until approx. month 9, stabilizing 
through month 12. Additionally, early rates more than tripled over the study period, from 
1.9 per 100 pt-years at month 2 in 2004 to 5.9 in 2008 to 6.4 in 2011.
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Conclusions: Withdrawal rates are high in the weeks immediately after dialysis 
initiation, a pattern more marked in recent years. Because patients who withdraw soon after 
initiation may be suboptimal dialysis candidates, future work should focus on determining 
whether a tailored approach, designed to identify individual patient goals and present 
the risks and benefits of dialysis and viable alternatives such as conservative care, might 
provide optimal patient-centric care.
Funding: Pharmaceutical Company Support - Financial support for the Peer 
Kidney Care Initiative is provided by 13 participating dialysis provider organizations: 
American Renal Associates, Atlantic Dialysis Management Services, Centers for Dialysis 
Care, DaVita HealthCare Partners, Dialysis Clinic, Inc., DSI Renal, Fresenius Medical 
Care, Independent Dialysis Foundation, Northwest Kidney Centers, Renal Ventures 
Management, Satellite Healthcare, The Rogosin Institute, and U.S. Renal Care.In 
collaboration with the Chief Medical Officers of these organizations, the Peer Kidney 
Care Initiative is operated by the Chronic Disease Research Group, a division of the 
Minneapolis Medical Research Foundation, in Minneapolis, MN., Private Foundation 
Support
TH-PO970
The Dialysis Sodium Gradient – A Modifiable Risk Factor for Fluid 
Overload  Emilie Trinh, Catherine L. Weber.  Nephrology, McGill Univ Health 
Centre, Montreal, QC, Canada.
Background: Fluid overload in patients on conventional hemodialysis is a frequent 
complication associated with increased hospitalizations, cardiovascular morbidity and 
all-cause mortality. There are multiple patient and physician-related factors that lead to 
fluid overload. Individualizing dialysate sodium prescription and minimizing the sodium 
gap are potential modifiable risk factors.
Methods: We performed a cross-sectional study on 111 prevalent stable conventional 
hemodialysis patients at the McGill University Health Center. The associations of sodium 
gradient with various hemodialysis parameters of fluid status including interdialytic weight 
gain percentage (IDWG%), ultrafiltration (UF) rate, blood pressure (BP), intradialytic 
hypotension and intradialytic hypertension were analyzed.
Results: The mean serum sodium gradient was 4.6 ± 3.6 mEq/L. with a mean pre-
dialysis sodium of 137.4 ± 2.5 mEq/L and a mean dialysate sodium of 142.0 ± 3.0 mEq/L. 
There was a direct correlation between sodium gradient and interdialytic weight gain 
percentage (r=0.49, p<0.01) as well as ultrafiltration rate (r=0.44, p<0.01). The average 
sodium gradient was significantly higher in patients with IDWG > 3% (6.36 vs. 3.16 
mEq/L, p<0.01) and in patients with UF rate > 10ml/kg/h (6.01 vs. 4.23 mEq/L, p=0.03). 
In a univariate logistic regression model, a higher sodium gradient was associated with 
increased risk of IDWG% > 3% (OR 1.34, p<0.01) and increased risk of UF rate >10 ml/kg/h 
(OR 1.16, p=0.03), but there was no associations with intradialytic hypotension (OR 1.01, 
p=0.87) or intradialytic hypertension (OR 1.07, p=0.21). Also, no significant associations 
were found between sodium gradient and blood pressure (pre-dialysis or post-dialysis) or 
number of antihypertensive medications.
Conclusions: A higher sodium gradient was associated with significant increases in 
IDWG and UF rate which are associated with poor outcomes. Sodium gradient was not 
associated with intradialytic hypotensive episodes. With the parameters we measured in 
this study, it appears that individualizing dialysate sodium prescription to minimize sodium 
gap leads to less fluid overload in conventional hemodialysis patients.
TH-PO971
Calcific Uremic Arteriolopathy: Mortality Outcomes with and without 
Sodium Thiosulfate Therapy  Chamberlain I. Obialo, Alexander Quarshie. 
Dept of Medicine, Morehouse School of Medicine, Atlanta, GA; Clinical 
Research Center, Morehouse School of Medicine, Atlanta, GA, Venezuela.
Background: Calcific uremic Arteriolopathy (CUA) or Calciphylaxis is commonly seen 
in patients with end stage kidney disease (ESKD) and carries a high mortality risk. There is 
no definite therapy for this condition but promising results have been reported in patients 
treated with intravenous sodium thiosulfate (STS). However, the mortality advantage of 
therapy with STS over therapy without STS remains unknown.
Methods: We retrospectively reviewed our ESKD patient’s records over a 10-year 
period and identified 45 biopsy confirmed cases of CUA. Associations between patients 
who received STS therapy and those who did not and various categorical end points were 
assessed using the Pearson chi-squared tests while differences in continuous end points were 
examined using Mann-Whitney- U tests. Survival analysis utilized Kaplan-Meier plots. All 
statistical tests were two-sided, and level of significance set at 0.05.
Results: The mean age of the 45 cases was 63, 60% female, mean body mass index 
was 34 and mean dialysis vintage was 4 years. Of the 45 cases, 23 (51%) received STS 
while 22 (49%) did not. The mean level of serum albumin, phosphorus and parathyroid 
hormone was 2.8 g/dl, 6.7 mg/dl and 989 pg/dl respectively. One –year mortality was 22% 
in STS vs. 50% in no STS cases, p = 0.05. The overall survival of the patients over the 
2- year study period was significantly superior in the recipients of STS than in those who 
did not receive STS, p = 0.03. 
Patients who did not receive STS were also more likely to have major surgeries than 
those who received STS, 86% vs. 52%, p = 0.01.
Conclusions: Sodium thiosulfate therapy appears to confer both short term and long 
term survival advantage over no STS. We encourage hospitals and dialysis companies to 
procure and make this agent more available to physicians.
Funding: Clinical Revenue Support
TH-PO972
Effect of High-Dose and High-Flux Hemodialysis on Markers of 
Inflammation in the HEMO Study  Kristen L. Nowak,1 Tom Greene,2 Jian 
Ying,2 Alfred K. Cheung,2 Michel Chonchol.1  1Univ of Colorado Denver; 
2Univ of Utah.
Background: Hemodialysis treatment induces markers of inflammation, which could 
affect clinical outcomes. This study sought to determine whether high-dialysis dose and 
high-flux dialysis would improve markers of inflammation compared with standard dialysis 
dose and low flux dialysis.
Methods: The HEMO Study was a randomized multicenter study of the effects of 
high-dose versus standard-dose and high-flux versus low-flux hemodialysis. Serum high 
sensitivity C-reactive protein (hs-CRP, pre-specified primary outcome for this set of 
analyses) and interleukin-6 (IL-6) were measured in stored serum samples in 1,846 HEMO 
participants. For each inflammatory marker we used a joint multi-state modeling approach 
to estimate the proportion of patients in 5 ordered states (S) over 3 annual assessments while 
accounting for mortality: S1=deceased (score=0); S2=alive in highest quartile (score=1); 
S3=alive in 3rd quartile (score =2); S4=alive in 2nd quartile (score=3); and S5=alive in lowest 
quartile (score=4). The average rank was computed over 3 yrs of follow-up and compared 
between the randomized groups.
Results: Randomized patients had high rates of coexisting conditions: 45% had 
diabetes, and 80% had a history of cardiac disease. Characteristics of the patients in the 
two dose groups were similar, as were the characteristics of those in the two flux groups. 
The state distribution of hs-CRP in each year by dose (KTV) group and by flux group for 
hs-CRP are shown in Figure 1. 
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hsCRP did not differ significantly between dose (p=0.83) or flux groups (p=0.53). 
Similar results were obtained for IL-6.
Conclusions: Over 3 years, neither high-dose nor high-flux dialysis exhibited a 
beneficial effect on markers of inflammation.
TH-PO973
Comorbidity Data Source May Impact SMR/SHR Calculation 
Jiannong Liu,1 Mahesh Krishnan,2 Jincheng Zhou,1 Kimberly M. Nieman,1 Yi 
Peng,1 David T. Gilbertson.1  1CDRG, MMRF, Mpls, MN; 2DaVita Healthcare 
Partners, Denver, CO.
Background: Standardized mortality and hospitalization ratios (SMRs and SHRs) 
are used to measure dialysis facility performance, with adjustment for demographics and 
comorbidities derived from the end-stage renal disease (ESRD) Medical Evidence (ME) 
Report. Sensitivities are low for ME-based comorbidities. We investigated the effect on 
SMR and SHR calculations by comparing ratios adjusted for claims-based comorbidities.
Methods: Using the USRDS ESRD database, we included US hemodialysis patients 
who initiated dialysis July 1-December 31, 2006-2010, had Medicare as primary payer, 
were aged ≥ 66 years, and had no prior transplant (TX). Patients were followed from 
dialysis initiation to the earliest of death, TX, modality change, or 1 year. SMRs and SHRs 
were calculated for patients in for-profit/non-profit and rural/urban facilities for ME-based 
and claims-based comorbidity, separately. Cox models were used for expected number of 
deaths and piecewise Poison models for expected number of hospitalizations. Agreement 
of comorbidity between the two sources was measured by a kappa statistic.
Results: 73,950 incident hemodialysis patients were included. Kappas for comorbidity 
agreement were low, less than 0.5, except for diabetes (0.77). Percent of patients with 
claims-based comorbidity was similar for for-profit and non-profit facilities; ME-based 
comorbidity was lower for for-profit facilities. Differences between ME-based and claims-
based SMR/SHRs were statistically significant. Compared with ME-based SMR/SHR, 
claims-based ratios decreased 0.9/0.6% for for-profit and 1/0.7% for urban facilities and 
increased 3.4/2.8% for non-profit and 5.9/4.1% for rural facilities 
Conclusions: Comorbidity data source may impact performance evaluation. The 
impact is larger for smaller groups, and may increase with prevalent patients included.
Funding: Pharmaceutical Company Support - DaVita Clinical Research, DaVita 
HealthCare Partners Inc., 
Denver, Colorado
TH-PO974
Thematic Analysis of the Medical Records of a National Cohort of Patients 
Who Initiated Maintenance Dialysis: 2000-2009  Susan P.Y. Wong,1 Elizabeth 
Vig,1 Nilka Rios Burrows,2 Chuan-fen Liu,1 Desmond Williams,2 Paul L. Hebert,1 
Ann M. O’Hare.1  1Univ of Washington; 2Center for Disease Control.
Background: Little is known about how decisions to initiate dialysis take shape in 
clinical practice.
Methods: We performed a qualitative thematic analysis of the medical records of 
patients who initiated maintenance dialysis to understand factors that impact decisions 
to initiate maintenance dialysis as they occur in clinical context. We analyzed key 
care processes, patient-provider interactions and patient and/or provider concerns and 
considerations relevant to the decision to initiate dialysis as documented in the electronic 
medical records of a national random sample of patients for whom the decision to initiate 
maintenance dialysis was made at the Department of Veteran Affairs between 2000 and 
2009 (n=1,691).
Results: We identified three dominant, overlapping themes pertaining to the decision 
to initiate dialysis: 1) dialysis initiation as process, which describes the decision to initiate 
dialysis as integrated with other treatment decisions and unfolding over time rather than 
an isolated decision occurring at a fixed point in time; 2) sources of momentum for dialysis 
initiation, which describes factors that appeared to hasten the process of dialysis initiation 
and included hospitalization for acute illness and efforts to optimize patients’ clinical 
status for future medical interventions; and, 3) push-pull dynamics between patients and 
providers, which describes the sometimes adversarial relationship between patients and 
providers during the process of dialysis initiation in which patients were often portrayed 
by providers as “resistant” to dialysis initiation while providers appeared paternalistic and 
safety conscious in their approach towards treatment decisions.
Conclusions: Our analysis of the medical record underscores the complexity of 
treatment decisions about dialysis initiation in real-world clinical settings and supports a 
re-conceptualization of dialysis initiation as a process that unfolds over time rather than 
as a discrete treatment decision occurring at a fixed point in time.
Funding: Other U.S. Government Support, Veterans Administration Support
TH-PO975
Trends in 30-Day Readmission Rates in Dialysis Patients During an Era 
of Medicare Payment Policy Changes, 1996-2012  Allan J. Collins,1 Peer 
Kidney Care Initiative Investigators.2  1MMRF; 2Peer Kidney Care Initiative.
Background: High hospital readmission rates, which may indicate inadequate quality 
of care and result in unnecessary expenditures, have been a recent focus for Medicare. 
Medicare has enacted payment-related policy changes: freezing the inpatient payment 
rate (1997), expanding “disproportionate share” hospital payments (early 2000s), tying 
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reimbursement for outpatient hemodialysis services to the number of monthly visits 
(2004), introducing the new Medicare prospective payment system (2011), and instituting 
the “hospital payment penalty” (2012). Given evidence demonstrating links between these 
changes and readmission rates in the general population, we sought to examine changes in 
30-day readmission rates in dialysis patients 1996–2012.
Methods: Data were obtained from the Centers for Medicare & Medicaid Services 
End-Stage Renal Disease database. Dialysis patients were assessed for discharges from 
short-term or critical access hospitals. Thirty-day readmission rates were calculated, without 
adjustment for differences in patient case-mix or hospital characteristics.
Results: All-cause readmission rates increased modestly over the period studied 
except for 2012. The nadir was 32.8% in 1998; the rate increased to 34.6% in 2005, fell 
to 34.1% in 2009, and peaked at 34.8% in 2010. Discharge data in the first 6 months of 
2012 showed further decrease (32.8%). In comparison, other studies show that the rate in 
the general Medicare population was relatively stable 2007-2011 (19.0%), and decreased 
in 2012 (18.4%).
Conclusions: Thirty-day readmission rates were substantial in dialysis patients 
compared with general Medicare patients, possibly reflecting case-mix. How public 
policy changes may have affected potentially avoidable readmissions should be more fully 
explored. Cause-specific readmission rates might provide a better reflection of quality of 
care and should be examined.
Funding: Pharmaceutical Company Support - Financial support for Peer is provided 
by 13 participating dialysis provider organizations: American Renal Associates, 
Atlantic Dialysis Management Services, Centers for Dialysis Care, DaVita HealthCare 
Partners, Dialysis Clinic, Inc. (DCI), DSI Renal, Fresenius Medical Care, Independent 
Dialysis Foundation, Northwest Kidney Centers, Renal Ventures Management, Satellite 
Healthcare, The Rogosin Institute, and U.S. Renal Care.
In collaboration with the Chief Medical Officers of these organizations, the Peer 
Kidney Care Initiative is operated by the Chronic Disease Research Group, a division of 
the Minneapolis Medical Research Foundation, in Minneapolis, Minnesota. Allan Collins, 
MD, FACP, is the Executive Director of Peer. Allan Collins serves as a co-investigator on 
Phase I and II studies for DaVita Clinical Research., Private Foundation Support
TH-PO976
The Impact of Volume Status on Nocturnal Hypoxemia in Patients 
Undergoing Maintenance Hemodialysis  Farhanah Yousaf, Mitesh K. Patel, 
Sherbeth Marie C. Young, Chaim Charytan, Alla Goldberg, Bruce S. Spinowitz. 
New York Hospital Queens, Flushing, NY.
Background: Hemodialysis patients experience changes in volume status according 
to hemodialysis schedule. Excess fluid volume may shift to the neck upon assuming a 
recumbent position during sleep, leading to engorgement of the great veins of neck and 
peripharyngeal edema. We explored the impact of volume status on nocturnal hypoxemia 
in the hemodialysis population.
Methods: Following local IRB approval, adult hemodialysis patients who were 
undergoing regular chronic hemodialysis (HD) for at least 3 months were consented to 
complete two nights of nocturnal oximetry using Pulsox 300i wristwatch. HD night was 
defined as the night of HD treatment whereas non-HD night was defined as the night on 
which no HD was performed. The first hour of recording was deleted in efforts to capture 
oximetry reading from sleep time only. Motion artifacts and aberrant data were also 
excluded from the analysis. Oxygen desaturation index (ODI) was defined as the number 
of desaturations ≥ 3% from baseline lasting ≥ 10 seconds, per hour. Paired t-test was used 
to compare HD and non-HD night related data.
Results: Twenty HD patients (11 males and 9 females) aged 54 ± 13 years with a mean 
body mass index of 25.5 ± 4.6 kg/m2 and neck circumference of 38.4 ± 5.8 cm participated 
in the study. Mean ODI was 21.2 ± 21.1 on HD night versus 20.0 ± 19.8 on non-HD night 
(p=0.6) with a mean interdialytic weight gain of 1.9 ± 1.3 Kg. The lowest recorded mean 
saturation was 76 ± 10 % on HD night versus 73 ± 11 % on non-HD night (p=0.3). Eleven 
of 20 patients, with a mean interdialytic weight gain of 2.1 ± 1.5 Kg, experienced worsening 
of ODI on non-HD night (16.9 ± 17.9) versus HD night (11.6 ± 13.8) [p=0.008]. Meanwhile, 
nine patients, with a mean interdialytic weight gain of 1.5 ± 0.9 Kg, exhibited improvement 
in ODI on non-HD night (23.8 ± 22.4) versus HD night (32.9 ± 23.1) [p=0.04].
Conclusions: Volume status alone does not explain HD to non-HD variation in 
nocturnal hypoxemia seen in ESRD population. Both central and obstructive mechanisms 
are likely involved. Additional research is warranted to further explore this phenomenon 
and develop preventive strategies.
TH-PO977
Hospital Readmission within 30 Days of Discharge Among Adults Receiving 
Dialysis  Lorien S. Dalrymple,1 Barbara A. Grimes,2 Patrick S. Romano,1 Yi 
Mu,1 Danh V. Nguyen,3 Kirsten L. Johansen.2,4  1UC Davis; 2UCSF; 3UC Irvine; 
4San Francisco VA.
Background: Hospital readmission is common in adults receiving dialysis. Few studies 
have examined the timing or causes of 30-day hospital readmission.
Methods: We used the USRDS to examine adults initiating dialysis Jan 2009 trough 
Dec 2010 who had Medicare as the primary payer. The cohort was followed from day 90 
of dialysis for up to one year, with censoring for death, renal recovery or transplant. We 
classified the principal cause of the index hospitalization and hospital readmission using 
Clinical Classification Software.
Results: Our cohort consisted of 103,381 patients. During follow-up, 50,639 patients 
experienced 89,728 index hospital admissions; 5% resulted in in-hospital death. Of the 
85,284 live hospital discharges, 25,792 (30%) were associated with 30-day readmission. 
The median time to readmission was 11 [5, 19] days. Leading causes of readmission by 
cause of index hospitalization are in Table 1.
Table 1. Causes of 30-Day Readmission
Causes of Readmission
Cause 
of Index 
Admission
Leading 
Cause 
2nd Leading 
Cause 
3rd Leading 
Cause 
4th Leading 
Cause 
5th Leading 
Cause 
All-Cause
N=89728
Complication 
of device, 
implant or 
graft
Septicemia CHF DM HTN
Complication 
of device, 
implant or 
graft
N=14195 
Complication 
of device, 
implant or 
graft
Septicemia DM CHF HTN
Septicemia
N=6049 Septicemia
Complication 
of device, 
implant or 
graft
DM Pneumonia CHF
HTN*
N=5380 HTN
Complication 
of device, 
implant or 
graft
CHF DM
Fluid and 
electrolyte 
disorders
CHF†
N=5322 CHF HTN
Complication 
of device, 
implant, graft
Fluid and 
electrolyte 
disorders
Septicemia
DM††
N=4986 DM
Complication 
of device, 
implant or 
graft
Septicemia HTN
Complica-
tions of 
surgical 
procedures or 
medical care
*HTN: Hypertension with complications and secondary hypertension;CHF: Congestive heart 
failure - nonhypertensive; DM: Diabetes mellitus with complications
For the 5 most common causes of hospitalization, the principal cause for readmission 
was in the same category as the initial admission, accounting for 18-32% of readmissions.
Conclusions: Thirty-day hospital readmission in Medicare recipients on dialysis is 
frequently for a cause related to the initial admission.
Funding: NIDDK Support, Pharmaceutical Company Support - Dialysis Clinic, Inc.
TH-PO978
Racial/Ethnic and Age Differences in Cause-Specific Deaths Among U.S. 
Dialysis Patients  Alison J. Yu,1 Keith C. Norris,2 Alfred K. Cheung,3 Guofen 
Yan.4  1Univ of Southern California; 2UCLA; 3Univ of Utah; 4Univ of Virginia.
Background: Recent research reported that Hispanics have the lowest all-cause 
mortality, African Americans (AAs) intermediate, and Whites the highest among U.S. 
dialysis patients over 30 years old. The objective of this study is to examine whether this 
risk pattern varied depending on the cause of death.
Methods: The study included 1,255,640 adult incident dialysis patients between 
1995 and 2010 in the USRDS, with no prior kidney transplantation. We examined 5 major 
cause-specific deaths: cardiovascular (CVD), infection, malignancy, others, and unknown. 
Cause-specific hazards for each cause-specific death were compared among AAs, Hispanics, 
and Whites for overall and stratified by age groups.
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Results: After adjustment for multiple covariates (Table), compared with Whites, 
in all age groups, Hispanics consistently had lower risks of cause-specific deaths for all 
major causes examined (HRs<1), while AAs also had lower risks except for the cause of 
infection, for which AAs had significantly higher risks in age groups of <50 and >80 years 
(HRs from 1.07-1.94). 
Table. Adjusted cause-specific hazard ratios (HRs) for AAs and Hispanics vs. Whites 
Age
Groups
CVD Infection Malignancy Others All-cause
AA His-panic AA
His-
panic AA
His-
panic AA
His-
panic AA
His-
panic
18-30 0.99* 0.52 1.94 0.81 0.52 0.60* 1.06* 0.62 1.17 0.60
31-40 0.85 0.61 1.51 0.95* 0.82* 0.65 0.75 0.63 0.97 0.68
41-50 0.74 0.60 1.07 0.79 0.75 0.66 0.59 0.56 0.79 0.63
51-60 0.69 0.63 0.83 0.71 0.86 0.61 0.54 0.56 0.72 0.64
61-70 0.74 0.70 0.84 0.81 0.82 0.62 0.50 0.59 0.73 0.69
71-80 0.78 0.78 0.98* 0.90 0.92 0.70 0.54 0.60 0.78 0.76
>80 0.84 0.84 1.07 1.01* 1.06* 0.89* 0.57 0.65 0.83 0.83
Note: all significant at p<0.05 except the ones indicated by *.
Conclusions: The racial difference observed in all-cause mortality, in which Hispanics 
have the lowest risk, AAs intermediate, and Whites the highest, was also noted for major 
cause-specific deaths in most age groups, except for the cause of infection. Both younger 
and older AAs are at the greatest risk of death due to infection. Further studies are needed to 
explore the specific reasons responsible for the higher risk of infection-related death in AAs.
Funding: NIDDK Support
TH-PO979
Dialysis Therapy and Mortality in Older Heart Failure Patients with 
Advanced Chronic Kidney Disease: The Kaiser Permanente MATCH Study 
David Law, Sijie Zheng, Sharina Belani, Jingrong Yang, Thida Tan, Juan Daniel 
Ordonez, Susan Kim, Alan S. Go.  Kaiser Permanente Northern California.
Background: Heart failure (HF) and chronic kidney disease (CKD) often coexist and 
those with both have much worse outcomes than having either alone, with limited data 
to guide optimal management. We evaluated the outcome of dialysis therapy in a diverse 
elderly cohort with HF and advanced CKD.
Methods: In Kaiser Permanente Northern California, a large integrated healthcare 
system, we identified members ≥70 years with HF and estimated glomerular filtration rate 
(eGFR) £20 ml/min/1.73 m2 between 2008-2012 and no prior renal replacement therapy, 
cancer, cirrhosis or organ transplant. Through 2013, we identified patients who started 
chronic dialysis and individually matched controls who were alive on the dialysis start date 
of the matched case along with age, gender, diabetes status, and high-dimensional propensity 
score to start dialysis. Demographics, clinical features and drug use were obtained from 
electronic records. We calculated rates of death through 2013 and examined the impact of 
dialysis on mortality using Cox regression.
Results: We identified 334 eligible HF-CKD cases who initiated dialysis and 899 
matched control HF-CKD patients. Mean age was 80.1±4.8 yrs, with 51% women, 33% 
black and 72% diabetic. Case and control patients were well-matched across characteristics, 
except for controls being less likely to be Hispanic or have proteinuria, or to receive alpha 
or calcium channel blockers or thiazide diuretics; and more likely to have prior intracranial 
bleed, liver disease, dementia and higher blood pressure, hemoglobin and mean eGFR (16.4 
vs. 12.0 ml/min/1.73 m2). Incidence of death was 32 per 100 p-y in combined case and 
control patients. Among matched patients, after further adjustment for residual differences 
in patient features, dialysis was independently associated with a 47% lower rate of death 
(hazard ratio 0.53, 95%CI:0.41-0.67).
Conclusions: In older adults with HF and advanced CKD, dialysis was independently 
associated with a lower mortality. Randomized trials are needed to determine the net 
outcomes of dialysis related to both length and quality of life in the elderly with HF and 
advanced CKD.
Funding: Private Foundation Support
TH-PO980
Gender, Poverty, and Dialysis Mortality in Adults with Sickle Cell Disease 
Tanjala S. Purnell, Xun Luo, Carlton Haywood, Sophie Lanzkron, Lauren Marie 
Kucirka, Sunjae Bae, Morgan Grams, Dorry L. Segev.  Johns Hopkins Univ.
Background: Chronic dialysis patients with sickle cell disease (SCD) have increased 
risk of mortality compared with the general US dialysis population. The contributions of 
gender and neighborhood poverty to dialysis mortality in SCD patients are largely unknown.
Methods: Using USRDS data, we linked all US adults with SCD who initiated dialysis 
between 1995-2012 with zip-code level US Census neighborhood data. We performed 
multivariable Cox regression models with adjustment for age, dialysis type, BMI, and 
diabetes status to compare mortality between men and women, stratified by neighborhood 
poverty level. Neighborhoods with ³20% of households living below the federal poverty 
level were defined as poor.
Results: The study cohort included 1,681 SCD patients on dialysis with 52% male, 
94.7% black, mean age 42.5, and 55.9% living in poor neighborhoods. 1-, 5-, and 10-year 
mortality in this population were 26.1%, 67.9%, and 85.5%. Overall, men had similar 
mortality to women (aHR: 0.96, 95% CI: 0.86-1.07, p=0.45). However, men living in 
poor neighborhoods had higher risk of death than women (aHR: 1.20, 95% CI: 1.04-1.40, 
p=0.015). (Figure 1) The median survival time from dialysis initiation for poor men with 
SCD was 2.37 years. In comparison, the median survival time for poor men without SCD 
was 3.77 years. 
Conclusions: Men with SCD who live in poor neighborhoods were at highest risk of 
death. Efforts to address socioeconomic barriers may be an important target for improving 
survival in this population.
Funding: NIDDK Support, Other NIH Support - NHLBI
TH-PO981
Peritoneal Dialysis (PD) Patient Outcomes Under the Dialysis Prospective 
Payment System (PPS)  Marc Turenne, Regina M. Baker, Jeffrey Pearson, 
Chad M. Cogan, Purna Mukhopadhyay, Elizabeth L. Cope.  Arbor Research 
Collaborative for Health, Ann Arbor, MI.
Background: The use of PD was expected to be incentivized by the expanded Medicare 
PPS that was implemented in 2011. There is early evidence under the PPS of additional 
incident ESRD patients and dialysis facilities using PD (Hirth et al 2013; Turenne et al 
2014). More widespread PD use could have implications for PD outcomes due to potential 
changes in PD selection or in the experience of dialysis providers with PD. This study 
assessed PD patient outcomes before and after the new PPS was implemented.
Methods: This study included n=36,582 incident ESRD patients for whom PD was 
identified as the intended initial dialysis modality on the CMS ESRD Medical Evidence 
Form during 2008-12. We evaluated 1-year PD technique failure and PD patient mortality 
using data from Medicare claims, the Standard Information Management System, 
CROWNWeb, and the CMS Death Notification Form. PD technique failure was ascertained 
when hemodialysis was used for at least 60 days.
Results: Selection of PD increased from 5.8% to 8.4% of incident patients between 
2008 and 2012 (see Figure). 
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During this period, 1-year PD technique failure decreased from 18.8% to 16.1% 
of patients and 1-year PD patient mortality decreased from 9.4% to 8.6% (see Figure). 
Outcomes were relatively stable or improving across patient age, race, and Hispanic 
ethnicity subgroups and for patients in both urban and rural areas.
Conclusions: In the context of expanding PD use under the new PPS, there is no 
early evidence of worsening overall PD patient outcomes or of growing disparities in PD 
patient outcomes by demographic group or by urban/rural location. Instead, there were 
lower levels of PD technique failure and PD patient mortality in the initial years of the 
new payment system.
Funding: Other NIH Support - National Institute on Minority Health and Health 
Disparities (NIH-NIMHD)
TH-PO982
Cognitive Impairment and Mortality in Adults on the Kidney Transplant 
Waitlist  Mara McAdams-DeMarco, Hao Ying, Israel O. Olorundare, Dorry 
L. Segev.  Johns Hopkins.
Background: Older adults with poor cognitive function are at increased mortality risk 
. It is unclear whether ESRD patients of all ages with cognitive impairment are at increased 
mortality risk of while on the kidney transplant (KT) waitlist.
Methods: 918 ESRD patients being evaluated for and waitlisted for KT (no previous 
listings) at Johns Hopkins were enrolled in a prospective cohort study (11/2009-5/2014). 
The Modified Mini Mental Status (3MS), a test of global cognitive function (range 0-100. 
higher scores represent better function) was assessed at KT evaluation. Global cognitive 
impairment was defined as 3MS score<80). Mortality risk by 3MS score and cognitive 
impairment (separately) was estimated using an adjusted Cox proportional hazards model; 
participants were censored at the waitlist removal, time of KT or administrative end of 
follow-up.
Results: At KT evaluation, the mean (SD and range) age was 54 (14; 18-86), 57% 
were male, and 46% were African American. The mean (SD and range) 3MS score was 
82.6 (11, 47-100) and 52% were classified as having cognitive impairment. 45 participants 
died over an average of 1.7 years of follow-up. Mortality risk was greater for adults on 
the KT waitlist who had worse 3MS scores (1 point decrease in 3MS score: HR=1.05, 
95% CI: 1.02-1.08, P=0.003) and those with cognitive impairment (HR=2.51, 95% CI: 
1.26-4.99, P=0.009) after adjusting for sex, age, race, education, and dialysis factors. The 
risk of mortality associated with cognitive impairment was similar for older (age≥65) and 
younger (age<65) participants (P=0.73). 
Conclusions: Among adults ESRD patients, impairment in global cognitive function 
more than doubled the risk of waitlist mortality. A simple screener for global cognitive 
function scores at the evaluation for first listing would not only identify adults with ESRD 
who have unrecognized cognitive impairment but also identify a high-risk population.
Funding: Other NIH Support - NIA, Private Foundation Support
TH-PO983
Indications, Technique, and Outcome of Plasmapheresis in a Large Pediatric 
Dialysis Center  Rainer Büscher, Lübbert Lübbers, Anja K. Büscher, Peter F. 
Hoyer.  Pediatric Nephrology, Univ of Duisburg-Essen, Pediatrics II, Essen, 
Germany.
Background: Plasmapheresis (PP) is a established therapeutic option for various 
indications in pediatric patients. However, there are only few reports with only little 
information on clinical outcome.
Methods: We performed a retrospective analysis involving 86 children and adolescents 
undergoing PP in our pediatric dialysis unit from 1997 to 2013.
Results: Within the observation period, 86 children (41 male), mean age 8.7±3.2 
years (3 months to 18.9 years) received PP for a total of 652 sessions (1-33 sessions/
patient; mean 6.4±3.1 sessions/patient). Most patients (30.2%) were treated for hemolytic-
uremic syndrome (HUS), 18.6% for liver failure and 7.8% for rejection following 
renal transplantation. Other indications included encephalitis (5.9%), thrombotic 
thrombocytopenic purpura (4.9%), autoimmune hepatitis (3.9%), rapid progressive 
glomerulonephritis (3.9%) and nineteen other indications (24.8%). Membrane filtration 
was used in all patients, fresh frozen plasma (64.7%) the most frequently used substitution 
fluid and heparin the most frequently used anticoagulant (85.5%). Complications during PE 
included emesis (17.4%), seizures (13%), hypotension (8.7%), diarrhea (8.7%), mild allergic 
reactions (4.4%) and headaches (4.4%). All complications could be resolved. Overall, PP 
achieved full disease remission in 52 patients (60.4%), 14 patients showed a partial response 
(16.3%) and 20 patients (23.3%) did not respond at all. Among these, 12 patients (15.1%) 
died within the following 30 days. When stratified by diagnosis, 65% of all HUS patients 
(n=17/26) achieved complete remission and 5 out of 6 patients with encephalitis (85%) 
showed no relapse. Only poor results could be achieved in 16 patients with liver failure, 
where PP was used as bridging therapy prior to liver transplantation (LTX). Ten patients 
62.5%) died prior or post LTX and 6 could be successfully transplanted.
Conclusions: Plasmapheresis is a safe method in children with a high efficacy in 
patients with hemolytic uremic syndrome, neurological autoimmune diseases and other 
primary renal diseases. Patients with liver failure who receive PP as bridging therapy 
show an infaust outcome.
TH-PO984
Who Makes the Best Exit Site: Nephrologist or Surgeon?  Vaibhav S. Keskar, 
Mohan B. Biyani, Brian Blew, Jeffrey Warren, Brendan Mccormick.  The  Ottawa 
Hospital, Univ of Ottawa, Ottawa, ON, Canada.
Background: Buried peritoneal dialysis(PD)catheters are placed months before 
dialysis is needed and the exit site is created at the initiation of dialysis by the nephrologist. 
In contrast, the exit site of an unburied catheter is created by the surgeon at the time of 
insertion. Our PD unit uses both methods of catheter placement. We undertook this study 
to compare the outcomes of the two methods of exit site creation.
Methods: The charts of all patients who initiation PD between Jan 2012 and Dec 
2013 were reviewed. At each clinic visit, exit sites were graded by the PD nurse into 
standard predefined groups: perfect, good, equivocal and infected. Primary outcome was 
the frequency of perfect exit sites at 2, 6, and 12 months after initiation of PD. Secondary 
outcomes were exit site infections, peritonitis and technique failure due to exit site infection.
Results: 119 patients started PD during the period of interest and 114 remained on PD 
at 2 months. 52 patients had buried catheters exteriorized at the time of starting PD (group 
A) and 62 patients had unburied catheters (Group B). Group A had more males (71% vs 
48%), had higher mean age (65±14 vs 59±15) and had most of the patients as incident 
dialysis patients. Diabetic nephropathy was the most common underlying disease in either 
group (61.53% and 51.61%). Group B had a higher frequency of perfect exit sites at 2 
months but this difference disappeared by 6 and 12 months. There was a trend towards 
more exit site infections in Group A but this did not translate into more technique failure.
Group A (Buried, 
n=52)
Group B (Unburied, 
n=62) p
% of perfect 
exit sites
2 months 40% 56% 0.02
6 months 57% 62% 0.34
12 months 62% 53% 0.65
Exit site infections 8 3 0.06
Tunnel infections 0 1 NS
Peritonitis 6 5 NS
Technique failure 2 1 NS
Conclusions: Buried catheters are less likely to have perfect appearance at two months 
compared to unburied catheters; however this is no longer significant at six and 12 months.
The trend towards more exit site infections with buried catheters suggests that there may be 
clinical consequences of the tissue trauma at time of exteriorization.Consideration should 
be given to the use of prophylactic antibiotics at exteriorization.
TH-PO985
Prevention of Peritoneal Dialysis Catheter-Related Infections – A 
Multicenter Randomized Controlled Trial  Mercedes L. Velo, Paula López, 
Carmen Felipe, Jose Ramon Rodriguez-Palomares, Gloria Del peso, Francisco 
Javier Ahijado, Fernando Tornero, Mar?a Jose Fernandez Reyes, Ana M. Tato, 
Maria Rosario Luque, Jose M. Portoles.  Grupo Centro Diálisis Peritoneal, 
Spain.
Background: Peritonitis, tunnel and catheter exit site (CES) infections are the most 
serious complications of peritoneal dialysis (PD). We studied the effect of antibiotic 
ointment (EUDRAC: 2009-016835-36) on catheter-related infections (CRI) and morbidity.
Methods: Allocation was stratified in blocs of 4/center. Ointment containing 2% 
colistin, tobramycin, amphotericin B and 4% vancomycin or normal saline were applied to 
the CES over 1 year. Follow-up period was 3 months after the last dose. Exit site infection 
(ESI) was defined as erythema, edema or local pain with purulent secretion and positive 
culture. Antimicrobial therapy was given according to local protocols.
Results: 140 patients were included, 6 didn’t meet entry criteria. Characteristics and 
dialysis parameters of the 65 in the control group (CG) and 69 intervention group (IG) 
patients were comparable.
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Study Control
Age, mean (SD) 56.5 58.9
Gender, male, % 65.2 53.1
Diabetes, % 24.6 26.6
Charlson index 3.2 3.3
Prior cardiovascular events, % 27.5 23.4
Time in PD, mean, years 1.3 (1.5) 2 (2.2)
APD/CAPD, % 30.4 25
Residual renal function, ml/min 4.5 (4.4) 6.3 (4.2)
KTv 2.2 (0.6) 2.3 (2.5)
Mean study duration was 0.6 (IG) vs 0.6 (CG) years (ns). 26 episodes of CRI (11 ESI, 
4 tunnel, 11 peritonitis) occurred in the CG and 12 in the IG (3 ESI, 0 tunnel, 9 peritonitis) 
(p<0.001). Etiology of ESI was Staphylococcus aureus (x7), Corynebacterium spp, 
Pseudomonas aeruginosa, E. coli, Serratia spp., coagulase-negative S. (x2) and 1 negative 
culture in the CG and S. aureus (x1), 1 Gram-negative bacillus and 1 negative culture in 
the IG. Systemic or topical antibiotics were given for ESI in 11 (CG) and 2 patients (IG) 
(p<0.01), respectively. Hospital admissions were 23 (CG) and 15 (IG). Local side effects 
were significantly increased in the IG.
Conclusions: Local prophylaxis with a broad-spectrum antimicrobial ointment is 
associated with a significant reduction in ESI and systemic antibiotic use without associated 
bacterial resistance. Significant local side effects were observed.
Funding: Private Foundation Support
TH-PO986
Association Between Plasma Fibroblast Growth Factor-23 and Carotid 
Artery Atherosclerosis in Peritoneal Dialysis Patients  Nanmei Liu.  Jimin 
Hospital of Shanghai.
Background: We investigate the association between plasma fibroblast growth 
factor-23 (FGF-23) level and carotid artery atherosclerosis of 125 stage 5 chronic kidney 
disease (CKD5) patients, who are doing continuous ambulatory peritoneal dialysis (CAPD) 
at renal division of Shanghai Jimin Hospital in China.
Methods: A retrospective cohort study of individuals 15 years of age and older, divided 
into two cohorts according to carotid intima-media thickness (CIMT) : CIMT normal 
cohort (CIMT<0.9mm) and CIMT thickening cohort (CIMT³0.9mm). Plasma FGF-23 
concentrations were determined by ELISA. CIMT thickness and atherosclerotic plaques 
were measured by carotid ultrasound.
Results: Of the 125 PD patients, the CIMT was thickened in 82 patients (65.6%). 
Compared with the CIMT normal patients, plasma FGF-23 concentration was significantly 
increased (p<0.01) in the CIMT thickening cohort (Table 1). Linear regression analysis 
discovered an obvious positive correlation between plasma FGF-23 and CIMT (r=0.416, 
P=0.006) (Table 2). Multiple regression analysis indicated that plasma FGF-23 level was 
independent risk factor for CIMT (β=0.421, t=2.607, P<0.01) (Table 3).
Conclusions: The level of plasma FGF-23 was positively correlated with CIMT and 
played an important role in development of carotid artery atherosclerosis in peritoneal 
dialysis patients.
Funding: Government Support - Non-U.S.
TH-PO987
Atherogenic Index of Plasma Is Associated with Insulin Resistance in Non-
Diabetic Peritoneal Dialysis Patients  Mi Jung Lee,1 Jae Eun Um,2 Meiyan Wu,2 
Tae ik Chang,3 Tae-Hyun Yoo.1  1Dept of Internal Medicine, Yonsei Univ College 
of Medicine, Seoul, Korea; 2Brain Korea  PLUS, Severance Biomedical 
Science Inst, Yonsei Univ College of Medicine, Seoul, Korea; 3Dept of Internal 
Medicine, NHIC Ilsan Hospital, Gyeonggi-do, Korea.
Background: Insulin resistance (IR) is an independent risk factor for cardiovascular 
morbidity and mortality. Although many factors including uremia, chronic inflammation, 
and abnormal adipokine levels are known to contribute to the development of IR, the role 
of pro-atherogenic lipoprotein on IR remains unknown in peritoneal dialysis (PD) patients. 
Therefore, we investigated the independent association between pro-atherogenic lipoprotein 
and IR in non-diabetic PD patients.
Methods: We conducted a cross-sectional study in 75 non-diabetic PD patients. 
Pro-atherogenic lipoprotein was assessed by the atherogenic index of plasma (AIP, log 
transformed triglyceride to high-density lipoprotein cholesterol ratio). IR was determined 
by homeostatic model assessment-IR (HOMA-IR). Patients were divided into the higher 
and lower HOMA-IR group according to the median value of HOMA-IR. Independent 
association between AIP and HOMA-IR was ascertained by multivariate linear regression 
analysis.
Results: The mean age of the patients was 52.1±11.2 years, 35 patients (46.7%) were 
male. The mean value of AIP was 0.38±0.33 and the median value of HOMA-IR was 1.58 
(interquartile range, 0.88 to 2.76). AIP was significantly greater in the higher HOMA-IR 
group (0.25±0.27 vs. 0.53±0.32, P<0.001). AIP was negatively correlated with systolic 
blood pressure (r=-0.32, P=0.005) and log adiponectin (r=-0.42, P=0.001) and positively 
correlated with sagittal abdominal diameter (r=0.25, P=0.033), residual renal function 
(r=0.29, P=0.012), serum albumin (r=0.26, P=0.026) and log HOMA-IR (r=0.54, P<0.001). 
In multiple linear regression analysis, AIP (β=0.251, P=0.037) was independently associated 
with HOMA-IR after adjustment for confounding factors.
Conclusions: Pro-atherogenic lipoprotein abnormality determined by high AIP might 
be implicated with development of IR in non-diabetic PD patients.
TH-PO988
Reducing Mortality in CAPD Patients by Statin  Yong kyu Lee, Tae ik Chang, 
Sug kyun Shin.  Nephrology Div, Dept of Internal Medicine, National Health 
Insurance Corporation, Ilsan Hospital, Goyang, Korea.
Background: Patients who are on CAPD (Continuous Ambulatory Peritoneal Dialysis) 
shows higher serum LDL cholesterol and Triglyceride compared to patients who are on 
hemodialysis. But higher cholesterol level does not seem to effect on raising mortality or 
cardiovascular morbidity and PD failure. On the contrary, lower serum cholesterol level 
in CAPD patients tends to raise mortality and morbidity due to poor nutritional status.
Methods: This study is a retrospective study designed to evaluate the effect of 
cholesterol level, statin on CAPD outcome and mortality. Patients who were on peritoneal 
dialysis for at least 6 months since March 1st, 2000 were included. A total of 467 patients 
were enrolled in this study. Patients’ biological parameter, biochemical parameter and 
morbidity/mortality during CAPD maintenance period were collected.
Results: Patients whose initial cholesterol level were above 240 mg/dL shows 
significantly low CAPD failure rate compared to patients whose initial cholesterol level 
were below 200 mg/dL (OR= 0.469, p=0.049). Patients whose average LDL-cholesterol 
during CAPD period were over 100mg/dL showed significantly higher mortality compared 
to patients whose initial LDL-cholesterol level were below 100mg/dL (OR=1.848, p=0.024). 
Patients whose compliance to statin during CAPD period was over 80% showed significantly 
low mortality compared to patients who did not take statin during CAPD period (OD=0.556, 
p=0.020). Patients showed no significant difference in motality due to total cholesterol, 
HDL cholesterol levels and patients showed no significant difference in CAPD failure due 
to HDL/LDL cholesterol, statin usage.
Conclusions: In CAPD patients, serum total cholesterol level should be targeted higher 
than HD or CKD patients. On the contrary, similar to HD or CKD patients, Statin should 
be administered and LDL cholesterol should be lowered during CAPD period to lower 
mortality. To identify the difference in cholesterol mechanism of CAPD patients further, 
in depth study over adequate cholesterol level in CAPD patients needs to be proceeded.
TH-PO989
Using Daily Remote Biometric Monitoring in Peritoneal Dialysis 
Susie Q. Lew,1 Manya Magnus,2 Neal Sikka.3  1Medicine, George Washington 
Univ, Washington, DC; 2Epidemiology and Biostatistics, George Washington 
Univ, Washington, DC; 3Emergency, George Washington Univ, Washington, DC.
Background: Peritoneal dialysis(PD) requires self-monitoring with daily blood 
pressure(BP), weight, & physical examination. Patients(Pts) don’t always perform 
procedures or record results. We aim to determine associations between daily remote 
biometric monitoring(RBM) & clinical and pt satisfaction outcomes.
Methods: Pts were provided with BP monitoring equipment & scale which were 
capable of announcing the results, transmitting the results via Bluetooth technology to a 
hub located in the pt’s home & via 2G/3G cellular signal to a Telehealth call center. PD 
nurses viewed results or alerted to abnormal results.
Results: 300 subjects(subjs) from 10 PD units were followed over at least 12 months. 
Demographics include male (56%), African American(AA)(62%), & median age 56 yrs 
(IQR 44-64) and 1.86 yrs on dialysis (IQR 0.62-3.73). AA subjs were more likely to use 
than non-AA (69% vs 55%, p<0.05). 51% of subjs used RBM, with 66% consistently using 
the equipment. RBM was associated with reduced risk of hospitalization (Coef -0.27, SE 
0.10, p=0.006). Subjs became increasingly less likely to breach any upper or lower alert 
threshold (OR 0.995, p=0.004). Subj satisfaction of RBM equipment for BP monitoring was 
87% & scale 90%. Rural exceeded non-rural subjs in utilizing RBM (OR 4.77, 95% CI 1.34-
16.98, p<0.02) Use of RBM was associated with improved perception of confidence with 
self-care requirements of PD: easier to collect measurements (OR 2.69, 95% CI 1.52-4.76, 
p<0.001); more secure in their measurements (OR 3.28, 95% CI 1.71-6.26, p<0.001);getting 
more support from their PD doctors and nurses (OR 2.03, 95% CI 1.01-4.12, p<0.05).
Conclusions: RBM was associated with increased frequency, accuracy, and 
communication of measurements to medical personnel, enhanced perception of 
autonomy and confidence in measurements, & reduction of hospitalizations & out of 
range measurements for BP. RBM was acceptable & satisfactory to PD pts. RBM offers 
additional tools to support PD pts in maintaining their measurement regimens & reduce 
negative health outcomes.
Funding: Other U.S. Government Support
TH-PO990
Impact of Patient-Centric Automated Peritoneal Dialysis User-Interface on 
Operator Learning and Confidence  Catherine Firanek, Mary Gellens, James 
A. Sloand.  Medical Affairs, Baxter Healthcare, Deerfield, IL.
Background: Automated peritoneal dialysis (APD) is an underutilized therapy for 
patients with end-stage renal disease (ESRD). The perception patients may not be able to 
manage their own treatment setups comes into play in choice of this treatment modality. 
Improvements to cycler technology may help to further simplify therapy for patients, 
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reducing barriers to uptake. This study aimed to determine whether a cycler-embedded, 
patient-centric interface offered an enhanced user experience compared to a conventional 
APD cycler.
Methods: 30 study participants (ages 29-84, mean 50 yrs, 67% male) diagnosed with 
ESRD were randomized into 2 groups using cycler with patient-centric user interface with 
advanced technology in development and a conventional APD cycler. Participants evaluated 
cyclers on 2 non-consecutive days using a different cycler each day. Each participant was 
given a brief orientation, setup task, training session, break, followed by a setup task and 
questionnaire. Study results were analyzed via Fisher’s exact, Mann-Whitney and Exact 
binomial tests.
Results: The cycler with patient-centric user interface and advanced technology (in 
development) scored better on reduced reliance on printed instructions (p<0.0001). Patients 
committed fewer deviations on the cycler in development vs the conventional cycler (2 of 
19 steps vs 14 of 19 respectively) after training (p=0.004), including disinfecting hands 
(p=0.02) and line handling (p=0.01), and were more confident that they set up the cycler 
according to specifications (p=0.043). The new cycler scored higher in overall preference 
among study participants: The cycler with a patient centric user interface was rated easier 
to learn (p=0.005) and to use (p=0.016), preferable to use (p=0.03), and users felt more 
confident about using the new cycler at home compared to conventional cycler (p=0.001).
Conclusions: A cycler with embedded, patient-centric interface was rated higher 
in terms of overall reliance on instructions, task competency, ease of use and learning, 
preference and overall confidence of using the cyclers. These findings indicate that APD 
operator learning and confidence can be enhanced with a patient-centric user-interface.
Funding: Pharmaceutical Company Support - Baxter Healthcare Corporation
TH-PO991
Single-Site Trans-Umbilical Peritoneal Dialysis Catheter Insertion 
Mangalakumar Veerasamy.  Nephrology, KMCH, Coimbatore, Tamilnadu, India.
Background: Traditional laparoscopic peritoneal dialysis catheter placement requires 
two ports insertion and this could lead to complications like leak and hernia at the port sites. 
We describe a novel approach of using single-site trans-umbilical ports that is associated 
with small scar (less than 1cm) and reduced complications.
Methods: Under general anaesthesia pneumo-peritnoeum was created as per standard 
method. One 10mm port and one 5mm port was inserted through trans-umbilical route to 
guide peritoneal dialysis catheter insertion. Hernial orifices were inspected and if there was 
any adhesion present that was released to facilitate free fluid movement. The catheter was 
inserted through a small incision 1 inch below umbilicus. The catheter was positioned in 
the pouch of Douglas using lap instrument passed through the trans-umbilical port. The 
other end of catheter was tunnelled in the standard manner and brought out though the 
exit site and the titanium adaptors were fixed as usual.To prevent the migration of catheter 
from the pelvic cavity a trans-facial loop was placed around the catheter(freely mobile but 
remains in pelvis). Omentum was folded and pulled upwards to the left upper guardant and 
fixed to anterior abdominal wall using a trans-facial loop. The latter prevented the omentum 
from wrapping dialysis catheter and causing malfunction. Then the port site was closed in 
three layers (Video available).
Results: 10 cases underwent catheter insertion with this approach (Male 7, Female 
3) and the mean follow up period is 11 months. None of them developed leak or catheter 
migration or any mechanical complication that might require catheter reposition or change.
Conclusions: Combined method of Single-site port placement, omentopexy and loop 
fixation of intra-abdominal segment of catheter offers the following advantages -small 
incision; hence risk of leak when catheter was used early after placement is low. The risk 
of hernia through port site is reduced and small scar will be welcome to image conscious 
patients. If there was any adhesion present that could be released with minimal trauma 
to peritoneal membrane. Placing a loop around the catheter prevented catheter migration. 
Omental wrapping was prevented by fixing this in the upper quadrant by trans-facial loop.
TH-PO992
Peritonitis and Survival following PD Catheter Insertion in Infants 
Joshua Zaritsky, Coral D. Hanevold, Troy Richardson, Jonathan Rodean, 
John P. Lawlor, Raymond P. Quigley, Alicia Neu, Bradley Warady.  SCOPE 
Collaborative, CHA, Overland Park, KS.
Background: Chronic peritoneal dialysis (PD) is the dialysis modality of choice 
for children. However, there are limited outcome data in those who undergo PD catheter 
(cath) insertion in the 1st year of life. Using data from the Children’s Hospital Association 
Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (ESRD) 
Collaborative (SCOPE), we examined peritonitis rates and survival in 156 infants who had 
a PD cath placed in the 1st yr of life.
Methods: Data on pt demographics, PD cath characteristics, peritonitis risk factors and 
outcomes from 157 cath insertions from 29 North American pediatric dialysis centers were 
reviewed and analyzed using chi square test for association or a Wilcoxon rank-sum test.
Results: In hospital and overall peritonitis rates during the 1st year post cath insertion 
were 1.73 and 0.76 per pt-year, respectively. Gram + organisms were responsible for 
38.7% of infections (figure); 28% were culture negative. Polycystic kidney disease and 
pulmonary hypoplasia were more frequent in infants with peritonitis, whereas anuria did 
not differ between groups (table). Use of a curled catheter or plastic adaptor, nephrectomy 
prior to or concurrent with cath insertion, and G-tube insertion after cath placement were 
more common in pts with peritonitis, while number of cuffs, surgical technique, cath use 
within 14 days and cath revision did not differ between groups. Infants with peritonitis had 
longer initial hospital stays and lower survival compared with those without peritonitis. 
Conclusions: In this large cohort of infants with ESRD, we found a high rate of 
peritonitis and identified several risk factors associated with peritonitis. Given that peritonitis 
was associated with increased initial hospital stay and mortality, attention to the potentially 
modifiable factors is needed.
TH-PO993
Risk Factors for All-Cause Unexpected Hospitalization After Peritoneal 
Dialysis Catheter Implantation  Zi Li,1 Zita C. Abreu,2 Joanne M. Bargman.2 
1Nephrology, West China Hospital, Sichuan Univ, Chengdu, Sichuan, China; 
2Nephrology, Toronto General Hospital Univ of Toronto, Toronto, ON, Canada.
Background: Implantation of the peritoneal dialysis catheter (PDC), usually an elective 
procedure, may necessitate unexpected hospitalization due to multiple co-morbidities and 
inherent instability of the end-stage renal disease patient. This information is important for 
administrative planning for a PD program. However, information on hospitalization after 
PDC implantation is limited and details about the reason for hospitalization are lacking.
Methods: We performed a prospective cohort study in consecutive patients 
who underwent PDC implantation at a single institution from 2007 to 2013. Clinical 
characteristics of enrolled patients, technique of the implantation procedure and all-cause 
unexpected hospitalization and morbidity within 14 days after implantation were analyzed.
Results: A total of 246 patients receiving 252 PDC implantations during the 6 years 
were studied. After 39 procedures (15.5%), patients had an unexpected hospital stay due to 
operative complications (33.3%), worsening of comorbid disease (35.9%), or a single-night 
hospital stay for observation (30.8%). Compared to discharged patients, the unexpected 
hospitalization ones were older (P=0.001), had higher rates of previous episodes of heart 
failure (P=0.006) and heart disease (P<0.001), had more use of general anesthesia (P=0.046), 
had more added procedures during the implantation (P=0.02) and had more episodes of flow 
obstruction and peritonitis (P=0.012 and P<0.001). Multivariable logistic regression showed 
that age, cardiac morbidity, use of general anesthesia, PDC flow problems and peritonitis 
after implantation were independent predictors of all-cause unexpected hospitalization.
Conclusions: For the first time, our study has analyzed the rate of unexpected 
hospitalization after PDC implantation and identified the salient risk factors. Increased 
focus to identify patients at greatest risk for hospitalization, evaluation of processes of 
care, and implementation of preventive strategies may be helpful to reduce unplanned 
hospitalization after catheter insertion.
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TH-PO994
Early Mechanical and Infective Complications in First Time Blind, Bedside, 
Midline Percutaneous Tenckhoff Catheter Insertion with Ultra Short Break-
in Period: Setting New Standards  Suceena Alexander,1 Ninoo G. George,2 
Santosh Varughese.1  1Nephrology, Christian Medical College, Vellore, Tamil 
Nadu, India; 2Nephrology, Billroth Hospitals, Chennai, Tamil Nadu, India.
Background: There are no large studies that have looked into ultra-short break-in 
period with blind, bedside, midline approach of Tenckhoff catheter insertion.
Methods: 284 consecutive adult patients underwent catheter insertion for chronic 
peritoneal dialysis at our centre from January 2009 to December 2013. Those with history of 
midline laparotomy scars and hernias were referred for open surgical insertion. 245 patients 
(86.3%) underwent the percutaneous and 39 patients (13.7%) underwent surgical insertions.
Results: The mean break-in period for the percutaneous group (PG) was 2.68 ± 2.63 
days and for the surgical group (SG) was 11.19 ± 6.96 days, p <0.001. Poor catheter 
outflow was present in 22 (9%) of PG and in 4 (10.3%) of SG (p= 0.80).Primary catheter 
non-function was present in 24 (9.8%) of the PG and in 4 (10.3%) of the SG (p= 0.73). 
Catheter survival at one year was 164/241 (89.1%) in the PG. The various outcomes are:
Outcomes Percutaneous N=245 Surgical N=39 P value
Failed Catheter Insertion,n(%) 2(0.8) 0 0.74
Poor outflow,n(%) 22(9) 4(10.3) 0.8
Dialysate leak,n(%) 16(6.5) 6(15.4) 0.055
Mesentric tear,n(%) 2(0.8) 0 0.74
Paralytic ileus,n(%) 0 1(2.6) 0.01
Exit site bleeding,n(%) 1(0.4) 0 0.69
Early peritonitis,n(%) 3(1.2) 0 0.49
Overall early mechanical 
complications,n(%) 40(16.3) 11(28.2) 0.07
Primary catheter non-
function,n(%) 24(9.8) 4(10.3) 0.73
Mortality,n(%) 68/241(28.2) 17/36(47.2) 0.02
Catheter survival at one 
year,n(%) 164/184(89.1) 29/35(82.9) 0.29
Median patient survival(mts) 43(95%CI:28.5-57.5) 35(95%CI:24-46) 0.60
Conclusions: The significantly shorter break-in period and smaller wound incisions 
reduce hospitalization and the need for bridging hemodialysis as well as having good 
patient and catheter outcomes.
TH-PO995
Comparing Outcomes of Percutaneous Peritoneal Dialysis Catheter 
Insertion by Nephrologist versus Open Surgical Insertion – Large Single 
Centre Experience  Louise E. Ross, Bhrigu Raj Sood.  South West Thames 
Renal and Transplantation Unit, Carshalton, Surrey, United Kingdom.
Background: Several studies suggest that percutaneous insertion of peritoneal dialysis 
(PD) catheters by nephrologists improves the uptake of PD. Percutaneously inserted PD 
catheter has the advantage of being less invasive, removing the need for general anaesthetic, 
reducing hospital stay, facilitating acute PD, therefore making PD more accessible. There 
are only a few small studies directly comparing the outcomes of patients who have had a 
percutaneous versus open method of implantation, with some suggesting poorer outcomes.
Methods: We retrospectively reviewed data on all patients who had a percutaneous or 
open surgical PD catheter inserted between August 2011 and December 2014 at a single 
renal centre, to identify the patients who developed an exit site infection (ESI) or episode 
of PD peritonitis within two and four weeks of catheter insertion. We also looked at patients 
who developed a functional catheter problem requiring manipulation or replacement of the 
catheter within the first year. Chi-squared test was used to assess statistical significance.
Results: 276 PD catheters were inserted in the said time period. 152 were inserted 
percutaneously and 124 with open surgery. There were less ESI (at 2 weeks - 2.6% versus 
6.5%; p=0.122, and at 4 weeks – 2.6% versus 10.5%; p=0.007) and less peritonitis (at 2 
weeks - 0.7% versus 3.2%; p=0.112, and at 4 weeks – 1.3% versus 5.6%; p=0.044) episodes 
in the percutaneous versus open surgical group. PD catheters requiring manipulation 
or replacement within the first year due to a functional problem was comparable in the 
percutaneously inserted catheters (9.2% versus 12.9%; p=0.327). There were no major 
complications in the form of viscus perforation or major haemorrhage in either group.
Conclusions: In our study, we found that infection related complications were better 
with percutaneous PD catheter insertion and mechanical failure rate was comparable to 
open surgical PD catheter insertion. In our practice we have found that percutaneously 
inserted PD catheters are a safe means of increasing patient access to PD, enabling more 
patients to have a home-based therapy.
TH-PO996
Shared Decision-Making in Chronic Kidney Failure: The Retrospection of 
Early-Stage Dialysis Patients in Germany  Maxi Robinski,1 Wilfried Mau,1 
Andreas Wienke,2 Matthias Girndt.3  1Inst of Rehabilitation Medicine, Martin 
Luther Univ Halle-:ittenberg, Halle Saale, Germany; 2Inst of Medical 
(pidemiology, Biostatistics, and Informatics, Martin Luther Univ Halle-
Wittenberg, Halle (Saale), Germany; 3Dept of Internal Medicine II, Martin 
Luther Univ Halle-:ittenberg, Halle Saale, Germany.
Background: To date, little is known about the extent to which patients with chronic 
kidney failure feel involved in decision-making regarding the life-changing dialysis 
treatment. Previous studies on mortality yielded equivalence of peritoneal (PD) and 
hemodialysis (HD). However, only 5% of the patients in Germany choose PD, even though 
many patients are eligible for both options and entitled to receive unbiased counselling.
Methods: In a nationwide multicenter study with federal funding (“CORETH-project”), 
we surveyed 781 patients on dialysis since 6 to 24 months with regard to their rating of shared 
decision-making (SDM) with their physician concerning the choice of renal replacement 
therapy. We used the “Shared Decision-Making Questionnaire” (Kriston et al. 2010), 
which is a highly reliable and well accepted measure. Furthermore, patients indicated the 
dominating reason for choosing their treatment as well as their treatment satisfaction (TS). 
Data were compared between propensity score-matched groups of patients (nPD=nHD=246).
Results: PD patients rated all aspects of SDM (for example, consideration of patient-
preferences or shared weighing of options) significantly more positive than HD patients 
(SDM-total score, p<.0001). PD patients predominantly (73%) indicated their independency 
as a motivator for the choice, whereas HD patients were largely (30%) subject to medical 
decisions only. Moreover, compared to HD, PD patients were more satisfied with the 
information received (p=.013). The SDM- and TS-total scores correlated significantly 
positive in the matched overall sample (r=.19, p<.0001).
Conclusions: Our findings heighten awareness for an unbiased nephrological 
counselling-culture and provide indications for a successful SDM-process when choosing 
dialysis modality. According to the results, an effective SDM can pave the way for dialysis 
patients’ quality of life and treatment success.
Funding: Government Support - Non-U.S.
TH-PO997
Depression and Cognitive Impairment in Peritoneal Dialysis: A Multi-
Center Cross-Sectional Study  Jie Dong,1 Hai-chen Pi,1 Zuying Xiong,2 
Jinlan Liao,2 Li Hao,3 Gui-ling Liu,3 Ye-Ping Ren,4 Qin Wang,4 Li-ping Duan,5 
Zhao-xia Zheng.5  1Renal Div, Dept of Medicine, Peking Univ First Hospital, 
Beijing, China; 2Renal Div, Peking Univ Shenzhen Hospital, Shenzhen, China; 
3Renal Div, The Second Hospital of Anhui Medical Univ, Hefei, Anhui, China; 
4Renal Div, The Second Affiliated Hospital of Harbin Medical Univ, Harbin, 
Heilongjiang, China; 5Renal Div, Handan Central Hospital, Handan, Hebei, 
China.
Background: Depression and cognitive impairment have been identified as independent 
risk factors for mortality in peritoneal dialysis (PD) patients. The relationship between 
depression and cognitive functions in PD patients was investigated in this multi-center 
cross-sectional study.
Methods: Study design: multi-center cross-sectional study. Setting & Participants: A 
total of clinically-stable 458 patients who performed PD for at least 3 months from 5 PD units 
were enrolled in this study. Factor: Depression. Outcomes: Global and specific cognitive 
impairment. Measurements: Global cognitive function was measured by using the Modified 
Mini-Mental State Examination (3MS), specific cognitive function by executive function, 
immediate memory, delayed memory, visuospatial skill and language ability by subtests 
of Repeatable Battery for the Assessment of Neuropsychological Status. Depression was 
diagnosed if the depression severity index>0.5 by using Zung’s Self-rating Depression Scale.
Results: The prevalence of depression and cognitive impairment evaluated by 3MS 
were 52% and 28.4% respectively. Patients with mild or moderate/severe depression 
had higher prevalence of general cognitive impairment, executive dysfunction, impaired 
immediate and delayed memory. After adjusting for demographic, comorbidity data and 
clinical parameters, depression scores were independently associated with lower scores of 
3MS, immediate and delayed memory, and language ability, and longer completion time of 
trails A and B. Even mild depression could independently predict higher risk of CI, executive 
dysfunction, impaired immediate and delayed memory after multivariable adjustments.
Conclusions: Even mild depression plays an important role in global and specific 
cognitive functions in PD patients.
Funding: Government Support - Non-U.S.
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TH-PO998
Proposed Model for the Care of Hospitalized Peritoneal Dialysis Patients 
Cynthia R. Christiano,1 Melanie I. Hames,1 Pankaj Jawa,1 Piper J. Hughes,3 
Maria H. Locklear.2  1Div of Nephrology, Brody School of Medicine at East 
Carolina Univ, Greenville, NC; 2Vidant Medical Center, Greenville, NC; 
3Internal Medicine, East Carolina Univ, Greenville, NC.
Background: Peritoneal dialysis (PD) has been prescribed throughout the United 
States, yet the optimal model of care for hospitalized PD patients remains unknown. With a 
growing interest in home modalities and emphasis on quality, it is imperative that we identify 
an effective and efficient way to care for this patient population during hospitalization.
Methods: We describe a model successfully implemented at Vidant Medical Center 
(VMC) in 2008. Prior to this date, the primary hospital nurses performed PD care. Due to 
the high risk, low volume nature of inpatient PD, this resulted in inconsistent care as well 
as decreased physician, nursing, and patient satisfaction. In 2008, an inpatient PD nursing 
team was created. This team, consisting of nephrology nurses with specialized PD training, 
is managed by VMC’s self-maintained dialysis unit. Staffed with 2 nurses during the day 
and 1 at night, they provide 24/7 care throughout the hospital, including the ICU and ED. 
Responsibilities include patient education, exit site care, catheter flushes, and all manual 
and automated PD exchanges. Upon discharge, the outpatient unit is contacted to ensure 
appropriate transition back to the outpatient setting.
Results: This model provides several benefits: 1) PD treatments are consistently 
completed and charted, 2) Increased physician, nursing, and patient satisfaction, 3) 
Continuity of care, and 4) Cost reduction (personnel and supplies). Since inception, this team 
has grown to 13 nurses. During FY2014, 2568 (1572 adult / 996 pediatric) PD treatments 
were performed, the majority CAPD. To ensure appropriate utilization of nursing resources, 
most are cross-trained to perform hemodialysis.
Conclusions: In conclusion, the creation of a specialized nursing team has been 
instrumental in optimizing the care of our hospitalized PD patients. This sustainable model 
provides effective, efficient care and should be considered for implementation by hospitals 
providing PD services.
TH-PO999
Elderly Peritoneal Dialysis Compared with Elderly Hemodialysis Patients 
and Younger Peritoneal Dialysis Patients: Competing Risk Analysis of a 
Korean Prospective Cohort Study  Hyunsuk Kim,1 Jung Nam An,2 Dong Ki 
Kim,1 Yong-Lim Kim,3 Yun Kyu Oh,2 Chun Soo Lim,2 Yon Su Kim,1 Jung Pyo 
Lee.2  1Internal Medicine, Seoul National Univ College of Medicine, Seoul, 
Republic of Korea; 2Internal Medicine, Seoul National Univ Boramae Medical 
Center, Seoul, Republic of Korea; 3Internal Medicine, Kyungpook National Univ 
School of Medicine, Daegu, Republic of Korea.
Background: The outcomes of peritoneal dialysis (PD) in elderly patients have not 
been thoroughly investigated. We aimed to investigate the clinical outcomes and risk factors 
associated with PD in elderly patients.
Methods: We conducted a prospective observational nationwide adult end-stage 
renal disease (ESRD) cohort study in Korea from August 2008 to March 2013. Among 
incident patients (n=830), patient and technical survival rate, quality of life, and Beck’s 
Depression Inventory (BDI) scores of elderly PD patients (≥65 years, n=95) were compared 
with those of PD patients aged ≤49 years (n=205) and 50~64 years (n=192); and elderly 
hemodialysis (HD) patients (n=315). The patient death and technical failure were analyzed 
by cumulative incidence function.
Results: The patient survival rate of elderly PD patients was inferior to that of younger 
PD patients (P<0.001). However, the technical survival rate was similar (P=0.097). 
Compared with elderly HD patients, the patient survival rate did not differ according to 
dialysis modality (P=0.987). Elderly PD patients showed significant improvement in the BDI 
scores, as compared with the PD patients aged ≤49 years (P=0.003). Low albumin, diabetes 
and low residual renal function were significant risk factors for the PD patient survival; and 
peritonitis was a significant risk factor for technical survival. Furthermore, low albumin 
and hospitalization were significant risk factors of patient survival among the elderly.
Conclusions: The overall outcomes were similar between elderly PD and HD patients. 
PD showed the benefit in BDI and quality of life in the elderly. Additionally, the technical 
survival rate of elderly PD patients was similar to that of younger PD patients. Taken 
together, PD may be a comparable modality for elderly ESRD patients.
TH-PO1000
Phosphorus Control and Phosphate Binder Pill Burden During Real-
World Use of Sucroferric Oxyhydroxide in Peritoneal Dialysis Patients 
Linda H. Ficociello, Vidhya Parameswaran, Mark Costanzo, Claudy Mullon, 
Franklin W. Maddux, Robert J. Kossmann.  Fresenius Medical Care North 
America (FMCNA), Waltham, MA.
Background: Achieving serum phosphorus (sPhos) control can be a challenge for 
dialysis patients (pts). This retrospective database analysis examined the real-world 
effectiveness of sucroferric oxyhydroxide (SO), an iron-based phosphate binder (PB), in 
adult peritoneal dialysis (PD) pts.
Methods: A cohort of PD pts prescribed SO as part of routine clinical care at FMCNA 
clinics was analyzed. Pts had ³1 sPhos measured during SO and had been previously treated 
with sevelamer, calcium acetate, calcium carbonate or dual therapy. Changes in sPhos, 
serum calcium (sCa), intact parathyroid hormone (iPTH), transferrin saturation (TSAT), 
ferritin (FER), and PB pills per day (PPD) were assessed 3-months before SO (baseline) 
and 3-months during SO (follow-up).
Results: Pts (n=328) were, on average, 53 years old, with a dialysis vintage of 3.9 years. 
At baseline, 56% of pts used sevelamer, 29% calcium acetate, 11% calcium carbonate, and 
5% dual therapy. Pts in-range increased from 13.5 to 23.8% (76% increase). Mean sPhos 
decreased from 6.92 to 6.67 mg/dl, p<0.001. PB PPD was reduced from 8.4 to 3.8 pills 
(4.6 fewer pills, p<0.001). There was no significant change in sCa (9.1 to 9.0 mg/dl) or 
iPTH (535 to 555 pg/ml). TSAT and FER increased from 35.4 to 36.6% and 752.1 to 814.9 
ng/ml, respectively. In pts not receiving IV iron (n=127), TSAT and FER did not change 
significantly (36.3 to 37.3% and 797.9 to 743.3 ng/ml, respectively).
Conclusions: In this large cohort of PD patients prescribed sucroferric oxyhydroxide 
as part of routine clinical care, a significant reduction in serum phosphorus (p<0.001) and 
a 76% increase in patients achieving in-range serum phosphorus (p<0.001) was observed. 
This was accomplished with a mean of 3.8 pills per day, a reduction of 4.6 pills (p<0.001).
Funding: Pharmaceutical Company Support - Frensenius Medical Care North 
America
TH-PO1001
Laparoscopic Findings of Visceral Peritoneal Injury in Patients Treated 
with Neutral pH Peritoneal Dialysis Solution  Yudo Tanno, Nanae Matsuo, 
Izumi Yamamoto, Yasuyuki Nakada, Ichiro Ohkido, Keitaro Yokoyama, Takashi 
Yokoo.  Div of Kidney and Hypertension, Dept of Internal Medicine, Jikei Univ 
School of Medicine, Tokyo, Japan.
Background: Encapsulating peritoneal sclerosis (EPS) is caused by a visceral 
peritoneal lesion, i.e., intestinal tract adhesion and encapsulation, it is important to evaluate 
changes in the visceral peritoneum. It has been reported that there was a decreasing trend 
of peritoneal injury with the use of PD solution with neutral pH as compared with acidic 
pH in the histopathological evaluation of the parietal peritoneum; however, there is no 
report evaluating changes in the visceral peritoneum, which is essentially important and 
should be evaluated. We previously reported laparoscopic approach for evaluation of EPS 
(KI 2012) in patients treated with PD solution with acidic pH. In this study, we examined 
macroscopic findings of the visceral peritoneum in patients treated with neutral pH solution 
alone for 4 years or more by laparoscopy.
Methods: 19 patients underwent laparoscopy at the time of PD catheter removal. 
Duration of PD in these patients was 64.5±18.8 months. Clinically, none of these patients 
had developed EPS by the time of the investigation. The findings of both parietal and 
visceral peritoneal tissues were categorized according to color changes, presence of 
neovascularizations and adhesions.
Results: It was found that longer the duration of PD, the worse the peritoneal injury. 
Although changes in the parietal and visceral peritoneum had heterogeneous distributions, 
the changes in the visceral peritoneum were milder, showing a discrepancy with the findings 
of the parietal peritoneum. As compared with laparoscopic findings in patients treated with 
PD solution with acidic pH, the degrees of color changes, presence of neovascularizations, 
and adhesions were all mild, however, severe adhesions were noted in patients with a 
history of PD peritonitis.
Conclusions: Although changes in the visceral peritoneum resulting from the use of 
PD solution with neutral pH show a decreasing trend as compared with acidic pH, there is 
a certain level of peritoneal change, suggesting the possibility of progression of peritoneal 
deterioration by long-term continuous use.
TH-PO1002
“Composite” Encapsulating Peritoneal Sclerosis: A New Presentation in 
a Long Time of Renal Replacement Therapy  Valerio Vizzardi.  O.U. of 
Nephrology, Spedali Civili and Univ of Brescia, Brescia, Italy.
Background: Encapsulating peritoneal sclerosis (EPS) is the more dangerous 
complication of peritoneal dialysis (PD). The EPS can occur during PD (classic EPS), 
after kidney transplantation (TX) or rapid shift to hemodialysis (HD) as the mode of renal 
replacement therapies (RRTs).
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Methods: single-center retrospective analysis of PD transplanted patients in 35 years. 
Evaluation of the characteristics of the EPS presentation.
Results: From July 1979 to December 2014, 173 PD patients underwent kidney 
transplantation (TX). Were diagnosed 5 cases (2.9%) of EPS: one after 6 months from the 
TX (typical posttransplant EPS), but the other 4 cases have occurred after more than 20 
years of different renal replacement therapy (medium 346±20 months, range 327-366) and 
at least a long time of TX (medium 227±24 months, range 207-259), also after many years 
of cessation from the last period in PD. The medium time in PD was 71±31 months (range 
36-99). Two patients died after 10 and 41 months after diagnosis, respectively after 332 and 
367 months in RRT. In our center during the same period other 21 EPS cases (2.8%) are 
occurred among the 747 PD patients never transplanted. No cases of EPS was manifested 
after direct transfer from PD to HD.
Conclusions: in our experience EPS prevalence in transplanted PD patients is not 
greater than not transplanted PD patients. In patients for many years in RRTs, EPS occurs 
even after a long time of the cessation of DP, especially after many treatments and long 
periods in TX. It is possible that the PD is acting only as a side event on the tissues affected 
by fibrotic processes formed for a long time in RRTs and/or due to the immunosuppressive 
therapy. To its features this form can be defined “composite EPS” and should also be 
considered in PD patients transplanted since many years.
TH-PO1003
Delta Neutrophil Index Is a Predictive Marker of Catheter Removal in 
Peritoneal Dialysis Patients with Peritonitis  Jae Eun Um,1 Sul A Lee,2 
Shin-Wook Kang.1,2  1Severance Biomedical Science Inst, Brain Korea  PLUS, 
Yonsei Univ College of Medicine, Seoul, Korea; 2Dept of Internal Medicine, 
Yonsei Univ College of Medicine, Seoul, Korea.
Background: Severe and prolonged peritonitis leads to peritoneal membrane failure 
and is the most common cause of technique failure in patients treated with peritoneal 
dialysis (PD). Recent studies reported that delta neutrophil index (DNI), which reflects the 
fraction of circulating immature granulocytes in the blood, is a practical severity marker 
of infection. This study investigated whether DNI could be a predictive marker of catheter 
removal in PD patients with peritonitis.
Methods: Patients treated with PD peritonitis at Severance Hospital between January 
2012 and January 2015 were enrolled. Demographic data, clinical, and laboratory 
parameters including DNI were collected at the time of peritonitis. DNI was calculated 
by automatic analyzer.
Results: A total of 125 PD peritonitis episodes in 92 patients were investigated. The 
mean age was 59.1±12.0 years and 55 (44.0%) were male. PD catheter was removed in 
31 (24.6%) patients. The median value of DNI in patients undergone PD catheter removal 
was significantly higher compared to that of patients who maintained PD catheters [DNI 
(interquartile range), 3.30 (0.0-65.0) vs. 0.70 (0.0-22.5), P=0.001]. DNI is significantly 
associated with percentage of segmented neutrophil (r=0.28) and serum albumin (r=-0.32), 
and dialysate leukocyte counts (r=0.20), but not with C-reactive protein (CRP) levels 
(r=0.08). Multivariate logistic regression analysis revealed that DNI was an independent 
predictor for PD catheter removal in patients with PD peritonitis (odds ratio=1.08, 95% 
confidence interval=1.01-1.12, P=0.04) after adjustment for serum albumin, CRP, leukocyte 
count of dialysis effluent, and septic shock. The area under the ROC curve (AUC) of DNI 
for PD catheter removal was 0.69 (P=0.001), whereas the AUC of dialysate leukocyte count 
was not statistically significant (0.52, P=0.70).
Conclusions: DNI levels reflected the severity of PD peritonitis. Higher levels of DNI 
could be an independent predictor for PD catheter removal in patients with PD peritonitis.
TH-PO1004
Peritonitis Rates Among African Americans and Caucasians Undergoing 
Peritoneal Dialysis  Aceela Muqri, Russell Griffin, Eric L. Wallace.  Univ of 
Alabama at Birmingham.
Background: African Americans (AA) are under-represented in the prevalent peritoneal 
dialysis (PD) population in the United States. There is relatively little conclusive data to 
explain the cause of this. One explanation is that AA may have higher rates of peritonitis 
than Caucasians leading to increased technique failure. This study aimed to determine if 
differences between AA and Non-AA rates of peritonitis at the University of Alabama at 
Birmingham Home Dialysis existed.
Methods: This is a single center retrospective cohort analysis on data from November 
2012 to November 2014. Baseline demographics as well as data on peritonitis episodes 
were analyzed. Peritonitis rate was defined as the absolute number of distinct peritonitis 
episodes divided by the number of patient months at risk. Relapsing peritonitis episodes 
were excluded. Chi-square analysis was used to compare baseline categorical variables and 
independent t test to compare length of time on dialysis. Rates of peritonitis were analyzed 
with Fischer exact test. Peritonitis free survival, hospitalization free survival and technique 
failure were analyzed by log rank comparison of Kaplan Meier curves.
Results: Between 2012 and 2014, 90 AA and 70 non-AA were treated at the UAB 
home dialysis units. Baseline demographics between the two groups were similar in Gender 
and cause of ESRD (p >0.2 in all causes ESRD). Non-AA were older than AA with an 
average age of 58 vs 50 respectively (p= 0.003). Average time on dialysis were similar (p 
=0.27) AA had an 82% increased rate of peritonitis over the time period (RR 1.82, 95% 
CI 0.99-3.37). This association no longer remained after adjustment for age at time of PD 
start (RR 1.66, 95% CI 0.89-3.10). There was no interaction with age and race in regards 
to the rate of peritonitis infection rate (p=0.4637). Technique survival was not different 
between AA and Caucasians. (p 0.44).
Conclusions: AA when compared to non-AA, trended towards a higher risk of 
peritonitis than Caucasians. Despite this, technique survival between races did not differ. 
This study does not support the hypothesis that the underlying cause of decreased prevalent 
AA PD patients is due to increased technique failure from disproportionate peritonitis rates.
TH-PO1005
Factors Associated with Peritoneal Dialysis Technique Failure: A Single 
Center Study  Anoop Sheshadri, Ramesh Saxena.  Dept of Nephrology, UTSW 
Medical Center, Dallas, TX.
Background: To review peritoneal dialysis (PD) technique survival and assess factors 
associated with PD technique failure at our center.
Methods: We performed a retrospective analysis of 315 patients with PD catheters 
placed between 01/2001 and 09/2009, reviewing medical records for demographic and 
clinical information. Primary outcome was PD technique failure, defined as permanent 
discontinuation of PD due to infectious or non-infectious complications, inadequate dialysis, 
or miscellaneous factors such as pain. Patients were followed at least 36 months after 
PD initiation. Survival analysis was performed using Kaplan-Meier methods. Covariates 
influencing survival were analyzed using Cox proportional hazards regression models.
Results: 
There were a total of 70 failures, 31 (44.3%) related to infectious complications, 22 
(31.4 %) to non-infectious complications (e.g. obstruction, leaks), 8 (11.4%) to inadequate 
dialysis, and 9 (12.9 %) to miscellaneous factors. Overall survival at 36 months was 
78.81%. Covariates significantly affecting technique failure include prior HD (1.83; 
1.14–2.92), non-infectious complications (1.82; 1.28–2.59), DM (1.62; 1.00–2.63), HIV 
(2.52; 1.01–6.24), peritonitis (1.94; 1.20–3.12), and exit site infections (1.79; 1.09–2.92). 
Previous abdominal surgeries (.90; .758–1.08) and BMI (1.005; .971–1.04) were not 
significantly associated with failure.
Conclusions: This is one of the largest single center studies of its type from a US PD 
program. It shows excellent 3 year PD technique survival, better than reported in similar 
studies. Our results confirm that diabetes mellitus, PD related infections, and non-infectious 
mechanical problems are independent risk factors for PD technique failure. Conversely, 
BMI, abdominal surgeries, and demographic characteristics such as race and gender do 
not have significant association and should not be considered barriers to PD initiation.
Funding: Clinical Revenue Support
TH-PO1006
Effect of Early Peritonitis on Clinical Outcomes  Kristin M. Corapi,1 Julia 
Beth Wenger,1 Jeffrey Perl,2 Sharon Nessim,3 Ishir Bhan,1 Joanne M. Bargman.4 
1Nephrology, Massachusetts General Hospital, Boston, MA; 2Nephrology, 
St. Michael¶s Hospital, Toronto, 2N, Canada; 3Nephrology, Jewish General 
Hospital, McGill Univ, Montreal, QC, Canada; 4Nephrology, Toronto General 
Hospital, Toronto, ON, Canada.
Background: Infection is a source of significant morbidity and mortality for peritoneal 
dialysis (PD) patients. Previous studies suggest that early peritonitis is associated with 
shorter technique survival; however these studies are limited by small samples, restricted 
generalizabilty, and a lack of standardized definitions. We used data from a large dialysis 
database to determine if the timing of the first peritonitis episode is associated with adverse 
clinical outcomes.
Methods: US and Canadian data from 1996 to 2005 in the Baxter POET (Peritonitis, 
Organism, Exit sites, Tunnel infections) database was analyzed. Patients who developed 
peritonitis within 6 months of PD initiation were identified as cases. Controls were patients 
whose first peritonitis occurred after 6 months. Patients who never developed peritonitis 
or who were on PD for less than 6 months were excluded. Patients were censored at the 
time of transplant, transfer to hemodialysis, or death.
Results: 920 cases and 2607 controls were identified. 
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Early (n=920) Late (n=2607) p value
Age (years) 57 58 0.7
% Male 54 46 0.6
% on CAPD 66 71 0.006
% with diabetes 47 40 <0.001
% New to PD
% Transfer from HD
% Other *
50
26
24
49
25
26
0.5
Presented as %, = mean, * failed transplant or moved from another unit 
Patients with early peritonitis had a significantly higher peritonitis rate than controls 
(1.26 and 0.67 episodes/patient year, p<0.001). Early peritonitis was also associated with 
shorter technique and patient survival. 
Conclusions: Our results suggest that patients with early peritonitis are at increased 
risk of adverse clinical outcomes such as future infection, technique failure, and death.
TH-PO1007
Underweight Predicts Technical Failure: A Retrospective Cohort Study of 
Incident Peritoneal Dialysis Patients  Xiaoyan Huang, Xiuqin Zeng, Qing 
Wang, Zibo Xiong, Yumei Liao, Zuying Xiong.  Div. of Nephrology, Peking 
Univ Shenzhen Hospital, Shenzhen, Guangdong, China.
Background: Technical failure is more common in peritoneal dialysis (PD) than in 
hemodialysis. High body mass index (BMI) increases mortality in the general population, 
but it may improve survival in hemodialysis patients. In PD patients, yet, reports regarding 
the association of BMI with technical survival are scarce and remain controversial.
Methods: In this retrospective cohort study, 348 incident PD patients (aged 48.2 ± 
15.5 years, 62% men) at Peking University Shenzhen Hospital from 2000 to 2014 were 
included. BMI was calculated with height and weight first recorded within 2 to 6 months 
after initiation of PD. Patients were categorized according to the World Health Organization 
recommendation for Asians. All patients were followed until October 31, 2014. Primary 
outcome was technical failure, defined as death or permanently transferred to hemodialysis. 
Secondary outcomes included all-cause mortality, cardiovascular and cerebrovascular 
mortality, occurrence of coronary heart disease and stroke, and incidence of peritonitis. 
Data were analyzed using Cox proportional hazards models.
Results: BMI in this cohort was 22.1 ± 3.0 kg/m2. During 2.5 (interquartile range: 
1.0-4.0) years, 60 cases of technical failure occurred. Incidence of technical failure was 
higher in patients with low BMI (13.4/100 person-years) than those with normal BMI 
(5.2/100 person-years) and with high BMI (6.3/100 person-years). After adjustment of 
age, sex, education, primary disease, and heart failure, hazard ratios (95% confidence 
intervals) were 3.60 (1.53, 8.45) and 0.93 (0.49, 1.76) for patients with low and high BMI, 
respectively, as compared to those with normal BMI. Similarly, the low BMI group had 
significantly higher rates of total as well as cardiovascular and cerebrovascular mortality 
than the normal BMI group, but such relationships did not exist in the high BMI group. No 
associations of BMI with occurrence of coronary heart disease and stroke and incidence 
of peritonitis were observed.
Conclusions: In incident PD patients, low BMI is associated with technical failure, 
all-cause mortality, and cardiovascular and cerebrovascular mortality.
Funding: Government Support - Non-U.S.
TH-PO1008
The Association Between Body Mass Index and Mortality in Peritoneal 
Dialysis Patients  Jin Ho Hwang,1 Geun joo Choi,2 Hyun Kang,2 Su Hyun 
Kim.1  1Internal Medicine, Chung-Ang Univ Hospital, Seoul, Republic of 
Korea; 2Anesthesiology and Pain Medicine, Chung-Ang Univ Hospital, Seoul, 
Republic of Korea.
Background: Unlike the general population, a higher body mass index (BMI) was 
consistently found to be a strong predictor of decreased mortality in patients with end-stage 
renal disease who receive maintenance hemodialysis (HD). This phenomenon has been 
referred to as the “Obesity paradox” or “reverse epidemiology”. Similar tendency has been 
observed in several studies with peritoneal dialysis (PD) patients, but the studies have 
reported conflicting results. We conducted this study to evaluate the association between 
BMI and all-cause mortality in PD patients.
Methods: A systematic search was conducted for published studies in Medline, 
EMBASE, and the Cochrane library databases from 1970 to April 2015. We identified studies 
evaluating the impact of BMI on mortality among PD patients. Data of hazard ratios and 95% 
confidence intervals (CIs) were obtained for respective BMI groups provided by each study. 
We performed meta-regression analysis using unrestricted maximum likelihood model.
Results: The Medline, EMBASE, and the Cochrane library search provided a total of 
3,047 articles. After screening of all titles, 513 abstracts were selected. Finally, 9 cohort 
studies with 33,090 patients were included in the final analysis. Log hazard ratio for all-
cause mortality showed a trend negatively associated with increasing four square root of 
BMI (slope coefficient: -0.1976, 95% CI -0.4110 to 0.0158, p= 0.0695).
Conclusions: In PD patients, BMI was inversely associated with mortality as in HD 
patients. Other outcomes such as cardiovascular death, peritonitis incidence, and technical 
failure will be additionally evaluated.
TH-PO1009
Is Obesity a Poor Prognostic Factor in Incident Peritoneal Dialysis Patients? 
Hyunjeong Cho,1 Hyo Jin Kim,1 Miseon Park,2 Dong Ki Kim,1 Kwon Wook 
Joo,1 Yon Su Kim,1 Curie Ahn,1 Kook-Hwan Oh.1  1Internal Medicine, Seoul 
National Univ College of Medicine, Seoul, Korea; 2Clinical Research Inst, Seoul 
National Univ Hospital, Seoul, Korea.
Background: Obesity is associated with an increased risk of death in the general 
population. Previous studies have demonstrated a discrepancy in the impact of body mass 
index (BMI) on mortality among peritoneal dialysis (PD) patients. We examined the effect of 
BMI on patient and technique survival in a prospective, incident PD cohort at a single center.
Methods: Subjects who started PD between 2000 and 2012 were enrolled in the study. 
Demographic and laboratory data were prospectively collected. Patients were categorized 
into four BMI groups: obese, ³25 kg/m2; overweight, 23 –24.9 kg/m2; normal, 18.5 –22.9 
kg/m2 (reference category); and underweight, <18.5 kg/m2. Patient and technique survival 
were compared using Cox proportional hazards model.
Results: A total of 632 incident PD patients were included in final analysis. The median 
follow-up period was 40 months (interquartile range, 19–64 months). In Kaplan–Meier 
survival curve, patient survival was not statistically different among all BMI categories (p = 
0.641, by log-rank test). The hazard ratio (HR) adjusted for age, sex, diabetes, comorbidities, 
albumin, hemoglobin for patient survival was not significant among BMI groups (p = 
0.837). In contrast, technique survival was significantly poorer in obese patients than in 
patients having a normal BMI (p = 0.029, by log-rank test). The HR for technique failure 
was significantly greater for obese PD patients in comparison with the reference category 
[1.8; 95% confidence interval (CI): 1.2 to 2.8; p = 0.008]. The reasons for technique failure 
included recurrent peritonitis (34%), inadequate dialysis (17%), mechanical problem (17%) 
and refractory exit-site/tunnel infection (11%) in obese patients.
Conclusions: In our PD patients, patient survival was similar in all BMI categories. 
Therefore, obese patients should not be discouraged from receiving PD purely on the basis 
of BMI. However, technique survival was significantly poorer for obese PD patients. Further 
study is warranted to improve technique survival in obese patients.
TH-PO1010
Phosphate Clearance in Peritoneal Dialysis: Residual Renal Function 
and Dialysis Modality  Carmen Gonzalez corvillo, Mariangeles Rodriguez 
Perez, Alejandro A. Suarez benjumea, Nuria Areste, Mercedes Salgueira lazo. 
Nephrology, Virgen Macarena-Rocio, Sevilla, Spain.
Background: Evaluate urinary and peritoneal excretion of phosphate and related 
factors in peritoneal dialysis(PD).Analyze phosphate clearance depending on PD modality 
and peritoneal membrane type.
Methods:  Observat ional  s tudy, in a  sample of  37PD pat ients .Mean 
age:60±14years.24 patients on APD(16CCPD,8NIPD)13 on CAPD.Mean Kt/
V:2.64±0.6.Mean residual renal function(RRF)6.3±4.4ml/min.Transmembranous peritoneal 
transport:6high(H),26high-average(HA)and 5low-average(LA).Renal and peritoneal 
phosphate clearance(ultrafiltration(UF)and diffusion(D))was analyzed.Urinary and dialysate 
P/Cr.Weekly peritoneal P clearance(WPCl).Serum P.PTH.Use and dosage of phosphate 
binders and vitaminD analogs.
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Results: Mean total P clearance:460±192mg/d.Mean renal P clearance:286±201mg/d 
and mean peritoneal P clearance:211±88mg/d.Mean P clearance through UF:22±15mg/d(9%)
and by D 194±85mg/24h(91%).Mean urinary and dialysate P/Cr were0.4±0.15 and 
0.59±0.24.Mean WPCl:31.4±13.1L/week.Mean serum P:4.9±1mg/dl and PTH294±166pg/
ml.86%of patients were on Sevelamer and 22%calcium based binders.43%were on vita
minD(55%calcitriol,45%paricalcitol).Positive correlation between peritoneal P clearance 
and UF(r=0.45 p=0.004)as well as between RRF and renal P elimination(r=0.83 p<0.001)
was observed.WPCl was higher in patients on CAPD than on APD(39,4±7 vs 27.1±13l/
week p<0.05)being the main difference patients subjected to continuous vs discontinuous 
modality(CAPD39.4±7 vs CCPD 31.4±12 vs NIPD 18.4±12 l/weekp<0.001).Regarding 
to the membrane,WPCl was higher in H patients vs. HA and LA.(46.5±6 vs 28.7±12 vs 
27.1±12l/week p<0.05).Negative correlation was detected between WPCl and serum 
P(r=-0.51p=0.001).Positive correlation was noted between WPCl and P clearance by 
D(r=0.87p<0.001).
Conclusions: A substantial percentage of daily P elimination took place through urinary 
excretion,that is why preservation of RRF is crucial.There is a correlation between peritoneal 
clearance and increase of UF.P removal is higher on continuous modalities,CAPD shows 
better results.H patients would have better P clearance.Therefore,D would be the main 
mechanism of P peritoneal elimination,aided by long dwell time.
TH-PO1011
Proteinuria at PD Initiation May Predict Residual Renal Function Loss in 
the Automated Peritoneal Dialysis Patients Using Biocompatible Solution 
Yoshifumi Hamasaki,1 Kent Doi,2 Rei Isshiki,1 Haruki Kume,3 Masaomi 
Nangaku,1 Eisei Noiri.1  1Nephrology and Endocrinology, The Univ of Tokyo, 
Tokyo, Japan; 2Emergency and Critical Care Medicine, The Univ of Tokyo, 
Tokyo, Japan; 3Urology, The Univ of Tokyo, Tokyo, Japan.
Background: Residual renal function (RRF) has a significant impact on the prognosis 
of dialysis patients. Peritoneal dialysis (PD), especially using biocompatible PD solution 
(BPDS) with neutral-pH and reduced glucose degradation products, has advantageous to 
preserve RRF (Kidney Int., 2013). It is still unclear what factors predict RRF loss in the 
PD patients using BPDS. We investigated the relationship between clinical parameters at 
PD initiation and the change of RRF in the PD patients using BPDS.
Methods: The data from patients who started PD as their first dialysis modality from 
2001 to 2014 at The University of Tokyo Hospital were collected retrospectively. All 
patients were treated by automated PD (APD) using BPDS. To identify predictors of RRF 
decline, we analyzed data including clinical parameters measured at PD initiation. Residual 
GFR was calculated as the average of 24-hour urinary urea and creatinine clearances. The 
rates of urine volume and residual GFR decline were calculated by the least squares linear 
regression formula. The outcome of dialysis modality change was defined as switching APD 
to hemodialysis (HD) or combined therapy of PD and HD due to RRF loss.
Results: 96 patients were analyzed in this study. On multiple regression analysis, 
the decline rates of urine volume and residual GFR were significantly correlated with 
proteinuria at PD initiation. When patients were divided into two groups according to 
urinary protein level, Kaplan-Meier analysis revealed the lower proteinuria group had 
higher persistence rate of APD and lower rate of dialysis modality change (Log rank; p 
= 0.001 and 0.004, respectively). On ROC analysis, urinary protein predicted the need of 
dialysis modality change within 2 years after PD initiation with statistical significance 
(AUC [95%CI] =0.78 [0.66-0.90]).
Conclusions: Proteinuria at PD initiation may predict RRF loss and the need of dialysis 
modality change in the APD patients using BPDS.
TH-PO1012
Urgent Start versus Traditional Start Peritoneal Dialysis: Does Race 
Influence Outcomes?  Vinay Narasimha Krishna, Manish K. Saha, Leslie 
J. Jackson, Gaurav Jain, Eric L. Wallace.  Univ of Alabama at Birmingham.
Background: Although urgent start (US) peritoneal dialysis (PD) and traditional start 
(TS) PD have similar outcomes, it is not known if differences in outcomes exist based on 
race. The objective of this study was to determine if differences in PD outcomes exist when 
stratified based on race and type of PD start.
Methods: Retrospective data from an electronic database on incident PD patients 
collected between November 2012 and March 2015 was analyzed. Patients were analyzed 
by US vs TS and then stratified into 4 groups: African American (AA) TS, Non-AA TS, 
AA US and Non-AA US. Chi-square analysis was used to compare categorical variables, 
while ANOVA was used to compare means across groups. Exact mid-p was used to compare 
rates of hospitalization, peritonitis and catheter revisions. Survival curves were used to 
evaluate the probability of hospital free, peritonitis free, and technique survival. Patients 
were censored in the technique survival analysis for death or transplant.
Results: 114 patients were started on PD during the study period, 33 of which were 
US. When comparing US to TS, patients were matched for age, gender, and average 
days on study (All p values >0.05). No significant differences were observed in rates of 
peritonitis, timing of peritonitis, technique failure, catheter revision or hospitalization rates 
between TS and US groups. Sub-group analysis based on race stratification showed that 
age at PD start was younger in AA TS vs Non AA TS (50±13 vs 60±14 years respectively, 
p=0.003). AA TS patients were 60% more likely to have technique failure than Non-AA 
US (p=0.03). Non-AA US patients were more likely to be free of hospitalizations than AA 
TS (p 0.03). Peritonitis rates for AA TS, Non-AA TS, AA US, and non-AA US were 0.3, 
0.14, 0.33, 0.36 per patient year respectively; catheter revision rates were 0.49, 0.3, 0.42 
and 0.3 per patient year respectively with no significant difference among the subgroups.
Conclusions: There were no significant differences in outcomes among TS and US 
groups. Sub-group analysis showed that non-AA US patients have the least technique 
failure and hospitalization rates while AA TS have the worst technique failure and 
hospitalization rates.
TH-PO1013
Reasons for Dialysis Modality Changes in an Integrated Healthcare System 
Leonid Pravoverov, Sijie Zheng, Joanna Mroz.  The Permanente Medical 
Group, Oakland, CA.
Background: In-center HD and PD are the 2 most common types of dialysis utilized in 
US. Few studies have examined characteristics of patients who changed dialysis modality. 
Kaiser Permanente Northern California is an integrated health care delivery system with 
3.7 million members. We retrospectively examined the characteristics and disease burden 
of patients who switched from modalities.
Methods: Retrospective examination of EMR from Jan 2009 – Oct 2014. Disease 
burden was assessed by internally developed comorbidity point score, which predicts 
negative outcomes in the next 12 months, based on documented comorbidities and 
hospitalizations.
Results: From 2010-2014, dialysis population in our integrated health system increased 
from 4005 to 4491 patients, and PD population grow from 621 to 1033. In this period, 
11% of patients who initiated dialysis switched modality. Majority of modality changes 
occurred within a year after dialysis initiation. 8% of HD patients switched to PD and 24% 
of PD patients switched to HD. Majority of patients who switched from HD to PD do so 
within 6 months of initiation. They have less comorbidities than those who stay on HD. 
They have a higher comorbidity score when they switch to PD but lower than repeated 
score of those who switched from PD to HD. They were younger than those remained on 
HD. Most patients who switched from PD to HD did so within a year. They have more 
comorbidities than those who stay on PD and have a higher comorbidity score when they 
switch to HD, even higher than the repeat score of those who switch from HD to PD. The 
difference in co-morbidity scores between the first and second measurement is higher for 
the PD to HD pattern. They have similar age to those who didn’t switch.
Conclusions: Patients who switched from HD to PD remain at approximately the same 
comorbidity score before and after switch. Comorbidity scores of patients who switched 
from PD to HD significantly increased, suggesting that change was influenced by decline 
in their overall condition. In our patient population, the switch from HD to PD is likely a 
patient’s decision, while the switch from PD to HD may be due to inability to continue PD.
TH-PO1014
Impact of Pre-Dialysis Immunosuppressive Treatment Time on Infectious 
Complications and Survival of Systemic Lupus Erythematosus (SLE) 
Patients on Peritoneal Dialysis  Junbao Shi,1,2 Joanne M. Bargman.2  1Dept of 
Nephrology, Peking Univ Third Hospital, Beijing, China; 2Div of Nephrology, 
Univ Health Network, Toronto General Hospital, Toronto, ON, Canada.
Background: SLE patients on peritoneal dialysis (PD) have a significant risk of 
infectious complications and poor outcomes.However, few studies have examined the 
relationship between pre-dialysis exposure to immunosuppressive (IS)therapy and the 
outcome on dialysis. The objective of this study was to investigate whether pre-dialysis IS 
treatment time influences the infectious complications and outcomes of SLE patients on PD.
Methods: Twenty-six SLE patients were treated with PD in a major academic centre 
from May 1996 to May 2014. Demographics, diagnostic tests and IS treatment, comorbid 
illnesses, biochemistry and clinical data upon initiation of PD and lupus activity, infective 
complications, hospitalizations and clinical outcomes during the study period were 
collected. Three years was chosen as the discriminant between longer and shorter duration 
of IS therapy.
Results: Two patients were lost to follow-up during the study period. Therefore, a 
total 24 patients were included for analysis.The SLE patients with longer duration of pre-
dialysis IS (n=17) were older than patients with shorter pre-dialysis IS(n=7)(38.6±11.0 vs 
27.1±7.8, P<0.05), but there were no significant differences in sex, race, PD duration, PD 
sub-modality and biochemistry between the two groups(P>0.05).Seven patients died during 
the follow-up period and all the deaths were from the group with longerpre-dialysis IS time 
(P<0.05). Three patients died from infections, two patients from cardiovascular disease, 
and two had sudden death at home. However, there were no significant differences in the 
incidence of peritonitis, exit site infection, other infections, or hospitalizations.
Conclusions: SLE patients undergoing PD with longer pre-dialysis exposure to IS 
drugs have a greater mortality that appears to be related to both infectious and noninfectious 
causes. Although incident to PD, they should be considered a high-risk subgroup.
TH-PO1015
Predicting Peritoneal Dialysis Prescriptions with a Fast Peritoneal 
Equilibration Test Using PD Adequest  J. Ken Leypoldt,1 Baris U. Agar,2 
James A. Sloand,1 Mary Gellens.1  1Medical Products (Renal), Baxter Healthcare 
Corporation, Deerfield, IL; 2Medical Products (R&D), Baxter Healthcare 
Corporation, Round Lake, IL.
Background: The fast peritoneal equilibration test (PET) is often used to determine 
peritoneal membrane transport status, but its accuracy in predicting parameters of peritoneal 
dialysis (PD) therapy adequacy using computer software, like PD Adequest, has not 
been quantified. In the current study, the ability of a new version of PD Adequest was 
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examined to 1) compare mass transfer-area coefficients (MTACs) for urea, creatinine and 
glucose during fast and standard PETs and 2) use those parameters to predict PD therapy 
prescription adequacy.
Methods: Data from 104 PD (41 CAPD, 63 APD) patients who underwent a 4-hour 
standard PET and an overnight exchange with the same glucose concentration were used to 
determine fluid and solute transport parameters. Calculated MTAC values for standard PET 
were compared with those for fast PET by using only data obtained at 4-hours during the 
standard PET and assuming a 200 mL residual volume in the prior exchange. The calculated 
membrane parameters were used to predict net ultrafiltration (UF), urea Kt/V and creatinine 
clearance (CrCl), and those predictions of therapy adequacy were also compared with the 
mean of 3 actual measurements of net UF, Kt/V and CrCl for each patient.
Results: Median urea, creatinine and glucose MTACs were 20.9, 10.1, and 9.1 mL/min 
during standard PET, and 21.0, 10.1 and 9.0 mL/min during fast PET; the corresponding 
median absolute difference between MTACs for urea, creatinine and glucose were 0.6, 
0.3 and 0.6 mL/min. Comparing predictions using standard and fast PETs, 81% of net 
UF were within 150 mL, 94% of Kt/V were within 0.1/wk and 93% of CrCl were within 
2 L/wk/1.73m2. The percent of predicted and actual measured values of net UF within 
300 mL, Kt/V within 0.2/wk and CrCl within 8 L/wk/1.73m2 were 44%, 63% and 77% 
for standard PET and 38%, 64% and 77% using fast PET; these differences were not 
statistically significant.
Conclusions: These results suggest that the predictions of PD therapy adequacy using 
PD Adequest are clinically equivalent when either fast or standard PET is employed.
Funding: Pharmaceutical Company Support - Baxter Healthcare Corporation
TH-PO1016
The Loss of Residual Diuresis Increases in Eryptosis in PD Patients 
Grazia Maria Virzì, Carla Estremadoyro, Sabrina Milan manani, Alessandra 
Brocca, Massimo de Cal, Ilaria Tantillo, Carlo Crepaldi, Claudio Ronco. 
Nephrology-IRRIV.
Background: Anemia in ESRD is attributed to impaired erythrocyte formation due to 
erythropoietin and iron deficiency. The accelerated clearance of erythrocytes may at least 
partially be due to enhanced eryptosis, a suicidal death of erythrocytes characterized by 
cell shrinkage and cell membrane scrambling with phosphatidylserine(PS)-externalization 
at the erythrocyte (RBC) surface. Exposed PS is recognized by macrophages that engulf 
and degrade the affected cells.Little is known about mechanisms underlying enhanced 
eryptosis in ESRD. At least in theory, eryptosis may be stimulated by some uremic toxins. 
The present study investigated eryptosis in peritoneal dialysis (PD) patients.
Methods: 46 PD patients (31 M, mean age:64±14yrs) and 17healthy subjects (CTR) 
were enrolled. All measurements were made in isoalted RBCs. PS exposure was estimated 
from FITC-AnnexinV binding by flow cytometric.
Results: 27 patients were treated with CAPD and 19 with APD. The mean length of 
treatment was 39±29months. The PS externalization on surface was significantly higher in 
PD patients than in CTR (2.6%; IQR 1.6-3.7 versus 0.8%; IQR 0.7-1.3 p<0.01). The median 
percentage of eryptosis showed no significant differences between patients with(n=18) and 
without diabetes, treated with CAPD or APD and with a negative or positive (n=18) history 
of peritonitis. Eryptosis showed significantly lower levels in PD patients with residual 
diuresis (n=23) than in patients without (3.7%, 2.6-5.6 versus 5%, 3.1-16; p=0.03). A 
significant negative correlation was observed between percentage of eryptosis and Body 
Composition Monitor-BCM for hydratation status (Spearman’s rho=- 0.4, p<0.05). There 
was no a statistically significant relationship between eryptosis and months of PD, urea, 
albumin and creatinine levels.
Conclusions: In conclusion, eryptosis has been shown to be significantly higher in 
PD patients than CTR. Our data suggest that the type and the lengthof PD treatment do 
not enhance eryptosis. On the contrary, the loss of residual diuresis lead to a significant 
increase in eryptosis:the residual diuresis may contribute to the elimination of potential 
uremic toxins that induce increased eryptosis.
Funding: Private Foundation Support
TH-PO1017
The Pattern of T Helper Lymphocytes Has No Clinical Implications in 
Peritoneal Dialysis Patients  Gyu Tae Shin, Seirhan Kim, Inwhee Park, 
Heungsoo Kim.  Dept of Nephrology, Ajou Univ School of Medicine, Suwon, 
Kyunggi, Korea.
Background: It has been reported that the imbalance between type-1 T helper 
lymphocytes (Th1) and type-2 T helper lymphocytes (Th2) exist in uremic patients. Th1 
dominance leads to increased cardiovascular risks and Th2 dominance to allergic diathesis 
and pruritus. In this study, we investigated the pattern of Th lymphocyte differentiation in 
peritoneal dialysis (PD) patients.
Methods: Peripheral blood mononuclear cells were isolated from venous blood using 
Ficoll gradient methods. Isolated lymphocytes were stimulated with ionomycin and phorbol 
myristic acetate in the presence of brefeldin A, and then stained with CD3-, CD8 surface 
markers, interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) for flow cytometry 
analysis. CD3-positive/CD8-negative cells were assumed as CD4-positive Th lymphocytes.
Results: We recruited 23 PD patients and 10 healthy controls. Th lymphocytes 
accounted for 68.9% of total T lymphocytes in PD patients and 72.9% in controls 
(p=non-significant). IFN-gamma positive T lymphocytes (Th1) accounted for 15.8% of 
Th lymphocytes in PD patients and 15.3% in controls (p=non-significant). IL-4 positive 
T ymphocytes (Th2) accounted for 2.6% in PD patients and 2.8% in controls (p= non-
significant). The percentage of Th1 or Th2 lymphocytes did not correlate with any of the 
demographic and laboratory findings including diabetes, PD vintage, PD regimens, Kt/V, 
left ventricular ejection fractions, serum chemistries and hematologic values. The patients 
who suffered from cardiovascular diseases (n=6) showed a similar percentage of Th1 
and Th2 lymphocytes compared with those who did not (n=17). The patients who had 
significant pruritus requiring medications (n=11) showed a similar percentage of Th1 and 
Th2 lymphocytes compared with those who did not (n=12).
Conclusions: The pattern of Th lymphocyte differentiation was similar between PD 
patients and healthy people, and it did not have an association with clinical findings in 
PD patients.
TH-PO1018
Hemostatic Profile of Patients on Automated Peritoneal Dialysis by 
Thromboelastography  Thalita Moura Braga, Erica Adelina Guimarães, 
Rodrigo Souza Adao, Rosilene M. Elias, Hugo Abensur.  Nephrology, Univ de 
São Paulo, São Paulo, Brazil.
Background: It’s believed that hypoalbuminemia induces hemostatic disorders in 
peritoneal dialysis (PD) patients. Beside to this the lipid profile may also contributes 
to atherogenicity. Thromboelastography (TEG®) is a skilled and snapshot method that 
provides a global hemostasis evaluation. We objective to investigate whether TEG profile 
of patients in automated PD (APD) reflects the coagulation factors abnormalities and it 
is influenced by peritoneal transport of small solutes, macromolecules, and lipid profile.
Methods: A cross-sectional study included 15 patients (5 men) with age 43±18 years 
on APD for 26±15 months. Serum, effluent peritoneal fluid, and urinary values of: urea, 
creatinine, albumin, and total protein were obtained. Kt/V, ultrafiltration (UF), complete 
lipid profile, serum coagulation factors, and TEG were also performed.
Results: The TEG revealed that 7 patients were hypercoagulant according to 
coagulation indices (IC) (2.9±0.6, normal range-NR:-3 to 3) and 14 patients presented high 
maximum amplitude (MA) (68.1±4.2 mm, NR:27 to 49 mm), that reflects fibrin strength 
and platelet aggregation. Hypercoagulant patients presented UF less than normal patients 
(926±499 vs. 1896±750 ml, p=0.01). Accordingly, MA and IC correlated negatively with 
UF (r=-0.545, p=0.04 and r=-0.725, p=0.002, respectively). Factor IX (high in 8 patients) 
correlated with non-HDL (r=0.639, p=0.02), LDL (r=0.612, p=0.03), and negatively with 
HDL cholesterol (r=-0.771, p=0.002). D-Dimer (high in 11 patients) correlated with serum 
urea (r=0.569, p=0.03) and clot elasticity (G) (r=0.589, p=0.03). Unexpectedly, both 
fibrinogen (high in 12 patients) and D-dimer did not correlate with protein loss. There 
were no patients with severe hypoalbuminemia in this sample.
Conclusions: The TEG demonstrates an unfavorable hemostatic profile in PD patients 
characterized by mainly major platelet aggregation, which corresponds to abnormal 
dosages of clotting factors and degradation products. This panorama did not depend on 
protein loss and serum albumin. Lipid metabolism alterations, uremia, and low UF can be 
implicated in this finding.
TH-PO1019
Dialysate Looses of Vitamin 25(OH)D in a Cohort of Patients Treated with 
Peritoneal Dialysis  Juan Carlos Ramirez-Sandoval, Maria Luisa Safar-Boueri, 
Jorge Jesus Silva, Olynka Vega-Vega, Ricardo Correa-Rotter, Reynerio Fagundo. 
National Medical Sciences and Nutrition Inst Salvador Zubiran, Mexico City, 
Mexico.
Background: Peritoneal dialysis (PD) is associated with 25(OH)vitamin D deficiency. 
To our knowledge, there are no cohort studies about 25(OH)vitamin D dialysate looses 
in PD.Objective: To characterize 25(OH) vitamin D losses in peritoneal effluent (PE) and 
their relation with changes in serum 25(OH)vitamin D levels during 4 months in a cohort 
of incident PD patients.
Methods: 52 patients with <6 mths but >1 mth on PD were invited from 2011 to 
2014. Those with severe infections, hospitalizations, and oral intake of D3 or D2 during 
follow up were excluded. Basal vitamin 25(OH) D in 24h PE and serum were measured. 
After 4 months, a 2nd assessment was performed. The principal outcome was the change 
in serum vitamin 25(OH) D levels.
Results: 43 patients were included, 22 (51%) men, median age was 39 y (Intercuartile 
range [IQR] 31-62), 29 (68%) had diabetes and 29 (67%) had some degree of renal residual 
function during all study. After 4 months of PD initiation, all patients had vitamin 25(OH)
D levels <20 ng/mL, 13 of them with levels less than 10 ng/mL.
Characteristics, (n=43)
*n(%) or median (IQR) Initial After 4 months p
Serum 25(OH)D, ng/mL 14.2 (10.3-20.2) 8.6 (8-9.3 ng/mL) <0.001
Peritoneal effluent 
25(OH)D, ng/mL losses, 
mcg/day
13 (9.2-17) 
*All detectable at this 
timepoint
10 (6-11) 
*Not detectable in 35/43 <0.001
PTH, pg/mL 521 (343-845) 590(288-791) 0.6
Ca, mg/dL 9.2 (8.5-9.6) 9.14(8.5-9.5) 0.6
P, mg/dL 4.9 (3.6-6.1) 5.4 (3.8-6.1) 0.3
The mean decrease of vitamin 25(OH)D levels was 5.8 ng/mL/6 months (IQR 2-9.3 
ng/mL). Basal PE losses in mcg/day and delta in serum vitamin 25(OH) D had a significant 
correlation 
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Conclusions: High effluent losses of vitamin 25(OH) D are observed in patients on PD 
and may explain very low levels observed during follow up in this cohort.
Funding: Government Support - Non-U.S.
TH-PO1020
Peritoneal Protein Excretion Was Lower in Nocturnal Intermittent 
Peritoneal Dialysis as Compared with Continuous Ambulatory Peritoneal 
Dialysis Not Associated With Peritoneal Transport Status in the Same 
Individual  Hironori Nakamura, Anayama Mariko, Yasushi Makino, Masaki 
Nagasawa.  Dept of Nephrology, Shinonoi General Hospital, Nagano, Japan.
Background: Recent studies have reported that peritoneal protein excretion (PPE) 
during peritoneal dialysis (PD) therapy is associated with cardiac disease and patient 
survival. However, little is known regarding the extent to which PPE can be influenced by 
PD prescription or peritoneal transport status.
Methods: The aims of this study were to compare PPE in the same individual with 
different PD prescriptions of either continuous ambulatory PD (CAPD) or nocturnal 
intermittent PD (NIPD), and to evaluate the correlation between PPE and dialysate to plasma 
creatinine ratio (D/P Cr). Seventeen patients, of whom 58.8% were male, were included 
in the study. A peritoneal equilibrium test was performed and the amount of total protein 
(TP) loss in the dialysate was measured during CAPD or NIPD therapy in the same patient.
Results: The mean age of the patients was 59.4 ± 18.0 years, body mass index was 
21.5 ± 3.4, serum TP (s-TP) was 5.8 ± 0.8 g/dL, serum albumin (s-Alb) was 3.0 ± 0.7 g/
dL, C-reactive protein (CRP) was 0.4 ± 0.7 mg/dL, and D/P Cr was 0.76 ± 0.15. During 
NIPD therapy, PPE was correlated with peritoneal clearance (γ = 0.63, p = 0.006), effluent 
volume (γ = 0.69, p = 0.002), and PPE to effluent volume ratio (γ = 0.80, p = 0.000), but 
not with s-TP, s-Alb, CRP, or D/P Cr. During CAPD therapy, PPE was negatively correlated 
with s-TP (γ = -0.62, p = 0.007) and s-Alb (γ = -0.58, p = 0.014), positively correlated 
with effluent volume (γ = 0.50, p = 0.037) and PPE to effluent volume ratio (γ = 0.72, p = 
0.001), but not with CRP or D/PCr. On comparing NIPD and CAPD, there was no difference 
in effluent volume (7341 mg vs. 7209 mg, respectively); however, both PPE and PPE to 
effluent volume ratio were significantly lower during NIPD than during CAPD [5586 
mg vs. 7779 mg (p = 0.004) and 0.74 mg/mL vs. 1.09 mg/mL (p = 0.004), respectively].
Conclusions: The current study demonstrated that PPE and PPE to effluent volume 
ratio were lower during NIPD than during CAPD in the same individual, independent of 
the peritoneal transport status.
TH-PO1021
Fungal Peritonitis in the Standardizing Care to Improve Outcomes in 
Pediatric ESRD (SCOPE) Collaborative  Raj P. Munshi,1 Christine B. 
Sethna,3 Sushil Gupta,2 Samhar I. Al-Akash,5 John P. Lawlor,6 Bradley Warady.4 
1Seattle Children¶s; 2Kosair Children¶s Hospital; 3North Shore-LIJ Medical 
Group; 4Childrens Mercey Hospital; 5Driscoll Childrens Hospital; 6Children¶s 
Hospital Association.
Background: The SCOPE Collaborative is a multicenter QI initiative with the 1° aim 
to reduce dialysis catheter associated infections. The objective of this study was to describe 
the epidemiology of fungal peritonitis (FP) among pediatric patients with an indwelling 
peritoneal dialysis (PD) catheter enrolled in SCOPE.
Methods: PD characteristics and patient outcome were collected between 10/11-12/14 
from 29 centers participating in SCOPE. Data was stratified based on fungal, bacterial/
culture-neg peritonitis and no peritonitis. Peritonitis was defined as any episode that was 
treated for peritonitis. Differences among groups were assessed by chi-square analysis.
Results: Of 880 patients, there were 416 peritonitis episodes of which 37(8.9%) were 
fungal. 36 individual (median age 28.3 months; 56% male) were responsible for the FP 
episodes, with 22(59.4%) episodes occurring in patients <2 years of age. 21(56.8%) episodes 
were preceded by a documented peritonitis episode, with 12(32.4%) of the peritonitis 
episodes diagnosed within 90 days of the fungal infection. Culture neg (28.6%) and Staph 
species (23.8%) were the predominant causes of the prior peritoneal infections. Presence 
of a G-tube (48.3%, p=0.003), vesicostomy (10.3%, p=0.036), upward orientation of 
the PD catheter exit site (13.3%, p=0.031), and history of touch contamination (10.3%, 
p=0.027) were more common in children with FP as compared to the other groups. FP 
resulted in 1(2.9%) death, 33(89.2%) catheter removals, and 29(78.4%) hospitalizations. 
1 child (2.9%) had successful treatment of a fungal peritonitis episode while leaving the 
PD catheter in place.
Conclusions: FP were responsible for 8.9% of peritonitis episodes with the majority 
of the episodes occurring in children <2 years of age. Additional risk factors included 
presence of a G-tube, vesicostomy, upward orientation of the exit site and history of touch 
contamination. The majority of the PD catheters were removed, with a preponderance of 
patients requiring hospitalization.
TH-PO1022
Relation of Central and Brachial Blood Pressure to Volume Status in 
Peritoneal Dialysis Patients  Yun Jung Oh,1 Su mi Lee,2 Ji Yong Jung,3 So 
Mi Kim,4 Chungsik Lee.1  1Dept of Internal Medicine, Cheju Halla General 
Hospital, Jeju, Republic of Korea; 2Dept of Internal Medicine, Dong-A Univ 
Hospital, Busan, Republic of Korea; 3Dept of Internal Medicine, Gacheon Univ 
Gil Hospital, Incheon, Republic of Korea; 4Dept of Internal Medicine, Jeju 
Natitonal Univ Hospital, Jeju, Republic of Korea.
Background: Euvolemia is an important predictor of outcome in peritoneal dialysis 
(PD), but chronic subclinical volume overload occurs frequently in PD patients. Even 
though volume overload is associated directly with hypertension, blood pressure (BP) 
not always reflect volume overload. Central BP has been shown to be a better predictor 
for target organ damages compared with brachial BP in general population. In this study, 
we evaluated comparative values of central BP and brachial BP for determining volume 
status in PD patients.
Methods: We enrolled 52 prevalent PD patients, and accessed volume status using 
Body Composition Monitor (BCM). Central BP was estimated using radial artery tonometry, 
and brachial BP measurement at office and 24-hour ambulatory blood pressure monitoring 
(ABPM) were performed. Volume overload was defined as an overhydration (OH) ³1.1 L.
Results: Average office central systolic BP (cSBP), office brachial systolic BP 
(bSBP), and ambulatory brachial systolic BP (24-bSBP) were 139.8±26.3, 140.7±19.2, and 
142.5±22.0 mmHg, respectively. In overall, 41(78.8%) patients were in volume overload 
status. A stronger association of central BP with volume overload compared with brachial 
BP was observed in the receiver operating curve analysis (area under the curve (AUC) 
of cSBP, bSBP, and 24-bSBP were 0.87±0.06, 0.78±0.09, and 0.83±0.06 respectively). 
In multivariate analysis adjusted for age, sex, PD vintage, diabetes, and cardiovascular 
disease, the odds ratio (OR) for central BP (OR 1.110; 95% CI 1.019-1.210) was higher 
than those for brachial BP (OR 1.085; 95 CI 1.014-1.161 for bSBP and OR 1.094; 95% 
CI 1.021-1.173 for 24-bSBP).
Conclusions: Office central BP was more strongly related to volume status than out-
of-office ambulatory brachial BP as well as office brachial BP, suggesting that central BP 
was more valuable than brachial BP in assessing volume status in PD patients.
TH-PO1023
Novel Regimen for Intraperitoneal Cefazolin and Ceftazidime in Peritoneal 
Dialysis Patients  Sadudee Peerapornratana,1 Pisut Katavetin,1 Pajaree 
Chariyavilaskul,2 Talerngsak Kanjanabuch,1 Kearkiat Praditpornsilpa,1 Somchai 
Eiam-ong.1  1Div of Nephrology, Dept of Medicine, Faculty of Medicine, 
Chulalongkorn Univ, Bangkok, Thailand; 2Dept of Pharmacology, Faculty of 
Medicine, Chulalongkorn Univ, Bangkok, Thailand.
Background: Current guideline suggested that intraperitoneal (IP) antibiotics should be 
administered only in a long peritoneal dialysis (PD) dwell (≥6 hours), which is not always 
practical because the long dwell might result in low ultrafiltration and volume overload. The 
objectives of this study were to develop a novel regimen for IP antibiotics in short dwell 
(£2 hours) during the automated PD cycling and examine the dialysate and plasma level 
of the most used empirical antibiotics for PD-related peritonitis, cefazolin and ceftazidime.
Methods: In the novel regimen, cefazolin and ceftazidime (20 mg/kg each) were 
added in a 5-liter bag of 2.5% dextrose PD fluid which was placed on the warmer of the 
PD cycling machine. Another 5-liter bag of PD fluid was connected to the machine, off the 
warmer. Patients underwent 5 exchanges of 2-liter PD fluid over 10 hours by the PD cycling 
machine without last fill or additional dwell. Cefazolin and ceftazidime concentrations 
in plasma and dialysate were determined by high performance liquid chromatography.
Results: Six PD patients without peritonitis were participated in the study. Dialysate 
cefazolin and ceftazidime were consistently high throughout the PD session in all patients 
(26-360 mg/L). Plasma cefazolin and ceftazidime exceeded the minimal inhibitory 
concentration (MIC) for susceptible organisms (8 mg/L) within 2 hours (cefazolin 28.5±8.0 
and ceftazidime 12.5±3.4 mg/L at 2 hours), peak at 10 hours (51.1±14.1 and 23.0±5.2 
mg/L) and then sustained well above the MIC at 24 hours (42.0±9.6 and 17.1±3.1 mg/L).
Conclusions: The novel regimen for IP cefazolin and ceftazidime in short dwell (£2 
hours) during the automated PD cycling could provide adequate dialysate and plasma 
concentration and would become a standard regimen for peritonitis in PD patients already 
using PD cycling machine as well as those who temporarily need shorter dwells during 
peritonitis due to increasing peritoneal solute transport.
Funding: Government Support - Non-U.S.
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TH-PO1024
Is Automated Peritoneal Dialysis Better Than Continuous Ambulatory 
Peritoneal Dialysis in Quality of Life, Depression, and Renal Treatment 
Satisfaction? A Prospective Multicenter Propensity-Matched Study 
Sun-Hee Park,1 Hee-Yeon Jung,1 Sukyung Lee,1 Ji-Young Choi,1 Se-Hee 
Yoon,2 Jang-Hee Cho,1 Chan-Duck Kim,1 Yong-Lim Kim.1  1Internal Medicine, 
Kyungpook National Univ School of Medicine, Daegu, Republic of Korea; 
2Internal Medicine, Konyang Univ, Daejeon, Republic of Korea.
Background: Health-related quality of life (HRQOL) is an important variable in 
the selection of dialysis modality among incident dialysis patients. However, relative 
superiority in HRQOL between automated peritoneal dialysis (APD) and continuous 
ambulatory peritoneal dialysis (CAPD) are not clearly known. The objective of this study 
was to compare HRQOL, depression, and renal treatment satisfaction over time between 
APD and CAPD patients.
Methods: Incident patients initiating APD and CAPD were prospectively enrolled from 
nationwide multicenters in Korea. HRQOL, depression, and renal treatment satisfaction 
were assessed at 1 and 12 months after the start of dialysis by Kidney Disease Quality of 
Life Short Form 36 (KDQOL-36), Beck’s Depression Inventory (BDI), and Renal Treatment 
Satisfaction Questionnaire (RTSQ), respectively. The mean changes of scores in APD and 
CAPD were compared by propensity score matching analysis.
Results: All 260 incident patients starting peritoneal dialysis (PD) from 11 centers 
were included in this study. A total of 170 patients were matched from 208 patients who 
completed all questionnaires and did not change PD modality during the 1-year follow-up 
period. The total scores at 1 month showed better HRQOL for APD than CAPD patients 
in symptom, patient satisfaction, pain, and social function domains. No differences were 
observed between the two groups in total scores of KDQOL-36 at 12 months. However, 
CAPD patients had a significantly greater improvement in symptom and health status 
domains. A significant improvement also occurred in BDI and RTSQ in CAPD patients.
Conclusions: APD is not better than CAPD in HRQOL, depression, and renal 
treatment satisfaction during initial first one year on dialysis. The relative positive effect of 
CAPD compared with APD on improvement of HRQOL, depression, and renal treatment 
satisfaction was confirmed.
TH-PO1025
Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis 
Cohort  Connie Rhee,1 Vanessa A. Ravel,1 Elani Streja,1 Rajnish Mehrotra,2 
Steven B. Kim,1 Jiaxi Wang,1 Danh V. Nguyen,1 Steven M. Brunelli,3 Csaba P. 
Kovesdy,4 Gregory Brent,5 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2UW; 3DaVita 
Clin Research; 4UTHSC; 5UCLA.
Background: Peritoneal dialysis (PD) patients have a high prevalence of thyroid 
dysfunction which may be due to 1) peritoneal effluent losses (vast majority of thyroid 
hormone is protein-bound) and 2) frequent exposure to povidone-iodine cleaning agents 
leading to iodine-induced hypo- and hyperthyroidism. In the general population thyroid 
dysfunction is associated with higher risk of cardiovascular (CV) disease and death. There 
has not been study of the association between hypo- or hyperthyroidism defined by TSH 
with mortality in PD patients.
Methods: We examined the association of thyroid functional status with all-cause 
mortality in a 5-year national cohort (1/2007-12/2011) of PD patients with at least one 
TSH measure. Thyroid functional status was defined as: hyper-, eu-, and hypothyroidism 
(TSH <0.5, 0.5-5, >5mIU/L). We examined time-dependent and baseline thyroid function 
to determine short- and long-term exposure–mortality associations, respectively, using Cox 
models with 3 adjustment levels: unadjusted, case-mix, and case-mix+laboratory adjusted.
Results: Among 1484 patients, 7% and 18% had hypo- and hyperthyroidism, 
respectively. In time-dependent analyses, hypo- and hyperthyroidism were each associated 
with higher mortality risk in all 3 Cox models (ref: euthyroidism). In baseline analyses, 
hypothyroidism was associated with higher death risk in unadjusted and case-mix models, 
but associations were attenuated to the null in case-mix+laboratory models.
Conclusions: Time-dependent hypo- and hyperthyroidism were each associated with 
higher mortality, suggesting short-term risk in PD patients. Further studies are needed to 
determine if CV pathways are implicated, and if thyroid-modulating therapies ameliorate 
mortality in this population.
Funding: NIDDK Support, Private Foundation Support
TH-PO1026
A Tale of APOL1 Mutation and Parvovirus Infection  Sherry Mansour,1 
Whitney E. Besse,1 Karan Jatwani,2 Ursula C. Brewster.1  1Nephrology, Yale 
School of Medicine, New Haven, CT; 2Internal Medicine, Government Medical 
College And Hospital Chandigarh, Nawanshahr, India.
Introduction: We present a case of a first trimester pregnant woman with nephrotic 
range proteinuria and fetal demise in the setting of an acute parvovirus infection. Kidney 
biopsy revealed collapsing FSGS, and exome sequencing revealed mutations in AP2L. 
The relationship between Parvovirus and FSGS is one that clinicians might overlook, 
and perhaps may play a more prominent role in these progressive cases especially with 
AP2L mutations.
Case Description: 37 yo Caribbean female presented at 8 weeks gestation with 
progressive swelling. Her daughter developed fifth’s disease one month prior. On 
presentation her BP was 146/95, HR 77 with pitting edema. Her creatinine was 6.3, BUN 43, 
albumin 1.5, and spot prt/crt 20.8. Parvovirus PCR was 2000 copies. Biopsy demonstrated 
collapsing FSGS secondary to Parvovirus B19 [Fig 1A 1B] 
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The hope was that this injury would improve with improvement in titers, so IVIG was 
started. A follow up PCR showed improvement to 200 copies but she remained nephrotic 
with proteinuria of 20-60 g. Re-biopsy revealed significant scarring and dialysis was initiated 
[Fig 1C]. Patient is now being evaluated for transplant. Given the unusual severity of this 
case, and her possible African ancestry, a genetic susceptibility to podocyte injury was 
entertained. Whole exome sequencing identified the patient to have two AP2L risk alleles.
Discussion: Parvovirus has been linked with collapsing FSGS, and in one study viral 
PCR was detected in 78% of kidney tissue with this diagnosis. The combination of B19 
infection and AP2L mutation likely made our patient particularly susceptible to injury. 
Our case raises the question of how often subclinical parvovirus infection may be involved 
in collapsing FSGS, and highlights how sudden and devastating it can be to the life of a 
prior healthy young woman.
TH-PO1027
Podocyte Myeloid Bodies without Confirmed Genetic Mutation in a Female: 
Fabry’s Disease?  Pravir V. Baxi,1 David J. Cimbaluk,2 David G. Warnock,3 
Robert J. Desnick,4 William Luke Whittier.1  1Nephrology, Rush Univ MC, 
Chicago, IL; 2Pathology, Rush Univ MC, Chicago, IL; 3Nephrology, UAB, 
Birmingham, AL; 4Genetics, Mt Sinai, New York, NY.
Introduction: Fabry’s disease (FD) is a X-linked lysosomal storage disorder caused by 
deficient alpha-galactosidase activity. A renal variant has been described with the R363H 
mutation. Due to random X-chromosomal inactivation, heterozygous females can present 
a diagnostic challenge. We report a case with a renal limited presentation, biopsy findings 
characteristic of FD but a negative whole blood DNA analysis.
Case Description: A 46 year-old Hispanic woman was evaluated for proteinuria. She 
was asymptomatic with no prior medical history or family history, and no exposure to 
silica, amiodarone, or hydroxychlorquine. Her exam was unremarkable: no neuropathy, 
skin changes, or corneal dystrophy. SCr was 0.6 mg/dL, UA 2+ protein with P/C ratio of 
1.94 g/g. Biopsy revealed diffuse enlargement of the podocytes with a foamy cytoplasm 
appearance and on EM, prominent podocyte lamellated lipid inclusions with foot process 
effacement and minimal endothelial deposits. 
Figure 1: Podocyte myeloid bodies; yellow line denotes foot process effacement, red 
star shows limited endothelial inclusions. Alpha-galactosidase activity was 0.187 U/L 
(lower limit of nl) and genomic sequencing of the GLA gene was negative. EKG, Echo, 
cardiac MRI, and brain MRI with and without gadolinium were nl.
Discussion: We present a pt with renal limited manifestations mimicking FD in the 
absence of known toxic exposure and a negative whole blood DNA mutation analysis. 
Treatment with enzyme replacement is not warranted without a positive genetic analysis. 
This case highlights the variable genotypic and phenotypic presentation, and raises the 
possibility that tissue-specific mosaicism could explain phenotypic variation in females 
with Fabry’s Disease.
TH-PO1028
Relapsing Thrombotic Microangiopathy following Persistent Intravenous 
Use of Reformulated Oxycontin  Melissa S. Nataatmadja, Dakshinamurthy 
Divi.  Dept of Nephrology, Gold Coast Univ Hospital, Southport, Queensland, 
Australia.
Introduction: Thrombotic microangiopathy (TMA), resembling thrombotic 
thrombocytopenic purpura (TTP), with normal ADAMTS13 activity has recently been 
observed in persons injecting Opana ER (oxymorphone), an oral opioid available in the 
United States. This phenomenon had not been reported outside the US, however, and the 
mechanism of inducing TMA is not yet known.
Case Description: A 29-year old female presented with hemolytic anemia and 
thrombocytopenia, with a hemoglobin of 70g/L and platelet count of 17 x 109/L. She 
was treated with therapeutic plasma exchange (TPE) for a working diagnosis of TTP and 
recovered, with no ongoing TPE requirement. She represented two weeks later, with a 
hemoglobin of 81g/L, platelets of 8 x 109/L, and additional renal impairment. She again 
commenced TPE and also prednisone. Her ADAMTS13 activity was >94%, atypical 
hemolytic-uremic syndrome (aHUS) was therefore considered, and genetic testing was 
ordered. She then admitted to a two-month history of injecting Oxycontin (oxycodone) and 
for the previous month had been using reformulated Oxycontin. TPE and prednisone were 
discontinued and she experienced physical and hematological recovery. Genetic testing for 
aHUS subsequently returned as negative.
Discussion: To our knowledge, this is one of only two documented cases of TMA 
following IV Oxycontin use, both of which were observed in Australia soon after 
reformulated Oxycontin replaced original Oxycontin. This report supports polyethylene 
oxide (PEO), a tamper-proof coating added to the reformulated Oxycontin and Opana ER, 
as the causative agent, as TMA has now been observed following the use of two different 
medications but with the same PEO coating. Additionally, our case is the first to demonstrate 
relapse of TMA following persistent intravenous drug use of either of these medications. 
Given the rarity of this illness, it is possible that an unidentified genetic or immunologic 
susceptibility causes some individuals to develop TMA in response to these drugs, whilst 
others do not. We encourage clinicians to consider IV drug use in all patients presenting 
TMA, as treatment approach may differ and the role of plasma exchange is not yet clear.
TH-PO1029
Ipilimumab Associated Kidney Injury  Andinet Gizaw, Jason M. Kidd. 
Nephrology, VCUHS, Richmond, VA.
Introduction: Melanoma is the most fatal form of skin cancer. Patients without 
surgically resectable disease require chemotherapy. Ipilimumab; a human monoclonal 
antibody against anti-CTLA-4 is an Immunomodulation agent, with proven benefit in overall 
survival in patients with unresectable, advanced (Stage 3,4) Melanoma. Cytotoxic T Cell 
Lymphocyte Antigen-4 (CTLA-4) is a negative regulator of T –Cell mediated anti-tumor 
immune response working as immune check points (down regulation). We present a case of 
acute kidney injury due to interstitial nephritis and minimal change disease from this drug.
Case Description: A 55 year old man with metastatic melanoma with right atrial 
mass, status post resection, was seen for evaluation of acute kidney injury and nephrotic 
range proteinuria. He developed lower extremity swelling with rash about 02 weeks after 
receiving a third dose of ipilimumab. He had a baseline serum creatinine of 1.2mg/dl. At 
the time of consultation, his serum creatinine was 2.97mg/dl, 9 grams of proteinuria on 24 
hours collection and serum albumin of 2.2. He was initially fluid resuscitated, however, 
creatinine increased to 5.2 mg/dl and he became oliguric. Urine microscopy was without 
casts and serology markers were negative. Renal biopsy was performed that showed an 
interstitium with eosinophil rich inflammatory cell infiltration and severe edema. Almost 
half of glomeruli were globally sclerotic, the others had minimally altered composition. 
Immunofluorescence was unremarkable. Electron microscopy showed diffuse effacement of 
podoyte foot processes. He was treated with high dose (2mg/kg) steroid and oral diuretics. 
Renal function has retuned to his prior baseline and he has subnephrotic proteinuria.
Discussion: This describes a case of nephrotic syndrome and interstitial nephritis 
related to the monoclonal antibody, Iplimumab. Interstitial nephritis has been described with 
this drug before. 1However, this is the first case to our knowledge of the administration of 
ipilimumab leading to acute kidney injury from interstitial nephritis and severe proteinuria 
from diffuse podocyte foot process effacement. Prompt recognition of this presentation is 
necessary to preserve renal function. 
1”kidney injury related to ipilimumab”, Invest New Drugs (2014) 32:769-773.
TH-PO1030
Kappa Light Chain-Associated Crystal-Storing Tubulopathy, 
Podocytopathy, and Histiocytosis in GI Tract, in a Patient with Multiple 
Myeloma  Michifumi Yamashita,1,3 Albert Q. Lam,2,3 Joseph V. Bonventre,2,3 
Vanesa Bijol.1,3  1Pathology, Brigham and :omen¶s Hospital, Boston, MA; 2Renal 
Div, Internal Medicine, Brigham and :omen¶s Hospital, Boston, MA; 3Harvard 
Medical School, Boston, MA.
Introduction: Multiple myeloma manifests with variety forms of kidney disease, 
such as AL amyloidosis, cast nephropathy, and light chain deposition disease. Among 
them, crystal-storing disease is a rare entity. We report an interesting case of a patient with 
extramedullary IgG/κ multiple myeloma, who presented with crystal-storing histiocytosis 
in GI tract, and subsequently developed crystal-storing tubulopathy and podocytopathy.
Case Description: A 65-year-old man with type 2 DM and HTN was found to have 
a 1 cm large cecal polyp on screening colonoscopy in 2009. The polyp showed diffuse 
infiltration by a plasma cell neoplasm and crystal-storing histiocytosis with κ light chain 
(LC) restriction. At that time, the patient showed intact bone marrow, normal renal function 
and proteinuria of 0.5 g/24h. He was subsequently closely followed with endoscopy, SPEP, 
and renal function tests. In 2014, he developed nephrotic range proteinuria (>4g/24h), 
slightly rising Cre to 1.12 mg/dl, and increased serum free κ LC (216 mg/L). Kidney 
biopsy was performed, revealing many proximal tubular epithelial cells containing PAS-
negative granular materials in the cytoplasm. The glomeruli were unremarkable except for 
mild mesangial expansion. No significant immune deposits were present in glomeruli or 
tubulointerstitium, but there was slightly stronger background IF reactivity for κ LC than 
Ȝ LC on frozen tissue sections. IF studies on protease-digested paraffin sections revealed 
strong κ LC reactivity of the materials aggregated in the tubular epithelial cells and 
podocytes, while Ȝ LC was negative. EM revealed extensive intracytoplasmic accumulation 
of crystalline material of rhomboid and rectangular shapes in proximal tubular epithelial 
cells and podocytes.
Discussion: LC-associated crystal-storing disease is a rare kidney disease. To our 
knowledge, this is the first reported case of coexisting crystal-storing tubulopathy, 
podocytopathy, and histiocytosis in the GI tract in a patient with multiple myeloma.
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TH-PO1031
Parvovirus B19-Preceding Collapsing Glomerulopathy in Renal Allograft 
Michifumi Yamashita,1,3 Martina M. McGrath,2,3 Anil K. Chandraker,2,3 Vanesa 
Bijol.1,3  1Pathology, Brigham and :omen¶s Hospital, Boston, MA; 2Renal Div, 
Internal Medicine, Brigham and :omen¶s Hospital, Boston, MA; 3Harvard 
Medical School, Boston, MA.
Introduction: Collapsing glomerulopathy (CG) is a distinct clinicopathologic entity 
with proliferation of glomerular epithelial cells and capillary collapse. It has been classically 
associated with HIV infection, but other predisposing conditions and etiologic factors 
include parvovirus and CMV infections, autoimmune diseases, hematologic malignancies, 
and certain drugs. The pathomechanism of CG in renal allograft is unclear. Here we report 
a case of parvovirus infection-preceding CG in allograft.
Case Description: A 72-year-old man with ESRD due to DM and HTN, status post 
DDRT in June 2014, who presented with rising Cre from 1.6 to 2.0 without viral illness, 
3 months after transplantation. The 1st biopsy showed several mesangial deposits with 
organized spherical substructural organization, averaging 18 nm in diameter, without 
evidence of allograft rejection. Extensive immunohistochemistry (IHC) workup revealed 
positive staining only for Parvovirus in mesangial area. 3 weeks after the biopsy, he 
developed Parvovirus B19 viremia with 4.8 x 109 IU/mL. 6 weeks later, he presented with 
rising Cre to 3.4, proteinuria 1.5 g/24hr, and improved Parvovirus viremia (3.3 x 105 IU/
mL). The 2nd biopsy revealed severe podocyte injury with features of CG: (1) Collapse of 
the tuft and prominent epithelial cells with intracytoplasmic protein reabsorption granules, 
(2) extensive effacement of foot process and other degenerative changes of podocytes, and 
(3) coarse protein reabsorption granules in tubular epithelial cells. Parvovirus could not be 
detected anymore by EM or IHC.
Discussion: This case clearly showed: (1) for the first time, Parvovirus B19 particles 
in glomeruli immunohistochemically and ultrastructurally, (2) Parvovirus B19 infection 
systemically and histologically preceding CG, and (3) when CG developed, serum 
Parvovirus B19 titer was significantly decreased, and the virus could not be detected in the 
kidney tissue by EM or IHC. The evidence suggests that the direct or the indirect association 
between Parvovirus B19 infection and CG in kidney allograft.
TH-PO1032
A Case Report of Obstructive Nephrolithiasis Secondary to Atazanavir 
Dina Abdelwahab, Anushree C. Shirali.  Internal Medicine, Section of 
Nephrology, Yale Univ School of Medicine, New Haven, CT.
Introduction: Atazanavir, a protease inhibitor used in the management of human 
immunodeficiency virus (HIV), is associated with crystalluria and nephrolithiasis. While 
crystalluria is seen in 10-20% of patients on atazanavir treatment, frank nephrolithiasis 
is less common. We report a case of nephrolithiasis associated with atazanavir in an HIV 
patient on long-term highly active anti-retroviral therapy (HAART).
Case Description: A 56-year-old male with a past medical history of HIV on HAART, 
HCV, DM type 2 and proteinuric CKD stage III presented with rise in serum creatinine from 
2.6 to 5.7 mg/dL over the preceding year. His CD4+ T-cell count was 514 and his viral load 
was less than 20 copies/ml on treatment with atazanavir, ritonavir and raltegravir, a regimen 
that had remained stable for 10 years. He had no history of diabetic retinopathy and his 
proteinuria was stable around 5.2 gm. Prior abdominal CT imaging had revealed bilateral 
non-obstructive nephrolithiasis 1 year prior to presentation. Evaluation of the decline in 
renal function included a CT scan of the abdomen, which showed a left-sided obstructive 
stone. The patient had no symptoms of renal calculi. He underwent ureteroscopy, laser 
lithotripsy and stent placement. Stone analysis revealed calculi composed of atazanavir and 
its metabolites. His HAART regimen was switched to dolutegravir, lamivudine and abacavir. 
Despite an initial stabilization in creatinine, the patient eventually progressed to ESRD.
Discussion: This case highlights the fact that patients treated with atazanavir may 
develop nephrolithiasis with chronic therapy. Evaluation of renal disease in patients on 
atazanavir should include renal imaging for detection of calculi, even in the absence of 
symptoms, in susceptible patients who have an unexplained drop in GFR. The risk of 
nephrolithiasis is particularly heightened in patients on ritonavir-boosted atazanavir and 
those with pre-existing chronic kidney disease. Other types of renal disease associated 
with atazanavir include acute interstitial nephritis and chronic interstitial nephritis and 
should prompt kidney biopsy in those patients without evidence of obstructive nephropathy. 
TH-PO1033
Paraneoplastic Tumor-induced Osteomalacia (TIO) in Small Cell 
Carcinoma: First Report of Positive Immunostaining for Fibroblast Growth 
Factor-23 in Small Cell Carcinoma  Smita Mahendrakar, Hone S. Kaw, Hiba 
M. Ahmed, Suneet Verma, Mandeep Samra, Jennine Michaud, Donghong Cai, 
Michael Yudd.  Nephrology, Dept of Veterans Affairs NJ Healthcare System, 
East Orange, NJ.
Introduction: We report a case of hypophosphatemia due to Fibroblast Growth 
Factor(FGF)-23 in small cell carcinoma (SCCA). This is the first reported case of positive 
immunohistochemical staining for FGF-23 in SCCA.
Case Description: 60 yr old male was admitted with abdominal pain, anorexia and 
weight loss . Labwork showed normal renal function, serum phosphorus (PO4) 0.8 mg/dl, 
bilirubin 4 mg/dl, increased LFT’s, and elevated fractional excretion of PO4 82%, with high 
serum FGF-23, 577 RU/ml. No lab findings of Fanconi Syndrome . CT showed pulmonary 
nodules and a massively enlarged liver with no focal lesions. Liver biopsy showed metastatic 
SCCA with diffuse sinusoidal pattern. Despite PO4 replacement, hypophosphatemia was 
difficult to correct. Chemotherapy was started, but patient died in 2 weeks. Tissue sections 
from the tumor and controls were stained separately using antibodies directed against 
epitopes comprising amino acid residues located within the C-terminal portion of FGF23.
Discussion: Immunostaining of tumor cells from the lung and liver were positive for 
FGF-23. This is the first case with documented elevated serum FGF-23 and positive FGF-
23 immunostaining of SCCA. Tumor-induced osteomalacia (TIO), is usually associated 
with benign tumors of mesenchymal origin, rarely with adenocarcinomas or small cell 
carcinoma. The syndrome is characterized by renal PO4 wasting due to excess FGF-23 
from the tumor, leading to hypophosphatemia. There are at least 10 cases of SCCA with 
phosphate wasting, but without FGF23 levels. Only four cases of TIO with documented 
elevated FGF-23 associated with tumors other than mesenchymal tumors: 2 cases of stage 
D2 prostate adenocarcinoma, one with metastatic colon cancer, and one with stage 4 ovarian 
cancer . All of these were advanced, metastatic disease. Of these, only the metastatic colon 
adenocarcinoma case was documented by FGF-23 immunohistochemical staining in the 
hepatic metastases. Our case is the first case of FGF-23-postive immunostaining in tumor 
cells of small cell CA.
TH-PO1034
Relapse of Kappa Restricted Chronic Lymphocytic Leukemia Associated 
with a Lambda Restricted Plasma Cell Clone Causing Renal Amyloid 
Sunil Rangarajan, James C. Harms, Huma Fatima, Randall S. Davis, Eric L. 
Wallace.  Univ of Alabama at Birmingham.
Introduction: Chronic lymphocytic leukemia (CLL) has been associated many 
glomerular diseases. Rarely, it has been associated with amyloidosis either as the sole 
clone responsible, or in association with a plasma cell clone possessing the same light 
chain as the CLL clone, or in very rare cases, a different light chain. We present a case 
of adult onset nephrotic syndrome secondary to amyloid-lambda light chain due to a 
small lambda-restricted plasma cell population, temporally associated with a relapse of a 
kappa-restricted CLL.
Case Description: A 66 year old male, diagnosed with kappa-restricted CLL in 
2009 achieved complete remission after 6 cycles of fludarabine, cyclophosphamide and 
rituximab. 5 years later, he presented with foamy urine, generalized swelling, and weight 
gain. Serum creatinine was 1.1. Initial spot urine protein / creatinine ratio showed proteinuria 
of 5g/g which later increased to 10g/g. During the previous year serum albumin fell from 
3.8 to 1.5 g/dL and the white blood cell count rose from 7.4 to 30 x103/cmm. While the 
lymphocyte frequency rose from 45% to 88%, serum free light chains were 45.1mg/L 
lambda, 21.5 mg/L kappa with a ratio of 0.48. Kidney biopsy showed AL-amyloidosis with 
immunofluorescence positive for lambda. Due to discrepancy in the clonality of previous 
circulating CLL expansion (kappa restricted) and renal amyloidosis (lambda restricted), 
a bone marrow biopsy was done. This showed a relapse of CLL with low level (<10%) 
plasma cell dyscrasia. Flow cytometry confirmed that the relapsed CLL population was 
kappa-restricted while the clonal plasma cell population expressed lambda. After 8 months 
of treatment with velcade, dexamethasone and revlimid, he showed minimal improvement 
in proteinuria.
Discussion: Though the co-existence of clonal plasma cells and CLL is known, the 
temporal association of this patient’s nephrotic syndrome secondary to amyloidosis from 
a unique plasma cell clone expressing a different light chain supports the hypothesis that, 
in CLL, sharing the same microenvironment as non-tumor cells may activate bystander 
B-cells to express free light chains and in this case lead to amyloidosis.
TH-PO1035
Recurrent 2,8-Dihydroxyadenine Deposition Successfully Treated with 
Kidney Transplantation  Paula A. Duran, Mohanram Narayanan.  Div of 
Nephrology, Baylor Scott & White Healthcare, Temple, TX.
Introduction: Adenine phosphoribosyltransferase (APRT) deficiency is an autosomal 
recessive purine metabolism disorder where adenine is oxidized by xanthine dehydrogenase 
to 2,8–dihydroxyadenine (2,8-DHA), forming insoluble urinary crystals, nephrolithiasis, 
CKD and ESRD. Literature reveals diagnosis of APRT deficiency is rare before kidney 
transplantation. Delay in diagnosis and xanthine oxidase inhibitor treatment predisposes 
to recurrent disease in renal allograft, with allograft loss in over 25% cases. Though APRT 
is ubiquitous in all cells, extrarenal symptoms are uncommon in affected individuals. 
Our patient presented with crystalline keratopathy resolving completely after kidney 
transplantation.
Case Description: 41 y/o Caucasian female with recurrent 2,8-DHA nephrolithiasis 
since age 23 was maintained on Allopurinol. Clinical course was significant for obstructive 
uropathy requiring multiple stent placements; continued decrement in renal function and 
blurry vision, intense photophobia, excessive tearing in both eyes. Corneal examination 
showed crystalline keratopathy. Genetic analysis indicated patient had mutant APRT alleles 
inherited from her parents. With progressively declining renal function she was evaluated 
for preemptive renal transplantation. She received a 0-antigen mismatched deceased donor 
renal allograft with uneventful post-transplant course. Allopurinol dose was increased to 
600 mg daily with complete resolution of disabling visual symptoms. Allograft function has 
been excellent with nadir creatinine of 0.82 and urine microscopy negative for DHA crystals.
Discussion: APRT deficiency is a rare genetic disorder not readily diagnosed but easily 
treated with Allopurinol to prevent urinary DHA crystallization. Typical recommended daily 
dose of Allopurinol is 200-300 mg, but reports from Iceland have shown excellent results 
in transplant recipients taking 600 mg that lacked statistical significance due to the small 
sample size. Allopurinol 600 mg should be considered post-transplant to prevent allograft 
loss. Our patient’s post-transplant dose was increased to 600 mg with remarkable resolution 
of crystal keratopathy and crystalluria while maintaining excellent allograft function.
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TH-PO1036
Minimal Change Disease Diagnosing Relapsing Mantle Cell Lymphoma 
Juan Calderon, Mark A. Perazella.  Nephrology, Yale Univ School of Medicine, 
New Haven, CT.
Introduction: Glomerular lesions are linked with hematologic malignancies, with 
minimal change disease (MCD) commonly associated with Hodgkin’s lymphoma. Diagnosis 
of the underlying hematologic disorder often precedes development of the glomerulopathy; 
however, in rare cases, MCD precedes discovery of the lymphoma by several months. We 
present a case of new onset nephrotic syndrome and AKI in association with undetected 
relapsing mantle cell lymphoma (MCL).
Case Description: A 74 y/o man with history of stage IV mantle cell lymphoma in 
remission developed AKI and new onset edema. Chemotherapy completed 1 year prior 
to presentation induced complete remission on bone marrow and follow-up PET scans. 
On presentation he denied B symptoms, had no new lymphadenopathy, and only noted 
decreased appetite. The patient was edematous and hypertensive. Serum Cr was 2.4 mg/dl 
up from 1.3 mg/dl. High-grade, non-quantifiable urine protein was noted by the lab. Urine 
sediment was remarkable for numerous granular casts, oval fat bodies, and few uric acid 
crystals. Serum uric acid was 13.2 mg/dl. Therapy for tumor lysis syndrome was instituted 
due to concern for relapsing lymphoma in the setting of AKI. However, PET/CT scan was 
completely normal with no evidence for lympoma. Furthermore, LDH was within normal 
limits. Kidney biopsy revealed normal glomeruli on light microscopy with acute tubular 
injury. EM revealed global effacement of foot processes. A diagnosis of MCD with focal 
tubular injury was made and steroid therapy was started. Peripheral flow cytometry and 
later a bone marrow biopsy confirmed a 23% tumor burden compatible with relapsed MCL. 
Targeted chemotherapy for MCL was initiated.
Discussion: We present the first report of MCD associated with relapsing MCL. 
Oncologic surveillance including PET scan failed to detect reccurrent MCL. BM biopsy 
and flow study was pursued following the diagnosis of MCD. Initial therapy with steroids 
alone was associated with a reduction in proteinuria. This improved further with therapy 
directed at the relapsed MCL suggesting a pathophysiologic relationship between these 
two disorders. Clinicians must remain cognizant of the possibility of malignancy when a 
suspicious glomerular lesion develops.
TH-PO1037
Renal Osteodystrophy  Hitarth S. Dave, Daniel E. Carl.  Dept of Internal 
Medicine, Div of Nephrology, Virginia Commonwealth Univ School of Medicine, 
Richmond, VA.
Introduction: It is believed that mineral metabolism changes start as early as stage II 
chronic kidney disease (CKD). The spectrum of CKD-mineral and bone disorder (MBD) 
ranges from low-turnover adynamic disease to high-turnover osteitis fibrosa.
Case Description: A 37-year-old female with end-stage renal disease (ESRD), 
currently undergoing hemodialysis, presented complaining of a 1-day history of inability 
to eat or drink. Prior to presentation, she had noticed 2-week history of difficulty speaking, 
and 8-month history of increasing facial size. On presentation, the blood pressure was 
180/68 mm Hg, and the oxygen saturation 98% while breathing ambient air. The physical 
examination revealed significant bony hypertrophy of the maxilla and mandible with edema 
of the overlying soft tissue. Computed tomographic (CT) scans of the maxilla and mandible 
showed severe expansion of the mandible and hard palate with complete replacement of 
the osseous matrix and surrounding mass effect on the maxillary sinuses and oropharynx 
with narrowing of the airway most severe at the angle of the mandible (Panel B). Panel A 
shows a scout image of the CT of head done eleven years ago for comparison. 
Laboratory data showed calcium 10.2 mg/dL (8.9-10.7 mg/dL), phosphorus 4.7 mg/dL 
(2.5-4.6 mg/dL), alkaline phosphatase 2784 units/L (0-120 unit(s)/L), intact PTH 5707.8 
pg/mL (12-65 pg/mL). She underwent tracheostomy and four-gland parathyroidectomy 
with autotransplantation in the subcutaneous abdominal tissue. Biopsy of the left maxillary 
bone revealed osteitis fibrosa consistent with renal osteodystrophy.
Discussion: Hyperparathyroidism can cause extraosseous calcification in arteries, 
joints, and viscera. Osteitis fibrosa cystica is characterized by increased bone turnover 
caused by secondary hyperparathyroidism. The prevention of a positive phosphate balance 
is the mainstay of treatment of high-turnover bone disease.
TH-PO1038
Bevacizumab Nephrotoxicity: Case Report and Literature Review 
Girish Singhania, Abhilash Koratala, Azra Bihorac.  Nephrology, Univ of 
Florida, Gainesville, FL.
Introduction: Bevacizumab (BCZ), an inhibitor of vascular endothelial growth factor 
(VEGF), is approved for the treatment of various cancers. We are reporting a case of BCZ 
induced acute kidney injury (AKI) with proteinuria (PTN) and thrombotic microangiopathy 
(TMA) and providing a summary of evidence after systematic review of reported cases 
in literature.
Case Description: A 57-year-old Caucasian woman with no history of kidney disease 
presented with abdominal pain 4 weeks after completing most recent cycle of BCZ (first 
dose 2 months before hospitalization) for colon cancer. She presented with new onset of 
hypertension (HTN), diffusely tender abdomen and a significantly low hemoglobin of 
4.6 g/dL. A non-contrast CT showed hemorrhagic pancreatitis. Her serum creatinine at 
presentation was 2.93 mg/dL (baseline: 0.5 mg/dL). Further workup showed platelets 
of 45,000/µL, haptoglobin of <10 mg/dL and LDH of 947 U/L. Peripheral blood smear 
showed 3 schistocytes/hpf. Urinalysis was positive for protein and 4 RBCs/hpf. 24 hour 
urine had 2.1 gms of protein. Hepatitis panel, ANCA and SPEP were negative. ADAMTS 
13 activity was normal. Based on clinical diagnosis of AKI, PTN and TMA related to 
BCZ, the drug was discontinued and patient was managed conservatively without plasma 
exchange (PE). The creatinine gradually improved to 1.5 mg/dL while platelet count and 
hemoglobin returned to baseline at discharge.
Discussion: We identified 24 cases reported in literature with mean age of 62 years. 
All patients presented with AKI and PTN with 61% being nephrotic range. The onset of 
PTN ranged from 2 weeks to 28 months after initiation of BCZ. HTN occurred among 
62% while TMA among 57% of patients. Most of the patients had partial or complete 
recovery of AKI and PTN with only 1 patient progressing to end-stage renal disease on 
follow up ranging from 2 to 33 months. The proposed mechanism of nephrotoxicity is 
thought to be related to low free VEGF levels leading to endothelial dysfunction and 
podocyte dysregulation. Treatment includes withholding the drug if PTN exceeds 2g/day 
or permanent discontinuation for nephrotic syndrome and ACEI or thiazide diuretics for 
treatment of HTN. Drug induced TMA with normal ADAMTS 13 levels rarely requires PE.
TH-PO1039
5-Oxoprolinuria: A Rare Cause of High Anion Gap Metabolic Acidosis due 
to Acetaminophen Ingestion  Ardavan Mashhadian,1,2 Sreesh G. Iyengar,1,2 
Seyed-ali Sadjadi,2 Lisa Aimee Hechanova.1  1Nephrology, Loma Linda Univ, 
Loma Linda, CA; 2Nephrology, Jerry L Pettis Memorial 9eterans Medical 
Center, Loma Linda, CA.
Introduction: Acquired 5-oxoprolinuria is a rare cause of high anion gap metabolic 
acidosis due to excessive acetaminophen ingestion. It largely goes unrecognized because an 
assay for 5-oxoproline is not widely available. The malnourished and chronically ill women 
with history of chronic acetaminophen ingestion are commonly affected. Acetaminophen 
levels are rarely in toxic range.
Case Description: A 57-year-old woman with a history of adiposis dolorosa was 
admitted for acute osteomyelitis. She was chronically taking acetaminophen containing 
pain medication. Her hospital course was complicated by anion gap metabolic acidosis 
and cardiorespiratory failure. Her acetaminophen level was not elevated. Usual causes of 
anion gap acidosis were ruled out. Finally, a urine organic acid screen showed elevated 
5-oxoproline levels. Acetaminophen containing pain medication was stopped, she was 
given IV hydration and sodium bicarbonate. Her anion gap metabolic acidosis would 
quickly resolve.
Discussion: Acute and chronic acetaminophen ingestion can lead to high levels of 
5-oxoproline. The pathophysiology behind acquired 5-oxoprolinuria has been mostly 
explained by reduced glutathione in prior case reports. 5-oxoproline is an intermediate 
in the gamma-glutamyl pathway, the metabolic cycle responsible for creating glutathione 
and shuttling amino acids into the cytosol. When glutathione levels are diminished, 
feedback inhibition ceases, causing an overproduction of 5-oxoproline. Sepsis, amongst 
others etiologies, have been implicated in glutathione depletion. 5-Oxoprolinuria clinically 
presents with altered mental status. One of the key aspects of diagnosing this disorder is 
the detection of 5-oxoproline in urine. N-acetylcysteine may be an effective treatment that 
acts to restore intracellular glutathione levels. Extracellular fluid expansion with dextrose 
containing saline promptly improves symptoms. In conclusion, 5-oxoprolinuria should be 
considered in any patient with unexplained metabolic acidosis and recent acetaminophen 
ingestion. Overlooking the diagnosis can be costly.
TH-PO1040
Severe Tubulointerstitial Nephritis with Lymphoid Follicles in Sjögren’s 
Syndrome  Maiko Nagata, Takehiko Kawaguchi, Mao Watanabe, Takafumi 
Yamakawa, Moritoshi Kadomura, Hiroshi Kitamura, Toshiyuki Imasawa. 
Internal Medicine, National Hospital Organization Chiba-East-Hospital, 
Chiba, Japan.
Introduction: Patients with Sjögren’s syndrome (SS) are at increased risk for the 
development of lymphoma. The prolonged state of immunologic and lymphoid hyperactivity 
in SS may predispose patients to the development of lymphoid neoplasm. However, biopsy 
specimens from some of these patients do not meet histologic criteria for frank malignancy. 
We report a rare case of severe tubulointerstitial nephritis with lymphoid follicles in SS.
Case Description: A 66-year-old woman, who had developed general malaise for a 
few years, was admitted to our hospital, because of the rapid rise in the serum creatinine 
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level in the past two months. Four months before the admission, she was found to have 
hypergammaglobulinemia, and a bone marrow–biopsy specimen revealed no hyperplasia 
of plasma cells. In the admission, the main laboratory values showed the following values: 
serum creatinine 1.8 mg/dl, IgG 6634 mg/dl, urinary b2MG 7829 mg/l, anti-SS-A≥500 
U/ml. Renal biopsy showed tubulointerstitial nephritis with marked lymphoplasmacytic 
infiltration. Most of the cells were plasma cells; some were immature. Immunostain studies 
showed plasma cells with a polyclonal pattern. Some lymphoid follicles were also present 
in the interstitial tissue. 
Additionally, lip biopsy showed microsalivary gland with concentrated lymphocyte 
infiltration. Most of the cells were B lymphocytes. Plasma cells with a polyclonal pattern 
were present in the peripheral germinal centers. Thus, the diagnosis was primary SS. 
Immunopathologic analysis of renal and lip biopsy specimens showed no features of 
malignancy. Steroid therapy led to prompt resolution of the infiltration.
Discussion: This is a rare case of severe tubulointerstitial nephritis with lymphoid 
follicles in SS. It may show a spectrum of lymphoproliferative disease in SS.
TH-PO1041
Scleroderma Renal Crisis with Normal Blood Pressure and Normal Serum 
Creatinine  Natanong Thamcharoen,1 Raquel M. Rosen,1 Vivette D. D’Agati.2 
1Dept of Medicine, Bassett Medical Center, Cooperstown, NY; 2Dept of 
Pathology, Columbia Univ College of Physicians and Surgeons, New York, NY.
Introduction: A serious complication of systemic sclerosis is scleroderma renal 
crisis (SRC) usually presenting with acute onset of high blood pressure, kidney failure 
and thrombotic microangiopathy. 10% of patients may not have hypertension known as 
normotensive scleroderma renal crisis but mostly presenting with elevated creatinine. 
We introduce a case of scleroderma renal crisis with normal blood pressure and normal 
serum creatinine.
Case Description: A 61 year-old woman was admitted with dysphagia, proximal 
muscles weakness and tightening of skin. She was diagnosed with systemic sclerosis from 
the findings. She later developed oliguria without elevation of creatinine (baseline creatinine 
0.4 increased to 0.8). Her blood pressure was in normal range. The urinalysis showed 5-10 
cell/HPF of red blood cell, no dysmorphic red blood cell or cast. She had proteinuria of 
441 mg/day. Kidney ultrasound did not show abnormalities. Anti-dsDNA, MPO antibody 
and proteinase-3 antibody were performed, they were all negative. Free light chain disease 
and amyloidosis were ruled out by normal serum protein electrophoresis and normal free 
light chain. Kidney biopsy was performed revealing arteriolar mucointimal edema and 
concentric intimal sclerosis, consistent with thrombotic microangiopathy.
Scleroderma renal crisis was diagnosed according to the pathology result. Lisinopril 
20 mg oral daily was started but kidneys continued deteriorating leading to hemodialysis.
Discussion: Recognizing the early signs of kidney injury is important to initiate the 
treatment scleroderma renal crisis(SRC). Physicians should suspect for SRC once patients 
have signs of acute kidney injury regardless of elevated blood pressure or creatinine.
TH-PO1042
Acetaminophen Associated 5-Oxoproline Acidosis in an Anuric End-Stage 
Renal Disease Patient  Michael Pham,1 Leslie F. Thomas,2 Christine Snozek.3 
1Internal Medicine, Mayo Clinic, Phoenix, AZ; 2Nephrology, Mayo Clinic, 
Phoenix, AZ; 3Laboratory Medicine 	 Pathology, Mayo Clinic, Scottsdale, AZ.
Introduction: Also known as pyroglutamic acid, 5-oxoproline is an intermediary in 
glutathione antioxidant metabolism. Reports of acetaminophen associated 5-oxoproline 
high-anion gap metabolic acidosis (HAGMA) has been slowly growing in the literature 
but remains under recognized in clinical practice.
Case Description: A 57 year old male with anuric end-stage renal disease (ESRD) was 
admitted for confusion and hypotension secondary to sepsis from infected lower extremity 
ulcers, poor oral intake, and excessive peritoneal dialysis. Laboratory evaluation revealed a 
depressed bicarbonate level of 17 mEq/L and an elevated albumin-corrected anion gap of 30 
mEq/L. Despite correction of an elevated L-lactate with fluid resuscitation and antibiotics, 
his HAGMA persisted. An exhaustive investigation was unable to find a convincing 
etiology including commonly attributable organic acids, D-lactate, paraproteinemias, toxic 
exposures, and medications. Further inquiry revealed a protracted course of therapeutic 
acetaminophen ingestion with a weighted average daily dose of ³1.3 grams in the four 
weeks leading to presentation. Serum 5-oxoproline was elevated to >100.0 mmol/L 
(normal <70.0 mmol/L). Serum acetaminophen was undetectable. All acetaminophen 
containing medications were subsequently stopped. His clinical course improved with 
supportive care and he was discharged home. After 5 weeks of acetaminophen cessation, 
his serum 5-oxoproline normalized to 27.1 mmol/L with anion-gap and bicarbonate levels 
returning to baseline.
Discussion: To our knowledge, we report the first case of acetaminophen associated 
5-oxoproline acidosis in an anuric ESRD patient. Risk factors are thought to be related to 
glutathione deficiency which in turn favors the 5-oxoproline pathway of the γ-glutamyl 
cycle and results in accumulation. These risk factors include reactive acetaminophen 
metabolites, alcohol abuse, malnutrition, sepsis, renal dysfunction, and liver disease. As 
an under recognized entity in clinical practice, 5-oxoproline should be considered in adults 
with unexplained HAGMA and the above risk factors.
TH-PO1043
Renal Amyloidosis Associated with Apolipoprotein C-II Deposition 
Lohit Garg,1 Gerta Mane,1 Sami S. Zarouk.2  1Dept of Internal Medicine, 
Beaumont Health, Royal Oak, MI; 2Dept of Nephrology, Beaumont Health, 
Royal Oak, MI.
Introduction: A 62-year-old female with no family history of renal disease presented 
with a creatinine at 2.3 mg/dL and hypertension. Baseline creatinine was 1.2 mg/dL one 
year prior to presentation and she had 1+ proteinuria on urinalysis 3 years earlier. Serologic 
work up was negative for ANA, C3, C4, hepatitis B and C, HIV and SLE. Monoclonal 
gammopathy evaluation showed IgA kappa monoclonal protein as two bands in the beta 
globulin region. Random urine for protein electrophoresis showed a small amount of IgA 
and free kappa monoclonal protein. Her random urine for protein/ creatinine ratio was 6.3.
A renal biopsy was consistent with amyloidosis in the mesangium that exhibited 
apple green birefringence on polarization microscopy after Congo Red staining. 
Immunofluorescent stains for kappa and lambda light chains were negative. Electron 
microscopy showed randomly arranged fibrils in the mesangium with features characteristics 
of amyloid fibrils. Bone marrow biopsy showed 6% plasmacytosis and minimal involvement 
with amyloidosis. Laser micro dissection and liquid chromatography mass spectrometry 
(LCMS) were performed on peptides extracted from Congo-red positive dissected areas. 
LCMS detected high levels of apolipoprotein C-II while analysis for lambda or kappa 
light chains, transthyretin and serum amyloid A were negative. It was concluded that these 
findings are unequivocally consistent with apolipoprotein C-II amyloid. Genetic testing 
was performed by direct sequencing of apolipoprotein C-II and showed mutation in patient 
as well as her son but not her daughter.
Discussion: Apolipoprotien C-II is a component of very low density lipoprotein and 
readily aggregates in lipid free conditions to form homogenous amyloid fibrils due to their 
intrinsic structure. To the best of our knowledge, this is the first case of apolipoprotein C-II 
renal amyloidosis. This case highlights the importance of performing DNA sequencing of 
exons of interest and LCMS on known amyloidogenic proteins to accurately diagnose and 
type the renal amyloidosis, which is critical for prognosis, treatment and genetic counseling.
TH-PO1044
Membranous Nephropathy in a Young Child with IPEX-Like Phenotype 
and a Novel Foxp3 Mutation  Olga Charnaya, Sun-Young Ahn, Asha Moudgil. 
Nephrology, Children¶s National Medical Center, :ashington, DC.
Introduction: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
(IPEX) syndrome typically presents with heterogenous manifestations. The syndrome is 
characterized by numerous auto-immune diseases due to dysfunction in the Foxp3 gene, 
which plays a critical role in maintaining immune tolerance.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR- Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
339A
J Am Soc Nephrol 26: 2015 Fellows Case Reports - I Poster/Thursday
Case Description: A 14-month-old male with a history of failure to thrive (FTT), 
eczema and diarrhea presented with cough and wheezing for 4 months. Pertinent findings 
on physical exam included weight < 2%ile, length 10%ile, BP 103/83 mmHg, and diffuse 
wheezing. Laboratory evaluation showed nephrotic range proteinuria (urine protein-to-
creatinine ratio of 6.3), low serum albumin 1.8 gm/dL, normal serum creatinine 0.3 mg/
dL, elevated LDL cholesterol 195 mg/dl, elevated serum glucose 303-426mg/dl, normal 
urine calcium-to-creatinine ratio 0.25, low C3 46 and C4 9.7, and negative ANA and anti 
DNA. Thyroid function tests were normal; islet cell antibodies were elevated at 80 (normal 
<1.2). A renal biopsy revealed membranous nephropathy with mild mesangial proliferative 
changes. Upon further evaluation, he was found to have fat malabsorption and numerous 
food allergies. Genetic sequencing identified a novel missense mutation, c.767T>C leading 
to substitution of the highly conserved amino acid threonine with methionine at position 
256 in the Foxp3 gene. This mutation was predicted to be deleterious by in silico analysis 
thereby suggesting the diagnosis of IPEX syndrome. Of note, Foxp3 protein expression 
was borderline low. The patient was treated with prednisone and tacrolimus with partial 
resolution of extra-renal symptoms, improvement in proteinuria and is currently awaiting 
bone marrow transplant.
Discussion: Infants with IPEX syndrome usually present with auto-immune 
enteropathy, FTT, eczema, type 1 diabetes mellitus and thyroid dysfunction. Renal 
involvement is rare and includes proteinuria, hematuria and renal insufficiency. Some 
children with novel mutations may have partial features as seen in this case. A diagnosis of 
IPEX should be considered in any male infant or young child with proteinuria in association 
with systemic features of autoimmunity.
TH-PO1045
Acute Rejection of a Kidney Transplant in a Patient with Common Variable 
Immunodeficiency Syndrome  Omar Mousa Al Nimri, Rakesh Malhotra, 
Paisit Paueksakon, Beatrice P. Concepcion.  Vanderbilt Univ Medical Center, 
Nashville, TN.
Introduction: Common Variable Immunodeficiency (CVID) is a primary 
immunodeficiency characterized by hypogammaglobulinemia. Clinical manifestations 
include recurrent bacterial infections, autoimmune disorders, chronic lung disorders, 
hepatitis and lymphoma. We report a case of a patient with known CVID whose post-
transplant course was complicated by acute cellular and humoral rejection which ultimately 
led to graft loss.
Case Description: A 44 y.o. male with ESRD was diagnosed in 11/2010 with CVID 
after developing peritonitis. He had a history of recurrent sinopulmonary infections and 
pneumococcal pneumonia. Immunoglobulin levels were undetectable and B, T and NK cell 
numbers normal. He was treated with monthly IVIG infusions. In 3/2012, he underwent 
living unrelated kidney transplantation (KT). Immunosuppression consisted of basiliximab, 
methylprednisonlone (MP), FK, MMF and prednisone. Baseline creatinine (Cr) post KT was 
1.3 mg/dL. In 8/2014 Cr was 3.6 mg/dL. Renal biopsy showed diffuse lymphoplasmacytic 
infiltrate with edema, frequent tubulitis and interstitial eosinophils. C4d and donor specific 
antibodies (DSA) were negative. He received IV MP 2.5 g and thymoglobulin 10.5 mg/kg 
as therapy for acute cellular rejection (ACR), CCTT Type 1. In 9/2014 Cr was 5 mg/dL. 
Rebiopsy showed resolution of ACR. However, he had chronic vascular rejection, focal 
acute tubular injury and transplant glomerulopathy with new diffuse (100%) C4d positivity. 
Class I DSA was positive at moderate levels. He was treated for acute humoral rejection 
with plasmapheresis and IVIG 2 g/kg. Renal function did not improve. In 11/2014 he was 
declared ESRD due to uremic symptoms and volume overload.
Discussion: To our knowledge, this is the first reported case of a patient with diagnosed 
CVID on maintenance IVIG who then underwent KT. The main concern for patients with 
CVID undergoing KT is the risk of infectious complications. However, this case illustrates 
that rejection can occur and adequate immunosuppression remains essential. Balancing 
immunosuppression with the risk of infection can be quite challenging in this patient 
population, making them high risk for transplantation.
TH-PO1046
Reverse Pseudohyperkalemia in a Patient with Non-Hodgkins Mantle 
Cell Lymphoma and Chronic Lymphocytic Leukemia  Chawmay Aye, 
Mitesh K. Patel, Farhanah Yousaf, Bruce S. Spinowitz, Alla Goldberg, Ritesh 
Raichoudhury.  New York Hospital Queens.
Introduction: Distinguishing pseudohyperkalemia from hyperkalemia is often 
challenging. Simple pseudohyperkalemia is common and is represented by a falsely 
increased serum potassium whereas reverse pseudohyperkalemia is characterized by a 
falsely elevated plasma potassium level. We report a case of reverse pseudohyperkalemia 
in a patient with non-Hodgkin’s mantle cell lymphoma and chronic lymphocyctic leukemia.
Case Description: A 74 year old South Asian female with a past medical history of 
non-Hodgkin’s mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), 
presented to the emergency department with a chief complaint of dizziness. She underwent 
chemotherapy session with Imbruvica one week prior to her presentation. Her initial vital 
signs included a blood pressure of 105/73, a pulse of 116 beats/min, a respiratory rate of 
17, and a temperature of 36.7 degrees Celsius. Physical exam was unremarkable. Her initial 
hematology panel consisted of a white blood count of 0.82 K/µL, hemoglobin of 10.2 g/
dL, and platelets of 40 K/µL. Patient was admitted with neutropenic sepsis and was started 
on Vancomycin, Meropenem, and Valtrex. Subsequent lab tests revealed a rising serum 
creatinine of 2 mg/dL and greater. One month into hospitalization, lab results showed a 
plasma potassium concentration of 8.22 mmol/L and a serum potassium concentration of 
5.6 mmol/L. Repeat testing four hours later was consistent and showed a plasma potassium 
concentration of 7.2 mmol/L and a serum potassium concentration of 5.4 mmol/L. Based 
on the blood plasma potassium results, the patient received emergent hemodialysis and 
potassium lowering agents.
Discussion: Reverse pseudohyperkalemia has been reported in adults with CLL but 
remains relatively an under-recognized entity among clinicians. The mechanisms producing 
reverse pseudohyperkalemia are unclear but potassium may be released from leukocytes 
due to heparin-induced cell damage and/or impaired Na-K ATPase activity in the presence 
of hematological malignancy. Early identification of reverse pseudohyperkalemia is crucial 
in preventing potassium lowering intervention related morbidity and mortality.
TH-PO1047
An Unusual Presentation of Fibromuscular Dysplasia  Omar Mousa Al Nimri,1 
Murray J. Mazer,2 Margaret L. Burks,3 Gerald Schulman,1 Rachel B. Fissell.1 
1Nephrology, Vanderbilt Univ Medical Center, Nashville, TN; 2Radiology, 
Vanderbilt Univ Medical Center, Nashville, TN; 3Internal Medicine, Vanderbilt 
Univ Medical Center, Nashville, TN.
Introduction: Fibromuscular dysplasia typically presents in middle aged women, often 
with hypertension. Depending on which arteries are involved, patients may present with 
transient ischemic attack, stroke [carotid artery FMD], or intractable hypertension [renal 
artery FMD]. We report an atypical case of fibromuscular dysplasia (FMD) in a male, that 
presented with renal infarction and no other symptoms.
Case Description: The patient is a 47yo male with no significant past medical history, 
including no history of Ehlers-Danlos syndronme or Marfan’s syndrome, who developed 
sudden left flank pain while driving. No urinary symptoms. No tenderness on exam. The 
pain was so severe that he went to a local ER. Initial evaluation notable for BUN 10 mg/
dL, Cr 1.06 mg/dL, urinalysis negative for blood, protein, and white blood cells. CT 
angiography revealed beading consistent with FMD at the distal main renal artery at the 
junction of the bifurcating branches, and tapered narrowing and occlusion most likely 
caused by spontaneous dissection with intramural hematoma, with upper pole infarct.
Subsequent transthoracic echo showed no vegetation or shunt, appearing to exclude 
embolus from heart or lungs. Hypercoagulable work-up was negative. Patient is being 
managed conservatively with no anticoagulation, and is doing well. His Cr has drifted 
down from a peak of 1.16 mg/dL to a new baseline of 0.99 mg/dL, he has not developed 
hypertension, and his flank pain has resolved.
Discussion: This case is notable because the FMD occurred in a male, and because 
renal infarction is a rare presentation of FMD. The actual cause of the infarction is most 
likely arterial dissection, with or without peripheral emboli.
Funding: Clinical Revenue Support
TH-PO1048
Clotting Filter Might Be an Early Clue to Fat Embolism Syndrome: Case 
Report and Literature Review  Deepak Jasuja, Melissa D. Anderson.  Div of 
Nephrology, Indiana Univ, Indianapolis, IN.
Introduction: Non traumatic causes of Fat Embolism Syndrome (FES) have been 
reported with bone marrow transplantation, osteomyelitis, pancreatitis, alcoholic fatty liver, 
and with liposuction. Etiology likely is fat particles entering the circulation with damage 
to capillary beds. Regardless of the mechanism initiating fat embolism, the end result is an 
intense inflammatory response. In the lungs, this induces lung injury that is indistinguishable 
from ARDS. FES can cause cerebral edema with raised intracranial pressure along with 
multi-organ failure and AKI.
Case Description: We present a 40-year-old African American lady who underwent 
non-myeloablative bone marrow transplant for Myelodysplastic anemia. One week after 
engraftment she developed sudden onset of respiratory distress leading to a cardio-
respiratory arrest. She developed ARDS, multiple organ dysfunction syndrome and CVVH 
was initiated for oliguric AKI and Metabolic acidosis .Soon after initiating CVVH her filter 
clotted with white, creamy plaque which cleared after 2 successive filters. Patient met Gurd 
and Wilson’s criteria for diagnosis of Fat Embolism Syndrome. She had abundance of 
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inflammatory cells on Broncho alveolar lavage including neutrophils and macrophages. Oil 
Red-O stain (stain for lipid) was performed to quantify macrophages displaying positivity. 
The initial Prep yielded 5 of 5 and the repeat prep yielded 11 out of 12 macrophages positive 
for Oil-Red-O. CT brain was performed which revealed large acute strokes with midline 
shift compatible with subfalcine herniation. No cerebral blood flow was identified on nuclear 
scan and patient was declared brain dead and terminally weaned.
Discussion: With the absence of specific tests or criteria the diagnosis of FES 
is dependent on the clinical acumen of the physician. Lipid inclusion in 30-70% of 
macrophages / inflammatory cells is most suggestive of FES . Only proven treatment 
is supportive care. We propose that a clotting filter might be an earlier clue to diagnose 
fat embolism syndrome and sending the filter for pathological analysis looking for lipid 
laden inflammatory cells is a less invasive approach as compared to quantification using 
Broncho-alveolar lavage.
TH-PO1049
Fatal Hyponatremia with Glycine Solution During Hysteroscopy – 
Proposal for New Mechanisms of Hyponatremia and Cerebral Edema 
Suchita J. Mehta, Subodh J. Saggi, Andrea Roche-Recinos, Man S. Oh. 
Nephrology, Suny Downstate, Brooklyn, NY.
Introduction: We report a fatal case of severe symptomatic hyponatremia and cerebral 
edema following hysteroscopy.
Case Description: 39 y/o woman underwent 70 mins hysteroscopic myomectomy, 
6L of glycine solution used for distension, without documented deficits. 3 hours later she 
developed pulmonary edema. Hyponatremia of 117mEq/L first noted 4 hours post surgery, 
baseline normal sodium. Course further complicated by agitation, vomiting, lethargy due 
to cerebral edema confirmed on C.T. Head 8 hours post-op, remained without brain stem 
reflexes. Post-op day 2 she also developed central diabetes insipidus. Remained brain dead, 
extubated and died after 12 days.
Discussion: Hyponatremia with glycine is iso-osmolar occurring as a result of dilution 
effect since glycine is retained in extra-cellular fluid before its metabolism by glycine 
cleavage enzyme. Two main questions with our postulated explanations: 1) How does 
cerebral edema develop with iso-osmolar hyponatremia? 2) Why is hyponatremia often 
more severe than predicted? Proposed mechanisms:1) Glycine can cross blood brain barrier 
(BBB) by passive diffusion, as shown in rats and cats. Sodium, however, does not exit 
brain via BBB as sodium transport across BBB occurs only inward. With glycine toxicity, 
glycine accumulates in the brain cells after crossing BBB followed by water resulting in 
brain edema. Possibility of glycine metabolism to ammonia leading to cerebral edema 
cannot be ruled although high levels were not seen in our case.
2) The greater reduction in serum sodium than expected can be explained by a smaller 
initial volume of distribution of glycine than the extracellular volume, which is attributed 
to rapidity of accumulation of glycine solution and the reduced muscle blood flow during 
surgery.
TH-PO1050
Cytomegalovirus-Induced Atypical Hemolytic Uremic Syndrome After 
Renal Transplant  Taranpreet Kaur,1 Andres G. Chiesa-vottero,2 Leal C. Herlitz,2 
Richard A. Fatica.1  1Nephrology, Cleveland Clinic; 2Pathology, Cleveland 
Clinic, Cleveland, OH.
Introduction: Atypical hemolytic uremic syndrome (aHUS) may occur as de novo 
disease and recurrence of primary renal disease in kidney transplant recipients. Causes of de 
novo HUS includes immunosuppressive drugs, ischemia reperfusion injury, acute humoral 
rejection, and viral infections. Some patients have a genetic susceptibility to the disease 
from underlying mutations in the complement regulatory proteins. Cytomegalovirus (CMV) 
has been rarely reported as a trigger for de novo post-transplant aHUS.
Case Description: A 61 year old male underwent deceased donor kidney transplant for 
ESRD from presumed FSGS. 1 year following transplant he was admitted with profound 
diarrhea and weight loss due to CMV colitis and high grade CMV viremia (410,462 copies/
ml). His immunotherapy was reduced and he was discharged home on oral valganciclovir 
with near resolution of symptoms. He was re-admitted 1 week later with nausea, abdominal 
pain, and acute kidney injury (Creatinine of 3.8 mg/dl, baseline of 1.8 mg/dl). His repeat 
CMV viral load was significantly better at 70,000 copies/ml. Labs were suggestive of 
microangiopathic hemolytic anemia: Hb 8 g/dl, platelets 58 K/ul, LDH 586 U/L, haptoglobin 
<20 mg/dl, and ADAMTS13 activity >67%. He received 4 sessions of plasmaphresis without 
improvement and required initiation of dialysis. Histologic features of acute and subacute 
endothelial injury, including segmental fibrin thrombosis of 2 arterioles were present on 
transplant kidney biopsy. His aHUS genetic panel revealed several mutations in different 
gene loci but no disease- associated mutation was identified. He was started on eculizimab. 
His hemolysis labs improved and he was taken off dialysis.
Discussion: CMV infection by way of endothelial injury can provoke aHUS in kidney 
transplant recipients and possibly be enhanced by genetic predispositions. Postulated 
mechanisms of CMV endothelial injury include increased leukocyte and platelet adhesion, 
endothelial expression of Von Willebrand factor, E-selectin, vascular cell adhesion 
molecule-1, and intercellular adhesion molecule-1. In our case, the aHUS process was 
halted by use of eculizumab.
TH-PO1051
Acute Interstitial Nephritis from Anti-PD-1 Therapy with Pembrolizumab 
in Two Patients with Advanced Non-Small Cell Lung Cancer 
Heidi Mae G. Timbol, Anushree C. Shirali.  Internal Medicine, Section of 
Nephrology, Yale Univ School of Medicine, New Haven, CT.
Introduction: Immune checkpoint inhibition with monoclonal antibodies (mAb) 
targeted against programmed cell death receptor 1 (PD-1) is emerging immunotherapy for 
various cancers. Pembrolizumab, an anti-PD-1 mAb, is being used in clinical trials with 
promising anti-tumor responses, but renal-specific adverse events are not clear. We report 
2 cases of acute interstitial nephritis (AIN) in patients who received Pembrolizumab for 
advanced non-small cell lung cancer (NSCLC).
Case Description: Two female patients, both 69 years of age, with metastatic NSCLC 
were seen in outpatient nephrology clinic for acute kidney injury (AKI). Both patients 
were enrolled in a clinical trial with Pembrolizumab, and their cases had been complicated 
previously by auto-immune adrenalitis. On labs, Patient A had an increase in creatinine to 
2.1 mg/dL prior to cycle 16, up from a baseline of 0.9 mg/dL. Patient B had a creatinine 
peak of 1.9 mg/dL after cycle 6, up from a baseline of 1.1 mg/dL. Medications were 
significant for long-standing pantoprazole use in both patients. Urine sediment showed 
many WBC clumps without casts or RBCs. Renal ultrasound was unremarkable. Volume 
expansion with normal saline and cessation of potential nephrotoxins failed to reverse renal 
dysfunction in either case. Each patient underwent CT-guided renal biopsy, which showed 
diffuse AIN. Steroid therapy with prednisone 60 mg/day with a slow taper was started and 
creatinine improved to baseline.
Discussion: These two cases highlight a new association between AIN and 
Pembrolizumab, which to the best of our knowledge has not been previously reported. 
While both patients were on pantoprazole therapy prior to their AKI, this medication 
was not new. Rather, the time course of AKI best fits with initiation of pembrolizumab. 
Additionally, their pre-existing drug-related auto-immune adrenalitis suggests a possible 
auto-immune component to AIN from anti-PD-1 therapy. With increasing use of these 
agents, clinicians should maintain a high index of suspicion for AIN as a cause of AKI and 
have a low threshold for kidney biopsy to confirm diagnosis and initiate early treatment.
TH-PO1052
Concurrent Anti-PLA2R and ADAMTS 13 Inhibitor – Coincidence or a 
Clue to Pathogenicity?  Laith Al-Rabadi,1 Moshe Shashar,1 Parikshit Duriseti,2 
Ami Patel,1 Aala Jaberi,1 Ashish Upadhyay,1 Joel M. Henderson,1 Vipul C. 
Chitalia,1 David J. Salant,1 Laurence H. Beck.1  1Boston Univ Medical Center; 
2Mamata Medical College, India.
Introduction: Thrombotic thrombocytopenic purpura (TTP) is a hematologic 
emergency associated with a decrease in ADAMTS13 activity, most often due to the presence 
of an inhibitor. Severe proteinuria is an unusual feature of TTP. The concurrent presence 
of anti-PLA2R and ADAMTS13 inhibitor has never been previously reported until now.
Case Description: Herein, we present a case of a 70 year old male who presented with 
generalized anasarca. Physical exam was remarkable for BP 180/100, and 2+ peripheral 
edema. Workup revealed Hgb 7.4, Plt 36, Creatinine1.43, LD 742 and undetectable 
haptoglobin. His peripheral smear showed many schistocytes. These findings were 
consistent with thrombotic microangiopathy. Urine analysis showed 2+ blood, 3+ protein. 
Examination of the urinary sediment revealed oval fat bodies, and some RBCs. The patient 
was started on plasma exchange and prednisone (1 mg/kg). Further studies revealed a serum 
albumin of 2.2 and urine protein/Cr of 9. Kidney biopsy showed features of membranous 
nephropathy with many subepithelial deposits flanked by new basement membrane material 
(spikes). The deposits were immunoreactive for PLA2R, with IgG1 but no IgG4 reactivity. 
In addition, there was moderately severe arterial and arteriolar sclerosis and segmentally 
prominent double contour formation in the glomeruli. These vascular changes suggest a 
primary form of endothelial injury and consistent with chronic thrombotic microangiopathy. 
VWF protease activity came back as less than 3% with an elevated inhibitor titer of 1.3 
(reference <0.4 BEU). Anti-PLA2R was detected in the serum at titer of 40.3 RU/ml. 
Both were exclusively of the IgG1 subtype by western blotting, atypical of the usual IgG4 
predominance for both autoimmune disorders.
Discussion: Although prednisone, plasmapheresis, and supportive therapy have 
thus far stabilized both diseases, rituximab would be our first choice for more definitive 
treatment of these concurrent autoimmune disorders. This unique case may help to further 
our understanding of the mechanistic pathways underlying both of those clinical entities.
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TH-PO1053
Carfilzomib Associated Acute Kidney Injury  Vladimir Liberman,1 Vivette D. 
D’Agati,2 Naveed N. Masani,1 Joseph Mattana,1 James Drakakis.1  1Medicine, 
Winthrop-Univ Hospital, Mineola, NY; 2Pathology, Columbia Univ Medical 
Center, New York, NY.
Introduction: Carfilzomib is a selective proteasome inhibitor approved in 2012 for 
the treatment of relapsed and refractory multiple myeloma. A phase 2 trial of the drug 
showed an increased serum creatinine in 17.7% of patients but the mechanism has been 
incompletely understood. We report a case of biopsy proven acute tubular injury one week 
after carfilzomib administration.
Case Description: A 60 year old man with IgG lambda multiple myeloma who received 
an autologous stem cell transplant 2 years ago presented to the hospital complaining of 
shortness of breath and chest discomfort. Physical examination revealed a blood pressure of 
141/74, clear lungs, normal heart sounds with no murmurs and pitting edema of both lower 
extremities. Serum potassium was 6.3 mEq/L and creatinine was 3.4 mg/dL (baseline 0.8 mg/
dL). Serum free lambda light chains were 3630 and free kappa light chains were 5.55. The 
patient had received an injection of carfilzomib 7 days prior to his arrival. He had no other 
exposure to nephrotoxic medications. Spot urine protein/creatinine ratio was 3g/g with an 
albumin/creatinine ratio of 140mg/g. Obstruction was excluded by ultrasonography and he 
received isotonic saline with only minimal improvement in kidney function at which point a 
kidney biopsy was performed. Renal biopsy showed focal mild myeloma cast nephropathy 
with diffuse acute tubular injury out of proportion to the sparse casts. The close temporal 
association with the initiation of carfilzomib suggests that it could have been responsible 
for the severe tubular injury given no other obvious insults.
Discussion: Carfilzomib has been associated with kidney injury as one of its adverse 
effects in its phase 2 trial. Most of the kidney injuries were reported as grade 1 or 2 based 
on the NIH grading system. Grade 3 and 4 renal impairment was reported in 38 patients 
(7.2%). This case of biopsy proven acute tubular injury suggests a mechanism by which 
carfilzomib may cause acute kidney injury in patients with multiple myeloma.
TH-PO1054
Podocyte Infolding Glomerulopathy in a Patient of African Decent 
Laith Al-Rabadi,1 Cathryn J. Byrne-dugan,2 David Olafsson,3 Saif Alrabadi,4 
Laurence H. Beck,1 Helmut G. Rennke,2 Stanley D. Crittenden.1  1Boston Medical 
Center; 2Brigham and :omen¶s Hospital; 3Univ of Iceland; 4Jordan Univ.
Introduction: Podocyte infolding glomerulopathy (PIG) is a rare entity primarily 
described in Japan which is frequently associated with autoimmune diseases like lupus. It 
is not known whether PIG represents a new disease entity or a transient morphologic state 
of well-known diseases (i.e. a subset of membranous nephropathy or lupus nephritis). PIG 
has been exclusively described in Asian populations, with no cases reported in patients 
of African descent. PIG is distinguished by its histologic features of podocyte membrane 
infolding into the basement membrane and the formation of microspheres and microtubules. 
The majority of cases do not contain electron-dense deposits, nor do they show any reactivity 
with IgG.Here we present the first reported case of PIG in a patient of African descent.
Case Description: A 58 year old Africa female from Ghana with history of systemic 
lupus erythematosus presented to the nephrology clinic for the evaluation of proteinuria. She 
was found to have a serum creatinine of 1.5 mg/dL and random urine protein to creatinine 
ratio of 1.5 g/g. Microscopic examination of the urine sediment did not reveal RBCs or 
cellular casts. Other notable lab findings include anti nuclear antibody titer of 1:2560 
and positive anti double stranded DNA. She underwent kidney biopsy. Light microscopy 
revealed thickened glomerular peripheral capillary walls, with numerous crater-like 
defects. Immunofluorescence was negative other than trace IgM and C3 reactivity along 
the peripheral capillary walls and in the mesangium. No electron dense deposits were found 
on electron microscopy (EM). However, widespread aggregates of spherical structures 
within the lamina rara externa and lamina densa along with diffuse invaginations of the 
podocytes at the subepithelial aspect of the basement membrane, with deposition of spherical 
microparticles were seen on EM.
Discussion: Further studies are warranted to investigate whether this represents a 
unique primary disease with a specific underlying pathology or if it is simply a morphologic 
reflection of a transition point for a previously discovered disease entity.
TH-PO1055
Amyloidosis  due to R554L Fibrinogen Aα-Chain Mutation 
Matthew R. Lynch,1 Ian Mccoy,3 Isaac Ely Stillman,2 Stewart H. Lecker.1  1Div. 
Nephrology, Beth Israel Deaconess Medical Center, Boston, MA; 2Pathology, 
Beth Israel Deaconess Medical Center, Boston, MA; 3Medicine, Beth Israel 
Deaconess Medical Center, Boston, MA.
Introduction: Cases of systemic amyloid caused by mutations in the fibrinogen 
A-alpha chain (Afib) were once thought to be quite rare, but may be more common than 
initially thought. Mutations in Afib leading to hereditary amyloidosis, primarily with 
renal manifestations, was first described in 1993. A significant minority of Afib amyloid 
patients have the R554L variant. To date, about 20 such cases have been published. Small 
sample sizes have limited definitive conclusions regarding genotype-phenotype correlation.
Case Description: A 66-year-old man with a history of hypertension, hyperlipidemia, 
and prior heavy NSAID use was referred for two years of stable, nephrotic-range proteinuria. 
Besides lower extremity edema managed with compression stockings, he was asymptomatic. 
He had no family history of kidney disease. His medications included losartan, torsemide, 
and simvastatin. His exam was unremarkable except for pitting edema to the knees. 
Laboratory studies revealed a stable serum creatinine of 1.1 mg/dl. A 24 hour urine protein 
measured 4180 mg. Urine sediment showed lipiduria but no cells or casts. Testing for 
hepatitis B and C, HIV, and ANCA was negative. Serum and urine protein electrophoresis 
showed no monoclonal protein. Renal ultrasonography was unremarkable. Kidney biopsy 
showed massive glomerular deposition of Congo Red positive and apple-green birefringent 
material. Liquid chromatography tandem mass spectrometry detected mutant R554L amino 
acid sequence in the fibrinogen A-alpha chain.
Discussion: Afib patients progress from presentation to ESRD over a mean of 4.6 
years with mean survival of 9.3 years after ESRD. Recurrent amyloidosis occurs in renal 
allografts, but this process takes several years. While orthotopic liver transplantation may 
cure the amyloidosis by replacing the source of the mutant fibrinogen, the procedure-related 
mortality is high, making the benefit of preemptive liver transplantation unclear. With 
increasing recognition of this disease, further investigation into curative therapy is needed.
TH-PO1056
Diabetes Insipidus Induced by Excessive Intake of Melatonin  Rahul N. Pawar, 
Savneek S. Chugh, Amy R. Patel.  Nephrology, Westchester Medical Center, 
Valhalla, NY.
Introduction: Melatonin is produced by the pineal gland and regulates the sleep/wake 
cycle in humans. Specific over the counter melatonin formulations can be used to treat 
circadian-rhythm-related sleep disorders and age-related insomnia. Acute intoxication of 
melatonin and its deleterious effects have rarely been reported.
A 24 year old female, with no known medical history, was brought to the hospital for 
altered mental status and possible drug overdose. Her vital signs were a Tmax of 101.8 
F, HR 170, BP 150/103, and a pulse oximetry of 98% on 2L NC. On physical exam, she 
had mildly dilated and sluggish pupils. Due to an altered sensorium, she was intubated for 
airway protection. Initial lab tests showed a sodium of 140 mEq/L, potassium 3.9 mEq/L, 
chloride 113 mEq/L, bicarbonate 25 mEq/L, BUN 8 mg/dL, and a creatinine of 0.6 mg/dL 
with no osmolar gap, but elevated AST 74 U/L, ALT 37 U/L and creatine phosphokinase of 
2,460. Urine toxicology screen was negative for PCP, cocaine, MDMA, and opioids with 
an undetectable blood alcohol level. On day 1, she developed polyuria with a urine output 
of more than 13.5 liters, a serum sodium of 147 mmol/L and urine osmolarity of 65 mOsm/
kg concerning for diabetes insipidus (DI). CT head and MRI of the brain were negative 
for intracranial lesions. Despite decreasing the rate of intravenous fluids, her urine output 
was more than 8L/day. Her urine osmolality increased to 444 mOsm/kg suggestive of a 
partial central DI. With the administration of DDAVP, her urine output decreased to 2-3L/
day. After extubation, the patient reported ingestion of an excessive amount of melatonin 
for insomnia, but no other medications. She received DDAVP for 4 days with complete 
resolution of hypernatremia and polyuria.
Discussion: Extensive literature review revealed that rat studies show how melatonin 
regulates the glomerular filtration of both sodium and water. It stimulates sodium tubular 
transport in the proximal tubules but its receptor or action on the distal tubule is unknown. 
Only a handful of cases have shown that it can cause polyuria. This rare case of polyuria 
from the acute ingestion of melatonin, which responded to DDAVP, may suggest its role 
in causing partial central DI.
TH-PO1057
Localization of Ectopic Fibroblast Growth Factor 23 Production in Tumor-
Induced Osteomalacia Using a 2-Step Selective Venous Sampling Method 
Karyne Pelletier, Veronique Bienvenue, Myriam Lessard, Stephan Troyanov. 
Medicine, Hôpital du Sacré-Coeur, Univ of Montreal, Montreal, QC, Canada.
Introduction: Tumor-induced osteomalacia (TIO) is a rare syndrome characterised 
by hypophosphatemia, impaired renal phosphate reabsorption and inappropriate reduction 
of serum 1,25(OH)vitamin D usually caused by benign mesenchymal tumors secreting 
FGF23. Affected individuals present severe osteomalacia with bone pain, pseudofractures 
and muscle weakness. Although TIO is cured by the resection of the causative tumor, 
definitive treatment is often delayed because current imaging techniques (MRI and bone, 
octreotide and PET scans) fail to localize the offending lesion. We propose localization of 
ectopic FGF23 tumors using 2-step selective venous sampling method.
Case Description: A 37-year-old patient presented with bone pain and 
hypophosphatemia. An initial workup showed >75% fractional excretion of phosphate, 
normal serum calcium and intact PTH, low 25(OH) vitamin D. Peripheral blood FGF23 
level was 310 RU/mL (N:19-114). Initial imaging failed to localize an obvious lesion. A 1st 
venous sampling suggested FGF23 drainage from the left subclavian vein. A second focused 
sampling pointed to the left external jugular vein. The excision of an initially unsuspected 
small mandibular lesion cured the patient. 
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Discussion: A recent cases review (Andreopoulou, J Bone Min Research 2011) supports 
the benefits of systemic venous sampling in locating FGF23 tumors in TIO. However, up 
to 30 samples are needed when using a single venous sampling method. Since lesions are 
small and may arise anywhere, we propose a 2-step approach simplifying the localization 
of causal lesions.
Funding: Government Support - Non-U.S.
TH-PO1058
Renal Transplant Dysfunction due to Calcium Casts following 
Parathyroidectomy  Maharajan Raman,1 Rajkumar Chinnadurai,1 Grahame N. 
Wood,1 Jamil Choudhury,2 Philip A. Kalra.1  1Renal Medicine, Salford Royal NHS 
Foundation Trust, Salford, Manchester, United Kingdom; 2Cellular Pathology, 
Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom.
Introduction: Parathyroidectomy for renal hyperparathyroidism can lead to significant 
drop in calcium levels due hungry bone syndrome, which can lead to seizure, coma 
or fractures. Current practice is to pre-load patients with hydroxycholecalciferol and 
calcium supplements to maintain safe calcium levels in the post-operative period. We 
report a case of calcium cast nephropathy causing significant renal dysfunction following 
parathyroidectomy.
Case Description: A transplant patient on Cinacalcet for tertiary hyperparathyroidism 
underwent parathyroidectomy(PTX). Post operatively her calcium levels were managed 
according to local protocol. Patient sub-acutely developed renal dysfunction and the trends 
in creatinine(Cr), corrected calcium(C.Ca) and parathyroid hormone levels(PTH) pre and 
post surgery are shown in the table below.
Pre PTX 1 month post
2 months 
post
3 months 
post
4 months 
post
6 months 
post
Cr (umol/L) 113 167 132 169 284 103
C.Ca (mmol/L) 2.73 2.62 2.55 2.71 2.67 2.38
PTH (ng/L) 329 - 54 - - -
Virology screen, immunology screen, urine culture, urine PCR, DSA, Cyclosporin 
levels and renal ultrasound were normal with no change in patients haemodynamic status. 
Hence a kidney biopsy was performed to identify the cause, which showed evidence of 
calcium casts with surrounding infllammation with no evidence of rejection. Her steroid 
dose was transiently increased due to the inflammation seen on the biopsy and all her 
calcium and hydroxycholecalciferol supplements were suspended, which lead to recovery 
of her renal function to baseline.
Discussion: Our patient had mild hypercalcaemia prior to parathyroidectomy with a 
stable renal function and following parathyroidectomy patient developed renal dysfunction 
despite similar levels of calcium, which can only be explained by iatrogenic calcium 
supplementation based on the renal biopsy. Perhaps routine monitoring of urinary calcium 
may help us guide the amount of calcium given to such patients and aiming for lower levels 
of calcium post parathyroidectomy rather than normal levels may prevent such phenomenon.
TH-PO1059
Severe Ketoacidosis After Bariatric Surgery in a Patient Treated 
with Canagliflozin  Hossein Ghofrani, Christopher C. Wong, Miroslaw 
Smogorzewski.  Div of Nephrology, Keck Hospital of USC, Los Angeles, CA.
Introduction: Euglycemic diabetic ketoacidosis is relatively uncommon and is usually 
caused by starvation and a lack of caloric intake. Sodium-glucose cotransporter-2 (SGLT-2) 
inhibitors have been very recently implicated as a cause of severe ketoacidosis. We report 
a case of euglycemic diabetic ketoacidosis in a patient who underwent bariatric surgery 
while taking an SGLT-2 inhibitor, canagliflozin.
Case Description: A 38 year old male with a history of DM type 2 and morbid 
obesity presented with fatigue, acute dyspnea, decreased exercise capacity and 2-3 pillow 
orthopnea for two days. Canagliflozin 300 mg daily was initiated 3 months prior to his 
current presentation due to poorly controlled DM-2. Ten days prior to his hospitalization, 
he underwent gastric sleeve bypass surgery and was discharged on post-op day 1. Upon 
admission in the ICU, his physical exam was benign except for a PR 108/min, RR 29/min, 
and a normal BP 128/69 mmHg. ABG showed pH 6.9, pCO2 13mmHg, pO2 99mmHg, 
bicarbonate 5mg/dL. His anion gap was 37, and serum glucose 152 mg/dL, with normal 
kidney function. Urine toxicology and blood levels of lactic acid and alcohol were negative. 
Urinalysis revealed pH 5.0, glucose >1000 mg/dL, and ketones>150 mg/dL. During the 
first day, he received 150 meq of sodium bicarbonate; his canagliflozin was held. He was 
intubated and started on a regular insulin drip along with 5% dextrose solution. He remained 
intubated and on an insulin drip for 7 days, receiving a total of 1266 units of insulin 
and extensive electrolyte replacement; blood glucose never exceeded 200 mg/dL while 
glycosuria persisted until day 7. C-peptide increased from 0.29 to 2.26 ng/mL. Once anion 
gap was closed and patient stabilized, he was extubated and weaned off the insulin drip.
Discussion: We present a new case of severe euglycemic DM ketoacidosis, induced by 
a combination of SGLT-2 inhibitor use and low caloric intake after bariatric surgery. Despite 
withdrawal of canagliflozin, its effect on glycosuria persisted for 7 days. Considering long 
biological effect of SGLT-2 inhibitors, they should be stopped weeks before a bariatric 
surgery to avoid ketoacidosis.
TH-PO1060
Severe Hypercalcemia in Erdheim-Chester Disease: A Rare Clinical 
Scenario  David H. Slade,1 Esho Georges,2 Ahmer Farooq,3 Kavitha Vellanki.2 
1Dept of Medicine, Loyola Univ Medical Center, MayZood, IL; 2Dept of 
Nephrology, Loyola Univ Medical Center, MayZood, IL; 3Dept of Urology, 
Loyola Univ Medical Center, MayZood, IL.
Introduction: Erdheim-Chester disease (ECD) is a rare form of histiocytosis with 
highly variable clinical manifestations. Only a few hundred cases have been reported in 
the literature to date. It is characterized by proliferation of non-Langerhans cells that can 
infiltrate all vital organs. Infiltration of the retroperitoneal space and subsequent fibrosis may 
cause bilateral ureteral obstruction leading to progressive renal failure. Here, we present a 
case of severe hypercalcemia, work up of which eventually lead to the diagnosis of ECD.
Case Description: A 58 year old Polish male with chronic kidney disease due to 
obstructive uropathy from bilateral ureteral obstruction was transferred to our center for 
suspected pyelonephritis. His course was complicated by persistent fevers with repeatedly 
negative infectious work up and severe hypercalcemia with ionized calcium levels peaking 
at 1.66 mm/L. Parathyroid hormone levels were appropriately suppressed. Work up for 
multiple myeloma showed no lytic lesions on bone scan, however, bilateral, symmetric, 
sclerotic lesions in the distal femurs and proximal tibias were incidentally noted. Based on 
these findings, ECD was suspected. This was confirmed with bone marrow biopsy which 
revealed multiple histiocytic and lymphocytic aggregates positive for the histiocyte marker 
CD68, but negative for CD1a (pathognomonic of the disease). He was subsequently started 
on BRAF (v-raf murine sarcoma viral oncogene homolog B1) inhibitor, vemurafenib 
with marked improvement in clinical symptoms. While he received pamidronate for 
hypercalcemia during the hospital stay, his ionized calcium levels have since normalized 
and continue to be within normal range 6 months after the initial presentation.
Discussion: In conclusion, ECD is a rare disorder with varied clinical manifestations 
and diagnosis is often elusive, requiring a high level of clinical suspicion. Although skeletal 
involvement is seen in 96% of the patients with ECD, there have been no reported cases of 
hypercalcemia, and our case is the first to report such an association.
TH-PO1061
APOL1 Polymorphisms in Deceased Donors and Primary Glomerular 
Disease Post-Kidney Transplant: First Case Report  Pratik B. Shah, 
Alexander C. Wiseman, James E. Cooper.  Renal Diseases and Hypertension, 
Univ of Colorado Medical Center, Aurora, CO.
Introduction: Genetic polymorphisms in APOL1 (G1/G2) are associated with 
glomerular disease and ESRD. An emerging issue is whether screening for APOL1 (G1/
G2) should be performed in living or deceased kidney donors.
Case Description: A 46 year-old Caucasian male with a history of SLE received a 
deceased donor kidney transplant. The deceased donor was a 12-year old African American 
male. 9 months post-transplant, he presented with acute kidney injury following an elective 
laparoscopic cholecystectomy (CCK). 2 weeks prior to surgery his SCr was at baseline, 
1.5 mg/dl with no proteinuria. On postop day 0-CCK, his SCr was 7.9 mg/dl, with spot 
UPC of 2 g/g Cr, platelet count of 58000, LDH of 2022 U/L, haptoglobin of <14 mg/dl. 
Renal transplant biopsy showed collapsing glomerulopathy with no evidence of thrombotic 
microangiopathy or rejection. Plasma CMV PCR was positive at 2340000 copies/ml. The 
patient’s acute kidney injury was attributed to collapsing glomerulopathy in the setting of 
acute CMV infection. The patient ultimately did not recover kidney function. The patient’s 
deceased donor DNA was analyzed for APOL1 risk variant genotyping and was positive 
for two APOL1 risk variants: compound heterozygosity for APOL1 G1, c.1024A>G; 
p.Ser342Gly and APOL1 G2 c.1164delTTATAA. The sister kidney from the same deceased 
donor had been transplanted to a 63 year old female with ESRD from diabetes. Six months 
post-transplant, she had new onset proteinuria of 2.5 g/d, and a renal biopsy demonstrated 
focal segmental glomerulosclerosis (FSGS). Her renal function and proteinuria remain 
stable 14 months post transplant.
Discussion: To our knowledge, this is the first case report of high risk variant APOL1 
in a deceased donor with subsequent primary glomerular disease in both the recipients. This 
suggests that deceased kidney donor APOL1 genotyping may be informative in predicting 
graft outcomes. This also highlights the important question of whether routine screening of 
African American donors for high risk APOL1 variants before renal transplant is warranted. 
This consideration must be balanced against the significant limitations in kidney availability.
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TH-PO1062
Atypical HUS in an Infant due to a Novel Gene Mutation  Mohamed Alseiari,1 
Robin Amy Kremsdorf,2 M. Khurram Faizan.2  1Rhode Island Hospital; 2Hasbro 
Children¶s Hospital; 3Hasbro Children¶s Hospital.
Introduction: Atypical HUS (aHUS) is a rare genetic renal disease associated with 
over- activation of the alternative pathway of complement. A variety of mutations have 
been described in the complement pathways genes in patients with aHUS. We report a 
case of aHUS with a novel genetic mutation in the Complement Factor B (CFB) gene.
Case Description: 10 months old Caucasian girl who presented with diarrhea, vomiting, 
and swelling in her extremities and face for 2 weeks preceded by an episode of cough, runny 
nose with non-bloody diarrhea. Upon presentation her BP was 150/90 mm Hg. Lab data 
showed Hgb 4.4 g/dl, Platelets, 46 x10exp9/L, Cr elevated to 0.46 mg/dl from baseline of 
0.3, Albumin 2.6 g/dl, LDH 632 IU/L, normal ADAMTS13 and C3 level 7.9 mg/dl. Urine 
revealed 32RBC/hpf with proteinuria, Urine protein Creatinine ratio 19 g/g. Peripheral 
blood smear revealed schistocytes. Stool was negative for Shiga toxin. Clinical presentation 
was strongly suggestive of aHUS and patient was treated with Eculizumab. She developed 
worsening anasarca with neck edema, requiring a tracheotomy after failed intubation. She 
required RRT for volume management during her hospital course after failing diuretics . 
Renal biopsy showed acute and chronic thrombotic microangiopathic changes consistent 
with aHUS. Genetic testing revealed a novel mutation in the complement Factor B gene 
in the region of binding to Von Willebrand factor. It also showed a heterozygous deletion 
of CFHR1 andCFHR4. Patient recovered renal function 3 weeks after presentation. C3 
remained low after recovery of renal function. RRT was stopped after two weeks and she 
was discharged on ACEI with Eculizumab every 2 weeks.
Discussion: Gain of function mutations in CFB are extremely rare in aHUS and occur 
in only 1% to 2% of cases of familial aHUS. There is increased C3b affinity and form 
hyperactive C3 convertase that is resistant to dissociation, thus increasing C3b formation. 
Anti C5 Antibody Eculizumab has revolutionized the care of aHUS, improving the overall 
prognosis of these patients. This case is the first case reported with this novel CFB gene 
mutation. No long term data avaiable regarding the outcomes of aHUS with Eculizumab 
therapy.
TH-PO1063
Oxymorphone-Induced Thrombotic Microangiopathy and Acute Kidney 
Injury  Girish Singhania, Shriharsha Kallahalli Jayaramu, Dara N. Wakefield, 
Amir Kazory.  Nephrology, Univ of Florida, Gainesville, FL.
Introduction: Intravenous (IV) administration of oral oxymorphone represents 
an emerging pattern of drug abuse with increasing popularity and unforeseen adverse 
consequences. Here, we present a case of IV Oxymorphone abuse associated with thrombotic 
microangiopathy (TMA) and acute kidney injury (AKI).
Case Description: A 32-year-old man with a history of IV drug abuse presented with 
non-healing left arm wound. Physical examination was unremarkable except for a left 
forearm abscess. However, laboratory studies revealed a serum creatinine (SCr) of 2.3 mg/
dL. He was found to have severe anemia with a Hb level of 5.8 g/dL, platelets of 135,000/
µL and evidence of hemolysis (LDH of 579 U/L, undetectable serum haptoglobin, and 
schistocytes on peripheral blood smear). He had proteinuria of 4.1 gm/day and the urine 
drug screen was positive for oxymorphone. Serum complement levels were normal as were 
all other immunologic studies. ADAMTS13 level was >100%. Kidney biopsy showed 
evidence of TMA supported by glomeruli filled with focal extravasated and crenated RBCs. 
Immunofluorescence (IF) was negative for immune complex deposition but C4d staining 
was positive. Conservative management including platelet transfusion, without plasma 
exchange (PE), was followed by stabilization of renal function.
Discussion: This patient presented with TMA, acute kidney injury, and normal serum 
ADAMTS13 activity. His urine oxymorphone was positive and he admitted to IV abuse of 
pulverized oxymorphone pills, which represents an emerging pattern of illicit drug abuse. 
The mechanism of oxymorphone-induced TMA remains unclear but it is suggested that 
the drug or some ingredients mixed in it triggers a cascade of immunological pathways 
leading to TMA. Previously reported cases had negative IF on kidney biopsy but positive 
C4d staining in this patient implies some degree of complement activation. Although PE 
was initially used in some cases, it has recently been shown that oxymorphone-induced 
TMA could successfully be managed without it. Based on this case coupled with previous 
reports, we suggest that health care providers should inquire about IV Oxymorphone abuse 
in the setting of unexplained TMA and acute kidney injury.
TH-PO1064
IgG-4 Related Tubulointerstitial Nephritis in a Young Patient with Enlarged 
Kidneys  Valerie Jorge Cabrera,1 Shirin Shirani,2 Joni H. Hansson.3  1Yale 
Nephrology, Yale School of Medicine, New Haven, CT; 2Nephrology, Yale New 
Haven Hospital/St. Raphael Campus, New Haven, CT; 3Nephrology, Yale New 
Haven Hospital/St. Raphael Campus, New Haven, CT.
Introduction: IgG-4 related disease is a recently recognized entity characterized by 
the infiltration of tissues with IgG-4 positive plasma cells. It occurs more commonly in 
middle age men and affected organs can be diffusely enlarged, sometimes with nodular 
lesions that can mimic tumors. We present the unique case of a young patient with a two 
year history of recurrent cellulitis, parotid gland enlargement, diffuse lymphadenopathy 
and nephromegaly.
Case Description: A 27 year old African American male presented with a rash 
and edema of his right lower extremity. He also reported night sweats and weight loss 
over 4 months. His past medical history included hypertension, recurrent cellulitis, 
nephrolithiasis, chronic kidney disease of unclear etiology, antithrombin III deficiency 
and pulmonary embolism. Prior imaging had shown bilateral hilar, retroperitoneal and 
mesenteric lymphadenopathy. However, lymph node and parotid gland biopsies were non 
diagnostic. On examination, he was afebrile but tachycardic. Parotid glands were enlarged 
and cardiovascular, lung and abdominal examination were unremarkable. His creatinine 
was 2.5 mg/dL, elevated from 1.8 mg/dL without significant proteinuria. A C3 level was 
41 mg/dL and C4 was less than 10 mg/dL. An IgG-4 level was elevated to 2045 mg/dL. 
A renal biopsy was obtained and although the lack of glomeruli was limiting, the tissue 
revealed a dense plasma cell rich infiltrate in the interstitium consistent with an interstitial 
nephritis. Immunostains were positive for IgG4 in the infiltrating plasma cells. Treatment 
was initiated with prednisone 40 mg daily. His creatinine decreased to 1.3 mg/dL with 
resolution of his symptoms.
Discussion: A number of conditions can lead to kidney enlargement. Diabetes, HIV, 
amyloidosis and leukemia/lymphoma are commonly included in the differential diagnosis. 
IgG-4 related disease should also be considered in the differential diagnosis of patients 
presenting with kidney enlargement and recurrent infections.
TH-PO1065
Karyomegalic Interstitial Nephritis: A Rare Cause of Kidney Disease 
Lindsay Sanders,1 Maxwell L. Smith,2 Ibrahim Qaqish,1 Sumi Sukumaran 
Nair,1 Leslie F. Thomas.1  1Nephrology and Hypertension, Mayo Clinic Arizona, 
Phoenix, AZ; 2Pathology, Mayo Clinic Arizona, Scottsdale, AZ.
Introduction: Karyomegalic interstitial nephritis (KIN) is a rare, progressive kidney 
disease associated with Fanconi-associated nuclease 1 (FAN1) mutation as well as exposure 
to heavy metal, ochratoxin,or viral pathogens. Less than 50 cases have been reported in 
the literature. Onset of the disease is often in the third decade and may be associated with 
a history of recurrent upper respiratory tract infections. There is no known treatment.
Case Description: A 45-year-old male was seen for renal impairment first noted at age 
40, with a serum creatinine of 1.6 mg/dL (eGFR 53 mL/min/1.73 m2). He had no known 
risk factors for chronic kidney disease. His only other personal medical history was for 
skin changes of his lower extremities consistent with pigmented purpuric dermatosis. He 
had no known exposures to heavy metals or toxins. He reported renal disease of unclear 
etiology in one sister. At time of consultation, he had a combined eGFR of 46. Urinalysis 
and serologic studies were normal, and ultrasound demonstrated kidneys of normal size 
with echogenic parenchyma. Renal biopsy demonstrated KIN. Significant findings by light 
microscopy included 1) 8 of 33 glomeruli appearing normal with the remaining 25 glomeruli 
being globally sclerosed, 2) moderate to severe fibrosis of the tubulointerstitial compartment 
with associated tubular atrophy, 3) marked pleomorphism of tubular cells with prominently 
enlarged nuclei, pleomorphic nuclei, and multinucleation, and 4) moderate predominately 
lymphocytic and plasma cellular inflammatory cell infiltrate. Electron microscopy showed 
a hypodense chromatin pattern with slight nuclear membrane irregularities.
Discussion: The diagnosis of KIN should be considered especially when there is a 
family history of kidney disease of unclear etiology. Karyomegalic cells can be found 
elsewhere in the body, including the brain, lung, and liver. Testing for heavy metals and 
ochratoxin may be useful. Urine cytology may identify atypical cells. Genetic testing 
should be considered, including for mutation of FAN1. Literature to date suggests steroid 
treatment may be of use in some cases.
TH-PO1066
Hypodipsic Hypernatremia: An Unusual Manifestation of Paraneoplastic 
Syndrome  Sahar Siddiqui, Sun-Young Ahn, Asha Moudgil.  Nephrology, 
Children¶s National Medical Center, :ashington, DC.
Introduction: Hypernatremia usually results from increased free water losses or 
impaired thirst perception.
Case Description: A 17-year-old female presented to the emergency room after an 
episode of syncope while waiting for school bus on a summer morning. She had intermittent 
episodes of slurred speech over the previous 2 weeks but denied polyuria, polydipsia, 
dizziness or headaches. She was diagnosed with primary amenorrhea one year ago. Physical 
Exam: Weight 46 kg (5%ile), height 150 cm (<3%ile), BP 92/58 mmHg and afebrile. She 
was slow to respond and had slurred speech. She was Tanner III for breast & I for pubic 
hair. The remainder of her exam was normal. Laboratory evaluation showed hemoglobin 
11.2g/dl, hematocrit 37.8%, platelet 100x109/L, sodium 177 mmol/l, potassium 4.3 mmol/l, 
chloride 139 mmol/l, CO2 32 mmol/l, BUN 55 mg/dl, creatinine 2.5mg/dl, glucose 91 mg/
dl, calcium 9.7 mg/dl,serum Osm 375 mOsm/kg, urine Osm 678 mOsm/kg, ADH level 
2.2 pg/ml(nl). Urinalysis: specific gravity 1.016, pH 5.5, 1+ protein, trace blood. A renal 
ultrasound showed a right suprarenal mass which was confirmed to be an adrenal mass on 
CT scan. Despite adequate intravenous hydration, her hypernatremia persisted. Due to low 
LH & FSH there was a concern for hypogonadotropic hypogonadism. However, brain MRI 
was normal. DDAVP was initiated with partial response. The patient underwent a right 
adrenalectomy; pathology was consistent with ganglioneuroma. At the time of discharge, 
her serum sodium was 138mmol/l and her serum creatinine 0.8 mg/dl.
Discussion: The cause of hypernatremia in this case was likely an impaired thirst 
mechanism in a cognitively normal child. Her partial response to DDAVP suggests an 
additional contribution from partial diabetes insipidus. Essential hypernatremia and an 
adrenal ganglioneuroma expressing sodium level sensors (Nax) were reported in a 6 year 
old child by Hiyama et al. (Neuron 2010; 66(4): 508-522). The mechanism of hypernatremia 
was postulated to be impaired thirst due to antibodies to Nax in the brain. A diagnosis of 
paraneoplastic syndrome should be considered in a patient with hypodipsic hypernatremia 
without structural hypothalamic lesions.
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TH-PO1067
IgG4 Mediated Isolated Reteroperitoneal Fibrosis Causing Obstructive 
Uropathy in a Patient with Subclinical Ankylosing Spondylitis 
Ayman H. Morgan, Vikram Aggarwal.  Internal Medicine/ Nephrology Div, 
SUNY Upstate Medical Univ, Syracuse, NY.
Introduction: Retroperitoneal fibrosis is a rare manifestation of systemic autoimmune 
disease, characterized by the presence of inflammatory and fibrous retroperitoneal tissue that 
often encases the ureters causing obstructive uropathy. Idiopathic retroperitoneal fibrosis 
is recently being recognized manifestation of IgG4-related disease. We report a case of 
histologically confirmed IgG4 related retroperitoneal fibrosis in a patient with subclinical 
Ankylosing spondylitis . This association has been rarely reported.
Case Description: A 70 year old male with PMH of HTN, diabetes and baseline 
creatinine of 1.2 mg/dl presented with weakness, vomiting and decreased urine output. 
Physical examination was unremarkable. Further evaluation revelaed serum creatinine of 
13.3 mg/dl and BUN=106 mg/dl. He also has mild hyperkalemia and anion gap metabolic 
acidosis. Urine analysis was negative for protein or RBC cast. A CT scan of the abdomen 
and pelvis, showed retroperitoneal mass, Aortitis, ankylosis of SI joint bilaterally with 
osseous fusion and bilateral mild hydronephrosis. Bilateral nephrostomy tubes were placed 
with excellent urine output as well as improvement of creatinine to baseline in 48 hours. He 
subsequently had a CT guided biopsy of the reteroperitoneal mass. Histopathology revealed 
dense fibrous tissue with significant IgG4 positive plasma cell infiltrate. Immunological 
workup showed elevated level of IgG4 as well as positive HLA-B27.Hence this obstructive 
uropathy was confirmed to be due to IgG4 related retroperitoneal fibrosis. He also met the 
clinical and imaging criteria for Ankylosing spondylitis. Treatment with oral corticosteroids 
was initiated by rheumatology.
Discussion: Our hypothesis is that the patient had a subclinical Ankylosing Spondylitis 
which trigged IgG4 mediated disease that lead to retroperitoneal fibrosis which caused 
bilateral obstructive uropathy. Hence role of ankylosing spondylitis in development of 
idiopathic retiperitonal fibrosis via IgG4 mediated pathways warrants further consideration 
and for nephrologists to be aware of this rather unusual presentation.
TH-PO1068
IgG4-Related Tubulo-Interstitial Nephritis with Low Complement C4, 
Circulating Immune Complexes and an Elevated IgG4, Presenting as 
Unilateral Hydronephrosis and Prostatitis  Cornelius J. Doorenbos,1 
Annemarie A. Van norel,1 Christiaan F.M. Klok,2 M.m. Smits,3 Peter Van den 
Tillaar.4  1Nephrology, Deventer Hospital, Deventer, Netherlands; 2Radiology, 
Deventer Hospital, Deventer, Netherlands; 3Pathology, Deventer Hospital, 
Deventer, Netherlands; 4Urology, Deventer Hospital, Deventer, Netherlands.
Introduction: IgG4-Related Disease is characterized by infiltrates of IgG4-positive 
plasma cells and eosinophils in different organs and is a rare cause of tubulointerstitial 
nephritis (TIN) and idiopathic retroperitoneal fibrosis.
Case Description: A 67 year old white male had a creatinine increase from 0.90 to 2.06 
mg/dl. He had fatigue and dyspnea. Complement C3 was normal, C4 low 0.06 g/l, C1Q-BA 
28% (N <8%), but ANA/ENA, DsDNA, AST, ANCA, HBV, HCV and M-protein were 
negative, IgG4 3.0 g/l (N 0.08-1.40 g/l). Urine showed 3 RBC/HPF, protein 0.36 g, albumin 
61 mg per 24h. On ultrasound both kidneys were 13 cm with right sided hydronephrosis 
and 300 ml urinary retention. CT-Urography showed obstruction of the right ureter at the 
iliac artery. A bladder catheter and ureteral stent did not improve renal function. A MAG-
III scan showed a non-functioning right kidney without hydronephrosis on ultrasound. On 
revision, the CT showed soft tissue surrounding the aorta and the right iliac artery. A kidney 
biopsy showed TIN with a dense infiltrate of IgG4-positive plasma cells and eosinophils 
with impressive fibrosis, a vein showed obliterative phlebitis, consistent with IgG4-related 
TIN. He was treated with prednisolon 40 mg daily and after 1 week he reported a dramatic 
clinical improvement, his creatinine decreased to 1.7 mg/dl.
Discussion: Hydronephrosis first dominated the clinical picture, delaying diagnosis, 
but the low C4, positive C1Q-BA and large kidneys suggested IgG4-related TIN. We found 
only one report of IgG4-related TIN with hydronephrosis, but that was after urinary tract 
tuberculosis. Rare cases were reported of IgG4-related segmental ureteritis or prostatitis 
without TIN and the cases of IgG4-related TIN had no hydronephrosis. The present case is 
the first with coincident biopsy-proven IgG4-related TIN, ureteral obstruction and prostatitis. 
Hydronephrosis does not exclude, but may be part of IgG4-related disease.
TH-PO1069
Monoclonal Light Chain Proximal Tubulopathy with Unique Ultrastructural 
Microtubular Inclusions  Hiba M. Ahmed,1 Hone S. Kaw,1 Mandeep Samra,1 
Smita Mahendrakar,1 Suneet Verma,1 Jennine Michaud,1 Fang Bu,2 Nicholas 
Cassai,2 Rosemary Wieczorek,2 Michael Yudd.1  1Nephrology, Dept of Veterans 
Affairs (VA) NJ Health System, East Orange, NJ; 2Pathology, New York Harbor 
Healthcare System, New York, NY.
Introduction: Renal disease related to monoclonal gammopathies is common and 
varied. An uncommon lesion is proximal light chain tubulopathy (PLCT), which may 
present with Fanconi syndrome (FS) and variable degrees of renal failure. Most have 
ultrastructural (US) findings of proximal tubule damage with crystalline inclusions of κ 
LC’s within proximal tubular cells (PTC). A minority of PLCT do not have crystals; these 
may have Ȝ LC restrictions. We describe a patient with a rare finding: PLCT with light 
chain (LC)-related microtubular inclusions.
Case Description: 74 year old man had progressive CKD over 2 years with serum 
creatinine 2.1 mg/dl. A serum M spike, 1.0 g/dl of IgGκ, was present. Urine protein, 1200 
mg/day, contained 13% albumin, and 45% M spike of IgGκ. No findings of FS. Renal 
biopsy abnormalities were limited mainly to the proximal tubules (PT). The PTC’s were 
bright red on trichrome stain and showed granular cytoplasmic changes and marked cell 
shedding. Congo red stain was negative. On immunofluorescence, the cytoplasm of PTC’s 
stained 3-4+ for total Ig and κ. IgG, IgM, IgA and Ȝ were negative. On EM, non-branching 
microtubules, ranging in size from 26- 36 nm were membrane bound within PT lysosomes. 
No amyloid filaments or crystalline structures were seen. Bone marrow subsequently showed 
a low grade B cell lymphoma with clonal κ B cells and small population of κ plasma cells.
Discussion: Two large biopsy reports of monoclonal renal disease found PLCT to 
be very uncommon, 0.5 – 4%. Most have findings of crystalline inclusions, less without 
crystals. To our knowledge, there are only 2 other cases with inclusions similar to our 
findings. Free LC’s are freely filtered and rapidly endocytosed into PTC’s via the tandem 
receptors megalin/cubulin for catabolism in the lysosomes. The variable domain of the 
abnormal LC’s may be resistant to proteolysis. Specific characteristics of the LC’s and 
their resistance to metabolism may determine the varied US appearances.
TH-PO1070
IgG1-kappa Monoclonal Membranous Nephropathy Associated with 
Systemic Lupus Erythematosus  Stephen W. Roderer, Anjali A. Satoskar, 
Tibor Nadasdy, Isabelle Ayoub, Brad H. Rovin, Samir Parikh.  The Ohio State 
Univ, Columbus, OH.
Introduction: Monoclonal gammopathy of renal significance is a recently described 
condition in which monoclonal protein is found in the kidney but often without a circulating 
clone. This has not been previously associated with SLE. Here, we describe two cases of 
monoclonal immune deposition causing membranous nephropathy in SLE.
Case Description: Case 1: An 18 year old female with SLE developed nephrotic 
syndrome with 4g/d proteinuria and normal serum creatinine. Immunofluorescence (IF) on 
renal biopsy showed diffuse IgG1-kappa staining in the mesangium and along the capillary 
loops. Lambda staining was negative. Electron microscopy (EM) showedintramembranous 
and subepithelial electon-dense deposits. Work up for systemic monoclonal gammopathy 
including bone marrow biopsy was negative. She was diagnosed with IgG1-kappa 
monoclonal membranous nephropathy associated with SLE. She was treated with 
mycophenolate mofetil and prednisone and achieved partial remission. Case 2: A 38 
year old female with SLE developed proteinuria of 2.5g/d and microscopic hematuria. 
Similar to case 1, IF on renal biopsy showed diffuse granular IgG1-kappa deposition in 
the mesangium and along the capillary loops. Lambda staining was negative. EM revealed 
mesangial and subepithelial electon-dense deposits. Work up for a systemic monoclonal 
gammopathy, including serum and urine immunofixation and serum free light chains was 
negative. A diagnosis of IgG1-kappa monoclonal membranous nephropathy associated 
with SLE was made. She was started on an ACEi and prednisone with improvement in 
proteinuria from 2.5g/d to 800mg/d.
Discussion: These 2 cases represent a newly described form of monoclonal 
membranous nephropathy associated with SLE. In both cases the monoclonal protein was 
restricted to the kidney. The pathogenesis is unclear but may be due to autoreactive b-cells 
producing an abnormal clone locally in the kidney. The clinical significance must still be 
elucidated but it may impact treatment and long-term outcomes so clinicians caring for 
SLE patients should be aware of this association. Further, these patients may develop a 
systemic monoclonal gammopathy, so close monitoring is necessary.
TH-PO1071
IgG1-κ Anti-Glomerular Basement Membrane Disease  Jehan Z. Bahrainwala,1 
Afshin K. Hannani,2 Jonathan J. Hogan.1  1Renal, Electrolyte and Hypertension 
Div, Hospital of the Univ of Pennsylvania, PA; 2Mercer Renal Insts Inc, Trenton, 
NJ.
Introduction: Anti-GBM disease is caused by polyclonal IgG that binds to the NC1 
domain of the a3 chain of type IV collagen on glomerular and pulmonary capillary walls. 
It presents with severe glomerulonephritis and/or pulmonary hemorrhage and typically 
does not relapse. A recent case report described relapsing, necrotizing and crescentic 
glomerulonephritis associated with linear IgG1-κ antibody staining on IF. Here, we report 
a second case of this entity.
Case Description: A 38 year old African American woman presented 4 years ago 
with respiratory (cough, hemoptysis) and gastrointestinal (emesis, diarrhea) symptoms. 
She had severe AKI (peak Cr 8.6 mg/dL), microscopic hematuria and a urine protein/
creatinine ratio (UPCR) of 3.3 g/g. A kidney biopsy showed focal necrotizing and crescentic 
glomerulonephritis with liner IgG1κ GBM staining and moderate-severe interstitial 
inflammation. No electron dense deposits were noted on EM. Anti-GBM (ELISA), ANCA 
and paraprotein studies were negative. She had a C3 level of 76(88-201) mg/dL and a 
normal C4. She underwent induction therapy with pulse methylprednisolone and oral 
prednisone 60 mg/day, PLEX x 4 sessions and oral cyclophosphamide (150 mg/day) for 
6 months; followed by azathioprine for 1 year. Her Cr improved to 1.2 mg/dL, UPCR to 
55mg/g and her hematuria resolved. 4 years after her initial presentation, she developed 
respiratory symptoms (cough, sinus congestion), RUQ pain, emesis, gross hematuria and 
AKI (Cr 2.4 mg/dL). A second kidney biopsy again demonstrated focal necrotizing and 
crescentic glomerulonephritis with liner IgG1κ GBM staining with mild interstitial fibrosis. 
Her serologic workup was again negative for Anti-GBM antibodies, ANCAs or paraprotein. 
She was treated with pulse steroids and rituximab 1000 mg IV X 2.
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Discussion: This is the second reported case of necrotizing and crescentic 
glomerulonephritis associated with IgG1-κ anti-GBM antibody. It is unknown if this disease 
is driven by an underlying autoimmune process or monoclonal gammopathy. Both cases 
are atypical for classic anti-GBM disease due to their relapsing nature.
TH-PO1072
First Reported Case of Collagenofibrotic Glomerulopathy in a Patient 
with Multiple Myeloma  Arun Rajasekaran,1 Indraneel Mogarala,2 Lillian W. 
Gaber,3 Jai Radhakrishnan,4 Ala Abudayyeh.5  1Internal Medicine, UCF College 
of Medicine, FL; 2Div of Renal Diseases & Hypertension, UT- Medical School 
at Houston, Houston; 3Pathology, The Methodist Hospital, Houston; 4Div of 
Nephrology, Columbia Univ Medical Center, New York; 5Section of Nephrology, 
The Univ of Texas MD Anderson Cancer Center, Houston.
Introduction: Collagenofibrotic glomerulopathy is an extremely rare idiopathic 
glomerular disease characterized by abnormal accumulation of atypical spiraled and 
frayed type III collagen fibrils in mesangial and subendothelial areas, and elevated 
serum procollagen III and hyaluronan levels. Proteinuria (commonest feature), edema, 
hypertension, and occasional progression to ESRD are commonly seen. We report the first 
published case of Collagenofibrotic glomerulopathy in Multiple Myeloma.
Case Description: A 54 year old  male with recent history of IgG Kappa Multiple 
Myeloma (May 2011); with underlying CKD stage 3 and baseline Creatinine at 2 mg/dl; in 
remission status-post autologous stem cell transplant (January 2012) and on Lenalidomide 
maintenance therapy, presented with proteinuria of 4g. Kidney biopsy revealed Nodular 
and Focal glomerulosclerosis with IF weakly (+) for IgG, IgA, IgM, c3, c4, c1q, Kappa and 
Lambda light chains with +3 staining for IgM and c1q. EM showed patchy foot process 
effacement with massive deposition of collagen-III fibers. The weak and non-specific 
staining, along with massive collagen-III fiber deposition fitted with the description of 
Collagenofibrotic glomerulopathy, and made an immune mediated kidney injury less likely.
Discussion: Discussion: Collagenofibrotic glomerulopathy is an extremely rare disease 
characterized by massive intraglomerular atypical type III collagen fiber deposition. 
Proteinuria is the cardinal manifestation of this disease. Clinically, patients present with 
edema and hypertension and often progress to ESRD. Etiology and pathogenesis remains 
elusive. Most cases are seen in Japan and an autosomal-recessive mode of inheritance has 
been described. Definitive diagnosis is established by identifying collagen-III fibrils by IF 
and EM with special staining. No specific treatment is available unfortunately.
TH-PO1073
Severe Acute Kidney Injury (AKI) with Organomegaly in a 
17 Days Old Newborn: When Pathology Makes the Difference 
Marie-Michele Gaudreault-Tremblay, Catherine Litalien, Natalie Patey, Aicha 
Merouani.  CHU Sainte-Justine, Montreal, QC, Canada.
Introduction: Acute tubulointerstitial nephritis (ATIN) is a significant cause of AKI 
in children and is often due to allergic drug reactions or infections. Diagnosis of ATIN is 
usually clinical and renal biopsy not routinely performed.
Case Description: A previously healthy 17 days old baby presented with decreased oral 
intake, vomiting and oligoanuria. His first laboratory results showed an elevated creatinine 
(1.7mg/dL) with metabolic acidosis, hyponatremia (Na107mEq/L), hyperkalemia (K 8.8 
mEq/L) and thrombocytopenia (platelets 16x1012/L). His urinalysis was abnormal (proteins 
3gr/L, WBC >50/hpf, RBC 21-3/hpf, positive nitrites). An ultrasound revealed bilateral 
kidney enlargement with a heterogeneous parenchyma and hepatosplenomegaly. Intravenous 
fluid, broad-spectrum antibiotics, calcium chloride and sodium bicarbonate were started. He 
was intubated for respiratory failure and required dialysis for fluid overload. With worsening 
of his condition, a kidney biopsy was performed and showed a massive and polymorph 
infiltrate with destruction of tubular structures [Fig.1, A-B]. Ischemic glomeruli, double 
glomerular membranes and mesangial oedema [Fig.1, C-D] were observed. Administration 
of steroids were followed by improvement of his renal function and cessation of dialysis 
after 6 days. The patient has been disease-free since.
Renal biopsy findings were consistent with severe ATIN. The most likely etiology for 
his ATIN was a urinary tract infection as this patient was not taking any medication and a 
follow-up cystography revealed a left grade III vesicoureteral reflux.
Discussion: ATIN is rare in neonates and usually drug-induced. This is the first report of 
a renal biopsy-proven ATIN in a neonate. Even if procedural risks of a renal biopsy are not 
negligible, it can make the difference in certain cases by dictating appropriate management.
TH-PO1074
AL Lambda Amyloidosis in Kidney Transplant Allograft as a Cause of 
Massive Nephritic Syndrome with AKI That Responded to Chemotherapy 
Noaman Siddiqi,1 Manish K. Saha.1  1Dept of Nephrology, Univ of Alabama, 
Birmingham, AL; 2Dept of Nephrology, Univ of Alabama, Birmingham, AL.
Introduction: This interesting case showed AL lambda amyloidosis in kidney 
transplant allograft as a cause of massive nephritic syndrome with AKI that responded 
to chemotherapy. 51 year old African American female with history of ESRD secondary 
to APKD s/p DDKT in Oct 2010 with Thymoglobulin induction, maintained on 3 drug 
immunosuppression including tacrolimus, mycophenolate and prednisone with baseline 
creatinine of 1.5, presented with anasarca and orthostatic hypotension. Her serum albumin 
was 1.2mg/d. She underwent extensive investigations including Echo, transplant allograft 
ultrasound all of which came back unremarkable. She has sudden onset sub nephritic range 
proteinuria in Aug 2013 which progressed to nephritic range in Feb 2014. She has 34g of 
protein on a 24h urine collection 90% of which was albumin. Her UPCR gradually got 
worse from 10 to 32 with worsening in serum Cr from 1.5 to 5.5. She has poor response 
to IV Lasix with albumin infusion and has severe orthostatic symptoms. Her SPEP and 
UPAP were negative. Serum IFE was also negative. Urine IFE showed lambda light chain. 
Serum free light chain showed elevated lambda levels. Due to worsening and explosive 
proteinuria with worsening anasarca renal allograft biopsy was done that showed lambda 
AL amyloidosis involving glomeruli, arterioles and arteries along with light chain proximal 
tubulopathy. Congophilic casts consistent with light chain cast nephropathy. Pt underwent 
bone marrow biopsy that did not show MM. She was treated with bortezomib combined 
with cyclophosphamide and dexamethasone and has good response with improvement in 
orthostatic hypotension, serum albumin level and lambda light chain got normal.
TH-PO1075
Granulomatous Interstitial Nephritis Caused by T-Cell Lymphoma 
Yoshitatsu Ohara,1 Namiko Kobayashi,1,2 Yohei Kono,1 Tomoharu Yoshimine,1 
Mariko Ichijo,1 Toshiyuki Hirai,1 Keiko Suzuki,3 Takayuki Toda,1 Michio 
Nagata,2 Noriaki Matsui.1  1Dept of Nephrology, Tsuchiura Kyodo General 
Hospital, Tsuchiura, Ibaraki, Japan; 2Renal Pathorogy, Univ of Tsukuba, 
Tsukuba, Ibaraki, Japan; 3Dept of Pathology, Tsuchiura Kyodo General Hospital, 
Tsuchiura, Ibaraki, Japan.
Introduction: Granulomatous tubulointerstitial nephritis (GTIN) occurs 0.5-1.3% in 
renal biopsy samples. Granuloma is basically caused by type IV allergy; T cell-mediated 
mechanism against drug, foreign bodies and microorganisms such as Mycobacterium. We 
here present, a rare case of GTIN associated with T cell lymphoma.
Case Description: Sixty-year-old man with uncontrolled diabetes complained right 
chest pain. Chest and abdominal CT revealed multiple abscesses formations in the right 
lung, right chest wall, liver and right retroperitoneum. Although no distinct bacterium 
was identified from the liver abscess, the patient was treated by antibiotics, tazobactam/
piperacillin(TAZ/PIPC). It was not effective. During the antibiotics treatment, renal 
dysfunction and skin rashes on extremities occurred. Renal biopsy revealed GTIN with 
collapsing glomeruli. Light microscopy showed diffuse interstitial inflammatory infiltrates 
predominantly with mononuclear cells including some atypical cells, which invaded tubular 
basement membrane resulting impaction of these cells in the tubular lumina. Since drug 
induced lymphocyte stimulation test (DLST) was positive for TAZ/PIPC, we once diagnosed 
as drug-induced GTIN in this patient. Despite stopping antibiotics, his renal function was 
not recovered. Meanwhile, atypical lymphoid cells were detected in the urine cytology and 
serum soluble IL2 receptor was significantly increased. Immunohistochemistry revealed 
hypercellularity of monotonous atypical lymphocytes stained with T-cell markers, CD3 
and CD5, and then diagnosed as GTIN caused by T-cell lymphoma. Although CHOP 
chemotherapy induced remission of lymphoma and disappearance of multiple abscess 
formation, the kidney dysfunction was unimproved.
Discussion: The case reminds us T-cell lymphoma as an additional cause of GTIN.
TH-PO1076
Pauci-Immune Glomerulonephritis and Escherichia Coli Bacteremia: A 
Mere Coincidence or a True Causal Association?  Marwan M. Abu Minshar, 
Wihib A. Gebregeorgis.  Nephrology, Wayne State Univ S.O.M, Detroit, MI.
Introduction: Antineutrophil cytoplasmic antibody (ANCA) associated vasculitides 
are systemic autoimmune diseases affecting small to medium sized blood vessels. Pauci-
immune necrotizing glomerulonephritis (GN) is one of the manifestations. Triggering 
factors for ANCA associated vasculitis are not well-defined. Systemic infections have been 
implicated in the pathogenesis.
Case Description: A 67 year old patient was admitted to the hospital from a nursing 
home for a Foley catheter associated Escherichia coli (E. coli) urinary tract infection & 
bacteremia leading to septic shock and acute kidney injury/acute tubular necrosis with a 
peak serum creatinine (Cr) of 3.8 mg/dl. She had recently been hospitalized for subarachnoid 
hemorrhage that was treated conservatively and her serum Cr at that time was 0.9 mg/dl. 
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She promptly responded to standard treatment of septic shock and her serum Cr improved 
to 1.6 mg/dl on discharge. Ten days later, she was readmitted to the hospital after a follow 
up visit to her primary physician where a routine blood work showed her serum Cr to 
be elevated to 6.8 mg/dl. Urine sediment revealed several RBCs and few granular casts. 
Anti-myeloperoxidase antibody was positive with a titer of 1:640. Other serological tests 
were negative. Her renal function declined further and she was initiated on hemodialysis. 
A renal biopsy was consistent with pauci-immune necrotizing and crescentic GN. She was 
treated with steroids, intravenous cyclophosphamide and plasmapheresis following which 
she came off dialysis & her serum Cr stabilized around 1.8 mg/dl.
Discussion: Anti-LAMP-2 antibodies, a subtype of ANCA antibodies directed against 
lysosome-associated membrane protein-2 (LAMP-2) have been reported in patients with 
pauci-immune necrotizing GN, often in coexistence with anti-PR3 & anti-MPO antibodies. 
Infections with bacteria that express the bacterial adhesin FimH (mostly E. coli), which has 
100% homology with the human LAMP-2 epitope, are believed to trigger autoimmunity via 
molecular mimicry. In our patient, the onset of ANCA positive necrotizing GN in a close 
temporal association with E. coli bacteremia suggests a possible causative relationship.
TH-PO1077
Cryoglobulinemic Vasculitis and Glomerulopathy Associated with Chronic 
Lymphocytic Leukemia  Narottam Regmi, Albert Braverman, Swaty Arora, 
Raavi Gupta, Subodh J. Saggi.  Nephrology, SUNY Downstate Medical Center, 
Brooklyn, NY.
Introduction: Cryoglobulinemia manifests as ischemic or occlusive vasculopathy with 
or without renal involvement. Early stage Chronic lymphocytic leukemia( CLL) has not been 
reported with vasculitic lesions as its first manifestation. We report a rare case of Stage I 
CLL with cutaneous,renal and cerebral lesions due to monoclonal Type I cryoglobulinemia.
Case Description: A 60year-old woman presented with abdominal pain due to 
retroperitoneal hematoma from a ruptured right gonadal artery, which was embolized. 
Labs included eukocytosis, anemia with mild azotemia.Flow cytometry was consistent with 
CLL.The patient was readmitted with a serum creatinine of 11.2 mg/dL and proteinuria 
and required hemodialysis. There were extensive lesions on her lower extremities and a 
necrotic left forearm ulcer. Renal biopsy revealed membranoproliferative glomerulonephritis 
with deposition of IgG kappa light chain cryoglobulins as intraluminal hyaline deposits 
(Figure 1), infiltrates consistent with CLL and thrombi in intrarenal arteries. Biopsy was 
complicated by hematoma leading to left nephrectomy. Plasmapheresis was initiated for 
cerebral infarcts related to cryoglobulinemia. Despite leukemia treatment and regular 
hemodialysis her clinical condition deteriorated and patient expired.
The pathophysiology of GN in CLL is possibly due to glomerular deposition of immune 
complexes and/or paraproteins.Review of the literature reveals a small number of cases of 
MPGN associated with CLL and cryoglobulinemia.
Discussion: Vasculitic presentations,bleeding or thrombotic and/or renal failure in 
the setting of CLL may be manifestations of cryoglobulinemia. Because of potential rapid 
progression, as in this case, regular urinalysis and testing for cryogloblulins should be 
considered in all stages of CLL, with possible renal biopsy when cryoglobulinemia and 
proteinuria are detected.
TH-PO1078
PGNMID in a Patient with Hepatitis C  Mohamed Alseiari, Susie L. Hu. 
Alpert Medical School of Brown Univ.
Introduction: Proliferative glomerulonephritis with monoclonal IgG deposits 
(PGNMID) is infrequently associated with hematological disease but more commonly 
presents like an immune-complex glomerulonephritis. Few have reported cases associated 
viral infections such as hepatitis C. We report a case of PGNMID in a patient with active 
HCV infection.
Case Description: A 56 year-old male with refractory hepatitis C (post treatment with 
interferon and Ribavirin), HTN and coronary artery disease presented with rising creatinine 
(peak 5.3 mg/dl) from baseline ( 0.9 ml/dl a year ago) and no kidney disease in family. He 
reported months of progressive fatigue, dyspnea on excretion, nausea, vomiting, and dark 
urine. He endorsed chronic Ibuprofen use for leg pain. On examination BP was normal 
with clear lungs and no edema. Urinalysis revealed blood but minimal proteinuria with 
urine protein to creatinine ratio of 0.5 g/g and albumin 4.2 g/dL. Complements were low 
(C3 83 mg/dL, CH50 <10 U/mL). HCV-RNA quantification was 1.7 million copies. SPEP, 
plasma light-chains, ANA, ANCA, Anti GBM, HIV, Hep B serologies were normal. Bone 
survey was negative. Renal biopsy revealed diffuse linear staining of glomerular basement 
with monoclonal IgG1/Kappa immunoglobulin and endocapillary focal glomerulonephritis, 
chronic interstitial nephritis with ATN. Renal function did not improve until Prednisone 
was initiated, down to 3.3 mg/dL. Cyclophosphamide was started after discussion with 
his gastroenterologist. Antiviral therapy has been delayed until further improvement of 
renal function.
Discussion: We report a case of PGNMID associated with HCV. There are 2 other 
reports of HCV associated PGNMID however with membranous glomerulonephritis 
pathology. 30% of PGNMID patients have same heavy- and light-chain isotypes as the 
glomerular deposits. Membranoproliferative (57%) or endocapillary proliferative (35%) 
are the most two common histological variants. Nasr et al in a series of 32 patients reported 
after an average of 30.3 months of follow-up, 38% had complete or partial recovery, 38% 
had persistent renal dysfunction, and 22% progressed to ESRD. Viral infection such as 
HCV associated immune disorders could be implicated in the pathogenesis. Currently, 
there is no consensus regarding the management of this entity.
TH-PO1079
Myeloma Cast Nephropathy with Acute Renal Failure, Skin Rash, 
Eosiphiluria, and Low Complement C4 Level  Mustafa G. Aly,1 Mamoun Elsir 
Bashir,1 Irfan Warraich,2 Aumyot Prongdong,1 Weeraporn Srisung.1  1Internal 
Medicine, Nephrology Dept, Texas Tech Univ Health Science Center, Lubbock, 
TX; 2Pathology Dept, Texas Tech Univ Health Science Center, Lubbock, T;.
Introduction: We here report myeloma cast nephropathy with skin rash, eosinophiluria 
and low complements which is a very atypical presentation of this renal condition.
Case Description: A 53y Caucasian female was admitted with 3 day confluent 
erythematous skin rash, acute renal failure with s.Cr 17.6 with a normal baseline renal 
function of s.CR 0.7mg/dL. Five days prior, she was prescribed cephalexin for root canal 
infection. Initial diagnosis of acute interstitial nephritis was made but patient didn’t respond 
after stopping antibiotics and steroid course trial. urine exam showed WBC clumps and no 
casts. Serological biomarkers were done and reported Negative ANA, ANCA, cryoglobulins, 
Hepatitis B, Hepatitis C and HIV. Complement C4 was low with normal C3. Patient’s 
laboratory workup showed normocytic normochromic anemia and pseudohyponatremia 
per osmolality check, SPEP and SFLC ordered and was positive for M-spike with free 
light chain analysis showing predominant Lambda more than 4 g/L. Renal biopsy showed 
myeloma cast nephropathy.
Bone marrow biopsy confirmed MM with 80% plasma cell. Patient received bortezomib 
+dexamethasone + cyclophosphamide chemotherapy and her renal function completely 
improved after being dialysis dependent for about 12 weeks with. Patient is being evaluated 
for BM transplant after chemotherapy response.
Discussion: Multiple Myeloma can cause renal damage in many ways which sometimes 
can be misleading and very uncharacteristic. Up to our knowledge, this presentation is quite 
uncommon in literature and hence we suggest including myeloma related kidney injury 
in such clinical presentation.
TH-PO1080
A Rare Case with ANCA-Related Necrotizing Glomerulonephritis without 
Nephritic Features or Systemic Vasculitis  Mustafa G. Aly,1 Faisal Jamal,1 
Maria Gabriela Suarez,1 Irfan Warraich,2 Aumyot Prongdong.1  1Internal 
Medicine, Nephrology Dept, Texas Tech Health Science Center, Lubbock, T;; 
2Pathology Dept, Texas Tech Health Science Center, Lubbock, T;.
Introduction: We report an atypical and unusual case of ANCA necrotizing 
glomerulonephritis with no significant nephritic features or systemic vasculitic picture.
Case Description: A 78 year-old African American female with history of controlled 
hypertension was admitted with diagnosis of pneumonia and renal failure and was treated 
empirically with antibiotics. Despite antibiotic treatment, she had persistent leukocytosis 
and pneumonia was ruled out by negative WBC scan and CT chest. Urine had pre-renal 
pattern and urinalysis was bland twice. Renal ultrasound was unremarkable except for 
hyperechoic kidneys. Despite aggressive hydration for 10 days, renal function continued 
to worsen. Patient was never oliguric. Serum biomarkers were checked due to unexplained 
renal failure which reported negative hepatitis B, C and HIV as well as normal Complement 
C3, C4, ANA, dsDNA and antiphospholipid panel. Normal SPEP with no M spike. UPEP 
showed faint IGG monoclonal band in the ALPHA-2 region. SFLC was negative. Bone 
marrow biopsy showed normal cellularity. Although patient had no obvious systemic 
vasculitic features, but due to renal failure and persistent non-specific respiratory symptoms, 
ANCA was checked and was positive for anti-MPO antibodies. Renal biopsy showed 
pauci-immune acute necrotizing glomerulonephritis (Figure 1) with negative Ant-GBM 
and immune fluorescence. Patient was treated with cyclophosphamide, high dose steroids 
and plasmapheresis.
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Discussion: The patient had advanced necrotizing GN but never developed nephritic or 
systemic vasculitic features and UA was persistently bland. The probability of diagnosing 
ANCA associated GN based upon above clinical presentation was significantly low, making 
this an unusual case.
TH-PO1081
Bilateral, Multifocal Renal Tumors Diagnosed as Birt-Hogg-Dubé 
Syndrome Confirmed by Genetic Analysis  Seokwoo Park,1 Sehoon Park,1 
Eunjeong Kang,1 Hae Il Cheong,2 Dong Ki Kim,1 Yon Su Kim,1 Kwon Wook 
Joo,1 Hajeong Lee.1  1Dept of Internal Medicine, Seoul National Univ Hospital, 
Seoul, Korea; 2Dept of Pediatrics, Seoul National Univ Children¶s Hospital, 
Seoul, Korea.
Introduction: Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant disorder 
characterized by skin fibrofolliculomas, pulmonary cysts and spontaneous pneumothorax, 
and renal cancers. The syndrome is caused by germline mutations of the FLCN gene 
located in 17p11.2 encoding folliculin. The risk of renal cancer is seven times higher in 
BHD patients. Bilateral, multifocal and chromophobe renal cell carcinoma is characteristic 
of renal cancers in BHD. Among about 110 pathogenic mutations reported in BHD, only 
twenty six of them have been associated with renal cancer. In this study, we described a 
case of 50-year-old woman with chromophobe renal cell carcinoma who had c.1557delT 
mutation in the FLCN gene which is novel in BHD-associated renal cancer.
Case Description: A 50-year-old-woman presented with flank pain. A CT scan of 
abdomen showed multifocal tumors in both kidneys. To differentiate the origin of the tumors, 
a chest CT and a whole body PET-CT were carried out, although there was no other lesion 
except a few lentiform cysts at basal lungs. Histologic evaluation through a needle biopsy 
revealed that the mass was chromophobe type renal cell carcinoma. The patient underwent 
partial nephrectomy. Given multifocal distribution of the renal cell carcinoma, we suspected 
an inherited form of kidney cancer. Although she denied any specific familial history, the 
cystic change of both lungs and chromophobe renal cell carcinoma pointed towards the 
possibility of BHD. DNA sequencing of the entire FLCN gene identified a heterozygous 
c.1557delT mutation in exon 14 [p.Phe(TTT)519Leu(TTA)fs*18].
Discussion: Once multifocal renal masses are diagnosed as renal cell carcinoma, 
histologic subtype, family history and other clinical features should be considered to 
recognize familial renal cancer syndromes. Multifocal chromophobe renal cell carcinoma 
should prompt genetic test for BHD even in a patient without typical skin lesion. In our 
patient, c.1557delT mutation was found out which has been first reported in BHD-associated 
renal cancers.
TH-PO1082
The First Case of Steroid Responsive Renal Involvement of Mycosis 
Fungoides without Sezary Syndrome  Jinuk Jeong, Kitae Bang, Jongho Shin. 
Dept of Internal Medicine, The Eulji Univ School of Medicine, Daejeon, Korea.
Introduction: Mycosis fungoides (MF) is a mature T cell non-Hodgkin lymphoma with 
presentation in the skin but with potential involvement of the nodes, bloods and viscera. 
Renal lymphomatous involvement in MF has received limited attension. We present a rare 
case of moderate dose steroid responsive lymphomatous renal involment with acure renal 
injury which occured in solitary kidney.
Case Description: A 39-year-old man presented with fever, right flank pain with a rise 
of creatinine 10.54mg/dl ,one month prior being 1.4mg/dl. He donated his left kidney 10 
years ago. He had recurrent prutitic rash before MF was diagnosed by skin biopsy. 4 years 
prior to his presentation, he received several different course of chemotherapy, including 
cyclophosphamide, adriamcin,vincristin, and prednisone (CHOP), alpha-interferon. 
Ultrasound revealed normal echogenicity with right kidney 14 cm. Urinalysis showed 
protein 1+, WBC cast and no hematuria. He was treated first with antibiotics in case of 
acute pyelonephritis. He defervessed within two days, However, his renal function kept 
declining. Hemodialysis was performed . On the 6th day. Renal biopsy was performed. 
Renal biopsy showed that Numerous atypical lymphocytes with hyperchromatic, indented, 
variably sized nuclei were infiltrated in the tubulointerstitium.
After treatment with methyprednisolone 40mg , level of creatinine improved up to 
baseline.
Discussion: To our knowledge, this is the first report of steroid responsive renal 
involvement of MF. Renal involvement in non-Hodgkin lymphoma has been reported, 
including AKI , glomerulonephritiws, and infiltration of renal parenchyma by lymphoma 
cell. Renal manifestations of MF are especially rare and there are only few cases pulblished 
to date. But there has been no case which showed steroid response except this case.
TH-PO1083
A Case of Cryoglobulinemic Nephropathy with Successful Childbirth 
After Recurrent Episodes of Nephrotic Syndrome During Pregnancy 
Miho Karube, Kazuhito Fukuoka, Yoshihiro Arimura.  The First Dept of Internal 
Medicine, Kyorin Univ School of Medicine, Mitaka, Tokyo, Japan.
Case Description: A 35-year-old woman was admitted to our hospital because of 
massive proteinuria that developed during the third pregnancy. The previous two pregnancies 
had been terminated because of similar episodes of nephrotic syndrome. No history of 
hypertension was observed, but during the course she presented cryoglobulinemia, a high 
titer of RF and low serum complements. The renal biopsy performed 10 days after the 
third termination revealed MPGN-like lesions with lobulation in glomeruli, double contour 
of GBM, endotheliosis, and moderate mesangial cell proliferation. Immunofluorescence 
study showed IgG, IgA, IgM, C3, C4, and C1q all positive mainly along the glomerular 
capillaries, and subendothelial deposits were confirmed by EM, thus she was diagnosed 
as cryoglobulinemic nephropathy. Because the histological findings of repeated renal 
biopsy were not improved two months after the disappearance of proteinuria, treatment 
with 30 mg/day of PSL was started, followed bv intravenous cyclophosphamide 6 times 
and plasma exchange, since she had a desire for baby. Finally at the fourth pregnancy, she 
bore a healthy baby weighing 2,342g on vaginal delivery at 36 weeks despite of recurrent 
appearance of nephrotic syndrome. After delivery, she was given 30 mg/day of PSL and 
proteinuria subsided.
Discussion: We experienced a rare case of the type III cryoglobulinemic nephropathy 
that repeatedly developed nephrotic syndrome during pregnancy, but finally bore a baby after 
immunosuppressive therapy. The pathogenesis of pregnancy-induced nephrotic syndrome 
in cryoglobulinemia in this patient was not known, aggressive treatment may be helpful 
for ameliorating nephropathy, leading to successful delivery.
TH-PO1084
A Case of Glomerular Lipidosis with Type III Hyperlipoproteinemia 
Exhibiting Nephrotic Syndrome  Rei Miura,1 Kaori Fujimoto,1 Aya 
Sakanashi,1 Tomoaki Onoue,1 Kengo Kajiwara,1 Masao Tomita,1 Taku Miyoshi,2 
Masataka Adachi,2 Yukimasa Koda,2 Masashi Mukoyama.2  1National Hospital 
Organization Kumamoto Medical Center; 2Kumamoto Univ.
Introduction: Lipid deposition and accumulation in glomeruli are sometimes 
recognized in kidney biopsy specimens, especially in focal segmental glomerulosclerosis 
and diabetic glomerulosclerosis, but glomerular lipidosis other than such conditions is 
rarely seen.
Case Description: A 77-year-old woman was admitted to our hospital because of 
nephrotic-range proteinuria. She was diagnosed as chronic thyroiditis 8 years before, 
after which she started to have levothyroxine and remained uneventful. Three weeks 
before coming to our hospital severe edema developed rapidly, and she gained 10 kg of 
body weight in 6 months. Laboratory examinations showed nephrotic syndrome with mild 
renal dysfunction (s-Alb 2.1 g/dL, urinary protein 7.97 g/gCr, s-Cr 0.95 mg/dL), marked 
dyslipidemia (T-Chol 712 mg/dL, TG 1191 mg/dL) and poorly controlled hypothyroidism 
(TSH 45.2 µIU/mL, free T4 0.83 ng/mL). Genetic test for APOE revealed homozygosity of 
apoE2 and immunoelectrophoresis for lipoprotein showed type III hyperlipoproteinemia. 
Renal biopsy revealed the presence of intracapillary lipid thrombi and foam cells; electron 
microscopy demonstrated lipid droplet accumulated mainly in mesangial cells, whereas 
podocytes, endothelial cells and tubular cells were rather unremarkable. Immunofluorescent 
studies showed no significant deposits in glomeruli. Intense lipid-lowering therapy with 
bezafibrate and ezetimibe improved hyperlipidemia, with only a partial effect on proteinuria 
(~5 g/gCr).
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Discussion: We report here a case of glomerular lipidosis associated with type III 
hyperlipoproteinemia exhibiting nephrotic syndrome. We suggest that hyperlipidemia with 
glomerular lipid accumulation would have a pathogenic role for glomerulopathy, but other 
factors might be involved in causing nephrotic syndrome.
TH-PO1085
Successful Treatment of Crescentic Glomerulonephritis (GN) in 
Hypocomplementemic Urticarial Vasculitis Syndrome (HUVS) 
Ramchandur Bakhtiani, Mark G. Parker.  Nephrology, Maine Medical Center, 
Portland, ME.
Introduction: HUVS is a rare autoimmune systemic disorder characterized by chronic 
urticaria, low complements and extracutaneous organ involvement. Kidney involvement 
is not uncommon (50% of cases), usually of benign nature. The glomerular injury pattern 
varies from mesangial proliferation to membranoproliferative glomerulonephritis (MPGN). 
Crescentic MPGN in HUVS is rare; only six cases have been reported in world literature, 
many with poor outcomes. We present a case of crescentic GN successfully treated with 
substantial remission.
Case Description: A 55-year-old Caucasian female with a previous episode of hives 
was admitted to hospital with features of both acute nephritic and severe nephrotic syndrome. 
She had 6 months history of persistent hives, fatigue, fevers, arthralgia, self-limited recurrent 
angioedema episodes, and generalized lymphadenopathy. Lymph node biopsy displayed 
reactive hyperplasia. Her serum creatinine was 4 mg/dl, urine protein to creatinine ratio was 
23, serum albumin was 1.4 gm/dl and urinary sediment showed > 100 RBCs, > 10 hyaline 
casts/HPF. Serologic workup was positive for very low C3 andC4 and ANA titer of 1:80. 
Anti-dsDNA, cryoglobulins, anti-SSA, anti-SSB, chronic hepatitis panel, and workup for 
paraproteinemia all were negative. C1q levels were undetectable. Anti C1q antibody was 
not performed. Renal biopsy revealed immune complex crescentic MPGN with IgG, IgA, 
IgM, C3 and C1q deposits on immunofluorescence. Treatment was started initially with 
high dose glucocorticoids followed by addition of mycophenolic acid and losartan. Her 
systemic symptoms and acute kidney injury resolved completely. Nephrotic syndrome 
improved slowly. After 6 months of therapy her proteinuria decreased to 4.5g per day and 
serum albumin increased to 3.8 g/dl.
Discussion: Crescentic GN associated with HUVS appears to convey a poor renal 
prognosis. Based on available information in five of six reported cases, three progressed 
to end stage renal disease; one had near complete renal recovery and another had partial 
recovery with persistent nephrotic range proteinuria. Relatively good outcome in our case 
may aid to our understanding of this uncommon and newly recognized disease process.
TH-PO1086
An Unusually Early Presentation of Pre-Eclampsia  David Bennett, Renu 
Regunathan-Shenk, Maya K. Rao.  Medicine, Div of Nephrology, Columbia 
Univ Medical Center, New York, NY.
Introduction: Pre-eclampsia affects approximately 3-6% of pregnancies in the United 
States. It is defined as new onset hypertension and proteinuria in pregnancy. By definition, it 
occurs after 20 weeks gestation. However, earlier cases have been reported in the literature.
Case Description: The patient is a 45 y/o woman, 16 weeks + 4 days pregnant with 
twins (IVF with donor embryo), with a PMHx significant for obesity and borderline HTN 
who presented with 6 weeks of progressive swelling that had worsened in the past week. 
3 weeks prior to presentation, the pregnancy was complicated by worsening hypertension, 
ranging 140’s-160’s/90’s-100’s, for which she was started on labetalol. On presentation, 
her exam was notable for BP 193/122, 1+ upper extremity edema, 2+ lower extremity 
edema, and bibasilar crackles on lung exam. On labs, Cr 0.85, 3+ protein on UA (previously 
negative) with 3 RBC’s and 6 WBC’s, ~12g of protein on 24hr urine collection, and serum 
albumin 2.3. Serologic work-up including ANA, C3, C4, HIV, Hepatitis B, Hepatitis C, 
SPEP, UPEP, and Kappa and Lambda Free Light Chains was negative. Platelet count 202, 
LDH 334 (elevated), and indirect bilirubin 0.2. AST, ALT, and Alkaline phosphatase were 
normal. The patient underwent a kidney biopsy which demonstrated subacute glomerular 
thrombotic microangiopathy with prominent endotheliosis, characteristic of pre-eclampsia. 
Termination of pregnancy was advised and performed. On post-discharge follow-up, spot 
urine protein-to-creatinine ratio (in mg/mg) decreased to 1.52 after ~1.5 months, 0.32 
after ~3.5 months, and 0.13 after ~6 months. BP improved as well and she is now off 
anti-hypertensives.
Discussion: This patient had multiple risk factors for pre-eclampsia including 
age, multiparity, obesity, IVF, and ovum donor pregnancy. Although kidney biopsies 
are associated with a higher complication rate in pregnant women, they often change 
management, as was the case for this patient. Given this case and others reported in 
the literature, the gestational age criteria for the diagnosis of pre-eclampsia should be 
reconsidered.
TH-PO1087
A Case of Autosomal Dominant Polycystic Kidney Disease and C3 
Glomerulonephritis  Conor Patrick Moran, Mamoun S. Elawad.  Dept of 
Nephrology, Altnagelvin Hospital, Western Health and Social Care Trust, 
Londonderry, United Kingdom.
Introduction: Autosomal Dominant Polcystic Kidney Disease, (AD-PKD), is the most 
common form of inherited renal disease. Proteinuria has been reported, however, nephrotic 
range proteinuria and nephrotic syndrome are rarely reported in the literature.  Only 30 
cases of patients with AD-PKD and glomerulopathy have been reported. The most common 
have been FSGS and Membranous Nephropathy. Two cases of Mesangioproliferative 
Glomerulonephritis and one case of Membranoproliferative Glomerulonephritis have 
been reported.
Case Description: We present a 47 year old female with Autosomal Dominant 
Polcystic Kidney Disease with C3 Glomerulonephritis.  The patient had been under 
regular and unremarkable Nephrology clinic follow-up for many years. In March 2014, 
she presented to with new proteinuria, (Urinary ACR 375.4mg/mmol), and evidence of 
C3 hypocomplementaemia, (0.3 g/L, normal: 0.8-1.7 g/L). Kidney function was newly 
impaired, (Creatinine 118, eGFR: 45.3 mL/min/1.73m2). C3 Nephritic factor was normal 
and a minute Cryoglobulin band was detected. ACE inhibitor therapy was commenced. 
Renal biopsy showed markedly enlarged and lobulated glomeruli with marked endocapillary 
proliferation. Widespread thickening of the glomerular basement membranes, (GBM), 
with numerous double contours was observed. Immunofluorescence revealed strong 
diffuse coarse positivity for C3 along the GBM with some focal mesangial C3. There was 
some IgM, but no IgG, in the GBM. In July 2014, there was no clinical response to ACE 
inhibition. Corticosteroids were commenced, (Prednisolone 1mg/kg), which achieved partial 
remission, (urinary ACR fell from 650.5mg/mmol to 79.7 mg/mmol), however, in August 
2014 she developed nephrotic syndrome requiring aggressive diuretic therapy. Addition of 
Rituximab therapy induced complete remission of proteinuria, (UACR 25-30 mg/mmol), 
with normalisation of C3 levels. Renal function remains stable.
Discussion: In a disease where CKD progression is predictable, glomerular pathology 
can accelerate this decline and histology should be sought. This is the second reported 
case of AD-PKD associated with Membranoproliferative C3 Glomerulonephritis in the 
literature to date.
TH-PO1088
To Deliver or Not to Deliver: The Dilemma of a Pregnant Patient with 
Medullary Cystic Kidney Disease Who Develops Acute Kidney Injury 
Sweta Carpenter, Rozina B. Ali, Sandeep Aggarwal.  Nephrology, Drexel Univ.
Introduction: Achieving maternity is quite a challenge for women with chronic kidney 
disease (CKD). Pregnant patients with CKD of any stage but especially stages 3–5 are at 
increased risk for fetal loss, prematurity and pre-eclampsia.
Case Description: We present a case of a 31 year old pregnant female with a past 
medical history of CKD stage 3B secondary to medullary cystic disease (MCD) who 
presented with acute kidney injury at 31 weeks gestation. Her other co-morbidities include a 
history of diabetes and idiopathic thrombocytopenia (ITP). On admission, the patient had a 
creatinine of 2.32 mg/dL and was found to have 7 gm proteinuria. During this pregnancy, her 
baseline creatinine was 1.6-1.8 mg/dL and prior to pregnancy she had baseline proteinuria 
of 2 gm. Given her elevated creatinine and degree of proteinuria, there was concern that 
the patient could have pre-eclampsia. A management dilemma occurred and it was unclear 
whether the patient should have an emergency C-Section for questionable pre-eclampsia. 
Unfortunately, the usual markers of pre-eclampsia such as proteinuria, elevated creatinine, 
hypertension, low platelets, and elevated uric acid levels were all present in our patient. 
These markers however could be present in our patient due to her underlying medical 
conditions of CKD, ITP, and MCD. After a multidisciplinary meeting with the obstetrician, 
nephrology, and hematology occurred, it was felt that the patient truly did not have pre-
eclampsia. A key decision was made and she was not induced. Her AKI was attributed to 
volume depletion and progression of CKD. Her creatinine eventually declined to 1.9-2 mg/
dL and her proteinuria decreased to 3-5 grams. The patient is now 34 weeks pregnant and 
her pregnancy has been maintained. As the weeks progress, there are increased chances 
of fetal development.
Discussion: Our case highlights that in patients with multiple co-morbidities and 
CKD, the diagnosis of pre-eclampsia can be challenging. Incorrectly labeling a patient 
as pre-eclamptic can lead to pre-term delivery and risks to the fetus. A multidisciplinary 
team effort along with fetal monitoring can help differentiate pre-eclampsia from other 
diagnoses, prolonging delivery.
TH-PO1089
Development of Aggressive De Novo Henoch-Schऺnlein Purpura, 10 Years 
Post-Kidney Transplant  Kamel Hatahet,1 Swati Rao,1 Avrum Gillespie,1 
Mythili Ghanta,1 Serban Constantinescu,1 Xu Zeng,2 Iris J. Lee.1  1Nephrology, 
Temple Univ School of Medicine, Philadephia, PA; 2Temple Univ School of 
Medicine, Philadelphia, PA.
Introduction: Histologic recurrence of IgA deposits in renal allografts is as high as 
60% in recipients with primary IgA nephropathy, however significant nephritis presenting 
as de novo Henoch-Schऺnlein Purpura (HSP) post-kidney transplant (KT) is rare with 
only a few cases reported.Our patient had biopsy proven diabetic nephropathy (DN), yet 
presented with severe HSP with multi-system involvement 10 years post-KT.
Case Description: A 63 y/o Hispanic female with DN received a living related KT 
in 2005 and was stably maintained on tacrolimus, prednisone, without mycophenolate 
mofetil (MMF) due to recurrent infections. 10-yrs post-KT, she developed diarrhea, 
melena and acute renal failure (Cr of 4.19 from 1.5) after completing a course of antibiotics 
for pneumonia. She developed diffuse purpuric rash and had hematemesis with severe 
abdominal pain. Abdominal CT scan showed enteritis of the small bowel. EGD demonstrated 
necrotic lesions in the esophagus and severe ulcerative duodenitis with biopsies showing 
leukocytic infiltration of vessels, and submucosa. Skin biopsy showed leukocytoclastic 
vasculitis. Urine had 4+protein, leukocytes, red blood cells, but no casts. Extensive infectious 
and serologic workup was negative. KT biopsy demonstrated membranoproliferative 
changes without crescents, coupled with findings of DN and advanced interstitial fibrosis 
and tubular atrophy. Immunofluorescence showed +4 deposits for IgA and C3 and the patient 
was diagnosed with HSP. Due to severe GI involvement the patient was treated with pulse 
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steroids. Given renal fibrosis and comorbidities, no further therapies were pursued. Repeat 
EGD showed improved duodenal lesions after steroids, however renal function declined 
and the patient required dialysis.
Discussion: IgA nephropathy histologically recurs post-KT but rarely impacts graft 
survival. De novo HSP with significant nephritis is infrequently described and treatment 
strategies in adults with aggressive disease remain unestablished. Interestingly MMF is 
used for severe HSP in children. Whether lack of MMF maintenance contributed to HSP 
in our patient remains unknown.
TH-PO1090
Harvoni Induced Acute Interstitial Nephritis  Jyotsana Thakkar, Kenar D. 
Jhaveri, Rimda Wanchoo.  Nephrology, North Shore-LIJ Hospital, NY.
Introduction: Harvoni is a new combination pill consisting of ledipasvir with 
sofosbuvir approved by FDA in October 2014 for the treatment of chronic Hepatitis C 
genotype 1 virus infection. No cases of Acute Kidney Injury (AKI) have been reported 
with this agent thus far. We report the first case of Harvoni associated biopsy proven acute 
interstitial nephritis (AIN).
Case Description: A 64 year old AA female with chronic Hepatitis C, hypertension, 
diabetes mellitus came to our clinic for evaluation of AKI superimposed on chronic kidney 
disease. Laboratory data revealed serum creatinine of 2.24 mg/dl (baseline Cr 1.5 mg/dl), 
hypoalbuminemia (3.2 gm/dL) with a spot urine protein/ creatinine ratio of 3.3 ( baseline 
of 1). Her AKI coincided with peripheral eosinophilia. Home medications included 
hydralazine, lantus, lisinopril and simvastatin. She had recently completed eight weeks of 
treatment for Hepatitis C with Harvoni and her most recent viral load was undetectable. 
She denied using any NSAID, antibiotics, PPI or herbal supplements. Physical exam was 
normal. AKI workup revealed negative ANCA , normal complement, normal serum free 
immunoglobulin light chain ratio and negative ANA panel.
Patient underwent kidney biopsy. Light microscopy showed 11 glomeruli, 3 were 
globally sclerosed, 3 had cellular crescents with mesangial nodular matrix expansion and 
moderate tubular atrophy. Interstitium showed moderate fibrosis with severe lymphocytic 
inflammation. Immunofluorescent microscopy was normal and electron microscopy showed 
diffusely thickened glomerular membrane and moderately effaced foot processes. A final 
diagnosis of acute interstitial nephritis with chronic diabetic nephropathy was made. Her 
clinical picture, pathology findings and time course of renal impairment coincided with 
Harvoni use and is suggestive of Harvoni induced AIN. She was initiated on steroid therapy 
and advised to stop further use of Harvoni. Her renal function is stable with no further 
deterioration after stopping offending agent.
Discussion: Harvoni has  a cure rate of up to 94-100% in patients with Hepatitis C 
genotype 1. We report first case of biopsy proven AIN with Harvoni. Hepatologists and 
nephrologists need to be aware of the potential side effect of this novel agent.
TH-PO1091
Thrombotic Microangiopathy Secondary to Smoldering Myeloma: A Form 
of MGRS  Jyotsana Thakkar, Rimda Wanchoo, Kenar D. Jhaveri.  Nephrology, 
North Shore-LIJ Hospital, NY.
Introduction: Thrombotic microangiopathy syndrome (TMA) is not a usual 
presentation of paraproteinemic diseases. We report a case of TMA secondary to smoldering 
myeloma presenting as monoclonal gammopathy of renal significance (MGRS).
Case Description: A 69 year old male with past history of hypertension, diabetes 
mellitus, prostate cancer, Chronic Kidney disease ( CKD) (baseline creatinine 1.3-1.5 mg/
dl), chronic back pain was referred to our clinic for evaluation of CKD. Home medications 
included enalapril, humalog, pioglitazone and acetaminophen as needed. Physical exam 
was normal except for elevated BP of 160/80 mmHg. Workup showed serum creatinine 
1.5 mg/dl, Spot urine protein/creatinine ratio of 0.2, Hb 15.5 gm/dl and platelets 113K/UL. 
Serum free light chain ratio was suggestive of elevated IgA kappa light chain and elevated 
K/L ratio. Bone marrow biopsy showed mild plasmacytosis (10% plasma cell). Skeletal 
survey was negative for lytic lesion. Patient was diagnosed with smoldering myeloma. 
Kidney biopsy was done to rule out MGRS.
Light microscopy showed 24 glomeruli, 11 of which were sclerotic. Immunofluorescence 
was negative. On Electron microscopy, extensive glomerular basement membrane (GBM) 
duplication with sub endothelial widening was seen. Between the duplicated GBM, two 
types of electron dense deposits were seen, consisting of short fibrils and well demarcated 
dense material giving bubbly appearance consistent with thrombotic microangiopathy. 
Serological workup for secondary causes of TMA including HIV, Hepatitis, CMV PCR, 
Parvovirus B19 PCR, antiphospholipid antibody, cryoglobulin, complement (C3, C4) , 
HTLV I/II immunoassay, beta 2 glycoprotein IgA Ab were negative. Given the smoldering 
nature of MM and the finding of TMA on kidney biopsy with no secondary cause, patient 
was considered to have MGRS presenting as renal limited TMA and is currently being 
treated with anti plasma cell agents.
Discussion: Case series of cancer related microangiopathic hemolytic anemia and 
TTP as initial presentation of multiple myeloma have been described before but not biopsy 
proven chronic renal limited TMA secondary to smoldering myeloma. We report first case 
of biopsy proven TMA likely secondary to smoldering myeloma.
TH-PO1092
A Case of Leukocyte Chemotactic Factor 2 Associated Amyloidosis 
Nada Bader, Saeed Kamran Shaffi.  Nephrology, Univ of New Mexico.
Introduction: Leukocyte chemotactic factor 2-associated amyloidosis (ALECT2) is 
a newly described form of nonhereditary amyloidosis. The disease usually presents with 
chronic kidney disease and bland urinary sediment with variable degrees of proteinuria. 
We describe a case of a young Hispanic female who presented with nephrotic syndrome 
without renal insufficiency.
Case Description: A 40 year old Hispanic female with history significant for 
uncontrolled type 2 diabetes, hypertension and rheumatoid arthritis, was referred to renal 
clinic for evaluation of nephrotic syndrome. Physical examination revealed periorbital and 
bilateral lower limb edema. Pertinent diagnostic data are shown in figure1.
Renal biopsy showed extensive amyloidosis involving the glomeruli, interstitium and 
arterioles. Immunofluorescence was negative for immunoglobulins and amyloid associated 
protein. Proteomic typing of the amyloid revealed ALECT2 associated amyloidosis. The 
patient was started on lisinopril and spironolactone, but her proteinuria failed to improve 
and she had progressive deterioration of renal function. Two years later, she developed 
ascites and elevated liver enzymes. Her presentation was concerning for hepatic amyloidosis; 
therefore, she was transferred to a liver transplant center for further evaluation.
Discussion: Based on two large renal biopsy series, ALECT2 accounts for 2.5-2.7% 
of all cases of renal amyloidosis. In a multicenter study involving 72 patients with renal 
ALECT2, 92% were Hispanic, 2.8% were below the age of 50 and 91.4% had a serum 
creatinine > 1.2mg/dl. One third had nephrotic range proteinuria, but only 10% of all 
patients presented with nephrotic syndrome. Pathogenesis is not clear. It is postulated 
that inflammatory processes lead to excessive production of an amyloidogenic variant of 
ALECT2. Accurate identification of the amyloid protein is essential as disease modifying 
treatments are available for certain types of amyloidosis.
TH-PO1093
Complement Polymorphisms in Patients with Thrombotic Microangiopathy 
Associated with Intravenous Abuse of Oral Formulation of Extended-
Release Oxymorphone (OPANA-ER)  Joe Ghata, Lukas Haragsim, Satish 
Kumar.  Nephrology, Univ of Oklahoma Health Science Center, Oklahoma 
City, OK.
Introduction: In 2012, the CDC reported 15 cases of unexplained renal failure 
and thrombotic migroangiopathy (TMA) in which all patients reported dissolving 
and intravenously injecting an oral preparation of oxymorphone (Opana ER) prior to 
presentation. Since then, 30 additional cases have been reported in the U.S. The mechanism 
of IV Opana-associated TMA is unclear. ADAMTS13 levels were normal. We report 
two patients with genetic polymorphisms of complement system proteins as a possible 
mechanism for Opana-associated TMA.
Case Description: Two patients, a 26 yo WM (Pt 1) and a 38 yo WM (Pt 2) presented 
with unexplained renal failure (serum creatinine 8.2 and 4.6 mg/dl respectively) in the setting 
of IV Opana Abuse. Both displayed a hematological constellation of microangiopathic 
hemolytic anemia, thrombocytopenia, consumed haptoglobin and elevated LDH. Both 
patients had normal INR/PT/PTT, ADAMTS13 (both > 55%) and fibrinogen levels. 
ANA, HIV, and hepatitis profiles were negative. Renal biopsy showed intermediate sized 
vessel TMA in both patients. Both received plasmapharesis for 5 days. Hematological 
microangiopathy resolved in Pt 2 but persisted in Pt 1. Both remained dialysis dependent. 
Genetic studies for complement-mediated HUS demonstrated both to be positive for a 
heterozygous polymorphism (IVSP-78 G>A) within an intron of the membrane cofactor 
protein (MCP/CD 46) and for a homozygous polymorphism (p.His402Tyr) in the 
complement factor H (CFH). In addition, both patients had an additional CFH polymorphism 
(p.Val62Ile; Pt 1 homozygous, Pt 2 heterozygous).
Discussion: Our patients suggest a 2 hit mechanism for IV Opana-associated TMA. 
Both had polymorphisms in complement system proteins MCP and CFH with a potential 
predisposition for complement-mediated HUS. The MCP/CD 46 polymorphism has 
been shown to be enriched in patients with complement-mediated HUS. Polymorphisms 
in complement system proteins could cause hyperactivation and dysregulation of the 
complement system and provide a genetic predisposition for thrombotic microangiopathy, 
with IV Opana abuse acting as a trigger.
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TH-PO1094
Acute Kidney Injury due to an Excessive Dose of Rivaroxaban  Sandar Win,1 
Kevin G. Lazo,2 Jordan L. Rosenstock.1  1Nephrology, NSLIJ/Lenox Hill 
Hospital, New York, NY; 2Internal Medicine, .
Introduction: Recently, over-anticoagulation with warfarin has been recognized as 
a cause of acute kidney injury (AKI) and has been termed warfarin related nephropathy 
(WRN). We report a patient who developed AKI and gross hematuria while taking the new 
oral anticoagulant (NOAC) rivaroxaban.
Case Description: A 45 y/o man presented to his physician’s office with abdominal 
pain. Computed tomography (CT) of the abdomen was done and thrombosis of the portal, 
splenic, and mesenteric vein was identified. He was admitted to the hospital and discharged 
on rivaroxaban 10mg 2 tablets daily. After 6 weeks, he was given a prescription for 
rivaroxaban 20 mg tab and told to take 1 tablet daily. He mistakenly took 2 tablets daily. After 
5 days, he noticed painless gross hematuria for several days. He reported to his physician’s 
office and his serum creatinine had increased to 2.7 mg/dL from a baseline of 1.5. He had 
a previous history of splenic vein thrombosis of unclear cause 2 years previously (treated 
with course of warfarin), hypertension, and diabetes. His medications included metformin, 
glipizide, gemfibrozil, valsartan, sitagliptin, and rivaroxaban. His vital signs were normal. 
Physical examination showed splenomegaly but was otherwise unremarkable. Urinalysis 
revealed many red blood cells with trace proteinuria. The urine protein to creatinine ratio 
was 257 mg. Serologies were negative and there was no evidence of intravascular hemolysis. 
Antiphospholipid antibodies were negative as was a hypercoaguable work-up. A bone 
marrow biopsy was unremarkable and paroxysmal nocturnal hemoglobinuria was ruled 
out. Renal dopplers were negative for renal vein thrombosis. Renal function remains stable 
after 3 months. Renal biopsy was not performed in the setting of required anticoagulation 
and likely diagnosis of anticoagulant related AKI.
Discussion: WRN is a newly recognized form of AKI in the setting of excessive 
anticoagulation with warfarin. This appears to be the first reported case of a WRN- like 
AKI due to the NOAC rivaroxaban, and was likely caused but inadvertent doubling of the 
patient’s dose. WRN can often be irreversible and in this patient as well no renal recovery 
was evident at 3 months.
TH-PO1095
Irreversible Acute Kidney Injury due to Oxalate Nephropathy from 
Intravenous Vitamin C  Tarvinder S. Matharu, Satish Kumar.  Nephrology, 
Univ of Oklahoma Health Science Center, Oklahoma City, OK.
Introduction: High doses of vitamin C are widely used in alternative medicine for 
treatment of cancer, viral illness and fatigue. Vitamin C is metabolized to oxalic acid in the 
body. High doses of vitamin C have the potential to cause hyperoxaluria, nephrolithiasis 
and oxalate nephropathy. We report a patient who developed severe, irreversible, acute 
kidney injury due to acute oxalate nephropathy from high dose intravenous vitamin C.
Case Description: 75 yo male with a history of hypertension, hypothyroidism, and mild 
pancytopenia, presented to a wellness clinic with fatigue and weight loss. He had a normal 
metabolic profile except hypercalcemia (corrected Ca, 12 mg/dl). He received IV vitamin C 
30 g/d for 7 days. Serum creatinine was 1.3 mg/dl prior to Vitamin C administration. One 
month following treatment, he was admitted to our hospital with serum Cr 9.1, Na 110, K 
3.1, Cl 70, CO2 16, BUN 152, Glucose 131, Ca 8.4, Uric Acid 12.1, CPK 175, Phos 11.9, 
and Mg 3.3. LFTs were normal. Urine vitamin C level was 40. An abdominal CT revealed 
diffuse mesenteric and retroperitoneal lymphadenopathy with hepatosplenomegaly and 
ascites. Liver was without cirrhosis. A renal ultrasound revealed normal sized, echogenic 
kidneys. Serum free light chains and serum and urine protein electrophoresis were normal. A 
renal biopsy demonstrated diffuse acute tubular injury and abundant tubular calcium oxalate 
deposits consistent with acute oxalate nephropathy. Bone marrow biopsy was normal and 
culture negative. A lymph node biopsy demonstrated diffuse T Cell Lymphoma. Patient 
was started on dialysis and remained dialysis-dependent at last follow up.
Discussion: Our patient developed severe, irreversible acute kidney injury from high 
dose intravenous vitamin C. The hypercalcemia was likely a contributing factor for the 
extensive deposition of calcium oxalate crystals in the kidney. A literature search identified 
2 previous reports of oxalate nephropathy from intravenous vitamin C. High dose vitamin 
C is a common component of alternative medical regimens for cancer and other illnesses. 
We urge caution in using high dose vitamin C especially in patients with pre-existing renal 
insufficiency or hypercalcemia.
TH-PO1096
Atypical Hemolytic Uremic Syndrome (aHUS) due to a Novel Sequence 
Variation of Diacylglycerol Kinase Epsilon (DGKE)  Shoba Narayan,1 Rupa 
A. Udani,2 Stefanie Dugan,2 Matthew W. Anderson,2 Dorit Ben-Ezer,1 Kenneth 
Dale Friedman.2  1Nephrology, Children¶s Hospital 2range County, 2range, CA; 
2Hematology, Blood Center of Wisconsin, Milwaukee, WI.
Introduction: aHUS is a congenital disease characterized by hemolytic anemia, 
thrombocytopenia, and organ dysfunction (e.g. renal failure). Genetic alternations resulting 
in uncontrolled activation of the complement system are found in 50-60% of aHUS cases. 
Recently autosomal recessive mutations in DGKE have been identified, indicating that 
intrinsic abnormalities in the signaling pathways controlling endothelial and platelet 
procoagulant tendency and podocyte function can also lead to aHUS. Patients with DGKE-
associated disease tend to present at earlier age, have nephrotic range proteinuria, fail to 
respond to eculizumab, and may develop renal failure, but do well after renal transplantation.
Case Description: We identified a novel homozygous sequence variation c.1344C>A, 
p.N448K in the kinase accessory site of DGKE in a family with aHUS. The index case 
presented at 1 year of age with nephrotic range proteinuria and hypertension. Renal biopsy 
at the time revealed TMA. Clinical course was complicated by ongoing proteinuria despite 
ACE-I and ARB therapies. At age 10, she does not have thrombocytopenia, schistocytes, 
abdominal or CNS manifestations, as typically noted in patients with complement-
mediated aHUS. Genetic testing was resent to identify mutations previously not available 
to guide further treatment. The patient also carries heterozygous sequence variation 
ADAMTS13 c.3287G>A, p.R1096H, associated with decreased ADAMTS13 function and 
is heterozygous for CFHR5. Subsequently, a younger sister presented with hypertension, 
hematuria and nephrotic range proteinuria. The symptomatic sister is also homozygous for 
this variant in DGKE and is heterozygous for CFHR5, but lacks the ADAMTS13 variant. 
Parents and siblings with heterozygous DGKE variants are healthy.
Discussion: This case is the first reported case of a kinase accessory domain of DGKE 
associated with aHUS. Additional studies are needed to determine the impact of DGKE 
mutations on the clinical course of patients with aHUS and their appropriate management.
TH-PO1097
Membranoproliferative Glomerulonephritis with Mixed Cryoglobulinemia 
in Patients with Autoimmune Hepatitis  Olorunkemi O. Oluwole, Anand 
Achanti, Jalal E. Hakmei, Sally Self, Milos N. Budisavljevic.  Nephrology, 
MUSC, Charleston, SC.
Introduction: Autoimmune hepatitis (AIH) is frequently associated with extrahepatic 
manifestations; however, glomerulonephritis is rarely seen. We describe two patients with 
biopsy proven AIH who developed membranoproliferative glomerulonephritis (MPGN) 
despite treatment with prednisone and azathioprine. Screening for hepatitis B and C virus 
was negative and neither patient had SLE.
Case Description: Case 1: A 56 year old female presented with microscopic hematuria 
(6-10 RBC), proteinuria (6.9 g) and acute kidney injury (creatinine 1.5 mg/dL). Her renal 
function deteriorated requiring hemodialysis treatment. Serology revealed mixed type III 
IgG/IgM cryoglobulins. Kidney biopsy showed mesangial proliferation, protein thrombi 
within capillary loops, reduplication of GBM and mesangial interpositioning, consistent 
with cryoglobulinemic MPGN. She was treated with plasma exchange and rituximab, 
with disappearance of cryoglobulins, normalization of urinary findings and resolution of 
AKI. Case 2:18 year old female presented with proteinuria (1.7 g), hematuria (44 RBC) 
and serum creatinine 0.8 mg/dl. Mixed type III cryoglobulins consisting of IgG/IgM were 
detected in the serum. Kidney biopsy revealed mesangial hypercellularity reduplication 
of GBM with subendothelial, mesangial and scattered subepithelial deposits. She was 
treated with plasma exchange, one dose of 1000 mg intravenous cyclophosphamide and 1 
gram of rituximab 4 weeks later. Treatment led to the disappearance of cryoglobulins and 
normalization of urinary findings. Serologic tests at presentation are presented in (table 1).
Case 1 Case 2
C3 (88-201 mg/dL) 27 42.2
C4 (16–47 mg/dL) <10 <10
ANA (Negative) Negative 1:160
Anti dsDNA (<30 IU/ml) 20 28.7
RF (0-24 IU/ml) 1770 Negative
ANCA (Negative) Negative 1:640
Discussion: Patients with AIH should be monitored for proteinuria and active urinary 
sediment due to the risk of glomerulonephritis, despite treatment with prednisone and 
azathioprine. MPGN is a rare, but important, complication of AIH. Prompt diagnosis by 
kidney biopsy and aggressive treatment of AIH associated MPGN with rituximab and/or 
cyclophosphamide may result in a favorable renal outcome.
TH-PO1098
A Case of Chinese Herb (Aristolochic Acid) Nephropathy Leading to ESRD 
Complicated by Bladder Cancer  Melin Joe Narayan, Bahar Bastani.  Dept 
of Nephrology, St. Louis Univ, St. Louis, M2.
Introduction: Chinese Herb (aristolochic acid) Nephropathy, is a rapidly progressive 
interstitial nephritis leading to ESRD with a high frequency of urothelial malignancy.
Case Description: We report a 59 year old white female who had received Chinese 
herbs for one and half years before she developed progressive renal insufficiency that 
over a six month period lead to ESRD requiring hemodialysis. A renal biopsy showed 
extensive tubular loss and collapse associated with interstitial edema and interstitial fibrosis 
consistent with the effects of tubular toxic damage caused by aristolochic acid. After one 
week of hemodialysis, the patient underwent a living unrelated kidney transplant from a 
friend. Alemtuzumab induction, steroid free maintenance on tacrolimus and mycophenolate 
(MMF) were started. She had no history of diabetes, hypertension or use of NSAIDS. 
She underwent monthly urinalysis and screening cystoscopy every six months to rule 
out urothelial malignancies. Twenty months post transplant she underwent right breast 
lumpectomy and radiation for intraductal carcinoma. Two and a half years after kidney 
transplant routine cystoscopy revealed a bladder mass, a biopsy of which showed high grade 
urothelial carcinoma with squamous differentiation invading into subepithelial connective 
tissue for which she underwent bilateral native nephrectomy, ureterectomy, cystectomy 
and transplant kidney ileal loop urinary diversion. One year later the patient was admitted 
with shortness of breath and was found to have a malignant pleural effusion of unidentified 
primary which led to her demise. A sample of the Chinese herb that she had used was found 
to contain aristolochic acid.
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Discussion: There has been a high risk of urothelial malignancies associated with 
Chinese herb/aristolochic acid exposure with 40 - 45% of these patients developing 
multifocal high grade transitional cell carcinoma leading to a suggestions for either 
prophylactic bilateral native nephrectomy and ureterectomy at the time of renal 
transplantation or screening cystoscopies every 6 months to identify early stage urothelial 
carcinoma. Our patient is a classic example of aristolochic acid associated nephropathy 
complicated with urothelial cancer.
TH-PO1099
Anti-Tumor Necrosis Factor Therapy – A Trigger for Anti-Glomerular 
Basement Membrane Disease  Carlos Antonio Cortes Sanchez, Hector R. 
Cordova, Krystahl Z. Andujar.  Medical Service, VA Caribbean Healthcare 
System, San Juan, PR.
Introduction: Tumor necrosis factor (TNF) has a key pathological role in diseases 
such as rheumatoid arthritis (RA). Vasculitis and other autoimmune diseases have been 
associated with the use of anti-TNF agents such as Adalimumab.
Case Description: A 73-year-old man with of RA, Hypertension, Diabetes Mellitus 
type 2 and Non-Hodgkin’s Lymphoma in remission for 3 years complained of decreased 
urine output, dark urine, poor appetite, weight loss and peripheral edema for three weeks. 
He was on chronic low dose Prednisone and Adalimumab intermittently during the previous 
21 months. Physical exam revealed bilateral lower extremity pitting edema but no skin 
lesions. Laboratories showed a serum creatinine of 9.3mg/dl (baseline of 1.3mg/dl). 
Urinalysis exhibited many RBC’s, proteinuria (2+) and pyuria without casts. The clinical 
picture suggested acute glomerulonephritis. Hemodialysis (HD) was started. 
Test Upon Admission
After 
Plasmapheresis
After Reexposure to 
Adalimumab
ANA 1:80 Speckled
C3/C4 Normal
Anti-GBM (N < 1.0 AI) 7.9 2.4 4.3
Atypical P ANCA (N < 1:20) Negative Negative Negative
P-ANCA (N < 1:20) 1:20 Negative Negative
MPO (N < 1.0 AI) 4.6 1.1 2.2
C-ANCA (N < 1:20) Negative Negative Negative
Prot3Ab (N < 1.0 AI) Negative Negative Negative
ASO Titer Normal
Serology tests were compatible with Anti-Glomerular Basement Membrane (GBM) 
Disease. Alveolar hemorrhage was not present. Plasmapheresis therapy decreased anti-GBM 
titers but there was no recovery of renal function. The patient continued using Adalimumab 
after discharge. He later returned with hemoptysis due to alveolar hemorrhage, which 
resolved after the discontinuation of Adalimumab. The patient remained HD-dependent.
Discussion: The temporal association of the illness with anti-TNF therapy and 
worsening of symptoms upon reexposure suggest an etiologic role of Adalimumab in the 
development of Anti-GBM Disease in our patient. Patients receiving anti-TNF therapy 
should have renal function closely monitored to allow early detection of this infrequent 
but life-threatening side effect.
TH-PO1100
Severe Pauci Immune Crescentic Glomerulonephritis Mimicking ANCA 
Related Vasculitis Caused by Clinically Silent Dental Abscess Leading 
to Bacterial Endocarditis  Anil K. Chunduri, Maria Saleem Khan, Anthony 
Alvarado, Tibor Nadasdy, Lee A. Hebert.  Nephrology, OSUMC, Columbus, OH.
Introduction: Severe crescentic GN is usually categorized based on the cause if it is 
Anti GBM or IC mediated disease. However, it is not widely appreciated that some instances 
of pauci immune GN are actually the result of severe occult systemic infections. We present 
a case of severe pauci immune crescentic GN whose initial assessment for infection was 
negative. The patient was assumed to have idiopathic AAV and was treated with high dose 
steroids. Despite no obvious signs of infection, bacteremia was on our differential due to 
pancytopenia. These findings are rarely common, if ever, associated with AAV.
Case Description: 55 year old male with PMH of CAD presented to an outside hospital 
with fatigue. Initial labs revealed Hb: 7.6g/dl, WBC; 2.8 K/µL, Plt: 44 K/µ, Creat: 2.26 mg/
dl. Infectious work up was negative. Autoimmune workup revealed: ANA positive (1:40 ), 
Anti GBM (<0.2), Anti PR3 (0.6), ANCA and Anti MPO: negative. C3 : 77mg/dlĻ, C4 :16.9 
mg/dl (wnl). Cryoglobulin (<5), Urine PC ratio was 1.2. Further workup included a bone 
marrow biopsy and kidney biopsy, which was suggestive of pauci-immune crescentic and 
necrotizing GN. He received treatment with steroids and was discharged on steroid taper. 
His creatinine upon discharge was 1.5 mg/dl. On follow up his creatinine was elevated 
to 3.5 mg/dl. He was transferred to our institution. Repeat Infectious work up revealed 
streptococcus viridians bacteremia, tricuspid and aortic valve endocarditis. A panoramic 
radiograph of his teeth showed periapical abscess. He was subsequently diagnosed with 
infection related acute pauci-immune crescentic necrotizing GN. Unfortunately this patient 
remained dialysis dependent at the time of discharge.
Discussion: It is well established but not widely appreciated that severe pauci-immune 
crescentic GN can be the direct result of infection. Thorough investigation is warranted even 
if the initial infectious workup is negative, if the patient does not have a positive response 
to conventional therapy to improve morbidity and mortality.
TH-PO1101
POEMS Syndrome with Cast Nephropathy  Amanda K. Hall,1 Josephine 
Abraham,1 Monica Patricia Revelo Penafiel,2 Frederic Clayton.2  1Div of 
Nephrology and Hypertension, Univ of Utah, Salt Lake City, UT; 2Div of 
Pathology, Univ of Utah, Salt Lake City, UT.
Introduction: POEMS syndrome(Polyneuropathy, Organomegaly, Endocrinopathy, 
Monoclonal protein, Skin changes) is a plasma cell disorder with peripheral neuropathy 
and any of the following features osteosclerotic bone, Castleman’s disease, increased 
levels of serum vascular endothelial growth factor(VEGF), organomegaly, endocrinopathy, 
edema or skin changes. We report a case of POEMS presenting with acute renal failure 
due to cast nephropathy.
Case Description: A 63-year-old Caucasian female presented with a 3 month history 
of increasing weakness and was diagnosed with chronic inflammatory demyelinating 
polyneuropathy. She was also noted to have new onset diabetes mellitus and hypothyroidism. 
She was treated with intravenous immunoglobulin(IVIG) with minimal response. She was 
admitted with acute renal failure initially thought to be secondary to IVIG, progressive 
weakness, and shortness of breath. Serum beta 2 microglobulin was elevated and kappa/
lambda ratio was abnormal with Bence-Jones proteinuria. Renal biopsy was deferred as the 
patient developed respiratory failure, subarachnoid hemorrhage, and a left middle cerebral 
artery stroke. Comfort measures were initiated. Bone marrow biopsy confirmed multiple 
myeloma with 20% clonal plasma cells. Autopsy showed hepatomegaly, splenomegaly, 
and peripheral nerve demyelination with active axonal loss. Renal examination showed 
cast nephropathy with monoclonal kappa light chains.
These features are characteristic of POEMS given the multiple myeloma with 
neuropathy, organomegaly, rash and new onset diabetes mellitus and hypothyroidism.
Discussion: POEMS is a paraneoplastic syndrome associated with plasma cell 
dyscrasia. Polyneuropathy with plasma cell disorder should prompt evaluation for POEMS 
as outcomes have been excellent with diagnosis and treatment.
TH-PO1102
Acute Interstitial Nephritis Associated with a New Breast Cancer 
Chemotherapy Regimen  Cory Handelsman,1 Michael T. Tanoue,2 Amy Kwon,2 
Steven Salvatore,3 Jeffrey I. Silberzweig.2,4  1Div of Nephrology, Weill Cornell 
Medical College; 2Dept of Medicine, Weill Cornell Medical College; 3Dept of 
Pathology, Weill Cornell Medical College, New York, NY; 4The Rogosin Inst, 
New York, NY.
Introduction: Acute interstitial nephritis (AIN) as a direct consequence of 
chemotherapy is infrequently described. A recent review implicated ifosfamide, tyrosine 
kinase inhibitors, and pemetrexed as culprits in this process. We describe a case of AIN 
related to the recently approved chemotherapy regimen of pertuzumab, trastuzumab, and 
docetaxel for HER-2 positive metastatic breast cancer. While diarrhea, rash, and pruritis 
are well-known side effects, this report is the first to show AIN as a consequence of this 
combination regimen.
Case Description: A 69-year-old woman recently diagnosed with HER-2 positive 
breast cancer and treated with six cycles of neoadjuvant pertuzumab, trastuzumab, and 
docetaxel was hospitalized for acute kidney injury after two days of diarrhea and vomiting. 
Admission labs demonstrated leukocytosis to 26,000/uL, serum creatinine of 5.9 mg/dL 
(baseline of 1.55 mg/dL), and elevated anion gap metabolic acidosis with a lactic acid of 4.5 
mmol/L. Urinalysis showed pyuria with occasional granular casts. Fractional excretion of 
sodium was 1.88%. Renal sonogram showed normal resistive indices with no evidence of 
hydronephrosis or calculi. Infectious workup, including blood, urine, and stool studies, was 
unrevealing. Despite aggressive hydration and resolution of diarrhea and vomiting within 
48 hours, her renal function worsened; her creatinine peaked at 9.0 mg/dL on hospital day 
3. She was non-oliguric throughout the admission. A renal biopsy revealed moderate to 
marked, diffuse acute and subacute, interstitial inflammation characterized by lymphocytic 
infiltration with moderate eosinophilia and diffuse tubular injury. Some endothelial injury 
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was present as well. The patient was diagnosed with AIN secondary to chemotherapy and 
treated with prednisone. Two weeks later, her symptoms had fully resolved and her serum 
creatinine had returned to baseline.
Discussion: This is the first documented case of AIN related to combination 
chemotherapy with docetaxel, pertuzumab, and trastuzumab.
TH-PO1103
Sarcoidosis-Lymphoma Syndrome Presenting with Severe Refractory 
Hypercalcemia  Osita W. Okechukwu,1 Barry M. Wall,2 Elvira Gosmanova,1 
Deepak Nandikanti.1  1Nephrology Div, UTHSC, Memphis, TN; 2Nephrology 
Section, VAMC, Memphis, TN.
Introduction: Sarcoidosis-lymphoma syndrome (SLS) is rare. Sarcoidosis (S) 
usually precedes lymphoma (L) by many months. Constitutional symptoms and hilar 
lymphadenopathy are typical initial manifestations of SLS. We report a SLS case presenting 
with severe acute hypercalcemia and acute kidney injury (AKI).
Case Description: Case Report:A 70 yr-old Caucasian male was hospitalized with 
symptoms of generalized weakness, poor oral intake, and altered mental status. Examination 
was significant for dry mucus membranes, depressed mentation, evidence of bilateral 
pleural effusions, mild ascites, and 2cm well-delineated hyper-pigmented erythematous 
plaques on anterior chest wall. Laboratory findings included a corrected serum Ca 19.4mg/
dL (2 months prior- 9.3mg/dL), ionized Ca 2.5 mmol/L, BUN 56mg/dL, serum creatinine 
2.9mg/dL (baseline 1.4 mg/dL),and mild anemia. Further work up revealed suppressed 
PTH (6.2pg/mL) normal LFT, PTHrP, serum and urine electrophoresis, calcidiol, calcitriol, 
ACE, CEA, PSA, and TSH. A working diagnosis of hypercalcemia of malignancy was 
made. Intravenous fluids, calcitonin, prednisone, and low dose pamidronate were initiated; 
however, hypercalcemia and AKI remained poorly responsive to conservative measures and 
hemodialysis was required. Skin biopsy of chest wall lesion demonstrated non-caseating 
granulomatous dermatitis consistent with sarcoidosis. Thoracentesis was performed and 
pleural fluid cytology showed occasional plasmacytoid/lymphoid cell and polyclonal T-cells 
on flow cytometry. However, flow cytometry of ascitic fluid was positive for monoclonal 
B cells.Computed tomography (CT) demonstrated diffuse soft tissue lung masses and 
abdominal carcinomatosis. Osseous survey was normal. CT-guided omental mass biopsy 
showed dense fibrous tissue with lymphoplasmacytic infiltrate. The diagnosis of SLS 
with associated B-cell lymphoma was made. Given poor functional status and widespread 
disease, the patient and his family opted for hospice care.
Discussion: Severe refractory hypercalcemia leading to AKI is unusual for sarcoidosis 
and should prompt investigation for concomitant lymphoma.
TH-PO1104
End Stage Renal Disease Secondary to Oxalate Nephropathy in a Patient 
with Undiagnosed Chronic Pancreatitis  Kalyani Chandra, Burl R. Don.  Div 
of Nephrology, UC Davis Medical Center, Sacramento, CA.
Introduction: Oxalate nephropathy is a rare, underdiagnosed, devastating disease 
characterized by extensive oxalate deposition, acute kidney injury and rapid progression 
to end stage renal disease (ESRD). Secondary hyperoxaluria occurs in enteric disorders 
associated with increased intestinal oxalate absorption and renal tubular injury. Chronic 
pancreatitis is a rare cause of oxalate nephropathy.
Case Description: A 66 year-old white man with history of diabetes mellitus, 
hypertension and recurrent kidney stones, was noted on routine labs to have an elevated 
serum creatinine level (6.88 mg/dL; baseline 1.17 mg/dL, 6 months prior). He reported 
having chronic diarrhea, fatigue, loss of appetite and weight loss over the past 6 months. 
Workup revealed pancreatic calcifications consistent with chronic pancreatitis. Urinalysis 
and renal ultrasound were normal. Renal biopsy revealed acute tubular necrosis with 
extensive oxalate deposition. A 24 hr urine collection noted increased oxalate and reduced 
citrate excretion. Despite a 6 month course of a low oxalate diet, pancreatic enzymes, 
calcium supplementation, and sodium citrate to alkalinize the urine, the patient’s renal 
function failed to improve, and he is preparing for home hemodialysis.
Discussion: Enteric hyperoxaluria can lead to acute oxalate nephropathy. It has been 
described in patients with post-gastric bypass surgery and inflammatory bowel disease. 
There are rare reports noting the association between chronic pancreatitis and oxalate 
nephropathy leading to chronic kidney disease (CKD) and rarely ESRD. The pathogenesis 
of hyperoxaluria in chronic pancreatitis remains uncertain, but it is postulated that fat 
malabsorption may increase free fatty acids that competitively inhibit the formation of 
calcium oxalate in the GI tract, combined with increased colonic mucosal permeability, 
leading to hyperoxalemia, hyperoxaluria and oxalate crystallization in the kidney. Treatment 
remains largely empiric, aiming at decreasing oxalate burden to the kidney as was done 
in this patient. Oxalate removal with dialysis has not been shown to be beneficial. Oxalate 
nephropathy can be a late complication of chronic pancreatitis leading to CKD and ESRD.
TH-PO1105
mRNA Expression of Proinflammatory Mediators in Common Variable 
Immunodeficiency with Granulomatous Interstitial Nephritis: Case Report 
Giacomo Mori, Giulia Ligabue, Sara De biasi, Milena Nasi, Andrea Cossarizza, 
Gianni Cappelli.  Univ Hospital - Modena.
Introduction: Common Variable ImmunoDeficiency (CVID) impact on kidney 
function is poorly understood.We present a case of a woman, 39years old,affected by CVID, 
expressing as hypogammaglobulinemia,anemia and chronic kidney failure secondary to 
granulomatous interstitial nephritis(IN).
Case Description: In 2013 serum creatinine(s-cr)rose from 0.8 to 2.6mg/dl,without 
urinary abnormalities or signs of inflammation.A kidney biopsy showed an IN,with 
granulomatous aspects.PolyomaBK,HIV1/2,ParvovirusB19,SV40 resulted negative,urinary 
PolyomaJC was positive.A PET-CT ruled out occult infections or reactive linphnodes.
Pathology of several purple-brownish skin lesions demonstrated a lymphocytic infiltrate 
and perivascular macrophages containing melanin pigment.ACE level was doubled.A course 
of metilprednisolone(350mg i.v. for 3 days,followed by oral tapering)was started;anemia 
improved with iron,vitamins and EPO;s-cr decreased to 1.9mg/dl.Along 2014 relevant 
metabolic acidosis persisted and s-cr gradually rose to 3.8mg/dl.Before starting a new 
course of steroids we evaluated mRNA expression of a panel of proinflammatory mediators 
in circulating monocytes.
Among the considered mediators AIM2,PTGS2 and IL1B genes were overexpressed.
AIM2 is central in innate immune response,recognizing cytosolic double-stranded DNA 
and inducing caspase-1-activating inflammasome formation in macrophages;PTGS(or 
Cyclooxygenase)is the key enzyme in prostaglandin biosynthesis,with two 
isozymes:PTGS1(constitutive) and PTGS2(inducible).PTGS2 upregulation leads to the 
prostanoid biosynthesis involved in flogosis and mitogenesis.IL1B(Interleukin1)is involved 
in cell proliferation,differentiation and apoptosis.IL1B induces PTGS2,mediating pain 
hypersensivity.Steroids allowed a regression of s-cr to 2.4mg/dl and of ACE to normality 
range.
Discussion: Innate immune response over activation could be the cause of a pathologic 
monocyte-macrophage stimulation responsible for tubulointerstitial damage.Further studies 
are needed to understand the therapeutic potential of biologic therapy of CVID related 
interstitial nephritis,with the aim of stopping the inflammatory cascade.
TH-PO1106
Nephrotic Range Proteinuria without a History of Penicillamine Therapy 
in a Patient with Wilson’s Disease  Hideki Matsumura,1 Akira Ashida,1 Yuko 
Fujii,1 Akihiko Shirasu,1 Hyogo Nkakura,1 Motoshi Hattori,2 Hiroshi Tamai.1 
1Pediatrics, Osaka Medical College, Osaka, Japan; 2Pediatric Nephrology, 
Tokyo :omen¶s Medical Univ, Tokyo, Japan.
Introduction: Wilson’s disease (WD) is a rare autosomal recessive genetic disorder 
of copper metabolism, characterized by hepatic and neurological abnormality. Although 
penicillamine is one of the key drugs for treatment of WD, in rare cases it may have a 
nephrotoxic effect leading to nephrotic syndrome due to membranous nephropathy. Here, 
we report a case of WD in a patient who showed nephrotic range proteinuria clinically and 
focal segmental glomerulosclerosis (FSGS) histologically, without a history of treatment 
with penicillamine.
Case Description: We treated an 18-year-old girl who had been diagnosed as having 
WD at the age of 6 years and treated with trientine. She had normal liver function and 
normal urinalysis parameters. At the age of 16 years, she had developed acute liver failure 
due to poor drug compliance. Although her liver function subsequently recovered after 
plasma exchange and medications including zinc and trientine, slight proteinuria began to 
appear. As the proteinuria increased gradually to within the nephrotic range, we performed 
a kidney biopsy one year later. The patient had normal blood pressure, no edema, and her 
body mass index was 26.9. Blood examinations demonstrated no hypoproteinemia, no 
immunological abnormalities and normal kidney function. Although urinalysis revealed 
no hematuria, the urine protein:creatinine ratio was increased to 2.98. A kidney biopsy 
demonstrated perihilar FSGS and arteriolar intimal thickening, without tubular-interstitial 
or glomerular basement membrane changes. We diagnosed the patient as having secondary 
FSGS and began administration of an angiotensin receptor blocker.
Discussion: Although the kidney manifestations in WD include aminoaciduria and 
nephrocalcinosis, these were not observed in our patient. As her symptoms were relatively 
milder than those of typical FSGS and she had several known causes of secondary FSGS 
including arteriolar intimal hyperplasia and obesity, our histological diagnosis was 
secondary FSGS. To our knowledge, this is the first report of histologically confirmed 
FSGS in a patient with WD.
TH-PO1107
Denosumab for the Treatment of Bisphosphonate Refractory Hypercalcemia 
of Malignancy  Theresa L. Nilson, Tammy Wan, Erik Lawrence Lum.  Div of 
Nephrology, Univ of California, Los Angeles, Los Angeles, CA.
Introduction: Hypercalcemia is common in malignancy, occurring in 20-30% 
of patients. Volume expansion with normal saline is the mainstay of therapy, with the 
addition of bisphosphonates in cases of severe hypercalcemia. Here we describe a case 
of bisphosphonate resistant hypercalcemia of malignancy and discuss potential treatment 
options for refractory cases.
Case Description: A 62 year-old male with T2 paraplegia following a fall 24 years 
ago presented to the ER for evaluation of a decubitus ulcer. On arrival his vital signs were 
unremarkable, and physical examination demonstrated a 10x10 cm stage IV decubitus ulcer 
with purulent drainage and exposed bone. Initial laboratory data demonstrated white blood 
cell count 18.7, hemoglobin 4.9 g/dL, normal basic metabolic panel and calcium 8.8mg/dL. 
He was transfused blood products and given antibiotic therapy. Bone biopsy demonstrated 
invasive squamous cell carcinoma. His calcium increased to 14.1mg/dL with elevated 
PTHrP 71pg/mL. He was diagnosed with humoral hypercalcemia of malignancy and treated 
with intravenous normal saline and pamindronate 90mg. His calcium initially reduced to 
11mg/dL, but rose again to 13.4mg/dL. He received a second dose of pamindronate, but 
the calcium continued to rise to 15.3mg/dL. He was given a single dose of denosumab 
120mg and his calcium decreased to 9.32 mg/dL over the next four days. The response 
was sustained without additional need for administration over the next two months before 
the patient expired due to complications related to his decubitus ulcer.
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Discussion: This case illustrates the potential effectiveness of denosumab for the 
treatment of hypercalcemia refractory to bisphosphonates. Denosumab is a human 
monoclonal antibody against RANK-Ligand (RANKL) whose use has previously been 
described for management of hypercalcemia, but required multiple infusions. Recognition 
of this additional treatment, with effectiveness from a single infusion, is critical in managing 
refractory hypercalcemia, as the only other known option is hemodialysis. Increasing 
availability of options for management of refractory hypercalcemia may allow patients to 
avoid complications associated with hemodialysis.
TH-PO1108
Collapsing and NOS Focal Segmental Glomerulosclerosis (FSGS): 
Progression Along a Spectrum or Different Diseases?  Suzanne L. Katsanos, 
Patrick H. Nachman, JulieAnne G. McGregor, Volker Nickeleit.  UNC Kidney 
Center, Chapel Hill, NC.
Introduction: Minimal change disease (MCD) and some variants of FSGS (tip lesion 
and not otherwise specified NOS) are thought to represent a histologic spectrum of a 
similar autoimmune pathogenic process (Habib, R. Proceedings IXth Int Cong of Neph). 
This contention has never been proven, however. Some cases of MCD are thought to be 
“unsampled” FSGS. A “transition” from MCD to FSGS is common in steroid-resistant forms 
(Tejani, A. Nephron 39). It has been proposed that collapsing FSGS is pathogenically and 
clinically distinct from other FSGS variants based on morphology, demographics, severity 
of nephrotic syndrome, and renal prognosis. The etiology has not been identified but viral 
agents, drugs, and cyclosporine toxicity have all been proposed.
Case Description: We present the case of a 37-year-old African American male 
with a complicated course of nephrotic syndrome. He was diagnosed with biopsy-proven 
MCD when 9 years old. He was treated with steroids followed by chlorambucil and 
then cyclophosphamide over the next several years. He was in complete remission off 
therapy for about 2 years until he re-presented with increased edema, proteinuria (3.8 
g/d), hypoalbuminemia, and acute kidney injury (AKI). A repeat biopsy (25 glomeruli) 
showed FSGS NOS. He was treated with steroids followed by mycophenolate mofetil and 
cyclosporine, resulting in complete remission. 7 years later, he developed edema, proteinuria 
(21 g/d) and AKI. Repeat biopsy showed 25 glomeruli demonstrating segmental tuft 
collapse, activation of endothelial cells, and segmented marked activation and crowding of 
podocytes consistent with collapsing FSGS. HIV, hepatitis B, and hepatitis C were negative.
Discussion: The transition from MCD to FSGS NOS is common in the literature. 
However, the transition from FSGS NOS to collapsing FSGS is rarely reported. This 
patient’s case raises questions about this transition from NOS to collapsing variant. 
Glomerular undersampling is unlikely given 25 glomeruli were examined each time. This 
could represent a progressive, patient-related pathogenetic process versus a de novo lesion 
(either related to a viral infection or medication, for example).
TH-PO1109
Lymphoma Associated Monoclonal Cryoglobulinemia in a Patient with 
Hepatitis C  Sangeeta Mutnuri,1 Marjan Afrouzian,2 Hania Kassem.1  1Dept of 
Nephrology, UTMB, Galveston, TX; 2Dept of Pathology, UTMB, Galveston, TX.
Introduction: We present a case of type I cryoglobulinemia and membranoproliferative 
glomerulonephritis (MPGN) in a patient with hepatitis C infection (HCV), leading to the 
diagnosis of a marginal zone lymphoma.
Case Description: A 47 year old male with HCV and hypertension presented with 
two month duration of shortness of breath and decreased urine output. On examination 
he was hypertensive (blood pressure: 183/111 mm of Hg), had lung crackles, lower 
extremity edema and hepatosplenomegaly. Laboratory tests were significant for 
pancytopenia, hypoalbuminemia and an elevated creatinine of 2.8mg/dl (0.8mg/dl four 
months ago). Urine exam revealed red blood cell (RBC) casts, dysmorphic RBC’s and 
nephrotic range proteinuria (9.5 gm). Immunochemistry revealed elevated rheumatoid 
factor, hypocomplementemia and cryoglobulinemia. These findings led to a suspicion 
of HCV induced cryoglobulinemic glomerulonephritis. Kidney biopsy was performed 
revealing MPGN type III with deposits. Fluorescence microscopy favored Kappa 
monoclonality. Electron microscopy of the deposits was consistent with cryoglobulins. 
Serum immunoelectrophoresis also confirmed IgM/Kappa monoclonality. As HCV is more 
commonly associated with polyclonal cryoglobulinemia this finding of monoclonality 
prompted a search for malignancy. A bone marrow biopsy showed lymphoid aggregates 
indicating marrow involvement by marginal zone lymphoma. The patient was initiated 
on rituximab/dexamethosone based regimen. The creatinine trended down to 1.87 mg/dl.
Discussion: Monoclonal cryoglobulinemia is related to lymphoproliferative diseases 
whereas HCV is associated with polyclonal cryoglobulinemia. This case stresses the 
importance of differentiating between the two entities especially in patients with co existing 
disorders. Making this crucial distinction helps predict the underlying etiology and treatment.
TH-PO1110
A Lupus Nephritis Patient Accompanied with Storiform Fibrosis 
Characteristic in IgG4-Related Kidney Disease in the Absence of Serum 
IgG4 Elevation and IgG4-Positive Plasma Cell Infiltration  Mamiko Imada, 
Naoki Takahashi, Daisuke Mikami, Seiji Yokoi, Kenji Kasuno, Hideki Kimura, 
Masayuki Iwano.  Div of Nephrology, Univ of Fukui, Fukui, Japan.
Introduction: IgG4-related kidney disease (IgG4-RKD) usually presents as 
tubulointerstitial nephritis with IgG4-postive plasma cell (PC) infiltration and serum IgG4 
elevation. IgG4-RKD has characteristic histological findings called storiform fibrosis and 
radiological findings showing multiple low-density lesions on contrast-enhanced CT scan. 
Recently, Hara et al. reported a case of IgG4-negative IgG4-RD (Mod Reumatol, 2014) 
which had a condition closely mimicking IgG4-RD despite the absence of serum IgG4 
elevation and IgG4-positive PC infiltration. Here we report a patient diagnosed with lupus 
nephritis (LN) with IgG4-negative IgG4-RD.
Case Description: A 59-year-old Japanese man was referred to our hospital with chest 
pain and mild proteinuria. Thoracic biopsy was performed for abnormal lung shadow and 
interstitial pneumonia was diagnosed. Although ANA titer was elevated to 2560-fold, anti-
DNA, anti-Sm, and anti-SS-A/-B antibodies were all negative. Serum C3 and C4 levels and 
complement activity were decreased. Serum IgG and IgE levels were elevated, but serum 
IgG4 level was within normal limits. On contrast-enhanced CT, multiple low-density lesions 
were observed in kidney. Renal biopsy findings revealed lymphoplasmacytic infiltration with 
storiform fibrosis and small numbers of eosinophils. Immunostainings revealed CD138- or 
IgG-positive PC infiltration without IgG4-positive PC. Immunofluorescence microscopy 
showed granular mesangial positivity for a “full-house” pattern. Electron microscopy 
disclosed mesangial and subendothelial dense deposition accompanied with virus-like 
particles. We diagnosed this patient with IgG4-negative IgG4-RD and LN (ISN/RPS II). 
After administration of 20 mg prednisolone, laboratory data was drastically improved.
Discussion: To our knowledge, this is the first report of a patient with LN and IgG4-
negative IgG4-RD. IgG4-negative IgG4-RD may be a chronic burnout phase of IgG4-RD. 
Further studies gathering similar cases would be needed to clarify whether or not IgG4-
negative IgG4-RD is included in a category of IgG4-RD.
TH-PO1111
A Case of Acute Phosphate Nephropathy in a Kidney Transplant Recipient 
Hetal Shah, M. Lee Sanders, Kelly A. Birdwell, Anthony J. Langone, Paisit 
Paueksakon, Beatrice P. Concepcion.  Vanderbilt Univ Medical Center, 
Nashville, TN.
Introduction: Acute phosphate nephropathy has been described after large doses 
of phosphate, typically in laxatives and bowel cleansing preparations. We present a case 
of acute phosphate nephropathy in a kidney transplant recipient who was taking oral 
phosphorus supplementation for hypophosphatemia.
Case Description: A 26 year-old man with a living related donor kidney transplant 
in 2011 complicated by recurrent IgA nephropathy with a baseline creatinine of 1.9 mg/
dL presented with nausea, vomiting, diarrhea, fatigue and elevated creatinine. Two weeks 
prior to presentation, he had been started on K-Phos-Neutral 500 mg three times a day for 
a phosphorus of 1.6 mg/dL. Intact parathyroid hormone (iPTH) was 58 pg/mL. He soon 
after developed diarrhea and ten days later developed nausea and vomiting. He was found 
to have a creatinine of 10.4 mg/dL, phosphorus 9.7 mg/dL, calcium 9.6 mg/dL and iPTH 
761 pg/mL. Urinalysis had a urine pH of 5, no red blood cells and trace protein. Renal 
biopsy was performed, and pathology revealed 30 foci of intratubular calcium phosphate 
crystals with associated acute tubular injury involving 30-40% of tubular profiles, along 
with known recurrence of IgA nephropathy. The patient underwent acute hemodialysis 
for oliguric acute kidney injury. Given the high serum phosphorus, he was dialyzed for 
four consecutive days until phosphorus level was less than 4 mg/dL and did not rebound. 
Patient was discharged requiring intermittent hemodialysis for an additional three weeks 
until he demonstrated renal recovery. His new baseline creatinine is 2.2 mg/dL and he has 
remained off hemodialysis.
Discussion: Hypophosphatemia is common in kidney transplant recipients. Although 
rare, acute phosphate nephropathy can occur in the setting of phosphorus repletion. This 
patient also had multiple risk factors, including baseline renal dysfunction, volume depletion 
and angiotensin receptor blocker use. Acute phosphate nephropathy can potentially lead 
to irreversible loss of renal function. While no specific treatment exists, in this case, 
aggressive hemodialysis to decrease serum phosphorus may have played a role in this 
patient’s eventual renal recovery.
TH-PO1112
Unusual Membranous Nephropathy in a Patient with Lupus 
Iheanyichukwu Ogu, Julia Lewis, Agnes B. Fogo.  Nephrology, Vanderbilt 
Univ Medical Center, Nashville, TN.
Introduction: Membranous nephropathy (MN) is an immunologically mediated 
glomerular disease. Distinguishing between primary and secondary MN is important in 
guiding diagnosis and treatment. We present a case of a patient with systemic lupus with 
pathologic features in a repeat biopsy suggestive of primary MN.
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Case Description: A 32 year old African American woman presented in 1998 with 
nephrotic range proteinuria (8g), edema and serum creatinine 0.6. She had negative work up 
for secondary causes including lupus. Renal biopsy showed mild matrix expansion, diffuse 
global basement membrane (GBM) spikes, preserved tubulointerstitial compartment; fine 
granular IgG(3+), C3(1+) IgM(trace), C1q(trace), IgA(negative) capillary loop staining 
with focal mesangial IgM and C1q staining; numerous subepithelial deposits, 90% foot 
process effacement, and unremarkable endothelial cells. She was started on an angiotensin 
receptor blocker but was lost to follow up. In 2011 she was diagnosed with Lupus and in 
July 2014, had proteinuria (1.9g). Repeat renal biopsy showed persistent MN with features 
concerning for lupus, with reticular aggregates, mildly increased mesangial matrix and 
cellularity, and 20% interstitial fibrosis. After referral to our clinic, additional testing on 
the 1998 biopsy (fig 1,2) showed diffuse global capillary wall Ig G1(1-2+), IgG2(2+), 
IgG3(negative), IgG4(3+), PLA2R(negative); and the 2014 biopsy (figs 3,4) showed 
diffuse global granular capillary wall IgG1(2+), IgG2(1-2+), IgG3(negative), IgG4(3+) 
and PLA2R near global(1-2+) granular capillary loop staining.
Discussion: The PLA2R staining and the dominance of IgG4 currently are consistent 
with primary MN. The negative PLA2R in 1998 may indicate early disease or epitope 
change. The mesangial deposits are nonspecific and could possibly represent a low grade 
lupus-related nephropathy. The presence of reticular aggregates is a marker of high interferon 
levels in patients with lupus, and does not necessarily mean lupus nephritis.
TH-PO1113
A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits 
Exhibiting Marked Nephrotic Syndrome Who Responded Well to the Renin-
Angiotensin System Blockade Alone  Yoshihiko Nishiguchi, Hideki Inoue, 
Tomoaki Onoue, Yutaka Kakizoe, Yuichiro Izumi, Takashige Kuwabara, Taku 
Miyoshi, Masataka Adachi, Yushi Nakayama, Masashi Mukoyama.  Nephrology, 
Kumamoto Univ Hospital, Kumamoto, Japan.
Introduction: Proliferative glomerulonephritis with monoclonal IgG deposits 
(PGNMID) is a newly recognized entity of glomerulonephritis caused by glomerular 
deposition of monoclonal IgG. The clinical and pathological features, treatment and 
prognosis of this entity remain elusive.
Case Description: A 79-year-old woman was admitted to our hospital due to 
hematuria and marked nephrotic-range proteinuria. Her serum creatinine level was 0.75 
mg/dL and urinary protein excretion was 20.8g/g creatinine. Renal biopsy showed a 
membranoproliferative feature without nodular formation. Immunofluorescence study 
showed capillary and mesangial deposits of IgG, C1q and C3. Moreover, IgG-kappa deposits 
were strongly stained and IgG3 deposits were restrictedly stained for IgG heavy-chain 
subclass analysis. Electron microscopy revealed amorphous electron-dense mesangial and 
subendothelial deposits. Monoclonal proteins were not detected in serum or urine samples. 
Serum cryoglobulin titer was negative. Serum free light-chain assay showed a normal kappa/
lambda ratio.These findings were consistent with the diagnostic criteria for PGNMID. 
Considering her age and tolerability, we started monotherapy with angiotensin II receptor 
blocker. This case showed drastic reduction in proteinuria with stable renal function within 
several months after the treatment with the renin-angiotensin system (RAS) blockade alone.
Discussion: We report here an exceptional case of PGNMID associated with the 
membranoproliferative feature successfully treated with RAS blockade alone, without 
steroid or other immunosuppressive agents. Further studies are needed to clarify clinical 
spectrum and prognosis of this newly described disease entity.
TH-PO1114
Brentuximab Induced Renal Steatosis – The Hint Is in the Urine 
Akhil Hegde, Ronald J. Falk, Abhijit V. Kshirsagar.  UNC Kidney Center, Univ 
of North Carolina at Chapel Hill, Chapel Hill, NC.
Introduction: We describe the onset of acute kidney injury (AKI), lipiduria and multi-
organ steatosis after the use of Brentuximab, a monoclonal antibody targeting CD30, in 
patients with recurrent Hodgkin Lymphoma (HL).
Case Description: A 61 year old female with recurrent HL, treated with Brentuximab 
180mg (4 and 2 weeks prior to admission), was admitted with a 1-month history of nausea 
and vomiting. She was found to have AKI, creatinine 1.7 - baseline 0.9 mg/dl, elevated 
liver enzymes (AST 324, ALT 282 U/L), a urine protein/creatinine ratio of 1.0g with a total 
cholesterol and HDL of 152 and 32 mg/dl. Urine microscopy revealed numerous free fatty 
droplets and fatty casts that did not have a maltese cross appearance under polarizing light. 
Sudan black dye demonstrated positive staining indicating non-cholesterol fat in the urine. 
PET/CT imaging did not show malignancy, but revealed severe fatty infiltration 
of multiple organs not present 4 months earlier. The patient’s clinical course worsened 
and the patient died on hospital day #6. An autopsy revealed hepatomegaly with severe 
steatosis, fatty infiltration of the pancreas and proximal renal tubular epithelial cell macro/
microvesicular steatosis with intra-glomerular lipiduria.
Discussion: The development of AKI, lipiduria, transaminitis and multi-organ steatosis 
after 2 doses of Brentuximab is concerning for a drug-induced injury. Sudan dye attaches 
to neutral lipids and is helpful in distinguishing the 2 categories of lipids. Only 2 weeks 
after the last dose of Brentuximab, the patient was found to have new fatty infiltration 
and a subsequent autopsy revealed intra-glomerular lipidosis. The first hint to systemic 
steatosis was the presence oval fat bodies in the urine. Typically, charged lipids have the 
appearance of a maltese cross under polarizing light, while neutral lipids do not refract 
polarized light in this manner.
TH-PO1115
Pheochromocytoma: An Unusual Cause of Thrombotic Microangiopathy 
Induced Acute Kidney Injury in Pregnancy – Wolf in Sheep’s Clothing 
Venkat Sainaresh Vellanki,1,2 Sachin V. Kodgire,2 Anila Abraham.3  1Nephrology, 
Manipal Superspecialty Hospital, Visakhapatnam, Andhra Pradesh, India; 
2Nephrology, Univ of Toronto, Toronto, ON, Canada; 3Renal Pathology, Center 
for Renal and Urological Pathology, Chennai, Tamil Nadu, India.
Introduction: Hypertensive disorders during pregnancy result in substantial maternal 
and fetal morbidity. Pheochromocytoma in pregnancy is extremely rare with a reported 
frequency of 0.002% and 50% maternal and fetal mortality.
Case Description: 25 year old female, 26 weeks of gestation with gestational 
diabetes presented with antenatal hemorrhage, confusion and uncontrolled hypertension 
with BP190/124mmHg. Investigations revealed hemoglobin 9 gm/dl, platelets 76000/
microliter, serum creatinine 2.4 mg/dl, LDH 245U/L, AST 30U/l, ALT 39U/L, urine 
dipstick protein 1+. Ultrasound confirmed abruptio placenta and intrauterine death of 
fetus needing emergency surgical evacuation. She developed intraoperative hypotension 
needing multiple blood transfusions and ventilatory support. Her renal function worsened 
needing initiation of hemodialysis. Septic and hemolytic work up were negative. She had 
paroxysmal episodes of uncontrolled hypertension and flash pulmonary edema needing 
frequent rescue hemodialysis and parenteral antihypertensives. Renal doppler was negative 
for renal artery stenosis. CAT scan showed left adrenal mass. Plasma normetanephrine was 
elevated at 1223 pg/ml suggestive of pheochromoctoma. BP was stabilized with four drugs 
and surgical resection of the tumor was done. A wedge kidney biopsy showed thrombotic 
microangiopathy (TMA). The tumor histopathology confirmed pheochromocytoma, positive 
for chromogranin and synaptophysin staining. Post operative, her creatinine stabilized at 
1.6mg/dl, BP and glycemic status returned to normal.
Discussion: Discussion: Pheochromocytoma in pregnancy is an extreme rarity with a 
frequency of 0.002%. It is often mistaken for other hypertensive disorders of pregnancy. This 
is the first case report of a patient with acute kidney injury in pregnancy from TMA secondary 
to pheochromocytoma. Patient made good renal recovery after resection of the tumor.
TH-PO1116
Immune Reconstitution Inflammatory Syndrome and Hypercalcemia with 
Acute Kidney Injury following Stribild Therapy  Christine A. Garcia, Kelly H. 
Beers, Catherine Miranda, Kamran Karimi, Yezina T Nigatu, Nand K. Wadhwa. 
Nephrology/Medicine, Stony Brook Medicine, Stony Brook, NY.
Introduction: Immune reconstitution inflammatory syndrome (IRIS) is an inflammatory 
disorder with paradoxical worsening of preexisting infectious processes following HAART 
in HIV-infected individuals. We describe a case of IRIS following Stribild (elvitegravir, 
cobicistat, emtricitabine, tenofovir) resulting in hypercalcemia.
Case Description: A 33 year-old woman with acquired immunodeficiency syndrome 
(AIDS) who had been on Stribild for two months presented to the ED with acute kidney 
injury with a serum creatinine of 2.93 mg/dL and Ca of 15.2 mg/dL. Her CD4 count was 
145 /uL and viral load 35 copies/mL. Four months prior, she was treated with amphotericin 
for cryptococcal lung infection and Cryptococcemia. One month prior, a right lower lobe 
mass histology had revealed necrotic tissue with inflammatory cells. On examination, she 
was alert, in no acute distress, with unremarkable physical examination. Her temperature 
was 36.7 degrees Celsius, heart rate 72/minute, BP 108/64 mm Hg, respiratory rate 16/
minute, and oxygen saturation 100% on room air. Chest X-ray showed an interval decrease 
in the right lower lobe mass. Serum intact PTH was 9.7 pg/mL. PTHr peptide, SPEP and 
UPEP were negative. Serum 25 (OH) D was 37 ng/mL, 1,25 (OH)2 D3 was 17 pg/mL, and 
24 hour urine Ca was 270 mg. Urine fractional excretion phosphorus was 28% with no 
glucosuria. She was diagnosed with IRIS and Stribild was discontinued. She was treated 
with IV fluids and calcitonin with an improvement in her renal function and normalization 
of her serum calcium over a period of 4 weeks. Lab data summarized.
Serum Creatinine 
mg/dL Serum Ca mg/dL CD4 /uL
HIV viral load 
copies/mL
Base level 0.70 9.0 40 119,698
2 weeks on Stribild 1.45 11.8 122 220
8 weeks on Stribild 2.93 15.2 145 35
6 weeks off Stribild 1.00 9.4 93 178,362
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Discussion: IRIS is thought to be due to increased T-lymphocyte proliferation after 
HAART in AIDS patients. IRIS typically manifests as a granulomatous inflammation. 
Corticosteroids are treatment of choice in IRIS in the setting of excess 1,25 (OH)2 D3. In 
our case, serum 1,25 (OH)2 D3 was low suggesting possible other mechanisms.
TH-PO1117
IgA-Dominant Postinfectious Glomerulonephritis: A Case Series 
Pranjal Sharma,1 Anitha Vijayan,2 Tingting Li.2  1Dept of Internal Medicine, 
Renal Div, :ashington Univ in St. Louis, St. Louis, M2; 2Dept of Internal 
Medicine, Renal Div, :ashington Univ in St. Louis, St. Louis, M2; 3Dept of 
Internal Medicine, Renal Div, :ashington Univ in St. Louis, St. Louis, M2.
Introduction: IgA dominant post-infectious glomerulonephritis (PIGN) is a distinct 
clinico-pathologic entity that typically occurs in diabetic patients and in association with a 
recent or active staphylococcal infection. Patients usually present with hematuria, proteinuria, 
and AKI. Renal pathology shows an immune-complex GN with varying light microscopic 
patterns and IgA-dominance or co-dominance with IgG on immunofluorescence. Here we 
report the clinical characteristics and outcomes of 10 patients with IgA dominant PIGN.
Case Description: After obtaining approval from the local IRB, retrospective, 
single-center review of data was performed and 10 patients with IgA dominant PIGN 
were identified.
Majority was white males, and 6/10 were diabetic. Eight patients had a Staphylococcal 
infection and one had active Hep C infection. Only 3/10 had low complements. 6/10 required 
RRT and 4 developed ESRD, of which 2 died at 2 and 5 months after initiation of RRT. Five 
were left with varying degree of CKD and one was lost to follow up. Three patients were 
treated with immunosuppression in addition to antibiotics-all had significant improvement in 
renal function; one patient who was initially RRT-dependent was able to come off dialysis. 
Patient Infection C3/C4 Hema-turia
Protein-
uria/ d
Peak 
SCr RRT
Follow 
Up
1 Hep C N/N Y 7.5 1.6 No CKD
2 MSSA L/L Y 0.6 6.9 Y CKD
3 MRSA/Pseu-domonas N/N Y 1.16 3.9 No NA
4 MRSA N/N Y 6.5 5 Y Died
5 MRSA N/N Y 3.7 10.9 Y CKD
6 MSSA L/L Y 1.2 7.5 Y ESRD
7 MRSA/VRE N/N Y 4.1 7 Y ESRD
8 MSSA N/N Y NA 6.5 Y Died
9 MRSA N/N Y NA 3.9 No CKD
10 Clostridium subterminalis N/L Y 2.8 5.2 No CKD
N=Normal;L=Low;Y=Yes 
Table 1. Clinical features and outcomes of pts with IgA-dominant PIGN
Discussion: IgA-dominant PIGN is an increasingly recognized disorder that occurs 
most commonly in diabetic patients with Staphylococcal infections. Overall renal prognosis 
is poor. Treatment with immunosuppression in addition to antibiotics may be considered.
TH-PO1118
Hematuria in a Young Female: This Was a Hard Nut to Crack 
Manish K. Saha, Gaurav Jain.  Nephrology, Univ of Alabama, Birmingham.
Introduction: Flank pain with hematuria usually indicates urolithiasis but in its absence, 
renal vascular abnormalities should be considered.
Case Description: A 27-year old female with history of sickle cell trait, was admitted 
for gross hematuria. She had flank pain at the end of her urine stream but denied associated 
fever, chills or dysuria. She was treated with ciprofloxacin for presumed UTI but due to 
weakness  she presented to our hospital. Her vital signs were stable and had a normal 
physical exam. Her hemoglobin was 5 gm/dl, creatinine at 0.6 mg/dl and urinalysis was 
evident for 3 plus proteinuria with >25 RBC/hpf and >50WBC /hpf. Her total protein 
to creatinine ratio was 2 and had a negative urine culture. She had normal complement, 
ANA screen and negative serology work up for autoimmune disease. Renal ultrasound 
(US) showed 10 cm (right) X 9.5 cm (left) kidneys. Her non-contrast CT abdomen and 
cystoscopy was non-diagnostic. To further evaluate her hematuria she underwent renal US 
with Doppler which showed narrowing of the left renal vein at the level of the superior 
mesenteric artery (SMA) with a peak velocity gradient greater than 10:1, consistent with 
left renal vein(LRV) stenosis or “nutcracker” syndrome (NCS). She subsequently underwent 
exploratory laparotomy with evidence of aortic and SMA scissoring compression of renal 
vein at its confluence with inferior vena cava (IVC). The IVC and left renal vein were 
mobilized and the compression was relieved. Patient continued to have hematuria with 
persistent proteinuria for few months postoperatively but eventually had resolution of both 
hematuria and resolution of proteinuria and hematuria.
Discussion: NCS refers to compression of left renal vein by abdominal aorta and 
SMA in fork-like fashion resulting in renal and pelvic venous congestion. The usual 
manifestations are microscopic to gross hematuria, pelvic or flank pain and orthostatic 
proteinuria .Hematuria results from the rupture of thin blood vessels into the collecting 
system due to elevated renal venous pressure. Symptomatic patients usually need surgical 
repair, LRV transposition and renal auto-transplantation in rare cases. NCS is an important 
differential in patient with hematuria-proteinuria and flank pain in young patients.
TH-PO1119
ANCA Negative Pauci-Immune Necrotizing Crescentic Glomerulonephritis 
in a Patient with Non Hepatitis C Mixed Essential Cryoglobulinemia 
Victor Nwazue,2 Ji ae Yoon,1 Balhinder S. Brar.3  1Medicine, Mercy St Vincent 
Medical Center, Toledo, OH; 2Nephrology, Univ of Toledo, Toledo, OH; 
3Nephrology, Mercy St. Vincent Medical Center, Toledo, OH.
Introduction: Mixed essential cryoglobulinemia (MC) is associated with a hepatitis C 
infection in 70-90% of patients and presents as membranoproliferative glomerulonephritis 
or rapidly progressive glomerulonephritis (RPGN) with or without crescents. We report 
an unusual presentation of type II MC without hepatitis C infection presenting as ANCA 
negative pauci-immune necrotizing and crescentic glomerulonephritis (CrGN).
Case Description: A 64 year old male presented with AKI (creatinine of 5.4 from a 
baseline of 0.8 mg/dl, 2 weeks earlier), 12-18 month history of arthralgias, fatigue, joint 
pains, petechial and purpuric spots on his extremities. His symptoms were exacerbated in the 
winter months. Lab tests revealed elevated cryoglobulin level (338mg/dL), low C4 (5 mg/
dl), positive rheumatoid factor, IgG monoclonal gammopathy (0.37g/dl). MPO ANCA, PR3 
ANCA, ANA, hepatitis B and C and HIV serologies were negative. Urinalysis showed 20-50 
RBCs, no casts and proteinuria of 2.5 g. Bone marrow biopsy showed < 5% plasma cells 
and no T cell aberrancy or B cell monoclonality. A kidney biopsy revealed pauci-immune 
necrotizing CrGN. Electron microscopy (EM) showed no deposits or fibrillar or tubular 
structures in the glomeruli. The patient was treated with hemodialysis (HD), 5 sessions of 
plasmaphresis and oral cyclophosphamide for 3 months. He responded to treatment with 
near complete resolutions of his symptoms and near normalization of kidney function.
Discussion: Pauci-immune CrGN is associated with either microscopic polyangitis 
or granulomatosis with polyangitis. These can present as RPGN and have either a positive 
MPO or PR3 ANCA but have no deposits on immunofluorescence and EM. CrGN in 
patients with MC is an immune complex disease, has distinct immune deposits in glomerular 
capillaries and fibrillar and tubular structures on EM. Our case was an unusual combination 
of 2 different pathologically and pathogenically distinct disease entities. To our knowledge 
this is the first reported case with these unusual manifestations.
TH-PO1120
Fibrillary Glomerulonephritis Presenting as Rapidly Progressive Crescentic 
Glomerulonephritis  Pallavi D. Shirsat,1,2 Chyi Chyi Chong,1,2 Ramesh 
Marahatta,1,2 Cherinet S. Adgeh,1,2 Neville R. Dossabhoy.1,2  1Dept of Nephrology, 
9eterans Affairs Medical Center, Shreveport, LA; 2Dept of Nephrology, LSU 
School of Medicine, Shreveport, LA.
Introduction: Fibrillary glomerulonephritis is a rare disease of unclear etiology, known 
to be associated with malignancy, autoimmune disorders, lymphoplasmacytic disorders and 
hepatitis C. It is seen in 0.5 to 1.0% of native kidney biopsies.
Case Description: We report a case of a 62 year old Caucasian male veteran who had 
a past medical history of hepatitis C, hyperlipidemia, s/p coronary bypass, multiple colon 
polyps s/p colectomy and CKD stage 3. Patient, on a routine follow up appointment, was 
noted to have rapid worsening of kidney function, with creatinine increase from baseline of 
1.4-1.8 up to 3.2 mg/dL. He was also noted to have 24 RBCs per HPF on urine microscopy. 
Urine protein:creatinine ratio was 4.5. Hepatitis C related membranous glomerulonephritis 
(GN) was high on the differential list. Hepatitis B and HIV serologies were negative. 
Complements, cryoglobulins, ANCA and serum protein electrophoresis were within 
normal limits. Patient underwent kidney biopsy, which showed crescentic GN, with linear 
pattern immunoglobulin deposition along the GBM (glomerular basement membrane) on 
light microscopy and immunofluorescence suggestive of anti-GBM disease. However, 
patient’s anti-GBM titer was negative Electron microscopy showed thickening of GBM 
due to fibrillary deposits. Similar fibrillary deposits were also seen in the mesangium, with 
haphazard distribution of fibrils measuring about 15 nm, consistent with fibrillary GN . 
Congo red stain for amyloid was negative. Patient was also found to have a 2.8 x 2.5 cm well-
circumscribed solid & cystic mass in right kidney on ultrasound, suspicious for renal cell 
carcinoma (RCC). A fine needle aspiration of the mass yielded cells consistent with RCC.
Discussion: Fibrillary GN is known to be associated with malignancy. It can rarely 
present clinically as rapidly progressive, crescentic GN, and masquerade as anti-GBM 
disease on immunofluorescence. Electron microscopy and serologic workup are needed 
to clinch the definitive diagnosis.
TH-PO1121
Pauci-Immune Necrotizing Crescentic Glomerulonephritis as the First 
Manifestation of Chronic Lymphocytic Leukemia Relapse  J. Saadi Imam,1 
Monia E. Werlang,1 Tatiana A. Thom,2 Nabeel Aslam.2  1Dept of Medicine, 
Divison of Internal Medicine, Mayo Clinic, Jacksonville, FL; 2Dept of Medicine, 
Div of Nephrology, Mayo Clinic, Jacksonville, FL.
Introduction: The association between hematological malignancy and auto-immune 
disease is a well-documented phenomenon. Chronic lymphocytic leukemia (CLL) patients 
have 5-10% risk of developing autoimmune cytopenias, and a rare subset of these CLL 
patients express anti-neutrophil cytoplasmic antibodies (ANCA) in the setting of a vasculitis. 
Here, we present a case of a patient with treated CLL whose relapse was identified by the 
new diagnosis of ANCA-associated pauci-immune glomerulonephritis.
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Case Description: A 73-year-old female with history of CLL, status post chemotherapy 
five years prior, presented with complaints of dyspnea on exertion, fatigue, oral ulcers, 
hemoptysis, rash, arthralgias, edema, and tea-colored urine for 3 months duration. Exam 
showed BP 157/94, bibasilar rales and gingival ulcers. Labs showed Hb 5.4g/dL, platelets 
113K, WBC 4.6K, S. creatinine 4.4mg/dL. Urinalysis showed 2+ protein, many RBCs 
and WBCs with granular casts. ANA, anti-PR3 and MPO were strongly positive. Kidney 
biopsy showed necrotizing crescentic pauci-immune glomerulonephritis in more than 50% 
of glomeruli. Taking into consideration the patient’s prior history of CLL, bone marrow 
biopsy was performed and showed scattered nodular lymphoid proliferation with flow 
cytometry confirming relapse of CLL. Given this finding, our patient was treated on the lines 
of CLL relapse with steroids and rituximab instead of using steroids, cyclophosphamide 
and plasmapheresis for the treatment of ANCA-associated vasculitis alone.
Discussion: The prevalence of ANCA positivity in CLL patients has been documented 
to be <2%. In our patient, ANCA-associated pauci-immune glomerulonephritis was the 
first manifestation of CLL relapse. Discovering CLL relapse mandated a change in the 
management from the standard treatment of pauci-immune glomerulonephritis to a regimen 
more appropriate for both conditions. Clinicians should be aware of this rare association of 
CLL with ANCA-associated vasculitis to choose the most appropriate treatment regimen 
for these patients.
TH-PO1122
Multiple Recurrences of Anti-GBM Disease: Diagnosis or Treatment 
Risk  Lamya Boujelbane, Patricia Liu, Sana Waheed, Laura J. Maursetter. 
Div of Nephrology, Univ of Wisconsin School of Medicine and Public Health, 
Madison, WI.
Introduction: Anti-GBM disease is commonly a monophasic illness. We present a case 
of a woman who had two recurrences of anti-GBM disease after her initial diagnosis in 2001.
Case Description: 33-year-old woman with history of tobacco use was diagnosed 
with anti-GBM disease after presenting with hematuria. A renal biopsy showed crescentic 
glomerulonephritis with linear IF staining for IgG. Serum anti-GBM and anti neutrophilic 
cytoplasmic antibodies (ANCA) levels were undetectable at diagnosis. Five years later, she 
presented with dyspnea and hemoptysis. She had a hemoglobin of 8.5 g/dL and a chest x-ray 
suggestive of diffuse alveolar hemorrhage. Her anti-GBM antibody level was 122 AU/ml. 
She was treated as a relapse of anti-GBM disease and, her anti-GBM antibody had decreased 
to 0 AU/ml and she had no hematuria. Now at 47 years of age, she presented with dyspnea. 
Her chest x-ray demonstrated bilateral perihilar opacities consistent with diffuse alveolar 
hemorrhage and urinalysis revealed 1+ hemoglobin. Anti-GBM antibody was not detected 
but she was treated for a presumed anti-GBM disease recurrence. With each recurrence of 
anti-GBM disease, her symptoms resolved with 7 sessions of plasmapheresis, 3 days of 
IV methylprednisone and 6 months of oral cyclophosphamide 2mg/kg/day. Her creatinine 
remains low at 0.7 mg/dl but she suffered a complication of osteonecrosis of the knee.
Discussion: Relapses are infrequent in anti-GBM disease but have been reported. 
Our case is unique because the patient had three episodes of presumed anti-GBM disease. 
Smoking has been linked to recurrent disease and could have been the trigger in this case. It 
is interesting that our patient had varying presence of circulating anti-GBM antibodies with 
each recurrence which poses the question of the accuracy of the diagnosis. One possible 
explanation is that only local antibodies were reactivated by smoke exposure without a 
systemic antibody production and we may be missing low level recurrences. An important 
question is whether the risk of exposure to immunosuppression is higher than the risk of 
repeat biopsy to confirm diagnosis to avoid treatment related complications.
TH-PO1123
Nephrotic Syndrome, Nodular Glomerulosclerosis and Impaired 
Glucose Tolerance (IGT) – A Case Report  Daniel Taiwo Adeneye, Mary 
C. Mallappallil, Gary R. Briefel.  Nephrology, Down State Medical Center, 
Brooklyn, NY.
Introduction: Diabetic nodular glomerulosclerosis is a recognized complication of 
overt diabetes but is hardly diagnosed in patients with IGT. Diabetic nephropathy(DN) 
without overt hyperglycemia vindicates other etiological factors. Pathogenesis of DN 
is poorly understood but the trigger is still hyperglycemia. Advanced DN without overt 
diabetes is rare and 3 case reports have been published.This is a 48 yr old AA woman 
who presented with nephrotic syndrome, renal failure, IGT and renal biopsy with nodular 
glomerulosclerosis.
Case Description: 48 yr old AA woman referred for elevated creatinine and proteinuria.
No gestational diabetes,tobacco,etoh and drug use history. BP -164/77mmgh, Pulse 70/min 
with pedal edema. BMI-28; fundoscopy not done. Urine protein 3+ and normal sediments, 
no cast. UPCR- 6G/G. (FPG)-118mg/Dl;Bun - 42mg/Dl, Creatinine 3.9mg/dl, Albumin 
2.4mg/Dl, Total protein- 4.6g/dl, Cholesterol- 278mg/dl, LDL 191mg/Dl. Hepatitis B, 
C, HIV, ANA, C3,C4, SSA, ANCA, Cryoglobulin, Spep/Upep- negative.USS; kidneys 
13/12cm,increased echogenicity. biopsy-glomeruli; 25% globally sclerosed, moderate 
interstitial fibrosis and tubular atrophy. I/F :negative staining for Igm,igg,iga,lamda,kappa, 
albumin,c3 and C1q. E/M ;no deposits in glomerular capillary walls or mesangium. 
GBM;diffuse thickening,focal podocytes effacement and nodular mesangial matrix.
Discussion: Nodular glomerulosclerosis is usually seen in advanced DN with overt 
diabetes after 15yrs in Type I and variable in Type 2. Our patient did not have a prior 
diagnosis of diabetes. A causal relationship can be established between IGT and DN;nodular 
glomerulosclerosis found on renal biopsy is usually seen in overt diabetes of long duration. 
Animal studies have shown that brief postprandial elevation of glucose may trigger renal 
injury viaTGFb that results in DN. The CKD was advanced and biopsy was undertaken at 
her insistence even after she was told;it may not impact outcome or treatment. 
This was an unexpected learning case that shows that the occurrence of diabetic 
nephropathy may correlate more with presence and not the intensity or duration of 
hyperglycemia. Further studies are needed to elucidate this phenomenon.
TH-PO1124
A Case of Catastrophic Antiphospholipid Syndrome Treated with Plasma 
Exchange  Takeyuki Takamura, Fumihiko Furuya, Tetsuharu Oku, Kenichiro 
Kitamura.  Third Dept of Internal Medicine, Univ of Yamanashi.
Introduction: Catastrophic antiphospholipid syndrome (CAPS) is characterized 
by diffuse vascular thrombosis, leading to multiple organ failure within a few days and 
resulting to poor prognosis. Antiphospholipid syndrome (APS) is an autoimmune thrombotic 
syndrome with recurrent thrombosis and occurs in both artery and vein, and from large 
to micro vessels. CAPS is also defined as a fetal variant of APS and develop thrombosis 
of three different organ systems with histopathologic evidence of multiple small vessel 
occlusions and high titers of antiphospholipid antibodies. Treatment for CAPS has not been 
established, and intensive anticoagulation or immunosuppressive therapy is carried out.
Case Description: A 68-year-old female who had been diagnosed as lupus 
erythematous and APS complicated with multiple cerebral infarctions and treated with 5 mg 
of oral predonisolone. After her admission, she developed de novo cerebral infarction and 
colonic perforation with ischemic enteritis. Following a partial colectomy, she developed 
gram-negative bacteremia, subsequently, multiple strokes, non-ST elevation myocardial 
infarction, renal failure, and pathological findings with multiple thrombi. These clinical 
findings indicated that patient’s features were consistent with CAPS. She was maintained 
with anti-bacterial agent, anticoagulant, and predonisolone. However, since renal failure 
and anuria had continued, she was treated with plasma exchange (PE) and hemodialysis. 
Thereafter the volume of urine output was gradually increased and her renal function was 
recovered.
Discussion: We report a case of CAPS with multiple organ failure and successfully 
treated with anticoagulant, predonisolone, and PE. The clinical manifestation of CAPS 
depends on the release of inflammatory cytokines from the affected organs by thrombosis 
and small vessel occlusion. Our patient’s successful course could be attributed to beneficial 
role of PE through the removal of excessive inflammatory cytokines.
TH-PO1125
Acute HIVAN in a HIV-Naïve Patient During Primary HIV Infection and 
High Viral Load  Amit N. Shah, Adam G. Winkler, Claude Bassil, Donald E. 
Wheeler, Jacques A. Durr.  Div of Nephrology, Univ of South Florida, Tampa, FL.
Introduction: A hitherto healthy 42 yo AA male felt chilly 6 days earlier. He took a 
NyQuil and skipped next day’s shift for body aches/GI cramps. He improved but again felt 
bad by HS, 48h later. Next AM in a local ER, his UA showed WBC/RBC, 3+ protein, and a 
SG of 1.030. Physical exam, chest X-ray, contrast abdominal CT, and eGFR, were normal. 
He improved and worked full capacity again, but got admitted 48h later after a brief syncope.
Case Description: Vital signs: T 103 °F, BP 100/60 mm Hg, and HR 76 bpm. He had 
transient mild diarrhea. Serum albumin (Alb) was 2.1 g/dl, creatinine (cr) 2 mg/dl, and 
WBC 3•103/ml. UA had WBC/RBC and >0.5 g/dl protein. UNa was 21 mmol/l. His urine 
protein was >12 g/24h. CRP was >2 (<0.5 ng/dl), and ESR 50 mm/h. CPK was 8717 U/l 
and < half by 48h. Hep B, C, and HIV-1/-2 Ab screens were (-), but (+) for HIV p24 Ag. 
He had >3•106 HIV copies/ml, and 213 CD4+ cells/ml. US showed normal-sized kidneys, 
no obstruction, but some cortical echogenicity.
His cr first improved for 72h, but then rose to >8 mg/dl in 1w. Dialysis and HAART 
were initiated. By then he had edema and Alb was 
1.2 g/dl. Renal biopsy showed collapsing GN, podocyte hypertrophy/hyperplasia, 
microcystic tubular dilatations, 3+ acute tubular injury, 2+ patchy (mostly lymphocytic) 
infiltrate with focal tubulitis, and no signs of chronicity. Prednisone was added. He 
seroconverted (HIV-1) 2w after his first chills.
Discussion: Of the case reports of primary renal HIV infection only 2 had biopsy-
proven HIVAN. One was HIV Ab (-) but had 700,000 HIV copies/ml (Levin ML et al. 
2001); the other was HIV Ab (+) by EIA but not by Western blot, and had 70,000 HIV 
copies/ml (Szabo S et al. 2002). Both had advanced RF and already other infections. Our 
patient had normal eGFR until his acute HIV infection. The high HIV Ag load alone, not 
replication, is the sole likely cause for HIVAN, consistent with the view that a direct toxic 
effect of some HIV gene product causes podocyte dedifferentiation, since viral particle 
endocytosis readily occurs in podocytes (as their normal filter cleaning role?), but lack of 
HIV entry receptors precludes local replication (Khatua AK et al. 2010).
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FR-PO001
A Case of Hypercalcemia with Renal Failure: Renal Sarcoid? 
Eduardo J. Zouain, Isha Gupta, Karim El Hachem, Steven D. Smith, Ira S. 
Meisels.  Nephrology Dept, Mt. Sinai St. Luke’s Hospital and Icahn School of 
Medicine at Mt. Sinai, New York, NY.
Introduction: Sarcoidosis is a multisystem granulomatous disease of unknown 
etiology characterized by noncaseating granulomas in involved organs. Renal involvement 
occurs in 35-50%, manifested by hypercalciuria, hypercalcemia, nephrocalcinosis, and 
nephrolithiasis. Granulomatous interstitial nephritis is the most typical histological finding, 
usually in the setting of systemic disease and rarely in the absence of extrarenal sarcoid.
Case Description: A 54 y/o male presented with AKI superimposed on CKD and severe 
hypercalcemia (Calcium 13.5mg/dl, Cai=1.7mmol/L, creatinine=7.59mg/dl). Six months 
prior he had a kidney stone removed at which time his creatinine was 2.4mg/dl with Ca=11 
but no further work up was performed. He was taking no medications and complained of 
back pain. Physical exam was unremarkable. A CT scan was negative for nephrolithiasis 
or hydronephrosis, chest X-ray revealed no abnormality. He was aggressively treated with 
IV NS and then Lasix with minimal improvement in the creatinine or the serum calcium. 
Work up for hypercalcemia included normal serum and urine immunofixation, negative 
PPD, normal PSA and normal skeletal survey. 25 Hydroxyvitamin D 27.8ng/ml (30-95ng/
mL), PTH suppressed at <3pg/ml, total 1, 25 HydroxyVitamin D 79pg/ml (18-72pg/mL), 
and Angiotensin Converting enzyme 82 (9-67U/L). A formal ophthalmologic exam and 
PFTs were normal. A diagnostic kidney biopsy was performed. 
Discussion: The diagnosis of sarcoid interstitial nephritis was strongly suggested by the 
renal biopsy given that other causes of granulomatosis were ruled out. The patient was started 
on prednisone 60mg/d with rapid resolution of the hypercalcemia and slow improvement in 
renal function (Creatinine 2.9mg/dl). A slow steroid taper over 1 year is planned.
FR-PO002
Pediatric Chronic Refractory SIADH: Use of Tolvaptan  Cristin Kaspar, 
Nianzhou Xiao, Timothy E. Bunchman, Megan M. Lo.  Pediatric Nephrology, 
Children’s Hospital of Richmond at Virginia Commonwealth Univ, Richmond, VA.
Introduction: The syndrome of inappropriate antidiuretic hormone (SIADH) is the 
most common cause of euvolemic hyponatremia in hospitalized patients, and standard 
therapies can be limited in their effectiveness. Arginine vasopressin receptor antagonists 
(AVR-A) oral tolvaptan and intravenous conivaptan have been FDA approved in adults, 
but reports on long-term use in pediatrics are lacking. We report on the dosing and safety 
of chronic AVR-A treatment in two patients with chronic SIADH. Dosing regimen was 
extrapolated from current pediatric and adult literature.
Case Description: Case A is a 13 year old, 43.5 kg female with a 12-year history of 
pituitary astrocytoma treated with an experimental chemotherapy agent. She developed 
chronic refractory SIADH and was treated with IV conivaptan load and continuous infusion 
of 0.2-0.5 mg/kg/day, discontinued after 74 hours. Oral tolvaptan for outpatient treatment 
was then started at 0.7 mg/kg/day (15 mg twice daily) which induced nausea and thirst but 
[Na+] rose only to 129 mmol/L. Dosage was titrated and weaned off after 82 days. Case B 
is a 13 year old, 47.3 kg female who developed refractory SIADH as her initial presentation 
of an olfactory neuroblastoma. She was treated with conivaptan load and infusion of 0.2 
mg/kg/day, titrated off after 32 hours. She received tolvaptan starting at 0.15 mg/kg/day 
and discontinued once the mass was excised after 27 days.
Discussion: Stable tolvaptan dosing was reached at 0.15-0.3 mg/kg/day (7.5 mg 
daily or twice daily) and weaned to 0.08 mg/kg (3.5 mg) daily or every other day before 
being discontinued in both patients. Case B had elevation of serum creatinine when on 
IV conivaptan and fluid restriction. Neither patient had complications of hypokalemia, 
hypernatremia, or liver dysfunction. Both patients required frequent monitoring of serum 
sodium and regular titration of dose and oral fluid intake. We recommend starting tolvaptan 
at 0.15-0.3 mg/kg/day. The use of tolvaptan in an outpatient setting for chronic hyponatremia 
is safe and effective in adolescent patients with close monitoring.
FR-PO003
Methylmalonic Acidemia: An Unexpected Consult for an Adult 
Nephrologist: A Case Report  Yogita Lakhera, Seyed-ali Sadjadi.  Nephrology, 
JL Pettis VA Medical Center, Loma Linda Univ School of Medicine, Loma 
Linda, CA.
Introduction: Organic acidemias are caused by deficiencies of enzymes involved 
in the breakdown pathways of amino acids, fatty acids and carbohydrate metabolism. 
Methylmalonic academy (MMA) is a heterogeneous group of disorders of impaired 
metabolism of methylmalonic acid. We present a patient with MMA who was admitted 
with severe metabolic acidosis.
Case Description: A 21 year old male with past medical history of end stage renal 
disease on peritoneal dialysis, chronic pancreatitis, diabetes mellitus and coeliac diseas 
presented to emergency room with diarrhea. He denied fever, abdominal pain and vomiting. 
He was hypotensive. Laboratory tests showed metabolic acidosis with anion gap of 33 
mMol/L and absence of leukocytosis. Arterial blood gas result was, pH:7.38, pCO2:18 
mmHg, paO2: 108 mmHg and HCO3: 10 mMol/L. Patient was kept NPO and acidosis 
worsened the next day.
Labs (mMol/L) Day 1 Day 2 Day of discharge
Na 144 156 133
K 3.9 2.5 3.9
Cl 96 104 89
CO2 15 5 22
Lacate 8.2 20.4 5.5
Initial treatment included fluid boluses with NS, bicarbonate drip and broad-spectrum 
antibiotics for suspected sepsis. Further history revealed that patient had MMA and then 
iv fluid was changed to D20NS with insulin drip. He was started on special formula feed 
for MMA. Daily peritoneal dialysis was continued. Serum ammonia, β-hydroxybutyrate 
and lipase levels were normal. Blood and stool cultures grew salmonella enteritidis and 
antibiotics were switched to iv ciprofloxacin and metronidazole. With assistance from 
metabolic specialist, nephrologist and endocrinologist, patient was treated successfully.
Discussion: MMA is a rare autosomal recessive disorder (incidence of 1:48,000), caused 
by deficiency of methylmalonyl-CoA mutase or its cofactor, cobalamin. It is associated 
with anion gap metabolic acidosis, hypoglycemia, ketonuria and hyperammonemia. 
Metabolic decompensation can occur during episodes of increased catabolism such as 
prolonged fasting. Treatment of acute illness includes, providing hydration with high 
caloric supplementation, stopping all protein intake for 1-2 days and reintroduction of a 
low protein diet later. Severe acidosis may require dialysis.
FR-PO004
Congenital Pituitary Stalk Interruption Syndrome (PSIS) Newly Diagnosed 
in Case of Hyponatremia in the Elderly  Kenji Kajitani, Takahito Ito, Kaori 
Takaori, Yoko Tomiyama, Ikue Nagayama, Masafumi Yamato, Akira Wada, 
Hirotsugu Iwatani.  Nephrology, Osaka National Hospital, Osaka, Japan.
Introduction: There are many diseases that cause hyponatremia. Among them, 
adrenal insufficiency (AI) is important due to its urgency. We present an extremely rare 
case of elderly-onset AI in congenital PSIS, which is highly suggestive of the mechanism 
of AI progression.
Case Description: A hyponatremic episode (Na 117 mEq/L) occurred in a 76 year-old 
Japanese man in conjunction with common cold. Laboratory analyses revealed a low serum 
cortisol level. He was short-statured, had no hair growth on his axilla and pubis, and had 
unusual pale pigmentation in skin. He presented with gynecomastia and micropenis. CT scan 
revealed anorchism. He was not mentally retarded. Serum hormonal analyses showed AI, 
hypothyroidism, growth hormone deficiency, hypogonadism and hyperprolactinemia. A set 
of CRH/TRH/GHRH/LHRH stimulation test disclosed hypothalamic panhypopituitarism. 
Brain MRI visualized severely pressed 2-mm thick pituitary, but not the pituitary stalk, 
indicating PSIS.
Discussion: We concluded that his PSIS was not an acquired but a congenital anomaly 
based on his episode of intrauterine growth retardation and anorchism in the light of 
embryology. In PSIS patients, the functions of pituitary are sometimes maintained even 
if partially, although hypophyseal portal vessel snaps apart. This is because hypothalamic 
hormones reach pituitary through the superior hypophyseal artery (SHA), the nutrient 
artery of both hypothalamus and pituitary. In this case, the echogram of the internal carotid 
artery, from which SHA branches showed severe atherosclerosis. We speculate that the 
progression of atherosclerotic changes impaired the blood flow of SHA and then decreased 
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the delivery of hypothalamic hormones to pituitary, resulting in elderly-onset AI. Thus, 
blood flow disturbance of SHA can induce AI in PSIS. In conclusion, a congenital disorder 
can be the cause for elderly-onset adrenal insufficiency. This case suggests that pituitary 
stalk interruption syndrome should be taken into account as a differential diagnosis for 
hyponatremia, even in the elderly, especially in short-statured patients.
FR-PO005
A Family Case of Hypoparathyroidism, Deafness, and Renal Dysplasia 
Syndrome with a Novel Mutation of GATA3  Tomoo Yabuuchi,1 Shoichiro 
Kanda,1 Naoya Morisada,2 Keiichi Takizawa,1 Yuji Tomii,1 Naoto Kaneko,1 
Hirotaka Hama,1 Eiji Nakano,1 Norimasa Tada,1 Kiyonobu Ishizuka,1 Hiroko 
Chikamoto,1 Yuko Akioka,1 Kazumoto Iijima,2 Motoshi Hattori.1  1Dept of 
Pediatric Nephrology, Tokyo Women’s Medical Univ, Shinjyuku-Ku, Tokyo, 
Japan; 2Dept of Pediatrics, Kobe Univ Graduate School of Medicine, Chuo-
ku, Kobe, Japan.
Introduction: Congenital anomalies of the kidney and urinary tract (CAKUT), a 
major cause of end-stage renal disease in children, often present as a systemic disorder with 
extrarenal symptoms. Extrarenal symptoms and family history are helpful in the genetic 
diagnosis of CAKUT. We report here a family case of hypoparathyroidism, deafness, and 
renal dysplasia (HDR) syndrome with a novel mutation of GATA3.
Case Description: Soon after birth, a female patient was diagnosed as having bilateral 
cystic dysplastic kidneys by renal ultrasonography. She also had hearing impairment 
at the infancy. She received peritoneal dialysis at the age of 3 years and received a 
cadaveric kidney transplant at the age of 10 years. When she was 14 years old, she visited 
the emergency department because of acute abdomen. Detailed examinations showed 
hematometra associated with vaginal atresia. Branchio-oto-renal syndrome was considered 
as her diagnosis based on her hearing impairment, bilateral cystic dysplastic kidneys, and 
normocalcemia However, we suspected that she had an HDR syndrome because we found 
that her mother had hypoparathyroidism after determining a detailed family history. Genetic 
analysis was approved by the central ethics board of Tokyo Women’s Medical University 
and Kobe University. This analysis showed a novel mutation, c. 1013G>T (C338F) of 
GATA3, the causative gene for HDR syndrome.
Discussion: Our patient did not show any symptoms of hypoparathyroidism. However, 
based on the family history, we performed a genetic analysis and found a novel mutation 
of GATA3. She was then diagnosed with atypical HDR syndrome. Therefore, determining 
a detailed family history is important in the precise diagnosis of CAKUT patients.
FR-PO006
Hypocomplementemic Urticarial Vasculitis Syndrome Resistant to 
Corticosteroid and Plasma Exchange Therapy  Yasuhiro Kawai,1 Kenji 
Ueki,1 Yuta Matsukuma,1 Hiroto Hiyamuta,1 Akihiro Tsuchimoto,1 Kiichiro 
Fujisaki,1 Kumiko Torisu,1 Kosuke Masutani,1 Kazuhiko Tsuruya,2 Takanari 
Kitazono.1  1Dept of Medicine and Clinical Science, Kyushu Univ, Fukuoka 
City, Japan; 2Dept of Integrated Therapy for Chronic Kidney Disease, Kyushu 
Univ, Fukuoka City, Japan.
Introduction: We present a case of HUVS resistant to corticosteroid and plasma 
exchange.
Case Description: A 36-year-old Japanese man with the history of diffuse pan-
bronchiolitis developed microscopic hematuria, proteinuria, and kidney dysfunction. 
Percutaneous kidney biopsy was performed at the other hospital, and the diagnosis was 
non-IgA mesangial proliferative glomerulonephritis. In spite of the administration of 
angiotensin II receptor blocker, progressive kidney dysfunction was evident. Then he was 
transferred to our hospital 4 months later. He also had a history of urticarial rash on his leg, 
and pigmentation was evident at the time of transfer. Urinalysis revealed 3+ proteinuria 
and 3+ hematuria, and urinary sediment showed red blood cells of 50-99/high power field. 
Urinary protein/creatinine (Cr) ratio was 2.9 g/gCr. Blood tests revealed a serum Cr level 
of 2.4 mg/dL, complement (C) 3 level 18 mg/dL, and C4 level 23 mg/dL. We performed 
kidney biopsy again, and found membranoproliferative glomerulonephritis with crescents. 
Since additional blood test revealed serum anti-C1q antibodies of 51,965 U/mL, the 
diagnosis of HUVS was made. We treated him with methylprednisolone pulse therapy 
followed by oral prednisolone, but his kidney function was unchanged and he developed 
bacterial pneumonia. Next, we added plasma exchange, and found a temporal decrease in 
proteinuria accompanied by a decrease of serum anti-C1q antibody level. But his kidney 
function did not recover, and the level of anti-C1q antibody raised again.
Discussion: HUVS is a small vessel vasculitis associated with recurrent urticarial rash, 
hypocomplementemia, and anti-C1q antibodies. Safe and effective treatment for HUVS 
has not been established. Although corticosteroid and plasma exchange showed temporal 
efficacy, it was impossible to suppress the progressive kidney dysfunction in this case.
FR-PO007
Acquired Fanconi Syndrome in a Patient with Acetaminophen Overdose 
Deepak Jasuja, Jay B. Wish.  Div of Nephrology, Indiana Univ, Indianapolis, IN.
Introduction: Acquired Fanconi syndrome is described in patients receiving 
antiretrovirals, aminoglycosides, platinum compounds and with proximal tubulopathies 
due to light chain disease/ paraproteinemias. We describe a case of acetaminophen induced 
acute tubular necrosis (ATN) presenting as Fanconi syndrome with hypophosphatemia, 
normoglycemic-glucosuria, aminoaciduria, and uric acid, potassium and bicarbonate 
wasting.
Case Description: A 35 year old woman with borderline personality disorder, 
depression, alcohol abuse, multiple suicide attempts, and previous acetaminophen 
overdose was transferred from outside hospital with fulminant hepatic failure secondary 
to acetaminophen poisoning. Nephrology was consulted for metabolic acidosis and AKI. 
On exam she was oriented to person only and following minimal commands. She had 
acute fulminant hepatic failure as evidenced by transaminase elevations, encephalopathy, 
and coagulopathy. On presentation her serum creatinine was 2.95 which rose over the next 
3 days to 9.06. Initial blood gas was consistent with metabolic acidosis and respiratory 
compensation. Serum potassium (K) was low (2.9-3.5) despite large doses of K supplements. 
Her K requirements abated when bicarbonate supplementation was discontinued. 
Acetaminophen level was elevated on transfer at 21 and urine drug screen was positive 
for opiates and benzodiazepines; toxic alcohols were negative. Serum uric acid was <1.5 
mg/dL and phosphorus <1 mg/dL. Glucose was 1-2+ on urinalysis with normal blood 
glucose. The following amino acids were elevated in her urine: aspartic acid, beta alanine, 
citrulline, gamma amino acid butyric acid, glutamic acid, leucine, ornithine, prolline, taurine 
and valine. This was a non-specific pattern of generalized aminoaciduria consistent with 
proximal tubulopathy and acquired Fanconi syndrome. The patient subsequently recovered 
renal function and the proximal tubulopathy resolved.
Discussion: It is important for nephrologists to be aware that ATN (in this case 
acetaminophen induced) can lead to acquired Fanconi syndrome and proximal tubulopathy 
which seem to resolve as ATN resolves. Aggressive treatment with bicarbonate supplements 
can exacerbate urinary K wasting and should be avoided.
FR-PO008
Spontaneous Remission of Non-Parasitic Chyluria  Hillel Sternlicht,1 
Lakshmi V. Ramanathan,2 Martin Fleisher,2 Edgar A. Jaimes,2 Ilya Glezerman.2 
1Div of Nephrology and Hypertension, Weill Cornell Medical Center, New York, 
NY; 2Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Introduction: Chyluria is a medical condition characterized by the presence of chyle 
in the urine. The disease is most prevalent in South East Asian countries mostly caused 
by parasitic (Wuchereria bancrofti) infections. Chyluria presents as a cloudy milk-colored 
urine accompanied by systemic symptoms such as weight loss, fatigue, and rarely, flank 
pain from retained clots.
Case Description: A 72 year-old woman presented to Nephrology clinic complaining of 
milky urine (Figure 1) and painless hematuria with clots for two months as well as twenty-
pound weight loss. Physical exam was unremarkable. Cystoscopy and urine cytology were 
unremarkable. Serum albumin was 3.2 g/dL. A urinalysis showed 3+ protein and 50 red 
blood cells per HPF. Urine sediment had no dysmorphic cells or casts. A 24-hour urine 
collection revealed 8.8 grams of protein. Chyluria screen was positive for chylomicrons and 
triglycerides. Midnight blood smears were negative for filarial parasites. Urine culture was 
negative for mycobacteriae or schistosomas. Serologic studies including IgG western blot 
for cysticercus and IgG ELISA for filariasis were negative. The rapid plasma reagin (RPR) 
was also negative. Imaging for a lymphatic leak by lymphoscintigraphy was unrevealing. 
The patient was managed conservatively and underwent spontaneous remission with 
disappearance of chyluria several months of her initial diagnosis.
Discussion: The most common cause of chyluria is parasitic infection with 
granulomatous diseases or structural etiologies less frequently encountered. Sclerotherapy of 
the renal pelvis is the definitive treatment. Idiopathic chyluria as shown in this case is rare. 
Conservative management of idiopathic disease may be warranted due to the possibility 
of spontaneous remission.
FR-PO009
Rebound Hypertension and Hypokalemia After Stopping Drospirenone 
Kalyani Chandra, Shubha Ananthakrishnan.  Nephrology, UC Davis Medical 
Center, Sacramento, CA.
Introduction: Drospirenone is the fourth generation oral contraceptive with 
antimineralocorticoid effects, which are reported to be generally mild. There have 
been several warnings issued for drospirenone, in relation to adrenal insufficiency and 
hyperkalemia. But, no reports thus far of the rebound effects like hypertension (HTN) and 
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hypokalemia, following the discontinuation of the medication, especially after prolonged 
use. Review of literature, to our best knowledge, suggests this to be the first case report 
demonstrating the association between HTN, hypokalemia and drospirenone.
Case Description: A 54 year-old Indian woman, previously normotensive, noted a 
new rise in home BP to 200/100 mm Hg and presented to the emergency department, where 
she was also noted to have mild hypokalemia to 3.1 mg/dL. Given the rather new onset 
of severe HTN and hypokalemia, work-up for secondary causes of HTN was done, which 
revealed normal aldosterone level (9 ng/dL), low plasma renin activity (PRA) (0.15 ng/
mL/hr) and high aldosterone/PRA ratio (60). Looking back into her history, it was noted 
that, the timing of symptoms was closely related to discontinuing Yasmin® (30 µg ethinyl 
estradiol and 3 mg drospirenone), which she was taking for over 6 yrs. She was thought to 
have rebound effect with relatively excess mineralocorticoid activity, precipitated by the 
abrupt discontinuation of drospirenone. With the introduction of low dose spironolactone, 
her symptoms significantly improved.
Discussion: Drospirenone (an analogue of spironolactone), which has 
antimineralocorticoid and antiandrogenic activities similar to endogenous progesterone, 
counteracts the estrogen-mediated stimulation of the renin-angiotensin-aldosterone system 
(RAAS). Due to these effects, it has the potential to decrease blood pressure and also 
cause hyperkalemia. At a dosage that suppresses ovulation, drospirenone induces mild 
natriuresis, which is followed by compensatory stimulation of the RAAS (comparable to 
a low sodium diet). When the prolonged ongoing suppression for the RAAS is removed, 
there might be a potential rebound effect with (relatively) high aldosterone state, resulting 
in sodium retention, leading to HTN. Spironolactone appears to be useful in this situation.
FR-PO010
Acthar Induced Hypokalemic Metabolic Alkalosis  Imran Quyyum, Neil 
W. Lyman.  Dept of Nephrology, St. Barnabas Medical Center, Livingston, NJ.
Introduction: Acthar, an ACTH formulation from porcine pituitary gland, is an 
effective therapy for Membranous Nephropathy (MN). A rare adverse effect of hypokalemic 
alkalosis has been described in infants only. We present a case report of an 84 y/o Caucasian 
female who developed severe hypokalemia and metabolic alkalosis with Acthar therapy 
and concomitant diuretic use.
Case Description: The patient presented with severe bilateral leg edema. Lower 
extremity doppler was negative for DVT. Echo revealed normal EF. UA showed 4+ protein 
and 2+ blood. Spot protein/creatinine ratio was 20g. Urine sediment had no RBC casts. Her 
scr was 1.99 mg/dL. (baseline 1.34 mg/dL). Albumin was 2.3 g/dL. Workup for malignancy 
was negative. Her serologies were unremarkable and a renal ultrasound was negative. 
Anti-PLA2 Ab was positive. Renal biopsy was consistent with MN. Acthar therapy was 
preferred due to her advanced age. Acthar 80 units 2x/week was added to her regimen of 
furosemide, amiloride, losartan and hydrochlorothiazide. Protein excretion decreased from 
20g to 5g. Scr and albumin improved to 1.16 mg/dL and 3.4 g/dL, respectively. Follow up 
labs revealed potassium of 2.1 mmol/L and serum bicarbonate of 40 mmol/L. Acthar and 
diuretics were held and K+ was repleted. Acthar at 40 units 2x/week was later restarted due 
to worsening renal function and proteinuia. However, patient was readmitted three weeks 
later with K+ of 2.3 mmol/L and bicarbonate of 35 mmol/L which prompted termination 
of Acthar. She currently remained in partial remission with less than 5g of proteinuria.
Discussion: ACTH increases endogenous steroid production via MelanoCortin 
Receptor (MCR) type 2. It also exerts direct beneficial effects on podocytes and glomerular 
cells via other MCR subtypes. ACTH is an effective, alternative therapeutic modality 
for MN as well as other causes of nephrotic syndrome. Importantly as our case report 
demonstrated, the concomitant use of ACTH and diuretic therapy can result in severe 
hypokalemic metabolic alkalosis. Clinicians should closely monitor serum electrolytes 
after initiating Acthar.
FR-PO011
Polycythemia in a Patient with Bartter’s Syndrome and Medullary 
Nephrocalcinosis  Girlie Singian Merdegia.  Medicine, Philippine General 
Hospital, Manila, Metro Manila, Philippines.
Introduction: Bartter’s syndrome is a tubular salt wasting disorder presenting 
with severe hypokalemic alkalosis, hypochloremia, and hyperreninemia with normal 
blood pressure.  Medullary nephrocalcinosis in this disorder is an infrequent finding 
and is still generally unrecognized. Polycythemia is an unusual presentation in patients 
with renal diseases, but has been described in literature among patients with nephrotic 
syndrome and distal tubular acidosis. It is noteworthy, however, that reports on secondary 
erythrocytosis among patients with Bartter’s syndrome is lacking. The exact mechanism 
for the polycythemia is still uncertain, although postulates include hypoxia induced by 
nephrocalcinosis causes stimulation of oxygen receptors thus increasing erythropoietin 
secretion, and stimulation of prostaglandin production may be contributory.
Case Description: A 27 year old Filipino male with recurrent bouts of severe 
hypokalemia since childhood presenting as bilateral lower extremity weakness necessitating 
recurrent hospital admissions was diagnosed with Bartter’s syndrome based on metabolic 
alkalosis, hypokalemia, hypochloremia, slight hyponatremia with normal serum calcium 
and magnesium levels. He had normal blood pressure and no frank hypercalciuria. His 
creatinine was elevated at baseline and his ultrasound revealed normal sized kidneys with 
bilateral nephrocalcinosis. He has elevated hemoglobin of 190 g/L, slight leukocytosis 
with no thrombocytosis. JAK2 mutation was negative and a bone marrow biopsy revealed 
mildly hypercellular marrow with trilineage hematopoiesis, mild plasmacytosis for which 
polycythemia vera was ruled out. Findings were said to be consistent with a reactive marrow. 
He underwent as needed phlebotomy and was maintained on potassium replacement, 
spironolactone and an ace-inhibitor.
Discussion: The association of Bartter’s syndrome with medullary calcinosis and 
secondary erythrocytosis is a rare entity with very limited data in literature. The mechanism 
leading to secondary erythrocytosis, as well as nephrocalcinosis among patients with 
Bartter’s syndrome remains uncertain. Clinicians should be aware of potential complications 
of this disorder so as to institute appropriate management.
FR-PO012
Homozygous Deletion of CFHR3-CFHR1 as a Cause for Atypical Hemolytic 
Uremic Syndrome in a Patient with Systemic Lupus Eyrthematosus 
Salem Almaani,1 Tibor Nadasdy,2 Samir Parikh.1  1Div of Nephrology, The 
Ohio State Univ, Columbus, OH; 2Dept of Pathology, The Ohio State Univ, 
Columbus, OH.
Introduction: Thrombotic microangiopathy (TMA) is a rare but devastating condition 
associated with systemic lupus erythematosus (SLE). In SLE, renal TMA is typically 
associated with the anti-phospholipid syndrome 9APS) or TTP. Here we report a case of 
atypical hemolytic uremic syndrome (aHUS) associated with SLE that was confirmed by 
complement genetic studies and treated successfully with Eculizumab.
Case Description: A 21 year old African American female with a history of SLE and 
class II+V lupus nephritis was hospitalized after presenting with AKI, thrombocytopenia 
(TCP), and a microangiopathic hemolytic anemia (MAHA). Initial lab values revealed a 
serum creatinine of 3.5 mg/dl, platelet count of 58, hemoglobin of 7.3, and LDH of 1484. 
Plasmapheresis and IV solumedrol was started empirically for presumed TTP and SLE flare. 
ADAMTS13 enzyme activity was normal and APS antibodies were negative. There was no 
improvement and the patient was started on dialysis. The patient required multiple blood 
transfusions as TCP and MAHA persisted. A kidney biopsy was performed and findings 
were consistent with severe TMA. The patient was empirically started on Eculizumab and 
after the first dose, TCP improved rapidly, with a platelet counts increase from 77K of 
170K. Complement mutation studies were obtained and revealed a homozygous deletion 
of CFHR3-CFHR1 genes. The patient continued on Eculizumab, and after 4 months she 
recovered renal function and was liberated from dialysis.
Discussion: This is the first report of aHUS associated with SLE in a patient with an 
identified complement mutation. Our patient had a homozygous deletion of CFHR3-CFHR1, 
which has previously been linked to aHUS. CFHR3-CFHR1-deficient plasma is thought to 
contribute to defective regulation of complement activation on the cell surface and occurs 
despite the presence of normal factor H and I levels. Treatment with Eculizumab is effective 
and should be started promptly so disease can be halted and chronic damage limited.
FR-PO013
A Novel Mutation in KLHL3 Gene Causes Familial Hyperkalemic 
Hypertension  Mohd Radzi Rodzlan Akib,1 Dearbhla Kelly,1 Xavier 
Jeunemaitre,2 Catherine A. Wall.1  1Nephrology, Adelaide & Meath Hospital, 
Dublin, Ireland; 2Département de Génétique et Centre de Maladies Vasculaire 
Rares Hôpital Européen Georges Pompidou, Paris, France.
Introduction: Familial hyperkalemic hypertension is an autosomal dominant disorder 
where mutations in the regulators of the thiazide-sensitive NaCl co-transporter (NCC) cause 
salt-dependent hypertension. Implicated genes include WNK1, WNK4, KLHL3 and CUL3. 
These lead to increased activity of the NCC in the distal nephron, excessive chloride and 
sodium reabsorption, and volume expansion. We describe a novel disease-causing variant 
in KLHL3 not previously reported in the literature.
Case Description: An 18 year-old man with no prior medical history presented with 
an incidental finding of serum potassium of 7.3mmol/L. He was hypertensive with blood 
pressure 150/90mmHg. His mother, maternal uncle and grandmother also had a history of 
early onset hypertension and unexplained hyperkalemia. 
His labs showed serum sodium 139mmol/L, chloride 103mmol/L, creatinine 
83mmol/L. His arterial blood pH was 7.37 with bicarbonate 21. His plasma renin activity 
was suppressed at 0.2ng/ml/H and his serum aldosterone was raised at 534.4pmol/L. The 
transtubular potassium gradient was 3.87. Genetic analysis of the patient and affected family 
members revealed a missense mutation affecting exon 13 of the gene KLHL3 (c.1492C >T 
p.His498Tyr) affecting a residue located in the 5th kelch motif of the protein . The patient 
was treated with dietary salt restriction and a thiazide diuretic.
Discussion: This man illustrates classic findings in familial hyperkalemic hypertension 
including hypertension, hyperkalemia, metabolic acidosis and positive family history. Cases 
such as this give us further insight into the molecular pathophysiology of blood pressure 
control. KLHL3 gene products play a key regulatory role in distal nephron Na reabsorption 
and may have potential as anti-hypertensive drug targets.
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FR-PO014
Renal Failure Run A-FUOwl: Disseminated Histoplasmosis  Eileen Smith, 
Rajeev Raghavan, Sreedhar A. Mandayam.  Baylor College of Medicine, 
Houston, TX.
Introduction: In patients with fever of unknown origin (FUO) and glomerulonephritis, 
Histoplasma capsulatum should be considered.
Case Description: A 37-year-old man presented to the hospital with 3 weeks of fatigue, 
15-pound weight loss, intermittent chest pain, dyspnea on exertion and 3 day history of 
erythematous pruritic rash on his neck. PMH included congenital aortic stenosis with AVR, 
complicated by endocarditis requiring repeat AVR. Physical exam found splenomegaly and 
a lacy erythematous rash on the neck and torso. On admission, creatinine was 3.15 mg/dL 
(baseline 1mg/dL last year) with gross hematuria, and new pancytopenia. Initial work-up 
for glomerular disease was non-diagnostic. He developed persistent cyclical fevers to 102°F 
during his hospital stay. Blood cultures, tagged WBC scan and TEE were negative. Kidney 
biopsy showed numerous electron-dense deposits suggestive of Membrano-Proliferative 
Glomerulonephritis with active interstitial inflammation. Further history revealed the 
patient regularly cleaned a chicken coop. An infectious work-up found the patient to be 
strongly positive for the Histoplasma capsulatum urinary antigen. With itraconazole for 
histoplasmosis and concomitant steroid therapy for glomerulonephritis, he defervesced 
and his creatinine improved to 1.4 mg/dL.
Discussion: Infection Related Glomerulonephritis (IRGN) is an immune-mediated 
disease caused by non-renal pathogens. The incidence is higher in developing countries: 
for example, per 100,000 individuals, the incidence of cases per year is 39 in India and 0.78 
in the United States. It is believed that sub-clinical IRGN is common and underdiagnosed. 
In a study of 1012 kidney biopsies, 10% had evidence of disease, such as subepithelial 
humps. Hematuria is present in > 80% of cases, and patients usuallly present with Nephritic 
Syndrome. Endemic mycoses as a cause of glomerular disease in humans are rare. An 
infection due to H. capsulatum can result from inhalation of aerosolized spores after 
disruption of chicken droppings harboring the fungus. We suspected endocarditis given 
his cardiac history, and kidney biopsy findings also supported infection. However, the 
splenomegaly, FUO, and exposure to fowls (FUOwls) established the diagnosis.
FR-PO015
Next Generation Sequencer Driven Exome Analyses Identified a MCKD1 
Family with New Mutation Before VNTR Of MUC1 DNA Sequence, 
Suffering from Mucosal Dysfunctions  Satoko Yamamoto,2 Jun-Ya Kaimori,1 
Masaki Hatanaka,2 Naotsugu Ichimaru,1 Shiro Takahara,1 Hiromi Rakugi,2 
Yoshitaka Isaka.2  1Dept of Advanced Technology of Transplantation, Osaka 
Univ Graduate School of Medicine, Suita, Osaka, Japan; 2Dept of Geriatrics 
& Nephrology, Osaka Univ Graduate School of Medicine, Suita, Osaka, Japan.
Introduction: Hereditary tubulo-interstitial nephritis (h-TIN) is characterized by 
family history, bland urine, normal size kidney, hyperuricemia, renal fibrosis and gradual 
renal function loss. MCKD1 type h-TIN is also recognized by the difficulty to identify 
mutant sequence by conventional Sanger Sequencer or next generation sequencer, because 
the cytosine insertion mutation locates in the GC rich valuable number tandem repeat 
(VNTR) region. The mutant MUC1 DNA sequence is supposed to produce truncated type 
protein, which is inhibited to be trafficked to the cell membrane. Because of the difficulty 
of identification, there may be lots of unknown symptoms in MDCK1.
Case Description: We identified 5 hereditary TIN patients in a family, three of those 
are renal transplant recipients, one is under dialysis, and the other was CKD. The CKD 
patient is 23 y.o female, whose renal function is gradually reducing for 10 years. Now 
her serum creatinin is over 3. Her renal MRI images showed normal size kidneys with no 
cysts. The patients are suffering from mucosal dysfunctions including GI ulcer, sinusitis, 
and dysphagia. We analyzed genome DNA sequence of hereditary TIN family by next 
generation sequencer driven trio exome analyses. They revealed that the 2 bp deletion 
mutation were located before VNTR. Interestingly, consequently produced mutant MUC1 
protein is a truncated protein with almost the same a.a. sequence repeats with previously 
reported mutant protein. The results were confirmed in the further analyses of other family 
members by conventional Sanger sequencer.
Discussion: We could identified the totally new mutation sequence of MDCK1 family, 
because it located before the GC rich VNTR sequence of MUC1. The newly identified 
mutant protein showed the almost same a.a. repeats sequence, suggesting these repeat 
sequence is implicated in the pathophysiology of MDCK1 type h-TIN.
Funding: Government Support - Non-U.S.
FR-PO016
Propofol-Induced Hyperkalemia in a Hemodialysis Patient  Ibrahim M. El-Ali, 
Chandana Shekar, Sarthak Virmani, Ruchir D. Trivedi.  Dept of Medicine, Div 
of Nephrology, Univ of Connecticut Health Center, Farmington, CT.
Introduction: Propofol induced hyperkalemia and propofol infusion syndrome are well 
described in the intensive care literature. Propofol induced sudden cardiac arrest, however, 
may be under recognized. We report a case in which a large bolus of propofol was associated 
with an acute increase in serum K+ precipitating potentially fatal cardiac arrhythmia.
Case Description: 59 y/o male on maintenance hemodialysis (HD), having missed 
2 HD sessions, presented with altered mental status and hyperkalemia. Patient required 
intubation for airway protection. Serum K+ was 8.2 mEq/L and confirmed with repeat of 
8.8 mEq/L. Propofol bolus was used as premedication for intubation followed by infusion 
at 20 mcg/kg/min. Ventricular fibrillation and cardiac arrest ensued soon after propofol 
bolus. Patient was managed with repeated calcium chloride bolus totaling 10 grams and 
urgent hemodialysis. Post-HD Serum K+ level was 4.5 mEq/L. Repeat K+ 10 hours after HD, 
with no other parameters being changed, was 7.1 mEq/L, increasing to 7.9 mEq/L within 
the next hour. Cardiac monitor showed widening QRS interval. No concurrent evidence 
of hemolysis, DIC or rhabdomyolysis. No exogenous K+was given. HD was re-initiated 
emergently to avoid recurrent cardiac arrhythmias. Propofol was discontinued with no 
recurrence of hyperkalemia.
Discussion: Direct mitochondrial respiratory chain inhibition similar to mitochondrial 
myopathy is the most plausible explanation for propofol infusion syndrome (PRIS); a rare 
but significant adverse effect of propofol. Impaired mitochondrial fatty acid metabolism 
leads to lactic acidosis causing trans-cellular potassium shifts to ECF resulting in 
hyperkalemia. Rapid rise of serum K+ is more closely correlated with onset of arrhythmia 
than absolute K+ levels. Propofol bolus can also cause sudden worsening of hyperkalemia via 
depressed beta adrenoceptor-agonist effect and acute transcellular shift of potassium. This 
complication can be fatal in ESRD patients who may have baseline hyperkalemia. Hence, 
propofol should only be used with extreme caution in ESRD patient population on HD.
FR-PO017
A CuriouSLE Tangled Case: Systemic Lupus Erythematosis as the Unifying 
Diagnosis for Fibrillary Glomerulopathy and Toxic Epidermal Necrolysis 
Kawan A. Swain, Hao Liu, Volker Nickeleit, Patrick H. Nachman.  Nephrology, 
Univ of North Carolina at Chapel Hill, Chapel Hill, NC.
Introduction: Fibrillary glomerulopathy is a rare cause of glomerular disease. Most 
cases are idiopathic but can be associated with autoimmune diseases.
Case Description: 58 yo Caucasian male with a past history of hypertension presented 
a week after developing an acute erythematous rash associated with fever, encephalopathy, 
and AKI. This was preceded by an 8 month history of intermittent night sweats, fever, and 
joint pain. The desquamating rash encompassed >30% BSA with mucosal involvement. 
Skin biopsy revealed acute vacuolar interface dermatitis consistent with toxic epidermal 
necrolysis (TEN). Labs showed pancytopenia without evidence of hemolysis. Serum Cr 
was 2.14 mg/dl (recently 0.9) and urine Protein/Cr was 1.1g. Urine microscopy showed 
numerous acanthocytes and a few RBC casts. Serologies revealed low C3 and C4, positive 
ANA 1:640 and ENA screen, but negative ANCA, cryoglobulins, infectious work up and 
antibodies to ds-DNA, Sm, RNP, Ro/SSA, La/SSB, Jo1 and Scl70. A kidney biopsy showed 
acute tubular injury and mild mesangial and endothelial proliferation without crescents or 
tuft necrosis. Immunofluorescence revealed diffuse 1-2+ staining for IgG, IgA, IgM, C3, 
C1q, kappa and lambda in the mesangium and capillary walls. Electron microscopy showed 
mesangial and capillary deposits with 20nm non-branching fibrils. Congo red stain was 
negative and IgG subclass stain did not reveal monoclonality. The findings were classified 
as a fibrillary glomerulonephritis. After initial methylprednisolone pulse, treatment with 
oral prednisone and mycophenolate mofetil resulted in resolution of rash, encephalopathy, 
and recovery of renal function and cell counts. The unifying diagnosis is new onset SLE, 
with TEN (possibly precipitated by naproxen) and fibrillary glomerulopathy.
Discussion: This case illustrates an uncommon presentation of an immune complex 
mediated fibrillary glomerulopathy consistent with SLE in an older male patient who 
presented with TEN. SLE has been rarely implicated as a cause of SJS/TEN when associated 
with initial photodistribution, absence of genital involvement, and a prolonged course.
FR-PO018
An Unusual Case of Renal Failure in an Adult: “Prune Belly Syndrome” 
Juan Antonio Medaura, Jeffrey D. Wallach, Sudhanshu Jain.  Nephrology, 
Harlem Hospital Center, New York, NY.
Introduction: Prune Belly Syndrome is a rare congenital disease characterized by 
hypoplastic abdominal wall musculature, severe urinary tract dilatation and bilateral 
undescended testes. The complete syndrome is seen only in males affecting 3.8 per 100,000 
live births. While the cause is unknown several aspects suggest an influence of genetic 
factors. Very few patients survive adulthood and all of them progress to ESRD.
Case Description: A 25-year-old male from Burkina Faso presented with a 10-day 
history of fever, rigors and right-sided flank pain. On exam he was found to have an empty 
scrotum and a distended bladder. He reported history of several urinary tract infections 
and urological surgeries during childhood. He was found to have azotemia (Sr. creatinine 
10.8 mg/dl and BUN 82 mg/dl) and an eGFR of 8 ml/ min/ 1.73m2. Urinalysis was cloudy 
with 2+ protein, 3+ leucocyte esterase, 2-5 WBC’s and moderate bacteria. Urine culture 
grew Enterococcus fecalis. CT of the abdomen showed a massively distended urinary 
bladder with diffuse wall thickening and calcification, severe bilateral hydroureter, mild 
left hydronephrosis, right renal atrophy.
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He received intravenous antibiotics and improved clinically.
Discussion: Although lower urinary tract and kidney malformations account for 40% 
of childhood ESRD it is a rare cause of kidney failure in adults. Mutation in the HNF1ȕ 
gene and homozygous loss-of-function mutation of muscarinic receptor M3 (CHRM3) 
were described. CHRM3 is the major receptor mediating urinary bladder contraction 
upon micturition. These patients have normal urethral patency on cystogram and detrusor 
hyporeflexia with high residual volumes after micturition seen on cystometry, identical to 
the findings in our report. This diagnosis in a 25 year old is rare, as most patients do not 
survive until adulthood or they are already ESRD.
FR-PO019
How ‘Idiopathic’ Is Idiopathic Hyeprammonemia?  Esho Georges, Kavitha 
Vellanki.  Nephrology, Loyola Univ Medical Center, Maywood, IL.
Introduction: Idiopathic hyperammonemia is characterized by progressive elevations 
in serum ammonia of unknown etiology, ultimately leading to cerebral edema and death. 
It is a rare fatal syndrome described in transplant setting; lung transplant recipients having 
the highest risk. Calcineurin inhibitors are thought to play a role but the exact mechanism 
is not known. Here we report an unusual case of severe hyperammonemia that has been 
linked to donor transmitted Ureaplasma infection.
Case Description: A 59 yr old Hispanic man with idiopathic pulmonary fibrosis received 
bilateral lung transplant at our center. His induction regimen included thymoglobulin and 
methylprednisolone and was maintained on tacrolimus, mycophenolate and prednisone. 
His post-operative course was fairly uncomplicated until he was found unresponsive due to 
seizure on day 14. Work up revealed serum ammonia level of 549 µg/dL. Tacrolimus was 
discontinued and he was started on lactulose, sodium benzoate, phenyl acetate and broad 
spectrum antibiotics and started on CVVHDF to help in management of hyperammonemia. 
Despite all these measures, ammonia levels remained persistently elevated at > 1700 µg/dL 
(Figure 1) and patient expired within 4 days. At autopsy, bronchoalveolar lavage (BAL) of 
transplanted lung tested positive for Ureaplasma urealyticum. On further testing, donor’s 
pre- transplant BAL was positive for the same organism. Lysis of urea by Ureaplasma 
generates free ammonia and when left untreated, can cause hyperammonemia. But the rise 
in serum ammonia levels of such a magnitude despite aggressive dialysis is unheard of.
Discussion: In conclusion; underlying infection with urea splitting organisms need 
to be considered when there is a high rate of ammonia production. And while we are in 
need of further studies, it may be worthwhile to empirically treat with azithromycin for 
Ureaplasma infection in so called “idiopathic hyperammonemia”.
FR-PO020
Pelvocalyceal Leakage on Ethanol Sclerotherapy for Recurrent Infected 
Renal Cyst in ADPKD  Eunyoung Lee, Joo-Hark Yi, Sang-Woong Han, 
Ho-Jung Kim.  Divsion of Nephrology, Dept of Internal Medicine, Hanyang 
Univ Guri Hospital, Guri-si, Gyeonggi-do, Republic of Korea.
Introduction: Though sclerotherapy has been commonly considered as a valid and 
safe therapeutic option for symptomatic renal cysts, it’s effectiveness in recurrent infected 
renal cyst in autosomal dominant polycystic kidney disease (ADPKD) is rarely reported.
Case Description: A 76-year-old woman with ADPKD was again admitted by infected 
(Lt) renal cyst (7.3 cm) on ultrasonography (US) with similar episode, 1 yr ago. She 
presented with a fever, dysuria and left CVA tenderness. Despite clinical and laboratory 
improvement with sensitive antibiotics against Klebsiella pneumonia for 14 days, the 
size of the infected renal cyst was paradoxically enlarged (8.9 cm) on follow-up US. 
Thus, percutaneous catheter was inserted for drainage and after 1 wk, tubogram showed 
no evidence of dye leakage (figure1-A). Following complete clinical recovery, absolute 
ethanol sclerotherapy was performed to prevent further recurrent cyst infection. However, 
she complained of severe burning pain in low abdomen at the beginning of the procedure. 
Tubogram dye was shown in pelvocaliceal system and ureter (figure1-B). Sclerotherapy 
was immediately stopped and saline irrigation was followed. Then, percutaneous catheter 
was remained into the cyst for further draining, and double-J catheter was inserted at 
ureteropelvic junction to prevent a ureteral stricture. Then, she underwent uneventful 
hospital course, and discharged on hospital day 42.
Discussion: Infected renal cyst wall, despite clinical recovery, could consist of already 
damaged tissue that may be easily broken by ethanol. Through this unexpected adverse 
complication, we learned that cyst ablation therapy with ethanol may not be an appropriate 
modality to prevent recurrent renal cyst infection in ADPKD.
FR-PO021
A CD2AP Mutation (p.T374A) Associated with Cognitive Decline and Focal 
Segmental Glomeruloscrlerosis in Young Adulthood  Dmitry Tsvetkov,1 
Yoland Marie Anistan,1 Christian Harteneck,2 Maik Gollasch.1  1Charité Univ 
Medicine Berlin, Nephrology/Intensive Care, Experimental and Clinical 
Research Center (ECRC) and Max Delbrück Center for Molecular Medicine, 
Berlin, Germany; 2Dept of Pharmacology and Experimental Therapy, Inst of 
Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls Univ 
Hospitals and Clinics, and Interfaculty Center of Pharmacogenomics and Drug 
Research, Univ of Tübingen, Tubi.
Introduction: Mutations in CD2-associated protein (CD2AP) gene have been identified 
in patients with focal segmental glomerulosclerosis (FSGS); however, reports of CD2AP 
mutations remain scarce.
Case Description: We performed Sanger sequencing in a 32-year old patient with 
steroid-resistant FSGS presented with a nephrotic syndrome (proteinuria >3.5 g/day). 
The patient reported that his mother and his only brother also have a kidney disease. 
Neurological examination showed a remarkable cognitive decline within the last 5 years. 
Therapy with steroid and low-intermediate doses of cyclosporine A led to a persistent 
reduction of proteinuria. Serum creatinine levels and glomerular filtration rate (eGFR) did 
not decline during this treatment.
Discussion: Our patient displayed mild cognitive decline, a phenotypic characteristic 
not previously associated with CD2AP-associated FSGS. His proteinuria was remarkably 
reduced by treatment with cyclosporine A. Our findings expand the genetic spectrum of 
CD2AP-associated disorders and broaden the associated phenotype with the co-occurrence 
of cognitive decline. Our case shows that cyclosporin A is a treatment option for CD2AP-
associated nephropathy.
FR-PO022
Acute Motor and Sensory Axonal Neuropathy-Associated Syndrome 
of Inappropriate Antidiuretic Hormone Secretion  Weeraporn Srisung,1 
Aumyot Prongdong,1 Pavis Laengvejkal,2 Camilo Pena,1 Mustafa G. Aly,1 Sorot 
Phisitkul.1  1Internal Medicine, TTUHSC; 2Neurology, TTUHSC.
Introduction: SIADH is associated with various conditions including Guillain-Barre’ 
syndrome (GBS). We report a case of SIADH associated with acute motor and sensory 
axonal neuropathy (AMSAN), a variant of GBS.
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Case Description: A 36-year-old man presented with a 6-week history of progressive 
ascending weakness. Physical examination showed hypovolemia with asymmetric motor 
weakness, more severe in the LEs, muscle wasting, absent LE reflexes, dysesthesia 
and no cranial nerve involvement. MRI head/spine was unremarkable. CSF analysis 
showed albuminocytologic dissociation and ruled out infection. HIV, viral hepatitis and 
paraproteinemia were absent. Anti GM1 and GQ1b were negative. Nerve conduction study 
showed axonopathic pattern on motor and sensory fibers bilaterally. AMSAN was diagnosed. 
He received IV immunoglobulin with gradual improvement of his weakness. On admission, 
serum chemistry panel showed Na 115 mmol/L with normal Cr. Urine showed Na <20 
mmol/L, and specific gravity 1.045. Urine Osm was not available initially. He received 
NS infusion for volume expansion. Interestingly, Na did not significantly improve after 
he became euvolemic. Fluid restriction was then tried with mild improvement. Endocrine 
work-up ruled out hypothyroidism and adrenal insufficiency. Repeat labs showed serum 
Na 124 mmol/L, urine Na 191 mmol/L and urine Osm 531 mOsm. Hence, SIADH was 
diagnosed. Other well-established causes of SIADH were ruled out thus AMSAN was 
believed to be the most likely cause of SIADH. Tolvaptan was started at 15 mg and resulted 
in significantly increased urine output (300-500 ml/hr). Na increased rapidly so D5W was 
started to prevent osmotic demyelination syndrome. Tolvaptan was restarted at 7.5 mg 2 days 
later with good response. He was discharged on tolvaptan 7.5 mg daily with Na 130 mmol/L.
Discussion: Although GBS is a well-established cause of SIADH, but to our knowledge, 
AMSAN-associated SIADH has only been rarely reported in literature. We suggest that 
SIADH should be high on the differential diagnosis for hyponatremia in patients with 
AMSAN, especially in the setting of euvolemia.
FR-PO023
Severe Renal Osteodystrophy as a Result of Fanconi Syndrome 
Rabie I. Adam-Eldien, Charles W. Heilig.  Nephrology, Univ of Florida, 
Jacksonville, FL.
Introduction: Fanconi syndrome is a disease of the proximal renal tubules in which 
glucose, amino acids, uric acid, phosphate, bicarbonate and other substances are not 
reabsorbed and lost in the urine.
Case Description: 22 year old African American female with an autosomal dominant 
Fanconi syndrome. Her disease is clinically manifested by severe rickets and short stature. 
Her short stature has not responded to growth hormone. She has multiple stress fractures, 
and she ambulates with a walker. Her disease is manifested chemically by generalized 
aminoaciduria, hyperchloremic metabolic acidosis, hyperphosphaturia, glucosuria, 
bicarbonaturia, and proteinuria. Her life compliance with the medication has been poor. She 
has a gastrostomy tube for medications administration. Her medications include Calcium 
Carbonate, Neutra-Phos, Rocaltrol, Polycitra and Zantac. Her physical examination showed: 
Height 98.5 cm, weight 15.8 kg, blood pressure 106/57, pulse 80. She can stand up with 
hips flexed and her trunk slightly forward because of the anterior and lateral bowing of the 
femur. She has widening metaphyses of the knees and the wrists. She has ricket changes, 
ankle prominence, and she has good range of motion. Extremities: Have severe ricket 
changes. Lower extremities are deformed with prominent femur curve bilaterally. The rest 
of her exam was unrevealing.
Urinalysis shows glucose 100 mg/dL, ketones 40 mg, blood trace, pH 7, protein greater 
than 300 mg. Chemistry showed, Sodium 134, potassium 3.4, bicarbonate 13, chloride 
114, glucose 142, BUN 5, creatinine 0.6, calcium 7.9, phosphorus 3.8. Osmolality 268. 
Alkaline phosphatase 865. White count 7.3, hemoglobin 14, hematocrit 41.3, platelets 385.
Discussion: Fanconi syndrome lead to multiple defects and impair proximal tubular 
reabsorption of glucose, phosphate, amino acids, HCO 3 , uric acid, water, K, and Na. It 
can be caused by a drug or accompanies another genetic disorder. In hereditary Fanconi 
syndrome, proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, polyuria, and 
polydipsia usually appear in infancy. If a patient is unable to keep up with the replacement 
of these substances secondary to compliance or lack of access, adverse permanent skeletal 
effects might result from that.
FR-PO024
An Unusual Organism with Unusual Renal Manifestations  Brian M. Zwecker, 
Sreedhar A. Mandayam, David Sheikh-Hamad.  Baylor College of Medicine.
Introduction: Infective endocarditis can cause renal failure due to immune complex 
mediated glomerulonephritis. We present a case of Nontuberculous mycobacterium (NTM) 
endocarditis associated with acute glomerulonephritis with tubulointerstitial nephritis.
Case Description: Our patient was a 59 y/o Venezuelan man with a history of cocaine 
use who presented with generalized weakness, intermittent nausea, and a 40lbs weight loss. 
He denied taking any medications or illicit drugs for the previous month. On examination, 
he was afebrile, HR 85, BP 112/43mmHg. Pulmonary exam was unremarkable, and heart 
auscultation revealed a 3/6 holosystolic murmur at the right upper sternal border. JVP 
was normal and there was no edema. Serum creatinine was 4.7mg/dL; BUN 56mg/dL; 
Hemoglobin 8.9g/dL; U/A revealed 2+ protein, 3+ blood, 65 RBCs/HPF, and no casts; Urine 
Pr/Cr 1.93g/g; HCV IgG positive; HCV PCR negative; low C3; urine drug screen negative. 
Blood cultures one-day after admission identified Staphylococcus and Corynebacterium 
species; on hospital day seven the pathogen identification was changed to Mycobacterium 
chelonae/abscessus complex. Renal biopsy revealed an acute diffuse mesangial proliferative 
and exudative glomerulonephritis associated with significant tubulointerstitial nephritis. 
Focal red blood cell casts were also seen on biopsy. TTE revealed a dilated left ventricle 
with severe aortic insufficiency and possible vegetations. Unfortunately, the patient died 
on hospital day seventeen from cardiogenic shock.
Discussion: Renal pathology associated with infective endocarditis is rare and typically 
associated with hematuria, proteinuria, and a mild rise in serum creatinine. Two prior 
case reports described glomerulonephritis associated with NTM, both of which showed 
improvement in renal function with treatment of the underlying infection. Additionally, 
interstitial nephritis in association with NTM has been reported in two immunosuppressed 
patients. Our case is the first to describe both glomerulonephritis and acute tubulointerstitial 
nephritis in association with nontuberculous mycobacterium. This serves as a reminder 
that infectious endocarditis can have varied renal manifestations whether the causative 
pathogen is common or uncommon.
FR-PO025
Severe Hyponatremia in a Young Patient with Recurrent Abdominal Pain 
Dimpu M. Patel, Manish K. Saha, Ashita J. Tolwani.  Nephrology, Univ of 
Alabama at Birmingham, Birmingham, AL.
Introduction: Acute intermittent porphyria (AIP) is a rare metabolic disorder. 
Hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone 
(SIADH) during acute attacks of AIP requires prompt diagnosis and treatment of both 
AIP and hyponatremia.
Case Description: A 21yo Asian female presented to the ED with sharp intermittent 
abdominal and flank pain. Upon arrival to the ED, she had a generalized tonic-clonic 
seizure requiring intubation for airway protection. Her only medications were trimethoprim-
sulfamethoxazole and ibuprofen prescribed 2 days prior. Previous ED visits for similar 
episodes of abdominal pain included an extensive workup with negative urine drug 
screen, abdominal CT scan, pelvic ultrasound, and surgical evaluation. Prior episodes were 
noted to occur during menstruation. Physical examination was unremarkable apart from 
tachycardia. Laboratory data was significant for sodium 113mEq/l, urine osmolality 282 
mOsm/kg, and serum osmolality 225 mOsm/kg. Renal function, cortisol, TFTs, LFTs, and 
CBC were normal. Her hyponatremia was initially corrected slowly with 3% saline and 
later with sodium chloride tablets after a diagnosis of SIADH was made. The constellation 
of recurrent abdominal pain and unexplained cause of SIADH in a young menstruating 
female led to the diagnosis of AIP. Studies sent for AIP demonstrated elevated urine total 
porphyrin 3,374 (normal 0-300 nmol/24 hr), urine porphyrin 115 (normal 0-4 mg/24hr), 
5-aminolevulinic acid (ALA)–delta 79.8 (normal < 7mg/24hr), and RBC protoporphyin 
162 (normal 0-80 mcg/dl). She was treated with a carbohydrate based diet and avoidance 
of medications known to precipitate an acute attack.
Discussion: AIP results from a deficiency of PBG deaminase, leading to accumulation 
of ALA and PBG. Acute abdominal pain and involvement of supraoptic nuclei of 
hypothalamus by the metabolites may trigger constant ADH secretion. Rarely renal and 
gastrointestinal sodium loss may also cause hyponatremia. Our patient likely had an acute 
attack triggered by her pain crisis, sulfonamide antibiotic and her menstrual cycle. In the 
appropriate clinic setting in young patients with hyponatremia, AIP should be considered 
in the differential diagnosis.
FR-PO026
A Case of Solute Diuresis  Muhammad K. Qaseem,1 Elizabeth A. Gilliams,1 
James L. Bailey.1  1Emory Univ School of Medicine, Atl; 2EUH.
Introduction: Polyuria is a common manifestation of many primary medical disorders. 
Here we present a case of Arigininosuccinate Lyase Deficiency(ASLD)who presented with 
altered mental status and later developed polyuria.
Case Description: A 24-year old male with history of ASLD was admitted to the 
Intensive Care Unit (ICU) for altered mental status with an ammonia level of 347mcmol/L. 
He was started on Ammonia Scavenger therapy with Ammunol(arginine, Na-benzoate and 
Na-phenylacetate). On hospital day 10 he developed hypokalemia, hypernatremia and 
polyuria of 5L. His labs are listed below.
Day-1 Day-14
Na=140 mmol/L Na=148 mmol/L
K=3.8 mmol/L K=2.6 mmol/L
Cl=112 mmol/L CL=118 mmol/L
CO2= 20 mmol/L CO2=26 mmol/L
Creatinine = 0.68 mg/dL Creatinine= 0.5 mg/dL
BUN= 3 mg/dL BUN= 2 mg/dL
Ammonia= 347 mcmol/L Ammonia= 47 mcmol/L
Urine studies showed urine Sodium of 253mmol/L,urine Potassium of 59mmol/L,urine 
chloride of 175 mmol/L,urine anion gap of 137,urine osmolality of 637 mOsm/kg and urine 
Creatinine of 63 mg/dL with a 5.3L of urine in 24 hours. He was receiving ½Normal Saline, 
Ammunol and Total Parenteral Nutrition(TPN). It was recommended to decrease the dose 
of ammunol to decrease the non-measured anions in the urine,stopping ½normal saline 
and change the TPN to have less solute load. With these interventions his urine output and 
hypokalemia improved to almost back to normal.
Discussion: Argininosuccinate lyase activity results in the breakdown of 
argininosuccinic acid to arginine and fumarate. ASLD can result in severe hyperammonemia. 
Treatment of acute decompensations with hyperammonemia involves discontinuing oral 
protein, using intravenous arginine and ammonia scavenging therapy. Polyruria in ASLD 
could be due to different mechanisms such as low BUN leading to poor urine concentrating 
ability with loss of free water or due to solute diuresis. Our patient’s high urine osmolality 
and high urine sodium indicated a mechanism other than Diabetes insipidus. After the solute 
content was decreased his urine osmolality decreased significantly along with his urine 
output. Hypokalemia also improved. Management of solute diuresis in this case was to 
reduce the solute intake of the patient but first and foremost requires an accurate diagnosis.
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FR-PO027
Life Threatening Hypokalemia and Metabolic Alkalosis Related to 
Paraneoplastic Cushing’s Syndrome  Chyi Chyi Chong,1 Pallavi D. Shirsat,1 
Ramesh Marahatta,1 Cherinet S. Adgeh,1,2 Neville R. Dossabhoy.1,2  1LSU Health 
Science Center, Shreveport; 2VA Medical Center, Shreveport.
Introduction: Paraneoplastic Cushing’s syndrome (CS) develops secondary to tumoral 
ATCH and less often CRH production. Classical stigmata of CS are often absent, and 
purple striae and buffalo hump are uncommon. Hypokalemia associated with metabolic 
alkalosis are more common with ectopic ACTH. We report a case of severe hypokalemia 
with metabolic alkalosis related to ectopic ACTH production.
Case Description: A 58 y/o African American male presented with complaints of 
feeling unwell,  weight loss and frequent diarrhea for at least one month. On admission, 
he was noted to be hypertensive with BP 157/87 mmHg. On physical exam, patient had 
mild wheezes at bases. Laboratory data was significant for Na 144 mEq/L, K 1.1 mEq/L, 
Cl 82 mEq/L, HCO3 50 mEq/L, BUN 14 mg/dL and Cr 1 mg/dL . Blood gas revealed 
pH 7.34, PCO2 92 mmHg, PO2 92.4 mmHg and HCO3 47 mmol/L. Pt unfortunately 
developed acute respiratory failure requiring intubation shortly after albuterol nebulizer 
treatment. He was also receiving Diamox in ICU. He required potassium supplement on 
average of 120 meq per day (Maximum 300 meq/day). Once diarrhea resolved and with 
discontinuation of Diamox, patient was still noted to be hypokalemic. Urine electrolytes 
performed: Na 31 mmol/L, K 107 mmol/L, Cr 41 mg/dL. Additional lab data: Renin <0.15 
ng/ml/hr, Aldosterone <1 ng/dl, ACTH level 126 pg/ml and 24hr urine cortisol 3846 mcg. 
In addition, patient has positive dexamethasone suppression test. CT abdomen and pelvis 
performed - suggestive of metastatic disease with lesions in liver, left adrenal gland and 
bone. He had liver biopsy, which revealed neuroendocrine carcinoma. Patient was started 
on Spironolactone and Triamterene for hypokalemia, and Ketoconazole to decrease ACTH 
and cortisol level. Potassium supplement requirement decreased to 40 meq/day.
Discussion: This is a rare case of paraneoplastic CS associated with neuroendocrine 
carcinoma. Early recognition and appropriate treatment for this syndrome are important, 
although overall clinical outcome remains poor.
FR-PO028
Overcorrection of Hyponatremia Secondary to Diuresis in Postpartum 
Maria Berenice Nava,1 Maya K. Rao.2  1Div of Nephrology, Columbia Univ, 
New York, NY; 2Div of Nephrology, Columbia Univ, New York, NY.
Introduction: Previous case reports have described hyponatremia in pre-eclampsia 
particularly with twin gestations. Overcorrection in the post-partum period is a potential 
risk and complicates management.
Case Description: Case report.
30 yo woman G1P0 with intrauterine insemination with triplets presented at 30 weeks 
gestation with pre-eclampsia and nephrotic syndrome for emergent cesarean section. On 
presentation she was hypertensive, massively edematous found to have a serum sodium 
of (sNa) 126 mEq/L (no prior values), serum creatinine 0.5 mg/dl, albumin was 2.4 g/dl. 
Urine osmolarity was 159 mOsm/kg and the serum osmolarity was 263 mOsm/kg, urine 
sodium 21mmol/L. Spot urine protein:creatinine ratio 3.5 grams. By POD 2, her sNa 
decreased to a nadir of 119 mEq/L and spot protein: creatinine ratio was 0.458 grams, 
free water restriction was started. She soon began to auto-diurese (2.6L in 4hrs) resulting 
in a rise in sNa to 127 mEq/L in 5 hrs with a urine osmolality of 159 mOsm/kg. She was 
started on DDAVP to slow down correction and sNa levels were checked every 4 hours. 
Her subsequent sodium levels remained at 127 mEq/L over the next 12 hrs. On POD # 
3 her sNa corrected to 133 mEq/L, she continued to have a urine output of 200-300 ml/
hr, therefore D5W was initiated and DDAVP was again administered. Her urine output 
decreased to <100ml/hr on POD#4, urine osmolality was 217 mOsm/kg, therefore D5W 
was discontinued. She received 4 additional doses of DDAVP. The patient was ultimately 
discharged on POD#10 with a sNa of 143 mEq/L and off DDAVP.
Discussion: Hyponatremia in pre-eclampsia with nephrotic syndrome has been reported 
in the literature and is thought to be secondary to low effective circulating plasma volume. 
In this case, we report rapid correction of serum sodium post-delivery likely due to volume 
redistribution and removal of ADH stimulus. Awareness of potential rapid correction and 
frequent monitoring of serum sodium is important in order to intervene early and prevent 
consequences of rapid sodium correction. Serum sodium post-delivery should be monitored 
very closely in cases such as these.
FR-PO029
Severe Hypocalcemia in a Hemodialysis Patient  Manish K. Saha, Maria E. 
Taylor, Alian Albalas, Denyse Thornley-Brown.  Nephrology, Univ of Alabama, 
Birmingham.
Introduction: Severe hypocalcemia in a hemodialysis patient is rare in the absence 
of parathyroidectomy ,vitamin D deficiency or calcimimetic drugs.
Case Description: A 58 year-old man was found to have severe asymptomatic 
hypocalcemia (5.9 mg/dL) with prolonged QTc (547 ms) four weeks after starting 
hemodialysis. He had a history of prostate cancer treated with radical prostatectomy, 
bisphosphonates and a GNRH analogue. Serum calcium prior to starting hemodialysis was 
8.6 mg/dL; serum albumin 3.2 gm/dL, PTH 352 pg/mL, 25OH-Vitamin D2 <4ng/mL, 25OH-
Vitamin D3 12 ng/ml, and phosphorus 6.3 mg/dL. His intravenous doxecalciferol dose was 
titrated to 20 mcg thrice weekly; oral calcium carbonate and 1,25-dihydroxycholecalciferol 
were titrated up. Dialysate calcium concentration was increased to 3.5 mEq/L. However, 
despite these measures, pre-dialysis calcium was 6 mg/dL. On further review, it was found 
that he had been started on denosumab six weeks prior to initiation of hemodialysis for 
bone pain due to skeletal metastases. Desonumab is a monoclonal antibody against RANKL 
(receptor activator of nuclear factor kappa-B ligand). Tumor cells in patients with skeletal 
metastases stimulate osteoblast to secrete RANKL, which stimulate osteoclast to promote 
osteolysis and increase calcium levels. Even after replenishing Vitamin D stores, our patient 
continues to need higher dialysate calcium.
Discussion: Common causes of hypocalcemia in dialysis patients include: vitamin D 
deficiency, autoimmune or surgical hypoparathyroidism, severe hyperphosphatemia due 
to tumor lysis or rhabdomyolysis and medications such as cinacalcet. Desonumab is an 
easily overlooked cause of hypocalcemia. Our patient had Vitamin D deficiency but had 
normal calcium level prior to starting denosumab. It is important to replete vitamin D and 
calcium stores prior to initiating denosumab in patients with chronic kidney disease as 
they may have resistance to standard therapy for hypocalcemia. It is also recommended to 
check calcium levels regularly while on this medication.
FR-PO030
Central Diabetes Insipidus with Pituitary Atrophy from Chronic Lithium 
Use  Joe Ghata, Satish Kumar.  Nephrology, Univ of Oklahoma Health Science 
Center, Oklahoma City, OK.
Introduction: Lithium use is commonly associated with nephrogenic diabetes insipidus 
(NDI) and rarely with central diabetes insipidus (CDI). The mechanism of Lithium 
associated CDI is unclear. We report a patient on chronic lithium therapy who developed 
CDI and partial NDI and who had atrophy of posterior pituitary atrophy on MRI.
Case Description: A 62 yo woman with diabetes mellitus 2 for 5 years, hypertension 
for 10 years, and bipolar disorder on lithium for 40 years was admitted to the ICU for 
altered mental status. ROS was negative for nausea, vomiting, diarrhea, acute intoxication 
or infectious prodrome. Physical exam was normal; she was clinically euvolemic. Urine 
output was 4-8 l/d and a serum Na was 178 mEq/l. Serum creatinine was 4.84 mg/dl, elevated 
from a baseline of 1.5 in 2012. Urine osmolality (U osm) was < 100 mosm/l. Intravenous 
D5W at 200 ml/h caused improvement in serum creatinine to 1.7 mg/dl but minimal 
reduction in serum Na. Water restriction produced a submaximal rise (<250 mosm/l) in U 
osm from 157 to 176. ADH levels were undetectable by RIA when serum Na was 165-175. 
Intravenous desmopressin produced submaximal elevation in urine osmolality from 80 to 
153 (91.25%), consistent with partial NDI (U Osm < 250 mosm/l) and partial CDI (>15 to 
99%). MRI demonstrated atrophy of the posterior pituitary, with non-specific volume loss, 
straightening of the infundibulum, and absence of bright spot corresponding to the posterior 
pituitary. Final diagnosis was both partial central and nephrogenic DI associated with lithium 
use. Eunatremia was eventually achieved with intranasal DDAVP and liberal fluid intake.
Discussion: This is the first report of radiological evidence of posterior pituitary atrophy 
with lithium-associated central DI. Possible mechanisms of posterior pituitary atrophy 
may include “burn-out” from chronic hypersecretion of ADH caused by lithium induced 
nephrogenic diabetes insipidus or autoimmune hypophysitis from circulating autoantibodies 
developed in response to chronic high ADH levels.
FR-PO031
Iatrogenic Hyponatremia  Isha Gupta, Eduardo J. Zouain, Karim El Hachem, 
Anip Bansal, Steven D. Smith, Germaine Z. Chan.  Dept of Nephrology, Mt. 
Sinai St. Luke’s Hospital, New York, NY.
Introduction: Vasopressin acts in the kidney via V2 receptors to regulate water 
resorption and on the vasculature via V1 receptors to regulate smooth muscle tone. It is 
often used in the management of shock, but rarely causes hyponatremia in hemodynamically 
unstable patients. We present here a case of a man who developed marked hyponatremia 
during vasopressin infusion.
Case Description: A 58 year old man with history of hypertension and coronary 
artery disease was admitted to intensive care unit for un-witnessed cardiac arrest. He was 
intubated and started on vasopressin and norepinephrine for cardiogenic shock. His lab 
data on admission revealed normal serum sodium, blood urea nitrogen and creatinine. 
His inpatient course was significant for development of hyponatremia within 2 hours of 
initiation of vasopressin infusion. Patient’s sodium dropped from 142 meq/L(normal range 
136-146 meq/L) to lowest value of 124 meq/L associated with oliguria (urine output 20ml/
hr). With cessation of vasopressin, urine output increased significantly to 500ml/hr and 
serum sodium increased from 124 meq/L to 142 meq/L. Dextrose infusion was started to 
prevent overly rapid correction. Please refer to graph for the changes in the serum sodium 
and urine output with vasopressin infusion over time. Patient had normal cortisol levels 
and thyroid function.
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Discussion: Vasopressin does not usually result in hyponatremia when used in 
management of shock. Possible explanations include lack of renal responsiveness secondary 
to renal hypoperfusion/acute kidney injury, or lack of intake of hypotonic fluids. In this 
case, the patient developed marked hyponatremia in setting of preserved renal function.
FR-PO032
Hyperkalemia Secondary to Octreotide Use in a Patient with Normal Kidney 
Function  Dron P. Bhandari, Jyotsana Thakkar, Hitesh H. Shah.  Nephrology, 
Hofstra North Shore-LIJ School of Medicine, Great Neck, NY.
Introduction: Octreotide, a somatostatin analogue works by reducing blood levels 
of a variety of hormones (e.g. growth hormone, insulin) and chemical messengers (e.g. 
gastrin, vasoactive intestinal peptide). Octreotide therefore has been used as an effective 
medication for the treatment of sulphonylurea-induced hypoglycemia, acromegaly, VIPoma 
and carcinoid syndrome. Octreotide-induced hyperkalemia has rarely been reported in the 
literature. We report a patient with normal renal function who developed hyperkalemia 
secondary to octreotide use.
Case Description: A 70-year-old male with long standing history of DM (since 
20 years), HTN, and metastatic neuroendocrine pancreatic cancer was referred by his 
oncologist for evaluation of severe hyperkalemia (serum potassium level of 6.6 mmol/L). 
Patient was diagnosed with pancreatic neuroendocrine tumor approximately 2 years prior 
to his presentation for which he underwent Whipple procedure. He was also receiving 
subcutaneous octreotide monthly for nearly 1.5 years prior to his presentation. There 
was no history of kidney disease or any urinary complaints. Other medications included 
aspirin, insulin, creon, levothyroxine and HCTZ. BP was normal and patient was noted 
to have bilateral lower extremity pitting edema on examination. Other labs done 5 days 
prior to presentation showed normal serum bicarbonate (25 mmol/L) level, normal serum 
creatinine (1.23 mg/dL) level, and elevated serum glucose (263 mg/dL) level. On reviewing 
medical records, our patient was noted to have chronic and persistent hyperkalemia over the 
previous six months that was medically managed by intermittent oral sodium polystyrene 
and low potassium diet. All other causes of hyperkalemia were clinically excluded. Serum 
potassium normalized after receiving medical management and holding octreotide treatment.
Discussion: We present a rare case of octreotide-induced hyperkalemia in a patient 
with normal renal function. We believe that hyperkalemia in our patient occurred as a 
result of octreotide-induced insulin suppression and resultant impaired cellular potassium 
uptake. Based on our experience, one should be aware of this potential life-threatening 
side-effect of octreotide therapy.
FR-PO033
Hypercalcemia and Acute Kidney Injury due to Immune Reconstitution 
Syndrome in an HIV Patient on HAART and MAC Therapy  Anand Achanti, 
Omar M. Shahateet, Karl Berthold Pembaur, Nithin Karakala, Juan Carlos Q. 
Velez.  Nephrology, Medical Univ of South Carolina, Charleston, SC.
Introduction: Hypercalcemia can occur in HIV-infected patients due to several 
conditions such as granulomatous diseases, lymphomas, and solid tumors. HIV 
patients are also susceptible to causes found in the general population, such as primary 
hyperparathyroidism, medications, and vitamin D supplementation.
Case Description: A 48 year old male with history of HIV and disseminated 
Mycobacterium avium complex (MAC) was sent to the hospital after being found to have 
a serum calcium of 15.5 mg/dl and serum creatinine of 5.8 mg/dL on routine labs. His only 
complain was weakness. Five months prior to presentation, patient had an adjustment of 
his highly active antiretroviral therapy (HAART) with a viral load of 76,000 copies/mL, 
CD4 count of 36/CUMM, serum calcium of 9.6 mL/dL, and serum creatinine of 2.6 mg/
dL at that time. Previous renal dysfunction was caused by interstitial nephritis diagnosed 
6 weeks prior. Patient reported increased compliance to his newregimen for several weeks 
prior to presentation, reflected by an increase in CD4 count of 138 /CUMM earlier and 
undetectable viral load upon presentation. Workup for hypercalcemia included: low PTH 
of 5.8 pg/mL, low PTH-rp of 0.7 pmol/L, and a high 1,25 Vitamin D of > 200 pg/mL. 
Serum and urine protein electropheresis showed a restricted kappa light chain band, but 
serum kappa/lambda ratio and bone marrow biopsy were normal. Imaging was negative for 
lymphoma. The patient was managed with volume repletion, prednisone 60 mg/d, and IV 
pamidronate 60 mg with gradual improvement of his calcium to 8.8 mg/dL and creatinine to 
2.8 mg/dL in 9 days. Steroids were tapered and the patient remained stable 6 months later.
Discussion: Our patient developed acute kidney injury secondary to severe 
hypercalcemia, likely due to renal vasoconstriction and volume depletion superimposed 
over interstitial nephritis. The etiology of hypercalcemia was likely immune reconstitution 
syndrome caused by the restoration of HAART. In patients with HIV and AIDS with history 
of granulomatous disease, it is important to monitor for hypercalcemia when initiating 
HAART therapy or adjusting therapy.
FR-PO034
Hypocalcemia in Severe Malnutrition, and Acute Pancreatitis Veils Vitamin 
D Intoxication  Kamran Karimi, Catherine Miranda, Yezina T. Nigatu, Kelly 
H. Beers, Nand K. Wadhwa.  Nephrology, Stony Brook Univ Medical Center, 
Stony Brook, NY.
Introduction: Although vitamin D has a wide therapeutic index, a routine use of high 
doses of vitamin D intake can cause toxicity. We report a case with severe hypocalcemia 
likely due to malnutrition and pancreatitis related to alcoholism followed by hypercalcemia 
from vitamin D toxicity.
Case Description: A 43 year-old woman with alcoholism was admitted with 
rhabdomyolysis and alcohol induced acute pancreatitis. On initial examination she was in 
moderate distress with altered mental status and diffuse abdominal pain. Her blood pressure 
was 102/67 mmHg, heart rate 136/min and temperature 38.3oC. Her lab data revealed WBC 
54.71 mm3, Hb 16.9 g/dL, PLTs 186 mm3, serum Na 129 mEq/L, K 3 mEq/L, bicarbonate 19 
mEq/L, BUN 32 mg/dL and creatinine 1.3 mg/dL, Ca 4.4 mg/dl, Mg 1.1 mg/dl, phosphorus 
1.7 mg/dL, CPK 1089 IU/L, albumin 2.9 g/dL. She received intravenous Ca, Mg, K and 
phosphorus in addition to oral supplements. On day 4, her serum Ca was 8.7 mg/dl, albumin 
2.5 g/dl, phosphorus 4.0 mg/dl and K 3.9 mmol/l without any supplement. Her serum Mg 
remained low and continued to receive oral and intravenous Mg supplements. Serum Ca 
was not checked between days 9-14 of her hospitalization. On day 15, her serum Ca was 
12.8 mg/dl, ionized Ca 6.4 mg/dl, vitamin D 25OH 370 ng/ml, vitamin D 1-25 OH2 149 
pg/ml and intact PTH 11.8 pg/ml. Her TSH, T4, ACE and vitamin A levels were normal. 
Her 24 hours urine revealed Na 140 mmol, K 70 mmol, creatinine 1110 mg, UN 4.1 g, Ca 
462 mg, Mg 403 mg , phosphorus 931 mg. She admitted taking vitamin D 50,000 units 
daily for many months for her psoriasis on her own. Her hypercalcemia was treated and 
her serum calcium stabilized over one week to 9.4 mg/dl while her vitamin D 25OH and 
vitamin D 1-25 OH2 remained elevated over the next 6 weeks.
Discussion: Her unusual presentation of hypocalcemia masked vitamin D toxicity till 
she resumed regular nutrition. Her hypocalcemia was likely related to malnutrition due to 
chronic alcoholism and possible calcium deposition due to acute pancreatitis. With proper 
nutrition during her hospitalization and improvement of her underlying condition led to 
hypercalcemia due to vitamin D toxicity.
FR-PO035
Re-Defining the Speed Limit in Osmotic Demyelination Syndrome? 
Mahrukh Rizvi, Rebeca D. Monk.  Nephrology, Univ of Rochester Medical 
Center, Rochester, NY.
Introduction: Osmotic demyelination syndrome (ODS) is a severe, debilitating, 
possibly fatal neurological condition that results from rapid correction of severe chronic 
hyponatremia. Imaging reveals central pontine myelinolysis (CPM). Potential added risk 
factors for ODS include Sodium (Na) < 120 mmol/L, alcoholism, malnutrition and liver 
transplant. Current recommendations advise raising serum sodium by less than 9 mmol/L 
in 24 hours. We present a case of ODS in a patient presenting with severe hyponatremia 
corrected at a maximum rate of 8meq/dL in 24 hrs.
Case Description: A 37 year old man with a history of alcohol abuse was sent in to the 
hospital by police after a car accident for jaundice. He endorsed two weeks of worsening 
jaundice and right upper quadrant (RUQ) pain. Admission vital signs were stable. Physical 
exam revealed marked jaundice, abdominal distention and RUQ pain. Work up revealed 
severe alcoholic hepatitis with cirrhosis and metabolic derangements including a Na of 
105 mmol/L, chloride of 69 mmol/L, urea nitrogen of 45 mg/dL, creatinine of 2.13 mg/
dL with unknown baseline. 3% saline with ddAVP was initiated for cautious correction of 
severe hyponatremia. Na incresaed at the desired rate, with maximum of 8 mmol/L over 
24 hours on day 1. Hospital course was complicated by altered mental status on day 3 for 
which he was initiated on CIWA. Over the course he had protracted encephalopathy with 
difficulty moving bilateral lower extremities, trouble swallowing and dysarthria. On day 
9 of his stay, a magnetic resonance imaging of the brain was obtained revealing CPM.
Discussion: Defining a safe rate of serum sodium correction that the brain can tolerate 
has been difficult. It has evolved to more cautious values over the past few decades. Our 
case adds to the available pool of data in the literature shedding further light on what may 
be “overcorrection.” Despite strict observance of therapeutic guidelines, a maximum 
correction of 8 mmol/L proved to be a sizeable enough increment to lead to ODS. This 
leads to reconsideration of a “safe” speed limit. Treatment should be tailored to individual 
patients and sodium corrected at a rate as low as possible, especially in the presence of 
other risk factors for ODS.
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FR-PO036
A Case of Axenfield-Rieger Syndrome Presenting with Elevated Serum 
Bicarbonate  Rudrick V. Ledesma, Maureen E. Brogan, Venkata Buddharaju, 
Rahul N. Pawar, Rajat Lamba.  Westchester Medical Center, NY.
Introduction: Elevated serum bicarbonate can be often misdiagnosed as metabolic 
alkalosis leading to improper management. Chronic resipratory acidosis caused by central 
hypoventilation can lead to elevated bicarbonate secondary to renal compensation. We 
present a case of central hypoventilation caused by cerebello-pontine lesion in a patient 
with Axenfield-Reiger syndrome (ARS).
Case Description: A 25 yo man with PMH of glaucoma, developmental delay, 
schizoaffective disorder sent to the ED for respiratory failure. He was seen earlier in renal 
clinic for evaluation of elevated serum bicarbonate. He was complaining of fatigue and 
insomnia. Arterial blood gas was done and showed a pH of 7.30, pCO2 of 79, PO2 of 63 and 
HCO3 of 38.9. He was eventually admitted for further management. While in the hospital, 
he continuously needed bilevel positive airway pressure. Chest ultrasound showed little 
to no movement of his diaphragm. EMG was negative. PFT was suboptimal as he wasn’t 
able to follow the instructions. MRI brain showed a mass on his right cerebello-pontine 
angle. He was also diagnosed with ARS during his hospital stay. The mass was resected 
and progressive improvement was observed in his respiratory status. He was eventually 
weaned off bilevel positive airway pressure and was discharged home without any need 
for respiratory support.
Discussion: Elevated serum bicarbonate can often pose a diagnostic challenge. 
Evaluation should start with an ABG which would differentiate a primary metabolic 
alklaosis from a renal compensation of respiratory acidosis. Differential diagnoses for 
respiratory acidosis include central hypoventilation, primary lung pathology, neuromuscular 
disease and airway pathology. Central hypoventilation could be secondary to lesions in the 
respiratory center. ARS presents as a spectrum of developmental disorders resulting from 
abnormal migration and differentiation of neural crest cells with both ocular and systemic 
manifestations. The regions in the brain that are usually affected are forebrain and pituitary 
gland. Our case is interesting as he had ARS with epidermoid cyst which we believe has 
led to central hypoventilation and elevated bicarbonate as compensatory mechanism.
FR-PO037
Signet-Ring Cell Carcinoma Presenting as Frequency of Urination 
Haya Waseem Siddiqi, Daniel E. Carl, Todd W. Gehr.  Nephrology, Virginia 
Commonwealth Univ, Richmond, VA.
Introduction: Urinary tract obstruction may occur at any site in the urinary tract and 
is important to recognize early since it is readily reversible if quickly corrected.
Case Description: 45 year old male with obesity, history of gastric bypass surgery, 
hypertension and obstructive sleep apnea who presented to our institution for evaluation 
of frequency of urination. He developed progressively worsening frequency of urination, 
occurring every hour during the day and night for 3 months prior to presentation. During 
this time, his serum creatinine was 1.6 mg/dL. He had been seen multiple times by an 
Urologist and Primary Care Providers outside our institution, and was diagnosed with 
prostatitis despite negative urine cultures and no pyuria. During the work up, an out-patient 
CT scan revealed mild bilateral hydroureter and mild left hydronephrosis. Furthermore, an 
office cystoscopy revealed diffuse inflammatory cystitis of the bladder and no definitive 
bladder outlet obstruction. Over the ensuing 3-4 weeks, he developed acute kidney injury, 
with a serum Cr that peaked at 6mg/dL. This prompted an admission to an outside facility. 
He was again found to have mild bilateral hydroureter, however, ureteral stents were 
attempted, but unsuccessful. A repeat cystoscopy revealed severely inflamed bladder 
tissue, the ureterovesical junction was not visualized, and urinary bladder biopsy was done. 
Patient was transferred to VCU for placement of percutaneous bilateral nephrostomy tubes 
by interventional. He had successful stent placement by IR followed by post obstructive 
diuresis treated with intravenous fluid hydration in the form of saline. His AKI improved 
as did the hydronephrosis evident on follow-up imaging study. His serum Cr improved to 
1.3 mg/dL and repeat CT scan with intravenous contrast was obtained for staging which 
showed circumferential bladder wall thickening with asymmetric soft tissue prominence 
along the right anterior dome most consistent with bladder neoplasm. Outside pathology 
report was consistent with signet cell carcinoma of bladder.
Discussion: Signet-ring cell carcinoma a rare bladder tumor can result in acute kidney 
injury secondary to bilateral ureteral obstruction.
FR-PO038
A Case of Tenofovir-Induced Nephrotoxicity  Keerti K. Bhanushali, Girish 
Singhania, Abhilash Koratala, Radhika Vemuri, William L. Clapp, Dara N. 
Wakefield, Saraswathi Gopal.  Nephrology, Univ of Florida, Gainesville, FL.
Introduction: Tenofovir (TFV) is a nucleotide reverse-transcriptase inhibitor used for 
treatment of HIV and hepatitis B. Most studies suggest that TFV has only a modest effect 
on estimated glomerular filtration and severe nephrotoxicity is uncommon. We describe a 
case of severe renal failure and mitochondrial tubulopathy related to TFV.
Case Description: A 55-year-old woman with HIV on TFV for several years, presented 
with vomiting and abdominal pain for 4 days. Physical exam was unremarkable. Laboratory 
data showed BUN 65 mg/dL, creatinine 9.07 mg/dL (baseline: normal), bicarbonate 12 
mmol/L, glucose 137 mg/dL, HIV RNA: 21 copies/mL and CD4: 292 cells/uL, glycosuria 
and proteinuria (157mg/24 hours). Serological tests for autoimmune processes were 
negative. Kidney biopsy showed proximal tubule (PT) injury and eosinophilic oval 
cytoplasmic inclusions on trichrome stain (fig. a) with no definite glomerular or mesangial 
abnormalities. Electron microscopy (EM) showed PT cells with cytoplasmic swelling, loss 
of membrane integrity, accumulation of enlarged dysmorphic mitochondria with intra-cristal 
widening and the matrix appearing as electron-dense bands, and focal loss of cristae (fig. b) 
consistent with mitochondrial injury (MI) seen in TFV nephrotoxicity. Despite discontinuing 
TFV, she remained dialysis dependent. 
Discussion: Currently available data supports renal safety of TFV in HIV patients. 
Severe renal dysfunction has only been reported sporadically. Although nucleoside reverse 
transcriptase inhibitors (adefovir) are known to impair mitochondrial replication by 
interfering with DNA polymerase-γ, evidence linking TFV specifically to MI is limited. 
Our case implies that TFV can cause significant renal failure and MI. Monitoring renal 
function and urinalysis during TFV treatment is key for early detection of nephrotoxicity.
FR-PO039
A Case of Severe Hypomagnesaemia in a Patient Treated with Trastuzumab 
Saifullah Kazi, Ghulam Akbar, Paul Robbins.  Nephrology, Lankenau Medical 
Center, Wynnewood, PA.
Introduction: A case of invasive ductal carcinoma that was treated with chemotherapy 
including Trastuzumab found to have severe hypomagnesemia requiring very aggressive 
repletion strategies.
Case Description: A 36 y/o non-alcoholic female with past medical history of 
hypertension well controlled on diet therapy, was diagnosed with invasive ductal carcinoma 
of the breast requiring initiation of chemotherapy with docataxel and carboplatin with 
Trastuzumab. She received a total of 6 cycles of chemotherapy every three weeks and 
Trastzumab 2gm weekly infusions. After completion of chemotherapy, the dose of 
Trastuzumab was increased to 6gm per infusion every three weeks. Her serum magnesium 
level which was 2.1mg/dl in the beginning of chemotherapy was noted to be low at 
0.5mg/dl when she presented with generalized weakness to the hospital six months into 
the treatment. At this time, she had completed her chemotherapy 2 months ago and now 
on Trastuzumab only. She was on lasix and proton pump inhibitors at that time, both of 
which were stopped immediately. However her serum magnesium remained low between 
0.6-1.0 mg/dl persistently for next few months requiring intravenous infusions every week. 
On repeated testing, fractional excretion of magnesium remained high indicating renal 
magnesium wasting. Although patient was hypokalemic initially, it corrected immediately 
after stopping loop diuretics and remained normal ruling against tubulopathies such as 
Gitelman or Barter syndrome. She remained hypomagnesemic despite completing one year 
course with Trastuzumab. She is receiving once a week intravenous infusions of magnesium 
and oral supplements three times a day and serum magnesium remains at 1.4-1.5mg/dl.
Discussion: Trastuzumab is a human epidermal growth factor (HER-2) inhibitor which 
belongs to the family of epidermal growth factor receptor (EGFR). EGFR is involved in 
increasing the magnesium absorption in the distal nephron by increasing the transcription 
of the genes regulating TRPM6 channels. Hypomagnesemia has been well reported in other 
EGFR inhibitor with Cetuximab used in colon cancer and Erlotinib used in lung cancer, 
but not reported in patients taking Trastuzumab, especially after escalating to higher doses.
FR-PO040
Capecitabine Induced Acquired Bartter’s-Like Syndrome  Eric A. Kirk, 
Jennifer Thompson, Juan Carlos Q. Velez, Nithin Karakala.  Nephrology, 
MUSC, Charleston, SC.
Introduction: Many forms of chemotherapy carry a risk of electrolyte abnormalities. 
Capecitabine is an antimetabolite of the fluoropyrimidine carbamate class of 
chemotherapeutic agents. Phase I and II trials have reported hypomagnesemia, hypokalemia 
and hypocalcemia as isolated electrolyte imbalances, and there are case reports of isolated 
hypomagnesemia and reports of a relatively large number of patients with hypokalemia. 
A Fanconi like pattern of electrolyte disorders has also been reported with capecitabine.
Case Description: A 68 year old female with neuroendocrine pancreatic cancer treated 
with capecitabine and temozolomide developed back spasms and was found to have severe 
hypokalemia (2.4mmol/L), hypomagnesemia (0.7mg/dL) hypocalcemia (6.4mg/dL) and 
metabolic alkalosis (bicarbonate 30mmol/L) in the absence of vomiting or diarrhea 5 weeks 
after starting a 2 week course of capecitabine (1400mg/m2 divided twice daily). She had 
evidence of renal salt wasting with sodium 256.5mEq, potassium 51.8 mEq,and calcium 
500mg in a 24 hour urine collection. No evidence of hypoparathyroidism, with intact PTH 
67.3pg/mL, 1,25 hydroxy vitamin D was 33pg/mL. Further capecitabine therapy was 
withheld. 24 hr urine collection was completed 1 week later with decreased renal loss of 
sodium, potassium and calcium and normalization of electrolytes.
Discussion: We present a case of life threatening hypokalemia caused secondary to 
capecitabine. As the patient had metabolic alkalosis it was unlikely that the patient had 
Fanconi’s as described in some case reports. Our case is unique as this patient developed 
a combination of hypokalemia, hypocalcemia, hypomagnesaemia and metabolic alkalosis 
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caused by capecitabine. The patient exhibited Bartter’s like physiology with increased renal 
loss of potassium, calcium, and magnesium and evidence of metabolic alkalosis. Unlike 
the proximal tubulopathy associated with capecitabine, the pathophysiology of acquired 
Bartter’s with is unknown but could be caused by direct inhibition of apical NaKCC or 
ROMK, or activation of the calcium sensing receptor on the basolateral surface in the 
thick ascending loop of Henle.
FR-PO041
Uncommon Case of Severe Hypercalcemia After Renal Transplantation 
Rapeepat Lekkham, Gitana Bradauskaite.  Nephrology, Einstein Medical Center, 
Philadelphia, PA.
Introduction: Following renal transplantation, hypercalcemia is frequently caused by 
persistent hyperparathyroidism, but other causes should be kept in mind. We report a case 
of hypercalcemia after renal transplant from unregulated extrarenal 1,25-dihydroxyvitamin 
D synthesis from disseminated tuberculosis and cryptococcosis.
Case Description: The patient was a 59-year-old male with unknown etiology of 
ESRD who received a living unrelated kidney transplant. He was stable on low dose 
immunosuppressive agents for history of BK virus infection. At 10 months post-transplant, 
the patient diagnosed with disseminated cryptococcosis with granulomatous mesenteric 
mass and positive serum cryptococcal antigen. High dose oral fluconazole was started. 10 
days later, he readmitted with severe hyponatremia, severe hypercalcemia (corrected serum 
Ca peak at 14.72 mg/dl) and acute renal failure (serum Cr peak at 5.8 mg/dl from baseline 
1.6 mg/dl). The iPTH level was suppressed to 2.8 pg/ml. The serum 1,25(OH)2D level was 
elevated and levels of 25(OH)D fell. Serum phosphate rose and ALP levels were elevated. 
PTH-related peptide was negative. Serum immunoelectrophoresis with immunofixation 
showed slightly elevated IgG kappa monoclonal gammopathy with normal ratio of free 
kappa and lambda light chain. Kidney biopsy revealed acute tubular necrosis, no evidence 
of granulomatous or lymphoproliferative disease. CT chest revealed right upper lobe mass 
with calcified granuloma at lung base. Culture from lung biopsy showed strongly positive 
for Mycobacterium Tuberculosis. Anti-tuberculosis drugs were started and mycophenolate 
mofetil was held. Elevated calcium levels were unresponsive to calcitonin, fluid neither 
diuretic. After his sputum AFB became negative, the oral prednisone was increased to 
20mg/day. Hypercalcemia and hyperphosphatemia normalized upon one month follow 
up and remained stable until finished 6 months course of anti-tuberculosis drugs and the 
creatinine returned to baseline.
Discussion: Unlike persistent hyperparathyroidism, underlying diseases of PTH 
independent hypercalcemia after renal transplantation like a granulomatous disease can lead 
to significant morbidity and mortality. Early recognition and prompt treatment is necessary.
FR-PO042
Treatment of Malignancy-Associated Hypercalcemia with Low Calcium 
Hemodialysis Yields Several Benefits for Cancer Patient  Rozina B. Ali, 
Akshatha Rao, Suzanne Boyle, Jesse M. Goldman.  Div of Nephrology and 
Hypertension, Drexel Univ College of Medicine, Philadelphia, PA.
Introduction: Hypercalcemia of malignancy can be fatal. In literature, primary 
treatment remains forced saline diuresis while dialysis is seldom considered. We present 
a case of severe, refractory hypercalcemia associated with diffuse large B-cell lymphoma 
that was treated with low calcium (Ca) hemodialysis (HD).
Case Description: A 56 year-old male presented with 3 weeks of weakness and 
confusion. Labs noted a serum creatinine (Cr) of 1.45mg/dL, Ca of >18mg/dL, and 
ionized Ca of >2.3. Urine microscopy had pigmented granular casts. Cause of acute 
kidney injury (AKI) was attributed to hypovolemia, acute tubular necrosis and Ca-induced 
vasoconstriction. He had a PTH of 7pg/ml, PTH-rp of 2.1pmol/l, vitamin D 25,OH 
of 25.4ng/ml and 1,25OH of 18.6pg/ml . Non-contrast CT chest demonstrated diffuse 
lymphadenopathy with LN biopsy showing diffuse large B-cell lymphoma. On day 1, patient 
received several liters of normal saline, calcitonin, and pamidronate. Despite maximal 
medical therapy, he had delirium, persistent AKI with Cr peak to 2.6 mg/dL and elevated 
Ca at 15mg/dL. On days 3, 4, and 5, he received consecutive 4-hour sessions of intermittent 
HD with low Ca (2meq/L) dialysate using a 0180 high flux dialyzer with blood flow of 
400mL/hr. On day 6, Ca decreased to 10.4 mg/dL and mental status improved. He received 
induction chemotherapy on day 13 with cyclophosphamide, doxorubicin, rituximab, and 
vincristine. At discharge, Cr was 1.66mg/dL and Ca level was 12mg/dL.
Discussion: Management of refractory severe hypercalcemia with low Ca HD is 
potentially underutilized. Conventional methods of management have therapeutic and 
temporal limitations. We found low Ca HD to be a useful adjunctive tool for treatment in 
our case of malignancy-related severe hypercalcemia. With low Ca HD, care must be taken 
to avoid hypotension from volume depletion and vasodilation from high Ca flux. Our patient 
tolerated dialysis without adverse events. Adding low Ca HD to other treatment modalities 
likely contributed to rapid symptom improvement and mitigation of further Ca-mediated 
renal injury, allowing for timely chemotherapy induction.
FR-PO043
A Curious Case of PPI Induced Renal Magnesium Wasting  Minesh Rajpal, 
Taranpreet Kaur, Reejis Stephen, Fahad Saeed.  Cleveland Clinic, Cleveland.
Introduction: Proton pump inhibitors (PPI) are known to impair absorption of 
magnesium (Mg) by inhibition of transient receptor potential melastatin-6 (TRPM6) 
and TRPM7 channels on the intestinal epithelium. We present a case of PPI induced 
hypomagnesaemia from renal Mg wasting.
Case Description: 41 year old female with history of thyroidectomy for cancer, 
parathyroidectomy, hypothyroidism, and gastro-esophageal reflux disease (GERD) referred 
to our nephrology clinic for severe symptomatic hypokalemia for a decade. She has poor 
appetite and weighs around 330 pounds but denies vomiting or diarrhea. Home BPs is low 
90’s /60’s mmHg. She denies licorice, diuretic or excessive alcohol use. She was adopted 
as a child with unknown family history. She was admitted for further work up. Her serum 
potassium (K) was 3.5 and Mg was 1.2. 24 hour urine collection was done and levels of 
sodium, K, Mg and aldosterone were found to be 48 mmol, 21 mmol, 49.6 mmol, and 7.5 
ng/dl respectively. Fractional excretion of Mg using the formula FEMg = 100 * (UrineMg 
* PlasmaCr) / (0.7 * PlasmaMg * UrineCr) was 121% confirming renal Mg wasting. 
Her serum bicarbonate of 22mmol/L and absence of salt wasting ruled out Gitelman 
syndrome. Review of medications revealed that she was chronically on esomeprazole 40 
mg daily for presumed GERD. Esomeprazole was stopped, and with continued magnesium 
supplementation her repeat K and Mg were within normal range as outpatient. Repeat 24 
hour urinary Mg was pending at the time of abstract submission.
Discussion: The kidneys are highly efficient organs in Mg conservation with most 
of filtered Mg being reabsorbed in the thick ascending limb of the loop of Henle. It is 
speculated that patients who develop hypomagnesaemia on long-term PPI treatment may 
harbor one or more heterozygous mutation(s) of the gene TMPR6, FXYD2, KCNJ10, or 
KCNA1 involved in the modulation of Mg reabsorption in the distal nephron, leading to 
diminished efficiency of the encoded protein(s). This situation could involve a continuous 
low-grade Mg leak and facilitate the development of Mg depletion when combined with 
factors that decreases intestinal magnesium absorption.
FR-PO044
Viral Inclusions Excluding BK: Case Report of JC Virus Renal Allograft 
Nephropathy  Deanne Leonard,1 Cherise M. Cortese,1 Xochiquetzal J. 
Geiger,1 Lynn D. Cornell,2 D. Jane Hata,1 Mary B. Prendergast.1  1Mayo Clinic, 
Jacksonville, FL; 2Mayo Clinic, Rochester, MN.
Introduction: JC virus, a DNA polyomavirus, infects 70-80% of asymptomatic adults 
with clinical significance in immunocompromised hosts; known for causing progressive 
multifocal leukoencephalopathy, a fatal disease resulting in demyelination from infected 
oligodendrocytes. The paucity of data on JC virus nephropathy makes it essential to report 
this case.
Case Description: 76 year old male with diabetes mellitus and end stage renal disease 
underwent a deceased donor kidney transplant with basiliximab induction and a standard 
steroid taper. He experienced self-limited diarrhea with negative work up. Maintenance 
immunosuppression included mycophenolate mofetil, prednisone and tacrolimus, with levels 
4.5-8.2. Serum CMV PCR: negative. Year 1, serum creatinine: 1.4mg/dL, urine protein 
to creatinine ratio 0.05 gm, negative urinalysis. Allograft biopsy: normal glomeruli, 5% 
tubular atrophy, mild tubulitis not meeting criteria for rejection and several large medullary 
viral inclusions but minimal plasma cells, C4D negative.
Serum/urine BK PCR: consecutively negative. Immunohistochemistry on tissue 
sections: positive for BK (SV40 T antigen which cross reacts with JC). In-situ hybridization 
for JC and BK viruses: positive in medullary tubular epithelial cell nuclei. Reduction in 
immunosuppression resulted in renal improvement.
Discussion: Kantarci et al, 2011 summarized only 9 cases ever in existence. It is 
important to note that the scarcity of cases results in a small pool of patients from which 
to draw direct correlations. This case emphasizes the importance of other polyoma 
viruses in biopsy positive “BK” with minimal plasma cells and negative serum/urine thus 
broadening the differential on viral nephropathy and emphasizing the existence of non 
BK viral nephropathy.
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FR-PO045
Successful Treatment of Anti-Angiotensin II Type 1 Receptor Antibodies 
Associated with Refractory Antibody-Mediated Rejection and Acute Cellular 
Rejection in Kidney Transplantation: A Case Report  Punlop Wiwattanathum, 
Atiporn Ingsathit.  Nephrology Unit, Faculty of Medicine Ramathibodi Hospital, 
Mahidol Univ, Bangkok, Thailand.
Introduction: Angiotensin II type 1 receptor (AT1R) antibody has been proved that 
it can be detrimental to kidney allograft. Similar to HLA-antibody, patients who have 
AT1R antibody are at risk for rejection and poor allograft outcome. There is no standard 
treatment in this situation but the aim is to remove pathologic antibodies and suppress 
antibodies production. Outcomes after treatment are unsatisfied and not well established. 
Herein we present a successful treatment kidney transplant pateint who experienced AT1R 
antibody associated rejection.
Case Description: A 50-year-old male with hypertension and ESRD underwent a 
disease donor kidney transplantation using a graft from acute kidney injury donor with peak 
serum creatinine of 1.24 mg/dl. No intraoperative complication occurred, urine flow rate of 
300 ml/hr was observed immediate postoperative but abruptly decreased to 20 ml/hr at 8 
hours posttransplantation. Acute rejection was suspected, thus allograft biopsy was done. 
The histopathological findings were compatible with acute cellular rejection combined with 
antibody-mediated rejection (ABMR). AT1-R antibody was detected at level of 15.0 u/ml. 
Anti-rejection therapies were offered with steroid, IVIG, plasmapheresis, anti-thymocyte 
globulin and rituximab. At 8 weeks posttransplantation, rejection was well controlled with 
stable serum creatinine of 1.5 mg/dl. 
Discussion: Although AT1R antibody associated rejection has rarely been reported, 
the outcomes after rejection are unsatisfied. Early detecting rejection and rapid antibody 
removal seem to be the most effective treatment that prolong allograft function in present 
time. There are limited and controversial data about long term graft survival by treating 
patient with angiotensin receptor blocker.
Funding: Government Support - Non-U.S.
FR-PO046
Hemodiafiltration for Hepatic Encephalopathy Induced by Budd-Chiari 
Syndrome in a Patient with End-Stage Kidney Disease  Takuya Wakamatsu, 
Suguru Yamamoto, Takeshi Nakatsue, Junichiro J. Kazama, Ichiei Narita.  Div 
of Clinical Nephrology and Rheumatology, Niigata Univ Graduate School of 
Medical and Dental Sciences, Niigata, Japan.
Introduction: Budd-Chiari Syndrome (BCS) is defined as portal hypertension 
caused by obstruction of the inferior vena cava at the liver. Severe BCS induces hepatic 
encephalopathy, and has known to be exacerbated during hemodialysis (HD) treatment 
in end-stage kidney disease (ESKD) patients, probably due to lowering branched-chain 
amino acid (BCAA)/aromatic amino acid (AAA) ratio and reducing blood flow in the 
portal vein. Hemodiafiltration (HDF) has been proposed be effective for some dialysis-
related complications due to better removal of middle sized uremic toxins and preservation 
of plasma osmolality, compared with HD. Here, we present a patient with ESKD who 
developed hepatic encephalopathy after progression of BCS, which was ameliorated by 
HDF.
Case Description: The patient was a 36-year-old woman complaining of a 
consciousness disorder. She was diagnosed with BCS as a consequence of antiphospholipid 
syndrome presented at 21 years of age. Her kidney function impaired gradually, and 
progressed to ESKD. After initiation of HD, transient loss of consciousness due to hepatic 
encephalopathy occurred frequently. After her blood purification therapy was changed to 
online HDF, her hepatic coma improved dramatically (West Haven grade, 0.07±0.27 vs. 
HD, 0.95±1.11). Compared with HD, increased the removal of AAAs (phenylalanine: 43.6% 
vs. HD, 10.7%; tyrosine: 73.0% vs. HD, 35.3%), contributing to the increased BCAA/AAA 
ratio was observed after HDF session.
Discussion: In this case, hepatic encephalopathy was worsened by HD treatment in 
a patient with ESKD due to BCS, and was improved by HDF, with increased removal of 
AAAs. Hepatic encephalopathy is thought to be exacerbated by HD due to portal systemic 
bypass or shunting and/or perturbation of the amino acid profile. Tryptophan, one type of 
AAA, has especially a high protein-binding rate (50%-80%), and only a small amount 
of protein-bound tryptophan is removed by HD. Therefore, one of the reasons why HDF 
ameliorates hepatic encephalopathy is increased removal of protein-bound AAAs, leading 
to increased BCAA/AAA ratio.
FR-PO047
De Novo Lupus Nephritis in a Stable Kidney Transplant Recipient 
Laura Panarey, Karthik M. Ranganna, Alden Michael Doyle.  Div of Nephrology 
& Hypertension, Drexel Univ Hahnemann Hospital, Philadelphia, PA.
Introduction: De Novo Lupus Nephritis (LN) is an exceedingly rare complication in 
kidney transplant recipients, previously reported only twice, neither recipient noted to have 
clinical manifestations of SLE. The scarcity of autoimmune disease in this population is 
not fully understood, but has been attributed to the maintenance immunosuppression used 
to prevent allorecognition and rejection.
Case Description: Herein, we present de novo LN in a 55-year-old woman with post 
streptococcus glomerulonephritis and HTN; 28 years status-post living-related kidney 
transplant. The patient had no personal or family history of autoimmune disease at time 
of transplant. Three years ago, she began complaining of episodic carpo-pedal spasm and 
scleritis; laboratory abnormalities included mildly low albumin and stable 1g proteinuria. 
Medications were stable and no potentially provocative antigens, vaccines or transfusions, 
were given during this period. Immunosuppression included cyclosporine and low dose 
prednisone. Seven months ago, the patient developed malar rash and hemo-proteinuria 
prompting immunological studies and kidney allograft biopsy. Anti-nuclear, double stranded 
DNA, smith and histone antibodies were all strongly positive with low serum complement 
levels. Serum creatinine increased by 0.5 mg/dL from baseline; urine protein to creatinine 
ratio revealed nephrotic range proteinuria peaking at 9.6grams. Immunofluorescence 
revealed granular “full house” pattern, C4d negative; Electron microscopy revealed 
intramembranous deposits. The patient was treated with high dose prednisone, continued 
cyclosporine and addition of mycophenolate mofetil.
Discussion: Although rare, de novo auto-immune disease should be considered for 
transplant patients despite maintenance immunosuppression.
FR-PO048
Atypical Hemolytic Uremic Syndrome Allograft Outcome in the Post 
Eculizumab Era  Laura Panarey, Karthik M. Ranganna, Alden Michael Doyle. 
Divsion of Nephrology & Hypertension, Drexel Univ Hahnemann Hospital, 
Philadelphia, PA.
Introduction: Atypical Hemolytic Uremic Syndrome (aHUS) is an exceedingly 
rare etiology of renal failure; recurrent forms of HUS are often linked to underlying viral 
illness or particular classes of immunosuppression in transplant recipients. Exceedingly 
rare are genetic etiologies of aHUS for which transplantation is undesirable due to very 
high recurrence rates of disease.
Case Description: Herein we describe a case of misdiagnosis; 78 year old man 
initially diagnosed with rapidly progressive glomerulonephritis (RPGN) by kidney biopsy 
developed anuria necessitating hemodialysis. The patient had no family history of kidney 
disease. Immunological work-up negative for Anti-nuclear or cytoplasmic antibodies; 
complement deemed within normal limits. Pt received a living-unrelated kidney transplant 
from a 40 year old healthy donor. Standard induction solumedrol and thymoglobulin. 
Initiation of maintenance calcineurin inhibitor (CNI), steroid, antimetabolite. Favorable 
outcomes were observed, creatinine 1.77 mg/dL and urine output upon discharge. One 
week post-transplant, patient was observed to have increased creatinine, peak 4mg/dL, 
not amenable to discontinuation of CNI or typical offending agents; prompting renal 
biopsy. Histologically Thrombotic Microangiopathy (TMA), C4d (-) observed and deemed 
comparable to native biopsy slides. Laboratory studies confirmed aHUS: (-) ADAMSTS13; 
low lactate dehydrogenase, elevated haptoglobin; peripheral smear shistocytes. Negative 
viral studies including Shiga toxin. Pt was treated with high dose solumedrol, plasma 
exchange and eculizumab; resolution of kidney function, creatinine 1.88 mg/dL, month 
post-transplant period. Interim six month follow-up, with twice monthly eculizumab reveal 
no recurrent TMA on biopsy; despite bouts of acute kidney injury related to CNI levels 
or volume fluctuations.
Discussion: aHUS, as presented above, may be misdiagnosed and therefore present at 
the time of post-transplant recurrence. With the advent of treatment, alternative pathway 
complement inhibitor eculizumab; a high degree of suspicion must be maintained when 
managing post-transplant dysfunction.
FR-PO049
An Unusual Manifestation of Disseminated Histoplasmosis in a Renal 
Transplant Patient  Kana N. Miyata, Lilly M. Barba.  Nephrology, Harbor-
UCLA Medical Center, Torrance, CA.
Introduction: Disseminated histoplasmosis is rare but can develop in 
immunocompromised patients. We present a case of histoplasmosis presenting as fever of 
unknown origin with oral and gastrointestinal (GI) manifestations.
Case Description: The patient is a 42 year-old man with ESRD secondary to unclear 
etiology, who had a living related renal transplant from his cousin 4 years ago in Mexico. 
He was born in El Salvador, moved to California at age 7, and had traveled to Mexico 
and Cuba (last travel 1 year ago). His post-transplant course was complicated by antibody 
mediated rejection and borderline acute cell mediated rejection 2 years ago, for which 
he was successfully treated with IVIG, plasma exchange, and rituximab. His medication 
included tacrolimus, MMF, and prednisone. He presented with 2-3 weeks of fever and 
mild abdominal pain after unsuccessful treatment with ciprofloxacin. He had fever of 38.7 
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°C, painless tongue ulcers (Fig.A), and mild periumbilical tenderness. CT chest/abdomen 
showed multiple lung nodules, mild mediastinal lymphadenopathy, and a severe wall 
thickening of the distal loop of ileum. Colonoscopy revealed an 8 mm ulcer at terminal ileum 
(Fig.B), whose pathology was positive for intracellular Histoplasma capsulatem. Urine 
histoplasma antigen was positive. He improved soon after oral itraconazole was started. 
Discussion: This is an unusual case of disseminated histoplasmosis. Histoplasmosis is 
most commonly diagnosed in the first year after transplant. Fever, fatigue, and dry cough 
are the most common presenting symptoms, and GI manifestations are recognized clinically 
in less than 10% of cases. Post-transplant histoplasmosis remains a rare event with only 1 
case per 1000 person-years but the mortality is as high as 10%. We should maintain a high 
index of clinical suspicion to diagnose and treat it properly.
FR-PO050
Successful Strategy for Management of Anuric Acute Kidney Injury 
Complicated by Severe Hyponatremia Using Continuous Venovenous 
Hemodialysis  Rahul N. Pawar, Rajat Lamba, Amy R. Patel, Venkata 
Buddharaju, Michael D. Klein.  Nephrology, Westchester Medical Center, 
Valhalla, NY.
Introduction: Anuric acute kidney injury (AKI) with hyponatremia presents a 
therapeutic challenge. Hemodialysis (HD) using a standard Na+ bath can cause excessive 
correction of [Na+], and a risk of osmotic demyelinolysis. We report the controlled correction 
of hyponatremia via continuous venovenous HD (CVVHD) against a standard bath using 
an infusion of dextrose 5% in water (D5W) to blunt the [Na+] shift.
An 83 year old man with respiratory failure developed altered mentation and oliguria. 
Labs demonstrated severe hyponatremia with [Na+] 119 mEq/L, [K+] 6.8 mEq/L, and AKI 
with BUN 46 mg/dL, creatinine 3.08 mg/dL. Emergent renal replacement therapy (RRT) 
was required, but HD would have risked overly rapid correction of [Na+]. Instead, we 
started CVVHD with a [Na+] 140 mEq/L bath. The dialysate rate was 2 L/hr and blood 
flow rate was 200 cc/min. Net target was zero, with all drips included in the calculation. 
We simultaneously infused D5W at 100 cc/hour. [Na+] was monitored every 4 hrs. The 
D5W was held if the CVVHD was stopped for any reason. The D5W was to be increased 
if the [Na+] rise was > 0.5 mEq/hr or 6 mEq in 24 hrs. It was to be reduced if the correction 
was suboptimal. The patient’s [Na+] rose from 118 mEq/L to 125 mEq/L on day 1, 125 
mEq/L to 131 mEq/L on day 2, and reached 137 mEq/L by day 3. The patient was then 
safely converted to HD .
Discussion: CVVHD is a safer option for RRT than HD in the setting of severe 
hyponatremia, but low Na+ CVVHD dialysate is not available. Some have suggested 
adjusting the dialysate [Na+] using sterile water to achieve the desired [Na+] prior to 
treatment. This may produce a predictable response in [Na+], but there are concerns for 
infection and/or dosing error which makes this strategy problematic. Reducing dialysate or 
effluent flow, though effective, often results in unacceptable clearances. We demonstrated, 
that CVVHD with a standard Na+ bath, a separate D5W drip, and strict monitoring of [Na+], 
can yield a predictable response in [Na+], obviating the cumbersome and risky point of care 
manipulations of the dialysate formula.
FR-PO051
Case Report: Renal Squamous Cell Carcinoma of a Native Kidney After 
Renal Transplant  Adam Daniel Jakes,1 Poonam Jani,2 Mini Menon,3 Kate 
Adams,4 Matthew Edey,3 Stewart Fleming,5 Sunil Bhandari.3  1Dept of Renal 
Medicine, Hammersmith Hospital, London, United Kingdom; 2Hull York Medical 
School, Hull, United Kingdom; 3Dept of Renal Medicine, Hull Royal Infirmary, 
Hull, United Kingdom; 4Dept of Infection & Tropical Medicine, Castle Hill 
Hospital, Hull, United Kingdom; 5St. James’s Univ Hospital, Leeds, United 
Kingdom; 6Cellular and Molecular Pathology, Ninewells Hospital, Dundee, 
United Kingdom.
Introduction: Renal squamous cell carcinoma is a rare primary tumour of the kidney, 
which rapidly invades local structures and has a poor prognosis. Presentation is usually 
non-specific and is associated with renal stone disease and chronic infection. We present a 
case of squamous cell carcinoma of a native kidney in a renal transplant recipient, which 
has not previously been described in the literature.
Case Description: A 46-year-old white male with previous renal stones and recurrent 
urinary infections underwent a right nephrectomy and subsequent renal transplantation due 
to failure of the remaining kidney. Five years post-transplant, an abdominal ultrasound 
scan was performed due to recurrent urinary infections and ongoing pyuria. This was 
reported as normal, but he later developed a discharging sinus in his left flank. A CT scan 
revealed a tracking peri-nephric abscess with an associated cystic lesion of the left kidney. 
A left nephrectomy was performed and histological examination suggested an invasive 
squamous cell carcinoma of the renal pelvis. The patient later required major surgery for 
chronic infection, and further imaging revealed metastatic disease, resulting in the decision 
to manage palliatively.
Discussion: Renal transplant recipients are three-four times more likely to develop 
a malignancy than the general population. The patient also had renal stone disease and 
recurrent urinary infections; further increasing his risk of developing this condition. 
Abdominal ultrasound was unhelpful and only a later CT scan revealed the underlying 
malignancy. Given the non-specific nature of the symptoms and the poor prognosis, 
healthcare professionals should have a lower threshold for diagnostic imaging in these 
patients. This should be expedited if there is a persistent abnormality on urinalysis.
FR-PO052
A Case of Hydronephrosis due to Adenovirus Hemorrhagic Cystitis 
following Peripheral Blood Stem Cell Transplantation for Malignant 
Lymphoma  Rio Noto,1 Hideki Yokoi,2 Akihiro Yoshimoto,1 Motoko Yanagita.2 
1Clinical Nephrology, Kobe City Medical Center General Hospital, Kobe, 
Hyogo, Japan; 2Nephrology, Kyoto Univ Graduate School of Medicine, Kyoto, 
Japan.
Introduction: In patients receiving stem cell transplantation (SCT), adenoviral 
infections are associated with mortality and morbidity. Cystitis is the most common clinical 
presentation of adenoviral urinary tract infection, which unusually causes inflammation 
of the upper urinary tract. We report a rare case of adenoviral ureteritis accompanied by 
hydronephrosis after autologous peripheral blood SCT.
Case Description: A 50-year-old male, who had undergone SCT 4 months ago for 
the treatment of nasal-type extranodal NK/T cell lymphoma and received tacrolimus as 
prophylaxis for graft-versus-host disease, developed fever, right back pain and dysuria. 
Computed tomography (CT) showed perirenal and periureteral fat heterogeneity and 
dilation of the right ureter. He was diagnosed as pyelonephritis caused by ureteral stones 
(already dropped), but antibiotics did not relieve symptoms. In addition, he exhibited a 
left solitary pulmonary mass, which was diagnosed as Mycobacterium avium complex 
(MAC) infection by lung needle biopsy. Cystoscopy and retrograde pyelography revealed 
hemorrhagic cystitis and right ureteral stenosis, where a catheter was placed. Viral PCR 
test was performed for differentiating hemorrhagic cystitis, and adenovirus was detected 
both in urine and in blood. Symptoms and abnormal findings on CT were improved by the 
placement of a catheter and the decrease of tacrolimus dosage.
Discussion: Differential diagnoses were urothelial carcinoma, recurrence of malignant 
lymphoma, retroperitoneal fibrosis and disseminated MAC disease. Urine cytology result 
was negative for malignancy. Gallium scintigraphy excluded recurrence of malignant 
lymphoma. Fat heterogeneity disappeared after catheter placement, suggesting that 
malignant lymphoma and retroperitoneal fibrosis were unlikely. MAC was not detected from 
blood and urine cultures. Clinical course and laboratory data indicated that inflammation 
of adenoviral hemorrhagic cystitis spread to the right ureter, leading to ureteral stenosis 
and hydronephrosis in an immunocompromised patient after SCT.
FR-PO053
Unusual Cause of Thrombocytopenia in a Dialysis Patient  Rahul N. Pawar, 
Savneek S. Chugh, Amy R. Patel, Rudrick V. Ledesma, Rajat Lamba. 
Nephrology, Westchester Medical Center, NY.
Introduction: Hemodialysis (HD) is an invasive treatment with many adverse effects, 
thrombocytopenia being one of them. Most of the cases of thrombocytopenia on dialysis 
are related to the use of heparin creating auto-antibodies leading to heparin induced 
thrombocytopenia (HIT). Here we report a case of severe thrombocytopenia, which was 
initially thought to be due to HIT, but later revealed to be secondary to a specific dialyzer 
membrane.
An 81 year old female started on HD 2 months prior for progressive CKD was sent to 
the ED for excessive bleeding around the tunneled catheter site and a platelet (PLT) count of 
27 K/uL. When she was first started on inpatient HD, she was found to be thrombocytopenic 
and heparin autoantibodies were weakly positive so she was started on argatroban. At the 
1st outpatient HD unit, her PLT count increased to 200 K/uL. After transferring to a 2nd 
outpatient HD center, her PLT count, once again, dropped to 27 K/uL along with recurrent 
bleeding at the catheter site. This prompted investigation of heparin exposure as a cause, 
but it was revealed that the patient never received heparin during any of her treatments. 
Despite being restarted on argatroban, her PLT count remained in the 20 K/uL range. The 
serotonin release assay was negative. It was noted that the hospital and the 2nd outpatient 
unit both used a F160NR dialyzer, different from the dialyzer used in the first outpatient 
unit. With the suspicion of a possible dialyzer reaction, the membrane was switched from 
F160NR to Gambro Revaclear. Her PLTs increased to 125 K/uL in 4 days. Discharge 
instructions indicated that the patient must use a Revaclear dialyzer. A week later, repeat 
PLT count was noted to be 200 K/uL.
Discussion: This case demonstrates a rare dialyzer reaction, in which a specific dialyzer 
membrane leads to severe thrombocytopenia and bleeding. It has been postulated that 
complement activation might have a role, but this patient had normal complement levels 
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and a negative coombs test. Heparin induced reactions are still the most common etiology 
of thrombocytopenia in HD patients, but other causes, such as a dialyzer reaction should 
be considered as part of the initial differential.
FR-PO054
Calcium Free Dialysis for Hypercalcemic Crisis  Karim El Hachem, Eduardo 
J. Zouain, Isha Gupta, Anip Bansal.  Nephrology, Mt Sinai- St Luke’s Hospital, 
New York, NY.
Introduction: Hypercalcemic crisis, a potentially life-threatening condition, has 
been defined as a calcium of 14 mg/dl or more with evidence of multi-organ dysfunction 
including cardiovascular, renal or CNS involvement. We describe a case of hypercalcemic 
crisis due to primary hyperparathyroidism treated with low calcium/calcium free dialysis.
Case Description: A 62 year old healthy man was brought by his wife to the ED 
for lethargy, worsening confusion over 3 days, weight loss and constipation. On exam, 
he was hemodynamically stable, had flat jugular veins and dry mucous membranes. His 
corrected calcium was 23.58 mg/dL with a creatinine of 3.60 mg/dL. He was aggressively 
hydrated with normal saline and received a total of 2 doses of Calcitonin 240 IU IM with no 
improvement in his mental status or in his calcium levels. He was then given Denosumab 
60 mg SQ and underwent a 3 hour session of low calcium dialysis (Ca bath 1.0 mEq/L). 
During the treatment, he was given NS boluses in addition to his maintenance NS 250 cc/
hr to avoid hypotension. He subsequently underwent 3 additional treatments (Treatments 
2 and 4- using calcium free dialysate and Treatment 3- using Ca 1.0 mEq/L) that were 
well tolerated. Following his 2nd treatment, his mental status improved significantly. After 
his 4th treatment, his calcium was 12.26 mg/dL. His intact PTH level was 1324 pg/mL. A 
Sestamibi thyroid scan showed a large left parathyroid mass. The patient underwent surgical 
resection of a 13 gm parathyroid adenoma after which his calcium normalized to 9.8 mg/
dL. His clinical course and a blood pressure trend during hemodialysis is reported below. 
Discussion: Calcium free dialysis and the use of low calcium dialysate was tolerated 
with no hemodynamic instability. Aggressive hydration is important to maintain tolerability. 
It can be safely used as a bridge to definitive surgical treatment in the setting of primary 
hyperparathyroidism.
FR-PO055
Antineutrophil  Cytoplasmic Antibody Crescentic  Allograft 
Glomerulonephritis following Sofosbuvir Therapy  Shilpa Gadde. 
Nephrology, Tulane Univ, New Orleans, LA.
Introduction: Sofosbuvir is used for the treatment of hepatitis C virus infection. We 
report first case of ANCA/RPGN following Sofosbuvir in a kidney transplant recipient.
Case Description: 51 yo male had a living unrelated donor kidney transplant, received 
alemtuzumab induction, and tacrolimus and mycophenolate maintenance. sCr was 1.4, 
1 week after transplant. 12 weeks post-transplant, sCr was 2.0; renal biopsy showed 
ATN and tubular isometric vacuolization. Tacrolimus was replaced with cyclosporine. 
His sCr stabilized at 1.6. He had HCV genotype 1a and high viral load. At week 40 after 
transplant, he was started on ribavirin and sofosbuvir. At 12 weeks of HCV treatment, sCr 
was 3.7. UA with 30 protein and 131 RBCs, and PCR was 0.6. Allograft biopsy showed 
TMA. Therefore, sofosbuvir, ribavirin and cyclosporine were stopped. He was started on 
prednisone and continued on mycophenolate. His sCr was at 2.4. 70 weeks after transplant 
(30 weeks after initiation of sofosbuvir and ribavirin treatment), he had a sCr of 4.3 and 
PCR of 5. Urinalysis showed >500 of protein, 70 RBCs. Biopsy showed cellular crescents 
in glomeruli with pauci-immune IF. EM had normal GBM with subendothelial “fluff”. 
p-ANCA titer was 1:320 and MPO ab >100. He was diagnosed with p-ANCA associated 
crescentic GN in the allograft. The patient was treated with solumedrol, cyclophosphamide 
and a course of plasmapheresis. He later started HD and Rituximab was added. He remains 
dialysis-dependent despite of our efforts in treating his RPGN.
Discussion: Renal biopsy showed 3 different pathologies. Initiallly tubular toxicity of 
tacrolimus. After sofosbuvir and ribavirin, he had TMA, we stopped his HCV treatment, 
although the concurrent cyclosporine use was implicated. 30 weeks after the initiation 
of sofosbuvir and ribavirin therapy he had ANCA-associated crescentic GN. Ribavirin 
had no reported cases of ANCA vasculitis. Sofosbuvir was approved in 2013 and we 
suspect it as likely cause of ANCA vasculitis. Therefore, our case represents the first case 
of drug-associated ANCA vasculitis in an allograft kidney. Further drug monitoring is 
necessary to elucidate the degree of association and possible causal effect of sofosbuvir 
and p-ANCA vasculitis.
FR-PO056
Malignant PEComa Post Combined Kidney and Pancreas Transplantation 
Rapeepat Lekkham, Mauricio Alexander Pedroza, Gitana Bradauskaite, 
Daranee Chewaproug.  Medicine, Nephrology, Albert Einstein Medical Center, 
Philadelphia, PA.
Introduction: Perivascular epitheliod cell tumors or clear cell “sugar” tumor or 
PEComas is a very rare mesenchymal neoplasm. The biological behavior of such tumors 
can range from benign to malignant. We report the first case of primary renal malignant 
PEComas with lung metastasis after combined kidney and pancreas transplantation.
Case Description: The patient was a 44-year-old Hispanic female with a history of 
DM type I with living related kidney transplant back in 1998 and followed by a pancreas 
transplant in 1999 with transplant pancreatectomy and retransplant of the second pancreas in 
2010. Her immunosuppressive agents were mycophenolic acid, prednisone and tacrolimus. 
Fifteen years post-kidney-transplant, she developed fever with chronic cough for a month. 
CT of the chest revealed multiple, bilateral, solid, non-cavitating pulmonary masses with 
mediastinal lymphadenopathy. CT of the abdomen showed right native kidney mass 
measured 5.8x5.8x8 cm. Right lower lobe lung biopsy showed perivascular epitheliod cell 
neoplasm. The PEComas of the lung are traditionally considered benign. To investigate 
the nature of the renal mass, the patient underwent right open radical nephrectomy. Again, 
the right nephrectomy pathology showed malignant PEComa, 10 cm with pure epitheliod 
with carcinoma-like growth pattern, involving the entire kidney. The tumor is histologically 
identical to the patient’s lung mass and confirms that the kidney mass is the primary 
tumor and the lung tumor is a metastasis. The patient also found metastatic osteolytic 
lesions involved pelvis, proximal femurs, cervical and thoracic spines. After confirmed 
the diagnosis of malignant PEComas, mycophenolic acid was stopped. She was started 
on Temsirolimus 25 mg intravenous weekly, tacrolimus was changed to rapamycin and 
continue with oral prednisone. Unfortunately 3 weeks later patient became unresponsive, 
cardiac arrest and passed away.
Discussion: Although the majority of PEComas is recognized as benign, but in the 
immunocompromised patient, especially with a history of multiple solid organ transplants 
like in our patient, the tumor could be presented in advance and aggressive way with fatal 
outcomes.
FR-PO057
A Case of Post-Transplant Kaposi Sarcoma Treated with Combination 
Chemotherapy and mTOR Inhibitor  Nadeen J. Khoury, Dina Abdelwahab, 
William S. Asch.  Internal Medicine/Nephrology, Yale Univ School of Medicine, 
New Haven, CT.
Introduction: Kaposi sarcoma is a viral-induced malignancy caused by human herpes 
virus 8. Clinical presentation varies from minimal mucocutaneous disease to extensive organ 
involvement. We present a case of transplant-associated visceral Kaposi sarcoma without 
cutaneous manifestations treated with sirolimus and liposomal doxorubicin.
Case Description: A 43 y old African American male with history of ESRD s/p 
deceased donor kidney transplant in 2013 induced with alemtuzumab, maintained on 
tacrolimus, mycophenolate and prednisone was admitted with worsening shortness of 
breath and productive cough. His course was complicated by hypoxemic respiratory 
failure requiring intubation. He received broad-spectrum antibiotics initially and his anti-
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proliferative was held. His exam was unremarkable except for an exophytic gingival lesion 
on his right mandible. His kidney function was at baseline. Imaging revealed diffuse lung 
and liver nodularities with bulky lymphadenopathy. An axillary lymph node biopsy was 
performed and was consistent with Kaposi sarcoma (HHV8+). Tacrolimus was stopped and 
the patient was transitioned to the mTOR inhibitor: sirolimus. He was initiated on liposomal 
doxorubicin after extubation with significant improvement in metastatic disease after four 
cycles. His renal function remained stable on sirolimus and prednisone.
Discussion: Post-transplant malignancies are common and constitute a major burden. 
Adjustment of immunosuppression is the mainstay of therapy in these cases. It is standard 
of care to switch from calcineurin inhibitors to sirolimus upon the diagnosis of Kaposi 
sarcoma. However, there’s no literature regarding chemotherapy in transplant-associated 
Kaposi sarcoma. Most of the available data is from the AIDS population that we extrapolated 
to our patient. His bulky disease triggered us to explore aggressive therapy. Combination 
chemotherapy and sirolimus seem to be a good therapeutic strategy that should be considered 
in cases of disseminated post-transplant Kaposi sarcoma.
FR-PO058
Warfarin-Related Nephropathy in a Kidney Transplant Patient 
Nadeen J. Khoury,1 Gilbert W. Moeckel,2 Mark A. Perazella.1  1Nephrology, 
Yale Univ, New Haven, CT; 2Dept of Pathology, Yale Univ, New Haven, CT.
Introduction: Anticoagulant-related nephropathy is a new entity manifesting as AKI in 
the setting of excessive anticoagulation. Initial cases were related to warfarin use; however, 
more recently AKI is reported with direct thrombin inhibitors. We present biopsy-proven 
warfarin-related nephropathy (WRN) in a transplant patient on anticoagulation for atrial 
fibrillation with INR<2.
Case Description: A 69 y old man with hypertension, atrial fibrillation (on warfarin), 
T2DM and ESRD s/p living unrelated kidney transplant with baseline sCr 2.0 mg/dl 
(on cyclosporine, mycophenolate and prednisone) presented with nausea, vomiting and 
abdominal pain. Acute cholecystitis was diagnosed and percutaneous cholecystostomy 
drainage performed. Initial labs revealed leukocytosis and AKI on CKD with sCr: 2.7 mg/dl. 
INR was 1.8. Urinalysis revealed 3+blood, 2+ protein with 179 RBCs/HPF, urine sediment 
1-2 RBC casts/LPF. Transplant kidney ultrasound was unremarkable. Complements were 
normal. Urine microscopy demonstrated persistent RBC casts and kidney biopsy was 
performed. Acute tubular injury with numerous occlusive RBC casts suggestive of WRN 
was observed. Kidney function slowly improved but sCr remained above baseline upon 
discharge. Warfarin was resumed due to high stroke risk.
Discussion: Our patient’s presentation with AKI in the setting of acute cholecystitis 
raised the possibility of sepsis-induced AKI. However, the presence of microscopic 
hematuria and numerous RBC casts suggested a glomerular process. Biopsy suggested 
WRN developing in the setting of CKD and anticoagulation. Our case is somewhat 
unusual given the INR<2. Most cases of WRN have an INR>3. However, the patient 
had risk factors that have been linked to WRN including CKD, diabetes mellitus and 
hypertension. Interestingly, INR levels several months prior were all consistently below 
2 yet the patient had 2 bleeding episodes requiring hospitalizations (GI bleed and thigh 
hematoma) suggesting an underlying bleeding predisposition. It is reasonable to consider 
WRN in cases of unexplained AKI with RBC casts in a patient with INR<3 in the presence 
of other risk factors and bleeding tendency.
FR-PO059
Successful Preemptive Kidney Transplantation Using Rituximab Induction 
in a Patient with Focal Segmental Glomerulosclerosis and Nephrotic 
Syndrome – Case Report  Aureliusz Kolonko, Grzegorz Piecha, Andrzej 
Wiecek.  Dept of Nephrology, Transplantation and Internal Diseases, Medical 
Univ of Silesia, Katowice, Poland.
Introduction: Focal segmental glomerulosclerosis (FSGS) recurs in 30% of patients 
receiving their first kidney transplant and often leads to graft loss. In the past, patients with 
FSGS and overt nephrotic syndrome were rarely transplanted, mostly due to the worries 
about its relapse. Rituximab (RTX), an anti-CD20-specific monoclonal antibody, was 
previously reported to be valuable option in resistant nephrotic syndrome and in relapsing 
FSGS after second kidney transplantation. Hereby, we present a successful first kidney 
transplantation of a young patient with FSGS and full-blown nephrotic syndrome, treated 
with RTX induction.
Case Description: The patient is a 24-year-old woman, who developed nephrotic 
syndrome at the age of 4. FSGS was confirmed early by renal biopsy, she was treated with 
cyclosporine A, mycophenolate mofetil (MMF), and steroids, with no remission. She 
was referred to preemptive, deceased donor kidney transplantation despite of 10 g/day 
proteinuria. She received induction therapy with two doses of RTX (375 mg/m2) at day 0 
and 7, followed by tacrolimus 5 mg BID, MMF 500 mg BID, and steroids therapy after 
transplantation. We observed immediate kidney graft function and protein-absent diuresis 
since 6th day post-transplant. Pre-transplant soluble urokinase plasminogen-type activator 
receptor (suPAR) serum concentration was 4550 pg/mL, it decreased to 2191 pg/mL at day 
13th and was 2073 pg/mL at 6 months posttransplant. Steroids were tapered and discontinued 
at 10 months post-transplant. Twenty months after transplantation serum creatinine is 0.8 
mg/dL and no proteinuria is observed.
Discussion: Successful kidney transplantation in a patient with pretransplant overt 
nephrotic syndrome secondary to FSGS, using rituximab as an induction therapy strongly 
suggest the need for larger clinical trials in such patients.
FR-PO060
Black Appearing Peritoneal Effluent  Manjunath Ramaiah, Carol Motes 
Headley, Geeta G. Gyamlani, Adnan Naseer, Barry M. Wall.  Nephrology, 
Veterans Affairs Medical Center, Memphis, TN.
Introduction: Endoscopic tattooing with India ink is a useful and safe tool for localizing 
small colorectal lesions.
Case Description: 60 year old man with End Stage Renal Disease due to Lupus 
Nephritis on Continuous Ambulatory Peritoneal Dialysis (CAPD), developed black 
effluent from the peritoneal dialysis drain bag following screening colonoscopy. Findings 
included an ulcerated tumor occupying 25% to 49% of the colon circumference. There 
was no evidence of bleeding and multiple forceps biopsies were taken. The tumor area was 
marked with tattoos using 3 injections (5 ml each) of India ink. He resumed CAPD and 
noticed his dialysate effluent was “black”. He presented to the ER with nausea, vomiting 
and black colored peritoneal fluid. Examination revealed a mildly tender abdomen without 
rebound or guarding. Vitals were stable and he was afebrile. CT scan of abdomen revealed 
small amount of free intraperitoneal air consistent with his peritoneal dialysis. Peritoneal 
effluent cell count was elevated at 0.619 K/ul and WBC count of 5.5 K/ul. His presentation 
was consistent with peritonitis (cloudy dark gray/black peritoneal effluent and elevated cell 
count)and empiric antibiotics were initiated with vancomycin, cefepime and metronidazole. 
Within 48 hours the peritoneal effluent was clear (cell count down to 0.105 K/uL). The 
effluent culture grew Escherichia coli and Providencia Stuartii. Dialysate remained normal. 
At the time of partial colectomy performed one month later, dark dye was still visible on 
mesenteric transverse colon, but no abscess was identified.
Discussion: Complications associated with India ink tattooing include abscesses, 
inflammatory pseudotumor, focal peritonitis and peritoneal staining, most of which have 
been attributed to inadequate dilution or sterilization of the India ink. Dye spillage into 
the peritoneal cavity has been reported to occur at a rate between 2.4% and 13%. This 
occurrence has been attributed to injection technique (deep), and the possibility of trans-
mural movement of the dye. In our patient the development of black appearing dialysate 
and bacterial peritonitis with gram-negative organisms is consistent with microperforation 
of the colon during the tattoing procedure.
FR-PO061
Sevelamer-Induced Colonic Injury – A Unique Case of Gastrointestinal 
Bleeding in End Stage Renal Disease Patient  Nivin Haroon,1 Unnikrishnan 
Ponnamma Kunjan Pillai,2 Zeenat Yousuf Bhat.1  1Internal Medicine/ 
Nephrology, Wayne State Univ, Detroit, MI; 2Internal Medicine/ Nephrology, 
Indiana Univ Ball Memorial Hospital, IN.
Introduction: End stage kidney disease patients experience significant morbidity and 
mortality. One common complication in this population is Gastro-intestinal bleeding(GIB) 
and common causes of GIB are platelet-dysfunction, anticoagulation use, Angiodysplasias 
and malignancies. Also medications like Sodium-polystyrene-sulfonate can cause direct 
mucosa damage. We report a case of GIB in Hemodialysis-patient attributed to Sevelamer-
induced colonic-ulceration.
Case Description: 56Y/O ESRD-Hemodialysis patient with multiple comordities 
including hypertension, systolic cardiac-dysfunction, Atrial-fibrillation, H/o Breast Cancer 
s/p mastectomy/chemo(2005),presented to the hospital with passage of bright red blood 
per rectum,accomapanied with syncope and shortness of breath. Her medications included 
Amiodarone, Aromasin, baby-Aspirin, Carvedilol, Diltiazem, Pantoprozole, Sevelamer, 
Cinacalcet. Her clinical examination was unremarkable(including neurologic exam)except 
for palor. Orthostatic vital signs not checked due to dizziness, Significant labs findings 
were-hemoglobin-5.7mg/dl, Serum Potassium-5.5meq/L,BUN and Serum-Creatinine 46mg/
dl and 8.5mg/dl respectively and INR-1.1. CT head- no acute abormalities, Mesenteric 
angiogram-no source identified, Endoscopic-Gastro-duodenoscopy- normal, colonoscopy- 
no active bleeder, multiple diverticulosis+. Bleeding scan showed activity near the hepatic 
flexure. She underwent emergent right-hemicolectomy for the continued bleeding. Pathology 
report showed metastatic Carcinoma involving proximal Colon, Colonic-Mucosa inflamed 
and ulcerated,cluster of organophilic Fish scale like crystals suggestive of Sevelamer crystals 
were noted in colonic mucosa. Patient improved post surgery.
Discussion: There is only handful of literature on the Sevelamer colonic toxicity. This 
case highlight the fact that with widespread use of sevelamer in dialysis patient, physicians 
should be aware of this entity. Our understanding of Sevelamer-associated mucosal injury 
is limited and there are no known prevention strategies available.
FR-PO062
Successful Eculizumab Therapy in De Novo Atypical Hemolytic Uremic 
Syndrome in a Renal Transplant Recipient  Adil Mohammad Hazara, Matthew 
Edey, Martin Chanayireh, Sunil Bhandari.  Hull and East Yorkshire Hospitals 
NHS Trust, Hull, United Kingdom.
Introduction: The use of terminal complement inhibitor eculizumab has not been 
well described in the treatment of de novo atypical hemolytic uremic syndrome (aHUS) 
post renal transplantation.
Case Description: We present a 47 years old female with end-stage renal disease 
due to reflux nephropathy who had received a living-donor renal transplant from her 
sister 18 months previously. Her maintenance immunosuppression medications included 
tacrolimus 6mg twice daily, mycophenolate sodium 720mg (AM) and 360mg (PM), and 
prednisolone 5mg on alternate days. She presented with 2 day history of diarrhea, vomiting 
and dehydration. Admission biochemistry revealed stage III acute kidney injury with a 
serum creatinine of 640 µmol/l (baseline 90 µmol/l). She was anemic (Hb 90 g/l) and 
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required multiple blood transfusions. Her trough tacrolimus level was raised at 22 ng/l. Stool 
microscopy and culture was negative for shiga-toxin producing bacteria. Blood film showed 
red cell fragments; serum lactate dehydrogenase was raised at 752 u/l. ADAMTS-13 activity 
was normal. Renal biopsy was consistent with thrombotic microangiopathy. Complement 
genetic analyses (factors H, I, B and MCP tested) did not reveal any pathogenic mutations. 
Anti-factor H antibodies were negative. She was treated, first with four cycles of plasma 
exchange and then commenced on eculizumab at 900mg infusion weekly for first four 
doses and then 1200mg fortnightly. Her renal and anemia parameters rapidly normalised. 
Fig 1. Changes in serum creatinine at the time of diagnosis (arrow), with plasma 
exchange (PEx) and following eculizumab treatment.
Discussion: Eculizumab has been used successfully in treatment of aHUS in our patient 
who had developed this condition de novo. Uncertainties still remain regarding the duration 
of treatment and long-term efficacy.
FR-PO063
Lowering of Dialysate Conductivity Stopped a Painful Sickle Cell Crisis 
in a ESRD Patient  Amit N. Shah, Jacques A. Durr.  Div of Nephrology, Univ 
of South Florida, Tampa, FL.
Introduction: Deoxy Hg-S gelation in sickle cell disease (SCD) is highly temperature-
sensitive, and causes RBC sickling that impairs capillary flow and cause painful crises 
(Embury SH, PMID 15280086). On O2 loss, the rate of gelation has a lag inversely related 
to the 30th power of its concentration (Hofrichter J, 4531026), and is in the range of capillary 
transit and circulatatory times. Within limits, RBCs behave like perfect osmometers 
(Ponder E, 16994612). This led to claim that as RBC shrink during medullary transit Hgb-S 
concentrates and sickling leads to papillary necrosis and hypostenuria in SCD (Perillie PR, 
13942410), Similarly, some claimed that induced hyponatremia treats SCD crisis (Rosa 
RE, 6999348), others did not (Charache S, 7296001).
Case Description: A 42 yo SCD ESRD patient is admitted ~ once a month for severe 
pain crisis that last for several days and are not relieved by oxycodone, dilaudid, nasal O2, 
or IV fluids, and not due to low dry weight. Her baseline HgB is 5-6 g/dl, and PNa is stable 
at ~ 140 mmol/l. One of us was in the dialysis unit as she had a severe crisis, and had 
exhausted all resources. We asked for permission to lower her dialysate Na by 5-8 mmol/l.
This abolished her pain within ~10 min. She says that this was the first time something 
helped.
Discussion: We wish to call our colleagues’ attention to this case, as SCD patients with 
ESRD and painful crises are not uncommon, and since an ingenious method (Du E, Proc 
Natl Acad Sci USA. 2015 Feb 3; 112(5): 1422–1427) is now available that allows to study 
RBC sickling kinetics during a mimicked capillary transit, under controlled conditions of 
temperature, tonicity, O2 tension, pH, etc. There was a strong correlation between sickling 
and MCHC-S concentration, and MCV. However, the slope was negative between cell 
velocity and cell volume (R = -0.89, P < 0.001). This method should help resolve which 
factor predominates during RBC swelling induced by acute hypotonicity: the desired 
decrease in Hg-S concentration, or undesired decrease in RBC velocity in the capillaries 
(low O2 tension). Our observation should trigger controlled studies. Would decreasing the 
dialysate temperature also have a positive effect?
FR-PO064
Hemophagocytic Lymphohistocytosis Associated Nephrotic Syndrome 
Caused by Cytomegalovirus Infection in a Renal Transplant Recipient 
Gaurav Agarwal,1 Abolfazl Zarjou,1 Todd M. Stevens,2 Shikha Mehta.1  1Div 
of Nephrology, Univ of Alabama at Birmingham; 2Dept of Pathology, Univ of 
Alabama at Birmingham, Birmingham, AL.
Introduction: Hemophagocytic lymphohistocytosis (HLH) is a life threatening 
syndrome representing severe uncontrolled inflammatory reaction caused by 
hypercytokinemia and excessive immune activation. It is rare in solid organ transplantation 
and caries a mortality of 47%.
Case Description: 31 year old black man with end stage kidney disease who was status 
post deceased donor kidney transplant, received induction with alemtuzumab and was 
maintained on prednisone, mycophenolate mofetil and tacrolimus. He presented 4 months 
post-transplant with diarrhea and fever and was diagnosed with CMV disease with a viral 
load of 2.7 million copies/ml. He had acute kidney injury with serum creatinine (Cr) of 3.3 
mg/dl. Despite 2 weeks of adequate antiviral therapy with IV ganciclovir and reduction of 
immunosuppression, patient continued to have high grade fever, worsening pancytopenia, 
AKI and developed new onset nephrotic range proteinuria of 15.5 gms/24 hrs. Kidney 
allograft biopsy revealed characteristic CMV inclusion bodies within glomerular endothelial 
cells and diffuse foot process effacement consistent with acute CMV glomerulopathy. 
There was no evidence of focal segmental glomerulosclerosis, thrombotic microangiopathy 
or rejection. He had pancytopenia, elevated ferritin level (15,605 ng/ml), transaminitis, 
hypertriglyceridemia, elevated LDH and D-dimer. Patient met the clinical criterion for 
HLH. His nephrotic syndrome was attributed to HLH associated with CMV infection. 
Treatment was started with anakinra 100 mcg subcutaneously daily. Patient responded to 
the therapy with initial decline in serum Cr to 2.4 mg/dl. At 2 months follow up, proteinuria 
has improved to 2.1 g/g, ferritin to 1875 ng/ml, but Cr remains elevated at 3.6 mg/dl.
Discussion: Most cases of HLH in kidney transplant recipients are triggered by CMV 
infection or other herpesviruses. This is a unique case of HLH and nephrotic syndrome 
caused by CMV infection which is likely secondary to cytokine storm and histiocyte 
proliferation. Treatment with anakinra could be beneficial in these patients.
FR-PO065
BK Nephropathy in Allogeneic Stem Cell Transplant Recipient without 
Thrombotic Microangiopathy and Graft-Versus-Host Disease: A 
Unique Observation  Rima N. Pai,1 Maria del Pilar Fernandez,2 Jai Prakash 
Babu Thippaiah Jadegondanahalli,2 William F. Glass,3 Sairah Ahmed,4 Ala 
Abudayyeh.1  1Section of Nephrology, UT MD Anderson Cancer Center; 
2Nephrology and Hypertension, UT-Houston Medical School; 3Pathology, 
Ut-Houston Medical School; 4Dept of Stem Cell Transplantation, UT MD 
Anderson Cancer Center.
Introduction: BK virus is emerging as an important pathogen in allogeneic stem cell 
transplant (SCT) recipients and more prevalent in patients of Graft versus Host Disease 
(GVHD) and Thrombotic microangiopathy (TMA).Due to immunosuppression, different 
drugs and/or drug combinations have been associated with BK nephropathy such as 
tacrolimus. BK virus causes chronic kidney disease, ureteral stenosis and hemorrhagic 
cystitis in stem cell transplant patients leading to increase mortality and long hospital 
stay. We present a unique case of BK nephropathy that has occurred in patient who was 
asymptomatic and without any co-infections, TMA, or GVHD. The patient was tapered off 
tacrolimus which showed improvement in the BK viral urine and serum load.
Case Description: A 31-year- old female with history of Acute Myeloid Leukemia 
(AML) underwent an allogeneic stem cell transplant a year ago. Patient was treated with 
4 cycles of Fludarabine, IDArubicin, CYTarabine (FIA) and sorafenib regimen. Post-
transplant course was complicated by GVHD of gastrointestinal tract and skin (Grade I) 
.Patient was maintained on tacrolimus and later tapered off .She remained asymptomatic; 
however, kidney function worsened with elevated creatinine at 1.8. BK Serum viral Load 
of 10,800 was seen. Therefore, renal biopsy was done which was consistent with BK 
nephritis. With limited effective therapeutic options, immunosuppression by tacrolimus was 
tapered off and Leflunomide was started showing a decrease in viral load and creatinine 
stabilizing to 1.37.
Discussion: A definitive diagnosis of BK nephritis is confirmed with a kidney biopsy. 
BK nephropathy is an important and often overlooked cause of chronic kidney disease 
in allogeneic stem cell transplant patients. This case report helps to recognize the much 
needed development of guidelines in detection and treatment of BKV for early intervention.
FR-PO066
Pharmacokinetics and Total Removal of Fosfomycin in a Patient with 
Chronic Kidney Failure Undergoing Haemodialysis  Julius Schmidt, Jan T. 
Kielstein.  Nephrology, Medical School Hannover, Hannover, Germany.
Introduction: Fosfomycin shows bactericidal activity against various gram-positive, 
gram-negative and anaerobic pathogens, including antibiotic resistant S. aureus. However, 
dosing of fosfomycin in critically ill patients undergoing renal replacement is based on 
scarce data.
Case Description: A female chronic dialysis patient (76 years, BMI 20) was admitted 
to our hospital due to distinct dorsalgia. Computed tomography of the lumbar spine unveiled 
spondylodiscitis of the thoracic vertebrae 11/12. A punch biopsy of the affected bone region 
showed focal osteomyelitis. As the patient was allergic to penicillin, antibiotic therapy with 
clindamycin and fosfomycin sodium (8 g per day, 3 g before, 5 g after IHD session) was 
initiated. Maximum plasma concentration after the 3 g infusion was 496 mg/L. IHD led to 
a distinct reduction of fosfomycin plasma levels of 61%, with a dialyzer clearance of 75 
ml/min. The total amount of fosfomycin in the total collected dialysate was 2430 mg. Cmax 
after the additional administration of 5 g of fosfomycin after IHD treatment was 467 mg/L. 
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Discussion: Fosfomycin dosing guidelines in dialysis patients are based on publications 
from the 1970s and 1980s. These publications indicate a high elimination of fosfomycin 
during hemodialysis with a dialyzer clearance of 60 ml/min. Modern dialysis even exceeds 
these clearance rates, as seen in this case report (75 ml/min). The large amount of fosfomycin 
in the total spent dialysate indicates the need for an additional dose after dialysis therapy. 
About 81% of the admitted dose of fosfomycin was found in the dialysate. This suggests, 
that intermitted hemodialysis can decrease fosfomycin serum levels beyond ranges, where 
minimal inhibitory concentrations in bone spongiosa can be achieved. Therefore, fosfomycin 
dosage after hemodialysis seems crucial to provide sufficient drug concentrations.
FR-PO067
Tumoral Calcinosis – A Rarely Seen Complication in Dialysis Patients 
Lathika Raakesh, Raakesh Hassan, Christopher C. Wong, Chong Parke. 
Nephrology, Univ of Southern California, Los Angeles, CA.
Introduction: Tumoral calcinosis is characterized by solitary or multiple painless, 
periarticular soft-tissue calcium deposits. Tumoral calcinosis was first described by Giard 
and Duret in 1898 and 1899. There are two categories, a familial variant also called 
Teutschlaender disease and Secondary tumoral calcinosis also called Uremic tumoral 
calcinosis.
Case Description: Case : 50 year old female with end stage renal disease secondary 
to hypertension presented for evaluation of painful left shoulder mass. She has been on 
dialysis for 12 yrs. Has multiple painful swellings on her hands, elbow and feet. States 
that her shoulder mass appeared 2 years ago and has progressively increased in size. Also 
complained excruciating pain causing trouble carrying out her daily activities. Her surgical 
history significant for a right neck dissection for a neck mass, parathyroidectomy and a 
remote history of partial thyroidectomy. Physical examination significant for multiple 
soft immobile nodular swellings on the left shoulder, dorsum of left foot, right elbow and 
index finger. Mass on the left shoulder about 12 X 10 cm in size, immobile, tender and 
firm to palpation. The swelling on the right elbow non tender to palpation and the one 
on the right index finger involved the distal and proximal interphalangeal joints Imaging 
studies showed nodular swellings with significant calcification. Excision of the left shoulder 
mass showed exudation of a chalky white material. Pathology results were consistent with 
tumoral calcinosis.
Discussion: Secondary tumoral calcinosis is associated with high serum Ca X P in 
dilaysis patients, secondary or tertiary hyperparathyroidism, aluminium intoxication and 
vitamin D overload. These lesions are painless but massive swellings can cause mechanical 
limitation, pain and neurovascular symptoms due to compression of adjacent structures. 
Management includes dietary phosphate restriction, noncalcemic phosphate binders, intense 
dialysis with a low-calcium dialysate and calcimimetics. Surgical excision is indicated 
in symptomatic lesions. Parathyroidectomy recommended in patients with persistently 
elevated PTH levels. Tumoral calcinosis resolves after successful renal transplantation.
FR-PO068
Palate Nodule in a Hemodialysis Patient: A Long and Winding Road Until 
Diagnosis  Precil Diego Miranda de Menezes Neves,1 Ramaiane Aparecida 
Bridi,1 Rosilene M. Elias,1 Fábio Luiz de Menezes Montenegro,1 Rosa M.A. 
Moyses.1,2  1Nephrology, Univ of São Paulo, Sao Paulo, Brazil; 2Univ Nove de 
Julho-UNINOVE, Sao Paulo, Brazil.
Introduction: Secondary hyperparathyroidism (SHPT) is a common condition in 
end-stage renal disease patients. We highlighted a complication that usually affects long 
bones, a brown tumor (BT). We report a case of a patient with SHPT, with a palate nodule, 
which diagnosis investigation led to a BT of maxilla.
Case Description: A 25 years-old female, previously hypertensive, who returned 
to hemodialysis after her kidney transplant fails. She was referred to our CKD-MBD 
service with a 3-month history of a progressively enlarging submucosal nodule with hard 
consistency on her posterior left palate. The mass was painful since the beginning, and 
presented progressive growth. She had no fever, neither consumptive symptoms nor palpable 
lymph nodes. Before coming to our service, she was referred to a maxillofacial surgery 
service, where a computed tomography (CT) and a biopsy were requested, as no initial 
suspected diagnosis was done. CT disclosed a lytic bone lesion located in alveolar process 
of maxilla, measuring 3.0 X 2.5cm, and damaging the superior molar roots, producing a 
bulging in the left maxillary sinus, nasal cavity and palate. Microscopy view evidenced 
the presence of multinucleated giant cells among ovoid and fusiform mesenchymal cells, 
large amount of hemorrhage and trabecular of lamellar bone tissue, being compatible with 
Brown Tumor. On review of her case, she confirmed that Sevelamer 1,6g thrice a day, 
but the administration of Vitamin D analogs was not possible due to hyperphosphatemia. 
Her serum intact Parathormone levels were 1,500pg/ml, Vitamin D 36ng/ml, ionized 
calcium: 4,8mg/dl, phosphorus: 6,1mg/dl. Technetium sestamibi parathyroid scan revealed 
hyperactive glands at both superior thyroid lobes and at the low cervical region. The patient 
was submitted to total parathyroydectomy, and the lesion is progressively decreasing despite 
of other modalities of treatment.
Discussion: Brown Tumors must be kept in mind as a differential diagnosis in patients 
with SHPT even when these lesions are located in unusual sites such as the maxilla.
FR-PO069
A Case of Levofloxacin Toxicity Treated with Continuous Veno-Venous 
Hemofiltration  Karl Berthold Pembaur, Jennifer Thompson, Nithin Karakala. 
Nephrology, MUSC, Charleston, SC.
Introduction: Levofloxacin is a commonly prescribed antibiotic. Multiple adverse 
events such as central nervous system and cardiovascular toxicity have been described. 
Cardiovascular toxicity, namely QT prolongation when present can be particularly 
dangerous and requires urgent management. Aside from stopping the drug there is paucity 
of data regarding other urgent treatment modalities such as CRRT when potential toxicity 
is suspected.
Case Description: A 53 year-old African American female with a history of ESRD 
on peritoneal dialysis (PD) for 2 years was admitted for concern of levofloxacin toxicity. 
She had been admitted to an outside hospital and discharged approximately 1 week prior 
to presentation with a levofloxacin prescription for presumed bronchitis. During initial 
evaluation, she admitted to taking levofloxacin 500 mg every 8H for the preceding 5 days. 
She admitted she had been performing PD every other day as she was concerned she was 
volume depleted. After 3 days she developed nausea, vomiting, left heel pain, left hand 
tremor, and palpitations. She had not performed peritoneal dialysis since the onset of her 
symptoms. Her initial physical exam was consistent for left hand tremor and Achilles tendon 
tenderness. Her QTc upon initial evaluation was 534. Serum levofloxacin level was ordered 
and a decision was made to start continuous veno-venous hemofiltration (CVVH) to increase 
clearance of levofloxacin. CVVH was stopped after clinical recovery of her symptoms and 
normalization of QTc. Her initial levofloxacin level was 36.65 mcg/mL (normal therapeutic 
range 8-12 mcg/mL) and serum levels were followed for the duration of treatment every 
12 hours. Below is a graphical trend of her levofloxacin levels. 
Discussion: Levofloxacin toxicity represents a unique and dangerous clinical challenge. 
This case report shows successful and effective treatment of critical toxicity with the use 
of CVVH.
FR-PO070
Utility of Cystatin C in the Setting of Urinoma  Lilian Saro-Nunez,1 Amrei 
Aufderheide,3 Alan Perlman.1,2  1Nephrology, Weil Cornell Medical College, NY, 
NY; 2Rogosin Inst, NY, NY; 3Technical Univ, Munich, Germany.
Introduction: Urinomas (i.e. presence of urine outside of the urinary tract) are common 
in the setting of urologic/pelvic surgery. Due to the resorption of extravasated urinary 
constituents such as urea nitrogen and creatinine, determination of renal function is typically 
confusing and often leads to the false impression of acute renal failure, a situation referred 
to as pseudo-renal failure. We describe the superior precision of cystatin C (CysC) vs serum 
creatinine (SCr) in estimating renal function in a patient with urinoma.
Case Description: 79 yo M with a history of urinary retention requiring a chronic 
indwelling Foley catheter presented with catheter obstruction leading to bladder rupture and 
apparent acute renal failure. Presenting SCr was 5.8mg/dl (baseline 1.5mg/dl). A cystogram 
was consistent with urinoma. Treatment of the bladder leak consisted of urinary catheter 
replacement and he maintained urine output of > 2L/24h for several days. SCr decreased 
to 2.9mg/dL. A second episode of catheter obstruction subsequently occurred resulting 
in a significant increase of the extraperitoneal bladder leak and acute rise of creatinine to 
4.6mg/dL. After placement of a larger catheter, his SCr decreased to 1.7mg/dL. During the 
second episode of urine leakage, simultaneous CysC levels were obtained. In contrast to 
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the marked variation of SCr during the onset and resolution of the urinoma, CysC levels 
demonstrated greater stability, increasing modestly from 1.6mg/L to 2.0mg/L during onset, 
followed by return to near baseline level of 1.7mg/L upon catheter replacement. CysC based 
eGFR values using CKD-EPI demonstrated similar relative stability, decreasing from 39 
to 29mL/min during the recurrent bladder rupture, followed by an increase to 36 mL/min 
after recatheterization. In contrast, the eGFR decline based upon SCr-based CKD-EPI 
equation was notably labile declining from 20 to 11mL/min during episode then increased 
to 38mL/min with treatment.
Discussion: These findings imply superiority of CysC over SCr in estimating renal 
function in patients with urinoma and pseudo-renal failure. Discordant estimates of eGFR 
between CysC and SCr may be indicative of urinoma.
FR-PO071
Two Cases of Nonocclusive Mesenteric Ischemia Triggered by Intradialytic 
Hypotension in Patients on Maintenance Hemodialysis  Norihiko Morisawa, 
Izumi Yamamoto, Yasuyuki Nakada, Yusuke Okabayashi, Yudo Tanno, Ichiro 
Ohkido, Takashi Yokoo.  Dept of Internal Medicine, Div of Nephrology and 
Hypertension Jikei Univ School of Medicine, Tokyo, Japan.
Introduction: Among dialysis patients, non-occlusive mesenteric ischemia (NOMI), 
defined as diffuse intestinal ischemia without any organic blood vessels occlusion, is rare 
(1%patient-year) but has a very high mortality (56-90%). The factors associated with 
mortality from this disease include age, diabetes, hypertension, intradialytic hypotension, 
atherosclerosis, medications, etc. Early diagnosis and treatment are important for improving 
survival in patients with this disease.
Case Description: We here report two cases of NOMI, who were triggered by 
hypotension during hemodialysis. Case1: A 52-year-old man who had a low left ventricular 
ejection fraction after myocardial infarction showed intradialytic prolonged hypotension. 
On physical examination, he was hypotensive with diffuse abrupt abdominal tenderness. 
The laboratory investigation showed a high white blood count of 20,000. Case 2: A 
88-year-old woman on maintenance hemodialysis for 5 years had hemorrhagic shock. 
On physical examination, she was also hypotensive with mild abdominal tenderness. 
The laboratory investigation showed a high white blood count of 16,000. We performed 
multiple detector computed tomography (MDCT) and found patent mesenteric vessels 
in both cases. Subsequent surgical procedure revealed the necrosis of terminal ileum in 
case 1 and autopsy revealed necrosis of cecum in Case 2. Finally, we diagnosed them as 
having NOMI. The former underwent surgical procedure and was discharged alive from 
the hospital but the latter was dead.
Discussion: Considering the fact that NOMI is very high mortarity disease, early 
diagnosis must be important. However, a diagnosis of this disease is very difficult because 
clinical manifestations are nonspecific. We speculated that the profile of hemodialysis is very 
similar to that of risk factors, therefore, we should evaluate patients who showed intradialytic 
hypotension with abdominal pain using multiple detector computed tomography.
FR-PO072
Aggressive Renal Cell Carcinoma in a Renal Allograft  Hafiz Ali Sroya, 
Antonia Harford.  Nephrology, UNM, Albuquerque, NM.
Introduction: Kidney cancers arising in renal allografts are very rare and most 
publications focus on cancers in native kidneys of transplant recipients. We are reporting 
a case of a renal cell carcinoma (RCC) arising 14 years post-transplant.
Case Description: A 46-years old man with a history of ESRD due to diabetic 
nephropathy underwent hemodialysis for one year prior to receiving a Living Un-Related 
Renal Transplant from his brother –in law, a 36 yo healthy male in 2001. The patient had 
immediate graft function post-transplant and was maintained on MMF, Cyclosporine and 
Prednisone. He underwent renal allograft biopsy in 2004 for a gradual decline in renal 
allograft function; this biopsy showed chronic transplant glomerulopathy. The patient had 
very gradual decline in renal allograft (CKD G3bA1) until Jan 2015, when he developed 
mild lower abdominal pain over several weeks. Imaging including abdominal US and 
CT revealed a 14 X 12 X 12 cm mass arising from the transplant kidney with extensive 
regional adenopathy involving the right common iliac vein and IVC with evidence of 
lung metastasis. Biopsy showed RCC, clear cell type with extensive necrosis. The venous 
involvement precluded surgical excision. The patient was treated with sunitinib. Several 
weeks later, he developed extensive bilateral pulmonary embolism treated with heparin 
infusion and IVC filter. Soon after the initiation of the heparin infusion he developed severe 
hematuria. Alcoholic embolization of the tumor was then performed. Immunosuppressive 
medications were tapered and the patient returned to hemodialysis.
Discussion: Characteristics of de novo kidney allograft RCCs are currently unknown. 
These tumors can be de novo or transmitted by the donor and differentiation between these 2 
modes of transmission may be difficult. The most common reported histologic type of graft 
tumor is papillary carcinoma; clear cell type as in our case is less usual. Tumors occurring 
in renal transplants are usually incidental, asymptomatic, low grade and small but may be 
symptomatic or with vague clinical picture, high grade, aggressive and very large size as 
in our case. Frequent and continued surveillance imaging of both the renal allograft and 
native kidneys is paramount.
FR-PO073
A Case of Acute Allograft Rejection Combined with BK Virus-Associated 
Nephropathy  Bernice Kim, Soo Ryeong Ryoo, Kyung Soo Kim.  Div of 
Nephrology, Dept of Internal Medicine, Dongguk Univ Ilsan Hospital, Goyang, 
Republic of Korea.
Introduction: Rejection and BK virus-associated nephropathy (BKVAN) are major 
causes of renal allograft dysfunction. Treatment can be difficult when both conditions 
coexist, because potent immunosuppression is required in acute rejection and reduction 
of immunosuppressive agents is essential in BKVAN. We present a case of acute allograft 
rejection combined with BKVAN.
Case Description: A 41-year-old male with end stage renal disease because 
of hypertensive nephrosclerosis received a deceased donor renal transplantation. 
Immunosuppressive therapy was started with mycophenolate mofetil, tacrolimus, 
methylprednisolone, and anti-thymocyte globulin. On post-operative day (POD) 19, 
serum creatinine (sCr) level was 1.89 mg/dl but was elevated to 2.4 mg/dL on POD 25. 
Diffuse C4d staining in peritubular capillaries was noted on kidney biopsy and acute 
antibody-mediated rejection was diagnosed. Plasmapheresis was initiated and intravenous 
immunoglobulin (IVIG) and rituximab were administered. After 10 days of treatment, 
sCr was decreased to 1.5 mg/dL. Additional episodes of sCr elevation occurred and more 
sessions of plasmapheresis and IVIG administration were done, but sCr was elevated to 
2.48 mg/dL on POD 67. Decoy cells were detected on urine cytology and high levels of 
viruria and viremia were found on polymerase chain reaction for BK virus DNA. On second 
kidney biopsy, findings of acute cellular rejection were noted and viral inclusion bodies in 
tubular epithelium were seen, suggestive of BKVAN. For treatment of BKVAN, reduction 
of immunosuppressive agents and administration of IVIG and leflunomide were performed. 
Steroid pulse therapy was done in regard of acute cellular rejecton. Despite therapy, his 
renal function did not recover completely and sCr was elevated to 3.2mg/dL on POD 138.
Discussion: It is difficult to treat when BKVAN and acute rejection coexist. In our 
patient, IVIG and leflunomide was administered and immunosuppression was reduced for 
BKVAN while steroid pulse therapy was performed for acute rejection, but his allograft 
function deteriorated. Studies are required to optimize the management of these difficult 
cases.
FR-PO074
Decreased Ultrafiltration in an End-Stage Renal Disease Patient with Sickle 
Cell Anemia: A Potential Strategy to Facilitate Kidney Transplantation 
Ekamol Tantisattamo,1 Siwadon Pitukweerakul,2 Praveen Ratanasrimetha.3 
1Nephrology, Northwestern Univ; 2Presence St. Francis Hospital, Evaston; 
3Faculty of Medicine Siriraj Hospital, Mahidol Univ, Bangkok, Thailand.
Introduction: Sickle cell crisis (SC) leads to mortality and morbidity in sickle 
cell anemia(SCA) patients. Volume depletion is a common precipitating cause. Volume 
overload may require increasing ultrafiltration(UF). We report a case of SCA woman 
with acute kidney injury (AKI) who suffered from recurrent episodes of SC and acute 
hemolytic anemia requiring blood transfusions after hemodialysis(HD) was initiated. She 
became more sensitized from blood transfusions. Decreased UF reduced episodes of SC 
and blood transfusions.
Case Description: A 39-year-old African American woman with a longstanding history 
of SCA presented with a severe episode of SC complicated by AKI requiring chronic 
HD 5 years ago. Since starting HD, she had more episodes of SC from once a year up to 
every other month and required more blood transfusions. She presented for a pre-kidney 
transplant evaluation. Her panel reactive antibody(PRA) increased from 28 and 0 to 44 
and 10, for class I and II, respectively. Upon interview, she has HD 3 times/week. Her 
estimated dry weight was 62 kg and intradialytic weight gain was 2-2.3 kg. She sometimes 
had intradialytic hypotension with BP of 90s/50s. As concern for over UF being a potential 
cause of volume depletion and subsequently precipitating SC, the UF was decreased. She 
had fewer episodes of SC and blood transfusions. She remained on the kidney transplant 
waiting list with this HD prescription and stable hemoglobin.
Discussion: Our patient presented with more frequent episodes of SC after HD 
initiation. Intradialytic hypotension indicates intravascular volume depletion which 
subsequently precipitating SC and hemolytic anemia. Volume management in SCA patients 
with ESRD is challenging and critical to avoid intravascular volume depletion. SC and acute 
hemolysis may be surrogate markers of over UF. Avoiding over fluid removal can prevent 
SC, acute hemolysis, and blood transfusion which potentially increases immunological 
barrier for kidney transplantation from sensitization.
FR-PO075
Recurrent Catastrophic Antiphospholipid Syndrome Treated with 
Eculizumab in a Peritoneal Dialysis Patient  Karl W. Schoenholzer,1 
Marianna De Francesco,1 Giulia Bedino,1 Josua Van den Berg,2 Silvio Pianca.1 
1Nephrology and Dialysis Div, Ospedale Regionale di Lugano, Lugano, 
Switzerland; 2Interventional Radiology Div, Ospedale Regionale di Lugano, 
Lugano, Switzerland.
Introduction: Catastrophic Antiphospholipid Syndrome (CAPS) is a severe variant 
of Antiphospholipid Syndrome (APS), a systemic autoimmune disease characterized by 
multiple arterial and/or venous thromboses in presence of elevated titers of antiphospholipid 
antibodies (aPL). These autoantibodies, promote thrombosis by activating endothelial cells 
and platelets. We describe a case of a clinical remission in recurrent CAPS via inhibition of 
terminal complement with Eculizumab in a Peritoneal Dialysis (PD) patient.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
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Case Description: A 48-year-old man has shown recurrent CAPS characterized by 
diffuse arterial thromboses in the heart, kidneys, liver and lungs, confirmed by positivity of 
aPL. Angiography revealed a bilateral subclavian arterial thrombosis, a right iliac arterial 
stenosis that was treated with a stent and a left renal arterial occlusion. The patient’s renal 
function was decreased until End Stage Renal Disease, secondary to chronic thrombotic 
microangiopathy, and PD therapy was started.During 14 months, our patient presented 
8 recurrent episodes of disease with pulmonary involvement characterized by multiple 
alveolar hemorrhages in concomitance with liver necrosis (biopsy proven) and miocardial 
ischemia. The patient was treated with high-dose pulse corticosteroids (methylprednisolone 
500 mg/day for 3 days) followed by prednisone (1 mg/Kg/day), plasma exchange (5 series 
with a total of 74 sessions), IV immunoglobulin (400 mg/Kg/day for 5 days), IV Rituximab 
(initial therapy and maintenance after 6 months), clopidogrel, aspirin and anticoagulation. 
Despite this standard therapy, we did not observe a sustained remission.
Discussion: After a review of the literature, we decided to administer Eculizumab, a 
monoclonal antibody against complement C5, that blocks and prevents the generation of the 
prothrombotic and proinflammatory molecules C5a and membrane attack complex C5b-9. 
The patient has been in remission with long-term Eculizumab treatment and anticoagulation 
therapy, without further thrombotic events during 1 year of follow-up.
Funding: Private Foundation Support
FR-PO076
A Case Report of Post-Transplant Lymphoproliferative Disorder in Kidney 
Allograft  Dina Abdelwahab, Nadeen J. Khoury, William S. Asch.  Div of 
Nephrology, Yale Univ, New Haven, CT.
Introduction: Renal tumors are rare in transplanted kidneys. Nephrectomy is the 
traditional approach for renal masses. We are reporting a renal mass that was found to be 
post-transplant lymphoproliferative disorder in the renal allograft which we chose to biopsy 
instead of using traditional surgical resection.
Case Description: A 63 year old female with past medical history of renal cell 
carcinoma in native kidney treated by right nephrectomy, ESRD secondary to MPGN status 
post living donor kidney transplant presented with abdominal pain, fever and diarrhea. 
Ultrasound of renal allograft showed a solid appearing 4.8x5.6x4.3 cm mass in the upper 
pole of the transplanted kidney which was predominantly homogenous with internal 
vascularity; MRI revealed a 6.2x 4.9 x4.5 cm mass with solid enhancing and non-enhancing 
components within the transplanted kidney concerning for renal cell carcinoma . Given 
her previous history of RCC there was an increased concern for recurrence. Nephrectomy 
would have been the traditional approach but that would have meant sacrificing her allograft 
and initiating hemodialysis. The mass was biopsied and pathology revealed post-transplant 
lymphoproliferative disorder. Microscopic description showed a small kidney portion with 
tubules and glomeruli overrun by a dense lymphoid infiltrate. Immunohistochemical stains 
revealed that the large atypical cells were positive for CD20, Bcl-2, Mum-1 and CD30 
but negative for BCL-6, CD10 and CD138. C-myc stained approximately 10-20% of cells 
and Ki-67 30-40%. In situ hybridization for Epstein Barr virus encoded RNA( EBER) was 
positive. Patient received 6 cycles of R-CHOP, follow-up MRI showed decrease in mass size.
Discussion: The biopsy of renal tumors for the diagnosis of small masses has not been 
widely adopted despite recent safety reports with advanced techniques and physicians’ 
expertise. It has been shown to be safe and reliable and should be considered in all patients 
with small masses especially in transplanted kidneys to decrease the risk of unnecessary 
surgical intervention.
FR-PO077
Renal Replacement Therapy for Severe Hyponatremia (PNa 99mEq/L), 
Using 5% Dextrose Solution Infusion Method  Masataka Hasegawa, Takuya 
Fujimaru, Yuki Heath, Fumika Taki, Miyuki Futatsuyama, Masahiko Nagahama, 
Yasuhiro Komatsu.  Nephrology, St. Luke’s International Hospital, Tokyo, Japan.
Introduction: Dialysis therapy for patients with severe hyponatremia poses risk of 
osmotic demyelination syndrome due to rapid correction of serum sodium concentration. 
To prevent rapid correction, low sodium dialysate or filtration fluid can be used; however, 
dialysate sodium concentration needs to be changed frequently as patient’s serum sodium 
concentration rises. Instead of using low sodium dialysate, infusion of 5% dextrose 
solution (D5W) to the dialysis circuit after dialyser/hemofilter can adjust the serum 
sodium concentration of returning blood to the desired level (D5W infusion method). We 
successfully treated a patients with severe hyponatremia, who required dialysis therapy 
for severe hyperkalemia and acute kidney injury (AKI), using continuous venovenous 
hemofiltration (CVVH) with D5W infusion method.
Case Description: A 46 year-old women presented to the emergency department with 
confusion and dysarthria, due to severe hyponatremia (PNa 99mEq/L). She also had anuric 
AKI (creatinine 10mg/dL), heperkalemia (K 7.7mEq/L) with ECG changes (widened QRS 
complex), and metabolic acidosis (pH 7.0, pCO2 7.7, HCO3- 1.9mEq/L). After admission, 
supportive therapy including fluid resuscitation, insulin with glucose and sodium bicarbonate 
failed to improve hyperkalemia and AKI. Decision of dialysis therapy was made, but to 
avoid rapid correction of serum sodium concentration, we started CVVH using D5W 
infusion method. CVVH using standard filtration fluid (Na conc. 140 mEq/L) was started 
(QB 100mL/min, Qf 1000mL/hr), with continuous infusion of D5W (rate: 400mL/hr) to 
the CVVH circuit after hemofilter. By adjusting the infusion volume of D5W, sodium 
concentration of returning blood can be adjusted to the desired level; if the correction rate 
is fasterthan expected, D5W infusion rate can beincreased. After 24 hours of CVVH, her 
serum sodium level increased to 108mEq/l. She recovered completely from hyponatremia 
and AKI without any sequelae.
Discussion: CVVH using D5W infusion method is safe and effective treatment modality 
for patients with severe hyponatremia requiring dialysis.
FR-PO078
Performing Chronic Hemodialysis Therapy in a Patient with Total Artificial 
Heart  Simona Pozzoli, Marco Simonini, Federico Pappalardo, Chiara Lanzani, 
Teresa Arcidiacono, Maria Teresa Sciarrone Alibrandi, Donatella Spotti, Paolo 
Manunta, Stefano Tentori, Giorgio Slaviero.  San Raffaele Scientific Inst, Italy.
Introduction: Total Artificial Heart (TAH) is an implantable artificial heart usually 
used as a temporary bridge till heart transplantation. Recently a review showed that bleeding 
(47%), AKI requiring hemodialysis (40%) and infection (33%) are the most common 
complications following implantation of a TAH. Currently there are no data in the literature 
on long term renal function outcome and on management of ESRD related complications. 
We present our experience on a patient with TAH in chronic hemodialysis therapy.
Case Description: A 55 years old Caucasian man was admitted on 1st March 2012 at 
our Hospital ER with cardiogenic shock for AMI with rupture of the papillary muscle. His 
medical history included hypertension and dyslipidemia in good pharmacological control. 
On 9th March TAH has been implanted in order to replace the lost heart function. From 
the day of admission to ICU, the patient developed oliguric AKI and CRRT was started. 
Subsequently, the patient was switched to four times a week haemodialysis. To maintain an 
appropriate circulating volume for the operation of cardiac device, atrial filling pressures 
were maintained between 5-5.5 mmHg and 6.0-6.5 mmHg in the right and left atrium 
respectively. At the same time it was decided to record the change of hematocrit which the 
patient was subjected during the dialysis sessions (via Blood Volume Monitor (BVM)) in 
order to identify the critical BVM value for the functioning of the cardiac device. In this 
way we were able to manage the patient’s dialysis sessions even once he was discharged 
from the hospital with the portable version of TAH.
Discussion: This patient received dialysis therapy four times a week in order to maintain 
a more content and constant weight till March 2015, when he underwent to combined 
heart and kidney transplantation. To the best of our knowledge this is the longer case of 
continuous dialysis therapy in a patient with total artificial heart. Total Artificial Heart is 
confirmed to be a valid therapeutic option for those patients waiting for heart transplantation 
even for long periods of time.
FR-PO079
Severe Varicella Zoster Virus Encephalitis and Retinal Necrosis in a Renal 
Allograft Recipient  Jean Luc Franck, Srijita Mukherjee, Tina Thomas, Sharon 
M. Graves.  Nephrology, Emory Univ, Atlanta, GA.
Introduction: Varicella zoster virus infection (VZV) has devastating potential 
complications and should be considered more often for testing by clinicians. Our case 
reflects the need to maintain a higher degree of suspicion for VZV by clinicians treating 
the immunosuppressed population.
Case Description: A 31-year-old man underwent living related renal transplantation 
in 2008 for chronic glomerulosclerosis. The clinical course was uneventful until January 
2015, when he was diagnosed with grade IA rejection after admitting to four months of 
nonadherance to his prescribed immunosuppression regimen, consisting of tacrolimus, 
mycophenolate mofetil, and prednisone. The rejection was addressed with pulse IV steroids 
and resumption of his oral immunosuppressant regimen. Over the next four months, the 
patient sought medical attention for worsening and persistent occipital headache. Lumbar 
puncture was performed and suggested a viral etiology.MRI imaging was performed 
and revealed a large cerebellar infarct and diffuse vasculitis. Upon transfer to our 
institution, the patient underwent emergent neurosurgical correction of acute obstructive 
hydrocephalus with decompressive craniotomy. Polymerase chain reaction (PCR) testing 
in the cerebrospinal fluid was positive for VZV. The patient was started on acyclovir and 
steroids for treatment of VZV encephalitis and diffuse vasculitis. Ophthalmologic evaluation 
revealed retinal necrosis of the left eye, with PCR testing of the anterior chamber fluid also 
positive for VZV. After four weeks of acute care, the patient is currently in rehabilitation.
Discussion: Varicella Zoster Virus infection requires timely diagnosis and treatment 
for positive outcomes in the immunosuppressed patient. Clinical presentation can 
vary dramatically, from subtle rash to encephalitis. Therefore, clinicians caring for 
immunosuppressed patients should more routinely consider VZV as part of the differential 
diagnosis. Our case raises several questions including consideration for lengthening duration 
of VZV prophylaxis in allograft recipients and consideration for resuming VZV prophylaxis 
when resuming immunosuppression after extended periods of nonadherance.
FR-PO080
Hemodialysis Related Acute Thrombocytopenia During Pregnancy 
Nikulkumar Chaudhari, Belinda Bun Jim, Anjali Acharya.  Dept of Nephrology, 
Jacobi Medical Center, Bronx, NY.
Introduction: Thrombocytopenia is not uncommon during pregnancy. It could be 
multifactorial and range from a mild asymptomatic condition to severe thrombocytopenia 
with fetal effects.
Case Description: A 29 year old woman with hypertension, CKD-IV from primary 
FSGS, presented at 10th week of gestation. Intermittent hemodialysis had to be initiated 
at 20th gestation week. Thrombocytopenia developed as described in the table below. 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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Relation of Hemodialysis Platelet Count 
Pre-dialysis 215,000-239,000
After 1st HD with Fresenius Optiflux Dialyzer 152,000
After 2nd HD 119,000
After 3rd HD 75,000
After 4th HD 82,000
Prior to 5th HD 48,000
Holding HD for next 3 days without any intervention Gradually increased to 121,000
Re-started and continued HD with Exeltra Dialyzer 150,000-220,000
Patient was not on antiplatelet agents and panel for HIT antibodies was negative. 
Patient remained asymptomatic throughout hospitalization. Hematological evaluation 
ruled out all routine causes of thrombocytopenia during pregnancy such as gestational 
thrombocytopenia, preeclampsia, HELLP, TTP/ITP and autoimmune causes. Given the 
chronological correlation of platelet decrease and hemodialysis it was concluded that 
thrombocytopenia was likely hemodialysis related. Patient was switched from a Fresenius 
dialyzer optiflux to Exeltra 210 high flux dialyzer.
Discussion: Complement activation, anti-coagulation use, exposure of blood to the 
roller pump, dialysis tubing, micro-bubbles, and use of cellulose membrane are potential 
causes of dialysis related thromocytopenia. In addition, sterilization techniques have shown 
to have a differential impact. A major difference between the two dialyzers used was the 
technique of sterilization. Electron beam radiation used in the Fresenius dialyzer might affect 
membrane integrity or physical properties that could lead to platelet activation, aggregation, 
or adsorption causing thrombocytopenia, which is not seen with gamma sterilization. 
Thrombocytopenia is an important, if rare, complication of hemodialysis that should 
be considered in the differential diagnosis of thrombocytopenia in pregnancy. Dialysis 
associated thrombocytopenia may occur despite the use of biocompatible membranes.
FR-PO081
A Rare Case of Nephrocalcinosis Caused by Hereditary Renal Hypouricemia 
Three Months After Kidney Transplantation  Yo Komatsuzaki,1 Izumi 
Yamamoto,1 Yasuyuki Nakada,1 Yusuke Okabayashi,1 Takafumi Yamakawa,1 
Akimitsu Kobayashi,1,2 Takahito Niikura,1,2 Yudo Tanno,1 Ichiro Ohkido,1 
Hiroyasu Yamamoto,1,2 Keitaro Yokoyama,1 Takashi Yokoo.1  1Dept of Internal 
Medicine, Div of Nephrology and Hypertension Jikei Univ School of Medicine, 
Tokyo, Japan; 2Dept of Internal Medicine, Div or Nephrology and Hypertension 
Atsugi City Hospital, Kanagawa, Japan.
Introduction: Renal hypouricaemia (MIM: 220150) is a syndrome that involves a 
defect in urate transporter1 (URAT1) for urate reabsorption at the brush border of the 
proximal tubule. Nephrocalcinosis and exercise-induced acute renal failure are two major 
complications affecting renal function. A C889T mutation in SLC22A12 encoding URAT1 
is the rare mutation in Japanese. Here we report a rare case of nephrocalcinosis caused by 
hereditary renal hypouricaemia three month after kidney transplantation.
Case Description: A 41-year-old man had undergone living-related kidney 
transplantation because of Henoch–Schönlein purpura nephritis. Three month protocol 
biopsy showed several localized nephrocalcinosis determined by either von kossa or 
de Galantha’s stain (staining for urate crystals). The evaluation for nephrocalcinosis 
showed hypouricaemia at 1.9 mg/ dl with a high fractional excretion of uric acid at 26.8% 
(normal range, 6–10%). DNA direct sequencing followed by restriction fragment length 
polymorphism showed that both the recipient and donor were heterozygous for C889T. 
This mutation induce stop codon, therefore subsequent immunostaining were performed 
using antibody to C terminals of URAT1 and found that of immunoreactivities were 
partially deleted. We finally diagnosed him as having hereditary renal hypouricemia. We 
directed them to avoid hard exercise, drink plenty of water, and alkalize their urine for the 
long term renal survival.
Discussion: Renal hypouricemia is a rare but have the possibilities to affect renal 
function. The patient did not show hypouricemia during hemodialysis because an 
anuric dialyzed patient with hereditary renal hypouricemia does not eliminate uric acid. 
Nephrocalcinosis could be a characteristic feature suspicious of renal hypouricemia. DNA 
direct sequencing and immunostaining help to diagnose renal hypouricemia.
FR-PO082
An Unusual Cause of Lymphadenopathy in a Renal Transplant Patient 
Anna Bertram,1 Marcus Hiss,1 Jan H. Braesen,2 Philip F. Halloran,3 Gunilla 
Einecke.1  1Nephrology and Hypertensiology, Hannover Medical School, 
Hannover, Germany; 2Pathology, Hannover Medical School, Hannover, 
Germany; 3Alberta Transplant Applied Genomics Centre, Univ of Alberta, 
Edmonton, Canada.
Introduction: We report an uncommon cause of lymphadenopathy in a kidney 
transplant patient.
Case Description: The 28y old male patient presented 10y after living donor kidney 
transplantation with painful inguinal swelling. He had returned to dialysis 8 months ago 
after graft failure due to antibody-mediated rejection (AMR), which had been unsuccessfully 
treated with plasmapheresis, intravenous immunoglobulins, and rituximab between 10/2013-
03/2014. To sustain diuresis, immunosuppression was continued with tacrolimus (trough 
level 7ng/mL) and 5mg prednisolone. At presentation, no local injury was detectable, and 
the patient denied systemic symptoms. Work-up including MRI revealed enlargement of 
inguinal and iliacal lymph nodes on his right side. Laboratory results showed elevated 
inflammatory parameters (CRP 120 mg/L; PCT 1.0 µg/L; leukocytes 13.2/nL). Tacrolimus 
trough level was 3.7 ng/mL, EBV-DNA in plasma was detectable at low values (3200 IU/
mL). To rule out PTLD, biopsy of a 3 cm inguinal lymph node (fig.1B) was performed. 
However, histology showed lymphangiitis and no sign of malignancy. Because the allograft 
in his right Fossa iliaca was tender, we performed a biopsy, as well, although ultrasound 
showed signs of chronic damage. Histology revealed severe ongoing cellular and AMR. 
Molecular analysis of the biopsy confirmed an unusually severe form of AMR with intense 
inflammation (fig.1B). Due to the clinical symptoms, we performed transplant nephrectomy. 
Inguinal lymphadenopathy regressed rapidly, and the patient made a full recovery. 
Discussion: This case illustrates that severe allograft rejection, confirmed on 
histopathological and molecular level, can in rare cases present with pronounced 
lymphadenopathy.
FR-PO083
Prevnar 13 Associated Immune Thrombocytopenic Purpura in a Renal 
Transplant Recipient  Sagar Gupta, Daniel C. Brennan.  Renal, WashU, St. 
Louis, MO.
Introduction: ACIP recommends all adults with immunocompromising conditions 
should receive PCV13 to prevent invasive disease caused by 13serotypes of S.pneumoniae.
We describe here a case of ITP associated with Prevnar13 administration in a renal allograft 
recipient,which is the first reported case of its kind.
Case Description: A 77 year old Caucasian male presented with chief complaint 
of increased bruising at insulin injection sites for one week.There was no history of 
fever,abdominal pain,diarrhea,bleeding episodes,neurological deficits,new medications 
or insect bites.He had ESRD secondary to hypertension and DM2.He received a living 
unrelated kidney allograft 22mo ago.He was on tacrolimus,MMF,prednisone,MMF 
later discontinued indefinitely due to BK viremia.Family history was non-contributory.
Medications included allopurinol,ASA,statin,bactrim,carvedilol,insulin glargine and 
aspart,prednisone and tacrolimus.He received Prevnar13 1 month ago.Exam showed normal 
vital signs and petechial rash in the areas of insulin injections.Lab testing resulted in Hb 
11.7 & WBC 7.7(baseline) and platelet 3000 (baseline 140).BUN 31 and Cr1.50 (baseline).
PT,PTT,LDH and haptoglobin were normal.No schistocytes seen.Infectious workup was 
negative and ADAMTS-13 activity resulted at 102%. The isolated thrombocytopenia was 
diagnosed as ITP and was attributed to the Prevnar 13 vaccine.He was started on pulse 
dose steroids and IVIG.He received 6 units platelets with counts increasing to 94000, 
later discharged on a prednisone taper.Weekly blood counts showed improvement to his 
baseline of 140,000 in 3 weeks.
Discussion: PCV13 contains the S.pneumoniae serotypes’ capsular polysaccharide 
covalently linked to an immunogenic carrier protein resulting in a T cell– dependent 
antigen,causing a T helper-cell response.The pathogenesis of ITP involves antibody 
production driven by CD4-positive helper T cells reacting to platelet surface glycoproteins.
Antibodies formed during viral or bacterial infections may also cross-react with normal 
platelet antigens (a form of molecular mimicry).Isolated cases of ITP have been reported 
but are relatively rare.Our case is further unique to occur in a pt on immunosuppression 
with a calcineurin inhibitor and corticosteroids.
FR-PO084
Placement of a Tunneled Hemodialysis Catheter in the Superior Vena Cava 
for Multiple Central Venous Occlusions  Qinghua Yin, Tianlei Cui, Li Zhou, 
Ping Fu, Fang Liu.  Div of Nephrology, West China Hospital of Sichuan Univ, 
Chengdu, Sichuan, China.
Introduction: A tunneled hemodialysis catheter is essential for dialysis access when the 
use of a functioning arteriovenous fistula  is not possible. In extreme situations of multiple 
central venous occlusions, it remains a challenge to establish durable vascular access. 
Unconventional routes to the central veins are typically used. We successfully performed 
placement of a tunneled hemodialysis catheter in the superior vena cava (SVC) with 
fluoroscopic guidance in a  hemodialysis patient with multiple central venous occlusions 
due to repeated catheterization. We report on a feasible option for hemodialysis patients 
with multiple central venous occlusions.
Case Description: A 49-year-old diabetic male who had been diagnosed with ERSD 
one year prior came to our medical center because of temporary catheter occlusion.CT 
venography revealed occlusion of the bilateral brachiocephalic, internal jugular and 
the common femoral veins, and central venography showed occlusion of the bilateral 
jugular and innominate veins.Guided by ultrasound, a percutaneous transhepatic route, as 
described by Duncan et al[9], was developed, which was applied to SVC venography and 
provided access for a 5F indwelling catheter, which was used to locate the distal end of 
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the SVC (Figure 2A). The puncture point of the skin was beneath and 0.5-1.0 cm outside 
of the junction of the right clavicle and head of the sternocleidomastoid, and the direction 
of the subcutaneous tunnel was along the distal end of the SVC, which was marked by 
a 5F indwelling catheter. Under fluoroscopic guidance, a micro-21G needle (Cook) was 
used to puncture the stump occlusion of the SVC; dark red blood was drawn when the 
micro-21G needle (depth approaching 15 cm) met the 5F indwelling catheter. Additionally, 
under anteroposterior and lateral fluoroscopic guidance, a 21G needle was punctured into 
the SVC (Figure 2B-C), and the tunneled hemodialysis catheter (cuff to tip 23 cm, Bard) 
was then exchanged with a 0.035-inch guide wire in the SVC. Chest radiography showed 
positioning of the hemodialysis catheter tip into the right atrium (Figure 2D). CT showed 
that the needle did not enter the chest.
Funding: Clinical Revenue Support
FR-PO085
Crystal Nephropathy in a Kidney Transplant Recipient due to Excessive 
Consumption of Oxalate Rich Diet and Vitamin C  Sudheer Muduganti,1 
Padmavathi Mali,2 Sandesh Parajuli,1 Maha A. Mohamed.1  1Nephrology, Univ 
of Wisconsin School of Medicine and Public Health, Madison, WI; 2Internal 
Medicine, Marshfield Clinic, Marshfield, :I.
Introduction: Acute kidney injury due to crystal nephropathy has been reported mainly 
in patients with gastrointestinal (GI) malabsorption or GI surgery. We present a rare case of 
crystal nephropathy in the kidney transplant recipient (KTR) without obvious GI risk factors.
Case Description: 68 year old obese female, who is living-unrelated KTR for five 
years, with a stable post-transplant course and a baseline serum creatinine (scr) of 1.1 mg/
dl, presents to our hospital with tiredness and diarrhoea for one week. She had extensive 
work up in the past for chronic diarrhoea which is described as “soft stool”. 24 hour fecal 
fat, serum amylase and serum lipase were normal. Upon presentation, scr was 7.1 mg/dl, 
which prompted us to perform an allograft kidney biopsy demonstrating multiple oxalate 
crystals deposited in the renal tubules. Reviewing her history further revealed that she was 
consuming 3 gm vitamin C (over the counter) daily for the last one month. Her preferred 
diet always consisted of oxalate rich foods (spinach). Renal functions improved in one 
month (scr 2mg/dl) with hydration, discontinuation of vitamin C, and changes in dietary 
habits. Urine studies obtained after one week of treatment showed normal urine calcium, 
low urine oxalate and citrate.
Discussion: Oxalate nephropathy can occur from hyperoxaluria due to ingestion of 
oxalate rich diet or substances which metabolize to oxalate like vitamin C or from enteric 
causes like malabsorption. In our patient, we ruled out enteric causes and determined oxalate 
nephropathy was secondary to ingestion of oxalate rich diet and excess vitamin C. Renal 
functions improved with modification of diet, hydration and discontinuation of offending 
agents. Although vitamin C and high oxalate diet are rare causes of oxalate nephropathy in 
patients with normal renal function, it may cause significant nephropathies in KTR. KTR 
patients therefore, should follow low oxalate diet and avoid excessive vitamin C even with 
normal renal functions to avoid development of crystal nephropathy.
FR-PO086
The Conundrum of Dry Weight in a Pregnant Dialysis Patient 
Sweta Carpenter, Akshatha Rao, Sandeep Aggarwal.  Nephrology, Drexel Univ.
Introduction: The frequency of pregnancy in women of child bearing age who are 
on dialysis ranges from 0.3-1.5% per year. When a dialysis patient does become pregnant, 
nephrologists become extra vigilant to ensure a successful outcome for both mother and 
child. An important question that often arises is how to adjust a patient’s dry weight as 
pregnancy progresses.
Case Description: We present a case of a 23 year old pregnant dialysis patient who 
was admitted to the hospital with shortness of breath at 26 weeks gestation. She had a past 
medical history of a miscarriage, hypertension, and a failed deceased donor renal transplant. 
At her outpatient dialysis unit, she was being dialyzed 6 times per week. Her dry weight was 
increased by 1.5 kg during the first trimester and during the second trimester by 1 pound a 
week to account for normal pregnancy weight gain. On this admission, her weight was 113.5 
kg and her estimated dry weight was 114 kg. Her vital signs on admission revealed that she 
was mildly hypertensive with a blood pressure of 150/94 and her oxygen saturation was 
90% on room air. After other etiologies were excluded, it was determined that the patient’s 
hypertension and hypoxia were due to volume overload despite the patient being below her 
expected dry weight. A fetal monitor was placed on the patient and she was dialyzed for three 
consecutive days with a net ultrafiltration of 7 liters. There were no signs of fetal distress 
during volume removal on the monitor. A uterine artery doppler was also performed and 
showed no signs of hypoperfusion to the fetus during dialysis. Subsequently, the patient’s 
shortness of breath and hypertension resolved. Upon discharge, her new dry weight was 
108 kg, which was 6 kg below her expected dry weight. The patient delivered a baby 
weighing 5.4 lbs at 37 weeks with Apgar scores of 8 and 9 at 1 and 5 minutes, respectively.
Discussion: In a pregnant dialysis patient, it is difficult to distinguish between normal 
pregnancy weight gain and extra fluid. A fetal monitor and uterine artery doppler during 
dialysis are useful tools that nephrologists can employ to titrate ultrafiltration goals. Better 
volume management in turn could avoid pre-term delivery.
FR-PO087
A Rare Cause of AKI in a Renal Transplant Recipient  Ronald Brian Vigo,1 
Sandra Barrow,1 Lillian W. Gaber,2 Wadi N. Suki.1  1Nephrology, Houston 
Methodist Hospital, Houston, TX; 2Pathology, Houston Methodist Hospital, 
Houston, TX.
Case Description: We present a 66 year-old African American woman who underwent 
pre-emptive living related donor kidney transplant for ESRD secondary to DMII and 
hypertension. She had immediate graft function and was discharged on the fourth post-
operative day with Na 136 mEq/L, K 3.5 mEq/L, Cl 102 mEq/L, total CO2 19 mEq/L, 
creatinine 1.3mg/dL and urine pH 7.0. Baseline renal biopsy was normal. Her medications on 
discharge included Prograf, Cellcept, Prednisone, Bactrim, Valcyte and sodium bicarbonate. 
She presented 10 days later with complaints of nausea, and vomiting as many as 10 times. 
Serum chemistries revealed the following: Na 136 mEq/L, K 5.0 mEq/L, Cl 95 mEq/L, and 
total CO2 20 mEq/L, consistent with a high-anion gap metabolic acidosis (AG 21). Serum 
creatinine was 1.3 mg/dL and urinalysis revealed a urine pH of 7.5, pyuria and bacteriuria. 
Urine culture grew E. Faecalis and renal transplant ultrasound was normal. She was started 
on IV antibiotics and IV fluids, including sodium bicarbonate. The following day, her 
chemistries revealed her anion gap metabolic acidosis had resolved, with total CO2 rising to 
27 mEq/L. However, serum creatinine increased to 1.8 mg/dL, and continued to rise further 
despite treatment. A renal allograft biopsy was performed. Microscopic examination of the 
biopsy revealed widespread nephrocalcinosis with calcium-phosphate deposition. PTH at 
the time was 255 pg/mL, Ca 8.5 mg/dL, iP 4.1 mg/dL and fractional excretion (FE) of Ca 
0.15%, FEiP 29%, and urine anion gap was 29.
Discussion: We propose that our patient had developed post-transplant RTA, given 
the presence of non-anion gap metabolic acidosis, low K, and urine pH of 7.0 in the 
immediate post-transplant period. Positive urine anion gap is suggestive of decreased 
ammonium excretion (although it should be confirmed with measurement of the urine 
osmolal gap and urinary PCO2). The combination of high urine pH, as a consequence of 
bicarbonate administration and decreased bicarbonate reabsorption, in conjunction with 
hyperparathyroidism and consequent increase phosphate excretion, provided the perfect 
medium for calcium phosphate precipitation.
FR-PO088
A Rare Case of Rabbit Anti-Thymocyte Globulin Induced Disseminated 
Intravascular Coagulation  Vasanthi Balaraman,1,2 Anup Patel.1  1Dept of 
Renal Transplant, Saint Barnabas Medical Center, Livingston, NJ; 2Dept of 
Nephrology, Newark Beth Israel Medical Center, Newark, NJ.
Introduction: Rabbit anti-thymocyte globulin (RATG) is a purified polyclonal 
immunoglobulin used for induction therapy in renal transplantation. Adverse effects include 
cytokine release syndrome, leukopenia, thrombocytopenia and serum sickness. We report a 
rare case of renal transplant recipient who developed severe coagulopathy and post-operative 
bleeding in whom RATG was used for induction.
Case Description: A 61 year old female with end stage renal disease received a 
deceased donor renal transplant. RATG (2 mg/kg) was initiated intraoperatively. Over the 
ensuing 2 hours, the patient became hemodynamically unstable with excessive bloody 
output from the surgical site drain. Exploration of the renal transplant revealed diffuse 
oozing from surrounding tissues but no bleeding from the arterial or venous anastomosis. 
Labs revealed an elevated prothrombin time of 27.0 sec, thrombin time of 36.4 sec, INR 
of 2.5 and d-dimer greater than 5250 ng/ml, reduced fibrinogen level of 135 mg/dl and 
platelet count of 66000/cmm. The RATG infusion was stopped. Multiple units of packed red 
blood cells, platelets, fresh frozen plasma and cryoprecipitate were transfused. There was 
persistent bloody output. A reexploration revealed persistent diffuse oozing which required 
packing of the transplant bed. On postoperative day 4, the patient’s condition improved.
Discussion: We suspect Disseminated Intravascular Coagulation(DIC) may be 
secondary to RATG in our case. The donor biopsy showed no evidence of DIC. Other causes 
including calcineurin inhibitors, hyperacute rejection and sepsis were ruled out. Only a few 
case reports of RATG induced coagulopathy exist in the literature. Weber et al reported 12 
hematopoietic stem cell transplant patients having coagulopathy after using RATG therapy. 
These cases had elevated D-dimer, tissue factor, thrombin-antithrombin III complex, and 
thrombomodulin, but had no bleeding, thromboembolic or vaso-occlusive complications. 
We contemplate that DIC is a rare but potential life threatening complication of RATG 
induction and awareness of this potential complication is important.
FR-PO089
A Page Transplant Kidney  Supreet Sethi, Shalini Bumb, Scott Leonard 
Sanoff.  Div of Nephrology, Dept of Internal Medicine, Duke Univ Health 
System, Durham, NC.
Introduction: Page kidney occurs by extrinsic compression of the renal parenchyma 
from a hematoma or a mass, leading to activation of the renin-angiotensin-aldosterone 
system and resulting in systemic hypertension.
Case Description: A young-adult male,with ESRD of uncertain etiology underwent 
living related kidney transplantation 3-months prior to presentation. His post-transplant 
serum creatinine (SCr) stabilized around 1.3-1.5mg/dl. He was maintained on a 3 drug 
immunosuppressive regimen including tacrolimus, prednisone and myfortic. The patient 
presented to the hospital with pain over allograft site and low grade fever.He reported an 
altercation with a family member without clear direct trauma to his right lower quadrant 
graft, but admitted to blunt trauma to his right flank region in a shoving match.Patient was 
hypertensive with blood pressures in the 170-180/100-110 mm Hg range. Labs revealed a 
SCr of 4.1mg/dl, potassium of 5.7mmol/L, hemoglobin of 10.8g/dl from a baseline of 12g/
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dl, and WBC of 15,000/uL. Urinalysis was bland.The patient was given a dose of solumedrol 
500mg due to concerns for rejection.US of the transplant kidney showed a 2.2 x 10.5 x 4.1cm 
subcapsular fluid collection exerting a mass effect on the transplanted kidney, concerning 
for sub-capsular hematoma. The main renal artery and vein were patent, but the resistive 
indices were elevated within the arcuate renal arteries.Cross-sectional imaging of the 
abdomen confirmed a moderate sized renal transplant subcapsular/perinephric hematoma.
The patient was managed conservatively and by hospital day 3, the renal function started 
improving. The patient was discharged with a SCr of 2.1mg/dl on hospital day 4 on his 
home regimen of amlodipine and labetalol.Most recently his SCr was 1.4mg/dl.
Discussion: The clinical syndrome of Page kidney in a kidney allograft due to 
subcapsular/perinephric hematoma following trauma or biopsy is characterized by acute 
hypertension with a concomitant acute decrease in kidney function. Our cases illustrates 
that this syndrome may occur without a history of direct trauma to the kidney, and that 
despite severe acute kidney injury, can be managed conservatively in some cases, with a 
good long term outcome.
FR-PO090
Black Colored Dialysate: A Rare Complication of Peritoneal Dialysis due 
to Cholecystitis  Yi Li,1 Basmah A. Abdalla,2 Pang-Yen Fan.2  1Dept of Internal 
Medicine, Univ of Massachusetts Medical School; 2Dept of Nephrology, Univ 
of Massachusetts Medical School.
Introduction: We report a rare complication of black colored dialysate in a patient 
with ESRD on peritoneal dialysis (PD) with acute cholecystitis.
Case Description: A 73 year old man was undergoing peritoneal dialysis for ESRD 
secondary to obstructive uropathy. He presented with black discoloration of his PD 
effluent, preceded by persistent abdominal pain and fever. Exam was notable for abdominal 
tenderness and a clean PD catheter exit site. Peritoneal fluid analysis was consistent with 
peritonitis. Contrast CT showed a distended indistinct gallbladder with punctate stones and 
an ill-defined wall. No biliary obstruction or dilatation identified. There was no evidence 
of pancreatitis and serum lipase level was 12. Subsequent HIDA scan was consistent with 
acute cholecystitis. A total bilirubin from PD effluent was 14.6mg/dL and serum bilirubin 
was only 0.8mg/dL. Both blood cultures and PD fluid cultures were negative. He received 
empiric antibiotics and a percutaneous cholecystostomy tube was placed and similar turbid 
dark fluid was aspirated from his gallbladder.
Discussion: Dark colored dialysate has been reported in hemorrhagic and non-
hemorrhagic pancreatitis. Acute bile leak or choleperitoneum is a recognized complication 
of cholecystectomy due to extrahepatic bile duct rupture or due to gall bladder rupture in 
patients without ESRD. There are few reports of biliary peritonitis due to intrahepatic bile 
duct rupture spontaneously and in the setting of cholelithiasis. An ascitic fluid bilirubin 
level of > 6mg/dL with an ascitic fluid/serum bilirubin ratio of >1.0 has been shown to 
correlate with choleperitoneum. The black colored PD effluent in our patient represented a 
biliary leak likely from increased permeability of the gallbladder wall or microperforation 
in the setting of non-perforated cholecystitis or from an unidentified intrahepatic bile duct 
rupture. In conclusion black colored PD effluent should prompt investigation for gall 
bladder disease and/or pancreatitis. Peritoneal fluid and serum bilirubin levels and lipase 
levels can aid in making a diagnosis.
FR-PO091
NK Cell Lymphoproliferative Disorder(PTLD) Associated with Pure Red 
Cell Aplasia in a Renal Transplant Recipient Treated with ATG – A Case 
Report and Literature Review  Daniel Taiwo Adeneye, Amarpali Brar, Fasika 
M. Tedla, Nabil Sumrani, Devon John.  Nephrology, Suny Downstate Medical 
Center, Brooklyn, NY.
Introduction: PRCA can be idiopathic or secondary to parvovirus 
infection,SLE,thymoma or lymphoma.PTLD are lymphoid proliferations that develop 
following immunosuppression for solid organ transplantation.While they are predominantly 
B cell PTLD, few NK/T cell PTLD have been published. Secondary PRCA may resolve 
with treatment of the underlying disorder while PRCA occurring in the setting of Nk/T cell 
PTLD (due to T cell inhibition of marrow erythroid cells) are treated like idiopathic PRCA 
as immunologically mediated disease.This is the first published report of PRCA associated 
with NK cell PTLD in a 41yr old renal transplant recipient.
Case Description: This is the first published report of PRCA associated with NK cell 
PTLD in a 41 year old renal transplant recipient.
A 41year old woman with ESRD from lupus nephritis,received living related renal 
transplant 9 years ago; admitted with hemoglobin of 5.6 g/dl with normal WBC count 
and platelet count. Patient had well-functioning allograft with serum Cr of 1.5.There was 
no evidence of joint swelling , rash, or alopecia. No proteinuria, RBC, WBC or cast on 
urine analysis. Serum Protein was 4.9 g/dl , Albumin 2.7 g/dl. LDH, haptoglobin, DS 
DNA,ANA,C3,C4,hepatitis B,C, HIV,Parvo virus PCR, EB PCR, free kappa/Lamda were 
normal. MCV was 95.9 fL. Peripheral smear showed many normal lymphocytes with normal 
count. Bone marrow biopsy showed normal lymphocyte population, many macrophages 
but absence of erythroid precursors. Flow cytometry revealed increased NK 56(-) ,CD3 
- ,CD8+ cells. Renal allograft Ultrasound, CT Chest and CT abdomen were normal. This 
patient had her last epogen in 2003 and anti- EPO antibody induced PRCA though possible 
is very unlikely. Patient received 2 units of packed red cells and Anti-Thymocyte globulin 
(ATG) daily for 5days. She was continued on tacrolimus with stable hemoglobin with no 
further need for transfusion.
Discussion: We present a case of PRCA in a renal transplant recipient due to NK cell 
lympho proliferative disorder which was successfully treated with ATG .
FR-PO092
New-Onset Diabetes After Transplantation in a Pediatric Patient with 
Congenital Anomalies of the Kidney and Urinary Tract: The Role of 
Hepatocyte Nuclear Factor 1β  Naoto Kaneko,1 Naoya Morisada,2 Keiichi 
Takizawa,1 Tomoo Yabuuchi,1 Hirotaka Hama,1 Norimasa Tada,1 Eiji Nakano,1 
Shoichiro Kanda,1 Kiyonobu Ishizuka,1 Hiroko Chikamoto,1 Yuko Akioka,1 
Kazumoto Iijima,2 Motoshi Hattori.1  1Dept of Pediatric Nephrology, Tokyo 
Women’s Medical Univ, Tokyo, Japan; 2Dept of Pediatrics, Kobe Univ Graduate 
School of Medicine, Kobe, Japan.
Introduction: Congenital anomalies of the kidney and urinary tract (CAKUT) are the 
most frequent cause of end-stage renal disease (ESRD) in children. New-onset diabetes after 
transplantation (NODAT) is one of the major complications following kidney transplantation 
(KTx). Mutations of hepatocyte nuclear factor 1β (HNF1B), a transcriptional factor 
involved in the development and maintenance of several organs, cause a multi-system 
disorder, including CAKUT, diabetes, liver dysfunction. We report a pediatric patient 
with renal hypodysplasia carrying a novel mutation of HNF1B who developed NODAT 
and liver dysfunction.
Case Description: The patient was a 14-year-old girl. She was diagnosed with bilateral 
hypodysplastic kidney in the newborn period. At the age of 3 years, she received living-
related KTx from her mother preemptively. At the age of 4 years, a steroid pulse for acute 
rejection resulted in development of diabetes mellitus (NODAT). At the age of 13 years, 
she complained of acute right flank pain and fever. Laboratory data showed elevated 
transaminase levels and computed tomography showed malformation of the bile duct. The 
causes of NODAT were initially thought to be steroid and tacrolimus. However, based on 
her clinical features, including CAKUT, NODAT, and liver dysfunction, screening for a 
mutation of HNF1B (approved by the central ethics board of Tokyo Women’s Medical 
University and Kobe University) was performed. Direct sequencing identified a novel 
splicing mutation of HNF1B, c.344+2T>C.
Discussion: CAKUT is the leading cause of ESRD in children and HNF1B is the most 
frequently mutated gene of CAKUT. Therefore, the contribution of HNF1B mutations to 
development of NODAT appears to be large in the field of pediatric KTx. An oral glucose 
tolerance test and screening for HNF1B mutations may be advisable before KTx in pediatric 
CAKUT patients.
FR-PO093
Acute Kidney Injury from Biopsy Proven Oxalate Nephropathy in a 
Combined Kidney and Lung Transplant Recipient  Minesh Rajpal, Reejis 
Stephen, Brian R. Stephany.  Cleveland Clinic, Cleveland.
Introduction: Acute oxalate nephropathy (AON) is a rare, but well reported cause of 
acute kidney injury (AKI) in patients with cystic fibrosis (CF) after lung transplant. We 
report the only known case of late AON of a transplanted kidney in a combined kidney 
and lung transplant patient without CF after undergoing medical and surgical management 
of infective endocarditis.
Case Description: A 62 year old Caucasian male with a remote history of Hodgkin’s 
disease complicated by radiation-induced pulmonary fibrosis and aortic stenosis underwent 
a simultaneous double lung transplant and bioprosthetic aortic valve replacement (AVR) in 
February 2013. His post operative course was complicated by recurrent bronchopneumonias 
secondary to MSSA requiring prolonged oxacillin as well as ESRD secondary to presumed 
unrecovered acute tubular necrosis (ATN).The patient subsequently underwent a successful 
living unrelated kidney transplant from his wife in October 2014 with baseline creatinine 
of 1.4mg/dl. Unfortunately, he developed E. faecalis bacteremia secondary to urosepsis 
and subsequent finding of multivalvular endocarditis with superior vena cava involvement. 
This was treated with a prolonged antibiotic course, but recurrent admissions thereafter for 
CHF and cardiorenal AKI necessitated a redo AVR along with mitral valve replacement and 
tricuspid valve repair, “Commando Procedure” on 3-9-2015. Immediate post-operative AKI 
occurred and was thought due to ATN given the presence of muddy brown casts on sediment 
exam along with hemodynamic instability requiring temporary intra- and post-operative 
vasopressor support. Anuric AKI persisted for four weeks leading to a surveillance kidney 
biopsy to investigate for superimposed rejection. Notable histologic findings were tubular 
injury consistent with ATN, but more prominent was that of extensive calcium oxalate 
deposits consistent with AON.
Discussion: In summary we report the first known case of AKI due to AON in a lung 
and renal transplant recipient after infective endocarditis requiring prolonged antibiotics 
and the Commando heart procedure. Though the clinical presentation mimics ATN it is 
important for clinicians to include AON in the differential diagnosis.
FR-PO094
Pax2 and PTIP Regulate AVPR2 Expression in the Inner Medulla 
Sanjeevkumar R. Patel, Saji Abraham.  Internal Medicine, Univ of Michigan, 
Ann Arbor, MI.
Background: In mammals, Pax genes encode developmental regulatory proteins that 
specify cell lineages and tissues in metazoans and Pax2 is essential for kidney development. 
Upon binding to DNA through the conserved paired-domain, Pax proteins can recruit both 
activating and repressing complexes that imprint distinct patterns of histone methylation 
associated with either gene activation or silencing. Expression of Pax2 persists in the 
medulla of the adult kidney, where it is proposed to prevent apoptosis in response to 
increased osmolality. Deletion of the Pax2 interacting protein PTIP in the inner medulla of 
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mice results in a concentrating defect in part related to a reduction of AVPR2 expression. 
As Pax proteins interact with PTIP, and Pax2 expression persists in the inner medulla, we 
hypothesized that Pax2 and PTIP are required for AVPR2 expression.
Methods: In IMCD-3 cells with control, Pax2 or PTIP deletion, we determined Pax2 
and AVPR2 expression at the mRNA and protein level in response to normal and elevated 
osmolality. By ChIP analysis, we identified sites of Pax2 and PTIP enrichment on the 
AVPR2 promoter and determined changes in histone modifications, PolII occupancy in 
both IMCD cells and in murine medullary tissue.
Results: Pax2 mRNA peaks 8 hours after an increase in osmolality, Pax2 protein peaks 
at 12 hours, and AVPR2 mRNA after 20 hours. Pax2, PTIP and the HMT activation complex 
localize to a 100 bp fragment of the AVPR2 promoter, resulting in increases in activation 
marks, recruitment of PolII to this locus and an increase in gene expression in both cell 
lines and murine tissue. We identify the minimal promoter that Pax2 binds to and drives 
expression of the AVPR2 locus. Deletion of this 100 bp region of DNA results in lack of 
gene expression in the absence and presence of Pax2. Deletion of PTIP results in loss of 
gene expression even though Pax2 localizes to the promoter region, as histone activation 
marks are not increased and PolII is not recruited to this locus.
Conclusions: Thus, Pax2 and PTIP both regulate the expression of AVPR2 in the murine 
inner medulla and in cells derived from this tissue. Pax2 provides the locus specificity for 
PTIP recruitment of the HMT activating complex and gene expression.
Funding: NIDDK Support
FR-PO095
Adenine Downregulates NKCC2 and AQP2 in the Rat Kidney and Causes 
Early Nephrogenic Diabetes Insipidus  Hassane Amlal, Rose P. Webster, Ingrid 
Fernandes dos Santos.  Internal Medicine, Univ of Cincinnati, Cincinnati, OH.
Background: Long-term feeding of adenine is extensively used to develop animal 
models of chronic renal failure with metabolic features resembling those observed in 
humans. However, the mechanisms by which adenine induces renal failure are poorly 
understood.
Methods: In this study, we examined the early effects of adenine (ADN) feeding on 
water metabolism and renal function in rats placed in metabolic cages. Rats were fed control 
diet or diet supplemented with 0.25% or 0.50% ADN, or 0.50% adenosine ad libitum with 
free access to dH2O, and monitored daily for food intake, water balance and urine osmolality, 
and euthanized for blood an kidney collections after 7 days.
Results: ADN-treated rats exhibited a sharp polyuria and polydipsia and decreased 
urine osmolality as early as 3 days, and the magnitude of these effects is dose-dependent. 
Further, ADN caused a significant reduction in food intake and body weight at 0.50% but 
not at 0.25%. None of these physiologic parameters was altered by adenosine treatment. 
dDAVP treatment induced a significant increase in urine osmolality in control but not in 
ADN-treated rats. Immunoblotting experiments demonstrated a sharp reduction in AQP2/
actin proteins ratio in the cortex (-75%), Outer medulla (-65%) and inner medulla (-80%) 
of kidneys of ADN-treated vs. control animals. The results also demonstrated that the 
abundance of NKCC2/actin proteins ratio was reduced to zero in the kidney outer medulla 
of ADN-treated vs. control rats. Blood chemistry of ADN-treated rats was normal except 
for a significant 3.8-fold increase in BUN, as compared to control rats.  When rats were 
fed adenine diet supplemented with 7% NaCl, their BUN was corrected to normal level, 
but still exhibited a significant reduction in urine osmolality.
Conclusions: In conclusion, adenine acts on renal tubules as a signaling molecule 
and causes nephrogenic diabetes insipidus, likely by directly downregulating NKCC2 and 
AQP2 in the kidney. The combination of renal fluid loss and decreased food intake likely 
plays an important role in the development of early acute renal injury that progresses to 
chronic kidney disease in long-term periods of adenine treatment.
Funding: NIDDK Support, Clinical Revenue Support
FR-PO096
AMPK Activation Increases Urine Concentrating Ability in a Rat Model of 
Congenital Nephrogenic Diabetes Insipidus  Orhan Efe, Huiwen Ren, Lauren 
M. Larocque, Janet D. Klein, Jeff M. Sands.  Medicine, Renal Div, Emory Univ 
School of Medicine, Atlanta, GA.
Background: The urine concentration mechanism is primarily regulated by vasopressin 
which activates NKCC2 and urea transporters to generate a hypertonic interstitium that 
promotes water reabsorption through AQP2. Congenital nephrogenic diabetes insipitus 
(NDI) is caused by vasopressin V2 receptor (V2R) mutations. Present treatment options 
are limited. We studied AMPK as an alternate pathway to stimulate transporters involved 
in urine concentration.
Methods: Tolvaptan (10 mg/kg/day), a selective V2R antagonist, was given by oral 
gavage to rats for 4 days,+/- metformin (800 mg/kg/day). Urine volume and osmolality 
were measured daily. Following sacrifice, kidneys were dissected into inner medullary tip, 
base and outer medulla, and UT-A1, AQP2, and NKCC2 were analyzed by Western blot. 
Immunohistology was used to localize AQP2, pAQP2, pAMPK, and NKCC2.
Results: Tolvaptan was used to produce a rat model of NDI. Urine volumes of 
tolvaptan-treated rats increased 105% within 24 h. Metformin was used to stimulate AMPK 
as a candidate NDI treatment. Metformin decreased urine volume by 110% back to control 
levels in 3 days. Urine osmolality in control rats (mean: 2107 mOsM) was significantly 
decreased by tolvaptan (mean: 1303 mOsM, p<0.05) and restored to near control levels 
by metformin (mean: 2335 mOsM, p<0.05). Metformin increased protein abundance of 
IM tip UT-A1 by 61% in tolvaptan treated rats (p<0.05). IM tip AQP2 was also increased 
44% but failed to reach statistical significance (p=0.057). In contrast, IM base UT-A1 and 
AQP2 protein levels were not changed with AMPK stimulation. Outer medullary NKCC2 
abundance was increased 117% with AMPK stimulation in control rats (p=0.004) but not in 
V2R-blocked rats. Immunohistochemistry showed that AQP2 and p-AQP2-Ser256 appear 
to be localized on the cell membrane with acute and chronic AMPK stimulation, both in 
control and V2R-blocked rats.
Conclusions: AMPK stimulation in V2R-blocked rats is able to reduce the urine 
concentrating defect by increasing UT-A1 and AQP2. These results indicate that specific 
AMPK pathway activators might provide a promising treatment for congenital NDI.
Funding: NIDDK Support
FR-PO097
HYAL2 Disruption Leads to Impaired Urinary Dilution Capacity in Mice 
Vanessa Colombaro,1 Inès Jadot,1 Anne-Emilie Decleves,1,2 Isabelle Habsch,1 
Bruno Flamion,1 Nathalie Caron.1  1Molecular Physiology Research Unit-
URPHyM, Univ of Namur, Namur, Belgium; 2Laboratory of Experimental 
Nephrology, Univ Libre de Bruxelles, Bruxelles, Belgium.
Background: Hyaluronan (HA) is a glycosaminoglycan present in high amount in the 
inner medulla of the kidney but almost absent in the cortex. Hyaluronidase 2 (HYAL2) is 
one of the two major hyaluronidases acting synergistically to degrade HA. Recently, it has 
been shown that Hyal2-/- mice display HA accumulation in the kidney. Renal HA content 
is known to vary with hydration status. Therefore, our study was set up to characterize the 
renal excretory capacities and renal water handling in response to water deprivation and 
acute water loading in Hyal2-/- mice.
Methods: Experiments were performed in Hyal2-/- mice and in their wild-type controls. 
After appropriate acclimation, water deprivation was performed during 24 hours. The 
capacity to excrete a water load was tested on an hourly basis for the next 6h after i.p. 
injection of 2 ml of sterile water. Diuresis and urinary osmolarity were measured. HA 
concentration was measured in the kidney tissue and its distribution through the different 
kidney zones was examined using immunohistochemistry. Expressions of aquaporin 
2 (AQP2) and p-Ser 256 AQP2 were also assessed using immunohistochemistry and 
immunobloting.
Results: After water deprivation, Hyal2-/- mice showed the same ability to concentrate 
urine as the Hyal2+/+mice. On the other hand, Hyal2-/- mice had a significant delay in the 
diuretic response induced by an acute water loading. As for renal HA content, Hyal2-/- mice 
maintained higher HA concentration than Hyal2+/+mice after both water deprivation and 
acute water loading. HA was present around tubules in all kidney zones including cortex. 
Plasma AVP levels, kidney AQP2 and kidney p-Ser AQP2 expressions were increased 
after water deprivation and decreased after acute water loading to the same extent in KO 
and WT mice.
Conclusions: HYAL2 deficiency and/or increased renal interstitial HA delays the 
diuretic response to acute water loading without any increase in plasma AVP or collecting 
duct AQP2 expression.
FR-PO098
Phosphorylated AQP2 and NR3a Reduce NSAID-Induced Urine 
Concentration Defect  Huiwen Ren,1,2 Baoxue Yang,2 Patrick A. Molina,1 
Jeff M. Sands,1 Janet D. Klein.1  1Medicine, Renal Div, Emory Univ School 
of Medicine, Atlanta, GA; 2Pharmacology, School of Basic Medical Sciences, 
Peking Univ, Beijing, China.
Background: Vasopressin increases urine concentration through activation of 
aquaporin-2 (AQP2) in the collecting duct. Nonsteroidal anti-inflammatory drugs (NSAIDs) 
block PGE2 synthesis, and may suppress AQP2, producing a urine concentrating defect. 
NR3a can regulate cellular Ca2+ entry and may influence AQP2 trafficking.
Methods: We treated rats with a nonselective NSAID, ibuprofen, and a COX-2-selective 
NSAID, meloxicam, daily for 2 weeks. We assessed urine osmolality and volume, and 
monitored p-AQPs by Western blotting. NR3a-/- mice were used to examine if NR3a has 
a protective role.
Results: Both NSAIDs significantly increased urine output and decreased urine 
osmolality by days 7 - 14. Meloxicam significantly reduced total AQP2 in inner medulla 
(IM) tip to 64% and base to 63% of control. Ibuprofen decreased total AQP2 in IM tip to 
70% of control, with no change in base. Meloxicam significantly increased the ratios of 
p256-AQP2 and p261-AQP2 to total AQP2 in IM tip (to 44% and 40%, respectively). Ibuprofen 
increased the ratio of p256-AQP2 to total AQP2 in IM tip but did not affect p261-AQP2/total 
AQP2. Both NSAIDs increased p264-AQP2 and p269-AQP2 ratios in tip and base. Ibuprofen 
increased UT-A1 levels in IM tip, but not base. NR3a, present in rat IM tip and base, was 
significantly increased in the meloxicam and ibuprofen treated IM bases (37% and 20%, 
respectively), but unchanged in IM tip. AQP2 and UT-A1 abundances were decreased both 
in wild type (AQP2: to 76%, UT-A1: to 62%) and NR3a-/- mice (AQP2: to 52 %, UT-A1: 
to 33%) by ibuprofen treatment. Meloxicam did not show any changes either in wild type 
or in NR3a-/- mice. Notably, ibuprofen treatment caused AQP2 and UT-A1 to decrease more 
in NR3a-/- mice than in wild type mice.
Conclusions: We conclude that NSAIDs reduce AQP2 abundance contributing to 
decreased urine concentrating ability. In compensation, p-AQP2 increases, resulting in 
increased AQP2 membrane insertion. The beneficial effects of NR3a may reflect the altered 
Ca2+ entry that could be limiting dephosphorylation of AQP2 and promoting improved 
water homeostasis.
Funding: NIDDK Support, Government Support - Non-U.S.
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FR-PO099
The Role of Klotho in Renal Sodium and Water Transport  Talita R. Sanches,1 
Fernanda O. Coelho,1 Lectícia Jorge,1 Leticia U. De Castro,1 Makoto Kuro-o,2 
Lucia Andrade.1  1Div of Nephrology, Univ of Sao Paulo, Brazil; 2Jichi Medical 
Univ, Japan.
Background: Klotho (Kl), a transmembrane protein hormone, counteracts aging. 
Aging is often paralleled by dehydration, which could promote age-related disorders, 
because it decreases renal Kl protein abundance, as well as increasing plasma osmolarity, 
antidiuretic hormone (ADH), aldosterone, and 1,25 vitamin D. ADH and aldosterone 
decrease Kl transcription in HEK293 cells and are elevated in the sera of Kl knockout 
mice. We explored the effects of Kl deficiency on renal transporters.
Methods: 8-12 week old male Kl+/+, Kl+/- and Kl-/- mice (n=6/group) were fed standard 
mouse chow and given ad libitum access to tap water. We evaluated serum levels of Na, K, 
Cl, Mg, creatinine and urea. We immunoblotted for sodium/hydrogen exchanger isoform 3 
(NHE3), renal outer medullary potassium channel (ROMK), the Na-K-2Cl cotransporter 
(NKCC2), alpha subunit of the epithelial sodium channel (αENaC) and aquaporin 2 (AQP2) 
in kidney membrane fractions; and for phosphorylated glycogen synthase kinase 3 beta 
(pGSK3β) in cytoplasmic fractions.
Results: Data are mean±SEM. 
Kl +/+ Kl+/- Kl-/-
Body weight (g) 25.1±3.4 24.5±3.0 9.5±2.2a
Na (mEq/L) 148±0.6 144±0.6 157±2.3a
K (mEq/L) 4.6±0.2 4.2±0.1 4.2±0.4
Cl (mEq/L) 114±1.4 111±1.5 121±4.0a
Mg (mg/dl) 1.6±0.1 1.7±0.0 2.5±0.1a
Urea (mg/dl) 50.5±3.3 52.0±2.1 101.6±7.8a
Creatinine (mg/dl) 0.1±0.0 0.1±0.0 0.12±0.02
NHE3* 99.1±1.1 92.5±2.2 58.2±4.5a
ROMK* 99.3±2.4 92.5±4.7 20.5±4.8a
NKCC2* 97.5±1.1 97.8±1.4 130.6±10.7a
αENaC* 99±0.4 98±0.9 48±4.9a
AQP2* 98.5±0.8 98.3±0.4 133.5±2.2a
pGSK3β* 100±0.7 98.3±0.7 60.3±1.3a
ap<0.05 vs. Kl+/+ and Kl+/-; *% Kl+/+ protein expression
Conclusions: In Kl knockout mice, there seems to be normal regulation of NKCC2 
and trafficking of AQP2 to the apical plasma membrane in response to ADH. However, Kl 
knockout mice present reduced sensitivity to elevated plasma aldosterone levels with no 
increase in αENaC or ROMK protein expression. A lack of Kl can deregulate the adaptive 
response. (FAPESP).
FR-PO100
Urine Aquaporin-2: Improvement in ELISA Measurements by Alkali 
Pre-Treatment and Mechanisms of the Secretion  Sei Sasaki,1,3 Yoko Saijo,2 
Yasukazu Ohmoto,2 Fusako Iwata,2 Daisuke Koga,2 Takayuki Shimada,3 Masaki 
Sakai,3 Yasuko Tanaka,3 Kenichi Ishibashi,3 Kiyonori Katsuragi.2  1Nephrology, 
Tokyo Medical and Dental Univ, Tokyo, Japan; 2Research and Development 
and Inst of Biomedical Innovation, Otsuka Pharmaceutical Co Ltd, Tokushima, 
Japan; 3Medical Physiology, Meiji Pharmaceutical Univ, Tokyo, Japan.
Background: Vasopressin-regulated water channel, aquaporin-2 (AQP2) is excreted 
in urine in the form of extracellular vesicles (mostly exosomes). Urine AQP2 has been 
measured in many clinical water-balance disorders as a potential biomarker for diagnosis 
and prognosis. However, despite such a clinical application, fluctuations of the measured 
values in ELISA were sometimes observed depending on storage conditions, and basic 
mechanisms of urinary AQP2 excretion are still largely unknown. We characterized urinary 
excretion of AQP2 by using a highly sensitive and specific ELISA system for human AQP2, 
which has been developed by us.
Methods: Human urine samples from healthy subjects were measured by a sandwich 
ELISA. Effects of maneuvers to disrupt the exosome membranes mechanically (freezing 
and thawing at different temperatures) and chemically (treating with alkali and detergents) 
prior to ELISA were examined. Stably AQP2-transfected MDCK cells were grown on 
permeable support and excretion of AQP2 to the medium was measured.
Results: 1. Urine samples stored at 4ºC or -80ºC did not show significant AQP2 values 
in ELISA, whereas those stored at -25ºC for more that 2 weeks provided the values. Urine 
samples treated with 0.4N NaOH/0.5% Triton X-305 showed the consistent and comparable 
values to those stored at -25ºC, indicating the need of disruption of the exosome membranes. 
2. Supernatants of 200,000g ultracentrifugation contained less than 0.5% of AQP2 of original 
urine samples. 3. In the culture, AQP2 concentration was more than 10 times higher in 
apical medium compared to basolateral, and apical AQP2 excretion was stimulated with 
3h-incubation of 10-5M forskolin and 100mM NaCl.
Conclusions: Almost all urine AQP2 is enclosed in exosomes, and pre-treatment 
of alkali (0.4N NaOH) allows consistent ELISA measurements. Mechanisms of urinary 
excretion of AQP2 can be examined in culture system.
Funding: Pharmaceutical Company Support - Otsuka Pharmaceutical, Government 
Support - Non-U.S.
FR-PO101
Inhibition of EGFR Activity Induces Aquaporin 2 Phosphorylation and 
Increases Water Reabsorption in Lithium Treated Mice  Pui Cheung, Naohiro 
Nomura, Anil V. Nair, Hua Ann Jenny Lu, Richard Bouley, Dennis Brown. 
Medicine, Massachusetts General Hospital, Boston, MA.
Background: Impairment of vasopressin (VP) receptor type 2 signaling in the kidney 
is detrimental to water homeostasis. However, strategies targeting cAMP signaling to treat 
diseases associated with water balance have so far been unsuccessful in humans, prompting 
a search for alternative pathways that modulate AQP2 trafficking.
Methods: The effect of erlotinib (Erl) oral gavage in a lithium induced nephrogenic 
diabetes insipidus mouse model was analyzed by measuring urine volume and osmolality. 
The effect of Erl on aquaporin 2 trafficking and expression in kidneys was studied by 
immunostaining and western blot analyses. EGF and Erl regulation of AQP2 trafficking 
and phosphorylation were studied using selective kinase inhibitors and phospho-specific 
antibodies on AQP2-expressing LLC-PK1 cells.
Results: EGF alone had only a subtle effect on AQP2 trafficking, but it exerted a 
significant antagonizing effect on VP-induced AQP2 phosphorylation and membrane 
accumulation. Conversely, erlotinib (Erl), an EGFR inhibitor, led to a VP-independent 
increase of apical AQP2 accumulation in collecting ducts, and significantly reduced urine 
volume by more than 40% after 4 days of treatment in lithium-induced NDI mice. Erl 
enhanced AQP2 plasma membrane localization in cells by increasing AQP2 exocytosis 
and decreasing endocytosis. This effect was cAMP, cGMP, and PKA independent. 
Despite apparently bypassing cAMP pathways, Erl resulted in AQP2 phosphorylation in 
a dose dependent manner at serine 256, an essential step in VP-induced AQP2 membrane 
accumulation. We propose that EGF has a tonic inhibitory effect on VP action, and that relief 
of such inhibition enhances AQP2 phosphorylation and results in membrane accumulation.
Conclusions: We showed a crosstalk between EGF and VP in the modulation of AQP2 
trafficking. EGFR inhibition increases AQP2 membrane expression bypassing the canonical 
VP/cAMP/PKA pathway and ameliorates lithium-induced NDI in mice. This study improves 
our understanding of the diversity of mechanisms that regulate water reabsorption in the 
body, and uncovers a novel pathway for potential therapeutic targets for NDI.
Funding: NIDDK Support
FR-PO102
ChIP-seq Analysis of Genomic Binding Sites for the Transcription Factor 
Elf1 in mpkCCD Cells  Hyun Jun Jung, Viswanathan Raghuram, Jae Wook 
Lee, Mark A. Knepper.  Systems Biology Center, NHLBI, NIH.
Background: Collecting duct cells selectively express a number of transport proteins 
(aquaporins and ion channels) vital to water and electrolyte balance. Previous studies 
of tissue-specific gene expression in collecting duct cells have implicated Ets family 
transcription factors (TFs)(Yu et al. PNAS 2009;106:2441). We integrated data from 
prior proteomics and transcriptomics studies of mouse mpkCCD cells using Bayes’ Rule 
to create a probability-based ranking of all known TFs with regard to likelihood of a role 
in collecting duct-specific gene expression. Among the top-ranked TFs were several Ets 
family TFs including Elf1.
Methods: To identify genomic binding sites for Elf1 in mpkCCD cells, we carried 
out ChIP-seq analysis using an antibody successfully employed in the Mouse ENCODE 
Project. The mpkCCD cells were treated with the vasopressin analog dDAVP (100pM) 
for 24 hr prior to crosslinking and chromatin immuno-precipitation (ChIP) (n=3). DNA 
libraries were prepared from immunoprecipitated DNA and sequenced using an Illumina 
HiSeq 2000 sequencer to identify TF-enriched genomic regions. Control ChIP was carried 
out with nonspecific IgG.
Results: The analysis (MACS peak-calling software) identified >2000 binding sites 
seen in all three replicates and not seen in IgG-only controls. The identified sites mapped to 
within 2000 bp of annotated transcription start sites (TSSs) of several genes whose transcript 
abundances were previously demonstrated to be regulated by vasopressin including Id3, 
Txnip, Jun, Sat1 and Spag1 (Khositseth et al. Mol Cell Proteomics 2011;10:M110). There 
was no Elf1 binding in the vicinity of any aquaporin or any ENaC subunit, indicating that 
any role of Elf1 in regulating these targets is likely to be indirect. However, Elf1 binding 
was mapped to additional TFs that are predicted to bind within 1000 bp upstream of TSSs 
for aquaporin-2, β-ENaC or γ-ENaC (Genomatix motif analysis). These TFs were Creb1, 
Gata3, Sox4, Junb, Sp1, Sp3, Gabpa, Nfkb1, Hmbox1, Rreb1 and Rxra.
Conclusions: These data provide an initial step in identification of the transcriptional 
network that determines cell-type-specific expression in renal collecting duct cells.
Funding: Other NIH Support - NHLBI Intramural Research Program
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FR-PO103
Deletion of Aquaporin 11 in Transgenic Mice prior to Post-Natal Day 12 
Results in Proximal Tubule Injury and Cyst Formation  Søren Nielsen,1 
Mads Vammen Damgaard,1,2 Michael R. Rutzler,1 Robert A. Fenton,2 Aleksandra 
M. Rojek.2  1Dept of Health Science and Technology, Aalborg Univ, Aalborg, 
Denmark; 2Dept of Biomedicine, Aarhus Univ, Aarhus, Denmark.
Background: AQP11 is expressed in the proximal tubule (PT). Neonate AQP11 KO 
mice show PT vacuolization and cysts, resulting in renal failure and death. This study 
examined; 1) whether AQP11 deficiency at specific stages of kidney development is 
important for PT injury and cyst formation; 2) if cysts are closed structures or dilations of 
PT; 3) the role of metabolic challenges on PT injury and cyst formation.
Methods: Tamoxifen-inducible AQP11 KO mice were generated.
Results: Deletion of Aqp11 at post-natal (PN) day 2, 4, 6, 8, 10, 12 or 21 was 
investigated alongside neonate total Aqp11 KO mice. PT cell vacuolization and tubular 
cysts developed only in mice where Aqp11 gene disruption was instigated before PN day 
12. Aqp11 gene deletion after PN week 3 did not result in PT injury or cyst formation. 
Similarly, 3 weeks of metabolic stress induced by repeated fasting (16hrs) / re-feeding 
(2hrs) of PN day 21 induced Aqp11 KO mice or total neonate AQP11 KO mice resulted 
in PT cytoplasmic vacuoles but not PT cysts. IP injection of biotinylated-dextran (10kDa) 
in adult, neonatally induced Aqp11 KO mice revealed endocytotic uptake in both cystic 
and PT epithelium. Thus apparent cysts were continuous with PT hence representing PT 
dilations. This was confirmed by serial sectioning and digital 3-D tracing of PT cysts in 
adult, neonatally induced Aqp11 KO mice. Electron microscopy of PT in kidneys from adult 
neonatally induced Aqp11 KO mice revealed dilated RER and extensive authophagosomes.
Conclusions: 1) AQP11 deficiency prior to PN day 12 leads to PT cell injury and 
severe PT tubular dilatation. 2) Aqp11 gene deletion after full kidney development results in 
normal PT morphology, and only present with PT injury in response to metabolic challenge. 
3) Apparent cysts represent PT dilations and are not closed cysts. Conclusion: AQP11 
deficiency prior to PN day 12 sensitizes PT cells of the developing kidney to cellular injury 
and causes severe PT dilations thus revealing a novel mechanism for PT cyst formation.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO104
Involvement of NADPH Oxidase 2 in the Kidney Injury of Aquaporin-11 
KO Mouse  Yuya Hoshino,1 Hiroko Sonoda,1 Kenichi Ishibashi,2 Masahiro 
Ikeda.1  1Veterinary Pharmacology, Univ of Miyazaki, Miyazaki, Japan; 2Medical 
Physiology, Meiji Pharmaceutical Univ, Tokyo, Japan.
Background: Aquaporin-11 (AQP11), the latest member of the AQP protein family 
to be described, is an intracellular AQP. Several in vivo studies have shown that AQP11 
deficiency causes kidney injury characterized by the formation of multiple cysts. Recentry, 
this kidney injury was reported to be related to the production of reactive oxygen species 
(ROS). However, the underlying molecular mechanism is largely unknown.
Methods: In this study, we examined the mechanism by which AQP11 deficiency 
induces ROS production using PCR array, real-time PCR, immunoblotting, and 
immunohistochemistry techniques. Also, a pathway analysis was performed with the results 
from the gene expression analysis.
Results: Immunohistochemistry studies showed that the number of 8-hydroxy-2’-
deoxyguanosine-positive cells in renal interstitium was increased in AQP11 KO mice 
in comparison with wild-type mice. In parallel, immunoblotting analysis showed the 
increased levels of renal protein carbonylation in the KO mice. The NADPH oxidase 
(NOX) enzyme family is important sources of ROS and so far, six members (NOX1, 
NOX2, NOX3, NOX4, DUOX1, DUOX2) have been identified in mouse. Among them, 
real-time PCR analysis showed that renal NOX2 mRNA level was markedly increased in 
the KO mice. Furthermore, mRNAs for the assembly factors (p40phox, p47phox, p67phox) 
for NOX2 in the kidney were dramatically up-regulated in the KO mice. Immunoblotting 
analysis revealed that renal NOX2 protein expression was significantly increased in the 
KO mice. Immunohistochemistry showed that NOX2-positive cells were observed in 
renal interstitium.
Conclusions: These data strongly suggested that increased ROS production in AQP11 
KO mice was mediated by NOX2, leading to the kidney injury.
FR-PO105
Intracellular Vacuoles in the Kidney of AQP11 Null Mice May Simulate the 
Cisplatin Nephrotoxicity  Kenichi Ishibashi, Ichiru Akinaga, Takashi Kusano, 
Sei Sasaki, Yasuko Tanaka.  Medical Physiology, Meiji Pharmaceutical Univ, 
Kiyose, Tokyo, Japan.
Background: Nephrotoxicity is a major side effect of cisplatin in chemotherapy. 
Despite years of research, the mechanism underlying cisplatin nephrotoxicity remains 
unclear and effective renal protective approaches during chemotherapy are still unavailable. 
Pathologically, cisplatin nephrotoxicity is characterized by cell injury with multiple 
intracellular vacuoles in the proximal tubule which are very similar to the kidney phenotype 
of AQP11 null mice before the polycyst development. We speculated that cisplatin may 
inhibit the function of AQP11 to induce intracellular vacuoles.
Results: As the importance of caspase (Casp) 12 in cisplatin nephrotoxicity has been 
reported in the literature (J Am Soc Nephrol. 16: 1985, 2005), the expression of Casps was 
examined by real-time PCR in the kidney of AQP11 null mice with intracellular vacuoles, 
i.e. two weeks after birth. Casp3/Casp8 for apoptosis were not induced, while Casp12 for 
ER stress were strongly induced by 9 folds and Casp1/Casp4 for inflammation by 6/7.5 
folds. We next examined the effect of cisplatin on AQP11 expression in the kidney. The 
real-time PCR showed the decrease of AQP11 expression by half in mice kidney at three 
days after 20 mg/g BW i.p. cisplatin with almost normal renal function. When AQP11 
hetero-mice were challenged with the same cisplatin treatment, the renal parameters were 
increased: (hetero/wild) BUN 159.1/53.4 mg/dl, Cr 0.33/0.17 mg/dl, UA 3.13/2.0 mg/dl. 
We next searched for the interventions which enhance AQP11 expression in the kidney. 
Two-day dehydration decreased the AQP11 mRNA expression while three-day glucose 5g/
kg BW i.p. or 1g/kg BW D-cysteine p.o. increased the AQP11 mRNA expression. We then 
treated AQP11 hetero-mice with the D-cysteine p.o. daily for three days after the cisplatin 
i.p. The increase of BUN by cisplatin was attenuated.
Conclusions: The results suggests that AQP11 may play an important role in the 
development of cisplatin nephrotoxicity. The enhancing the AQP11 expression in the 
kidney will be a renoprotective strategy in cisplatin nephrotoxicity.
Funding: Government Support - Non-U.S.
FR-PO106
Development of a Model on Chronic SIADH: Effect of Water Challenge 
and Treatment on Behavior, Learning, Memory and Brain Edema 
Marta Tejedor, Ana Durán Vila, Carmen Grande, Margarita Fernández, Teba 
González, Maria Melendo, Ana Morales, Cristina Vila, Juan Carlos Jado, Ignacio 
Lizasoain, Alberto Tejedor Jorge.  Nephrology, Hospital_Gregorio_Marañon, 
Madrid, Spain.
Background: AIM: to develop a model on chronic SIADH and study the effects of 
acute water overload on behavior, brain edema and response to treatment.
Methods: We induced chronic SIADH by daily injection of ddAVP and water over a 3-5 
day period to balb-c mice. We induced acute on chronic SIADH by giving an acute i.p. water 
challenge of 5% of body weight. We assessed behavioral changes by filming spontaneous 
activity in cages and under controlled conditions in a Morris water maze. We studied brain 
edema by means of continuous Percoll gradients to fraction grey and white brain substance. 
We administered tolvaptan to evaluate their effects in the abovementioned conditions.
Results: ddAVP administration alone was able to induce significant changes in 
spontaneous behavior despite minimal changes in natremia (3mEq/l). These changes 
were earlier and more severe if a chronic water overload was given. Overall, learning and 
memory improved over time with training, measured by times of resolution (p=0.004) and 
trajectory (p=0.002) in a water maze. This was more evident in the control group than in 
the SIADH group (learning (p=0.06), memory (p=0.08)). The mean trajectory length to 
resolve the maze was 185±55 cm in the control group, 360±44 cm in SIADH with no acute 
water overload (p<0.05) and 808±94 cm in SIADH with an acute water challenge of 5% 
(p<0.05). Treatment with tolvaptan significantly shortens the length of the trajectory to 
nearly baseline values. The SIADH group who received a 5% water challenge developed 
significant brain edema which was reversed by tolvaptan. No significant changes were seen 
in animals who did not receive the water challenge. An acute water overload of 5% in SIADH 
was equivalent to a 10% one in controls, as shown by similar worsening in the water maze.
Conclusions: ddAVP injection alone is enough to induce subtle behavioral changes, 
even in the absence of significant hyponatremia. Acute on chronic SIADH significantly 
worsens brain edema and resolution of a water maze, and such changes can be reverted 
by tolvaptan.
FR-PO107
Warburg-Like Proliferation Underlies Lithium-Induced Nephrogenic 
Diabetes Insipidus  Theun de Groot, Peter M.T. Deen, Mohammad Alsady. 
Dept of Physiology, Radboud Univ Medical Center, Netherlands.
Background: Lithium is the first-choice medication for treatment of bipolar disorders 
and is used by 0.1% of the western population. Unfortunately, lithium treatment is associated 
with development of severe renal side effects. In approximately 50% of treated patients, 
lithium causes a urinary concentrating defect, which develops in ~20% of patients into 
symptomatic Nephrogenic Diabetes Insipidus (NDI). This disorder is characterized by 
polyuria and polydipsia and is caused by downregulation of AQP2 water channels in 
principal cells of the renal collecting duct. Furthermore, lithium induces proliferation of 
these cells in vitro and in vivo. Cell proliferation is often characterized by aerobic glycolysis 
(Warburg effect). Here, we investigated whether lithium may induce Warburg-like aerobic 
glycolysis and whether inhibition of this Warburg effect may rescue lithium-induced-NDI 
(Li-NDI).
Methods: Polarized mouse cortical collecting duct (mpkCCD) cells were cultured 
as a 2D transwell model and exposed to lithium chloride on the apical side (10 mM) and 
basolateral side (1 mM) to mimic clinical conditions in patients. C57BL6/J mice were fed 
a normal rodent diet or a diet with lithium chloride in a concentration of 40 mmol/kg of 
chow. During the last 48 hours of the experiment, mice were housed in metabolic cages 
in order to determine water intake and urine output/osmolality during the last 24 hours.
Results: Lithium induced proliferation of mpkCCD cells as shown by increased levels 
of the proliferation markers PCNA and cyclin D1. In addition, lactate and succinate, main 
products of the Warburg effect, were both increased in lithium-treated mpkCCD cells and 
mice. This was accompanied by a decrease in the ratio of phospho-pyruvate dehydrogenase 
pPDH/PDH, confirming the induction of aerobic glycolysis by lithium in mice. Interestingly, 
inhibition of lithium-induced glycolysis with 2-deoxyglucose (2DG) attenuated lithium-
induced AQP2 downregulation in mpkCCD cells.
Conclusions: Our results reveal that lithium induces aerobic glycolysis in mpkCCD 
cells and mice. Targeting of aerobic glycolysis with 2-deoxyglucose rescued lithium-induced 
AQP2 downregulation and may represent a potential therapy for Li-NDI.
Funding: Government Support - Non-U.S.
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FR-PO108
RNA-seq Profiling of the Cortical Collecting Duct in Vasopressin Escape 
Jae Wook Lee,1 Carolyn M. Ecelbarger,2 Mark A. Knepper.1  1NHLBI, NIH, 
Bethesda, MD; 2Georgetown Univ, Washington, D.C.
Background: Vasopressin escape is a protective mechanism that limits hyponatremia 
in the syndrome of inappropriate antidiuresis (SIADH). Using RNA-seq, we investigated 
transcriptomic changes in microdissected cortical collecting duct (CCD) of rats undergoing 
vasopressin escape.
Methods: Male Sprague-Dawley rats (120-160 g) were placed on continuous dDAVP 
(5 ng/hr) infusion for 5 days, and received either a high water load (50 mL/d, “escape”) 
or a normal water load matching insensible losses plus urine output (25 mL/d, “control”). 
Rats were sacrificed at day 1, 2, and 4, and 4 mm of CCDs were collected by manual 
microdissection. RNAs were processed into cDNA libraries and 50-bp paired-end reads 
were obtained using an Illumina platform. Reads mapping to Ensembl genes were counted 
for differential-expression analysis.
Results: Sequence depths were 40-65 million reads, with 80% of reads mapping to 
Ensembl genes. At day 2, 180 transcripts were downregulated and 339 transcripts were 
upregulated at a false discovery rate < 0.1. Consistent with increased water excretion 
in vasopressin escape, transcripts of aquaporin-2 and aquaporin-3 were significantly 
downregulated at day 1, 2 and 4. Among downregulated transcripts were transcription 
factors (Hes1, Hmx2, Hoxb5, Hoxb6, Hoxb7, Jun, and Tox3) and a cyclin-dependent 
kinase inhibitor (Cdkn1b). Among upregulated transcripts were proteins involved in cell 
division, such as centromere proteins (Cenpa, Cenpf, Cenpl, and Cenpt); cyclins (Ccna2, 
Ccnb2 and Ccdn1); a cyclin-dependent kinase (Cdk1); components of DNA replication 
machinery (Pold3 in DNA polymerase complex; Mcm2, Mcm3, Mcm4, Mcm6, and Mcm7 
in MCM replicative helicase complex; Orc5 in origin recognition complex); polo-like 
kinase 1 (Plk1); and forkhead box protein M1 (Foxm1). GO terms related to cell division 
were enriched in upregulated transcripts (“cell cycle phase”, adjusted p=8×10-23; “mitosis”, 
2×10-13). Immunohistochemistry showed PCNA-positive cells in CCD of escape rats but 
none in control rats.
Conclusions: RNA-seq revealed that increased rate of cell division may be an activated 
mechanism involved in remodeling of the CCD to restore water homeostasis as a part of 
the renal adaptation to SIADH.
Funding: Other NIH Support - Division of Intramural Research, NHLBI Projects 
ZIA-HL001285 and ZIA-HL006129
FR-PO109
Silencing of the Kinome Identifies a Novel Modulator of Aquaporin-2 
Trafficking  Hana Cernecka,1 Dorte Faust,1 Kerstin Zuehlke,1 Marc Wippich,2 
Katina Lazarow,2 Martin Neuenschwander,2 Jens Peter von Kries,2 Enno 
Klussmann.1  1Anchored Signalling, Max Delbrück Center for Molecular 
Medicine in the Helmholtz Association, (MDC), Berlin, Germany; 2Leibniz-Inst 
für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany.
Background: Arginine vasopressin (AVP)-dependent water reabsorption requires the 
redistribution of aquaporin-2 (AQP2) from intracellular vesicles into the plasma membrane 
of renal principal cells. Despite identification of several proteins participating in the 
control of AVP-dependent AQP2 trafficking, the molecular mechanisms underlying the 
AQP2 redistribution are largely unknown. The aim of this study was to identify proteins 
controlling the localization of AQP2 and thereby to elucidate molecular mechanisms 
underlying the AQP2 translocation.
Methods: We established a large-scale siRNA screening using mouse collecting 
duct cells, stably expressing human AQP2. The expression of 719 kinases was knocked 
down and the AQP2 localisation was analysed by automated immunofluorescence 
microscopy. Generated images were analysed automatically to quantitatively evaluate 
cellular phenotypes in an unbiased approach by utilizing CellProfiler. Machine learning 
in combination with advanced statistical and computational techniques were applied.
Results: The screening revealed 13 genes whose expression was relevant for the AQP2 
redistribution. One of them is a recently identified member of the cyclin-dependent kinase 
family. Its knockdown blocks the AQP2 translocation and simultaneously increases the 
AQP2 protein abundance.
Conclusions: Our approach contributes to understanding the molecular mechanisms 
underlying the control of AQP2 trafficking and to identify potential therapeutic targets 
for the treatment of diseases caused by or associated with aberrant AVP-mediated water 
reabsorption such as diabetes insipidus or heart failure.
Funding: Government Support - Non-U.S.
FR-PO110
The Circadian Clock in the Kidney Controls Several Essential Metabolic 
Pathways  Svetlana Nikolaeva,1,2 Camille Ansermet,1 Gabriel Centeno,1 Robert 
Koesters,3 Sylvain Pradervand,4 Olivier Bonny,1,5 Dmitri Firsov.1  1Pharmacology 
and Toxicology, Univ of Lausanne, Lausanne, Switzerland; 2Sechenov Inst of 
Evolutionary Physiology and Biochemistry, St. Petersburg, Russian Federation; 
3Univ Pierre et Marie Curie, Paris, France; 4Genomic Technologies Facility, 
Univ of Lausanne, Lausanee, Switzerland; 5Service of Nephrology, CHUV, 
Lausanne, Switzerland.
Background: The circadian clock is the central mechanism for regulating body 
metabolism and energy homeostasis. However, the role of the intrinsic renal circadian 
system in the control of renal and/or systemic metabolic pathways remains elusive.
Methods: A combined metabolomic/transcriptomic approach was performed on plasma 
or kidney tissue samples obtained from mice devoid of the molecular clock in renal tubular 
cells (Bmal1lox/lox/Pax8-rtTA:LC1Cre mice/ cKO mice).
Results: We found that cKO mice exhibit significant changes in several essential 
metabolic pathways, including (i) increased renal arginine production resulting in the 
increased plasma arginine and asymmetric dimethylarginine levels; (ii) significantly 
increased arginase activity in the PST resulting in the increased renal polyamines production 
and increased plasma urea levels; (iii) increased plasma levels of several phosphatidylcholine 
and sphingomyelin species; and (iv) a significant reduction in plasma carnitine levels, 
paralleled by a significant decrease in the expression levels of Slc22a5 (OCTN2) transporter 
involved in the apical carnitine reabsorption in the proximal tubule. Transcriptome analysis 
revealed a significant reduction in expression levels of all transcripts encoded by the 
mitochondrial genome as well as of a great number of nuclear transcripts encoding proteins 
involved in the mitochondrial oxidative phosphorylation. In parallel kidneys from cKO 
mice exhibited a significant decrease in the NAD/NADH ratio suggesting an increased 
glycolysis and/or decreased mitochondrial function.
Conclusions: These results suggest that the local renal circadian clock control a variety 
of metabolic processes both on the intra-renal and systemic levels.
Funding: Government Support - Non-U.S.
FR-PO111
Mouse Monocarboxylate Transporter 9 Functions as a Urate Transporter 
Promsuk Jutabha, Naoyuki Otani, Motoshi Ouchi, Naohiko Anzai.  Dept of 
Pharmacology and Toxicology, Dokkyo Medical Univ School of Medicine, 
Mibu, Tochigi, Japan.
Background: Monocarboxylate transporter 9 (MCT9/SLC16A9) has been suggested 
to be involved in the onset of hyperuricemia or gout by genome-wide association studies 
(GWAS). Since no experimental data about MCT9 function has been reported, we tried to 
clarify its physiological roles.
Methods: The expression of SLC16A9 was investigated by quantitative RT-PCR 
(qRT-PCR) against human tissue cDNAs. Using oocyte expression system, we injected 
mouse MCT9 (mMCT9) cRNA to perform the functional characterization of mMCT9.
Results: qRT-PCR showed that the mRNA expression of MCT9 is quite higher in 
kidney than other tissues. Its expression is also found in spleen, ovary, pancreas, prostate 
and testis. Xenopus oocytes expressing mMCT9 mediated the transport of [14C]urate in 
Na+-, Cl-- and voltage-independent manner. Radiolabelled urate uptake via mMCT9 was not 
inhibited by 2.5 mM unlabelled urate and was not trans-stimulated by intracellularly-injected 
monocarboxylates (counterions for URAT1) nor dicarboxylates (counterions for OATs).
Conclusions: Here, we suggested, for the first time, that MCT9 functions as a low 
affinity urate facilitatory transporter in kidneys.
Funding: Government Support - Non-U.S.
FR-PO112
Mutation in the Creatine Transporter MCT12 Causes Low Plasma Level 
and Increased Fractional Excretion of Guanidinoacetate but Not Glucosuria 
Nasser Dhayat,1 Alexandre Simonin,1 Giuseppe Albano,1 Ganesh Pathare,1 
Christine Deisl,1 David Mordasini,1 Bruno Vogt,1 Barbara Kloeckener,3 Daniel 
G. Fuster.1  1Div of Nephrology, Hypertension and Clinical Pharmacology, 
Univ of Bern, Bern, Switzerland; 2Inst of Medical Molecular Genetics, Univ of 
Zürich, Zürich, Switzerland.
Background: A heterozygous mutation (c.643C>A; p.Q215X) in the creatine 
transporter gene MCT12 (also known SLC16A12) was recently identified as the cause of a 
syndrome with juvenile cataracts, microcornea and glucosuria in a single family. While the 
MCT12 mutation co-segregated with the eye phenotype, poor correlation with the glucosuria 
phenotype questioned a pathogenic role of the mutation in the kidney.
Methods: We undertook a detailed phenotypic investigation of the index family and 
performed complementary in vitro studies.
Results: Here we show that MCT12 resides on basolateral membranes of proximal 
tubules. Patients with MCT12 mutation exhibit reduced plasma levels and increased 
fractional excretion of guanidinoacetate, but normal creatine levels, suggesting that 
MCT12 may function as a guanidinoacetate transporter in vivo. However, functional 
studies in Xenopus oocytes revealed that MCT12 transports creatine but not its precursor 
guanidinoacetate. This indicates that impaired MCT12-mediated cellular creatine efflux 
affects guanidinoacetate homeostasis indirectly, e.g. by an increase of the cellular creatine 
concentration, which is known to inhibit guanidinoacetate synthesis. Genetic analysis 
revealed a separate, hitherto undescribed heterozygous mutation in SGLT2 (c.265G>A; 
p.A89T) in the family that segregated with the renal glucosuria phenotype. When 
overexpressed in HEK293 cells, the mutant SGLT2 transporter is not efficiently translocated 
to the plasma membrane and displays greatly reduced transport activity.
Conclusions: Our data indicate that MCT12 functions as basolateral exit pathway for 
creatine in the proximal tubule. Heterozygous mutation of MCT12 affects systemic levels 
and renal handling of guanidinoacetate. Furthermore, our data reveal the presence of a 
digenic syndrome in the index family with simultaneous MCT12 and SGLT2 mutation. 
Thus, glucosuria is not part of the MCT12 mutation syndrome.
Funding: Government Support - Non-U.S.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
382A
J Am Soc Nephrol 26: 2015 Hypertension: Basic Poster/Friday
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NaDC1 Knockout: Effects on Blood Pressure and Urine pH 
Federico Jose Teran,1 Weitao Huang,1 L. Lee Hamm,1,2 Kathleen S. 
Hering-Smith.1  1Nephrology, Tulane Univ School of Medicine, New Orleans, 
LA; 2Research, SLVHCS, New Orleans, LA.
Background: NaDC1 reabsorbs filtered citrate (Cit); thus its regulation is important 
in preventing calcium nephrolithiasis. Importantly NaDC1 reabsorbs other Krebs cycle 
intermediates such as succinate (Suc) and αKG. Recently Suc and αKG have been found 
to be important in paracrine signaling as their luminal presence stimulates distal nephron 
G-protein coupled receptors GPCR91 and GPCR99 respectively. Luminal Suc via GPCR91 
has been found to stimulate renin release; while αKG via GPCR99 stimulates bicarbonate 
secretion by type B intercalated cells. The purpose was to determine whether knockout 
of NaDC1 produces hemodynamic or urine pH changes that might be anticipated by 
activation of these receptors.
Methods: Adult NaDC1 KO, heterozygous (Het), and wild-type mice (WT), under 
normal or acid diet for 72 hr, were studied using standard clearance techniques. After 
anesthesia direct measurements of hemodynamic parameters were determined in real 
time. Urine, blood and tissue were collected for measurement of Suc, Cit, αKG, and pH.
Results: NaDC1 KO produced 2, 4, and 10-fold increases in urinary Suc, Cit, and 
αKG, respectively. There was substantial residual reabsorption of Cit and Suc in KO 
mice, indicating other transporters involved in reabsorption of these substrates. Despite 
the increase in urinary αKG there was no significant increase in urine pH (normal or acid 
diet); in fact on normal diet urine pH was lower in KO mice (5.41 ± 0.04 vs 5.90 ± 0.13 
WT; p < 0.001). The lower urine pH in KO mice on normal diet may be a response to loss 
of potential bicarbonate in the form of increased Krebs cycle intermediate excretion. There 
was no change in the ability of KO animals to excrete ammonia. In regard to potential 
hemodynamic effects mediated by NaDC1 KO and increased urinary Suc, no change in 
MAP was determined comparing WT, Het or KO either on normal or acid diet.
Conclusions: In sum, NaDC1 is responsible for significant reabsorption of filtered 
αKG and Suc, but knockout of NaDC1 does not impair acid-base homeostasis or BP 
changes on normal or acid diets.
Funding: NIDDK Support
FR-PO114
The Ablation of Dendritic Cells Prevents the Upregulation of the Intrarrenal 
Renin-Angiotensin System and Renal Sodium Transporters in Response 
to Angiotensin II and High Salt Diet  Patricio A. Araos,1 Daniel E. Hevia,1 
Carolina E. Prado,2 Eugenia L. Fuentes,1 Rodrigo Pacheco,2 Luis F. Michea.1 
1Univ de Chile, Chile; 2Fundación Ciencia y Vida, Chile.
Background: Blood pressure depends on the renal sodium reabsorption mediated 
by the tubular transporters that are modulated by the intrarenal renin–angiotensin system 
(iRAS). Angiotensin II (AngII) and a high salt diet (HS) cause hypertension (HT) and the 
upregulation of the iRAS and sodium transporters. Our previous studies showed that the 
ablation of Dendritic Cells (DC) in mice prevented the development of HT in response to 
AngII+HS. In the present study, we evaluated if the ablation of DCs alters the modulation 
of the iRAS and tubular sodium transporters by AngII+HS.
Methods: CD11c.DOG mice, for selective loss of DCs (CD11cHi) cells after Diphteria 
Toxin (DT) injection, received vehicle, AngII+HS (AngII, 450 mg Kg/day+1% NaCl in 
drinking water) or AngII+HS+DT (DT, 8ng/g) during 14 days; Paired WT mice received 
vehicle, AngII+HS or AngII+HS+DT. We measured blood pressure (days 0, 4, 8, 14), 
and at day 14 we harvested tissues to measure the abundance of renal DCs (MHC-II+ 
and CD11c+) by inmunofluoresce, the iRAS, the sodium-proton exchanger 3 (NHE3), the 
sodium-chloride cotransporter (NCC) and the Epithelial Sodium Channel (αENaC) by 
qRT-PCR and Western blot.
Results: The injection of DT prevented the development of HT in response to AngII+HS 
only in CD11c.DOG mice. CD11c.DOG and WT mice showed increased abundance of 
DCs in the cortex (peritubular); Only the CD11c.DOG mice showed a sharp reduction of 
renal DCs after DT injection. Both, in WT as in CD11c.DOG mice the administration of 
AngII+HS increased the iRAS (in fold of induction: Angiotensinogen, 1.5; Angiotensin 
converting enzyme, 1.9; and Angiotensin II receptor type I, 5), NHE3, NCC and αENaC 
(in fold of induction: 4.2; 6; 2), respectively vs vehicle–treated mice (p<0.05; n=5-9). The 
injection of DT concomitant to AngII+HS prevented the changes in sodium transporters 
and iRAS in CD11c.DOG mice (p<0.05 compared to AngII+HS; n=5-9).
Conclusions: We conclude that DCs are required for the modulation of iRAS and 
tubular sodium transporters by AngII+HS. 
Funding: FONDECYT1130550, IMII P09-016-F.
FR-PO115
Splenectomy Differentially Affects Angiotensin-II and L-NAME Murine 
Models of Hypertension  Joseph C. Gigliotti, Sylvia Cechova, Thu H. Le. 
Univ of Virginia.
Background: The immune system plays a major role in animal models of hypertension 
(HTN) and end-organ damage. However, few studies have assessed the role of lymphoid 
organs in the pathogenesis of HTN. We have shown previously that prior splenectomy 
(SPLX) significantly alters tissue inflammation; however the effect of SPLX on HTN 
remains unclear. Therefore, the objective of the current study is to determine whether prior 
SPLX influences the development of HTN in 2 different mouse models.
Methods: Mice underwent SPLX or sham surgery 7 days prior to the induction of HTN 
using angiotensin-II (AngII, 400ng/kg*d) or nitric oxide synthase inhibition using L-NAME 
(30mg/kg*d). Systolic blood pressure (SBP) was measured by tail-cuff manometer daily and 
mice were euthanized 14 days after induction of HTN. Heart weight/body weight (H/BW) 
ratios were calculated and kidney leukocyte infiltration was analyzed by flow cytometry.
Results: Mice with prior SPLX+AngII had significantly lower (P=0.03) SBP at both 
week 1 (148±7) and week 2 (135±7) as compared to Sham+AngII (174 and 173±7mmHg). 
Similarly, SPLX+AngII mice had significantly smaller (P=0.007) H/BW (4.3±0.3) as 
compared to Sham+AngII treated mice (5.2±0.4mg/g BW). Interestingly, no difference was 
observed in renal CD45+ (9.8±3 vs 10.6±3x105 cells/g, P=0.64) or CD3+ T-cell infiltration 
(8.8±0.2 vs 9.6±0.1x104 cells/g, P=0.64) between the Sham+AngII and SPLX+AngII 
treated mice, respectively. Furthermore, SPLX did not appear to influence the development 
of L-NAME HTN. SPLX+L-NAME mice had similar P=0.84) SBP (145±4mmHg) as the 
Sham+L-NAME group (146±4mmHg, n=6) after 2 weeks. Relative heart weights were 
also similar (P=0.45) between SPLX+L-NAME (4.9±0.2) and Sham+L-NAME treated 
mice (4.8±0.3mg/g BW).
Conclusions: Our data suggests that the full pressor response to AngII is dependent 
on the spleen. However, the effect of the spleen appears to be independent of renal 
inflammation. Moreover, the protective effect of the spleen is specific to AngII-dependent 
HTN and does not appear to be generalizable to all mouse models of hypertension. Further 
studies are needed to understand the physiological link between lymphoid organs (such as 
the spleen), renal inflammation, and the development of chronic HTN.
FR-PO116
Salt Overload Promotes Severe Renal Injury and Activates AngII, Renal 
NF-κB and Other Components of Innate Immunity in a Model of Arterial 
Hypertension  Victor F. Avila, Orestes Foresto-Neto, Simone CA Arias, Camilla 
Fanelli, Flavia G. Machado, Mariliza V. Rodrigues, Claudia R. Sena, Viviane 
D. Faustino, Lisienny CT Rempel, Gizely CS Moreira, Vivian L. Viana, Denise 
M. Malheiros, Jose E. Krieger, Roberto Zatz, Clarice K. Fujihara.  Univ of São 
Paulo, São Paulo, Brazil.
Background: Hypertension (HTN) develops in rats that received the NF-κB inhibitor 
pyrrolidinedithiocarbamate (PDTC) during lactation. High salt (HS) and uninephrectomy 
(UNx) aggravate HTN, increase renal AngII and lead to severe renal injury. Here, we further 
investigated the mechanisms of renal injury and the effect of Losartan (L) in this model.
Methods: Munich-Wistar pups received PDTC (PDTClact) or no treatment (C) 
during lactation. At 10 wks of age, all rats underwent UNx and were divided in: C, given 
normal salt diet (NS); PDTClact, given NS; PDTClact+HS, given HS; PDTClact+HS+L, 
given HS and L, 50 mg/kg/d. After 3 mo, we assessed: tail-cuff pressure (TCP, mmHg), 
glomerulosclerosis (GS), interstitial collagen 1 (COL), arteriolar lesions (AL), interstitial 
AngII+, macrophages (Mø) and lymphocytes (Ly), cells/mm2, TLR4 and nuclear NF-ȀB 
(x C), and serum IL-6 (pg/mL).
Results: 
C PDTClact PDTClact+HS PDTClact+HS+L
TCP 144±2 167±3a 195±4ab 163±5ac
GS% 2±1 1±1 12±2ab 7±2abc
AL% 0±0 1±1 17±5ab 10±4ab
AngII+ 2±1 2±1 7±1ab 4±1abc
Mø 33±3 34±4 140±21ab 42±7c
Ly 37±3 43±4 141±25ab 65±8abc
COL% 2.8±0.2 2.8±0.4 7.3±1.2ab 3.5±0.5c
NF-κB 1.0±0.2 1.7±0.4 2.6±0.5a 0.9±0.3c
IL-6 23±3 32±3 40±4a 28±1c
TLR4 1.0±0.1 1.5±0.4 2.9±0.7ab 0.9±0.2c
Mean±SE, ap<0.05 vs C, bp<0.05 vs PDTClact, cp<0.05 vs PDTClact+HS 
HS+UNx led to severe HTN and renal/vascular injury, intense Mø/Ly infiltration, 
increased AngII+ and TLR4, and NF-κB activation, with increased plasma IL-6, all 
correlating positively with TCP. L strongly attenuated renal damage, normalizing renal 
TLR4, renal NF-κB and plasma IL-6.
Conclusions: In PDTClact, renal injury caused by HS+UNx involves activation of renal 
AngII and innate immunity, including the NF-κB system. FAPESP/CNPq.
FR-PO117
Interleukin-6 Inhibition Attenuates Hypertension and Proteinuria in Dahl 
Salt-Sensitive (SS) Rats  Shireen Hashmat,1 Justine M. Abais-Battad,2 Hayley 
Lund,2 Scott K. Van Why,1 David L. Mattson.2  1Pediatrics, Medical College of 
Wisconsin; 2Physiology, Medical College of Wisconsin, Milwaukee, WI.
Background: The infiltration of T lymphocytes in the kidney accompanies hypertension 
and renal damage in Dahl SS rats. Pharmacological or genetic reduction of T cells attenuates 
hypertension and renal damage in SS rats fed high salt. An examination of the infiltrating 
T cells in the kidney demonstrated that interleukin 6 (IL-6) mRNA levels are >50-fold 
higher in T cells isolated from the kidney in comparison to circulating T cells. IL-6 is 
a pro-inflammatory cytokine which positively correlates with hypertension in humans.
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Methods: Experiments were performed to assess the potential role of IL-6 in Dahl SS 
hypertension by administering goat anti-rat IL-6 neutralizing antibody (anti-rIL-6; 4 µg /day, 
IP; R&D Systems, Minneapolis, MN) or normal goat IgG control (4 µg/day, IP) for 11 days.
Results: The MAP and urine protein excretion rates (Upro) were similar between 
the groups of SS rats (n=13-16/group) when fed low salt (0.4% NaCl) chow. Following 
11 days of high salt (4.0% NaCl), the rats receiving anti-rIL-6 demonstrated a significant 
reduction in immunoreactive IL-6 in the renal medulla compared to control group (954±133 
pg/ml vs 1802±336 pg/ml). Moreover, the increase in MAP following 11 days of 4.0% 
NaCl intake was significantly attenuated in treated (MAP=138±3 mmHg) vs the control 
group (MAP=149±3 mmHg). The Upro as a marker of renal damage was also significantly 
attenuated in treated (193±17 mg/day) vs control group (252±20 mg/day). To investigate 
mechanisms of action, a flow cytometry analysis of infiltrating immune cells in the kidney 
(n=4-5/group) was performed. The total number of leukocytes (CD45+) was significantly 
lower in the treated vs the control group averaging 4.8±0.5x106 vs 6.8±0.5x106 cells/kidney. 
The total number of monocytes and macrophages (CD11b/c+) was significantly lower in 
the treated vs the control group by 31%. The total number of T cells and T regulatory cells 
were not different among the groups.
Conclusions: The present studies indicate that IL-6 may participate in the development 
of SS hypertension and end-organ damage by mediating the infiltration of leukocytes into 
the kidney.
FR-PO118
High Salt Affects Toll-Like Receptor-Induced Gene Expression in 
Macrophages  David Severs, Martin Hoogduijn, Alexander H. Danser, Robert 
Zietse, Ewout J. Hoorn.  Internal Medicine, Erasmus Medical Center, Rotterdam, 
Netherlands.
Background: High dietary salt intake is a major risk factor for cardiovascular disease. 
A high-salt (NaCl) diet increases NaCl concentrations in the skin. In the skin, macrophages 
respond to high NaCl by the osmosensitive transcription factor NFAT5 and promote NaCl 
efflux via lymph vessels. Other effects of NaCl on local macrophages have remained largely 
elusive. Recent evidence suggests that NFAT5 also regulates multiple Toll-like receptor 
(TLR)-induced genes such as NOS2, TNF and IL6 in macrophages, independently of 
osmotic stress. We aimed to investigate the effects of NaCl-generated hypertonicity on 
the expression of these genes in TLR-activated macrophages.
Methods: We simulated the hypertonic skin microenvironment by culturing 
macrophage-like RAW 264.7 cells in NaCl-induced hypertonic media (340-480 mOsm/
kg) and compared this with normotonic media (320 mOsm/kg). After 1 to 24 hours of 
stimulation with lipopolysaccharide (LPS) or Zymosan A, a TLR2 ligand, we measured 
nitrite production, and analyzed TLR response genes by quantitative RT-PCR, and p38-
MAPK, NFAT5, and NOS2 by immunoblot.
Results: NaCl significantly and dose-dependently increased nitric oxide (NO) 
production (2-fold), NOS2 mRNA (3-fold) and NOS2 protein expression (2.25-fold) in 
LPS- and Zymosan A-stimulated cells. In contrast, equiosmolar mannitol or urea did not 
affect expression levels. NaCl also increased LPS-induced p38 phosphorylation and total 
NFAT5 protein expression. Similarly, NaCl increased TNF mRNA expression 1.25-fold. 
Remarkably, NaCl significantly downregulated LPS-induced expression of CCL5 (4-fold), 
IL6 (2.4-fold) and IL12b mRNA (3.5-fold).
Conclusions: Elevated concentrations of NaCl, comparable with those found in the 
skin after high dietary salt intake, amplify expression of NOS2 and TNF in TLR-stimulated 
macrophages. This effect is likely mediated via p38 and NFAT5. Increases in NOS2 and TNF 
expression were paralleled by a sharp decline in mRNA expression of other proinflammatory 
genes. Modulation of TLR-mediated macrophage activation by NaCl may be relevant both 
for the physiological response to high dietary salt and salt-sensitive hypertension.
FR-PO119
Indoxyl Sulfate Upregulates Aortic Expression of (Pro)renin Receptor by 
Reactive Oxygen Species and Activation of AhR/NF-κB Pathway in Vascular 
Smooth Muscle Cells  Maimaiti Yisireyili,1 Toshimitsu Niwa.2  1Cardilogy, 
Nagoya Univ Graduate School of Medicine, Nagoya, Aichi, Japan; 2Faculty of 
Health and Nutrition, Shubun Univ, Ichinomiya, Aichi, Japan.
Background: Chronic kidney disease (CKD) is considered major causes of death in 
cardiovascular disease (CVD) patients. (Pro)renin receptor (PRR) is significantly expressed 
in the kidney of CKD and vascular system. In this study we aimed to clarify the role of 
indoxyl sulfate (IS), a uremic toxin, in PRR activation in rat aorta and human aortic smooth 
muscle cells (HASMCs).
Methods: CKD rats and IS-administrated rats were subjected for in vivo experiments. 
Human aortic smooth muscle cells (HASMCs) was treated with or without indoxyl sulfate.
Results: Immunohistochemistry showed increased expression of PRR and renin/
prorenin in aorta of CKD rats and IS-administrated rats compared with normal rats. IS 
elevated the expression of PRR and prorenin in HASMCs. N-acetylcysteine, an antioxidant, 
and diphenyleneiodonium, an inhibitor of nicotinamide adenine dinucleotide phosphate 
oxidase, suppressed IS-induced expression of PRR and prorenin in HASMCs. Knock 
down of organic anion transporter 3 (OAT3), aryl hydrocarbon receptor (AhR) and nuclear 
factor-κB p65 (NF-κB p65) with small interfering RNAs inhibited IS-induced expression of 
PRR and prorenin in HASMCs. Knock down of PRR inhibited cell proliferation and tissue 
factor expression induced by not only prorenin but also IS in HASMCs.
Conclusions: IS promotes aortic expression of PRR and renin/prorenin through OAT3-
mediated uptake, production of reactive oxygen species, and activation of AhR and NF-κB 
p65 in vascular smooth muscle cells.
FR-PO120
Role of Skin and Endothelial Surface Layer Heparan Sulfates in Blood 
Pressure Regulation  Rik Hg Olde Engberink,1 Naomi Van Vlies,2 Bert-jan 
Van den Born,3 Ed van Bavel,4 Liffert Vogt.1  1Nephrology, AMC, Amsterdam, 
Netherlands; 2Laboratory of Genetic Metabolic Disease, AMC, Amsterdam, 
Netherlands; 3Vascular Medicine, AMC, Amsterdam, Netherlands; 4Biomedical 
Engineering and Physics, AMC, Amsterdam, Netherlands.
Background: Besides the skin, the endothelial surface layer (ESL) contains many 
glycosaminoglycans (GAGs) that can osmotically inactivate Na+ and may affect blood 
pressure (BP). EXT genes regulate heparan sulfate (HS) polymerization, the predominant 
ESL GAG. In mice with heterozygous loss of EXT1 and EXT2 (EXT), and wildtype (WT) 
mice, we investigated the role of HS in the skin and ESL in BP regulation after an acute 
and chronic NaCl load.
Methods: We investigated BP effects of a 7-d normal (0.3%, NSD) and high (8.0%, 
HSD) NaCl diet, with tail cuff measurements, and an acute 1.8% NaCl load (8 µl/g) with 
intracarotid measurements. We used intravital microscopy to estimate ESL thickness in <40 
µm cremaster vessels on both diets. We used high performance liquid chromatograph-mass 
spectrometry to measure skin HS disaccharide concentration.
Results: Baseline BP was equal in WT and EXT mice (p=0.9), with no difference 
between NSD and HSD. Relative to WT, acute NaCl infusion increased BP in EXT mice 
(p=0.02), while heart rate remained equal (p=0.5). After a NSD and HSD, EXT mice had 
a 78% reduction of ESL thickness compared to WT mice (Fig A). HSD increased ESL 
thickness in WT, especially in 20-40 µm vessels, but not in EXT mice (Fig BC). Skin HS 
concentration and sulfation patterns were equal between diets in WT mice (Fig DE). On 
NSD, EXT mice had more highly sulfated HS compared to WT (Fig DE). EXT mice on a 
HSD had the highest skin HS concentration, of which most were low-sulphated. 
Conclusions: An intact ESL is pivotal to prevent a BP increase during acute NaCl 
excess. Skin GAGs may be particularly important to prevent detrimental NaCl effects on 
the long-term, especially when the ESL is damaged.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO121
Functional and Dynamic Microcompartmentation of Cav-1/TRPV4/KCa in 
Caveolae of Endothelial Cells  Andreas Hofmeister, Sybelle Goedicke-Fritz, 
Anuradha Kaistha, Ivica Grgic, Joachim Hoyer.  Dept of Internal Medicine and 
Nephrology, Philipps-Univ Marburg, Marburg, Germany.
Background: Ca2+-activated K+ channels (KCa) play an important role in the 
endothelium-dependent hyperpolarization and regulation of vascular tone and blood 
pressure. For activation, KCa depend on an increase of intracellular calcium which is largely 
mediated by Ca2+-permeable cation channels including the transient receptor potential 
V4 (TRPV4). It has been proposed that KCa and Ca2+-permeable cation channels may be 
clustered in localized positions within the cell membrane to form functional units and 
that caveolae may constitute the scaffolding for such microcompartmental organization.
Methods: Here, we sought to elucidate the composition and functional relevance of 
these microcompartments in vitro and in vivo.
Results: We show that TRPV4 and small-conductance KCa2.3 are enriched in caveolae 
of human microvascular endothelial cells. Using immunoprecipitation, immunocytology 
and superresolution microscopy, we found a caveolae-dependent association between 
caveolin-1, TRPV4 and small conductance KCa2.3, but not intermediate conductance KCa3.1, 
in endothelial cells under static condition. Mechanical stimulation of cells via exposure to 
shear stress led to a partial de-novo colocalization of KCa3.1 with Cav-1 and TRPV4. In a 
mouse model of genetic Cav-1 deficiency, we found significantly reduced KCa-mediated 
currents as determined by patch-clamping in carotid artery endothelial cells (CAEC) from 
Cav-1-/- mice compared to wildtype. Functionally, Cav-1 deficiency was associated with 
impaired endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilation in 
response to shear stress and acetylcholine.
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Conclusions: In summary, our findings provide evidence for a dynamic 
microcompartmentation of TRPV4/KCa in caveolae of endothelial cells and highlight the 
importance of Cav-1 for endothelial KCa functions and flow-induced vasodilation.
Funding: Government Support - Non-U.S.
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Adenosine A1 Receptor Exacerbates Water-Sodium Retention in 
Deoxycorticosterone Acetate-Salt Hypertensive Mice  Janet Yanqing Mei,1 
Xiaoxiao Shi,1 Dongli Tian,1 Xiaoyan Peng,1 Wei Chen,2 Limeng Chen.1 
1Nephrology Dept, Peking Union Medical College Hospital, Beijing, China; 
2Cardiology Dept, Peking Union Medical College Hospital, Beijing, China.
Background: Water-sodium retention is the key change in salt sensitive hypertension. 
Adenosine A1 receptor (A1AR) engages in tubuloglomerular feedbacks; its activation is 
followed by increased secretion of atrial natriuretic peptides (ANP) in the heart. We aim 
to study the function of A1AR in water-sodium retention.
Methods: DOCA-salt hypertensive model was established by removal of left kidney, 
implantation of a DOCA pellet (200mg, 60-day release), and feeding with high salt diet 
(8%NaCl). Arterial blood pressure and heart rate were measured by tail-cuff method. 
Urine samples were collected using metabolic cage. The CD73 (an adenosine synthetase), 
A1AR, ANP and Corin (a protease cleaves pro-ANP, producing ANP) mRNA expression 
were measured by real-time PCR.
Results: Wildtype DOCA-salt mice showed higher blood pressure (124.7±20.3 vs. 
105.8±14.1 mmHg, P<0.01), slower heart rate (562.0±90.8 vs. 681.5±90.1, P<0.01), 
and increase in 24h urine output (3606±2359 vs. 1399±752 ml, P<0.01). The adenosine 
pathway was activated in DOCA-salt mice evidenced by increased CD73 (2.22 and 17.7 
times increased expression in kidney and heart, P=0.034 and 0.001) and A1AR expression 
(2.54 and 11.12 times increased expression in kidney and heart, P=0.032 and 0.009). The 
cardiac mRNA expression of ANP and Corin were also significantly higher in DOCA-salt 
mice (176.67 and 30.93 times increased expression, P=0.030 and 0.005). The A1AR-/- mice 
showed no significant changes in blood pressure or heart rate between DOCA-salt and sham 
group. The elevation in 24h urine output (7003±3742 vs. 3606±2359 ml, P=0.031) and 
24h urine sodium excretion (1246.5±860.0 vs. 149.7±48.9 mmol/d, P=0.028) was more 
prominent compared to wildtype DOCA-salt mice. There was no change in either ANP or 
Corin mRNA expression.
Conclusions: A1AR may exacerbate water-sodium retention in salt sensitive 
hypertension. The reduction in glomerular hyperperfusion and hyperfiltration through 
tubuloglomerular feedback possibly outweighs the up-regulation of Corin and subsequent 
ANP expression.
FR-PO123
Dietary Fructose Increases Renal Sympathetic Nerve Activity in Response 
to High Salt Diet in Awake Freely Moving Rats  Noreen F. Rossi,1,2 Kevin 
L. Gordish,1,3 Pablo A. Ortiz,1,3 William H. Beierwaltes.1,3  1Physiology, Wayne 
State Univ School of Medicine, Detroit, MI; 2Nephrology, John D. Dingell VA 
Medical Center, Detroit, MI; 3Hypertension Research, Henry Ford Health 
Systems, Detroit, MI.
Background: High consumption of fructose containing foods is increasingly prevalent. 
Fructose intake is associated with metabolic syndrome including hypertension. Fructose 
upregulates renal Na and Cl transport and induces neuroexcitation, both of which may 
increase blood pressure. Here we tested the hypothesis that fructose-fed rats fed a high salt 
diet will have higher plasma renin activity (PRA), renal sympathetic nerve activity (RSNA) 
and mean arterial pressure (MAP) than glucose-fed rats on similar diet.
Methods: Male Sprague Dawley rats were instrumented for telemetric MAP and 
RSNA measurements. They were placed on 20% glucose (GF) or 20% fructose (FF) in 
their drinking water and 0.4% NaCl diet for 10 days then switched to 4% NaCl diet with 
further monitoring. RSNA recordings were obtained using LabChart 7 Pro. Rats were also 
subjected to air jet stress and nasopharyngeal reflex testing.
Results: Baseline MAP was similar in both groups, but was 20 mmHg higher in FF 
vs GF rats after high salt diet (P < 0.05). Baseline integrated RSNA did not differ between 
GF and FF rats. RSNA decreased in GF rats to 0.961 ± 0.182 mV.s after high salt diet. In 
contrast, integrated RSNA increased from 1.199 ±0.245 to 1.600 ± 0.231 mV.s after high 
salt intake in FF rats (P < 0.05 vs high salt GF rats). Air jet stress and nasopharyngeal 
reflex responses in MAP and RSNA in GF rats were as expected and brief but in FF rats 
both responses were significantly greater and sustained for a longer period of time. High 
salt suppressed. PRA by only 40% in FF rats: 2.05 ± 0.27ng Ang I/ml/hr (high salt) vs 3.48 
± 0.45 ng Ang I/ml/hr (baseline; P < 0.05).
Conclusions: We found that the expected suppression of RSNA by high salt diet is 
completely reversed into stimulation with high fructose diet. The suppression of PRA by 
high salt diet is blunted and the response to acute stressors enhanced, thus suggesting 
increased RSNA is a critical component of fructose-induced salt-sensitive hypertension.
Funding: NIDDK Support, Veterans Administration Support
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A 20% Fructose Diet Enables Low Concentrations of Angiotensin II 
to Activate Sodium Transport in the PT via Protein Kinase C (PKC) 
Pablo D. Cabral, Jeffrey L. Garvin.  Physiology & Biophysics, Case Western 
Reserve Univ, Cleveland, OH.
Background: Consumption of high-fructose corn syrup is implicated in the 
development of hypertension but the mechanisms are poorly understood. The proximal 
tubule (PT) reabsorbs ~70% of the filtered fluid, Na and most of the bicarbonate via 
Na/H exchanger 3. Enhanced PT transport is implicated in many forms of hypertension. 
Angiotensin II (Ang II), atrial natriuretic peptide (ANP) and dopamine regulate Na transport. 
Enhanced effects of Ang II and decreased actions of ANP and dopamine in the PT may cause 
salt-sensitive hypertension. Hypothesis: A 20% fructose diet enables low concentrations of 
Ang II to activate Na transport in the PT via protein kinase C (PKC).
Methods: We isolated and perfused PTs from Sprague Dawley rats that were fed either 
a control or a 20% fructose diet for 1 week. NHE activity was measured as the recovery of 
intracellular pH after an NH4Cl acid pulse using the pH-sensitive dye BCECF. The rate of 
pH recovery was measured in Fluorescent Units per second (FU/sec).
Results: Ang II (10-12M) did not stimulate NHE under normal conditions. When rats 
were fed a 20% fructose diet, this concentration stimulated NHE activity from 0.6±0.1 to 
1.3±0.1 FU/sec (p<0.002;n=5). In the presence of the PKC inhibitor Gö6976 (10-7M), Ang II 
was unable to stimulate NHE activity (from 1.9±0.6 to 1.2±0.2 FU/sec;n=12). The dopamine 
1 receptor agonist fenoldopam (10-6M), decreased NHE activity to the same extent in PTs 
from rats fed either a control or a 20% fructose diet (-0.6±0.2 vs -1.1±0.4 FU/sec;n=5). 
ANP (10-8M) also decreased NHE activity to the same extent in PTs from rats fed either a 
4% NaCl diet or a 4% NaCl plus 20 % fructose diet (-0.9±0.4 vs -1.1±0.5 FU/sec;n=12).
Conclusions: A 20% fructose diet enables low concentrations of Ang II to activate Na 
transport in the PT via PKC without affecting the inhibitory effects of dopamine and ANP 
on NHE activity in the PT. These results may partially explain the mechanism by which a 
fructose diet induces hypertension.
Funding: NIDDK Support
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Megalin-Dependent Intrarenal Generation of Angiotensin II Induced by 
Podocyte Injury  Taiji Matsusaka,1 Fumio Niimura,1 Akira Nishiyama,2 Akihiko 
Saito,3 Motoko Yanagita,4 Iekuni Ichikawa.1,5  1Tokai Univ School of Medicine, 
Japan; 2Kagawa Univ School of Medicine, Japan; 3Niigata Univ School of 
Medicine, Japan; 4Kyoto Univ School of Medicine, Japan; 5Shinsyu Univ, Japan.
Background: We previously demonstrated that podocyte injury enhances glomerular 
filtration of liver-derived angiotensinogen (Agt) and renal angiotensin(A)II generation and 
that filtered Agt is reabsorbed by proximal tubular cells dependently on megalin. In the 
present study, we tested whether megalin is involved in intrarenal AII generation.
Methods: For this purpose, we generated proximal tubule specific megalin knockout 
(KO) mice by crossing megalin-loxP, Ndrg1-Cre, and Kap-Cre mice. Renal AII contents 
were measured by radioimmunoassay.
Results: In megalin KO mice (n=12), renal megalin mRNA was decreased to 2.5% of 
that in control mice (n=16). Renal Agt staining was markedly diminished, with increase in 
urinary Agt in KO mice. However, renal AII levels were similar between KO and control 
mice (108±11 vs. 101±17 fmol/g). We next tested the effect of megalin KO on AII generation 
in the kidney with abnormally increased filtered load of Agt in mice with podocyte-specific 
injury, by crossing with NEP25 mice. Control NEP25 mice (n=10) showed markedly 
intense renal Agt staining and enhanced renal AII level (450±61). Megalin KO/NEP25 
mice (n=12) showed diminished renal Agt staining and significantly attenuated renal AII 
level (119±23, p<0.01). KO/NEP25 mice showed similar renin and Agt mRNA, and more 
preserved Ace mRNA in the kidney.
Conclusions: These indicate that, in podocyte injury, abnormally increased filtered load 
of Agt is reabsorbed via megalin by proximal tubular cells and induces the inappropriate 
activation of intrarenal renin-angiotensin system, which may be involved in the progression 
of tubulointerstitial damage secondary to podocyte injury.
Funding: Government Support - Non-U.S.
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Ciliary Neurotrophic Factor Deficiency Protects from Cardiovascular 
Death in Angiotensin II-Induced Hypertension  Ivo Quack,1 Yuriko Mori,2 
Sebastian Alexander Potthoff,1 Magdalena Woznowski,1 Eva Koenigshausen,1 
Lorenz Sellin,1 Lars C. Rump,1 Johannes Stegbauer.1  1Nephrology, Univ 
Hospital Duesseldorf, Duesseldorf, Germany; 2Nuclear Medicine, Univ Hospital 
Duesseldorf, Duesseldorf, Germany.
Background: It has been shown that the JAK 2 / STAT3 signaling cascade modulates 
Ang II (Ang II)-dependent hypertension. The ciliary neutrophic factor (CNTF) is an 
interleukin-6-like cytokine so far known for mediation of survival and differentiation 
of neuronal cells via JAK2 / STAT3. This study focuses on the role of CNTF in Ang II-
dependent hypertension.
Methods: Two weeks after uninephrectomy, Ang II osmotic minipumps (1000 ng/
min/kg BW) were implanted in CNTF-KO and age-matched C57/Bl6J male mice (WT). 
Blood pressure (BP) were measured for 3 weeks by radiotelemetry, starting one week 
before implantation. Histological and mRNA analysis were performed at the end of the 
observation period. Renal vascular function was evaluated in the isolated perfused kidney.
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Results: At baseline systolic BPs were similar in CNTF-KO and WT mice (119±2 
vs.124±1 mmHg). CNTF deficiency significantly attenuated BP increase under Ang II 
infusion (week 1: 139±3 vs. 153±3 mmHg; week 2: 151±5 vs. 168±4 mmHg; n=19; P<0.01). 
Strikingly, in the CNTF-KO group signifcantly less animals died of cardiovasular causes 
(4,2% (KO) vs. 29,2% (WT P<0.05). In accordance, end organ damage (cardiac hypertrophy, 
renal vascular fibrosis and tubulo-interstitial damage) was attenuated in the CNTF-KO 
group. In the isolated perfused kidney, pressor response to Ang II was significantly attenuated 
in CNTF-KO mice. Administration of CNTF (0.5nM) nearly restored the Ang II dependent 
pressor response. This effect was mediated through a JAK2/STAT3 dependent pathway as 
static (0.1µM), a selective STAT3 inhibitor abolished the CNTF induced increase in pressor 
response in kidneys of CNTF-KO. On cellular basis, CNTF induced phosphorylation of 
STAT3 and MYPT in VSMCs.
Conclusions: Better survival and less end organ damage strongly suggest that CNTF 
has a major impact on blood pressure regulation. CNTF seems to modulate the Ang II 
induced vasoreactivity via a JAK2 / STAT3 dependent mechanism. Thus, CNTF might 
qualify as therapeutic target in hypertension.
Funding: Government Support - Non-U.S.
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Angiotensin II AT1 Receptor Potentiates Prostaglandin E2 Vasoconstrictor 
Effects  Maria Palazzo Kraemer,2 Fred S. Lamb,3 Richard M. Breyer.1  1Div of 
Nephrology and Hypertension, Dept of Veterans Affairs and Vanderbilt Univ, 
Nashville, TN; 2Dept of Biochemistry, Vanderbilt Univ, Nashville, TN; 3Dept of 
Pediatrics, Vanderbilt Univ, Nashville, TN.
Background: Prostaglandin E2 (PGE2) is a key modulator of blood pressure and arterial 
tone. It usually has vasodepressor effects however under certain circumstances can act as 
a vasopressor. Recent reports demonstrated that sub-threshold concentrations of KCl and 
phenylephrine augment PGE2-mediated constriction in rat femoral arteries, however the 
effects of angiotensin II (Ang II) on PGE2-mediated contraction are unknown.
Methods: Wire myography was performed on femoral arteries isolated from WT or 
EP deficient mice.
Results: PGE2 had no effect on mouse femoral arteries at doses up to 1 µM. Pretreatment 
of arterial rings with 1 nM Ang II potentiated PGE2-evoked constriction in a dose dependent 
manner (AUCuntreated 1.784±0.353, AUCAng II 23.27±9.820,P<0.05). To identify the relevant 
E-Prostanoid (EP) receptor, femoral arteries from EP1, EP2, and EP3 receptor null mice 
were tested. Arteries isolated from EP1-/- or EP2-/- but not EP3-/- mice responded to PGE2 
after Ang II priming. Pretreatment of arterial rings with 1 µM losartan, an AT1 angiotensin 
receptor antagonist, blocked PGE2-induced constrictor effects primed with Ang II (% KCl, 
Ang II 21.72 ± 5.296, Ang II + losartan 3.025 ± 1.046, n=3). No constriction was observed 
in Ca2+-free buffer; re-addition of extracellular Ca2+ to the arterial bath restored PGE2-
induced contractions (n=5). The Rho-kinase inhibitor Y-27632 blocked contraction (n=3).
Conclusions: Taken together these data are consistent with angiotensin AT1 and 
prostaglandin EP3 receptors mediating a synergistic Ca2+/Rho-kinase-dependent contractile 
response. The synergistic interaction of Ang II and PGE2 may have physiological relevance 
in the context of hypertension.
Funding: NIDDK Support, Veterans Administration Support
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Angiotensin II Increases Uromodulin Expression and Excretion in Rats 
Independent of Blood Pressure and Alterations in Tubular Reabsorption 
Magali Araujo, William J. Welch, Gabriel A. Cordeiro dos Santos, Daurea M. 
Vieira Paiva, Christopher S. Wilcox.  Medicine, Georgetown Univ, Washington, 
DC.
Background: Increased uromodulin (UMOD) has been associated with salt-sensitive 
hypertension and chronic kidney disease. Evidence suggests that UMOD regulates the 
trafficking and activity of the Na-K-2Cl cotransporter (NKCC2) and the inward-rectifier 
type potassium channel (ROMK), the two main transporters involved in Na+ reabsorption 
by the TAL. Angiotensin II (AngII) increases net TAL Na+ transport and Na+ apical entry; 
however its interaction with UMOD remains elusive. We hypothesized that ANG II interacts 
with UMOD to modulate Na+transport.
Methods: Sprague-Dawley rats (n=5) were infused with a subpressor dose of AngII 
(100ng/kg/min) or vehicle for 3 days. Blood pressure (BP) was measured by telemetry. 
On day 2, rats were placed in metabolic cages for 24 h and urine was collected for UMOD 
and Na/K measurements. On day 3, proximal and distal reabsorption were measured by 
renal micropuncture and the renal medulla was harvested for determination of UMOD 
expression by western blot.
Results: Blood pressure was unchanged after 3 days of AngII (veh: 89±3, AII: 
81±1mmHg). AngII treated rats had significantly increased UMOD excretion compared 
with control rats (Veh: 17.63± 2.19, AII: 28.09±3.6, mg/24h, p<0.05). Sodium excretion was 
unchanged (veh: 3.46±0.6 AII: 3.38±0.6 mmol/24h). There were no changes in proximal 
fractional reabsorption (Veh: 57±2%, AII: 59±0.6%) and distal fractional reabsorption 
(Veh: 83±3%, AII: 87±2%). UMOD expression in the renal medulla was 3 fold higher in 
AngII treated rats compared to vehicle rats.
Conclusions: Our data demonstrate that AngII increases UMOD expression and 
excretion independent of blood pressure and alterations in tubular reabsorption. These 
results suggest that the interaction of AngII with UMOD precedes Na+ transport alterations 
and therefore can be an important mechanism involved in the development of hypertension.
FR-PO129
Effects of Systemic Deletion of Angiotensin Receptor-Binding Molecule 
on the Aging Kidney  Kazushi Uneda, Kouichi Tamura, Hiromichi Wakui, 
Akinobu Maeda, Kengo Azushima, Sona Haku, Ryu Kobayashi, Masato Ohsawa, 
Yoshiyuki Toya, Satoshi Umemura.  Dept of Medical Science and Cardiorenal 
Medicine, Yokohama City Univ Graduate School of Medicine, Yokohama, Japan.
Background: The renin-angiotensin system plays a key role in the maintenance 
of cardiovascular and renal homeostasis, principally via appropriate activation of the 
angiotensin II type 1 receptor (AT1R). On the other hand, exaggerated activation of AT1R 
signaling would exert detrimental effects, such as various aging-related diseases including 
renal dysfunction. We previously identified an AT1R-associated protein (ATRAP/Agtrap), 
which is a molecule directly interacting with the AT1R. Accumulating results indicate that 
ATRAP exerts functionally selective inhibition on exacerbated AT1R activation in response 
to pathological stimuli. The present study was performed to investigate pathophysiological 
significance of ATRAP in aging-related phenotypes by employing systemic ATRAP-
knockout mice (ATRAP-KO mice).
Methods: ATRAP-KO mice and their wild-type control mice (WT mice) were fed the 
standard diet and maintained until death to estimate their life spans. Their growth (body 
weight change and appearance) and physiological parameters (blood pressure, caloric 
intake and glucose and lipid metabolism) were also analyzed. Furthermore, aging-related 
organ damages in the hearts, aortas and kidneys were examined in young (3 to 4 months 
old) and aged (22 to 25 months old) mice in both groups.
Results: There was no difference in the growth between two groups. In addition, 
ATRAP-KO mice did not show any evident alteration of physiological parameters. However, 
the life span of ATRAP-KO mice was significantly shorter than that of WT mice (KO vs 
WT; median life span, 100.4 weeks vs 123.1 weeks, log-rank test, P<0.001). By further 
analysis we found no significant difference in cardiovascular aging-related phenotype 
between two groups. On the other hand, renal fibrosis was exacerbated in aged ATRAP-KO 
mice compared to aged WT mice.
Conclusions: In the present study, ATRAP-KO mice showed accelerated renal fibrosis 
with shortened life span. Therefore, ATRAP deficiency seems to exacerbate the aging-related 
renal fibrosis and to inhibit the longevity.
FR-PO130
Effects of Deficiency of Angiotensin Receptor-Binding Molecule on Blood 
Pressure Regulation in Chronic Kidney Disease  Ryu Kobayashi, Kouichi 
Tamura, Hiromichi Wakui, Kengo Azushima, Sona Haku, Kazushi Uneda, 
Kotaro Haruhara, Kohji Ohki, Sho Kinguchi, Masato Ohsawa, Yoshiyuki 
Toya, Satoshi Umemura.  Dept of Medical Science and Cardiorenal Medicine, 
Yokohama City Univ Graduate School of Medicine, Yokohama, Kanagawa, 
Japan.
Background: The renin-angiotensin system plays a key role in the maintenance of 
cardiovascular and renal homeostasis, principally via appropriate activation of Ang II type 
1 receptor (AT1R). On the other hand, exaggerated activation of AT1R signaling would 
exert detrimental effects, such as promoting various aging-related diseases including 
chronic kidney disease (CKD). We previously identified an AT1R-associated protein 
(ATRAP/Agtrap), which is a molecule directly interacting with the AT1R.Accumulating 
results indicate that ATRAP exerts functionally selective inhibition on exacerbated AT1R 
activation in response to pathological stimuli. The present study was performed to investigate 
pathophysiological significance of ATRAP in mice model of CKD by employing systemic 
ATRAP-knockout mice (ATRAP-KO mice).
Methods: ATRAP-KO mice and their wild type control mice (WT mice) were subjected 
to 5/6 nephrectomy (Nx) as CKD model. To examine the effects of ATRAP deficiency, 
blood pressure and other parameters were measured in ATRAP-KO mice and WT mice 
after 5/6 Nx.
Results: At baseline, blood pressure was similar in ATRAP-KO and WT mice. In 
ATRAP-KO mice, blood pressure increased from 2 to 8 weeks after 5/6 Nx and was 
significantly higher than that in WT mice (ATRAP-KO vs WT; systolic blood pressure 
at 4 weeks after 5/6 Nx, 124±2 mmHg vs 107±1mmHg, P<0.01). With respect to the 
mechanism of elevated blood pressure in ATRAP-KO mice after 5/6 Nx, plasma volume 
was significantly higher in ATRAP-KO mice than in WT mice after 5/6 Nx, in spite of no 
significant difference in creatinine clearance between two groups after 5/6 Nx.
Conclusions: Although ATRAP-KO mice show similar blood pressure and renal 
function with WT mice in normal condition, ATRAP-KO mice exhibited significantly 
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increased blood pressure and plasma volume after 5/6 Nx compared with WT mice. 
Therefore, endogenous ATRAP may exert a protective function against pathological blood 
pressure elevation in CKD.
FR-PO131
In Vivo Action of Angiotensin II Type 1a Receptor in Renal Injury Induced 
by Deoxycorticosterone Acetate-Salt Hypertension  Mikako Hisamichi,1 
Atsuko Ikemori,1,2 Takeshi Sugaya,1 Daisuke Ichikawa,1 Kenjiro Kimura,3 Yugo 
Shibagaki.1  1Div of Nephrology and Hypertension, Dept of Internal Medicine, 
St. Marianna Univ School of Medicine, Kawasaki, Japan; 2Dept of Anatomy, 
St. Marianna Univ School of Medicine, Kawasaki, Japan; 3Dept of Internal 
Medicine, Tokyo Takanawa Hospital, Tokyo, Japan.
Background: The AT1a receptor plays a major role in the renal action of Ang II 
and is expressed in vascular smooth muscle cells of the afferent arterioles.In this study, 
we investigated the morphological change in deoxycorticosteron acetate (DOCA)-salt 
hypertensive pathology in order to confirm the in vivo function of the AT1a receptor against 
renal damage due to hypertension.
Methods: To examine urinary L-type fatty acid binding protein (L-FABP) as an 
indicator of tubulointerstitial damage, we used human L-FABP chromosomal transgenic 
mice (L-FABP+/- AT1a+/+) and L-FABP transgenic mice in addition to disrupting the AT1a 
receptor gene (L-FABP+/- AT1a-/-). L-FABP+/- AT1a+/+ and L-FABP+/- AT1a-/- mice were 
administered DOCA tablets plus 1% NaCl water for 28 days.
Results: In the DOCA salt hypertensive model with L-FABP+/- AT1a+/+ (L-FABP+/- 
AT1a+/+-DOCA), slight expansion of the glomerular area and tubulointerstitial damage 
were observed, but not glomerular sclerosis. In the AT1aknockout mice administered 
DOCA-salt (L-FABP+/- AT1a-/--DOCA mice), glomerular sclerosis with expansion of the 
mesangial area was found, and the degree of tubulointerstitial damage was more severe 
compared to L-FABP+/- AT1a+/+-DOCA mice. Both urinary albumin and L-FABP levels 
were significantly higher in the L-FABP+/- AT1a-/--DOCA mice than in the L-FABP+/- 
AT1a+/+-DOCA mice. This renal damage induced in the L-FABP+/- AT1a-/--DOCA mice was 
significantly attenuated by reduction of blood pressure using Hydralazine. Activation of 
the AT1a receptor may contribute to myogenic response of the afferent arteriole involved 
in the renal autoregulatory mechanism.
Conclusions: In conclusion, kidneys without AT1a receptors exhibited an increased 
vulnerability to hypertension, and therefore activation of the AT1a receptor inhibited the 
transmission of the elevated systemic pressures to the glomeruli.
FR-PO132
Renal Blood Flow and Oxygenation During Renin-Anigotensin-Aldosterone 
System Activation – Two Sides of the Same Coin?  René van der Bel,1 Aart 
J. Nederveen,2 Bram F. Coolen,2 Wouter V. Potters,2 Hein J. Verberne,3 Liffert 
Vogt,1 Erik Stroes,1 C.T.P.  (Paul) Krediet.1  1Internal Medicine, AMC, Univ of 
Amsterdam, Netherlands; 2Radiology, AMC, Univ of Amsterdam, Netherlands; 
3Nuclear Medicine, AMC, Univ of Amsterdam, Netherlands.
Background: In chronic kidney disease, renal hypoxia and renin-angiotensin-
aldosterone system (RAAS) activation may augment each other. Although renal oxygenation 
(RO) measured by Blood Oxygen Level Dependent (BOLD) MRI is not correlated to 
Glomerular Filtration Rate (GFR), recent data suggest that RO relates to inter-individual 
variation in RAAS activity. To further explore this we measured the effects of Angiotensin 
II (Ang-II) on renal blood flow (RBF) and RO in healthy humans.
Methods: After a 30 min baseline phase, 8 healthy volunteers (age 19-22 years) were 
subjected to continuous Ang-II infusion at 0.3, 0.9 and 3.0 ng/kg/min for 12 minutes per 
dose. RO and RBF were assessed by BOLD and phase contrast MRI, respectively (Ingenia 
3.0T, Philips Healthcare). Off-line, R2* values were calculated for cortex and medulla, via 
mono-exponential fitting to multi-echo 2-dimensional fast field-echo data (TR 140 ms; FA 
70°; min TE 2 ms; DTE 5 ms; 16 echoes; voxel 1.2 mm2 by 4 mm). RBF was calculated in 
the proximal renal artery after manual vessel segmentation. During a second visit (n=6), 
GFR and Effective Renal Plasma Flow (ERPF) were measured by 125I-thalamate and 
131I-hippuran clearing test during equal Ang-II infusion.
Results: Mean arterial blood pressure increased from 83.0±2.85 at baseline to 91.3±3.76 
mmHg (p=0.002). RBF decreased dose dependently from 11.1±2.08 to 8.05±1.02 (p=0.02) 
ml/s. GFR and ERPF both decreased (10±7.1%, p=0.016; 24±4.5%, p<0.001). RBF and 
ERPF measurements strongly correlated (R = 0.75 p<0.001). There was a trend towards 
a cortical R2* increase by 7.2±3.76% (p=0.014); medullar R2* did not change. Cortical 
DR2* and DRBF inversely correlated (R=0.42, p=0.044). Cortical DR2* and ∆GFR 
correlated (R=0.48, p=0.017).
Conclusions: Ang-II causes a dose dependent DRBF. The observed DRO seem to 
differ between cortex and medulla. Only for the cortex BOLD may provide an index of 
tissue perfusion.
FR-PO133
Chloride Contributes to Hypertension and Renal Injury in Aldosterone-
Salt Treated Rats  Takahiro Yamauchi, Shigehiro Doi, Toshiki Doi, Kensuke 
Sasaki, Toshinori Ueno, Ayumu Nakashima, Takao Masaki.  Dept of Nephrology, 
Hiroshima Univ Hospital, Hiroshima, Japan.
Background: Aldosterone-salt treatment is known to induce renal inflammation and 
plays an important role in the development of renal fibrosis as well as elevation in blood 
pressure.In addition to sodium, chloride has recently been reportedly to be involved in renal 
damage, raising the possibility that sodium-bicarbonate may ameliorate renal injury and 
hypertension in rats treated with aldosterone. This study investigated the role of chloride on 
renal damage and hypertension by comparing rats treated with aldosterone in combination 
with either sodium chloride or sodium carbonate.
Methods: Following a left nephrectomy, 8-week-old male Sprague-Dawley rats were 
implanted with a osmotic infusion mini-pump and then allocated to the following 3 groups; 
1) drinking a 1% NaCl solution with aldosterone infusion (NaCl-aldosterone treated group), 
2) drinking a 1% NaHCO3 solution with aldosterone infusion (NaHCO3-aldosterone treated 
group), and 3) drinking water with vehicle infusion. Blood pressure levels were measured 
weekly by the tail cuff method. After 6 weeks, the rats were sacrificed and their renal tissues 
examined by immunoblotting and immunohistochemistry.
Results: The NaCl-aldosterone group had higher blood pressure levels than the 
NaHCO3-aldosterone group. Protein expression of αENaC and Pendrin in the membrane 
fraction was also increased in the NaCl-aldosterone group compared with the NaHCO3-
aldosterone group. In addition, the NaCl-aldosterone group had high protein levels of 
NCC and phosphorylated NCC in the whole protein and membrane fractions. On the other 
hand, the expression of inflammatory (CD3, CD68, IL17A, IL-23 receptor) and fibrotic 
markers (α-smooth muscle actin, collagen1) were greater in the NaCl-aldosterone group.
Conclusions: These findings suggest that chloride plays an important role in the 
development of NaCl-aldosterone-induced hypertension and renal injury.
FR-PO134
RAGE-DNA Aptamer Improves Aldosterone-Induced Renal Injury 
Possibly via Inhibition of Rac1-MR Axis in Mice with Hypertensive 
Nephropathy  Kensei Taguchi,1 Sho-ichi Yamagishi,2 Yuichiro Higashimoto,3 
Yosuke Nakayama,1 Katsuhiko Asanuma,4 Seiji Ueda,1 Kei Fukami.1  1Div of 
Nephrology, Dept of Medicine; 2Dept of Pathophysiology and Therapeutics of 
Diabetic Vascular Complications; 3Dept of Chemistry, Kurume Univ School of 
Medicine, Kurume, Japan; 4Div of Nephrology, Kyoto Univ Graduate School 
of Medicine, Kyoto, Japan.
Background: Advanced glycation endproducts (AGEs) stimulate the generation of 
reactive oxygen species (ROS) and subsequently enhance various intracellular pathways 
through the interaction with receptor for AGEs (RAGE). Although AGEs-RAGE axis has 
been mainly investigated in diabetic nephropathy, its pathophysiological role in hypertensive 
nephropathy (HN) is unknown. In addition, recent evidence has suggested that aldosterone 
(aldo)-mineralocorticoid receptor (MR) system plays a crucial role for the pathogenesis 
of HN. In this study, we examined whether AGEs-RAGE system could interact with 
aldo-MR axis in deoxycorticosterone acetate(DOCA)-induced HN in mice. Further, we 
explored the inhibitory effects of DNA-aptamer directed against RAGE (RAGE-aptamer) 
on the progression of HN.
Methods: Uninephrectomized 8-week-old C57Bl/6J male mice were divided into 
three groups; 4% salt diet (control), 4% salt diet with DOCA (50mg), and DOCA with 
hydralazine (Hyd). RAGE-aptamer constructed by SELEX method was continuously 
administrated with osmotic mini pump.
Results: DOCA elicited-UAE was independent of blood pressure. Renal ROS 
generation, RAGE protein expression and plasma carboxymethyl lysine (CML) 
levels were elevated in DOCA/salt mice. RAGE was colocalized MR in podocytes by 
immunohistological analysis. Further, GTP-bound Rac1 activation and MR overexpression 
were observed in DOCA/salt mice. DOCA-elicited increase in UAE, renal ROS generation 
and RAGE expression, plasma CML levels were improved by RAGE-aptamer independent 
of blood pressure. Interestingly, RAGE-aptamer suppressed GTP-bound Rac1 activity and 
MR overexpression in DOCA/salt mice.
Conclusions: AGEs-RAGE axis and Rac1-MR pathway could be correlated with 
each other, which could lead to podocyte injury in HN. RAGE-aptamer may be a novel 
therapeutic strategy for the progression of HN.
FR-PO135
Dipeptidyl Peptidase-4 Inhibitor Ameliorates the Aldosterone-Induced 
Renal Fibrosis  Kang-Yung Peng, Vincent Wu.  Dept of Internal Medicine, 
National Taiwan Univ, Taipei, Taiwan.
Background: Renal fibrosis is considered a common outcome of a wide variety of 
chronic kidney diseases with diverse causes. However, no antifibrotic agent has been 
approved in clinical practice yet. In this study, we examined the effect of dipeptidyl 
peptidase-4 (DPP-4) inhibitor against renal fibrosis induced by aldosterone.
Methods: Human proximal tubular epithelial cells (HK2) were used to examine 
the inhibitory effect of DPP-4 inhibitor on aldosterone induced epithelial-mesenchymal 
transition (EMT). Besides, aldosterone infusion mice were used to evaluate the effect 
of DPP-4 inhibitor, linagliptin, on aldosterone induced renal fibrosis. Expression of 
TGF-β, OPN and molecules involved in EMT were examined using western blot and 
immunohistochemistry. Renal fibrosis was determined by Masson’s trichrome staining.
Results: In vitro studies showed that aldosterone significantly increases the expression 
of TGF-β, OPN and markers of EMT in HK2 cells, while these effects were abolished in 
that treated with DPP-4 inhibitor. Similarly, the aldosterone-infused mice exhibited severe 
kidney fibrosis. The expression of TGF-β, OPN, vimentin and α-SMA were induced by 
aldosterone, and oral DPP-4 inhibitor ameliorated the kidney fibrosis and lessened the 
increase in fibrotic proteins without significant changes in blood pressures. 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
387A
J Am Soc Nephrol 26: 2015 Hypertension: Basic Poster/Friday
Conclusions: In this study, our results suggest that DPP-4 inhibitor possesses anti-EMT 
effect to ameliorate the aldosterone-induced renal fibrosis, which may partly attribute to 
regulating TGF-β/OPN pathways. These findings may guide us in therapeutic strategies 
for aldosterone-induced renal fibrosis.
FR-PO136
G-Protein-Coupled Receptor 40 Mediates the Regulation of Epithelial 
Sodium Channel by Epoxyeicosatrienoic Acid Signaling  Seong Kwon Ma, Ha 
Yeon Kim, Chang Seong Kim, Eun Hui Bae, Soo Wan Kim.  Internal Medicine, 
Chonnam National Univ Medical School, Gwangju, Republic of Korea.
Background: Epoxyeicosatrienoic acid(EET) plays diverse functions including cellular 
proliferation, anti-inflammation and vasorelaxation. Although it has been demonstrated 
that EET also regulate epithelial sodium channel (ENaC), the potential functional receptor 
mediating the biological effect of EET has remained elusive. In the present study, we 
investigated the role of GPR40 mediating ENaC regulation of EET in mouse cortical 
collecting duct (M1-CCD) cell line.
Methods: M1-CCD cells were cultured with aldosterone in the absence or presence 
of 14,15-EET. In addition, M1-CCD cells treated with aldosterone were cultured in the 
absence or presence of GW9110, a GPR40 antagonist.
Results: The mRNA and protein of ENaC-α and GPR40 were endogenously expressed 
in the M1-CCD cells as well as the cortical collecting ducts of murine kidney. Treatment 
with aldosterone increased the protein expression of ENaC-α and mineralocorticoid 
receptor (MR). These changes were abolished by 14,15-EET treatment, and treatment with 
14,15-EET increased the phosphorylation of ERK1/2. Inhibition of GPR40 by treatment 
with GW9110 enhanced the aldosterone-induced upregulation of ENaC-α and MR, while 
decreased ERK1/2 phosphorylation.
Conclusions: In conclusion, EET inhibits aldosterone-induced ENaC activation by the 
inhibition of MR and activation of ERK1/2. GPR40 inhibition augmented the aldosterone-
induced ENaC activation by the activation of MR and inhibition of ERK1/2. These findings 
suggest that GPR40 mediated the ENaC regulation by EET signaling.
FR-PO137
The Extra Renal Effect of Hydrochlorothiazide on Systemic Blood Pressure: 
Role of Vasodilation in Volume Depleted States  Saeed Alshahrani,1 Jack 
Rubinstein,2 Min Jiang,2 Sharon L. Barone,23 Jie Xu,2 Kamyar A. Zahedi,23 
Manoocher Soleimani.1,2,3  1Pharmacology, Univ of Cincinnati, Cincinnati, OH; 
2Internal Medicine, Univ of Cincinnati, Cincinnati, OH; 3Research Services at 
VA Hospital, Cincinnati, OH.
Background: Thiazides are specific inhibitors of the Na+-Cl- Co-transporter (NCC) 
in the distal nephron, and the most commonly used diuretics for the treatment of mild 
hypertension. The mechanism of hypotensive action of thiazides is not clear. The accepted 
belief is that the primary effect of thiazides is through the enhancement of salt excretion; 
however, several studies point out the extra renal effects of thiazides. The blood pressure 
response to thiazides requires an initial volume loss of about 1.5 kg, which it is not observed 
in individuals who are ingesting a high-salt diet.
Methods: Balance studies were performed in age/sex-matched wild type and NCC 
deficient mice. The blood pressure was measured using computerized tail cuff method. 
Cardiac functions were analyzed by echocardiography.
Results: Hydrochlorothiazide (HCTZ) significantly reduces systemic blood pressure 
when NCC KO mice are volume-depleted and their renin-angiotensin system (RAS) is 
activated, however, it had no effect on blood pressure of salt replete NCC KO mice. The 
reduction in blood pressure in salt depleted animals was dramatic, happened within hours 
after HCTZ and occurred in the absence of any increase in salt excretion, indicating its 
extra-renal origin. Echocardiography showed no significant changes in cardiac output in 
response to HCTZ. The antihypertensive effects of HCTZ were abrogated in the presence 
of a blocker of large conductance Ca+2 activated K+ (BK) channels, Paxilline. Western 
blots demonstrated significant enhancement of BK expression in vascular system of salt 
depleted, NCC-deficient mice.
Conclusions: Our results indicate that vasoconstriction secondary to RAS activation 
amplifies the extra-renal hypotensive action of HCTZ through vasodilation irrespective of 
the status of its renal target. Patients on a combination diuretic regimen such as furosemide 
and HCTZ are at increased risk of hypotension and kidney hypoperfusion subsequent to 
systemic vasodilation by HCTZ.
Funding: Veterans Administration Support, Government Support - Non-U.S.
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Mitochondrial Oxidative Stress-Activated Renal Local RAS Promotes 
the Expression and Function of NCC in Proteinuric Kidney Disease 
Songming Huang,1,2 Yibo Zhuang,1 Guixia Ding,1 Zhanjun Jia,1,2 Aihua Zhang.1,2 
1Nephrology Dept, Nanjing Children Hospital, Nanjing Medical Univ, Nanjing, 
China; 2Nanjing Key Laboratory of  Pediatrics.
Background: The fluid retention and hypertension are common complications of 
kidney diseases, whose pathogenic mechanisms remain elusive.
Methods: Kidney tissues from mice subjected to albumin overload via i.p injection 
for 12 days and renal biopsy specimens were analyzed.
Results: Following albumin overload, we found a striking increase of Na+-Cl- 
cotransporter (NCC) expression by 2.3-fold in mouse kidneys determined by Western 
blotting and qRT-PCR. To evaluate NCC function in these mice, NCC inhibitor 
hydrochlorothiazide (10mg/kg) was administered via a single i.p injection. In agreement 
with NCC upregulation, the response to hydrochlorothiazide was significantly enhanced 
in albumin overloaded mice. Considering the established role of renin-angiotensin system 
(RAS) in regulating sodium transporters, we examined key components of RAS and found 
a striking elevation of angiotensinogen (AGT) and angiotensin converting enzyme (ACE) 
by 2-3 folds in line with enhanced urinary AngII excretion. In proteinuric patients, we 
also observed 4-fold upregulation of NCC and remarkable stimulation of ACE detected 
by immunohistochemistry in accord with significantly increased urinary Ang II output. To 
further investigate the role of RAS in NCC upregulation, we did primary culture of renal 
tubular cells and observed that albumin directly increased NCC paralleled with significant 
induction of AGT, ACE, and Ang II. Strikingly, administration of specific ACE inhibitor 
captopril to the cells remarkably abolished albumin-induced enhancement of NCC and 
RAS components. Additionally, albumin overload significantly reduced mitochondrial 
superoxide dismutase (SOD2) by 60%, and administration of a SOD2 mimic (MnTBAP) 
entirely abolished the stimulation of NCC, AGT, and ACE in mice with albumin overload.
Conclusions: The findings demonstrated an important role of albuminuria in 
upregulating NCC expression via a mitochondrial oxidative stress-initiated stimulation of 
renal local AGT/ACE/Ang II, which may contribute to the fluid retention and hypertension 
in proteinuric kidney disease to some extent.
Funding: Government Support - Non-U.S.
FR-PO139
Prophylactic and Therapeutic Tenapanor Are Vascular Protective in a Rat 
Model of CKD  Ann-Cathrine Jönsson-Rylander,1 Margareta Behrendt,1 Craig F. 
Plato,2 Denise L. Schwabauer,2 Peter J. Greasley.1  1AstraZeneca R&D, Mölndal, 
Sweden; 2Plato Biopharma Inc., Denver, CO.
Background: Tenapanor (AZD1722), an inhibitor of the Na+/H+ exchanger NHE3, 
reduces absorption of gut sodium and phosphate. It is being developed for renal and 
constipation-related indications.
Methods: 5/6 nephrectomized Sprague Dawley rats were fed 4% NaCl chow to 
induce salt-sensitive arterial hypertension. Oral tenapanor (1 mg/kg/day) was initiated 
either at the start of NaCl intake (prophylactic; Px) or 2 weeks later (therapeutic; Tx), and 
was administered for up to 6 weeks. Disease controls (DCs; vehicle-treated) and healthy 
controls (HCs; sham operated, normal chow) were included to enable assessment of disease 
progression. Systemic hemodynamics and urinary and plasma biomarkers were assessed 
every 2 weeks. Ex vivo vascular function (isometric tension recording) or arterial stiffness 
(pulse wave velocity) was evaluated at 2 and 6 weeks.
Results: Compared with DCs, rats in the Px and Tx groups had reduced urinary 
albumin, protein, sodium and phosphorus excretion (p<0.05), and looser stools. Systolic, 
diastolic and mean BP increased in DCs but were normalized in the Tx group. Arterial 
stiffness was reduced by Px and Tx tenapanor (p<0.05). Compared with HCs, DCs had 
impaired aortic vasoconstrictor and vasodilator function at 2 weeks (p<0.05) and significant 
endothelial dysfunction at 6 weeks. Px tenapanor normalized, and Tx tenapanor attenuated 
arterial hypertension, vascular stiffness, vasoconstrictor and endothelium-dependent and 
independent vasodilator function (Table).
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Conclusions: Tenapanor prevented most of the maladaptive consequences in a rat model 
of renal insufficiency-induced salt-sensitive arterial hypertension and CKD. The benefit 
of Tx treatment was similar to that elicited by Px use, suggesting disease modification.
Funding: Pharmaceutical Company Support - AstraZeneca
FR-PO140
Urinary Exosome Profiling in Thiazide Induced Hyponatremia 
Sarath Kiran Channavajjhala,1 Theresa Peltz,3 Wenjing Jia,1 Ian Hall,1 Kevin 
O’Shaughnessy,2 Matthew A. Bailey,3 James W. Dear,3 Mark Glover.1  1Div of 
Therapeutics and Molecular Medicine, Univ of Nottingham, United Kingdom; 
2Clinical Pharmacology Unit, Univ of Cambridge, United Kingdom; 3Centre 
for Cardiovascular Science, Univ of Edinburgh, United Kingdom.
Background: Thiazides are one of the most widely used and cost-effective class 
of anti-hypertensive medication. Thiazide-Induced Hyponatremia (TIH) is one of their 
major adverse effects and the leading cause of drug-induced hyponatremia requiring 
hospitalization. A priori TIH must result from excessive saliuresis and/or water reabsorption. 
The water and electrolyte transporter composition of urinary exosomes (UE) reflects their 
cellular origin and are a promising way to study renal dysfunction. This study assessed the 
expression of AQP2 and NCC in the UE of TIH patients.
Methods: 100 patients admitted to hospital with severe TIH donated urine samples 
during acute TIH and at two months post thiazide cessation. Matched normonatremic 
controls were recruited both on and off thiazides (groups 1 & 2 respectively). UE from 
a representative sample of each patient group were isolated and AQP2 and NCC were 
evaluated by Western blotting and Nanoparticle Tracking Analysis (NTA). AQP2 and 
NCC expression was normalized by urinary creatinine. Immunoblots were also corrected 
for total protein and results expressed as units of optical density/Ucr.
Results: Westerns showed that UE expression of AQP2 was higher in cases during acute 
TIH compared to convalescent (32.93 vs 28.71, P<0.01) and compared to control groups 1 
& 2 (15.61 and 15.09 respectively, P<0.001). NCC expression was lower in TIH patients 
acutely compared to convalescent (17.72 vs 31.86, P<0.05) and compared to both control 
groups (30.32 and 31.17, P<0.05). NTA also demonstrated increased AQP2 expression in 
acute & convalescent TIH.
Conclusions: This study highlights the utility of UE analysis to probe the molecular 
pathophysiology of TIH. Increased AQP2 and reduced NCC expression suggests that TIH 
results from increased water reabsorption and sodium wasting in the distal nephron. TIH 
studies may further understanding of renal physiology and inform the design of new thiazide 
medicines less prone to cause hyponatremia.
Funding: Government Support - Non-U.S.
FR-PO141
Epigenetic Modulation of Renal Arterioles Induced by DOCA-Salt Loading 
in Mice  Hiroyuki Inoue, Kazutoshi Miyashita, Masaaki Sato, Kentaro Fujii, 
Aika Hagiwara, Masanori Tamaki, Hiroshi Itoh.  Internal Medicine, School of 
Medicine, Keio Univ, Tokyo, Japan.
Background: The relationship between salt intake and development of hypertension is 
familiar; however, the mechanism for the onset has not been fully revealed. Our previous 
report showed that the medial hypertrophy of renal arterioles after transient salt loading in 
spontaneous hypertensive rat caused lasting elevation in blood pressure. The present study 
investigated the significance of epigenetic modulation of the gene expressions which are 
relevant to the medial hypertrophy after transient salt loading.
Methods: Male 6 week old C57bl6 mice were implanted deoxycorticosterone acetate 
(DOCA) pellets and given drinking water containing 1% NaCl for 2 weeks for generation 
of salt-induced hypertension. The blood pressure was measured by a tail-cuff method 
during and after the transient salt loading. Histological examinations of the kidney were 
performed during and after the salt loading. Gene expressions in the kidney such as matrix 
metalloproteinases (MMPs), which promote the medial hypertrophy, were quantified. 
Epigenetic modulation of the genes were analyzed.
Results: Transient salt loading caused elevation in blood pressure during the loading 
period. Blood pressure after stopping salt-loading was also significantly higher than that 
before salt loading. Salt loading caused medial hypertrophy of renal arterioles, and it 
remained after stopping salt loading, as to cause lasting renin elevation. Real time PCR 
revealed that MMP2 and MMP9 were increased during the salt loading. CGN5, CBP and 
p300, which are histone acetyltransferases, were elevated. Sirt1, Sirt3, HDAC1 and HDAC5, 
which are histone deacetylases, were decreased. Histone H3K9 and H4K16 acetylations in 
the MMP2 gene were enhanced by the salt loading.
Conclusions: The lasting medial hypertrophy and renin elevation after transient 
salt loading were suggested to be caused by the increased expression of MMPs along 
with augmented histone acetylations by the salt loading. Increased expressions of 
acetyltransferases along with decreased expressions of Sirts and HDACs by transient salt 
loading would be involved in the enhancement of the histone acetylations.
FR-PO142
Radio-Frequency Catheter-Based Renal Denervation in Hypertensive 
Sheep with Chronic Kidney Disease Impairs Responses to Hemorrhage 
Reetu R. Singh,1 Karen M. Moritz,2 Kate M. Denton.1  1Physiology, Monash 
Univ, Clayton, VIC, Australia; 2School of Biomedical Sciences, The Univ of 
Queensland, St. Lucia, QLD, Australia.
Background: Renal sympathetic nerves modulate kidney function and blood pressure 
(BP). Trials using catheter-based renal denervation (cDNX) in hypertensive patients yielded 
results both in support of and, against its efficacy in lowering BP. A critical question is 
whether cDNX has adverse consequences, in situations of clinical challenge, such as 
hemorrhage in denervated patients where intact nerves would be required. This study 
examined consequences of cDNX 1) on BP and renal function and 2) on reflex activation of 
sympathetic nerve activity (SNA) in hypertensive sheep with chronic kidney disease (CKD).
Methods: Sheep with established hypertension and renal dysfunction (CKD group) 
with an appropriate control group were used. At 10 months of age, some animals underwent 
cDNX (CKD-cDNX; control-cDNX) while the remaining underwent sham procedure 
(CKD-intact; control-intact). At 2 months post-cDNX, BP, renal function, and plasma renin 
activity (PRA) were assessed before, during and after hemorrhage (20% blood volume 
withdrawn over 15 minutes).
Results: CKD sheep had higher BP compared to all groups but CKD-cDNX sheep 
had similar BP to control sheep. Basal renal function was not further reduced. In response 
to hemorrhage, BP fell in all groups but the greatest decrease occurred in CKD-cDNX. In 
Control-intact sheep this fall in BP gradually recovered, associated with increase in PRA 
reflecting an increase in reflex SNA. In contrast, in Control-cDNX and CKD-cDNX groups, 
PRA did not increase and BP did not recover reflecting an absence of increase in reflex SNA.
Conclusions: cDNX effectively reduced BP at 2 months post-cDNX in previously 
hypertensive sheep but had no effect on renal function. However, the lack of reflex activation 
of neural mechanisms observed during hemorrhage suggest, that cDNX may impair a 
patient’s ability to adequately respond to physiological challenges.
Funding: Government Support - Non-U.S.
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Interleukin-10 Mediates the Renoprotective Properties of Mesenchymal 
Stem Cells-Derived Extracellular Vesicles in Porcine Metabolic Syndrome 
and Renal Artery Stenosis  Alfonso Eirin,1 Xiang-yang Zhu,1 Christopher 
M. Ferguson,1 Scott Riester,2 Andre J. Van Wijnen,2 Amir Lerman,3 Lilach O. 
Lerman.1,3  1Divs of Nephrology and Hypertension, Mayo Clinic; 2Orthopedic 
Surgery, Mayo Clinic; 3Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Background: Mesenchymal stem/stromal cells (MSCs) are immunomodulatory 
and have unique potential to restore the renal microvasculature, but may generate safety 
concerns. MSC-derived extracellular vesicles (EVs) emerged as a novel non-cellular 
alternative. Using a swine model of metabolic syndrome (MetS) superimposed on renal 
artery stenosis (RAS) we tested whether intrarenal injection of EVs attenuates renal injury 
and if this capacity is mediated by their cargo of the anti-inflammatory cytokine IL-10.
Methods: MetS pigs were studied after 16 weeks of RAS untreated or treated 4 weeks 
earlier with a single intrarenal delivery of labeled EVs harvested from autologous MSCs 
(2.5x10^5/Kg) with or without pre-silenced IL-10 (IL-10 knock-down). Lean and MetS 
Sham served as controls (n=7 each). Single-kidney renal blood flow (RBF) and glomerular 
filtration rate (GFR) were studied in-vivo, and microvascular architecture (micro-CT) and 
fibrosis ex-vivo.
Results: EVs were detected in the stenotic-kidney 4 weeks after injection. RBF and 
GFR, which increased in MetS compared to Lean, fell in MetS+RAS, but improved in 
EV-treated pigs (Table). EVs also improved cortical microvascular density and renal 
fibrosis (Figure). Yet, these renoprotective effects were blunted in pigs treated with IL-10 
depleted EVs.
Conclusions: Intrarenal delivery of MSC-EVs improves renal structure and function 
in chronic experimental MetS+RAS, partly mediated by their cargo of IL-10. These 
observations suggest that EV-based regenerative strategies might be useful for patients 
with MetS+RAS.
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Role of Mitochondrial Dysfunction and ROS Production in Ang II-Induced 
NLRP3 Inflammasome Activation  Wen Yi, Liu Yiran, Tang Taotao, Bi-Cheng 
Liu.  Inst of Nephrology, Southeast Univ, Nanjing, Jiangsu Province, China.
Background: The type 1 angiotensin (AT1) receptor plays an important role in 
maintaining blood pressure. Previous studies suggested that the activation of immune 
responses by angiotensin (Ang) II during hypertension may aggravate renal damage. NLRP3 
inflammasome activation promotes renal inflammation and contributes to chronic kidney 
damage. Further investigation should be performed to explore the correlation between the 
RAS and NLRP3 inflammasome activation, and possible mechanisms.
Methods: C57BL/6 AT1R-/- and NLRP3-/- mice underwent left nephrectomy followed 
1 week for recovery. Blood pressure measurements were recorded at baseline and following 
4 weeks of chronic Ang II or saline infusion. At the end of the experiment, the kidney were 
harvested and fixed. AT1R siRNA and mitoTEMPO treatment were performed before the 
Ang II stimulation in HK2 cells. The expression levels of NLRP3 inflammasome and 
mitochondrial dysfunction were measured.
Results: Ang II significantly induced kidney injury and NLRP3 inflammasome 
activation. Mitochondria swelling and fragmentation were observed by transmission electron 
microscope. AT1-/- blocked Ang II-induced hypertension, inhibiting the mitochondrial 
dysfunction and NLRP3 expression. Deficiency of NLRP3 attenuated kidney injury in 
hypertension with no significant influence to blood pressure. In vitro studies showed that 
Ang II stimulation increase the mitochondrial damage and NLRP3 activation in dose- 
and time- dependent manner. AT1R silence effectively blocked Ang II-induced damage. 
MitoTEMPO attenuated the activation of NRLP3 inflammasome through clearance of 
reactive oxygen species (ROS). Moreover, Ang II-induced mitochondrial dysfunction was 
markedly inhibited by silence of NLRP3.
Conclusions: Ang II stimulation induces NLRP3 inflammasome activation through 
AT1a receptor. Ang II-induced NLRP3 activation is mediated by mitochondrial dysfunction, 
with overproduction and accumulation of ROS. NLRP3 inflammasome activation plays 
an important role in kidney injury, and blocking it can be a potential therapeutic target for 
hypertension-associated kidney damage.
Funding: Other NIH Support - National Nature Science Foundation of China
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The Endoplasmic Reticulum Stress Inhibitor 4-Phynelbutyric Acid Prevents 
the Development of Essential Hypertension in Young Spontaneously 
Hypertensive Rats  Safaa Naiel,1 Chao Lu,2 Jeffrey G. Dickhout.1,2  1Medicine, 
McMaster Univ, Hamilton, ON, Canada; 2St. Joseph’s Healthcare Hamilton, 
Hamilton, ON, Canada.
Background: Essential Hypertension is the leading global risk factor for premature 
death. This complex multifactoral disease has no known cause and has been shown to 
contribute to the progression of chronic kidney disease (CKD). Mechanistically both 
Endoplasmic Reticulum (ER) stress and the Unfolded Protein Response (UPR) have 
been implicated in the pathobiology of this disease. A small molecular chaperone, 
4-phenynelbutyric acid (4-PBA), is known to inhibit ER stress. In our previous studies, 
we found that 4-PBA is able to lower blood pressure in animal models of hypertension. It 
remains unclear however if ER stress is a cause of hypertension or a consequence.
Methods: Young spontaneously hypertensive rats (SHR) were used in this study and 
Wistar Kyoto (WKY) rats were used as its normotensive control. High blood pressure 
begins to develop in the young SHR at 4-weeks of age. Radio-telemetry transmitters (HD-
X11 transmitter, Data Sciences International) were implanted to monitor blood pressure 
development, heart rate and ECG activity in both SHR and WKY. SHR and WKY were 
both randomized into 4-PBA (1 g/kg/day) or vehicle groups at 4-weeks of age to determine 
if ER stress inhibition would prevent the development of hypertension. Resistance vessels, 
such as mesenteric arteries and renal arteries were collected after 8 weeks and analyzed for 
specific ER stress markers using real-time polymerase chain reaction (RT-PCR).
Results: 4-PBA treatment significantly lowered systolic, diastolic and mean arterial 
pressures in the SHR rats, but not in the WKY rats. 4-PBA treatment also significantly 
abolished pre-hypertensive tachycardia in the SHR. Additionally, 4-PBA significantly 
prevented the expression of UPR markers CHOP and GRP78 in SHR resistance blood 
vessels.
Conclusions: ER stress appears to play a causative role in the development of 
hypertension. Novel pharmacological strategies aimed at ER stress inhibition might 
represent useful therapeutic tools for people with a high risk of developing hypertension 
and progressive CKD. Funding: Government Support – MOP-133484.
Funding: Government Support - Non-U.S.
FR-PO146
Macrophage Endothelin-B Receptors Clear Endothelin-1 and Regulate 
Blood Pressure  Neeraj Dhaun.  Queen’s Medical Research Inst, University 
of Edinburgh.
Background: Hypertension is common. Its cause remains unclear in the majority 
of those affected. Recent data suggest that macrophages (Mĭ) contribute to, and protect 
from, hypertension. Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor 
with additional pro-inflammatory properties. The effects of ET-1 on Mĭ biology are not 
well studied.
Methods: To examine the interactions between the ET and Mĭ systems we 
administered incremental doses of intravenous ET-1 to CD11b-diphtheria toxin receptor 
(DTR) mice given diphtheria toxin (DT) and to mice lacking ETB receptors solely on 
myeloid cells (LysMETB-/-). We also cultured bone marrow derived Mĭ (BMDM) from both 
these mice and human monocytes in vitro. Finally, we examined BP and the ET system in 
patients receiving Mĭ depleting and non-depleting therapy.
Results: Mĭ depletion or loss of function – Cd11b-DTR mice given DT and LysMETB-/- 
mice – were not associated with a difference in baseline BP or endothelial dysfunction. In 
both, administration of ET-1 resulted in an exaggerated hypertensive response compared 
to controls. At a dose of ET-1 1nmol/kg the maximal change in BP was ~2-fold greater 
in Mĭ deficient mice compared to control groups. In vitro, mouse BMDM and human 
Mĭ possess both ETA and ETB receptors. Whereas stimulation of mouse and human Mĭ 
with exogenous ET-1 did not polarize Mĭ to a classical or alternative phenotype, both 
displayed chemokinesis to ET-1. This was reduced by selective ETA and completely blocked 
by ETB receptor antagonism.BMDM stimulation with LPS/INFγ led to an increase in the 
concentration of ET-1, an effect that was blocked by phosphoramidon, an inhibitor of 
endothelin converting enzyme. Importantly, using pharmacological and gene targeting 
studies we show a novel clearance mechanism for ET-1 through ETB receptor mediated 
dynamin-dependent endocytosis present in both murine and human Mĭ. Finally, patients 
receiving Mĭ depleting therapy we show that BP is higher and the ET system more activated 
than in those receiving non-depleting therapies.
Conclusions: Overall, these data suggest that Mĭ and ET-1 may play an important 
role in BP control and potentially have a critical role as a therapeutic target in hypertension.
FR-PO147
Role of the Myeloid Endothelin-B Receptor in Angiotensin II Mediated 
End-Organ Damage  Neeraj Dhaun.  Inst de Recherche, PARCC, Inserm, Paris.
Background: Hypertension is common and in the majority of cases its cause remains 
unknown. Recent interest has focused on the role of macrophages (Mࢥ) in blood pressure 
(BP) regulation. Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor 
mediating its effects through two receptors – the endothelin-A receptor (ETA) and 
endothelin-B (ETB) receptor. The ETB receptor has a specific role in ET-1 clearance. We 
investigated the role of the Mࢥ ETB receptor in a model of angiotensin II (Ang II)-mediated 
end-organ damage.
Methods: Mࢥ ETB receptor deficient mice (LysMETB-/-) and controls were exposed to 
Ang II infusion for 6 weeks under a high salt diet. We assessed BP via telemetry, cardiac 
structure and function and endothelial function by Doppler ultrasound, end-organ injury 
and plasma and urine ET-1.
Results: At baseline, components of BP did not differ between groups and increased 
similarly with Ang II. Whereas after 6 weeks of Ang II LysMETB-/- and controls had similar 
left ventricular hypertrophy and cardiac insufficiency, endothelial function was better in 
LysMETB-/- at both baseline and after Ang II (% dilation of basilar artery in response to 
CO2, LysMETB-/- vs. controls: baseline: 20 vs.11%, p<0.01; at 6 weeks: 11 vs.0%, p<0.01). 
Baseline renal function and proteinuria did not differ between groups. After Ang II, 
LysMETB-/-showed similar renal function compared to controls but less proteinuria (urine 
albumin:creat, mg/mmol: 208±10 vs. 530±25, p<0.01), glomerulosclerosis (34±2 vs. 61±4%, 
p<0.001), and fewer renal Mࢥ compared to controls (F4/80 staining per high power field, 
LysMETB-/- vs. controls: 1.1±0.7 vs. 3.2±0.5%, p=0.02), although similar levels of CD3+ T 
cells. Plasma ET-1 was no different at baseline but increased more in LysMETB-/-with Ang 
II vs. controls after 6 weeks Ang II: 3.7±0.7 vs.1.4±0.2pg/ml, p=0.03). Urine ET-1 was 
similar baseline and 6 weeks.
Conclusions: Deletion of the Mࢥ ETBR is associated with a blunting of the effects of 
systemic Ang II infusion as reflected by less endothelial dysfunction, reduced inflammation 
and end-organ damage. The mechanisms for these effects are the focus of ongoing research.
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FR-PO148
A Novel Reduced Uterine Perfusion Pressure (RUPP) Model of Preeclampsia 
in Mice  Tomofumi Fushima,1 Yuji Oe,2 Emiko Sato,1,2 Sadayoshi Ito,2 Hiroshi 
Sato,1,2 Nobuyuki Takahashi.1,2  1Graduate School of Pharmaceutical Sciences, 
Tohoku Univ, Sendai, Miyagi, Japan; 2Div of Nephrology, Endocrinology, and 
Vascular Medicine, Tohoku Univ, Sendai, Miyagi, Japan.
Background: Preeclampsia (PE) is a pregnancy-related hypertension with proteinuria 
that typically develops after 20 weeks of gestation. PE is caused by a reduction in uterine 
blood flow due to abnormal trophoblast invasion of the spiral arteries. The ischemic placenta 
releases anti-angiogenesis factors such as sFlt-1, leading to maternal hypertension and 
proteinuria. The reduced uterine perfusion pressure (RUPP) model is widely used in rats, 
but not in mice, hindering the clarification of genetics of PE. The aim of the present study 
is to establish a novel PE model using an improved RUPP method in mice.
Methods: As shown in the Figure.1, uterine vessels of pregnant ICR mice were ligated 
at 14.5 dpc, and BP, renal phenotype and pregnancy outcome were analyzed. 
Results: RUPP in mice increased blood pressure.  B,B’ ligation mice showed 
increased urinary albumin excretion, mesangial expansion and endotheliosis as shown by 
the reduction of glomerular open capillary area.  RUPP increased the risk of miscarriages 
and premature deliveries, and significantly reduced fetal weights at 18.5 dpc compared 
to those of sham mice.
Conclusions: We developed a novel RUPP mouse model that recapitulates the 
phenotype of PE. This model is expected to be useful for investigating pathogenesis pf PE 
and evaluating its new therapies.
FR-PO149
Sildenafil Treatment Is Protective against Progression of Renal Injury in 
the Preeclamptic Dahl Salt Sensitive Rat  Ellen Elizabeth Gillis, Jennifer N. 
Mooney, Michael R. Garrett, Jennifer M. Sasser.  Pharmacology and Toxicololgy, 
Univ of Mississippi Medical Center, Jackson, MS.
Background: Preeclampsia, a hypertensive disorder of pregnancy, is characterized 
by transient glomerular damage and increased risk for kidney disease later in life. Recent 
studies in our lab have identified the Dahl salt sensitive (Dahl S) rat on a 0.3% NaCl diet 
as a spontaneous model of superimposed preeclampsia. We hypothesized that sildenafil 
treatment would result in an improvement in renal function during the preeclamptic 
pregnancy exhibited by the Dahl S rat.
Methods: Female Dahl S rats (n=4-9) were mated, and rats were randomly divided 
into control and sildenafil treated groups. Sildenafil was administered to the treated group 
via food on gestational days 10-20 at a dose of 50 mg/kg/d. Rats were placed in metabolic 
cages on gestational day 19 for 24-hr urine collection, and blood and tissues were harvested 
on gestational day 20. Urinary protein excretion, nephrin excretion, and plasma and urinary 
creatinine concentrations were measured by Bradford assay, Exocell ELISA, and the picric 
acid method, respectively. Kidney sections were stained with Masson’s trichrome, and 
glomeruli were measured (n=20 per rat) and analyzed using Nikon software.
Results: Sildenafil treatment significantly improved renal function, as observed in the 
increase in creatinine clearance and corresponding decrease in plasma creatinine (Table, 
*p<0.05 vs control). Treated rats exhibited less renal injury, with a significant decrease in 
proteinuria and nephrinuria during late pregnancy (Table). Histological analysis showed 
that the treated rats did not exhibit glomerulomegaly during pregnancy compared to the 
untreated controls (Table).
Conclusions: This study provides preclinical evidence that sildenafil prevents the 
progression of renal injury during preeclampsia.
Creatinine 
Clearance 
(ml/min)
Plasma 
Creatinine 
(mg/ml) 
Protein-
uria (mg/
day) 
Nephrin-
uria (ȝg/
day) 
Glomerular 
Area (rela-
tive units) 
Glo-
merular 
Diameter 
(relative 
units) 
Control 0.31± 0.05 2.03± 0.04 209± 42 1433± 245 8217± 404 108± 12 
Sildenafil 0.51± 0.06 *
1.52± 
0.19 * 105± 14 *
675± 
132 *
6675± 
258 * 96± 2 *
Funding: NIDDK Support, Other NIH Support - NHLBI, Private Foundation Support
FR-PO150
Recessive Mutations of the Interaction Partners, TENC1, DLC1 or MAGI2, 
Cause Nephrotic Syndrome in Humans  Shazia Ashraf,1 Jia Rao,1 Merlin 
Airik,1 Svjetlana Lovric,1 Jennifer A. Lawson,1 Weizhen Tan,1 Carolin Sadowski,1 
Werner Lukas Pabst,1 Daniela A. Braun,1 Heon Yung Gee,1 Richard P. Lifton,2 
Martin Zenker,3 Friedhelm Hildebrandt.1,4  1Div of Nephrology, Boston Children’s 
Hospital, Boston, MA; 2Dept of Genetics, Yale Univ School of Medicine, New 
Haven, CT; 3Inst of Human Genetics, Univ Hospital Magdeburg, Magdeburg, 
Germany; 4HHMI.
Background: Identification of monogenic causes of nephrotic syndrome (NS) 
has furthered the understanding of its pathogenesis. However, many genes and disease 
mechanisms remain unknown.
Methods: We performed homozygosity mapping (HM) and whole exome sequencing 
(WES) in individuals of consanguineous families with NS to identify the underlying 
mutations. To identify additional families, we performed microfluidic PCR (Fluidigm 
Access Array™) and next generation sequencing (NGS) to screen worldwide cohort of 
~2000 individuals with severe NS.
Results: By WES in consanguineous family A1358, we identified a homozygous 
missense mutation (p.R292Q) in the TENC1 (Tensin-2) gene in an amino acid residue 
conserved since Ciona intestinalis. By microfluidic PCR and NGS, we detected additional 
mutations in TENC1 in three unrelated families with NS. Later, we also discovered 
mutations in 2 different families with NS in DLC1 gene, a known binding partner of TENC1. 
Interestingly, most of the individuals with TENC1 or DLC1 mutations had steroid sensitive 
NS or histologically showed biopsy of MCNS. Furthermore, in 2 families with NS and 
neurological impairment, we identified 2 different homozygous truncating mutations in 
MAGI2 gene. Deficiency of Tenc1 or Magi2 has been previously shown to cause NS in 
mice. By Co-IP, we now show that TENC1 and DLC1 interact with MAGI2 in HEK293T 
cells and these interactions are abrogated in one of the MAGI2 mutant. Knockdown of 
TENC1, DLC1 or MAGI2 in cultured podocytes exhibited an altered podocyte migration 
rate. Immunoflorescence microscopy showed that TENC1 and DLC1 colocalize with 
phosphotyrosine at the focal adhesions in cultured human podocytes.
Conclusions: We, thus, identified mutations of TENC1, DLC1 and MAGI2 as three 
novel single-gene causes of NS revealing a potential new pathogenic pathway for NS.
Funding: Other NIH Support - DK076683
FR-PO151
Mutation of DHTKD1 Can Cause Nephrotic Syndrome with Neurological 
Impairment and Ketoadipic Aciduria  Weizhen Tan,1 Shazia Ashraf,1 Svjetlana 
Lovric,1 Jia Rao,1 Merlin Airik,1 David Schapiro,1 Daniela A. Braun,1 Heon Yung 
Gee,1 Martin Zenker,2 Friedhelm Hildebrandt.1,3  1Div of Nephrology, Boston 
Children’s Hospital, Harvard Medical School, Boston, MA; 2Inst of Human 
Genetics, Univ Hospital Magdeburg, Magdeburg, Germany; 3Howard Hughes 
Medical Inst, Chevy Chase, MD.
Background: Steroid-resistant nephrotic syndrome (SRNS) is the second most 
frequent cause of end-stage kidney disease in children. Identification of single-gene causes 
of SRNS has furthered the understanding of its pathogenesis. However, additional genes 
and disease mechanisms remain obscure. To identify a new causative gene for SRNS with 
neurological impairment, we combined homozygosity mapping (HM) and whole human 
exome sequencing (WES).
Methods: In two siblings (of consanguineous parents) with SRNS, neurological 
impairment, and ketoadipic aciduria, HM yielded 8 segments of homozygosity by descent 
with a cumulative genomic length of ~485 Mb. We performed WES in both siblings to 
identify the underlying single-gene disease-causing mutation.
Results: WES in this consanguineous family detected a homozygous missense mutation 
(p.Val296Met) in the DHTKD1 (dehydrogenase E1 and transketolase domain containing 1) 
gene in an amino acid residue that is evolutionary conserved to prokaryotes (Saccharomyces 
cerevisiae). The mutation segregated with the affected status in this family and was absent 
from the 1,000 genomes project and Exome Aggregation Consortium (ExAC) databases. 
DHTKD1 functions as a 2-oxoglutarate-dehydrogenase E1 component and plays an 
important role in energy production in mitochondria through the tricarboxylic-acid cycle. 
Mutations in DHTKD1 have previously been identified as cause of 2-aminoadipic and 
2-oxoadipic aciduria via impaired turnover of decarboxylation 2-oxoadipate to glutaryl-
CoA1. [1] Danhauser K. et al., Am J Hum Genet, 91:1082-1087, 2012.
Conclusions: We identified a recessive mutation of DHTKD1 as a novel single-gene 
cause of SRNS with neurological impairment and ketoadipic aciduria. Further genetic and 
functional studies will shed light on the involvement of this protein in the pathogenesis of 
NS and will provide a further step in understanding the disease mechanism.
Funding: Other NIH Support - R01-DK076683, Private Foundation Support
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FR-PO152
Genes Encoding Nuclear Pore Outer Ring Components NUP85, NUP107, 
and NUP133 Are Mutated in Patients with Nephrotic Syndrome 
Svjetlana Lovric,1 Weizhen Tan,1 David Schapiro,1 Shazia Ashraf,1 Daniela A. 
Braun,1 Jia Rao,1 Richard P. Lifton,2 Heon Yung Gee,1 Friedhelm Hildebrandt.1,3 
1Div of Nephrology, Boston Children’s Hospital, Harvard Medical School, 
Boston, MA; 2Dept of Genetics, Yale Univ School of Medicine, New Haven, CT; 
3Howard Hughes Medical Inst, Chevy Chase, MD.
Background: Steroid resistant nephrotic syndrome (SRNS) almost invariably 
progresses to end-stage kidney disease. Although more than 30 single-gene causes of 
SRNS are known, a large proportion of SRNS remains unexplained. Recently, mutations 
in genes encoding proteins of the nuclear complex (NPC), NUP93 and NUP205 were 
identified as novel causes of nephrotic syndrome. Study of these proteins has implicated 
SMAD signaling in the pathogenesis of nephrosis.
Methods: To identify additional novel causes of nephrotic syndrome, we performed 
a candidate screen of 17 nuclear pore complex (NPC) genes in an international cohort of 
>900 individuals with SRNS via microfluidic multiplex PCR (Fluidigm Access ArrayTM) 
and next generation sequencing (Illumina MiSeqTM).
Results: In two families we identified two homozygous missense mutations, p.A477V 
and p.R645W, (conserved to S. cerevisiae) in the NPC outer ring protein NUP85. We then 
sequenced the exons of 1,000 additional families in genes encoding other outer ring proteins 
and found mutations in NUP107 (1 family, p. Y889C, conserved to C. elegans) and NUP133 
(2 families, p.S974R and p.R231G, p.L1055S, conserved to D. rerio). Although the structure 
resolution of the NPC 3D complex is incomplete, we modeled the interacting portions 
of the Y-subcomplex proteins NUP107 and NUP133. Two of the mutations, p.S974R in 
NUP133 and p.Y889C in NUP107, are located in the interacting alpha helix between the 
two proteins. 5 of 6 families demonstrated FSGS on biopsy.
Conclusions: As a novel cause of SRNS we identified mutations in 3 different NPC 
outer ring proteins NUP85, NUP107, and NUP133 that form an integral part of the 
Y-subcomplex. Further functional studies are needed to illuminate how the defect of NPC 
contributes to the pathogenesis of nephrotic syndrome.
Funding: Other NIH Support - DK076683
FR-PO153
Defining the Genetic Epidemiology of a Phenotypically Well-
Characterized Adult-Onset Focal and Segmental Glomerulosclerosis 
Cohort  Moumita Barua,1 Daniel C. Cattran,1 Heather N. Reich,1 Michelle A. 
Hladunewich,6 Mark Leung,2 Weili Li,3,4 Andrew D. Paterson,5 York P. Pei.1 
1Nephrology, Toronto General Hospital, UHN, Toronto, ON, Canada; 2Biology, 
Univ of Waterloo, Waterloo, ON, Canada; 3The Centre for Applied Genomics, 
Hospital for Sick Children, Toronto, ON, Canada; 4Dalla Lana School of Public 
Health, Univ of Toronto, Toronto, ON, Canada; 5Genetics and Genome Biology, 
Hospital for Sick Children, Toronto, ON, Canada; 6Nephrology, Univ of Toronto, 
Toronto, ON, Canada.
Background: The genetic epidemiology underlying adult-onset sporadic FSGS has 
not been well characterized and rigorous correlation of rare genetic forms of disease with 
clinical outcomes is also lacking. We defined the genetic epidemiology of the phenotypically 
well characterized sporadic and familial Toronto GN FSGS cohort using next-generation 
sequencing.
Methods: We have ascertained the clinical information and performed whole exome 
sequencing in adult-onset disease of 90 sporadic FSGS cases, 41 steroid-sensitive nephrotic 
syndrome (SSNS) cases and 22 families with FSGS. A variant in a known FSGS gene 
was called disease-causing if it was novel or had a MAF £1% for dominant and recessive 
genes, respectively, in 1000 genomes project, NHLBI exome sequencing project and 
ExAC; compound heterozygosity was consistent with reported inheritance pattern for that 
gene; segregated in affected family members; and called damaging by at least two in silico 
prediction programs or affected highly conserved residues.
Results: In 7 of 90 sporadic FSGS cases, a disease-causing mutation was found in 
the following genes: WT1, TRPC6, PAX2 and COL4A5. No mutations in the known FSGS 
genes were identified in 41 SSNS cases. In contrast, in 4 of 23 autosomal dominant and 
recessive families with FSGS, a disease-causing mutation was identified in the following 
genes: INF2, TRPC6, LMX1B and ADCK4. Mutations in the known FSGS genes were 
found in 7.8 and 17.4% of sporadic and familial cases of adult-onset disease, respectively, 
but none were discovered in patients with SSNS.
Conclusions: Our results are consistent with extensive genetic heterogeneity in 
FSGS. We will test the association of rare variants with phenotype. Clinical outcomes 
will be described.
Funding: Private Foundation Support
FR-PO154
A Novel Mouse Mutant with a Point Mutation in Laminin α5 Exhibits 
Chronic Nephrotic Syndrome  Sara Falcone,1 Thomas Nicol,1 Cheryl 
Scudamore,2 Frederick W.K. Tam,3 Charles D. Pusey,3 Jeffrey H. Miner,4 Steve 
Dm Brown,1 Paul K. Potter.1  1Mammalian Genetics Unit, MRC Harwell, 
Harwell, Oxfordshire, United Kingdom; 2Mary Lyon Centre, MRC Harwell, 
Harwell, Oxfordshire, United Kingdom; 3Renal Section, Imperial College, 
London, United Kingdom; 4Renal Div, Washington Univ, St. Louis, MO.
Background: Diseases associated with ageing pose an increasing social and financial 
burden on society and represent an imperative for research in the biomedical sciences. 
We are undertaking the first large-scale project to investigate the interaction between 
genetic variation and the pleiotropic effects of ageing, employing random mutagenesis and 
phenotyping to generate new models of late onset or age-related disease.
Methods: Mutant mice are being aged to 18 months and undergo comprehensive 
phenotyping across a wide range of disease areas at several time points throughout the life 
of the mice. To date we have identified lines with a variety of late onset phenotypes which 
are being characterised in detail.
Results: Mutant mice were identified at 6 months of age with elevated creatinine 
and urea levels, which reached end stage renal failure at approximately 10 months of 
age. Mapping and whole genome sequencing identified a Lama5 E884G mutation in the 
L4a domain of Lama5. Time course studies of Lama5 E884G homozygotes showed reduced 
serum albumin (18.0 ± 1.2 vs 24.9 ± 3.1, g/l, mean SD) and proteinuria from 12 weeks of 
age with a gradual loss of renal function over time. Affected mice also have significantly 
elevated cholesterol levels and a progressive nephropathy leading to diffuse glomerular 
fibrosis, dilated protein filled tubules and pigment deposition suggesting this is a model 
of nephrotic syndrome. The mutation does not affect expression of the LAMA5 protein 
within the glomerular basement membrane.
Conclusions: We have identified a novel mouse mutant with a missense mutation 
Lama5 resulting in nephrotic syndrome. Recent patient sequencing data suggests LAMA5 
mutations are associated with focal segmental glomerulosclerosis (Chatterjee et al, PLoS 
One, 8:e76360) and we are investigating this in our model. Other models of late-onset renal 
disease are also being investigated.
Funding: Government Support - Non-U.S.
FR-PO155
Exome Sequencing Suggests a Role for Nephron Number in FSGS 
Adele Mitrotti,1 David Fasel,1 Yifu Li,1 Monica Bodria,1 Landino Allegri,3 Gerald 
B. Appel,1 Jai Radhakrishnan,1 Loreto Gesualdo,4 Gian Marco Ghiggeri,5 Richard 
P. Lifton,2 Ali G. Gharavi,1 Simone Sanna-Cherchi.1  1Medicine, Columbia Univ 
Medical Center, New York, NY; 2Genetics, Yale, New Haven, CT; 3Medicine, 
Univ of Parma, Parma, Italy; 4Medicine, Univ of Bari, Bari, Italy; 5Medicine, 
Gaslini Children Hospital, Genova, Italy.
Background: Exome sequencing is a powerful tool to identify disease-causing 
mutations. Identification of novel genes for dominant FSGS has proven difficult.
Methods: We performed exome sequencing in 41 patients from 31 families affected 
by FSGS. Exome sequencing was conducted on Illumina HiSeq2500. Annotations were 
conducted with semi-automated scripts developed in the lab.
Results: We detected diagnostic variants for FSGS in 4 genes in 5/31 families (16%): 
TRPC6, INF2, LMX1B, and LAMB2. We detected two variants of unknown significance 
in FSGS-associated genes (EMP2, INF2). We detected 7 variants in additional 6 patients 
(19%) in genes that predispose to different kidney diseases when mutated (FN1, SIX5, 
COL4A4, FRAS1, FREM1, FREM2, UMOD). While these conditions can represent 
phenocopies of FSGS, it is possible that genes involved in renal development predispose 
to proteinuria and adaptive FSGS.
Analysis of the remaining 20 families (65%) did not reveal any gene with rare 
segregating mutations present in multiple independent families.
Conclusions: Mutations in genes known to be associated to FSGS are identified in 
a small proportion of cases. Mutations in genes involved in GBM assembly or kidney 
development can result in defects that present as FSGS. These findings can point to a 
correct genetic diagnosis and the identification of mutations in genes involved in CAKUT 
suggests that glomerular sclerosis could be the manifestation of a maladaptive reaction to 
reduced nephron mass from birth.
Funding: NIDDK Support, Private Foundation Support
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FR-PO156
Role of CD2AP Mutations in Steroid Resistant Nephrotic Syndrome 
Revisited – New Insights from Next Generation Sequencing  Ania B. Koziell,3 
Katrina Soderquest,3 Andrey S. Shaw,1 Michael A. Simpson.2  1Immunology 
and Pathology, Washington Univ School of Medicine, St. Louis, MI; 2Genomics 
Medicine Group, King’s College London, London, United Kingdom; 
3Experimental Immunobiology, King’s College London, London, United 
Kingdom.
Background: Steroid Resistant Nephrotic Syndrome (SRNS) is a rare disease 
icharacterised by glomerular filter malfunction. Analysis of inherited cases has identified 
mutations in >50 genes. However, clinical data can be limited and the true pattern of 
inheritance difficult to verify. In light of recent advances in next generation sequencing 
(NGS) and rare disease genetics, we re-examined CD2AP, a gene considered to cause 
autosomal dominant SRNS in early life.
Methods: In-house whole exome sequencing (WES) data on 200 deeply phenotyped 
SRNS patients was tested to assess the ability of CD2AP mutations to act as autosomal 
dominant. All protein altering CD2AP variants detected with a MAF < 0.05 were selected 
for further examination in the Exome Aggregation Consortium (ExAC) database. Samples 
with likely pertinent variants in CD2AP were also analysed for causal mutations in other 
SRNS genes.
Results: Variants with a frequency of > 1 in 1000 in the ExAC database were considered 
unlikely to cause autosomal dominant SRNS based on frequency of SRNS in populations. 
Two rare CD2AP variants remained after filtering but one case also demonstrated a rare 
heterozygous non-synonymous disease causing variant in SYNPO (allele frequency 
0.0002179 in ExAc, non-homozygous) and the other a variant in NPHS2 (not seen in 
ExAc). SYNPO interacts with CD2AP and combined, these genes causes FSGS in mice. 
The NPHS2 variant neighboured a mutation linked previously to bigenic heterozygosity 
with CD2AP in SRNS.
Conclusions: Some heterozygous CD2AP variants occurred in normal controls or were 
detected co-incident disease causing variants. This indicates that mutations behaving as 
a dominant negative in a small number of cases may in fact demonstrate more complex 
inheritance on interrogation of a larger cohort. Computational analysis of WES provides a 
useful adjunct to rapidly examine and ascertain actual heritability in rare disease populations, 
especially in seemingly sporadic cases.
FR-PO157
Chemical Chaperone 4-PBA Is Not Nephroprotective in Experimental 
Podocin Nephropathy  Tanja Tamara Wlodkowski,1 Mansoureh Tabatabaeifar,1 
Geraldine Mollet,2 Corinne Antignac,2 Franz S. Schaefer.1  1Pediatric Nephrology 
Div, Heidelberg Univ Hospital, Germany; 2Inserm U983, Hopital Necker, 
France.
Background: 4-PBA has been demonstrated to improve protein trafficking from ER 
to plasma membrane and function of mutant ∆F508-CFTR protein in cystic fibrosis. In 
hereditary nephrotic syndrome the most common NPHS2 (podocin) mutation, R138Q, leads 
to retention of podocin in the ER and therefore to defective intracellular protein trafficking. 
In order to investigate beneficial effect of chemical chaperone in podocin nephropathy, we 
administered 4-PBA to knock-in mice carrying this mutation. Analogous to human disease, 
these mice develop heavy proteinuria, podocyte loss, focal segmental glomerulosclerosis 
and progressive renal failure.
Methods: In C57BL/6 mice with Nphs2Flox/R140QCre+, hemizygosity for mutant podocin 
was induced by tamoxifen injection. From the time of induction the animals (n=5) received 
4-PBA added to the chow (200 mg/kg/d) or remained untreated (Co). Weight, blood pressure 
and proteinuria were monitored weekly. Biochemical and histopathological changes were 
examined after 4 weeks of treatment.
Results: All animals developed massive proteinuria (116% of untreated controls). 
Hypoalbuminemia at 4 weeks was slightly ameliorated (21.1 (Co) vs. 24.7 g/dl; n.s.). 
Serum urea, cholesterol and creatinine levels were deteriorated by 4-PBA treatment. 
Podocyte loss (podocytes per glom: (53% (Co), 69% (4-PBA) of healthy animals, n.s) and 
glomerular sclerosis index (1.75(Co), 1.82(4-PBA) were unchanged, whereas an increase in 
tubolointerstitial fibrosis was noted in 4-PBA treated animals (1.36 (Co) vs. 3.82 (4-PBA).
Conclusions: In an in vivo model of hereditary podocin nephropathy, prophylactic 
4-PBA treatment showed no beneficial effect on proteinuria and podocyte loss but aggravated 
tubolointerstital fibrosis and renal failure. Our findings argue against a nephroprotective 
action of 4-PBA in this hereditary podocytopathy.
FR-PO158
Prominent Renal Complications in the c.80A>G in MMACHC Gene 
Fang Wang, Xiaoyu Liu, Huijie Xiao, Yong Yao, Jie Ding, Yanqin Zhang.  Dept 
of Pediatrics, Peking Univ First Hospital, China.
Background: Cobalamin C defect is a clinically heterogeneous disease caused by 
mutations in the MMACHC gene. The aim of the present study was to delineate renal 
phenotype in Chinese children with Cobalamin C defect.
Methods: Detailed clinical data were collected and analyzed, and all coding exons of 
MMACHC gene were PCR-amplified and sequenced from genomic DNA.
Results: Four unrelated Chinese children (1 female, 3 male) with unexplained 
microscopic hematuria and proteinuria were included. The onset age of renal symptoms 
ranged from 9 months to 4 years. Two patients had nephrotic-level proteinuria in their 
initial visit, and renal dysfunction was detected in 2 patients in 3 months and 6 years after 
onset, respectively. Only 1 patient had hypertension in 6 years after onset. All patients 
had moderate anemia, and megaloblastic anemia was detected in 2 patients. None of 4 
patients had thrombocytopenia or pancytopenia. One of 4 patients had mild development 
backward. Four patients had hyperhomocysteinemia, and 2 of 4 patients presented with 
remarkable elevated urinary methylmalonic acid. Renal biopsy in 3 patients showed 
thromboticmicroangiopathy. Mutations in MMACHC gene was found in four patients. 
Two patients were a compound heterozygote for c. 658_660delAAG andc.80A>G, one 
patient was a compound heterozygote for c.609G>A and c.80A>G, and one patient was a 
homozygote for c.80A>G. Three patients were in follow up. After vitamin B12 [in the form 
of hydroxycobalamin (OHCbl), i.m.], folic acid and L-carnitine betaine supplementation, 
urine protein became negative in 2 patients and reduced in 1 patient, and renal function 
in 1 patient was improved. In all 3 patients, hemoglobin increased to normal, plasma 
homocysteine decreased and still was abnormal. In 2 patients with remarkable elevated 
urinary methylmalonic acid, the level of urinary methylmalonic acid was normal in 1 
patient and decreased in another patient. Blood pressure of the patient with hypertension 
was well-controlled using calcium channel blocker.
Conclusions: Prominent renal complications can be found in c.80A>G in MMACHC 
gene, and treatment resulted in improvement of renal and hematological signs.
Funding: Government Support - Non-U.S.
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The Susceptible Human Leukocyte Antigen Class II Genes and the Encoding 
Amino Acid Residues on Major Histocompatibility Complex Molecules to 
Primary Membranous Nephropathy  Li-jun Xie,1,2 Zhen Qu,1 Zhao Cui,1 
Gang Liu,1 Yun-hua Liao,2 Ming-hui Zhao.1  1Renal Division, Peking Univ 
First Hospital, Beijing, China; 2Div of Nephrology, the First Affiliated Hospital, 
Guangxi Medical Univ, Nanning, China.
Background: Primary membranous nephropathy (MN) is an organ-specific 
autoimmune disease. M-type phospholipase A2 receptor (PLA2R) appears to be the specific 
target antigen, which needs to be presented by major histocompatibility complex (MHC) 
class II molecule. In genome wide association studies, risk alleles at PLA2R1 loci and 
single nucleotide polymorphism (SNP) (rs2187668) within HLA-DQA1 closely associate 
with the disease. However, the full association of HLA class II genes and MHC molecule 
amino acids has not been investigated in MN.
Methods: We genotyped 860 Chinese individuals, including 261 primary MN patients 
and 599 healthy controls, for DRB1, DQA1, DQB1 and DPB1, 4 digits resolution HLA 
alleles, and extracted the encoding amino acid sequences from IMGT/HLA database. 
Circulating anti-PLA2R antibody was detected in all patients.
Results: We found that DRB1*1501 (OR=3.49, P=1.77×10-21) and DRB1*0301 
(OR=3.44, P=3.46×10-10) were two independent risk alleles for MN. In patients with positive 
anti-PLA2R antibodies, DRB1*1501 (OR=6.06) and DRB1*0301 (OR=4.92) showed even 
higher risk for the disease. The SNP (rs2187668) is the tag SNP of DRB1*0301. After 
conditioning on DRB1*1501 and DRB1*0301, no other HLA allele showed significant 
association with MN. At amino acid level, the most significant and independent associations 
were mapped to amino acid position 13 (P=5.78×10-25) and position 71 (P=7.99×10-25) on 
MHC DRβ1 chain. After conditioning on these positions, no other amino acid position 
showed significant association with MN. Alanine on position 71 and Arginine on position 
13 were encoded by DRB1*1501; lysine on position 71 was encoded by DRB1*0301. These 
amino acids were susceptible to MN and showed positive association with the presence of 
anti-PLA2R antibodies (P=0.001).
Conclusions: We concluded that two alleles of HLA class II genes, and the encoding 
three amino acid residues on two positions at the epitope-binding pockets of MHC DRβ1 
chain, were responsible for higher risk to MN.
Funding: Government Support - Non-U.S.
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Somatic Mosaicism and Variant Frequency Detected by Next Generation 
Sequencing in X Linked Alport Syndrome  Naohiro Kamiyoshi,1 Kandai 
Nozu,1 Tomohiko Yamamura,1 Takeshi Ninchoji,1 Yuko Shima,2 Koichi 
Nakanishi,2 Norishige Yoshikawa,3 Kazumoto Iijima.1  1Pediatrics, Kobe Univ 
Graduate School of Medicine, Kobe, Hyogo, Japan; 2Pediatrics, Wakayama 
Medical Univ, Wakayama, Japan; 3Pediatrics, National Center for Child Health 
and Development, Tokyo, Japan.
Background: Alport syndrome is a hereditary disorder of type IV collagen, 
characterized by chronic kidney disease progressing to end-stage renal disease, sensorineural 
hearing loss, and ocular abnormalities. Approximately 85% of Alport syndrome patients 
show X-linked inheritance (XLAS) and variants in the type VI collagen, a5 gene (COL4A5), 
which encodes the type IV collagen α5 chain. Although male patients with XLAS usually 
develop end-stage renal disease before 30 years of age, some male patients show a milder 
phenotype and develop end-stage renal disease later in life. However, the molecular 
mechanisms associated with this milder phenotype have not been fully identified.
Methods: We genetically diagnosed 186 male patients with suspected XLAS between 
January 2006 and August 2014. Genetic examination involved: (1) extraction and analysis of 
genomic DNA using polymerase chain reaction and direct sequencing using Sanger’s method 
for all patients; and (2) next-generation sequencing to detect variant allele frequencies for 
four patients who suspected somatic mosaic variants.
Results: We identified somatic mosaic variants in the COL4A5 in four patients. 
Interestingly, two of these four patients with variant frequencies in kidney biopsies or 
urinary sediment cells of ≥50% showed hematuria and moderate proteinuria, while the 
other two with variant frequencies of <50% were asymptomatic or only had hematuria.
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Conclusions: De novo variants can occur even in asymptomatic male cases of XLAS 
resulting in mosaicism, with important implications for genetic counseling. This is the 
first study to show a tendency between the variant allele frequency and disease severity 
in male XLAS patients with somatic mosaic variants in COL4A5. Although this is a very 
rare status of somatic mosaicism, further analysis is needed to show this correlation in a 
larger population.
FR-PO161
A New Non-Invasive Method to Examine Collagen α5(IV) Expression Using 
Plucked Hair Follicles: Analysis of an X-Linked Alport Family with a Novel 
COL4A5 Splice Region Variant  Andrew F. Malone, Steven Daniel Funk, 
Jeffrey H. Miner.  Renal Div, Dept of Medicine, Washington Univ, St. Louis, MO.
Background: Alport syndrome is a hereditary disease caused by mutations in COL4A5 
in 85% of cases. Many different mutation types in this gene have been described. Levels and 
patterns of type IV collagen deposition are variable in the glomerular basement membranes 
of Alport kidneys. As COL4A5 is also expressed in the skin, we sought to characterize 
COL4A5 deposition in the basement membrane of plucked hair follicles from a family with 
a novel COL4A5 variant as a way of confirming the functional significance.
Methods: Whole-exome sequencing was done on the proband of a family with biopsy 
(renal and skin)-confirmed Alport syndrome. Sanger sequencing was performed on all 
affected family members and a married-in unaffected individual. Immunofluorescence 
microscopy was performed on whole mount and sectioned hair follicles co-stained with 
monoclonal antibodies to collagen a2 and α5(IV). Staining intensity between males and 
females, affecteds and unaffecteds, was analyzed.
Results: Family WU1 is a 3 generational family with chronic kidney disease secondary 
to Alport syndrome. Affecteds are in each generation, and both males and females are 
symptomatic. Whole-exome sequencing of affected individual 3227 revealed a novel splice 
region variant c.1780-6T>G in COL4A5. There were no other potentially pathogenic variants 
found in COL4 or other podocyte genes. This variant was confirmed by Sanger sequencing 
and segregated with disease. Reduced and abnormal expression of COL4A5 protein was 
confirmed in affected family members by immunofluorescence microscopy of hair follicles.
Conclusions: We confirmed linkage of a novel splice region variant in COL4A5 to 
Alport syndrome in a family with a typical X-linked inheritance pattern; this variant may 
be pathogenic. We developed and validated a new approach to characterize the expression 
of COL4A5 protein using immunofluorescence microscopy of plucked hair follicles. 
Furthermore, we demonstrated variability of COL4A5 expression between patients in this 
family, suggesting intermittent failure of splicing and/or variable lyonization in females.
Funding: NIDDK Support
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X-Linked Alport Dogs Demonstrate Mesangial Filopodial Invasion of the 
Capillary Tuft as an Early Event in Glomerular Damage  Sabrina D. Clark,1 
Mary B. Nabity,1 Rachel Cianciolo,2 Brianna M. Dufek,3 Dominic E. Cosgrove.3 
1Veterinary Pathobiology, Texas A&M Univ, College Station, TX; 2Veterinary 
Biosciences, The Ohio State Univ, Columbus, OH; 3Genetics, Boys Town 
National Research Hospital, Omaha, NE.
Background: X-linked Alport syndrome (XLAS), caused by a mutation in the type 
IV collagen COL4A5 gene, accounts for approximately 80% of the cases of human Alport 
syndrome. Dogs with XLAS have a similar clinical progression. Prior studies in autosomal 
Alport mice demonstrated early mesangial cell invasion as the source of laminin 211 in 
the glomerular basement membrane (GBM), leading to proinflammatory signaling. Thus 
far, these findings have not been confirmed in a large animal model.
Methods: XLAS dogs and unaffected littermates were monitored with serial 
clinicopathologic data and renal biopsies. Biopsies were obtained at the onset of 
microalbuminuria (MA), overt proteinuria (urine protein:creatinine (UPC) > 2), onset 
of azotemia, moderate azotemia, and at euthanasia. Glomeruli were analyzed by 
immunohistochemistry.
Results: With disease progression, XLAS dogs showed a progressive decrease in 
renal function (based on serum creatinine, symmetric dimethylarginine (SDMA), UPC, 
and iohexol clearance) and increase in interstitial fibrosis and glomerulosclerosis (based on 
light microscopy and/or immunostaining for aSMA and fibronectin). The only identifiable 
structural abnormality at the time of MA was segmental multilamination of the GBM 
observed on transmission electron microscopy (TEM), which was more extensive when 
overt proteinuria developed. Co-localization studies showed that mesangial laminin 211 
and integrin α8β1 accumulate in the GBM, which was identified with laminin β2. This 
was first observed when overt proteinuria developed and coincided with evidence of 
mild cellular interpositioning on TEM, consistent with invasion of the capillary loops by 
mesangial cell processes.
Conclusions: These findings confirm, in a large animal model, the induction of 
mesangial filopodial invasion of the glomerular capillary tuft leading to the irregular 
deposition of mesangial laminin 211 as an early initiating event in Alport glomerular 
pathology.
Funding: Pharmaceutical Company Support - IDEXX Laboratories, Inc
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Drug Repurposing for the Treatment of Experimental Alport Syndrome 
Vanessa R. Williams,1 Ana Konvalinka,2 Xuewen Song,2 Eun Hui Bae,3 Fei 
Fang,1 Rohan John,4 York P. Pei,2 James W. Scholey.1,2  1Inst of Medical Science, 
Univ of Toronto, Canada; 2Div of Nephrology, Univ of Toronto, Canada; 
3Internal Medicine, Chonnam National Univ Medical School, Korea; 4Pathology, 
Univ of Toronto, Canada.
Background: Alport Syndrome (AS) is a hereditary nephropathy caused by mutations 
in genes that encode type IV collagen, leading to progressive injury and eventually end-stage 
renal disease. Currently there are few effective therapies for AS. Therefore we applied a 
drug repurposing strategy, utilizing data on drugs currently approved for use in humans, 
to identify a novel AS treatment.
Methods: 129/SvJ Col4a3-/- (KO) and wild-type (WT) mice were studied at 4 and 7 
weeks (N = 8/group). Histological analyses of formalin-fixed mouse kidney sections were 
performed. Plasma and 24-hour urine samples were collected. Global gene expression 
profiling of RNA from renal cortex was performed with the Affymetrix Mouse Gene 2.0 
ST Array. Significance Analysis of Microarrays (SAM) was used to identify differentially 
expressed genes. In silico drug repurposing with the Connectivity Map (CMAP) was used 
to identify drugs expected to effectively treat murine AS.
Results: Mice with AS developed a progressive rise in albuminuria and serum 
creatinine. These changes were associated with glomerulosclerosis and tubulointerstitial 
fibrosis. SAM was used to generate a disease signature of differentially expressed genes, 
comparing 7-week-old KO versus WT mice. The disease signature was used to query the 
CMAP. Vorinostat, a lysine deacetylase inhibitor, was the top drug predicted to reverse 
the signature. KO mice were treated with vehicle or vorinostat daily from 4 to 7 weeks 
of age. Vorinostat treatment induced hyperacetylation of kidney lysine residues. This was 
associated with reduced albuminuria, decreased aSMA protein expression, and reduced 
gene expression of inflammatory cytokines.
Conclusions: In silico drug repurposing identified a novel therapeutic approach to 
AS. In vivo testing of the putative therapy showed that vorinostat exerts a renoprotective 
effect. Further studies will better define the mechanisms underlying the protective effect 
of this novel therapy.
Funding: Private Foundation Support, Government Support - Non-U.S.
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KCTD1 Mutations in Scalp-Ear-Nipple (‘Finlay-Marks’) Syndrome: A 
Further Cause of Thin Basement Membrane Nephropathy  Dongmao Wang,1 
Peter Diakumis,2 Melanie Bahlo,2 Deb J. Colville,1 Judith A. Savige.1  1Medicine, 
The Univ of Melbouren (Melbourne Health), Melbourne, VIC, Australia; 
2Bioinformatics, WEHI, Melbourne, VIC, Australia.
Background: Scalp-Ear-Nipple syndrome is an ectodermal dysplasia, with a scalp 
defect, prominent ears and absent breasts. It results from mutations in KCTD1, an inhibitor 
of the transcription factor, AP2. AP2 regulates the expression of the collagen IV a3 and 
a4 chains, which are major components of the glomerular, corneal and retinal basement 
membranes. This study characterised the clinical phenotype in Scalp-Ear-Nipple syndrome 
and how mutations caused disease.
Methods: Two unrelated families with Scalp-Ear-Nipple syndrome were examined 
by a renal physician and an ophthalmologist. One family member provided a skin biopsy 
that was used to derive a fibroblast cell line. Urine specimens from two family members 
were used to study the expression of the collagen IV a3 and a4, and laminin a5 and b1 
transcripts.  The ER size was measured using immunohistochemistry  before and after 
treatment with PBA, a chemical chaperone.
Results: Seven family members had developed renal cysts and impaired renal 
function by late adulthood, and all 14 who were examined had astigmatism. A renal biopsy 
demonstrated a thinned glomerular membrane. One individual had a thinned cornea and 
the two who were examined with optical coherence tomography had a small optic disc, 
and thinned retinal nerve fibre layer. 
There was reduced transcription of the collagen IV a3 and a4 chains in the urine. The 
fibroblast cell cultures confirmed reduced laminin transcripts. ER size was increased in 
the fibroblast cells in vitro  but 4PBA chaperone treatment reduced ER size. However no 
KCTD1 mutations were identified in 20 individuals with Thin membrane nephropathy and 
no COL4A3/COL4A4 mutations nor in 20 individuals with familial astigmatism.
Conclusions: The clinical features of Scalp-Ear-Nipple syndrome are due to KCTD1 
mutations that affect basement membrane collagen IV and laminin expression. Chemical 
chaperones represent a potential treatment to delay renal failure.
FR-PO165
Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is 
Influenced by Age and Genotype  Behzad Najafian,1 Camilla Tøndel,2 Einar 
Svarstad,2 Michael L. West,3 Michael Mauer.5  1Univ of Washington; 2Univ of 
Bergen; 3Dalhousie Univ; 4Univ of Washington.
Background: Podocyte injury plays a key role in Fabry nephropathy, a major 
complication of Fabry disease. Identification of factors affecting podocyte injury may help 
to understand the pathophysiology of Fabry nephropathy. We studied effects of age and 
gendotype on podocyte GL3 accumulation in Fabry patients.
Methods: Kidney biopsies from 55 male Fabry disease patients, age 25 [4-65] (median 
[range]) years were studied using electron microscopic stereology. Podocyte GL3 volume 
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density [Vv(GL3/Podo)] was estimated and correlated with age and GLA mutation. The 
latter, known in 38 of these patients, included 35 classical, 2 cardiac variant (N215S) and 
one late onset (R363H) GLA mutation.
Results: There was a wide range of Vv(GL3/Podo) among the patients, 0.41 [0.003-
0.58]. Vv(GL3/Podo) increased linearly with age in younger patients up to age 30 years 
(r=0.56, p=0.001), but plateaued thereafter, varying within the narrow range of 0.35-0.58. 
There were 4 outliers, ages 37-50 with low Vv(GL3/Podo) (range 0.003-0.22), including 
patients with N215S (n=2) and R363H mutations and one patient whose GLA mutation 
was unavailable. Vv(GL3/Podo) directly correlated with urine albumin creatinine ratio 
(r=0.67, p=0.02) and foot process width (r=0.49, p=0.05) in males younger than 30 years. 
Volume density of podocytes per glomerulus was inversely correlated with age (r=-0.69, 
p=0.0001) across the age range with no plateauing, suggestive of continuous podocyte loss.
Conclusions: The fraction of podocyte cytoplasm filled with GL3 inclusions increase 
with age up to about age of 30 in Fabry males with classical GLA mutations and is 
associated with podocyte injury and albuminuria. Plateauing of podocyte GL3 volume 
density after age of 30 is suggestive of a threshold beyond which GL3 accumulation may 
not be compatible with podocyte survival. The clinical progression of Fabry nephropathy 
beyond age 30 in FD males with classical mutations could be reflected in other podocyte 
parameters such as podocyte hypertrophy and/or loss. Thus further studies are underway 
to explore these possibilities.
Funding: NIDDK Support, Pharmaceutical Company Support - Sanofi
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Outcomes of Patients Over 65 in the Canadian Fabry Disease Initiative 
Study  Michael L. West,1 Daniel G. Bichet,2 Aneal Khan,3 Joe T. Clarke,4 Sandra 
Sirrs,5 Steve Doucette,6 Christiane Auray-Blais,7 Kaye Lemoine.8  1Medicine, 
Dalhousie Univ, Halifax, NS, Canada; 2Medicine, Univ of Montreal, Montreal, 
QC, Canada; 3Genetics, Univ of Calgary, Calgary, AB, Canada; 4Emeritus, 
Univ of Toronto, Toronto, ON, Canada; 5Medicine, Univ of British Columbia, 
Vancouver, BC, Canada; 6Dept of Community Health and Epidemiology, 
Dalhousie Univ, Halifax, NS, Canada; 7Pediatrics, Univ of Sherbrooke, 
Sherbrooke, QC, Canada; 8Nursing, Nova Scotia Health Authority, Halfax, 
NS, Canada.
Background: The Canadian Fabry Disease Initiative (CFDI) is a multicentre 
prospective study of outcomes with enzyme replacement therapy (ERT) in Fabry disease. 
ERT has been shown to be of benefit in reducing Fabry cardiac and renal disease. There is 
uncertainty as to the benefits of ERT in older patients. We compared outcomes of ERT in 
patients over 65 years of age with the overall CFDI population.
Methods: Patients are reviewed every 6-12 months as to clinical status. ERT is provided 
every 2 weeks according to national guidelines with intravenous dose agalsidase alfa (0.2 
mg/kg) or agalsidase beta (1.0 mg/kg). Cardiovascular risk factor modification is promoted 
with use of ASA, statins and ACEi/ARB. Clinical outcomes are defined as stage 5 CKD, 
stroke/TIA, acute deafness, cardiac arrest, CHF, arrhythmia, unstable angina, MI, PTCA, 
pacemaker/ICD, AVR/CABG and death.
Results: As of Jan 2015, 429 subjects were enrolled. There were 51 patients over 65 
y, 68.6% female, and 60.8% on ERT with mean age 71.8 y. There were no differences in 
mean age, cardiac variant genotype, or time in the CFDI between those on ERT and those 
not. Compared with patients not on ERT, those on ERT had lower eGFR, greater proteinuria 
and higher LVMI at both baseline and 6 y later. Three patients not on ERT had 5 clinical 
events, prevalence 15%, no deaths with clinical event rate of 1/34.5 patient years. Twenty 
patients on ERT had 5 deaths, 38 clinical events, prevalence 64.5% and clinical event rate of 
1/9.3 patient years. Death was more likely in females 21% vs. males 8.3%. Patients over 65 
y had greater prevalence of cardiac indications for ERT than the overall CFDI population. 
Time to first clinical event was earlier in those on ERT (p=0.003).
Conclusions: Older patients with Fabry disease continue to have clinical events, 
mainly cardiac, despite ERT but appear to be living longer. Use of the Canadian Fabry 
Disease guidelines appears to successfully target high-risk older patients. ERT use in this 
subgroup appears to be of benefit.
Funding: Pharmaceutical Company Support - Genzyme, a Sanofi Company
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A Founder Haplotype of APOE-Kyoto Mutation Associated with 
Lipoprotein Glomerulopathy  Zhangxue Hu.  Dept of Nephrology, West China 
Hospital, Chengdu, Sichuan, China.
Background: Lipoprotein glomerulopathy (LPG) is a rare dominant inherited kidney 
disease with incomplete penetrance, histological characterized by the formation of 
intraglomerular lipoprotein thrombi. Their main clinical manifestation includes proteinuria, 
the elevated level of serum triglyceride and apolipoprotien E (apoE). Approximately 15 
APOE mutations associated with LPG have been reported so far, the most common being 
APOE-Kyoto mutation. Our previous study revealed the largest population of LPG from 
a county 200 kilometer near Chengdu city, in Sichuan province, China. All these patients 
shared APOE Kyoto mutation in e3 allele, which suggests that the APOE-Kyoto mutation 
spread from one founder.
Methods: we enrolled 26 patients with LPG from twenty-six unrelated Chinese families 
who were diagnosed by renal biopsy. After informed consents were obtained from them and 
their families, APOE mutation was detected by PCR-RFLP with Aor51HI, and a haplotype 
analysis of APOE was carried out by DNA sequencing using the method of TA cloning.
Results: We investigated the haplotype of APOE allele from twenty-six unrelated 
LPG families, and found the haplotype of APOE-Kyoto mutant allele was identical, and 
was likely derived from haplotype 1 of APOE3; as for the counterpart APOE allele, the 
haplotype of counterpart APOE allele was not identical. Also, we identified a new haplotype 
of APOE4 named 32.
Conclusions: The haplotype of APOE-Kyoto mutation allele associated with LPG in 
the narrow country was identical, suggesting that mutation is common in chinese patients 
through a founder effect. And patients didn’t have a common haplotype of counterpart 
APOE allele as the asymptomatic carriers, which association with the onset of LPG isn’t 
known. To the new haplotype 32 of APOE4, its clinical value isn’t clear now.
Funding: Government Support - Non-U.S.
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Eleven Pregnancies in Four Women with Atypical Hemolytic Uremic 
Syndrome  Martina M. Gaggl,1 Christof Aigner,1 Zoltan Prohaszka,2 Gere 
Sunder-Plassmann,1 Alice Schmidt.1  1Dept of Medicine III, Div of Nephrology 
and Dialysis, Medical Univ of Vienna, Vienna, Austria; 2IIIrd Dept of Internal 
Medicine, Research Laboratory, Semmelweis Univ, Budapest, Hungary.
Background: Pregnancy activates the maternal alternative pathway of the complement 
system due to presentation of paternal antigens. In females with atypical Hemolytic Uremic 
Syndrome (aHUS) – a disease of the complement regulatory proteins and C3 – each 
pregnancy can trigger life-threatening disease episodes.
Methods: Data were collected from patients with aHUS, enrolled in the Viennese 
TMA Cohort. Pregnancies occurred between 2002 and 2015.
Results: We report 11 pregnancies in 4 women (table 1). Two had an established 
diagnosis of aHUS prior to the first pregnancy (case 2 and 3). Case 1 presented with end-
stage renal disease due to TMA (biopsy-proven) 12 months after her first delivery and case 
4 presented postpartum after her uncomplicated first delivery. In 8 pregnancies females 
received preventive plasma infusions (PI, 200-1600 mL) 2 to 4 weeks apart. After kidney 
transplantation case 1 received a maintenance therapy (PIs once a month), which was 
intensified during the II. pregnancy to every other week. Two pregnancies (case 1 III., case 
4 III.) are currently ongoing without evidence of a disease flare so far. Nine pregnancies 
went without any complication and the offspring are healthy. One pregnancy (case 3, III., 
without PIs) resulted in an intrauterine fetal death at gestation week 36, but without signs 
of TMA in the mother. 
Case 1 Case 2 Case 3 Case 4
Ethnicity Caucasian Caucasian African African
Genetics: Disease-causing 
mutation CFH CFI, MCP CFH C3
Risk-haplotype/
polymorphism CFH-H3 C3
CFH, CFI, C3, 
CFB
CFH-H3, 
CFI, 
MCPggaac
Maintenance treatment PI none none none
Age of diagnosis of aHUS 
(yrs) 19 3 24 20
Age at renal transplant 
(yrs) 25 - 26 -
Number of pregnancies 3 2 3 3
Age at I. pregnacy 18 19 29 20
Conclusions: Our case series underscores the fact that the recommendation to avoid 
pregnancies in aHUS is questionable. The strategy to prevent disease episodes with plasma 
infusions might be superior to primary monitoring and initiation of treatment in acute 
disease episodes.
FR-PO169
Orally Administered Complement 5a Receptor Inhibitor CCX168 
Development in Atypical Hemolytic Uremic Syndrome  Miriam Galbusera,1 
Sara Gastoldi,1 Valentina Portalupi,1 Elena Mondo,1 Pirow Bekker,2 Thomas J. 
Schall,2 Marina Noris,1 Giuseppe Remuzzi.1  1Mario Negri Inst; 2ChemoCentryx.
Background: The orally administered complement 5a receptor (C5aR) inhibitor 
CCX168 is in Phase 2 development for antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis, atypical hemolytic uremic syndrome (aHUS), and IgA nephropathy. 
The anaphylatoxin C5a is a potent neutrophil attractant involved in neutrophil priming and 
activation as well as inducing endothelial cell injury. The latter causes increased neutrophil 
and platelet adhesiveness, leading to thrombosis, one of the hallmarks of aHUS. We report 
here progress in the aHUS program.
Methods: In an ex vivo thrombus formation system, serum from aHUS patients induces 
thrombus formation on microvascular endothelial cells. CCX168 was compared with the 
anti-C5 antibody eculizumab and soluble complement receptor 1 (sCR1) in this assay.
Results: CCX168 resulted in a dose-dependent inhibition of thrombus size.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
395A
J Am Soc Nephrol 26: 2015 Mendelian Disease of the Kidney Poster/Friday
° P<0001 vs control; * P<0.05, ** P<0.0001 vs untreated. 200 ng/mL CCX168, equal to 
trough plasma levels achieved with 30 mg CCX168 twice daily (b.i.d) in patients, showed 
maximal inhibition of aHUS serum-induced thrombus formation, comparable to sCR1 and 
eculizumab at 100 mg/mL, the trough level observed in aHUS.
Conclusions: CCX168 was effective in reducing aHUS-induced thrombus formation, 
similarly to eculizumab and sCR1. A Phase 2 study was launched. Ten patients with aHUS 
who are on dialysis are treated with CCX168 30 mg b.i.d. for 15 days. The primary aim 
is to evaluate whether in vivo CCX168 treatment dampens the ex vivo prothrombogenic 
properties of serum from these patients. Secondary outcome measures include the effect of 
CCX168 on biomarkers of complement, soluble thrombomodulin and VCAM-1, platelet 
count, hemoglobin, LDH, neutrophil count, and the pharmacokinetic profile of CCX168.
FR-PO170
Whole Exome Sequencing Reveals Mutation of PAPLN as a Novel Cause 
of Congenital Abnormalities of the Kidney and Urinary Tract (CAKUT) 
Jing Chen,1,6 Asaf Vivante,1,6 Julian Jakob Schulz,1 Shirlee Shril,1 Stefan Kohl,1 
Daw-yang Hwang,1 Richard P. Lifton,2,3 Elijah O. Kehinde,4 Velibor Tasic,5 
Friedhelm Hildebrandt.1,3  1Dept of Medicine, Boston Children’s Hospital, 
Harvard Medical School, Boston, MA; 2Dept of Human Genetics, Yale Univ 
School of Medicine, New Haven, CT; 3Howard Hughes Medical Inst, Chevy 
Chase, MD; 4Dept of Surgery, Kuwait Univ, Safat, Kuwait; 5Dept of Pediatric 
Nephrology, Univ Children’s Hospital, Skopje, Macedonia, The Former Yugoslav 
Republic of; 6These authors contributed equally to this work.
Background: Congenital anomalies of the kidney and urinary tract (CAKUT) are 
the most common cause of chronic kidney disease in children. Knowledge from animal 
models suggests that single gene mutations in genes governing kidney and urinary tract 
development may lead to CAKUT in humans. However, the genetic pathogenesis of human 
CAKUT remains mostly elusive.
Methods: To identify novel monogenic causes of CAKUT we applied homozygosity 
mapping with whole exome sequencing (WES) to 36 families with CAKUT. Then 
we investigated a worldwide cohort of ~1,600 families with CAKUT with a barcoded 
array based multiplex exon PCR (48x48 Fluidigm Access Array™) and next generation 
sequencing (Illumina MiSeq™).
Results: In a consanguineous family with isolated CAKUT we detected a homozygous 
protein truncating mutation (p.Arg480*) in the PAPLN gene by WES. PAPLN encodes 
papilin, a component of the extracellular matrix (ECM) that plays a role in ECM 
development and interacts with ADAMTS metalloproteases. Papilin contains several 
thrombospondin type I domains homologous to ADAMTS-1, in which mutations leads to 
very distinct CAKUT phenotype in mice.
Conclusions: We identified a recessive truncating mutation in PAPLN as a novel 
monogenic cause of CAKUT, suggesting that CAKUT in humans may result from disruption 
of ECM degradation and turn over.
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Whole Exome Sequencing Identifies Mutations in TUBAL3 as a Novel 
Cause of Congenital Abnormalities of the Kidney and Urinary Tract 
(CAKUT)  Shirlee Shril,1,6 Asaf Vivante,1,6 Jan Halbritter,1 Jing Chen,1 Julian 
Jakob Schulz,1 Stefan Kohl,1 Daw-yang Hwang,1 Elijah O. Kehinde,2 Richard 
P. Lifton,3 Martin Zenker,4 Friedhelm Hildebrandt.1,5  1Dept of Medicine, Boston 
Children’s Hospital, Harvard Medical School, Boston, MA; 2Dept of Surgery, 
Kuwait Univ, Safat, Kuwait; 3Dept of Genetics, Yale Univ School of Medicine, 
New Haven, CT; 4Dept of Human Genetics, Otto von Guericke Univ, Magdeburg, 
Germany; 5Howard Hughes Medical Inst, Chevy Chase, MD; 6These authors 
contributed equally to this work.
Background: Congenital anomalies of the kidney and urinary tract (CAKUT) are 
the leading cause of end-stage kidney disease in children. The morphogenesis of kidney 
and urinary tract is modified by genetic mutations that lead to CAKUT. Identifying these 
mutations will not only provide a deeper insight on disease mechanisms but also aids in 
improving diagnosis. TUBAL3 was identified as a potential candidate gene for causing 
CAKUT.
Methods: Homozygosity mapping with whole exome sequencing(WES) was 
performed in 20 consanguineous families with CAKUT from India. Homozygous recessive 
mutations within the homozygous region were further evaluated as the strongest candidates. 
Furthermore, we screened an additional cohort of 900 patients with CAKUT for additional 
mutations with a barcoded array based multiplex exon PCR (48x48 Fluidigm Access 
Array™) followed by next generation sequencing (Illumina MiSeq™) All identified 
mutations were confirmed by Sanger sequencing.
Results: A homozygous truncating mutation (p.Tyr179*) in the gene TUBAL3 was 
identified in the consanguineous Indian family A3838 using WES. We then independently 
detected another mutation homozygously (p.Gly10Ser) in the gene TUBAL3 in a family 
A1347 of Kurdish descent. TUBAL3 (Tubulin, alpha-like 3) is a protein coding gene and is 
very conserved across species. Tubulin is the major constituent of microtubules.
Conclusions: We identified recessive mutations in TUBAL3 as a novel single-gene 
cause of CAKUT. Futher genetic information and functional studies will help understand 
disease mechanisms and the role of TUBAL3 in the pathogenesis of CAKUT.
FR-PO172
Association of PAX2 and Other Gene Mutations with the Clinical 
Manifestations of Renal Coloboma Syndrome  Kengo Furuichi,1 Toshiya 
Okumura,2 Yasuyuki Shinozaki,2 Yasunori Iwata,2 Norihiko Sakai,1 Takashi 
Wada.2  1Div of Blood Purification, Div of Nephrology, Kanazawa Univ 
Hospital, Kanazawa, Japan; 2Div of Nephrology, Kanazawa Univ Hospital, 
Kanazawa, Japan.
Background: Renal coloboma syndrome (RCS) is characterized by kidney hypoplasia 
or dysplasia and abnormality of the optic nerve. Diagnosis of RCS is based on the 
morphological examination of the kidney, ophthalmologic findings, and family history. 
Approximately 170 cases with PAX2 gene mutations have been reported in cases with 
RCS worldwide. However, around 50% cases of RCS have no mutation in PAX2 gene.
Methods: To investigate the incidence and effects of mutations of PAX2 and 25 related 
genes, 26 patients with RCS were screened using next-generation sequence analysis, and 
candidate mutations were confirmed using Sanger sequencing. The correlation between 
mutations and clinical manifestation was evaluated.
Results: Thirty patients, including two family cohorts (n = 5 and 2), 19 patients with 
sporadic RCS, and 4 coloboma only control cases were evaluated in the present study. 
Screening the sequences of PAX2 and 25 other genes identified 46 nonsynonymous single 
nuclear changes and 9 indels, Among these candidate gene abnormalities, eleven PAX2 
mutations, including four novel mutations, were confirmed using Sanger sequencing, as 
were mutations in CHD7, SALL4, KIF26B, and SIX4. A SALL4 mutation was detected in 
one patient, and CHD7, KIF26B, and SIX4 mutations were detected in another patient, of 
whichKIF26B mutation is novel. Kidney function and proteinuria were more severe in 
patients with PAX2 mutations than in those without themutation. Moreover, the coloboma 
score was significantly higher in patients with PAX2 gene mutations. Three out of five 
patients with PAX2 mutations had focal segmental glomerulosclerosis diagnosed from 
kidney biopsies.
Conclusions: Our data indicate that PAX2 mutation is a key mutation in RCS and may 
make a major contribution to the pathogenesis of kidney and eye abnormalities. However, 
other factors and gene mutations may play a role, and further human and animal studies 
will be required to define the mechanism of pathogenesis of RCS.
Funding: Government Support - Non-U.S.
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Whole Exome Sequencing Identifies a Mutation in TTC25 as a Novel 
Monogenic Cause of Congenital Anomalies of the Kidney and Urinary 
Tract (CAKUT)  Julian Jakob Schulz,1 Asaf Vivante,1 Jing Chen,1 Shirlee 
Shril,1 Elijah O. Kehinde,2 Friedhelm Hildebrandt.1,3  1Dept of Medicine, Boston 
Children’s Hospital, Harvard Medical School, Boston, MA; 2Dept of Surgery, 
Kuwait Univ, Safat, Kuwait; 3Howard Hughes Medical Inst, Chevy Chase, MD.
Background: Congenital anomalies of the kidney and urinary tract (CAKUT) cover 
a wide range of renal malformations which account for most cases of pediatric CKD. So 
far more than 30 monogenic CAKUT-causing genes have been identified. However, for 
most cases the underline genetic cause is still unknown.
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Methods: To identify causative genes for CAKUT we investigated consanguineous 
families with CAKUT by applying whole exome sequencing (WES) combined with 
homozygosity mapping.
Results: In one family we detected a homozygous loss-of-start mutation in the gene 
TTC25 (tetratricopeptide repeat-containing 25). This mutation (p.Met1Thr; c.2T>C) was 
present in an affected child that had a posterior urethral valve, vesicourethral reflux and 
bilateral hydronephrosis. TTC25 plays a role in ciliogenesis, pronephric cilia function and 
signal transduction in the sonic hedgehog pathway (Hayes, J. M. et al., 2007. Dev. Biol. 
312: 115; Xu Y et al., 2015. PLOS ONE 10(4): e0124378). The latter has been shown 
to coordinate bladder as well as urethra formation in mice (Haraguchi R et al., 2007. 
Development 134(3):525; Haraguchi R et al., 2012. PLOS ONE 7(7): e42245).
Conclusions: By WES and homozygosity mapping we identified TTC25 as a novel 
monogenic CAKUT-causing gene if mutated.
Funding: NIDDK Support
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Phenotypic Analysis of a Cohort of Patients with Hepatocyte Nuclear Factor 
1 Beta (HNF1β) Mutations and Correlation with Established Scoring 
Systems  Emma Kaye Montgomery,1 John Andrew Sayer.1,2  1Renal Services 
Centre, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne 
and Wear, United Kingdom; 2Inst of Genetic Medicine, International Centre for 
Life, Newcastle Univ, Newcastle upon Tyne, Tyne and Wear, United Kingdom.
Background: Hepatocyte nuclear factor 1 beta (HNF1β) mutations may lead to a wide 
spectrum of clinical phenotypes including developmental defects of the kidney, pancreas, 
liver, and Mullerian duct. HNF1β mutations account for Renal Cysts and Diabetes (RCAD) 
syndrome. We reviewed patients with known HNF1β mutations to determine the range of 
phenotypes and identified if these patients would have been detected based on established 
scoring systems.
Methods: We selected patients who had been screened for HNF1β mutations from 2009 
to 2014 within our hospital. Serum magnesium, potassium, urate and creatinine levels were 
noted as well as renal morphology based on imaging. All positive and negative patients for 
HNF1β mutations had their phenotypes quantified and correlated with published HNF1β 
scoring systems and screening criteria.
Results: 135 patients were screened over 5 years. The cohort included 17 patients from 
10 families with confirmed HNF1β mutations. The majority of these patients had CKD 
stage 3, with a mean creatinine of 144 umol/L. Only 35% of mutation positive patients had 
both renal cysts and diabetes. 57% of patients had hypomagnesaemia, 50% of the patients 
had hyperuricemia and 4 patients had clinical symptoms of gout with 75% of these patients 
presenting with gouty symptoms before the age of 30. Using a published HNF1β scoring 
system, 16 patients reached a threshold score of >8, sufficient for a presumed diagnosis, 
validating the sensitivity of the scoring system in our cohort. Based on alternative screening 
criteria, all 17 patients would have been identified for screening.
Conclusions: The majority of patients with HNF1β mutations demonstrated 
hypomagnesaemia (50%), hyperuricaemia (53%) and deranged liver function tests (59%). 
RCAD remains a misnomer and patients with HNF1β mutations have a wide phenotypic 
spectrum, with only one third having renal cysts and diabetes. The use of a HNF1β scoring/
screening system will help to improve detection rates.
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CTNS Gene Mutations and Variants in Adult Hemodialysis Patients 
Craig B. Langman,1 Paul C. Grimm,2 Elena N. Levtchenko,3 Krishna R. Polu.4 
1Feinberg Sch Med, Northwestern U; 2Stanford U. Sch. of Med; 3Univ of Leuven; 
4Raptor Pharmaceuticals, Novato, CA.
Background: Nephropathic Cystinosis (NC), a rare, systemic, autosomal recessive 
disease due to CTNS gene mutations causes end-stage renal disease (ESRD). While most 
cases of NC are recognized in infancy (95%), late-onset NC with ESRD is rare but might 
be under-diagnosed. NC is rarely diagnosed in African-Americans (AA). Objective: To 
identify CTNS mutations and possible pathogenic variants (∆) in a representative sample 
of ESRD patients (pts) in the US.
Methods: Genomic DNA was extracted from whole blood from 4007 adult 
hemodialysis pts from the Davita biorepository. Fluidigm’s Access Array IFC was used 
for the CTNS target enrichment. Enriched DNA was sequenced on the Hiseq 2500 using 
2 x 100bp read length.Reads were mapped to the human genome version hg19 using the 
BWA aligner. Mutations and ∆ were called using both GATK and Samtools and confirmed 
by Sanger sequencing.
Results: 16 pts had homozygous (HoZ) and 52 pts had compound heterozygous 
(HTZ) CTNS sequence ∆. 1/68 pts had a known diagnosis of NC (W138X). In HoZ pts, 6 
had known mutations in CTNS (V42I;5/6 were AA) consistent with NC. 9 had upstream 
promoter mutations (UPM) (7 with -294C>T and 2 with -295G>C, a mutation locus with 
known disease association), and 3 of these pts were AA. In 52 HTZ CTNS sequence ∆, 2 
AA pts had UPM. The other 50 had combinations of changes in the CTNS coding sequence 
& promoter region.
Conclusions: The unexpected frequency of CTNS gene mutations & ∆ suggest that 
late-onset NC may be underrecognized in ESRD. These CTNS alterations need further study 
to determine pathogenicity and association with NC. In addition, CTNS mutations & ∆ in 
AA sub population signals a need for evaluation for a diagnosis of late onset nephropathic 
cystinosis in ESRD.
Funding: Pharmaceutical Company Support - Raptor Pharmaceuticals
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Shirlee Shril,1 Weizhen Tan,1 John Andrew Sayer,2 Danko Milosevic,3 Michelle 
Baum,1 Velibor Tasic,4 Friedhelm Hildebrandt.1,5  1Nephrology, Boston Children’s 
Hospital, Boston, MA; 2Inst of Genetic Medicine, Newcastle Univ, Newcastle 
upon Tyne, United Kingdom; 3Dept of Pediatric Nephrology, Univ of Zagreb 
Medical School, Zagreb, Croatia; 4Medical Faculty Skopje, Univ Children’s 
Hospital, Skopje, Macedonia, The Former Yugoslav Republic of; 5Howard 
Hughes Medical Inst, Chevy Chase, MD.
Background: Urinary stone disease (USD) is a prevalent condition that affects 10-
15% of adults in their lifetime. It is associated with high morbidity due to colicky pain, the 
necessity for surgical intervention, and sometimes progression to chronic kidney disease. 
In recent years, multiple monogenic causes of USD have been identified. However, the 
prevalence of each monogenic gene has yet to be systematically studied in a pediatric 
urinary stone cohort.
Methods: To determine the percentage of cases that can be explained molecularly by 
mutations in 1 of 30 known urinary stone genes, we conducted a high throughput exon 
sequencing analysis in an international cohort of consecutively recruited individuals from 
three renal stone clinics. The cohort consisted of 143 individuals under 18 year of age, 
with nephrolithiasis (n=123) or isolated nephrocalcinosis (n=20).
Results: We detected likely causative mutations in 16 of 30 analyzed genes, leading 
to a molecular diagnosis in 20% (29 of 143) of affected individuals; 14 of the 32 detected 
mutations were not previously described as disease causing (43.8%). We show that mutations 
in recessive genes are more likely to cause infantile onset disease, whereas mutations in 
dominant genes are more likely to manifest later.
Conclusions: We present the first exclusively pediatric cohort examined for monogenic 
causes of urinary stone disease, and our data demonstrates that important therapeutic and 
preventative measures may result from mutational analysis in individuals with early-onset 
USD.
Funding: Other NIH Support - DK1069274, DK1068306, and DK064614
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Mild Inhibition of Alanine-Glyoxylate Aminotransferase Translation as a 
Possible Treatment of Primary Hyperoxaluria Type I  Roman Lyakhovetsky,1 
Yaacov Frishberg,1 Bodo B. Beck,2 Ruth Belostotsky.1  1Pediatric Nephrology, 
Shaare Zedek Medical Center, Jerusalem, Israel; 2Inst of Human Genetics, 
Cologne, Germany.
Background: Primary hyperoxaluria type 1 (PH1) is a kidney stone disease, often 
leading to ESRD, caused by absence, deficiency or mistargeting of the liver peroxisomal 
alanine-glyoxylate aminotransferase (AGT), encoded by AGXT. The most frequent mutation 
G170R, responsible for 30% of PH1 cases in Caucasians, results in aberrant mitochondrial 
localization rather than catalytic inactivity. Modulating AGT maturation and folding has 
long been perceived as a therapeutic approach. Yet, numerous attempts over the years failed 
to rescue AGT mutants. We propose mild translational inhibition as a novel approach to 
improve folding and localization of AGT mutants.
Methods: The antihelminthic FDA-approved drug emetine, was used as a translation 
inhibitor. To ensure selective and specific discrimination between the mitochondrial (major) 
and the peroxisomal (minor) subpopulations of mutated AGT we developed the GlowAGT 
assay based on the recently described self-assembly split GFP approach.
Results: Using GlowAGT, WT-AGT but not G170R-AGT was detectable by GFP 
fluorescence, although both variants were visible by indirect immunofluorescence. Long-
term treatment with low concentrations of emetine showed statistically significant increase of 
fluorescent subpopulation of G170R-AGT. GFP fluorescence was exclusively co-distributed 
with the peroxisomal staining in all cases.
Conclusions: We have developed and applied successfully GlowAGT as a unique 
self-assembly split-GFP-based assay for detecting peroxisomal subpopulation of AGT. 
Using GlowAGT we show that mild translation inhibition by emetine is a novel therapeutic 
approach for PH1 caused by AGT misfolding/mislocalization 
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Functional Analysis of CLCNKB Mutations Causing Bartter Syndrome 
Type III  Yohan Bignon,1 Mathilde Keck,1 Stéphane Lourdel,1 Rosa 
Vargas-Poussou,2 Jacques Teulon,1 Olga Andrini.1  1Metabolisme et Physiologie 
Renales, Centre de Recherche des Cordeliers, UPMC, Paris, France; 2Dept of 
Human Genetics, Hopital Europeen Georges Pompidou, Univ Paris 5, Paris, 
France.
Background: Bartter Syndrome type III is a human autosomal recessive disease 
characterized by salt wasting, hypokalemic metabolic alkalosis and secondary 
hyperaldosteronism. Therefore, patients affected by Bartter syndrome type III display 
polyuria, polydipsia, dehydration, nephrocalcinosis and failure to-thrive. The disease 
is caused by inactivating mutations in the CLCNKB gene encoding for the ClC-Kb 
Cl- channel that is present in the distal nephron, where it mediates the basolateral step 
of Cl- absorption [2]. In this study, we have investigated the functional consequences of 
five previously reported pathogenic ClC-Kb missense mutations (A204T, A210V, P216L, 
G424R, G437R [3]).
Methods: We characterized the electrical activity, total protein expression, surface 
expression and subcellular localization of mutated forms of ClC-Kb in X. laevis oocytes 
and mammalian cell lines.
Results: Currents produced by G424R and G437R ClC-Kb channels were reduced by 
50%, in proportion to membrane targeting without any change in total protein abundance. 
A210V and P216L mutants did not produce any current but their membrane insertion was 
only partially reduced (50-80%). Protein abundance of A210V was decreased by half. 
Conversely, that of P216L was comparable to WT ClC-Kb, suggesting that the P216L 
mutation might alter channel gating. Finally, A204T seems to be electrically functional, 
rather well inserted into the plasma membrane and protein level is comparable to that of 
wild-type ClC-Kb.
Conclusions: In conclusion, the loss-of-function of ClC-Kb mutants is the result 
of different molecular defects including lower stability of the mutant protein, impaired 
membrane targeting and altered channel gating. References: [1] Simon D.B. et al, Nature 
Genetics 17, 171–178 (1997) [2] Andrini O. et al, American Journal of Physiology Renal 
Physiology, in press (2015).
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Changes in Urologic and Medical Treatment of Cystinuric Patients Over 
Time  Caroline Prot-Bertoye,1 Said Lebbah,2 Michel Daudon,3 Isabelle Tostivint,4 
Olivier Traxer,5 Bertrand Knebelmann,6 Marie Courbebaisse.1  1Physiology, 
APHP, Georges Pompidou European Hospital, Paris, France; 2Biostatistics, 
AP-HP, Necker Hospital for Sick Children, Paris, France; 3Physiology, AP-HP, 
Tenon Hospital, Paris, France; 4Nephrology, AP-HP, Pitié-Salpétrière Hospital, 
Paris, France; 5Urology, APHP, Tenon Hospital, Paris, France; 6Nephrology, 
AP-HP, Necker Hospital for Sick Children, Paris, France.
Background: Cystinuria is the most common monogenic nephrolithiasis disorder, but 
few studies have described its urological and medical treatment in a large cohort.
Methods: We retrospectively collected data from 442 French cystinuric patients. 
Clinical and laboratory data, urological and medical treatments were described. A mixed-
effects logistic regression model was used to estimate the effects of urinary pH, urinary 
specific gravity, and cysteine-binding thiol agents (CBT) on the risk of cystine crystalluria.
Results: The median follow-up [min-max] was 15.8 years [0.1-65.6]. The average 
annual rate of surgical procedures increased with time (P<0.001). During the period 2000-
2004, 7.3 % of patients had at least one flexible ureteroscopy, versus 23.2 % after 2005 
(P<0.001). CBT were prescribed for 55.3% of patients. Prescription of tiopronin increased 
with time in newly symptomatic patients (P<0.001). At least one side effect was recorded in 
23.7% of patients treated with tiopronin, and 30.2% of patients treated with D-penicillamine 
(P=0.23). Increasing urinary pH and decreasing urinary specific gravity significantly reduced 
the risk for a patient to have a cystine crystalluria whereas D-penicillamine and tiopronin 
did not reduce this risk. The estimated probability of cystine crystalluria was 45%, 38%, 
31% and 25% for an urinary pH of 6.5, 7.0, 7.5 and 8 and was 52%, 31% and 16% for an 
urinary specific gravity of 1015, 1010 and 1005.
Conclusions: The number of urological interventions and the prescription of tiopronin 
has increased over time. We show for the first time that D-penicillamine and tiopronin 
don’t impact cystine crystalluria although inducing frequent adverse effects in the same 
proportions. Urinary pH above 7.5 and morning urinary specific gravity below 1005 should 
be the goals of medical therapy.
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Defect of Interdependent Membrane Targeting and Endocytosis of 
Cubilin and Amnionless Leads to Imerslund-Gräsbeck Syndrome 
Tomohiro Udagawa,1 Ken-ichiro Miura,1 Akihiko Saito,2 Yutaka Harita.1 
1Pediatrics, Graduate School of Medicine, The Univ of Tokyo, Bunkyo-ku, 
Tokyo, Japan; 2Applied Molecular Medicine, Niigata Univ Graduate School of 
Medical and Dental Sciences, Chuo-ku, Nigata, Japan.
Background:  Imerslund-Gräsbeck syndrome (IGS) is an autosomal recessive disorder 
characterized by low-molecular-weight proteinuria and megaloblastic anemia. IGS is 
caused by mutations of either cubilin (CUBN) or amnionless gene (AMN). Cubilin forms 
protein complex with amnionless (cubam complex) and functions as the receptor-mediated 
endocytotic machinery.
Methods: A six year-old boy with history of megaloblastic anemia was diagnosed with 
IGS because of low-molecular weight proteinuria. Whole-exome sequencing identified novel 
heterozygous missense mutations, one each in CUBN and AMN. The CUBN mutation was 
de novo and the AMN mutation was inherited from a healthy parent.
Results: Renal biopsy showed translocation of amnionless from the apical membrane to 
the cytoplasm of proximal tubular cells.  Using cultured cells, the mechanism of membrane 
trafficking of cubam and the effect of the mutations were analyzed. Although wild-type 
cubilin and amnionless were interdependently targeted to the cell membrane, the CUBN 
or AMN mutation abrogated membrane expression and endocytosis without affecting the 
interaction between cubilin and amnionless. Coexpression of amnionless induced maturation 
of cubilin protein, and the modification were identified by stable isotope labeling using 
amino acids in cell culture (SILAC)-based quantitative mass spectrometry. Notably, the 
CUBN mutation completely abrogated the amnionless-dependent glycosylation of cubilin. 
Tunicamycin or substitution of several Asn residues to Asp abrogated membrane targeting 
of cubam without affecting cubilin and amnionless interaction, further supporting a role 
of cubilin glycosylation.
Conclusions: Our results demonstrate that digenic heterozygosity can lead to IGS 
and suggest that interdependent membrane trafficking of cubam complex mediated by 
posttranslational modification is crucial for the renal and intestinal absorption.
FR-PO181
Metabolic Control of Nephron Progenitor Cell Renewal and Differentiation 
Anna Abrams, Jiao Liu, Zubaida R. Saifudeen.  Pediatrics, Tulane Univ, New 
Orleans, LA.
Background: Nephron progenitor cells (NPC) availability and differentiation 
potential determine nephron endowment. Emerging data from embryonic stem cells and 
other developing systems emphasizes the significance of energy metabolism in cell fate 
determination. Systemic metabolic dysfuntion such as hyperglycemia alters neural and 
adipocyte stem cell fate. Nephron deficit in kidneys of infants of diabetic mothers (idm) is 
known; however the effect on NPC and nephrogenesis under maternal hyperglycemia are 
unknown. Metabolic parameters of renewing NPCs are also unknown. Based on published 
stem cell data, we hypothesized that NPC self-renewal and differentiation are balanced 
by energy metabolism.
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Methods: a. Fetal kidneys were exposed to maternal hyperglycemia using 
Streptozotocin (STZ). P0 kidney sections were immunostained to detect apoptosis (active 
caspase3) in the CM (Six2 and NCAM) and nascent nephrons (Lef1 and NCAM). b. 
Glycolysis was inhibited ex vivo in E12.5 kidneys by pharmacological inhibition of 
PFKFB3 (YN1 5-25nM). c. Glycolysis and oxidative phosphorylation were measured in 
NPC of Six2CreGFP+;p53fl/fl, a genetic model of impaired cap mesenchyme renewal.
Results: a. CM of P0 kidneys of STZ-treated females showed increased apoptosis 
and reduction in nascent nephron number (Lef1+ and NCAM+). b. Glycolysis inhibition 
resulted in a smaller dispersed CM, accelerated but not ectopic differentiation of the NPC 
with up to a 50% increase in Lhx1+ nascent nephrons 24-48h post-treatment, and decreased 
Cited1 expression by QPCR in isolated NPC. UB tip and branch numbers were unchanged. 
Thus, increased nephrogenesis was independent of UB branching. Expression of Wnt4 was 
unchanged. c.Conditional deletion of p53 in NPC also resulted in dispersed CM, depletion 
of the Cited1+/Six2+ NPC independent of apoptosis, and hypoplastic kidneys with fewer 
nascent nephrons. Isolated mutant cells show reduced basal oxygen consumption rate and 
decreased maximal respiratory capacity. Accordingly, the mutant cells exhibit a significant, 
nearly two-fold decrease in ATP (p<0.005, n=3).
Conclusions: Our data are consistent with the idea that the metabolic status of the 
NPC is a critical determinant of NPC renewal and differentiation.
Funding: NIDDK Support, Other NIH Support - NIH-NIGMS
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Prorenin Receptor Signaling Promotes Nephron Induction During Mouse 
Kidney Development  Renfang Song,1 Graeme James Preston,1 Laura R. Kidd,2 
Ihor V. Yosypiv.1  1Pediatrics, Tulane Univ, New Orleans, LA; 2Pathology, Tulane 
Univ, New Orleans, LA.
Background: Deficient nephrogenesis is the major factor contributing to congenital 
renal hypodysplasia (RHD), one of the leading causes of childhood end-stage kidney 
disease. Nephron induction is driven by reciprocal interactions between progenitor cells 
of the cap mesenchyme and the ureteric bud (UB).
Methods: To determine the potential role of the prorenin receptor (PRR) in 
nephrogenesis, we generated mice with a conditional deletion of the PRR in Six2-positive 
nephron progenitors of the cap mesenchyme and their epithelial derivatives (Six2PRR-/-).
Results: Inactivation of PRR in nephron progenitors caused a marked decrease in the 
number of developing nephrons, severe congenital RHD with collapsed glomeruli and an 
enlarged Bowman’s space (such as those seen with a collapsing FSGS), podocyte foot 
process effacement and early postnatal death within 48 hours from birth. UB branching was 
greatly reduced, likely secondary to decreased nephrogenesis. Reduced congenital nephron 
endowment resulted from premature depletion of nephron progenitor cell population due 
to impaired progenitor cell proliferation and loss of normal molecular inductive response 
to canonical Wnt/ȕ-catenin signaling Zithin the metanephric mesenchyme. At  months 
of age, heterozygous Six2PRR+/- mice exhibited focal glomerulosclerosis, decreased kidney 
function and massive proteinuria.
Conclusions: Collectively, these results are consistent with a cell-autonomous 
requirement for the PRR within nephron progenitors for progenitor maintenance, induction 
of nephrogenesis, normal kidney development and function. Thus, PRR is a potential 
candidate for future genetic screening studies in patients with congenital RHD and 
proteinuric kidney disease.
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Functional Dissection of Enhancers for Bmp7 in Kidney Development 
Taro Tsujimura,1,2,3 Osamu Takase,1,2,3 Masaomi Nangaku,2 Keiichi Hishikawa.1,2,3 
1Advanced Nephrology and Regenerative Medicine, The Univ of Tokyo 
Hospital, Tokyo, Japan; 2Div of Nephrology and Endocrinology, The Univ of 
Tokyo Hospital, Tokyo, Japan; 3Div of Tissue Engineering, The Univ of Tokyo 
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Background: Bmp7 is a critical player in the kidney development, as shown by 
its sever retardation in the KO mice of the gene and their subsequent perinatal lethality 
due to the malfunction. Previous studies identified two potential enhancers for the Bmp7 
expression in the developing kidney around the locus: one residing inside the 1st intron of 
Bmp7 for expression in the developing ureteric bud; the other located downstream of the 
3’ end of Bmp7, which is rather active in the metanephric mesenchymal cells. Consistently, 
Bmp7 is also expressed in these two distinct domains. However, neither the requirement of 
these elements nor the precise roles of Bmp7 secreted from these different cell types for 
the kidney development has been uncovered so far. In this study, we aimed to characterize 
the roles of the two enhancers to better understand the cis-regulation of Bmp7 and the 
kidney development.
Methods: We established and analyzed homozygous mice carrying a large genomic 
deletion of the downstream region of Bmp7 including the mesenchymal enhancer.
Results: We found that they have significantly smaller body size than their wild type 
littermates, although they are viable unlike the KO mice of Bmp7. We previously showed 
that the same deletion also disrupts the topological partition of the chromatin conformation 
between the Bmp7 domain and the neighboring one of another developmental gene, Tfap2c, 
resulting in a merger between them (Tsujimura et al. PLoS Genetics 2015). Interestingly, 
upon this deletion, we scored significant up-regulation of Tfap2c in the kidney probably 
by the action of the intron enhancer.
Conclusions: These results suggest that the endogenous genomic context guarantees 
robustness in the regulation of the kidney development by linking the more important 
ureteric bud enhancer to Bmp7 tightly. The differential roles of the two enhancers will be 
further discussed based on the histological and functional analysis of the kidney in the 
homozygous deletion mice.
Funding: Government Support - Non-U.S.
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BMP7 Regulates Expansion of the Postnatal Nephron  Mary E. Taglienti,1 
Seymour Rosen,2 Jordan A. Kreidberg.1,3,4  1Dept of Medicine, Boston Children’s 
Hospital, Boston, MA; 2Dept of Pathology, Beth Israel Deaconess Medical 
Center, Boston, MA; 3Dept of Pediatrics, Harvard Medical School, Boston, 
MA; 4Harvard Stem Cell Inst, Cambridge, MA.
Background: The factors that regulate the expansion of nephrons after their initial 
induction and differentiation are largely unknown. Bone morphogenic protein 7 (BMP7) 
is a crucial factor driving proliferation and self-renewal of nephron progenitor cells during 
the development of the embryonic kidney. In this study we investigated a potential role for 
BMP7 as a regulator of post-induction nephron growth and differentiation.
Methods: The Bmp7 gene was conditionally mutated in progenitor cells using Six2-
GFP/Cre. Kidneys from mutant and control mice were analyzed using a novel approach 
to quantify proximal tubule expansion as an indicator of nephron growth in the postnatal 
mouse.
Results: Kidneys of Bmp7 conditional mutant mice were smaller with reduced numbers 
of nephrons. Bmp7 was expressed in developing nephron tubules of control kidneys and 
was absent from mutant kidneys. Proximal tubule growth, as determined by computationally 
measuring the area of lectin-stained proximal tubules in postnatal kidneys, was reduced 
in mutant kidneys. However, the proximal tubule area per glomerulus was increased in 
mutant kidneys, indicating that those nephrons that were induced underwent hypertrophy. 
Proliferation, as defined by Ki67+ nuclei per LTL lectin+ cells within the proximal tubule 
compartment, was initially greater in mutants but declined by P10.
Conclusions: Loss of Bmp7 in progenitors leads to low nephron number. Bmp7 appears 
to be an important driver of postnatal nephron expansion. This phenotype is similar to 
oligomeganephronia and may be used to understand the basis for nephron hypertrophy in 
low nephron number situations.
Funding: NIDDK Support
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Grainyhead-Like 2 (Grhl2) Regulates Collecting Duct Barrier Function, 
Aquaporin 2 Expression and Urinary Concentration  Christian Hinze,1,2 
Janett Ruffert,2,5 Katharina Walentin,2 Max Werth,3 Jonathan M. Barasch,3 
Andong Qiu,3 Kerim Mutig,4 Sebastian Bachmann,4 Kai M. Schmidt-Ott.1,2  1Dept 
of Nephrology, Charité-Universitätsmedizin, Berlin, Germany; 2Max Delbrueck 
Center for Molecular Medicine, Berlin, Germany; 3Div of Nephrology, Columbia 
Univ, New York; 4Dept of Anatomy, Charité-Universitätsmedizin, Berlin, 
Germany; 5Urological Research Laboratory, Charité-Universitätsmedizin, 
Berlin, Germany.
Background: Osmotic homeostasis is tightly regulated by the kidney and its collecting 
ducts which form tight barriers, thereby maintaining steep concentration gradients and 
allowing transcellular reabsorption of water via aquaporins. The transcription factor 
grainyhead-like 2 (Grhl2) is highly expressed in renal collecting ducts. Using cultured 
collecting duct cells, we recently showed that Grhl2 regulates epithelial barrier formation 
and lumen expansion via a target gene set comprising the transcription factor Ovo-like 2 
(Ovol2), the small GTPase Rab 25 (Rab25) and the tight junction component claudin 4 
(Cldn4). The role of Grhl2 in the collecting duct in vivo is unknown.
Methods: To investigate the role of Grhl2 in the renal collecting duct, we generated a 
collecting duct-specific knockout with Hoxb7/Cre; Grhl2flox/- mice, which exhibit a deletion 
of Grhl2 protein in most cells of the collecting duct. The molecular and cellular alterations 
in their kidneys and their response to water deprivation were analyzed.
Results: Transcriptional profiling of Hoxb7/Cre; Grhl2flox/- mice kidneys and control 
littermates showed deregulation of Ovol2, Rab25 and Cldn4, but also differential expression 
of Aquaporin 2 (Aqp2). Following water deprivation, Grhl2-deficient mice displayed 
significantly lower urinary osmolality at 6 hours (P=0.001) and 24 hours (P=0.04) when 
compared to control mice. Moreover, Grhl2-deficient mice had more than 35% more 
urine volume during the first 24 hours in response to water deprivation when compared 
to controls (P=0.005).
Conclusions: Our data indicate that Grhl2 critically participates in water homeostasis, 
epithelial barrier function and Aqp2 expression. This might be of relevance to diseases 
involving defective renal responses to water deprivation.
FR-PO186
Loss of the Transcription Factor Tcf21 in the Renal Stroma Leads to Polyuria 
and Defects in Tubular Development  Shintaro Ide,1 Yoshiro Maezawa,1 
Rizaldy P. Scott,2 Tuncer Onay,2 Kana Ide,1 Minoru Takemoto,1 Koutaro Yokote,1 
Susan E. Quaggin.2  1Clinical Cell Biology and Medicine, Chiba Univ Graduate 
School of Medicine, Chiba, Japan; 2Feinberg Cardiovascular Research Inst 
and Div of Nephrology and Hypertension, Northwestern Univ, Chicago, IL.
Background: Renal stromal cells serve as a supportive framework for nephrons and 
the collecting duct network, produce erythropoietin, and contribute to renal fibrosis when 
they undergo myofibroblast-like transformation. Tcf21/Pod1 is a bHLH transcription factor 
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strongly but not restrictively expressed in the developing renal stroma. Conventional Tcf21 
knockout mice die perinatally and have maldevelopment of nephrons and mispatterning 
of the renal interstitium. However, the precise function of Tcf21 within renal stromal 
cells has yet to be clarified as Tcf21 is also expressed within the condensing metanephric 
mesenchyme during development.
Methods: In order to characterize the role of Tcf21 in stromal development and 
function, we bred floxed Tcf21 mice with Foxd1-Cre mice allowing specific inactivation 
of Tcf21 within the developing renal stroma and its derivatives.
Results: Mice lacking Tcf21 in the renal stroma (Tcf21str/str) do not have an overt 
phenotype at birth and exhibit normal ureteric bud branching in embryonic kidney explant 
cultures. However, by 4 weeks postnatal, Tcf21str/str mutant mice develop polyuria similar 
to diabetes insipidus. Polyuric mutant mice produce urine with significantly reduced 
osmolarity and creatinine levels but with higher levels of sodium and chloride relative 
to control littermates. Mutant kidneys are smaller, have a disorganized interstitium, and 
shriveling of the medullary rays due to a reduction in the loops of Henle and collecting 
ducts, whereas proximal tubule densities appear undisturbed.
Conclusions: Specific inactivation of Tcf21 in the stroma causes polyuria underscoring 
an important role of the renal interstitium in regulating postnatal development of tubules 
critical for urine concentration. Identification of direct targets of Tcf21 will provide novel 
insights regarding interactions between stromal cells, renal tubules and the collecting ducts.
Funding: Government Support - Non-U.S.
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Genetic Deletion of Cyclooxygenase-2 Impairs Glomerular Slit Diaphragm 
Formation During Late Stages of Kidney Development  Kirsten Madsen,1,2 
Niels Marcussen,2 Boye Jensen.1  1Dept of Cardiovascular and Renal Research, 
Univ of Southern Denmark, Odense, Denmark; 2Dept of Pathology, Odense 
Univ Hospital, Odense, Denmark.
Background: Renal cyclooxygenase-2 (COX-2) expression is necessary for normal 
glomerular development. Impaired COX-2 activity has been associated with decreased 
expression of VEGF, a vascular growth factor of significant importance for glomerular 
capillary development. Therefore experiments were designed to test the hypothesis that 
COX-2 expression supports glomerular development through stimulation of capillary 
loop formation.
Methods: Kidney tissue was collected from a developmental series of COX-2 knock-
out (KO) mice and wild-type littermates (WT).
Results: Renal COX-2 expression showed developmental regulation with significantly 
higher COX-2 expression at postnatal (P) days 1 and P7 than at any later time points (P14, 
P21 and P40). Quantitative unbiased stereology at P28 showed significantly reduced 
glomerular number in COX-2 KO mice compared to WT littermates (8188 ± 781 and 12251 
± 454 glomeruli/kidney respectively, P=0.0001). Subcapsular accumulation of small and 
immature glomeruli was seen in COX-2 KO mice whereas glomeruli deeper in the cortex 
towards the medullary junction appeared normal. Tissue abundance of VEGF, angiopoietin-1 
and -2 mRNAs was significantly reduced in COX-2 KO mice compared to WT at P7. By 
electron microscopy at P28, immature subcapsular glomeruli showed normal appearance 
of fenestrated endothelial cells but severe podocyte foot process effacement and absence 
of mesangial cells. Normal morphology was confirmed in glomeruli deeper in the cortex. 
At P7, COX-2 KO mice showed reduced expression of slit diaphragm proteins nephrin 
and podocin but not synaptopodin compared to WT.
Conclusions: In summary, deletion of COX-2 leads to decreased renal expression 
of vascular growth factors without changes to glomerular endothelial cell ultrastructure 
and severe podocyte foot process effacement and impaired expression of slit diaphragm 
proteins. In conclusion, COX-2 activity is necessary for normal podocyte function and slit 
diaphragm formation during late stages of kidney development.
Funding: Private Foundation Support
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Functional Cross Talk Between Tyrosine Phosphorylation of Crumbs 
Homolog 2 and Mechanistic Target of Rapamycin Complex1 in Developing 
Podocyte  Sho Hamano, Yukino Nishibori, Kunimasa Yan.  Dept of Pediatrics, 
Kyorin Univ School of Medicine, Mitaka, Tokyo, Japan.
Background:    Mutation of crumbs homolog 2 (CRB2) is a novel cause of congenital 
nephrotic syndrome. CRB2 is suggested to function in apical polarity and epithelial integrity; 
however, how CRB2 functions in podoyte development is unknown. Other isoform: CRB3 
is known to be involved in deactivation of mechanistic target of rapamycin complex1 
(mTORC1): a master regulator for cell growth. The objective of the present study is to 
determine functional cross talk between CRB2 tyrosine phosphorylation and mTORC1 
pathway and the relevance of CRB2-mTORC1 interaction to podocyte development.
Methods:    MDCK cells expressing mouse full-length CRB2 or mutated-CRB2 
lacking tyrosine phosphorylation site were established. Specific antibodies against CRB2 
intracellular domain (int-CRB2Ab) or tyrosine phosphorylation site (pY-CRB2Ab) were 
generated. The samples from cultured cells and rat kidneys were subjected to Western blot 
study and immunofluorescence microscopy.
Results:    Int-CRB2Ab determined CRB2 to locate at the apicobasolateral membrane 
in wild-CRB2 cells. Specificity of pY-CRB2Ab was confirmed by using samples from 
mutated-CRB2 cells and wild-CRB2 cells treated with protein tyrosine phosphatases 
inhibitor. Int-CRB2Ab identified that CRB2 expression commenced at the comma-shaped 
body stage, observed in the apical side of glomerular epithelium. CRB2 in the S-shaped 
body was still visible at the apical side of immature podocytes, then translocated along the 
lateral side to basal side during capillary stage.At the mature stage, CRB2 was observed in 
the podocyte foot processes. In contrast, phosphorylation of CRB2 was determined faintly 
in immature podocyte at the S-shaped body stage, intensely at the capillary stage and then 
disappeared at the mature stage. mTORC1 pathway was strongly activated in the podocyte 
at the mature stage, but was not in immature podocyte. Finally, mTORC1 in mutated-CRB2 
cells was activated more than that in wild-CRB2 cells.
Conclusions:    CRB2 tyrosine phosphorylation may regulate energy system of 
developing podocytes through suppressing excessive mTORC1 activation.
FR-PO189
Specific Deletion of Early B Cell Factor 1 within the Kidney Mesanguim 
Recapitulates the Abrogated Renal Development Present in the Global 
Knockout  Jackie A. Fretz, Tracy Nelson, Li Li.  Orthopaedics and 
Rehabilitation, Yale School of Medicine, New Haven, CT.
Background: Globally deficient mice lacking the transcription factor Ebf1 (Ebf1 
KO) are extremely sick owing to the multiple functions of Ebf1 across the body. We 
recently described a novel function of Ebf1 as an essential component of the latest stages 
of metanephric development. Within the kidney Ebf1 is present within multiple cell types 
including distinct tubular epithelium, interstitial pericytes, glomerular mesanguim, and 
podocytes. This investigation aimed to identify if the actions of Ebf1 in the mesangium and 
pericytes was driving the developmental defects present in the global knockout.
Methods: In this study we made a specific deletion of Ebf1 within the Foxd1+ lineage 
using a cre-driver that targets the progenitors of the kidney glomerular mesanguim and 
interstitial pericytes and mating these with mice where the 3rd exon of Ebf1 (encoding part 
of the DNA-binding domain) is flanked by flox sites. This is the same genetic region that 
is excised in the global deletion model.
Results: Restricted deletion of Ebf1 from Foxd1-lineage cells resulted in development 
of hypoplastic kidneys, poorly differentiated peripheral glomeruli, and decreased proximal 
tubular mass. Renal insufficiency was apparent at P21 (one week later than Ebf1 KO mice), 
with the appearance of proteinuria and 2+ leukocytes in urine. Growth of the animals is 
normal until P25, and approximately a third of the Foxd1+,Ebf1fl/fl mice die before they 
are 3 months old. This phenotype is similar to that seen in the Ptgs2/Cox-2 insufficient 
models (chemical inhibition and genetic deletion), and mechanistic investigation revealed 
impaired Ptgs2 expression in both the global KO and Foxd1-specific Ebf1 deletion models.
Conclusions: Taken together these results suggest that Ebf1 regulates metanephric 
development mainly through its actions in the mesangial lineage where it participates in 
proper regulation of prostaglandin biosynthesis.
Funding: NIDDK Support
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Epithelial Cell Fate in the Nephron Tubule Is Mediated by the 
Etv5a Transcription Factor During Zebrafish Kidney Development 
Amanda N. Marra, Rebecca A. Wingert.  Biological Sciences, Univ of Notre 
Dame, Notre Dame, IN.
Background: Kidney development requires the differentiation and organization of 
discrete nephron epithelial lineages, however the genetic and molecular pathways involved 
in these events remain poorly understood. The embryonic zebrafish kidney, or pronephros, 
provides a simple and useful model to study nephrogenesis.
Methods: The pronephros is comprised of two types of epithelial cells: transportive 
and multi-ciliated cells (MCCs). Transportive cells occupy distinct tubule segments and are 
characterized by expression of solute transporters, while MCCs function in fluid propulsion 
and are dispersed in a “salt-and-pepper” pattern in the tubule. Epithelial cell identity is 
reliant on interplay between the Notch signaling pathway and retinoic acid (RA) signaling, 
where RA promotes MCC fate by inhibiting Notch signaling in renal progenitors, while 
Notch activity acts downstream to trigger transportive cell formation and restrict MCC 
identity. Previous research has shown that etv5a and its ETS family members are required 
for ciliogenesis in other zebrafish tissues.
Results: Here, we mapped etv5a expression to renal progenitors that occupy domains 
where MCCs later emerge. Thus, we hypothesized that etv5a is required for ciliogenesis 
of MCCs in the nephron. etv5a loss of function produced a decline of MCC number and 
reduced expression of the MCC markers odf3b and centrin, where rescue experiments 
partially restored wild-type MCC number. In epistatic studies, exogenous RA treatment 
expanded the etv5a domain, indicating that etv5a acts downstream of RA. Additionally, 
treatment with exogenous RA partially rescues the reduced MCC phenotype after loss of 
etv5a. Further, abrogation of Notch with the small molecule inhibitor DAPT increased 
etv5a expression, while overexpression of Notch using a transgenic line reduced the etv5a 
domain, suggesting Notch acts upstream to inhibit etv5a.
Conclusions: Taken together, these findings provide novel insights about the 
mechanisms of epithelial cell development during nephrogenesis.
Funding: NIDDK Support, Other NIH Support - Office of the Director
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Emx1 Is Essential for Distal Segment Development During Nephrogenesis 
Elvin E. Morales, Rebecca A. Wingert.  Biological Sciences, Univ of Notre 
Dame, Notre Dame, IN.
Background: Vertebrate kidneys are comprised of functional subunits called nephrons 
that typically have three basic parts: a renal corpuscle, a tubule with proximal and distal 
segments, and a duct. The developmental pathways that establish nephron segment identities 
from renal progenitors remain poorly understood.
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Methods: The zebrafish embryo forms a simple two-nephron pronephric kidney that 
possesses a conserved segment anatomy with higher vertebrates. emx1 is a homeobox gene 
that, along with its paralog emx2, is known for playing essential roles in brain development. 
While both genes are expressed in the pronephros, their roles in nephrogenesis have not 
been established. Using whole mount in situ hybridization, we found that emx1 and emx2 
were dynamically expressed in renal progenitors, and became localized to the distal and 
proximal segments, respectively.
Results: In knockdown studies, emx1 morphants formed a normal distal domain, 
marked by clcnk, but within it formed an expanded distal early (DE) segment, marked by 
slc12a1, and a reduced distal late (DL) segment, marked by slc12a3. These data suggest 
that emx1 is essential to promote the DL, and may restrict the DE and/or negotiate the site of 
the DE/DL boundary. Furthermore, emx1/2 expression is responsive to changes in retinoic 
acid (RA), which is essential to induce proximal segments and repress distal segments 
during nephrogenesis. RA treated embryos had a restricted emx1 domain and expanded 
emx2 domain, while exposure to the RA biosynthesis inhibitor DEAB conversely expanded 
emx1 and restricted emx2 expression. These data suggest that RA signaling acts upstream of 
both genes in renal progenitors, positively regulating emx2 and negatively regulating emx1.
Conclusions: Future studies will define the role of emx2, independently explore emx1/2 
nephron patterning functions with CRISPR-Cas lines, and assess the relationship of these 
emx genes to other factors, such as irx3b, that have been shown recently identified to be 
components of the gene regulatory networks that direct nephron segmentation. Preliminary 
data looking at factor interactions suggest that emx genes may be located downstream of 
them or work independently.
Funding: NIDDK Support, Other NIH Support - Office of the Director
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Prostaglandins as Regulators of Nephron Proximo-Distal Cell Fate 
Decisions  Shahram Jevin Poureetezadi, Christina N. Cheng, Rebecca A. 
Wingert.  Biological Sciences, Univ of Notre Dame, Notre Dame, IN.
Background: To date, there have been a number of important discoveries furthering 
our understanding of nephron segmentation. Despite this, the factors that direct nephron 
cell-fate decisions remain largely unknown. Danio rerio, the zebrafish, possess an embryonic 
kidney composed of two nephrons and a blood filter that share a remarkable degree of 
genetic, structural, and functional homology with the human nephron and when coupled 
with genetic tractability, ex utero development, and optically transparent embryos make it 
a cutting-edge model to study nephrogenesis.
Methods: The zebrafish embryonic kidney, the pronephros, is organized in a proximal-
distal pattern of contiguous segments much like the human nephron. The proximal segments, 
the proximal convoluted tubule (PCT) and the proximal straight tubule, share a name with 
their mammalian counter parts; the distal segments, the distal early (DE) and the distal 
late (DL) – are homologous to the mammalian thick ascending limb (TAL) and distal 
convoluted tubule (DCT) respectively. We performed a chemical genetic screen using 
zebrafish embryos during nephrogenesis and analyzed the effects on segmental patterning.
Results: Interestingly, a large number of prostaglandin (Pg) pathway components 
were identified among our hits. Prostaglandins (Pgs) are fast-acting lipids necessary for an 
array of physiological functions. We discovered that treatment with bioactive Pg agonists 
restrict the PCT and DL, while inducing an expansion of the PST. Genetic knockdown and 
small molecule inhibition of the Pg producing Cox1/2 enzymes or the Pg Ep G-protein 
receptors triggered an expansion of the DE segment at the expense of the DL. Further, we 
saw that modifying levels of Pg pathway components significantly altered renal progenitor 
expression domains, including sim1a and mecom, which are required for normal proximal 
and distal tubule patterning, respectively.
Conclusions: Thus, we show here for the first time that Pg signaling has an impactful 
role in nephron cell-fate decisions, suggesting that Pgs may have considerable implications 
for therapeutic treatment of congenital kidney diseases as well as end-stage renal disease.
Funding: NIDDK Support, Other NIH Support - Office of the Director
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Cloning of the Zebrafish Kidney Mutant Zeppelin Reveals That Brca2/
Fancd1 Is Essential for Renal Development  Paul T. Kroeger, Rebecca A. 
Wingert.  Biological Sciences, Univ of Notre Dame, Notre Dame, IN.
Background: Zebrafish kidneys are conserved with other vertebrates, making them 
an excellent genetic model to study renal development. The kidney collects metabolic 
waste using a blood filter with specialized epithelial cells known as podocytes. Podocyte 
formation is poorly understood but relevant to many kidney diseases, as podocyte injury 
leads to progressive scarring and organ failure.
Methods: zeppelin (zep) was isolated in a forward screen for kidney mutants and 
identified as a homozygous recessive lethal allele, which has a loss of podocyte numbers, 
deficient filtration, and fluid imbalance. Addition of retinoic acid did not rescue the zep 
mutant phenotype. Although mutants had normal proliferation and cell death, the interrenal 
gland was increased in size, suggesting a possible cell fate switch between these related 
lineages. This data was corroborated by interrenal gland volume identified by FISH analysis. 
3β-HSD staining indicated the interrenal gland produced more hormones in the zep mutants, 
possibly suggesting an alternative mechanism of an endocrine feedback loop leading to 
overproliferation of interrenal cells.
Results: Meiotic mapping and whole genome sequencing of zep identified a splicing 
mutation in breast cancer 2, early onset (brca2)/fancd1, which was confirmed by sequencing 
of individual fish. Several independent brca2 morpholinos phenocopied zep, causing 
edema and podocyte reductions, as well as an increase in the size of the interrenal gland. 
Additionally, 3β-HSD staining suggests that morphants have an increased number of cells 
that generate hormones, similar to zep. Histological analyses of the adult kidney in zep 
heterozygotes, brca2ZM_00075660 juveniles and adults showed renal pathologies associated 
with glomerular defects. Taken together, these data suggest for the first time that brca2/
fancd1 is essential for kidney development and homeostasis.
Conclusions: These findings impart novel insights into genetic components that impact 
kidney biology, and as Brca2/Fancd1 mutations cause Fanconi anemia and several common 
cancers, specifically breast and ovarian cancer in humans, this work has identified a new 
model to understand the role of Brca2/Fancd1 in disease.
Funding: NIDDK Support
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Development of the Vasculature in the Bladder  Julia K. Schaffer,1 Kenneth 
A. Walker,2 Caitlin M. Schaefer,2 Daniel S. Bushnell,2 Elina Mukherjee,2 Sunder 
Sims-Lucas,2 Carlton M. Bates.2  1Div of Newborn Medicine, Univ of Pittsburgh; 
2Div of Nephrology, Univ of Pittsburgh, Pittsburgh, PA.
Background: Developing bladder consists of differentiating outer muscle, middle 
stromal, and inner epithelial layers. To date, formation of the bladder vascular network has 
not been determined. Aim: To determine vascular patterning through bladder development.
Methods: We examined developing bladder vasculature from embryonic day (E) 11.5 
through postnatal day (P) 30 by general histology and immunohistochemistry (including 
morphometry with GSL1 lectin staining). We performed quantitative realtime PCR (qPCR) 
for genes associated with vascular formation (e.g. Angiopoietin 1 and Vegfa ligands and 
Tie2 and Vegfr2 receptors) and hypoxia inducible factors (Hifs).
Results: In early bladder development (E11.5-13.5) vascular branches from the 
umbilical arteries grow towards a network of developing vessels within the primitive 
bladder mesenchyme. However, by E15.5, connections between the umbilical arteries and 
the maturing vascular network in the bladder are diminished, suggesting major vascular 
remodeling. Perfusion (presence of red blood cells) of most bladder vessels was identified 
even at early developmental time points. Morphometric assessment revealed a peak in 
relative vascular tissue content in the bladder at E15.5, which regressed with further 
maturation. This reduction in vascular content after E15.5 suggests vascular pruning and 
further remodeling. qPCR revealed that Angpt1 and Vegfr2 expression peaked during 
early embryonic development, whereas expression of the Angpt1 receptor, Tie2, peaked in 
early postnatal mice. The Vegfr2 ligand Vegfa displayed consistent expression at all ages. 
Interestingly, Hif1a and Hif2a demonstrate inverse mRNA expression profiles with Hif1a 
highest in embryonic bladders and Hif2a expression peaking in adult bladders.
Conclusions: Unexpectedly, bladder vasculature appears to arise from angiogenic 
vessels that arise from the umbilical artery. Subsequently, early bladder vessels undergo 
pruning with age. Key molecules that regulate vascular development, including hypoxia 
inducible factors, have differential expression patterns.
Funding: Private Foundation Support
FR-PO195
Exploring the Relation Between Cells and Extracellular Matrix in the 
Developing Human Fetal Kidney  Astgik Petrosyan,1 Estefanie Rodriguez,1 
Ruby Kim,1 Hasmik Soloyan,1 Brendan Grubbs,2 Matthew Edward Thornton,2 
Roger E. De Filippo,1 Laura Perin,1 Stefano Da Sacco.1  1Urology, Children’s 
Hospital Los Angeles, Los Angeles, CA; 2Univ of Southern California.
Background: It is widely accepted that, during development, the renal compartment 
undergoes dramatic changes in regards to cell specification and differentiation, matrix 
deposition and spatial organization. However, despite the growing number of studies 
focusing on kidney mouse development, very little is known of changes, including cell 
differentiation and extracellular matrix (ECM) deposition, occurring during human 
development. To fill this gap, we have characterized human embryonic kidneys (hEK) at 
different weeks of gestation to better understand renal progenitor biology and cell-matrix 
interactions.
Methods: Histological analysis were carried out on hEK between 11-22 weeks of 
gestation for ECM components (such as collagen IV a1-6 chains, collagen I, fibronectin) 
and progenitor/mature renal cells markers such as WT1, Pax-2, Six-2, Cited1, VE-Cadherin, 
a-SMA.
Results: We observed dynamic changes in the hEK throughout the progression of 
the gestational ages. In particular, decrease in nephrogenic zone size along with a higher 
presence of C- and S-shaped structures and fully developed glomeruli and tubules was 
confirmed in 19-22 week samples. Identification of progenitors or mature renal cells and 
fibrous proteins confirmed that ECM composition varies depending on the differentiation 
state of the surrounding cells. Collagen IV and fibronectin were absent in nephrogenic zone 
and condensing mesenchyme but found in C- and S-shaped bodies. In addition, Pdgfra 
(marker of cortical interstitial cells) was strongly expressed in the stromogenic zone and 
later restricted to the interstitium, co-localized with collagen I, suggesting a strong link 
between cell specification and matrix environment.
Conclusions: Our data suggest that, during hEK development, cell specification is 
accompanied by marked changes in ECM composition. This characterization might increase 
our knowledge of reparative processes enabling investigations focused on matrix remodeling 
and progenitor cell activation, thus ultimately enhancing the chances to treat renal damage.
Funding: Private Foundation Support
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Enalapril Treatment Modulates Lymphangiogenesis and Fibrogenic 
Machinery in the Developing Rat Kidney  Kee Hwan Yoo, Hyung Eun 
Yim, In Sun Bae, Byungkwan Kim, Young Sook Hong, Joo Won Lee.  Dept of 
Pediatrics, Korea Univ Medical Center, Seoul, Republic of Korea.
Background: The renin angiotensin system plays a pivotal role in both renal 
development and progressive renal disease.Lymphangiogenesis occurs during normal 
organ development and pathological processes. In this study, we aimed to investigate the 
effect of angiotensin II inhibition on the expression of fibrogenesis-related molecules and 
lymphatic vessels in the developing rat kidney.
Methods: Newborn rat pups were treated with enalapril (30 mg/kg) or vehicle for 
7 days after birth. We investigated the intrarenal expression of fibroblast growth factor 
(FGF)-1, FGF-2, FGF receptor (R)-1, fibroblast-specific protein (FSP)-1, intercellular 
adhesion molecule-1, toll-like receptor (TLR)-2, and TLR-4 with Western blotting and 
immunohistochemistry at postnatal day 8. For the determination of lymphatics, the lymphatic 
vessel markers of vascular endothelial growth factor (VEGF)-C, VEGFR-3, and podoplanin 
were assessed. For the detection of cell proliferation and collagen fibers, Ki-67 and Sirius 
red stainings were performed.
Results: In the enalapril-treated group, intrarenal FGF-1, FGF-2, FGFR-1 and 
VEGF-C protein expression were decreased, compared to the controls (P < 0.05). 
Immunohistochemistry for the lymphatic vessel markers of VEGF-C, VEGFR-3, and 
podoplanin showed reduced lymphatic immunostainings in the enalapril-treated kidneys. 
However, FSP-1 expression was prominent in the interstitium and glomeruli in enalapril-
treated kidneys. While cell proliferation was reduced in the enalapril-treated group, collagen 
deposition was enhanced in the enalapril-treated kidneys (P < 0.05). Intercellular adhesion 
molecule-1, TLR-2, and TLR-4 protein expression showed no differences between the 
two groups.
Conclusions: Enalapril treatment during postnatal 7 days may induce perturbations 
in FGF/FGFR signals, cell proliferation, and lymphangiogenesis required for renal 
development and maturation and activate in part the fibrogenic machinery in the developing 
rat kidney.
FR-PO197
The Effect of Prenatal Hypoxia and a Postnatal High Salt Diet on Renal 
Structure in the Aged Mouse  Sarah L. Walton,1 Reetu R. Singh,2 Joan Li,3 
Helle Bielefeldt-Ohmann,4 Tamara Paravicini,1 Melissa H. Little,3 Karen M. 
Moritz.1  1School of Biomedical Sciences, Univ of Queensland, Brisbane, 
Queensland, Australia; 2Dept of Physiology, Monash Univ, Melbourne, Victoria, 
Australia; 3Inst for Molecular Bioscience, Univ of Queensland, Brisbane, 
Queensland, Australia; 4School of Veterinary Science, Univ of Queensland, 
Gatton, Queensland, Australia.
Background: Chronic fetal hypoxia leads to growth restriction and increased risk of 
adulthood disease. This study examined the long-term renal outcomes of offspring prenatally 
exposed to hypoxia, and whether a postnatal high salt diet could exacerbate impairments.
Methods: Pregnant CD1 mice were housed in a hypoxic chamber (12.0% O2; N=8, 
HYP) or control (21% O2; N=8, CON) environment from embryonic day (E) 14.5 to birth 
(E19.5). A subset of male offspring was randomly allocated to a control diet (0.2% NaCl; 
NS) or high-salt diet (5% NaCl; HS) from 10 weeks of age. Blood pressure was measured 
at 12 months of age and kidneys were collected. Kidney sections were examined for 
nephron number, glomerulosclerosis, interstitial fibrosis, renal vascular remodeling, and 
alpha-smooth muscle actin (α-SMA) expression by a researcher blinded to treatment groups.
Results: Prenatal hypoxia led to a decrease in nephron number and elevated blood 
pressure. Kidneys of HYP offspring showed expansion of the mesangial matrix, thickening 
of glomerular basement membranes and increased glomerulosclerosis compared to CON. 
These changes were exacerbated by the HS diet. Interstitial fibrosis and renal vascular 
remodeling scores were increased in CON and HYP offspring fed the HS diet, with the 
effect greatest in HYP offspring. α-SMA staining of CON kidneys was confined to vascular 
smooth muscle cells; however, aberrant glomerular and interstitial α-SMA staining was 
observed in CON offspring fed the HS diet and HYP offspring fed NS and HS diets.
Conclusions: Prenatal hypoxia led to reduced nephron number and pathological renal 
abnormalities, likely contributing to elevated blood pressure. The combination of prenatal 
hypoxia and a postnatal high salt diet significantly exacerbated renal abnormalities and 
signs of injury.
Funding: Government Support - Non-U.S.
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Folic Acid Alleviates Reduced Ureteric Branching and Nephrogenesis 
Induced by Maternal Undernutrition in Rat Embryonic Kidney 
Midori Awazu, Mariko Hida.  Dept of Pediatrics, Keio Univ School of Medicine, 
Tokyo, Japan.
Background: We reported that maternal undernutrition reduces nephron number, 
ureteric branching, and global DNA methylation. Also, blockade of DNA methyltransfarase 
1, which maintains DNA methylation, inhibited ureteric branching in organ culture. Since 
the supplementation of folic acid (FA), a methyl-group donor, ameliorates hypertension due 
to maternal low protein diet, we examined whether FA rescues the kidney developmental 
defects induced by maternal undernutrition.
Methods: The kidneys of embryonic day 14 and 18 (E14 and E18) fetuses from dams 
given food ad libitum (CON), those subjected to 50% food restriction throughout pregnancy 
(NR), and NR supplemented with FA 5 mg/kg (NRFA) were examined (n=3-7 litters). 
Ureteric buds were visualized by pancytokeratin staining. DNA methylation was assessed 
by methylated DNA quantification kit. E13 metanephroi from normal rats were subjected 
to organ culture in DMEM with or without FA 8 µg/ml for 3 days.
Results: Maternal undernutrition significantly reduced fetal body weight (0.143±0.004 
vs 0.173±0.003 g), kidney surface area (2.4±0.3 vs 3.8±0.5), and ureteric tip number 
(4.0±0.4 vs 8.5±0.8) at E14. FA supplementation did not affect body weight (0.147±0.003 
g) or kidney surface area (2.2±0.4), but restored ureteric tip number (7.0±0.7, P<0.05 vs 
NR). At E18, FA supplementation again did not affect body weight (1.28±0.02 vs NR: 
1.24±0.05 g) or kidney weight (6.1±0.8 vs NR: 5.5±0.4 mg). FA, however, partially restored 
the glomerular density (15.6±2.7/mm2, P<0.05 vs NR) that was significantly lower in NR 
(10.3±0.9) than CON (20.2±3.7). DNA methylation of NR was significantly reduced in 
NR (8.7±1.1%) vs CON (29.8±5.6%) at E18. IN NRFA, DNA methylation was partially 
restored to 20%. In the metanephroi cultured under FA deficiency, the ureteric tip number 
was significantly reduced (6.6±0.3, n=10) vs controls (9.9±0.9, n=7). The kidney surface 
area was also significantly reduced by FA deficiency (3.0±0.2 vs 3.8±0.2).
Conclusions: FA is needed for the metanephric development, and its supplementation 
alleviates the reduced ureteric branching and nephrogenesis in the offspring of nutrient 
restricted rats probably by restoring DNA methylation.
Funding: Government Support - Non-U.S.
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A Perinatal Switch in Iron Utilization Determines Postnatal Chronic Kidney 
Disease  Rongjia Deng,1 Rosemary V. Sampogna,1 Andong Qiu,1,2 Jonathan M. 
Barasch.1  1Columbia Univ; 2Tongji Univ, China.
Background: Iron deficiency affects 2 billion people world-wide and is a threat to 
embryonic and early postnatal development. Periconceptual maternal iron deficiency 
(PM-ID) results in hypoplastic postnatal kidneys but it is not clear whether PM-ID causes 
cell-lineage or cell-stage specific hypoplasia, nor which species of iron is involved.
Methods: We investigated a mouse model of dietary iron deficiency and a series of 
deletions of the transferrin receptor,TfR1 (cell autonomous transferrin iron deficiency, 
ATF-ID) in different cellular lineages using a novel TfR1-floxed construct.
Results: Severe PM-ID depleted both Tf iron and NTBI (non-transferrin bound iron) 
resulting in severely hypoplastic proximal tubules and even anephria during gestation, 
whereas the overall structure of ureteric bud was maintained. Milder PM-ID resulted in 
surviving but severe postnatal kidney hypoplasia, disruption of the growth of the proximal 
tubule and TALH and increased mortality before weaning. To determine the mechanism 
of hypoplasia we examined mesenchymal, ureteric and stromal ATF-ID with different Cre 
drivers. Mesenchymal ATF-ID (Six2Cre or KspCre) demonstrated increasing demand 
for transferrin by the time of birth, resulting in worsening proximal tubule hypoplasia, 
remarkable cystic transformation and interstitial fibrosis, and even anephria (ProPax3Cre) 
after birth, the timing of which coincided with accelerated segment-specific growth. The 
combination of ATF-ID and PM-ID further worsened nephron development. In contrast, 
the collecting ducts (HoxB7Cre) and stroma (Foxd1Cre) did not depend on transferrin.
Conclusions: In sum, NTBI supported prenatal and postnatal stromal and ureteric 
development and the initial stages of metanephric development, whereas Tf iron was 
required for perinatal maturation of the nephron. Tf-iron depletion resulted in hypoplasia, 
cysts, and fibrosis, the timing and specificity of which was the result of a sequence 
of utilization of NTBI followed by Tf-iron. We propose that a peri-natal switch in the 
mechanisms of iron utilization accompanies the compartmentalization of the kidney and 
reflects changing cellular control of iron delivery. Iron deficiency is a cause of CKD.
Funding: NIDDK Support, Private Foundation Support
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Troy/TNFRSF19 Marks a Progenitor/Stem Cell Population in the Kidney 
Frans Schutgens,1,2 Maarten B. Rookmaaker,1 Robert Vries,2 Marianne C. 
Verhaar,1 Hans Clevers.2  1Nephrology and Hypertension, UMC Utrecht, Utrecht, 
Netherlands; 2Hubrecht Inst, Utrecht, Netherlands.
Background: Segment committed stem cells play a crucial role in renal development 
and regeneration. Identification of these stem cells is an important step towards the 
development of new diagnostic and therapeutic strategies for renal diseases. In this study, 
we evaluated Troy, an adult stem cell marker in other organs, as a marker for segment 
committed stem cells in the developing and adult kidney.
Methods: Renal Troy expression was assessed during embryonic development and adult 
turnover using Troy-GFP mice. The contribution of Troy+ cells to renal development and 
turnover was investigated using in vivo lineage tracing in Troy-GFP-CreERT2;Rosa-LacZ 
mice and the clonality of this contribution in Troy-GFP-CreERT2;Rosa-4color mice. Tracing 
was induced during or after cessation of nephrogenesis (p1 or p35) by tamoxifen injection. 
Daughter cells were identified using immunohistochemistry for tubular segment-specific 
markers. In addition, in vitro stem cell capacity was assessed by a sphere-forming assay.
Results: During embryonic development Troy+ cells were present in the ureteric bud 
[1A], whereas in adult kidney Troy+ cells were present in the papilla. After p1 induction, 
Troy+ cells gave rise to tubular structures by clonal expansion that persisted up to 2 years 
after induction [1B-1E]. Immunohistochemistry revealed predominant co-staining with 
collecting duct marker AQP2 [1C]. Troy+ cells continued to contribute to collecting duct 
formation after cessation of nephrogenesis. Finally, Troyhi cells had a higher in vitro sphere 
forming capacity than Troydim and Troylo cells [1F-1H]. 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
402A
J Am Soc Nephrol 26: 2015 Stem Cells Poster/Friday
Conclusions: These data show that Troy marks a stem/progenitor population for the 
collecting duct in the developing kidney. Moreover, our data also suggest a role for Troy+ 
progenitor cells in the adult kidney.
FR-PO201
Preserved Nephrogenesis following Partial Nephrectomy in Early Neonates 
Yuhei Kirita,1 Daisuke Kami,2 Ryo Ishida,1 Tetsuro Kusaba,1 Takaomi Adachi,1 
Satoshi Gojo.2  1Nephrology, Graduate School of Medical Science, Kyoto 
Prefectural Univ of Medicine, Kyoto, Japan; 2Regenerative Medicine, Graduate 
School of Medical Science, Kyoto Prefectural Univ of Medicine, Kyoto, Japan.
Background: For a long time, although the appendage regeneration has been limited to 
non-mammalian vertebrates, the rodent neonates demonstrated the capability to regenerate 
the resected cardiac apex. In this study, we hypothesized that neonatal kidney could maintain 
the capability of neonephrogenesis.
Methods: One sixth-partial resection at the inferior pole of right kidney was performed 
on neonatal rats at postnatal day 1 (P1) and day 4 (P4) under the hypothermic anesthesia. The 
animals were sacrificed with time to examine by pathology and quantitative PCR, including 
key transcription factors, cytokines, and signaling molecules related to nephrogenesis, 
whether the resected portions were regenerated, or not.
Results: The pathological findings in nephrectomized kidney on P1 (P1X-kidney) 
seemed to bulge the newly formed cortex from the edge of the wound with the minimum 
inflammations, on the contrary, the inflammations was prominent in nephrectomized 
kidney on P4 (P4X-kidney). Immunohistochemistry in P1X-kidney demonstrated the 
preservation of the nephron number and the cortex area 28 days post-resection. On the 
other hand, P4X-kidney showed that those significantly decreased. Numerous apoptosis 
and sparse cell proliferation were significantly recognized in P4X-kidney, and P1X-kidney 
expressed the opposite findings. An array of quantitative PCR postulated the implication 
of Six2 expression to those differences between P1 and P4 kidney following the partial 
nephrectomy. The Six2 expression was reinforced in P1X-kidney more than age matched 
control kidney, whereas it had already gone in P4X-kidney.
Conclusions: Our results indicate that rat kidney maintains the capability to generate 
new nephrons in early neonates. Neonatal period could offer the unique model to study 
the regenerative or reparative phenomena.
FR-PO202
BrdU Labeling Adult Renal Stem Cells in Development Kidney  Li Ni, 
Jing Chen.  Nephrology, Huashan Hospital, Shanghai Medical College, Fudan 
Univ, Shanghai, China.
Background: The labeling-retaining cell (LRC) approach is a reliable way to identify 
adult stem cells.To identify the best labeling time for adult renal stem cells,we administered 
BrdU in different periods of the kidney development.
Methods: A pulse of BrdU was administered at different periods during E11.5-20.5, 
respectively, covering the whole process of the kidney development.The adult kidney were 
examined the distribution of BrdU-positive cells.A subtotal nephrectomy(Nx) was induced 
in adult mice to observe the response of BrdU-retaining cells to injury.
Results: In adult kidneys,the distribution of BrdU-retaining cells was heterogeneous 
with different BrdU-labeling time.With BrdU labeled at E11.5-13.5,lots of BrdU-positive 
cells were located in the papilla and inner medulla,only few scattered in the proximal 
tubules.With BrdU labeled at P0.5-2.5,lots of cells in the inner medulla and outer medulla 
could retain the immunoreactivity of BrdU.With BrdU labeled at P3.5-5.5,P6.5-8.5,or 
P9.5-11.5,the distribution of BrdU-positive cells was mainly in the outer medulla,few in 
the cortex inner medulla,no longer in the papilla.With BrdU labeled at P12.5-14.5 and 
P15.5-17.5,lots of BrdU-positive cells were in the outer medulla,but no longer in the papilla 
or inner medulla.With BrdU labeled at P18.5-21.5,BrdU-positive cells were only found 
in the cortex.The proximal tubules were the only nephron segments stably containing few 
BrdU-retaining cells after a chase period of six months.After Nx in adult mice,BrdU-positive 
cells were more significantly increased in the cortex near the incision edge.BrdU-positive 
cells mainly distributed in the proximal tubules at the site of injury.Some BrdU-positive 
cells did not express PCNA,even though numerous PCNA-positive cells were found near 
the incision edge of kidney.In contrast,originally retained abundant BrdU-positive cells 
in the outer medulla and inner medulla significantly reduced and disappeared rapidly in 
the vicinity of incision.
Conclusions: The locations of LRCs were different if BrdU was administered in 
different periods of kidney development.Most of BrdU-retaining cells were quiescent,few 
of them in the proximal tubule and papilla may be the renal progenitor cells.
FR-PO203
Tissue-Specific Transport and Injury Response in Kidney Tubules Derived 
from Human Pluripotent Stem Cells  Benjamin S. Freedman,1,2,3 Craig R. 
Brooks,1,2 Albert Q. Lam,1,2 Ryuji Morizane,1,2 Joseph V. Bonventre.1,2  1Brigham 
and Women’s Hospital; 2Harvard Medical School; 3Univ of Washington School 
of Medicine.
Background: Human pluripotent stem cells (hPSCs) can differentiate into cells 
expressing markers of kidney proximal tubules, but the functional capacity of these 
structures remains poorly understood. We developed a new, adherent, 3D culture system 
to evaluate transport and injury characteristics in hPSC-derived kidney tubules, compared 
to undifferentiated hPSCs.
Methods: hPSCs sandwiched in extracellular matrix were maintained in pluripotency-
sustaining media to form undifferentiated cavitated spheroids (SOX2+OCT4+), or 
differentiated with growth factors into nephron progenitor cells (PAX2+SIX2+) and 
subsequently proximal tubules (LTL+LRP2+). hPSC spheroids or differentiated tubules 
were incubated with small molecule fluorescent probes to monitor transport into lumens, 
or with nephrotoxic chemicals to assess upregulation of kidney injury molecule-1 (KIM-1).
Results: Kidney tubule lumens selectively accumulated rhodamine-dextran (RD) and 
fluorescein methotrexate (MTX) transport cargoes. Inhibition of actin polymerization with 
Latrunculin B, or permeabilization of tight junctions with EDTA, significantly reduced cargo 
accumulation. When treated with the nephrotoxic compounds gentamicin or cisplatin, ~ 
70 % of hPSC-derived proximal tubules expressed KIM-1 at the apical/luminal surface. In 
contrast, the lumens of undifferentiated hPSC spheroids did not accumulate RD and MTX, 
nor express KIM-1 after toxic injury with cisplatin or gentamicin.
Conclusions: hPSC-derived kidney tubules are capable of transport and injury 
responses, which are characteristic of kidney proximal tubules and distinct from 
undifferentiated hPSC epithelia. The accessibility of this system to small molecules and 
live-cell microscopy enables rapid and real-time visualization of transport processes and 
testing of molecular pathways. KIM-1 expression in hPSC-derived kidney tubules may 
provide a quantifiable standard with which to predict human nephrotoxicity. Our findings 
introduce a framework in which to evaluate the functionality of hPSC-derived kidney 
epithelia, prior to transplantation into ESRD patients.
Funding: NIDDK Support, Private Foundation Support
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Progress in the Development of Human iPSC Derived Proximal Tubule-
Like Cells for Drug Toxicity Screening  Anja Wilmes, Georg Kern, Caroline 
Rauch, Gerhard Gstraunthaler, Paul Jennings.  Dept of Physiology, Medical 
Univ of Innsbruck, Innsbruck, Tirol, Austria.
Background: Nephrotoxin exposure can initiate acute kidney disease and accelerate the 
progression of chronic kidney disease. The proximal tubule is a frequent target as it transports 
a wide variety of chemical entities, some of which can cause tubular injury. Primary cell 
culture and cell lines have been used successfully to investigate molecular mechanisms 
of chemical toxicity. However, there are several disadvantages of traditional cell culture, 
including limited tissue availability, phenotypic alterations due to immortalisation and a 
lack of genetic diversity. With the dawn of induced pluripotent stem cell (iPSC) technology, 
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many of these disadvantages could potentially be overcome. To this end we have been 
attempting to develop a protocol to produce proximal tubule-like cells from human iPSCs 
with xenobiotic transport capabilities.
Methods: Human iPSCs were differentiated into the intermediate mesoderm (IM) 
using Wnt and retinoic acid activation (CHIR99021 and TTNBP). Cells were further 
differentiated using combinations of different growth factors.
Results: The derived cells exhibit cobble stone morphology and express certain 
proximal tubule proteins such as claudin-2. Additionally, the cells can be maintained for 
up to 4 weeks in culture. Preliminary results demonstrate the ability of the differentiated 
cells to take up organic cations (4-Di-10-ASP) and organic anions (6-CF) and to extrude 
p-glycoprotein substrates (calcein-AM).
Conclusions: While further characterization will be needed, the initial results are 
promising, indicating that proximal tubule-like cells derived from iPSCs could be a new 
tool for screening the nephrotoxic potential of compounds.
Funding: Private Foundation Support, Government Support - Non-U.S.
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The Direct Differentiation Method of Renal Tubular Cells by Synthetic 
mRNAs of Transcription Factors Identified from TF-Inducible Human 
ES Bank  Ken Hiratsuka,1 Toshiaki Monkawa,1 Shintaro Yamaguchi,1 Ryuji 
Morizane,1 Shigeru B.h. Ko,2 Minoru S.h. Ko,2 Hiroshi Itoh.1  1Dept of Internal 
Medicine, Keio Univ School of Medicine, Shinjuku-ku, Tokyo, Japan; 2Dept of 
System Medicine, Keio Univ School of Medicine, Shinjuku-ku, Tokyo, Japan.
Background: To find transcription factors which promote differentiation towards renal 
tubular cells, we utilize the human ES lines with doxycycline-controllable transcription 
factors (TF-inducible hES bank). To establish the differentiation method of renal tubular 
cells, we transfect the synthetic human mRNA of the target transcriptional factors into 
human ES cells.
Methods: We performed exhaustive search for DNA microarray data after TF induction 
in the hES bank, and analyzed them in silico to find the specific transcription factors, which 
expressed in kidney epithelial cells. We synthesized the synthetic human mRNA of the target 
transcription factors. By using the lipofection method, we transfected the synthetic mRNA 
of target transcription factors to human ES cells, and cultured them. The morphological 
changes, mRNA expressions, and protein expressions were analyzed.
Results: Some candidate transcription factors, which expressed in human kidney 
epithelial cells, were identified by in silico analysis. We successfully made synthetic mRNA 
of candidates of transcription factors. Five days after the transfection of the synthetic 
mRNA to human ES cells, we were able to observe characteristic morphological changes 
in the differentiated cells. The mRNA expression of OSR1, ITGA8, AQP1, and MEGALIN 
were increased. Moreover, the protein expression of AQP1 and LTL were also detected 
in the differentiated cells.
Conclusions: We identified specific transcription factors for differentiation toward 
kidney (especially, proximal tubular cells) , and demonstrated that the differentiation of 
proximal tubular cell phenotype from human ES cells by a novel method using synthetic 
mRNA.
FR-PO206
Differentiation of Human iPSC into Functional Podocytes  Caroline Rauch,1 
Anja Wilmes,1 Elisabeth Feifel,1 Georg Kern,1 Paul Jennings,1 Gerhard 
Gstraunthaler.1  1Innsbruck Medical Univ; 2Innsbruck Medical Univ; 3Innsbruck 
Medical Univ; 4Innsbruck Medical Univ.
Background: Podocyte injury and subsequent loss of glomerular integrity is a major 
cause for chronic kidney disease (CKD). Two-thirds of patients with CKD suffer from 
disorders that arise from the glomerulus,  mainly due to podocyte injury. Podocytes are 
highly specialized cells with a complex cytoarchitecture composed of foot processes that 
form the glomerular filtration barrier. The study of the molecular processes of glomerular 
injury is hampered by the fact that cultured primary podocytes have a limited capacity 
to divide and are difficult to maintain. However, generation of pluripotent stem cells 
(induced PSCs) from somatic cells allows the possibility of a new source of human cells. 
The high differentiation capacity of iPSCs would potentially enable the establishment of 
differentiation protocols for iPSC-derived podocytes which can overcome the burden of 
primary podocytes in culture.
Methods: To this end we applied and optimized a previously published protocol for 
podocyte differentiation (Song et al., 2012; PMID: 23029522). Human iPSCs are grown 
in differentiation media for ten days, containing growth factors known to be important 
for in vivo podocyte differentiation, BMP-7, activin A, and retinoic acid. Conditionally 
immortalized human podocyte cultures served as controls.
Results: After three days in differentiation media, iPSCs showed a clear 
podocyte morphology with podocyte foot processes. To further prove the state of 
podocyte differentiation, expression of specific podocyte markers was examined via 
immunofluorescence. Marked expression of the podocyte specific markers podocin and 
synaptopodin could be successfully verified on differentiated iPSCs. In addition, iPSC-
derived podocytes showed significant release of VEGF into the culture medium. Finally, 
doxorubicin, a podocyte specific toxin, was highly toxic to these cells with an IC50 of 
1µM after 48h.
Conclusions: Podocytes generated from iPSCs have far reaching applications in 
disease modelling, tissue engineering, drug screening and discovery, and toxicity testing.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Sourcing of Renal Tubular Epithelial Cells from Human Stem Cell-
Derived Kidney Organoids  Elijah Weber,1 Benjamin S. Freedman,2 Jonathan 
Himmelfarb,3 Edward J. Kelly.1  1Pharmaceutics, Univ of Washington, Seattle, 
WA; 2Nephrology, Univ of Washington, Seattle, WA; 3Kidney Research Inst, 
Univ of Washington, Seattle, WA.
Background: Human pluripotent stem cells (hPSCs) provide a self-renewing, 
reproducible source of kidney cells for laboratory investigation and regenerative medicine 
approaches. We tested the potential of hPSC-derived renal tubular epithelial cells (RTECs) 
to grow and maintain differentiation in 2D and 3D cultures, compared to primary RTECs 
from adult kidneys.
Methods: hPSCs were treated with growth factors to promote differentiation 
into nephron progenitor cells (PAX2+SIX2+) and subsequently proximal tubules 
(LTL+ZO1+LRP2+). RTECs purified from tubular organoids were re-plated on tissue 
culture plates with or without extracellular matrix. RTECs were analyzed for proliferation, 
kidney-specific marker expression, and their capacity to seed a ‘kidney on a chip’ 3D 
microphysiological system (MPS).
Results: RTECs purified from hPSC organoids grew to confluent monolayers in 
minimal RTEC growth media on extracellular matrix. hPSC-derived RTECs resembled 
primary RTECs morphologically. Marker immunofluorescence analysis revealed that 
purified hPSC-RTECs possessed ZO1+ tight junctions and reacted with LTL. Sub-cultivation 
was limited to 2-3 passages, after which hPSC-RTECs underwent epithelial-to-mesenchymal 
transition and senesced. In a 3D MPS, hPSC-derived RTECs formed tubular structures 
comparable to primary RTECs. Immunofluorescence staining demonstrated positive 
signals for the tubule transporters SGLT2 and OAT3 as well as the epithelial markers 
CD13 and E-cadherin.
Conclusions: We have shown that hPSC-RTECs can propagate in vitro and maintain 
their differentiated characteristics, with morphology and markers similar to primary RTECs. 
When hPSC-RTECs are grown in a 3D MPS, they maintain an epithelial phenotype and 
express membrane transporters essential for functions including glucose reabsorption and 
organic anion secretion. This system establishes a platform in which to optimize hPSC-
RTEC expansion and function in a 3D, microfluidic context, with relevance for human 
disease modeling in vitro and bioengineering of regenerative therapeutics.
Funding: Other NIH Support - UH3TR000504, Other U.S. Government Support
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Genome-Wide Methylation Analysis of Epigenetic Memory in Human 
Kidney Derived iPS Cells  Osamu Takase, Taro Tsujimura, Masaomi Nangaku, 
Keiichi Hishikawa.  Dept of Advanced Nephrology and Regenerative Medicine, 
The Univ of Tokyo, Tokyo, Japan.
Background: Epigenetic memory such as DNA methylation signature of iPS cells 
derived from parental cells was reported to determine the differentiation fate of the iPS 
cells (Nature 2012). Last year, we reported the result of kidney specific induction protocol 
(Nature Commun, 2013) by using two different kinds of human iPS cells established from 
human fibroblast (F-iPS) and human kidney epithelial cells (K-iPS), and demonstrated 
more efficient induction of markers of kidney development (WT-1, Pax-1, Sall-1) and 
differentiation (AQP-1, Nephrin) in K-iPS as compared with F-iPS cells.
Methods: In this study, we performed a genome-wide methylation analysis of K-iPS 
and F-iPS cells, and tried to clarify the mechanism of kidney lineage specific induction 
of human iPS cells.
Results: Among 27,578 sites, we focused on high CpG promoter lesion (GC>0.55, 
CpG>0.75). 56 genes such as Kid1 and SOD2 were strongly methylated in F-iPS than in 
R-iPS. 17 genes such as KCNK12 and GATA4 were strongly methylated in R-iPS than 
in F-iPS. The markers of kidney development were strongly methylated in F-iPS than in 
K-iPS cells (Pax-2; 23.6 vs 2.1, Sall-1; 28.7 vs 4.3). However, the marker of differentiation 
was strongly methylated in K-iPS (AQP-1; 1.7 vs 1.1).
Conclusions: These results demonstrate that epigenetic memory in parental cell 
determine the induction of human iPS cells toward kidney lineages, and the role of key 
genes in kidney lineage specific induction will be discussed.
Funding: Government Support - Non-U.S.
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Mechanism of Kidney Repair in the Omentum-Kidney Model – 
Tubulogenesis and Differentiation of Free-Lying WT-1 Cells to Podocytes 
Occurring in the Fusion Zone  Ignacio Garcia-Gomez,1,3 Krishnamurthy P. 
Gudehithlu,2 Peter D. Hart,1,2,4 Jose A.L. Arruda,1,3 Ashok K. Singh.1,2,3  1Hektoen 
Inst of Medicine, Chicago, IL; 2Div of Nephrology, John H. Stroger, Jr. Hospital 
of Cook County, Chicago, IL; 3Section of Nephrology, Univ of Illinois at Chicago, 
Chicago, IL; 4Internal Medicine, Rush Univ Medical College, Chicago, IL.
Background: When activated omentum was fused to the injured kidney it induced 
glomerular repair and ameliorated chronic kidney disease (Garcia-Gomez et al JASN 2014). 
The fusion zone between the omentum and the injured kidney was highly proliferative (high 
Brdu uptake), with abundant free-lying nephron progenitor WT-1 cells.  In this study, we 
examined the fusion area to further understand the mechanisms of repair in this model.
Methods:    In 5/6 surgically nephrectomized rats polydextran gel was introduced 
intraperitoneally to activate the omentum and fuse to the injured kidney.  Nephrectomized 
rats with complete omentectomy were used as control. Kidney tissues were examined 1- 3 
weeks after injury by histology and immunofluorescence (Pax-2, WT-1 and podocalyxin). 
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E15 embryonic rat kidney served as control for immune-staining. Two-week fusion zone 
tissue and tissue far from fusion zone, control and normal was quantified for mRNA for 
selected developmental genes (WT-1, Wnt-4, Pod1, Lim1, HNF-6, BMP-7) by RT-PCR.
Results: We found that the fusion zone tissue showed proliferation and expansion 
of collecting ducts, as evidenced by intense staining for Pax2, in a pattern similar to that 
seen in E15 embryonic rat kidney.  Further, several islands of WT-1 cells in the fusion 
zone differentiated to podocytes, as judged by co-expression of podocalyxin.  mRNA for 
Wnt-4 and WT-1 increased by 10-20 folds and mRNAs for other developmental genes 
increased by 2-5 folds in the fusion zone. Control tissue did not show the above changes.
Conclusions: The fusion zone tissue between the injured kidney and omentum appears 
to be a highly active tissue with proliferation and differentiation of kidney progenitor cells 
(WT-1, Pax-2, podocalyxin) taking place, and thus providing a healing environment to 
the injured kidney.
Funding: Private Foundation Support
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Transcriptional and Functional Characterization of Clinical Grade Isolated 
Human Kidney Derived Perivascular Stromal Cells  Danielle Leuning, 
Marlies Reinders, Ellen Lievers, Cees van Kooten, Marten A. Engelse, Ton J. 
Rabelink.  Nephrology, LUMC, Netherlands.
Background: Mesenchymal stromal cells (MSCs) are immunomodulatory cells and 
have shown beneficial effects in kidney disease. It has previously been shown that human 
perivascular stromal cells (PSCs) from several different organs share characteristics of 
bone marrow derived MSCs (bmMSC), however, at the same time there are tissue specific 
properties. We hypothesized that human kidney derived PSCs (hkPSCs) are, due to tissue 
specific imprinting, more potent in kidney repair compared to bmMSCs and sought to find 
a novel clinical grade isolation method.
Methods: Human transplantation grade kidneys (n=3) were digested with continuously 
circulating proteolytic enzymes. The resulting crude cell suspension was cultured in αMEM 
5% platelet lysates and cells were selected for plastic attachment and NG2 cell enrichment 
(fig A). Culture was continued until spindle shaped cells appeared (kPSCs) and were 
compared to bmMSCs between passages 5-10.
Results: hkPSCs have comparable marker expression, cytokine excretion patterns, 
vascular stabilization and immunosuppressive capacity compared to bmMSCs. hkPSCs 
showed a distinct gene expression profile including an increased expression of HoxD11, a 
homeobox factor important in nephrogenesis. In a wound scratch assay, kidney epithelial 
wound healing with conditioned medium of hkPSCs was significantly faster and after 7 
hours approx. 80% closure was seen with hkPSC conditioned medium, which was only 
40% with bmMSC supernatant (p<0.01) (fig B, C).
Conclusions: Here we show a novel, clinical grade isolation method of hkPSCs and 
compared these cells to bmMSCs. hkPSCs showed a distinct expression profile and are 
able to enhance kidney tubular epithelial wound healing to a greater extent than bmMSCs. 
Therefore hkPSCs are a promising new cell therapeutic candidate to explore for treatment 
of kidney disease.
Funding: Government Support - Non-U.S.
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Functional Alterations of Adipose-Derived Mesenchymal Stem Cells 
from Human with Atherosclerotic Renovascular Disease Under Hypoxic 
Conditions  Ahmed Saad, Allan B. Dietz, Sandra Herrmann, Alfonso Eirin, 
Abdelrahman Abdallah Abohashem Aly, Hui Tang, Soon Hyo Kwon, Kyra L. 
Jordan, John R. Woollard, Joseph P. Grande, Lilach O. Lerman, Stephen C. 
Textor.  Mayo Clinic.
Background: Atherosclerotic renal vascular disease (ARVD) induces microvascular 
loss and interstitial inflammation, ultimately leading to ischemic injury. Mesenchymal 
stem cells (MSCs) can induce angiogenesis, decrease inflammation, and limit apoptosis 
in experimental animals. Aging and co-morbid conditions may blunt these properties in 
older human subjects. This study tested the hypothesis that hypoxic preconditioning of 
adipose tissue-derived MSCs would modify expression of MicroRNAs (miR) associated 
with MSCs survival, angiogenic, and anti-inflammatory properties.
Methods: MSCs obtained from subcutaneous tissue of 7 patients with ARVD (Age 
75.3±4) were cultured under normoxic or hypoxic conditions (1% O2) for 4 days. Hypoxic 
MSCs were returned to normoxia thereafter. Levels of the pro-survival and pro-angiogenic 
factors vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) were 
measured in the supernatant by ELISA. Expression of MiRs- 210, 21 and 145 in MSCs 
was measured by quantitative rt-PCR and apoptosis by flow cytometry for Annexin V.
Results: Hypoxic conditions increased VEGF and IGF (p<0.05) in MSC supernatant, 
but had no effect on apoptotis.
MiR-210 rose more than 68 fold in hypoxic MSCs over control conditions (p<0.0001), 
and reversed when returned to normoxia. Levels of miR-21 and 145 rose in hypoxic MSCs 
(p<0.05) and remained so after restoring normoxic conditions.
Conclusions: Hypoxia augmented angiogenic cytokine secretion and both reversible 
(miR-210) and irreversible (miR-21 and miR-145) micro-RNA expression in MSC 
from older human subjects with ARVD. These data support a potential role for hypoxic 
preconditioning to enhance the angiogenic potency of MSCs in humans with ARVD.
Funding: NIDDK Support
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Safety of Intra-Arterial Autologous Adipose-Derived Mesenchymal Stem 
Cells in Human Atherosclerotic Renovascular Disease  Ahmed Saad, Sandra 
Herrmann, Michael A. Mckusick, Sanjay Misra, James Glockner, Alfonso 
Eirin, Joseph P. Grande, Allan B. Dietz, Lilach O. Lerman, Stephen C. Textor. 
Mayo Clinic.
Background: Atherosclerotic Renovascular disease (ARVD) reduces blood flow (RBF) 
and GFR, and amplifies kidney hypoxia and inflammation. Adipose-derived mesenchymal 
stem cells (aMSCs) improve renal function in swine ARVD, in part by improving cortical 
micro-vascularization, but their safety and efficacy in humans are unknown. We report 
initial results from a pilot study of unilateral intra-arterial administration of low dose of 
autologous aMSCs in human subjects with ARVD under an FDA-approved IND.
Methods: Seven patients (Age 75.3±4) with severe ARVD were studied during fixed 
Na+ diet and ACE/ARB Rx before and 3 months after unilateral arterial injection of 2x105 
autologous aMSCs/kg. Stenotic-kidney (SK) cortical and medullary perfusion, volume 
and RBF were measured using multidetector CT and GFR by iothalamate clearance. SK 
deoxyhemoglobin levels (R2*) and fractional hypoxia were measured by 3T BOLD-
MRI. Renal vein levels of neutrophil gelatinase-associated lipocalin (NGAL), monocyte 
chemotactic protein-1 (MCP-1), and tumor necrosis factor (TNF-α) were also measured.
Results: All patients tolerated aMSC without adverse effects. SK cortical volume 
and whole kidney RBF increased after three months (Figure 1), as did measures of tissue 
oxygenation, whereas no changes observed in the contralateral untreated kidneys (CLK) 
(data not shown). SK GFR did not change, nor did renal vein levels of TNF- α, MCP-1, 
or NGAL.
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Conclusions: Intra-arterial autologous aMSCs were tolerated with no adverse effects. 
This low dose, delivered without renal revascularization, was associated with increased 
tissue oxygenation and cortical RBF, consistent with improved renal microcirculation. Our 
results provide first-in-humans evidence to support a role for aMSC to restore local blood 
flow and oxygenation in ARVD.
Funding: NIDDK Support
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Cell Therapy with Serelaxin Promotes Angiogenesis and Anastomosis 
which Is Critical for the Preservation of Vascular Integrity After Kidney 
Injury  Brooke M. Huuskes,1 Alexander Ruvantha Pinto,2 Chrishan S. Samuel,3 
Sharon D. Ricardo.1  1Dept of Anatomy and Developmental Biology, Monash 
Univ, Clayton, Victoria, Australia; 2Australian Regenerative Medicine Inst, 
Monash Univ, Clayton, Victoria, Australia; 3Dept of Pharmacology, Monash 
Univ, Clayton, Victoria, Australia.
Background: We previously reported that the combination of mesenchymal stem 
cells (MSCs) and serelaxin (Rln) attenuates ureteral obstruction (UUO)-induced fibrosis. 
However the affect on endothelial cell regeneration is yet to be elucidated. Here we tested the 
hypothesis that a mechanism of repair after fibrosis is induced via endothelial anastomosis 
and sprouting in the presence of MSCs and Rln.
Methods: Live cell imaging of human bladder endothelial cells (HBECs) and human 
umbilical vein endothelial cells (HUVECs) in tube forming assays were conducted with 
MSC-conditioned media and Rln (1-100mg/mL) to observe their affects on anastomosis. 
Spheroid assays determined the effects of MSC and Rln on HBECs and HUVECs sprouting 
in vivo. Proliferation of HBECs and HUVECs in the presence of MSCs and Rln was 
investigated. A qPCR for angiogenic genes was performed on MSCs cultured with or without 
Rln (100ng/mL). Endothelial integrity was visualized using CD31 protein localization in 
kidneys from mice 3, 5 and 7days post-UUO, with or without MSCs Rln (n=4-6/group).
Results: Anastomosis of HBECs was modulated in the presence of MSC-conditioned 
media and Rln with tube number and branch length increased compared to control. 
HUVECs readily formed sprouts in culture, which was enhanced when both Rln and MSCs 
were present. The migration capacity of MSCs towards injured HBECs was significantly 
increased when Rln was added. Rln induced the expression of angiogenic genes from the 
MSCs. Immunofluorescent microscopy of CD31 determined a decrease of endothelial 
integrity in a time-dependent manner in vivo. However the administration of MSCs and 
Rln preserved the vasculature.
Conclusions: These results suggest that both anastomosis and sprouting is enhanced 
only when both MSCs and Rln are used in combination. This may be in part due to Rln-
induced release of angiogenic factors from MSCs which may aid in revascularization of 
the fibrotic kidney.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Effects of Adipose Derived Stem Cells in a Model of Chronic Renal Hypoxia 
Crysthiane Saveriano Rubiao, Jose Tarcisio Giffoni, Rosemara Silva Ribeiro, 
Milene Subtil Ormanji, Vanessa A. Varela, Mirian A. Boim.  Nephrology, Federal 
Univ of Sao Paulo, Sao Paulo, Brazil.
Background: Chronic renal artery stenosis causing chronic hypoxia may lead to 
irreversible damage of the kidney with progressive deterioration of renal function. Due to 
reduced regenerative abilities of the kidney, mesenchymal stem cells (MSC) emerge as an 
alternative therapy. The aim of this study was to investigate the effects of MSC, isolated 
from adipose tissue (ASC) on renal fibrogenesis induced by chronic renal artery stenosis.
Methods: Left renal artery of male Wistar rats was partially occluded and ASC 
were injected through caudal vein. ASC were characterized by their immunophenotype/ 
multipotentiality. To analyze the migration and retention time, labeled ASC were injected 6 
weeks after renal occlusion (RO) and analyzed 24, 48, 72 hours or 15 days after injection by 
flow cytometry. Caudal systolic blood pressure (SBP) was weekly estimated. Renal function 
and the mRNA expression levels of collagen I (Col I), Fibronectin (FN) and TGF-β were 
determined by qPCR, 6 weeks after renal artery occlusion in the following groups: Sham; 
Stenotic control (StC, receiving PBS i.v.); Stenotic + ASC (S+ASC). ASC were injected 
3 and 5 weeks after RO i.v.
Results: After 48 hours cells were retained in both kidneys, stenotic and contralateral 
followed by heart and lung. After 15 days the presence of ASC decreased significantly 
in the lungs and heart but they were still present in the kidneys. StC animals showed 
progressive increase in SBP while the S+ASC rats had a stabilization of SBP with no further 
increases after 5 weeks. Plasma creatinine was similar among groups however, StC animals 
developed proteinuria which was reduced by ASC treatment. There was an increase in the 
expression of ColI, FN and TGFβ in the stenotic kidney (cortex and medulla) which was 
reversed by ASC treatment.
Conclusions: In conclusion ASC prevented further increase in SBP and reduced the 
expression of molecules induced-fibrosis. ASC migration and retention in the clipped and 
contralateral kidneys can be potentially beneficial to restore damaged tissue and to preserve 
the function of the contralateral kidney.
Funding: Government Support - Non-U.S.
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Therapeutic Effects of Erythropoietin Producing Kidney Mesenchymal 
Stem Cell Derived Microparticles on Anemia in Chronic Kidney Disease 
Mice  Hoon Young Choi, Mirae Lee, Yuri Kang, Ah Ran Choi, Sung-Kyu Ha, 
Hyeong Cheon Park.  Dept of Internal Medicine, Gangnam Severance Hospital, 
Yonsei Univ College of Medicine, Seoul, Korea.
Background: Progression of chronic kidney disease (CKD) results in aggravation 
of erythropoietin (EPO)-dependent anemia. Microparticles (MPs) shed from kidney 
mesenchymal stem cells (KMSC) have been demonstrated to confer protective effects 
against acute kidney injury and kidney fibrosis via transfer of messenger RNA. Previous 
studies have demonstrated improvement of renal anemia by EPO transfected MSC. We 
investigated whether MPs derived from EPO producing KSMC can exert therapeutic 
effects on anemia in CKD mice.
Methods: Mouse model of CKD and renal anemia was induced by the electrocoagulation 
of right renal cortex and sequential left nephrectomy. Six weeks post-nephrectomy, CKD 
and anemia was confirmed via blood urea nitrogen (BUN) and hemoglobin measurements as 
well as renal histology. Stable human EPO-producing KMSC (EPO-KMSC) and their MPs 
isolated by differential ultracentrifugation were injected intraperitoneally into established 
CKD mice and followed for 2 weeks (EPO-KMSC: 1×106 per mice, MP: 2×107 per mice). 
BUN and hemoglobin were evaluated and degree of renal tubulointerstitial damage was 
examined for 2 weeks after CKD.
Results: EPO secretion from EPO-KMSC was confirmed to sustain over 4 weeks in 
vitro and RT PCR revieled the presence of EPO mRNA within MPs. Injected EPO KMSC-
derived MPs were demonstrated within tubulointerstitial area. Animals that received EPO-
KMSC and MPs demonstrated significantly lower BUN levels compared to CKD control 
mice (60±2, 62±7 vs.83±7 mg/dL, P<0.05, respectively). Importantly, hemoglobin levels 
were significantly higher in CKD mice treated with EPO-KMSC and MPs compared to 
CKD control mice (11.7±0.1, 11.3±0.5 vs.9.7±0.5 g/dL, P<0.05, respectively).
Conclusions: The use of EPO secreting MSC is a viable strategy for cell therapy in 
renal anemia. Our results suggest that EPO-KMSC derived MPs as well as EPO-KMSC 
can improve renal function and renal anemia in CKD mice.
FR-PO216
Transplantation of Human Embryonic Mesenchymal Stem Alleviates Lupus 
Nephritis in MRL/lpr Mice  Yuan Li,1 Yaping Fan,2 Shi Hui,3 Chen Xiao Lan.4 
1Affiliated Hospital of Nantong Univ, Nantong, China; 2Affiliated Hospital of 
Nantong Univ, Nantong, China; 3Affiliated Hospital of Nantong Univ, Nantong, 
China; 4Affiliated Hospital of Nantong Univ, Nantong, China; 5Affiliated Hospital 
of Nantong Univ, Nantong, China.
Background: Compared with bone marrow derived MSC, embryo-derived MSC have 
greater expansion and differentiation potentials. T helper cell 17(Th17) and interleukin 
17(IL-17) is closely related to the occurrence and development of Lupus. The glial cell-
derived neurotrophic factor (GDNF) which is closely related to the kidney development 
is found to be a kidney protection factor and can increase the renal protective effects of 
stem cells as well. Persephin (PSP) is a member of the family of GDNF and also involves 
in the kidney development. We investigated the effects of human embryonic MSC (hMSC) 
in lupus nephritis in MRL/lpr mice.
Methods: The MRL/lpr mice were divided into 2 groups: Control, hMSC group. hMSC 
were injected at one dose of 1×106/200ul twice (at the 16th, 19th weeks of age) through 
tail vein. Mice were sacrificed at 24th weeks of age.
Results: Multi-treatment of hMSC was able to increase the survival, decrease the levels 
of 24-h proteinuria, and anti-double-stranded DNA (dsDNA) antibody. hMSC treatment 
Alleviated the extent of renal injury such as crescent formation and Interstitial inflammatory 
cell infiltration in MRL/lpr mice. hMSC treatment also inhibited Th17 cell differentiation 
in spleen and decrease the serum level of IL-17. The level of GDNF and PSP was increased 
in renal of hMSC treatment MRL/lpr mice.
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Conclusions: These findings indicated that hMSCs transplantation might be a 
potentially promising approach in the treatment of lupus nephritis, possibly by inhibiting 
Th17 cell differentiation and increasing GDNF and PSP level in renal.
Funding: Government Support - Non-U.S.
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Microarray Analysis of Gene Expression to Compare Low Serum Cultured 
Adipose Derived Stromal Cell with High Serum  Yutaka Kamimura, Naotake 
Tsuboi, Takayuki Katsuno, Shoichi Maruyama.  Nephrology, Nagoya Univ 
Graduate School of Medicine, Nagoya, Aichi, Japan.
Background: We established human adipose tissue-derived stromal cells (hASCs) 
cultured in low (2%) serum (hLASCs), which demonstrated great therapeutic potential 
for inflammatory diseases. We have already reported that hLASCs significantly attenuated 
rat folic acid-induced acute kidney injury than did hASCs cultured in high (20%) serum 
(hHASCs). However, the mechanism for hLASCs to exert greater anti-inflammatory 
function than hHASCs was partly evaluated. In the current study, we compared gene 
expression profiles and functional difference between hLASCs and hHASCs.
Methods: Human abdominal subcutaneous adipose tissue was obtained from patients 
underwent liposuction. Cells were cultured under the two conditions; a low serum culture 
medium containing 2% fetal bovine serum (FBS) and a high serum culture medium 
containing 20% FBS. Total RNA was isolated from hLASCs and hHASCs. We performed 
cDNA microarray analysis in total RNA from hLASCs and hHASCs and confirmed 
microarray data by real-time PCR. Moreover, we performed in vitro functional analysis 
in some identified molecules.
Results: 312 genes were significantly (False Dicovery Rate:FDR < 0.01) up-regulated 
(Fold Change > 5.0) and 211 genes were down-regulated in hLASCs. Microarray analysis 
revealed several differentially expressed genes including C-X-C chemokine receptor type 7 
(CXCR7), superoxide dismutase (SOD) 3, Toll-like receptor (TLR) 3. Data were validated 
by real-time PCR, confirming the differential expression profiles of CXCR7 (Fold change 
26.54), SOD3 (Fold change 4.79) and TLR3 (Fold Change 2.22) in hLASCs. Related to 
CXCR7 function, hLASCs demonstrated accelerated cell migration depending on SDF-1α, 
a CXCR4/7 agonist, compared to hHASCs. For TLR activation, hLASCs secreted more 
IL-6 and MCP-1 in response to poly:IC for TLR3 stimulation than hHASCs, but not to 
LPS for TLR4 ligand.
Conclusions: Our data suggest hLASCs can be characterized by cell migration, intense 
oxidative stress and immune response through toll-like receptor activation, which determine 
therapeutic potential of hASC.
FR-PO218
Renoprotective Effects of Tonsil-Derived Mesenchymal Stem Cells in 
Gentamicin-Induced Acute Kidney Injury (AKI)  Duk-Hee Kang, Eun Sun 
Ryu, Hyun-soo Shin, Jiyeon Ko.  Ewha Womans Univ School of Medicine.
Background: Gentamicin (GM)-induced AKI occurs in 10-20% of treated patients. GM 
is accumulated in renal epithelial cells, which causes the loss of the brush border, apoptosis 
and overt necrosis of renal tubules. Recent developments in stem cell research have shown a 
promise for the treat-ment of AKI, however the mechanisms underlying the improvement in 
kidney function provided by stem cell therapy remain unclear. Tonsil-derived mesenchymal 
stem cells(T-MSCs) can be isolated from tonsils of the patient undergoing tonsillectomy, 
andare reported to be effective in treatment of various diseases. The aim of this study is to 
investigate the therapeutic potential of T-MSCs in the treatment of AKI induced by GM.
Methods: Twenty male Sprague-Dawley rats were divided into four groups: Control, 
GM (140 mg/kg/day, ip for 10 days), GM+T-MSCs (1x107 cells, intravenous injection at 1 
day after the 1st GM injection) and T-MSC group. To examine the intra-renal localization of 
T-MSCs, T-MSCs were labeled with PKH-26 red fluorescence before infusion. Measurement 
of BUN, Cr, proteinuria and histologic analysis including TUNEL staining were performed 
on 16 days of GM injection. Effect of T-MSC on renal tubular cells was also evaluated using 
a transwell co-culture system of NRK cells and T-MSC. Intracellular ROS was analyzed by 
measuring NOX activity, H2O2 generation, NOX mRNA expressions with DCF-DA staining.
Results: PKH-26-labeled T-MSCs were observed in renal tubular cells in GM+T-MSCs 
group. The infusion of T-MSCs preserved renal function with a decrease in proteinuria. 
T-MSCs also ameliorated renal tubular dilatation and reduced apoptosis of renal tubular cells 
in the rats with GM-induced AKI. The infusion of T-MSCs downregulated the expression 
of Bax, Cytochrome c, Cleaved caspase-9 and -3 and upregulated Bcl-2 of renal cortical 
tissue. In-vitro study revealed an amelioration of GM-induced oxidative stress and apoptosis 
of NRK cells by T-MSC.
Conclusions: Our results suggest that T-MSCs protect the kidney from GM-induced 
AKI, possibly via the mechanism of modulation of oxidative stress and apoptosis.
Funding: Government Support - Non-U.S.
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Exosomes Secreted by Human Urine-Derived Stem Cells Could Prevent 
Kidney Complications from Type I Diabetes in Rats  Zhenzhen Jiang, Yumei 
Liu, Ying Fan, Jing Zhang, Yang Fei, Niansong Wang.  Dept of Nephrology and 
Rheumatology, Shanghai Jiao Tong Univ Affiliated Sixth People¶s Hospital, 
Shanghai, China.
Background: Stem cells are currently the main candidates for the development of 
new treatments for diabetic nephropathy, as they may exert their therapeutic effects mainly 
through paracrine mechanisms. Exosomes derived from stem cells have been reported to 
play an important role in kidney injury.
Methods: Exosomes from conditioned medium of human urine-derived stem cells 
(USCs-Exo) were isolated using ultra-filtration and purification methods. USCs-Exo was 
then verified by morphology characteristics and specific biomarkers. After the establishment 
of the streptozotocin (STZ) induced Sprague - Dawley (SD) rats’ model, the effects of 
USCs-Exo on kidney injury were observed via tail intravenous injection of USCs-Exo or 
control weekly until 12 weeks. In vitro, podocytes cultured in high glucose medium were 
treated with USCs-Exo to test the protective effect of USCs-Exo on podocytic apoptosis.
Results: USCs were cultured and were verified by positive markers of CD29, CD73, 
CD90 and CD44 antigens, and negative markers of CD34 and HLA-DR. USCs-Exo were 
100 nm spherical vesicles under transmission electron microscopy and the specific markers 
including CD9, CD63 and CD81. Intravenous injections of USCs-Exo could potentially 
reduce the urine volume and urinary microalbumin excretion, prevent podocytes and tubular 
epithelial cells apoptosis, suppress the caspase-3 overexpression and increase glomerular 
endothelial cells proliferation in diabetic rats. In addition, USCs-Exo could reduce podocytic 
apoptosis induced by high glucose in vitro.
Conclusions: USCs-Exo may have the potential effect to prevent kidney injury from 
diabetes by inhibiting podocytes apoptosis and promoting vascular regeneration.
FR-PO220
Characterization of a Nanotube-Based Mechanism for Hematopoietic Stem 
Cell-Mediated Kidney Repair in Cystinosis  Spencer M. Goodman,1 Swati 
Naphade,1 Jay Sharma,1 Heloise P. Gaide Chevronnay,2 Pierre J. Courtoy,2 
Stephanie Cherqui.1  1Dept of Pediatrics, Div of Genetics, Univ of California, 
San Deigo, La Jolla, CA; 2Cell Biology Unit, de Duve Inst, Univ Catholique de 
Louvain, Brussels, Belgium.
Background: Cystinosis is a lysosomal storage disorder caused by mutations in 
the CTNS gene, encoding the lysosomal transmembrane transporter cystinosin. As a 
consequence, cystine builds up in all tissues and eventually causes multi-organ degeneration. 
Patients develop renal Faconi syndrome before the age of one, and ultimately, end-stage 
renal failure. We previously showed in Ctns-/- mice that transplantation of hematopoietic stem 
cells (HSCs) resulted in abundant integration of bone marrow-derived cells into all tissues 
and long-term kidney preservation. To address the cellular mechanism of kidney rescue, 
we observed that HSCs differentiated into macrophages that extended intercellular bridges 
called tunneling nanotubes (TNTs). TNTs were seen transporting cystinosin-GFP lysosomes 
into diseased proximal tubular cells (PTCs) across the tubular basement membrane.
Methods: In vitro co-culture of primary DsRed Ctns-/- fibroblasts with IC21 
macrophages expressing CTNS-GFP allowed visualization of bidirectional lysosome 
transfer. We designed an application using ImagePro to automatically quantify TNTs via 
morphological filters. In vivo, we further evidenced glomerular rescue by HSCs in DsRed 
Ctns-/- mice transplanted with GFP-expressing HSCs. Cells and glomeruli are currently 
analyzed by confocal and electron microscopy.
Results: We thus showed that HSC-derived cells result in morphological and functional 
preservation of both PTCs and glomeruli in grafted Ctns-/- mice. However, while PTC rescue 
implied differentiation of donor cells into F4/80+ macrophages, glomeruli-engrafted HSCs 
were apparently not macrophages. Work is ongoing to characterize the cellular mediators 
of glomeruli repair.
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Conclusions: In conclusion, HSC transplantation can repair and preserve near-normal 
kidney architecture in cystinosis. Understanding mechanisms underlying kidney repair could 
spur the development of novel stem cell-based therapies for degenerative renal disorders.
Funding: NIDDK Support, Other NIH Support - NINDS, Private Foundation Support
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Towards the Clinical Application of Gene-Modified Hematopoietic Stem 
Cell Transplantation for Cystinosis  Tatiana Vm Lobry, Jay Sharma, Sarah Ur, 
Celine Rocca, Betty Cabrera, Stephanie Cherqui.  Pediatrics, Univ of California 
San Diego, San Diego, CA.
Background: Cystinosis is an autosomal metabolic disease caused by mutations in 
the CTNS gene, encoding a lysosomal cystine transporter, leading to cystine accumulation 
and multi-organ failure. Affected individuals present before 2 years of age with a Fanconi 
syndrome and eventually progress to end-stage renal failure. Treatment with cysteamine 
does not prevent these complications. We showed previously that wild-type HSC 
transplantation could treat cystinosis in the Ctns-/- mice. Thus, we developed an autologous 
transplantation strategy of HSCs genetically modified ex vivo to express a functional CTNS 
gene. Preclinical studies using a SIN-lentivirus vector containing CTNS to transduce Ctns-
/- HSCs and transplanted in Ctns-/- mice led to cystine reduction in all tissues and kidney 
function improvement.
Methods: Pharmacological and toxicological studies are in progress. We established 
the optimal conditions to transduce human CD34+ HSCs with our lentiviral vector to obtain 
a Vector Copy Number (VCN) included between 1 and 3. We performed Colony Forming 
Unit (CFU) assays to ensure normal proliferation and differentiation of transduced human 
CD34+ HSCs from healthy donors and cystinotic patients and the In Vitro Immortalization 
(IVIM) assay, a genotoxicity test. Serial transplantations in the Ctns-/- mice will assess the 
safety of our vector in vivo.
Results: While we obtained VCN within the range for healthy donors CD34+ HSCs, the 
VCN for the CTNS-/- CD34+ HSCs is below 1, requiring further optimization. CFU assays 
did not show aberrant differentiation of the transduced CD34+ cells from the healthy donors 
and cystinotic patients. Finally, no immortalized clones were observed with the IVIM assays 
suggesting a good safety profile of our vector. These results will be included in our IND 
for a phase 1 clinical trial for cystinosis. The in vivo serial transplantations are in progress.
Conclusions: This work represents the first stem cell and gene therapy treatment 
strategy for cystinosis and should lead to a phase I clinical trial.
Funding: NIDDK Support, Private Foundation Support
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Mesenchymal Precursor Cell Therapy for Diabetic Nephropathy: 24 Week 
Results from a Phase 2A Randomized Controlled Trial  David K. Packham,1 
Ian R. Fraser,2 Peter G. Kerr,3 Silviu Itescu,4 Karen R. Segal.4  1MRRG, 
Melbourne, VIC, Australia; 2Epworth H, Melbourne, VIC, Australia; 3Dept 
Neph, Monash M C, Melbourne, VIC, Australia; 4Mesoblast PLC, NY, NY.
Background: Renal inflammation and endothelial dysfunction contribute to the 
etiology of diabetic nephropathy (DN). Bone marrow derived mesenchymal precursor 
cells (MPC) can modulate both inflammatory cells and microvasculature. We conducted 
a randomized, placebo (PBO) controlled, dose-escalating trial of allogeneic MPC in 30 
subjects with type 2 DN.
Methods: Patients (24 men, 6 women) with an estimated glomerular filtration rate 
(eGFR) of 20-50 ml/min/1.73/m2 and on a stable regimen of renin-angiotensin inhibition 
were randomized to a single IV infusion of PBO (saline) or 150 million (M) or 300M MPCs 
(N=10 per group). Patients have been followed-up for 24 w. Baseline mean age was 70 
years mean eGFR was 34.6, 35.7 and 34.6 ml/min/1.73/m2 for PBO, 150M and 300M, 
and 19/30 patients had eGFR>30.
Results: There were no treatment-related adverse events. For eGFR change from 
baseline at 24 w, the least square mean (LSM) differences from PBO were 3.2+2.5 (8.1%) 
in both 150M and 300M groups. PBO-adjusted treatment differences were greater in pooled 
MPC with baseline eGFR>30: 4.9+2.3 (+12%) at 24w. The LSM differences from PBO for 
mean individual annualized slopes of eGFR change over 24w was 6.8+4.8 in both treatment 
groups. Baseline IL6 levels correlated with SCr and eGFR improvement at 12 w in the 
MPC groups (r=0.57 and 0.50; both p<0.05) but not in PBO. The LSM differences from 
PBO for mean individual annualized slopes of eGFR change over 24w was 7.8+4.8 ml/
min/1.73 m2/y in pooled MPC patients with baseline IL-6 >3.5 pg/dl and 5.6+5.0 in MPC 
patients with baseline IL-6 <3.5 pg/dl, suggesting greater preservation or improvement in 
eGFR relative to PBO in the presence of elevated IL-6.
Conclusions: In this first in humans study, a single MPC infusion improved or stabilized 
GFR over 24w. Baseline eGFR>30 and high IL-6 levels suggest two biomarkers that may 
predict efficacy with MPC treatment. Positive response to MPC therapy may be enhanced by 
the presence of non-fibrotic, but at-risk, renal tissue and aberrant pro-inflammatory milieu.
Funding: Pharmaceutical Company Support - Mesoblast PLC
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Long-Term Effect of Methylprednisolone Pulse and Autologous SVF 
(Stromal Vascular Fraction) Therapy in Severe IgA Nephropathy with CKD 
Stage III  Byoung-Soo Cho,1 Yumi Choi,2 Jin-Soon Suh.3  1TheAll Medical Hub 
Kidney Center, MIRAE ING Research Inst, Seoul, Republic of Korea; 2Dept of 
Pediatrics, Gwangmyeong Sung-Ae Hospital, Gwangmyeong-si, Gyeonggi-do, 
Republic of Korea; 3Dept of Pediatrics, College of Medicine, The Catholic Univ 
of Korea, Bucheon-si, Gyeonggi-do, Republic of Korea.
Background: Up to date there is no specific method of treatment in severe IgA 
nephropathy with CKD, but giving ACE inhibitor, angiotensin II receptor blocker(ARB), 
omega-3 etc. and eventually almost all cases fall into CKD V and need KTP or dialysis. 
Cell-based therapy is an emerging field in nephrology field especially adipose derived 
stem cells(ASCs). The beneficial effects of mesenchymal stem cell occur through 
differentiation-independent pathways include increased cell survival and proliferaton, 
decreased inflammation, immune modulation, tissue regeneration etc.
Methods: We tried methylprednisolone(MP) pulse therapy followed by autologous 
SVF(stromal vascular fraction), which contained ASCs in severe IgA nephropathy with 
CKD stage III. This case was 44years old female patient, Renal biopsy finding showed 
Grade IV(Lee’s classification) with CKD stage 3. MP pulse was tried 6 cycles followed by 
autologous SVF were injected through intravenously 4 times at 3 weeks interval.
Results: Initial renal biopsy findings before treatment(Tx) showed 61% scerotic 
glomeruli, however follow up renal biopsy 18 months after Tx showed 41% sclerotic 
glomeruli and disappeared immune deposits, The serum creatinine level before Tx was 
1.77mg/dl with GFR 35ml/min, however 18 months after Tx serum creatinine was 1.03mg/
dl with GFR 61ml/min.
Conclusions: In conclusion MP pulse therapy with autologous SVF treatment in 
intractable IgA nephropathy might be a promising therapeutic means without any notable 
side-effect or complications especially in early stage CKD, although the efficacy and safety, 
of SVF infusion therapy needs long term studies.
FR-PO224
Extracellular Vesicles in Glomerular VEGF Homeostasis  Sargis Sedrakyan,1 
Stefano Porta,2 Hasmik Soloyan,1 Nikita Tripuraneni,1 Roger E. De Filippo,1 
Benedetta Bussolati,2 Laura Perin.1  1Children’s Hospital Los Angeles; 2Univ 
of Turin.
Background: Strict regulation of VEGF signaling between podocytes and glomerular 
endothelial cells (GEC) is critical for GEC survival and function, therefore, loss of 
glomerular VEGF homeostasis during disease progression can impact GEC integrity leading 
to decline in glomerular function. Importantly, recent studies have described extracellular 
vesicles (EVs) to play important role in stem cell mediated paracrine modulation, 
including in kidney. We have already established that amniotic fluid stem cells (AFSC) 
are renoprotective, and we hypothesize that EVs released within damaged glomeruli are 
involved in VEGF regulation. Herein, we investigate the impact of AFSC derived EVs in 
the maintenance of glomerular VEGF homeostasis.
Methods: Using qPCR and ELISA we measured VEGF expression along the course 
of disease progression in isolated glomeruli of mice affected by Alport Syndrome (AS). 
Endothelium morphology was evaluated by IHC and TEM. GEC were FACS sorted from a 
GEC specific Tek reporter mice and studied by gene and protein arrays for VEGF/VEGF-R, 
oxidative stress, and apoptotic pathways. Co-cultured GEC and AFSC overstimulated with 
VEGF were used to study the direct role of EVs in VEGF regulation. EVs were characterized 
and injected into AS mice for in vivo evaluation.
Results: Mice at advanced stages of Alport disease presented with aberrant VEGF 
activity within glomeruli, significant GEC apoptosis, oxidative stress and loss of GEC 
fenestrations. Delivery of AFSC derived EVs normalized VEGF expression and ameliorated 
endothelial damage. Importantly, the soluble receptor of VEGF, sFlt1—involved in 
regulating VEGF signaling—was also modulated upon treatment, indicating a VEGF/sFlt1 
mechanism of regulation by EVs. In vitro experiments further confirmed the direct role of 
EVs in VEGF/sFlt1 regulatory mechanism.
Conclusions: In conclusion, our data demonstrate for the first time the aberration of 
VEGF signaling within AS glomeruli. We further showed that AFSC derived EVs play an 
important role in maintaining glomerular homeostasis of VEGF signaling, so critical to 
normal GEC integrity and function, presenting with a potential for new targeted therapies 
in CKD.
Funding: Other U.S. Government Support
FR-PO225
Renal Exosomes Store and Transfer the Ischemia Preconditioning State 
and Protect Rats with Severe Renal Ischemia  Katherine J. Kelly,1 Jesus 
H. Dominguez.1,2  1Medicine, Indiana Univ Medical School, Indianapolis, IN; 
2Medicine, Veterans Administration, Indianapolis, IN.
Background: Acute Kidney Injury (AKI) is a risk factor for chronic kidney disease 
(CKD) and end-stage renal disease (ESRD). We have reported that intravenous renal cell 
transplants (IRCT) improve outcomes in rats with AKI (AJP 303:F357, 2012). IRCT 
action was mediated by relatively small number of anchored and retained cells, and we 
hypothesized that cells amplified renal protection by releasing exosomes (EX) acting at 
a distance.
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Methods: We tested if renal EX from cultured cells used for IRCT improved AKI. 
Normal Sprague Dawley rats (SD, n = 4-7) were subjected to 45 minutes of bilateral ischemia 
(IR). Renal exosomes (600 ug/protein/rat) were then given intravenously .
Results: There were 5 groups of rats: 1, sham, no IR; 2, renal ischemia (IR) untreated 
(NO-EX);  IR treated with heat inactivated EX (HI-EX); 3, IR treated with normal EX (NL-
EX),  RI  treated with EX released by kidney cells subjected to ischemia preconditioning 
(IPC-EX).   In sham, serum creatinine was 0.3±0.03 at 24 hrs and 0.3±0.02 at 48 post-
surgery. In NO-EX it was 2.1±0.6  and 1.7, post IR, respectively. In HI it was 2.2±0.1 and 
1.6±0.3. However, in NL-EX it was 2.4±0.4 and 0.78±0.1. The most striking effect was 
from IPC-EX: 2.0±0.2, and 0.54±0.1, p <0.05 vs. all including NL-EX. Kidney weight 
(mg/gm body weight) 6 days post IR was also improved by EX: 3.8±0.1 in sham;  6.7±0.6 
in NO-EX;  6.7±0.6 in HI; 5.2±0.2 in NL-EX 5.2±0.2, and 4.4±0.2 in IPC-EX, which was 
significantly lower than all IR groups,  including NL-EX.  Neutrophils (PMN) in IPC-EX 
were also reduced by 65 % (p<0.05) when compared to NL-EX.  IPC-EX reduced renal 
C3 expression in glomeruli and tubules by 73 % and 82 % respectively (p < 0.05 for both). 
IPC-EX also protected 76 % of renal tubules when compared to NO-EX.
Conclusions: IPC is effective but impractical. However, EX given IV can communicate 
the IPC state, reach the kidneys, modulate inflammation and protect function and structure 
following severe IR.
Funding: NIDDK Support, Other U.S. Government Support, Veterans Administration 
Support
FR-PO226
The Impact of Preexisting Chronic Kidney Disease on the Severity and 
Recovery of Acute Kidney Injury  Sung Yoon Lim,1 Young Ju Na,1 Myung-gyu 
Kim,1 So-young Lee,2 Sang-Kyung Jo,1 Won-Yong Cho.1  1Dept of Nephrology, 
Korea Univ Hospital, Seoul, Korea; 2Dept of Nephrology, Eulji Univ Hospital.
Background: Recent observational studies have shown that a substantial proportion of 
patients with acute kidney injury (AKI) have often progression to chronic kidney disease 
(CKD). Among several risk factors for the development of CKD after AKI, decreased 
baseline glomerular filtration rate (GFR) represents an important risk factor. However, 
precise mechanisms involved in the development of fibrosis after AKI with preexisting 
CKD have not been completely ascertained. Here in this study, we assessed the impact of 
preexisting CKD on the severity and recovery of AKI in mouse model of 5/6 nephrectomy.
Methods: Male CD-1 mice underwent 5/6 nephrectomy or sham operation, and 6 
weeks later ischemia reperfusion injury (IRI) was performed. On day 1, 7 and 28 after 
IRI, functional, histological, and molecular parameters were compared between them.
Results: Twenty five minutes clamping of renal pedicle in 5/6 nephrectomized mice 
did not provoke more severe functional, histological deterioration compared to normal 
mice on day 1 and 7. Similar elevations in SCr were observed in both groups until day 7 
after IRI; however, SCr remained higher on day 28 in 5/6 nephrectomized mice compared 
to normal mice, suggesting that preexisting CKD does not modify severity of AKI but 
adversely affect the recovery process. From day 7 to 28, mRNA expression of p21, and 
protein level of pH3, both representing cell cycle arrest were significantly increased in 5/6 
nephrectomized mice (CKD+AKI) compared to sham (sham+AKI).  Treatment with p53 
inhibitor after IRI resulted in not only decreased p21 and pH3 protein level, but also fibrosis 
in CKD+AKI mice, suggesting that epithelial cell cycle arrest is partially responsible for 
impaired recovery from AKI in 5/6 nephrectomized mice.
Conclusions: Taken together, reduced nephron mass do not seem to increase severity 
of AKI, but have negative effect on repair process, leading to development of fibrosis.
FR-PO227
Impaired Functional Recovery from Acute Kidney Injury in Rats with 
Preexisting Chronic Kidney Disease Predicts the Severity of De Novo 
Hypertension  Aaron J. Polichnowski,1,2 Karen A. Griffin,1,2 Mana Dissadee,1,2 
Anil K. Bidani.1,2  1Edward Hines Jr. VA Hospital, Hines, IL; 2Medicine, Loyola 
Univ Medical Center, Maywood, IL.
Background: The mechanisms by which AKI accelerates the progression of CKD 
remain poorly understood. We have recently demonstrated that preexisting CKD predisposes 
to impaired recovery from AKI as evidenced by exaggerated levels of tubulointerstitial 
fibrosis and modest elevations in blood pressure at 4 weeks post injury. However, a rigorous 
examination of the relationship between impaired functional recovery from AKI and the 
development of hypertension has not been examined.
Methods: Male SD rats underwent normotensive 3/4 nephrectomy (3/4 NX) and were 
chronically instrumented with a BP radiotelemeter. Two weeks later, rats were subjected to 
40 min IR (n=20) or sham IR (n=8). BP was assessed every 10 min, 24 hr/day for 4 weeks 
and glomerular filtration rate (GFR) was then assessed in the conscious state (FITC-inulin).
Results: As compared to baseline values, systolic BP was significantly elevated 
(P<0.05) in rats at 4 weeks post IR (134±2 vs. 149±5 mmHg, respectively) but not sham 
IR (139±4 vs. 140±2 mmHg, respectively). GFR was significantly less (P<0.05) in rats 
subjected to IR vs. sham IR (1.1±.1 vs. 1.4±.1 ml/min, respectively). As shown in Figure 1, 
a very strong negative correlation was observed between GFR and the increase in systolic 
BP over the 4 week protocol. SCr values 48 hours post AKI did not correlate with either 
GFR or the change in systolic BP at 4 weeks post AKI, indicating that the development 
of hypertension following IR was due to impaired recovery from AKI as opposed to a 
greater severity of AKI. 
Conclusions: The development of hypertension following AKI in the presence of pre-
existing CKD is likely to significantly contribute to the subsequent progression of CKD.
Funding: NIDDK Support, Veterans Administration Support
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Exocytosis of Endothelial Lysosome-Related Organelles Hair-Triggers a 
Patchy Loss of Glycocalyx at the Onset of Sepsis  Joseph A. Zullo,1 Jie Fan,2 
Tala F. Azar,1 Wan-yi Yen,2 Min Zeng,2 Jun Chen,1 Brian B. Ratliff,1 Jungol 
Song,3 John Tarbell,2 Bingmei M. Fu,2 Michael S. Goligorsky.1  1New York 
Medical College; 2The City College of The City Univ of New York; 3Ulsan 
Medical College, Seoul, Republic of Korea.
Background: Endothelial surface glycocalyx (ESG) is a well-known regulator 
of leukocyte surveillance, vascular permeability, and a sensor of shear stress. ESG is 
degraded during sepsis, thus contributing to systemic multiorgan involvement. Our previous 
demonstration of a very early post-stress exocytosis of lysosome-related organelles (LRO) 
with their lytic enzymes led us to hypothesize that exocytosis of LRO may catapult a 
synchronized degradation of ESG.
Methods: To test this hypothesis we first analyzed the time-course of exocytosis of 
Weibel-Palade bodies and secretory lysosomes after application of lipopolysaccharides 
(LPS) to endothelial cells.
Results: Time-lapse video microscopy revealed that LROs undergo agitation 
and vectorial movement with a time course of a few minutes after LPS. In addition, 
spectrophotometry measurements illustrated an increase of lysosomal cargo, cathepsin 
B, within the media after 10min of LPS exposure. Two therapeutic maneuvers, a nitric 
oxide intermediate, NG-hydroxy-L-arginine (NOHA), and culture media conditioned by 
endothelial progenitor cells (EPC-CM) reduced the directionality and motility of LRO. The 
patchy loss of ESG occurring with the similar fast kinetics was confirmed using confocal 
fluorescence microscopy and Stochastic Optical Reconstruction Microscopy. The loss of 
ESG was blunted by pretreatment with NOHA or EPC-CM. Moreover, these treatments 
resulted in a significant reduction of mortality of septic mice.
Conclusions: In summary, above studies provide the first demonstration of the very 
early patchy disintegration of ESG which can be prevented by pretreatment with NOHA 
and EPC-CM, maneuvers that reduced exocytosis of LRO. Data support the hypothesis 
assigning to stress-induced exocytosis of these organelles the role of a hair-trigger for 
local degradation of ESG that in turn initiates leukocyte infiltration, increase in vascular 
permeability, and partially accounts for the later morbidity and mortality.
Funding: NIDDK Support
FR-PO229
Vitamin D Deficiency Contributes to Vascular Damage in Sustained 
Ischemic Acute Kidney Injury  Ana C. de Bragança,1 Rildo A. Volpini,1 Purvi 
Mehrotra,2 Carlie M. Ivancic,2 Lucia Andrade,1 David P. Basile.2  1Nephrology, 
Univ of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil; 2Cellular and 
Integrative Physiology, Indiana Univ School of Medicine, Indianapolis, IN.
Background: It has been shown that injury to the renal vasculature may play an 
important role in the pathogenesis of ischemic acute kidney injury (AKI). Reductions in 
microvasculature density may play a critical part in the progression of chronic kidney disease 
(CKD) following AKI-induced ischemia/reperfusion injury (IRI). Vitamin D deficiency 
(VDD) is associated to tubulointerstitial damage and fibrosis progression following IRI-
AKI. We evaluated the effect of VDD in sustained IRI-AKI, hypothesizing that VDD 
contributes to vascular damage.
Methods: Wistar rats were fed 25(OH)D-free or standard diets for 35 days. On day 
28, rats were randomized into four groups: control (sham), VDD, bilateral IRI and VDD 
IRI. Rats were analyzed 7 days after the surgeries.
Results: VDD rats showed impaired capillary density (by cablin staining) and reduced 
VEGF expression, even in the absence of injury. In addition, VDD IRI rats manifested a 
remarkable capillary rarefaction and also had increased RW/BW, tissue injury scores, FSP-1, 
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α-SMA when compared to either VDD or IRI rats. VDD IRI also had increased levels of 
infiltrating activated CD4+ and CD8+ cells secreting higher levels IFN-γ and IL-17 while 
the number of regulatory T cells was reduced, relative to IRI rats.
Control n=6 VDD n=5 IRI n=7 VDD IRI n=7
RW/BW ratio 0.34±0.009 0.33±0.005 0.50±0.031a,d 0.58±0.030a,d,i
Vessel density % 100.0±14.08 77.45±3.33 75.50±6.91 53.42±8.58b
FSP1 +cells/field 5.99±1.28 7.35±0.79 18.31±1.72b,e 27.0±3.11a,d,i
α-SMA % 0.15±0.04 0.16±0.01 2.89±0.43 7.74±1.56b,d,h
VEGF % 30.56±3.05 20.51±5.49 16.56±2.08 13.42±4.49c
ap<0.001, bp<0.01 and cp<0.05 vs Control; dp<0.001 and ep<0.01 vs VDD; hp<0.01 and ip<0.05 vs IRI 
Conclusions: VDD impairs renal capillary density and exacerbates fibrotic damage and 
pro-inflammatory milieu following AKI, which may contribute to the transition of CKD 
following AKI. Funding: CAPES/CNPq/FAPESP, NIH DK63114 (DPB).
Funding: NIDDK Support
FR-PO230
Exosome-Mediated Delivery of Pro-Survival MicroRNA-486-5p in Acute 
Kidney Injury  Jose L. Vinas, Dylan Burger, Alex Gutsol, William A. Knoll, 
David Allan, Kevin D. Burns.  Nephrology, Dept of Medicine, Ottawa Hospital 
Research Inst, Univ of Ottawa, Ottawa, ON, Canada.
Background: We recently showed that administration of human endothelial colony 
forming cells (ECFCs) and their exosomes to mice with ischemic acute kidney injury 
(AKI) attenuated renal damage. Our data also indicate that ECFCs release exosomes that 
are highly enriched in micro-RNA (miR)-486-5p and protect against hypoxia-induced 
endothelial cell apoptosis. MiR-486-5p targets phosphatase and tensin homologue (PTEN), 
which may enhance the pro-survival Akt pathway. In this study, we further examined the 
role of exosomes and miR-486-5p on the Akt pathway in vivo, and tested the hypothesis 
that exosomes transfer miR-486-5p to endothelial cells in vitro.
Methods: Mice with ischemic AKI were injected (i.v.) with exosomes at reperfusion. 
Kidneys were subjected to immunoblots and RT-PCR for miR-486-5p. Transfer of 
ECFC exosomes and miR-486-5p was studied in human umbilical vein endothelial cells 
(HUVECs).
Results: Bioinformatic analysis of the 10 most abundant miRs in ECFC exosomes 
revealed that they were all involved in the Akt pro-survival pathway. Inmice with 
AKI, exosome treatment significantly increased renal miR-486-5p levels (P<0.01 vs 
ischemia alone, n=6-7), associated with decreased PTEN expression, and increased Akt 
phosphorylation. In cultured HUVECs, ECFC exosomes labeled with the fluorescent dye 
PKH-26 localized to the perinuclear compartment. Treatment of HUVECs with ECFC-
derived exosomes or co-culture of ECFCs with HUVECs caused a 40-fold increase in levels 
of miR-486-5p. Transfection of ECFCs with pre-miR-486-5p, followed by co-culture with 
HUVECs was associated with a further marked increase (~20-fold) in miR-486-5p levels in 
HUVECs (P<0.001 vs control, n=3). This effect was blocked by pre-incubation of HUVECs 
with ethylisopropyl amiloride (an inhibitor of exosome uptake).
Conclusions: These data suggest ECFC-derived exosomes exert renoprotective effects 
in AKI, possibly via the transfer of miR-486-5p to endothelial cells. Exosome-mediated 
transfer of miRs could represent a strategy to target pro-survival pathways in the injured 
kidney.
Funding: Private Foundation Support
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The Role of Vascular Endothelial Cells in the Protective Effect of Delayed 
Ischemic Preconditioning in Renal Ischemia/Reperfusion Injury  Xialian Xu, 
Xiaoyan Jiao, Nana Song, Xiaoqiang Ding.  Div of Nephrology, Zhongshan 
Hospital, Shanghai, China.
Background: We have previously reported that up-regulation of miR-21 contributed to 
the protective effect of delayed ischemia preconditioning (IPC) in renal ischemia/reperfusion 
injury (IRI). The role of vascular endothelial cells in renal IRI is not well-understood. In 
the present study, we examined the role of vascular endothelial cells in the protective effect 
of miR-21 in renal delayed IPC.
Methods: For the delayed IPC and IR model, 4 d after IPC (15min ischemia) or 
sham surgeries, preconditioned mice were subjected to 35 min occlusion of bilateral renal 
pedicles, followed by 24 h reperfusion. Human umbilical vein endothelial cells (HUVEC) 
were treated with cobalt chloride for hypoxia model in vitro. Locked nucleic acid (LNA) 
modified anti-miR-21 or anti-scrambled was transfected into cells or delivered into the mice 
via tail vein injection less than 1 hour prior to IPC. Vascular permeability was determined by 
the Evans Blue dye. Cell apoptosis was estimated by Annexin V-FITC apoptosis detection. 
Expression of programmed cell death 4 (PDCD4) protein and miR-21 was examined by 
western blot and real-time PCR, respectively.
Results: Compared with the Sham+IR group, mice in the IPC+IR group showed 
significant improvement of renal function and histology injury (P<0.01). MiR-21 was 
up-regulated in the IPC+IR group with concomitant decline of PDCD4 (P<0.05) and 
improvement of vascular permeability (P<0.05). In vitro, miR-21 in HUVEC was increased 
in hypoxia, while PDCD4 expression was decreased. Knockdown of miR-21 by LNA anti-
miR-21 attenuated the protection conferred by delayed IPC, with concomitant up-regulation 
of PDCD4 (P<0.05) and exacerbated renal vascular permeability (P<0.05). Cell apoptosis 
significantly decreased after knockdown of miR-21 in vitro.
Conclusions: Up-regulation of miR-21 in renal delayed IPC improved the apoptosis of 
vascular endothelial cell by inhibiting its target PDCD4. This may be another mechanism 
underlying the protective effect of the delayed IPC.
Funding: Government Support - Non-U.S.
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Role of Vascular Mineralocorticoid Receptor in Renal Ischemia/Reperfusion 
Jonatan Barrera-Chimal,1 Alan Le Mercier,1 Sonia Prince,1 Soumaya El 
Moghrabi,1 Norma Bobadilla,2 Frederic Jaisser.1  1INSERM U1138, Centre de 
Recherche des Cordeliers, Paris, France; 2Inst de Investigaciones Biomédicas 
UNAM and INNSZ, Mexico City, Mexico.
Background: Renal ischemia/reperfusion (IR) is a major cause of acute kidney injury 
and is associated with chronic kidney disease (CKD) development. Mineralocorticoid 
receptor (MR) antagonism prevents the acute and chronic consequences of renal IR. Whether 
the benefit of the MR antagonists is due to the blockade of the MR in the vessels is unclear.
Therefore we want to study the specific contribution of endothelial and smooth muscle 
cells (SMC) MR in acute and chronic consequences of renal IR.
Methods: To inactivate MR in endothelial cells (MRendoKO mice), floxed MR mice 
(MRflfl) were crossed with mice expressing the inducible Cre recombinase under the VEcadh 
promoter. To allow inactivate MR in smooth muscle cells (MRSMCKO mice), MRfl/fl mice 
were crossed with mice expressing the inducible Cre recombinase under the SMA promoter. 
Sham surgery or bilateral renal IR for 20 min was performed in MRfl/fl and KO mice and 
the animals were studied at short term (24 h) and long term (30 days) after reperfusion.
Results: In MRfl/fl mice, IR induced renal dysfunction (plasma creatinine from 8.9±0.3 
in sham to 33.8±4.8 umol/L in IR), tubular injury and increased mRNA levels of kim-1 
(400-fold) and NGAL (220-fold). The MRendoKO mice displayed similar alterations induced 
by IR as MRfl/fl mice. In contrast, after 24 h of IR, the MRSMCKO mice presented normal renal 
function (plasma creatinine was 9.6±0.7 and 14.0±1.9 umol/L in sham and IR, respectively), 
absence of histological alterations and reduced kim-1 and NGAL levels. 
After 30 days, the MRfl/fl mice developed CKD characterized by renal dysfunction 
(plasma creatinine from 10.5±0.1 in sham to 15±0.8 umol/L in IR), tubule-interstitial 
fibrosis and increased mRNA levels of fibronectin and Galectin-3 (2-fold). The MRSMCKO 
mice developed similar alterations.
Conclusions: We provide evidence that the deficiency of MR in the SMC protects 
against the development of acute kidney lesions induced by IR, however MR deficiency 
in SMC did not impact the appearance of CKD induced by IR, suggesting that MR in 
other cell types is involved.
Funding: Government Support - Non-U.S.
FR-PO233
Renal Vein Hydrodynamic Fluid Delivery Ameliorates Established Renal 
Injury following Ischemia/Reperfusion Injury  Jason Andrieu Collett,1 Purvi 
Mehrotra,1 David P. Basile,1 Robert L. Bacallao.2,3  1Cellular and Integrative 
Physiology, Indiana Univ School of Medicine, Indianapolis, IN; 2Div of 
Nephrology, Indiana Univ School of Medicine, Indianapolis, IN; 3Richard L. 
Roudebush VA Medical Center, Indianapolis, IN.
Background: Past and current treatment for Acute Kidney Injury (AKI) is mainly 
supportive in nature; no therapeutic modalities to date have shown efficacy in treating 
the condition. While numerous experimental approaches can prevent AKI, there are few 
potentially translatable studies which may influence the course of established AKI. The 
goal of this study was to target vascular congestion and inflammation, which contribute 
to impaired renal perfusion and renal damage, following the established injury. We 
hypothesized that high-pressure retrograde hydrodynamic delivery (HD) of saline will 
improve established AKI, in part, by improving vascular congestion.
Methods: Male Sprague Dawley rats underwent left unilateral ischemia (35 min) 
and right unilateral nephrectomy or bilateral IRI (35min) and reperfusion for 24 hours 
to induce AKI. 0.5ml of isotonic saline was then injected into either the vena cava (VC) 
or retrograde to left kidney via the renal vein (RV) under high pressure (~60mmHg). 
Recovery was evaluated via serum creatinine and accumulation of immune cells were 
evaluated using FACS.
Results: Average serum creatinine at 24hrs was similar between groups (sCre=3.3mg/
dl), however, RV-HD treated rats showed a rapid improvement in serum creatinine over the 
following 24 hours vs VC HD rats (24 to 48 hr ∆ serum creatinine -0.544 mg/dl vs. +0.6375 
mg/dl; p=0.0237). To evaluate effects on inflammation, bilateral IRI rats subjected to left-RV 
HD resulted in a significant reduction in CD4+ (54%±18; p<0.05), CD8+(60%±8; p<0.05), 
B cells (56%±3.5; p<0.05) and DC/Macs (71%±13; p<0.05) compared with VC rats.
Conclusions: These results indicate that high pressure retrograde HD may provide 
a novel and effective therapeutic strategy for the treatment of AKI and transition of AKI 
to CKD.
Funding: NIDDK Support, Veterans Administration Support
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FR-PO234
Human Adipose Stromal Cells Ameliorate Renal Injury and Attenuate 
Capillary Rarefaction following Ischemia-Reperfusion  Jason Andrieu Collett, 
Purvi Mehrotra, Dmitry O. Traktuev, Stephanie Merfeld-Clauss, Keith March, 
David P. Basile.  Indiana Univ School of Medicine, Indianapolis, IN.
Background: Acute kidney injury (AKI) is a syndrome characterized by the rapid loss 
of the kidney’s excretory function, resulting in excess of 17 million hospital admissions a 
year. Although the tubular epithelium is the primary target of ischemic injury, early damage 
to endothelial cells contribute to AKI by resulting in impaired perfusion. Moreover, renal 
capillary density is permanently compromised in rats following AKI induced by ischemia 
reperfusion (IRI), which is hypothesized to promote CKD. Therefore, strategies to preserve 
capillaries may impact both short-term recovery and long-term function post-AKI. 
Adipose stromal cells (ASCs) have pro-angiogenic and anti-inflammatory properties. It 
is hypothesized that ASCs facilitate repair by capillary preservation, revascularization of 
damaged endothelium and decreased inflammation.
Methods: Male Sprague Dawley rats were subject to bilateral IRI (40 min). At the time 
of reperfusion, ~2x106 human ASCs (hASCs; n=15) or vehicle (n=14) were injected into 
the suprarenal abdominal aorta. Recovery was evaluated via serum creatinine and capillary 
specific staining. Accumulation of immune cells in the kidney were evaluated using FACS.
Results: hASC-treated rats had a 90% survival by day 7, compared with 70% for 
vehicle. Serum creatinine showed a significant reduction in hASC-treated rats vs vehicle 
at 48 hrs, (35%; p=0.0008). By day seven, vehicle-treated rats showed a reduction in renal 
capillary density relative to sham (43%), which was significantly attenuated in hASC-treated 
rats (28%). Additionally, hASCs-treated rats exhibited a significant decrease in CD4+ 
(62%±16.8) and CD8+ (72%±3.5) T-cell infiltration (p<0.05). Further, IL-17 cytokine 
secreted by CD4+T cells was also reduced by ~40% in hASC-treated rats (185±66) as 
compared to vehicle (299±83.9). Conversely, the number of regulatory T cells was increased 
in hASC-treated rats compared with vehicle (35%; p<0.05).
Conclusions: These results suggest that ASCs may ameliorate injury, at least in part, 
by preserving capillary density, decreasing inflammation and restoring renal function.
Funding: NIDDK Support
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Studying the Effect of Induced Expandable Human Kidney Progenitor Cells 
on Renal Function Using Transcutaneous Assessment  Zeneida Herrera Perez,1 
Oren Pleniceanu,2 Dorit Omer,2 Benjamin Dekel,2 Norbert Gretz.1  1Medical 
Research Center, Medical Faculty Mannheim, Univ of Heidelberg, Mannheim, 
Germany; 2Sheba Center for Regenerative Medicine, Sheba Medical Center, 
Tel Aviv, Israel.
Background: The use of induced stem cells from adult tissues is a promising therapeutic 
approach for the treatment of kidney diseases. However, traditional techniques to monitor 
recovery from damage or a delay in chronic renal disease development after cell therapy are 
cumbersome and time-consuming, as well as inaccurate to detect early changes in function. 
A recent method allows the evaluation of renal function transcutaneously, using an optical 
device and the exogenous renal marker FITC-sinistrin, with no need for plasma or urine 
samples. For the first time, we have studied the effect of human adult kidney epithelial 
cells (hKEpCs) induced to stably overexpress the SIX2 or OSR1&SIX2 genes in a cisplatin 
(CP)-induced injury model using the transcutaneous assessment of renal function.
Methods: Three different animal groups were established: induced SIX2-hKEpCs, 
SIX2&OSR1&mCherry-hKEpCs and CP control group. On days 2 and 7 following a 
single dose of CP (7mg/kg b.w.), rats received intravenously either vehicle or 1x106 of the 
corresponding cell type. Kidney function was assessed over 14 days transcutaneously. In 
addition, urinary and plasma parameters, as well as histological changes were evaluated.
Results: Before cell treatment, all the groups experienced a comparable decrease in 
renal function with respect to baseline. Transcutaneous measurement showed that both cell 
types improve renal function compared to control group, with a substantial amelioration 
on day 7 after CP administration. The rise of creatinine and urea serum levels was also 
ameliorated in the cell treated groups and the histological analysis supported the beneficial 
of hKEpCs administration shown in renal function.
Conclusions: SIX2- and SIX2&OSR1mCherry-hKEpCs display therapeutic potential 
in CP-induced injury, preventing loss of kidney function and diminishing renal tissue 
damage. The transcutaneous assessment of renal function is a suitable method to detect 
changes due to disease progression or therapeutic interventions.
FR-PO236
Indole Analogs Have Novel Therapeutic Effects on Mitochondrial Diseases 
and Kidney Injury  Takehiro Suzuki,1 Tetsuro Matsuhashi,1 Akihiro Matsuo,1 
Yuki Oba,1 Koichi Kikuchi,1 Hisato Shima,1 Eikan Mishima,1 Yasutoshi 
Akiyama,1 Joseph V. Bonventre,2 Sadayoshi Ito,1 Takaaki Abe.1  1Tohoku Univ, 
Japan; 2Brigham and Women’s Hospital.
Background: Mitochondrial dysfunction causes various mitochondrial diseases and 
kidney injuries. Anti-oxidant quinones have been used clinically to prevent the disease 
progression but the effectiveness is yet to be established. We recently found that an 
indole-derivative increased ATP levels in Hep3B cells and analyzed 41 newly synthesized 
indole derivatives. Among those compounds, we focused on the most potent derivative 
#5(MA-5). The aim of this study was to clarify the effects of MA-5 in mitochondrial 
diseases and kidney injury.
Methods: Fibroblasts from patients with mitochondrial diseases (Leigh 
syndrome,MELAS,Leber disease,and Kearns-Sayersyndrome)were cultured in ROS 
generating condition with BSO(L-buthionine-(S,R)-sulfoximine)andcell viabilities, cellular 
ROS and glutathione levels were measured. The redox property of MA-5 was examined by 
cyclic voltammetry. The site of MA-5 distribution was visualized by fluorescence-labeled 
MA-5(MA-5 FL). MA-5 was administrated, at 50mg/kg body weight by gavage, to mice 
3 hr before they were exposed to kidney ischemia (26 min) reperfusion injury (IRI) or 
cisplatin (20 mg/kg body weight). Plasma creatinine (Cr), blood urea nitrogen (BUN) and 
renal pathology were assessed.
Results: MA-5 improved cell viabilities in a dose dependent manner in mitochondrial 
disease fibroblasts. MA-5 exhibited irreversible oxidation peaks by cyclic voltammetry, 
suggesting that MA-5 did not have antioxidant property like anti-oxidant quinones. MA-5 
did not affect the cellular ROS or GSH levels. MA-5 FL co-localized with the mitochondrial 
marker, mitotracker. In IRI, Cr at 48 hr after ischemia (0.88 + 0.38 mg/dl vs 1.60 + 0.66, 
control) and tubular cell injury were significantly reduced in MA-5-treated group. BUN 
(70.9 + 10.1 vs 101 + 13.0 mg/dl) and tubular injuries, at 96 hr after cisplatin injection, 
were significantly reduced in Indole #5 treated groups.
Conclusions: MA-5 exhibited therapeutic effects in fibroblasts from mitochondrial 
disease patients as well as renoprotective effects in both IRI and cisplatin nephrotoxicity.
FR-PO237
Mechanism of 5-Hydroxytryptamine 1F Receptor Stimulation of 
Mitochondrial Biogenesis in the Kidney  Whitney Sharee Gibbs, Craig 
Cano Beeson, Rick G. Schnellmann.  Dept of Drug Discovery and Biomedical 
Sciences, Medical Univ of South Carolina, Charleston, SC.
Background: Pharmacological induction of mitochondrial biogenesis (MB), the 
process of creating new mitochondria to replace damaged mitochondria, is a potential 
therapeutic target for AKI. Our laboratory has demonstrated that LY344864, a selective 
5-HT1F receptor agonist, promotes recovery from AKI as demonstrated by an increase in 
MB and decreased BUN and Kim-1 in a mouse model of ischemia/ reperfusion AKI. While 
the 5-HT1F receptor is a Gi- coupled GPCR, the mechanism of 5-HT1F receptor mediated 
MB is unknown.
Methods: Mitochondrial respiration was measured in renal proximal tubule cells 
(RPTC) using a Seahorse XF Extracellular Flux Analyzer. Signaling pathways were explored 
using pharmacological inhibitors and immunoblot analysis.
Results: LY344864 (10 nM) increased FCCP-uncoupled respiration in RPTC, a marker 
of MB. LY344864 induced FCCP-uncoupled respiration was attenuated by pretreatment with 
gallein, L-NAME, and ODQ, pharmacological inhibitors of Gβγ, nitric oxide synthase, and 
soluble guanylyl cyclase, respectively. LY344864 upregulated p-Akt and p-eNOS protein 
expression after 15 min and 1 hr exposures, respectively. Gallein blocked increases in both 
p-Akt and p-eNOS following LY366864 treatment. Following pretreatment with MK2206, 
an Akt inhibitor, the increase in p-eNOS protein expression was attenuated.
Conclusions: This study reports the novel finding that Gβγ heterodimer initiates MB 
and does so through a new pathway. Specifically, 5-HT1F stimulation of Gβγ activates Akt 
and eNOS, leading to the induction of MB. The identification of this pathway provides 
additional therapeutic targets for a drug intervention which could treat AKI.
Funding: NIDDK Support, Other NIH Support - NIGMS Support, Veterans 
Administration Support
FR-PO238
Formoterol Induces Renal Mitochondrial Biogenesis Through Gβγ-
Dependent Signaling  Robert Bruce Cameron, Craig Cano Beeson, Rick G. 
Schnellmann.  Drug Discovery and Biomedical Sciences, Medical Univ of South 
Carolina, Charleston, SC.
Background: Acute kidney injury (AKI) carries a high morbidity and mortality 
with no effective treatments beyond renal replacement therapy. AKI is characterized by 
mitochondrial dysfunction, particularly in the renal proximal tubule cells (RPTC). The 
induction of mitochondrial biogenesis (MB) is a therapeutic target for AKI. Our group has 
shown that formoterol, a β2 adrenoceptor agonist, can induce MB in vitro and in vivo, and 
stimulate recovery of mitochondrial and renal function following AKI in mice. However, 
the signaling events leading to formoterol-induced MB remain unknown.
Methods: RPTC were pretreated with DMSO, 100 nM gallein, 10 µM L-NAME, or 
100 nM MK2206 for 30 min and then treated with formoterol (30 nM). FCCP-uncoupled 
oxygen consumption rates (FCCP-OCR) were measured using the Seahorse XF-96 analyzer 
and protein phosphorylation was determined by immunoblot analysis.
Results: Formoterol increased Akt phosphorylation in RPTC at 30 min, and this increase 
was attenuated by the Gβγ inhibitor gallein. Gallein also attenuated formoterol-induced 
increases in FCCP-OCR, a biomarker of MB. Formoterol increased the phosphorylation of 
eNOS, a downstream target of Akt, at 1 hr, and pretreatment with the Akt inhibitor MK2206 
blocked Akt and eNOS phosphorylation. Additionally, treatment with the NOS-inhibitor 
L-NAME attenuated formoterol-induced increases in FCCP-OCR.
Conclusions: This study demonstrates that formoterol-induced MB occurs via b2-
adrenoceptor coupling to Gβγ. Gβγ leads to the activation of Akt and eNOS, promoting MB. 
Stimulation of these signaling pathways represents an attractive therapeutic target for AKI.
Funding: NIDDK Support, Other NIH Support - 5T32HL007260-38, 
5T32GM008716-14, Veterans Administration Support
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FR-PO239
Identification of Slow-Cycling Cells in the Kidney Using TetOP-H2B-GFP 
Mice  Shunsuke Takahashi, Akito Maeshima, Masao Nakasatomi, Hidekazu 
Ikeuchi, Toru Sakairi, Yoriaki Kaneko, Keiju Hiromura, Yoshihisa Nojima.  Dept 
of Medicine and Clinical Science, Gunma Univ Graduate School of Medicine, 
Maebashi, Gunma, Japan.
Background: Renal tubular epithelium can regenerate after a variety of insults. 
During tubular regeneration, survived tubular cells proliferate, migrate and differentiate 
into mature tubular epithelum. Using BrdU pulse/chase method, we previously reported 
that slow-cycling cells (label-retaining cells: LRCs) are present in renal tubules and act as 
the source of regenertaing cells after renal ischemia (JASN 14:3138-46. 2003). However, 
it is difficult to isolate and characterize LRCs in vitro, because there is no LRCs specific 
markers idenitified. In this study, we utilized the transgenic mice with doxycycline-inducible 
expression of an H2B-GFP fusion protein (TetOP-H2B-GFP mice), in which dividing cells 
can be labeled with GFP under doxycycline control.
Methods: TetOP-H2B-GFP mice were treated with doxycycline for the indicated 
periods (pulse). After several chase periods, kidneys were removed for analysis. Localization 
of GFP-positive cells was examined by immunostaining with several nephron markers and 
their cell number was quantitatively assessed.
Results: 1) After a pulse of doxycycline, GFP-positive cells were found in the kidney 
of TetOP-H2B-GFP mice. Most GFP-positive cells were AQP-1-positive tubular cells. 2) 
As pulse periods become longer, the number of GFP-positive tubular cells increased (pulse 
8h-0.5%, pulse 24h-10%, pulse 72h-18%, pulse 1 week-40%, pulse 3 weeks-50%). 3) After 
a short pulse (8h) of doxycycline with no chase, all GFP-positive cells were present as a 
single cell, but after 2 weeks or 4 weeks chase periods, GFP-positive cells were found in 
clusters of two cells or three cells. 4) In TetOP-H2B-GFP mice treated with a long pulse 
(3 week) of doxycycline, the number of GFP-positive cells decreased according to chase 
periods (Chase 0w-50%, Chase 4w-40%, Chase 8w-5%).
Conclusions: These data suggest that slow-cycling cells can be detected as GFP-
positive cells using TetOP-H2B-GFP mice under doxycycline control. This model will be 
applicable for selective isolation and in vitro characterization of slow-cycling tubular cells.
FR-PO240
Renal ERK1/2 Regulates PGC-1a and Mitochondrial Biogenic Homeostasis 
Physiologically and During Renal Injury  Justin B. Collier, Ryan Whitaker, 
Rick G. Schnellmann.  Drug Discovery and Biomedical Sciences, Medical Univ 
of South Carolina, Charleston, SC.
Background: Acute kidney injury (AKI) is defined as a sudden decline in kidney 
function and the outcomes of AKI have not changed in the past few decades. Previous 
studies demonstrated that persistent disruption of mitochondrial homeostasis (e.g. 
peroxisome proliferator-activated receptor gamma coactivator-1a (PGC-1a), a master 
regulator of mitochondrial biogenesis (MB)), is an important contributor to renal ischemia 
reperfusion (IR) injury and repair. While the MAPK extracellular-regulated kinases 1/2 
(ERK1/2) regulates numerous cell signaling pathways, the role of ERK1/2 activation in 
MB physiologically and as a consequence of renal IR injury remains limited.
Methods: Renal proximal tubule cells (RTPC) were treated with the specific MEK1/2 
inhibitor trametinib (10nM) for various time points. Control mice were treated with 
trametinib (1mg/kg). Trametinib was administered 1 hour before 18 min of bilateral IR. 
Signaling pathways were explored using qRT-PCR and immunoblot analysis.
Results: Trametinib blocked ERK1/2 phosphorylation in RPTC within 10 min that 
continued for 24 hr. Trametinib also inhibited ERK1/2 phosphorylation in vivo at 4 and 
24 hr. Trametinib increased PGC-1a mRNA at 1, 4, and 24 h in RPTC. The mRNA levels 
of PGC-1a target genes NDUFS1, NRF1, and TFAM increased at 1, 4, and/or 24 h after 
ERK1/2 inhibition in RPTC. Trametinib administered to control mice increased PGC-1a, 
NRF1, and TFAM mRNA at 4 h in the renal cortex and increased PGC-1a and TFAM 
protein. In the IR AKI model, pERK1/2 increased 4-fold at 1 and 3 h post IR. Increased 
pERK1/2 was linked to decreased mRNA levels of PGC-1a, NRF1, TFAM, and NDUFS1. 
Trametinib treatment attenuated suppression of mRNA PGC-1a and NRF1 at 3 h, increased 
TFAM protein 2.5-fold, and attenuated renal dysfunction as measured by BUN and KIM-1.
Conclusions: ERK1/2 downregulates renal mitochondrial homeostasis under 
physiological conditions and ERK1/2 inhibition during renal IR promotes recovery of 
PGC-1α and MB, and contributes to both mitochondrial and renal recovery. These results 
reveal a novel target for pharmacological intervention in AKI.
Funding: Other NIH Support - NIGMS, Veterans Administration Support
FR-PO241
The Guanylyl Cyclase Activator BAY 58-2667 Stimulates Mitochondrial 
Biogenesis and Promotes Recovery from Ischemia-Reperfusion Induced 
AKI  Ryan Whitaker, Rick G. Schnellmann.  Drug Discovery and Biomedical 
Sciences, Medical Univ of South Carolina, Charleston, SC.
Background: Mitochondrial dysfunction is an important pathophysiological 
component of acute kidney injury (AKI). As reduced mitochondrial function can impair 
energy-dependent renal repair processes following AKI, stimulation of mitochondrial 
biogenesis (MB), the generation of new, functional mitochondria, could promote renal 
recovery. We explored the efficacy of the guanylyl cyclase activator, BAY 58-2667, to 
induce MB and promote renal recovery following ischemia-reperfusion (I/R)-induced AKI.
Methods: Mitochondrial respiration was measured in primary renal proximal tubules 
cells (RPTC) using the Seahorse XF96 Extracellular Flux Analyzer. I/R injury was induced 
in male C57BL/6 mice aged 8-10 weeks by bilateral clamping of the renal pedicle for 19 
minutes. Mice received daily treatment with saline vehicle or BAY 58-2667 (0.1 mg/kg) 
beginning at 24 h after I/R.
Results: Treatment of RPTCs with BAY 58-2667 increased FCCP-uncoupled 
respiration, a marker of MB. BAY 58-2667 also increased mitochondrial gene and protein 
expression, and mtDNA content in the renal cortex of naïve mice. Beginning 24 h after 
I/R injury, daily treatment with BAY 58-2667 accelerated recovery of renal function 
evidenced by reduced BUN and renal expression of NGAL and Kim-1 at 6 d. Histological 
examination demonstrated reduced renal tubular necrosis in BAY 58-2667 treated mice at 
6 d. Furthermore, BAY 58-2667 decreased renal expression of the inflammatory cytokines 
TNF-α and IL-1β, and reduced oxidative DNA damage. These changes were associated 
with the recovery of renal MB signaling evidenced by increased mRNA expression of 
PGC-1α, NRF1, ND1, COX1 and ATPSβ, as well as mtDNA content and protein expression 
of PGC-1α and COX1. In addition, mitochondrial function was recovered as renal ATP 
returned to sham control levels. Finally, BAY 58-2667 blunted the progression of renal 
fibrosis evidenced by reduced COL1A2 and aSMA expression.
Conclusions: These data demonstrate that activation of guanylyl cyclase by BAY 
58-2667 promotes recovery from AKI by stimulation of MB, reduction of inflammatory 
and oxidative damage, and inhibition of renal fibrosis.
Funding: NIDDK Support
FR-PO242
Adult Human Renal Papilla CD133+ Cells Improve Erythropoietin 
Production, Show Long Term Engraftment and Repair Glycerol-Induced 
Kidney Injury in SCID Mice  Shikhar Aggarwal,1 Cristina Grange,2 Benedetta 
Bussolati.1  1Dept of Biotechnology and Health Sciences, Univ of Turin, Turin, 
Italy; 2Dept of Medical Sciences, Univ of Turin, Turin, Italy.
Background: Acute kidney injury (AKI) often involved deregulation of erythropoietin 
(EPO) production in the kidney. Novel treatment foresees introduction of cell therapies 
or strategies involving pharmacological modulations of intrinsic populations to produce 
EPO and repair of renal injury. CD133+ adult human renal cells have been identified by 
our group as a promising adult renal progenitor cell. Of note, papillary CD133+ cells show 
activation of hypoxia-inducible genes and are specifically involved in EPO production. 
However, their role in EPO production and fate to repair renal injury for long time has not 
yet been deconstructed in mice.
Methods: AKI is induced in immunodeficient mice using glycerol (8mg/gbw, i.m.) 
and adult human CD133+ papillary cells (0.5 million cells per mice) are injected (i.v.) 1 day 
after the injury. Mice are euthanized at different time intervals (day 15/day 30) and blood 
and other tissues (kidneys, lungs, liver) are collected for EPO, creatinine/urea, histological/
morphological analysis and molecular analysis (RNA, DNA and protein) respectively.
Results: Data showed that adult human CD133+ papillary cells improve EPO production 
(of both human and mice origin) in the injured mice and protect against AKI in mice at day 
15 and day 30 as compared to control group. The group of injured mice that received cells 
showed higher level of human and mice specific EPO, lower level of creatinine and urea 
in serum, lower level of kidney injury marker, KIM-1 and improved histology. CD133+ 
papillary cells also reduced development of fibrosis in the injured tissues during repair (as 
shown by lower expression of alpha-SMA, profibrotic gene TGF-β and trichromic stain). 
In addition, immunohistochemical and fluorescence studies show localization of CD133+ 
papillary cells within interstitium and tubules of the injured renal tissues.
Conclusions: Thus, our data supports that these CD133+ papillary cells may provide 
an important source of EPO stimulation in situ and repair.
Funding: Government Support - Non-U.S.
FR-PO243
Early Mesenchymal Stem Cell Administration Prevents Acute Kidney 
Injury Superimposed on Chronic Kidney Disease in Rats and High Risk 
Patients  Anna Gooch,1 Nicole Molin,1 Ping Zhang,1 Zhuma Hu,1 Christof 
Westenfelder.1,2  1Medicine, U of Utah and VAMC, Salt Lake City, UT; 
2Physiology, U of Utah, Salt Lake City, UT.
Background: We showed that ischemic-reperfusion injury (I/R) causes renal and 
urine levels of the chemokine SDF-1 (CXCL12) to rise significantly within ~ 2 hrs. This 
rise mediates the homing of infused, CXCR4 (SDF-1 receptor)-expressing Mesenchymal 
Stem Cells (MSCs) to the sites of injury, where they act renoprotectively. CKD is a 
major risk factor for AKI. We tested here whether MSC administration is effective both 
in preventing I/R AKI superimposed on CKD and in arresting the AKI-induced further 
deterioration of CKD.
Methods: Rats: Groups of 6 rats underwent 5/6th Nephrectomy. Once CKD was 
established (~8 weeks), I/R AKI of the kidney remnant was induced and rats were treated 
either with vehicle or 2x106 MSC/kg bw, i.a. SCr and urine SDF-1/creatinine levels were 
assessed at pre- and post-operatively. Patients: 12 subjects with established CKD and at 
high risk for cardiac surgery associated AKI were treated i.a. with 2x10e6 MSCs per kg 
bw immediately post on-pump CABG or valve surgery. SCr and urinary SDF-1/creatinine 
levels were determined pre- and post-op. RIFLE criteria defined post-op AKI. Study subject 
data were compared to well-matched historical controls.
Results: Rats: MSCs significantly hastened improvement in AKI vs. controls. Urine 
SDF-1 levels remained low by 24 hrs in MSC vs. vehicle treated animals. Patients: No 
study subject had AKI at discharge, but 2 met post-op AKI Risk criteria. Urinary SDF-1/Cr 
ratios were significantly elevated at 2 and 6 hrs in subjects who developed AKI Risk, but 
remained stable in those who did not. In contrast to historical controls, 6 months post-op, 
no treated subject’s CKD had worsened.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
412A
J Am Soc Nephrol 26: 2015 AKI: Basic Repair and Regeneration Poster/Friday
Conclusions: MSC administration offers renoprotection from AKI on CKD when given 
immediately post insult. Early, specific biomarker-guided diagnosis of AKI identifies the 
optimal time for MSC-based therapy. Another clinical trial in high-risk cardiac surgery 
patients showed that giving MSCs 24-48 hrs post insult, based on the late and non-specific 
rise in SCr, abolished their protective effects.
Funding: Veterans Administration Support
FR-PO244
Improved Survival of Graft Bone Marrow-Derived Mesenchymal Stem Cells 
in the Ischemia-Reperfusion-Induced Injured Kidney with Overexpression 
of Heme Oxygenase-1  Nanmei Liu.  Jimin Hospital of Shanghai.
Background: one marrow-derived mesenchymal stem cells (BMSCs) transplantation 
offers therapeutic potential for acute kidney injury (AKI), but with limited efficacy. This 
study investigated the effect of HO-1 overexpression on the donor BMSCs’ survival, and 
its impact on the repair of AKI was also observed.
Methods: Ischemia/reperfusion (I/R)-AKI kidney homogenate supernatant (KHS) was 
prepared. SD BMSCs, eGFP-BMSCs and HO-1-BMSCs were harvested and treated by 
the AKI-KHS. Cell viability, apoptosis and cell cycle were evaluated. Activities of oxidant 
stress-related enzymes, expression of p65 and the protein levels of Caspase-3 and Bcl-2 
in BMSCs were tested. Survivals of the implanting BMSCs in the AKI rat model as well 
as the renal function were also assayed.
Results: HO-1-BMSCs showed a high expression of HO-1 and AKI-KHS treatment 
further enhanced this level. This increased HO-1 expression promoted BMSCs survival 
under the AKI microenvironment with decreased apoptotic cells as well as less proportion 
of G0/G1 cells. AKI-KHS induced reduction of SOD activity and GSH-Px in BMSCs with 
increased MDA and XOD levels, however, HO-1 overexpression changed this phenomenon. 
Activation of NF-κB p65 was inhibited in HO-1-BMSCs. Western blot showed decreased 
Caspase-3 expression and increased Bcl-2 expression in HO-1-BMSCs. The in vivo study 
showed increased survival of HO-1-BMSCs in the AKI kidneys, which was associated 
with improved renal function.
Conclusions: HO-1 overexpression could enhance survival of BMSCs under the I/R-
AKI microenvironment both in vitro and in vivo as the result of ROS elimination. Activity of 
NF-κB p65 and Caspase-3/Bcl-2 signal transduction pathways were involved in this process.
Funding: Government Support - Non-U.S.
FR-PO245
Induced Pluripotent Stem Cell-Conditioned Medium Mitigates 
Renal Ischemia-Reperfusion Injury by Suppressing Oxidative Stress 
Wei-Cheng Tseng,1 Der-Cherng Tarng.2  1Div of Nephrology, Dept of Medicine, 
Taipei City Hospital Heping-Fuyou Branch, Taipei, Taiwan; 2Div of Nephrology, 
Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Ischemic acute kidney injury (AKI) carries high mortality and current 
treatment remains unsatisfying. Induced pluripotent stem cell (iPS) is a promising 
therapeutic option for AKI; nonetheless, teratoma formation addresses critical safety 
concerns for iPS cell tranplantation. iPS-derived conditioned medium (iPS-CM) is 
comparable with iPS cells on ameliorating acute lung injury but the benefiicial role of 
iPS-CM on AKI remains unclear.
Methods: Rat model of renal ischemia-reperfusion injury (IRI) and NRK52E cells 
subjected to hypoxia-reoyxgenation (H/R) were used to explore the role of iPS-CM on AKI. 
BUN, creatinine, tubular cell apoptosis, level of reactive oxygen species (ROS), expressions 
of proinflammatory cytokines and animal survival were investigated.
Results: Administration of iPS-CM intraperitoneally significantly improved renal 
function and decreased tubular cell apoptosis after renal IRI. Moreover, elevated ROS 
level in IRI-rat kidneys was markedly attenuated by iPS-CM. Co-culture of NRK52E cells 
with iPS-CM also significantly diminished H/R-induced apoptosis and ROS production. 
Furthermore, iPS-CM downregulated both H/R- and IRI-stimulated expressions of p38 
MAPK, TNF-α, NF-κB and caspase 3. Additionally, the IRI-related IL-6 and MCP-1 
expressions were also suppressed by iPS-CM. Finally, after being subjected to renal IRI, 
the rats treated with iPS-CM demonstrated better survival as compared those treated with 
phosphate-buffered saline or normal control medium.
Conclusions: iPS-CM decreases renal IRI-related lethality by suppressing ROS, 
inflammation, and tubular cell apoptosis. iPS-CM may be a potential therapeutic option 
for kidney repair in ischemic AKI.
FR-PO246
Vascular Adhesion Protein-1 (VAP-1) Inhibition Ameliorate Cisplatin 
Induced Acute Kidney Diseases and Disorders (AKD)  Daisuke Katagiri,1,2 
Yoshifumi Hamasaki,1 Kent Doi,1,3 Kousuke Negishi,1 Takeshi Sugaya,4 
Masaomi Nangaku,1,2 Eisei Noiri.1  1Nephrology and Endocrinology, The Univ 
of Tokyo, Tokyo, Japan; 2Apheresis and Dialysis, The Univ of Tokyo, Tokyo, 
Japan; 3Emergency and Critical Care Medicine, The Univ of Tokyo, Tokyo, 
Japan; 4CMIC Ltd, Tokyo, Japan.
Background: Cisplatin (CP) is a platinum compound that is used as an effective 
chemotherapeutic agent for many malignancies. Its nephrotoxicity is dose dependent, which 
often limits its administration. Research in the field of acute kidney diseases and disorders 
(AKD), including acute kidney injury (AKI), is important to prevent their progression to 
chronic kidney disease (CKD).
Methods: A new clinically relevant animal model using multiple low doses of CP was 
used to evaluate AKD. Human liver fatty acid-binding protein (L-FABP) transgenic (Tg) 
mice were administered 10 mg/kg of CP (three times, at 0, 1, 3 weeks) for four weeks. 
Vascular adhesion protein-1 (VAP-1) inhibitor that was recently reported to prevent fibrosis 
in organs was studied in this model. For treating group, mice received 2 mg/kg/day of 
PXS-4728A, a selective VAP-1 inhibitor, starting 3 weeks after the first CP administration.
Results: Moderate renal interstitial fibrosis occurred with multiple CP administration. 
Urinary L-FABP, one of the promising AKI biomarkers, increased about 10-fold one week 
after every CP injection. Although no further elevation of L-FABP was observed at 3W, 
following the omission of CP at 2W, L-FABP did not revert to baseline levels. Treatment 
of PXS-4728A for one week attenuated interstitial fibrosis in this model. VAP-1 inhibitor 
treatment remarkably reduced 4-HHE- and 8-OHdG-positive areas. The mRNA expressions 
of TGF-β, α-SMA, VEGF, and MCP-1 in the kidney were increased significantly by multiple 
CP treatments and attenuated by VAP-1 inhibitor treatment. Further, the inhibition of lipid 
accumulation in the S3 segments, together with L-FABP suppression was confirmed.
Conclusions: Multiple treatments with CP lead to moderate kidney dysfunction with 
increased biomarkers and renal fibrosis. As a standing point of onco-nephrology, VAP-1 
inhibitors are promising candidates for the prevention of CKD in patients using CP for 
the treatment of malignancy.
Funding: Government Support - Non-U.S.
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Pulsed Focused Ultrasound Improves Mesenchymal Stem Cell Therapy 
for Acute Kidney Injury by Upregulating Renal Interferon-Gamma to 
Stimulate Stem Cell Production of Interleukin-10  Scott R. Burks, Matthew 
Nagle, Michele Bresler, Saejeong Kim, Blerta Milo, Joseph A. Frank.  Frank 
Lab, NIH Clinical Center, Bethesda, MD.
Background: Pulsed focused ultrasound (pFUS) to kidneys enhances mesenchymal 
stem cell (MSC) homing to kidneys and improves outcomes when treating early or 
established acute kidney injury (AKI) compared to MSC infusions alone. However, 
mechanisms of improved combination therapy are unclear.
Methods: AKI was induced in C3H or interferon-γ (IFNγ)-deficient mice with cisplatin 
(15 mg/kg). pFUS (40W, 5%dc) was delivered to kidneys ~3hr before infusion of 106 
human MSC. MSCs were observed by immunostaining for human mitochondria. For some 
experiments, MSCs were treated in culture with recombinant INFγ or siRNA against IL-10. 
Cytokines were analyzed by mouse- and human-specific ELISAs. Serum creatinine and 
blood urea nitrogen values were measured spectraphotometrically.
Results: Proteomic profiling of AKI kidneys revealed that pFUS upregulated renal IFNγ 
and after MSC homed to pFUS-treated kidneys, they produced more human IL-10 compared 
to MSC in kidneys without pFUS. pFUS+MSC in IFNγ-ko mice led to greater MSC homing 
to pFUS-treated kidneys, but MSCs failed to produce greater IL-10 and pFUS+MSC yielded 
identical outcomes as MSC alone (ie, no improvement from pFUS+MSC). Supplementing 
MSC with IFNγ improved AKI outcomes in C3H mice in the absence of pFUS, while the 
improved outcomes seen pFUS+MSC were abrogated by knocking down IL10 in MSC.
Conclusions: pFUS pretreatment of kidneys during AKI alters the renal molecular 
environment to increase MSC homing to treated kidneys. However, improved disease 
outcomes from combination therapy are the result of pFUS upregulating IFNγ in the kidney 
so that MSCs homing to pFUS-treated kidneys are subsequently conditioned to produce 
more IL10, which has been shown to improve AKI.
Funding: Other NIH Support - NIH Intramural Research Program
FR-PO248
Stem Cells from Human Exfoliated Deciduous Teeth Ameliorate Acute 
Kidney Injury in Mice  Yuka Hattori,1 Hangsoo Kim,2 Naotake Tsuboi,2 Akihito 
Yamamoto,1 Seiichi Matsuo,2 Shoichi Maruyama.2  1Oral and Maxillofacial 
Surgery, Nagoya Univ Graduate School of Medicine, Japan; 2Nephrology, 
Nagoya Univ Graduate School of Medicine, Japan.
Background: Preclinical studies have indicated that administered mesenchymal 
stem cells (MSCs) ameliorated various types of renal injury and promoted the subsequent 
kidney repair. Recently, stem cells from human exfoliated deciduous teeth (SHED), which 
has been discarded as a medical waste, has received attention as a novel kind of MSCs. 
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The purpose of this study is to clarify the therapeutic effects of SHED on AKI induced 
by IRI.
Methods: Seven days after heminephrectomy, the renal artery and vein were clamped 
for 20 min to induce ischemia in male C57BL/6 mice. SHED or PBS as a control was 
administered into subrenal capsule right after the reperfusion. Blood, urine and tissue 
samples were collected. In order to confirm renoprotective potential of conditional media 
of SHED (SHED-CM) in vitro, H2O2 stimulation assay and scratch wound assay using 
mouse tubular epithelial cells (TECs) were also performed.
Results: Serum creatinine and BUN levels and urinary Kim-1 excretion were 
significantly decreased in SHED-treated group. Inflammatory cell infiltrations and 
inflammatory cytokine/chemokine concentrations of kidneys were significantly reduced 
in SHED-treated group. In in vitro assay, MCP-1secreted from TEC wasreduced andTEC 
proliferation and migration were significantly promoted by SHED-CM treatment.
Conclusions: In the present study, SHED administration successfully attenuated mouse 
IRI-induced AKI. Our results indicate that SHED exerted anti-inflammatory activity in 
early stage of inflammation and promote cell proliferation by paracrine effect, thereby 
renoprotective effect in a mouse model of ischemic kidney injury. These results suggest 
that SHED might offer novel stem cell resource, which can be applied for the treatment 
of ischemic kidney injury.
FR-PO249
Endothelial Autophagy and Endothelial-to-Mesenchymal Transition 
(EndoMT) in eEPC Treatment of Ischemic AKI  Daniel Patschan, Susann 
Patschan, Gerhard A. Mueller.  Clinic of Nephrology and Rheumatology, Dept 
of Internal Medicine, Göttingen, Nierdersachsen, Germany.
Background: Autophagy potentially prolongs the cellular lifespan. Early Endothelial 
Progenitor Cells (eEPCs) protect mice from ischemic AKI. The mid-term prognosis in AKI 
critically depends on vascular rarefication and interstitial fibrosis with the latter partly 
being induced by mesenchymal transdifferentiation of endothelial cells (EndoMT). Aim of 
the study was to determine the impact of eEPC preconditioning with different autophagy 
inducing agents (SAHA / Temsirolimus - Tems) in ischemic AKI.
Methods: Male C57/Bl6N mice were subjected to bilateral renal ischemia (40 
minutes). Animals were injected with either untreated of SAHA- or Temsirolimus-pretreated 
syngeneic murine eEPCs at the time of reperfusion. Mice were analyzed 48 hours and 4 
weeks later. In addition, cultured eEPCs were treated with TGF-β +/- SAHA, autophagy 
(perinuclear LC3-II) and Stress Induced Premature Senescence (SIPS - SA-b-Gal) were 
evaluated 96 hours later.
Results: Cultured eEPCs showed reduced perinuclear density of LC3-II+ vesicles 
and elevated levels of SA-b-Gal after treatment with TGF-β alone, indicating impaired 
autophagy and aggravated SIPS. These effects were completely abrogated by SAHA. 
Systemic administration of either SAHA or Tems pretreated eEPCs resulted in elevated 
intrarenal endothelial p62 at 48 h and 4 weeks. This effect was most pronounced after 
injection of SAHA treated eEPCs. At 4 weeks endothelial expression of mesenchymal 
aSMA was reduced in animals receiving untreated and SAHA pretreated cells. In addition, 
SAHA treated cells reduced fibrosis at week 4. Tems in contrast aggravated EndoMT. 
Postischemic renal function declined after renal ischemia and remained unaffected in all 
experimental cell treatment groups.
Conclusions: In ischemic AKI, intrarenal endothelial autophagy may be stabilized 
by systemic administration of pharmacologically preconditioned eEPCs. Early EPCs can 
reduce postischemic EndoMT and fibrosis in the mid-term. Autophagy induction in eEPCs 
my either increase or decrease the mesenchymal properties of intrarenal endothelial cells. 
Thus, endothelial autophagy induction in ischemic AKI is not a renoprotective event per se.
FR-PO250
Impact of Timing Administration of Mesenchymal Stromal Cells on Serum 
Creatinine following Renal Ischemia/Reperfusion in Rats  Pauline Erpicum,1,2 
Pascal Rowart,2 Laurence Poma,2 Jean-marie H. Krzesinski,1,2 Oliveir Detry,3 
Francois Jouret.1,2  1Nephrology, Univ of Liege Hospital (ULg CHU), Liege, 
Belgium; 2GIGA Cardiovascular Sciences, Univ of Liege, Liege, Belgium; 
3Abdominal Surgery and Transplantation, Univ of Liege Hospital (ULg CHU), 
Liege, Belgium.
Background: Experimental models of renal ischemia/reperfusion (I/R) have suggested 
protective effects of mesenchymal stromal cells (MSC) therapy. Still, parameters of 
MSC injection, including volume, route and timing of cell administration, remain largely 
debated. Particularly, MSC infusion in mouse has been shown to be beneficial “a priori” 
but deleterious “a posteriori” of renal I/R injury.
Methods: In order to further investigate the influence of the timing of MSC 
administration, we used 10-week-old Lewis rats categorized in 4 groups. Groups 1 (MSC 
D-7, n=10) and 2 (MSC D+1, n=7) received caudal i.v. injection of MSC (1,5x106 in 1 mL 
of saline) 7 days before or 1 day after renal I/R, respectively. Control groups 3 (saline D-7, 
n=6) and 4 (saline D+1, n=6) received equal volume of saline at similar time points. Left 
renal ischemia (by clamping of the renal pedicle) lasted 45 minutes. Right nephrectomy 
was simultaneously performed. Blood sample was collected from inferior vena cava at 48 
hours post reperfusion. MSC phenotype was confirmed by FACS analysis.
Results: In groups 1 and 3, serum creatinine (SCr) reached 1.4 ± 0,7 versus 2,4 ± 0,8 
mg/dL, respectively (p<0.05). In groups 2 and 4, SCr was 4,9 ± 0,7 versus 3,3 ± 0,9 mg/
dL, respectively (p<0.001). Furthermore, SCr levels were statistically worse when MSC 
were administered after renal I/R in comparison to a priori infusion (p<0.0001).
Conclusions: MSC administration 7 days prior to renal I/R may attenuate kidney injury 
in comparison to (i) saline infusion or (ii) MSC infusion 1 day after renal I/R. Conversely, on 
the basis of SCr levels, MSC therapy performed after renal I/R worsens kidney injury in rats.
Funding: Government Support - Non-U.S.
FR-PO251
Cytosolic Phospholipase A2 Regulates the G2 to M Transition by Modulating 
the Activity of Tumor Suppressor Sirtuin 2  Said Movahedi naini, Joseph V. 
Bonventre.  Brigham and Women Hospital, Renal Division, Boston, MA.
Background: SIRT2, a tumor suppressor gene, contributes to the control of the G2 to 
M transition checkpoint of the cell cycle under cellular stress. However, the mechanisms 
underlying both SIRT2 activation and the regulation of the G2 to M transition remain 
largely unknown. Here, we describe the regulatory function of cPLA2α on SIRT2 activity 
and the G2/M transition.
Methods: G2 to M transition in vitro was evaluated in LLC-PK1 cells overexpressing 
SIRT2 or cPLA2α and in mouse embryonic fibroblasts (MEFs) derived from cpla2α-/- mice. 
G2 to M transition in vivo was assessed in cpla2α-deficient mice during moderate IRI and 
under mitotic stress induced by colchicine. G2 and mitotic cells were identified by staining 
with pH3 and MPM-2 antibodies, respectively. Analysis of the phosphorylation state of 
SIRT2 was carried out in the presence or absence of cPLA2α in vitro by kinase assay and 
in vivo using a SIRT2 ser331 phosphospecific antibody.
Results: cPLA2α, SIRT2, and cyclin A-Cdk2 form a multiprotein complex at the 
G2/M transition in vivo and in vitro. cPLA2α acts as a bridge in this complex to promote 
binding of SIRT2 to cyclin A-Cdk2. Cyclin A-Cdk2 then phosphorylates SIRT2 at ser331. 
Phosphorylation of SIRT2 at ser331 diminishes its catalytic activity and reduces its binding 
affinity to centrosomes and mitotic spindles. This detachment of SIRT2 from mitotic spindles 
in the presence of cPLA2α promotes G2 to M transition. In cpla2α-/- MEFs and kidney 
tubular cells SIRT2 was hypophosphorylated at the G2/M transition. Lack of cPLA2α in 
these cells resulted in a reduction in the number of mitotic cells in response to mitotic stress.
Conclusions: cPLA2α isa regulator of the G2 to M transition in vitro and during 
ischemia/reperfusin injury in kidney epithelial cells. This function of cPLA2α may be further 
exploited to better understand the important link between cPLA2α and tumorigenesis and 
between inflammation and the age-related disorders such as Alzheimer’s disease, in which 
SIRT2 has been implicated.
Funding: NIDDK Support
FR-PO252
The Cytohesin Guanosine Exchange Factors Are Required to Promote 
HGF-Mediated Renal Recovery After Acute Kidney Injury in Mice 
Lorraine C. Santy, Marta Reviriego-Mendoza.  Dept of Biochemistry and 
Molecular Biology, Pennsylvania State Univ, Univ Park, PA.
Background: The lack of current treatment and preventable measures for acute 
kidney injury (AKI) in hospitalized patients results in an increased mortality rate of up to 
80% and elevated health costs. The molecular aspects of kidney injury and repair are still 
uncertain. Hepatocyte growth factor (HGF) promotes recovery of the injured kidney by 
inducing survival and migration of tubular epithelial cells to repopulate bare tubule areas. 
HGF-stimulated kidney epithelial cell migration requires the activation of ADP-ribosylation 
factor 6 (Arf6) and Rac1 via the cytohesin family of Arf-guanine-nucleotide-exchange-
factors (GEFs), in vitro.
Methods: We used an ischemia and reperfusion injury (IRI) mouse model to analyze 
the effects of modulating this signaling pathway on kidney recovery. We treated IRI mice 
with either HGF, the cytohesin inhibitor SecinH3, or a combination of both. Kidney 
function was assessed by measuring creatinine (Cre) and blood urea nitrogen (BUN) levels. 
Standard H&E staining was used to assess kidney structures and immunohistochemistry 
was performed to detect active-Rac1 and active-Arf6.
Results: Simultaneous treatment with SecinH3 and HGF blocks the ability of HGF 
to promote kidney recovery as evidenced by Cre and Bun levels. Immunohistochemistry 
showed that HGF treatment promoted recovery of tubule structure, and had enhanced levels 
of active, GTP-bound Arf6 and GTP-Rac1. SecinH3 treatment, however, caused a dramatic 
decrease in GTP-Arf6 and GTP-Rac1 levels when compared to kidney sections from HGF 
treated IRI mice. Additionally, SecinH3 counteracted the renal reparative effects of HGF.
Conclusions: We show that HGF-dependent damaged kidney recovery requires 
the function of a cytohesin-dependent signaling module, and that inhibiting cytohesins 
counteracts HGF-stimulated recovery. In addition, we demonstrate that HGF treatment 
of ischemic mice promotes the activation of Arf6 and Rac1 in the recovering kidneys in a 
cytohesin-dependent manner, and that cytohesin activity is required to promote epithelial 
repopulation of kidney tubules and thus kidney recovery.
Funding: NIDDK Support
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Regulation of Kidney Injury Molecule-1-Mediated Efferocytosis by Rho 
GTPases  Ola Ismail,1 Xizhong Zhang,2 Lakshman Gunaratnam.1,2  1Dept of 
Medicine, Western Univ, London, ON, Canada; 2Matthew Mailing Centre and 
Lawson Research Inst, London Health Sciences Centre, London, ON, Canada.
Background: Kidney injury molecule 1 (KIM-1) is a phagocytic receptor for 
apoptotic cells that is specifically upregulated on the apical membrane of proximal tubule 
cells (PTECs) after acute kidney injury. KIM-1-mediated clearance of apoptotic cells 
(efferocytosis) has been shown to protect from tissue damage during acute kidney injury 
by down-regulating innate immunity and inflammation. As cytoskeletal remodeling is 
essential for phagocytosis, we examined the relative importance of Rac1 and RhoA, two 
key Rho GTPases that mediate actin remodeling, in KIM-1-dependent efferocytosis. We 
also investigated a possible link between Ga12, which we previously identified as a KIM-
1-interacting protein, and these Rho GTPases.
Methods: To study the role of Rac1 and RhoA in KIM-1-mediated uptake of apoptotic 
cells, we utilized chemical inhibitors or plasmids encoding dominant negative forms of 
Rac1 and RhoA proteins, and measured the uptake of apoptotic cells by flow cytometery. 
Using commercially available GTPase pull-down assays, we measured the endogenous Rac1 
and RhoA activity in KIM-1-expressing cells after apoptotic cell-stimulation. To decipher 
whether these Rho GTPases are down-stream mediators of Ga12-KIM-1 signaling, we 
silenced Ga12 using siRNA and measured Rac1 and Rho GTPase activity.
Results: Inhibition of Rac1 resulted in a significant decrease in KIM-1-mediated 
phagocytosis, whereas inhibition of and RhoA increased it. RhoA activity gradually 
increased during phagocytosis and peaked during the later stages of phagocytosis, whereas 
Rac1 activity remained constant over the entire course of phagocytosis. Furthermore, 
silencing a key KIM-1-interacting protein, Ga12, caused a significant decrease in RhoA 
activity.
Conclusions: We conclude that Rac1 and RhoA play opposing roles during KIM-
1-mediated efferocytosis, where RhoA serves to mediate signaling by KIM-1 and its 
interacting partner, Ga12.
Funding: Government Support - Non-U.S.
FR-PO254
Periostin Induces Kidney Fibrosis After Ischemia-Reperfusion Injury via 
p38 MAPK Pathway  Jung Nam An,1,2 Seung Hee Yang,3 Jin Ho Hwang,4 Chun 
Soo Lim,1,2 Yun Kyu Oh,1,2 Yon Su Kim,2 Jung Pyo Lee.1,2  1Seoul National Univ 
Boramae Medical Center; 2Seoul National Univ Hospital; 3Seoul National Univ 
Kidney Research Inst; 4Chung-Ang Univ Hospital, Republic of Korea.
Background: Periostin, a matricellular protein, has been reported to play a crucial 
role in inflammatory and fibrotic mechanism. We hypothesized that periostin involves in 
the progression of acute kidney injury to kidney fibrosis.
Methods: To establish a kidney progression model, we induced unilateral ischemia-
reperfusion injury of left kidney pedicle for 30minutes in wild type (WT) C57BL/6 mice 
and Postn nullmice (Postn-/-), and observed during 4 to 6 weeks. In addition, inner medulla 
collecting duct cell line was subjected to put in the hypoxic incubator (1% O2, 5% CO2, 
and 94% N2) for 24 and 72 hours.
Results: After 4 to 6 weeks, the left kidneys in Postn null mice were significantly less 
atrophied and less small in weight compared to those of WT mice. Apparent tubular atrophic 
changes and collagen fiber deposition, and expressions of collagen I, S100A4, and periostin 
were also remarkably alleviated in Postn null mice compared within WT mice. Furthermore, 
the expressions of phosphorylated p38 mitogen-activated protein kinase (p-p38 MAPK) and 
cleaved caspase-3 were significantly decreased in Postn null mice compared to in WT mice. 
Postn null mice also attenuated intra-kidney mRNA expression of fibrosis markers, p53, 
caspase 9, and p-p38 MAPK. In vitro, hypoxic injury during 72 hours resulted in cellular 
morphologic changes and increased the expressions of several fibrosis markers, periostin, 
and p-p38 MAPK. Treatment of recombinant periostin in hypoxic condition magnified the 
cellular changes and the expression of p-p38 MAPK, which were comparable to treatment 
with transforming growth factor-β1. In contrast, inhibition of p38 MAPK attenuated the 
periostin induced inflammation and fibrosis.
Conclusions: In conclusion, periostin is related to the progression via p38 MAPK 
pathway to kidney fibrosis following acute kidney injury triggered by hypoxic or ischemic 
insult. Periostin ablation could have protective effects in kidney progression.
FR-PO255
Tim-3/Gal-9 Pathway Activation Ameliorates Renal Ischemia Reperfusion 
Injury by Shifting the Balance of Activated CD4+ T Cell Immune Response 
in Mice  Yamei Wang, Yuhong Tao.  Dept of Pediatrics, West China Second 
Univ Hospital, Sichuan Univ, Chengdu, Sichuan, China.
Background: Renal ischemia reperfusion injury (IRI) is characterized by kidney 
inflammation. Galectin-9 (Gal-9) is identified as a T-cell immunoglobulin domain and 
T mucin domain protein-3 (Tim-3) ligand, and Tim-3/Gal-9 interaction acts as a specific 
inhibitor of immune response. The purpose of this study was to study whether activation of 
Tim-3/Gal-9 pathway can ameliorate renal IRI by shifting the balance of activated activated 
CD4+T cell immune response in mice.
Methods: Expression of renal Gal-9 and Tim-3 were detected in mice with left renal 
IRI at baseline, day 3,10. The percentage of Th1, Th17 and Foxp3+Tregs and their mRNA 
expression in kidney were measured.rAAV9 carryingGal-9 was injected to mice two weeks 
before kidney IRI to overexpress Gal-9 and activate Tim-3/Gal-9 pathway. Then, CD4+T 
cell subsets and cytokines in kidney were evaluated at day 3 and 10.
Results: The expression of Gal-9 and Tim-3 in IR kidney at day3 and 10 increased 
(P<0.05). The percentage of Foxp3+ Treg in CD4+T cells and Foxp3 mRNA was up-regulated 
with time. Compared with normal control kidney, the mRNA levels of Foxp3, Gal-9 and 
Tim-3 of kidney at day 3, 10 after renal IRI were increased in IRI kidney. Compared with 
empty virus group at 3 days and 10 days after IRI, over-expression of Gal-9 can reduce 
tubular damage in the healing phase of renal IRI. Protein plex results showed that the 
expression levels of inflammatory cytokines including TNF-α, IFN-γ, IL-17 and IL-6 was 
decreased, while the expression level of IL-10 was increased. The mRNA level of Foxp3 
in kidney, the percentage of Foxp3+Treg cells in IRI kidneys was increased. However, the 
proportions of Thl, Thl7 cells and the gene levels of T-bet and RORyt were decreased. In the 
bilateral renal IRI model, the mice mortality was decreased after rAAV-Gal-9 intervention.
Conclusions: Tim-3/Gal-9 pathway activation can ameliorate kidney damage and 
increase survival rate of mice after renal IRI, inhibit Th1 and Th17 cell-mediated immune 
responses, and promote the proliferation of Foxp3+Treg after renal IRI, which may be an 
important mechanism for renal protection of Gal-9 /Tim-3 pathway.
Funding: Government Support - Non-U.S.
FR-PO256
Administration of an Inhibitor of IκB Kinase Inhibitor at 24 Hours After 
Acute Kidney Injury Improves Functional Recovery and Prevents Renal 
Fibrosis  Florence Lilian Johnson,1 Nimesh Patel,1 Massimo Collino,2 Christoph 
Thiemermann.1  1Translational Medicine and Therapeutics, The William Harvey 
Research Inst, Queen Mary Univ of London, London, United Kingdom; 2Dept 
of Drug Science and Technology, Univ of Turin, Turin, Italy.
Background: Acute kidney injury (AKI) is a major risk factor for the development 
of chronic kidney disease (CKD). Renal ischemia may cause post-inflammatory scarring 
leading to the loss of nephrons and the development of fibrosis. Nuclear factor kappa-B 
(NF-κB) is a family of transcription factors activated post-ischemia, but its role in the 
progression of AKI to CKD is unknown.
Methods: Male Wistar rats were subject to a RH nephrectomy and LH unilateral renal 
ischemia for 30 min, or nephrectomy only (sham) (n=8). Animals subject to ischemia 
(control animals) were allowed to recover and culled at 1 (n=4), 2 (n=4), 7 (n=4), 14 (n=4) 
or 28 (n=7) days (d) post reperfusion. A separate group of animals subjected to ischemia 
were administered IKK16, an inhibitor of IκB kinase (IKK), at 24h post AKI (1mg/kg i.v 
in 10% DMSO), and culled at 2 (n=4), 7 (n=8) or 28d (n=7).
Results: Compared to sham-operated rats, rats subjected to unilateral renal ischemia 
developed AKI (increases in serum creatinine and decreases in the estimated creatinine 
clearance). The delayed administration of IKK16 at 24h post AKI (at peak creatinine 
values) significantly improved renal functional recovery and structural injury at 48h post 
AKI. Compared to sham-operated rats, rats culled at 7d post AKI demonstrated significant 
increases in α smooth muscle actin (α-SMA) and CD68+ staining for myofibroblasts and 
macrophages, respectively. IKK16 administration significantly decreased α-SMA and 
CD68+ staining at 7d post AKI. Rats culled at 28d post AKI demonstrated a significant 
increase in Sirius red staining compared to sham rats, indicating the development of fibrosis. 
Administration of IKK16 at 24h significantly attenuated Sirius red staining, and therefore 
the level of fibrosis at 28d.
Conclusions: Inhibition of IKK at 24h post AKI (at peak creatinine values) improves 
renal functional recovery at 48h post AKI, and reduces the degree of fibrosis observed at 28d.
FR-PO257
The Peroxisome Proliferator-Activated Receptor γ (PPAR-γ) Agonist 
Pioglitazone Prevents NF-κB Activation in Cisplatin Nephrotoxicity by 
Reducing p65 Acetylation Through AMPK-SIRT1/p300 Pathway  Junhua Li, 
Ying Zhang, Jiong Zhang, Ying Yao, Gang Xu.  Dept of Nephrology, Tongji 
Hospital, Huazhong Univ of Science and Technology, Wuhan, China.
Background: NF-κB is a ubiquitously expressed transcription factor controlling the 
expression of numerous genes involved in inflammation. The aim of this study was to 
evaluate whether the activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) 
could attenuate cisplatin-induced NF-κB activation in cisplatin nephrotoxicity.
Methods: Acute kidney injury model was established of by intraperitoneal injection of 
cisplatin. C57BL/6 mice were divided into three groups: normal group; model group; and 
treatment group, with pioglitazone gavage of three days. Respectively after injection in 24, 
48 and 72 hours, the mice serum were collected for renal function and kidney specimen for 
pathological, Western blot, immunohistochemistry and real time PCR detection.
Results: Our results showed PPAR-γ agonist Pioglitazone could decrease the 
expression of NF-κB p65 transcription target genes such as pro-inflammation cytokines 
interleukin 6 (IL-6), interleukin-1 b(IL-1b), and tumor necrosis factor-a(TNF-α) and 
inhibit cell apoptosis and MPO infiltration in cisplatin nephrotoxicity. Suppressing NF-κB 
activity following Pioglitazone treatment was involved in inhibiting IκB-α degradation, 
phosphorylation modification and NF-κB p65 subunit translocation induced by cisplatin 
injection. The NF-κB p65 subunit translocation is dependent on p65 acetylation, which 
is mainly regulated by SIRT1 or p300. Of note, The subsequent AMP kinase (AMPK) 
activation not only decreases the p300 phosphorylation, activation and its interaction with 
p65, but also increases the SIRT1 expression, activation and binding to p65, leading to a 
significant reduction p65 acetylation. Interestingly, the reduction in expressions of IL-6, 
TNF-α and IL-1β, inhibition of cell apoptosis and MPO infiltration following Pioglitazone 
treatment in cisplatin nephrotoxicity were attenuated by the PPAR-gantagonist GW9662.
Conclusions: Our results suggest that PPAR-γ agonist Pioglitazone prevents NF-κB 
activation in cisplatin nephrotoxicity by reducing p65 acetylation through AMPK-SIRT1/
p300 pathway.
Funding: Government Support - Non-U.S.
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Competitive Inhibition of CD95L Reduces Inflammation, but Only Modestly 
Improves Outcomes in Experimental Isquemia-Reperfusion Injury 
Luis Eduardo Becker, Clara Daschner, Martin G. Zeier, Christian Morath. 
Nephrology, Univ of Heidelberg, Heidelberg, Germany.
Background: After previous encouraging results in CD95L (FasL) mutant mice 
in ischemia-reperfusion injury (I/R) models, we sought to investigate the effect of the 
competitive pharmacologic inhibition of CD95 (FAS) in kidney I/R using APG101, an 
orphan drug developed for the treatment of recurrent glioma, which has shown a good 
patient tolerability in phase I and II clinical studies.
Methods: C57BL/6 mice treated with different dosages of APG 101 (10, 30 or 100 
µg/kg-body weight, single-dose, 12h before I/R) or vehicle (PBS) alone were submitted 
to a 30min bilateral renal I/R. Sham-op animals were either treated with the highest 
APG101 dose or PBS. The experiment was further divided into two observation periods: 
day 2 (injury phase) and day 7 (recovery phase). Serum and kidney tissue analysis were 
performed focusing on function recovery, cell proliferation, macrophage infiltration and 
relevant markers of the target pathway. Results are given as mean±SD.
Results: Optimal serum CD95L saturation was only achieved in the APG 100µg/kg 
group (98.4±0.35% and 96.9±1.3% at day 2 and 7, respectively), so that experiments were 
further conducted with this dosage. At day 2, serum creatinine was significantly higher 
in the I/R PBS group, but not in the I/R APG group compared to sham-op (0.26±0.12 
and 0.20±0.07 vs. 0.09±0.03 mg/dl P<0.05), a similar pattern was seen in macrophage 
infiltration and MCL-1 mRNA expression in the kidney, both persisting until day 7. 
Apoptosis, however, was similar between the I/R groups in both observation periods. APG 
treatment markedly reduced cell proliferation in both sham and I/R animals compared to 
PBS (0.5±0.9 vs. 8.4±5.7 Ki67 positive cells/hpf, p=0.0004), which was observed at day 
2, but didn’t persist until day 7.
Conclusions: Despite an anti-inflammatory effect, the APG101-induced impairment 
of the tubular cell proliferation may have hampered the early recovery phase after I/R 
leading to the modest results.
FR-PO259
Oral Treatment with PBI-4050 Reduces Ischemia-Reperfusion-Induced 
Fibrosis  Jean-François Thibodeau, Mikaël Tremblay, Brigitte Grouix, Lilianne 
Geerts, Alexandra Felton, François Sarra-Bournet, Pierre Laurin, Lyne Gagnon. 
ProMetic BioSciences Inc., Laval, QC, Canada.
Background: PBI-4050, a novel first-in-class orally active compound which is 
currently in clinical phase Ib/II in CKD patients, displays antifibrotic activities via a novel 
mechanism of action. In a double-blind ascending dose (400 to 2400 mg) clinical phase I 
trial, PBI-4050 was found to be safe and well tolerated up to 2400 mg without any significant 
side effects. Clinically, ischemia is a leading cause of acute kidney injury (AKI), which 
may result from a variety of conditions, such as decreased cardiac output, renal vascular 
occlusion or obstruction, and kidney transplantation. The aim of this study was to investigate 
the anti-fibrotic activity of PBI-4050 in a mouse model of acute ischemic kidney injury.
Methods: Renal ischemia-reperfusion (IR) injury was induced by the clamping of 
the left renal pedicle for 60 minutes in C57BL/6 mice (6-8 week old). Mice were treated 
with oral administration of vehicle or PBI-4050 (200 mg/kg) from day -3 to day 13 and 
sacrificed at day 14.
Results: Renal IR-injury induced a rise in serum creatinine at day 2 that was prevented 
by oral treatment with PBI-4050. At day 14, mice suffering from renal IR demonstrated 
a loss in hematocrit which was also prevented by PBI-4050 treatment. Furthermore, 
histomorphometric analysis demonstrated a significant increase in renal fibrosis, determined 
by medullary collagen accumulation in mice with IR-injury, which was significantly 
reduced by PBI-4050 treatment. In addition, PBI-4050-treatment reduced kidney type-III 
collagen mRNA expression.
Conclusions: Taken together, these pre-clinical results suggest that PBI-4050 offers 
the potential as a novel therapy for the treatment of AKI and may delay or prevent the onset 
of fibrosis in renal transplant recipients.
FR-PO260
Cisplatin Acute Kidney Injury and Conversion to Chronic Kidney Disease 
Robert L. Safirstein,1,2 Heino Velazquez,1,2 Richard Torres,2 Gilbert W. Moeckel,2 
Gary V. Desir.1,2  1Nephrology, VACT HealthCare System, West Haven, CT; 
2Nephrology, Yale Univ, New Haven, CT.
Background: Chronic Kidney Disease (CKD) develops in humans after repeated 
doses of cisplatin (CP). We report on a new model to investigate the mechanism of this 
form of CKD.
Methods: 8-week old C57Bl6 mice were given either a single or double dose (2 
weeks apart) of CP (15 mg/kg) and studied 2,4,6,9 and 16-25 weeks after the first dose. 
GFR was measured by inulin clearance followed by intravascular perfusion-fixation. 
Immunohistochemistry and Multiphoton Microscopy (MPM) were applied to the fixed 
tissue.
Results: GFR fell precipitously to below 50% of controls 2 weeks after the second dose 
and progressed without hypertension, loss of glomerular number, or glomerulosclerosis. 
Kidney weight fell as a result of loss of cortical tissue. Collagen deposition increased but 
was mainly restricted to peritubular locations along the cortico-medullary region. Influx of 
macrophages, increased cell cycle activity (Ki67) and apoptosis (TUNEL) were followed 
by vascular rarefaction. Ki67 failed to increase after the second dose as it did after a single 
dose. The cyclin-dependent kinase inhibitor protein p21 increased and paralleled the lack 
of cell cycle activity. Abnormal glomerulotubular junctions (GTJ) developed only after 
the second dose, which included loss of megalin positive parietal epithelial cells and the 
formation of atubular glomeruli. These changes correlated well with the development of 
progressive renal insufficiency.
Conclusions: MPM uncovered abnormalities of the GTJ that marked the transition 
from AKI to CKD in CP-induced CKD. Coupled with the failure of the proximal tubule 
(PT) to re-enter the cell cycle suggests a causal relationship between failed repair of this 
segment and the conversion of AKI to CKD. The increased expression of the p21 gene 
seen here and its demonstrated role in progression in the renal ablation model of CKD 
suggests its sustained activation may cause the conversion of AKI to CKD. Understanding 
why injured PT cells fail to re-enter the cell cycle following the second dose of CP is likely 
to yield new means to prevent CP-induced CKD, which may be applicable to other forms 
of AKI to CKD conversion.
Funding: NIDDK Support, Veterans Administration Support
FR-PO261
The MEK1/2 Inhibitor, U0126, Decreases Cisplatin-Induced AKI and Slows 
Cancer Growth in Mice  Kameswaran Ravichandran, Abdullah Ozkok, Qian 
Wang, Alkesh Jani, Charles L. Edelstein.  Univ of Colorado Denver.
Background: Nephrotoxicity is cisplatin’s major dose-limiting side effect as a 
chemotherapeutic agent. We have developed a model of 4 week, low dose cisplatin (Cis)-
induced AKI in mice with cancer. In the 4 week model of AKI, there is an increased ERK 
expression in kidneys.
Methods: Wild type C57BL/6 mice were injected subcutaneously with murine lung 
cancer cells derived from C57BL/6 mice. Ten days later, Cis (10 mg/kg/week) was given 
for 4 weeks. Mice were treated with the ERK inhibitor U0126 (5 mg/kg 2 times a week 
for 4 weeks).
Results: There was a significant decrease in BUN, SCr and serum NGAL in mice treated 
with Cis+U0126 vs. Cis only. Tumor weight and volume was decreased in mice treated 
with vehicle+U0126 vs vehicle alone demonstrating that U0126 decreases tumor growth. 
Tumor weight and volume was decreased in mice treated with Cisplatin+U0126 vs. Cisplatin 
alone demonstrating that U0126 significantly increased the therapeutic effect of cisplatin.
Vehicle Vehicle+ U0126 Cis Cis+ U0126
BUN (mg/dL) 26.7 27.1 58.9* 40.1**
Scr (mg/dL) 0.1 0.1 0.3* 0.18***
sNGAL (ng/mL) 90 ± 13 185±34 569* 313**
Tumor weight (g) 1.8 1+ 0.9+ 0.5**
Tumor volume week 1 (mm3) 19 1 8 1.8
Tumor volume week 4 (mm3) 789 235+ 341+ 70++
N=11-15 per group. *P<0.01 vs. Vehicle. ** P<0.05 vs. Cis. *** P<0.05 vs. Cis, NS vs. vehicle. 
+P<0.01 vs Vehicle. ++P<0.01 vs. Vehicle and Cis
Conclusions: U0126 decreased cisplatin-induced AKI. In addition, U0126 decreased 
tumor growth and improved the therapeutic effect of cisplatin. Discovery of a drug that 
decreases cisplatin-induced AKI and improves the therapeutic effect of cisplatin would be 
a significant finding for patients with cancer.
Funding: Veterans Administration Support
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Glycogen Synthase Kinase-3 Regulates Fibroblast Activation and 
Development of Fibrosis following Renal Ischemia/Reperfusion in Mice 
Shailendra Pratap Singh,1 Shixin Tao,1 Timothy A. Fields,1 Raymond C. Harris,2 
Reena Rao.1  1The Kidney Inst, Dept of Medicine, Univ of Kansas Medical 
Center, Kansas City, KS; 2Dept of Medicine, Vanderbilt Univ Medical Center, 
Nashville, TN.
Background: Glycogen synthase kinase-3β (GSK3β) is a serine /threonine protein 
kinase that plays an important role in renal tubular injury and regeneration in acute 
kidney injury. However its role in the development of renal fibrosis, often a long-term 
consequence of acute kidney injury is unknown. Using a mouse model of renal fibrosis 
induced by ischemia/reperfusion (I/R) injury, we demonstrate increased GSK3β expression 
and activity in fibrotic kidneys.
Methods: Bilateral I/R was carried out on male C57/BL6J mice; both renal pedicles 
were exposed by flank incision and clamped for 30 minutes at 370C. GSK3inhibitor 
(TDZD-8) was administered by daily IP injection at 1mg/Kg BWt. dose starting 1h before 
(TDZD-pre) or 48h after I/R (TDZD-post). Studies were also carried out in rat fibroblast 
NRK-49F cells.
Results: GSK3β expression and activity increased significantly starting 48h after 
I/R and remained high in the fibrotic kidneys 12 days after I/R. GSK3β was detected in 
renal myofibroblasts and tubules. GSK3 inhibition suppressed fibrosis, with significantly 
reduced myofibroblast population, extracellular matrix deposition, inflammatory mediators 
and TGF-β signaling in TDZD-pre and TDZD-post treatment groups compared to vehicle 
treated group. In vitro, TGF-β1 treatment increased GSK3β expression in NRK-49F cells 
and GSK3 inhibition abolished TGF-β1 induced SMAD-3 activation and α-SMA expression. 
Importantly, overexpression of constitutively active GSK3β stimulated α-SMA expression 
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even in the absence of TGF-β1 treatment. These results suggest that TGF-β regulates GSK3β 
expression, which in turn is important for TGF-β/ SMAD-3 signaling and fibroblast-to-
myofibroblast differentiation.
Conclusions: The study thus demonstrates that GSK3 could promote renal fibrosis 
by activation of TGF-β signaling and the use of GSK3 inhibitors might represent a novel 
therapeutic approach for progressive renal fibrosis that develops as a consequence of AKI.
Funding: Other NIH Support - RO1 DK-083525
FR-PO263
Regulating Cx43 and TRPC6 Expression Protects Renal Epithelial Damage 
in a Rat AKI Model  Zilong Li, Wei Wang, Juan Wang, Lining Wang.  Dept 
of Nephrology, First Affiliated Hospital of China Medical Univ, Shenyang, 
Liaoning, China.
Background: Intracellular Ca2+ homeostasis plays an essential role in maintaining 
normal cell function. Connexin43 (Cx43) and transient receptor potential channel (TRPC6) 
has been reported to regulate Ca2+ entry in some pathologic conditions. The aim of this 
study was to elucidate whether the modifier protein of glyceraldehyde-3-phosphate 
dehydrogenase (MP) and ATP-MgCl2 could regulate Cx43 and TRPC6 in a rat model of 
acute kidney injury (AKI).
Methods: Male Sprague-Dawley rats were divided into the following groups: normal 
control, gentamicin-treated, MP plus gentamicin-treated, ATP-MgCl2 plus gentamicin-
treated (n=15 for each), as well as control group for MP and ATP-MgCl2 alone (n=5 for 
each). Levels of serum creatine (sCr) for each group were measured on the 14th days of 
treatment. The “in vivo cryotechnique” was used for preparing kidney specimen as before. 
Immunohistochemistry staining for Cx43 and TRPC6 was performed.
Results: The gentamicin-treated group showed a significant increase in sCr compared to 
the normal control group. Co-treatment of gentamicin with MP and/or ATP-MgCl2 produced 
marked decreases preventing the increase of sCr. Under light microscope, the gentamicin-
treated group showed tubular epithelium damage indicating AKI. This was attenuated by 
MP and/or ATP-MgCl2 co-treatment. Immunohistochemistry staining indicated that MP 
and/or ATP-MgCl2 co-treatment prevented gentamicin-induced down-regulation of Cx43 
and TRPC6 in renal epithelium cells using the “in vivo cryotechnique”. Furthermore, the 
expressions of Cx43 and TRPC6 in gentamicin-treated group showed much weaker intensity 
using conditional fixation method compared to that using “in vivo cryotechnique” suggesting 
there might be artificial damage during the conditional fixation procedure.
Conclusions: Using a rat model of AKI, MP and ATP-MgCl2 were able to prevent the 
down-regulation of Cx43 and TRPC6, which might reduce Ca2+ entry and its downstream 
signaling, thus minimizing the damage in the renal epithelium cells.
FR-PO264
S-Glutathionylation of TAZ Might Contribute to Acute Kidney Injury 
and Repair  Rajesh kumar Gandhirajan,1 Benedikt Bernd Walla,1 Manaswita 
Jain,1 Malte P. Bartram,1 Markus M. Rinschen,1 Thomas Benzing,1,2 Bernhard 
Schermer.1,2  1Dept II of Medicine and Center for Molecular Medicine, Univ of 
Cologne, Cologne, NRW, Germany; 2Cluster of Excellence on Cellular Stress 
Responses in Ageing-Associated Diseases (CECAD), Univ of Cologne, Cologne, 
NRW, Germany.
Background: The clinical syndrome of acute kidney injury (AKI) is one of the most 
important diseases in nephrology and associated with increased morbidity and mortality. 
Kidney displays a remarkable potential for repair even after severe acute injury. Recent 
studies identified the Hippo pathway as a master regulator of organ growth and proliferation 
and uncovered the importance of the two mammalian Hippo-signaling effector molecules 
YAP and TAZ as regulators of proliferation and apoptosis during kidney development. 
The objective of the current study is to demonstrate that TAZ undergoes redox regulation 
via s-glutathionylation.
Methods: Immunoprecipitation, reporter gene assay, XTT assay, cycloheximide assay.
Results: Our findings indicate that exposure to hydrogen peroxide (H2O2) increased 
TAZ/TEAD transcriptional activity without affecting YAP/TEAD. Consistently, TAZ/TEAD 
interaction was slightly enhanced upon H2O2 exposure. Furthermore, H2O2 exposure 
increased nuclear localization of TAZ in a stable NIH3T3/Flp-in cell line expressing 
TAZ-GFP. We confirmed s-glutathionylation using recombinant TAZ protein in vitro and 
biotinylated glutathione ester in cell culture. To identify cysteine residues undergoing 
s-glutathionylation we generated TAZ C>A mutants. Reporter assays revealed that TAZ 
C358A showed increased transactivation of TEAD, the effect on cell proliferation and 
migration was also enhanced in TAZ C358A mutant. Finally, cycloheximide chase assay 
revealed that all of the TAZ mutants exhibited increased stability following 6h incubation.
Conclusions: Our data indicate a novel mechanism how pro-proliferative TAZ 
activity is regulated by ROS via s-glutathionylation, which could play an important role 
in tissue injury and repair. Currently, we are following the hypothesis that ROS derived 
from constitutively active NOX4 could modulate TAZ activity in the kidneys and we are 
investigating the importance of s-glutathionylation of TAZ in vivo.
FR-PO265
Bud-Like Structure Capable of Developing to Lamellipodia in Wound 
Healing of Tubular Epithelium – A Scanning Electron Microscopic 
Approach  Kiyoko Inui,1 Hiroyuki Morita,2 Yoshihiko Inoue,1 Shinya Omiya,1 
Tomoaki Miyazaki,1 Ashio Yoshimura.1  1Div. of Nephrology, Showa Univ 
Fujigaoka Hosp., Yokohama, Kanagawa, Japan; 2Div. of Endocrinology and 
Metabolism, Aichi Medical Univ School of Medicine, Nagakute, Aichi, Japan.
Background: Cell migration is essential in wound healing during which filamentous 
(F)-acin assembly plays a pivotal role. Cell biological approaches, using confocal 
microscopy, succeeded in identifying molecules regulating the assembly, such as the Arp2/3 
complex, N-WASP, cofilin, and profilin. Although cells form filopodia (microspike) and 
lamellipodia (membrane), and move forward, much remains to be seen in the ultrastructure 
of these processes.
Methods: Rat tubular epithelium (NRK-52E) was cultured, grown to confluency, and 
scratched. The cells were subjected to scanning electron microscopy (SEM) at various 
time points. In separate experiments, immunoelectron microscopy was performed using an 
antibody against Arp3. Lastly, 60% confluent NRK-52E cells were cultured in the presence 
or absence of si-RNA for Arp3, grown to confluency, and scratched. The cells were observed 
periodically at the SEM levels, and, the length of time for complete recovery was compared.
Results: As shown in the figure, SEM elucidated elaborated network of filopodia 
containing “bud-like structure” (bud) that may develope to lamellipodia. Arp3 was expressed 
in filopodia and lamellipodia but not in a bud. The Si-RNA knockdown significantly prolong 
the length of time for the recovery. It at least partially inhibited the formation of filopodia 
network and lamellipodia but not the formation of a bud.
Conclusions: This is the first SEM analysis of scratch wound healing in cultured tubular 
epithelium, and that the bud was previously undescribed. Although the Arp2/3 complex 
does not apparently induce lamellipodia formation of a bud, further molecular analysis 
may shed a new light into cell motility in wound healing.
FR-PO266
Inhibition of Microtubule Dynamics Delays Kidney Recovery After 
Ischemia/Reperfusion Injury in Mice  Sang Jun Han,1 Jee in Kim,2 Kwon Moo 
Park.1  1Dept of Anatomy and BK21 Plus, Kyungpook National Univ School of 
Medicine, Daegu, Republic of Korea; 2Dept of Molecular Medicine and MRC, 
Keimyung Univ School of Medicine, Daegu, Republic of Korea.
Background: Ischemia/reperfusion (I/R) is a major cause of acute kidney injury 
(AKI). If recovery from AKI is delayed, kidney progresses toward chronic renal failure. 
Microtubules, a component of the cytoskeleton, contribute to cell damages, cell shape, cell 
motility, and cell division. Here, we investigate that the role of microtubule network on the 
kidney injury, recovery and progression of fibrosis after I/R injury.
Methods: Mice were subjected to 30 minutes of bilateral renal ischemia, and mice were 
sacrificed 16 days after ischemia. Some mice were administered either saline (vehicle) or 
paclitaxel (taxol), a microtubule stabilization agent; 1 day before ischemia (pretreatment) 
or from 1 day after ischemia until sacrifice every 2 days (post-treatment).
Results: Pretreatment of taxol did not affect post-I/R renal function compared with 
vehicle-treated I/R group. Post-treatment of taxol delayed renal functional and histological 
recovery with retardation of tubular regeneration, and accelerated proliferation of interstitial 
cells after ischemia. Post-treatment of taxol from 24 hours after ischemia enhanced cell cycle 
arrest, progression of fibrosis, and macrophage infiltration into the kidney. Furthermore, 
post-treatment of taxol suppressed repolarization of primary cilia in tubular epithelial cells.
Conclusions: In conclusion, our results demonstrate that microtubule stabilization or 
inhibition of cell proliferation delays kidney tubule cell restoration after ischemic injury, 
whereas interstitial cell proliferation is accelerated, leading to kidney fibrosis. It suggests 
that regulation of microtubule dynamics is critical to repair from AKI and progression of 
AKI to chronic kidney disease.
Funding: Government Support - Non-U.S.
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FR-PO267
Tubulin Acetylation in the Kidney Tubular Cells After Ischemia/Reperfusion 
Injury  Jihyeon Kim, Sang Jun Han, Kwon Moo Park.  Dept of Anatomy and 
BK21, Kyungpook National Univ, Daegu, Korea.
Background: Acetylation of tubulin is known to play an important role in the 
stabilization of microtubules. Kidney ischemia/reperfusion (I/R) is a major cause of acute 
renal failure. I/R causes damage to the cytoskeleton in the tubular epithelial cells.
Methods: We investigated the tubulin acetylation in kidney tubular epithelial cells 
after I/R injury using western blotting and immunohistochemical staining. Mice were 
subjected to either 30 min of ischemia or sham-operation. Kidneys were harvested at 
various times after ischemia.
Results: Acetylated-α-tubulin expression dramatically decreased 24 hours after 
ischemia and then gradually increased over time. However, total α-tubulin expression 
was not significantly changed after I/R. In normal kidney, immune-reactivities of kidney 
epithelial cell to acetylated α-tubulin antibody were different in tubules; the orders were the 
collecting duct, the distal tubules and the proximal tubule. Twenty-four hours after ischemia, 
acetylated α-tubulin expression increased in the proximal tubule and the distal tubule with 
strong expression in the nuclei of the tubular cells. In the glomerulus, acetylated α-tubulin 
was also observed and the expression was very strong in the podocyte and Bowman’s 
capsule. Twenty-four hours after ischemia, acetylated α-tubulin expression in the podocyte 
was lower than that of normal cells. Nine days after ischemia, acetylated α-tubulin expression 
in the podocyte and interstitial cell increased. Expression of α-tubulin acetyltransferase-1 
(αTAT1), an enzyme involved in acetylation of α-tubulin, continuously decreased after 
ischemia. Histone deacetylase 6 (HDAC6), an enzyme involved in deacetylation of tubulin, 
also significantly decreased after ischemia.
Conclusions: Ischemia/reperfusion reduced tubulin acetylation in renal tubular cells, 
suggesting that I/R-induced decrease of tubulin acetylation is associated with reduction of 
stability of microtubule in cells.
Funding: Government Support - Non-U.S.
FR-PO268
Hypertension Aggravates Acute Kidney Injury (AKI) and Accelerates 
Progression to Chronic Kidney Disease (CKD) in CD1 Mice  Robert Greite,1 
Anja Thorenz,1 Faikah Gueler,1 Katja Hueper,2 Song Rong,3 Hermann G. Haller,1 
Jan H. Braesen.4  1Nephrology, Hannover Medical School, Hannover, Germany; 
2Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, 
Germany; 3Central Animal Facility, Hannover Medical School, Hannover, 
Germany; 4Pathology, Hannover Medical School, Hannover, Germany.
Background: AKI can be complicated by hypertension due to activation of the RAAS 
system. However, the most frequently used laboratory mouse strain (C57Bl/6) lacks blood 
pressure elevation after renal injury. In this study we provide evidence that hypertension 
aggravates post-ischemic AKI and accelerates progression to chronic kidney disease 
(CKD) in CD1 mice.
Methods: IRI was induced by transient clamping of the renal pedicles for 35 minutes 
in CD1 compared to C57Bl/6 mice. Survival, renal function (creatinine, BUN), glomerular 
filtration rate (GFR) and renal blood flow (RBF) were measured by inulin/PAH-clearance 
and renal perfusion impairment was assessed by functional magnetic resonance imaging 
(MRI). Systemic blood pressure was measured by a tail cuff method at different time 
points after IRI. Morphological changes were investigated by Masson Goldner staining and 
immunohistochemistry for inflammation (myeloid cell infiltration) and fibrosis (collagen 
and fibronectin expression). In addition, silver stain was done to quantify mesangial 
matrix expansion.
Results: Renal function impairment after IRI was similar in CD1 and C57Bl/6 mice 
but only the CD1 mice developed severe blood pressure elevation (+20 mmHg) within 2 
weeks. Functional MRI revealed long lasting impairment of renal perfusion in CD1 mice 
and markedly better recovery in C57Bl/6 mice. Similar results were obtained by PAH 
clearance measurements. Histologically, AKI score and inflammation was similar at day 
1 after IRI in both mouth strains. Within 14 days after IRI CD1 mice developed severe 
tubulo interstitial fibrosis. In contrast, C57Bl/6 recovered and had only mild focal cortical 
scaring after 14 days. Silver stain revealed significant mesangial matrix expansion only in 
CD1 mice correlating with accelerated glomerulosclerosis.
Conclusions: CD1 mice show severe blood pressure elevation in ischemia induced 
AKI which accelerates the progression to CKD.
Funding: Government Support - Non-U.S.
FR-PO269
Pericyte MyD88 Controls Inflammatory and Fibrotic Responses to Kidney 
Injury  Irina Alexandra Leaf,1 Ivan G. Gomez,1 Bryce Gordon Johnson,1 William 
A. Altemeier,2 Jeremy Stuart Duffield.1  1Research & Development, Biogen, 
Cambridge, MA; 2Medicine, Univ of Washington, Seattle, WA.
Background: Sterile inflammation is increasingly recognized as a central problem 
in many acute and chronic diseases but the mechanisms controlling responses to sterile 
inflammation are poorly understood. Injured or dying cells release products, or Danger 
Associated Molecular Patterns (DAMPs), recognized by immune receptors contributing 
to disease progression. Here we show that DAMPs isolated from injured kidney activate 
TLR2/4 and MyD88 dependent transcription of immune genes in non-immune kidney 
resident cells, pericytes. When treated with extracellular DAMPs pericytes form an active 
NLRP3 inflammasome, process pro-IL1 and pro-IL18 to their active secreted forms and 
undergo pyroptosis, thereby contributing to inflammation and leukocyte trafficking.
Results: Recent studies have indicated that kidney pericytes represent a major source 
of interstitial myofibroblasts in renal fibrogenesis. We show that treatment with DAMPs in 
vitro activate pericyte to myofibroblast transition indicated by upregulation of transcription 
of fibrotic genes Col1a1 and Acta2 and production of SMA. MyD88-/- pericytes showed 
significant reduction in fibrogenesis markers. In wound healing assays DAMPs caused 
pericyte migration, which was significantly reduced in the absence of MyD88. Cell-specific 
ablation of MyD88 in perivascular and stromal cells in models of ischemic acute kidney 
injury in mice significantly attenuates innate immune activation, injury and fibrogenic 
responses. In addition, we show that human pericytes respond to DAMPs in a similar 
manner by activating immune genes, secreting pro-inflammatory cytokines and inducing 
pyroptotic cell death.
Conclusions: In conclusion, pericytes respond to sterile inflammation via two divergent 
mechanisms both of which are controlled by MyD88: activation of immune signaling 
which enables detection and amplification of the inflammatory signal; and activation of 
fibrogenesis contributing to pathology. Therefore, this regulation could be an important 
new therapeutic target for tissue injury.
Funding: Pharmaceutical Company Support - Biogen
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Gadd45-Gamma Protects against Acute Kidney Injury  Gyu Tae Shin, 
Inwhee Park, Heungsoo Kim.  Dept of Nephrology, Ajou Univ School of 
Medicine, Suwon, Kyunggi, Korea.
Background: Growth arrest and DNA-damage-inducible protein-gamma (Gadd45-
gamma) is a protein which plays a role in the G2/M cell cycle checkpoint. We previously 
suggested that Gadd45-gamma may be involved in chronic kidney damage. In the present 
study, we investigated the function of Gadd45-gamma in acute septic and toxic kidney injury.
Methods: Acute kidney injury (AKI) was induced in vivo by intraperitoneal injection 
of lipopolysaccharide (LPS, 10mg/kg) and cisplatin (20mg/kg) in wild-type (WT) and 
Gadd45-gamma KO mice. Proteome array kits were used to detect differentially regulated 
proteins in serum (40 pro-inflammatory proteins) and kidney cortex (111 proteins). Stable 
Gadd45-gamma knockdown cell lines were established in primary human renal epithelial 
(HRE) cells using shRNA expression vectors. Gadd45-gamma was over-expressed using the 
recombinant adenovirus harboring the Gadd45-gamma open reading frame. Differentially 
regulated genes in cisplatin treated HRE cells were determined using the microarray analysis.
Results: Gadd45-gamma was significantly induced as early as 2 h after LPS injection 
in the kidney of WT mice. At 24 h after LPS injection, both WT and KO mice showed AKI 
evidenced by high urinary NGAL and elevated serum creatinine levels, where KO mice 
showed significantly higher serum creatinine levels with lower creatinine clearance than 
WT mice. Pro-inflammatory cytokines in serum were not different, however, the expression 
of several chemokines in kidneys were significantly higher in KO mice. In contrast, the 
expression of pro-fibrotic cytokines was significantly lower in KO mice. At 48 h after 
cisplatin injection, only KO mice showed significantly elevated serum creatinine levels with 
heightened NGAL expression. In cisplatin treated HRE cells, pro-inflammatory cytokines 
were significantly up-regulated by Gadd45-gamma knockdown, and down-regulated by 
Gadd45-gamma overexpression, whereas pro-fibrotic cytokines were significantly down-
regulated by Gadd45-gamma knockdown.
Conclusions: The up-regulation of Gadd45-gamma protects against acute kidney injury, 
however, maladaptively increases the expression of pro-fibrotic molecules.
FR-PO271
Pyridorin® Reduces Renal Injury and Post Injury Fibrosis After Ischemia 
Reperfusion Induced Acute Kidney Injury  Nataliya Skrypnyk,1 Paul A. 
Voziyan,1 Haichun Yang,1 Carrie Turich Taylor,2 Raymond C. Harris,1 Billy 
G. Hudson,1 Mark P. de Caestecker.1  1Div of Nephrology, Vanderbilt Univ, 
Nashville, TN; 2NephroGenex, Inc., Raleigh, NC.
Background: Pyridorin (PYR), an inhibitor of pathogenic oxidative chemistries, has 
a favorable safety profile in clinical trials and has been shown to scavenge reactive oxygen 
species (ROS) and reactive carbonyl species (RCS) in vitro and in vivo animal studies. ROS 
and RCS are highly up regulated during kidney injury. In this study we propose that PYR 
treatment will reduce injury and ameliorate long-term fibrosis after ischemia-reperfusion 
acute kidney injury (IR-AKI).
Methods: Ischemia-reperfusion mouse models: 1) unilateral ischemia reperfusion 
(UIR) (31min), injury evaluation on day 3 after injury (UIR D3); and 2) UIR with delayed 
contralateral nephrectomy (DCN) on day 9, fibrosis and injury evaluation on day 28 (UIR 
DCN D28).
Results: Preventive treatment with PYR at 500 mg/kg/day (PYR500) and 1000 mg/
kg/day (PYR1000) via drinking water in the UIR D3 model demonstrated dose dependent 
reduction in mRNA levels of kidney injury markers Kim1 and NGAL, tubular injury score, 
and an oxidative stress marker, isofuran-to-isoprostane ratio. Plasma PYR levels were 
proportional to PYR dose. There was a dose dependent reduction in fibrosis after PYR 
pre-treatment in the UIR DCN D28 model. PYR1000 reduced mRNA levels of Col1a1, 
Col3a1 and aSMA. PYR pre-treatment was more effective at inhibiting expression of these 
pro-fibrotic markers compared with post-injury treatment, which only reduced expression 
of aSMA mRNA in the UIR DCN D28 model.
Conclusions: PYR pre-treatment ameliorates I/R-AKI in dose dependent manner. Pre-
treatment with PYR is more effective than post injury treatment and can inhibit progression 
to chronic kidney disease. These studies suggest PYR as a prospective drug for treatment 
of patients at risk of AKI. Funded by research grant from NephroGenex, Inc.
Funding: Pharmaceutical Company Support - NephroGenex, Inc
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FR-PO272
Canonical BMP Signaling via BMPR1A and Smad1/5/8 Mediates 
the Transition to Fibrosis After Renal Ischemia Reperfusion Injury 
Emilia Vigolo,1 Lajos Marko,2 Christian Hinze,1 Dominik N. Müller,1,2 Ruth 
Schmidt-ullrich,1 Kai M. Schmidt-Ott.1,2,3  1Max Delbrueck Center for Molecular 
Medicine, Berlin, Germany; 2Experimental and Clinical Research Center, 
Charitè, Berlin, Germany; 3Dept of Nephrology, Charitè - Universitaetsmedizin, 
Berlin, Germany.
Background: Ischemia reperfusion injury (IRI) of the kidney leads to acute kidney 
injury (AKI) and frequently precipitates the development of tubulointerstitial fibrosis. 
Bone morphogenic protein (BMP) signaling has been implicated in the pathogenesis and 
progression of the disease, but its tubular-specific role is unclear.
Methods: We induced IRI in mice by clamping the left renal pedicle for 25 minutes. The 
severity of the damage was confirmed by histology scoring, elevated mRNA expression of 
renal injury markers NGAL and KIM-1 and increased urinary NGAL (uNGAL) excretion 
24h post-ischemia. Activation of canonical BMP signaling was detected by nuclear 
pSmad1/5/8 immunostaining and Western blotting. To achieve a doxycycline-dependent 
Cre-mediated inactivation of BMP receptor 1a (Bmpr1a) in renal tubules, we generated 
Pax8rtTa;LC1;Bmpr1a fl/fl mice (Bmpr1a cKO).
Results: Canonical BMP activity, as revealed by pSmad1/5/8, was widely detected in 
healthy wild-type (wt) mouse kidney tubules. IRI caused a sustained injury in wt kidneys 
as shown by elevated NGAL and KIM-1 expression and increased uNGAL excretion. In 
parallel, we observed a transient decrease of pSmad1/5/8 with minimal activity at 48 hours 
and a subsequent re-activation at 7 days post-ischemia. Bmpr1a cKO mice displayed normal 
renal tissue morphology and renal functions at baseline. Following IRI, Bmpr1a cKO mice 
exhibited an initial injury similar to controls, but at 7 days post-ischemia, the expression of 
collagen IV and TGF-β1 were significantly up-regulated in Bmpr1a cKO kidneys compared 
to controls. Unlike controls, Bmpr1a cKO mice failed to reactivate tubular pSmad1/5/8 
activity at 7 days after injury. 21 days following IRI, Bmpr1a cKO kidneys displayed an 
increased percentage of tubulointerstitial fibrosis compared to controls.
Conclusions: Tubular Bmpr1a-dependent Smad1/5/8 signaling is transiently decreased 
after renal IRI and its reactivation limits the progression of tubulointerstitial fibrosis.
FR-PO273
PNUTS (Phosphatase 1 Nuclear-Targeting Subunit) Is Down-Regulated 
in Acute Kidney Injury and by Aging, and Regulates Cell Cycle, Fibrosis, 
DNA Damage of Renal Tubular Cells  Yuki Osakabe, Tatsuki Matsumoto, 
Kazu Hamada-Ode, Yoshiko Shimamura, Koji Ogata, Kosuke Inoue, Yoshinori 
Taniguchi, Taro Horino, Shimpei Fujimoto, Yoshio Terada.  Kochi Univ, Japan.
Background: PNUTS (phosphatase 1 nuclear-targeting subunit, also known as 
PPP1R10) has recently reported to be regulated in cardiac aging and play roles in DNA 
damage. Aging and fibrosis play crucial roles in AKI to CKD transition, however the precise 
mechanism are not known. Because the biological role of PNUTS in aged kidney, fibrosis, 
and cell cycle in AKI is poorly understood, we studied the regulation and the functional 
roles of PNUTS in AKI and aging.
Methods: We used an in vivo mice aristolochic acid(AA)-induced AKI model and 
cultured renal tubular cells (NRK-52E cells). To assess aging effects, we evaluated PNUTS 
expression, renal function, and renal fibrosis in AA-induced AKI model in different 
aged mice (20-, 50- and 90-week-old). To elucidate the function of PNUTS, cell cycle 
regulation (by FACS), DNA damage (by gammaH2AX expression), and fibrosis (by 
CTGF expression) were examined in NRK-52E cells transfected with siRNA for PNUTS 
or PNUTS expression vector.
Results: In mice with AA-induced AKI, protein and mRNA expression of PNUTS 
were reduced compared with control mice. Moreover, PNUTS expression were decreased 
in accordance to aging. Reduction of renal function and renal fibrosis were more apparent 
in aged AKI mice. Immunohistological examination revealed the reduced expression of 
PNUTS in the proximal tubular cells in AA-induced AKI. PNUTS mRNA and protein 
expression showed a dose-dependent reduction by H2O2 in NRK-52E cells. Overexpression 
of PNUTS reduced H2O2-induced caspase3 activity and apoptotic (TUNEL positive) 
cell number. Transfection of siPNUTS significantly increased G2/M phase cells, CTGF 
expression, and DNA damage.
Conclusions: These results indicate that PNUTS expression was reduced in AA-
induced AKI and in aged mice. Expression of PNUTS was partially regulated by oxidative 
stress. PNUTS regulates cell cycle, CTGF expression, DNA damage, and apoptosis in 
NRK-52E cells. These results suggest that regulation of PNUTS may play a key role in 
the pathophysiology of AKI and age-related renal damage.
FR-PO274
Class Ia HDAC Inhibitors Restore BMP-7 Expression and Inhibit the 
Pathogenesis of Renal Fibrosis following Chronic Renal Injury  Qiusha Guo, 
Scott R. Manson, Katelynn H. Moore, Paul F. Austin.  Dept of Surgery, Div of 
Urology, Washington Univ, St. Louis, MO.
Background: BMP-7 is a potent anti-fibrotic cytokine that is also required for the 
repair of renal injuries. However, chronic renal injury leads to the loss of BMP-7 and 
fibrosis. Here, we delineate the molecular mechanisms that lead to the loss of BMP-7 
expression and examine potential therapeutic strategies for stimulating the innate repair 
mechanisms of the kidney.
Methods: BMP-7 expression was studied in vitro in inner medullary collecting duct 
(IMCD) cells and in vivo in a murine model of unilateral ureteral obstruction (UUO). 
The therapeutic effects of broad spectrum histone deacetylase (HDAC) inhibition with 
Trichostatin A (TSA) and Class Ia HDAC inhibition with MS-275 were evaluated by 
assessing renal pathology.
Results: UUO results in an 83.1% decrease in BMP-7 mRNA expression that is 
paralleled by a 63.0% decrease in the acetylation of histone proteins in the proximal Bmp7 
promoter, a process that results in gene repression. These changes are HDAC-dependent 
and blocked by treatment with TSA. An in vitro pharmacologic screen in IMCD cells 
revealed that MS-275 stimulates BMP-7 expression, while inhibitors of other HDAC 
isoforms have no effects. These results were confirmed by using siRNA-mediated genetic 
ablation to demonstrate specificity and chromatin immunoprecipitation to show binding 
of the Class Ia HDAC proteins HDAC1 and HDAC2 to the Bmp7 promoter. MS-275 also 
stimulates the anti-fibrotic functions of BMP-7 in vitro by suppressing the expression of the 
TGF-β-dependent pro-fibrotic genes COLIa1 and aSMA by 68.2% and 97.6%, respectively. 
Finally, these effects extend to the obstructed kidney in vivo where HDAC inhibition results 
in a 2.7-fold increase in BMP-7 expression, 42.7% decrease in fibroblast activation, and 
63.7% decrease in renal fibrosis.
Conclusions: These findings demonstrate that HDAC1 and HDAC2 are responsible 
for the loss of BMP-7 expression and its renal protective functions in the injured kidney. 
Furthermore, our study suggests that Class I HDAC inhibitors have a tremendous therapeutic 
potential for stimulating kidney repair and inhibiting disease progression following chronic 
renal injury.
Funding: NIDDK Support, Private Foundation Support
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Gli2 in Perivascular MSC Is Required for Kidney Fibrosis and Can Be 
Targeted Pharmacologically  Rafael Kramann, Susanne V. Fleig, Steven L. 
Fabian, Omar H. Maarouf, Janewit Wongboonsin, Yoichiro Ikeda, Benjamin D. 
Humphreys.  Renal Div, Brigham and Women´s Hospital, Boston, MA.
Background: We recently demonstrated that perivascular mesenchymal stem cell 
(MSC)-like cells are defined by expression of Gli1 and are critical myofibroblast precursors. 
We now investigate the role of Gli transcriptional activators in myofibroblast progenitors 
during kidney fibrosis and value as therapeutic targets.
Methods: We utilized mouse genetics, drug binding, RNAi and retroviral 
overexpression to dissect the roles of Gli1 vs. Gli2 in myofibroblast activation and 
fibrosis. We pharmacologically targeted Gli proteins with Darinaparsin, an arsenical, and 
GANT61, a small molecule Gli inhibitor. We evaluated them in two separate mouse CKD 
models. We measured hedgehog pathway activity and expression of Gli in human kidney 
fibrosis specimen.
Results: In vitro knockdown of Gli1 had no appreciable effect whereas knockdown of 
Gli2 induced a G0/G1 cell cycle arrest of mouse fibroblasts. Conversely, Gli2 overexpression 
rescued this cell-cycle effect and drove proliferation. In vivo, knockout of Gli1 showed 
no effect on fibrosis severity after UUO whereas either conditional knockout of Gli2 or 
overexpression of the Gli3 repressor in Gli1+ pericytes ameliorated fibrosis and induced a 
G0/G1 cell cycle arrest specifially in myofibroblasts, consistent with our in vitro results. 
We show that darinaparsin directly binds to Gli2, lowers Gli2 protein levels and induces 
a G0/G1 cell cycle arrest. This effect of darinaparsin absolutely requires Gli2, and Gli2 
overexpression rescued the cell cycle defect. When administered in a therapeutic dosing 
strategy after UUO or IRI, darinaparsin potently reduced Gli1 and Gli2 expression, 
induced myofibroblast specific G0/G1 cell-cycle arrest and ameliorated fibrosis. GANT61, 
structurally unrelated to darinaparsin, showed the exact same effects. In human kidneys 
with fibrosis there is strong upregulation of Gli1 and Gli2 mRNA, suggesting this pathway 
is conserved in humans.
Conclusions: Gli2 is a critical driver of myofibroblast proliferation and a novel 
therapeutic target in kidney fibrosis.
Funding: NIDDK Support
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Klotho Influences the Fate of Fibrosis in Cardio-Renal Protection 
Steven M. Weldon,1 Hu Sheng Qian,1 Nestor X. Barrezueta,1 Jorge L. 
Villalona,1 R. Paul Fracasso,1 Glenn A. Reinhart,1 Jian Xie,2 Chou-Long 
Huang,2 Noelynn Oliver.1  1CardiMetabolic Disease Research, Boehringer 
Ingelheim Pharmaceuticals Inc, Ridgefield, CT; 2Univ of Texas SW Medical 
Center, Dallas, TX.
Background: Soluble Klotho is an endogenous hormone produced predominantly 
by extracellular domain shedding of membrane Klotho in the kidney. Although Klotho 
is thought to provide cardio-renal protection through its regulation of ion transport and 
growth factor signaling, specific cellular localization and function of Klotho in the normal 
and diseased kidney are not clearly defined.
Methods: We evaluated Klotho expression and localization in human and mouse kidney 
via in situ hybridization (ISH), immunohistochemistry (IHC) or RNAseq. Cardio-renal 
protective effects of soluble human Klotho administration were studied in mouse unilateral 
ureteral obstruction (UUO; 5 day) and isoproterenol-induced cardiac hypertrophy (ISO, 
5 mg/lg/d x 10d) models.
Results: In normal adult human kidney (fresh nephrectomy and autopsy, n=9), Klotho 
was highly expressed in distal tubules (DT) and in both cortical and outer medulla collecting 
ducts (CD). Proximal tubule and podocyte expression was low but detectable. Following 
UUO, renal Klotho RNA was decreased 61% and protein content was reduced greatly 
in the distal nephron vs Sham kidney. Klotho treatment (10 ug/kg, Q2D, IP) attenuated 
UUO-induced tubulointerstitial fibrosis (picrosirius red stain, n=10) by 67%* (*p<.05) and 
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biomarker mRNA (40%*:FN1; 25%:aSMA; 16%:TGFb) vs Vehicle control. In the ISO 
model, Klotho (10 ug/kg QD, IP) inhibited cardiac hypertrophy (HW:BW, n=6); 5.4±.08 
(p<.01) in Klotho- vs 5.8±0.08 in Vehicle control.
Conclusions: Klotho is highly expressed in normal human and mouse distal nephron. 
Klotho mRNA and protein are reduced in preclinical models of cardiac and renal disease. 
Delivery of recombinant Klotho attenuates severity of pathology and biomarker expression 
in the UUO model of renal fibrosis and ISO-induced cardiac hypertrophy.  Klotho 
pharmacotherapy has the potential to prevent CKD progression as well as the progression 
of extra-renal Klotho-dependent diseases.
FR-PO277
Kidney Interstitial Cell Derived Tenascin C Plays an Important Role in 
Promoting Injury-Repairing of the Kidney by Stimulating Cell Proliferation 
Min Zhang, Qionghong Xie, Xiaoyi Mao, Da Shang, Chuanming Hao.  Div of 
Nephrology, Huashan Hospital, Shanghai, China.
Background: Tenascin-C (TNC) is a glycoprotein expressed in extracellular matrix 
during development and injury repairing. This study explored the role of TNC in acute 
kidney injury (AKI).
Methods: A TNC promoter driven inducible CreER2 knock-in mouse line with EGFP 
reporter (IRES-EGFP) as generated (TNC-CreER-eGFP). AKI was induced by 40 minutes 
of ischemia followed by reperfusion in unilateral nephrectomized mice (UN+UIR). Cell 
lineage tracing was conducted in TNC-CreER;R26-tdTomato mice to examine the origin 
of TNC expressing cells. The effect of TNC on cell proliferation was examined using a 
cell count kit in cultured HK2 cells. TNC expression was also examined in human biopsies 
with IRB approval.
Results: In normal kidney, TNC was restricted in renal papilla in both mice and human. 
Following IR, TNC was markedly induced in renal cortex, particularly in injured areas. 
TNC reporter showed that induced TNC expression is localized in interstitial cells, but 
not tubular epithelial cells. TNC induction was also shown in human renal biopsies with 
AKI. Co-staining IF showed that TNC was expressed by the PDGFRβ(+) renal interstitial 
cells, but not NG2(+) pericyte, F4/80(+) macrophage and FSP-1(+) cells. Lineage tracing 
revealed that TNC expressing cells following IR were not derived from the renal medullary 
interstitial cells that constitutive express TNC, suggesting new TNC induction. To examine 
the role of TNC induction following AKI, TNC-/- mice were generated. TNC deletion 
significantly increased mortality (0% vs 50% on day 7, n=14, P=0.002), with significantly 
higher BUN levels (108 vs 22 mmol/L on day 2, P<0.05) compared with wide type mice. 
More severe kidney damage in TNC knockouts was also supported by histology study. To 
examine the mechanism by which TNC protected the kidney from injury, HK2 cells were 
cultured. Exogenous TNC significantly increased cell proliferation by 50%.
Conclusions: TNC is induced in renal interstitial cells after IR-induced AKI, protecting 
the kidney from injury. The protective effect of TNC on AKI may be associated with 
promoting renal recovery by stimulating epithelial cell proliferation.
Funding: Government Support - Non-U.S.
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TAZ and YAP Are Mechanoregulators of TGF-β-Smad Signaling and Renal 
Fibrogenesis  Darren A. Yuen, Stephen G. Szeto, Masahiro Narimatsu, Ahmad 
Mohammad Omar Sidiqi, Mingliang Lu, Jeffrey Wrana, Andras Kapus.  Univ 
of Toronto, Canada.
Background: Fibrosis is a final common injury pathway responsible for the progression 
of most forms of CKD, for which no specific treatments exist. Driven largely by TGF-β 
signalling, fibroblast-myofibroblast transition is crucial for fibrogenesis. While it is known 
that fibroblast activation is mechanosensitive, with soft matrix akin to a healthy kidney 
impairing TGF-β responsiveness, the underlying mechanisms remain poorly understood. 
TAZ and YAP are homologous transcription co-factors with TGF-β regulatory activity, 
whose nuclear localization and activity are regulated by matrix stiffness. Here, our aim 
was to examine how stiffness regulates TGF-β signalling via TAZ/YAP, and to test if TAZ/
YAP inhibition can attenuate renal fibrosis.
Methods: The effects of matrix stiffness on TAZ/YAP localization and TGF-β/Smad 
signalling were examined in rat renal fibroblasts (NRK49Fs) cultured on soft (2 kPa) and 
stiff (100 kPa) gels. To test the effect of TAZ/YAP inhibition, NRK49F cells and mice 
were treated with verteporfin (VP), a drug used as a macular degeneration treatment with 
recently described TAZ/YAP inhibitory properties.
Results: In NRK49F cells, stiff matrix resulted in nuclear TAZ/YAP localization and 
enhanced TGF-β signalling. Growth on soft matrix, in contrast, lead to reduced TAZ/
YAP nuclear localization, and impaired TGF-β-induced Smad2/3 nuclear accumulation 
and transcriptional activity. VP treatment of NRK49F cells grown on stiff plastic surfaces 
resulted in a dramatic loss of TAZ/YAP, leading to a similar inhibition of TGF-β/Smad 
signalling. VP-induced TAZ/YAP loss also enhanced proteasomal Smad2/3 degradation 
following TGF-β stimulation. In vivo, VP similarly reduced renal TAZ/YAP and Smad2/3 
levels in UUO mice, leading to diminished myofibroblast accumulation and interstitial 
collagen deposition.
Conclusions: Our data suggest that renal fibrogenesis is regulated by a novel 
mechanical stimulus (stiffness) that, through control of the mechanosensory proteins TAZ 
and YAP, modulates TGF-β/Smad signalling. Furthermore, we identify verteporfin as a 
potential anti-fibrotic treatment that interferes with this pro-fibrotic mechano-chemical 
synergy.
Funding: Government Support - Non-U.S.
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Targeted Deletion of Numb from Proximal Tubules Attenuates Interstitial 
Fibrosis by Mitigating G2/M Arrest  Fengxin Zhu, Jing Nie.  Div of 
Nephrology, Nanfang Hospital, Guangzhou, Guangdong, China.
Background: Progressive tubulointerstitial fibrosis (TIF) is the final common pathway 
leading to end stage renal disease. Tubular epithelial cells (TECs) have a crucial role in 
the pathogenesis of TIF. Numb is a multifunctional protein involved in diverse cellular 
processes. However, little is known about the physiologic and pathologic role of Numb 
in kidney.
Methods: We examined the expression and distribution of Numb in normal adult mouse 
kidney as well as in mouse model of renal fibrosis induced by unilateral ureteral obstruction 
(UUO). To explore Numb’s role in renal fibrosis, we generated a conditional knockout 
mouse model in which Numb is selectively ablated from proximal tubules (PEPCK-Numb-
KO). To confirm the role of Numb in regulating cell cycle, Numb was overexpressed in 
NRK52E cells by infecting with a Numb adenovirus (Ad-Numb) and endogenous Numb 
was knocked down by siRNA in HK-2 cells before aristolochic acid (AA) treatment. To 
examine the role of p53 in Numb-induced G2/M arrest, Ad-Numb infected HK-2 cells were 
incubated with pifithrin-α, a p53 inhibitor.
Results: Numb is expressed in renal tubules and glomeruli. The expression of Numb in 
renal tubules was significantly increased after UUO. After UUO, PEPCK-Numb-KO mice 
exhibited significantly attenuated TIF. Ectopic expression of Numb increased the fraction of 
cells in G2/M stage and upregulated the expression of TGF-β1 and CTGF in NRK52E cells. 
Knocking down endogenous Numb attenuated AA-induced G2/M arrest and profibrotic 
cytokines production. Furthermore, G2/M arrest and expression of profibrotic cytokines 
were significantly reduced in PEPCK-Numb-KO mice after UUO. Inhibiting p53 activity 
dramatically mitigated Numb-induced G2/M arrest and profibrotic cytokines production.
Conclusions: In summary, our studies demonstrate that Numb has a profound effect 
on promoting G2/M arrest of TECs through stabilizing p53 protein. Depletion of Numb 
markedly attenuates G2/M arrest of proximal tubules which in turn reduces TIF. Collectively, 
these data indicate that targeting Numb might be a novel therapeutic approach for the 
treatment of fibrotic kidney diseases.
Funding: Government Support - Non-U.S.
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Identification of a New Aldosterone Synthase Inhibitor with Anti-Fibrotic 
Activity in Animal Models  Bert Oehlen, Siobhan McCormack, Ping Zhou, 
Liming Zhang, Xingxi Peng, Jingsong Li, Xiaokang Zhu, Bijoy Panicker, Itzhak 
D. Goldberg.  Angion Biomedica Corp., Uniondale, NY.
Background: The renin-angiotensin-aldosterone system (RAAS) plays a critical 
role in renal physiology. Inhibitors of ACE and ARBs are currently the mainstay in 
the clinical management of chronic kidney disease (CKD). Despite initial success in 
reducing aldosterone, concentrations return to pretreatment levels in 30-40% of patients. 
This “aldosterone escape” significantly limits the therapeutic effectiveness. Through 
mineralocorticoid receptor dependent and independent processes, aldosterone is thought 
to directly accelerate renal damage by sustaining inflammation and fibrosis. An attractive 
approach to deal with aldosterone escape is to inhibit aldosterone synthase (AS), the enzyme 
responsible for aldosterone production (encoded by the CYP11B2 gene).
Methods: We have identified a promising series of potent and selective small molecule 
inhibitors of AS. Lead compound ANG3586 has 7 nM potency against AS and excellent 
selectivity against other P450 enzymes. It is orally bioavailable in rodents and appears to 
be well tolerated. ANG3586 was tested in the rat remnant kidney model (25 mg/kg, po, bid) 
and the mouse unilateral ureteral obstruction (UUO) model (25 mg/kg, po, bid, ten days).
Results: In the rat remnant kidney model, animals with overt renal dysfunction were 
treated with vehicle or ANG3586. The elevated blood pressure in 5/6 nephrectomized 
animals was reduced to normal by compound treatment. ANG3586 also markedly reduced 
kidney collagen content and improved renal histology. Renal function, as determined by 
serum BUN and creatinine levels, urine albumin to creatinine ratio and urine NGAL, was 
found to be markedly improved. In the mouse UUO model, ANG3586 reduced the increase 
in kidney weight, kidney collagen and alpha-smooth muscle actin staining. Since UUO 
does not result in distinctly increased blood pressure, the anti-fibrotic activity appears 
independent of blood pressure lowering activity of ANG3586.
Conclusions: Taken together, ANG3586 shows promise as a potential novel anti-
fibrotic agent.
Funding: NIDDK Support
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Tubulointerstitial Fibrosis Increases Peritubular Capillary Permeability 
and Induces Subsequent Hypoxia  Jun Zou,1,2 Jae Won Yang,1 Haichun Yang,1 
Agnes B. Fogo.1  1Dept of Pathology, Microbiology, and Immunology, Vanderbilt 
Univ, Nashville, TN; 2Div of Nephrology, XinHua Hospital, Shanghai Jiao Tong 
Univ, Shanghai, China.
Background: We previously showed that folic acid-induced tubulointerstitial injury 
sensitizes to subsequent glomerular injury. In this study, we evaluated whether the function 
of peritubular capillaries and oxygen supply changes contribute to this cross-talk of tubular 
to glomerular injury.
Methods: Col I-luciferase mice, which have luciferase inserted in the collagen 
I promoter, were mated with Nep25 mice, which express human CD25 receptor on 
podocytes, and develop glomerulosclerosis when immunotoxin is administered. Mice 
were treated with folic acid (FA, 240mg/kg BW, i.p.) or vehicle (VEH). At day 42, 
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mice were sacrificed to assess interstitial fibrosis, peritubular capillary number (CD31 
immunostaining), endothelial function (in vivo injection of Evans blue dye), and tissue 
hypoxia (hypoxyprobe, pimonidazole).
Results: Folic acid induced acute tubular injury over two weeks, evidenced by increased 
urinary NGAL and Kim-1 levels. Six weeks later, tubular epithelial cells had regenerated and 
urinary NGAL and Kim-1 returned to baseline level. However, bioluminescence imaging, 
an indicator of collagen I mRNA transcription, showed higher density in folic acid vs 
vehicle (FA 31.6±5.1×104 vs. VEH 3.2±0.6×104 p/sec/cm2/sr, P<0.05). Interstitial fibrosis 
and collagen I were increased in FA compared to VEH (picrosirius red area, FA 14.5±1.6 
vs. VEH 7.4±0.7%, P<0.05; collagen I IHC, FA 16.7±1.2 vs. VEH 10.6±1.3%, P<0.05), 
with a patchy distribution. Folic acid did not reduce peritubular capillary density (FA 
5.5±0.7 vs. VEH 6.0±0.8%, pNS). However, peritubular capillary permeability, measured 
by extravasated Evans blue dye in the kidney, significantly increased in folic acid-treated 
group (FA 50.4±5.3 vs. VEH 28.6±3.2mg/g, P<0.05). Pimonidazole staining intensity was 
increased,suggesting tubulointerstitial hypoxia.
Conclusions: We conclude that tubulointerstitial fibrosis may lead to increased 
peritubular capillary permeability and subsequent hypoxia, which may contribute to 
crosstalk of interstitial fibrosis promoting glomerular injury.
Funding: NIDDK Support
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Homocysteine Induces Collagen I Expression by Downregulating Histone 
Methyltransferase G9a  Wenjing Lei, Jing Nie.  State Key Laboratory of Organ 
Failure Research, National Clinical Research Center of Kidney Disease, Div 
of Nephrology, Nanfang Hospital, Southern Medical Univ, Guangzhou, China.
Background: Hyperhomocysteinemia (HHcy) leads to several clinical manifestations 
including renal fibrosis. Excess deposition of extracellular matrix (ECM) components 
including collagen is the eponymous lesion of renal fibrosis.
Methods: Wild-type C57BL/6 mice, at the age of 6-9 weeks, were fed with either 
standard rodent chow or HM diet . After 2 weeks on the diet, mice were sacrificed. 
Kidney tissues were removed. HK-2 cells were cultured in DMEM containing DL-Hcy. 
The expression of G9a and Collagen I were examined by Western blot and qPCR. Renal 
pathological changes were assessed in tissue sections stained with Collagen I and Masson 
staining. HK-2 cells were transfected with pCol-GL3 reporter plasmid, pRL null together 
with siG9a or Flag-tagged G9a to examine the promoter activity of COL1A1. The level on 
G9a and H3K9me2 on the promoter of COL1A1 was assessed by CHIP assay.
Results: we demonstrated that elevated concentration of Hcy induced the expression of 
collagen type I in cultured HK-2 cells as well as in kidney tissue of HHcy mice. Meanwhile, 
Hcy inhibited the expression of histone methyltransferase G9a. Mechanistically, silencing 
endogenous G9a by siRNA enhanced the promoter activity of COL1A1 in HK-2 cells. 
Conversely, overexpressing G9a inhibited the promoter activity of COL1A1. CHIP assay 
demonstrated that G9a binds to the neuron-restrictive silencer element (NRSE) on the 
promoter of COL1A1. Hcy treatment decreased the binding of G9a on NRSE, which in 
turn decreased the level of H3K9me2 on the promoter of COL1A1, led to upregulation 
of COL1A1.
Conclusions: These results show that homocysteine induces collagen I expression 
by downregulating histone methyltransferase G9a and provide a novel mechanism on 
explaining how HHcy promotes ECM production.
Funding: Government Support - Non-U.S.
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The Podocyte Adhesome Exhibits Matrix Ligand Specificity with 
Implications for Glomerular Disease  Michael J. Randles,1,2 Roy Zent,3 Martin 
J. Humphries,1 Rachel Lennon.1,2  1Wellcome Trust Centre for Cell-Matrix 
Research, Faculty of Life Sciences, Univ of Manchester, Manchester, United 
Kingdom; 2Inst of Human Development, Faculty of Medical & Human Sciences, 
Univ of Manchester, Manchester, United Kingdom; 3Dept of Medicine, Vanderbilt 
Univ Medical Center, Nashville, TN.
Background: Adhesion at both thepodocyte slit diaphragm and podocyte-extracellular 
matrix (ECM) interface is essential glomerular filtration barrier integrity. These structures 
converge onto many of the same signalling pathways, including those controlling the actin 
cytoskeleton. Podocytes adhere to laminin-521 in the glomerular basement membrane via 
integrin α3β1 and evidence suggests that attachment to collagen IV is upregulated in disease 
states. Whether changes in ECM ligand alter podocyte adhesion signalling remains unclear.
Methods: We analysed podocyte morphology following engagement of either 
laminin-521 or type IV collagen (α1α1α2) and isolated basolateral adhesion complexes for 
analysis by mass spectrometry (MS). To isolate nephrin-nephrin complexes for analysis by 
MS we generated nephrin-FLAG podocyte and recombinant nephrin.
Results: Human podocytes cultured on type IV collagen spread rapidly in an 
unpolarised manner forming radial actin stress fibres. By comparison, elongated cells 
with multiple lamellipodia and filopodia-like projections were formed on laminin 521. 
These cell phenotypes were enhanced with overexpression of the key slit diaphragm 
protein nephrin. The composition of isolated adhesion complexes was determined by 
ECM ligand and nephrin expression status. MS and protein interaction network mapping 
highlighted PKCα as a key signalling node in laminin adhesion complexes. Analysis of 
nephrin-nephrin complexes highlighted significant overlap with ECM adhesion signalling 
suggesting crosstalk mechanisms.
Conclusions: In human podocytes we discovered that both ECM ligand and 
overexpression of nephrin influences morphology, adhesion complex composition and 
intracellular signalling. Enhanced understanding about the pathways that control podocyte 
adhesion may ultimately inform therapeutic strategies to correct or repair glomerular 
barrier function.
Funding: Private Foundation Support
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Low-Density Lipoprotein Receptor-Related Protein 5 Drives 
Tubulointerstitial Fibrosis via Regulation of TGF-β Signaling  Xuemin He, 
Rui Cheng, Jian-xing Ma.  Dept of Physiology, Univ of Oklahoma Health 
Sciences Center, Oklahoma City, OK.
Background: Low-density lipoprotein receptor-related protein 5 (LRP5), a co-receptor 
of the canonical Wnt/β-catenin pathway, was recently reported to drive idiopathic pulmonary 
fibrosis through activating β-catenin. In this study, we examined the potential role of LRP5 
in the regulation of TGF-β signaling in tubulointerstitial fibrosis.
Methods: LRP5-deficient (Lrp5-/-) mice and age-matched wild-type (WT) mice 
were subjected to unilateral ureteral obstruction (UUO). Renal expressionfibrotic factors, 
including α-SMA, CTGF, collagens and fibronectin, was quantified by picro-sirius red 
staining, western blot analysis and immunostaining. Primary tubular epithelial cells 
(PTECs) were cultured from Lrp5-/- mice and WT mice. Co-Immunoprecipitation was 
performed in a human proximal tubular epithelial cell line (HKC-8) over-expressing LRP5 
and TGF-β receptors.
Results: Lrp5-/-mice with UUO showed ameliorated renal fibrosis and alleviated TGF-β 
signaling compared with WT mice with UUO. However, activation of the Wnt/β-catenin 
signaling was not different between Lrp5-/- mice and WT mice, indicating that attenuated 
tubulointerstitial fibrosis in Lrp5-/- mice was not due to mitigated activation of the fibrotic 
Wnt/β-catenin pathway. Instead, LRP5-/-/UUO kidneys displayed alleviated TGF-β signaling 
in comparison to that in WT/UUO kidneys. Overexpression of LRP5 in HKC-8 resulted in 
enhanced TGF-β signaling including enhanced TGF-β-driven transcriptional activity and 
elevated expression of fibrosis markers regulated by TGF-β signaling. Knock-down of LRP5 
in HKC-8 cells diminished the activation of the TGF-β signaling pathway. Meanwhile, 
LRP5-/- PTECs also displayed attenuated activation of the TGF-β signaling, compared to 
WT PTECs. In addition, immunoprecipitation assay demonstrated physical association 
between LRP5 and TGF-β receptor I, suggesting that LRP5 might act as a co-receptor 
of the TGF-β signaling pathway in the regulation of tubulointerstitial fibrogenic process.
Conclusions: LRP5 promotes tubulointerstitial fibrosis via regulation of the TGF-β 
signaling. This activity is independent of its role in the Wnt/β-catenin pathway.
Funding: Other NIH Support - GM104934
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Loss of Endothelial Nitric Oxide Augments Smad3 Linker Phosphorylation 
and Precedes Insulin Resistance in High-Fat Diet Induced Obesity 
Yu bo yang Sun, Xinli Qu, Jinhua Li.  Anatomy and Developmental Biology, 
Monash Univ, Melbourne, Victoria, Australia.
Background: Deficiency of endothelial nitric oxide synthase (NOS3/eNOS) confers 
susceptibility to diet-induced obesity and it’s complications. eNOS-derived nitric 
oxide (NO) acts as a potent vasodilator, enhances insulin sensitivity and also inhibits 
inflammation. TGF-β/Smad signaling plays an important role in regulating glucose and 
energy homeostasis. Smad3 deficient mice are protected from diet-induced obesity and 
obesity-related kidney injury. This study investigated whether the loss of endothelial-
derived NO promotes Smad3 activation, which precedes insulin resistance in high-fat diet 
(HFD) induced obesity.
Methods: C57B6L/J wild type, eNOS deficient (eNOS-/-) with C57B6L/J background 
mice were given HFD or normal diet (ND) treatment for 1, 3, 7 days and 4, 8 or 16 weeks.
Results: Within 7 days of HFD treatment in WT mice, Western blotting showed a 
marked decrease in total eNOS level. Phosphorylation of Smad3 linker region was only 
seen 4 weeks after HFD treatment, indicating endothelial injury precedes phosphorylation 
of Smad3 linker region. Compared to WT mice, eNOS-/- mice on HFD showed early onset 
of peripheral and renal insulin resistance, increased microalbuminuria, elevated blood 
pressure, which suggested that endothelial injury drives renal metabolic disorders induced 
by HFD. Confocal microcopy demonstrated that fibronectin and collagen IV significantly 
increased in glomeruli in the HFD-treated eNOS-/- group compared to that in HFD-treated 
WT group. An in vitro model, palmitate acid addition to culture endothelial cells induced 
rapid C-terminal phosphorylation of Smad3, subsequent loss of eNOS, phosphorylation of 
Smad3 linker region and insulin resistance. L-NAME, a specific NOS inhibitor, significantly 
increased phosphorylation of Smad3 linker region and insulin resistance. Finally, endothelial 
cell overexpressing eNOS significantly inhibited Smad3 linker region phosphorylation and 
protected insulin sensitivity.
Conclusions: In summary, our studies showed that eNOS and Smad3 signaling pathway 
play essential roles in HFD-induced renal injury. eNOS/Smad3 pathway may be a novel 
therapeutic target in obesity-related kidney disease.
Funding: Government Support - Non-U.S.
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HIF1α and HIF2α Both Mediate Glomerulosclerosis but Differentially 
Regulate the COL1A2 Promoter  Bethany Baumann, Tomoko Hayashida, 
Xiaoyan Liang, H. William Schnaper.  Northwestern Univ, Chicago, IL.
Background: TGFβ increases HIF1α and HIF2α levels in normoxia and both HIFs 
contribute to TGFβ induction of type I collagen in vitro, suggesting a potential role for 
HIFs in renal disease regardless of oxygen tension. Here, we studied the role of HIFs in 
mouse glomerulosclerosis (GS).
Methods: HIF1af/f or f/+, bactin-Cre-ERT2, NEP25 mice express human Tac on 
podocytes. LMB2, a toxin/anti-Tac chimera, binds to Tac, ablating podocytes to cause 
GS. Systemic Cre recombination was induced by tamoxifen at 4 weeks of age and LMB2 
injected at 9 weeks. Mice were sacrificed 4 weeks later. HIF2af/f or f/+ mice were generated 
on a 129 background and bred with PDGFRβ-Cre mice to delete HIF2α from pericytes and 
mesangial cells. GS was induced by Adriamycin injection at 8 weeks of age. Mice were 
sacrificed 2 weeks later. Disease progression was analyzed by histology, scoring 50-100 
glomeruli/animal on a fibrosis scale of 0-4, and by qPCR for COL1A2 mRNA with laser-
captured glomeruli. In vitro studies investigating a mechanism by which HIFs regulate 
COL1A2 promoter were also performed.
Results: HIF1α: Histologically, control mice scored 0.46 (+/- 0.12), diseased WT mice 
3.13 (+/- 0.19), and diseased HIF1α KO mice 1.42 (+/- 0.28). Glomerular COL1A2 mRNA 
with LMB2 injection was increased 3.4x over the healthy controls in WT, but only 1.9x 
with HIF1α KO. In vitro, TGFβ induced COL1A2 promoter activity by 2.4x, which was 
abrogated when a hypoxia response element (HRE) 335 bp 5’ to the transcription start site 
was mutated. By DNA precipitation assay, HIF1a binding to a -335 COL1A2 HRE probe 
was detected after TGFβ treatment. Interestingly, Smad3 also bound the -335 COL1A2 HRE 
probe in both TGFβ-treated cell lysate and whole kidney lysate from WT HIF1α NEP25 
mice with GS. HIF2α: HIF2af/f PDGFRβ-Cre mice showed less GS than HIF2α+/+ mice by 
histology. In vitro, HIF2α enhanced COL1A2 promoter activity independently of the -335 
HRE. Instead, HIF2α increased the transcriptional activity of Smad3.
Conclusions: Both HIF1α and -2α contribute to the development of GS in mice. 
Our in vitro studies strongly suggest that HIF1α and -2α each enhance TGFβ-mediated 
fibrogenesis, but through distinct mechanisms.
Funding: NIDDK Support
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MiR302a-3p Modulates Renal Epithelial-Mesenchymal Transition in 
DKD by Targeting ZEB1  Wenbin Tang, Linfeng Zheng, Renheng Yan, Jiayi 
Yang, Linlin Peng, Qiaoling Zhou, Liping Chen.  Dept of Nephrology, Xiangya 
Hospital, Central South Univ, Kidney Inst, Changsha, Hunan, China.
Background: Recent study found that miRNAs are involved in diabetic kidney disease 
(DKD). The objective of this study is to determine the role of miR302a-3p in the process 
of renal epithelial-mesenchymal transition (EMT) in DKD.
Methods: The levels of miR302a-3p in the plasma of DKD patients were detected 
by realtime PCR and the relationship of miR302a-3p and UAE or eGFR were analyzed. 
Secondly, miR302a-3p expression was determined in HK-2 cells treated with high glucose 
for different time. And then miR302a-3p mimics and inhibitor were transfected to HK-2 
cells following exposure to high glucose and low glucose respectively. The expressions of 
ZO-1, vimentin and ZEB-1 were determined by realtime PCR and western blot.
Results: The expression of circulating miR-302a-3p was significantly increased in the 
diabetes mellitus group (DM,n=22) compared with control (healthy persons, n=30) and then 
decreased in the early stage of diabetic nephropathy group (DNE, n=20). Furthermore, its 
expression in clinical diabetic nephropathy group (DNC, n=18) was decreased significantly 
compared with DM group. Circulating miR-302a-3p had negative relevance with UAE 
in DNE group(r=-0.649, P=0.002) and DNC group(r=-0.681, P=0.006); It had positive 
relevance with eGFR in DNC group(r=0.486,P= 0.041). In vitro, miR-302a-3p expression 
in HG group increased at 6h and aescended to the highest level at 12h and then gradually 
decreased at 48h and 72h. More interesting, ZEB1 protein expression had an opposite 
change which gradually decreased from 6h to 24h and then gradually increased from 48h 
to 72h. Moreover, overexpression of miR-302a-3p suppressed expression of ZEB1 in the 
post-transcriptional level and reversed high glucose-mediated downregulation of E-cadherin 
and upregulation of vimentin. Meanwhile, loss of miR-302a-3p expression can lead to EMT 
of HK-2 cells just as high glucose stimulation.
Conclusions: miR-302a-3p may play a protective role by targeting ZEB1 in renal 
epithelial- mesenchymal transition in DKD. It may serve as a potential novel target in 
pre-EMT states for the amelioration renal fibrosis seen in DKD.
Funding: Other NIH Support - National Natural Science Funds of China (Grant 
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Kruppel-Like Factor 15 Works as an Early Anti-Fibrotic Transcriptional 
Regulator in Angiotensin II-Induced Renal Fibrosis via Down-Regulation 
of Connective Tissue Growth Factor  Xiangchen Gu,1 Xiang Gao,1 Changlin 
Mei.1  1Kidney Inst of PLA, Dept of Medicine, Changzheng Hospital, Second 
Military Medical Univ, Shanghai, China; 2Kidney Inst of PLA, Dept of Medicine, 
Changzheng Hospital, Second Military Medical Univ, Shanghai, China; 3Kidney 
Inst of PLA, Dept of Medicine, Changzheng Hospital, Second Military Medical 
Univ, Shanghai, China.
Background: Angiotensin II (Ang II) has been regarded as an important profibrogenic 
cytokine in renal fibrosis. One of the main targets of Ang II in renal fibrosis is CTGF. 
Krüppel-like factor 15 (KLF15) is recognized as an important negative transcription factor 
in renal fibrosis. This study is aimed to detect the possible role and mechanism of KLF15 
in renal fibrosis induced by Ang II.
Methods: Firstly, mice were randomized into control group, Ang II group, Ang 
II+losartan group, the renal fibrosis levels and KLF15 were measured by Real-Time PCR 
and IMF methods respectively at 4 weeks or 6 weeks. Then NRK-49F were stimulated 
with Ang II and (or) infected with Ad-GFP-KLF15, and the expressions of KLF15, CTGF 
and extracellular matrix were detected by Real-Time PCR and Western Blot. CoIP and 
ChIP assay were also performed to investigate the relationship among coactivator P/CAF, 
transcription regulator KLF15, and CTGF promoter.
Results: The murine model of Ang II-induced renal fibrosis demonstrated a significant 
decrease in renal KLF15 expression at 4 weeks and progressive renal fibrosis at 6 weeks. 
Losartan effectively prevented the decrease in KLF15 expressions induced by Angiotensin 
II. Stimulated with Ang II, NRK-49F exhibited significant decreases in KLF15, accompanied 
by a marked increase in CTGF and extracellular matrix. Losartan prevented the decrease in 
Ang II induced KLF15. Furthermore, overexpression of KLF15 inhibited Ang II induced 
CTGF in NRK-49F. CoIP and ChIP demonstrated KLF15, could directly bind to P/CAF, 
and repressed its recruitment to CTGF promoter.
Conclusions: These results unveiled that Ang II could downregulate KLF15 via AT1 
receptor. Transcription repressor KLF15 is likely to inhibit Ang II induced CTGF by 
repressing coactivator P/CAF’s recruitment to CTGF promoter.
Funding: Government Support - Non-U.S.
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Biomarkers of Collagen Type III and VI Turnover Can Identify Renal 
Allograft Failure in Kidney Transplant Recipients  Federica Genovese,1 
Signe Holm Nielsen,1,2 Daniel Guldager Kring Rasmussen,1,3 Morten Asser 
Karsdal,1 Stephan J.L. Bakker,4 Peter Olinga,4 Elisabeth G.D. Stribos,4 Henricus 
A.M. Mutsaers.4  1Fibrosis Biology and Biomarkers, Nordic Bioscience, Herlev, 
Denmark; 2System Biology, Denmark Technology Univ, Kgs. Lyngby, Denmark; 
3Southern Denmark Univ, Odense, Denmark; 4Univ of Groningen, Groningen, 
Netherlands.
Background: Chronic allograft loss poses a major problem in improving long-term 
survival in renal transplant recipients (RTR). Interstitial fibrosis and tubular atrophy are 
already present in 40% of kidney allografts 3-6 months after transplantation. Extracellular 
matrix (ECM) turnover levels, reflecting the onset of fibrosis, can be early and superior 
prognostic markers for renal allograft function. We evaluated a non-invasive tool measuring 
the plasma and urinary biomarker profile related to ECM turnover.
Methods: 78 patients attending the University Medical Center Groningen during one 
week for a routine check-up after kidney transplantation were enrolled in the study. Plasma 
and/or 24h-urine samples were collected from 75 and 42 RTR, respectively. Afterwards, 
markers of collagen remodeling were determined by competitive ELISAs.
Results: There was no correlation between age or time after transplant and glomerular 
filtration rate (eGFR) in this population. Urinary levels of C3M, a marker for collagen 
type III degradation, were strongly correlated with eGFR (p<0.0001), with lower levels 
in advanced disease stages compared to early and mild stages. Plasma levels of Pro-C6, a 
marker for collagen type VI formation, significantly increased with disease progression and 
strongly correlated with eGFR (p<0.0001). In contrast, plasma C3M and urinary Pro-C6 
levels showed no correlation with renal function.
Conclusions: We identified two biomarkers of tissue turnover associated with ECM 
remodeling and subsequent fibrosis in the transplanted kidney leading to loss of renal 
function. As such they have great potential as early diagnostic markers for kidney allograft 
failure.
FR-PO290
Hyaluronidase-2 Dependent Regulation of CD44 Variant Expression in 
Anti-fibrotic versus Pro-Fibrotic Cells  Soma Meran, Adam Midgley, Robert 
Steadman, Aled O. Phillips.  Nephrology, Cardiff Univ, Cardiff, United Kingdom.
Background: Hyaluronan (HA) is a GAG with increased expression in progressive 
renal disease, and its expression correlates with poor renal outcomes. The HA receptor 
(CD44) is a transmembrane protein that can undergo alternative exon splicing to produce 
over 20 CD44 variant isoforms. We identified that the standard isoform (CD44s) is critical 
for myofibroblast formation, whereas the variant isoform (CD44v7/8) promotes reversal of 
myofibroblast phenotype. Hyaluronidase-(Hyal)2 is a weak HA degrading enzyme and is a 
key mediator in reversal of myofibroblast phenotype, but its mechanism is unknown. Here 
we investigate whether Hyal2 plays a regulatory role in alternative splicing of CD44v7/8 
variant isoform expression.
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Methods: Fibroblasts & renal epithelial cells were incubated with TGFb1 to induce 
myofibroblast formation, and compared to cells incubated with TGFb1 & BMP7 to 
induce myofibroblast reversal. QPCR, confocal microscopy, ChIP, siRNA & plasmid 
overexpression were used to assess Hyal2 effects.
Results: Hyal2 was upregulated by both profibrotic (TGFb1) & anti-fibrotic (BMP7) 
cellular treatments. However in profibrotic cells, Hyal2 was cytoplasmic, whereas in 
antifibrotic cells Hyal2 translocated to the nucleus. In profibrotic cells Hyal2 did not 
associate with CD44. In contrast in antifibrotic cells Hyal2 associated with CD44s at the 
nucleus, whilst CD44v7/8 located to the cell surface. In antifibrotic cells Hyal2 nuclear 
translocation was crucial for increased CD44v7/8 mRNA & protein expression. CD44v7/8 
was subsequently necessary for HA internalization and consequent reversal of myofibroblast 
phenotype. ChIP demonstrated association between Hyal2 and introns flanking the 
CD44v7/8 exon nucleotide sequence similar to Ago2 splice facilitator. Moreover, Hyal2 
inhibition attenuated BMP7 driven upregulation of splice regulators SLM2 & SRSF6.
Conclusions: Hyal2 displays nonenzymatic activity & translocates to the nucleus 
regulating expression of CD44v7/8 splice variant, which is crucial for reversing 
myofibroblast phenotype. Hence Hyal2 is a novel splice regulator and a critical regulator 
in reversal of myofibroblast phenotype & fibrosis prevention.
FR-PO291
FGF Signaling Contributes to Podocyte Injury in Murine HIV-Associated 
Nephropathy  Koji Okamoto,1 Eisei Noiri,2 Jeffrey B. Kopp.1  1Kidney 
Section, NIDDK, NIH, Bethesda, MD; 2Dept of Nephrology, Endocrinology, 
Hemodialysis & Apheresis, Univ Hospital, The Univ of Tokyo, Tokyo, Japan.
Background: We reported that fibroblast growth factor receptor (FGFR), its ligand 
fibroblast growth factor 2 (FGF2), and their amplifying co-factor glypican 5 (GPC5) play 
important roles in idiopathic nephrotic syndrome and diabetic nephropathy (Okamoto, 
Nature Genetics, 2011). We have investigated the role of the FGF2 signal pathway in 
HIV-associated nephropathy (HIVAN).
Methods: FGF2 ligands and FGFR expression were studied in a mouse podocyte cell 
line and a HVAN transgenic mouse, both of which express the HIV accessory protein Vpr in 
the presence of doxycycline. To study FGF2 trapping in glomeruli, biotinylated FGF2 was 
administered intravenously and detected with fluorescent streptavidin. Vpr mice and control 
mice received FGF2 (5 mg/animal/weekly for 4 weeks) or FGF antagonist (PD173074, 
50mg/animal/ bi-weekly for 4 weeks.
Results: In cultured mouse podocytes FGFR3 mRNA was increased 11-fold after 
Vpr induction. In Vpr mice compared with control mice, renal cortex FGF2 content was 
increased 3-fold, as assessed by ELISA. Intra-glomerular protein expression of FGFR3 
and GPC5 were increased, as detected by immunofluorescent staining. These results 
suggest that Vpr mouse glomeruli might have increased FGF2 binding capacity and so we 
tested the binding capacity of FGF2 in vivo. One hour after intravenous administration 
of biotinylated FGF2, more biotin signal remained in glomeruli of Vpr mice compared 
with control mice (60% increase). Urine albumin/creatinine ratios (g/g) were significantly 
increased in FGF2-treated Vpr mice compared to untreated Vpr mice on day 14 (0.55±0.19 
vs 2.3±0.6), day 21 (1.17±0.16 vs 18.7±5.1) and day 28 (1.87±0.44 vs 21.8±9.9). Further, 
the FGF antagonist decreased albuminuria in Vpr mice at day 21 (0.47±0.16 vs 1.1.7±0.16 
g/g) and at day 28 (0.36±0.41 vs 1.87±0.44 g/g).
Conclusions: In a HIVAN mouse model, podocyte Vpr expression increased protein 
expression of FGF2, FGF receptors and GPC5. Administration of FGF2 increased 
albuminuria, and treatment with an FGF antagonist reduced albuminuria, suggesting a 
pathogenic role for FGF2 in this murine HIVAN model.
FR-PO292
Role of AMP-Activated Protein Kinase Signaling in Fibroblast Activation 
and Renal Fibrosis  Yuguo Wang, Yanlin Wang.  Medicine, Baylor College of 
Medicine, Houston, TX.
Background: Renal fibrosis is a common manifestation of chronic kidney disease 
resulting in progressive loss of kidney function. Although activated fibroblasts are 
responsible for the production and deposition of the extracellular matrix, the molecular 
mechanisms underlying fibroblast activation are not fully understood. In this study, we 
examined the functional role of AMP-activated protein kinase a1 (AMPKa1) in the activated 
of fibroblasts and the development of renal fibrosis.
Methods: To examine the functional role of AMPKa1, we generated mice with 
fibroblast-specific deletion of AMPKa1 using Cre-LoxP strategy. Unilateral ureteral 
obstruction (UUO) and ischemia-reperfusion injury (IRI) models were used to induce renal 
fibrosis. Cultured cells were used to examine AMPKa1 signaling in fibroblast activation.
Results: AMPKa1 is induced in the kidney during the development of renal fibrosis. 
Mice with mesenchymal-specific deletion of AMPKa1 were born normal and had no 
obvious morphological abnormality in the kidney. Compared with Cre negative, floxed 
AMPKa1 mice, mice with fibroblast-specific deletion of AMPKa1 exhibited fewer α-smooth 
muscle actin (α-SMA) positive myofibroblasts and expressed less α-SMA protein in the 
kidney following UUO or IRI. Furthermore, mesenchymal-specific deletion of AMPKa1 
significantly reduced total collagen deposition and suppressed expression of extracellular 
matrix proteins (collagen I and fibronectin) in the kidney in response to UUO or IRI. In 
cultured fibroblasts, activation of AMPKa1 caused cofilin phosphorylation, cytoskeleton 
remodeling, and myocardin-related transcription factor A (MRTF-A) nuclear translocation 
leading to fibroblast activation and extracellular matrix protein production.
Conclusions: Our results have shown that AMPKa1 is critically involved in fibroblast 
activation through regulation of cytoskeleton dynamics and MRTF-A nuclear translocation. 
Therefore, AMPKa1 may represent a novel therapeutic target for chronic kidney disease.
Funding: NIDDK Support
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Increased Expression of Complement C1 from Pericyte/Myofibroblasts 
Contributes to Renal Fibrosis via Activation of Wnt/β Catenin Signaling 
Sandhya Xavier,1 Susan G. Landes,1 Amandeep Bajwa,1 Jing Yu,2 Jeremy 
Stuart Duffield,3 Didier Portilla.1  1Dept of Medicine and Center for Immunity, 
Inflammation and Regenerative Medicine, Univ of 9irginia, 9A; 2Univ of 
Virginia; 3Biogen Idec.
Background: Pericytes/fibroblasts are progenitors of scar-forming cells known as 
myofibroblasts. We have characterized the inflammatory nature of pericytes/fibroblasts 
isolated from UUO mice. We have also shown that Wnt/β-catenin signaling is activated 
during kidney fibrosis. Role of complement C1 on pericyte function or in Wnt activation 
remains unknown.
Methods: We used the unilateral ureteral obstruction (UUO) and folic acid nephropathy 
models. Pericytes were isolated using magnetic beads containing anti-PDGFβ Receptor 
ab. Expression of C1 complex was examined by western blotting, immunofluorescence, 
and realtime-PCR in tissue and in cell lysates and supernatants obtained from pericytes 
cultured from sham, day3 and day10 UUO mice kidneys. Topflash reporter assays were 
used to study Wnt signaling.
Results: Expression of C1q chains a,b,c, as well as subunits C1r and C1s were increased 
during fibrosis along with increased expression of TGF-β, α-SMA and Wnt target genes 
wisp1 and 2. Immunostain showed C1q localization in the interstitial compartment of UUO 
but not in sham mice consistent with PCR and western blot data. In cultured pericytes, C1 
complex component C1q protein was increased in culture supernatants of Day3 and Day10 
but not in shams. Expression of C1q proteins was absent in supernatants of UUO pericytes 
isolated from C1qKO mice. Topflash reporter assays for Wnt signaling showed that pericytes 
from UUO kidneys had pronounced activation of the reporter following Wnt3a treatment 
as compared to shams, and this effect was blunted in pericytes isolated from C1qKO mice.
Conclusions: We demonstrate both in vivo and in vitro that increased expression of 
the C1 complex occurs in response to kidney injury along with activation of Wnt signaling. 
Given previous data, showing that inhibition of C1 complex using C1INH prevents renal 
fibrosis, we conclude that its inhibition in pericytes/myofibroblasts leads to inhibition of 
Wnt activation and reduced renal fibrosis.
Funding: NIDDK Support, Veterans Administration Support
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The Role and Association of Inflammatory and Apoptotic Caspases in 
Tubulointerstitial Fibrosis  Chun Zhang, You Ke, Hua Su.  Nephrology, 
Huazhong Univ of Science and Technology, Wuhan, Hubei, China.
Background: Caspases are a family of cysteine proteases with pivotal functions in 
apoptotic and inflammatory signaling. According to their difference of structures and 
functions, 14 mammalian Caspases are classified into three categories, which are apoptosis 
activator, apoptosis executioner and inflammatory mediator. Caspase-1 is an inflammatory 
caspase, and Caspase-7 belongs to apoptosis executioner. The roles and association of 
these two distinct types of Caspases protein in tubulointerstitial fibrosis (TIF) are not 
well recognized.
Methods: Unilateral Ureteral Obstruction (UUO) animal model was constructed on 
wild-type(WT) and caspase-1 knock out (KO) mice. In vitro study, the cultured tubular 
epithelial cell line NRK-52E (TECs) was employed and the expression of caspase-1 and 
caspase-7 was modulated by transfection of Lentiviral shRNA.
Results: In current study, we found both Caspase-1 and Caspase-7 protein levels 
were elevated in UUO WT mice. While in UUO mice with Caspase-1 KO background the 
increased Caspase-7 was suppressed significantly along with the minimized extracellular 
matrix accumulation which was demonstrated by western blot, immunohistochemistry 
and Masson trichrome staining. In vitro TGF-β1 stimulation promoted the expression 
of Caspase-1 and Caspase-7 simultaneously in TECs. Notably, genetic deletion of either 
Caspase-1 or Caspase-7 could abrogate TGF-β1 driven TECs’ transdifferentition and 
apoptosis. In addition, knocking down Caspase-1 dampened Caspase-7 upregulation in 
TGF-β1 treated TECs which was consistent with in vivo study. However genetic deletion 
of Caspase-7 did not influence Caspase-1’s abundance.
Conclusions: Our observation firstly links inflammatory and apoptotic Caspases 
together in TIF and further elucidates Caspase-1 activation is an upstream event of apoptotic 
Caspase-7 induction during TIF and TECs’ transdifferentition and apoptosis.
Funding: Government Support - Non-U.S.
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MAD2B-SnoN-Smad3 Signaling Pathway Is Implicated in Fibroblast 
Activation and Tubulointerstitial Fibrosis  Chun Zhang, Hui Tang, Hua Su. 
Nephrology, Huazhong Univ of Science and Technology, Wuhan, Hubei, China.
Background: Mitotic arrest deficient protein MAD2B, an anaphase-promoting complex 
(APC)/cyclosome inhibitor, is indispensible for mitotic checkpoint control. Previously we 
found MAD2B was expressed in glomerular and tubulointerstitial compartment. In addition 
our data indicated MAD2B was involved in podocyte injury triggered by high glucose. But 
its role in renal fibrosis remains elusive.
Methods: The object of this study included patients with renal tubulointerstitial fibrosis 
(TIF) (secondary glomerulonephritis and interstitial nephritis were excluded) , Unilateral 
Ureteral Obstruction(UUO) mice and in vitro cultured tubular epithelial cell line (NRK-52E) 
and renal fibroblast cell line (NRK-49F). In vivo gene silencing of MAD2B was carried 
out by intrarenal Lentiviral gene delivery.
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Results: By immunohistochemistry and western blot, it showed the expression of 
MAD2B was increased obviously in TIF patients and UUO mice. Next we assessed the 
types of cells attributing to the elevated MAD2B abundance. It is well-known that TECs 
and fibroblast are the main culprits in TIF. Our data suggested under TGF-β1 exposure 
the level of MAD2B in NRK-52E was not altered, whereas in NRK-49F MAD2B was 
upregulated in a time dependent manner significantly. Furthermore TGF-β1 induced 
fibroblast activation can be abrogated by MAD2B genetic deletion. Intriguingly, SnoN, a 
repressor of Smad3, was decreased in NRK-49F cells treated with TGF-β1 which could 
be alleviated by MAD2B knocking down. Consistently, in UUO mice the expression of 
SnoN was significantly reduced in renal cortex accompanying with enhanced p-Smad3. And 
locally genetic deletion of MAD2B by Lentiviral transfection preserved SnoN abundance 
and consequently suppressed Smad3 signaling which finally dampened the fibroblast 
activation and ECM accumulation in UUO mice.
Conclusions: Our observation proposes that MAD2B participates in fibroblast 
activation and tubulointerstitial fibrosis by repressing SnoN and subsequent activating 
Smad3 signaling pathway. Regulation of MAD2B-SnoN pathway may be a promising 
therapy for tubulointerstitial fibrosis. However, the regulatory mechanisms between MAD2B 
and SnoN still need further investigation.
Funding: Government Support - Non-U.S.
FR-PO296
Losartan Reduces Renal Fibrogenesis by Up-Regulating Klotho in Uremic 
Rats  Edgar Maquigussa, Josne Carla Paterno, Gabriel H. Pokorny, Mariana S. 
Perez, Nestor Schor, Mirian A. Boim.  Nephrology, UNIFESP, Sao Paulo, Brazil.
Background: Klotho is a transmembrane protein expresses mainly in the kidney. 
Soluble klotho acts as an endocrine factor with diverse functions through mechanisms 
involving Wnt and TGFb1 signaling. Renal fibrosis is the end stage of the progressive 
chronic kidney disease (CKD) and renal klotho is markedly decreased in CKD patients. 
Renin angiotensin system (RAS) blockade is a relevant therapy to reduce CKD progression 
and the beneficial effects go further to the antihypertensive effect. The aim of this study was 
to investigate a possible link between RAS and Klotho by evaluating the effects of losartan 
on Klotho/Wnt signaling in 5/6 nephrectomy model of CKD in rats.
Methods: Adult male Wistar rats were underwent 5/6 nephrectomy (Nx). The Nx 
animals were separated into three groups: control, with no treatment (Nx), treated with 
losartan (LOS; 25 mg/kg/day, p.o.) or propranolol (PROP; 25mg/kg/day, p.o.). Results were 
compared with SHAM group. Blood pressure was measured by tail-cuff plethysmography. 
After 8 weeks, animals were sacrificed and the remmnant kidney was removed to determine 
the renal expression of collagen, fibronectin, epithelial-to-mesenchymal transition (EMT) 
markers (FSP1 and a-SMA) and Klotho signaling (Klotho, Wnts and GSK3β) by real 
time PCR.
Results: Nx rats presented hypertension that was blunted by both losartan and 
propranolol. The expression levels of collagen and fibronectin were increased in Nx group 
which was reverted only in LOS group. The presence of the EMT markers, FSP1 and 
a-SMA , was observed in Nx group which was decreased with losartan treatment. Klotho 
was reduced in Nx animals and LOS but not propranolol significantly increased klotho 
expression. Nx animals showed uperegulation of GSK3β, Wnt 7a and Wnt 3. LOS treatment 
prevented the increase in Wnt 7a and GSK3β but not Wnt 3.
Conclusions: These data suggest that the beneficial effect of losartan on renal fibrosis 
is independente of blood pressure reduction and may be, at least in part, due to upregulation 
of klotho. Since, the antihypertensive agent, propranolol induced no change in klotho 
expression. The interation between the RAS and Klotho can inactivacte the Wnt pahtway.
Funding: Government Support - Non-U.S.
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PBI-4050 Inhibits the Development of Renal Fibrosis in a Model of 
Tubulointerstitial Fibrosis  Ming-Zhi Zhang,1 Lyne Gagnon,2 Raymond C. 
Harris.1  1Medicine, Vanderbilt Univ, Nashville, TN; 2ProMetic Biosciences, 
Laval, QC, Canada.
Background: Kidney fibrosis occurs in chronic kidney diseases and leads to gradual 
loss of kidney function. Although the etiology of kidney fibrosis is multifactorial, there is 
increasing evidence linking chronic inflammation to kidney fibrosis. PBI-4050, a novel 
first-in-class orally active low molecular weight compound currently in phase II clinical 
trials, has anti-fibrotic and anti-inflammatory properties in different in vivo models. 
Activation of epidermal growth factor receptor (EGFR) contributes to the development of 
renal fibrosis, and homozygous transgenic mice with overexpression of an EGFR ligand, 
human heparin-binding EGF (HB-EGF), in renal proximal tubule develop spontaneous 
tubulointerstitial fibrosis by 3-4 weeks of age. We examined whether PBI-4050 affected 
the development of renal fibrosis in homozygous HB-EGF mice.
Methods: Homozygous HB-EGF mice on a C57/BL6 background were treated with 
PBI-4050 (200 mg/kg/day) by daily gastric gavage from 4 to 14 weeks of age.
Results: Immunohistochemical analysis showed that in untreated homozygous HB-EGF 
mouse kidney, ERK was activated in both proximal tubule epithelial cells (PTEC) and their 
surrounding interstitial cells. PBI-4050 treatment led to marked decreases in ERK activity 
in proximal tubule epithelial cells and interstitial cells, suggesting that PBI-4050 inhibits 
not only HB-EGF/EGFR-mediated p-ERK activation in PTEC, but also subsequent ERK 
activation in the interstitial cells, leading to inhibition of the development of renal fibrosis. 
PBI-4050 treatment significantly reduced the development of renal interstitial fibrosis. PBI-
4050 caused marked decreases in renal macrophage infiltration (F4/80 staining) as well 
as oxidative stress (nitrotyrosine staining). In addition, PBI-4050 treatment reduced the 
expression levels of the pro-fibrotic and fibrotic components including CTGF and TGF-β, 
α-SMA (a marker of myofibroblasts), fibronectin, collagen I and collagen IV.
Conclusions: These studies suggest that PBI-4050 significantly inhibits the 
development of renal fibrosis in homozygous HB-EGF mice through multiple mechanisms, 
including through anti-inflammatory effects.
Funding: NIDDK Support, Pharmaceutical Company Support - ProMetic Biosciences
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FHL2 Promotes Tubular Epithelial-to-Mesenchymal Transition by 
Regulating β-Catenin Activity  Ting Cai, Danqin Sun, Chunsun Dai, Junwei 
Yang, Weichun He.  Center for Kidney Disease, nd Affiliated Hospital of 
Nanjing Medical Univ, Nanjing, Jiangsu, China.
Background: Fibrotic kidneys exhibit aberrant activation of β-catenin signaling, one of 
the main pathways that play a critical role in mediating tubular epithelial-to-mesenchymal 
transition (EMT). FHL2 (four-and-a-half-LIM-only protein 2), an adapter protein, is an 
endogenous regulator of β-catenin.
Methods: To determine whether FHL2 is also involved in the EMT process, we 
investigated its regulation and function during TGF-β1-stimulated EMT.
Results: TGF-β1 induced FHL2 mRNA and protein expression in rat proximal tubular 
epithelial cells (NRK-52E) in a time- or dose- dependent fashion, an effect that was largely 
dependent on intracellular Smad signaling. Overexpression of FHL2 suppressed E-cadherin, 
increased α-smooth muscle actin (α-SMA), vimentin and fibronectin expression, whereas 
knockdown of FHL2 via small interfering RNA partially reduced TGF-β1-mediated 
α-SMA, vimentin and fibronectin expression, and restored E-cadherin. TGF-β1 induced 
FHL2 physically interact with β-catenin in the nuclei in NRK-52E cells. Ectopic expression 
of FHL2 promoted β-catenin nuclear translocation, induced β-catenin-mediated gene 
transcription, and upregulated the expression of β-catenin target genes such as plasminogen 
activator inhibitor-1 (PAI-1) and Twist. Conversely, downregulation of FHL2 expression 
reduced β-catenin nuclear translocation, abolished β-catenin-mediated gene transcription, 
and inhibited PAI-1 and Twist expression in the basal and TGF-β1-stimulated conditions. In 
a mouse model of obstructive nephropathy, FHL2 expression increased in a time-dependent 
manner, suggesting that it may play a role in tubular EMT and renal fibrosis in vivo.
Conclusions: We conclude that FHL2, through manipulating β-catenin activity, plays 
an important role in regulating TGF-β1-mediated EMT and could be a potential future 
therapeutic target to prevent progression of renal fibrosis.
Funding: Government Support - Non-U.S.
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Depletion of Endothelial Sirtuin 1 Aggravates Capillary Rarefaction and 
Tissue Fibrosis following Kidney Injury  Yujiro Kida, Michael S. Goligorsky. 
New York Medical College.
Background: Capillry rarefaction and tissue fibrosis are hallmarks of chronic kidney 
diseases. Although recent studies point to sirtuin 1 (SIRT1) in endothelial cells as being 
protective against tissue injury, mechanisms of this effect are  incompletely understood.
Methods: We deleted SIRT1 catalytic domain in endothelial cells in mice (Sirt1 mutant 
mice). Both wild type control and Sirt1 mutant mice were subjected to kidney injury by 
unilateral ureteral obstruction (UUO). In in vitro studies, we used human umbilical vein 
endothelial cells (HUVECs).
Results: After UUO kidney injury, compared to control kidneys, Sirt1 mutant 
kidneys demonstrated significantly exaggerated (1) capillary rarefaction (2) expansion 
of myofibroblast population, and (3) tissue fibrosis compared to wild type kidneys. In 
HUVECs, siRNA knockdown or chemical inhibition of SIRT1 significantly suppressed 
transcriptional expression of platelet derived growth factor-β (PDGF-B) and vascular 
endothelial growth factor receptor-2 (VEGFR2). Both effects were partially abrogated by 
Notch inhibition. This indicates that SIRT1 enhances PDGF-B and VEGFR2 expression 
via Notch inhibition in endothelial cells. In scratch wound healing assay, SIRT1 inhibition 
impaired migration of HUVECs under oxidative stress by hydrogen peroxide, indicating 
SIRT1 dysfunction decreases migratory phenotype of endothelial cells. In transwell co-
culture assay, endothelial SIRT1 inhibition impaired recruitment of PDGFRβ+ cells to 
HUVECs. Consistent with this finding, detachment of PDGFRβ+ pericytes was increased 
in Sirt1 mutant kidneys compared to control kidneys, suggesting that pericyte detachment 
and subsequent pericyte-myofibroblast transition are augmented in Sirt1 mutant kidneys, 
resulting in excessive fibrosis.
Conclusions: Functional depletion of SIRT1 in endothelial cells aggravates capillary 
rarefaction and fibrosis at least in part due to impaired endothelial expression of VEGFR2 
and PDGF-B, respectively.
Funding: NIDDK Support
FR-PO300
In Vivo Reprogramming of Myofibroblasts with Endothelial Progenitor 
Cell Extract Ameliorates Fibrosis  Kei Matsumoto,1,2 Sandhya Xavier,1 Jun 
Chen,1 Yujiro Kida,1 Brian B. Ratliff,1 Stefan Rose-john,3 Michael S. Goligorsky.1 
1New York Medical College; 2Showa Univ, Tokyo, Japan; 3Christian-Albrechts 
Univ, Kiel, Germany.
Background: Accumulation of myofibroblasts is a hallmark of renal fibrosis. We 
hypothesized that exposing myofibroblasts to the extract of endothelial progenitor cells 
(EPC extract) could reverse endothelial-mesenchymal transition.
Methods: We used α-SMA-GFP mice to visualize fibroblast-to-myofibroblast 
conversion and embryonic mouse EPC to prepare extract. Cell phenotype was assessed 
using standard biochemical and molecular biology techniques.
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Results: In vitro treatment of TGF-β1-activated fibroblasts with EPC extract 
prevented expression of α-SMA, but did not enhance expression of endothelial markers. 
In two distinct models of renal fibrosis, unilateral ureteral obstruction (UUO) and chronic 
phase of folic acid-induced nephropathy (FAN), subcapsular injection of EPC extract to 
the kidney prevented and reversed accumulation of α-SMA-positive myofibroblasts and 
reduced fibrosis. Screening the composition of EPC extract for cytokines revealed that it is 
enriched in LIF and VEGF. Only LIF was capable of reducing fibroblast-to-myofibroblast 
transition of TGF-β1-activated fibroblasts. In vivo subcapsular administration of LIF 
reduced the number of myofibroblsts, improved the density of peritubular capillaries, 
but did not reduce the degree of fibrosis. Effects of LIF, as well as Hyper-IL-6, in the 
presence of TGF-β1 were mediated via gp130/STAT3 pathway resulting in induction of 
pluripotency transcription factors KLF4, c-Myc, OCT4, and Nanog in association with the 
open chromatin conformation.
Conclusions: EPC extract does not reverse endothelial-mesenchymal transition, 
but it prevents and reverses fibroblast-to-myofibroblast transition and renal fibrosis. The 
component of EPC extract, LIF, is capable of preventing development of the contractile 
phenotype of activated fibroblasts, but does not eliminate TGF-β1-induced collagen 
synthesis in cultured fibroblasts and models of renal fibrosis. LIF component of EPC extract 
is a participant of its antifibrotic effect, but not the sole one, as other yet undisclosed factors 
contribute to the antifibrotic effect of the extract.
Funding: NIDDK Support
FR-PO301
Mitochondrial Metabolic Switch to Glycolysis in Proximal Tubular 
Epithelial Cell in Fibrotic Kidneys  Lei Jiang, Junwei Yang.  Center for 
Kidney Disease, Second Affiliated Hospital, Nanjing Medical Univ, Nanjing, 
Jiangsu, China.
Background: Renal proximal tubule is susceptible to hypoxic injury since its reliance 
on aerobic oxidative metabolism. Mitochondrial dysfunction contributes to progression 
of chronic renal disease. However, the profile of the energy metabolism of renal tubule 
in progression of fibrosis is uncertain, and the relationship between the change of energy 
metabolism and tubular epithelial cell damage is unclear.
Methods: Gene expression profiles related to energy metabolism of the proximal tubule 
in fibrotic kidneys were analized. 2-Deoxyglucose (2-DG) was given to CD-1 mice under 
UUO intraperitoneally. Primary tubular epithelial cells (PTC) cultured from normal CD-1 
mice renal cortex was used. 2-DG (inhibitor of glycolysis), bromopyruvic acid (inhibitor of 
hexokinase), dichloroacetic acid (inhibitor of glycolysis), oligmycin (inhibitor of oxidative 
phosphorylation), etomoxir (inhibitor of fatty acid oxidation), DON (inhibitor if glutamine 
metabolism), PKM2 siRNA or HIF-1a siRNA was used in PTC with or without TGF-β1 
stimulation. The oxygen consumption rate (OCR) and extracellular acidification rate (ECR) 
were detected by Seahorse Metaboic Analyzer.
Results: 1.Glycolysis was upregulated in the proximal tubule in fibrotic kidney. 2.Genes 
related to gycolysis were upregulated, however, genes related to oxidative phosphorylation, 
fatty acid metabolism and glutamine metabolism were downregulated. The key limiting-rate 
enzymes for glycolysis were upregulated in the fibrotic kidney. 3.2-DG could block the renal 
fibrosis under UUO. 4.OCR was decreased under TGF-β1 stimulation in PTC, however, 
ECAR was increased after TGF-β1 stimulation. 5. Inhibiting oxidative phosphorylation, 
fatty acid oxidation or glutamine metabolism could increase the lactate production in PTC. 
Lactate could directly induce PTC damage. 6. Inhibiting glycolysis could ameliorate the 
damage of PTC under TGF-β1 incubation.
Conclusions: The mitochondrial metabolism including oxidative phosphorylation, 
fatty acid oxidation and glutamine metabolism is defective in proximal tubular epithelial 
cell in fibrotic kidney. The metabolism is switch to glycolysis, and the glycolytic product 
lactate further aggravates the injury.
Funding: Government Support - Non-U.S.
FR-PO302
The Effects of CCN3/NOV on the Formation of Extracellular Matrix in 
Human Mesangial Cells  Haifei Liu, Long Chen, Hong Liu, Bi-Cheng Liu. 
Dept of Nephrology, Zhong Da Hospital, Southeast Univ, Nanjing, jiangsu, 
China.
Background: Glomerulosclerosis is characterized by mesangial cells proliferation 
and progressive extracellular matrix (ECM) accumulation . Mesangial cells are activated 
in a variety of damage factors, leading to ECM deposition. ECM accumulation is the net 
result of the balance between synthesis and degradation. CCN3, a matricellular protein of 
the CYR61-CTGF-NOV (CCN) family, associates specifically with ECM. A recent study 
found that treatment with the matricellular protein CCN3 can block and/or reverse fibrosis 
development in obesity with diabetic nephropathy. However, whether CCN3 can alleviate 
the formation of glomerulosclerosis by inhibiting the production of ECM and/or promoting 
the degradation of ECM is still unknown. This study aims to explore the potential role of 
CCN3 in ECM accumulation of mesangial cells induced by TGF-βeta.
Methods: Human mesangial cells lines were stimulated with TGF-βeta (2ng/ml) and 
CCN3 for different concentration (5 to 500 ng/ml) after 24 hours of serum starvation. 
The expressions of fibronectin (FN), type I collagen (COLI), matrix metalloproteinase-2 
(MMP-2), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 
(TIMP-1) were evaluated with RT-PCR and Western blot.
Results: In human mesangial cells lines, TGF-βeta significantly upregulated FN, COLI 
and TIMP-1 at mRNA and protein levels (P < 0.05). However, a 1-hour pretreatment of 
the cells with CCN3 for different concentration (5, 50, 500 ng/ml) virtually blocked this 
TGF-βeta induced effect on them (P < 0.05). On the other hands, TGF-βeta downregulated 
MMP-2 and MMP-9 at mRNA and protein levels, whereas a 1-hour pretreatment of the 
cells with CCN3 for different concentration (5, 50, 500 ng/ml) enhanced the expression 
of MMP-2 and MMP-9 (P < 0.05).
Conclusions: This study identifies that CCN3 as a new actor alleviates the formation 
of glomerulosclerosis by inhibiting the production of ECM and promoting the degradation 
of ECM.
Funding: Government Support - Non-U.S.
FR-PO303
Spleen Tyrosine Kinase (Syk) Inhibition Suppresses Renal Fibrosis Through 
Anti-Inflammatory Effects and Down-Regulation MAPK-p38 Pathway 
Kuan-hsing Chen, Hsiang-Hao Hsu, Cheng-chieh Hung.  Nephrology, Chang 
Gung Memorial Hospital, Taoyuan, Taiwan.
Background: Spleen tyrosine kinase (Syk) is a 72-kDa, a member of the Src family 
of non-receptor tyrosine. The central role of Syk in signaling processes is known to be 
involved in adaptive immunity, but also in autoinflammatory and allergic disease. However, 
the possible role of the anti-fibrogenic properties in renal interstitial fibrosis had not been 
established.
Methods: In vitro study: Cultured rat renal interstitial fibroblasts (NRK-49F) were 
stimulated with recombinant human TGF-β1 1ng/ml for different periods before harvesting. 
Alternatively, NRK-49F cells were pre-incubated with Syk inhibitor for 30 mins before 
TGF-β1 treatment. Total RNA was extracted for RT-PCR and total cell lysates were extracted 
for Western Blot analysis. In vivo study: Urinary unilateral obstruction model was induced 
in adult male B6 mice[/italic](3–5 months, 20–25 g). Mice with UUO were given with 
intra-peritoneal Syk inhibitor (20 and 40 mg/kg, bid) or saline daily, one day prior the UUO 
surgery. Both obstructed and contralateral kidneys were harvested 7 days after surgery. 
Kidney tissues were prepared for further pathological and molecular biological analysis.
Results: Our results demonstrated that the inhibition of Syk in NRK49F cells inhibited 
the stimulation effect of TGF-β leading to fibroblast transition to the myofibroblast 
phenotype (upregulation of α-SMA) and extracellular matrix proteins accumulation, 
collagen type I, type IV. In addition, in UUO model, Syk inhibitor attenuated the tubule-
interstitial fibrosis and expression of α-SMA, collagen I and fibronectin in UUO kidney. 
The anti-fibrosis of Syk inhibitor in UUO model may be related to anti-inflammatory effects 
(down-regulate inflammatory cytokines and reduce macrophage infiltration). Moreover, the 
effects of Syk inhibitor in inhibition of kidney myofibroblast activation by TGF-β1 were 
associated with down-regulation of MAPK-p38 pathways.
Conclusions: In conclusion, we demonstrated that Syk inhibitor ameliorates TGF-β1 
induced kidney myofibroblast activation and also reduces the tubulointerstitial fibrosis in 
UUO mice. The mechanisms may be related to anti-inflammatory effects and down-regulate 
MAPK-p38 pathway.
Funding: Government Support - Non-U.S.
FR-PO304
Optimization of Identification of the Glomerular Extracellular Matrix 
Proteome  Liliane Hobeika,1 Michelle T. Barati,1 Jon B. Klein,1,2 Kenneth R. 
McLeish,1,2 Michael Merchant.1  1Medicine, Univ of Louisville; 2Dept of Veterans 
Affairs, Louisville, KY.
Background: Increased glomerular extracellular matrix (ECM) is present in many 
glomerular diseases, eg. diabetic nephropathy and FSGS. Defining the ECM proteome by 
mass spectrometry (MS) offers the opportunity to determine the mechanism for increased 
ECM and identify disease specific markers. The optimal conditions for ECM isolation and 
MS analysis have not been determined. This study compared three extraction techniques 
in glomeruli isolated by laser capture microdissection (LCMD) from two types of tissue 
preparation.
Methods: Frozen (FR) and formalin-fixed paraffin embedded (FFPE) tissue from the 
same human kidney were cut into 10mm sections, stained with hematoxylin, glomeruli 
isolated by LCMD. Glomerular proteins were extracted by a) Protease MAX surfactant + 
boiling (MAX) or sequential decellularized with b) SDS or c) NH4OH/TritonX-100 (TX) 
followed by extraction of residual ECM by MAX. Proteins were trypsinized, peptides 
identified by MS, and data analyzed with Mascot/Sequest search strategy. ANOVA was 
used to determine differences in protein abundances.
Results: The total protein yield and number of proteins identified were determined in 
various numbers of glomeruli slices ranging 50 to 150. There was no significant increase 
in yield above 75 glomeruli slices. Compared to MAX (2032), extraction with SDS or 
TX increased the total number of proteins identified (2207 and 2246). The total number 
of proteins identified from FR and FFPE tissue did not differ for any of the extraction 
methods. More proteins were identified in residual ECM from FFPE than FR with TX (1863 
vs 1713) and SDS (1826 vs 1385). By GO annotation, sequential extraction improved the 
abundance of ECM, as shown by identification of an increased number of, and increased 
total sequence coverage of, collagen isoforms. More proteins were identified in the cellular 
fraction from FR compared to FFPE with TX (1646 vs 1294) and SDS (1804 vs 1115).
Conclusions: Using LCMD, sequential extraction with SDS or TX, and peptide 
identification by MS, the glomerular ECM proteome of patients can be identified from a 
number of glomeruli compatible with a typical renal biopsy embedded in paraffin.
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BMP-7 Inhibits Renal Akt Signaling  Debra F. Higgins, Catherine Godson. 
School of Medicine, Conway Inst, Univ College Dublin, Dublin, Ireland.
Background: Bone morphogenetic protein-7 (BMP-7), a member of the TGFβ-
superfamily, counteracts pro-fibrotic TGFb1 and protects from fibrosis in acute and chronic 
renal injury models.
Methods: Using the chronic renal fibrosis model, unilateral ureteral obstruction 
(UUO), we investigated the effect of exogenous-rhBMP-7 on signaling pathways involved 
in hypoxia and TGFb1-induced fibrosis. Mice undergoing UUO were treated with either 
vehicle or rhBMP-7 (300mg/kg i.p.), kidneys were harvested on day 8 post-obstruction and 
analysed for markers of renal fibrosis and activation of SMAD, MAPK, and PI3K signaling.
Results: In response to UUO, SMAD1/5/8 activity was lost in vehicle-treated kidneys 
yet maintained in BMP-7-treated kidneys. Collagen accumulation was significantly 
increased in obstructed kidneys of vehicle-treated animals compared with contralateral and 
this response was not observed in BMP-7-treated obstructed kidneys. Immunohistochemical 
analysis of type I, III, and IV collagen revealed that accumulation of type I collagen was 
significantly impaired in BMP-7-treated obstructed kidneys. Activation of SMAD2, 
SMAD3, ERK, p38 and Akt signaling pathways occurred during fibrogenesis and BMP-7 
significantly attenuated SMAD3 and Akt signaling in vivo. In the kidney, inner medullary 
collecting duct and tubular epithelial cells are responsive to BMP-7. Analysis in mouse 
inner medullary collecting duct (mIMCD) and human tubular epithelial (HK-2) cell lines 
stimulated with either TGFb1 or hypoxia (1% oxygen) to induce Akt activation provided 
further evidence that BMP-7 could specifically inhibit PI3K / Akt signaling.
Conclusions: These data demonstrate an important mechanism by which BMP-7 
orchestrates renal protection through Akt inhibition and strengthens the argument for use 
of Akt inhibitors as anti-fibrotic therapeutics.
Funding: Pharmaceutical Company Support - Hoffmann La Roche, Government 
Support - Non-U.S.
FR-PO306
Prevention of Renal Interstitial Fibrosis by Simultaneous Deletion of Bax 
and Bak  Hee-Seong Jang,1 Babu J. Padanilam.1,2  1Cellular and Integrative 
Physiology, Univ of Nebraska Medical Center, Omaha, NE; 2Internal Medicine, 
Section of Nephrology, Univ of Nebraska Medical Center, Omaha, NE.
Background: Proximal tubular injury and apoptosis are key mediators of development 
of kidney fibrosis, a hallmark of chronic kidney disease. However, the molecular mechanism 
by which tubular apoptotic cell death leads to kidney fibrosis is poorly understood.
Methods: Here we tested the roles of Bax and Bak, two crucial proteins involved 
in intrinsic apoptotic cell death, in progression of kidney fibrosis. Mice with proximal 
tubule-specific Bax deletion, systemic deletion of Bak and dual deletion of Bax and Bak 
were subjected to unilateral ureteral obstruction (UUO).
Results: Dual deficiency of Bax and Bak inhibited tubular apoptosis and atrophy. 
Consistent with decreased tubular injury, dual ablation of Bax and Bak suppressed 
UUO-induced inflammation and kidney fibrosis with decreased tubular cell cycle arrest, 
expression of fibrogenic and inflammatory cytokines, and oxidative stress in the kidney. 
Bax or Bak deficiency was insufficient to prevent apoptosis and all other aforementioned 
malevolent effects, suggesting compensatory mediation by each other in the respective 
signaling pathways.
Conclusions: These data suggest that dual ablation of Bax and Bak in the kidney is 
required to prevent UUO-induced tubular apoptosis and the consequent kidney inflammation 
and fibrosis.
Funding: NIDDK Support
FR-PO307
Investigating the Role of Cilia in Regulating Fibrosis in the Kidney and 
Liver Using PKD Mouse Models  Kurt Zimmerman, Cheng ’Jack’ Song, 
Bradley K. Yoder.  Cell, Developmental, and Integrative Biology, UAB, 
Birmingham, AL.
Background: Cystic kidney disorders are frequently caused by mutations in cilia 
associated proteins (intraflagellar transport, IFT) or ciliary signaling proteins (polycystin-1 
or polycystin-2). Comorbidities commonly associated with renal cysts include biliary 
duct abnormalities with associated fibrosis in both tissues. In the kidney of cilia mutants, 
ischemia reperfusion (IR) injury greatly exacerbates the rate of cyst development; however, 
it is not known whether injury will similarly affect the liver and how loss of cilia affects 
injury induced fibrosis.
Methods: To address these questions, we are utilizing Oak Ridge Polycystic Kidney 
(ORPK) mice that have a congenital hypomorphic IFT88 mutation and conditional mutant 
mice where cilia are disrupted in the kidney (CaggCreER). The conditional mutant mice 
undergo IR injury and are analyzed to evaluate disease progression, inflammatory responses, 
and production of extracellular matrix (ECM) and pro-fibrotic growth factors.
Results: Our preliminary studies in the kidney indicate that IFT88 mutant mice 
receiving IR injury have increased ECM transcripts for Col1a2, Col3a1, and fibronectin 
compared to the sham operated kidney. Despite the increased ECM production, the 
pro-fibrotic growth factor TGF-β, which is frequently associated with fibrosis, was not 
significantly elevated in mutant mice. However, another TGF-β family member, inhibin βA, 
was increased in the injured kidney of mutant mice suggesting a possible mechanism for 
ECM production. ORPK mutant mice have a noticeable liver phenotype characterized by 
biliary hyperplasia and, similar to the kidney, an increase in Col3a1 and Col1a2 transcripts. 
ORPK mutant mice also have increased transcript levels of the monocyte chemoattractant 
protein, MCP1, and the pro-inflammatory cytokine, IL-1β. Furthermore, in both mutant 
kidney and liver there is an increase in the number of infiltrating macrophages, which 
may drive fibrosis.
Conclusions: Together, our preliminary data suggest that defects in cilia formation 
promote fibrotic disease progression possibly through altered cytokine production and 
enhanced recruitment of infiltrating monocytes.
Funding: NIDDK Support, Other NIH Support - MERIT fellow grant number: 
2K12GM088010-06 to Kurt Zimmerman
FR-PO308
Klotho Suppresses Epithelial-Mesenchymal Transition /or Transformation 
in Adriamycin Nephropathy  Tsuneo Takenaka,1 Tsutomu Inoue,2 Matsuhiko 
Hayashi.3  1International Univ of Health and Welfare; 2Saitama Medical Univ; 
3Keio Univ.
Background: Klotho interacts with various proteins to alter their function. Klotho may 
bind to the receptor for WNT and TGFbeta, inhibiting their signals.
Methods: Experiments were performed to assess how klotho protects kidney from 
its injury. Adriamycin (5 mg/Kg) was injected into rats to induce nephropathy. Human 
recombinant klotho (K, 30 micro-g/kg/day), 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-
dione (GSK3beta blocker, 0.2mg/kg/day, T) or vehicle (A) was administered. Rats which 
were untreated with Adriamycin were used as control (U). Animals were killed 8 weeks 
later. Renal expressions of Wnt1, GSK3beta, TGFbeta1, Twist and collagen I were assessed 
with RT-PCR against GAPDH. Western blot was used for p-GSK3beta and beta-action.
Results: Adriamycin increased albuminuria, renal expression of Wnt1, p-GSK3beta, 
TGF, Twist and collagen 1 in comparison to the control. Klotho and T suppressed 
adriamycin-induced albuminuria and the phosphorylation of GSK3beta with sustained 
elevations of Wnt1, supporting that klotho inhibit Wnt signaling without changes in Wnt 
level. While klotho and T reduced TGFbeta, klotho preferentially ameliorated Twist and 
collagen I in comparison to T. 
U A K T
Alb/Cr 8±2 316±39* 152±21*# 163±29*#
CCr 1.1±0.1 0.9±0.1 1.0±0.1 1.0±0.1
Wnt1 0.2±0.1 3.6±0.3* 3.3±0.3* 3.5±0.3*
p-GSK3beta 0.2±0.1 0.9±0.1* 0.5±0.1*# 0.5±0.1*#
TGFbeta 0.1±0.1 1.2±0.2* 0.7±0.1*# 0.7±0.1*#
Twist 0.2±0.1 1.8±0.2* 0.6±0.1*# 1.0±0.2*#$
Collagen I 0.3±0.2 2.3±0.4* 0.7±0.2*# 1.4±0.3*#$
Alb/Cr: Albuminuria(mg)/Creatinine(g), CCr: creatinine clearance (ml/min/g.kidney.wt) *: p<0.05 vs 
U, #: P<0.05 vs A, $: p<0.05 vs K.
Conclusions: Our data indicate that WNT is involved in pathogenesis of Adriamycin 
nephropathy. Furthermore, the present findings demonstrated that the inhibition of WNT 
contributed to glomerular protective actions of klotho. Finally, our results suggest that 
klotho suppresses Epithelial-Mesenchymal Transition /or Transformation by inhibiting 
TGFbeta as well as WNT signaling.
Funding: Government Support - Non-U.S.
FR-PO309
The Molecular Mechanism of miR-382 in the Pathogenesis of Renal 
Tubulointerstitial Fibrosis  Yi Fang,1,2 Ting Xie,1 Hui Zhang,1 Sheng 
Wu.1  1Nephrology, Zhongshan Hospital Fudan Univ, China; 2Shanghai Key 
Laboratory of Kidney Diseases and Blood Purification.
Background: To investigate the roles of microRNA-382 (miR-382) in the pathogenesis 
of renal tubulointerstitial fibrosis.
Methods: Human kidney epithelial (HK2) cells that transfected with a miR-382 
inhibitor (antagomiR-382) was used to exam the effect of miR-382 abundance on cell 
polarity, as well as to test the complementary relationship between miR-382 and its predicted 
target gene, heat shock 60kDa protein 1(HSPD1), which was further verified by site-directed 
mutagenesis. We also examined the in vivo role of miR-382 in the development of renal 
interstitial fibrosis, in a mouse unilateral ureteral obstruction (UUO) model. Locked nucleic 
acid-modified anti-miR-382 was intravenous delivered via tail vein less than 30mins prior 
to UUO, and repeated the dosage 24 hours after the surgery. For clinical verification, renal 
biopsy specimens from 12 IgA nephropathy (IgAN) patients were collected, 6 with moderate 
to severe tubulointerstitial fibrosis (TIF) and 6 with no TIF. The relative abundance of miR-
382 and HSPD1protein was analyzed using in situ hybridization and immunohistochemistry.
Results: HSPD1 was confirmed to be a new, direct target gene of miR-382 by in vitro 
transfect technique and mutation experiments. The development of epithelial transition 
or renal interstitial fibrosis was accompanied with up-regulated abundance of miR-382. 
Down-regulation of miR-382 was associated with significant attenuation of interstitial 
fibrosis, but increase protein expression of HSPD1and thioredoxin, both in the obstructed 
mouse kidneys and renal biopsy specimen from IgAN patients.
Conclusions: MiR-382, a profibrotic microRNA, is up-regulated with the development 
of renal interstitial fibrosis in humans and in mice. The down-regulation of HSPD1 and 
the decreased ability of anti-oxidative stress are secondary to the increased abundance 
of miR-382.
Funding: Government Support - Non-U.S.
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Assessing the Role of Gremlin-1 on Renal Fibrosis In Vitro  Marcela Herrera, 
Lihuan Liang, Asha Seth, Carol Patricia Moreno Quinn.  Cardiovascular & 
Metabolic Diseases, Medimmune, Cambridge, United Kingdom.
Background: Bone Morphogenic Proteins (BMPs) signal through SMAD1/5/7 to 
upregulate genes that antagonize fibrosis. The endogenous antagonist gremlin-1 binds 
and antagonizes extracellular BMPs, inhibiting their anti-fibrotic effects. Gremlin-1 is 
up-regulated in the proximal tubule (PT) of DN patients. We hypothesized that Gremlin-1 
participates in the development of renal fibrosis by inducing a pro-fibrotic phenotype in 
proximal tubules and renal interstitial fibroblasts.
Methods: To test this hypothesis we used HK-2 (human PT cell line) and NRK49F (rat 
renal fibroblasts) cell lines where the pro-fibrotic phenotype was induced by Transforming 
Growth Factor b1 (TGFb: 2.5 ng/mL, 72 hrs). Gremlin-1 secretion and protein expression 
was measured by Western blotting and gene expression by qPCR.
Results: In PT cells, TGFb stimulated gremlin-1 protein secretion by 2.3 fold (from 
57 ± 5 to 134 ± 2 arbitrary units; p<0.05), increased fibronectin-1 (FN1, an extracellular 
matrix component) by 50% (p<0.05) and reduced expression of e-cadherin (e-CAD, 
an epithelial marker) by 95% (p<0.05). All changes also occurred at the mRNA level. 
Gremlin-1 siRNA significantly reduced gremlin-1 mRNA expression and efficiently blocked 
the TGFb-induced Gremlin-1 release by 100%. However, Gremlin-1 knockdown did not 
prevent the pro-fibrotic changes of TGFb. In contrast to PT cells, TGFb did not induce 
gremlin-1 secretion in renal fibroblasts. TGFb increased FN1 and a-smooth muscle actin 
(aSMA, marker of fibroblast activation) in a dose-dependent manner. Addition of gremlin-1 
(mimicking the in vivo setting) did not exacerbate fibrosis at any dose of TGFb. Addition of 
recombinant BMP2 was not sufficient to prevent TGFb-induced fibrosis in either cell type. 
Recombinant BMP2 alone (1 nM) increased SMAD5 phosphorylation and the expression 
of ID1 (a marker of BMP signalling) at 1 and 24 hrs post treatment. The stimulatory effect 
of BMP2 was blocked by pre-treatment with recombinant Gremlin-1 (2 nM). These data 
confirm intact BMP2/gremlin-1 signalling in both cell types.
Conclusions: Our data does not support the participation of gremlin-1 in TGFb-
dependent renal fibrosis in vitro.
Funding: Pharmaceutical Company Support - Medimmune
FR-PO311
Vitamin (Vit) D Repletion Ameliorates Muscle Wasting and Muscle Fibrosis 
in Mice with Chronic Kidney Disease  Wei Ding, Wai W. Cheung, Mary 
Christine Esparza, Ping Zhou, Richard L. Lieber, Robert H. Mak.  Pediatric 
Nephrology, Univ of California, San Diego, La Jolla, CA.
Background: Cachexia presenting as muscle wasting and weakness is prevalent in 
CKD patients and may impact their quality of life. We investigated the effects of vitamin 
D repletion in a mouse model of CKD-associated cachexia and vitamin D deficiency.
Methods: CKD in c57BL/6 mice were induced by 5/6 nephrectomy. CKD and sham 
mice were treated with 25VitD (25 mg/kg/day), 1,25VitD (40 ng/kg/day) or vehicle (V) 
for 6 weeks via a subcutaneous osmotic pump. CKD+V mice were fed ad libitum while 
other groups of mice were pair-fed to CKD+V mice. Parameters of energy homeostasis, 
skeletal muscle histomorphometry and in vivo muscle function were measured. The 
expression of key molecules implicated in myogenesis and fibrosis pathway was assessed 
using a focused PCR array.
Results: Serum 25VitD and 1,25VitD levels were significantly lower in CKD than 
sham mice (p<0.01) and was increased, within the physiological range, by 25VitD and 
1,25VitD repletion in CKD mice. CKD mice exhibited reduced weight gain, increased 
energy expenditure, loss of lean mass and decreased muscle function (measured by grip 
strength and rotarod tests) than sham mice (p<0.01). Increased energy expenditure in CKD 
mice was associated with upregulation of uncoupling proteins (UCPs) in skeletal muscle 
and adipose tissues. Soleus muscle fiber area and in vivo muscle function was significantly 
reduced in CKD mice than sham controls (p<0.05). Skeletal muscle fibrosis, a major 
pathological hallmark of myopathies, is evident in CKD mice. Soleus collage content was 
significantly increased in CKD than sham mice (p<0.01). Gene expression of myogenesis 
and fibrotic pathways were increased in CKD than sham mice (p<0.01). Perturbations in 
weight gain, energy expenditure, UCPs, loss of lean mass, muscle function tests, soleus 
muscle fiber area, soleus collagen content as well as aberrant gene expression involved in 
myogenesis and muscle fibrotic pathway in CKD mice were normalized by 25VitD but 
only partially attenuated by 1,25VitD repletion.
Conclusions: 25VitD and 1,25VitD repletion have differential effects on muscle 
wasting and muscle fibrosis in CKD mice.
Funding: Other NIH Support - R24-HD050837
FR-PO312
The Effect of Cell Culture Surface Coating on Glomerular Endothelial 
Cell Phenotype  Kamilla Pajecka,1,2 Troels Krarup Hansen,1 Julie Williams.2 
1Endocrinology and Internal Medicine, Aarhus Univ Hospital, Aarhus, 
Denmark; 2Diabetes Complications Biology and Pharmacology, Novo Nordisk 
A/S, Maaloev, Denmark.
Background: Glomerular endothelial cells (GEnCs), podocytes and the glomerular 
basement membrane are the major constituents of the glomerular filtration barrier (GFB), 
which is fundamentally impaired in diabetic nephropathy (DN). The DN drug-candidate 
screening process involves in vitro use of the GFB components either singly or in 
combination. The aim of this study was to determine the effect of commercially available 
extracellular matrix (ECM) components on GEnC characteristics.
Methods: Primary human GEnCs were from Cell Systems. Cell culture surface coating 
included: collagen IV (COLIV), laminin521 (hLN521), laminin111 (hLN111) or Attachment 
Factor (AF; Cell System’s proprietary GEnC coating). Cell adhesion was monitored by the 
xCELLligence system. The mRNA expression was assessed by qPCR. The localization of 
zonula occludens (ZO)-1 protein was studied by fluorescent immunolabeling.
Results: Coating with AF or COLIV increased the cell index (CI) of GEnCs in the cell 
adhesion phase (0-6h) but not in the spreading and proliferation phase (6-72h). Coating 
with hLN521 displayed a continuous increase in CI over 72h. On the contrary, hLN111 
caused a significant decrease in CI over 72h. Cells grown on AF or COLIV showed similar 
mRNA expression pattern of chosen genes as cells grown on uncoated surfaces. By contrast, 
coating with hLN521 decreased the expression of COL4A1, COL4A2, MMP2 [all 2-fold] 
and TGFB1 [1.5-fold] as compared to no coating. Likewise, ITGA1, ITGA2, ITGAV, 
ICAM1, NOX4 were decreased with hLN521 in a dose-dependent manner. Expression 
of LAMA5, COL4A5, ITGA3 and NOS3 were unchanged in all groups. Tight junction 
formation was assessed by ZO-1 immunostaining. Laminin521, contrary to other ECM 
coatings, stimulated tight junction formation in GEnCs.
Conclusions: Usage of AF or COLIV in GEnC culture shows little advantage. DN-
associated hLN111 is a poor attachment substrate resulting in GEnC loss. This is in contrast 
to the more physiologically relevant hLN521 which promotes cell adhesion, spreading, 
proliferation and tight junction formation.
Funding: Pharmaceutical Company Support - Novo Nordisk A/S, Government 
Support - Non-U.S.
FR-PO313
Development of an Ex Vivo Model to Elucidate the Matrix Turnover 
Profile in Renal Interstitial Fibrosis  Signe Holm Nielsen,1,2 Zsolt Soma 
Karpati,1 Daniel Guldager Kring Rasmussen,1,3 Morten Asser Karsdal,1 Federica 
Genovese.1  1Fibrosis Biology and Biomarkers, Nordic Bioscience, Herlev, 
Denmark; 2System Biology, Denmark Technology Univ, Kgs. Lyngby, Denmark; 
3Southern Denmark Univ, Odense, Denmark.
Background: Renal interstitial fibrosis is characterized by dysregulated extracellular 
matrix (ECM) turnover and protease activity. ECM protein fragments generated by protease 
cleavage can be measured by specific ELISAs, providing a protein fingerprint of the disease. 
The aim of this study was to set up an ex-vivo model for renal interstitial fibrosis in order 
to investigate the ECM turnover profile in the fibrotic kidney.
Methods: 14 male 12 weeks old Sprague-Dawley rats underwent Unilateral Ureteral 
Obstruction (UUO) surgery by ligation of the right ureter. The left kidney (contralateral) 
was used as internal control. 6 rats were sham-operated and used as control group. Rats 
were terminated 2 weeks after the surgery, when advanced fibrosis is known to be present. 
The kidneys were excised and precision-cut tissue slices (PCTS) were cultured for 5 days 
in serum free medium. Markers of collagen type I formation (P1NP), collagen type III 
degradation (C3M) and α-smooth muscle actin (α-SMA) were measured in the PCTS 
supernatants. The extent of tubulointerstitial fibrosis was evaluated by histology.
Results: P1NP, C3M and α-SMA were significantly increased in supernatants of tissue 
slices from the UUO ligated kidneys compared to the contralateral kidneys (p<0.001) and 
to sham operated animals (p<0.0001). However the markers had a high inter-individual 
variability in the UUO group. When comparing the levels of the markers from the UUO 
kidney to those from the corresponding contralateral kidney, animals with pronounced 
differences were those presenting advanced fibrosis in histology.
Conclusions: The UUO PCTS ex vivo model provides a valuable translational tool 
for investigating the ECM remodeling associated with renal interstitial fibrosis. Since the 
protein fingerprint technology allows the measurement of the markers measured in the 
supernatants also in circulation and in urine, these markers have the potential to accurately 
and non-invasively describe the tissue remodeling during fibrosis.
FR-PO314
Collagen Degradation Profile in a Nephrotoxic Nephritis Model 
Signe Holm Nielsen,1,2 Daniel Guldager Kring Rasmussen,1,3 Gabriela 
Campanholle,4 Robert V. Martinez,4 Morten Asser Karsdal,1 Federica Genovese.1 
1Fibrosis Biology and Biomarkers, Nordic Bioscience, Herlev, Denmark; 
2System Biology, Denmark Technology Univ, Kgs. Lyngby, Denmark; 3Southern 
Denmark Univ, Herlev, Denmark; 4Inflammation and Immunology, :RD, Pfizer 
Inc., Cambridge, MA.
Background: The nephrotoxic nephritis (NTN) mouse model is characterized by a 
rapid onset of nephritis, followed by tissue destruction and progression to renal scarring. 
We aimed at identifying markers for early disease onset that were directly linked to the 
events of scar formation in the kidney.
Methods: Neo-epitope degradation fragments of collagen type I, III and IV generated 
by MMP cleavage were measured by specific ELISAs (namely C1M, C3M and C4M) 
in urine of NTN and healthy mice terminated at 7 and 21 days after injury (NTN: n=21, 
Controls: n=6). Urinary albumin/creatinine (ACR), urinary proteinuria, plasma creatinine 
and blood urea nitrogen (BUN) were measured as markers of renal function. Interstitial 
fibrosis and glomerulosclerosis were evaluated by histology and quantification of α-SMA 
and collagen type I in immunohistochemistry.
Results: While C1M levels in urine were not different between NTN mice and controls, 
C3M levels were elevated in NTN rats at 7 days (p<0.05) and decreased to levels close to 
the controls at 21 days. This elevation was also reflected in proteinuria, peaking at 7 days, 
but not in BUN and plasma creatinine. C4M levels were elevated at 21 days and not at 7 
days (p<0.01), and correlated with the extent of interstitial fibrosis.
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Conclusions: Different degradation markers of the most abundant proteins in the 
renal interstitial matrix (collagen type I and III) and in the tubular basement membrane 
and mesangium (collagen type IV - a1 chain) presented a different longitudinal release 
in urine. While degradation of collagen type III is an early event in this model, maybe 
reflecting the early inflammatory state, degradation of collagen type IV appears later, when 
the formation of the scar is evident in histology. These markers could potentially be used to 
non-invasively describe the fibrotic events in the kidney in experimental models and, since 
the targeted epitopes are conserved in human, they could be applied in clinical settings.
FR-PO315
Evidence of Podocyte Protrusions into the Basement Membrane in 
Glomerular Disease  Sophie C. Collinson,1 Michael J. Randles,1,2 Mira Krendel,3 
Eva Koenigshausen,4 Lorenz Sellin,4 Ian Roberts,5 Jeffrey H. Miner,6 Rachel 
Lennon.1,2  1Inst of Human Development, Faculty of Medical & Human Sciences, 
Univ of Manchester, United Kingdom; 2Wellcome Trust Centre for Cell-Matrix 
Research, Faculty of Life Sciences, Univ of Manchester, United Kingdom; 3Dept 
of Cell and Developmental Biology, SUNY Upstate Medical Univ, Syracuse, NY; 
4Dept of Nephrology, Heinrich Heine Univ, Duesseldorf, Germany; 5Dept of 
Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom; 6Renal 
Div, Washington Univ School of Medicine, St. Louis, MO.
Background: Glomerular disease is a leading cause of kidney failure. Podocyte 
foot process effacement and glomerular basement membrane (GBM) disruption are 
frequent abnormalities regardless of the underlying molecular etiology. Standard electron 
microscopy techniques provide 2D information and 3D ultrastructural relationships are 
poorly understood. We hypothesized that creation of detailed 3D models of the glomerulus 
would identify novel pathological features.
Methods: Serial block face-scanning electron microscopy was performed on a 
series of genetic mouse models of glomerular disease with established albuminuria. 3D 
reconstructions of glomeruli were created using IMOD 4.7.11.
Results: Sub-podocyte expansions of the GBM were dominant features in Glepp1-/-, 
Myo1e-/- and Col4a3-/- mice and overall GBM thickness was significantly different to 
matched wild-type (WT) controls (p<0.0001). There was a corresponding reduction in 
podocyte foot process number in each of the models (p<0.0001). Furthermore we identified 
novel podocyte protrusions into the GBM in all mutant mice and these were not present 
in WT controls. There was no evidence of endothelial or mesangial cell protrusions into 
the GBM and no correlation between GBM thickness and the site of podocyte protrusions.
Conclusions: 3D ultrastructural imaging revealed expected GBM abnormalities in 
addition to podocyte protrusions, resembling invadasomes, in the GBM. This novel finding 
provides new insight into disease mechanisms and suggests that a common matrix-adhesion 
pathway is activated regardless of the primary molecular insult.
Funding: Private Foundation Support
FR-PO316
Multi-Clonal Population of Cells of Renin Lineage (CoRL) Transdifferentiate 
into Podocytes and PECs in Experimental FSGS  Natalya V. Kaverina,1 Diana 
G. Eng,1 Jeffrey W. Pippin,1 Michael E. Rusiniak,2 Kenneth W. Gross,2 Stuart J. 
Shankland.1  1Devision of Nephrology, Univ of Washington, Seattle, WA; 2Dept 
of Molecular and Cellular Biology, Roswell Park Cancer Inst, Buffalo, NY.
Background: Focal segmental glomerulosclerosis (FSGS) is secondary to podocyte 
injury and loss. Because adult podocytes cannot proliferate, their replacement by progenitors 
is critical for their repair and regeneration in disease.Here we explored whether single or 
multiple clones of cells of renin lineage (CoRL) serve as a local progenitor source to replace 
reduced podocytes in experimental FSGS.
Methods: Experimental FSGS was induced following abrupt podocyte depletion 
by administration of a cytotoxic anti-podocyte antibody in two confetti mouse reporters. 
First, to confirm adult podocyte regeneration following abrupt depletion, podocytes were 
genetically fate-mapped in adult NPHSP2Cre/ConfettiTG/WT reporter mice with experimental 
FSGS. Second, to prove that adult podocyte regeneration by CoRL was multi-clonal, 
CoRL were fate mapped in RenCre / ConfettiTG/WT reporter mice with experimental FSGS.
Results: FSGS in NPHSP2Cre/ConfettiTG/WT  mice was characterized by marked podocyte 
depletion (45% decrease) on d7. A multi-clonal repopulation of podocytes resulted in an 
increase in their overall number to 77% of normal by d28. No podocyte proliferation was 
detected by BrdU staining. In RenCre/ConfettiTG/WT mice, a multi-clonal expansion of 4 
color-labeled CoRL (GFP, RFP, CFP, YFP) was detected in glomeruli at FSGS d28. A 
subset of all clonal reporters co-expressed 5 podocyte markers (podocin, synaptopodin, 
p57, WT-1, nephrin). CoRL were also observed along Bowman’s capsule and co-expressed 
PEC markers (PAX2, claudin-1). BrdU staining did not co-localize with CoRL reporters.
Conclusions: Following an abrupt depletion of adult podocytes in experimental FSGS, 
their number was increased in the absence of podocyte proliferation. Regeneration of adult 
podocytes was likely in part due to multiple clones of CoRL serving as local progenitors.
Funding: Other NIH Support - 5 R01 DK 056799-10, 5 R01 DK 056799-12, 1 R01 
DK097598-01A1
FR-PO317
Macula Densa-Derived Factors Control Glomerular Cell Remodeling 
Anne Riquier-brison, Donna Ralph, Jasmine Ann Arevalo Castillejos, Janos 
Peti-Peterdi.  Physiology and Biophysics, Univ of Southern California, Los 
Angeles, CA.
Background: Macula densa (MD) cells are strategically positioned at the vascular 
entrance of the glomerulus and control renal hemodynamics and renin. In this study, we 
addressed a novel, non-traditional role of MD cells regulating glomerular cell plasticity/
remodeling by mesenchymal progenitor cells.
Methods: For genetic cell fate tracking, tamoxifen-induced NG2CreERT2-Tomato 
mice were fed either a control or salt-deficient + ACE inhibition (SD+ACEi) diet, for 2 
weeks to achieve strong MD stimulation.
Results: We observed a 5-fold increase in renal interstitial density of NG2-derived 
(NG2+) cells (5.9±1.1 cells per field in control, 30.2±4.5 in SD+ACEi), and the homing 
of NG2+ cells to the mesangium under the MD and into the glomerulus. This effect was 
blunted by the selective COX-2 inhibitor SC58236 (COX-2i) or the nNOS inhibitor 7-NI 
(13±2.2 cells per field with COX-2i and 11.6±1.7 with 7-NI). Immunofluorescence (IF) 
of Claudin-1 showed a 4-fold increase in the number of NG2+ cells in the glomerular 
parietal layer (0.5±0.2 cells per glomerulus in control, 2.0±0.4 in SD+ACEi). Podocin IF 
identified a few NG2+ podocytes. NG2+ cell homing was blunted by COX-2i and 7-NI 
(1.2±0.3 cells per glom with COX-2i, 0.8±0.3 with 7-NI). Co-localization of endogenous 
NG2-Tomato fluorescence with IF of renin revealed an increase in the proportion of NG2+ 
renin-expressing cells from 22.0%±6.6 to 70.6%±7.4 after SD+ACEi, inhibited by COX-
2i. Similarly, the density of proliferating cells expressing Ki67 increased after treatment 
(2.0±0.5 Ki67+ cells per field in control, 11.3±2.8 in SD+ACEi, p<0.05), in particular in 
the vicinity of the juxtaglomerular area, inhibited by COX-2i (5.6±1.0) and 7-NI (2.7±0.3).
Conclusions: Our results suggest that NG2+ pericytes may be an important progenitor 
cell population in the kidney. In response to MD-derived (from COX-2 and nNOS) paracrine 
factors, NG2+ cells from the renal interstitium proliferate and migrate towards the MD 
along the afferent arteriole and via the vascular pole into the glomerular epithelium and 
mesangium. In conclusion, MD cells play new important roles in the maintenance and 
remodeling of the glomerulus.
Funding: NIDDK Support
FR-PO318
A Novel Method for Assessing Podocyte Depletion in Whole Glomeruli 
Victor G. Puelles,1 James William Van der Wolde,1 Luise A. Cullen-McEwen,1 
Keith E. Schulze,2 Jonathan Guy Bensley,1 Kieran M. Short,1 Georgina Caruana,1 
Stacey Hokke,1 Stephen D. Firth,2 Ian S. Harper,2 David J. Nikolic-Paterson,3 
John F. Bertram.1  1Dept of Anatomy and Developmental Biology, Monash 
Univ, Melbourne, Victoria, Australia; 2Monash Micro Imaging, Monash Univ, 
Melbourne, Victoria, Australia; 3Dept of Nephrology, Monash Medical Centre, 
Melbourne, Victoria, Australia.
Background: Podocyte depletion plays a major role in the development and progression 
of glomerulosclerosis. Given that glomerulosclerosis is often focal, affecting some but not 
all glomeruli, our aim was to develop a rapid, accurate and precise method for quantifying 
podocyte depletion in whole glomeruli.
Methods: PodCreiDTR mice, in which expression of the human diphtheria toxin 
(DT) receptor is driven by the podocin promoter, and iDTR mice (controls) were injected 
with DT (100ng/kg). Tissue was collected at day 35 for podocyte analysis (n=3 mice per 
group). 800mm thick kidney slices were immunostained with antibodies against p57 and 
synaptopodin. Slices were cleared with benzyl alcohol, benzyl benzoate (BABB). An SP8 
confocal microscope (Leica, Germany) fitted with a BABB objective (NA: 0.95; working 
distance: 2mm) was used. Total podocyte number was obtained by manual counting and 
using a semi-automated system (Imaris, Bitplane) in 88 whole glomeruli - 38 from iDTR 
mice and 50 from PodCreiDTR mice.
Results: In iDTR mice (controls), total podocyte number per glomerulus was almost 
identical between manual counts (66.61±11.92) and Imaris (65.47±9.26; P=0.65). In 
PodCreiDTR mice, total podocyte number was also similar between manual counts 
(52.96±11.74) and Imaris (53.51±11.35; P=0.81). With both methods, podocyte counts were 
obtained in less than 2 minutes per glomerulus, a significant time reduction compared to 
existing methods. Imaris also facilitates the estimation of podocyte and glomerular volumes 
for a complete assessment of podocyte morphology.
Conclusions: This is the first method to combine immunofluorescence, BABB-clearing 
and confocal microscopy to count podocytes in whole glomeruli. The method is accurate, 
precise and rapid, and provides a novel approach for podocyte morphometrics in settings 
where sufficient tissue is available for analysis.
FR-PO319
Characterization of Heterogeneous Podocyte Biomechanics Using Atomic 
Force Microscopy  Evren U. Azeloglu,1 Jia-Jye Lee,2 Kevin D. Costa.2 
1Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount 
Sinai, New York, NY; 2Cardiology (Medicine), Icahn School of Medicine at 
Mount Sinai, New York, NY.
Background: Biomechanical signals play a key role in glomerular physiology, where 
pathological changes in blood pressure can significantly affect podocyte morphology and 
function. While there has been a great focus on mechanobiological signaling in podocytes, 
their spatial biomechanical properties have been largely overlooked due to a lack of in 
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vitro systems that can spatially segment subcellular components. We have developed a 
novel microengineered culture system that mechanically induces arborization of podocytes 
such that they form functional peripheral shape-induced processes that locally express slit 
diaphragm markers and bundled actin fibers in vitro. We then used atomic force microscope 
elastography to quantitatively characterize the subcellular biomechanical properties of 
isolated human podocytes.
Methods: Glass coverslips were micropatterned with interconnected channels using 
standard photolithography techniques. Immortalized human podocytes were plated on 
micropatterned slides, and cultured at 37ºC for five days. They were then transferred to an 
Asylum Bioscope AFM and probed with 2 mm deep indentations at a rate of 1 mm/sec. 
Depth-dependent pointwise apparent elastic modulus was computed at each indentation 
point to create a 3-D elastography map of cellular biomechanics.
Results: Live-cell imaging showed dynamic cycling of f-actin in peripheral shape-
induced processes of micropatterned podocytes. These cells exhibited heterogeneous 
depth-dependent biomechanical properties where processes were significantly stiffer than the 
central cell body. Increase in stiffness correlated with presence of crosslinked actin bundles.
Conclusions: We saw significant increase in stiffness of peripheral processes in 
podocytes, which reaffirm the key structural role of the interdigitating foot processes 
in maintenance of the glomerular filtration barrier. Our microengineered culture system 
provides a new means to rapidly test the micromechanics of podocytes with high spatial 
resolution in a physiologically relevant in vitro setting.
Funding: Private Foundation Support
FR-PO320
Identification and Validation of Fluid Flow Shear Stress (FFSS)-Induced 
Changes in Podocyte Signaling Pathways Using Bioinformatic Tools 
Tarak Srivastava,1 Hongying Dai,1 Ashraf El-Meanawy,2 Ellen T. McCarthy,3 
Virginia J. Savin,4 Ram Sharma,4 Mukut Sharma.4  1Nephrology, The Children’s 
Mercy Hospital, Kansas City, MO; 2Nephrology, Medical College of Wisconsin, 
Milwaukee, WI; 3Kidney Inst, Univ of Kansas Medical Center, Kansas City, KS; 
4Renal Research Laboratory, Kansas City VA Medical Center, Kansas City, MO.
Background: The flow of filtrate through Bowman’s space generates FFSS over 
podocytes. Adaptive hyperfiltration is characterized by increased single nephron GFR 
(SNGFR), capillary pressure (PGC) and glomerular hypertrophy. The mechanism of podocyte 
injury from hyperfiltration-induced FFSS is not known.
Methods: We performed microarray analysis (Affymetrix GeneChip Mouse Exon 1.0 
ST Array) on immortalized podocytes without FFSS (Control), immediately after FFSS 
(End-FFSS), 2 hours (post-2hr FFSS), and at 24 hours (post-24hr FFSS) after cessation 
of FFSS at 2 dynes/cm2 for 2 hr. Mouse exon 1.0 ST Array has ~4 probes/ exon and ~40 
probes/ gene. Data from the microarray were log transformed, normalized and filtered to 
generate a set of 17,494 genes. Genes that were significant at p<0.01 were analyzed using 
Ingenuity Pathway Analysis (IPA) and Enrichr Program to identify key pathways.
Results: IPA showed Akt, COX-2, and AMPK (at End-FFSS); TGF-β (at post-2hr 
FFSS); and p38MAPK, ERK1/2 (at post-24hr FFSS) in the main network. Enrichr Kinase 
Enrichment Analysis showed GSK3β, ERK1/2 in all three treatment groups compared with 
the control group. ChIP-x Enrichment Analysis identified transcription factor β-catenin. 
Western blotting, fluorescence microscopy and immunocytochemistry were used to validate 
changes in these signaling molecules.
Conclusions: Increased FFSS affects pathways that mediate podocyte survival and 
inflammation, and provide targets to address the mechanism of hyperfiltration-mediated 
glomerular injury.
FR-PO321
A Podocyte-Based Screening Assay Identifies Paullone-Derivatives as Novel 
Podocyte Protective Agents  Ha won Lee, Samia Khan, Mohd Hafeez Faridi, 
Terese D. Geraghty, Mehmet M. Altintas, Jochen Reiser, Vineet Gupta.  Dept 
of Internal Medicine, Rush Univ Medical Center, Chicago, IL.
Background: Podocyte injury and loss is an early hallmark in the pathogenesis of a 
variety of glomerular diseases. Therefore, podocytes are an excellent cellular target for 
the development of kidney directed therapeutics. We recently described a novel cell-based 
high content screening (HCS) assay for quantifying podocyte damage in vitro. Here, we 
describe utilization of this HCS assay to identify a family of novel small molecules that 
significantly protect podocytes from injury.
Methods: We utilized cultured murine podocytes in an HCS assay using 96-
well imaging plates. Phenotypic changes with podocyte damaging agent puromycin 
aminoglycoside (PAN) were analyzed and quantified using automated methods using 
thousands of podocytes per condition. Identified hits were confirmed and a number of 
biochemical and cell biological assays were used to validate the findings.
Results: We identified a family of small molecules, paullones, as highly potent agents 
that protected podocytes from damage. Kenpaullone and three other paullones (paullone, 
1-azakenpaullone, and alsterpaullone) showed dose-dependent protection of podocytes 
from PAN-damage induced loss in F-actin fibers. Among the four paullones identified, 
alsterpaullone showed the highest level of protection. At a molecular level, alsterpaullone 
reduced the elevation in the expression of Desmin, a podocyte damage marker, and inhibited 
PAN-induced podocyte migration. While PAN treatment reduced AKT phosphorylation 
in podocytes, alsterpaullone maintained the levels of phosphorylated AKT in podocytes.
Conclusions: Employment of our newly described podocyte-based screening assay 
results in the discovery of podocyte-directed therapeutics for treating a number of glomerular 
diseases. Paullones represent a family of small molecules that show podocyte protection 
from damage. We also describe a proposed molecular mechanism for the efficacy of these 
novel agents. We hope that these methodologies will lead to the development of novel 
types of specific kidney protective drugs.
FR-PO322
Novel Podocyte Quantification Assay to Ascertain Patient Serum Toxicity 
Elena Torban,1 Nadezda Kachurina,1 Chen-Fang Chung,1 Sima Babayeva,1 
Nada Alachkar,2 Thomas Kitzler.1  1Dept of Medicine, McGill Univ-McGill Univ 
Health Center, Montreal, QC, Canada; 2Div of Nephrology, The Johns Hopkins 
Univ School of Medicine, Baltimore, MD.
Background: Focal segmental glomerulosclerosis (FSGS) is a glomerular kidney 
disease that affects the podocytes and progresses to renal failure within 5-7 years, requiring 
dialysis or renal transplantation. In > 50% of patients, the disease is idiopathic and may 
recur post-transplant suggesting the presence of a pathogenic toxic factor/s circulating in the 
blood. The identity of this factor and the pathogenic mechanisms remain enigmatic. Recent 
in vitro studies from our lab showed that plasma from recurrent FSGS patients disturbs 
the human podocyte cytoskeleton and focal adhesion complexes (FACs). We developed a 
novel unbiased assay to quantify the toxic effects of patient plasma and nephrotoxic drugs 
on cultured human podocytes and to identify strategies that block serum toxicity.
Methods: Cultured human differentiated podocytes are exposed to adriamycin, 
recombinant TNFa or human sera from patients with various forms of FSGS. FACs are 
visualized with anti-vinculin antibody, and cell images are analyzed to define the number of 
FACs/1000mm2 cell area. We analyzed sera from 12 patients: 2 with idiopathic, 4 recurrent 
FSGS, 4 non-recurrent FSGS and 2 de novo FSGS.
Results: Both adriamycin and recombinant TNFa disrupt podocyte actin cytoskeleton 
and FACs in a dose-dependent manner. Comparing to healthy control, sera from patients 
with idFSGS (no known mutations identified), rFSGS and de novo FSGS post-transplant 
drastically reduces FACs number, yet sera from nrFSGS post-transplant does not statistically 
affect FACs. In ~ 60% of the patients with serum toxicity, these effects on podocytes can 
be averted by TNFa pathway blockade.
Conclusions: Our in vitro podocyte assay provides, for the first time, means to 
reliably identify those patients with idiopathic FSGS who are at high risk of recurrence 
post-transplant. It may also identify FSGS patients who may be candidates for anti-TNFα 
therapy that could prevent progressive glomerular injury.
Funding: Government Support - Non-U.S.
FR-PO323
Agalsidase Treatment Clears Gb3 from a Podocyte Model of Fabry 
Disease  Linda Blomberg,1 Fabian Braun,1 Markus M. Rinschen,1 Max Liebau,2 
Susanne Brodesser,3 Bernhard Schermer,1,3 Thomas Benzing,1,3 Christine E. 
Kurschat.1,3  1Dept II for Internal Medicine, Univ Hospital Cologne, Cologne, 
NRW, Germany; 2Dept of Pediatrics, Univ Hospital Cologne, Cologne, NRW, 
Germany; 3Cologne Excellence Cluster on Cellular Stress Responses in Aging-
Associated Diseases, Univ of Cologne, Cologne, NRW, Germany.
Background: In Fabry disease the deficiency of the enzyme α-galactosidase A leads 
to an accumulation of globotriaosylceramide (Gb3).An enzyme replacement therapy with 
agalsidase alfa (Replagal®) or beta (Fabrazyme®) is licensed since 2001. The establishment 
of an α-galactosidase A-deficient human podocyte cell line has already been published 
by our group. These podocytes accumulate Gb3, exhibit dysregulated AKT and mTOR 
signaling and dysregulated autophagy. We analyzed changes in cellular signal transduction 
in α-galactosidase A-deficient podocytes treated with agalsidase alfa to further investigate 
the molecular mechanisms underlying podocyte damage.
Methods: For seven days, α-galactosidase A-deficient podocytes were treated with 250 
nM agalsidase alfa. Cells were grown on collagen-coated coverslips, fixed with PFA and 
processed according to standard protocols for immunofluorescence. For mass spectrometry 
and immunoblot detection, cell lysates were used.
Results: Compared to control cells, α-galactosidase A-deficient podocytes showed 
massive Gb3 accumulation in immunofluorescence and mass spectrometry analysis. The 
Gb3 content in Fabry podocytes was significantly reduced after treatment with agalsidase 
alfa. Interestingly, the strong Gb3 clearance dysregulation of the AKT and mTOR signaling 
pathways remained unchanged upon treatment with 250 nM agalsidase alfa for 7 days. In 
both treated and untreated Fabry podocytes autophagic activity was elevated.
Conclusions: A significant reduction of accumulated Gb3 in Fabry podocytes was 
shown with enzyme replacement therapy. Surprisingly, no significant changes in agalsidase-
treated podocytes were detected for key enzymes of autophagy regulation under these 
conditions. In ongoing studies we will use mass spectrometry and different treatment 
conditions to focus on identifying additional proteins modified by Gb3 accumulation.
Funding: Pharmaceutical Company Support - Shire, Government Support - Non-U.S.
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FR-PO324
Loss of Robo2 in Podocytes Protects Adult Mice from Acute Glomerular 
Injury  Anna Pisarek-Horowitz, Xueping Fan, Hila Milo Rasouly, Stefanie Chan, 
Hui Chen, Ramon G. Bonegio, Joel M. Henderson, David J. Salant, Weining 
Lu.  Renal, Boston Univ Medical Center, Boston, MA.
Background: SLIT2 and its receptor ROBO2 play an important role during kidney 
development. We have recently found that ROBO2 is expressed in developing glomerular 
podocytes. However, the role of ROBO2 in the adult mouse kidney, particularly under 
acute glomerular injury conditions, is not clear.
Methods: To test the hypothesis that loss of Robo2 in glomerular podocytes affects 
the outcome of acute glomerular injury, we applied two in vivo acute glomerular injury 
models induced by nephrotoxic serum (NTS) injection and protamine sulfate (PS) perfusion, 
in Robo2 podocyte specific knockout mice (Robo2 cKO) and wild type controls. Kidney 
glomerular ultrastructure was analyzed by scanning and transmission electron microscopy 
before and after injury. Podocyte foot process width and slit diaphragm density were 
measured to quantify the severity of the glomerular injury. Urine albumin to creatinine ratio 
was measured in the NTS model. Podocyte specific gene expression was analyzed using 
TaqMan real time PCR for mRNA and Western blot for protein levels.
Results: Robo2 podocyte specific knockout mice developed less proteinuria after the 
NTS injury with lower urine albumin/creatinine ratio as compared to the wild type controls. 
Electron microscopy showed that Robo2 cKO mice have milder foot process effacement 
and less defects in the slit diaphragm induced by either NTS or PS injury. TaqMan and 
Western blot analyses revealed that nephrin, a crucial transmembrane component of the 
podocyte slit-diaphragm, was significantly up-regulated at both mRNA and protein levels 
in the Robo2 cKO mice before NTS injury and at the late stage of heterologous phase after 
the NTS injury. In addition, the mRNA levels of Robo2 and Slit2 in the wild type kidneys 
were also upregulated after the NTS injury.
Conclusions: SLIT2-ROBO2 signaling pathway plays an important role in the adult 
mouse kidney podocytes and loss of Robo2 protects mice from acute glomerular injury. 
Our findings suggest that SLIT2-ROBO2 signaling might also have a negative impact on 
nephrin expression during podocyte injury and be a potential therapeutic target.
Funding: NIDDK Support, Private Foundation Support
FR-PO325
Inducible Knockdown of Shroom3 Induces Proteinuria with Podocyte 
Dedifferentiation  Madhav C. Menon, Chengguo Wei, Karen Lok Yee Keung, 
Ilana Greene, Weijia Zhang, John C. He, Barbara T. Murphy.  Medicine, Icahn 
School of Medicine at Mount Sinai, New York, NY.
Background: Intronic loci in Shroom3 have been associated with CKD and CAN. 
A role for Shroom3 in the podocyte cytoskeleton has been shown. However Shroom3 
knockout mice die neonatally with neural tube defects and detailed renal phenotypes 
are unknown. Here we report our findings from Doxycycline (DOX) inducible, shRNA-
mediated shroom3 knockdown mice.
Methods: In these mice Shroom3-specific shRNA expression was induced upon DOX-
feeding, with RTTA expression in all cells driven by CAGS-promoter. Six-wk old mice 
were fed DOX-feed/water. Non-DOX fed littermates were controls (n=6 each). At 4- and 
8-weeks, renal tissue was obtained for histology. Twenty-five glomeruli were analyzed per 
mouse and quantification was using imageJ.
Results: DOX-mice developed significantly increased Albumin-to-creatinine ratios 
starting at 2 weeks compared to controls.
Proteinuria persisted at 8 weeks of DOX-feeding. No light microscopic changes were 
detectable on PAS-stained sections in DOX- or control-mice in glomerular mesangial matrix 
expansion or intratubular protein casts upto 8-weeks of DOX feeding. Assessment of WT-1 
stained nuclei/ glomeruli by immunofluorescence (IF) showed no reduction in podocyte 
number at 4- or 8-weeks in DOX-mice compared to controls (p=ns; n=3 each). However, 
by IF, significant reduction in area and intensity of glomerular synaptopodin staining was 
observed by 4 weeks in DOX-mice compared to controls (p<0.01; n=3 each at 4-wks, Fig 
2). Electron microscopic studies are ongoing.
Conclusions: Our preliminary findings suggest that inducible and global knockdown of 
Shroom3 induces proteinuria with features of podocyte dedifferentiation without evidence 
of podocyte loss. Further studies are needed to elucidate the precise role of Shroom3 in 
proteinuria and its function in the glomerular filtration barrier.
FR-PO326
Protective Role of Cyclodextrin in Focal Segmental Glomerulosclerosis 
(FSGS)  Alla Mitrofanova,1,2 Patricia R. Wahl Pristau,1 Ximena A. Morales,1 
Mayrin Correa-Medina,1 Christopher E. Pedigo,1 Gloria Michelle Ducasa,1 
George William Burke,2 Sebastian Martini,3 Matthias Kretzler,3,4 Sandra M. 
Merscher,1 Alessia Fornoni.1  1Katz Family Drug Discovery Center, Nephrology 
& Hypertension, Univ of Miami, FL; 2Surgery, Univ of Miami, FL; 3Internal 
Medicine, Nephrology, Univ of Michigan, MI; 4Computational Medicine & 
Bioinformatics, Univ of Michigan, MI.
Background: We recently demonstrated that cholesterol accumulation contributes to 
podocyte injury in diabetic kidney disease (DKD), where 2-hydroxypropyl-β-cyclodextrin 
(CD) protects podocytes from cholesterol-dependent damage in vitro and in vivo. We 
hypothesize that lipid related genes are affected in glomeruli of patients with primary FSGS 
and treatment with CD protects podocytes in experimental FSGS.
Methods: Microarray analysis on glomerular transcripts of lipid-related genes from 
patients with FSGS (n=54) and from normal living donors (n=6) were obtained from patients 
enrolled in NEPTUNE, a longitudinal observational cohort looking at individuals with 
proteinuria. 5-week-old BALB/c female mice were injected with a single intravenous dose 
of adriamycin (ADR, 11 mg/kg) to develop FSGS-like lesions. 24-hours after ADR injection, 
osmotic pumps with CD in 0.9% saline solution (40 mg/kg/day) were implanted under the 
skin for 10 weeks. Measurements of body weight and urine collections for ACR (Albumin/
creatinine ratios) were performed weekly. At time of sacrifice, serum creatinine and Blood 
Urea Nitrogen (BUN) were determined and kidneys collected for histological analysis.
Results: Microarray analysis of the glomerular transcripts in the NEPTUNE cohort 
demonstrated that cholesterol efflux related genes, such as PLIN3, S1PR2, S1PR4, S1PR1, 
and lipid dysmetabolism related genes, such as SCD, LDLR, ABCG1, were increased in 
FSGS. CD administration reduced mesangial expansion as well as ACR and BUN observed 
at 10 weeks in the ADR+CD group compared to the ADR group (p<0.05). No changes in 
body weight were found.
Conclusions: We concluded that glomerular lipids are altered in FSGS and that 
2-hydroxypropyl-β-cyclodextrin protected podocytes in an experimental model of FSGS. 
Our data suggest that CD could be used as a safe and effective drug therapy in FSGS patients.
Funding: NIDDK Support
FR-PO327
Podocyte-Derived CXCL12 Has a Dual Role in Glomerular Injury and 
Regeneration  Simone Romoli, Santhosh Kumar Vr, Shrikant R. Mulay, Hans 
J. Anders.  Nephrologisches Zentrum, Klinikum der Univ Muenchen, Munich, 
Bavaria, Germany.
Background: Stromal-derived factor (SDF)-1/CXCL12 is a homeostatic chemokine 
facilitating homing and activation of stem cells. Podocytes constitutively produce CXCL12, 
hence, we speculated on a role of CXCL12 in glomerular regeneration upon injury.
Methods: Glomerular injury was induced by a single i.v. injection of 13mg/kg 
adriamycin (ADR) in male Balb/c mice, which received either the CXCL12 inhibitor 
NOX-A12 or the inactive control s.c. at 13.4mg/kg thrice a week. Human renal progenitor 
cell properties (RPC) were used for in-vitro studies.
Results: ADR-induced proteinuria peaked at day 7 (injury phase), which subsequently 
declined without returning back to baseline and being associated within FSGS lesions after 
14 days (repair phase). CXCL12 blockade aggravated ADR-induced A/C and podocyte 
loss at day 7, which implies an autocrine role of CXCL12 for podocyte survival. In 
contrast, CXCL12 blockade reduced A/C levels and the glomerular sclerosis scores as 
well as increased podocyte numbers at 14 days indicating a beneficial effect of CXCL12 
blockade during the repair phase. The pro-survival effect of CXCL12 on podocytes was 
further confirmed in a model of diphtheria toxin-induced podocyte depletion using CXCL12 
blockade. To investigate the dual effect of CXCL12, we focused on the Notch signaling 
pathway. ADR injection reduced renal Notch expression, which was reversed following 
CXCL12 blockade. In-vitro studies with RPC revealed that CXCL12 suppressed RPC 
proliferation, which was reversed with CXCL12inhibitor. Similar results were obtained 
when RPC were exposed to supernatants from necrotic podocytes. CXCL12 blockade also 
increased the capacity of RPC to differentiate into podocytes.
Conclusions: Podocyte-derived CXCL12 has a dual role in glomerular injury. CXCL12 
protects podocytes during the injury phase in an autocrine manner by suppressing Notch 
signaling, which otherwise triggers mitotic catastrophe and podocte loss. Podocyte-derived 
CXCL12 assures Notch-mediated quiescence of RPC. Our data also demonstrate that 
therapeutic CXCL12 inhibition in glomerular injury can improve long term outcomes 
possibly by enforcing the intrinsic regenerative capacity of RPC.
FR-PO328
Shank2 Modulates  Glutamatergic  S ignal ing  in  Podocytes 
Evgenia Dobrinskikh,1 Linda Lewis,1 R. Brian Doctor,2 Judith Blaine.1 
1Medicine, Univ of Colorado, Aurora, CO; 2Biology, Univ of Mississippi, 
Oxford, MS.
Background: Shank2 is a large scaffolding protein that is a master regulator of 
glutamate receptors at the neuronal postsynaptic density. Knockout (KO) of Shank2 
in mice leads to autistic behaviours and abnormal glutamatergic signaling in neurons. 
Podocytes have also been shown to express functional N-methyl D aspartate (NMDA) 
and metabotropic glutamate receptor 1 (mGluR1) receptors which are both members of 
the glutamate receptor family.
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Results: We have found that podocytes express Shank2 in vivo and in vitro. Since 
Shank2 plays an important role in regulating glutamate receptor function, we examined the 
effect of Shank2 knockout on NMDA and mGluR1 expression and function in podocytes. 
Shank2 KO resulted in decreased expression of NMDA and mGluR1 receptors in glomeruli. 
We isolated podocytes from wild type and Shank2 knockout mice and created conditionally 
immortalized podocyte lines. Conditionally immortalized Shank2 KO podocytes also 
demonstrated decreased expression and altered localization of glutamate receptors. In 
neurons, activation of glutamate receptors modulates intracellular calcium levels by allowing 
calcium influx into the cell (NMDA receptors) or release of calcium from intracellular stores 
(mGluR1). Using Fluo-4, a cell permeant calcium sensing dye, we examined intracellular 
calcium levels in wild type and Shank2 KO podocytes. At baseline, Shank2 knockout 
podocytes had significantly fewer calcium spikes than wild type podocytes. Treatment 
with NMDA and glutamate increased the number of calcium spikes in both wild type and 
Shank2 KO podocytes but the number of spikes in the KO podocytes was significantly 
reduced compared to wild type. Podocytes have been shown to communicate with each 
other via calcium waves. To examine podocyte to podocyte communication after injury, 
we “burned” a podocyte using high intensity laser power and then examined calcium wave 
propagation from the site of injury. After burning, wild type podocytes exhibited calcium 
waves emanating from the injured podocyte whereas no waves were seen in the knockouts.
Conclusions: Taken together these data indicate that Shank2 regulates glutamate 
receptor function in podocytes.
Funding: NIDDK Support
FR-PO329
Podocytes Transcytose Albumin and IgG Using the Neonatal Fc Receptor 
(FcRn) In Vitro and In Vivo  Evgenia Dobrinskikh,1 Linda Lewis,1 Jeffrey 
B. Kopp,2 Judith Blaine.1  1Medicine, Univ of Colorado, Denver, CO; 2Kidney 
Disease Section, NIDDK, NIH, Bethesda, MD.
Background: Proteinuria is strongly associated with kidney disease progression. 
Podocytes are key constituents of the glomerular filtration barrier (GFB), which determines 
the selectivity of protein filtration. By even the most conservative estimates between 2 and 
9 g of serum proteins a day normally pass through the GFB. The molecular mechanisms 
whereby podocytes handle albumin and IgG remain to be fully determined.
Results: We have found that transcytosis is the major pathway whereby cultured 
podocytes handle albumin and IgG. In other epithelial cell types, the neonatal Fc receptor 
(FcRn) is required to transcytose endocytosed albumin and IgG, thereby salvaging these 
proteins from degradative pathways. To examine the role of FcRn in albumin and IgG 
transcytosis in podocytes, we knocked down FcRn in cultured podocytes using lentiviral 
shRNA. FcRn knockdown (KD) resulted in a 71±3% decrease in FcRn expression compared 
to control. In an in vitro transcytosis assay, FcRn KD increased intracellular accumulation 
and decreased appearance of albumin and IgG in the supernatant, suggesting impaired 
transcytosis, but the differences were not statistically significant, possibly due to residual 
FcRn. We therefore isolated podocytes from wild type (WT) and FcRn knockout (KO) mice 
and created conditionally immortalized WT and KO podocyte lines. Knockout of FcRn 
resulted in significantly increased intracellular accumulation, assessed by immunostaining 
and Western blot (densitometric analysis of intracellular protein 1 hr after loading showed 
0.37 ± 0.1 (WT) vs 0.97 ± 0.2 (KO), p<0.05 for albumin and 0.52 ± 0.04 (WT) versus 1.03 
± 0.19 (KO), p<0.05 for IgG), and decreased appearance of supernatant albumin or IgG, 
indicating defective transcytosis. We extended our studies to an in vivo model by creating 
a podocyte-specific FcRn KO mouse. Podocyte-specific FcRn KO mice demonstrated 
intraglomerular accumulation of IgG by 8 weeks of age, assessed by immunostaining. 
Studies of albuminuria are in progress.
Conclusions: Taken together, these studies indicate that podocytes in vitro and in vivo 
transcytose albumin and IgG using FcRn.
Funding: NIDDK Support, Private Foundation Support
FR-PO330
Transcriptional Reprogramming by Wilms’ Tumor 1 and FoxC2 in 
Glomerular Disease  Sandrine S. Ettou,1 Lucy Jung,3 Martin Kann,1,2 Mary E. 
Taglienti,1 Peter Park,3 Jordan A. Kreidberg.1  1Nephrology, Boston Children’s 
Hospital, Boston, MA; 2Internal Medicine and Center for Molecular Medicine, 
Univ of Cologne, Cologne, Germany; 3Center for Biomedical Informatics, 
Harvard Medical School, Boston, MA.
Background: Foot process effacement and proteinuria, representing a breakdown of 
the glomerular filtration barrier (GFB) are typically accompanied by decreased expression 
of key podocyte proteins. We sought to determine whether decreased expression of key 
podocyte proteins was caused by transcriptional reprogramming in the injured podocyte. We 
reported a Wilms’ tumor-1 (WT1) ChIP-Seq study that identified components of the GFB 
and many other important podocyte genes as WT1 bound genes. Many WT1 target genes 
in podocytes also appear to be bound by FoxC2, including Podocin (Nphs2), Sulfatase 1 
(Sulf1) and Synaptopodin (Synpo).
Methods: We now use ChIP-Seq to study the DNA binding of WT1 to target genes in 
the context of Adriamycin-induced podocyte injury that is considered a model for human 
FSGS. WT1 ChIP-Seq was performed using isolated glomeruli from 6 days post-injection 
or control Balb/C mice. FoxC2 binding was determined by direct ChIP-qPCR.
Results: Following injury, expression of WT1 and FoxC2 decreased in podocytes, as 
did binding of WT1 and FoxC2 to their common targets. WT1/FoxC2 target gene expression 
was also reduced. In contrast to these WT1/FoxC2 target genes that represent a set of genes 
required for normal podocyte function, we identified a second set of WT1-bound genes, 
not bound by FoxC2, including Hdac5 and 7, whose expression increased after podocyte 
injury and for which WT1 binding decreased, suggesting that WT1 acts as a repressor for 
a distinct set of target genes.
WT1 binding at known target genes showed both decreased and increased peak intensity 
after treatment suggesting that WT1 regulation of gene expression is complex and may 
involve activating and repressive functions.
Conclusions: These results suggest a model whereby WT1 and FoxC2 activate 
gene expression in normal podocytes, WT1 represses other genes in normal podocytes 
independently of FoxC2.
Funding: Other NIH Support - R01
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A Basophilic Kinase Site at the N-Terminus of TRPC6 Controls Channel 
Activity  Henning Hagmann,1 Markus M. Rinschen,1 Alexander Kuczkowski,1 
Stuart E. Dryer,2 Bernhard Schermer,1 Thomas Benzing,1 Paul T. Brinkkoetter.1 
1Nephrology, Univ Hospital Cologne, Cologne, Germany; 2Bichemistry, Univ 
of Houston, Houston, TX.
Background: The non-selective cation channel TRPC6 plays a pivotal role in the 
development of proteinuric kidney disease. Hyperactivity of TRPC6 either through gain of 
function mutations, increased total protein levels or membrane abundance of the channel 
protein has been associated with glomerular disease.
Results: To investigate regulation of the TRPC6 channel activity we conducted mass 
spectrometry experiments to screen for phosphorylation sites in the TRPC6 protein. We 
identified several new as well as previously known phospho-peptides. The serine residues 
in position 13 and 14 of the human TRPC6 protein are phosphorylated and embedded in a 
basophilic kinase motif. Substitution of the serine residue in position 14 with alanine (S14A) 
leads to reduced TRPC6 conductance in voltage clamp experiments in Xenopus oocytes. 
The atypical cyclin-dependent kinase (Cdk5), a serine- threonine-kinase expressed in the 
podocyte, is directed to basophilic motives. In the podocyte, Cdk5 is activated by the specific 
activators p35, p25, and Cyclin I. In cell culture experiments a direct phosphorylation of 
TRPC6 by Cdk5/p35 at position S14 could be confirmed with mass spectrometry and 
radioactive in-vitro kinase assays. Co-expression of Cdk5/p35 and TRPC6 enhanced 
channel conductivity of TRPC6 in voltage clamp experiments. This effect was abrogated 
by the amino acid substitution S14A.
Conclusions: A basophilic kinase site at the N-terminus of TRPC6 was identified 
which controls channel activity. As exemplarily shown for Cdk5/p35, basophilic kinases 
phosphorylate TRPC6 at serine 14 and affect channel function. This site may serve as a 
molecular switch for TRPC6 activity and as a potential future drug target.
Funding: Private Foundation Support
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Hantaviruses Associate with Actin Fibers and Cause Podocyte Damage 
Stefan Hägele,1 Alexandra Kowalski,1 Jochen Reiser,2 Martin G. Zeier,1 Ellen 
Krautkrämer.1  1Nephrology, Univ Hospital Heidelberg, Heidelberg, Germany; 
2Dept of Internal Medicine, Rush Univ Medical Center, Chicago, IL.
Background: Characteristic for the clinical picture of Old World hantaviruses is an 
acute renal failure with often massive non-selective proteinuria. Previously, we showed that 
cell-to-cell contact proteins were disrupted and levels were decreased in infected human 
renal cells, correlating with the clinical picture. However, the exact mechanisms driving 
hantaviral pathogenesis are not well characterized.
Methods: Renal biopsies of patients with acute hantavirus infection were analyzed 
by electron microscopy. A human podocyte cell line was used for infection with Hantaan 
virus (HTNV). Cell-to-cell contact proteins were analyzed by immunoblotting, qRT-PCR 
and immunofluorescence. The cytoskeleton was examined by confocal microscopy and by 
depolymerising drugs. Cell motility was measured by migration assays.
Results: Analysis of renal biopsies revealed podocyte foot process effacement with 
loss of cell-to-cell contacts. To examine the underlying mechanism of hantavirus-induced 
alterations, we performed in vitro infection studies. We showed that HTNV had no influence 
on transcription levels of cell-to-cell contact proteins, indicating another mechanism of 
cell-to-cell contact disruption. Next, we focused on an impact on the cytoskeleton which 
is important for barrier function. We detected a filamentous pattern of the hantaviral 
nucleocapsid (N) protein which was associated with actin fibers. This N protein localization 
depends on the integrity of the actin cytoskeleton, because the filamentous pattern 
disappeared after actin depolymerization. Correspondingly, we measured decreased viral 
release levels after loss of N protein filaments. During infection, we revealed impaired 
podocyte motility as a functional consequence due to hantavirus-induced effects on actin 
dynamics.
Conclusions: These results demonstrate that hantavirus infection leads to podocyte 
injury by morphological changes. Disruption of cell-to-cell contacts may be caused by the 
association of N protein and actin leading to changes in podocyte motility. These findings 
provide useful insights into the mechanism inducing renal failure.
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ARF6: A New Player in Injury-Induced Podocyte Effacement  Jamie Lin,1 
Jin Seok Jeon,2 Qingfeng Fan,1 Lawrence B. Holzman.1  1Renal-Electrolyte 
and Hypertension Div, Univ of Pennsylvania Perelman School of Medicine, 
Philadelphia, PA; 2Dept of Nephrology, Soon Chun Hyang Univ Hospital, 
Seoul, Korea.
Background: The transmembrane slit-diaphragm protein nephrin is tyrosine-
phosphorylated and endocytosed during acute podocyte injury, resulting in cell spreading 
and effacement in vivo. We hypothesize that these events are facilitated by ARF6, a small 
GTPase that regulates endocytosis, endosomal trafficking, and actin dynamics possibly 
through regulation of Rac1, a Rho GTPase.
Methods: Using human podocyte cultures transfected with chimeric nephrin 
intracellular domain, we investigated the molecular mechanisms underlying its role in 
nephrin signaling. Using wild-type, constitutively-active, dominant-negative, and siRNA-
knock-down of ARF6, we assessed lamellipodia activity (a marker of cell spreading) and 
podocyte motility.
Results: Results of co-immunopreciptation suggested that activated nephrin formed a 
signaling complex with ARF6. Furthermore, nephrin tyrosine phosphorylation increased 
ARF6 activity in cultured podocytes. A constitutively active ARF6 mutant resulted in 
increased lamellipodia formation compared to wild-type ARF6, while dominant-negative 
ARF6 mutant resulted in decreased lamellipodia formation. A scratch assay of ARF6 
knock-down cultured podocytes revealed slowed cell migration.
Conclusions: Together, our results suggest that ARF6 is an important protein involved 
in the regulation of injury-induced podocyte cytoskeletal rearrangement. Inhibition of ARF6 
might prevent podocyte effacement and confer a protective phenotype in vivo, making it 
an attractive target for the amelioration of glomerular disease.
Funding: NIDDK Support
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Albumin Sieving Coefficient in Isolated Perfused Kidney: Effects of EDTA 
Turgay Saritas, Ralf Hausmann, Thiago Strieder, Jürgen Floege, Marcus J. 
Moeller.  Nephrology and Immunology, Univ Hospital RWH Aachen, Aachen, 
NRW, Germany.
Background: It is still controversial how the glomerular filter works. The widely 
accepted pore model is limited by multiple unresolved and incomplete issues. Previously, 
we have proposed that an electrical field is generated across the glomerular filter by forced 
filtration of the small solutes in plasma (i.e. water, Na+, K+, Cl-, HCO3-, and divalent ions). 
The electrophoretic force of this electrical field retains plasma proteins within the circulation. 
If validated, this novel ‘electro-kinetic model’ could explain most of the remaining issues 
about the glomerular filter. The model predicts a crucial role of the divalent cations in the 
perfusate (Ca2+and Mg2+) for the generation of the electrical field (‘streaming potential’). 
The aim of the present study was to test this.
Methods: According to the current physical model for the generation of streaming 
potentials with a reversed polarity, a physical phenomenon termed ‘over-charging’ is 
predicted to occur which requires the presence of divalent cations. Thus, to verify the 
‘electrokinetic model’, divalent cations are predicted to be required for generation of the 
electrical field and a physiological low albumin sieving coefficient. Isolated perfused rat 
kidneys (IPK) were perfused-fixed with glutaraldehyde to exclude any cellular effects. 
Subsequently, the absolute concentrations of the major divalent cations (Ca2+, Mg2+) were 
manipulated in our IPK model. Albumin solutions containing 0.9 mM Ca2+ and 0.5 mM 
Mg2+or 0.52 mM ethylenediaminetetraacetic acid (EDTA) were used to perfuse the IPK to 
achieve normal or very low Ca2+ and Mg2+ concentrations within the perfusate.
Results: Decreased polycation concentrations resulted in a significant increase of the 
albumin-sieving coefficient from a baseline value of 0.0031±0.00024 to 0.0068±0.0014 
(+120%, n=5, p< 0.05). Changes in albumin sieving coefficient were partially reversible. 
The glomerular filtration rate was stable.
Conclusions: The results indicate that Ca2+ and Mg2+ are required for the integrity of the 
glomerular filter. Cellular artifacts or active transport processes were excluded by fixation. 
The results support the electrokinetic model of glomerular filtration.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
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γ Isoform of Phosphoinositide 3 Kinase Plays a Role for Podocyte Damage 
and Is a Potential Marker for Glomerular Sclerosis  Tomoko Hayashida, 
Xiaoyan Liang, H. William Schnaper.  Pediatrics, Northwestern Univ, Chicago, IL.
Background: We recently reported that, in the Adriamycin (ADR)-induced mouse 
glomerular sclerosis (GS) model, the γ isoform of the p110 catalytic subunit (p110γ) 
of phosphoinositide 3 kinase is selectively upregulated in podocytes of the sclerosing 
glomeruli, and that a specific inhibitor to p110γ (AS605240) prevented proteinuria and 
GS. Here, we evaluated the molecular mechanisms by which p110γ mediates podocyte 
damage in vitro and a possible role for p110γ in a mouse genetic model of GS in vivo.
Methods: CD2AP+/-, synaptopodin+/- mice develop FSGS-like lesion to a variable 
degree at age 8-9 months. Mice were sacrificed at 8 months old and glomerular COL1A2 
mRNA content was evaluated by qPCR of laser-captured glomeruli. Fixed kidney sections 
were stained for p110γ, and positive staining was counted in manually identified glomeruli 
(~100 gloms per section) using the TissueGnostics system. In vitro, podocytes were 
isolated from wild type (WT) or p110γ kinase-dead knock-in (KD) mouse mated with the 
Immortomouse, and cellular signaling was evaluated in cells overexpressing GFP-actin with 
or without ADR treatment by live-cell imaging with an Andor spinning confocal microscope.
Results: The mice showed variable levels of proteinuria and GS. p110γ-positive cells 
per total nuclei in glomeruli correlated significantly with glomerular COL1A2 mRNA 
content. In culture, p110γ KD podocytes, but not WT cells, demonstrated increased 
membrane ruffling along with distinct Rac1 staining at the membrane, and KD podocytes 
were resistant to in vitro ADR treatment. WT cells expressing constitutively active p110γ 
showed decreased cytoskeletal assembly and cytoDEATH early apoptosis marker staining 
was detected, suggesting that p110γ activity directly mediates podocyte dysfunction.
Conclusions: p110γ expression in podocyte correlates with degree of GS, and therefore, 
a potential maker for GS. p110γ activity mediates podocyte damage by affecting signals 
that is critical for cytoskeletal structure.
Funding: NIDDK Support
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Effects of FSGS-Associated Mutations on the Stability and Function of 
Myosin-1  Mira Krendel, Jing Bi, Robert T. Carroll, Michael L. James, Jessica 
L. Ouderkirk, Vladimir Sirotkin.  Cell and Developmental Biology, SUNY 
Upstate Medical Univ, Syracuse, NY.
Background: Myo1e is expressed in podocytes and plays a key role in regulating the 
integrity of their cell-cell junctions, however, the effects of FSGS mutations on Myo1e 
motor activity and stability have not been directly tested. In this study, we used a simple 
model organism, fission yeast Schizosaccharomyces pombe, to test the effects of FSGS-
associated mutations on myosin activity. Fission yeast has only one class I myosin, Myo1, 
which is involved in actin patch assembly at the sites of endocytosis.
Methods: The amino acid residues mutated in the FSGS patients are conserved between 
human Myo1e and yeast Myo1, which allowed us to introduce equivalent mutations into 
yeast myosin and use the resulting mutant strains for functional analysis. Myo1-mGFP 
localization and stability was analyzed using fluorescence imaging and Western blotting, 
while Myo1 functional activity was tested using growth and endocytosis assays.
Results: Yeast strains expressing mutant Myo1 exhibited defects in growth and 
endocytosis similar to those observed in the myo1 deletion strain. These mutations also 
disrupted Myo1 localization to endocytic actin patches and resulted in mis-localization 
of Myo1 to eisosomes, linear membrane microdomains found in yeast cells. While both 
mutants examined in this study exhibited loss of function, one of these mutants was also 
characterized by the decreased protein stability.
Conclusions: Using the yeast model system we were able to determine that the kidney 
disease-associated mutations impair myosin functional activity and have differential effects 
on protein stability. This study provides the first example of using fission yeast as a model 
system to test the effects of FSGS mutations on Myo1e function. This novel system allowed 
us to definitively establish for the first time the connection between the myosin motor 
activity and its ability to support normal glomerular filtration.
Funding: NIDDK Support
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Vinculin Binds Zonula Occludens-1 (ZO-1) and Is Required for Podocyte 
Stabilization of the Slit Diaphragm following Injury  Xuefei Tian, Kazunori 
Inoue, Shuta Ishibe.  Dept of Internal Medicine, Yale Univ School of Medicine, 
New Haven, CT.
Background: Cell-matrix interactions and intercellular junctions in podocytes are 
important factors to prevent protein leakage through the glomerular filtration barrier. 
Vinculin, a cytoplasmic protein, links the actin filaments to integrin-based cell-matrix 
proteins and cadherin-based intercellular junctions. We have observed that vinculin is 
highly expressed in podocytes, and appears to be critical in maintaining slit diaphragm 
integrity following injury through its interaction with ZO-1.
Methods: Wild type and Vinculin (Vcl) podocyte knock out (KO) mice were analyzed 
to determine the role of vinculin in vivo, and primary podocytes were isolated for in vitro 
studies.
Results: Podocyte specific ablation of Vcl resulted in no significant difference in body 
weight, albuminuria, and kidney histology up to 18 months when compared to littermate 
controls. However, Pod-Vcl KO mice had significantly increased albumin/creatinine ratios 
following lipopolysaccharide (LPS) or rabbit anti-mouse glomerular basal membrane 
(NTS) induced podocyte damage respectively (284±40 vs 411±31 µg/mg, and 205±28 vs 
314±38 µg/mg, P<0.05). In addition, loss of Vcl in podocytes resulted in worsened foot 
process effacement. Co-immunoprecipitation assays demonstrated that vinculin associates 
with ZO-1 in the primary podocytes and isolated glomeruli respectively. Cell fractionation 
of control and Pod-Vcl KO podocytes treated with either LPS or protamine sulfate (PS) 
revealed a mislocalization of ZO-1 and nephrin to the cytoplasm in the mutant podocytes 
when compared to the control. These findings were further validated by immunofluorescence 
imaging of the primary podocytes following LPS or PS stimulation and from isolated 
glomeruli following LPS or NTS stimulation. No changes in cell adhesion or focal adhesion 
number were observed between the control and Pod-Vcl KO podocytes following LPS or 
PS stimulation on various substrates.
Conclusions: Our results reveal an association between vinculin and ZO-1 in podocytes. 
Loss of Vcl in podocytes results in the mislocalization of slit diaphram proteins ZO-1 and 
nephrin following injury, thus exacerbating proteinuria.
Funding: NIDDK Support
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AT1 Receptors in Podocytes Control GFR and Susceptibility to Kidney 
Injury  Stacy Alana Johnson,1 Tiffani N. White,1 Susan B. Gurley,1,2 Thomas 
M. Coffman.1,2,3  1Duke Univ; 2Durham VA; 3Duke-NUS.
Background: Angiotensin II, acting via AT1 receptors, plays a critical role in CKD 
progression. Pharmacologic blockade of AT1 receptors reduces albuminuria and this is 
linked to its efficacy in CKD. Within the kidney, the density of AT1 receptor expression 
is highest in the glomerulus, where AT1 receptors are expressed in multiple cell lineages 
and are involved in regulating glomerular pressures and GFR. However, the key cellular 
sites of action in the glomerulus involved in physiological regulation and in promoting 
proteinuria have not been directly defined. Since podocyte dysfunction and injury have 
been implicated in the pathogenesis of many glomerulopathies, we investigated the role 
of AT1 receptors in podocytes using cell-specific gene targeting.
Methods: Because the minor AT1 receptor isoform (AT1B) is expressed at significant 
levels in podocytes, we generated mice lacking all AT1 receptors in the podocyte (PodKOs) 
by carrying out podocyte-specific, Cre-mediated excision of a conditional allele of the major 
AT1 receptor isoform (AT1A) on an AT1B-null background.
Results: PodKO mice develop normally with kidney weights similar to controls 
(6.9±0.5 vs 7.0 ± 0.3 mg/g BW) and their glomerular morphology appears normal. GFR 
was significantly reduced in 24-week old PodKOs (8.9±3.5 µl min-1g-1) compared to controls 
(29.5±4.5 µl min-1g-1; p=0.04), but there was no significant difference in the low levels 
of albumin excretion between the groups. To determine whether the elimination of AT1 
receptors from podocytes impacts albuminuria and kidney injury in a model with high levels 
of Ang II, a transgene (RenTg) driving constitutive expression of renin was crossed onto the 
PodKO background. At 24 weeks of age, levels of albuminuria were increased in RenTg 
mice (210±71 µg/24 hr) compared to controls (29±9 µg/24 hr; p=0.02), but this increase 
in albuminuria was unaffected in RenTg-PodKOs (229±38 µg/24hr). Despite similar levels 
of albumin excretion, kidneys from RenTg-PodKO mice had exaggerated kidney injury 
with more glomerulosclerosis, mesangial expansion and tubular casts.
Conclusions: Our results suggest that AT1 receptors in podocytes do not promote 
albuminuria and may protect against glomerular injury.
Funding: Private Foundation Support
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H2O2 Production by Nox4 Drives Ang II – Dependent Calcium Influx 
Through TRPC6 Channels in the Podocytes  Daria Ilatovskaya, Oleg Palygin, 
Leonid S. Shuyskiy, Alexander Staruschenko.  Physiology, Medical College of 
Wisconsin, Milwaukee, WI.
Background: Improper Ca2+ handling by the podocyte can result in cell damage and 
loss of function. Podocyte depletion and associated glomerulosclerosis are typical for 
progressive chronic nephropathies, which have been associated with elevated levels of 
ROS, including H2O2. One of the key mediators of Ca2+ flux in the podocytes is a TRCP6 
channel. The goal of this study was to provide a mechanistic insight into the Ang II-
dependent regulation of TRPC6 channel.
Methods: Changes in intracellular Ca2+ levels were measured with live confocal 
microscopy in podocytes of isolated glomeruli. Patch clamp analysis was performed to 
assess the activity of TRPC channels in this preparation. Enzymatic biosensors technique 
was applied to determine H2O2 release in the kidney cortex and isolated glomeruli.
Results: NADPH oxidase 4 (Nox4) is one of the main renal sources of H2O2. Here 
we demonstrated substantial attenuation of Ang II-evoked H2O2 release in the kidney 
and glomeruli suspension of the Nox4-/- rats, generated on the Dahl salt-sensitive (SS) 
background. Furthermore, basal Ca2+ levels and Ca2+ influx in response to Ang II were 
decreased in the podocytes of Nox4-/- rats compared to SS rats. Basal Ca2+ level increase 
was also attenuated in Nox4-/- podocytes when rats were fed a high salt diet. To further test 
effects of H2O2, we employed patch clamp analysis. The data revealed an acute increase 
in TRPC6 channel open probability in response to H2O2. A dose-dependent increase in 
intracellular Ca2+ was observed when H2O2 was applied (2.5 µM to 300 µM; EC50=56 
µM). Lower concentrations of H2O2 caused a transient Ca2+ peak, whereas doses of 50 µM 
and higher evoked a long-term Ca2+ elevation attributed to apoptotic effects. Experiments 
with TRPC6-/- and TRPC5/6 double KO mice showed a diminished Ca2+ response to H2O2.
Conclusions: Our data indicate that in the podocytes Ang II stimulates generation of 
H2O2 by the Nox4, which evokes a dose-dependent Ca2+ influx through TRPC6 channels. 
This mechanism might be an important determinant of podocyte loss in kidney diseases 
associated with oxidative stress and elevated interstitial Ang II levels.
Funding: Other NIH Support - R01 HL108880, R01 122662 (NHLBI)
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Role of Unliganded Vitamin D Receptor (VDR) in Providing Podocyte 
Protection During AT1R Blockade (BLK) in Adverse Milieus  Tejinder Singh,1 
Kamesh R. Ayasolla,1 Shabirul Haque,1 Nirupama Chandel,1 Himanshu 
Vashistha,2 Ashwani Malhotra,1 Leonard G. Meggs,2 Pravin C. Singhal.1 
1Medicine, Hofstra North Shore LIJ Medical School, Great Neck, NY; 2Medicine, 
Ochsner Health System, New  Orleans, LA.
Background: AT1R-BLK is used extensively to slow down the progression of kidney 
diseases. We hypothesized that AT1R-BLK provides podocyte protection through regulation 
of VDR and silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) 
expression under adverse milieus (AMs).
Methods: Human podocytes (HPs) were treated with losartan (AT1RB) or VDR agonist 
(EB1089;VDA) with or without AMs (HIV/high glucose/Ang II; 48h) and evaluated for 
mRNA and protein expressions of Cytochrome P450 Family 24 (CYP24)A1, VDR and 
molecular markers of co-repressor and co-activator complexes. Protein interactions in these 
complexes were evaluated by immunoprecipiatation (IP) studies followed by Western blot 
analysis. Role of protesomal degrdation of VDR in AMs was determined.
Results: Both AT1R-BLK and VDA stimulated VDR complexes formation that differed 
in their composition and in their functionality. AT1R-BLK- induced VDR complexes 
contained unliganded VDR, SMRT, and phospho-histone deacetylase (HDAC)3, whereas, 
VDA-VDR complexes were constituted by liganded VDR and CBP/p300. AT1R-BLK-
induced complexes attenuated podocyte acetyl- histone (Ac-H)3 levels and CYP24A1 
expression, thus indicating their de-acetylasing and repressive properties. On the other 
hand, VD-VDR complexes not only increased podocyte Ac-H3 levels but also enhanced 
CYP24A1 expression, thus suggesting their acetylating and gene activation properties. 
AT1R-BLK- induced podocyte SMRT inhibited expression of the pro-apoptotic gene BAX 
through down regulation of Wip1 and phosphorylation of Chk2 in high glucose milieu. Since 
SMRT-depleted podocytes lacked AT1R-BLK-mediated protection against DNA damage, 
it appears that SMRT is necessary for DNA repairs during AT1R-BLK.
Conclusions: AT1R-BLK provides podocyte protection in AMs predominantly 
through SMRT expression and partly through unliganded VDR expression in 1, 25(OH)2D 
deficient states, on the other hand, ATR1-BLK contributes to liganded VDR expression in 
1, 25(OH)2D sufficient states.
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Enhanced S-Nitrosylation and N-Glycosylation of Podocin-R138Q 
May Contribute to Its Defective Trafficking and Rapid Degradation 
Maria Carmen Serrano-Perez,1 Fabien Nevo,1 Christelle Arrondel,1 Alda Tufro,2 
Corinne Antignac,1 Geraldine Mollet.1  1Inserm U1163 - Imagine Inst - Paris 
Descartes Univ-Sorbonne Paris Cité, France; 2Yale Univ School of Medicine- 
Dept of Pediatrics.
Background: Missense mutations in the NPHS2 gene, encoding podocin, are a major 
cause of inherited and sporadic cases of steroid-resistant nephrotic syndrome (SRNS). 
Among them, those encoding endoplasmic reticulum (ER)-retained mutant proteins, e.g. 
R138Q, correlate with the most severe cases of SRNS.
Methods: We generated two human podocyte cell lines stably expressing 2HA-
podocinwt or 2HA-podocinR138Q to perform comparative studies on podocin post-translational 
modifications and podocin degradation.
Results: We detected increased podocin S-nitrosylation and N-glycosylation in 
2HA-podocinR138Q vs. 2HA-podocinwt podocytes, which may modify podocin topology, 
degradation and trafficking. We also suggest that a further interaction of podocinR138Q 
with the ER-chaperone calnexin may contribute to its ER-retention. In line with the 
higher degradation rate of podocinR138Q previously found in R140Q knock-in mice, we 
found that non-glycosylated (ng) podocinR138Q has a dramatically shorter half-life than 
podocinwt. Moreover, the N-glycosylated forms of podocinR138Q are more stable than its 
non-glycosylated fraction. We also show that ng-podocinR138Q is mainly degraded by 
the proteasome, whereas ng-podocinwt can be degraded by both the proteasomal and the 
lysosomal proteolytic machineries. Furthermore, preventing ng-podocinR138Q degradation 
allows its partial localization to the podocyte filopodia, improves the ratio between its non-
glycosylated and glycosylated forms and reduces its interaction with calnexin.
Conclusions: These findings show podocin S-nitrosylation for the first time and suggest 
that increased S-nitrosylation and N-glycosylation may contribute to the defective trafficking 
and degradation of podocinR138Q, the product of the most frequent human podocin missense 
mutation, and possibly of other ER-retained podocin missense mutants.
Funding: Government Support - Non-U.S.
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RAS Inhibition Enhances Proliferation and Migration of Cells of Renin 
Lineage (CoRL) as Progenitors in Experimental FSGS  Julia Lichtnekert,1 
Diana G. Eng,1 Jeffrey W. Pippin,1 Kenneth W. Gross,2 Stuart J. Shankland.1 
1Div of Nephrology, Univ of Washington, Seattle, WA; 2Dept of Molecular and 
Cellular Biology, Roswell Park Cancer Inst, Buffalo, NY.
Background: RAS inhibitors are used therapeutically in proteinuric glomerular 
diseases. In focal segmental glomerulosclerosis (FSGS) where podocyte number is depleted, 
recent data showed that ACE-Inhibitors could improve podocyte number. Because adult 
podocytes cannot proliferate, their replacement by renal progenitors is critical for their 
regeneration in disease. The impact of RAS blockade on adult podocyte progenitors is 
not well understood.
Methods: Experimental FSGS characterized by podocyte depletion was induced by 
an anti-podocyte antibody in two strains of Cells of Renin Lineage (CoRL) reporter mice 
(RenCre and RenCreER) where CoRL are fate mapped. Diseased mice were randomized 
at day 3, when podocyte number was depleted by 40%, to receive Enalapril or Losartan, or 
the controls Hydralazine or water. BrdU was injected to monitor proliferation.
Results: Following initial podocyte depletion in all groups, podocyte number (measured 
by p57 staining) was higher in both Enalapril and Losartan groups on d14 and d28. This 
was accompanied by significantly lower proteinuria and glomerulosclerosis. The number 
of CoRL increased in the intra-glomerular compartment in FSGS mice given water or 
hydralazine. However, the number of labeled CoRL further increased significantly in 
FSGS mice given Enalapril or Losartan. A subset of CoRL detected in the glomerular 
compartment co-expressed several markers for podocytes and PEC’s. RAS inhibition 
increased BrdU staining in CoRL in the juxta- and intraglomerular compartments, but 
was not seen in podocytes.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
433A
J Am Soc Nephrol 26: 2015 Cell Biology: Glomerular - I Poster/Friday
Conclusions: Following the abrupt depletion of adult podocytes in experimental FSGS, 
RAS blockade significantly increased their number despite the absence of their proliferation. 
This regeneration of adult podocytes is likely in part due to proliferation and migration of 
CoRL progenitor cells into the glomerular compartment. We show the first time that RAS 
inhibition has the potential to stimulate progenitor cells necessary for kidney repair and 
regeneration following podocyte depletion.
FR-PO343
ShcA Influences Nephrin Endocytosis and Protects from Glomerular Injury 
Claire E. Martin,1 Kelly A. Petersen,1 Lamine Aoudjit,2 Tomoko Takano,2 Nina 
Jones.1  1Molecular and Cellular Biology, Univ of Guelph, Guelph, ON, Canada; 
2Dept of Medicine, McGill Univ, Montreal, QC, Canada.
Background: The transmembrane protein nephrin is a key component of the slit 
diaphragm (SD). It has recently been postulated that nephrin turnover plays a key 
role in maintaining a healthy SD, and multiple theories regarding the role of nephrin 
phosphorylation in endocytosis are emerging. Tyrosine phosphorylation of the cytoplasmic 
tail of nephrin facilitates recruitment of several signaling proteins that regulate podocyte 
shape and thereby permselectivity of the SD. Previous work from our lab has identified and 
mapped the interaction between nephrin and the ShcA adaptor protein and demonstrated an 
early requirement for ShcA in maintenance of the filtration barrier in mice. Given ShcA’s 
established role in endocytosis, we now hypothesize that ShcA may regulate nephrin 
endocytosis to ultimately maintain filtration barrier integrity.
Methods: Multiple approaches were used to measure the influence of ShcA and 
ShcA domain mutants on the levels of surface nephrin and signaling downstream of 
nephrin. Puromycin aminonucleoside (PAN) nephrosis was induced in Sprague-Dawley 
rats for 0, 4, 7, or 14 days and nephrin endocytosis was monitored via biotinylation and 
immunofluorescence experiments.
Results: We demonstrate that ShcA expression is increased in podocytes in response to 
PAN injury, which is accompanied by activation of the stress-activated p38 and JNK MAP 
kinases. Interestingly, we found that transactivation of AP-1, which occurs downstream of 
nephrin as well as p38 and JNK, is attenuated by ShcA, and this effect is reversed by mutation 
of the ShcA SH2 domain, which mediates nephrin binding. Further investigation revealed 
that ShcA promotes nephrin endocytosis in a phospho-dependent manner by enhancing 
Src-mediated nephrin phosphorylation, its own binding to nephrin and endocytosis into 
EEA1-positive endosomes both in vitro and in PAN-treated rats.
Conclusions: Together these findings suggest a protective effect of ShcA in podocytes 
by influencing phospho-dependent nephrin endocytosis and possibly attenuating nephrin-
mediated p38/JNK signaling in response to injury.
Funding: Government Support - Non-U.S.
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Podocyte Specific Response to Complement Challenge  Anne Katrin Dettmar,1,2 
Magdalena Riedl,2 Fred G. Pluthero,2 Moin Saleem,3 Jun Oh,1 Christoph Licht.2 
1Dept of Pediatrics, Univ Medical Center Hamburg-Eppendorf; 2Dept of 
Pediatric Nephrology, Hospital for Sick Children; 3Academic Renal Unit, 
Univ of Bristol.
Background: There is a multilayered system of fluid phase and surface bound 
complement regulatory proteins, which ensure that complement activation occurs only 
site specific and spares the body’s own cells. Unrestricted complement activation is 
a main cause for damage in complement-mediated glomerulopathies such as C3G or 
membranous nephropathy (MN). In MN, podocytes, key components of the glomerular 
filtration barrier, are target of overshooting complement activation.The aim of this study 
was to characterize the complement defense mechanisms in podocytes and their response 
to complement challenge (CC).
Methods: We analyzed complement regulators by immunofluorescence, flow 
cytometry and qRT-PCR in immortalized human podocytes and compared them to blood 
grown endothelial cells (BOECs). Functionality of secreted complement factor H (CFH) 
was tested via a cofactor assay. In a model for CC (sensitization with antibodies against 
membrane-anchored complement regulators CD46, CD55 and CD59 and normal human 
serum (NHS)) we analyzed C3c deposition, LDH-release, and cell morphology.
Results: Podocytes showed similar levels of CD46, CD55 and CD59 as BOECs. 
Expression of CFH-mRNA was higher in podocytes (1.03 +/-0.27 vs. 0.25 +/-0.09 fold 
change, p=0.03). Podocyte secreted CFH served as active cofactor to CFI in splitting C3b. 
CC led to increased C3c deposition (NHS vs CC: 660+/-189 vs 5290+/-2231 MFI, p=0.05), 
which was complement dependent (heat inactivated serum: 211+/-25, p=0.04) . There was a 
significant increase in LDH release (NHS vs. complement 1.92 +/-0.98 vs. 2.30 +/-0.86 fold 
increase, p=0.02), and podocytes showed a reduction of stress fibres and cell size after CC.
Conclusions: In summary, podocytes expressed complement regulators in response 
to complement activation similar to the response found in BOECs. CFH, less abundant in 
BOECs, may play an important role in a complement specific stress response of podocytes. 
These findings might help to understand the role of podocytes in local complement activation 
and will help to identify new therapeutic strategies in future.
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Ephrin-B1 Is Essential for the Formation and the Maintenance of the 
Integrity of the Slit Diaphragm Component: Inducible Podocyte-Specific 
Ephrin-B1 Deletion Causes Irregular Localization of Nephrin, NEPH1, 
CD2AP and ZO-1  Yoshiyasu Fukusumi, Hiroshi Kawachi.  Dept of Cell 
Biology, Inst of Nephrology, Niigata Univ Graduate School of Medical and 
Dental Sciences, Niigata, Japan.
Background: Ephrin and eph function as receptor-ligand pairs, and are reported to 
play multiple functions in several tissues. We have reported ephrin-B1 was expressed at the 
podocyte slit diaphragm (SD) and had an interaction with nephrin, a critical component of 
the SD (Kidney Int 72: 954, 2007). However, the function of ephrin-B at the SD is remained 
uncertain. In this study, the role of ephrin-B at the SD and the functional association of 
epnrin-B and nephrin were elucidated.
Methods: (i)The expressions of the SD components (nephrin, NEPH1, podocin, 
CD2AP and ZO-1) were analyzed in tamoxifen-inducible podocyte-specific Ephrin-B1 
knockout (KO) mice (Podocin-CreERT2; Ephrin-B1 flox/flox). (ii)The effect of the nephrin 
stimulation on the molecular conformation of ephrin-B were analyzed.
Results: (i)Tamoxifen-induced inactivation of the ephrin-B1 gene at E18.5 resulted in 
the dislocalization of nephrin, NEPH1, CD2AP and ZO-1, although podocin dislocalization 
was not detected. These alterations of the molecular arrangement of the SD components were 
also detected in the mice of which ephrin-B1was deleted at 3 month-old with tamoxifen 
(KO vs. cont, n=5: nephrin, score 3.11 vs 3.40, p<0.01; NEPH1: 2.97 vs 3.36, p<0.05; 
CD2AP, 3.01 vs 3.24, p<0.05; ZO-1: 3.28 vs 3.66, p<0.05). (ii) Not only nephrin but also 
ephrin-B was phosphorylated in the rat nephrotic model caused by the injection with the 
antibody against nephrin, although phosphrylation of these molecules was not detected 
in normal rats. The phosphrylation of these molecules were detected already at 1 h after 
the antibody injection. The ephrin-B phosphorylation was also induced by the treatment 
with the anti-nephrin antibody in HEK293 cells co-transfected with ephrin-B and nephrin.
Conclusions: Ephrin-B1 is essential for the formation and the maintenance of the 
proper arrangement of the SD molecules. The stimulation to nephrin with the antibody 
phosphorylated not only nephrin but also ephrin-B, indicating ephrin-B is functionally 
associated with nephrin.
Funding: Government Support - Non-U.S.
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Ubiquitin C-Terminal Hydrolase-L1 Deficiency in Podocytes Protects 
from Immune Complex Nephritis in Mice  Julia M. Fehlert,1 Marlies Sachs,1 
Thorsten Wiech,2 Rolf A. Stahl,1 Catherine Meyer-Schwesinger.1  1Nephrology, 
III. Medical Clinic, Univ Medical Center Hamburg-Eppendorf, Hamburg, 
Germany; 2Pathology, Univ Medical Center Hamburg-Eppendorf, Hamburg, 
Germany.
Background: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) is a central 
deubiquitinating enzyme of the neuronal ubiquitin proteasomal system. UCH-L1 is thought 
to regulate the intracellular pool of monoubiquitin in neurons. Recently we identified a 
de novo expression of UCH-L1 in podocytes of patients with membranous nephropathy. 
Upregulation of UCH-L1 correlated with disease progression, accumulation of ubiquitinated 
proteins and altered expression of podocyte-specific proteins in human and rodent podocytes. 
Inhibition of UCH-L1 enzymatic function in a rat model of membranous nephropathy 
decreased the abnormal protein accumulation and ameliorated the clinical course of disease. 
We generated mice with podocyte-specific UCH-L1-deficiency to investigate the role of 
UCH-L1 de novo expression in injured podocytes.
Methods: Mice with podocyte-specific UCH-L1-deficiency were generated by Cre-
Lox technology and back-crossed into the C57/BL6 background. Podocyte phenotype was 
evaluated by morphological (immunohistochemistry, electron microscopy) and biochemical 
techniques (Western blotting, proteasomal activity assays, real-time PCR) in unchallenged 
and anti-podocyte antibody challenged wildtype and knock-out mice.
Results: Unchallenged podocyte-specific UCH-L1-deficient mice exhibited normal 
podocyte morphology throughout life and delayed age-related proteinuria accompanied 
by a decreased accumulation of poly-ubiquitinated proteins. Following induction of anti-
podocyte nephritis, podocyte-specific UCH-L1-deficient mice showed decreased signs of 
podocyte injury and decreased proteinuria despite a comparable immunologic reaction to the 
injected anti-podocyte antibodies. Podocyte-specific proteins such as nephrin and podocin 
were stabilized and protein accumulation was decreased. UCH-L1-deficiency resulted in 
increased proteasomal capacity and activity in injured podocytes.
Conclusions: Podocyte-specific UCH-L1-deficiency protects podocytes from age-
related degenerative changes and from immune complex nephritis through increased 
proteasomal capacity.
Funding: Government Support - Non-U.S.
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Adhesion and Repulsion of Podocytes: Role of EphB-Receptors 
Eva Koenigshausen, Julius Hoffacker, Lukas Ludwig Peter Heimann, Nils Tim 
Haep, Magdalena Woznowski, Ivo Quack, Lars C. Rump, Lorenz Sellin.  Univ 
Hospital Duesseldorf.
Background: Eph-receptor kinases mediate cell adhesion and repulsion at specialized 
cell contacts. Eph-receptor kinases bind to their cell-membrane bound ligands, the ephrines. 
Ephrinb1 and EphB4 have been localized at the slit diaphragm. The molecular function 
of the EphB1,2,3 receptors in podocytes is unknown so far. Proteinuria is a hallmark for 
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glomerular disease and results from disruption of the glomerular filter. The slit diaphragm 
is a specialized cell-cell contact between adjacent podocytes. Maintenances of the correct 
positioned, adjacent podocytes has not been well understood.
Methods: RNA was isolated from differentiated human podocytes and isolated murine 
glomeruli and PCR performed. Human podocytes were retrovirally transduced with EphB2-
YFP or ephrinb1-CFP. EphB2-YFP and ephrinb1-CFP podocytes were differentiated in 
co-cultures and time lapse video imaging was performed. In addition, a co-culture of 
differentiated EphB2-YFP and ephrinb1-CFP cells was examined. To investigate the role 
of the intracellular domains of the EphB2 receptor and ephrinb1 ligand, truncated mutants 
of EphB2 (EphB2.DC-YFP) and ephrinb1 (ephrinb1.DC-CFP) were analyzed.
Results: Human podocytes as well as murine glomeruli express EphB1, 2 and 3 
receptors. Co-cultures of differentiating EphB2-YFP and ephrinb1-CFP podocytes show 
repulsion between the two cell types. Transendocytosis (YFP particles in CFP cells and 
vice versa) occurs in both cell types during repulsion. The repulsion is dependent on the 
intracellular domain of EphB2 as EphB2.DC-YFP cells adhere to ephrinb1-CFP and 
ephrinb1.DC-CFP cells. However, repulsion is maintained in co-cultures of EphB2-YFP 
with ephrinb1.DC-CFP cells. Co-culture experiments of differentiated, confluent podocytes 
confirm the results presented above.
Conclusions: EphB2 receptors mediate podocyte repulsion upon binding to their 
ligand ephrinb1. The EphB2 receptor cytoplasmic domain seems to be crucial for repulsion. 
Maintaining the correct podocyte distance within the highly organised glomerular 
architecture is not been well understood. These cell culture data provide a promising 
concept of potential regulation of podocyte distance in vivo.
FR-PO348
Overexpression of the Splice Isoform VEGF165b Is Sufficient for Kidney 
Function when All VEGF Isoforms Are Depleted  Megan Stevens, Chris R. 
Neal, Andy Salmon, David O. Bates, Steven J. Harper, Sebastian Oltean.  Univ 
of Bristol, United Kingdom.
Background: Chronic kidney disease is associated with reduced VEGF-A expression. 
However, the role VEGF-A splice isoforms play in kidney physiology and pathology is 
unclear. Use of an alternative 3’ splice site in the terminal exon of VEGF-A results in 
the expression of anti-angiogenic VEGF165b. Previous studies suggest that VEGF165b is 
protective in renal function in diabetic rodent models. This study aimed to investigate 
whether constitutive podocyte over-expression of VEGF165b is able to rescue the injury 
phenotype seen in the inducible podocyte-specific VEGF-A KO mouse. The mechanism 
of action of VEGF165b within the glomeruli was also investigated.
Methods: Podocyte-specific VEGF-A KO was induced via doxycycline for 10-14 
weeks in WT, VEGF-A KO and VEGF-A KO x neph-VEGF165b mice. In situ hybridization 
confirmed a knock-down of VEGF-A. The kidney functional phenotype was determined 
through the urinary albumin creatinine ratio (uACR) and measurement of glomerular water 
permeability. Electron microscopy was used to examine the ultra structure of the glomeruli, 
and immunofluorescence to determine the expression levels of podocyte and endothelial-
specific proteins. Glomerular endothelial cells (GEnCs) in culture were used to determine 
the mechanism of action of VEGF165b through VEGFR-2.
Results: The VEGF165b isoform alone is sufficient to rescue the increase in albuminuria 
and glomerular water permeability in the context of progressive depletion of all VEGF-A 
isoforms. Ultra structural studies show glomerular basement membrane thickening and 
increased podocyte slit width in the VEGF-A KO mouse, with both being rescued in the 
VEGF165b over-expressors. VEGF165b also restores PECAM expression in GEnCs, and 
glomerular capillary circumference. Mechanistically, VEGF165b increases VEGFR-2 
expression and phosphorylation both in vivo and in vitro. Furthermore, it down regulates 
genes involved in the migration and proliferation of GEnCs, which are otherwise up 
regulated by VEGF165.
Conclusions: Our study indicates that VEGF-A splice isoform manipulation could be 
a novel therapeutic avenue in chronic glomerular disease.
Funding: Other NIH Support - Medical Research Council & The Richard Bright 
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Rituximab Prevents TNFα Induced Podocyte anb3 Integrin Activation 
Farah Leclercq, Christopher E. Pedigo, Alessia Fornoni, Sandra M. Merscher. 
Katz Family Drug Discovery Center, Nephrology, Univ of Miami, FL.
Background: Focal Segmental Glomerulosclerosis (FSGS) is a disease characterized 
by podocyte damage and scarring of the glomeruli. FSGS accounts for up to 20% of 
end stage renal disease (ESRD) cases in the United States. Podocyte urokinase-receptor 
(uPAR) dependent aVb3 integrin activation and decreased glomerular sphingomyelin 
phosphodiesterase acid-like 3b (SMPDL3b) expression were described in glomerular 
biopsies from patients with FSGS. Circulating TNFα is increased in a fraction of patients 
with FSGS and anti-TNFα therapy has shown efficacy in a subset of patients with recurrent 
FSGS. We hypothesized that TNFα reduces SMPDL3b expression resulting in anb3 
Integrin activation.
Methods: Differentiated human podocytes were cultured in the presence of TNFα 
(100ng/ml). Caspase 3 activity was determined in human podocytes. Protein and mRNA 
was isolated and the expression of key genes was investigated by Western blot analysis and 
quantitative real time PCR. Rituximab was used at the dose of 100 ug/mL.
Results: TNFα treatment of human podocytes significantly reduced SMPDL3b 
expression (p<0.05), increased uPAR expression (p<0.05) and b3 integrin activation 
(p<0.05). TNFα treatment induced caspase 3 activity, which was prevented by preserving 
SMPDL3b expression with Rituximab (p<0.05) or by inhibiting b3 integrin activation 
with cycloRGD (p<0.05). Likewise, SMPDL3b overexpressing podocytes were protected 
from TNFα induced b3 integrin activation. Injection of recombinant TNFα in mice led to 
increased glomerular uPAR mRNA expression (p<0.05) and caused albuminuria (p<0.05), 
which was significantly attenuated with Rituximab (p<0.05).
Conclusions: TNFα decreases SMPDL3b expression, increases uPAR expression and 
activates b3 integrin signaling leading to podocyte injury and apoptosis. Our data suggest 
that treatments targeting the TNFα–SMPDL3b-b3 integrin axis may prevent podocyte 
injury in FSGS.
Funding: NIDDK Support, Pharmaceutical Company Support - Hoffman La Roche
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Deletion of the Major Soluble Flt1 Isoform from Mice Reveals New Vegf 
Decoy Variants  Biao Li,2 Tuncer Onay,1 Chengjin Li,2 Vera Eremina,2 Susan 
E. Quaggin.1,2  1Feinberg Cardiovascular Research Inst; 2Lunenfeld-Tanenbaum 
Research Inst.
Background: sVEGFR1 (sflt1) is an alternative splicing product of VEGFR1 (flt1) 
gene. Both flt1 and sflt1 can function as “decoy receptors” for VEGF. sflt1 plays a key 
role in maintaining avascularity of the cornea, and increased circulating levels of sflt1 
are linked to preeclampsia. Moreover, deletion of flt1 from mouse podocytes results 
in proteinuria at 6 weeks of age, while deletion of the kinase signaling domain of this 
receptor alone results in no renal phenotype. In vitro studies showed that sflt1 can induce 
formation of foot process-like structures in human podocytes. We hypothesize that sflt1 
regulates podocyte cytoskeletal dynamics and glomerular barrier function by titrating local 
glomerular Vegf levels.
Methods: To determine function of the soluble variant of Flt1 in the glomerulus, 
we generated a conditional KO model for the single sFlt1 (sFlt1 cKO) isoform reported 
in mice (removal of intron 13). Renal phenotype was examined by evaluating kidney 
function and histology. qPCR and Northern blot were used to identify splice variants of flt1; 
3’RACE was used to clone the spliced genes. Proteins of splice variants were generated 
by BacMam system.
Results: We generated sflt1 cKO mice, and confirmed the deletion of Flt1 intron 
13 using Southern blot. Surprisingly, it did not result in any overt kidney phenotype by 
6 months of age. Northern blot and Western blot analyses revealed the existence of a 
major compensatory isoform, previously reported as human-specific. We also confirmed 
the existence of 17 new sFlt1 isoforms in RNA isolated from mice and 12 from human 
preeclamptic placentas.
Conclusions: We report a large number of novel, soluble flt1 isoforms in both mouse 
and human placenta samples.  We posit that the presence of these isoforms compensates 
for the loss of sflt1 in our transgenic model.   The functions of these isoforms warrant 
further investigation and may provide insight into regulation of Vegf levels, podocyte 
function and preeclampsia.
Funding: Government Support - Non-U.S.
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Polarity Signaling at the Kidney Filtration Barrier: Questioning the 
Function of Par3A  Sybille Köhler,1,2 Markus M. Rinschen,1,2 Carien M. 
Niessen,4 Wilhelm Bloch,3 Bernhard Schermer,1,2 Thomas Benzing,1,2 Paul 
T. Brinkkoetter.1,2  1Dept II of Internal Medicine and Center for Molecular 
Medicine, Univ Hospital Cologne, Germany; 2Cologne Excellence Cluster on 
Cellular Stress Responses in Aging-Associated Diseases (CECAD), Univ of 
Cologne, Germany; 3Dept of Molecular and Cellular Sport Medicine, German 
Sport Univ Cologne, Germany; 4Dept of Dermatology and CECAD Cologne, 
Univ of Cologne, Germany.
Background: The slit diaphragm (SD) represents the only cell-cell contact in-between 
neighbouring podocytes. Classical adherence as well as tight junction proteins are part 
of this protein-protein supercomplex including ZO-1, occludin, catenins and cadherins. 
Polarity signaling is critical to maintain the SD complex as the Par3/Par6/aPKC complex 
clusters at the SD via direct interaction of Par3 with neph/nephrin via its PDZ-domains.
Methods: To understand the role of the Par3 proteins at the slit diaphragm, we generated 
a novel podocyte specific Par3A knockout mouse model where exon 6 is flanked by loxP 
sites. Following podocin:cre mediated recombination expression of all known Par3A 
isoforms should be abrogated. We validated cre recombinase efficiency, lack of Par3A 
mRNA and protein expression by qPCR from isolated primary podocytes as well as by 
immunofluorescence stainings on renal sections.
Results: Mice were born in predicted Mendelian frequency. Par3Apko mutants appeared 
as healthy as wt Par3Aflox/flox mice at birth and did not show any signs of disease in their 
later life. Even challenging Par3Apko mice with the albumin overload model did not result 
in an overt glomerular phenotype. Therefore, we performed additional immunoprecipitation 
experiments for aPKCiota out of immortalized mouse podocytes and carried out nLC-MS/
MS analysis to identify the aPKCiota podocyte interactome. Interestingly, the most abundant 
aPKCiota interacting proteins were Par6 and Lgl1/2.
Conclusions: Our results challenge the current view of the aPKC/Par3/Par6 complex 
and its role at the slit diaphragm. In contrast to tight junctions where aPKC-signaling 
depends on clustering by Par3A, its role at the SD is independent of Par3A. Here Lgl1/2 
seem to be the predominant interactors clustering aPKC/Par6 at the SD.
Funding: Government Support - Non-U.S.
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Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor (FSPF) 
Interacts with Glomerular Filtration Barrier Through Glycoconjugates 
Ram Sharma,1 Ellen T. McCarthy,2 Tarak Srivastava,3 Virginia J. Savin,1 Mukut 
Sharma.1  1Renal Research, KC VA Medical Center- MBRF, Kansas City, MO; 
2Kidney Inst, KU Medical Center, Kansas City, KS; 3Renal Div, UMKC Children’s 
Mercy Hospital, Kansas City, MO.
Background: Galactose (Gal) blocks the FSGS serum-induced increase in in vitro 
glomerular albumin permeability (Palb) (Trans Res 2008, 151:288-292) and decreases 
proteinuria in some patients with recurrent FSGS (NDT 2009, 24:2938-2940). Thus, the 
interaction of FSPF with glomerular cell surface glycoconjugates may play an essential 
role in its effect on the filtration barrier.
Methods: We selected sugars and lectins to model the interaction between glomerular 
glycoconjugates and FSPF. We used, (i) affinity techniques to evaluate the binding of FSPF 
with immobilized sugars (ii) immobilized neuraminidase to remove sialic acid to assess its 
significance in FSPF-induced increase in Palb and (iii) Gal/N-acetyl Gal (GalNac)-specific 
lectins to determine their effect on Palb as FSPF mimetics.
Results: Plasma FSPF activity was retained by immobilized Gal, GalNac or 
galactosamine. Gal dose-dependently blocked FSPF-induced increase in Palb (10-9-10-6 M) 
and partially reversed the effect of FSPF on Palb (p<0.01). In contrast, glucose, glucosamine 
or mannose did not interact with FSPF. Removal of sialic acid by neuraminidase diminished 
the FSPF-induced increase in Palb. We screened twenty Gal/GalNac-specific lectins as 
potential mimetics of FSPF. Only Dolichos biflorus agglutinin (DBA, 10 mg/mL) and 
Helix pomatia lectin (10 mg/mL) increased Palb to 0.65 and 0.55, respectively (p<0.001). 
The increases in Palb, like that induced by FSPF were blocked by Gal (100 µM) (p<0.001).
Conclusions: One or more carbohydrate-recognizing domains of FSPF participate 
in its interaction with specific sugar(s) of glomerular cells resulting in altered filtration 
barrier function. Our novel findings regarding the affinity of FSPF for select sugars, the 
loss of activity after removal of sialic acid and the direct effect of certain lectins on barrier 
function provide new information regarding the molecular composition of FSPF and its 
interaction with glomerular proteins/glycolipids.
Funding: NIDDK Support, Veterans Administration Support
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EPB41l5 Is a Critical Regulator of the Kidney Filtration Barrier 
Christoph Schell,1 Martina Suhm,1 Manuel Rogg,1 Martin Helmstaedter,1 Mariko 
Hirano-Kobayashi,2 Tobias B. Huber.1  1Dept of Nephrology, Univ Medical 
Center Freiburg, Freiburg, Baden-Württemberg, Germany; 2Laboratory for 
Vertebrate Body Plan, Center for Developmental Biology - RIKEN, Kobe, 
Kobe, Japan.
Background: Podocyte loss represents the final common pathway of various glomerular 
pathologies. Hence, tightly regulated adhesion towards the glomerular basement membrane 
is a fundamental biological process of glomerular podocytes.
Methods: Based on podocyte single cell isolation and a mass-spec candidate approach 
the composition of podocyte focal adhesions was resolved. Combining a drosophila 
nephrocyte model with a newly generated conditional mouse model and various high 
resolution microscopy techniques (TEM, STORM) the candidate protein EPB41l5 was 
analyzed.
Results: Knockdown of the Epb41l5 homolog Yurt in drosophila nephrocytes resulted 
in mis-localization of slit membranes and defective endocytic capacity. Evaluation of a 
conditional knockout model revealed a rapid loss of podocytes implicating deregulated 
adhesion of podocytes. Employing immunogold electron microscopy and STORM super 
resolution microscopy EPB41l5 was clearly localized towards the basal compartment of 
podocytes, in close proximity to INTEGRIN-beta1. Further functional experiments revealed 
that loss of EPB41l5 resulted in decreased activation of INTEGRIN-beta 1, reflected by 
altered migratory behavior of primary podocytes.
Conclusions: Our findings indicate that EPB41l5 is a highly conserved, specific 
regulator of podocyte adhesion by modulating focal adhesion composition and function. 
Future studies will need to clarify its potential implications in genetic and acquired 
glomerular pathologies.
FR-PO354
The Effect of Anti-PLA2R Autoantibodies on Human Podocytes In Vitro 
Maryline Fresquet,1 Rachel Lennon,1 Paul E. Brenchley.2  1Wellcome Trust Centre 
for Cell-Matrix Research, Univ of Manchester, Manchester, United Kingdom; 
2Inst of Cardiovascular Sciences, Manchester Royal Infirmary, Manchester, 
United Kingdom.
Background: PLA2R was identified as a major target antigen in idiopathic membranous 
nephropathy. 70% of patients have circulating autoantibodies which bind this receptor on the 
podocyte leading to immune complex deposition in the glomerular basement membrane. We 
recently identified the major epitope on PLA2R recognised by anti-PLA2R autoantibodies, 
produced the first 3D model of PLA2R domains and demonstrated that autoantibodies are 
of high affinity. We seek to understand if affinity-pure anti-PLA2R alone in the absence of 
complement can modulate podocyte function.
Methods: We prepared affinity purified human anti-PLA2R (91% IgG4, 9% IgG2) and 
assessed podocyte morphology following autoantibody treatment using immunofluorescence 
staining of actin and measurement of cell surface area and circularity. Integrity of the 
filtration barrier was assessed by Electric Cell-substrate Impedance Sensing and the 
response of a confluent monolayer of differentiated podocytes to 10mg/ml purified human 
anti-PLA2R and purified human IgG was measured. Cell apoptosis was determined by 
cleaved caspase-3 staining in podocytes and oxidative stress was measured with CellROX 
reagent in differentiated podocytes challenged with the autoantibody.
Results: We have developed an in vitro podocyte model to define mechanisms of 
anti-PLA2R effects on cell morphology and function. Purified anti-PLA2R altered podocyte 
shape, with rounding and loss of actin stress fibres within 24 hours. Integrity of a confluent 
podocyte monolayer was significantly reduced at 72 hours by anti-PLA2R but not by the 
IgG control. Within 30 minutes of anti-PLA2R treatment, there was evidence of caspase-3 
cleavage in podocytes peaking at 6 hours promoting apoptosis. In the same time frame 
anti-PLA2R induced free radical generation (P<0.0001, treated v. untreated), triggering 
oxidative stress which could be neutralised using a scavenger.
Conclusions: Anti-PLA2R in the absence of complement activation modulates podocyte 
cell biology by inducing changes in cell shape and monolayer permeability, activation of 
free radical production and apoptosis.
Funding: Private Foundation Support
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Deletion of the Ste20-Like Kinase, SLK, in Podocytes Induces Injury 
Andrey V. Cybulsky,1 Elena Torban,1 Joan Papillon,1 Julie Guillemette,1 Natalya 
Belkina.2  1Medicine, McGill Univ, Montreal, QC, Canada; 2NIH, Bethesda, MD.
Background: SLK is essential for embryonic development, and may play a key role 
in wound healing, tumor growth and metastasis. Expression and activation of SLK is 
increased during recovery from ischemic acute kidney injury. Overexpression of SLK in 
glomerular epithelial cells/podocytes in vivo induces injury and proteinuria. Conversely, 
insufficient SLK expression leads to abnormalities in cell adhesion, spreading, and motility. 
Tight regulation of SLK expression thus appears to be critical for normal renal structure 
and function. We address the functional role of SLK in podocytes.
Methods: Podocyte-specific SLK knockout (KO) mice were produced by breeding mice 
with loxP sites surrounding exons 4-7 with podocin (NPHS2)-Cre mice. LoxP-mediated 
excision results in deletion of the kinase domain. Deletion of SLK exons 4-7 in glomeruli 
was confirmed with PCR.
Results: Podocyte-specific deletion of SLK resulted in albuminuria at 4-5 months of 
age in male mice, and 8-9 months in female mice, which persisted for up to 13 months 
(albumin/creatinine in KO was 2-3-fold above control). At 11-12 months, KO mice did 
not show renal histologic abnormalities by light microscopy, and glomerular area of KO 
was comparable to control. However, by electron microscopy, KO mice showed focal foot 
process effacement and microvillous transformation of podocyte plasma membranes. Mean 
foot process width was ~2-fold greater in KO, compared to control. By immunofluorescence 
microscopy, WT1-positive cells were reduced by 35% in KO mice compared to control, and 
staining for nephrin and podocalyxin was reduced in KO mice by 20-30%. SLK is reported 
to phosphorylate ezrin. Staining for phospho-ezrin/radixin/moesin (ERM) was reduced by 
20% in KO glomeruli, in keeping with reduced SLK catalytic activity in glomeruli; however, 
tubular phospho-ERM staining was comparable in KO and control.
Conclusions: Podocyte-specific deletion of SLK leads to albuminuria, loss of podocytes 
and morphologic evidence of podocyte injury. Thus, SLK is essential to the maintenance 
of podocyte integrity as mice age. The mechanism may, at least in part, relate to ezrin 
phosphorylation and cytoskeletal integrity.
Funding: Government Support - Non-U.S.
FR-PO356
A Podocyte-Specific Knockout of the DNA Repair Gene Ercc1 Leads to 
Proteinuria and Focal Segmental Glomerulosclerosis  Fabian Braun,1 Roman 
Aaron Akbar,1 Björn Schumacher,2 Wilhelm Bloch,3 Bernhard Schermer,1,2 
Thomas Benzing,1,2 Christine E. Kurschat.1,2  1Nephrology, Univ Hospital 
Cologne, Cologne, Germany; 2CECAD, Univ Hospital Cologne, Cologne, 
Germany; 3German Sport Univ Cologne, Cologne, Germany.
Background: The prevention and therapy of aging-related diseases will become a major 
health problem. Among elderly patients mild to severe impairment of kidney function is 
common. Models to study renal aging have not been established yet.In a previous study, 
we identified a progeria mouse model of Ercc1-deficiency to exhibit expression profiles 
similar to those of glomerular aging in wt mice. Ercc1 is involved in nucleotide excision 
repair, facilitating 5’ incision around bulky DNA lesions. In humans, the lack of Ercc1 
leads to a progeria phenotype. Thus, a podocyte-specific knockout of Ercc1 may help us 
gain new insights into glomerular and podocyte aging processes.
Methods: Ercc1flox/flox mice were bred in a mixed CD1/FVB background with CD1 
mice expressing Cre recombinase under the podocin promoter. We analyzed weight, urine 
and serum of animals at 7, 9, 11 and 13 weeks of age. Kidneys were fresh-frozen in OCT, 
fixed in paraformaldehyde and embedded in paraffin or prepared for electron microscopy.
Results: Ercc1pko mice are born in normal mendelian ratios and show no developmental 
abnormalities. We detected an onset of proteinuria at week 8 to 10. Animals maintain a 
normal weight curve compared to controls until week 11 to 18. 7 week old kidneys show 
no morphological changes in light or electron microscopy. Male and female mice develop 
foot process effacement and focal segmental glomerular sclerosis at 9 weeks of age. This 
phenotype is aggravated by week 11. PAS staining of end-stage kidneys reveals sclerosed 
glomeruli, interstitial fibrosis with tubular atrophy and tubular protein casts. We observed 
an increase in DNA damage shown by positive pH2A.X staining in glomerular nuclei at 
week 11.
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Conclusions: Our study reveals a critical role for nucleotide excision repair in murine 
podocytes. This severe and early phenotype underlines the importance of podocyte DNA 
maintenance in these postmitotic cells. In ongoing studies we will characterize the role of 
Ercc1 in a podocyte cell culture model.
Funding: Government Support - Non-U.S.
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Mice Heterozygous for Rac1 in the Podocyte Are Protected against 
Nephrotoxic Serum Nephritis-induced Albuminuria, but Knockout Mice 
Are Not  Stephanie Wylie,1 Jinghui Luo,1 Yingbao Yang,1 David J. Salant,2 
Jeffrey B. Hodgin.1  1Pathology, Univ of Michigan, Ann Arbor, MI; 2Renal 
Section, Boston Univ Medical Center, Boston, MA.
Background: Podocyte injury, either by genetic or acquired abnormalities, can lead 
to progressive proteinuria and glomerulosclerosis. Current treatments are not designed 
to specifically target the podocyte but are used for broader immunotherapeutic or anti-
inflammatory properties, thus podocyte-targeted therapies are needed. Rac1, a member 
of the Rho GTPase family, has been suggested as a therapeutic target for podocyte injury. 
However we previously demonstrated that podocyte-specific Rac1 knockout mice have 
exacerbated albuminuria with a hypertensive injury model. We hypothesize that partial 
reduction of podocyte Rac1 is protective.
Methods: We employed the nephrotoxic serum (NTS) nephritis model, which 
causes predominant podocyte injury and high-grade proteinuria without appreciable 
inflammation, in wild-type (WT), podoRac1-KO (podoRac1-KO), and podocyte-specific 
Rac1 heterozygous mice (podoRac1-HET). A separate group of NTS treated WT mice 
were given EHT1864 (40mg/kg), a Rac inhibitor. Mice were injected with NTS (1.5 mg/
kg body weight) (n=8-10 mice per group) and placed in metabolic cages for 1 or 2 days 
for daily urine collection. Urine albumin was measured by SDS-PAGE gel with standard 
curve, normalized by urine creatinine.
Results: NTS treatment resulted in robust albuminuria in wild-type mice on days 1 
and 2 with albumin-to-creatinine ratios (ACR) of 400-500 ug/mg. However, podoRac1-KO 
mice showed an equally robust albuminuric response on day 1, but less on day 2 compared 
to wild-type,suggesting accelerated recovery. In contrast, NTS treated podoRac1-HET mice 
demonstrated nearly 70% reduction in ACR compared to wild-type (130 versus 390 ug/
mg, P<0.01). The Rac inhibitor EHT1864 was equally effective.
Conclusions: These results demonstrate that a partial reduction in Rac1 activity, through 
genetic or pharmacologic inhibition, provides a protective effect against NTS-mediated 
podocyte injury, whereas Rac1 deletion is not beneficial. Our findings should help guide 
the development and assessment of Rac1 inhibitors to target podocyte injury.
Funding: NIDDK Support, Private Foundation Support
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The Ectodomain of Syndecan-4 Increases Surface Expression of Podocyte 
TRPC6 Channels: An Essential Role for Integrin Signaling  Eunyoung Kim, 
Hila Roshanravan, Stuart E. Dryer.  Biology and Biochemistry, Univ of Houston, 
Houston, TX.
Background: Excessive activation of podocyte TRPC6 channels has been implicated 
in glomerular diseases. Syndecan-4 (Sdc-4) is a type-1 single-pass proteoglycan that can 
be cleaved to produce a soluble product capable of paracrine and autocrine signaling. A 
previous study (1) showed that the Sdc-4 core protein increases the surface expression of 
TRPC6 in podocytes. Here we show that the Sdc-4 ectodomain can also modulate TRPC6 
channels and we describe some of the pathways that surround this effect.
Methods: Cell surface expression of TRPC6 was monitored using surface biotinylation 
assays and whole-cell patch clamp recordings from cultured mouse podocytes. Signaling 
pathways were examined using assays for activated components and selective inhibitors. 
Protein interactions were examined by co-immunoprecipitation and confocal microscopy.
Results: We have confirmed previous studies showing effects of over-expression and 
knockdown of Sdc-4 core protein on podocyte TRPC6 (1). In addition, exposing podocytes 
to Sdc-4 ectodomain caused an increase in the surface abundance of TRPC6, accompanied 
by an increase in cationic currents evoked by diacylglycerol (OAG). Sdc-4 ectodomain 
increased the generation of reactive oxygen species (ROS) and effects of Sdc-4 on TRPC6 
were blocked by the ROS quencher TEMPOL. Exposure to Sdc-4 ectodomain caused 
activation of NFATc1 and Rac1, inhibition of RhoA, and increased the total abundance of 
b3-integrin. However, Sdc-4 ectodomain effects on surface expression of TRPC6 persisted 
after inhibition of calcineurin or NFAT. The Sdc-4 core protein immunoprecipitated and 
co-localized with b3-integrin in podocytes. Moreover, effects of Sdc-4 ectodomain were 
inhibited by cilengitide, an inhibitor of outside-in signaling through av-containing integrins. 
Exposure to TNF caused a marked increase in shedding of Sdc-4 ectodomain from podocytes 
into the surrounding medium. This also occurred after over-expression of Sdc-4 core protein.
Conclusions: Locally produced Sdc-4 ectodomain may play a role in regulating 
podocyte TRPC6 channels and may contribute to glomerular pathology. (1) Liu et al. 
(2012). Atherioscler Thromb Vasc Biol 32: 378-385.
Funding: Private Foundation Support
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Regulation of Fascin-1 by Mechanical Stress in Podocytes  Felix Kliewe,1 
Christian Scharf,2 Sandra Schordan,1 Elisabeth Rumpel,1 Katrin Darm,2 
Silke Vogelgesang,3 Kerstin U. Amann,4 Henny Wegner,1 Jürgen Giebel,1 
Karlhans Endlich,1 Nicole Endlich.1  1Anatomy and Cell Biology, Univ 
Medicine of Greifswald, Greifswald, Germany; 2ENT, Univ Medicine of 
Greifswald, Germany; 3Pathology, Univ Medicine of Greifswald, Germany; 
4Nephropathology, Univ Hospital of Erlangen, Germany.
Background: Glomerular hypertension causes glomerulosclerosis via the loss of 
podocytes, which are challenged by an increased mechanical load. We and others have 
demonstrated that podocytes are mechanosensitive cells. However, the response of 
podocytes to stretch remains incompletely understood.
Methods: Using 2D fluorescence difference gel electrophoresis (2D DIGE), we 
analyzed the proteome of cells of our mouse podocyte cell line that were cultured on flexible 
membranes with or without cyclic biaxial mechanical stress (0.5 Hz, 5% linear strain, 3 d).
Results: Mechanical stress profoundly altered the podocyte proteome. Several 
spots containing the actin-bundling protein fascin-1 were differentially regulated by 
mechanical stress. By immunofluorescence, fascin-1 was found to colocalize with nephrin 
in mouse kidney sections. The presence of fascin-1 in foot processes was confirmed by 
immunoelectron microscopy. Knockdown of fascin-1 in cultured podocytes increased 
the cell loss in response to mechanical stress. The mRNA levels of fascin-1 were not 
affected by mechanical stress. However, mechanical stress resulted in an almost complete 
dephosphorylation of fascin-1. It is known that phosphorylation at Ser-39 regulates the 
bundling activity of fascin-1, e.g. required for filopodia formation. Podocytes expressing 
wild type GFP-fascin-1 and non-phosphorylatable GFP-fascin-1-S39A showed marked 
filopodia formation, being absent in podocytes expressing phosphomimetic GFP-fascin-
1-S39D. Finally, the immunofluorescence signal of phosphorylated fascin-1 was strongly 
reduced in glomeruli of patients with diabetic nephropathy as compared to glomeruli of 
healthy controls.
Conclusions: In summary, mechanical stress dephosphorylates fascin-1 in podocytes 
thereby increasing the actin-bundling activity of fascin-1. Fascin-1 may play an important 
role in the adaptation of podocytes to mechanical stress.
Funding: Government Support - Non-U.S.
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Deletion of the Vps34 Downstream Effector PIKfyve Establishes Milder 
Endocytic Dysfunction in Healthy Glomerular Podocytes Compared 
to Proximal Tubular Cells  Madhusudan Venkatareddy, Rakesh Verma, 
Sanjeevkumar R. Patel, Puneet Garg.  Internal Medicine/ Nephrology, Univ of 
Michigan, Ann Arbor, MI.
Background: The mechanisms by which the glomerular filtration barrier prevents 
the loss of large macromolecules and at the same time maintain the filter remain poorly 
understood. Recent studies have proposed that podocytes play an active role in both 
endocytosis of filtered macromolecules and maintaining the filtration barrier.
Methods: We generated podocyte and proximal tubular specific deletion of PIKfyve 
using the cre-loxP system. Indirect IF and immune EM was used to assess the endocytic 
pathways.
Results: Deletion of a key endosomal trafficking regulator, the class III phosphoinositol 
3-kinase or Vps34 in podocytes results in aberrant endosomal membrane morphology and 
podocyte dysfunction. We recently demonstrated that the vacuolation phenotype in cultured 
Vps34-deleted podocytes is due to the absence of a substrate for the Vps34 downstream 
effector PIKfyve. PIKfyve is a Fyve finger domain containing phosphoinositide 5-kinase 
that phosphorylates Vps34-generated phosphatidylinositol (PtdIns)3P to produce PtdIns(3,5)
P2. PIKfyve perturbation and PtdIns(3,5)P2 reduction have been shown to result in 
massive membrane vacuolation along the endosomal system. We show here that deletion of 
PIKfyve in endocytically active proximal tubular cells resulted in the development of large 
cytoplasmic vacuoles that appear as a result of arrested endocytic traffic progression at a 
late-endosome stage. In contrast, deletion of PIKfyve in podocytes did not alter significantly 
the endosomal morphology even in aged, 18-month-old mice. However upon culturing, 
the PIKfyve-deleted podocytes obtained from the knockout mouse developed massive 
cytoplasmic vacuoles. Measurement of phosphoinositides using HPLC shows reduction 
of both PtdIns(3,5)P2 and PtdIns(5)P in PIKfyve deleted podocytes in vitro confirming 
reduced PIKfyve enzymatic activity following deletion. Using double fluorescent mtmG 
mouse we were able to confirm Cre-mediated gene deletion in both podocytes and proximal 
tubular cells in vivo.
Conclusions: In summary, these data suggest that healthy podocytes have a low level 
of endocytic flux in vivo.
Funding: NIDDK Support
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Albumin-Induced Podocyte Injury Can Be Endocytosis-Independent 
Shipra Agrawal,1 Xiaojing Nie,1 Tetsuya Kitao,1 Melinda A. Chanley,1 William 
E. Smoyer.1,2  1Clinical and Translational Research, Research Inst at Nationwide 
Childrens Hospital, Columbus, OH; 2Pediatrics, Ohio State Univ, Columbus, 
OH.
Background: Endocytosis plays a crucial role in podocytes in nephrotic syndrome, 
wherein podocytes are exposed to serum levels of albumin. We have previously reported 
an association between podocyte exposure to albumin (and its associated factors) and 
proteinuria, cell injury and induction of pro-inflammatory genes. We thus hypothesized that 
albumin-induced podocyte injury can also be partially endocytosis independent.
Methods: Endocytosis was analyzed by fluorescence microscopy and fluorometry in 
cultured differentiated podocytes at varying temperatures and times and in the absence and 
presence of inhibitors of clathrin- and caveolae-mediated endocytosis. Cells were analyzed 
for viability, activation of major kinases (p38, ERK1/2, JNK, MK2), and expression of 
pro-inflammatory, heat shock, and glucocorticoid-regulated genes.
Results: Endocytosis was detected in podocytes at 37°C, but not at 4°C, and was 
attenuated by inhibitors for both clathrin- and caveolae-mediated endocytosis. Inhibition 
of endocytosis, however, did not correlate with reductions in kinase activation or pro-
inflammatory gene induction. While albumin exposure resulted in lower endocytosis in 
murine vs. human podocytes, murine cells activated kinases, induced pro-inflammatory 
genes and exhibited cell death more than human podocytes.
Conclusions: Inhibition of both clathrin- and caveolae-mediated albumin endocytosis 
did not correlate with activation of kinases and induction of pro-inflammatory genes in 
podocytes. Moreover, disparate responses were identified in human vs. mouse podocytes 
with regard to albumin endocytosis, cell injury, kinase activation, and pro-inflammatory gene 
induction. Taken together, our data suggest that although podocytes endocytose albumin 
in both clathrin- and caveoloe-mediated manners, albumin-induced podocyte injury can 
occur in an endocytosis-independent manner.
Funding: NIDDK Support
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Genome-Modified Pluripotent Stem Cells Reveal a Critical Role for 
Podocalyxin in Human Podocyte Morphogenesis  Benjamin S. Freedman,1,2,3 
Craig R. Brooks,1,2 Jing Zhou,1,2 Joseph V. Bonventre.1,2  1Brigham and Women’s 
Hospital; 2Harvard Medical School; 3Univ of Washington School of Medicine.
Background: Human pluripotent stem cells (hPSCs) can self-renew extensively and 
differentiate into diverse tissues. We investigated the potential of hPSCs to differentiate 
into kidney podocytes, and used CRISPR/Cas9 gene editing to explore the function of 
podocalyxin, an apical sialomucin altered in glomerular disease states.
Methods: Cas9 nuclease and guide RNAs targeting PODXL were transfected into 
hPSCs. PODXL-/- clones were identified by chromatogram and immunoblot analysis. 
hPSCs were differentiated stepwise with growth factors into kidney progenitor cells 
(SIX2+PAX2+) and subsequently kidney tubular organoids. Podocyte marker expression 
was investigated by confocal microscopy in unmodified or PODXL-/- organoids of otherwise 
identical genetic background.
Results: In kidney organoids, podocyte markers including podocalyxin, WT1, and 
synaptopodin were strongly expressed in tight clusters of spherical cells, which resembled 
capillary loop stage podocytes by electron microscopy. These cells did not react with LTL, 
but arose in capsule-like termini in LTL+LRP+ proximal tubules. Podocalyxin coated the 
plasma membrane, whereas ZO-1, synaptopodin, and β-catenin co-localized in linear tracks 
between adjacent cells. PODXL-/- hPSCs differentiated into similar clusters, which did not 
express podocalyxin. In PODXL-/- clusters, ZO-1, synaptopodin, and β-catenin failed to 
organize into linear tracks, instead migrating laterally in a diffuse expression pattern. This 
correlated with a ~ 40 % decrease in intercellular distance between nuclei, compared to 
unmodified isogenic controls.
Conclusions: hPSCs can differentiate into cells resembling immature podocytes. 
Podocalyxin is dispensable for podocyte specification, but is required for proper organization 
of junctional complexes and podocyte spacing. Our findings suggest a functional role 
for podocalyxin in the establishment of human podocyte architecture. Genome-modified 
hPSC-podocytes present a new tool for investigating human podocytes, with potential for 
‘disease in a dish’ models and therapeutic screens.
Funding: NIDDK Support, Private Foundation Support
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Molecular Targeting of Neph1 Signaling: A Therapeutic Approach to 
Protect Podocyte Injury  Deepak Nihalani,1 Ehtesham Arif,3 Fnu Ashish,2 
Lawrence B. Holzman.1  1Medicine, Univ of Pennsylvania, Phladelphia, PA; 
2Proteomics, Inst of Microbial Technology, Chandigarh, India; 3Medicine, 
Temple Univ, Philadelphia, PA.
Background: Glomerular injuries that induce podocyte dysfunction are the leading 
causes of renal malfunction. Podocyte proteins Nephrin and Neph1 are essential components 
of the glomerular filtration barrier and signaling from these proteins is involved in 
maintaining podocytes structure and function. Thus understanding the mechanisms that 
regulate signaling and organization of these proteins are therapeutically valuable.
Methods: This study presents a novel hypothesis that attenuating Nephrin and Neph1 
signaling is therapeutically significant in protecting podocytes from injury. Consistent with 
this hypothesis, using a unique protein transduction approach, we recently demonstrated 
that inhibiting Neph1 signaling protected podocytes from injury. Since we first reported the 
solution structures of Neph1CD and ZO-1-PDZ1, we used them to identify novel molecules 
or compounds that can specifically bind Neph1 and target its interactions.
Results: Using a novel approach of targeting protein-protein interaction, we identified 
many potential molecules and to test the proof of principle and the validity of this approach, 
one of the compounds ID (isodesmosine) was commercially procured and investigated. 
Biochemical experiments suggested that addition of ID under in vitro and in vivo conditions 
significantly increased and stabilized the interaction between Neph1 and ZO-1. As a 
consequence, induction of glomerular injury by PAN (puromycinaminonucleoside) did 
not alter the distribution of Neph1 at the podocyte cell membrane; in addition, these cells 
resisted injury induced changes in their actin cytoskeleton. Furthermore, using an in vivo 
zebrafish model system, we demonstrated that pre-treatment with ID rescued zebrafish from 
adriamycin induced toxicity and preserved their renal filtration system.
Conclusions: Collectively, this is the first study that provides compelling initial 
evidence that molecular approaches can be used to directly target slit diaphragm proteins 
to prevent podocyte damage.
Funding: NIDDK Support
FR-PO364
Extracorporeal Mesenchymal Stromal Cell Therapy for Critical Care 
Biju Parekkadan.  Surgery (Bioengineering), Harvard Medical School, 
Massachusetts General Hospital, Boston, MA.
Background: Human mesenchymal stromal cells (MSCs) metabolize and secrete 
anti-inflammatory and regenerative factors that can be of systemic benefit to acute, 
critical injury. When transplanted MSCs are limited in dose and rapidly cleared by the 
body, therefore prohibiting controlled exposure to this cell therapy. We have developed a 
bioreactor technology to maintain MSC viability at high fidelity and continuously deliver 
secreted factors into the blood stream in a clinical setting.
Methods: MSCs were integrated into hollow-fiber bioreactor devices whereby the 
cells, separated by a permeable membrane, can directly and dynamically provide systemic 
therapy without entering the body. We present a human scale prototype of the technology 
that has shown sustained cell viability and function throughout cGMP manufacturing in 
preparation for a Phase I human trial set to begin in 2015.
Results: The presentation will also report encouraging in vivo therapeutic trials in a 
large animal (canine) model of ischemic acute kidney injury (AKI) where 91% of animals 
survived compared to 50-60% in control arms. Pharmacological analysis of this bioreactor 
technology in vivo allowed for an unprecedented look at MSC function during product use 
and verified potency that is unattainable by conventional intravascular delivery of MSCs.
Conclusions: A combined approach to optimize MSC therapy that employs 
pharmacology principles and cell delivery strategies will be essential to translating this 
cell therapy product to humans for AKI and other critical organ dysfunction syndromes.
Funding: NIDDK Support, Pharmaceutical Company Support - Sentien 
Biotechnologies, Inc.
FR-PO365
Extracorporeal Diffusive Clearance of Silicon Nanopore Membranes in a 
Pumpless Porcine Blood Circuit  Steven Kim,1 Willieford Moses,2 Jaehyun 
Park,3 Clarence Chow,3 Charles Blaha,3,4 Zohora Iqbal,3 Rishi Kant,3 Benjamin 
Chui,5 Ken Goldman,6 William Henry Fissell,7,4 Shuvo Roy.3,4  1Nephrology, 
UCSF; 2Surgery, UCSF; 3Bioengineering, UCSF; 4Silicon Kidney, LLC; 5Ben 
Chui Consulting; 6H-Cubed; 7Nephrology & Hypertension, Vanderbilt Univ.
Background: Silicon nanopore membranes designed for hemofiltration (HF-SNM) 
have demonstrated increased permeability compared to polymer membranes. Previously, 
we reported in-vitro data showing a 3-fold improvement in diffusive clearance using SNM 
optimized for diffusion (HD-SNM). Here we test the diffusive clearance of HD-SNM vs 
HF-SNM in an extracorporeal porcine model without a blood pump.
Methods: A microelectromechanical systems fabrication technique was used to 
decrease the SNM thickness (HD-SNM 100µm vs HF-SNM 400µm). Polyethylene glycol 
coated HD-SNM (n=3) and HF-SNM (n=3) with sub-10nm pore sizes were tested in a single 
channel flow circuit (h=1mm). Vascular access was obtained by placing tunneled catheters 
within the carotid artery and jugular vein of healthy ~50kg pigs. Blood flow was achieved 
via the arterial-venous pressure differential (35-120ml/min). Dialysate was recirculated in 
a counter-current fashion (30ml) and flow rates were adjusted to ensure 0 transmembrane 
pressure. Dialysate creatinine concentration was measured hourly and serum creatinine 
was measured at time 0 and 6 hours. The pore size of each SNM was measured before and 
after blood exposure using hydraulic permeability.
Results: Blood flow was achieved using only the arterial-venous pressures differential 
with <5mmHg pressure drop. The average plasma creatinine concentration was 1.38±0.1mg/
dL. The creatinine clearance was 37.2±3.9ml/min/m2 (HF-SNM) vs 126.0±27.1ml/min/
m2 (HD-SNM) at 92.5±36.6ml/min. There was no detectable albumin transport into the 
dialysate. The HD-SNM maintained mechanical integrity at over 250mmHg in-vitro. The 
pore size change following blood exposure was 1.4±2.3nm vs 1.9±1.2nm for HF-SNM 
and HD-SNM, respectively.
Conclusions: This study demonstrates the successful transport of creatinine in an 
extracorporeal circuit without a blood pump. We also showed a ~3-fold improvement in 
diffusive clearance of creatinine using HD-SNM in a blood circuit.
Funding: NIDDK Support, Private Foundation Support
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FR-PO366
Hemofilter Design Based on Computational Simulations of Pulsatile Flow 
Amanda Buck,1 Joseph J. Groszek,2 Clark David Kensinger,3 Daniel Colvin,1 
Shuvo Roy,4 William Henry Fissell.2  1Dept of Radiology and Radiological 
Sciences, Vanderbilt Univ; 2Div of Nephrology and Hypertension, Vanderbilt 
Univ; 3Dept of Surgery, Vanderbilt Univ; 4Dept of Bioengineering and 
Therapeutic Sciences, Univ of California San Francisco.
Background: In the US, the ratio of patients with end stage renal disease (ESRD) 
on dialysis to annual kidney transplants for ESRD is 20:1 (USRDS 2014 Annual Data 
Report), underscoring the grave need for an artificial kidney alternative. Hypothesis: For the 
development of a hemofiltration device, computational fluid dynamics (CFD) simulations 
can predict potentially thrombogenic zones [e.g. low and high wall shear stress (WSS) 
areas, associated with stasis and shear induced cell damage, respectively] and can be used 
to refine device design to minimize such areas.
Methods: CFD simulations of pulsatile blood flow through a prototype hemofilter were 
validated in vitro using MR velocimetry. Hemofilters were implanted in large animals (n=4) 
for 30 days or until thrombosis and then explanted. Based on the CFD results, a subsequent 
flow path was devised to minimize predicted thrombogenic regions, and simulations were 
conducted on the second design.
Results: The in vitro and in silico models showed strong agreement. Pulsatile CFD 
simulations of the prototype device demonstrated zones of low WSS, and clot formation 
occurred in two of the four implants at the CFD-predicted sites. Flow simulations of the 
second-generation design showed reduced areas of low WSS.
Conclusions: Thrombogenic low WSS regions predicted in silico correspond with clot 
formation in vivo. In addition to predicting areas of thrombogenicity, CFD can be used to 
guide hemofilter device design to minimize these sites.
Funding: NIDDK Support, Private Foundation Support
FR-PO367
Characterization of Dialyzer Membranes by MALDI-Mass-Spectrometric 
Imaging Techniques  Joachim Jankowski, Vera Jankowski.  Inst of Molecular 
Cardiovascular Research, Univ Hospital RWTH, Aachen, Germany.
Background: Dialyzer polymer membranes are grossly classified as cellulose-based 
and synthetically produced membranes. Although cellulose membrane’s clearance and 
mechanical properties qualify it for use in dialyzer membranes, hydroxyl groups of 
these membranes lead to strong activation of the complement system. Therefore, recent 
membranes are manufactured from synthetic polymers.
Methods: For physical and chemical characterization of these materials of dialyzer 
a wide range of analytical methods is available. Over the last few years, MALDI mass-
spectrometry has been developed as a powerful tool for space-resolved analysis, not least 
because of its mass accuracy and high sensitivity. MALDI imaging techniques combine 
the potential of mass-spectrometric analysis with imaging as additional spatial information 
with relevance for biocompatibility of the dialyzer membranes. MALDI imaging enables 
the visualization of localization and distribution of biomolecules, chemical compounds 
and other molecules on different surfaces.
Results: In this study, surfaces of polymeric dialyzer membranes, consisting of 
polysulfone (PS) and polyvinylpyrrolidone (PVP) were investigated, regarding to chemical 
structure and compound’s distribution. According to the manufacturing process luminal and 
abluminal membrane surfaces are characterized by differences in chemical composition and 
physical characteristics. The MALDI imaging demonstrated that the abluminal membrane 
surface is more consisting of polysulfone than polyvinylpyrrolidone, the luminal membrane 
surface displayed more PVP than PS. The addition of PVP as hydrophilic modifier to 
polysulfone-based membranes increases the biocompatibility of the dialysis membranes. 
The analysis of polymer distribution is a relevant feature for characterization of dialysis 
membranes.
Conclusions: In conclusion, MALDI imaging is a powerful technique for polymer 
membrane analysis, regarding not only detection and identification of polymers but 
also localization and distribution in membrane surfaces, which has strong impact on the 
biocompatibility of the dialyzer membranes.
FR-PO368
Effect of Peristalsis with Pediatric Catheters  Anna Lorenzin, Francesco 
Garzotto, Claudio Ronco.  Nephrology and International Renal Research Inst 
Vicenza, St. Bortolo Hospital, Vicenza, Italy.
Background: Thanks to the technological advances of the last years,Continuous Renal 
Replacement Therapy CRRT machines have been upgraded and equipped with circuits 
specific for pediatric patients.To date,to treat these patients the most used catheter is the 
bilumen 7French,however with a neonate it is inadequate for the dimensions.It is not clear 
if it is possible to use a smaller catheter with adult CRRT machine or a specific pediatric 
machine is needed.We set up a dedicate circuit to assess the usability of a peristaltic blood 
pump designed for adults and compare it with a pediatric pump in terms of access pressure.
Methods: We performed in vitro test with milk as medium.The circuit was composed 
of a bilumen catheter(4Fr-5cm,5Fr-7cm,7Fr-13cm),an arterial pressure sensor,a blood pump 
and a venous pressure sensore(Fig1).We compared two differet blood pumps:an adult one 
with10,5cm diameter and a pump line with inner and external diameter of 3.9and7.8mm; a 
pediatric pump of CARPEDIEM machine with 4cm diamenter and a pump line with inner 
and external diameter of 3.5and5.5mm.We set the pumps to have flow rates of7,10,15,20ml/
min and we recorded the pressure values.
Results: We are presenting the data of the two pumps with 5Fr catheter and 15ml/
min flow rate.Analyzing the arterial pressure values,we found that the spikes are more 
frequent with the CARPEDIEM pump than with the adult one. The min and max value 
are respectively(-50,-28mmHg)and a mean Dp=18mmHg with CARPEDIEM pump,(-61;-
20mmHg)and a mean Dp=40mmHg with adult pump (Fig2).
Conclusions: We can notice that there is ah high discrepancy in terms of Dp between 
the two pumps:high values of Dp lead to an high shear stress.As the shear stress in one of 
the main causes of hemolysis,it seems that a specific pediatric machine is advisable for 
neonates that need small catheter.Further investigation have to be perform with blood to 
confirm our results.
FR-PO369
Hemodialysis with CARPEDIEM Machine: An In Vitro Test  Anna Lorenzin, 
Dario Galeano, Stefania Aresu, Francesco Garzotto, Claudio Ronco.  Nephrology 
and International Renal Research Inst Vicenza, St. Bortolo Hospital, Vicenza, 
Italy.
Background: Despite the development of continuous renal replacement therapies 
machines,their employment still remain unsuitable in new born and infants.This gap has 
been filled thanks to the coming of a specific pediatric dialysis machine,CARPEDIEM.
To date it is set up only for continuous hemofiltration CVVH;to provide a wider range of 
applications,specific filters have been conceived to implement a continuous hemodialysis 
CVVHD.We tested a prototype kit to evaluate its performance in terms of clearance K.
Methods: We performed in vitro test with plasma for the 3 filters HD010 HD020 
HD035(surface 0.1,0.2,0.35m2).Fibers were put manually into the housing of CVVH 
filters.CVVHD in cocurrent configuration(otherwise a longer circuit is required)is carried 
out using infusion pump as dialysate pump and ultrafiltration as effluent pump.All the 
combinations of plasma and dialisate flow rate are set(QP=5,10,15ml/min,QD=5,10,15ml/
min),net ultrafiltration is 0ml.Plasma samples are collected every QP,QD change(time interval 
8min)to evaluate K of urea and creatinine using the standard formula.
Results: Among all filters,our tests estimated a common trend of urea K(min 3.0, 
max 10.5ml/min)and cretinine K(min 3.4, max 11.8ml/min).Filters efficiency increases 
with the increase of both the flow rates QP,QD(fig1),moving towards a plateau at the higher 
flows configuration.
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Conclusions: CVVHD with CARPEDIEM seems to be effective for diffusion trasport 
of small molecular weight solutes,according to specific clinical needs.In the light of these 
findings CARPEDIEM can be a promising alternative to peritoneal dialysis, i.e. in treating 
electrolyte imbalance with accurate fluid removal.Limitation:handmade filters could induce 
variability in the results due to disposition and variable number of fibers.
FR-PO370
Removal of Protein-Bound Uremic Toxins: Simulating the Effect of Toxin 
Displacement versus Increase in Dialyzer Clearance  Vaibhav Maheshwari,1 
Stephan Thijssen,1 Doris H. Fuertinger,1 Franz Kappel,2 Peter Kotanko.1  1Renal 
Research Inst, NY; 2Univ of Graz, Austria.
Background: Protein-bound uremic toxins (PBUT) exert numerous deleterious effects. 
Their removal with standard hemodialysis (HD) is poor. Meyer et al. have modeled the 
impact of increasing dialysate flow rate and dialyzer mass transfer area coefficient on PBUT 
removal [JASN, 2004]. Here, we compare those results to a novel approach based on PUBT 
displacement by infusion of binding competitors [Tao, Blood Purif, 2015].
Methods: We developed a multi-compartment patient model and a dialyzer model 
depicting spatiotemporal dynamics based on law-of-mass-action kinetics. We chose indoxyl 
sulfate (IS) as a prototypical PBUT and ibuprofen as the binding competitor. We modeled 
IS removal during a 4-hr HD (Qp=250 mL/min, Quf=750 mL/h, initial total IS 100 µmol/L, 
initial free fraction of IS 8%), with IS dialyzer clearances from 150 to 200 mL/min. This 
was compared to IS removal achieved by ibuprofen infusion (800 mg/200 mL) into the 
arterial line at 50 mL/hr (IS clearance 150 mL/min).
Results: IS removal during HD with a clearance of 150 mL/min was 438 µmoles 
(plasma reduction ratio 34%), which conforms to literature data [Niwa, Blood Purif, 2012]. 
With IS clearance of 200 mL/min, removal improved by 8.7% to 476 µmoles. With ibuprofen 
infusion (IS clearance back at 150 mL/min), removal improved by 11.2% to 487 µmoles.
Conclusions: Our model yields predictions of IS kinetics that agree with empirical 
and modeled data [Niwa et al.; Meyer et al.]. Of note, a mere 8.7% improvement in IS 
removal would require an increase in dialysate flow rate from 800 to 1350 mL/min plus 
a 70% increase in membrane surface area. The modeled ibuprofen infusion alone yields 
an 11.7% improvement even absent an increase in dialyzer clearance. The use of binding 
competitors holds great promise. These results require validation in vivo.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO371
Membrane Driving Blood Flow for Extracorporeal Therapies 
Francesco Garzotto, Sean M. Bagshaw, Anna Lorenzin, Mauro Neri, Claudio 
Ronco.  Nephrology, St. Bortolo H.
Background: From the first application of ContinuousVenoVenousHemofiltration 
CVVH, the blood flow has been driven by a peristaltic pump. Several attractive alternatives, 
with both advantages and disadvantages, have been proposed for many years. SAM 
(Spectral Medical Inc.; Toronto, Canada) is a novel instrument, in which the pumping of 
whole blood and fluids is performed through the use of pistons, chambers and valves. A 
plastic cartridge blood circuit system fig1b incorporates all of the pumps, air trap system, 
pressure monitors and clamps. This circuit is covered on one side by a plastic membrane 
adhered to the pumping pistons via a drawn vacuum. Aim of the present is to evaluate the 
new pumping system.
Methods: We set up the machine for CVVH. An 11.5 Fr 20 cm catheter was connected 
to the lines. We ran the machine for 6 hours in order to characterize the performance of 
the system. 
During the first cycle, suction generated by the drawing back of the piston, moves 
the blood into the arterial-chamber AC. Positive pressure generated by the piston then 
drives the blood through the circuit. The camshaft design can allow different profiles for 
Withdrawal and infusion flows. The largest Priming volume measured (both the ACs full), 
is 98 ml with a stroke volume for each AC of 14ml.
Results: We did not observe a reduction of blood flow due to a loss of membrane 
elasticity. The use of an “all integrated” cassette reduces the number of manual operations, 
avoiding operator related errors and favoring an easy and time saving set up.
Conclusions: S.A.M could represent a valid alternative to the classic peristaltic 
pumping system driven machines. Analyzing the pumping-system/cassette equipment, 
we identified potential advantages, in addition to usability, such as: accurate balancing 
system, blood flow ideally designed to avoid a membrane protein layer, constant blood flow 
over time, accurate volumetric balancing system, less clotting activations, and an optimal 
withdrawal flow profile. More tests should be performed in order to validate the device in 
various aspects and conditions.
FR-PO372
Membrane versus Peristaltic Blood Pumps for Extracorporeal Therapies: 
Comparison on Index of Hemolysis  Francesco Garzotto,1 Sean M. Bagshaw,2 
Claudio Ronco.1  1Nephrology and IRRIV, St. Bortolo H., Italy; 2Critical Care 
Medicin, Univ of Alberta Hospital.
Background: Hemolysis during extracorporeal treatments mainly occurs as a 
consequence of mechanical stress on the blood. Red blood cell deterioration is undetected 
because it is far from any acute hemolytic threshold but represents a potential harm 
for patients. A new membrane-piston driven pump has been recently proposed on the 
S.A.M.(©Spectral Medical Inc, Toronto) device designed for continuous renal replacement 
therapies (CRRT). Aim of this investigation is to compare the membrane with peristaltic 
pumps by measuring the Normalized Index of Hemolysis NIH during in vitro testing.
Methods: Three sessions of hemoperfusion with a line inserted in place of a hemofilter 
were performed both with SAM and Prismaflex (©Baxter International).A single pool of 
fresh heparinized bovine blood (Heparin 500 u/L,Hb 12‡1 g/dl,Base Excess 0+/-5 mmol/L) 
were split into three aliquots containing 900 mL (Control, SAM, Prismaflex) and circulated 
for 6 hours/session. Bloo±d samples were drawn at baseline, 30 min and every 1 hour. NIH 
were calculated as median hourly variation of free hemoglobin and used for comparison. 
Data was compared with two tailed Student’s t-test based on F-Test results.
Results: NIH values of 0.12±0.03 and 0.13±0.09 mg/100L for SAM and Prismaflex 
respectively are lower than those reported in literature due to the simplified circuit used (no 
vascular access and filter). Creation of hemoglobin between sam and control, and prisma and 
control are non-significant fig 1a. Slope of the curves that describe the creation of hemolysis 
are nearly identical with a slow rate of production of free hemoglobin. 
The r2  close to 1 demonstrate a good linearity of the damage.
Conclusions: Device compatibility in terms of lethal damage to blood cells, is an 
important aspect of the development of artificial organs. Since a validation based on 
dangerous level of free hemoglobin do not exist, an empirical evaluation using comparative 
test suggest that piston driven membrane is safe from a hemolysis point of view.
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FR-PO373
Enhanced Middle Molecule Clearance by a Biomimetic Dialyzer Membrane 
Joseph J. Groszek,1 Jin Cheng,1 Charles Blaha,2 Rishi Kant,2 Jaehyun Park,2 
Benjamin Chui,3 Ken Goldman,4 Shuvo Roy,2 William Henry Fissell.1 
1Nephrology and Hypertension, Vanderbilt Univ, Nashville, TN; 2Bioengineering 
and Therapeutic Sciences, Univ of California, San Francisco, San Francisco, 
CA; 3Ben Chui Consulting, Sunnyvale, CA; 4H-Cubed, Inc, Olmstead Falls, OH.
Background: Although polymer dialyzers attain very high small solute clearance 
rates, polydisperse pore sizes limit middle molecule clearance by conventional polymer 
dialyzers. We hypothesized that a biomimetic membrane with uniform slit pores would 
enhance middle molecule clearance.
Methods: thin film silicon membrane samples (surface area 1.4 x 10-5 m2) with 
monodisperse slit-shaped 5-8 nanometer pores (“SNM-HD”) were manufactured as 
previously described, surface-modified with polyethylene glycol and mounted in a custom 
designed cartridge. Membrane pore size was estimated from hydraulic permeability 
measurements. Human blood was spiked with PABA and fluorescent-labelled Ficoll, a 
polydisperse globular polysaccharide. Blood flow was set at 100 ml/min and dialysate flow 
varied between 70 and 140 ul/min. Blood and dialysate concentrations of PABA and Ficoll 
were measured by size-exclusion chromatography. Clearance as a function of dialysate flow 
rate was extrapolated to estimate KoA as a function of molecular weight.
Results: B2M clearance in high-flux dialyzers is typically 5-8% of the value of urea 
clearance. PABA clearance was 139 ml/min/m2.  15.7Angstrom Ficoll (same radius as 
B2M) clearance in the SNM dialyzers was 16.9 ml/min/m2, 3-5 fold higher than reported 
B2M clearance in polymer dialyzers.
Conclusions: A biomimetic membrane of uniform slit pores potentially offers much 
higher middle molecule clearance than conventional polymer dialyzers.
Funding: Other U.S. Government Support
FR-PO374
Anti-Fouling of Silicon Nanopore Membranes Using SLIPS  Bas Meusen,1,2 
Steven Kim,1 Zohora Iqbal,1 Charles Blaha,1 William Henry Fissell,3,4 Shuvo 
Roy.1,3  1UCSF; 2Univ of Eindoven; 3Silicon Kidney; 4Vanderbilt Univ.
Background: Silicon Nanopore Membranes (SNM) have been developed for 
application in an implantable bioartificial kidney. However, SNM are subject to fouling 
and thrombosis with continuous blood exposure. Thin polymer coatings have been applied 
to SNM as a strategy to limit cell adhesion and protein adsorption. Slippery Liquid Infused 
Porous Surface (SLIPS) is a bioinspired “omniphobic” surface coating that has been reported 
to prevent thrombosis and fouling on arteriovenous shunts. Here we present the application 
of SLIPS coating to SNM and evaluate protein adsorption in vitro.
Methods: SNM with ~10 nm pores were coated with SLIPS and incubated with BSA-
FITC (2 mg/ml in PBS) for 24 hours at 37°C. Uncoated (bare) silicon substrates served as 
controls. Fluorescence microscopy and ellipsometry were used to evaluate the surfaces and 
water transport through the SNM was tested using established hydraulic permeability assays.
Results: SLIPS strongly reduced BSA-FITC adsorption on SNM compared to 
bare silicon. Ellipsometry confirmed the presence of SLIPS coating with a thickness of 
0.5±0.2nm, which is theoretically thin enough to keep open the pores open in the membrane. 
However, hydraulic permeability testing revealed no ultrafiltration through the SNM for at 
least 24 hours and transmembrane pressures of up to 5 psi.
Conclusions: SLIPS is a promising and easy-to-apply protein repellent coating, 
but its highly omniphobic characteristic prevents ultrafiltration even through pores that 
are over 5x the coating thickness. For use in the bioartificial kidney, SLIPS has relevant 
implications as an anti-fouling coating where an ultra-thin blood compatible, but non-
filtering surface is desired.
Funding: Other NIH Support - NIBIB
FR-PO375
Measuring Spatial Trends of Single Nephron Filtration with Molecular 
MRI  Edwin Baldelomar,1 Jennifer R. Charlton,2 Kevin M. Bennett.1  1U. of 
Hawaii, Honolulu, HI; 2U. of Virginia, Charlottesville, VA; 3U. of Hawaii at 
Manoa, Honolulu, HI.
Background: To better develop drugs to treat kidney disease their physiological 
mechanisms during development, noninvasive techniques to measure whole kidney 
function at the level of the single nephron are needed. We investigated the combined use 
of two MRI contrast agents, cationic ferritin (CF) and Gd-DTPA, to measure local (voxel) 
macromolecular uptake and glomerular filtration rates of single nephrons over the whole rat 
kidney with 3D MRI using the isolated, perfused rat kidneys under physiological conditions.
Methods: Krebs-Ringer (KR) bicarbonate solution with 7.5 mg/100mL of Fraction-V 
BSA and a bubbling infusion of carbogen was perfused into isolated rat kidney. Temp was 
maintained at 37oC. CF in KR solution (0.071 mg/mL of CF), was infused into the system 
first. After CF, KR solution was re-infused to wash. Next, a bolus of 0.25 mmol Gd-DTPA 
in 10mL of KR solution was infused into the perfusion system. (All rates = 5ml/min) 
Kidneys were imaged during the perfusion with MRI. Voxel time courses were then fitted 
to a bi-exponential model.
Results: Glomeruli were distinguished by uptake of CF and a distribution of CF 
accumulation rates and gd-DTPA elimination rates was visible. (Fig 1a-b) We used the 
location of the glomeruli in 3D and the time course of CF labeling (Fig 1c-d) to discern 
spatial trends in uptake rate of CF. Time course structures also mapped well with the 
different morphological structures in the kidney (Fig 1e).
Conclusions: CF and gd-DTPA were used in conjunction to map glomerular filtration 
in the isolated, perfused rat kidney in 3D. To our knowledge this is the first report to assess 
spatial trends with macromolecular and free filtration dynamics in the whole kidney.
Funding: NIDDK Support, Other NIH Support - NIH DK-091722
FR-PO376
Automated Quantification of Renal Microvascular Abnormalities: A Novel 
Computational Mapping Approach  Kyle I. Harrington, Beverly Elizabeth 
Faulkner-Jones, Katie Bentley, Seymour Rosen.  Pathology, Beth Israel 
Deaconess Medical Center, Boston, MA.
Background: Alteration of the microvasculature is considered to be crucial 
to the understanding of chronic kidney disease, yet few studies have quantified the 
microvasculature in normal and diseased kidneys.
Methods: We created customized software for automatically quantifying morphology 
of renal microvasculature. 10 kidneys (2 nephrectomies, 8 biopsies) were studied; 
3 cases of relatively normal tissue, others chosen because of a significant degree of 
tubulointerstitial injury and included a variety of diseases (diabetes, amyloidosis, end-stage 
glomerulonephritis, and renal artery stenosis). Images of CD34 stains were segmented, 
high-pass filtered based on size, and glomeruli were manually segmented. Morphological 
signatures were calculated using 3 parameters: roundness, angulation, and density.
Results: The normal cortex, as a whole, presented heterogeneity in histogram analysis. 
However, color density mapping and histogram studies revealed 3 distinct regions: glomeruli 
(GM), labyrinth (LB), and medullary ray (MR). MR was characterized by correlated 
angulation (Fig 1). Microvascular density varied in LB but peaked at 3% coverage within 
a 200um circular radius (Fig 2). Density in MR was approximately the same. As expected, 
GM density was far greater, sometimes exceeding 11% coverage. With disease, capillary 
shape did not shift, roundness factor remaining in 0.2-0.3 range (circular profile 1.0). 
However, diminishment in capillary density was overt (Fig 3), and distribution shifts were 
marked (peak A) or more moderate (peak B). 
Conclusions: Our results demonstrate that automated quantification is capable of not 
only distinguishing between anatomical features of kidneys, but also characterizing the 
degree of abnormality in diseased tissue.
FR-PO377
Angio-µCT: New Polymer-Based Contrast Agent Makes Kidney 
Morphometry Look Attractive  Ruslan Hlushchuk, Sebastien Barre, Carlos 
Correa Shokiche, Valentin Djonov.  Inst of Anatomy, Univ of Bern, Bern, 
Switzerland.
Background: The fundamental features of the morphological substrate of the renal 
function are nephron number and glomerular volume. The accurate estimation of these 
parameters has become increasingly important. The present golden-standard method of 
kidney morphometry is the exhaustive physical fractionator/dissector method. It is extremely 
time-consuming and laborious, let alone disturbing proceeding artefacts. Purpose: to 
develop a contrast agent appropriate for high-resolution µCT ex vivo with superior perfusion 
features in order to visualize the vasculature and glomeruli of rodent kidney. The elucidated 
approach should allow fast and reliable estimation of such parameters as nephron number, 
glomerular volume, glomerular size distribution and kidney volume.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
441A
J Am Soc Nephrol 26: 2015 Bioengineering and Informatics Poster/Friday
Results: the developed contrast agent (µAngiofil) turned out appropriate for µCT ex 
vivo with superior perfusion and contrast-to-noise features. The obtained µCT datasets were 
of superior quality and allowed clear visualization of the microvasculature and glomeruli.
In kidney, modern high-resolution microCT (SkyScan-1172) provided the whole mouse 
kidney vasculature in 3D with the spatial resolution of approx. 2 µm. The sample is fixed 
prior the microCT-scan and therefore can be processed for the histological evaluation after 
the scan. This circumstance brings multiple advantages, including much easier localization 
of the µCT-findings in the post-scan histological sections.
Conclusions: using µAngiofil we obtained 3D-µCT datasets of superior quality, which 
are sufficient for estimation of relevant kidney morphometry parameters. The developed 
angio-µCT-based approach will substitute the existing golden-standard. Besides classical 
kidney morphometry, it provides the data on the vasculature through the whole kidney in 
3D what makes the technique even more beneficial.
Funding: Government Support - Non-U.S.
FR-PO378
Rising Accuracy of Transcutaneous GFR Measurement  Jochen Friedemann,1,2 
Ralf Heinrich,3 Yury Shulhevich,1,2 Johannes Pill,2 Daniel Schock-Kusch.1,2 
1Mannheim Univ of Applied Sciences, Inst for Process Control and Innovative 
Energy Conversion, Germany; 2Mannheim Pharma & Diagnostics GmbH, 
Germany; 3Freudenberg New Technologies SE & Co. KG, Weinheim, Germany.
Background: Transcutaneous measurement of GFR (tGFR) is now getting used 
frequently in animal studies. tGFR allows consecutive GFR measurements in the same 
animal even on a daily basis as no blood sampling is required. Here we describe and 
validate a novel three compartment model (tGFRnew) for tGFR assessment by FITC-Sinistrin 
clearance, automatically correcting influences like bleaching of skin fluorescence.
Methods: Bolus clearance tGFR was measured in awake Spraque Dawley (SD) 
rats using the commercially available NIC-Kidney system, immediately followed by a 
blood sampling based constant infusion clearance (cGFR). GFR was calculated by a one 
compartment model (tGFRstd), tGFRnew and cGFR. Also 46 tGFR measurements in SD rats 
were reevaluated by tGFRnew.
Results: Results are given in table 1. Mean values of the three methods are comparable 
with no significant difference. The accuracy (larger STD) of tGFRstd is lower compared to 
tGFRnew and cGFR. This finding was verified by the 46 measurements in SD rats (tGFRstd: 
0.97 ± 0.18 ml/min/100g b.w.; tGFRnew 0.95 ± 0.14 ml ml/min/100g b.w.). 
n=11 SD rats cGFR tGFRstd tGFRnew 
ml/min/100g b.w.
mean ± STD 0.94 ± 0.13 1.00 ± 0.18 0.88 ±0.12
effect size10% 0.73 0.55 0.73
Conclusions: The results indicate that tGFR-new yields data in comparable accuracy 
as cGFR. For an apriori estimation of the sample size to detect a change in GFR of 10% 
in the SD rats investigated, the effect size rises from 0.55 (tGFRstd) to 0.73 (tGFRnew). The 
required sample sizes in fig. 1. illustrate the strong contribution of tGFRnew to the concepts 
of refining and reduction of animal studies. 
Figure 1: Impact of the increased effect size yield with tGFRnew compared to tGFRstd.
FR-PO379
Quantification of the Progressive Fibrosis Development in Mouse Kidney 
Unilateral Ureteral Obstruction Model Using Fluorescence Lifetime and 
Second Harmonic Generation Imaging Microscopy  Evgenia Dobrinskikh,1 
Suman Ranjit,2 John Ross Montford,1 Alexander Dvornikov,2 David J. Orlicky,1 
Allison M.b. Lehman,1 Raphael A. Nemenoff,1 Enrico Gratton,2 Seth B. 
Furgeson,1 Moshe Levi.1  1Univ of Colorado Denver; 2Univ of California Irvine.
Background: Renal fibrosis is considered to be the final common pathway for 
most forms of chronic kidney disease (CKD) and involves glomerular sclerosis and/
or tubulointerstitial fibrosis. There is great interest in identifying renal fibrosis in the 
early stages of CKD to prevent progression. Unilateral ureteral fibrosis (UUO) is a well-
characterized model of CKD and renal fibrosis. Kidney injury and fibrosis usually are 
assessed by Picrosirius Red staining or immunohistochemistry for collagen isoforms.
Methods: The goal of this study is to compare histologic measures of renal fibrosis to 
Fluorescence Lifetime Imaging (FLIM) and Second Harmonic Generation (SHG) techniques 
in our deep imaging microscope DIVER.FLIM and SHG allow quantification of collagen 
in unstained tissue and can be adapted for live animal imaging. Male C57BL/6 mice were 
subjected to UUO of right kidney. At 7, 14 and 21 days, both kidneys were harvested. The 
uninjured left kidney was used as a control. Serial sections of both kidneys were analyzed 
by Picrosirius Red staining or FLIM with SHG.
Results: We performed quantification of Picrosirius Red stained-kidneys using 
polarized light. This showed progressive increase for the number of positive pixels for 
fibrosis in the left kidney 9631.9±0.1626.2, 16167.8±6647.7 and 20511.5±5727.6 compared 
to 5625.3±770.6, 3909.33±2395.9 and 4493.8±2018.4 in the control kidney respectively. 
Using the Phasor approach to FLIM, comparisons between the two kidneys show that 
the auto fluorescence lifetime signature give rise to two well separate phasor clusters. 
Quantification of ten different fields of view for each kidney at the above time-points for 
SHG signal confirms Picro-Sirius Red scoring.
Conclusions: Finally, the combined FLIM and SHG images let us establish a criterion 
for quantitative determination of fibrosis directly from the microscope images.
Funding: NIDDK Support
FR-PO380
Chemical Imaging: A Novel Approach to Obtaining Label-Free Biochemical 
Information in Renal Transplant Patients with Recurrent Diabetic 
Nephropathy  Michael J. Walsh,1 Vishal K. Varma,1 Andre Kajdacsy-Balla,1 
Sanjeev Akkina,2 Suman Setty.1  1Dept of Pathology, Univ of Illinois at Chicago, 
Chicago, IL; 2Dept of Nephrology, Univ of Illinois at Chicago, Chicago, IL.
Background: The main treatment for end-stage renal disease is kidney transplantation, 
which over time undergo chronic rejection including changes in the glomerular, 
tubulointerstitial and vascular compartments. Also, recurrence of disease in diabetics can 
mimic transplant glomerulopathy. We have identified biochemical markers using Chemical 
imaging that were associated with recurrent diabetic nephropathy. Chemical Imaging is 
an emerging approach to obtain images of the biochemical composition of tissue biopsies 
in a label-free fashion.
Methods: An initial study focused on identifying patients with no evidence of diabetic 
nephropathy and patients with advanced diabetic nephropathy in native kidneys. Serial 
sections were acquired and stained with PAS or imaged using chemical imaging. IR spectra 
were extracted to identify biomarkers associated with diabetic nephropathy progression. 
A second study identified transplant patients who underwent very rapid recurrent diabetic 
nephropathy and patients with no evidence of diabetic nephropathy.
Results: Biomarkers were identified that were changed in renal structures associated 
with the progression of diabetic nephropathy, including increased levels of glycation. These 
biomarkers were found to be increased in the cohort of transplant patients that underwent 
rapid diabetic nephropathy recurrence. In addition, the early biopsies from the patients that 
underwent later diabetic nephropathy progression were biochemically different from the 
non-progressive patients, suggesting that chemical imaging may identify pre-histological 
biomarkers that will predict outcome.
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Conclusions: We have identified a number of biomarkers that are associated with 
the advancement of diabetic nephropathy and that we can track the early recurrence of 
diabetic nephropathy in surveillance biopsies. In addition, we have highlight a ‘biochemical-
signature’ that may be predictive of the later progression of diabetic nephropathy recurrence.
Funding: NIDDK Support
FR-PO381
Contrast-Enhanced Ultrasound Characterizes Kidney Lesions with 
Accuracy Comparable to Contrast-Enhanced CT or MR  Emily H. Chang,1 
Sandeep Kasoji,1,2 Paul Dayton,1,2 Wui K. Chong,1 Kimryn Rathmell.1  1Univ 
of North Carolina, Chapel Hill, NC; 2North Carolina State Univ, Raleigh, NC.
Background: Incidental kidney lesions are often detected on imaging performed for 
other reasons. Indeterminate lesions are further characterized with a contrast-enhanced 
computed tomography(CT) or magnetic resonance imaging(MRI). These tests have many 
limitations and are contraindicated in patients with allergies to contrast, metallic hardware 
and chronic kidney disease(CKD). An accurate alternative study is needed. Contrast-
enhanced ultrasound (CEUS) is one potential alternative. CEUS uses microbubbles, 
non-nephrotoxic, gas filled bubbles with lipid or albumin shells, as the contrast agent. We 
investigated the accuracy of CEUS for malignancy in patients with incidental kidney lesions.
Methods: CEUS was performed on 33 patients. Results were independently interpreted 
by 2 blinded readers and risk-stratified by the Bosniak classification system. Sensitivity, 
specificity and predictive values were calculated for lesions with histologic diagnosis as the 
gold standard. As histology was available for resected lesions only, we performed secondary 
analyses using an expanded gold standard definition that included clinical recommendation.
Results: Of the 33 patients, 12 had CKD and 14 had histologic diagnoses. There was 
100% inter-reader agreement in the primary analysis (Figure 1A) and 97% agreement 
in the secondary analysis (Figure 1B). Sensitivities (94-100%), positive (70-93%) and 
negative predictive (90-100%) values for CEUS were comparable to CT (83-100, 50-67 
and 77-100%, respectively) and MRI (81-100, 60-78 and 80-96%, respectively). CEUS 
specificity (0-56%) was lower than MRI (71-100%). 
Conclusions: CEUS has excellent potential as an alternative diagnostic tool for kidney 
lesions among patients with CT/MRI contraindications. Further evaluation is needed.
Funding: Other NIH Support - CTSA (Clinical and Translational Science Awards) 
funding, University of North Carolina at Chapel Hill (UL1TR001111)
FR-PO382
Lead-Free Drape Applied to Xray Detector Significantly Decreased 
Radiation Scatter During Access Intervention  Jie Cui,1 Fengyong Liu,2 
Zubin Irani.3  1Nephrology Dept, Massachusetts General Hospital, Boston, 
MA, China; 2Interventional Radiology Dept, Chinese People’s Liberation Army 
General Hospital, Beijing, China; 3Div of Vascular Imaging and Intervention, 
Massachusetts General Hospital, Boston, MA, China.
Background: Exposure from scattered radiation can be very high during access 
interventional procedures because of the relatively closer operative position. The purpose 
of this study is to evaluate whether applying a lead-free, sterile, disposable drape can 
decrease scatter radiation exposure during access intervention.
Methods: An upper extremity phantom was placed on the angiography table to mimic 
real-time patient’s upper extremity access. Using this model, measurement of scatter 
radiation was made every one foot away from the phantom before and after applying 
the drape using a collimated and low-output condition. The scattered radiation dose was 
measured three times in each spot. And the measurement was taken at 0.9m (waist level) 
as well as neck level (1.5m). Statistical significance was compared using t-test.
Results: Scatter radiation was attenuated throughout the measurement field when 
the drape was applied. The degree of scatter radiation reduction was distance and height 
dependent. Scatter radiation decreased 61.6% at the waist level and 81% at the neck level 
(P<0.05).
Conclusions: The application of this sterile, lead-free drape can significantly reduce 
scatter radiation in the procedure room. This novel technique can be used to reduce exposure 
radiation dose to the operators.
FR-PO383
Pathogenesis of Brain Damages in Chronic Kidney Disease and Clues for 
Early Diagnosis  Yao-ping Lin,1,2 Der-Cherng Tarng.1,2  1Medicine, National 
Yang-Ming Univ, Taipei, Taiwan; 2Medicine, Taipei Veterans General Hospital, 
Taipei, Taiwan.
Background: There is globally increased prevalence of chronic kidney disease 
(CKD). Vigorous efforts have been devoted to ameliorate renal deterioration and prevent 
cardiovascular morbidity/mortality. However, patients also have enough incubation 
time to develop deranged cognition that severely disturbs quality of life. Neurological 
pathology/damages may occur in CKD patients long before any overt clinical symptoms 
can be noticed. Given the similar embryological development as brain, the eyes can be the 
windows to pinpoint the internal brain pathology. Herein we employed proteomics, animal 
model and behavior analysis to investigate the possible overlapping biological signatures 
in the eyes and brain of CKD.
Methods: Subtotal nephrectomized rats were established as CKD model. Open field 
and object recognition tests were adopted as neurologiocal screen. Brain and eyes were 
harvested for proteomic analysis. Western blotting and immunohistochemistry were used 
to confirm and localize the identified proteins. To elucidate the global protein changes in 
the brain and eye of SNX rats, the data was analyzed by Ingenuity Pathways Analysis 
(Ingenuitys Systems, http://www.ingenuity.com/).
Results: The eye pathology appeared in parallel with the brain damages. The significaly 
dysregulated proteins in the SNX rat eyes were spectrin beta 3, 26S proteasome non-ATPase 
regulatory subunit 2,6-phosphofructokinase, dihydropyrimidinase-related protein, and the 
heat shock 70, 90α, and chaperonin containing Tcp1, subunit 6A (Zeta 1).
All these proteins have been linked to the neuro-degeneration in humans.
Conclusions: There were overlapping eye and brain biological networks. Our 
results might pave the way for early diagnosis of CKD-neurological pathology via eye 
examinations, and targeted interventions towards the neurological diseases.
Funding: Government Support - Non-U.S.
FR-PO384
Metabolomic Profiling of Chronic Kidney Disease Using a Local Exhaustive 
Exploration Approach  Margaux Luck,2 Eric Thervet,1 Cécilia Damon,2 Nicolas 
Pallet.1  1Nephrology, Georges Pompidou European Hospital, Paris, France; 
2Hypercube Inst, Paris, France.
Background: 1H Nuclear Magnetic Resonance (NMR)-based metabolic profiling 
is useful for the diagnosis of CKD stages. Due to the high dimension of NMR spectra 
datasets and the complex mixture of metabolites in biological samples, the identification of 
discriminant biomarkers of a disease is challenging. None of the widely used chemometric 
methods in NMR metabolomics performs local exhaustive exploration of the data.
Methods: We developed a descriptive and easily understandable approach searching 
for discriminant local phenomena. We selected the most discriminant features from the 
dataset based on both the normalized mutual information and the chi-2 test. We studied the 
local distribution of the patient subgroups with identical degree of CKD severity on each 
feature, using the proprietary algorithm HyperCube, which searches for local overdensities 
of an explanatory variable modality, and identifies a combination of variables as well as 
their value ranges that give the optimal prediction of the outcome of interest. Further, 
logistic regression on these discriminant features was used to build a predictive model of 
the CKD severity stage.
Results: We explored a complex dataset that includes 1H-NMR urinary metabolomics, 
clinical, demographic, clinical chemistry and histo-pathological variables, in a cohort of 
110 individuals with a CKD. The HyperCube algorithm combined with logistic regression 
supports the discriminant metabolites obtained with standard Orthogonal Projection to 
Latent Structure Discriminant Analysis (O-PLS-DA) model. Unlike the O-PLS-DA model, 
HyperCube algorithm provided clues into the distribution of the CKD severity subgroups 
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with respect to spectral data. The built predictive model identifies metabolomics profiles 
composed of metabolites such as citrate, dimethylsulfone, trigonelline and glycine. The 
majority of the predictive variables were urinary metabolites identified by 1H-NMR, 
indicating that CKD significantly impacts the urinary metabolome.
Conclusions: Our findings indicate that HyperCube is a valuable analytical method 
for the description of CKD severity phenotypes.
FR-PO385
RNA-seq Profiling in Uninephrectomized Rats  Jae Wook Lee, Mark A. 
Knepper.  NHLBI, NIH, Bethesda, MD.
Background: Renal hypertrophy occurs as a compensatory response to reduction 
in nephron mass. To identify early gene expression changes in renal hypertrophy, we 
profiled whole-kidney transcriptome in the contralateral kidney of uninephrectomized 
rats using RNA-seq.
Methods: 5-week-old male Sprague-Dawley rats received right uninephrectomy (UNx, 
n=4 at each time point) or sham surgery (S, n=4 at each time point). Rats were sacrificed at 
24, 48, and 72 hours after surgery. 1.5 µg of total RNAs from the left kidney was used to 
make cDNA libraries for Illumina sequencing. Reads were mapped to Ensembl genes and 
Wald test for a negative binomial model was used to call differentially expressed genes.
Results: Total RNA yields did not differ significantly between UNx and sham kidneys. 
Each library had 35-42 million reads and more than 80% of reads were uniquely aligned. 
At 24 h, 45 transcripts were upregulated and 72 downregulated in UNx. Upregulated 
transcripts included connective tissue growth factor (Ctgf), regulator of cell cycle (Rgcc), 
serum/glucocorticoid-regulated kinase (Sgk1), glucocorticoid-induced leucine zipper 
protein (Tsc22d3), a zinc finger transcription factor (Zbtb16), and genes related to steroid 
biosynthesis (e.g. Insig1). At 48 h, 183 transcripts were upregulated and 103 downregulated 
in UNx. Among upregulated transcripts were cell-cycle genes including centromere 
proteins (Cenpa, Cenpf, and Cenpi); MMC helicase subunits (Mcm3, Mcm5, and Mcm8); 
cyclins (Ccna, Ccnd1, Ccne, and Ccnf); cyclin-dependent kinase (Cdk1); and polo-like 
kinase (Plk1). Among downregulated transcripts at 48 h were transcription factors (Jun, 
Hmx2, Klf9, Klf15, Foxo3, Zfp36, Zfp354a, Zbtb16, and Zhx3). At 72 h, 769 transcripts 
were upregulated and 704 downregulated in UNx. Upregulated transcripts included Ctgf, 
Sgk1, Zbtb16, and cyclins (Ccnb1, Ccna2, Ccnb1). Interestingly, Ctgf, Sgk1, Zbtb16, and 
Tsc22d3 showed a triphasic response, upregulated at 24 h and 72 h and downregulated at 
48 h, consistent with an underdamped control system.
Conclusions: RNA-seq revealed upregulation of multiple transcripts involved in cell 
division as a central mechanism of compensatory response in the contralateral kidney 
after uninephrectomy. Genes upregulated at 24 h such as Ctgf, Rgcc, Sgk1,and Tsc22d3 
may trigger this response.
Funding: Other NIH Support - Division of Intramural Research, NHLBI Projects 
ZIA-HL001285 and ZIA-HL006129
FR-PO386
The Application of Potential Label-Free Mid-Infrared Biomarkers in 
Patients with Biopsy-Proven Kidney Diseases  Mei-Ching Yu,1,2 Peter R. Rich,3 
Vinod Sathyanarayana Dibbur,2 Jennifer Smith,2 Robert J. Unwin,4 Frederick 
W.K. Tam.2  1Paediatric Nephrology, LinKou Chang Gung Medical Centre, 
Taiwan; 2Imperial College Kidney & Transplant Centre, Hammersmith Hospital, 
United Kingdom; 3Structural and Molecular Biology, Univ College London; 
4UCL Centre for Nephrology, Univ College London, Royal Free Hospital.
Background: We have previously discovered novel spectral markers, the urinary 1545 
cm-1 & plasma 1460 cm-1 peaks,indicating progression of experimental GN using Fourier 
transform infrared spectroscopy (FTIR) (2013 & 2014 ASN). In this study, the aims were to 
investigate these spectral markers in patients with different biopsy-proved kidney diseases, 
and the correlations between the spectral markers with clinical features.
Methods: The urine and plasma samples were collected at the time of renal biopsy 
from 50 patients at Imperial College Renal & Transplant Centre, London, UK and compared 
with healthy volunteers. All samples were measured by FTIR spectrometer and analysed 
by the established method. The biochemistry results such as urine protein/creatinine ratio 
(uPCR), Scr and renal histopathology were collected.
Results: In comparison with healthy volunteers, patients with GN, diabetic nephropathy 
(DN), membranous nephropathy and FSGS exhibited significantly higher levels of the urine 
1545 cm-1 marker. Furthermore, this urine spectral marker correlated with uPCR in both 
GN and DN (p<0.05).There was significant elevation of the plasma 1460 cm-1 marker in 
all the disease groups compared with healthy volunteers.
Interestingly, for DN, this plasma spectral marker correlated positively with the degree 
of interstitial fibrosis, tubular atrophy and Scr (p<0.05).
Conclusions: Our results show the use of the specific urine and plasma FTIR biomarkers 
will be a novel approach to investigate progressive kidney diseases, including GN and DN, 
without chemical manipulation of samples.
Funding: Private Foundation Support
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Omics Investigation of Urine Samples with and without Addition of a 
Protease Inhibitor  Claire Boulange,1 Ilse M. Rood,2 Petra Zürbig,3 Manuja 
Kaluarachchi,1 Elaine Holmes,1,4 Franz S. Schaefer,5 John C. Lindon,1,4 Jack F. 
Wetzels,2 Jeroen Deegens.2  1Metabometrix Ltd, London, United Kingdom; 2Dep 
of Nephrology, RadboudUMC, Nijmegen, Netherlands; 3Mosaiques Diagnostics 
GmbH, Hannover, Germany; 4CSM, Dep of Surgery & Cancer, Imperial College 
London, London, United Kingdom; 5Dep of Nephrology, Univ of Heidelberg, 
Heidelberg, Germany.
Background: Urine is an ideal biofluid for biomarker discovery. To conserve the protein 
profile integrity, samples are stored with a protease inhibitor (PI). It is unknown whether 
the PI alters the metabolomic and proteome profiles. This study aimed to test the influence 
of the PI on metabolomic and proteomic analysis of urine samples.
Methods: We collected 10 urines from normal controls (NC; n=4) and membranous 
nephropathy patients (MN; n=6) and the samples were aliquoted. A PI (mini complete, 
Roche) was added to an aliquot of each sample. Urine samples were stored at -80°C. For 
metabolomics, samples were analyzed by 1H NMR spectroscopy and HILIC-UPLC-MS. 
Multivariate analysis (MVA) was used to elucidate any PI effect in normal urine and 
proteinuria. For peptidomics, capillary electrophoresis-coupled mass spectrometry was 
used to profile the low molecular weight proteome in urine.
Results: Unsupervised MVA of urine NMR metabolic profiles showed clear 
discrimination between NC-PI, NC+PI, MN-PI and MN+PI. Supervised MVA of PI+ and 
PI- samples revealed subtle changes in metabolite levels and the presence of intense signals 
between 3.63 to 3.91 ppm in the PI+ samples, obscuring endogenous metabolite peaks. 
Unsupervised MVA of HILIC-UPLC-MS data showed discrimination between MN-PI 
and NC-PI. Supervised MVA of PI+ and PI- samples showed no detectable difference 
between these two sample types. For peptidomics, MVA between PI+ and PI- resulted in 
no statistically significant peptide differences. Further validation with a proteome classifier 
for CKD (CKD273) showed no statistical significant difference between samples with 
and without PI.
Conclusions: The PI addition did not affect the distinction between MN and NC in 
the metabolome and proteome analysis. However, PI may affect the analysis of metabolic 
subclasses using NMR. Therefore, samples with PI can be used, but with caution.
Funding: Other NIH Support - The research leading to these results has received 
funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) 
under grant agreement no. 305608 (EURenOmics).
FR-PO388
CNVkit – Software Tools for Analyzing Genomic Structural Variants 
David Fasel, Miguel Verbitsky, Simone Sanna-Cherchi.  Medicine, Columbia 
Univ Medical Center, New York, NY.
Background: Copy number variations (CNVs) are increasingly recognized as genetic 
susceptibility factors for kidney disease. Determining whether CNVs are pathogenic or 
associated with a specific phenotype is challenging and few tools exist to aid in this process. 
Here we describe new software tools that provide semiautomated and flexible annotation 
and case-control analyses.
Methods: Copy number variations can be detected by multiple technologies, including 
DNA microarrays and next-generation sequencing (NGS). They span a few hundred base 
pairs to several million, often disrupting multiple genes. Our first software tool allows for 
customizable annotation of CNVs, and is flexible to keep up with changing annotation 
databases. The second tool compares the genomic coordinates of CNVs in case and control 
populations, and finds matching CNVs based on the percentage of mutual overlap. The 
tool then performs a Fisher’s Exact tests on each pair of matching CNVs. The tool can 
also be used to compare CNVs with known pathogenic or benign variants. The software 
runs using command-line inputs and is able to handle data from tens of thousands of 
individuals in a timely fashion.
Results: CNVkit was recently used as a key component of a study (Verbitsky, JCI 2015), 
which compared CNVs in 419 children with chronic kidney disease against those found in 
21,575 controls, and against predefined coordinates of known genomic imbalances. The 
software was used to homogenize results and output from different detection platforms, 
including array CGH, DNA SNP microarrays, and NGS, and to perform joint analyses. It 
was also used to identify copy number variable regions by using a sliding window approach 
to detect regions or genes that are enriched for deletions or duplications.
Conclusions: Structural variants are major susceptibility factors to congenital kidney 
malformations and pediatric kidney disease, and should be considered when investigating 
the cause of genetic disorders. CNVkit provides freely available and easy-to-use tools to 
help CNV annotation and interpretation.
Funding: NIDDK Support, Private Foundation Support
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Quantifying Uropathogenic Bacteria Infection in 3D  Neal A. Paragas,1 
Alexander Klose.2  1Medicine, Univ of Washington, Seattle, WA; 2In Vivo 
Analytics, Inc, New York, NY.
Background: Urogenital tract infection is a disease that annually afflicts more than 
250 million people worldwide; however, the number of antibiotic resistant strains have 
been increasing while newly validated antibiotics have been lagging behind. We have 
developed a method to monitor and quantify a uropathogenic bacterial infection with the 
multispectral bioluminescence tomography (BLT) of a novel bioluminescent uropathogenic 
E. coli (UPEC-lux).
Methods: We modeled pyelonephritis by transurethral injection of UPEC-lux. First, 
we acquired bioluminescence images with a bioluminescent optical imager at four different 
spectral windows centered at 575, 615, 655, 695 nm and with bandwidth of 50 nm. The 
multi-orientation images were acquired using a mirror gantry for simultaneous imaging 
of the dorsal and ventral view. The animal was placed in a fixed position into a novel 
body shape conforming animal mold, placed onto the mirror gantry and spectral images 
were acquired. For in vivo bacterial quantification, a novel calibration device using tissue 
mimetic material was used.The light intensity imaging data became input to a novel BLT 
reconstruction algorithm based on an expectation-maximization (EM) method and the 
simplified spherical harmonics (SP3) equations for modeling in vivo light propagation. 
Post reconstruction, we calculated the total photon emission density of a volume of interest 
(VOI).We then calculated the in vivo organ bacterial load by co-registering it to a novel 
organ probability map.
Results: The EM method reconstructed the 3D photon emission density of the UPEC-
lux and mapped the signal to a novel organ probability map. We analyzed these UPEC-lux 
in a model of pyelonephritis and we were able to determine the bacterial load in the kidney 
by BLT which correlated to CFUs from serial dilution of kidney homogenate (Pearson 
correlation coefficient R2=0.92). For the first time, we could demonstrate the feasibility 
of determining the bacterial burden in the kidneys.
Conclusions: The ability to monitor bioluminescent signal non-invasively will be 
a powerful tool to understand the pathophysiology of urinary tract infections and a new 
method to test novel antibiotics.
Funding: NIDDK Support
FR-PO390
Public Engagement of Kidney Related Health Information on the Internet 
Samir Sulaiman, Joseph A. Vassalotti, Vijay Lapsia.  Medicine, Icahn School 
of Medicine, New York, NY.
Background: The National Kidney Disease Education Program (NKDEP), a part of 
the National Institutes of Health (NIH) provides an authoritative, up-to-date and trusted 
consumer health information resource for patients with kidney disease. We hypothesized 
that the US government (GOV) supported websites would have the highest consumer 
engagement of kidney related health information on the internet.
Methods: We used traffic rank based on publicly available data obtained from alexa.
com and semrush.com, as a marker of website consumer engagement and popularity. We 
identified the top websites in the health category and disease sub-categories. The websites 
were classified based on ownership and data collected on unique US visitors, rank, page 
views per visitor and daily time spent.
Results: In the general health category, the NIH website ranked at the top; however, 
the consumer focused NLM website ranked 9th, behind webmed.com (2nd) and mayoclinic.
org (5th). Among the top 25 websites across all disease categories, Davita.org, a for-profit 
business, was the only kidney related website. Cancer was the only disease condition with 
more than 1 website in the top 25 (7 total). The NKDEP ranked 8th in the genitourinary 
disorders group. The NKDEP had fewer unique US visitors (59,408) compared to Davita.
com (307,729) and Kidney.org (241,550).
Rank Website Unique US Visitors *
Global 
Rank US Rank
Daily 
Pageviews 
per Visitor
Daily 
Time
1 Davita.com 307,729 41,440 8,699 3.98 5:36
2 Kidney.org 241,550 59,136 17,450 1.94 3:02
3 Depend.com 107,230 199,782 40,617 2.5 3:16
4 Kidneyfund.org 81,945 197,479 53,036 1.73 3:02
5 Auanet.org 37,892 229,408 68,797 2.2 2:34
6 ic-network.com 44,773 270,113 58,424 2.5 3:45
7 Urologyhealth.org 68,523 184,328 86,788 1.24 2:06
8 Nkdep.nih.gov 59,408 subdomain data NA
9 Renalinfo.com NA 738,600 401,828 2.1 1:55
10 Kidneyurology.org NA 929,030 415,571 1 1:43
*Estimates as of 05/15/2015 
NA: Not available 
Conclusions: In terms of consumer engagement, the kidney specific NIH website - 
NKDEP, as well as the non-profit kidney.org supported by the National Kidney Foundation 
were out performed by Davita.com, a publicly listed for-profit company by an unexpectedly 
wide margin.
FR-PO391
Media Awareness and Reporting of Dialysis Disruptions and Death from 
Natural Disasters in the United States  Samir Sulaiman, Lindsay E. Jubelt, 
Vijay Lapsia.  Medicine, Icahn School of Medicine, New York, NY.
Background: Patients receiving in-center hemodialysis are particularly vulnerable 
during and after disasters. Evidence of morbidity/mortality from disruption to dialysis 
in a disaster is limited and is so far based on statistical inference. We investigated media 
awareness and reporting of dialysis disruptions and death during natural disasters in the US.
Methods: We identified all major disaster declarations by the US Federal Emergency 
Management Agency. Disasters since 2000, excluding man-made and wildfires, with at 
least 1 known death were included. We then conducted a systematic Google News search 
to identify articles within 30 days of each disaster in the electronic mass media (media). 
Articles were screened for dialysis related key words and classified into 3 categories 
according to reported potential for missing dialysis, missed dialysis or death.
Results: Of 887 natural disasters from 2000-2015, 120 had at least 1 reported death 
(total 4,383 deaths). Hurricanes and winter storms had the highest impact on dialysis 
patients with 5 reported deaths. Of 19 hurricanes incidents, 13 articles referred to dialysis, 
reporting 7 dialysis disruptions, 4 dialysis deaths and 12 instances of potential disruptions 
to dialysis. Only 1 of the 61 deaths reported during 3 winter storms was dialysis related, 
with 2 instances of dialysis disruptions and 3 instances with potential for dialysis disruption. 
Tornadoes, which occurred most often and resulted in the second highest mortality had no 
coverage in the media during its aftermath. 
Variable Number Deaths
Articles 
with dialy-
sis disrup-
tions
Instances 
of Di-
alysis 
Death
Instances 
of Dialysis 
Disrup-
tions
Potential 
For Dialysis 
Disruptions
Hurricanes 19 2,702 13 4 7 12
Tornadoes 84 1,454 0 0 0 0
Earthquakes 2 3 0 0 0 0
Floods 11 162 0 0 0 0
Tsunami 1 1 0 0 0 0
Wildfires 0 0 0 0 0 0
Winter Storms 3 61 5 1 2 3
Total 120 4,383 18 5 9 15
*Dialysis Death: Death due to disaster related disruption to dialysis 
Conclusions: Based on media reports, hurricanes and winter storms are major 
contributors of treatment disruption and mortality in patients on dialysis. Media reports 
can help identify the magnitude of disruption to dialysis operations as well as deaths.
FR-PO392
A Comparison of Physician Reporting versus Computer Algorithms for 
CMS Data Reporting on Form CMS-2728  Mohammed Said Malas,1,2 
Ranjani N. Moorthi,1 Jon D. Duke,2 Sharon M. Moe.1  1IU, Indianapolis, IN; 
2RI, Indianapolis, IN.
Background: The CMS-2728 form (ESRD Medical Evidence Report) assesses 23 
comorbidities chosen to reflect poor outcomes and increased mortality risk. Previous 
studies have questioned the validity of physician data entry on forms CMS-2728 and 
the relationship to hard outcomes. We hypothesize that reporting of comorbidities by a 
computer algorithm identifies more comorbidities and therefore is superior to physicians’ 
completion of the forms.
Methods: We collected data from CMS-2728 forms for all 296 patients who had 
incident ESRD diagnosis and received chronic dialysis between 2005 and 2014 at Indiana 
University outpatient dialysis centers. We analyzed patients’ data from electronic records 
systems that collated information from multiple sources. Previously utilized computer 
algorithms or natural language processing was used to extract data on 10 comorbidities 
(Table) for a period of up to 10 years prior to ESRD incidence. These algorithms incorporate 
billing codes, prescriptions, and other elements that are relevant to each comorbidity. We 
compared the presence of these comorbidities on the forms to the determined presence 
according to the algorithms.
Results: The computer algorithms had higher reporting of comorbidities compared to 
physician completion of the forms (Table). This remained true when decreasing the data 
span to one year and using only single health center data sources. 
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Comorbidity
Computer algorithms Physician completed forms
p-value
% Present % Absent % Checked % Unchecked
CHF 44.3 55.7 16.9 83.1 <0.01
DM 57.4 42.6 36.8 63.2 <0.01
HTN 95.3 4.7 88.9 11.1 <0.01
CAD 28 72 9.8 90.2 <0.01
COPD 14.5 85.5 5.4 94.6 <0.01
Alcohol abuse 12.8 87.2 3.7 96.3 <0.01
Cancer 15.9 84.1 6.1 93.9 <0.01
Substance abuse 27.7 72.3 4.4 95.6 <0.01
CVA 11.1 88.9 6.1 93.9 <0.01
Inability to 
ambulate 6.8 93.2 3 97 <0.05
Conclusions: Data reporting using computer algorithms may increase the capture of 
comorbidities for form CMS-2728 which may result in more accurate standardized mortality 
ratio for dialysis units and improve quality reporting.
Funding: Pharmaceutical Company Support - Regenstrief Institute
Merck pharmaceuticals, Private Foundation Support
FR-PO393
Kidney Dashboard: An Integrated Support Tool for Clinical Care and 
Research Involving Kidney Patients  Jamie S. Hirsch,1,2 Hojjat Salmasian,2 
Amy Y. Chan,3 David Vawdrey,3,2 Matthew Fred,3 Krzysztof Kiryluk.1  1Div 
of Nephrology, Dept of Medicine, Columbia Univ, New York, NY; 2Dept of 
Biomedical Informatics, Columbia Univ, New York, NY; 3NewYork-Presbyterian 
Hospital, New York, NY.
Background: Large amounts of data are contained in electronic health records (EHR), 
and retrieval of relevant information for nephrology patients is cognitively complex and 
time-consuming. This results in inefficiencies, missed opportunities to improve care, and 
difficulty adhering to complex clinical guidelines. We developed a Kidney Dashboard, an 
integrated tool that gathers and analyzes information to facilitate the care and research of 
kidney patients.
Methods: Relevant clinical data were catalogued and categorized, including visit 
history, billing data, vital signs, labs, imaging, pathology, and medications. We automated 
generation of derived data, such as estimation and trending of eGFR, proteinuria, and 
automated CKD staging. We implemented a comprehensive rule-based alert system based 
on KDIGO guidelines to provide real-time clinical decision support.
Results: The Dashboard was created within the clinical information system at 
NewYork-Presbyterian Hospital, incorporating inpatient and outpatient data from multiple 
sources. It uses a tile layout, where each tile represents a relevant section of data that 
matches clinician workflow, e.g., renal function, anemia, bone and mineral metabolism, 
glomerulonephritis, etc. Repeat eGFR and proteinuria data are presented as interactive 
longitudinal graphs. The Dashboard integrates delivery of comprehensive stage-specific 
decision support and creates a portable phenotypic patient profile for genetic and 
epidemiologic research in kidney disease.
Conclusions: The Kidney Dashboard aims to improve care and facilitate research 
by consolidating all relevant EHR data at the point-of-care and generating phenotypic 
profiles of kidney patients. This project promotes precision nephrology, exemplifying 
the next generation of “smart” EHR tools. Following its public release, effectiveness of 
the Dashboard will be studied in focus groups and by time-motion studies and audit log 
analyses. The improvement in adherence to KDIGO guidelines will be tested prospectively.
FR-PO394
Forecasting a Renal Prognosis of IgA Nephropathy Using Machine 
Learning: Validation Study  Hajeong Lee,1 Junhyug Noh,2 Hyosang Kim,3 
Won Seok Yang,3 Yon Su Kim,1 Dong Ki Kim.1  1Internal Medicine, Seoul 
National Univ Hospital; 2Computer Science and Engineering, Seoul National 
Univ College of Engineering; 3Internal Medicine, Asan Medical Center.
Background: We aimed to develop and validate individual outcome prediction models 
in IgAN patients using machine learning.
Methods: We included adult IgAN patients from Seoul National University Hospital 
(SNUH, n = 1,540) and Asan Medical Center (AMC, n = 1,044) at the time of renal biopsy. 
They were divided into development (followed up ³10 years) and prediction (follow up <10 
years) sets, respectively. The outcome was 10-year renal survival (10YRS) probability. We 
developed prediction models from SNUH test set by using logistic regression (LR) with 
Lasso method, a classification and regression tree (CART), and neural network (NN) using 
16 clinico-pathologic variables. We also used bagging, random forest (RF) and boosting 
for ensemble learning. Finally, those models were validated internally in SNUH prediction 
set and externally in AMC development and prediction sets.
Results: Considering missing data, 1,514 and 847 patients were included from SNUH 
and AMC cohorts. In the LR model, eGFR, hemoglobin, proportions of GS and SS, 
interstitial fibrosis (IF) were selected as predictors for ESRD. In the CART model, eGFR 
53.3 ml/min/1.73m2 was proved to be a watershed for 10YRS, followed by, proportion of 
GS and SS, IF, hemoglobin and proteinuria, sequentially. In addition, the ensemble learners 
showed good performance (accuracies of bagging, 0.868; RF, 0.874; boosting, 0.862). Those 
individual learners were validated internally with good performance (sensitivities of LR, 
0.855; CART, 0.921; NN, 0.952; bagging, 0.857; RF, 0.921; boosting, 0.921). And finally, 
we proved the robustness of those models from external validation. Good performances of 
both development (sensitivities of LR, 0.847; CART, 0.867; NN, 0.855; bagging, 0.852; 
RF, 0.872; boosting, 0.851) and prediction sets (sensitivities of LR, 0.980; CART, 0.902; 
NN, 0.941; bagging, 0.882; RF, 0.902; boosting, 0.922) were showed.
Conclusions: We developed robustness of prediction models using machine learning 
for the individual’s likelihood of 10YRS in IgAN with both internal and external validation.
FR-PO395
Quantifying the Gender Reimbursement Gap in Nephrology  Sadeem Ali, 
Xiangming Fang, Pankaj Jawa, Tejas P. Desai.  Nephrology, East Carolina 
Univ, Greenville, NC.
Background: 2015 Medscape Compensation Report suggests that female providers 
earn less than male providers but the sample size was 19657; only 1% Nephrologists. To 
analyze the financial disparities, we compared total Medicare reimbursements paid to 
males & females.
Methods: We obtained reimbursement data from 2014 Medicare Provider Utilization 
& Payment Data Physician Public Use File. We consolidated all reimbursements by NPI 
number & categorized them by specialty & sex. We adjusted reimbursement differentials 
against number of Medicare beneficiaries seen & services provided. Linear regression 
models were used to compare reimbursements.
Results: We analyzed 246,996 providers in 13 specialties; 3% were Nephrologists. 
Female Nephrologists were reimbursed less $41,776.96 (unadjusted); the 6th worst female-
to-male reimbursement differential. In the adjusted analysis, female Nephrologists had the 
worst reimbursement differential: less $17,971.66.
Unadjusted Lower Upper Adjusted Lower Upper
All 34125.68 34991.61 33259.79 19980.23 20599.45 19361.00
Cardiology 49532.75 54955.76 44109.75 8455.53 11946.07 4964.98
Endocrinology 21583.72 24379.99 18787.44 6217.03 7598.03 4836.03
Critical Care 21161.13 28712.74 13609.52 4532.58 8341.91 723.24
Family Practice 15029.77 15627.83 14431.70 8505.32 8957.32 8053.33
Gastroenterol-
ogy 26556.29 28968.12 24144.45 4931.95 6055.77 3808.14
Hematology/
Oncology 94350.55 109996.00 78705.13 7824.90 13788.98 1860.82
Infectious 
Disease 19176.82 23177.82 15175.83 6849.35 9562.13 4136.56
Internal 
Medicine 24158.97 25003.32 23314.62 11202.12 11792.19 10612.05
Nephrology 41776.96 47751.56 35802.36 17971.66 22675.94 13267.37
Hematology 52257.03 86317.14 18196.91 10160.85 21535.90 +1214.21
Medical 
oncology 81433.39 106482.80 56383.97 6330.41 16167.31 +3506.49
Rheumatology 85356.80 98925.86 71787.74 17127.52 23448.97 10806.07
Pulmonary 32543.52 36514.82 28572.21 11461.55 13870.45 9052.66
Female Reimbursement Deficits (). Lower & Upper Refer To 95% Confidence 
Interval Bounds.
Conclusions: When adjusted for the number of beneficiaries seen & services provided, 
female Nephrologists endure the largest reimbursement gap by sex in any specialty. Steps 
should be considered to close his gap.
FR-PO396
Protein Engineering for Renal Delivery of Molecular Therapies  Pan Liu, 
Jing Jin.  Dept of Medicine-Nephrology/Hypertension, The Feinberg School of 
Medicine, Chicago, IL.
Background: Targeted delivery of therapeutic enzymes to the kidney is desirable 
for treatment of renal diseases and beyond. Previously, approaches that exploit the renal 
excretion of low–molecular weight proteins (LMWP) have been attempted. However, these 
carriers can only deliver chemical compounds, and their efficiency is further hampered by 
fast renal clearance. In order to deliver enzyme cargos, we designed carrier proteins for 
specific and long-lasting renal delivery. We engineered a fusion protein comprised of a 
kidney-targeting polybasic tag (PBT) and an Fc segment for extended stability.
Methods: PBT-Fc and Fc-only control were produced as recombinant proteins. We 
used Duramycin as an LWMP control for alternative means of renal targeting through 
excretion. The probes were then separately labeled with a radionuclide 99mTechnetium 
(99mTc) tracer. Following i.v. injection of the probes to rats, we performed SPECT in whole 
body scanning. Radiographs were obtained in a time series for up to 1 hour. In parallel, we 
performed histology studies of kidney sections to determine the sub-anatomical patterns 
of the injected probes.
Results: Prominent and sustained kidney localization of 99mTc-PBT-Fc (>95%) was 
observed by SPECT, a pattern in contrast to that of the 99mTc-Fc control that was mainly 
in blood circulation during the course of observation (only <5% is in the kidney). 99mTc-
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Duramycin reached the kidney quickly and then followed through urinary excretion to the 
bladder. By 20 minutes less than 5% remained in the kidney. The imaging results were 
consistent with IHC findings from mouse kidney following probe injections, which shows 
the PBT-Fc, but not Fc-alone, binding the glomeruli and tubule basement membrane shortly 
after injection. PBT-Fc sustained in the kidney for at least 10 days.
Conclusions: Our engineered PBT-Fc carrier exclusively targets kidney through 
binding to the glomeruli and tubule basement membrane. This recombinant probe also 
achieves long-lasting kidney retention (days as compared to minutes for LMWP), yet 
another desirable property for targeted therapeutic delivery. This vehicle will potentially 
be useful for delivery of molecular therapies, particularly enzyme proteins, to the kidney.
FR-PO397
Dynamic Culture on an Orbital Shaker Alters the Phenotype of Primary 
Human Renal Tubular Epithelial Cells  Nicholas J. Ferrell,1 Jin Cheng,1 
Simeng Miao,2 William Henry Fissell.1  1Nephrology, Vanderbilt Univ Medical 
Center, Nashville, TN; 2Biomedical Engineering, Vanderbilt Univ, Nashville, TN.
Background: Primary cells cultured in vitro gradually lose features characteristic to 
the in vivo cell type, variously termed “senescence” or “culture stress.” Culture conditions 
that help maintain cell-specific phenotype are advantageous for cell biology and tissue 
engineering. Here we evaluated the phenotype of primary renal tubular epithelial cells 
after applying apical fluid shear stress using an orbital shaker.
Methods: Human renal tubular epithelial cells were isolated from donor kidneys not 
suitable for transplant. Cells were cultured on Transwell inserts under static conditions or on 
an orbital shaker at a frequency producing fluid shear stresses of 2 dyn/cm2. Transepithelial 
resistance was measured daily. After 2 weeks in culture, cell density was analyzed by 
counting DAPI stained nuclei, and expression of tubule-specific markers was measured 
by PCR and western blotting.
Results: Dynamic culture significantly increased steady state transepithelial resistance 
from 344±31 to 544±32 -cm2 (p<0.001) and resulted in a 21.5±2.1% (p<0.001) increase in 
cell density. Gene expression of tubule epithelial cell markers (GGT1, COL4A1, COL4A2, 
NHE3, and NAPP2) increased with fold changes in expression of 4.3±0.3, 4.1±0.3, 3.1±0.2, 
2.1±0.4, and 1.9±0.2, respectively. Cells grown under shear also showed increased protein 
expression of gamma-glutamyl transpeptidase.
Conclusions: Primary renal tubular epithelial cells grown on an orbital shaker with 
physiological levels of fluid shear stress appear to express proximal tubule markers more 
than cells grown in static conditions. This may be due to increased nutrient delivery 
and waste removal with improved mixing at the apical brush border, or due to specific 
gene regulation related to mechanotransduction. Further mechanistic insight may allow 
investigators to develop improved in vitro culture systems for cell biology and tissue 
engineering and more accurate in vitro models of disease.
Funding: NIDDK Support
FR-PO398
CRISPR/Cas9-Mediated Site-Specific Mutation in Rat Angiomotin Gene 
via Direct Injection of One-Cell Embryos  Yaochun Zhang,1 Zakir Hossain,2 
Bo Lan,1 Chang-Yien Chan,1 Hui Kim Yap,1 Kar Hui Ng.1  1Dept of Paediatrics, 
National Univ of Singapore, Singapore; 2Cancer Science Inst of Singapore, 
National Univ of Singapore, Singapore.
Background: Genetically modified animals represent a crucial tool for understanding 
gene function in development and disease. The recently developed CRISPR/Cas9 system 
is an efficient gene-targeting technology to generate genetically modified animals. We 
have performed exome sequencing in a Singapore Chinese family with X-linked recessive 
membranous nephropathy associated with Fanconi syndrome and anti-tubular basement 
antibodies, and identified AMOT, coding for angiomotin, as a novel candidate gene with a 
putative disease-causing mutation p.S50G in the N-terminal of the p130-AMOT isoform. 
Preliminary work confirmed the expression of angiomotin in renal tubular cells. This study 
aimed to introduce the mutation into rat genome via direct injection of CRISPR/Cas9 into 
one-cell embryos, establishing rat models for downstream pathological studies.
Methods: The tracrRNA:crRNA fused single guide RNA (sgRNA, 20ng/µl), together 
with Cas9 protein (40ng/µl) and a single-stranded oligonucleotide (ssODN, 3ng/µl), which 
encodes the p.S50G mutation of angiomotin and serves as template for HR-mediated repair, 
were introduced into the rat pronucleus via microinjection. Pups produced from the injected 
embryos were first detected by mismatch-sensitive T7 endonuclease I digestion. Animals 
carrying mutations were sequenced to determine the precise sequence.
Results: In the 32 survived pups, one (3.1%) founder rat was identified to carry the 
heterozygous mutation. After crossing F0 with a wild-type rat, ten F1 rats were delivered, 
of which four males (40%) were carrying the mutation on their X chromosomes, while 2 
(20%) were heterozygous females. No phenotype data is available currently as the animals 
are only three weeks old. Homozygous female rats are expected to be produced by crossing 
between the F1 animals.
Conclusions: In conclusion, a heritable site-specific mutation was successfully 
introduced into the rat genome with the CRISPR/Cas9 system. This one-step method of 
generating site-specific mutations in rats will greatly accelerate the in vivo study of gene 
functions.
Funding: Government Support - Non-U.S.
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Double Transduction of a Cre/LoxP Lentiviral Vector: A Simple Way to 
Generate Cell-Specific Knockdown Mice  Shin-Wook Kang, Bo Young Nam, 
Meiyan Wu, Tae-Hyun Yoo.  Brain Korea 21 PLUS, Severance Biomedical 
Science Inst, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Genetically engineered mice have been used to elucidate the function 
of specific genes. Transgenic mice generated by conventional knockout techniques using 
oocytes or embryonic stem cells are most commonly used to downregulate genes, but this 
method has certain limitations. Therefore, a novel method to knock down specific genes 
in a cell specific manner in adult mice was devised by lentivirus (LV)-assisted transfer of 
short hairpin RNA.
Methods: In vitro, the LV suspension containing LV-Hoxb7 Cre and/or LV-Aquaporin 3 
shRNA (shAQP3) was added to cultured mouse renal collecting duct cells (CDs) and mouse 
mesangial cells (MMCs). In vivo, first, LV-Hoxb7 Cre was injected into the loxP-EGFP 
mice to check the Hoxb7 promoter efficiency. Second, LV-loxP shAQP3 was injected into 
the Hoxb7 Cre transgenic mice to check shAQP3 function. Third, consecutive injections 
of LV-Hoxb7 Cre and LV-loxP shAQP3 were made to C57BL6/J mice.
Results: In vitro, LV-Hoxb7 Cre worked only in CDs due to the presence of Hoxb7 in 
CDs but not in MMCs. Furthermore, combined infection of CDs with LV-Hoxb7 Cre and 
LV-loxP shAQP3 significantly inhibited the protein expression of AQP3 along with the 
disappearance of EGFP protein expression, suggesting that LV-Hoxb7 Cre and LV-loxP 
shAQP3 used in this study worked together effectively. In vivo, kidney CD-specific AQP3-
knockdown mice were generated by consecutive injection of LV-Hoxb7 Cre and LV-loxP 
shAQP3 in adult C57BL6/J mice. In mice treated with LV-Hoxb7 Cre alone, mCherry 
protein expression occurred only in CDs, while LV-loxP shAQP3 injection alone led to an 
increase in EGFP expression in all cells. In the kidney, AQP3 expression in mice injected 
with LV-Hoxb7 Cre or LV-loxP shAQP3 alone did not differ, but consecutive injection of 
LV-Hoxb7 Cre and LV-loxP shAQP3 significantly reduced AQP3 expression. However, 
the expressions of AQP3 in other organs did not differ between the groups.
Conclusions: Double transduction of Cre- and loxP-based LV can be a simple way 
to generate cell-specific knockdown mice, and this method may also be applicable to 
other species.
FR-PO400
Local Delivery of Interleukin-10 via Injectable Hyaluronic Acid Hydrogels 
to Prevent Local and Systemic Injury in Ischemic Acute Kidney Injury 
Danielle Soranno,1 Chris Altmann,2 Sarah Faubel,2 Ana Andres-hernando.2 
1Pediatrics & Bioengineering, Nephrology, Univ of Colorado, Aurora, CO; 
2Medicine, Nephrology, Univ of Colorado, Aurora, CO.
Background: AKI is pro-inflammatory and causes systemic complications via 
IL-6. Here, we use injectable hyaluronic acid (HA) hydrogels to deliver IL-10, an anti-
inflammatory cytokine, to improve local and systemic outcomes of AKI.
Methods: Four treatment groups were followed for 28 days following AKI (15 µL 
of therapy delivered 3 days status-post AKI), and compared to healthy and untreated AKI 
controls (n=5): IL-10 in saline delivered under the left kidney capsule (LK IL-10); IL-10 
suspended in HA delivered subcutaneously (SQ gel/IL-10); HA with or without IL-10 
injected under the left kidney capsule (LK gel, LK gel/IL-10); HA hydrogels were developed 
as previously reported. Serial measurements of blood urea nitrogen and creatinine were 
followed at 1, 4, and 28 days. Serum IL-6 was measured at sacrifice. Immunohistochemistry 
(IHC) was performed to identify collagen type III deposition. Positive cells were quantified 
(20 images/section, in cortex). ANOVA with Dunnett’s posthoc was used to determine 
significance.
Results: All treatment groups normalized BUN, Cr and serum IL-6 by day 28 while the 
untreated AKI cohort had a persistent increase in BUN, Cr and IL-6. All treatment groups 
showed a significant reduction in collagen deposition in both left and right kidneys compared 
to untreated AKI, with variable effect depending on the mode of HA/IL-10 delivery.
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Conclusions: Injectable HA hydrogels can be used to deliver IL-10 and improve 
local and systemic outcomes of ischemic AKI. Therapy improved renal function, reduced 
collagen deposition, and reduced systemic IL-6 28 days following AKI. HA alone improved 
outcomes; the addition of IL-10 to the HA resulted in further histological improvement.
Funding: Private Foundation Support
FR-PO401
Substrate Stiffness Regulates Renal Epithelial Cell Cilia Formation via 
Autocrine TGFβ Signaling  Mingfang Ao,1 Jin Cheng,1 Nicholas J. Ferrell,1 
H. David Humes,3 Shuvo Roy,2 William Henry Fissell.1  1Nephrology and 
Hypertension, Vanderbilt Univ, Nashville, TN; 2Bioengineering and Therapeutic 
Sciences, Univ of California, San Francisco, San Francisco, CA; 3Nephrology, 
Univ of Michigan, Ann Arbor, MI.
Background: The primary cilium senses the extracellular environment. Malformation 
of primary cilia has been shown to result in kidney disease. Although much is known 
regarding ciliogenesis, the role of mechanical features of the microenvironment in cilia 
formation is poorly understood.
Methods: Human primary proximal tubule epithelial cells (HRECs) and LLC-PK1 
cells were plated on collagen-coated polyacrylamide gels with different stiffness (0.5 KPa, 
1 KPa, 10 KPa and 40 KPa) and grown for 5 to 7 days. Cilia formation was analyzed by 
immunofluorescence staining of AC-tubulin followed with microscopy imaging. Protein 
expression was measured by immunoblotting. Recombinant TGFβ 1 and an inhibitor 
of TGFbRII SB431542 were used for TGFβ signaling modulation. LiCl was utilized to 
stimulate P-GSK3b.
Results: Stiff hydrogels (10 KPa and 40 KPa) gave rise to higher ciliary density than 
compliant gels (0.5 KPa and 1KPa) did (60% vs 20%). Furthermore, this phenotype could 
be altered by manipulation of transformation growth factor beta (TGFβ) signaling: addition 
of TGFβ 1 could increase the cilia frequency even when the cells were on compliant gels; 
similarly, inhibition of TGFβ receptor II impairs cilia formation in the context of stiff 
substrates. Further supporting a role for TGFB, substrate stiffness was associated with 
increased SMAD2 and GSK3B phosphorylation. Incubation with LiCl also increased 
GSK3B phosphorylation and cilia formation independent of TGFβ.
Conclusions: Substrate stiffness determines cilia formation through TGFβ signaling 
via downstream GSK3β phosphorylation. This work highlights that substrate mechanical 
properties have a strong influence on markers of differentiation. This has relevance for tissue 
engineering efforts and also suggests a mechanism of disease progression in the scarred 
kidney. This may broaden researches on kidney disease and contribute to disease therapy.
Funding: Other U.S. Government Support
FR-PO402
An Additive Role of Microfluidics on KLF 15-Induced Differentiation of 
Human Primary Podocyte  Seung Hee Yang,1 Eunjin Bae,2 Sejoong Kim,2 
Kwon Wook Joo,1,2 Chun Soo Lim,1,2 Yon Su Kim,1,2 Dong Ki Kim.1,2  1Kidney 
Research Inst; 2Internal Medicine, Seoul National Univ College of Medicine, 
Seoul.
Background: Podocyte de-differentiation is one of major problems during the process 
of primary podocyte culture. Recently, much interest has been focused on the topic; yet 
lengthy podocyte differentiation process hinders a progress. Krüppel-like factor 15 (KLF 
15) was reported to be a novel transcriptional regulator of podocyte differentiation and 
its expression was increased by retinoic acid (RA) which promotes the differentiation of 
podocytes. But, the duration of podocyte differentiation process remains long. Here, we 
present a novel in vitro protocol to induce podocyte differentiation.
Methods: To mimic in vivo biological environment of glomerulus, a polydimethly 
siloxane (PDMS) microfluidic device was used. The human primary podocytes were 
cultured in the 500 mm by 130 mm microfluidic channel and were stimulated with a laminar 
fluidic shear stress of 0.5 dyn/cm2 for 5 days. Various dose of RA was used to promote 
podocyte differentiation.
Results: In this research, we were able to reduce the time required for podocyte 
differentiation with higher shear stress and higher dose of RA. A couple of tests 
were conducted to verify the podocyte differentiation through the protocol. First, the 
phenotype of podocytes changed from cobblestone like shape to arborized cells. Through 
immunofluorescence staining, the increased expression of cytoplasmic synaptopodin 
and intercellular junction ZO-1 was confirmed. Moreover, KLF 15 expression was also 
increased.These molecules were also quantified with mRNA expression through real-time 
PCR. The size of podocytes became larger and the height of podocytes increased by a factor 
of 2.3 fold. Lastly, the podocytes aligned with the direction of flow.
Conclusions: In conclusion, we were able to promote podocyte differentiation in the 
shorter processing time with microfluidics and RA. Yet, more effort to mimic biological 
aspects of kidney such as complex structure with multiple cell layers and round surface 
is necessary.
FR-PO403
CCL18 Correlates with Disease Activity in ANCA-Associated Necrotizing 
Glomerulonephritis  Silke R. Brix,1 Christian F. Krebs,1 Martin Busch,2 
Thorsten Wiech,3 Ulf Panzer,1 Rolf A. Stahl.1  1III. Medizinische Klinik, 
Universitätsklinikum Hamburg-Eppendorf, Germany; 2Klinik für Innere 
Medizin III, Universitätsklinikum Jena, Germany; 3Inst für Pathologie, 
Universitätsklinikum Hamburg-Eppendorf, Germany.
Background: Microarray analysis of renal tissue from patients with antineutrophil 
cytoplasmic antibody (ANCA)-associated necrotizing glomerulonephritis (GN) revealed 
the CC chemokine ligand 18 (CCL18) as the highest up-regulated chemokine. The renal 
production of CCL18 was associated with fresh glomerular lesions and impairment of renal 
function. The cellular sources of CCL18 were identified as macrophages and dendritic 
cells. CCL18 serum levels were elevated in patients with newly diagnosed ANCA GN as 
well. In order to test whether CCL18 might serve as a biomarker of relapsing renal ANCA 
disease, we prospectively analyzed CCL18 serum levels.
Methods: Hundred thirty-five patients with biopsy proven ANCA GN were 
prospectively analyzed for CCL18 serum levels. Patients included in the study were in 
remission on maintenance therapy (n=117) or without immunosuppressive treatment 
(prednisolone 5mg or less was accepted) (n=18). Serum levels of CCL18 were measured 
by ELISA every three months. Renal relapse was defined as either rising serum creatinine 
with urinary red cell casts or biopsy-confirmed active ANCA-associated glomerular lesions 
(i.e. fibrinoid necrosis and/or cellular crescents) accompanied by an intensification in 
immunosuppressive treatment.
Results: During a mean follow up time of 11.6 ± 8.3 months, 16 patients developed a 
renal relapse. CCL18 levels were higher in relapsing patients when compared with patients 
who remained in remission (p<0.0001; 167.50 ± 85.04 ng/ml vs. 83.17 ± 46.38 ng/ml). 
CCL18 serum levels increased at the time of relapse and decreased after immunosuppressive 
therapy was restarted or intensified (n=16; ANOVA; p<0.001).
Conclusions: CCL18 serum levels are associated with disease activity in patients with 
ANCA GN and might serve as a marker of renal relapses in the surveillance of these patients.
Funding: Government Support - Non-U.S.
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Prognostic Value of Persistent Heamaturia and Proteinuria in ANCA-
Associated Vasculitis: Data from the European Vasculitis Study Group 
(EUVAS) Therapeutic Trials  Alexandre Karras,1,3 Thomas F. Hiemstra,2,3 
Rachel B. Jones,2,3 David R.W. Jayne.2,3  1Nephrology, HEGP Hospital, Paris, 
France; 2Nephrology, Addenbrooke’s Hospital, Cambridge, United Kingdom; 
3On behalf of the EUVAS Study Group.
Background: Renal involvement is frequent ANCA-associated vasculitis (AAV), due 
to crescentic glomerulonephritis (CGN). Heamaturia (Hu) and proteinuria (Pu) are detected 
during the initial and active phase of CGN but the prognostic value of the persistence 
of these urinary abnormalities during the remission phase of AAV is still controversial.
Methods: Data were combined from three EUVAS trials (IMPROVE, RITUXVAS, 
MYCYC), providing data for Hu and Pu at month 6 (M6) following initiation of 
immunosuppression and patient follow-up until month 18 (M18). Hu was defined as 
the presence of >10 RBC/mm3. Proteinuria was evaluated by protein-to-creatinine ratio 
(PCR, g/mmol).
Results: Data concerning 337 patients were available for analysis. ANCA specificity 
(PR3/MPO) was 58/37%, renal involvement was present in 73% of cases and initial mean 
eGFR was 46±32 ml/min/1.73m2. Hu was still positive at M6 in 27% of cases, although 
96% of patients were in AAV remission. Positivity of Hu at M6 was associated with more 
severe initial nephropathy but was not predictive of renal dysfunction at last FU (mean 
eGFR at M18 was respectively of 55±24 and 60±24 ml/min for Hu+ and Hu- patients, 
p=NS). Proteinuria at M6 was <0.03 g/mmol in 53% of cases, between 0.03 and 0.1 g/
mmol in 25%, >0.01 g/mmol in 22%. Among patients with M6 Pu >0.1 g/mmol, 29% had 
CKD stage 4 or 5 at M18, vs 3.5% and 11.5% respectively for patients with M6 PCR <0.03 
and 0.03-0.1 g/mmol. Multivariate analysis using a mixed effects model demonstrated that 
decrease of eGFR during follow-up was independently associated with age (p<0.001), 
baseline eGFR (p<0.001) and M6 proteinuria (p=0.002), but not with M6 haematuria 
(p=0.284) nor ANCA specificity (p=0.82).
Conclusions: Persistence of micro-hematuria during the remission phase of AAV 
is associated with more severe initial renal involvement but does not predict poor renal 
outcome. Degree of proteinuria at M6 reflects more severe kidney damage and is an 
independent predictor of CKD progression in AAV nephropathy.
FR-PO405
ANCA Associated Vasculitis: Safe and Effective Induction of Remission 
with Low Dose Cyclophosphamide, Rituximab, and Reduced Exposure to 
Glucocorticoids  Frank B. Cortazar, Karen A. Laliberte, Andrew P. Murphy, 
Katherine M. Cosgrove, William Franklin Pendergraft, John Niles.  Renal 
Associates, Massachusetts General Hospital, Boston, MA; Kidney Center, Univ 
of North Carolina (UNC), Chapel Hill, NC.
Background: Rapid induction of remission in ANCA-associated vasculitis(AAV) is 
essential to prevent irreversible organ damage.Current regimens use glucocorticoids(GC) 
combined with either cyclophosphamide(CYC) or rituximab(RTX).To effectively induce 
remission while minimizing GC exposure,we devised a standard induction(SI) protocol 
that combines RTX,low-dose bridging oral CYC,and a rapid GC taper.
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Methods: Retrospective analysis of AAV pts treated w/ new SI regimen:RTX 1gm 
Q2wk x 2 doses,oral CYC 3mg/Kg/d x1 wk and 1.5mg/Kg/d x2 mths(adj for eGFR),and 
pulse solumedrol followed by a rapid prednisone(pred) taper to £15mg/d by 5wks.
Remission defined as BVAS-WG 0 and pred dose ≤7.5mg/d.Pts received SI alone or SI+ 
plasma exchange (PE).
Results: 74 pts treated with SI and 35 pts w/SI+PE (table1).Time to remission in the 
SI and SI+PE was 117±53 and 122±39 days,respectively (p=0.67).Cumulative incidence 
plots(Figure 1). Among survivors,100% of SI and 97% of SI+PE achieved remission. 3 pts 
(4%) in SI and 1 (3%) in SI+PE died during induction.There were 0.04 treatment-related 
serious adverse events/pt month in both groups.
Baseline SI SI+ PE p value
Age 61 ± 16 65 ± 17 0.24
% Women 62 49 0.17
% MPO 67 60 0.35
Baseline Cr (mg/dL) 1.8 ± 1.1 4.9 ± 1.9 <0.01
% Dialysis Dependence 1 11 <0.01
Initial BVAS-WG 6.3 ± 2.8 8.7 ± 3.3 <0.01
Conclusions: RTX with low-dose bridging CYC allows for successful induction of 
remission in essentially all AAV pts while attenuating exposure to high dose GC.Treatment-
related adverse events were minimal.Our data provide an impetus for a randomized trial 
comparing this new regimen with the standard of care.
Funding: Clinical Revenue Support
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Reduced Risk of Cancer with Substitution of Cyclophosphamide 
with Azathioprine for Maintenance Treatment of ANCA Associated 
Glomerulonephritis  Sanjeevan Sriskandarajah,1 Knut Aasarod,2 Tor Aage 
Myklebust,3 Anna Reisaeter,4 Rune Bjoerneklett.1,5  1Renal Research Group, Dept 
of Clinical Medicine, Univ of Bergen, Bergen, Norway; 2Dept of Nephrology, 
St. Olav Univ Hospital, Trondheim, Norway; 3Cancer Registry of Norway, 
Oslo, Norway; 4Norwegian Renal Registry, Oslo Univ Hospital Rikshospitalet, 
Oslo, Norway; 5Dept of Medicine, Haukeland Univ Hospital, Bergen, Norway.
Background: ANCA associated vasculitis (AAV) is associated with an increased risk of 
cancer and a dose-dependent oncogenic effect of cyclophosphamide (CYC) appears to be a 
major explanatory mechanism. The concept that Azathioprine (AZA) can safely substitute 
for CYC in maintenance treatment of AAV was demonstrated in the CYCAZAREM study 
(2003) and has been adopted by all hospitals treating ANCA associated glomerulonephritis 
(AAGN) in Norway. In the present study, risk of cancer in patients with AAGN using CYC 
versus AZA for maintenance treatment has been compared.
Methods: Patients diagnosed with AAGN registered in the Norwegian Kidney Biopsy 
Registry 1988-2012 were included. The study cohort was linked to the Cancer Registry 
of Norway. Standardized incidence ratios of cancer were calculated. A competing risk 
regression model, using death as a competing risk, and with adjustment for; age, gender, 
ANCA category and kidney transplantation were used to compare the CYC and AZA groups 
regarding risk of cancer. The observation period was time from diagnostic kidney biopsy 
to death, first-time cancer or end of year 2013.
Results: We identified 485 patients with AAGN for analysis. Mean age was 58 years 
(SD 17 years) and 267 (55%) were males. Mean duration of follow-up was 7.2 years (SD 
6 years and range 0.0-24.3 years). During follow-up 53 cancers (first cancer, all-sites) 
appeared, SIR 1.26 (0.97-1.67). In the CYC maintenance group 49 cancers appeared, SIR 
1.40 (1.06-1.87) and in the AZA maintenance group 4 cancers, SIR 0.57 (0.22-1.98). Risk 
of cancer was significantly lower in the AZA as compared to the CYC maintenance group 
(p<0.05), estimated risk reduction being approximately 60%.
Conclusions: Substitution of CYC with AZA for maintenance treatment of AAGN is 
associated with significantly reduced risk of cancer.
FR-PO407
Double Positivity for ANCA and Anti-GBM Antibodies: Clinical 
Characteristics and Long-Term Outcomes of a Multi-Centre Cohort 
Stephen Paul McAdoo,1 Anisha Tanna,1 Sophie Ohlsson,2 Zdenka Hruskova,3 
Maria Weiner,4 Jeremy B. Levy,1 Vladimir Tesar,3 Marten Segelmark,4 Charles 
D. Pusey.1  1Imperial College London; 2Lund Univ; 3Charles Univ Prague; 
4Linkoping Univ.
Background: Co-presentation with both ANCA and anti-GBM disease is a rare 
phenomenon. Current studies of such cases include small numbers and report variable 
outcomes. We aim to describe the clinical features and outcomes of a large cohort of 
contemporary patients identified from three large European centres.
Methods: This is a retrospective cohort study, which included patients with both 
ANCA and anti-GBM antibodies (‘double-positive’, DP) from three centres, who presented 
after 2000, and for whom at least 1 year follow-up data was available. We have compared 
parameters to patients presenting with ‘single-positive’ (SP) anti-GBM disease.
Results: We have identified 78 anti-GBM+ patients, of whom 37 (47%) were DP for 
ANCA (70% MPO, 27% PR3, 3% MPO+PR3). DP patients were older (mean age 63 vs 54 
yrs, p=0.048) and had longer symptom duration before diagnosis (6 vs 2.5 wks, p=0.049). 
There were no differences in renal function, dialysis-requirement, or frequency of lung 
haemorrhage between groups, although DP patients had more chronic injury on renal biopsy 
(33% vs 7% tubular atrophy, p=0.001). SP and DP groups were treated similarly. There 
were no differences in early (3 month) or late (5 year) patient or renal survival (5 year 
survival 78% vs 81%, p=0.49), although DP patients had a significant risk of relapse (8 
vs 0 relapses over median follow-up of 3.9 years, p=0.01) that in all cases was associated 
with recurrence or rising titre of ANCA.
Conclusions: This is the largest reported series of European patients with double 
seropositivity for ANCA and anti-GBM antibodies. Patient and renal-survival was 
comparable to SP anti-GBM disease, although DP patients have greater risk of relapse related 
to their ANCA status, and so require long-term follow-up and consideration of maintenance 
immunosuppression. DP cases had a longer prodrome of symptoms and evidence of chronic 
damage of renal biopsy, suggesting that ANCA-induced glomerular inflammation may 
precede and contribute to the development of anti-GBM disease.
Funding: Government Support - Non-U.S.
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Pulse Methylprednisolone for Induction of Remission in Severe ANCA 
Associated Vasculitis Is Associated with an Increase in Adverse Events but 
No Improvement in Outcome  Dimitrios Chanouzas,1 JulieAnne G. McGregor,2 
Alan D. Salama,3 Wladimir M. Szpirt,4 Neil Basu,5 Matthew David Morgan,1 
Caroline J. Poulton,2 Juliana Bordignon Draibe,3 Elizabeth Krarup,4 Paula I. 
Dospinescu,5 Jessica Anne Dale,1 William Franklin Pendergraft,2 Keegan Lee,3 
Martin Egfjord,4 Susan L. Hogan,2 Lorraine Harper.1  1Univ of Birmingham, 
United Kingdom; 2Univ of North Carolina Kidney Center; 3Univ College 
London, United Kingdom; 4Copenhagen Univ Hospital, Denmark; 5Univ of 
Aberdeen, United Kingdom.
Background: Intravenous pulse methylprednisolone (MP) is frequently used as part 
of remission induction in severe ANCA associated vasculitis (AAV). However, there are no 
studies assessing its efficacy in the setting of AAV, while treatment related complications 
remain the main source of morbidity.
Methods: We retrospectively analysed outcomes of 114 patients that presented with 
severe AAV at 5 large centers in the United Kingdom, United States and Denmark between 
2000-2013. All patients received high dose oral corticosteroids, cyclophosphamide and 
plasma exchange. Rituximab treated patients were excluded. The chi square and Mann 
Whitney U tests were used for statistical analysis.
Results: Fifty-two patients received MP (median dose 1.5g over 3 days) in addition 
to standard therapy while 62 did not. Patient characteristics and disease severity were 
comparable between the two groups. There was no difference in survival at 3 months 
(MP: 94.2 vs non MP: 91.9%, p=0.633) or 12 months (84.6 vs 80.6%, p=0.579). Renal 
recovery amongst survivors (63.5 vs 72.6%, p=0.297) and relapse rates at 12 months (11.6 
vs 8.6%, p=0.617) were similar. MP therapy was associated with more infections per patient 
at 3 months (0.7 vs 0.3, p=0.005) and more new onset diabetes (28.6 vs 6.6%, p=0.002).
Conclusions: Within the limitations of this study we found that the addition of MP 
to standard therapy for remission induction in severe AAV led to a significant increase in 
adverse events with no improvement in survival, renal recovery or relapse rates. Our results 
question the currently widespread use of MP in severe AAV and suggest that a randomised 
controlled trial is urgently needed in order to definitively address this issue.
FR-PO409
Serum B Lymphocyte Stimulator (BlyS) Levels as Markers of Disease 
Activity in Anti-Neutrophil Cytoplasm Antibody (ANCA) Associated 
Vasculitis (AAV)  Anisha Tanna, Stephen Paul McAdoo, Frederick W.K. Tam, 
Charles D. Pusey.  Imperial College, London.
Background: B lymphocyte stimulator (BlyS) has been implicated in the pathogenesis 
of AAV. Previous studies have shown elevated levels in active disease, and following anti-
CD20 therapy. Antineutrophil cytoplasm antibodies (ANCA) are not reliable predictors 
of disease activity and relapse and alternative markers are needed in order to tailor 
immunosuppressive therapy. The aim of this study was to determine the clinical significance 
of serum BlyS levels in our patients with AAV.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
449A
J Am Soc Nephrol 26: 2015 Clinical Glomerular and Tubulointerstitial Disorders - II Poster/Friday
Methods: Serum samples were obtained from patients with AAV at our centre, and 
BlyS levels detected using sandwich ELISA. Clinical data were obtained by review of 
patient records.
Results: Samples were collected from 68 patients with AAV and 13 healthy controls. 
Thirty one patients were male, 44 Caucasian and 21 Indoasian. Fifty patients had 
granulomatosis with polyangiitis, 13 patients had microscopic polyangiitis and 5 had 
eosinophilic granulomatosis with polyangiitis. Significantly higher BlyS levels were found 
in patients with active disease than those in remission and healthy controls.
Thirty seven patients who had been treated with Rituximab had significantly higher 
BlyS levels (p<0.0001). Eighteen patients had relapsed at 1 year following recruitment. 
These relapsing patients had significantly higher BlyS levels than those patients who did 
not relapse (p=0.0016).
Conclusions: This study supports the role of BlyS in the pathogenesis of AAV. BlyS 
levels could be used as markers of disease activity and predictors of relapse. With increased 
use of rituximab in AAV, further studies are needed to assess the impact of B cell depletion 
on B cell survival factors. These findings highlight the potential role for BlyS antagonists 
in the maintenance of remission of AAV.
Funding: Government Support - Non-U.S.
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Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody 
Associated Glomerulonephritis  Sophia Lionaki,1 Clio Mavragani,2 George 
Liapis,3 George Somarakis,4 John N. Boletis,1 Alexandros Drosos,4 Athanasios 
Tzioufas,2 Haralampos Moutsopoulos.2  1Nephrology, Laiko Hospital, Athens, 
Greece; 2Pathophysiology, Univ of Athens, Greece; 3Pathology, Laiko Hospital; 
4Rheumatology, Univ of Ioannina.
Background: Prompt, aggressive therapy is vital foranti-neutrophil cytoplasmic 
antibody (ANCA)-associated glomerulonephritis (GN). In this regard, we aimed to identify 
predictors of distinct renal histopathological classes at the time of clinical diagnosis.
Methods: An inception cohort of patients with biopsy proven ANCA-associated GN 
was studied retrospectively. Demographics, clinical, laboratory, serological and radiological 
parameters were analyzed. Patients were classified on the basis of renal histopathology, 
according to the report by Berden et al (JASN 2010) for ANCA-associated GN by a renal 
pathologist into: focal class, crescentic class, mixed class and sclerotic class. A risk score was 
developed for each histopathological class using univariate and logistic regression analyses.
Results: Variables independently associated with focal class included disease duration 
up to diagnosis < 8 weeks, absence of red blood cell (RBC) casts by urine microscopy and 
eGFR > 49ml/min/1.73m2; with crescentic class > 40 erythrocytes/hpf, identification of 
RBC casts in urine, ear nose and throat (ENT) involvement and eGFR < 49ml/min/1.73m2; 
with mixed class age > 54 years, male gender, and absence of ENT involvement. In the 
presence of 2 or 3 risk factors a predictive risk score of each histopathological class was 
calculated: odds ratio (OR), 95% confidence intervals (CI), for focal class (³2 risk factors) 
17.5 (95% CI) [4.9-62.9], 38.0 [6.8-213.7] for crescentic class (³3 risk factors), and 8.3 
[1.0-67.5] (³2 risk factors) for mixed class.
Conclusions: We propose a predictive algorithm of specific histolopathological classes 
of ANCA-associated GN, which might provide a crude estimation of the disease activity 
in the glomeruli at presentation. This tool might assist the clinician in making decisions 
regarding the level of intensity of inductive immunosuppressive therapy at clinical diagnosis.
FR-PO411
Rituximab as a Cyclophosphimide Sparing Agent for Patients with Multi-
Relapsing ANCA-Associated Small Vessel Vasculitis  Sophia Lionaki,1 
George E. Fragoulis,2 Alice Venetsanopoulou,2 John N. Boletis,1 Panagiotis 
Vlachogiannopoulos,2 Haralampos Moutsopoulos,2 Athanasios Tzioufas.2 
1Nephrology, Laiko Hospital, Greece; 2Pathophysiology, Univ of Athens, Greece.
Background: To evaluate the clinical efficacy and outcomes, of patients with multi-
relapsing ANCA-associated Vasculitis (AAV), who received induction therapy with 
rituximab for a new disease relapse.
Methods: We retrospectively studied all patients with biopsy proven AAV, who were 
treated with rituximab upon a new relapse. A control group consisted of patients from 
the era prior to the initiation of rituximab in the treatment of AAV, was selected using the 
following criteria; i/history of relapse, ii/organ involvement at relapse, iii/ treatment with 
the standard regimen. Patients and controls were matched for age, gender, and disease 
duration. Comparisons of disease outcomes along with the frequency and severity of adverse 
events were performed between groups. Rituximab was used with high dose glucocorticoids 
and depending on the organ involvement a short course of cyclophosphamide was added.
Results: Of 147 patients with AAV and a mean total follow up time of 78.2 months, 18 
patients (12.2%) received induction treatment with rituximab for disease relapse. Time to 
1st relapse from the 1st diagnosis of AAV was shorter in the rituximab group and the mean 
number of relapses per patient was significantly higher in this group. The mean BVAS 
score was similar between groups at study entry while 13/18 patients received a 3-month 
course of cyclophosphamide in addition to rituximab.
Characteristic Rituximab group, N=18
Control group, 
N=18 p-value
Number of relapses per patient up to study entry 
(median) (range) 2 (1-4) 1(1-2) 0.009
Subsequent relapse, N(%) 3(11.1) 4(22.2) 1.00
Cyclophosphimide exposure post study entry 
(mean±sd) (grams) 24.39 (±32.5) 3.25(±3.09) 0.02
Follow up time post study entry (months)(range) 37(6-68) 53(8-228) 0.07
Conclusions: Rituximab was shown efficacious in patients with multiple relapsing 
AAV including cases with renal and pulmonary involvement. It allowed us to minimize 
the ultimate exposure to cyclophosphamide in these patients, which is crucial, as they 
accumulate remarkable toxicity in long-term.
FR-PO412
Differences Between Patients with Definite and Suspected ANCA-Associated 
Vasculitis in a Secondary Care Hospital  Eline Houben,1 Willem A. Bax,1 
Walentina A. Slieker,2 Bastiaan Van Dam,1 Fenneke C.P. Frerichs,1 Gideon 
Verhave,1 Erik Lars Penne.1  1Dept of Nephrology, MCA-Gemini Group, Alkmaar, 
Netherlands; 2Laboratory of Clinical Chemistry, Hematology and Immunology, 
MCA-Gemini Group, Alkmaar, Netherlands.
Background: ANCA-associated vasculitis (AAV) is a rare disease with a broad 
spectrum of symptoms. Therefore, diagnosing AAV is often challenging. In an effort to 
provide guidance for clinicians, we aimed to identify differences between ANCA positive 
patients with a definite and suspected diagnosis of AAV.
Methods: In this retrospective study, all patients that tested positive for MPO and/
or PR3 ANCA between 2005 and 2015 in a secondary care hospital in the Netherlands 
were analyzed. Patients were divided into subgroups according to clinical diagnosis and 
the Birmingham Vasculitis Activity Score (BVAS). Possible predictors for AAV, such as 
patient characteristics, clinical symptoms and ANCA titers were identified. Patients were 
also screened for commonly used exclusion criteria in trials.
Results: We included 240 patients with a positive MPO and/or PR3 ANCA, of which 
120 patients were clinically diagnosed with AAV (group 1); all had a BVAS ≥ 3. Of the 
patients without the diagnosis AAV, 50 had a BVAS ³3 (group 2) and 70 had a BVAS < 3 
(group 3). In group 2, 39 patients had an alternative diagnosis, including other rheumatic 
diseases and infection. In a multivariable linear regression model, higher ANCA titers, higher 
BVAS and Ear Nose Throat (ENT) symptoms were predictive for AAV (all p<0.001). Of the 
patients diagnosed with AAV, 21 (18%) would have been excluded from most trials, based 
on a malignancy (n=13) or drug use associated with vasculitis (n=8). Notably, characteristics 
of these patients did not differ significantly from the other AAV patients.
age male% Median PR3 MPO BVAS
renal 
symptoms %
ENT 
symptoms 
%
Group 1 62±14 63 94 (45-179)
38 (18-
101) 6 (4-8) 68 67
Group 2 56±21 50 20 (10-32)*
9 (6-
15)* 4 (4-5)* 56 20*
Group 3 50±21 53 24 (11-51)*
9 (7-
18)* 2 (0-2)* 23 7*
* p≤0.001 as compared to Group 1
Conclusions: MPO and PR3 ANCA can be positive in a variety of diseases that may 
mimic AAV. Higher ANCA titers, BVAS and ENT symptoms were predictive for AAV in 
ANCA positive patients.
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FR-PO413
Rituximab and Low-Dose Cyclophosphamide Therapy for Renal ANCA-
Associated Vasculitis: Long-Term Follow-Up  Nicholas R. Medjeral-Thomas,1,2 
Nicholas D. Mansfield,1 Stephen Paul McAdoo,1,2 Anisha Tanna,1,2 Megan 
Griffith,1,2 Jeremy B. Levy,1 Tom Cairns,1 H. Terence Cook,1,2 Alan D. Salama,1 
Ruth M. Tarzi,2 Charles D. Pusey.1,2  1Imperial College Renal and Transplant 
Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; 
2Imperial College London, London, United Kingdom.
Background: The previously reported study of rituximab (RTX) and low-dose 
cyclophosphamide (CYP) followed by azathioprine maintenance for ANCA-associated 
renal vasculitis (AAV), suggested it was efficacious in inducing remission and has an 
acceptable side-effect profile (N Mansfield et al 2011). We have followed the cohort for 
over seven years and report the regimen’s efficacy and safety profile.
Methods: Long-term outcomes were retrospectively ascertained from all 23 previously 
treated patients.
Results: Mean time since starting the treatment regimen was 83 months; twenty-one 
patients started the regimen more than five years ago. All patients achieved clinical remission 
within six weeks, with depletion of circulating CD19-positive B cells and significant 
reduction in median anti-PR3/MPO ANCA titre. After 84 months follow-up, five renal and 
four non-renal relapses were observed and treated in five patients. Median eGFR improved 
from 28 ml/min (range 11-63) at presentation to 49 ml/min (range13-87) after one year and 
was maintained at 50 ml/min (8-90) at five years (n=21) and 46ml/min (22-76) at seven 
years follow-up (n=9). To date, three infections requiring hospital admission and four 
malignancies have been recorded.
Conclusions: This rituximab-based low-dose cyclophosphamide regimen followed 
by maintenance therapy provides safe and effective long-term treatment at more than five 
years follow-up.
FR-PO414
The Histopathologic and Clinical Determinants of the Change in 
GFR During the 1st year of Treatment in ANCA-Associated Vasculitis 
Pierre-Luc Lavoie,1 Remi Goupil,1 Michelle Goulet,2 Maxime Rheaume,2 
Soumeya Brachemi,3 Stephan Troyanov.1  1Nephrology, Hôpital du Sacré-Coeur, 
Univ de Montréal, Montréal, QC, Canada; 2Internal Medicine, Hôpital du 
Sacré-Coeur, Univ de Montréal, Montréal, QC, Canada; 3Nephrology, CHUM, 
Montréal, QC, Canada.
Background: Identifying the predictors of the change in GFR in ANCA-associated 
vasculitis (AAV) is helpful to avoid prolonged immunosuppression in those where no 
benefits exist and to consider modifying therapy in those who should improve but fail 
to do so.
Methods: We retrospectively reviewed cases of AAV with a renal biopsy in 3 hospitals 
to determine predictors of the change in GFR (deltaGFR) during the 1st year of treatment. We 
considered demographics, pathology findings, treatments and complications incurred. In 
particular, we addressed the histopathologic classification (Berden JASN 2010) proposing 
focal, crescentic, mixed and sclerotic subsets.
Results:    Of 120 patients with AAV, 71 had a renal biopsy and received 
immunosuppression. They presented at an age of 59±13 with 48% female, 49% anti-
MPO+ and a GFR of 32±30 mL/min including 22 patients on dialysis. Induction 
consisted of cyclophosphamide (93%), rituximab (6%), plasma exchange (27%) and 
pulse methylprednisolone (69%) in addition to oral corticosteroids. During the 1st year, 
patients recovered 15±20 mL/min/1.73m2 with 11 no longer requiring dialysis. The deltaGFR 
increased up until 6 months, although it varied greatly individually. Age, hypertension, 
MPO positive serology, the extent of crescentic and sclerotic glomeruli, tubular atrophy 
and the histopathological classification were associated with a lower GFR at diagnosis. 
However, at one year only the histopathologic classification and the number of admissions 
for treatment-related complications predicted a lower deltaGFR. The focal, crescentic, mixed 
and sclerotic subsets experienced a 19±23, 17±15, 11±12 and -1±26 mL/min deltaGFR,, 
respectively (p=0.026, trend test).
Conclusions: The change in GFR during the 1st year of treatment in AAV increased 
15±20 mL/min. It appeared maximal at 6 months into therapy. The histopathologic 
classification helped predict the deltaGFR at 12 months, with a reduced benefit of therapy 
in the sclerotic subset.
FR-PO415
Analysis of Clinical Features in ANCA-Associated Vasculitis: 30 Years 
Single Center Experience – Relationship Between RPGN and Renal 
Prognosis  Soko Kawashima, Shinya Kaname, Yoshinori Komagata, Yoshihiro 
Arimura.  First Dept, Kyorin Univ School of Medicine, Mitaka, Tokyo, Japan.
Background: The clinical features of AAV, with respect to rapidly progressive 
glomerulonephritis (RPGN), have been changing, but were not well examined in Japan, 
where MPO-ANCA-associated vasculitis (MPO-AAV) are dominant in contrast to the 
Western countries. Thus, we retrospectively analyzed the clinical database of the179 patients 
with AAV who were admitted to our hospital for the last 30 years.
Methods: At the onset, all patients fulfilled the Chapel Hill Consensus Conference 
(CHCC) classification criteria for MPA, GPA and EGPA. We divided the AAV patients 
into the 4 groups based on the presence or the absence of RPGN and hemodialysis, and 
compared the clinical features and renal prognosis. Among 179 AAV patients, 166 cases 
(92.7 %) were MPO-ANCA positive and 14 cases (7.8%) were PR3-ANCA positive.
Results: RPGN was observed in 100 (55.9%) of the 179 patients, including 49 cases 
of maintenance hemodialysis group (A), 2 cases of temporary dialysis group (B) and 49 
cases of non-dialysis group (C), in addition to 79 cases without RPGN and dialysis (D). 
Significant differences were observed in BVAS, CRP, eGFR and serum Cr concentration. 
There were no differences for treatment choice, rate of kidney biopsy and frequency of 
relapses among the groups. Comparison among the different periods for every 10 years 
show the tendency of an increase in age of onset and the downward trend of serum Cr 
concentration, rate of RPGN and maintenance hemodialysis, BVAS scores, and frequency 
of relapses and mortality.
Conclusions: These results have clearly shown the changing features of AAV in 
Japan, with an earlier detection and the improvement of renal and patient survival during 
the periods.
FR-PO416
The Effect of Race on 5-Year Survival Outcomes in ANCA-Associated 
Renal Vasculitis  Luxme Nadarajah, Vasantha M. Muthuppalaniappan, Ravindra 
Rajakariar.  Nephrology, Barts and The London NHS Trust, United Kingdom.
Background: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis is a 
multi-systemic autoimmune disease characterized by inflammation of microscopic vessels. 
Renal involvement occurs in 70% of patients, with 1 year mortality rates exceeding 15%. 
With a prevalence of two cases per 100,000 populations there is a significant preponderance 
to Caucasians (C). Little is known about the outcomes in patients from Indo-Asian (IA) 
and Afro-Caribbean (AC) race despite an increasing number of cases seen with the disease.
Methods: We performed a single center, retrospective study, observing 5-year survival 
outcomes and relapse rates between C, IA and AC in ANCA-associated renal vasculitis. 
Electronic case notes over a 10-year period (2004-2014) were used collect data to include 
age at time of diagnosis, Birmingham vasculitis activity score (BVAS) at presentation, race, 
presence of diabetes and renal function. 5-year survival outcomes were analyzed using a 
cox proportional hazard model.
Results: In total 121 patients were included in the study, there were 84 (70%) C’s, 
31 (25%) IA’s and 6 (5%) were of AC background. Median age was 66 years, 56% were 
men, 20% were diabetic and average BVAS score at presentation was 5. One-year relapse 
rates were low with 8 (6%) relapses seen. No significant difference in 5-year survival 
outcome was found between the races. Age at presentation significantly affected survival 
outcomes (p=0.007).
Conclusions: We conclude that survival outcomes for IA and AC are not worse 
compared to those of C origin. Age remains to be a significant predictor in determining 
mortality outcomes. This study provides valuable clinical information in an area that has 
not been well studied.
FR-PO417
Possibility of Increasing Prevalence of Otitis Media with ANCA Associated 
Vasculitis in Japan  Takeshi Nakatsue,1 Yukiko Nozawa,1 Hiroe Sato,1 Yoko 
Wada,1 Takeshi Kuroda,2 Masaaki Nakano,3 Ichiei Narita.1  1Div of Clinical 
Nephrology and Rheumatology, Graduate School of Medical and Dental 
Sciences, Niigata Univ, Niigata, Japan; 2Health Administration Center, Niigata 
Univ, Niigata, Japan; 3Dept of Medical Technology, School of Health Sciences, 
Faculty of Medicine, Niigata Univ, Niigata, Japan.
Background: A new disease concept, otitis media with ANCA associated vasculitis 
(AAV), has been advocated.
Methods: One hundred and fifty seven patients (74 males and 83 females) with AAV (81 
microscopic polyangiitis, 54 granulomatosis with polyangiitis (GPA), and 22 eosinophilic 
GPA) were admitted to Niigata University Hospital from 1989 through 2014. Twenty seven 
patients (17%, 13 males and 14 females) with otitis media were recruited. Their clinical 
features and laboratory data were analyzed.
Results: Fifteen patients were diagnosed as having definite GPA. Five were probable 
GPA. Lung or kidney lesions were not detected in other seven patients (Ears (E) only group). 
The initial symptoms in 22 patients (81 %) were ears’ one, such as impaired hearing (91 
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%), congested feeling (32 %), otalgia (14 %), or tinnitus (14 %). No evidence of vasculitis 
was proved in E only group. MPO- and PR3-ANCA were positive in 19 (70 %) and six 
cases (22 %), respectively. PR3-ANCA was observed only in definite GPA. MPO-ANCA 
titer in definite or probable GPA and in E only group were 103 ± 73.4 U/ml and 41.8 ± 
26.4 U/ml, respectively (p<0.05). From 1989 through 2009, 10 cases of otitis media with 
AAV (OMAAV) (0.48 /year) out of 84 cases of AAV (4.0 /year) were observed, whereas 
17 cases of OMAAV (3.4 /year) out of 73 cases of AAV (14.6 /year) were observed from 
2010 through 2014 (p<0.05). All of E only group was seen in this period. Hypertrophic 
pachymeningitis was seen in seven cases (26 %). Otitis media was involved in bilateral 
ears in 19 cases (70 %). Lung and kidney lesions were in 20 and 11 cases, respectively. 
Necrotizing crescentic glomerulonephritis were observed in six cases. Some renal biopsies 
were avoided because of patients’ impaired hearing.
Conclusions: OMAAV is increasing. Chest X ray, urinary test, and measuring ANCA 
should be considered in refractory otitis media.
FR-PO418
Temporal and Spatial Clustering of Anti-Glomerular Basement Membrane 
Disease  Mark N. Canney,1,2 Paul O’Hara,1 Caitriona M. McEvoy,1 Aileen C. 
Niland,1 Mark Alan Little.2  1Irish Anti-GBM Study Group; 2Trinity Health 
Kidney Centre, Trinity College Dublin.
Background: An environmental trigger has been proposed as an inciting factor in 
anti-glomerular basement membrane (anti-GBM) disease. We aimed to define country-wide 
incidence of anti-GBM disease, investigate clustering of cases in time and space and to 
assess the impact of spatial variability in incidence on outcomes.
Methods: National multicentre observational study of anti-GBM disease cases 
diagnosed in Ireland 1.6.2003-31.5.2014. We ascertained cases by screening immunology 
laboratories for instances of positive anti-GBM antibody and the national renal 
histopathology registry for biopsy-proven cases. We defined the population at risk using 
census figures. A variable-window scan statistic was used to detect temporal clustering. A 
Bayesian autoregressive spatial model was used to provide standardised incidence ratio 
(SIR) estimates for each county. Patient and renal survival were assessed using Kaplan-
Meier and log-rank test.
Results: Seventy-nine cases were included. National incidence was 1.64 (95% CI 0.82-
3.35) pmp/year. A temporal cluster was identified (n=10) in a 3 month period in early 2013; 
6 (60%) were resident in the southeast. Spatial analysis revealed wide regional variation 
in SIR (fig 1A) and a cluster (B,C) in the northwest (n=7, SIR 1.71, 95% CI 1.02-3.06).
However, being in a cluster or distance from diagnosis site to treating center did not 
significantly impact on patient (HR 1.8, 95% CI 0.9-3.8) or renal survival (HR 0.7, 95% 
CI 0.4-1.1).
Conclusions: Country-wide incidence of anti-GBM disease is higher than reported 
by single centre studies. We detected clustering of cases in time and space supporting the 
hypothesis of an environmental trigger. Wide regional variation in incidence highlights 
the need for country-wide epidemiological studies of anti-GBM disease to further our 
understanding of its aetiology.
Funding: Government Support - Non-U.S.
FR-PO419
Venous Thromboembolism in ANCA Vasculitis Is Associated with Elevated 
Microparticle Tissue Factor Activity  Elizabeth J. Brant, Carmen E. Mendoza, 
Yichun Hu, Susan L. Hogan, Ronald J. Falk, Patrick H. Nachman, Vimal K. 
Derebail, Donna O. Bunch.  UNC Kidney Center, Univ of North Carolina at 
Chapel Hill, Chapel Hill, NC.
Background: Venous thromboembolism (VTE) is a severe complication of ANCA 
vasculitis (AAV). Mechanisms of VTE are not known, but tissue factor (TF)-bearing 
microparticles (MPs) from activated or apoptotic cells may play a role. We hypothesized 
that elevated microparticle tissue factor activity (MPTFa) is associated with VTE in AAV.
Methods: Patients without VTE (VTEneg) were enrolled prospectively during active 
disease. Patients with VTE (VTEpos) were included whether active or in remission at the time 
of VTE. Longitudinal platelet-free plasma (PFP) samples from 28 patients and 16 healthy 
controls (HC) were assayed for MPTFa. All patients had ³3 samples spanning ³12 months. 
MPs isolated by centrifugation were incubated with Factor VIIa and Factor X. Absorbance 
was measured after addition of Factor Xa chromogenic substrate. Recombinant relipidated 
human TF was used as a standard. Values were expressed as a percent of MPTFa from a 
positive control (PFP from LPS-stimulated HC blood). Fisher’s exact tests and Wilcoxon 
tests were used to compare categorical and continuous variables, respectively.
Results: Demographics were similar among patients and HC. VTEpos and VTEneg 
patients did not differ in ANCA serotype or titer, BVAS, D-dimer, other laboratory data, 
or organ involvement. VTEpos patients had significantly higher peak MPTFa than VTEneg 
patients (median 10.5 (IQR 9.7, 31.3) vs 2.8 (IQR 0.8, 5.2), p<0.0001) and tended to have 
recurrently elevated levels. MPTFa of VTEneg patients was similar to HC (median 2.0 (IQR 
1.1, 3.3), p=0.4). All VTEpos patients had peak MPTFa above normal (mean + 2SD of HC 
= 6.5) versus 2/20 VTEneg patients (p<0.0001).
Conclusions: Patients with AAV who develop VTE have a notable propensity for 
increased MPTFa at times both near and remote from VTE. Conversely, those without 
VTE rarely exhibit MPTFa significantly higher than healthy controls during their disease 
course. Further study is needed to determine if elevated MPTFa can identify AAV patients 
at high risk for VTE and whether MPTFa contributes to thrombogenesis.
Funding: NIDDK Support, Private Foundation Support
FR-PO420
CD80 and Angiopoietin-Like 4 in Glomerulopathies  Gabriel M. Cara-Fuentes,1 
Alfonso Segarra,2 Eduardo H. Garin.1  1Pediatrics- Div of Nephrology, Univ of 
Florida, Gainesville, FL; 2Nephrology, Vall D’Hebron, Barcelona, Catalonia, 
Spain.
Background: Proteinuria in MCD is thought to be due to an increased CD80 podocyte 
expression. Recently, podocyte angiopoietin-like 4 (Angptl4), has been suggested to induce 
proteinuria in MCD. Objective: To determine the pattern of CD80 and Angptl4 in MCD 
and other glomerulopathies.
Methods: 34, 30 and 32 patients with biopsy-proven MCD, FSGS and MN respectively, 
were included. Urinary and serum CD80 and Angptl4 were measured by Elisa. Differentiated 
human podocytes were incubated for 6 h with 15% of serum from MCD patients in relapse 
or in remission. Podocyte expression of CD80 and Angptl4 were measured by Western-Blot 
analysis. Urinary Angptl4 pI was measured by 2D electrophoresis Statistical analysis:Mann-
Whitney U test, Wilcoxon matched-pairs signed rank test for comparison of paired groups, 
and Spearman correlation.
Results: Urinary CD80 was increased in MCD patients during relapse, but not in 
patients with FSGS or MN, or normal controls. Serum CD80 was lower in patients with 
glomerulopathies during relapse compared to normal controls. Urinary Angptl4 was 
increased in patients with glomerulopathies compared to normal controls, whereas serum 
Angptl4 was higher in normal controls compared to patients with glomerulopathies. 
Both urinary CD80 and Angptl4 correlated with proteinuria in MCD, FSGS and MN. 
Podocytes exposed to sera from MCD patients in relapse showed a significant increase in 
CD80 expression but not Angptl4 when compared to MCD patients in remission. Urinary 
Angptl4 pI was 5.4.
Conclusions: 1) Decreased serum CD80 and Angptl4 in nephrotic syndrome is likely 
due to increased urinary losses. 2) Increased urinary CD80 was only observed in MCD 
patients in relapse while increased urinary Angptl4 was seen in all the glomerulopathies. 
3) Podocyte CD80 but not Angptl4 expression was increased by serum from MCD patients 
in relapse. 4) Urine Angptl4 in MCD has a pI of 5.4, suggesting no role on Glomerular 
Basement Membrane charge. 5) While CD80 seems to play a role in proteinuria in MCD, 
Angptl4 detected in urine in MCD and other glomerulopathies is likely the result of an 
increased glomerular permeability.
FR-PO421
ApoL1 Polymorphism Determines HIV Boarding in Human Podocytes 
Pravin C. Singhal,1 Xiqian Lan,1 Ashwani Malhotra,1 Karl Leon Skorecki,2 
Joanna Mikulak.3  1Dept of Medicine, Hofstra North Shore LIJ Medical School, 
Great Neck, NY; 2Medicine, Rambam Health Care Campus, Haifa, Israel; 
3Clinical and Experimental Immunology, Humanitas Clinical and Research 
Center, Milan, Italy.
Background: Patients of African ancestry with untreated HIV infection, carrying the 
G1 or G2 kidney disease risk variants (Vs) at the APOL1 gene are at a >10-fold greater 
risk for developing HIV-associated nephropathy (HIVAN) compared to those without these 
risk variants. Although podocytopathy in HIVAN has been attributed to the direct effect 
of HIV infection, the mechanistic contribution to kidney injury of the APOL1 allelic state 
remains to be elucidated.
Methods: We evaluated the priming effect of IL-1β on human podocyte (HP) APOL1 
expression. To evaluate the effect of IL-1ß on HIV-1 processing in podocytes, HPs were pre-
stimulated with human recombinant IL-1ß for 6h and then incubated with HIV-1 followed 
by analysis for the HIV-1 strong stop DNA by qPCR analysis. HPs treated under similar 
conditions were evaluated for Dc-sign (a receptor known to contribute for podocyte HIV 
entry) expression. To determine the effect of over expression of APOL1 (G0) and APOL1 
variants (G1/G2) HPs were either transfected with APOL1G0/G1/G2 plasmids, or HPs 
were pre-stimulated with 10 ng/mL of IFN-γ and then incubated with HIV-1 and analyzed 
for HIV-1 strong stop DNA concentration at various time points and also measured for 
their lysosomal bioactivity.
Results: APOL1 expression increased after incubation of podocytes with the HIV. 
In turn, APOL1 expression was further enhanced in response to augmented entry of virus 
consequent to enhanced expression of Dc-sign and IL-1 β treatment, consistent with viral 
load dependency. Podocytes over-expressing the non-risk APOL1 gene (G0), either through 
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pre-treatment with IFN-γ or through transfection with the specific APOL1-expressing 
plasmid displayed diminished HIV accumulation. In contrast, comparably increased 
expression of the APOL1 variants was not only permissive for HIV entry but also facilitated 
HIV accumulation through down regulation of lysosomal bioactivity.
Conclusions: These findings indicate that ApoL1 polymorphism may determine HIV 
boarding in human podocytes.
Funding: NIDDK Support
FR-PO422
Podocyte Depletion in Alport Syndrome Complex  Larysa T. Wickman, 
Jeffrey B. Hodgin, Su Qing Wang, Farsad Afshinnia, David B. Kershaw, Roger 
C. Wiggins.  Univ of Michigan.
Background: Increasing evidence suggests that podocytes may play a role in Alport 
Syndrome Complex (ASC) progression of renal disease. We previously reported that 
podocyte detachment rate measured in urine is increased in ASC, suggesting that podocyte 
depletion could play a role in causing progressive loss of kidney function. This result 
therefore raised the question as to whether progression in ASC could be due to progressive 
podocyte depletion from glomeruli.
Methods: To address this question we measured podocyte nuclear number, density and 
cell area (Glepp1 positive) density in the same 3um thick formalin-fixed paraffin-embedded 
histologic section. Twenty six kidney biopsies from 21 patients were collectively designated 
as ASC including both classic Alport Syndrome (with thin and thick GBM segments and 
lamellated lamina densa [n=20]) and Thin GBM [n=6]. Twenty protocol kidney biopsies 
from deceased kidney transplant donors were used as age-matched controls.
Results: When compared to controls, podocyte number per glomerulus, % podocyte 
depletion, nuclear density and cell area density were all decreased in the ASC cohort 
(P<0.01). The mean podocyte volume (MPV) was correspondingly larger for ASC than 
control (P<0.05) representing podocyte hypertrophy to compensate for reduced podocyte 
number and density. Podocyte depletion was present in ASC biopsies prior to detectable 
histologic abnormalities. No abnormality was detected by light microscopy at <30% 
podocyte depletion, minor pathologic changes (mesangial expansion and adhesions 
to Bowman’s capsule) were present at 30-50% podocyte depletion, and FSGS was 
progressively present above 50% podocyte depletion. Estimated GFR did not change 
measurably until >70% podocyte depletion. Low level proteinuria was an early event at 
about 25% podocyte depletion and increased in proportion to podocyte depletion.
Conclusions: These data support the concept that progressive podocyte depletion 
occurs from an early stage in ASC leading to FSGS-like pathologic changes and eventually 
to End Stage Kidney Disease. Early intervention to reduce podocyte depletion is projected 
to prolong kidney survival in ASC.
FR-PO423
Actinin-4, Synaptopodin, Nephrin, and Neph-1 Expression in Protienuric 
Patients  Ashwani Kumar,1 Ritambhra Nada,1 Charan Singh Rayat,1 Krishan L. 
Gupta.2  1Dept of Histopathology, Post Graduate Inst of Medical and Research, 
Chandigarh, India; 2Dept of Nephrology, Post Graduate Inst of Medical and 
Research, Chandigarh, India.
Background: Podocytes have an important role in glomerular filtration barrier. 
Primary podocytopathies and secondary podocyte injuries in presence of immune deposits 
at different locations results in proteinuria. We compared expression of podocyte structural 
proteins; alpha actinin-4 (αAct-4), synaptopodin (Syn), and slit diaphragm proteins; nephrin 
(Nep), and neph-1 by immunofluorescence (IF) in minimal change disease (MCD), focal 
segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN), and IgA 
nephropathy (IgAN).
Methods: Two hundred cases (n-50 each) along with controls were stained with FITC 
tagged αAct-4, Nep, Syn, and Neph-1 antibodies. Immunofluorescence was graded as mild, 
moderate, and intense. Immunogold staining with αAct-4, and Syn antibodies was done to 
see localization electronmicroscopically (EM).
Results: The αAct-4 showed mild to moderate intensity (40% & 60%) in controls 
and most of the cases in all proteinuric groups. Up-regulation was noted in 52% cases of 
MGN and only 14-19% of other groups. Loss of αAct-4 was seen in about 15-25% in all 
groups except MGN where it was rare. Syn showed mostly mild staining (70%) in controls. 
Marked up-regulation (61%) was seen in the majority of MGN cases whereas moderate 
intensity was seen in other groups (MCD>IgAN>FSGS). Loss of staining was less but 
equally present in all groups. Nep showed mild intensity in controls; however moderate 
to intense staining was seen in MGN (46% & 14%), whereas loss of staining was noted in 
all other groups (FSGS-54%, MCD-43, IgAN-59%). Neph-1 also showed mild staining in 
controls. However, up-regulation was seen in only MGN (47%). Similar to Nep, complete 
loss of Neph-1 was seen in FSGS-74%, MCD-53%, and IgAN-54%. These differences in 
staining of MGN were statistically significant when compared with controls and with other 
groups. EM showed αAct-4 and Syn in podocyte body and processes.
Conclusions: Structural proteins and slit diaphragm proteins are up-regulated in 
MGN whereas the variable degree of loss is commonly seen in FSGS, MCD, and IgAN.
Funding: Government Support - Non-U.S.
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Use of Spot Urine Protein Creatinine Ratio to Predict Proteinuria in 
Nephrotic Syndrome in NEPTUNE  Marie C. Hogan,1 Jonathan P. Troost,2 
Peter J. Nelson,3 Heather N. Reich,4 Sharon G. Adler,5 Daniel C. Cattran,4 Gerald 
B. Appel,6 Debbie S. Gipson,2 Wenjun Ju,2 Matthias Kretzler,2 John C. Lieske.1 
1Mayo; 2UMich; 3UWash; 4UT; 5UCLA; 6ColumbiaU.
Background: Random urine protein creatinine ratio (UPC) is used to estimate 24 
hr urine protein excretion (24P) yet little data are available wrt sensitivity & specificity, 
especially in pts with glomerular proteinuria.
Methods: The Nephrotic Syndrome Study Network (NEPTUNE) studies newly 
diagnosed patients with MCD, FSGS, & MN. Total protein, alb & creat are measured in 
random & 24 hr urine collections at a central biobank at postbiopsy baseline & subsequent 
visits within 2 yrs of dx.
Results: Of 603 participants, 302 have same day spot & 24 hr ur samples with a 
total of 827 samples across all visits eligible for this analysis. Urine protein excretion (g; 
median; 25, 75%) was higher in adults (1.0; 0.3, 2.3) than peds (0.2; 0, 0.7). Spot UPC 
correlated better with 24 hr UPC than 24P in both adults (r=0.79 vs 0.60) & peds (r=0.84 
vs 0.67). Using these data we derived equations to predict 24P from spot UPCs: for adults 
24P == [10]^((0.88*(log_10 [Spot UP:C))] ) & for peds was 24P =[10]^((1.06*(log_10 
[Spot UP:C))]). The efficiency (AUC) of spot UPC to accurately predict 24P values above 
thresholds of 0.5g, 1.0g, 2.0g, 3.0g, 6.0g and 10.g ranged from 0.83-0.97 in adults & peds. 
In subgroup analysis the correlation between log-transformed UPC and log-transformed 
24P was similar in all age ranges & diseases, but stronger in obese vs. normal wt subjects 
(bNormal wt =0.78 (0.69, 0.88); bOverwt=0.85 (0.78, 0.93); bObese=0.93 (0.85, 1.0) p=0.03).
Conclusions: Among MCD, FSGS, & MN pts UPC correlates only moderately with 
24P. 24P is best derived from spot UPC using a non-linear estimating equation. Wt influences 
reliability of spot UPC. Our data also suggest UPC can be used with caution to identify 
those pts with 24P above clinically relevant cut points. As 24P is susceptible to collection 
errors & implications of threshold values may be dependent on patient size, additional 
studies to evaluate spot UPC vs 24P and clinical outcomes are warranted.
Funding: NIDDK Support, Other NIH Support - The Nephrotic Syndrome Study 
Network Consortium (NEPTUNE); U54-DK-083912, is a part of NCATS Rare Disease 
Clinical Research Network (RDCRN), supported through a collaboration between 
the Office of Rare Diseases Research (ORDR), NCATS, and the National  Institute of 
Diabetes, Digestive, and Kidney Diseases. RDCRN is an initiative of ORDR, NCATS. 
Additional funding and/or programmatic support for this project has also been provided by 
the University of Michigan,  NephCure Kidney International and the Halpin Foundation., 
Private Foundation Support
FR-PO425
Rituximab in Steroid Dependent and Calcineurin Inhibitor (CNI) 
Dependent/Intolerant Adult Idiopathic Minimal Change Disease and Focal 
Segmental Glomerulosclerosis  Harbir Singh Kohli, Raja Ramachandran, 
Vivekanand Jha, Krishan L. Gupta.  Nephrology, PGIMER, Chandigarh, UT, 
India.
Background: Steroid dependent (SD) nephrotic syndrome (NS) is managed with 
CNIs but the long-term results are limited by CNI nephrotoxicity and dependence. This 
prospective study was done to evaluate the effect of rituximab in those SD-NS who were 
either CNI dependent or had CNI induced nephrotoxicity.
Methods: This prospective study was undertaken in patients of SD MCD/FSGS 
patients were given initially CNI (tacrolimus). Of these, who were either tacrolimus (TAC) 
dependent (relapse NS on tapering or stopping after 1 year at least) or had TAC induced 
nephrotoxocity (rise in serum creatinine >2 times the baseline) were enrolled for rituximab 
administration during Oct 2013 to Oct 2014. Patient with at least 6 months follow-up were 
analysed. After achieving remission with oral prednisolone the steroids were tapered to stop 
and single dose of Rituximab (375 mg/m2) was administered. CD-19 count was performed 
at Day 2 and at 3 months. Outcome studied was remission complete or partial at the end 
of 6 months. Complete remission (CR): 24-hour urine protein < 500 mg/day with normal 
serum albumin (³3.5 gm/dl). Partial remission (PR): 24 hour urine protein ≥500 mg/day but 
<2 gm/day or <50% of baseline with normal serum albumin (³3.5 gm/dl).
Results: A total of 12 cases, 10 Tac dependent (duration of TAC-35 ±12.6 months) 
and 2 with nephrotoxicity were studied. Basic disease was MCD in 4 (33.3%) and FSGS 
In 8 (66.7%). Mean age was 21.8± 8.4 yrs. Mean proteinuria, serum albumin and serum 
creatinine prior to enrollment in the study were 3.24±1.57 gm/day, 2.52±0.78 gm/dl and 
0.79±0.15 mg/dl respectively. All achieved target CD-19 (<1%) with single infusion and 4 
(25%) cases had risen in their CD 19 at 3 months and were given second dose. At 6 months, 
CR and PR was achieved in 9(75%) and 1(8.3%) respectively. There were 2 non-responders 
(16.6%). Of the 10 responders,3 have completed 1 yr of follw-up and are in remission. 
Adverse event (pneumonia) was noted in 1 patient (8.3%).
Conclusions: Rituximab appears to be a promising agent in the management of adult 
CNI dependent or intolerant NS due to MCD/FSGS with minimal short-term adverse events.
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Treatment and Outcomes in Minimal Change Disease: Experience of a 
Single UK Centre  Anthony Fenton, Stuart W. Smith, Peter Hewins.  Dept 
of Renal Medicine, Univ Hospitals Birmingham NHS Foundation Trust, 
Birmingham, United Kingdom.
Background: Minimal change disease (MCD) accounts for 10-25% of nephrotic 
syndrome in adults. We retrospectively reviewed the treatment and outcomes of MCD 
patients in our centre.
Methods: We identified adults who had undergone renal biopsy between June 1996 
and March 2012 which was reported as being consistent with MCD, and who had at least 
12 months of follow-up. Electronic hospital records were used for data collection.
Results: There were 78 cases, with median follow-up of 72 months. Baseline and 
treatment data are shown in the table (averages are mean, or median where distribution 
is skewed). 27% had a history of nephrotic syndrome in childhood. All but one patient 
(who entered remission spontaneously) were treated with prednisolone, and 97% achieved 
complete remission at a median time of 33 days (6-309), although 12% needed a second-
line agent to do so. Mean number of relapses during the first 24 months was 1.0. 68% 
experienced at least one relapse, and 45% patients required second-line agents at some 
point. Regarding complications: 12% developed thromboembolic disease, 14% had an 
admission-requiring infection, and 41% had at least one episode of AKI. Mean follow-up 
creatinine was 91 mmol/L, but significantly higher in those who had had AKI (104 vs 
85 p=0.04) and those who had received an ACEi (99 vs 78 p=0.01). Of 16 patients who 
underwent subsequent biopsy (all of whom had received a CNI), 8 showed evidence of 
CNI damage, and 5 were consistent with FSGS. Diabetes mellitus developed in 12% cases, 
and 8% patients died during follow-up.
Conclusions: Almost all treated adult MCD patients enter remission, although second-
line agents are frequently required. Despite therapy, complications remain common, 
including AKI which is associated with residual reduced excretory function.
Demographics, clinical features, and therapies
Age (years) 36
Sex (% male) 60
Ethnicity (%)
White
South Asian
Black
Other
72
18
8
3
Baseline clinical findings
Creatinine ȝmol/L
eGFR (ml/min/1.73m2)
Urine ACR (mg/mmol)
Serum albumin (g/L)
Serum cholesterol (mmol/L)
Haematuria (%)
AKI (%)
91
80
645
22
9.6
15
28
Treatment (%)
Prednisolone
CNI
Cyclophosphamide
Levamisole
MMF
Rituximab
ACEi/ARB
99
32
13
9
8
5
63
FR-PO427
Predictors for Relapse in Adult Minimal Change Disease  Hajeong Lee, Dong 
Ki Kim, Kwon Wook Joo, Yon Su Kim, Chun Soo Lim.  Internal Medicine, 
Seoul National Univ Hospital.
Background: Minimal change disease (MCD) is well-known benign primary 
glomerulonephritis in adults because of their distinct rare renal progression to end-stage. 
However, their relapse-associated morbidity has been underestimated. In this study, we 
aimed to explore the predictors of relapse in adult MCD patients.
Methods: We reviewed clinical and pathologic characteristics of adult primary MCD 
patients from Seoul National University Hospital from 1979 to 2013. Patients who were 
presented by nephrotic syndrome and followed up more than 12 months were included. 
Patients suspicious for secondary MCD were excluded. Initial treatment regimens, their 
response, and complication were also reviewed. The number of relapse were classified 
as follows, no relapse, 1-2 relapses (relapse group 1), and ≥ 3 relapses (relapse group 2).
Results: A total of 195 patients were included in the final analysis. Among them, median 
age at the time of diagnosis was 38 (23–53) years and 113 (57.9%) were men. During 
median follow up of 81 (44–153) months, more than 90% of patients reached to remission 
after initial treatment. However, only 64 (32.8%) patients did not experience any relapse. 
Remaining 131 patients, 69 (35.4%) relapsed once or twice and 62 (31.8%) relapsed more 
than three-times. The younger, the more relapse was found. In addition, severity of nephrotic 
syndrome including was proportional to the relapse. Interestingly, proportion of mesangial 
proliferation was higher in no-relapse group compared with relapse group 1 and 2 (P = 
0.033). Initial treatment regimen did not affect relapse, however, patients who received 
shorter treatment duration tended to relapse more. Considering complications, relapse group 
2 showed significantly higher proportion of thromboembolic event than other two groups. 
Multivariate analyses found that younger age, lower serum albumin, mesangial proliferation 
and treatment duration remained as independent risk factor for relapse.
Conclusions: We proved that patients with younger age, severe nephrotic syndrome, 
lower mesangial proliferation and shorter treatment duration were prone to relapses. 
Moreover, relapse is morbid due to higher thromboembolic events in adult MCD patients.
FR-PO428
Rituximab in Relapsing Minimal Change Glomerulonephritis: Clinical 
Outcomes and Financial Analysis  Kevin William Loudon, Clare Morlidge, 
Suresh Mathavakkannan, Ken Farrington, Barbara Thompson, Paul Warwicker. 
Dept of Renal Medicine, Lister Hospital, United Kingdom.
Background: Minimal change disease (MCD) accounts for 10-15% of adult 
nephrotic syndrome, with frequent relapses or steroid-dependency occurring in 25-
30%. Glucocorticoids and calcineurin inhibitors are the mainstay of treatment, but can 
be associated with significant toxicity. Rituximab holds potential to induce long term 
remission in these patients, but in the United Kingdom is currently not funded based on 
perceived excessive cost.
Methods: Nine patients with frequently relapsing MCD (histologically confirmed) 
were given total dose Rituximab 1g – 2.4g divided into two - four doses from 2012 - 2014. 
Time from diagnosis to first Rituximab dose was 140 months (10 – 336). Cost effectiveness 
of Rituximab was assessed based on comparing annual relapse rates; inpatient/outpatient 
attendances and immunosuppressant medication in the two years prior, and one year post 
Rituximab. Data was obtained retrospectively using hospital finance records, NHS standard 
tariff and the British National Formulary (2015) respectively.
Results: In all nine patients Rituximab induced complete remission. All steroid-sparing 
agents were discontinued. Four patients remain on low dose prednisolone (less than 4mg). 
Mean follow-up was 15 months (6 – 30) with only one relapse at 19 months. Annual relapse 
rates fell from 1.83/year (0.5 – 6.0) to 0.12/year (0-0.57). Inpatient days fell from a mean 
of 4.2 days/year (0-39.6) to 1.7 days/year (0-4.5). Outpatient consultations fell from 12.5/
year (5-26.4) to 7.3/year (4.5-25). Mean annualised pre-Rituximab costs were £6172 and 
post Rituximab, £5046, in 6/9 patients with sufficient length of follow up for comparison. 
No major complications were noted following treatment.
Conclusions: In patients with relapsing MCD, Rituximab proved to be cost effective 
and well tolerated. Burden of medication with attendant side effects, as well as inpatient 
and outpatient attendance were significantly reduced. Annualised costings showed a 
modest saving post Rituximab. Further randomised studies are required to confirm and 
extend these findings.
FR-PO429
Long-Term Outcomes of Nephrotic Syndrome, from Childhood into 
Adulthood  Rebecca C. Hjorten, Frederick J. Kaskel, Kimberly J. Reidy. 
Pediatrics, Div of Nephrology, Albert Einstein College of Medicine, Children’s 
Hospital at Montefiore, Bronx, NY.
Background: Steroid Resistant Nephrotic Syndrome (SRNS) is known to have several 
long term sequelae including chronic and End Stage Kidney Disease (CKD and ESKD). 
However there are few studies on the long-term outcomes of steroid sensitive nephrotic 
syndrome. Presented here is a single center, retrospective case series from an urban, 
ethnically diverse population in the Bronx.
Methods: We utilized a medical record data mining tool to identify patients by 
ICD-9 code (1) with a diagnosis of nephrotic syndrome prior to age 18 (2) with a 
documented albumin <3.5 g/dL or random urine protein > 1 g/dL and (3) with at least one 
hospital encounter after age 18. Patients with a history of renal biopsy or who received 
immunosuppressant medication other than steroids were termed complicated nephrotic 
syndrome (CNS). All others were termed simple nephrotic syndrome (SNS). Patients 
with a diagnosis of asthma prior to age 18 with at least one hospital encounter after the 
age of 18 were used as controls. Each cohort was evaluated for diagnosis of hypertension, 
osteoporosis, cataracts, infertility and malignancy. Their last height, weight and creatinine 
were used to evaluate their height and weight percentile, BMI and estimated GFR by the 
MDRD equation.
Results: All three groups – SNS (n=173), CNS (n=169) and control (n=18225) had 
similar age at diagnosis, length of follow-up. Both the SNS and CNS groups had a greater 
proportion of short stature, cataracts, infertility and malignancy (Chi square statistic p < 
0.05) [table 1]. In addition they had a greater percentage of patients with CKD by eGFR 
which is most notable at CKD stages 4 and 5 (Chi square statistic p < 0.05).
Conclusions: Our results show that even patients with uncomplicated nephrotic 
syndrome are at risk for significant outcomes, including chronic kidney disease. Further 
study is needed, however it implies that all patients with a diagnosis of nephrotic syndrome 
will need to be counseled regarding the risks associated with their diagnosis and should 
have long term monitoring for these outcomes, including worsening renal function, 
hypertension and malignancy.
Funding: Other NIH Support - NIH T32 Training Grant
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
454A
J Am Soc Nephrol 26: 2015 Clinical Glomerular and Tubulointerstitial Disorders - II Poster/Friday
FR-PO430
Apolipoprotein CI Levels Are Associated with the Urinary Protein/Urinary 
Creatinine Levels in Pediatric Idiopathic Steroid-Sensitive Nephrotic 
Syndrome  Jun Odaka, Takahiro Kanai, Takane Ito, Jun Aoyagi, Takanori 
Yamagata.  Pediatrics, Jichi Medical Univ, Shimotsuke, Tochigi, Japan.
Background: Various humoral factors have been proposed as causal agents of 
idiopathic steroid-sensitive nephrotic syndrome (ISSNS). In the present study, we analyzed 
serum proteins using mass spectrometry (MS) in a search for proteins that might be related 
to ISSNS pathophysiology.
Methods: We collected serial serum samples from 33 children with ISSNS. The serum 
samples were collected in each phase as follows: Phase A1 [the acute phase prior to steroid 
treatment (STx)], Phase A2 [remission with STx], and Phase A3 [remission without any 
medication]. We also included two control groups comprised of children with normal 
urinalysis (Group B) and children with a nephrotic syndrome other than ISSNS (Group 
C). The urinary protein/urinary creatinine (UP/UCr) ratios were not statistically different 
between Phase A1 and Group C. We used surface-enhanced laser desorption/ionization 
time of flight MS to analyzed samples.
Results: A total of 207 peptide ion peaks were detected in the range of m/z 2000–10000. 
Four peptide ions (m/z 6444, 6626, 8695, and 8915) were significant elevated during Phase 
A1 compared with Phase A2, Phase A3, and Group C. The intensities of m/z 6626, 8695, 
and 8915 were significantly correlated with UP/UCr levels. The m/z 6626 was identified 
as apolipoprotein CI (Apo CI).
Conclusions: Apo CI was detected as a protein associated with the UP/UCr levels in 
pediatric ISSNS. Our findings provide new insight into elucidating the pathophysiology 
of ISSNS.
Funding: Government Support - Non-U.S.
FR-PO431
Ofatumumab in Two Nephrotic Syndrome Children  Marina Vivarelli,1 
Manuela Colucci,1 Alice Bonanni,2 Francesco Emma,1 Gian Marco Ghiggeri.2 
1Nephrology and Dialysis, IRCCS Bambino Gesu’ Pediatric Hospital, Rome, 
Italy; 2Nephrology and Dialysis, Gaslini Pediatric Hospital, Genova, Italy.
Background: Rituximab (RTX), an anti-CD20 monoclonal antibody, is an effective 
treatment in patients with frequently-relapsing or steroid-dependent nephrotic syndrome 
(Ravani, JASN 2015). However, some patients develop adverse reactions. We describe 
the use of a humanized anti-CD20 monoclonal antibody, ofatumumab (OFA), as a viable 
alternative.
Methods: Patient 1 is a 3-yr-old boy who presented at 18 months with NS initially 
resistant to treatment with oral prednisone. He was then treated with 3 iv boluses 
of methylprednisolone followed by cyclosporinA, with remission. Upon steroid 
discontinuation, NS relapsed. Prednisone was restarted and a single dose of RTX was 
planned, but was never completed as at start of infusion a severe allergic reaction (urticaria, 
dyspnea) occurred. Patient 2 is a 14-yr-old boy with SDNS since the age of 2 years 
treated with oral prednisone, cyclosporinA and micophenolate mofetil (MMF), with the 
development of severe obesity. A first infusion of RTX at age 12 was well tolerated and 
allowed prednisone discontinuation for over 2 years. Then a prolonged (>30 days) relapse 
occurred under treatment with oral prednisone, MMF and cyclosporinA. Therefore, a 
second RTX infusion was attempted, but the child presented severe dyspnea and it was 
interrupted. The use of OFA at 1,5 g/1.73 m2, described in steroid-resistant NS children 
(Basu, NEJM 2014), was attempted. In patient 2 OFA was preceded by three boluses of iv 
methylprednisolone to induce remission.
Results: In pt 1, OFA infusion was uneventful. In pt 2, a mild allergic reaction was 
observed and treated. Remission was maintained during the follow-up period (9 months 
for pt 1, 5 months for pt 2), despite the interruption of prednisone treatment in both 
patients, and in pt 1 of cyclosporinA, while in pt 2 of MMF with ongoing cyclosporinA at 
last follow-up. After OFA infusion, CD19+ B cells reappeared at 7 months in pt 1, while 
remained depleted (0%) at 5 months in pt 2.
Conclusions: OFA could be a therapeutic option in managing severe forms of drug-
resistant nephrotic syndrome in patients who have developed intolerance to RTX.
Funding: Private Foundation Support
FR-PO432
Population-Based Identification of Children with Primary Nephrotic 
Syndrome: Kaiser Permanente Nephrotic Syndrome Study  Alan S. Go,1 
Dongjie Fan,1 Thida Tan,1 Janet M. Wojcicki,2 Jingrong Yang,1 Juan Daniel 
Ordonez,1 Glenn Matthew Chertow,3 Sijie Zheng,1 David Law.1  1Kaiser 
Permanente Northern California; 2Univ of California, San Francisco; 3Stanford 
Univ.
Background: Few population-based data exist about children with primary nephrotic 
syndrome (NS) in the US. We identified a cohort of children with primary NS in a large 
integrated healthcare system.
Methods: Kaiser Permanente Northern California cares for >750,000 children. We 
identified members age<18 yrs between 1996-2012 who had nephrotic range proteinuria 
(UACR>3500 mcg/mg, PCR>3.5 mg/mg, 24-hr protein>3500 mg, dipstick>300 mg/dL) 
or diagnosed NS (ICD-9 581.x) in electronic records and lab databases. Nephrologists 
reviewed records for clinical presentation, lab and biopsy results to confirm primary NS.
Results: We identified 179 children with NS due to minimal change disease (72%), 
focal segmental glomerulosclerosis (23%) or membranous nephropathy (5%); incidence was 
1.47 per 100,000 (95% CI:1.27-1.70). Biopsies were available in 40% of cases. Baseline 
features at diagnosis are shown by cause of NS:
Overall 
(N=179)
Minimal 
Change 
Disease 
(N=129)
FSGS 
(N=42)
Membranous 
Nephropathy 
(n=8)
Median (IQR) age, yr 6.9 (3.7-12.9) 5.9 (3.6-9.9)
11.4 (6.3-
16.2) 14.5 (3.3-16.5)
Female, N(%) 77 (43) 58 (45) 16 (38) 3 (38)
Race, N(%)
White 46 (26) 31 (24) 12 (29) 3 (38)
Black 23 (13) 15 (12) 7 (17) 1 (13)
Asian/Pacific Islander 31 (17) 29 (23) 2 (5) 0
Other/unk 79 (44) 44 (41) 21 (49) 4 (49)
Hispanic ethnicity, N(%) 57 (32) 37 (29) 17 (41) 3 (38)
Baseline lab results
Median (IQR) serum 
creatinine, mg/dL 0.4 (0.3-0.7) 0.4 (0.3-0.6) 0.7 (0.4-1.3) 0.4 (0.4-0.9)
Missing, N(%) 67 (37) 46 (36) 20 (48) 1 (13)
Median (IQR) serum 
albumin, mg/dL 1.7 (1.5-2.2) 1.6 (1.5-2.1) 2.0 (1.6-2.7) 2.1 (1.7-3.8)
Missing, N(%) 86 (48) 56 (43) 26 (62) 4 (50)
Total cholesterol, mg/dL, 
N(%)
<=240 10 (5) 8 (6) 2 (5) 0
>240 56 (31) 43 (33) 10 (24) 3 (38)
Missing 113 (63) 78 (61) 30 (71) 5 (62)
Conclusions: Leveraging electronic health records and linked data sources, we 
identified a population-based cohort of children with primary NS that will provide a 
unique platform for describing the natural history of NS and identifying predictors of 
adverse outcomes.
Funding: Private Foundation Support
FR-PO433
Abatacept Treatment and B7-1 Immunostaining in Patients with 
Primary and Post-Transplant FSGS  Rutger J. Maas,1 Brigith Willemsen,2 
Henry Dijkman,2 Catharina M. Haring,3 Jeroen Deegens,1 Jack F. Wetzels.1 
1Nephrology, Radboud Univ Medical Center, Nijmegen, Netherlands; 2Pathology, 
Radboud Univ Medical Center, Nijmegen, Netherlands; 3Nephrology, Deventer 
Hospital, Deventer, Netherlands.
Background: Podocyte B7-1 expression has been implicated in the pathogenesis of 
idiopathic nephrotic syndrome for many years. Recently, podocyte B7-1 was described as 
a potential therapeutic target by demonstrating efficacy of B7-1 blocking agent abatacept 
in five patients with primary and post-transplant FSGS (Yu et al. New Engl J Med 2013). 
The authors speculated that patients who will respond to abatacept can be identified by 
positive B7-1 immunostaining on kidney biopsy. Here, we report our experience with 
abatacept and B7-1 staining in patients with FSGS.
Methods: Patients with no or partial proteinuria remission after plasmapheresis for 
treatment of FSGS received abatacept (2 or 3 doses of 10 mg/kg). After several trials of 
unsuccessful immunofluorescence staining, we performed B7-1 immunohistochemistry 
on paraffin embedded tissue with a primary antibody mouse anti CD80 (R&D systems).
Results: Three patients with post-transplant FSGS, and one patient with FSGS in the 
native kidney (Table, Patient 4) were treated with abatacept. All transplant patients had 
developed nephrotic proteinuria immediately after transplantation. Patient 1 had been treated 
with plasmapheresis for many years, and was previously unresponsive to B7-1 blocking 
agent belatacept. None of the patients had proteinuria remissions after abatacept, nor did 
we observe positive podocyte B7-1 immunostaining.
Conclusions: In our hands B7-1 staining was absent in patients with FSGS. Our data 
caution against too much optimism regarding the efficacy of abatacept. 
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Clinical Characteristics of FSGS patients treated with abatacept
Variable Patient 1 Patient 2 Patient 3 Patient 4 
Gender Female Male Male Male
Age 39 27 20 19
Previous treatment for FSGS PP PP PP
Steroid; 
MMF; 
rituximab; PP
Time between proteinuria onset 
and abatacept 4 years 17 days 17 days 4 years
Urinary PCR before / after 
treatment (g/10 mmol) 16 / 15 7.2 / anuric 20.1 / 8.7 4.5 / 5.7
Screat before / after treatment 
(ȝmol/L) 115 / 100 dialysis 218 / 204 81 / 86
PP = plasmapheresis 
Funding: Private Foundation Support
FR-PO434
Steroid Resistant Nephrotic Syndrome: A Prospective, Open Label Study 
of the Safety and Efficacy of Combination Tacrolimus and ACTHar Gel 
Therapy  James A. Tumlin,1 Claude Mabry Galphin,1 Brad H. Rovin.2  1Univ 
of Tennessee College of Medicine, Chattanooga, TN; 2The Ohio State Univ, 
Columbus, OH.
Background: Steroid resistant nephrotic syndrome (SRNS) in adults is associated 
with increased risk for progression to ESRD. Tacrolimus is a calcineurin inhibitor (CNI) 
that is an alternative to steroids, but is associated with progressive fibrosis and loss of 
GFR. ACTHar gel has shown benefit in the treatment of SRNS. To investigate additive 
effects, we followed 23 SRNS patients receiving combination therapy with Tacrolimus 
and ACTHar Gel.
Methods: 23 patients with SRNS (IMGN 8, 11 FSGS and 4 other) receiving ACE/
ARB and 8 weeks of oral steroids prior to combination therapy of ACTH and Tacrolimus. 
Eleven patients received 2 or more drug therapies. Of the 23, 17 (71%) initially received 
ACTH followed by Tacrolimus. Duration of ACTH/TAC therapy averaged 6.2 months 
[range 1-12 months]. Complete or partial responses were defined as UP/Cr ratio of < 0.30 
or > 50% reduction in pre-ACTH/TAC proteinuria, respectively.
Results: 
Table-1 Number Age Baseline Peak ACTH ACTH+ TAC
Responder 17 Yrs 6.2+1.4 11.0+1.4 3.3+1.0 1.4+0.4
IMN 6 58+3 6.6+2.3 13.1+2.7 4.9+1.2 1.2+0.5
FSGS 9 67+5 4.3+2.3 10.4+1.4 2.6+0.5 1.7+0.9
Other 2 58+1 9.9+5.6 12.4+3.0 0.3+0.2 0.63+0.7
Non-
Responder 6 52+5 5.7+1.6 11.6+1.5 7.5+1.5 7.8+1.5
IMN 3 46+7 6.3+2.2 11.6+2.9 7.6+2.5 9.2+4.3
FSGS 3 52+8 6.0+2.3 11.8+0.5 7.4+1.6 7.3+1.6
Of the 23 patients, 6 (26%) achieved a complete response; a partial responses were 
observed in 11 (48%) for an overall response of 74%. Proteinuria levels (expressed as a 
UP/Cr ratio) before and after treatment are listed in the Table. There was no difference 
in the rate or time to complete or partial remission between IMGN and FSGS (IMGN: 
75%;7.0+1.5mths; FSGS: 82%;6.1+0.8 mths).
Conclusions: Combination therapy with ACTHar Gel and Tacrolimus achieved a 75% 
and 82% complete or partial response rate in patients with steroid resistant IMGN and 
FSGS patients respectively. The mean time to partial response was 6.2 months, but could 
range up 12 months. Combination therapy ACTH and Calcineurin inhibitors may offer an 
effective alternative therapy to SRNS.
Funding: Pharmaceutical Company Support - Mallinckrodt Pharmaceuticals; 
Dialysis Corporation Inc., Genzyme Pharmaceuticals, Private Foundation Support
FR-PO435
Treatment of Nephrotic Syndrome Secondary to Primary FSGS – 
Prednisolone or Tacrolimus? A Two Centre Experience  Hannah R. Wilson,1 
Thomas M. Connor,2 Tom Cairns,2 Mona Saleh Wahba,1 Marie B. Condon,1 
Megan Griffith.2  1St. Helier Hospital, London, United Kingdom; 2Hammersmith 
Hospital, London, United Kingdom.
Background: Focal segmental glomerulosclerosis (FSGS) is a significant cause 
of end-stage renal failure. Patients with nephrotic syndrome have a worse prognosis. 
Current guidelines advise prolonged prednisolone (pred) at 1mg/kg. Tacrolimus (Tac) is 
an alternative for patients, but long-term therapy is often necessary, and there are concerns 
about toxicity.
Methods: Retrospective review of all patients with nephrotic syndrome secondary 
to primary FSGS treated with a minimum of 12 mths follow-up at 2 centres. All patients 
received standard therapy with max tolerated ACEi +/- ARB. Complete remission (CR) 
was defined as normal serum albumin with PCR <50; partial remission (PR) as proteinuria 
≤50% baseline. Results described as Median (Range). p value <0.05 significant.
Results: 
Demographics Pred n=15 Tac n=23 p value
Age 50 (19-75) 45 (19-78) ns
Gender 8M, 7F 12M, 11F ns
Ethnicity
Caucasian
Afro-carib
Asian
12
1
2
9
5
9
ns
Follow up (mths) 43 (12-257) 45 (12-86)
Baseline parameters
Creatinine umol/L
%creat>125
UPCR
Albumin
167 (61-480)
67%
906 (478-1910)
23 (10-30)
101 (52-312)
26%
1035 (602-3626)
16 (9-27)
<0.05
ns
<0.001
Results Pred Tac p value
Duration (mths) 13 (2-56) 32 (5-74)
Dose 60mg (40-60) 3 mths16mg (2-60) 6 mths
6.4mg/L 3 mths
6.3mg/L 12 mths
2nd Agent
9 (6 Non-response; 
1 Relapse; 2 Pred 
sparing)
2 (Relapse)
Response to primary agent (pts)
Remission
PR
CR
60% (9)
60% (9)
33% (5)
91% (21)
91% (21)
87% (20)
<0.05
<0.05
<0.005
Time to remission (wks) PR 8 (3-40)CR 10 (5-44)
PR 9 (2-52)
CR 25 (3-117)
ns
ns
Relapse 22% (2) 25% (5) ns
ESRF 26% at 1,13,19,69 mths 0 <0.05
Creat latest f/u 92 (61-390) 92 (54-234) ns
Adverse events
Deaths
Diabetes/Insulin
Severe Infection
1 (lung ca)
3
4
1 (colon ca)
0
1
<0.01
Conclusions: In the Tac cohort a higher remission rate was demonstrated and a 
suggestion of fewer adverse events although numbers are small. However the baseline 
parameters show the GFR was significantly lower in the prednisolone group. Patients 
treated with Tac had a longer duration of treatment but appeared to have a better adverse 
event profile overall. A randomised controlled trial is required to investigate this further.
FR-PO436
Differences in Initial End Stage Renal Disease (ESRD) Treatment Modality 
Across Glomerulonephritis Subtypes  Michelle M. O’Shaughnessy,1 Maria 
E. Montez-Rath,1 Richard A. Lafayette,1 Wolfgang C. Winkelmayer.2  1Div of 
Nephrology, Stanford Univ School of Medicine; 2Section of Nephrology, Baylor 
College of Medicine.
Background: Kidney transplantation (Tx) is the treatment of choice for end-stage renal 
disease (ESRD). Hemodialysis (HD) and peritoneal dialysis (PD) outcomes are largely 
equivalent. Whether access to these modalities is equal across glomerulonephritis (GN) 
subtypes has not been established.
Methods: We identified all patients in the US Renal Data System 18-75 years who 
initiated ESRD therapy with Tx, HD, or PD (1996-2011) and had ESRD attributed to 
6 GN subtypes [focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN), 
membranous nephropathy (MN), membranoproliferative GN (MPGN), lupus nephritis 
(LN), vasculitis]. Odds ratios (ORs) for PD vs HD and for Tx vs HD were computed using 
multinomial logistic regression (IgAN as reference group), with multivariate adjustment 
for demographic, socioeconomic, and comorbidity differences.
Results: Among 75,278 patients studied, demographic, socioeconomic, and 
comorbidity characteristics differed considerably across GN subtypes. In unadjusted 
analyses, patients with FSGS, MN, MPGN, LN, and vasculitis were significantly less 
likely to receive Tx or PD as a first ESRD treatment modality than patients with IgAN: 
OR for Tx 0.52, 0.35, 0.48, 0.23, and 0.13, respectively; OR for PD 0.77, 0.66, 0.59, 0.48, 
and 0.30, respectively (all p<0.0001). After adjustment, differences were attenuated but 
patients with secondary GN subtypes (LN, vasculitis) remained significantly less likely to 
receive Tx or PD as compared to patients with IgAN (figure). 
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Conclusions: Patients with ESRD attributed to secondary GN subtypes (LN, vasculitis) 
are significantly less likely to receive Tx or PD as an initial ESRD treatment than patients 
with primary GN subtypes. The clinical appropriateness and sequelae of this apparent 
inequity must be determined.
Funding: Private Foundation Support
FR-PO437
Non Collapsing Focal and Segmental Glomerulosclerosis in Patients with 
HIV  Julien Hogan,1,2 Claire Cartery,2 Emmanuelle M. Plaisier.2  1Pediatric 
Nephrology, Robert Debré Hospital, Paris, France; 2Nephrology and Dialysis, 
Tenon Hospital, Paris, France.
Background: With the improvement of the treatments against HIV, non collapsing focal 
and segmental glomerulosclerosis (FSGS) has become more frequent than HIV associated 
nephropathy (HIVAN). However, the physiopathology of non-collapsing FSGS among 
HIV patients remains poorly understood. We thus aimed to compare patients with HIV and 
non collapsing FSGS with patients with HIVAN and with non HIV patients with FSGS.
Methods: HIV patients with a kidney biopsy in our center between 2000 and 2012 
(24 non collapsing FSGS and 13 HIVAN) and two control groups (10 primary and 12 
secondary FSGS) were included. Clinical and biological data were collected; viral load in 
serum and urine was assessed by PCR and histological exam was performed together with 
immunohistochemical staining for PCNA to study epithelial cells proliferation.
Results: Clinical and biological features of HIV patients with non-collapsing FSGS 
were close to those of controls with secondary FSGS. Among HIV patients, the prevalence 
of cardiovascular risk factors was greater in those with non collapsing FSGS than in 
those with HIVAN (79% vs. 38%, p=0.01) but was comparable to the one in controls 
with secondary FSGS (100% vs. 79%, NS). HIV patients with non collapsing FSGS and 
controls with secondary FSGS had more frequently arteriolosclerosis on the biopsy than 
patients with HIVAN (75% and 82% vs 36%, p<0.01). Visceral epithelial cells expression 
of PCNA showed that, despite a stronger staining in collapsing lesions, it can be found 
among all patients groups and in any FSGS lesion type. The majority of HIV patients with 
non collapsing FSGS had undetectable viral load in serum and urine.
Conclusions: Major clinical, biological and histological differences between HIV 
patients with non collapsing FSGS and HIVAN support the hypothesis of two distinct 
physiopathological entities. They are striking similitudes between non collapsing FSGS 
in HIV patients and secondary FSGS found in patients with polyvascular disease. Non 
collapsing FSGS in HIV patients might be due to nephronic reduction secondary to 
vascular lesions in an ageing population with major metabolic abnormalities associated 
with antiviral drugs.
FR-PO438
Diabetic Glomerulosclerosis or Idiopathic Nodular Glomerulosclerosis 
– Role for Insulin Resistance  Manish Anand, Mehri Mollaee, Ravi 
Sunderkrishnan, Andres Rodrigo Caero, Mehrdad Hamrahian.  Nephrology, 
Thomas Jefferson Univ Hospital.
Background: Diabetic nephropathy (DN) is characterized histologically by nodular 
mesangial sclerosis, a thickened glomerular basement membrane, and hyalinized 
arterioles. Differential diagnoses by light microscopy (LM) include membranoproliferative 
glomerulonephritis, amyloidosis, monoclonal immunoglobulin deposition disease, and 
fibrillary or immunotactoid glomerulopathy. These can readily be excluded by special 
stains, immunofluorescence (IF) and electron microscopy (EM). Idiopathic nodular 
glomerulosclerosis (ING) is the term used to denote classic DN confirmed by LM, IF, and 
EM, but in the absence of diabetes mellitus (DM). Case reports suggest insulin resistance 
(IR) as a possible cause.
Methods: Data was collected retrospectively on 21 cases of diabetic glomerulosclerosis 
or ING biopsied due to proteinuria (1+ on urinalysis to 12.3 grams/day), with or without 
renal insufficiency (creatinine 0.6-4.4mg/dL).
Results: 13 patients were male with majority of patients being African American 
(10) and non-Hispanic white (7). 1 patient was post-renal transplant and another post-
liver transplant. None of these patients were diagnosed with DM, although some had 
intermittently elevated blood glucose and borderline HbA1c. All patients had hypertension, 
but only 5 were active tobacco users and 8 were former smokers. BMI range was 21-43kg/
m2. Hemoglobin A1c range was 4.6-6.1% in 10 patients and 6 patients denied DM by 
telephone survey. The remaining 5 patients had no history of DM per records with few 
elevated random plasma glucose levels noticed on steroids. None of them fulfilled current 
diagnostic criteria for DM. Metabolic syndrome (MS) defined by Adult Panel III criteria 
was evident in 11 patients.
Conclusions: The pathogenesis of ING remains unclear. It involves the interplay of 
hypertension, obesity, and heavy smoking. We feel that IR is critically important, whether 
evident as subtle, prediabetic elevations of blood glucose, MS, or elevated HOMA-IR score 
being the only manifestation. Insulin sensitivity assessed by HOMA-IR score is possibly 
an important predictive factor in pathophysiology of ING and needs to be tested routinely.
FR-PO439
Association of Serum Albumin Level and Venous Thromboembolic Events 
in Seven-Thousand Patients with Nephrotic Syndrome  Geeta G. Gyamlani,1 
Miklos Zsolt Molnar,2 Jun Ling Lu,2 Keiichi Sumida,2 Kamyar Kalantar-Zadeh,3 
Csaba P. Kovesdy.1,2  1VA Medical Center, Memphis, TN; 2Univ of Tennessee 
Health Science Center, Memphis, TN; 3Univ of California, Irvine, CA.
Background: Prior studies have shown that low serum albumin in patients with 
nephrotic syndrome (NS) is associated with an increased risk of venous thromboembolic 
(VTE) events. This is based on small studies with a low number of thromboembolic events 
and short term follow-up.
Methods: From a nationally representative cohort of over 3 million US veterans with 
baseline estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2,we identified 7037 
patients with NS based on ICD9 codes. Association between serum albumin and risk of 
incident VTE events (based on ICD9 codes) was assessed using Cox regression analysis with 
adjustments for age, gender, race, comorbidities, eGFR, BMI and anticoagulant treatment.
Results: Mean age was 57±11 years, and patients were 96% male, 32% African-
American and 60% diabetic. There were a total of 158 VTE events over a median follow-up 
was 8.1 years; 16 events (4.1%, event rate (ER): 8.5/1000 patient-years(PY)) in patients 
with albumin <2.5 g/dl, 18 events (3.4%, ER: 5.7/1000 PY) in patients with albumin 2.5-
2.99 g/dl, 89 events (2.5%, ER: 3.4/1000 PY) in patients with albumin 3-3.99 g/dl and 35 
events (1.4%, ER: 1.9/1000 PY) in patients with albumin ≥4 g/dl. Compared to patients with 
albumin ≥4 g/dl, those with albumin levels of 3-3.99 g/dl (adjusted HR:1.51; 95%CI:1.01-
2.26), 2.5-2.99 g/dl (2.24, 1.24-4.05) and < 2.5 g/dl (2.79, 1.45-5.37) experienced a linearly 
higher risk of VTE events.
Conclusions: Lower serum albumin is a strong incremental risk factor for VTE events 
in NS. The risk increases proportionately with declining albumin levels. Our finding may 
have important clinical implications regarding initiation and duration of prophylactic 
anticoagulation.
Funding: NIDDK Support, Veterans Administration Support
FR-PO440
Hypercoagulopathy Is Directly Correlated with Disease Severity in 
Nephrotic Syndrome  Amanda P. Waller,1 Samir Parikh,2 Brad H. Rovin,2 
William E. Smoyer,1 Marvin T. Nieman,3 Matthias Kretzler,4 Bryce A. Kerlin.1 
1Clin/Trans Research, Nationwide Children’s, Columbus, OH; 2Nephrology, 
Ohio State Univ, Columbus, OH; 3Pharmacology, Case Western Reserve Univ, 
Cleveland, OH; 4Nephrology, Univ of Michigan, Ann Arbor, MI.
Background: Nephrotic syndrome (NS), a leading cause of end stage kidney disease, 
is characterized by massive proteinuria, hypoalbuminemia, and an increased risk for venous 
thromboembolism (VTE). We recently reported that hypercoagulopathy is proportional to 
the severity of both proteinuria and hypoalbuminemia in two animal models of NS. This 
study was designed to determine if this relationship translates to human NS.
Methods: Aliquots of plasma anticoagulated with 0.32% (final concentration) sodium 
citrate were obtained from the NEPTUNE biorepository (n=147 patients), along with 
corresponding clinical lab data (e.g. urine protein:creatinine (uP:C), serum albumin (sAlb)). 
Samples collected from a local patient cohort (n=21) were used to validate biorepository 
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specimen integrity. Endogenous thrombin potential (ETP) was determined using the 
Technothrombin TGA kit and RC Low reagent after 2:1 dilution with buffer. Plasma 
antithrombin (pAT) activity was measured by the amidolytic method.
Results: As expected, NEPTUNE patients exhibited a wide range of proteinuria 
values (median (range) uP:C: 1.85 mg/mg (0-17.6)). Hypoalbuminemia and proteinuria 
severity in these patients were proportional to ETP (R2=0.252 & 0.128, respectively, 
P<0.001). These correlations were stronger in the subset of patients with uP:C>2 
(R2=0.331 & 0.157, respectively, P<0.001). Plasma AT activity was also significantly 
correlated to hypoalbuminemia and proteinuria severity (R2=0.125 & 0.031, P<0.001 & 
0.03, respectively). There was no correlation between AT activity and ETP. Results were 
similar in the validation cohort.
Conclusions: Both hypoalbuminemia and proteinuria severity in humans with NS is 
significantly, albeit weakly, correlated to ETP (an established marker of thrombotic risk). 
Adjusting these data for confounding clinical variables (e.g. smoking status, BMI, etc.) 
may aid in the modeling and development of evidence-based cut-offs to guide indications 
for prophylactic anticoagulation.
Funding: NIDDK Support
FR-PO441
Successful Social Media Recruitment into the NephCure Kidney Network, 
a Rare Disease Patient Registry  Laura H. Mariani,1 Joanna Dauber,2 Chelsey 
Fix,2 Alyssa Fisher,2 Jane Shen,2 Lalita Subramanian,1 Marilyn Hailperin,2 
Elizabeth L. Cope.1  1Arbor Research Collaborative for Health; 2NephCure 
Kidney International.
Background: Participation in clinical research for primary Nephrotic Syndrome 
(NS) has been limited by the rarity of the disease. There is growing interest in leveraging 
social media to expand demographic and geographic reach for recruitment. Because of the 
isolating nature of rare diseases, patients turn to social media for support, creating online 
communities that, if accessible, could potentially serve as a resource for recruitment.
Methods: The NephCure Kidney Network (NKN) is a web-based patient opt-in registry 
for primary NS. Participants provide data, including kidney disease history, demographics, 
and research participation preferences. Recruitment efforts launched in March 2014 relied on 
email campaigns to contacts of the patient advocacy group, NephCure Kidney International 
(NKI), but then expanded in September 2014 to include social media. Weekly posts were 
made to NKI’s Facebook page, with analysis of performance based on impressions (# of 
people reached) and engagements (likes, clicks, shares, comments). Relationships with 
other closed Facebook kidney disease groups were established and posts made to their sites.
Results: 45,151 impressions and 2,927 engagements were made from 9/2014-6/2015. 
Relationships were made with 54 kidney disease groups (>15,000 members) from which to 
find NS patients. Engagements were highest on posts focusing on patient-centeredness in 
research and lifestyle. 414 patients (51% female, 47% <18 yo, 22% racial/ethnic minority) 
from 27 countries enrolled between 3/2014 and 6/2015, with 27% of enrollees having no 
previous engagement with NKI. 94% reported a willingness to be contacted about research, 
including 77% willing to donate a biospecimen. However, only 16% currently or previously 
participated in a clinical trial. 78% were willing to travel >50mi to participate in a study 
and 34% were willing to travel >500mi.
Conclusions: A recruitment strategy which includes social media is an efficient, cost-
effective opportunity to engage rare disease patients across a wide geography, including 
those who have not previously participated in research.
Funding: Other U.S. Government Support, Private Foundation Support
FR-PO442
The Expression of Podocyte Protein PREX2 in Glomerular Diseases 
Anna Levin,1 Julia Wijkstrom,1 Jenny Hulkko,1 Jenny C. Nystrom,2 Kerstin 
Ebefors,3 Annette Bruchfeld,1 Jaakko Patrakka,4 Kjell Hultenby,5 Annika 
Wernerson.1  1CLINTEC, Karolinska Inst (KI), Stockholm, Sweden; 2Dept of 
Physiology, Sahlgrenska Academy, Gothenburg, Sweden; 3Dept of Molecular 
and Clinical Medicine, Sahlgrenska Academy, Gothenburg, Sweden; 4Dept of 
Medicine, KI, Stockholm, Sweden; 5LabMed, KI, Stockholm, Sweden.
Background: Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 
2 (PREX2)is a 183 kDa protein that functions as a RAC guanine nucleotide exchange 
factor (GEF), activating Rac proteins. It has been discovered in several tissues, e.g. brain, 
lung, liver and kidney. The specific function of PREX2 in the kidney is unknown. The aim 
of the present study was to investigate the localization of PREX2 in the kidney and the 
possible role in renal disease.
Methods: RT-PCR, Western Blot and immunohistochemistry (IHC) was used to identify 
the localization of PREX2 in renal tissue. The mRNA expression in diseased kidney was 
analyzed by microarrays on isolated glomeruli from patients with IgA Nephropathy (IgAN), 
Membranous Nephropathy (MN) and normal tissue. Immuno electron microscopy (iEM) 
was used to semiquantify PREX2 in renal biopsies from patients with IgAN (n=6), Minimal 
Change Nephropathy (MCN, n=5) and control tissue from healthy kidney donors (n=5). 
The morphology was correlated to proteinuria at time of biopsy.
Results: RT-PCR and Western Blot showed the presence of PREX2 in glomerulus. 
IHC and iEM revealed that PREX2 was localized to podocyte foot processes. In disease 
samples, mRNA levels were not changed in IgAN and MN. Semi-quantitative iEM showed 
a significantly lower expression of PREX2 in IgAN and MCN compared to controls. A 
tendency towards a negative association between PREX2 and proteinuria was seen, although 
this was not significant.
Conclusions: We found that PREX2 is a new podocyte-associated protein. Although 
no difference in mRNA levels were found, the expression of PREX2 was significantly 
lower in IgAN and MCN compared to controls. The function of PREX2 in the glomerular 
filtration barrier will now be further investigated in an extended patient cohort and in 
genetically modified animals.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO443
Urinary and Serum Soluble Urokinase Receptor Levels Predicts the 
Therapeutic Response of Nephrotic Syndrome  Keiji Fujimoto, Yuki 
Matsui, Norifumi Hayashi, Junko Imura, Hiroki Adachi, Hideki Yamaya, 
Hitoshi Yokoyama.  Div of Nephrology, Kanazawa Medical Univ, Uchinada, 
Ishikawa, Japan.
Background: It is necessary to develop noninvasive biomarkers to predict the treatment 
response for nephrotic syndrome (NS), and to differentiate their histological types in the 
initial phase.
Methods: The subjects were 32 patients with primary NS [8 with focal segmental 
glomerulosclerosis (FSGS), 12 with minimal change nephrotic syndrome (MCNS), 10 with 
membranous nephropathy (MN), and 2 with membranous proliferative glomerulonephritis]. 
Using ROC analysis, we examined whether or not it is possible to differentiate refractory 
NS from non-refractory NS, and MCNS from FSGS based on the pretreatment values of 
clinical markers [urinary protein (UP), serum/urinary soluble urokinase receptor (s-/u-
suPAR), urinary L-FABP, and eGFR], and values and changes (∆) after 2 months (2M). 
We also examined the renal expression of activated b3 integrin (AP-5) by immuno-staining 
in primary NS and normal tissues.
Results: The following parameters were useful for differentiating refractory NS from 
non-refractory NS: 2MUP (AUC=0.968, p=0.001), 2Ms-suPAR (AUC=0.913, p=0.002), 
D2Mu-suPAR (AUC=0.906, p=0.007), D2Ms-suPAR (AUC=0.881, p=0.005), and D2MUP 
(AUC=0.833, p=0.014).  On the other hand, D2Ms-suPAR (AUC=0.905, p=0.007) and 
D2Mu-suPAR (AUC=0.816, p=0.048) were useful for differentiating MCNS from FSGS. 
In addition, u-suPAR before treatment was positively correlated with UP (ȡ=0.501, p=0.003) 
and urinary L-FABP (ȡ=0.427, p=0.017).  The expression of activated b3 integrin was 
primarily strong in the proximal tubular epithelial cells in FSGS or MN, but, weak in 
MCNS and normal tissues.  Otherwise, there was no expression of activated b3 integrin 
on podocytes in both normal and diseased tissues.
Conclusions: It may be possible to evaluate the treatment response of NS and to 
differentiate MCNS from FSGS based on changes in s/u-suPAR within 2 months after the 
start of treatment.  As a mechanism involved in proteinuria in NS patients, u-suPAR may 
inhibit protein reabsorption in the proximal tubules through the activation of b3 integrin.
FR-PO444
Turkish Atypical Hemolytic Uremic Syndrome Registry: Initial Pediatric 
Results  Nesrin Besbas,1 Oguz Soylemezoglu,2 Bora Gülhan,1 Z.birsin Özçakar,3 
Emine Korkmaz,4 Fatih Ozaltin.1,4  1Pediatric Nephrology, Faculty of Medicine 
Hacettepe Univ, Ankara, Turkey; 2Pediatric Nephrology, Faculty of Medicine 
Gazi Univ, Ankara, Turkey; 3Pediatric Nephrology, Ankara Univ Faculty of 
Medicine, Ankara, Turkey; 4Nephrogenetics Laboratory Dept of Pediatric 
Nephrology, Hacettepe Univ, Ankara, Turkey.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, genetic, life-
threatening disease of chronic complement activation leading to systemic thrombotic 
microangiopathy and end-organ damage. The national aHUS registry was initiated in 
November 2013 and collects information on the progression and treatment of disease.
Methods: A clinical diagnosis of aHUS is required for inclusion. Demographic, 
medical histories, treatments, efficacy and safety outcomes data are collected initially 
and every 3 months.
Results: By May 15, 2015, 122 pediatric patients (55.8% female and 44.2 % male) were 
enrolled from 22 centers covering all the country. Mean age at diagnosis was 4.38±4.23 
years. A total of 90 patients (74.6%) had oliguria or anuria at the time of diagnosis. Serum 
complement 3 was low in 49 patients (40.2%). Neurologic system involvement was 
present in 34 patients (27.2%). Renal biopsy was performed in 37 patients (30.7%). Renal 
replacement therapies (RRT) were initiated in 61.5 % of the patients at administration 
where only 10% of the patients were discharged with RRT. Genetic studies including the 
complement pathway, DGKE and factor H antibodies were studied in 73% of patients. 
Plasma infusion or plasma exchange was the initial treatment in 82% of patients and 59 % of 
patients (n=72) had eculizumab treatment. At the time of discharge after initial management, 
78 patients (63.9%) and 92 patients (75.4%) achieved renal and hematological remission, 
respectively. Four patients died at the acute stage of the disease. Mean duration of follow-
up was 2.28±2.30 years. During follow-up, eculizumab was stopped in 18 patients and 
re-started in four of them due to relapse.
Conclusions: The pediatric aHUS Registry will provide data to help increase our 
knowledge of the aHUS patient with different genetic background and also evaluate the 
long-term safety and efficacy of treatment options including the eculizumab.
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FR-PO445
Long-Term Outcomes of Thrombotic Microangiopathy Treated with 
Plasma Exchange – A Systematic Review  Bashiar Thejeel,1,2 Amit X. Garg,2,3,4 
Aiden Liu,2 Arthur Iansavichus,2 Ainslie M. Hildebrand.2,4  1Schulich School of 
Medicine; 2Kidney Clinical Research Unit, London Health Sciences Centre; 
3Epidemiology and Biostatistics, Western Univ; 4Nephrology, Western Univ.
Background: With the adoption of plasma exchange as standard treatment for 
thrombotic microangiopathy, more patients are surviving and longer-term outcomes have 
greater relevance.
Methods: We conducted a systematic review of observational studies between 1980 and 
2013 that reported outcomes of adults with thrombotic microangiopathy at least 6 months 
after initiating plasma exchange. We searched several databases from 1980 to 2013 for 
eligible articles published in any language. We abstracted data in duplicate and assessed 
the methodological quality of each study using an assessment tool developed based on 
recommended validity criteria.
Results: We screened 6672 articles, reviewed 213, and included 34 studies totaling 
1182 patients (study median [range], 24 [10-118]). The mean (or median) follow-up 
ranged from 6 months to 13 years. The cumulative incidence of relapse and mortality was 
highly variable and ranged from 3 to 84% and 0 to 61%, respectively. The incidence of 
other outcomes across 10 studies also varied (outcomes included hypertension, kidney 
disease, preeclampsia, stroke, seizure, severe cognitive impairment, and depression); in 
3 other studies long-term neurocognitive function and health-related quality of life were 
significantly lower than the general population.
Conclusions: In summary, patients who survive an episode of thrombotic 
microangiopathy may be susceptible to long-term vascular complications including chronic 
kidney disease, but the magnitude of this risk and how to mitigate it remains unclear from 
prior studies.
FR-PO446
Eculizumab Prevents Thrombotic Microangiopathy in Atypical Hemolytic 
Uremic Syndrome Patients: Long-Term Follow-Up  Jan Menne,1 Yahsou 
Delmas,2 Eric Rondeau,2 Christoph Licht,4 Jimmy Wang,5 Chris Mix,5 John F. 
Kincaid,5 Francois Provot,6 Larry A. Greenbaum,7 Fadi Fakhouri.8  1Klinik für 
Nieren- und Hochdruckerkrankungen, Hannover, Germany; 2CHU de Bordeaux, 
France; 3Hôpital Tenon & Univ Paris VI, Paris, France; 4Hospital for Sick 
Children, ON, Canada; 5Alexion Pharmaceuticals, Inc., Cheshire, CT; 6CHU 
de Lille, France; 7Emory Univ, Atlanta, GA; 8CHU de Nantes, France.
Background: In 5 previous studies of patients (pts) with aHUS, ECU effectively 
treated and prevented thrombotic microangiopathy (TMA) and improved renal function 
and hematological parameters for up to 2 yrs.
Methods: An observational, multicenter, long-term follow-up study of aHUS pts 
treated with ECU in 5 prior clinical studies. The primary endpoint was exposure/follow-
up TMA event rate post-parent study on-(ON) and off-treatment (OFF; among pts who 
discontinued ECU).
Results: 85 pts enrolled (Table); of these, 74 pts had ON and 37 pts had OFF treatment 
periods with median follow-up of 24.6 and 16.6 months, respectively. The TMA event rate 
was 6.7 per 100 pt-yrs for ON pts, and 23.5 per 100 pt-yrs for OFF pts. The rate of TMA 
in ON pts was greater in those not receiving on-label dosing (Table). OFF pts had higher 
eGFR at time of discontinuation than ON pts. Age, frequencies of higher-risk complement 
factor mutations and kidney transplant status were not different between ON and OFF pts. 
Treatment status and higher-risk mutations independently predicted TMA.
Conclusions: The TMA event rate was 3.5-fold higher after ECU discontinuation vs. 
on ECU. TMA event rates were lowest during on-label dosing, higher during off-label 
dosing, and highest off-treatment. Pts with aHUS have a progressive increase in the risk of 
TMA events during periods of reduced dosing and after discontinuation of ECU compared 
with on-label ECU dosing. Medical writing support – Kenyon Ogburn PhD, of Alexion.
Funding: Pharmaceutical Company Support - Alexion Pharmaceuticals, Inc.
FR-PO447
An Update on Tailored Eculizumab Maintenance Treatment in Patients 
with Atypical Haemolitic Uremic Syndrome  Gianluigi Ardissino,1 Francesca 
Tel,1 Sara Testa,1 Ilaria Possenti,1 Donata Cresseri,1 Samantha Griffini,1 Elena 
Grovetto,1 Stefania Salardi,1 Silvana Tedeschi,1 Nicolò Borsa,2 Massimo Cugno.1 
1Center for HUS Management, Fondazione IRCCS Ca’ Granda Policlinico, 
Milan, Italy; 2Molecular Otolaryngology & Renal Research Laboratory, The 
Univ of Iowa.
Background: Atypical hemolytic uremic syndrome (aHUS) is a severe, systemic 
thrombotic microangiopathy often related to mutations in the genes encoding complement 
regulatory proteins. Since 2009, Eculizumab (ECU) has been successfully used in patients 
(pts) with aHUS. The standard maintenance treatment suggests ECU administration every 
two weeks (wks), life-long but the best treatment schedule is not yet defined. To update on 
our experience on individualized ECU treatment schedule for preventing relapses based on 
drug biological activity, with the rational of improving the patient’s quality of life, reducing 
the risk of adverse reactions and reducing the heavy costs of the treatment.
Methods: Pts undergoing ECU treatment for aHUS at our Center were addressed to a 
progressive extension of the interval between ECU doses from the standard 2 wks to 3 or 
4 wks with a strict monitor of global complement activity. AP50 was routinely determined 
before each ECU administration and the interval between doses was adjusted with the target 
of maintaining AP50<25%. Strict monitoring of indicators of disease reactivation, namely 
blood in the urine with home dipstick, was regularly performed.
Results: The interval between doses was extended in 33 pts (13 ≤ 18 yrs) with a 
median age of 28.1 yrs (5-62), 17 F, 21 with native kidney and 12 with graft. Identified 
mutations were: CFH:15; CFI:2; CD46:1; MCP:1; CFHR3-CFHR1 homoz. deletion with 
(3) or w/o (1) antiFHAb:4; multiple mutations:3; Idiopathic:7. In 19 pts the optimal interval 
between ECU doses was 4 wks while in 14 pts it was 3 wks. No relapses was observed 
over a cumulative observation period of 748 mos (mean 23 mos/pt).
Conclusions: In patients with aHUS, our experience supports the possibility of 
tailoring ECU maintenance treatment schedule based on global complement activity. In a 
cohort of 10 adult pts the described novel approach leads to an average estimated saving 
>2 million USD/yr.
FR-PO448
Chemokines as Potential Biomarkers of Renal Involvement in Scleroderma 
Edward Stern,1,2 Voon Ong,1 Aine Burns,2 Robert J. Unwin,2 Christopher Paul 
Denton.1  1Centre for Rheumatology, UCL, London, United Kingdom; 2Centre 
for Nephrology, UCL, London, United Kingdom.
Background: Renal disease in scleroderma (SSc) remains a major clinical challenge. 
Previous studies showed up to 50% of SSc patients have CKD. We sought to gain insight 
into the pathogenesis of SSc-CKD by examining markers of disease in serum and urine.
Methods: We collected urine and serum from 80 SSc patients, with or without renal 
disease, for comparison with patients with CKD of other causes (n=10) and healthy controls 
(n=12). We performed multiplex analysis of candidate markers of disease activity or severity 
in SSc and renal injury: MCP-1, MCP-3, IL-6, IL-18, TNFa, and VEGF.
Results: 40 SSc patients had CKD defined by eGFR and urinalysis. Serum MCP-1 
was increased in SSc compared with controls, with SSc-CKD significantly lower than SSc 
without CKD. Mean serum MCP-1 was 132 pg/ml (95% CI 105-162) for SSc with normal 
renal function compared with 65 pg/ml in SSc-CKD (49-81, p<0.001 for this comparison). 
MCP-1 was not increased in CKD of other causes (mean 47 pg/ml, 23-85) compared with 
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controls (mean 53 pg/ml, 25-85, p=0.848). Conversely, urine MCP-1:creatinine ratio was 
higher in SSc-CKD (mean 64, 32-111) than in SSc with normal renal function (mean 23, 
18-28, p=0.046). MCP-3 was upregulated in the urine of patients with SSc with or without 
CKD (mean MCP-3:creatinine ratio 3.6, 2.5-4.6) compared with healthy controls (mean 0.9, 
0.5-1.4, p=0.016). There was no difference between groups in serum MCP-3.
Conclusions: This is the first study to measure MCP-1 and MCP-3 in the urine of 
SSc patients. Elevated urine MCP-1 in SSc-CKD suggests increased expression in the 
renal tract and may help define organ-specific effects of this potential pathogenic mediator 
that has previously been reported to be increased in serum in association with pulmonary 
complications. In contrast to MCP-1, other markers of SSc severity (e.g. IL-6) or renal 
injury (e.g. IL-18) did not differentiate between groups. Our findings support further 
investigation of urine concentrations of chemokines MCP-1 and MCP-3 as markers or 
mediators of CKD in SSc.
Funding: Government Support - Non-U.S.
FR-PO449
Towards a Deeper Understanding of Fibrillary Glomerulonephritis: 
Clinicopathologic Analysis of Patients in a Long-Term Inception Cohort 
Fernanda Payan Schober,1 Caroline J. Poulton,1 Yichun Hu,1 Harsharan Kaur 
Singh,2 Volker Nickeleit,2 William Franklin Pendergraft.1  1UNC Kidney Center, 
UNC Chapel Hill, Chapel Hill, NC; 2UNC Pathology, UNC Chapel Hill, Chapel 
Hill, NC.
Background: Fibrillary glomerulonephritis is an uncommon primary glomerular 
disease. Accordingly, there are no clinical trials to guide treatment making this a challenging 
disease to manage. Here, we report clinical characteristics and treatment outcomes of 
patients with fibrillary glomerulonephritis diagnosed and/or treated at UNC or through the 
Glomerular Disease Collaborative Network and compare them to a previously published 
cohort from Mayo clinic†.
Methods: Patients were identified through the UNC Division of Nephropathology 
database. Clinical data were extracted from the electronic medical records starting at the 
time of diagnosis.
Results: There were 31 patients with fibrillary glomerulonephritis who were 
treated at UNC and another 245 patients who were diagnosed by the UNC Division of 
Nephropathology. Demographic and clinical data from the date of biopsy are displayed 
in the table.
UNC
(n=31)
UNC Path
(n=245)
Mayo
(n=66) p-value
Sex
Female (%)
Male (%)
19 (61%)
12 (39%)
153 (62%)
92 (38%)
36 (55%)
30 (45%) 0.487
Race
white 
black
other
18 (60%)
8 (27%)
4 (13%)
167 (68%)
38 (16%)
40 (16%)
68 (95%)
2 (3%)
1 (2%)
< 0.0001
Age
mean (%)
15-34
35-54
>54
49.6 + 10.4
4 (13%)
18 (58%)
9 (29%)
56.7 + 11.5
8 (3%)
91 (37%)
146 (60%)
53 + 12
1 (8%) 
9 (39%)
12 (53%)
0.0011
0.0049
Serum creatinine (mg/dl) 2.1 + 1.2 3.3 +3.4 2.1 + 1.6 0.0041
24hr urine protein (gm) 6.5 + 4.0 7.5 + 28.2 5.6 + 4.2 0.8454
Serum albumin (g/dl) 3.0 + 0.9 3.1 + 0.8 3.2 + 0.7 0.4751
Conclusions: This clinicopathologic analysis of patients with fibrillary 
glomerulonephritis is the largest study of its kind in the literature to date. The patients in our 
cohort were more ethnically diverse than the Mayo clinic group but presented with similar 
degree of kidney impairment and nephrotic range proteinuria. Fibrillary glomerulonephritis 
is an understudied glomerular disease that portends a poor prognosis warranting the need 
for prospective multi-center treatment studies to determine durable therapeutic avenues. 
†Nasr, S. et al. CJASN. 6:775-784; 2011.
Funding: NIDDK Support
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Clinical, Histologic, and Genetic Predictors of Response to MMF in C3 
Glomerulopathy  Rupali Surendra Avasare,1 Pietro A. Canetta,1 Andrew 
S. Bomback,1 Yasar Caliskan,2 Yasemin Ozluk,2 Gerald B. Appel.1  1Div. of 
Nephrology, Columbia Univ Medical Center, New York, NY; 2Div. of Nephrology, 
Istanbul Faculty of Medicine, Istanbul; 3Dept of Pathology, Istanbul Faculty 
of Medicine, Istanbul.
Background: Treatment of C3 Glomerulopathy (C3G) with anti-complement therapy 
has yielded mixed results and there is no consensus on optimal treatment. We reviewed the 
experience of our C3G patients who received a course of mycophenolate mofetil (MMF) 
to determine predictors of treatment response.
Methods: In a retrospective chart review of patients with biopsy-diagnosed C3G, we 
identified 24 patients treated with a course of MMF (> 6 months) with >1 year follow-up. 
The primary outcome was either complete remission (stable GFR with decline in proteinuria 
to < 0.5 g/gCr) or partial remission (stable GFR with >50% decline in proteinuria to 
between 0.5 – 3.5 g/gCr) at last follow-up. Responders and nonresponders were compared 
by two-tailed T test or Mann-Whitney U test for continuous variables and Fisher exact test 
for categorical variables.
Results: There were 15 men and 9 women with 21 White and 3 Black patients. 
Median age was 27 years (IQR 21 – 37). Median creatinine was 1.17 (IQR 0.87 – 1.74) 
mg/dl, eGFR 59 (IQR 34 - 89) ml/min/1.73m2. Median proteinuria was 3.6 g/gCr (IQR 
1.6 – 7.7). Of 24 patients treated with MMF, 14 (58%) were responders (8 CR, 6 PR). 22 
of 24 patients received steroids. The only variable associated with remission was elevated 
soluble membrane attack complex (sMAC) level (responders 100%, nonresponders 25%, 
p <0.05). Age, eGFR, proteinuria, hypocomplementemia, complement factor mutations 
or autoantibodies, interstitial fibrosis/tubular atrophy, location of deposits on electron 
microscopy, and presence/absence of immunoglobulin staining on IF were no different 
between responders and nonresponders.
Conclusions: 14 of 24 C3G patients treated with a course of MMF experienced 
remission. Elevated sMAC level was associated with response to MMF. While not a specific 
anti-complement therapy, MMF may be an effective treatment for some patients with C3G. 
This and other series suggest elevated sMAC may indicate treatment-susceptible disease.
FR-PO451
Genetic Sequences May Influence Clinical Progression or Clinical 
Presentations of C3 Glomerulopathy  Hostensia M. Beng, Basema I. Dibas, 
Hsiao Ling Lai, Guillermo Hidalgo.  Pediatrics, ECU, Greenville, NC.
Background: We describe clinical course of 2 girls with C3 Glomerulopathy (C3 GN) 
with different genetic sequences and clinical courses.
Methods: Case 1(A). 12 yrs old AAF who presented with stage 2 HTN and & nephrotic 
range proteinuria (u. p/cr 4.6). A renal biopsy showed C3 GN. She received steroids. 
(HD) was initiated (s.cr 2.24 mg/dL, BUN 127mg/dL). She received 5 anti-hypertensive 
medications & 3 PE sessions. She had no improvement, D#29 she received Eculizumab 900 
mg q wk & after 2 doses of Eculizumab, GFR improved and no longer required HD or PE. 
Case 2 (B). 15 yrs old WF who presented at 7 yrs of age with hematuria, stage 2 HTN & 
nephrotic range proteinuria (u. p/cr 13). Kidney biopsy showed C3 GN. She received only 
Lisinopril and had maintained normal GFR without RRT/steroids. Though she continued 
to have nephrotic range proteinuria.
Results: Both presented with hematuria, HTN and nephrotic range proteinuria and their 
biopsies showed C3 GN, persistent nephrotic range proteinuria despite improvement in GFR 
and normal levels of FH, properdin, C5b9. Gene analysis for A showed deletion of CFHR3, 
CFHR1 and carry a variant of unknown significance in CFH and CFI. B in contrast had 
abnormal high complement plasma Bb antibody and 0% complement alternative pathway.
Conclusions: CFH competes with CFB for C3b binding, it impedes the formation of 
AP C3 convertase. CFH accelerates AP C3 convertase decay & is a cofactor for complement 
factor I (CFI) - mediated proteolysis of C3b. Complement regulatory protein with CFI 
cofactor activity. CFI is a serine protease encoded by the CFI gene on chromosome 4q25. 
Looking closely at the genetic difference in our two patients, we hypothesized that the 
genetic variants defects in CFH could have led to a more severe clinical presentation of 
A and mild disease presentation in B with AP alternative pathway abnormality. Genetic 
sequences may influence clinical manifestation/ progression of the C3GN.
FR-PO452
Membranoprol i ferat ive  Glomerulonephri t i s  C3  Depos i t s : 
Clinicopathological Study  Luis A. Castillo,1 Eduardo I. Navarro,2 Ismael 
Lopez,2 Kelly Camacho,2 Mayra Olivero,2 Ismael Lopez,2 Gustavo Aroca 
Martinez,1,2 Henry J. Gonzalez Torres,2 Raul Garcia.1,2  1Nephrology, Clínica de 
la Costa, Barranquilla, Atlántico, Colombia; 2Medicine, Univ Simón Bolívar, 
Barranquilla, Atlántico, Colombia.
Background: Membranoproliferative glomerulonephritis (MPGN) is a pattern of 
damage characterized in the light microscopy by mesangial hypercellularity, thickening 
of the glomerular basement membrane and mesangial interposition in the capillary wall. 
Recent advances in the understanding of its underlying pathogenesis led to a classification 
scheme based on the findings in the inmunofluorencencia. Alteration complement regulation 
has proven to be a risk factor for the development of MPGN.
Methods: Cross-sectional study. The data were extracted from NefroRed©, a software 
platform that contains the socio-demographic, anthropometric, clinical and laboratory data 
of 1200 patients with kidney biopsies from 2008 to 2014. It was selected for the study 
those patients that showed the pattern of glomerulonephritis and membranoproliferative 
and C3 deposits only or predominant. Each biopsy was studied by light microscopy and 
immunofluorescence, light microscopy included hematoxylin-eosin, PAS, and Jones y 
Tricrómico. Immunofluorescence was performed using antibodies directed against IgG, 
IgA, IgM, C1q, C3, albumin, fibrinogen, Lightweight Kappa and Lambda chains.
Results: Mean age of men was 42.3 years and women was 36.7 years. The minimum 
age was 18 years. The maximum age was 69 years; 51.8% (n = 14) of patients were women.
The 1200 biopsies showed 58 injuries MPGN (5%) of these 58 cases only 27 (32%) lesions 
showed C3 deposits only or predominant.
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Conclusions: 30% of patients with GMP have as pathogenic mechanism the 
complement activation with complement C3 deposition in the glomerulus. Our research 
group has found C3 deposition causally related to GMP. The most common clinical 
presentation is nephrotic syndrome.
FR-PO453
Steroids Alone for the Treatment of C3 Glomerulonephritis with 
Monoclonal Gammopathy  Insara Jaffer Sathick,1 Ladan Zand,1 Samih H. Nasr,2 
Sanjeev Sethi,2 Fernando C. Fervenza,1 Nelson Leung.1,3  1Div of Nephrology 
and Hypertension, Mayo Clinic; 2Div of Anatomic Pathology, Mayo Clinic; 
3Div of Hematology, Mayo Clinic.
Background: C3 glomerulonephritis (C3GN) is a rare disease with no trial data to 
guide treatment. In patients with C3GN with monoclonal gammopathy, steroids alone may 
be a viable treatment option.
Methods: We present our experience in managing C3GN with monoclonal gammopathy 
with prednisone.
Results: 5 patients presented to our institution from 2011 to 2014 with biopsy proven 
C3GN and underlying monoclonal gammopathy. Median age of this cohort was 63 years. 
Median estimated GFR by MDRD equation was 35.4 ml/min1.73m2 and median proteinuria 
was 2 g/day at presentation. All patients had IgG kappa monoclonal gammopathy. Patient 5 
required renal replacement therapy but recovered renal function. All patients were treated 
with Prednisone 60mg/day tapering to zero in all except one. Patient 2 and 4 continue on 
2.5-5mg/day. Median duration of follow up was 26.9 months. Median estimated GFR at 
follow up was 40.16 ml/min1.73m2. All patients showed improvement in proteinuria. 3/5 
patients showed improvement in kidney function.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age 69 63 47 69 23
Gender M M F M M
eGFR at 
presentation 
(MDRD) ml/
min1.73m2
24.6 26.2 48.2 37.6 35.4
Proteinuria (g/
day) 1.87 2 2.8 2.6 1
Serum M spike 
(g/dl) 0.6 0.5 0.5 1 0.8
Bone Marrow 
Biopsy
<5% kappa 
restricted 
cells
10%kappa 
restricted cells
Normocel-
lular
<5%kappa 
restricted 
cells
Hypercellular
Presenting 
features
CKD, 
hematuria CKD, hematuria
AKI, 
nephritic 
syndrome
CKD, 
hematuria
AKI with flu 
like symptoms
Alternative 
complement 
pathway evalu-
ation
C3nephrit-
ic facor 
negative
Elevated solu-
ble membrane 
attack complex 
(sMAC)
No abnor-
mality
C3 
nephritic 
factor 
positive, 
elevated 
sMAC
Heterozygous 
for CFH/DDD/
C3GNassoci-
ated allele.C3 
nephritic factor 
positive
Proteinuria on 
follow up (g/
day)
0.14 0.55 0.82 0.62 0.01
eGFR on fol-
low up 24.6 30 40 40 58
Conclusions: Our experience suggests that prednisone alone may be a treatment 
option in some patients with C3GN associated with a monoclonal gammopathy. Work up 
should be done to exclude a plasma cell neoplasm and inherited complement abnormalities.
FR-PO454
The National Study of Membranoproliferative Glomerulonephritis and 
C3 Glomerulopathy: Characterisation of the Initial United Kingdom 
Paediatric Cohort  Edwin KS Wong,1 Claire L. Harris,2 Kevin J. Marchbank,1 
Isabel Y. Pappworth,1 Rebecca Walters,1 Hannah J. Lomax-Browne,3 Daniel P. 
Gale,4 Tim Goodship,1 David Kavanagh,1 Roger D. Malcomson,5 Paul Morgan,2 
Matthew C. Pickering,3 H. Terence Cook,3 Sally A. Johnson.1  1Newcastle Univ; 
2Cardiff Univ; 3Imperial College London; 4Univ College London; 5Leicester 
Royal Infirmary.
Background: The National Registry of Rare Kidney Diseases (RaDaR) in the 
United Kingdom allows recruitment, research and longitudinal follow-up of patients with 
membranoproliferative glomerulonephritis (MPGN) and C3 glomerulopathy (C3G). The 
aim of the MPGN/C3G Rare Disease Group (RDG) is to deep phenotype and analyse 
complement abnormalities in a paediatric cohort of MPGN/C3G.
Methods: The MPGN/C3G RDG recruited patients with MPGN/C3G for central 
review of biopsies and clinical data, and studied complement abnormalities previously 
described in MPGN/C3G.
Results: 83 prevalent patients with MPGN/C3G were identified and centrally reviewed. 
79 could be classified: 40 had immune-complex MPGN, 25 had C3GN and 14 had DDD. 
Complement abnormalities are shown in Table 1. Follow-up data on 73 patients is shown 
in Figure 1.
MPGN–IC C3GN DDD
Low C3 at presentation 22/28 (79) 16/18 (89) 10/11 (91)
C3 nephritic factor 9/21 (43) 6/18 (33) 6/7 (86)
Anti-FH autoantibodies 7/39 (18) 3/24 (13) 3/14 (21)
Rare variant (C3, FB, FH, FI) 4/35 (11) 1/22 (5) 1/12 (8)
Positive/number tested (%)
Conclusions: RaDaR has facilitated the development of a large nationwide cohort 
of paediatric patients with MPGN/C3G who have now undergone deep phenotyping and 
genotyping centrally. Acquired complement abnormalities were common; rare genetic 
abnormalities were infrequent. Patients with DDD had the worst renal outcome. Ongoing 
recruitment and longitudinal follow up will clarify prognosis according to phenotype/
genotype and allow stratification into future treatment studies.
FR-PO455
Plasma Neutrophil Gelatinase-Associated Lipocalin, Procalcitonin and 
C-Reactive Protein as the Predictor of Acute Pyelonephritis in Children 
with Febrile Urinary Tract Infections  Byungkwan Kim, Hyung Eun Yim, Kee 
Hwan Yoo.  Dept of Pediatrics, Korea Univ Medical Center, Seoul, Republic 
of Korea.
Background: We have recently reported that plasma and urinary neutrophil gelatinase-
associatedlipocalin (NGAL) levels are useful for the prediction of acute pyelonephritis 
(APN) in pediatric urinary tract infection (UTI). This study was aimed to determine the 
accuracy of NGAL measurements, compared with serum measurements of procalcitonin, 
C-reactive protein (CRP), and white blood cells (WBCs) in predicting APN and associated 
renal problems in children with febrile UTIs.
Methods: Total 138 children with febrile UTIs (59 APN, 79 lower UTI) were enrolled. 
Patients with renal failure, congenital urologic anomaly except vesicoureteral reflux 
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(VUR), and recurrent UTIs were excluded. Serum levels of NGAL, procalcitonin, CRP 
and WBC counts were measured at admittance. Laboratory, clinical, and imaging results 
were reviewed.
Results: Receiver operating curve analyses showed NGAL (area under the curve 
(AUC) 0.893), procalcitonin (AUC 0.855), CRP (AUC 0.879), and WBCs (AUC 0.654) had 
good diagnostic profiles for identifying APN (all P < 0.05). Using the best cut-off values 
(NGAL 117 ng/mL, procalcitonin 0.173 ng/mL, CRP 2.78 mg/dL, WBC 15,870/mm3), odds 
ratios for APN were all highly increased after adjusting for age and gender (NGAL 41.2, 
procalcitonin 22.8, CRP 25.3, WBC 4.2). The sensitivity and specificity of plasma NGAL 
for diagnosing APN was the highest among all examined biomarkers (sensitivity 88.1%, 
specificity 84.8%). Univariate analysis showed that female gender, NGAL, procalcitonin, 
CRP, and WBCs were associated with APN (all P < 0.05). However, multivariate analysis 
revealed that only plasma NGAL was an independent predictorof APN (P < 0.001). NGAL, 
procalcitonin, and CRP levels also showed good predictive values for the presence of VUR 
(AUCs of NGAL, procalcitonin, and CRP 0.798, 0.756, 0.845).
Conclusions: Plasma NGAL, procalcitonin and CRP are sensitive predictors for 
identifying APN and VUR. Plasma NGAL can be more reliable than serum procalcitonin, 
CRP, and WBCs in predicting APN in children with febrile UTIs.
FR-PO456
A Prospective Evaluation of Renal Contrast-enhanced Ultrasound (CEUS) 
in the Detection of Pyelonephritis  Florian Buchkremer,1 Daniel Drozdov,2 
Werner C. Albrich,3 Andreas H. Bock.1  1Div of Nephrology, Kantonsspital 
Aarau, Aarau, Switzerland; 2Medical Univ Dept, Kantonsspital Aarau, Aarau, 
Switzerland; 3Div of Infectious Diseases, Kantonsspital St. Gallen, St. Gallen, 
Switzerland.
Background: Contrast-enhanced ultrasound (CEUS) has been described as a promising 
method for detecting acute pyelonephritis (PN) and its complications. We evaluated its value 
in diagnosis and risk stratification in the setting of a randomized controlled trial (RCT).
Methods: Immunocompetent adults with community-acquired urinary tract infection 
(UTI) presenting in the emergency department of Kantonsspital Aarau were enrolled in 
a RCT designed to evaluate the performance of a PCT/pyuria guided algorithm versus 
standard guidelines (Drozdov et al. BMC Medicine 2015). Outcomes included antibiotic 
exposure, duration of therapy, persistent infections and recurrences/re-hospi-talizations. 
As part of the protocol, all hospitalized UTI patients with fever and/or flank pain were to 
undergo renal CEUS in addition to standard greyscale and Doppler examination within 
the first 72h of admission. Findings suggestive of PN such as triangular, hypoechogenic, 
hyoperfused areas were recorded.
Results: Of 70 UTI study patients hospitalized with fever and/or flank pain, 41 
(59%) underwent the ultrasound study. Dropout reasons included missing consent (5), 
early discharge (6) or technical (18). Examined and non-examined patients did not differ 
significantly in baseline characteristics or outcome. Findings suggestive of PN were found 
in 5/41 (12%). In 3 patients, this was evident in greyscale/Doppler already, in 2 additional 
patients, critical findings were only present in CEUS. The presence of PN-suggestive 
findings was not predictable from any baseline clinical characteristic. Patients with and 
without PN-suggestive findings did not appear to differ in outcome.
Conclusions: Ultrasound evidence of pyelonephritis is rare in patients hospitalized 
for UTI with fever or flank pain. Adding CEUS to basic greyscale and Doppler ultrasound 
may substantially increase the number of positive findings.
Funding: Government Support - Non-U.S.
FR-PO457
ISN 0by25 AKI Global Snapshot Project: AKI Disposition  Michael V. Rocco,1 
Ravindra L. Mehta,2 Giuseppe Remuzzi,3 Jing Zhang,2 Melanie Godin,4 
Emmanuel A. Burdmann,5 John Feehally,6 Fredric O. Finkelstein,7 Guillermo 
Garcia-Garcia,8 Raul Lombardi,9 Etienne Macedo.5  1Wake Forest U; 2U 
California San Diego; 3Mario Negri Inst; 4Sherbrooke U; 5U Sao Paulo; 6U 
Leicester; 7Yale U; 8Hosp Civil de Guadalajara; 9Servicio Medico Integral.
Background: The 0by25 AKI Global Snapshot Project (GSP) was a point prevalent 
survey of AKI pts seen in health care facilities throughout the world.
Methods: A web based survey tool was used to obtain data from individual clinicians 
about pts with AKI based on KDIGO criteria. Detailed methodology may be found in the 
ISN GSP abstract on provider characteristics. Countries were defined by gross national 
income per capita (GNI): Low and lower middle income (LLMIC), upper middle income 
(UMIC) and high income (HIC).
Results: Nephrology management of AKI was more common in LLMIC (85.1%) 
versus HIC (58.4%) or UMIC (58.1%). Location of pts 7 days after AKI diagnosis varied 
by GNI category (p<0.0001).
Location 7 
days after AKI 
confirmation
Frequency Percent HIC UMIC LLMIC
ICU 567 16.5 23.5 17.2 7.2
Hospital ward 1980 57.5 57.1 58.2 56.8
Transfer to another 
hospital 51 1.5 0.7 1.5 2.3
Outpatient clinic 127 3.7 3.1 2.2 6.6
Other health 
facility
14
0.4
0.3
0.5 0.4
Home 612 17.8 13.8 17.2 23.3
Rehab/Nursing 
home 10 0.3 0.8 0.1 0
Unknown 84 2.4 0.8 3.2 3.3
AKI recovery was more often complete in LLMIC (34.5%) than in HIC (29.9%) or 
UMIC (25.9%). Patients were discharged home in 83.4% in HIC, 86.1% in UMIC and 
92.0% in LLMIC (p<0.0001). Data from 3861 pts showed that 88.8% were alive at the 
time of the last observation; this rate did not vary by GNI category (p=0.922). Scheduled 
follow-up for AKI was arranged in only 14% of pts, with non-significant differences among 
GNI categories (p=0.5)
Conclusions: Pts with AKI had hospital stays that typically exceeded 7 days, although 
this was less likely in LLMIC. Survival rates did not vary by GNI category. Pts were more 
likely to be sent home in LLMIC compared to HIC and UMIC; this observation may at least 
be partially due to the greater prevalence of patients in ICUs 7 days after AKI diagnosis 
in HIC vs. LLMIC countries. Scheduled follow-up for AKI was infrequent and did not 
vary by GNI category.
Funding: Pharmaceutical Company Support - Astute Medical (San Diego, CA, 
USA), Danone Nutricia Research (Palaiseau, France) and Bellco (Mirandola, Italy)., 
Private Foundation Support
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ISN 0by25 AKI Global Snapshot Project: Indications for Initiating and 
Withholding Dialysis in AKI Worldwide  Etienne Macedo,1 Ravindra L. 
Mehta,2 Giuseppe Remuzzi,3 Jing Zhang,2 Melanie Godin,4 Michael V. Rocco.5 
1U Sao Paulo; 2U California San Diego; 3Mario Negri Inst; 4Sherbrooke U; 
5Wake Forest U.
Background: The 0by25 AKI Global Snapshot Project (GSP) was a point prevalent 
survey of AKI pts seen in health care facilities throughout the world.
Methods: A web based survey tool was used to obtain data from individual clinicians on 
pts who had a confirmed diagnosis of AKI based on KDIGO criteria. Detailed methodology 
may be found in the ISN GSP abstract on provider characteristics. Countries were defined 
by gross national income per capita (GNI): Low and lower middle income (LLMIC), 
upper middle income (UMIC) and high income (HIC).  We analyzed the frequency of AKI 
requiring dialysis and the reasons for starting or withholding dialysis.
Results: Of 3855 pts, 768 (20%) were dialyzed. Mortality rate was significantly 
different in dialyzed (17%) vs. non-dialyzed (9%) pts (p<0.0001). Among dialyzed pts, 
the mortality rate was similar in countries of different GNI categories. The main reason 
to start dialysis was solute control, with a similar distribution among country categories. 
Reasons for 
dialysis Frequency Percent
HIC 
(n=236)
UMIC 
(n=230) 
LLMIC 
(n=323) p value
Fluid overload 406 51.5 55.1 50.4 49.5 0.4
Solute control 610 77.3 72.5 73.9 83.3 0.004
Electrolyte 
or acid/base 
disturbance
450 57.0 53.8 58.7 58.2 0.49
Intoxication/
poisoning 31 3.9 3.4 8.7 0.9 <0.0001
Other 28 3.5 1.3 5.7 3.7 0.037
Of the non-dialyzed pts (3087), 244 (8%) had a clinical indication but were not 
dialyzed. Reason for withholding dialysis was different across country levels. In HIC, the 
main reason to withhold dialysis was futile treatment (79%). In UMIC, main reason was 
patient cultural beliefs (25%) and in LLMIC financial restriction was as frequent as futile 
perception (30 and 32%).
Conclusions: Solute control is the most common indication for AKI dialysis around 
the globe. Lack of resources is a frequent cause of withholding dialysis in LLMIC, while 
physician perception of futile treatment is the main reason in HIC. Knowledge of local 
deficits will be important to guide future interventions and to develop strategies to improve 
outcomes.
Funding: Pharmaceutical Company Support - Astute Medical (San Diego, CA, 
USA), Danone Nutricia Research (Palaiseau, France) and Bellco (Mirandola, Italy)., 
Private Foundation Support
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FR-PO459
ISN 0by25 AKI Global Snapshot Project: Differences in Location and 
Process of Care Among AKI Patients Around the Globe  Etienne Macedo,1 
Ravindra L. Mehta,2 Giuseppe Remuzzi,3 Jing Zhang,2 Melanie Godin,4 
Michael V. Rocco.5  1U Sao Paulo; 2U California San Diego; 3Mario Negri 
Inst; 4Sherbrooke U; 5Wake Forest U.
Background: The Global Snapshot (GSP) was a prospective cross-sectional study 
designed to capture standardized information on incidence, causes and treatment of AKI 
in all health care settings throughout countries of diverse economic status.
Methods: A web based survey tool was used to obtain data from pts with a confirmed 
diagnosis of AKI based on KDIGO criteria in 72 countries. Detailed methodology is found 
in the ISN GSP abstract on provider characteristics. We analyzed the characteristics of pt 
location and process of care by gross national income per capita (GNI) country levels. 
Countries were defined as: Low and lower middle income (LLMIC), upper middle income 
(UMIC) and high income (HIC).
Results: Based on GNI, 23 countries were classified as LLMIC, 20 as UMIC and 
29 as HIC.
HIC UMIC LLMIC 
N of patients 1241 1594 1118
Age (adult, yrs)* 67 (55,78) 65 (52,77) 53 (38,65)
% Pediatric (n=343) 13 4 9
Age (peds, yrs) 0.4 (0.03,6.0) 8 (2,16.5) 4 (0.3,13.5)
Location where pts develop AKI **
Community acquired 51.0 51.1 79.5
Location where patient seen **
Emergency department 19.5 17.8 16.0
ICU 38.8 26.8 29.5
Ward or stepdown unit 39.1 50.6 47.2
Outpatient clinic 2.7 4.8 7.3
Outcomes
Dialysis (%)* 63.3 58.3 71.8
Mortality in adults (%) 13.1 13.7 11.9
Mortality in pediatric (%)* 1.2 12.5 19.6
* p < 0.05 **p<0.0001
Urinalysis was more often performed in LLMIC (86%). More pts in LLMIC were 
dialyzed (71%). The mortality rate of dialyzed pts and the number of non-renal organ 
failures present was similar by GNI level. Mortality in community acquired AKI was 
higher in LLMIC (11%) vs 7% in HIC. LLMIC had higher mortality among ICU pts (21%) 
vs 13% in HIC (p=0.014). In pediatric pts, mortality was 19.6% in LLMIC compared to 
1.2% in HIC (p<0.001).
Conclusions: Community acquired and pediatric AKI had a significantly higher 
mortality in LLMIC. Although mortality rates of dialyzed and non-dialyzed pts was similar, 
pts from HIC countries were significantly older. Improvement in risk assessment and early 
treatment of AKI in areas with fewer resources could lead to improvement in AKI outcomes.
Funding: Pharmaceutical Company Support - Commercial Support Astute Medical 
(San Diego, CA, USA), Danone Nutricia Research (Palaiseau, France) and Bellco 
(Mirandola, Italy)., Private Foundation Support
FR-PO460
ISN 0by25 AKI Global Snapshot Project: KDIGO Classification and AKI 
Diagnosis Around the Globe  Etienne Macedo,1 Ravindra L. Mehta,2 Giuseppe 
Remuzzi,3 Jing Zhang,2 Melanie Godin,4 Michael V. Rocco.5  1U Sao Paulo; 
2U California San Diego; 3Mario Negri Inst; 4Sherbrooke U; 5Wake Forest U.
Background: The Global Snapshot (GSP) was a prospective cross-sectional study 
designed to capture standardized information on incidence, causes and treatment of AKI 
in all health care settings throughout countries of diverse economic status.
Methods: A web based survey tool was used to obtain data from pts with a confirmed 
diagnosis of AKI based on serum creatinine (sCr) and urine output (UO) KDIGO criteria 
in 72 countries. Detailed methodology is found in the ISN GSP abstract on provider 
characteristics. Countries were defined by gross national income per capita (GNI): Low 
and lower middle income (LLMIC), upper middle income (UMIC) and high income (HIC).
Results: Of 4024 pts, 2891 (71%) had an available baseline sCr (BsCr), absence was 
greater in LLMIC (45% vs 18% in HIC, 21% in UMIC). AKI on CKD was seen in 40%. 
At AKI confirmation day, only 50% of pts had UO volume assessed. 
Studies available at AKI 
diagnosis HIC (n=1260) UMIC (n=1605) LLMIC (n-1153)
Baseline sCr (mg/dl)* 1.04 (0.71,1.60) 1.10 (0.86,1.71) 1.30 (1.00,2.24)
CKD (%)* 26.4 23.4 13.5
sCr at AKI diagnosis (mg/dl)* 2.43 (1.62,4.10) 2.30 (1.53,3.80) 3.26 (2.00,5.80)
UO past 24 hours of AKI 
diagnosis (ml)* 648 (275,1200) 900(400,1500) 500(200,1000)
sCr (alone) (%) 67.5 79.5 63.9
Oliguria (alone) (%)** 10.5 2.3 7.9
sCr + UO (%) 89.6 97.7 92.1
AKI stage at diagnosis
1 424(36.7) 644(43.6%) 308(29.5%)
2 192(16.6%) 22(15.4%) 133(12.7%)
3 540(46.7%) 606(41.0%) 605(57.8%)
* p<0.001. **UO criteria by modified KDIGO: Oliguria defined as UO <400 ml or <0.5 ml/kg/hr 
last 24 h
In LLMIC, 58% of pts were classified as AKIN stage 3 at AKI diagnosis. sCr was 
significantly higher in these pts (3.26 mg/dL) compared to 2.43 in pts from HIC and 2.3 
in pts from UMIC.
Conclusions: BsCr was often present in pts from HIC and UMIC, where 1/3 of AKI 
cases occurred in CKD pts. Absence of BsCr was a common issue in LLMIC, associated 
with higher levels of sCr and KIDGO stage at AKI diagnosis. UO is often not computed 
in pts who develop AKI. Systematic assessment of urine output in high-risk pts could help 
identify AKI earlier.
Funding: Pharmaceutical Company Support - Astute Medical (San Diego, CA, 
USA), Danone Nutricia Research (Palaiseau, France) and Bellco (Mirandola, Italy)., 
Private Foundation Support
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ISN 0by25 AKI Global Snapshot Project: Risk Factors for AKI 
Ravindra L. Mehta,1 Giuseppe Remuzzi,2 Jing Zhang,1 Melanie Godin,3 Michael 
V. Rocco,4 Jorge Cerda,5 John Feehally,6 Fredric O. Finkelstein,7 Nathan 
W. Levin,8 Marcello Tonelli.9  1U California San Diego; 2Mario Negri Inst; 
3Sherbrooke U; 4Wake Forest U; 5Albany Med Coll; 6U Leicester; 7Yale U; 
8Renal Research Inst; 9U Calgary.
Background: The 0by25 AKI Global Snapshot Project (GSP) was a point prevalent 
survey of AKI pts seen in health care facilities throughout the world.
Methods: A web based survey tool was used to obtain data from individual clinicians 
about pts who had AKI based on KDIGO criteria. Detailed methodology is found in the 
ISN GSP abstract on provider characteristics. Countries were defined by gross national 
income per capita (GNI): Low and lower middle income (LLMIC), upper middle income 
(UMIC) and high income (HIC).
Results: Participants were distributed from North/East Asia 26.4%, South Asia 18.9%, 
Latin America/Caribbean 14%, Africa 13.4%, North America 7.3%, Western Europe 
6.2%, Oceania/Southeast Asia 4.3%, Russia/Commonwealth Independent States 3.9%, 
Middle East 3.4%, Eastern/Central Europe 2.2%. Ethnic groups included 53% Asian, 19% 
Caucasian, 9% Hispanic, 8% African, 7% Middle Eastern and 1.5% Native/Aboriginal. 
Causes of AKI varied by GNI and were compared by Kruskal-Wallis test. 
Risk factors for 
AKI Frequency Percent HIC UMIC LLMIC p value
Dehydration 1536 38.2 39.1 32.3 45.6 <0.0001
Hypotension/shock 1615 40.2 44.8 38.2 38.2 0.0003
Cardiac 905 22.5 24.3 27.9 13.1 <0.0001
Liver 331 8.2 7.7 9.2 7.5 0.18
Acute kidney 
disease 488 12.2 11.1 9.4 17.2 <0.0001
Urinary 
obstruction 320 8.0 7.9 6.9 9.5 0.0421
Infection 1291 32.1 28.8 32.2 35.7 0.0013
Pregnancy related 56 1.4 0.4 0.9 3.1 <0.0001
Systemic diseases 322 8.0 9.4 9.4 4.6 <0.0001
Nephrotoxic 
agents 980 24.4 29.0 21.7 23.1 <0.0001
Poisoning 73 1.8 2.1 1.4 2.0 0.32
Envenomation
35
0.9
0.3
0.7 1.7 0.0005
Post-surgical 269 6.7 9.2 6.8 3.8 <0.0001
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Other organ failures present were pulmonary 16.4% (more common in HIC), 
cardiovascular 23.1% (less common in LLMIC), neurologic 8.3%, hepatic 10.4%, 
hematologic 9.5% (more common in LLMIC) and none 53.9%
Conclusions: Hypotension was the most common cause of AKI in HIC and UMIC; 
dehydration was most common in LLMIC. Acute kidney disease, pregnancy and 
envenomation were more common in LLMIC.
Funding: Pharmaceutical Company Support - Astute Medical (San Diego, CA, 
USA), Danone Nutricia Research (Palaiseau, France) and Bellco (Mirandola, Italy)., 
Private Foundation Support
FR-PO462
ISN 0by25 AKI Global Snapshot Project: Evaluation and Treatment 
Jorge Cerda,1 Ravindra L. Mehta,2 Giuseppe Remuzzi,3 Jing Zhang,2 Melanie 
Godin,4 Michael V. Rocco,5 Emmanuel A. Burdmann,6 Guillermo Garcia-Garcia,7 
Vivekanand Jha,8 Andrew J.P. Lewington,9 Raul Lombardi.10  1Albany Med Coll; 
2U California San Diego; 3Mario Negri Inst; 4Sherbrooke U; 5Wake Forest U; 
6U Sao Paulo; 7Hosp Civil de Guadalajara; 8George Inst Global Health; 9Leeds 
Teaching Hosp; 10Servicio Medico Integral.
Background: The 0by25 AKI Global Snapshot Project (GSP) was a point prevalent 
survey of AKI pts seen in health care facilities throughout the world.
Methods: A web based survey tool was used to obtain data from individual clinicians 
about pts who had AKI based on KDIGO criteria. Detailed methodology may be found in 
the ISN GSP abstract on provider characteristics. Countries were defined by gross national 
income per capita (GNI): Low and lower middle income (LLMIC), upper middle income 
(UMIC) and high income (HIC).
Results: Initial evaluation of AKI included urinalysis in 73.6%, ultrasound in 55% and 
renal biopsy in 4.1%, with all three more commonly being performed in LLMIC. Initial 
treatment of AKI included fluids in 74.3%, vasopressors in 23.8%, diuretics in 41.4%, 
antibiotics in 63.8% and urinary diversion in 19.5%. The receipt of dialytic therapy occurred 
in 790 of 4018 pts (19.7%), with use in 18.8% in HIC, 14.3% in UMIC and 28.0% in 
LLMIC. In 244 instances where dialysis was recommended but not performed, futility was 
cited in 58.6% and cultural beliefs were cited in 25.4%. Unavailability of staff or material 
resources to perform dialysis was reported in 1.4% of HIC, 3.8% of UMIC and 16.4% of 
LLMIC. Inability to afford therapy was 1.4% in HIC, 1.9% in UMIC and 16.4% in LLMIC 
(p<0.0001). The ratio of pts not able to receive dialysis by those that did receive dialysis 
was 0.21 in HIC, 0.25 in UMIC and 0.18 in LLMIC. There were significant differences 
in the renal modality used.
Treatment (n=790) Frequency Percent HIC UMIC LLMIC
IHD 516 65.3 63.3 58.3 71.8
PD 41 5.2 4.6 3.0 7.1
CRRT 157 19.9 31.7 29.1 4.6
UF 10 1.3 2.5 1.7 0
SLED 103 13.0 3.4 10.9 21.7
Other 8 1.0 0.6 1.4 0
Unknown 1 0.1 0 0.2 0
Conclusions: Lack of resources. staff or finances to perform dialysis was most prevalent 
in LLMIC. When dialysis was provided, it was less likely to be CRRT and more likely to 
be SLED in LLMIC.
Funding: Pharmaceutical Company Support - Astute Medical (San Diego, CA, 
USA), Danone Nutricia Research (Palaiseau, France) and Bellco (Mirandola, Italy)., 
Private Foundation Support
FR-PO463
ISN 0by25 AKI Global Snapshot Project: Provider Characteristics 
Melanie Godin,1 Ravindra L. Mehta,2 Giuseppe Remuzzi,3 Jing Zhang,2 
Michael V. Rocco,4 Jorge Cerda,5 Vivekanand Jha,6 Nathan W. Levin,7 Andrew 
J.P. Lewington,8 Etienne Macedo,9 Marcello Tonelli.10  1Sherbrooke U; 2U 
California San Diego; 3Mario Negri Inst; 4Wake Forest U; 5Albany Med Coll; 
6George Inst Global Health; 7Renal Research Inst; 8Leeds Teaching Hosp; 9U 
Sao Paulo; 10U Calgary.
Background: The ISN 0by25 AKI Global Snapshot Project (GSP) was designed to 
determine the spectrum of AKI pts seen in health care facilities throughout the world.
Methods: Health care providers joined the GSP after gaining approval from their local 
IRB. Providers chose one “index” day between 9/29/2014 and 12/7/2014 to provide data 
on AKI pts under their care. De-identified data on pts who met criteria for AKI by modified 
KDIGO criteria were entered through a secure website using a standard questionnaire 
developed by the 0by25 AKI workgroup. Data collected included pt demographics, initial 
clinical data, diagnostic, treatment and outcome information. Countries were grouped into 
three categories based on gross national income per capita (GNI); high income with GNI 
>US$12476, low and lower middle income with GNI <US$4035, and upper middle income 
with GNI between levels 1 & 3.
Results: 324 surveys from 72 countries were received describing 4024 pts with 
AKI. Providers included 248 nephrologists, 20 nephrology fellows, 14 intensivists, 26 
pediatric nephrologists. Location of facilities by region included 52 from Africa, 47 from 
Latin America & Caribbean, 45 from North America, 45 from South Asia, 40 from North 
and East Asia, 34 from Western Europe, 19 from Russia/Commonwealth of Independent 
States, 17 from Oceania & South East Asia, 14 from Middle East and 11 from Eastern & 
Central Europe. Size of catchment population for each facility was: >5 million in 28%, 
0.5-1.5 million in 26%, 0.1-0.5 million in 19% and 1.5-3 million in 11%. Type of facility 
was institute in 47%, public hospital or health care concern in 37%, private multispecialty 
group in 14%. Dialysis was available in 97% of facilities.
Conclusions: This project is the first worldwide point prevalent survey of AKI. 
It demonstrates the feasibility of obtaining data on AKI using a secure website from 
practitioners in varied health care settings from six continents.
Funding: Pharmaceutical Company Support - Astute Medical (San Diego, CA, 
USA), Danone Nutricia Research (Palaiseau, France) and Bellco (Mirandola, Italy)., 
Private Foundation Support
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Postoperative Acute Kidney Injury in Non-Cardiac Surgery  Seokwoo Park, 
Dong Ki Kim, Kook-Hwan Oh, Kwon Wook Joo, Yon Su Kim, Hajeong Lee. 
Internal Medicine, Seoul National Univ Hospital, Seoul, Korea.
Background: Prevention of acute kidney injury (AKI) and amelioration of its severity 
remain important issues of improving surgical patient outcomes. Therefore, preoperative 
renal risk evaluation and patient optimization is crucial for nephrologists. Although there 
are several studies dealing with postoperative AKI in cardiac surgery, they have been 
seldom studied in non-cardiac surgery.
Methods: We included adult (age ≥ 18 years) patients who received major non-cardiac 
surgery in Seoul National University Hospital from 2004 to 2013. We extracted their clinical 
data from our electronic medical record system. Acute Kidney Injury Network criteria 
(AKIN) was used to define and classify AKI.
Results: Among a total of 95,266 operations, 1,560 cases (1.64%) developed AKI. 
Patients with AKIN stage I were 964 (1.01%), stage II, 117 (0.12%), and stage III, 479 
(0.50%). AKI was most prevalent in urologic surgery, followed by general surgery, 
orthopedic surgery, and neurologic surgery. Patients who developed AKI tended to be older 
(53.7 vs. 58.9 years), and male (45.6% vs. 65.6%). Patients with AKI had higher prevalence 
of underlying diseases such as liver/heart/hematologic/vascular and neurologic disease than 
those without. Moreover, they showed higher baseline systolic blood pressure and lower 
baseline diastolic blood pressure than those without. Baseline renal function was lower 
in AKI-developed patients than the others (0.90 vs. 1.13 mg/dL, P <0.001). Multivariate 
logistic regression analyses found that older age, male sex, lower baseline renal function, 
presence of hypertension, longer duration of surgical time and orthopedic or urologic surgery 
were significant risk factors for postoperative AKI in noncardiac surgery.
Conclusions: In this study, we demonstrated the incidence of postoperative AKI in 
non-cardiac major operations. Moreover, we found clinical risk factors for postoperative 
AKI development. Further investigation of prediction models for postoperative AKI in 
major non-cardiac surgery should be warranted for development of preoperative renal 
optimization strategy.
FR-PO465
Impact of Hospital CABG Volume and AKI Needing Dialysis on CABG 
Hospitalizations  Ankit Sakhuja,1 Jesse D. Schold,2 Edward G. Soltesz,3 
Sevag Demirjian.2  1Div of Nephrology, Univ of Michigan; 2Nephrology and 
Hypertension, Cleveland Clinic; 3Thoracic and Cardiovascular Surgery, 
Cleveland Clinic.
Background: Acute Kidney Injury (AKI) is common after Coronary Artery Bypass 
Grafting (CABG) and associated with poor outcome. Increased hospital procedure volume 
has been associated with better outcomes. We examined (1) impact of number of annual 
CABG procedures per hospital (CABG-vol) on AKI needing dialysis (AKI-D) and mortality, 
and (2) if it modifies the relationship between AKI-D and mortality.
Methods: Using Nationwide Inpatient Sample database from 2000-2010 we identified 
admissions with CABG using ICD-9-CM codes. Those with AKI-D were identified and 
those with kidney transplant or on maintenance dialysis were excluded. Multivariable 
logistic regressions were used to assess impact of CABG-vol on AKI-D and mortality. We 
used restricted cubic splines to account for non-linear relationship between CABG-vol 
and mortality. A priori interaction term between CABG-vol & AKI-D was assessed in 
model for mortality.
Results: Of estimated 3,337,292 (95% CI: 3,103,610-3.570,973) hospitalizations for 
CABG, 0.7% (24,126) had AKI-D. Those with AKI-D were older, more females (37.5% 
vs 29.1%; p<0.001) and blacks (7.4% vs 5.5%; p<0.001). On adjusted analysis, CABG-
vol was not correlated with odds of developing AKI-D (0.99; 95% CI 0.99-1.00) but was 
associated with mortality (Fig 1). 
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AKI-D was a significant predictor of mortality with OR 13.75 (95% CI: 11.37-16.64). 
Interaction term between CABG-vol & AKI-D was not significant (p=0.8).
Conclusions: Lower annual CABG hospital procedure volume is significantly 
associated with higher mortality but not with higher incidence of AKI-D. AKI-D is 
associated with higher mortality in those undergoing CABG, however, there is no differential 
effect of hospital volume on adjusted odds of mortality due to AKI-D.
FR-PO466
Five-Year Risk of Renal Outcomes After Pediatric Cardiac Surgery 
Jason Henry Greenberg,1 Michael Zappitelli,2 Heather Thiessen Philbrook,1 
Prasad Devarajan,3 Catherine Krawczeski,3 Steven G. Coca,1 Chirag R. Parikh.1 
1Program of Applied Translational Research, Yale School of Medicine; 2Dept 
of Pediatrics, McGill Health Centre; 3Dept of Pediatrics, Cincinnati Children’s 
Medical Center.
Background: Pediatric cardiac surgery is associated with a high risk of acute kidney 
injury(AKI) and other short-term adverse outcomes. However, the risk for long-term renal 
outcomes after cardiac surgery is unknown.
Methods: We performed 5 year follow-up on the Translational Research Investigating 
Biomarker Endpoints in AKI(TRIBE-AKI) cohort. TRIBE-AKI is a three-center prospective 
cohort study of children 1 month to 18 years old who underwent cardiopulmonary bypass.
Results: Out of 305 children who survived their index hospitalization, 4(1.3%) died 
after discharge and 128(42%) participated in the 5 year follow-up. Mean age of the cohort at 
follow-up was 9.2 years and 53% were male. 56 out of 128 patients had perioperative AKI 
defined as a post-operative serum creatinine rise by 50% or 0.3mg/dL from pre-operative 
baseline. At a median of 5.4 years of follow-up, hypertension, microalbuminuria, eGFR<90, 
and eGFR<60 were identified in 13%, 6.3%, 7.0%, and 0.8% of patients, respectively. CKD, 
defined as eGFR<90 or microalbuminuria, was present in 13% of children. There were no 
significant differences in renal outcomes between patients with and without perioperative 
AKI. 5(4.0%) patients had been seen by a pediatric nephrologist. The 5-year post-operative 
prevalence of hypertension in our cohort was >8 fold higher than found in the general 
pediatric population(Table).
Conclusions: Overall, there is a high prevalence of CKD and hypertension in children 
5 years after cardiac surgery. Despite this high prevalence of CKD, very few children were 
seeing a pediatric nephrologist. These findings may have implications for renal care and 
late cardiovascular disease in children after cardiac surgery. 
Definition TRIBE-AKI 5 Year Follow-up
General pediatric 
population
Hypertension BP>95th percentile 13%(CI 7.8-19%) 1.6%(CI 1.0-2.4%)
Microalbuminuria Albumin/Creatinine>30mg/g 6.3%(CI 3.2-12%) 9.9%
eGFR<90 Bedside CKID formula 7.0%(CI 3.7-13%) Not available
CKD eGFR<90 or albuminuria 13.3%(CI 8.5-20%) Not available
Funding: NIDDK Support
FR-PO467
Changes of Epidemiology and Influencing Factors of Acute Kidney 
Injury After Cardiac Surgery – A Five-Year Study from 2009 to 2013 
Zhouping Zou,1,2 Jiarui Xu,1,2 Wenlv Lv,1,2 Bo Shen,1,2 Yi Fang,1,3 Jianzhou 
Zou,1,2 Jie Teng,1,2 Xiaoqiang Ding.1,2,3  1Dept of Nephrology, Zhongshan 
Hospital, Fudan Univ, Shanghai, China; 2Shanghai Inst for Kidney and Dialysis, 
Zhongshan Hospital, Fudan Univ, Shanghai, China; 3Shanghai Key Laboratory 
of Kidney Disease and Blood Purification, Zhongshan Hospital, Fudan Univ, 
Shanghai, China.
Background: Cardiac Surgery is a common cause of acute kidney injury (AKI). We 
collected the epidemiological data of patients with AKI from 2009 to 2013 in order to 
explore the influencing factors of changes of epidemiology after cardiac surgery.
Methods: Clinical data of patients undergoing cardiac surgery,which included 
demographic data of preoperative,intraoperative,postoperative were prospectively 
collected in our hospital from January 2009 to December 2013. The main endpoint was 
poor prognosis which included overall mortality and abandom of treatment. The second 
point was renal outcome.
Results: A total of 11693 patients enrolled, including 6637 males and 5056 females. 
The overall AKI incidence was 34.5%(n=4030). The AKI incidence increased during the 
five years from 34.2% to 36.5% (P<0.05) .There was no significantly statistical differences 
in AKI-RRT incidences during the five years (p=0.360); The hospital mortality of AKI 
decreased from 6.3% in 2009 to 3.8% in 2013. The incidence of poor prognosis in AKI 
were 8.3%,7.5%,6.8% ,5.1%,8.0% (P=0.196).The mortality of AKI-RRT decreased from 
47.1% to 29.5%, but there was no statistical difference (P = 0.230). The incidence of 
poor prognosis in RRT decreased from 66.7% to 57.4%, also no significantly statistical 
difference (P =0.825).Multivariate logistic regression analysis showed that male,age(every 
additional 10 years),body mass index(every additional 5kg/m2),hypertension,chronic heart 
failure,pre-operative serum creatinine >115mmol/L,CPB(every additional 30min) were the 
risk factors of AKI after cardiac surgery.
Conclusions: The incidence of AKI after cardiac surgery increased from 2009 to 2013 
and the rate of poor prognosis did not change. The incidence of AKI-RRT and the rate of 
poor prognosis remained high. The prevention and treatment of AKI still need improvement.
Funding: Government Support - Non-U.S.
FR-PO468
The Very Long-Term Co-Morbidity Adjusted Impact of AKI following 
Cardiac Surgery: A 15-Year Follow-Up Study  Alejandro Ferreiro,1 Raul 
Lombardi.2  1Nephrology, INCC. Facultad de Medicina, Montevideo, Uruguay; 
2Critical Care Medicine, SMI, Montevideo, Uruguay.
Background: AKI is a frequent complication of cardiac surgery (CS) associated to 
high mortality. The co-morbidity adjusted residual impact on very long-term mortality 
(> 12 year) of AKI, excluding the initial catastrophic impact on early mortality has never 
been addressed before. Objectives: to evaluate the net attributable impact of AKI after 
CS on long-term mortality.
Methods: All adult patients submitted to CS between 1/1/2000 and 31/12/2013 
(n=7755) were enrolled. The INCC prospective-collected database with more than 750 
variables (demographics, comorbidities, type of CS, intraoperative and postoperative 
variables, peri-operative support and short time outcomes) was used. Long-term survival 
(up to 15 year by December 2014) was obtained by systematic telephone survey (minimum 
1-year follow-up) and the National Population Registry. AKI stages were defined according 
to KDIGO definition. Demographics, logistic EuroSCORE (and their single components), 
type of CS, baseline renal function (Cockroft-Gault formula) were used for comorbidity risk-
adjustment. Statistical analysis: “t”test, c2 test, Kruskal-Wallis test, Kaplan-Meier curves 
with long-rank test and Cox regression for multivariate survival analysis. Only patients 
alive after the first 1 year follow-up entered in the long-term survival analysis (n= 6956).
Results: AKI incidence: 38.4%. RRT: 1.7%. Long-term (15 years) actuarial survival 
after 1 year follow-up: no AKI 0.58; AKI (I): 0.47; AKI (II): 0.39; AKI (III): 0.27 (p<0.001). 
In multivariate Cox regression analysis, AKI stages I, II and III (OR 1.17; 1.24; 1.62 
respectively) were independently associated with mortality between 1 year after CS and 
15 year follow-up, even after adjustment with logistic EuroSCORE (OR 1.02), age (OR 
1.038), diabetes (OR 1.58), pre operative eGFR (OR 0.996) and no-isolated coronary 
bypass surgery (OR 1.24).
Conclusions: AKI and its severity are independently associated with very long-term 
mortality, even after discarding short term events (1 year), in cardiac surgery. Should AKI 
be causative or a surrogate marker of late events in the long term follow up is a matter of 
concern to be evaluated.
FR-PO469
Incidence and Influencing Factors of Cardiac Surgery-Associated Acute 
Kidney Injury Based on the KDIGO Criteria: A Retrospective Cohort Study 
Changchun Cao,1 Xiangcheng Xie,1 Xin Wan.1  1Nanjing Hospital Affiliated to 
Nanjing Medical Univ (Nanjing First Hospital); 2Nanjing Hospital Affiliated 
to Nanjing Medical Univ (Nanjing First Hospital); 3Nanjing Hospital Affiliated 
to Nanjing Medical Univ (Nanjing First Hospital).
Background: The incidence and influencing factors of cardiac surgery-associated 
acute kidney injury (CSA-AKI) based on the KDIGO criteria have not been well studied. 
This study was aimed to evaluate the incidence, risk or protective factors of acute kidney 
injury (AKI) in patients after cardiac surgery.
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Methods: A retrospective analysis of 2575 patients undergoing first documented cardiac 
surgery with cardiopulmonary bypass (CPB) between January 2008 and December 2012 in 
our hospital was conducted. Perioperative variables were collected and analyzed. Univariate 
and multiple logistic regression models were used for determining the association between 
the development of AKI and risk factors.
Results: Of 2575 patients, 931 (36%) developed AKI. A total of 30(1.2%) patients 
required renal replacement therapy. The overall in-hospital mortality rate was 1.5% (38 of 
2575). CSA-AKI was significantly associated with in-hospital mortality (adjusted HR: 2.22, 
95% CI 1.16-4.24, P = 0.016), especially in patients needing RRT (adjusted HR: 18.68, 
95% CI 8.58-40.68, P < 0.001). The independent risk factors identified by multivariate 
analysis were shown in [table 1].
Variable Odds ratio 95 % CI P
Male 1.14 1.17-1.71 <0.001
BMI 1.29 1.11-1.49 0.001
History of hypertension 1.49 1.21-1.84 <0.001
Insulin-controlled diabetes 1.56 1.06-2.30 0.025
Creatinine (>88.4ȝmol/L) 1.88 0.94-3.72 0.074
Red blood cells transfused(U) 1.08 1.05-1.11 <0.001
CPB duration ≥110min 1.31 1.07-1.61 0.009
Mechanical ventilation≥9h 1.45 1.20-1.75 <0.001
Ulinastatin administration 0.69 0.56-0.88 0.006
Body temperature (>38°C) after 
surgery within 3 days 1.23 1.02-1.50 0.032
Conclusions: This study demonstrates that mechanical ventilation duration, 
erythrocytes transfusion and postoperative body temperature above 38°C within 3 days 
were considered independent risk factors for CSA-AKI. Use of ulinastatin was associated 
with lower incidence of CSA-AKI.
Funding: Government Support - Non-U.S.
FR-PO470
Acute Kidney Injury Post-Major Orthopaedic Surgery: A Single Centre 
Experience  Tracey Ying,1 Samantha Chan,1 Stephen E. Lane,2,3 Christine 
A. Somerville.1  1Dept of Renal Medicine, Univ Hospital Geelong, Geelong, 
Victoria, Australia; 2Barwon Health Biostatistics Unit, Univ Hospital Geelong, 
Geelong, Victoria, Australia; 3School of Medicine, Deakin Univ, Geelong, 
Victoria, Australia.
Background: Given the increasing incidence of AKI and the burden this places on the 
medical system, there is a clear need to expand the practise of ‘preventative nephrology’ – 
the optimisation of renal function through minimisation of potential insults. Renoprotection 
is particularly critical in the perioperative setting, a period of high renal vulnerability. 
However, there is currently little evidence regarding numerous theoretical risk factors for 
postoperative AKI.
Methods: All patients undergoing MOS at our centre between 2008 and 2014 were 
included. Out of 2227 surgeries audited for AKI using comparisons of preoperative and 
postoperative creatinine, 164 cases were identified (per RIFLE criteria) and matched to 
controls 2:1 for age, sex, procedure and chronic kidney disease stage. Their records were 
reviewed for established and proposed risk factors for postoperative AKI: diuretic, non-
steroidal anti-inflammatory (NSAID) and angiotensin-converting enzyme inhibitor (ACEi) 
or angiotensin receptor blocker (ARB) use. Associations of proven and hypothetical risk 
factors were estimated using conditional logistic regression.
Results: Controlling for known risk factors, both diuretic and ACEi or ARB use were 
found to be associated with an approximately twofold increased risk of AKI (diuretic – OR 
2.06 95%CI:1.30-3.26, p<0.005, ACEi/ARB – OR 2.09 95%CI:1.31-3.32, p<0.005). A 
dose-effect model accounting for preoperative, intraoperative and postoperative NSAID 
administration demonstrated a linear relationship between the number of times NSAIDs 
were given and postoperative AKI risk (OR 1.35 95%CI:1.05-1.73, p<0.05).
Conclusions: Perioperative diuretic, NSAID and ACEi or ARB use were shown to be 
significantly associated with postoperative AKI, indicating that these medications should 
be used with caution in MOS. Further prospective studies are required to confirm this.
FR-PO471
Incidence of In-Hospital Acute Kidney Injury by Surgery and Invasive 
Surgical Procedures Among Non-Emergency Hospital Admissions 
Joshua Taylor Swan,1,2 Beverly A. Shirkey,1 Linda W. Moore,1 Wadi N. Suki,1 
A. Osama Gaber.1,3  1Houston Methodist Hospital; 2Texas Southern Univ; 3Weil 
Cornell Medical College.
Background: This study aimed to identify non-emergency invasive surgical procedures 
that are associated with the highest burden of in-hospital AKI.
Methods: Urgent and elective admissions to a quaternary teaching hospital in 2012-
2013 with a principal procedure within 1 day of admission were included. Principal 
procedures were categorized using AHRQ’s Clinical Classifications Software (CCS). 
Patients <18 years, nephrectomy, and those with preexisting AKI or stage 5 CKD were 
excluded. AKI was defined as an increase in SCr by >=0.3 mg/dL or >=50% over a 72-hour 
interval, staged per KDIGO.
Results: AKI occurred during 18% (2,244) of 12,237 admissions. Of AKI cases, 82% 
(1,828) were stage 1, 12% (273) stage 2, and 6% (143) stage 3. Patients were 69% white, 
51% female, aged 61±16, and 9% with CKD. Ten CCS groups with the largest number of 
AKI cases are presented.
CCS Category, CCS code Admissions,n
Any 
AKI,
n (%)
Stage 1 
AKI,
n (%)
Stage 
2 AKI,
n (%)
Stage 
3 AKI,
n (%)
Organ transplantation (other than bone 
marrow, corneal or kidney), 176 234 161 (69) 92 (39)
42 
(18)
27 
(12)
Heart valve procedures, 43 713 323 (45) 263 (37) 47 (7) 13 (2)
Coronary artery bypass graft (CABG), 
44 403 176 (44) 152 (38) 19 (5) 5 (1)
Diagnostic bronchoscopy and biopsy 
of bronchus, 37 248 73 (29) 65 (26) 5 (2) 3 (1)
Other OR heart procedures, 49 251 59 (24) 46 (18) 10 (4) 3 (1)
Other OR procedures on vessels other 
than head and neck, 61 286 64 (22) 54 (19) 3 (1) 7 (2)
Diagnostic cardiac catheterization; 
coronary arteriography, 47 300 52 (17) 46 (15) 4 (1) 2 (1)
Colorectal resection, 78 439 57 (13) 44 (10) 7 (2) 6 (1)
Arthroplasty knee, 152 1100 126 (11) 113 (10) 7 (1) 6 (1)
Hip replacement; total and partial, 153 873 99 (11) 89 (10) 7 (1) 3 (0)
Conclusions: This study presents the incidence of AKI after invasive surgical principal 
procedures, and this data will help prioritize research to prevent in-hospital AKI. Non-
kidney transplant, heart valve, and CABG surgical procedures were associated with the 
largest number of AKI cases at this single center, and non-kidney organ transplants were 
associated with a high severity of AKI.
FR-PO472
Acute Kidney Injury following Gastrointestinal Surgery  Þórir E. Long,1,4 
Dadi Helgason,1 Sólveig Helgadóttir,2,4 Tomas Gudbjartsson,3,4 Gisli H. 
Sigurdsson,2,4 Martin I. Sigurdsson,2,5 Olafur S. Indridason.6  1Dept of Medicine; 
2Dept of Anesthesia; 3Dept of Cardiothoracic Surgery, Landspitali; 4Faculty 
of Medicine, Univ of Iceland; 5Dept of Anesthesia, Brigham and Women´s 
Hospital, Boston, MA; 6Div of Nephrology, Landspitali - The National Univ 
Hospital, Reykjavik, Iceland.
Background: Acute kidney injury (AKI) is a serious postsurgical complication but 
AKI after nonvascular abdominal surgery has not been thoroughly studied. The aim of 
this study was to examine the incidence of AKI after such operations, its risk factors and 
survival of patients.
Methods: We studied all nonvascular abdominal operations performed on adults 
2007-2014 at Landspitali, the major hospital in Iceland. AKI was diagnosed according to 
the creatinine based KDIGO criteria. Risk factors for AKI were evaluated using logistic 
regression analysis. Survival was compared between AKI and non-AKI patients using 
Kaplan-Meier method after propensity score matching (1:1, nearest neighbor matching).
Results: A total of 10,022 patients underwent 11,552 operations during the study 
period, 38.0% were acute operations. Median age at operation was 52 yrs (IQR 32-66) 
and 59.5% of patients were female. AKI occurred after 246 operations (2.1%), with 157 
(1.4%), 57 (0.5%) and 32 (0.3%) of stage 1, 2 and 3, respectively. Incidence of AKI was 
higher after major (5.3%), open (4.9%) and acute operations (3.0%) compared to minor 
(1.1%), laparoscopic (0.5%) and non-acute operations (1.8%). In multivariable analysis, 
postoperative AKI associated with age (OR 1.03 (95%CI (1.04-1.04)), male sex 1.5 (1.1 
– 2.0), open operation 3.0 (2.2-4.2), re-operation 4.8 (3.7-8.6), hypertension 1.7 (1.2-2.4), 
eGFR <60ml/min/1.73 m2 2.0 (1.4-2.7) and ASA score 6.1 (4.2-8.8). Survival was worse 
for AKI patients compared to the propensity score matched contros, both at 30 days (82.4% 
vs, 94.7%, p=0.03) and at 1-year (69.9% vs. 82.6%, p=0.03).
Conclusions: The incidence of AKI is relatively low after gastrointestinal surgery 
compared to cardiac and vascular surgery. The rate of AKI is substantially higher after major 
and open operations and in patients with preexisting kidney disease. AKI is associated with 
increased short- and long-term mortality.
Funding: Private Foundation Support
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Risk Factors Associated with Post-Operative AKI After General Surgery 
Pradeep Arora,1 Leili Pourafkari,2 James W. Lohr,1 Hasan H. Dosluoglu,3 Nader 
Nader.1  1Div of Nephrology, VAMC, Buffalo, NY; 2Anesthesiology, VAMC, 
Buffalo, NY; 3Surgery, VAMC, Buffalo, NY.
Background: AKI after cardiac and vascular surgery has been extensively studied. 
However there is no study which has evaluated the factors associated with development 
of stage 1 AKI by AKIN criteria in general surgery patients.
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Methods: We conducted a cohort study using a prospective database of patients 
undergoing surgical procedures since 2000 in the VA Western New York Healthcare 
System which are in part reported to the National Surgical Quality Improvement Program 
(NSQIP). Demographic, social history, co-morbid diseases, including coronary artery 
disease (CAD), congestive heart failure (CHF), chronic obstructive lung disease (COPD), 
peripheral vascular disease (PVD), cerebrovascular accidents (CVA), hypertension, and 
diabetes, were prospectively entered into the Veterans Affairs Surgical Quality Improvement 
Program (VASQIP) database at the time of surgery. Preoperative laboratory data were also 
entered for each participant. Univariate and multivariate logistic regression were performed 
to estimate the odds of AKI after surgery.
Results: A total of 13300 patients who underwent non-cardiac and non-vascular surgery 
whose data was available to define AKI between 2000-2014 were included in this analysis. 
A total of 1621 patients developed AKI stage 1. In univariate analysis, increasing age, male 
gender, ASA class, poor functional status, presence of COPD, Ascites, CVA, CVD, DM, 
CHF, HTN, preop coronary intervention or MI, HCT <24, Low serum albumin, increased 
operating room (OR) time and blood transfusions were associated with increased odds of 
AKI. Results of multivariate analysis are shown in table 1.
Variable Odds ratio with 95% CI
Age 1.02 (1.02-1.03)
CHF 1.22 (1.03-1.47)
COPD 1.11 (1.02-1.21)
DM 1.21 (1.12-1.32)
OR time 1.15 (1.10-1.20)
Pre creatinine 1.21(1.08- 1.36)
HCT <24 1.75(1.59-1.92)
Transfusion during surgery 1.34 (1.07-1.69)
Serum albumin 0.72 (0.62-0.81)
Conclusions: AKI is associated with increased length of hospital stay and mortality. 
Efforts to recognize and intervene in preoperative modifiable factors to prevent AKI will 
improve outcomes in general surgical patients.
FR-PO474
The Comparison of the Incidence of Acute Kidney Injury Post Coronary 
Artery Bypass Graft versus Percutaneous Coronary Intervention: National 
Inpatient Sample Experience  Wen Shen, Fernando Rodrigo Aguilar, 
Alex Montero.  Divsion of Nephrology & Hypertension, Georgetown Univ, 
Washington, DC.
Background: AKI, a common complication after coronary revascularization, is 
associated with increased risk of short-term and long-term mortality, and renal loss. Although 
survival benefit of CABG over PCI was shown in patients with diabetes and congestive 
heart failure, the incidence of AKI post coronary revascularization needs to be considered 
when comparing the risks and benefits of CABG vs PCI.
Methods: We extracted total 485742 cases from National Inpatient Sample (NIS) to 
create a propensity-score matched cohort of patients who had multivessel coronary disease 
and underwent first-time CABG or PCI between 2004-2012. Patients received concomitant 
valvular repair or both CABG and PCI on same admission, history of organ transplant, CKD 
stage IV or ESRD on dialysis were excluded. Both groups were matched for age, gender, 
race, payer, prior MI, unstable angina, heart failure, CVA, stroke or TIA, peripheral arterial 
disease, mitral or aortic valve disease, atrial flutter/fibrillation, ventricular fibrillation or 
tachycardia, CKD, diabetes, HTN, dyslipidemia, smoking, cirrhosis, obesity, anemia and 
in-hospital GI bleeding. The odds ratios were estimated by logistic regression analysis.
Results: The incidence of AKI in CABG group was higher than PCI group (8.41% vs 
4.00%, OR 2.20, 95% CI 2.15-2.25, P< 0.001). The incidences of severe AKI requiring 
RRT were similar in both groups (0.95% vs 0.91%, P=0.147). Compared with PCI group, 
CABG group had higher total in-hospital mortality (1.99% vs 1.48%, OR 1.34, 95% CI 
1.24-1.40, P<0.0001).The in-hospital mortality in patients with AKI was higher in CABG 
(0.92% vs 0.59%, P<0.0001).
Conclusions: Patients received CABG were at higher risk of developing AKI and 
associated with higher total in-hospital mortality. The in-hospital mortality in patients 
with AKI was higher in CABG.
FR-PO475
Dialysis-Requiring Acute Kidney Injury Among Hospitalized Adults 
with Documented Hepatitis C Virus Infection: A Nationwide Inpatient 
Sample Analysis  Girish N. Nadkarni,1 Achint Patel,1 Priya Simoes,1 Rabi 
Yacoub,1 Narender Annapureddy,2 Sunil Kamat,3 Ioannis Konstantinidis,1 Ponni 
Perumalswami,1 Andrea D. Branch,1 Steven G. Coca,1 Christina M. Wyatt.1 
1Mount Sinai Medicine; 2Vanderbilt Univ; 3Kokilaben Dhirubhai Ambani 
Hospital and Medical Research Inst.
Background: Chronic Hepatitis C virus (HCV) infection causes kidney injury,; data on 
acute kidney injury (AKI) epidemiology in HCV are limited. We aimed to describe national 
temporal trends of severe AKI requiring dialysis (“AKI-D”) in hospitalized adults with HCV.
Methods: We extracted our study cohort from the Nationwide Inpatient Sample (NIS) 
of the Healthcare Cost and Utilization Project using data from 2004-2012. We defined HCV 
and AKI-D based on previously validated ICD-9-CM codes. We analyzed temporal changes 
in proportion of hospitalizations complicated by AKI-D and utilized survey multivariable 
logistic regression models to estimate its impact on in-hospital mortality.
Results: We identified a total of 4,603,718 adult hospitalizations with associated HCV 
from 2004-2012, of which 51,434 (1.12%) were complicated by AKI-D. The proportion 
complicated by AKI-D increased significantly from 0.86% in 2004 to 1.28% in 2012. Trend 
was similar when stratified by cirrhosis and paralleled that in HCV negative hospitalizations.
In-hospital mortality was significantly higher in hospitalizations complicated by AKI-D 
vs. those without (27.38% vs. 2.95%; adjusted odds ratio 2.09, 95% Confidence Interval 
1.74-2.51) which remained stable over the study period.
Conclusions: The proportion of HCV hospitalizations complicated by AKI-D increased 
significantly between 2004-2012. Similar to observations in the general population, AKI-D 
was associated with two-fold increase in odds of in-hospital mortality. These results highlight 
the burden of severe AKI in hospitalized adults with HCV infection.
Funding: NIDDK Support
FR-PO476
The Burden of Dialysis Requiring Acute Kidney Injury in Decompensated 
Cirrhosis: A Nationwide Inpatient Sample Analysis  Girish N. Nadkarni,1 
Achint Patel,1 Priya Simoes,1 Rabi Yacoub,1 Ioannis Konstantinidis,1 Sunil 
Kamat,3 Narender Annapureddy,2 Chirag R. Parikh,4 Steven G. Coca.1  1Mount 
Sinai Medicine; 2Vanderbilt Univ; 3Kokilaben Dhirubhai Ambani Hospital; 
4Yale Univ.
Background: Cirrhosis affects nearly 5.5 million patients with an estimated cost 
of 4 billion. Previous studies about dialysis requiring acute kidney injury (AKI-D) in 
decompensated cirrhosis (DC) are from a single center or year. We aimed to describe 
national trends of incidence & impact of AKI-D in DC hospitalizations.
Methods: We extracted our cohort from Nationwide Inpatient Sample (NIS) from 
2006-2012. We identified hospitalizations with DC & AKI-D by validated ICD9 codes. 
We analyzed temporal changes in proportion of DC hospitalizations complicated by 
AKI-D & utilized multivariable logistic regression models to estimate AKI-D impact on 
in-hospital mortality.
Results: We identified a total of 36,55,700 adult DC hospitalizations from 2006-2012 
of which 78,015 (2.1%) had AKI-D. Proportion with AKI-D increased from 1.5% in 2006 
to 2.23% in 2012; this was stable between 2009-12 despite increase in absolute number 
from 6773 to 13930.
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The overall hospital mortality was significantly higher in hospitalizations with 
AKI-D vs. those without (40.87% vs. 6.96%; p<0.001). After adjusting for demographics, 
mortality risk ,acute/chronic comorbidities & hospital level factors, the adjusted odds 
ratio for mortality was 2.17(95% CI 2.06-2.28;p<0.01) with AKI-D, which was stable 
from 2006-2012.
Conclusions: The proportion of DC hospitalizations with AKI-D increased from 
2006-09 & although, this was stable from 2009-12, there was an increase in absolute 
case number. These results elucidate burden of AKI-D on DC hospitalizations & excess 
associated mortality as well as highlight the importance of prevention, early diagnosis & 
testing of novel interventions in this vulnerable population.
Funding: NIDDK Support
FR-PO477
Temporal Trends of Burden of Dialysis Requiring Acute Kidney Injury 
in Cerebrovascular Accident Hospitalizations  Girish N. Nadkarni,1 Achint 
Patel,1 Abhimanyu Mahajan,2 Ioannis Konstantinidis,1 Yuri Ahuja,3 Rabi 
Yacoub,1 Charuhas V. Thakar.4  1Icahn School of Medicine at Mount Sinai; 2Henry 
Ford Hospital; 3Yale Univ; 4Univ of Cincinnati & Cincinnati VA Medical Center.
Background: The epidemiology of dialysis requiring acute kidney injury (AKI-D) 
in acute ischemic stroke(AIS) and intracerebral hemorrhage(ICH) admissions is poorly 
understood with previous studies being from a single center and/or year.
Methods: We used the Nationwide Inpatient Sample to evaluate the yearly incidence 
trends of AKI-D in AIS and ICH admissions from 2002 to 2011. We also evaluated the 
trend of impact of AKI-D on in-hospital mortality and adverse discharge utilizing adjusted 
odds ratios (aOR) after adjusting for demographics and comorbidity indices.
Results: We extracted a total of 3927267 AIS and 704648 ICH admissions, AKI-D 
occurred in 1.5 and 3.5 per 1000 in AIS and ICH admissions respectively. Incidence of 
admissions complicated by AKI-D doubled from 0.9/1000 to 0.1.7/1000 in AIS and from 
2.1/1000 to 4.3/1000 in ICH admissions.
In AIS admissions, AKI-D was associated with 30% higher odds of mortality (aOR 
1.30; 95% CI 1.12-1.48;p<0.001) and 18% higher odds of adverse discharge (aOR 1.18; 
95% CI 1.02-1.37;p<0.001). Similarly, in ICH admissions, dAKI was associated with 
twice the odds of mortality (aOR 1.95; 95% CI 1.61-2.36;p<0.01) and 74% higher odds 
of adverse discharge (aOR 1.74; 95% CI 1.34-2.24;p<0.01).
Conclusions: Incidence of dAKI complicating CVA hospitalizations continues to grow 
and is associated with increased mortality and adverse discharge. This highlights the need 
for early diagnosis and better risk stratification in this vulnerable population.
FR-PO478
Long-Term Healthcare Utilization and Mortality After Acute Kidney 
Injury in Critically Ill Children  Erin Hessey,1 Genevieve Morissette,2 Rami 
Ali,2 Marc Dorais,3 Philippe Jouvet,2 Ana Palijan,1 Veronique Phan,2 Michael 
Pizzi,1 Michael Zappitelli.1  1McGill U, Montreal; 2U de Montreal, Montreal; 
3StatScience, NDIP, Canada.
Background: Acute kidney injury (AKI) is common in the pediatric intensive care 
unit (PICU). The late illness burden of child AKI is unknown. We will evaluate if AKI in 
the PICU is associated with increased mortality and health care service use 5 years after 
discharge.
Methods: Retrospective cohort study of children admitted to two Montreal, Canada 
PICUs, 2003-2005 (N=2500). Exclusions: no health number, deceased in PICU. Clinical 
chart data was merged with provincial administrative health data. AKI (main exposure): 
by Kidney Disease Improving Global Outcomes serum creatinine (SCr) definition (if no 
PICU-SCr drawn, non-AKI was assumed). 5-year outcomes: all-cause mortality; healthcare 
utilization (HCU), defined as the number of hospitalizations, emergency room (ER) and 
physician visits per 100 person years. AKI-outcome relation was evaluated with multivariate 
logistic (mortality) and linear regression (HCU), adjusting for gender, age, cardiac surgery, 
PRISM (mortality) score, vasopressors and infection.
Results: Of 2407 children (mean±SD age=6.0±5.7yrs; PRISM = 8.2±5.9); 56% male; 
448 (18.6%) developed AKI. AKI (yes/no) was associated with mortality in univariate 
(p<0.05) but not multivariate analysis. Stage 2 AKI or worse was associated with 5-year 
mortality (adjusted[adj]OR=1.9, 95% CI= 1.1-3.2). AKI (yes/no) was associated with 
increased 5-year hospitalizations (adj p<0.05) and physician visits (adj p<0.001), but not 
ER visits (adj p=0.8). There was a graded increase in 5-year HCU with higher AKI severity. 
Conclusions: PICU-AKI is associated with long-term increased mortality risk and 
HCU. Research should evaluate cost-effective interventions to improve child AKI treatment 
and evaluate effects on late outcomes.
Funding: Government Support - Non-U.S.
FR-PO479
Acute Kidney Injury: A 12 Month Follow, the Incidence and Mortality 
Hsu pheen Chong, Paul R. Cannon, Caroline J. Whyte, Kottarathil Abraham 
Abraham.  Nephrology, Aintree Univ Hospital, United Kingdom.
Background: Acute Kidney Injury (AKI) affects nearly 1 in 5 hospital admission. It 
carries a poor prognosis with mortality ranging from 10-80% dependent on the population 
studied. Aintree University Hospital caters to about a population of 506,000 in North 
Liverpool. An observational study was carried out in this catchment area to ascertain the 
incidence of AKI, the length of stay and its effect on 12 months mortality.
Methods: Patients who were admitted between the time periods of August 2012 until 
January 2013 were included in this study. Liaising with the biochemistry department, 
all patients who had a rise in their creatinine based on the Acute Kidney Injury Network 
Criteria received an e-alert sign on the computer system. Clinical outcomes were obtained 
from each patient record.
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Results: There were a total of 36,957 patients admitted during that 6 month time period 
of which a total of 358 cases of AKI were identified. There was total of 183 male patients 
and 171 female patients. Four of the male patients had a further AKI alert during the same 
hospital admission. The mean age was 72.18 years. Pre-renal causes were identified as 
the main contributors to the cases. Majority of the AKI alerts were Stage 1 AKI which 
was 70%, Stage 2 AKI was 25% and Stage 3 AKI was 5 % of the total cases. The data 
also revealed that the average length of stay (ALOS) did not differ in each of the stage. A 
patient ALOS for Stage 1 AKI 23.3 days, Stage 2 AKI 24 days and Stage 1 AKI 21 days. 
Of the total number of cases of patients with AKI, 50.6% (179/354) of the patients had died 
within the 12 months period. Looking into the mortality rate of each individual stages of 
AKI; the mortality rate at 12 months for Stage 1 AKI is 46.5%. For Stage 2 AKI, 62.7% 
and for Stage 3 AKI, 47.6%.
Conclusions: From the date collected, it shows that the degree of AKI does not affect 
the length of stay of patients. Despite the different stages of AKI indicating the severity 
of the injury, mortality rate for Stage 1 and Stage 3 did not differ. This indicates that AKI 
carries a high mortality rate regardless of the severity of the injury. Early recognition leads 
to early intervention in the prevention of AKI.
FR-PO480
Acute Kidney Injury: Adding Informatics to Injury – (Electronic Injury 
Alerts)  Conor Patrick Moran,1 Ying C. Kuan,1 Patrick Lm Lynch,2 Francis 
Mccarroll.1  1Dept of Nephrology, Altnagelvin Hospital, Londonderry, United 
Kingdom; 2Dept of Clinical Chemistry, Altnagelvin Hospital, Londonderry, 
United Kingdom.
Background: Acute Kidney Injury, (AKI), is common with a variably reported 
mortality, (15-60%). UK national audit reported that up to 30% of cases were avoidable 
and that as much as 43-61% of post-admission AKI experienced an unacceptable delay in 
recognition of insult. There has been a paucity of work with regards to AKI recognition and 
prevention. National guidelines have recommended the use of electronic alerts (e-alerts) 
for AKI detection.
Methods: We introduced AKI e-alerts with accompanying electronic guidance in late 
October 2014 and prospectively collected data on the patients identified with severe AKI. 
Data collection was carried out for 3 months, (n=110). The demographics of this cohort 
were compared with a historical cohort of severe AKI (n=89).
Results: Mean age, (72 years vs. 73 years), gender distribution, (M:F: 46% / 54% vs. 
47% / 53%), and median time to death, (10 days vs. 9 days), were comparable. Thirty day 
mortality was similar with regards to hospital acquired AKI, (27.3 % vs. 26.1%). 30 day 
mortality was significantly lower for community-acquired AKI: (10.7%). Mean and median 
age was demonstrated to be higher in the group of patient who died, (Mean: 80.1 years vs. 
75.7 years), (Median: 82 years vs. 82 years) – negative skew due to outliers.
Conclusions: Although our initial data suggests an electronic AKI alert has no 
discernable effect on 30 day mortality rate and time to death. We feel that e-alerts with the 
addition of further Quality Improvement work will eventually result in a steady reduction 
in AKI mortality.
FR-PO481
Tenofovir Nephrotoxicity Is an Important Cause of Acute Kidney Injury 
in HIV Infected Inpatients  Teg Marcos Veiga, Adriana Belo Prazeres, Daiane 
Silva, Gisele Vajgel Fernandes, Geraldo Jose de Amorim, Luis H.B.C. Sette, 
Lucila Maria Valente.  Nephrology, Univ Federal de Pernambuco, Recife, 
Pernambuco, Brazil.
Background: Tenofovir disoproxil fumarate (TFD) is widely prescribed as a first 
choice therapy for HIV infection, because of its convenient dosing schedule, efficacy and 
relatively low side effects. However, renal toxicity may lead to acute kidney injury (AKI), 
chronic kidney disease (CKD), and proximal tubular injury. Here we describe clinical 
characteristics and outcomes of AKI associated to TDF.
Methods: In a retrospective cohort (between Mar/2011 to Feb/2015), we have described 
data of HIV-infected inpatients, in a single center infectious disease ward, referred to the 
Nephrology group due to AKI. AKI was defined according to AKIN criteria.
Results: During the study period, 72 patients were evaluated; the baseline 
characteristics are showed in table1. Nephrotoxic AKI was present in 36 cases, of which 
19 cases (52%) were associated withTFD and the drug was withdrawn in all cases. Seven 
patients had TFD nephrotoxicity without other associated factors and only three patients 
achieved renal function recovery, but no one needed dialysis or died during follow up.
Parameters N=19
Age 41.3 ± 11.3
Male 11 (58%)
Charlson Comorbidity Index 8
SCr baseline (mg/dL) 0.89
SCr at referral (mg/dL) 3.35
AKIN
1
2
3
4 (21.0%)
3 (15.8%)
11 (58%)
Use of other nephrotoxic drug 6 (31.6%)
UCI admission 5 (26.3%)
Follow up (days) 19.3
Hemodialysis 7 (36.8%)
Renal function recovery* 8 (42%)
Mortality
Hemorrhagic shock
4 (21.0%)
1 (25.0%)
Sepsis 3 (75.0%)
* Definied as recovery to baseline SCr ± 25% 
Conclusions: AKI associated to TFD nephrotoxicity was very prevalent in the HIV 
infected inpatients and showed high morbidity, including almost a third of patients requiring 
dialysis and more than a half not recovering renal function after withdrawing the drug.
FR-PO482
Cisplatin-Associated Nephrotoxicity: Not as Frequent as Previously 
Reported  Shveta S. Motwani, Sushrut S. Waikar, Benjamin D. Humphreys, 
Gary C. Curhan.  Nephrology, Brigham and Women’s Hospital, Boston, MA.
Background: Cisplatin-associated nephrotoxicity (CaN) is a frequent problem amongst 
patients with various cancers. Most older studies have reported 25-30% of patients who 
receive cisplatin experience acute kidney injury. However, these data have not been re-
evaluated systematically recently despite rapid advances in oncologic care. Therefore, we 
examined the proportion of patients who develop acute kidney injury after exposure to 
the first cycle of cisplatin in a large patient database. We also examined the frequency of 
kidney injury stratified by sex and cisplatin dose regardless of cancer type.
Methods: We collected data on patients ≥ 18 years of age who had received cisplatin 
as a primary, secondary or adjuvant or neo-adjuvant therapy at a tertiary-care medical 
center (Massachusetts General Hospital) between 2006 and 2014. Detailed data regarding 
cisplatin dose, demographic characteristics, concurrent medical history and laboratory data 
including serum creatinine (Cr) and electrolytes were collected. CaN was defined as an 
elevation of Cr by ≥ 0.3 mg/dl during a 14 day period after administration of cisplatin (peak 
Cr)compared with baseline (bl Cr). Patients with bl Cr of >1.5 were excluded.
Results: Of the 1979 patients in our study, 55% were male with a mean ± SD of age of 
61.6 ± 12.8, A bl Cr was 0.9 ± 0.2. 241 of 1979 (12.2%) patients developed CaN. However, 
it ranged from 7.8% in the medium dose group (cisplatin dose 75-130 mg) to 18.2% in the 
high dose group (>130mg) without a clear dose response relation.
In addition, a significantly lower frequency of CaN was noted amongst females 
compared with males (9.3% vs 14.5%, p<0.001).
Conclusions: Cisplatin-associated nephrotoxicity occurs less frequently than previously 
reported. This may reflect changes in preventive care such as more aggressive hydration 
with electrolyte-rich solutions.
Funding: Other NIH Support - T32 training grant
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FR-PO483
Characteristics of 681 Patients with Atypical Hemolytic Uremic Syndrome 
in the Global aHUS Registry  Christoph Licht,1 Gianluigi Ardissino,2 Gema 
Ariceta,3 David J. Cohen,4 Christoph Gasteyger,5 Larry A. Greenbaum,6 Sally A. 
Johnson,7 Masayo Ogawa,8 Varant Kupelian,8 Franz S. Schaefer,9 Johan Vande 
Walle,10 Veronique Fremeaux-bacchi.11  1The Hospital for Sick Children, ON, 
Canada; 2Fondazzione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milan, Italy; 3Hospital Univ Vall d’Hebron, Barcelona, Spain; 4Columbia 
Univ Medical Center, NY, NY; 5Alexion Pharma International Sarl, Lausanne, 
Switzerland; 6Emory Univ, Atlanta, GA; 7Great North Children’s Hospital, 
Newcastle, United Kingdom; 8Alexion Pharmaceuticals, Inc., Cheshire, CT; 
9Heidelberg Univ Hospital, Heidelberg, Germany; 10Univ Hospital Ghent, 
Ghent, Belgium; 11Assistance Publique, Paris, France.
Background: The observational atypical hemolytic uremic syndrome (aHUS) 
Registry collects patient (pt) information and facilitates availability of follow-up data for 
eculizumab (ECU).
Methods: Pts with clinical diagnoses of aHUS (irrespective of identified complement 
abnormality or treatment) are eligible. Demographic, medical/disease history, and treatment 
outcomes data are collected at enrollment and prospectively.
Results: By January 30, 2015, 681 pts enrolled (Table); 62.7% of adults were women. 
Thrombosis occurred more frequently in adults than pediatric pts. Nonrenal comorbid 
conditions occurred in both age groups. ECU was administered to 56.2% (87.7% prior 
to enrollment).
Conclusions: Registry baseline characteristics show differences between pediatric and 
adult aHUS pts, notably different frequencies of thrombosis. Ongoing and future analyses 
will further enhance understanding of aHUS history and progression. Medical writing 
support - Kristen W. Quinn, PhD, of Peloton Advantage, funded by Alexion 
Funding: Pharmaceutical Company Support - Alexion Pharmaceuticals, Inc.
FR-PO484
Long-Term Renal Function After Recovery from Dialysis-Requiring Acute 
Kidney Injury  Sokratis Stoumpos, Colin C. Geddes.  Renal and Transplant 
Unit, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.
Background: Current guidelines suggest that people should be monitored for the 
development of chronic kidney disease (CKD) for at least 2-3 years after acute kidney 
injury (AKI), even if serum creatinine has returned to baseline. The aim of this study 
was to determine the long-term renal outcome of patients experiencing AKI secondary 
to hypoperfusion injury and/or sepsis who recovered to apparently normal renal function.
Methods: We conducted a population-based cohort study of all adult patients in our 
catchment area (serving a population of approximately 1.5 million), with AKI who required 
in-hospital dialysis in the nephrology unit, survived for at least 12 months after discharge 
and had estimated glomerular filtration rates (eGFR) greater than 60mL/min 1 year after the 
episode of AKI between September 1, 1989, and March 5, 2015. Patients with underlying 
nephropathy and AKI due to causes other than hypoperfusion injury and/or sepsis were 
excluded. Follow up was censored to the date of the last serum creatinine recorded.
Results: From the 770 patients identified with dialysis-requiring AKI, 310 patients 
met the study inclusion criteria. Mean age at time of AKI was 49.0 (SD 16.4) years, 58.7% 
were male and the median duration of haemodialysis was 6 (IQR 3-11) days. After a median 
follow-up of 7.3 (IQR 4.6-12.6) years from first dialysis for AKI, eGFR was >60mL/min in 
285 (91.9%) patients, 45-59mL/min in 18 (5.8%), 30-44mL/min in 6 (1.9%) and 15-29mL/
min in 1 (0.3%) patient. None of the patients developed CKD stage 5 or end stage renal 
disease. 86 (27.7%) patients died during the duration of follow-up.
Conclusions: The excellent outcome for patients with normal renal function 1 year 
after an episode of dialysis-requiring AKI suggests that these patients are unlikely to derive 
benefit from life-long follow up of kidney function after AKI.
FR-PO485
Use of ACEIs and ARBs in Patients with Chronic Kidney Disease and 
Superimposed Community-Acquired Acute Kidney Injury  Patrick Saudan,1 
Cyrielle Alves,2 Fabien Stucker,3 Belen Ponte,1 Pierre-Yves F. Martin,1 Thomas 
Perneger,4 Sebastian Carballo.2  1Nephrology Unit, Depatment of Medical 
Specialties, Geneva Univ Hospitals, Geneva, Switzerland; 2Dept of General 
Internal Medicine, Geneva Univ Hospitals, Geneva, Switzerland; 3Nephrology 
Unit, Hôpital de la Providence, Neuchatel, Switzerland; 4Clinical Epidemiology 
Unit, Geneva Univ Hospitals, Geneva, Switzerland.
Background: Due to their long-term nephroprotective effect, ARBs and ACEIs 
are often used in patients with CKD despite their association with an increased risk of 
superimposed AKI. We aimed to better define its occurrence in relation to their use.
Methods: We undertook a prospective observational study within the Emergency 
Department, screening for any patient > 16 years admitted with an eGFR < 60 ml/mn. 
Patients with CKD (previously known for an eGFR < 60 ml/mn) were included and 
superimposed AKI was defined as a decline in eGFR compared to previous values according 
to KDIGO AKI criteria.
Results: From May 1st up to June 21st 2013, there were 8464 admissions of whom 
361 (4%) had a eGFR < 60 ml/mn and were known to have CKD. Use of ACEIs, ARBs, 
diuretics, NSAIDs was respectively found in 19, 23, 37 and 4 % of patients. AKI was 
superimposed in 102 (28%) CKD patients. Etiology was prerenal (73%), renal (17%) and 
postrenal (9%).Stage I/II/III AKI were 87, 5 and 8% respectively. One year survival rates 
were 81 and 78 % (p=0.62) in patients with stable CKD and those with superimposed 
community-acquired AKI. Multiple logistic analysis showed that its occurrence was 
associated with male gender (OR 2.03; 95%CI:1.23-3.35, p=0.005), diuretic use (OR 1.61; 
95%CI:1-2.60, p=0.05) and ARBs use (OR 1.61; 95%CI:1-2.60, p=0.05). ACEIs use was 
found to be slightly nephroprotective (OR 0.49; 95%CI:0.25-0.96, p=0.04).
Conclusions: Mild community-acquired superimposed AKI in CKD patients does not 
seem to increase one year-mortality and is more frequently encountered in male patients 
and those treated with diuretics and ARBs, but not ACEIs. Although their impact on renal 
hemodynamics is supposed to be similar, further studies should be implemented in CKD 
patients to examine whether ARBs are more detrimental than ACEIs in terms of risk of 
superimposed AKI.
FR-PO486
Renal and Patient Outcomes of Dialysis Dependent Patients with ATN Who 
Survive Hospitalization  Mohammad Alhaji, Rabeeh I. El-refadi, Jerry Yee, 
Bronwyn Larissa Small, Javier Rodriguez Sanchez, Jian Li, Lenar T. Yessayan. 
Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI.
Background: Acute tubular necrosis (ATN) accounts for the majority cases of acute 
kidney injury (AKI) in critical care units. The in-hospital mortality rate of dialysis requiring 
ATN in critically ill patients exceeds 50%. However, renal and patient outcomes among 
dialysis dependent patients with ATN who survive the hospitalization are lacking. 
Objective: To determine 90 day renal recovery and mortality rates, 1 year cardiovascular 
and hospital readmission rates of patients with ATN discharged on hemodialysis.
Methods: We prospectively enrolled 38 Medicare beneficiaries who developed 
hemodialysis-dependent ATN and survived to discharge at a single center from January 1, 
2013 to June 30, 2014. The ATN was identified by urine microscopy and clinical judgment. 
ATN causes, patients’ comorbid conditions, potential contributors to ATN and indications 
for RRT were recorded. Cumulative hazard estimates of events and survival curves were 
generated using the Kaplan-Meier method.
Results: Twenty six patients (38%) had CKD, 18 had diabetes (47%), 29 had 
hypertension (76%), 10 had history of liver disease (26%).The 90 day renal recovery and 
mortality rates were 42% and 11% respectively. Of those who recovered kidney function, 
Only 1 patient recovered kidney function beyond 60 days. The 1 year cardiovascular event 
rates and readmission rates were 22% and 62% respectively.
Conclusions: Patient with dialysis dependent ATN following a hospitalization are 
unlikely to get off dialysis support beyond 60 days after discharge. In the first year post 
discharge, they experience a significant number of cardiovascular events and hospital 
readmissions. Identifying modifiable risk factors for readmission in this cohort may reduce 
health care costs.
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FR-PO487
Long-Term Follow-Up of Children with STEC-HUS Caused by 
E. coli O104:H4 (German HUS Outbreak 2011): A GPN Registry 
Markus J. Kemper,1 Wiebke Aulbert,1 Thurid Ahlenstiel-Grunow,2 Brigitta 
Kranz,3 Jun Oh.1  1Pediatric Nephrology, Univ Medical Center Hamburg-
Eppendorf, Hamburg, Germany; 2Pediatric Nephrology, Medizinische 
Hochschule, Hannover, Germany; 3Pediatric Nephrology, Univ Hospital, 
Münster, Germany.
Background: In 2011 E. coli O104:H4 caused the largest outbreak of HUS in adults 
and children. A total of 90 children were affected, of whom 64 (71%) required dialysis 
for a median of 11 days.
Methods: Currently follow-up data are available from 60 of 90 children (67%, 31 
girls) from 11 pediatric centers in Germany. Median follow-up is 2.7 (range 1.2-3.6) years, 
median current age of patients is 14.7 (3.4-18.7) years.
Results: Median current serum-creatinine is 0.7 (0.3-8.9) mg/dl. In two patients 
(2.2%) with CKD stage 3 and 4 at discharge GFR improved and they are now in CKD 
Stage 2. One patient remained dialysis dependent initially and one reached ESRD after 
3.5 years; both underwent successful living-related kidney transplantation. All these 4 
patients were treated with eculizumab in the initial phase of STEC-HUS including 2 who 
also received plasmapheresis. Proteinuria is currently present in 17 (19%) patients and 
9 (10%) require treatment for hypertension. Three patients have neurologic symptoms 
(headache, performance deficit, spastic movement disorder) and 3 patients have EEG 
abnormalities without symptoms.
Conclusions: Long-term follow-up is important after O104:H4 associated STEC-
HUS. CKD stage 3-5 at discharge is a risk factor for ESRD, however some children show 
a significant improvement over time. Patients with proteinuria and hypertension need 
long-term follow-up. Follow-up studies after STEC HUS should include neurological 
investigations.
FR-PO488
SOFA Scores as Predictors of Mortality and Dialysis Dependency in 
Acute Kidney Injury  V. Shane Pankratz,1 Christos Argyropoulos,1 Khaled 
Abdel-Kader,2 Kelly V. Liang,3 Paul M. Palevsky,3 Mark L. Unruh.1  1Dept of 
Internal Medicine, Div of Nephrology, Univ of New Mexico School of Medicine, 
Albuquerque, NM; 2Dept of Medicine, Div of Nephrology and Hypertension, 
Vanderbilt Univ School of Medicine, Nashville, TN; 3Dept of Medicine, Renal-
Electrolyte Div, Univ of Pittsburgh School of Medicine, Pittsburgh, PA.
Background: The Sequential Organ Failure Assessment (SOFA) score measures the 
severity of organ failure, and baseline SOFA scores have been used to predict mortality 
in patients with Acute Kidney Injury (AKI). We evaluated whether SOFA scores, either 
upon initiation of dialysis or clinically updated, predict mortality and dialysis dependency 
following AKI.
Methods: Data from patients enrolled in the Acute Renal Failure Trial Network (ATN) 
study, a randomized multicenter trial of the intensity of renal support in AKI, were used in 
Cox proportional hazards regression and multinomial logistic models to assess the degree 
to which SOFA scores predict mortality and dialysis dependency.
Odds Ratio(95% Confidence Interval) 
Endpoint Day 28 Day 60 1-year
Death 1.23(1.18-1.28) 1.20(1.15-1.24) 1.17(1.13-1.21)
Dialysis Dependency 0.92(0.89-0.96) 0.91(0.87-0.96) 0.87(0.79-0.95)
Results: SOFA scores were associated with increased mortality risk following 
AKI among the 1,124 ATN participants, but the concordance statistic was low, at 0.651 
(standard error [se]=0.014). When time-dependent analyses were used to take advantage of 
prospectively updated SOFA scores, the concordance statistic increased to 0.753 (se=0.013). 
In analyses that examined mortality and dialysis dependency as competing outcomes at 
three fixed time points, increased SOFA scores were associated with higher mortality risk, 
and lower risk of dialysis dependency.
Conclusions: Similar to the general ICU population, updated SOFA scores better 
prognosticate the risk of death in patients with AKI. Higher SOFA scores are associated with 
increased mortality risk, but decreased dialysis dependency risk, when the two outcomes 
are evaluated as competing risks. Future studies should focus on prognostic tools that 
simultaneously prognosticate survival and need for dialysis in AKI patients.
Funding: Private Foundation Support
FR-PO489
Risk Factors of Acute Kidney Injury and In-Hospital Mortality in Adult 
Patients Receiving ExtraCorporeal Membrane Oxygenation (ECMO) 
Sung Woo Lee,1 Seon Ha Baek,1 Jae Yoon Park,2 Shin-Young Ahn,1 Sejoong 
Kim,1 Ho Jun Chin,1 Dong-Wan Chae,1 Ki Young Na.1  1Seoul National Univ 
Bundang Hospital; 2Seoul National Univ Hospital.
Background: Although acute kidney injury (AKI) is the most frequent complication in 
patients receiving extracorporeal membrane oxygenation (ECMO), little has been studied 
about the risk factors of AKI and in-hospital mortality. Thus we performed the study to 
identify factors associated with AKI and in-hospital mortality.
Methods: We analyzed 322 adult patients receiving ECMO from January 2005 to 
November 2014 in two tertiary care hospitals. AKI and its stages were defined by Kidney 
Disease Improving Global Outcomes classifications. Variables within 24 h before ECMO 
initiation were collected and analyzed for the association with AKI and in-hospital mortality.
Results: Stage 3 AKI was associated with in-hospital mortality with HR (95% CI) of 
2.690 (1.410-5.132), compared to no AKI (p=0.003). Simplified acute physiology score 
2 was also significantly associated with in-hospital mortality with HR (95% CI) of 1.022 
(1.004-1.040) with every 1 score increase (p=0.014). Initial pump speed of ECMO was 
significantly related to in-hospital mortality with HR (95% CI) of 1.397 (1.024-1.904) with 
every 1000 rpm increase (p=0.035). The pump speed was also significantly associated 
with total AKI (p=0.035) and stage 3 AKI (p=0.044) with ORs (95% CI) of 2.219 (1.059-
44.652) and 1.676 (1.015-2.770), respectively. We also found that red cell distribution 
width (RDW), serum level of total bilirubin, and the duration of ECMO were significantly 
related to AKI and/or stage 3 AKI.
Conclusions: Initial pump speed was significant risk factor of in-hospital mortality 
and AKI in patients receiving ECMO. RDW, serum level of total bilirubin and the duration 
of ECMO were risk factors of AKI.
FR-PO490
Comparison of Clinical Characteristics of Patients with Acute Kidney 
Injury After Intravenous versus Inhaled Colistin Therapy  Hyunju Yoon, In 
O Sun, Kwang Young Lee, A young Cho.  Div of Nephrology, Dept of Internal 
Medicine, Presbyterian Medical Center, Jeonju, Jeonbuk, Republic of Korea.
Background: The aim of this study is to investigate the incidence and clinical 
characteristics of intravenous or inhaled colistin associated acute kidney injury (AKI) 
using the RIFLE criteria.
Methods: From 2010 to 2014, 160 patients were treated with intravenous or inhaled 
colistin. Of these, we included 139 patients who received colistin for >72 h, and compared 
the incidence and clinical characteristics of patients in the intravenous (n=120) and inhaled 
(n=19) groups.
Results: The patients included 116 men and 23 women, with a mean age of 68 years 
(range, 20-91). Patients were infected with either A. baumannii (54%) or P. aeruginosa 46 
(%), and pneumonia (91%) was the most common type of infection. The mortality rate was 
43.9%, and AKI occurred in 83 (60%) patients. At the end of therapy, bacteriologic cure rate 
was 64%. There were no differences in the clinical characteristics between the intravenous 
and inhaled groups except for age. In comparison with patients in the intravenous group, the 
patients in the inhaled group were older (74 ± 8 vs 67 ± 14 years, p=0.03). The incidence 
of AKI was not different between the two groups (62% vs 47%, p=NS), and there was no 
difference in the severity of AKI according to the RIFLE criteria. Of the 83 patients with 
AKI, 8 and 1 patients underwent renal replacement therapy.
Conclusions: In our study, the incidence of AKI in patients undergoing colistin therapy 
was 60%, and there was no difference in safety between the intravenous and inhaled colistin 
groups. Therefore, it is also important to monitor renal function during colistin therapy 
regardless of the route of administration.
FR-PO491
Acute Kidney Injury following Coronary Angiography  Dadi Helgason,1 Þórir 
E. Long,1 Gisli H. Sigurdsson,2 Martin I. Sigurdsson,3 Olafur S. Indridason.4 
1Dept of Medicine; 2Deparment of Anesthesia, Landspitali; 3Dept of Anesthesia, 
Brigham and Women´s Hospital, Boston, MA; 4Div of Nephrology, Landspitali 
- The National Univ Hospital of Iceland, Reykjavik, Iceland.
Background: Acute kidney injury (AKI) is a known complication of coronary 
angiography (CA). The aim was to study the incidence, risk factors and outcome of AKI 
following CA in a whole nation.
Methods: This was a retrospective analysis of data from all CA in Iceland during 
a 9 year period. AKI was diagnosed according to the creatinine based KDIGO criteria 
and survival status for all patients was verified at Statistics Iceland. The epidemiology 
and clinical outcomes were compared between three 3-year periods using Chi-squared 
and Kaplan Meier method, and multivariate logistic regression was performed to find 
predictors of AKI.
Results: From Jan 1st 2005 to Dec 31st 2013 10713 patients underwent 13890 CA of 
whom 40% entailed an intervention. Median (range) age was 65 (19-96) years and 70.7% 
were men. AKI was diagnosed in 214 patients (1.5%); 168 (1.2%), 27(0.2%) and 19 (0.1%) 
of stage 1, 2 and 3, respectively. There was a trend towards a decreasing incidence of AKI: 
1.8% in the first 3 year period, 1.3% in the second and 1.4% in the last (p=0.05). AKI was 
more common in the intervention group, 2.2% vs. 1.1% (p<0.0001). Patients with AKI were 
older, had more often prior history of AKI, more co-morbid diseases and lower baseline 
eGFR compared to non-AKI patients. In multivariate analyses age over 70 years (OR=1.01, 
95% CI= 1.007-1.016), angiography with intervention (OR=1.01, 95% CI=1.008-1.016) 
COPD (OR=1.01, 95% CI =1.003-1.025), liver disease (OR=1.03, 95% CI=1.014-1.058) 
baseline eGFR<60 (OR=1.03 95% CI 1.027-1.039) and a prior history of AKI (OR=1.07, 
95% CI= 1.051-1.080) were independent predictors of AKI after CA. One year survival 
of AKI patients did not differ between time periods: 67.0%, 63.1% and 69.0% in the first, 
second and third, respectively, p=0.3).
Conclusions: There is a trend towards a decrease in AKI incidence following CA in 
recent years. Aged patients with multiple co-morbidities and prior history of AKI need 
special attention in connection with this this procedure.
Funding: Private Foundation Support
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FR-PO492
Acute Kidney Injury in the First Hundred Days After Hematopoietic Stem 
Cell Transplantation: Experience with 222 Transplanted Patients in a Single 
Center  Miguel A. Solis, Sandra Tejedor, Isidro Torregrosa, Carmen Ramos, 
Isabel Juan, Patricia Tomas, Patricia Zambrano Esteves, Juan José Guzmán 
Herrera, Maria Jesus Puchades, Alfonso M. Carrasco.  Nephrology, Univ Clinic 
Hospital, Valencia, Spain.
Background: Hematopoietic stem cell transplantation recipients are at an increased 
risk of Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD). An earlier diagnosis 
could dramatically improve the patients’ prognosis. Objective. To analyze the incidence 
of AKI in the first 100 days of Hematopoietic stem cell transplantation recipients and the 
relationship with mortality.
Methods: We carried out a retrospective study including 222 adult patients who 
underwent Hematopoietic stem cell transplantation between 2006 and 2010 at our institution. 
AKI was defined using the RIFLE criteria in the first 100 days after transplantation.
Results: 222 patients were included in the study, 137 males and 85 females. Median 
follow-up was 30 months, range 1-60 months. In the first 100 days after transplantation 
AKI developed in 78 patients according to the RIFLE criteria (35.1%). A total of 85 patients 
died during follow-up vs 47 who had developed AKI (38,2% versus 61%, p<0.05).Detailed 
patients´characteristics are summarized in table 1.
Sex Male: 137.Female: 85
Median Age, years. 48.9,SD 13.43.
Type of transplantation.
Autologus: 117 (52.7%)
Allogeneic: 105 (47.3%) 
ablative: 57 (25.7%)
non ablative (miniAlo): 48 (21.6%)
Previous transplantation. 37(16.7%)
Follow-up, months. 30, range 1 to 60.
AKI. RIFLE criteria.
78 (35.1%)
R 36 (16.2%)
I 30 (13.5%)
F 9 (4.1%)
AKI in Type of Transplantation.
Autologus: 11.1%
Allogeneic: 59.6%
miniAllo: 66.7%
Overall Mortality 85 (38.2%)
Mortality in AKI. 47 (61%)
Conclusions: AKI incidence in hematopoietic stem cell transplantation recipients is 
very high. There is a statistically significant relationship between AKI and death in these 
patients. Earlier AKI identification could prevent kidney damage progression and improve 
patient outcome over time.
FR-PO493
STOP-Acute Kidney Injury (AKI): A Streamline Approach to the 
Management AKI Leads to Reduction of Mortality Rates  Hsu pheen Chong, 
Thangavelu Chandrasekar.  Nephrology, Aintree Univ Hospital, United Kingdom.
Background: Acute Kidney Injury (AKI) has a mortality rate of 30%, greater than 
common conditions such as myocardial infarction (8%) and stroke (9%). It is estimated 
that 15% of all inpatients at University Hospital Aintree (UHA), Liverpool, UK, suffer 
an AKI making it a condition of considerable importance in everyday practice. Through 
clinical audit, it was found that mortality rate of AKI in UHA was 33% on wards other 
than renal ward (9%).
Methods: To reduce AKI mortality by 30% and length of stay by 20% over a 12 
month period from Oct 2013 using standardised, evidence based approach. Using plan, do, 
study act (PDSA) methodology, we developed and tested an automated e-alert diagnostics 
system, an AKI treatment bundle and a patient information leaflet. The STOP-AKI project 
was launched. Our Primary drivers were early and accurate identification of AKI, effective 
intervention and monitoring, staff and patient engagement. Initially, trialled at ward level, 
the project was scaled up to admission areas (Accident and Emergency Department and the 
Medical Assessment Unit) becoming part of routine management for all admitted patients.
Results: Fall in mortality rates from a baseline of 24% to 18.5 %, representing an 
overall reduction in mortality of 23%. Length of stay fell by 11% equating in a 2.0 day 
reduction in length of stay.
Conclusions: The STOP-AKI project led to the development of an AKI bundle in Oct 
2013. This has achieved not only a significant reduction in patient mortality and length of 
stay but in addition a more structured and stream lined way of approaching the patients 
with AKI in our hospital. With the bundle being rolled out to primary care and the rest of 
our inpatient wards, we anticipate a further reduction in mortality.
FR-PO494
Race and Risk of Acute Kidney Injury (AKI) in VA Patients  Michael Heung,1 
Diane Steffick,1 Deidra C. Crews,2 Neil R. Powe,3 Sharon Saydah,4 Meda E. 
Pavkov,4 Kara Zivin,1,5 Rajiv Saran.1  1Univ of Michigan; 2Johns Hopkins Univ; 
3Univ of California San Francisco; 4Centers for Disease Conrol and Prevention; 
5VA Ann Arbor Health System.
Background: African Americans (AA) are at increased risk for AKI compared 
to Caucasians (C); potential explanations include differences in risk factors, genetic 
susceptibility and socioeconomic factors. We explored the influence of race on AKI risk 
in the Veterans Administration (VA), an integrated healthcare system.
Methods: Retrospective cohort analysis of all hospitalizations for VA patients with 
known AA or C race in 2011. AKI was defined by KDIGO criteria (>= 0.3mg/dL increase 
in serum creatinine from pre-admission baseline). Modified Poisson regression models 
estimated the effect of AA race on risk of AKI, adjusting for age, sex, baseline eGFR, 
comorbidities (DM, HTN, coronary heart disease,CHD; CHF), geographic region and 
severity of illness during hospitalization. Additional models including albuminuria were 
run for those with available data.
Results: We identified 180,429 VA hospitalizations. Compared to C, AA had higher 
prevalence of DM (43.1% v. 41.1%, P<.001), lower prevalence of CHD (45.7% v. 58.8%, 
p<.001), lower Charlson comorbidity scores (1.4 v. 1.6, p<.001) and higher baseline eGFR 
(89.2 v. 81.7, p<.001). AKI occurred in 19.5% of admissions (35,134) involving 23.2% 
of AA and 18.5% of C. In adjusted models, AA race remained an independent risk factor 
for AKI (RR 1.26, 95% CI 1.24-1.28). In the subgroup with albuminuria data (40,668), 
the risk was slightly attenuated (RR 1.20, 95% CI 1.16-1.24). A similar increased risk of 
hospital-acquired AKI in AA compared to C (RR 1.19, 95% CI 1.15-1.23) was found.
Conclusions: Although AA Veterans had higher baseline eGFR and lower comorbidity 
scores compared to C, AA had an increased risk of developing AKI, even after accounting for 
differences in risk factors & geographic region. This increased risk for AKI in AA persisted 
when examining AKI that developed during hospitalization. Given that VA patients have 
similar healthcare access and benefits, our results suggest that the increased AKI risk seen 
in AA is unlikely to be fully accounted for by disparities in access to care.
Funding: Other NIH Support - Centers for Disease Control and Prevention, Veterans 
Administration Support
FR-PO495
Mortality Risk Factors in Mexican Patients with Acute Kidney Injury 
Luis Alberto Evangelista-Carrillo,1 Enrique Rojas-Campos,2 Salvador 
Mendoza Cabrera,1 Benjamin Gomez-Navarro.1  1Nefrologia y Trasplantes, 
IMSS, Guadalajara, Jalisco, Mexico; 2Unidad Médica de Investigación en 
Enfermedades Renales, IMSS, Guadalajara, Jalisco, Mexico.
Background: Acute Kidney injury (AKI) data in Latin American is scarce.
Methods: Aim: To determine patient survival, mortality risk factors and treatment in 
AKI patients from a tertiary hospital. Methods: Prospective cohort Dic 2010-2012 of 275 
patients with AKI whom need Nephrology consultation. Recollected data at admission, 
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Nephrologists consultation and 30 days follow up included demographics and biochemical 
variables, time between AKI onset and Nephrology consultation, fluid balance, mortality 
scale, treatment and date of death or patient discharge.
Results: The overall mortality was 49%. Mean age 58 years. The principal diagnosis at 
admission was coronary syndrome. The AKI at the moment of consultation was 3 in the 64%. 
VARIABLE CONSERVATIVE HEMODIALYSIS CRRT
Age (mean) 60.8± 17.7‡ 53.1± 19.1 58.3± 16.7
Nephrology 
consultation 
(time since first 
creatinine increase 
hours)
50.5± 48.9 71.7± 69.8 61.3± 83.5
Mortality (%) 38 52.9 72 
24 hrs uresis (L) 2.1±1.4 ‡ 1.2±1.4 1.4±1.2
Fluid gain 3.1±4.4 ‡ 4.5±4.8 6.6±6.2
Base creatinine 
(mg/dl) 0.96±0.26 1.01±0.35 1.02±0.30
Creatinine at 
nephrology 
consultation
2.98±2.04 ‡ 4.97±3.21 2.92±1.72
APACHE II 19±6‡ 20±5 24±5
‡p<0.05 
Difference in characteristics accord therapy. 
Mortality predicted analysis.
Conclusions: This is the first report of epidemiology of AKI in Mexico. The 
conservative treatment is associated with mortality. The consultation with nephrology 
was late. Use of diuretic, vasopressor and uresis less than 1 liter per day at the nephrology 
consultation time were associated with mortality.
FR-PO496
Cast Nephropathy versus Acute Tubular Necrosis in Newly Diagnosed 
Multiple Myeloma: A Comparative Study  Insara Jaffer Sathick,1 Samih H. 
Nasr,2 Nelson Leung.1,3  1Div of Nephrology and Hypertension, Mayo Clinic, 
Rochester, MN; 2Div of Anatomic Pathology, Mayo Clinic; 3Div of Hematology, 
Mayo Clinic, Rochester, MN.
Background: Myeloma cast nephropathy (MCN) and acute tubular necrosis (ATN) 
are recognized causes of acute kidney injury (AKI) in newly diagnosed multiple myeloma 
patients. However it is currently not known if there is a difference in outcomes between 
these two groups. We conducted a retrospective study to compare the clinical characteristics 
and renal response rates in patients presenting with acute kidney injury at the time of 
myeloma diagnosis.
Methods: We included all patients with AKI at the time of multiple myeloma diagnosis 
with biopsy-confirmed diagnosis of MCN or ATN between 1998 and 2013. Patients with 
chronic kidney disease (estimated GFR by MDRD equation<45ml/min/1.73m2) and 
relapsed multiple myeloma were excluded. We assessed survival and renal outcomes. Six 
month landmark survival analysis was done with Kaplan Meier estimates. Renal response 
was classified according to IKMG consensus criteria.
Results: Out of a total of 51 patients who were included in the study, 42 had MCN and 
9 had ATN. Baseline characteristics were not significantly different between the groups 
except urine albumin percentage of >6% was predictive of ATN.
MCN 
(n=42)
ATN 
(n=9) p value
Median Age, years 63 64 0.19
Gender, M:F % 60:40 56:44 0.4
eGFR at presentation by MDRDml/min/1.73m2 9.8 11.6 0.3
Serum M spike(g/dl) 0.6 1.4 0.2
Proteinura(g/day) 3.1 2.7 0.2
Urine albumin >6% 37% 77% 0.03 
Serum free light chain level(mg/dl) 680 596 0.3
Myeloma ISS stage 3 78% 81% 0.7
Calcium(mg/dl) 9.4 9.8 0.2
Dialysis requirement 51% 33% 0.3
Median duration of dialysis, days 95 21 0.4
Dialysis independence 42% 100% 0.02
Stem cell transplant for myeloma 60% 45% 0.3
Time to Renal Response, months 3.6 1.86 0.04 
Time to Myeloma Response, months 7.3 8.4 0.7
Median Survival, months 49.7 57.1 0.4
Conclusions: Our data suggests that AKI due to ATN at the time of myeloma diagnosis 
is more likely to recover compared to MCN with a faster time to response. However this 
does not seem to affect overall survival.
FR-PO497
Hospital Manifesting AKI Presents Worst Outcome Than Community 
Acquired AKI  Xose luis L. Perez-Fernandez,1 Florentina E. Sileanu,2 Joan 
Sabater Riera,1 Kathleen D. Liu,3 John A. Kellum.2  1Servei de Medicina 
Intensiva, Hospital Univ de Bellvitge, L’Hospitalet de Llobregat, Barcelona, 
Spain; 2Critical Care, Univ Pittsburgh Medical Center, Pittsburgh, PA; 
3Nephrology & Critical Care, Univ California San Francisco Parnassus MC, 
San Francisco, CA.
Background: The objective of this study was to evaluate outcomes in critically ill 
patients with severe community-acquired AKI (CA-AKI) and hospital-manifesting AKI 
(HM-AKI). Secondary objectives were to identify characteristics that differ between patients 
with CA-AKI and HM-AKI to design future preventive strategies.
Methods: Observational retrospective study conducted at two tertiary care hospitals 
between 2000-2008 (UPMC, Pittsburgh, USA) and 2006-2012 (HUB Barcelona, Spain). 
Those with CA-AKI met criteria for KDIGO Stage 3 AKI at hospital admission whereas 
those with HM-AKI did not have AKI at hospital admission. HM-AKI subjects met KDIGO 
Stage 3 AKI criteria within 24 hours of ICU admission, withat least 72 hours elapsing 
between hospital admission and ICU admission. The relationship of type of AKI (CA-AKI, 
HM-AKI) with 90-day survival was analysed using Cox regression models controlling for 
differences between survivors and non-survivors.
Results: 534 patients met inclusion criteria. 92.5% of these patients required RRT 
at some point during ICU admission. 189 (35.4%) patients had AKI manifest while in-
hospital, and these patients had a significantly higher 90-day mortality compared to 345 
(64.6%) patients presenting with CA-AKI (68.3% vs 58.6%; p=0.03). Age, SOFA score, 
time from hospital admission to ICU, HM-AKI (compared to CA-AKI), and medical (vs 
surgical) admission, were all associated with lower 90 day survival. In the multivariate 
analysis, HM-AKI remained an independent risk factor for death compared to CA-AKI 
(HR 1.5; 95%CI (1.1 – 2)).
Conclusions: AKI manifesting after hospital admission has significantly worse 
outcomes compared to AKI present at hospital admission even among patients progressing 
to stage 3 by ICU admission. Future interventions should be directed to prevent AKI in 
patients admitted to hospital, especially those who present with the risk factors identified 
in this study.
Funding: Government Support - Non-U.S.
FR-PO498
Assessing Patient Awareness in Moderate to Severe Acute Kidney Injury 
Sharidan Parr, Marcus G. Wild, Swee-Ling Levea, Talat Alp Ikizler, Edward D. 
Siew, Kerri L. Cavanaugh.  Vanderbilt Center for Kidney Disease, Vanderbilt 
Univ Medical Center, Nashville, TN.
Background: We aimed to evaluate awareness and knowledge of kidney disease in 
patients experiencing moderate to severe AKI, which is important for implementing targeted 
patient self-care risk-reduction strategies.
Methods: We surveyed 150 hospitalized patients in one academic medical center who 
experienced KDIGO Stage II or III AKI. We characterized patients’ awareness that AKI 
had occurred, and specific AKI knowledge and perceptions about kidney communication 
from their health providers. Laboratory data, disease severity, nephrology consultation, 
and need for dialysis were abstracted from the medical record.
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Results: Median participant age was 54 years; 53% were male; 81% were white; 
90% had high school education or higher; 30% had health literacy scores ≤6; baseline 
serum creatinine (SCr) was 0.9 mg/dL; peak SCr was 2.9 mg/dL; 50% had Stage 2 AKI 
and 50% had Stage 3 AKI. In total, 80% of patients were unaware that they experienced 
AKI, including 7 patients requiring dialysis. Predictors of awareness included female 
gender (71% vs 41%), peak serum creatinine (4.5 vs 2.7), Stage III AKI (82% vs 42%), 
nephrology consultation (68% vs 31%), dialysis (29% vs 6%), duration of injury (6 vs 3 
days), discharge SCr (2.2mg/dL vs 1.5mg/dL), and reporting a discussion of AKI with a 
provider during the hospitalization (43% vs 21%) (p values <0.05 for all comparisons). 
We found poor patient recognition of preventable causes of AKI and most patients desired 
more information [Figure 1].
Conclusions: Most patients with moderate to severe AKI are unaware of their condition, 
lack understanding of risk factors for future AKI, and desire more information about AKI. 
Optimizing AKI awareness and understanding to promote patient-centered communication 
and care will require targeted educational strategies during and after hospitalization.
Funding: NIDDK Support
FR-PO499
Acute Kidney Injury Correlates with Remote Organ Injury and Predicts 
Outcome in Primary Acute Liver Failure  Alexander Lukasz,1 Michael 
P. Manns,3 Johannes Hadem,3 Philipp Kümpers.1  1Dept of Nephrology 
and Rheumatology, Univ Hospital Muenster, Muenster, Germany; 2Dept of 
Nephrology & Hypertension, Hannover Medical School, Hannover, Germany; 
3Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical 
School, Hannover, Germany.
Background: In patients with acute liver failure (ALF) acute kidney injury (AKI) is 
not well defined. In this study, we examine whether the occurrence of AKI predicts the 
combined endpoint of death or liver transplantation in a cohort of patients with primary 
ALF admitted to intensive care unit (ICU).
Methods: 130 patients with primary ALF of different entities (drug-induced, viral, 
indeterminate or others) were included. Patients without hepatic encephalopathy were 
excluded. According to the acute Acute Kidney Injury Network (AKIN) definition AKI 
severity (stage 1, 2 or 3) was classified. The primary outcome studied was event-free 28-
day survival (death or transplantation).
Results: 76 patients (58%) had normal renal function, while AKIN I/II and III was 
present in 15 (12%) and 39 patients (30%) on ICU admission, respectively. Between 
different ALF entities, AKI prevalence and severity was similar (Chi-Square; p=0.28). 
AKI severity correlated closely with the extent of remote-organ damage as assessed by 
Simplified Acute Physiology Score (SAPS) III (r=0.56, p=0.0061) and Sequential Organ 
Failure Assessment (SOFA) score (r=0.57, p<0.0001), respectively. Kaplan-Meier analysis 
demonstrated that 37 of 39 ALF patients with AKIN III reached the composite endpoint of 
death or transplantation during 28-day follow-up compared to 59 of 76 no-AKI and 10 of 
15 AKIN I-II, respectively (Log-rank test: p<0.0001). Adjusted Cox’s proportional hazards 
analyses identified AKI on ICU admission as an independent predictor of the composite 
end point of death or transplantation [HR 3.1 (95% CI 1.9-4.9) for no AKI vs. AKIN III].
Conclusions: Our data indicate that AKI is a frequent complication in primary ALF. 
AKI correlates with several features of remote-organ damage and independently predicts 
outcome in this cohort.
FR-PO500
Reduction of Nephrotoxic Medication Associated Acute Kidney Injury: 
Results from a Three Year Sustained Harm Reduction Program 
Stuart Goldstein, Eric S. Kirkendall, Theresa A. Mottes, Kendria Nicole 
Simpson, Stephen E. Muething.  Pediatrics, Cincinnati Children’s Hospital, 
Cincinnati, OH.
Background: Acute kidney injury (AKI) represents one of the most common co-
morbidities in hospitalized children. Our previously reported nephrotoxic medication 
(NTMx) exposure and AKI screening project (Nephrotoxic Injury Negative by Just-in-time 
Action [NINJA]) showed a 25% NTM-AKI rate and a 42% reduction in AKI days/100 
days of NTMx-exposure in Year 1 of the program. This occurred due to rapid recognition 
of AKI and NTMx-exposure reduction. We now report on the 3-year NINJA results to 
assess for sustained harm reduction.
Methods: A daily serum creatinine (SCr) was recommended for all children admitted 
to a non-critical care unit who received >3 NTMx simultaneously or an IV aminoglycoside 
for >3 days (high NTMx-exposure) to assess for AKI development. We tracked biweekly 
outcomes from Sep 2011 through Mar 2015: 1) High NTMx-exposures per 1000 pt-days 
2) AKI episodes per 1000 pt-days 3) AKI rates per exposure case (%) and 4) AKI days per 
100 high NTMx-exposure days (intensity). AKI was defined by KDIGO SCr criteria. We 
used statistical process control charts to assess for changes from baseline rates.
Results: 1,783 patients accounted for 2,358 separate admissions and 3,243 individual 
episodes of high NTMx exposure. 170 patients (9.7%) had 2+ exposures. We observed 
two decreases in NTMx-exposure and AKI rates. Overall, the high-NTMx exposure rate 
decreased by 38% (11.63 to 7.24 admissions/1000 pt-days), and the AKI rate decreased 
by 64% (2.96 to 1.06 admissions with AKI/1000 pt-days). The NINJA project saved pts 
from 633 exposure and 398 AKI episodes (when compared to baseline rates). Medications/
medication classes or admitting services for exposed or AKI pts did not differ between the 
3 months preceding and following either time point improvement. AKI rates per exposure 
(23.3% to 15.4%) and AKI intensity (27.7 to 19.1 AKI days/100 exposure days) also 
decreased in Year 1; both improvements persisted for the entire period.
Conclusions: Implementation of systematic surveillance for NTMx-AKI can lead to 
sustained reductions in avoidable harm.
Funding: Private Foundation Support
FR-PO501
Early and Late Aute Kidney Injury in Severely Burned Patients 
Stanislaw Niemczyk,1 Wojciech Witkowski,2 Wojciech Klimm,1 Agnieszka 
Surowiecka- Pastewka,2 Marek Kawecki,3,5 Katarzyna Szamotulska.4  1Dept of 
Internal Medicine, Nephrology and Dialysotherapy, Military Inst of Medicine, 
Warsaw, Poland; 2Dept of Burns, Plastic and Reconstructive Surgery, Military 
Inst of Medicine, Warsaw, Poland; 3Dept of Treatment of Burns, Centre for the 
Treatment of Burns, Siemianowice Slaskie, Poland; 4Dept of Epidemiology and 
Biostatistics, Inst of Mother and Child, Warsaw, Poland; 5Dept of Emergency 
Medicine, Faculty of Health Sciences, Academy of Technology and Humanities, 
Bielsko-Biala, Poland.
Background: Evaluation of factors influencing early and late acute kidney injury 
(AKI) in severely burned patients and assessment of the relationship between time of 
occurrence of AKI and mortality.
Methods: Retrospective analysis of severely burned patients with>30%total body 
surface area (TBSA), admitted to two centers for the treatment of burns. We selected 
and analysed 239 severely burned patients. Renal function was evaluated at three points: 
admission, critical or middle point of hospitalization and the endpoint death or discharge 
from the center. AKI criteria: decrease in glomerular filtration rate (GFR)>60 ml/min at 
admission, decrease in GFR>75% compared to baseline, decrease in the daily diuresis<500 
ml.
Results: At admission 15.1% of the patients had GFR <60 ml/min. AKI occurred in 
38.5%. The occurrence of AKI was associated with: elderly age (p<0,001), female gender 
(p=0,017), overweight and obesity (p=0,055); extentand depth of burns, respiratory failure, 
low protein concentration (for all p<0,001), low blood pressure (p=0,014) and high white 
blood cells count (WBC) (p=0,010). Early AKI was detected in 28%. Mortality was 
100% with the initial GFR>60ml/min, 100% with the initial GFR <60 ml/min and early 
deterioration of renal function, 80% with the initial GFR <60 ml/min and late worsening, 
and 60% with the initial GFR <60 ml/min and no worsening. Late AKI was observed in 
10% of patients and mortality was 79.2%. Mortality in the group with AKI was 88.0% 
versus 24.5% without AKI.
Conclusions: The frequent occurrence of AKI, especially early, worsens the prognosis 
for survival. The assessment of renal function should be included in the prognostic scales 
for burned patients.
FR-PO502
Acute Kidney Injury and Risk of Incident Heart Failure Among U.S. 
Veterans  Nisha Bansal,1 Michael Edwin Matheny,2 Svetlana Eden,2 
Robert Greevy,2 Sharidan Parr,2 James Fly,2 Khaled Abdel-Kader,2 Jonathan 
Himmelfarb,1 Ian H. De Boer,1 Talat Alp Ikizler,2 Edward D. Siew.2  1UW; 
2Vanderbilt.
Background: Acute kidney injury (AKI) is common and associated with poor long-term 
outcomes. Heart failure (HF) is a leading cause of cardiovascular disease among patients 
with chronic kidney disease (CKD). The relationship between AKI and HF remains unknown 
and may identify a novel mechanistic link between kidney and cardiovascular disease.
Methods: We studied a national retrospective cohort of 111,488 U.S. Veterans 
hospitalized between 2003-2012 without history of HF. AKI was defined as a 0.3 mg/dl or 
50% increase in serum creatinine using the difference between peak hospitalization and 
baseline creatinine (as determined by mean outpatient creatinine over previous year) and 
staged according to Kidney Disease Improving Global Outcomes (KDIGO) criteria using 
change in serum creatinine. Incident HF was defined as > 1 hospitalization or >2 visits with 
a diagnosis of HF, as determined from validated ICD9 codes, through 2012. Propensity 
scores using 37 relevant inpatient and outpatient covariates were generated and patients 
with and without AKI were matched 1:1. Cox proportional hazards were used to determine 
the association of AKI with risk of incident HF, adjusting for baseline age, eGFR, coronary 
heart disease and hypertension. Patients who died or had an outcome after the end of the 
study were censored.
Results: There were 17,272 matched pairs with and without AKI in the study. Patients 
with and without AKI during the index hospitalization were well matched with median 
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age of 66 years and 22% were African-American. Median pre-admission eGFR was 65.6 
ml/min/1.73 m2, 37% had diabetes and 72% had hypertension prior to admission. Over 
a median follow-up time of 41 months, 11% of those without AKI vs. 14% in those with 
AKI had incident HF. AKI was associated with increased risk of incident HF (adjusted 
HR=1.3 [95% CI:1.2, 1.4]).
Conclusions: AKI is an independent risk factor for incident HF adding further evidence 
to the long-term cardiovascular consequences of AKI. Future studies to identify underlying 
mechanisms, modifiable risk factors, and patients at highest risk for AKI are needed.
FR-PO503
Incidence of Acute Kidney Injury Among Patients with Chronic Kidney 
Disease: A Single-Center Retrospective Database Analysis  Taro Horino,1 
Yutaka Hatakeyama,2 Hiromi Kataoka,2 Tatsuki Matsumoto,1 Kazu 
Hamada-Ode,1 Yoshiko Shimamura,1 Koji Ogata,1 Kosuke Inoue,1 Yoshinori 
Taniguchi,1 Yoshio Terada,1 Yoshiyasu Okuhara.2  1Dept of Endocrinology, 
Metabolism and Nephrology, Kochi Medical School, Kochi Univ, Nankoku, 
Japan; 2Center of Medical Information Science, Kochi Medical School, Kochi 
Univ, Nankoku, Japan.
Background: Acute kidney injury (AKI) is a serious complication among hospitalized 
individuals and is closely associated with chronic kidney disease (CKD).This study 
investigated the incidences of AKI in the various CKD stages.
Methods: This retrospective cohort study evaluated 125,059 individuals who visited 
Kochi Medical School hospital between October 19, 1981 and December 31, 2013. AKI 
was defined and staged according to the Kidney Disease Improving Global Outcomes 
criteria, using measured serum creatinine levels.
Results: We analyzed data from 122,653 Japanese patients, including 57,105 (46.6%) 
men. The incidence of AKI in this cohort was 7.8% (95% confidence interval: 7.7–8.0%). 
Compared to non-AKI patients, patients with stage 1–2 AKI were more likely to be men. 
Patients with stage 1–2 AKI were significantly older than non-AKI or stage 3 AKI patients. 
The incidences of AKI were 6.7 %, 5.9%, 10.4%, 18.4%, 30.0%, and 48.8% in individuals 
with estimated glomerular filtration rates of ≥90, 60–90, 45–60, 30–45, 15–30, and £15 mL/
min/1.73 m2, respectively. These incidences of AKI were significantly different, compared 
to the incidence for the baseline eGFR.
Conclusions: We found that CKD was a risk factor for AKI, and that the incidence of 
AKI was positively associated with pre-existing reduced kidney function (stage of CKD). 
We suggest that outpatients should be monitored for AKI, given its unexpected incidence 
in that population.
FR-PO504
Acute Kidney Injury in Patients without Atherosclerotic Cardiovascular 
Disease and Long-Term Risk of Myocardial Infarction, Revascularization, 
and Death  Martin Holzmann,1 Linda C. Ryden,1 Ulrik Sartipy.1  1Karolinska 
Inst; 2Karolinska Inst; 3Karolinska Inst.
Background: Acute kidney injury (AKI) is associated with death and cardiovascular 
disease (CVD). Prior studies on AKI have been conducted in populations with established 
CVD, or in mixed populations. We sought to investigate the association between AKI and 
risk of coronary artery disease (CAD), and death in patients with no prior history of any 
atherosclerotic disease.
Methods: All patients who underwent an isolated surgical aortic valve replacement 
in Sweden 1999-2011 were eligible. Patients with any history of atherosclerotic disease, 
i.e myocardial infarction, angina, prior revascularization (PCI/CABG), ischemic stroke, 
peripheral vascular disease, and aortic aneurysm were excluded (n=4230). The primary 
outcome was myocardial infarction, and/or revascularization, and the secondary outcome 
all-cause mortality. AKI was defined according to AKIN criteria.
Results: We included 4823 patients (44% women), with a mean age of 67 (13) years. 
489 (10%), 73 (1.5%), and 32 (0.7%) patients developed AKI stage 1, 2 and 3, respectively. 
During a mean of 6.4 (SD 3.5) years (31 009 person-years) in total 151 (3.1%) patients had 
a myocardial infarction/revascularization, and in total 850 (18%) patients died. Number of 
CVD events were: 130 (3.1%), 16 (3.3%), and 5 (4.8%); and number of deaths: 694 (16%), 
122 (25%), and 34 (32%)in AKI stage 0, 1 and 2-3, respectively. There was no significant 
association between AKI stage 1 or 2-3 and CVD events: crude HR: 1.13 (95% CI 0.68-
1.90), and 1.66 (95% CI 0.68-4.09); adjusted HR: 1.11 (95% CI 0.64-1.91), and 1.59 (95% 
CI 0.58-4.32) compared with no AKI. There was a significant association between AKI 
stage 1 or AKI stage 2-3 and all-cause mortality: crude HR: 1.81 (95% CI 1.49-2.20), and 
2.60 (95% CI 1.84-3.67); adjusted HR: 1.12 (95% CI 0.92-1.37), and 1.86 (95% CI 1.31-
2.65) compared with no AKI.
Conclusions: In a cohort of patients without any established atherosclerotic disease 
we found no association between AKI and subsequent coronary artery disease. However, 
patient with AKI stage 2-3 had an almost doubled risk of death during follow-up.
FR-PO505
Acute Kidney Injury Increases Medical Costs Even in the Pre-AKI Stage 
Jeonghwan Lee,1 Seon Ha Baek,2 Shin-Young Ahn,2 Ho Jun Chin,2 Ki Young Na,2 
Dong-Wan Chae,2 Sejoong Kim.2  1Internal Medicine, Hallym Univ Hangang 
Sacred Heart Hospital, Seoul, Republic of Korea; 2Internal Medicine, Seoul 
National Univ Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea.
Background: Early detection of acute kidney injury (AKI) is important to prevent the 
progression of AKI and to improve clinical outcomes. However the significance of mild 
increase in serum creatinine below AKI stage is not well established. In this study, we defined 
pre-AKI as the 25-50% increase of serum creatinine levels from the baseline levels. We 
aimed to investigate the influence of AKI stage including pre-AKI on clinical outcomes.
Methods: All clinical and laboratory data were retrieved from electronic medical record 
database. We enrolled a total of 20819 patients who admitted Seoul National University 
Bundang Hospital from January 1, 2013 to December 31, 2013. We excluded patients who 
had not checked serum creatinine levels during admission or who were on dialysis due to 
end-stage renal disease.
Results: The proportion of patients who had AKI during admission were 21.6% 
(pre-AKI), 15.8% (AKI stage 1), 5.9% (AKI stage 2), and 3.2% (AKI stage 3). In-hospital 
mortality increased according to the stage of AKI [log-rank P < 0.001; HRs 1.878 (1.189-
2.966) AKI stage 1; 6.039 (3.948-9.239) AKI stage 2; 12.064 (7.992-18.210) AKI stage 3]. 
Patients with pre-AKI showed no differences in mortality compared to patients without AKI 
[HRs 1.180 (0.708-1.966), P = 0.527]. However, patients with pre-AKI were characterized 
with increased length of stay (no AKI 7.4 ± 9.0 days, pre-AKI 13.0 ± 13.3 days, P < 0.001) 
and increased medical costs (no AKI: 2806 ± 3286 USD, pre-AKI: 4701 ± 3476 USD, P < 
0.001) during admission. Patients with Pre-AKI were more on surgical condition (51.1% 
vs 34.0%, P < 0.001) compared to patients without AKI.
Conclusions:  Patients with pre-AKI stage are associated with longer length of hospital 
stay and increased medical costs during admission. Clinical significance of pre-AKI should 
be paid attention.
FR-PO506
Impact of Fluid Overload on Acute Kidney Injury Diagnosis and Associated 
Outcomes in Critically Ill Patients: A Retrospective Cohort Study 
Luis Ignacio Bonilla,1,2 Sara Samoni,2 Maria Fernanda Golzarri,1 Salvador 
Roberto Lopez,2,3 Jordana S. Lemus,4 Guillermo Cardenas,4 Claudio Ronco.2 
1Internal Medicine, Hospital General Dr. Manuel Gea Gonzalez, Mexico City, 
Mexico; 2IRRIV, International Renal Research Inst Vicenza, Vicenza, Italy; 
3Nephrology, National Inst of Cardiology, Mexico City, Mexico; 4ICU, Hospital 
General Dr. Manuel Gea Gonzalez, Mexico City, Mexico.
Background: Fluid overload(FO)changes the volume of distribution of creatinine,which 
is equivalent to total body water(TBW),this can alter the serum creatinine(sCr)
concentrations;higher TBW result in lower sCr leading to underestimation of AKI.
Adjustment of sCr is done by applying a formula(Adjusted Cr=sCrx[1+(cumulative fluid 
balance/TBW)]).We hypothesized that in pts with >5%of FO the adjustment of sCr for TBW 
would diagnose more pts with AKI and diagnose AKI earlier than in pts with <2.5%of FO.
Methods: We made a retrospective analysis of 120 records of pts from 2 centers.We 
calculated daily fluid balance and divided it by the body weight to obtain a percentage 
of FO.Pts were divided into 2 groups,A and B,with <2.5%and >5%of FO,respectively.
Measured daily sCr was corrected using the TBW formula and presence of AKI was 
evaluated daily according to KDIGO guidelines.We compared the prevalence,day of 
diagnosis and associated outcomes between the 2 groups.
Results: Mean age in the cohort was 54.4yrs,56.3% were male.In group A 24(34.8%)of 
pts were diagnosed with AKI before adjustment and 25(36.2%)after adjustment(p=0.167).In 
group B 21(48.8%)and 25(58.1%)were diagnosed with AKI before and after adjustment,res
pectively(p=0.023).Mean detection day of AKI without and with adjustment in group A was 
3.22±2.4 and 2.84±2.1,respectively(p>0.001) and in group B 3.4±2.3 and 3±2.2(p>0.001).
Mortality in group A was 10.14%and in group B 32.56%(p=0.005).
Conclusions: Correction of measured sCr for TBW in patients with >5%of FO is 
useful to diagnose more patients with AKI.Usage of the formula demonstrated usefulness 
for early diagnosis in patients with <2.5%and >5%of FO and we recommend its application 
in order to improve AKI prevention and treatment.FO of >5%is associated with increased 
mortality and worse outcomes in critically ill pts.
FR-PO507
Placental Growth Factor (PLGF) Is the Novel Predictor of CKD 
Progression: The Results from NARA-CKD Study  Masaru Matsui, Katsuhiko 
Morimoto, Miho Tagawa, Ken-ichi Samejima, Yasuhiro Akai, Yoshihiko Saito. 
First Dept of Internal Medicine, Nara Medical Univ, Kashihara, Japan.
Background: PlGF plays a critical role in atherogenesis through vascular 
inflammation. We have already reported an independent association of PlGF with survival 
and cardiovascular risk in the patients with chronic kidney disease (CKD) in the Novel 
Assessment of Risk management for Atherosclerotic diseases in CKD (NARA-CKD) 
study; however, the relations between circulating levels of PlGF and the progression of 
CKD remains unknown.
Methods: A prospective cohort study of 402 participants undergoing renal biopsy 
was conducted to elucidate the predictive value of PlGF on renal prognosis in the patients 
with CKD.
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Results: Histologically, elevated PlGF was significantly associated with the severity 
of tubulointerstitial damage and the intimal thickening of small renal arteries. During a 
median follow-up of 2.7 years, 82 patients reached primary end-points which were defined 
as the requirement of renal replacement therapy (38 patients) and the decline of eGFR by 
more than 25% from baseline (44 patients). Although baseline eGFR was not statistically 
different among patients in all PlGF quartiles, the rate of eGFR decline in the patients with 
the highest PlGF quartile was significantly faster than those with other quartiles. After 
adjustment of known confounding factors, PlGF was significantly associated with the risk 
of deterioration of renal function with the adjusted hazard ratio of 1.75 [1.38-2.26]) for each 
quartile increment of PlGF. The combined use of eGFR and PlGF significantly improved 
the predictive accuracy for CKD progression compared with eGFR alone (c statistics from 
0.689 to 0.772, p<0.001).
Conclusions: Elevated PlGF is a novel and independent predictor of renal prognosis 
in the patients with CKD.
FR-PO508
Steeper Decline in Renal Function After a Hypertensive Disorder of 
Pregnancy: A Longitudinal Study  Nina Paauw,1 Anne Marijn van der Graaf,2 
Rita Bozoglan,2 David P. van der Ham,3 Gerjan Navis,2 Ron T. Gansevoort,2 
Henk Groen,4 Titia Lely.1  1Obstetrics, UMC Utrecht, Netherlands; 2Nefrology, 
UMC Groningen, Netherlands; 3Obstetrics, Martini Hospital, Netherlands; 
4Epidemiology, UMC Groningen, Netherlands.
Background: Hypertensive disorders of pregnancy (HDP) occur in 10% of pregnancies. 
Population based studies report increased risk for ESRD after HDP. Longitudinal renal 
function after HDP has not been studied. Our aim was to longitudinally assess renal function 
and occurrence of CKD in women after HDP compared to controls.
Methods: Data from the PREVEND study, a population based prospective cohort with 
median follow-up of 11 years, were used to identify women without and with self-reported 
HDP (non-HDP, n=1805 and HDP, n=977). A case cohort, 10 years post-partum was created 
by record linkage, with subgroups: normal pregnancy (control, n=202), pregnancy-induced 
hypertension (PIH, n=56) and preeclampsia (PE, n=29). Renal function and the prevalence 
of CKD were compared.
Results: eGFR was lower at baseline and during follow-up in HDP vs non-HDP (A). 
In addition, the decline in eGFR was steeper in HDP vs non-HDP (B). At baseline and 
during follow-up there was more anti-hypertensive-drug use, including ACEi in the HDP 
group. 24-h albuminuria at baseline was higher in HDP vs non-HDP and remained steadily 
higher in HDP during follow-up. A trend towards increased risk of CKD was observed 
in HDP; HR 1.13 (0.92-1.38). In the case cohort, eGFR was significantly lower (C) and 
24-h albuminuria significantly higher (p=0.03) in the PE vs controls. 7.8% of the controls, 
10.9% of the PIH and 19.2% of the PE group met the criteria for CKD.
Conclusions: We report a lower renal function and a steeper renal function decline 
over time after HDP. Women with severe hypertensive disorders of pregnancy (PE) have 
the highest risk for renal function loss.
Funding: Private Foundation Support
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Pregnancy Outcomes in Women with Chronic Kidney Disease in South 
Australia  Shilpa Jesudason,1,3 Alyssa Kate Fitzpatrick,4 Britt Melinda 
Catcheside,2 Wendy Katharine Scheil,2 Stephen P. McDonald.1,3  1Central and 
Northern Adelaide Renal and Transplantation Services, Adelaide, Australia; 
2South Australian Pregnancy Outcomes Unit, Adelaide, Australia; 3School of 
Medicine, Univ of Adelaide, Adelaide, Australia; 4Univ of Oxford, Oxford, 
United Kingdom.
Background: Chronic kidney disease (CKD) affects an estimated 3% of women in their 
childbearing years. CKD in pregnancy is associated with adverse maternal and neonatal 
outcomes. This study represents the first attempt to capture the distribution of CKD among 
pregnant women in the Australian context.
Methods: Data was obtained from the South Australian Pregnancy Outcomes Unit 
Supplementary Birth Record for singleton pregnancies from 1990-2012. Women with 
CKD were identified by renal ICD-9 codes for immunological renal conditions, cystic/
genetic renal disease, vesicoureteral reflux, hypertensive CKD, urological conditions, 
pyelonephritis, and unspecified renal disease. Uncomplicated urinary tract infections were 
excluded. Data was obtained on maternal demographics, obstetric care and infant outcomes. 
Chi-squared or Fisher’s exact tests were used to examine the crude association between 
renal disease and adverse outcomes.
Results: 1392 births to women with renal disease codes were identified from 407,580 
recorded births. Women with renal disease were significantly more likely to be Aboriginal 
(5.2% vs 2.6%, p<0.001), to have the lowest socioeconomic status (31.4% vs 26.2%, 
p<0.001) and to smoke (24.1% vs 18.4%, p<0.001). Higher unadjusted risks of adverse 
outcomes were noted in the renal group, including gestational hypertension (10.6% vs 5.0%, 
p<0.001) and emergency caesarean section (20.0% vs 15.0%, p<0.001). Women with renal 
disease were more likely to have a preterm birth <34 weeks (6.7% vs 2.1%, p<0.001), or a 
late preterm birth 34-36 weeks (10.8% vs 4.5%, p<0.001). They were also more likely to 
be diagnosed with intrauterine growth restriction (11.2% vs 9.5%, p=0.03) and to deliver 
a low birth weight baby <2500g (13.4% vs 5.5%, p<0.001).
Conclusions: Indigenous Australian women and women with low socioeconomic 
status are disproportionately burdened by CKD in pregnancy. The data showed increased 
adverse maternal and neonatal outcomes among women with CKD.
FR-PO510
Identification of Renal Disease in Women with Hypertensive Pregnancies 
Kate Bramham, Katherine R. Clark, Daniel Stott, Daniela Paraschiv, Nicholas 
Kametas.  Antenatal Hypertension Clinic, King’s College Hospital, London, 
United Kingdom.
Background: Hypertension in pregnancy can be associated with renal injury which 
may be masked by gestational change. Postpartum assessment is an opportunity to detect 
persistent renal abnormalities. However previous studies are small and often exclude those 
with pre-existing hypertension, a risk factor for CKD. Aim: To determine the postpartum 
prevalence of renal abnormalities in women with chronic hypertension, pregnancy induced 
hypertension (PIH) or pre-eclampsia (PE) in a previous or current pregnancy.
Methods: Women with singleton pregnancies referred to a hypertension pregnancy 
clinic (Feb 2011-Nov 2014) attending postpartum review (offered to all) were included. 
Those with previously diagnosed CKD were excluded. Demographics, 24 hour urine protein, 
estimated GFR (CKD-EPI) and blood pressure after six weeks postpartum were recorded.
Results: Overall 120 (29.7%) of women were found to have features of renal disease 
postpartum. Subgroup analysis according to hypertensive groups is shown in Table 1. 
Chronic 
Hypertensive 
(N=115)
History of PE/PIH
(N=102)
PE/PIH in current 
pregnancy
(N=187)
Body mass index, Kg/m2 31.7 (7.4) 28.7 (6.9) † 27.2 (5.3) †
Maternal age, years 35.8 (5.1) 34.1 (4.9) 32.3 (5.6) † §
Postnatal visit – weeks from 
delivery 7.2 (1.7) 7.6 (2.5) 7.2 (1.6)
Systolic blood pressure 
mmHg 137.4 (14.2) 128.2 (18.0) † 126.7 (14.2) †
Diastolic blood pressure
mmHg 87.2 (9.2) 81.1 (11.7) † 80.2 (10.0) †
Normal renal function
n (%) 72 (62.6) 131 (70.0) 81 (79.4)
Proteinuria≥150mg/24h & 
eGFR>90ml/min n (%) 22 (19.1) 30 (29.4) 11 (5.8)
Proteinuria<150mg/24h & 
eGFR<90 ml/min n (%) 17 (14.7) 22 (11.7) 9 (8.8)
Proteinuria>150mg/24h & 
eGFR <90ml/min n (%) 4 (3.5) 4 (4.0) 1 (0.5)
PE:Pre-eclampsia; PIH: Pregnancy induced hypertension † P<0.001 Compared with chronic 
hypertension. § P<0.001 Compared with history of PE/PIH.
Conclusions: A substantial proportion of women with hypertension in pregnancy have 
renal abnormalities after six weeks postpartum. Identification of risk factors for progression 
of CKD in this population through longitudinal studies is needed.
FR-PO511
Changes of Markers of Prothrombotic State in Membranous Nephropathy 
Complicated with Type 2 Diabetes  Yuanmeng Jin.  Nephrology, Ruijin 
Hospital, Shanghai Jiao Tong Univ School of Medicine, Shanghai, China.
Background: Membranous nephropathy (MN) complicated with type 2 diabetes 
showed high incidence of thrombosis, which was related to abnormity of prothrombotic 
state. This investigation was designed to explore changes of prothrombotic state and 
mechanism of thrombosis in MN complicated with type 2 diabetes.
Methods: We enrolled total 30 patients with nephrotic syndrome (NS), 12 patients were 
pure MN, 6 patients were diabetic kidney disease (DKD), 12 patients were MN complicated 
with type 2 diabetes (MN+DM). All patients were diagnosed by renal biopsy. 14 healthy 
people were enrolled for normal control. The markers for prothrombotic state, including 
endothelial function (vWF, AngiotensinII), coagulation function (Protein C, Protein S, 
Antithrombin III, Thromboelastogram index), fibrinolytic function (Fibrinogen, Fibrinogen 
degradation product, D-D dimer) were tested.
Results: Compared to CKD group, vWF levels in MN and DKD group were higher, 
but was significantly higher in MN+DM group. Protein C and thromboelastogram index in 
MN+DM group were higher than control, which were not significantly changed in MN and 
DKD group. Fibrinogen levels in both MN+DM and MN group were higher than others, 
and D-D dimer levels were especially higher in MN+DM group, even compared to MN 
group. There were no changes of other marks in four groups.
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Conclusions: Under NS state, MN+DM patients existed more serious prothrombotic 
state, compared to pure MN and DKD. The mechanism is related to disorders of endothelial 
function, coagulation function, as well as fibrinolytic function. More attention should be 
paid to treatment of prothrombotic statein MN+DM patients.
Funding: Government Support - Non-U.S.
FR-PO512
Serum C3 and Renal Outcome in Patients with Primary Focal Segmental 
Glomerulosclerosis  Jian Liu, Jingyuan Xie, Jun Tong, Hong Ren, Weiming 
Wang, Nan Chen.  Dept of Nephrology, Rui Jin Hospital, Shanghai Jiao Tong 
Univ, School of Medicine, Shanghai, China.
Background: The role of complement in the pathogenesis or progression of FSGS is 
uncertain. The aim of this observational cohort study was to identify the clinical implications 
of serum C3 levels and to investigate their utility as predictor of renal outcomes in patients 
with FSGS.
Methods:    591 biopsy-proven primary FSGS patients were recruited. Clinical, 
histological and progression data were recorded. Decreased serum C3 level was defined 
as C3 <85 mg/dl. The study endpoint was end-stage renal disease (ESRD).
Results:    Of the patients, there were 117 patients (25.1%) with low serum C3. At the 
time-point of  renal biopsy, compared to patients with C3 ≥85 mg/dl, those with C3 <85 
mg/dl had higher level of serum creatinine, lower levels of eGFR, proteinuria, hemoglobin, 
triglyceride, cholesterol, IgA, more severe segmental sclerosis, tubular atrophy and 
interstitial fibrosis. Multivariate linear regression analysis showed low C3 level was an 
independent risk factor for eGFR (HR=42.56, 95%CI 11.21- 73.91, p<0.01) after adjusted 
by sex, age and clinical indicators. The follow-up was assessed in 221 patients. During a 
mean follow-up of 53.3 months, ESRD occurred in 32 patients (37.2%) with low serum 
C3 compared with 22 patients (16.3%) with normal C3 levels (P <0.001). Serum C3 level 
had a significant predictive value for renal outcome (AUC = 0.650, P = 0.001), The risk of 
reaching ESRD was significantly higher in patients with low serum C3 level (HR 4.044; 
95% CI= 2.238 to 7.309; P < 0.0001).
Conclusions: Complement activation may occur in patients with FSGS. It is associated 
with clinical and histological severities. Low serum C3 is an independent risk factor for 
the decline of eGFR, and is associated with poor renal outcome in patients with FSGS.
FR-PO513
Role of Proteolytic Fragment suPAR D2-D3 in Prediction and Cause of 
FSGS  Sanja Sever,1 Marina V. Kasaikina,1 Eileen Kapples,1 Jian Cai,2 Jon 
B. Klein,2 Nada Alachkar,3 Changli Wei,4 Changkyu Gu,1 Jochen Reiser.4 
1Nephrology, Massachusetts General Hospital, Charlestown, MA; 2Univ of 
Louisville School of Medicine, Louisville, KY; 3Nephrology, Johns Hopkins 
Univ School of Medicine, Baltimore, MD; 4Medicine, Rush Univ Medical 
Center, Chicago, IL.
Background: Primary FSGS is a kidney disorder that leads to end stage renal disease 
and affects tens of thousands people annually. Several studies suggest the soluble urokinase-
type plasminogen activating receptor (suPAR) to be a predisposing circulating factor and 
prognostic marker of FSGS through its interaction with avb3 integrin.
Methods: We collected serum samples from kidney transplant recipients with FSGS. 
We also analyzed sera from healthy controls and patients with sepsis and on peritoneal 
dialysis. These sera were used to assess integrin activation in podocytes. Western blot 
was utilized to identify full length and D2-D3 fragment of suPAR. Transgenic mice were 
created to drive mouse suPAR D1-D2-D3 and suPAR D2-D3 expression from adipocytes 
and consequent release into circulation.
Results: We found that multiple disorders, including FSGS, sepsis, and peritoneal 
dialysis, are associated with an increase in bulk serum suPAR levels; however, only a 
subset of sera from FSGS patients induced integrin activation in podocytes. Western 
blot identified a fragment of suPAR (containing the D2-D3) only in the subset of sera 
from patients with recurrent FSGS. In vitro, the EC50 response of D2-D3 for activating 
integrin avb3 was approximately ten fold than for D1-D2-D3. Exposure of podocytes to 
physiological concentrations of the D2-D3 increased the amount of surface uPAR and 
facilitated podocyte motility. Injections of the D2-D3, but not full-length suPAR, induced 
transient proteinuria in mice. Transgenic mice for D2-D3 developed rising serum suPAR 
levels and a variable degree of proteinuria.  A composite risk analysis score was developed 
that included presence of the D2-D3 in patient serum, podocyte integrin activation capacity, 
and total suPAR serum level for the prediction of recurrent FSGS.
Conclusions: suPAR D2-D3 fragment is a prognostic marker and risk factor for 
recurrent FSGS.
Funding: NIDDK Support
FR-PO514
Prognosis, Survival and Renal Function in Patients with Lupus Nephritis 
Gustavo Aroca Martinez,1,2 Andres A. Cadena,2 Eduardo Egea Bermejo,4 Jossie 
E. Fontalvo,1 Yeneris Gaviria,1 Henry J. Gonzalez Torres,1 Moises A. Arquez 
Mendoza,1 José Rafael Consuegra,1 Santos Depine.1  1Medicine, Univ Simon 
Bolivar, Barranquilla, Atlantico, Colombia; 2Nephrology, Clinica de la Costa, 
Barranquilla, Atlantico, Colombia; 3Medicine, Univ Nacional de Colombia, 
Colombia, Atlantico, Colombia; 4Medicine, Univ del Norte, Colombia, Atlantico, 
Colombia.
Background: Lupus nephritis is the most common glomerulonephritis in the Colombian 
Caribbean region, despite there is less published information about its evolution and 
clínico-pathotogical aspects. Objective: To evaluate prognosis, survival and renal function 
of patients with LN residing in the Colombian Caribbean region controlled between 
2008 - -2014.
Methods: 229 patient study with LN corroborated by histology according to the 
International Society of Nephrology Clasification /Renal Pathology Society (ISN/ RPS. 
2003) treated with induction and maintenance therapy and with a systemized following 
of at least 2 years. The pharmacological treatments included prednisolone, azathioprine, 
and Cyclophosphamide mycophenolate mofetil in isolation or combined and the clinical 
laboratory and histopathology variables were correlated as predictive value of therapeutic 
response. To achieve this as methodology a non-parametric descriptive statistics ANOVA 
(k-w) was used and canonical correspondence analysis.
Results: 229 patients in total of 34±12 of age, which 88% women, whose evolution 
were controlled during 24±6 months. The most common form of clinical presentation was 
nephrotic syndrome and asymptomatic hematuria-proteinuria (68.07%) the type III and 
IV of LN (84,23%) were associated with patients under 25 of age and a negative response 
to treatment. The estimated glomerular filtration rate measured by MDRD4 showed a 
significant improvement at 24 weeks with regard the baseline figure of 74,36.
Conclusions: The early detection and reference of NL patients allows an early approach 
and therapy. Which will prevent chronic kidney disease.
FR-PO515
Association of ABO Blood Group with Progression of IgA Nephropathy 
Meng Yang, Jingyuan Xie, Yan Ouyang, Xiaoyan Zhang, Xiao Li, Wen Zhang, 
Weiming Wang, Nan Chen.  Dept of Nephrology, Ruijin Hospital, Shanghai 
Jiaotong Univ School of Medicine, Shanghai, China.
Background: ABO blood group antigens are major histocompatibility antigens and 
little is known about its association with progression of IgA nephropathy (IgAN).
Methods: Biopsy-proven primary IgAN patients were retrospectively recruited. 
Clinical, histological and progression data were recorded. Patients with eGFR<15ml•min-
1•(1.73m2)-1 at time of biopsy were excluded. Renal tissue was semi-quantitative 
scoredaccording to the Oxford scoring system. ABO blood group was determined by 
standard erythrocyte antiserum agglutination method. All patients were divided into B 
antigen group (type B and AB) and non-B antigen group (type A and O) based on their 
ABO types.
Results: Among the 752 IgAN patients recruited in this study, 210 patients were type A 
(27.9%), 221 were type B (29.4%), 72 were type AB (9.6%) and 249 were type O (33.1%). 
When renal biopsy was performed, patients in B antigen group had higher eGFR (82.44 
vs. 65.68 ml/min), lower systolic blood pressure (sbp) (125.36 vs. 129.29 mmHg) and 
uric acid (373.59 vs. 393.93 mmol/l) than patients in non-B antigen group. No significant 
difference was detected between histological lesions and these two groups. Totally, 100 
patients progressed to end-stage renal disease (ESRD) after a median follow-up period of 
51.05 months, including 32 (15.2%) type A, 18 (8.1%) type B, 2 (2.8%) type AB and 48 
(19.3%) type O patients. Kaplan-Meier analysis showed that median ESRD-free survival 
time of patients in B antigen group was significantly longer than patients in no-B antigen 
group [148.2±5.5 months vs. 138.8±7.5 months, p<0.001]. Furthermore, patients in B 
antigen group were associated with a decreased risk of ESRD (HR=0.56, 95%CI 0.33-0.94) 
after adjusted by age, sex and clinical variables including eGFR, sbp, serum albumin, urine 
protein and hemoglobin by Cox proportional hazards model.
Conclusions: Our data suggested that B antigen had an independent protective effect 
against the progression of IgAN.
FR-PO516
The Analysis of the Long-Term Outcomes of Patients with Primary IgA 
Nephropathy  Hao Li, Jian Liu, Wei Huang, Pingyan Shen, Zhaohui Wang, Ya 
Li, Xiaoxia Pan, Jingyuan Xie, Weiming Wang, Nan Chen.  Dept of Nephrology, 
Shanghai Ruijin Hospital, Shanghai Jiaotong Univ School of Medicine, 
Shanghai, China.
Background: Primary IgA nephropathy (IgAN) is one of the most common glomerular 
diseases in China. In this study we try to investigate the clinical characteristics and the 
relationship between CKD stages and long-term outcomes of patients with primary IgAN 
through the retrospective analysis of their clinical data.
Methods: Patients with biopsy-proved primary IgAN from 2002 to 2013 were included 
in the retrospective analysis. They were older than 18 years old and their follow-up time was 
more than 12 months. We collected their medical history, laboratory test reports and other 
clinical data. Then we enrolled 297 patients who were followed up for 5 years for further 
research. Kaplan-Meier method was used to calculate the renal survival rate of the patients.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
477A
J Am Soc Nephrol 26: 2015 CKD: Risk Factors for Incidence and Progression - II Poster/Friday
Results: A total of 1052 cases were included. There is an equal proportion of male and 
female(50.4% vs 49.6%). The mean age was 36.86±11.58 years old. Five-year renal survival 
rate of these cases was 92%, and ten-year renal survival rate was 88%. We enrolled 297 cases 
who were followed up for 5 years. These patients were divided into rapid progression and 
stable progression, we found that cases in rapid progression group had more proteinuria, 
higher blood pressure, poorer renal function , lower serum albumin and lower hemoglobin, 
compared with other groups. When cases were divided according to CKD stages, the results 
showed no significant difference of outcomes among patients in CKD1-3a stage (P > 0.05). 
Their five-year renal survival rate was more than 95%. But patients in CKD3b-4 stage had 
worse outcomes. The five-year renal survival rate of patients in CKD3b stage was 85.3%, 
while it is only 65.3% for patients in CKD4 stage.
Conclusions: Five-year and ten-year renal survival rate of patients with IgAN was 
92% and 88%, respectively. Patients in CKD3b or CKD4 stage at biopsy may have a lower 
renal survival rate and a worse outcome. At the time of renal biopsy, patients with impaired 
renal function, mass proteinuria, hypertension, anemia and low serum albumin may have 
a greater risk of progressing to end-stage renal disease .
FR-PO517
Variability of GFR Decline in Alport Syndrome: Insights from a Provincial 
Database  David Langsford,1 Mila Tang,2 Ognjenka Djurdjev,3 Lee Er,3 Adeera 
Levin.1,3  1UBC; 2BC Renal Agency.
Background: Alport syndrome (AS) is one of the inherited causes of CKD due to 
mutations in the collagen genes making up the glomerular basement membrane collagen. 
Design of clinical trials for intervention in AS proves challenging without a clear 
understanding of renal progression over time as observational data is lacking due to small 
sample size. We present here the utilization of population based data in a simulation to 
mimic clinical trial recruitment and endpoints to provide insights in trials design for AS.
Methods: AS patients were identified within a provincial CKD clinical database 
(PROMIS) in British Columbia, Canada for this observational simulation study. Patients 
were excluded if they have fewer than 4 eGFR-MDRD measurements or 2 as a study entry 
point to generate 100 random samples. Primary outcome was annual rate of eGFR change 
over 2 years categorized into: > -5 mL/min per year (progressor), -5 and 2 mL/min per 
year (stable), >2 mL/min year (regressor).
Results: 37 pts met inclusion criteria; median follow-up was 48.2 months, and median 
age of 36. The sample sizes for each random sample at the 3 enrolment eGFR levels 
were: 11, 12 and 10 respectively. Of those that ‘enrolled’ at eGFR 45-60 mL/min, 72.7% 
(IQR:63.6%,81.8%) progressed, and 22.7% (IQR:9.1%, 36.4%) remained in stable state. 
For those recruited at eGFR 30-45 mL/min, 41.7% (IQR:41.7%,50%) had disease 
progression and 50% (IQR:50%, 58.3%) remained in stable state. Of those enrolled at 
eGFR 15-30 mL/min, 50% (IQR:50%,60%) were in stable state, 30.0% (IQR:20%, 30%) 
had disease progression, and 20% (IQR:20%,20%) had an improvement in eGFR.
Conclusions: Heterogeneity and non-linearity of AS renal progression ought to be taken 
into account when designing trials of interventions aimed at improving renal outcomes.
Funding: Pharmaceutical Company Support - Regulus Therapeutics
FR-PO518
Discovery of Urine MicroRNA Biomarkers in a Pre-Clinical Model of Alport 
Nephropathy  Martin Beaulieu,1 Shirley Phillips,1 Vivek Kaimal,2 Shweta 
Pandya,2 Nelson Chau,2 Adam Pavlicek,2 Steven Lockton,1 Deidre Mackenna,2 
Neil W. Gibson.2  1microMarkers, Regulus Therapeutics, San Diego, CA; 2R&D, 
Regulus Therapeutics, San Diego, CA.
Background: MicroRNAs (miRs) are a class of short (~23 nucleotide), highly 
conserved non-coding RNA that inhibit translation and facilitate degradation of messenger 
RNA (mRNA). MiRs are stable in biological samples and their levels can be deregulated 
in cells undergoing pathophysiological stress. We developed a miR profiling platform to 
discover novel biomarkers in bio-fluids. In this study, we aimed to profile miRs in urine, 
serum and kidney tissue from a pre-clinical model of Alport nephropathy in order to identify 
microRNA biomarkers with the ability to reflect disease progression.
Methods: Urine from 19 Col4a3-/- mice (SV129 background) and 21 wild type litter 
mates was collected in metabolic cages over 22 hrs at 4, 6 and 8 weeks of age. The animals 
were sacrificed at week 8 to obtain kidney tissue and serum samples. Traditional markers 
of disease progression including blood urea nitrogen (BUN) and urinary microalbuminuria 
were measured using an Alera Clinical Chemistry analyzer. Following miR extraction, miR 
profiling was executed on a high-throughput, RT qPCR based system that reproducibly 
quantifies over 750 miRNAs.
Results: We identified miRs differentially expressed in the kidney (213), serum (60) and 
urine (67) of the Col4a3-/- mice (FDR adjusted p-value < 0.05). Changes in miR expression 
in kidney were similar to other renal fibrosis models (e.g. increases in miR-21) reflecting 
the similarity in pathogenesis across disease models. A urine miR classifier was able to 
detect the Col4a3-/-mice with 100% accuracy as early as 4 weeks of age.
Conclusions: We have developed a high-throughput, multiplex miR profiling platform 
with the capacity to profile tissues and bio-fluids. We discovered several urine microRNAs 
with highly significant differential expression in the Col4a3-/- mouse model when compared 
to wild type mice. Our data suggest that urine is a favorable bio-fluid for the development 
of non-invasive microRNA based tests.
FR-PO519
Micrornas as Predictive Biomarkers of Chronic Kidney Disease (CKD) in 
Patients (Pts) Undergoing Radical Nephrectomy (RN) for Kidney Cancer 
Francesco Trevisani,1 Michele Ghidini,1 Jens C. Hahne,1 Andrea Lampis,1 
Paolo Manunta,2 Maria Teresa Sciarrone Alibrandi,2 Giacomo Dell’Antonio,2 
Lorena Citterio,2 Laura Zagato,2 Francesco Montorsi,2 Fabio Benigni,2 Alberto 
Briganti,2 Roberto Bertini,2 Andrea Salonia,2 Cristina Carenzi,2 Matteo Fassan,3 
Massimo Rugge,3 Paolo Rigotti,3 Giovambattista Capasso,4 Luciano Cascione,5 
Chiara Braconi,1 Nicola Valeri.1  1ICR, London, United Kingdom; 2San Raffaele 
Inst, Milan, Italy; 3Univ of Padua, Padua, Italy; 4Univ of Naples, Naples, Italy; 
5IOR, Bellinzona, Switzerland.
Background: MicroRNAs(miRs) are small non-coding RNAs involved in cell 
homeostasis and disease. Our study identified clinical and molecular markers associated 
with increased risk of developing CKD after RN for renal clear cell carcinoma(RCC).
Methods: 80 pts who underwent RN for RCC at a single institution between 2008-
2013 were included. Inclusion criteria: normal renal function at surgery time(eGFR > 
60 ml/min CKD-EPI formula 2009, serum creatinine < 1.1 mg/dl, no proteinuria). No 
pre-existing glomerulopathy. No evidence of metastatic disease. Minimum follow-up:12 
months post-surgery. FFPE normal adjacent tissue to RCC(>3cm) was micro-dissected 
to isolate cortex(10 glomeruli) and medulla and was subject to RNA extraction. miRs 
analysis was performed using Nanostring nCounter and validated by Real-Time, digital 
droplet PCR and in situ hybridization(ISH). Cox regression analyses were used to define 
variables associated with increased risk of CKD.
Results: 47.4% of pts developed CKD(stage 3a-3b-4 KDIGO) 12 months after 
RN. At multivariable Cox Regression, type II diabetes(pvalue:0.009),basal serum 
creatinine(pvalue:0.002) and miR-193b over-expression(pvalue:0.017) were independently 
associated with increased risk of CKD. ISH showed miR-193b over-expression in the 
tubular-interstitial compartment associated with abnormalities in keeping with early 
inflammatory and fibrotic changes. MiR-193b detection in matched urine samples is 
ongoing.
Conclusions: Tissue and urinary miRs deregulation may represent an early marker of 
kidney dysfunction and may anticipate clinical and laboratory evidence of CKD providing 
an important tool for personalized follow-up and prevention in pts undergoing RN for RCC.
Funding: Other NIH Support - Institute of Cancer Research
Societa’ Italiana di Nefrologia
FR-PO520
Urinary Angiotensinogen to Creatinine Ratio Is a Specific Biomarker for 
Renal Progression in Autosomal Dominant Polycystic Kidney Disease 
Hayne C. Park,1 Hyunjin Ryu,2 Miyeun Han,2 Hyun Suk Kim,2 Kook-Hwan 
Oh,2 Young-Hwan Hwang,3 Curie Ahn.2  1Internal Medicine, Armed Forces 
Capital Hospital, Seongnam-Si, Gyeonggi-Do, Korea; 2Internal Medicine, 
Seoul National Univ College of Medicine, Seoul, Korea; 3Internal Medicine, 
Eulji General Hospital, Seoul, Korea.
Background: Urinary angiotensinogen to creatinine ratio (AGT/Cr) is elevated in 
autosomal dominant polycystic kidney disease (ADPKD), but whether AGT/Cr is a specific 
biomarker of ADPKD progression is not known. This study was performed to measure 
urinary AGT/Cr in subcohorts according to primary renal disease (glomerulonephritis (GN), 
diabetic nephropathy (DN), hypertensive nephropathy (HTN), ADPKD) and to demonstrate 
its usefulness as a specific biomarker in ADPKD.
Methods: Nine nephrology centers recruited adult subjects with chronic kidney 
disease (CKD) and classified into subgroups according to primary renal disease. First-
voided morning urine was collected from all patients upon enrollment and stored at -80°C 
until measurement. Urinary AGT was measured by commercial sandwich enzyme-linked 
immunosorbent assay (ELISA). Urinary AGT/Cr levels and associated factors were 
compared among CKD subgroups.
Results: A total of 1528 patients were enrolled in KNOW-CKD cohort study (NCT 
01630486)from Apr 2011 to Dec 2013. Among them, 153 patients were excluded (73 
unclassified subgroups, 71 without urinary AGT measurement, 9 without available eGFR) 
and a total of 1375 (519 GN, 310 DN, 292 HTN, 254 ADPKD) patients were included 
in the final analysis. The mean age was 53 years and baseline serum creatinine was 1.9 
± 1.2 mg/dL. The GN and ADPKD subgroups showed younger age and earlier elevation 
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of urinary AGT/Cr levels according to CKD stages. When we performed the risk factor 
analysis seperately in GN and ADPKD subgroups, the highest quartile of urinary AGT/
Cr was associated with GN subcohort, female gender, hypertension, decreased eGFR, 
decreased plasma Hb, and higher degree of albuminuria. However, in multivariate logistic 
regression analysis, ADPKD subcohort demonstrated higher urinary AGT/Cr compared to 
GN subcohort after adjusting other co-factors.
Conclusions: Urinary AGT/Cr is greatly increased in ADPKD independent of 
albuminuria and renal function.
Funding: Government Support - Non-U.S.
FR-PO521
Using Biomarkers to Predict Progression to End-Stage Renal Disease within 
6 Months of Liver Transplant  Joseph T. Bahng,1 Kimberly Autumn Forde,1 
Peter Abt,1 Michael R. Bennett,2 Anirban Ganguli,1 Mary Ann C. Lim,1 Debra 
J. Mccorriston,1 Mary C. Shaw,1 Deirdre L. Sawinski.1  1Perelman School of 
Medicine at the U. of Pennsylvania; 2Cincinnati Children’s Hospital.
Background: Liver transplant (LT) recipients are at increased risk for CKD and 
progression to ESRD. Creatinine, the standard for assessing renal function, provides limited 
prognostic information for recovery from AKI. Our aim is to create a predictive model 
for progression to ESRD within 6mos of LT incorporating clinical data and biomarkers.
Methods: We enrolled 202 patients, of whom 138 have 6mos follow up. 13 patients 
progressed to ESRD, defined as GFR<20 ml/min, dialysis, or transplant evaluation. Logistic 
regression models evaluated neutrophil gelatinase-associated lipocalin, IL-18, Cystatin-C, 
Kidney Injury Molecule-1, & liver fatty acid binding protein for inclusion. Receiver 
operating characteristic curves and concordance statistics were used to assess the models.
Results: In one model, MELD score at LT, pre-LT AKI, pre-LT renal replacement 
therapy, & highest creatinine 3mos pre-LT were associated with ESRD at 6mos (p<.05). 
In another model with biomarkers, only urinary IL-18 was included for its association with 
ESRD (p=.2). The C-statistics for both models were similar (C=0.80 and 0.82, respectively).
Recipient Characteristics COHORTn = 138
ESRD
n = 13
NO ESRD
n = 125 p-value
Age Median (IQR) 59 (54, 64) 60 (46, 64) 59 (54, 64) .94
Male Sex n (%) 92 (69.2) 6 (54.6) 86 (70.5) .31
Race n (%)
Caucasian
African American
Other
99 (71.7) 8 (61.5) 91 (72.8)
.3925 (18.1) 4 (30.8) 21 (16.8)
14 (10.1) 1 (7.7) 13 (10.4)
Hepatitis C n (%) 71 (51.8) 8 (61.5) 63 (50.8) .80
Diabetes Mellitus n (%) 46 (33.6) 2 (16.7) 44 (35.0) .34
Hypertension n (%) 53 (40.2) 4 (33.3) 49 (39.2) .77
Highest Creatinine 3Mos Pre-
transplant median (IQR)
1.49 (1.03, 
2.95)
4.37 (2.34, 
5.45)
1.4 (1.01, 
2.71) .001
MELD at LT median (IQR) 28 (22, 35) 36.5 (31, 44) 28 (22, 34) .01
AKI Pre-LT n (%) 64 (49.2) 10 (83.3) 54 (45.8) .02
Renal Replacement Therapy 
Pre-LT n (%) 15 (11.0) 6 (50.0) 9 (7.2) <.01
Conclusions: Biomarkers did not significantly improve ESRD prediction over clinical 
characteristics. The overall event rate was low and longer follow up may be needed.
FR-PO522
Detection of Inflammatory BioMarkers in Urine Using a Dried, Shelf Stable 
Transport Device, ViveST™  Daniel R. Mcclernon,1 Timothy W. Murray,2 
Anita M. Mcclernon.1  1bioMONTR Labs, Research Triangle Park, NC; 2Vivebio 
LLC, Alpharetta, GA.
Background: Current medical practice assesses health of implanted kidney by 
monitoring non-specific signals (serum creatinine) after rejection has started and gold 
standard diagnostic method is invasive kidney biopsy. Studies of non-invasive biomarkers 
(CXCL9) have shown utility (CTOT-01) in identifying subsets of patients at risk for acute 
rejection. A urine based test for post surgical evaluations to pinpoint rejection and expedite 
therapeutic intervention is needed. Here we describe detection of CXCL9/MIG and 
CXCL10/IP-10 in urine in combination with a novel collection device ViveST, eliminating 
need for cold chain transport and storage.
Methods: Urine collected and centrifuged (4oC)@2,000xg (30 min). Supernatant 
decanted into clean tubes and diluted 1:1 with proprietary diluent buffer. Recombinant 
Human CXCL9/MIG and CXCL10/IP-10 (R&D Systems) was reconstituted using 
molecular grade water to concentrations of 10,000pg/uL and serially diluted. Urine was 
spiked with diluted recombinant human MIG or IP-10. 1mL aliquots were loaded onto 
ViveST and dried. ViveST samples were reconstituted with 1mL of molecular grade 
water and analyzed concurrently with frozen aliquots using quantitative sandwich enzyme 
immunoassay techniques specific for MIG or IP-10. Linear regression analysis from seven 
levels of calibration standard used to calculate MIG and IP-10 concentration.
Results: ViveST samples yielded MIG or IP-10 concentrations similar to corresponding 
frozen aliquots (see table). Replicate aliquots gave similar results.
Level
MIG (pg/uL) IP-10 (pg/ul) 
ViveST
(n=3) 
Frozen
(n=1)
Male Urine Female Urine 
ViveST
(n=2)
Frozen
(n=2)
ViveST
(n=2)
Frozen
(n=2)
1 117 98 >1572 >1572 >1572 >1572
2 67 53 >1572 >15772 >1572 >1572
3 34 27 1534 1472 1541 1501
4 14 11 1096 1029 1157 1042
5 5 2
Not included in Experiment6 0 2
7 0 0
Conclusions: MIG and IP-10 can be detected in urine as inflammatory biomarker to 
assess risk of transplant rejection. ViveST can be used as ambient storage and transport 
device eliminating need for cold chain storage. Additional studies warranted assessing 
detection of biomarkers at therapeutically relevant concentrations.
Funding: Pharmaceutical Company Support - Vivebio LLC
FR-PO523
Albuminuria-Induced Apoptosis in Children with Nephrotic Syndrome Is a 
Result of the Dysbalance in Apoptosis Controlling System  Ievgeniia Burlaka. 
Dept of Pediatrics No.4, National O.O. Bogomolets Medical Univ, Kyiv, Ukraine.
Background: Albuminuria promotes cell death, and is associated with faster 
progression of chronic kidney disease (CKD). However, the molecular mechanisms 
regulating cell death in response to albuminuria are not fully understood.
Methods: 53 patients aged 10-15 years with active stage of nephrotic syndrome were 
included to the study. Immunohistochemical examination of pro-apoptotic factor Bax, anti-
apoptotic factor Bcl-xL, number of apoptotic cells in kidney biopsy specimens were done. 
Comparison of the level of these parameters between the different segments of nephron at 
different stages of glomerulosclerosis has been performed.
Results: Measurement of the pro-apoptotic factor Bax in kidney slices obtained 
from children with morphological form of nephrotic syndrome focal segmental 
glomerulosclerosis (FSGS) showedthe presence of high level of Bax in both glomerular 
and tubule-interstitial segments. Higher immunosignal of Bax was evaluated in glomeruli 
with FSGS I-II st. as compared to tubular segment. When FSGS III-IV st. observed higher 
expression of Bax was detected in surrounding tubule-interstitial segment. Expression of 
the anti-apoptotic factor Bcl-xL was studied. Higher expression of Bcl-xL was recorded 
in tubule-interstitial segment as compared to glomeruli when FSGS I-II st. occurs. When 
FSGS III-IV st.occurshigher immunosignal of Bcl-xL is localized in surrounding tubule-
interstitial segment with almost complete absence in glomeruli. The number of apoptotic 
cells was analysed. Quantitative analysis of apoptosis in kidney sections of patients with 
FSGS I-II st. revealed higher apoptotic index (AI) in glomeruli as compared to tubule-
interstitial component. In kidney sections with FSGS III-IV st. higher AI was found in 
tubule-interstitial compartment.
Conclusions: Thus, progression of kidney injuries in nephrotic syndrome is associated 
with increased activity of pro-apoptotic factor Bax and simultaneous reduction of anti-
apoptotic factor Bcl-xL. The level of the expression of Bax and Bcl-xL depends on the stage 
of FSGS and indicates the step-dependent manner of glomerular and interstitial injuries 
development upon the chronic influence of albuminuria.
Funding: Government Support - Non-U.S.
FR-PO524
eGFR, Renal, and Cardiovascular Risk and Nucleoside/Nucleotide 
Backbones of Human Immunodeficiency Virus Patients in the USA 
Jonathan A. Winston,1 Grace Mccomsey.2  1Icahn School of Medicine at Mount 
Sinai; 2Case School of Medicine.
Background: HIV treatment involves choices in complex environments, and must 
balance disease management and potential safety issues (kidney and Cardiovascular diseases 
(CVD)) in an aging population. This study examined renal, CVD and comorbid conditions, 
and treatment of HIV patients.
Methods: Patients diagnosed with HIV using ICD-9 codes were selected from the 
Quintiles database (33M patients). Patients enrolled for ≥ 1 year during 2012-14, maintaining 
a single antiretroviral therapy, and for whom baseline eGFR could be computed were 
stratified based on backbone: regimens including tenofovir disoproxil fumarate (TDF), 
abacavir (ABC), or other (OTH). eGFR and rate of CV comorbidities at baseline were 
assessed.
Results: 14,942 HIV patients (mean age: 43; 76% male) were included; 85% TDF, 7% 
ABC, 7% OTH. Mean baseline eGFR was 99 mmol/l, with differences observed among 
regimens (102 TDF, 82 ABC, 87 OTH). Classified by degree of kidney impairment at 
baseline, regimen was highly correlated with level of impairment, with normal or mild 
impairment (eGFR≥60) more likely to be treated with TDF, and patients with moderate to 
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severe impairment (eGFR<60) more likely to be on ABC. Several CVD risk factors were 
more prevalent in ABC patients compared to TDF, hypertension (25% v 13%), dyslipidæmia 
(30% v 16%), and diabetes (12% v 5%) (p<0.001 in all) being the most common.
Conclusions: HIV patients often present with prevalent CVD risk and reduction in 
kidney function. Physicians make treatment choices that reflect concern for kidney function, 
consistent with labeling. This choice may come with cost, with more CVD risk factors 
correlated with alternative choices of NRTis. As some antiviral regimens may be associated 
with CVD while others with kidney disease, understanding CVD risk profile versus kidney 
function protection may help optimize care of patients. 
Funding: Private Foundation Support
FR-PO525
Total Kidney Volume Computation in ADPKD: Different Methods in 
Comparison  Kanishka Sharma,1 Anna Caroli,1 Katja Petzold,4 Andreas L. 
Serra,4 Giuseppe Remuzzi,1,3 Andrea Remuzzi.2  1Bioengineering, Mario Negri 
Inst, Bergamo, Italy; 2Biomedical Engineering, Univ of Bergamo, Bergamo, 
Italy; 3Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni 
XXIII, Bergamo, Italy; 4Univ of Zurich, Zurich, Swaziland.
Background: In ADPKD, kidney enlargement is associated with renal function decline, 
and total kidney volume (TKV) is gaining acceptance as surrogate marker of disease 
progression. In view of its effective use, TKV assessment should be as quick and accurate 
as possible. Aim of this study was to compare different TKV quantification methods.
Methods: TKV was computed on 13 MRIs from ADPKD patients enrolled in the 
EuroCYST Initiative (TKV=[707-6605] ml) by two tracers twice, using 4 methods: 1) 
polyline manual tracing with ImageJ software; 2) free-hand manual tracing with Osirix 
software; 3) semi-automatic tracing with customised ImageJ Livewire Plugin; 4) TKV 
estimation using mid-slice (Bae KT, Am J Nephrol 2013). Reproducibility, reliability, and 
agreement between methods were assessed.
Results: All of the methods were comparable in terms of intra- and inter-rater reliability 
(CCC=1, ȡ>0.95). ImageJ polyline and Livewire tool showed highest agreement (30±65 
ml difference), while mid-slice method showed largest discrepancies. 
Mid-slice method required significantly less time than all other methods (~5 min), 
followed by Osirix free-hand (20±9 min), Livewire tool (24±9 min), and finally ImageJ 
polyline (35±12 min).
Conclusions: Mid-slice is much faster than whole kidney contouring for TKV 
quantification, but can provide only a clinical estimate of TKV. Whole kidney contouring 
must be used to monitor ADPKD progression and assess the efficacy of novel therapies. 
Livewire tool provides the best compromise between accuracy and time required. 
Acknowledgments. This study was funded in part by the European Community (FP7-
PEOPLE-MCA-ITN-317246, TranCYST project).
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FR-PO526
Renal Reserve: Development of a Kidney Stress Test  Kyle Rodenbach,1 Dana 
F. Fuhrman,2 Paula S. Maier,1 Katherine D. Shaw,1 George J. Schwartz.1  1Peds, 
Univ of Rochester, Rochester, NY; 2Peds, Univ of Pittsburgh, Pittsburgh, PA.
Background: Renal reserve (RR) is the difference in stimulated versus baseline 
glomerular filtration rate (GFR); it might predict future kidney health. The purpose of this 
study was to compare a meat versus liquid protein load in a cystatin-C-based (Cys-C) RR 
test using cimetidine-inhibited creatinine clearance (Cr Cl) and iohexol infusion clearance 
(Io Cl) for validation.
Methods: Participants (N=18) were screened for health status, blood pressure, and 
proteinuria. They followed a low protein diet and took cimetidine (20 mg/kg) for two days 
prior to the study. Water loading was used to maintain urine flow, and two hours were 
allotted for iohexol steady state equilibration. Participants 1-10 received a burger (1 g/kg 
protein); 11-15 received a ProCel® shake (1 g/kg protein); and 16-18 received a high dose 
ProCel® shake (1.5 g/kg protein). Data were analyzed for significance of RR. Cystatin-C 
estimated GFR (Cys-C eGFR) was calculated using the CKD-EPI Cys-C formula (Inker 
NEJM 2012) following IFCC calibration (ERM-DA471).
Results: Participants (N=18) had a mean (SD) age of 22 (2) years and were 39% male 
and 72% white. Baseline GFR (SD) in mL/min/1.73m2 averaged 103.4 (14.7) for Cr Cl; 
108.9 (9.0) for Io Cl (N=8); and 117.4 (6.1) for Cys-C eGFR. For the burger group (N=10), 
mean RR (SD) in mL/min/1.73m2 was 17.1 (11.6) for Cr Cl (P=0.001); 8.4 (4.3) for Io 
Cl (P<0.001); and 4.7 (2.4) for Cys-C eGFR (P<0.001). For 1.0-1.5 g/kg shakes (N=8), 
mean RR (SD) in mL/min/1.73m2 was 15.8 (5.8) for Cr Cl (P<0.001), 11.7 (9.0) for Io Cl 
(P=0.008), and 2.4 (2.9) for Cys-C eGFR (P=0.05). The burger and shake groups did not 
differ significantly in RR determined by Cr Cl, Io Cl, or Cys-C but Cys-C-based RR was 
significantly less than Io-based RR for both groups. There were no differences in post-load 
versus pre-load Cr/Io clearance ratios.
Conclusions: Cys-C-based RR following a burger provides a simple stress test of 
kidney function which was validated by classical renal clearances and can be applied to 
those who recover from acute kidney injury. Why Cys-C-based RR was smaller than Io 
RR, the reference standard, is a topic for future investigation.
Funding: Other NIH Support - CTSI, University of Rochester, Private Foundation 
Support
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AT1 Receptor Antagonism Before Ischemia Prevents Acute Kidney Injury 
Transition to Chronic Kidney Disease  Roxana Rodríguez Romo, Kenia 
Benitez, Rosalba Perez-villalva, Jonatan Barrera, Arturo Gómez, Gerardo 
Gamba, Norma O. Uribe-uribe, Norma Bobadilla.  Molecular Physiology 
Unit, Unidad de Fisiología Molecular, Inst de Investigaciones Biomédicas, 
UNAM e Inst Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 
Mexico, Mexico.
Background: Despite the clinical recovery of an acute kidney injury (AKI) episode, 
progression to chronic kidney disease (CKD) could be observed on long time follow-up. 
The mechanisms are poorly understood. To analyzed if angiotensin II receptor blockade 
(ARB) before the ischemic insult is effective in abrogating the severity of the AKI episode 
and/or the progression to CKD.
Methods: Male Wistar rats were divided into 4-groups of rats: sham; sham plus 
losartan 3-d before surgery; bilateral renal ischemia for 45-min (UTxI); and losartan 
administration (3-d) before ischemia (Los-Pre). Animals were studied after 1, 3, 5, 15 days 
or 9-months. At the end of each experimental period, physiological, histopathological, 
inmunohistochemestry, biochemical and molecular studies were performed.
Results: UTxI group developed CKD characterized by renal dysfunction, proteinuria, 
renal hypertrophy, glomerulosclerosis, tubular atrophy and tubulointerstitial fibrosis. At 
the ultra-structural glomerular level, foot process effacement was observed, which was 
associated a reduction in immune-gold staining for nephrin. Renal injury was mediated by 
increased oxidative stress, inflammation and up-regulation of TGFβ, aSMA, and Colagen I 
protein levels. TGFβ overexpression was mainly observed in epithelial cells. Interestingly, 
in spite of, ARB did not prevent or reduced AKI severity; it was enough effective to prevent 
CKD. The renoprotection conferred by ARB was associated with the early recovery of 
renal blood flow, lesser inflammation and greater nuclear hypoxic inducible factor 1α 
(HIF1α) staining.
Conclusions: Our data shows that in spite of, losartan pre-treatment did not protect 
the rats against AKI, it was effective to prevent the transition to CKD. The mechanisms by 
which losartan prevented CKD were in part due to the early renal blood flow recovery, lesser 
inflammation and greater HIF1α nuclear translocation within the 15 days post-ischemia.
Funding: Government Support - Non-U.S.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
480A
J Am Soc Nephrol 26: 2015 CKD: Risk Factors for Incidence and Progression - II Poster/Friday
FR-PO528
Specific Endothelial Heparin-Binding EGF-Like Growth Factor Deletion 
Ameliorates Renal Injury Induced by Chronic Angiotensin II Infusion 
Fenghua Zeng, Lance A. Kloepfer, Raymond C. Harris.  Medicine, Vanderbilt 
Univ, Nashville, TN.
Background: Transactivation of EGFR by angiotensin II (Ang II) plays important 
roles in the initiation and progression of chronic kidney diseases (CKD). In vitro studies 
suggested that HB-EGF may be a critical mediator in this process, whereas its role in vivo 
has not been reported.
Methods: Age-matched male littermates of HB-EGFlox/lox mice with endothelial-SCL-
cre-ER (T) (+) or (-) were used. Tamoxifen injections produced control (HBlox/lox) and 
mice with specific deletion of HB-EGF from endothelium (HBendo-/-), which underwent 
uninephrectomy and osmotic minipump-mediated infusion with saline or Ang II for 8 weeks. 
Systolic blood pressures (SBP) were measured by tail-cuff. Renal injury was evaluated 
by albuminuria using urinary albumin/creatinine ratios and by morphology with periodic 
acid-Schiff (PAS) staining. Renal EGFR activation was determined by immunoblotting 
and immunostaining. Endothelium/podocyte injury, inflammation and renal fibrosis were 
evaluated by immunostaining.
Results: Compared to control, kidneys from HBendo-/- mice with Ang II-infusion had 
significantly reduced EGFR activation. Endothelial HB-EGF deletion did not significantly 
prevent the hypertension induced by Ang II infusion, albeit lower SBP was detected in 
HBendo-/- mice compared to HBlox/lox mice. However, it decreased Ang II-infusion related 
renal injury, as demonstrated by 1) less albuminuria; 2) less glomerulosclerosis with 
glomerular score of 0.793 versus 1.652 in the control; 3) preserved endothelial integrity 
and decreased podocyte injury, as shown by more glomerular tufts area and WT1 positive 
cells, and less apoptotic cells measured by cleaved caspase 3 and TUNEL staining; 4) 
reduced inflammation in perivascular area and interstitium measured by F4/80 and CD3 
immunostaining; and 5), reduced renal fibrosis, as shown by α-SMA immunostaining.
Conclusions: Shedding of HB-EGF from endothelium plays an important role in Ang 
II induced renal injury by linking Ang II-AT1R with EGFR transactivation. Inhibition of 
HB-EGF shedding could be a potential therapeutic strategy for CKD.
Funding: NIDDK Support, Veterans Administration Support
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Effects of Acute Kidney Injury (AKI) Severity and Co-Morbidities on 
Chronic Kidney Disease (CKD) Progression  Gregory John Wilson,1,2 Adrian 
Lawrence Kark,1,2 Andrew John Mallett,1,2,3,4 Anne Salisbury,1,2,4 Zaimin Wang,2,4 
Helen G. Healy,1,2,4 Wendy E. Hoy.2,4  1Kidney Health Service, Royal Brisbane 
and Women’s Hospital, Australia; 2CKD.QLD and NHMRC CKD.CRE, The 
Univ of Queensland, Australia; 3Inst for Molecular Bioscience and School of 
Medicine, UQ, Australia; 4Centre for Chronic Disease, UQ, Australia.
Background: AKI is a common and important cause of CKD. It remains unknown how 
AKI severity influences CKD progression. Which co-morbidities influence the progression 
of CKD also remains undetermined.
Methods: We aimed to explore whether AKI severity and patient comorbidities 
influence CKD progression. Patients with CKD associated with a clinical diagnosis of 
AKI were identified in the Royal Brisbane & Women’s Hospital cohort (n=1150) of the 
CKD.QLD registry. AKI events were confirmed through historical creatinine values (2005 
onward), and severity determined using AKIN criteria. CKD progression was assessed 
by change in glomerular filtration rate per year (DeGFR/yr) based on initial and final 
eGFR(CKD-EPI) values. All co-morbidities identified at the time of enrolment into the 
registry were explored.
Results: 384 patients were recorded as having a primary or secondary AKI diagnosis; 
157 of these (99 male, mean age 67yrs) were biochemically confirmed. 133 patients (84.7%) 
were identified as Stage 1 AKI, 16 (10.2%) as Stage 2 and 8 (5.1%) as Stage 3. A one-
way ANOVA revealed that AKI severity did not modulate CKD progression. However, 
numerically DeGFR/yr was largest for Stage 3 patients (5.1mL/min/1.72m2), and smallest 
for Stage 1 patients (1.6mL/min/1.72m2). The only two co-morbidities found to influence 
CKD progression were diabetes mellitus (DM; 35.6% of patients) and peripheral vascular 
disease (PVD; 12.1% of patients). CKD progression was significantly increased in patients 
with DM compared with patients without (DeGFR/yr 3.7mL/min/1.72m2, p<0.001), and 
patients with PVD compared with those without (DeGFR/yr 4.4mL/min/1.72m2, p<0.05).
Conclusions: Surprisingly, AKI severity did not alter CKD progression. Both DM and 
PVD influenced CKD progression in patients with AKI suggesting an increased vulnerability 
to AKI in these patients.
FR-PO530
Association Between Gut Microbiome and Cardiovascular Risk in Chronic 
Kidney Disease Patients with Type 2 Diabetes Mellitus  Ruchi Singh, Tetyana 
L. Vasylyeva.  Pediatrics, Texas Tech Health Sciences Center, Amarillo, TX.
Background: Diabetes is one of the leading causes of CKD. It is well established 
that patients with T2DM often experience persistent low-grade inflammation leading 
to microvascular deterioration and progression of vascular complications along with 
impaired gut motility, which impacts their microbiomes. The aim of the study is the 
assessment of gut microbiota, plasma zonulin, and inflammatory cytokines (TNF-α, IL-6) 
in conjunction with FGF-23, ET and levels of LPS in CKD (stage 4 and 5) patients with 
Diabetic Nephropathy (DN).
Methods: Healthy controls were matched by age and gender. Their dietary habits 
have been reviewed. Total of 40 subjects participated in the study. TNF-α, IL-6, FGF 23, 
LPS. ET-1 and zonulin, levels were measured by ELISA and quantitative analysis of gut 
microbiota composition (454 pyro sequencing).
Results: Higher circulation serum zonulin, TNF-α, and IL-6, FGF 23 LPS, ET-1 levels 
were found in the CKD (stage 4 and 5) with T2DM. Gut microbiota in T2DM patients 
with advanced CKD was substantially different from healthy population with increased in 
percentage of LPS producing bacteria. Significant diversity was observed in gut microbiota 
in study subjects compared to control group. CKD patients had high serum concentration 
of zonulin, a marker of leaky gut syndrome. Zonulin concentration was found positively 
correlated with LPS, inflammatory markers and FGF-23.
Conclusions: Gut microbiota is a modifiable factor and zonulin could be a potential 
future target to control chronic inflammatory responses. Gut microbiota and increased 
gut permeability in patients with advanced CKD secondary to DN results in high level of 
circulation LPS that mediates chronic inflammation which was implicated in deterioration 
of cardiovascular health.
FR-PO531
Metabolomics of Chronic Kidney Disease in Cohort of Patients Given 
Probiotics  Subodh J. Saggi,1 Eli A. Friedman,1 Natarajan Ranganathan,3 
Kelly Mercier,2 Susan Mcritchie,2 Susan Sumner.2  1Nephrology/Medicine, 
SUNY Downstate Medical Center, New York, NY; 2Metabolomics, Research 
Triangle Inst, Research Triangle Park, NC; 3Kibow Biotechnology Inc., Kibow 
Biotechnology Inc., Newtown Square, PA.
Background: Persistent reduction in Glomerular Filtration Rate (GFR) below 60 ml/
min/1.73 m2 BSA over 3 months are hall marks of Chronic Kidney Disease (CKD). Urea is 
still considered a major uremic toxin clinically despite the description of middle molecules 
as being toxic. Persistent elevation of BUN may accompany reductions in GFR in some 
patients. We were specifically interested in obtaining pilot data identifying metabolites 
that differentiated patients with CKD whose BUN decreased after 4 months of probiotics 
treatment and its possible mechanisms.
Methods: Broad spectrum 1H-NMR metabolomics was used to analyze baseline and 6 
month plasma samples frozen from a phenotypically characterized cohort of patients with 
CKD Stage 3 and below from a prior Probiotic RenadylTM study. NMR spectral data of 
baseline and 6 month plasma samples were analyzed after identical treatment of all samples. 
A total of 24 baseline samples were differentiated by a change in their BUN. Principal 
components analysis and orthogonal partial least squares discriminant analysis was used to 
analyze the data and determine the metabolites that best differentiated the phenotypic groups.
Results: Characteristics of the cohort population were age 57.7 ± 14 yrs, mean BMI 
31.3 ± 6.1 Kg/m2, 10 males and 14 females, 20 with HTN, 8 with DM, 11 Caucasian and 
9 AA, 3 other, 1 unknown. 16 patients who had a decrease in BUN after 4 months of 
probiotics treatment could be differentiated based on baseline samples from those whose 
BUN increased or did not change.The majority of the metabolites that differentiated the 
groups were microbiome related metabolites.
Conclusions: Metabolomics analysis revealed a signature of metabolites that were 
associated with a decrease in BUN, and holds promise for use in predicting individuals 
with CKD that would most benefit from use of probiotics. The majority of the metabolites 
important to the differentiation of groups map to pathways involved in microbial 
metabolism.
Funding: Other NIH Support - NIH Common Fund for Metabolomics at RTI North 
Carolina: 1U24DK097193
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Potential Uremic Toxin Precursors in the Gut Identified by Metabonomics 
and Proteomics  Liwen Zhang,1 Hongli Jiang.2  1School of Medicine, Xi’an 
Jiaotong Univ, Xi’an, Shaanxi, China; 2Hemodialysis Center, First Affiliated 
Hospital of Medicine School, Xi’an Jiaotong Univ, Xi’an, Shaanxi, China.
Background: Many factors, e.g., the intestinal bacterial disorder, result in the species 
and amounts of harmful substances in the gut increasing, which leads to the increase of 
uremic retention molecules (URMs) in blood. These URMs may be classified according to 
their site of origin, that is, endogenous metabolism, microbial metabolism, or exogenous 
intake. The latter two are known as gut-derived uremic toxins, i.e., gut is a significant origin 
of URMs; but, it is currently unclear of the profile of these uremic toxins.
Methods: Excluding special factors which affected the intestinal environment, the 
subjects were divided into two groups: hemodialysis patients with end-stage renal disease 
(HD group, n = 20) and healthy controls (CT group, n = 20). Fecal metabonomics based on 
the ultra-performance liquid chromatography-tandem mass spectrometry was undertaken 
to explore the low molecular weight metabolites, and fecal proteomics based on the two-
dimensional gel electrophoresis was employed to investigate the high molecular weight 
proteins. The data was analyzed with statistic and bioinformatic methods.
Results: Thirty-three metabolites and 31 proteins were identified. Among them, 17 
metabolites and 13 proteins were significant higher in HD group than those in CT group, 
including phenols, which are well-known uremic toxins originating from the gut; reactive 
carbonyl compounds (RCC), which are well-known URMs in serum but first identified in 
the gut; other harmful metabolites (e.g., fenthion, halosulfuron-methyl and diethylpropion), 
and two inflammation-associated proteins. However, the levels of 16 metabolites and 18 
proteins were lower in HD group comparing to CT group, including ajoene, which has 
been shown to exhibit anti-microbial and anti-cancer functions, and three proteins, which 
have indicated anti-inflammatory and anti-cancer activities.
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Conclusions: This study not only demonstrated RCC URMs originated from the gut, 
but also identified numerous potential uremic toxin precursors and deficient beneficial 
substances in the gut of uremic patients.
Funding: Government Support - Non-U.S.
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AST-120 Affects the Level of Circulating TNF-Alpha Receptors That Predict 
Both Renal and Cardiovascular Outcomes in Patients with Advanced Renal 
Dysfunction  Ran-hui Cha,1 Dong Ki Kim,2 Yon Su Kim.2  1Internal Medicine, 
National Medical Center, Seoul, Republic of Korea; 2Internal Medicine, Seoul 
National Univ College of Medicine, Seoul, Republic of Korea.
Background: Tumor necrosis factor alpha and its two receptors have a critical role in 
kidney diseases. We aimed to establish the role of circulating TNF-alpha receptors (cTNFRs) 
as a new biomarker of renal disease and to identify the impact of AST-120 on the level.
Methods: 579 patients from 11 medical centers in Korea were prospectively recruited 
and followed up for 36 months after randomization into AST-120 and control arms. A total 
of 6 gram of AST-120 was given to participants in AST-120 arm as well as conventional 
treatment. cTNFRs were measured by ELISA method at the time of randomization and 
1 year after. The renal outcome was composite of serum creatinine (SCr) doubling, 50% 
reduction of estimated glomerular filtration rate (eGFR), or initiation of renal replacement 
therapy.Major adverse cardiovascular events (MACE) were also evaluated.
Results: A total of 465 patients were analyzed. Mean SCr and eGFR level was 2.8 ± 
0.67 mg/dl and 26.79 ± 7.263 ml/min/1.73m2, respectively. The levels of cTNFRs throughout 
the study period were not different between two treatment arms. But the higher AST-120 
compliance patients had, the lower cTNFRs they showed in the AST-120 arm. The highest 
tertile of cTNFRs showed the highest cumulative rate of composite renal outcomes followed 
by the intermediate tertile of cTNFRs after the adjustment for traditional risk factors. More 
change of cTNFRs was also independently associated to the more occurrence of composite 
renal outcomes. MACEs occurred more frequently in patients with higher baseline cTNFRs 
and more change of cTNFRs (log-rank P = 0.01, 0.002 and 0.021 for cTNFR1, cTNFR2, 
and change of cTNFR2, respectively) and the significance of cTNFR2 remained after 
adjustment for diabetes, CKD stage, and proteinuria.
Conclusions: Baseline and change of cTNFRs did not improve the predictability of 
composite renal outcomes in comparison with classic biomarkers. But cTNFRs predicted 
both renal and cardiovascular outcomes in patients with advanced renal dysfunction. And 
AST-120 was effective to lessen the increase of cTNFRs.
FR-PO534
Swimming Exercise Training (EXE) Normalize Blood Urea Nitrogen (BUN), 
Decrease Glomerulosclerosis, and Attenuates the Loss of Myokine IL6 in 
Rats with Chronic Kidney Disease (CKD) by 5/6 Nephrectomy (5/6Nx) 
Rafael Luiz, Rodolfo Rosseto Rampaso, Kleiton Augusto Santos Silva, Luciana 
Jorge, Edson Andrade Pessoa, Maria A. Gloria, Mario Luis Ribeiro Cesaretti, 
Nestor Schor.  Nephrology, Federal Univ of São Paulo, São Paulo, Brazil.
Background: The aim of this study was to evaluate the EXE effects on renal function, 
glomerulosclerosis and myokine IL6 (has been associated with stimulation of hypertrophic 
muscle growth and myogenesis through regulation of the proliferative capacity of muscle 
stem cells) in rats with 5/6Nx.
Methods: Adult Wistar rats were divided in groups (n=8): Control (CS), Control+EXE 
(CE), Sedentary 5/6Nx (NS) and 5/6Nx+EXE (NE). The protocol was employed in 5/6Nx 
rats after 7 days from the surgical procedures. EXE periods were 60min/day/5 days a week 
during 8 weeks. It was evaluated arterial pressure (AP), maximal exercise test (MEtest), 
creatinine clearance (CrCl), BUN, proteinuria (uProt), glomerulosclerosis, myokine IL6 
(by Luminex) as well mortality rate.
Results: EXE did not modify the increment in MAP but prevent, at least in part, a 
lower decline in the MEtest caused by 5/6Nx (29±1 vs 16±2 m/min, p<0.05). A higher 
CrCl in NE was observed compared with NS, 2.27±0.33 vs 0.96±0.20 ml/min, respectively 
(p<0.05). BUN was normalized in NE (43.62±7.30 mg/dL). Proteinuria was not significantly 
different in NE vs NS group (36.87±3.53 vs 40.13±2.35 mg/24h). Glomerulosclerosis was 
48% higher in NS vs NE. Myokine IL6 (pg/ml) was decreased in NS (286.40±14) and 
attenuated the loss in NE (384.00±20.82). A higher mortality rate was observed in NS 
(70%) vs NE group (39%, p<0.05).
Conclusions: Results suggested that the EXE minimize the impact of 5/6Nx, by 
decreasing glomerulosclerosis and reducing the impact on CrCl (42%). Finally, attenuating 
myokine IL6 in NE, the decreasing mortality rate in NE vs NS and by minimizing the 
impact of 5/6Nx on CrCl indicate that EXE in this protocol, induced protection on renal 
function. Thus, it is reasonable to suggest that EXE could be an additional strategy to be 
employed in CKD.
FR-PO535
Does Autophagosome-Proteolysis Contribute to CKD-Induced Muscle 
Atrophy?  Zhen Su,1 Haidong Wang,3 Janet D. Klein,3 William E. Mitch,2 
Xiaonan H. Wang.3  1Dept of Nephrology, The First Affiliated Hospital of 
Wenzhou Medical Univ, Wenzhou, Zhejiang, China; 2Nephrology, Baylor College 
of Medicine, Houston, TX; 3Renal Medicine, Emory Univ, Atlana, GA.
Background: CKD-induced muscle wasting results from activation of the 
ubiquitin proteasome system (UPS). Since FoxO simulates the UPS but also activates 
autophagosomes, we hypothesized that autophagosome-induced proteolysis may contribute 
to CKD-induced muscle wasting.
Methods: CKD model in mice: subtotal nephrectomy for one month. Muscle 
overloading model: removal of gastrocnemius and soleus to overload the plantaris muscle 
(mimics resistant exercise) in normal and CKD mice. Acupuncture with low frequency 
electric stimulation (Acu/LFES) was applied 15 minutes daily for 2 weeks (Hu, JASN, 
26:626 2015).  Electrical stimulation used a consistent pulse, electric frequency 20HZ, 
current 1mA.
Results: Both exercise and Acu/LFES reduced CKD muscle loss. In muscles of 
CKD mice, mRNAs related to autophagy-lysosomal function, Bnip3, Atg12, Atg8, LC3II 
and Beclin-1, were upregulated and Bnip3, Beclin-1 and LC3II proteins were increased. 
Acu/LFES treatment reversed these changes. Exercise in control mice also increased 
autophagy-lysosomal related protein LC3-II, Beclin-1, P62 and Vps34. The levels of these 
mediators were not additive to changes observed in mice with CKD. We cultured C2C12 
myotubes in uremic serum and found increased autophagy markers, indicating activation 
of autophagosomes. Acidification alone did not stimulate autophagy markers. Based on 
the C2C12 results, the UPS, but not autophagosomes, is responsible for degradation of 
structural proteins (myosin and actin).
Conclusions: 1) autophagosome-mediated proteolysis occurs in CKD-induced muscle 
atrophy. In mice with CKD, the UPS was principally involved in muscle proteolysis; the 
role of autophagosomes was convoluted. 2) Prevention of muscle atrophy by exercise is 
not due to inhibition of the autophagy-lysosomal proteolysis pathway in CKD. 3) Muscle 
atrophy cannot be equated with increased autophagy markers. 4) Acu/LFES and exercise 
promote different autophagy consequences.
Funding: NIDDK Support, Other NIH Support - R01 AR060268, 
R01 DK037571
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Indoxyl Sulfate, a Uremic Toxin, Accelerates Skeletal Muscle Atrophy in 
CKD Condition  Yuki Enoki,1 Hiroshi Watanabe,1 Masafumi Fukagawa,2 Toru 
Maruyama.1  1Dept of Biopharmaceutics, Graduate School of Pharmaceutical 
Sciences, Kumamoto Univ, Kumamoto-shi, Japan; 2Div of Nephrology, 
Endocrinology and Metabolism, Tokai Univ School of Medicine, Isehara-shi, 
Japan.
Background: Skeletal muscle atrophy is often observed in chronic kidney disease 
(CKD) patients, especially in patients underlying hemodialysis. Uremic toxins have 
been known to link to CKD complications. However there has been no report on the 
relationship between uremic toxins and skeletal muscle atrophy. The purpose of this study 
is to investigate the involvement of uremic toxins on skeletal muscle atrophy observed 
in CKD condition.
Methods: In vitro cytotoxicity of uremic toxins on cell proliferation and differentiation 
was evaluated by using a mouse myoblast cell line (C2C12). The effect of uremic toxin 
on proteolysis and protein synthesis system in C2C12 was also evaluated. In the animal 
study, we examined the contribution of uremic toxin on muscle atrophy using uremic toxin 
overloaded half- or 5/6-nephrectomized mice.
Results: We focused on six protein bound solutes including indoxyl sulfate (IS), 
indole acetic acid, p-cresyl sulfate, hippuric acid, kynurenic acid and 3-carboxy-4-methyl-
5-propyl-2-furanpropanoic acid. Among these uremic toxins, IS significantly inhibited 
proliferation and differentiation of C2C12 myoblast cell, and decreased phosphorylation 
of Akt. Moreover, IS significantly increased atrophy-related genes expression but it did 
not affect differentiation-related genes expression. In the animal experiments, IS-overload 
reduced body weights and skeletal muscle weights of half- or 5/6-nephrectomized mice, 
and consequently weakened its muscular endurance. IS-overload mice showed increased 
skeletal muscle atrophy-related genes expression. In the same experimental condition, IS 
also induced the expression of inflammatory cytokine and transforming growth factor-β 
in skeletal muscle cells.
Conclusions: IS is the potent uremic toxin inducing skeletal muscle atrophy associated 
with CKD by increasing muscle atrophy-related genes.
FR-PO537
Myostatin Stimulates Progenitor Cells to Differentiate into Fibrocytes 
Leading to Muscle Fibrosis in Chronic Kidney Disease  Liping Zhang,1 
Jiangling Dong,1,2 William E. Mitch.1  1Medicine/Nephrology, Baylor College of 
Medicine, Housron, TX; 2Life Science& Engineering College, Northwest Univ 
for Nationalities, Lanzhou, Gansu, China.
Background: In chronic kidney disease (CKD), fibrosis develops in damaged kidneys 
leading to loss of functions. Fibrosis in muscle also complicates CKD but the identity of 
cells developing into fibrocytes and mechanisms causing fibrosis are not defined. The 
potential precursors of muscle fibrosis are mesenchymal progenitor cells (fibrotic and 
adipogenic progenitors (FAPs)) while mechanisms causing fibrosis include myostatin as 
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CKD raises its expression and muscle injury can stimulate injured muscles to develop 
fibrocytes. Our hypothesis is that CKD stimulates myostatin expression causing FAPs to 
differentiate into fibrocytes.
Methods: 1). we isolated and cultured FAPs, adding recombinant myostatin to 
determine if it causes FAPs to proliferate and differentiate into fibrocytes. 2) We isolated 
GFP-labelled FAPs from transgenic, GFP-expressing mice and transplanted them into tibialis 
anterior (TA) muscles of CKD mice. We assessed conversion of FAPs into GFP-fibrocytes 
using α-SMA expression. 3) CKD mice were injected with an anti-myostatin peptibody 
to determine if myostatin stimulates muscle fibrosis. 4) Interactions between myostatin 
signaling and FAP conversion to fibrocytes were tested by knocking down Smad3 with a 
lentivirus expressing Smad3 SiRNA.
Results: In cultured FAPs, myostatin stimulated their proliferation and conversion into 
fibrocytes and there is proliferation of FAPs in injured muscles of CKD mice. GFP-labelled 
FAPs transplanted into TA muscles of CKD mice differentiate into fibrocytes identified as 
expressing the fibrosis marker, α-SMA. FAP proliferation and muscle fibrosis were prevented 
in CKD mice injected with the anti-myostatin peptibody. Finally, Smad3 knock-down 
blocked FAP differentiation into fibrocytes indicating that a myostatin to Smad3 pathway 
is responsible for the conversion of FAPs to fibrocytes.
Conclusions: CKD stimulates myostatin production to activate FAPs which 
differentiate into fibrocytes. The process is blocked by an anti-myostatin peptibody, 
providing a new target for preventing muscle fibrosis as a complication of CKD.
Funding: NIDDK Support, Other U.S. Government Support, Private Foundation 
Support
FR-PO538
Effect of Methoxy Polyethylene Glycol – Epoetin Beta on Plasma Levels 
of IL-1β, TNF-RI, TNF-RII, sFAS, sFASL, TGFβ, MMP-9 in Patients with 
CKD  Piotr Bartnicki,1 Ewa Majewska,2 Zbigniew Baj,2 Jacek Rysz.1  1Dept of 
Nephrology, Hypertension and Family Medicine, Medical Univ of Lodz, Poland; 
2Dept of Pathophysiology and Immunology, Medical Univ of Lodz, Poland.
Background: In patients with CKD are observed disturbances of immune cells function 
and endothelium dysfunction with high tissues fibrosis. ESAs using in these patients, beyond 
anemia correction seem to have renoprotective effect and slow progression of CKD. In this 
study we aimed to determine effect of methoxy polyethylene glycol – epoetin beta (Mircera) 
on plasma levels of selected parameters in predialysis patients with CKD.
Methods: 28 patients with CKD and anemia, treated with Mircera, were enrolled to 
the study. The healthy control group included 15 volunteers. Plasma levels of evaluated 
parameters were measured with available enzyme – linked immune-sorbent assay (ELISA) 
kits.
Results: The results of our study are shown in the table.
CKD before treatment CKD after treatment Control group
Hb [g/dl] 9.6 (9.1 – 10.1) * 11.6 (11.1 – 12.1) * • 14.4 (13.3 – 14.9)
eGFR [ml/min] 16.4 (13.9 – 21.8) * 16.6 (14 .0 – 23.3) * 65 (63 – 74)
IL-1β [pg/ml] 2.72 (1.63 – 3.81) * 2.97 (2.24 – 3.7) * 1.29 (1.25 – 1.33)
TNF-RI [pg/ml] 5268 (3741 - 6795) * 5430 (3906 - 6954) * 1136 (912 -1360)
TNF-RII [pg/ml] 8092 (7183 - 9001) * 9308 (7912 - 10703) *• 2360 (1899 - 2821)
sFAS [pg/ml] 3325 (2444 - 4207) * 3174 (2666 - 3682) * 507 (333 - 580)
sFASL [pg/ml] 90.3 (61 – 119.6) * 87.5 (66.1 – 108.9) * 60.1 (20.4 – 100.8)
TGFβ [pg/ml] 25.2 (16.3 – 34.1) * 25.3 (12.1 – 38.5) * 12.3 (8.7 – 15.9)
MMP-9 [ng/ml] 1125 (659 – 1591) * 687 (330 – 1044) *• 273 (157 – 389)
*p < 0.05 to control group, •p < 0.05 to CKD before treatment
Conclusions: Plasma concentrations of evaluated parameters are significantly higher in 
CKD patients in comparison to control group. After ESA treatment plasma level of TNFII 
was significantly higher and MMP-9 was significantly lower in CKD patients. These data 
suggest that Mircera used in correction of anemia in CKD might influence on immune cells 
function, apoptosis and tissue fibrosis.
FR-PO539
Qualitative Changes in Erythrocytes in Chronic Kidney Disease 
Ken Aizawa, Ryohei Kawasaki, Yoshihito Tashiro, Michinori Hirata, Koichi 
Endo, Ken-ichi Serizawa, Yasushi Shimonaka.  Product Research Dept, Chugai 
Pharmaceutical Co., Ltd., Kamakura, Japan.
Background: Therapeutic control of anemia in chronic kidney disease (CKD) is 
assessed by monitoring hemoglobin (Hb) levels. However, monitoring Hb alone could 
potentially fail to reveal pathological changes in erythrocytes, because erythrocyte lifespans 
are shorter in CKD. Shortening of erythrocyte lifespans may attenuate erythropoietin 
responsiveness, resulting in poor prognosis of CKD. Erythrocyte lifespans are thought to 
be shortened by qualitative changes such as deterioration of deformability and stability, 
but it is not yet clear whether these aspects are changed in CKD.
Methods: To assess qualitative changes in erythrocytes were first confirmed in a 
rat model of iron-deficiency anemia. Deformability was quantified by laser diffraction 
ektacytometry and stability was quantified by hemolysis test. We next produced CKD model 
rats by anti-Thy1.1 antibody injection plus uninephrectomy. Epoetin beta pegol (C.E.R.A., 
25 mg/kg) was intravenously injected the day after surgery. At 11 wks, Hb levels, erythrocyte 
deformability and stability, plasma urea nitrogen (UN) and creatinine (pCre) were assessed.
Results: Iron-deficiency rats showed significant anemia and had impaired erythrocyte 
deformability and stability. These changes in erythrocytes were almost normalized by 
administration of iron sucrose. In the CKD model, Hb level was significantly decreased and 
deformability and stability of erythrocytes were significantly impaired. Stability significantly 
recovered and deformability tended to recover in the C.E.R.A. group, although there was no 
significant difference in Hb levels between the disease group and C.E.R.A. group. Kidney 
function (UN and pCre) correlated significantly with stability, but not with deformability. 
Morphologic parameters (mean corpuscular volume and red cell distribution width - standard 
deviation) did not reflect changes in deformability and stability.
Conclusions: Deformability and stability of erythrocytes were impaired in CKD rats, 
and may be linked with kidney dysfunction. Focusing on qualitative aspects of erythrocytes 
may provide a better understanding of pathological conditions and therapeutic benefit in 
anemia.
FR-PO540
Eryptosis in Chronic Kidney Disease  Grazia Maria Virzì, Anna Clementi, 
Alessandra Brocca, Massimo de Cal, Claudio Ronco.  Nephrology-IRRIV.
Background: Even though anemia in CKD results mainly from the lack of 
erythropoietin, accelerated erythrocyte death(eryptosis) seems to be a contributor 
factor. Eryptosis is characterized by cell shrinkage and cell membrane scrambling with 
phosphatidylserine(PS)-exposure at the erythrocyte (RBC) surface. Eryptosis may 
be triggered by some uremic toxins. P-cresol is an uremic toxin which has negative 
cardiovascular and cytopathic effects. This study explored if eryptosis is triggered by 
p-cresol and if different stages of CKD may influence erythrocyte death.
Methods: RBCs from healthy subjects were incubated in vitro at a hematocrit of 
0.4% in RPMI with different concentrations of p-cresol (0-2.5-5-10-20-40mg/l) and with 
plasma from CKD patients (5 for each stage) for 24hours. PS exposure was estimated from 
AnnexinV binding in flow cytometer.
Results: Increasing concentrations of p-cresol modified significantly the percentage 
of PS exposure on RBC surface, thus suggesting that increasing concentrations of p-cresol 
may stimulate eryptosis in vitro. Moreover, there was no significant difference in terms of 
median values of eryptosis between CKD stages, but a positive trend was evident: eryptosis 
increase with CKD progression.
CKD1 CKD2 CKD3 CKD4 CKD5
ERYPTOSIS % 4.7 (4.2-5.0) 3.5 (3.4-5.4) 3.7 (3.2-6.7) 6.4 (4.3-10.3) 6.4 (5.0-12.6)
Conclusions: In addition to its known cardiovascular and cellular effects, p-cresol 
seems to stimulate eryptosis in vitro and increasing concentrations of this uremic toxin 
may be responsible for higher levels of eryptosis in vivo. Our data show that CKD 
plasma contains components able to trigger eryptosis and different stages of CKD may 
be responsible for different levels of RBC death, thus suggesting that progression of 
CKD may increase eryptosis in vivo. These results suggest a role of uremic toxicity in 
the genesis of eryptosis and renal anemia. It is necessary to increase the sample size to 
validate our hypothesis.
Funding: Private Foundation Support
FR-PO541
Palmitate Exacerbates Renal Anemia: Suppression of Renal Erythropoietin 
Production via Endoplasmic Reticulum Stress  Reiko Inagi,1 Thitinun 
Anusornvongchai,1 Yu Ishimoto,2 Akira Okada,2 Norio Suzuki,3 Masayuki 
Yamamoto,3 Masaomi Nangaku.2  1Div of CKD Pathophysiology, The Univ of 
Tokyo Graduate School of Medicine, Tokyo, Japan; 2Divs of Nephrology and 
Endocrinology, The Univ of Tokyo Graduate School of Medicine, Tokyo, Japan; 
3Tohoku Univ School of Medicine, Sendai, Japan.
Background: Derangement of erythropoietin (EPO) production in renal EPO-
producing (REP) cells causes renal anemia. Palmitate induces endoplasmic reticulum (ER) 
stress that contributes to glomerular and tubular cell damages. Thus, we evaluated the effect 
of palmitate-ER stress axis on EPO production in REP cells.
Methods: C57/BL6 or the mice, in which the renal EPO gene was replaced with 
GFP or REP cells were lineage labeled with tdTomato, were daily injected with palmitate 
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(BSA-conjugated, PAL) or BSA for 11 days or fed with high palmitate (10%) diet for 4 
months. The hypoxia-induced EPO production or ER stress status in kidney, especially in 
REP cells, were then assessed by real-time PCR, WB, and IF assay. In in vitro study, we 
used HepG2 (hepatic EPO producing cells) treated with PAL.
Results: PAL (injection and diet) suppressed EPO production in vivo and in vitro under 
hypoxia (HIF activation with CoCl2). It was associated with activation of ER stress signal 
(ATF4 and XBP-1, p<0.05). ATF4 activated by PAL significantly bound to a novel ATF4 
binding site (TGACCTCT) at the 3’-enhancer region of EPO gene and suppressed the 
enhancer activity and subsequent EPO mRNA expression. HepG2 overexpressing dominant 
negative ATF4 ameliorated the suppression of EPO production by PAL. Importantly, PAL 
did not change the REP cell number, while REP cells markedly declined EPO production 
by PAL. In contrast, the number of REP cells positive for ATF4 was increased by PAL, 
indicating that suppression of EPO production in REP cells by PAL was mediated by ATF4 
activation, namely ER stress.
Conclusions: EPO production by REP cells was suppressed by palmitate, especially 
under hypoxic condition, via the ER stress pathway (ATF4 activation). The link between 
dyslipidemia (palmitate) and ER stress may contribute to development and progression 
of renal anemia, and subsequent CKD and highlight the impact of palmitate diet on CKD 
prevention.
Funding: Government Support - Non-U.S.
FR-PO542
The Function of Integrinβ4 in Epithelial-to-Mesenchymal Transition of HK2 
Cells  Qi Wang, Yan Wang, Xiaoyan Huang, Zibo Xiong, Zuying Xiong.  Dept 
of Nephrology, Peking Univ Shenzhen Hospital, Shenzhen, Guangdong, China.
Background: To explore the function of integrinβ4 in epithelial-to-mesenchymal 
transition (EMT)of HK2 cells, and further study the role of integrinβ4 in renal fibrosis.
Methods: (1) Cultered HK2 cells were divided into 4 groups: 0ng/ml TGFb1 treated 
group (negative control), 1ng/ml TGFb1 group , 3ng/ml TGFb1 group and 9ng/ml TGFb1 
group .(2) We constructed a stable shRNA mediated repression of integrinβ4 in HK2 cells 
and divided into 4 groups: control-shRNA HK2 cells without TGFb1; control-shRNA HK2 
cells with 5ng/ml TGFb1; β4-shRNA HK2 cells without TGFb1; β4-shRNA HK2 cells with 
5ng/ml TGFb1 (3) The vivo experiment was performed in IgA nephropathy kidney tissues 
obtained from 45 patients that underwent a biopsy procedure during 2013-2014. According 
to the degree of tubulointerstitial lesion, kidney specimens were divided into 3 groups: mild 
lesion, moderate lesion, and severe lesion. We handle normal kidney portions as controls. 
The expressions of integrinβ4, E-cad, CTGF and α-SMA were assessed by qRT-PCR and 
westernblot; immunofluorescence was used in different degrees of tubulointerstitial lesions.
Results: (1) Compared with negative control, integrinβ4 and E-cad were significantly 
lower, however, CTGF and α-SMA were increased (2) Integrinβ4 and E-cad in β4-shRNA 
HK2 cells group were lower than control-shRNA HK2 cells, in contrast, CTGF and α-SMA 
were increased; integrinβ4 and E-cad with TGFb1 treatment were significantly lower than 
without TGFb1 groups, CTGF and α-SMA expressions were increased. (3) Compared 
with mild lesion group, E-cad staining in moderate lesion group and severe lesion group 
reduced, α-SMA staining and integrinβ4 staining increased. After being further analyzed, 
the most of integrinβ4 staining located in neonatal renal tubules.
Conclusions: Integrinβ4 was decreased in the process of EMT, and reduced integrinβ4 
can exacerbate HK2 cells from epithelial cells transition to mesenchymal cells, therefore loss 
of integrinβ4 may be the marker of TIF. However, the results of vivo experiment appeared 
to contradict vitro experiments, the reason of this phenomenon may be that many neonatal 
renal tubules possess the ability of proliferation.
Funding: Government Support - Non-U.S.
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Signal Regulatory Protein-α Is Elevated in Uremic Cardiomyopathy and 
May Exacerbate Muscle Fibrosis  Sandhya S. Thomas, Jiangling Dong, Liping 
Zhang, William E. Mitch.  Medicine, Baylor College of Medicine, Houston, TX.
Background: Insulin resistance in chronic kidney disease (CKD) begins early in the 
disease, compromising anabolic responses to insulin/IGF-1 signaling. We have previously 
demonstrated that a novel protein, signal regulatory protein alpha (SIRPα) is involved in 
insulin signaling, exacerbating skeletal muscle metabolism. We now describe for the first 
time elevation of SIRPα in CKD cardiac muscle which not only adversely influences insulin 
signaling, but may exacerbate muscle fibrosis.
Methods: CKD was created via subtotal nephrectomy and mice with CKD greater than 
2 months hearts were harvested and left ventricle muscle samples were examined for SIRPα, 
IRS-1, α-SMA, GAPDH. Additionally, C2C12 myoblasts were treated to overexpress SIRPa 
vs. GFP plasmid. Also, myoblasts were transfected with silencing RNA (SiRNA) SIRP-α 
or scrambled SiRNA (control). Western blots analysis was performed based on skeletal 
and cardiac muscle cell lysates.
Results: After ~2 months of CKD, the mice experience left ventricle hypertrophy 
with a heart weight to body weight that is significantly larger vs. control mice. SIRPa was 
significantly increased in cardiac muscles of mice with CKD, with reduction in tyrosine 
phosphorylation of IRS-1. This finding was previously reported in skeletal muscles of mice 
with CKD. Additionally, fibrosis marker α-SMA was increased in cardiac muscles of mice 
with CKD vs. control mice. In order to determine a cause and effect relationship, SIRPa 
was overexpressed utilizing a SIRPa plasmid vs. GFP plasmid for control. In myoblasts 
in which SIRPa was overexpressed, fibrosis marker α-SMA increased. Finally, when we 
silenced SIRPα in muscle cells treated with a cytokine mixture, containing cytokines present 
in CKD patients, fibrosis marker α-SMA was downregulated.
Conclusions: These results imply that SIRPα increases fibrosis, and suggesting that 
SIRPα may have influences on cardiac muscle fibrosis via a new pathway in chronic kidney 
disease. Ultimately blocking SIRPα in heart muscle may improve cardiac fibrosis associated 
with chronic kidney disease.
Funding: Veterans Administration Support
FR-PO544
Retinal Microvascular Abnormalities and Incidence and Progression of 
Chronic Kidney Disease  Charumathi Sabanayagam,1,2 Peng Guan Ong,1 Boon 
Wee Teo,3 Carol Y. Cheung,1,2 Ching-Yu Cheng,1,2 Ecosse L. Lamoureux,1,2 
Tien yin Wong.1,2  1Singapore Eye Research Inst, Singapore; 22ffice of Clinical 
Sciences, Duke-NUS Graduate Medical School, Singapore; 3National Univ of 
Singapore, Singapore.
Background: To examine the longitudinal association of a panel of retinal vascular 
parameters, markers of microvascular damage, with the incidence and progression of 
chronic kidney disease (CKD) in middle-aged Asian adults.
Methods: The population consisted of a cohort of Malay adults aged 40-80 years 
examined from 2004-06 and again from 2010-2012 (n=1464; 1306 free of CKD and 158 
with pre-existing CKD). The outcomes were incidence (estimated glomerular filtration rate 
[eGFR]<60 mL/min/1.73m2+25% decrease in eGFR) and progression of CKD (drop in 
eGFR category [≥60, 30-59, 15-30, <15]+25% decrease in eGFR or an annualized eGFR 
rate>3 mL/min/1.73m2/year). Retinal vascular parameters (arteriolar and venular caliber, 
tortuosity, branching angle, and fractal dimension were measured from baseline retinal 
photographs using a computer-assisted program (Singapore I Vessel Assessment, SIVA). 
Retinopathy was graded using a standard protocol.  Associations were examined using 
Cox proportional hazards regression models adjusting for age, sex, blood glucose, systolic 
blood pressure and baseline eGFR.
Results: Over a median follow-up of 6.6 years, 6.4% (70% had diabetes) developed 
incident CKD and 26.6% (62% had diabetes) developed progressive CKD. In multivariable 
models, retinal arteriolar narrowing, retinal venular widening, and presence of retinopathy 
were significantly associated with incident CKD. The HR (95% CI) of incident CKD was 
1.31 (1.01-1.72) per SD decrease in arteriolar caliber, 2.20 (1.10-4.41), for tertile 3 vs. tertile 
1 of venular caliber; 2.06 (1.24-3.44) for retinopathy. Increased arteriolar tortuosity alone 
was associated with progressive CKD (1.57 [1.04-2.37] per SD decrease. All associations 
were consistently present among those with diabetes.
Conclusions: Retinal vascular abnormalities increased the risk of CKD by more than 
two times in Asian adults. Our findings provide evidence that retinal imaging may be a 
useful tool to improve risk stratification for CKD.
Funding: Government Support - Non-U.S.
FR-PO545
Relationship Between Serum Bilirubin and Hyalinization of Renal 
Arterioles  Tsuyoshi Miyagi,1 Kentaro Kohagura,2 Yusuke Ohya,1 Kunitoshi 
Iseki.2  1Dept of Cardiovascular Medicine, Nephrology and Neurology, Univ 
of the Ryukyus, Nshihara-cho, Okinawa, Japan; 2Dialysis Unit, Univ of the 
Ryukyus, Nishihara-cho, Okinawa, Japan.
Background:  It has been suggested that there is a relationship between serum bilirubin 
and microangiopathy. In the present study, we examined the relationship between serum 
bilirubin levels and the hyalinization of renal arterioles in patients with chronic kidney 
disease (CKD).
Methods: We reviewed the clinical records of 138 patients with CKD (mean age: 44 
years) who underwent renal biopsy at our department during a 3-year period starting in 
2010. Patients who were receiving calcineurin inhibitors were excluded. The subjects were 
divided into three groups based on their total serum bilirubin levels: tertile group 1 (0.2–0.4 
mg/dl; 40 patients), tertile group 2 (0.5–0.7 mg/dl; 61 patients), and tertile group 3 (0.8–1.4 
mg/dl; 37 patients). Using the pathological specimens obtained from renal biopsies, the 
hyalinization of renal arterioles was semiquantitatively evaluated, and the mean score of 
renal arteriolar hyalinization grade was used for analysis.
Results: Tertile group 1 had markedly higher urinary protein levels and markedly 
lower serum hemoglobin (Hb) levels than tertile group 3. We defined total serum bilirubin 
levels under 0.5 mg/dl (tertile group 1) as low levels and divided them into two groups of 
values under and above 0.5 mg/dl. These were set as explanatory factors, and a multiple 
regression analysis was performed, with the degree of hyalinization of renal arterioles 
as the objective variable. A low serum bilirubin level was a significant risk factor for the 
hyalinization of renal arterioles (R2 = 0.45, β = 0.26, p = 0.003), even when adjustments 
were made for age, sex, HbA1c levels, mean blood pressure, history of smoking, and LDL 
cholesterol levels. Furthermore, even when the explanatory factor of serum Hb level was 
added, the results of the analysis remained the same.
Conclusions: Low serum bilirubin levels may be a risk factor for the hyalinization of 
renal arterioles independent of classical risk factors of cardiovascular disease.
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FR-PO546
Autonomic Nervous Dysfunction in Predialytic Chronic Kidney Disease: 3 
Years Observational Follow-Up Study  Su Min Park, Sang Heon Song, Eun 
Young Seong, Ihm Soo Kwak, Harin Rhee, Il Young Kim, Woo Jin Jung, Jong 
Man Park, Dong Won Lee, Soo Bong Lee, Min Jung Kim, Joo Hui Kim.  Internal 
Medicine, Pusan National Univ School of Medicine, Busan, Republic of Korea.
Background: Generally, sympathetic overactivity and impairment of the 
parasympathetic system are often seen in patients with dialytic CKD, COPD, RA as well as 
elderly. Also, arterial stiffness and edema have been related with mortality in patients with 
cardiovascular disease. However, to date, few data regarding autonomic nervous system, 
vascular stiffness, edema in pre-dialytic CKD was proposed. This study was designed to 
explore the interrelationship of those parameter in pre-dialytic CKD (G3, 4) and uncover 
the risk factor related with renal functional deterioration.
Methods: Thirty-three patients were enrolled. Hydration status (extracellular water 
[ECW]/total body water [TBW]) was determined by bioimpedance analysis. Brachial-ankle 
pulse wave velocity (baPWV) and neck ultrasonography for carotid plaque and intima-
media thickness were conducted for checking up of vascular status. CAN was scored using 
Ewing’s method and we also expressed the standard deviation of normal-to-normal interval 
(SDNN), low frequency/high frequency ratio (LF/HF ratio). Serial serum creatinine change 
over a median follow-up of 3 years was used for assessment of renal function.
Results: Of the 33 patients, 14 (42%) have suffered with CAN. Patients with CAN 
have higher progressive declining rate of renal function, baPWV, systolic BP compared 
with patients without CAN. The group having declining renal function has higher CAN 
score, baPWV and lower SDNN compared with preserved renal function group. CAN score 
correlated positively with ECW/TBW (r=0.405, p=0.019), mean PWV (r=0.623, p<0.001) 
and SBP(r=0.513, p=0.002). CAN score correlated negatively with declining rate of renal 
function(r=-0.471, p=0.006), Hb(r=-0.659, p<0.001) and albumin(r=-0.484, p=0.004).
Conclusions: Autonomic nervous dysfunction including lower SDNN and increased 
arterial stiffness including high baPWV may be important risk factors for deterioration 
of renal function in pre-dialytic CKD patients. Also, autonomic nervous dysfunction was 
related with arterial stiffness and edema.
FR-PO547
Inhibition of EGFR Alleviates the Development and Progression of 
Hyperuricemic Nephropathy in Rats  Na Liu,1 Li Wang,1 Andong Qiu,2 
Shougang Zhuang.3  1Nephrology, Shanghai East Hospital, Tongji Univ School of 
Medicine, Shanghai, China; 2School of Life Science and Technology, Advanced 
Inst of Translational Medicine, Tongji Univ, Shanghai, China; 3Dept of Medicine, 
Rhode Island Hospital and Brown Univ School of Medicine, Providence.
Background: Hyperuricemia is an independent risk factor for chronic kidney disease 
and contributes to kidney fibrosis. In this study, we investigated the effect of epidermal 
growth factor receptor (EGFR) inhibition on the development of hyperuricemic nephropathy 
(HN) and the mechanisms involved.
Methods: In this experiment, we did Cell Culture and Treatments, processed the 
establishment of Hyperuricemic nephropathy (HN) model, assessment of serum uric 
acid, renal Function and other biochemistry index, performed Immunoblot Analysis, 
Immunohistochemical Staining, as well as ELISA analysis.
Results: In a rat model of HN induced by feeding a mixture of adenine and potassium 
oxonate, increased EGFR phosphorylation and severe glomerular sclerosis and renal 
interstitial fibrosis were evident, accompanied by renal dysfunctionandincreased urine 
microalbumin excretion. Administration of gefitinib, a highly selective EGFR inhibitor, 
prevented renal dysfunction, reduced urine microalbumin and inhibited activation of 
renal interstitial fibroblasts and expression of extracellular proteins. Gefitinib treatment 
also inhibited hyperuricemia-induced activation of the transforming growth factor-β1 
(TGF-β1) and nuclear factor-κB (NF-κB) signaling pathways and expression of multiple 
profibrogenic cytokines/chemokines in the kidney. Furthermore, gefitinib treatment 
suppressed xanthine oxidase activity, which mediates uric acid production,andpreserved 
expression of organic anion transporters 1 and 3, which promotes uric acid excretion in 
the kidney of hyperuricemic rats.
Conclusions: Thus, blocking EGFR can attenuate development of HN via suppression 
of TGF-β1 signaling and inflammation, and promotion of the molecular processes that 
reduce uric acid accumulation in the body.
FR-PO548
Probiotic and Yogurt Consumption Is Associated with a Lower Prevalence 
of Albuminuria: A Cross-Sectional Analysis of NHANES  Rabi Yacoub, 
Girish N. Nadkarni, Deepak Kaji, Shanti N. Patel, John C. He, Steven G. Coca, 
Jaime Uribarri.  Medicine/Nephrology, Icahn School of Medicine at Mount 
Sinai, New York, NY.
Background: Animal data suggest that probiotic supplements may retard CKD 
progression. Yogurt is the most widely available probiotic food in the United States. 
However, the relationship between frequent yogurt consumption or probiotic use, and 
kidney parameters has not yet been evaluated. We aimed to study this association in the 
National Health and Nutrition Examination Survey (NHANES) database.
Methods: We utilized NHANES data with reported one year yogurt consumption 
frequency and probiotic use (2003-2005).The “consumers group” was defined as either 
yogurt consumption ≥ thrice weekly or regular use of probiotic, and we analyzed its 
association with albuminuria and eGFR after adjustment for demographic and clinical 
parameters.
Results: We had complete data on 6853 participants (mean age 48.3±20,45.2% 
male), of which,1559 (20.3%) were frequent consumers and 918 participants (12.2%) had 
detectable albuminuria (Median=67.1, IQR =41.6-157.1 mcg/mg). Frequent consumers had 
a trend towards lower mean UACR compared to non-consumers (mean difference [MD]: 
-12.3, 95% CI -29.8 to 5.2, P=0.17) that was attenuated after complete adjustment. On 
the other hand, frequent consumers had decreased odds of albuminuria (UACR > 30 mcg/
mg) compared to non-consumers (adjusted Odds Ratio 0.79; 95% CI 0.63-0.97; P=0.03).
Unadjusted Adjusted ۆ
OR 95% CI P OR 95% CI P
Albuminuria 0.69 0.58-0.84 <0.001 0.79 0.63-0.97 0.03
CKD 0.79 0.65-0.96 0.02 0.89 0.69-1.14 0.34
MD 95% CI P MD 95% CI P
UACR -12.3 -29.8 to 5.2 0.17 -0.5 -16.9 to 15.9 0.95
eGFR 1.1 -0.3 to 2.6 0.14 0.6 -0.3 to 1.6 0.21
ۆ Gender, age, race, medical history of hypertension and diabetes, socioeconomic status (family 
income to poverty index), HgbA1c, BMI, insulin, statin, RAAS blockers use and probiotic use 
duration
Neither CKD III-V prevalence, nor continuous eGFR was significantly different 
between the consumers and non-consumers.
Conclusions: We observed an inverse association of probiotic/yogurt consumption and 
albuminuria in a large, nationally representative general population sample. Future studies 
evaluating the association between probiotic/yogurt use and kidney diseases are warranted.
FR-PO549
Assessment of Serum Levels of Heavy Metals in Patients with Chronic 
Kidney Disease of Unknown Etiology  Om Prakash Kalra,1 Akash Gupta,1 
Alpana Raizada,1 Sunil Agarwal,1 Basu Dev Banerjee.2  1Medicine, UCMS 
and GTB Hospital, Delhi, India; 2Biochemistry, UCMS and GTB Hospital, 
Delhi, India.
Background: Chronic kidney disease (CKD) encompasses a wide spectrum of different 
etiological processes associated with abnormal kidney function and gradual progressive 
decline in glomerular filtration rate. CKD of unknown etiology (CKDu) has emerged as 
an important entity accounting for approximately 10% of CKD patients worldwide. Of the 
environmental toxins implicated in causation of CKDu, heavy metals form an important 
group. In the present study, we estimated the serum levels of lead, cadmium, arsenic and 
chromium in patients with CKDu and evaluated their role in the etiopathogenesis of CKDu.
Methods: The study was conducted in the Departments of Medicine and Biochemistry 
at University College of Medical Sciences and GTB Hospital, Delhi from December 2013 - 
April 2015. It was a case control, cross sectional study. Ninety subjects in the age group 18 
– 60 years of either sex were divided into 3 groups: Group I: Healthy controls (n=30), Group 
II: Individuals satisfying case definition of CKDu(n=30) and Group III: Individuals having 
CKD of known etiology (CKDk)(n=30). Detailed history, complete physical examination, 
routine investigations, urine albumin excretion (UAE) estimation was done. Estimation 
of serum level of heavy metals was done using Atomic Absorption Spectrophotometery.
Results: The median levels of lead, cadmium and chromium were significantly higher in 
patients of group II and this difference was statistically significant as compared to subjects of 
group I and III.The median levels of arsenic in patients of group II and III were similar but 
significantly higher than patients of group I. The levels of arsenic, cadmium and chromium 
detected in healthy controls (group I) were negligible. UAE in patients of group II and III 
were similar but significantly higher than patients of group I.
Conclusions: As compared to healthy controls, the serum levels of lead, cadmium, 
arsenic and chromium were found to be significantly higher in patients of CKDu. The study 
indicates a possible role of heavy metals in causation of CKDu.
FR-PO550
High Prevalence of Elevated Molybdenum Levels in CKD Patients 
Guido Filler,1,2,3 Vladimir Belostotsky,4 Marta Caroline Kobrzynski,1 Shih-Han 
S. Huang,1,2 Liju Yang.3  1Paediatrics, Univ of Western Ontario, London, ON, 
Canada; 2Medicine, Univ of Western Ontario, London, ON, Canada; 3Pathology 
and Laboratory Medicine, Univ of Western Ontario, London, ON, Canada; 
4Paediatrics, McMaster Univ, Hamilton, ON, Canada.
Background: Molybdenum (Mo, atomic number 42) is an essential trace element 
present in water and is crucial for human survival because four mammalian enzymes 
harbor a pterin-based Mo cofactor (Moco) at their active site and are Mo-dependent. 
Mo can be lethal in high doses, and chronic toxicity in animals leads to stunted growth, 
skeletal abnormalities, anemia, and histological changes in the kidney and liver. There is 
no information about Mo levels in patients with CKD.
Methods: After approval by the ethics board, and as part of a larger study on zinc 
supplementation in CKD, we studied 87 plasma Mo and copper (Cu) levels in 50 children 
with an eGFR < 90 and > 15 mL/min/1.73 m2 using the Schwartz formula. Where available, 
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we also recorded the cystatin C eGFR using the Filler formula in 35 children. Mo and Cu 
levels were measured using High Resolution Magnetic Sector Inductively Coupled Plasma 
Mass Spectrometry (HR-ICP-MS).
Results: The mean Schwartz eGFR was 46±23 and the Cystatin C eGFR was 48±20 
mL/min/1.73 m2. The median Mo level was 2.26 (interquartile range 1.7, 3.3 ug/L, mean 
2.78±1.70 ug/L), significantly higher than the upper reference interval of 1.4 ug/L, and 
with an exponential increase with lower eGFR.
The mean Cu level was 1124±378 ug/mL, not significantly different from the reference 
interval of 822 to 1201 ug/mL. eGFR was significantly negatively correlated with Mo levels 
(Spearman r = -0.57, p=0.0002).
Conclusions: With worsening kidney function, Mo levels accumulate, while Cu levels 
remain unaffected.
Funding: Clinical Revenue Support
FR-PO551
High Prevalence of Elevated Vanadium Levels in CKD Patients 
Guido Filler,1,2,4 Vladimir Belostotsky,3 Marta Caroline Kobrzynski,1 Liju Yang.4 
1Paediatrics, Univ of Western Ontario, London, ON, Canada; 2Pathology 
and Laboratory Medicine, Univ of Western Ontario, London, ON, Canada; 
3Paediatrics, McMaster Univ, Hamilton, ON, Canada; 4Medicine, Univ of 
Western Ontario, London, ON, Canada.
Background: Vanadium (V, atomic number 23) is an essential trace element present 
in many industrial products, especially in steel, which can be very toxic if levels are too 
high.The excretion of vanadium by the kidneys is rapid with a biological half-life of 20-40 
hours in the urine. Chronic poisoning is associated with respiratory symptoms, nervous 
disturbances, vegetative symptoms, tremors, palpitation of the heart, extrasystoles, anemia, 
leukopenia, and punctate basophilia of the erythrocytes. While adult data suggest that V 
is accumulating in dialysis patients, there is no information about V levels in patients 
with CKD.
Methods: After approval by the ethics board, and as part of a larger study on zinc 
supplementation in CKD, we studied 87 plasma V levels in 50 children with an eGFR < 90 
and > 15 mL/min/1.73 m2 using the Schwartz formula. Where available, we also recorded the 
cystatin C eGFR using the Filler formula in 35 children. V levels were measured using High 
Resolution Magnetic Sector Inductively Coupled Plasma Mass Spectrometry (HR-ICP-MS).
Results: The mean Schwartz eGFR was 46±23 and the Cystatin C eGFR was 48±20 
mL/min/1.73 m2. The mean V level was 0.117 (interquartile range 0.082, 0.1840 ug/L, 
mean 0.1170±0.4899 ug/L), significantly higher than the upper reference interval of 0.1 
ug/L (p=0.0057), and with a trend towards exponential increase with lower eGFR (r=-
0.3075, p=0.0604.
Conclusions: We observed a high prevalence of elevated V levels in the CKD patients. 
With worsening kidney function, V levels accumulate.
Funding: Clinical Revenue Support
FR-PO552
Chronic Nicotine (Ch-Nic) Exacerbates Subpressor Angiotensin II (SP-
AngII) Induced Renal Dysfunction in Part via the Renal Sympathetic 
Nervous System  Kiran B. Chandrashekar,1 Rodrigo Maranon,2 Arnaldo F. 
Lopez-Ruiz,1 Andrea P. Soljancic,1 Istvan Arany,1 Luis A. Juncos.1  1Nephrology, 
UMMC, Jackson, MS; 2Physiology, UMMC, Jackson, MS.
Background: Ch-Nic exacerbates SP-AngII-induced renal dysfunction and vascular 
remodeling while having minimal changes on blood pressure. However, the mechanisms 
are incompletely understood. Because Ch-Nic activates the renal sympathetic nervous 
system, we hypothesized that this activation contributes to nicotine’s deleterious effects 
on SP-AngII-induced renal dysfunction and injury.
Methods: Sprague Dawley rats underwent either sham or renal denervation (RD) 
surgery and then subdivided to get nicotine (12 g/ml) or vehicle (saccharine 2%). These were 
randomized to get either SP-AngII (SQ, 200ng/kg/min) or vehicle (saline). Hemodynamics 
were measured in anesthetized animals and tissue collected for biochemical analysis.
Results: 
Systolic BP 
(mmHg)
RVR 
(ml/min/
mmHg)
Pl. 
Creatinine 
(mg/dl)
NGAL UI/mg 
creat
TGF (ng/µg 
protein)
Ct+Sham 107± 6 15± 0.7 0.7± 0.02 0.26± 0.03 10± 1
CT+ RD 107± 5 14± 1 0.7± 0.02 0.3± 0.4 9.5± 1
Ch-Nic+ 
Sham 108± 5 14± 0.2 0.9± 0.03 0.5± 0.06 20± 0.6
Ch-Nic+RD 101± 3 15± 0.7 0.7± 0.04 0.4± 0.02 16± 1.6
SP-
AngII+Sham 162± 4*† 23± 1.3*† 2.4± 0.1*† 4.3± 0.4*† 29± 1.3*†
SP-AngII+RD 123± 3*# 17± 0.8# 2± 0.07#† 2.7± 0.2*#† 25± 1.3*†
Sp-AngII+Ch-
Nic+Sham 172± 4*# 31± 1.2*#† 3± 0.1*#† 8.3± 0.4*#† 40± 1.4*#†
SP-
AngII+CH-
NIC+RD
134± 2*Ȝ 18± 0.2Ȝ 2.4± 0.04*Ȝ 3.7± 0.3*#† 27± 1.2*#Ȝ
Conclusions: Renal denervation ameliorated SP-AngII-induced HTN, renal 
dysfunction, inflammation and injury. While RD did not appear to provide additional benefit 
to blood pressure control in Ch-Nic+SP-AngII group, it provided protection against the 
renal effects of Ch-Nic in the SP-AngII rats. These results support a role for the sympathetic 
nervous system in SP-AngII-induced renal dysfunction, as well as in the exacerbating effect 
of Ch-Nic on SP-AngII mediated renal dysfunction.
FR-PO553
Elevated Plasma Chymase Is Associated with Risk of Chronic Kidney 
Disease  Jing Chen,1,2 L. Lee Hamm,1 Damodar R. Kumbala,3 Chung-shiuan 
Chen,2 Kevin K. Wu,2 Swapna G. Kallu,1 Ravi Siriki,1 Shilpa Gadde,1 Arnold 
B. Alper,1 Myra A. Kleinpeter,1 Vecihi Batuman,1 Eric E. Simon,1 L. Gabriel 
Navar,1 Jiang He.2,1  1Medicine, Tulane School of Medicine, New Orleans, LA; 
2Epidemiology, Tulane School of Public Health and Tropical Medicine, New 
Orleans, LA; 3Nephrology, Ochsner Health System, New Orleans, LA.
Background: Chymase is the primary enzyme that mediates angiotensin II formation 
independent of angiotensin-converting enzyme and also play a role in activating 
transforming growth factor-βeta and matrix metalloproteinase-9. Experimental studies 
suggest that it may cause renal and cardiac fibrosis. However, the association of circulating 
chymase with chronic kidney disease (CKD) is not well studied.
Methods: We investigated the association of chymase and the risk of CKD in 163 CKD 
patients and 186 controls without CKD. CKD was defined as estimated glomerular filtration 
rate (eGFR) <60 ml/min/1.73 m2 or presence of albuminuria. Multivariable analyses were 
used to examine the relationship of plasma chymase and CKD.
Results: The multivariable-adjusted medians (interquartile ranges) were 1.6 (1.1, 
2.2) in patients with CKD vs. 1.2 (0.7,1.9) pg /mL in controls without CKD (p=0.002 
for group difference) after adjusting for age, gender, race, physical activity, smoking, 
drinking, systolic blood pressure, glucose, low-density lipoprotein cholesterol, body mass 
index, and history of cardiovascular disease. After adjustment for the above risk factors, 
the odds ratio for CKD comparing the highest to the lowest tertile of chymase was 2.85 
(95% confidence interval, 1.41-5.76).
Conclusions: These data indicate that elevated circulating chymase is associated 
with risk of CKD.
Funding: Other NIH Support - the National Center for Research Resources, National 
Institutes of Health, Bethesda, MD.
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FR-PO554
Methionine Sulfoxide Reductase A (MsrA) Protects Progression of Kidney 
Fibrosis After Unilateral Ureteral Obstruction  Mi Ra Noh,1 Jee in Kim,2 
Kwon Moo Park.1  1Dept of Anatomy and BK21 Plus, Kyungpook National Univ 
School of Medicine, Daegu, Republic of Korea; 2Dept of Molecular Medicine 
and MRC, Keimyung Univ School of Medicine, Daegu, Republic of Korea.
Background: Methionine sulfoxide reductase A (MsrA) reduces oxidized methionine 
and protects cells against oxidative stress. Oxidative stress accelerates kidney fibrosis. Here, 
we investigated the role of MsrA in unilateral ureteral obstruction (UUO)-induced kidney 
fibrosis using MsrA gene-deleted mice.
Methods: MsrA+/+ and MsrA-/- male mice were subjected to UUO. Kidneys were 
harvested 5 days after the UUO surgery.
Results: UUO reduced Msrs expression and activity in the kidney. UUO resulted 
in expansion of interstitial area with increased collagen deposition. In addition, UUO 
increased the levels of α-smooth muscle actin and collagen III expression. MsrA deficiency 
significantly enhanced collagen deposition and expression of those proteins. UUO resulted 
in the increase of hydrogen peroxide (H2O2) formation and lipid peroxide in both MsrA+/+ 
mouse kidneys and MsrA-/- mouse kidneys, and these increases were significantly higher in 
MsrA-/- mouse kidneys than in MsrA+/+ mouse kidneys. Furthermore, post-UUO increases in 
the oxidized glutathione ratio to total glutathione were significantly greater in MsrA-/- mouse 
kidneys than in MsrA+/+ mouse kidneys. Number of F4/80 expressing cells increased in the 
kidney after UUO. These increase of F4/80 expressing cells were greater in MsrA-/- mouse 
kidneys than in MsrA+/+ mouse kidneys. Levels of Ly6G, a marker of granulocyte, were 
also higher in MsrA-/- mouse kidneys than in MsrA+/+ mouse kidneys.
Conclusions: In conclusion, MsrA protects kidney against UUO-induced fibrosis, 
suppressing oxidative stress and inflammatory responses.
Funding: Government Support - Non-U.S.
FR-PO555
The Soluble Urokinase-Type Plasminogen Activator Receptor Serum Levels 
in Adults with Nephrotic Syndrome  Qiuling Fan.  Nephrology, The First 
Hospital of China Medical Univ.
Background: The serum levels of soluble urokinase type fibrinolytic enzyme activators 
receptor (suPAR) in adults with nephrotic syndrome were analyzed.
Methods: The serum levels of soluble urokinase type fibrinolytic enzyme activators 
receptor (suPAR) in 70 nephrotic syndrome patients with membranous nephropathy, diabetic 
nephropathy group, lupus nephritis, minimal change kidney disease and focal segmental 
glomerular sclerosis group was detected by enzyme-linked immunosorbent assay. The 
relationship between the the clinical parameters and suPAR levels were analyzed.
Results: Serum soluble urokinase receptor levels of nephrotic syndrome patients are 
significantly higher than the normal control group (P < 0.01). The serum suPAR levels of 
FSGS and MN patients were significant higher than MCD patients(P < 0.05). Serum suPAR 
level was positively correlated with age, serum creatinine, blood urea nitrogen (rs=0.401 
p=0.001;rs=0.286  p=0.016;rs=0.249  p=0.037;rs=0.245  p=0.041;rs=0.247  p=0.039), 
and negatively correlated with eGFR (rs=-0.265  p=0.026;rs=-0.237  p=0.048;rs=-0.309 
p=0.009).
Conclusions: Serum suPAR level was positively correlated with age, serum creatinine, 
blood urea nitrogen, and negatively correlated with eGFR. The serum suPAR levels of 
FSGS and MN patients were significant higher than MCD patients and may be a potential 
marker to distinguish FSGS and MCD.
FR-PO556
Urinary Sodium: Impact on Blood Pressure and Progression of Chronic 
Kidney Disease  Adriano Luiz Ammirati, Maria Eugenia F. Canziani. 
Nephrology, Federal Univ of Sao Paulo, Sao Paulo, Brazil.
Background: Chronic kidney disease (CKD) is characterized by chronicity and 
progression of renal damage. The presence of hypertension is relates to the progression of 
renal damage. Diets high in salt have been associated with an increased risk of hypertension. 
Sodium analysis in the urine of 24 h is considered the standard method to estimate the 
daily intake of this mineral. The aim of this study was to evaluate the impact of sodium 
intake estimated by urinary sodium in the urine of 24 hours (Nau24hs) on renal outcomes 
and their impact on hypertension.
Methods: Data were collected from medical records of 118 patients with CKD in 
conservative treatment, that had one Nau24hs dosage and a follow-up of at least five years. 
Information collected initially and after 5 years were: demographics, etiology of CKD; 
comorbidities, blood pressure; routine laboratory tests and estimated creatinine clearance 
(EPI-CKD). The Nau24hs values were classified into two groups by the median and also 
divided into tertiles and compared with the rate of progression of CKD (fall of the estimated 
clearance greater than 20% at 5 years) and the change in blood pressure.
Results: Patients had a mean of 186 ± 64 MEq /L of Nau24hs which represented a 
high sodium intake (10 grams; 96% of patients with sodium intake greater than 6 grams). 
Patients with Nau24hs> 170 mEq /L had higher systolic blood pressure and those with 
Nau24hs> 200 mEq / L had higher systolic and diastolic blood pressure when compared 
to other patients. In addition, patients with higher Nau24hs present significant decrease 
in systolic blood pressure over 5 years. The decrease in creatinine clearance over 5 years 
(29% of patients) were more frequent in diabetics and those who did not use converting 
enzyme inhibitors and are also associated with the presence of proteinuria. There was no 
association of Nau24hs with the progression of renal dysfunction.
Conclusions: In patients with stable and low rate of CKD progression urinary sodium 
was associated with high blood pressure, but was not associated with more pronounced 
worsening of long-term renal function, probably because these patients were treated more 
intensively over the pressure control.
FR-PO557
Risk of End-Stage Renal Disease with Longitudinal Change in Filtration 
Markers  Casey Rebholz, Lesley Inker, Yuan Chen, Meredith C. Foster, John 
H. Eckfeldt, Paul L. Kimmel, Vasan S. Ramachandran, Harold I. Feldman, 
Chi-yuan Hsu, Andrew S. Levey, Josef Coresh.  Chronic Kidney Disease 
Biomarkers Consortium.
Background: Change in estimated glomerular filtration rate (eGFR) based on creatinine 
has been proposed as a surrogate outcome in clinical trials of chronic kidney disease (CKD). 
Risk of end-stage renal disease (ESRD) associated with change in other kidney filtration 
markers has not been previously assessed in chronic kidney disease (CKD) populations.
Methods: We conducted prospective analyses of the Modification of Diet in Renal 
Disease (MDRD; N=840; mean age 52 years) and African-American Study of Kidney 
Disease and Hypertension (AASK; N=1,094; mean age 55 years) trials. Creatinine, cystatin 
C, b2-microglobulin, and β-trace protein levels were measured in serum samples collected 
at baseline and at the 24-month follow-up visit and were expressed using CKD-EPI eGFR 
equations. Multivariable Poisson regression was used to estimate associations between 
continuous percent change in eGFR for each marker (alone and in combination) with 
subsequent risk of developing ESRD. Seemingly unrelated regression was used to compare 
the strength of risk estimates from different models.
Results: In MDRD and AASK, respectively, there were 310 and 161 incident ESRD 
cases during a median follow-up of 4.7 and 7.1 years. Percent change in eGFR from the 
four filtration markers was significantly associated with incident ESRD risk (Table). The 
average of percent change in eGFR based on all four filtration markers was more strongly 
associated with ESRD risk than percent change in eGFR-creatinine alone. 
Conclusions: Decline in kidney function over two years, assessed using eGFR-
creatinine as well as multiple other filtration markers, is associated with ESRD. Novel 
filtration markers (cystatin C, b2-microglobulin, β-trace protein) may provide additional 
information about CKD progression beyond creatinine.
Funding: NIDDK Support
FR-PO558
Validation and Clinical Associations of a Predictive Model for Progression to 
Renal Replacement Therapy: A Retrospective Cohort Study  James Ritchie,1 
Afshan Ahmed,1 Olivier J. Wouters,2 Darren Green,1 Smeeta Sinha,1 Donal J. 
O’Donoghue,1 Philip A. Kalra.1  1Salford Royal NHS Foundation Trust, United 
Kingdom; 2London School of Economics and Political Science, United Kingdom.
Background: Timely planning for initiation of renal replacement therapy (RRT) is vital. 
Despite existing, validated risk-prediction models, RRT preparation is often based upon 
clinical judgment. Here, we consider the benefits of applying an existing model (Tangri et 
al. JAMA, 2011) in a UK secondary care population.
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Methods: Patients with ≥5 years of potential follow-up were identified from the 
Chronic Renal Insufficiency Standards Implementation Study (CRISIS). 5-year RRT 
risk was estimated using a logistic regression model incorporating age, gender, eGFR, 
albuminuria, PO4, Ca+, HCO3 and albumin.
Results: 728 patients were included in this analysis (median follow-up 4.4 [IQR 2.4-
5.6] years), with 118 patients (16%) progressing to RRT. Mean baseline age was 64±14 
years and eGFR 34±14 ml/min/1.73m2. 
Risk was right skewed, with 328 (45%) of patients having a 5-year risk of <5%. 80 
patients (11%) had a 5-year RRT risk of >50%. The overall area under the curve was 0.89. 
This did not vary by primary disease: glomerulonephritis (0.87); pyelonephritis (0.95); 
polycystic kidney disease (0.91); and diabetic nephropathy (0.88). 
In higher-risk groups, a greater proportion of patients commenced RRT using peritoneal 
dialysis, and a smaller proportion commenced RRT as an in-patient. The proportion of 
patients transplant listed at the time of starting RRT was greater in the lower risk group 
than the higher risk group.
Risk group and 
number of patients
Number 
starting 
RRT
Months 
to RRT
In-
patient 
start
Transplant 
eligable / listed
Peritoneal 
dialysis
LOW:
<20%
n=538 (73%)
23 (4%) 48(12) 14% 81% / 60% 18%
MEDIUM:
20 - 40%
n=91 (13%)
32 (35%) 37(15) 9.5% 77% / 54% 22%
HIGH:
>40%
n=98 (14%)
64 (64%) 20(14) 5.7% 72% / 49% 30%
Time to RRT presented as mean (standard deviation). Percentages represent the proportion of patients 
within that risk group. 
Conclusions: The risk model performed well in our patient population and was disease 
agnostic. Further work will consider potential causes of the differences in modality and 
in-patient starts between risk groups.
FR-PO559
Do Electronic Health Records Contain Enough Information to Calculate 
End-Stage Renal Disease Risk Scores?  C. Blake Cameron,1 Benjamin Neely,2 
Mark Dakkak,1 Uptal D. Patel,1,2 L. Ebony Boulware.1  1Duke Univ School of 
Medicine; 2Duke Clinical Research Inst, Durham, NC.
Background: Physicians often can’t predict which patients with CKD will progress 
to end-stage renal disease (ESRD) in the near future, contributing to poor outcomes and 
expensive care. It is unknown to what extent validated ESRD prediction models can 
be applied to real-world electronic health records (EHRs) for use by population health 
management programs to target those at greatest risk for renal progression.
Methods: We characterized EHR availability of laboratory results (urine albumin-to-
creatinine ratio and serum albumin, bicarbonate, calcium, and phosphorous) required for 
use in a validated ESRD risk prediction model at Duke University. We identified outpatients 
with at least two eGFR results, and we defined CKD as the presence of at least two eGFR 
results <60 mL/min/1.73m2 separated by ≥90 days.
Results: Among 151,097 eligible patients, the median age was 59.4 years, 85,533 
(56.6%) were female, 45,425 (30.1%) were African-American, and 31,581 (20.9%) had 
evidence of CKD stages 3-5. Few CKD patients had results for urine albumin-to-creatinine 
ratio (n=3,487, 11.0%) or serum phosphorus (n=9,696, 30.7%), but more had serum albumin 
(n=28,192, 89.3%), bicarbonate (n=24,650, 78.1%), or calcium (n=31,463, 99.6%) results. 
Although more lab results were available among patients with worse CKD (p<0.001), the 
full set of results needed to calculate ESRD risk were available for only a few (n=1,407, 
4.5%) patients. 
Result Availability GFR <15 (n=2,061)
GFR 15-29 
(n=3,909)
GFR 30-44 
(n=10,144)
GFR 45-59 
(n=15,467)
Serum phosphorous 1,695 (82.2%) 2,048 (52.4%) 3,088 (30.4%) 2,865 (18.5%)
Urine ACR 157 (7.6%) 570 (14.6%) 1,302 (12.8%) 1,458 (9.4%)
All 5 results present 123 (6.0%) 393 (10.1%) 551 (5.4%) 340 (2.2%)
Conclusions: Few patients with CKD had the full set of laboratory results needed to 
employ a validated ESRD risk prediction model for population health management. Urine 
ACR and serum phosphorous results were often unavailable. To improve risk stratification, 
efforts are needed to more frequently obtain these laboratory tests during clinical care or 
to develop refined models that use more readily available information.
Funding: Other NIH Support - Duke Training Grant in Nephrology - 5T32DK007731
FR-PO560
Effect and Safety of Sofosbuvir (SOF) Containing Direct-Acting Antiviral 
(DAA) Hepatitis C Virus (HCV) Therapy in a Real-World Population with 
Chronic Kidney Disease (CKD)  Guillermo Ortiz,1 Gregory L. Hundemer,1 
Elke Backman,2 Ravi I. Thadhani,1 Raymond T. Chung,3 Meghan E. Sise.1 
1Nephrology Div, MGH, Boston, MA; 2Pharmacy, MGH, Boston, MA; 
3Gastrointestinal, MGH, Boston, MA.
Background: Early trials of SOF-based regimens excluded patients with CKD, thus 
little is known about safety, efficacy, and effect on kidney function.
Methods: We retrospectively evaluated 72 patients with CKD starting DAA treatment 
(tx) between 11/2013-12/2014. CKD was defined by average eGFR <60mL/min or 
albuminuria >30mg/g 6 months prior to tx. Safety, tolerability and laboratory results were 
assessed by chart review. Models predicting sustained virological response (SVR) were 
performed.
Table 1: Logistic regression model predicting SVR (n=61)
Univariate Multivariable
BL Predictors OR (95% CI) P Value OR (95% CI) P Value
Age, per 10 years 1.25 (0.58,2.67) 0.57 0.68 (0.16,2.85) 0.60
Female 3.10 (0.62,15.55) 0.17 4.20 (0.41,43.45) 0.23
Black 0.44 (0.11,1.79) 0.25 0.22 (0.03,1.62) 0.14
HCV Genotype 3 0.08 (0.01,0.84) 0.04* 0.07 (0.00,5.56) 0.23
Early discontinuation 0.11 (0.02,0.69) 0.02* 0.06 (0.00,0.90) 0.04*
Cirrhosis 1.85 (0.51,6.77) 0.35 1.00 (0.17,5.89) 1.00
Prior HCV tx 0.58 (0.17,1.99) 0.39 1.17 (0.20,6.88) 0.87
Liver or kidney 
transplant 1.02 (0.29,3.54) 0.98 0.34 (0.04,2.69) 0.31
Baseline eGFR, per 10 
ml/min decrease 1.79 (1.27,,2.50) <0.01* 2.10 (1.22,3.63) 0.01*
Results: Subjects were aged 61±8 years, 60% white, 22% black, 12% Hispanic, and 
74% male. 50% were diabetic, 39% cirrhotic, 54% HCV tx naïve, 39% had prior liver 
or kidney transplant, and 7% were HIV/HCV coinfected. DAA regimens were: SOF/
simeprevir 50%, SOF/ledipasvir 13%, SOF/ribavirin 28%, other SOF regimens 10%. 8% 
had a transient creatinine rise ³0.5mg/dL during tx. Average eGFR on tx was similar to 
baseline [mean (95% CI): 57 (52-62) vs. 58 (53 – 63) mL/min, respectively P=0.26]. SVR 
was 77% (95% CI 66-88). 76% experienced at least 1 adverse effect (AE); only 5 (7%) 
discontinued tx due to an AE.
Conclusions: SOF-containing DAA regimens are effective and relatively safe in 
patients with CKD. Although AEs were common, serious AEs or significant nephrotoxicity 
were rare. Lower eGFR at baseline predicted an increase likelihood of HCV cure with 
SOF-based regimens.
FR-PO561
Risk of Liver Injury Afterα-Glucosidase Inhibitors Therapy in Advanced 
Chronic Kidney Disease Patients: A Population-Based Study  Vincent Wu,1 
Chih-chin Kao,2 Taomin Huang.1  1Internal Medicine, National Taiwan Univ 
Hospital, Taipei; 2Internal Medicine, Taipei Medical Univ Hospital.
Background: α-glucosidase inhibitors (AGIs) are commonly used to control 
postprandial blood glucose. However, AGIs-related liver injury has been reported, but 
whether the relationship of AGIs and liver injury applies to advanced chronic kidney 
disease (CKD) patients remains uncertain.
Methods: In the nationwide case-control study, we recruited advanced diabetic CKD 
patients, who has taken AGIs from January 1, 2000 through December 31, 2010 as cases 
and matched 5295 matched controls. Recent and former AGIs users were defined as 
patients who received the AGIs prescription 30-60 days and 30-210 days before the event 
of liver injury. The risk of AGIs-related liver injury was examined via time-dependent cox 
proportional hazards model and stratified analysis.
Results: The age of enrollee is 63 ± 11 years and nearly 51% is men. Liver injury 
developed in 3.9% of cases and 3.3% of control patients. Patients who received insulin 
treatment (p=0.03 ), had chronic liver disease (p=0.01 ) were predictive to liver injury. 
AGIs use did not increase the risk of liver injury in advanced CKD patients (p= 0.22), both 
among recent users (P=0.28) or former users (P=0.22). The stratified analysis showed no 
increased risk of liver injury in virus hepatitis, liver cirrhosis, subsequent end stage renal 
disease or patients who has diabetic related comorbidities. (all p> 0.05) . 
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Conclusions: Available evidence supports expansion of AGIs use in patients with 
advanced CKD, without increased risk of liver injury. Neither accumulated dose- dependent 
effect of AGIs, or subsequent ESRD will aggravated AGIs-associated liver injury. Further 
randomized controlled trials are warranted to confirm our results.
Funding: Government Support - Non-U.S.
FR-PO562
Add-On Renoprotective Effect of Pentoxifylline in Pre-Dialysis Advanced 
Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone 
System Blockade – A Nationwide Database Analysis  Ko-Lin Kuo,1 Szu-Chun 
Hung,1 Jia-sin Liu,2 Der-Cherng Tarng.3  1Taipei Tzu Chi Hospital, Taiwan; 
2National Health Research Insts, Taiwan; 3Taipei Veterans General Hospital, 
Taiwan.
Background: Pentoxifylline decreases proteinuria in patients with glomerular 
disease due to its anti-inflammatory and anti-fibrotic properties. A combination therapy of 
pentoxifylline with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin 
II receptor blocker (ARB) decreased proteinuria and the glomerular filtration rate (GFR) 
decline in early chronic kidney disease (CKD). Whether adding pentoxifylline to ACEI/
ARB provides additional benefits on renal outcome or survival is unclear in CKD stage 5 
patients who have not yet received dialysis (CKD 5 ND).
Methods: A prospective cohort study was conducted based on the Taiwan National 
Health Insurance Research Database. From January 1, 2000 to June 30, 2009, we enrolled 
14,117 CKD 5 ND patients with serum creatinine levels >6 mg/dL and hematocrit levels 
<28% and who have been treated with ACEI/ARB.All patients were further divided into 
two groups with or without pentoxifylline within 90 days after starting erythropoiesis-
stimulating agent therapy (index date). Patient follow-up took place until dialysis, death 
before initiation of dialysis or December 31, 2009.
Results: With a mean follow-up of 12 months, 9,867 patients (69.9%) required long-
term dialysis and 2,805 (19.9%) died before progression to end-stage renal disease requiring 
dialysis. After propensity score-matching, add-on use of pentoxifylline was associated with 
a lower risk for long-term dialysis or death in those treated with ACEI/ARB (HR, 0.94; 
95% CI, 0.90-0.99) or ARB alone (HR, 0.91; 95% CI, 0.85-0.97).
Conclusions: Pentoxifylline exhibited an add-on renoprotective effect in reducing 
the risk for long-term dialysis in CKD 5 ND patients who received renin-angiotensin-
aldosterone system blockade. Randomized studies are needed to validate this association.
FR-PO563
Novel Therapy Regimens Have Reduced the High Risks of Bladder 
and Haematological Malignancies in ANCA-Associated Vasculitis 
Chinar Rahmattulla,1 Annelies Evaline Berden,1 Sophie-charlotte Wakker,1 
Marlies Reinders,1 Ernst C. Hagen,2 Ron Wolterbeek,1 Jan A. Bruijn,1 Ingeborg 
M. Bajema.1  1Leiden Univ Medical Center; 2Meander Medical Center 
Amersfoort.
Background: The introduction of immunosuppressive therapy has dramatically 
improved the prognosis of anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV). As a result, attention has shifted to long-term complications in patients. 
In this study, we investigate the incidence of malignancies in AAV patients. Additionally, 
we investigate the effect of therapy on malignancy incidence.
Methods: We included patients with histopathologically-proven AAV diagnosed at 
a large university hospital. Malignancy incidence was assessed with the Dutch National 
Pathology Database, which covers all the histologically confirmed malignancies diagnosed 
in The Netherlands. We used the Netherlands Cancer Registry incidence rates for comparing 
the malignancy incidence in our AAV cohort to that of the general Dutch population.
Results: Thirty-six of 138 patients with AAV developed a total of 85 malignancies 
during a mean follow-up of 9.7 years. We observed 61 non-melanoma skin cancers 
(NMSCs), three colon carcinomas, three breast carcinomas, three prostate carcinomas, 
two lung carcinomas, two soft tissue sarcomas, two unknown primary malignancies, and 
a variety of malignancies that occurred only once. The gender-, age-, and calendar year-
adjusted malignancy risk was 2.21-fold (95%CI: 1.64–2.92) higher than that of the general 
population. Only the incidence of NMSCs was significantly increased compared to the 
general population (standardized incidence ratio: 4.23, 95%CI: 2.76–6.19). Malignancy 
risk was associated with the duration of cyclophosphamide therapy, and was not increased 
in patients that received cyclophosphamide for less than 1 year.
Conclusions: AAV patients have a higher risk of malignancies than the general 
population, but this risk is accounted for solely by NMSCs. Throughout the years, the risk of 
other malignancies – specifically bladder and haematological malignancies – has decreased 
in patients with AAV. This finding reflects the beneficial results of ongoing efforts to reduce 
cyclophosphamide exposure by developing new therapy regimens.
FR-PO564
Effect of Lowering LDL-Cholesterol with Simvastatin plus Ezetimibe 
on Non-Vascular Outcomes in Patients with Chronic Kidney Disease 
(CKD): Results from the Study of Heart and Renal Protection (SHARP) 
Christina A. Reith, Natalie Staplin, William G. Herrington.  On behalf of the 
SHARP Collaborative Group. CTSU, Univ of Oxford.
Background: The Study of Heart and Renal Protection (SHARP) was a randomized 
placebo-controlled trial of LDL cholesterol (LDL-C)-lowering among 9270 patients with 
CKD which showed that combination therapy with ezetimibe 10mg/ simvastatin 20mg 
(E/S) reduced vascular events with no significant adverse effects on muscle, hepatobiliary 
outcomes or cancer. However, assessment of the effects of lowering LDL-C on other non-
vascular outcomes has not been extensively explored in patients with CKD.
Methods: All post-randomization serious adverse events (SAEs) were routinely 
recorded. Post-hoc intention-to-treat analyses were performed of the effect of allocation 
to treatment on time to first non-vascular SAE by system of disease with sub-categories.
Results: During 4.9 years’ median follow-up, similar numbers of participants in the 
two groups experienced non-vascular SAEs overall (3533 [76.0%] E/S vs 3505 [75.9%] 
placebo; risk ratio [RR] 1.00, 95% CI 0.95-1.05). After due allowance for multiplicity, 
there was no evidence of any significant hazard of E/S on non-vascular SAEs by system 
of disease. Within the class of endocrinology SAEs, there were no significant effects of 
E/S on any particular individual category of SAE: new-onset diabetes (172 [4.8%] E/S vs 
162 [4.5%] placebo; RR 1.06, 95% CI 0.86-1.32 among 3596 vs 3580 participants without 
diabetes at baseline), diabetes-related complications (136 [2.9%] E/S vs 126 [2.7%] placebo; 
RR 1.08, 95% CI 0.84-1.37), and other endocrine disorders (58 [1.2%] E/S vs 39 [0.8%] 
placebo; RR 1.47, 95% CI 0.99-2.19). 
Conclusions: In the SHARP trial, allocation to ezetimibe 10mg plus simvastatin 20mg 
reduced vascular events with no evidence of significant non-vascular hazards.
Funding: Pharmaceutical Company Support - Merck/Schering-Plough 
Pharmaceuticals (North Wales, PA, USA), Government Support - Non-U.S.
FR-PO565
Association of β-Blocker Therapy with Renal Outcomes in CKD Patients 
without prior Cardiovascular Disease  Naohiko Fujii,1 Takayuki Hamano,2 
Yoshitsugu Obi,3 Yoshitaka Isaka.2  1Univ of Pennsylvania, Philadelphia, PA; 
2Osaka Univ, Suita, Osaka, Japan; 3Univ of California, Irvine, Irvine, CA; 
4Osaka General Hospital, Osaka, Japan.
Background: Sympathetic overactivity due to impaired kidney function can deteriorate 
hypertension, renal failure, and cardiovascular disease (CVD) among CKD patients. 
Mortality benefit of its antagonist, β-blocker (BB), has been shown in patients with prior 
CVD; however, such evidences are scarce in CKD patients without CVD. Our aim is to 
evaluate the association between BB and renal outcomes in such patients.
Methods: We extracted 340 predialysis CKD patients without prior CVD but with drug 
information at baseline from a Japanese CKD cohort (OVIDS-CKD, N=738). The primary 
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endpoint was a composite of Cr doubling, initiation of RRT, and death. We performed Cox 
proportional hazards analyses to estimate the hazards ratio (HR) of BB use at baseline 
adjusting for other parameters, such as age, sex, eGFR, proteinuria, diabetes, BMI, blood 
pressure, the number of anti-hypertensive drugs, ACEI/ARB use, Hb, Alb, corrected Ca, 
iP, and FGF23. We also employed 1:k (k = 1-6) propensity-score full matching, where one 
BB user matched to at most k non-users.
Results: BB users showed significantly-lower eGFR, more proteinuria, higher BMI, 
more anti-hypertensive drugs, lower Alb, higher 1-84 PTH, higher FGF23, and lower 
25OHD levels, most of which suggested a poor risk for CVD at baseline. During a median 
follow-up of 4.4 years, 109 patients reached the outcome. Of those, 12 patients died before 
RRT, 71 reached a doubling of Cr, and 26 started dialysis. A multivariable Cox model with 
covariates that were significantly-different between BB users and non-users at baseline 
showed non-significant HR of 1.58 (C.I. 0.86 – 2.90). We also evaluated a fully-adjusted 
model and a parsimonious model with a stepwise backward-elimination method; however, 
the results remained non-significant. The 1:k (k=1-6) full matching using propensity score 
did not show significant results, either. (0.93 (0.52 – 1.68)).
Conclusions: The BB therapy was not associated with renal outcomes in CKD patients 
without prior CVD. Confirmation in a larger study is required.
Funding: Pharmaceutical Company Support - Kyowa Hakko Kirin
FR-PO566
Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile 
Infection in Patients Treated with Antibiotics in the Nephrological and 
Transplantation Department  Marcin Adamczak, Agata Kujawa-Szewieczek, 
Katarzyna Kwiecien, Sylwia Malgorzata Dudzicz, Magdalena Gazda, Andrzej 
Wiecek.  Dept of Nephrology, Transplantation and Internal Medicine, Medical 
Univ of Silesia, Katowice, Poland.
Background: Lactobacillus plantarum 299v (LP299v) has been introduced into the 
clinical practice in order to reduce gastrointestinal symptoms during antibiotic exposure. 
However it remains controversial whether or not probiotics are also effective in the 
prevention of Clostridium difficile infections (CDI) among patients receiving antibiotics. 
The aim of this clinical, retrospective, single-centre study was to analyze the C.difficile 
infections among patients receiving antibiotics and hospitalized in the period before and 
after initiation of LP299v routine use, as a prevention of CDI, in the nephrology and 
transplantation ward.
Methods: Among 3533 patients hospitalized in Department of Nephrology, 
Transplantation and Internal Medicine, Medical University of Silesia in Katowice during 
two years (October 2012 – October 2013 and December 2013 – December 2014) 23 patients 
with CDI were diagnosed and enrolled in this study. Since November 2013 prevention of 
C. difficile infection with the oral use of LP299v was performed in all patients treated 
with antibiotics and who were at a high risk of developing CDI (patients after organ 
transplantation and receiving immunosuppressive drugs for any other reasons). For the 
further analysis the observation period was divided into two twelve-months intervals before 
(October 2012 to October 2013) and after initiation of LP299v use as the prophylactic 
manoeuvre against CDI (December 2013 to December 2014).
Results: It was found a significant (p=0.0001) reduction of the number of cases of C. 
difficile infection after beginning of LP299v routinely used (n=2; 0.11% of all hospitalized 
patients) compared with the previous twelve-months period of observation (n=21; 1.21% 
of all hospitalized patients).
Conclusions: Routine use of Lactobacillus plantarum 299v during treatment with 
antibiotics may prevent C. difficile infection, particularly in patients at high risk of CDI in 
the nephrology and transplantation ward.
Funding: Government Support - Non-U.S.
FR-PO567
In Patients with Chronic Kidney Disease, Comanagement by Nephrologists 
Is Associated with Lower Risk of Medication Errors  Justin XG Zhu, Danielle 
Marie Nash, Eric Mcarthur, Alexandra Farag, Amit X. Garg, Arsh Jain.  London 
Health Sciences Centre, London, ON, Canada.
Background: Patients with chronic kidney disease (CKD) are commonly prescribed 
drug doses that are excessive for their kidney function. Many CKD patients are followed 
solely by a family physician. We wish to determine whether care by both a nephrologist 
and family physician (i.e. comanagement) versus family physician alone is associated with 
lower risks of inappropriate antibiotic dosing in patients with stage 4 or 5 CKD.
Methods: A retrospective case-control study was conducted, among individuals aged 
>66 years, with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 using 
linked healthcare databases from 2003-2014. Cases were antibiotic prescriptions dosed 
inappropriately, whereas controls were prescriptions dosed appropriately. Exposure was 
comanagement, defined as at least one outpatient visit with a nephrologist in the 1 year 
prior to antibiotic prescription. A multivariable logistic regression model was used to 
determine the independent association between comanagement and inappropriate dosing.
Results: Of 21,848 eligible prescriptions studied, 64% were inappropriately dosed. 
The patients were 82 (IQR 76-87) years of age with comorbidities including: hypertension 
(89%), diabetes (49%), coronary artery disease (49%), and congestive heart failure (38%). 
77% of all prescriptions were prescribed by family physicians and 2% were prescribed by 
nephrologists. Multivariable analysis revealed that patients with appropriate prescriptions 
were more likely to have seen a nephrologist in the one year prior with an unadjusted 
odds ratio of 1.07 (95% CI 1.01-1.14, p=0.02), adjusted odds ratio 1.23 (95%CI 1.15-
1.32, p<0.001).
Conclusions: In patients with stage 4 or 5 CKD prescribed an antibiotic, those with 
an appropriate dose were 23% more likely to have been cared for by a nephrologist in 
the previous year. Although we cannot conclude what caused the improved prescribing 
practice, this improvement may, in part, explain the improved patient outcomes associated 
with seeing a nephrologist in observational studies.
FR-PO568
Variation in Co-Medication Use According to Kidney Transplant 
Immunosuppressive Regimen: Application of Integrated Registry and 
Pharmacy Claims Data  Krista L. Lentine,1 Abhijit S. Naik,2 Mark Schnitzler,1 
David A. Axelrod,3 Jiajing Chen,1 Daniel C. Brennan,4 Dorry L. Segev,5 Bertram 
L. Kasiske,6 Vikas R. Dharnidharka.4  1Saint Louis Univ; 2Univ Michigan; 
3Dartmouth; 4Washington Univ; 5Johns Hopkins; 6Univ Minnesota.
Background: While modern immunosuppressive therapies (ISx) have substantially 
reduced acute rejection, ISx medications have many side effects, and transplant recipients 
must take an array of “co-medications” to help mitigate complications. Co-medication 
utilization patterns are not well described in large, representative samples due to lack of 
available data.
Methods: We integrated national U.S. transplant registry data with pharmacy records 
(2005-2010) from a large pharmaceutical claims clearinghouse to examine treatments 
for anemia, metabolic disorders and infections according to ISx regimen in mo 6-12 
post-transplant (N=22,453). Associations of ISx with co-medication use (adjusted odds 
ratio, aOR) were examined with multivariate logistic regression including adjustment for 
recipient, donor and transplant factors.
Results: Compared to a reference regimen of tacrolimus (Tac), mycophenolate (MPA) 
and prednisone, rapamycin-based ISx was associated with significantly (P<0.05) higher 
use of ESAs (aOR 2.52), iron (aOR 2.26), statins (aOR 1.47), fibrates (aOR 2.35), and 
phosphorous binders (aOR 2.85) (Figure). Cyclosporine-based ISx was associated with 
more common use of anemia treatments. Compared to those taking triple ISx, recipients 
of tacrolimus-based dual and mono-therapies had lower use of statins, ACEi/ARBs, and 
anti-bacterial agents. Recipients of steroid-free ISx were less commonly treated for new 
onset diabetes. 
Conclusions: Alternate ISx regimens are associated with varying treatment 
requirements for hematologic, metabolic and infectious complications. Co-medication 
use should be considered in the cost-effectiveness and individualization of ISx regimens.
Funding: NIDDK Support
FR-PO569
Association of Urinary Biomarkers of Injury and Repair with Incident 
Chronic Kidney Disease in Type 2 Diabetes: An Ancillary Study of the 
ACCORD Trial  Girish N. Nadkarni,1 Veena Rao,2 Faramarz Ismail-beigi,3 
Vivian A. Fonseca,4 Sudhir V. Shah,5 Michael S. Simonson,3 Prasad Devarajan,6 
Chirag R. Parikh,2 Steven G. Coca.1  1Mount Sinai; 2Yale Univ; 3Case Western 
Reserve Univ; 4Tulane Univ; 5UAMS; 6Univ of Cinncinnati.
Background: Urinary kidney injury molecule (KIM)-1, monocyte chemoattractant 
protein (MCP)-1, interleukin (IL)-18, & YKL-40 are biomarkers representing renal injury, 
inflammation and fibrosis. We evaluated their association with incident CKD3b in the 
ACCORD trial.
Methods: We designed a case-cohort study of 721 participants & measured KIM-1, 
MCP-1, IL-18, and YKL-40 on baseline urine samples with Mesoscale platform. Biomarker 
associations with CKD3b were modeled continuously & by tertiles using Cox proportional 
hazards models.
Results: Mean age was 62 , 51% were female & baseline eGFR was 88 ml/min. There 
were 159 incident CKD3b events over median(IQR) of 4.2(3.9-4.7) years. Top tertiles of all 
biomarkers had higher proportions of incident CKD3b. After adjusting for demographics, 
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clinical characteristics, baseline eGFR & UACR, highest tertiles of uMCP1 & uKIM1 had 
adjusted HRs of 1.82(95% CI 1.18-2.81) & 1.51(95% CI 1.01-2.27) respectively. Area 
under ROC improved from 0.70(with eGFR & UACR) to 0.72 with addition of uMCP1 & 
uKIM1(p<0.05). No association was seen for urinary IL-18 & YKL-40.
Events Adjusted HR(95% CI)
MCP1
<=116 36 Ref
117-253 62 1.85(1.23-2.81)
>=254 61 1.90(1.26-2.88)
Per log increase NA 1.23(1.06-1.44)
IL18
<=26 49 Ref
27-60 62 1.22(0.82-1.80)
>=60 48 1.07(0.70-1.64)
Per log increase NA 1.09(0.92-1.28)
KIM-1 
<=586 42 Ref
587-1549 54 1.38(0.91-2.10)
>=1550 63 1.51(1.01-2.27)
Per log increase NA 1.14(0.98-1.32)
YKL40 
<=197 54 Ref
198-682 61 1.38(0.94-2.02)
>=673 44 0.95(0.62-1.44)
Per log increase NA 0.97(0.89-1.06)
Baseline Covariates:Age; Sex; Ethnicity; eGFR, UACR, MAP, BMI; cardiac history; ACEI/ARB 
use; smoking; HbA1C; intensive diabetes control and duration
Conclusions: Urinary levels of MCP1 and KIM1 are independently associated with 
incident CKD3b & marginally added to risk prediction after accounting for clinical variables 
including eGFR/albuminuria.
Funding: NIDDK Support
FR-PO570
Association of Tenofovir Disoproxil Fumarate Exposure with Urine 
α1-microglobulin, a Biomarker of Proximal Tubule Dysfunction 
Vasantha Jotwani,1 Rebecca Scherzer,1 Michelle M. Estrella,2 Chirag R. Parikh,3 
Joachim H. Ix,4 Michael Shlipak.1  1UCSF; 2Johns Hopkins; 3Yale; 4UCSD.
Background: Tenofovir disoproxil fumarate (TDF) is a well-recognized contributor to 
HIV-related kidney disease, via proximal tubular injury. Urine α1-microglobulin (α1m), a 
low molecular weight protein indicative of proximal tubule dysfunction, may enable earlier 
detection of TDF-associated toxicity.
Methods: In this cross-sectional study of 883 HIV-infected men enrolled in the 
Multicenter AIDS Cohort Study, we evaluated associations of TDF exposure with urine α1m 
levels, using multivariable generalized gamma regression models to adjust for traditional 
and HIV-related risk factors.
Results: Mean age was 52 and mean eGFR was 90 ml/min/1.73m2. Median TDF 
exposure duration was 4.2 years (IQR:2.3,6.1) among the 573 (65%) current and 112 
(13%) former TDF users. Cumulative TDF duration was linearly associated with higher 
urine α1m levels (p<0.0001).
In adjusted analyses, each year of TDF exposure was associated with 8% higher urine 
α1m, a 4-fold effect size relative to age (2% per year). Compared with men who never 
received TDF, α1m levels were 43-50% higher in former and current TDF users. Time since 
last TDF exposure was only modestly associated with lower α1m.
Adjusted associations of TDF exposure with urine α1m levels
TDF Exposure % Estimate
1 
(95%CI) P Value
Cumulative TDF exposure (per year) 8 (6,11) <0.001
Current vs never TDF use 50 (25,80) <0.001
Past vs never TDF use 43 (11,84) 0.006
Duration off TDF (per year) -3 (-8,4) 0.41
1Estimated % difference in α1m attributable to each TDF exposure variable, adjusted for demographics, 
traditional kidney risk factors, and HIV-related factors
Conclusions: In HIV-infected men, TDF exposure was strongly associated with 
higher urine α1m levels. α1m is a promising biomarker for the detection and monitoring 
of TDF-associated tubular toxicity.
Funding: NIDDK Support
FR-PO571
Impact of Kidney Function and Urinary Protein Excretion on Pulmonary 
Function  Yusuke Nakade,1,3 Tadashi Toyama,2 Shinji Kitajima,2 Yasuyuki 
Shinozaki,2 Akinori Hara,2 Miho Shimizu,2 Yasunori Iwata,2 Norihiko Sakai,2 
Kengo Furuichi,2 Takashi Wada.1,2,3  1Clinical Laboratory, Kanazawa Univ 
Hospital, Kanazawa, Ishikawa, Japan; 2Div of Nephrology, Kanazawa Univ 
Hospital, Kanazawa, Ishikawa, Japan; 3Dept of Laboratory Medicine, Kanazawa 
Univ Hospital, Kanazawa, Ishikawa, Japan.
Background: Although the cardiorenal relationship in patients with chronic kidney 
disease (CKD) has been investigated, information about the lung-kidney relation is limited. 
Here, we investigated the impacts of kidney function and urinary protein excretion on 
pulmonary dysfunction.
Methods: The data of pulmonary function tests (PFTs) and kidney function tests from 1 
April 2005 to 30 June 2010 were selected from our laboratory database. Data were classified 
into 4 categories according to eGFR and proteinuria. Category 1: eGFR ≥ 60 ml/min/1.73 
m2 and urinary protein < 0.3 g/gCr; Category 2: eGFR < 60 ml/min/1.73 m2 and urinary 
protein < 0.3 g/gCr; Category 3: eGFR ≥ 60 ml/min/1.73 m2 and urinary protein ≥ 0.3 g/
gCr; Category 4: eGFR < 60 ml/min/1.73 m2 and urinary protein ≥ 0.3 g/gCr. Pulmonary 
function data were evaluated according to these 4 categories.
Results: A total of 133 participants without major respiratory disease, abnormal 
computed tomography and smoking history were enrolled. Hb-adjusted %DLCO in category 
4 (46.2 ± 7.5) and category 2 (63.6 ± 17.8) were significantly lower than that in category 
1 (75.8 ± 18.9) (P < 0.05). Hb-adjusted %DLCO was strongly correlated with eGFR in 
participants with urinary protein ≥ 0.3 g/gCr (R = 0.81, P < 0.001). In addition, eGFR was 
associated with Hb-adjusted %DLCO (P = 0.023) and urinary protein tended to be associated 
with Hb-adjusted %DLCO (P = 0.095) after adjusting for physical features and the presence 
or absence of DM and Hypertension.
Conclusions: This study suggests that eGFR and urinary protein excretion were 
associated with pulmonary function (Hb-adjusted %DLCO ).
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FR-PO572
Renal Biomarkers in Diabetes, Role Beyond Nephropathy, Relation to 
Retinopathy  Mohamed E. Elraggal,1 Ahmed Fathy Elkeraie,2 Ahmed M. 
Abdelhadi,3 Ashraf Nabiel Abdalla.4  1Nephrology, Kidney and Urology 
Center, Alexandria, Egypt; 2Nephrology, Alexandria Univ, Alexandria, Egypt; 
3Ophthalmology, Alexandria Univ, Alexandria, Egypt; 4Pharmacology, Umm 
Al-Qura Univ, Saudi Arabia.
Background: Diabetic nephropathy and retinopathy remain two of the most frequent 
complications of diabetes and is the leading cause of end-stage renal disease (ESRD) and 
blindness worldwide. The concordance rate between both complications is often present 
in diabetic patients.
Methods: We tried to study the relation between renal biomarkers including serum 
creatinine (SCr), urinary albumin/creatinine ratio (ACR), serum cystatin-C (cysC) and 
urinary NGAL (uNGAL) with diabetic retinopathy (DR) in 100 diabetic patients. Patients 
were classified according to severity into 3 stages: no diabetic retinopathy (No DR), Non-
Proliferative DR (NPDR) and proliferative DR (PDR).
Results: Urinary ACR, serum cysC and uNGAL were higher significantly among 
patients with DR (NPDR & PDR) than patients without, while SCr showed a non significant 
rise with progression of retinopathy. All markers were higher among PDR than NPDR group.
No DR NPDR PDR P
SCr (mg/dl)
Mean ± SD 0.86 ± 0.14 0.96 ± 0.31 1.13 ± 0.49 0.175
Urinary ACR (mg/g)
Mean ± SD 34.54 ± 55.59 87.43 ± 93.27 118.48 ± 122.75 <0.001*
P between each stage p1<0.001•, p2= 0.003•, p3= 0.184
Serum cysC (mg/L)
Mean ± SD 0.73 ± 0.19 0.89 ± 0.31 1.0 ± 0.43 0.043*
P between each stage p1= 0.041•, p2= 0.017•, p3=0.358
uNGAL (ng/ml)
Mean ± SD 11.14 ± 9.1 22.6 ± 23.79 26.07 ± 23.96 0.016*
P between each stage p1= 0.033•, p2= 0.013•, p3=0.622
p1: p value for comparing between No DR and NPDR 
p2: p value for comparing between No DR and PDR 
p3: p value for comparing between NPDR and PDR 
Statistically significant at p ≤ 0.05
Conclusions: Renal biomarkers namely urinary ACR, serum cysC and uNGAL may 
point to a more advanced stage of diabetic retinopathy, which might be an aid to identify 
the degree of retinopathy beside the traditional fundus examination in diabetic patients.
FR-PO573
Prognostic Importance of Urea and Urea: Creatinine Ratio for Mortality as 
Compared to Creatinine Concentrations Alone in the General Population 
Ronan Cusack,2 Austin G. Stack,1,2,3 John P. Ferguson.2  1Nephrology, Univ 
Hospital Limerick, Ireland; 2Graduate Entry Medical School, Univ of Limerick, 
Ireland; 3Health Research Inst, Univ of Limerick, Ireland.
Background: High Creatinine (Cr) concentrations reflect poor kidney function and 
are associated with a higher risk of death. It is unclear whether other measures of kidney 
function such as blood urea nitrogen (BUN) concentration and BUN/creatinine ratio, are 
better predictors of mortality in the general population.
Methods: A cohort of 15,773 non-pregnant subjects age >20, representative of the 
U.S. population, were identified from the Third National Health and Nutrition Examination 
Survey (1988-1994). Vital status was obtained through linkage with the National Death 
Index through to 2006. Subjects were classified into categories of Cr, BUN and BUN/
Creatinine Ratio (B/Cr). Weighted multivariable Cox regression models, compared hazard 
ratios [HR] and 95% CI for death among the decile groups and the prognostic capacity of 
differing models was compared using Akaike Information Criterion (AIC).
Results: In multivariable analysis, BUN was found to be the most important single 
predictor of mortality with Cr being second best. A strong interaction (P< 0.001) between 
BUN and Cr with mortality was identified and explored by fitting stratified models, as 
shown below.
Creatinine 
(µmol/L)
< 70.7 70.7-79.6 79.6-88.4 88.4-97.2 97.2-106.1 106.1-114.9 > 114.9
Urea 
(mmol/L)
< 2.86 1.55 (0.75-3.18) 1.00
0.60 (0.28-
1.26)
0.51 (0.16-
1.67)
0.21 (0.06-
0.69)
0.20 (0.06-
0.62)
0.09 (0.02-
0.45)
2.86-7.5 1.04 (0.81-1.34) 1.00
0.99 (0.82-
1.20)
1.04 (0.87-
1.25)
1.04 (0.83-
1.29)
0.97 (0.77-
1.23)
1.28 (1.00-
1.64)
> 7.5 0.84 (0.31-2.25) 1.00
1.78 (0.72-
4.40)
1.13 (0.55-
2.34)
1.49 (0.70-
3.19)
1.98 (0.96-
4.09)
2.31 (1.15 
-4.63)
Conclusions: Both BUN and Cr independently predict death in the general population. 
Among patients with malnourished states (Low BUN); higher SC were associated with 
lower mortality. In contrast, among patients with normal-high BUN concentrations, higher 
Cr was associated with elevated death risk. Risk Prediction models should take BUN levels 
into consideration when estimating future death risk.
Funding: Government Support - Non-U.S.
FR-PO574
Serum Uric Acid and the Development of Chronic Kidney Disease in a 
General Japanese Population: The Hisayama Study  Keita Takae,1,2 Masaharu 
Nagata,1,2 Kazuhiko Tsuruya,2 Takanari Kitazono,2,3 Yutaka Kiyohara,1,3 
Toshiharu Ninomiya.2,3  1Dept of Environmental Medicine, Graduate School 
of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 2Dept of Medicine and 
Clinical Science, Graduate School of Medical Sciences, Kyushu Univ, Fukuoka, 
Japan; 3Center for Cohort Studies, Graduate School of Medical Sciences, 
Kyushu Univ, Fukuoka, Japan.
Background: Growing evidence suggests that high serum uric acid (SUA) levels 
are causally related to an increased risk of kidney dysfunction. However, the association 
remains inconclusive in general Asian populations. Additionally, there are limited studies 
investigating the influence of SUA levels on the development of albuminuria.
Methods: A total of 2,059 community-dwelling Japanese subjects aged ≥40 years 
without chronic kidney disease (CKD) were followed for 5 years. CKD were defined as 
eGFR <60 mL/min/1.73m² or urine albumin/creatinine ratio (UACR) ³30 mg/g, The odds 
ratios (ORs) for the development of CKD and the rates of decline in eGFR were estimated 
according to quartile of SUA (≤4.0, 4.1-4.9, 5.0-5.8, and ≥5.9 mg/dL).
Results: During follow-up period, 396 subjects experienced CKD, of whom125 had 
eGFR <60 mL/min/1.73m² and 312 had UACR ³30 mg/g. The age- and sex-adjusted 
incidence rate of CKD increased significantly with higher SUA levels (p for trend <0.001). 
Compared with those with SUA of ≤4.0 mg/dL, the multivariable-adjusted ORs for the 
development of CKD were 1.21 (95% confidence intervals, 0.84-1.74), 1.47 (1.01-2.17), 
and 2.10 (1.37-3.23) in subjects with SUA of 4.1-4.9 mg/dL, 5.0-5.8 mg/dL, and ≥5.9 mg/
dL, respectively. Likewise, there were positive associations of SUA levels with the adjusted 
risk of developing eGFR <60 mL/min/1.73m² (OR 1.00 [reference] in ≤4.0 mg/dL, 2.30 
[1.10-4.82] in 4.1-4.9 mg/dL, 2.81 [1.34-5.88] in 5.0-5.8 mg/dL, and 3.73 [1.65-8.44], in 
≥5.9 mg/dL) and UACR ³30 mg/g (1.00 [reference], 1.12 [0.76-1.65], 1.35 [0.90-2.03], 
and 1.81 [1.14-2.87], respectively). Additionally, higher SUA was significantly associated 
with a greater decline in eGFR (p for trend = 0.002).
Conclusions: Higher SUA level is a significant risk factor for the development of both 
kidney dysfunction and albuminuria in a general Japanese population.
FR-PO575
Do Protein-Energy Wasting Criteria Reflect Protein/Energy Wasting? 
Xiaorui Chen,1 G. Wei,1 Robert E. Boucher,1 Dominique Ferranti,3 Michel 
Chonchol,1 Kalani L. Raphael,1 Srini Beddhu.1,2  1U of Utah; 2VA SLC; 3UC 
Denver.
Background: The term protein-energy wasting (PEW) implies a state of depleted 
protein and/ or energy stores. An International Society of Renal Nutrition and Metabolism 
(ISRNM) panel proposed objective criteria for the definition of PEW syndrome. However, 
the extent to which these variables used in PEW syndrome definition are indicative of 
low protein or energy stores is unknown. Muscle is the largest protein store and fat mass 
is the largest energy store in the body. Therefore, we examined the associations of these 
variables with lean body mass (LBM) and fat mass (FM) measured by DXA scans in 
11,834 participants in the 1999-2004 National Health and Nutrition Examination Survey 
(NHANES).
Methods: Definitions of PEW variables are summarized in the table. The associations 
of each PEW variable with LBM and FM in the entire cohort and CKD (CKD-EPI eGFR < 
60) sub-population were examined in linear regression models using svy suite in STATA 13.
Results: Mean age was 46.0 yrs, 50.3% were male, 9.5% were black. 6.7% had CKD. 
Unintentional weight loss and low levels of serum albumin, serum cholesterol, BMI and 
MAMC were associated with lower LBM and FM. On the other hand, low protein and 
energy intakes were associated with higher LBM and FM. 
PEW variables
Lean body mass (kg) Fat mass (kg)
β (95% CI)
Albumin<3.25 g/dl -3.5 (-7.5, 0.4) -3.6 (-7.2, -0.1)
Cholesterol<100 mg/dl -2.5 (-6.8, 1.8) -5.2 (-10.6, 0.1)
BMI<20 kg/m2 -9.7 (-10.3, -9.1)
-14.6 
(-14.9,-14.2)
Unintentional wt loss>
10% over 1 yr -2.2 (-3.3, -1.0) -3.8 (-5.2, -2.4)
Body fat %<10% NA NA
Low MAMC* -8.6 (-9.0, -8.3) -8.4 (-8.9, -7.9)
Protein intake<0.6 g/kg/d 3.6 (3.0, 4.2) 6.4 (5.7, 7.0)
Energy intake<25 kcal/kg/day 4.3 (3.9, 4.7) 7.3 (6.9, 7.7)
* 10% or more lower than the 50th percentile of reference group 
Results were similar in the CKD sub-population.
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Conclusions: Serum chemistry, body weight and muscle mass PEW criteria appear to 
be indicative of both protein stores (as indicated by LBM) and energy stores (as indicated 
by FM). Dietary variables are not reflective of protein or energy wasting. A modified 
PEW syndrome definition without the dietary variables would be a better indicator of 
PEW syndrome.
Funding: NIDDK Support
FR-PO576
Low-Proteinuric CKD and Risk of ESRD in Nephrology Clinics: Emerging 
Role of Serum Phosphorus  Luca De Nicola,1 Michele Provenzano,1 Paolo 
Chiodini,2 Giuseppe Conte,1 Roberto Minutolo.1  1Nephrology, Second Univ, 
Naples, Italy; 2Med Stat, Second Univ, Naples, Italy.
Background: In low-proteinuric (LP) CKD, factors other than proteinuria (Uprot) 
likely act as predictors of ESRD. However, comprehensive assessment of epidemiologic 
features of LP versus high-proteinuric (HP) patients is still lacking. This information is 
critical in renal clinics where LP patients are common.
Methods: We pooled three prospective cohorts that in 2000-2010 enrolled 2,488 CKD 
patients stage III-V under stable care from ≥6 months in 40 Italian renal clinics. Patients 
were followed for ESRD (chronic dialysis-transplant) up to 12/2014. Patients were classified 
in two groups, LP (56%) and HP (44%), by Uprot £0.5 and >0.5 g/24h, respectively.
Results: Besides lower Uprot (median, IQR: 0.15, 0.06-0.28 vs 1.20, 0.78-2.05 g/24h), 
LP differed from HP because male gender (55 vs 62%), diabetes (28 vs 35%) and use of 
anti-RAS (73 vs 78%) were less frequent. In LP, moreover, age (70±12 vs 65±14 y), GFR-
EPI (35.2±13.3 vs 26.6±13.2 mL/min/1.73m2) and Hb (12.7±1.7 vs 12.3±1.8 g/dL) were 
higher while systolic BP (137±18 vs 140±18 mmHg) was lower. Serum phosphorus (P) was 
lower in LP (3.68±0.73 vs 3.95±0.83 mg/dL, with P>4.5 mg/dL in 10 vs 20%) [P<0.001 
for all comparisons]. History of cardiovascular disease (CVD), BMI and uric acid levels 
did not differ. Over a median follow-up of 38 months, ESRD occurred in 154 LP and 422 
HP, (incidence rate 2.9 and 12.2/100 pts/y). At multivariable Cox analyses (HR, 95% CI), 
significant predictors of ESRD were male gender, younger age and lower eGFR in both LP 
and HP. Only in LP, however, higher P (1.28, 1.02-1.61) and lower BMI (0.96, 0.93-0.99) 
predicted renal risk while CVD (1.28, 1.03-1.60), Hb (0.90, 0.85-0.97) and anti-RAS (0.74, 
0.60-0.91) had a prognostic role exclusively in HP. A negative interaction P*Uprot was 
detected in HP (beta= -0.046, P=0.004). Results were consistent across cohorts.
Conclusions: In renal clinics, LP patients are prevalent and characterized by nontrivial 
renal risk despite higher eGFR. Risk factors for ESRD are peculiar; in particular, results 
in LP and HP suggest that lower Uprot allows full expression of the negative role of P, the 
effect being evident for P levels mostly normal.
FR-PO577
Trends in CKD Awareness in the U.S. Population, 1999-2012, Overall and 
by KDIGO Risk Groups  Yunnuo Zhu,1 Tanushree Banerjee,1 Delphine S. 
Tuot,1 Jennifer L. Bragg-Gresham,2 Mark Eberhardt,3 Sharon Saydah,3 Rajiv 
Saran,2 Neil R. Powe.1  1UCSF; 2UM; 3CDC.
Background: Despite medical knowledge of chronic kidney disease (CKD) as a risk 
factor of cardiovascular disease, hypertension, and progression to kidney failure, a majority 
of patients are not aware of their disease. Early identification and management of CKD 
can decrease its rate of progression.
Methods: We used cross-sectional National Health and Nutrition Examination Survey 
data (1999-2012) of non-pregnant adults aged ³20 years with CKD who had complete 
urinary albumin and creatinine data (N=8,480-10,296). CKD stages 1-4 were classified 
using KDIGO’s prognosis of CKD risk levels based on GFR and albuminuria. The risk 
categories range from low to very high risk and predict the risk of CKD progression, ESRD, 
and mortality. eGFR was estimated using the MDRD equation. CKD awareness was defined 
by answering “yes” to the question “Have you ever been told that you had weak or failing 
kidneys?” amongst those with CKD. We used weighted, age-adjusted regression analyses 
via SAS SURVEYREG to analyze prevalence and trends.
Results: Overall prevalence of CKD awareness across all risk groups in 2009-2012 was 
4.7% and had not significantly changed compared to 4.4% in1999-2004 or 4.7% in 2005-
2008 (p trend=0.96). Awareness in the very high KDIGO risk group for progression was 
greatest and increased from 40.5% in 1999-2004 to 51.6% in 2009-2012 (p trend=0.007). 
The prevalence of self-report CKD awareness was 16.6% in the next highest risk group in 
2009-2012 but did not exhibit a statistically significant trend (p trend=0.56). The moderately 
increased risk group showed a decrease in awareness from 6.3% in 1999-2004 to 4.1% in 
2009-2012 that was not statistically significant (p trend=0.14). Awareness in the low-risk 
group was the lowest of all risk groups at 2.0% in 2009-2012 and showed no change over 
time (p trend=0.67).
Conclusions: Although overall awareness of CKD has not changed over time, 
awareness among those at highest risk for CKD progression has increased. Recent education 
efforts to increase awareness among providers and patients may be reaching those at greatest 
risk and acceleration might help mitigate CKD progression and associated comorbidities.
Funding: Other U.S. Government Support
FR-PO578
Intermittent Abnormal Kidney Function and Mortality in Community 
Dwelling Individuals  Donal J. Sexton,1 Scott Reule,2 Robert N. Foley.2 
1Medicine, HRB Clinical Research Facility, NUIGalway, Galway, Ireland; 
2Medicine, Univ of Minnesota, Minneapolis.
Background: The health implications of persistently abnormal kidney function as 
measured by estimated glomerular filtration rate and spot urinary albumin excretion has 
been well characterized to date. However little data is available regarding the implications 
of intermittent abnormalities in these tests as defined by established thresholds.
Methods: We evaluated the frequency of intermittent abnormal kidney function and its 
association with all-cause mortality in the US general population using the National Health 
and Nutrition Examination Survey III, 1988-1994. Mortality linkage data were available 
through December 2006. Estimated glomerular filtration rate (eGFR) calculated using the 
CKD-EPI equation and urinary albumin-creatinine ratios (ACR) were measured twice, a 
mean of 17 days apart (N=1161).
Results: Proportions of abnormal tests included: for eGFR < 60ml/min/1.73m2 either 
test 7.32 %, first test 5.94%, second test 5.68%, first test only 1.64%, second test only 
1.38%, both tests 4.31%. Compared to participants with eGFR ≥ 60 ml/min/1.73m2 on 
both testing occasions, adjusted hazard ratios were 1.8 (95%CI 1.3, 2.4) for intermittent 
and 1.7 (95%CI 1.1, 2.5) for persistent abnormal eGFR. Proportions with ACR ≥ 30 mg/g 
were as follows: either test 16.54%, first test 11.63%, second test 13.35%, first test only 
3.19%, second test only 4.91%, both tests 8.44%. Compared to those with ACR < 30 mg/g 
on both occasions’ mortality hazard ratios for intermittent abnormal function was 2.1 
(95%CI 1.6, 2.7), and persistent abnormal 2.0 (95%CI 1.5, 2.8). Models were adjusted for 
age, sex, race, diabetes mellitus, cardiovascular disease (congestive heart failure, previous 
myocardial infarction or stroke), current smoking, self reported hypertension, systolic and 
diastolic blood pressure, total cholesterol and body mass index.
Conclusions: CKD as defined by established thresholds may be persistent or 
intermittent in community dwelling individuals. Participants with intermittently abnormal 
kidney function as defined by current thresholds were at similar mortality risk to those with 
persistently abnormal function on both occasions.
FR-PO579
Renal Outcome of APRT Deficiency Presenting in Childhood 
Hrafnhildur L. Runolfsdottir,1 Runolfur Palsson,1,2 Inger Maria Agustsdottir,3 
Olafur S. Indridason,2 Vidar O. Edvardsson.1,3  1Faculty of Medicine, Univ of 
Iceland; 2Div of Nephrology; 3Children´s Medical Center, Landspitali – The 
National Univ Hospital of Iceland, Reykjavik, Iceland.
Background: Adenine phosphoribosyltransferase (APRT) deficiency is an inherited 
disorder of purine metabolism that leads to nephrolithiasis and chronic kidney disease 
(CKD). Scarce data are available on APRT deficiency presenting in childhood.
Methods: All patients in the APRT Deficiency Registry of the Rare Kidney Stone 
Consortium who presented with clinical manifestations of the disorder and/or were 
diagnosed with the disease before age 18 years were included in the study. Presenting 
features, time to diagnosis and disease course were examined. Glomerular filtration rate 
(eGFR) was estimated with the modified Schwartz equation in children and the MDRD 
equation in adults. CKD was defined as eGFR <60 ml/min/1.73 m2 and acute kidney injury 
(AKI) according to the KDIGO criteria. Data are presented as median (range).
Results: Nineteen children presented at the age of 1.6 (0.2-16.5) years. Presenting 
features included reddish-brown diaper spots in 11 patients (58%), kidney stones in 8 (42%), 
lower urinary tract symptoms in 8 (42%) and AKI in 2. The diagnosis was promptly made in 
7 patients, while it was delayed in 12 (63%) patients for 15.2 (0.8-39.2) years. One patient, 
who did not receive drug treatment, developed ESRD at age 11 years. Twelve patients were 
placed on allopurinol at the age of 2.1 (0.6-16.5) years. During follow-up of 18.9 (1.7-31.5) 
years, 3 of these patients developed 4 kidney stone events and AKI occurred in 2 patients 
during episodes of volume depletion; none had developed CKD. Six patients did not begin 
pharmacotherapy until age 29.8 (20.5-42.4) years. At last follow-up, at 43.9 (32.5-56.9) 
years of age, 3 had experienced a total of 9 kidney stone events, 2 had suffered AKI, 3 had 
stage 3 CKD and one had progressed to ESRD at the age of 44 years.
Conclusions: A substantial proportion of patients with APRT deficiency present in 
childhood. The commonly observed delay in diagnosis and treatment may have grave 
consequences. APRT deficiency must be excluded in all children with kidney stones, renal 
dysfunction and reddish-brown diaper spots.
Funding: Other NIH Support - This study was supported by the Rare Kidney Stone 
Consortium (U54KD083908), a part of the National Center for Advancing Translational 
Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN). RDCRN is 
an initiative of the Office of Rare Diseases Research (ORDR). The Rare Kidney Stone 
Consortium is funded through collaboration between NCATS and National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK).
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
493A
J Am Soc Nephrol 26: 2015 CKD: Epidemiology, Outcomes: Noncardiovascular Poster/Friday
FR-PO580
Association of Chronic Kidney Disease with Increased Risk of Recurrence 
of Upper Urinary Tract Urothelium Cancer – A Population-Based Study 
Shang-Jyh Hwang,1,3 Ming-Yen Lin,1 Huei-Lan Lee,1 Wei-Ming Li,1 Chun-Nung 
Huang,1 Wen-Jeng Wu,1 Li-Tzong Chen,3 Sheng-wen Niu.1  1Medical Univ 
Hospital, Kaohsiung, Taiwan; 2National Health Research Insts, Miaoli, Taiwan.
Background: Taiwan has significantly high incidence of upper urinary tract urothelial 
cancer (UTUC) and end-stage renal disease (ESRD). UTUC coexisted with chronic kidney 
disease (CKD) may deteriorate cancer progression and increase mortality risk. The aim of 
study was to explore the association of CKD with the risk of UTUC recurrence.
Methods: We conducted a population-based cohort study through Taiwan National 
Health Insurance Research Dataset. Incident UTUC patient was extracted from Taiwan 
Cancer Registry Dataset and linked to claim data. Status of CKD including non-dialysis 
CKD, dialysis ESRD, and renal transplant were identified before the index date of UTUC. 
Recurrence was defined as either new tumor lesion in bladder, or at the other site of urinary 
tract, or occurrence of distant metastasis within 3 months after first surgery. Differences 
of characteristics between CKD and non-CKD group was described as mean ± standard 
deviation or percentage and tested by independent t test and chi-square test. Competing 
risk approach was used for estimating cause-specific hazard ratio (CSHR) and 95% 
confidence interval (CI).
Results: Totally, 4,002 UTUC patients from 2001 to 2005 were included and traced 
until disease recurrence or end of 5 years after the index date of UTUC. Near half patients 
accompanied with various stages and status of CKD at index date. UTUC patients with 
CKD were younger, more female, and had more co-morbidities than patients without 
CKD. After adjusting factors of age, tumor grade, and co-morbidities, CKD significantly 
increased risk of UTUC recurrence in female (CSHR: 1.72, 95%CI: 1.13-2.61, p=0.01), 
but not in male (CSHR: 0.91, 95%CI: 0.44-1.86, p=0.79).
Conclusions: CKD increases risk of recurrence in female UTUC patient and is an 
important prognostic indicator.(This study was granted by the Ministry of Science and 
Technology(NSC 102-2314-B-037-012-MY3) and by the Ministry of Health and Welfare 
(MOHW103-TD-B-111-05, MOHW104-TDU-B-212-124-003, budget from health and 
welfare surcharge of tobacco product).)
Funding: Government Support - Non-U.S.
FR-PO581
Single Centre Experience of Late Referral and Achievement of Useable 
Dialysis Access Over a 9-Year Period  Mohamed Salah Eldin Khogali.  Renal 
Dept, Dorset County Hospital, Dorchester, Dorset, United Kingdom; Renal Dept, 
Dorset County Hospital, Dorchester, Dorset, United Kingdom.
Background: We describe a single centre, retrospective analysis of late (≤ 90 
days) referral for dialysis over a 9 year period from April 2003 till March 2012. Factors 
that contributed to late referral and success in creating permanent dialysis access were 
determined.
Methods: Data on adult patients referred ≤ 90 days from dialysis were collected 
including patient demographics, source of referral, mortality, reason for late referral, 
creation of permanent dialysis access and use of permanent dialysis access at first dialysis.
Results: One hundred and twenty-seven patients were referred in ≤ 90 days over the 
9 year period. Ninety-nine (78%) patients were referred within 30 days prior to dialysis 
and 28 (22%) patients within 30 – 90 days. Their median age was 63 years and 80 (63%) 
patients were male. Twenty- five (20%) patients were diabetic. Forty (33%) patients died 
within the first year after referral, 25 (21%) patients within the first 6 months and 15 (12%) 
patients between 6 months and 1 year.(figure1) Sixty-five patients (51 %) presented late 
due to acute renal failure (myeloma 24, vasculitis 14, irreversible acute kidney injury 10, 
renal cell carcinoma 5, glomerulonephritis 3 and others 9). Twenty-nine patients (23%) 
referred by physicians and surgeons, and 24 patients (19%) referred by GPs were late 
referrals of patients with known chronic renal failure. Nine patients (7%) presented late 
due to lack of understanding of their disease, denial, and fear of the unknown. One hundred 
and ten patients had permanent dialysis access created and 17 patients no permanent access 
procedures. The average time to create permanent dialysis access was 44 days post-dialysis 
commencement. Six permanent haemodialysis accesses were created pre-dialysis, 56 
post-dialysis; 19 peritoneal dialysis accesses were created pre- dialysis, 29 post-dialysis.
Conclusions: Overall the number of patients presenting late for dialysis has decreased. 
Late referral has a poor 1 year survival and most patients require haemodialysis long-term. 
Only a minority of patients referred late have permanent dialysis access created and used 
at their first dialysis.
FR-PO582
Abnormal Global Glomerular Sclerosis Rate in Remnant Kidney of 
Ipsilateral Nephroureterectomy Is Associated with Higher Risk of End-
Stage Renal Disease within Five Years in Patients of Upper Urinary Tract 
Urothelial Carcinoma  Sheng-wen Niu,1 Peir-In Liang,1 Shih-Mong Yeh,1 
Ming-Yen Lin,1 Shang-Jyh Hwang,1,2 Wen-Jeng Wu.1  1Kaohsiung Medical 
Univ, Taiwan; 2National Health Research Insts.
Background: Aristolochic acid in Chinese herbs induce renal tubuleinterstitial disease 
and increase the risk of upper urinary tract urothelial carcinoma(UTUC). However, we 
are still not sure if UTUC itself has impact on renal outcome. We studied the pathological 
changes of remnant kidney tissue from UTUC patients post ipsilateral nephroureterectomy 
to investigate the correlation between renal histopathology and outcome of end-stage 
renal disease.
Methods: This cohort study included 132 cases of non-dialysis UTUC patients post 
ipsilateral nephroureterectomy from 2002 to 2010. We collected clinical and laboratory data 
before surgery, tumor size, whether into dialysis after surgery, and followed up to dialysis 
or to December 31, 2014. Renal histopathology was read by 3 specialists: nephrologists 
or pathologist. We used logistic regression for studying tubuleinterstitial fibrosis score 
and global glomerular sclerosis (GGS) rates and Cox regression to investigate factors 
associated with renal survival.
Results: There was no significant factor associated with tubuleinterstitial fibrosis, 
but advanced CKD was significantly related to GGS rate adjusted with age and gender 
[OR(95%CI): 4.8(1.4-16.9), p=0.014]. Kaplan-Meier survival curve showed five-year 
renal survival rate was 86.3%. Factors affect five-year renal survival were hypertension 
[HR(95%CI): 4.0(1.1-15.2), p=0.043] and GGS rate [HR(95%CI): 17.4(2.4-124.1), 
p=0.004].
Conclusions: Our findings demonstrated that UTUC patients with hypertension before 
surgery or abnormal GGS rate in remnant kidney have higher risk of entering dialysis within 
five years post ipsilateral nephroureterectomy.(This study was granted by the Ministry of 
Science and Technology (NSC 102-2314-B-037-012-MY3) and by the Ministry of Health 
and Welfare (MOHW103-TD-B-111-05, MOHW104-TDU-B-212-124-003, budget from 
health and welfare surcharge of tobacco product)).
Funding: Government Support - Non-U.S.
FR-PO583
Renal Outcomes following Transjugular Intrahepatic Portosystemic Shunt 
Placement for Refractory Ascites: A Large Case Series  Andrew S. Allegretti,1 
Guillermo Ortiz,1 Jie Cui,1 Ishir Bhan,1 Raymond T. Chung,2 Zubin Irani.3  1Div 
of Nephrology, MGH, Boston, MA; 2Div of Hepatology, MGH, Boston, MA; 
3Dept of Radiology, MGH, Boston, MA.
Background: Patients with cirrhosis and refractory ascites have decreased effective 
circulating volume that contributes to impaired renal perfusion and diminished estimated 
glomerular filtration rate (GFR). Reversing these hemodynamic alterations via transjugular 
intrahepatic portosystemic shunt (TIPS) procedure may improve GFR.
Methods: Multicenter, retrospective review of patients who underwent first-time TIPS 
placement for refractory ascites from 1995 to 2014. Patients were analyzed at 90 days prior 
to TIPS, immediately pre- and post-TIPS, and 90 days after TIPS. Change in renal function 
90 days after TIPS was analyzed by GFR tertiles (T1: > 60 mL/min, T2: 37-60 mL/min, 
T3: <37 mL/min) at the time of TIPS procedure.
Results: 153 TIPS cases were analyzed. Mean GFR was 62 (95% CI 58, 69) mL/min 
at 90 days prior to TIPS, 53 (48, 58) mL/min immediately pre-TIPS, 64 (59, 69) mL/min 
post-TIPS, and 74 (CI 68, 80) mL/min 90 days after TIPS.
GFR improved by 16 (11, 21) mL/min from pre-TIPS to 90 days after TIPS (p <0.0001). 
Comparison of Tertiles 1, 2, and 3 showed respectively: GFR increased by T1: 6 (-1, 14), 
T2: 22 (15, 30), and T3: 22 (12, 33) mL/min (p = 0.006); 90-day mortality was T1: 20%, 
T2: 17%, and T3: 49% (p = 0.0007); encephalopathy rate at 90 days was T1: 21%, T2: 
42%, and T3: 65% (p = 0.0005).
Conclusions: There was a significant improvement in GFR from pre-TIPS to 90 days 
after TIPS. Those with the lowest GFRs at the time of TIPS had greater improvement in 
renal function but also had higher 90-day mortality and encephalopathy rates post-TIPS.
Funding: NIDDK Support
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FR-PO584
The Epidemic of Chronic Kidney Disease in Rural and Remote Canadian 
First Nations: Results from Manitoba’s FINISHED Screening Program 
Paul Komenda,1,3 Barry Ad Lavallee,1,2 Thomas W. Ferguson,3 Navdeep Tangri,1,3 
Allison Dart,1 Bing Hu,4 Audrey Gordon,4 Caroline D. Chartrand,2 Lorraine 
L. Mcleod,2 Claudio Rigatto.1,3  1Medicine, Univ of Manitoba, Winnipeg, MB, 
Canada; 2Diabetes Integration Project, Winnipeg, MB, Canada; 3Community 
Health Sciences, Univ of Manitoba, Winnipeg, MB, Canada; 4Seven Oaks 
General Hospital Research Centre, Winnipeg, MB, Canada.
Background: Chronic Kidney Disease (CKD) is a global epidemic affecting 10-15% 
of the general population. Canadian First Nations children and young adults are known to 
suffer from a high rate of proximate risk factors for CKD, in particular elevated rates of 
diabetes. The rates of CKD are not well defined in this population. We used data from The 
First Nations Community Based Screening to Improve Kidney Health and Prevent Dialysis 
(FINISHED) project, a 3-year initiative completed in 2015 that accomplished community 
wide screening in 11 rural and remote First Nations communities in Manitoba, Canada.
Methods: Detailed methods of the FINISHED study have been previously published 
(Lavallee et al. CJKHD, 2015). An interdisciplinary team screened for CKD in adults and 
children aged 10 + using both urine albumin-to-creatinine ratio (ACR) and eGFR in 11 
communities across 2 tribal councils. We present here the data on demographic variables, 
risk factors for CKD, and the prevalence and severity of CKD in the adult (age 18+) 
screening cohort.
Results: 1346 adults were screened. 26.7% of those screened had CKD defined as 
elevated urine ACR (micro- or macroalbuminuria) or eGFR < 60 ml/min/1.73m2. Road 
access communities had a lower prevalence of CKD (18.4%) than remote air access 
communities (36.0%). Macroalbuminuria (urine ACR > 300 mg/g) was present in 5% of 
those screened (2.8% in road access and 7.5% in air access communities).
Conclusions: Rural and remote Canadian First Nations suffer up to a 3-fold higher 
prevalence of CKD than the general population and a nearly 5-fold higher prevalence of 
macroalbuminuria. This prevalence is comparable to high-risk populations such as those 
with diabetes and/or hypertension. Given these risks, screening and treatment interventions 
may be cost-effective, as they have been shown to be in other high-risk populations.
Funding: Government Support - Non-U.S.
FR-PO585
Age and Gender Specific Lifetime Risk of Renal Replacement Therapy 
Jan A.J.G. van den Brand,1 Maria Pippias,2 Vianda S. Stel,2 Jack F. Wetzels,2 
Kitty J. Jager.2  1Dept of Nephrology, Radboud Univ Medical Center, Nijmegen, 
Netherlands; 2ERA-EDTA Registry, Academic Medical Centre Univ of 
Amsterdam, Amsterdam, Netherlands.
Background: Kidney transplantation is the preferred treatment of end stage renal 
disease (ESRD). Graft and patient survival are highest after transplantation with a graft 
from a living donor. However, persons who donate a kidney are themselves at risk of ESRD. 
Personalized risk prediction requires age and gender specific risk estimates. Here, we report 
lifetime risk of renal replacement therapy (RRT) for ESRD by age and gender across Europe.
Methods: We defined ESRD as chronic RRT and age 80 as the lifetime horizon. Death 
was considered a competing event. We obtained RRT incidence rates by age and gender 
from the ERA-EDTA Registry. Mortality rates were calculated from census data provided 
by EuroStat. We used these rates to estimate cumulative incidence of RRT by age and 
gender for countries providing individual patient data to the ERA-EDTA Registry. We 
pooled lifetime RRT risks using inverse variance weighted means.
Results: At index age 20, lifetime RRT risk for females ranged between 0.40% and 
0.87% across countries, and for males between 0.77% and 1.59%. At age 60, lifetime RRT 
risk ranged between 0.26% and 0.68% for females and 0.56% and 1.32% for males. Pooled 
lifetime RRT risk in Europe was 0.62%, 0.58% and 0.43% in 20, 40 and 60 year old females. 
In males the respective risks were 1.16%, 1.10% and 0.87% for index ages 20, 40 and 60. 
The figure shows pooled lifetime RRT risk estimates by index age. 
Conclusions: Lifetime RRT risk differs across Europe. Women are at lower risk 
compared to men. These data offer a basis to provide personalized prediction of lifetime 
ESRD risk when evaluating a potential kidney donor. The estimates presented here are 
population averages. We expect that lifetime risk is lower in persons with normal eGFR 
and no albuminuria.
FR-PO586
Characterizing Risk Among Type 2 Diabetics with Preserved EGFR and 
Abnormal Urine Albumin Excretion  Robert M. Perkins,1 Alex R. Chang,2 
H. Lester Kirchner.2  1Bayer HealthCare, Whippany, NJ; 2Geisinger Medical 
Center, Danville, PA.
Background: Updated CKD risk stratification guidelines promote earlier identification 
of higher-risk patients. Two conditions are required to improve outcomes among such 
patients: robust risk characterization, and the presence of modifiable factors.
Methods: We investigated a retrospective cohort of all adult type 2 diabetic patients 
receiving care in an integrated health care system in central Pennsylvania during the period 
1/1/2004-12/31/2014. Patients were risk stratified using the 2002 NKF and, separately, the 
2012 KDIGO CKD classification systems. We compared the predictive performance of the 
two classification systems for death and ESRD using Akaike Information Criterion (AIC) 
obtained from multivariate, Cox proportional hazards models. Using only the KDIGO 2012 
classification system, we then investigated patients categorized as stage G1 or G2 (with 
‘high’ or ‘very high’ albuminuria) for the presence of modifiable risk factors.
Results: 17,385 type 2 diabetics comprised the study population (median follow-up 
6.8 years). Median age and eGFR were 60 years and 95 ml/min/1.73m2, respectively. 53% 
were male, 44% had a smoking history, and 16% and 5% had a history of coronary disease 
and CHF, respectively. Although both classification systems discriminated risk reasonably 
well, the KDIGO 2012 system—incorporating uACR—had lower AIC scores and was 
more likely to minimize information loss. Across all risk factors examined, less than half 
the population was receiving recommended care.
Conclusions: This investigation confirms the feasibility of early risk characterization 
among patients with preserved eGFR and abnormal urinary albumin excretion. Care gaps 
are highly prevalent among these individuals and may serve as targets to improve long 
term outcomes.
FR-PO587
Detecting Bowel Cancer in Chronic Kidney Disease (CKD): The Detect 
Study  Germaine Wong.  Univ of Sydney, Australia.
Background: CKD confers a 20% higher risk of colorectal cancer (CRC) than the 
general population, and has a very poor prognosis, with less than 50% of kidney transplant 
recipients surviving one year after diagnosis. The benefits and harms of screening for 
advanced colorectal neoplasms in CKD are unknown. We aim to determine the prevalence 
and spectrum of advanced colorectal neoplasms in CKD, and to evaluate the test performance 
characteristics of immunochemical faecal occult blood testing (iFOBT) for screening 
advanced colorectal neoplasms in CKD.
Methods: Participants with CKD stages III-V, on dialysis and with a kidney transplant, 
aged between 35 and 74 years were recruited from 10 centres in Spain, Canada, Australia 
and New Zealand. All received two screening iFOBTs, and those with at least one or more 
positive screens underwent colonoscopy, with test negatives verified by clinical follow 
up and data linkage.
Results: Of the1602 patients recruited to the study, [CKD stages III-V: n= 734 (45.8%); 
dialysis: n=392 (24.7%) and transplant n=476 (29.7%)], 345 (21.5%) had one or more 
positive screens. The prevalence of advanced colorectal neoplasms (7 colorectal cancers 
and 101 advanced colorectal adenomas) among those with CKD stages III-V, on dialysis 
and with kidney transplants was 5.7% (95%CI: 4.3%-7.6%), 7.9% (95%Cl: 5.6%-11.0%) 
and 5.9% (4.1%-8.4%) (p=0.10), respectively. The majority of the polyps were located in 
the sigmoid and transverse colon (n=63, 58%). The risk of serious complications including 
peritonitis and perforation was minimal (less than 1%). Overall, the positive predictive 
value (PPV) of iFOBT was 35.4% (95%CI: 29.9% - 41.3%).
Conclusions: Overall, the screening program appears acceptable to patients, appears 
safe, has reasonable predictive values and has detected a higher prevalence of advanced 
CRC neoplasms than in the general population.
Funding: Government Support - Non-U.S.
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FR-PO588
Subclinical Pulmonary Congestion Is Pervasive in Nephrotic Syndrome 
Francesca Mallamaci,1,2 Francesco Marino,2 Carmela Martorano,2 Rocco 
Tripepi,1 Marianna Bellantoni,1 Giovanni Tripepi,1 Carmine Zoccali.1  1National 
Research Council of  Italy, Inst of  Clinical Physiology, Reggio Cal Unit, CNR-
IFC, Reggio Calabria, Italy; 2Nephrology, Transplantation  and Hypertension 
Unit United Hospitals, Reggio Calabria, Italy.
Background: In patients with Nephrotic Syndrome (NS) the lung is considered as an 
organ protected from the risk of edema. However information on objectively measured 
lung water in NS patients is lacking.
Methods: We measured lung water with an ultrasound technique (US) and with standard 
transthoracic impedance in an incident series of 42 asymptomatic patients with active NS. 
Eleven of these patients were re-studied during NS remission. Twenty-one healthy subjects 
formed the control group. US lung studies were performed after 5 and 60 minutes of supine 
resting and after 5 minutes of standing. Transthoracic impedance was measured after 30 
min of supine resting only.
Results: In patients with active NS the median number of US-B lines (a metric of lung 
water) after 5 min in supine position was markedly higher [12; Interquartile range :7-25; 
p<0.001] than in healthy subjects [4; 2-9]. The difference between patients [16, 11-35] 
and controls [4; 2-9] amplified (p<0.001) after 60 min of supine resting and attenuated 
after 5 min of standing [9; 7-25 vs 4; 3-5, p=0.001]. After NS remission, the number of 
US B lines reduced to 5 (4-18) at 5 min and to 6 ( 5-22) at 60 min (P<0.001) approaching 
the normal range. Lung congestion in patients with active disease was fully confirmed by 
transthoracic impedance measurements (p<0.001 vs healthy controls).
Conclusions: Asymptomatic pulmonary congestion is pervasive in patients with NS. 
A clinical trial is needed to assess the usefulness of the application of this technique for 
the management of patients with NS.
FR-PO589
The Incidence of Malignancies prior to the Diagnosis of ANCA-Associated 
Vasculitis (AAV) Is Not Increased in Comparison to the Incidence in the 
General Population  Emma Elisabeth Van Daalen,1 Chinar Rahmattulla,1 Ron 
Wolterbeek,2 Jan A. Bruijn,1 Ingeborg M. Bajema.1  1Pathology, Leiden Univ 
Medical Center, Leiden, Netherlands; 2Medical Statistics and Bioinformatics, 
Leiden Univ Medical Center, Leiden, Netherlands.
Background: Several studies have found an increased malignancy risk before the 
diagnosis of AAV, especially in granulomatosis with polyangiitis (GPA), whereas data on 
microscopic polyangiitis (MPA) are scarce. It has been hypothesized that malignancies and 
AAV have common pathways in their pathogenesis (Ann Rheum Dis 2004, Rheumatology 
2009). We studied the malignancy risks in patients before their AAV diagnosis to further 
elucidate this hypothesis.
Methods: We retrospectively retrieved data on 138 patients with biopsy-proven AAV 
diagnosed in the Netherlands. Malignancies prior to AAV diagnosis were identified using 
the Dutch National Pathology Database. The malignancy incidence was compared to the 
incidence in the general population, as reported by the Netherlands Cancer Registry. The 
Standardized Incidence Ratios (SIRs) were calculated, matching for gender, age and calendar 
time period. Separate analyses were performed for GPA and MPA.
Results: Twelve patients were diagnosed with cancer before the AAV diagnosis 
(mean follow-up: 11.8 years). Overall malignancy risk was not increased (SIR: 0.92, 
95%CI: 0.48-1.61). Malignancy risks were also not increased for malignancies of the skin, 
bladder, kidney, lung, stomach, rectum and uterus (SIRs ranging from 1.71 to 4.77, not 
significantly increased). There was no difference in malignancy risk between GPA (SIR: 
1.23, 95%CI: 0.49-2.53) and MPA (SIR: 0.98, 95%CI: 0.27-2.50) patients (relative risk: 
1.26, 95%CI: 0.32-5.86).
Conclusions: We did not find an increased incidence of malignancies prior to AAV 
diagnosis compared to the general population. This is in contrast with previous studies, 
in which GPA was associated with preceding renal cell carcinoma, bladder cancer and 
non-melanoma skin cancer. Most other studies have not included microscopic polyangiitis 
patients, for which malignancy risk was not increased in our study. Our findings do not 
support the hypothesis that malignancies and AAV have a shared pathogenic pathway.
FR-PO590
Gastrointestinal Symptoms and Hypoalbuminemia in Chronic Kidney 
Disease Patients  Xuehan Zhang,1,2 Nisha Bansal,3 Alan S. Go,4 Chi-yuan Hsu.2,4 
1Peking Union Medical College Hospital; 2Univ of California-San Francisco; 
3Univ of Washington; 4Kaiser Permanente Northern California.
Background: Hypoalbuminemia is an important risk factor for adverse outcomes in 
patients with CKD. Little is known about the relationship between gastrointestinal (GI) 
symptoms and serum albumin level in CKD.
Methods: This is a cross-sectional study of participants (N=3599) in the Chronic 
Renal Insufficiency Cohort (CRIC) study which collected information regarding potential 
uremic symptoms. For each of the 4 following symptoms: “bad taste in mouth,” “loss of 
appetite,” “nausea,” “vomiting,” we created a severity score by multiplying the number 
of symptomatic days in the past month by a severity scale of 1 to 3 (mild, moderate and 
severe). We then summed up the individual severity scores for an overall “GI symptom 
score.” Dietary protein intake was measured via 24-hour urine. The main outcome was 
serum albumin level.
Results: Mean eGFR was 42.9±13.4ml/min/1.73m2, and serum albumin level was 
3.95±0.46 g/dL. 1702 subjects had one or more symptoms. Patients with lower eGFR were 
more likely to have GI symptoms. 
Odds Ratio (95% CI)
Symptom
eGFR≥60ml/
min/1.73m2
(n = 370)
eGFR 45-60ml/
min/1.73m2
(n = 1166)
eGFR 30-45ml/
min/1.73m2
(n = 1375)
eGFR<30ml/
min/1.73m2
(n = 688)
A bad taste in your 
mouth? 1.0 (reference)
0.99 (0.75-
1.32)
P=0.9
1.22 (0.92-
1.62)
P=0.2
1.34 (0.99-1.82)
P=0.06
Loss of appetite? 1.0 (reference)
1.21 (0.88-
1.68)
P=0.2
1.83 (1.34-
2.52)
P<0.001
2.01 (1.43-2.82)
P<0.001
Nausea or being 
sick to your 
stomach?
1.0 (reference)
0.95 (0.72-
1.25)
P=0.7
1.24 (0.95-
1.63)
P=0.1
1.32 (0.98-1.78)
P=0.06
Vomiting? 1.0 (reference)
1.08 (0.70-
1.67)
P=0.7
1.67 (1.11-
2.54)
P=0.02
1.76 (1.13-2.75)
P=0.01
Compare with those without symptoms, CKD patients with progressively higher tertiles 
of GI symptom score were more likely to have lower serum albumin levels (-0.07, -0.09 
and -0.13 g/dL, respectively)(all p<0.01). Patients with more GI symptom also had lower 
dietary protein intake (r=-0.141, P<0.01).
Conclusions: Increased prevalence of GI symptoms become apparent among CKD 
patients at relatively high eGFR levels (45 ml/min/1.73m2). These symptoms correlated 
with important nutritional parameters.
FR-PO591
Obstruct ive  Lung Funct ion in  CKD: NHANES 2007-2012 
Sankar D. Navaneethan,1 Susana Arrigain,1 Mahboob Rahman,1 Jesse D. 
Schold.2  1Cleveland Clinic; 2CWRU.
Background: Lung diseases are one of the leading causes of death in the general 
population. We aimed to study the prevalence of obstructive lung function in those with 
CKD. In addition, factors associated with obstructive lung function were examined.
Methods: Participants aged 20-79 years from the National Health and Nutrition 
Examination Survey (NHANES) 2007-2012 who underwent spirometry testing using 
similar protocols were included in this analysis. Global Initiative for Chronic Obstructive 
Lung Disease classification of COPD ( FEV1/FVC <0.7) based on post-bronchodilator 
spirometric results was used to establish the prevalence of obstructive lung function with 
weights adjusted for non-response to spirometry. CKD was defined as presence of eGFR 
<60 ml/min/1.73 m2 and/or UACR >30 mg/g. Factors associated with obstructive lung 
function were identified using logistic regression model for the entire cohort, CKD and 
non-CKD groups separately (using baseline spirometry).
Results: Out of 11,995 participants (CKD=1563; Non-CKD=10,432) who completed 
the baseline spirometry testing, 1,986 participants were eligible for but only 1049 complete 
post-bronchodilator spirometry. Prevalence of obstructive lung function using baseline 
spirometry data were 25% in CKD and 13% in non-CKD and GOLD criteria were 17% in 
CKD and 8% in non-CKD. Each 5 ml/min lower eGFR and proteinuria were associated 
with higher odds of having obstructive lung function in the entire cohort.
Old age, white race, smoking and self-reported COPD were associated with obstructive 
lung function in both CKD and non-CKD groups.
Conclusions: In this representative cohort of US population, prevalence of obstructive 
lung function is higher in those CKD. Lower eGFR and proteinuria are associated with 
obstructive lung function. Further studies examining the impact of lung diseases in CKD 
are warranted.
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FR-PO592
Association of Serum Osteoprotegerin with Bone Loss in Chronic Kidney 
Disease: From the KNOW-CKD Study  Chang Seong Kim,1 Eun Hui Bae,1 
Seong Kwon Ma,1 Kook-Hwan Oh,2 Curie Ahn,2 Soo Wan Kim.1  1Dept of 
Internal Medicine, Chonnam National Univ Medical School, Gwangju, Republic 
of Korea; 2Dept of Internal Medicine, Seoul National Univ, Seoul, Republic 
of Korea.
Background: Osteoprotegrin (OPG), a potent inhibitor of oesteoclast activation, 
decreases bone resorption and has protective effects on bone mineral density (BMD). 
This study examined the association between serum OPG and bone loss in patients with 
chronic kidney disease (CKD), a condition associated with increased risk of bone fracture 
and mineral and bone disorder.
Methods: BMD at the lumbar spine, total hip and femur neck was assessed by dual 
energy X-ray absorptiometry; and serum OPG was measured at baseline in 1,423 CKD 
patients in the prospective KoreaN Cohort Study for Outcome in Patients With Chronic 
Kidney Disease. Osteoporosis was defined to T score ≤ –2.5 in patients aged over 50.
Results: Increasing quartiles of serum OPG were significantly associated with lower 
BMD (lumbar spine, total hip and femur neck) compared with the lowest quartile of serum 
OPG. Multivariable linear regression model indicated that serum OPG was independently 
associated with decreased lumbar spine and total hip BMD (B, –0.489; 95% confidence 
interval [CI], –0.883,–0.095; P = 0.015, B, –0.349; 95% CI, –0.672,–0.027; P = 0.027, 
respectively); but femur neck BMD was not associated with serum OPG in women. No 
independent association was found between serum OPG and BMD in men after adjustments. 
In multivariable logistic regression analysis, serum OPG was associated with increased risk 
of osteoporosis in women, but was not in man (odds ratio [OR], 4.01; 95% CI, 1.27–12.67, 
P = 0.018; OR, 0.31; 95% CI, 0.06–1.52, P = 0.311, respectively).
Conclusions: Serum OPG was independently associated with lumbar spine and total 
hip BMD and increased risk of osteoporosis in female CKD patients. However, these 
associations were not found in male CKD patients.
Funding: Government Support - Non-U.S.
FR-PO593
Growth in Children with Chronic Kidney Disease: A Report from the 
KNOW-Ped CKD (Korean Cohort Study for Outcome in Patients with 
Pediatric Chronic Kidney Disease)  Eujin Park,1 Yo Han Ahn,1 Kyoung Hee 
Han,2 Seong heon Kim,3 Joo Hoon Lee,4 Young seo Park,4 Hee Gyung Kang,1 
Hae Il Cheong,1 Curie Ahn,5 IL-Soo Ha.1  1Dept of Pediatrics, Seoul National 
Univ Children’s Hospital, Seoul, Korea; 2Dept of Pediatrics, Jeju National Univ 
School of Medicine, Jeju, Korea; 3Dept of Pediatrics, Pusan National Univ 
Children’s Hospital, Yangsan, Korea; 4Dept of Pediatrics, Asan Medical Center, 
Univ of Ulsan College of Medicine, Seoul, Korea; 5Dept of Internal Medicine, 
Seoul National Univ Hospital, Seoul, Korea.
Background: Growth impairment is common in children with chronic kidney disease 
(CKD) with profound and lifelong psychosocial impact. We investigated the characteristics 
of growth in Korean children with CKD.
Methods: Clinical characteristics along with anthropometric measurements were 
examined in subjects of KNOW-Ped CKD, Korean Cohort Study for Outcome in Patients 
With Pediatric Chronic Kidney Disease. Findings of 322 children (M:F 218:104), who 
were enrolled to the study from July 2010 to December 2013 in seven major pediatric 
nephrology centers of Korea, were analyzed to investigate the characteristics of growth 
in Korean pediatric CKD.
Results: Mean height- and weight- z scores of Korean pediatric CKD patients were 
-0.88±1.43 and -0.91±1.65. Mean BMI- z score was -0.36±1.25. Height defect was observed 
from early stage of CKD with mean height z-score 0.42 in CKD stage I. Short stature (z 
score < - 1.88, 20% of the subjects) and underweight (z score < - 1.65, 28% of the subjects) 
were associated with female sex, age younger than 2-year-old at enrollment, co-morbidity, 
and advanced CKD stage. Low BMI was associated with high blood pressure, co-morbidity 
and younger age. The final height-z score was -0.86±1.19, which is shorter than predicted 
adult height-z score (-0.33±0.7) calculated from their parental height.
Conclusions: Growth failure is one of the most important complications in pediatric 
CKD patient. More profound height, weight and BMI impairment were associated with 
younger age and co-morbidity. Children with these findings need close attention on their 
growth and may require earlier intervention to avoid severe growth impairment.
Funding: Government Support - Non-U.S.
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Risk of Early Preterm Delivery in Pregnant CKD Patients – A Model for 
Counseling – The TOCOS Cohort (Torino Cagliari Observational Study) 
Giorgina B. Piccoli,1 Rossella Attini,2 Gianfranca Cabiddu,3 Antonello Pani,3 
Tullia Todros.2  1ss Nefrologia Dept of Clinical and Biological Sciences, Univ 
of Torino, Italy; 2Dept of Surgery, Univ of Torino, Italy; 3Nephrology, Brotzu 
Hospital, Cagliari, Italy.
Background: Chronic kidney disease (CKD), whose prevalence almost equals 
preeclampsia in pregnancy, increases the risks of adverse pregnancy outcomes; the degree 
is only partially known.
Methods: Objective: Development and internal validation of a prediction model to 
quantify the risks of early preterm delivery (<34 gestational weeks) selected as most relevant 
pregnancy outcome, in pregnant women with CKD. We developed the model in CKD 
women. A homogeneously followed-up, low-risk pregnant population served as controls. 
Setting: The two largest Italian Outpatient Units dedicated to the multidisciplinary follow-up 
of CKD in pregnancy. Patients: Pregnant women with CKD: 503 live-born singletons in 
CKD; 835 low-risk controls (2000-2013). Measurements: Outcome: early pre-term delivery. 
The candidate variables were readily measurable, available, inexpensive (hypertension, 
proteinuria, kidney disease and function). Bootstrapping was used for internal validation.
Results: Early preterm delivery was more frequent in CKD (12.5%) versus controls (1%) 
(p<0.0001). The most parsimonious model (Likelihood ratio test p<0.0001; McFadden’s 
pseudo R2=0.2290) summarized various combinations of CKD stages, hypertension and 
proteinuria and defined a scale of risk. First step included CKD stage1, normotension and 
proteinuria<1g/24h (OR:2.8); second step included CKD stages 2-5 without hypertension 
and proteinuria, and CKD stage1 with either hypertension or proteinuria (OR:19.5 and 20.9); 
third step included CKD stages 2-5 with either hypertension or proteinuria (OR:44.7); the 
combination of hypertension and proteinuria was associated with the highest risk, but the 
low number of cases prevented precise quantification. Limitations: the study was performed 
in two Centers only. The number of cases with severe CKD is small.
Conclusions: The model may support counselling and clinical management by 
grading the risk for adverse pregnancy outcomes. Further studies are needed to externally 
validate the model.
FR-PO595
Solitary Kidney Is Associated with a Higher Risk of Adverse Outcomes 
in Pregnancy  Jessica B. Kendrick,1,2 John R. Holmen,3 Gerard John Smits,1 
Michel Chonchol.1  1Univ of Colorado Denver, Aurora, CO; 2Denver Health 
Medical Center, Denver, CO; 3Intermountain Health Care, Salt Lake City, UT.
Background: Chronic kidney disease is associated with adverse outcomes in pregnancy. 
Data regarding the effect of decreased glomerular filtration rate on pregnancy in women 
with a single kidney primarily has come from studies of kidney transplant recipients and 
living kidney donors. We set out to determine the risk of adverse outcomes in women with 
a single kidney from etiologies other than donation.
Methods: Using data from an integrated health care delivery system from 2000 through 
2014, we conducted a study of 1,556 pregnant women hospitalized for childbirth. A total 
of 333 women had a single kidney with normal kidney function and were matched 1:3 by 
age and race to women with two kidneys. Adverse pregnancy outcomes included preterm 
delivery, delivery via cesarean section, preeclampsia/eclampsia, length of stay at hospital and 
low birth weight (<2,500 g). Multivariate logistic regression analysis was used to examine 
the association between a single kidney and adverse pregnancy outcomes.
Results: Of the women with a solitary kidney, the mean (SD) age and mean (SD) 
gestational age at delivery was 28±6 years and 38±2 weeks, respectively. Compared to 
women with two kidneys, those with a single kidney had an increased risk of preterm 
delivery (OR 2.33, 95% CI 1.61-3.38), delivery via cesarean section (OR 1.85, 95% CI 
1.33-2.56), and preeclampsia/eclampsia (OR 1.87, 95% CI 1.23-2.85). Women with a single 
kidney also had an increased risk of a length of stay > 3 days in the hospital (OR 1.50, 95% 
CI 1.01-2.20) and low infant birth weight (OR 2.99, 95% CI 1.95-4.59).
Conclusions: Women with a solitary kidney from causes other than kidney donation 
have a higher risk of adverse outcomes in pregnancy.
Funding: NIDDK Support
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Thiamine Deficiency in Non-Dialysis CKD Patients  Yukako Ohyama, 
Toshikazu Ozeki, Shun Minatoguchi, Hideaki Shimizu, Yoshiro Fujita. 
Nephrology and Rheumatology, Chubu Rosai Hospital, Nagoya, Japan.
Background: Thiamine deficiency is associated with malnutrition, alcoholism and 
chronic diseases such as cancer. Long use of diuretics also induces thiamine deficiency, 
which is due to an increased urinary loss of thiamine. Some papers report that thiamine 
tend to accumulate because of decreased urinary flow in chronic kidney disease (CKD) 
patients. Others report that a protein restricted diet causes thiamine deficiency in CKD 
patients. This study aimed to examine the prevalence and factors associated with thiamine 
deficiency in CKD patients.
Methods: This is a single center cross-sectional study in patients with non-dialysis 
CKD under regular follw-up in nephrology center of Chubu Rosai Hospital from July 1, 
2014 to January 31, 2015. The patients who meet the CKD criteria of Japanese Society 
of Nephrology were selected. We use the deta from medical records, questionnaires and 
nutrition surveys.
Results: The study population consisted of 149 patients aged 71.2 ± 10.9 years with 
estimated GFR of 33.2 ± 18.2 ml/min per 1.73m2 . They were divided to low thiamine group 
( serum thiamine level<30ng/ml ) and high thiamine group ( serum thiamine level³30ng/
ml ). In univariate comparisons, patients with low thiamine group had significantly lower 
protein intake which is estimated by the nutrition survey. The use of loop diuretics was 
not associated with thiamine deficiency. In multivariate analyses, high age, low eGFR 
and low protein intake, especially less than 0.8g/kg, were independently associated with 
thiamine deficiency.
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Odds Ratio( 95% CI ) P Value
Age (years) 1.12(1.00-1.26) 0.047*
Sex (men) 0.89(0.12-6.45) 0.91
Malignancy (yes) 0.59(0.05-6.49) 0.67
Alcoholism (yes) 0.00(0.00-) 1.00
frosemide (yes) 0.04(0.00-1.22) 0.07
eGFR 0.86(0.75-0.98) 0.02*
protein intake <0.6 g/kg 46.21(1.77-1208.48) 0.02*
protein intake ≥0.6 and <0.8 g/kg 30.93(1.47-649.92) 0.03*
protein intake ≥0.8 and <1.0 g/kg 12.57(0.84-187.20) 0.07
protein intake ≥1.0 g/kg 1.00(reference)
Conclusions: Protein intake is an important factor for thiamine levels of CKD patients. 
Protein restriction for CKD patients especially with high age and low eGFR have a high 
risk of thiamine deficiency.
FR-PO597
Controlled Attenuation Parameter Measured by FibroScan Is Closely 
Associated with Metabolic Syndrome in Patients with Chronic Kidney 
Disease  Meiyan Wu,1 Sul A Lee,2 Chang-Yun Yoon,2 Tae ik Chang,3 Shin-Wook 
Kang,1,2 Tae-Hyun Yoo.1,2  1Severance Biomedical Science Inst, Brain Korea 
21 PLUS, Yonsei Univ College of Medicine, Seoul, Korea; 2Dept of Internal 
Medicine, Yonsei Univ College of Medicine, Seoul, Korea; 3Dept of Internal 
Medicine, NHIC Ilsan Hospital, Gyeonggi-do, Korea.
Background: Hepatic steatosis can be determined by the measurement of liver 
controlled attenuation parameter (CAP) using FibroScan. Although the practical methods 
predicting the risk of metabolic syndrome (MS) development are lacking, recent studies 
represent that this parameter is closely correlated with the presence of MS in the general 
population. Therefore, we investigated whether CAP measured by FibroScan could predict 
the presence of MS in chronic kidney disease (CKD) patients.
Methods: A total of 468 CKD patients were evaluated. MS was defined by using the 
Modified National Cholesterol Education Program (Adult Treatment Panel III) criteria. 
Multivariate logistic regression analysis was used to identify the independent association 
between CAP and MS.
Results: The mean age of the patients was 57.5 years and 225 patients (48.1%) were 
male. The mean value of CAP was 241.7 dB/m. CAP was independently associated with 
body mass index (β=7.818, P<0.001), triglyceride (β=0.246, P=0.002) and estimated 
glomerular filtration rate (eGFR) (β=0.581, P=0.005). MS was diagnosed in 142 (30.3%) 
patients. In patients with MS, diabetes was more prevalent (59.9 vs. 25.8%, P<0.001), 
hemoglobin (13.1±2.4 vs. 12.6±2.1 g/dL, P=0.026) and CAP (262.0±60.6 vs. 232.9±49.0 
dB/m, P<0.001) levels were significantly higher, while eGFR (82.9±27.5 vs. 91.6±26.0 
mL/min/1.73m2, P=0.001) was lower compared with patients without MS. Multivariate 
logistic regression analysis revealed that high CAP levels were independently correlated 
with the increased risk of MS (per 1 dB/m increase, odds ratio=1.010, 95% confidence 
interval=1.002-1.018, P=0.014) after adjustment for confounding factors.
Conclusions: High CAP levels measured by FibroScan were significantly associated 
with an increased risk of MS in CKD patients. These data suggests liver FibroScan could 
be a practical method for evaluating he risk of MS development in CKD patients.
FR-PO598
Outcomes in Women Switched from Mycophenolate to Azathioprine in 
Advance of Pregnancy  Kate S. Wiles,1 Adam D. Jakes,2 Asra Alwandi,1 Kate 
Bramham,1 Paramit Chowdhury,1 Lucy C. Chappell,1 Catherine Nelson-piercy,1 
Liz Lightstone.2  1Guy’s and St. Thomas’ NHS Foundation Trust; 2Imperial 
College London.
Background: Mycophenolate is teratogenic and should be replaced in advance of 
pregnancy. There is concern that this change may have adverse consequences including 
transplant rejection and disease flare. The aim of this study was to determine the risk of 
adverse outcome in women switched from mycophenolate to azathioprine.
Methods: Records of women attending regional renal pre-pregnancy counselling 
clinics 2011-2014 were examined. Women taking mycophenolate were included and the 
decision to switch to azathioprine reviewed. Outcomes were a decline in eGFR within 
a year, renal biopsy, disease flare or rejection, and conversion back to mycophenolate. 
Pregnancy outcomes were analysed.
Results: Data were available for 60 women (31 kidney transplant, 4 kidney-pancreas 
transplant and 25 glomerulonephitis, predominantly lupus). Most women were considered 
eligible for a switch to azathioprine and one woman chose to switch against advice.
Decision to switch n %
Yes 44 73
No: Unstable graft function 7 12
No: No immediate plans for pregnancy 5 8
No: Active lupus 2 3
No: Advanced renal dysfunction as a barrier to pregnancy 2 3
There was a mean fall in eGFR of 4.8ml/min/1.73m2/year in the women who did 
not conceive within 12 months of the switch (n=26). This decline included two flares of 
biopsy-confirmed lupus nephritis and one case of progressive antibody mediated rejection 
in the woman advised not to switch. 3/45 (7%) of women had a renal biopsy. There were 
no cases of acute rejection. 10/45 (22%) of women were converted back to mycophenolate, 
3 empirically and 7 with a clinical indication. There were 14 pregnancies. 63% were 
complicated by pre-existing hypertension or pre-eclampsia. 67% of women had a Caesarean 
delivery and 33% of babies were preterm (<37 weeks).
Conclusions: Most women taking mycophenolate can be converted to azathioprine. 
Drug switch was not associated with acute rejection, but lupus flare did occur. Most women 
did not require conversion back to mycophenolate. Pre-eclampsia and pre-term delivery 
are associated with chronic kidney disease and are not thought to be due to medication use.
FR-PO599
Chronic Kidney Disease Linearly Predicts Outcomes After Elective Total 
Joint Arthroplasty  Edward J. Filippone,1 Timothy L. Tan,1 Dean D. Tan,1 
Michael M. Kheir,1 Antonia F. Chen.1  1Medicine, Thomas Jefferson Univ, 
Philadelphia, PA; 2Orthopedics, Thomas Jefferson Univ.
Background: Kidney disease has been widely associated with increased complications 
in total joint arthroplasty (TJA). The purpose of this study is to determine the association of 
kidney disease severity as measured by the chronic kidney disease (CKD) staging system 
with complications and outcomes after TJA.
Methods: A retrospective review of an institutional database of 12,308 primary TJAs 
(6,361 hips and 5,947 knees) from 2008 to 2013 was performed. The following preoperative 
variables were obtained from medical records: chemistry 7 panel, Elixhauser comorbidities, 
and demographic factors. CKD stages were defined based on estimated glomerular filtration 
rate in ml/min/1.73m2 (eGFR): (1) 90+, (2) 60-89, (3A) 45-59, (3B) 30-44, (4) 15-29, and 
(5) <15. Multivariate analysis was performed to assess the independent influence of CKD 
stage on the aforementioned endpoints.
Results: Patients with CKD stage greater than 2 demonstrated an increased risk of 
transfusions (CKD 3A odds ratio [OR]: 1.67, CKD 3B OR: 2.80, CKD 4 OR: 2.24), length 
of stay greater than 3 days (CKD 3A OR: 1.34, CKD 3B OR: 1.39, CKD 4 OR: 3.57), 
and in-hospital complications (CKD 3A OR: 1.21, CKD 3B OR: 1.80, CKD 4 OR: 3.36) 
compared to all patients with eGFR > 60. Additionally, the relationship between eGFR 
and the above complications were found to increase linearly rather than exponentially at a 
certain threshold. In contrast, CKD stage was not associated with septic or aseptic revisions.
Conclusions: Severe CKD is associated with an increased risk of transfusion, length 
of stay, and in hospital complications. Rather than finding a clear threshold, complications 
increased linearly with disease severity. Surgeons should be cognizant of this increase when 
evaluating TJA patients with renal disease.
FR-PO600
The Assessment of Incidental Risk for Microalbuminuria According to the 
Level of Depression Scale  Dong-Young Lee,1 Younjoo Jung,1 Beom Kim,1 
Kyoung Hyoub Moon,1 Sung Keun Park.2  1Internal Medicine, VHS Medical 
Center, Seoul, Korea; 2Total Health Care, Kangbuk Samsung Hospital, Seoul, 
Korea.
Background: Depression is one of the most common psychiatric disorders. The 
burden of disease for depression goes beyond function and extends to somatic health. A 
growing body of evidence shows that depression is significantly associated with chronic 
kidney disease. Nonetheless, the incidental relationship between microalbuminuria and 
depression was not identified yet. Therefore, we conducted this study to investigate 
incidental relationship of microalbuminura with depression scale.
Methods: This study was conducted for 45,293 Korean men and their spouses without 
microalbuminuria who got medical health check up in Kangbuk Samsung Total healthcare 
center in 2010. To assess the degree of their depression, Center for Epidemiologi Studies-
Depression Scale (CES-D) was used (CES-D ≤ 15: normal, CES-D 16-20: moderate 
risk group, CES-D > 21: high risk group). On the basis of CES-D score in 2010, they 
were classified into 3 groups (normal, moderate, high risk group) and monitored for the 
development of microalbuminuria from January, 2011 to April, 2015.
Results: While the general incidence was 1.7%, the incidence of microalbuminuria 
increased in proportion to the risk score of depression evaluated by CES-D (CES-D ≤ 15: 
0.4%, CES-D 16-20: 1.8%, CES-D > 21: 3.6%).  When the hazzard ratio (HR) of normal 
group (CES-D ≤ 15) was set to reference value (HR: 1.00), the HRs for microalbuminuria 
also increased according to the score of CES-D scale. In addition, these associations were 
preserved even after adjusting for the various metabolic covariates such as age, physical 
activity, total cholesterol , LDL-cholesterol, triglyceride, body mass index, and obesity 
[CES-D 16-20: 1.98, CES-D > 21: 3.37).
Conclusions: Our study showed that the risks of microalbuminuria in proportion to 
the severity of depression. These findings imply the clinical role of the depression for 
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development of the microalbuminuria. Especially, considering the clinical significance 
of microalbuminuria as an early predictor of health outcomes related to chronic kidney 
disease, our study implications can be expanded to other diseases entity.
FR-PO601
Outcomes in CKD Patients with Hospital Acquired Complications 
Babak Bohlouli,1 Terri Jurgens Jackson,2 Marcello Tonelli,3 Scott Klarenbach.1 
1Medicine, Univ of Alberta, Edmonton, AB, Canada; 2Northern Clinical 
Research Centre, Univ of Melbourne, Epping, Vic, Australia; 3Medicine, Univ 
of Calgary, Calgary, AB, Canada.
Background: Patients with CKD are at increased risk of hospital acquired 
complications (HACs) including those considered preventable. The impact of HACs on 
patient and health system outcomes has not been well described.
Methods: Subjects hospitalized from April 1, 2003 to March 31, 2008 from a population 
based cohort (Alberta Kidney Disease Network) were studied. Outpatient eGFR and 
proteinuria (protein/creatinine ratio or dipstick) in the year prior to index hospitalization 
were used to define CKD status. Co-morbid conditions were identified using validated 
algorithms applied to administrative data. ICD 10 CA was used to classify reason for 
admission. A specific diagnostic indicator (type II) was used to identify hospital acquired 
complications (HACs) that were sub-classified as “potentially” and “always” preventable. 
We studied the following outcomes: re-admission within 90 days of discharge, all cause 
mortality at 90 days, and index hospitalization costs. Multivariable regression models 
examined the association of HACs with re-admission, mortality, and incremental health 
care costs, accounting for confounders.
Results: Of 536,549 subjects, 45,377 (8.5%) with CKD were hospitalized. In patients 
with HACs, the OR of re-admission and death at 90 days was 1.37 (95% CI: 1.32 – 1.43), and 
3.31 (95% CI: 3.06 – 3.58) respectively compared with those without HAC. Hospitalizations 
with any HAC were associated with median incremental health costs of $4028 (95% CI: 
$3898 – $4158). A graded association was observed for those outcomes with increasing 
number of HACs and severity of CKD. Similar results were noted when only potentially 
preventable HACs were considered.
Conclusions: Complications occurring during hospitalization in patients with CKD 
is independently associated with an increased risk of hospital re-admission, health care 
costs, and mortality. Targeted strategies to reduce HACs in this patient population may 
have a significant benefit.
FR-PO602
Plasma Proteins Associated with Declining Renal Function in Patients with 
Type 1 Diabetes: Results of a Global Proteomic Analysis Using SOMAscan 
Platform  Andrew L. Schlafly, Monika A. Niewczas, Marcus G. Pezzolesi, 
Andrzej S. Krolewski.  Joslin Diabetes Center, Boston, MA.
Background: Increases in serum creatinine and cystatin C are considered measures 
of declining renal function in patients with diabetes.
Methods: To search for other proteins correlated with declining renal function, we 
conducted a follow-up study, following 30 patients with T1D and proteinuria for 1-3 
years. Mean eGFR was 67 ml/min at baseline, and was 59 ml/min at the end of follow-up. 
Plasma concentrations of circulating proteins were measured on the SOMAscan platform 
at baseline and at the end of follow-up. The platform measured 954 proteins for each of the 
30 patients, with median limit of detection (LOD) of 1.6pg/mL,dynamic range of 8 logs, 
and median coefficient of variation (CV) of 5% for individual proteins measured repeatedly 
in replicate runs of plasma samples.
Results: Renal function change during follow-up in each patient was expressed as the 
difference between eGFRcre at baseline and at follow-up and was referred to as ∆GFR 
(mean: -7.7 ml/min, range: -44 ml/min to 11 ml/min). For each protein, the Spearman rank 
correlation coefficient between ∆GFR and the percent change in the protein’s level (RFU) 
was used to measure the protein’s association with renal function decline. In 27 proteins, 
concentrations increased with decreasing renal function (r: -0.67 to -0.46, p<0.01). In 16 
proteins, concentrations decreased with decreasing renal function (r: 0.46 to 0.57, p<0.01). 
The top 5 proteins in each category are shown below.
Negatively correlated proteins: Positively correlated proteins:
Name r Spearman P Name r Spearman P
IL-17F -0.67 5.5E-05 ATS1 0.57 1.0E-03
ARMEL -0.62 2.2E-04 CDC2 0.54 2.2E-03
TNFRSF19L -0.62 2.4E-04 FGF6 0.53 2.6E-03
TNFRSF1A -0.57 1.1E-03 CA1 0.50 4.7E-03
Cystatin C -0.56 1.1E-03 CDH12 0.50 4.8E-03
Conclusions: In conclusion, increasing or decreasing concentrations of plasma 
proteins with eGFR loss may reflect worsening renal function, as is the case with cystatin 
C. However, changes in plasma concentration of these proteins may represent the extent 
and intensity of the disease process underlying progressive renal decline, which is most 
likely the case with IL-17F and the TNFR’s.
Funding: NIDDK Support, Pharmaceutical Company Support - Bristol-Myers Squibb
FR-PO603
Mass Spectrometry Imaging Reveals Disease Specific Alterations in Protein 
Abundance in Human Diabetic Nephropathy  Haichun Yang,1 Audra M. Judd,2 
Michelle Reyzer,2 Jeremy L. Norris,2 Richard M. Caprioli,2 Raymond C. Harris,3 
Agnes B. Fogo.1  1Pathology, Microbiology and Immunology, Vanderbilt Univ; 
2Mass Spectrometry Research Center, Vanderbilt Univ; 3Nephrology, Vanderbilt 
Univ, Nashville, TN.
Background: Diabetic nephropathy (DN) is a major complication in diabetic patients. 
However, progression and albuminuria are variable among patients with DN. Matrix-
assisted laser desorption/ionization imaging mass spectrometry (MALDI) is a technology 
that acquires molecular information from thin tissue sections in a spatially-defined manner. 
We examined MALDI mass spectra to discover alterations in protein expression in human 
DN glomeruli, and compared to the morphology and clinical features.
Methods: DN biopsies (n=36) and normal kidney (n=9) were assessed. DN cases 
were divided into mild, moderate and severe, based on biopsy findings. Follow-up was 
available in 23 patients, and patients were sub-grouped into stable DN (decreased eGFR 
≤50%, n=13) vs. progressive DN (decreased eGFR >50%, n=10). Peptide mass spectra were 
acquired over the mass-to-charge range 600-4500 from at least 12 glomerular areas per case.
Results: DN patients had reduced eGFR and increased proteinuria, compared to 
normal. Mass spectrometry showed 168 peptide peaks, with 8 peaks increased and 21 
peaks decreased in DN compared to Normal. Moderate and severe DN showed more 
nodular glomerulosclerosis than mild DN by study design (moderate 2.13±0.10, severe 
2.17±0.22 vs. mild 0.43±0.30, 0-4+ scale, p<0.05) and mesangial expansion (moderate 
1.97±0.09, severe 2.28±0.15 vs. mild DN 1.21±0.15, p<0.05). Peptide maps were more 
similar in moderate vs severe DN groups, compared to mild DN. Thirteen of 168 peptide 
peaks were significantly different among three groups. In progressive DN, 10 peptide peaks 
were decreased and 1 was increased, compared to stable DN. Of note, these peaks differed 
from those associated with the morphologic phenotype.
Conclusions: We conclude that different peptide maps correlate with DN onset, 
severity and prognosis, and that clinical and morphological phenotypes have differing 
proteomic correlates. These peptides will now be further validated and identified by MS/
MS fragmentation and database searching.
Funding: NIDDK Support
FR-PO604
Urine Metabolomic Profiling Reveals a Unique Signature for Type 2 
Diabetes  Jane J. Kim, Rintaro Saito, Satoshi Miyamoto, Minya Pu, Loki 
Natarajan, Kumar Sharma.  Univ of California, San Diego.
Background: Increased circulating branched chain amino acids (BCAAs) are 
associated with type 2 diabetes (T2D) and insulin resistance. However, it is not clear 
whether increased plasma BCAA concentrations result from increased synthesis, or impaired 
degradation or excretion. Here, we employ a targeted metabolomics approach to evaluate 
diabetic patients without overt kidney disease to identify urine metabolites associated with 
T2D, presenting potential urine biomarkers for clinical prediction and further insight into 
disease pathogenesis.
Methods: We measured 105 urine metabolites by GC/MS in a screening T2D cohort 
(n=27), validation T2D cohort (n=14), and healthy control group (n=23). We also examined 
kidney cortex of db/db and control db/m mice to measure gene expression by Illumina 
microarray and protein expression by western blot.
Results: Following FDR correction, 57 metabolites were found to be different in the 
screening cohort compared to controls. When these 57 metabolites were carried forward 
for analysis in a validation T2D cohort, 24 of these urine metabolites were confirmed to be 
different from controls using Bonferroni adjustment for multiple comparisons. 16 of the 24 
significant metabolites were amino acids, and 8 of these represented BCAA degradation 
products. To further investigate BCAA metabolism, we examined kidney tissue from db/
db mice and found that the gene expression of key enzymes related to BCAA catabolism 
was decreased. Western blot studies confirmed that renal expression of branched-chain 
ketoacid dehydrogenase, a mitochondrial enzyme complex that catalyzes an irreversible 
step in BCAA catabolism, was reduced in db/db mice compared with controls.
Conclusions: Prior studies have reported impaired mitochondrial BCAA metabolism in 
adipose, muscle and liver. However, our results show a robust pattern of increased BCAA 
metabolites, likely reflecting increased BCAA catabolism and/or increased metabolic flux. 
The reduced renal expression of BCAA enzymes supports a role for dysregulated BCAA 
metabolism by the kidney. The elevated BCAA metabolites may have an affect on regulating 
insulin resistance and the development of kidney disease with T2D.
Funding: NIDDK Support
FR-PO605
Urinary Matrix Metalloproteinase Activities Are Associated with Renal 
Hyperfiltration in Adolescents With Type 2 Diabetes  Petter Bjornstad,1 Laura 
Pyle,3 Janet Snell-bergeon,1 Karen S. Moulton,2 Kristen Nadeau.3  1Barbara 
Davis Center for Diabetes; 2Univ of Colorado Denver; 3Children’s Hospital 
Colorado.
Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal 
disease. Matrix metalloproteinases (MMP) modify extracellular matrix during vascular 
remodeling and are known to be elevated in diabetes, and associated with DN in type 1 
diabetes. We hypothesized that activities of latent MMP and neutrophil gelatinase-associated 
lipocalin (NGAL) proteins in urine would be associated with microalbuminuria and 
hyperfiltration in adolescents with type 2 diabetes (T2D).
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Methods: 295 adolescents with T2D (14.0±1.8 years, <2 years duration, BMI ≥85%, 
and HbA1c ≤8%) in the Treatment Options for Type 2 Diabetes in Adolescents and Youth 
(TODAY) study had urine and blood evaluated at baseline and annually for 5-years. MMP2, 
MMP9 and NGAL activities were measured by gelatin zymography and normalized to 
urine creatinine. Microalbuminuria was defined as albumin-to-creatinine ratio (ACR) 
³30mg/g. Estimated GFR was calculated by Schwartz (eGFR=36.5*height/creatinine) and 
hyperfiltration defined as ³135mL/min/1.73m2. Mixed models evaluated the longitudinal 
relationships between MMP-2, MMP9 and NGAL with eGFR, ACR, hyperfiltration and 
microalbuminuria respectively. MMP2, MMP9 and NGAL-MMP9 activities were natural 
log-transformed (ln) due to skewed distribution.
Results: MMP2, MMP9 and NGAL-MMP9 were associated with eGFR, but not ACR 
over time after adjusting for age, sex, HbA1c, SBP and treatment group. One standard 
deviation increase in ln MMP2, ln MMP9 and ln NGAL-MMP9 were each associated 
with a greater odds of having microalbuminuria and hyperfiltration over time, respectively. 
Table Mixed-logistic regression models
Hyperfiltration Microalbuminuria 
OR*, 95% CI, P-value
MMP2 1.3 (1.1-1.5) 0.001 1.6 (1.3-1.9) <0.0001
MMP9 1.2 (1.0-1.4) 0.046 1.4 (1.2-1.7) 0.001
NGAL-MMP9 1.2 (1.0-1.5) 0.03 1.4 (1.1-1.7) 0.004
*Odds ratio of hyperfiltration or microalbuminuria per 1 SD increase in natural log transformed 
variable adjusted for age, sex, SBP, HbA1c and treatment group 
Conclusions: In conclusion, urinary MMP and NGAL activities were associated with 
early DN in adolescents with T2D over time.
Funding: Other NIH Support - Juvenile Diabetes Research Foundation Grants 
1-2007-622 (K. S. Moulton) and 5–2008-291 (K. Nadeau); National Institutes of Health 
Grants RC4 DK090852 (K. S. Moulton) and K23 RR020038 (K. Nadeau)
FR-PO606
A Serum Metabolite Classifier Predicts Response to ARBs in Diabetes 
Michelle Pena,1 Bernd Mayer,2 Andreas Heinzel,2 Peter Rossing,3 Hiddo Jan 
Lambers Heerspink.1  1UMC Groningen; 2Emergentec Biodevelopment; 3Steno 
Diabetes Center.
Background: Individual patients show a large variability in albuminuria response to 
Angiotensin Receptor Blockers (ARB). Identifying novel biomarkers that predict ARB 
response may help optimize treatment. We aimed to discover and validate a novel serum 
metabolite classifier that predicts response in urinary albumin excretion (UAE) to ARBs 
in diabetes.
Methods: Flow injection analysis/liquid chromatography-tandem mass spectrometry 
based targeted metabolomics was performed on serum samples from type 2 diabetes 
patients (n=49) enrolled in a clinical study assessing the effect of irbesartan 300mg/
day. Individual serum metabolites were selected with LASSO regression to predict UAE 
response to irbesartan. The classifier was developed with ridge regression. Improvement in 
risk prediction was tested on top of a control model (age, sex, HbA1c, SBP, GFR, UAE) by 
assessing differences in explained variation (R2) between the control model and the classifier 
model. The classifier was externally validated in a clinical study in type 1 diabetes patients 
(n=50) testing the effect of losartan 100mg/day. Metabolite mapping was performed on 
a molecular model of diabetic kidney disease to identify underlying molecular processes 
contributing to ARB response.
Results: The classifier included 21 metabolites. Median reduction in UAE was -42% 
[-69,-8] in type 2 diabetes. The classifier was significantly associated with UAE response 
to irbesartan (p<.001) and significantly improved prediction of UAE response on top 
of the control model (R2 increase from 0.10 to 0.69; p<.001). In the external validation 
cohort, median reduction in UAE was -43% [-62,-23]. The classifier significantly improved 
prediction of UAE response to losartan (R2 increase from 0.17 to 0.52; p<.001). Metabolites 
included in the classifier were assigned to stress/inflammation pathways and downstream 
consequences of fibrosis and extra cellular matrix remodeling. Moreover, ADMA, impacting 
eNOS activity, appears to be a specific factor relevant in ARB response.
Conclusions: A classifier of 21 serum metabolites was identified and externally 
validated to significantly improve prediction of albuminuria response to ARBs in diabetes.
FR-PO607
Is Urinary Proteomics Useful to Predict Retinopathy in Type 2 Diabetic 
Patients in the DIRECT 2 Study  Mie K. Eickhoff,1 Marie Frimodt-Moller,1 
Morten Lindhardt,1 Mohammed Dakna,2 Harald Mischak,2,3 Direct Steering 
Group,5 Peter Rossing.1,4  1Steno Diabetes Center, Gentofte, Denmark; 
2Mosaiques Diagnostics GmbH, Hannover, Germany; 3BHF Glasgow 
Cardiovascular Research Centre, Univ of Glasgow, Glasgow, United Kingdom; 
4HEALTH, Univ of Aahus, Denmark; 5Univ College London, London, United 
Kingdom.
Background: Diabetic microvascular complications affect the kidney and the eyes, 
being a leading cause of renal failure and blindness. Urinary proteomics has shown promise 
as an early indicator of future development of diabetic nephropathy. Here we investigate 
if this could also predict progression of diabetic retinopathy.
Methods: In a post-hoc study of the DIRECT 2 study, a randomized, controlled clinical 
trial of candesartan for prevention of retinopathy, we studied patients with type 2 diabetes 
and normoalbuminuria (n=792), followed for a mean of 4.7 years. We address the predictive 
ability of a previously defined CKD risk score based on proteomic measurement of 273 
urinary peptides (CE-MS). We also assessed the possibility of a new EYEscore based 
on discriminative features choosen out of 1161 peptides in a training set of 528 patients. 
Progression were either 2 step (E2) (primary) or 3 step (E3) change in retinopathy on the 
concatenated Early Treatment Diabetic Retinopathy Study severity scale.
Results: Progression of retinopathy was seen in 37% of E2 and 19% of E3 patients. 
None of the peptides were significantly differentially expressed in cases vs control. In 
Cox models five peptides were associated with E3 but not E2 in the training set but 
were not validated. The CKD risk score was able to predict E3 (HR 1.54 95% CI 1.02 to 
21.34, p=0.042) but not E2 (HR 1.14 p=0.34) during follow-up, independent of treatment 
(candesartan/placebo), age, gender, systolic BP, baseline UAER, baseline eGFR, HbA1c 
and diabetes duration.
Conclusions: In this cohort of patients with type 2 diabetes and normoalbuminuria 
from a large intervention study, the CKD classifier was an independent predictor of severe 
but not mild progression in retinopathy. It was not possible to develop a retinopathy specific 
marker panel with clinically relevant accuracy.
Funding: Pharmaceutical Company Support - The DIRECT study was jointly funded 
by AstraZeneca and Takeda.
FR-PO608
Urine Exosomal Analysis Reflects Underlying Kidney Pathology Better 
Than Whole Urine Analysis  Krishnamurthy P. Gudehithlu,1 Ignacio 
Garcia-Gomez,4 Jane Vernik,1,2 Carolyn S. Brecklin,1,3 Mark A. Kraus,1,2 David 
J. Cimbaluk,2 Peter D. Hart,1,2 George Dunea,1,3,4 Jose A.L. Arruda,1,3,4 Ashok 
K. Singh.1,3,4  1Div of Nephrology, John H. Stroger, Jr. Hospital of Cook County, 
Chicago, IL; 2Dept of Internal Medicine, Rush Univ Medical College, Chicago, 
IL; 3Section of Nephrology, Univ of Illinois at Chicago, Chicago, IL; 4The 
Hektoen Inst of Medicine, Chicago, IL.
Background: Predicting or diagnosing underlying kidney pathology by analyzing 
whole urine has remained unrealized. This is because whole urine mostly represents proteins 
from the plasma and little from the kidney. Urinary exosomes, on the other hand, being 
kidney-derived, contain proteins of the kidney. We experimentally tested the hypothesis, 
‘urine exosomal proteome more truly represents the underlying pathology of kidney 
disease than a whole urine based analysis.’ Comparison between whole urine and urine 
exosomal gelatinase and ceruloplasmin, two kidney disease markers, was performed on 
normal and diabetic kidney disease patients.
Methods: Urinary exosomes were separated from urine by ultra-centrifugation. 
Gelatinase, an enzyme which measures matrix degrading activity collectively from 
several matrix metalloproteinases (mainly MMP-2, 9), was measured by an activity assay 
using fluorosceinated gelatin as the substrate, and ceruloplasmin, an oxido-reductase 
enzyme involved in iron metabolism, was measured by sandwich ELISA. Biopsies were 
immunostained for MMP-9 and ceruloplasmin.
Results: We found that changes in both, gelatinase (decreased activity; 20-50%; p<0.05) 
and ceruloplasmin (increased levels; 300%; p<0.05), in the urinary exosomes of diabetic 
kidney patients were in agreement with the alterations of these two proteins in the kidney 
tissue as judged by immune-staining. In contrast, the levels of these two proteins in the whole 
urine were highly variable (p=NS) and in disagreement with the results of immune-staining.
Conclusions: In conclusion, our findings support our hypothesis that protein markers 
found in urinary exosomes better reflect the changes in the kidney than protein measurements 
carried out in whole urine samples.
Funding: Private Foundation Support
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Neutrophil Gelatinase Associated Lipocalcin as an Early Biomarkers of 
Nephropathy in Diabetic Patients and Effect of RAAS Blockade on NGAL 
as Marker of Tubular Damage in Diabetic Nephropathy  Anupama Kaul, 
Dharmendra Bhadauria, Narayan Prasad, Amit Gupta, Raj K. Sharma. 
Nephrology, Sanjay Gandhi Post Graduate Inst of Medical Sciences, Lucknow, 
India.
Background: T2DM is the primary cause leading to kidney disease . Novel, more 
sensitive biomarkers that may be used to detect diabetic nephropathy at an early stage, and 
possibly also detect disease progression or regression after drug therapy.
Methods: • -150 Diabetic patients were enrolled in the study from nephrology and 
endocrinology OPD at Sanjay Gandhi Post Graduate Institute Of Medical Sciences ,lucknow 
India from 2012-14, 50 each of normo-,micro- and macroalbuminuric with 50 normal 
healthy control. Serum NGAL and cystatin C were measured at enrollment and after 12-
15 months. ACEI as intervention was given in all normo hypertensive ,microalbuminuric 
and macroalbuminuric Diabetics and after follow up period 1 year repeat NGAL levels 
assessment. Normoalbuminuric ,normotensive individuals with raised NGAL at the baseline 
and follow up after 1 year were assessed.
Results: • As compared to control population the normoalbuminuric Diabetics had 
higher serum as well as urinary NGAL levels but lesser than microalbuminuria.Mean NGAL 
levels were not significantly different between Normoalbuminuric diabetes and controls. 
At re-evaluation, mean NGAL value and mean eGFR value in patients with diabetes had 
increased (p=0.078 and p=0.006 respectively). At both baseline and reevaluation, NGAL 
positively correlated with cystatin C ( p<0.001) and creatinine (p=0.010). NGAL correlated 
negatively with eGFR(r=-0.26, p=0.049) .Among micro,macroalbuminuric diabetics the 
baseline urine albumin excretion rate was significantly correlated with the rate of eGFR 
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decline (P<.0.004). The baseline serum NGAL levels were also correlated with the rate of 
eGFR decline (P = 0.066). During ACE inhibitor treatment ie Ramipril 5mg daily , urine-
NGAL was reduced (95% CI) 11% (not significant).
Conclusions: Urine-NGAL are elevated in Type 2 diabetic patients, with or without 
albuminuria, indicating tubular damage at an early stage. ACE inhibitor Ramipril reduced 
urine-NGAL predominantely in Micro/macroalbuminuric diabetic patients .
FR-PO610
Mechanism of Increased Urinary Full-Length Megalin Excretion in Type 
2 Diabetes Mellitus Patients with Nephropathy  Shankhajit De,1 Shoji 
Kuwahara,2 Michihiro Hosojima,3 Tomomi Ishikawa,1 Ryohei Kaseda,3 Yusuke 
Yoshioka,4 Yoshiki Suzuki,5 Ichiei Narita,1 Takahiro Ochiya,4 Akihiko Saito.2 
1Clin Nephrol & Rheumatol, Niigata Univ, Niigata, Japan; 2Applied Mol Med, 
Niigata Univ, Niigata, Japan; 3Clin Nutr Sci, Niigata Univ, Niigata, Japan; 
4Mol & Cell Med, NCCRI, Tokyo, Japan; 5Health Admn Center, Niigata Univ, 
Niigata, Japan.
Background: Megalin, an endocytic receptor of proximal tubule cells (PTCs), is 
excreted into urine in both of the extracellular domain and the full-length forms. Previously 
we developed urinary ELISA systems to measure the two forms of megalin and found that 
the excretion of the full-length form, mainly present in the insoluble urinary fraction, may be 
a candidate biomarker for the progression of diabetic nephropathy (DN). We thus aimed to 
investigate the molecular mechanism of urinary excretion of the full-length form of megalin.
Methods: Megalin content of urinary extracellular vesicles (EVs) from normal 
control and type 2 diabetes mellitus (T2DM) patients with different albuminuria stages 
were measured by western blotting. By immunoelectron microscopy and Nanoparticle 
Tracking Analysis using NanoSight®, we characterized the size and number of the EVs. 
To study increased EVs excretion in vitro, we cultured immortalized rat proximal tubule 
cells (IRPTCs) and treated with advanced glycation end products-modified bovine serum 
albumin (AGEs).
Results: The number of urinary EVs excretion is increased in T2DM patients in 
comparison with the normal control subjects in a correlation with the progression of DN. 
The megalin content of the EVs are also increased in those patients, indicating increased 
excretion of PTC-derived EVs in DN condition. However, other tubular segment markers in 
EVs are not well correlated with the disease progression. By immunoelectron microscopy 
we found that megalin is excreted through the smaller vesicles which are likely to be 
exosomes in nature. Treatment on IRPTCs with AGEs for 24h causes lysosomal dysfunction 
which subsequently increases multivesicular body formation as well as release of megalin-
containing exosomes.
Conclusions: Exocytosis-mediated urinary excretion of full-length megalin via 
exosomes might be a useful biomarker for early detection and progression of DN.
Funding: Government Support - Non-U.S.
FR-PO611
Urinary Excretion of Kidney Aquaporins as Possible Biomarker of Diabetic 
Nephropathy  Luigi Rossi,1 Maria Celeste Nicoletti,2 Monica Carmosino,2 
Antonella Di Franco,1 Francesca Indrio,1 Rosa Lella,1 Luigi Laviola,1 Maria 
Svelto,2 Loreto Gesualdo,1 Giuseppe Procino.2  1DETO, Univ of Bari, Bari, 
Italy; 2Dept of Biosciences, Biotechnologies and Biopharmaceutic, Univ of 
Bari, Bari, Italy.
Background: Diabetic nephropathy (DN) is is classified into four hierarchical 
glomerular lesions on the basis of histological analysis of kidney biopsies. This is clearly 
a highly invasive diagnostic approach numerous studies have been conducted to identify 
a non-invasive biomarker of the disease, but none of these is considered to be sufficiently 
specific and sensitive Experimental evidences showed that the water channel aquaporins 
(AQP), expressed at the plasma membrane of epithelial cells lining in the kidney tubule, 
are often dysregulated during DN. Interestingly, apical membrane protein are excreted in 
the urinary space as nano-scale exosome vesicles, to an extent proportional to their amount 
expressed at the plasma membrane, thus allowing their quantitation in urine samples.
Methods: In this work we compared excretion of AQP5 and AQP2 (uAQP5 and 
uAQP2) in the urine of 35 diabetic patients: 12 with histological diagnosis of DN, 12 
with with normal renal function and normoalbuminuric DM (D) and 11 with non-diabetic 
nephropathy (NDN). Both proteins were quantified by ELISA method on urine samples 
and the results were validated by Western blotting analysis on the exosome fraction isolated 
by ultracentrifugation.
Results: BothELISA and Western blotting analysis independently showed that uAQP5 
was three- to fourfold higher in DN patients (7458 ± 2576, p <0.05) compared to the other 
two groups (D 847,2 ± 70,51; NDRD1882 ± 215). uAQP5 was not statistically different 
between D and NDN patients. Strikingly, uAQP5 dramatically increased in parallel with 
the clinical severity of DN. The same analysis showed comparable results for uAQP2.
Conclusions: Our data showed, for the first time, that uAQP5 and uAQP2 dramatically 
and specifically increase in patients with DN and positively correlate with the histological 
class of DN. Taken together these data suggest a possible role of AQP5 and AQP2 as novel 
non-invasive biomarkers to help diagnosing DN and classifying its histological stage.
FR-PO612
Urinary Neutrophil Gelatinase-Associated Lipocalin as Complementary to 
Albuminuria Biomarker of Early Stage Diabetic Kidney Disease in Type 2 
Diabetes  Agnieszka Gala-Bladzinska,1 Paulina Dumnicka,2 Agnieszka Zylka,1 
Beata Kusnierz-cabala,3 Marek Kuzniewski.4  1St’ Queen Jadwiga District 
Hospital No 2, Rzeszów, Poland; 2Dept of Medical Diagnostics, Jagiellonian 
Univ Medical College, Kraków, Poland; 3Dept of Diagnostics, Chair of Clinical 
Biochemistry, Jagiellonian Univ Medical College, Kraków, Poland; 4Dept of 
Nephrology, Jagiellonian Univ Medical College, Kraków, Poland.
Background: Two clinical phenotypes of diabetic kidney disease (DKD) have been 
reported, i.e. with or without increased albuminuria. The aim of this study was to assess 
the usefulness of uNGAL for the preclinical diagnosis of DKD in the course of diabetes 
mellitus type 2 (DMt2).
Methods: The study group consisted of 115 DMt2 patients (63F, 58M) aged 18 
and over (62±14), with normal to moderately increased albuminuria (i.e. urine albumin/
creatinine ratio (UACR) <300 mg/g) and eGFR (CKD-EPI) ≥60ml/min/1.73m². Control 
group included 22 non-diabetic persons with comparable age (57±14; p=0.1) and sex (9F, 
13M; p=0.5), and with similar comorbidities. Urine concentrations of NGAL, albumin and 
creatinine (uCr) were measured in the first morning urine sample. Urine albumin/creatinine 
ratio (UACR), and analogically, uNGAL/uCr were calculated.
Results: In control group, maximum uNGAL/uCr was 39.64 µg/g. In DMt2 group, 
24 patients (21%) had higher results, with the maximum value of 378.6 µg/g. Twenty 
three (20%) of DMt2 patients had UACR >30 mg/g; of those, 11 had uNGAL/uCr >39.64 
µg/g. Among patients with uNGAL/uCr >39.64 µg/g, 13 did not have markedly increased 
albuminuria (UACR in those patients ranged from 2.35 to 16.10 mg/g). Women with DMt2 
had significantly higher uNGAL/uCr than men (median 28.06; IQR 9.05-65.60 versus 11.40; 
3.36-18.02 µg/g; p<0.001), without significant difference in UACR (p=0.09). uNGAL/
uCr in DMt2 patients correlated significantly with HbA1c (R=0.28; p=0.013), however, it 
did not correlate with eGFR (R=-0.54; p=0.1), age (R=0.14; p=0.1), or time from DMt2 
diagnosis (R=0.13; p=0.1).
Conclusions: Increase in urine NGAL and uNGAL/uCr may indicate early tubular 
damage particularly worse diabetes control patients, especially female with DMt2.
Funding: Private Foundation Support, Clinical Revenue Support
FR-PO613
Plasma Bradykinin and Early Diabetic Nephropathy in Type 1 Diabetes 
Mellitus  E. Jennifer Weil,1 Gudeta D. Fufaa,1 Robert G. Nelson,1,6 Michael 
Merchant,4,6 Brad H. Rovin,2,6 Michael Mauer,3,6 Jon B. Klein.4,5,6  1NIDDK; 
2Ohio State Univ; 3Univ of Minnesota; 4Univ of Louisville; 5Robley Rex VAMC; 
6for the CKD Biomarkers Consortium.
Background: Bradykinin (BK) and its modified forms are potential biomarkers of 
diabetic nephropathy (DN). We examined their association with development of DN 
lesions in normoalbuminuric normotensive subjects with normal or increased glomerular 
filtration rate (GFR) and type 1 diabetes (T1D) from the Renin-Angiotensin System Study 
(N Engl J Med 2009;361:40-50).
Methods: Plasma concentrations of BK and modified BKs were measured at baseline 
by a quantitative mass spectrometry-based multiple reaction monitoring assay in samples 
from 246 subjects who underwent kidney biopsies at baseline and after 5 years. Relationships 
of BK and modified BKs with morphometric variables were assessed using multiple linear 
regression after adjustment for age, sex, T1D duration, HbA1c, mean arterial pressure, 
albumin excretion rate (AER) and GFR (iohexol).
Results: Baseline mean age was 29.8 years, mean duration of T1D 11.3 years, median 
AER 5.1 mg/min, and mean GFR 128 mL/min/1.73 m2. After multivariable adjustment, 
higher BK concentration was associated with the peripheral glomerular basement membrane 
surface density 5-year/baseline ratio (partial r=0.167, P=0.010; figure) and with the 
5-year measurement alone (partial r=0.179, P=0.006). BK was not associated with other 
morphometric variables and modified BKs were not associated with any of these variables.
Conclusions: Elevated plasma BK concentration measured before clinical findings 
of DN in people with T1D was associated with increased peripheral glomerular basement 
membrane surface density, suggesting that it may reflect an adaptive response to early 
glomerular changes in DN.
Funding: NIDDK Support
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FR-PO614
Serum Omentin and Progression of Diabetic Nephropathy  Tetsuharu Oku, 
Fumihiko Furuya, Takeyuki Takamura, Kenichiro Kitamura.  Third Dept of 
Internal Medicine, Univ of Yamanashi, Chuo, Yamanashi, Japan.
Background: A novel adipokine, omentin, preferentially produced by visceral 
adipose tissue compared with subcutaneous adipose tissue. Animal experiments indicated 
that treatment with recombinant omentin enhanced insulin-stimulated glucose uptake in 
subcutaneous and omental adipocytes. Furthermore, serum omentin levels are decreased in 
obesity and diabetics. The purpose of this study was to elucidate whether serum omentin is 
associated with progression of diabetic nephropathy in diabetic patients.
Methods: The prospective follow-up study; 114 diabetes patients were followed 
for 5.0 ± 1.1 years. Patients were divided at baseline into three groups according to their 
urinary albumin-to-creatinine ratio (UACR): 68 patients with normoalbuminuria (UACR 
<30 mg/gCr), 31 patients with microalbuminuria (30 mg/gCr ≤ UACR < 300 mg/gCr), 
and 17 patients with macroalbuminuria (UACR ³300 mg/gCr). Progression of albuminuria 
was the main outcome. Omentin was measured by ELISA, and the values were adjusted 
for age, BMI, and sex before analysis.
Results: Progression either to the next albuminuria level in 16 patients or to end-stage 
renal disease (ESRD) occurred in 5 patients. No difference in adiponectin concentrations was 
observed between progressors and nonprogressors in patients with normoalbuminuria. In 
the patients with microalbuminuria and macroalbuminuria, progression of albuminuria was 
associated with higher omentin. Progression to ESRD was also associated with estimated 
glomerular filtration rate (eGFR). When these covariates were inserted in a Cox regression 
analysis, eGFR and omentin were significantly associated with progression of albuminuria.
Conclusions: Increased serum omentin levels predict the progression from 
microalbuminuria to macroalbuminuria and macroalbuminuria to ESRD in diabetic patients.
FR-PO615
The Expressions of Vitamin D and Its Receptor in Patients with Diabetes 
Associated with Proteinuria and Diabetic Nephropathy  Yang Yang, Jia Guo, 
Zhangsuo Liu.  The Firts Affiliated Hospital of Zhengzhou Univ, Zhengzhou, 
Henan, China.
Background: Vitamin D receptor (VDR) is a member of the nuclear receptor 
superfamily, and there was no report about the expression of Vitamin D and its receptor in 
patients with diabetes associated with proteinuria and diabetic nephropathy. So, this study 
aimed to test the expression trends of VDR in blood, urine specimens and renal tissues 
of diabetic nephropathy, and the relationship with urinary protein, to explore the role of 
VDR in diabetic nephropathy.
Methods: 1. 65 patients who had been diagnosed with T2DM (with or without 
albuminuria) were enrolled in this study and 25 healthy control subjects were enrolled 
(NC group).The patients were classified according to the ratio of urinary excretion of 
albumin/creatinine (ACR). Diabetic patients without proteinuria (DM group, ACR: less 
than 30 mg/g, n = 25), with microalbuminuria (DN1 group, ACR: 30 to 300 mg/g, n = 
24) and clinical proteinuria (DN2 group, ACR: more than 300 mg/g, n = 18). 25 diabetic 
nephropathy patients who were diagnosed by renal biopsy (DN3 group). 2. The expressions 
of VD and VDR in the plasma and urine supernatant were measured by ELISA, and the 
VDR in blood cells was measured by qRT-PCR, The expressions of VDR in kidney tissue 
were measured by immunohistochemical staining.
Results: Plasma VD and VDR levels were significantly lower in DN2 and DN3 groups 
as compared with NC group (plasma VD 0.78±0.24 and 0.88±0.29 vs. 2.32±1.33ng/ml, 
P<0.05, VDR 157.52±98.36 and 164.20±64.50 vs. 325.33±194.68ng/ml, P<0.05). [circ2]
Urinary VD and VDR levels were significantly elevated in DN2 and DN3 groups as 
compared with NC group (urinary VD 1.34±0.58 and 1.42±0.44 vs. 1.18±0.65ng/ml, P<0.05, 
VDR 83.60±31.78 and 88.40±28.10 vs. 60.93±12.03ng/ml, P<0.05). The expressions of 
VDR in kidney tissue in DN groups were obviously lower than those in control groups, 
differences were statistically significant(P<0.05).
Conclusions: These results verify that VDR declined with the increase of the amount 
of urine protein . Based on these results, VDR may play a role of renal protection in 
diabetic nephropathy.
FR-PO616
Mitochondrial DNA in the Plasma and Urine: A Potential Biomarker to 
Predict the Progression of Nephropathy in Type 2 Diabetes Mellitus  Li Fang, 
Junwei Yang.  Center for Kidney Disease, Second Affiliated Hospital, Nanjing 
Medical Univ, Nanjing, Jiangsu, China.
Background: Mitochondrial dysfunction and chronic sterile inflammation are the 
most common features of type 2 diabetes mellitus. Thus, our objective was to investigate 
whether extracellular mitochondrial DNA (mtDNA) in the plasma and urine could be used 
as a biomarker predicating the progression of type 2 diabetes and nephropathy.
Methods: A total of 42 people with type 2 diabetes and 35 ages-, sex- matched people 
without diabetes were enrolled in this study. The absolute quantification of mtDNA content 
was measured by real-time polymerase chain reaction. Relationships among different 
variables were analyzed by general linear model correlation.
Results: The plasma mtDNA contents were significantly lower in the people with 
type 2 diabetes, particularly in those participants with clinically significant proteinuria. 
The plasma mtDNA content was negatively correlated with diastolic blood pressure, urine 
microalbumin and 24-hour urine protein; while positively correlated with platelets count, 
serum albumin and alkaline phosphatase. The urinary mtDNA contents did not change 
obviously; however, the creatinine-adjusted values were significantly higher in the group 
with diabetes. Besides, the urinary mtDNA-to-creatinine ratio was negatively correlated 
with the duration of diabetes, fasting glucose and glycosylated hemoglobin.
Conclusions: Our results indicated that lower plasma mtDNA content and higher 
urinary mtDNA-to-creatinine ratio might be the potential biomarkers predicting the 
progression of nephropathy in type 2 diabetes.
Funding: Government Support - Non-U.S.
FR-PO617
Involvement of Fractalkine and Its Receptor CX3CR1 in Disease 
Progression of Patients with Diabetic Nephropathy  Takahiro Uchida,1 
Takashi Oda,2 Hidehito Matsubara,1 Atsushi Watanabe,1 Hanako Takechi,1 
Toshihiko Imakiire,1 Naoki Oshima,1 Hiroo Kumagai.1  1Dept of Nephrology and 
Endocrinology, National Defense Medical College, Tokorozawa, Japan; 2Dept 
of Nephrology, Tokyo Medical Univ Hachioji Medical Center, Hachioji, Japan.
Background: Upregulated expression of fractalkine (CX3CL1) and its receptor 
CX3CR1 has been reported in some renal diseases. However, whether they are involved 
in human diabetic nephropathy (DN) is unclear. We therefore examined expression of 
these molecules in human DN.
Methods: Twelve patients with DN who were diagnosed by renal biopsy were 
studied. Expression of CX3CL1 and CX3CR1+ cells and degree of inflammatory cells 
were evaluated. Glomerular endothelial cell (GEC) was assessed by measuring the 
immunofluorescence (IF) intensity of CD34 staining.
Results: Expression of CX3CL1 or CX3CR1 was not observed in normal control 
tissues. CX3CL1 was expressed on GECs, tubular epithelial cells, and endothelial cells 
of peritubular capillaries in renal tissues with DN. Expression of CX3CL1 on GECs was 
found in 9 patients, and its expression was seen with an increase tendency in patients 
with early stage of DN; CX3CL1 expression was found in all patients with the early stage 
of DN, whereas its expression was found only in 5 out of 8 patients with the advanced 
stage. CX3CR1 expression was also upregulated in renal tissues with DN. The majority 
of the CX3CR1+ cells in glomeruli were GECs; CX3CR1+ inflammatory (CD45+) cells 
composed only a small number of CX3CR1+ cells in glomeruli, most of which were 
CD68+ macrophages. Double stainings for CX3CL1 and CD34, and for CX3CR1 and 
CD34 revealed that both CX3CL1 and CX3CR1 were expressed on GECs with decreased 
expression for CD34.
Conclusions: These data demonstrate that CX3CL1 and CX3CR1 were upregulated 
in human DN from early stage. Interestingly, not only CX3CL1 but also CX3CR1 were 
expressed on GECs, and their expression on GECs may be involved in GEC injury. Targeting 
CX3CL1 and CX3CR1 may be promising therapeutic approaches for DN.
FR-PO618
Klotho Association with Markers of Mineral Metabolism and Insulin 
Resistance in Diabetic Patients with Chronic Kidney Disease  Ana Paula Silva, 
Filipa Brito Mendes, Pedro L. Neves.  Nephrology, Centro Hospitalar do 
Algarve, Faro, Portugal.
Background: Klotho is a protein implicated in multiple organic processes, being able 
to regulate growth factors signaling pathways, ion channels and transporters. Several animal 
and clinical demonstrated that Chronic Kidney Disease (CKD) is associated with Klotho 
deficiency. Moreover, Klotho seems to play a renoprotective role through its anti-oxidation 
properties, protection of vasculature, and promotion of vascularization and inhibition of 
fibrinogenesis. In this study we investigated potential associations between serum Klotho 
levels and known markers of mineral metabolism and insulin resistance, in order to better 
understand how Klotho affects/is affected by these variables in diabetic patients with CKD.
Methods: In this study we included 107 type 2 diabetic patients (67 males, 62,6%) 
with CKD stage 2-3, a mean age of 66.6 ±9.7 years. Several laboratory parameters were 
assessed: eGFR, phosphorus, vitamin D, PTH, urine albumin/creatinine ratio (UACR), 
IL-6, FGF-23, OxLDL and the homeostasis model assessment (HOMA). Simple linear 
and multiple regressions model were used to investigate possible correlations between 
these variables and Klotho.
Results: In the simple linear model, Klotho levels were correlated with age (r=-0.232,p= 
0.016), phosphorus (r=-0.381,p< 0.001), PTH (r=-0.606,p< 0.001), UACR (r= -0.336,p< 
0.001), HOMA (r= -0.482, p< 0.001), IL-6 (r= -0.571, p < 0.001), FGF-23 (r=-0.695, p < 
0.001), OxLDL (r=-0.598,p < 0.001), eGFR (r=0.228, p = 0.018) and vitamin D (r= 0.661, 
p < 0.001) levels. Applying the multivariate linear regression, only the UACR (r=-0.636 p= 
0.036), HOMA (r=-0.322,p=0.018), FGF-23 (r=-0.668,p < 0.001) and Vitamin D (r=8.465 
p=0.010) independently influenced the Klotho levels.
Conclusions: In our study,Klotho levels are influenced by FGF-23, vitamin D and 
insulin resistance, variables that are affected by the renal function. However, in the multiple 
regression model the eGFR lost its relationship with Klotho, and Klotho was associated 
mainly with the UACR and insulin resistance. More studies are needed to clarify of the 
relationship with UACR and confirm if proteinuria is more critical in the definition of the 
Klotho levels.
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FR-PO619
Macrophage Accumulation and Phenotype in Human Diabetic Nephropathy 
Ying Yang, Yinfeng Guo, Zhixia Song, Min Zhou, Xiaoliang Zhang.  Southeast 
Univ.
Background: Macrophage, especially its distinct phenotype is involved in the progress 
of DN. M1 is characterized with pathogenic function, while M2 displays anti-inflammatory. 
This study tries to examine the macrophage phenotype and its relationship to the renal 
function and histological changes in human DN.
Methods: We studied retrospectively 46 patients with DN who were confirmed by 
diagnosis of renal biopsy. Biopsies were divided into I IIa IIb III IV classes according to the 
pathologic classification of DN. Patients with renal trauma or renal tumor were considered 
as control group. Serum creatinine, proteinuria were calculated. Kidney tissues were used 
to assess histological changes and the presence of macrophage marker CD68, M1 marker 
iNOS, M2 marker CD206, Arg-1, TREM1 and TREM2.
Results: In biopsy renal tissue of human DN, Expression of CD68, M1 were 
significantly increased in the glomeruli (2.835±1.045/gcs VS 1.203±0.547/gcs for 
normals P=0.031; 2.330±1.343/gcs VS 0.896±0.548/gcs for normals P=0.046) and 
interstitium (0.037±0.142%area VS 0.019±0.002%area P= 0.016; 0.018±0.008%area 
VS 0.009±0.005%area P=0.023). While M2 were mainly observed in the interstitium 
(0.019±0.008%area VS 0.010±0.004%area P=0.038). Interstitium M2 correlated strongly 
with interstitium M1 infiltration. Additionally there was a positive correlation between 
the glomerular CD68, M1 numbers and serum creatinine (r=0.619, p=0.001; r=0.463, 
p=0.017), proteinuria (r=0.641, P=0.000; r=0.508, P=0.008), mesangical matrix, interstitial 
collagen deposition. Likewise, the expression of interstitial CD68, M1, M2 also correlated 
strongly with serum creatinine (r=0.638, P=0.000; r=0.606, P=0.001; r=0.520, P=0.006), 
proteinuria (r=0.749, P=0.000; r=0.651, P=0.000; r=0.694, P=0.000), mesangical matrix, 
interstitial collagen deposition. Besides TREM1,2-positive cells were apparent in the 
interstitium and the expression levels significantly correlated with interstitium M1,M2 
expression respectively.
Conclusions: Macrophage infiltration and polarization participate in the development 
of diabetic nephropathy.
Funding: Government Support - Non-U.S.
FR-PO620
Risk of Diabetes Increased According to the Level of Urinary Albumin 
Excretion Even Within Normal Range  Dong-Young Lee,1 Beom Kim,1 
Kyoung Hyoub Moon,1 Sung Keun Park,2 Younjoo Jung.1  1Internal Medicine, 
VHS Medical Center, Seoul, Republic of Korea; 2Total Heath Care Center, 
Kangbuk Samsung Hospital, Sungkyunkwan Univ, School of Medicine, Seoul, 
Republic of Korea.
Background: Urine albumin creatinine ratio (UACR) as a reliable index of urinary 
albumin excretion is getting great attention on its predictive role for various diseases 
related with diabetes. Nevertheless, predictive value of UACR within normal range was 
not clarified for diabets yet. Therefore, this study was aimed at examining the clinical 
association between normal range of UACR and development of diabetes.
Methods: We identified 1,274 non-diabetic Korean men within normal range of UACR 
in 2005, and followed them up until 2010. All subjects were classified into three categories 
with respect to baseline UACR, from the lowest to the highest. The incidence rates of 
diabetes were compared according to the tertile groups of UACR, and the independent 
hazard ratios (HRs) of UACR levels for diabetes was measured by Cox proportional 
hazards analysis.
Results: During follow-up, diabetes developed in 97 out of 1,274 subjects (7.6%). 
Incidence rate of diabetes increased in proportion to the levels of UACR (tertile 1; 4.9%, 
tertile 2; 7.3%, tertile 3; 10.6%, p<0.001).
UACR
Tertile 1(<3.17) Tertile 2 (3.17≤, <4.95)
Tertile 3 
(≥4.95)
Age (year) 49.5 52.6 53.9
SBP (mmHg) 113.9 114.6 119.9
DBP (mmHg) 77.0 78.3 81.4
FBS (mg/dL) 96.5 98.5 99.8
HOMA-IR 1.83 1.91 2.07
HbA1C (%) 5.3 5.4 5.4
sCr (mg/dL) 1.16 1.11 1.12
Hypertension (%) 19,8 23.7 37.5
Development of diabetes (%) 4.9 7.3 10.6
table1. Baseline characteristics of participants according to tertile groups of UACR levels 
(N=1,274) 
All variable are shown by mean value. P-value were ≤0.001 except development of diabetes (P=0.002)
The subjects with incident diabetes had the higher normal range of UACR than those 
without incident diabetes (5.3±4.2 µg/mg and 6.7±4.2 µg/mg, p=0.013). When tertile 1 was 
considered as reference, HRs for diabetes was higher in tertile 3 (2.06; 1.16-3.37), even 
after adjusting for age, BMI, total cholesterol, log(HOMA-IR) and eGFR.
Conclusions: Elevated UACR, even within normal range, was significantly associated 
with the future development of diabetes.
FR-PO621
Albuminuria Is Positively Associated with Elevated Numbers of 
Circulating Endothelial Pre- and Mature Cells, but Inversely Associated 
with Circulating Fibrocytes  Tine Hansen,1 Bernt Johan Illum von Scholten,1 
Alexander Rosendahl,2 Regine Bergholdt,2 Peter Rossing.1  1Steno Diabetes 
Center, Gentofte, Denmark; 2Novo Nordisk A/S, Måløv, Denmark.
Background: Diabetic nephropathy is characterized as a microvascular disease with 
enhanced vascular leakiness in the kidney and aberrant tissue remodelling. Abnormal 
number and function of endothelial cells, stem cells and activation of leukocytes is 
considered as contributing mechanisms to the “kidney-micro”-vascular leaky syndrome. 
We determined if circulating endothelial pre- and mature cells, fibrocytes or monocyte 
sub-populations were abnormally regulated in type 2 diabetic patients with albuminuria.
Methods: Cross-sectional study of 37 type 2 diabetic patients; 18 with normoalbuminuria 
(<30mg/24h) and 19 with albuminuria (³30mg/24h). 8-color flow cytometry analysis of 
peripheral blood was performed. ANCOVA compared expression of cell markers and 
absolute number of specific cell populations in patients with normoalbuminuria vs. 
albuminuria.
Results: Expression of VEGFR2 was significantly enhanced in patients with 
albuminuria (p=0.009). Also, the total number of circulating mature endothelial cells (CEC) 
was significantly enhanced in albuminuria (p<0.001). Circulating fibrocyte number and 
collagen-1 expression was inversely associated with albuminuria (p£0.037) and TGFbeta 
stabilizing and M2-associated galectin-3 expression on M1-like and M0-like monocytes 
was positively associated with albuminuria (p£0.029). In contrast, expression of the M1-
associated marker CD11c (p=0.042) was inversely associated with albuminuria on all 
monocytes, particularly on M0-like macrophages (p=0.014).
Conclusions: The enhanced number of CEC together with elevated expression of 
VEGFR2 may indicate an aberrant function of the CEC with reduced capacity to heal 
the kidney microvascular disease. The imbalanced M2-polarization of monocytes and 
aberrant fibrocyte count may favour improper repair leading to excessive tissue fibrosis. 
Hence therapeutic approaches addressing migratory pattern of CEC, providing adjuvant 
activating signals or restoring the immune balance might provide novel individualized 
treatment regimes.
FR-PO622
Prognostic Value of Tubulointerstitial Lesions and Urinary N-Acetyl-β-
D-Glucosaminidase in Patients with Type 2 Diabetes and Biopsy-Proven 
Diabetic Nephropathy  Koki Mise,1 Junichi Hoshino,1 Toshiharu Ueno,1 
Masayuki Yamanouchi,1 Noriko Hayami,1 Tatsuya Suwabe,1 Kenmei Takaichi,2 
Yoshifumi Ubara.1  1Nephrology Center, Toranomon Hospital Kajigaya, 
Kawasaki, Kanagawa, Japan; 2Nephrology Center, Toranomon Hospital, 
Tokyo, Japan.
Background: Recently, it has been reported that some biomarkers of renal tubular 
injury are useful to predict the renal prognosis in the early stage of diabetic nephropathy 
(DN). However, how closely such biomarkers reflect actual tubulointerstitial damage 
remains unknown.
Methods: Among 210 patients with type 2 diabetes and biopsy-proven DN, 152 
patients were enrolled, 89% of whom had overt proteinuria. The endpoint was defined as 
a 50% or more decrease of the estimated glomerular filtration rate (eGFR) from baseline 
or commencement of dialysis due to end-stage renal disease. The Cox proportional hazard 
model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for 
the death-censored endpoint.
Results: A significant correlation was found between baseline urinary N-acetyl-β-D-
glucosaminidase (NAG) excretion and the score for interstitial fibrosis and tubular atrophy 
(IFTA score) (r=0.39, P<0.001). The influence of urinary NAG on the renal prognosis was 
attenuated after adjustment for known promoters of progression (+1SD for log NAG, HR: 
0.87 [95% CI: 0.66-1.13]). On the other hand, the IFTA score was significantly related 
to the outcome even after adjustment for those covariates (+1 for IFTA score, HR: 2.20 
[1.50-3.21]).
Conclusions: The assessment of urinary NAG excretion did not improve the prognostic 
power of known indicators of progression, whereas the IFTA score did. The IFTA score may 
be more useful for predicting the renal prognosis than current tubulointerstitial markers, 
especially in patients with advanced DN.
Funding: Private Foundation Support
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FR-PO623
Is There Any Benefit of Performing Renal Biopsies in Patients with Diabetic 
Nephropathy when No Other Diagnosis Than Diabetic Nephropathy Is 
Found?  Rosa M. Montero,1 Dimitrios Anestis Moutzouris,1 Ranmith Perera,2 
David Goldsmith.1  1Nephrology & Transplantation, Guy’s & St Thomas’ NHS 
Foundation Trust, London, United Kingdom; 2Histopathology, Guy’s & St 
Thomas’ NHS Foundation Trust, London, United Kingdom.
Background: The risk of renal biopsy has long been thought to outweigh the benefit 
of performing these on patients with diabetes mellitus (DM) leading to small numbers of 
renal biopsies in this population. Those biopsied have a propensity to more proteinuria or 
haematuria precipitating biospy. Glomerular lesions alone have long been the hallmark of 
diabetic nephropathy (DN) however looking back at the biopsy can there be more to see?
Methods: All native renal biopsies diagnosed with DN from 2009-2014 were retrieved 
from archive at Guy’s & St Thomas’ NHS foundation trust. Renal biopsies were performed 
in patients with DM who had heavy proteinuria or haematuria on presentation. Biopsies with 
a DN diagnosis alone were identified and Tervaert’s new DN classification was applied. 
Clinical outcome data was collected from electronic patient records. Cox regression models 
were used to perform statistical analysis.
Results: 3000 native kidney biopsies were performed from 2009-2014. 34 DM patients 
had DN alone on renal biopsy, 12 T1DM and 22 T2DM. 20 male, 14 females.Ethnicity:35% 
white, 35% black, 3% asian, 27% other. Age range:24-86 years (median 55). UPCR 13-
1492 mg protein/mmol creatinine (median 392) eGFR 7-74.9 (median 23). 8.8% 5 year 
mortality. Glomerular IV and Interstitial fibrosis III lesions were significant predictors of 
renal survival (p=0.013 HR 27.5, p=0.006 HR 21.3, respectively). Renal survival ranged 
from 1-60 months post renal biopsy (median 3).
Conclusions: Interstitial fibrotic lesions are as important as glomerular lesions in 
predicting renal survival. Determining the significance of the compartments in predicting 
outcome may be more sensitive; however few biopsies are undertaken in this population. The 
role of an earlier renal biopsy showing less well established features in the DN population 
that could be reversed may need us to review our practice unless sensitive and specific 
biomarkers are found to correlate with the underlying histopathology.
FR-PO624
Understanding the Relationship Between Histopathology and Renal 
Function in Hypertension and Diabetes  Matthew Palmer,1 Jordana B. 
Cohen,2 Mendy Liang,2 Steven S. Pullen,3 Katalin Susztak.2  1Pathology, 
Univ of Pennsylvania, Philadelphia, PA; 2Nephrology, Univ of Pennsylvania, 
Philadelphia, PA; 3CardioMetabolic Research, Boehringer Ingelheim, 
Ridgefield, CT.
Background: Much of the literature relating clinical and pathologic variables in patients 
with diabetes mellitus (DM) and hypertension (HTN) has relied on biopsy series. To gain 
unbiased insight into the degree of interstitial fibrosis (IF) and glomerular sclerosis (GS) 
associated with decline of renal function in DM and HTN, we have correlated histopathology 
with renal function, DM and HTN status in patients undergoing tumor nephrectomies.
Methods: Data and renal tissue were collected on nephrectomy patients from 7 centers. 
We used Spearman correlation coefficients to compare eGFR with pathologic assessment 
of IF (estimate) and GS (manual count). Bivariate linear regression was used to assess the 
association between log-transformed percent IF or GS and eGFR, stratifying by presence 
of DM or HTN.
Results: Of 251 patients, there were 60 without DM or HTN, 89 with HTN alone, and 
102 with DM (+/- HTN). Median age was 62, 42% were female, 60% were Caucasian, 
median systolic blood pressure was 134 mmHg, and median eGFR was 66.5. There was a 
significant association between decline in eGFR and both IF (rho=-0.50, p<0.01) and GS 
(rho=-0.53, p<0.01). eGFR of 60 was associated with a geometric mean (95% CI) IF and GS 
of 7.3% (5.1-10.3) and 8.3% (5.7-12.1) for patients without DM or HTN, 9.2% (7.5-11.2) 
and 8.7% (7.0-10.8) for patients with HTN, and 10.9% (8.8-13.5) and 9.6% (8.0-11.6) for 
patients with DM. Stage 3 CKD was associated with a median IF and GS of 10% (IQR 
5-15) and 11.3% (IQR 5.7-18.8) overall, and with median IF and GS of 10% (IQR 5-20) 
and 11.9% (IQR 5.7-20.8) in DM.
Conclusions: While IF and GS are similar at a given eGFR, patients with DM have a 
trend toward a greater degree of IF and GS at the same level of eGFR compared to those 
with isolated HTN.  Stage 3 CKD is associated with median IF of 10% though there is 
high individual variation. This highly variable histopathology should be considered when 
patients with DM are included into clinical studies, and kidney biopsies might be useful 
to include in categorization.
Funding: Pharmaceutical Company Support - Boehringer Ingelheim
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Efferent Arterioles Are Special Target for Obesity  Noriko Uesugi, Michio 
Nagata.  Kidney and Vascular Pathology, Faculty of Medicine, Tsukuba Univ, 
Tsukuba, Ibaraki, Japan.
Background: The link between obesity and renal disease is unclear. Hyperfiltration 
is suspected to induce arteriolar hyalinosis and glomerular hypertrophy in moderate to 
severe obesity. To assess morphological changes in mild obesity, we investigate human 
non-tumor renal tissue from 7 mild obese cases (Ob)(BMI 27)(Age 61y.o, S-Cre 0.8md/
dl. 4 with hypertension) and compared with 7 hypertensive case (HT) and 4 control(Con).
Methods: Total 150 of serially cut paraffin sections were double immunostained with 
CD34 as endothelial marker, and smooth muscle actin as medial marker, followed by PAS 
stain. Incidence of hyalinosis in afferent and efferent arterioles, intraglomerular cystic 
dilatation connecting to efferent arterioles, segmental sclerosis, sclerotic glomeruli(GS) 
and average size of glomeruli were assessed using 30-40 glomeruli per case.
Results: The morphological data were as follows; average glomerular diameter 
203±26*, 181±19, 156±4 um, incidence of afferent arteriolar hyalinosis 43±13*,47±29*, 
20±16 % and that of efferent arterioles, 30±10**, 13±14, 5±4% for Ob, HT and Con, 
respectively (*P<0.05 vs Con, **P<0.05 vs Con and HT). Higher incidence of cystic 
dilatation near efferent arterioles was noticed in Ob (21±15%) than HT and Con (2±15, 
0%, respectively)(P<0.05).Obese cases revealed neither significant intimal thickening nor 
distortion in the interlobular arteries, no segmental sclerosis, low incidence of GS (11±7%) 
and minimal interstitial damage(<10%.).
Conclusions: Efferent arterioles are targets for obesity, which suggest that specific 
mechanism of glomerular hyperfiltration involves  obese cases, even in mild form.
Funding: Government Support - Non-U.S.
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A Pathological Scoring System to Predict Renal Outcome in Diabetic 
Nephropathy  Junichi Hoshino, Koki Mise, Toshiharu Ueno, Keiichi Sumida, 
Masayuki Yamanouchi, Noriko Hayami, Tatsuya Suwabe, Shigeko Hara, 
Yoshifumi Ubara, Kenmei Takaichi.  Nephrology Center, Toranomon Hospital, 
Tokyo, Japan.
Background: With association between diabetic nephropathy (DN) and renal outcome 
increasingly clear, we aimed to create a new DN pathological scoring system that could 
predict renal outcome.
Methods: We studied 205 patients with DN confirmed by renal biopsy between March 
1985 and January 2010 who met inclusion criteria. Renal biopsy included clinical parameters 
and Tervaert classifications. Hazard ratios (HRs) for end-stage renal disease (ESRD) 
were estimated by adjusted Cox regression. Overall pathological risk score (D-score) was 
calculated by summing the products of beta-coefficient and bootstrap-inclusion fractions, 
its predictive utility evaluated by Kaplan-Meier methods and c-statistics with 10-fold 
cross-validation for 10-year risk of ESRD.
Results: D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 
4, 6, and 6. Those of interstitial fibrosis and tubular atrophy classes 0, 1, 2, and 3 were 0, 
7, 9, and 11, and those of interstitial inflammation classes 0, 1, and 2, respectively, 0, 3, 
and 4. D-score of hyalinosis class 2 was 3, and that of arteriosclerosis class 2 was 1. So a 
patient’s D-score could be 0-25.
HRs for ESRD in patients with D-score£14, 15-18, 19-21, and 22-25 were, respectively, 
1.00 (ref.) 16.21 (1.86-140.90), 19.78 (2.15-182.40), and 45.46 (4.63-446.68) after adjusting 
for clinical factors. When comparing c-statistics, a model that included D-score in addition 
to age, eGFR, and proteinuria, showed a slight improvement from 0.901 (0.861-0.942) 
to 0.932 (0.898-0.965). The net reclassification index also showed better reclassification 
(0.24 (-0.02 to 0.49)).
Conclusions: In addition to clinical parameters, D-score may have improved prediction 
of 10-year risk of ESRD. Patients with D-score £14 had excellent renal prognosis.
Funding: Private Foundation Support
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Hyperphosphatemia and Tubulointerstitial Injury in the Progression of 
Diabetic Nephropathy  Song Jiang, Yu Pan, Dandan Qiu, Yu An, Hao Chen, 
Yongchun Ge, Honglang Xie, Zhihong Liu.  National Clinical Research Center 
of Kidney Diseases, Research Inst of Nephrology, Jinling Hospital, Nanjing, 
Jiangsu, China.
Background: Our aim was to evaluate the relationship between tubulointerstital injury 
and hyperphosphatemia in the patients with type 2 diabetes and diabetic nephropathy 
(T2DN), and investigate the association of hyperphosphatemia with the renal outcome, 
especially in the T2DN patients with eGFR≥60 ml/min per 1.73m2.
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Methods: A total of 396 patients with T2D and biopsy-proven DN from Nanjing DN 
registration system who received follow-up for at least 1 year were recruited and median 
5-year follow-up. Renal outcomes were defined by progression to end-stage renal disease 
and doubling of serum creatinine.
Results: Of the participants, the mean baseline eGFR was 73.86±33.52mL/min per 1.73 
m2. The levels of the urinary tubulointerstitial injury markers including the NAG, RBP and 
NAGL were significantly difference among quintiles of serum phosphorus (P<0.01). The 
participants whose eGFR≥90 ml/min per 1.73 m2 had a higher rate of tubulointerstitial injury 
(interstitial fibrosis tubular atrophy scores of 2 and 3, P=0.005; interstitial inflammation 
scores of 1 and 2, P=0.035) in hyperphosphatemia (>1.45 mmol/L) group than in lower 
phosphorus group (<1.17 mmol/L). Participants with baseline levels of serum phosphorus 
in higher quintiles had a higher cumulative incidence of ESRD (log-rank, P<0.01). In the 
analyses adjusted by age, sex, diabetes status, BP, FBG, BMI, proteinuria, cholesterol, and 
eGFR, the relationship between higher serum phosphorus and an increased risk of ESRD 
remained. The association between serum phosphorus and ESRD risk persisted and was 
stronger when the sample was restricted to those with a baseline eGFR equal to 60-90 
mL/min per 1.73 m2, but not when it was restricted to patients with a baseline eGFR of 
30-60 mL/min per 1.73 m2.
Conclusions: These findings indicated the baseline serum phosphorus is associated 
with tubularinterstitial injury of T2DN patients. And serum phosphorus >1.45mmol/L is 
an independent risk factor of ESRD in T2DN, especially in the patients with eGFR≥60 
ml/min per 1.73m2.
Funding: Government Support - Non-U.S.
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Longitudinal Changes in Estimated Glomerular Filtration Rate in Youth 
with Type I Diabetes  Katherine D. Westreich,1,2 Nora Fino,1,3 Maryam 
Afkarian,1,4 David M. Maahs,1,5 Amy K. Mottl.1,2  1for the SEARCH for Diabetes 
in Youth Study; 2Univ of North Carolina; 3Wake Forest School of Medicine; 
4Univ of Washington; 5Univ of Colorado Denver.
Background: Diabetes is the leading cause of kidney disease in the US. The natural 
history of kidney function early in type I diabetes (T1D) is relatively unknown.
Methods: SEARCH for Diabetes in Youth is a multicenter cohort study of incident 
diabetes in youth <20 yrs at diagnosis. Cystatin C (CysC) was measured at two study visits; 
values were calibrated for assay drift and standardized to the reference material. GFR was 
estimated using the CysC-based Filler equation, the only pediatric equation validated in 
hyperfiltration. Participants were stratified by change in eGFR: gain of >3ml/min/1.73m2/
yr, loss of >3ml/min/m2/yr, or stable. Nominal multinomial regression was used to predict 
eGFR outcome category. Covariates included gender, race/ethnicity, and follow up age, 
fasting glucose, HbA1c, insulin sensitivity score, renin-angiotensin inhibition, and systolic 
blood pressure Z-score (SBPZ).
Results: The analysis included 905 participants with T1D (mean age 14 ±4 yrs; duration 
4.2 ±1.9 yrs, HbA1c 8.7% ±1.8%; SBPZ -0.3 ±1.0 and CysC 0.73 ±0.12 mg/L). Follow up 
CysC was measured 4.6 ±1.3 yrs later. 323 (36%) participants lost eGFR (mean 150+30 fell 
to 119+23, p<0.0001); 197 (22%) gained eGFR (mean 122+22 rose to 151+29, p<0.0001) 
and 385 (42%) had stable eGFR. Odds ratios (OR) for predictor variables significant in 
any pairwise comparison are shown below.
Variable
OR (95%CI)
eGFR loss vs stable 
(ref)
OR (95% CI)
eGFR gain vs stable 
(ref)
OR (95% CI)
eGFR loss vs gain 
(ref)
N 323 vs 385 197 vs 385 323 vs 197
Age (per 1 year) 0.92 (0.88-0.97) 1.07 (1.00-1.14) 0.87 (0.81-0.93)
Female gender NS 1.64 (1.14-2.38) 0.59 (0.40-0.88)
SBP Z-score (per 1 
point) 1.16 (1.03-1.30) 1.15 (1.00-1.33) 1.36 (1.17-1.59)
Fasting glucose (per 
100mg/dl) NS 1.22 (1.01-1.30) 0.80 (0.66-0.98)
HbA1c (per 1%) NS 1.15 (1.01-1.29) NS
Conclusions: Changes in eGFR are heterogeneous early in T1D and are predicted 
in part by SBPZ, age, gender, glucose and HbA1c. Continued follow up will determine 
whether early changes in eGFR may identify those at risk for subsequent kidney disease.
Funding: NIDDK Support, Other U.S. Government Support
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A Cross-Sectional Study for Evaluating the Diagnostic Accuracy of Cystatin 
C and N-Acetyl β-D Glucosaminidase in Predicting Diabetic Nephropathy 
Dhara Nrupal Patel, Kiran Kalia.  BRD School of Biosciences, Sardar Patel 
Univ, Anand, Gujarat, India.
Background: Diabetic nephropathy (DN) is classified into V stages. Amongst which, 
stage I-II are reversible proximal tubule damage stages, and III- V are well established 
irreversible glomerular damage stages. The inability of creatinine and microalbuminuria 
to detect early reversible stages urges the necessity of new efficient diagnostic biomarkers. 
Thus, we have selected proximal tubule originated proteins; cystatin c (cyst c) and N-acetyl 
β-D Glucosaminidase (NAG) to study their efficacy in detecting early manifestations of DN.
Methods: Urinary/serum cyst c and NAG were estimated in total 491 age-matched 
patients enrolled for our cross-sectional study. Their efficacy was compared with urinary 
microalbuminuria, serum creatinine and eGFR in patients with varying type 2 diabetes 
(T2DM) duration and various stages of DN.
Results: Patients with 5-10 yrs of T2DM duration showed a significant increase in cyst 
c level while urinary NAG increased in T2DM patients with 10-15 yrs of diabetic duration. 
The ROC curve signifies diagnostic efficacy of urinary cyst c (AUC 0.820) over urinary 
NAG (AUC 0.678), in detecting T2DM patients susceptible to develop DN. 
Conclusions: Urinary cyst c in comparison to urinary NAG plays a significant role 
in predicting the early renal decline in T2DM patients with varying duration of diabetes. 
Furthermore, the presence of such low molecular weight protein and renal origin enzyme 
indicates pathogenesis of proximal tubule in early stages of DN.
FR-PO630
The Relationship Between Diabetic Retinopathy and Diabetic Kidney 
Disease in a Population-Based Study in Korea (KNHANES V2-3) 
MinJeong Lee,1 Won june Lee,2 Seirhan Kim,1 Gyu Tae Shin,1 Heungsoo Kim.1 
1Dept of Nephrology, Ajou Univ School of Medicine, Suwon, Republic of Korea; 
2Dept of Opthalmology, 102 Replacement Depot, Republic of Korea Army, 
Chuncheon, Republic of Korea.
Background: Previous studies of the association between diabetic kidney disease 
(DKD) and diabetic retinopathy (DR) used only albuminuria/proteinuria as chronic kidney 
disease (CKD) markers and, hence, did not consider eGFR. This study aimed to evaluate 
the prevalence of DKD and the association between DKD, as evaluated by both proteinuria 
and eGFR, and DR in the large cohort of patients with type 2 diabetes from the Korea 
National Health and Nutrition Examination Survey (KNHANES V).
Methods: From the fifth (2011, 2012) KNHANES, 971 participants with type 2 
diabetes were included. Selected samples were weighted to represent the entire civilian 
population in Korea. DKD was defined as diabetes with the presence of albuminuria and/
or impaired GFR. Nonproteinuric DKD was defined as estimated glomerular filtration rate 
(eGFR) calculated by Modification of Diet in Renal Disease (MDRD) equation < 60 ml/
min/1.73m2 and no albuminuria. Multivariate logistic regression analysis was performed 
to determine risk factors, including DR, associated with DN in the Korean population.
Results: Among the 971 DM patients, the prevalence of microalbuminuria was 19.3 % 
and that of macroalbumunuria was 5.5 %. The prevalence of eGFR < 60ml/min/1.73m2 was 
9.1%, and half of those were nonproteinuric DKD. We observed a prevalence of 20.0% for 
DR and 3.8% for Proliferative DR(PDR). Multiple logistic regression analysis revealed that 
HTN [aOR = 1.75; 95% CI = 1.19 – 2.59], HbA1c[aOR = 1.24; 95% CI = 1.12 - 1.39], and 
PDR[aOR=2.80; 95% CI = 1.32 – 5.96] were independent factors correlated with proteinuric 
DKD, and the older age [adjusted odds ratio (aOR) = 1.19; 95% confidence interval (CI) = 
1.09 – 1.31] and the presence of hypertension [aOR = 5.50; 95% CI = 1.37 – 22.71] were 
significantly associated with nonproteinuric DKD.
Conclusions: Nonproteinuric renal dysfunction in type 2 DM is not rare. PDR is 
associated with proteinuric DKD, however, DR and PDR are not significantly associated 
with nonproteinuric DKD.
FR-PO631
A Decrease in Blood Pressure During Follow-Up Is Associated with an 
Increased Risk of All-Cause Mortality in Patients with Type 2-Diabetes 
and Renal Impairment – The Swedish National Diabetes Register (NDR) 
Hanri Afghahi,1 Stefan Franzén,2 Ann-marie Svensson,2 Bjorn Eliasson,3 
Maria Svensson.3  1Nephrology, Skaraborg Hospital, Skövde, Sweden; 2Center 
of Registers, Gothenburg, Sweden; 3Medicine, Sahlgrenska Univ Hospital, 
Gothenburg, Sweden.
Background: A U-shaped relationship between systolic blood pressure (SBP) and 
risk of all-cause of mortality has been found in patients with type 2 diabetes (T2D) and 
renal impairment (RI). We here assess the association between time-dependent mean SBP, 
change in SBP during follow up and risk of all-cause mortality.
Methods: 27 732 patients with T2D and RI (eGFR<60ml/min/1.73m2 MDRD) 
classified into 10 mmHg intervals according to SBP at baseline were followed for 4.7 
years. The risk of all-cause mortality was estimated using time-dependent mean SBP and 
change in SBP from last observation by time-dependent adjusted cox model. A smoothing 
spline describe the influence of mean SBP and the change in SBP on the hazard function.
Results: During follow-up 8265 deaths occurred. Using SBP 130-139 mmHg as a 
reference group a time-dependent mean SBP <130 mmHg was associated with increased 
risk of all-cause mortality in all (HR 1.28, 95% CI 1.20, 1.36) and in patients without 
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previous congestive heart failure (n=23 799) (HR 1.26, 95% CI 1.17, 1.36). In addition, a 
25-50 mmHg decrease in SBP from the last observation was associated with an increase 
in risk of all-cause mortality (HR 1.44, 95% CI 1.33, 1.56) compared to a change in the 
range -10 to 10 mmHg.
Conclusions: A systolic blood pressure < 130 mmHg and a decrease in systolic blood 
pressure during follow up with or without previous congestive heart failure, is associated 
with an increase the risk of all-cause mortality in patients with type 2-diabetes and 
renal impairment.Intensity of hypertensive medication and co-morbidities are important 
confunders and will be further evaluated.
FR-PO632
Increased Expression of WNT5a in Renal Tubules Is Associated with 
Diabetic Nephropathy in Humans  Malik Asad Anjum,1 An Xiao,1 Dean 
Troyer,1,2 Michael J. Solhaug,1 Anca Dobrian,1 Jerry L. Nadler,1 Liwei Huang.1 
1Internal Medicine, Eastern VIrginia Medical School, Norfolk, VA; 2Pathology, 
Sentara Norfolk General Hospital, Norfolk, VA.
Background: Diabetic nephropathy (DN) is the leading cause of end stage renal disease 
worldwide. In recent years, convincing data has come forward suggesting that inflammatory 
pathways play a pivotal role in the pathogenesis and progression of DN. Identification of 
these inflammatory pathways and associated biomarkers may help in the early diagnosis 
of DN and development of novel targeted therapeutic strategies to help prevent, treat and 
even slow the progression of DN. Wnt5a, a secreted glycoproteins, plays an important 
role in normal kidney development and is also a pro-inflammatory factor which has been 
associated with renal fibrosis and disruption of matrix metabolism. The objective of our 
study was to investigate the expression of WNT5a in diabetic kidneys in humans.
Methods: 11 subjects with biopsy confirmed DN were included in our experimental 
group. Normal kidney tissues from non-diabetic subjects who underwent nephrectomy for 
renal cell carcinoma were used as controls. Exclusion criteria for the experimental group 
were HIV positivity, chronic/acute inflammatory diseases (including hepatitis C) and 
steroids/immunosuppressant medication. WNT5a expression was evaluated in paraffin 
embedded tissues.
Results: Immunohistochemical analysis of WNT5a expression showed positive staining 
on the apical side of the plasma membrane of the renal tubular epithelial cells in control 
kidney tissues. The intensity of the staining is increased in patients with DN compared 
to normal kidney control tissues. In patients with DN, WNT5a expression is localized 
both in the cytoplasm and on the apical side of the plasma membrane of the renal tubular 
cells. WNT5a is also expressed on glomerular cells, but there are no differences in Wnt5a 
expression between the tissues from diabetic subjects and controls.
Conclusions: Our results suggest that WNT5a expression in renal tubules might have 
a pathogenic role in the development of human renal tubular fibrosis. These studies are the 
first to demonstrate an increase in WNT5a expression in renal tubules in DN.
Funding: NIDDK Support
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Accuracy of Serum Creatinine and Glomerular Filtration Rate Estimation 
for Adjusting Metformin Prescription in European Type 2 Diabetics 
Olivier Moranne,1 Coraline Fafin,1 Pierre Delanaye,2 Martin Flamant.3 
1Nephrology, CHU, Nice, France; 2Nephrology, Hospital, Liege, Belgium; 
3Physiology, APHP, Paris, France.
Background: There is a debate in the literature about the thresholds of serum creatinine 
(Scr) above which the drug is contraindicated (1.5 mg/dL in men & ³1.4mg/dL in women). 
For KDIGO, recommendation is a dose-adjustment between 45 and 30mL/min and a 
withdrawal below 30mL/min. However, in DM2, estimation of renal function based on 
Scr alone or on eGFR may vary from the true renal function (mGFR). The purpose of our 
study was to define the performance of the GFR assessment method (Scr or eGFR calculated 
with Cockcroft-Gault (CG) or CKD-EPI) in terms of metformin dose adjustment in DM2 
who underwent a GFR measurement.
Methods: In 243 DM2 patients, GFR was measured by urinary clearance of 51CrEDTA. 
Non indexed GFR was used. We analyzed the agreement between classification of patients 
based on mGFR and, first, Scr alone with a cutoff value of 1.5mg/dL in men and 1.4mg/dL 
in women, second, on eGFR with threshold values of 45 ou 30mL/min. When both methods 
classified the patient in the same subgroup, the data were considered concordant otherwise 
overprescription (underprescription) was defined for discordance according to mGFR.
Results: Age was 61 ± 12 y/o, median mGFR was 42 [30-61] mL/min. Based on mGFR 
, the distribution of the patients according the following GFR class: [90-45] 110(45%), 
[44-30] 74(30%), < 30: 59(24). In patients with a Scr above the cutoff value, mGFR(mL/
min) was <30 mL/min in respectively 23/40 women and 33/106 men. With a threshold 
of 45mL/min then 30 mL/min, concordance was found in 80/85% then 88/88% of the 
patients for the CG and CKD-EPI. With a threshold of 30 mL/min, discordance was an 
overestimation [or underestimation] in 22(9%) and 19(8%) [or 14(6%) and 11(5%)] of the 
patients with the CG and CKD-EPI.
Conclusions: In this population creatinine-derived equations outperformed Scr 
alone in correctly classifying the patients in prescription subgroups. However, even with 
creatinine-based equations, discordance with mGFR occurs in 12-20% of the patients. New 
strategies such as drug concentration monitoring may be necessary to improve appropriate 
prescription of metformin in DM2.
FR-PO634
The Association Between Changes in Albuminuria and Clinical Outcomes 
in the ADVANCE (Action in Diabetes and Vascular Disease: PreterAx and 
DiamicroN MR Controlled Evaluation) Trial  Min Jun,1,2 Vlado Perkovic,1 
Mark Woodward,1 Hiddo Jan Lambers Heerspink,3 Tanvir Chowdhury Turin,2 
John P. Chalmers,1 Meg J. Jardine,1 Braden J. Manns,2 Marcello Tonelli,1 Brenda 
Hemmelgarn.2  1George Inst; 2U/Calgary; 3U/Groningen.
Background: Change in albuminuria may have useful prognostic value. We sought to 
assess the association between change in urine albumin-to-creatinine ratio(UACR) and the 
risk of all-cause death, cardiovascular disease(CVD), and end-stage renal disease(ESRD) 
in the ADVANCE trial.
Methods: We defined UACR change(baseline to 2 years) as ³30% decrease, <30% 
decrease to <30% increase(minor change; reference), and ³30% increase. Follow-up for 
outcome ascertainment commenced at the second UACR measurement. We used Cox 
regression to estimate the hazard ratio(HR), after adjustment for demographics, ADVANCE 
randomized treatment assignments, comorbidities, laboratory measurements(including 
baseline UACR), and drug use.
Results: From baseline to 2 years, 34% of 9195 patients experienced a UACR decrease 
of ³30%, 26% experienced a minor change, and 40% experienced an increase of ³30%. 
Over the next 2.9 years(median), 520 deaths, 524 CVD events, and 12 ESRD events were 
recorded. An increase of ³30% in UACR was associated with 50% higher mortality when 
compared to a minor change ([Figure 1] HR 1.50, 95%CI:1.18-1.90). Increase in UACR 
was not associated with increased CVD or ESRD, although the direction of effect was 
similar. A ³30% UACR decrease was not significantly associated with the risk of death or 
CVD when compared to those with minor change but was significantly associated with 
lower ESRD risk(HR 0.10, 95%CI:0.01-0.79).
Conclusions: In type-2 diabetes patients, ³30% increase in albuminuria predicted 
higher mortality while ³30% decrease was associated with decreased ESRD risk. Our 
results suggest change in albuminuria may be a potential prognostic marker for clinical 
outcomes in type-2 diabetes.
FR-PO635
Changes in Glycaemia During Haemodialysis (HD) Are Not Associated 
with Changes in QTc Interval in Insulin-Treated Diabetic Patients 
Naveen H. Siddaramaiah,1 Didem Tez,1 Thanh Phan,1 Nicholas J. Linker,1 Mary 
Bilous,1 Sue Winship,1 Sally M. Marshall,2 Rudolf W. Bilous.1  1The James Cook 
Univ Hospital, Middlesbrough, United Kingdom; 2Newcastle Univ, Newcastle 
upon Tyne, United Kingdom.
Background: QTc prolongation is a risk factor for cardiac arrhythmias, which can 
lead to sudden cardiac death (SCD). Risk of SCD is higher in the 24hour period before and 
after the first dialysis of the week perhaps due to greater shifts in electrolyte levels but the 
impact of changes in glycaemia is not known. Aim : To explore the effect of changes in 
glycaemia and electrolyte levels during HD on QTc interval in C-peptide negative insulin 
treated diabetic patients.
Methods: 15 diabetic (mean age 54.6yrs) and 5 non-diabetic (mean age 59.6yrs) 
patients on HD, underwent Holter and continuous glucose monitoring for a week. Blood 
sampling and 12 lead ECGs were done at the beginning, middle and end of 3 HD sessions. 
Standard dialysate (5mM glucose) was used. QTc interval was measured taking the mean 
of 3 consecutive normal QRS complexes.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
506A
J Am Soc Nephrol 26: 2015 Diabetes Mellitus and Obesity: Clinical Poster/Friday
Results: QTc interval was prolonged significantly at the end of HD in all sessions 
(p<0.001). Change in glucose level (mean±SD -1.8±4.2 vs -1.7± 3.0) did not have a 
significant effect on the change in QTc interval (p=0.396), which was not different in 
diabetic subjects compared to non-diabetic group (p=0.390). Serum K+, Mg2+ and Ca2+ levels 
dropped significantly (p<0.001) during all 3 HD sessions. There was no significant difference 
in the starting level and the drop in K+, Mg2+ and Ca2+. The change in Mg2+ (p<0.05) and 
Ca2+ (p<0.05) levels but not K+ (p=0.202) were more pronounced in diabetic subjects. The 
change in Mg2+ levels in diabetic subjects was associated with QTc prolongation (p<0.05).
Conclusions:    Significant QTc prolongation occurs at the end of HD in people with 
and without diabetes, often reaching abnormal levels and appears to be related more to 
changes in blood electrolytes than glycaemia. The fall in serum Mg2+ levels during HD had 
a larger effect on QTc than K+ or Ca2+ and this appears to have a more pronounced effect 
in diabetic subjects. The changes in QTc may increase the risk of cardiac dysrhythmia and 
sudden death in HD patients.
FR-PO636
Markers of Inflammation and Endothelial Dysfunction Are Associated with 
Cardiovascular Morbidity and Mortality in Type 2 Diabetic Patients with 
Microalbuminuria  Bernt Johan Illum von Scholten,1 Henrik Reinhard,1 Tine 
Hansen,1 Casper Schalkwijk,2 Coen Stehouwer,2 Hans-Henrik Parving,3 Peter 
Karl Jacobsen,3 Peter Rossing.1  1Steno Diabetes Center, Denmark; 2Maastricht 
Univ Medical Center, Netherlands; 3Rigshospitalet, Denmark.
Background: Accumulating evidence suggests that inflammation and endothelial 
dysfunction link type 2 diabetes (T2D) to cardiovascular disease (CVD). We evaluated the 
predictive value of markers of inflammation and endothelial dysfunction for combined fatal 
and non-fatal CVD and for all-cause mortality in patients with T2D and microalbuminuria 
but without known coronary artery disease (CAD).
Methods: Prospective study including 200 patients. All received intensive multifactorial 
treatment. Markers of inflammation (TNF-α, ICAM-3, hsCRP, SAA, IL-1β, IL-6, IL-8) 
and endothelial dysfunction (thrombomodulin, VCAM-1, ICAM-1, E-selectin,P-selectin) 
were measured at baseline. Adjusted models included sex, age, total cholesterol, smoking, 
HbA1c, creatinine, systolic blood pressure and urinary albumin excretion. Fully adjusted 
models additionally included NT-proBNP and coronary artery calcium score (CAC).
Results: Participants were 76% men, age (± SD) 59 ± 9 years, HbA1c was 7.9 ± 1.3% 
and UAER (IQR) was 103 (39–230) mg/d. Occurrence of CVD (n=40) and mortality (n=26) 
was traced after 6.1 years (median). In adjusted Cox analysis, higher TNF-α predicted the 
CVD endpoint and mortality (p£0.002). After fully adjustment higher TNF-α remained 
predictive of both endpoints (p£0.007). Higher thrombomodulin and ICAM-3 were 
associated with risk of CVD and mortality in adjusted analyses (p£0.05) and predicted 
mortality after fully adjustment (p<0.001). Higher VCAM-1 and ICAM-1 were associated 
with risk of mortality in adjusted (p£0.002) and fully adjusted models (p£0.005). The 
composite z-score of all markers of inflammation and of endothelial dysfuntion predicted 
CVD and mortality (p£0.008).
Conclusions: In patients with T2D and microalbuminuria without known CAD, 
biomarkers of inflammation and endothelial dysfunction were independently associated with 
risk of CVD and mortality. Especially TNF-α was a robust predictor, even after adjusting 
for albuminuria, NTproBNP and CAC.
FR-PO637
Predictors of Glycemic Status and Associations with Mortality in Incident 
Diabetic Hemodialysis Patients  Connie Rhee,1 Steven B. Kim,1 Rajnish 
Mehrotra,2 Elani Streja,1 Danh V. Nguyen,1 Steven M. Brunelli,3 Gregory Brent,4 
Csaba P. Kovesdy,5 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2Univ Washington; 
3DaVita Clinical Research; 4UCLA; 5UTHSC.
Background: In the general population, intensive glycemic targets confer higher 
mortality in diabetics with cardiovascular risk. In diabetic hemodialysis (HD) patients, 
some but not all studies show that lower glycemic levels defined by HbA1c are associated 
with higher mortality. We sought to examine predictors of low glycemic status in HD 
patients, and hypothesized that lower glycemic levels are associated with higher mortality.
Methods: In a 5-year national cohort (1/2007-12/2011) of incident diabetic HD 
patients with one or more HbA1c measures during the 1st 91-days of dialysis, we examined 
predictors of low HbA1c (<6%; ref 6-<8%; ≥8% separately examined) using logistic 
regression. We then examined the association of HbA1c with all-cause mortality. Baseline 
and time-dependent HbA1c as a proxy of long-term and short-term exposure—mortality 
associations, respectively, were examined using case-mix+laboratory adjusted Cox models.
Results: Among 63,607 diabetic HD patients, 37% had low HbA1c levels. Female 
gender and non-Hispanic race/ethnicity; lower BMI and nPCR; and higher serum 
bicarbonate, creatinine, and albumin were associated with higher risk of low HbA1c. 
Baseline HbA1c levels <7% were associated with lower mortality. However, time-dependent 
HbA1c levels <5% were associated with higher mortality.
Conclusions: Baseline HbA1c levels <7% were associated with lower mortality, 
suggesting that moderately low glycemic status has long-term benefits in diabetic HD 
patients. Yet time-dependent HbA1c levels <5% were associated with higher mortality, 
suggesting that very low glycemic status carries short-term risk. Further studies are needed 
to determine if pharmacotherapies targeting these glycemic ranges reduce mortality in 
diabetic HD patients.
Funding: NIDDK Support, Private Foundation Support
FR-PO638
Waist-Hip Ratio Is Associated with Renal Hyperfiltration in the Non-
Diabetic, Middle-Aged General Population  Vidar T. N. Stefansson,1 Jørgen 
Schei,1 Trond G. Jenssen,1,3 Toralf Melsom,1,2 Bjorn Odvar Eriksen.1,2  1Metabolic 
and Renal Research Group, UiT the Arctic Univ of Norway, Tromsø, Norway; 
2Section of Nephrology, Univ Hospital of North Norway, Tromsø, Norway; 3Dept 
of Organ Transplantation, Oslo Univ Hospital, Oslo, Norway.
Background: Renal hyperfiltration (RHF) is a maladaptive response to increased 
metabolic stress in the kidneys which may result in chronic kidney disease. Diabetes causes 
RHF, but whether obesity in non-diabetic persons is a cause of RHF has not been adequately 
studied in the general population. This study aimed to establish whether RHF assessed 
by measured glomerular filtration rate (GFR) is associated with obesity independently of 
metabolic and cardiovascular risk factors.
Methods: We performed a cross-sectional study of a representative sample of 1594 
persons recruited from the general population of the municipality of Tromsø, Norway, 
aged 50-62 without prevalent cardiovascular disease, diabetes or renal disease. GFR was 
measured by iohexol clearance. Obesity was classified according to body mass index (BMI), 
waist circumference (WC) and waist-hip ratio (WHR). RHF was defined as >90th percentile 
of residuals from a linear regression of absolute GFR on age, sex, weight and height.
Results: In multivariable adjusted logistic regression models, the odds ratios (95% 
confidence intervals) for RHF were 1.56 (1.11-2.18) per 0.10 increase in WHR, 0.82 (0.51-
1.32) per 5kg/m2 of BMI and 1.23 (0.92-1.65) per 10 cm of WC. WHR was consistently 
associated with RHF across different models. Higher BMI and WC were significantly 
associated with RHF only when an alternative definition of RHF, not adjusted for body 
weight, was used. Higher BMI, WC and WHR were also independently associated with 
increasing GFR analyzed as a continuous variable.
Conclusions: Central obesity measured as WHR is associated with RHF and higher 
GFR independently of age, sex, body weight, metabolic indices (including fasting glucose, 
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insulin and HbA1C) and cardiovascular risk factors (including ambulatory blood pressure, 
antihypertensive medication and smoking status). WHR may be a better indicator of the 
renal effects of obesity than BMI or WC.
Funding: Pharmaceutical Company Support - Boehringer-Ingelheim, Private 
Foundation Support, Government Support - Non-U.S.
FR-PO639
Obesity Associates with High Hemoglobin A1c but Low Alternative Indices 
in Both Diabetic and Nondiabetic Hemodialysis Patients  Mark E. Williams,1 
Neal Mittman,2 Lin Ma,3 Julia I. Brennan,4 Chinu M. Jani,4 Curtis D. Johnson,4 
Franklin W. Maddux,3 Eduardo K. Lacson.3,5  1Joslin Diabetes Center, Boston, 
MA; 2Kidney Care of Brooklyn and Queens, Brooklyn, NY; 3Fresenius Medical 
Care North America, Waltham, MA; 4Spectra Laboratories, Rockleigh, NJ; 
5Physician, Lexington, MA.
Background: The GIDE (Glycemic Indices in Dialysis Evaluation) study is evaluating 
several glycemic markers in hemodialysis (HD) cohorts with and without diabetes. We have 
reported that alternative glycemic indices may be elevated out of proportion to hemoglobin 
A1c (HgbA1c). Because obesity is known to affect markers of glycemia, we examined its 
association with these indices.
Methods: A combined cohort of 2,394 active HD patients (1,424 with diabetes, 970 
without) from 26 U.S. FMCNA facilities had baseline indices [HgbA1c; albumin-adjusted 
and unadjusted fructosamine (AlbF; F) and glycated albumin (GA) or percent GA] measured 
Jan-Mar 2013 and monthly until April, 2015. Mean of body mass index (BMI) was 
determined for the entire cohort. Obesity=BMI³30kg/m². Cox models adjusted by age, sex, 
race, ethnicity, vintage, HD catheter, baseline comorbidity and laboratory albumin values 
were to utilized to determine associate between obesity with death outcome.
Results: Average BMI (kg/m2, mean±SD) by risk as determined by indices (low=within 
target range, high=above target range) are shown in (table 1). 
Indices Low Risk High Risk p-value
HgbA1c > 7% 28.8 ± 11.4 31.6 ± 8.2 < 0.0001
Percent Glycated Albumin > 15.7% 29.8 ± 12.4 28.9 ± 9.9 < 0.0001
Fructosamine > 285 ȝmol/L 31.0 ± 14.6 28.7 ± 9.4 < 0.0001
AlbF ≥ 974 ȝmol/g 29.5 ± 11.8 28.6 ± 7.4 < 0.0001
Glycated Albumin > 300 ȝmol/L 29.3 ± 11.4 29.2 ± 10.4 0.0008
HgbA1c ≥ 8% 29.1 ± 11.1 31.6 ± 8.7 < 0.0001
The Hazard Ratio (HR) for death was reduced with obesity [HR=0.76, 95%CI (0.62, 
0.94), p=0.01].
Conclusions: Obesity is positively correlated with HgbA1c but negatively correlated 
with other glycemic indices in hemodialysis patients. Further studies are needed to elucidate 
underlying mechanisms and assess the relationship of these findings to superior survival 
outcomes in obese HD patients.
FR-PO640
BMI and Causes of Death in Chronic Kidney Disease  Sankar D. Navaneethan,1 
Jesse D. Schold,2 Susana Arrigain,2 John P. Kirwan,3 Joseph V. Nally.1 
1Nephrology, Cleveland Clinic; 2Quantitative Health Sciences, Cleveland Clinic; 
3Pathobiology, Cleveland Clinic.
Background: Chronic kidney disease (CKD) is associated with higher risk for 
cardiovascular related death. In CKD, a higher body mass index (BMI) is associated with 
a lower risk for death, but cause specific death details are unknown across the BMI range.
Methods: We included 54,506 patients with CKD (two estimated glomerular filtration 
rate <60 ml/min/1.73 m2 90 days apart; January 2005 – December 2012) from our 
institutional electronic medical record-based CKD registry. We examined the associations 
between various causes of death (cardiovascular, malignancy and non-cardiovascular/
non-malignancy related deaths obtained from the State of Ohio mortality files) across the 
BMI range using the Cox proportional hazards model.
Results: During a median follow-up of 3.7 years (25th percentile-75th percentile: 1.8-
5.8), 14,518 patients died. In the multivariable model, an inverted J-shaped association 
was noted between BMI and overall, cardiovascular, malignancy-related, and non-
cardiovascular/ non-malignancy related deaths.
Similar associations were noted for BMI 25-29.9, 30-34.9, and 35-39.9 kg/m2 
categories. BMI >40 kg/m2 was not associated with cardiovascular and non-cardiovascular/
non-malignancy related deaths in CKD. Sensitivity analyses yielded similar results even 
after including only those with >2 year follow-up, adjusting for proteinuria, and excluding 
diabetes and hypertension from the models. However, the inverse associations between 
higher BMI and cardiovascular deaths were not observed among smokers.
Conclusions: In those with CKD, compared to BMI of 18.5-24.9 kg/m2, those who 
are overweight, class 1 and 2 obesity are associated with lower risk for cardiovascular, 
malignancy-related and non-cardiovascular/non-malignancy related deaths. Future studies 
are needed to confirm these findings.
Funding: Pharmaceutical Company Support - CCF CKD registry creation was 
supported by an unrestricted grant from Amgen to the Department of Nephrology and 
Hypertension at Cleveland Clinic
FR-PO641
Weight Reduction with Low Calorie Diet Reduces Urinary Megalin and 
Improves Albuminuria in Obese Men  Tetsuro Takeda,1 Akihiko Saito.2 
1Nephrology, Dokkyo Medical Univ Koshigaya Hospital, Koshigaya, Saitama, 
Japan; 2Applied Molecular Medicine, Niigata Univ, Niigata, Japan.
Background: Megalin, an endocytic receptor in proximal tubules, is involved in 
the mechanisms of albuminuria in diabetic nephropathy. A urinary full-length megalin 
(C-megalin) assay is linked to the severity of diabetic nephropathy and IgA nephropathy. 
Also, albuminuria is a frequent sign of obese individuals and could be reduced by losing 
body weight. We investigated the relationship between level of urinary C-megalin and 
albuminuria on a weight reduction program in obesity.
Methods: Thirty-three obese male volunteers (age 36.6 ± 6.9 years, BMI >25 kg/
m2) were enrolled but 30 subjects completed the 12-week weight reduction program. 
The program consisted of replacement of evening meal by a low calorie formula food 
(MICRO-S®) for first 4 weeks and followed by bi-weekly dietary counseling session with 
nutritionist. Of these, 20 subjects with metabolic syndrome were included (based on the 
Japanese criteria). Urinary albumin Cre ratio (ACR) and urinary C-megalin were measured 
at baseline and after the program.
Results: The mean weight loss was 5.2 ± 2.9 kg (5.6% of the original BW). The baseline 
ACR ranged from 2.8 to 52.9 mg/gCre. After the program, BMI, waist circumference, BP, 
total cholesterol, and FFA were significantly decreased. HDL-cholesterol and adiponectin 
were significantly increased. Overall, ACR was not changed (11.9 ± 12.4 ĺ 8.8 ± 5.3 
mg/gCre). However, in the cases with ACR >8 mg/gCre at baseline (n=11), ACR was 
more effectively reduced (22.9 ± 15.1 ĺ 12.7 ± 6.4 mg/gCre) without a change in eGFR. 
The reduction of ACR was correlated with the reduction of urinary C-megalin. No other 
parameters like insulin resistance were associated with the reduction of ACR or C-megalin.
Conclusions: Losing BW with a formula food is effective in reducing urinary ACR 
in obese men. This improvement of ACR is related to the reduction in urinary C-megalin. 
Since albumin is excreted into urine by its increased glomerular leakage and/or decreased 
proximal tubular reabsorption via megalin and cubilin, our observations suggest that megalin 
metabolism in proximal tubules may determine albuminuria in obesity.
Funding: Pharmaceutical Company Support - Denka Seiken Co. Ltd., Niigata, Japan, 
Government Support - Non-U.S.
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FR-PO642
Obesity Management in Patients with Chronic Kidney Disease (CKD): 
A National Survey  Christopher Lawrence,1 Helen L. MacLaughlin,2 Ken 
Farrington,1 Andrew H. Frankel.3  1Lister Hospital, United Kingdom; 2Kings 
College London, United Kingdom; 3Imperial College London, United Kingdom.
Background: Obesity contributes to the development and progression of CKD and 
may be a barrier to, or increase risks of, transplantation. Evidence for how the renal multi-
disciplinary team (MDT) should proceed is limited and sometimes counterintuitive i.e. 
association of increased weight and better survival on hemodialysis. The study assessed 
approaches to obese patients with CKD across the UK and describes the availability of, 
and extent of co-working with, bariatric services.
Methods: An online survey tool was designed and sent by the British Renal Society to 
UK renal clinical directors and dieticians. The survey focussed on patients with CKD stage 
≥ 3, with proteinuria and co-existent Obesity stage II (BMI > 35kg/m2) as these patients 
are most likely to progress to ESRD.
Results: 58/71 (82%) of UK units responded with respondents split between dieticians 
(53%) and nephrologists (47%). Most respondents (78%) thought the prevalence of obesity 
has increased over the last decade. There was no consensus on the BMI cut off for kidney 
transplantation: £30, 16%; £35, 71%; ≤40, 12%; none, 2%. The 3 most common actions 
for initial obesity management were: to provide education/motivation (81%); dietetic 
referral (60%) and test fasting glucose and lipids (43%). Thereafter only 33% would refer 
to bariatric services. The main perceived barriers to weight loss were: lack of patient 
motivation (79%); no funding (60%); lack of services (53%). 54% of renal units co-locate 
with bariatric services. Only 33% of renal units can refer directly to local/regional bariatric 
service, the remainder were uncertain of referral pathways (27%) or relied on primary care 
physicians to refer. Only 5 units (9%) have a joint care pathway for obese patients with 
CKD undergoing bariatric surgery.
Conclusions: The response to obesity in CKD falls short of National (NICE) guidelines. 
The increasing prevalence of obesity is a challenge to the renal MDT. Strategies to tackle 
this include wider recognition of the problem; identifying and sharing best practice and 
development of a robust evidence base to foster investment in renal dietetic and support 
services.
FR-PO643
Effects of Renin-Angiotensin Blockade (RASB) on the Components 
of Early Interstitial Expansion in Patients (pts) with Type 1 Diabetes 
(T1D)  Zarah Khan, Michael Mauer, Maria Luiza A. Caramori.  Medicine and 
Pediatrics, Univ of Minnesota, Minneapolis, MN.
Background: Interstitial expansion is important for GFR loss in the later stages of a 
variety of disease processes, including diabetic nephropathy (DN). The Renin-Angiotensin 
System Study (RASS; NEJM 2009;361:40) considered whether RASB with enalapril or 
losartan compared to placebo could slow progression of early DN lesions over 5 years (yrs) 
in 285 normoalbuminuric (NA), normotensive (NT), normal GFR T1D pts. RASS found no 
treatment benefit of RASB on DN lesions but observed an unexpected ~50% increase in the 
light microscopic measures of the fractional volume of renal cortex which is interstitium 
[Vv(Int/Cortex)]. However, possible effects of RASB on individual Int components, i.e., 
Int collagen (Col), Int cells (C), peritubular capillaries (PTC) and undefined Int space (S) 
were not assessed. Here we report these additional studies.
Methods: Baseline and 5-yr renal biopsies from 21 RASS pts (52% males), from a 
single research center, 7 from each treatment group, with a wide range of change in Vv(Int/
Cortex), mean age of 34±10 yrs, and T1D for 11±4 yrs were selected. These pts were 
matched for age and sex, and selected for electron microscopic (EM) measurements of the 
fractional volume (Vv) of each of the Int components by masked unbiased random sampling 
and laborious morphometric point counting methods. Renal volume (RV) was measured by 
ultrasound and calculated using the kidney’s length, width, and anterior-posterior diameter 
by the formula L×W×AP×0.523.
Results: At baseline, 49% of the Int was made up by Col, 12% by C, 26% by PTC, 7% 
by S, and 2% by artifact. Overall there was no change in Int composition during RASS. 
Compared across treatment groups, there were no statistically significant effects of treatment 
group on the Vv of any of the Int components. RV (171±5 cm³) remained stable in all groups.
Conclusions: RASS found that NA, NT, normal GFR T1D pts had surprisingly 
rapid increases in Vv(Int/Cortex) which was uninfluenced by RASB. Here, using EM 
morphometric analyses, we showed that RASB also did not affect Int composition, since 
the Vv of each component at 5 yrs was not different from baseline in any of the groups.
Funding: NIDDK Support
FR-PO644
Liraglutide Improves Glycemic and Blood Pressure Control and Preserves 
Renal Function and Left Ventricular Function in Patients with Type 2 
Diabetes Mellitus with Renal Impairment  Takeyuki Hiramatsu, Akiko Ozeki, 
Kazuki Asai, Akinori Hobo, Hideaki Ishikawa, Shinji Furuta.  Nephrology, 
Konan Kosei Hospital, Konan, Aichi, Japan.
Background: Diabetes mellitus(DM) is a progressive multifactorial disease associated 
with cardiovascular complications. To prevent progression of systemic cardiovascular 
complications in DM patients, glycemic control is important. However using of anti-diabetic 
agents was restricted in patients with renal impairment. In this study, we examined the 
efficacy and safety of the glucagon-like peptide analogue, liraglutide to treat type 2 DM 
patients with renal impairment.
Methods: Twenty type 2 diabetes patients with renal insufficiency (Age; 65.4y, DM 
duaration;11.9y, eGFR;21.6ml/min/1.73m2) were enrolled. Anti-diabetic agents were 
swiched to liraglutide from others. Prior to liraglutide therapy, 9 patients used insulin, 8 
used oral antidiabetic agents, and 3 were only diet therapy. During 24 months liraglutide 
use, we examined the change of blood pressure and renal function. Echocardiography was 
examined at baseline and 24 months after liraglutide initiation.
Results: Hemoglobin A1c, and systolic/diastolic blood pressure levels were gradually 
decreased with liraglutide use. Renal function indicated by eGFR was not changed 
[table1], and the slope of the reciplocal of serum creatinine was improved after use 
of liraglutide(p<0.001). Moreover Liraglutide induced ameliorating left ventricular 
function(LVMI and EF).
baseline at 12 months p value
at 24 
months p value
HbA1c (%) 6.90 ± 0.87 6.15 ± 0.65 0.009 6.04 ± 0.52 0.002
SBP (mmHg) 142.3 ± 12.4 130.9 ± 14.9 0.018 125.1 ± 13.4 0.007
DBP(mmHg) 82.6 ± 9.9 75.3 ± 10.0 0.062 71.4 ± 8.8 0.004
eGFR (ml/
min/1.73m2) 21.6 ± 11.4 24.1 ± 14.6 n.s. 22.4 ± 13.0 n.s.
LVMI (g/m2) 178.6 ± 59.7 n.d. 143.7± 40.2 0.047
EF (%) 0.60 ± 0.13 n.d. 0.64 ± 0.15 0.395
No adverse events were seen.
Conclusions: These findings suggest that liraglutide therapy for type 2 diabetes patients 
with renal impairment was safe and effective for decreasing glucose levels and blood 
pressure. Moreover it preserved renal function and improving left ventricular function.
FR-PO645
Do SGLT2 Inhibitors Affect GFR and Albuminuria in Diabetic Patients? 
A Systematic Review and Meta-Analysis  Lubin Xu, Yang Li, Peng Xia, 
Limeng Chen.  Dept of Nephrology, Peking Union Medical College Hospital.
Background: SGLT2 inhibitors are a new class of antihyperglycemic drugs that lower 
blood glucose levels by inhibiting renal reabsorption of glucose. SGLT2 inhibitors can have 
potential renoprotective capacities through modulation of tubuloglomerular feedback and 
alleviation of hyperfiltration. However, there are also concerns about deleterious effects 
on renal function caused by volume depletion.
Methods: We performed this systematic review and meta-analysis to assess the effects 
of SGLT2 inhibitors on estimated GFR (eGFR) and urinary albumin/creatinine ratio 
(ACR) in diabetic patients.We conducted a systemic search of Pubmed, Embase, Cochrane 
Central Register of Controlled Trials and Sinomed through April 2015 to identify published 
randomized double-blind controlled trials of SGLT2 inhibitors reporting renal outcomes. 
Two reviewers worked independently to extract data and assess the quanlity of included 
studies. Random effects model were used in data synthesis.
Results: We retrieved 2279 studies, 53 of which met the predefined criteria. Among 
included studies, 33 studies examined short-term effect with follow up less than 26 weeks, 
and 20 studies examined long-term effects with follow-up longer than 48 weeks. 4 studies 
included subjects with CKD 2-4. SGLT2 inhibitors did not cause statistically significant 
changes in eGFR (mean change,-0.19 ml/min/1.73m^2, 95% CI, -0.86 to 0.47) or in ACR 
(mean change, -23.76 mg/g, 95% CI, -66.75 to 19.23). 
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Subgroup analysis in CKD patients showed a trend of eGFR decrease (mean change: 
-1.20 ml/min/1.73m^2, 95% CI, -2.65 to 0.26) and trend of ACR reduction (mean change: 
-59.73 mg/g, 95% CI, -144.49 to 25.04), neither of which were statistically significant.
Conclusions: So far, there is not enough evidence of SGLT2 affecting glomerular 
filtration rate and albuminuria in diabetic patients.
Funding: Government Support - Non-U.S.
FR-PO646
Meglitinides Increase the Risk of Hypoglycemia in Diabetic Patients with 
Advanced Chronic Kidney Disease  Pei-chen Wu,1 Vincent Wu.2  1Internal 
Medicine, MacKay Memorial Hospital, Taipei, Taiwan; 2Internal Medicine, 
National Taiwan Univ Hospital, Taipei, Taiwan.
Background: There are few studies on the safety of short-acting meglitinides in 
diabetic patients with advanced chronic kidney disease (CKD). The aim of this study was 
to explore the risk of hypoglycemia in patients with severely impaired renal function taking 
meglitinides in comparison with that on other antidiabetic agents.
Methods: This was a nationwide cohort study using data from the Taiwan National 
Health Insurance Research Database. We included diabetic patients with advanced CKD 
who had a serum creatinine level of > 6 mg/dL (equivalent to an estimated glomerular 
filtration rate of < 15 ml/min/1.73m2) and a hematocrit level of ≤ 28% and received 
erythropoiesis-stimulating agent treatment between 2000 and 2010. Fresh users and nonusers 
of meglitinides were matched using propensity scoring, and the risk of hypoglycemia 
was analyzed using Cox proportional hazards models with end-stage renal disease and 
antidiabetic drugs as time-dependent variables.
Results: A total of 2,793 fresh users of meglitinide and 2,793 matched meglitinide 
nonusers were analyzed. Meglitinide use increased the risk of hypoglycemia (HR, 1.93; 
95% CI, 1.56-2.39), and so did sulfonylurea and insulin.
Variable Hazard Ratio (95% confidence interval) p-Value
Age (per year) 1.01 (1.01–1.02) 0.001
Male gender 1.20 (1.02–1.41) 0.028
Meglitinide 1.93 (1.56–2.39) <0.001
Sulfonylurea 1.94 (1.62–2.33) <0.001
Insulin 2.19 (1.86–2.59) <0.001
End-stage renal disease 0.53 (0.42–0.65) <0.001
Conclusions: The use of short-acting meglitinides is also associated with increased 
risk of hypoglycemia in diabetic patients with advanced CKD.
FR-PO647
Effects of Statins on Diabetic Kidney Disease in Patients with Type 2 
Diabetes  Ko Hanai, Tetsuya Babazono, Yasuko Uchigata.  Diabetes Center, 
Tokyo Women’s Medical Univ School of Medicine.
Background: Renoprotective properties of statins have received much attention; 
however, a recent large cohort study found no beneficial effect of statins on diabetic kidney 
disease (DKD). Furthermore, whether there are differences among statins in their effects on 
the kidneys remains unclear. Here, we compared effects of 4 statins on progression of DKD.
Methods: This was a single-center historical cohort study of Japanese adult ambulatory 
patients with type 2 diabetes. We studied 412 patients who were newly prescribed one of 
the following 4 statins: pravastatin, rosuvastatin, atorvastatin and pitavastatin, and who had 
estimated GFR (eGFR) ³30 mL/min/1.73 m2. As the control group, 946 patients without 
prescription history of statins were enrolled. Two outcomes were defined: 1) annual decline 
in eGFR and 2) progression to a more advanced stage of albuminuria. To adjust for the 
effects of confounding factors, we used the propensity score (PS) as the covariate. PS was 
estimated using a multinomial logistic regression model that included 18 clinical parameters. 
Furthermore, to take into account the varying number and spacing of eGFR measurements, 
and the variable follow-up period for each individual, we conducted the linear mixed-
effects model regression analysis. The intercept and slope were treated as random effects.
Results: During the median follow-up period of 5.3 years (range, 2.0–8.6 years), the 
adjusted eGFR decline (± standard error) in the control group (1.6 ± 0.1 mL/min/1.73 m2/
year) was significantly slower than that in rosuvastatin (2.4 ± 0.2, p=0.001), atorvastatin 
(2.6 ± 0.3, p<0.001) and pitavastatin group (2.3 ± 0.3, p=0.036), but not in pravastatin 
group (1.7 ± 0.2, p=0.780). Next, during the median follow-up period of 4.2 years (range, 
0.1–8.5 years), 138 patients showed progression of albuminuria stage. The adjusted 
hazard ratio (vs. control group) for the albuminuria progression was 0.85 (p=0.690), 0.86 
(p=0.679), 1.01 (p=0.980), and 0.69 (p=0.462) in pravastatin, rosuvastatin, atorvastatin 
and pitavastatin group, respectively.
Conclusions: Statins may have no beneficial effect on the progression of DKD. Instead, 
some statins are likely to be associated with faster renal function decline.
FR-PO648
Glucose Targets for Preventing Diabetic Kidney Disease and Its Progression: 
A Meta-Analysis  Marinella Ruospo,1,2 Valeria M. Saglimbene,1 Suetonia 
Palmer,3,4 Salvatore De Cosmo,5 Antonio Pacilli,5 Mariacristina Vecchio,6 
Jonathan C. Craig,4,7 Giovanni F.M. Strippoli.1,4,7,8  1Diaverum Medical 
Scientific 2ffice; 2Amedeo Avogadro Univ of Eastern Piedmont; 3Univ of Otago 
Christchurch; 4Cochrane Kidney and Transplant; 5Scientific Inst CSS; 6Danone 
Research; 7Univ of Sydney; 8Univ of Bari.
Background: Diabetes is the leading cause of end-stage kidney disease (ESKD). Blood 
pressure lowering and glucose control are considered central to protection of kidney function 
in diabetic nephropathy, however the optimal target range for blood glucose for preventing 
adverse kidney outcomes among adults with diabetes remains unclear. We evaluated the 
benefits and harms of intensive versus standard glycemic control for preventing the onset 
and progression of kidney disease.
Methods: Using standard Cochrane methods, we did a systematic review and meta-
analysis of randomized controlled trials that evaluated intensive versus standard glycemic 
control administered to adults and children with type 1 or type 2 diabetes with or at risk 
of kidney disease. Intensive glycemic control was defined by a treatment targeting an 
HbA1c below 7% or fasting glucose levels <120 mg/dL. Effect sizes were calculated 
using a random-effects model. Studies were critically appraised using Cochrane methods.
Results: 10 studies involving 28,885 participants were eligible for inclusion. In studies 
at low risks of bias, intensive glycemic control had uncertain effects on doubling of serum 
creatinine (0.71, CI 0.34-1.47) and end-stage kidney disease (1.21, CI 0.12-11.98). Tight 
glycemic control reduced the onset (0.82, CI 0.71-0.93) and progression (0.56, CI 0.36-
0.87) of microalbuminuria.  In absolute terms, treating 1000 patients with tight glycemic 
control for 1 year might prevent 7 experiencing new-onset albuminuria and 22 with 
worsening albuminuria.
Conclusions: Intensive glycemic control among adults with diabetes had very uncertain 
effects on developing of ESKD and progression of kidney failure, while providing small 
clinical benefits on the onset and progression of microalbuminuria.
FR-PO649
Patient Benefits and Cost Savings Predicted for Mineralocorticoid-Receptor 
Antagonist Treatment of Early and Advanced Diabetic Kidney Disease 
Michael Blankenburg,1 Henri J. Folse,2 Christina Nowack,3 Bastian Hass.1 
1Bayer Pharma AG, Berlin, Germany; 2Evidera, San Francisco, CA; 3Bayer 
Pharma AG, Wuppertal, Germany.
Background: Exploratory studies suggest that mineralocorticoid-receptor antagonists 
(MRAs) may improve outcomes in patients with diabetic kidney disease (DKD). Finerenone 
(BAY 94-8862) is a selective, potent and non-steroidal MRA for the treatment of patients 
with DKD and is currently being studied in two clinical phase III trials, “FIDELIO” and 
“FIGARO”.
Methods: A Markov cohort model was used to emulate disease history, treatment 
effects, and outcomes for DKD patients with various disease severities (by albuminuria, 
measured by urinary-albumin-creatinine ratio [UACR], and chronic kidney disease [CKD] 
stage, measured by estimated glomerular filtration rate [eGFR]). Efficacy of finerenone is 
accomplished by reducing albuminuria evidenced by phase 2 trial data. The model has US 
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settings and a 40-year time horizon. Inputs are from NHANES 1999-2008, USRDS 2009, 
various registries and trials. Sensitivity analyses explored which patient subpopulation 
would benefit to what extent from finerenone treatment.
Results: The model predicts that finerenone is an effective treatment option for DKD 
patients, primarily by virtue of reduced risk of end-stage renal disease (ESRD) and renal 
death (absolute risk reductions [ARR] of up to 9.7% and 9.3%, respectively, for advanced 
DKD, i.e. macro-albuminuria and CKD3/4) and increased health-related quality of life, and 
that it would generate cost savings on renal replacement therapy (up to $19,100 for advanced 
DKD). From a clinical outcomes perspective the optimal time point to begin finerenone 
treatment appears to be after patients have progressed to either macro-albuminuria or 
CKD stage 3, as represented by both phase III trial populations. Reduced CV events and 
CV mortality, however, are greatest (ARR of up to 3.8% and 4.5%, respectively) when 
finerenone treatment is started in early disease states, as represented by the phase 3 trial 
population “FIGARO”.
Conclusions: Treatment with the MRA finerenone appears to be of significant benefit 
to patients and the healthcare system, particularly if initiated in advanced stages of DKD.
Funding: Pharmaceutical Company Support - Bayer Pharma AG
FR-PO650
Independent Association of Systolic Blood Pressure and Hemoglobin A1c 
Levels on Clinical Outcomes in Diabetic Patients with Normal Kidney 
Function  Aidar Gosmanov,1 Jun Ling Lu,1 Miklos Zsolt Molnar,1 Keiichi 
Sumida,1 Praveen Kumar Potukuchi,1 Kamyar Kalantar-Zadeh,2 Csaba P. 
Kovesdy.1,3  1Univ of Tennessee Health Science Center, Memphis, TN; 2Univ of 
California, Irvine, CA; 3VA Medical Center, Memphis, TN.
Background: Systolic blood pressure (SBP) goal of <140mmHg is recommended 
for majority of patients with diabetes mellitus (DM). It is however unknown if glycemic 
control modifies the association of uncontrolled hypertension (HTN) with mortality and 
morbidity in DM patients.
Methods: We examined 894,661 US veterans with DM and baseline eGFR >60 
ml/min/1.73m2 (mean age 66.6±10.9 years, 97% males, 17% African-Americans). The 
association of mutually exclusive combined categories of hemoglobin A1c (A1c; <6.5, 
6.5-6.9, 7.0-7.9, 8.0-8.9, 9.0-9.9, and ³10%) and SBP (<120, 120-139, 140-159, 160-179, 
and ³180mmHg) with the risk of all-cause mortality, incident CKD, coronary heart disease 
(CHD), and stroke was examined in Cox models adjusted for baseline characteristics, 
statin use, and co-morbidities, using patients with A1c 6.5-6.9% and SBP of 120-139 
mmHg as referent.
Results: A total of 221,983 (25%) patients died, and 178,628 (20%), 43,374 (5%) and 
36,936 (4%) developed incident CKD, CHD and stroke, respectively, during a median 
follow up of 7.4 years. SBP displayed a U-shaped association with mortality in each A1c 
category. Conversely, SBP >120-139 mmHg was associated with a monotonous increase in 
the risk of CKD, CHD and stroke in all A1c categories. A1c levels were linearly associated 
with worse outcomes for all end points and in all SBP categories. 
Conclusions: SBP above 120-139 mmHg and higher A1c levels were associated 
with higher mortality and morbidity in diabetic patients, independent of each other. Tight 
glycemic control may reduce mortality and morbidity across all SBP categories in patients 
with normal kidney function.
Funding: NIDDK Support, Veterans Administration Support
FR-PO651
High Acid Diets Increase Urinary Nitrogen Excretion and May Decrease 
Muscle Mass in Obese Diabetics  Lynda A. Frassetto, Umesh Masharani, 
Anthony Sebastian.  UCSF, San Francisco, CA.
Background: We have previously shown that decreasing dietary acid loads with 
bicarbonate supplements lowers urinary nitrogen (N) excretion in postmenopausal women. 
Here we examined whether we could lower urinary N excretion in obese diabetics by 
increasing plant food intake (“Paleo diet”) compared with a “usual” acid diet (America 
Diabetes Association diet).
Methods: 12 obese well controlled type 2 diabetics (7 Paleo, 5 ADA) were enrolled 
in a 21 day no-weight loss controlled metabolic diet study. Daily protein intake per 2500 
kcal averaged 116 g on the Paleo and 127 g on the ADA diets (p=0.7). Fasting arterialized 
blood and 24-hour urine samples were collected at baseline (pre, days -2 to 0) and the 
last 3 diet days (on, +19 to 21). Each subject’s tests were averaged by period, and the 
group averages analyzed by one-way ANOVA and between groups by t-test. Urinary N 
excretion was adjusted per 70 kg. Body composition [total (T), fat free mass (FFM), kg] 
was measured by bioimpedance (BIS).
Results: mean±SD. ADA or Paleo pre-on; a, p<0.05; ∆ Paleo vs ∆ ADA: b, p<0.1; 
c, p<0.05; d, p<0.01. 
Index Test ADA pre ADA on Paleo pre Paleo on Δ Paleo vs Δ ADA
BIS T 108±37 106±36 92±18 90±18 -0.2±1.0
FFM 74.5±26.7 73.4±26.0a 58.2±14.0 57.6±15.7 -0.6±1.4
Urine Cr N, g/d 0.44±0.13 0.46±0.13 0.46±0.15 0.44±0.11 -0.44±0.83
Cr CL 
mL/min 168±68 173±80 160±70 145±37 -20±40
Urea N, 
g/d 9.5±3.6 11.2±2.6 10.8±5.7 8.8±4.1 -3.7±2.9
c
Urea CL 
mL/min 57±20 70±29 59±19 52±17 -20±15
c
NH4 N, 
g/d 0.42±0.10 0.47±0.12 0.43±0.22 0.20±0.06
a -0.28±0.07d
Total N, 
g/d 10.0±3.6 11.7±2.6 11.3±5.9 9.3±4.2 -2.3±1.5
b
NAE 
meq/d 118±47 112±52 92±34 31±24
a -55±50b
Both groups had equally modest nonsignificant declines in weight.
Conclusions: The higher acid diet had significantly greater loss of fat free mass 
associated with a greater loss of urinary urea and ammonium. A plant based low acid 
weight loss diet may be better in maintaining lean body mass compared to a usual acid diet.
Funding: Clinical Revenue Support
FR-PO652
Clinical Benefit of Pre-Dilution On-Line Hemodiafiltration for Removal 
of Low-Molecular-Weight Proteins and Fibroblast Growth Factor-23 
Kenji Sakurai,1 Takeshi Saito,1 Fumi Yamauchi,1 Hiromi Hosoya,1 Yoshitaka 
Kurihara,1 Daisuke Ishii,2 Kazunari Yoshida,3 Kenichi Kokubo,4 Akihiro C. 
Yamashita.5  1Hashimoto Clinic, Kanagawa, Japan; 2Urology, Kitasato Univ, 
Kanagawa, Japan; 3Organ Transplant Medicine, Kitasato Univ, Kanagawa, 
Japan; 4Medical Engineering and Technology, Kitasato Univ, Kanagawa, Japan; 
5Chemical Science and Technology, Hosei Univ, Tokyo, Japan.
Background: Increased concentration of fibroblast growth factor 23 (FGF-23) is 
reportedly associated with increased risk of cardiovascular complication and mortality 
in dialysis patients. Therefore, there is a possibility that reduction of FGF-23 levels may 
improve prognosis of dialysis patients with elevated its levels. We compared the removal 
performance of low-molecular-weight proteins (LMWP) and FGF-23 between pre-dilution 
on-line hemodiafiltration (HDF) and hemodialysis (HD) with super high-flux dialyzer.
Methods: The study involved 31 patients (15:HDF, 16:HD, 4 hrs, Qd:600 mL/min). 
Blood flow rates were 284±20 for HDF, 281±14 mL/min for HD. Replacement fluid volume 
in HDF was 49.2±9.9 L/session. Removal rates (RR,%) and removal amounts (RA,mg) of 
urea nitrogen (UN), creatinine, β2-microglobulin (β2-M, MW:11.8kDa), α1-microglobulin 
(α1-M, 33kDA) and FGF-23 (32kDa) were examined. We followed the changes in FGF-23 
levels of patients for 4 month period.
Results: Kt/V, RRs of UN and creatinine were significantly higher in HD than in HDF, 
whereas RRs and RAs of β2-M, α1-M, and FGF-23 were significantly higher in HDF. RRs 
of β2-M and α1-M were 80.3±3.7 and 42.0±6.1 for HDF, 73.5±4.1 and 25.0±6.8 for HD, 
respectively. RR and RA of FGF-23 were 66.9±6.5 for HDF, 51.1±8.3 for HD and 0.11±0.01 
for HDF, 0.01±0.01 for HD, respectively.
Conclusions: The results confirmed that HDF was superior to HD in removing LMWP 
and FGF-23, which are removed mainly by convection. The convection volume can be much 
easily controlled in HDF than in HD that utilizes internal filtration. The RRs of FGF-23 
were 24 points higher than those of α1-MG in both modes despite the small difference in 
MW, suggesting that distribution volume of FGF-23 was smaller than that of α1-MG. No 
clear tendency was detected in changes of FGF-23 during 4-month observation period.
FR-PO653
Comparison of Removal Performance of Small- to Large-Molecular-
Weight Substances Between Pre-Dilution On-Line Hemodiafiltration 
and Hemodialysis with Super-High-Flux Dialyzer  Kenji Sakurai,1 Takeshi 
Saito,1 Fumi Yamauchi,1 Hiromi Hosoya,1 Yoshitaka Kurihara,1 Daisuke Ishii.2 
1Hashimoto Clinic, Sagamihara Kanagwa, Japan; 2Urology, Kitasato Univ, 
Sagamihara Kanagwa, Japan.
Background: In pre-dilution on-line hemodiafiltration (HDF), net dialysate flow 
rate is reduced, because replacement fluid accounts for 30 to 50% of total dialysate flow 
(Qdtotal). Therefore, removal efficiency of small-molecular-weight substances by diffusion 
is reduced, whereas that of low-molecular-weight proteins (LMWPs) by convection is 
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improved. In hemodialysis (HD) using super high flux dialyzer, the increased blood flow 
rate (Qb) increases amount of internal filtration, thereby improving the removal efficiency 
of LMWPs. In this study, we compared the removal efficiency of small- to large-molecular-
weight substances between HDF and HD to verify the superiority of HDF.
Methods: The study involved 62 patients (31: HD, 31: HDF). Super high flux dialyzers 
for HD and high-performance hemodiafilters for HDF were used. Qd was 500 for HD and 
Qdtotal was 600 mL/min for HDF. Replacement fluid volume for HDF was 44.4 ± 10.0 L/
session. Qb was 256 ± 23, 257 ± 25 mL/min and Treatment time was 4.1 ± 0.2, 4.0 ± 0.1 hours 
in HD and HDF, respectively. Removal rates (RR) of b2-microglobulin(b2-M;11.8kDa), 
prolactin(PRL;23kDa), α1-microglobulin(a1-M;33kDa) and a1-acid glycoprotein(a1-
AGP;44.1kDa) were investigated. Kt/V for urea and plasma clearances (CL) of b2-M, 
PRL and a1-M were measured.
Results: RR (%) of each substance was significantly higher in HDF than in HD (P < 
0.001): b2-M,79.8 ± 3.2 vs. 70.8 ± 4.7; PRL, 75.3 ± 5.5 vs. 66.2 ± 6.6; a1-M, 40.0 ± 4.1 
vs. 31.5 ± 6.4; a1-AGP, 11.9 ± 4.3 vs. 7.4 ± 4.8. Kt/V was 1.56 ± 0.22 (HDF) and 1.51 ± 
0.19 (HD). Plasma CLs (mL/min) of b2-M were 95.7 ± 3.6 and 73.6 ± 3.7, those of PRL 
were 37.3 ± 4.3 and 28.1 ± 5.5 in HDF and HD, respectively.
Conclusions: The performance of HDF in removing LMWPs was superior to that of 
HD and there was no significant difference in Kt/V in both modes. An increased convection 
by HDF greatly contributed to improved removal of LMWPs and appropriate control of 
dialysate flow rate improved the removal efficiency for small molecular substances to the 
level achieved by HD.
Funding: Private Foundation Support
FR-PO654
The Effect of Increasing Kt/Vurea in the HEMO Study on Levels of Non-
Urea Solutes  Timothy W. Meyer,1 Tammy L. Sirich,1 Tariq Shafi,2 Tanushree 
Banerjee,3 Neil R. Powe,3 Thomas H. Hostetter.4  1Med, Stanford, CA; 2Med, 
Johns Hopkins, MD; 3Med, UCSF, CA; 4Med, Case Western, OH.
Background: In the HEMO study, outcomes were no better in patients randomized to 
“high dose” thrice weekly hemodialysis providing spKt/Vurea 1.73 than in those randomized 
to “standard” hemodialysis providing spKt/Vurea 1.32.
Methods: This study assessed whether “high-dose” treatment lowered levels of non-
urea solutes. Solutes were measured by LC/MS/MS in plasma samples obtained at least 3 
months after randomization in 1281 HEMO subjects.
Results: (mean±sd; CI, confidence interval).
Solute standard high-dose % change (95% CI) p value
Trimethylamine oxide µM 107±63 97±65 – 9 (–15, –2) 0.007
Phenylacetylglutamine mg/dl 4.6±3.1 4.3±2.6 – 7 (–13, –0) 0.04
Symmetric dimethylarginine µM 4.3±1.4 4.2±1.3 – 4 (–7, –1) 0.018
Asymmetric dimethylarginine µM 0.92±0.24 0.93±0.23 – 1 (–2, 3) 0.74
p-Cresol Sulfate mg/dl 3.3±1.7 3.4±1.7 + 2 (–4, 8) 0.46
Increasing Kt/Vurea caused statistically significant but only modest reductions in the 
levels of trimethylamine oxide, phenylacetylglutamine, and symmetric dimethylarginine. 
Mathematical modeling showed that limited reduction in the levels of these solutes was 
a predictable consequence of the intermittency of treatment. Their reduction ratios with 
standard treatment are high and the increased intensity of treatment reflected by a 30% 
increase in Kt/Vurea in HEMO’s high dose arm could not remove much more solute. 
Remarkably, increasing Kt/Vurea in HEMO caused no reduction in the levels of asymmetric 
dimethylarginine or p-cresol sulfate, two solutes which have been associated with 
cardiovascular disease in dialysis patients. Modeling showed that stability of their plasma 
levels could be accounted for by increased solute production accompanying the increase 
in Kt/Vurea and/or the presence of non-dialytic clearance.
Conclusions: Levels of non-urea solutes may fall only slightly or not at all when Kt/
Vurea is increased above standard levels for thrice weekly treatment. Treatments that are more 
effective in reducing solute levels may be required to improve outcomes.
Funding: NIDDK Support, Veterans Administration Support
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Improved Protein-Bound Uremic Toxins Dialytic Removal with Use of 
Albumin Binding Competitors: An In Vitro Human Whole Blood Study 
Xia Tao,1 Stephan Thijssen,2 Peter Kotanko,2 Chih-Hu Ho,3 Michael E. Henrie,3 
Eric W. Stroup,3 Garry J. Handelman.1  1Univ of Massachusetts, Lowell, MA; 
2Renal Research Inst, NY, NY; 3Fresenius Medical Care, Ogden, UT.
Background: Protein-bound uremic toxins (PBUT) are intensively studied retained 
solutes that accumulate in chronic kidney disease patients. Efficient removal of PBUTs 
by hemodialysis (HD) is difficult because of limited free fraction in blood. We propose an 
innovative method for improving the dialytic removal of PBUTs by increasing their free 
fractions with use of protein binding competitors.
Methods: The binding properties of indoxyl sulfate (IS), indole-3-acetic acid (IAA) 
and hippuric acid (HIPA), and their binding competitors, ibuprofen (IBU), furosemide 
(FUR) and tryptophan (TRP) were studied by rapid equilibrium dialysis (RED) to select 
suitable model compounds for the HD study. The method was then tested in an in vitro 
HD experimental model with human whole blood spiked with PBUTs. After 10 min 
baseline test, the binding competitors were introduced upstream of dialyzer blood inlet. 
The removal of uremic toxins was estimated as the amount leaving dialysate outlet relative 
to the amount entering blood inlet.
Results: The infusion of IBU and FUR mixture (647µmole/l and 126µmole/l in 
blood, respectively) in the HD model increased removal of IS from 6.3 ± 0.1 to 15.2 ± 0.3 
% (mean ± SEM) (2.4-fold) and IAA removal from 15.9 ± 0.2 to 29.8 ± 0.6% (1.9-fold). 
TRP (1mmole/l in plasma) infusion increased the removal of IS and IAA to 9.4 ± 0.1% 
and 26.0 ± 0.3% (1.4- and 1.3-fold, respectively). Only moderate effects were observed 
in the change of HIPA removal. 
Conclusions: This method increases the removal of PBUTs and has no effect on non-
protein-bound solutes. Achieving higher dialytic removal of PBUTs by infusion of binding 
competitors is feasible and efficient to apply in current HD settings.
Funding: Pharmaceutical Company Support - Renal Research Institute
FR-PO656
Variable Recovery Time After Hemodialysis Treatment  Antonia Harford,1 
Susan Paine,2 Ronald Schrader,2 Ambreen Gul,2 Dana Miskulin,3 Philip Zager.1,2 
1UNM; 2DCI; 3Tufts.
Background: Prolonged recovery time after hemodialysis (HD) may predict adverse 
clinical outcomes. In the Frequent Hemodialysis Network a patient’s response to the 
Recovery Question was consistent over time. To determine if this consistency is also present 
among patients undergoing thrice weekly HD we compared responses to the Recovery 
Question after each treatment in a given week.
Methods: We asked 256 patients in 3 DCI HD facilities “How long did it take you to 
recover after your last treatment?” The number of patients who answered the question on 
the 1st, 2nd, and 3rd treatment was 221, 207, and 200, respectively; 148 patients (57.8%) 
answered the question on all 3 occasions. Recovery time was categorized as <0.5 hours(h), 
³0.5 h -< 6 h, and ≥ 6 h.
Results: Among the 148 patients who answered the Recovery Question 3 times, 
recovery times were 6.9, 4.5 and 9.3 hours after the 1st, 2nd, and 3rd HD. There were 
46% of patients who had consistent responses on all 3 treatments; 16%, 15% and 15%, had 
consistently short (<0.5h), moderate (0.5-<6h) and long (≥ 6h) recovery times, respectively. 
There were 64% who had similar recovery times on the 1st vs.2nd and 1st vs. 3rd HD of 
the week. Only 57% had consistent recovery times on 2nd and 3rd treatments.
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Among the patients with consistent short vs. long recovery, there were no differences 
in age, race, and vintage. There was a trend for women (59%) to be more likely to have 
recovery ≥ 6h vs. men (33%) (p=0.09). After the 1st dialysis of the week, recovery was 
more likely (40%) to be ≥ 6h among patients dialyzed with a dialysate sodium concentration 
(DNa) <140 mEq/L vs. with a (DNa) ≥ 140 mEq/L (22%). However, similar differences 
were not observed for the 2nd and 3rd treatments.
Conclusions: There is significant variability among individual patients answers during 
the week when the recovery question is asked after each treatment.
FR-PO657
Quality Control and Improvement Union of Hemodialysis Centers: A New 
Management Model  Liangying Gan, Mei Wang.  Dept of Nephrology, Peking 
Univ People’s Hospital, Beijing, China.
Background: With the increasing incidence of end stage renal disease (ESRD) in China, 
more dialysis facilities are needed. There are huge variations of patient care staffing levels 
and quality of care. How to maximize the utilization of existing health resources, optimize 
the management of hemodialysis patients and improve quality control are important issues. 
The aim of this study was to investigate the feasibility and effects of quality control and 
improvement union comprised of best hospitals and basic hospitals on patients’ medical 
quality control and improvement.
Methods: The HD union was constructed and specific measures was determined 
including, 1) Quarterly continuous quality improvement (CQI) meetings, 2) education 
based on typical cases including extensive discussions, guidelines and latest research 
results introductions, 3)lectures focusing on key questions, 4) opening green channel and 
construction of two-way referral system. Paired t-test was used to compare the differences 
of medical parameters of each hemodialysis center before and two-years after construction 
of HD union.
Results: The leading center of HD union was the HD center from Peking University 
People’s Hospital. Cooperating centers were other eight centers from class three and class 
two hospitals. After quarterly CQI meetings, all union members learned how to do medical 
quality control and improvement, constructed standards and procedures for diagnosis, cure 
and nursing of their HD center, established the institutions of lab exam and regular round 
frequency, added necessary examinations and implemented all-around management of 
HD patients. Green channel for intractable cases transfer were applied successfully. There 
were statistical improvements of medical quality including dialysis frequency, hemoglobin, 
calcium, phosphorus, and metabolic acidosis control. Other parameters including Kt/V, 
iPTH, albumin and Bp improved but without significant difference.
Conclusions: Quality control and improvement union of hemodialysis centers is an 
effective integrated management model in Beijing China. It can improve medical quality 
of basic hospitals by balancing the technical advantages of grade A class three hospitals 
and basic hospitals.
Funding: Government Support - Non-U.S.
FR-PO658
Feasibility of Mindfulness Meditation Training During Dialysis for Patients 
with Chronic Kidney Disease and Effect on Tolerability of Sessions 
James C. Wasserman,1 Daniel Schupack,2,3 Andrew E. Williams,4 Paul K. Han,2,3 
George K. Dreher,3 Mary Bitterauf.5  1Div of Nephrology, Maine Medical Center, 
Portland, ME; 2Center for Outcomes Research and Evaluation, Portland, ME; 
3Maine Medical Center, Portland, ME; 4Maine Medical Center Research Inst, 
Portland, ME; 5MaineHealth, Falmouth, ME.
Background: Hemodialysis (HD) for CKD entails >/= 12 h of weekly treatment, 
creating significant distress for patients. Mindfulness-Based Stress Reduction (MBSR) 
has effectively helped patients with other chronic diseases cope with distressing symptoms 
and treatments. An abbreviated form of MBSR (Mindfulness Meditation Training, MMT) 
was incorporated into HD sessions to explore its feasibility, acceptability and potential 
effectiveness.
Methods: 12 patients were randomly assigned to MMT during HD or usual care. The 
MMT group underwent weekly 1-h individual sessions during HD for 4 wk. Within-session 
change in affective response was assessed with the Self-Assessment Manikin, a validated 
measure of affective valance, arousal and dominance. Anxiety, depression, self-rated health 
and coping skills were also assessed with validated measures. Patient perceptions were 
assessed with qualitative interviews at study’s end.
Results: In qualitative interviews, patients reported improved tolerability of HD 
session length, positive intention to continue meditation and no significant issues with 
MMT sessions or home practice. There were no significant between-group differences in 
affective response, anxiety, depression, self-reported health or coping skills at baseline or 
in change over time. Retention rate was 91.7% overall and 83.3% for the MMT group.
Conclusions: MMT appears to be a feasible and acceptable intervention for CKD 
patients during HD, although effectiveness remains to be demonstrated. Small sample size 
and low baseline distress levels in the study population likely limited the power to establish 
effects of MMT. Further research is needed to determine if abbreviated MBSR is sufficient 
to benefit tolerability of HD in this population. Focus on patients with higher baseline 
distress levels in future research would increase the likelihood of observing clinical benefit.
FR-PO659
Fluid Management Parameters Are Associated with Dialysis Recovery 
Time in Conventional Hemodialysis  Wael F. Hussein,1,2 Rohini Arramreddy,1,2 
Marc Reiterman,2 Sumi J. Sun,2 Brigitte Schiller.1,2  1Dept of Medicine, Div of 
Nephrology, Stanford Univ, Palo Alto, CA; 2Satellite Healthcare, San Jose, CA.
Background: Longer dialysis recovery time (DRT) is associated with increased 
mortality and shorter time to hospitalization. We studied the association of fluid management 
and hemodynamics with recovery time in conventional hemodialysis (HD) patients.
Methods: Self-reported DRT, obtained by asking “How long does it take you to recover 
from a dialysis session?”, was recorded for 2,689 patients undergoing thrice weekly adequate 
HD in 46 centers in 3 states. Ordinal logistic regression was used to study the association 
between patient and dialysis characteristics with DRT. Statistical adjustments were made 
for patient demographics, comorbidities and body weight.
Results: Forty-three percent of patients were female, 20% were black, median age 
and vintage were 63 and 3.3 years, median dialysis session length was 203 min (IQR: 
180-220). DRT in categories of immediate recovery, >0 to ≤ 2 hours (hrs), > 2 to ≤ 6 hrs, 
> 6 to ≤ 12 hrs, and > 12 hours, were reported in 27%, 28%, 17%, 9%, and 20% of the 
patients respectively. In multivariable analysis, longer DRT was associated with female 
gender, non-black race, lower serum albumin, chronic heart failure, cerebrovascular 
disease, missed dialysis sessions, higher pre-dialysis systolic blood pressure and larger 
UF volume. Ultrafiltration rates (UFR) were divided into three categories: <10, 10 to <13, 
and ³13 ml/kg/hr. Compared to the lowest UFR category, UFR ³13 ml/kg/hr was associated 
with longer DRT; OR of 1.16 (95% CI 0.99 – 1.36) and 1.28 (95% CI 1.06 – 1.54) in the 
unadjusted and the adjusted analyses respectively. IDH was associated with longer DRT 
in the unadjusted (per 10% higher frequency, OR 1.04 [95% CI 0.01 – 1.07]) and adjusted 
analyses (OR 1.03 [95% CI 1.00 – 1.07]).
Conclusions: Long DRT affects a large proportion of HD patients. Optimizing UFR 
and controlling IDH are critical measures to improve quality of life for these patients.
FR-PO660
Different Adsorptive Properties of Hemodialysis Membranes May Cause 
Selective Depletion of Plasma Proteins  Jan Mares, Lukas Kielberger. 
Nephrology, Charles Univ, Plzen, Czech Republic.
Background: During hemodialysis (HD) session, plasma proteins are adsorbed to 
the surface of HD membrane. The resulting biofilm affects both dialyzer permeability 
and biocompatibility. The aim of this study was to analyze its composition in different 
HD membranes.
Methods: Twelve long-term HD patients were assigned to 4h HD with three different 
dialyzers in a cross-over design: ethylene-vinyl-alcohol/EVAL (KF-201-1.8C, Asahi 
Kasei), polysulfone (F8 HPS, Fresenius), and vitamin E-substituted polysulfone (ViE-18, 
Asahi Kasei). After HD session, the biofilm was eluted with acetic acid. Obtained proteins 
(200 µg) were separated by 2-dimensional electrophoresis and fractions showing distinct 
abundance across groups were identified by tandem mass spectrometry. Blood was sampled 
along the session to enable subsequent confirmatory studies (ELISA). Data are given as 
means ± SEM, statistical significance was calculated by ANOVA (general linear model).
Results: The amount of protein eluted from KF dialyzers was higher than from F8 or 
ViE: 42±9.6, 9±3.3, and 12±6.9 mg, (p<0.001), respectively. Totally, 303 protein fractions 
were detected, 235 common to all eluates. In 48 fractions, spot intensities varied between 
groups suggesting different adsorption (p<0.05). Among them, 11 individual plasma proteins 
were identified: mannose-binding lectin associated serum protease 1 (MASP1 p=0.012), 
clusterin (p=0.003), retinol-binding protein 4 (RBP4, p=0.018), α1-microglobulin (AMBP, 
p<0.001), complement factor H (CFH, p=0.004) and its related proteins 1, 2, 5 (FHR, 
p<0.001), fibrinogen β, γ (p<0.001), and ficolin-2 (FCN2, p<0.001). EVAL membrane 
bound less FCN2, MASP1, and clusterin but more AMBP, CFH, and FHRs than polysulfone 
membranes. The most prominent difference was established in FCN2, it was therefore 
selected for a confirmatory study. It showed a sustained decline of plasma FCN2 levels at 
all timepoints during HD with F8 but not KF dialyzer to 40±3.6% and 111±5.3% of pre-
dialysis levels, respectively (p<0.001).
Conclusions: Different HD membranes show variable binding characteristics for 
particular plasma proteins. It can be responsible for their increased clearance and temporary 
depletion as demonstrated in case of ficolin-2.
Funding: Government Support - Non-U.S.
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FR-PO661
Mathematical Model of Protein Transport and Plasma Refilling in 
Hemodialysis  Bengt Lindholm,1 Mauro Pietribiasi,2 Malgorzata Debowska,2 
Alicja Wojcik-Zaluska,3 Wojciech T. Zaluska,4 Jacek Waniewski.2  1Baxter 
Novum & Renal Medicine, Karolinska Inst, Stockholm, Sweden; 2Inst 
Biocybernetics & Biomedical Engineering, Warsaw, Poland; 3Rehabilitation 
and Physiotherapy, Medical Univ Lublin, Lublin, Poland; 4Nephrology, Medical 
Univ Lublin, Lublin, Poland.
Background: Mathematical modeling offers a way to estimate quantities we cannot 
access directly during hemodialysis (HD). Here we propose a whole-body model of vascular 
refilling describing water and protein shifts across the capillary membrane during HD. 
The model was applied to reproduce profiles of plasma volume and serum total protein 
concentration in patients (pts) undergoing HD.
Methods: The double-pool model (vascular and interstitial space) was based on balance 
equations of protein mass and water volume in each compartment. The net transport across 
the capillary wall is the sum of the flow through the membrane’s pores and lymphatic flow. 
The capillary membrane is described according to the three-pore theory. Two transport 
parameters of the model, the relative number of large pores (αLP) and the total permeability 
surface area product (LpS) of the capillary membrane, were estimated from volumetric 
data and blood samples collected in 20 stable, non-diabetic pts during 60 HD sessions.
Results: LpS and αLP were estimated to 10.0 ± 8.4 mL/min/mmHg and 0.062 ± 0.041. 
The model predicted profiles of plasma volume and serum total protein concentration with 
an average rootmean-square error < 2%, with larger errors only in pts with very high initial 
drop in blood volume. When increasing the assumed value of interstitial/serum protein 
ratio from 0.3 to 0.6, while the total refilling rate remained similar, the value of individual 
pore flows changed so that filtration through large pores at its peak was 40 % smaller 
and absorption through small and ultrasmall pores was 80 and 60 % higher, respectively.
Conclusions: The model proposes a mechanistic interpretation of fluid transport 
processes induced by ultrafiltration during HD. The estimated values of individual flows 
through each kind of pore and lymphatic absorption represent the relative impact of these 
not-measurable quantities on total vascular refilling.
Funding: Pharmaceutical Company Support - Baxter Healthcare, Government 
Support - Non-U.S.
FR-PO662
Hemodiafiltration at Increased Plasma Ionic Strength for Improved Protein-
Bound Toxin Removal  Detlef H. Krieter,1 Eric Devine,2 Thomas Koerner,1 
Marieke Rueth,2 Christoph Wanner,1 Joachim Jankowski,3 Horst-Dieter Lemke.2 
1Nephrology, Univ Hospital Würzburg, Würzburg, Germany; 2eXcorLab GmbH, 
Obernburg, Germany; 3Inst of Molecular Cardiovascular Research, Univ 
Hospital RWTH Aachen, Aachen, Germany.
Background: Protein-bound uremic toxin (PBT) removal by hemodialysis (HD) is 
limited resulting in dialysis associated cardiovascular morbidity. Enhancing ionic strength 
in the dialyzer decreases protein binding and may result in a larger unbound and removable 
toxin fraction. This was implemented through high sodium concentration ([Na+]) in the 
substituate of predilution hemodiafiltration (HDFmod).
Methods: Ex vivo predilution HDF with blood tested increasing [Na+] to demonstrate 
efficacy and hemocompatibility. Hemocompatibility was further assessed in sheep using 
two different HDFmod setups and [Na+] between 350 and 600 mmol/L. Safety and efficacy 
of para-cresyl sulfate (pCS) and indoxyl sulfate (IS) removal was further investigated in a 
randomized clinical pilot trial comparing HDFmod to HD and standard HDF.
Results: Compared to physiological [Na+], ex vivo HDFmod at [Na+] of 500 mmol/L 
demonstrated up to 50 % higher IS removal. Hemolysis in sheep was low even at [Na+] of 
600 mmol/L, not exceeding 0.016 ± 0.001 g/dL of free Hb. In patients, the reduction ratio 
of free IS was 20 % higher in HDFmod at [Na+] of 240 mmol/L compared to HD (72.6 ± 
6.1 vs. 60.4 ± 16.5 %; P=0.026). Compared to HD and HDF (23.0 ± 14.8 and 25.4 ± 10.5 
mL/min, resp.), the dialytic clearance of free IS was 37 and 24 % higher in HDFmod (31.6 
± 12.8 mL/min; P=0.017), but [Na+] significantly increased over time (arterial plasma at 
0 min and 240 min; 132 ± 2 vs. 136 ± 3 mmol/L; P<0.001).
Conclusions: Ionic strength modification with HDF is technically feasible, enhancing 
PBT removal without adverse effects. More effective HDFmod will require higher temporary 
[Na+] in blood, but accumulation of [Na+] has to be avoided.
Funding: Government Support - Non-U.S.
FR-PO663
A Filter Placed Along the Path of the Water Treatment System Can Reduce 
Inflammation in Patients on Chronic Dialysis  Elena Mancini,1 Annunziata 
Tartaglione,2 Emanuele Mambelli,1 Paolo Gaibani,2 Annalisa Boneschi,1 
Raffaele Longo,1 Maria paola Landini,2 Antonio Santoro.1  1Nephrology 
Dialysis Hypertension, Policlinico S.Orsola-Malpighi, Bologna, Italy; 2Inst of 
Microbiology, Policlinico S.Orsola-Malpighi, Bologna, Italy.
Background: Contamination of dialysisfluids is one of the most important etiologic 
factors of chronic inflammation in HD patients, leading to malnutrition/atherosclerosis. 
Besides intact bacteria and endotoxins, bacterial DNA fragments have to be considered, 
because, due to their small size, they pass through the most sophisticated water treatment 
systems.
Methods: We have evaluated the effect on the water quality and patient inflammation 
of a new ultraphilter placed on the water circuit before the dialysis machine. The filter, 
with peculiar characteristics (DSU, Nephros Inc, River Edge, NJ), was applied to all the 
dialysis seats (n=34; 130 patients) in our Centre (Study period, S). At baseline, during S, and 
the 3 following months without ultrafilter (control period, C), apart from routine controls, 
every month we performed both conventional microbiological analyses and bacterial DNA 
fragment research in the dialysate and in the patients.
Results: Conventional microbiological analyses proved negative at every phase of the 
study, while the search for bacterial DNA was positive in 8/34 samples at baseline (219 
genomic copies/reaction). At the end of S, no dialysate sample was still positive (0.029 
genomic copies/reaction; p=0.04 sign test). During the following period C, dialysate samples 
became once again positives. A similar trend was observed in the patient plasma: 113.5 
copies/reaction at baseline, 19.9 at the end of S, 84.8 at the end of C (p=0.013). C reactive 
protein measured in each patient was significantly reduced during S (p=0.04).
Conclusions: In conclusion, the traditional treatment did not prevent the appearance 
of bacterial DNA fragments in dialysis fluids. This can foster the onset of inflammation. 
The ultraphilter tested actually improved the purity of the water and its regular use seems 
to reduce microinflammation. This could, in turn, have repercussions on different aspects 
such as resistance to erythropoietin as well as the processes of precocious atherosclerosis.
Funding: Clinical Revenue Support
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Effect of Computationally-Optimized Vibration on Clearance of Solutes 
During In Vitro Hemodialysis  Katherine N. Gharibian,1 Susan J. Lewis,1 
Joseph L. Bull,2 John J. Pitre,2 Bridget A. Scoville,3 Thomas Velenosi,4 Brad 
Urquhart,4 Noel Perkins,5 Bruce A. Mueller.1  1College of Pharmacy, Univ of 
Michigan, Ann Arbor, MI; 2Dept of Biomedical Engineering, Univ of Michigan, 
Ann Arbor, MI; 3Saint Alexius Medical Center, Hoffman Estates, IL; 4Dept of 
Physiology and Pharmacology, Western Univ, London, ON; 5Dept of Mechanical 
Engineering, Univ of Michigan, Ann Arbor, MI.
Background: Our previous in vitro studies demonstrated that the addition of vibration 
enhances dialytic clearance of solutes by a median of 18% during CVVHD. In this study, we 
applied computational fluid dynamics to determine vibration’s effects during hemodialysis 
and validated them using an in vitro hemodialysis model.
Methods: Based on predictions of a computational fluid dynamics model, two 
vibration settings (120 Hz/0.176 mm & 360 Hz/0.0765 mm) were selected and applied to 
a F8 dialyzer (1.8 m2; Fresenius) during in vitro hemodialysis using blood/dialysate flow 
rates of 300/600 mL/min, respectively. Mean transmembrane clearances were analyzed 
for six solutes: urea, creatinine, gentamicin, vancomycin, indoxyl sulfate, and hippuric 
acid. Albumin, free hemoglobin, and LDH concentrations were measured after 4 hours of 
dialysis with applied vibration to assess blood and dialyzer integrity.
Results: A one-way ANOVA yielded no significant difference between the control 
group and non-control vibration groups in solute clearance: urea, F(2,27)=1.801, p=0.184; 
creatinine, F(2,27)=2.525, p=0.099; gentamicin, F(2,33)=0.273, p=0.763; vancomycin, 
F(2,33)=0.003, p=0.997; indoxyl sulfate, F(2,33)=0.390, p=0.680; hippuric acid, 
F(2,33)=0.398, p=0.675. Four hours of vibration had no significant effect on blood and 
dialyzer integrity as measured by concentrations of albumin (F(1,22)=0.185, p=0.735), 
hemoglobin (F(1,22)=1.038, p=0.319), and LDH (F(1,22)=0.185, p=0.672).
Conclusions: Although vibration has been shown to enhance solute clearance in 
CRRT and PIRRT, in this study, computationally-optimized vibration failed to significantly 
enhance solute clearance in an in vitro hemodialysis model using flow rates typically seen 
with intermittent hemodialysis.
Funding: Other NIH Support - National Center for Advancing Translational Science 
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Sevelamer Hydochloride Improves Oxidative Stress in Maintenance 
Hemodialysis Patients  Siren Sezer, Bahar Gurlekdemirci, Cihat Burak Sayin, 
Emre Tutal, Zeynep Bal, Fatma Nurhan ozdemir Acar.  Dept of Nephrology, 
Baskent Univ Faculty of Medicine, Ankara, Turkey.
Background: Oxidative stress plays a key role in the pathogenesis of cardiovascular 
diseases . Superoxide dismutase (SOD) and malondialdehyde (MDA)are well-known 
antioxidant enzymes that detoxifies advanced glycation end products (AGEs). We thought 
that avoiding calcium intake and through pleiotropic effects, sevelamer hydrochloride 
might be a differential influence in terms of oxidative stress. The aim of this study is to 
evaluate the effects of phosphate binders (PBs) on the components of the oxidative stress 
and clinical and biochemical parameters including pulse wave velocity in our maintenance 
hemodialysis (MHD) patients.
Methods: A total of 111 patients (mean age: 52.2 ± 14.3 years; mean duration of 
dialysis: 9.7 ± 4.6 years) undergoing maintenance hemodialysis and using the same PBs at 
least one year were enrolled into the study. Patients were divided into two groups according 
to usage of PBs as sevelamer based PB (group 1; n: 84 and calcium based PB (group 2; 
n.27). Biochemical parameters were assessed from monthly clinical visits. Serum AGE, 
MDA and SOD levels were determined by ELISA method. Pulse wave velocity (PWv) 
was determined by using the SphygmoCor system.
Results: Groups were similar in means of demographic characteristics and URR levels.
Patients in group 1 had significantly lower AGE (p: 0.018), higher MDA (p: 0.027) and SOD 
(p: 0.012) levels. Although both baseline and first year PWv values were similar in two 
groups, PWv values significantly decreased in group 1 (p: 0.001) where increased in group 
2 (p: 0.021) in the second year analysis. In linear regression analysis, serum AGE levels 
were detected as the unique predictor of DPWV (p: 0.005). For each 1 u/mL of increased 
level of AGE resulted in 0.53 cm/sec of increased level of PWv (p: 0.005, CI: 0.016-0.089).
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Conclusions: Despite similar phosphorus levels and dialysis adequency, sevelamer 
decreases serum AGE and increases serum MDA and SOD levels as well as improves PWv. 
Thus, sevelamer improves the oxidative stress and cardiovascular risk by pleiotropic effects 
when compared to calcium based phosphate binders.
FR-PO666
Preliminary Study About Optimal Dosage of Heparin Locking Solution to 
Maintain the Patency of Hemodialysis Catheter  Jung-woo Noh, Eunjung 
Kim, Ja-Ryong Koo.  Internal Medicine, Nephrology, Hallym Univ Medical 
Center, Hallym Kidney Research Inst, Seoul, Korea.
Background: Hemodialysis catheters(HC) are routinely heparin locked to maintain 
patency. This practice may cause bleeding episodes. The amount of heparin for heparin 
locking solution at many dialysis centers has been decreased recently to reduce the risk of 
bleeding. However, the effect of this change on patency of HC is unknown. We compared 
the patency of HC between four types of heparin amount of 4000, 5000, 7500, and 15000 
units(U).
Methods: This observational study included 126 chronic hemodialysis patients using 
HC in Hallym University Medical Center from March 2011 to July 2014. 29 patients received 
a 4000 U, 41 patients received a 5000 U, 44 patients received a 7500 U and 41 patients 
received a 15000 U of heparin. The primary outcome was composite outcome: frequency 
of thrombolytic instillation, change of hemodialysis line due to dysfunction of HC and HC 
obstruction due to thrombosis. We also compared activated partial thromboplastin time 
(aPTT) levels between groups just before and 10 minutes after the end of each hemodialysis.
Results: The composite outcome were 2.44±5.42, 1.06±3.46, 0.40±1.18 and 0.52±1.16 
episodes/100 catheter-days, respectively(p=0.03). 4000U group showed especially high rate 
of events compared to other groups receiving more than 5000 U of heparin. However, event 
rate of HC obstruction due to thrombosis was not significantly different: zero episodes/100 
catheter-days for 4000IU and 15000IU groups, 0.01±0.05 episodes/100 catheter-days for 
5000IU group and 0.14±0.61 episodes/100 catheter-days for 7500 IU group. At 10 minutes 
after heparin lock, prolonged aPTT was observed in all groups. When 10 minutes aPTT 
levels between 4000 U group and other groups are compared, those of 7500 U(p=0.007) 
and 15000 U(p=0.004) groups were significantly prolonged. But there were no bleeding 
complications in those groups.
Conclusions: Low concentration heparin lock solution with total amount of 4000 U 
do not increase HC obstruction due to thrombosis, but increase in thrombolytic instillation 
and set change. Higher concentration heparin lock solution with total amount over 7500 U 
prolonged the aPTT without bleeding complication.
Funding: Clinical Revenue Support
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Association Between Depressive Symptoms and Dependency with Mortality 
in Hemodialysis Patients After 5 Years of Follow-Up  Joaquin Manrique,1 
Maria del cielo Mena,2 Eva Cerdán,2 Laura Catalan.2  1Servicio de Nefrologia, 
Complejo Hospital de Navarra, Pamplona, Spain; 2Nursing Staff. Servicio de 
Nefrologia, Complejo Hospital de Navarra, Pamplona, Spain.
Background: The prevalence of depression and its role in mediating survival of patients 
with end-stage renal disease (ESRD) has been highly controversial. Moreover, according to 
the population ages, their limitations in performing daily activities affect their well-being 
as well as increase the burden on caregivers and the use of health services.
Methods: We determine whether depressive symptoms and dependency are associated 
with mortality in a longitudinal study of 148 hemodialysis (HD) outpatients followed for 
5 years. Depressive symptoms were assessed using the Beck Depression score (BDs), and 
dependence by Barthel scale (BS) performed by nursing HD staff.
Results: 26.8% of patients had depressive symptoms (BD>10) and the mean baseline 
BDs was 11.4+/-8.1). 23% patients were moderate or severely dependent (BS<90). 40.5% 
died during the study follow-up period (a rate similar to that found in this population). 
We observed a significant association between BS and BDs (r2=-0.5; p<0.001). Patients 
with greater disability (BS<90) had worse depressive score (p<0.001). After 60 months of 
follow-up, survival rates were 80.5% for BDs≥8 and 94.3% for BDs < 8 (p=0.05), and 71.4% 
for dependent and 95.5% for no dependent patients (p<0.001). Other variables, including 
age, gender, and dialysis period, were not significantly associated with mortality. Cox 
proportional hazards regression was performed to predict the mortality hazard associated 
with baseline level of depressive affect and dependence, controlling for the effects of 
variation in patient age and dialysis duration.
Conclusions: Our study shows that the disability in self-care and the presence of 
depressive symptoms are common among patients on haemodialysis. Both of them may 
act as independent risks factors for mortality. Strategies could be helpful to routinely 
identify those dialysis patients at risk of functional impairment and depression to limit 
their disabilities. Self-report scales and those performed by nursing staff could improve 
the integral treatment of those patients.
FR-PO668
Limitations of Access Recirculation due to a Low Access Flow Rate on 
Middle Molecule Clearance During Post-Dilution Hemodiafiltration 
J. Ken Leypoldt,1 Markus Storr.2  1Renal Therapeutic Area, Baxter Healthcare 
Corporation, Deerfield, IL; 2Research & Development, Gambro Dialysatoren 
GmbH, Hechnigen, Germany.
Background: Post-dilution hemodiafiltration (HDF) with a high convective volume 
(CV) is associated with lower overall patient mortality, potentially due to high middle 
molecule (MM) clearance from the patient (Kp). A higher CV can most readily be achieved 
by extending the treatment time or increasing the blood flow rate (BFR); however, the effect 
of access recirculation due to a low access flow rate (AFR) when increasing the BFR on 
MM Kp during HDF has not been previously quantified.
Methods: A theoretical mass balance model for assessing the effect of a low AFR 
on MM Kp was formulated. Access recirculation was assumed to occur when the BFR 
exceeded the AFR. The model demonstrated that MM Kp was dependent on HDF membrane 
properties, AFR, BFR, CV and the fluid removal rate from the patient (FRR).
Results: Example results are tabulated for a patient with a hematocrit of 33% at 
different AFRs and BFRs maintaining a fixed filtration fraction of 25% during a 4-hour 
HDF treatment with a FRR of 0.5 L/hour. MM filter clearance was assumed to depend on 
CV with a diffusive clearance of 75 mL/min and a sieving coefficient of 0.7: 
MM Kp (mL/min) at BFR (mL/min)/CV (L)
AFR (mL/
min) at 300/18.0 at 320/19.2 at 340/20.4 at 360/21.6 at 380/22.8 at 400/24.0 
≥400 127.5 131.0 134.5 138.0 141.5 145.0
320 127.5 131.0 129.8 129.0 128.5 128.1
When the AFR is higher than the BFR, MM Kp increases with increasing CV. At low 
AFR, increasing the BFR above the AFR resulted in a lower MM Kp than expected. Indeed, 
increasing the BFR above the AFR can even lead to a reduction in MM Kp.
Conclusions: High convective volumes during post-dilution HDF achieved by using 
high blood flow rates may not result in higher middle molecule clearance if the access flow 
rate is low. Routine assessment of access recirculation or access flow rate may be necessary 
during post-dilution HDF with high blood flow rates to improve patient outcomes.
Funding: Pharmaceutical Company Support - Baxter Healthcare Corporation
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Protein Biofilm and Its Relation to Dialyzer Permeability for 
Middle Molecular Weight Markers in Three Polysulfon Membranes 
Lukas Kielberger, Jan Mares.  1st Dept of Internal Medicine, Charles Univ 
Teaching Hospital, Plzen, Czech Republic.
Background: Membrane permeability, particularly in terms of middle molecular 
clearances, is largely dependent in vivo on the formation of a protein biofilm. Our aim was to 
assess its dynamics during HD session together with molecular composition of the biofilm.
Methods: 12 HD patients were assigned in a cross-sectional design to Xevonta® 
Hi23 (B-Braun, 2.3 m2), CorDiax FX100® (Fresenius, 2.2 m2) and Polyflux® 210H 
(Gambro, 2.1 m2) dialyzers. Blood pre- and post- dialyzer was sampled at 0, 15, 60, and 
240 min; spent dialysate was collected over the first 15 min and then until the end of the 
session. b2 microglobulin (b2M), myoglobin (MB), retinol-binding protein (RBP), and α1-
microglobulin (α1m) levels were determined as permeability markers covering an interval 
of molecular weight (MW) 11-26 kDa. After HD, protein biofilm was eluted from dialyzer 
and subjected to proteomic analysis.
Results: At the beginning, Xevonta and FX dialyzers showed significantly higher in 
vivo sieving coefficients for all MWs up to 26 kDa (α1m ) than Polyflux dialyzer (p<0.01). 
After 15 min, Xevonta and FX permeability decreased significantly (p<0.01) in all MW 
classes while in Polyflux, only MW³21 kDa (RBP4) were affected (p<0.01). The total 
protein content of membrane biofilm was similar in all three dialyzers: 118±85, 41±10, and 
40±17 mg protein per dialyzer for Xevonta, FX, and Polyflux, resp. Significant differences 
in protein composition were captured in 48 out of 231 protein fractions. Among them, 
complement factor H-related protein 3 (FHR3), insulin-like growth factor binding protein 
4 (IBP4), or multiple fibrin fragments (FDP) were identified. While FDP and IBP4 were 
prevalent in eluates from FX and Xevonta dialyzers (p=0.005 and 0.001, resp.), FHR3 was 
abundant in Xevonta only (p=0.01).
Conclusions: Even with modern biocompatible dialyzers, in vivo permeability 
decreases along HD session, probably due to biofilm formation. The decrease occurred 
irrespective of total protein adsorbed, compromising rather membranes primarily more 
permeable and higher MWs. Differences in biofilm composition are complex and may 
impact both dialyzer permeability and biocompatibility.
Funding: Government Support - Non-U.S.
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FR-PO670
Protective Effects of Intravenous L-Carnitine (LC) Administration 
on Development of Cardiomyopathy in Hemodialysis (HD) Patients 
Takuhisa Uchino,1 Jyunichiro Hashiguchi,1 Satoshi Funakoshi,1 Hiroshi 
Ichinose,1 Osamu Sasaki,1 Kenji Sawase,1 Miki Yano,1 Yutaka Mori,3 Kazunori 
Utsunomiya,3 Yoko Obata,2 Tomoya Nishino,2 Miwa Shirahama,1 Takashi 
Harada.1  1Nagasaki Kidney Center, Nagasaki, Japan; 2Nagasaki Univ Graduate 
School of Medicine, Nagasaki, Japan.
Background: Due to loss via dialyzer patients on maintenance HD often suffer 
from dialysis-related carnitine deficiency, causing various clinical symptoms. Carnitine 
Consensus Conference in 2003 convened by The National Kidney Foundation had reported 
that the level of evidence was “moderate” for cardiomyopathy.Recent studies have shown 
that L-carnitine can improve left ventricular (LV) function in HD patients. In this study we 
aimed to investigate whether intravenous administration of LC can prevent the development 
of cardiomyopathy in HD patients as assessed by M-mode ultrasound cardiography (UCG).
Methods: Thirty-eight HD patients without reduced left ventricular function were 
treated with intravenous administration of 1000mg / body of LC at the end of every HD 
session for 12 months. M-mode UCG assessments were undergone in all subjects at the 
tree points; 1 year prior to the treatment, the start of LC administration and1 year after 
the treatment.
Results: As shown in Figure 1, average %FS (fractional shortening) significantly 
declined during 1 year before the start of LC, then stabilized after the treatment, suggesting 
LC administration might protect the progression of LV contraction impairment. Average 
early diastolic filling velocity (E) / atrial filling velocity (A) ratio showed similar pattern, 
suggesting LC treatment could be protective in LV diastolic disorder. LC treatment also 
might delay LV hypertrophy progression.
Conclusions: Intravenous LC administration can be a candidate therapy for protection 
of the development of cardiomyopathy in HD patients.
Funding: Private Foundation Support
FR-PO671
Symptoms and Quality of Life Among Patients Receiving HD  Mark L. Unruh,1 
Kim J. Cox,2 Stephen H. A. Hernandez,2 Sanah Parvez,1 Mark Parshall.2  1Div of 
Nephrology, Univ of New Mexico; 2College of Nursing, Univ of New Mexico.
Background: Health-related quality of life (HRQOL) assessment is a required 
condition of coverage for HD providers, but standard measures may not adequately reflect 
the impact of symptoms and treatment on QOL for patients receiving HD or the concerns 
that matter most to them. The purpose of this qualitative study is to more fully characterize 
patients’ perspectives on the symptoms and treatment experiences affecting their QOL.
Methods: We conducted semi-structured interviews with a diverse sample of 50 
HD patients (48% Female; 42% Hispanic; 30% American Indian; 14% Black; 12% Non-
Hispanic White) to elicit their experiences with diagnosis and treatment of ESRD and the 
symptoms and aspects of treatment that have the greatest impact on their QOL. Interviews 
were audio-recorded, transcribed, and analyzed for themes using an interpretive-approach.
Results: Participants recalled that the initial diagnosis of ERSD was received with shock 
and denial. Over time, patients reported that QOL was associated with “taking control” of 
some features of their treatment. Common symptoms associated with HD, such as cramping 
and fatigue, were described as potentially manageable when patients were able to participate 
in decisions about fluid removal and scheduling of HD treatments. Patients who formed 
a partnership with their providers to negotiate fluid removal reported fewer episodes of 
severe cramping and improved QOL. Similarly, being able to choose among a variety of 
days and shifts for HD treatment enabled patients to manage fatigue, work hours, travel, 
and attendance at social events. These factors were critically important to the QOL in our 
relatively young sample (median age = 53; median duration of HD treatment = 4 years).
Conclusions: This is one of the largest and most diverse qualitative studies of symptoms 
among patients undergoing HD. There were few differences in symptoms or the impact of 
treatment on QOL among racial and ethnic groups. Findings highlighted the importance 
of fluid management and fatigue to patient experience.
Funding: Pharmaceutical Company Support - Dialysis Clinic Inc.
FR-PO672
Longitudinal Measures of Protein Carbamylation and Mortality on Dialysis 
Sahir Kalim,1 Anders H. Berg,2 Rayhnuma Ahmed,1 Joshua Wibecan,1 Caitlin A. 
Trottier,1 S. Ananth Karumanchi,2 Ravi I. Thadhani.1  1MGH; 2BID.
Background: Single time-point measures of carbamylation have recently been 
associated with mortality in dialysis patients. This study investigated whether repeated 
measurements of carbamylation over time, allowing calculation of the rate of change, 
improved on mortality prediction.
Methods: In a nested case-control study, we measured % carbamylated albumin 
(C-Alb, a measure of carbamylation load) in a cohort of incident hemodialysis patients. 
122 subjects who died within 1 year of initiating dialysis (cases) were randomly selected 
and matched for demographics to 244 individuals who survived at least 1 year on dialysis 
(controls). C-Alb was assayed within 14 days of dialysis initiation and every 90 days for 1 
year or until death. Logistic regression quantified case-control differences.
Results: In adjusted models, there was no case-control difference in day14 C-Alb 
(P=0.83) and, as expected, carbamylation decreased in both groups with dialysis initiation. 
By day 90, unit increase in C-Alb was predictive of 1-year mortality (OR 1.7, 95%CI 1.1-2.8; 
P=0.02) despite no differences in Kt/V. Final C-Alb (last measure taken at study completion 
or preceding death) was a stronger mortality predictor than C-Alb from any other time 
point (OR 2.4, 95%CI 1.4-4.0; P=0.003). A smaller % decrease in C-Alb between any 2 
time points carried an increased mortality risk (e.g. C-Alb from day 14 to final = -21% in 
cases vs. -35% in controls; OR 1.6, 95%CI 1.2-2.0; P =0.002). Sensitivity analysis showed 
follow up time did not bias the results.
Conclusions: C-Alb decreases with dialysis initiation. Smaller decreases in C-Alb over 
time, resulting in persistently high carbamylation, may herald increased mortality risk during 
year 1 of dialysis. Because dialysis intensity and amino acid therapy reduce carbamylation, 
the utility of C-Alb as a therapeutic guide should be investigated.
Funding: NIDDK Support, Other NIH Support - This work was conducted with the 
support of a KL2/Catalyst Medical Research Investigator Training award (an appointed 
KL2 award) from Harvard Catalyst | The Harvard Clinical and Translational Science 
Center (National Center for Research Resources and the National Center for Advancing 
Translational Sciences, National Institutes of Health Award KL2 TR001100)., Private 
Foundation Support
FR-PO673
Recruitment Challenges in the Blood Pressure in Hemodialysis Pilot Study 
Jennifer J. Gassman,1 Dana Miskulin,2 Philip Zager,3,4 David W. Ploth,5 Manisha 
Jhamb,6 Lavinia A. Negrea,7 Mahboob Rahman.7  1Cleveland Clinic; 2Tufts; 
3UNM; 4DCI; 5MUSC; 6Univ of Pittsburgh; 7Case Western.
Background: The optimal BP target in hemodialysis (HD) patients is unknown. The 
Blood Pressure in Dialysis (BID) Pilot Study is an ongoing NIDDK/Dialysis Clinic Inc. 
funded multi-center randomized trial treating hypertensive HD patients to a standardized 
predialysis systolic BP (SDUSBP) of 110-140 vs.155-165 mm Hg, to assess feasibility and 
safety and inform the design of a full-scale trial.
Methods: We consented 281 participants who entered baseline from 12/2011 to 
1/2015. We randomized 126 participants. Achievement of the SDUSBP goal was assessed 
by determining 2-week running mean SDUSBP in each patient. Participants are followed 
for 12 months. BP was measured at each dialysis session, home, and ABPM. BP and 
medications were backtitrated until predialysis SDUSBP was greater than 155 mm Hg. 
Outcomes include protocol adherence, SDUSBP adherence and left ventricular mass by 
MRI. To recruit, we identified hypertensive patients, 125 approached for consent refused. 
Reasons for refusal included perception of study being burdensome 34 (27%) and reluctance 
to change medications/goals 10(8%).
Results: Of the 281 participants who entered the baseline period 155 (55%) were 
not randomized, 38(25%) changed their minds, 9(6%) unlikely to adhere, 6(4%) had 
contraindications to MRI, 6(4%) could not perform required procedures, and 65(42%) were 
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unable to achieve the lower limit goal of a SDUSBP >155 mm Hg despite backtitration. 
Retention has been excellent. Patient characteristics are balanced between treatment arms. 
There is good separation between arms.
Conclusions: We anticipate that a Phase III BID clinical trial will require >1200 
participants. MRI will be eliminated and the protocol will be simplified. Routine BPs run 
higher than SDUSBP and too low a BP was the primary reason for failure to randomize. 
The anticipated revised protocol will facilitate recruitment and randomization. Clinical 
sites should plan to enroll twice the number that need to be randomized to achieve the 
randomization target in the full-scale study.
Funding: NIDDK Support, Pharmaceutical Company Support - Dialysis Clinic, Inc.
FR-PO674
Association of Time-Averaged Concentration of Hemoglobin with 
Mortality: Results from a Large U.S. Hemodialysis Cohort  Hanjie Zhang,1 
Stephan Thijssen,1 Peter Kotanko.1,2  1Renal Research Inst, New York, NY; 2Icahn 
School of Medicine at Mount Sinai, New York, NY.
Background: In hemodialysis (HD) patients the time averaged concentration of 
hemoglobin (Hb_tac) can be estimated from pre- and post-HD hemoglobin (Hb) levels. 
It has been suggest that Hb_tac may be an appropriate indicator for anemia management 
(Siga, Int Urol Nephrol 2014). However, the association between Hb_tac and mortality 
has not yet been evaluated.
Methods: We analyzed Hb data obtained by Crit-Line™ monitor (CLM) in chronic 
HD patients. A 6-month baseline period with at least 10 CLM measurements preceded a 
12-month follow-up during which outcomes were noted. We used Hb values from HD 
sessions following a short interdialytic interval. Hb_tac was computed as follows (Krisper, 
NDT 2003): HbBtac = HbBpre * 0.5 + HbBpost * 0.38 + 1.28. We defined HbBpre as the 
average Hb between minutes 5 to 20 from the start of the CLM recording, and Hb_post 
as the average of Hb between minutes 5 to 20 from the end of the CLM recording. The 
relation between Hb_tac during baseline and mortality was explored by spline analysis 
of hazard ratio (HR).
Results: We studied 982 patients (figure 1A) with a total of 19,142 CLM measurements. 
Average Hb_tac was 10.72 g/dL (SD 0.81, range 7.27 – 14.62 g/dL). The mortality rate 
during follow-up was 11.6 per 100 patient-years. The minimal HR (figure 1B) was 0.82 at 
HbBtac of 10.87 g/dL. The solid line represents mean HR, the dotted lines 95% confidence 
intervals. 
Conclusions: Hb_tac is associated with mortality, levels around 10.9 g/dL are 
associated with the lowest mortality risk. Studies are required to further explore methods 
to estimate Hb_tac based on Hb measurements by the CLM and the usefulness of Hb_tac 
as an indicator of anemia control.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO675
Development and Validation of a Predictive Mortality Risk Score in Chinese 
Incident Maintenance Hemodialysis Patients  Xi Yao.  Kidney Disease Center, 
The First Affiliated Hospital, College of Medicine, Zhejiang Univ, Hangzhou, 
Zhejiang, China.
Background: We aimed to predict 2-Year all-cause mortality in incident maintenance 
hemodialysis (MHD) patients by using available clinical and laboratory data, and to 
establish a risk scoring model.
Methods: Data of incident MHD patients were from Zhejiang Dialysis Quality and 
Management Center(ZDQM) during the period from January 2008 to June 2012. All 
patients were ³18 years old and survived at least 3 months after starting dialysis treatment, 
who were followed up for two years. Patients were randomly divided into training dataset 
(60%, n=2551) and validation dataset(40%, n=1744). The predictive model was developed 
by using a logistic regression model according to the clinical data in training dataset. The 
risk model were tested by using the area under the receiver operating characteristic(ROC) 
curve. The risk scoring model for 2-Year mortality was set up according to the coefficient 
and rank of variables in the risk model.
Results: In our predictive model, predictors were age, causes of end stage kidney 
disease(ESRD), vascular access catheter, history of cancer, serum albumin and serum total 
calcium.The area under the ROC curve of predictive model in training dataset was 0.767, 
Hosmer-Lemeshow Chi-test, P=0.925, which was highly discriminatory when applied to 
validation dataset(ROC 0.732), and the sensitivity and specificity were 71.5% and 64.2%, 
respectively. The risk scores of low, intermediate, high and very high mortality risk strata 
were <9, 10~13, 14~17 and ³18 points, respectively. Observed and predicted mortality risk 
in the training dataset and validation dataset had a significantly linear relationship(r2 = 
0.998 and 0.984) across risk strata.
Conclusions: The risk-score model can accurately predict 2-Year all-cause mortality 
in Chinese MHD patients and external validation is needed in future.
FR-PO676
Prediction of Changes in Serum Albumin Levels Among Hemodialysis 
Patients by Serum Neutrophil Gelatinase-Associated Lipocalin Levels 
Hirotaka Imamaki,1 Akira Ishii,1 Hideki Yokoi,1 Masato Kasahara,2 Keita P. 
Mori,1 Takashige Kuwabara,1,3 Kazuwa Nakao,4 Masashi Mukoyama,1,3 Motoko 
Yanagita,1,4 Kiyoshi Mori.4  1Dept of Nephrology, Graduate School of Medicine, 
Kyoto Univ, Kyoto, Japan; 2Inst for Advancement of Clinical and Translational 
Science, Kyoto Univ Hospital, Kyoto, Japan; 3Dept of Nephrology, Kumamoto 
Univ Graduate School of Medical Sciences, Kumamoto, Japan; 4Medical 
Innovation Center, Kyoto Univ Graduate School of Medicine, Kyoto, Japan.
Background: Circulating concentration of neutrophil gelatinase-associated lipocalin 
(NGAL or LCN2) is elevated in acute and chronic kidney diseases. Recently, we reported 
that, in a cross-sectional study, serum NGAL concentrations in maintenance hemodialysis 
(HD) patients were determined independently by % creatinine generation rate, white blood 
cell count and anion gap, indicating that NGAL is a marker of good nutritional conditions. 
Clinical impact of NGAL was further evaluated in a prospective analysis.
Methods: Correlations of baseline nutritional indices with baseline and follow-up 
serum albumin levels and with changes in albumin levels after a year were investigated 
among 87 HD patients using linear regression analysis.
Results: Follow-up albumin levels were positively correlated to baseline NGAL, 
albumin, geriatric nutritional risk index, creatinine, %creatinine generation rate, anion gap, 
choline esterase, triglyceride levels and neutrophil counts, and negatively to age. Similar 
findings were obtained for baseline albumin levels. Importantly, albumin increase was 
positively correlated to baseline NGAL (r=0.36, P<0.01) and neutrophil but negatively 
correlated to baseline albumin levels. Typically, some cases with hypoalbuminemia and high 
NGAL levels experienced elevation in serum albumin levels after recovery from infection 
(or inflammatory disorders). On the other hand, in some cases with preserved albumin levels 
and low NGAL levels, serum albumin levels decreased once severe infection developed 
and reduced albumin levels persisted even after recovery from infection.
Conclusions: Serum NGAL level in HD patients appears to be a unique biomarker 
allowing prediction of alteration in serum albumin levels in a year.
Funding: Pharmaceutical Company Support - Tanabe Mitsubishi Pharmaceutical 
Company, Government Support - Non-U.S.
FR-PO677
Race, Health-Related Quality of Life and Mortality in a Large Cohort of 
Brazilian Multiracial Hemodialysis Population  Marcelo Barreto Lopes, 
Priscila S. Carvalho, Jéssica S. Fernandes, Raissa B. Peixoto, Pedro Guimarães 
Silva, Jean M. Monteiro, Gildete Barreto Lopes, Antonio Alberto Lopes.  Federal 
Univ of Bahia, Salvador, BA, Brazil.
Background: Studies developed in patients undergoing maintenance hemodialysis 
(MHD) in the United States (US) indicate that the survival and the health-related quality 
of life (HRQOL) are better in African Americans and other racial minorities than in Whites. 
Similar to the US, Brazil is a country with a diverse racial population. There is a lack of 
studies to investigate if there are differences in HRQOL and mortality by race in Brazilian 
MHD patients. The present study developed in a multiracial Brazilian MHD population 
investigated associations of race (Whites as reference) with HRQOL and survival.
Methods: A prospective cohort of 1084 MHD patients (11.8% White, 61.3% mixed 
race and 26.8% Black) enrolled in the Prospective Study of the Prognosis of Chronic 
Hemodialysis Patients (PROHEMO) developed in nephrology clinics of Salvador, Brazil. 
The predictor variable was race (White as reference). Outcomes were mortality and HRQOL 
scores, using the KDQOL-SF. Multivariable linear regression was used for differences in 
scores and Cox regression for mortality. Associations were adjusted for age, sex, diabetes, 
heart failure, blood hemoglobin and vintage.
Results: Mean age was significantly lower (P<0.001) in Blacks (49.2±14.0 yr) and 
mixed races (47.6±14.5 yr) than in Whites (55.0±13.7 yr). In the multivariable linear 
regression, differences were not observed by race for PCS, MCS, disease burden and effects 
of kidney disease. For symptoms/problems, a significantly (P=0.043) higher adjusted score 
(difference=3.6) was observed in Whites (than in Blacks). In the Cox model with complete 
adjustment for covariates, the hazard ratio (HR) was 0.95 (95% confidence interval (CI) 
=0.66-1.35) for the comparison between mixed race and White and 1.10 (95% CI=0.75-
1.61) for the comparison between Blacks and Whites.
Conclusions: In disagreement with studies developed in the United States, this study 
developed in a multiracial Brazilian hemodialysis did not show worse HRQOL and higher 
mortality in whites as compared with patients of mixed race and Blacks.
Funding: Government Support - Non-U.S.
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FR-PO678
Low Lymphocyte Counts Are an Independent Predictor of Mortality 
in Chronic Hemodialysis Patients: A Retrospective Cohort Study 
Dieter De Clerck, Christian L. Tielemans, Karl M. Wissing.  Nephrology, Univ 
Ziekenhuis Brussel, Brussels, Belgium.
Background: Mortality in chronic hemodialysis populations remains high. 
Lymphopenia has been associated with increased cardiovascular risk in the general 
population but few data are available on the effect of low lymphocyte counts on long-term 
survival of hemodialysis patients.
Methods: Retrospective study of a single-center cohort of 689 hemodialysis patients 
using monthly laboratory results and dialysis parameters extracted from a center database 
and a national registry. The effect of baseline and time-changing lymphocyte counts on 
overall mortality was studied using the Kaplan Meier and Cox proportional hazard methods.
Results: Lymphopenia (<1200/µL) was present in approximately one third of incident 
hemodialysis patients and correlated with older age, lower creatinine, lower phosphorus, 
higher KT/V and a positive history of ischemic heart disease. Lymphopenia was not 
associated with classical markers of malnutrition-inflammation complex such as albumin, 
normalized protein catabolic rate, BMI and CRP. Baseline lymphopenia was associated 
with a 54 percent increase in the hazard of death (HR 1.54 (1.17 to 2.0; P=0.002)) as 
compared to the tertile of patients with highest lymphocyte counts. Lymphocyte counts 
tended to decrease during long-term follow up and their introduction as a time-changing 
variable further increased the HR to 2.1 (1.48 to 2.84; P<0.0001). The association remained 
significant in the multivariate Cox model after adjustment for age, phosphorus, creatinine, 
albumin, BMI, CRP, KT/V and history of ischemic heart disease.
Conclusions: Lymphopenia is highly prevalent in hemodialysis patients and is a strong 
predictor for patient death. The association was stronger when lymphocyte counts were 
considered as a time-changing variable and independent of other risk factors for patient 
death. Lymphopenia was not associated with markers of the malnutrition-inflammation 
complex (MIC) and therefore appears a useful prognostic tool in addition to classical 
markers such as CRP and albumin levels.
FR-PO679
Current Status of Hemodialysis in China  Li Zhang, Delong Zhao, Xueying 
Cao, Xiang-Mei Chen, Guangyan Cai.  Chinese PLA General Hospital, Chinese 
PLA Inst of Nephrology, State Key Laboratory of Kidney Diseases, National 
Clinical Research Center for Kidney Diseases.
Background: In May 2010, the first nationwide, web-based prospective renal data 
registration platform, the Chinese Renal Data System (CNRDS) was launched in China. 
The purpose of this study was to determine the current status of hemodialysis in China by 
analyzing the data from CNRDS.
Methods: The data from CNDRS were used for dialysis cases including demographic, 
clinical, and laboratory data. We analyzed the data from CNRDS by the end of 2014.
Results: (1) There were 4047 domestic hemodialysis centers and 339748 survival 
patients were registered by the end of 2014. (2) In the 339748 patients, 58.85% were male. 
The average age was 54.9 years and average dialysis duration was 42.2 months. The three 
leading causes of ESRD were glomerulonephritis, diabetic nephropathy and hypertensive 
renal diseases. (3)14322 patients died in 2014, with an average age of 61.9 years and average 
dialysis duration of 39.7 months. The main causes of death were cardiovascular events and 
stroke, followed by infection and gastrointestinal bleeding. (4) In the patients, 44.1% had 
predialysis blood pressure less than 140/90mmHg, 55.4% had hemoglobin concentration 
³100g/L and 80.3% had albumin levels ³35g/l. 39.6% had serum calcium between 2.10 and 
2.50mmol/L. 34.7% had serum phosphorus between 1.13-1.78mmol/L. 53.9% had PTH 
between 130 and 600pg/ml.
2011 2012 2013 2014
predialysis blood 
pressure (mmHg) 148±21/85±13 148±21/85±13 148±20/84±13 148±21/84±13
hemoglobin (g/L) 95±23 97±22 97±22 101±22
serum calcium 
(mmol/L) 2.15±0.36 2.15±0.40 2.15±0.40 2.17±0.35
serum phosphorus 
(mmol/L) 1.92±0.76 1.91±0.79 1.91±0.79 1.92±0.71
PTH (pg/ml) 394±452 405±459 405±459 402±455
albumin (g/L) 38±6 38±6 38±6 39±6
Conclusions: As Chinese National Health and Family Planning Commission have 
enhaced the basic medical security system on hemodialysis, both the population and the 
quality of hemodialysis have increased in recent years.
Funding: Government Support - Non-U.S.
FR-PO680
Outcomes and Quality of Care in Rural versus Urban Managed Dialysis 
Patients  James M. Zacharias,1 Allison Dart,2 Harvey M. Chochinov.3  1Dept of 
Medicine, Univ of Manitoba, Winnipeg, MB, Canada; 2Dept of Pediatrics, Univ 
of Manitoba, Winnipeg, MB, Canada; 3Dept of Psychiatry, Univ of Manitoba, 
Winnipeg, MB, Canada.
Background: A proportion of patients are managed in remote satellite units in 
Manitoba, Canada. Urban nephrologists oversee all dialysis care; however family physicians 
(FP) co-manage patients. This study examines outcomes and quality of care indicators in 
rural vs.urban managed patients.
Methods: Prospectively collected clinical data from the Manitoba Renal Program and 
administrative health data housed at the Manitoba Centre for Health Policy were analyzed 
retrospectively. All adult (>18yo) incident hemodialysis patients on dialysis >90 days, from 
1995 to 2010 were included. Individuals dialyzing in rural satellite units (n=510) more 
than 50% of the time were compared to their urban (n=2629) counterparts. Differences 
in cohort characteristics were analyzed at baseline as well as differences in primary care 
quality indicators. Regression analyses examined differences in hospitalizations and days in 
hospital. Cox proportional hazard models were performed to examine differences in survival.
Results: Patients in rural satellite units vs urban were younger, 58 vs 61yrs (p=0.002), 
but were more likely to have DM 69.4 vs 55.3% (p<0.0001), PVD 9.4 vs 4.0% (p<0.001) 
and IHD (MI, Angiogram or PTCA) 42.8 vs 34.2% (p=0.002). More rural patients accessed 
a FP at least once per year 85.7% vs 67.3% (p<0.0001) and 85.3% vs 68% (p<0.0001) 
had at least 25% continuity with the same FP. Despite increased FP utilization Pap smear, 
mammogram, DM eye exam and use of a Statin post MI were not significantly different. 
There were no differences in hospitalization outcomes between groups. However, survival 
was significantly better in the rural cohort OR 0.77 (CI 0.68-0.88, p<0.0001), after 
controlling for sex, income, charlson, era, age and region at the start of dialysis.
Conclusions: Survival in a cohort of patients dialyzing in remote satellite units was 
found to be superior to their urban counterparts, after controlling for co-morbidities. A 
potential reason might be increased primary care involvement, although differences were 
not seen in traditional quality of care indicators.
Funding: Private Foundation Support
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Applying Hemodialysis Clinical Quality Indicators to Individual Patients: 
A Useful Mortality Prognostic Tool in Clinical Practice?  Tiago Assis Pereira, 
Artur P. Mendes.  Unidade Linda-a-velha, Diaverum, Linda-a-Velha, Oeiras, 
Portugal.
Background: Hemodialysis (HD) care is routinely assessed by a set of clinical and 
laboratorial parameters, known as Clinical Quality Indicators (CQI). CQI registry and 
monitoring constitutes an instrument to evaluate the quality of care provided at each HD 
Unit. The purpose of this study was to determine whether CQI, applied on an individual 
patient basis, is a predictor of mortality.
Methods: Retrospective study that included 334 patients of a HD Unit from 2011 to 
2014. Demographic, clinical and laboratories data were collected. The CQI considered were 
eleven, whose intended target were: spKt/V ≥ 1.4; weekly dialysis time ≥ 720 minutes; 
Albumin ≥ 3.5 g/dL; Hemoglobin between 10 and 12 g/dL; phosphatemia between 2.5 and 
5.5 mg/dL; CaxP product < 55 mg2/dL2; PTH levels between 150 and 600 pg/ml; Ferritin 
between 200 and 800 mg/dL; Mean arterial pressure < 105 mmHg; interdialytic weight 
gain (IWG) < 4% and fistulae as vascular access. Single CQI were rated in a binary form 
(0 = not reached target/1 = reached target) at each monthly evaluation and the average 
were determined. Ultimately, the eleven parameters were added in a single variable for 
each patient (CQIp).
Results: During follow-up, 33% of patients died. In the Cox regression model, age 
(HR 1.09; CI 1.07-1.11; p <0.001), diabetes (HR 2.88; CI 1.92-4.32; p <0.001), peripheral 
arterial disease (HR 1.63; CI 1.09-2.44; p = 0.016) and CQIp (HR 0.73; CI 0.62-0.87; p 
<0.001) were shown to be independent predictors of mortality, after adjustment for other 
clinical and demographical factors. When CQIp was replaced by its constituent variables, 
albumin (HR 0.016; CI 0.08 -0.32; p <0.001), PTH (HR 2.8; CI 1.10-3.93; p = 0.023), 
IWG (HR 0.34; CI 0.14-0.83; p = 0.018) and fistulae presence (HR 0.61, CI 0.4-0.93, p = 
0.021) presented statistical significance.
Conclusions: A set of parameters, generally applied as a quality care indicators, proved 
to be an independent predictor of death when applied to individual patients. This should 
be regarded as an easy and practical prognostic tool to be applied in current practice.
FR-PO682
Association of Estimated Glomerular Filtration Rate at Commencement 
of Maintainence Dialysis with Mortality Among Patients with Advanced 
Chronic Kidney Disease in Singapore  Tazeen H. Jafar,1 Jin Ai Zhen,2 John 
C. Allen,1 Saeideh Tavajoh,1 Khuan yew Chow.1  1Duke-NUS Graduate Medical 
School Singapore; 2National Disease Registry 2ffice, Health Promotion Board, 
Singapore.
Background: Recent evidence suggest that higher estimated glomerular filtration rate 
(eGFR) at commencement of dialysis may be associated with increased mortality. However, 
there is scarcity of data on patients of Southeast Asian origin. We analyzed and compared 
mortality risk in patients with early and late start dialysis as measured by kidney function 
at dialysis initiation among Southeast Asian population of Singapore.
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Methods: We performed a retrospective analysis of patients enrolled in the Singapore 
Renal Data system database from 2008 to 2011. Patients were classified into groups by 
eGFR at dialysis initiation.
Results: In this total incident population (n=3708), a total of 1510 individuals died 
during a median follow-up period of 2.8 years. The hazard ratio (HR) and 95% CI associated 
with different levels of eGFR at commencement of RRT are shown in table below. The main 
multivariable model (n=3189 without missing information on covariates) associated with 
the eGFR at dialysis initiation within the groups: age, gender, level of education, smoking, 
presence of diabetes, ischemic heart disease, cerebrovascular disease, and peripheral 
vascular disease, malignancy, hepatitis B, hepatitis C, kidney transplant, and modality of 
dialysis. Additional models accounted for serum albumin (n=2657) , and serum ferritin 
(n=2462), and serum calcium (n=1628). 
eGFR 
ml/min/1.73m2
Dialysis Patients
N=3189 Deaths
Adjusted HR 
(95%CI) p trend
<5 1345 395 1.00 <0.0001
5-10 1541 656 1.19 (1.04-1.36)
>10 303 180 1.81 (1.49-2.19)
The results were consistent after accounting for serum albumin, serum ferritin, and 
serum calcium in the multivariable models.
Conclusions: Late initiation of dialysis is associated with a lower risk of mortality in 
comparison with early dialysis initiation in Southeast Asians in Singapore.
FR-PO683
Predicting Mortality for Patients Who Are on Hemodialysis–A National 
Cohort Study in Taiwan  Jinn-Yang Chen.  Div of Nephrology, Taipei Veterans 
General Hospital, Taipei, Taiwan.
Background: Comorbid conditions and medical history provide prognostic information 
for dialysis patients. The objective of this study was to develop a prognostic model to 
predict short-term (6-months and 1-year) and long-term (2.5-years) survival for incident 
hemodialysis (HD) patients.
Methods: Incident Taiwanese hemodialysis patients from 2006 to 2010 were extracted 
from National Health Insurance claim records. Prognostic model was developed by using 
comorbid conditions (summaried as Taiwan index), monthly income and medical history 
during one year before initiation of dialysis. Somer’s D statistic was used to assess the 
discrimination ability of our model.
Results: A total of 36,875 incidence HD patients were included in this study and the 
last followed-up day was December 31, 2011. More comorbid burden, male gender, history 
of acute kidney injury, dementia, admitting to intensive care unit, staying at nursing home 
and ever using ventilator were significant prognostic factors. Monthly income only had 
marginal effects on survival at 2.5 years. For discrimination ability, our model has Somer’s 
D statistics of 0.76, 0.76, and 0.75 for 6-months, 1-year, and 2.5-years survival, respectively.
Conclusions: Three prognostic models with same covariates for short-term and long-
term survival in HD patients were found in this study. The consistency in model performance 
helps clinicians and patients to make decision.
Funding: Government Support - Non-U.S.
FR-PO684
Twice Weekly Treatment Eligibility for Incident Hemodialysis (HD) Patients 
Suresh Appasamy, Andrew I. Chin, Thomas A. Depner.  Div of Nephrology, Univ 
of California, Davis, Sacramento, CA.
Background: KDOQI guidelines advise that hemodialysis treatments constitute a 
patient burden and a risk to native kidney function that can be lowered by reducing HD 
frequency from 3 to 2/week in patients with substantial residual kidney function. To 
determine eligibility for twice weekly HD we analyzed 24 hour residual urea clearances 
(Kru) and volume removal requirements in all incident patients with urine output >100 
ml/day in 4 HD centers.
Methods: From the years 2000-2014, 420 out of 734 incident patients who survived ≥6 
mos, starting HD 3/week had Kru measurements within 1-3 months after starting HD. The 
fractional weekly renal clearance (KrT/V) was subtracted from the continuous equivalent 
minimum goal stdKT/V of 2.0 volumes/week to determine the minimum required standard 
dialyzer clearance (stdKdT/V). With N set as 2/week, eKT/V was back-calculated from the 
Leypoldt equation for stdKT/V, spKT/V from the Tattersall equation for eKT/V, and Kd 
from modeled V and T that was limited to a maximum of 4 hours. Patients were excluded 
if the ultrafiltration (Uf) rate needed to control volume was >10 ml/kg/hr, MAP dropped 
>10 mm, or the patient exhibited symptoms of nausea, vomiting, or cramps.
Results: Patients: N=420, age 57±15 yrs, 58% male, 51% diabetic, 66% TD Catheters. 
Urine collections: 974±617 mL, Kru 3.0±2.1 mL/min, KrT/V 0.7±0.5. Uf 2.1±1.2 L/dialysis 
(3x/week), 2.8±1.6% of dry weight. 
Eligibility target for 2/week HD Patients achieving target
spKT/V <1.4 per 4 hour HD 225 (54%)
Uf rate ≤ 10 mL/kg/hr 206 (49%)
MAP drop < 10 mmHg 343 (82%)
Dialysis symptoms < 10 per month 407 (97%)
In the 225 patients who could achieve the target stdKT/V with 2/week HD, the mean 
spKT/V required was 0.83±0.36. A total of 105 or 25% of patients with measured Kru 
met all 4 criteria.
Conclusions: Urine collections disclosed that 225 or approximately 30% of 734 
incident patients were eligible for 2/week HD based on solute kinetics alone. Using 
conservative criteria, half of these were judged ineligible because of Uf requirements or 
HD-induced symptoms. Opportunity exists for incremental HD in a significant number 
of incident patients.
FR-PO685
The Relationship of Diabetes and Congestive Heart Failure to Costs of Care 
in End Stage Renal Disease Patients  Sheetal Chaudhuri, Jane Brzozowski, 
Hao Han, Len A. Usvyat, John W. Larkin, Mahathi Mothali, Terry Ketchersid, 
Franklin W. Maddux.  Fresenius Medical Care North America, Waltham, MA.
Background: Many Medicare patients (Pts) with end stage renal disease (ESRD) are 
known to have co-morbidities of diabetes mellitus (DM) and/or congestive heart failure 
(CHF). Total costs of care for ESRD Pts are likely to be dependent on patient comorbidities 
and likely to vary by geography. We investigated the relationship of DM and CHF based 
on Pts’ geographic location.
Methods: ESRD Pts with evidence of dialysis at any time during Jan 1, 2010 through 
Dec 31, 2011 and Medicare as their primary payer were analyzed. Pts were stratified based 
on Metropolitan Statistical Areas (MSA) and Medicare Part A and B costs were calculated 
from 100% Medicare data. T-test comparisons were performed for quartiles of total cost of 
care for eight groups: based on vintage (incident [<90 days on dialysis] or prevalent [>3 
years on dialysis]), as well as, comorbidities (no DM and no CHF, with DM and no CHF, 
no DM and with CHF and with both DM and CHF).
Results: Claims for 107,659 Pts were analyzed. Total cost of care increased significantly 
as the percent (%) of Pts with CHF and DM increased; cost of care declined significantly 
as the % of Pts with neither DM nor CHF increased by MSA. Cost of care did not change 
with the increase in % of Pts without DM and with CHF. Yet, costs of care declined as 
% of Pts with DM and without CHF increased by MSA. These patterns were observed in 
both incident and prevalent Pts. 
Conclusions: These results identify differences in association between ESRD related 
co-morbidities and total costs of care: the % of Pts with both DM and CHF is higher in 
areas with higher total costs. Surprisingly, costs of care are lower in areas where the % of 
Pts with DM but without CHF is higher. Risk Adjustments should be considered.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO686
Long Term Outcomes Over 2 Years following a Dialysis Adequacy Quality 
Improvement Initiative  Sajeda Youssouf,1,2 Philip A. Kalra,1,2 Janet Hegarty.1,2 
1Salford Royal NHS Foundation Trust; 2Manchester Academic Health Sciences 
Centre.
Background: Dialysis adequacy is known to correlate with clinical outcomes such 
as mortality. Evidence based guidelines recommend that haemodialysis patients should 
achieve a urea reduction ratio of >65%. UK Renal Registry data shows wide variation 
in facility attainment of target URR. In 2010 the Salford Renal Network implemented an 
ambitious programme to uplift attainment of key quality of care indicators to within the top 
10% in the UK; dialysis adequacy was a target in 2 phases of improvement in 2010-2012.
Methods: Our network implemented a quality improvement programme using 
collaborative methodology. We set four teams a different clinical indicator to work on over 
12 month cycles for 2 successive years, guided by QI facilitation input. Unit A worked 
on URR in phase 1 and developed a package of changes using plan-do-study-act (PDSA) 
testing that was used for improvement by Unit B in phase 2. We analysed the long-term 
outcomes in these units for a further 2 years until May 2014.
Results: Both units reached their aim of >90% of patients achieving target URR>65% 
within their improvement year. Both units sustained the improvements for 2 years with no 
additional resource input after the collaborative. Changes included protocolised nurse-led 
changes to dialysis prescriptions, multidisciplinary review of vascular access, a nurse-led 
anticoagulation protocol, blood sampling protocol, and monthly reports.
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Pre-
intervention
Post-
intevention
Outcome at 2 
years p value
Percentage of patients with 
URR > 65% Unit A 75.8% 91.4% 97.8% 0.003
Mean URR, % (SD) Unit A 70.3 ± 8.3 74.5 ± 5.5 74.9 ± 4.9 0.002
Percentage of patients with 
URR > 65% Unit B 68.9% 91.1% 93.0% 0.002
Mean URR, % (SD) Unit B 69.4 ± 9.1 72.9 ± 9.2 72.8 ± 5.9 0.003
Conclusions: Longer term outcomes from QI interventions are underreported with 
limited evidence on sustainability. We implemented multifaceted interventions to improve 
dialysis adequacy in our network to within the top 10% in the UK. Implementing evidence-
based changes led by frontline staff trained in QI has sustained these improvements for 2 
years after a formal QI intervention, improving quality of care for our patients.
FR-PO687
Clinical Effectiveness of Intermittent Infusion Hemodiafiltration (I-HDF) 
Compared with Conventional Hemodialysis: A Multicenter Clinical Trial 
Michio Mineshima, Kei Eguchi.  Clinical Engineering, Tokyo Women’s Medical 
Univ, Tokyo, Japan.
Background: Intermittent infusion hemodiafiltration (I-HDF) using backfiltration 
of an ultrapure dialysis fluid has been developed to improve the peripheral circulation of 
the patient receiving a typical hemodialysis (HD) with repeated intermittent infusion by 
an automated dialysis machine, GC-110N (JMS Co. Ltd., Tokyo, Japan). In a typical HD 
treatment, excessive water removal often induces hypotension and muscle spasm. In the 
I-HDF, some 200-300 mL of ultrapure dialysis fluid was infused into the blood component 
through the dialysis membrane at a rate of 100 mL/min, every 30 min. I-HDF, namely, 
means a HDF treatment with small amount of infusion volume, 1.4 to 2.1 L(= 200-300 
mL x 7 times)/session.
Methods: In this paper, clinical effectiveness of I-HDF was evaluated in comparison 
with conventional HD (CHD) during a multi-center clinical trial that twenty chronic renal 
disease patients participated.
Results: A significantly lower value for time-averaged blood volume reduction was 
obtained with I-HDF compared with CHD in spite of there being no difference in the 
total amount of water removal. It was due to a higher plasma refilling rate in I-HDF. In 
addition, increasing peripheral blood flow rate in the patient’s toe was detected by a laser 
flowmeter for each infusion in many patients. The cleared space value defined as amount 
of normalized solute removal during a treatment were higher with I-HDF than CHD for 
inorganic phosphate and α 1-MG. Moderate α 1-MG clearance reduction was found in 
I-HDF due to the prevention of membrane fouling by intermittent backfiltration of the 
dialysis fluid. No significant difference of albumin leakage between I-HDF and CHD. 
Reduction ratio of the systolic blood pressure and the number of treatments by medical 
staff in I-HDF were lower than those in CHD.
Conclusions: Intermittent Infusion HDF using an automated dialysis machine was 
effective for improvement of the peripheral circulation of patients receiving conventional 
HD.
FR-PO688
Impact of Post-Hospital Phone and Telehealth Case Management to 
Reduce Admissions in Hemodialysis Patients  Rebecca L. Wingard,1 Billie 
Axley,1 Kathryn A. McDougall,1 Andrew D. Howard,2 Joelle Heilemann,1 Fern 
Parlier,1 Sophia Rosen,1 Len A. Usvyat,1 Alexis Porras,1 Franklin W. Maddux.1 
1Fresenius Medical Care, Waltham, MA; 2Metropolitan Nephrology Associates, 
Clinton, MD.
Background: 2012 30-day readmissions for hemodialysis (HD) patients (pts) were 
high at 35% (USRDS). Right TraCTM (RT) used post-hospital RT case manager (RTCM) 
calls to reduce post-hospital admissions. Telehealth vs. phone calls was also studied.
Methods: In 28 clinics from Feb-Nov ‘14, RTCMs attempted weekly phone calls 
to pts at home or dialysis clinic, or via telehealth in the clinic for 30 days post-hospital. 
RTCMs assisted pts with discharge instructions and addressed changes in dry weight, 
medications, nutrition, access, and taught Red Flags (symptoms that signal potential 
readmission). Telehealth was performed via iPad tablet in the clinic, configured for secure 
video tele-communication using clinic’s local wifi. 90-day admit rates post-hospital 
adjusted for comorbidities and RTCM telehealth ratings were measured; comparison was 
done using Poisson models.
Results: For pts with no RTCM calls (n=1702) vs. pts with initial call (n= 801), 
annualized 90-day admits per pt year (ppy) were 5.6 and 4.6, respectively (p=0.89, Fig 
1). 90-day admits ppy for pts with initial call and >= 1 follow-up call (n=591) were 3.9 
(p=0.0025 vs. no calls). For pts with initial call by phone (n=785) vs telehealth (n=34), 
90-day admits ppy were 4.6 and 2.6, respectively (p=0.47). RTCM telehealth ratings ranged 
4.3-4.7, and cited enhanced pt-RTCM relationship and assessment (Fig 2). “Able to see 
pt” rated lowest, due to wifi connectivity.
Conclusions: RTCM calls during 30 days post-hospital showed significantly lower 
90-day admits ppy for pts with initial and >=1 follow-up call. Telehealth had lower 90-day 
admits ppy vs. phone calls, although not significant. Further study is needed, especially 
in view of high RTCM ratings.
FR-PO689
Reduced Hemodialysis (HD) Patient Hospital Admissions and 
Readmissions Associated with Right TraC™ Care Transitions Program 
Rebecca L. Wingard,1 Billie Axley,1 Kathryn A. McDougall,1 Andrew D. 
Howard,2 Cathleen Okeefe,1 Sharon Deluca,1 Janice B. Sitzlar,1 Len A. Usvyat,1 
Franklin W. Maddux.1  1Fresenius Medical Care, Waltham, MA; 2Metropolitan 
Nephrology Associates, Clinton, MD.
Background: 30-day readmissions for HD patients (pts) are high at 35% in 2012 
(USRDS). The Right TraC (RT) Program addressed factors in the complex process of care 
transitions, with the aim to reduce hospital admissions and readmissions.
Methods: 26 HD clinics (3682 pts) were in RT. Interventions deployed in 3 phases 
(Apr ‘13-Nov ‘14). I: Pre- and post-hospital checklists for clinics to manage pt teaching, 
anemia, nutrition, medications, and dry weight. II: Telephonic case management for 
30 days post-discharge. III: Dialysis LinkTM centralized clinical info exchange among 
providers. Admission and readmission rates per pt year (ppy) for “baseline year” (2012) 
vs. “full intervention year” (2014) were compared to 18 control clinics (2449 pts) matched 
for clinic size, admission and readmission rate, and urban vs. rural location at baseline. 
Poisson models with random effects for pt and clinic, adjusted for age, vintage, race, gender, 
ethnicity, DM, CHF, and COPD were constructed to assess the difference between baseline 
and intervention and between RT and control clinics.
Results: 30-day readmissions ppy declined from baseline to full intervention year in 
RT (0.88 to 0.65, p<0.001) and controls (0.73 to 0.6, p=NS); comparison of the change 
between groups was not significant (Fig 1). Admissions ppy declined from 2.5 to 1.95 for 
RT (p<0.001), and 2.14 to 1.9 for controls (p=NS); comparison of the change between 
groups was significant with greater decline for RT (p<0.001, Fig 2).
Conclusions: RT interventions were associated with significant declines in admissions 
and 30-day readmissions. The difference in the changes between RT vs. controls was 
significant for admissions, but not significant for 30-day readmissions.
FR-PO690
Predicting Early Mortality Among Hemodialysis Patients Using USRDS 
Data  Fang Wang,1,2 Zhi He,3 Jennifer L. Bragg-Gresham,1 Yuan Yang,3 Haoyu 
Gu,3 Yi Li,3 Kamyar Kalantar-Zadeh,4 Elani Streja,5 Rajiv Saran.1  1Div of 
Nephrology-Dept of Internal Medicine and KECC, Univ of Michigan, Ann 
Arbor, MI; 2Renal Div Dept of Medicine, Peking Univ First Hospital, Beijing, 
China; 3Dept of Biostatistics and KECC, Univ of Michigan, Ann Arbor, MI; 
4Univ of California Irvine, Orange, CA; 5Harold Simmons Center, Orange, CA.
Background: Higher early mortality of hemodialysis (HD) is recognized. We sought 
to quantify the risk of early mortality and develop a robust prediction model which could 
potentially guide clinical decision-making.
Methods: The 2007-2012 data from the United States Renal Data System (USRDS) 
on incident HD patients, age >18 years, were randomly split as ‘training’ and ‘validation’ 
samples. Cox proportional hazards model with piece-wise constant coefficients was used 
to model all-cause mortality during day 0-90 and day 91-365 of HD. Those transferred to 
peritoneal dialysis or transplantation were censored. The resulting model was validated 
by C statistic.
Results: The mean age (n=611,094) was 63.6±14.9 years, with 130,473 deaths during 
the first year of HD. Mortality rates were 35 per 100 person-years in the first 90 days and 
21 per 100 person-years during day 91-365. The prediction equation for early mortality 
involved 23 variables including demographics characteristics, pre-ESRD care, laboratory 
values, co-morbidities as well as institutionalization status. In adjusted analyses, selected 
variables with significant time-varying effects are listed in the Table.
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The prediction model reached a C statistic of 0.70 (95% CI, 0.57-0.82).
Conclusions: We have developed a predictive model for early mortality in a national 
cohort of incident HD patients and identified risk factors with time-varying effects. We 
intend to further refine and validate this model before recommending in clinical practice.
Funding: NIDDK Support
FR-PO691
Recent Evidence on the Impact of Medicare’s Bundled, Prospective Payment 
System for Renal Dialysis  Richard Hirth,1 Tammie A. Nahra,1 Adam S. Wilk,1 
Marc Turenne,2 John Wheeler,1 Kathryn Sleeman,1 Wei Zhang,1 Jonathan H. 
Segal.1  1Univ of Michigan; 2Arbor Research Collaborative for Health.
Background: Medicare implemented an expanded prospective payment system (PPS) 
in 2011, including services previously paid by fee-for-service. One intent of the PPS was 
to incentivize providers to be more efficient in the mix of services provided.
Methods: We used Medicare claims to assess monthly trends from 1/2010-12/2014 
for injectable drugs that were previously billed separately. For 2010, we assessed actual 
spending. For 2011-14, we projected spending based on reported utilization.
Results: ESA use declined in the months immediately pre- and post-PPS, continuing to 
decline through 2012. In 2013, ESA use leveled off. Use of iron products, often improving 
the efficacy of ESAs, increased through 2011 and then began to decline. Total drug cost, 
including ESAs, iron, and vitamin D, fell by more than 50%, from a high of $76.16 per 
session in early 2010 to a low of $37.67 toward the end of 2012. This decline was driven 
by reduced drug utilization. Since early 2013, total drug costs have risen a bit due to higher 
drug prices. Beginning in 2013, drug costs have remained at about 42 per session, reflecting 
gently declining use and higher drug prices.[Fig.1] The reduction in drug spending of about 
$34 per session over a period of 4 years exceeds the Medicare mandated reduction in the 
base rate over the same period. 
Conclusions: The expanded bundle dialysis PPS provided incentives for both lower 
medication utilization overall and the use of lower cost therapies. These incentives seem 
to have motivated an immediate movement toward lower cost methods of care. Facilities 
have been able to maintain a lower cost of care over the last two years. CMS continues 
to monitor facility costs and will continue to make a reduction to the ESRD PPS Market 
Basket through CY 2018, in accordance with section 217 of PAMA.
Funding: Other U.S. Government Support
FR-PO692
Effect of Medicare’s Payment Adjustment for Low-Volume Dialysis 
Facilities on Facility Closures  Richard Hirth,1 Tammie A. Nahra,1 Adam S. 
Wilk,1 Marc Turenne,2 Jonathan H. Segal,1 John Wheeler,1 Kathryn Sleeman,1 
Wei Zhang.1  1Univ of Michigan, Ann Arbor, MI; 2Arbor Research Collaborative 
for Health, Ann Arbor, MI.
Background: Small dialysis facilities may face higher per-treatment costs due to 
economies of scale. Since 2011 a low-volume payment adjustment (LVPA) raised Medicare 
payments 18.9% to facilities with <4,000 treatments in each of the 3 prior calendar years. A 
goal of this policy is to preserve access to care by preventing the closure of small facilities.
Methods: We tested the hypothesis that the LVPA prevented closures by examining the 
year-to-year closure rates of U.S. dialysis facilities during 2007-2013, before and after the 
policy, comparing facilities providing <4000 and >4000 annual treatments. Analyses with 
linear regression relate facility outcomes to prior year size, ownership, for-profit status, 
hospital affiliation, patient mix, rural location, modality mix and county characteristics, to 
examine the effect of the LVPA on # of treatments provided by facilities.
Results: Among low-volume facilities, year-to-year closure rates were 3.8%, 4.9% 
and 4.0% pre-LVPA, falling to 1.1%, 0.5% and 0.8% post-LVPA. Among facilities with 
>4000 treatments, closure rates also decreased, but to a much smaller extent (from 1.0%, 
1.2% and 0.8% pre-LVPA to 0.6%, 0.2% and 0.3% post-LVPA).
Conclusions: In Medicare’s bundled payment system, closure rates decreased overall, 
with a much larger absolute reduction among small facilities. The gap in closure rates 
between small and large facilities fell from about 3% points before the policy to about 
0.5% points after. LVPA appears to have helped prevent small dialysis facility closures, 
but it may also motivate some small facilities to avoid growing in order to retain the LVPA. 
Emphasizing a dialysis facility’s importance for patient access rather than size alone may 
help inform payment policy modifications.
Funding: Other U.S. Government Support
FR-PO693
Delayed Thrombectomy Increases Risk for Dialysis Catheter Placement 
Scott Reule, Sunil Akkina, Andrew J. Esten, Paul E. Drawz.  Dept of Medicine, 
Univ of Minnesota, Minneapolis, MN.
Background: Arteriovenous dialysis accesses (fistulas or grafts) are associated with 
significant rates of thrombosis. Though timely thrombectomy may have a significant impact 
on immediate and long-term access survival, it is not always readily available. The goal of 
this study was to evaluate whether delayed thrombectomy increases risk for loss of dialysis 
access and subsequent placement of a dialysis catheter.
Methods:    All patients at the Fairview Health System with thrombectomy as the 
primary reason for admission between January 2008 and April 2015 were included in this 
retrospective observational study.  The electronic medical record was reviewed to evaluate 
type of access, timing of admission and declot, and access on discharge and 6 and 12 
months after discharge. Baseline characteristics and proportions were determined for the 
overall population as well as stratified by tertile of time to thrombectomy, defined as the 
time from admission to the declot procedure. The outcomes of interest included need for 
dialysis catheter at discharge and 6 and 12 months after discharge. Logistic regression was 
used to evaluate the risk for dialysis catheter use adjusting for prior intervention, access 
type, and time to thrombectomy.
Results: Of 444 patients identified using procedural codes, 122 were admitted primarily 
for thrombectomy. The mean age was 60.4 years, 65% were male, and 44.3% utilized 
arteriovenous fistula for access. Mean time to thrombectomy was 0.45 days (range: 0.05-
1.13 days). Fifteen patients utilized a catheter for hemodialysis on discharge. Delayed 
thrombectomy was associated with a two-fold increase in requirement for catheter at 
discharge (OR 2.02; CI 1.19-3.43) and at 6 months (OR 2.04; CI 1.20-3.48). This association 
remained present at 12 months (OR 1.75; CI 1.02-3.00).
Conclusions:    In this study of patients cared for within a large academic health 
system, a one day delay in thrombectomy doubled the risk for need for a dialysis catheter at 
discharge and 6 and 12 months after discharge. These results indicate that a clotted dialysis 
access should be considered a medical emergency.
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FR-PO694
Intradialytic Body Weight Reduction and Outcome of Vascular Access: 
Analyses of Data from the Japan Dialysis Outcomes and Practice Patterns 
Study (J-DOPPS)  Manabu Asano,1 Kenichi Oguchi,1 Akira Saito,2 Yoshihiro 
Onishi,3 Yosuke Yamamoto,4 Shunichi Fukuhara,2 Takashi Akiba,2 Tadao 
Akizawa.2  1Bosei Hospital, Saitama, Japan; 2J-DOPPS Research Group, 
Japan; 3iHope International, Kyoto, Japan; 4Inst for Advancement of Clinical 
and Translational Science, Kyoto Univ Hospital, Kyoto, Japan.
Background: There is no doubt that large-volume ultrafiltration is one of the important 
risk factors for vascular access (VA) thrombus in hemodialysis patients. However, the 
relationships between intradialytic body weight reduction and VA patency are still in the 
middle of being discussed. We tried to determine whether large-volume ultrafiltration was 
practically associated with VA failure by means of the results obtained from the phase 3 
and 4 J-DOPPS.
Methods: Referring data from the phase 3 and 4 J-DOPPS, the current analyses were 
limited to 2736 patients who were evaluable for VA patency and body weight change during 
dialysis. They were assigned to one of the following three groups according to the tertiles 
(T1-T3) of intradialytic fluid removal per body weight: T1, -9.5% to 3.8%; T2, 3.8% to 
5.1%; and T3, 5.1% to 13.7%. The hazard ratio of VA failure was compared across these 
tertile groups using Cox regression models. The models were adjusted for the following 
risk factors: age, gender, BMI, diabetes, hemoglobin, phosphorus, Kt/V, ESA use, and 
antiplatelets use. Primary VA survival was defined as the days until the first VA intervention. 
Secondary VA survival was defined as the days until new VA creation.
Results: The incidence rates (events/100 person-years) of primary and secondary VA 
events were 4.7 and 1.3 for T1, 5.6 and 1.6 for T2, and 6.7 and 1.7 for T3, respectively. 
The adjusted hazard ratios versus T1 for primary VA patency were 1.16 (95% confidence 
interval [CI], 0.88 to 1.52) for T2 and 1.41 (95% CI, 1.07 to 1.87) for T3. The hazard ratios 
versus T1 for secondary VA patency were 1.29 (95% CI, 0.78 to 2.13) for T2 and 1.45 
(95% CI, 0.86 to 2.45) for T3.
Conclusions: This study shows that large-volume ultrafiltration during dialysis tends 
to increase VA failure in hemodialysis patients.
FR-PO695
Post-Endovascular Intervention Venous Access Pressure Ratio (VAPR) 
Predicts Access Survival  Lalathaksha Murthy Kumbar,1 Gerard Zasuwa,1 
Anatole Besarab,2 Kim Hirschman,3 Jerry Yee.1  1Henry Ford Hospital, Detroit, 
MI; 2Stanford, Palo Alto, CA; 3Vasc-Alert, LLC, Evanston, IL.
Background: The Vascular access pressure ratio test identifies vascular access (VA) 
dysfunction in hemodialysis patients when 3 consecutive VAPR (VAP/MAP) measurements 
are >0.55. We hypothesized whether a post-interventional VAPR decline predicts VA 
outcomes in patients with VA dysfunction.
Methods: Retrospective analysis of all VA procedures from 09/2013 to 04/2015. 
Data collection included demographics, comorbidities, VA features, mean VAPR <30 
days pre- and post-procedure, time-to-next procedure, and access patency. Kaplan-Meier 
arteriovenous graft (AVG) and fistula (AVF) survival curves were compared by the log-rank 
test. A Cox-proportional hazard model was used to determine the association of VAPR ∆% 
(Pre-Post)/Pre×100%) with access survival.
Results: Analysis of 92 subjects [females 57% (n=53); black 88%; and diabetes mellitus 
61% (n=56)] included 46 AVF with 94 procedures and 46 AVG with 86 procedures. Mean 
VAPR ∆% was 26 ± 61 (SD) and 16 ± 54 for AVF and AVG, respectively. VAPR decline 
was absent in 13 AVF. AVF with no VAPR decline (<0%) post-intervention when compared 
to AVF with any decline (>0%) required more subsequent procedures (64% vs 47%), with 
fewer days to next procedure (75 vs 149 d), and lower survival (p=0.002). For AVG, a post-
intervention VAPR decline >10% (p=.04) projected AVG survival. 34% of AVG procedures 
had <10% decline (n=30) and required more subsequent procedures than AVG with >10% 
decline (64% vs 39%). AVF without VAPR decline had a 3-fold greater risk of failure 
(p=0.003). The risk of failure was 2.0-fold greater (p=0.04) for AVG with <10% decline.
Conclusions: A >10% post-intervention reduction of VAPR in AVG and any VAPR 
reduction in AVF predicts greater VA survival. 
FR-PO696
Abnormalities in Mineral Metabolism and Dialysis Arteriovenous Fistula 
Thrombosis in the HEMO Study  Anna Jeanette Jovanovich,1,2 Eugene J. 
Nuccio,2 Alfred K. Cheung,3,4 Tom Greene,4 Michel Chonchol.2  1Denver VA 
Medical Center; 2Unversity of Colorado Denver; 3VA Salt Lake City; 4Univ 
of Utah.
Background: Vitamin D deficiency and fibroblast growth factor 23 (FGF23) excess 
are highly prevalent among patients requiring chronic hemodialysis. This study aims to 
determine the association of 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D 
(1,25(OH)2D), and FGF23 serum levels with arteriovenous fistula (AVF) thrombosis in 
hemodialysis patients.
Methods: The HEMO Study was a randomized multicenter study evaluating the effects 
of high-dose versus standard-dose and high-flux versus low-flux hemodialysis. Serum 
25(OH)D, 1,25(OH)2D, and intact FGF23 levelswere measured in stored serum samples 
obtained at baseline in 881 patients in this cohort.Cox proportional-hazards models were 
used to examine the association of 25(OH)D), 1,25(OH)2D, and FGF23 serum levels with 
time to first AVF clotting event after controlling for important clinical covariates in the 
HEMO Study.
Results: Patients had a mean age of 57±14 years, 55% were females, and 46% were 
white. During a median follow-up of 3.0 years, 111 AVF clotted. Median (IQR) serum 
25(OH)D, 1,25(OH)2D, and FGF23 levels were 19.1 [14.2, 26.6] ng/mL, 6.3 [2.9, 14.5] 
pg/mL, and 3118 [726, 12928] pg/mL. Among patients with levels in the highest tertiles 
compared to the lowest tertile, both 1,25(OH)2D and FGF23 were significantly associated 
with an increased risk of clotting in adjusted analyses, hazard ratio (HR) 2.79 (95% CI, 
1.21-6.46) and HR 1.35 (95% CI, 1.002-1.83), respectively. No statistically significant 
associations were observed between 25(OH)D serum levels and AVF thrombosis.
Conclusions: Calcitriol and FGF23 excess were associated with an increased risk of 
AVF thrombosis among chronic hemodialysis patients.
Funding: NIDDK Support, Veterans Administration Support
FR-PO697
Ultrasound-Guided Evaluation of New AV Fistulas Safely Decreases Time to 
First Cannulation  Farzin Farpour,1,2 Roshan A. Patel,1,2 George N. Coritsidis.1,2 
1Nephrology, Elmhurst Hospital, Icahn School of Medicine at Mount Sinai, 
Elmhurst, NY; 2Nephrology, Broadway Atlantic Dialysis Center, Elmhurst, NY.
Background: The use of bedside ultrasonography (USG) in various medical specialties 
has exploded over the last decade. For the past year, we have been using bedside USG 
for earlier AV fistula utilization and for diagnosing potential problems. Prior to the use of 
USG, cannulation was based on physical exam. We were interested to see whether use of 
bedside USG helps in early cannulation of AVF.
Methods: USG procedures from February 2014 to February 2015 were reviewed. Time 
to cannulation in the year prior to the introduction of USG (2013 - 2014) was calculated 
and compared to similar data with USG use. By week 4 all new fistulas underwent the first 
USG exam.Examinations were performed by the renal attendings and fellows each exam 
lasting about 5 minutes. SonoSite M- Turbo ultrasound machine was used.
Results: Total of 44 USG examinations were performed on 14 patients while monitoring 
new AVF maturation. In 10 patients USG-guided cannulation occurred at an average of 
6.2 ± 0.9 weeks compare to 10.2 ± 0.9 weeks prior to USG use (P=0.006). There were no 
complications seen with the earlier USG-guided cannulations. Subsequent cannulations 
by the nursing staff were successful without USG. In 4 patients failure of maturation was 
diagnosed by USG at an average of 3.8 ±0.9 weeks vs 9.6 ±1.2 weeks prior to USG (P=0.08). 
Antibiotic dosing occurred 21 times prior to USG compared to 11 times with USG, despite 
the similar catheter rates for both years.
Conclusions: USG use facilitates early AVF cannulation with decreased time to first 
use. Identification of potential AVF issues and their referral are accomplished earlier. This 
may translate to earlier catheter removal and fewer infections.
FR-PO698
Arteriovenous Grafts Reduce Catheter Dependence in the Elderly 
Thomas M. Loh, Matthew E. Bennett, Francis E. Loh, Eric K. Peden.  Vascular 
Surgery, Houston Methodist, Houston, TX.
Background: Arteriovenous fistulas (AVF) are the permanent access of choice. The 
benefits of AVF, durability and longevity, are minimized in the elderly where more than 
40% of patients will die within their first year of initiating hemodialysis. We investigate an 
expanded role for primary arteriovenous grafts (AVG) in this population.
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Methods: We retrospectively review consecutive patients over the age of 70 who 
underwent upper extremity access creation from January 2008 to July 2014. Data collection 
included demographics, past medical histories, subsequent interventions, volume flows, 
access usage, and patient survival.
Results: We performed 366 AVF and 124 AVG creations in 442 patients over the age 
of 70 (197 women, 245 men). There were no significant differences in the comorbidities 
between the two access types. The AVG group was significantly older and more likely to 
be female, 79.2 yo vs. 77.2 yo (p<0.001) and 60% vs. 41% (p<0.001) respectively. Patients 
with AVF were significantly more likely to never use their permanent access, 25% vs. 11% 
(odds ratio: 2.6, p=0.002) and if utilized, cannulated significantly later, 3.6 ± 0.2 months vs. 
1.3 ± 0.1 months (p<0.001). Catheter dependence at 6 months was 40% for AVF and 28% 
for AVG. (Figure 1) Secondary patency at 18 months was 64% for AVF and 63% for AVG. 
Conclusions: Prosthetic grafts should be considered as the preferred permanent 
access type in the elderly. Better predictors of mortality, including frailty scores, should 
be investigated for determining the best choice of permanent access in elderly patients.
FR-PO699
Anticoagulation-Free Dialysis Is Not Associated with Failure to Meet 
Ultrafiltration Target: A Single-Center Inpatient Dialysis Study 
Rozina B. Ali, Akshatha Rao, Sandeep Aggarwal.  Div of Nephrology and 
Hypertension, Drexel Univ College of Medicine, Philadelphia, PA.
Background: Conventional outpatient hemodialysis utilizes various forms of 
anticoagulation to prevent access and extracorporeal circuit clotting. In contrast, to reduce 
the risk of bleeding events, inpatient dialysis units do not frequently use anticoagulation. 
We aimed to investigate the consequences of anticoagulation-free dialysis and the factors 
associated with failure to achieve ultrafiltration target (UFT) in our inpatient unit.
Methods: We performed a retrospective analysis of 250 consecutive hemodialysis 
treatments in 125 chronic patients. Patients were excluded if they were admitted for initiation 
of dialysis or required systemic anticoagulation. We looked at both instances of successful 
achievement and failure of UFT. We looked at the following factors: type of access, episode 
of intradialytic hypotension (IDH), episode of access clotting, and episode of extracorporeal 
circuit clotting. No anticoagulation was used in the HD treatments. Correlation analyses 
were performed and categorical data was analyzed using chi-square test. STATA, version 
11, was used for statistical analyses.
Results: Overall the incidence of failure to meet UFT was 35%. Association of failure 
to meet UFT and episode of IDH was noted (p=0.000, Pearson chi2(1) = 13.5). There was 
no correlation between meeting UFT and type of access (graft r=-0.09, fistula r=0.13, and 
catheter r=-0.07), access clotting (r=0.07), and extracorporeal circuit clotting (r=-0.08).
Conclusions: Our study of 250 anticoagulation-free hemodialysis treatments suggests 
that access and extracorporeal circuit clotting was not associated with failure to meet 
ultrafiltration target. However, the failure to achieve ultrafiltration target was significantly 
associated with intradialytic hypotension. Larger cohort, multi-center prospective trials 
should be performed to look at causality of failure to meet ultrafiltration targets in the 
hospitalized patient.
FR-PO700
Evaluation of the Ability of Transonic Monitoring to Predict Dialysis Access 
Stenoses  Jerard Zaki Kneifati-Hayek,1 Gaurav Ghosh,2 Stephen Kruger,3 Jeffrey 
I. Silberzweig.1,2,3  1Dept of Medicine, New York-Presbyterian Hospital, New 
York, NY; 2Weill Cornell Medical College, New York, NY; 3The Rogosin Inst, 
New York, NY.
Background: Patency of vascular access is critical to successful maintenance 
hemodialysis. It is well established that lesions are easier to treat if they can be identified 
prior to thrombosis. Non-invasive evaluation of access blood flow with the Transonic device 
is established for this purpose. We previously analyzed its performance after two years 
and demonstrated >99% sensitivity and specificity1. We now seek to extend that work by 
looking at performance over a fifteen-year period.
Methods: Transonic studies are performed on approximately 1500 maintenance dialysis 
patients with AV grafts or fistulae in our 7 clinics in New York City. Transonic flow rates 
<600 cc/min or decreases by >10% from prior readings prompt referral to Interventional 
Radiology or Vascular Surgery. We report on the sensitivity, specificity and predictive 
values for patients treated between 1998 and 2012.
Results: Sensitivity was 42%; specificity 72%. Positive predictive value (PPV) was 
20%; negative predictive value (NPV) was 88%. 
We evaluated our ability to predict stenosis based on decreased dialysis clearance: for 
Kt/V, PPV was less than 10% and NPV less than 80% for different cutoff points; for URR, 
PPV was less than 10% and NPV less than 80%.
Conclusions: We hypothesize that the large numbers of false positive and false negative 
results were caused by scheduled referrals to Interventional Radiology, which have become 
routine. This study suggests that routine Transonic studies may no longer be as important 
as they were in 2000; however, Transonic studies provide better predictive ability than 
reductions in urea-based dialysis clearance.
FR-PO701
Hemodialysis Vessel Mapping in Women and Men  Rita L. McGill, Robin 
Ruthazer, Dana Miskulin, Klemens B. Meyer, Daniel E. Weiner.  Tufts Medical 
Center, Boston, MA.
Background: Men initiate hemodialysis (HD) with fistulas (AVF) more often than 
women, and this gap widens following initiation. Angiography and Doppler vessel mapping 
may promote AVF creation by detecting vessels not found by physical examination. Women 
may benefit more from imaging, as they are less likely to have veins that are visible upon 
inspection, even when suitable for AVF construction. We hypothesized that the sex disparity 
in AVF use may in part reflect a disparity in vessel mapping rates.
Methods: After restricting to patients with pre-dialysis Medicare claims, we used 
CPT codes to ascertain all vascular imaging during the 2 years before starting HD and 
up to 12/31/2012, in the subset of adult HD patients entering USRDS in 2010 or 2011 
with central venous catheters (CVC) as sole vascular access. Doppler studies performed 
on the same day as an angiogram were excluded. Angiograms and Dopplers per 100,000 
patients-months were calculated. Incidence rate ratios (IRR) between women and men 
were adjusted for age, race, BMI, diabetes, and vascular disease using Poisson regression.
Results: Among women with preHD claims, 62% had CVC-only and 14% AVF; 
men had 57% CVC-only and 20% AVF. 18494 men and 16686 women with CVC-only 
contributed 615257 and 558647 patient-months of data. No imaging was performed in 
57% of men and 54% of women. The distribution of studies in men and women showed:
MEN WOMEN
N 18494 16686
ANGIOGRAPHY (# studies performed) 5705 5851
# individuals with Angiography 4058 (22%) 3986 (24%)
Crude IRR Angiography --- 1.13 [1.09, 1.17]
Adjusted IRR Angiography --- 1.11 [1.07, 1.15]
DOPPLER VEIN MAPPING (#studies performed) 5815 5746
# individuals with Doppler 4953 (27%) 4743 (28%)
Crude IRR Doppler --- 1.09 [1.05, 1.13]
Adjusted IRR Doppler --- 1.07 [1.03, 1.11]
# individuals with ANY imaging studies 8011 (43%) 7654 (46%)
Conclusions: Vascular imaging was performed in fewer than 50% of individuals starting 
hemodialysis with CVC. Higher rates of vascular imaging in women were statistically but 
not clinically significant. Promotion of vein mapping and angiography in women merits 
exploration as a means to decrease the disparity in fistula rates between women and men.
Funding: Other NIH Support - NIH/NIDDK T32 DK007777 “Epidemiology, Clinical 
Trials and Outcomes Research In Nephrology”
Tufts CTSI Grant  [UL1 TR001064]
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FR-PO702
Association of Bacteremia with Arteriovenous Access Failure in 
Hemodialysis Patients  Syed Mustafa Ahmed, Laura Plantinga, Rachel E. 
Patzer, Jason Cobb, William M. McClellan.  Emory Univ, Atlanta, GA.
Background: Obesity, female sex, diabetes, peripheral vascular disease, and 
pacemakers are known risk factors for arteriovenous fistula (AVF) and arteriovenous graft 
(AVG) failure. We examined whether bacteremia in hemodialysis (HD) patients with AVF/
AVG represents an additional, independent risk factor for subsequent AVF and AVG failure.
Methods: We conducted a retrospective observational study among 29,571 U.S. 
patients from the United States Renal Data System who started HD with AVF and AVG 
between 1/1/2009 and 9/30/2010. We used inpatient ICD-9 codes after dialysis start to define 
bacteremia and AVF/AVG failure. We then used a multivariable Cox proportional hazards 
model to assess relationship between exposure to bacteremia and time to access failure.
Results: Overall, 12.2% of patients with bacteremia experienced an access failure, 
compared to 4.0% of patients without bacteremia (P<0.001). This difference persisted over 
a median follow-up of 582 days. With adjustment for known confounders, patients who 
had bacteremia after dialysis start were at >3-fold greater risk of subsequent access failure, 
relative to those who did not (HR=3.18, 95% CI: 1.71– 5.95).
Conclusions: This observational study indicates that decreased AVF and AVG survival 
may be associated with exposure to bacteremia among HD patients.
FR-PO703
Comparison of Loss of Vascular Access Patency in Hemodialysis Patients 
with End-Stage Renal Disease due to Systemic Lupus Erythematosus versus 
Other Causes  Laura Plantinga, Sung S. Lim, Rachel E. Patzer, Stephen O. 
Pastan, Cristina Drenkard.  Emory Univ, Atlanta, GA.
Background: Previously we found that U.S. patients with systemic lupus erythematosus 
(SLE) and end-stage renal disease (ESRD) were 40% less likely than other ESRD patients 
to have a permanent vascular access in place at the start of dialysis. Here, we examine 
whether subsequent loss of patency differs in SLE vs. other ESRD patients who have a 
permanent vascular access.
Methods: A cohort of 106,993 U.S. patients starting hemodialysis with an arteriovenous 
fistula or graft (7/05-9/11) was identified from a national registry of treated ESRD (United 
States Renal Data System). Kaplan-Meier analyses and multivariable Cox proportional 
hazards models were used to estimate the association between SLE vs. other ESRD (by 
provider-reported attributed cause at start of dialysis) and the time to first inpatient ICD-9 
code for loss of vascular access patency, with censoring for death or the end of follow-up.
Results: A total of 597 (0.6%) incident hemodialysis patients with a permanent 
vascular access had ESRD attributed to SLE. Over a median total follow-up of 1.9 years 
(IQR, 0.9-3.3 years), SLE vs. other ESRD patients had similar likelihood of loss of patency 
[HR=0.87 (95% CI, 0.70-1.09)].
Results were similar within the first year of dialysis [HR=0.91, 95% CI, 0.62-1.33] 
and, with adjustment for demographics and clinical variables, the association remained 
null [HR=1.13 (95% CI, 0.80-1.65)].
Conclusions: These results suggest that, among those patients who do start dialysis 
with a permanent vascular access, those with SLE are not more likely than other patients to 
experience a loss of vascular access patency requiring hospitalization. Further analyses will 
examine whether these patterns persist when outpatient procedures are included; however, 
confounding by indication would remain a potential bias.
FR-PO704
The Placement of Tunneled Central Venous Catheters Through 
Percutaneous Puncture of Superior Vena Cava in Hemodialysis Patients 
Tianlei Cui, Xiaoxi Zeng, Yanhuan Feng, Ping Fu.  Nephrology Dept, West 
China Hospital, Sichuan Univ, Chengdu, Sichuan, China.
Background: After the exhaustion of traditional insertion sites of tunneled central 
venous catheters (tCVCs), it can be challenging to place the tCVCs in exotic locations. 
A retrospective case series in West China Hospital was studied to assess the placement 
of tCVCs through percutaneous puncture of superior vena cava (SVC) in patients with 
innominate veins occlusion.
Methods: Sixteen patients (male: 62.5%; mean age: 64.7 years; mean duration of HD: 
5 years) who underwent placement of tCVCs through percutaneous puncture of SVC were 
retrospectively analyzed. They had either exhausted AV access sites or chosen not to undergo 
other vascular access placement. All of the patients had occlusion in innominate veins on 
both sides. The outcomes were function measurements of tCVCs, and safety parameters. 
The technique: With patients supine, following the guidance of fluoroscopy, a 5-F catheter 
was placed at the distal end of SVC through the femoral vein, iliac vein or hepatic vein, 
serving as a fluoroscopic target. Later, guided by fluoroscopy vertically and horizontally, 
the puncture needle and sheath were placed into SVC through a percutaneous route with 
the insertion site at 0.5-1.0 cm lateral-inferior to the clavicle head of sternocleidomastoid, 
allowing the access of the guidewire and the placement of a tCVC.
Results: The procedure succeeded in all of the patients. During the follow-up (mean: 
12 months, range: 3-36 months), access failure due to thrombosis was observed in one 
patients, and the failure was treated by aspirin and Clopidogrel. The remaining continued 
to function well until the end of the follow-up or until the death of the patients (n=3). The 
procedure was generally safe. No pneumothorax occurred. The most common complication 
was mediastinal hematoma after the failure of SVC puncture. The fluoroscopy could reveal 
the hematoma during the procedure. The largest hematoma was 2cm in diameter in the 
current series and it resolved spontaneously.
Conclusions: In patients with innominate veins occlusion and exhaustion of the 
conventional insertion sites, the tCVCs can be safely placed through SVC puncture using 
percutaneous route.
FR-PO705
Analysis of Survival of Cardiac Function in Maintained Hemodialysis 
Patients with Arteriovenous Fistula and Tunneled Cuffed Catheter 
Li Hua Wang, Fang Wei, Ai Li Jiang.  Dept of Kidney Disease and Blood 
Purification Centre, Inst of Urology 	 Key Laboratory of Tianjin, nd Hospital 
of Tianjin Medical Univ, Tianjin, China.
Background: Untill now ,there is little data of cardiofucntion regarding to different 
type of vascular access.This study was to investigate survival of patients with arteriovenous 
fistula and tunneled catheter on maintained hemodialysis in terms of cardiacfunction.
Methods: A total of 219 patients who received maintained hemodialysis were included 
in this study. Patients were divided into two groups: arteriovenous fistula group and tunneled 
catheter group.The baseline anthropometric and 1aboratory parameters were measured. The 
time and cause of mortality were documented.
Results: There were significant difference of left ventricular hypertrophy[x2=6.645, 
P=0.001], left ventricular stystolic dysfunction[>x2=4.007, P=0.045], between two groups. 
But there was no significant difference of left ventricular diastolic dysfunction between 
two groups.Kaplan-Meier survival curves showed that the mortality was enhanced among 
tunneled catheter group.
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Patients with left ventricular hypertrophy ,left ventricular stystolic dysfunction, left 
ventricular diastolic dysfunction in arteriovenous fistula group have a high survival rate 
compared wtih tunneled catheter group. Furthermore iPTH, calcium, stystolic blood pressrue 
and diastolic blood pressure were the independent risk factors of mortality for patients on 
maintained hemodialysis by COX regression model.
Conclusions: Different type of vascular access may have influence on mortality in 
patients on maintained hemodialysis. Those with tunneled catheters have lower survival 
rate when left ventricular dysfunction occurred.
FR-PO706
A Retrospective Study of Preferable Alternative Sites to Right Internal 
Jugular Vein for Tunneled Hemodialysis Catheters Insertion: Right 
External Jugular Vein versus Left Internal Jugular Vein  Yufei Wang, Pei 
Wang, Xianhui Liang, Xiaoqing Lu, Zhangsuo Liu, Yingjin Qiao, Sijie Zhou. 
Blood Purification Center, The First Affiliated Hospital of Zhengzhou Univ, 
Zhengzhou, Henan, China.
Background: It has been recommended by the KDOQI guidelines that right internal 
jugular vein (RIJV) is a preferred insertion site for hemodialysis (HD) catheters, and both 
right external jugular vein (REJV) and left internal jugular vein (LIJV) are alternative 
sites for those who have encountered severe thrombosis and/or occlusion of RIJV. The 
retrospective study aimed to determine if superiority exists in the two alternative sites by 
comparing the outcomes of tunneled (cuffed) dialysis catheters (TDCs) through REJVs 
versus LIJVs in HD patients who had failed RIJV.
Methods: From January 1, 2013 to December 31, 2014, 28 LIJV-TDCs and 21 REJV-
TDCs were inserted in our hospital. All events were recorded from patient charts until 
May 31,2015. Using SPSS 22.0 software, data were analyzed by the Fisher exact test or 
chi-square test. Event free catheter survival was estimated by the Kaplan-Meier method. 
Multivariable Cox hazards analysis was fitted to detect the independent risk factors of 
events. A p-value of <0.05 was considered statistically significant.
Results: A total of 20924 (LIJVs, 11782; REJVs, 9141) catheter-days were evaluated 
and the mean was 427.02 days. Most of the patients (53.1%) were older than 65 years 
with an average dialysis time of 25.3 months. The event free catheter survival time was 
(516.20±55.60)d in REJV-TDCs and (343.91±40.63)d in LIJV-TDCs (P=0.038). Mean 
effective blood flow was higher in REJV-TDCs than that in LIJV-TDCs (270.95±24.93 
vs 244.82±30.35ml/min, P=0.02). A substantial trend toward statistical significance was 
found between two groups in incidence of all events, including death, death related to 
catheter complication and catheter removal. The total historic catheters indwelling time 
was identified as an independent risk factor for severe TDCs events by Cox regression 
hazards test (p= 0.01).
Conclusions: REJV might be superior to LIJV as an alternative insertion site for TDC 
placement in in HD patients who had failed RIJV.
FR-PO707
Haemodialysis Recirculation in Patients with Catheter Access  Damien Ashby. 
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, 
United Kingdom.
Background: Recirculation is a well described impairment of the haemodialysis circuit 
which reduces dialysis dose and electrolyte clearance. Catheter tips are designed to minimise 
recirculation based on in vitro experiment, with most designs having a tip separation of 
25mm, but clinical studies of catheter-related recirculation have not been published.
Methods: In a group of stable adult patients receiving haemodialysis by tunnelled 
catheters, recirculation was calculated by 3-sample urea measurement, and analysed in 
relation to line tip separation (measured by chest X-ray) and routinely collected clinical 
parameters. All patients were using paired Tesio catheters.
Results: In 54 haemodialysis patients (aged 28-90, 61% male) median recirculation 
was 3.7% with IQR 1.9-6.3%, range 0-19.7%, and a heavily left-skewed distribution (modal 
range 0-2%). Greater than 5% recirculation was seen in 30% of patients. Tip separation 
(range 3-52mm) was strongly associated with recirculation (R=-0.33, p=0.014), which also 
appeared to have a weak association with body weight (R=0.21, p=0.13). 
Defining thresholds to avoid high recirculation (>5%): with tip separation over 25mm 
high recirculation was seen in 6 patients. Increasing threshold tip separation to 30mm 
reduced the number of patients with high recirculation to 2. The same was achieved using 
a weight-based tip separation threshold of 0.5mm/kg. High recirculation was associated 
with high erythropoietin requirement (R=0.29, p=0.030) but not with low Kt/V (p=0.26).
Conclusions: Significant recirculation affects a significant minority of patients dialysing 
on tunnelled catheters, and is closely related to tip separation. A tip separation threshold of 
25mm may be inadequate to avoid high recirculation, and 30mm or perhaps a weight-based 
threshold may be superior. Erythropoietin resistance is a possible consequence of this type 
of haemodialysis recirculation.
Funding: Clinical Revenue Support
FR-PO708
Risk Factors for Fatal Dialysis Access Haemorrhage  Nicole M. Lioufas,1 
Jonathan E.H. Ling,1 Gail Theresa Read,1 Matthew D. Jose.1,2  1Royal Hobart 
Hospital, Hobart, Tasmania, Australia; 2School of Medicine, The Univ of 
Tasmania, Australia.
Background: Haemodialysis requires access to the circulation via an arteriovenous 
fistula or graft, or a synthetic vascular catheter. Annually there are deaths associated with 
catastrophic bleeding from dialysis vascular access.
Methods: A systematic search strategy including data from the National Coronial 
Information System (NCIS, containing coroner’s reports from all Australian states and New 
Zealand), the Australian and New Zealand Dialysis and Transplant registry (ANZDATA), 
published cases from Australia and New Zealand, individual renal units and State Renal 
Network reports. Data was analysed for all deaths where cause of death was reported as 
being due to dialysis access haemorrhage from 1st January 2000.
Results: A total of 83 patients (mean age 67 years (range 30 – 89), 55% female) 
receiving renal replacement therapy died due to dialysis vascular access haemorrhage. 
These were identified through NCIS 54, ANZDATA 64, State networks 3, Publications 2 
and individual renal units 2. Most deaths were attributable to problems with vascular access 
including infection (22%), dialysis catheter problems (17%), recent access intervention 
(15%) or use of a thigh arteriovenous fistula (11%). Bleeds commonly occurred at home 
in people treated with satellite haemodialysis. Modality at the time of death was home 
haemodialysis in 12 people. Use of Warfarin or cognitive impairment was identified in 
only 1 death each. Coronial inquests and Root Cause Analyses were identified in only 7 
deaths with recommendations involving communication, staffing, clinical policy, practice 
changes and equipment modification.
Conclusions: Death due to dialysis access haemorrhage is an uncommon, catastrophic, 
but potentially preventable event. A number are preceded by vascular access infection, 
vascular access complications or recent intervention. Only a minority of deaths have been 
investigated, but where they have, critical recommendations for optimising future care 
are presented.
FR-PO709
Subcutaneous Implantable Electronic Devices in Chronic Kidney Disease 
and Hemodialysis Patients  Rizwan K. Alimohammad, Rahim Dhanani, James 
O’Brien, Syed S. Haqqie, Arif Asif.  Albany Medical College.
Background: While epicardial leads have been reported to bypass central venous 
stenosis, their placement is much more invasive and requires the services of a cardiothoracic 
surgeon. Recent data have demonstrated successful defibrillation using a subcutaneous 
ICD (SICD). While the use of these devices is expanding, their insertion in advanced 
renal failure and hemodialysis patients is somewhat limited. In this analysis, we present 
9 CKD and 4 hemodialysis patients treated successfully with an SICD. Demographic 
characteristics revealed; male=8, diabetes=8, hypertension=13, coronary artery disease=10, 
peripheral vascular disease=8. Two of the four hemodialysis patients had an AVF while 
two were dialyzing with a tunneled dialysis catheter. Mean GFR for the CKD patients 
was 40±3 ml/min. Patients received the SICD device for primary prevention of sudden 
cardiac death (cardiomyopathy with low ejections fraction). 3/13 patients had non-ischemic 
cardiomyopathy (CMP) with an ejection fraction of <25% while 10/13 suffered from 
ischemic CMP with an EF of <30%. There were no procedure-related complications in 
terms of excessive bleeding, hematoma or infection. At an average follow-up of 6 months, 
one death has occurred that was unrelated to the procedure or arrhythmia. Subcutaneous 
ICD is a minimally invasive procedure when compared with an epicardial device. By 
leaving the venous system untouched, this approach offers the advantage of reduced risk 
of central venous stenosis and infection over an endocardial ICD with transvenous leads. 
This approach is particularly helpful for CKD and hemodialysis patients who rely on venous 
capital for their survival. SICD has been FDA approved and is currently being utilized in 
the United States and Europe.
Methods: Restrospective evaluation of SICD in patients with CKD and ESRD.
Results: Thirteen patients with CKD and ESRD on dialysis received successful SICD.
Conclusions: SICD can be successfully used in patients on hemodialysis and CKD.
FR-PO710
Modified Non-Transposed Brachiobasilic Arteriovenous Fistula for 
Hemodialysis: A Randomized Controlled Study  Dayong Hu,1 Chunyu Zhou,1 
Chandra Mohan,2 Changbin Li,1 Jie Tang,3 Ai Peng.1  1Shanghai Tenth People’s 
Hospital, Tongji Univ School of Medicine, Shanghai, China; 2Univ of Houston, 
Houston, TX; 3DHHA-Univ of Colorado School of Medicine, Aurora, CO.
Background: Transposed brachiobasilic arteriovenous fistula (BBAVF) is technically 
challenging. It not only associates with severe arm swelling and pain, but also takes longer 
to be ready for use. Here we introduce a novel modified non-transposed BBAVF (mNT-
BBAVF), and compare its outcomes to those of the standard brachiocephalic arteriovenous 
fistula (BCAVF).
Methods: From January 2010 to December 2012, 74 incident hemodialysis patients 
with suitable basilic and cephalic veins were randomized equally into mNT-BBAVF and 
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BCAVF groups. All participants were followed for 12-months after surgery. The main 
outcomes were blood flow velocities and volumes, vessel diameters, primary unassisted 
fistula patency rate (PUFPR), the cumulative fistula survival rate (CFSR) and complications.
Results: The baseline demographic and clinical characteristics were well matched 
between mNT-BBAVF and BCAVF groups. Blood flow velocities and flow volumes of the 
corresponding fistula segments increased significantly in both groups. Compared to BCAVF 
where only proximal cephalic vein increased in size, the proximal cephalic vein, distal 
cephalic vein and distal basilic vein in mNT-BBAVF all increased significantly compared to 
baseline over the 12-month period (p<0.01). Therefore, in addition to the proximal cephalic 
vein, the distal cephalic vein and distal basilic vein were also available for cannulation in 
mNT-BBAVF. At 12 months, the PUFPR of mNT-BBAVF was significantly better than 
that of BCAVF (73.0% vs. 45.9%, HR: 2.60; 95%CI: 1.21 to 5.59; p=0.01). Although, the 
CFSR did not differ between the two groups (91.9% vs. 78.4%, HR: 1.68; 95%CI: 0.55 to 
5.17; p=0.37). Finally, there were no significant differences in complications between the 
two intervention groups at 1 and 12 month follow-ups, other than severe arm pain which 
was much less reported among patients with mNT-BBAVF at 1 month (vs. BCAVF, p=0.03).
Conclusions: mNT-BBAVF is an effective alternative for the construction of upper 
arm vascular access.
FR-PO711
Management of Catheter Related Bacteraemias: New Insights into an Old 
Problem  Benjamin A. Oliveira,1 Conor James Byrne.1  1Renal Medicine, Royal 
London Hospital, London, United Kingdom; 2Renal Medicine, Royal London 
Hospital, London, United Kingdom.
Background: Catheter related bacteraemias (CRB) pose a significant risk for those 
dialysing via such devices. Strategies are needed to minimise this risk as much as possible, 
especially in light of growing concerns over antibiotic resistance. Our unit routinely uses 
citrate to lock catheters. We sought to audit our CRB rate and long term complication 
rate. We believe this contemporary data will be useful to all involved in caring for patients 
with catheters.
Methods: We retrospectively reviewed all blood cultures taken from our institution’s 
dialysis patients for 1 year (October 2013 and September 2014). The records of patients with 
positive cultures were reviewed to ascertain if the infection was related to their access. Data 
was then collected on the type of organism grown, management of the episode, recurrence 
rate, and any long term complications.
Results: 1014 cultures were taken from approximately 930 haemodialysis patients. 
45% of these were dialyzing via a catheter. There were 52 instances of CRB giving a CRB 
rate of 0.34 per 1000 catheter days. 65% were due to gram-positive organisms, 29% were 
due to gram-negative organisms and 6% were fungal related. The overall recurrence rate 
was 26%. Catheter removal was performed in 32 instances (62%). Infective complications 
occurred in 5 (16%) patients with gram-positive infections and 6 (54%) of those with 
gram-negative infections; a statistically significant difference. The majority of these were 
endocarditis. CRB accounted for a total of 583 hospital in-patient days.
Conclusions: We observed significantly more infective complications with gram-
negative organisms compared with gram-positive. This probably reflects the underlying 
characteristics of these patients rather than the pathogenicity of the organisms per se (19% 
of patients with gram-negative infections were intravenous drug users). Never the less our 
data suggests that gram negative infections are a risk factor for complications and clinicians 
should consider further investigations in these cases. Our CRB rate was low compared to 
quoted rates in the literature; this may reflect routine the use of citrate lock in our catheters.
FR-PO712
Assessment of Arteriovenous Fistula Access Flow Using Video Image 
Processing Technology  Schantel Williams,1 Hannah Putnam,1 Viviane 
Calice-Silva,1,2 Israel David Campos Gonzalez,1 Peter Kotanko,1,3 Fansan Zhu.1 
1Renal Research Inst, NY, NY; 2Pontifícia Univ Católica do Paraná, Curitiba, 
Brazil; 3Icahn School of Medicine at Mount Sinai, NY, NY.
Background: Vascular stenotic lesions are the main cause of failure in arteriovenous 
fistulas (AVF). Routine measurement of access flow (AF) is important in the timely detection 
of changes and planning interventions. The aim of this pilot study was to investigate whether 
video image processing (VIP) techniques can be used to detect AVF motion and explore 
the relationship between motion patterns and AF.
Methods: Skin above the AVF was imaged for 1 minute using a digital single lens reflex 
camera prior to HD. The video was processed using Eulerian video magnification (Wu et 
alACM Trans.Graph.31(4), 2012) to amplify AVF motions. Thereafter the motion-amplified 
video was converted to quantitative waveform data using an algorithm based on change in 
color of each image (Matlab Image Processing Toolbox). Monthly AF measurements were 
recorded and correlated with the post-processed AVF waveform pattern.
Results: We studied 12 hemodialysis patients (51.5±11.3 years, 50% male) with a 
mean±SD AF 1501±392ml/min (N=9; AF was unavailable in 1 subject). Amplitude of skin 
displacement was 0.069±0.04mm (N=9; technical issues occurred in 2 subjects). While 
amplitudes of that size are hardly visible to the naked eye, they were clearly discernible 
in post-processed amplified videos. Amplitude was notably smaller in subjects with lower 
AF (Fig. 1). Amplitude analysis of the amplified video indicates a relationship with AF 
(R2=0.73, p<0.01; N=9). 
Conclusions: Our proof-of-concept study demonstrates this video imaging and 
analysis technique has potential to provide a quick, noninvasive, low cost way to obtain 
quantitative information related to AF. Research is underway to assess the impact of clinical 
interventions of the amplitude pattern.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO713
Pre-Emptive Correction of Arteriovenous Access Stenosis: Systematic 
Review and Meta-analysis of Randomized Controlled Trials  Pietro Ravani,1 
Robert R. Quinn,1 Matthew J. Oliver,2 Divya J. Karsanji,1 Matthew T. James,1 
Jennifer M. MacRae,1 Suetonia Palmer,3 Giovanni F.M. Strippoli.4  1U of Calgary, 
Canada; 2U of Toronto, Canada; 3U of Otago, New Zealand; 4Diaverum, Italy.
Background: Elective stenosis correction in an arteriovenous (AV) access that is 
suitable for hemodialysis may prolong its survival, as compared to salvage procedures 
postponed to when the AV access becomes dysfunctional.
Methods: We did a systematic review and meta-analysis of randomized controlled 
trials (RCTs) evaluating pre-emptive correction of an AV access stenosis vs. stenosis 
correction in a dysfunctional access (deferred correction) in adults treated with hemodialysis 
therapy. We searched the Cochrane Kidney and Transplant Specialized Register (which 
includes MEDLINE and EMBASE) to 29 October 2014. Outcomes of interest were 
access loss (primary outcome), access thrombosis, infection, mortality, hospitalization, 
and access-related procedures. We did sub-group analyses of access outcomes by access 
type. We summarized the evidence using the Grading of Recommendations Assessment, 
Development, and Evaluation criteria.
Results: We included 14 studies (involving 1,390 participants; follow-up 6-38 months; 
N=58-189 participants). Nine studies enrolled adults without access stenosis (primary 
prophylaxis; three studies including people using fistulas) and five enrolled adults with a 
highly suspected or documented stenosis in a functioning access (secondary prophylaxis; 
three studies in people using fistulas). Relative to deferred salvage, access surveillance with 
pre-emptive correction of an AV stenosis did not reduce the risk of thrombosis (RR 0.95; 
95% CI 0.8-1.12) or access loss (RR 0.9; 95% CI 0.71-1.15) in grafts (moderate-grade 
evidence), but reduced the risk of thrombosis (RR 0.5; 95% CI 0.35-0.71) and access 
loss (RR 0.5; 95% CI 0.29 to 0.86) in fistulas (low-grade evidence). Results were either 
heterogeneous or imprecise for mortality, rates of infection, procedures and hospitalization. 
There was unclear or high risk of bias in most studies.
Conclusions: Pre-emptive correction of a new or documented stenosis may not improve 
graft outcomes, but may prevent fistula thrombosis or loss.
Funding: Government Support - Non-U.S.
FR-PO714
Real-Time Kt/V Tracking Profile as a Predictor of Dialysis Access 
Recirculation  Abhilash Koratala, Girish Singhania, A. Ahsan Ejaz.  Nephrology, 
Univ of Florida, Gainesville, FL.
Background: On-line monitoring of ultraviolet absorption of spent dialysate in 
routine hemodialysis allows continuous measure of removed solutes from spent dialysate. 
We studied whether real-time Kt/V tracking profile could be a predictor of dialysis access 
recirculation.
Methods: End-stage renal disease patients undergoing maintenance dialysis with Dialog 
(B Braun AG) dialysis machine with a built-in UV-Spectrophotometer (Option Adimea, B 
Braun AG), high-flux polysulfone dialyzers, and at blood flow rate (Qb) 400-450mL/min and 
dialysate flow rate (Qd) 800ml/min were included in all recording sessions. Real-time Kt/V 
tracking profile and venous (PV) and arterial pressures (PA) were recorded and hemodialysis 
access recirculation values were biochemically measured using standard protocol.
Results: Distinct real-time Kt/V profiles were identified in patients with significant 
access recirculation (>5%) vs. none (Control). 
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In the control profile, real-time Kt/V (Fig 1a, solid line) closely followed the target 
line (Fig 1a, dashed line) and was associated with normal PA and PV. In patients with high 
access recirculation, real-time Kt/V tracking line deviated widely from the target line 
(High Recirc Kt/V Profile; Fig 1b, c, d) and remained deviant throughout the treatment 
session. Fig 1d. demonstrates a case wherein the initial low Qb provided false impression 
of normal access function, however increasing Qb resulted in unmasking of high access 
recirculation, i.e., appearance of High Recirc Kt/V Profile. High access recirculation was 
confirmed by biochemical methods. Interestingly, all High Recirc Kt/V Profile events were 
associated with abnormal recirculation values, but not all were associated with elevated PV.
Conclusions: Real-time Kt/V tracking profile provides a non-invasive, inexpensive 
and quick assessment of access recirculation in hemodialysis patients.
FR-PO715
Recurrent Vascular Access Stenosis as a Novel Marker for Cardiovascular 
Outcome in Hemodialysis Patients  Hyo Jin Kim, Hajeong Lee, Dong Ki Kim, 
Kook-Hwan Oh, Yon Su Kim, Curie Ahn, Kwon Wook Joo.  Internal Medicine, 
Seoul National Univ College of Medicine, Seoul, Korea.
Background: Vascular access (VA) is essential component and its stenosis is a major 
complication in hemodialysis (HD) patients. Nevertheless, there are few data for outcomes 
of patients who had recurrent VA stenosis. We have explored the influence of recurrent VA 
stenosis on cardiovascular (CV) event, patient death, and VA failure.
Methods: This is a single-center, retrospective study. Patients who had VA operation at 
Seoul National University Hospital between January 2009 and March 2014 were enrolled. 
Patients who had two or more instances of percutaneous angioplasty or revision operation 
within 180 days were categorized recurrent group. The primary outcome was CV events, 
as coronary artery or heart failure or cerebrovascular, and or peripheral vascular events. 
The secondary outcomes were all-cause mortality (ACM), composite of ACM or CV 
events, and VA failure. The two groups were compared before and after matching with 
propensity scores (PSM).
Results: A total of 766 patients (59.7% male, age 59.6 ± 14.3 years) were analyzed. 
Recurrent group patients (n = 77; 10.1%) were older and had higher underlying CV disease 
and dyslipidemia. A total 213 patients (142 in non-recurrent, 71 in recurrent group) were 
selected by PSM. During 28.7±15.8 months follow-up, 46 patients (21.6%) had CV 
outcomes, 30 patients (14.1%) died, and 14 patients (6.6%) experienced vascular access 
failure. After adjustment, recurrent group was an independent risk factor for CV events 
(adjusted hazard ratio [HR] 2.66; 95% confidence interval [CI] 1.46–4.86, P = 0.001) 
and composite of ACM or CV events (adjusted HR 1.99; 95% CI 1.21–3.27, P = 0.007). 
However, it was not associated with increased ACM and VA failure.
Conclusions: Recurrent VA stenosis was a novel independent risk factor for CV event 
in HD patients, rather than VA failure. For patients suffered from recurrent vascular stenosis, 
diligent monitoring should be warranted not only for VA patency but also for CV events.
FR-PO716
Stent Insertion Is an Important Tool in Maintaining Arteriovenous Access 
Patency  Stephen G. John,1 Kumar Abayasekara,2 Peter M. Bungay,3 Mario 
De Nunzio,3 James E. Kirk,3 John Graham Pollock,3 Peter D. Thurley,3 Paul J. 
Owen,1 Richard J. Fluck,1 Lindsay J. Chesterton.1  1Nephrology, Royal Derby 
Hospital; 2Vascular Surgery, Royal Derby Hospital; 3Radiology, Royal Derby 
Hospital, Derby, United Kingdom.
Background: Definitive access for haemodialysis (HD) remains the cornerstone 
of optimal dialysis. However, HD patients are becoming older, access attempts more 
problematic and vein preservation remains critical. Clinical examination and access 
monitoring enable appropriate, timely, endovascular intervention. Stents may be inserted 
for recurrent stenosis or after endovascular rupture, but their role remains debatable. We 
report on our single-centre experience of access surveillance and endovascular intervention, 
highlighting the role of stent insertion.
Methods: Electronic hospital records were retrospectively analysed in all access-related 
stents inserted from 2006-2014 by 5 vascular radiologists.
Results: 49 stents were inserted during 45 procedures in 39 patients. 12 had diabetes. 
Mean age was 64.5±25.5 yrs, median dialysis vintage was 1162±1504 days (range 
5-5027). Median time from access creation (82% arteriovenous fistula) to stent insertion 
was 318±926 days (range 31-3752). 34 stents were inserted peripherally (cephalic arch 
and distally), the majority in the cephalic arch. Equal numbers of covered and bare-metal 
stents were inserted. 4 stents were placed in thrombosed access. 7 procedures were due to 
surveillance alone, a further 8 due to surveillance and pressure/flow problems. 12 stents 
were inserted for rupture or dissection (overall access procedure complication rate 1%). 
Median time from first stent to access failure/ceased HD was 333±653 days, assisted by 
median 2 (range 0-11) further procedures. Treatment for rupture was not associated with 
significantly shorter access longevity. Only 10 patients’ access failed during follow-up. 
Our overall HD definitive access prevalence rate was 86-90%.
Conclusions: Appropriate HD access is essential in minimising HD morbidity. We 
reserve stent insertion for rapidly-recurring stenosis or rupture during endovascular 
procedures. Our data suggest that appropriate, judicious stent insertion in an appropriately 
structured pathway results in access durability and longevity.
FR-PO717
Association of Vascular Access Flow and Volume Status on Fistula Arm 
by Bio-Impedance Analysis in Hemodialysis Patients  Hun Jeong,2 Hyung 
Jong Kim,1 Eun jung Ko,1 Younhee Lee.1  1Internal Medicine, CHA Bundang 
Medical Center, CHA Univ, Seongnam, Korea; 2Internal Medicine, Seoul Bukbu 
Hospital, Seoul, Korea.
Background: Multi-frequency bioimpedance is a tool of body composition measure and 
can monitor changes in extracelluar volume during dialysis. Arterio-venous fistulae(AVF) 
could potentially affect fluid retention in the arm. We investigated whether multi-frequency 
bioimpedance could detect AVF stenosis or association of AVF with fluid retention in the 
AVF arm.
Methods: We measured the extracellular water(ECW) and total body water(TBW) in 
AVF arm following hemodialysis by multi-frequency bioimpedance(Inbody S10®) using 
an eight-electrode contact technique. We measured AVF flow by transonic ultrasonography 
using an ultrasound dilution technology (HD 03®) in hemodialysis.
Results: Total 28 patients (male 13 patients) were enrolled and the mean age of patients 
was 54.89 ± 13.21 years. ECW/TBW ratio of fistula arm was a significantly higher than 
ECW/TBW ratio of non-fistula arm(0.389 ± 0.01 vs 0.382 ± 0.001; p<0.05). ECW/TBW 
ratio of fistula arm was a significantly negative correlation with access flow level (mL/
min) on fistula(p< 0.05). The 5kHz reactance of fistula arm was a significantly positive 
correlation with access flow level (mL/min) on fistula(p<0.05).
Conclusions: Absolute and also relative extracellular fluid volumes are increased in 
the fistula arm of hemdialysis. We thought that extracellular fluid volumes in the fistula 
arm were associated with access flow level (mL/min) and/or relative fistula stenosis. 
We suggest that multi-frequency bioimpedance can be a useful assistant tool of vascular 
access flow measure.
FR-PO718
Does Pre- and Post-Angioplasty Doppler Ultrasound Evaluation Help 
Predicting Vascular Access Outcome?  Maria Guedes Marques, Pedro Maia, 
Fernando Neves, Aníbal Ferreira, Carlos Oliveira, Carlos Barreto, João Cruz, 
Dulce Carvalho, Telmo Carvalho, Pedro M. Ponce.  Vascular Access Center - 
Nephrocare Lumiar, Portugal.
Background: KDIGO Guidelines recommend post-angioplasty (PTA) lesion should 
have <30% residual stenosis (RS) and hemodynamic parameters should improve. Access 
blood flow (ABF) is one of the most used. Primary end point: how post-PTA ABF 
improvement could predict vascular access (VA) outcome. Secondary: compare doppler 
ultrasound (DU) and angiography diagnostic accuracy; determine how other factors could 
predict outcome.
Methods: Prospective study in 80 patients with dysfunctional VA. DU evaluation 
was performed pre and post-PTA. Several parameters were recorded. Secondary patency 
verified during first 6 months.
Results: Initial DU in 80 patients; 26 excluded due to abnormalities absence or 
impossible endovascular approach - final 54. Two thirds male; age 68±15y; VA time 
36±29months; initial ABF 537±248ml/min; final ABF 1013±354ml/min. Number and 
location of stenosis was highly correlated between DU and angiography (Pearson 0,828; 
p 0.000); mismatching in central vessels. Overall survival 83% at first trimester and 63% 
at semester; significantly better for fistulas (76%) than grafts (51.7%), p 0.044. Final 
angiographic RS>30% occurred in 14.8% patients, who had significantly better survival, 
p 0.038. Initial ABF<500 ml/min and multiple stenosis didn’t affect the outcome (p 0.189 
and p 0.811). A >2-fold ABF increase had no significant impact on fistulas survival (p 
0.339) but it was highly significantly associated with worst outcomes in grafts (23.1% vs 
73.5%, p 0.009). VA failure HR was 3.3 for grafts (p 0.034).
Conclusions: DU diagnostic accuracy is highly correlated with angiography. Although 
less accurate for central lesions, has a key role due to morphologic and hemodynamic 
assessment. PTA is a powerful therapy with immediate benefit; however final angiographic 
RS is not predictive of outcome. Grafts have worst patency, demanding more interventions. 
PTA is associated with mechanical endothelial injury. Higher ABF induce more turbulent 
flow that is likely to cause more intimal hyperplasia, which could explain the shorter 
patency, especially in grafts where inflammation is higher.
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FR-PO719
Why Are Catheters Still Used to Initiate Hemodialysis Treatment of ESRD? 
Tanya Tocharoen Tang, Shubhada N. Ahya, James J. Paparello, Murray L. 
Levin.  Dept of Medicine/Div of Nephrology and Hypertension, Northwestern 
Univ, Chicago, IL.
Background: Complications of long-term use of tunneled catheters for hemodialysis 
involve a high risk of infection, thrombosis, hospitalization and expense. This study reviews 
a single center experience to identify factors that may contribute to the high rate of patients 
initiated with tunneled HD catheters.
Methods: We conducted a 13-question survey of 47 CKD patients who had been newly 
initiated on dialysis through a tunneled central vein dialysis catheter during their hospital 
admission in a university hospital from December 2013-May 2015.
Results: Of 47 subjects, 27 were male and 20 female. Subjects’ mean age was 60 
years old. Demographics included 26/47 (55%) African Americans, 7/47 (15%) Hispanics, 
12/47 (26%) Caucasians and 2/47 (4%) Asian. Ninety-six % of patients (45/47) had been 
seen by a physician within the past year, and had been told their kidney function was poor. 
Eighty-three % of patients (39/47) were referred to a nephrologist. Thirty-six patients saw a 
nephrologist and, of those patients, only 13 patients were referred to a surgeon for access. 
Of the patients who saw a nephrologist, twenty two % (6/36) did not follow through with 
access placement secondary to noncompliance. Thus, of 47 patients starting hemodialysis 
with a catheter, only 7 had actually seen a surgeon for access placement. The largest drop 
off in the continuum of care of the patient is between seeing the nephrologist and seeing 
the surgeon. Since half of the patients surveyed received care elsewhere, it indicates this 
finding is not unique to our institution.
Conclusions: There are numerous points in the path to arteriovenous access where 
attrition occurs. Nephrologists and primary care physicians must oversee proper follow up 
and follow through to assure successful access placement. In our study, we found that there 
is a big attrition point from nephrology to surgery referral. A coordinator to help follow up 
patients or a joint clinic are options to improve this problematic step.
FR-PO720
The Association of Overhydration Status with Megafistulas in End-Stage 
Renal Disease Patients on Hemodialysis  Mihaly B. Tapolyai,1 Maria Faludi,1 
Melinda Forró,1 Andras Tisler,2 Tibor Fulop,3 Klara Berta.1  1Dialysis, Fresenius 
Medical Care Semmelweis Univ, Budapest, Hungary; 2Nephrology, Semmelweis 
Univ, Budapest, Hungary; 3Nephrology, Univ of Mississippi, Jackson, MS.
Background: Megafistulas are tortuous dilated fistulas that fold up on themselves and 
become visible on the arm and shoulders all the way to the clavicles. They may exacerbate 
low cardiac output, as well as represent a problematic dilatation of the dialysis access. 
We sought to investigate the association of bioimpedance apparatus (BCM) measured 
extracellular fluid volume overhydration (OH%) and the presence of megafistulas.
Methods: In a cross sectional study we compared the pre-dialysis BCM-measured 
OH% in 12 prevalent chronic dialysis patients with megafistulas (MEGA) who had negative 
angiographies with that of 52 control dialysis patients (CONTR).
Results: 10/12 MEGA patients had OH% >/=16% as compared to 20/52 CONTR 
patients (Chi square p: 0.02).
The degree of OH% was 20.2 ±7.4% among the MEGA vs. 14.4 ±7.1% in the CONTR 
group (Student t p: 0.01), representing 4.2 ±3.2 vs 2.8 ±1.6 L of excess fluid (p: 0.03). MEGA 
patients took an average of 1.7 ±1.4 vs. 0.8 ±0.8 (p: 0.002) antihypertensive medications 
compared to the CONTR patients yet their blood pressure was 156/91 vs 141/78 mmHg 
(p: 0.03/<0.0001). We found no difference in fistula vintage, body mass index, age, 
inflammatory markers, diabetes status or diuretic use. The odds ratio of overhydration 
being associated with a megafistula is 5.3 (p: 0.01).
Conclusions: There is an association of BCM-measured overhydrated clinical state 
with the presence of megafistulas; either as an increased volume capacitance or as a 
potential cause.
FR-PO721
The Observation of the Tunneled Cuffed Catheter Insertion Through 
Right Innominate Vein in Hemodialysis Patient  Yanhuan Feng, Tianlei Cui, 
Ping Fu.  Div of Nephrology, West China Hospital of Sichuan Univ, Chengdu, 
Sichuan, China.
Background: The routine vascular access for hemodialysis is often available due to 
thrombosis and occlusion after frequent cannulation, which leads to an increase in cost 
and difficulty of catheterization or recanalization. Further catheterization may accelerate 
exhaustion of vascular resources. We inserted cuff catheter through right innominate vein 
in patients with thrombosis or occlusion of right internal jugular vein and subclavian vein 
so as to preserved precious vascular access at other parts of body. Here we report our 
observation of right innominate vein catheterization.
Methods: We enrolled patients who had been receiving regular HD in our center and to 
whom catheter cannot be inserted due to thrombosis or occlusion of internal jugular vein and 
subclavian vein. We performed cuff catheter insertion by puncturing right innominate vein in 
8 patients and recorded their clinical features, lesion position, and efficacy of the treatment.
Results: Among the 8 cases, where mean age is 67.6 years (range from 54-78), 3 of them 
are male and 5 are female. All the patients received central venous catheterization for more 
than 2 times, with median time of having a catheter for 36 months. The vascular ultrasound 
and CTA reveals that all of them suffered thrombosis or occlusion of right internal jugular 
vein and subclavian vein. By puncturing right innominate vein, all the patients’ vascular 
accesses have been successfully established, with the end of cuff catheter located in the right 
atrium, superior vena cava(SVC) or SVC/ right atrial junction. No obvious discomfort has 
been reported, nor did complications such as hematoma and pneumothorax recorded. The 
mean follow-up period lasts for 12 months, all vascular access of these cases are patency.
Conclusions: For HD patients with limited vascular resources such as thrombosis or 
occlusion of right internal jugular vein and subclavian vein, the application of tunneled 
cuffed venous catheter through innominate vein has been proved to be safe and effective. 
It could preserve vascular access by bypassing the stenotic lesion internal jugular vein or 
subclavian vein, and reduce the incidence of vascular access exhaustion.
Funding: Government Support - Non-U.S.
FR-PO722
Tunneled Hemodialysis Catheter and Hemodialysis Outcomes  Vedran Pasara, 
Mladen Knotek.  Dept of Medicine, Renal Div, Univ of Zagreb, Merkur Hospital, 
Zagreb, Croatia.
Background: Studies have reported that tunneled dialysis catheter (TDC) is associated 
with inferior hemodialysis (HD) patient (pt) survival, as compared to arteriovenous fistula 
(AVF). Since many cofactors may also affect survival of HD pts, it is unclear whether 
the risk for the worse survival arises from TDC per se, or from associated conditions. 
Therefore, the aim of this study was to determine the long-term outcome of HD patients, 
with respect to vascular access (VA).
Methods: Thisretrospective case-control studyincluded all 156 pts with TDC placed 
from 2010 to 2012 at Clinical Hospital Merkur. Control group consisted of 97 pts dialyzed 
through AVF. The groups were matched according to dialysis unit and time of VA placement. 
The site of choice for the placement of TDC was right jugular vein. Kaplan-Meier analysis 
with log-rank test was used to assess pt survival. A multivariate Cox regression analysis 
was used to determine independent variables associated with the pt survival.
Results: Cumulative one-year survival of pts who were dialyzed exclusively through 
TDC was 86.4 % and of those who were dialyzed exclusively through AVF the survival 
was 97.1 % (p=0.002). In a multivariate Cox regression analysis, male sex and older 
age were independently negatively associated with the survival of HD pts, while shorter 
duration of HD before the creation of the observed VA, hypertensive renal disease 
and glomerulonephritis were positively associated with survival. TDCturned to be an 
independent negative risk factor for survival of HD pts (HR 23.037, 95% CI 6.221-85.308).
TDC AVF p
Patient age at the initiation of 
HD (yrs)* 62.08±14.39 63.85±13.23 0.215
Patient age at current VA creation 
(yrs)* 63.69±14.20 64.01±13.39 0.737
Sex (m/f) 88/68 64/33 0.081
HD vintage (days)** 658 (374, 1114) 536 (320, 1139) 0.836
Diabetes mellitus 44.2% 40.2% 0.464
Coronary artery disease 20.5% 20.6% 0.851
Cerebrovascular disease 16.7% 4.1% 0.001
Peripheral vascular disease 19.9% 20.6% 0.902
*mean ± SD; ** median with IQR
Conclusions: TDC is an independant negative risk factor for the survival of patients 
on HD.
Funding: Government Support - Non-U.S.
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FR-PO723
Carpal Tunnel Syndrome Is Associated with Arteriovenous Fistula in 
Hemodialysis Patients  Il Young Kim,1 Min Jung Kim,1 Joo Hui Kim,1 Dong 
Won Lee,1 Soo Bong Lee,1 Su Min Park,2 Jong Man Park,2 Woo Jin Jung,2 
Sang Heon Song,2 Eun Young Seong,2 Harin Rhee,2 Ihm Soo Kwak.2  1Internal 
Medicine, Pusan National Univ Yangsan Hospital, Yangsan, Republic of Korea; 
2Internal Medicine, Pusan National Univ Hospital, Busan, Republic of Korea.
Background: Carpal tunnel syndrome (CTS) is associated with various systemic 
diseases such as rheumatoid arthritis, hypothyroidism, peripheral neuropathy and diabetes 
mellitus (DM). In hemodialysis patients, several factors can contribute to CTS, including 
amyloid deposition, generalized fluid retention, increased synovial volume, edema around 
the nerve, and an ischemic or ‘steal’ effect distal to a dialysis access. This study aimed 
to evaluate the influence of arteriovenous fistula (AVF) dysfunction on the development 
of CTS.
Methods: The study included 43 patients (23 male & 20 female) on maintenance 
hemodialysis via AVF and 97 healthy controls. The median nerves of study population 
were examined by ultrasonography. Cross-sectional area (CSA) of the median nerve was 
measured at the distal wrist (CSA-D), and proximal forearm (CSA-P), and wrist-to-forearm 
ratio (WFR; CSA-P/CSA-D) was calculated for each hand. We also investigated the history 
of percutaneous transluminal angioplasty (PTA) in them.
Results: The mean age of hemodialysis patients was 60.4 ± 16.0 years. The mean 
duration on hemodialysis was 48.3 ± 39.6 months. The WFRs in hemodialysis patients were 
higher than those in healthy controls (1.37 ± 0.45 vs. 1.21 ± 0.25, P < 0.05). The hands with 
AVF (n = 43) showed higher WFR than those without AVF (n = 43) in hemodialysis patients 
(1.35 ± 0.47 vs. 1.25 ± 0.26, P < 0.05). The WFRs in patients with a history of PTA were 
higher than those in patients without a history of PTA (1.46 ± 0.56 vs. 1.23 ± 0.32, P < 0.05).
Conclusions: In maintenance hemodialysis patients, WFR of median nerve was 
significantly increased in the hand with AVF. Moreover, development of CTS was related 
not only to AVF itself, but also to AVF function.
FR-PO724
Factors Affecting Patency of Haemodialysis Arterio-Venous Fistulae and 
Grafts  Ayesha Irtiza-Ali, Salman Ahmed, Nicola Ding, Joseph Russell, Nihil 
Chitalia, Maggi Steele, Hannah R. Wilson, David Makanjuola.  Renal Unit, St. 
Helier Hospital, Carshalton, United Kingdom.
Background: Arterio-venous fistulae (AVF) are the preferred access for haemodialysis 
(HD), and where these cannot be created, arterio-venous grafts (AVGs) are the next best 
option. AVFs/AVGs however, not uncommonly fail to mature. The causes of this are 
varied, but loss of patency due to thrombosis and/or significant stenoses are major causes. 
We investigated the factors affecting patency of AVFs/AVGs in order to identify whether 
there were any characteristics which were predictive of this.
Methods: All AVFs/AVGs created in our unit between 2006 and 2014 were reviewed. 
Reasons for loss of primary patency were obtained from the dialysis access database. 
Characteristics reviewed were age, gender, co-morbidity score, diabetes status and site of 
AVF. Patients were grouped as follows: patency <30 days, patency <90 days, patency >90 
days and patency >365 days.
Results: There were 1897 () AVFs and 251 () AVGs created. 649 (34.2%) of AVFs 
were lower arm, all the AVGs were upper arm, or lower limb. 1346 (62%) were male. The 
main reasons for AVF loss were clotted/stenosed vessels in 76% of cases. There was no 
association between ethnicity or gender with regard to patency rates. Other variables are 
shown in table 1.
Variable <30 days <90 days >90 days >365 days
AVF % patent 88% 70% 70% 39%
Age (mean) 72 years 72 years 70 years 71 years
AVG % patent 88% 75% 62% 35%
Age (mean) 70.5 years 70.5 years 66.8 years 67.1 years
Diabetic 31% 36% 35% 34%
Davies Co-
morbidity score
0 (no co-
morbidities) 17.3% 13.1% 14.4% 14.3%
1 (1-2 co-
morbidities) 60.3% 62.3% 60.9% 64.2%
2 (3 or more co-
morbidities) 11% 13.1% 13.8% 13.0%
Conclusions: We did not find any definite predictive factors for loss of primary patency 
in the variables we studied. In particular, co-morbidity score, age and diabetes showed no 
association with poorer outcomes. There is quite a significant ‘drop off’ in primary patency 
at 12 months. In the majority of cases, this was due to thrombosis of the HD access. This 
highlights the importance of close surveillance, as measures to maintain patency (surgical 
or radiological) are more likely to be required in this period.
FR-PO725
Drug-Eluting Stents versus Bare-Metal Stents During Percutaneous 
Coronary Intervention in Patients on Dialysis  Tara I. Chang,1 Maria E. 
Montez-Rath,1 Mark A. Hlatky,1 Wolfgang C. Winkelmayer.2  1Stanford; 2Baylor 
College of Medicine.
Background: In patients undergoing percutaneous coronary intervention (PCI), drug-
eluting stents (DES) reduce the need for repeat revascularization (RR) compared with bare-
metal stents (BMS). The effects on death and MI are more controversial, with mixed results 
from observational studies and generally null results from clinical trials. However, few 
previous studies have focused patients with end-stage renal disease (ESRD). We compared 
the effectiveness of DES with BMS in a representative cohort of US patients on dialysis.
Methods: Using the US Renal Data System, we identified 36,117 patients on dialysis 
with Medicare Parts A+B who had PCI with stenting after DES became available in the US 
(4/23/03 – 12/31/10). We used propensity-score matching (PSM) and inverse probability 
of treatment weighting (IPTW) with Cox regression to examine the association of DES 
versus BMS on the following 1-year outcomes: death, death or MI, and death, MI or 
RR. Due to concerns about residual indication bias, we conducted a second, temporal 
analysis that leveraged the large changes in the prevalence of DES use during three 
distinct eras: Transitional (4/23/03 -6/30/04); Liberal (7/1/04 – 12/31/06); and Selective 
(1/1/07 – 12/31/10).
Results: In the PSM and IPTW analyses, DES was associated with lower risks of all 
three outcomes compared with BMS.
Table: Hazard ratios (95% CI) for DES vs BMS
Death Death/MI Death/MI /RR
PSM 0.82 (0.78-0.86) 0.84 (0.91-0.87) 0.87 (0.84-0.91)
IPTW 0.82 (0.79-0.85) 0.85 (0.82-0.87) 0.88 (0.85-0.90)
DES use varied by era: Transitional=56%, Liberal=85%, and Selective=62%. In the 
temporal analysis, outcomes in the Liberal DES era were significantly better than in the 
Transitional Era, but not consistently better than in the Selective Era.
Conclusions: Adoption of DES for PCI was associated with improved outcomes in 
US patients with ESRD on dialysis.
Funding: NIDDK Support
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FR-PO726
Eleven Year Trends in Myocardial Infarction and Stroke in the Incident and 
Prevalent Dialysis Population  Kevin Chan,1 Len A. Usvyat,1 Ann Mooney,1 
Dugan Maddux,1 Karen G. Butler,1 Sophia Zhao,2 Franklin W. Maddux.1 
1Medical 2ffice, Fresenius Medical Care North America, :altham, MA; 2Div 
of Nephrology, Massachusetts General Hospital, Boston, MA.
Background: Myocardial infarction (MI) and cerebrovascular (CVA) events are highly 
prevalent in the chronic dialysis population. We aimed to quantify the annual incidence and 
trends of MI and CVA events from 2004 to 2014 in a large dialysis population.
Methods: We analyzed >600,000 patients receiving chronic dialysis from a large 
dialysis provider from January 2004 to December 2014. For each calendar year, we 
calculated the incidence of MI and CVA (event per 100 patient years) identified by ICD9 
code for the population in the first 120 days of chronic dialysis (incident period) and in the 
subsequent period after the first 120 days (prevalent period). Linear regression was used 
to quantify statistically significant trends in MI and CVA rate of the eleven year period.
Results: Over an eleven year period in the incident population, the mean incidence 
of MI and CVA was 3.3 and 3.2 events per 100 patient years respectively. Among the 
prevalent population, the mean incidence of MI and CVA was 1.9 and 1.8 events per 100 
patient years respectively. Using linear regression models, the incidence of MI and CVA 
was found to decrease by 0.14 (p=0.005) and 0.11 (p=0.0009) per year among incident 
patients. Similarly, the incidence of MI and CVA was found to decrease by 0.06 (p=0.0007) 
and 0.10 (p<0.0001) per year among prevalent patients. See Figure 1. 
Conclusions: Both MI and CVA rates are decreasing among incident and prevalent 
dialysis populations over the past eleven years.
FR-PO727
Relationship of Ticagrelor Dose and Platelet Reactivity in Patients with End 
Stage Renal Disease on Hemodialysis  Jin sug Kim, Tae won Lee, Chun-Gyoo 
Ihm, Sang ho Lee, Se yun Kim, Shin yeong Lee, Yu ho Lee, Kyung-hwan Jeong. 
Internal Medicine, KyungHee Univ School of Medicine, Seoul, Korea.
Background: In our previous study, ticagrelor has superiority on platelet inhibition 
than clopidogrel in patients with end stage renal disease(ESRD) on hemodialysis(HD). One 
study compared two doses of ticagrelor(90 or 60mg) and placebo, reported that ticagrelor 
significantly reduced the risk of cardiovascular death, MI, or stroke and increased the risk of 
bleeding. The rate of bleeding is more frequent in 90mg group. We hypothesized there was 
some relationship between ticagrelor dose and platelet inhibition. We investigated efficacy 
and safety of standard and low dose ticagrelor, and clopidogrel in ESRD patients on HD.
Methods: In a single-center, prospective, randomized study, 50 ESRD patients were 
randomly assigned to receive clopidogrel(75mg once daily), standard dose ticagrelor(90mg 
twice daily) or low dose ticagrelor(90mg once daily) for 14days. Platelet function assessment 
which included transmittance aggregometry, and VerifyNow TM P2Y12 assay were then 
used to serially measure. Maximal platelet aggregation (MPA), inhibition of platelet 
aggregation (IPA), and P2Y12 reaction units (PRUs) were evaluated.
Results: Baseline characteristics, and concomitant medication of three groups were 
not significantly different. The standard dose ticagrelor showed significant lower MPA and 
higher IPA as compared with clopidogrel at 1,5,and 48 hours, and 14days after (p<0.05). 
Low dose ticagrelor showed significant lower MPA and Higher IPA at 5hours after(p<0.001). 
Although there was no statistical significance, after 1,48hours and 14days revealed lower 
MPA and higher IPA, as compared with clopidogrel. There was no significant difference 
between two ticagrelor doses. Two doses of ticagrelor showed significant lower PRUs, as 
compared with clopidogrel(p<0.001). 2 patients of standard dose ticagrelor and 1 patient 
of clopidogrel discontinued study because of bleeding. There was no bleeding in low 
dose ticagrelor.
Conclusions: Low dose ticagrelor may result in greater platelet inhibition than 
clopidogrel in ESRD patients on HD. Further studies with large number and various doses 
of medicine are needed.
FR-PO728
Prognostic Accuracy of Serial versus Single Troponin Measurements in 
Hemodialysis Patients  Thomas A. Mavrakanas,1,2 Allan Sniderman,3 Ahsan 
Alam.1  1Div of Nephrology, McGill Univ Health Center, Montreal, QC, 
Canada; 2Div of General Internal Medicine, Geneva Univ Hospitals, Geneva, 
GE, Switzerland; 3Div of Cardiology, McGill Univ Health Center, Montreal, 
QC, Canada.
Background: Cardiac troponin I (TnI) elevation in stable patients receiving chronic 
hemodialysis (HD) is associated with increased mortality. The frequency of measuring 
TnI to determine risk is not yet known. This study aimed to assess whether using serial 
TnI measurements improves the predictive accuracy for mortality compared with a single 
measurement.
Methods: Pre-dialysis TnI levels were measured in 130 stable HD patients monthly 
for 3 consecutive months. A value above the laboratory reference range (>0.06 mg/L) was 
considered to be elevated. To assess the prognostic accuracy of TnI measurement, three 
different approaches were used to determine high risk: i) only the first month’s value was 
elevated; ii) at least one of three monthly TnI values were elevated; iii) at least two of the 
three monthly TnI values were elevated. All the patients were followed-up for 12 months. 
Multivariate Cox proportional hazard analysis was used to examine the association of 
TnI elevation with the outcomes of mortality or a composite of mortality with major 
cardiovascular events. The performance of each TnI classification method was compared 
using net reclassification index (NRI).
Results: Of 130 patients, 36 had an elevated TnI in the first month, 44 had at least 
one elevated TnI value, and 26 had 2-3 elevated TnI values. The composite outcome was 
significantly higher in patients with an elevated TnI compared with patients who had normal 
TnI levels, regardless of the method used [HR i) 3.66 (1.76-7.63) ii) 3.55 (95%CI 1.68-7.52) 
iii) 3.81 (95%CI 1.83-7.94)]. Similar associations were seen with the outcome of mortality 
alone. Patients classified as high risk using at least one elevated serial TnI measure, were 
associated with a NRI of 0.035, as compared with a single TnI measurement. If patients 
were classified as high risk using at least two elevated TnI values, the NRI was -0.072.
Conclusions: Serial TnI measurements are associated with only marginal improvement 
in predicting mortality or MACEs as compared with a single TnI measurement.
Funding: Government Support - Non-U.S.
FR-PO729
High Ultrafiltration Rates Are Associated with Increased Troponin Levels 
in Stable Hemodialysis Patients  Thomas A. Mavrakanas,1,2 Allan Sniderman,3 
Murray L. Vasilevsky,1 Ahsan Alam.1  1Div of Nephrology, McGill Univ Health 
Center, Montreal, QC, Canada; 2Div of General Internal Medicine, Geneva 
Univ Hospitals, Geneva, GE, Switzerland; 3Div of Cardiology, McGill Univ 
Health Center, Montreal, QC, Canada.
Background: An elevated troponin level in asymptomatic patients on hemodialysis 
is associated with a higher risk of mortality and cardiovascular events. The underlying 
mechanism for this association has not been elucidated. The objective of this study was 
to assess whether intra- and inter-dialytic parameters are associated with higher troponin 
I (TnI) levels.
Methods: Stable chronic hemodialysis patients at 2 tertiary care centers were enrolled in 
this study. Pre-dialysis TnI levels were measured with monthly bloods for three consecutive 
months. TnI was measured by immunoassay and was considered to be elevated if it exceeded 
the laboratory reference range (0.06 mg/L). We examined the association of the dialysis 
vintage, session duration, intradialytic hypotension (IDH), high ultrafiltration rate (UFR), 
defined as a UFR ≥ 12.4 ml/kg.h, and interdialytic weight gain (IDWG) using a mixed 
linear fixed effects model for repeated measures.
Results: 236 patients were enrolled in the study: mean age 67.5 years old, 56% 
male, 47% had diabetes and 28% had pre-existing coronary artery disease. There were 
88 elevated TnI values (13% of all measured) in 52 patients. In univariate analysis, high 
UFR and dialysis vintage, but not IDH or IDWG, were associated with TnI variability. In 
multivariate analysis, both high UFR (p=0.02) and dialysis vintage (p=0.01) explained TnI 
variability. The intraclass correlation coefficient was found to be 1%, suggesting that the 
observed variability is within and not between subjects, with session related parameters 
being more important than inter-individual differences.
Conclusions: In this observational study we identify potentially modifiable factors 
associated with TnI elevation. Strategies to prevent hemodialysis-induced myocardial 
injury may include efforts to avoid excessive ultrafiltration, minimize IDWG, or offer more 
frequent dialysis, but these need to be validated by interventional studies.
Funding: Government Support - Non-U.S.
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Prognostic Value of High-Sensitivity Troponin T in Stable Dialysis Patients 
Titi Chen, Angela Makris.  Dept of Nephrology, Liverpool Hospital, Liverpool, 
New South Wales, Australia.
Background: We evaluated the prognostic value of high-sensitivity cardiac troponin T 
(hs-TNT) in predicting myocardial infarction (MI) and death in dialysis patients after 4 years.
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Methods: A retrospective review of a cohort of 354 hemo- (HD, 254) and peritoneal-
dialysis (PD, 109) patients was followed up to 4 years after baseline hs-TnT. All-cause 
mortality, cardiac mortality and new MI were assessed.
Results: The median hs-cTNT was 60 ng/L (interquartile range IQR 38-105 ng/L) with 
no observed difference between HD and PD patients (P=0.18). Patients dying (n=148) had 
higher baseline hs-TNT (median 90 vs 50 ng/L, P<0.001). Similar trends were observed 
for both HD and PD subgroups. Patients with cardiac mortality (n=25) had higher baseline 
hs-TNT compared with non-cardiac mortality (121 vs 75.5 ng/L, P=0.013). These trends 
were only observed in the HD subgroup. Patients with a new MI (n=65) had no difference 
in their baseline hs-cTNT (66 vs 59 ng/L, P=0.064) compared to controls. The group was 
divided into quartiles based on hs-cTNT. Incremental increase in mortality (P<0.001), 
cardiac mortality (P<0.001) and MI (P=0.033) were observed with increasing hs-cTNT 
quartiles. Similar trends were observed for both HD and PD subgroups except MI in the 
HD subgroup. For every increase of 25 ng/L in hs-cTNT, the unadjusted hazard ratio (HR) 
was 1.094 for cardiac mortality (P=0.043, 95%CI 1.003-1.192), 1.123 for MI (P=0.000, 
95%CI 1.053-1.198). The adjusted HR for MI was 1.107 (P=0.018, 95%CI 1.018-1.205). 
Kaplan-Meier curves demonstrated increasing hs-cTNT quartiles was associated with an 
increase in the incidence of cardiac mortality (P=0.014) and MI (P=0.013) but not overall 
mortality. 178 patients had hs-cTNT repeated at 4 years. There was a significant increase in 
hs-cTNT from a baseline of 60 ng/L (IQR, 38-105 ng/L) to a 4-year concentration of 64 ng/L 
(IQR, 42-104 ng/L) (P=0.000). This was true for both patients with (P= 0.008) or without 
(P<0.001) new MI. Similar trends were observed for both HD and PD subgroup analysis.
Conclusions: Hs-cTnT has a useful role in predicting all-cause mortality, cardiac 
mortality and MI in stable dialysis population. There was an increase in hs-cTNT level 
over a 4-year period.
FR-PO731
Temporal Trends in Myocardial Infarction Incidence and 30-Day Mortality 
in U.S. Dialysis Patients  Charles A. Herzog,1 Keri L. Monda,2 Anne C. 
Beaubrun,2 Wolfgang C. Winkelmayer,3 Til Stürmer,4 Allan J. Collins,1 Akhtar 
Ashfaq,2 Kenneth J. Rothman,5 David T. Gilbertson.1  1Chronic Disease Research 
Group, MMRF; 2Ctr for Observational Rsrch, Amgen; 3Baylor College of 
Medicine; 4UNC Gillings School of Global Public Health; 5RTI Health Solutions.
Background: Acute myocardial infarction (MI) is a catastrophic event in dialysis pts. 
Few data exist on current MI hospitalization rates. We assessed trends in type of MI (ST-
elevation MI [STEMI], non-ST-elevation MI [NSTEMI], and unclassifiable MI [other]), 
and death rates by type of MI in 2005-2011.
Methods: Using Medicare claims data, we created yearly cohorts of dialysis pts point 
prevalent on January 1 of each year 2005-2011. We assessed STEMI, NSTEMI, and other 
MI hospitalization rates, and calculated annualized 30-day death rates following MI.
Results: In 2005 there were 10,275 NSTEMI, 1,892 STEMI, and 1,918 other MI vs 
2011 16,235 NSTEMI, 1,269 STEMI, and 1,634 other MI. Demographics: mean age 67; 
5% < 45, and 6% > 84 yrs; 47% female; 48% white, 32% black; 55% ESRD from DM. 
While overall MI rate increased slightly from 2005-2011 (80.1 /1,000 PY in 2005 vs 91.2 
in 2011), STEMI and other MI decreased by 44% and 29% respectively, while NSTEMI 
increased by 31%. Short term mortality was relatively unchanged for NSTEMI (295 
deaths/1000 PY), increased slightly for STEMI (495/1000 PY in 2005 to 565/1000 PY in 
2011), and was highest following other MI (881/1000 PY in 2005 and 915/1000 PY in 2011).
Conclusions: In the recent treatment era there has been little change in either rates of 
overall MI hospitalization or 30-day mortality. The increase in NSTEMI rates may be due to 
greater utilization of more sensitive cardiac biomarkers (cardiac troponins) for MI diagnosis. 
MI remains a catastrophic event for dialysis pts. Aggressive interventions to reduce the 
burden of ischemic heart disease and to improve its prognosis in dialysis pts are warranted.
Funding: Pharmaceutical Company Support - Amgen, Private Foundation Support
FR-PO732
Risk of Acute Coronary Events and Coronary Interventions for Overweight 
and Obese Patients versus Normal Weight Patients Undergoing Dialysis – A 
National Study  Austin G. Stack,1,2,3 Mohamed Elsayed,1,2 Muhammad Umair 
Sharif,1,2 John P. Ferguson.2  1Nephrology, Univ Hospital Limerick, Ireland; 
2Graduate Entry Medical School, Univ of Limerick, Ireland; 3Health Research 
Inst, Univ of Limerick, Ireland.
Background: Although elevated body mass index (BMI) is associated with increased 
risk of cardiovascular events in the general population, it is suggested that the converse 
may hold true for patients on dialysis.
Methods: We tested this hypothesis in a national cohort of 1,072,737 incident Medicare-
eligible US patients, who began dialysis between 5/1995 and 12/2008. Hospitalizations 
attributed to first myocardial infarction (MI) [ICD 9 codes; 410] and major coronary 
interventions (coronary angioplasty, stent, and coronary bypass surgery) following first MI 
were obtained from the US Renal Data System. Multivariable Cox regression compared 
hazard ratios [HR] of MI and subsequent coronary interventions among BMI categories.
Results: The adjusted HR of MI was highest for underweight patients and lowest 
for morbidly obese patients, decreasing significantly with increasing BMI category. 
Overweight patients were significantly more likely to receive a coronary intervention 
post-MI compared to normal weight individuals but this benefit did not extend to morbidly 
obese or underweight patients.
HR of MI
HR of 
Intervention 
Post STEMI
HR of Intervention 
post Non-STEMI
BMI Category (Kg/m2) N (%)
Underweight (< 18.5) 58, 659 (5.7)
1.04 (1.00-
1.08)
0.79 (0.56-
1.12) 1.00 (0.82-1.24)
Normal (18.5-25) 380, 587 (37.0) 1.00 1.00 1.00
Overweight (25-30) 290, 542 (28.3)
0.96 (0.94-
0.98)
1.31 (1.11-
1.54) 1.17 (1.06-1.29)
Class I Obesity (30-35) 159, 895 (15.6)
0.90 (0.87-
0.92)
1.24 (1.01-
1.52) 1.01 (0.89-1.15)
Class 2 Obesity (35-40) 75, 823 (7.4)
0.85 (0.82-
0.88)
1.20 (0.91-
1.59) 1.05 (0.89-1.26)
Class 3 Obesity (> 40) 63, 027 (6.1)
0.84 (0.81-
0.88)
1.04 (0.74-
1.45) 0.89 (0.72-1.10)
Conclusions: In contrast to the general population, higher BMI is associated with 
lower risk of major coronary events in US dialysis patients suggesting a protective effect. 
Furthermore, access to coronary interventions following a major coronary event is not 
equal across BMI categories.
Funding: Government Support - Non-U.S.
FR-PO733
Propensity-Based Comparison of Haemodialysis and Peritoneal Dialysis 
with Risk of Haemorrhagic and Ischaemic Stroke Among New Dialysis 
Patients  Austin G. Stack,1,2,3 Mohamed Elsayed,1,2 Muhammad Umair Sharif,1,2 
John P. Ferguson.2  1Nephrology, Univ Hospital Limerick, Ireland; 2Graduate 
Entry Medical School, Univ of Limerick, Ireland; 3Health Research Inst, Univ 
of Limerick, Ireland.
Background: The risk of stroke is between 6-10 fold higher in dialysis patients 
compared to the general population. It is hypothesised that the choice of dialysis modality 
at initiation may influence the risk of stroke.
Methods: We tested this hypothesis in a national cohort of 1,097,747 US patients 
(n=86,168 on PD) who were Medicare eligible and began dialysis between 5/1995 to12/2010 
and followed until 9/2011. Hospitalizations attributed to first Haemorrhagic Stroke 
(H-CVA) and Ischaemic stroke (I-CVA) were obtained from the US Renal Data System 
files and merged with data from the medical evidence, treatment history and mortality files. 
Multivariable Cox regression compared the hazards ratio [HR] of H-CVA and I-CVA for PD 
versus HD with a propensity-matched intent-to-treat (ITT) approach and as-treated analysis. 
Patients were censored at transplantation, death, recovery of kidney function, or end of 
study (Sept1 2011). Approval was received from University Hospitals Ethics Committee.
Results: The adjusted PD/HD HRs for first hospitalized H-CVA using the intent-to-
treat model was 0.89 (0.83,0.95) and this decreased from 0.73 (0.61,0.87) in the period 
1995-1998 to 0.64 (0.51,0.80) in the period 2007-2010. In contrast, overall HRs for I-CVA 
were 1.15 (1.12-1.18) and this decreased from 1.20 (1.13-1.27) in the period 1995-1998 to 
1.06 (0.97-1.15) in the period 2007-2010. The as-treated model suggested more favourable 
outcomes for H-CVA with overall HR of 0.61 (0.57,0.67) and for I-CVA with a HR 0.96 
(0.93-0.99) in 2007-2010 period. Patients who switched from PD to HD or HD to PD 
had significantly higher HR of H-CVA, while patients who switched from PD to HD had 
higher HR of I-CVA.
Conclusions: PD and HD contribute differentially to the overall risk of I-CVA and 
H-CVA among new dialysis patients. While PD is similar to HD with regard to hazards 
of I-CVA, it appears to protect against the hazard of H-CVA. These associations should 
be taken into consideration when choosing treatment options for new dialysis patients.
Funding: Other NIH Support - Health Research Board & Irish Heart Foundation
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FR-PO734
Predictors of Sudden Cardiac Death in Hemodialysis Patients with and 
without Previous Arrhythmia – Results from a Multinational Cohort 
Viviane Calice-Silva,1 Stephan Thijssen,2 Xiaoling Ye,2 Aileen Grassmann,3 
Daniele Marcelli,3 Bernard J. Canaud,3 Peter Kotanko,2 Roberto Pecoits-Filho.1 
1Pontifícia Univ Católica do Paraná, Brazil; 2Renal Research Inst; 3Fresenius 
Medical Care, Germany.
Background: Cardiac dysfunction, rapid electrolyte shifts and high ultrafiltration rates 
during hemodialysis (HD) are associated with increased vulnerability to arrhythmogenic 
events. Patients with previous arrhythmia(ARR) are at a higher risk of sudden cardiac death 
(SCD – Herzog et al, 2011). Our aim was to analyze predictors of SCD in HD patients 
with and without previous ARR.
Methods: Incident HD patients from the Monitoring Dialysis Outcomes (MONDO) 
cohort who received in-center treatment between 1/2006-12/2011 and survived at least 90 
days on HD were included and followed until 12/2012. Causes of death were classified as 
SCD according ICD-10/ICD-9. Patients with comorbidity or prior hospitalization due to 
ARR and/or ARR predisposition were identified. Cox proportional hazards models were 
constructed to explore associations between baseline parameters and SCD.
Results: We studied 19,129 patients (16 countries). 7,538 patients with complete 
data were included in the models, 613 died of SCD. Mean age 62.7(±15.5)years, 58.1% 
male, 48.4% diabetics. Age, ischemic heart disease, albumin, serum sodium, interdialytic 
weight gain in % of post-HD weight and pre-HD-systolic blood pressure were identified 
as predictors of death in both subgroups. Distinct predictors are shown below.
Table 1: Predictors of SCD in patients with (N=158) and without ARR history and/or predisposition 
(N=455).
Parameter SCD with ARR
Hazard Ratio(±SE) P-value
Serum bicarbonate [mmol/L] 0.07(0.04) 0.04
Leukocytes [1000/mm3] 0.023(0.005) <.0001
SCD without ARR
Hemoglobin [g/dL] -0.11(0.04) 0.005
Dialysate sodium [mmol/L] 0.093(0.03) 0.0008
Catheter as vascular access 0.41(0.1) <.0001
Conclusions: Despite the small sample size, some predictors of SCD seem to differ 
depending on the presence or absence of arrhythmia history or predisposition. These findings 
may assist the identification of patients at high risk for SCD. Further studies have to be 
done to corroborate these results.
FR-PO735
The Risks of Acute Health Events After Incident Atrial Fibrillation in 
Older Hemodialysis Patients  Medha Airy,1 Benjamin A. Goldstein,2 Mark 
A. Hlatky,3 Nisha Bansal,4 Alan S. Go,5 Wolfgang C. Winkelmayer.1  1Baylor 
College of Medicine, Houston, TX; 2Duke Univ, Durham, NC; 3Stanford Univ, 
Palo Alto, CA; 4Univ of Washington, Seattle, WA; 5Kaiser Permanente Northern 
California, Oakland, CA.
Background: Limited data exist about whether incident atrial fibrillation/flutter 
(AF) impacts the risks of major acute health events in patients with ESRD undergoing 
hemodialysis (HD).
Methods: From the US Renal Data System, we studied older (≥67 years) adults with 
³2 years of uninterrupted Medicare A&B coverage before starting HD (2006-11) and no 
known AF prior to ESRD. Incident AF was ascertained from ICD-9 diagnosis codes (427.3x) 
in inpatient claims. We used extended Cox regression adjusted for sociodemographic 
characteristics and key comorbidities to estimate hazard ratios (HR [95% confidence 
intervals]) for death, ischemic stroke, myocardial infarction (MI), and hip fracture (as a 
negative control outcome). AF was treated as a time-varying covariate, with time since 
first AF diagnosis further categorized as £30, 31-90, and >90 days. Patients were censored 
at time of kidney transplant or end of data (12/31/2011).
Results: We identified 85,377 eligible HD patients; 16.7% developed incident AF and 
58.2% died during follow-up. Incident AF was associated with higher adjusted mortality: 
8-fold higher during the first 30 days (HR=8.2 [7.9-8.6]), 4-fold higher between 31-90 days 
(HR=4.2 [4.0-4.4]), and 2-fold higher beyond 90 days after AF diagnosis (HR=2.2 [2.1-
2.2]). Incident AF also increased the adjusted rate of ischemic stroke 1.5-2.5-fold: during 
the first 30 days (HR=2.1 [1.6-2.7]), 31-90 days (HR=2.5 [2.0-3.0]), and beyond 90 days 
(HR=1.5 [1.3-1.7]). Quantitatively similar findings were obtained for MI. However, the 
adjusted rate of hip fracture was only marginally increased following AF diagnosis (<=30 
days: 1.1 [0.7-1.6]; 31-90 days: 1.4 [1.0-1.8]; >90 days: 1.2 [1.1-1.4]. All associations were 
attenuated when requiring incident AF to be indicated as principal discharge diagnosis.
Conclusions: While AF was independently associated with higher risks of ischemic 
stroke, MI, and hip fracture in older ESRD patients on HD, it was more strongly associated 
with excess all-cause mortality.
Funding: NIDDK Support
FR-PO736
The CRASH-ILR Study: Half a Million Hours of Continuous ECG 
Monitoring in a Hemodialysis Population  Robert Lewis,1 Darren Green,2 
Philip A. Kalra,2 Donah Zachariah,3 Paul Kalra,1 Paul R. Roberts.4  1Portsmouth 
Hospitals NHS Trust, Portsmouth, United Kingdom; 2Salford Royal NHS Trust, 
Salford, United Kingdom; 3Royal Bournemouth Hospital, Bournemouth, United 
Kingdom; 4Southampton Univ Hospitals Trust, Southampton, United Kingdom.
Background: Sudden cardiac death (SCD) may cause 25% of all hemodialysis (HD) 
patient deaths. Multiple potential mechanisms may contribute to the risk of life-threatening 
arrhythmias in this population. The CardioRenal Arrhythmia Study in Hemodialysis has 
continuously monitored patients using an Implantable Loop Recorder (ILR) for more 
than 500,000 hours.
Methods: 30 patients (60% male) aged 67±12 years on established HD for 39 ±44 
months with varied etiology of CKD (diabetes 37%, hypertension 23%) and ejection 
fraction of 56±8% were implanted with a Reveal XT ILR (Medtronic, MN, USA). Patients 
transmitted data at each HD session and were asked to activate their ILR if symptomatic 
with palpitations, dizziness or syncope.
Results: Patients were monitored for an average of 17,810±8,108 hours performing 
94±92 transmissions. 6 patients (20%) died during the study. The final arrhythmia was VF 
in 2 patients and agonal bradycardia in 3. One patient died from SCD 2 weeks after device 
explantation due to infection. All 3 bradycardic deaths occurred in patients during end-of-
life care. 1 VF death occurred during a GI bleed: the other was unheralded. A surviving 
patient received a biventricular pacemaker for 2:1 block detected by ILR. Atrial arrhythmias 
(AA) were noted in 7 (23%), 4(13%) of which were incident. 1 patient had asymptomatic 
sustained VT managed with antiarrhythmic drugs. Frequent ectopy was recorded in 2 
patients. There were 19 symptomatic activations in 6 patients all corresponding to sinus 
rhythm (or AA in cases of permanent AF). 6 patients had device explantation, 4 after renal 
transplantation and 2 due to device infection.
Conclusions: CRASH-ILR is the longest ILR follow up in HD patients to date and 
provides new insights into arrhythmia and SCD. Arrhythmias occurred in 15 (50%) of the 
study population. Mortality was high, but this was due to SCD as an expected end-of-life 
event in 5 of 6 patients.
Funding: Pharmaceutical Company Support - Medtronic, MN, USA
FR-PO737
Revisiting Ultrafiltration Rate (UFR), Treatment Time (TT) and Mortality 
in Thrice Weekly Hemodialysis  Jennifer L. Bragg-Gresham, Brett W. Plattner, 
Debabrata Ray, Yi Li, Rajiv Saran.  KECC, Univ of Michigan, Ann Arbor, MI.
Background: UFR and TT are two potentially modifiable practices for improving 
outcomes in HD. UFR > 13ml/kg/hour has been associated with higher mortality. We re-
examined this association, focusing on the effect of higher UFR at TT ≥ 4 hours, as longer 
TT has been claimed to be ‘protective’, even though TT > 4 hours is logistically difficult 
to implement in the prevailing US practice setting.
Methods: Using recently available national data from CROWNWeb (CW), we 
analyzed 232,759 adults on thrice-weekly, in-center HD. Baseline CW data was extracted 
from June 2012. Patients were followed through December 31, 2013. Cox regression was 
used to examine the association between UFR (calculated as the intradialytic weight loss / 
TT and expressed in ml/kg post HD-weight/hr) and mortality, adjusting for demographics, 
comorbidities, dialysis vintage, interdialytic weight gain (IDWG) and dialysis dose (Kt/V), 
stratified by TT. Average follow-up was approx 1 year.
Results: Individuals receiving TT ≥ 240 were younger, more likely to be black and 
male, and had larger BMI. In both strata of TT (< 240 and ³240) those patients with UFR 
>13 tended to be younger, non-black race, have a lower BMI, longer HD vintage, higher 
Kt/V, and higher IDWG than patients with UFR < 13. Congestive heart failure was more 
prevalent in patients with UFR ≤ 13 regardless of TT. In both strata of TT, patients with a 
UFR >13 had higher hazard of mortality, with a larger risk found in those with TT ≥ 240. 
Conclusions: A higher UFR (>13) was associated with higher mortality irrespective of 
TT category. The association was surprisingly stronger among those receiving longer TT. 
In the US, longer TT is prescribedin order to achieve small solute targets (confounding-
by-indication) and not necessarily to lower the UFR, as high UFR is a consequence of high 
IDWG and the average shorter TT.
Funding: NIDDK Support
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FR-PO738
Sudden Death and Dialysate Potassium in Hemodialysis: Results 
from the Dialysis Outcomes and Practice Patterns Study (DOPPS) 
Angelo Karaboyas,1 Jarcy Zee,1 Steven M. Brunelli,2 Len A. Usvyat,3 Daniel E. 
Weiner,4 Franklin W. Maddux,3 Allen R. Nissenson,5 David C. Mendelssohn,6 
Michel Y. Jadoul,7 Friedrich K. Port,1 Bruce M. Robinson,1,8 Francesca Tentori.1,9 
1Arbor Research Collaborative for Health, Ann Arbor, MI; 2DaVita Clinical 
Research, Minneapolis, MN; 3FMCNA, Waltham, MA; 4Tufts Medical Center, 
Boston, MA; 5DaVita Healthcare Partners, Inc., El Segundo, CA; 6Humber River 
Regional Hospital, Toronto, Canada; 7Univ Catholique de Louvain, Belgium; 
8U of Michigan, Ann Arbor, MI; 9Vanderbilt U, Nashville, TN.
Background: Sudden death (SD) is common in hemodialysis (HD) patients. We 
investigated trends in dialysate (DK) and pre-dialysis serum (SK) potassium across the 
Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 1-5 (1996-2015) and 
evaluated whether the risk of SD is higher with lower DK.
Methods: 67,263 patients in 21 countries were studied. Instrumental variable methods 
were used to model the effect of DK on SK. Adjusted Cox regression was used to test the 
associations of baseline DK and SK with all-cause death, and an arrhythmia composite 
(AC) of SD or arrhythmia-related hospitalization.
Results: In the US, DK and SK (mEq/L) have been stable over time (70% DK=2, 25% 
DK=3; mean±StdDev SK=4.7±0.7). In Europe, DK has increased (currently 15% DK=1-
1.5, 45% DK=2, 33% DK=3) while mean SK has decreased from 5.2 to 4.9. SK was only 
0.08 mEq/L higher per 1 mEq/L higher DK. SK ≥ 6 (ref 4.5-4.9) was associated with death 
(HR=1.12, 95% CI: 1.05-1.19) and AC (HR=1.17, 1.04-1.33). Compared to DK=2, DK=3 
was not associated with death or AC, overall or at any level of SK (Fig).
Conclusions: In this large international cohort, SK was associated with elevated risk 
of SD, but risk of SD was similar for DK=2 or DK=3 across SK levels. Because DK had 
minimal influence on pre-dialysis SK, efforts to limit dietary K intake may be a more 
effective strategy to lessen the risks associated with high SK. 
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Societa Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx, Private 
Foundation Support
FR-PO739
Acute Health Events and the Risk of Incident Atrial Fibrillation in Older 
Patients Undergoing Maintenance Hemodialysis  Medha Airy,1 Benjamin 
A. Goldstein,2 Mark A. Hlatky,3 Alan S. Go,4 Nisha Bansal,5 Wolfgang C. 
Winkelmayer.1  1Baylor College of Medicine, Houston, TX; 2Duke Univ, Durham, 
NC; 3Stanford Univ, Palo Alto, CA; 4Kaiser Permanente Northern California, 
Oakland, CA; 5Univ of Washington, Seattle, WA.
Background: Acute health events might increase the risk of developing atrial fibrillation 
(AF). We examined the incidence of new onset AF relative to several acute events in patients 
with ESRD initiating hemodialysis (HD).
Methods: From the USRDS, we studied older (67+ years) patients with 2 years of 
Medicare A&B coverage prior to initiating HD (2006-11) who had no documented diagnosis 
of AF, or claims indicating ischemic stroke, myocardial infarction (MI), or hip fracture 
prior to ESRD. We used time-varying Cox regression to estimate adjusted hazard ratios 
for incident AF relative to the acute events of interest, adjusted for socio-demographics 
and baseline comorbidities. The incidence of AF after either an acute stroke, MI, or hip 
fracture was modeled in time-varying fashion, during the periods of <=30, 31 to 90, and 
>90 days after the acute event. Patients were censored at kidney transplantation or end of 
database (12/31/2011).
Results: 85,377 older HD patients met the inclusion criteria. The risk of AF was 
approximately doubled in the 90 days after an ischemic stroke, and remained elevated 
thereafter (Table). The risk of AF after an acute MI followed a similar pattern, with highest 
risk in the 30 days after the MI. The risk of AF after hip fracture followed a slightly different 
pattern, peaking between 30 and 90 days after the event, with no significant late hazard 
after 90 days. These associations were essentially unchanged when requiring that the acute 
health event be reported as principal diagnosis.
Time since event: Ischemic Stroke Myocardial Infarction Hip Fracture
<=30 days 2.1 (1.7-2.7) 2.9 (2.5-3.4) 1.5 (1.1-2.0)
30-90 days 1.9 (1.5-2.4) 2.3 (2.0-2.6) 2.1 (1.7-2.5)
>90 days 1.5 (1.3-1.6) 1.6 (1.5-1.7) 1.1 (1.0-1.3)
Conclusions: The risk of incident AF among patients on HD is increased after a stroke, 
MI, or hip fracture. Risks were highest in the first 90 days after the event, and remained 
elevated >90 days after an ischemic stroke or MI, but not after a hip fracture.
Funding: NIDDK Support
FR-PO740
Arrhythmias as a Potential Cause of Dizziness and Syncope in Patients 
with End-Stage Renal Disease  Kati Kaartinen,1 Jani Ahvonen,2 Seppo 
Ojanen,2 Joonas Markku Rautavaara,5 Olli Anttonen,2 Tuomas Kerola,2 Kati 
Vaaraniemi,3 Marja H. Miettinen,3 Juhani Koistinen,4 Atte Aitkoski,5 Tuomo 
Nieminen.5  1Dept of Nephrology, Helsinki Univ Central Hospital, Helsinki, 
Finland; 2Dept of Nephrology, Päijät-Häme Central Hospital, Lahti, Finland; 
3Dept of Nephrology, Central Hospital of Central Finland, Jyväskylä, Finland; 
4Dept of Cardiology, Vaasa Central Hospital, Vaasa, Finland; 5Dept of Internal 
Medicine, Univ of Helsinki, Helsinki, Finland.
Background: It is unknown how often arrhythmias underlie dizziness and syncope 
in end-stage renal disease. We launched a study to implant subcutaneous loop recorders 
for their estimation.
Methods: Data is shown for 40 patients (62.4±8.2 years [mean±SD], range 39 to 78 
y, 26 M) with stage 4 or 5 renal failure and f-u of > 2 months. Main kidney diseases were 
diabetic (18), polycystic disease (8) and chronic glomerulonephritis (6). One patient was pre-
dialytic, five had peritoneal dialysis, and rest were on hemodialysis. Median time since the 
start of dialysis was 1.6 years. Seven patients (18%) had either chronic or paroxysmal atrial 
fibrillation (AF) prior to the implantation of the recorder, being in line with published data.
Results: During the f-u of 14±7 months, recorder revealed bradyarrhythmia in six 
(15%) patients with an R-R arrest of >5.0 sec with a max. of 9.0 sec; two patients with 
symptoms thus far received a pacemaker. AF occurred in 21 (53%) patients. The median 
time to detect new AF was 235 days. Four patients (10%) had non-sustained ventricular 
tachycardia unknown before the recorder data.
Conclusions: Arrhythmias are more typical than estimated in patients with severe 
kidney disease. Particularly, symptomatic bradycardia is relatively common and can be 
easily treated with a pacemaker. AF is three times more common than known before. These 
findings may change diagnostics and treatment of dizziness in these patients.
Funding: Private Foundation Support, Clinical Revenue Support
FR-PO741
Blood Pressure and Risk of Cardiovascular Events Among Hemodialysis 
Patients: The CRIC Study  Nisha Bansal,1 Charles E. McCulloch,2 Feng Lin,2 
Cassianne Robinson-Cohen,1 Mahboob Rahman,3 John W. Kusek,4 Amanda Hyre 
Anderson,5 Raymond R. Townsend,5 Jackson T. Wright,6 Alan S. Go,7 Arnold 
B. Alper,8 Radhakrishna Reddy Kallem,5 Chi-yuan Hsu.2  1UW; 2UCSF; 3UH; 
4NIDDK; 5UPenn; 6Case Western; 7KPNC; 8Tulane.
Background: Among hemodialysis (HD) patients, previous studies have reported a 
U-shaped association between systolic blood pressure (SBP) and risk of mortality. However, 
the shape of the association between SBP and risk of cardiovascular events (CVD) is not 
well characterized.
Methods: We studied participants on HD in the Chronic Renal Insufficiency Study 
(CRIC). SBP was measured at the dialysis unit (“dialysis-unit-SBP”, N=403) and at the 
CRIC study visit (“out-of-dialysis-unit SBP”, N=326). We studied the association of SBP 
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with time to adjudicated CVD (defined as heart failure, myocardial infarction, peripheral 
vascular disease and stroke), adjusting for demographics, diabetes, smoking, BMI, prior 
CVD, kt/v, serum albumin and hemoglobin.
Results: Mean age was 60 (±11) years, 42% were women and 64% were Black. There 
were a total of 121 CVD events over a median time of 1.15 years. The association between 
dialysis-unit-SBP was U-shaped, with the greatest risk of CVD at the highest and lowest 
quartiles of dialysis-unit-SBP.
Conversely, the association between out-of-dialysis-unit-SBP was linear, with the 
highest quartile having greater than 2-fold risk of CVD than the lowest quartile.
Conclusions: Among HD patients, the association of SBP measured in the dialysis 
unit with CVD is U-shaped, while the association of SBP measured outside the dialysis 
unit with CVD is linear, similar to what has been reported for mortality (Bansal et al, 
Hypertension 2015). Targeting SBP measured outside the dialysis unit may improve CVD 
outcomes in HD patients.
Funding: NIDDK Support
FR-PO742
Intradialytic Dynamics of Systolic Blood Pressure in Hemodialysis Patients 
Based on Survival Status  John W. Larkin,1 Dugan Maddux,1 Yue Jiao,1 Jeroen 
Kooman,2 Frank van der Sande,2 Hao Han,1 Sophia Rosen,1 Len A. Usvyat,1 
Peter Kotanko,3,4 Franklin W. Maddux.1  1Fresenius Medical Care North America 
(FMCNA), Waltham, MA; 2Maastricht Univ Medical Centre, Maastricht, 
Netherlands; 3Renal Research Inst, New York, NY; 4Icahn School of Medicine 
at Mount Sinai, New York, NY.
Background: Low systolic blood pressure (SBP) before dialysis has been reported 
to be associated with worsened outcomes in hemodialysis (HD) patients (Maddux et al., 
ASN 2014). However, the dynamics of intradialytic SBP and patient outcomes have not 
been well characterized in this population. We aimed to understand the dynamics of SBP 
during dialysis in patients based on their survival status.
Methods: We studied HD patients treated at FMCNA facilities in 2014 with recorded 
intradialytic SBP data. The population mean intradialytic SBP was computed in 20 minute 
intervals during dialysis per patient per treatment; all treatments were then averaged per 
patient and thereafter for the entire cohort. Patient survival was recorded in 2014 (i.e. 
“alive” or “died”).
Results: 31,053 and 2,835 patients (338,771 and 20,380 measurements respectively) 
were used for calculation of the mean SBP at each 20 minute time point in “alive” and 
“died” groups, respectively. The results show that the mean intradialytic SBP declines to 
a similar extent in both patients who died and survived, but patients that died exhibited a 
lower initial predialysis SBP and greater overall intradialytic variability.
Conclusions: These investigations of the dynamics of intradialytic SBP identify 
increased variability during dialysis and lower starting levels in patients who died. In both 
patients who were alive and died, SBP declines to a similar extent throughout dialysis. These 
findings suggest that lower predialysis SBP and intradialytic variability may be associated 
with mortality in the HD population.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO743
Choosing the Right Analysis of Repeated Events for Clinical Trials in 
Dialysis  George Tomlinson,1 Stephanie Dixon,2 Amit X. Garg,3 Charmaine E. 
Lok.1  1Medicine, Toronto General Hospital, Toronto, ON, Canada; 2ICES-KDT; 
3London Health Sciences Centre.
Background: Cardiovascular (CV) events are a leading cause of morbidity and 
mortality in hemodialysis (HD) patients. There is a paucity of randomized clinical trials 
(RCT) in nephrology and fewer positive ones, perhaps due to incorrect choice of endpoints 
or inadequate power. We simulated RCTs with repeated CV events and competing non-CV 
death to determine how different analytic methods affected study power (sample size).
Methods: We simulated 1000 RCTs of 1100 patients, with frequency and timing of 
CV events (CV death, MI, stroke, PVD, CV revascularization, and leg amputation) based 
on real observations in an Ontario HD administrative cohort (n=9647) from 2004-2011. In 
simulations, patients were randomized to placebo or a treatment with a known effect and 
censored at 4 years or non-CV death. We analyzed this data with 1) a Cox model for time 
to first event, 2) a model with non-CV death as a competing risk, 3) a negative binomial 
(NB) model and 4) several adaptations of the Cox model for repeated events (e.g., Wei, Lin 
and Weissfeld, WLW). To check for 2 potential problems (finding a difference when there 
was none and missing a true difference), we ran simulations in 2 scenarios: 1) with zero 
treatment effect, we calculated the false positive rate; 2) when the treatment delayed CV 
events by 33%, we calculated the true positive rate (power) based on the 1000 simulations.
Results: In the source (real) data, 45% of patients had ³2 CV events; the overall CV 
event rate was 0.26/yr. When there was no effect of treatment, the NB model had a false 
positive rate of 11%; for all other models, it was the expected 5%. For the time to first 
event, competing risk and the WLW marginal Cox model, power was similar (72%) and 
notably higher than for the remaining Cox-type models (52%-61%).
Conclusions: The WLW Cox model for repeated events was as powerful as models 
for time to first event but has the advantage of assessing the impact on all (repeated) events 
a patient experiences. This highlights the importance of choosing the appropriate analytic 
method when designing a clinical trial in HD patients to maximize the likelihood of both 
a positive and a meaningful result.
Funding: Government Support - Non-U.S.
FR-PO744
Routine Predialysis Measurements of Systolic Blood Pressure Are Higher 
Than Predialysis Standardized Measurements of Systolic Blood Pressure 
Dana Miskulin,1 Jennifer J. Gassman,4 David W. Ploth,5 Manisha Jhamb,6 
Lavinia A. Negrea,7 Mahboob Rahman,7 Ronald Schrader,2 Susan Paine,2 Philip 
Zager.2,3  1Tufts; 2UNM; 3DCI; 4Cleveland Clinic; 5MUSC; 6Univ of Pittsburgh; 
7Case Western.
Background: Measurement of blood pressure (BP) in the dialysis unit does not follow 
American Heart Association recommendations. We determined the differences between 
systolic BP (SBP) measured in routine practice versus a standardized procedure.
Methods: The Blood Pressure in Dialysis Study is a pilot, multicenter, randomized 
clinical trial that assesses treatment of hypertensive HD patients to two BP targets. 
Measurement of predialysis SBP is done after 5 minutes rest, 3 readings 1 minute apart, 
with attention to cuff size, placement and patient positioning. We compared the 2-week 
averaged routine predialysis SBP (RDUSBP) taken immediately prior to enrollment with the 
2-week averaged predialysis standardized SBP (SDUSBP) in the first 2 weeks of baseline. 
The within subject variability in SBP, (s2W) was estimated by mixed linear regression.
Results: We studied 186 patients. The two week averaged RDUSBP was a mean (SD) 
10.3 (16.6) mm Hg higher than 2 week averaged SDUSBP (p<0.001).
The RDUSBP was ± 5 mm Hg of the SDUSBP in 20% of patients, 6-15 mm Hg higher 
in 30%, 15-25 mm Hg higher in 17%, >25 mm Hg higher in 17% and >5 lower in 16%. 
Estimates of s2W for RDUSBP (15.72) and SDUSBP (19.62) were not significantly different, 
(p>0.99). Differences between RDUSBP and SDUSBP tended to be greatest among those 
with a high body mass index.
Conclusions: SDUSBP were, on average, 10 mm Hg lower than RDUSBP measured 
in the dialysis unit. Reliance on routine BP measurements may lead to over-treating 
hypertensive HD patients. More attention to the measurement of BP in dialysis unit is 
needed.
Funding: NIDDK Support, Pharmaceutical Company Support - Dialysis Clinic, Inc.
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FR-PO745
Comparison of Central and Peripheral Blood Pressure in Predicting 
Cardiovascular Surrogates in Patients with End-Stage Renal Disease 
Kyoung Sook Park, Younkyung Kee, Shin-Wook Kang, Tae-Hyun Yoo.  Dept 
of Internal Medicine, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Hypertension is an established cardiovascular (CV) risk factor and is 
closely related with mortality in end-stage renal disease (ESRD) patients. Recent studies 
have demonstrated that central blood pressure (cBP) is a significant predictor of CV disease 
in the general population, because cBP reflects the loading conditions of the coronary and 
cerebral arteries and vascular damage. Therefore, we investigated the association between 
cBP and CV surrogates compared with peripheral blood pressure (pBP) in patients with 
ESRD.
Methods: A cohort of 92 ESRD patients from the Cardiovascular and Metabolic Disease 
Etiology Research Center between November 2013 and February 2015 was selected. cBP 
was measured by SphygmoCor noninvasively. CV surrogates were determined by carotid 
intima-media thickness, pulse wave velocity (PWV) and left ventricular mass index (LVMI). 
Linear regression analysis and Steiger’s Z test were used to compare predictive ability of 
cBP and pBP for CV surrogates.
Results: The mean age was 53.2 years and 52 (56.5%) were male. Mean systolic cBP 
(cSBP) and central pulse pressure (cPP) was 140.2±28.9 and 57.1±22.8 mmHg. Mean 
systolic pBP (pSBP) and peripheral pulse pressure (pPP) was 145±25.8 and 65.8±22.2 
mmHg. There was an independent association of cSBP and pSBP with PWV (ß=0.408, 
P<0.01; ß=0.322, P=0.001) and LVMI (ß=0.370, P=0.001; ß=0.382, P<0.001). cPP and 
pPP also were independently associated with PWV (ß=0.381, P<0.001; ß=0.353, P=0.001) 
and LVMI (ß=0.411, P<0.001; ß=0.497, P<0.001) after adjustment for confounding factors. 
However, there were no significant differences in the predictive value of cSBP and pSBP 
for estimating PWV (adjusted R2, 0.494 vs. 0.431, P=0.07) and LVMI (adj R2, 0.215 vs. 
0.220, P=0.885). No significant difference was found for cPP and pPP for predicting PWV 
(adj R2, 0.451 vs. 0.429, P=0.546) and LVMI (adj R2, 0.220 vs. 0.269, P=0.320).
Conclusions: Although cBP values were closely associated with CV surrogates, 
these values did not provide additional information beyond pBP in predicting CV risk in 
patients with ESRD.
FR-PO746
Early Mortality in Hemodialysis Patients Anticoagulated for Atrial 
Fibrillation  Stanislav S. Bushik,1 N. Stanley Nahman,1 Riad Elmor,2 Jennifer 
L. Waller,2 Robert A. Sorrentino,1 William R. Maddox,1 Mufaddal F. Kheda,1 
Matthew J. Diamond.1  1Medicine, Georgia Regents Univ, Augusta, GA; 
2Biostatistics & Epidemiology, Georgia Regents Univ, Augusta, GA.
Background: Atrial fibrillation (AF) is prevalent in the Hemodialysis (HD) population 
and portends a high mortality rate. AF also causes embolic stroke and is treated with lifelong 
oral anticoagulation (OAT). We have previously shown early increased mortality in HD 
patients receiving OAT without significant stroke reduction (JASN, 25:609A, 2014). It is 
unclear why OAT increased early mortality in these patients. To address this question, we 
queried the USRDS for unique risk factors for mortality in this cohort.
Methods: All incident adult HD cases from the USRDS for 2005-2008 were queried 
for demographics, access type, risk factors before dialysis, and mortality. Data were derived 
from ICD9 and CPT codes, or Form 2728. Proportional hazards models were used to 
estimate the hazard ratio (HR) for death within 90 days.
Results: 34,522 incident HD patients with AF were identified, 6664 (19.3%) of whom 
died within 90 days of the initiation of dialysis. For the entire group, demographics showed: 
83.1% Caucasian, mean age 75.4 years (SD=9.0), and 41.5% female. When controlling 
for diabetes, cardiomyopathy TIA, pulmonary hypertension, aortic stenosis, CHF, MI, 
coagulation defects, obesity, cardiac device, age and access type the HR for death in the 
OAT group was 1.10 (95% CI 1.04 - 1.16). The 1-, 2- and 3-month mortality rates were 6%, 
15% and 22% in OAT and 5%, 12% and 19% in non-OAT, respectively. Major bleeding 
episodes were not significantly associated with mortality (p=0.59).
Conclusions: OAT therapy in HD patients with AF may contribute to the increased 
death rate observed during the first 90 days of dialysis, but not apparently due to bleeding. 
We speculate that OAT use may be associated with non-hemorrhagic complications that 
may lead to increased mortality in the HD population. Defining this level of clinical detail 
is beyond the scope of an administrative dataset like the USRDS. Future studies addressing 
non-hemorrhagic effects of OAT may provide new insights on possible causes of early 
mortality in these patients.
Funding: Private Foundation Support
FR-PO747
Reduced Temperature Hemodialysis Augments Dialysis Induced 
Improvement of Cardiac High Energy Phosphate Levels  Rajan Patel, Elaine 
Rutherford, Kathryn K. Stevens, Sandosh Padmanabhan, Alan G. Jardine, Patrick 
B. Mark.  Inst of Cardiovascular and Medical Sciences, Univ of Glasgow, 
Glasgow, United Kingdom.
Background: 31Phosphorus magnetic resonance spectroscopy (31P-MRS) measures 
levels of high enery phosphates, including phosphocreatinine:β ATP (PCr:β ATP) ratio 
which evaluates cardiac metabolic activity. PCr:β ATP is significantly reduced in end stage 
renal disease (ESRD) patients. Reducing hemodialysate temperature by 1-2°C improves 
intradialytic hypotension and cardiac function. The effects of reduced temperature dialysis 
on cardiac metabolism have not been evaluated. We compared myocardial function and 
PCr:βATP ratios levels before and after normothermic and reduced temperature dialysis.
Methods: Twelve hemodialysis patients underwent cardiac MRI and 31P MRS of their 
left ventricle (LV) within 30 minutes before (pre) and after (post) three normothermic 
(36.5°C) and three reduced temperature (35.0°C) maintenance dialysis sessions. Left 
ventricular dimensions were measured by an observer blinded to intervention. PCr: β ATP 
were calculated from 31P-MR spectra.
Results: Reduced temperature hemodialysis was significantly associated with increased 
predialysis LV ejection fraction (36.5°C:64.5%±6.6 vs. 35.0°C:69.0%±6.1;p=0.03). At both 
temperatures, hemodialysis was significantly associated with increased mean LV ejection 
fraction (36.5°C:pre 64.5%±6.6,post 70.9%±6.8, p=0.002;35.0°C :pre 69.0%±6.1, post 
74.2%±8.3, p<0.01). PCr:βATP was significantly higher after normothermic (p<0.01) and 
reduced temperature hemodialysis (p=0.03: ). Mean increase in PCr:βATP was higher 
after reduced temperature compared to normothermic hemodialysis (+51.5% vs +74.1% 
respectively). 
Conclusions: Hemodialysis is associated with improved myocardial metabolic activity 
and this effect may be amplified by reducing the dialysate temperature even in patients 
with no intradialytic hypotension.
FR-PO748
Risk Grading by CHA2DS2_Vasc Score Is Useful in Non-Dialysis Subjects 
with Atrial Fibrillation while It Is Not Useful in Dialysis Patients Because 
of Their Very High CHA2DS2_Vasc Scores  Masaki Ohsawa.1,2  1Dept of 
Internal Medicine, Iwate Medical Univ, Morioka, Japan; 2Dept of Internal 
Medicine, Morioka Tsunagi Onsen Hospital, Morioka, Japan; 3Dept of Hygiene 
and Preventive Medicine, Iwate Medical Univ, Iwate Prefecture, Japan.
Background: Whether CHA2DS2_Vasc score is useful for predicting the risk of 
outcomes has not been sufficiently examined in dialysis patients with AF.
Methods: Two prospective studies of 1,109 dialysis patients (AF group (n=35); non-AF 
group (n=1,074)) and 26,469 community dwellers (AF group (n=26,058); non-AF group 
(n=411)) living in the same area were conducted. Subjects were subdivided into four groups 
according to CHA2DS2_Vasc score (G1: CHA2DS2_Vasc score = 0~1; G2: score = 2; G3: 
score = 3; G4: score = 4+). Crude mortality rates of all-cause and cardiovascular death 
and crude incidence rates of stroke (per 1000 person-years) were estimated in each group.
Results: Results were shown in the table. 
AF (-) AF (+) CHADS2 Vasc 0-1 2 3 4+
community dwellers
subjects (n) 26058 411 108 133 88 82
all-cause death 
(mortality rate) 993 (6.8) 57 (26.3) 11 (11.8) 17 (23.4) 12 (26.0) 17 (43.6)
cardiovascular death 
(mortality rate) 211 (1.5) 27 (12.5) 4 (6.8) 8 (11.0) 6 (13.0) 9 (23.1)
stroke (incidence 
rate) 692 (4.8) 57 (28.2) 9 (16.2) 18 (26.5) 13 (30.3) 17 (47.8)
dialysis patients
AF (+) subjects (n) 35 6 1 6 22
all-cause death 
(mortality rate) 26 (278.9) 2 (81.4) 1 (404.9) 3 (158.1)
20 
(423.7)
cardiovascular death 
(mortality rate) 9 (96.6) 0 (0) 0 (0) 1 (52.7) 8 (169.5)
stroke (incidence 
rate) 5 (59.7) 0 (0) 0 (0) 0 (0) 5 (132.4)
AF (-) subjects (n) 1074 218 331 242 283
all-cause death 
(mortality rate)
384 
(88.7) 26 (25.9) 83 (58.3)
100 
(106.4)
175 
(181.8)
cardiovascular death 187 (43.2) 14 (13.9) 41 (28.8) 55 (58.5) 77 (80.0)
stroke (incidence 
rate)
192 
(49.7) 21 (21.5) 49 (37.4) 48 (59.4) 74 (96.4)
Mortality/incidence rates are expressed as per 1000 person-years.
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Conclusions: CHA2DS2_Vasc score is useful for predicting the risk of outcomes in 
non-daialysis subjects with AF and dialysis subjects without AF. Dialysis patients with AF 
already had very high scores and the risk grading by CHAD2DS2_Vasc score is not useful.
Funding: Government Support - Non-U.S.
FR-PO749
Post Stroke In-Hospital Disability Deterioration and Mortality of 
Community-Onset Stroke in Patients with and without End-Stage Renal 
Disease  Tomoko Usui,1 Norio Hanafusa,1 Hideo Yasunaga,2 Masaomi Nangaku.1 
1Dept of Hemodialysis and Apheresis, The Univ of Tokyo Hospital, Japan; 2Dept 
of Clinical Epidemiology and Health Economics, School of Public Health, the 
Univ of Tokyo, Japan.
Background: Increasing evidence suggests that end-stage renal disease is associated 
with higher risk and severity of cerebrovascular disease. However, the risk factors for post 
stroke disability and mortality is not clear. We examined the association between risk factors 
including dialysis treatment and disability deterioration and mortality during hospital stay 
of community-onset stroke.
Methods: The Japanese Diagnosis Procedure Combination database includes 
administrative claims and discharge abstract data of about 50% of all acute-care inpatients 
in Japan. Using this database, we extracted data of inpatients age ³20 years old, admitted 
within 3 days after community-onset stroke between July 2010 and March 2013. Disability 
level was divided into modified Rankin Scale (mRS) 0-1, 2-3, 4-5, and 6 (death). Disability 
deterioration was defined as an increase in disability level. The odds ratio (OR) for in-
hospital disability deterioration and mortality was calculated using a logistic regression 
model.
Results: Out of 438,569 patients, 7,633 (1.7%) had dialysis therapy. The median length 
of stay was 21 and 20 days for patients with and without dialysis, respectively. During 
the hospital stay, there were 101,024 (23.0%) disability deterioration and 46,029 (10.5%) 
death. The patients with dialysis had higher rate of disability deterioration (26.7%) and 
mortality (13.0%) compared to those without. After adjustment with age, gender, BMI, 
mRS, Activities of Daily Living, smoking habits, hypertension, diabetes, dyslipidemia, atrial 
fibrillation, coronary heart disease, heart failure, peripheral arterial disease, cerebrovascular 
complications, antiplatelet, anticoagulant, and thrombolytic medications, multivariate-
adjusted ORs of dialysis for deterioration of disability was 1.57 (95%CI 1.48-1.66), and 
in-hospital mortality was 1.72 (95%CI 1.59-1.86).
Conclusions: Dialysis treatment was an independent risk factor for in-hospital disability 
deterioration and mortality of community-onset stroke.
FR-PO750
Proportion of Treatments with Low Systolic Blood Pressure and Short 
Term Mortality in Incident Hemodialysis Patients  Dugan Maddux,1 John W. 
Larkin,1 Danqing Xu,2 Len A. Usvyat,1 Frank van der Sande,3 Jeroen Kooman,3 
Peter Kotanko,4 Franklin W. Maddux.1  1Medical 2ffice, Fresenius Medical 
Care North America, Waltham, MA; 2Univ of California at Santa Barbara, 
Santa Barbara, CA; 3Maastricht Univ Medical Centre, Maastricht, Limburg, 
Netherlands; 4Renal Research Inst, New York, NY.
Background: Prior studies have associated low mean predialysis systolic blood 
pressures (preSBP) with increased 120 day risk for mortality in incident hemodialysis 
(iHD) patients (Maddux et al., ASN 2014). This study aimed to investigate how the percent 
(%) of low mean preSBP during the prior weeks’ hemodialysis (HD) treatments affects the 
short term risk of mortality in iHD patients.
Methods: For this study, 50,525 iHD patients at Fresenius Medical Care North America 
(FMCNA) clinics were investigated from 1/1/2004 to 12/31/2010. From the first date of 
outpatient chronic dialysis (FDD), the % of the prior weeks’ mean preSBP <110 mmHg 
was calculated for the first 4 months of HD. Mortality risk in the following week (7 days) 
was analyzed by the % of the prior week’s mean preSBP <110 mmHg at weeks 2, 4, 6, 
12, and 16 from FDD.
Results: We observed that the short term risk for mortality in the following week 
increases in iHD patients as the % of the prior week’s mean preSBP <110 mmHg increases 
at weeks 2, 4, and 6 from the FDD; the risk for mortality was found to be the greatest at 
week 2 and was slightly reduced by week 6. Conversely, by week 12 and 16 from the FDD, 
the % of the prior week’s mean preSBP <110 mmHg was not found to be related with the 
risk of mortality in the next week. 
Conclusions: This study demonstrates that increases in the % of low mean preSBP 
during the prior weeks’ hemodialysis (HD) treatments is associated with heightened short 
term risks of mortality during the first 6 weeks of iHD, but not during weeks 12 and 16 
from the FDD.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO751
The Possibility of Faster Progression of Brain Atrophy in Patients on 
Peritoneal Dialysis Compared with Hemodialysis  Kazuhiko Tsuruya,1 Hisako 
Yoshida,1 Takanari Kitazono.2  1Dept of Integrated Therapy for Chronic Kidney 
Disease, Graduate School of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 
2Dept of Medicine and Clinical Sciences, Graduate School of Medical Sciences, 
Kyushu Univ, Fukuoka, Japan.
Background: Brain atrophy has been reported in chronic kidney disease (CKD) 
patients, especially in hemodialysis (HD) patients. Recently, we reported faster decline in 
normalized gray matter volume (GMV) in peritoneal dialysis (PD) patients compared with 
non-dialysis-dependent CKD (ND) (Tsuruya, et al. Am J Kidney Dis, 2015). However, it 
has not been reported on the comparison of the progression rate of brain atrophy between 
PD and HD patients. In the present study, we compared it among PD, HD, and ND patients.
Methods: A total of 151 patients of 38 PD patients aged 60 ± 12 years (men 23, diabetes 
11), 24 HD patients aged 64 ± 6 years (men 18, diabetes 9), and 89 ND patients (CKD 
stage 3a, 34; stage 3b, 31; stages 4-5, 24) patients aged 62 ± 11 years (men 46, diabetes 
25, eGFR 38.9 ± 11.6 mL/min/1.73m2) were recruited and underwent MRI scanning at 
baseline and after two years. T1-weighted MRI images were analyzed with statistical 
parametric mapping software. Total gray matter, total white matter, and cerebrospinal 
fluid were segmented and each volume was quantified. Normalized GMV was calculated 
as percentage of intracranial volume to normalize for head size variability. We compared 
the annual change in normalized GMV among CKD stages.
Results: Annual change in normalized GMV was significantly higher in PD patients 
than other CKD patients. This finding remained significant even after adjustment for 
potential confounding factors.
Conclusions: Progression of brain atrophy is significantly higher in PD patients than 
other CKD patients including HD patients, independent of age, gender, diabetes, and 
blood pressure level.
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FR-PO752
In Centre Nocturnal Haemodialysis: Improving Outcomes and Experience 
for Patients  Matthew P.M. Graham-Brown,1,2 Darren Robert Churchward,1,2 
Alice C. Smith,1,2 Richard J. Baines,1,2 James O. Burton.1,2  1John Walls Renal 
Unit, Univ Hospitals of Leicester, Leicester, United Kingdom; 2Dept of Infection, 
Immunity and Inflammation, Univ of Leicester, Leicester, United Kingdom.
Background: Extended periods of haemodialysis (HD) improve patient outcomes. 
Home HD schedules can deliver extended dialysis, but there are patient and physician 
related barriers that make home therapies impossible for many. We explored in centre 
nocturnal HD (INHD) as a method of offering extended periods of HD to patients unsuitable 
for home therapy.
Methods: Ten prevalent HD patients switched from standard HD (3x4 hours) to INHD 
(3x>5 hours) for four months. Mean ultrafiltration (UF) volumes (L), relative UF rates (ml/
kg/hour) and absolute UF rates (ml/hour) were calculated. Additional, biochemical and 
haematological data, data on dialysis adequacy and blood pressure control were collected. 
Changes in quality of life (QoL) were assessed using SF12, EQ-5D and the Hospital Anxiety 
and Depression Score (HADS) questionnaires.
Results: Seven patients completed four months of INHD. Mean dialysis time per session 
was 355 minutes (SD±43.92). Mean total UF volume increased from 2.0±5.1L to 2.6±3.4L 
(p=0.02), but there was a reduction in absolute mean UF rates from 513±121ml/hour on 
standard dialysis, to 356±66 ml/hour on INHD (p=0.03) and a decrease in mean relative 
UF rates from 6.5±1.7ml/kg/hr to 4.6±1.6ml/kg/hr (p=0.03). Adequacy measured by urea 
reduction ratio improved from 72±2% to 80±3% (p<0.001), with a trend towards improved 
phosphate control to within therapeutic targets; from1.7±0.6mmol/L to 1.2±0.2mmol/L 
(p=0.08). In addition, there were improvements in all QoL scores. Mean EQ-5D visual 
analogue score improved from 48±16.9 to 72±13.2 (p=0.003). Mean HADS anxiety score 
decreased from 9±5.83 to 3.57±3.04 (p=0.03). SF12 physical component score improved 
from 31.31±3.32 to 41.69±10.19 (p=0.05).
Conclusions: Despite an increase in total UF volume, extended INHD led to an overall 
reduction in UF rate that has been shown to abrogate HD induced cardiac injury. Other 
physiological benefits included improved urea clearance and better phosphate control. 
There were also significant improvements in patient QoL measures over four months.
FR-PO753
Association of Multiple Strokes on Mortality in Incident Hemodialysis 
Patients: An Application of Multistate Model to Determine Transition 
Probabilities  James B. Wetmore,1 Jonathan D. Mahnken,2 Milind A. Phadnis.2 
1Medicine, Div of Nephrology, Hennepin County Medical Center, Minneapolis, 
MN; 2Biostatistics, Univ of Kansas Medical Center, Kansas City, KS.
Background: Little is known about the effect of multiple, or subsequent, ischemic 
strokes in patients receiving dialysis.
Methods: A retrospective cohort study of incident hemodialysis patients with Medicare 
Parts A and B coverage who had experienced a first ischemic stroke was performed. A 
multistate model with Cox proportional hazards was used to predict transition probabilities 
from first ischemic stroke to subsequent stroke or to death. Demographic and clinical factors 
associated with the respective transition probabilities were determined.
Results: Overall, 12,054 individuals (mean age 69.7 years, 41.3% male, 53.0% 
Caucasian and 34.0% African-American) experienced a first stroke. Female sex was 
associated with an increased risk of having a subsequent stroke (adjusted hazard ratio1.37, 
95% confidence intervals 1.20 – 1.56, P < 0.0001); African-Americans, as compared 
to Caucasians, had lower likelihood of dying after a first stroke (0.81, 0.77 – 0.85, P < 
0.0001). A subsequent stroke trended towards having a higher likelihood of transitioning 
to death compared to a first new stroke on dialysis (1.72, 0.96 – 3.09, P = 0.071). The 
probability of transitioning to a subsequent stroke increased over the first 6 months, peaked 
at approximately 12 months, then declined steadily over time (Figure). When a subsequent 
stroke occurs at 24 months, probability of survival dropped >15%, in absolute terms, from 
0.254 to 0.096, with substantial drops observed at subsequent time points such that the 
probability of survival was more than halved.
Conclusions: Likelihood of subsequent ischemic stroke and of survival in dialysis 
patients appears to vary by sex and race.
Funding: NIDDK Support
FR-PO754
Electrocardiographic Manifestation in End-Stage Renal Disease Patients 
with Different Renal Replacement Treatment  Thasinas Dissayabutra,1 Eiji 
Kusano.2  1Biochemistry, Chulalongkorn Univ, Pathumwan, Bangkok, Thailand; 
2Internal Medicine, Div of Nephrology, Jichi Medical Univ, Shimotsuke, Tochigi, 
Japan.
Background: End-stage renal disease commonly coexists with certain type of 
cardiovascular diseases, partially reflects the burden of cardiac in uremic state and dialysis 
methods. Hemodynamic changes are different between predialysis state, hemodialysis (HD), 
peritoneal dialysis (PD) and post-kidney transplant (Post-KT) patients. This study aimed to 
investigate the cardiac disorders using electrocardiographic (ECG) features between each 
stage of CKD patients, including HD, PD and Post-KT.
Methods: ECG records were analyzed retrospectively in 974 participants, including 
(a) 48 Early CKD (CKD stage 1-2), (b) 188 Advanced CKD (CKD stage 3, 4 and 5), (c) 
567 Hemodialysis (HD), (d) 112 chronic ambulatory peritoneal dialysis (PD) and (d) 59 
post-kidney transplant (KT) patients. ECGs were analyzed by two examiners for major 
ECG abnormalities.
Results: A few ECG abnormalities were observed in Early CKD, but highly frequent 
QTc prolongation and first degree atrio-ventricular block (AVB) were detected in Advanced 
CKD. PD patients developed more left ventricular hypertrophy (LVH) and premature 
ventricular contraction than HD counterparts. 
Four-consecutive-year annual ECGs showed the significant increase of AVB, LVH and 
QTc prolongation in HD patients. QTc prolongation recovery was observed in KT with 
the fewer LVH prevalence. We found that the age was a dependent factor for AVB and 
RBBB development, and the remaining GFR correlated with the prevalence of AVB and 
QTc prolongation in CKD patients.
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Conclusions: Prolonged QTc, first-degree AVB, LVH and PVC were prevalent in ESRD 
and depended on renal replacement therapy method. The physicians should be cautious 
and promptly treat to the fatal arrhythmias.
Funding: Government Support - Non-U.S.
FR-PO755
The Relation Between Sclerostin, Peripheral Vascular Calcification, and 
Cardiovascular Events in ESRD Patients  Young Ju Na, Sung Yoon Lim, 
Myung-gyu Kim, Sang-Kyung Jo, Won-Yong Cho.  Nephrology, Korea Univ 
Hospital, Seoul.
Background: Sclerostin, a negative regulator of Wnt signaling pathway produced 
by osteocyte, is a potent regulator of bone metabolism and a novel candidate for the 
bone vascular axis in chronic kidney disease patients. Although sclerostin is known as an 
inhibitor of vascular calcification, recent studies demonstrated conflicting results about the 
association between sclerostin and cardiovascular events or mortality. In this study we tested 
the association between sclerostin, peripheral vascular calcification, and cardiovascular 
events in end stage renal disease (ESRD) patient starting peritoneal dialysis.
Methods: In this prospective study, we included 45 ESRD patients admitted to Korea 
University Anam Hospital for starting peritoneal dialysis. Circulating sclerostin level was 
measured in all patients before the start of peritoneal dialysis. Simple vascular calcification 
score (SVCS) was measured using plain radiographic films of both hands and the pelvis. 
Median follow up period was 36 months.
Results: Higher sclerostin level was associated with male sex, diabetes mellitus, 
higher left ventricle (LV) mass index, and lower LV fractional shortening in univariate 
analysis. ESRD patients with severe vascular calcification (SVCS ³3) had significantly 
higher prevalence of diabetes mellitus. They had higher pulse wave velocity, alkaline 
phosphatase, and lower cholesterol levels, LV fractional shortening and in multivariate 
analysis, the presence of diabetes mellitus (OR, 44.59, p=0.023), lower cholesterol levels 
(OR, 0.94, p=0.032) were independent risk factors predicting severe vascular calcifications. 
In multivariate Cox regression model, higher pulse wave velocity (HR 1.03, p=0.028) was 
significant predictor for cardiovascular events. In addition higher sclerostin group (HR 
9.82, p=0.094) and lower albumin levels (HR 0.23, p=0.081) display a strong tendency of 
increased cardiovascular events.
Conclusions: This study showed the possible important role of sclerostin in the 
development of vascular calcification and cardiovascular events in PD patients. Longer 
term follow up with larger sample size will be needed to clarify this issue.
FR-PO756
Use of Anticoagulants in Patients with Atrial Fibrillation and End Stage 
Renal Disease: A Study of Real World Data  Lloyd P. Haskell,1 Chris Knoll,2 
Patrick Ryan,3 Zhong Yuan.3  1Cardiovascular, Janssen R and D, Raritan, NJ; 
2Epidemiology, Janssen R and D, Raritan, NJ; 3Epidemiology, Janssen R and 
D, TItusville, NJ.
Background: End stage renal disease (ESRD) in patients with atrial fibrillation (AF) 
is a significant cause of morbidity and mortality.While these patients are at high risk for 
stroke, there are limited data with respect to use of anticoagulants in clinical practice and 
current guidelines are not clear on how to manage them.
Methods: US-based, four large healthcare databases (Truven MarketScan Commercial 
Claims/Encounters [CCAE], Medicare Supplemental [MDCR], Medicaid [MDCD]) and 
Optum Clinformatics [Optum]) were used to establish cohorts of patients with AF and 
ESRD, who were identified using ICD-9 codes. The first encounter with evidence of both 
conditions during the inception period of 2010-2012 was the index date; patients must have 
had at least 1 year enrolment prior to and after the index date to be eligible for the study. 
The use of anticoagulants was examined during the follow-up period.
Results: Table 1 shows patient demographics and use of anticoagulants by data source. 
As expected, the privately-insured patient populations (CCAE and Optum) as well as the 
Medicaid population [MDCD] were younger as compared with the Medicare eligible 
population (MDCR). Across study cohorts, approximately 37% to 40% of patients with AF 
and ESRD received at least one dispensing of warfarin, with the exception of the Medicaid 
population (14%). About 3% to 4% of patients (except for Medicaid) received at least one 
dispensing of novel oral anticoagulant therapy (rivaroxaban, apixaban, or dabigatran).
Table 1. Use of Anticoagulants in Patients with AF and ESRD
Datasource N Mean Age [S.D.] Male, %
Novel Oral 
Anticoagulants Warfarin
Commercial 3650 56 [7.7] 66.2% 2.5% 37.7%
Medicare 9866 77 [7.7] 59.7% 3.4% 40.1%
Medicaid 5663 64 [3.7] 41.6% 0.6% 14.0%
Optum 2825 65 [12.4] 66.8% 4.1% 37.5%
Conclusions: Less than 40% of patients with AF and ESRD received anticoagulant 
therapy. As these are high risk patients, anticoagulant therapy may be underutilized. Further 
research is necessary to investigate clinical outcomes associated with anticoagulation in 
these patients.
FR-PO757
Factors Determining Changes in Mortality Rates in Incident Hemodialysis 
Patients  Jochen G. Raimann,1 Len A. Usvyat,2 Dugan Maddux,2 Jeroen 
Kooman,3 Frank van der Sande,3 Kevin Chan,2 Franklin W. Maddux,2 Peter 
Kotanko.1,4  1Renal Research Inst; 2Fresenius Medical Care North America; 
3Maastricht Univ Medical Centre; 4Icahn School of Medicine at Mount Sinai.
Background: The higher risk of death for incident hemodialysis (HD) patients 
decreases during the first year (Chan, 2011). Next to vintage, risk is also affected by patient 
characteristics, and the evolution of clinical and laboratory parameters. We analyzed how 
mortality rates change in different age groups, levels of albumin, in black and white, and 
in diabetic and non-diabetic patients after HD initiation.
Methods: We analyzed patients commencing HD in Fresenius Medical Care North 
America clinics between 1/1/2005 and 11/30/2014. We calculated proportions of patients 
dying from all causes in diurnal intervals starting with the first day on HD up to 1000 days. 
Only patients who had their first outpatient treatment on day 1 of their first ever HD were 
analyzed. We analyzed differences in mortality in the following strata: a) age groups (<40, 
between 40 and 65, and >65 years); b) serum albumin greater and below 3.8 g/dL; c) black 
and white; and d) diabetic and non-diabetic patients. We fitted penalized B-splines with 
95% CIs through all available daily rates.
Results: We studied 334,880 patients. For all groups, mortality rates dropped within 
the first year. There were differences between groups of age, albumin and between black 
and white patients, but none between diabetic and non-diabetic patients.
Conclusions: Mortality rates decrease substantially once patients initiate HD. After 
approximately one year on HD, mortality remains consistent in all groups, but remains 
lower for those with higher albumin, younger age and black race. Diabetes appears to not 
affect mortality. Since only patients starting in an outpatient setting were included, selection 
bias may apply differently to the patient groups.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO758
Strong Association of Geriatric Nutritional Risk Index with the Infection-
Related Mortality in Hemodialysis Patients: The Q-Cohort Study 
Yuta Matsukuma,1 Shigeru Tanaka,1 Masatomo Taniguchi,1 Toshiaki Nakano,1 
Kosuke Masutani,1 Hideki N. Hirakata,2 Kazuhiko Tsuruya,1,3 Takanari 
Kitazono.1  1Dept of Medicine and Clinical Science, Kyushu Univ, Fukuoka, 
Japan; 2Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan; 3Dept of 
Integrated Therapy for Chronic Kidney Disease, Kyushu Univ, Fukuoka, Japan.
Background: Geriatric Nutritional Risk Index (GNRI) is a simple but useful predictive 
marker for all–cause and cardiovascular mortality inhemodialysis(HD) patients. However, 
it is unclear whether the GNRI could predict the infection–related mortality in HD patients. 
We herein investigated the association between GNRI and the infection–related mortality 
in Japanese HD patients.
Methods: A total of 3,452 Japanese HD patients aged >18 years were prospectively 
followed for 4 years. Patients were divided into three groups by tertile of GNRI: Tertile1 
(T1): <92.67; T2: 92.67–98.63; T3: >98.63. We estimated the relationship between GNRI 
and the all–cause mortality and infection–related mortality using a Cox proportional hazards 
model. To assess the additional predictive value of GNRI in risk assessment, we compared 
the c–statistics between serum albumin and GNRI.
Results: During the follow–up period, 566 patients died totally, and 121 patients 
died of infection–related mortality. All–cause mortality and infection–related mortality 
increased linearly with lower GNRI levels. After adjusting for confounding risk factors, 
the GNRI was an independent predictor of not only all–cause but also infection–related 
mortality (hazard ratio 6.51, 95% confidence interval 3.16–13.4 , p <0.001 for T1 vs. T3, 
and hazard ratio 3.04, 95% confidence interval 1.44–6.43, p = 0.004 for T2 vs. T3). When 
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GNRI was incorporated into a model with potential risk factors instead of serum albumin, 
the c–statistics increased significantly both in all–cause mortality (0.783 vs. 0.787, p = 
0.021) and in infection–related mortality (0.802 vs. 0.812, p = 0.011).
Conclusions: A lower GNRI is strongly associated with infection–related mortality 
in HD patients, and Our finding suggest that the predictive value of GNRI is superior to 
serum albumin.
FR-PO759
Survival in Elderly on Dialysis and Impact of Institutionalization 
Amarpali Brar, David Kau, Moro O. Salifu, Mary C. Mallappallil.  Renal, SUNY 
Downstate, Brooklyn, NY.
Background: We hypothesized that in the very elderly dialysis patients in the United 
States, institutionalization in nursing homes would increase mortality in addition to age 
alone.
Methods: Data was obtained from the U.S. Renal Data System. Incident dialysis 
patients from 2001 to 2008 above the age of 70 were included. Follow-up period was 
from incident dialysis date to either death or last follow up on September 30, 2009. 
Patients above 70 were categorized into four groups according to age as 70-75 years, 
76-80 years, 81-85 years, greater than 85 years and further divided into institutionalized 
and non-institutionalized.
Results: A total of 349,440 patients were identified above the age of 70 years at the time 
of initiation of dialysis. Major causes of end stage renal disease were diabetes, hypertension, 
glomerulonephritis, cystic kidney disease, and urological causes. Mean survival for non 
instutionalised patients was 3.15 ± 0.01 years for those between 70-75 years of age, 
2.55±0.01 years for 76-80 years of age, 2.12±0.01 years for 81-85 years of age and 1.64± 
0.01 years for those above 85 years at the time of initiation of dialysis respectively. For 
institutionalized patients, mean survival was significantly lower, 1.71±0.03 years for 70-75 
years old, 1.44± 0.02 years for 75-80 years old , 1.25±0.02 years for 81-85 years old and 
more than 85 years and 1.04 ±0.02 for > 85 years age group, p=0.0001.The oldest group in 
non-institutionalized over the age of 85 years had a similar survival as the institutionalized 
ESRD patients 70-75 years of age.
Conclusions: There was increased mortality in institutionalized elderly patients as 
compared to non instutionalised elderly patients in the same age group. Keeping with 
the increased frailty and decreased benefits of therapies in the very elderly especially in 
those with additional co-morbidities besides age, palliative and end of life care should 
be considered.
FR-PO760
Geriatric Nutritional Risk Index Is a Simple Predictor of Mortality in 
Chronic Hemodialysis Patients  Kosaku Nitta, Ken Tsuchiya.  Dept of 
Medicine, Kidney Center, Tokyo Women’s Medical Univ, Shinjuku-ku, Tokyo, 
Japan.
Background: Malnutrition is common in hemodialysis (HD) patients, and it is 
associated with increasing risk of mortality. The geriatric nutritional risk index (GNRI) 
has been developed as a tool to assess the nutritional risk. The aim of the present study was 
to examine the reliability of the GNRI as a mortality predictor in a Japanese HD cohort.
Methods: We prospectively examined the GNRI of 332 maintenance HD patients aged 
65.4 ± 13.2 years, 213 males, and followed up on them for 36 months. The patients were 
divided into quartiles (Q) according to GNRI values (Q1: <91.6, Q2: 91.7-97.0, Q3: 97.1-
102.2, Q4: >102.3). Predictors for all-cause mortality were examined using Kaplan–Meier 
and Cox proportional-hazards analyses.
Results: The GNRI presented a normal distribution. During the follow-up period 
of 36 months, a total of 76 patients died. The overall mortality at the end of the 3-year 
observational period was 22.3 %. At the 3-year follow-up period, Kaplan-Meier survival 
rates for all-cause mortality were 72.3%, 79.3%, 84.9%, and 92.6% in Q1, Q2, Q3, and Q4, 
respectively (p = 0.0067). Multivariate Cox proportional-hazards analysis demonstrated 
that the GNRI was a significant predictor of adjusted all-cause mortality (HR 0.958; CI 
0.929–0., p < 0.001).
Conclusions: The results of the present study demonstrate that the GNRI is a strong 
predictor of overall mortality in HD patients. However, cardiovascular mortality was not 
associated with GNRI values, and did not differ among the GNRI quartiles. The GNRI 
score can be considered a simple and reliable marker of predictor for mortality risk in 
Japanese HD patients.
FR-PO761
Frailty and Clinical Outcomes in Chronic Dialysis Patients  Dong Ho Yang,1 
Eun jung Ko,1 Hye yun Jeong.1  1Internal Medicine, CHA Bundang Medical 
Center, Seongnam, Republic of Korea; 2Internal Medicine, CHA Gumi Medical 
Center, Gumi, Republic of Korea.
Background: Frailty is a biological syndrome of decreased reserve and resistance to 
stressors and is independently associated with mortality and hospitalization in the general 
population. We investigated the relationship between frailty and clinical outcomes in 
chronic dialysis patients.
Methods: In this prospective study, 1,658 patients receiving chronic dialysis were 
enrolled. Chronic dialysis was defined as dialysis for more than 6 months. Of the 1,658 
patients, 1,255 received hemodialysis. The remainder received peritoneal dialysis. Fried’s 
criteria for frailty as modified by Woods et al. was used. A trained interviewer asked study 
participants about 5 frailty phenotypes (slowness, weakness, exhaustion, shrinking, and 
physical inactivity) using the RAND 36-item Short Form.
Results: The mean age was 55.2±11.9, and 55.2% were male. Overall, 577 (34.8 %) 
patients met the study definition of frailty. Another 757 (45.7%) patients were pre-frail. 
Table 1 shows the prevalence of frailty and its components by age group. During the 
30-month follow-up period, 607 patients (79 non-frail, 249 pre-frail, and 279 frail) were 
hospitalized; and 87 patients (10 non-frail, 24 pre-frail, and 53 frail) died (P<0.001). Frailty 
was strongly associated with hospitalization (adjusted hazard ratio [HR] 1.80; 95% CI 1.4 to 
2.3) and mortality (HR 2.37, 95% CI 1.11 to 5.02) in multivariate analysis. The relationship 
between frailty and hospitalization was strongest among patients age 40 to 49, with a HR 
of 3.02 (95% CI 1.48 to 6.20). 
Table 1. The prevalence of frailty and its components by age. 
Age group (years)
P value
< 40 40-49 50-59 60-69 ≥ 70
Frail, % 21.1 20.6 32.8 38.0 63.8 <0.001
Pre-frail, % 57.8 55.9 47.2 41.0 26.5 <0.001
Slowness/Weakness, % 33.0 40.9 35.2 34.6 30.6 0.130
Exhaustion, % 60.8 59.7 65.3 66.2 80.2 0.001
Inactivity, % 58.3 45.6 42.8 35.6 50.6 0.013
Shrinking, % 13.7 7.6 9.8 10.6 10.1 0.777
Conclusions: We found a high prevalence of frailty in chronic dialysis patients across 
all age groups. The risk of hospitalization and mortality in the 30-month follow-up period 
significantly increased in frail chronic dialysis patients.
FR-PO762
Outcomes of Early Initiation of Dialysis in Elderly Patients with End-Stage 
Renal Disease: A Propensity-Matched Analysis of a Prospective Cohort 
Study  Jae Yoon Park,1 Kyung Don Yoo,1 Jeonghwan Lee,2 Dong Ki Kim,1 
Kwon Wook Joo,1 Shin-Wook Kang,3 Chul Woo Yang,4 Yong-Lim Kim,5 Chun 
Soo Lim,1 Yon Su Kim,1 Jung Pyo Lee.1  1Seoul National Univ College of 
Medicine, Seoul, Korea; 2Hallym Univ Hangang Sacred Heart Hospital, Seoul, 
Korea; 3Yonsei Univ College of Medicine, Seoul, Korea; 4The Catholic Univ of 
Korea College of Medicine, Seoul, Korea; 5Kyungpook National Univ School 
of Medicine, Daegu, Korea.
Background: The optimal timing for initiating dialysis in end-stage renal disease 
(ESRD) remains controversial, especially in elderly patients. We therefore investigated 
the effect of dialysis initiation timing on clinical outcomes in elderly patients with ESRD.
Methods: A total of 665 patients aged equal or over 65 years who started dialysis 
from August 2008 to February 2015 were enrolled in Clinical Research Center for End 
Stage Renal Disease cohort study in Korea. They were divided into 2 groups based on the 
median estimated glomerular filtration rate, which was 8.85 mL/min/1.73m2. The primary 
outcome was patient survival and the secondary outcomes were cardiovascular events and 
Kidney Disease Quality of Life Short Form 36 (KDQOL-36) score.
Results: Overall cumulative survival rates were lower in early initiation group (Log-
rank P<0.001). However, the survival rates showed no significant difference after matching 
propensity score. Additionally, early initiation of dialysis was not associated with survival 
rates after adjustment for age, sex, Charlson comorbidity index, hemoglobin, serum albumin, 
serum calcium and phosphorus level. Although the early initiation group showed lower 
physical component summary in KDQOL-36 at 3 months after dialysis, the difference of 
the scores was not significant at 12 months after dialysis.
Conclusions: Early initiation of dialysis was not associated with prognosis in elderly 
patients with ESRD. The physical functioning was worse for 3 months after dialysis but it 
became similar to late initiation of dialysis at 1 year after dialysis.
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FR-PO763
1- and 2-Year Mortality Prediction Models for Patients Starting Chronic 
Dialysis  Mikko Haapio,1 Jaakko Helve,1 Carola Gronhagen-Riska,1,2 Patrik 
Finne.1,2  1Nephrology, Univ of Helsinki and Helsinki Univ Hospital, Helsinki, 
Finland; 2Finnish Registry for Kidney Diseases, Helsinki, Finland.
Background: Mortality risk of patients with end-stage renal disease (ESRD) is highly 
elevated compared to patients without ESRD. Taking into account our limited nephrological 
care resources and the simultaneously increasing number of ESRD patients there is a great 
need for means of mortality risk estimation to assist both in individualized patient care 
as well as in sound use of resources. Some mortality prediction models already exist, but 
many have shown a lack of comprehensiveness in data or in patient recruitment in their 
development.
Methods: Our objective was to design a prediction model for 1- and 2-year all-
cause mortality in patients starting chronic renal replacement therapy. In addition, we 
aimed to build an easy-to-apply model consisting of only a few variables. We used the 
comprehensive data of the Finnish Registry for Kidney Diseases with complete coverage 
of Finnish ESRD patients. Model training group included all incident adult patients who 
started chronic dialysis in Finland from 1 January 2000 to 31 December 2008 (n=4335). 
The external validation cohort consisted of all those who started dialysis from 1 January 
2009 to 31 December 2012 (n=1768). Prediction algorithms for 1- and 2-year mortality were 
developed using multivariate logistic regression with stepwise selection of variables. Our 
primary analyses included 32 variables, from which the most important ones were selected.
Results: Both final prognostic models, including only 6-7 variables, showed adequate 
discrimination (c-statistic 0.77 and 0.74 for 1- and 2-year mortality, respectively). Because 
of a significantly lower mortality in the newer (validation) cohort, both models somewhat 
overestimated mortality risk.
Conclusions: Mortality prediction algorithms could be more widely implemented into 
clinical treatment-planning of ESRD patients. Our prediction models perform sufficiently 
and are convenient to use, and could assist in individualized risk-stratification and, 
furthermore, in equal and fair sharing of limited health care resources.
FR-PO764
Comorbidity Burden at Dialysis Initiation and Mortality: A Retrospective 
Cohort Study  Alwyn Titus Gomez,1 Bryce A. Kiberd,1 Talal A. Alfaadhel,2 
Brenda Hemmelgarn,3 Karthik K. Tennankore.1  1Medicine, Dalhousie Univ, 
Halifax, NS, Canada; 2Medicine, Univ of Toronto, Toronto, ON, Canada; 
3Medicine, Univ of Calgary, Calgary, AL, Canada.
Background: Contemporary assessments of the validity and prognostic value of 
comorbidity indices in dialysis are lacking. We sought to assess the validity of two 
comorbidity indices used for dialysis patients and to determine if a high degree of 
comorbidity was associated with mortality.
Methods: We conducted a retrospective cohort study of incident chronic dialysis 
patients in a tertiary care institute from 2006-2013. The Charlson Comorbidity Index 
(CCI) and End-Stage Renal Disease Comorbidity Index (ESRD-CI) were calculated in all 
patients at dialysis initiation. These indices combine individual medical conditions into an 
overall score. Comorbid conditions were ascertained using electronic records. The primary 
outcome was all-cause mortality.
Results: The cohort consisted of 771 patients. Most were male (62%) and Caucasian 
(91%). Patients had a high prevalence of diabetes (48%) and history of myocardial infarction 
(31%). The c-index was 0.61 for the CCI, and 0.63 for the ESRD-CI. In an adjusted analysis, 
ESRD-CI scores of 4, 5 and ≥6 were associated with a similar mortality risk (Table 1). 
There was a small increased mortality risk for CCI scores of 4, 5 and ≥6.
Conclusions: The CCI and ESRD-CI had a limited ability to discriminate risk of 
death for incident dialysis patients. Although a higher comorbidity burden was associated 
with mortality, increases in index scores did not considerably change the risk of death.
Table 1. Multivariable Cox survival analysis for the ESRD-CI and CCI
End-Stage Renal Disease Comorbidity Index
Score Relative Hazard > Confidence Interval@
0/1 Reference
2 1.63 [1.12 to 2.36]
3 1.28 [0.84 to 1.91]
4 1.95 [1.34 to 2.85]
5 1.89 [1.25 to 2.86]
≥6 1.99 [1.41 to 2.81]
Charlson Comorbidity Index
Score Relative Hazard > Confidence Interval@
2 Reference
3 1.76 [1.10 to 2.82]
4 1.86 [1.22 to 2.83]
5 2.38 [1.53 to 3.72]
≥6 2.71 [1.81 to 4.06]
*Adjusted for age, sex, race, cause of end-stage renal disease, type of dialysis (hemodialysis or 
peritoneal dialysis), estimated GFR, albumin, phosphate and hemoglobin
FR-PO765
Cumulative Risk of Death in Propensity-Matched Incident Dialysis 
Patients: A Nationwide Prospective Multicenter Cohort Study in Korea 
Hee-Yeon Jung,1 Sukyung Lee,1 Ji-Young Choi,1 Se-Hee Yoon,2 Jang-Hee 
Cho,1 Sun-Hee Park,1 Chan-Duck Kim,1 Yong-Lim Kim.1  1Internal Medicine, 
Kyungpook National Univ School of Medicine, Daegu, Republic of Korea; 
2Internal Medicine, Konyang Univ, Daejeon, Republic of Korea.
Background: Our previous study reported the superior outcome of peritoneal dialysis 
(PD) than hemodialysis (HD) in the early dialysis period. This study investigated the impact 
of dialysis modality after the early period of incident dialysis patients.
Methods: Incident dialysis patients were enrolled from Korean nationwide prospective 
cohort from September 2008 to December 2013. The patients were stratified by modality 
at day 90 after the first dialysis or the modality at dialysis initiation if death occurred prior. 
The survival of PD and HD patients were compared by propensity score matching analysis. 
Relative risk of death was estimated using the cumulative hazard ratio from the stratified 
Cox proportional hazard model adjusted for residual confounding.
Results: A total of 1348 patients were matched from 2658 incident dialysis patients 
with mean follow-up of 29.9 ± 14.1 months. All clinical parameters including baseline 
residual renal function were comparable between PD and HD patients. The cumulative risk 
of death was significantly lower in PD than HD from 6 months after dialysis initiation. The 
cumulative hazard ratio for death was 0.70 (95% confidence interval [CI] 0.41-0.98) at one 
year for PD compared with matched HD and 0.68 (95% CI 0.46-0.90) at two years. The 
cumulative survival probability was higher in PD patients for up to 3.5 years on dialysis, 
with no difference after the period.
Conclusions: Overall survival in maintenance dialysis patients favored PD in the early 
period of dialysis and the survival advantage lasted to 3.5 years after initiation of dialysis. 
However, PD and HD patients had similar survival outcomes thereafter.
FR-PO766
Inflammation and Fluid Overload a Complex Interaction: Results from 
the International MONDO Initiative  Marijke J.E. Dekker,1 Len A. Usvyat,2,3 
Daniele Marcelli,3 Frank van der Sande,4 Constantijn Konings,1 Peter Kotanko,2 
Jeroen Kooman.4  1Catharina Hospital Eindhoven; 2Renal Research Inst; 
3Fresenius Medical Care; 4Maastricht Univ Medical Center.
Background: In hemodialysis (HD) patients, the presence of inflammation or fluid 
overload (FO) is associated with increased mortality. The combined presence of these two 
is associated with even a greater risk of death. This study aims to unravel the temporal 
relationship between fluid status alterations and inflammation.
Methods: We conducted a longitudinal study (baseline and follow-up 3 months each) in 
a European subset of the MONDO-Initiative. Fluid status was assessed by multifrequency 
bioimpedance and inflammation by C-reactive protein (CRP). We divided patients into 4 
groups based on fluid- and inflammation status. FO was defined as overhydration above 
>2.5L. Inflammation was defined as CRP >10mg/L.
Results: We included 5954 patients (56.1% male, age 63 years, vintage 5.1 years). At 
baseline inflammation and FO were jointly present in 1092 (18.3%) patients. 141 (11.8%) 
developed inflammation during follow up. Of the 1192 (20%) patients with inflammation but 
with normal fluid status at baseline, 111 (10.2%) had FO during follow up. Inflammation at 
baseline predicted FO during follow up (odds ratio(OR) 1.20(95% CI 1.05-1.37)). Likewise, 
FO during baseline predicted inflammation during follow up (OR 1.30 (95% CI 1.15-1.47)). 
However, in a minor of patients the presence of FO and/or inflammation appears to be a 
relatively stable condition. The presence of both inflammation and FO during baseline was 
associated with an increased mortality risk compared to the absence of both. 
Conclusions: FO and inflammation are associated in prevalent HD patients. FO is a 
predictor for inflammation and vice-versa inflammation predicts FO. The combined presence 
of FO and inflammation is associated with poor survival.
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FR-PO767
Blood Volume Analysis as a Guide for Dry Weight Determination in Chronic 
Hemodialysis Patients  Line Malha,1,2 Hasan Fattah,3 Frank Modersitzki,1 David 
S. Goldfarb.1,2  1Internal Medicine, Div of Nephrology, NYU School of Medicine, 
New York, NY; 2Internal Medicine, Nephrology Section, New York Harbor VA 
Healthcare System, New York, NY; 3Internal Medicine, Div of Nephrology, 
Virginia Commonwealth Univ Medical Center, Richmond, VA.
Background: Volume overload and depletion both lead to high morbidity and mortality. 
Achieving euvolemia is a challenge in patients with end stage kidney disease (ESKD) on 
hemodialysis (HD). Blood volume analysis (BVA) uses radiolabeled albumin to determine 
intravascular blood volume (BV). The measured BV is compared to an ideal BV (validated in 
healthy controls). We hypothesized that BVA could be used in HD to evaluate the adequacy 
of the current clinically prescribed “estimated dry weight” (EDW) and to titrate EDW in 
order to improve overall volume status. We were also interested in the reproducibility of 
BVA results in ESKD. This is the first longitudinal study of BVA in HD patients.
Methods: 12 adults on chronic HD were recruited; 10 completed the study. BVA (Daxor, 
New York, NY, USA) was used to measure BV at baseline. EDW was kept the same if the 
patient was deemed to be euvolemic by BVA otherwise, the prescribed EDW was changed 
with the aim that measured BV would match ideal BV. A second BVA measurement was 
done 1-3 months later in order to measure BV again.
Results: Based on BVA, 6/10 patients were euvolemic at baseline and 5/10 were 
euvolemic at the second measurement. When comparing patients who had their prescribed 
EDW changed after the initial BVA to those who did not, both groups had similar 
differences between measured and ideal BV (P=0.75). BV values were unchanged at the 
second measurement (P=0.34) and there was no linear correlation between BV change 
and weight change (r2 =0.8).
Conclusions: This pilot study is the first longitudinal measurement of BVA in HD 
patients. It revealed that changing weight did not proportionally change intravascular BV. 
BV remained stable for 1-3 months. BVA may not be helpful in clinically stable HD patients 
but studies on patients with hemodynamic instability and uncertain volume status are needed.
Funding: Pharmaceutical Company Support - Daxor provided BVA equipment and 
supplies but was not involved in study design or execution and did not participate in the 
analysis of data or preparation of the manuscript
FR-PO768
Effects of Physician Payment Reform on Provision of Home Dialysis 
Kevin F. Erickson,1 Wolfgang C. Winkelmayer,2 Glenn Matthew Chertow,1 Jay 
Bhattacharya.1  1Medicine, Stanford Univ, Palo Alto, CA; 2Medicine, Baylor 
College of Medicine, Houston, TX.
Background: Patients with end-stage renal disease can receive dialysis at home or 
in-center.  In 2004 the Centers for Medicare and Medicaid Services reformed physician 
payment for in-center hemodialysis care from a capitated to a tiered fee-for-service model, 
augmenting physician payment for frequent in-center visits. We evaluated whether payment 
reform influenced dialysis modality assignment.
Methods: Using a national cohort of patients starting dialysis in the US in the three 
years before and after payment reform, we conducted difference-in-difference analyses 
comparing patients with Traditional Medicare coverage (who were affected by the policy) 
to others with Medicare Advantage (who were unaffected by the policy).  We also examined 
whether the policy had a more pronounced influence on dialysis modality assignment in 
areas with lower costs of traveling to dialysis facilities.
Results: Patients with Traditional Medicare coverage experienced a 12% (95% CI, 2% 
to 21%) reduction in home dialysis use following payment reform compared to patients 
with Medicare Advantage.  Patients living in areas with larger dialysis facilities (where 
payment reform made in-center hemodialysis comparatively more lucrative for physicians) 
experienced a 16% (95% CI, 8% to 23%) reduction in home dialysis use following payment 
reform compared to patients living in areas with smaller facilities (where payment reform 
made in-center hemodialysis comparatively less lucrative for physicians).
Conclusions: National physician payment reform intended to improve the quality of 
dialysis care resulted in fewer patients receiving home dialysis.  This highlights a major 
failure of the policy and the importance of considering unintended consequences of future 
physician payment reform efforts.
Funding: NIDDK Support, Other NIH Support - Funding: F32 HS019178 from 
AHRQ (Dr. Erickson); DK085446 (Dr. Chertow); Dr. Winkelmayer receives research 
and salary support through the endowed Gordon A. Cain Chair in Nephrology at Baylor 
College of Medicine. Dr. Bhattacharya would like to thank the National Institute on Aging 
for support for his work on this paper (R37 150127-5054662-0002).
FR-PO769
Characteristics and Outcomes Amongst Patients Who Switch Dialysis 
Provider  Scott Reule, Paul E. Drawz, Robert N. Foley.  Dept of Medicine, 
Univ of Minnesota, Minneapolis, MN.
Background: Associations between provider switch and inferior clinical outcome have 
been demonstrated in primary care settings. It is plausible that similar associations extend 
into those on renal replacement therapy (RRT) as nephrology care often extends beyond 
that of RRT management alone. There is a paucity of literature available describing the 
characteristics and outcomes amongst those whom switch dialysis provider.
Methods: Using USRDS data, a change in provider will be defined the presence of any 
non-contiguous facility codes while receiving maintenance RRT. As patients transitioning 
to maintenance RRT may experience early adverse outcomes, only those patients having 
initiated RRT with a vintage of at least 1 year were included in the analysis.  Means 
and proportions were calculated for continuous and categorical variables, respectively. 
Logistic regression was used for adjusted comparisons with adjustments for baseline 
demographic characteristic including age, sex, and race. All estimates with p-value < 0.05 
were considered significant.
Results: Applying these criteria, a total of 187,510 (9.1%) of prevalent patients 
requiring RRT were identified as having changed provider at least once. The mean age of 
those who have changed provider (vs. no change) was 41.3 years (vs. 57.3 years), 57% 
were male (vs. 55.1%), 51.3% were white (vs. 49.1%), diabetes as comorbidity in 29.9% 
(vs. 49.4%), heart disease in 10.9% (vs. 21.1%), and 23.2% utilized peritoneal dialysis at 
initiation (vs. 9.75%). Risk of death was lower in those who change provider (OR 0.69; 
CI 0.68 – 0.70) and odds were higher for both listing for (OR 2.9; CI 2.9 – 3.0) and receipt 
of renal transplantation (OR 4.1; CI 4.0-4.2).
Conclusions: Patients who switch dialysis providers constitute a distinct population 
of patients who are younger and lack comorbid conditions frequency observed in those 
on dialysis. Compared to those who do not switch providers, those who switch are more 
likely to be listed for and receive renal transplant.
FR-PO770
Effects of Sildenafil in Dialysis Patients with Erectile Dysfunction: A 
Systematic Review and Meta-Analysis  Anawin Sanguankeo,1,2 Sikarin 
Upala.1,2  1Internal Medicine, Bassett Medical Center and Columbia Univ 
College of Physicians and Surgeons, Cooperstown, NY; 2Preventive and Social 
Medicine, Faculty of Medicine Siriraj Hospital, Mahidol Univ, Bangkok, 
Thailand.
Background: Erectile dysfunction (ED) is prevalent in dialysis patients. Sildenafil, 
a PDE-5 inhibitor, has been shown to be very effective against ED in general population. 
However, there is some evidence that dialysis patients are resistant to sildenafil treatment. 
We performed this meta-analysis to evaluate efficacy of sildenefil in dialysis patients with 
ED compared with control.
Methods: We comprehensively searched the databases of MEDLINE, EMBASE, 
and Cochrane Databases. The inclusion criteria were published RCT comparing sildenafil 
therapy to placebo or controls on ED in patients with dialysis. The primary outcome was 
change in International Index of Erectile Function (IIEF) score. The diagnosisof ED was 
confirmed with a score of 21 or less in IIEF.
Results: From 153 full-text articles, 3 studies involving 153 dialysis patients were 
included in the meta-analysis. All included studies were RCT comparing sildenefil with 
active control in either hemodialysis or peridoneal dialysis patients. A meta-analysis 
using fixed-effects model was performed. Those who received sildenafil had a significant 
improvement in IIEF with a MD of 10.48 (95% CI: 9.96 to 11.00, p-value<0.01). 
Conclusions: This is the first meta-analysis to show that sildenafil is effective in 
dialysis patients with erectile dysfunction compared with control. Further study comparing 
other benefits and side effects of PDE-5 inhibitor in dialysis patients should be conducted.
FR-PO771
Validation of Screening Questionnaires for Sleep Apnea in Hemodialysis 
Population  Farhanah Yousaf, Mitesh K. Patel, Saw H. Mu, Alla Goldberg, 
Chaim Charytan, Bruce S. Spinowitz.  New York Hospital Queens.
Background: Sleep apnea hypopnea syndrome (SAHS) is common in end stage renal 
disease (ESRD). We investigated the validity of Berlin and STOP-BANG questionnaires 
against nocturnal oximetry in identifying high risk hemodialysis patients for SAHS.
Methods: After obtaining local IRB approval, adult hemodialysis patients who were 
undergoing regular chronic hemodialysis for at least 3 months were consented and asked to 
complete Berlin and STOP-BANG questionnaires. Nocturnal oximetry from hemodialysis 
night using Pulsox 300i wristwatch was also completed. The saturation recordings were 
downloaded and analyzed using Profox software. The first hour of recording was deleted 
in efforts to capture oximetry reading from sleep time only. Motion artifacts and aberrant 
data were also excluded from analysis. Oxygen desaturation index (ODI) was defined as 
the number of desaturations ≥ 3% from baseline lasting ≥ 10 seconds, per hour. Sensitivity, 
specificity, positive and negative predictive values were calculated for the Berlin and 
STOP-BANG questionnaires.
Results: Twenty HD patients (11 males and 9 females) aged 54 ± 13 years with a 
mean body mass index of 25.5 ± 4.6 kg/m2 and neck circumference of 38.4 ± 5.8 cm 
participated in the study. ODI was ≥ 5 in 80% of patients. Both Berlin and STOP-BANG 
questionnaires had modest sensitivities (69-71%) but poor specificities (17-50%). Positive 
predictive value and negative predictive value was 67% and 67% for Berlin questionnaire, 
respectively. STOP-BANG questionnaire had a positive predictive value of 85% and a 
negative predictive value of 29%.
Conclusions: Reliable screening tools for SAHS in ESRD population are limited. 
Both Berlin and STOP-BANG questionnaires lack specificity to be utilized in this setting. 
Additional studies are warranted to elaborate the role of screening questionnaires for SAHS 
in end stage renal disease population.
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FR-PO772
Moderate to Severe Nocturnal Hypoxemia and Executive Dysfunction in 
Patients Undergoing Maintenance Hemodialysis  Farhanah Yousaf, Mitesh 
K. Patel, Chaim Charytan, Alla Goldberg, Bruce S. Spinowitz.  New York 
Hospital Queens.
Background: Nocturnal hypoxemia and executive dysfunction is common in end stage 
renal disease. We investigated the impact of moderate to severe nocturnal hypoxemia on 
executive function in patients undergoing maintenance hemodialysis.
Methods: Following local IRB approval, adult hemodialysis patients were consented 
to complete 1 night of nocturnal oximetry using Pulsox 300i wristwatch. The first hour 
of recording was deleted in efforts to capture oximetry reading from sleep time only. 
Oxygen desaturation index (ODI) was defined as the number of desaturations ≥ 3% from 
baseline lasting ≥ 10 seconds, per hour. Trail making tests A and B were also completed 
during dialysis session. Trail making test A and B performance was compared using t-test 
in patients with ODI < 15 versus those with ODI ≥ 15. Executive dysfunction was defined 
as trail making A and B completion time > 75 seconds and 180 seconds, respectively.
Results: Nine of 20 patients aged 45 ± 12 years with a mean body mass index (BMI) 
of 23 ± 3 kg/m2 and neck circumference of 35 ± 4 cm had ODI < 15. The remaining eleven 
patients aged 60 ± 12 years with a mean BMI of 28 ± 5 kg/m2 and neck circumference of 41 
± 6 cm had ODI ≥ 15. Patients with ODI ≥ 15 took significantly longer (77 ± 34 seconds) 
to complete trail making test A versus patients with ODI < 15 (45 ± 23 seconds). Five of 
11 (45%) patients with ODI ≥ 15 required > 75 seconds to complete trail making test A 
compared to only 1 patient out of 9 (11%) with ODI < 15. Mean duration for completion of 
trail making B test was also longer in patients with ODI ≥ 15 (157 ± 87 seconds) compared 
to ODI < 15 (117 ± 67 seconds) [p=0.3]. Two of 11 patients with ODI ≥ 15 and 2 of 9 
patients with ODI < 15 required > 180 seconds to complete trail making test B.
Conclusions: Patients with ODI < 15 performed better on trail making test A, were 
younger with a smaller BMI and neck circumference, compared to those with ODI ≥ 15. 
Additional research is warranted to confirm these findings. Whether treatment of moderate 
to severe nocturnal hypoxemia may slow or prevent executive function decline in patients 
undergoing maintenance hemodialysis remains to be determined.
FR-PO773
Indoxyl Sulfate (Indican) and Sleep Disorders in Hemodialysis Patients: 
The Retained Organic Solutes and Clinical Outcomes (ROSCO) Study 
Yunnuo Zhu,1 Tanushree Banerjee,1 Tariq Shafi,2 Timothy W. Meyer,3 Michal 
L. Melamed,4 Thomas H. Hostetter,5 Neil R. Powe.1  1UCSF; 2JHU; 3Stanford; 
4Albert Einstein; 5Case Medical Center.
Background: Although sleep disorders are common in dialysis patients, the 
pathophysiology of sleep disturbance is unclear. Protein-bound solutes inadequately 
removed during dialysis may contribute to sleep disorders.
Methods: We examined the association of total and free levels of IS with sleep disorder 
in 1,241 prevalent dialysis patients from the HEMO study. IS levels were measured using 
mass spectroscopy and modeled as tertiles.  Sleep disorder was assessed using a 5-level 
categorical question in the Short Form (36) Health Survey. We used ordinal logistic 
regression to assess the relation of IS with sleep disorder, adjusting for confounders 
including age, race, gender, ICED score, body mass index, diabetes, congestive heart 
failure, serum albumin, creatinine, and phosphate levels. The lowest tertile of IS was the 
reference group. Effect modification was tested for IS levels with Kt/V and gastrointestinal 
(GI) disease (due to IS’s GI origin).
Results: Patients were on average 57.5 years old, 62.8% were black, and 43.2% were 
male. There was a significant association between increasing tertiles of free IS and more 
severe sleep disorder in both unadjusted [OR 1.44 (95% CI: 1.1-1.89)] and adjusted models 
[1.78 (1.24-2.58)]. There was effect modification by Kt/V (p=0.03) but none by GI disease 
(p=0.17). Similar results were observed with total IS and sleep disorder [2.09 (1.37-3.19)]. 
Stratified analyses by Kt/V did not show an association between higher tertiles of free IS 
and sleep disorder in the high Kt/V group [0.72 (0.45-1.14)].  However greater odds of 
sleep disorder with highest tertile of IS were noted in the low Kt/V group. This relation was 
also present for total IS; those with low Kt/V had greater odds of sleep disorder with the 
highest total IS tertile [2.11 (1.29-3.45)] but not with the high Kt/V group [0.91 (0.61-1.35)].
Conclusions: Higher levels of IS are significantly associated with sleep disorder. 
Patients with a lower dialysis dose may be more susceptible. Further research on whether 
removal of IS improves sleep outcomes is needed.
FR-PO774
Quantifying Physical Activity Levels and Sleep in Hemodialysis Patients 
Using a Commerically-Available Activity Tracker  Maggie Han,1 Schantel 
Williams,1 Anna Meyring-Wosten,1 Viviane Calice-Silva,1,2 Melissa Mendoza,1 
Hanjie Zhang,1 Xiaoling Ye,1 Stephan Thijssen,1 Peter Kotanko.1,3  1Renal 
Research Inst, New York, NY; 2Pontifícia Univ Católica do Paraná, Curitiba, 
Brazil; 3Icahn School of Medicine, New York, NY.
Background: Hemodialysis (HD) patients are less active than their healthy counterparts 
(Johansen, Kidney Int, 2000). In addition, HD patients frequently experience poor sleep. 
Our aim was to objectively quantify activity and sleep quality in HD patients.
Methods: The number of steps taken and sleep data were collected by the Fitbit®Flex™ 
in ambulatory chronic HD patients for 5 weeks. A questionnaire was given at the end of the 
study. Sleep efficiency is defined as the ratio of sleep duration to time in bed.
Results: We collected data of 22 HD patients (55% males, 86% black, age 54±10 
years). Average steps walked were 7,584±5,429 (Table 1). 36% of patients were sedentary, 
walking less than 5,000 steps per day. Patients walked 2,000 steps less on Sundays compared 
to the rest of the week (P<0.0001). Slightly more steps were taken on HD days. Patients 
slept less than 6 hours, which was significantly less than the NIH recommendation of 7 
hours (P<0.0001). Sleep efficiency was 80±14%, significantly less than 85%, the lower 
limit of what is defined as poor sleep quality (P<0.05). When asked to what extent they 
agreed with the statement “I have walked more than usual”, 36% replied “not at all”, 23% 
replied “somewhat” or “moderately”, and 41% replied “definitely” or “most definitely”.
Table 1
Physical Activity[Steps/d] Sleep Quality
All Days HD Day Non-HD Day
Monday-
Saturday Sunday
Sleep 
Duration† 
[min/day]
Sleep 
EfficiencyÁ
[Sleep Duration/
time in bed]
7,584± 
5,429
7,859± 
5,007
7,390± 
5,707
7,879± 
5,508
5,851± 
4.594** 340± 145** 80± 14%*
*P<0.05 
**P<0.0001 
†NIH recommends 420 min/day 
‡<0.85 is poor sleep quality
Conclusions: The activity tracker was well accepted by patients. Programs and 
interventions to increase activity should target Sundays in particular. The described 
methodology may assist in identifying patients with poor sleep quality and facilitate the 
deployment of programs to improve sleep quantity and quality.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
FR-PO775
Using Decision Tree Analysis to Identify Risk Factors for Functional 
Impairment in Hemodialysis Patients  J. B. Chen.  Div of Nephrology, 
Kaohsiung Chang Gung Memorial Hospital and Chang Gung Univ College of 
Medicine, Kaohsiung, Taiwan.
Background: Hemodialysis (HD) patients frequently developed functional impairment. 
The study used decision tree analysis to identify risk factors for functional impairment in 
HD patients.
Methods: A total 1166 maintenance HD patients were enrolled in one hospital-based 
HD center. The observational period was from 2009 to 2013. Karnofsky Performance 
Status Scale (KPS) was used to quantify functional status. KPS assessment was based on 
HD nurse single visit yearly for consecutive five years. High KPS score was defined as ≥ 
80 and low score as < 80. Decision tree analysis was used to analyze odds ratio (OR) of 
functional impairment from variables in demographics, laboratory test and primary renal 
disease classification.
Results: Subjects (853) with high KPS scores demonstrated significantly younger age 
(58.2 vs 71.3 years), longer HD duration (7.2 vs 4.7 years), higher nutritional indices, higher 
Kt/V (1.65 vs 1.59) and lower cardiothoracic (CT) ratio compared to subjects (313) in low 
KPS scores. A total 3509 KPS values were collected. 2697 (76.9%) values belonged to high 
functional scores, 812 (23.1%) values in low functional scores. The first variable chosen by 
decision tree analysis to split the data was age (67.5 years). There were six leaf nodes and 
twenty-eight subgroups. In age > 67.5 years group, the orders of consecutive chosen were 
serum albumin level (≤ 3.75 g/dL, OR 27.58, p= 1.77E-199), Cr level (≤8.93 mg/dL, OR 
5.60, p =1.68E-37), HD duration (≤ 0.95 year, OR 39.40, p =1.68E-27), ferritin (>664.5 
ng/ml, OR 26.26,  p =2.06E-13), P level (>5.35 mg/dL, OR 9.28,  p =8.88E-24), Hb level 
(>10.85 g/dL, OR 0.89,  p =1.00). In age ≤67.5 years group, the orders of consecutive 
chosen were primary renal disease classification, Cr level (£10.43 mg/dL, OR 11.23, p= 
2.03E-72), age (≤58.5 years, OR 1.65, p = 0.06), iPTH level (> 356.4 pg/ml, OR 0.44, p 
= 0.72), CT ratio (> 0.44, OR 11.16,  p =9.17E-35).
Conclusions: : By decision tree analysis, age was the main risk factor for functional 
impairment in HD patients. Overall, the weight contribution of different risk factors for 
functional impairment in HD patients were identified by classification tree analysis.
Funding: Private Foundation Support
FR-PO776
Working Patients and Years on Dialysis: A Review  Deborah S. Evans,1 Duane 
V. Dunn,1 Martha Donaho,1 Laura M. Stewart,1 Rich Mutell,2 Paul J. Broughton,2 
Allen R. Nissenson,1 Deborah A. Benner.1  1DaVita HealthCare Partners Inc, 
Denver, CO; 2Apex Health Innovations, Simi Valley, CA.
Background: Unemployment rates are high among dialysis patients; a 2011 study 
found approximately 71% of working-age dialysis patients are unemployed.1 Another 
study found that dialysis negatively impacts employment status and has the largest effect 
between dialysis years 1 and 2.2 We examined whether prolonged dialysis (dialysis vintage) 
affected employment status.
Methods: Dialysis vintage data and mean age were obtained from a sample of 16,069 
employed patients from a large dialysis organization (Nov 2014-April 2015). Employment 
status was defined as regular full-time (³30 hrs/wk), regular part-time (<30 hrs/wk), and 
per diem (<24 hrs/wk).
Results: Regular full-time employed patients were older (52.6 yrs) than part-time 
(49.1 yrs) and per diem (49.0 yrs) patients. Employment status was highest among all 
patients for all categories of employment during year 1 of dialysis (35.7%) and dropped 
significantly by year 2 (14.4%) [Table]. Employment status continued to drop as vintage 
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increased and was lowest in the 10-year group (1.9%). Although there were more full-time 
employed patients in year 1 (42.4%) than part-time (28.3%) or per diem (28.9%), by year 
10, only 1.3% remained employed full-time. Employment status rates were similar among 
per diem and part-time employees. 
Conclusions: Our study found that dialysis vintage negatively impacts employment 
status and has the largest effect between years 1 and 2. Further study is needed to reveal 
if any underlying factors contribute toward this decrease, but these results should alert 
dialysis staff that support and intervention may be needed to help patients stay employed. 
References: 1) Muehrer RJ et al. Clin J Am Soc Nephrol. 2011;6(3):489-496. 2) van Manen 
JG et al. Perit Dial Int. 2001;21(6):595-601.
FR-PO777
Provider Visit Frequency During Hemodialysis and Its Effect on End Stage 
Renal Disease Comorbidities  Juan E. Kusnir, Roberto J. Echeverri, Joslyn 
Wiley, Hazem Abu Grara, Rene Armando Garcia, Alberto J. Sabucedo, Marco 
A. LadinoAvellaneda.  Div of Nephrology, Miami VA Medical Center/Univ of 
Miami, Miami, FL.
Background: In the United States, patients with End Stage Renal Disease (ESRD) 
on Hemodialysis visit their Nephrologist one to four times per month during their dialysis 
sessions. Medicare reimbursement policy encourages frequent provider visits for patients 
with ESRD on hemodialysis. We believe that increasing the number of face-to-face 
provider visits improves the care and clinical outcomes of comorbidities related to ESRD 
(hypertension, hyperphosphatemia, and hyperkalemia).
Methods: We used a Pre and Post-test pilot study design to evaluate the effect on 
laboratory measurements and blood pressure by increasing the frequency of Nephrologist 
face-to-face visits at the Miami VA Medical Center. Seventeen patients that were evaluated 
during a period of six months were included in the analysis. In the initial three months, the 
patients were evaluated four times per month (usual care). The number of face-to-face visits 
was increased to eight times per month (or twice weekly) for the following three months.
Results: A paired-sample t-test was conducted to compare the mean systolic blood 
pressure measure before and after the intervention. Additional provider face-to-face visits 
per month were associated with a significant difference in the systolic blood pressure before 
and after the intervention (p= 0.004, t=3.303, Mean=8.235, and Standard Deviation=16). 
In addition, we found improvement of the phosphorus levels with a difference that was 
statistically significant (p= 0.028, t=2.419, Mean=0.512, and Standard Deviation=16). 
Patients reported increased perceived quality of care when they had the opportunity of 
seeing the Nephrologist more frequently.
Conclusions: Hypertension and electrolyte abnormalities are known risk factors that 
increase morbidity and mortality in patients with End Stage Renal Disease. Adherence to 
medications is a major problem in patients on Hemodialysis therapy. Increasing the number 
of visits per month with the Nephrologist during Hemodialysis sessions increases adherence 
to a renal diet, medication use and patient satisfaction.
FR-PO778
Response Rate of Hepatitis B Virus Vaccination in Various Stages of Chronic 
Kidney Disease  So Mi Kim,1 Eun kyoung Lee,2 Yun Jung Oh.3  1Divsion of 
Nephrology, Dept of Internal Medicine, Jeju National Univ Hospital, Jeju, 
Jejudo, Republic of Korea; 2Divsion of Nephrology, Dept of Internal Medicine, 
Dankook Univ Hospital, Cheonan, Chungnam, Republic of Korea; 3Divsion of 
Nephrology, Dept of Internal Medicine, Cheju Halla General Hospital, Jeju, 
Jedudo, Republic of Korea.
Background: Although hepatitis B virus (HBV) vaccination is recommended for all 
dialysis patients, the response rate of HBV vaccination in dialysis patients is very low. 
Therefore, we tried to investigate the necessity of early HBV vaccination in pre-dialysis 
patients analyzing the response rate of vaccination in various stages of chronic kidney 
disease (CKD).
Methods: A total of 87 patients in 3 different stages of CKD was enrolled in this study. 
Patients in stage 3 (n=30) and 4 (n=28) were received the HBV vaccine as standardized 
schedule, consisting of 1 mL of the recombinant vaccine, Hepavax-gene TF at 0, 1, and 
6 months. And then, the patients with stage 5 (n=29) were received the same vaccine for 
doubling doses at 0, 1, 2, 6 months. Three months after each of the last vaccination, serum 
level of Anti-HBs was measured in all patients.
Results: There was no significant difference in baseline characteristics including age, 
sex, presence of DM among the 3 groups. The overall seroconversion rate after vaccination 
was 79.4 %. The seroconversion rate was significantly higher in patients with stage 3 than 
other patients (stage 3 : 94%, stage 4 : 79%, stage 5: 66%, p=0.031). Analyzing based on 
dialysis, seroconversion rate was also significantly higher in pre-dialysis patients than that 
in dialysis patients (pre-dialysis group : 86%, dialysis group: 63%, p=0.02 ). There was no 
significant factor to contribute seroconversion in multivariate analysis.
Conclusions: Our study showed the high seroconversion rate after HBV vaccination 
in CKD patients with stage 3 and pre-dialysis. Therefore, the HBV vaccination should be 
considered in early CKD stages.
FR-PO779
Hepatitis C Infection in Hemodialysis Patients Is Associated with Increased 
Anemia-Related Events in the DOPPS  Brian Bieber,1 Michel Y. Jadoul,2 Paul 
Martin,3 Takashi Akiba,4 Chizoba Nwankwo,5 Jean Marie Arduino,5 Ronald 
L. Pisoni,1 David A. Goodkin.1  1Arbor Research Collaborative for Health; 
2Univ Catholique de Louvain; 3Univ of Miami; 4Tokyo Women’s Medical Univ; 
5Merck & Co., Inc.
Background: Hepatitis C virus infection (HCV) remains common among hemodialysis 
(HD) patients, is associated with elevated mortality risk, and is rarely treated. The association 
of HCV with anemia-related events is not well characterized.
Methods: The Dialysis Outcomes and Practice Patterns Study (DOPPS) is a prospective 
cohort study of adult in-center HD patients (pts) in 21 countries, including nations recently 
joining the DOPPS (China, Russia, Turkey, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, 
United Arab Emirates). We studied 67,290 pts in DOPPS phases 1-5 (1996-2015). Pts 
were considered to have HCV infection (HCV+) at DOPPS enrollment based on an 
established diagnosis of HCV infection or positive HCV serology. Associations of HCV 
with transfusions, GI bleed hospitalizations, and Hgb excursions below 8.5 g/dL were 
estimated via Cox regression (adjustments listed in table).
Results: HCV+ (vs. HCV-) pts were younger (58 vs. 63 yrs), had longer time on 
dialysis (3 vs. 8 yrs), and were more likely to have hepatitis B (8% vs. 2%) and cirrhosis 
(9% vs. 1%). Mean baseline Hgb levels for HCV+ pts were similar to HCV- pts (10.8 vs. 
10.9 g/dL) and ESA doses by region were similar. In adjusted analyses, HCV+ pts were 
more likely to be transfused, be hospitalized for a GI bleed, and to have their Hgb drop 
below 8.5 g/dL (table).
Conclusions: The disease burden of HCV+ pts on HD includes a greater likelihood 
of experiencing anemia requiring transfusion. The reasons for this are unclear but may 
include gastrointestinal blood loss due to portal hypertension as well as hypersplenism. 
Anemia in turn may contribute to a reluctance to initiate antiviral therapy for HCV infection.
Funding: Pharmaceutical Company Support - Merck & Co., Inc, Amgen, Kyowa 
Hakko Kirin, AbbVie, Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical 
Care Renal Pharma, Ltd. BHC Medical, Janssen, Takeda, Kidney Foundation of Canada 
(for logistics support), Hexal AG, DGfN, Shire, WiNe Institute, Societa Italiana di 
Nefrologia (SIN). All grants are made to Arbor Research Collaborative for Health., 
Private Foundation Support
FR-PO780
Outbreaks of Hepatitis C Virus Infection Reported in U.S. Hemodialysis 
Facilities, 2008-2014  Duc B. Nguyen, Melissa Collier, Anne Moorman, Yury 
Khudyakov, Priti R. Patel.  US Centers for Disease Control and Prevention.
Background: Hepatitis C virus (HCV) infection is more prevalent among hemodialysis 
(HD) patients than the general population. HCV transmission of in dialysis units may 
contribute, and is difficult to detect due to lack of symptoms and systematic screening. We 
summarized HCV outbreaks reported to CDC to characterize their frequency and factors 
contributing to transmission in HD facilities.
Methods: We defined a healthcare-associated outbreak as ³2 new HCV infections 
(positive anti-HCV £1 year after negative anti-HCV, or positive anti-HCV with acute 
hepatitis) in the same facility. We reviewed outbreaks in 2008–2014 reported to CDC. 
For HD unit outbreaks, we summarized type of facility, number of new cases, number of 
patients notified for HCV testing, infection control lapses identified, and results of HCV 
molecular testing. Intrafacility transmission was confirmed if there was epidemiologic and 
molecular evidence of transmission.
Results: During 2008–2014, 22 outbreaks of HCV infection in healthcare settings 
were reported to CDC; 11 (50%) of these outbreaks occurred in outpatient HD clinics. 
Seventy-nine (median 4, range 2–21) new HCV infections were identified. More than 1,800 
HD patients were notified and screened for HCV in outbreak facilities. Intrafacility HCV 
transmission was confirmed in all 11 outbreaks. New cases had treatment time and location 
overlap with their HCV-infected source patient. For 9 outbreaks, lapses in infection control 
were identified, including environmental disinfection (8), hand hygiene (5), injectable 
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medication handling (3), separation of clean and contaminated workspaces (2), and vascular 
access care (1). Multiple lapses were identified in 7 outbreaks. No specific infection control 
lapses were identified at the time of the investigation in 2 outbreaks.
Conclusions: Outpatient hemodialysis clinics remain a common setting for healthcare-
related HCV outbreaks. Infection control lapses were frequently identified in reported 
outbreaks. Rigorous adherence to recommended infection control practices is needed to 
protect patients and prevent future outbreaks in this setting.
Funding: Other U.S. Government Support
FR-PO781
Influenza and Outcomes in ESRD Patients  David T. Gilbertson,1 Anne C. 
Beaubrun,2 Kenneth J. Rothman,3 Jiannong Liu,1 Brian D. Bradbury,2 Akhtar 
Ashfaq,2 Charles A. Herzog,1 Allan J. Collins.1  1Chronic Disease Research 
Group, MMRF; 2Ctr for Observational Rsrch, Amgen; 3RTI Health Solutions.
Background: Yearly influenza vaccination is recommended for all ESRD patients, due 
to a high risk of influenza-related complications. Through the CDC’s Outpatient Illness 
Surveillance, information on patient visits to health care providers for influenza-like illness 
(ILI) is collected. These data give estimates of the percent of all OP visits that are for 
presumed influenza, and give national information on timing and severity of each influenza 
season. We assessed the association between CDC ILI data and outcomes in ESRD patients.
Methods: We aggregated weekly ILI data from 2000-2012 to monthly, and calculated 
the monthly number of deaths and hospitalizations among US ESRD patients during the 
same time period. Using time series decomposition, we subtracted out seasonal and trend 
components from both series, and computed correlations between the ILI and mortality/
hospitalization data.
Results: 
The figure displays deaths and ILI data after removing seasonal and trend components. 
There were 2 influenza seasons (2003-2004 and 2009-2010) during this time period where 
the peak was at the end of the calendar year (early in the influenza season) instead of at 
the beginning of the next calendar year. Similar “early” peaks are seen in deaths among 
ESRD patients. There is also correlation between other peaks and valleys of the ILI data 
and ESRD deaths; correlation coefficient = 0.63. Correlations were also calculated with 
cause-specific hospitalizations: 0.69 for ILI-influenza/pneumonia; 0.42 for ILI-any infection; 
0.16 for ILI-MI; and 0.02 for ILI-stroke.
Conclusions: The association between ILI and outcomes in ESRD patients is strong. 
While influenza vaccination rates among ESRD patients have improved over the last decade, 
the overall rate is still below 70%, suggesting room for further improvement.
Funding: Pharmaceutical Company Support - Amgen
FR-PO782
The Burden of Pneumonia in Patients Receiving Dialysis: Incidence, Case 
Fatality, and Costs to Medicare  Scott Sibbel,1 Reiko Sato,2 Abigail Hunt,1 
Wendy Turenne,1 Steven M. Brunelli.1  1DaVita Clinical Research, Minneapolis, 
MN; 2Pfizer Inc, Collegeville, PA.
Background: End-stage renal disease patients receiving dialysis are at particular risk 
for infection. We assessed the clinical and economic burden of pneumonia in a population 
of Medicare-enrolled ESRD patients with respect to incidence and case fatality rates, rates 
of all-cause hospitalization, and costs.
Methods: Patients included in the analysis received dialysis between 01 Jan 2009 
and 31 Dec 2011, and were enrolled in Medicare Parts A and B. Pneumonia episodes were 
identified from institutional and supplier claims. Patients were considered at-risk from 
the first date of Medicare coverage and were censored from the analysis upon transplant, 
withdrawal from dialysis, recovery of renal function or death. Linear mixed effects models 
were used to assess hospitalization rates and costs over the 3 months prior to and 12 months 
following a pneumonia diagnosis.
Results: The pneumonia incidence rate for the study period was 21.4 events/100 
patient-years with the majority of episodes (90.1%) requiring inpatient treatment. The 
30-day case fatality rate was 10.7%; case fatality rates were higher for older patients and 
for pneumonia requiring inpatient treatment (11.2%). All-cause hospitalization rates were 
greater in the month of the pneumonia episode vs month -3 prior to diagnosis (IRR, 4.61; 
95%CI: 4.46, 4.76) and remained higher than baseline over the 1-year follow-up period. 
Mean per patient per month costs were $10,976 (95% CI: $10,717, $11,275) higher in the 
month of the index episode compared to month -3, largely driven by increased inpatient 
costs, and remained elevated through end of follow-up.
Conclusions: Pneumonia episodes are frequent among ESRD patients and result in 
hospital admissions and greater overall costs to Medicare (~$20,000 incremental) over 
the following year.
Funding: Pharmaceutical Company Support - Pfizer Inc
FR-PO783
Opioid Use Associates with Infection Related Morbidity and Mortality in 
Hemodialysis Patients  Abhijit V. Kshirsagar, Diane Reams, Magdalene M. 
Assimon, Anne Mobley Butler, Jennifer E. Flythe, M. Alan Brookhart.  Univ 
of North Carolina at Chapel Hill.
Background: Opiates are frequently prescribed for pain in the US hemodialysis (HD) 
population but have intrinsic properties that increase risk of infection, a common cause 
of morbidity and mortality for patients. Data regarding the association of opioids with 
infection are lacking.
Methods: We conducted a retrospective cohort study using data from a large national 
dialysis provider linked with the United States Renal Data System and Medicare Part D 
(2006-2010). We used a new user design – comparing only new users of opioids to new users 
of prescription non-steroidal anti-inflammatory drugs (NSAIDS) to address confounding, 
as well as excluding patients with cancer, use of hospice services, or use of > 1 opiate. 
We assessed treatment effects on infection-related morbidity and mortality using inverse 
probability of treatment weighted Kaplan-Meier methods, adjusting for many comorbid, 
lab, and clinical variables.
Results: 5,113 patients met entry requirements, of which 3,439 (67.3%) received an 
opioid. Relative to new NSAID users, new opioid users had similar baseline laboratory 
values, but were slightly younger, and had a higher prevalence of comorbidities, including 
recent infections (8.7% vs 6.8%), diabetes (52.3% vs 49.3%), and chronic obstructive 
pulmonary disease (COPD), 17% vs 12.2%. After multivariable adjustment, we observed 
an elevated risk of 90-day infection-related hospitalization, (Risk Difference (RD) 2.5/100 
patients, 95% CI 0.6-4.5) (Figure 1), and 90-day risk of infection-related mortality (RD 
0.6%, 95% CI 0.3-0.9), no figure. For subgroups, infection-related hospitalizations were 
elevated among females and patients with diabetes, COPD, and lower dialysis vintage.
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Conclusions: Our results suggest that opioid initiation increases the short-term risk 
of infection-related morbidity and mortality among HD patients.
Funding: Clinical Revenue Support
FR-PO784
A Retrospective Review of the Two-Step Tuberculin Skin Test in Manitoba’s 
Dialysis Population  Rukhsana A. Foster,2 Thomas W. Ferguson,1 Claudio 
Rigatto,1,2 Navdeep Tangri,1,2 Blake R. Lerner,2 Reid Whitlock,1 Paul Komenda.1,2 
1Community Health Sciences, Univ of Manitoba, Winnipeg, MB, Canada; 
2Medicine, Univ of Manitoba, Winnipeg, MB, Canada.
Background: Reactivation of latent Mycobacterium Tuberculosis (LTBI) is a health 
concern for patients on dialysis due to their immunosuppressed state. The most frequently 
used test for LTBI screening in this population is the Tuberculin Skin Test (TST). The 
diagnostic accuracy (sensitivity and specificity) and clinical utility of the TST in a 
contemporary North American dialysis population is unknown.
Methods: We performed a retrospective cohort study of 483 hemodialysis and 
peritoneal dialysis patients across 4 dialysis units. All patients received a two-step TST and 
full TB risk assessment between February 2008 and December 2008. We then linked the 
cohort with the Manitoba Health TB Registry to ascertain if treatment was received for LTBI.
Results: At an induration cut-off of 5mm, 62 (13%) patients had a positive two-step 
TST. Patients with a BCG vaccination were more likely to test positive (50 vs. 34%, p = 
0.05). Using a diagnostic gold standard of an abnormal chest X-ray as a proxy for LTBI, the 
sensitivity of the TST was only 13.9%, and the specificity was 87.7 %. Only 8 of 62 patients 
(13%) received treatment for LTBI. None of the patients who tested negative were treated.
Conclusions: The TST has limited diagnostic and clinical utility for LTBI screening 
in patients on dialysis. Further research into the diagnostic accuracy of interferon-gamma 
release assays, and a revision of LTBI screening guidelines in patients on dialysis should 
be considered.
FR-PO785
Reliability and Construct Validity of the Coping Strategy Inventory-
Short Form in Hemodialysis (HD) Patients in 13 Countries in the Dialysis 
Outcomes and Practice Patterns Study (DOPPS)  Elodie Speyer,1 Hal 
Morgenstern,1,2 Yasuaki Hayashino,3 Peter G. Kerr,4 Hugh C. Rayner,5 Ronald 
L. Pisoni.1  1Arbor Research Collaborative for Health; 2Univ of Michigan; 3Tenri 
Hospital; 4Monash Health & Monash Univ; 6Birmingham Heartlands Hospital.
Background: In international studies, questionnaires are often translated into several 
languages without consideration of cultural and linguistic differences that may compromise 
the reliability and validity of survey instruments, especially those measuring psychosocial 
factors. The Coping Strategies Inventory-Short Form (CSI-SF) is a 16-item questionnaire, 
developed in English, and previously validated in US cardiac failure patients. It is scored by 
computing 4 scales (each with 4 items) to measure 4 different coping strategies. The aim was 
to assess reliability and construct validity of the CSI-SF in HD patients across 13 countries.
Methods: The CSI-SF was self-administered to HD patients across 13 countries in 9 
languages in DOPPS 4 (2009-11). Cronbach’s alpha was used to assess internal consistency. 
Exploratory and confirmatory factor analyses were used to assess the factor structure of 
the CSI-SF by country and language.
Results: 6,656 HD patients completed the CSI-SF and were included in this analysis 
(55% male; median age=63, range: 18-96 yrs). Using the English version in 4 countries 
and the Swedish version, we found good internal consistency (α=0.63-0.77) for 3 of the 4 
scales; the 4th scale was internally consistent if two items were dropped. In these countries, 
both types of factor analyses indicated a factor structure perfectly consistent with these 
same 4 scales. In the 8 other non-English versions, results were very different: internal 
consistency was lower for the 4 scales; no country showed an exploratory factor structure 
similar to that found previously, nor was the 4-factor structure confirmed with factor analysis.
Conclusions: The CSI-SF is reliable for measuring coping in HD patients in English 
and Swedish versions, as tested in the DOPPS. The importance of coping for predicting 
outcomes in HD patients can now be described in these countries. More research is needed 
for measuring coping strategies in other countries and languages.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
FR-PO786
Associations Among Psychosocial/Medical Factors and Quality of Life 
in Hemodialysis Patients with End-Stage Renal Disease  Gun woo Kang. 
Internal Medicine, Catholic Univ of Daegu School of Medicine, Daegu, Korea.
Background: Patients with end-stage renal disease(ESRD) have a significant 
impairment in quality of life(QoL). Most previous studies have focused on medical factors 
mainly. However, quality of life can also be affected by psychosocial problems in the 
circumstances of chronic illness. The aim of this study was to identify the associations 
among psychosocial factors, medical factors and QoL in hemodialysis(HD) patients.
Methods: The study included 101 patients with ESRD who were undergoing HD(mean 
age 57.1 ± 12.1 years). Psychosocial factors were evaluated using the Hospital Anxiety and 
Depression Scale(HADS), Multidimensional Scale of Perceived Social Support, Montreal 
Cognitive Assessment and Pittsburgh Sleep Quality Index. In addition, for evaluating 
caregivers’ burden in part of psychosocial factors, HADS and Zarit Burden Interview 
of main caregivers were administered. We also accessed medical factors(Kt/V and urea 
reduction ratio, etc.) with laboratory results(body mass index, albumin, hemoglobin, etc.). 
The QoL was evaluated using WHO Quality of Life-BREF(WHOQOL-BREF). Canonical 
correlation analysis was used to investigate the patterns of associations.
Results: The canonical correlation between psychosocial factor and QoL was 
significant. The first canonical correlation was 0.673(proportion = 60.6%, p = 0.001) and 
the second was 0.519(proportion = 26.9%, p = 0.006). However, the canonical correlation 
between medical factor and QoL was not significant(the first: p = 0.586, the second: p = 
0.713). 
Canonical function Canonical correlation Proportion P-value
Between Quality of life and medical factors 
The 1st 0.436 0.382 0.586
The 2nd 0.412 0.332 0.713
Between Quality of life and psychosocial factors 
The 1st 0.673 0.606 0.001
The 2nd 0.519 0.269 0.006
Conclusions: The QoL of patients with ESRD was not associated with medical factor, 
but psychosocial factor in canonical correlation analysis. This finding may suggest that 
medical workers should recognize and treat psychosocial problems as well as clinical 
problems. We also would like to emphasize the comprehensive approach with cooperation 
between psychiatrists and nephrologists for improvement of QoL in ESRD patients.
FR-PO787
Longitudinal Associations of Dietary Protein and Energy Intake with 
Protein-Energy Wasting Syndrome in Hemodialysis Patients  Srini Beddhu,1,2 
Xiaorui Chen,1 G. Wei,1 Robert E. Boucher,1 Dominique Ferranti,1 Kalani L. 
Raphael,1,2 Tom Greene,1 Michel Chonchol.3  1U of Utah; 2VA SLC; 3UC Denver.
Background: Low dietary protein intake (DPI) (<0.6 g/kg/d) and low dietary energy 
intake (DEI) (<25 kcal/kg/day) are included in the definition of protein-energy wasting 
(PEW) syndrome. Therefore, we examined the longitudinal associations of baseline DPI 
and DEI with PEW syndrome (defined by modified criteria that excludes dietary variables) 
at 1 year of follow-up in 1480 MHD pts in the HEMO Study.
Methods: DPI and DEI were obtained by 24-h dietary recall. PEW syndrome at month 
12 was defined as the presence of 2 out of the 3 criteria: serum chemistry (albumin by BCP 
method < 3.5 g/dl or cholesterol < 100 mg/dl), body weight (BMI < 23 kg/m2 or wt loss > 
10% over 1 yr), and muscle mass ( mid-arm muscle circumference 10% or more less than 
the 50th percentile of reference population). PEW syndrome at month 12 was related to 
baseline DPI and DEI in logistic regression models.
Results:  17.4% had PEW at month 12. The prevalence of PEW syndrome at month 
12 by baseline DPI and DEI quartiles are summarized in the figure. 
The associations of baseline DPI and DEI with PEW syndrome at month 12 in logistic 
regression models are summarized in table. 
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Associations of baseline DPI or DEI with the presence of PEW syndrome at month 12*
OR (95% CI)
Model 1$ Model 2#
DPI<0.6 g/kg/d 0.39 (0.25, 0.62) 0.40 (0.26, 0.63)
DEI <25 kcal/kg/day 0.29 (0.21, 0.40) 0.30 (0.22, 0.41)
*Each cell represents a separate logistic regression model, $ Adjusted for demographics, ESRD 
duration, Kt/V group, flux group, smoking and alcohol use, #Adjusted for above plus diabetes, 
CAD, CVD, PVD, CHF and arrythmias
Conclusions: The contrarian finding of lower risk of PEW in those with low DEI and 
DPI could reflect mathematical coupling (as both DEI and DPI include body wt in the 
denominator and those with PEW have lower body wt).
Funding: NIDDK Support
FR-PO788
PEW Syndrome, Inflammation and Mortality in Hemodialysis Patients 
Srini Beddhu,1,2 Xiaorui Chen,1 G. Wei,1 Robert E. Boucher,1 Dominique 
Ferranti,1 Kalani L. Raphael,1,2 Tom Greene,1 Michel Chonchol.3  1U of Utah; 
2VA SLC; 3UC Denver.
Background: The term ‘malnutrition-inflammation complex syndrome’ implies that 
malnutrition and inflammation are tightly interlinked. Therefore, we examined whether the 
mortality associations of markers of inflammation and protein-energy wasting syndrome 
(PEW) are attenuated by each other in 906 maintenance hemodialysis (MHD) patients 
in the HEMO Study, a multi-center RCT that examined the effects of dialysis dose and 
dialyzer flux on mortality.
Methods: High sensitivity Creative Protein (hsCRP), tumor necrosis factor (TNF)-a 
and interleukin (IL)-6 were measured in the month 12 stored samples. Weight loss was 
estimated from baseline and month 12 post-dialysis weights and hence, PEW syndrome 
at month 12 was defined as the presence of 2 out of 3 criteria: serum chemistry (albumin 
by nephelometry < 3.5 g/dl or cholesterol < 100 mg/dl), body weight (BMI < 23 kg/m2 
or wt loss > 10% from baseline), and muscle mass ( mid-arm muscle circumference 10% 
or more less than the 50th percentile of reference population). Cox models were used to 
relate month 12 PEW syndrome and hsCRP, TNF-a and IL-6 with subsequent mortality.
Results: Mean age was 57 ± 14 yrs. 45% were women. 67% were black. PEW 
syndrome was present in 17.4% at month 12. Median (IQR) serum hsCRP was 6.3 (2.6 
-16.4) mg/L, IL-6 3.3 (2.0-7.6) pg/ml, and TNF-a 31.2 (21.3-46.1) pg/ml. There were 388 
deaths over 2189 years of follow-up. PEW syndrome had 2 fold higher risk of mortality 
which was only marginally attenuated by adjustment for markers of inflammation (table). 
CRP and IL-6 were associated with higher mortality risk independent of PEW. TNF-a was 
not associated with mortality. 
Model 1* Model 2* Model 3*
PEW syndrome 2.22 (1.78, 2.76) - 2.09 (1.68, 2.61)
Each doubling of CRP - 1.10 (1.04, 1.17) 1.10 (1.03, 1.17)
Each doubling of 
TNF-a - 1.04 (0.90, 1.19) 1.03 (0.90, 1.17)
Each doubling of IL-6 - 1.13 (1.08, 1.19) 1.12 (1.07, 1.18)
*Adjusted for age, gender, race, duration of ESRD, Kt/v group, smoking, alcohol use, DM, IHD, CVD, 
PVD, CHF and arrhythmia. 
Conclusions: PEW and inflammation are independent predictors of mortality. These 
results suggest PEW and inflammation might not be tightly interlinked.
Funding: NIDDK Support
FR-PO789
Impacts of Geographic Distance on Peritoneal Dialysis (PD) Utilization: 
Refining Models of Treatment Selection  Virginia Wang,1,2 Matthew L. 
Maciejewski,1,2 Cynthia Coffman,1,2 Linda L. Sanders,1 Shoou-Yih D. Lee,3 
Richard Hirth,3 Joseph M. Messana.3  1Duke Univ, Durham, NC; 2Durham VA 
Med Ctr, Durham, NC; 3Univ of Mich, Ann Arbor, MI.
Background: Proximity to dialysis services may ease patient travel burden. Different 
frequency of visits to dialysis facilities and resulting differences in travel distance may 
affect patients’ selection of hemodialysis (HD) versus PD. PD has historically been less 
commonly available in dialysis facilities and less commonly used than HD. We refine 
methods of prior research to reassess the relationship between patients’ distance to dialysis 
care and modality choice to better reflect the conditions of patients’ choice set of providers’ 
location (absolute distance) and available services (relative distance).
Methods: Retrospective cohort of 70,131 patients initiating dialysis and 4,795 dialysis 
facilities in 2006 using USRDS data. The primary outcome was patient PD use. Independent 
variables included absolute distance from patients’ home to nearest HD facility, relative 
distance dichotomized as the nearest PD facility closer or same distance as nearest HD 
facility, and their interaction. Logistic regression was used to model distance on PD use, 
controlling for patient and market factors.
Results: 9% of new dialysis patients used PD in 2006. There was a positive, non-linear 
relationship between absolute distance to closest HD services and PD use (p=0.0006). In 
terms of relative distance, odds of PD increased if a PD facility was closer or the same 
distance as the nearest HD facility (p=0.006). The interaction of absolute and relative 
distance was not significant.
Conclusions: Distance is an important factor in patient decision-making when initiating 
PD, particularly for those living farther away from commonly offered HD services. Analyses 
of treatment selection must appropriately model distance to reflect logistics of treatment 
options and service availability to patients.
Funding: NIDDK Support, Other U.S. Government Support
FR-PO790
Association of Pre-Transplant Dialysis Modality and Post-Transplant 
Outcomes: A Meta-Analysis  Emily Joachim, Ali I. Gardezi, Sudheer 
Muduganti, Sana Waheed, Jung-Im Shin, Brad C. Astor, Micah R. Chan.  Univ 
of Wisconsin School of Medicine and Public Health, Madison, WI.
Background: Patients who undergo dialysis prior to renal transplant have overall 
worse outcomes than patients who receive a preemptive transplant. However, individual 
studies give conflicting results regarding whether post-transplant outcomes differ based 
on pre-transplant dialysis modality (peritoneal dialysis (PD) versus hemodialysis (HD)).
Methods: We searched English-language literature from January 1, 1980 through 
August 31, 2014, national conference proceedings and reference lists of all included studies. 
We used combinations of terms related to dialysis (hemodialysis, peritoneal dialysis, or 
renal replacement therapy), kidney transplant and outcomes. Studies were included if they 
measured post-transplant patient mortality for both pre-transplant HD and PD. Studies were 
excluded if they were not in English or if they included pediatric patients.
Results: A total of 15 studies reported five-year patient mortality. These included 
166,531 patients on HD and 51,980 patients on PD pre-transplant. The pooled hazard ratio 
for five-year patient mortality after renal transplant was 0.91 (CI 0.85-0.97) in favor of 
pre-transplant PD over HD (p=0.006). 
There was moderate heterogeneity among these studies (I2=41.4%, p=0.05). Six 
studies included an adjusted risk ratio (RR); the pooled RR for these studies was 0.89 (CI 
0.82-0.97) in favor of PD (p=0.006). There was significant heterogeneity among these six 
studies (I2=72.7%, p=0.003).
Conclusions: Based on these results, pre-transplant peritoneal dialysis is associated 
with better post-transplant survival at five years compared to hemodialysis. Further work 
should explore potential reasons for this difference and compare additional outcomes such 
as graft survival, delayed graft function and rejection.
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FR-PO791
Impact of Poverty and Health Care Insurance on Pre-End Stage Renal 
Disease Care in Dialysis Patients  Robert Nee,1 Lawrence Agodoa,2 Kevin C. 
Abbott.1  1Nephrology, Walter Reed National Military Medical Center, Bethesda, 
MD; 2NIDDK, National Insts of Health, Bethesda, MD.
Background: Access to nephrology care prior to end-stage renal disease (ESRD) 
is significantly associated with lower rates of morbidity and mortality. We assessed the 
association of area and individual-level indicators of poverty and types of health care 
insurance on pre-ESRD care provided by nephrologists.
Methods: In this retrospective cohort study using the United States Renal Data System 
database, we identified 739,537 patients initiated on maintenance dialysis from January 1, 
2007 through December 31, 2012. We assessed the Medicare-Medicaid dual eligibility status 
as an indicator of individual-level poverty and ZIP code-level median household income 
(MHI) data obtained from the 2010 United States Census. We conducted multivariable 
logistic regression of pre-ESRD care as the outcome variable, as reported on the Centers 
for Medicare and Medicaid Services Form 2728.
Results: The proportions of dual-eligible and non-dual eligible patients who had 
pre-ESRD care were 53.06% and 61.82%, respectively (p<0.001). Dual-eligibility was 
associated with significantly lower likelihood of pre-ESRD care (adjusted odds ratio 
[aOR] 0.83; 95% confidence interval [CI] 0.82-0.84). Patients in the lowest area-level MHI 
quintile had an aOR 0.89 (95% CI 0.88-0.90) compared to those in higher quintile levels. 
Both African American (AA) and Hispanic patients were significantly less likely to have 
received pre-ESRD care (aOR 0.85, 95% CI 0.84-0.86 and aOR 0.71, 95% CI 0.70-0.72, 
respectively). Interaction terms for dual eligibility and AA race and Hispanic ethnicity were 
significant (p<0.001 and p=0.002, respectively).
Conclusions: Individual and area level measures of poverty were independently 
associated with lower likelihood of pre-ESRD care. Efforts to improve pre-ESRD 
nephrology care may require focusing on the poor and minority groups. [Disclaimer: The 
views expressed in this paper are those of the authors and do not reflect the official policy 
of the Department of the Army, Department of the Navy, Department of Defense, or the 
United States government].
FR-PO792
Development and Validation of the Charlson Comorbidity Scoring 
System for Korean Incident Peritoneal Dialysis Patients  Hyunjeong Cho,1 
Myoung-Hee Kim,2 Seung Seok Han,1 Jae Yoon Park,1 Hyunjin Ryu,1 Hyo 
Jin Kim,1 Dong-Ryeol Ryu,3 Hajeong Lee,1 Jung Pyo Lee,4 Chun Soo Lim,4 
Kook-Hwan Oh,1 Kwon Wook Joo,1 Yon Su Kim,1 Dong Ki Kim.1  1Internal 
Medicine, Seoul National Univ College of Medicine, Seoul, Korea; 2Dental 
Hygiene, College of Health Science, Eulji Univ, Gyeonggi-do, Korea; 3Internal 
Medicine and Ewha Medical Research Inst, School of Medicine, Ewha Womans 
Univ, Seoul, Korea; 4Internal Medicine, Seoul National Univ Boramae Medical 
Center, Seoul, Korea.
Background: The Charlson Comorbidity Index (CCI) has widely used for predicting 
mortality and adjusting as a confounder in statistical analyses. However, the CCI remains 
disputed as an index to be applied to ESRD populations because the CCI was developed for 
general population. In this study, we modified the CCI and developed a modified Charlson 
comorbidity index in incident peritoneal dialysis patients (mCCI-IPD) to improve risk 
stratification for mortality.
Methods: The mCCI-IPD was developed based on 7,606 Koreans who received their 
first peritoneal dialysis treatment between 2005 and 2008. Data were obtained from the 
Korean Health Insurance dataset. The mCCI-IPD score was the sum of the weights which 
were assigned to individual comorbidities according to their relative prognostic significance 
determined by multivariate Cox proportional hazards model. The modified index was 
validated in an independent prospective cohort (n=664).
Results: The Cox proportional hazards model showed that the CCI comorbidities except 
ulcers, peripheral vascular disease, dementia and connective tissue disease significantly 
predicted mortality. Thus, the mCCI-IPD included 11 comorbidities with re-assigned 
severity weights. In the validation cohort, both the CCI and the mCCI-IPD were correlated 
with mortality. However, the analyses using continuous net reclassification improvement 
revealed that the mCCI-IPD improved net mortality risk reclassification by 30.8% (95% 
CI, 7.6-54.1; P=0.009) relative to the CCI.
Conclusions: The mCCI-IPD performed the better risk stratification for mortality in 
incident peritoneal dialysis patients than the CCI. It suggests that the mCCI-IPD may be 
a preferred tool for clinical study of peritoneal dialysis patients.
FR-PO793
Diabetes, Black Race, Female: Risk Factors for Hospitalization After 
Dialysis Start in a Nationwide Cohort Sample  LaTonya J. Hickson,1,2 Bjoerg 
Thorsteinsdottir,2,3 Priya Ramar,2 Jordan K. Rosedahl,2 Cynthia S. Crowson,2 
Robert C. Albright,1 Nana-Hawa Yayah Jones,4 Rozalina G. McCoy,2,3 Suzanne 
M. Norby,1 Andrew D. Rule,1 Amy W. Williams,1 Nilay D. Shah.2  1Nephrology 
and Hypertension, Mayo Clinic, Rochester, MN; 2Mayo Clinic Kern Center for 
the Science of Health Care Delivery, Mayo Clinic; 3Primary Care IM, Mayo 
Clinic; 4Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, 
OH.
Background: Young dialysis patients have a high frequency of hospitalizations and 
readmissions. Multiple factors likely contribute to this occurrence, but have not been 
fully elucidated.
Methods: Young, incident dialysis patients aged 20-44 years included in the US Renal 
Data System with first dialysis service in 2005-2011. Multivariable multinomial logistic 
regression models examined associations and interactions between baseline predictors and 
hospitalizations through claims in the first 3-15 months; all p-values <0.05.
Results: For 46,895 patients (mean age: 36; 58% male; 46% black, 48% white, 4% 
asian, 2% other race, 41% with diabetes, 23% with Charlson score ≥4) mean hospitalization 
rate was 2.3 per year. Subgroups for low to high utilizers included: 0 (45%), >0-4 (25%), 
>4-10 (20%) and >10 (10%) per year. Compared to the 0 hospitalization group, the >10 
group had more females (48% vs 39%), more blacks (51% vs 45%), fewer Asians (2% vs 
5%), more diabetics (52% vs 34%), more with Charlson score≥4 (41% vs 14%). Diabetics 
were more likely to be high utilizers (odds ratio [OR]: 1.98(1.84,2.14)) adjusting for age 
(OR:1.30(1.23,1.37) per 10 year decrease; sex (OR:1.23 (1.15,1.32) females vs males), black 
race (OR:1.24(1.16,1.34) blacks vs whites). Charlson score ≥4 were also more likely to be 
high utilizers (OR: 7.00(6.25,7.84) vs Charlson score 0-1), with highly comorbid females 
having nearly twice the risk as highly comorbid males (OR: 12.62 vs 6.23, interaction 
p<0.001) when compared to low comorbid males.
Conclusions: Hospitalizations are frequent among young incident dialysis patients, 
particularly among diabetics, blacks, females, and those with multiple comorbidities. 
Further investigation into socioeconomic factors and causes of hospitalizations is needed 
to clarify these finding for targeted interventions.
FR-PO794
Does Race Affect the Cause of Mortality in End Stage Kidney Disease? 
Luxme Nadarajah, Kieran Mccafferty, Muhammad M. Yaqoob.  Barts and the 
London, Nephrology, London, United Kingdom.
Background: Cardiovascular disease accounts for 50% of mortality in end-stage 
kidney disease (ESKD). Caucasians (C) are more likely to die from cardiovascular disease, 
infection and withdrawal compared to Afro-Caribbean’s (AC). Little is known about the 
causes of mortality for Indo-Asian (IA) patients; with the rise in diabetes mellitus (DM) it 
is inevitable that more patients from IA backgrounds will get ESKD. We aim to investigate 
whether there are any differences in causes of mortality based on race.
Methods: We performed a single center, prospective, observational study. Electronic 
case notes were used to extract data to include cause of death, age of initiation of RRT, 
age of death, dialysis vintage (DV), gender and presence of DM. Patients were excluded 
if RRT was less than 90 days, or if they were transplanted.
Results: In total 3431 patients commenced RRT during the study period, 802 patients 
died, 364 were C, 259 IA and 178 were AC. There were no significant differences between 
the groups for age at initiation, DV, and age of death. Significantly fewer IA died during 
the follow up period compared to C (p<0.0001) and AC (P<0.0001). More IA and AC were 
diabetic (p< 0.0001). Cardiovascular deaths were more common in C and AC patients 
compared to those of IA race (p=0.001). IA’s had higher sepsis related deaths when 
compared C or AC (p< 0.0001).
Caucasian Indo-Asian Afro-Caribbean
Total Number of patients 1055 1616 760
Number of deaths (%) 365 (34) 259 (16) 178(23)
Cardiovascular (%) 101 (28) 48 (19) 54 (30)
Sepsis (%) 79 (22) 97 (37) 36 (20)
Withdrawal (%) 68 (19) 48 (19) 34 (19)
Mailgnancy (%) 43 (12) 42(16) 17 (10)
CVA (%) 14(4) 8 (3) 10 (6)
Other (%) 59 (16) 16 (6) 27 (15)
Conclusions: Despite the increased prevalence in DM, IA patients do not have worse 
survival outcomes or cardiovascular deaths compared to C and AC. We believe that the 
elevated sepsis related mortality in IA patients is secondary to the higher prevalence of 
diabetes. This data enables stratifying management therapies dependent on race and may 
help in designing cardiovascular end points trials in racially diverse group of patients.
Funding: Other NIH Support - William Harvey Research Institute
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
547A
J Am Soc Nephrol 26: 2015 Dialysis: Epidemiology, Outcomes, and Clinical Trials: Noncardiovascular - II Poster/Friday
FR-PO795
Association of Dialysis Provider Assignment with Early Dialysis Mortality 
in U.S. Veterans: A Transition of Care in CKD Study  Elani Streja,1 Melissa 
Soohoo,1 Connie Rhee,1 Vanessa A. Ravel,1 Joline L.T. Chen,1 Jennie Jing,1 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2UTHSC.
Background: Mortality is high during the first months after initiating kidney 
replacement therapy including in US veterans. Only 10% of veterans receive dialysis 
therapy in a Veterans Administration (VA) healthcare based dialysis clinic and the majority 
of veterans are assigned to non-VA centers and dialysis chains.
Methods: We examined all-cause mortality during the 3, 6, 12 and 24 month period 
after transition in a cohort of 52,158 US veterans who transitioned to ESRD over 4 years 
(10/2007-9/2011) and the association of dialysis provider assignment. Baseline provider 
was determined by facility information and divided into 5 categories: DaVita(DV), 
Fresenius(FR), Other Chain(OC), Non-Chain(NC), and VA. Associations were examined 
in Cox proportional hazard models and adjusted for age, gender, race, ethnicity, initial 
vascular access and primary cause of ESRD.
Results: Upon dialysis transition, patients were 70±12 yrs old, 6% female, 25% African-
American, 19% initially used AV fistula and 42% had diabetes as the cause of ESRD. At 
baseline, 24%, 28%, 13%, 21%, and 10% of veterans received treatment at DV, FR, OC, 
NC, and VA facilities, respectively. Over the first 3, 6, 12 and 24 mos after transition, 
5489(11%), 9283(18%), 14339(27%) and 21697(42%) veterans died, respectively (Figure 
left). Compared to patients initiating treatment at the VA, all patients receiving treatment at 
other facilities had higher risk of mortality through all periods of follow-up, after adjusting 
for case mix covariates (Figure right).
Conclusions: Veterans transitioning to dialysis treatment in a VA hospital based 
dialysis center have the best survival over the first 2 years of follow up. Whether the better 
survival of VA dialysis care is from selection bias versus true superior care in the VA system 
warrants additional studies.
Funding: NIDDK Support
FR-PO796
Time-Varying Racial/Ethnic Differences in Mortality After Initiation of 
Dialysis in U.S. Dialysis Patients  Guofen Yan,1 Keith C. Norris,2 Alison J. Yu,3 
Tom Greene,4 Jennie Z. Ma,1 Wei Yu,1 Alfred K. Cheung.4  1Univ of Virginia; 
2UCLA; 3Univ of Southern California; 4Univ of Utah.
Background: While survival advantage for African Americans (AAs) and Hispanics, 
compared to Whites, has been observed for decades, our understanding of the mechanism 
is still incomplete. Using national dialysis patients, we examined whether this survival 
advantage exists across the entire course of ESRD or just within a certain time interval 
after initiation of dialysis.
Methods: The study included 1,255,640 adult incident dialysis patients between 1995 
and 2010 in the USRDS. We calculated age-specific hazard ratios (HRs) of death for AAs 
and Hispanics vs. Whites, adjusted for covariates, for every 6-month interval in the first 4 
years of dialysis and for the period thereafter.
Results: For each age group above 40 years (Table), lower risk of death for AAs than 
Whites (HR<1) did not vary greatly across these time intervals. In contrast, in each age group 
under 40 years, the HR for AAs vs. Whites evolved over time, which was highest in the first 
year, declined in the second year, and reached stable over time. Hispanics exhibited lower 
mortality risks in all age groups that remained relatively constant over time (not shown). 
Table. Adjusted HRs for AAs vs. Whites
Age
Groups
Months after Initiation of Dialysis
1 – 6 7-12 13 – 18 19 – 24
25 
-30
31 – 
36
37 – 
42
43 – 
48 >48
18-30 1.72 1.50 1.14 1.28 1.09 0.92 0.91 0.93 0.93
31-40 1.34 1.32 1.07 0.92 0.86 0.89 0.68 0.72 0.83
41-50 0.89 0.93 0.85 0.76 0.72 0.71 0.70 0.68 0.78
51-60 0.76 0.74 0.70 0.69 0.66 0.66 0.65 0.67 0.76
61-70 0.72 0.73 0.70 0.70 0.70 0.68 0.68 0.71 0.81
71-80 0.76 0.80 0.74 0.76 0.76 0.77 0.78 0.79 0.86
>80 0.84 0.83 0.80 0.78 0.83 0.85 0.81 0.84 0.88
Note: most of these HRs were significant at p<0.05.
Conclusions: AAs over 40 years old and Hispanics of all ages have uniformly lower 
risks of death than Whites across the course of ESRD. For younger AAs, conversely, their 
higher-mortality risk period is limited to the first two years of dialysis. Further studies to 
delineate the factors responsible for excessive mortality associated with racial subgroups 
will improve care for all dialysis patients.
Funding: NIDDK Support
FR-PO797
Real Threat of ESRD in China: A Ten-Year Experience from Nanjing 3 
Million Insurance Covered Population  Yu-Chen Han,1 Ling Sun,1 Han-Ming 
Huang,2 Kun ling Ma,1 Bei Wang,3 Bi-Cheng Liu.1  1Zhongda Hospital, Southeast 
Univ School of Medicine, Nanjing, Jiangsu, China; 2Nanjing Municipal Human 
Resources and Social Security Bureau, Nanjing, Jiangsu, China; 3Southeast 
Univ School of Public Health, Nanjing, Jiangsu, China.
Background: In the past decade, Chinese government has made great efforts to 
provide an affordable and equitable access to renal replacement therapy (RRT) for most 
of ESRD patients. Here we analyzed the ten years registry data of 3 million Nanjing Urban 
Employee Basic Medical Insurance (UEBMI) covered population and firstly provided the 
epidemiological data about ESRD in this developing country.
Methods: Using the electric registry system of UEBMI, we included all subjects 
insured by UEBMI in Nanjing from 2005 to 2014, and identified subjects who developed 
ESRD in this cohort. The prevalence and incidence of ESRD was analyzed based on this 
unique data system.
Results: During the 10-year period, the incidence rate of ESRD in UEBMI cohort in 
Nanjing gradually declined from 289.3pmp in 2005 to 218.8pmp in 2014. However, the 
prevalence rate increased steadily from 891.7pmp in 2005 to 1228.6pmp in 2014. The 
annual mortality rate declined from 138.4 per 1000 patient-years in 2005 to 97.8 per 1000 
patient-years in 2014. Long-term survival rate of ESRD fluctuated during the past decade, 
with 1-year survival rate ranging from 85.1% to 91.7%, 3-year survival rate from 69.9% 
to 78.3% and 5-year survival rate from 58% to 65.4%.
Conclusions: This study firstly provided an epidemiological data about ESRD based on 
the complete electric registry data system in large population in China. Due to the lack of 
a national complete registry data system, the real burden of ESRD in China is still unclear. 
Nanjing is one of the biggest cities in China. Our present study based on the ten years 
complete electric registry data system provided a convincing data about the real threat of 
ESRD in China. According to this study, we estimated that China will probably have over 
1.5 million ESRD patients in the near future with the establishment of improved healthcare 
system. It is therefore utmost important for both medical communities and government to 
take active measures to control this coming disaster.
Funding: Government Support - Non-U.S.
FR-PO798
An Evaluation of Completeness of Monthly Clinical Data in CROWNWeb, 
a New Data Source for the United States Renal Data System (USRDS) 
Valarie B. Ashby,1 Lingqun Liu,1 Xizhao Li,1 Tempie H. Shearon,1 Bruce M. 
Robinson,2 Douglas E. Schaubel,1 Yi Li,1 Rajiv Saran.1  1Univ of Michigan, Ann 
Arbor, MI; 2Arbor Research Collaborative for Health, Ann Arbor, MI.
Background: CROWNWeb (CW) is a web-based system which collects administrative 
and clinical data from all Medicare-certified dialysis facilities in the US. It includes patient 
admission, tracking, and discharge information, CMS forms, and clinical data elements, and 
is not limited to Medicare patients. Monthly clinical data submission began in May 2012. 
Previously, monthly clinical data were only available to the USRDS through administrative 
claims for Medicare patients.
Methods: CMS data were used to analyze 355,846 and 370,610 dialysis patients in 
2013 and 2014, respectively, who remained on dialysis the entire year (those who were 
incident, died, or lost to follow-up were excluded). The percentages of patients with any 
and high-level reporting of selected CW clinical data were calculated, with ‘high-level’ 
defined as 10+ months (except 3+ months for peritoneal dialysis (PD) Kt/V). The percentage 
of high-level reporting for patient subgroups was also calculated.
Results: The percentages of patients with CW data (any, high) are shown below. 
All measures had an increase in reporting from 2013 to 2014. High-level reporting in 
2014 ranged from 75% (Hemodialysis (HD) Kt/V) to 90% (vascular access type). For 
all measures, reporting was higher for HD than PD patients, for adults than children, and 
for patients with (versus without) diabetes as cause of ESRD. 72% of HD patients had 
high-level reporting for all 6 HD measures. 70% of PD patients had high-level reporting 
for all 5 PD measures.
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Conclusions: CW is now an integral part of the USRDS. Our study suggests a generally 
high and improving level of completeness of clinical data elements in CW. These data will 
enhance the value of the USRDS database for researchers in coming years.
Funding: NIDDK Support
FR-PO799
Facility Size and Impact of Extreme Measure Values on DFC Star Ratings 
Christopher J. Harvey,1 Claudia Dahlerus,1 Zezhi (zac) Zhang,1 Joseph M. 
Messana,1 Ji Zhu,1 Cindy Liao,1 Natalie Scholz,1 K. A. Wisniewski,1 Richard 
Hirth,1 Elena K. Balovlenkov,2 Joel S. Andress,2 Yi Li.1  1Biostatistics, Kidney 
Epidemiology and Cost Center, Univ of Michigan, Ann Arbor, MI; 2Centers for 
Medicare and Medicaid Services.
Background: In 2015 CMS implemented star ratings for dialysis facilities to make 
it easier for consumers to compare dialysis facilities by providing a summary of each 
facility’s performance on a set of 9 DFC quality measures. Our study compares two scoring 
approaches to the star rating to assess the impact of each on controlling outlying measure 
values with regard to facility size.
Methods: Fixed percentiles are applied to assign 10% of facilities 1-star or 5-stars based 
on performance. 2013 data were extracted from the 2015 January DFC file. Probit ranking 
and z-score transformation were applied to the DFC measures to develop an overall score 
and final star rating. We compared the final distribution of star ratings for each approach 
and assessed impact on smaller facilities. We represent the rating by number of patients 
in each facility contributing to the hospitalization measure, and split ~6000 facilities into 
groups of ~100 and calculated percentage of each star rating in each group.
Results: Use of original measure values and z-scores allowed skewed measures to 
highly influence the ratings, but preserved original measure distributions. Probit ranking 
resulted in giving more 5-star ratings to smaller facilities and z-scored approach resulted 
in assigning more 1-star and 5-star ratings to smaller facilities (Figure 1). 
Conclusions: Small facilities have more variation in measures and be over represented 
in the 1 or 2-star categories. Probit ranking (current DFC Star Rating method) controlled 
impact of outlier measure values. Z-score methods appeared to allow greater impact of 
extreme values. However, facility size may also be related to quality of care.
Funding: Other U.S. Government Support
FR-PO800
P11 as Marker and Vitamin D as Treatment Option of Depression in 
Maintenance Dialysis Patients  Ga Hee Lee, Sihyung Park, Bongsoo Park, 
Kyubok Jin, Yang Wook Kim.  Haeundae Paik Hospital.
Background: Depression is a disabling condition impairing all aspects of human 
functions. The serotonin system has been implicated in the pathophysiology of depression. 
Recently, as a member of the S100 family of proteins, P11 is known to have relation to 
depression by interacting with serotonin receptors and affected by inflammation. Because 
of nutritional deficiency and limited physical activities, dialysed patients are easy to have 
vitamin D deficiency. Recent studies reported that vitamin D might play a role in depression. 
So, we planned this study to assess the possibilities of the P11 as a depression marker and 
the vitamin D as a treatment option in dialysed patients.
Methods: As a single center cross-sectional study, we examined the peripheral blood 
mononuclear cells P11 mRNA, IL-6, TNF-α, 25-hydroxycholecalciferol (25-(OH)D3) of 
patients with hemodialysis (HD, N=27), peritoneal dialysis (PD, N=39) and healthy group 
(N=7). Groups were divided by presence of depressive mood and categorized by severity 
of depressed mood via Beck Depression Inventory (BDI).
Results: In non-depressive group (BDI <10), The dCt means of P11 were high in HD 
group (5.51 ± 0.7 (HD, N=15) vs. 1.39 ± 0.33 (PD, N=11) and 2.29 ± 0.37 (control, N=7), p 
<0.05). The mean IL-6 levels were low in control group (6.43 ± 1.34 pg/mL (HD) and 7.53 
± 1.39 pg/mL (PD) vs. 2.23 ± 0.49 pg/mL (control), p <0.05). The mean TNF-α levels were 
low in control group (4.31 ± 0.26 pg/mL (HD) and 4.15 ± 0.25 pg/mL (PD) vs. 1.85 ± 0.53 
pg/mL (control), p < 0.05) respectively. In depressive group (BDI ³10), P11 levels showed 
relationships with depression severity in peritoneal dialysis group (spearman rho=0.2, p 
=0.09). In hemodialysis group, 25-(OH)D3 level was lower in depressive group (11.98 ± 
3.8 vs. 7.5 ± 2.7, p = 0.005), but there was no difference in peritoneal dialysis group (6.3 
± 3.3 vs. 7.4 ± 7.1, p=0.55).
Conclusions: By diagnostic tool, P11 can be used in peritoneal dialysis group as a 
depression marker despite taking the effect of inflammation into consideration, but not in 
hemodialysis group. As other treatment option, 25-(OH)D3 can be used in hemodialysis 
group for depression management, but not in peritoneal dialysis group.
FR-PO801
Efficacy of Loop Diuretics in the Management of Undocumented End Stage 
Renal Disease Patients Receiving Emergency Hemodialysis  Salman Ahmed, 
Biruh Workeneh.  Dept of Internal Medicine, Section of Nephrology, Baylor 
College of Medicine, Houston, TX.
Background: Nearly eleven million undocumented immigrants reside in the United 
States. An estimated six thousand undocumented patients suffer from End Stage Renal 
Disease (ESRD). These patients routinely present to public hospitals for life-saving 
emergent dialysis treatments. Since these patients lack a dialysis unit, they often do not 
have medication management by a nephrologist. This can result in poorer outcomes.
Methods: We reviewed charts of 93 undocumented patients who presented for at least 
three emergent hemodialysis (HD) treatments during three consecutive months to the Ben 
Taub General Hospital, a centrally located county facility in Houston, TX. We abstracted 
prescription data for furosemide and several commonly prescribed medications. We also 
abstracted data regarding the number of ER visits, number of HD sessions, and mean, 
median, and peak potassium values.
Results: On average, the diuretic group had 3.1 (SE=1.8) fewer ER visits during 
the three-month period for emergency dialysis, compared with subjects not on diuretics 
(p=0.10). There was no significant relationship between furosemide total daily dose (TDD) 
and potassium levels. Patients on diuretics were more likely to also be taking ESAs and 
sevelamer (P£0.05). In a multiple regression model, the diuretic group had significantly 
fewer ER visits after adjusting for use of ESAs and sevelamer use (p=0.007). The association 
between diuretic use and ER visits is significantly associated with concomitant ESA use 
(p=0.04). Among subjects using ESAs, patients on diuretics have about 7.7 (95% CI: 
1.9,13.6) fewer ER visits compared with the non-diuretic group.
Conclusions: There was no significant independent association between loop diuretic 
dosage and number of ER visits, although there was a strong trend. The subset of patients 
on ESAs and loop diuretics had decreased ER utilization, and this may be explained by 
increased doctor-patient time, less symptomatology while on ESAs, or other, as-yet-
undetermined mechanisms.
FR-PO802
Unfractionated Heparin May Contribute More to Dialysis-Associated 
Bleeding Risk Than Low-Molecular Weight Heparin  Suzanne H. Forbes,1 
Sean Platton,2 Michael K. Almond,3 Laura Green,2 Neil Ashman.1  1Nephrology, 
Royal London Hospital; 2Haematology, Royal London Hospital; 3Nephrology, 
Southend Hospital.
Background: Haemodialysis (HD) patient are well recognised to be at increased risk 
for major bleeding. The contribution of circuit anticoagulation to this risk is unknown. The 
use of unfractionated heparin (UFH) vs low-molecular weight heparin (LMWH) is debated. 
APTT/anti-Xa levels suggest anticoagulation is cleared by the end of HD but these tests are 
poorly correlated with bleeding phenotype. We used thrombin generation (TG) to assess 
coagulation throughout HD with UFH or LMWH.
Methods: We studied 127 patients; 60 LMWH, 61 UFH, 6 heparin-free. Blood was 
taken at t0=pre-anticoagulation, t1=1hr, t2=2hrs, t3=end. TG was performed on platelet 
poor plasma, measuring lag time, exogenous thrombin potential (ETP) & peak thrombin.
Results: Results are shown in table 1. With LMWH 42% failed to generate thrombin 
at t3 compared with 57% of UFH, indicating significantly impaired clotting (p=0.05). In 
those who did generate thrombin at t3, this was considerably below baseline. 
The magnitude of this was significantly greater with UFH for lag time (p=0.03), ETP 
(p=0.06) and peak thrombin (p=0.05). Heparin-free patients showed minimal change.
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UFH LMWH Heparin-free
t0 
Lag
ETP
Peak Thrombin
Platelet Count
Hb
4.53
1960
226
226
10.4
4.63
2153
325
190
10.7
4.88
2037
291
248
9.46
Average 
anticoagulation dose
Bolus 1328u
Infusion 991u/hr
Lockout time 33mins
3129iu -
%change t0: t3
Lag
ETP
Peak
↑71
Ļ35
Ļ65
↑41
Ļ29
Ļ48
↑10
Ļ1
Ļ2
Conclusions: Standard HD anticoagulation results in impaired haemostasis after HD 
as measured by TG, UFH more so than LMWH, which is not seen in heparin-free patients. 
This shows the HD process itself does not impact TG, rather exogenous anticoagulation. This 
should prompt cautious anticoagulation use, especially UFH, in patients at risk of bleeding.
FR-PO803
Anti-Platelet Factor 4 Antibodies: A One HIT Wonder  Suzanne H. Forbes,1 
Sean Platton,2 Michael K. Almond,3 Neil Ashman,1 Laura Green.2  1Nephrology, 
Royal London Hospital; 2Haematology, Royal London Hospital; 3Nephrology, 
Southend Hospital.
Background: Hemodialysis (HD) patients are exposed to regular anticoagulation, 
usually unfractionated heparin (UFH) or low-molecular weight heparin (LMWH). For 
standard HD (4 hrs, 3 days/week) this equates 26 full days exposure/yr. Recently there was 
interest in the presence of heparin induced thrombocytopenia (HIT) in HD, and the causative 
anti-platelet factor 4 (PF4) antibody. There are several publications suggesting the presence 
of the antibody, without the clinical syndrome of HIT, is present in up to 25% HD patients, 
and may be an independent risk factor for cardiovascular and vascular access morbidity.
Methods: We looked for HIT antibodies in 2 prevalent HD cohorts, one with UFH, 
one LMWH (line lock sodium citrate). We tested serum for anti-PF4 antibodies using 
several established tests; STic Expert® (IgG-specific exclusion test), Diamed (particle gel 
immuno-assay), poly-specific IgGA/M ELISA, IgG-specific ELISA.
Results: We included 127 patients: 60 receiving tinzaparin, 61 receiving UFH and 6 
dialysing heparin-free. Serum samples were taken at the start of a standard HD session. 
The average duration on dialysis was 3.4 years. Results of the various tests are shown. 
TEST UFH LMWH Heparin-free
Platelet Count 226 190 248
STic Expert positive - 52%negative - 48%
positive - 40%
negative - 60%
positive - 0%
negative - 100%
Diamed positive - 1%negative - 99%
positive - 1%
negative - 99%
negative - 0%
positive - 100%
Poly-specific ELISA median OD - 0.2 (positive>0.4)
median OD - 0.15 
(positive>0.4)
median OD - 0.09 
(positive>0.4)
IgG specific ELISA median OD - 0.13 (positive>0.4) 
median OD - 0.07 
(positive>0.4)
median OD - 0.05 
(positive>0.4)
Only 1 patient tested antibody positive (OD 0.5) in the LMWH group. Platelet 
count and reactivity (using ADP, epinephrine, collagen) did not differ between the STiC 
positive/negative groups, the UFH/LMWH groups, or those with higher or lower tertiles 
of ELISA OD.
Conclusions: Despite the previously reported concern over the presence of HIT 
antibodies in HD patient, we comprehensively show here no evidence of antibody positivity 
in HD patients. Exclusion tests such as STiC expert are not useful in these patients.
FR-PO804
Upper Gastrointestinal Bleeding Among Dialysis Patients in an Endemic 
Area for Chronic Liver Disease: Taiwan National Cohort Study 
Chih-Chiang Chien,1,2 Chien-Ya Hung.1  1Chung Hwa Univ of Medical 
Technology, Tainan, Taiwan; 2Chi Mei Medical Center, Tainan, Taiwan.
Background: End-stage renal disease (ESRD) and chronic liver disease (CLD) both 
increase the risk for upper gastrointestinal (UGI) bleeding. The prevalence of ESRD and 
CLD are high in Taiwan. The aim of this study was to evaluate the incidence, risk factors, 
and categories of UGI bleeding in ESRD dialysis patients.
Methods: Using Taiwan’s National Health Insurance research database, we enrolled 
42,457 incident ESRD dialysis patientswho began dialysis between 1999 and 2004. The 
patients were followed until death, dialysis cessation, or 31 December 2008. Cumulative 
incidence of UGI bleeding after initiation of dialysis was calculated using Kaplan-Meier 
methods. Predictors for UGI bleeding were determined using Cox models.
Results: During the follow-up period, 5,528 patients had a UGI bleeding. Male, 
elderly, receiving hemodialysis (HD) and patient with comorbidites had a higher rate of 
UGI bleeding. The 1-, 3-, 5- and 7-year cumulative incidence rate of UGI bleeding were 
9.8%, 21%, 25.3% and 28% in patients with liver cirrhosis (LC) on HD, 5.8%, 16.2%, 
22.2% and 24.4% in patients with LC on PD, 3.7%, 9.2%, 13.2% and 16.4% in patients 
without LC on HD, and 2.1%, 5.5%, 8.2% and 10.4% in patients without LC on PD (log-
rank: p <0.001). After multivariate adjustment, prior gastrointestinal bleeding (HR 1.731, 
95% CI, 1.635-1.834), LC (1.682, 95% CI, 1.524-1.856), alcoholism liver disease (1.536, 
95% CI, 1.635-1.834), and receiving HD (1.316, 95% CI, 1.153-1.502) were independently 
risks for UGI bleeding in ESRD dialysis patient . Gastric ulcers were found to be the most 
common source of bleeding (50.3%), while bleeding resulting from a gastrojejunal ulcer 
was least frequent .
Conclusions: ESRD dialysis patients had a higher risk for UGI bleeding, especially 
those with prior gastrointestinal bleeding, LC, and alcoholism liver disease. In addition, 
receiving HD is a strong predictor for UGI bleeding. More attention should be paid to select 
dialysis modality, especially in high risk patients.
FR-PO805
Palmitoylethanolamide Is a Promising Potential Therapeutic Target for 
Increasing High Density Lipoprotein Cholesterol Levels  Hamid Moradi,1,2 
Miki Igarashi,1 Melissa Soohoo,1 Elani Streja,1 Hamid M. Said,1,2 Moti L. 
Kashyap,1,2 Daniele Piomelli,1 Kamyar Kalantar-Zadeh.1,2  1UC Irvine; 2VA 
Long Beach.
Background: End stage renal disease (ESRD) is associated with significant increased 
risk of cardiovascular (CV) mortality. High density lipoprotein (HDL) deficiency and 
dysfunction is a major contributor to CV disease in ESRD. Strategies aimed at improving 
HDL level and function are crucial in improving CV outcomes. Palmitoylethanolamide 
(PEA) is an anti-inflammatory lipid derived mediator that activates PPARalpha nuclear 
transcription factor. We hypothesized that serum PEA will correlate with HDL and PEA 
can increase HDL via activation of apolipoproteinAI (ApoAI) expression.
Methods: Serum PEA concentration was determined in 50 patients on maintenance 
hemodialysis (MHD) using LC/MS technology and correlated with clinical laboratory 
indices including a lipid panel. Liver cells (Hepatoma cell line HepG2) were exposed to 
various concentrations of PEA in-vitro for 24 hours and subsequently mRNA expression of 
ApoAI, the major protein component of HDL, was measure using real-time PCR.
Results: Serum PEA concentrations strongly correlated with serum HDL levels in MHD 
patients (r=0.57, p <0.0001). PEA also correlates with total cholesterol (r=0.36, p=0.009) 
however not with LDL or triglycerides. In the in-vitro studies, PEA at a concentration 
of 60 micromolar and 120 micromolar was increased ApoAI expression significantly in 
HepG2 cells after 24 hours.
Conclusions: For the first time we report that serum PEA concentrations strongly 
correlate with serum HDL concentrations in MHD patients. Involvement of PEA in HDL 
production is confirmed in in-vitro studies where incubation of liver cell in PEA resulted in 
increased ApoA-I expression. These novel findings indicate that PEA may be a promising 
therapeutic target in HDL deficiency treatment associated with not just ESRD but any 
proatherosclerotic condition.
Funding: NIDDK Support
FR-PO806
Arachidonoylglycerol, a Major Activator of the Endocannabinoid System, 
Is Significantly Increased in Patients with Kidney Disease  Hamid Moradi,1,2 
Miki Igarashi,1 Melissa Soohoo,1 Elani Streja,1 Connie Rhee,1 Hamid M. 
Said,1,2 Moti L. Kashyap,1,2 Nosratola D. Vaziri,1 Daniele Piomelli,1 Kamyar 
Kalantar-Zadeh.1,2  1UC Irvine; 2VA Long Beach.
Background: Chronic kidney disease (CKD) is associated with oxidative stress and 
inflammation. There is evidence that cannabinoid 1 receptor activation leads to increased 
oxidative stress and inflammation. We previously showed that 2-arachidonoylglycerol (2-
AG), one of the main activators of the endocannabinoid system, is significantly increased 
in the kidney of animals with ischemia-reperfusion (IR) injury. We hypothesized that serum 
2-AG levels will be significantly elevated in CKD patients.
Methods: Serum concentrations of AG were determined in 21 healthy controls, 
50 randomly assigned age and gender matched patients on maintenance hemodialysis 
(MHD), 13 patients on peritoneal dialysis (PD) and 6 patients with CKD stage IV using 
LC/MS technology. In MHD patients, serum levels of AG were correlated with various 
laboratory indices.
Results: Serum levels of 1-AG and 2-AG were significantly and incrementally 
increased with CKD compared to healthy controls. MHD patients had the highest AG levels 
which positively and significantly correlated with number of treatments per week (r=0.47, 
p=0.008), AST/ALT (r=0.5, p=0.001), platelet count (r=0.40, p=0.008), ferritin (r=0.36, 
p=0.016) and negatively with HDL cholesterol (r= -0.43, p=0.04).
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Conclusions: For the first time we report that serum AG concentrations are significantly 
increased in CKD patients. These novel findings are in line with our report on IR acute 
kidney injury and with a recent study which showed that in an oxidative stress setting, 
monoacylglycerol lipase, an enzyme responsible for AG breakdown is inhibited leading 
to increased levels. Moreover, the substantial increase in MHD patients is intriguing given 
association of MHD with increased oxidative stress, inflammation and platelet activation.
Funding: NIDDK Support
FR-PO807
Newly Launched Cellulose Tri-Acetate Membrane with Asymmetric 
Structure Dramatically Improves Peripheral Circulation and Hemodynamic 
Stability During Hemodialysis  Ikuto Masakane.  Yabuki Hospital, Nephrology, 
Yamagata, Japan.
Background: The most important concern about the biocompatibility of dialysis 
membrane is the activation of platelets and it would lead hemodynamic instability during 
dialysis session. The newly launched CTA with asymmetric thick structure (ATA) was 
produced in order to reduce stimulant property to platelets and the rapid reduction of the 
serum levels of small uremic solutes by thickening the membrane. We evaluated the solute 
removal performance and biocompatibility of ATA.
Methods: Seven chronic hemodialysis patients were enrolled to the current study. The 
conventional CTA was used for the first 4 months and ATA was used for the next 4 months. 
We evaluated the solute removal property by the clearance of urea, beta-2 microglobulin 
(B2MG) and removed amount of alpha-1 microglobulin (ǹ1mG) and albumin loss in spent 
dialysate. The biocompatibility was evaluated by changes in WBC and platelet count, IL-6, 
Pentorexine-3 (PTX-3) and high sensitive CRP (hsCRP). The peripheral circulation was 
estimated by the Skin Perfusion Pressure (SPP) by PAD-3000® (Kaneka Medix, Osaka, 
Japan). Intra-dialytic hemodynamic stability was evaluated by arterial blood pressure and 
subjective feelings of the patients.
Results: The clearance of Urea was significantly reduced through dialysis session in 
both groups but the B2MG clearance was maintained only in ATA. The total removed amount 
of B2MG and the albumin leakage were not different between 2 groups. The removal of 
ǹ1mG was significantly higher in ATA than CTA. The platelet count didn’t change in ATA 
during dialysis session but significantly decreased in CTA. WBC counts, IL-6, PTX-3, hs 
CRP in both groups didn’t change. The systolic blood pressure and frequency of intra-
dialytic hypotension were not different in both groups whereas some of the patients felt 
that post-dialytic fatigue improved in ATA. SPP was maintained during dialysis session in 
ATA but deteriorated in CTA.
Conclusions: The new ATA membrane could reduce the activation of platelets and 
maintain the peripheral circulation during a dialysis sessions and the time-dependent 
deterioration of solute removal. The new ATA membrane may improve the QOL and 
prognosis of chronic dialysis patients.
FR-PO808
Mathematical Modeling of Fluid Transport in Peritoneal Cavity 
Fansan Zhu,1 Samer R. Abbas,1 Roxana M. Bologa,2 Aurelita Lanto,2 Peter 
Kotanko,1,3 Nathan W. Levin.1  1Renal Research Inst, New York, NY; 2Rogosin 
Inst, New York, NY; 3Icahn School of Medicine at Moun Sinai, New York, NY.
Background: The current standard method (peritoneal equilibration test (PET)) is 
used to obtain transport characteristics of the peritoneal membrane for creatinine, urea and 
electrolytes, but not for fluid volume. Consequently, ultrafiltration profiles are difficult to 
obtain because the weight difference between the inlet and outlet dialysate show only net 
removal during PD. The aim of this study was to investigate whether the rate of change in 
fluid (VPC) in peritoneal cavity and body tissue fluid volume (VT) can be simulated with 
a two compartment model.
Methods: Segmental bioimpedance was continuously monitored in ten PD patients to 
provide VPC during standard PET in the clinical unit (Zhu, et al, Am J Kidney Dis, 2003). VT 
was measured with whole body bioimpedance technique (Hydra 4200). A two compartment 
model of VPC and VT (Fig. 1(a)) was established (Eq.1-Eq.6). Two transport coefficients: k1 
and k2 represent the rate of fluid shift from VPC to VT by reabsorption and from VT to VPC 
, driven by the glucose gradient. k1 and k2 were estimated by best fitting with the actual 
measurements based on the Marquardt–Levenberg algorithm .
Results: Parameter estimation was successful (residuals<0.01) in all but one patient, 
who experienced technical problems during the measurements. Fig. 1 (b) shows change 
in VPC and VT by modeling simulation in a patient. K2 correlated inversely with the initial 
tissue fluid volume VT0 (k2=-0.0002* VT0 +0.0024, R2=0.46, p<0.05).
Conclusions: This model describes dynamics of fluid transport during PD treatment. 
K1 and k2 reflect the characteristics of peritoneal membrane in individual patient. 
The relationship of K2 and VT0 suggests that fluid status could be a factor affect in 
ultrafiltration,which could be helpful in clinical practice. 
FR-PO809
Linagliptin Ameliorated Methylglyoxal-Induced Peritoneal Fibrosis in 
Mice  Takuo Nagai, Shigehiro Doi, Ayumu Nakashima, Takao Masaki.  Dept 
of Nephrology, Hiroshima Univ Hospital, Hiroshima, Japan.
Background: Recent studies have reported that methylglyoxal (MGO) was increased 
in peritoneal dialysis patients, playing an important role in the development of peritoneal 
fibrosis. On the other hand, linagliptin, a dipeptidyl peptiase-4 (DPP-4) inhibitor, exhibits 
beneficial effects in diabetes patients independent of blood glucose concentration. In this 
study, we examined whether linagliptin suppressed MGO-induced peritoneal fibrosis in 
mice.
Methods: Male C57/BL6 mice were divided into three groups: a vehicle group, an MGO 
injection group, or an MGO injection plus linagliptin group (n=6 per group). Peritoneal 
fibrosis was induced by a daily intraperitoneal injection of saline containing 40 mmol/L 
MGO for 21 days. Saline was given in the vehicle group. Linagliptin was administered at 
a dose of 10 mg/kg by oral gavage once a day.
Results: Immunohistochemical staining revealed that linagliptin suppressed the 
expression of α-smooth muscle actin and fibroblast-specific protein-1, the deposition of 
collagen 1 and collagen 3 and infiltration of macrophages (F4/80). In addition, linagliptin 
reduced TGF-β1 concentration in peritoneal fluid of MGO-treated mice. Peritoneal 
equilibration tests showed improvement of peritoneal function in mice receiving linagliptin 
treatment.
Conclusions: These results suggest that oral administration of linagliptin ameliorated 
MGO-induced peritoneal fibrosis.
Funding: Private Foundation Support
FR-PO810
Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal 
Cellular Stress Responses – A Randomized Controlled First-in-Man Trial 
Andreas Vychytil,1 Klaus Kratochwill,1,2 Michael Boehm,1 Rebecca Herzog,1,2 
Katharina Gruber,1 Anton Lichtenauer,1,2 Lilian Kuster,1,2 Dagmar Csaicsich,1 
Andreas Gleiss,1 Martin Bilban,1 Seth L. Alper,3 Christoph Aufricht.1  1Medical 
Univ of Vienna, Vienna, Austria; 2Zytoprotec GmbH, Vienna, Austria; 3Beth 
Israel Deaconess Med. Ctr., Harvard Medical School, MA.
Background: Peritoneal dialysis (PD) fluid cytotoxicity and intermittent bacterial 
infections contribute to membrane failure and peritonitis in PD patients. Recent meta-
analyses revealed no significant influence of newer biocompatible PD fluids on peritonitis 
rate or peritoneal membrane function, but glutamine addition to standard PD fluids has 
shown cytoprotective effects both in vitro and in vivo.
Methods: In this open-label randomized controlled cross-over phase I/II trial 
(NCT01353638), 20 stable PD patients each underwent two 4 h peritoneal equilibration 
tests with glucose-based PD fluids supplemented with or lacking 8 mM alanyl-glutamine 
dipeptide (AlaGln), and separated by a 4 week washout phase. Effects of AlaGln on 
peritoneal inflammation and stimulated cytokine release were also tested in a mouse model 
of PD-associated peritonitis.
Results: Intraperitoneal (IP) exposure to AlaGln-supplemented PD fluid increased 
dialysate [glutamine] more rapidly (at 2 h mean 0.55-0.71 mM, p<0.05) and increased heat 
shock protein expression in peritoneal effluent cells (median 2.12-3.20, p<0.05), but did 
not alter peritoneal ultrafiltration, small solute transport, cell counts, or biomarkers. AlaGln 
increased ex vivo LPS-stimulated TNF-α release (effect CI 60-100 pg/mL, p<0.001) and, 
in patients with previous peritonitis, decreased dialysate [IL-8] (effect CI 0.1-4.3, p<0.05). 
IP AlaGln also reduced inflammation and enhanced cytokine release in the mouse model. 
No adverse effects of AlaGln were noted.
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Conclusions: AlaGln addition to standard PDF acutely attenuated PD-related 
pathomechanisms in humans and in mice. These data encourage our ongoing phase II trial 
testing IP AlaGln supplementation as a routine therapeutic intervention in clinical PD.
Funding: Pharmaceutical Company Support - Zytoprotec GmbH
FR-PO811
Dipeptide Alanyl-Glutamine Protects from Peritoneal Fibrosis and 
Attenuates IL-17 Dependent Pathways During Peritoneal Dialysis 
Evelina Ferrantelli,1 Georgios Liappas,2 Marc Vila cuenca,1 Marc G. Vervloet,3 
Robert H.j. Beelen,1 Manuel Lopez-Cabrera.2  1Dept of Molecular Cell Biology 
and Immunology, VU Univ Medical Center, Amsterdam, Netherlands; 2CSIC-
UAM, Centro de Biología Molecular Severo Ochoa, Madrid, Spain; 3Dept of 
Nephrology, VU Univ Medical Center, Amsterdam, Netherlands.
Background: Peritoneal dialysis (PD) is complicated by chronic inflammation and 
progressive peritoneal membrane damage. Alanyl-Glutamine (Ala-Gln), a stable dipeptide 
commonly used in parenteral nutrition, has immunomodulatory effects and improved 
resistance of mesothelial cells to PD fluids. Recently, IL-17 was identified as novel player 
in PD induced peritoneal damage. In this study we investigated if intraperitoneal Ala-Gln 
administration confers protection against peritoneal damage by modulating IL-17 expression 
in uremic rodent PD models.
Methods: Uremia was obtained by performing 5/6 nephrectomy and animals were 
daily instilled with PD fluid enriched or not with Ala-Gln during a period of 5 and 8 weeks 
respectively for rats and mice. Mice were injected weekly with recombinant IL-17 or with 
αIL-17. Histological analysis was carried out in parietal peritoneum. Gene expression in the 
parietal peritoneum biopsies was evaluated by real-time quantitative PCR. Protein levels 
were determined by ELISA in peritoneal effluents.
Results: Supplementation of PD fluid with Ala-Gln resulted in reduced peritoneal 
thickness (70.90 ±13.45 vs 16.23 ± 0.70, P<.001), aSMA expression and angiogenesis. 
Addition of Ala-Gln also showed attenuation of PD induced IL-17 mediated pathways, 
reflected by substantial reduction/normalisation of peritoneal levels of IL-17 (32.55 ±3.32 
vs 7.99 ± 1.59, P<.001), TGFβ, IL-6 and ROR(γ)t. Moreover, repeated exposure of the Ala-
Gln treated group to recombinant IL-17 increased peritoneal fibrosis which was however 
restored upon IL-17 neutralization.
Conclusions: These results suggest that intraperitoneal administration of Ala-Gln 
ameliorates PD induced peritoneal damage at least in part by modulating IL-17 expression. 
Therefore, this evidence paves into investigations whether Ala-Gln could be a potential 
strategy to ameliorate peritoneal deterioration during PD.
FR-PO812
JAK1/2 Inhibitor Preserves Peritoneal Membrane Function in a Non-
Uremic Peritoneal Dialysis Rat Model  Tiane Dai,1 Ying Wang,1 Panida 
Ditsawanon,2 Pornanong Aramwit,2 Janine A. La page,1 Sharon G. Adler.1 
1Internal Medicine, LA Biomed at Harbor-UCLA Medical Center, Torrance, 
CA; 2Pharmacy Practice, Chulalongkorn Univ, Bangkok, Thailand.
Background: We previously showed JAK/STAT pathway activation in the peritoneal 
membrane (PM) of rats receiving PD with 4.25% Dianeal for 10 days; concomitant 
treatment with a JAK1/2 inhibitor (JAKi) attenuated PM inflammation, fibrosis, and 
hypervascularity. We also showed that the mean concentration of MCP-1 was higher in the 
PD fluid of patients on long-term PD (>6mos) vs new patients (<2wks), demonstrating the 
potential for clinical relevance (KI.2014). These experiments were performed to determine 
if a JAKi could prevent deterioration of peritoneal membrane function after longer-term 
exposure to PD fluid.
Methods: Tunneled PD catheters were placed in rats who received BID infusions of 
normal saline (n=3), 4.25% Dianeal (n=3), or 4.25% Dianeal + JAKi (n=3) for 12 weeks. 
Peritoneal equilibration testing (PET) was performed at baseline and again after 12 weeks 
of fluid instillation. For PET calculations, dialysate glucose was measured enzymatically 
at time 0 and at 90 minutes after fluid instillation. Plasma and dialysate total protein were 
measured at 90 minutes after dialysate instillation. D/D0 glucose and D/P total protein were 
calculated as [D/D0 glucose (at 12 wks)]; and [D/P total protein (12 weeks – Baseline)/
Baseline] for each rat. Results are expressed as mean + SD for each group.
Results: Both D/Do glucose and D/P total protein functional measurements demonstrate 
that JAKi protects the peritoneal membrane from the damaging effects of 4.25% Dianeal.
Conclusions: Membrane failure limits the use of PD long-term. Strategies that 
preserve PD function are critically needed. Together with our prior results, these studies 
demonstrate the capacity of JAKi to preserve rat PD membrane structure and function 
during PD fluid exposure.
Funding: Other NIH Support - NIH/National Center for Advancing Translational 
Science (NCATS) UCLA CTSI Grant Number UL1TR000124, Government Support - 
Non-U.S.
FR-PO813
MicroRNA Expression Profiling in Peritoneal Fibrosis  Yoshiyuki Morishita,1 
Daisuke Nagata.2  1Div of Nephrology, Dept of Integrated Medicine, Saitama 
Medical Center, Jichi Medical Univ, Saitama, Japan; 2Div of Nephrology, Dept 
of Internal Medicine, Jichi Medical Univ, Shimotuke, Tochigi, Japan.
Background: Peritoneal fibrosis (PF) is an intractable complication leading to 
peritoneal membrane failure in peritoneal dialysis (PD). The aim of this study was to 
identify the microRNAs (miRNAs) involved in PF.
Methods: miRNA screen was performed using microarray analysis in peritoneal tissue 
of PF rats induce by intraperitoneally injection of PD fluid containing methylglyoxal (MGO). 
The expression level of identified miRNAs of serum and drained dialysate were evaluated 
the association of peritoneal membrane functions measured by peritoneal equilibration test 
(D/P Cr and D/D0 glucose) in 33 PD patients. Furthermore, an identified miRNA inhibitor 
(anti-miRNA-21-5p locked nucleic acid: anti-miRNA-21-LNA) was intraperitoneally 
injected to PF model mice to investigate its effects for PF.
Results: The initial profiling study identified 6 miRNAs (miRNA-21-5p, miRNA-221-
3p, miRNA-223-3p, miRNA-142-3p, miRNA-327 and miRNA-34a-5p) increased more than 
two fold and no miRNA decreased less than half in peritoneum tissue of PF rats compared 
with control rats. Among them, serum level of miRNA-21-5p (D/P Cr r=0.44, p=0.01; D/
D0 glucose r=-0.433, p=0.01), miRNA-327(D/P Cr r=0.48, p<0.01; D/D0 glucose r=-0.50, 
p<0.01) and miRNA-221-3p (D/P Cr r=0.50, p<0.01; D/D0 glucose r=-0.50, p<0.01) and 
drained dialysate level of miRNA-221-3p (D/P Cr r=0.52, p<0.01; D/D0 glucose r=-0.46, 
p<0.01) and miRNA-34a-5p (D/P Cr r=0.44, p<0.01; D/D0 glucose r=-0.48, p<0.01) were 
significantly correlated with peritoneal membrane functions in PD patients. Anti-miRNA-
21-LNA significantly inhibited miRNA-21-5p expression in peritoneum of PF mice. It also 
inhibited peritoneal fibrous thickening and maintained better peritoneal membrane functions. 
It significantly increased PPAR-α expression in peritoneum of PF mice.
Conclusions: The results of present study suggested several miRNAs involved in PF, 
and they may be used as the novel diagnosis biomarkers and therapeutic targets for PF.
Funding: Government Support - Non-U.S.
FR-PO814
Nanoparticules of Lipids Associated with Paclitaxel as an Alternative 
Strategy to Block Peritoneal Fibrosis  Filipe M. Silva,1 Rafael Pepineli,1 
Elerson Costalonga,1 Raul Cavalcante Maranhão,2 Irene L. Noronha.1 
1Nephrology Div, Univ of Sao Paulo, Brazil; 2Laboratory of Lipids Metabolism, 
Univ of Sao Paulo, Brazil.
Background: Peritoneal fibrosis (PF) and loss of ultrafiltration represent important 
complications of long term peritoneal dialysis, with limited options of treatment. Advances 
in nanotechnology enabled drug release systems that can provide the release of an active 
drug in the target tissue. Nanoparticles similar to LDL were developed, linked to Paclitaxel 
(NanoPACL), an antiproliferative drug. NanoPACL have the ability to bind to LDL receptors 
present on the cell surface, particularly in immune-inflammatory sites. The aim of this study 
was to analyze the effect of NanoPACL administration in an experimental model of PF.
Methods: PF was induced in Wistar rats by daily IP injections of chlorhexidine 
gluconate (CG) at 0.1% during 15 days. Animals (n=20) were divided into 4 groups: 
Control, normal rats; PF, rats receiving injections of GC; Nano, PF rats treated with 
nanoparticles without Paclitaxel, via IP; NanoPACL, PF rats treated with NanoPACL 
(4mg/kg every 3 days, via IP). Euthanasia was performed on day 30. Peritoneal thickness 
and function, immunohistochemistry and qPCR were analyzed.
Results: NanoPACL significantly reduced peritoneal thickness, α-SMA expression 
and cell proliferation compared with control groups. Treatment with NanoPACL decreased 
TGF-β and Smad 3 mRNA expression and preserved peritoneal function characterized by 
preservation of UF and reduced mass transfer of glucose (MTG).
Control PF Nano NanoPACL
Peritoneal thickness 
(ȝm) 39±5 130±27* 95±10* 40±9
#†
UF (mL) 4±3 -12±2* -7±1* 5±1#†
MTG (g/Kg BW) 342±3 406±6* 393±2* 368±2*#†
α-SMA (%) 0±0 8±1* 7±1* 3±1*#
PCNA (cells/mm2) 1±0 234±32* 203±24* 28±10*#†
TGF-ß 1±0,1 5±1* 4,3±1* 1,8±1#†
Smad3 1±0,1 6±1* 6±1* 3±1#†
*p<0,05 vs Control;#p<0,05 vs PF;†p<0.05 vs Nano.
Conclusions: NanoPACL administration was effective in preventing PF and preserving 
peritoneal function, possibly by local effect of Paclitaxel.
Funding: Government Support - Non-U.S.
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FR-PO815
Vitamin D Receptor Activator (VDRA) Attenuates Epithelial-to-
Mesenchymal Transition (EMT) via Modulation of NAPDH Oxidase 
(NOX) Activity and Mitochondrial Dysfunction in Human Peritoneal 
Mesothelial Cells (HPMC)  Duk-Hee Kang, Jiyeon Ko, Hyun-soo Shin, Eun 
sun Ryu, Hyun-yon Jung, Shina Lee, Dong-Ryeol Ryu, Seung-Jung Kim, Kyu 
Bok Choi.  Dept of Internal Medicine, Ewha Womans Univ School of Medicine, 
Seoul, Republic of Korea.
Background: EMT is known as a key mechanism of peritoneal fibrosis in peritoneal 
dialysis. Oxidative stress induced by NOX and mitochondrial dysfunction is one of the 
mechanisms responsible for EMT. Paricalcitol, a selective VDRA, is known to exert anti-
fibrotic effect organ fibrosis, however there are no studies about the role of paricalcitol 
on peritoneal fibrosis. We investigated whether paricalcitol imposed any effect on 
TGFb1-induced EMT of HPMC with an exploration of mechanism of antifibrotic effect 
of paricalcitol in terms of modulation of oxidative stress.
Methods: EMT was evaluated by morphological changes of HPMCs and the 
expressions of E-cadherin and α-smooth muscle actin. Intracellular ROS was analyzed by 
measuring NOX activity, H2O2 generation, NOX mRNA expressions with DCF-DA and 
MitoSoxR staining. Activation of Erk1/2, p38 MAPK, nuclear translocation of β-catenin 
and snail expression were assessed by western blotting and immunocytochemistry. Effect 
of paricalcitol on ROS generation and EMT was analyzed in HPMC exposed to TGFb1.
Results: TGFb1 (1ng/ml) induced EMT of HPMCs with an increase in ROS generation 
and NOX activity from 30 minutes, and mitochondrial ROS production from 6 hours. TGFb1 
also increased the phosphorylation of Erk and p38 MAPK from 1hour, which was followed 
by nuclear translocation of β-catenin and snail up-regulation in HPMC. Paricalcitol (50nM) 
ameliorated TGF-β1-induced EMT in HPMC, which was associated with a decrease in both 
NOX- and mitochondria-mediated ROS production. TGFb1-induced EMT was partially 
alleviated by N-acetyl cysteine (5mM) or apocynin (100µM), which was further inhibited 
by an addition of rotenone (1µM) or paricalcitol.
Conclusions: One of the VDRAs, paricalcitol, ameliorated TGFb1-induced EMT of 
HPMCs by a decreased in ROS generation in HPMCs. Anti-oxidant effect of paricalcitol 
seems to be related to the direct inhibition of NOX and mitochondria-mediated ROS 
production.
Funding: Government Support - Non-U.S.
FR-PO816
Adenosine Monophosphate-Activated Protein Kinase (AMPK) Agonist 
Attenuated Epithelial-to-Mesenchymal Transition (EMT) of Mesothelium 
and Peritoneal Fibrosis via an Amelioration of Oxidative Stress 
Duk-Hee Kang,1 Jiyeon Ko,1 Eun sun Ryu,1 Hyun-yon Jung,1 Shina Lee,1 
Dong-Ryeol Ryu,1 Seung-Jung Kim,1 Kyu Bok Choi,1 Sun-Hee Park,2 Yong-Lim 
Kim.2  1Dept of Internal Medicine, Ewha Womans Univ School of Medicine, 
Seoul, Republic of Korea; 2Kyungpook National Univ School of Medicine, 
Daegu, Republic of Korea.
Background: Phenotype transition of peritoneum has been regarded as an early 
mechanism of peritoneal fibrosis. Metformin, one of the AMPK agonists, has recently 
received a new attention due to an inhibitory effect on EMT of cancer cells. We investigated 
whether metformin imposed any effect on EMT of HPMC with an exploration of cellular 
mechanism for anti-fibrotic effect of metformin.
Methods: EMT was evaluated by morphological changes and the expressions of 
E-cadherin and α-SMA after stimulation of TGFb1 (1ng/ml). ROS generation was analyzed 
by DCF-DA, NOX activity, NOX mRNA expressions, and MitoSoxR staining. Activation 
of Smad2/3, MAPK, nuclear translocation of β-catenin and snail expression were also 
assessed. Animal model of peritoneal dialysis (PD) was established by daily infusion of 
4.25% glucose-based dialysate for 8 weeks via intraperitoneal catheter. Effects of metformin 
(50 mg/kg/day, ip) on EMT, peritoneal thickening and an expression of markers of oxidative 
stress were investigated.
Results: TGFb1-induced EMT in HPMC was ameliorated by metformin. TGFb1 
increased ROS generation and NOX activity from 30 min, and mitochondrial ROS 
production from 6 hrs. TGFb1 increased the phosphorylation of smad2/3 and MAPK, which 
was followed by nuclear translocation of β-catenin and snail up-regulation. Metformin 
ameliorated ROS production, the activation of smad2/3 and MAPK, and snail expression. 
In PD model, metformin decreased peritoneal thickness and EMT with an increase in 
ratio of reduced to oxidized glutathione and superoxide dismutase activity. Metformin 
also decreased the expression of nitrotyrosine in peritoneum and 8-OHdG in dialysate.
Conclusions: AMPK may play a role in preservation of peritoneal function by 
protecting the peritoneum from phenotype transition and fibrosis via an amelioration of 
oxidative stress.
Funding: Government Support - Non-U.S.
FR-PO817
Twist Accelerates Human Peritoneal Mesothelial Cells Proliferation and 
Fibrosis by Regulating YB-1  Lijie He.  Dept of Nephrology, Xijing Hospital, 
Xi’an, China.
Background: We have previously shown that E-box–binding transcription factor Twist 
is overexpressed in high glucose damage of human peritoneal mesothelial cells (HPMCs) 
and is involved in peritoneal membrane (PM) fibrosis in vitro. Here, we further identify 
its precise function related to peritoneal membranes (PM) fibrosis.
Methods: We have previously shown that E-box–binding transcription factor Twist 
is overexpressed in high glucose damage of human peritoneal mesothelial cells (HPMCs) 
and is involved in peritoneal membrane (PM) fibrosis in vitro. Here, we further identify 
its precise function related to peritoneal membranes (PM) fibrosis.
Results: Here, up-regulated expression and activation of Twist and YB-1 were found 
in HPMCs under extensive periods of PM fibrosis ex vivo. In immortal HPMCs and in 
HG-induced PD animal model, Twist and YB-1 were also up-regulated and a transformed 
fibroblastic phenotype of HPMCs was found stimulated by high glucose (HG, 60 mmol/L).
Evidence from chromatin immunoprecipitation and reporter assays further supported 
that YB-1 were transcriptionally regulated by Twist directly binding to E-box. Collectively, 
these data suggested that YB-1 was a major downstream target of Twist. Re-expression of 
Twist led to decrease HPMCs growth, induced cell cycle arrest and increase PM fibrosis. 
Silencing of Twist or YB-1 could promote cell cycle progress of HG-induced HPMCs 
growth, increasing cyclin D1/CDK2 and cyclin E/CDK4 expression and also inhibited 
PM fibrosis
Conclusions: Our data suggested that activation of Twist/YB-1 pathway might 
contribute to the growth retardation of HPMCs and the progressive PM fibrosis during PD.
Funding: Government Support - Non-U.S.
FR-PO818
The Expression of miRNA200a in Peritoneal Dialysis Associated Peritoneal 
Fibrosis  Xin Wei.  Nephrology Dept, The First Affiliated Hospital of Nanchang 
Univ, Nan Chang, China.
Background: Peritoneal fibrosis (PF) is an almost invariable consequence of peritoneal 
dialysis (PD), which is an established alternative for the replacement therapy of end-stage 
renal disease. We know that miR-200a belong to miR-200 family,which is closely related 
to a variety of fibrotic diseases.However, the role of miR-200a in peritoneal fibrosis is 
largely unknown.
Methods: The peritoneal fibrosis mouse model associated with PD was established by 
intraperitoneal injection of lipopolysaccharide + 4.25% peritoneal dialysate. The expression 
of miRNA was detected by microarray. The expression of miRNA profiles between fibrotic 
and normal peritoneal tissues was compared (n=3 in each group). The differentially 
expressed miRNA (miR-200a) was validated by real-time PCR in lager sample size cohorts 
(n=15). The expressions of miR-200a were also detected in the epithelial-mesenchymal 
transition (EMT) process of peritoneal mesothelium cells.
Results: In mice model of PD, peritoneal tissue was markedly thickened and with a 
massive extracellular matrix accumulation. By miRNA microarray analysis, miR-200a 
was significantly down regulated (3.31 folds change, P<0.05) infibrotic peritoneal tissues. 
The down-regulated expression level of miR-200a was also validated by real-time PCR in 
larger cohorts (P<0.05). Then, the expression level of miR-200a was detected in the EMT 
process of human peritoneal mesothelium cells. During the process of TGF-β1 induced 
EMT, miR-200a was significantly down-regulated compared with the control (P<0.05) 
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Conclusions: Down-regulated expression of miR-200a was observed both during 
peritoneal fibrosis and TGF-β1 induced EMT in vivo and in vitro, suggesting that miR-
200a may be involved in the peritoneum fibrosis by regulating the target genes of EMT.
Funding: Government Support - Non-U.S.
FR-PO819
Peritonitis Induces Native and EDA+ Fibronectin Synthesis in Human 
Peritoneal Mesothelial Cells Through PI3K and MAPK Activation 
Susan Yung, Na Li, Mel Chau, Mandy K. M. Kam, Daniel Tak Mao Chan.  Dept 
of Medicine, The Univ of Hong Kong, Hong Kong.
Background: Peritonitis is a severe complication of peritoneal dialysis (PD), which 
could lead to progressive structural and functional deterioration of the peritoneum and 
PD failure. EDA+ fibronectin (FN) is induced during disease states, but its expression in 
PD associated peritonitis has not been investigated. We examined peritoneal expression 
of native and EDA+ FN in an experimental model of peritonitis and their association with 
mesothelial epithelial-to mesenchymal transition.
Methods: Male C57BL/6 mice were challenged with PBS or lipopolysaccharide 
(LPS, 500mg) by intraperitoneal injection for 2, 3 and 6 times (n=6), after which time the 
parietal peritoneum was excised for further studies. Confluent, growth arrested human 
peritoneal mesothelial cells (HPMC) were stimulated with spent peritonitis PD fluid, LPS, 
or exogenous TGF-β1 or CTGF (growth factors that are increased during peritonitis) either 
alone or in combination, for periods up to 72h to investigate their effect on cell morphology, 
and FN, collagen and SNAIL synthesis.
Results: Mice exposed to six, but not fewer, challenges of LPS exhibited mesothelial 
denudation, influx of infiltrating cells and substantial submesothelial thickening attributed 
to increased collagen and native and EDA+ FN deposition. Peritonitis PD fluid induced 
phenotypic changes, and SNAIL, collagen I, and native and EDA+ FN synthesis in HPMC. 
Exogenous TGF-β1, but not CTGF, significantly increased native and EDA+ FN by 4.3-
fold and 6.2-fold respectively (P<0.05 for both). Cells co-stimulated with TGF-β1 and 
CTGF showed synergistic increase of native and EDA+ FN. This was mediated in part 
through PI3K, ERK and p38 MAPK activation. TGF-β1 and CTGF neutralizing antibody 
significantly decreased native and EDA+ FN synthesis, but had no effect on collagen I or 
SNAIL expression in HPMC.
Conclusions: Our data demonstrated that peritonitis, especially when recurrent, induced 
progressive peritoneal deposition of collagen, and native and EDA+ FN. TGF-β1 and CTGF 
synergistically induced native and EDA+ FN synthesis in HPMC, and play important roles 
in peritoneal fibrosis induced by bacterial peritonitis.
Funding: Government Support - Non-U.S.
FR-PO820
Effects of Astragaloside IV against the TGF-β-Induced Epithelial-to-
Mesenchymal Transition in Peritoneal Mesothelial Cells by Promoting 
Smad 7 Expression  Lu Zhang,1,2 Zhenghong Li,2 Weiming He,2 Lingdong Xu,2 
Jing Wang,3 Jun Shi,1 Meixiao Sheng.1,2  1the First Clinical Medical College, 
Nanjing Univ of Chinese Medicine, Nanjing, Jiangsu Province, China; 2Renal 
Div, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, 
China; 3Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 
Jiangsu Province, China.
Background: To investigate the effect of Astragaloside IV (AS-IV) on the regulation of 
the TGF-β1 Smad signaling pathway in mesothelial cells with an epithelial-to-mesenchymal 
transition (EMT).
Methods: EMT of human peritoneal mesothelial cells (HMrSV5) was induced using 
2 ng/ml TGF-β1. Cells were randomly divided into a vehicle group, a vehicle group with 
AS-IV, a TGF-β1 treated group, and a TGF-β1 treated group receiving varied doses of AS-IV 
or NAC. Real-time quantitative PCR and western blot were used to detect the expression 
of genes and proteins associated with the TGF-β1/Smad signaling pathway and EMT. 
DCFH-DA was used to detect the generation of ROS in HMrSV5 cells, and a transwell 
migration assay was used to verify the capacity of AS-IV to inhibit EMT in HMrSV5 cells. 
Lentiviruseswere used as carriers for theoverexpression or knockdown of the Smad7 gene.
Results: Expression levels of E-cadherin (epithelial marker) was decreased and 
vimentin, α-SMA (EMT markers) and collagen I (extracellular matrix protein) phospho-
Smad2/3, Snail1 and Snail2 was increased significantly in the TGF-β1-treated HMrSV5 
cells. AS-IV was associated with downregulated expression of vimentin and phospho-
Smad2/3 in a dose-dependent manner, while the expression of Smad7 increased. Silenced 
or forced expression of Smad7 verified its role in the inhibitory effect of AS-IV on TGF-
β1-induced EMT in HMrSV5 cells.
Conclusions: AS-IV effectively promotes the upregulation of Smad7 in the TGF-β1/
Smad signaling pathway during the EMT of HMrSV5 cells, indicating its potential 
therapeutic effect for the control of PF.
Funding: Government Support - Non-U.S.
FR-PO821
Extracellular Vesicles in Peritoneal Effluent  Deirisa Lopes Barreto,1 Anita 
N. Böing,2 Rienk Nieuwland,2 Anita Grootemaat,2 Raymond T. Krediet.1 
1Nephrology, AMC-UvA, Netherlands; 2Clinical Chemistry, .
Background: Continuous and long-term exposure to peritoneal dialysis (PD) solutions 
induces constant low-grade inflammation and remodeling of peritoneal membrane 
morphology. Although the biochemical composition of peritoneal effluent offers the 
opportunity to explore the peritoneal membrane status in a simple and non-invasive manner, 
to date no clinically useful effluent biomarker has been identified that reflects the peritoneal 
membrane integrity sufficiently. As human body fluids contain extracellular vesicles (EVs), 
which are now believed to provide novel biomarkers for diseases, we investigated the 
presence of EVs in peritoneal effluent.
Methods: Peritoneal effluent of a short-term PD patient was collected from a 
regular dialysis dwell. After centrifugation, aliquots of cell-free effluent were frozen in 
liquid nitrogen and stored at -80°C until analysis. EVs were isolated by size exclusion 
chromatography. Thereafter, transmission electron microscopy (TEM) and flow cytometry 
(comprising markers for epithelial and mesothelial cells, leucocytes, platelets and 
erythrocytes) were used to detect the presence of single EVs.
Results: EVs and liposomes were identified by TEM and flow cytometry. EVs exhibited 
their characteristic cup shape. The majority of EVs had a mean diameter <100nm, and 
were present in similar amounts as in human plasma. Most EVs originate from epithelial 
and mesothelial cells. Moreover, EVs stained positive for leucocyte antigens, mesothelin 
and cancer antigen 125. 
Conclusions: This is the first study to demonstrate the presence of EVs in human 
peritoneal effluent. Furthermore, the cellular origin of most peritoneal EVs is established. 
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We postulate that the presence and composition of such EVs in peritoneal effluent will 
closely mirror the peritoneal membrane morphology. Future studies will be necessary to 
investigate the clinical relevance for the detection of peritoneal membrane damage and 
potential use of these peritoneal EVs in PD patient care.
FR-PO822
miR-200a Negatively Regulates TGF-β1-Induced Peritoneal Mesothelial 
Cell Epithelial-Mesenchymel Transition by Targeting ZEB1 and ZEB2 
Expression  Xin Wei, Guojun Hao, Qinkai Chen.  Nephrology Dept, The First 
Affiliated Hospital of Nanchang Univ, Nan Chang, China.
Background: Peritoneal fibrosis (PF) is an almost invariable consequence of peritoneal 
dialysis (PD), which is an established alternative for the replacement therapy of end-stage 
renal disease. In our previous study, we found that the expression level of miR-200a were 
down-regulated in fibrotic peritoneum and the epithelial-mesenchymal transition (EMT) 
process of peritoneal mesothelial cell.However, the role of miR-200a in EMT of peritoneal 
mesothelial cell and peritoneal fibrosis is largely unknown.
Methods: Human peritoneal mesothelial cell line (HMrSV5) was cultured in the 
presence or absence of TGF-β1. The protein expression levels of EMT index and E-box-
binding homeobox (ZEB) 1/2 were determined by western blot. The level of miR-200a 
was determined by real-time PCR. miR-200a mimic or inhibitor and it negative control 
RNA,were transfected into HMrSV5 cells using Liptofectamine 2000.
Results: We found that miR-200a mimic can attenuated TGF-β1 induced peritoneal 
mesothelial cell EMT and synthesis of extracellular matrix. It was also demonstrated that 
the miR-200a was responsible for protecting peritoneal mesothelial cells from mesenchymal 
transition by targeting suppression of ZEB1/2.
Conclusions: The results suggested that miR-200a may not only be a useful biomarker 
of EMT in ovarian cancer, but also of potential therapeutic value in peritoneal fibrosis.
Funding: Government Support - Non-U.S.
FR-PO823
Identification and Functional Characterization of Human Peritoneal 
Fibroblast Subsets According to the Expression of CD90/Thy-1 
Edyta Kawka,1 Andras Rudolf,2 Maria Bartosova,3 Rusan Catar,1 Janusz 
Witowski,2 Duska Dragun,1 Achim Joerres,1 Claus P. Schmitt.3  1Dept of 
Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, 
Berlin, Germany; 2Depts of Pathophysiology and Clinical Immunology, Poznan 
Univ of Medical Sciences, Poznan, Poland; 3Center for Pediatric and Adolescent 
Medicine, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Background: The exact origin of myofibroblasts in PD-associated peritoneal fibrosis 
is unknown. Lineage tracing studies suggest that resident submesothelial fibroblasts may be 
their major precursors. Here, we set out to identify HPFB subsets in human peritoneum and 
examined co-expression of CD90/Thy-1 with markers of the myofibroblastic phenotype.
Methods: HPFB were isolated from omentum, purified and then separated (MACS) 
into CD90/Thy-1+ and CD90/Thy-1- populations for assessment of myofibroblastic markers: 
qPCR, immunofluorescence, and ELISAs. Moreover, the presence of FSP-1+ and CD90/
Thy-1+ fibroblasts was studied by immunofluorescence in peritoneal biopsies of 12 PD, 5 
uremic patients, and 8 healthy controls.
Results: Cells positive for FSP-1 or CD90/Thy-1 were absent in healthy controls, but 
were detectable in uremic and PD patients. In those, the majority (>95%) of FSP-1+ HPFB 
were also CD90/Thy-1+. In vitro studies showed that CD90/Thy-1+ HPFB had a 1.2-fold 
higher proliferation rate (MTT assay; n=12, p<0.05) than CD90/Thy-1- . Expression of 
myofibroblastic markers in CD90/Thy-1+ cells was significantly higher with α-SMA, 
collagen-1 and TGF-β1 being increased (2.5-, 1.6- and 1.8-fold, respectively; n=13, p<0.05). 
Furthermore, CD90/Thy-1+ HPFB revealed increased contractile properties as reflected by 
1.2-fold greater reduction in collagen gel contraction assays (n=3).
Conclusions: The vast majority of FSP-1+ HPFB detected in the peritoneum of uremic 
and PD patients expressed CD90/Thy-1. In contrast, this phenotype was not detected in 
normal peritoneum. In vitro studies demonstrated increased expression of myofibroblastic 
markers in CD90/Thy-1+ HPFB. These cells may thus contribute to peritoneal fibrosis which 
often develops in patients during chronic PD.
FR-PO824
Innovative Index to Follow the Peritoneal Infections and for Monitoring 
the Recovery Process After Pertionitis  Grazia Maria Virzì, Sabrina Milan 
manani, Alessandra Brocca, Massimo de Cal, Ilaria Tantillo, Carlo Crepaldi, 
Claudio Ronco.  Nephrology, San Bortolo Hospital-IRRIV.
Background: Cell-free DNA is present in the peritoneal effluent of stable PD patients, 
but there is no data on cfDNA in case of peritonitis. We investigated the variation of 
peritoneal cfDNA (pcfDNA) levels in PD-related peritonitis.
Methods: We enrolled 53 PD patients: 30 without any history of systemic inflammation 
and peritonitis in the last 3 months (groupA) and 23 with acute peritonitis (groupB). 
PcfDNA were quantified i by Real-Time PCR. Peritoneal samples on day 1-3-10-30 and 
until the 120th from the start of peritonitis were collected for WBC counts and pcfDNA 
evaluation in group B.
Results: Quantitative analysis of pcfDNA showed significantly higher levels in groupB 
compared with groupA (p<0.01), similarly as WBC. PcfDNA showed significantly higher 
levels in groupB on day1-3-10 and 30 compared with groupA (p<0.05). A significant positive 
correlation was observed between pcfDNA level and WBC on day1 (rho=0.89) and day3 
(rho=0.5)(both p<0.05). No statistically significant correlation was observed on day10 and 
30. In groupB, pcfDNA tends to progressively decrease. From this decreasing curve, we 
estimated that 49 days are necessary to reach the value of 51 GE/ml (75percentile in groupA) 
and 63 days to reach 31 GE/ml (median). We observed a new rapid increase of cfDNA 
level (consistent with WBC) in 5 relapsing patients, at the first day of relapsing peritonitis.
Conclusions: in conclusion, pcfDNA increased in peritoneal effluent in PD-realated 
peritonitis and tended to progressively decrease in relation with membrane repair process. 
Peritoneal cfDNA could be a new method to determine acute damage and an inverse index 
of repair process. PcfDNA could help to evaluate functional and structural integrity of 
peritoneal membrane and to follow the evolution of infections during peritonitis.
FR-PO825
The Role of Cell-Free DNA for Managment in PD-Related Peritonitis 
Grazia Maria Virzì, Sabrina Milan manani, Alessandra Brocca, Massimo de Cal, 
Ilaria Tantillo, Carlo Crepaldi, Claudio Ronco.  Nephrology, IRRIV-St Bortolo.
Background: Peritonitis and exit site infections are the major complications of PD 
and remains the major cause of switch from HD. In this study, we investigated the role of 
peritoneal cell-free DNA (cfDNA) and its association with peritonitis.
Methods: We enrolled 23 PD patients with peritonitis and without any history of 
systemic inflammation (14 male, mean age: 68±16yrs). cfDNA were extracted and quantified 
in peritoneal effluent by Real Time PCR for β-globin gene.
Results: All patients were treated and clinically recovered from peritonitis in 
13.5±5.4days.18/23 patients had a first episode of peritonitis and responded to first-line 
antibiotics (65% Gram+, 22% Gram- and 13% sterile), whereas 5/23 had a relapsing 
episode of peritonitis (responded to other course of intra-peritoneal antibiotics). There 
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was no difference in cfDNA levels between Gram+/Gram-peritonitis; patients with single 
episode and relapsing peritonitis, but there was a significantly difference in cfDNA between 
PD patients with positive and negative outcomes (n=4), defined as death (p<0.05). CfDNA 
showed significantly higher levels in 3 patients required catheter removal(p<0.05).There 
was no difference in cfDNA levels between PD patients with a negative history of previous 
peritonitis (n=3) and PD patients with a positive history (n=20)(p=0.48). there was no 
statistically significant correlation between cfDNA and number of previous peritonitis 
(rho=0.13, p=0.55).
Conclusions: This pilot study provided substantial basis for further investigations 
of molecular mechanisms of peritoneal injury and potential clinical application of 
cfDNA. cfDNA could provide some additional information about patient’s outcome and 
management. These results can be considered hypothesis generating, and stimulate further 
exploration of a prognostic and predictive role of cfDNA in PD-related peritonitis.
FR-PO826
Epimorphin Expressions in Mice Model of Peritoneal Fibrosis 
Muneharu Yamada, Takashi Oda, Shuuhei Komatsu, Taito Oshima, Tadasu 
Kojima, Yasuyo Sudo, Tomohiro Tomiyasu, Noriko Yoshikawa, Masahru 
Yoshida.  Nephrology, Hachioji Medical Center of Tokyo Medical Univ, Hachioji, 
Tokyo, Japan.
Background: Long-term peritoneal dialysis induces peritoneal fibrosis in 
submesothelial areas. Epimorphin is a mesenchymal protein that regulates epithelial 
morphogenesis through epithelial-mesenchymal interactions, has recently attracted attention 
as an important modulator of tissue repair. We previously reported that epimorohin was 
involved in the repair of fibrosis in mice (Lab Invest 2010). In this study, we evaluated the 
epimorphin expressions in the peritoneal fibrosis mice model.
Methods: Peritoneal fibrosis was induced by the injection of 0.1% chlorhexidine 
gluconate in 15% ethanol and 85% normal saline (CG-injected mice) into peritoneal 
cavity of 10 week-old male C57/Bl6 mice every other day. Control mice received 
intraperitoneal injection of normal saline. The mice were sacrificed 3 weeks after the first 
CG injection and peritoneal tissues were dissected out. Morphologic peritoneal changes 
were assessed by Masson’s Trichrome staining. Epimorphin expressions were assessed by 
immunohistochemically and real-time RT-PCR.
Results: In CG-injected mice, the marked thickening of the submesothelial compact 
zone was shown in Masson’s trichrome staining. IF staining for epimorphin was positive 
in the submethothelial area corresponding to the fibrotic area. Epimorphin staining was 
significantly stronger than that in control mice. Such an increase in epimorphin expression 
was confirmed by and by real-time RT-PCR (n=5, p<0.05 vs control).
Conclusions: These findings suggest that epimorphin expression may have pivotal 
role in the repair of peritoneal fibrosis similar to that of UUO release model in mice as 
reported previously.
Funding: Government Support - Non-U.S.
FR-PO827
Peritoneal Mesothelial Cells (PMCs) Injury Induced by Neutral Peritoneal 
Dialysis Solution (NPDS) and Its Amelioration by Molecular Hydrogen (H2) 
Wan-jun Zhu,1,2 Kimio Watanabe,1 Hiroyuki Terawaki,1 Yoshimitsu Hayashi,1 
Naoki Nakanishi,3 Shigeru Kabayama,2 Masaaki Nakayama.1  1Dept of Kidney 
and Hypertension, Medical School, Fukushima Medical Univ, Fukushima, 
Japan; 2Medical Device, Nihon Trim Co. Ltd, Osaka, Japan; 3Business Strategy 
& Management, Nihon Trim Co. Ltd, Osaka, Japan.
Background: PMCs play pivotal roles in suppression of peritoneal fibrosis, adhesion, 
and bacterial infection in PD therapy. It is reported that histological changes of peritoneum 
and incidence of encapsulating peritoneal sclerosis, have been decreased by NPDS 
intruduction. However, meta-analysis did not show superiority of NPDS in incidence of 
bacterial peritonitis, suggesting bio-incompatibility of current NPDS. H2 has anti-oxidative 
effects in biological way, and its clinical application has been studied. The present study 
aims to examine PMC injury by NPDF, and its ameliorating effect of H2.
Methods: Male SD rats (n=24) were divided into three groups: control (Con), 2.5% 
glucose lactate-based NPDS (PD), and the same NPDS with dissolved H2 (400 ppb) 
(HPD). The latter two groups were given NPDS or H2-NPDS intraperitoneally for 10-day 
20 mL once a day. Peritoneal tissues were subjected to morphological analysis including 
immunohistochemistry (cytokeratin, vimentin, proliferation; Ki67, and apoptosis; M30 
cytodeath), and PMCs obtained to gene analysis by real time PCR, and microarray assay.
Results: The collagen thickness increased in PD and HPD, however, there were 
significant changes in stainings of vimentin, M30 cytodeath, and Ki67 in PD as compared 
to Con, while no change in HPD. In gene cluster analysis, there were changes by 8.7% in 
whole gene expression between PD and Con, and 3.7% changes between PD and HPD. In 
PCR, no difference was found in Epithelial-Mesenchymal Transition (Snail, TGF-β, aSMA) 
among the groups, while wound healing (MMP9, CTGF, Fibronectin, FAK), cytokines 
(IL1b, TNFa,NFkb) were decreased in PD as compared to Con, but no changes in HPD.
Conclusions: The current lactate-based NPDS may disturb wound healing and 
local immunity of PMCs, and H2 dissolved dialysate correct them. H2 could increase 
biocompatibility of PDS in preserving physiological function of PMCs in PD therapy.
FR-PO828
Bicarbonate-Buffered Peritoneal Dialysis Solution Suppresses Lactate-
Induced Apoptosis via Monocarboxylate Transporter-1 in Human 
Peritoneal Mesothelial Cells  Akihiro Kuma, Tetsu Miyamoto, Ryota Serino, 
Yumi Furuno, Yoko Fujimoto, Hiromichi Ueno, Yutaka Otsuji, Masahito 
Tamura.  Dept of Nephrology, Univ of Occupational and Environmental Health, 
Kitakyushu, Japan.
Background:   Long-term peritoneal dialysis is associated with functional and 
structural alterations of the peritoneal membrane. Lactate-buffered peritoneal dialysis 
fluid (L-PDF) has impaired biocompatibility due to the presence of supra-physiological 
levels of lactate. Although bicarbonate-buffered PDF (B-PDF) has been developed, its 
biocompatibility remains unclear. Here, we investigated the effects of L- or B-PDF on cell 
viability and apoptosis in cultured human peritoneal mesothelial cells (HPMCs), focusing 
on monocarboxylate transporters (MCT).
Methods: HPMCswere cultured in mediums containing 10% fetal bovine serum and 
L-PDF with 1.5% glucose (L1) or 2.5% glucose (L2), B-PDF with 1.5% glucose (B1) or 
2.5% glucose (B2), or no PDF (control). Cell viability and apoptosis were measured with 
the WST-1 and TUNEL assays, respectively. The roles of MCT-1 and -4 on lactate-induced 
apoptosis were evaluated by siRNA transfection for MCT-1 and -4.
Results:   Cell viability was significantly decreased in cells incubated with L1 
(12±2%, control=100%) and L2 (2±1%), compared with B1 (74±2%) and B2 (72±1%) 
after 72 h incubation. Apoptotic cells were also increased in L1 (69±16%), L2 (73±8%) 
compared with B1 (3±0%) and B2 (4±1%). MCT-1 and -4 protein and mRNA expression 
levels, examined by Western blotting and real-time-PCR, respectively, were similar in all 
cells. Protein expression levels of MCT-1 and -4 were almost completely diminished after 
transfection of siRNAs for MCT-1 and -4, respectively. MCT-1 siRNA increased the levels 
of cell viability by 3.2–3.7-fold and decreased the amount of apoptotic cells from 64±8% 
to 47±4% in cells treated with L1 for 72 h. Interestingly, MCT-4 siRNA had no effect on 
cell viability and apoptosis.
Conclusions: Our results showed that L-PDF induced apoptosis by importing lactate 
via MCT-1 in HPMCs, and suggest that B-PDF improved biocompatibility by inhibiting 
mesothelial cell apoptosis.
FR-PO829
MiRNA-143/145 Gene Cluster Enhances Cell Deformation and Fibrosis of 
Human Peritoneal Mesothelial Cells via Modulating TPM4  Lijie He, Shiren 
Sun.  Dept of Nephrology, Xijing Hospital, Xi’an, Shaanxi, China.
Background: In this study, we work for the function and mechanism of miR-143/145 
gene cluster in human peritoneal mesothelial cells (HPMC), who were as possible triggers 
for peritoneal membrane fibrosis.
Methods: To investigate if miR-143/145 gene cluster could promote PM fibrosis, 
all these immortal HPMCs were characterized by fibrosis related markers and tested the 
expression of miRNA-143/145 cluster and tropomyosin4 (TPM4) by real time PCR or 
Western blot. We also used PD dialysis rat model to observe the response of PM to miR-
143/145 gene cluster and their possible target.
Results: Here, we found that miR-143/145 gene cluster, which are examined to be 
highly expressed in HG-induced HPMCs (HG, 60 mmol/L) and in PD animal model. 
TPM4 were found significantly lower expression in HG-induced HPMCs. So our study 
showed that high glucose from PD fluid could promote the expression of miR-143/145 
of HPMCs and reduce the expression of TPM4, compared with normal glucose-cultured 
HPMCs . Reporter assays further supported that TPM4 were post-transcriptionally regulated 
together by miR-143/145 gene cluster. Collectively, these data suggested that TPM4 was 
a downstream target of miR-143/145 gene cluster. Re-expression of miR-143/145 gene 
cluster by miR-143 or miR-145 mimic led to cell deformation, and reduced cell adhesion, 
following the down-regulating expression of TPM4 and E-cadherin, but up-regulating 
expression of α-SMA, CTGF, collagens and fibronectin which might increase PM fibrosis. 
Depletion of miR-143/145 cluster in HG-induced HPMCs enhanced cell adhesion, marking 
by up-regulating E-cadherin and TPM4 but down-regulating α-SMA, CTGF, collagens and 
fibronectin in vitro. Mechanistically, miR-143/145 gene cluster were characterized to target 
the messenger RNA TPM4 to contribute to the cell adhesion, deformation and fibrosis.
Conclusions: Our data suggested that miR-143/145-TPM4 pathway might contribute 
to the cell deformation of HPMCs and the progressive PM fibrosis during PD.
Funding: Government Support - Non-U.S.
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FR-PO830
Mitochondrial DNA Copy Number Is Associated with Peritoneal Dialysis 
Failure in Younger and Metabolically Healthier Peritoneal Dialysis Patients 
Jae Eun Um,1 Jong Hyun Jhee,2 Kyoung Sook Park,2 Chang-Yun Yoon,2 Mi 
Jung Lee,2 Jung Tak Park,2 Shin-Wook Kang,1,2 Tae-Hyun Yoo.1,2  1Severance 
Biomedical Science Inst, Brain Korea 21 PLUS, Yonsei Univ College of 
Medicine, Seoul, Korea; 2Dept of Internal Medicine, Yonsei Univ College of 
Medicine, Seoul, Korea.
Background: Insulin resistance and inflammation are known to be closely related to 
adverse outcomes in peritoneal dialysis (PD) patients. Recently, mitochondrial function has 
been reported to play a key role in glucose metabolism as well as systemic inflammation in 
various populations. However, the clinical consequences of mitochondrial function in PD 
patients are not well known. Therefore, this study was aimed to investigate the relationship 
of mitochondrial DNA (mtDNA) copy number and clinical outcome in PD patients.
Methods: A total of 120 prevalent PD patients were recruited. mtDNA copy number 
was counted by a PCR based method. Primary outcome was PD catheter removal due 
to ultrafiltration failure. Metabolic syndrome was defined using the Modified National 
Cholesterol Education Program (Adult Treatment Panel III) criteria. Cox proportional 
hazard analysis was performed to determine the independent association of mtDNA copy 
number with primary outcome.
Results: The mean age was 52.3 years and 52 patients (42.5%) were male. The mean 
mtDNA copy number was 29.1±14.9. During a mean follow-up duration of 59.4±39.3 
months, primary outcome was observed in 54 patients (45.0%). There were no significant 
differences in baseline characteristics between non-PD failure and PD failure group except 
for serum adiponectin levels (20.5±7.3 vs. 17.5±7.3 mg/mL, P=0.028). mtDNA copy number 
was not significantly associated with PD failure in multivariate Cox analysis [hazard ratio 
(HR)=0.995, 95% confidence interval (CI)=0.976-1.015, P=0.634]. However, a subgroup 
analysis revealed that mtDNA copy number was an independent predictor of PD failure in 
patients younger than 55 years without metabolic syndrome (HR=0.819, 95% CI=0.692-
0.970, P=0.020) after adjustment for confounding factors.
Conclusions: mtDNA copy number may be associated with ultrafiltration failure in 
younger and metabolically healthier patients treated with PD.
FR-PO831
IL-6 Induces VEGF Production by Human Peritoneal Mesothelial Cells 
During Peritonitis Through SP4-Mediated Trans-Signaling with sIL-
6R  Rusan Catar,1 Janusz Witowski,1,2 Nan Zhu,1 Christian Luecht,1 Andras 
Rudolf,2 Duska Dragun,1 Achim Joerres.1  1Nephrology and Medical Intensive 
Care, Charité-Universitätsmedizin Berlin, Berlin, Germany; 2Pathophysiology, 
Poznan Univ of Medical Sciences, Poznan, Poland.
Background: Vascular endothelial growth factor (VEGF) has been implicated in 
peritoneal angiogenesis and membrane remodelling in peritoneal dialysis (PD). Human 
peritoneal mesothelial cells (HPMC) have been identified as a major source of VEGF in 
the peritoneum. However, the exact mechanism of VEGF induction in HPMC is unclear. 
Since IL-6 concentrations in the drained dialysate correlate with VEGF levels, the link 
between the two has been suggested. While HPMC do not bear classical IL-6 receptor, 
they can respond to IL-6 trans-signalling that involves soluble IL-6 receptor (sIL-6R). 
Here, we have examined whether this mechanism can underlie VEGF synthesis by HPMC.
Methods: HPMC were isolated from normal omentum. Dialysate effluent was 
obtained from stable PD patients and during peritonitis. VEGF mRNA and protein levels 
were measured by RT-qPCR and ELISA, respectively. The involvement of transcriptional 
factors was assessed by EMSA, transient transfections with VEGF promoter constructs, 
and siRNA silencing.
Results: IL-6 and sIL-6R alone had no effect on VEGF release by HPMC . However, 
the exposure to IL-6+sIL-6R resulted in a time- and dose-dependent induction of VEGF 
mRNA and protein. The combination of IL-6+sIL-6R activated the VEGF promoter region 
that contained high affinity binding sites for the transcription factor SP4. Specific mutation 
of the SP4 binding site eliminated VEGF promoter activation. In turn, the induction of 
SP4 was controlled by STAT3. Exposure of HPMC to dialysate effluent obtained during 
acute peritonitis and containing increased levels of IL-6 and sIL-6R resulted in a dose-
dependent VEGF induction. This effect was significantly attenuated in cells treated with 
siRNAs for either SP4 or STAT3.
Conclusions: Dialysate IL-6 and sIL-6R act through the trans-signalling pathway 
controlled by the STAT3-SP4 axis to up-regulate mesothelial VEGF production during 
peritonitis.
Funding: Government Support - Non-U.S.
FR-PO832
1H NMR Based Metabolome Can Predict Relapsing Peritonitis and 
Differentiate Bacterial and Fungal Peritonitis as Well  Narayan Prasad,1 
Raj K. Sharma,1 Amit Gupta,1 Dinesh Kumar.2  1Nephrology and Renal 
Transplantation, SGPGIMS, Lucknow, UP, India; 2CBMR.
Background: Conventional culture methods for microbes are inherently slow 
and inefficient.Treatment of bacterial(BP) and fungal peritonitis(FP) are different and 
quick differentiation is needed. Presently, there is no biomarker to predict relapsing 
peritonitis(RP). Bacteria and fungus may have different metabolome as one is prokaryotic 
and other eukaryotic.
Methods: Five unused PD fluid, 13 effluent from normal PD and 45 effluents from 15 
patients(at baseline,1 week and 2 weeks of therapy) with BP including 3 who relapsed and 
3 FP were included. Half of each was subjected to total and differential WBC count and 
culture; and half was frozen at -80° C for NMR analysis. BP and FP was diagnosed based on 
identification of organism. RP was defined as per standard definition. High Resolution NMR 
spectra were recorded at 298 K on a Bruker Avance III 800 MHz spectrometer. Standard 
1D 1H NMR spectra were acquired using the Carr–Purcell–Meiboom–Gill (CPMG) pulse 
sequence.To confirm the assignment of marker peak, two-dimensional (2D) 1H-1H TOCSY 
and 1H-13C HSQC spectra were also acquired.
Results: Five unused and 13 normal PD effluents after 6 hours of dwell did not show 
any marker peak at NMR spectra at 0.67 ppm while 15 cases of BP showed marker peak; 
however marker peak disapeared after resolution of peritonitis at 1 week and 2 weeks of 
antibacterial therapy except for 3 cases who relapsed in whom marker peak was persisting 
despite absence of clinical peritonitis. The 3 cases of FP did not show any such marker peak 
differentiating it from BP. Marker signal represent trans-methylene protons of cyclopropane 
ring moiety as reported earlier and depicted in Figure 1.
Conclusions: The cyclopropane signal at 0.67 ppm can be marker signal to differentiate 
BP and FP and persistence of this signal at 2 weeks after clinical resolution of peritonitis 
predicts RP.
FR-PO833
Peritoneal Mesothelial Cell Sodium Glucose Co-Transporter 1 (SGLT1) 
Regulates VEGF Production: Potential Target in Ultrafiltration Failure 
Eric L. Wallace,1 Phillip H. Chumley,1 Leslie J. Jackson,1 Juling Zhou,1 Michal 
Mrug,1 Jeremy Goodman,1 Joanne E. Murphy-Ullrich,1 Edgar A. Jaimes.2  1Univ 
of Alabama at Birmingham; 2Memorial Sloan Kettering Cancer Center.
Background: D-glucose and vascular endothelial growth factor (VEGF) are important 
in the development of ultrafiltration failure (UFF) in peritoneal dialysis (PD) . The role 
of glucose transport in peritoneal mesothelial cells (PMC) in UFF is unknown. Herein we 
hypothesize that the glucose transporter SGLT1 is increased in response to high glucose 
and regulates VEGF production.
Methods: PMC, obtained from omental digestion of non-PD patients and from spent 
PD dialysate, were incubated for 48 hrs under 200mM D-glucose or L-glucose, 200mM 
mannitol, 200mM 3OMG a non-metabolizable glucose analog transported by SGLT1, 7.5% 
icodextrin, with and without 50µM phlorizin (Ph), an SGLT1 inhibitor. VEGF was measured 
by ELISA. mRNA for VEGF and SGLT1 was measured by RT-PCR. Immunofluorescence 
microscopy for cytokeratin and SGLT1 was performed on human peritoneal biopsies 
performed at PD catheter insertion (CI) and at catheter revision (CR) after 6 months of PD.
Results: SGLT1 expression was minimal in PMC in biopsies at CI, but abundantly 
present in PMC in biopsies at CR. PMCs cultured under 200 mM D-glucose had a 6 fold 
increase in SGLT1 mRNA vs 5mM D-glucose and an increase in VEGF: 70 ±1.9 pg/mg to 
2,456 ±189 pg/mg (p<0.05). D-glucose stimulation of VEGF was partially inhibited by 50 
µM Ph : 6,098± 405 pg/mg to 3,991±289 pg/mg (p=0.003). 3OMG also stimulated VEGF: 
71± 1.9 pg/mg to 1,474 ±160 pg/mg (p < 0.01) that was inhibited by Ph 623 ± 74 pg/mg), 
suggesting Ph inhibition of VEGF is partly independent of glucose metabolism (p<0.05). 
200mM L-glucose stimulated VEGF less than D-glucose (543 ± 35pg/mg, p < 0.01). This 
stimulation was inhibited by Ph (123 ± 12 pg/mg). 7.5% icodextrin vs 5mM Glucose did 
not stimulate VEGF production (47 ± 5.1 pg/mg, p<0.005).
Conclusions: SGLT1 expression in PMC is upregulated in response to high D-glucose 
in vivo and in vitro. Glucose transport regulates VEGF production under high D-glucose 
conditions, which may provide a therapeutic target for UFF.
Funding: Pharmaceutical Company Support - Baxter Healthcare Corp
FR-PO834
Correlation Between Fibroblast Growth Factor-23, Endothelial Dysfunction, 
and Inflammatory Markers in Chronic Peritoneal Dialysis Patients and 
Their Response to Antioxidant Therapy  Mitul Bora.  Nephrology, Ayur 
Sundra Super Speciality Hospital, Guwahati, Assam.
Background: Cardiovascular disease (CVD) is the major cause of morbidity and 
mortality in dialysis patients. Various non-traditional factors like inflammation, acute phase 
reactants and endothelial dysfunction have been proposed for this increased incidence of 
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CVD. Increased intact parathyroid hormone and FGF-23 levels are associated with the 
progression of vascular calcification in peritoneal dialysis (PD) patient. N-acetylcysteine 
(NAC) acts on atherosclerosis and also improves the endothelial functions. This study 
was designed to evaluate the correlation between FGF-23, endothelial dysfunction and 
markers of inflammation in chronic PD patients and to evaluate the effect of three months 
of therapy of NAC on these parameters.
Methods: All patients underwent Doppler studies to assess endothelial function by 
the flow mediated dilatation (FMD) of the brachial artery and carotid arterial intima media 
thickness (CIMT).Brachial artery was imaged during reactive hyperemia (endothelium-
dependent, flow-mediated dilatation, FMD) and during glyceryl trinitrate-mediated 
dilatation (nitroglycerine-mediated dilatation, NMD, endothelium-independent) in all PD 
patients. NAC was given in the dose of 1200 mg in two divided doses for a period of three 
months. The associations between different parameter were analyzes using Spearman 
correlations. All these parameters were repeated after three months of therapy with NAC.
Results: A total of 73 chronic PD patients were enrolled in this study.FGF-23 showed 
strong positive correlation with serum homocysteine level (r=1.00, P<0.001), hsCRP 
(R=0.977, P <0.001). ,Endothelium Dependent Dilatation [(EDD) (r = 0.968, P < 0.001)] 
and CIMT (r = 0.994, P < 0.001), but negatively correlated with Endothelium Independent 
Dilatation (EID) and Vitamin D level. All these parameters including FGF-23, hsCRP, 
homocysteine , CIMT and EDD were significantly reduced after three months of therapy 
with NAC.
Conclusions: FGF-23 correlated well with inflammatory markers and endothelial 
function. With three months of therapy, NAC significantly reduces the CIMT, inflammatory 
markers and improves the endothelial function in chronic PD patients.
FR-PO835
SRF Enhances Cell Adhesion, Migration and Peritoneal Fibrosis via 
Modulating miRNA-199a/214 Cluster in Human Peritoneal Mesothelial 
Cells  Lijie He, Shiren Sun.  Dept of Nephrology, Xijing Hospital, Xi’an, 
Shaanxi, China.
Background: Our previous work showed that serum response factor (SRF) was 
involved in fibrosis of peritoneal membrane, but the exact underlying mechanism were 
still unclear. Here we further study the role of miR-199a/214 cluster and the relationship 
of SRF in peritoneal fibrosis.
Methods: We isolated HPMCs from the effluents of end-stage renal disease (ESRD) 
patients with peritoneal dialysis (PD), and also used PD dialysis rats model to observe 
the response of PM to miR-199a/214 cluster and the predicted target CDH1 and CLDN2.
Results: In this study, we found that miR-199a-5p/214 cluster, which was examined 
to be highly expressed in HG-induced HPMCs by real time PCR, was directly regulated 
by SRF after HG stimulation. All these HG induced immortal HPMCs became scatter, 
have the migration ability, lost cell-cell adhesion, and characterized by phenotype markers 
change with the elevated expression of miRNA-199a/214 cluster, which were also found 
in these long time treatment of CAPD patients ex vivo or in PD rats. The overexpression 
of miR-199a/214 cluster leaded to the lower expression of the cell-cell adhesion markers 
E-cadherin and claudin-2 protein, and the silencing of miR-199a/214 cluster by lentivirus 
could inhibit HG-induced damage and alleviate fibrosis in PD rats. Depletion of miR-214/
miR-199a cluster in HG stimulated HPMCs reduces cell to cell adhesion, migration and 
phenotypic transition by up-regulating E-cadherin, claudins and downregulating α-SMA 
in vitro. While overexpression of miR-214 and miR-199a-5p by mimic into HPMCs 
caused the opposite effects. ChIP and luciferase reporter assays revealed that the active 
and overexpression of SRF directly promotes the transcription of miR-199a/214, which are 
examined to be highly expressed in HG-induced HPMCs. Mechanistically, miR-199a-5p 
and miR-214 were characterized to target the E-cadherin and claudin-2 messenger RNA 
CDH1 and CLDN2 to contribute to the adhesion of cell to cell or cell to matrix induced 
by HG of HPMCs in vitro.
Conclusions: Together, this study reveals a new SRF-miR-199a/miR-214 cluster-
CDH1/CLDN2 EMT axis which highlights the potential  damage of HG and fibrosis in PD.
Funding: Government Support - Non-U.S.
FR-PO836
Therapeutic Targeting of EGFR Protects against Peritoneal Fibrosis in Rats 
Li Wang,1 Na Liu,1 Andong Qiu,1 Shougang Zhuang.1  1Dept of Nephrology, 
Shanghai East Hospital, Tongji Univ School of Medicine, Shanghai, China; 
2Dept of Medicine, Rhode Island Hospital and Alpert Medical School, Brown 
Univ, Providence, RI.
Background: Long-term PD leads to peritoneal damage and subsequently to peritoneal 
fibrosis that is characterized by fibroblast activation, collagen fibril accumulation, 
inflammation, and angiogenesis, but there is still no available treatment for peritoneal 
fibrosis thus far.
Methods: In the current study, we explored the therapeutic effect of gefitinib, a specific 
inhibitor of epidermal growth factor receptor (EGFR), on the development and progression 
of peritoneal fibrosis induced by chlorhexidine gluconate (CG) and high-glucose dialysis 
fluid in rats.
Results: Daily intraperitoneal injections of CG or high-glucose dialysis fluid 
induced peritoneal fibrosis as indicated by thickening of the submesothelial area with an 
accumulation of collagen fibrils and activation of myofibroblasts. This was accompanied 
by time-dependent EGFR phosphorylation. Administration of gefitinib, a specific EGFR 
inhibitor, immediately after injury prevented the onset of peritoneal fibrosis, and delayed 
treatment until a certain degree of peritoneal fibrosis has occurred halted the progression 
of peritoneal fibrosis. Gefitinib treatment abrogated increased phosphorylation of EGFR, 
Smad3, STAT3 and nuclear factor (NF)-κB during peritoneal fibrosis. Gefitinib also 
inhibited overproduction of transforming growth factor-β1 and multiple proinflammatory 
cytokines as well as infiltration of macrophages to the injured peritoneum. Moreover, 
gefitinib significantly reduced peritoneal increase of CD31 (+) blood vessels and vascular 
endothelial growth factor (+) cells after injury.
Conclusions: These results demonstrate that EGFR contributes to peritoneal fibrosis, 
inflammation and angiogenesis and suggest that EGFR inhibitors may have therapeutic 
potential in peritoneal fibrosis.
Funding: NIDDK Support
FR-PO837
Effects of Alanyl-Glutamine Addition in Peritoneal Dialysis Fluid on 
Peritoneal Immune Modulation – A Pilot Clinical Trial  Klaus Kratochwill,1,2 
Rebecca Herzog,1,2 Manoj K. Bhasin,3 Seth L. Alper,3 Andreas Vychytil,1 
Christoph Aufricht.1  1Medical Univ of Vienna, Vienna, Austria; 2Zytoprotec 
GmbH, Vienna, Austria; 3Beth Israel Deaconess Med. Ctr., Harvard Medical 
School, Boston, MA.
Background: Low peritoneal glutamine levels may contribute to reduced immune 
defense and increased inflammation in the peritoneal cavity. As a pilot clinical trial, PD 
patients were treated with PD fluid supplemented with 8 mM alanyl-glutamine (AlaGln) 
and the effect on peritoneal cell immuno-competence was studied by functional assays and 
transcriptomics using RNA-sequencing (RNAseq) and microRNA (miRNA) profiling of 
cells derived from PD effluents.
Methods: In an open-label, randomized, crossover clinical trial at the Medical 
University of Vienna (EudraCT-2012-004004-36), 6 stable PD patients received either 
standard PD fluid (Physioneal40 3.86%, Baxter) or AlaGln-supplemented PD fluid for 
an overnight dwell followed by a 4 h peritoneal equilibration test. Cytokine release from 
ex vivo-stimulated effluent cells was assessed as a measure of immuno-competence. 
Cells were also analyzed by RNAseq (TruSeq Single-end mRNA, Illumina) and miRNA 
microarray analysis (Affymetrix) using an integrated bioinformatics workflow developed 
in the Bhasin Lab.
Results: AlaGln treatment significantly increased cytokine release following 
ex-vivo stimulation, consistent with restoration of previously suppressed peritoneal 
immunocompetence. Peritoneal effluent cell transcripts of 9,797 genes were identified. 
Unsupervised clustering and principal component analysis revealed partial separation 
between treatments. Supervised analysis using the paired approach identified 13 
differentially expressed miRNAs and 41 differentially expressed genes with >1.5-fold 
change (P<0.01). Functional enrichment analysis of these genes indicated pathways linked 
to immune response and modulation.
Conclusions: In summary, AlaGln-mediated improvement in peritoneal leukocyte 
immuno-competence was correlated with changes in peritoneal leukocyte transcriptome 
status in well-described clinical samples. To strengthen these promising data, larger 
numbers of patients will be treated with AlaGln for a prolonged period in an international 
multi-center RCT.
Funding: Pharmaceutical Company Support - Zytoprotec GmbH
FR-PO838
Choice of Dialysis Modality for Children with End Stage Renal Disease 
Julien Hogan,1,2 Cécile Couchoud.2  1Pediatric Nephrology, Robert Debré 
Hospital, Paris, France; 2REIN Registry, Agence de la Biomédecine, La Plaine 
Saint Denis, France.
Background: Despite many studies that aim to assess the best modality of dialysis, 
results remain conflicting both in adults and in children. This lack of medical evidence 
leads commentators to emphasize the importance of patients’ choice in the decision process. 
Thus, we try to assess factors that impact the choice of the dialysis modality in children 
and to determine which from medical factors, center practices or patients’ or families’ 
wishes plays the major role.
Methods: All incident patients <20 years old at start of dialysis, recorded in the French 
ESRD registry between 2002 and 2013 were included. We used multivariate hierarchical 
logistic regression models to study patients and centers characteristics associated with the 
probability of starting with peritoneal dialysis (PD). The effect of centers was assessed by 
including centers as a random effect.
Results: Among 806 patients treated in 177 centers, 601 (74.6%) started with 
hemodialysis (HD) and 205 (25.4%) with PD. A higher probability of PD was found in 
younger children while starting treatment in emergency was associated with a low use of 
PD. Low and high educational level of the town of residence were both associated with less 
probability of PD when compared with average educational level. There was a significant 
variability between centers, that was not explained by patients’ case-mix. Being treated in 
specialized pediatric centers was associated with less probability of PD, while the probabilty 
of PD was proportional to the rate of PD in the center.
Conclusions: Although little evidence exists to favor a dialysis modality over the other 
in children, HD remains the predominant modality in France. PD is still mostly offered to 
the youngest children while it remains underused in patients starting RRT in emergency. 
However, we found that besides medical factors, centers practices play a major role in 
the choice of dialysis modality. This raise concerns about the place left to patients’ and 
families’ choices and to what extend doctors may influence the final decision. Further 
pediatric studies focusing on children and parents’ wishes are needed in order to provide 
cares as close as possible to there expectations.
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FR-PO839
Clinical Course of Children Born with Chronic Kidney Disease – A Single 
Centre Experience  Christina Taylan,1 Bernd Hoppe,2 Eva Maria Haffner,2 Lutz 
Thorsten Weber.1  1Pediatric Nephrology, Univ Hospital of Cologne, Cologne, 
Germany; 2Pediatric Nephrology, Univ Hospital of Bonn, Bonn, Germany.
Background: The number of babies born alive suffering from chronic kidney disease 
(CKD) is constantly increasing.
Methods: We analyzed the outcome of infants with CKD and renal replacement therapy 
(RRT) started within their first year of life. Between 2007 and 2013 17 infants (11 male; 6 
female) developed end-stage renal disease resulting in RRT in our department.
Results: All of them received peritoneal dialysis (PD) initially at a median age of 34 
[1-334] d. During follow-up 10 children underwent renal transplantation (RTx), 1 child 
was still on PD at last follow-up, 1 child had to go back to hemodialysis after graft loss 
and 2 had a recovery of renal function. 3 out of 17 children died during the PD period. 
Causes of death were severe sepsis twice and one cerebral bleeding. The mean GFR at 
last follow-up (2.2±0.73 years) of patients who underwent RTx was 105±22.8 ml/min/1.73 
m2. Mean time on dialysis was 17.8±14.3 months before RTx, mean age at transplantation 
was 29.2±14.2 months. Mental development was measured by Mental Development Index 
T1 (Bayley Scales of infant development BSID-II) at an average age of 12 [9-16] months 
and showed developmental delay at the motor, mental and behaviour rating scale. At time 
of transplantation 6/10 infants had tube feeding, 9/10 were <3. percentile of height, 3/10 
were <3. percentile of body weight.
Conclusions: RRT started in the first year of life was associated with reasonable 
outcome and should be offered to all infants with end stage renal disease.  It is, however, 
associated with a high risk of developmental delay. This work emphasizes the great 
demands made on an interdisciplinary team of pediatric nephrologists, psychologists and 
social workers.
FR-PO840
Altered Myogenesis and Oxidative Stress in a Rat Model of Chronic Kidney 
Disease  Keith Avin,1 Neal X. Chen,2 Jason M. Organ,3 Kalisha O’Neill,2 Sharon 
M. Moe.2,4  1Dept Physical Therapy, Indiana Univ, Indianapolis, IN; 2Div of 
Nephrology, Indiana Univ, Indianapolis, IN; 3Dept of Anatomy, Indiana Univ, 
Indianapolis, IN; 4VAMC, Indianapolis, IN.
Background: Skeletal muscle atrophy and impaired muscle function are associated 
with lower quality of life, and greater disability and mortality risk in those with chronic 
kidney disease (CKD). However, the pathogenesis of atrophy is unknown.
Methods: We used a slowly, progressive, naturally occurring, CKD rat model (Cy/+ 
rat) and its normal littermate (NL). At 35 weeks, we tested muscle strength, sacrificed and 
collected tissues and blood. RNA and protein were isolated from skeletal muscle and real 
time PCR and western blot performed.
Results: CKD rats developed sarcopenia evident by reduced cross sectional area 
(p<0.05), increased connective tissue deposition on histology (p<0.05), and impaired 
strength (p<0.05). Strength was defined as the maximal amount of force produced during 
maximal, electrically stimulated dorsiflexion. These findings of atrophy can be explained by 
reduced regeneration, increased catabolism, or differentiation of muscle stem cells toward 
myofibroblasts. By PCR, there was increased activation and differentiation of muscle stem 
cells (reduced Pax-7, increased MyoD and myogenin (p<0.05)) and increased proteolytic 
markers (Atrogin-1 and MuRF-1 (p<0.05). Fibrosis may be enhanced via decreased miR-
29b (p<0.05) and increased Wnt5a (p<0.01). Finally myostatin was increased in blood 
and muscle RNA expression yet no difference in the activin type IIB. The long term 
consequences of the impaired balance of increased proteolysis and inadequate regeneration 
is further supported by mitochondrial derangement (electron microscopy) and increased 
mitochondria complexes I, II and IV (p<0.05) despite increased expression of the anti-
oxidant nuclear erythroid 2-related factor 2 (p<0.05).
Conclusions: In a rat model of CKD, sarcopenia was present despite the activation 
of myogenic factors. The atrophy is due to a combination of factors including increased 
myostatin, increased expression of atrogenes, and the presence of oxidative damage. 
Augmentation of the myogenic and antioxidant responses through treatments may prevent 
progressive sarcopenia in CKD.
Funding: Other NIH Support - NIH R01AR058005
FR-PO841
Can Calcitriol and Calcidiol to Regulate Toll Like Receptors 7, 9 and IL-6 
and IFN-γ Expression on Lymphocytes Incubated with Uremic Serum? 
Maria Dalboni,1,3 Marion Schneider,1 Lilian Cuppari,1 Caren Cristina Grabulosa,1 
Silvia Regina Manfredi,1 Edgar Maquigussa,1 Danilo Takashi Aoike,1 Miguel 
Cendoroglo Neto,1,2 Jose Tarcisio Giffoni.1  1Div of Nephrology, Univ Federal 
São Paulo, Sao Paulo, Brazil; 2Medicine, Tufts-New England Medical Center, 
Boston; 3Medicine, Univ Nove de Julho, Sao Paulo, Brazil.
Background: The uremic environment has been reported to induce an inflammatory 
response and TLR is one of the mechanisms that may be involved in this response. In 
addition, it has been recognized that low levels of this vitamin can be associated with the 
deregulation of the inflammatory response. Thus, the purpose of this study was evaluate the 
effect of 25 (OH)D3 and 1,25 (OH)2D3 on lymphocytes B and T for IL-6, IFN-γ TLR-7 , 
TLR-9, VDR, CYP27 and CYP24 expression in presence of uremic serum.
Methods: PBMC isolated by Ficoll-Hipaque from health subjects were used to 
analyze lymphocytes. These cells were incubated with normal or uremic serum in presence 
or absence of 25 (OH)D3 or 1,25 (OH)2D3 for 24 h in a 37ºC, 5% CO2. We use flow 
cytometry to evaluate IL6, IFN-γ, TLR7, TLR9, VDR, CYP27 and CYP24 expression on 
lymphocytes B and T.
Results: Uremic serum induced a significant increase in IL6, IFNγ, TLR7, TLR9, 
VDR, CYP27 and CYP24 expression in B and T lymphocytes (p <0.05). Both lymphocytes 
incubated with 25 (OH)D3 or 1,25 (OH)2D3 had a significant reduction in IL-6 and TLR9. 
As CYP24 had a higher expression and this can to induce a degradation of 1,25 (OH)2D3, 
we did a CYP24 silencing, and observed an additional decreased in IL6, IFNγ, TLR7 and 
TLR9 expression on B and T lymphocytes for both treatment when compared to effect 
of these vitamins alone (p <0.05). In the same condition, we also observed an increase 
VDR expression.
Conclusions: Our results suggests that both 25 (OH)D3 and 1,25 (OH)2D3 had 
immunomodulatory effects in B and T lymphocytes. This in vitro model confirm the anti-
inflammatory role of Vitamin D in uremia environment. However, these effects of Vitamin 
D were enhanced after CYP24 silencing. So, this data support that CYP24 inhibitors may 
also be a target of treatment in association with vitamin D supplementation to improve a 
immunological response mechanisms.
FR-PO842
Toll Like Receptors 2, 4, TNF-α, IL-6 and IL-10 Expression on Leukocytes 
from Hemodialysis and Pre-Dialysis Patients  Maria Dalboni,1,3 Jose Tarcisio 
Giffoni,1 Silvia Regina Manfredi,1 Jacqueline Ferritto Rebello,3 Rodrigo Barbosa 
de oliveira Brito,3 Miguel Cendoroglo Neto,1,2 Caren Cristina Grabulosa.1 
1Nephrology Div, Univ Federal de São Paulo, Sao Paulo, Brazil; 2Medicine, 
Tufts-New England Medical Center, Boston; 3Medicine, Univ Nove de Julho, 
Sao Paulo, Brazil.
Background: Toll-like receptors (TLR) are involved in immunologic response. The 
TLRs expression and cytokines association in neutrophils and monocytes from CKD patients 
is unclear.To evaluate TLR-2, TLR-4, TNF-α, IL-6 and IL-10 expression in neutrophils 
(PMN) and monocytes (MN) from Hemodialysis (HD) and Pre-dialysis (PD) patients.
Methods: Blood samples from 43 hemodialysis (HD) patients (collect before the 
beginning of the second week hemodialysis session), 46 pre-dialysis (PD)(estimated by 
Modification of Diet in Renal Disease (MDRD) and 70 age-and gender-matched healthy 
volunteers (CONT) were analyze for TLR2 and TLR4 expression on PMN and MN by Flow 
cytometry. The TNF-α, IL-6 and IL-10 cytokines were analyzed by ELISA.
Results: The expression of TLR2 and TLR4 on neutrophils from HD patients was 
higher than PD and CONT patients (p<0.001). In monocytes, TLR-2 expression was higher 
in HD patients compared to others groups (p <0.001) and TLR4 expression was higher 
inPD patients compared to the CONT and HD patients (p<0.001). Regarding to cytokines, 
we observed that HD patients showed an increase of TNF and IL-6 levels compared to 
CONT (4.6±5.3 vs 1.9±1.3 and 6.0±3.2 vs 2.5±2.1; p<0.001, respectively) and IL-10 from 
HD patients were higher than PD and CONT patients (115± 166 vs 36±82 and 27±62, 
respectively).We also observed a significant correlation between TLR2 and TLR4 and 
TNF-α on neutrophils (r = 0.30 ; p = 0.02 and r = 0.34; p = 0.01, respectively). In respect 
to monocytes, only TLR2 had correlation with TNF-α and IL-6 (r = 0.30; p = 0.02 and r 
= 0.24 ; p = 0.03, respectively).
Conclusions: It is possible that the deregulation of TLR2 and TLR4 expression on 
leukocytes may be caused by uremic toxins in CKD population. Besides, the high expression 
of TLR2 and TLR4 in these cells resulted in an increase of TNF-α and IL-6 levels, suggesting 
that TLRs are associated with inflammatory mechanisms in uremic patients.
FR-PO843
Effect of Cholecalciferol Supplementation on Toll-Like Receptors 7, 9 
Expression and IL-6 and IFN-γ Intracellular on B and T Lymphocytes 
on Chronic Dialysis Patients  Maria Dalboni,1,3 Marion Schneider,1 Lilian 
Cuppari,1 Caren Cristina Grabulosa,1 Silvia Regina Manfredi,1 Edgar 
Maquigussa,1 Danilo Takashi Aoike,1 Miguel Cendoroglo Neto,1,2 Jose Tarcisio 
Giffoni.1  1Div of Nephrology, Univ Federal de Sao Paulo, Sao Paulo, Brazil; 
2Medicine, Tufts-New England Medical Center, Boston; 3Medicine, Univ Nove 
de Julho, Sao Paulo, Brazil.
Background: Vitamin D deficiency is highly prevalent among patients in all stages 
of CKD. Studies have reported that the Vitamin D deficiency is associated with mortality 
and morbidity in CKD patients and may modulate TLRs that are involved in inflammatory 
responses. Thus, the purpose was evaluate the effect of cholecalciferol on IL-6, IFN-γ 
TLR-7 and TLR-9 expression in lymphocytes B and T in patients on dialysis with vitamin 
D hipovitaminosis.
Methods: In a randomized, placebo-controlled, double-blind study, we investigated the 
effect of cholecalciferol (100,000 UI once per week or placebo) for 3 months, in patients 
on chronic dialysis, who had nutritional vitamin D deficiency . The 25(OH)D3 detection 
was performed by quimioluminescence and IL6, IFN-γ, TLR7, TLR9, VDR, CYP27 and 
CYP24 expression by flow cytometry on lymphocytes B and T.
Results: After 3 months of treatment , Cholecalciferol increased 25(OH)D3 levels 
(16,00±4,44 vs 42,81±13,06, p=0,01) and reduced PTH levels (525,3 (128-1775) vs 484,8 
(86-2264, p=0,03), but have no impact on FGF23 levels. Additionally, we observed a reduced 
expression of TLR7 (305±78 vs 252±45, p=0,01), TLR9 (1864±700 vs 1084±370, p=0,001 
and CYP24 (284±136 vs 200±86, p=0,01), and increased of VDR (730±360 vs 965±440, 
p=0.006) and CYP27 (245±38 vs 442±380, p=0.04) expression.
Conclusions: Cholecalciferol treatment in dialysis patients showed to be efficient 
to correct hipovitaminosis D. In addition, we observed impact of 25(OH)D3 repletion on 
reduction of expression of the TLR7, TLR9, IFN-γ and improve of regulatory mechanisms 
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associated with intracellular production of vitamin D on lymphocytes from CKD patients. 
These results suggests that cholecalciferol treatment play an important role on TLRs 
expression as an anti-inflammatory and that this may contributed to a better systemic 
inflammation response in CKD patients.
FR-PO844
The Effect of Selenium Deficiency on Thyroid Hormone and Cardiovascular 
Diseases in Hemodialysis Patients  So Mi Kim,1 Eun kyoung Lee,2 Yun 
Jung Oh,3 Ja Seon Kim.4  1Div of Nephrology, Dept of Internal Medicine, Jeju 
National Univ Hospital, Jeju National Univ School of Medicine, Jeju, Jejudo, 
Republic of Korea; 2Div of Nephrology, Dept of Internal Medicine, Dankook 
Univ Hospital, Cheonan, Chungnaam, Republic of Korea; 3Div of Nephrology, 
Dept of Internal Medicine, Cheju Halla General Hospital, Jeju, Jejudo; 4Div 
of Nephrology, Dept of Internal Medicine, Incheon sarang Hospital, Incheon, 
Kyoungkido, Republic of Korea.
Background: Selenium deficiency is known to associate with impairment of thyroid 
hormone and cardiovascular diseases such as ischemic heart disease (IHD), cardiomyopathy 
or sudden death. In hemodialysis (HD) patients, various causes may contribute to selenium 
deficiency, including malabsorption, alteration of metabolism, and removal through dialysis 
itself. Therefore, we tried to investigate the effect of selenium deficiency on thyroid hormone 
and cardiovascular diseases in HD patients.
Methods: This cross-sectional study enrolled 83 HD patients. They were divided into 
two groups based on serum selenium levels: 62 patients were normal level and 22 patients 
were selenium deficient. Thyroid hormones such as TSH, free T4 were measured. And 
cardiovascular diseases, including IHD, heart failure or cardiomyopathy, were evaluated.
Results: Thyroid hormone impairment, including hypothyroidism and subclinical 
hypothyroidism, showed higher tendency in selenium deficient group than that in non- 
selenium deficient group. (27 % vs 10 % P=0.06) The prevalence of IHD was significantly 
higher in selenium deficient group than that in the non-selenium deficient group. (59% vs 21 
%, p=0.04) But there was no difference in heart failure and cardiomyopathy. The patients 
with thyroid hormone impairment showed high prevalence of IHD, and the coincidence of 
thyroid hormone impairment and IHD was also significantly higher than that in selenium 
deficient group than that in non-selenium deficient group. (18% vs 4%, p=0.014).
Conclusions: This study showed the significant high prevalence of thyroid hormone 
impairment and IHD in HD patients with selenium deficiency. Selenium deficiency may 
be affect heart disease, associating with thyroid hormone impairment.
FR-PO845
Associations of Prelude (Pre-ESRD) BMI and Weight Change with Early 
Dialysis Mortality Among U.S. Veterans: A Transition of Care in CKD 
Study  Elani Streja,1 Melissa Soohoo,1 Joline L.T. Chen,1 Amanda R. Tortorici,1 
Jennie Jing,1 Danh V. Nguyen,1 Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh.1 
1UC Irvine; 2UTHSC.
Background: In end stage renal disease (ESRD) lower body mass index (BMI) portends 
a higher risk of mortality while obesity is protective, the so-called obesity paradox. However, 
the association of BMI and change in BMI over time in the pre-ESRD period and early 
post-ESRD mortality is unknown. We hypothesized that lower and decreasing BMI prior 
to transition to ESRD may be associated with higher early dialysis death.
Methods: In a cohort of 22,716 US veterans who transitioned to dialysis between 
10/2007 and 9/2011 with available BMI values within the last 2 year prelude period (prior 
to ESRD transition), we examined the association of 6 month average BMI and 2 year BMI 
slope as continuous predictors of all-cause mortality in the first 3 months after transition, 
using restricted cubic spline analyses and Cox models adjusted for age, sex, race, ethnicity, 
cause of ESRD, and region. In the models of BMI slope, we also adjusted for BMI level 
at the time of transition.
Results: The mean±SD age was 69±11 yrs, 27% were African-American, 7% Hispanic, 
and 49% diabetic. There was a reverse J-shaped association between BMI and mortality, 
where patients with BMI <27 kg/m2 were at higher risk of death (Figure A). When 
examining changes in weight over the 2-year prelude there was a U-shaped association 
where patients with little to no-change in BMI (-1 to +1 kg/m2 per year) exhibited the best 
survival (Figure B).
Conclusions: Among veterans transitioning to dialysis, obese patients and those 
patients with little to no weight change in the last 2 years prior to ESRD have the greatest 
survival in the first 3 months post transition. Weight change in late stages of pre-dialysis 
CKD, possibly due to uremic wasting and fluid gain, portend poor outcomes, and could 
be used to identify at-risk patients.
Funding: NIDDK Support
FR-PO846
Nutritional Assessment for Incident Elder Dialysis Patients  Ikuto Masakane,1 
Yuya Sakai,2 Miho Suzuki.2  1Yabuki Hospital, Nephrology, Yamagata, Japan; 
2Yabuki Hospital, Dept of Health and Nutrition.
Background: Nutritional status is one of the most powerful predictors of patient 
survival in chronic dialysis patients especially in elders. It is generally accepted that 
aging itself is one of the risk factors of malnutrition. Recently the patients who started 
dialysis have become older and older as the average age of incident dialysis patients in 
Japan is nearly 70 years old. It is very meaningful to evaluate the status of malnutrition 
in new elder dialysis patients, its time-course and to establish strategies for preventing 
progression of malnutrition.
Methods: The nutritional status of 257 incident dialysis patients in YHG was 
retrospectively evaluated by MIS. The nutritional status on 37 patients out of the 257 patients 
has been followed for 3 years. The “malnutrition” was diagnosed as “moderate-severe” in 
MIS and fulfill of the diagnosis of PEW. Patients greater than 75 years old were categorized 
as Elder and patients under 75 years old were as Non-elder. The statistical significance of 
time-dependent changes in nutritional status was evaluated by paired-T test.
Results: The prevalence of malnutrition at the point of dialysis initiation by MIS 
in average was 7%, 12% in Elder and 5% in Non-elder. The nutritional status had been 
improved in the non-elder but not in the elder. The lean body mass had decreased in the 
first year of dialysis vintages in both groups and had remained the same in the following 2 
years. Body fat mass had increased consistently for 3 years in non-elderly. It had increased 
for the first 2 years but had begun to decrease in the third year in the elder. Protein and 
energy intake per ideal body weight were lower in elder dialysis patients.
Conclusions: Malnutrition in elder dialysis patients was often accompanied by the 
initiation of chronic dialysis therapy and would gradually develop in the maintenance 
period. In order to protect the progression of malnutrition several proposals were addressed 
as the proper timing of the initiation of dialysis before the deterioration of daily activities; 
nutritional education for sufficient energy and protein intake, exercise education and 
sufficient dialysis prescription with biocompatible dialysis membranes.
FR-PO847
Uric Acid Is a Determinant of Glomerular Filtration Rate in Inflammatory 
Conditions  Suad Ma Hannawi, Issa AL Salmi.  Medicine, The Ministry of 
Health, Dubai, United Arab Emirates; The Renal Medicine Dept, The Royal 
Hospital, Muscat, Oman.
Background: The presence of gout or a baseline serum uric acid in the upper range 
are possibly stronger predictors of first CV events than some traditional CV risk factors or 
parameters of inflammation. Presence study analysis UA determinants in relation to GFR.
Methods: Patients attending the only centre of MOH in Dubai were studied during their 
OPD rheumatology visit from Jan 2014 till Dec 2014. Many laboratory tests including UA 
were performed. MDRD formula was used to get eGFR. Simple statistical and regression 
models were performed. Variables that not normally distributed being log transformed.
Results: 79 (88.6%F,11.4%M) were recruited with mean age46.4(13.4) years. Mean 
UA was249.8 (84.4), eGFR137.1(50.5)(59.6,306.1).
Regression analysis found a negative relationship between UA and GFR (P<0.001,-
0.004,-0.002) and positive relationship between uric acid and age (p=0.032, 0.001-0.011), 
urea (p<0.001,0.041-0.137), microalbuminuria (p=0.046,0.000-0.001), microalbumin/cr 
(p=0.024,0.001-0.013), SBP(P=0.014,0.001-0.009), DBP(p==0.025,0.001-0.014), age 
at Dx RA (P=0.028,0.001-0.010), monocyte% (p=0.009,0.013-0.088), monocyte count 
(p=0.003,0.015-0.776) TG (p=0.034,0.009-0.216), BUT also negative with cholesterol
(p=0.033,-0.148,-0.007),
Uric acid multiple model has maintained a strong correlation with eGFR (p=0.005), 
monocyte count (0.009), cholesterol (p.007),microalbuminuria(p=0.01), after adjustment 
for all the above mentioned variables.
Conclusions:  UA is determined by eGFR and other renal parameters in inflammatory 
condition. On the other hand, uric acid increase the risk of renal impairment and CVD in 
inflammatory condition. Thus, uric acid level might be an elemental key factor that result in 
high renal and CV associated morbidity and mortality in the inflammatory diseases. UA is 
a powerful independent predictor of prevalent renal dysfunction but was also a significant 
predictor of progression of renal disease. UA may not be just an innocent bystander but may 
be an active player in the pathogenesis of renal disease by causing endothelial dysfunction, 
intrarenal vascular disease and renal impairment in inflammatory conditions.
FR-PO848
Does Nutritional Status and Serum Electrolytes Change when Dialysis 
Patients Reduce Their Fluid Overload?  Penny Faith Sheppard,1 Suzette 
Thompson,2 Laura Rosales,1 Nathan W. Levin,1 Peter Kotanko,1 Fansan Zhu.1 
1Renal Research Inst, New York, NY; 2Fresenius Vascular Care, New York, NY.
Background: Electrolyte balance between the intracellular (ICV) and extracellular 
(ECV) fluid compartment is essential in the control of normal physiological functions. 
Nutritional status is mainly reflected by ICV. In hemodialysis (HD) patients the relationship 
between electrolyte control and management of fluid balance is not completely understood. 
We aimed to evaluated whether the degree of reduction of fluid overload affects the 
measurement of ICV, and concentrations of serum albumin (Alb), sodium, potassium, 
and calcium.
Methods: Fifty six HD patients were studied. At baseline (BL), the fluid status was 
evaluated by calf biompedance spectroscopy (cBIS). If patient’s dry weight (DW) was not 
reached by criteria of cBIS DW, the post target weight was gradually reduced (Zhu et al, 
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Physiol Meas, 29:S530-S516, 2008). At six months follow up, the patients either reached 
DW or did not (NDW) due to difficulty in prolonging treatment time. ECV and ICV, weight, 
and systolic blood pressure (SBP) were measured pre and post HD. Comparison of all 
parameters between BL and follow up were made using student t test.
Results: Thirty one patients reached DW and 25 did not. Weight and ECV were 
significantly reduced during follow up. However, ICV, electrolytes and Alb concentrations 
did not change between different fluid statuses. Post HD SBP significantly decreased from 
BL to the end of the study in DW but not in NDW groups.
Conclusions: Although extracellular fluid (ECV) was largely reduced, the ICV and 
serum concentrations of sodium, potassium, and calcium did not differ significantly. This 
implies that there is no fluid or mass shift from ICV to ECV, suggesting over all isotonic 
removal of sodium and that nutritional status is not changed by attainment of dry weight.
FR-PO849
Trends in Weight Change During the First Two Years of Transition to 
Hemodialysis Treatment  Vyvian Ngo,1 Elani Streja,1 Anna Mathew,2 Tae 
Hee Kim,1 Yoshitsugu Obi,1 Connie Rhee,1 Csaba P. Kovesdy,3 Kamyar 
Kalantar-Zadeh.1  1UC Irvine; 2Hofstra North Shore LIJ Health System; 3UTHSC.
Background: Some hemodialysis patients may undergo rapid weight loss in the first few 
months of starting dialysis, but the nature of this trend has not yet been characterized in large 
nationally representative studies. We hypothesized the trajectory of weight change during 
the first 24 months of hemodialysis therapy may differ by baseline body mass index (BMI).
Methods: We examined percent post-dialysis weight (kg) change from baseline 
in 37,759 incident hemodialysis patients who initiated dialysis in a large US dialysis 
organization in calendar years 2007-2011 and who survived the first 2 years of hemodialysis. 
Trends of percent weight change over time were analyzed using crude and case-mix adjusted 
mixed effects models. Baseline BMI was categorized into 8 categories (<18.5, 18.5-<20, 
20-<23, 23-<25, 25-<30, 30-<35, 34-<40, 40+ kg/m2).
Results: Patients were 60±14 years old, 64% diabetics, 44% female, and had an average 
starting weight of 82±22 kilograms. Patients reached a nadir of weight at the 5th month 
of dialysis with an average 2% weight loss from baseline. At 14 months, patients’ weight 
stabilized at an average of 1% drop from baseline. However, trends differed across groups 
of baseline BMI groups. Underweight (BMI <18.5) did not experience weight loss but 
instead gained approximately 6% of their weight by the 24th month. Obese patients (BMI 
>40) did not reach a nadir and lost approximately 6% of their weight by the 24th month. 
Conclusions: Baseline BMI can affect the trajectory of weight change over the first 
two years in hemodialysis patients. Further studies are needed to better understand the 
cause of these differences and their impact on clinical outcomes.
Funding: NIDDK Support
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Significance of Renal Autonomic Nerves in the Reduction of Body Weight 
by SGLT2 Inhibitors  Aika Hagiwara, Kazutoshi Miyashita, Masaaki Sato, 
Hiroyuki Inoue, Kentaro Fujii, Masanori Tamaki, Hiroshi Itoh.  Nephrology, 
Endocrinology and Metabolism, School of Medicine, Keio Univ, Shinjuku, 
Tokyo, Japan.
Background: Sodium-glucose co-transporter (SGLT) 2 inhibitors decrease not only 
serum glucose level but also body weight significantly. Similarly, it is reported that renal 
denervation (RDN) decreases body weight, in addition to blood pressure. The urinary 
glucose might have a relationship with sympathetic activation that controls body weight. 
however, the relationship has not been elucidated.
Methods: The present study examined the roles for renal autonomic nerves in the 
weight reduction by SGLT2 inhibitors through performing RDN on mice fed on a high-fat 
diet. The C57BL/6 mice fed on a high-fat diet were divided into 4 groups; control group, 
RDN group, SGLT2 inhibitor group and SGLT2 inhibitor with RDN group. The body 
weight, glucose tolerance, tissue weights, tissue hormone sensitive lipase (HSL) activity 
and noradrenalin concentration were examined. The SGLT2 inhibitor (tofogliflozin 50 mg/
kg pellet) was administered to mice from 8 weeks old mixing it in the high-fat diet (60 
Kcal% fat). RDN was performed at 7 weeks old by surgically stripping the renal arteries 
and coating the vessels with a solution of 10% phenol in ethanol.
Results: The body weight at 16 weeks old significantly decreased in the SGLT2 inhibitor 
group. In that group, the catecholamine levels in subcutaneousfat and the activity of HSL 
which was measured by the phosphorylation level were increased. On the other hand, RDN 
with SGLT2 inhibitor group significantly weakened the degree of the reduction of body 
weight by the SGLT2 inhibitor associated with suppression of the catecholamine levels 
and the activity of HSL in the adipose tissue. In RDN without SGLT2 inhibitor group, the 
body weight significantly decreased; however, HSL in the adipose tissue was not activated.
Conclusions: These results indicate that HSL activation in the adipose tissue mediated 
by the renal autonomic nerves was involved in the mechanism of weight-reduction by 
SGLT2 inhibitors. The renal autonomic nerves were suggested to have a role in the control 
of tissue HSL activity and body weight.
FR-PO851
The Combination of Walking Exercise and Branched Chain Amino Acid 
Recovered Response of Protein Synthesis in Low Protein Diet Fed Chronic 
Kidney Disease Model Rats  Takuya Yoshida, Hiromichi Kumagai.  Dept of 
Clinical Nutrition, Univ of Shizuoka, Shizuoka, Japan.
Background: Low protein diet (LPD) protects progression of renal injury in patients 
with chronic kidney disease (CKD). However, LPD may accelerate muscle wasting in these 
patients. The exercise and branched chain amino acid (BCAA) are known to increase  the 
muscle synthesis by activating mTOR signals pathway. The aim of this study is to investigate 
whether walking exercise and BCAA would increase muscle protein synthesis in LPD fed 
CKD (5/6 nephrectomized) rats.
Methods: CKD rats were fed LPD or LPD fortified with BCAA diet (BD), and about 
half of the each group were loaded with the walking exercise (7 weeks of treadmill, 15 
m/min, 1 hour/day, 5 days/week). After 7 weeks, the kidney and the soleus muscle were 
collected to evaluate the renal fibrosis and the muscle protein synthesis, respectively.
Results: The renal function and fibrosis were not different between LPD and BD fed 
CKD rats, and the walking exercise did not accelerate renal damage in both LPD and BD 
fed CKD groups. The walking exercise increased the phosphorylation of p70s6kinase, 
a biomarker of mammalian target of rapamycin complex 1 activity, in soleus muscle of 
LPD and BD fed CKD rats. However, the phosphorylation of p70s6kinase was lower in 
LPD fed CKD rats when compared with sham-operated groups and BD fed CKD group.
Conclusions: CKD reduces activation of muscle protein synthesis. Combination of 
walking exercise and BCAA recovered the muscle protein synthesis in CKD rats. These 
results suggest combination of walking exercise and BCAA may be beneficial to improve 
the muscle protein synthesis in CKD.
Funding: Government Support - Non-U.S.
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Unacyl-Ghrelin: A Key Molecule in Uraemic Cachexia in Children and 
Adolescents  Alice Monzani,1 Michela Perrone,2 Sara Testa,2 Fabio Paglialonga,2 
Silvia Consolo,2 Gianluigi Ardissino,2 Francesca Tel,2 Marta Lepore,2 Stefani 
Rotondo,2 Antonietta Biasuzzi,2 Luciana Ghio,2 Gianni Bona,1 Alberto Edefonti.2 
1Div of Pediatrics, Univ del Piemonte Orientale, Novara, Italy; 2Pediatric 
Nephrology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico, Milan, Italy.
Background: Cachexia and poor growth are common in children with chronic kidney 
disease (CKD). Several mechanisms are involved, including loss of appetite and poor food 
intake. Unacyl-ghrelin (UAG) is known to produce an inhibitory effect on feeding. We 
measured UAG levels in children and adolescents with CKD stage II-IV on conservative 
treatment (CKD-CT), on haemodialysis (CKD-HD) and after transplantation (Tx), compared 
to healthy controls, in relation to biochemical and anthropometric parameters.
Methods: Plasma UAG levels were measured by ELISA in 43 CKD-CT, 20 CKD-HD, 
48 Tx and 43 healthy children. Urea and creatinine levels were measured in all subjects 
and GFR was calculated by Schwartz formula. Weight, height and bicipital, tricipital, 
subscapular and suprailiac folds were measured, and BMI z-score, fat-mass and fat-free 
mass pro body weight (FM/BW and FFM/BW, respectively) were calculated.
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Results: Mean UAG levels were significantly higher in CKD-HD (1444.75±1211.44 
pg/ml) than in CKD-CT (582.24±546.93 pg/ml, p=0.001), in Tx (491.05±532.82 pg/
ml,p<0.0001) and controls (245.29±181.07 pg/ml, p<0.0001). UAG levels were positively 
correlated with serum creatinine and urea and negatively correlated with GFR, also after 
adjustment for gender, age, pubertal status and BMI z-score (p<0.0001 for each model). 
A negative correlation was found between UAG and BMI z-score (R=-0.371, p<0.0001) 
and between UAG and both FM/BW and FFM/BW (R=-0.518, p <0.0001 and R = -0.319, 
p = 0.004, respectively).
Conclusions: UAG seems to be a promising inverse biomarker of nutritional status in 
children with CKD, strictly related to the degree of renal impairment.
FR-PO853
Visceral Fat Area Is Associated with Renal and Cardiac Function 
in a Population with Normal or Mildly Impaired Renal Function 
Sung jun Kim,1,2 Yunju Nam,1 Hyeon Seok Hwang,1 Seok Joon Shin,1,2 Hye 
Eun Yoon.1,2  1Internal Medicine, The Catholic Univ of Korea, Seoul, Korea; 
2Internal Medicine, Incheon St. Mary’s Hospital, Incheon, Korea.
Background: Visceral fat is involved in the development of metabolic and 
cardiovascular diseases. This study was to evaluate the association between visceral fat 
area (VFA) and renal and cardiac function and arterial stiffness in a population with normal 
or mildly impaired renal function.
Methods: This cross-sectional study included 719 middle-aged adults who underwent 
a voluntary health check-up program. Participants with estimated glomerular filtration rate 
(eGFR) below 60 mL/min/1.73m2 were excluded. VFA was measured using bioimpedance 
analysis. Subjects were divided into tertiles according to their VFA. The associations 
between VFA and eGFR, brachial–ankle aortic pulse wave velocity (baPWV), and 
echocardiographic parameters were investigated.
Results: Across the tertiles of VFA, there was a significant trend for decline in eGFR 
(P<0.001), increase in baPWV (P<0.001) and left ventricular mass index (LVMi, P<0.001), 
and decrease in the ratio of early mitral inflow velocity to peak mitral annulus velocity 
(E/E’, P<0.001). VFA showed significant correlations with eGFR (r = -0.15, P<0.001), 
baPWV (r = 0.28, P<0.001), LVMi (r = 0.31, P<0.001), and E/E’ (r = 0.21, P<0.001). In 
multivariate analysis, VFA was linearly associated with eGFR (β = -0.06, 95% confidence 
interval [CI] -0.11 – -0.01, P=0.02), LVMi (β = 0.08, 95% CI 0.06 – 0.10, P<0.001), and 
E/E’ (β = 0.01, 95% CI 0.006 – 0.019, P<0.001), after adjustments for cardiovascular risk 
factors. In contrast, total body fat was not associated with eGFR.
Conclusions: VFA is associated with renal and cardiac function in middle-aged adults 
with normal or mildly impaired renal function. Measuring VFA may predict risks of renal 
and cardiac diseases.
Funding: Government Support - Non-U.S.
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Serum Ferritin <70 µg/L Predicts Functional Iron Deficiency in Patients 
with Chronic Kidney Disease  Neha Garg, Mrinalini Kotru, Om Prakash 
Kalra, Meera Sikka.  Pathology, UCMS and GTBH, Delhi, New Delhi, India.
Background: Chronic Kidney Disease (CKD) is a major public health problem with 
anemia occurring early in the course of disease. Its most common cause is erythropoietin 
deficiency which can be effectively treated with erythropoiesis stimulating agents. However 
most of the patients do not respond adequately due to development of Functional Iron 
Deficiency (FID). The current diagnostic criteria for FID as recommended by KDOQI 2006 
tend to miss the diagnosis of FID. The study was conducted to explore the role of hsCRP and 
Interleukin-6 (IL-6) along with Serum Ferritin (SF) in improving the efficacy of this criteria.
Methods: 77 clinically diagnosed patients of CKD (Stage 3, 4 and 5) of either sex, 
age >18 years with Hb <11 g/dL were included in the study. Complete clinical history and 
physical examination was done. Complete hemogram with peripheral smear, serum iron, 
total iron binding capacity, Transferrin Saturation (TSAT), SF, transferrin receptors (sTfR), 
hsCRP, IL-6, ESR were estimated.
Results: sTfR/log ferritin (taken as gold standard) detected 31/77 patients as having iron 
deficient erythropoiesis. Out of these 31 patients, 12 patients had SF <12 µg/L indicating 
absent iron stores. Remaining 19 patients had FID. In these cases, TSAT <20% and SF >100 
µg/L detected FID in only 2 patients with a sensitivity of 6.45%. SF at a cut-off <70 µg/L 
showed the best sensitivity (83.87%) and specificity (73.91%) in detecting FID in these 
patients and identified 14/19 cases of FID. The 5 FID cases who were missed had raised 
hsCRP. In the absence of raised hsCRP, SF <70 µg/L had very good sensitivity (100%). 
However, in the presence of raised hsCRP sensitivity was reduced (79.16%).
Conclusions: TSAT <20% and SF >100 µg/L had a sensitivity of only 6.45%. However, 
SF <70 µg/L emerged as the most sensitive and specific in identification of iron deficient 
erythropoiesis. SF >12 µg/L - SF <70 µg/L was able to identify 14/19 cases of FID. Also, 
hsCRP could be used to stratify the CKD group in which FID could be detected with high 
sensitivity and specificity.
Funding: Government Support - Non-U.S.
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Chronic Inflammation Is Associated with Poor Clinical Outcomes 
Independent of Mineral Metabolism Abnormalities in the HEMO Study 
Anna Jeanette Jovanovich,1,2 Eugene J. Nuccio,2 Alfred K. Cheung,3,4 Tom 
Greene,4 Michel Chonchol,2 Kristen L. Nowak.2  1Denver VA Medical Center; 
2Univ of Colorado Denver; 3VA Salt Lake City; 4Univ of Utah.
Background: Epidemiological studies show a high prevalence of chronic inflammation, 
vitamin D deficiency, and fibroblast growth factor 23 (FGF23) excess in hemodialysis 
patients. Whether the relationships of high circulating C-reactive protein (CRP) and 
interleukin-6 (IL-6) with all-cause mortality and cardiac and infectious events are attenuated 
in the presence of circulating markers of mineral metabolism is unknown.
Methods: We studied the association of inflammatory markers (CRP and IL-6) with all-
cause mortality, and cardiac and infectious hospitalizations and deaths among 1340 subjects 
from the Effect of Dialysis and Membrane Flux in Maintenance Hemodialysis (HEMO) 
trial. Cox regression models adjusted for important confounding variables: demographics, 
comorbidities, Kt/V, dialyzer, smoking, albumin, and mineral metabolism markers 
including serum calcium, phosphorus, intact parathyroid hormone, 25-hydroxyvitamin D, 
1,25-dihydroxyvitamin D, and FGF23.
Results: Mean age was 58±14 years, 56% were female, and 63% were black. Median 
(IQR) CRP and IL-6 levels were 6.1 (2.6-15.2) mg/L and 3.2 (1.7-6.9) pg/mL, respectively. 
Over mean 2.84 years follow-up, there were 582 deaths, 514 cardiovascular events, and 
499 infectious events. Among subjects with levels in the highest quartile compared to the 
lowest quartile, both CRP and IL-6 were significantly associated with all-cause mortality in 
adjusted analyses, odds ratio (OR) 1.96 (95% CI, 1.27-3.02) and OR 1.51 (95% CI, 1.02-
2.23), respectively. However, only CRP, was associated with cardiovascular disease events 
(OR 1.90; 95% CI, 1.04-3.44) and infectious events (OR 3.84; 95% CI, 1.37-10.74) among 
subjects with levels in the highest quartile compared to the lowest quartile.
Conclusions: CRP and IL-6, were significantly associated with all-cause mortality 
independent of mineral metabolism abnormalities. Only CRP was significantly associated 
with cardiovascular disease and infectious disease events independent of mineral metabolism 
abnormalities among subjects in the HEMO trial.
Funding: NIDDK Support, Veterans Administration Support
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Assessment of Protein-Energy Wasting: Comparing a New PEW Score and 
the MIS in Chronic HD Patients  Camiel LM de Roij van Zuijdewijn,1 Muriel 
P. Grooteman,1 Peter J. Blankestijn,2 Menso Jan Nubé,1 Pieter M. Ter Wee.1 
1Nephrology, VU Univ Medical Center, Amsterdam, Netherlands; 2Nephrology, 
Univ Medical Center Utrecht, Utrecht, Netherlands.
Background: the assessment of protein-energy wasting, a syndrome of decreased 
bodily protein and energy fuels, remains debated. Recently, a French group introduced a new 
PEW score, encompassing BMI, serum creatinine, nPNA and serum albumin. In a cohort 
of chronic hemodialysis patients, we compared the predictive value of this score with the 
Malnutrition Inflammation Score (MIS) using all-cause mortality as end point. Furthermore, 
we investigated which of these scores correlates best with quality of life (QOL).
Methods: from data of the CONvective TRAnsport STudy (CONTRAST), the new 
PEW score and the MIS were determined at baseline. QOL was measured with the Kidney 
Disease QOL-Short Form 36, which results in 2 general and 12 kidney-disease specific 
domains of QOL. Discrimination and calibration for mortality were tested by Harrell’s C 
Statistic and the Hosmer-Lemeshow Goodness-of-Fit test, respectively. Spearman’s rank 
correlation coefficient ȡ was used to determine correlations between a test and the various 
QOL domains.
Results: 489 out of 714 patients were analyzed. 183 died during follow-up (mean 
3.15±1.78 years). Discrimination for mortality was higher for MIS than the new PEW score 
(Harrell’s C statistic 68.0 [95% CI 65.7-69.8] and 61.0 [95%CI 59.0-63.3], respectively). 
Furthermore, mortality calibration was adequate for MIS (p=0.65), but not for the new 
PEW score (p=0.03). Lastly, MIS correlated with 13 domains of QOL (ȡ’s between -0.47 
and -0.12), whereas the new PEW score only correlated with the physical component 
score (ȡ 0.18).
Conclusions: both the MIS and the new PEW discriminate for mortality, but the MIS 
performs better. Furthermore, only the MIS is properly calibrated. Third, the MIS correlates 
with more QOL domains with higher correlation coefficients. Therefore, we conclude that 
MIS is preferred over the new PEW score in assessing PEW.
FR-PO857
Change in MIS Over 1 Year Is Not Associated with Mortality in Chronic 
Hemodialysis Patients  Camiel LM de Roij van Zuijdewijn,1 Muriel P. 
Grooteman,1 Menso Jan Nubé,1 Peter J. Blankestijn,2 Pieter M. Ter Wee.1 
1Nephrology, VU Univ Medical Center, Amsterdam, Netherlands; 2Nephrology, 
Univ Medical Center Utrecht, Utrecht, Netherlands.
Background: protein-energy wasting, a state of decreased bodily protein and energy 
fuels, has been associated with increased mortality as measured by the Malnutrition 
Inflammation Score (MIS), a composite, clinical, nutrition-related score. Longitudinal data 
on this score, however, are limited. We checked whether a change in MIS over 1 year of 
follow-up is associated with mortality.
Methods: data from CONTRAST were used, a well-defined cohort of end-stage kidney 
disease patients. Patients were selected for analysis if MIS was available at baseline (M0) 
and at 12 months (M12). Delta (∆) MIS was calculated as MIS (M12) – MIS (M0). As the 
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association between ∆MIS and mortality was not linear, patients were divided into quartiles 
of ∆MIS. Cox proportional hazards models, crude and adjusted for potential confounders, 
were used to calculate hazard ratios (HRs) of patients with severe deteriorating MIS 
(increase >2 points), mild deteriorating MIS (increase of 1 or 2 points), stable MIS versus 
patients with an improving MIS.
Results: 404 patients were available for analysis. Mean age was 63.0±13.5 and 62.4% 
were male. During follow-up (median 3.1 years), 135 patients died. Median ∆MIS was 1.0 
(IQR -1.0 to 3.0). Survival curves are shown in fig 1. HR of patients with a mild deteriorating 
or stable MIS versus patients with an improving MIS was 0.85 (95%CI 0.53-1.39) and 
0.97 (95%CI 0.56-1.67), respectively; for patients with a severe deteriorating MIS, HR 
was 1.63 (95%CI 1.02-2.51). After correction for age, sex, dialysis vintage and dialysis 
modality, this association did not remain significant (p>0.1). 
Conclusions: a change in MIS over 1 year is not associated with mortality in a 
multivariable survival analysis.
FR-PO858
Soluble CD14, a Marker of Endotoxemia, Associates with Survival and 
Cardiovascular Disease in CKD Patients  Ruben Poesen,1 Ian Barrows,2 
Ali Ramezani,2 Pieter Evenepoel,1 Kathleen Claes,1 Bjorn Meijers,1 Dominic 
S. Raj.2  1Nephrology, Univ Hospitals Leuven, Belgium; 2Renal Diseases and 
Hypertension, George Washington Univ.
Background: CKD goes along with gut microbial dysbiosis and gut barrier dysfunction, 
possibly contributing to endotoxin translocation. Subsequent binding of endotoxin to toll-
like receptor-4 and its co-receptor CD14 activates the innate immune system. As half-life 
of systemic endotoxin is very short, soluble CD14 (sCD14) has been proposed as better 
marker of endotoxin exposure. Whether sCD14 relates to adverse outcome in CKD patients 
not yet on dialysis is unknown.
Methods: We performed a prospective study in CKD patients stage 1-5. Plasma sCD14 
was determined with ELISA. Determinants of sCD14 were examined with regression 
analysis. The relationship between sCD14, survival and cardiovascular disease (CVD) 
was explored using Kaplan Meier and Cox PH analysis.
Results: 495 CKD patients were followed from 2005 until 2010. Median plasma 
sCD14 was 3.72µg/mL (IQR 3.15–4.40). Lower eGFR and higher CRP were the strongest 
determinants of higher sCD14 (both P<0.0001). During follow-up, we observed 53 deaths 
(Tertile 1/2/3: 12/17/24 events, log rank P 0.02, see figure). In Cox PH analysis, sCD14 
remained a significant predictor of death (univariate HR per SD increase of 1.809 (1.356–
2.413), P<0.0001), even after adjustment for renal function, Framingham risk factors, CRP 
and albumin (HR 1.899 (1.316–2.739), P 0.0006). We also noted 78 CV events (Tertile 
1/2/3: 18/29/31 events, P 0.01, see figure). This association remained borderline significant 
in the fully adjusted model (HR 1.299 (0.999–1.689), P 0.05). 
Conclusions: Plasma sCD14 is elevated in patients with advanced CKD, suggesting 
increased endotoxin exposure. sCD14 is independently associated with survival and CVD, 
pointing to a role of endotoxemia as driving force behind adverse outcome in CKD.
Funding: Government Support - Non-U.S.
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Gut Microbiota Derived Trimethylamine-N-Oxide Is Not a Biomarker 
for Mortality and Cardiovascular Disease in European CKD Patients 
Ruben Poesen, Pieter Evenepoel, Bjorn Meijers.  Nephrology, Univ Hospitals 
Leuven, Belgium.
Background: Trimethylamine-N-oxide (TMAO) is a gut microbiota derived metabolite 
of dietary choline, lecithin and l-carnitine with recent evidence suggesting involvement 
of TMAO in development of atherosclerosis. Recently, TMAO has been associated with 
mortality and cardiovascular disease in a general US population as well as in US CKD 
patients not yet on dialysis. As there may be population-specific differences in diet and/or 
microbial metabolism, we questioned whether TMAO also relates with adverse outcome 
in European CKD patients.
Methods: We performed a single-center prospective study in patients with CKD stage 
1-5. Baseline serum levels of TMAO were determined using LC-MS. Correlation between 
eGFR and serum TMAO was explored using Spearman’s rank correlation analysis. The 
relationship between TMAO, survival and cardiovascular disease was examined using Cox 
proportional hazard analysis.
Results: 488 CKD patients were followed from November 2005 until December 
2010. Median serum level of TMAO was 11.6 µM (IQR 5.7 – 21.8). We observed a highly 
significant inverse correlation between eGFR and serum TMAO (rho 0.71, P < 0.0001). 
During follow-up, we noted a total of 51 deaths and 75 cardiovascular events. In univariate 
cox proportional hazard analysis, TMAO was a significant predictor of mortality (HR 
1.521 (1.183 – 1.956), P 0.001) and cardiovascular disease (HR 1.570 (1.283 – 1.921), P 
< 0.0001). However, significance was lost after adjustment for eGFR for overall mortality 
(HR 1.126 (0.795 – 1.595), P 0.50), as well as for cardiovascular events (HR 1.256 (0.958 
– 1.647), P 0.10).
Conclusions: Serum levels of TMAO rise in parallel to a declining renal function 
and further analysis of 24h urine samples is ongoing to elucidate its renal handling. In 
this European cohort of CKD patients, we were not able to find an association between 
TMAO and adverse outcome that is beyond renal function, which is in contrast to previous 
observations in US populations, both general and CKD. This may question the validity of 
TMAO as a universal biomarker for cardiovascular disease, possibly due to population-
specific differences in diet and/or microbial metabolism.
Funding: Government Support - Non-U.S.
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Microbiota Derived Phenylacetylglutamine Associates with Survival and 
Cardiovascular Disease in CKD Patients  Ruben Poesen, Pieter Evenepoel, 
Bjorn Meijers.  Nephrology, Univ Hospitals Leuven, Belgium.
Background: Lately, there is increasing interest in gut microbiota derived uremic 
retention solutes as driving force behind adverse outcome in CKD. Both p-cresyl sulfate 
and indoxyl sulfate are considered representatives of this group, also commonly referred 
as to protein-bound solutes due to their high protein binding and dependence on active 
tubular secretion for renal clearance. Phenylacetylglutamine is another microbial metabolite 
subjected to high tubular secretion, although protein binding is rather low. We questioned 
whether this solute also relates to adverse outcome in CKD patients not yet on dialysis.
Methods: We performed a prospective study in CKD patients stage 1-5. Serum levels 
of phenylacetylglutamine were determined using LC-MS. Correlation between eGFR and 
serum phenylacetylglutamine was explored using Spearman’s rank correlation analysis. The 
relationship between phenylacetylglutamine, survival and cardiovascular disease (CVD) 
was examined using Kaplan Meier and Cox PH analysis.
Results: 488 CKD patients were followed from November 2005 until December 2010. 
Median serum level of phenylacetylglutamine was 6.2 µM (IQR 3.0–13.2). We observed 
a highly significant inverse correlation between eGFR and serum phenylacetylglutamine 
(rho -0.76, P<0.0001). During follow-up, we noted a total of 51 deaths and 75 CV events 
with a gradual and significant increase with higher tertiles of phenylacetylglutamine 
(both log rank P<0.0001). In univariate Cox PH analysis, phenylacetylglutamine was 
a significant predictor of mortality (HR 1.962 (1.481–2.598), P<0.0001) and CVD (HR 
1.997 (1.590–2.508), P<0.0001), even after adjustment for renal function, Framingham risk 
factors, calcium-phosphorus-PTH, CRP and albumin (HR 1.611 (1.140–2.275), P 0.007 
for mortality and HR 1.668 (1.295–2.149), P<0.0001 for CVD).
Conclusions: Serum levels of microbiota derived phenylacetylglutamine are elevated 
in patients with more advanced CKD. Serum phenylacetylglutamine is also a strong and 
independent risk factor for mortality and CVD. Further analysis of 24h urine samples is 
ongoing to differentiate between impact of higher urinary excretion as surrogate of intestinal 
generation vs. impact of lower tubular secretion.
Funding: Government Support - Non-U.S.
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Sarcopenia Among Prevalent Hemodialysis Patients: Weighing the Evidence 
Piyawan Kittiskulnam,1 Juan Jesus Carrero,2 Glenn Matthew Chertow,3 George 
A. Kaysen,4 Kirsten L. Johansen.1  1UCSF; 2Karolinska Inst; 3Stanford Univ; 
4UC Davis.
Background: There is no consensus on the best way to define sarcopenia in ESRD. 
Use of muscle/height2(Ht2) is suggested by geriatric societies but may underestimate 
sarcopenia, particularly in the setting of excess adiposity. We compared three definitions 
of sarcopenia in a prevalent HD cohort.
Methods: ACTIVE/ADIPOSE enrolled HD patients from San Francisco and Atlanta 
from 6/09 to 8/11. Bioelectrical impedance spectroscopy was performed before a midweek 
dialysis session (n=645), and total-body muscle mass was estimated using an equation 
containing age, sex, body weight (BW), and intracellular water. We defined sarcopenia 
as muscle mass ³2SD below sex-specific means for adults 18-49 y from NHANES data 
indexed to Ht2, %BW, and body surface area (BSA) by DuBois formula. We compared the 
prevalence of low muscle mass among the three methods and assessed their correlation 
with handgrip strength.
Results: Mean age was 57±14 years, 41% were women, 61% black. The prevalence of 
sarcopenia was 8% by muscle/Ht2, 25% by muscle/%BW and 32% by muscle/BSA. Most 
sarcopenic patients by muscle/BSA method had normal BMI, while >50% of sarcopenic 
patients by %BW were obese. Almost none of the overweight or obese patients were 
identified as sarcopenic by muscle/Ht2.
Patients who were classified as sarcopenic by muscle mass/BSA but not Ht2 had 
significantly higher BMI and %body fat than those who were sarcopenic by both methods 
(25.2 vs 21.3 kg/m2,p<0.001 and 31.1 vs 24.4%,p<0.001, respectively). Handgrip strength 
was moderately correlated with muscle/BSA (r=0.6) but weakly correlated with muscle/
Ht2(r=0.3) and %BW (r=0.4).
Conclusions: Skeletal muscle mass normalized to Ht2 may underestimate the prevalence 
of sarcopenia, particularly in overweight HD patients. Detection of sarcopenia among 
overweight/obese patients requires adjustment for body size or adiposity.
Funding: NIDDK Support
FR-PO862
Does a Probiotic Supplementation Alter the Indoxyl Sulfate Levels in 
Non-Dialysis Chronic Kidney Disease Patients? A Randomized Placebo-
Controlled Clinical Trial  Denise Mafra,1 Natalia Alvarenga Borges,1 
Milena Barcza Stockler-Pinto,2 Denis Fouque,4 Amanda F. Barros.2  1Medical 
Sciences Graduate Program, Federal Univ Fluminense, Rio de Janeiro, Brazil; 
2Cardiovascular Sciences Graduate Program, Federal Univ Fluminense, Rio de 
Janeiro, RJ, Brazil; 3Post Graduate Program in Dentistry, Estácio de Sá Univ, 
Rio de Janeiro, RJ, Brazil; 4Dept of Nephrology, Centre Hopitalier Lyon Sud, 
Univ Claude Bernard, Lyon, France; 5Graduate Program in Science Applied 
to Health Products, Federal Univ Fluminense, Rio de Janeiro, RJ, Brazil; 
6Medicine Faculty, Federal Univ Fluminense, Rio de Janeiro, RJ, Brazil.
Background: The imbalance in gut microbiota associated with alterations in colonic 
epithelium contributes to the accumulation of gut-derived uremic toxins in chronic kidney 
disease (CKD) patients. Therapeutic strategies like probiotic supplementation may modulate 
the gut microbiota and reduce the toxins levels. To determine the effect of probiotics 
supplementation on indoxyl sulfate (IS) plasma levels in non-dialysis CKD patients.
Methods: In this double-blind, placebo-controlled trial, 29 non-dialysis CKD patients 
were recruited. Patients were randomized to receive probiotic (1 capsule, containing 30 
billion of colony forming units - S. thermophilus, L. acidophilus, and B. longum, n= 17) 
or placebo (n= 12) for 3 months. IS plasma levels were quantified with HPLC, calprotectin 
and protein C reactive were analyzed by immunoenzymatic assay. Five patients in probiotic 
group and three in placebo were lost to follow-up.
Results: Plasma IS increased significantly in patients who received probiotics whereas 
the other parameters did not change.
Parameters Probiotic (N=12) Placebo (n=9)
Before After 3 months Before After 3 months
Total IS (mg/L) 8.0 (0.1 - 99.5) 72.0 (6.1 - 240.0)*
5.5 (0.64 - 
21.2)
15.8 (4.9 - 
84.3)
Calprotectin (ng/dL) 12.8± 4.6 14.0± 6.5 12.2 ± 4.8 11.4 ± 3.1
CRP (mg/dL) 4.8 (1.3 - 6.1) 3.6 (1.2 - 6.0) 1.2 (0.4 - 3.7) 0.4 (0.4 - 6.8)
Conclusions: Data from this randomized study suggest that administration of probiotics 
alone may increase plasma IS levels in non-dialysis CKD patients. These findings support 
the need for more studies with probiotics in CKD patients.
Funding: Government Support - Non-U.S.
FR-PO863
Prevention of the Progression of Both Renal Dysfunction and the 
Atherosclerotic Change in Chronic Kidney Disease (CKD) Stage 3-4 Patients 
due to Benign Nephrosclerosis  Yoshihiko Inoue, Tomoaki Miyazaki, Shinya 
Omiya, Kiyoko Inui, Daisuke Komukai, Ashio Yoshimura.  Div of Nephrology, 
Showa Univ Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Background: Effect of EPA for CKD patients is not fully known. We studied the 
efficacy of EPA to prevent the progression of both renal impairment and atherosclerosis in 
CKD stage 3-4 patients due to benign nephrosclerosis (BNS).
Methods: 31 CKD stage 3-4 patients due to BNS with dyslipidemia were followed 
for 3 years after the start of EPA treatment. The dosage of 1800 mg/day of EPA was newly 
prescribed. T-cho, LDL-cho, Triglycerides (TG), eGFR, the amount of proteinuria, EPA, 
arachidonic acid (AA), Dihomo-gamma-linolenic acid (DGLA) and docosa hexaenoic acid 
(DHA) were studied. Both right and left (RL) brachial-ankle pulse wave velocity (baPWV), 
RL maximum carotid intima-media thickness (max IMT), RL maximum carotid plaque 
thickness and RL ankle-brachial index (ABI) were evaluated at before treatment (baseline), 
after 1,2-year and at the end of the study (3-year).
Results: EPA, EPA/AA ratio, TG. RL baPWV, RL max IMT and eGFR showed 
significant improvement at 3-year (table 1).
Baseline End of the study(3-year) P
EPA (ȝg/ml) 70.4±38.7 236.8±99.2 <0.01
EPA/AA 0.39±0.23 1.39±0.56 <0.01
TG (mg/dl) 243.8±127.0 136.7±37.3 <0.01
Right baPWV (cm/s) 1686.0±369.2 1580.3±289.4 <0.05
Left baPWV (cm/s) 1723.4±378.8 1618.2±245.0 <0.05
Right max IMT (mm) 0.96±0.35 0.79±0.26 <0.05
Left max IMT (mm) 0.92±0.31 0.76±0.24 <0.05
eGFR (ml/
min/1.73m2) 44.0±11.2 48.5±14.6 <0.05
Furthermore, both EPA and DHA levels were significantly low in eGFR exacerbation 
patients group (n=9) compared with the improvement group (n=22) at both baseline and 
3-year. Patients showing the highest EPA levels at baseline (EPA: 124.6±18.8 mg/ml, n=8) 
showed significant improvement in both eGFR and baPWV compared with those with the 
lowest EPA levels (30.1±8.1 mg/ml, n=8). There was no difference on both plaque thickness 
and ABI between baseline and 3-year.
Conclusions: EPA powerfully prevents the progression of both renal dysfunction and 
the atherosclerotic change in CKD stage 3-4 patients due to BNS.
FR-PO864
Relationships Between Composition of Gut Microbiota and Uremic Toxins 
Mami Kikuchi,1 Ryoko Tateoka,1 Yoshiharu Itoh,1 Wataru Suda,2,3 Masahira 
Hattori.2,4  1Kureha Corporation, Tokyo, Japan; 2The Univ of Tokyo, Chiba, 
Japan; 3Keio Univ, Tokyo, Japan; 4Waseda Univesity, Tokyo, Japan.
Background: Gut microbiota is known to function in producing uremic toxins 
(UTs) and their precursors, such as indoles, phenols and so on. However the relationships 
between specific bacteria and UTs are not clear. To elucidate the production of UTs by gut 
microbiota, we collected blood, urine and feces samples in normal rats, rats subjected to 5/6 
renal removal. AST-120, a spherical carbon adsorbent of intestinal small-molecular-weight 
UTs and/or their precursors, was used to evaluate the effects of UTs on gut microbiota.
Methods: Serum and urine levels of UTs were quantified by SRM of LC/ESI-MS/MS. 
Gut microbiota from feces were analyzed using 454-pyrosequencing of a hypervariable 
V1-V2 region of the 16S rRNA gene in combination with barcode sequences. We used 
the GLSEARCH program and self-build 16S sequences database and genome database to 
determine the closest species. We identified the indole and/or phenol producing species 
using BLASTX.
Results: In CKD rats, urinary excretion and serum concentrations of UTs, such as 
indoxyl sulfate and phenyl sulfate, were higherthan control rats. In AST-120-administered 
CKD rats, urinary excretion and serum concentrations of UTs decreased compared to CKD 
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rats. The overall bacterial community composition was compared according to the UniFrac 
distance metric among control rats, CKD rats, and CKD + AST-120 rats. A principal 
coordinate analysis plot reveled clustering of each group. We identified the intestinal 
microbiome containing tryptophanase and/or tyrosine phenol-lyase gene in the genome 
sequences from NCBI bacterial genome. These enzymes metabolize tryptophan to indole 
and tyrosine to phenol, respectively.
Conclusions: Our data suggest that UT production is not only the cause of uremic 
symptoms but also correlated with a subset of indigenous gut microbes and affects the 
composition of gut microbiota.
FR-PO865
Association of Urine Volume at the Start of Dialysis and Subsequent 
Changes in Serum Albumin Level in Incident Hemodialysis Patients 
Rieko Eriguchi,1 Yoshitsugu Obi,1 Connie Rhee,1 Steven M. Brunelli,2 Joline 
L.T. Chen,1 Anna Mathew,3 Tae Hee Kim,1 Elani Streja,1 Csaba P. Kovesdy,4 
Kamyar Kalantar-Zadeh.1  1UC Irvine; 2DaVita Clin Research; 3Hofstra North 
Shore-LIJ Health System; 4UTHSC.
Background: Previous studies have shown that low serum albumin(Alb) levels are 
associated with higher mortality in hemodialysis (HD) patients. While serum Alb is a 
critical inflammatory and nutrional marker, low Alb may also result from albuminuria. It is 
unknown if a change in serum Alb over time is due to the loss of residual kidney function. 
While data on urine Alb was unavailable, we hypothesized that higher urine volume (UV) 
is associated with a decrease in Alb.
Methods: Among 38,504 incident HD patients receiving care from a large dialysis 
organization from 2007-2011, we examined serum albumin level trajectory over 5 years 
(divided into 20 patient quarters) across five strata of baseline UV: <300, 300-<600, 600-
<900, 900-<1200, ³1200 mL. The association between baseline UV and serum albumin 
trend was examined using mixed effects models with adjustment for age, gender, race, 
diabetes, and insurance type.
Results: Patients were 62±15 years old, 38% female, 28% black, and 46% diabetic. 
Higher baseline UV was incrementally associated with higher Alb levels across strata: 
3.44±0.48g/dL, 3.50±0.46g/dL, 3.57±0.44g/dL, 3.59±0.45g/dL, and 3.65±0.46g/dL, 
respectively.[Figure] Serum Alb increased over the first 6 patient quarters (18 months) on 
dialysis and then stabilized. Patients with higher UV not only had a higher baseline serum 
Alb level, but also maintained a higher serum Alb level over follow-up.
Conclusions: Higher baseline UV appears to be associated with sustained higher 
serum Alb levels over time. Improvement in hypoalbuminemia as a result of transition to 
dialysis therapy appears to be independent of residual kidney function and may suggest 
an inherent advantage of dialysis initiation.
Funding: NIDDK Support
FR-PO866
Individual Variation of Hippuric Acid and P-Cresyl Sulfate Plasma Levels 
Correlate with Variation of Intestinal Microbial Phylotypes in Hemodialysis 
Patients  Griet Lrl Glorieux,1 Sara Vieira-Silva,2 Sunny Eloot,1 Eva Schepers,1 
Annemieke Dhondt,1 Raymond C. Vanholder,1 Jeroen Raes,2 Geert Huys,3 Marie 
Joossens.2  1Renal Div, Ghent Univ Hospital, Gent, Belgium; 2Microbiology 
and Immunology, KULeuven, Leuven, Belgium; 3Microbiology, Ghent Univ, 
Gent, Belgium.
Background: In chronic kidney disease (CKD),a myriad of metabolites accumulate 
in the circulation. A substantial part is generated by intestinal microbiota. We hypothesize 
that there is a link between plasma levels of these uremic metabolites and the composition 
of the intestinal microbiota.
Methods: Over 4 months,up to 8 consecutive plasma and fecal samples from 16 
hemodialysis patients (14M/2F;74±10y;vintage:43±30mo) were collected. Uremic 
metabolites were quantified by UPLC. Fecal microbial DNA was amplified for 16S rDNA 
(V4 hypervariable region) sequencing (Illumina MiSeq). After quality and chimera filtering 
(UCHIME),data was rarefied to 10,000 reads/sample and taxonomically annotated (RDP). 
Correlation between the maximum intra-patient variability of metabolite levels and the 
corresponding time-points of fecal microbial phylotypes was assessed. In addition, cross-
sectional correlations at t0 were evaluated. Statistical analyses were performed with R 
package phyloseq,using Spearman correlation,with multiple testing correction (FDR) per 
metabolite for the number of genus-level phylotypes.
Results: Within this patient group,we observed a strong positive correlation between 
an increase in total hippuric acid and unclassified Peptostreptococcaceae (ȡ=0.83;corrected 
p-value=0.012). We also found a positive trend for total p-cresyl sulfate and unclassified 
Clostridiales and unclassified Ruminococcaceae (ȡ=0.77 and 0.74;corrected p-value=0.074 
and 0.078,respectively). Cross-sectionally at t0,strong negative correlations between 
indoxyl sulfate, indole acetic acid and specific unclassified bacterial phylotypes (ȡ=-0.79 
and -0.84;corrected p-value=0.028 and 0.004) were observed.
Conclusions: There is a link between plasma levels of specific uremic metabolites 
and fecal bacterial phylotypes,suggesting that these microbiota might be a target for 
reducing uremic metabolite levels in patients with CKD. Data needs validation on larger 
patient groups.
Funding: Government Support - Non-U.S.
FR-PO867
Decreased Vitamin K Intake in Italian Hemodialysis Patients  Maria Fusaro,1 
Claudia D’Alessandro,2 Marianna Noale,1 Giovanni Tripepi,4 Luciana Bonfante,3 
Nicola Veronese,6 Irene Santinello,3 Sabina Zambon,5 Sandro Giannini,5 
Maurizio Gallieni,6 Adamasco Cupisti.2  1CNR - Padua, Italy; 2Div of Nephrology 
Dept of Clinical and Experimental Medicine, Univ of Pisa; 3Nephrology Unit, 
Univ of Padua; 4CNR-IFC Clin. Epid. and Physiopath. of Renal Dis. and Hypert. 
of Reggio Calabria; 5Clinica Medica 1, Univ of Padua, Italy; 6Univ of Padova; 
7Dialysis Unit St Carlo, Milan, Italy.
Background: Vitamin K is involved in the production of Bone and Matrix Gla Proteins 
(BGP and MGP, respectively), regulating bone and vascular health. We carried out a pilot 
study to evaluatevitamin K intake in hemodialysis (HD) patients.
Methods: We measured vitamin K1 intake (7-day food record) in 78 italian 
hemodialysis patients (48 M, 30 F) compared to intake in 39 healthy adults (28 M, 11 F).
Results: HDpatients had a mean (± SD) age of 62.8±15.0 years, median dialytic age of 
97 months, mean BMI of 25.4±4.5 Kg/m2. Mean serum levels of interest for CKD-MBD 
were: Ca 9 mg/dL, P 4.3 mg/dL, PTH 231.5 pg/mL, ALP 81.5 U/l. Control group mean age 
was 54.6±13.9 years. HD patients had a significantly lower intake of vitamin K1 compared 
to controls (see Table).We also evaluated and compared between HD patients and controls 
the intake of other fat soluble vitamins and of nutrients closely associated with bone and 
mineral disorders in CKD patients (see table). All were decreased in HD patients. 
Data Patients Controls p value
Vitamin K1 (mcg/day) [Median] 70.1 109.2 0.0009
Vitamin A (mcg/day) [Median] 306 495.0 <0.0001
Vitamin D (mcg/day) [Median] 1.2 1.74 0.0326
Active Vitamin E (mcg/day) [Median] 7.1 11.24 <0.0001
Calcium (mg/day) [Median] 364.5 587.8 <0.0001
Phosphorus (mg/day) [Median] 749.2 1079.2 <0.0001
Magnesium (mg/day) [Median] 144.9 212.7 <0.0001
Conclusions: This Vitamin K intake study is the first carried out on Italian diet. 
We found a decreased intake of Vitamin K1 in HD patients. This finding supports the 
hypothesis of supplementing vitamin K for the prevention of vascular calcifications and 
bone disorders in HD patients. Benefits of vitamin K supplementation should be proved 
by a randomized trial.
FR-PO868
Association of Geriatric Nutrition Risk Index with Body Fluid Composition, 
Renal Adverse Outcomes and Mortality in Patients with Chronic Kidney 
Disease  Reibin Tai, Yasushi Ohashi, Toshiyuki Aoki, Shizuka Kobayashi, 
Atsushi Aikawa, Ken Sakai.  Dept of Nephrology, School of Medicine, Faculty 
of Medicine, Toho Univ, Tokyo, Japan.
Background: Decreased body stores of protein and energy fuels may express by the 
geriatric nutritional risk index (GNRI) consisting of body mass index (BMI) and serum 
albumin levels. We studied the association of the GNRI with body fluid composition, renal 
adverse outcomes and all-cause mortality in patients with chronic kidney disease (CKD).
Methods: Body fluid composition was measured in 306 patients with CKD from 
2005 to 2014 and was separated into three components – (a) free water mass consisting 
of muscle, fat, and minerals, (b) intracellular water (ICW) content, and (c) extracellular 
water (ECW) content. Patients were categorized according to tertiles of GNRI levels. Of 
those, 275 patients were followed until March 2015. The adverse renal outcomes were 
defined by a decline of 50% or more from baseline glomerular filtration rate or initiation 
of renal replacement therapy.
Results: Patients with the lower tertiles of the GNRI levels were more likely to be higher 
age, have a lower BMI, diastolic blood pressure, serum albumin, hemoglobin, glomerular 
filtration rate, and proteinuria (P < 0.05). In the body fluid composition, those tended to 
have lower free water mass (r = 0.73, P <0.001) and the ratio of extracellular water to 
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intracellular water (r = 0.37, P <0.001). Compared with patients with the middle tertile of 
the GNRI levels during a median 2.5-year follow-up, the lowest tertile of the GNRI levels 
had higher mortality (6.8 vs. 1.7 per 100 patient-years, P < 0.001), but had no worse adverse 
renal outcomes (16.5 vs. 9.0 per 100 patient-years, P = 0.08). In multivariate analysis, the 
lower GNRI levels independently remained as a risk factor for all-cause mortality (hazard 
ratio, 3.16; 95% CI, 1.30–8.84; P < 0.001).
Conclusions: The GNRI may be a simple and useful tool for predicting the risk of 
mortality even in CKD population including patients with massive proteinuria. These 
findings emphasize the importance of adequate body stores of protein and energy fuels 
in patients with CKD.
FR-PO869
A Novel Index for Estimation of Muscle Mass Using Biomarkers of Kidney 
Function: Sarcopenia Index  Kianoush Banaei-Kashani,1,2 Lucie Kukralova,3 
Erin N. Frazee,4 Rahul Kashyap.2  1Div of Nephrology and Hypertension, Dept 
of Internal Medicine, Mayo Clinic, Rochester, MN; 2Div of Pulmonary and 
Critical Care, Dept of Internal Medicine, Mayo Clinic, Rochester, MN; 3Faculty 
of Medicine in Hradec Kralove, Charles Univ, Prague, Czech Republic; 4Dept 
of Pharmacy, Mayo Clinic, Rochester, MN.
Background: Sarcopenia is associated with poor patients’ outcomes in Intensive Care 
Unit (ICU). Tools to evaluate sarcopenia are DXA scan, CT and MRI, which may not be 
feasible for critically ill patients. We hypothesize a novel index which can be used as a 
surrogate for sarcopenia among ICU patients.
Methods: This is a secondary analysis of prospectively enrolled critically ill patients. 
Adult ICU patients (>18 years) with shock, sepsis, use of IV antibiotics and contrast media 
exposure, in 24 hours of enrollment, intra-abdominal hypertension or severe Trauma were 
included. We excluded patients with pre-existing acute kidney injury, pregnancy, and 
kidney transplant, or those who were on dialysis or were moribund. We measures paraspinal 
muscle surface area at L3 level, using Slice-O-Matic software (TomoVision®,Magog, 
Canada). Sarcopenia Index (SI) was calculated as [Serum Creatinine (Scr) ÷ Cystatin C 
(CysC)] X 100.
Results: A total of 226 patients met the inclusion criteria. Among these enrollees, 
110 patients who had abdominal CT within ± 4 weeks of their index ICU admission were 
included in the final analysis. The median age (IQR) was 67 (57-77) years and 59 (54%) 
were male. SI and Paraspinal Muscle Surface Area were found to be statistically correlated 
(R2 = 0.26, p<.0001).
Conclusions: SI has a fair correlation with gold standard in critically ill patients. 
This index would be a surrogate for sarcopenia for patients who cannot tolerate transfer 
to imaging testing.
FR-PO870
Association with Activities of Daily Living and Geriatric Nutritional Risk 
Index Improves the Prediction of Mortality in Patients on Hemodialysis 
Kaoru Yasuda,1 Shoichi Maruyama,2 Kunio Morozumi.1  1Nephrology, Masuko 
Memorial Hospital, Nagoya, Aichi, Japan; 2Nephrology, Nagoya Univ, Nagoya, 
Aichi, Japan.
Background: Protein energy wasting (PEW) is a typical status of Malnutrition seems to 
be a prevalent complication in end-stage renal disease (ESRD), and is associated with poor 
prognosis. We previously reported that Geriatric Nutritional Risk Index (GNRI) is useful 
marker for the assessment of malnutrition status in hemodialysis (HD) patients. However 
the interaction between actual activities of daily living(ADL) and GNRI is uncertain. 
We investigated the prognostic value of the ADL and GNRI, and hypothesized that the 
combination of both indicators could improve predictive values for mortality in HD patients.
Methods: A total of 304 stable HD patients were enrolled. They were divided into 
tertiles according to the ADL defined by the Renal Data Registry of Japanese Society for 
Dialysis Therapy; tertile A: < independence, B: care-needed (mild) and C: care-needed 
(moderate or severe). They were also divided into tertiles of GNRI levels; L: <91.7, M: 
91.7-97.8 and H: >97.8, and GNRI were 95.9±7.6,94.9±5.8,87.1±11.0in A, B and C of 
ADL, respectively (p<0.0001 in both).
Results: During the follow-up period (40 month), 59 patients were died (19.4%). 
Kaplan-Meier survival rates for 4 years were 88.9%, 82.1% and 53.1% in A, B and C of 
ADL, and were 63.5%, 82.8% and 88.8% in L, M and H of GNRI, respectively (p<0.0001 
in both). The adjusted HR for mortality was 3.21 (95% CI, 1.57-6.95, p=0.0006, C vs 
A) and 3.24 (95% CI, 1.62-7.06, p=0.0019, L vs H). In the combined setting of ADL 
and GNRI with 9 groups (3x3), the risk of mortality was 8.02-fold (95%CI 2.56-35.4, 
p=0.0001, C+L vs A+H).
Conclusions: ADL and GNRI could strongly predict the mortality, and combination of 
both setting also improved the prediction of mortality with ESRD patient on HD.
Univariate Multivariate
HR (95%CI) P value HR (95%CI) P value
Life activity 
(vs. A) <0.0001 0.0006
B 1.69 (0.82-3.60) 0.15 1.15 (0.54-2.51) 0.71
C 5.80 (3.02-11.8) <0.0001 3.21 (1.57-6.95) 0.0012
GNRI (vs. >97.9) <0.0001 0.0019
91.7-97.9 2.31 (1.29-4.32) 0.0042 1.65 (0.75-3.79) 0.21
<91.7 3.99 (2.04-8.54) <0.0001 3.24 (1.62-7.05) 0.0006
FR-PO871
Delta Neutrophil Index Is a Predictive Marker of Disease Severity in 
Patients with Acute Pyelonephritis  Sul A Lee,1 Jong Hyun Jhee,1 Jae Eun Um,2 
Meiyan Wu,2 Hyung Jung Oh,1 Jung Tak Park,1 Seung Hyeok Han,1 Shin-Wook 
Kang,1,2 Tae-Hyun Yoo.1  1Dept of Internal Medicine, Yonsei Univ College of 
Medicine, Seoul, Korea; 2Severance Biomedical Science Inst, Brain Korea 21 
PLUS, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Delta neutrophil index (DNI) is the fraction of immature granulocytes 
provided by a complete blood count analyzer. Previous studies demonstrated that DNI was 
a novel marker to predict clinical outcomes in sepsis patients. Therefore, this study was 
aimed to evaluate DNI as a predictive marker of disease severity in patients with acute 
pyelonephritis (APN).
Methods: Patients who were diagnosed with APN at Severance Hospital from 
December 2009 to July 2012 were retrospectively investigated. DNI levels were measured 
at the time of admission. Patients were classified into two groups according to the median 
value of DNI. Severe APN was defined as one or more of following conditions; bacteremia, 
acute kidney injury, hypotension requiring use of vasopressors, and admission of intensive 
care unit. Independent risk factors for severe APN were determined by multivariate logistic 
regression analysis. Area under the receiver operating characteristic curves (AUC) was 
compared among DNI, white blood cell (WBC) count, and C-reactive protein (CRP).
Results: A total of 258 patients were included in this study. The median age was 61.0 
(19.0 – 87.0) years, and 237 patients (91.9%) were female. The median DNI levels were 
2.5%. Severe APN was significantly more prevalent in the high DNI group. Multivariate 
analysis showed that DNI independently predicted severe APN (per 1% increase, odds 
ratio=1.287, 95% confidence interval=1.135-1.458, P<0.001). Furthermore, DNI was a 
better predictive marker of severe APN than WBC count [AUC (95% confidence interval); 
0.697 (0.637-0.753) vs. 0.562 (0.499-0.624), P=0.001] and not inferior to CRP levels [0.697 
(0.637-0.753) vs. 0.633 (0.571-0.692), P=0.118].
Conclusions: DNI at admission could be a valuable predictor of disease severity in 
patients with APN.
FR-PO872
An Improved Magnesium Formulation for Mitigating Cisplatin-Induced 
Renal Epithelial Cell Injury  Malvika H. Solanki,1,2,3 Rachel Lauren Mintz,2 
Xiangying Xue,2 Prodyot K. Chatterjee,2 Christine N. Metz.1,2,3  1Elmezzi 
Graduate School of Molecular Medicine, NY; 2Feinstein Inst for Medical 
Research, NY; 3Hofstra-North Shore-LIJ School of Medicine, NY.
Background: Cisplatin is a potent chemotherapy for treating cancer. It causes 
nephrotoxicity in ~25% and hypomagnesemia in ~90% patients. This hypomagnesemia 
is treated with oral magnesium (Mg) chloride (MgCl2) and/or i.v. Mg sulfate (MgSO4). 
Poor Mg intake and Mg deficiency are not uncommon in the US. Our previous studies 
revealed the beneficial effects of MgSO4 in reducing cisplatin-induced acute kidney injury 
(AKI) (Solanki et al, AJP Renal 2014). This study compared the efficacy of various Mg 
formulations in reducing cisplatin-induced renal epithelial cell injury.
Methods: LLC-PK1 renal epithelial cells were maintained in media containing 100%Mg 
(i.e. the amount of Mg found in growth media) or 10%Mg (Mg-deficient) for 3 days. 
To mimic Mg replacement, the 10%Mg cells were restored to 100%Mg using: MgSO4, 
Mg-L-threonate (MgT), MgCl2, and Mg gluconate (MgG) (keeping elemental Mg equal) 
and then treated with vehicle or cisplatin. Oxidative stress, cytotoxicity and inflammation 
were measured by DCF-DA assay, MTT assay and TNFα production, respectively. ERK 
activation was measured by in-cell-western.
Results: Cisplatin-induced oxidative stress, cytotoxicity, and inflammation were 
exacerbated by Mg deficiency, while Mg supplementation with all formulations consistently 
and significantly attenuated these effects. MgT was the most effective Mg-formulation 
for reducing cisplatin-induced oxidative stress and inflammation. Mechanistic studies 
revealed that cisplatin-induced ERK activation was modulated by Mg status and MgT 
was most protective.
Conclusions: Mg supplementation protected against cisplatin-induced oxidative stress, 
cytotoxicity and inflammation in renal epithelial cells. This is the first study to reveal the 
effectiveness of MgT over other Mg-formulations in reducing cisplatin-induced renal 
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epithelial cytotoxicity. Note: MgT has significantly lower GI-effects (bloating and diarrhea) 
than other Mg formulations. These results warrant further in vivo and clinical studies to 
investigate the beneficial role of MgT in protecting against cisplatin-AKI.
Funding: Private Foundation Support
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Impact of Uremic Serum on the Barrier Function and Inflammation in 
Human Colonocytes  Laila Santos Andrade,1 Maria Dalboni,2 Jose Tarcisio 
Giffoni,2 Caren Cristina Grabulosa,2 Lilian Cuppari.1,2  1Nutrition Graduation 
Program, Federal Univ of São Paulo, São Paulo, Brazil; 2Medicine, Div of 
Nephrology, Federal Univ of São Paulo, São Paulo, Brazil.
Background: In chronic kidney disease (CKD) it has been suggested that alterations 
of the gut are associated with inflammatory state and uremic toxicity. Studies suggest 
that uremia may impair the intestinal barrier function, by promoting increased intestinal 
permeability. In this study we aimed to evaluate the in vitro effect of uremic serum on the 
transepithelial electrical resistance (TER), inflammation and apoptosis in the intestinal 
epithelial cells.
Methods: Pools of serum were prepared from blood samples from patients maintained 
on hemodialysis (Pre-HD and Post-HD), and of patients with CKD stage 4 (NND-CKD). A 
pool of serum form healthy individuals served as control (CTL). When the TER exceeding 
1,000  /cm² was reached, the T84 cells were incubated for 24 h in medium containing 
10% pool of serum from each group. At the conclusion of the incubation period, the TER 
was measured again and the following parameters were determined by flow cytometry: 
expression of toll-like receptor (TLR), production of reactive oxygen species (ROS) and 
apoptosis. TNF-α and IL-6 in the culture supernatant was determined by ELISA. A total 
of nine experiments were performed.
Results: No differences among groups were found regarding TER (p= 0.443), apoptosis 
(p= 0.751), ROS (p= 0.999), expression of TLR-2 (p= 0.493), TLR-4 (p= 0.418) and TLR-9 
(p= 0.937) and secretion of TNF-α (p= 0.438). IL-6 secretion was higher (p<0.001) by cells 
incubated with post-HD pool (2.07±0,93pg/ml) when compared with cells incubated with 
CTL pool (0.67±0.35), NND-CKD (0.61±0.53) and pre-HD (0.11±0.45).
Conclusions: The results obtained from this model suggest that uremic serum per 
se does not seem to impair the integrity of intestinal epithelial cells. The increased IL-6 
secretion in post-HD condition may be a consequence of pro-inflammatory stimulus of 
the dialysis process.
Funding: Government Support - Non-U.S.
FR-PO874
Prediction of One-Year Mortality and Hospitalization Risk Using 
Nutritional Indicators and Their Trajectories in a Large Prevalent 
Hemodialysis Cohort  Michelle M.Y. Wong,1 Stephan Thijssen,1 Yuedong 
Wang,2 Len A. Usvyat,3 Qingqing Xiao,1 Peter Kotanko,1 Franklin W. Maddux.3 
1Renal Research Inst; 2Univ of California - Santa Barbara; 3Fresenius Medical 
Care North America.
Background: Existing nutritional scores developed in the hemodialysis (HD) 
population do not consider temporal trajectories of nutritional parameters. We aimed 
to develop predictive models for mortality and hospitalization using readily available 
nutritional indicators and their rates of change.
Methods: Using retrospective data from a large US HD provider, a cohort with 
HD vintage ³1 year (N=21,082 and N=23,384 in mortality and hospitalization analyses, 
respectively) was randomly split 2:1:1 for model development, testing and validation. 
Parameters included demographics, nutritional/inflammation parameters, and slopes of 
all continuous variables over 6 months. Follow-up period was January-December 2012. 
Performance of generalized linear models and generalized additive models (GAM) was 
evaluated with area-under-the-curve (AUC), sensitivity and specificity.
Results: For both mortality and hospitalization prediction, GAM performed best. The 
best mortality model included neutrophil:lymphocyte ratio (NLR) slope, serum bicarbonate 
slope, albumin, creatinine, age, sex and vintage (AUC 0.85, 95% CI 0.83-0.86; sensitivity 
0.70; specificity 0.83). The best hospitalization model included NLR slope, albumin, 
congestive heart failure, serum bicarbonate slope, creatinine, serum phosphate slope, 
vintage, diabetes, serum phosphate, volume of urea distribution, age and enPCR (AUC 
0.70, 95% CI 0.62-0.79; sensitivity 0.41; specificity 0.88).
Conclusions: We developed novel and accurate predictive models for mortality and 
hospitalization using nutritional indicators and their slopes over time. Future studies are 
needed to assess if its application can improve nutritional intervention allocation and 
outcomes in HD patients.
Funding: Pharmaceutical Company Support - Renal Research Institute
FR-PO875
Extracellular Fluid/Intracellular Fluid (ECF/ICF) Volume Ratio Is a 
Novel Risk Indicator of Death and Highly Related to Malnutrition-
Inflammation-Arteriosclerosis (MIA) Complex in Hemodialysis (HD) 
Patients  Eunjung Kim, Soyon Rhee, Jiwon Ryu, Hee Jung Jeon, Jung-woo 
Noh, Ja-Ryong Koo.  Nephrology, Hallym Univ Hospital, Dongtan/Seoul, Korea.
Background: Fluid overload and malnutrition are well recognized risk factors 
contributing to the high mortality in HD patients. Recent studies suggest pathophysiological 
link between fluid overload and malnutrition as a part of MIA complex. Because the ECF 
and ICF volume can represent fluid volume and nutritional status respectively, ECF/ICF 
ratio could be defined as a novel integrated marker reflecting both fluid overload and 
malnutrition. Accordingly we investigated the relationship of ECF/ICF ratio to survival in 
the context of MIA complex in chronic HD patients.
Methods: 77 HD patients (age 53±13 year, diabetes 38%) were prospectively enrolled. 
ECF/ICF volume was measured by multi-frequency bioimpedance analysis. Nutrition, 
inflammation, arteriosclerosis and volume status were measured by serum albumin, 
C-reactive protein (CRP), pulse wave velocity (PWV) and serum B-type natriuretic 
peptide(BNP) respectively.
Results: Mean ECF/ICF ratio was 0.56±0.06 and cut-off value for maximum 
discrimination of survival was 0.57 by ROC curve. As compared with low ECF/ICF group 
(ratio<0.57, 58%), high ECF/ICF group (ratio³0.57, 42%) had higher all-cause mortality, 
CRP, PWV, BNP and lower serum albumin level. During the 5-year follow-up, 24 all-
cause death occurred (18 in high ECF/ICF group versus 6 in low ECF/ICF group, log rank 
P<0.001). In Cox analysis adjusted for age, diabetes, BP and cardiac function, the ECF/
ICF ratio was an independent predictors of all-cause death (HR=1.25, 95% CI=1.10-1.54, 
per Δ0.01 in ECF/ICF ratio) and nullify the effect of MIA component and volume marker 
on survival. The degree of malnutrition (albumin), inflammation (CRP), arteriosclerosis 
(PWV) and fluid overload (BNP) were correlated well with ECF/ICF ratio.
Conclusions: Chronic HD patient with high ECF/ICF ratio is not only fluid overloaded 
but malnourished and have stiff artery with more inflammation. As a novel integrated marker 
of fluid overload and malnutrition, ECF/ICF ratio is highly related to MIA complex and a 
major risk indicator of death in chronic HD patients.
FR-PO876
Weight Gain After Listing Independently Predicts Pre-Transplant 
Sensitization Status  Pritika Shrivastava,1 Krista L. Lentine,2 Ankit Sakhuja,1 
Fidel Barrantes,3 Diane M. Cibrik,1 Yihung Huang,1 Abhijit S. Naik.1  1Univ of 
Michigan; 2Saint Louis Univ; 3Renal Medical Associates, NM.
Background: Non-alloimmune stimuli such as infections, vaccinations and pro-
inflammatory events cause sensitization to HLA antibodies and increased panel reactive 
antibodies. Obesity is recognized as an inflammatory state. Given relationship between 
obesity and inflammation we speculated that weight gain on the waitlist may increase 
sensitization status at the time of transplantation.
Methods: Using national data from the Organ Procurement and Transplantation 
Network we identified first time kidney only transplant recipients, aged 18-70, transplanted 
between January 1,2009 and June 30,2013.Previous non-renal transplants were excluded. A 
calculated panel reactive antibody of 20 % or more at the time of transplant was considered 
to be “sensitized”. Using a priori chosen variables we performed a logistic regression model 
with sensitized status at time of transplantation as the dependent variable and change in 
BMI from listing to transplantation, BMI at transplant, recipient age, prior transfusion 
status, prior pregnancy, dialysis time and race as independent variables.
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Results: Among 55,894 patients transplant recipients. 39.45 % were female of which 
67.33 % were previously pregnant. Overall 15.12 % had received prior blood transfusions.
Mean BMI at wait listing and transplantation was similar at 28.4± 5.5 kg/m2. Greater 
than 50 % patients with BMI ≥ 30 kg/m2 at listing had an increased their BMI by time of 
transplantation,while >50 % patients in BMI<30 kg/m2 had lost weight. A 1-unit increase in 
BMI (kg/m2) after transplantation was associated with an increased risk of being sensitized, 
aOR:1.01 (1.01-1.02). Other independent predictors included prior transfusion aOR:1.25 
(1.18-1.33), AA race aOR:1.26 (1.19-1.32), pregnancy aOR:3.32 (3.04-3.63), dialysis time 
aOR:1.23 (1.11-1.14).
Conclusions: The majority of obese patients gain weight on the waitlist. We identified 
weight gain on the waiting list to be associated with a small but statistically significant 
increase in odds of being sensitized. Further studies are needed to determine the impact of 
malnutrition-inflammation complex on pretransplant sensitization.
FR-PO877
High Salt Diet Impairs the Immune Defense against Uropathogenic 
Escherichia coli in Murine Pyelonephritis  Katarzyna Jobin, Katharina 
Hochheiser, Maike Giesing, Christian Kurts.  Inst of Experimental Immunology, 
Univ of Bonn, Bonn, Germany.
Background: Recent studies demonstrated that NaCl stimulates immune responses, for 
example by promoting Th17 cells differentiation, macrophage recruitment into tissues and 
pro-inflammatory cytokine release from epithelial cell lines. Specially, high salt diet (HSD) 
exacerbated experimental autoimmune encephalomyelitis and improved immune defense 
against L. major infection. Little is known about the influence of HSD on anti-microbial 
responses in the kidney – an organ with extremely high sodium chloride concentration.
Methods: Wild type female mice were given normal salt diet (NSD) or HSD one week 
prior to infection with uropathogenic E. coli into the bladder resulting in pyelonephritis 
development. 20 h after the infection, kidneys were harvested and analyzed for CFU and 
immune cell subsets by flow cytometry.
Results: HSD exacerbated pyelonephritis as measured by CFU. Additionally, in kidney 
medullas of mice fed HSD the number of PMNs, Ly6chi macrophages and NK cells was 
significantly decreased in comparison with NSD fed mice. Although PMNs from mice given 
HSD produced more ROS than PMNs from mice on NSD, in vitro studies demonstrated that 
less medullary PMNs from mice fed HSD than NSD were able to perform phagocytosis.
Conclusions: Contrary to the expectations, HSD worsened experimental pyelonephritis, 
possibly through affecting immune cell activation and/or migration into the kidney medulla. 
This finding may be of clinical significance and, if confirmed in human studies, decreasing 
salt intake during bladder infection or pyelonephritis could support antibiotic therapy. 
Further studies are needed to elucidate the immune mechanisms underlying the negative 
effect of HSD on pyelonephritis.
Funding: Government Support - Non-U.S.
FR-PO878
Gut Microbiota Lactobacillus Protects against the Progression of Renal 
Impairment Through the Modulation of TLR2-Mediated Gut Barrier 
Stability in Rats  Ayumi Yoshifuji, Shu Wakino, Junichiro Irie, Takaya Tajima, 
Kazuhiro Hasegawa, Hirobumi Tokuyama, Hiroshi Itoh.  Keio Univ, Japan.
Background: Gut microbiota has been shown to have some role in the pathogenesis 
of various diseases and previous study demonstrated that Lactobacillus(Lact) decreased in 
number in CKD. In this study, we elucidated the significance of Lact in the pathogenesis 
of CKD.
Methods: Six-week-old spontaneously hypertensive rats (SHR) were rendered CKD 
by 5/6th nephrectomy (Nx). The SHRs were divided into three groups; sham-operated SHR 
(SHR), SHR with Nx (Nx) and Nx given Lact (Nx+Lact). After 12 weeks, biochemical 
parameters, urinary protein excretion, IL-6, histological changes in the kidney, and 
molecular changes of tight junctions and TLR2 expression were explored. Furthermore, 
concentrations of fecal uremic toxins were measured. To confirm the effect of Lact, rats 
are administered with broad antibiotics as pseudogerm-free condition and kept for 8 weeks 
with Lact. Human colon cell line, Caco-2 cells were treated with uremic toxin precursor, 
indole in the presence or absence of Lact or OxPAPC, an inhibitor of toll-like receptor, 
putative receptor recognizing Lact. The expressions of colon tight junction proteins were 
examined by immunoblotting.
Results: The gut flora analysis revealed that the decrease in Lact in Nx, which was 
restored in Nx+Lact. However, fecal uremic toxins did not show significant changes. 
Both serum indoxylsulfate and IL-6 increased in Nx. These increases were ameliorated 
in Nx+Lact. The decreases in the tight junction proteins Occludin and Zo-1 as well as in 
TLR2 in Nx were mitigated by Lact. In the pseudogerm-free condition, Lact decreased 
the urinary protein excretion. In Caco-2 cells, the downregulations of Occludin and ZO-1 
by indole were ameliorated by Lact. OxPAPC inhibited the Lact-induced restoration of 
these tight junctions.
Conclusions: The supplementation of Lact improves the gut environment through 
the activation of TLR2 pathway. This improvement would contribute to the decrease in 
systemic uremic toxin levels, systemic inflammation and urinary protein excretion. This 
probiotic therapy can provide novel therapeutic strategy against the progression of CKD.
Funding: Government Support - Non-U.S.
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Relationship Between Serum Uric Acid Change and Renal Injuries: An 
Observational Cohort Research from Pinggu District, Beijing  Xiaohong Fan, 
Wenling Ye, Jianfang Cai, Jie Ma, Ying Sun, Xuewang Li, Xuemei Li.  Dept of 
Nephrology, Peking Union Medical College Hospital.
Background: Hyperuricemia is thought to be a risk factor of CKD and ESRD. This 
research aims to demonstrate the relationship between serum uric acid change (ΔUA)based 
upon baseline from general population and indexes of renal injuries.
Methods: This cohort research was based on 5 years’ follow up of an epidemiological 
studyin 2008 in Pinggu District, Beijing. Baseline population was 7086, and 5364 subjects 
were followed up in 2014. All subjects were interviewed with questionnaires, tests of 
anthropometric indicators, blood and urine sample collection. Serum creatinine, cystatin C, 
etc were tested. Urine sample was used to test ACR, α1mG, and NAG. Hyperurincemia is 
defined as serum uric acid is above 420mmol/L for men, and above 360mmol/L for women. 
According to baseline of 2008 and blood uric acid level of 2014 (Normal, N; High, H), 
patients were grouped as: N/N, H/N, N/H, H/H(group1-4). One-way ANOVA was applied 
to evaluate differences of indexes among all groups. Risk factors of CKD (ACR³3.39mg/
mmol & eGFR<60ml/min/1.732)were evaluated with Multiple Logistic regression analysis.
Results: 1. 5364 patients(M:F 1:1.1)were included. In 2008 prevalence of 
hyperurincemia was 5.9%(7.0% for men, 5.0% for women), and Prevalence of 
hyperurincemia was 6.2%(8.5% for men, 4.2% for women)in 2014. 2.ΔeGFR of group 
N/H,H/H were significantly higher than that of group N/N,H/N, indicating that GFR of 
hyperurincemia patients following up in 2014 declined more than that of patients without 
hyperurincemia; serum cystatin C in 2014 increased significantly from group 1 to group 
4; there was no significant difference among all groups inα1mG,NAG/Cr. 3. ΔUA, age, 
BMI, hypertension, DM were independent risk factors of CKD. HR of CKD in group 
N/H,H/H was 1.87 times(95%CI 1.30-2.68, P=0.001) and 4.2 (95%CI 2.60-6.70, P<0.001)
times of group N/N.
Conclusions: In general population, elevation of serum uric acid is the independent 
risk factor of GFR decline and serum cystatin C ascent. It is also the independent risk 
factor of the development of CKD, and the decline of uric acid in the blood may reduce 
the risk of renal injuries.
Funding: Government Support - Non-U.S.
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Leucine Disposal Rate for Assessment of Amino Acid Metabolism in 
Maintenance Hemodialysis Patients  Gerald Denny,1 Serpil Muge Deger,1,2 
Feng Sha,1 Cindy Booker,1,2 Charles D. Ellis,1 Talat Alp Ikizler.1,2  1Nephroloy, 
Vanderbilt Univ, TN; 2Veteran Affairs, TN.
Background: Protein energy wasting (PEW) is common in patients undergoing 
maintenance hemodialysis (MHD) and is closely associated with poor outcomes. Insulin 
resistance and associated alterations in amino acid metabolism is a potential pathway leading 
to PEW. In this study we hypothesized that measurement of leucine disposal rate (LDR) 
during a hyperinsulinemic-euglycemic-euaminoacidemic clamp (HEAC) procedure would 
accurately measure the sensitivity of insulin for its actions on concomitant carbohydrate 
and protein metabolism in MHD patients.
Methods: We examined 15 MHD (aged 52±13 years, BMI 29± 5 kg/m2) patients and 16 
control subjects (aged 46±10 years and BMI 28±7 kg/m2) by hyperinsulinemic euglycemic 
clamp (HEGC) procedure followed by HEAC clamp procedure to obtain glucose disposal 
rate (GDR) and LDR, respectively.
Results: The GDR by HEGC was 4.9±1.9 mg/kg/min in the MHD subjects compared 
to 6.3±4.1 mg/kg/min in the controls (P=0.47). The LDR during HEAC was 0.09±0.03 mg/
kg/min for MHD patients vs 0.12±0.05 mg/kg/min for control (P=0.11). The GDR derived 
by HEGC and LDR correlated well in the control population (r=0.793, P=0.001), but less 
so in the MHD subjects (r=0.346, P=0.25).
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Conclusions: Leucine disposal rate reliably measures amino acid utilization in MHD 
patients. The lack of correlation between GDR versus LDR in MHD subjects requires further 
investigation for understanding the effects of insulin signaling on protein metabolism in 
MHD patients.
FR-PO881
Age and Dependence on Dialysis Are More Important Predictors of 
Immune Response to Influenza Vaccine Than Inflammation and Iron Status 
Jaromir Eiselt,1 Lukas Kielberger,1 Daniel Rajdl,2 Jaroslav Racek.2  1Internal 
Dept 1, Charles Univ, Plzen, Czech Republic; 2Dept of Biochemistry, Charles 
Univ, Plzen, Czech Republic.
Background: The immune response to influenza vaccine is not uniform and may be 
influenced by many factors, e.g. comorbidities, age, inflammation or iron metabolism. The 
aim of our study was to identify factors associated with low production of hemagglutination-
inhibition antibodies (HIA) after vaccination in hemodialysis (HD) patients and controls.
Methods: We evaluated the immune response to the influenza vaccine in a total of 
122 stable HD patients and in 37 subjects without renal dysfunction. To identify factors 
associated with immune response, a stepwise backward and forward algorithm for a linear 
regression model was used with postvaccination increase in HIA titre against H1N1 vaccine 
strain as dependent variable and following independent variables: age, dependence on 
dialysis, diabetes, iron, transferrin, transferrin saturation, ferritin, hepcidin, interleukin-6, 
C-reactive protein, albumin, prealbumin and pre-vaccination HIA protective titre.
Results: The rate of HIA production was lower in HD patients than in controls. Factor 
increases in geometric mean titer for the H1N1 strain were 2.9 in HD and 6.6 in controls 
(p½0.001), with the respective figures being 2.8 and 3.1 (p=ns) for the H3N2 strain, and 
2.4 and 4.7 (P‹0.05) for the B strain. Also, post-vaccination seroconversion rates were 
lower in the HD group than in controls (43% versus 73% against the H1N1 strain; p‹0.05; 
43% versus 53% against the H3N2 strain; p=ns; and 36% versus 62% against the strain B; 
p‹0.05). According to the regression model (adjusted R2 0.298, p‹0.00001), the predictors 
of low HIA production against H1N1 strain were high age (p‹0.0001), dependence on 
dialysis (p=0.011) and high transferrin saturation (p=0,03).
Conclusions: The immune response to the influenza vaccine was lower in HD patients 
than in controls. Besides dependence on dialysis, the most significant predictors of low 
antibody production were high age of vaccinated subjects and high transferrin saturation. 
Immune response was independent of other markers of iron metabolism and inflammation.
Funding: Government Support - Non-U.S.
FR-PO882
Intravenous Administration of L-Carnitine (LC) May Maintain the Muscle 
Volume in Hemodialysis (HD) Patients  Jyunichiro Hashiguchi,1 Takuhisa 
Uchino,1 Miki Yano,1 Satoshi Funakoshi,1 Osamu Sasaki,1 Hiroshi Ichinose,1 
Kenji Sawase,1 Yoko Obata,2 Tomoya Nishino,2 Yutaka Mori,3 Kazunori 
Utsunomiya,3 Takashi Harada.1  1Nagasaki Kidney Center, Nagasaki, Japan; 
2Nagasaki Univ Graduate School of Medicine, Nagasaki, Japan; 3Jikei Univ, 
Tokyo, Japan.
Background: Patients on maintenance HD usually suffer from dialysis-related carnitine 
deficiency, causing various clinical symptoms. At Carnitine Consensus Conference in 
2003 convened by The National Kidney Foundation, the level of evidence was strongest 
for the treatment of anemia, and weakest for the response of muscle weakness. We hereby 
investigated whether intravenous administration of LC can maintain the muscle volume 
in HD patients as assessed by % creatinine generation rate (CGR).
Methods: Thirty-eight HD patients were enrolled in this study after appropriate 
informed consent. Subjects were treated with intravenous administration of 1000mg / body 
of LC at the end of every HD session for 12 months, then assessed by %CGR. Normalized 
protein catabolic rate (nPCR), geriatric nutritional risk index (GNRI) as well as serum 
albumin or hemoglobin levels were measured at the tree points; 1 year prior to the treatment, 
the start of LC administration and1 year after the treatment.
Results: As shown in Figure 1, average %CGR significantly declined during 1 year 
before the start of LC, and then stabilized 1 year after the treatment, suggesting LC 
administration might prevent the loss of muscle volume. Serum albumin, hemoglobin, 
nPCR and GNRI stayed the same level during observation period.
Conclusions: Intravenous LC administration may potentially maintain the muscle 
volume in patients undergoing HD.
Funding: Private Foundation Support
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FR-PO883
Nutrition Analysis Mobile Application in Patients with Chronic Kidney 
Disease  Chayakrit Krittanawong,1 Sakkarin Chirapongsathorn,2,3 Zhen Wang,4 
Hua Ann Jenny Lu.5  1Div of Cardiovascular Disease, Mayo Clinic, Rochester, 
MN; 2Div of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; 
3Div of Gastroenterology, Dept of Medicine, Phramongkutklao Hospital and 
College of Medicine, Royal Thai Army, Bangkok, Thailand; 4Dept of Healthcare 
Policy and Research, Mayo Clinic, Rochester, MN; 5Div of Nephrology, 
Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Background: While mobile phone applications have become increasingly important 
in the last decade, few eating healthy mobile applications exist for patients. Yet in their 
daily lives, patients on a restricted diet often lack instant access to health information with 
regards to the food that is in front of them. It is therefore an objective of this pilot project 
to introduce a device that patients can utilize to overcome such problems.
Methods: The nutrition analysis application is named “GoFoody Project” and primarily 
consists of two functions: a scanning system and a recommendation system.
Results: The first major component of this invention is the food scanning and 
recognition process, which is comprised of two sub-processes: a photo recognition and a 
barcode scanning. In the photo recognition, the user can take a picture of food and send 
it to the cloud database for further processing, regardless of their location. Second, the 
recommendation system compares the patient’s medical profile with their consumptions 
records in order to make health and dietary suggestions.
Conclusions: Over the next few years, we anticipated that this invention will be popular 
in grocery stores such as Walmart, Target, etc. We plan to demonstrate our invention to the 
healthcare industry by using the example of computer vision technology and cloud database.
FR-PO884
Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and 
Associated Liver and Kidney Disease  Emma Borgeson,1,2 Kumar Sharma,1 
Catherine Godson.2  1Center for Renal Translational Medicine, Inst for 
Metabolomic Medicine, UC San Diego, San Diego, CA; 2Diabetes Complications 
Research Centre, Conway Inst, Univ College Dublin, Dublin, Ireland.
Background: Visceral obesity and adipose inflammation is considered a driving 
force of systemic disease, e.g. chronic kidney disease (CKD). Inflammatory resolution 
is actively regulated by specialized pro-resolving mediators (SPMs), including the lipid 
LXA4. Impairment of SPMs may underlie development of obesity-related pathology. Here 
we explored the therapeutic potential of LXA4 in experimental obesity-induced systemic 
disease, e.g. liver cirrhosis and CKD.
Methods: C57BL/6 or Adiponectin-/- mice were fed a standard (10% fat) or high fat 
(60% fat) diet for 12 wks. LXA4 (5ng/g) and benzo-LXA4 analogue (1.7 ng/g) were given 
as interventional therapeutics i.p. 3 times weekly, between wk 5-12. Furthermore, omental 
adipose tissue biopsies were isolated from obese (BMI 35-50) bariatric surgery patients 
(n=4). Adipose explants were incubated with vehicle or LXA4 (1 nM) for 6h at 37 °C, and 
leukocytes were characterized by flow cytometry.
Results: Obesity caused distinct pathologies, including impaired glucose-tolerance, 
adipose inflammation, fatty liver and CKD. Lipoxins attenuated obesity-induced CKD; 
reducing glomerular expansion, mesangial matrix and urinary H2O2. Furthermore, LXA4 
reduced liver weight, serum alanine-aminotransferase and hepatic triglycerides. LXA4 
decreased obesity-induced adipose inflammation, attenuating TNF-α and CD11c+ M1-
macrophages (MFs), while restoring CD206+ M2-MFs and increasing Annexin-A1. Lipoxins 
did not affect renal or hepatic MFs, suggesting protection occurred via attenuation of 
adipose inflammation. Lipoxins restored adipose expression of autophagy markers LC3-
II and p62. LX-mediated protection was demonstrable in adiponectin-/- mice, suggesting 
that the mechanism was adiponectin independent. The ongoing clinical studies are 
characterizing whether Lipoxins promote an M1-to-M2 MFs phenotype shift in human 
omental adipose tissue.
Conclusions: In conclusion, Lipoxins protect against obesity-induced systemic disease 
and these data support a novel therapeutic paradigm for treating obesity and associated CKD.
Funding: Other NIH Support - NIH DP3 award (DK094352-01), Veterans 
Administration Support, Government Support - Non-U.S.
FR-PO885
Prevalence of Protein-Energy Wasting Syndrome and Its Association with 
Anemia, Erythropoietin Resistance, Overhydration and Body Composition 
in Hemodialysis Patients  Carlos Adrián Chávez- Mendoza, Jose Luis Ortega 
vargas, Jorge Osvaldo Montes rivera, Ricardo Correa-Rotter, Olynka Vega-Vega. 
Nephrology and Mineral Metabolism, National Inst of Medical Science and 
Nutrition Salvador Zubiran, Mexico City, Mexico.
Background: The prevalence of protein-energy wasting syndrome (PEW) in Mexican 
hemodialysis (HD) patients is unknown. Accordingly, there is no information on which 
clinical, biochemical, quality of life (QL), and body composition (BC) variables are 
associated or predictive of PEW in this population.
Methods: Observational comparative study that included 191 prevalent HD patients. 
BC was determined by BIS employing (BCM,Fresenius®), QL was measured with 
KDQOL-36 and presence of PEW according to ISRNM criteria.
Results: General characteristics are shown in Figure 1, prevalence of PEW was 
22%(n=41). No differences between groups (with or without PEW) were present 
in:age, Charlson index, number and type of drugs employed, time on dialysis, vascular 
access, history of PD or kidney transplant and hospitalization days in the last year. PEW 
patients had a higher prevalence of DM(p=0.04), lower Hb(p=0.006) and higher EPO 
requirements(p=0.04) despite similar iron reserves. In terms of BC, PEW patients had 
more overhydration (OH) and higher extracellular water (ECW), and lower lean and fat 
tissue indexes (LTI,FTI). Surprisingly, QL indicators were not different between groups. 
In a Cox multivariate logistic regression model analysis, predictors of PEW were:degree 
OH(OR 3.2,95% CI 1.2-8.3,p<0.001), and ECW(OR 0.51,95% CI 0.22-0.89,p<0.01).
Conclusions: Prevalence of PEW in the studied population was lower compared to 
other series. PEW patients exhibit a state of overhydration which is given by increased 
ECW, and accompanied by loss of LTI and FTI. No PEW impact on QL was observed. 
PEW patients have increased anemia and higher requirements of EPO possibly associated 
to chronic inflammation.
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Efficacy of Nutrition Counseling on Protein Intake Restriction in Chronic 
Kidney Disease Patients – Niigata Part of SOFT-J (Study on Regional 
Variation of FROM-J Intervention by JSN)  Ryohei Kaseda,1 Michihiro 
Hosojima,1 Toshiko Murayama,1 Akihiko Saito,1 Yoshiki Suzuki,1 Kunihiro 
Yamagata,2 Ichiei Narita.1  1Niigata Univ, Japan; 2Tsukuba Univ, Japan.
Background: Low adherence is frequently observed in patients with chronic kidney 
disease (CKD) who are following a diet therapy. This study evaluated the efficacy of nutrition 
counseling focused on protein restriction for CKD patients in clinics by national registered 
dietician using iPad and textbook used in FROM-J (Frontier of Renal Outcome Modification 
in Japan) study, aiming at promoting relationship between home doctor and nephrologist.
Methods: 47 patients with CKD stage3 (eGFR 30-59 ml/min/1.73m2), age 40-85 
were recruited. Nutrition counseling was conducted once for 30 min by national registered 
dieticians using iPad and textbooks in clinics without any dieticians in the staff. Optimal 
protein and energy intake were prescribed as 0.9 g/kg/day and 25-30 kcal/kg/day, 
respectively. The amount of protein intake was estimated from dietary records and by 
24 hours urine collection before and 2 months after counseling (pre/post, respectively).
Results: All patients recorded their daily diets, 26/47 provided 24 hours urine 
collections. Counseling significantly decreased protein intake (record pre 1.10±0.23 g/kg/
day post 1.00±0.26 p=0.001, urine pre 1.02±0.29 post 0.91±0.22 p=0.04). Although energy 
intake slightly decreased (record pre 31.9±6.4 kcal/kg/day post 30.1±5.2 p=0.03), this was 
not below the prescribed optimal calories. Salt intake decreased in recorded data but not in 
urine data (record pre 8.4±2.8 g/day post 7.6±2.7 p=0.03, urine pre 9.0±4.2 post 9.1±4.4 
p=0.86, respectively). There was no significant difference in body mass index, eGFR, 
HbA1c (diabetic patients), LDL cholesterol, uric acid and blood pressure.
Conclusions: iPad and textbook counseling by dieticians is effective in reducing 
protein intake without compromising necessary caloric requirements, even in clinics 
without regular nephrologist or dietary staff. Informational technology may be an effective 
method of delivering on-demand nutritional counseling that can directly benefit patient care.
FR-PO887
Activin B Has a Functional Role in Hepcidin Induction by Inflammation 
Jodie L. Babitt, Susanna Canali, Amanda B. Core, Maria Merkulova, Kimberly 
Zumbrennen-Bullough.  Nephrology Div, Program in Membrane Biology, 
Center for Systems Biology, Massachusetts General Hospital, Harvard Medical 
School, Boston, MA.
Background: Induction of the iron regulatory hormone hepcidin contributes to the 
anemia of chronic kidney disease by restricting iron availability. Bone morphogenetic 
protein 6 (BMP6) signaling is a central transcriptional regulator of hepcidin. Recently, the 
transforming growth factor-β (TGF-β)/BMP superfamily member Activin B was implicated 
in hepcidin induction by inflammation via noncanonical SMAD1/5/8 signaling, but its 
mechanism of action and functional significance in vivo remain uncertain.
Methods: Hep3B cells and primary hepatocytes were treated with Activin B, BMP6, 
or Activin A, without or with siRNA knockdown of Activin/BMP pathway components, 
and were tested for SMAD2/3 versus SMAD1/5/8 phosphorylation and hepcidin 
expression. Liver Activin B expression was measured and the effect of the Activin inhibitor 
follistatin-315 was examined in multiple rodent models of anemia of inflammation.
Results: Activin B, but not Activin A, stimulated SMAD1/5/8 signaling and hepcidin 
expression in liver cells to a similar degree as canonical SMAD2/3 signaling, and with 
similar potency and kinetics compared with BMP6. Activin B induced hepcidin via classical 
Activin type II receptors ACVR2A and ACVR2B, noncanonical BMP type I receptors ALK2 
and ALK3, and SMAD5. The co-receptor hemojuvelin (HJV) bound directly to Activin B 
and facilitated Activin B-SMAD1/5/8 signaling. Activin B-SMAD1/5/8 signaling occurred 
selectively in hepatocyte-derived cells and was not enabled by HJV in other cell types. 
Liver Activin B mRNA expression was increased in multiple rodent models of inflammation 
associated with increased hepcidin and hypoferremia. Follistatin-315 had no effect on basal 
hepcidin expression, but blunted hepcidin induction by inflammation in mice.
Conclusions: Our data elucidate a novel mechanism for noncanonical SMAD activation 
by BMP/TGF-β superfamily members, and support a functional role for Activin B in 
hepcidin induction by inflammation in vivo. Targeting the Activin B-hepcidin pathway 
may lead to new therapies for anemia of inflammation including the anemia of chronic 
kidney disease.
Funding: NIDDK Support
FR-PO888
Effects of a Very Low Protein Diet Supplemented with Amino and Keto 
Acids on Skeletal Muscle Protein Synthesis and Degradation in Patients 
with Chronic Kidney Disease  Giacomo Garibotto,1,2 Antonella Sofia,2 Valeria 
Cademartori,2 Emanuele L. Parodi,2 Francesca Ansaldo,2 Daniela Verzola.1 
1DIMI, Nephrology Div Genoa Univ, Genoa, Italy; 2Dept Intern. Med., IRCCS 
AOU San Martino-IST, Genoa, Italy.
Background: Chronic kidney disease (CKD) is characterized by progressive loss of 
muscle mass, an effect which could be accelerated by low (LPD) and very low protein diets 
(VLPD), even if essential amino/keto analogue (AA/KA) supplements are used. However, 
to what extent skeletal muscle protein metabolism adapts to a supplemented VLPD in CKD 
patients is still unexplored.
Methods: To determine the muscle responses to a supplemented VLPD (0.45 g/kg+0.1 
g/kg AA/KA, 35 kcal/Kg/day), as compared to a standard (0.55 g/kg,35 kcal/Kg/day) LPD, 
forearm [2H]phenylalanine kinetics were evaluated in six CKD patients( 5M/2F, age 71±1 
yrs, eGFR 11±1 ml/min) assigned to a LPD (4 weeks), followed by a 4- week supplemented 
VLPD period. Studies were performed after an overnight fast (post-absorptive state) and 
results express basal rates of protein turnover.
Results: After supplemented VLPD, as compared to a standard LPD: a) whole body 
protein turnover declined only slightly (0.51±2 vs. 0.55±2 µmol/min/kg, VLPD vs. LPD 
, p=NS) ; b) forearm protein net balance, i.e. the difference between protein synthesis and 
degradation, was less negative by 18% ( from -11±3 to -9 ±2 nmol/min.100 ml, p<0.02) 
; (c) the efficiency by which amino acids are cycled back from protein degradation into 
protein synthesis increased by 15% ( p<0.05); d)muscle protein degradation was unchanged 
(from 44±4 to 46±5 nmol/min.100 ml , p<0.02); e) Protein synthesis increased by 17% 
(from 33±1 to 38±4 nmol/min.100 ml, p<0.05).
Conclusions: Our data show that in patients with CKD stage 5 the response of muscle 
protein turnover to a AA/KA supplemented VLPD, as compared to a standard LPD, is 
characterized by similar reduced rates of protein degradation, but an increase in muscle 
protein synthesis, with enhanced recycling of amino acid derived from catabolism. Net 
protein balance is less negative, which suggests that the use of AA/KA supplemented VLPD 
may be nutritionally safer than a standard LPD.
Funding: Pharmaceutical Company Support - Fresenius-Kabi Ketosteril Award 2012, 
Government Support - Non-U.S.
FR-PO889
Risk of Anemia and Blood Transfusion following Reduction of Maximum 
ESA Doses  Kelvin C.W. Leung, Robert R. Quinn, Braden J. Manns, Jennifer 
M. MacRae, Pietro Ravani.  Medicine, Univ of Calgary, Calgary, AB, Canada.
Background: The cost of providing erythropoietin stimulating agents (ESAs) for renal 
patients is currently covered in the province of Alberta, Canada. Due to the high costs 
associated with therapy, the provincial funding agency reduced the maximum weekly ESA 
dose by 50%. We sought to determine the clinical impact of this policy change on the risk 
of severe anemia (hemoglobin [HGB] <90g/L) and transfusions.
Methods: All patients in the Southern Alberta Renal Program with a HGB >90g/L 
and receiving more than darbepoetin 75ug/wk or epoetin 15000 units/wk were reduced to 
an equivalent of darbepoetin 75ug/wk in September 2013. Serum HGB, iron stores, serum 
albumin, and parathyroid hormone assessed at baseline, 3 months, and at 6 months (end of 
study). Blood transfusion data was extracted from provincial electronic records. Patients 
were returned to a higher ESA dose when the HGB declined to ≤90g/L. We performed 
Kaplan-Meier analysis and multivariable regression analysis to calculate the median time 
to a drop in HGB level to ≤90g/L (primary outcome) and the receipt of blood transfusions 
(secondary outcome) following ESA dose reduction. ESA doses were re-established in 
people who reached the primary end-point.
Results: patients (mean age 61±16 years) met the inclusion criteria. The majority of 
patients were treated with hemodialysis (75%) and received darbepoetin (81%). The mean 
baseline darbepoetin dose (or equivalent for those treated with epoetin) was 110±28ug/week; 
mean baseline HGB was 106±12g/L. A HGB of ≤90g/L was reached in 50% of the cohort 
by 4.1 months (median 1.8 months, IQR 0.4-2.8 months). Blood transfusions occurred in 
15% of the cohort during the study and 12% in preceding 3 months (p=0.77). In multivariate 
analysis, only higher baseline HGB levels were associated with reduced hazard of a drop 
in HGB to ≤90g/L. Baseline ESA dose, magnitude of ESA dose reduction, and baseline 
iron stores was not independently associated with our primary outcome.
Conclusions: HGB declines below 90 g/L in about four months following ESA dose 
reduction. The short-term risk of blood transfusion remains similar. The clinical and 
economic implications of this policy remain to be determined.
FR-PO890
Association of Moderate Ascorbic Acid Supplementation with Plasma 
Ascorbic Acid and Oxalate Levels in Prevalent Hemodialysis Patients 
William D. Sirover,1 Yuguan Liu,2 Amanda Logan,3 Krystal Hunter,3 Craig B. 
Langman,4 Lawrence S. Weisberg,1 Garry J. Handelman.2  1Nephrology, Cooper 
Univ Healthcare, Camden, NJ; 2Nutrition, Univ of MA Lowell, Lowell, MA; 
3Cooper Research Inst, Cooper Univ Healthcare, Camden, NJ; 4Nephrology, 
Northwestern Univ, Chicago, IL.
Background: Ascorbic acid (AA) supplementation may improve anemia in 
hemodialysis (HD) patients. Oxalate (Ox), an AA-metabolite, is excreted in the urine and 
is also removed during HD. When the plasma Ox concentration (plasma [Ox]) reaches 30 
µM, Ox may deposit pathologically in organs. Moderate oral AA supplementation--up to 
100 mg of AA/day--is often prescribed to HD patients. Of concern, patients who received 
earlier forms of HD could develop pre-HD Ox levels of 30 µM or higher when taking this 
degree of AA. We hypothesize that moderate AA use is not associated with an increase in 
pre-HD plasma [Ox] when patients receive high-flux HD.
Methods: In 2011, we surveyed outpatients on HD regarding AA supplement use. 
Pre-HD AA and Ox levels were measured. The treatment group consisted of patients who 
took up to 100 mg of oral AA/day. Patients who took no AA comprised the control group.
Results: There was no difference in pre-HD plasma [Ox] (mean±SD) between the 
treatment and the control groups, 21.9±10.1 µM vs. 20.6±10.6 µM, respectively (P=0.42). 
Median plasma AA concentration was 47.2 µM (IQR 24.6-83.6) in the treatment group and 
15.8 µM (IQR 8.5-67) in the control group, (P<0.001).
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Treatment 
Group(N=132)
Control 
Group(N=54) P-value
AA supplementation (number)
50-75 mg/day
100 mg/day
19
113
--
--
Age(yrs) 61±15 61±17 0.98
spKt/V 1.76±0.27 1.73±0.31 0.50
Albumin(gm/dL) 3.9±0.3 3.9±0.4 0.38
BMI(kg/M2) 28.6±7.8 28.4±8.1 0.90
Conclusions: These findings support the notion that moderate AA supplementation 
may be able to safely and effectively raise plasma AA levels.
Funding: Private Foundation Support
FR-PO891
Chronic Kidney Disease Is Associated with Altered Muscle Mitochondrial 
Energetics by Functional MR Spectroscopy and Optical Spectroscopy 
Baback Roshanravan,1 Bryan R. Kestenbaum,1 Jorge Gamboa,2 Jonathan 
Himmelfarb,1 Ian H. De Boer,1 Kevin Conley.1  1Medicine, Kidney Research 
Inst - Univ Washington, Seattle, WA; 2Vanderbilt Univ, Nashville, TN.
Background: Exercise intolerance and muscle weakness are frequent clinical 
complications of CKD associated with adverse health outcomes, yet the pathophysiology 
underlying these conditions is poorly understood.
Methods: Cross-sectional study of in vivo muscle mitochondrial energetics using 31P 
Magnetic Resonance Spectroscopy and optical spectroscopy (MRS/OS) in 12 subjects 
with non-diabetic CKD (eGFR<60) and 26 controls. 31P MRS and OS were performed on 
the hand muscle under controlled ischemia. ATPflux (ATPase rate) was measured from 
phosphocreatine breakdown. Hemoglobin and myoglobin desaturation rates were assessed 
by OS to measure muscle oxygen uptake (O2 uptake). The primary outcome was the coupling 
efficiency of mitochondrial oxidative phosphorylation ATP production (ATPflux) per unit 
of oxygen consumed (O2 uptake) or P/O ratio. Grip strength and timed up and go were 
assessed. Pearson’s correlation coefficient was calculated for univariable associations. We 
used multivariable linear regression adjusting for age.
Results: Mean age of CKD patients was 53±13yrs. Physical performance of the CKD 
group was no different from predicted normal values. Mean P/O values were 1.46±0.7 in 
the CKD group vs. 2.22±0.6 in the control group (age-adjusted P=0.002). The strongest 
correlates of P/O ratio age (ȡ=-0.42), followed by eGFR (ȡ=0.32). In contrast to controls, 
patients with CKD had higher O2 uptake (P=0.03) without concomitant change in ATPase 
rate. 
Conclusions: Application of non-invasive tools reveals that CKD is associated with 
greater muscle O2 uptake reflecting uncoupling of oxidative phosphorylation. These results 
suggest altered mitochondrial respiration in skeletal muscle of patients with CKD prior 
to dialysis.
Funding: NIDDK Support
FR-PO892
Improving Outcomes with Nutrition in Older People with Advanced Chronic 
Kidney Disease – Baseline Data from a Pilot Randomised Controlled Trial 
Lina Johansson,1 Mary Hickson,1 Edwina A. Brown.2  1Nutrition and Dietetics, 
Imperial College Healthcare NHS Trust, London, United Kingdom; 2Imperial 
Kidney and Transplant Centre, Imperial College Healthcare NHS Trust, London, 
United Kingdom.
Background: It is difficult to determine when to start dialysis in older people as 
creatinine and eGFR can be misleading. Dialysis start is often determined by weight loss, 
symptoms, potassium and fluid overload, all of which are potentially modifiable with 
nutrition. This pilot RCT aims to determine whether dietary interventions can result in 
improved patient outcomes, including time to dialysis, in older people with advanced 
chronic kidney disease (CKD).
Methods: Patients ≥65 years, with eGFR 10-20mls/min were randomised to an 
observational or intervention group (greater dietetic input). Data will be collected every 
6 months for up to 2 years: nutritional status (Subjective Global Assessment), symptoms 
(Palliative Outcome Scale – Symptoms Renal), function (4 metre walk gait speed test 
and Jamar handgrip dynamometer) and fluid overload using Body Composition Monitor 
(Fresenius).
Results: 80 patients were recruited, baseline data presented. The 2 groups have 
statistically similar baseline demographic and clinical characteristics. Overall, 30% have 
malnutrition of which 58% are overweight/obese. 28% have nutritionally relevant potentially 
uraemic symptoms (nausea, vomiting and/or poor appetite). Fluid overload (>2L) was 
observed in 22% of those that were assessed (n=58). 
Demographics Control (n =40) Intervention (n=40)
Male n (%) 27 (67.5) 26 (65.0)
Age years, mean (SD) 74.5 (6.8) 76.0 (7.4)
Diabetes n (%) 19 (47.5) 18 (45.0)
Biochemistry
eGFR mls/min, mean (SD) 16 (4) 16 (3)
Potassium >5.5mmol/L % 10 5
Nutritional status and symptoms
Subjective Global Assessment (SGA) 
malnourished % 38 23
Nausea, vomiting and/or poor appetite % 25 30
Physical function
Gait speed <0.8m/sec, indicative of gait 
impairment % 45 48
Handgrip strength ≤20kg women or ≤ 30kg 
men, indicative of weakness % 50 58
Conclusions: There is a high prevalence of indications for dietetic interventions 
within older people with advanced CKD at baseline which may positively affect outcomes 
within two years.
Funding: Government Support - Non-U.S.
FR-PO893
Retention of Acetylcarnitine in Chronic Kidney Disease Causes Insulin 
Resistance in Skeletal Muscle  Yasunori Miyamoto,1 Teruo Miyazaki,2 
Akira Honda,2 Homare Shimohata,1 Kouichi Hirayama,1 Masaki Kobayashi.1 
1Nephrology, Tokyo Medical Univ Ibaraki Medical Center, Ami, Ibaraki, Japan; 
2Joint Research Center, Tokyo Medical Univ Ibaraki Medical Center, Ami, 
Ibaraki, Japan.
Background: Insulin resistance occurs frequently in patients with chronic kidney 
disease (CKD) and ameliorates after introduction of hemodialysis (HD). However, 
the mechanisms of insulin resistance associated with CKD are unclear. An increased 
mitochondrial acetyl-CoA/CoA ratio causes insulin resistance in skeletal muscle, and 
this ratio is regulated by carnitine acetyltransferase (CAT), which transfers excess acetyl 
moieties to carnitine (CT). Because the resulting acetylcarnitine (AcCT) is excreted in 
urine, we hypothesized that retention of AcCT might be a cause of insulin resistance in 
patients with CKD.
Methods: Serum samples were collected from 64 patients with CKD (including 14 
HD patients) and 31 control subjects who underwent a medical examination. CT and AcCT 
concentrations in sera were measured by HPLC-ESI-MS/MS. The effects of exogenous 
AcCT (0-300 µM) on insulin-dependent 2-deoxyglucose (2DG) uptake, mitochondrial CT 
and AcCT levels, and the mitochondrial acetyl-CoA/CoA ratio were examined in a cultured 
skeletal muscle cell line (C2C12 myotubes).
Results: The serum concentration of AcCT, but not that of CT, significantly increased 
with reduction of renal function, as classified by eGFR (stage £2 3.7 ± 0.6 µM, stage 3a 
6.1 ± 1.1 µM, stage 3b 10.9 ± 1.9 µM, stage 4 16.3 ± 2.1 µM, stage 5 28.2 ± 5.9 µM, mean 
± SEM). After introduction of HD, the increased AcCT levels were significantly reduced 
(pre 16.8±2.5 µM, post 6.3 ± 0.7 µM). In vitro experiments in skeletal muscle cell lines 
showed that uptake of 2DG was significantly and dose-dependently inhibited by addition 
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of AcCT. The added AcCT was converted to CT through the reverse reaction of CAT, 
and thus the acetyl-CoA concentration and acetyl-CoA/CoA ratio in mitochondria were 
significantly elevated.
Conclusions: The results suggest that increased AcCT in patients with CKD causes 
insulin resistance in skeletal muscle by stimulating the reverse reaction of CAT, which 
leads to accumulation of acetyl-CoA in mitochondria.
Funding: Government Support - Non-U.S.
FR-PO894
High Protein Intake in Relation to Incident End-Stage Renal Disease 
(ESRD) Among Blacks and Whites in the Southern Community Cohort 
Study (SCCS)  Rakesh Malhotra, Edmond Kato Kabagambe, Kerri L. 
Cavanaugh, William J. Blot, Talat Alp Ikizler, Loren Lipworth.  Vanderbilt 
Univ Medical Center.
Background: Dietary composition could contribute in part to observed racial disparities 
in ESRD incidence. Diabetes, a major risk factor for ESRD, may lead to differences in 
dietary intake and metabolism. We examined whether protein intake is associated with 
ESRD risk and whether the association varies by race and diabetes.
Methods: We conducted a nested case-control study of ESRD within the SCCS, a 
prospective study of low income blacks and whites in the southeastern US (2002-2009). 
Through 2012, 1,074 incident ESRD cases were ascertained by linkage with the USRDS, 
and matched to 3,230 controls on age, sex and race. A validated food frequency questionnaire 
was administered at baseline. Odds ratios (OR) and 95% confidence intervals (CI) for ESRD 
were computed in relation to protein intake, expressed as daily % of total energy intake and 
modeled in 1 standard deviation (SD) increments in unconditional logistic regression models 
stratified by race and diabetes. ORs were adjusted for age, sex, BMI, education, income, 
hypertension, total energy intake and % energy from saturated and polyunsaturated fat.
Results: Median daily % energy intakes from protein were higher among whites than 
blacks and those with vs without diabetes, but differences between ESRD cases and controls 
were small (15.9 and 15.7%, respectively, for blacks with diabetes, 14.6 and 14.6% for 
blacks without diabetes, 16.6 and 16.4% for whites with diabetes, and 15.1 and 15.1% 
for whites without diabetes). For a 1 SD (3.17%) increase in daily % energy intake from 
protein, adjusted ORs (95% CI) for ESRD were 1.18 (1.05-1.34) for blacks with diabetes, 
1.06 (0.93-1.21) for blacks without diabetes, 0.89 (0.61-1.30) for whites with diabetes and 
1.00 (0.74-1.33) for whites without diabetes.
Conclusions: Our results raise the possibility that among blacks with diabetes, a diet 
higher in protein is associated with increased incidence of ESRD. If confirmed, future 
studies might examine contributors leading to adverse outcomes associated with high 
protein intake in this subpopulation.
Funding: Other NIH Support - Grant R01 CA92447 from the National Cancer 
Institute (NCI), including American Recovery and Reinvestment Act funding (3R01 
CA029447-08S1)
FR-PO895
Effects of Lanthanum Carbonate on Intestinal Bacterial Flora in Chronic 
Renal Failure Mice  Minoru Satoh, Hiroyuki Kadoya, Seiji Itano, Atsushi 
Uchida, Yuji Sogawa, Hajime Nagasu, Tamaki Sasaki, Naoki Kashihara. 
Dept of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, 
Okayama, Japan.
Background: The intestinal microbial flora consists of diverse bacterial species that 
inhabit the gastrointestinal tract. These bacteria are integral to the ontogeny and regulation 
of the immune system, and maintenance of intestinal homeostasis. In the chronic kidney 
diseases, changes of the intestinal bacterial flora have been reported, which contribute 
to nutritional disorder, systemic or local inflammation, and the uremic toxin production. 
Phosphate promotes a bacterial growth. So, by phosphate adsorption, intestinal bacterial 
flora may be changed. We examined whether phosphorus adsorption with lanthanum 
carbonate could change intestinal bacterial flora in renal failure mice.
Methods: We used 5 weeks old male ICR-derived glomerulonephritis (ICGN) mice 
(n=10) for renal failure group and ICR mice (n=10) for control group. Each group mice 
were fed with standard diet or diet supplemented with 3% lanthanum carbonate for 10 
weeks. Gene expression patterns of a whole bacterial flora in the intestine were analyzed by 
terminal restriction fragment length polymorphism analysis method. Fecal bacteria products 
(phenol, para-cresol, indole and skatole) were examined by quantitative chemical analysis.
Results: The ratio of “bad” bacteria clostridia was increased, and the ratio of 
opportunistic pathogen bacteroides was decreased in intestinal bacterial flora of ICGN 
mice. By the lanthanum carbonate administration, the ratio of clostridium was decreased, 
and the ratio of beneficial bacterium lactobacilli was increased. Fecal bacteria products 
phenol and para-cresol were increased in feces of ICGN mouse, but indole was not changed. 
Skatole was not detected in feces of both mice. Among intestinal bacterial flora, the ratio of 
clostridium showed a positive correlation, and the ratio of bacteroides showed a negative 
correlation of phenol production.
Conclusions: The intestinal bacterial flora in chronic renal failure mice was changed 
by lanthanum carbonate administration.The change of the bacterial flora affected the fecal 
bacteria products, which may contribute the production of serum uremic toxin.
FR-PO896
High-Fat Diet Induces the Production of IKKİ by Macrophages to Promote 
Nephrotoxicity  Xin Wan,1 Binbin Pan,1 Changchun Cao.1  1Nanjing Hospital 
Affiliated to Nanjing Medical Univ Nanjing First Hospital.
Background: The NF-κB activation may participate in lipid nephrotoxicity which may 
be regulated by inhibitor kappa B kinase epsilon (IKKİ). To investigate the role of IKKİ 
in this procession, mice experiment was performed.
Methods: Mice were grouped: (1) wild-type with normal fat diet (WN), (2) wild-type 
with high fat diet (WH), (3) IKKİ knockout with normal fat diet (KN), (4) IKKİ knockout 
with high fat diet (KH). Renal function, lipid, histological changes and tubular proliferation 
were analysed. IL-1β, TNF-β, p50 and p65 were determined by western blot. NF-κB level 
was tested by EMSA. Expression of IKKİ was evaluated via immunohistochemistry and 
immunofluorescence.
Results: Cystatin C levels were significantly higher in WH group than others. Staining 
with hematoxylin-eosin revealed that tubular lesions in WH group (3.53 ± 0.21) were more 
severe than in WN group (0.32 ± 0.11). By Immunohistochemistry, WH group exhibited 
marked macrophages infiltration than WN, KN and KH groups. Western blot showed 
significant increase of IL-1β, TNF-β and marked increment in the expression of NF-κB 
pathway components consists of p50 and p65 in WH group, while these increases were 
blocked in KN and KH groups. Furthermore, NF-κB level in WH group was higher than 
other groups. WH group exhibited remarkable macrophages infiltration than other groups 
by Immunofluorescence. Immunohistochemistry showed remarkable increases in the 
expression of IKKİ in the WH group compared with other groups. Immunofluorescence 
analysis demonstrated that the expression of IKKİ was located around macrophages. 
Conclusions: IKKİ mediates lipid nephrotoxicity by HFD induced macrophages 
infiltration to activate NF-κB signal pathway.
Funding: Government Support - Non-U.S.
FR-PO897
Clinical Determinants of Toll Like Receptor 4-Mediated Inflammatory 
Response in Skeletal Muscle of Patients with Chronic Kidney Disease 
Daniela Verzola,1 Alice Bonanni,1 Antonella Sofia,1 Francesca Ansaldo,1 Elisa 
Veziano,1 Valeria Cademartori,1 Emanuele L. Parodi,1 Giuliano Brunori,2 Chiara 
Venturelli,2 Giacomo Garibotto.1  1DIMI, Nephrology Div., Univ of Genoa, 
Genoa, Italy; 2Nephrology Div., Santa Chiara Hospital, Trento, Italy.
Background: Inflammation in skeletal muscle is implicated in the pathogenesis of 
insulin resistance and cachexia. We previously observed that the Toll-like receptor-4 (TLR4) 
dependent muscle signaling is upregulated in muscle of CKD subjects.
Methods: We studied the associations between muscle (rectus abdominis) TLR4 
protein (western blot and immunoistochemistry) and gene (rt-PCR) expression and clinical 
parameters in 38 CKD stage 5 patients (23M/15F, eGFR 8±1 ml/min).
Results: CKD subjects had significantly elevated TLR4 gene expression and protein 
content in muscle (~4-fold increase vs. controls p<0.05). LogTLR4 protein content in 
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muscle was inversely related to Subjective Global Assessment (SGA) (r=-0.410, p<0.03), 
eGFR (r=-0.46; p=0.014), hemoglobin (r=-0.380, p<0.05) and directly related to cholesterol 
levels (r=0.398, p<0.05). 
There was no relationship between muscle logTLR4 and age, BMI, muscle area, 
nPNA, calorie intake, albumin, CRP, BUN, bicarbonate, triglycerides, fibrinogen, and 
phosphate levels. At multivariate analysis SGA and eGFR only contributed significantly 
to the prediction of TLR4 expression in muscle (p<0.003).
Conclusions: Both low SGA score (which indicates an overall concept of nutritional 
status) and eGFR (an index of residual renal function) play an independent role to predict 
TLR4 content in muscle of CKD patients.TLR4 content in muscle rises progressively along 
with progressive decline of residual renal function, with a 2-fold increase in TLR4 as eGFR 
declines from 12 to 5 ml/min. Both wasting and progressive loss of residual renal function 
are predictive of muscle inflammation.
Funding: Government Support - Non-U.S.
FR-PO898
Randomized, Double-Blind, Crossover Clinical Trial on Oral Rice 
Endosperm Protein Supplementation to Patients on Maintenance 
Hemodialysis  Michihiro Hosojima,1 Hisaki Shimada,2 Shigeru Miyazaki,2 
Yoshitsugu Obi,3 Hazuki Kondo,4 Mikio Fujii,4 Reiko Watanabe,5 Shoji 
Kuwahara,6 Ryohei Kaseda,1 Ichiei Narita,7 Yoshiki Suzuki,8 Motoni Kadowaki,9 
Akihiko Saito.6  1Dept of Clin Nutr Sci, Niigata Univ, Japan; 2Shinraku-en 
Hospital, Japan; 3Univ of California; 4Kameda Seika Co., Ltd., Japan; 5Univ 
of Niigata Prefecture, Japan; 6Dept of Appl Mol Med, Niigata Univ, Japan; 
7Div of Clin Nephrol & Rheumatol, Niigata Univ, Japan; 8Health Administr 
Center Div, Niigata Univ, Japan; 9Faculty of Agriculture, Niigata Univ, Japan.
Background: Protein-energy wasting, a state of metabolic and nutritional 
derangements, is an important risk factor that affects outcomes of patients with CKD, 
particularly in ones with ESRD and on maintenance dialysis (MHD).Purified rice endosperm 
protein (REP) contains less phosphorus (150 mg/100g) compared with soybean (787 
mg/100g) and casein (737 mg/100g) proteins, and may improve nutritional status without 
imposing further metabolic derangements.
Methods: We carried out a randomized, double-blind, placebo-controlled, cross-over 
study to evaluate the effect of REP supplementation (5 g per day × 4 weeks) on nutritional 
and metabolic status in 50 MHD patients (UMIN000010876). The primary outcome was 
the change in urea kinetic-based normalized protein nitrogen appearance (nPNA), an 
indicator of protein intake in MHD patients. The inclusion criteria were: (1) nPNA < 1.2g/
kg/day, (2) serum albumin concentration ≤ 3.8mg/dl, (3) body mass index ³19 kg/m2 and 
<23 kg/m2, (4) <5% variation in dry weight during the period of preceding 6 months, and 
(5) duration of MHD ≥ 2 years.
Results: By intention-to-treat analyses, REP increased nPNA by 0.07 (95%CI, 0.03-
0.11) g/kg/day compared with placebo, whereas Dserum phosphorus concentration was 
not significantly different between the groups [0.18 (95%CI, -0.23-0.58) mg/dL]. REP 
did not show significant effects on other nutritional parameters. Per-protocol analyses 
yielded similar results. There were no specific complications associated with the REP 
supplementation.
Conclusions:  Purified REP may be useful for dietary supplementation in MHD patients. 
Further studies are warranted to evaluate its long-term or high-dose efficacy.
Funding: Government Support - Non-U.S.
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Association of Serum Phosphate Levels and Mortality Risk in Patients 
with Chronic Kidney Disease: A Systematic Review and Meta-Analysis 
Anawin Sanguankeo,1,2 Sikarin Upala.1,2  1Internal Medicine, Bassett Medical 
Center and Columbia Univ College of Physicians and Surgeons, Cooperstown, 
NY; 2Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, 
Bangkok, Thailand.
Background: Abnormalities of serum phosphate are associated with increased risk for 
mortality in end stage renal disease (ESRD) or dialysis patients. Use of phosphate binders 
has shown to reduce risk of mortality in these population and is recommended in several 
guidelines. However, there is still controversy on the management of serum phosphate in 
patients with chronic kidney disease (CKD). This meta-analysis evaluated the impact of 
serum phosphate on mortality in patients with CKD not requiring dialysis.
Methods: We comprehensively searched the databases of MEDLINE, EMBASE, and 
Cochrane Databases. The inclusion criteria were published RCT and prospective cohort 
studies assessing effects of high serum phosphate (compared to normal range) and a 1-mg/
dL increase in phosphorus level in patients with CKD (eGFR <60 ml/min/1.73 m2). We 
excluded ESRD, dialysis, or renal transplant patients. The primary outcome was risk of 
all-cause mortality. We used hazard ratio (HR) or risk ratio (RR) in the multivariate model 
as an effect estimate.
Results: From 15 full-text articles, five studies involving 6,536 patients were included 
in the meta-analysis. All were prospective cohort studies of CKD stage 3 or 4 patients. 
There was an increase all-cause mortality risk in higher phosphorus levels (HR = 1.36, 
95% CI: 1.24 to 1.0, p<0.01, I2=0%)  compared with normal phosphorus levels. A 1-mg/
dL (0.1 mmol/L) elevation in serum phosphate also increases mortality risk with HR=1.23 
(95% CI: 1.14-1.34, p<0.01, I2=0%).
Conclusions: Elevated serum phosphate levels were independently associated with 
increased mortality risk among patients with CKD. Randomized controlled trials are needed 
to assess the benefits of using phosphate lowering therapy in patients with CKD before 
developing ESRD or dialysis.
FR-PO900
Serum Phosphorous Levels prior to Transition to Dialysis and Early 
Dialysis Mortality Among U.S. Veterans: A Transition of Care in CKD 
Study  Amanda R. Tortorici,1 Yoshitsugu Obi,1 Melissa Soohoo,1 Connie Rhee,1 
Elani Streja,1 Jennie Jing,1 Rajiv Saran,2 Bruce M. Robinson,2 Yi Li,2 Danh V. 
Nguyen,1 Keith C. Norris,3 Csaba P. Kovesdy,4 Kamyar Kalantar-Zadeh.1  1UC 
Irvine; 2UM-KECC; 3UCLA; 4UTHSC.
Background: Previous studies have shown that higher phosphorous (Phos) levels were 
monotonically associated with higher risk of death in patients with chronic kidney disease 
and end-stage renal disease (ESRD). However, the impact of pre-ESRD Phos levels on 
early post-ESRD mortality is not known.
Methods: In US veterans who transitioned to dialysis between 10/2007 and 9/2011, 
we identified 10,724 patients with available Phos measurements within the last 6 month 
prelude period (prior to transition). We examined the association of Phos (averaged over 
6 months) as a continuous predictor of all-cause mortality within the first 3 months post 
transition, using restricted cubic spline analysis and Cox models adjusted for age, sex, race, 
ethnicity, cause of ESRD, and region of residence.
Results: The mean±SD age of the cohort was 66±11 years, among whom 34% were 
African-American, 8% were Hispanic, and 52% had diabetes listed as their primary cause 
of ESRD. We observed a reverse J-shaped association between pre-ESRD Phos and 
3-month post-ESRD mortality risk. Patients with Phos levels <4.7 mg/dL had a higher 
risk of mortality, and patients with Phos levels >9.0 mg/dL trended towards a higher 
risk of mortality as well. However, patients with Phos levels between 4.7 and 7.2 mg/dL 
demonstrated lower mortality risk.
Conclusions: Among veterans transitioning to dialysis, both lower and higher Phos 
levels were associated with higher risk of early post-ESRD mortality, while patients with 
Phos levels between 4.7 to 7.2 mg/dL had the lowest risk of mortality. Further studies are 
needed to determine if using dietary and medication interventions to attain this Phos range 
confers higher survival in this population.
Funding: NIDDK Support
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The Comparison of Serum Calcium, Phosphorus and Intact Parathyroid 
Hormone Between Peritoneal Dialysis Patients and Hemodialysis Patients 
Guisen Li, Li Wang.  Nephrology, Sichuan Academy of Medical Sciences & 
Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China.
Background: In this study, we compared the serum calcium, phosphorus and intact 
parathyroid hormone between peritoneal dialysis patients and hemodialysis patients to 
study the difference in MBD biochemical variables between PD and HD.
Methods: 507 patients were enrolled from July 1, 2014 to December 31, 2014, including 
148 patients received peritoneal dialysis and 359 patients received hemodialysis patients 
(HD) more than 3 months. Basic clinical information, data of dialysis, serum calcium, 
phosphorus and iPTH levels were collected in all patients, and comparative analysis was 
carried out based on those information.
Results: The age and the dialysis vintage was significantly higher in HD group than 
in the PD group (P <0.001).Serum phosphorus was lower, percentage of phosphorus in 
target was higher and percentage of calcium in target was lower (P =0.271) in PD group 
than in HD group(P<0.001). The serum phosphorus levels of PD patients with peritoneal 
high transport characteristics or high average transport were much lower than those with 
low transport or low average transport(P = 0.0167). The levels of serum phosphorus 
(P <0.001), iPTH(P = 0.0167)and alkaline phosphatase(P<0.001)were much lower in 
patients with RRF³2ml/min than those with RRF<2ml/min. The levels of serum calcium (P 
<0.01), corrected calcium(P<0.01), phosphorus (P = 0.025), iPTH( P<0.001)and alkaline 
phosphatase(P <0.01)were much lower in patients with urine volume ³100ml/d than those 
<100ml/d. There was a negative correlation between RRF and serum phosphorus(r=-0.291, 
P <0.001)and iPTH(r=-0.271, <0.01)in PD group. The weekly total KT/V(r=-0.201,P = 
0.019) and weekly total creatinine clearance(Ccr)(r=-0.407, P<0.001)negatively related 
to serum phosphorus. The Ccr(r=-0.241,P <0.01)negatively correlated with serum iPTH.
Conclusions: The serum levels of phosphorus is lower and the percentage of achieving 
target of serum phosphorus is higher in PD patients than HD patients.The peritoneal high 
transport characteristics, RRF³2ml/min, urine volume ³100ml/d and the nutrition status have 
obvious influence on the serum phosphorus and iPTH levels in PD patients.
FR-PO902
Increased Risk of Cerebral Hemorrhage in Hemodialysis Patients with 
Hyperphosphatemia: The Q-Cohort Study  Shunsuke Yamada,1 Masanori 
Tokumoto,3 Masatomo Taniguchi,1 Takanari Kitazono,1 Kazuhiko Tsuruya.2 
1Medicine and Clinical Science, Kyushu Univ, Fukuoka, Japan; 2Integrated 
Therapy for Chronic Kidney Disease, Kyushu Univ, Fukuoka, Japan; 3Internal 
Medicine, Fukuoka Dental College, Fukuoka, Japan.
Background: Mounting evidences have shown that hyperphosphatemia, an established 
component of CKD-MBD, accelerates cardiovascular disorders in dialysis patients. 
However, previous studies did not separately determine the effects of hyperphosphatemia 
on the onset of cerebrovascular disorders and cardiovascular disorders in dialysis patients.
Methods: The present study is an observational study consisting of 3431 outpatients 
undergoing hemodialysis. The associations between the baseline serum phosphate (Pi) level 
and the onset of cerebral bleeding and infarction were examined. Independent variable was 
serum Pi level. Dependent variable was the onset of cerebral hemorrhage and infarction. 
Age, sex, diabetes mellitus, history of cardiovascular events, dialysis vintage, Kt/V for 
urea, systolic blood pressure, hemoglobin, serum levels of calcium, parathyroid hormone, 
albumin, alkaline phosphatase, creatinine, and C-reactive protein, and use of vitamin D and 
Pi-binder were used as covariates. Cox proportional hazard model was used for analyses. 
All statistical analysis was conducted by JMP11.2 (SAS institute).
Results: The mean age of the examined population was 63.7±12.8 years, female was 
41%, and the proportion of diabetes mellitus was 29%. Mean serum levels of calcium, Pi, 
and intact parathyroid hormone were 9.41±0.76 mg/dL, 4.92±1.2 mg/dL, 168±210 pg/
mL, respectively. During the mean observational period of 3.1 years, 77 patients newly 
developed brain hemorrhage and 140 developed brain infarction. Hyperphosphatemia 
(Pi≥6 mg/dL) did not increase the risk of brain infarction, but increased the risk of brain 
hemorrhage by 2.2 fold, compared with the target Pi range (3.5£Pi<6.0 mg/dL), even after 
adjustment for the potential confounders.
Conclusions: Hyperphosphatemia is closely associated with the onset of cerebral 
hemorrhage but not with cerebral infarction. Our results highlight the importance of Pi 
management in the prevention of cerebral hemorrhage in dialysis patients.
Funding: Private Foundation Support
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Development and Evaluation of Novel Correction Equations for Serum 
Calcium Concentrations in Hemodialysis Patients  Yoshitsugu Obi,1 Wei 
Ling Lau,1 Elani Streja,1 Connie Rhee,1 Steven M. Brunelli,2 Csaba P. Kovesdy,3 
Kamyar Kalantar-Zadeh.1  1UC Irvine; 2DaVita Clinical Research; 3UTHSC.
Background: Ionized calcium (iCa),but not total calcium (tCa), is the physiologically 
relevant component of blood calcium. However, these measurements correlate poorly 
in hemodialysis patients even after correction for serum albumin, which may be partly 
explained by electrolyte and acid-base derangements in this population.
Methods: In 1,366 patients who initiated conventional HD over four years (1/2007-
12/2010),we identified 6,830 iCa measurements where serum albumin, tCa, sodium, 
chloride, phosphorus, and bicarbonate were measured simultaneously. We randomly 
divided patients into a derivation set (n=681) or a validation set (n=685) to develop and 
evaluate new correction equations for serum tCa concentrations by comparing correlation 
r and Bayesian information criterion (BIC) in linear regression analysis as well as receiver 
operating characteristic (ROC) curves for hypercalcemia determined by iCa (≥5.28 mg/dL).
Results: Albumin was associated with iCa, but its coefficient was -0.15, not -0.8 
as shown in the conventional correction equation. Furthermore, albumin-corrected tCa 
showed lower correlation than uncorrected tCa with iCa (r=0.69 and 0.76, respectively). 
Two equations were developed from the derivation set as follows; [EQ1] 1.1*tCa – 
0.12*(phosphorus + 1) and [EQ2] 1.1*tCa – 0.08*(anion gap – 2). In the validation set, EQ1 
and EQ2, compared to the conventional correction by albumin, showed better correlation 
with iCa (r=0.78 and 0.80, respectively), lower BIC (96% and 92%, respectively), and higher 
area under the ROC curve for iCa-defined hypercalcemia (P<0.01 for both). 
Conclusions: Novel correction equations for tCa show better association with iCa 
and hypercalcemia evaluated by iCa. Its clinical usefulness needs to be evaluated in 
further studies.
Funding: NIDDK Support
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Relationship Between Dietary Phosphorus Intake and Protein and Energy 
Intakes in Hemodialysis Patients  David E. St-Jules,1 David S. Goldfarb,2,3 
Mary Lou Pompeii,1 Kathleen Woolf,4 Kamyar Kalantar-Zadeh,5 Mary A. 
Sevick.1  1NYU School of Medicine; 2NY Harbor VA Medical Center; 3NYU 
Langone Medical Center; 4NYU Steinhardt; 5UCLA School of Public Health.
Background: Excess dietary phosphorus may contribute to mineral and bone 
disorders in hemodialysis (HD) patients. However, many high phosphorus foods are also 
important sources of dietary protein, which raises concerns that phosphorus restriction 
may compromise protein status.
Methods: We conducted a cross-sectional study of 190 African American and white 
men and women on intermittent HD for >3 months. Dietary data were collected by three 
24-hour recalls, which were analyzed using NDSR®. Only participants who completed all 
three recalls and reported intakes >500 kcal/d were included (n=137).
Results: Dietary phosphorus and protein were highly correlated (R2=0.73). Based on 
linear regression, a 1,000 mg/d phosphorus restriction would provide about 78 g protein/d 
(or 1.1 g protein/kg/d for a 70-kg person). When adjusting for energy intake, the association 
of dietary phosphorus and protein was far less apparent (R2=0.42). Further, the highest 
phosphorus intake was about two times greater than the lowest phosphorus intake for 
each energy and protein intake level (500 kcal and 5% of kcal increments), reaching 600 
mg/d for some groups.
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Conclusions: Although dietary phosphorus and protein are highly correlated, this 
relationship appears to be driven in part by the amount of Calories consumed. Moreover, 
phosphorus intake ranges widely within energy and protein intake increments, suggesting 
that reductions in dietary phosphorus may be achieved in many HD patients without 
compromising the protein status.
Funding: NIDDK Support, Other NIH Support - NIH/NINR/R01-NR010135, NIH/
NINR/NIDDK/NHLBI/NIA- K24-NR012226, NIH/NIA/R01-AG027017, NIH/NIA/
P30-AG024827, NIH/NIA/K07-AG033174
FR-PO905
Assessment of Barriers to Phosphorus Control in Dialysis Patients 
Rashmi Bisla, Jasmin Sandhu, Vinod K. Bansal, Stephanie Kliethermes, 
Anuradha Wadhwa.  Loyola Univ Medical Center, Maywood, IL.
Background: High phosphorus levels are associated with increased cardiovascular 
and all-cause mortality but Phosphorus control continues to be a challenge amongst 
dialysis patients. In this study, we conducted a survey to assess phosphorus control and 
identify barriers to phosphorous control in patients receiving dialysis at Loyola outpatient 
dialysis unit.
Methods: The study consisted of 17 question survey evaluating patients knowledge 
and understanding of phosphorus control, self care practices and social support as potential 
barriers to phosphorus control. Patients were approached during dialysis to participate. 
Objective patient data and laboratory data was collected from electronic medical records. 
Study was approved by Loyola IRB.
Results: Of the 99 eligible subjects, 57 completed the survey. Mean age of the 
participants was 62 years, 52% were males and 75% were African Americans. Patients 
were categorized into uncontrolled (phosphorus>=5.5 mg/dL) and controlled phosphorus 
group. The two groups had similar demographics, co-morbidities, dialysis adequacy and 
medication pill burden. Approximately 80% of patients with uncontrolled phosphorus 
were aware of normal phosphorus levels in dialysis patients, complications associated with 
high phosphorus and identified majority of foods with high phosphorus compared to 53%, 
43% and 57% in the controlled phosphorus group, respectively. Patients with uncontrolled 
phosphorus frequently identified cheating on diet and missed medication dose as reasons 
for lack of phosphorus control. There was no difference among the two groups relative to 
social support or self-care practices. 75% patient in controlled and 55% in uncontrolled 
group were interested in learning more about phosphorus control.
Conclusions: Patients with uncontrolled phosphorus had significantly greater 
knowledge and understanding of phosphorus control. While continued education of patients 
regarding phosphorus control is important, qualitative research to study patients’ behavioral 
aspects is needed to better understand barriers to phosphorus control.
FR-PO906
Use of a Simple, Widely Available Laboratory Test to Quantify and Explain 
Variation in Phosphorus Levels in Beverages  Elizabeth J. Lindley,1 David 
Francis Keane,1 Tracey Ying,2 John W. MacD. Agar,2 Gunnar H. Heine,3 Juergen 
Geisel.3  1Leeds Teaching Hospitals NHS Trust, United Kingdom; 2Geelong 
Hospital, Australia; 3Saarland Univ Medical Centre, Germany.
Background: Restriction of dietary phosphorus (P) is essential in the management of 
hyperphosphataemia in CKD. Beers and wines contain inorganic P that is readily absorbed 
but data on these beverages, and less well-known soft drinks, is difficult to obtain. An assay 
used routinely in hospital laboratories has been validated for measurement of P in a range 
of beverages (Lindley, J Ren Nutr 2014) enabling renal unit staff to compile information 
on locally sourced products and investigate variation between brands.
Methods: Beverages were processed as if they were urine samples and tested using 
the standard phosphomolybdate assay. 12 beers popular in the German Saarland were 
tested to find out if lower P brands could be identified. 10 wines from a micro-winery in 
New South Wales containing little or no di-ammonium phosphate (DAP, a widely-used 
yeast nutrient) were compared with 8 Australian wines from UK supermarkets. Classic 
Coca-Cola, which is strictly regulated world-wide, was used to check agreement between 
analysers in different countries.
Results: The P content of alcoholic beers in the Saarland selection varied from 12 to 27 
mg/dL. There was no association between P and alcohol level. P levels in the non-alcoholic 
beers tested to date were 9 and 18 mg/dL DAP-free white wines contained 6 to 8 mg/dL 
P, while reds contained 14 to 20 mg/dL. DAP increased the P level by about 2 mg/dL for 
every 100 mg/L added to the wine must. Much higher P levels in the supermarket wines 
(up to 31 mg/dL) suggest routine addition of 500 to 700 mg/L DAP.
Conclusions: Phytic acid in cereal grains and grape pips provides P for the seedlings. 
Inorganic P is released from this indigestible molecule by the enzyme phytase during malting 
(sprouting) and fermentation. Biological variation, differences in production that affect the 
breakdown of phytic acid and addition of DAP contribute to the wide range of P content 
in beer and wines. Until appropriate labelling becomes mandatory, tables of measured P 
content by brand could help patients trying to restrict their P intake.
Funding: Government Support - Non-U.S.
FR-PO907
Recruitment and Retention to a Randomised Trial of Low versus High 
Serum Phosphate Levels in Hemodialysis Patients  Ramya Bhargava,1 Paul 
E. Brenchley,1 Philip A. Kalra,2 Alastair J. Hutchison.1  1Manchester Royal 
Infirmary, United Kingdom; 2Salford Royal Hospital, United Kingdom.
Background: High phosphate is linked with increased mortality in dialysis patients in 
retrospective observational studies but cause and effect is unproven. A large scale RCT of 
high versus low serum phosphate would be required to determine whether serum phosphate 
reduction improves length or quality of life of dialysis patients. We performed a feasibility 
study to investigate whether such a large scale RCT might be possible in the future.
Methods: After consent, 104 HD patients were randomized to low (2.5-4.4 mg/dL) 
or high phosphate (5.6-7.5 mg/dL) groups. Non-calcium binders, and an adherence self-
help program were used to titrate to target PO4 over 8 weeks. A 10 month maintenance 
period followed. Primary endpoint; % patient months within target range over 10 months. 
Secondary end points: % nephrologists agreeing to enrol patients, % eligible patients willing 
to participate, drop-out rate over 12 months, pill burden per subject.
Results: 768 HD patients were screened, 263 suitable, 202 approached, 128 consented, 
and 104 randomised (13.5% of screened). 21 of 24 nephrologists (87.5%) agreed to enrol 
patients after assessing the protocol.
High PO4 Low PO4
Randomised N 51 53
Completed follow-up N, (%) 31 (60.8) 38 (71.7)
Premature trial exit N, (%) 20 (39.2) 15 (28.3)
Transplanted N, (%) 4 (7.8) 1 (1.9)
Deceased N, (%) 8 (15.7) 2 (3.8)
Withdrew consent N, (%) 4 (7.8) 8 (15.1)
Withdrawn by investigator N 4 (7.8) 1 (1.9)
% pt mths within PO4 range 49.5 35.7
Conclusions: Less than 50% of PO4 levels were within target range over 10 months, 
and this will be analyzed as time-averaged results. More patients withdrew consent in the 
low PO4 group, with GI side-effects plus high pill burden being possible contributory 
factors. 65% patients completed the study with a drop-out rate of 35%. Drop-out due to 
death was substantially greater in the high PO4 group, but randomization was not stratified 
for other risk factors, and the overall mortality rate of 10% is lower than the expected 
dialysis rate of 13-17% per annum.
Funding: Pharmaceutical Company Support - Shire pharmaceuticals provided an 
unrestricted educational grant towards the salary of the research fellow for 12 months., 
Government Support - Non-U.S.
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Randomization to High or Low Phosphate Control in Hemodialysis: Is 
Such a Study Feasible?  Ramya Bhargava,1 Paul E. Brenchley,1 Philip A. 
Kalra,2 Alastair J. Hutchison.1  1Manchester Royal Infirmary, United Kingdom; 
2Salford Royal Hospital, United Kingdom.
Background: High phosphate is linked with increased mortality in dialysis patients in 
retrospective observational studies but cause and effect is unproven. A large scale RCT of 
high versus low serum phosphate would be required to determine whether serum phosphate 
reduction improves length or quality of life of dialysis patients. We performed a feasibility 
study to investigate whether such a large scale RCT might be possible in the future.
Methods: From a pool of 768 HD patients, 104 were suitable and consented to a 
binder washout period, and were randomized to low phosphate (2.5 to 4.4 mg/dL) or high 
phosphate (5.6 to 7.5 mg/dL) groups. Subjects were titrated to target over 8 weeks with 
lanthanum or sevelamer binders only, then followed for 10 months. The pill burden in each 
group and secondary hyperparathyroidism were assessed. Serum albumin as a measure of 
nutritional status was recorded.
Results:
HRG LRG P value
Number randomised 51 53
Randomisation PO4 (mg/dL) 2.1+/- 0.1 2.2 +/- 0.1
Week 8 PO4 (mg/dL) 2.0 +/- 0.4 1.6 +/- 0.4 <0.05
Randomization PTH(pg/ml) 436 +/- 62 424 +/- 54
Week 8 PTH(pg/ml) 362 +/- 258 472 +/- 380
Randomization Albumin(g/L) 32 +/- 0.8 32 +/- 0.8
Week 8 Albumin(g/L) 34 +/- 0.6 34 +/- 0.7
Week 8 Pill burden 6 (2,15) 1.5 (0,9) <0.05
Mortality 8 2
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Conclusions: 1. Statistically significant separation in serum phosphate was achieved 
between the two groups (fig 1) with no apparent increase in secondary hyperparathyroidism. 
3 patients in the HRG commenced Cinacalcet during the course of the study because 
serum PTH > 1200mg/dL. 2. As expected, LRG had a significantly larger pill burden than 
the HRG, with 20 patients in the LRG taking 9 or more binder pills. 3. Despite increased 
pill burden, albumin levels were not different between groups. 4. Crude mortality 4 times 
higher in the HRG.
Funding: Pharmaceutical Company Support - Shire pharmaceuticals provided 
an unrestricted educational grant towards the research fellow’s salary for 12 months., 
Government Support - Non-U.S.
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Efficacy and Safety of PT20: A Novel Iron-Based Phosphate Binder 
Geoffrey A. Block,1 George G. Hon,2 Nuno Faria,3 Jonathan Powell.3  1Denver 
Nephrologists PC, Denver, CO; 2Kidney Wellness Center, Long Beach, CA; 
3Human Nutrition Research, Medical Research Council, Cambridge, United 
Kingdom.
Background: PT20, a novel iron based phosphate binder (P-binder), has been 
specifically engineered with adipic acid substitution to improve phosphate binding 
capacity and affinity of ferric oxides. PT20 has shown high binding affinity for phosphate 
in preclinical studies.
Methods: Patients were on hemodialysis with serum phosphate (P) levels between 4.0 
and 8.0mg/dL plus serum ferritin levels <1000 ng/mL at their screening visit. All patients 
were then washed out of previous P-binders and required to have an increase in serum 
P of at least 1.0 mg/dL to enter study. 153 subjects were randomized to either 400mg, 
800mg, 1600mg, 3200mg PT20 or placebo, each taken TID with meals for 28 days. Doses 
were not modified during the treatment period. Primary end point was change in serum P 
from Baseline to Day 29. Secondary endpoints assessed safety as well as haematological 
parameters.
Results: PT20 treatment significantly reduced serum P levels and demonstrated a 
dose response effect (ITT population; p<0.001). All dose groups showed a reduction in 
mean serum P levels greater than placebo. Mean reduction in P over the 28 days was (mg/
dL) 1.36 / 3200mg; 1.29 / 1600mg; 0.59 / 800mg; 0.40 / 400mg and 0.17 / Placebo dose. 
Limited iron absorption from PT20 was observed across all groups. Adverse events (AE) 
were mostly GI in nature but generally uncommon and not dose related (diarrhoea (15 and 
6%; P binder average and placebo); discoloured faeces (10 and 0 %); Vomiting (4 and 0 %); 
nausea (4 and 0%); constipation (1 and 11 %)). 12 patients’ experienced serious adverse 
events that were not considered related to PT20.
Conclusions: Use of adipate-modified iron oxide (PT20) resulted in a statistically 
significant and dose-dependent reduction in serum phosphate over a 28 day period. The 
safety profile and tolerability were acceptable with AEs being mostly GI in nature, with 
no pattern of serious adverse events related to treatment. Limited iron absorption from 
PT20 was observed.
Funding: Pharmaceutical Company Support - Phosphate Therapeutics Ltd
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Phase III Study to Investigate the Efficacy, Safety, and Tolerability of PA21 
(Sucroferric Oxyhydroxide) Compared with Sevelamer Hydrochloride in 
Japanese Hemodialysis Patients with Hyperphosphatemia  Fumihiko Koiwa,1 
Masafumi Fukagawa,2 Keitaro Yokoyama,3 Tadao Akizawa,4 Akira Terao.5  1Div 
of Nephrology, Dept of Medicine, Showa Univ Fujigaoka Hospital, Yokohama, 
Japan; 2Div of Nephrology, Endocrinology and Metabolism, Tokai Univ School 
of Medicine, Isehara, Japan; 3Div of Nephology and Hypertension, Dept of 
Internal Medicine, The Jikei Univ School of Medicine, Tokyo, Japan; 4Div of 
Nephrology, Dept of Medicine, Showa Univ School of Medicine, Tokyo, Japan; 
5Biostatistics, Faculty of Pharmaceutical Sciences, Josai Univ, Sakado, Japan.
Background: An open-label, randomized, parallel-group, multicenter, active-controlled 
phase III study was performed to assess the efficacy, safety, and tolerability of the non-
calcium, iron-based phosphate binder PA21 (sucroferric oxyhydroxide: SFOH) vs sevelamer 
hydrochloride (SEV) in Japanese hemodialysis (HD) patients with hyperphosphatemia.
Methods: In total, 213 patients were randomized to SFOH (750–3000 mg/day; starting 
dose 750 mg/day; 250 mg tablets; n=108) and SEV (3–9 g/day; starting dose 3 g/day or 6 
g/day; 250 mg tablets; n=105) for 12 weeks. Doses were titrated during Weeks 2–8 to reach 
predefined serum phosphorus (sP) concentrations of 3.5–6.0 mg/dL, but were unchanged 
during Weeks 8–12.
Results: Mean sP concentrations at the last evaluation were 5.00 mg/dL for SFOH vs 
5.34 mg/dL for SEV (between-group difference: -0.34 mg/dL). Moreover, the value was 
significantly lower in the SFOH compared to the SEV (an analysis of covariance with sP 
concentrations at Week 0 as a covariate, P = 0.02). The average number of tablets was 4.8 
tablets/day for SFOH vs 17.6 tablets/day for SEV.
Conclusions: Study met the non-inferiority primary end point. SFOH showed even a 
larger serum phosphorus reduction in Japanese HD patients, compared with SEV (p=0.02), 
and was associated with a lower pill burden and good tolerability.
Funding: Pharmaceutical Company Support - Kissey Co, Ltd
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Phase III Study to Investigate the Long-Term Efficacy, Safety, and 
Tolerability of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis 
Patients with Hyperphosphatemia  Fumihiko Koiwa,1 Masafumi Fukagawa,2 
Keitaro Yokoyama,3 Tadao Akizawa.4  1Div of Nephrology, Dept of Medicine, 
Showa Univ Fujigaoka Hospital, Yokohama, Japan; 2Div of Nephrology, 
Endocrinology and Metabolism, Tokai Univ School of Medicine, Isehara, Japan; 
3Div of Nephology and Hypertension, Dept of Internal Medicine, The Jikei Univ 
School of Medicine, Tokyo, Japan; 4Div of Nephrology, Dept of Medicine, Showa 
Univ School of Medicine, Tokyo, Japan.
Background: An open-label, multicenter study was performed to assess the long-term 
efficacy, safety, and tolerability of the non-calcium, iron-based phosphate binder PA21 
(sucroferric oxyhydroxide: SFOH) after 52-weeks of treatment in Japanese hemodialysis 
(HD) patients with hyperphosphatemia.
Methods: In total, 161 patients were treated with SFOH (750–3000 mg/day; starting 
dose 750 mg/day; available as 250 mg and 500 mg tablets). SFOH was administered at Week 
0, after treatment with any prior phosphate binders had been discontinued. Doses of SFOH 
were titrated to maintain predefined serum phosphorus (sP) concentrations of 3.5–6.0 mg/dL.
Results: Mean sP concentrations decreased from 5.46 mg/dL at Week 0 to 5.00 mg/dL 
at the last evaluation. Mean sP concentrations were maintained within the target range of 
3.5–6.0 mg/dL throughout the 52-weeks treatment period. The average number of SFOH 
tablets was 3.3 tablets/day, and the average dose of SFOH was 1,141 mg/day. Overall, the 
incidence of adverse events and adverse drug reactions was 94.4% and 32.9%, respectively. 
Frequently observed adverse drug reactions were diarrhea (22.4%) and constipation 
(2.5%); no severe diarrhea or constipation was reported. Despite slight increases in serum 
ferritin and transferrin saturation, no clinical signs of iron accumulation or overload were 
observed at 52 weeks.
Conclusions: SFOH demonstrated a sustained sP-lowering effect 52-weeks of treatment 
in Japanese HD patients, and was associated with a low pill burden and good tolerability.
Funding: Pharmaceutical Company Support - Kissey pharmaceutical Co, Ltd
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Improved Serum Phosphorus Control and Decreased Phosphate 
Binder Pill Burden Amongst African American Hemodialysis Patients 
Taking Sucroferric Oxyhydroxide  Linda H. Ficociello, Lin Ma, Vidhya 
Parameswaran, Claudy Mullon, Franklin W. Maddux, Robert J. Kossmann. 
Fresenius Medical Care North America (FMCNA), Waltham, MA.
Background: A retrospective database study was conducted on the real-world 
effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus (sPhos) 
among hemodialysis (HD) patients (pts). This analysis focuses on the subset of patients 
who self-reported race as Black or African American.
Methods: All patients were prescribed SO as part of standard care at FMCNA clinics 
and had ³1 sPhos measured during SO use. Changes in sPhos, serum calcium (sCa), intact 
parathyroid hormone (iPTH), transferrin saturation (TSAT), ferritin (FER), and phosphate 
binder pills per day (PPD) were assessed 3-months before (baseline; BL) and 3-months 
during SO treatment (SO-TX).
Results: On average, pts (n=1015) were 51 years old with a dialysis vintage of 5.2 
years and hyperphosphatemia (BL sPhos= 6.93 mg/dl). BL phosphate binder used were: 
sevelamer (52.1%), calcium acetate (26.3%), calcium carbonate (4.7%), lanthanum (7.2%), 
dual PB therapy (4.1%) and no PB specified (5.5%). As shown in Figure, pts in-range for 
sPhos increased from 12.9 to 20.2% (57%, p<0.001). Significant decreases in mean sPhos 
(6.93 to 6.73 mg/dl) and PPD (8.5 to 3.7 pills) were observed (p<0.001 for both). There 
was minimal change in sCa (9.3 to 9.27 mg/dl, p=0.05) or iPTH (685.3 to 700.9 pg/ml, 
p=0.15). Iron indices increased (FER: 1010.7 to 1076.3 ng/ml, p<0.001; TSAT: 33.6 to 
34.8%, p<0.001). In pts not receiving IV Iron, changes in TSAT (35.1 to 34.2%) and FER 
(1245.1 to 1193.6 ng/ml) were not significant.
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Conclusions: In a cohort of African American hemodialysis patients prescribed 
sucroferric oxyhydroxide, a 57% increase in patients with in-range (3.5-5.5 mg/dl) serum 
phosphorus (p<0.001) along with a decrease in pill burden (4.8 fewer pills, p<0.001) was 
observed.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
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Real-World Use of Sucroferric Oxyhydroxide in Hemodialysis Patients: 
Changes in Serum Phosphorus Control and Phosphate Binder Pill Burden 
Linda H. Ficociello, Lin Ma, Vidhya Parameswaran, Claudy Mullon, Franklin 
W. Maddux, Robert J. Kossmann.  Fresenius Medical Care North America 
(FMCNA), Waltham, MA.
Background: Approximately 40% of US dialysis patients (pts) do not achieve serum 
phosphorus (sPhos) goals (US-DOPPS Practice Monitor, 4/2015). This retrospective 
database analysis assessed the real-world effectiveness of sucroferric oxyhydroxide (SO) 
to control sPhos in hemodialysis (HD) pts.
Methods: In-center HD pts prescribed SO as part of routine clinical practice at FMCNA 
clinics with ³1 sPhos during SO use were included. Changes in sPhos, serum calcium 
(sCa), intact parathyroid hormone (iPTH), transferrin saturation (TSAT), ferritin (FER), 
and phosphate binder (PB) pills per day (PPD) were assessed 3-months before (baseline) 
and 3-months during SO treatment (follow-up).
Results: On average, pts (n=3151) were 54 years old with 4.3 years dialysis vintage 
and hyperphosphatemia (baseline sPhos = 6.94 mg/dl). PB prescribed at baseline were: 
sevelamer (47%), calcium acetate (26%), calcium carbonate (6%), lanthanum (7%), other 
PB (.1%), dual PB (7%), and no PB specified (7%). Pts with in-range sPhos (3.5-5.5 mg/dl) 
increased from 13 to 20.4% (57% increase). Mean sPhos (6.94 to 6.73 mg/dl, p<0.001) and 
mean sCa (9.21 to 9.18 mg/dl, p=0.003) decreased significantly. IPTH changed minimally 
(594.6 to 604.9 pg/ml, p=0.06). TSAT and FER increased (both p<0.001) from 33.6 to 35.1% 
and 947.9 to 1005.3 ng/ml, respectively. In pts not receiving IV iron, there was no significant 
change in TSAT (35.5% to 34.6%) and minimal decrease in FER (1122.9 to 1063.7 ng/ml, 
p=0.008). PB PPD decreased by 4.7 pills (8.4 to 3.7 pills, p<0.001).
Conclusions: In a large HD patient cohort prescribed sucroferric oxyhydroxide as 
part of routine clinical care, in-range serum phosphorus increased by 57% (13 to 20.4%, 
p<0.001) and mean pills per day decreased by 4.7 pills (8.4 to 3.7 pills, p<0.001).
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
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Serum Phosphorus Control and Phosphate Binder Pill Burden Among 
Hemodialysis Patients Who Switched from Calcium Based Phosphate 
Binders to Sucroferric Oxyhydroxide  Vidhya Parameswaran, Lin Ma, Linda 
H. Ficociello, Claudy Mullon, Franklin W. Maddux, Robert J. Kossmann. 
Fresenius Medical Care North America, Waltham, MA.
Background: A retrospective database analysis of in-center hemodialysis (HD) 
patients (pts) who switched from calcium-based phosphate binders (PB) to sucroferric 
oxyhydroxide (SO) was conducted to study the real-world effectiveness of SO in controlling 
serum phosphorus (sPhos).
Methods: In-center HD pts who had ≥ 1 sPhos measured during SO treatment and 
switched from calcium-based PB were included. Comparisons were made between baseline 
(3 months prior to SO) and follow-up (3 months during SO) levels of sPhos, serum calcium 
(sCa), intact parathyroid hormone (iPTH), transferrin saturation (TSAT), ferritin (FER), 
and PB pills per day (PPD).
Results: Analyzed pts (n=1011) were, on average, 54 years old with dialysis vintage 
of 4.5 years and hyperphosphatemia (baseline sPhos=6.98 mg/dl). Prior therapy included 
81.7% calcium acetate and 18.3% calcium carbonate. There was a significant decrease in 
sPhos (6.98 to 6.77 mg/dl, p<0.001) and PB PPD (8.2 to 3.7 pills, p<0.001). A 47% increase 
(13.5% to 19.8%, p<0.001) in the number of pts with in-range sPhos (3.5-5.5 mg/dl) was 
observed. Levels of iPTH (539.3 to 552.9 pg/ml) and sCa (9.12 to 9.1 mg/dl) did not change 
significantly. Significant differences in TSAT (34.0 to 34.8%, p-value=0.007) and FER 
(931.7 to 973.1 ng/ml, p<0.001) were observed. In pts not receiving IV iron (n=103), there 
were no significant changes in TSAT (34.5% to 33.4%) and FER (1039 to 1003.4 ng/ml).
Conclusions: In a HD cohort switched from calcium-based binders to sucroferric 
oxyhydroxide as part of routine clinical care, a 47% increase (p<0.001) in the number of 
patients with in-range serum phosphorus and reduction of serum phosphorus (0.21 mg/
dl, p<0.001) was observed. Pill burden decreased significantly (4.6 fewer pills, p<0.001).
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
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Phosphate Binder VS-505 Prevents Hyperphosphatemia from Altering Aortic 
Gene Expression in 5/6 Nephrectomized Uremic Rats  J. Ruth Wu-Wong,1 
Xiaoan Ruan,2 Yung-wu Chen,1 Jerry Wessale.1  1Vidasym; 2Jackson Lab.
Background: Chronic kidney disease (CKD) patients are known to have impaired 
vascular function. Clinical studies have linked hyperphosphatemia to a higher cardiovascular 
mortality in CKD.
Methods: We compared gene expression profiles in aorta isolated from 5/6 
nephrectomized (NX) uremic Sprague Dawley rats fed a normal diet vs. a high phosphate 
(Pi) diet. Real-time RT-PCR analysis was conducted on selected genes in aorta prepared 
from 5/6 NX uremic rats on a high Pi diet for 4 weeks treated with or without the phosphate 
binder VS-505, a non-absorbable, calcium- and aluminum-free, chemically-modified, plant-
derived polymer currently being evaluated in hemodialysis patients.
Results: An increase in serum Pi was observed in uremic rats on the special diet (3.92 
± 0.42 vs. 3.29 ± 0.55 mmol/L on normal diet). A total of 135 target genes were affected 
(out of 15923 genes; 2-fold change, p<0.01) by increased serum Pi, with 122 up-regulated 
and 13 down-regulated. Target genes fell into various categories including carboxylic acid 
metabolism, lipid metabolism, mitochondrion, and oxidoreductase activity. In a separate 
study, VS-505 (0.2 - 5% by weight in food) prevented the increase in serum Pi (3.06 ± 
0.30 mmol/L in the 5% VS-505 group vs. 3.74 ± 0.68 mmol/L in the vehicle-treated group, 
p<0.01), and it increased fecal Pi in a dose-dependent manner in the uremic rats on high-Pi 
diet (2.48 ± 0.60 mmol/24 hr in the 5% VS-505 group at Week 4 vs. 0.84 ± 0.55 mmol/24 hr 
at pre-dosing, p<0.001). VS-505 did not affect food/water consumption, feces appearance, 
intestine histomorphology and NPT2b gene expression. VS-505 treatment prevented the 
effects of hyperphosphatemia on altering the expression of aortic genes related to oxidative 
stress and inflammation such as activin A receptor-type 1c, glycogen synthase 2, heat shock 
70KD protein 1A, stearoyl coenzyme A desaturase 1, and uncoupling protein 1.
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Conclusions: These results suggest that hyperphosphatemia affects aortic gene 
expression linked to oxidative stress and inflammation, and that the adverse cardiovascular 
effects of high serum Pi may be prevented by oral treatment with the phosphate binder 
VS-505.
Funding: NIDDK Support
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Fractional Excretion of Phosphorus Misrepresents Hormonal Effects on 
Phosphate Reabsorption in Chronic Kidney Disease  Kenneth R. Phelps,1,2 
Darius Mason,1,2,3 Sun J. Kang.1  1Stratton VAMC, Albany, NY; 2Albany Medical 
College, Albany, NY; 3Albany College of Pharmacy and Health Sciences, 
Albany, NY.
Background: The serum P concentration ([P]s) = EP/Ccr + TRP/Ccr, where EP/Ccr and 
TRP/Ccr are rates of urinary excretion and tubular reabsorption of P per volume of filtrate. 
EP/Ccr is proportional to filtrate [P] in the cortical distal nephron ([P]f); we have argued that 
[PTH] correlates with EP/Ccr for this reason in CKD. Fractional excretion of P (FEP), usually 
calculated as [P]u[cr]s/[P]s[cr]u, also equals 1/{1 + (TRP/Ccr)/(EP/Ccr)}. Since EP equals influx 
of P (IP), the second expression shows that both IP and TRP determine FEP. We hypothesized 
that FEP correlates with [PTH] and [FGF23] in CKD because IP affects all 3 variables.
Methods: We measured fasting [cr]s, [cr]u, [P]s, [P]u, [PTH]1-84 (Scantibodies) and 
intact [FGF23] (Immutopics) in 30 patients with stages 3-4 CKD. We calculated EP/Ccr as 
[P]u[cr]s/[cr]u, TRP/Ccr as [P]s – EP/Ccr, and FEP as [P]u[cr]s/[P]s[cr]u. We performed simple 
linear regressions as in the table and a multilinear regression of FEP on EP/Ccr, TRP/Ccr, 
[PTH], and [FGF23].
Results: FEP correlated directly with [PTH], [FGF23], and EP/Ccr, and inversely with 
TRP/Ccr. [PTH] and [FGF23] correlated directly with EP/Ccr. TRP/Ccr was not associated 
with [PTH] or [FGF23]. In the multilinear regression, EP/Ccr and TRP/Ccr caused > 90% of 
variation in FEP; [PTH] and [FGF23] did not contribute significantly. 
Regression R2 P Regression R2 P
FEP on [PTH] 0.24 0.006 [PTH] on EP/Ccr 0.28 0.003
FEP on [FGF23] 0.17 0.02 [FGF23] on EP/Ccr 0.26 0.004
FEP on EP/Ccr 0.76 < 0.001 TRP/Ccr on [PTH] 0.07 0.15
FEP on TRP/Ccr 0.34 < 0.001 TRP/Ccr on [FGF23] 0.001 0.84
Conclusions: TRP/Ccr was unrelated to [PTH] and [FGF23] even though both hormones 
reduce P reabsorption. Although FEP varied inversely with TRP/Ccr, correlations of FEP with 
[PTH] and [FGF23] did not result from effects of the hormones on TRP/Ccr, and therefore did 
not reflect quantitative relationships between hormone concentrations and P reabsorption. 
The correlations occurred because FEP, [PTH], and [FGF23] were associated with EP/Ccr. 
FEP should not be used to relate P reabsorption to hormones in CKD.
Funding: Veterans Administration Support, Pharmaceutical Company Support - 
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Attributes of the Walton-Bijvoet Nomogram at Normal and Reduced 
Glomerular Filtration Rate  Kenneth R. Phelps,1,2 Darius Mason,1,2,3 Sun J. 
Kang.1  1Stratton VAMC, Albany, NY; 2Albany Medical College, Albany, NY; 
3Albany College of Pharmacy and Health Sciences, Albany, NY.
Background: The serum P concentration ([P]s) is the sum of EP/Ccr and TRP/Ccr (urinary 
excretion and tubular reabsorption of P per volume of filtrate). In Bijvoet’s infusion studies, 
observed TRP/Ccr equaled maximum TRP/Ccr (TmP/GFR) at fasting fractional P excretion 
(FEP) > 20%; as FEP fell, (TmP/GFR) – (TRP/Ccr) rose. These observations were incorporated 
into a nomogram that derives TmP/GFR from [P]s and FEP. Although the nomogram was 
based on data obtained at GFR > 40 mL/min, it is used to assess P reabsorption in CKD. 
We examined this practice.
Methods: We collected fasting morning serum (s) and urine (u) from 30 patients with 
stages 3-4 CKD and 28 controls with MDRD eGFR > 60. We calculated EP/Ccr as [P]u[cr]
s/[cr]u, TRP/Ccr as [P]s – EP/Ccr, and FEP as [P]u[cr]s/[cr]u[P]s. After ascertaining TmP/GFR 
from the nomogram, we calculated (TmP/GFR)/[P]s), (TmP/GFR – TRP/Ccr) and (TmP/GFR)/
(TRP/Ccr). We performed group comparisons with the Mann-Whitney U test.
Results: In CKD, EP/Ccr and FEP were higher, and eGFR, TRP/Ccr, TmP/GFR, (TmP/
GFR)/[P]s, (TRP/Ccr)/(EP/Ccr), (TmP/GFR – TRP/Ccr), and (TmP/GFR)/(TRP/Ccr) were lower 
than in controls. [P]s was not different in the 2 groups. In CKD, FEP was > 20% in 27/30 
patients; mean (TmP/GFR – TRP/Ccr) and (TmP/GFR)/(TRP/Ccr) approximated 0 and 1, 
respectively.
Parameter CKDa Controlsa
eGFR, ml/min/1.73m2 29.5 (1.7) 86.0 (1.9)
[P]s, mg/dL 3.5 (0.1) 3.4 (0.1)
EP/Ccr, mg/dL 1.4 (0.1) 0.4 (0.03)
TRP/Ccr, mg/dL ([P]s - EP/Ccr) 2.2 (0.1) 3.1 (0.1)
(TRP/Ccr)/(EP/Ccr) 2.1 (0.3) 8.8 (0.9)
FEP, % 40 (3) 11 (0.7)
TmP/GFR, mg/dL (nomogram) 2.1 (0.1) 3.4 (0.1)
(TmP/GFR)/[P]s 0.63 (0.03) 0.97 (0.02)
(TmP/GFR) - (TRP/Ccr), mg/dL 0.02 (0.01) 0.3 (0.05)
(TmP/GFR)/(TRP/Ccr) 1.0 (0.003) 1.1 (0.02)
aValues are mean (SEM). P = 0.73 for [P]s and < 0.001 for all other comparisons.
Conclusions: FEP is > 20% at (TRP/Ccr)/(EP/Ccr) < 4. In this circumstance, TmP/GFR 
= TRP/Ccr = [P]s – EP/Ccr whether EP/Ccr is increased by P influx or low Ccr. Use of the 
nomogram and calculation of TRP/Ccr require the same variables. In CKD, the nomogram 
is accurate but unnecessary if (TRP/Ccr)/(EP/Ccr) is < 4.
Funding: Veterans Administration Support, Pharmaceutical Company Support - 
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Role of KHSRP and Pin1 in Mediating the Parathyroid Hormone Response 
in the Proximal Tubule  Rebecca Murray,1,2 Michael Merchant,2 Syed J. 
Khundmiri,1,2,3 Barbara Clark,4 Eleanor D. Lederer.1,2,3  1Physiology & Biophysics, 
Univ of Louisville, Louisville, KY; 2Medicine, Univ of Louisville, Louisville, KY; 
3Robley Rex VAMC, Louisville, KY; 4Biochemistry & Molecular Biology, Univ 
of Louisville, Louisville, KY.
Background: Parathyroid hormone (PTH) regulates the type IIa sodium-phosphate 
cotransporter (Npt2a), the major regulated proximal tubule phosphate transporter, at 
both the protein and mRNA level. We previously identified KHSRP as a PTH-responsive 
phospho-protein that binds Npt2a mRNA and may mediate its degradation. Pin1, a 
peptidyl- prolyl isomerase, is the upstream regulator of KHSRP function and localization. 
Non-phosphorylated Pin1 binds KHSRP, promoting KHSRP dephosphorylation and 
maintaining its cytosolic localization. We hypothesize that PTH stimulates Npt2a mRNA 
destabilization through PKA-mediated phosphorylation of Pin1.
Methods: To address this hypothesis, we treated opossum kidney (OK) cells, a proximal 
tubule cell line, with 100nM PTH or 10µM 8-bromo-cAMP (8-Br [to directly activate 
PKA]) in the presence or absence of 1µM H-89 (a PKA inhibitor).
Results: 2h PTH induced a 2.5-fold increase in Pin1 phosphorylation. IP of KHSRP 
followed by immunoblot for Pin1 showed that Pin1 associates with KHSRP under basal 
conditions, but not following 2h PTH or 8-Br treatment. Pre-treatment with H-89 blocked 
the PTH/8-Br-induced disassociation. 2h PTH did not alter total expression of KHSRP, 
but stimulated its translocation to the nucleus.
Conclusions: We conclude that PTH-mediated destabilization of Npt2a mRNA likely 
involves PKA-mediated regulation of Pin1 and KHSRP activity. Funding provided by 
VA to EDL.
Funding: Veterans Administration Support
FR-PO919
Phosphate Depletion-Induced Metabolic Acidosis and Alkali Urine 
May Be Caused by Inappropriate Stimulation of Apical Cl-/HCO3- 
Exchanger (Pendrin) in Mouse Kidney Type B Intercalated Cells (IC-B) 
Yukiko Yasuoka,1,2 Tomomi Oshima,1 Yuichi Sato,3 Hiroshi Nonoguchi,4 
Katsumasa Kawahara.1,2  1Physiol., Kitasato U. Sch. of Med., Sagamihara, 
Japan; 2Cell & Mol. Physiol., Kitasato U. Grad. Sch. of Med. Sci., Sagamihara, 
Japan; 3Mol. Diag., Kitasato U. Grad. Sch. of Med. Sci., Sagamihara, Japan; 
4Internal Med., Kitasato U. Medical Center, Kitamoto, Japan.
Background: Mice treated with a low phosphate (Pi) diet can maintain normal levels 
of plasma Pi concentration via stimulation of bone reabsorption, but show hypercalcemia, 
hypercalciuria, and hypophosphaturia. Recently, the Ca-sensing receptor (CaSR) was 
found to be localized in the basolateral membrane of IC-B as well as in the thick ascending 
limb of Henle’s loop (Yasuoka et al, 2014). This study was aimed to determine whether 
hypercalcemia and/or hypercalciuria affect urine pH as expected in mice treated with either 
dietary Pi depletion or CaCl2-loading.
Methods: C57Bl/6J mice (10 wks, male) were divided into three groups: (1) normal 
diet (1% Pi, n=6), (2) low-Pi (LP) diet (0.02% Pi, n=4), (3) CaCl2-loading (1% Pi, +1% 
Ca (CaCl2), n=6). All diets contain 1% Ca (CaCO3). On day 7, a 24-hr urine, blood, and 
kidney samples were collected.
Results: Serum and urinary Ca were markedly and significantly increased in the LP 
and CaCl2 groups [serum, 9.1 and 8.9 mg/dl; and urine, 2,400 and 2,140 µg/day], compared 
with control [serum, 7.6 mg/dl; urine, 108 µg/day]. Although serum pH decreased similarly 
and significantly to 7.25 and 7.20 in both groups, pH of the urine decreased to 5.6 (P < 0.05) 
in the CaCl2 group and, surprisingly, increased to 7.4 (P < 0.05) in the LP group (control, 
serum pH 7.35; urine, pH 6.3). Kidney histology and immunohistochemistry showed that 
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the IC-A cell height and basolateral Cl-/HCO3- exchanger type 1 (AE1) staining significantly 
increased in the CaCl2 group, whereas the IC-B cell height and apical Pendrin and basolateral 
AE4 staining significantly increased in the LP group.
Conclusions: Pi-depletion induced metabolic acidosis may be due to imbalanced 
urinary alkalinization and acid absorption caused by inappropriate stimulation of Pendrin 
and AE4 through the hypercalcemia-induced activation of the basolateral CaSR in IC-B.
FR-PO920
MUCIN1 Increases Renal Calcium Channel TRPV5 Activity to Enhance 
Calcium Reabsorption in a Galectin-3 Dependent Fashion  Matthias Wolf,1 
Mingzhu Nie,1 Zhufeng Yang,2 Jie Liu,1 Denise K. Marciano,2 Manjot S. Bal.1 
1Pediatrics, UTSW Medical Center, Dallas, TX; 2Internal Medicine, UTSW 
Medical Center, Dallas, TX.
Background: MUCIN1 (MUC1) mutations cause autosomal dominant tubulo-
interstitial kidney disease (ADTKD-MUC1), a condition similar to a nephropathy caused 
by Uromodulin (UMOD) mutations (ADTKD-UMOD). We previously showed that UMOD 
may protect against calcium-containing kidney stones by increasing TRPV5 cell surface 
abundance and tubular calcium reabsorption, which may decrease the risk of urinary 
supersaturation. The role of MUC1 in kidney is unclear. As UMOD and MUC1 share 
characteristics regarding disease phenotype, protein function, and structure, we examined 
the hypothesis that MUC1 enhances TRPV5 channel activity.
Methods: We expressed TRPV5 and MUC1 variants in HEK293 cells and studied 
TRPV5 current density by whole-cell patch-clamp recording.
Results: MUC1 coexpressed with TRPV5 resulted in a higher TRPV5 current density 
compared to mutant MUC1+C or control. MUC1 increased TRPV5 current density when 
applied extracellularly and required TRPV5 N-glycan for upregulation. Immunofluorescence 
imaging showed apical MUC1 expression along the distal nephron which is compatible 
with TRPV5 regulation in DCT. To test if MUC1 affects TRPV5 endocytosis, we tested 
if MUC1 upregulates TRPV5 in caveolin-1 deficient fibroblasts, as TRPV5 undergoes 
endocytosis via caveolin-1. While MUC1 alone had no effect, cotransfection of recombinant 
caveolin-1 with MUC1 restored TRPV5 upregulation by MUC1. The extracellular domain 
of MUC1 contains variable number tandem repeats (VNTRs) which bind galectin-3, a lectin 
involved in lattice formation of channels. Using galectin-3 siRNA, we identified galectin-3 
as a prerequisite for TRPV5 upregulation by MUC1. This was confirmed by the inability 
of MUC1 lacking VNTR to upregulate TRPV5. In urine samples of patients with calcium-
containing kidney stones we found less urinary MUC1 compared to control individuals.
Conclusions: MUC1 upregulates TRPV5 by extracellular lattice formation with 
TRPV5 N-glycan via galectin-3 which impairs TRPV5 channel endocytosis. These data are 
consistent with MUC1 contributing to protection against calcium-containing kidney stones.
Funding: NIDDK Support
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NCC Activty Modulation as a Mechanism for PTH Regulation of DCT 
Calcium Transport  Benjamin S. Ko,1 Robert S. Hoover.2  1Dept of Medicine, 
Univ of Chicago, Chicago, IL; 2Dept of Medicine, Emory Univ, Atlanta, GA.
Background: The distal convoluted tubule (DCT) is a major site of both calcium and 
sodium transport. While altered DCT calcium handling is not required for thiazide-induced 
hypocalciuria, studies have documented increased DCT calcium reabsorption in response to 
thiazide administration. This suggests that DCT sodium transport does affect DCT calcium 
transport, and while thiazide induced hypocalciuria is due to a proximal effect, modulation 
of NCC activity may affect DCT calcium transport by TRPV5. Since parathyroid hormone 
(PTH) is known to increase TRPV5 activity and decrease NCC activity, we theorized that 
decreased NCC-mediated sodium reabsorption may contribute to the enhanced TRPV5 
calcium reabsorption seen with PTH administration.
Methods: Radiotracer uptake and biotinylation in mDCT15 cells were used to measure 
sodium and calcium uptake as well as surface expression of NCC and TRPV5.
Results: mDCT15 cells expressed ruthenium red sensitive 45Ca2+ uptake of 5.9±0.2 
nmol/mg/min and surface expressed TRPV5. PTH increased 45Ca2+ uptake to 8.8±0.7 nmol/
mg/min (n=4, p<0.01 compared to control) and decreased NCC activity from 75.4±2.7 to 
20.3±1.3 nmol/mg/min (n=4, p<0.01 compared to control). Knockdown of RasGRP1, the 
pathway by which PTH affects NCC, had no baseline effect on 45Ca2+ uptake but significantly 
attenuated the increased 45Ca2+ uptake response to PTH from a 45% increase (6.0±0.2 to 
8.7±0.4 nmol/mg/min) in non-targeting controls to only a 20% increase (6.1±0.1 to 7.3±0.2 
nmol/mg/min (n=4, p<0.01 compared to non-targeting treated groups)). Inhibition of 
PKC and PKA, the known pathways by which PTH acts upon TRPV5, resulted in further 
attenuation of the PTH effect.
Conclusions: Here, through the use of a cell model with native NCC and TRPV5 
activity, we report that modulation of NCC activity does indeed contribute to the TRPV5 
response to PTH, implying a role for hormonal modulation of NCC activity in distal 
calcium handling. Further study is needed to determine the mechanism for these findings.
Funding: NIDDK Support, Veterans Administration Support
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How Disruption of Distal Nephron Salt Reabsorption Causes Calcium 
Wasting, Tubule Calcification and Skeletal Changes  Sharon L. Barone,1,2 
Jie Xu,1 Mujan Varasteh kia,1 Saeed Alshahrani,1 Marybeth Brooks,1 Kamyar 
A. Zahedi,1,2 Manoocher Soleimani.1,2  1Internal Medicine, Univ of Cincinnati, 
Cincinnati, OH; 2Research Services, Veterans Affairs Medical Center, Cincinnati, 
OH.
Background: Carbonic anhydrase II/sodium chloride co-transporter (NCC) and 
pendrin/NCC double knockout mice (dKO) develop salt wasting and are growth retarded. 
We propose that the disruption of sodium and chloride reabsorption in these mice causes 
phosphate and calcium wasting and leads to bone and skeletal anomalies.
Methods: Renal alterations that lead to distorted calcium and phosphate reabsorption 
and contribute to tubular calcification and growth retardation in the dKO mice were 
examined.
Results: dKO mice are volume depleted, exhibit kidney hypoperfusion, and have 
increased urinary calcium and phosphate excretion. These mice also exhibit skeletal 
anomalies and osteopenia and develop tubular calcium phosphate deposits. Parathyroid 
hormone (PTH) and fibroblast growth factor-23 (FGF-23) levels are normal in dKO mice. 
The urinary content of prostaglandin E2 (PGE2) is significantly elevated, along with 
the expression of microsomal prostaglandin E synthase 1, while the sodium phosphate 
transporter IIa (NaPi-IIa) is downregulated in the kidneys of dKO mice. qRT-PCR analyses 
revealed that the expression levels of NKCC2 variants A and F are reduced while NKCC2-B 
levels are increased in dKO animals. The latter changes lead to decreased NKCC2 activity 
in the medullary thick limb and increased calcium excretion, while NaPi-IIa downregulation 
reduces the reabsorption of phosphate in the proximal tubles. Placement of dKO mice on 
a high salt diet or their treatment with indomethacin corrected the above derangements. 
These results show an important role for salt wasting and dehydration-induced PGE2 
synthesis in renal calcium and phosphate excretion as well as in bone calcium mobilization.
Conclusions: Our studies suggest the presence of PGE2-mediated pathways, which 
are activated in response to salt wasting and volume contraction and independent of PTH 
and FGF-23 activity can lead to anomalous mobilization and excretion of calcium and 
phosphate, and ultimately lead to skeletal abnormalities and growth retardation.
Funding: NIDDK Support, Veterans Administration Support
FR-PO923
Hypercalcemia-Induced Natriuresis Is Mediated by Endothelin-1 (ET-1) 
Natsuko Tokonami, Lydie Cheval, Pascal Houillier.  ERL 8228 – U1138 Équipe 
3, Univ Pierre-et-Marie-Curie, Univ Paris Descartes, INSERM, CNRS, and 
Centre de Recherche des Cordeliers, Paris, France.
Background: Acute hypercalcemia commonly increases urinary sodium and water 
excretions. We previously showed that targeting the calcium receptor CaSR does not affect 
sodium transport in the renal tubule (Loupy, et al., JCI, 2012), suggesting that the natriuretic 
effect of hypercalcemia does not involve CaSR. Since hypercalcemia increases the renal 
expression of ET-1, we tested if ET-1 mediates the natriuretic effect of hypercalcemia.
Methods: Forty-two 8 week-old, male C57Bl6 mice were studied. Osmotic minipumps 
were implanted to infuse hPTH(1-34) and maintain the concentration of PTH to normal 
range throughout the experiment. Hypercalcemia was induced by the oral administration 
of dihydrotachysterol (DHT: 7.5mg/kg food/day). Eighteen mice were treated with an 
ET-1 receptor antagonist, macitentan (Maci, 27mg/kg BW/day), with or without DHT.
Results: On 3rd day of treatment, mice treated by DHT developed hypercalcemia 
(5.0±0.1 vs 2.4±0.1 mmol/L control mice) and exhibited increased water and sodium 
excretion as compared to control mice (2.0 ± 0.1 vs 1.4 ± 0.1 mL/day and 46±4 vs 36±2 
mmol Na/mmol creatinine, respectively, p<0.01 for both). Mice treated with Maci+DHT 
had similar levels of hypercalcemia and polyuria as mice treated with DHT only. However, 
mice treated with Maci+DHT showed no increase in urinary sodium excretion. Mice treated 
with Maci only were similar to control mice. A 3-4 fold increase in the renal level of ET-1 
mRNA was observed in mice treated with DHT and Maci+DHT.
Conclusions: Hypercalcemia increases the renal production of ET-1, which is likely 
responsible for the increase of urinary sodium excretion. In contrast, ET-1 is not involved 
in hypercalcemia-induced polyuria.
Funding: Government Support - Non-U.S.
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The Uremic Toxin Indoxyl Sulfate (IS) Activates the Extracellular 
Regulated Kinase 1/2 (ERK1/2) Pathway in Primary Human Endothelial 
Cells (ECs) by Stimulating Ca2+-Influx via the Na+/Ca2+ Exchanger (NCX) 
Luxme Nadarajah, Steven Michael Harwood, Petros Andrikopoulos, Muhammad 
M. Yaqoob.  William Harvey Research Inst, Barts and the London School of 
Medicine, London, United Kingdom.
Background: Cardiovascular complications are a major cause of morbidity/mortality 
in CKD and endothelial dysfunction is a major contributing factor. The uremic toxin IS 
accumulates in the plasma of end-stage renal disease (ESRD) patients and causes oxidative 
stress and endothelial dysfunction. However, the underlying molecular mechanism(s) are 
largely unknown. We recently reported that Ca2+ influx through the ion transporter NCX 
activated the ERK1/2 pathway in ECs stimulated with thrombin in a reactive oxidant 
species (ROS)-dependent manner (Andrikopoulos et al., 2015 JBC). In the present study we 
investigated whether ERK1/2 activation in response to IS also required Ca2+-influx via NCX.
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Methods: Primary human umbilical vein endothelial cells (HUVECs) were serum 
starved in a physiological buffer and preincubated with reverse-mode (Ca2+ infux) NCX 
inhibitors SN-6 or SEA0400 and the general NCX inhibitor ORM-10103. NCX1 protein 
was knockdown using siRNA. ERK1/2 activation was determined by western blot. [Ca2+]i 
was measured in ECs loaded with the fluorescent Ca2+ indicator Fluo-4NW.
Results: We report that IS, at concentrations found in the plasma of ESRD patients 
(25mg/ml) activated the ERK1/2 pathway and extracellular Ca2+ was required for activation. 
Furthermore, inhibitors of reverse-mode NCX suppressed IS-induced activation of 
ERK1/2 in a time- and dose-dependent manner and attenuated IS-induced Ca2+ transients. 
Knock-down of NCX1 (the main NCX isoform in HUVECs) by siRNA confirmed the 
pharmacological data.
Conclusions: We propose that Ca2+ influx through reverse-mode NCX is required for 
IS-induced ERK1/2 activation. Given the known role of ERK1/2 activation in the expression 
of pro-inflammatory molecules such as COX-2 and VCAM-1 in ECs, reverse-mode NCX 
could be a novel target for improving endothelial function in CKD.
FR-PO925
Chronic Kidney Disease Impairs Myocardial Perfusion and Disturbes 
Cardiac Calcium Handling  Melissa Verkaik,1,2,4 Maarten Oranje,2 Desiree 
Abdurrachim,3 Pieter M. Ter Wee,1 Etto C. Eringa,2 Marc G. Vervloet.1  1Dept 
of Nephrology, VU Univ Medical Center, Amsterdam, Netherlands; 2Dept of 
Physiology, Inst of Cardiovascular Research ICaR-VU, VU Univ Medical Center, 
Amsterdam, Netherlands; 3Biomedical NMR, Dept of Biomedical Engineering, 
Eindhoven Univ of Technology, Eindhoven, Netherlands; 4On behalf of the 
NIGRAM Consortium.
Background: The molecular and microcirculatory changes that may underlie the 
increased prevalence of heart failure and cardiac mortality in CKD are ill-defined. We 
hypothesized that CKD directly impairs both myocardial perfusion and disturbed cardiac 
diastolic and systolic function due to disturbed calcium fluxes across the myocardial 
sarcoplasmatic reticulum.
Methods: Eight week old C57Bl/6J mice were subjected to partial nephrectomy 
(5/6Nx) or sham-surgery, and after 6 weeks mice were subjected to myocardial contrast 
echocardiography (MCE) to test myocardial perfusion. Cardiac function was assessed 
using Cine MRI. In single intact cardiomyocytes diastolic and systolic function, as well as 
intracellular Ca2+ transients were measured by fura-2 loaded cardiomyocytes.
Results: No difference was found between groups for heart weights over tibia length, 
neither for ejection fraction, cardiac output, end diastolic and systolic volume, and E/A ratio. 
Sham mice increased myocardial blood volume during acetylcholine infusion, which was 
absent in 5/6Nx mice (D17%, p=0.023). In isolated cardiomyocytes, time to reach systole 
was increased in 5/6Nx mice (52.3±0.8 vs. 56.7±0.8 ms, p<0.001), which is explained by 
a decrease in velocity of cytosolic Ca2+ increase (78.8±2.2 vs. 66.0±2.0 Fura340/380/s, 
p<0.001). The removal of Ca2+ from cytosol during diastole was slower in 5/6Nx mice 
(-7.12±0.23 vs. -5.74±0.18 Fura340/380/s, p<0.001), due to reduced phosphorylation of the 
SERCA-regulating protein phospholamban (p=0.024), as shown by semiquantitative WB.
Conclusions: CKD compromises both myocardial microvascular perfusion reserve, and 
systolic and diastolic function in cardiomyocytes. Calcium fluxes across the sarcoplasmic 
membrane are disturbed, due to a reduced amount of phosphorylated phospholamban, 
which activates the sarcoplasmic reticulum Ca2+channel SERCA.
FR-PO926
Recessive Mutations in SLC34A1 (NaPi-IIa) as a Cause of Idiopathic 
Infantile Hypercalcemia  Karl P. Schlingmann,1 Birgitta Kranz,1 Martin 
Kaufmann,3 Elisabeth A.M. Cornelissen,4 René J. Bindels,5 Asaf Vivante,6 
Robert Kleta,7 Elena N. Levtchenko,8 Glenville Jones,3 Carsten A. Wagner,2 
Martin Konrad.1  1General Pediatrics, Wilhelms Univ, Munster, Germany; 
2Inst of Physiology, Univ of Zurich, Zurich, Switzerland; 3Biomedical and 
Molecular Sciences, Queen’s Univ, Kingston, Canada; 4Pediatric Nephrology, 
Radboud Univ, Nijmegen, Netherlands; 5Physiology, Radboud Univ, Nijmegen, 
Netherlands; 6Children’s Hospital Boston, Boston; 7Univ College London, 
London, United Kingdom; 8Pediatric Nephrology, Univ Hospitals, Leuven, 
Belgium.
Background: Idiopathic infantile hypercalcemia (IIH) is characterized by severe 
hypercalcemia with failure to thrive, vomiting, dehydration, and nephrocalcinosis. Initially, 
mutations in CYP24A1 encoding the vitamin D catabolizing enzyme 25-hydroxyvitamin 
D3-24-hydroxylase were discovered that lead to an accumulation of active 1,25-(OH)2D3 
with subsequent hypercalcemia and hypercalciuria.
Methods: In a subgroup of IIH patients without mutations in CYP24A1 we now 
performed a positional candidate gene approach in order to identify a second IIH gene locus.
Results: We identified a shared homozygous interval on chromosome 5q35 with a 
maximum LOD score of 6.91. The sequence analysis of SLC34A1 encoding proximal-tubular 
sodium-phosphate co-transporter NaPi-IIa revealed recessive mutations in the 4 index 
cases as well as in 18 additional sporadic IIH patients. The clinical reevaluation revealed 
renal phosphate wasting but no signs of rickets. Functional studies of mutated NaPi-IIa 
in Xenopus oocytes and OK cells demonstrated a disturbed membrane trafficking as well 
as a loss of phosphate transport activity. The reexamination of Slc34a1 knockout mice 
highlighted the critical role of phosphate depletion and FGF-23 suppression. In affected 
patients, clinical and laboratory findings persist after omitting vitamin D prophylaxis but 
rapidly respond to phosphate supplementation.
Conclusions: Therefore, an early differentiation between CYP24A1 (24-hydroxylase) 
and SLC34A1 (NaPi-IIa) defects appears crucial for a effective therapy in children with IIH.
FR-PO927
Identification of SLC41A3 as a Novel Player in Renal Magnesium 
Homeostasis  Jeroen H.F. De Baaij, Anke Lameris, René J. Bindels, Joost 
Hoenderop.  Dept of Physiology, Radboud Univ Medical Center, Nijmegen, 
Netherlands.
Background: Hypomagnesemia is a common clinical cause of muscle cramps, epilepsy 
and cardiac arrhythmias. In the distal convoluted tubule (DCT) of the kidney, transcellular 
reabsorption of Mg2+ regulates the body Mg2+ balance by determining the final urinary Mg2+ 
excretion. In the DCT, Mg2+ is reabsorbed from the pro-urine via the apical Mg2+ channel 
TRPM6. Until now, the basolateral Mg2+ extrusion mechanism in DCT is still unknown, 
but recent findings suggest that proteins of the SLC41 family may contribute to cellular 
Mg2+ extrusion. The aim of this study was, therefore, to investigate the role of SLC41A3 
in Mg2+ homeostasis using the Slc41a3 knockout mouse.
Methods: The Slc41a3 knockout mice were studied by serum and urinary electrolyte 
analysis. To determine the effect of SLC41A3 on intestinal Mg2+ absorption, the Mg2+ 
absorption capacity was measured using the stable 25Mg2+ isotope.
Results: Tissue expression screening was performed by RT-PCR, showing that Slc41a3 
is the only SLC41 isoform with enriched expression in DCT compared to other segments 
in the kidney. Interestingly, serum and urinary electrolyte determinations demonstrated 
that Slc41a3 knockout mice suffer from hypomagnesemia due to renal Mg2+ wasting. 
Serum and urinary Na+, K+ and Ca2+ levels were not affected. 25Mg2+ uptake was similar in 
wild type and knockout mouse, although Slc41a3 knockout animals exhibited increased 
intestinal expression of Mg2+ transporters Trpm6 and Slc41a1. Remarkably, 10% of the 
Slc41a3 knockout mice developed severe unilateral hydronephrosis, as demonstrated by 
the presence of transitional epithelium lining the fluid cavity. Feeding the Slc41a3 knockout 
mice a low Mg2+ diet may have instigated the formation of hydronephrosis.
Conclusions: In conclusion, SLC41A3 was established as a new important factor for 
renal Mg2+ handling, suggesting that SLC41A3 is the basolateral Mg2+ extrusion mechanism 
in the DCT. Slc41a3-/- mice provide the first mouse model with isolated hypomagnesemia, 
without concomitant electrolyte disturbances. In the future, SLC41A3 mutations should be 
considered in patients with unilateral hydronephrosis and/or hypomagnesemia.
Funding: Government Support - Non-U.S.
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Dietary Inulin Supplementation Stimulates Magnesium Absorption in 
Patients with Proton Pump Induced Hypomagnesemia  Jeroen H.F. De Baaij,1 
Mark Wilhelm Hess,1 Joost Hoenderop,1 Joost P.H. Drenth,2 René J. Bindels.1 
1Dept of Physiology, Radboud Univ Medical Center, Nijmegen, Netherlands; 
2Dept of Gastroenterology, Radboud Univ Medical Center, Nijmegen, 
Netherlands.
Background: Hypomagnesemia is a common and severe side effect of patients using 
proton pump inhibitors (PPI), causing severe muscle cramps and depression. Given that 
PPI-users are dependent on PPIs for gastric acid protection, drug withdrawal or antacid 
switching is often not possible to prevent hypomagnesemia. This study, therefore, aimed 
to restore serum Mg2+ levels during PPI use by the dietary application of fructose-oligo-
saccharide-enriched inulin fibers.
Methods: This clinical trial prospectively determined serum Mg2+ concentrations in 
133 patients using PPIs. Under maintenance of PPIs, eleven identified cases of PPI-induced 
hypomagnesemia were exposed to 2 repetitive dietary supplementations with inulin for 
14-days each followed by 14-days washout and compared to 10 healthy non-PPI users. The 
primary endpoint was serum Mg2+. Secondary endpoints were serum Ca2+, K+, and Na+ levels.
Results: Hypomagnesemia is present in 13% of the study population. Dietary 
supplementation with inulin significantly enhanced mean serum Mg2+ levels by + 0.1 
mmol/L in PPIH patients and by + 0.06 mmol/L in healthy controls. Moreover, in patients 
with PPIH concomitant treatment effects were observed for serum Ca2+ (+ 0.09 mmol/L) 
and serum K+ (+ 0.07 mmol/L), no effects were seen on serum Na+. Patients with PPIH 
had adequately renal excretion of Mg2+ and Ca2+, which increased due to inulin following 
increases in serum levels. Additionally, two SNPs in TRPM6 (rs3750425 and rs2274924) 
were identified that cause a 4.75 times higher risk to develop hypomagnesemia.
Conclusions: Inulin fibers are a new promising prebiotic treatment strategy to treat 
intestinal- and renal-caused hypomagnesemia. For the first time we provide a successful 
alternative for oral Mg2+ supplementation.
Funding: Government Support - Non-U.S.
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The Distal Convoluted Tubule Plays a Key Role in Tacrolimus-Induced 
Hypomagnesemia and Hypercalciuria  Rebecca A. Lazelle,1 Sabina K. Jelen,2 
Chao-Ling Yang,1 Joost Hoenderop,2 René J. Bindels,2 David H. Ellison.1,3  1Div 
of Nephrology & Hypertension, Oregon Health and Science Univ, Portland, 
OR; 2Radboud Inst for Molecular Life Sciences, Radboud Univ Medical 
Center, Nijmegen, Netherlands; 3Renal Section, Portland VA Medical Center, 
Portland, OR.
Background: The immunosuppressive drug tacrolimus, used to prevent graft rejection, 
often leads to hypomagnesemia and can also cause hypercalciuria. A decrease in renal 
Mg2+ and Ca2+ reabsorption is thought to be involved, but the molecular mechanisms are 
unclear. Tacrolimus requires a binding partner, FKBP12, to inhibit its canonical target, 
calcineurin. We generated a mouse model in which FKBP12 can be deleted along the 
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nephron (KS-FKBP12-/-). We then tested if either FKBP12 disruption or calcineurin 
inhibition along the nephron alters the mRNA abundance of renal ion transport proteins 
leading to hypomagnesemia and hypercalciuria.
Methods: KS-FKBP12-/- mice were generated using an inducible CRE/LOX system 
driven by the Pax8 promoter. Mice were treated with doxycycline (KS-FKBP12-/-) or vehicle 
(control). We tested the effects of tacrolimus (3 mg/Kg daily for 18 days) on plasma [Mg2+], 
urinary Ca2+ excretion, and mRNA abundance of renal proteins involved in ion transport 
using metabolic cages, colorimetric assays and qRT-PCR.
Results: As expected, tacrolimus caused hypomagnesemia and hypercalciuria in control 
mice. Effects which were absent in KS-FKBP12-/- mice (P<0.05 2-Way ANOVA). In control 
mice, tacrolimus reduced the mRNA abundance of proteins involved in Mg2+ and Ca2+ 
transport by the distal convoluted tubule (DCT) including, TRPM6, calbindin-28K and the 
Sodium Calcium Exchanger-1. In contrast, tacrolimus had no effect in KS-FKBP12-/- mice 
(p<0.05 by 2-way ANOVA). The abundance of mRNA encoding Claudin 16 and 19, thick 
ascending limb (TAL) proteins involved in Mg2+ and Ca2+ handling, were not affected by 
tacrolimus treatment in either group.
Conclusions: Tacrolimus reduces the abundance of mRNA encoding proteins involved 
in Ca2+ and Mg2+ transport by the DCT. These effects require FKBP12, suggesting that 
calcineurin inhibition is essential. The results show that the DCT plays a key role in these 
troubling side effects.
Funding: NIDDK Support, Private Foundation Support
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Regulation of Magnesium Reabsorption and Transient Receptor Potential 
M6 Channel Activity by Protein Kinase A Signaling  Joost Hoenderop,1 
Maxime G. Blanchard,1 Wararat Kittikulsuth,2 Anil V. Nair,1 Jeroen H.F. De 
Baaij,1 Jonathan R. Genzen,3 Donald E. Kohan,2 René J. Bindels.1  1Physiology, 
Radboud Univ Medical Center, Nijmegen, Netherlands; 2Nephrology, Univ of 
Utah, Salt Lake City, UT; 3Pathology, Univ of Utah, Salt Lake City, UT.
Background: The transient receptor potential melastatin type 6 (TRPM6) epithelial 
magnesium (Mg2+) channel participates in Mg2+ transport in kidney and intestine. Previous 
reports have suggested a hormonal cAMP-dependent regulation of Mg2+ reabsorption in the 
kidney. The molecular details of this process are, however, unknown. Adenylate cyclase type 
3 (Adcy3) has been shown to colocalize with the Na+,Cl- cotransporter (NCC), a marker of 
the distal convoluted tubule, the principal site of TRPM6 expression.
Methods: Given the critical role of TRPM6 in Mg2+ reabsorption, an inducible kidney-
specific Adcy3 deletion mouse model was characterised for blood and urinary electrolyte 
disturbances under normal and low Mg2+ diet. Using patch clamp, cell surface biotinylation 
and Total Internal Reflection Fluorescence (TIRF) live cell imaging of transfected HEK293 
cells TRPM6 channel activity was measured.
Results: Urinary Mg2+ excretion was increased (~1.7-fold) in AC3 deleted mice 
compared to controls where as serum Mg2+ concentrations were not different. Renal 
TRPM6 mRNA levels were increased by ~2-fold in AC3 deleted mice. Serum Mg2+ was 
significantly lower in AC3 deleted animals for 7 days on the low Mg2+ diet compared to 
the control animals. In HEK293 cells, it was demonstrated that cAMP signaling rapidly 
potentiates the activity of TRPM6 by promoting its accumulation at the plasma membrane 
and by increasing its single channel conductance. Comparison of electrophysiological data 
between the phosphorylation-deficient S1252A and phosphomimetic S1252D mutants 
suggests that phosphorylation at this intracellular residue participates in the observed 
stimulation of channel activity.
Conclusions: These data support a physiologically relevant magnesiotropic role of 
cAMP signaling in the kidney by a direct stimulatory action of protein kinase A on the plasma 
membrane trafficking and function of TRPM6 ion channels in the distal convoluted tubule.
Funding: Government Support - Non-U.S.
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Renal Handling of Magnesium in Individuals on Long Term Proton Pump 
Inhibitor Therapy  Saubhik Sural.  Nephrology, Peerless Hospital& B K Roy 
Research Centre, Kolkata, West Bengal, India.
Background: Proton Pump Inhibitors (PPI) are a group of very commonly 
used medication.Recently the US---FDA has issued warning regarding the risk of 
hypomagnesemia in patients receiving long term PPI therapy. The present study was 
conducted with the objective of evaluating the serum magnesium and renal handling of 
magnesium in long term PPI patients.
Methods: The study was designed as a case control study consisting of adult patients on 
long term PPI therapy (Omeprezole; Rabeprezole; Pantoprezole etc) for more than 1 year. 
Patients on PPI with diabetes, chronic kidney disease or on diuretics were excluded. Age 
and sex matched healthy controls not on any medication were included as controls. Serum 
Magnesium and Urinary Fractional Excretion of magnesium (FE---Mg) were measured 
using an automated clinical chemistry autoanalyser . Study was conducted for one year 
followed by statistical analysis of data with Graph-pad software.
Results: The mean age of the long term PPI group was 47.5years and 45.9years in 
the control population with no statistical difference between the two groups. Among study 
patients long term PPI users (n = 43) had a mean(SD) Mg level of 1.79 (0.17) mg/dL; and 
non--users (n = 43) 2.06 (0.30) mg/dL; p = 0.001. PPI use was associated with lower serum 
Mg levels (95% CI = 0.30 to 0.19). The FE---Mg of long term PPI users had a mean (SD) 
of 1.37(0.65) % and the control population 2.72(0.88); p = 0.001.Among the PPI group 9 
patients (20%) had a serum Mg less than the lower limit of our population reference interval 
(1.7 mg/dl). None of them were clinically symptomatic for hypomagnesemia.The serum 
magnesium levels showed a negative correlation with the duration of PPI therapy( r= 0.502 
; p 0.01). The FE---Mg of the PPI group is significantly reduced suggesting increased renal 
conservation of magnesium in order to maintain near normal serum levels.
Conclusions: Compensatory renal conservation of Mg occours in long term PPI 
receiving patients. Thus if patients with impaired renal handling of Mg (diabetes; CKD or 
those on diuretics) receive long term PPI therapy they might possibly be at a greater risk 
of clinically significant hypomagnesemia.
FR-PO932
Magnesium Protects against Phosphate-Induced Kidney Injury in Mice 
with Uninephrectomy  Yusuke Sakaguchi,1 Takayuki Hamano,2 Isao Matsui,1 
Akihiro Shimomura,2 Yasuo Kusunoki,1 Sayoko Yonemoto,1 Daisuke Mori,1 
Hiromi Rakugi,1 Yoshitaka Isaka.1  1Geriatric Medicine and Nephrology, Osaka 
Univ Graduate School of Medicine, Suita, Osaka, Japan; 2Comprehensive 
Kidney Disease Research, Osaka Univ Graduate School of Medicine, Suita, 
Osaka, Japan.
Background: We have recently reported that the risk of progression of CKD associated 
with high serum phosphate (P) was significantly attenuated in patients who had higher serum 
magnesium (Mg) levels (Kidney International in press), although the causality remains 
unclear. Here we studied whether Mg protects against kidney injury induced by P overload.
Methods: Eight-week-old C57BL6 mice underwent uninephrectomy and were divided 
into 4 groups: 1. high P (1.25 % P)-normal Mg (0.05% Mg) diet; 2. high P (1.25% P)-low Mg 
(0.005% Mg) diet; 3. low P (0.25% P)-normal Mg (0.05% Mg) diet; 4. low P (0.25% P)-low 
Mg (0.005% Mg) diet. Twenty-four-hour urine samples were collected for the measurement 
of daily urinary excretion of P. After 6 weeks of dietary intervention, mice were sacrificed 
and kidney tissues were harvested for histological analysis and mRNA quantification.
Results: Mice fed with the high P-low Mg diet showed severe tubular injury, interstitial 
fibrosis, and a marked accumulation of F4/80 positive cells in the interstitium; these changes 
were largely attenuated in mice in the high P-normal Mg diet group. Creatinine clearance in 
the high P-low Mg diet group was significantly lower than that in the high P-high Mg diet 
group (0.04±0.02 vs 0.27±0.14; p<0.05). Both TGF-βeta1 and TNF-alpha mRNA expression 
levels in the whole kidney were upregulated in the high P-low Mg diet group compared 
with those in the high P-normal Mg diet group. No histological evidence of kidney injury 
was found in both of the low P groups. Since urinary P excretion in the high P-low Mg 
diet group was equivalent (at 3 weeks) to or even lower (at 6 weeks) than that in the high 
P-normal Mg diet group, it is unlikely that the exacerbation of kidney injury in the high 
P-low Mg diet group was owing to an increased intestinal absorption of P.
Conclusions: Low Mg diet aggravates phosphate-induced kidney injury. Mg may be 
beneficial to reduce the phosphate toxicity to the kidney.
FR-PO933
Low Serum Magnesium Is Associated with an Increased Risk of Death from 
Coronary Heart Disease and Sudden Cardiac Death  Brenda C.T Kieboom,1,2 
Robert Zietse,2 Oscar Franco,1 Albert Hofman,1 Bruno H. Stricker,1,2 Ewout 
J. Hoorn.2  1Epidemiology, Erasmus MC, Univ Medical Center Rotterdam, 
Rotterdam, Netherlands; 2Internal Medicine, Erasmus MC, Univ Medical Center 
Rotterdam, Rotterdam, Netherlands.
Background: Low serum magnesium has been associated with cardiovascular disease 
(CVD) mortality in population-based studies. However, results are conflicting and it remains 
unclear if this effect is mediated by an effect on atherosclerosis or heart rhythm.
Methods: We examined the relationship between serum magnesium and CVD mortality 
in 9,820 participants aged ≥ 45 years from the population-based Rotterdam Study. We used 
multivariable-adjusted Cox proportional hazard regression models and divided serum 
magnesium into quartiles, with the second and third quartile combined as reference group.
Results: During a median follow-up of 8.7 years, 780 participants died of CVD, 
including 431 deaths from coronary heart disease (CHD) and 217 sudden cardiac deaths 
(SCD). Low serum magnesium (£0.80 mmol/L) was associated with an increased CVD 
mortality risk (HR 1.25, 95% 1.05-1.50), including both death from CHD (HR 1.42, 95%CI 
1.04-1.95) and SCD (HR 1.68, 95%CI 1.20-2.37). Low serum magnesium was associated 
with an increased QTc-interval, due to a strong effect on heart rate(RR interval -7.7 ms, 
95%CI -14.7 to -0.7), but additional adjustment for heart rate did not change the association 
with SCD. Low serum magnesium was associated with increased intima media thickness 
(0.01 mm, 95%CI 0.004-0.020), and this explained part of the effect of magnesium on CHD 
mortality. Notable, high serum magnesium (≥ 0.89 mmol/L) was also associated with an 
increased risk of SCD (HR 1.50, 95%CI 1.05-2.16), but reduced risk of death from CHD 
(HR 0.64, 95%CI 0.43-0.95).
Conclusions: Low serum magnesium is associated with an increased risk of death 
from CHD, which is partly explained by an effect on atherosclerosis. Both low and 
high serum magnesium are associated with an increased risk of SCD. Although serum 
magnesium strongly affects heart rate, this did not explain the relationship between serum 
magnesium and SCD.
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FR-PO934
Oral Magnesium Supplementation Improves Serum Calcification 
Propensity in Chronic Kidney Disease Stage 3-4  Iain B. Bressendorff,1 Ditte 
Hansen,2 Morten Schou,3 Andreas Pasch,4 Matthias Bachtler,5 Lisbet Brandi.1 
1Dept of Cardiology, Nephrology and Endocrinology, North Zealand Hospital, 
Hillerød, Denmark; 2Dept of Medicine, Div of Nephrology, Roskilde Hospital, 
Roskilde, Denmark; 3Dept of Cardiology, Herlev Hospital, Herlev, Denmark; 
4Dept of Clinical Chemistry, Univ Hospital Bern (Inselspital), Bern, Switzerland; 
5Dept of Clinical Research, Univ of Bern, Bern, Switzerland.
Background: In previous experimental studies of chronic kidney disease (CKD) 
magnesium has been shown to improve vascular calcification. Serum calcification propensity 
measured using the T50 analysis has been shown to predict all-cause mortality among 
patients with chronic kidney disease (CKD) stage 3-4.
Methods: In a proof-of-concept randomized placebo-controlled double-blinded trial 
of placebo versus slow-release magnesium oxide at two different doses (360 mg once 
daily or 360 mg twice daily) for eight weeks in 34 subjects with CKD stage 3-4 and 
plasma magnesium <0.82 mmol/L, T50 was measured to examine whether magnesium 
supplementation affects serum calcification propensity.
Results: In subjects randomized to magnesium 360 mg twice daily (n = 11) plasma 
magnesium increased by 0.11 mmol/L (confidence interval; 0.05 - 0.17, p = 0.003) and 
T50 increased by 40 minutes (confidence interval; 18 - 63, p = 0.003) after eight weeks 
of treatment (Figure 1), while there were no changes in plasma phosphate, calcium or 
parathyroid hormone. There were no significant changes in T50 in the placebo (n = 12) or 
magnesium 360 mg once daily (n = 11) groups.
Conclusions: Oral magnesium oxide 360 mg twice daily improves serum calcification 
propensity in CKD stage 3-4 after eight weeks of treatment. Larger, long-term trials are 
needed to assess whether this translates into reductions in vascular calcification (e.g. 
coronary artery calcium score or pulse wave velocity) and cardiovascular endpoints.
Funding: Private Foundation Support, Government Support - Non-U.S.
FR-PO935
The Novel NaPi-IIb Inhibitor ASP3325 Does Not Mitigate Hyper-
phosphatemia in Chronic Kidney Disease Patients on Hemodialysis 
Tobias E. Larsson,1 Chisato Kameoka,2 Ikumi Nakajo,2 Yuta Taniuchi,2 Satoshi 
Yoshida,2 Tadao Akizawa,3 Ronald Alfons Smulders.1  1Astellas Pharma 
Europe BV, Leiden, Netherlands; 2Astellas Pharma Inc., Tokyo, Japan; 3Dept 
of Nephrology, Showa Univ School of Medicine, Tokyo, Japan.
Background: The sodium-dependent phosphate co-transporter type 2b (NaPi-IIb) 
is considered an important mediator of active inorganic phosphate (Pi) transport and 
absorption in the small intestine. ASP3325 is a novel NaPi-IIb inhibitor effective for 
reducing the plasma Pi level in a rat model of adenine-induced renal failure and is currently 
in development for the treatment of hyperphosphatemia in chronic kidney disease (CKD).
Methods: Two phase 1 studies were conducted. Study 1 was a randomized double-
blind placebo-controlled single and multiple ascending dose study in healthy subjects 
(HS). Dose levels ranged from 1-600 mg as a single dose and from 10-100 mg t.i.d. for 
7 days. Study 2 was a multicenter open-label study in hyperphosphatemic CKD patients 
on hemodialysis. After an initial washout period of Pi binders, 100 mg ASP3325 was 
administered t.i.d. for 14 days.
Results: In Study 1, 124 HS were randomized either to ASP3325 (n=90) or placebo 
(n=34). ASP3325 was absorbed with a tmax ranging from 1.4 to 6.7 h; t1/2 ranged from 15.5 
to 22 h following single dosing under fasted conditions. AUC and Cmax increased almost 
dose proportionally following dosing up to 100 mg t.i.d. under fed conditions. Urinary and 
fecal Pi excretion did not change following ASP3325 administration for 7 days. In Study 
2, 9 patients received ASP3325 just before a meal while 10 patients received ASP3325 
just after a meal. ASP3325 was generally well tolerated, however gastrointestinal related 
adverse events were reported in 21.1% of the patients. ASP3325 did not reduce the serum 
Pi level irrespective of timing of administration in relation to meals.
Conclusions: ASP3325 showed no effect on Pi parameters in both HS and CKD 
patients on hemodialysis. The role of orally administered NaPi-IIb inhibitors as treatment 
for hyperphosphatemia in humans remains uncertain.
Funding: Pharmaceutical Company Support - Astellas Pharma Inc.
FR-PO936
Novel NaPi-IIb Inhibitor ASP3325 Inhibits Phosphate Absorption in 
Intestine and Reduces Plasma Phosphorus Level in Rats with Renal Failure 
Keiichi Taniguchi, Kazuhiro Terai, Yoh Terada, Yuichi Tomura.  Drug Discovery 
Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Background: The sodium-dependent phosphate co-transporter type 2b (NaPi-IIb) is 
considered to be an important mediator of intestinal inorganic phosphate (Pi) absorption 
and therefore recognized as a target molecule for treatment of hyperphosphatemia. We 
evaluated the pharmacological characteristics of ASP3325, a novel NaPi-IIb inhibitor being 
developed to treat hyperphosphatemia in chronic kidney disease (CKD).
Methods: The inhibition ratio of 33P-Pi uptake during AP3325 (0.03-1000 nmol/L) 
treatment was measured in HEK293 cells stably expressing rat or human NaPi-IIb. To 
assess the contribution of NaPi-IIb to intestinal Pi absorption, ASP3325 and 32P-Pi were 
orally administered in sequence, and then serum 32P-Pi levels were measured. For normal 
rats, an ASP3325 containing-diet was provided for three days and the rate of Pi excretion 
in urine was measured on the final day. For rats with adenine-induced renal failure, an 
ASP3325 containing-diet was provided for two weeks after which plasma levels of 
phosphorus were measured.
Results: ASP3325 inhibited 33P-Pi uptake with an IC50 value of 7.0 nmol/L in HEK293 
cells expressing human NaPi-IIb and an IC50 value of 88 nmol/L in HEK293 cells expressing 
rat NaPi-IIb. In normal rats, oral administration of ASP3325 at 1 and 3 mg/kg significantly 
reduced the area under the concentration curve of serum 32P-Pi levels from 0 to 30 min 
post 32P-Pi administration. ASP3325 (0.001%-0.01%) reduced urinary Pi excretion dose-
proportionally, and treated with 0.01% ASP3325 reduced excretion by 31.2% compared 
to vehicle (P<0.01). In rat with adenine-induced renal failure, ASP3325 (0.001%-0.01%) 
exhibited a dose-related reduction in plasma levels of phosphorus. Following two weeks of 
treatment, plasma level of phosphorus in the vehicle-treated group was 11.43 ± 0.66 mg/dL 
and in the 0.01% ASP3325-treated group was 6.61 ± 0.47 mg/dL (P<0.01).
Conclusions: ASP3325 inhibited NaPi-IIb-mediated Pi transport and decreased plasma 
levels of phosphorus in rats with renal failure as well as urinary Pi excretion in normal rats. 
ASP3325 might therefore be a novel candidate for the treatment of hyperphosphatemia 
in humans.
FR-PO937
Statin Therapy Reduces Phospate Levels in Dialysis Patients: Results from 
the Epidemiological Vitamin K Italian Study (VIKI Study)  Maria Fusaro,1 
Sandro Giannini,2 Marianna Noale,1 Giovanni Tripepi,4 Piergiorgio Messa,3 
Andrea Aghi,2 Nicola Veronese,2 Maurizio Gallieni,5 Sabina Zambon.2  1CNR, 
Padua; 2Univ of Padua; 3Ospedale Maggiore Policlinico, Milan; 4CNR, Reggio 
Calabria; 5San Carlo Borromeo, Milan.
Background: Statin therapy is the mainstay approach to reduce VC and prevent CV 
events in patients with dyslipidemia. The aim of this study was to investigate an association 
between statin therapy and plasma phosphate levels in patients on hemodialysis recruited 
in the VIKI Study.
Methods: The VIKI Study is a multicenter, cross-sectional study in 387 CKD patients 
on hemodialysis from 18hospital in Italy. We determined plasma levels of vitamin 25(OH)
D, vitamin K, osteocalcin (bone-Gla-Protein or BGP), matrix-Gla-protein (MGP) and 
routine biochemistry. Assessment of VC was centralized (Witteman’s method: by measuring 
the length of calcific deposits along the anterior and posterior wall of the aorta). Plasma 
phosphate levels were dichotomized according to the median value (>4.6 vs <4.6 mg/dl).
Results: 33% of the VIKI Study population (n=126) was on statin therapy. Patients on 
statin had significantly lower HDL cholesterol (mean±SD: 40.4±11.1 vs 43.3±13.4 mg/dl, 
p=0.0473) and higher plasma triglyceride levels (median: 164.0 vs 142.0 mg/dl, p=0.0041) 
than those not on statin. Plasma phosphate levels were significantly lower in patients on 
statin therapy (4.57±1.12 vs 4.86±1.33 mg/dl, p=0.0365). The analysis of the vitamin K 
components showed that patients on statin therapy had higher plasma MK7 levels (median: 
1.16 vs 0.84ng/ml, p=0.0241), while concentrations of vitamin 25(OH)D were significantly 
reduced (median: 26.0 vs 30.7 nmol/l, p=0.0198). In a multivariate analysis adjusted for 
BMI, angina, LDL, BGP and antibiotics, statin therapy was significantly associated with 
lower plasma phosphate levels (OR 0.61, 95%CI 0.38-0.98, p=0.0411), while BMI (OR 
1.06, 95%CI 1.01-1.12, p=0.0250) and serum BGP levels ≥ 182 mcg/L (OR 1.58, 95%CI 
1.01-2.48, p=0.0472) were associated with higher phosphate concentrations.
Conclusions: To our knowledge this is the first evidence of an association between 
statins and reduced plasma phosphate levels in CKD patients.
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FR-PO938
Epidemiology of Kidney Stone Disease in Icelandic Children 1985-2013 
Solborg E. Ingvarsdottir,1 Olafur S. Indridason,2 Runolfur Palsson,2,3 Vidar O. 
Edvardsson.1,3  1Children´s Medical Center, Landspitali – The National Univ 
Hospital of Iceland; 2Div of Nephrology, Landspitali – The National Univ 
Hospital of Iceland; 3Faculty of Medicine, Univ of Iceland, Reykjavik, NA, 
Iceland.
Background: The aim of the study was to examine time trends in the incidence and 
prevalence of kidney stone disease in Icelandic children and adolescents over the past 3 
decades.
Methods: Computerized databases of all major hospitals and medical imaging centers 
in Iceland covering the years 1985 to 2013, were searched for ICD, radiology and surgical 
procedure codes indicative of kidney stones for subjects <18 years of age. Incidence was 
calculated for the time periods 1985-1989, 1990-1994, 1995-1999, 2000-2004, 2005-2009 
and 2010-2013, based on population information for Icelandic children in these years. 
Prevalence was calculated for the years 1999-2013.
Results: From 1985 to 2013, there were 186 incident patients, 110 (59%) of whom 
were female. Median (range) age at diagnosis was 15.0 (0.2-17.99) years. The annual 
incidence increased from a mean of 3.7/100,000 in the first 5 years to 11.0/100,000 in the 
years 1995-2004, but decreased thereafter and was 7.8/100,000 in 2010-2013. This trend 
was more pronounced in boys, for whom the incidence was 4.7/100,000 in the first time 
period, 11.0/100,000 during 2000-2004 and only 2.4/100,000 in 2010-2013. The incidence 
for girls increased from 2.7/100,000 in the first time period to 14.2/100,000 in 1995-1999 
and has since then leveled off and was 13.6/100,000 in 2010-2013. The largest incidence 
rise was seen in girls aged 14-17 years, for whom it increased from 9.8/100,000 in 1985-
1989 to 39.2/100,000 in 2010-2013. The mean annual prevalence of kidney stone disease 
in 1999-2013 was 44/100,000 for boys and 51/100,000 for girls.
Conclusions: The incidence rise observed and current incidence of kidney stones in 
Icelandic children is similar to that recently reported in the USA. A significant incidence 
increase was observed for both genders in the late 1980’s and early 1990’s but thereafter 
trended downwards in boys and remained stable in girls. These trends can not be adequately 
explained and warrant further study.
Funding: Government Support - Non-U.S.
FR-PO939
Kidney Stone Recurrence in Icelandic Children  Solborg E. Ingvarsdottir,1 
Olafur S. Indridason,2 Runolfur Palsson,2,3 Vidar O. Edvardsson.1,3  1Children´s 
Medical Center; 2Div of Nephrology, Landspitali – The National Univ Hospital 
of Iceland; 3Faculty of Medicine, Univ of Iceland, Reykjavik, Iceland.
Background: The 5-year recurrence rate of kidney stones in adults is in the range of 
30-50%. No population-based data are available on the recurrence of childhood kidney 
stone disease. The purpose of this study was to examine the recurrence rate of stone disease 
in Icelandic children.
Methods: Patients were identified by searching computerized databases of all the major 
hospitals and the only freestanding radiology clinic in Iceland for diagnostic, radiology 
and surgical codes indicating kidney stones in 1985-2013. We subsequently examined 
medical records of patients with kidney stone disease for information on stone recurrence. 
A recurrent stone event was defined as radiologic signs of a new stone or a new episode of 
flank pain and hematuria. The Kaplan-Meier method was used to assess stone-free survival 
and the log-rank test to compare groups.
Results: We identified 186 children with stone disease during the study period. There 
were 76 boys with a median (range) age of 14.6 (0.2-17.9) years and 110 girls aged 15.4 
(0.8-17.9) years. The follow-up time was 13.0 (0-36) years. A total of 67 children (37%) 
experienced a second stone event, at a median of 1.9 (0.9-18.9) years after the initial 
diagnosis. The recurrence rate was 26%, 35%, 41% and 46% after 5, 10, 15 and 20 years 
of follow-up, respectively. There was no significant difference in recurrence rate between 
boys and girls (p=0.24) and those aged under and over 13 years at diagnosis (p=0.56), but a 
significant difference between patients diagnosed in 1985-1994, 1995-2004 and 2005-2013 
was observed, with a 5-year recurrence rate of 9%, 24% and 38%, respectively (p=0.002).
Conclusions: In our population-based pediatric study, the recurrence rate of kidney 
stones is similar to that reported in adults. Further, the rate of recurrence appears to be 
increasing as has recently been reported for the incidence of childhood stone disease. 
Increased recurrence rate may be related to improved diagnosis and documentation of stone 
events and/or environmental factors affecting urinary lithogenicity.
Funding: Government Support - Non-U.S.
FR-PO940
Clinical Stone Events in Patients Diagnosed with Asymptomatic 
Nephrolithiasis  Berglind Eik Gudmundsdottir,1 Rebekka Sigrún Lynch,2 
Runolfur Palsson,2,3 Vidar O. Edvardsson,1,2 Olafur S. Indridason.3  1Childrens 
Medical Center, Landspitali; 2Faculty of Medicine, Univ of Iceland; 3Div of 
Nephrology, Landspitali - The National Univ Hospital of Iceland, Reykjavik, 
Iceland.
Background: More frequent use of high-resolution medical imaging in recent years 
has resulted in increased detection of asymptomatic kidney stones (KS). The purpose of 
this study was to investigate the frequency of clinical stone events in incident patients 
with asymptomatic KS.
Methods: We searched databases at all major hospitals and imaging centers in Iceland 
for radiologic and diagnostic codes indicative of KS in the years 2000-2008. We found 
2550 incident cases, review of medical records identified 218 patients with no past history 
of nephrolithiasis or symptoms consistent with KS, who, therefore, were considered to 
have asymptomatic KS. The patients’ records were then thoroughly reviewed for the 
development of a clinical stone event defined as abdominal/flank pain and hematuria 
associated with stone passage and/or a stone removal procedure. End of follow-up was 
between June 2014 and April 2015 or at patient’s death. Event-free survival was examined 
by the Kaplan-Meier method.
Results: Of the 218 patients, 54.6% were men, the median (range) age was 65 (11-91) 
years. The diagnosis of KS was made by computed tomography in 156 (71.6%), ultrasound 
in 49 (22.5%) and by plain X-ray in 13 patients. The median follow-up time was 6.0 (0.0-
14.5) and 6.7 (0.0-14.9) years for men and women, respectively. Twenty patients (9.2%) 
underwent a stone removal procedure shortly after diagnosis,. Additional 29 patients (13.3%) 
had a clinical stone event at a median of 2.8 (0.2-14.4) and 1.2 (0.1-9.3) years following 
diagnosis for men and women, respectively. When a procedure performed to remove an 
asymptomatic stone was considered a clinical event, a total of 49 patients experienced a 
clinical stone event, and the 5 and 10 year event-free survival was 80% (95% CI, 74-85) 
and 73% (95% CI, 65-80), respectively.
Conclusions: Approximately 10% of asymptomatic KS were considered clinically 
significant at diagnosis. In the remaining patients, a clinical stone event was unlikely to 
occur over a decade following diagnosis of asymptomatic stone disease.
FR-PO941
Population Attributable Fraction of Modifiable Risk Factors for Kidney 
Stones  Pietro Manuel Ferraro,1,2 Eric N. Taylor,2 Giovanni Gambaro,1 Gary 
C. Curhan.2  1Div of Nephrology, Catholic Univ of the Sacred Heart, Rome, 
Italy; 2Channing Div of Network Medicine, Harvard Medical School, Boston.
Background: Several dietary and lifestyle factors are associated with a higher risk of 
developing kidney stones. In this study, we estimated the population attributable fraction 
(PAF) of modifiable risk factors for kidney stones including body mass index (BMI), fluid 
intake, DASH-style diet, dietary calcium intake and intake of sugar-sweetened beverages 
(SSB).
Methods: We used data from three large ongoing cohorts, the Health Professionals 
Follow-up Study (41,937 men) and the Nurses’ Health Studies (NHS) I (59,864 older 
women) and II (90,449 younger women). Information on risk factors and incident 
kidney stones was obtained from validated questionnaires. Cox proportional hazards 
regression models adjusted for age, race, geographic area, history of diabetes, history of 
hypertension and use of thiazides were used to estimate the association of each risk factor 
with development of kidney stones. PAF estimates were obtained by published equations.
Results: The study included 192,250 participants who contributed a total of 3,079,449 
person-years of follow-up, during which 6,225 participants developed incident kidney 
stones. All the modifiable risk factors were independently associated with incident stones 
in each of the cohorts. The PAF ranged from 5.1% for higher SSB intake to 25.2% for lower 
fluid intake; the PAF for all the five risk factors combined was 58.1% in HPFS, 46.5% in 
NHS I and 44.2% in NHS II.
Conclusions: Modifiable risk factors, specifically BMI, low fluid intake, low DASH-
style diet, low dietary calcium intake and high intake of SSB, account for about 50% of 
incident kidney stones in three large prospective cohorts, suggesting that a large proportion 
of kidney stones could be prevented. Assuming a causal relation, these estimates suggest 
that prevention measures aimed at reducing those factors could effectively reduce the 
burden of kidney stones in the general population.
Funding: Other NIH Support - DK094910, DK91417, CA186107, CA176726 and 
CA167552
FR-PO942
Assessment of Health-Related Quality of Life (HRQoL) in Rare Kidney 
Stone Formers (RKSF)  Frank Modersitzki,1 Alicia Meek,2 David S. Goldfarb.1 
1Medicine, New York Univ School of Medicine, New York, NY; 2Medicine, Mayo 
Clinic, Rochester, MN.
Background: Assessment of HRQoL in RKSF is important for following disease 
course and evaluating treatments. We previously showed that SF with cystinuria reported 
lower HRQoL than non-cystinuria SF. We now report on baseline characteristics of RKSF 
in the Rare Kidney Stone Consortium (RKSC) Registries, to be followed prospectively.
Methods: Patients were enrolled from 3 RKSC registries: primary hyperoxaluria 
(PH), cystinuria and Dent disease. In adults, HRQoL is measured using the SF-36v2 and 
in children, the SF-10. Participants choose between online assessment or paper-based 
questionnaire. Results are calculated as norm-based scores (NBS) based on US Standard 
Population = 50.
Results: 280 participants were enrolled; 200 adults, 80 children; 163 males, 118 
females. Mean age was 34 years: for adults 44y and children 10y. 189 adults and 68 children 
were included in the baseline analysis: PH: 145, cystinuria: 71, Dent: 41. Domain scores 
for children are presented without cystinuria ( n<10). For all participants, SF-36 NBS and 
summary scores for adults are below 50, except for the domain Physical Functioning (mean 
= 51.2). The lowest total domain score was in General Health with 45.8 +11.8. Adults had 
significantly different results in Role-Physical, Bodily Pain, Vitality, Social Functioning, 
Mental Health and Mental Component Score based on disorder. The lowest score was 
found in cystinuria for General Health (mean = 43.9). The summary scores for Physical 
Health (PHS) and Psychosocial (PSS) in children were 47.4 +14.2 and 51.80 +9.6 with 
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lowest summary scores for Dent disease 46.5 PHS and 48.8 PSS. The PSS was lower in 
Dent disease than PH and cystinuria (p = 0.03). PHS was significantly different in SF-10 
specific age groups (p=0.05).
Conclusions: RKSF have worse HRQoL than US adults. HRQoL profiles in adults 
vary with genetic disorder. Cystinuria was associated with the worst domain and summary 
scores. Children RKSF have lower HRQoL PHS compared with adults, with the worst 
results in children with Dent Disease. We will correlate HRQoL with stones  and disease 
course in the next 4 years.
Funding: NIDDK Support, Other NIH Support - NCATS
FR-PO943
Supplemental Calcium Increases the Growth Rate of Renal Calculi in 
Stone Formers  Christopher J. Loftus, Josephine Volovetz, Alexander Chaitoff, 
Jennifer C. Hu, Carol Swetlik, Joseph Roy Abraham, Manoj Monga, Juan C. 
Calle.  Glickman Urology and Nephrology Inst, Cleveland Clinic, Cleveland, 
OH.
Background: Though dietary calcium is associated with a decreased risk of stone 
formation, post-menopausal women supplemented with calcium have an increased risk of 
urinary tract stones. Prior studies have examined the effect of supplemental calcium on 
the risk of passing symptomatic stones but its role in the pathogenesis of stone formation 
is not clear.
Methods: We retrospectively identified 6050 patients with a history of urolithiasis. 
Eligible patients had 2 unenhanced CT scans greater than 30 days but less than 2 years 
apart during the time of supplementation. For those on no supplementation, the most recent 
data were used. Of these, 426 patients met the criteria: 195 on calcium, 127 on vitamin 
D only, and 104 on none. Patients on calcium received 439mg/d± 2793IU vitamin D3/d 
or 5607IU D2/d and patients on vitamin D only received 3085 IU D3/d or 6296 IU D2/d. 
Stone burden was calculated as the sum of the maximum diameters of all stones on CT, 
and rate of stone growth was calculated by the change in consecutive stone burdens divided 
by the elapsed time between scans.
Results: Stone composition was similar among all groups: 65.5% calcium oxalate, 
20.0% calcium phosphate, and 11.8% uric acid. Stone formation rate in mm/year±standard 
deviation was 7.8±20.8 for calcium group, 3.3±11.4 for vitamin D, and 4.49±13.8 for 
none. Those supplemented with calcium had a higher rate of stone formation than those 
supplemented with vitamin D alone, p=0.0105. Supplement group was statistically 
significant when controlling for serum PTH and calcium on multiple logistic regression. 
BMI, gender, age and dose of calcium were not significantly associated with stone formation 
rate while dose of vitamin D3 had an inverse association, p=0.0490.
Conclusions: Supplementation with calcium was associated with a significant increase 
in stone growth rate in stone formers. Vitamin D supplementation showed no added risk 
and may potentially have a protective effect. Though the pathophysiology is unclear, these 
data suggest patients at risk of stone formation should be cautious of supplementation use.
Funding: Private Foundation Support
FR-PO944
Effects of Calcium and Vitamin D Supplementation on Known Stone 
Formers  Christopher J. Loftus, Josephine Volovetz, Alexander Chaitoff, Carol 
Swetlik, Jennifer C. Hu, Joseph Roy Abraham, Manoj Monga, Juan C. Calle. 
Glickman Urology and Nephrology Inst, Cleveland Clinic, Cleveland, OH.
Background: While high dietary calcium has protective effects against kidney stone 
formation, the effect of supplementation with calcium and vitamin D on the risk of kidney 
stone formation remains unclear. Post-menopausal women supplemented with calcium 
have an increased risk of urinary tract stones; however, there is conflicting evidence for 
the effects of supplementation on urinary excretion of calcium.
Methods: We identified 6050 patients with a history of urolithiasis by CT scan, 2061 
of which had 24-hour urine collections before and after starting supplementation. For 
patients on no supplement, the most recent data were used. A total of 1,486 patients were 
supplemented with calcium, 417 with vitamin D only, and 158 with no supplementation. 
Patients on calcium received an average of 460mg/d± 2726IU vitamin D3/d or 5678IU 
D2/d and patients on vitamin D only received 3005IU D3/d or 6307IU D2/d.
Results: Stone composition did not differ among groups: 70.0% calcium oxalate, 
16.6% calcium phosphate, and 10.8% uric acid stones. There was a significant decrease in 
urinary calcium excretion in patients supplemented with calcium (p=0.021) and vitamin D 
(p=0.011) and significant decreases in urinary oxalate in those supplemented with calcium 
(p<0.0001) and vitamin D (p<0.0001). No differences were seen in the amount of change 
between supplemented groups for any urinary excretion values. 
Calcium Vitamin D None p-value difference between groups
serum Calcium (mg/dL) -0.005 -0.005 0.01 0.86
serum Vitamin D (ng/mL) 3.7 7.6 -1.2 <0.0001*
serum PTH (pg/mL) 8.1 -0.43 -5.3 0.024*
urinary Calcium (mg/d) -5.1 -8.9 5.3 0.19
urinary Oxalate (mg/d) -4.2 -3.1 -2.0 0.38
The table shows changes from baseline. Among all groups, higher serum calcium 
was associated with higher urinary calcium excretion (p<0.0001); higher serum calcium 
(p=0.0007)and vitamin D (p=0.026) were associated with and lower oxalate excretion.
Conclusions: Both calcium and vitamin D supplementation decreased urinary calcium 
excretion. High serum calcium but not vitamin D was associated with higher urinary calcium 
excretion in both men and women.
Funding: Private Foundation Support
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Tolvaptan Therapy Effectively Decreases Urinary Calcium Oxalate, 
Calcium Phosphate, and Uric Acid Supersaturations in Stone Formers 
Wisit Cheungpasitporn,1 Stephen B. Erickson,1 Andrew D. Rule,1 Felicity T. 
Enders,2 John C. Lieske.1  1Div of Nephrology and Hypertension, Mayo Clinic, 
Rochester, MN; 2Dept of Health Sciences Research, Mayo Clinic, Rochester, MN.
Background: Drinking large amounts of fluids is universally recommended for urinary 
stone prevention but can be difficult to do for many stone formers. Tolvaptan, a V2 receptor 
antagonist, blocks water reabsorption in the collecting duct. This in turn should increase 
serum osmolality and stimulate thirst. The net effect should be lower supersaturation of 
stone forming salts, but this has not been proven.
Methods: This double blind, randomized, placebo-controlled, crossover study was 
conducted in 21 adult calcium urinary stone formers, stratified as majority calcium oxalate 
(CaOx, n=10) or calcium phosphate (CaP, n=11). Patients were randomized to receive 
tolvaptan 45 mg/day or placebo for week 1, followed by washout week 2, and then crossover 
to drug or placebo for week 3. The 24 hr urine volume and chemistries were assessed at 
the end of week 1 and week 3.
Results: Tolvaptan versus placebo decreased urinary osmolality (204±96 vs 529±213 
mOsm/kg, P<0.001) and increased urinary volume (4.8±2.9 vs 1.8±0.9 L, P<0.001). 
However, the majority of urinary salt excretion rates (mg/24 hrs) including sodium and 
calcium did not significantly change. Thus, urinary CaOx SS (-0.01±1.14 vs 0.95±0.87, 
P<0.001) and CaP SS (-1.66±1.17 vs -0.13±1.02, P<0.001) both decreased. Urinary Uric 
Acid (UA) SS also fell (-2.05±4.05 vs -5.24±3.12, P=0.03). The tolvaptan treatment effect 
on urinary supersaturation did not different between CaOx and CaP stone types (P>0.05 
for all interactions). Serum sodium increased slightly while on tolvaptan (142±3 vs 141±2 
mEq/L, P=0.01).
Conclusions: Use of tolvaptan increased urinary volume but did not appreciably change 
daily excretion of urinary constituents. The net effect was thus a fall in CaOx, CaP and 
UA SS. This study highlights the dramatic benefit increased free water ingestion alone can 
have on urinary supersaturation. Use of tolvaptan or other V2 receptor antagonists could 
be a useful strategy for selected stone formers not responsive to intensive dietary and/or 
behavioral counseling.
Funding: Other NIH Support - The investigators acknowledge support from the 
Rare Kidney Stone Consortium (U54KD083908), a member of the NIH Rare Diseases 
Clinical Research Network (RDCRN), funded by the NIDDK and the National Center 
for Advancing Translational Sciences (NCATS), and the Mayo Clinic O’Brien Urology 
Research Center (U54 DK100227)., Pharmaceutical Company Support - Research work 
for this review was supported by Otsuka America Pharmaceutical, Inc.
FR-PO946
Effect of Increasing Doses of Cystine Binding Thiol Drugs (CBTDs) on 
Cystine Capacity (CysCap) in Patients with Cystinuria  Deepa A. Malieckal,1,2 
Felicity T. Enders,3 Frank Modersitzki,1 John R. Asplin,4 David S. Goldfarb.1,2 
1Internal Medicine, Div of Nephrology, New York Univ School of Medicine, New 
York, NY; 2Internal Medicine, Div of Nephrology, NY Harbor VA Healthcare 
System, New York, NY; 3Health Sciences Research, Div of Biomedical Statistics 
& Informatics, Mayo Clinic, Rochester, MN; 4Litholink Corp, Chicago, IL.
Background: We have proposed that CysCap is a superior measure of lithogenicity 
when using CBTDs in cystinuria. CBTDs significantly increase urinary CysCap compared 
to no CBTD. We studied the effect of increasing doses of CBTDs on CysCap in patients 
with cystinuria.
Methods: 6 patients on CBTDs took 4 different doses of their usual CBTD over 4 
weeks: 0, 1, 2, and 3gm for 7 days in random order. On day 6 and 7 they reproduced a 
self-selected diet and on day 7 of each of the 4 weeks, they did a 24h urine collection to 
measure CysCap. CysCap values were compared for each of the 4 weeks. 3 patients took 
tiopronin and 3 patients took d-penicillamine. Alkali doses were unchanged.
Results: All patients had more positive CysCap when switched from 0 to 1gm of CBTDs 
(p<0.03). There was no further change in CysCap with doses >1gm. Generalized least 
squares regression demonstrated that only the dose of CBTDs was a predictor of CysCap 
(p<0.03). Although reproducibility of diet and collections was not attained (based on 24h 
urine sodium and creatinine), urine sodium and volume were not predictors of CysCap. 
Those patients with the most negative CysCap values had the greatest positive effect when 
taking 1gm compared with 0gm CBTD.
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Conclusions: Prescribing doses of CBTDs greater than 1 gm did not improve 
lithogenicity significantly. Higher doses may not have clinical benefit. Prescribing the 
minimum effective dose based on CysCap can potentially decrease the adverse effects 
often associated with CBTDs.
Funding: NIDDK Support, Other NIH Support - Rare Diseases Clinical Research 
Network - Rare Kidney Stone Consortium
FR-PO947
Claudin-14 Gene Polymorphisms May Regulate Urine Calcium Excretion 
Teresa Arcidiacono, Marco Simonini, Lorenza Macrina, Paolo Manunta, 
Donatella Spotti, Giuseppe Vezzoli.  Nephrology and Dialysis Unit, San Raffaele 
Scientific Inst, Milan, Italy.
Background: Claudins are a family of proteins that form paracellular calcium channels 
in tight-junctions and may thus regulate tubular permeability to divalent cations. Claudin-14 
is expressed in the ascending limb of Henlke’s loop and inhibits calcium reabsorption. A 
previous GWA showed that two polymorphisms (SNPs) of CLDN14 (rs219778 e rs219781) 
were associated with kidney stones and calcium excretion in an Iceland population. The 
present study is aimed to explore the effect of CLDN14 SNPs on calcium excretion.
Methods: We ha performed a retrospective study on 380 hypertensive patients never 
treated with antihypertensive drugs. These patients underwent a saline load test (i.v. infusion 
with NaCl 0.9% 2 litres in 2 hours) to evaluate sodium sensitivity. Kidney stones in their 
clinical history was ascertained by interview. Calcium was measured in 24-h urine and 
in every 2 hours during the saline load test. Patient genotypes of the CLDN14 gene were 
obtained from the GWA data.
Results: Kidney stones were reported by 9.3% of patients. No association was found 
between CLDN14 SNPs and stones. As previously observed, rs219778 was associated with 
24-hour calcium excretion that was also associated with many SNPs of the CLDN14 gene. 
The most significant association occurred with rs219755 (GG 5.62±3.10, GA 4.86±2.49, 
AA 3.11±1.82 mmol/24h ; p=0.00014). The association with calcium excretion was also 
observed when calcium excretion after saline load was considered (considering rs219755: 
GG 0.75±0.51, GA 0.72±0.46, AA 0.44±0.27 mmol/2h; p=0.02).
Conclusions: CLDN14 genotype is associated with calcium excretion. This association 
is observred even after saline load test, a well known stimulus to urinary calcium excretion.
Minor alleles of these SNPs could cause a reduction of calcium excretion and could be 
protective against kidney stones and hypercalciuria. The lack of association among stones 
and CLDN14 SNPs could be due to the method used to identify stone formers.
FR-PO948
Independent Effect of Blood Glucose Level on Urinary Citrate and pH 
Majuran Perinpam,1 Erin Bakshis Ware,3,4 Jennifer Smith,3 Stephen T. Turner,1 
Sharon R. Kardia,3 John C. Lieske.1,2  1Nephrology and Hypertension, Mayo 
Clinic, Rochester, MN; 2Laboratory Medicine, Mayo Clinic, Rochester, MN; 
3Dept of Epidemiology, School of Public Health, Univ of Michigan, Ann Arbor, 
MI; 4Inst for Social Research, Univ of Michigan, Ann Arbor, MI.
Background: Urinary citrate is an important kidney stone inhibitor and its excretion 
is influenced by systemic acid base status and diet. However, the effects of demographics 
and other factors on urinary citrate excretion are not well defined, including the independent 
influence of blood glucose.
Methods: Twenty-four hour urine samples were collected from non-Hispanic white 
sibships in Rochester, MN. Height, weight, blood pressure, blood glucose, serum creatinine 
and cystatin C were measured. Diet was assessed using the Viocare food frequency 
questionnaire. The effects of blood glucose, demographics and diet on urinary citrate 
excretion, urine pH and net gastrointestinal (GI) alkali absorption were evaluated in bivariate 
and multivariable models, plus interaction models that included age, sex, and weight.
Results: Samples were available from 709 individuals (mean age 66±9 years). In 
general urine citrate and urine pH correlated positively with higher net alkali absorption 
(p<0.0001). Urine pH was higher in women for any given net alkali absorption value, but 
not after adjustment for covariates. In multivariable models urinary pH decreased with 
higher serum creatinine, blood glucose, dietary protein and increased with dietary potassium. 
Meanwhile, in multivariable models urinary citrate increased with age, weight, eGFRCys, 
blood glucose and decreased with loop diuretic and thiazide use. Association of urinary 
citrate and age was influenced by blood glucose (p=0.01).
Conclusions: In our study urinary citrate and pH correlated positively with net GI alkali 
absorption. Blood glucose had independent effects on urine pH and urinary citrate. This 
study provides the first evidence that blood glucose could influence stone risk independent 
of urinary pH and uric acid crystallization. These observations could provide new insights 
into the association of obesity and urinary stone disease.
Funding: Other NIH Support - This work was supported by R01 DK077950, R01 
DK073537, U01 HL054457, R01 HL087660, the Mayo Clinic O’Brien Urology Research 
Center P50 DK083007, and Grant Number UL1 TR000135 from the National Center 
for Advancing Translational Sciences (NCATS), all funded by the National Institutes of 
Health.
FR-PO949
Renal Oxalate Secretion Reduces Risk of Systemic Oxalosis in Primary 
Hyperoxaluria  Brady A. Brabec, Kristin C. Mara, Felicity T. Enders, Ramila 
A. Mehta, John C. Lieske, Dawn S. Milliner.  Nephrology and Hypertension, 
Mayo Clinic, Rochester, MN.
Background: Primary Hyperoxaluria (PH) is a rare genetic disease causing high hepatic 
production of oxalate. Renal excretion of oxalate keeps plasma oxalate (Pox) controlled 
but leads to stones and often ESRD. Systemic oxalosis occurs when GFR is reduced and 
Pox rises above the supersaturation threshold (approximately 45 mmol/L). Renal handling 
of oxalate in relation to GFR is poorly understood.
Methods: PH patients ≥ 12 years without ESRD were identified from the Rare Kidney 
Stone Consortium registry. We used the most recent simultaneous Pox, serum creatinine 
and 24 hour urine oxalate (Uox). Net oxalate secretion (Sox) equals Uox-GFR×Pox. 
Proximal tubular oxalate (PTox) is Uox corrected for creatinine and estimated proximal 
tubule water absorption. eGFR is by CKD-EPI (adults) or modified Schwarz (adolescents). 
We grouped patients by CKD stage and balanced eGFR groups. Analysis was by Fischer 
exact test and ANOVA.
Results: 45 patients were identified (33 PH-1; 5 PH-2; 7 PH-3). Median age was 23.2 
(IQR: 16.7, 32.9) and eGFR was 66.1 mL/min/BSA (54.4, 80.8). Pox, Sox and Uox rose 
sharply when eGFR fell below 45 mL/min. Similar results were seen in eGFR groups. 
PTox and Pox increased proportionally (p<0.001).
CKD stage (n) CKD 1 (7) CKD 2 (25) CKD 3a (6) CKD 3b (7) p value
PH type 1 6 16 5 6 0.505
Uox mmol/day (SD) 1.01 (0.52) 1.40 (0.72) 1.38 (0.58) 2.60 (0.98) 0.0008
Pox ȝmol/L (SD) 3.67 (2.82) 5.12 (4.09) 6.18 (5.20) 14.84 (5.85) <0.0001
PTox ȝmol/L (SD) 0.21 (0.15) 0.47 (0.29) 0.55 (0.22) 1.26 (5.85) <0.0001
Sox mmol/day (SD) 0.36 (0.62) 0.88 (0.72) 0.92 (0.32) 1.74 (0.95) 0.007
Conclusions: Compensation for high oxalate production in PH is maintained through 
CKD stage 3a. Higher PTox in CKD stage 3b may accelerate proximal tubular CaOx 
crystallization. Risk for systemic oxalosis is low until at least CKD stage 4.
Funding: NIDDK Support, Other NIH Support - U54-DK083908, Private Foundation 
Support
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
586A
J Am Soc Nephrol 26: 2015 Mineral Disease: Nephrolithiasis Poster/Friday
FR-PO950
Effect of Antibiotic Treatment on Oxalobacter formigenes Colonization 
Lama Nazzal, Sukhleen Bedi, Fritz Francois, David S. Goldfarb, Guillermo I. 
Perez perez, Martin J. Blaser.  Medicine, New York Univ, New York, NY.
Background: Kidney stones are a disease of worldwide prevalence with significant 
public health implications. About 60–80% of stones are composed of calcium oxalate 
(CaOx). Hyperoxaluria is a major risk factor. Oxalobacter formigenes (OF), a member of 
the human colonic microbiota, plays a major role in net colonic oxalate absorption and 
secretion. We now report OF colonization rates in a young healthy population, the stability 
of colonization, and the effects of antibiotic treatment on OF colonization.
Methods: We followed 64 healthy subjects tested for Helicobacter pylori (HP), 
who were treated with antibiotics (Amoxicillin and clarithromycin for 2 weeks) for HP 
eradication. Using species-specific PCR, we tested for OF colonization at baseline and 
at follow-up.
Results: Of the 64 subjects (M/F: 24/40; mean age 25.0 + 5.5y) tested for OF, 25 
(39%) were positive at baseline. Of 7 OF+ subjects at baseline, subject to HP elimination, 
6 became OF-negative at 6 wks, only 2 reverted to positive at week 24, and 4 patients 
remained negative at follow up (Mean 21.0 + 6wks). Of 16 untreated positive people, 12 
(75%) remained positive at follow up (Mean 18.8 +7.7w), but of 26 untreated negative 
subjects, only 6 (23%) were positive at follow up (mean 19.7+ 6.6wks), significantly fewer 
than the untreated positives (p=0.001 by Fisher exact test).
Conclusions: We conclude that OF status remains stable over a follow-up period of 
several months, with antibiotics suppressing colonization in the majority of people in the 
short term. The differential long-term effect of antibiotics on OF colonization and its effect 
on urinary oxalate excretion, will be important to evaluate.
FR-PO951
Identification of Calcium-Oxalate Binding Proteins in Human Urine That 
Prevent Crystal Adhesion in an In Vitro Model of Kidney Stone Formation 
Scott R. Manson, Joel F. Koenig, Qiusha Guo, Katelynn H. Moore, Paul F. 
Austin.  Dept of Surgery, Div of Urology, Washington Univ, St. Louis, MO.
Background: There are limited therapeutic options for the treatment of stone disease 
and about 50% of patients experience at least one recurrence. Existing treatment protocols 
focus on altering urine concentrations, which presents challenges due to the idiopathic 
nature of many stones and the variety of underlying factors. In this study, we examine the 
hypothesis that there are naturally occurring urinary proteins capable of binding calcium 
oxalate crystals, promoting their clearance, and preventing stone formation. Elucidating 
these interactions may provide novel therapies.
Methods: Calcium oxalate monohydrate (COM) crystals and fluorescently-labeled 
derivatives (COM-FITC) were synthesized in vitro. Stone formation was modeled in 
vitro by assessing the adhesion of COM-FITC crystals to confluent monolayers of inner 
medullary collecting duct (IMCD) epithelial cells. Affinity chromatography was used to 
isolate COM-binding proteins from human urine.
Results: COM and COM-FITC crystals synthesized in vitro exhibited the typical 
prismoidal morphology of urinary crystals. Incubation of IMCD cells with COM-FITC 
crystals resulted in rapid binding to the cell surface with high affinity. The addition of urinary 
proteins purified from human urine inhibited COM-FITC binding by 76.2%. Furthermore, 
urinary proteins inhibited the growth of COM crystals in free solution by 63.7%. In using 
affinity chromatography to isolate COM-binding proteins, we found that this technique 
was highly specific as only 17.2% of urinary proteins exhibited binding activity. The bound 
fraction was eluted, purified by electrophoresis, and four prominent proteins were identified 
(97 kD, 69 kD, 56 kD, 45 kD).
Conclusions: This study demonstrates that urinary proteins bind to COM crystals and 
inhibit their adhesion to the renal epithelium. Further characterization of these proteins 
may facilitate the design of peptide-based therapies that prevent crystal adhesion and stone 
formation as well as the development of diagnostic biomarkers that stratify patients and 
guide treatment decisions in at-risk populations.
Funding: NIDDK Support, Private Foundation Support
FR-PO952
Hydroxyapatite Induces Tolerance in Primary Human Monocytes Exposed 
to Calcium Oxalate Crystals  Benjamin Canales,1 Paul R. Dominguez 
Gutierrez,1 Sergei Kusmartsev,1 Johannes Vieweg,1 Saeed R. Khan.2  1Urology, 
Univ of Florida, Gainesville, FL; 2Pathology, Immunology, and Laboratory 
Medicine, Univ of Florida, Gainesville, FL.
Background: Although most crystal deposits within tissue produce inflammation, 
renal interstitial hydroxyapatite deposits do not, accumulating as Randall’s plaque. To 
further explore this lack of response, we investigated the effect of oxalate, hydroxyapatite, 
and combination of both on time dependent, immunological responses in human THP-1 
(monocyte) cells, the precursors to tissue macrophages.
Methods: Using 1 ug/ml LPS and untreated as positive and negative controls, THP-1 
cells were exposed to varying concentrations of soluble potassium oxalate (KOx) or CaOx 
and HA crystals (10, 100, and 1000 ug/m). In addition, a group of primary human monocytes 
cells were pre-treated with 100 ug/ml of HA or CaOx followed by secondary treatment 
with 100 ug/ml HA, 100 ug/ml CaOx, and 1 ug/ml LPS. THP cells were collected at 2, 4, 
and 8 hours after various treatments, and RNA was analyzed by quantitative real time PCR.
Results: THP-1 cells responded strongly to CaOx in a dose dependent manner 
producing TNFa, IL-1b, IL-8, and IL-10 with little to no response to KOx and HA. Pre-
exposure of human monocytes to HA had little effect on cytokine response to subsequent 
CaOx and LPS exposure; however, pre-exposure to CaOx followed by HA negated all 
further cytokine production.
Conclusions: In our human monocyte model, the order of CaOx and HA exposure 
affects monocytic response. HA neither stimulates cytokine production nor inhibits 
cytokine production when pre-treating monocytes prior to CaOx exposure. Pre-treated 
CaOx monocytes, however, had decreased cytokine and chemokine expression when 
secondarily treated with HA. This tolerance mechanism may partially explain the lack of 
papillary inflammation in the pathogenesis of Randall’s plaque.
Funding: NIDDK Support, Other NIH Support - T32
FR-PO953
A Low Sodium Diet Inhibits Stone Formation in Genetic Hypercalciuric 
Stone-Forming Rats  Kevin K. Frick,1 Nancy S. Krieger,1 John R. Asplin,2 
Ignacio Granja,2 Min Ho Kim,1 Felix M. Ramos,1 David A. Bushinsky.1 
1School of Medicine & Dentistry, Univ of Rochester, Rochester, NY; 2Litholink 
Corporation, Laboratory Corporation of America Holdings, Chicago, IL.
Background: Increasing dietary (D) sodium (Na) intake results in greater urine 
(u) calcium (Ca) excretion, leading to the recommendation that D Na be restricted in 
hypercalciuric stone formers to decrease stone recurrence. However, there is no direct 
clinical evidence that reduction in D Na intake alone will reduce recurrent stone formation.
Methods: To determine if D Na restriction reduces kidney stone formation, we utilized 
101st generation genetic hypercalciuric stone-forming (GHS) rats fed either a low (LNa, 
0.05%) or normal (NNa, 0.4%) Na D for 18 wks. Urine was collected at 6 wk intervals; 
a mean was determined for each analyte and then an overall 18 wk mean calculated. 
Radiographic analysis for stone formation was done at 18 wks.
Results: As anticipated, LNa decreased mean uNa (NNa=2.48±0.03 mmol/24h; 
LNa=0.39±0.02, p<0.001) and uCl (NNa=2.65±0.13 mmol/24h; LNa=1.19±0.06, p<0.001). 
Overall mean uCa was lower with LNa than NNa (NNa=17.3±0.5 mg/24h; LNa=15.2±0.5, 
p<0.01) as was u phosphate (P) (NNa=16.5±0.6 mg/24h; LNa=13.8±0.4, p<0.001). Urine 
oxalate (Ox), pH, NH4+, citrate and volume did not differ with diet Na. There were no 
significant differences in u supersaturation with respect to CaP or CaOx. Serum Ca was 
slightly increased with LNa (NNa=10.9±0.1 mg/dL; LNa=11.4±0.1, p<0.01) though 
there were no differences in serum P, PTH or FGF23. Radiographic analysis of kidneys 
demonstrated a significant decrease in calcification with LNa (calcification scores with a 
range of 0-3: NNa=1.14±0.15; LNa=0.32±0.12, p<0.001).
Conclusions: Thus a low Na diet reduced uCa and stone formation in GHS rats even 
though urine supersaturation was not altered. These data, in a genetic model of hypercalciuria 
and stone formation, lend support to the use of dietary Na restriction to prevent recurrent 
Ca nephrolithiasis.
Funding: NIDDK Support
FR-PO954
Ethylene Glycol Induced Hyperoxaluria in Rats: A Transcriptional Study 
Sunil Joshi,1 Wei Wang,1 Ammon B. Peck,2 Saeed R. Khan.1  1Pathology, 
Immunology, and Laboratory Medicine, College of Medicine, Univ of Florida, 
Gainesville, FL; 2Infectious Diseases and Pathology, College of Veterinary 
Medicine, Univ of Florida, Gainesville, FL.
Background: Hyperoxaluria, if remains undiagnosed, can cause renal injury and 
inflammation leading to a number of diseases including advanced stages of renal failure. In 
order to look into the different pathways and molecular mechanisms involved in the kidneys 
of hyperoxaluric rats, we performed genome wide analysis of differentially expressed genes 
in the kidneys of rats fed ethylene glycol (EG).
Methods: Male rats were divided into two groups. Rats in one group were fed normal 
diet and the other group diet supplemented with 1.25% EG. Urinary assays were done at 
different time intervals and after 14 and 28 days rats were euthanized, kidneys explanted 
and total RNA extracted for micro array analysis using Agilent 8 x 60K single color arrays. 
Data was analyzed using bio-conductor Limma (Linear models for micro array analysis) 
package using R. Gene ontology (GO) and KEGG pathway analyses was also performed. 
Immunohistochemical (IHC) and Eosin and Hematoxylin (E &H) staining was also done 
for highly significant genes.
Results: All rats became hyperoxaluric from day 7 and had crystal deposition at 
different time intervals. Urinary LDH, sodium and creatinine were significantly different 
in the EG group as compared to the control. There was significant expression of different 
genes encoding for macromolecular modulators such as osteopontin (OPN), monocyte 
chemoattractant protein-1 (MCP-1), lipocalin 2 (Lcn-2), fibronectin (Fn-1), clusterin (CLU) 
and kidney injury molecule-1 (KIM-1) along with nicotine amide dinucleotide  phosphate 
(NADPH) oxidase-4 (NOX-4) and glutathione peroxidase (Gpx-2). Gene analysis showed 
17 and 33 differentially expressed pathways for day 14 and day 28 respectively.
Conclusions: Results highlight that the EG treated rats showed heavy deposition of 
crystals and there were 15 pathways that were common between day 14 and day 28 giving 
a deep insight into the molecular mechanisms and pathways activated in hyperoxaluric rats.
Funding: Other NIH Support - R01-DK078602 and R01-DK092311
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Sulfate and Thiosulfate Competitively Inhibit Oxalate Transport via 
a Drosophila Prestin (dPrestin, dSlc26a6)-Dependent Mechanism 
Greg M. Landry,1,2,3 Taku Hirata,1,3 Jacob B. Anderson,1 Christopher Joseph roel 
Gallo,1 Michael F. Romero.1,2,3  1Physiology and Biomedical Engineering, Mayo 
Clinic College of Medicine, Rochester, MN; 2Nephrology and Hypertension, 
Mayo Clinic College of Medicine, Rochester, MN; 3O’Brien Urology Research 
Center, Mayo Clinic College of Medicine, Rochester, MN.
Background: Nephrolithiasis affects approximately 12% of men and 6% of women 
in industrialized countries with the majority of stones being composed of calcium oxalate 
(CaOx).
Methods: Using Drosophila melanogaster as a robust and translatable model of CaOx 
nephrolithiasis, we studied the effects of sulfate and thiosulfate on oxalate transport, and 
subsequent CaOx crystal formation, as a proof of principle in providing a nidus to identify 
new therapeutic interventions.
Results: Results indicate that dprestin transports thiosulfate with a much higher affinity 
than sulfate (dprestin sulfate Km = 8.65 ± 3.87 mM compared to dprestin thiosulfate Km 
= 0.23 ± 0.03 mM). Additionally, both sulfate (48 h) and thiosulfate (24 and 48 h) were 
effective at decreasing Malpighian tubule CaOx crystallization with the opposite results 
observed at 48 h in Malpighian tubules where dPrestin was not expressed indicating a role 
for principle cell-specific dPrestin in luminal oxalate transport.
Conclusions: Given the higher affinity of thiosulfate for dprestin when compared to 
those which are reported for oxalate (dprestin average Km for oxalate= 0.87 ± 0.16 mM 
and for thiosulfate = 0.22 ± 0.03 mM), we have concluded that the ability of thiosulfate to 
act as a competitive inhibitor of oxalate at the transporter level, specifically dPrestin, may 
explain the decrease in CaOx crystallization seen in the presence of thiosulfate, but not 
sulfate. Overall, our findings predict that thiosulfate or oxalate-mimics may be effective 
as therapeutic competitive inhibitors of CaOx crystallization.
Funding: NIDDK Support
FR-PO956
Complement Receptor 3 Mediates Renal Protection in Experimental C3 
Glomerulopathy  Thomas D. Barbour, Guang Sheng Ling, Marieta Milkova 
Ruseva, Liliane Fossati-Jimack, H. Terence Cook, Marina Botto, Matthew 
C. Pickering.  Centre for Complement and Inflammation Research, Imperial 
College, London, United Kingdom.
Background: C3 glomerulopathy (C3G) is a progressive form of glomerulonephritis 
(GN) that is frequently associated with abnormalities in regulation of the alternative pathway 
(AP) of complement. Mice with deficiency of factor H (Cfh-/-), a negative AP regulator, are 
an established experimental model of C3G in which abundant complement C3 accumulates 
along the glomerular basement membrane.
Methods: We examined the spontaneous renal phenotype in Cfh-/- mice with and 
without accompanying deficiency of complement receptor 3 (CR3), the main receptor for 
iC3b. We performed accelerated serum nephrotoxic nephritis (ANTN) in CR3-deficient 
mice to assess the role of CR3 in glomerular injury outside the setting of FH deficiency. The 
effect of iC3b ligation of CR3 on macrophages and other leukocytes during inflammation 
was assessed in vitro.
Results: In 8-month old Cfh-/- mice, accompanying CR3 deficiency was associated with 
significantly increased albuminuria, glomerular hypercellularity and macrophage influx, and 
mortality. Bone marrow (BM) transplantation experiments in Cfh-/- recipients indicated that 
the protective effect of CR3 was dependent on BM-derived cells. ANTN produced severe, 
crescentic nephritis in CR3-deficient mice (but not wild-type mice). In vitro ligation of 
CR3 using iC3b-coated particles down-regulated the proinflammatory cytokine response 
of both murine and human macrophages to lipopolysaccharide stimulation in vitro. These 
cytokine-modulating effects were cell-type specific, an observation that may reconcile some 
of the conflicting reports concerning the immune role of CR3 in the literature.
Conclusions: Deficiency of CR3 unexpectedly enhanced the severity of both 
experimental C3G and immune complex GN. Our findings suggest that pharmacological 
potentiation of the CR3-iC3b interaction could be therapeutically useful in patients with 
chronic GN.
FR-PO957
Two Autoimmune Forms of C3-Glomerulopathy Are Defined by 
Complement Convertases Deregulating Autoantibodies  Christine Skerka,1 Fei 
Zhao,1 Giuseppe Remuzzi,2 Rossella Piras,2 Peter F. Zipfel.1,3  1Dept of Infection 
Biology, Leibniz Inst for Natural Product Research and Infection Biology, Jena, 
Germany; 2Laboratory of Immunology and Genetics of Transplantation and 
Rare Diseases, IRCCS- Istituto di Ricerche Farmacologiche, 24020- Ranica 
(Bergamo), Italy; 3Friedrich Schiller Univ, Jena, Germany.
Background: In C3Glomerulopathy (C3G) defective complement activation on level 
of the C3 convertase is caused by mutations in genes coding for complement components 
or regulators as well as by autoantibodies. C3 nephritic factor (C3NeF) has been reported in 
50-80% of C3G patients. Notably also autoantibodies to C3b and Factor B were identified 
in C3G patients, which do not score in the standard C3NeF assay. Here we compare how 
the new C3 convertase reacting antibodies and also C3Nef affect complement regulation 
on the level of the C3- and the C5 convertases.
Methods: The autoantibodies were isolated from the serum of C3G patients (n=34), 
assayed for binding to the C3 convertase by ELISA and further characterized by using a 
number of functional complement assays.
Results: Among the 34 C3G patients, 19 patients were identified with autoantibodies 
which bind to the C3 convertase, but lack C3NeF. 15 patients were identified C3NeF 
positive. According to the binding to the C3 convertase, high titer (HT) and low titer (LT) 
antibodies were identified among isolated autoantibodies from all 34 C3G patients. HT as 
well as LT antibodies strongly activated the C5 convertase and enhanced C5a generation. 
Interestingly all antibodies bound to the C3 convertase, but only HT and not LT antibodies 
enhanced C3 convertase activity. The HT but not the LT antibodies increased C3 convertase 
assembly, stabilized the convertase and increased C3a generation.
Conclusions: Two classes, HT and LT, of complement C3 convertase binding 
autoantibodies were identified in C3NeF- positive and negative C3G patients. These 
antibodies deregulate complement by two different mechanisms: HT antibodies activate 
complement on the C3- and C5 convertase levels, while LT antibodies activate only on C5 
convertase level. We speculate that these functional different autoimmune forms explain 
responder and non-responder types to therapeutic C5 inhibitors.
Funding: Government Support - Non-U.S.
FR-PO958
Autoimmune C3 Glomerulopathy: Can Complement Inhibiting Drugs 
Reduce Complement Activation by C3 Convertase Autoantibodies? 
Friederike Sophie Schulze,1 Fei Zhao,1 Giuseppe Remuzzi,2 Marina Noris,2 
Christine Skerka,1 Peter F. Zipfel.1,3  1Hans Knöll Inst, Jena; 2Mario Negri 
Inst for Pharmacological Research, Bergamo; 3Friedrich Schiller Univ, Jena.
Background: C3 glomerulopathy is a severe kidney disorder that is caused by 
deregulation of the alternative complement pathway. Identified causes include genetic 
mutations, copy number variations in the CFHR gene cluster as well as autoimmune factors. 
Some patients but not all respond to therapy with the complement inhibitor Eculizumab. 
Recently a new class of C3 convertase antibodies was identified in C3G patients who 
lack classical C3Nephritic factor (C3Nef). We aim at characterising how these new 
autoantibodies cause complement deregulation and how complement inhibitors affect the 
action of these autoantibodies.
Methods: IgGs were purified from patients with C3 convertase antibodies lacking 
C3Nef (n=19) and also from C3Nef+ patients (n= 15). These purified IgGs were tested for 
their impact on complement activity and the effect of soluble CR1 (sCR1) and Eculizumab 
was examined by ELISA, Western blot and complement activation assays.
Results: C3 convertase antibodies from patients lacking C3Nef deregulated 
complement. Some antibodies stabilized the C3 convertase and all activated the terminal 
complement pathway. C3Nefs activated complement in a related manner. In probes 
with C3 convertase antibodies sCR1 did inhibit excessive complement activity. Also 
Eculizumab prevented antibody mediated complement activation. Both inhibitors blocked 
C3Nef-mediated complement deregulation in a related manner. For some probes from 
either C3NeF+ or C3NeF- patients a higher dose of sCR1 was necessary to affect C3 
convertase activity.
Conclusions: A subgroup of C3G patients present with C3 convertase-binding 
antibodies but lack C3Nef. Some C3 convertase antibodies deregulate the C3 convertase and 
all stabilize the C5 convertase. The complement inhibitors sCR1 and Eculizumab reduced 
complement activity. Patients with antibodies causing only excessive C5 convertase activity 
may benefit from Eculizumab, whereas patients with excessive C3 convertase may require 
additional C3 convertase inhibition.
Funding: Government Support - Non-U.S.
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Respiratory Syncytial Virus May Exacerbate Kidney Damage in IgA 
Nephropathy Through C3a/C3aR and C5a/C5aR Signaling Amplifying the 
Effects of Th17 Cells  Xiaozhao Li,1 Xinyue Hu,2 Ting Meng,1 Juntao Feng,2 
Qiaoling Zhou.1  1Dept of Nephrology, Xiangya Hospital of Central South Univ, 
Changsha, Hunan, China; 2Dept of Clinical Laboratory, Xiangya Hospital, 
Central South Univ, Changsha, Hunan, China.
Background: The exacerbation of IgA nephropathy (IgAN) is related to respiratory 
tract infection with respiratory syncytial virus (RSV), but the mechanism is unknown. In 
this study we investigated the role of complement activation productsC3a/C5a and their 
receptor C3aR/C5aR in response to the effect of T helper 17 (Th17) cells in the pathogenesis 
of IgAN associated with RSV.
Methods: IgA nephropathy was induced in BALB/c mice with lipopolysaccharide, 
carbon tetrachloride and bovine serum albumin. Then the mice were sensitized with 
C3aRA( C3aR antagonist) and C5aRA( C5aRA antagonist ) respectively and infected 
with respiratory syncytial virus (RSV) in sequence. Urine Albumin-Creatinine ratio and 
sediments were measured. The pathological changes in kidney and lung tissues were 
observed under microscopy. C3aR and C5aR proteins in kidney tissue were examined by 
immunohischemical staining. Th17 cells and regulatory T cells (Tregs) in kidneys were 
tested by flow cytometry. C3a,C5a, IL-17A, IL-6 and IL-21,IL 22 in the kidneys were 
detected by ELISA.
Results: The IgAN mice had albuminuria and microscopic hematuria, renal mesangial 
proliferation, IgA deposition, high electron dense deposition in glomerular mesangial 
region, decreased frequency of Tregs, increased frequency of Th17 and Th17-Treg ratio. 
Furthermore, C3a, C5a, C3aR, C5aR and Th17-related cytokines IL-17A, IL-6 and 
IL-21 were all increased in the kidneys of IgAN mice. Compared with IgAN mice, the 
manifestations in RSV-IgAN mice were more severe, but alleviated in C3aRA-treated 
groups and C5aRA-treated groups respectively.
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Conclusions: RSV infections may exacerbate kidney damage in IgAN through C3a/
C3aR and C5a/C5aR signaling amplifying the Effects of Th17 Cells. The first two authors 
contributed equally to this work.
Funding: Government Support - Non-U.S.
FR-PO960
Functional Glomerular Decay Accelerating Factor Induction by Heme: Role 
of HO-1  Maria Detsika,1 Giouli Makri,1 Vasileios Atsaves,1 Pu Duann,2 Elias A. 
Lianos.1,2  1Medicine, Univ of Athens, Greece; 2Medicine, Rutgers Biomedical 
and Health Sciences, NJ.
Background: In hemolytic disorders and glomerular injury associated with hematuria 
intraglomerular free heme increases and may activate the alternative complement (C)- 
pathway. Rat glomeruli express decay accelerating factor DAF in glomerular epithelial cells 
(GEC). We assessed whether heme upregulates glomerular DAF to minimize C activation 
and explored underlying mechanisms.
Methods: hmox1+/- and hmox1-/- rats were generated by Zinc Finger Nuclease (ZNF)-
mediated HO-1 gene disruption and rats with GEC targeted HO-1 overexpression (GECHO-1) 
by Sleeping Beauty Transposon mediated transgenesis using a nephrin promoter. Wild type 
(WT) or hmox1+/-, hmox1-/- or GECHO-1 glomeruli were treated for 18 h with heme (hemin, 
FePP) or non-iron porphyrins with opposite effects on HO activity: 1) HO inducers, Cobalt 
(CoPP) and the non-metal protoporphyrin IX (PPIX) and 2) HO inhibitors: Zinc (ZnPP), 
Tin (SnPP) protoporphyrins, Tin (SnMP) and Chromium (CrMP) mesoporphyrins. C3b 
deposition in glomeruli was triggered by exposure to 10% rat serum. DAF, HO-1 and 
C3b levels were assessed by western blotting or Real-time PCR. HO enzyme activity was 
measured by standard methods.
Results: Constitutive DAF (mRNA and protein) decreased in both hmox1+/- and 
hmox1-/- and increased in GECHO-1 glomeruli. Heme, at concentrations encountered in 
hemolytic disorders (50-400 µM), increased DAF expression in WT glomeruli. This 
effect was attenuated in both hmox1+/- and hmox1-/- and augmented in GECHO-1 glomeruli. 
Heme-mediated DAF induction in hmox1-/- glomeruli persisted despite complete HO-1 
absence. Of the non-Fe porphyrins, CoPP, ZnPP, and PPIX increased DAF and HO-1. 
SnPP induced DAF but not HO-1. SnMP and CrMP had no effect on either protein. Hemin 
or SnPP-mediated DAF induction reduced C3b deposition. This was reversed by PI-PLC 
which removed membrane bound DAF.
Conclusions: HO-1 regulates constitutive DAF expression and heme-mediated DAF 
induction. The latter is independent of metal moiety and HO enzyme activity, requires the 
porphyrin ring and may also occur via a HO-1 independent mechanism. DAF induction 
by heme is functional and attenuates C-activation.
Funding: Government Support - Non-U.S.
FR-PO961
Complement Activation Impairs Endothelial Cell Migration – Possible Role 
in TMA Pathogenesis  Magdalena Riedl, Daniel Schlam, Fred G. Pluthero, 
Walter H. Kahr, Christoph Licht.  Cell Biology Program, The Hospital for Sick 
Children, Toronto, ON, Canada.
Background: Cell migration is a key requirement in multiple physiological scenarios 
including angiogenesis and endothelial cell repair. Thrombotic microangiopathy (TMA) is 
characterized by endothelial cell (EC) activation and injury, in atypical hemolytic uremic 
syndrome caused by complement activation on ECs. We hypothesized that EC injury in 
aHUS was – at least in part – caused by complement-mediated inhibition of cell migration.
Methods: To test this hypothesis blood outgrowth ECs were exposed to complement 
by blocking EC surface regulators (CD46, CD55, CD59) and incubating ECs with 50% 
normal human serum (NHS; complement active). Heat inactivated serum (HIS; complement 
inactive), C5-depleted serum (terminal pathway inactive) and media served as controls.
Results: Wound healing assay in fluidic conditions (wound infliction via trypsin/
EDTA) showed within 1.5h a wound area decrease to 62.5±4% when perfused with media. 
Subsequent (1.5h) HIS perfusion allowed for further wound area reduction to 38±6%, similar 
to C5-depleted serum (46±5%). In contrast, exposure to complement (NHS) inhibited further 
wound closure (wound area 63±7%, p<0.05). The proliferation rate (% BrdU positive cells 
after 2 h) was similar between controls and complement-exposed ECs (20±2 vs. 21±3%), 
and no apoptosis or necrosis was detected within a 30min - 4h observation period (Annexin 
V, live dead aqua dye). However, we demonstrated an instantaneous but transient cell 
membrane perforation (via C5b-9, FM1-43X dye) with subsequent Ca2+ influx (Fura-2). 
Consequences of this sublytic C5b-9 deposition caused immediate and sustained (2h) 
cyto-skeletal (live cell imaging of F-actin, Rho-GTPases), cell-cell contact (decreased VE-
Cadherin expression, decreased transendothelial resistance) and cell motility abnormalities 
(live cell imaging) in complement-exposed ECs, all leading to defective cell migration.
Conclusions: Our data suggest that sublytic EC complement exposure results in 
impaired cell migration leading to EC injury and defective EC repair – findings extending 
our current concept of TMA pathogenesis.
FR-PO962
Uncommon Features in Antigen Binding Sites of Human Anti-Glomerular 
Basement Membrane Autoantibodies  Mary H. Foster, Elizabeth Sarah 
Buckley, Amy G. Clark.  Medicine, Duke Univ Medical Center and Durham 
VAMC, Durham, NC.
Background: Detection of pathogenic anti-alpha3(IV)NC1 collagen autoAb in 
the serum or kidneys is required for diagnosis of anti-GBM nephritis and Goodpasture 
Syndrome, yet little is known about the origin and structure of human autoAb in these 
diseases. The heterogeneity of serum Ig, lack of ready access to key tissues in patients, 
and inability to reproduce complex immunological microenvironments in vitro present 
formidable barriers. Humanized models provide a novel platform to circumvent these 
obstacles.
Methods: We generated Hu-HSC mice by injection of human CD34+ hematopoietic 
stem cells into immunodeficient NOD-scid-gamma hosts. Mice with an established 
human immune system (mean blood chimerism 15.0±15.9% at 3 mons post-injection) 
were immunized twice with alpha3(IV)NC1 collagen prior to tissue harvest. Human B 
cells were EBV transformed using CpG oligos and kinase inhibitors, screened for antigen 
binding, electrofused with a human heterohybridoma, and subcloned. The mAb sequences 
were determined using PCR of cDNA with published primer panels and analyzed using 
IMGT/V-QUEST.
Results: Sequence analysis of 6 non-clonally related human anti-alpha3(IV)NC1 mAb 
reveals skewed gene use and unusual motifs in the critical HCDR3 that is predominantly 
responsible for antigen binding. 4 of 6 (67%) human mAb are encoded by an IGH J6 
allele, the extended sequence of which enriches for aromatic tyrosine residues in HCDR3. 
The HCDR3 are exceptionally long, with mean length 26.4 amino acids (a.a.) compared 
to average human HCDR3 of 15.2 a.a., and include hydrophobic motifs, an autoimmune 
signature uncommon in Ig repertoires of healthy individuals and of unimmunized Hu-HSC 
mice. Similar motifs were observed in murine anti-alpha3(IV)NC1 mAb, despite substantial 
species differences in Ig gene loci and a.a. composition.
Conclusions: Our results suggest that binding of alpha3(IV)NC1 collagen by human 
anti-GBM autoAb requires unusual structural motifs that can access recessed hydrophobic 
epitopes and that are normally excluded from the healthy human immune repertoire. Similar 
motifs in man and mouse suggest origins by convergent selection.
Funding: NIDDK Support, Veterans Administration Support
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Antigenicity Alteration of Deglycosylated Myeloperoxidase  Juntao Yu,1 Zhao 
Cui,2 Minghui Zhao.2  1Academy for Advanced Interdisciplinary Studies, Peking 
Univ, Beijing, China; 2Renal Div, Peking Univ First Hospital, Beijing, China.
Background: Myeloperoxidase (MPO) is a kind of enzyme located in the azurophilic 
granules of neutrophils, which is the most common target antigen of anti-neutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Chinese patients. Native 
MPO possesses five N-glycans at positions 323, 355, 381, 483 and 729. The alteration of 
MPO antigenicity after deglycosylation of these glycans is not elucidated.
Methods: We prepared deglycosylated MPOs via glycosidases based on commercial 
human-derived intact MPO, and then detected the antigenicity of deglycosylated MPOs in 
40 patients with anti-glomerular basement membrane (GBM) disease without MPO-ANCAs.
Results: We found antibodies against deglycosylated MPOs existed in patients with 
anti-GBM disease. 12/40 (30%) patients were positive for MPO treated with PNGase F 
(naked MPO without hydrocarbon side-chain). 12 (30%) patients were positive for MPO 
treated with Endo H (MPO with one GluNAc only). Antibody against the intact native 
MPO was not detectable in all these patients. Furthermore, clinical analysis presented that 
the levels of antibodies against deglycosylated MPOs were positively associated with renal 
dysfunction. The plasma levels of antibodies against naked MPO without glycan were 
positively correlated with the concentrations of serum creatinine (P=0.006, R2=0.178). 
The plasma levels of antibodies against MPO with one GluNac only were also positively 
correlated with the concentrations of serum creatinine (P=0.002, R2=0.234).
Conclusions: The existence of patients’ antibodies towards deglycosylated MPO first 
discovered the new epitope exposure of MPO after the loss of hydrocarbon side-chain, 
explicating the possible reasons for antigenicity alteration, and then prompting some clinical 
significance of these antibodies.
Funding: Government Support - Non-U.S.
FR-PO964
Autoantibodies to a Cryptic Myeloperoxidase-Specific Immunodominant 
Epitope Correlate with Disease Activity in Patients with MPO-ANCA 
Vasculitis  Jacob J. Hess, Meghan E. Free, Olivier Lardinois, Donna O. Bunch, 
Caroline J. Poulton, JulieAnne G. McGregor, J. Charles Jennette, Ronald J. Falk, 
William Franklin Pendergraft.  UNC Kidney Center, Univ of North Carolina, 
Chapel Hill, NC.
Background: ANCA vasculitis is commonly characterized by polyclonal autoantibody 
reactivity to one of two autoantigens, proteinase 3 (PR3) and/or myeloperoxidase (MPO). 
ANCA positivity has been observed in patients with active and quiescent disease. A subset 
of MPO-ANCA in many patients recognize a peptide sequence referred to as KIV. This 
peptide is buried within MPO suggesting that this epitope may be exposed by mechanisms 
that are not yet understood. We assessed human anti-KIV reactivity longitudinally in a large 
cohort of patients with MPO-ANCA vasculitis to better understand the temporal association 
of the autoantibody response.
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Methods: Serum, plasma, and extensive clinical data from patients with ANCA 
vasculitis were prospectively collected every 3 months. A highly sensitive and specific 
indirect ELISA using KIV peptide was developed to longitudinally screen patient samples 
for reactivity over their disease course. To minimize non-specific antibody signal, reactivity 
to a scrambled peptide of the same amino acid composition was also measured. A positive 
signal was defined as two standard deviations above the healthy control mean (HC n=85).
Results: Of 67 patients with MPO-ANCA vasculitis, 28 were positive for human 
anti-KIV autoantibodies at least once during their disease course spanning an average 
follow-up of 3.3 years. The majority of these patients displayed positivity during initial 
stages of disease that receded over time while other patients exhibited recrudescence of 
reactivity. Further structural analysis of autoantibody binding to native MPO confirmed 
this peptide to be a cryptic epitope.
Conclusions: These findings suggest that conformational changes in MPO that expose 
this cryptic epitope may be important in the pathogenesis of MPO-ANCA vasculitis and 
may provide insight into the etiology of this disease. Furthermore, this assay could help to 
more clearly define temporal disease activity.
Funding: NIDDK Support
FR-PO965
An Anti-GBM Autoantibody Gene Contributes Risk to Distinct Anti-
Collagen Responses  Amy G. Clark, Inge M. Worni-Schudel, Mary H. Foster. 
Medicine, Duke Univ Medical Center and Durham VAMC, Durham, NC.
Background: The mechanism by which anti-GBM nephritis is initiated and regulated 
remains an enigma. Recent studies indicate that anti-GBM patients’ serum IgG react with 
multiple collagen chains and with atypical alpha3(IV)NC1 epitopes, and that diverse murine 
anti-collagen autoAb are genetically linked. We examined these relationships in a novel 
autoAb transgenic (Ig Tg) model expressing an IGKV3 gene used at low frequency in adult 
mice but enriched in anti-GBM Ig and arthritogenic anti-collagen II IgG.
Methods: Mice expressing an IGKV3-encoded Ig kappa light chain Tg were bred 
with B6 kappaKO mice, such that all kappa is Tg-derived, and use of lambda chains 
reflects regulation by editing. Purified B cells or whole splenocytes were cultured +/- 
Toll-like receptor ligands (TLR4L or TLR7/TLR9L). Quantitation of Tg autoAb binding 
to alpha3(IV)NC1 collagen or collagen II was performed by ELISA (expressed as OD405 
on Ag-coated minus diluent-coated wells, n=6-10 mice/group, mean ± SD).
Results: Tg receptor expression was detected on 65±14% of B cells, with in vivo 
regulation suggested by low serum kappa levels (µg/ml, 27±28 vs 1029±611 for nonTg 
kappa+ controls, p<0.01). AutoAb were not detected in supernatants from unstimulated 
cells (mean OD 0.003±0.006), but were detected after TLRL stimulation. AutoAb specificity 
varied according to TLRL and with: (1) B cell surface lambda (editor) expression: anti-
collagen II Ig, OD 0.271±0.122 vs 0.037±0.056, p<0.001, for high-lambda-expressing 
mouse Tg lines L16/L21 (mean lambda+ 47.5±12.4% of cells) vs low-lambda line L24 
(mean 25±11.7% lambda+); and, (2) Presence of non-B cells: anti-alpha3(IV)NC1 collagen 
Ig, OD 0.124±0.104 vs 0.038±0.033, p<0.001, for whole splenocyte cultures vs purified B 
cells (all data shown for TLR7/TLR9L).
Conclusions: This new model confirms a role for IGKV3 genes in determining 
different anti-collagen specificities, including reactivity to GBM. This and data not shown 
suggest that the different specificities are not crossreactive, arise from non-overlapping 
cell populations, and are regulated in vivo by mechanisms that can be overcome by TLRL 
or hematopoietic cell interactions.
Funding: NIDDK Support, Veterans Administration Support, Pharmaceutical 
Company Support - Novartis Foundation 
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FR-PO966
Autoantibodies Target Multiple Epitopes in THSD7A in Primary 
Membranous Nephropathy  Hong Ma, David J. Salant, Laurence H. Beck. 
Medicine, Renal Section, Boston Univ Medical Center, Boston, MA.
Background: Thrombospondin type-1 domain-containing 7A (THSD7A) is a large type 
1 transmembrane glycoprotein expressed by the podocyte. It serves as the in situ antigen in 
a subset of primary membranous nephropathy patients. Its extracellular domain consists of 
a regularly repeating structure composed of thrombospondin type-1 and F-spondin repeats, 
as well as a highly basic region. We sought to investigate the location(s) of the humoral 
epitopes targeted by anti-THSD7A antibodies in membranous nephropathy.
Methods: N- and C-terminal truncation mutants of THSD7A, as well as constructs 
comprising single or multiple adjacent domains, were expressed in HEK293T cells. 
Reactivity with human autoantibodies was assessed by western blot, dot blot, and 
immunoprecipitation.
Results: Patient sera displayed varying degrees of reactivity to these recombinant 
constructs, with most sera reacting with 2 or more distinct domains in the more C-terminal, 
extracellular region of the molecule. A subset of patients also recognized an additional 
epitope in the N-terminal portion of the molecule. Reactivity with the larger constructs, 
such as THSD7A serially truncated from the N- or C-termini, was stronger than that against 
constructs composed of 1 to 4 adjacent domains, and could be detected by western blot, 
dot blot, and immunoprecipitation. Reactivity with single domains or several multiple 
adjacent domains was most prominent when detected by immunoprecipitation, and less 
consistently detected by western blot, which may suggest the presence of conformation-
sensitive epitopes within the molecule.
Conclusions: As in PLA2R-associated membranous nephropathy, the humoral response 
to the target antigen THSD7A involves multiple epitopes within the molecule. Reactivity 
with autoantibody appears to depend on the conformation of an extended THSD7A 
extracellular region. Further analysis of additional anti-THSD7A positive sera will help 
to better define the dominant epitopes within the molecule, understand the pathogenesis of 
this autoimmune disease, and identify potential targets for novel therapeutics.
Funding: NIDDK Support
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Intramolecular Epitope Spreading in Phospholipase A2 Receptor in IMN 
Quansheng Zhu,1 Hong Tang,1 Phat H. Duong,1 Meryl A. Waldman.2  1Medicine, 
UCLA, Los Angeles, CA; 2NIDDK/Kidney Disease Section, National Insts of 
Health, Bethesda, MD.
Background: Idiopathic membranous nephropathy (IMN) is an organ specific 
autoimmune disease. The major antigen responsible for developing IMN in patients has 
been identified to be the phospholipase A2 receptor (PLA2R) expressed in the glomerular 
visceral epithelial cells. Clinical studies demonstrated that over 70% of IMN patients possess 
circulating autoantibodies that target PLA2R triggering immune complexes formation in 
situ and deposition in the glomerular subepithelial spaces. The immunodominant epitope 
in PLA2R was recently located to the extreme N-terminus of the receptor encompassing 
the CysR-FnII-CTLD1 region. In the rat model of MN, epitope spreading was detected 
in the antigenic protein, megalin that is correlated with the disease progresses. Whether 
epitope spreading occurs in human IMN and its relationship to disease progresses is unclear.
Methods: Serum samples from biopsy-proven IMN patients were collected and 
screened for anti-PLA2R antibodies using Western-blot and epitope-specific ELISA assays. 
The reaction of autoantibody and PLA2R epitope protein was further analyzed using 
immunoprecipitation and immunoblocking assays.
Results: Western-blot analysis using patient sera against full-length PLA2R or the 
dominant epitope region indicated that, 3 of the 12 serum samples that were positive with 
anti-PLA2R autoantibodies failed to recognize the dominant epitope protein. Further test 
of these 3 samples against a series of truncated PLA2R extracellular domains on Western-
blot demonstrated that the autoantibodies bind strongly to the CysR-FnII-CTLD1-3 region 
of PLA2R. Interestingly, serial analysis of sera from a patient with worsening proteinuria 
showed that, the autoantibodies first recognized the CysR-FnII-CTLD1-3 region and then 
spread to the CysR-FnII-CTLD1 region, suggesting epitope spreading is associated with 
the disease progresses.
Conclusions: Our results demonstrate for the first time that intramolecular epitope 
spreading occurs in PLA2R in IMN. This finding supports the important role of the dominant 
epitope in IMN pathogenesis and disease progresses.
FR-PO968
Demonstration of a High Titer Low Affinity Anti-PLA2R Autoantibody in an 
IMN Patient En Route to End-Stage Renal Disease  Michael Shye,1 Theresa 
L. Nilson,1 Ritu Vahi,1 Miguel Fernando Palma Diaz,2 P.C. Pham,1 Phat H. 
Duong,1 Liyo Kao,1 Douglas Yao,1 Ira Kurtz,1 Quansheng Zhu.1  1Medicine, Univ 
of California, Los Angeles, Los Angeles, CA; 2Pathology, Univ of California, 
Los Angeles, Los Angeles, CA.
Background: Clinical studies have established that over 70% of patients with idiopathic 
membranous nephropathy (IMN) possess high levels of circulating autoimmune antibodies 
targeting phospholipase A2 receptor (PLA2R) in the glomerular visceral epithelial cells 
(podocyte). Binding of autoantibodies to PLA2R triggers immune complex formation in 
situ that impairs podocyte biology resulting in foot process effacement and subsequently 
proteinuria in patients. In this study, we monitored the fluctuation of autoantibody level in a 
patient progressing to the end-stage renal disease (ESRD) under the supportive treatments.
Methods: Serum samples from an IMN patient progressing to ESRD under supportive 
treatments over a period of 6 month were collected (5 clinical visits) and tested for the 
level of anti-PLA2R antibodies using western-blot, indirect immunofluorescence staining 
and epitope-specific ELISA assay. The reaction of autoantibodies toward the dominant 
epitope region of PLA2R was further analyzed using immunoprecipitation under the non-
denaturing and denaturing conditions.
Results: A sharp decline of autoantibody reactivity toward PLA2R in sera from the 
last two visits was detected on Western-blot as the patient approaching ESRD. In contrast, 
an epitope-specific ELISA assay indicated that the autoantibodies were remained at high 
levels in these two serum samples, and this observation is further confirmed by by the 
immunofluorescence staining analysis. Test of epitope-antibody reaction under the non-
denaturing and denaturing conditions revealed that, the properties of the autoantibodies 
in the last two visits differ significantly from that in the first three visits, which have low 
affinity toward PLA2R and only bind to the non-denatured form of the epitope.
Conclusions: Our results demonstrate that a high titer low affinity anti-PLA2R 
autoantibody presents in an IMN patient at the late stages of IMN approaching ESRD under 
the supportive treatments. This autoantibody has altered reactivity toward PLA2R that only 
binds to the non-denatured immunodominant epitope of the receptor.
FR-PO969
Immune Complex Binding to Renal Endothelial Cells Induces TRAIL and 
Promotes Apoptosis  Scott E. Wenderfer, Adisak Suwanichkul.  Pediatrics, 
Baylor College of Medicine, Houston, TX.
Background: Circulating immune complexes (IC) deposit in the glomeruli of the 
kidney in many autoimmune diseases, leading to proliferative glomerulonephritis. IC 
binding can promote proliferation or induce apoptosis in human macrovascular EnCs. 
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Tumor necrosis family (TNF) superfamily members regulate proliferation and apoptosis, 
and both ligands and receptors are produced by glomerular endothelial cells (EnC). Tnfsf10/
TRAIL is up-regulated in the kidneys of patients with IC disease.
Methods: Renal EnCs were cultured from C57BL/6 mice and primary human 
glomerular EnCs were obtained commercially. Cells were treated with heat aggregated 
IgG or peroxidase anti-peroxidase IC. Quantitative RT-PCR was used to measure mRNA 
levels of TNF superfamily members. A cellular ELISA was used to assess TRAIL protein 
expression on EnC surfaces. Apoptosis was assessed using XTT and H2AX phosphorylation, 
and caspase 3 activity assays, as well as TUNEL staining. In vitro findings were validated 
in a non-inflammatory murine model of acute IC kidney injury.
Results: TRAIL mRNA expression is up-regulated by renal endothelial cells in vitro 
in the presence of IC binding and in vivo. Membrane TRAIL expression on EnCs also 
increases after treatment with IC in a dose dependent manner. Receptors for TRAIL, DR5, 
DR6 are also expressed by EnCs at RNA and protein level. Using XTT cell proliferation 
assays, there is a modest decrease in EnC metabolism or proliferation after treatment with 
IC. Caspase 3 activity and DNA double strand breaks were both increased in cultured EnCs 
after treatment with IC in a dose dependent manner. Results were similar for both murine 
and human glomerular EnCs.
Conclusions: Results suggest that IC binding to glomerular EnCs in vitro is pro-
apoptotic. Several TNF superfamily members known to promote apoptosis and their 
receptors are also up-regulated on EnCs treated with IC. Targeting TRAIL binding to 
DR5 and its downstream signaling pathways may reduce EnC activation or injury in IC 
kidney diseases.
Funding: NIDDK Support
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Paired Immunoglobulin-Like Type2 Receptor α (PILRα) Negatively 
Regulates  Immune Complex-Mediated Glomerulonephrit is 
Yutaka Sugiyama, Naotake Tsuboi, Yutaka Kamimura, Shoichi Maruyama, 
Seiichi Matsuo.  Nephrology, Nagoya Univ Graduate School of Medicine, 
Nagoya, Japan.
Background: PILRα expressed mainly on macrophages, dendritic cells and 
granulocytes, has been described for its regulatory functions for leukocyte β2 integrin 
activation in acute inflammation including LPS-induced endotoxin shock model. Here, we 
investigated roles of PILRα in immune complex (IC)-mediated glomerular inflammation.
Methods: IC-mediated glomerulonephritis was induced by intravenous administration 
of nephrotoxic serum (NTS) after pre-immunization with rabbit IgG in C57BL/6 (WT) 
and PILRα-/- mice. Functional analysis for renal injury was performed by urine albumin 
and serum creatinine (sCr) concentrations at day 7, 14 and 21. Diseased kidneys from both 
mouse strains were harvested for histology, renal leukocyte infiltrates by flow cytometry 
and renal cytokine profiles by ELISA after induction of NTS glomerulonephritis. In vitro, 
αmβ2 integrin-dependent neutrophil adhesion on IC was evaluated in both mouse strains.
Results: BUN and sCr concentrations were significantly elevated in PILRα-/- mice 
compare to wild type mice at day 14 and day 21 and those were highly associated with 
deteriorated proteinuria. In histological analysis, glomerular damages, corroborated with 
both glomerular PAS deposits and glomerular crescent formation, were more severe in 
PILRα-/- mice at day 21 (p<0.05). Moreover, glomerular neutrophil accumulation was 
remarkably observed in PILRα-/- mice compare to WT mice at day 21. In addition, total 
infiltration of Ly6Ghigh neutrophils, F4/80+ macrophages and CD3+CD4+ T cells in whole 
kidneys were increased in PILRα-/- mice than WT mice at day 14 and day 21. Renal 
proinflammatory cytokine profiles for IL-1β and IL-6 on day 21 also demonstrated severe 
renal inflammation in PILRα-/- mice. In vitro, PILRα deficient neutrophils showed enhanced 
adhesion and spreading on IC compared to WT.
Conclusions: PILRα-/- deficiency resulted in deteriorated renal damage in mouse 
IC-mediated glomerulonephritis compare to WT mice, indicating that PILRα negatively 
regulates IC-mediated leukocyte recruitment by inhibition of αmβ2 integrin activation.
FR-PO971
Role of Interferon Regulatory Factor 5 and Toll-Like Receptor 7 in Immune-
Complex Glomerulonephritis  Abraham Cohen-Bucay, Barry K. Horne, Yao 
Xie, Prachi Shukla, Ian R. Rifkin, Ramon G. Bonegio.  Renal Section, Boston 
Univ Medical Center, Boston, MA.
Background: Immune-complex glomerulonephritis (ICGN) is a common cause of 
glomerular inflammation characterized by the in situ formation of immune complexes 
and activation of the complement cascade. Interferon regulatory factory 5 (IRF5) is 
a transcription factor acting downstream of toll-like receptors 7 (TLR7) to trigger an 
inflammatory response. Recent genetic studies have associated systemic lupus erythematosus 
and other autoimmune syndromes with gain-of-function polymorphisms in the IRF5 gene. 
We therefore hypothesized that deletion of IRF5 or TLR7 would ameliorate ICGN.
Methods: We induced nephrotoxic nephritis using an endotoxin-free IgG1 fraction 
of sheep nephrotoxic serum (NTS) in FcgRIIb-/- mice that either express (Control) or do 
not express IRF5 (IRF5-KO) or TLR7 (TLR7-KO). During the first five days following 
tail-vein injection of NTS, at a time when the heterologous antibody response peaked, we 
euthanized the mice and compared histology, albuminuria, renal immune cell infiltrate 
and gene expression.
Results: The control mice developed severe glomerulonephritis characterized by 
massive albuminuria, prominent kidney mononuclear cell infiltration and presence of 
crescents or necrosis in 28±6% of glomeruli. In contrast, TLR7-KO and IRF5-KO developed 
significantly less severe disease with crescents/necrosis in only 6±2% of glomeruli (p<0.01), 
and significantly decreased mononuclear cell infiltration (including both patrolling and 
resident monocytes). Albuminuria was similar in the control and IRF5-KO mice, but 
significantly lower in the TLR7-KO mice.
Conclusions: IRF5 and TLR7 signaling is required for the development of glomerular 
inflammation during the heterologous phase of ICGN. However, proteinuria was only 
ameliorated in the TLR7-KO, but not in the IRF5-KO mice. Therefore an IRF5-independent 
pathway downstream of TLR7 is responsible for the proteinuria. Consequently, we conclude 
that the TLR7/IRF5 pathway may represent a novel therapeutic target for the control of 
glomerular inflammation.
Funding: NIDDK Support, Other NIH Support - NIAMS
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Therapeutic TLR9 Inhibition Prevents the Establishment of Anti-
Myeloperoxidase Autoimmunity and the Development of Glomer-
ulonephritis in Mice with Established Autoimmunity  Sharon Lee Ford,1,2 
Poh-Yi Gan,2 A. Richard Kitching,1,2 Stephen R. Holdsworth,1,2 Shaun A. 
Summers.1,2  1Depts of Medicine & Nephrology, Monash Health, Clayton, 
VIC, Australia; 2Centre for Inflammatory Diseases, Monash Univ, Clayton, 
VIC, Australia.
Background: We have shown TLR9 ligation enhances anti-myeloperoxidase (MPO) 
autoimmunity (AI) and glomerulonephritis (GN) through dendritic cell (DC) activation. 
We assessed therapeutic TLR9 inhibition on both the development of anti-MPO AI induced 
through DC vaccination and subsequent development of GN by TLR9 responsive innate 
effector cells.
Methods: Injection of MPO/Freud’s Adjuvant or transfer of MPO/CpG (TLR9 ligand) 
pulsed bone marrow derived DCs established anti-MPO AI. To stimulate effector cells, 
intraperitoneal (IP) CpG or MPO/Freud’s Adjuvant was injected after inducing anti-MPO 
AI, prior to triggering renal injury (using anti-glomerular basement membrane globulin). 
TLR9 signaling was inhibited with an inhibitory oligodeoxynucleotide before both induction 
of AI and triggering renal injury.
Results: Mice receiving MPO/CpG DCs + IP CpG compared to MPO/CpG DCs + IP 
GpC (Control) developed heightened immune responses (cells/spleen:5.4±6 vs 3.6±5x108, 
p<0.05) and renal injury (urea:31±7 vs 11±0.3µmol/L, p<0.05; abnormal glomeruli:93±3 vs 
15±3%, p<0.0001) confirming effector cell TLR9 ligation is required for disease induction 
and a target for therapeutic inhibition. TLR9 inhibition prevented MPO/FCA induced 
systemic anti-MPO autoimmunity measured by MPO specific dermal DTH swelling (2.6±1 
vs 18.6±3Dmm, p<0.05) and decreased frequency of MPO stimulated IL-17A producing 
cells (6±1 vs 21±3cells, p<0.01) compared to control. TLR9 inhibition prevented IL-17A 
driven AI in mice receiving MPO/CpG DCs (DTH:2.3±1 vs 18.6±3Dmm, p<0.001, IL-
17A:21±6 vs 43±8cells, p<0.05). The TLR9 inhibitor was effective at preventing injury when 
given to mice with established anti-MPO AI compared to control (DTH:3±1 vs 13±4mm 
footpad swelling, p<0.05, urea:26±1 vs 34±3µmol/L, p<0.05, abnormal glomeruli:43±9 
vs 79±5%, p<0.01).
Conclusions: Therapeutic TLR9 inhibition prevents the development of anti-MPO 
AI and is a therapeutic option to prevent the development of renal injury once anti-MPO 
AI is established.
Funding: Government Support - Non-U.S.
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TLR9 Activation Aggravates Murine IgA Nephropathy; Possible Role of 
BAFF Mediated Pathway  Yuko Makita, Hitoshi Suzuki, Akiko Takahata, 
Toshiki Kano, Satoshi Horikoshi, Yusuke Suzuki.  Div of Nephrology, Dept of 
Internal Medicine, Juntendo Univ School of Medicine, Bunkyo-ku, Tokyo, Japan.
Background: Contribution of Toll like receptors (TLRs) which play a key role in 
the innate immune system has been discussed in the pathogenesis of IgAN. We recently 
demonstrated that TLR9 is importantly involved in progression of kidney injuries in IgAN 
prone mice. On the other hand, role of B cell activating factor (BAFF) is discussed in the 
pathogenesis of human IgAN. Present study examined the contribution of BAFF in the 
TLR9 mediated progression of IgAN using IgAN prone mice.
Methods: Commercially available quiescent IgAN prone mice (ddY mice) at 4 weeks 
of age were used for this study. They were divided into two groups with (n=8) or without 
(n=8) TLR9 ligand (CpG-ODN) for 12 weeks. Renal histological lesions and serum levels 
of IgA, IgG and IgA-IgG immune complexes (IC) were evaluated at 16 weeks of age. Serum 
levels of aberrantly glycosylated IgA was measured by the binding of Sambucus nigra bark 
lectin and Ricinus communis agglutinin I. Splenic expressions of TLR9, MyD88, BAFF 
and its receptor (TACI) were also quantitatively evaluated.
Results: CpG-ODN treated, but not non-treated mice, showed mesangial deposition of 
IgA, IgG and C3. Moreover albuminuria and renal histological scores based on mesangial 
proliferation and mesangial matrix expansion in CpG-ODN treated mice were significantly 
higher than those in non-treated mice. The expressions of MyD88, BAFF and TACI were 
also significantly increased by treatment with CpG-ODN. Interestingly there were significant 
correlation between BAFF expression and serum levels of aberrantly glycosylated IgA 
and IgA-IgG IC.
Conclusions: Present study indicated that TLR9 activation exacerbates murine IgAN 
via increase of aberrantly glycosylated IgA and nephritogenic IC. In addition, present 
findings also suggested that TLR9 mediated BAFF expression may be involved in the 
nephritogenic IgA and IC production.
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FR-PO974
Key Role of Apoptosis Inhibitor of Macrophage in Phlogogenic Action 
of Glomerular Nephritogenic IgA in IgA Nephropathy  Akiko Takahata,1 
Kento Kitada,2 Chieko Nogi,1 Satoko Arai,2 Yuko Makita,1 Hitoshi Suzuki,1 
Junichirou Nakata,1 Satoshi Horikoshi,1 Toru Miyazaki,2 Yusuke Suzuki.1 
1Div of Nephrology, Dept of Internal Medicine, Juntendo Univ School of 
Medicine, Bunkyo-ku, Tokyo, Japan; 2Laboratory of Molecular Biomedicine for 
Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of 
Medicine, The Univ of Tokyo, Bunkyo-ku, Tokyo, Japan.
Background: Apoptosis inhibitor of macrophage (AIM), a protein mainly produced 
by macrophages, has been reported to be related to autoimmune diseases as well as 
arteriosclerosis.
Methods: We evaluated the role of AIM in IgA nephropathy (IgAN) using IgAN 
prone mice, grouped ddY (gddY) (J Am Soc Nephrol,2012(8):1364-74). Serum of gddY 
mice was injected to AIM-deficient (AIMKO) and wild-type (WT) mice, and proteinuria 
and glomerular depositions were evaluated over time. In addition, nephritogenic IgA, 
produced by gddY splenic B cells hybridomas, was injected to AIMKO and WT to perform 
the same evaluation.
Results: We found excessive expression of AIM in gddY, which were co-localized with 
glomerular IgA. Glomerular IgA depositions were observed in AIMKO and WT 2h after 
the injections of gddY serum and purified nephritogenic IgA. The depositions were cleared 
soon thereafter in WT but later in KO after being accumulated. However, proteinuria was 
confirmed in WT, but not in KO. Moreover, CD45+ macrophages infiltration was significantly 
delayed and less in KO than in WT. To identify the role of macrophages in the clearance 
of the glomerular immunoglobulin depositions, Gr1-/FcγIV+ macrophages were depleted 
by injecting WT mice with clodronate liposomes and later with gddY serum. However, 
the depletion of macrophages did not change the degree of glomerular depositions in WT, 
as in non-depleted WT.
Conclusions: These findings suggest that AIM is a critical molecule in the glomerular 
IgA clearance and subsequent inflammatory triggering induced by infiltrating macrophages 
in IgAN. Furthermore, AIM may also contribute to such inflammatory responses by 
glomerular resident cells such as mesangial cells.
Funding: Government Support - Non-U.S.
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Expression of Mesangial Tissue Transglutaminase Is Independent 
of Aberrantly Glycosylated IgA in Patients with IgA Nephropathy 
Akihiro Kato,1,2 Kazuo Takahashi,1,2,3 Tomohiro Mizuno,1,2 Stacy D. Hall,3 
Yoshiyuki Hiki,4 Kiyotaka Hitomi,5 Jan Novak,3 Yukio Yuzawa.1  1Fujita Health 
Univ School of Medicine, Toyoake, Aichi, Japan; 2Meijo Univ, Nagoya, Aichi, 
Japan; 3Univ of Alabama at Birmingham, Birmingham, AL; 4Fujita Health Univ 
School of Health Sciences, Toyoake, Aichi, Japan; 5Nagoya Univ Graduate 
School of Pharmaceutical Sciences, Nagoya, Aichi, Japan.
Background: It has been reported that tissue transglutaminase (TG2) is essential for 
mesangial deposition of IgA1 and development of mesangial inflammation in a mouse 
model of IgA nephropathy (IgAN). We have shown that some IgAN patients have an active 
form of TG2 in the mesangial area and that mesangial TG2 activity is associated with 
elevated proteinuria and proliferation of mesangial cells (MC). The impact of aberrantly 
glycosylated IgA1 on mesangial TG2 expression merits investigation, as circulating immune 
complexes, including those containing aberrantly glycosylated IgA1, are deposited in the 
mesangium in IgAN.
Methods: To understand the role of mesangial TG2 in IgAN, expression of TG2 in 
cultured MC stimulated by sera from IgAN patients with mesangial TG2 activity (IgAN-
TG2A), IgAN patients without mesangial TG2 activity (IgAN-TG2N), disease controls 
(DC), or healthy controls (HC) were assessed. Expression of TG2 in MC stimulated by 
purified serum IgA1 or enzymatically deglycosylated IgA1 was also assessed. Furthermore, 
we characterized hinge-region (HR) O-glycosylation profiles of serum IgA1 from IgAN-
TG2A and IgAN-TG2N using high-resolution mass spectrometry.
Results: MC stimulated with sera from IgAN-TG2A showed more binding of IgA 
and expressed more TG2 than those stimulated with sera from IgAN-TG2N, DC, or HC 
(P< 0.01). Mass spectrometric analysis identified 13 IgA1 HR O-glycoforms with up to 3 
galactose-deficient glycans. The number of galactose-deficient glycans was not significantly 
different between IgA1 from IgAN-TG2A and IgA1 from IgAN-TG2N (0.76 vs. 0.79 mol/
HR). Enzymatically deglycosylated IgA1 did not change TG2 expression on MC compared 
to IgA1 from HC.
Conclusions: Sera from IgAN patients enhanced mesangial TG2 expression. Aberrantly 
glycosylated IgA1 alone was insufficient to increase TG2 expression by MC.
Funding: Pharmaceutical Company Support - Kyowa Hakko Kirin Co., 
Otsuka Pharmaceutical Co., Baxter, Chugai Pharmaceutical Co., Mitsubishi Tanabe 
Pharmaceutical Co., Government Support - Non-U.S.
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Characterization of a Signaling Network That Enhances Production of 
Galactose-Deficient IgA1 in IgA1-Secreting Cells from Patients with IgA 
Nephropathy  Koshi Yamada,1,2 Colin Reily,1 Zhi qiang Huang,1 Joshua Charles 
Anderson,1 Milan Raska,1,3 Hitoshi Suzuki,1,2 Bruce A. Julian,1 Christopher 
D. Willey,1 Jan Novak.1  1Univ of Alabama at Birmingham, Birmingham, AL; 
2Juntendo Univ Faculty of Medicine, Tokyo, Japan; 3Palacky Univ, Olomouc, 
Czech Republic.
Background: Interleukin (IL)-6, leukemia inhibitory factor (LIF), and oncostatin 
M (OSM) cytokines are likely involved in the pathogenesis of IgA nephropathy (IgAN). 
IL-6/LIF/OSM cytokines activate B cells through similar receptors and the downstream 
JAK/STAT pathways. We identified key roles of STAT transcription factors in IL-6/LIF/
OSM-mediated enhancement of production of IgA1 with galactose-deficient O-glycans 
(Gd-IgA1) by IgA1-secreting cells from IgAN patients. Our study defines how these 
signaling pathways influence IgA1 O-glycosylation.
Methods: IgA1-secreting cells from IgAN patients and healthy controls (HC) were 
stimulated with IL-6/LIF/OSM with or without JAK/STAT inhibitors. Gd-IgA1 levels 
were determined by lectin ELISA. Cell lysates from IgAN and HC cells were analyzed 
by global tyrosine-kinome profiling using PamStation®12 platform and Western blotting. 
The role of STAT3 or STAT1 in mediating IL-6/LIF/OSM, signaling was confirmed by 
siRNA knock-down (k/d).
Results: siRNA k/d of STAT3 and STAT1 reduced production of Gd-IgA1 in IgAN 
cells induced by IL-6 and LIF/OSM, respectively. A specific inhibitor of JAK/STAT 
signaling reduced IL-6/LIF-enhanced production of Gd-IgA1, but only in IgAN cells. Global 
tyrosine-kinome profiling identified nine target peptides that were selectively inhibited 
by the tested JAK/STAT inhibitor in the IgAN cell lysates. Bioinformatics analyses and 
pathway mapping identified abnormal signaling in JAK/STAT and MAPK cascades as the 
highest ranked pathway.
Conclusions: IL-6/LIF/OSM cytokines enhanced production of Gd-IgA1 via 
overactivation of JAK/STAT pathways in IgAN cells. Global tyrosine kinomic profiling 
validated this finding and also indicated participation of MAPK. Elucidating the mechanisms 
of abnormal signaling associated with Gd-IgA1 production in IgA1-scereting cells may 
provide new targets for treatment of IgAN.
Funding: NIDDK Support
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TGF-β1 Has the Same Effect with IL-4 on Alteration of IgA1 Glycosylation 
Through Down-Regulation of Core 1 β1, 3-Galactosyltransferase and Cosmc 
Jun Xiao.  Nephrology, Dept of Nephrology, the First Affiliated Hospital of Nan 
Chang Univ, Nanchang, JiangXi, China.
Background: Aberrantly glycosylated IgA1 plays a pivotal role in the pathogenesis of 
IgA nephropathy (IgAN). Transforming growth factor-β1 (TGF-β1) mediates the progression 
of IgAN is well established as a critical IgA isotype switching factor. The effect of TGF-β1 
on IgA1 glycosylation has not been illuminated and related mechanism is still unknown.
Methods: We analysed the mRNA levels of Core1ß1, 3-galactosyltransferase 
(C1GalT1) and its molecular chaperone Cosmc and subsequent O-glycosylation of IgA1 
in a human B-cell line stimulated with TGF-β1. The surface IgA1-positive human B-cell 
line was cultured with different concentration of recombinant human TGF-β1 (5, 10, 15, 
30ng/ml). The production and glycosylation of IgA1 were determined by sandwich ELISA 
and enzymelinked lectin binding assay, respectively. The mRNA levels of C1GalT1 and 
Cosmc were quantitatively measured by real-time PCR.
Results: IgA1 production was stimulated by low concentration of TGF-β1 (5, 10ng/
ml), while was suppressed by high concentration (15,30ng/ml). The terminal glycosylation 
of secreted IgA1 was altered in response to TGF-β1. TGF-β1 stimulation significantly 
decreased the mRNA levels of both C1GalT1 and Cosmc.
Conclusions: TGF-β1 may play a key role in controlling glycosylation of the IgA1, 
and may be partly due to the down-regulation of C1GalT1 and Cosmc.
Funding: Other NIH Support - Natural Science Foundation of China (81160091)
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Epigenetic Modulation of Vitamin D Receptor (VDR) in HIV-Associated 
Nephropathy (HIVAN)  Nirupama Chandel, Kamesh R. Ayasolla, Shabirul 
Haque, Rivka Lederman, Ashwani Malhotra, Pravin C. Singhal.  Medicine, 
Hofstra North Shore LIJ Medical School, Great Neck, NY.
Background: HIV has been reported to induce podocyte injury through down regulation 
of VDR in HIVAN. However, the exact mechanism is not clear. Since HIV has been reported 
to modulate gene expression via epigenetic phenomena, we hypothesized that HIV would 
be down regulating podocyte VDR expression in HIVAN via chromatin mofications.
Methods: Renal tissues and cortical sections from four week old control (FVB/N) 
and HIV-transgenic (Tg26) mice (n=4) were evaluated for the expression of SNAIL, 
VDR, trimethylationof histone 3 at lysine 4 residue (H3k4me3). Human podocytes (HPs) 
transduced with either empty vector (EV) or HIV (HIV/HPs) were evaluated for the 
expression of SNAIL, VDR, and H3K4me3. Stably transfected 293T cells (SNAIL/293T) 
were evaluated for the same profile. Genomic DNAs of HPs were evaluated for cytosine 
methylation by Epitect kit and bisulphite pyrosequencing. Composition of SNAIL repressor 
complex was determined by immunprecipitation (IP) studies. Trimethylation at SNAIL 
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promoter and binding at VDR promoter were evaluated by ChIP assays. To reverse the VDR 
expression, HIV/HPs were treated with either VDR agonist (VDA) alone or in combination 
with either an HDAC inhibitor or a demethylating agent.
Results: Renal tissues of Tg26 mice displayed enhanced expression of SNAIL and 
H3K4 me3  but down regulation of VDR. Podocytes in renal cortical sectins of Tg26 mice 
displayed enhanced expression of SNAIL and down regulation of VDR. HIV/HPs and 
SNAIL/293T displayed upregulation of SNAIL but down regulation of VDR. HIV/HPs 
displayed H3K4 trimethylation at SNAIL promoter and enhanced expression of histone 
deacetylase (HDAC) 1, DNA methyl transferase (Dnmt) 3b. IP studies revealed the 
association of HDAC1, Dnmt3b, Dnmt1, and mSin3A with the SNAIL. VDR agonists, 
HDAC inhibitor, and demethylating agents alone could not reverse VDR exprssion 
optimally, but could do so, when used in combination.
Conclusions: SNAIL recruits multiple chromatin enzymes to form a repressor 
complexes that down regulate VDR expression in HIV milieu. To upregulate VDR optimally 
in HIV milieu, reversal of chromatin modifications are deemed essential.
Funding: NIDDK Support
FR-PO979
ANCA Disease Patients Demonstrate a Higher Frequency of CD33+ Myeloid 
Cells with Variable Suppressive Abilities  Meghan E. Free,1 Katie Stember,2 
JulieAnne G. McGregor,1 J. Charles Jennette,2 Ronald J. Falk,1 Maureen Su.3 
1UNC Kidney Center, Univ of North Carolina at Chapel Hill, Chapel Hill, NC; 
2Pathology and Laboratory Medicine, Univ of North Carolina at Chapel Hill, 
Chapel Hill, NC; 3Pediatrics, Univ of North Carolina at Chapel Hill, Chapel 
Hill, NC.
Background: Myeloid-derived suppressor cells (MDSCs), or CD33+ myeloid cells, 
have been extensively studied in cancer as potent suppressors of T cell activation. Regulatory 
T cells do not control T cell proliferation in patients with anti-neutrophil cytoplasmic 
autoantibody (ANCA) disease, therefore we sought to determine the role of CD33+ myeloid 
cells in ANCA disease as an alternative suppressive mechanism.
Methods: Analyses were performed using flow cytometry on peripheral blood 
mononuclear cells (PBMCs) from 63 patients stained with relevant antibodies. Suppressive 
potential of CD33+ myeloid cells was assessed with a standard T cell suppression assay.
Results: Flow cytometric analysis of PBMCs revealed an increased population of 
lineage negative, HLA-DR negative, CD11bhigh and CD33+ myeloid cells in patients 
with ANCA disease compared to healthy controls (mean 2.72% versus 0.18% of PBMCs). 
This CD33+ myeloid cell population also contained MPO and PR3. Suppression assays 
utilizing patient CD33+ myeloid cells and autologous T cells have demonstrated variable 
suppressive capacities with the majority of patients exhibiting modest (30-60%) suppression.
Conclusions: CD33+ myeloid cells are increased in patients with ANCA disease and 
represent a potential source of T cell suppression not previously investigated. Intriguingly, 
the patients who demonstrated the highest frequency of CD33+ myeloid cells were those 
who had sequentially received rituximab and cyclophosphamide.
Funding: NIDDK Support
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Endothelial NF-κB Induction by ANCA-Activated Neutrophils  Mira Choi,1 
Adrian Schreiber,1 Claudia Eulenberg,2 Ralph Kettritz,1 Claus Scheidereit.3 
1Dept of Nephrology, Charité Berlin, ECRC, Berlin, Germany; 2Experimental 
and Clinical Research Center (ECRC), Berlin, Germany; 3Max-Delbruck 
Center, Berlin, Germany.
Background: Activation of the NF-κB/Rel family and subsequent transcriptional 
upregulation of inflammatory mediators plays a central role in vascular diseases. ANCA 
vasculitis is a inflammatory condition where ANCA-activated neutrophils (PMN) interact 
with the endothelium resulting in necrotizing vasculitis. We hypothesized that ANCA-
activated PMN promote endothelial NF-κB and vascular inflammation.
Methods: NF-κB activation was assessed by IκBα degradation, EMSA, RT-PCR 
and IHC. NF-κB was studied in renal tissue from mice and patients with ANCA-induced 
NCGN, ANCA-stimulated PMN and endothelial cells.
Results: In kidney extracts from mice in which we had induced anti-MPO Ab-mediated 
NCGN, we observed a significant correlation between the percentage of crescents and NF-
κB activity by EMSA (R2=0.72, n=20). Similar correlations were found for crescents and 
upregulation of the NF-κB dependent genes TNFa and IκBα. In renal biopsies from patients 
with ANCA-induced NCGN, we observed strong phospho-p65 staining in the glomerular 
convolute. Regarding the importance of PMN-EC interactions in ANCA vasculitis, we 
studied NF-κB activation in PMN and ECs in vitro. Low-dose TNFa priming resulted 
in little IκBα degradation in PMN, but this effect was not further increased by mAb to 
PR3/MPO. We studied NF-κB activation in EC when co-incubated with mAb-stimulated 
PMN and observed significant IκBα degradation in EC (n=10). We confirmed this with 
human ANCA preparations. Cell-free PMN supernatants were sufficient for endothelial 
NF-κB activation indicating that direct cell-cell contact was not required. Consequences of 
endothelial NF-κB activation were the upregulation of endothelial TNFa and IL-8 mRNA 
and its release as cytokines into the supernatant, which lead to increased recruitment and 
adhesion of new PMN.
Conclusions: Renal NF-κB activation and NCGN severity were closely correlated. Our 
in vitro data demonstrate that ANCA-activated PMN induce endothelial NF-κB activity 
thereby promoting vascular inflammation by recruiting more PMN. Inhibiting endothelial 
NF-κB may help limiting the ANCA-mediated damage.
Funding: Government Support - Non-U.S.
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Ubiquitin C-Terminal Hydrolase-L1 Controls Dendritic Cell Cross Priming 
of the CD8+ T Cell Response  Anna Reinicke,1 Malte Mühlig,1 Pina Schmucker,1 
Timo Lischke,2 Elisabeth Mettke,3 Christian Kurts,3 Hans-willi Mittrücker,2 
Catherine Meyer-Schwesinger.1  1Nephrology, III. Medical Clinic, Univ Medical 
Center Hamburg-Eppendorf, Hamburg, Germany; 2Immunology, Univ Medical 
Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Immunology, 
Inst for Experimental Immunology, Bonn, Germany.
Background: Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) is a central 
deubiquitinating enzyme of the ubiquitin proteasomal system. UCH-L1 is thought to regulate 
the pool of ubiquitin. Within the kidney, UCH-L1 is de novo expressed in glomerular 
podocytes in human and rodent glomerulonephritis. Mice with constitutive UCH-L1-
deficiency exhibit an exacerbated course of immune-complex nephritis suggesting that 
UCH-L1 affects the ability to mount an effective renal immune response. Aims of the study 
were 1. To identify the origin of renal tubulo-interstitial UCH-L1-expressing cells, 2. To 
analyze the response of UCH-L1-deficient mice to a bacterial infection, 3. To analyze the 
role of UCH-L1 in dendritic cells (DCs).
Methods: Constitutive UCH-L1-deficient mice were generated by Cre-Lox technology. 
The immunologic phenotype was investigated by challenging UCH-L1-deficient mice with 
Listeria monocytogenes. Cross presentation and cross priming assays were performed in 
vitro and in vivo. The DC phenotype was assessed in naïve and stimulated DCs by FACS, 
Western, proteasomal and deubiquitinase-based activity assays, and real-time PCR.
Results: UCH-L1 is expressed in DCs isolated from kidney and spleen, and in bone-
marrow derived cultured DCs. UCH-L1 expression in bmDCs is regulated by IFN-γ and 
LPS. UCH-L1 activity is upregulated by LPS stimulation while other deubiquitinating 
enzymes upregulate their activity in the absence of UCH-L1. DCs are specially equipped 
to cross present antigen to stimulate a CD8+ T cell response. Cross-presentation of 
cell-associated antigen in UCH-L1-deficient DCs is significantly reduced in vitro and 
in vivo while activation of a CD4+ T cell response is unaffected. Finally, exposure to L. 
monocytogenes results in a significantly decreased generation of antigen-specific CD8+ 
T cells.
Conclusions: We describe a hitherto unrecognized role for UCH-L1 in controlling 
CD8+ T cell activation by DCs.
Funding: Government Support - Non-U.S.
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CD103+ Dendritic Cells Elicit CD8+ T Cell Responses to Accelerate Kidney 
Injury in Adriamycin Nephropathy  Qi Cao,1 Qing Li,1 Xin M. Wang,2 
Chengshi Wang,1 Yuan Min Wang,3 Stephen I. Alexander,3 Yiping Wang,1 David 
C. Harris.1  1Centre for Transplant and Renal Research, Westmead Millennium 
Inst for Medical Research, The Univ of Sydney, Sydney, NSW, Australia; 2Flow 
Cytometry Facility, Westmead Millennium Inst for Medical Research, The Univ 
of Sydney, Sydney, NSW, Australia; 3Centre for Kidney Research, Children’s 
Hospital at Westmead, Sydney, NSW, Australia.
Background: CD103+ dendritic cells (DCs) in non-lymphoid organs exhibit two 
main types of function, namely maintaining tolerance by induction of regulatory T cells 
and protecting against tissue infection through activation of CD8 T cells. However, the 
characteristics and functions of CD103+ DCs in kidney remain unclear.
Methods: Adriamycin nephrosis (AN) was induced in BALB/c mice. The distribution, 
phenotype and function of kidney CD103+ DCs were assessed in normal and AN mice. 
CD103+ DCs were depleted by neutralizing CD103-saporin (SAP) antibody in AN mice 
to examine their role in vivo.
Results: In the present study, we showed that CD103+ DCs are one of four 
subpopulations of renal mononuclear phagocytes in normal kidney; they expressed DC-
specific surface markers, transcription factors and growth factor receptors, and were found 
in kidney cortex but not medulla. The number of kidney CD103+ DCs was significantly 
increased in mice with Adriamycin nephropathy (AN) and depletion of CD103+ DCs 
attenuated kidney injury in AN mice. The possible mechanisms underlying the pathogenic 
role of CD103+ DCs were examined. In vitro, kidney CD103+ DCs preferentially primed 
CD8 T cells, and did not directly induce tubular epithelial cell apoptosis. Adoptive transfer 
of CD8 T cells significantly exacerbated kidney injury in AN SCID mice, whereas depletion 
of CD103+ DCs impaired activation and proliferation of transfused CD8 T cells, and thereby 
reduced kidney injury in AN SCID mice treated with CD8 T cells.
Conclusions: Kidney CD103+ DCs display a pathogenic role via activation of CD8 
T cells in Adriamycin nephropathy.
Funding: Government Support - Non-U.S.
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Advanced Glycation End Products Induced the Imbalance Between Th17 
and Treg Cells via RAGE Pathway in Diabetic Nephropathy  Yanlin Zhang, 
Ao Cheng.  Dept of Nephrology, The First Affiliated Hospital of ;iamen Univ, 
Xiamen, Fujian, China.
Background: There was imbalance of Th17/Treg cells in patients with diabetic 
nephropathy, but the mechanism was still unclear. Advanced glycation products (AGEs) 
often accumulated in the patients with diabetic nephropathy, The main purpose of this 
experiment is to explore whether AGEs can cause the imbalance of Th17/Treg cells throug 
RAGE signaling pathway.
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Methods: (1) Recruitment of 20 healthy adults and 40 diabetic nephropathy patients of 
CKD stages 3 to 5, and detection AGEs content and ratio of Th17 cells / Treg cells to verify 
the correlation. (2) Prepared AGE-HSA in vitro and isolated and cultured the initial CD4+ 
T cells from healthy volunteers peripheral blood to explore the effect of AGE-HSA on the 
differentiation of initial CD4+ T cell: AGE-HSA with different dose and time stimulated 
initial CD4+ T cells, or pretreatment with RAGE-siRNA or RAGE neutralizing antibody, 
and to detect the ratio of Th17 cell and Treg cells by flow cytometry and determine the 
expression mRNA of RORgt and Foxp3, and the expression of mRNA and protein of 
STAT3 and HIF-1α.
Results: (1)In patients with diabetic nephropathy, there is accumulation of AGEs and 
increasing of Th17 cells and the reduction of Treg cells. The ratio of Th17 cells and Treg 
cell is imbalance (increase in the proportion). There was a positive correlation between the 
concentration of AGEs and ratio of Th17 cells and Treg cells; (2) the AGE-HSA in a dose 
dependent manner induced the initial CD4+ T cells to differentiate Th17 cells, and blocking 
RAGE could mitigate this effect; (3) AGE-HSA increased the expression of RORgt in the 
initial CD4+T cells, but had no effect on Foxp3. After blocking RAGE, it could inhibits 
the expression of RORgt induced by AGE-HSA; (4) the expression of STAT3 and HIF-1α 
was raised in the initial CD4+ T induced by AGE-HSA, while blocking RAGE, expression 
of STAT3 and HIF-1α. induced by AGE-HSA was inhibited.
Conclusions: In the patients with diabetic nephropathy, there was positively correlated 
between the content of AGEs and the proportion of Th17 cells and Treg cells, and AGE-HSA 
can induce the initial T CD4+ cells to generate Th17 cells by RAGE- RORgt signaling.
Funding: Government Support - Non-U.S.
FR-PO984
RORgt Activation in biTregs Promotes Lupus Nephritis  Malte A. Kluger, 
Anna Nosko, Paul Diefenhardt, Boeren Goerke, Matthias C. Meyer, Michael 
Luig, Rolf A. Stahl, Oliver M. Steinmetz.  Nephrology, Hamburg Univ Medical 
Center.
Background: We recently characterized Foxp3+ regulatory T cells, co-expressing the 
Th17 characteristic transcription factor RORgt, as an independent and bi-functional T cell 
lineage (biTregs). biTregs secrete both, anti-inflammatory (IL-10, IL-35), but also pro-
inflammatory (IL-17) cytokines. Studies in a model of acute crescentic glomerulonephritis 
suggest that pro-inflammatory biTreg functions are mediated by RORgt. This is of high 
clinical relevance, since multiple RORgt blocking agents are currently under development.
Methods: Systemic lupus erythematosus (SLE)/Pristane in biTregROR-mice.
Results: Time course analyses showed increasing infiltration of biTregs into kidneys 
of pristane injected mice with a maximum at around 5 months. Subsequently percentages 
decreased and were back to baseline at 8 months. To study the functional role of RORgt 
in biTregs, Foxp3Cre x RORCflox mice were generated (biTregROR-). Renal histology at 8 
months showed severe proliferative glomerulonephritis in pristane injected wild type mice. 
Histological injury in the biTregROR- group, in contrast, was significantly ameliorated. Renal 
leukocyte infiltration and albuminuria were also reduced by knockout of RORgt in biTregs. 
As one possible explanation for the improved outcome, we found that biTregs from wild 
type mice produced pro-inflammatory IL-17 at all observed time points, while biTregs from 
biTregROR- mice did not. In order to assess effects of biTreg expressed RORgt on development 
of systemic auto-immunity, we studied humoral immune responses. Analyses, however, 
showed unaltered serum anti-U1-RNP auto-antibody levels of all isotypes. Likewise, 
renal IgG and complement C3 deposition remained unchanged. This indicates that RORgt 
activation in biTregs directs renal injury by cellular effectors but does not play a major 
role for generation of humoral auto-immunity.
Conclusions: Our data provide first evidence for presence and functional importance of 
biTregs in SLE. Importantly, biTreg expressed RORgt was identified as a factor promoting 
development of renal injury. Our data therefore favor RORgt directed interventions as 
innovative new therapeutic option for lupus nephritis.
FR-PO985
IL-2/Anti-IL-2 Complex Attenuates Lupus Nephritis by Expansion 
of Regulatory T Cells  Hye Jin Lim, Ji-Jing Yan, Hyunjin Ryu, Tai Yeon 
Koo, Kyungok Min, Jae-Ghi Lee, Bohae Kang, Curie Ahn, Jaeseok Yang. 
Transplantation Center, Seoul National Univ Hospital, Republic of Korea.
Background: Regulatory T(Treg) cells play an important role in the pathogenesis and 
control of autoimmune diseases. Systemic lupus erythematosus(SLE) is an autoimmune 
disorder characterized by the production of antibodies to self-nucleic acids, immune 
complex deposition, and tissue inflammation such as glomerulonephritis. We therefore 
hypothesized that the IL-2/anti-IL-2 complex(IL-2C), a mediator of Treg expansion, can 
ameliorate progression and reduce the mortality of lupus-prone mice.
Methods: NZWB/F1 female mice progressively produce high levels of autoantibodies 
and resultant deposition of immune-complexes drives lupus-like glomerulonephritis. 
NZWB/F1 female mice were treated intraperitoneally with IL-2 /anti-IL-2 mAb(JES6-1) 
4 times a week starting at 24 weeks of age, and were analyzed at 36 weeks of age. Lupus-
like disease progression was assessed by measurement of proteinuria, dsDNA, cytokine 
levels and kidney histology,as well as by flow-cytometric analysis of cellular infiltration.
Results: IL-2C induced an effective and sustained expansion of CD4+Foxp3+CD25+ 
Tregs in both kidney and spleen. Compared with the vehicle-treated controls, NZWB/F1 
female mice treated with IL-2C showed less proteinuria, less acute and chronic pathological 
lesions in the kidney and better survival. There were significant differences in glomerular 
injury, tubular injury and vasculitis scores, as well as in the quantitative analysis of IgG 
and C3 deposition between the two groups. Disease activity markers were reduced in 
serum of the IL-2C group. IL-2C treatment reduced plasma cell populations in spleen, 
inhibition of B and T cell infiltration of the kidney tissue, and suppressed IFN-γ+CD4+ and 
Th17+CD4+cells in both spleen and kidney. When compared with combination therapy of 
steroid and mycophenolate mofetil, IL-2C treatment showed similar or better outcomes. 
Depletion of Tregs with anti-CD25 antibodies abrogated the beneficial effects of IL-2C.
Conclusions: IL-2C protects lupus-prone mice against lupus nephritis by expanding 
Tregs and suppressing inflammation. Therefore, IL2-C could have a therapeutic potential 
in lupus nephritis.
FR-PO986
Hyporesponsive T-Cell Phenotype Predicts a Subset of Focal Segmental 
Glomerulosclerosis (FSGS) Patients Responsive to Rituximab 
Chang-Yien Chan,1 Isaac Liu,1 Lourdes Paula Real Resontoc,1 Kar Hui Ng,1 
Yiong Huak Chan,1 Yew Weng Perry Lau,1 Stanley C. Jordan,2 Kong Peng Lam,3 
Wee Song Yeo,1 Hui Kim Yap.1  1Paediatrics, National Univ of Singapore, 
Singapore; 2Cedars Sinai Medical Center; 3Bioprocessing Technology Inst, 
A-Star, Singapore.
Background: Rituximab has been used with variable success in difficult FSGS, but the 
immunological basis of its efficacy is poorly characterized. This study aimed at identifying 
T-cell subsets in pediatric FSGS patients in order to define an immunological signature 
predictive of a favorable response to rituximab.
Methods: 22 FSGS patients (median age 14.4 years, range 6.2-25.0 years) were 
recruited prospectively to receive rituximab (375mg/m2 fortnightly to a maximum of 4 
doses). Median duration of follow-up was 26.7 months (range 6.5-66.6 months). Baseline 
immunological subsets were compared with 30 healthy controls, and subsequently examined 
for association with response to rituximab. Good response was defined as complete 
resolution of proteinuria accompanied by cessation of prednisolone and calcineurin 
inhibitors within 3 months.
Results: Of the 22 patients, 12 (54.5%) responded to rituximab therapy. Activated 
CD154+CD4+CD3+ subsets before rituximab were significantly lower in responders 
(54.9±8.10%) compared to non-responders (78.9±5.18%) (p=0.03) and controls 
(75.7±2.49%) (p<0.001). IFN-γ+CD3+ subsets were similarly decreased in responders 
(0.55±0.24%) compared to non-responders (7.21±2.11%) (p=0.005) and controls 
(12.4±2.15%) (p<0.001). IL-2+CD3+ subsets were also lower in responders(0.24±0.14%) 
compared to non-responders (4.42±1.59%) (p=0.007) and controls (6.3±1.5%) (p=0.003). 
Significant recovery of all 3 activation subsets occurred 3 months post-rituximab treatment.
Using ROC curve analysis, activatedCD154+CD4+CD3+ (AUC 0.82, 95% CI 0.63-1.00), 
IFN-γ+CD3+ (AUC 0.86, 95% CI 0.67-1.00) and IL-2+CD3+ (AUC 0.82, 95% CI 0.63-1.00) 
were good predictors of response to rituximab.
Conclusions: We have identified prognostic markers which define a subset of FSGS 
patients bearing an immunological signature representing hyporesponsiveness to T-cell 
stimulation, with good response to rituximab therapy.
FR-PO987
Cytokine Profiling in Rituximab-Treated Pediatric Focal Segmental 
Glomerulosclerotic Nephrotic Patients  Wee Song Yeo, Chang-Yien Chan, 
Hui Kim Yap.  Pediatrics, Yong Loo Lin School of Medicine, National Univ of 
Singapore, Singapore, Singapore.
Background: Focal segmental glomerulosclerosis (FSGS) is the most common 
histological pattern seen in pediatric steroid-dependent and steroid-resistant nephrotic 
patients. In recent years, rituximab is increasingly used in nephrotic patients who have 
failed therapy with conventional immunosuppressants. This study aimed to examine the 
cytokine profile in rituximab-treated pediatric FSGS nephrotic patients and elucidate the 
cytokine profile differences between responders and non-responders.
Methods: Our study population consisted of 13 pediatric FSGS patients who underwent 
rituximab therapy. Plasma cytokine profiling was performed on each of these patients 
utilizing multiplexed Luminex® Cytokine Human 27-Plex assay pre- and post-rituximab 
therapy. Statistical analysis was performed using Wilcoxon signed-rank test with a p-value 
of less than 0.05 considered as statistically significant.
Results: Five (38%) of the patients responded to rituximab, defined as having achieved 
complete resolution of proteinuria accompanied by cessation of prednisolone and calcineurin 
inhibitors within 3 months. All patients in the study demonstrated an increase in plasma 
interferon-gamma-inducible protein (IP)-10 levels post-rituximab therapy (554.3±62.4 pg/
ml (pre) vs 793.4±125.5 pg/ml (post), p=0.008). Comparing the cytokine profile between 
responders and non-responders, responders demonstrated a positive mean-fold change 
in macrophage inflammatory protein (MIP)-1α, in contrast to non-responders which 
demonstrated a negative mean fold change (0.23±0.16 vs -0.17±0.08, p=0.04). There were, 
otherwise, no noted significant differences in the other cytokines i) pre-/post-rituximab and 
ii) between responders and non-responders.
Conclusions: Our study results suggest the development of a pro-inflammatory state in 
our patients post-rituximab therapy.The increase in plasma IP-10 in patient post-rituximab 
may account for the phenomenon of rituximab-associated colitis. The finding of increased 
plasma MIP-1α in responders compared to non-responders is novel. Further mechanistic 
studies are required to ascertain the role of MIP-1α in the mechanism of action of rituximab.
Funding: Government Support - Non-U.S.
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FR-PO988
Gut-Kidney Axis in the Pathogenesis of IgA Nephropathy  Gabriella Lauriero,1 
Eustacchio Montemurno,1 Maria De angelis,2 Valentina Maranzano,1 Lucia 
Vannini,3 Loreto Gesualdo.1  1DETO-Nephrology Unit, Univ of Bari, Italy; 
2DiSSPA, Univ of Bari, Italy; 3Dept of Agricultural and Food Sciences, Univ 
of Bologna, Italy.
Background: IgA nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide. It is characterized by deposition of deglycosylated IgA1 and IgG antibodies 
in the glomeruli and its pathogenesis is only partially defined. Intestinal microbiota could 
be involved in IgAN, as suggested by the observation that B-cell activation factor (BAFF) 
transgenic mice had high levels of aberrantly glycosylated serum polymeric IgA, the 
presence of commensal flora and the circulation of corresponding specific IgA antibodies 
being essential for the development of IgA deposits. BAFF is an important regulator of B 
cell maturation, survival and function. The aim of the study was to analyze the role played 
by gut-kidney axis in the pathogenesis of IgAN.
Methods: 16 healthy controls (HC) and 32 IgAN patients (16 non progressors - NP 
and 16 progressors - P) were included in the study. Serum creatinine, estimated Glomerular 
Filtration Rate, 24h-proteinuria and histological lesions following Oxford Classification 
(MEST score) were analyzed. Gut microbiota, urinary and fecal metabolome of all subjects 
were characterized by 16S sequencing, Biochrom 30 series amino acid analyzer and 
gas-chromatography mass spectrometry/solid-phase microextraction (GC-MS/SPME). 
Galactose-deficient IgA1 (Gd-IgA1) were measured by helix aspersa agglutinin binding 
assay. BAFF serum levels were quantified by ELISA.
Results: Some traits of the gut microbiota and urinary and fecal metabolome profiles 
significantly differed between P, NP and HC. Gd-IgA1 and BAFF were significantly higher 
in IgAN patients, particularly in P, compared to HC (Gd-IgA1: p £0.01 P vs HC; p £0.05 
NP vs HC; BAFF: p £0.01 P vs HC). IgAN patients with histological grade at diagnosis 
M1, E1, S1 and T1 had significantly higher levels of serum BAFF than HC. Moreover, 
serum BAFF levels were positively correlated with 24h-proteinuria (r =0.47, p =0.0069) 
and with the levels of fecal phenolic metabolites (r =0.61, p =0.0003).
Conclusions: Gut-kidney axis might play an important role in the pathogenesis of IgAN.
FR-PO989
Intestinal Macrophages Polarized to Activation of Pro-Inflammatory and 
Had Dysfunction of Phagocytosis Leading to Aggravate Microinflammation 
and Assist Bacterial Translocation as Carrier in Uremia Rats  Lingshuang Sun, 
Hongli Jiang, Hua Liu, Meng Wei.  Dialysis Dept of Nephrology Hospital, First 
Affiliated Hospital of Medicine School.
Background:  This study investigated whether intestinal macrophages are related 
to low-grade inflammation and bacterial translocation (BT) during uremia, and whether 
probiotics can alter the macrophage activity.
Methods:  Male Sprague-Dawley rats were randomly divided into 3 treatment groups: 
sham, uremia (untreated), and uremia + probiotic.The expression of cell surface antigen 
CD11a (a.k.a., lymphocyte function-associated antigen 1 [LFA1]), inducible nitric oxide 
synthase (iNOS), ICAM1, and TGF-β were analyzed by immunohistochemistry. Gene 
and protein expression of early growth response protein 1 (EGR1) and TLR4 in intestinal 
specimens were determined. Density of labeled macrophages and tracer bacteria in 
intestinal and extraintestinal tissues were examined by immunofluorescent microscopy, 
and macrophage micromorphology were examined by transmission electron microscopy.
Results: Intestinal segments ofthe uremia exhibited markedly high intensity of CD11a, 
iNOS, ICAM1, and TGF-β staining. Gene and protein expression levels of intestinal TLR4 
and EGR1 were also highest in this group. Intestinal segments of uremic rats exhibited high 
density and broad distribution of tracer bacteria and macrophages. Intestinal macrophages 
in untreated rats showed fewer cytoplasmic protrusions and pseudopodia. Administration 
of probiotics resulted in restoration of macrophage classic activation and phagocytosis that 
was associated with a reduction in BT.
Conclusions:  In the uremic state,intestinal macrophages are polarized toward a 
proinflammatory phenotype that results in low-grade inflammation. Abnormal intestinal 
macrophage activation and impaired phagocytic function are associated with increased BT. 
Probiotics may reduce BT by enhancing phagocytosis of intestinal macrophages.
Funding: Government Support - Non-U.S.
FR-PO990
Linking Pi3K/AKT Signaling to RNase 7 Production and Urinary Tract 
Sterility  Tad Eichler, Robert Easterling, Brian Becknell, John David Spencer. 
The Research Inst at Nationwide Children’s, Columbus, OH.
Background: Antimicrobial peptides (AP) play a role in shielding the uroepithelium 
from uropathogenic E. coli (UPEC). We have identified RNase 7 (R7) as a potent, epithelial-
derived AP that is secreted by the bladder urothelium and renal intercalated cells. R7 serves 
as front-line shield to protect the urothelium from UPEC. Currently, there is a limited 
understanding of the mechanisms that regulate R7 production, and if dysregulated R7 
production increases UTI risk. Using a chemical inhibitors transcriptome PCR array, we 
identified the PI3K/AKT pathway as a unique regulator of R7. Here, we confirm that PI3K/
AKT regulates R7 expression and relate changes in R7 to UTI pathogenesis.
Methods: To evaluate the role of PI3K/AKT in regulating R7, we treated primary human 
renal epithelial cells (REC) with insulin, a known PI3K agonist and/or insulin+wortmannin 
(wort), a PI3K/AKT inhibitor. PI3K/AKT activation was confirmed by Western blot. qRT-
PCR and ELISA quantitated R7. UPEC growth in insulin and/or insulin+wort treated REC 
media was assessed. Since patients with diabetes mellitus (DM) have decreased PI3K/AKT 
activity and increased UTI risk, we measured serial urinary R7 levels in new onset Type 
1 DM (n=16) before and after starting insulin.
Results: Insulin-dependent phosphorylation of the PI3K/AKT in REC was detected by 
1hr. Insulin induced R7 gene expression and protein expression 3-fold (25.23±3.61ng/mL 
to 72.12±16.20ng/mL, p=0.026). R7 induction was abolished with wort, confirming PI3K/
AKT involvement in R7 production. Media from insulin treated REC suppressed UPEC 
growth compared to media from REC pretreated with wort or vehicle control, suggesting 
that PI3K/AKT and R7 is involved in UTI pathogenesis. Urinary R7 levels were significantly 
lower in DM patients compared to healthy controls (13.61±3.94 vs 71.95±15.40ng R7/mg 
UCr, p<0.02). After 24-hr of insulin, urinary RNase7 levels increased.
Conclusions: PI3K/AKT activation is required for R7 induction. R7 induction 
suppresses UPEC growth. Diabetics, with decreased PI3K activity, have lower urinary R7 
levels. These data may indicate why UTIs are more prevalent with DM and may provide 
new regulatory targets for UTI treatment.
Funding: NIDDK Support
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Serum Acetate and Lipopolysaccharide Levels Correlate with Disease 
Activity in Patients With Lupus Nephritis  Daniel Tak Mao Chan, Ping Lung 
Chan, Qing Zhang, Kin Yi Au, Desmond Y.H. Yap, Mel Chau, Susan Yung. 
Dept of Medicine, The Univ of Hong Kong, Hong Kong.
Background: Lupus nephritis is a severe manifestation of systemic lupus erythematosus 
and is associated with poor prognosis. The gut microbiota has been implicated in the etiology 
of autoimmune diseases. Bacterial products from the gut may enter the circulation and 
induce inflammatory responses. Acetate is a short chain fatty acid (SCFA) produced by gut 
microbiota and lipopolysaccharide (LPS) is a component of the outer wall of Gram-negative 
bacteria. We measured serum acetate and LPS levels and intra-renal expression of their 
cell surface receptors in lupus nephritis patients to investigate the potential relationship 
between gut microbiota and lupus nephritis pathogenesis.
Methods: Serum acetate and LPS levels were measured in patients with biopsy-proven 
severe proliferative lupus nephritis, patients with non-lupus glomerular diseases and healthy 
controls (n=50 for each group). Intra-renal expression of LPS-binding protein (LBP) and 
GPR-41 and GPR-43 (SCFA receptors) was also examined.
Results: Serum acetate and LPS levels were significantly higher in patients with lupus 
nephritis compared to levels in patients with non-lupus renal diseases (P<0.05, for both) 
and healthy subjects (P<0.01, for both). In lupus nephritis patients, serum acetate and LPS 
levels were significantly higher during disease flare (P=0.04 and P=0.0015 respectively 
compared to levels during remission). Serum LPS level correlated with acetate level (r=0.52, 
P<0.001), and inversely correlated with that of IgG (r=-0.61, P<0.01). Renal LBP, GPR-
41 and GPR-43 expression was markedly increased in lupus nephritis patients compared 
to healthy controls, and was predominantly detected in the tubulo-interstitium, associated 
with inflammatory cell infiltration, fibrosis and tubular atrophy. LBP, GPR-41 and GPR-
43 expression showed similar staining intensities and localization in patients with lupus 
nephritis and those with non-lupus renal diseases.
Conclusions: Our data suggest that acetate and LPS may be involved in the 
pathogenesis of lupus nephritis and non-lupus glomerular diseases.
Funding: Government Support - Non-U.S.
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Noninvasive Assessment of Macrophage Activation in Experimental 
Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves 
as a Surrogate of Disease Activity  Sebastian Braehler, Dongyue Huang, 
Matthew David Cheung, Walter J. Akers, Alfred Hyoungju Kim.  Washington 
Univ School of Medicine, St. Louis, MO.
Background: Glomerulonephritis (GN) represents a major cause of morbidity & 
mortality. The standard for diagnosing GN is through renal biopsy, but this is not performed 
uniformly across many centers. There is an unmet need to identify a noninvasive approach 
for recognizing GN. Recent advances in deep tissue imaging using probes detected by 
near-infrared (NIR) wavelengths have enabled the noninvasive probing of biologic activity. 
Macrophage infiltration of the kidney is observed in early GN and once activated, express 
the cysteine protease cathepsin B. Thus, renal macrophage activation can be assessed 
using an NIR probe that becomes fluorescent upon cleavage by cathepsin B. We tested the 
ability of using NIR optical imaging to assess renal macrophage activation as a noninvasive 
marker for early-stage GN.
Methods: GN was induced in 129 mice by nephrotoxic serum (NTS) delivered 
intravenously (IV). Proteinuria was assessed using albumin ELISA & chromogenic 
creatinine assay. H&E and PAS stained slides of mouse kidneys were observed using light 
microscopy. Presence of renal macrophages was confirmed using FACS. NIR optical 
imaging of anesthetized mice was performed following IV administration of a cleavable 
sensor for cathepsin B & fluorescence intensity of kidney regions quantified.
Results: In mice with uninflamed kidneys, we confirmed the paucity of renal 
macrophages. Accordingly, there was minimal renal fluorescence signal as determined by 
fluorescent molecular imaging of cathepsin B activity. 3 days post-NTS administration, 
we observed a massive influx of macrophages into the kidney, along with nephrotic range 
proteinuria. This correlated with a significant increase in renal fluorescence intensity signal 
in NTS mice compared to control mice.
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Conclusions: Induction of GN by NTS caused significant macrophage infiltration, 
which was detected noninvasively by a cathepsin B-activatable probe and NIR optical 
imaging. These data establish the proof-of-principle that NIR optical imaging may represent 
a translatable approach to establishing early stages of GN.
Funding: Private Foundation Support
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Improved Tissue Clearing and 2-Photon Imaging of Mouse Kidneys Reveals 
Immune Cell Architecture in Nephrotoxic Nephritis  Matthew David Cheung, 
Dongyue Huang, Alfred Hyoungju Kim.  Rheumatology, Washington Univ 
School of Medicine, St. Louis, MO.
Background: Tissue clearing approaches such as CLARITY renders tissue transparent, 
and in combination with two-photon microscopy, enables microscopic visualization deep 
internal structures within unaltered organs. These cutting edge approaches have drastically 
improved the understanding of cellular circuits in the brain. However, application of this 
approach has only recently been described for the kidney. Here, we clear mouse kidneys 
to better understand the immune cell architecture following induction of nephrotoxic 
nephritis (NTN) using a modified lipid removal approach that also worked for human 
kidney fragments.
Methods: 129 mice were injected intravenously with nephrotoxic serum to induce 
NTN. Mice were perfused with an acrylamide monomer solution to form the basis of the 
hydrogel. Lipid removal was accomplished using 8% sodium dodecyl sulfate (SDS). An 
aminoalcohol solution was used to quench light absorbing heme in red blood cells trapped 
within the tissue. Cleared mouse kidneys were stained with antibodies specific for B cells, 
T cells, macrophages, and dendritic cells (DCs). Human kidney fragments were incubated 
in acrylamide monomer solution, then cleared as mentioned above. Cleared tissue was 
imaged using two-photon microscopy.
Results: Compared to previously published protocols, perfusion of acrylamide 
monomers into mice significantly accelerated the tissue clearing process. Enhanced tissue 
clearing was observed when we incubated kidneys in aminoalcohols. We observed vast 
networks of lymphocytes, macrophages, and DCs in cleared NTN kidneys compared to 
control kidneys. Human kidneys also were cleared using this approach, and we noted DC 
networks in healthy donor controls.
Conclusions: We identified a new protocol that enhanced and accelerated tissue 
clearing in mouse and human kidneys. Using this approach, we found elaborate networks 
of lymphocytes and monocyte-derived cells in NTN mouse kidneys. We also observed DC 
networks in healthy human kidney donor fragments. These data demonstrate the utility of 
tissue clearing in evaluating cellular architecture in mouse and human kidneys.
Funding: Private Foundation Support
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Natural IgM Mediates Ischemic AKI  Lindsey R. Goetz,1 Jennifer Laskowski,1 
Brandon Renner,1 Rachel A. Woolaver,1 Liudmila Kulik,1 Kazue Takahashi,2 
Matthew C. Pickering,3 Joshua M. Thurman.1  1Dept of Medicine, Univ of 
Colorado Denver School of Medicine, Aurora, CO; 2Dept of Radiology, 
Massachusetts General Hospital, Boston, MA; 3Centre for Complement and 
Inflammation Research, Imperial College London, London, United Kingdom.
Background: Glomerular IgM deposition occurs in numerous “non-immunologic” 
kidney diseases and has been shown in chemical and inflammatory models of injury. We 
recently demonstrated that complement activation within the kidney leads to neo-epitope 
formation. Because the alternative complement pathway is activated in renal ischemia/
reperfusion (I/R) injury, we hypothesized that complement activation during renal 
I/R generates neo-epitopes recognized by natural IgM antibodies that then exacerbate 
inflammatory injury.
Methods: To investigate this hypothesis, we used a 24 minute I/R model.
Results: We first subjected soluble IgM deficient (sIgM-/-) mice to renal I/R and found 
a trend toward less severe injury in these mice vs. wild type (wt) controls (mean BUN of 
135 ± 39 [SD] and 152 ± 26 mg/dL, respectively; n ≥ 6, p = NS). To accentuate complement 
activation in this model, we then exposed mice heterozygous for complement regulatory 
protein factor H (fH+/-) to the same I/R protocol and found that the fH+/- mice sustained worse 
renal injury and had greater glomerular IgM deposition than wt controls (mean BUN of 114 
± 46 and 63 ± 48 mg/dL, respectively; n ≥ 14, p = 0.009 and mean glomerular IgM RFUs of 
44 ± 7 and 22 ± 7, respectively; n = 8, p = 0.0002). To further evaluate IgM pathogenicity, 
we induced I/R injury in mice deficient in both factor H and IgM (fH+/-/sIgM-/-) and noted 
a trend toward attenuation of renal injury in the fH+/-/sIgM-/- vs. fH+/- mice (mean BUN of 
106 ± 69 and 127 ± 52 mg/dL, respectively; n ≥ 7, p = NS) with data collection ongoing.
Conclusions: These data suggest that natural IgM contributes to ischemic renal injury 
by binding neo-epitopes generated during complement activation in the kidney. This adds 
to a growing body of evidence suggesting a common final pathway of IgM-mediated 
glomerular injury in a variety of “non-immunologic” renal disorders and offers a novel 
therapeutic target for the treatment of these diseases.
Funding: NIDDK Support
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Activation of Toll-Like Receptor 2 in the Pathogenesis of Contrast-Induced 
Nephropathy  Kristina Angela Rathmell,1 Altaf-M Khan,1 Federico Jose Teran,1 
Kathleen S. Hering-Smith,1 Eric E. Simon,1,2 Vecihi Batuman.1,2  1Medicine, 
Nephrology & Hypertension, Tulane Univ, School of Medicine, New Orleans, 
LA; 2VA, SLVHCS, New Orleans, LA.
Background: Innate immunity mediated by Toll-like receptors (TLRs) is involved in 
the pathophysiology of contrast-induced nephropathy (CIN). We studied the expression 
of TLRs and associated molecules in CIN using human renal proximal tubule epithelial 
cells (RPTECs) and aged diabetic (db/db) mice.
Methods: We cultured RPTECs in normal (5 mM) or high (35 mM) glucose media 
for 24 h and then exposed them to nonionic (iodixanol or iohexol) and ionic (Urografin) 
contrast media (CM) at a dose of 25–100 mg iodine/ml for another 24 h in the same media. 
24-wk-old male db/db mice were given nonionic CM i.v. (3 g of iodine/kg bw) after 24 h 
water deprivation. All mice were sacrificed 24 h after CM injection.
Results: The mRNA expressions of TLR2 increased by 2.5 fold (p < 0.05), TICAM-1 
by 1 fold (p < 0.01) and TNF-α by 1.7 fold (p < 0.05) in RPTECs exposed to iohexol 
compared to untreated RPTECs in a dose-dependent fashion. RPTECs in high glucose 
for 48 h and exposed to iodixanol showed significantly increased apoptosis compared to 
RPTECS in normal glucose. 24-wk-old db/db mice became obese, polyuric, glucosuric, 
ketonuric, and had increased GFR, systolic blood pressure, urine NGAL, and renal tubular 
damage compared to nondiabetic (db/m) control mice. 24 h after iohexol injection, db/db 
mice showed a significant decrease in GFR, metabolic acidosis and significant increases 
in serum creatinine, urine and kidney KIM-1 levels and kidney damage histologically 
compared to control db/db mice. After iohexol administration, the mRNA level of TLR2 
was significantly increased by 2.4 fold (p < 0.01) in kidney compared to control mice but 
there was no change in TLR4 expression. The expression of CD11b and CD68 were also 
significantly upregulated in kidney.
Conclusions: High glucose RPTECs and diabetic (db/db) mice are vulnerable to 
CIN. Innate immunity mediated by TLR2 plays a major role in the pathogenesis of CIN 
as demonstrated by in vitro and in vivo studies. TLR2 may prove to be a promising drug 
target for the development of new therapeutics against CIN.
Funding: Private Foundation Support
FR-PO996
Heparanase Deficiency Improves Renal Function During Experimental 
Glomerulonephritis  Marjolein Garsen,1 Marilen Benner,1 Henry Dijkman,2 
Jin-ping Li,3 Ton J. Rabelink,4 Israel Vlodavsky,5 Jo H.M. Berden,1 Angelique 
Rops,1 Michael Elkin,6 Johan Van der vlag.1  1Nephrology, Radboud Univ 
Medical Center, Nijmegen, Netherlands; 2Pathology, Radboud Univ Medical 
Center, Nijmegen, Netherlands; 3Medical Biochemistry and Microbiology, 
Uppsala Univ, Uppsala, Sweden; 4Nephrology, Leiden Univ Medical Center, 
Leiden, Netherlands; 5Cancer and Vascular Biology Research Center, Bruce 
Rappaport Faculty of Medicine, Haifa, Israel; 6Sharett Inst, Hadassah-Hebrew 
Univ Medical Center, Jerusalem, Israel.
Background: Heparanase (HPSE), a heparan sulfate (HS)-specific endoglucuronidase, 
mediates the onset of proteinuria and renal damage during experimental diabetic 
nephropathy. Glomerular HPSE expression is increased in the majority of proteinuric 
diseases. The exact role of HPSE in the development of other inflammatory glomerular 
diseases is still unknown.
Methods: Here, we evaluated the role of HPSE in two models of experimental 
glomerulonephritis, being anti-glomerular basement membrane and lipopolysaccharide 
(LPS)-induced glomerulonephritis, in wild type (WT) and HPSE-deficient mice.
Results: Induction of experimental glomerulonephritis led to an increased HPSE 
expression in WT mice, which was associated with a decreased glomerular HS expression 
and albuminuria. Albuminuria was reduced in the HPSE-deficient mice in both models, 
which was accompanied by a better renal function and less renal damage. Notably, 
glomerular HS expression was preserved in the HPSE-deficient mice. Glomerular leukocyte 
and macrophage influx was reduced in the HPSE-deficient mice, which was accompanied 
by a reduced expression of both Th1 and Th2 cytokines. In vitro, tumor necrosis factor 
(TNF)-α and LPS directly induced HPSE expression and increased transendothelial albumin 
passage in a HPSE-dependent manner.
Conclusions: Our study shows that HPSE deficiency ameliorates proteinuria and renal 
damage in experimental glomerulonephritis by preserving glomerular HS expression, and 
reducing leukocyte and macrophage influx, and by affecting the local cytokine milieu.
FR-PO997
Iron Chelation as a Novel Renoprotective Strategy in Lupus Nephritis 
Erika I. Boesen.  Cellular & Integrative Physiology, Univ of Nebraska Medical 
Center, Omaha, NE.
Background: Poorly liganded iron damages tissue via several mechanisms. Multiple 
iron homeostasis proteins have been proposed as urinary biomarkers of lupus nephritis, and 
we have previously found that renal tissue iron levels are increased in the (NZBxNZW)F1 
mouse model of lupus nephritis. Anemia is also common in lupus patients. Together, these 
data suggest that dysregulation of body iron homeostasis may occur in lupus. This pilot 
study tested whether (i) iron chelation is renoprotective in the (NZBxNZW)F1 model of 
lupus nephritis, and (ii) whether this therapy adversely affects hematological parameters.
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Methods: Female (NZBxNZW)F1 mice were treated with the iron chelator deferiprone 
from 20 weeks of age onwards. Albuminuria was monitored in 24h urine samples 
collected weekly, and mice were sacrificed at >2+ (>100mg/dL by dipstick) or 40 weeks 
of age, whichever was sooner. Hematocrit, red cell hemoglobin, plasma non-heme iron 
concentration as well as kidney and liver iron concentrations were measured at sacrifice.
Results: As shown in Figure 1, there was a trend towards later onset of albuminuria in 
deferiprone-treated mice compared with vehicle treated mice (median onset of albuminuria 
39 and 32 weeks, respectively). 
Liver iron concentration was significantly lower in deferiprone-treated mice 
than vehicle-treated mice, consistent with effective iron chelation. Renal cortical and 
outer medullary iron concentrations were not significantly different between groups. 
Unexpectedly, hematocrit was significantly improved by treatment with deferiprone (48±1% 
versus 39±3% in vehicle-treated mice; P<0.01), whereas red cell hemoglobin and plasma 
non-heme iron concentrations were not different between groups.
Conclusions: Our pilot data suggest that iron chelation may delay the onset of 
albuminuria in a mouse model of lupus nephritis without adversely affecting hematological 
parameters.
Funding: Private Foundation Support
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IKK2 Inhibition Inhibits the Initiation, but Aggravates the Progression 
of Crescentic Glomerulonephritis  Janine Gotot,1 Eveline Piotrowski,2 
Gisa Tiegs,3 Ulf Panzer,2 Christian Kurts,1 Friedrich Thaiss.2  1Rheinische 
Friedrich-Wilhelms-Univ, Inst of Experimental Immunology, Bonn, Germany; 
2Universitätsklinikum Hamburg-Eppendorf, III Medizinische Klinik, Hamburg, 
Germany; 3Univ Medical Center Hamburg-Eppendorf, Inst of Experimental 
Immunology and Hepatology, Hamburg, Germany.
Background: The NFκB transcription factor family facilitates the activation of dendritic 
cells (DC) and CD4+ T helper (Th) cells, which are important for protective adaptive 
immunity. Inappropriate activation of these immune cells may cause inflammatory disease, 
and NFκB inhibitors are promising candidate drugs.
Methods: Here, we investigated whether inhibiting the NFκB component IKK2 can 
attenuate crescentic glomerulonephritis, a severe DC- and Th cell-dependent kidney disease 
by induction of the paasive and the accelerated NTN mouse model.
Results: Prophylactic pharmacological IKK2 inhibition reduced DC activation, Th 
cell activation and ameliorated glomerulonephritis in mice. However, therapeutic IKK2 
inhibition during ongoing disease, which is relevant for clinical situations, unexpectedly 
aggravated the nephritogenic immune response and disease symptoms. This resulted from 
systemic loss of regulatory T cells (Treg), which have been previously shown to protect 
against crescentic glomerulonephritis and which require IKK2 as well.
Conclusions: In conclusion, although IKK2 inhibition can suppress the induction of 
nephritogenic immune responses in vivo, it may aggravate such responses in clinically 
relevant situations, because it also impairs Treg and thereby unleashes pre-existing 
nephritogenic responses. Our findings argue against using IKK2 inhibitors in chronic 
glomerulonephritis, and perhaps also in other immune-mediated diseases.
Funding: Government Support - Non-U.S.
FR-PO999
Transfused M2 Macrophages Ameliorate Renal Injury in Murine 
Nephrotoxic Serum Nephritis  Qiuna Du, Naotake Tsuboi, Yutaka Sugiyama, 
Seiichi Matsuo, Shoichi Maruyama.  Nephrology, Nagoya Univ Graduate School 
of Medicine, Nagoya, Japan.
Background: Glomerular leukocyte infiltration is a hallmark of glomerulonephritis. 
In addition to the effector roles of glomerular macrophages (Mࢥ) for tissue injury, recent 
studies found involvement of alternatively activated macrophages (M2 Mࢥ) in resolution 
of kidney inflammation. The aim of this study is to directly assess the potential of M2 Mࢥ 
to protect against renal injury in murine nephrotoxic serum (NTS) nephritis.
Methods: Bone marrow (BM)-derived Mࢥ and mouse iPS-derived Mࢥ were obtained 
under the stimulation of IL-4/IL-13 to differentiate M2a Mࢥ with high expression of 
CD206. FACS and RT-PCR were performed to assess efficient Mࢥ differentiation. 0.6 x 
10A6 of M2a Mࢥ were intravenously transferred 4 days after NTS nephritis induction. 
Immunostaining was used to detect Mࢥ, T cell and neutrophil infiltration. Renal cytokines 
were determined by ELISA. BM-derived M2a Mࢥ from EGFP transgenic mice (EGFP+M2a 
Mࢥ) was exploited to investigate the cell distribution.To investigate in vitro function of 
M2a Mࢥ on other leukocyte subsets, BM-derived M1 Mࢥ and splenic CD4+CD25-T cell 
were co-cultured with EGFP+M2a Mࢥ.
Results: M2a Mࢥ expressed higher levels of arginase-1 and IL-10/IL-12 mRNAs 
than M0 Mࢥ. Proteinuria was significantly attenuated by injection of M2a Mࢥ compared 
with disease-control mice at day 14 and day 21. Treatment with M2a Mࢥ prevented 
glomerular neutrophil and T cell accumulation. In addition, renal levels of IL-6, MCP-
1, IL-1β and TNF-α were significantly decreased in M2a Mࢥ-treated mice on day 21. 
EGFP+ M2a Mjs were seen in the kidney and spleen 24h after cell injection.M1 Mjs 
were demonstrated phenotypic conversion to an M2a cells following the co-culture with 
EGFP+M2a Mࢥ, while EGFP+M2a phenotype was relatively stable. M2a Mࢥ suppressed 
T-cell proliferation and promoted induction of Tregs in vitro. Immunostaining displayed 
that Foxp3+ T cells were significantly increased in spleen in mice treated with M2a Mࢥ 
compared with disease control group.
Conclusions: Administration of M2 Mࢥ may have therapeutic potency for glomerular 
injury by further M2 cell conversion and induction of regulatory T cells.
FR-PO1000
Electroacupuncture (EA) and Moxibustion (MO) Decrease the Mortality 
Rate and Attenuate Inflammation on Already Established Chronic Kidney 
Disease  Josne Carla Paterno, Marcelo Andery Naves, Rafael Luiz, Nestor 
Schor, Vicente De paulo castro Teixeira.  Nephrology, UNIFESP/EPM, Sao 
Paulo, Brazil.
Background: Chronic kidney disease (CKD) is now considered a serious worldwide 
public health and associated high morbidity and mortality. Traditional Chinese Medicine 
(TCM) has been increasingly recognized as an effective therapeutic in several fields of 
medicine. Among its therapeutic strategies are electroacupuncture (EA) and moxibustion 
(MO). The aim of this study was to investigate the effects of EA and MO on inflammatory 
factors in CKD model.
Methods: Male wistar rats were submitted to 5/6 nx and divided into three groups: 
Control (NX): only 5/6 nx; Sham-EA-MO (NX-Sham): 5/6 nx and twice weekly 30 min 
EA-MO session in sham-points; and EA-MO (NX-ACUP): 5/6 nx and twice weekly 30 min 
EA-MO session in three real acupuncture points. All procedures began 4 weeks after 5/6 
Nx, when the chronic lesions were already established. We measured 24h-proteinuria, tail 
cuff blood pressure (TBP), renal transforming growth factor-βeta1 (TGF-β1), IL-1, IL-6, 
IL-2,MCP-1 and mortality rate. The statistical significance of the results was evaluated by 
ANOVA followed by Tukey test. Values were expressed as mean± SD.
Results: 
Parameters NX NX-Sham NX-ACUP
24h-proteinuria (mg/24h) initial 11.4±4.1 12.7±3.1 12.3±4.7
24h-proteinuria (mg/24h) final 198.7±15.3 175.8±9.8 78.3± 10.2*
TBP (mmHg) initial 104.7±6.8 107±8.4 106.5±9.6
TBP (mmHg) final 237.9±13.3 219.9±14.9 135.9±10.7*
TGF-β1 (pg/mL) 572.4±39.2 581.3±45.7 347.9±39.8*
IL-1 (pg/mL) 137.8±11.8 130.8±12.8 40.4±10.9*
IL-2 (pg/mL) 397.8±41.1 391.8±39.8 220.6± 61.2*
IL-6 (pg/mL) 335.8±59.5 297.7±52.6 188.4±54.1*
MCP-1 (pg/mL) 379.6±53.4 369.1±58.3 214.5±43.5*
Mortality Rate (%) 58.9±7.8 54.3±8.9 17.7±6.3*
*(p=<0.05) vs NX and NX-Sham
Conclusions: EA and MO modulated immune and inflammatory responses in CKD, 
leading to lower production of intrarenal TGF-β1, IL-1, IL-6, IL-2, MCP-1 and decrease 
mortality rate. Thus, it is reasonable to suggest that EA and MO could be an additional 
strategy to be employed in CKD.
Funding: Government Support - Non-U.S.
FR-PO1001
A Randomized Multicomponent Intervention to Reduce Disparities in 
Transplant Referral: Results from the RaDIANT Community Study 
Rachel E. Patzer,1 Leighann Sauls,2 Jennifer C. Gander,1 Laura Plantinga,1 
Sudeshna Paul,1 Eric M. Gibney,3 Laura L. Mulloy,4 Stephen O. Pastan.1 
1Emory Univ; 2Southeastern Kidney Council; 3Piedmont Hospital; 4Georgia 
Regents Univ.
Background: The Reducing Disparities In Access to kidNey Transplantation 
(RaDIANT) Community Study is a dialysis facility-level randomized clinical trial to test 
the effectiveness of a multicomponent intervention in improving kidney transplant (KTx) 
referral and reducing racial disparities in referral in Georgia.
Methods: In 2013, 134 dialysis facilities were randomized to receive either usual 
KTx education (n=67) or a multicomponent intervention conducted by, consisting of 
KTx education and engagement activities targeting dialysis facility leadership, staff, and 
patients (n=67) over 12 months. Paired t tests, overall and by race [white and African-
American (AA)], were used to compare referral at 9 months of intervention vs. baseline, 
in intervention and control facilities.
Results: Facilities that received the intervention had a greater absolute increase in 
referral over 9 months than facilities that performed usual KTx education (+7.8% vs. -2.5%).
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A total of 51 of the 67 (76.1%) intervention facilities improved their percentage of 
patients referred for KTx over the 9 month study period. Intervention vs. control facilities 
had a greater increase in referral among AA (+7.3% vs. -2.5%) than white (+0.4% vs. -1.2%) 
patients over 9 months. Among the 26 dialysis facilities that had an AA vs. white racial 
disparity in referral at baseline, 69.2% no longer had a racial disparity in referral by 9 months.
Conclusions: Data from RaDIANT Community Study intervention facilities suggest 
that a large, randomized, quality improvement program among dialysis facilities in GA 
may improve KTx access. Availability of data after 12 months of the intervention will allow 
final assessment of the effectiveness of the intervention.
FR-PO1002
Association of Neighborhood Poverty and Living Donor Kidney Transplant 
Rates by Race  Douglas Scott Keith, Angie G. Nishio-Lucar, Gayle M. Vranic. 
Medicine, Univ of Virginia, Charlottesville, VA.
Background: Despite a growing shortage of deceased donor kidneys in the US, living 
donation (LD) rates have declined steadily since 2004. We sought to understand the impact 
of candidate socioeconomic environment on living donation rates.
Methods: We identified all candidates listed for kidney or kidney pancreas transplant in 
the SRTR database from 2000-2010. Data was linked to US census data on median income 
by zip code. Candidate zip code of residence was used as a surrogate for neighborhood 
poverty. Univariate and Cox regression analyses were performed to evaluate the independent 
effects of candidate age, race/ethnicity [Caucasian, African American (AA), Hispanics, 
Asian, Other], gender, etiology of ESRD, dual listing for pancreas, level of educational 
attainment, insurance type, PRA, initial listing status (active vs. inactive), dialysis status at 
listing, first organ procurement organization of listing, year of listing, and median income 
of zip code by decile. Sensitivity analyses comparing zip code to candidate insurance 
type and educational status, other markers of socioeconomic status, were performed and 
yielded similar results.
Results: Increasing median income of candidate zip code was associated with higher 
rates of LD for all racial and ethnic groups. Overall LD rates were highest among Caucasians 
followed by Hispanics and Asians. AA had by far the lowest overall LD rates with LD rates 
of AA candidates living in the wealthiest neighborhoods only slightly higher than rates 
seen among the lowest quintile median income areas for Caucasians. 
Conclusions: Neighborhood poverty is associated with decreased likelihood of LD. 
This impact was most pronounced among AA. Efforts should be made to remove financial 
disincentives to living donation to address racial and socioeconomic disparities in access 
to the life-saving treatment of transplant.
FR-PO1003
Deceased Donor Renal Transplant eGFR at Six Months Has Improved in 
the Last 13 Years in Spite of Declining Donor Quality  Douglas Scott Keith, 
Gayle M. Vranic, Angie G. Nishio-Lucar.  Medicine, Univ of Virginia, 
Charlottesville, VA.
Background: Deceased donor quality has declined in the last decade but long-term 
graft outcomes are improving. We sought to analyze the trend in graft function at six months 
post-transplant in relation to this improvement.
Methods: All adult deceased donor kidney transplant recipients with at least six months 
graft survival recorded in the SRTR databased between 2000 and 2012 were analyzed. The 
CKD EPI eGFR was determined based on the patient characteristics and serum creatinine 
at six months post-transplant. KDPI of the donors was also calculated. Linear regression 
was used to determine the effect of covariates on eGFR.
Results: 111,678 deceased donor recipients were identified. 4918 (4.4%) recipients 
with no six month creatinine recorded were excluded. The median eGFR improved 
from 54.5 ml/min./1.72m2 in 2000 to 58.9 in 2012 (p<0.001) while the median KDPI 
increased from 41% to 46%(p<0.001). The use of tacrolimus/mycophenolate derivative 
also increased from 33.1% to 89.8%. Every 10 unit increase in KDPI resulted in a 3 ml/
min/1.72m2 decline in eGFR.
Linear Regression Analysis B ml/min/1.72m2 Std. Error
Constant 73.87 0.59
KDPI -0.304 0.002
Acute Rejection in First Six Months -10.94 0.23
En Bloc Pediatric Kidney 25.82 0.49
Dialysis in the First Week Post-Transplant -4.91 0.14
Tacrolimus/Mycophenolate Derivative 1.08 0.58
Neoral/Mycophenolate Derivative -4.74 0.60
CNI/mTOR -4.69 0.64
CNI/Azathioprine -2.93 0.78
Other combination -2.10 0.60
KDPI adjusted median eGFR increased 13%.
Conclusions: Graft function improved significantly over the 13 year period in spite of 
declining donor quality and appears to be an important factor in the improvement in long-
term graft survival. The transition to tacrolimus/mycophenolate derivative as the dominant 
maintenance immunosuppression appeared to be an important factor in this improvement.
FR-PO1004
Recipient Age and KDPI Are the Most Potent Predictors of Early Acute 
Rejection in Deceased Donor Kidney Transplantation  Douglas Scott Keith, 
Gayle M. Vranic, Angie G. Nishio-Lucar.  Medicine, Univ of Virginia, 
Charlottesville, VA.
Background: The rate of acute rejection in first six months after deceased donor 
kidney transplant is now under 10% in the modern era of immunosuppression. We sought 
to determine the factors predictive of acute rejection in this era.
Methods: All recipients transplanted between 2001 and 2012 in the SRTR database 
were included in the analysis. Logistic regression was performed to determine the odds 
ratio of acute rejection in the first six months adjusting for multiple covariates.
Results: The acute rejection rate was 7.1% during the study period. KDPI and recipient 
age were the most important factors influencing rejection rates with recipients under 30 
years old having a rate of rejection more than double that of recipients 60 years or older 
and recipients receiving donor kidneys with a KDPI over 90% having a 2 fold increase in 
rejection rate over those receiving a kidney with a KDPI less than 30%.
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Odds 
Ratio Lower C.I. Upper C.I.
Age in Years (Reference 70 or older)
0-17 2.30 2.00 2.66
18-29 2.18 1.92 2.48
30-39 1.65 1.47 1.86
40-49 1.37 1.22 1.53
50-59 1.19 1.07 1.32
60-69 0.99 0.89 1.11
KDPI Group (Reference 0-9%)
10-19% 1.00 0.91 1.11
20-29% 1.07 0.96 1.18
30-39% 1.22 1.10 1.36
40-49% 1.33 1.20 1.47
50-59% 1.39 1.26 1.54
60-69% 1.53 1.38 1.69
70-79% 1.52 1.37 1.69
80-89% 1.80 1.61 2.00
90-100% 2.03 1.81 2.28
Other Covariates in model: Recipient gender, race, retransplant,
cause of ESRD, duration of dialysis, delayed graft function,
pra, HLA mismatch, induction, maintenance immunosuppression, and transplant year
The only factors in the KDPI determination associated with rejection were donor age, 
donor hypertension, HCV seropositivity, and black donor race, with age accounting for 
most of the effect.
Conclusions: KDPI and recipient age are the most important factors associated with 
rejection. Risk stratification for donor recipient pairs based on age and KDPI should be 
considered when determining induction and maintenance immunosuppression needs.
FR-PO1005
Transplantation of Cadaveric Kidneys from Infants and Toddlers into 
Adults in the Era of Extreme Donor Shortage  Jimena A. Blandon,1 Nader 
Najafian,2 Neerja Agrawal.3  1Nephrology, Cleveland Clinic Florida, Weston, 
FL; 2Nephrology, Cleveland Clinic Florida, Weston, FL; 3Nephrology, Cleveland 
Clinic Florida, Weston, FL.
Background: Kidney transplantation is the treatment of choice for patients with 
ESRD.  The number of patients in the waiting list for a deceased donor kidney transplant 
continues to increase. In this era of extreme donor shortage we present our experience 
with transplantation of cadaveric kidneys from infant and toddler into adult recipients.
Methods: This was a retrospective study of twelve adult deceased donor kidney 
transplant recipients from pediatric donors ages 0-5 years. Medical records were reviewed 
from visits previous to transplantation to the most recent follow up after transplant.
Results: Twelve consecutive adultpatients were transplanted with pediatric en bloc 
kidneys from donors 0-5 years between February 2014 to February 2015. Ten of the donors 
were standard criteria brain death (DBD) and two were donors with cardiac dead (DCD), 
KDPI scores ranged from 47 to 87%, donor age from 6 months to 5 years, weight 6 to 15 
Kg. Recipients were equally distributed by gender, average age 56 years, mean BMI 22. 
All patients were followed in average 6 months to 1 year. In the early post transplant period 
9 recipients were noted to have glucosuria with normal blood glucose and mild metabolic 
acidosis. These findings were noted on average up to 3 to 6 months after transplant and 
resolved thereafter. Nine patients had follow up renal ultrasound with finding of increase in 
kidney size 0.3 to 1.2 cm on average at 3-6 months in follow up. There were no perioperative 
complications, allograft failure, rejection, vascular complications or recurrence of the 
primary disease. The average serum creatinine remains at 0.89 to date.
Conclusions: We report excellent outcomes after adult kidney transplant from cadaveric 
donor ages 0 to 5 years of age. Younger age and low weight of the donors did not adversely 
effect our results. No vascular complications, rejection or allograft loss was noted. All of 
our patients have excellent allograft function 6-12 months post transplant.
FR-PO1006
The Role of Dobutamine Stress Echo in Identifying Cardiac Ischaemia, 
Cardiovascular Events and Role of Subsequent Cardiac Angiography 
Maria Ventura, Robin Ramphul, Sami Firoozi, Juan Carlos Kaski, Rajan Sharma, 
Debasish Banerjee.  Renal and Cardiology Depts, St. George’s Univ Hospitals 
NHS Foundation Trust.
Background: Dobutamine Stress Echo (DSE) is an established method of identifying 
cardiovascular (CV) risk in patients undergoing kidney transplantation, however the role 
of coronary angiography (CA) is not clear. The aim of this study was to investigate the 
role of DSE and CA in predicting cardiac ischaemia and CV events in this population.
Methods: We reviewed data on all patients, 92 out of 233, that were referred between 
1/2/2012 and 31/12/2014 and underwent DSE on risk stratification according to our protocol.
Results: 92 high risk patients underwent DSE. 28 of 92 patients had a positive DSE 
(i.e. suggestive of myocardial ischaemia) and 6 of these 28 had an event (event rate 13% 
per year) whereas there were only 5 events amongst the 64 patients in the DSE negative 
group (event rate 5% per year) (figure 1; log rank p=0.13). There were no perioperative 
events. 23 of 28 patients with a positive DSE had a CA, 14 had significant (> 50% stenosis) 
coronary artery disease (CAD) and another 3 had non-significant CAD (<50% stenosis). 
7 of 14 patients with significant CAD had coronary stents; and 6 of 14 had events (event 
rate 26% per year). There was no difference in survival between the patients stented and 
those who were not (figure 2; log rank p=0.9).
Conclusions: DSE is a suitable method to stratify cardiovascular risk and predict 
significant CAD on CA, however subsequent PCI does not conclusively show decreased 
event rates. Larger studies are required to establish the role of revascularisation.
FR-PO1007
Racial Differences in Survival of Incident Home Hemodialysis and Kidney 
Transplant Patients  Miklos Zsolt Molnar,1 Vanessa A. Ravel,2 Elani Streja,2 
Csaba P. Kovesdy,1 Rajnish Mehrotra,3 Kamyar Kalantar-Zadeh.2  1Univ of 
Tennessee Health Science Center, Memphis, TN; 2Univ of California, Irvine, 
CA; 3Univ of Washington, WA.
Background: Previous studies have indicated that patients on maintenance dialysis 
have worse survival compared to kidney transplant (KTx) recipients. However, none of 
these studies have compared mortality in United States(US) patients using alternative 
dialysis modalities such as home hemodialysis(HD) with KTx recipients.
Methods: Comparing patients who started home HD with those who received KTx 
in the US between 2007-2011, we created a 1:1 propensity-matched cohort of 4,000 
patients and examined the association between treatment modality and mortality using 
Cox proportional hazard models.
Results: The mean±SD age of the matched home HD and KTx patients at baseline 
were 54±15 and 54±14 years, 65% were male (both groups), 70% and 72% of patients 
were white and 19% were African American (both groups), respectively. Over 5 years of 
follow-up, home HD patients had 4-times higher mortality risk compared to KTx recipients 
in the entire patient population (HR:4.06, 95%CI:3.27-5.04)), and similar differences were 
found across each race stratum (Figure). 
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However, during the first year of therapy, while white home HD patients had higher 
mortality risk (HR:4.21, 95%CI:3.10-5.73) compared to their KTx counterparts, there 
was no significant difference in mortality risk between African American home HD and 
KTx patients (HR: 1.62, 95%CI:0.77-3.39). These results were consistent across different 
types of kidney donors.
Conclusions: Among all patients, home HD is associated with 4 times higher mortality 
compared to KTx regardless of the type of kidney donor, whereas among African Americans 
home HD and KTx have similar survival during the first year of therapy. Further studies 
on racial disparities of home HD and KTx are warranted.
Funding: Other NIH Support - R21AG047306 and R01DK95668
FR-PO1008
Survival of Elderly Incident Home Hemodialysis and Kidney Transplant 
Patients  Miklos Zsolt Molnar,1 Vanessa A. Ravel,2 Elani Streja,2 Csaba P. 
Kovesdy,1 Danh V. Nguyen,2 Rajnish Mehrotra,3 Kamyar Kalantar-Zadeh.2 
1Univ of Tennessee Health Science Center, Memphis, TN; 2Univ of California, 
Irvine, CA; 3Univ of Washington, WA.
Background: The proportion of elderly (≥65 years) patients with kidney failure is 
increasing. Previous data suggest that the projected increases in the life spans of kidney 
transplant (KTx) patients compared to conventional dialysis were 2.8 and 1.1 years for 
patients aged 65-69 and 70-74 years, respectively. However, no studies have compared 
mortality of elderly patients using alternative dialysis modalities such as home hemodialysis 
(HD) with KTx recipients.
Methods: Comparing elderly patients, who started home HD with those who received 
KTx in the US between 2007-2011, we created a 1:1 propensity score (PS) matched cohort of 
960 elderly patients (480 KTx and 480 HD) and examined the association between treatment 
modality and all-cause mortality using Cox proportional hazard models.
Results: The mean±SD age of the PS matched home HD and KTx patients at baseline 
were 71±6 years and 71±5 years, 69% were male (both groups), and 81% and 79% of 
patients were whites in home HD and KTx group, respectively. Median follow-up time 
was 205 days (IQR: 78-364 days) for home HD patients and 795 days (IQR: 366-1,221 
days) for KTx recipients. There were 97 deaths (20%, mortality rate 253 [297-309]/1000 
PY) in the home HD group, and 48 deaths (10%, 45 [34-60]/1000 PY) in the KTx group. 
Over 5 years of follow-up, home HD patients had almost 5-times higher mortality risk 
compared to KTx recipients in the entire patient population (HR: 4.74, 95%CI:3.25-6.91). 
These results were consistent across different types of kidney donors and recipients 
characteristics.
Conclusions: Elderly home HD patients appear to have almost 5 times higher mortality 
compared to KTx recipients regardless of the type of kidney donor.
Funding: Other NIH Support - R21AG047306 and R01DK95668
FR-PO1009
Beyond the Bones – The Association Between Vitamin D, Graft Outcomes 
and Vascular Disease  Aravind Cherukuri,1 Santhanakrishnan Balasubramanian,2 
Rebekah Molyneux,2 Richard J. Baker.2  1Univ of Pittsburgh; 2Univ of Leeds.
Background: Vitamin D deficiency in KTRs is an emerging theme. The purported 
associations between Vitamin D deficiency and various metabolic, cardiovascular and 
non-metabolic adverse events have not been thoroughly studied in kidney transplant 
recipients (KTRs).
Methods: Here, we examined the association between Vitamin D deficiency and graft 
loss, mortality, NODAT, cardiovascular events and development of cancers.
Results: 504 KTRs had their vitamin D checked in 2008 and were followed up for 
6 years. Vitamin D deficiency was defined as a level<50nmol/L. In this population, the 
prevalence of vitamin D deficiency was high at 66.5% with a significantly higher prevalence 
in older (71.9% vs. 60.9%, P=0.006) and female recipients (male 62.1% vs. female 73.2%, 
P=0.006) and in relatively new transplants (recent transplants 72.3% vs. old transplants 
60.6%, P=0.003). KTRs who were vitamin D deficient had significantly worse overall (77% 
vs. 92%, P<0.0001), death censored graft survival (89% vs. 96%, P=0.009), development 
of NODAT (19.8% vs. 10% p=0.005) and cardiovascular events (9.9% VS. 2.9%, p=0.002) 
when compared to those with normal levels. In a stratified analysis, this was noted to be 
worse in KTRs on maintenance steroids, with relatively worse baseline renal function 
and proteinuria, with secondary hyperparathyroidism, deceased donor transplants and 
earlier vs. late transplants. Although vitamin D deficiency is not associated with a higher 
incidence of malignancy, it is associated with higher mortality in those with cancer (33.3% 
VS. 12.9%, p=0.005). In a multivariate Cox model, vitamin D deficiency was associated 
with significantly worse overall graft (HR 2.7, P=0.001) and death censored graft survival 
(HR 2.4, P=0.04), NODAT (HR 2.3, p=0.03) and cardiovascular events (HR 4.0, P=0.004) 
independent of age, PTH levels, gender, graft number, type of transplant, time since 
transplantation, graft type and renal function measured by both proteinuria and eGFR.
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Conclusions: In conclusion, vitamin D deficiency which is highly prevalent in KTRs 
is associated with adverse clinical outcomes. Our study stresses the need for a prospective 
trial of vitamin D replacement in KTRs.
Funding: Private Foundation Support
FR-PO1010
Acute Tubular Necrosis Changes in Living Kidney Donor Implant Biopsy 
Associates with Higher Rejection Rates Post-Transplant  Chunping Yu, 
Nissreen Elfadawy, Andres G. Chiesa-vottero, Leal C. Herlitz, Emilio D. Poggio. 
Dept of Nephrology and Hypertension, Glickman Urological and Kidney Inst, 
Cleveland Clinic, Cleveland, OH.
Background: Ischemic injury may occur during organ retrieval. In deceased kidney 
donor transplants, delayed graft function, a form of acute tubular necrosis (ATN), associates 
with acute graft rejection. Histological changes consistent with ATN can also be seen in 
implant biopsies of living donors(LD), however, the influence of ATN-like changes at 
time on donation from LD on recipient graft outcomes is unclear, especially its impact 
on graft rejection.
Methods: We retrospectively studied all LD kidney transplants at our center from 
Jan 2005 to Dec 2014 who had an implant biopsy. We perform protocol biopsies at 3-6,12 
and 24 months post-transplant and for cause biopsies in all of our patients. Post-transplant 
biopsy results were reviewed, and patients with subclinical and clinical borderline and/or 
BANFF scored graft rejection were captured.
Results: The study included 350 LD kidney transplant recipients, the mean age was 
47.8±13.7 years (range 10-75) and224(64%) were male. The incidence of ATN in implant 
biopsies was 16% (n= 56). Patients with ATN had a trend toward higher risk of graft 
rejection in post-transplant biopsy compared with those without ATN (32.1% vs. 21.7%, 
p=0.09). When the study population was stratified by time interval from transplant to post-
transplant biopsy, there was a statistically significant higher incidence of graft rejection 
in those biopsies performed between 1 and 24 months post-transplant (31.0% in the ATN 
group vs.17.8% in the non-ATN group, respectively, p=0.02). No statistical correlation 
was found between ATN and graft rejection after 24 months post-transplant. Importantly, 
implant ATN has no impact on GFR at 3, 6, 12, 24 months post-transplant.
Conclusions: Histological changes consistent with ATN in LD kidney implant biopsy 
are associated with higher rates of graft rejection between 1 and 24 months post-transplant. 
However, ATN does not affect graft function at 3, 6, 12, or 24 months.
FR-PO1011
Impact of Pre-Transplant Cardiovascular Risks on Renal Allograft 
Survival: A Multi-Center Prospective Study  Jung Nam An,1,2 Song Vogue 
Ahn,3 Chun Soo Lim,1,2 Yon Su Kim,2 Young hoon Kim,4 Jung Pyo Lee.1,2 
1Seoul National Univ Boramae Medical Center; 2Seoul National Univ College 
of Medicine; 3Yonsei Univ Wonju College of Medicine; 4Asan Medical Center 
and Univ of Ulsan College of Medicine, Republic of Korea.
Background: Cardiovascular (CV) disease is a leading cause of mortality in patients 
with end-stage renal disease. Even after successful renal transplantation, CV risks can 
induce CV morbidity and mortality in renal transplant recipients. However, the impact of 
pre-transplant CV risks on renal allograft outcomes has not been reported.
Methods: We analyzed the graft outcomes of 2902 renal transplant recipients who were 
enrolled in a multi-center cohort from 1997 to 2012. We calculated pre-transplant CV risk 
scores by the Framingham risk model using age, sex, total cholesterol levels, smoking and 
a history of hypertension. Cox proportional hazard models were used to assess hazard ratios 
(HRs) with and without competing risks of post-transplant CV deaths, adjusting for risk 
factors of allograft failure including recurrence of glomerulonephritis and acute rejection.
Results: Hypertension and vascular disease (a composite of ischemic heart disease, 
peripheral vascular disease, and cerebrovascular disease) were noted in 84.1% and 6.5% 
of the patients, respectively. During a median 6.4 years of follow-up, 122 (4.2%) patients 
died and 286 (9.9%) patients developed allograft failure. In multivariable-adjusted models, 
pre-transplant vascular disease was associated with increased risk of renal allograft failure 
(HR 2.43; 95% confidence interval [CI] 1.58-3.71). The HR for renal allograft failure 
comparing the highest with the lowest tertiles of pre-transplant CV risk scores was 1.49 
(95% CI 1.11-2.00). In competing risk models, the HR of pre-transplant vascular disease 
was 2.01 (95% CI 1.20-3.36) and the HR for renal allograft failure comparing the highest 
with the lowest tertiles of pre-transplant CV risk scores was 1.44 (95% CI 1.05-1.98).
Conclusions: Both pre-transplant CV risk and vascular disease are independently 
associated with renal allograft failure in this multi-center prospective study. Pre-transplant 
CV risk assessment could be useful to predict renal allograft failure.
FR-PO1012
Blood Pressure (BP) Control in Kidney Transplant Recipients: A Single 
Centre Experience  Kristin Vibeke Veighey, Jacqueline C. Nevols, Panagiotis 
Chondrogiannis, Amanda Jane Laird, Irene Synodinou, Doreen Zhu, 
Katherine A. Alington, Nichola Dawn Pugh, Chuin ying Ung, Gopalakrishnan 
Venkat-Raman.  Wessex Kidney Unit, Portsmouth Hospitals NHS Trust, 
Portsmouth, United Kingdom.
Background: Cardiovascular disease is the leading cause of death among kidney 
transplant recipients (KTRs), however there remains uncertainty regarding optimal BP 
targets. Current UKRA, KDIGO and KDOQI guidelines advocate BP control to 130/80 
in KTRs; UKRA/KDIGO advocate tighter control (125/70) in proteinuric KTRs. We 
examined BP control and proteinuria in all KTRs under longterm follow up at one centre, 
and adherence to these recommendations.
Methods: As of 1 March 2015, 839 KTRs were attending for regular clinic review 
(excluding recent KTRs<1yr). We performed a retrospective database review of BP, 
proteinuria, renal function and antihypertensive use.
Results: The cohort was 60% male with mean allograft age 10±0.28 years. Mean decline 
in eGFR was 0.83ml/min/m2 per year (p=0.0004). Mean SBP was 134±0.56, DBP 79±0.37. 
48% had SBP <130, 62% DBP <80, 39% both. 78% received ³1 antihypertensive, 42% 2-3, 
4% ≥4 agents. Only 9% had PCR measured. In those with PCR≥50, 19% had BP treated to 
125/75. Dipstix proteinuria was recorded in 58% and showed a significant association with 
SBP (p=0.01). There were significant correlations between reducing eGFR and increasing 
PCR (R2=0.11, p<0.0001), and between PCR and ACE/ARB use (p= 0.0002). There was 
no correlation between CNI level and BP (CyA p=0.88, FK506 p=0.49). There was a 
significant stepwise decrease in renal function (sCr p=0.005, eGFR p=0.01) and increase 
in dipstix proteinuria (p=0.03) when data were analysed in SBP groups <120, 120-140 
and >140. In terms of DBP, the stepwise decrease in renal function remained (sCr p=0.01, 
eGFR p<0.0001) when data were analysed in groups <70, 70-90 and >90. DBP≥90 had the 
most significant impact on eGFR. DBP was not associated with proteinuria.
Conclusions: The optimal BP target remains uncertain. Adherence to current guidelines 
is reasonable in our unit but could be improved. This study again demonstrates that SBP 
is the key risk factor for proteinuria, however increases in DBP >90 were most strongly 
associated with graft dysfunction.
FR-PO1013
Dobutamine Stress Echocardiography (DSE) Significantly Reduces the Need 
for Coronary Angiography in Renal Transplant Recipients  Robin Ramphul, 
Maria Ventura, Sami Firoozi, Juan Carlos Kaski, Rajan Sharma, Debasish 
Banerjee.  Renal and Cardiology Unit, St. Georges Univ Hospitals NHS 
Foundation Trust, United Kingdom.
Background: There is significant controversy regarding optimal cardiac workup 
strategy for kidney transplantaion. Some centres perform coronary angiograms (CA) in all 
patients whereas others have adopted a tailored approach using non-invasive techniques such 
as Exercise Tolerance Testing (ETT) and ischaemia assessment with cardiac imaging. This 
study examines the role risk stratification and DSE for cardiac workup in this patient group.
Methods: We analysed data on patients referred between 1/2/2012 and 31/12/2014 
who were risk stratified and investigated according to the protocol (figure 1).
Results: Of 233 patients referred 92 were high risk and went on to have DSE. All other 
patients underwent echocardiography with/without ETT (35 ETT, 122 echocardiography 
and 33 CA). 16 patients had CV events, but none were perioperative. Overall event rate 
was 4% per year. 11 of 92 patients who had DSE had events. 11 of 33 patients who had CA 
had event. 28 of 92 patients had a positive DSE (i.e. suggestive of myocardial ischaemia) 
and of these 23 went on to CA. 6 of 28 patients with a positive DSE and 5 of 64 with a 
negative DSE had an event (figure 2, log rank p=0.1). 25 of 33 patients had evidence of 
coronary artery disease (CAD) at CA of which 13 received coronary artery stents. There 
was no significant difference between those with significant (>50% stenosis) CAD on CA 
who had events (8 of 21 patients) compared to those without significant (<50% stenosis) 
CAD who had events (3 of 12) (log rank p = 0.7). 6 patients with significant CAD who 
had PCI had events. 35 patients underwent ETT, 4 had CA following positive ETT. One 
patient with negative ETT had an event.
Conclusions: A careful risk stratification and using DSE decreases the need for CA 
and achieves very low event rates.
FR-PO1014
Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the 
Relationship with Hard Outcomes  Sophie Liabeuf,1 Lucie Desjardins,1 Ziad 
Massy,2 François Brazier,1 Dimitri Titeca Beauport,1 Momar Diouf,1 Griet Lrl 
Glorieux,3 Raymond C. Vanholder,3 Maite Jaureguy,1 Gabriel Choukroun.1 
1Nephrology, Amiens; 2Nephrology, Ambroise Paré; 3Nephrology, Gent.
Background: Kidney transplant recipients are at greater risk of cardiovascular disease 
(CVD). Indoxyl sulfate (IS) is a protein-bound uremic toxin that is known to be associated 
with the risk of CVD and mortality in both pre-dialysis and dialysis patients. Data on levels 
of protein-bound uremic toxins in kidney transplant patients are scarce. The objective 
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of the present study was to evaluate the levels of IS in kidney transplant patients and 
their relationships with biochemical parameters and hard outcomes (including mortality, 
cardiovascular (CV) events and graft loss).
Methods: In 311 consecutive kidney transplant patients, total and free IS levels were 
measured immediately before transplantation (T0) and then 1 month (M1) and 12 months 
(M12) afterwards. In a case controlled substudy (n=90), IS levels in transplant patients 
were compared with those in non-transplant patients with chronic kidney disease matched 
for age, gender and estimated glomerular filtration rate (eGFR). Over a mean ± standard 
deviation follow-up period of 113 ± 29 months, 55 deaths, 70 CV events and 71 graft 
losses were recorded.
Results: We observed a rapid, consistent, significant decrease in IS levels after kidney 
transplantation. Majority of IS levels were below or near the normal value at M1 and M12. 
We did not observe a correlation between IS levels and eGFR at M1 and M12. Total and free 
IS levels at M12 were significantly higher in non-transplant patients (0.34±0.23 mg/dl and 
0.04±0.007 mg/dl, respectively) than in transplant patients (0.21±0.17 mg/dl and 0.01±0.1 
mg/dl; (p=0.003 and <0.0001 respectively), despite having similar eGFRs. Lastly, IS levels 
were not associated with overall mortality, CV events or graft loss at T0, M1 or M12.
Conclusions: Free and total IS levels were significantly lower in transplant recipients 
than in non-recipients matched for, age, gender and renal function - suggesting that kidney 
transplantation protects against an increase in IS levels. Importantly, serum IS levels were 
not associated with hard outcomes at any of the three time points.
FR-PO1015
Identification of Metabolic and Cardiovascular Risk in Pediatric Kidney 
Transplant Recipients: Body Mass Index, Waist Circumference, or Waist-
to-Height ratio?  Kristen Sgambat, Asha Moudgil.  Children’s National, 
Washington DC.
Background: In the general population, abdominal obesity is more closely associated 
with metabolic and cardiovascular (CV) risk than high BMI. The ideal measure of obesity to 
identify risk in pediatric kidney transplant (Tx) recipients, who have impaired growth and 
altered body composition, has not been established. In this prospective study we compared 
ability of BMI, Waist Circumference (WC), and Waist-to-Height ratio (WHr) to identify 
metabolic and CV risk in pediatric kidney Tx recipients.
Methods: Kidney Tx recipients 3-20 years old and 0-30 months post-Tx had WC, 
BMI, WHr, blood pressure (BP), fasting lipids, leptin, HbA1c%, standard and speckle 
echocardiogram and carotid intima-media thickness (CIMT) measured. Patients were 
classified as obese or lean by 3 methods: WC (ATP cut-point males>94th%ile,females>84
th%ile), WHr(CDC cut-point>0.539), and BMI(≥95th%). Logistic regression determined 
association of groups with metabolic and CV risk factors.
Results: The study group comprised of 33 Tx recipients, age 13.6±0.3 years. 
Prevalence of obesity by BMI, WC, and WHr was 21.2%, 33.3%, and 48.5%. Prevalence 
of hypertriglyceridemia(TG) was 24.2%, high LDL 15.2%, low HDL 57.5%,high leptin 
39.3%, high HbA1c% 12.1%,left ventricular hypertrophy(LVH) 30.3%, hypertension(HTN) 
69.6%, and high CIMT48.4%. In all groups (WHr, WC, and BMI), obese children were more 
likely than lean to have HTN(OR4.5,2.2,3.6,p<0.01),LVH(OR5.4,7.4,8.8,p<0.001), low 
HDL(OR5.0,7.4,3.8, p<0.001), and high leptin(OR19,13.1,7.3,p<0.001). Obese children in 
WHr and WC groups, but not BMI group, had greater chance of high TG(OR5.4,3.2,p<0.01), 
high CIMT(OR2.0,4.5,p<0.05),and impaired myocardial strain(OR1.2,1.1,p<0.01). Five 
patients with short stature (height z -2.56) and CV risk factors (3.0±0.5 factors/patient) 
were not identified as obese by WC criteria(height z-0.08,p=0.003).
Conclusions: WC and WHr are more effective than BMI for detecting metabolic and 
CV risk amongst pediatric Tx recipients. WC may underestimate prevalence of obesity 
in children of short stature, and therefore WHr may be a more sensitive method for 
identification of children with increased metabolic and CV risk in the kidney Tx population.
FR-PO1016
Knowledge About Benefits of Kidney Transplant: A Survey of Dialysis 
Patients  Naman Trivedi, Fareeha Khalil, Ming Wang, Eric Chang, Nasrollah 
Ghahramani.  Pennsalvania State Univ College of Medicine.
Background: Kidney transplant (KT) is the treatment of choice for end stage renal 
disease (ESRD). Knowledge of dialysis patients about the benefits of KT is an important 
determinant of their active engagement in the decision making process. We studied factors 
associated with patients’ knowledge about benefits of KT.
Methods: We sent flyers to 1,283 dialysis units. Of 2536 interested participants fulfilling 
inclusion criteria, we randomly selected and invited 1400 to complete the questionnaire. 
Independent variables were demographic factors, distance to dialysis unit, and modes of 
education about options. In multivariate analysis, we calculated odds ratios (OR) and 95% 
confidence intervals (CI) for the probability of responding correctly to each of 4 questions 
about benefits of KT.
Results: 673 participants responded to questions about overall survival benefit of KT 
(correct: 32%), benefits of KT for diabetic patients (correct: 46%), for patients > 60 (correct: 
29%) and for patients transplanted pre-emptively (correct: 17%). Receiving 3 or more 
modes of education about KT was associated with higher likelihood of correct response to 
questions about overall survival benefit of KT (OR:2.19;CI:1.50 to 3.20), survival benefits 
of KT for diabetics (OR:2.04;CI:1.39 to 3.01) and patients transplanted pre-emptively 
(OR:1.67;CI:1.06 to 2.64). White race was associated with higher likelihood of correct 
response to questions about overall survival benefit of KT (OR:1.59;CI:1.11 to 2.28) and 
the benefit of KT for patients > 60 (OR:1.54;CI:1.07 to 2.21). Age > 60 was associated 
with lower likelihood of correct response to the question about overall survival benefit of 
KT (OR:0.65;CI:0.45 to 0.94), benefits of KT for diabetics (OR:0.54;CI:0.38 to 0.77), and 
for patients > 60 (OR:0.64;CI:0.44 to 0.93). Patients on dialysis > 5 years were less likely 
to be aware of the benefit of KT for diabetics (OR:0.68;CI:0.48 to 0.98).
Conclusions: Dialysis patients’ knowledge about survival benefits of KT is rather 
limited. The most significant modifiable contributor to improvement in knowledge is 
diversity of modes of education about KT. Other factors include race, age and number 
of years on dialysis.
Funding: NIDDK Support
FR-PO1017
Pretransplant HbA1c Predicts New-Onset Diabetes After Transplantation 
Among Renal Transplant Recipients  Jung-Im Shin, Mari Palta, Arjang 
Djamali, Brad C. Astor.  Univ of Wisconsin School of Medicine and Public 
Health, Madison, WI.
Background: New-onset diabetes after transplantation (NODAT) is a common 
complication among renal transplant recipients and is associated with a higher risk of 
cardiovascular events and poorer graft and patient survival. The association of pretransplant 
HbA1c with NODAT remains unclear. Identifying recipients at greatest risk of NODAT may 
help guide monitoring and treatment strategies to prevent or delay the onset of NODAT.
Methods: We assessed the association between pretransplant HbA1c and NODAT in 
1522 non-diabetic recipients using data from the United States Renal Data System (USRDS) 
from 2004-2011. Cox proportional hazards models adjusted for demographics, cause of 
ESRD, year of transplantation, number of prior transplants, duration of pretransplant 
dialysis, comorbidities, lipid levels, hemoglobin level, body mass index, HCV and CMV 
serostatus, donor type and age, HLA mismatch, and posttransplant steroid and tacrolimus 
use.
Results: Median HbA1c was 5.4% and 531 (34.9%) patients had HbA1c ≥ 5.7% (i.e., 
prediabetes) A total of 404 (26.5%) patients developed NODAT during a median follow-up 
of 1.7 years. Pretransplant HbA1c was associated with the risk of NODAT in a non-linear 
fashion. The adjusted hazard ratio (HR) associated with 1% higher pretransplant HbA1c 
was 0.94 (95% confidence interval (CI): 0.62, 1.42) for HbA1c lower than 5.4% and 1.87 
(95% CI: 1.30, 2.68) for HbA1c higher than 5.4%. 
Conclusions: Pretransplant HbA1c is independently associated with the risk of 
NODAT among renal transplant recipients. A continuous relationship between pretransplant 
HbA1c and the risk of NODAT suggests that greater risk starts at levels below the standard 
threshold for prediabetes.
FR-PO1018
Choice of Equation to Estimate Kidney Function Has Large Impact on 
Timing of Kidney Transplant Waitlist Qualification  Benjamin J. Lee,1 
Charles E. McCulloch,2 Isabel Elaine Allen,2 Sindhu Chandran,1 Chi-yuan 
Hsu.1  1Medicine, UCSF, San Francisco, CA; 2Epidemiology and Biostatistics, 
UCSF, San Francisco, CA.
Background: Because mortality on the kidney transplant waitlist is high (4-6% per 
year), being placed on the waitlist earlier versus later has important clinical consequences. 
Per U.S. Organ Procurement and Transplantation Network (OPTN) rules, patients begin 
accruing time on the waitlist when renal function declines beyond a threshold defined as 
“measured (actual urinary collection) creatinine clearance level or calculated glomerular 
filtration rate (Cockcroft-Gault or other reliable formula) less than or equal to 20 mL/min”.
Methods: We assessed the relative performance of three commonly used kidney-
function equations (Cockroft-Gault, MDRD, and CKD-EPI). We first compared the 
equations mathematically to determine under what age and serum creatinine combinations 
each pair of equations yields discordant waitlist qualification statuses (i.e., a patient would 
qualify for the waitlist if one equation were used but not the other). We then applied the 
equations to serial creatinine measurements from three patient cohorts: one of waitlisted 
patients at a major U.S. academic center and two national, multicenter cohorts of CKD 
patients (the NIH-sponsored AASK and MDRD studies).
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Results: Mathematically (assuming average weights), the Cockroft-Gault equation 
almost always yields higher numeric values compared with the MDRD and CKD-EPI 
equations. When applied to the three actual patient cohorts, Cockroft-Gault consistently 
disadvantaged patients, delaying average time to waitlist qualification by 1 to 2 years.
Conclusions: This study identified a potential source of significant inequity (on the 
order of 1-2 years) in wait-time accrual for kidney transplantation that stems from imprecise 
rules for waitlist qualification. The OPTN may need to revise the language in their kidney 
transplantation policies so that consistent methods to assess renal function are adopted and 
patients are not inadvertently disadvantaged.
Funding: NIDDK Support
FR-PO1019
New Onset Diabetes Has Unfavorable Effect on Patient but Not on Allograft 
Survival  Thomas Dienemann,1,2,3 Naohiko Fujii,1,2 Roy D. Bloom,1,2 Harold I. 
Feldman,1,2 Yimei Li.2  1Dept of Medicine, Perelman School of Medicine- Univ 
of Pennsylvania, Philadelphia, PA; 2Dept of Epidemiology and Biostatistics, 
Perelman School of Medicine, Philadelphia, PA; 3Dept of Renal Medicine and 
Hypertension, Univ of Erlangen, Erlangen, Germany.
Background: New onset diabetes after transplantation (NODAT) has been linked to 
higher rates of graft loss and shorter patient survival. More recent awareness, improvements 
in care, and changes in immunosuppression may have modified this association.
Methods: Retrospective single center analysis of 1427 (age>18) first time renal 
transplant recipients (KTR) without pre-transplat(Txp) diabetes. Patients with <1 year of 
follow up and those with allograft failure in the first year post-Txp were excluded. NODAT 
was defined as prescription of a glucose lowering medication 1 year after Txp. Cox models 
adjusted for mult. potential confounders were used to examine the relationship of NODAT 
with allograft and patient survival.
Results: The incidence of NODAT was 16.1%. Median follow up was 5.9 
years(IQR3.5-9.2) for allograft and 6.3(IQR3.8-9.8) for patient survival. Age, BMI, non-
white race and HCV were independently associated with NODAT (all p<0.01). Compared 
with KTRs without DM NODAT was not associated with an increased risk of overall 
graft failure (aHR1.15, CI0.86-1.52) or death censored graft survival (DCGS) (aHR1.12, 
CI0.73–1.71) in multivar. analysis. NODAT remained borderline significant after adj. for 
multiple other factors for patient survival (aHR1.39, CI1.00–1.91 p=0.49), but not for 
death with functioning graft (aHR1.34, CI0.89–2.02). The associations between NODAT 
and outcomes were not detectably different over time (p=0.095 for patient survival and 
p=0.25 for DCGS).
Conclusions: In this cohort of KTRs NODAT had no impact on graft survival but was 
indep. associated with reduced overall survival.
FR-PO1020
Frequency of Hospital Readmission Post Kidney Transplantation 
Essy Mozaffari,1 Jay Lin,2 Melissa Lingohr-Smith.2  1Chimerix Inc., Mendham, 
NJ; 2Novosys Health, Green Brook, NJ.
Background: Early hospital readmission following kidney transplantation has been 
identified to be a strong predictor of adverse sequelae that can have significant clinical and 
economic implications. Our goal was to quantify the frequency of hospital readmissions 
post kidney transplantation, as well as the reasons for the rehospitalizations.
Methods: Patients who received a kidney transplant between Jan 2009 and Sept 
2013 were identified from the Premier Hospital database by ICD-9-CM code. The first 
transplant procedure was defined as the index event. The frequency and causes for hospital 
readmissions were evaluated during the first 12-month after index transplant hospitalization 
using hospital discharge records.
Results: Of patients who received kidney transplant (n=5,402; mean age: 50.8 years) 
61% were male. Most patients received transplant in urban (98%), large (≥600 beds: 61%), 
teaching hospitals (84%). During index transplant hospitalizations 35 deaths occurred, 
resulting in 5,367 evaluable patients. Among this study population, 43% had a hospital 
readmission for any cause during the 12 months following kidney transplant, with 41% 
occurring within 1 month and 67% occurring within the first 3 months. Readmissions were 
most frequently related to opportunistic infections (25%) including viral infections (6%), 
followed by renal impairment (25%), and neutropenia (4%). Among the readmissions related 
to viral infections, the majority were related to CMV (79%). Readmission of patients with 
high severity APR-DRG levels of 3 (major) and 4 (extreme) at 30% and 9%, respectively 
(severity of illness level rated 1-4: minor, moderate, major, and extreme).
Conclusions: Over 4 in 10 of the kidney transplant recipients in this study were 
rehospitalized post transplantation. A significant number of the readmissions occurred in 
the first month post-transplant and the majority were within the first three months; almost 
4 in 10 readmissions were classified as major or extreme severity level. Among hospital 
readmissions, more than half of them were related to an opportunistic or viral infection, 
underscoring unmet needs for the prevention of these infections.
Funding: Pharmaceutical Company Support - Chimerix Inc.
FR-PO1021
Role of Non-Invasive Cardiac Stress Studies During Assessment for Kidney 
Transplantation in Pre-Dialysis Recipients  Talvinder S. Bhogal, Simon 
James Gray, Patrick Hamilton, Durga A.K. Kanigicherla.  Manchester Inst of 
Nephrology & Transplantation, United Kingdom.
Background: Non-invasive cardiac stress studies (NISS) are routinely undertaken 
during listing of patients for kidney transplantation. Although guidelines recommend NISS 
in high risk patients based on studies reported on patients on RRT. However role of NISS 
in pre-dialysis population is unknown. We analysed the role of NISS in listing process and 
impact on longer term outcomes.
Methods: Retrospective study of all patients undergoing assessment for kidney 
transplantation at our centre between 2009 and 2014. 695 patients were assessed, including 
397 who were pre-dialysis (naïve to RRT).
Results: 306 (77.1%) patients underwent NISS (98% were myocardial perfusion 
studies). Baseline and outcomes during follow-up are below.
No NISS Normal NISS Abnormal NISS
Number of patients 91 225 81
Baseline % or Median
Age 36 57 60
Males 59 51 69
BMI 27 28 30
Diabetes 5 31 53
Any vascular disease 3 24 31
Follow up
Follow-up (in months) 34 25 29
Coronary intervention before 
listing 0 0 4
Number listed for kidney Tx 77 71 53
Transplants completed 57 28 17
Cardiovascular events 0 7 19
Death 1 14 11
Only 3 patients with abnormal NISS (1% of all who had NISS) had flow limiting 
lesions, needing interventions (2CABG and 1PCI). At last follow up, compared to those 
with normal NISS, patients with abnormal studies a) were less likely to be listed for kidney 
transplantation, b) had increased cardiovascular events (p=0.01). But there was no significant 
difference in patient survival.
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Conclusions: Our study illustrates lack of benefit of non-invasive myocardial perfusion 
studies in identifying treatable coronary artery disease during pre-transplant assessment in 
pre-dialysis patients. Better risk stratification strategies are needed to inform assessment 
of kidney transplantation.
FR-PO1022
Longitudinal Association of Recipient Nonmuscle Myosin IIA Gene 
rs5756168 with Transplanted Kidney Doppler Ultrasound Blood Flow 
Indexes  Joanna Pazik,1 Ewa Nowacka-Cieciura,1 Zbigniew Lewandowski,2 
Monika Oldak,3 Dominika Ozi?b?o,4 Magdalena Durlik.1  1Transplantation 
Medicine and Nephrology, Medical Univ of Warsaw, Warsaw, Poland; 
2Epidemiology, Medical Univ of Warsaw, Warsaw, Poland; 3Histology and 
Embryology, Medical Univ of Warsaw, Warsaw, Poland; 4Inst of Physiology 
and Pathology of Hearing, Warsaw, Poland.
Background: MYH9 gene polymorphisms associate with nephron injury in 
hypertensive nephrosclerosis and FSGS. We have shown the association of rs5756168 
with transplanted kidney eGFR(ATC 2015). MYH9gene polymorphisms correlate with 
cerebrovascular blood flows. In transplanted kidneys resistance and pulsatility indexes 
predict graft function.
Methods: The study aims at evaluating the association of donor/recipient MYH9 
SNPs (rs3752462, rs11089788, rs5756168, rs136211 rs2239784) and transplanted kidney 
pulsatility (PI) and resistive (RI) indexes. Recipients engrafted 2007-2012 with availabile: 
donor/recipient DNA, kidney spectral Doppler ultrasound (US) were included. For 
genotyping custom TaqMan genotyping assays were used. Mixed models were used to 
assess relations of SNPs and PI, RI values.
Results: Genotyping was performed in 295 kidney recipients and their donors, in 202 
at least one US was done. In the longitudinal observation between first day and 2 years 
after engraftment, recipients carrying two T alleles in rs5756168 showed significantly 
different PI indexes in opposition to allele C carriers, p=0.04, for RI the differences did 
not reach statistical significance (p=0.14). In two-factor analyses the effects of rs5756168 
was maintained in first transplants for RI (p=0.02) and PI (p=0.02), in recipients with TIT 
>24h (p 0.03 and 0.07, respectively), with grafts from donors>55 years old (p=0.05 for PI 
only), with panel reactive antibodies <20% (p=0.01 and 0.04 for PI and RI), patients on 
immunosuppression without induction (p=0.07 for PI only) and on tacrolimus treatment 
(p=0.05 for PI p=0.05).
Conclusions: Identified association of transplanted kidney blood flow parameters 
and MYH9 polymorphism additionally confirms MYH9 effect on graft functioning shown 
in our previous study cited above. The study supported by grant from National Science 
Center NN402566840.
Funding: Government Support - Non-U.S.
FR-PO1023
Determinants of Hepcidin, the Key Regulator of Iron Homeostasis, in 
Renal Transplant Recipients  Michele F. Eisenga,1 Stefan P. Berger,1 Robin 
P.F. Dullaart,1 Aiko P.J. De Vries,2 Stephan J.L. Bakker,1 Carlo A. Gaillard.1 
1Internal Medicine, UMCG; 2Internal Medicine, LUMC.
Background: Hepcidin is synthesized in the liver and secreted into the circulation. 
Circulating concentrations may be influenced by body iron availability, inflammation, insulin 
resistance and tissue hypoxia. Moreover, hepcidin is a small 2.8 kD molecule. Therefore, 
renal clearance may be an important additional determinant of circulating hepcidin. We 
aimed to investigate whether markers of iron availability (ferritin), inflammation (C-reactive 
protein (CRP)), insulin sensitivity (fasting insulin), tissue hypoxia (erythropoietin) and 
estimated glomerular filtration rate (eGFR) are determinants of serum hepcidin in a 
population of renal transplant recipients (RTR) with a large variation in renal function.
Methods: The study was performed in an extensively phenotyped RTR cohort recruited 
in the University Medical Center Groningen. Serum hepcidin was assessed by ELISA ECL 
immunoassay. Statistical analyses were performed using univariable linear regression 
followed by stepwise backward linear regression. P-values for inclusion and exclusion 
were set at 0.2 and 0.1, resp.
Results: We included 561 RTR (age 51±12 years; 55% males at 7.8±6.4 years after 
Tx). Mean hemoglobin (Hb) was 8.6 ±1.0 mmol/l. Median [IQR] serum hepcidin was 
7.2 [3.2-13.4] ng/mL. Mean eGFR was 47±16 ml/min/1.73m2. In univariable analysis, 
ferritin (ß=0.69, p<0.001), CRP (ß=0.24, p<0.001), eGFR (ß=-0.14, p=0.001), Hb (ß=-
0.12, p=0.006), EPO (ß=0.12, p=0.006), fasting insulin (ß=-0.09, p=0.03) and age (ß=0.09, 
p=0.03) were associated with serum hepcidin. In multivariable analysis, concentrations 
of ferritin (ß=0.66, p<0.001), CRP (ß=0.19, p<0.001), erythropoietin (ß=-0.13, p<0.001), 
fasting insulin (ß=-0.08, p=0.01) and Hb (ß=-0.06, p=0.06) (total model R2=0.53) were 
identified as independent determinants of serum hepcidin, while the univariable association 
of eGFR was lost.
Conclusions: Despite large variation in eGFR, fifty-three percent of the variation 
in serum hepcidin concentrations in RTR can be attributed to variation in iron status, 
inflammation, insulin sensitivity and tissue hypoxia reflected by erythropoietin, rather 
than to variation in renal clearance.
FR-PO1024
Associations of Serum Soluble α-Klotho, Fibroblast Growth Factor 23, 
and 25 (OH) Vitamin D with Kidney Function and Left Ventricular 
Hypertrophy in Japanese Kidney Transplant Recipients  Makoto Tsujita,1 
Shoichi Maruyama.2  1Transplant Surgery, Nagoya Daini Red Cross Hospital, 
Japan; 2Nephrology, Nagoya Univ School of Medicine, Japan.
Background: Deterioration of kidney function and left ventricular hypertrophy (LVH) 
is crucial for kidney transplant recipients. Any marker for predicting kidney function and 
LVH is needed to prevent complications.
Methods: This was a retrospective cohort study. Forty-seven consecutive patients were 
enrolled in this study at Nagoya Daini Red Cross Hospital in 2011.
Serum intact fibroblast growth factor (FGF) 23, soluble α-Klotho(sαKlotho), 25(OH)
Vitamin D[25(OH)D], estimated glomerular filtration (eGFR), left ventricular mass index 
(LVMI) and other clinical parameters after 1 year and eGFR after 3 years since kidney 
transplantation were measured to investigate the usefulness of these markers for predicting 
kidney function and LVH.
Results: The median serum sαKlotho, intact FGF23, 25(OH)D were 516.3 pg/ml, 58.7 
pg/ml, and 5.7 ng/ml, respectively. Serum sαKlotho levels were associated with difference 
between eGFR after 1 year and after 3 years (DeGFR) (r = 0.37, p= 0.01), but not with 
difference between LVMI after 1 year and after 3 years (∆LVMI). Patients were divided 
into two groups based on median serum FGF23 level. Higher serum intact FGF23 levels 
were associated with ∆LVMI. Serum 25(OH)D levels were associated with eGFR after 1 
year (r = 0.34, p < 0.05), but not with DeGFR and ∆LVMI. Multivariate regression analysis 
revealed that serum sαKlotho was the strongest predictor of kidney function and serum 
intact FGF23 was that of LVMI.
Conclusions: Serum sαKlotho may be a good marker for kidney function and intact 
FGF23 for LVH in Japanese kidney transplant recipients.
FR-PO1025
Lower Frailty Risk but Fewer Kidney Transplants in Blacks: USRDS 
Special Study Data  Nancy G. Kutner, Rebecca H. Zhang, Janice P. Lea, Stephen 
O. Pastan, Rachel E. Patzer.  Emory Univ, Atlanta, GA.
Background: Frailty, a measure of physiologic reserve, may indicate risk for adverse 
outcomes among kidney transplant (KT) recipients according to recent research. Non-frailty 
may therefore be a preferred characteristic of candidates for KT. Frailty status, age, race, 
and KT receipt were investigated during the 2009-13 USRDS study of a maintenance 
hemodialysis (MHD) cohort (ACTIVE-ADIPOSE study).
Methods: Frailty was assessed at study enrollment in 745 prevalent MHD patients 
(Atlanta and San Francisco areas; mean [SD] age = 57.1 [14.1]) using the Fried index 
(includes recent unintentional weight loss, reported exhaustion, low measured grip 
strength, slow measured walk speed, low reported physical activity; these indicators are 
both performance-based and patient-reported, and presence of 3+ criteria indicates frailty). 
Additional (1-2) frailty assessments were obtained annually for participants who remained 
on MHD post baseline. KT following most recent frailty assessment was monitored in the 
USRDS through February, 2013.
Results: % frail varied by age, gender, and race (Figure). 95% of the 40 KT recipients 
during the study period were non-frail; 82.5% were < 65 years old; 52% were men. Among 
all non-frail patients <65 (n=115 whites and 358 blacks) in the study cohort, 10.7% of 
whites and 3.1% of blacks received a KT. However, a multivariable regression analysis, 
with adjustment for a large number of demographic, treatment and clinical variables, 
showed that blacks had lower odds for frailty compared with whites (OR 0.58; 95% CI 
0.34-0.99; p = 0.04). 
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Conclusions: Most study participants who received a KT were non-frail, but the 
proportion of black KT recipients was small despite blacks’ lower observed risk for frailty 
compared with whites. Closer alignment of frailty status with support for KT access may 
have implications for reducing racial disparity in KT rates.
Funding: NIDDK Support
FR-PO1026
Circulating Inflammatory Cell Subsets Are Associated with Cardiac 
Function in Renal Transplant Recipients  Jill Neale,1 Danielle Richler-Potts,1 
Maurice Dungey,1 Patrick Highton,1 N. Martin,2 Nicolette C. Bishop,2 Alice C. 
Smith.1  1Leicester Kidney Exercise Team, Univ of Leicester, United Kingdom; 
2School of Sport, Health and Exercise Sciences, Loughborough Univ, United 
Kingdom.
Background: Cardiovascular (CV) disease is a major cause of mortality and 
morbidity in renal transplant recipients (RTRs). Systemic and vascular inflammation is 
paradoxically common despite immunosuppression and is an important non-traditional CV 
risk factor. Monocytes are heterogenous: the intermediate phenotype (CD14++CD16+) is 
particularly pro-atherogenic and pro-inflammatory compared to the classical phenotype 
(CD14++CD16-). Regulatory T-cells (TRegs) maintain peripheral tolerance and minimise 
tissue damage. This study aimed to explore the association of circulating inflammatory cell 
subsets with cardiac function in RTRs.
Methods: 18 stable RTRs (Mean age 55 years, 61% male) and 5 healthy controls 
participated. Blood monocytes and T cells were analysed by flow cytometry, and cardiac 
hemodynamic function measured by bioreactance (NICOM).
Results: Circulating pro/anti-inflammatory cell subsets differed significantly in RTRs 
and controls. Mean %[SEM] intermediate monocytes was higher in RTRs (7.2[0.8]) vs 
controls (3.2[0.5], p=0.01), while classical monocytes and TRegs were lower in RTRs 
(83.2[1.3] vs 89.1[1.6], p=0.03 and 2.8[0.2] vs 5.0[1.0], p=0.001 respectively). In RTRs, % 
intermediate monocytes was inversely correlated with stroke volume (SV: r=-0.48, p=0.05) 
and cardiac output (CO: r=-0.52, p=0.03) and positively correlated with total peripheral 
resistance (TPR: r=0.50. p=0.04), while the opposite was seen with % classical monocytes 
(SV r=0.56, p=0.02; CO r=0.62,p=0.006; TPR r=-0.54, p=0.02).
Conclusions: Our results reveal a significant bias towards pro-inflammatory circulating 
leucocyte subsets in RTRs (increased intermediate monocytes, reduced classical monocytes 
and TRegs), which likely promotes an atherogenic environment. Furthermore, the observed 
significant correlations between pro- and anti-inflammatory monocyte subsets and indices 
of cardiac function strongly support an important pathogenic role for these cell subsets, 
which represent a potential therapeutic target in this vulnerable population.
Funding: Private Foundation Support
FR-PO1027
Iron Deficiency Is Associated with Mortality Independent of Anemia in 
Renal Transplant Recipients  Michele F. Eisenga,1 Stefan P. Berger,1 Jenny 
E. Kootstra-Ros,2 Else van den Berg,1 Gerjan Navis,1 Peter Van der meer,3 
Stephan J.L. Bakker,1 Carlo A. Gaillard.1  1Nephrology; 2Clinical Chemistry; 
3Cardiology, UMCG.
Background: Anemia and iron deficiency (ID) are highly prevalent in renal transplant 
patients (RTR). Anemia is associated with poor outcome, but the role of ID is unknown. 
Therefore, we aimed to investigate the association of ID, irrespective of anemia, with 
all-cause mortality in RTR.
Methods: In a previously defined cohort of RTR, with hemoglobin data available, 
we additionally assessed serum iron, transferrin and ferritin. ID was defined as transferrin 
saturation(TSAT)<20% and ferritin <300 ng/ml. Anemia was defined as Hb<13 g/dL (M) 
or <12 g/dL (F). Cox regression analyses were used to investigate prospective associations 
with all-cause mortality.
Results: We included 701 RTR (age 53±13 years; 57% males at 8.1±7.5 years after 
renal transplantation). Mean Hb was 8.2±1.1 mmol/L, serum iron 15.3±6.0 µmol/L, and 
ferritin 118 (55-222) µg/L. Prevalences of anemia, ID, and iron deficiency anemia (IDA) 
were 34%, 30%, and 13%, resp. During follow-up for 3.2±0.8 yr, 81 (12%) of RTR died. 
In univariable analysis, ID was associated with mortality (HR 2.04 [95%CI 1.31-3.16], 
p=0.001; fig. 1). Furthermore, both anemia (1.72 [1.11-2.66], p=0.02) and IDA (2.43 [1.48-
4.00, p<0.001) were associated with mortality. After adjustment for age, gender, BMI, eGFR 
and anemia, the association of ID with mortality remained (1.82 [1.16-2.85], p=0.009). In 
contrast, the association of anemia with mortality disappeared after adjustment for eGFR 
and ID (1.15 [0.71-1.86, p=0.57), while the association of IDA remained after adjustment 
for eGFR (1.83 [1.10-3.05], p=0.02).
Conclusions: ID is highly prevalent among RTR and is associated with an increased 
risk of mortality, independent of anemia. Since iron deficiency is a modifiable factor, 
correction of iron deficiency could be a target to improve survival.
FR-PO1028
Indoleamine 2,3-Dioxygenase Activity and Late Graft Failure After 
Kidney Transplantation  Laura V. de Vries,1 Claude P. Van der Ley,2 Casper 
F.M. Franssen,1 Gerjan Navis,1 Stephan J.L. Bakker,1 Ido Peter Kema.2  1Dept 
of Nephrology, UMCG, Netherlands; 2Dept of Laboratory Medicine, UMCG, 
Netherlands.
Background: Long-term graft survival after kidney transplantation remains a major 
clinical problem. Therefore, markers that allow for early identification of patients at risk for 
late graft failure (LGF) are urgently needed. Indoleamine 2,3-dioxygenase (IDO) catabolizes 
tryptophan along the kynurenine pathway. Recent studies found IDO activity associated 
with occurrence of acute rejection and renal function decline shortly post-transplant. We 
hypothesized that IDO activity could also be a marker for LGF after kidney transplantation.
Methods: We prospectively included outpatient renal transplant recipients (RTR) 
with a functioning graft >1 yr, between 2001-2003. Follow-up was recorded until May 
2009. Death-censored GF was defined as return to dialysis or re-transplantation. Serum 
kynurenine (KYN) and tryptophan (TRP) were measured with LC-MS/MS; KYN/TRP is 
a widely accepted measure of IDO activity.
Results: We studied 562 RTR (age 51±12 yrs, 56% men, 6.0 [2.6-11.6] yrs post-
transplant). Baseline concentration of serum KYN was 1.8 [1.4-2.2] µmol/l, that of TRP was 
40.0 [34.5-46.0] µmol/l, and KYN/TRP was 44.3 [35.0-57.9] µmol/mmol. In multivariable 
linear regression analyses, KYN/TRP was positively associated with proteinuria (β=0.17, 
P<0.001) and waist circumference (β=0.12, P<0.001), and inversely with eGFR (β=-0.54, 
P<0.001) and HDL-c (β=-0.14, P<0.001). During follow-up for 6.9 [6.1-7.4] years, 51 
(9.2%) RTR developed GF. In multivariable Cox-regression analyses, KYN/TRP was 
positively associated with GF (age, sex, eGFR, and proteinuria adjusted HR 3.6 [95% CI 
1.3-9.9], P=0.01). Further adjustment for waist circumference and HDL-c did not materially 
change this association (HR 3.1 [95% CI 1.3-8.9], P=0.02).
Conclusions: IDO activity, as measured by KYN/TRP, is cross-sectionally associated 
with eGFR, proteinuria, waist circumference, and HDL-c. Prospectively, it is associated 
with increased risk for LGF after kidney transplantation. Increased IDO activity may not 
only be a marker for LGF, but also an interesting target for intervention to prevent decline 
of renal transplant function leading to LGF.
FR-PO1029
The Significance of Preoperative Left Ventricular Diastolic Dysfunction and 
Left Atrial Enlargement on Clinical Outcomes in Kidney Transplantation 
Jin Ho Hwang,1 Jung Nam An,2 Jaeseok Yang,3 Curie Ahn,3 Chun Soo Lim,2 Yon 
Su Kim,4 Young hoon Kim,5 Jung Pyo Lee.2  1Internal Medicine, Chung-Ang 
Univ Hospital, Seoul, Republic of Korea; 2Internal Medicine, Seoul National 
Univ Boramae Medical Center, Seoul, Republic of Korea; 3Transplantation 
Center, Seoul National Univ Hospital, Seoul, Republic of Korea; 4Internal 
Medicine, Seoul National Univ College of Medicine, Seoul, Republic of Korea; 
5Surgery, Asan Medical Center and Univ of Ulsan College of Medicine, Seoul, 
Republic of Korea.
Background: In spite of improved survival of kidney transplant (KT) recipients, 
cardiovascular mortality is the leading cause of death following KT. Echocardiography is 
commonly performed as a screening test to evaluate cardiac function before KT. However, 
there are only limited data on echocardiographic parameters to evaluate the effect of left 
ventricular diastolic dysfunction (LVDD) and left atrial enlargement (LAE) on the long 
term outcome in KT recipients.
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Methods: A total of 2,779 adult recipients who underwent pretransplant 
echocardiography from 1997 to 2012 were evaluated. We divided the patients into two 
groups by two different categories: LVDD grade 0-1 vs. 2-3, and LA size£38 mm vs. >38 
mm. Post-KT fatal/non-fatal acute coronary syndrome (ACS), graft failure (GF), and all-
cause mortality was evaluated.
Results: During a mean follow-up of 4.5 years, fatal/non-fatal ACS was occurred 
in 49 (1.8%) patients. A total of 231 (12.4%) patients experienced GF and 116 (6.2%) 
died. The recipients with LVDD grade 2-3 (P=0.005) and LAE (P=0.001) showed higher 
occurrence of fatal/non-fatal ACS after KT. Graft failure and all-cause mortality was 
not different between the groups depending on both the LVDD grades and LAE. In a 
multivariate analysis, increased age (P<0.001), previous history of CV event (P<0.001) 
and LVDD of grade 2-3 (hazard ratio[HR]:2.98, 95% confidence interval[CI]:1.535-
5.787;P=0.001), and LAE (HR:1.052, 95% CI:1.006-1.101;P=0.025) were associated with 
ACS. However, none of LVDD and LAE was significantly associated with mortality and 
GF in a multivariate analysis.
Conclusions: In patients of KT candidate, pretransplant LVDD and LAE were 
independently associated with high occurrence of ACS after KT.
FR-PO1030
Effect of Dietary Sodium Restriction on Blood Pressure and Urinary 
Protein Excretion in Renal Transplant Recipients on RAAS-Blockade 
Laura V. de Vries,1 Linn Charlotte Dobrowolski,2 C.T.P.  (Paul) Krediet,2 
Frederike J. Bemelman,2 Stephan J.L. Bakker,1 Gerjan Navis.1  1Dept of 
Nephrology, UMCG, Netherlands; 2Renal Transplant Unit, AMC, Netherlands.
Background: In CKD patients on RAAS-blockade, it is well established that dietary 
sodium restriction exerts renoprotection by reduction of blood pressure (BP) and by 
reduction of urinary protein excretion (UPE), which is partly independent of BP. In renal 
transplant recipients (RTR), the effect of sodium restriction is not well-documented. We 
therefore studied the effects of dietary sodium restriction on BP and UPE in RTR.
Methods: We performed a randomized, cross-over trial in stable outpatient RTR 
with creatinine clearance >30 ml/min, BP >120/80 mmHg, UPE <1.5g/day, and use of 
RAAS-blockade. Exposures consisted of a 6-week regular sodium (RS) diet (target: 150 
mmol/24h) and 6-week low sodium (LS) diet (target: 50 mmol/24h). End points were BP, 
UPE, urinary albumin excretion (UAE), and eGFR at the end of each diet period. Dietary 
compliance was assessed by 24h urinary sodium excretion.
Results: We randomized 23 RTR, of which 22 RTR (age 58±8 yrs, 50% men, eGFR 
51±21 ml/min) completed the study. One patient dropped out, due to orthostatic complaints 
on the LS diet. Sodium intake was 156 [130-193] vs. 68 [55-86] mmol/24h on RS vs. LS 
diet resp. (P<0.0001). Sodium restriction significantly reduced systolic and diastolic BP. 
There was, however, no material change in UPE, UAE and eGFR.
RS LS P-value
SBP (mmHg) 140±14 129±12 <0.0001
DBP (mmHg) 86±8 79±8 <0.0001
Serum creatinine (µmol/l) 123 [108-146] 125 [107-157] 0.3
eGFR (ml/min*1.73) 50±18 49±20 0.8
UPE (g/24h) 0.2 [0.0-0.3] 0.2 [0.0-0.3] 0.9
UAE (mg/24h) 29 [11-99] 22 [13-94] 0.3
Conclusions: Dietary sodium restriction effectively reduces BP in stable RTR on 
RAAS-blockade, but, at variance with findings in CKD, has no material effect on UPE or 
UAE, even with strict dietary compliance. This discrepancy might be due to relatively low 
UPE in the study population, or differences in pathogenesis of UPE/UAE or co-medication 
in RTR. Sodium restriction, therefore, is relevant to BP management in RTR on RAAS-
blockade, but our data do not support independent renoprotective effects.
FR-PO1031
Individual Blood Calcification Propensity in a Cohort of Renal Transplanted 
Patients  Carlo M. Alfieri,1 Andreas Pasch,2 Anna Regalia,1 Maria Meneghini,1 
Maria Teresa Gandolfo,1 Valentina Binda,1 Deborah Mattinzoli,1 Masami 
Ikehata,1 Piergiorgio Messa.1  1Nephrology, Dialysis and Renal Transplantation, 
Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy; 
2Nephrology, Hypertension and Clinical Pharmacology, Univ Hospital and 
Univ of Bern, Bern, Switzerland.
Background: Vascular calcifications and related cardiovascular disease have a strong 
impact in kidney transplantation(KTx).Calciprotein particle maturation time(T50) is a new 
measure of individual blood calcification propensity.Our aim is to explore in a cohort of 
KTx patients:1)the levels of T50 and their modifications during the 1st year of KTx;2)the 
relationship between T50 and routine clinical and biochemical parameters;3)the relationship 
between T50,bone mineral density(BMD)and aortic calcifications(ACI).
Methods: 70 KTx pts(M=38,Age:48±12 yrs),transplanted between 2005 and 2009 
were recruited.Along with T50 evaluation,routine clinical and biochemical parameters and 
FGF-23,OPG, fetuin A and 25-(OH)-Vitamin D were tested at 1st,6th and 12thmth after KTx.
At 1st and 12th mth, femoral Dual X-ray absorptiometry and vertebral column X-ray for 
BMD(g/cm2) and ACI(Kauppila) evaluation were performed.T50(min.) was determined 
using a Nephelostar nephelometer(BMG Labtech, Offenburg, Germany) in the laboratory 
of one of the authors.
Results: T50 at 1st,6th and 12th mth were of 243[72–283],218[79-275] and 227[79-279] 
resp.,with a reduction of T50 at the 12thmth of KTx(p=0.04).In multivariate analysis,T50 
was influenced by acid uric and fetuin-A(1st mth:p=0.02 and 0.001), by alkaline 
phosphatase,fetuin-A and 25-(OH)-Vitamin D (6th mth:p=0.01, p=0.001 and p=0.03 
resp.), and by estimated glomerular filtration rate,body mass index and 25-(OH)-Vitamin 
D(12th mth:p=0.01, p=0.03 and 0.01 resp).Both at baseline and at 12thmth of Ktx a direct 
correlation between BMD and T50 was demonstrated (p=0.002-p=0.04 respectively).No 
correlation between T50 and ACI score was demonstrated.
Conclusions: The main results of our study are that 1)during the 1st year of KTx,T50 
decreases significantly, and 2)has a strong and direct relation with Fetuin-A and 25OH 
vitamin-D,both implicated in bone-vascular axis;3)T50 is associated with BMD but not 
of ACI status.
FR-PO1032
Prediction of Acute Rejection in Kidney Transplant Recipients Using a 
Multicenter Cohort  Kyung Don Yoo,1 Junhyug Noh,2 Hajeong Lee,1 Dong Ki 
Kim,1 Chun Soo Lim,1 Young hoon Kim,3 Yon Su Kim,1 Gunhee Kim,2 Jung Pyo 
Lee.1  1Seoul National Univ College of Medicine; 2Seoul National Univ College 
of Engineering; 3Ulsan Univ College of Medicine.
Background: More than 20% of kidney transplant recipients (KTR) are likely to have 
rejection episode, which is associated with graft loss. However, the impact of risk factors on 
acute rejection had not been well clarified. Here, we aimed to build new prediction models 
through considering variables related to immunologic and non-immunologic factors using 
machine learning methods.
Methods: This multicenter cohort study included adult KTR admitted to 2 major 
experienced tertiary hospitals in Korea between 1997 and 2014. A total of 3,117 KTRs 
were enrolled. Biopsy-proven acute rejection (BPAR) of these recipients were investigated 
by the individual learners such as decision tree, logistic regression, and ensemble learners 
such as random forest.
Results: We analyzed 2,045 recipients’ records, with more than 50 attributes. Among 
them, we chose 21 independent attributes which could affect BPAR incidence for building 
our models. In the decision tree model for the prediction of BPAR after three years of KT, 
HLA DR mismatch was found to be the most important predictor. In the case of HLA DR 
mismatch, donor specific antibody (+) predicted in 66.6% of BPAR incidence at three 
year after transplantation, and also posttransplant infection episode showed significant 
association with BPAR. In the case of HLA full matched, old age with heavy weighted 
recipient showed high probability of BPAR (71.4%). The final modeling represent AUC 
performance 0.670 (logistic regression) and 0.665 (random forest) in the BPAR prediction.
Conclusions: In this study, machine learning modeling could present an accurate and 
versatile tool for forecasting probability of having BPAR episode during the early years 
following the transplant.
FR-PO1033
Prediction of Long-Term Prognosis of the Kidney Transplantation Using 
Comorbidity Score  Jae Yoon Park, Eunjin Bae, Sejoong Kim, Dong Ki Kim, 
Chun Soo Lim, Kwon Wook Joo, Yon Su Kim, Jung Pyo Lee.  Seoul National 
Univ College of Medicine, Seoul, Korea.
Background: Comorbidity assessment is important to the informed interpretation of 
kidney allograft outcomes. Weights assigned to comorbidities to predict survival may vary 
based on the type of index disease and advances in the management of the comorbidities. We 
aimed to develop a modified Charlson comorbidity index (CCI) in renal allograft recipients 
(mCCI-KT), thereby improving risk stratification for mortality.
Methods: A total of 3,765 recipients in multicenter cohort were included to develop 
comorbidity score. The weights of comorbidities per the CCI were recalibrated using a 
Cox proportional hazards model. The modified score was validated in an independent 
nationwide cohort (n=1,538).
Results: The Cox proportional hazards model revealed that peripheral vascular disease, 
mild liver disease, and diabetes with end-organ damage in the CCI significantly predicted 
mortality. Thus, the mCCI-KT included 3 comorbidities with recalibrated severity weights. 
In the validation cohort, both the CCI and the mCCI-KT were correlated with mortality. 
The mCCI-KT showed modest increases in c statistics compared with the CCI (0.565 
versus 0.534, P=0.002).
Conclusions: The mCCI-KT stratifies the risk better for mortality in renal allograft 
recipients compared with the CCI, suggesting that it could be a preferred index for use 
in clinical practice.
FR-PO1034
Patient Uncertainty Regarding Kidney Transplantation Associated with 
Length of Dialysis prior to Transplant Evaluation  Laura J. McPherson,1 
Mohua Basu,1 Stephen O. Pastan,1 Sumit Mohan,2 Rachel E. Patzer.1  1Emory 
Univ, Atlanta, GA; 2Columbia Univ, New York, NY.
Background: End stage renal disease (ESRD) patients’ uncertainty about undergoing 
kidney transplantation (KTx) ---i.e., decisional conflict---may be affected by cumulative 
time spent on dialysis prior to KTx evaluation. We aimed to investigate the association 
between time from dialysis start to KTx evaluation and decisional conflict.
Methods: In an ongoing clinical trial of study patients measuring the effectiveness 
of a shared decision tool at a single KTx center, ESRD patients were asked 10 questions 
assessing decisional conflict related to KTx, with possible scores ranging from 0 (none) 
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to 100 (high). Patients were dichotomized as having (score > 0) or not having (score of 
0) decisional conflict. Time from dialysis start to KTx evaluation was abstracted from 
electronic medical records, and time on dialysis prior to evaluation was categorized as 
never on dialysis, <1 year, and >1 year. Logistic regression was used to assess odds ratios 
(ORs) for decisional conflict by time on dialysis prior to KTx evaluation.
Results: Of 70 surveyed patients, 64% were male, 62% were African American, and 
66% had hypertension; the average age was 51 years. Patients with any decisional conflict 
(65%) were more likely to be male and African American in addition to having lower 
literacy and numeracy scores. Crude logistic regression showed that, compared to patients 
who had never been on dialysis prior to KTx evaluation, patients on dialysis for <1 year 
and >1 year evaluation were 1.4 (95% CI: 0.4, 4.9) and 2.5 (95% CI: 0.7, 9.2) times more 
likely to have decisional conflict, respectively.
Conclusions: Results suggest that longer time on dialysis prior to KTx evaluation may 
be associated with decisional conflict regarding KTx. Identifying characteristics of patients 
with longer time on dialysis prior to KTx evaluation could help inform intervention efforts 
to improve patients’ abilities to make decisions about treatment of their kidney disease.
Funding: Private Foundation Support
FR-PO1035
Haptoglobin and Long-Term Outcomes in Renal Transplant Recipients 
Isidor Minovic,1 Ineke J. Riphagen,1 Else van den Berg,1 Jenny E. Kootstra-Ros,2 
Ido Peter Kema,2 Andy P. Levy,3 Johanna M. Geleijnse,4 Gerjan Navis,1 Stephan 
J.L. Bakker.1  1Nephrology, UMCG, Netherlands; 2Laboratory Medicine, UMCG, 
Netherlands; 3Medicine, Technion, Israel; 4Human Nutrition, Wageningen Univ, 
Netherlands.
Background: Haptoglobin (Hp) is a hepatocyte-derived protein that protects against 
oxidative damage by binding free hemoglobin (Hb). Being an acute-phase protein, Hp is 
upregulated by inflammation. We hypothesized that both low and high Hp are risk factors 
for all-cause mortality and graft failure in renal transplant recipients (RTR).
Methods: Hp was measured using a turbidimetric immunoassay in a well-characterized 
prospective RTR cohort. Cox regression analysis was used to assess the association of Hp 
with endpoints.
Results: We included 707 RTR (57% male, age 53±13 y, eGFR 49±18 ml/min/1.73m2 
and 58% used a calcineurin inhibitor). Median Hp was 1.4 [IQR 1.0-1.8] g/L. Hp phenotype 
1-1, 1-2, and 2-2 distribution was 18%, 50%, and 33% resp., with Hp levels of 1.7 [1.3-
2.1], 1.4 [1.1-1.8] and 1.1 [0.9-1.7] g/L resp. (P<0.001). After median 38 [32-46] mnths 
follow-up, 81 (12%) RTR died and 45 (6%) developed graft failure. Hp showed a U-shaped 
association with mortality (P=0.01, fig. 1), but not with graft failure (P=0.7). Accordingly, 
the lowest (<0.9 g/L) and highest (>1.6 g/L) quintile of Hp levels were associated with 
mortality (HR 2.65 [95% CI 1.11-6.35] and 3.30 [1.41-7.72], resp.). Adjustment for sex, 
age, hsCRP, serum albumin, eGFR, BMI, HbA1c, LDH and Hp polymorphism did not 
materially influence the association of low Hp with mortality (HR 3.55 [1.42-8.84]). 
However, adjustment for hsCRP and serum albumin markedly weakened the association 
of high Hp with mortality (HR 2.06 [0.84-5.08]).
Conclusions: Low Hp is independently associated with mortality, but not graft failure, 
in RTR. High Hp was also associated with mortality, but this association largely depended 
on hsCRP and serum albumin.
Funding: Private Foundation Support
FR-PO1036
Pre-Transplantation Flow-Citometry Crossmatch Can Be a Predictor of 
Outcome when Donor-Specific Antibodies Are Present  Anna Rita Aguirre, 
Patricia Soares Souza, Gislene Oliveira Bezerra, Flavio Jota Paula, Elias 
David-Neto, Maria cristina R. Castro.  Renal Transplant Service, Hospital das 
Clinicas - Univ of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Background: Clinical relevance of pre-transplant (Tx) donor-specific-antibodies 
(DSA) detected by single antigen beads (SAB) when pre-Tx CDC-AHG crossmatch 
(XM) is negative is still unclear. The aim of this study was to evaluate the importance of a 
positive flow-citometry-XM (FCXM) in patients with DSA over patient and graft survival.
Methods: Retrospective study, performed between Jan09 and Dec13 evaluating FCXM 
influence over antibody-mediated rejection (AMBR) incidence, and over graft and patient 
survival. Biopsies were classified according to Banff’09 criteria and DSA by Luminex SAB.
Results: From 2009-2013, 1002 kidney transplants (Tx) were performed in our center. 
261(26%) were sensitized (PRA>0%) and 87 (8.7%) presented pre-Tx DSA. 60 (69%) 
of them had FCXM performed with serum collected before transplantation: 22 (36%) 
positive and 38 (64%) negative. There was no difference between the highest DSA-MFI 
between Tx with positive or negative FCXM [FCXM+ 5080 (1046-13560) vs FCXM– 3120 
(597-14600)], or between the sums of all DSA-MFI of each patient between these groups 
[FCXM+ 6589 (1046-13560) vs FCXM– 3247 (597-15669); P 0,05]. DSA+/FCXM+ Tx 
had a significantly higher incidence of ABMR than DSA+/FCXM- Tx [FCXM+ 12 (54.5%); 
FCXM– 9 (23.7%); p 0.024]. After a median follow-up time of 34 mo, graft survival (GS) 
between Tx with positive and negative FCXM differed significantly (41% vs 92%; p < 
0.0001). Among FCXM+ patients, GS was not influenced by ABMR (p=0,256). However, 
among patients with ABMR, FCXM+ had worse graft survival then FCXM- (FCXM+ 
25% vs FCXM– 90%; p 0.011). Patient survival did not differ between FCXM+ (82%) 
and FCXM- (95%) neither was affected by ABMR.
Conclusions: A positive pre-Tx FCXM is related to a higher incidence of ABMR in 
the first year after Tx and to worse graft survival, and did not influence patient survival.
FR-PO1037
Pre-Transplant Mental Health Disorders and Non-Adherence and Post-
Transplant Outcomes in Kidney Transplant Recipients  Istvan Mucsi, 
Franz-Marie Gumabay, Marta Novak, Joseph Kim, Olusegun Famure.  Multi-
Organ Transplant Program, Univ Health Network and Univ of Toronto, Toronto, 
ON, Canada.
Background: Mental health disorders (MH) and non-adherence (NA) have been 
associated with lower access to kidney transplantation (KT) and poorer clinical outcomes. 
We examined the relationship between history of MH problems, NA, and post-transplant 
outcomes (i.e., biopsy proven acute rejection: BPAR; death censored graft failure: DCGF; 
or total graft failure: TGF).
Methods: This was a single-centre retrospective cohort study of adult patients 
transplanted at our KT program from July 1, 2004 and Dec 31, 2012, and followed up until 
June 30, 2014. Patients with complete information about pre-transplant MH problems or 
pre-transplant history of NA in their medical record (n=955) were included. Univariable 
and multivariable associations between MH, NA and time to event (for BPAR, TGF and 
DCGF) were explored using log rank analysis and Cox proportional hazards models.
Results: The mean (±SD) age was 50.5 (±13.4) years, 61% of patients were male and 
27% had a history of diabetes. Twenty-two percent had a positive history of MH disorders 
and 11% had a history of NA. Fifteen percent of the patients had BPAR, 5.6% had DCGF 
and 13% had TGF (death or DCGF). Participants with a history of pre-transplant NA but 
not with history of MH had higher risk for BPAR (log rank test p = 0.049 and p=0.46 for 
NA and MH, respectively). This difference, however, was not significant after adjusting for 
socio-demographic characteristics, donor type and HLA mismatch: adjusted HR (95% CI) 
1.36 (0.84-2.23) and 1.16 (0.77-1.75) for Na and MH, respectively. Neither the history of 
pre-transplant MH nor pre-transplant NA was associated with DCGF or TGF. These results 
remained qualitatively unchanged after multivariable adjustment : adjusted HR (95% CI) 
1.81 (0.96-3.42) and 0.99 (0.58-1.70) for Na and MH, respectively.
Conclusions: A history of pre-transplant mental health disorders or non-adherence 
are not associated with poor post-transplant outcome in a select group of patients who are 
cleared for transplantation. Patients with such problems should have equal access to kidney 
transplantation compared to patients with no MH problems.
Funding: Government Support - Non-U.S.
FR-PO1038
HLA Profile and Short and Long Term Outcomes in African American 
Donors and Recipients  Rabi Yacoub, Girish N. Nadkarni, John C. He, Paolo 
Cravedi, Rebecca L. Kent, Ioannis Konstantinidis, Karen Lok yee Keung, 
Sander Florman, Peter S. Heeger, Barbara T. Murphy, Madhav C. Menon. 
Mount Sinai, NY.
Background: We have previously reported the apparent greater impact of HLA-
matching over HLA-mismatching on both early allograft events as well as graft survival 
in the United Network for Organ Sharing database (UNOS). Here, we specifically studied 
the influence of HLA-matching and mismatching on allograft outcomes among African-
American (AA) recipients and AA-donor organs in deceased donor kidney transplantation 
(DDKT).
Methods: We utilized data from the UNOS database (1995 – 2012), and analyzed 10 
year death censored graft survival (DCGS), 1 year clinical acute rejection (1y-AR), and 
delayed graft function (DGF) using Cox-regression and logistic regression in a combined 
multivariable model including HLA-matching and mismatching adjusted for key covariates. 
We performed sensitivity analysis using a subgroup of DDKT patients after 2003 with less 
heterogeneous HLA nomenclature, and resampling analysis using bootstrapping.
Results: We had complete data (outcomes and predictors) for 96236 recipients (Age 
49.23±15.13, 60.4% male). AA-recipients constituted 30.2% while AA-donor organs were 
utilized 13.1% of DDKT (n=29071&12575, respectively). Similar to the whole UNOS 
cohort, among AA-recipients both HLA-matching and –mismatching individually had 
significant stepwise association with all outcomes (10-yr DCGS, 1y-AR & DGF). However, 
distinct from the whole cohort, we identified that when added in a combined model along 
with other covariates and adjusted for each other, HLA-matching and -mismatching had 
equal effects on each of the three examined outcomes. Among AA-donors, neither HLA-
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matching, nor –mismatching had any effect on the three examined outcomes in either 
individual or combined multivariable models. Sensitivity analysis in the 2003-2012 cohort 
showed similar results.
Conclusions: Our analysis in this large cohort reports for the first time the absence of 
any effect from HLA-matching or –mismatching on allograft outcomes among AA-donor 
kidneys. These findings suggest that the allocation algorithm for AA-donor organs may 
need to be re-evaluated without including HLA-match status.
FR-PO1039
Femoral Bone Mineral Density Is Related with Aortic but Not with 
Coronary Calcifications in KTx Patients  Carlo M. Alfieri, Anna Regalia, 
Maria Meneghini, Maria Teresa Gandolfo, Valentina Binda, Masami Ikehata, 
Deborah Mattinzoli, Piergiorgio Messa.  Nephrology, Dialysis and Renal 
Transplantation, Ospedale Maggiore Policlinico, Milan, Italy.
Background: Our study wants to evaluate in a cohort of kidney transplanted(KTx) 
patients,undergone to femoral DEXA:1)the prevalence of bone mineral anomalies;2)the 
factors related to femoral bone mineral density(f-BMD) 3)the relationship of f-BMD 
with aortic calcifications(ACI) and coronary calcifications(CAC).Lumbar DEXA was not 
considered to avoid confounders between abdominal vascular calcifications(VC)and BMD.
Methods: 293pts(M=170) transplanted in our Unit(2004-2013) were evaluated.Clinical 
and routine biochemical exams(plus PTH,FGF-23,Fetuin and VitD) were tested at 1(T0) 
and 12(T1)mths of KTx.At the same time,DEXA,lumbar X-Ray(193pts) and coronary 
tomography(86pts) for f-BMD(g/cm2),ACI(Kauppila) and CAC(Agatson) evaluations were 
performed.ACI increase(ACI-Prog):any increase in ACI.Presence of CAC(CAC+):Agatson 
score >400,CAC increase(CAC-Prog):assessed using Sevrukov formula.
Results: At T0 and T1,OPN in 53%and 52%,OPR in 15% and 12% of pts resp.F-BMD 
was associated with:age,alkaline phosphatase(ALP) (at T0 and T1), fetuin and P (at T0).A 
logistic regression with BAbn(OPN+OPR as a whole)as dependent variable confirmed 
age and ALP as the only independent associated variables(T0 and T1).ACI were found in 
55% and 61% of pts(T0-T1).ACI were higher in BAbn(T0 and T1).ACI-Prog(26%) had 
lower f-BMD(T0 and T1);F-BMD showed a discriminatory role in ACI-Prog(ROC-Curve, 
T0:AUC 0.66,p=0.02;T1:AUC=0.70,p=0.005).CAC+was found in 13%,20% and 28%pts 
at T0,T1 and T2.CAC-Prog was found in 13% at T1 and in 49% of pts at T2.F-BMD did’t 
correlated with CAC at T0,T1,T2, and both at T1 and at T2 its levels weren’t different 
between CAC-Prog and CACnot-Prog.
Conclusions: High prevalence of BAbn and VC from the beginning of KTx is present.
Age and ALP are strongly associated with f-BMD;2)ACI and CAC progress in a high %of 
patients, in the early post-KTx period;3)However,though f-BMD was significantly related 
with ACI-Prog,no association was observed with CAC worsening,possibly suggesting that 
different mechanism(s) might underlie VC processes at different sites.
Funding: Private Foundation Support
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Relationship Between Pre-Transplant Physical Function and Quality of 
Life following Kidney Transplant  Elizabeth C. Lorenz, Andrea L. Cheville, 
Walter K. Kremers, Fernando G. Cosio, Nathan Lebrasseur.  Mayo Clinic, 
Rochester, MN.
Background: Decreased physical function predicts adverse outcomes following non-
transplant surgery. The goal of this study was to assess whether pre-transplant physical 
function predicts impaired quality of life (QOL) following kidney transplant.
Methods: We conducted a prospective cohort study involving all recipients of living 
donor kidney transplants at our center from 2012 until 2014. Physical function was measured 
using the Short Physical Performance Battery (SPPB), a composite measure of gait speed, 
balance and chair rise time (score range 0-12, with higher score indicating better physical 
function). QOL was measured 12-months post-transplant using the Short Form 36 Health 
Survey (SF36) with standardized scores adjusted for age and gender. Below-average 
physical and mental QOL was defined as physical (PCS) and mental component summary 
scores (MCS) < 45, respectively.
Results: Among the cohort of 140 patients, mean age was 51 ± 15 years, 61% were 
male, 91% were Caucasian, 21% had diabetes and 26% had a pre-transplant SPPB score < 
12. A pre-transplant SPPB score < 12 was associated with a significantly lower 12-month 
PCS score (48.1 ± 9.0 vs 51.6 ± 8.5, p=0.04) but not a lower MCS score (54.2 ± 9.4 vs 
55.2 ± 8.4, p=0.90) .
Below-average physical QOL at 12-months was observed in 23% of patients and was 
associated with pre-transplant BMI (OR 1.12 per 1 kg/m2 increase, CI 1.02-1.23, p=0.02) 
and a pre-transplant SPPB score < 12 (OR 3.05, CI 1.17-7.97, p=0.02). In contrast, pre-
transplant dialysis, diabetes, maintenance steroids and 12-month eGFR were not associated 
with physical QOL.
Conclusions: Decreased pre-transplant physical function predicts impaired physical 
QOL one year after kidney transplant. Further studies are needed to determine whether 
physical rehabilitation interventions can improve post-transplant QOL.
FR-PO1041
1st Report of Korean Organ Transplantation Registry (KOTRY) 
Tai Yeon Koo,1 Hye Jin Lim,1 Kyungok Min,1 Hyunjin Ryu,1 Jong Cheol 
Jeong,2 Jaeseok Yang,1 Myoung Soo Kim,3 Jae-Joong Kim,4 Curie Ahn,1 Kotry 
Study Group.5  1Transplantation Center, Seoul National Univ Hospital; 2Dept 
of Nephrology, Ajou Univ School of Medicine; 3Dept of Surgery, Yonsei Univ 
College of Medicine; 4Devision of Cardiology, Asan Medical Center; 5Korean 
Organ Transplantation Registry, Republic of Korea.
Background: The Korean Organ Transplantation Registry (KOTRY) were launched in 
2014 to construct the nationwide transplant database system which encompasses outcomes 
of various transplanted organs by support of the Korea Centers for Disease Control and 
Prevention.
Methods: In 2014, kidney, liver and heart transplant cohorts were established with 
participation of 29/58 centers for kidney, 13/35 centers for liver, and 4/8 centers for heart, 
covering more than 80% of total cases. Lung and pancreas transplant cohorts are also in 
progress since 2015. A web-based database system and attached biobank system have been 
developed. Annual data report and related information of database development process 
are available at http://www.kotry.org. From July 2014 to December 2014, 419 transplants 
in kidney transplantation (KT), 430 in liver transplantation, and 77 in heart transplantation 
were registered.
Results: Among 419 KT, deceased donor (DD) was performed in 156 patients (37.2%). 
Mean age was 47.7±11.2 and 56.8% of transplants were males. Diabetic recipients were 
23.2%, and 5.5% of transplants were older than 65 years. Their original kidney disease was 
most often chronic glomerulonephritis (39.6%), followed by diabetic nephropathy (18.6%). 
Preemptive KT was 29.3% among living donor KT. The high panel-reactive antibody 
(>50%) accounted for 9.8% of transplants. Positive results of T or B flow cytometric 
crossmath were found in 1.9% and 4.5% of transplants, respectively. ABO incompatible KT 
was performed in 21.7% of living donor KT. Mean age of donors was 45.3±13.2 and 59.9% 
were males. Among DD, expanded-criteria donor was 23.7%. Mean serum creatinine of 
living donor before and after KT were 0.81±0.18mg/dl, and 1.16±0.27mg/dl, respectively.
Conclusions: The KOTRY is expected to provide infrastructures for research in the 
field of KT and invaluable data for the Asian organ transplantation field.
Funding: Government Support - Non-U.S.
FR-PO1042
Pre-Transplant Midodrine Use: A Newly Identified Risk Marker for 
Complications After Kidney Transplantation  Tarek Alhamad,1 Daniel C. 
Brennan,1 Zaid Brifkani,1 Mark Schnitzler,2 Vikas R. Dharnidharka,1 Krista L. 
Lentine.2  1Washington Univ; 2St. Louis Univ.
Background: Midodrine is increasingly prescribed to decrease the severity and 
complications of hypotension in dialysis patients. The impacts of midodrine use before 
kidney transplantation on graft and patient outcomes early after transplantation are not 
well described.
Methods: We analyzed linked national U.S. transplant registry, pharmacy records 
and Medicare claims data to follow 16,322 kidney transplant recipients (2005-2008), of 
whom 308 (1.9%) had filled midodrine prescriptions in the year prior to transplantation. 
We examined associations of midodrine use with DGF, graft survival and death as reported 
to the registry, and with clinical complications captured in Medicare claims.
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Results: At 3mo, patients who used midodrine before transplant had higher rates of 
DGF, 32% vs. 19%; hypotension, 14% vs. 4%; acute myocardial infarction (AMI), 4% vs. 
2%; cardiac arrest, 2% vs. 0.9%, graft failure, 5% vs. 2%; and death, 4% vs. 1% than the 
non-users (P<0.05). After multivariate adjustment including recipient, and donor factors, 
as well as for the propensity of midodrine exposure, pretransplant midodrine use was 
independently associated with risks of DGF (aOR 1.95; CI 1.49-2.56), death-censored 
graft failure (aHR 1.94; CI 1.14-3.27), death (aHR 3.55; CI 1.99-6.33), as well as many 
potentially mediating complications. Patterns were similar at 12mo. 
Conclusions: Although associations may in part reflect underlying conditions, the 
need for midodrine before kidney transplantation is a bio-marker for increased risks of 
complications including graft failure and death. As the new KAS is expected to increase 
ESRD duration at the time of allocation for many patients, monitoring recipient comorbidity 
burden through novel methods including pharmacy claims, and associated impacts on 
transplant outcomes, are important priorities.
Funding: NIDDK Support
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Impact of Proton Pomp Inhibitors on Hypomagnesemia and Arterial 
Stiffness in Renal Transplant Recipients  Siren Sezer,1 Bahar Gurlekdemirci,1 
Saliha Uyanik,2 Mehtap Erkmen Uyar,1 Mehmet Haberal.3  1Dept of Nephrology, 
Baskent Univ Faculty of Medicine, Ankara, Turkey; 2Dept of Internal Medicine, 
Baskent Univ Faculty of Medicine, Turkey; 3Dept of General Surgery, Baskent 
Univ Faculty of Medicine, Turkey.
Background: Hypomagnesemia predicts cardiovascular morbidity and mortality in 
the general population and accelerated loss of kidney function in renal transplant recipients 
(RTRs). Proton pomp inhibitors (PPIs) or H2 receptor blockers (H2RBs) are frequently 
used agents after RT. The aim of this study was to evaluate the effects of PPIs on serum 
magnesium levels and arterial stiffness in RTRs.
Methods: We performed a retrospective study of 354 maintenance RTRs (mean age: 
38.6 ± 10.7 years) with stable allograft function who had received their transplant at least 
36 months previously. All acute cellular and humoral rejections were excluded. According 
to using stomach-protecting agents (SPAs), patients were divided in to three groups: PPIs 
(Group 1, n: 164), H2RBs (Group 2, n: 96) and control group who don’t receive SPAs 
(Group 3, n: 94). Estimated glomerular filtration rate (eGFR) was calculated by using the 
MDRD4 equation. Pulse wave velocity (PWv) was determined from pressure tracing over 
carotid and femoral arteries using the SphygmoCor system.
Results: Groups were similar in means of demographic characteristics and eGFR 
levels. Mean serum magnesium levels were significantly lower in group 1, however similar 
in group 2 and 3 (1.5 ± 0.04 mg/dl, 1.7 ± 0.02 mg/dl and 1.7 ± 0.01 mgdl, respectively). 
PWv values were significantly higher in group 1, whereas similar in group 2 and 3 (7.3 
± 0.2 cm/sec, 6.3 ± 0.1cm/sec and 6.2 ± 0.1 cm/sec, retrospectively). In linear regression 
analysis; type of SPAs (p: 0.001), serum calcium (p: 0.031), magnesium (p: 0.07) and folic 
acid levels (p: 0.013) were detected as the predictors of PWv.
Conclusions: We concluded that PPIs inhibit magnesium absorbtion independent 
from calcium metabolism in RTRs. Moreover, PPIs leads to increased arterial stiffness and 
cardiovascular risk in RTRs. Thus physicians should be aware of the side effects of PPIs 
to scale down the cardiovascular morbidity and mortality.
FR-PO1044
Comorbidity Burden of Kidney Transplant Recipients Predicts Emergency 
Usage Despite increased Family Physician Visits  Hatem A. Alnasser,1 
Sita Gourishankar,1 Kevin C. Wen.1  1Univ of Alberta, Canada; 2King Fahad 
Specialist Hospital, Saudi Arabia.
Background: Kidney transplant(KTX) recipients utilize many aspects of the healthcare 
system, especially emergency(ER) visits. Unterman et al showed that within a four year 
period, 378 KTX recipients generated 828 ER visits1. This study aims to understand factors 
leading to ER usage by KTX recipients.
Methods: This is a single center retrospective study in conjunction with patient 
questionnaire, collected from March 2012 - 2013. The questionnaire inquired the frequency 
of the family physician(GP) visits and ER usage within the past year. Patient demographics 
and comorbidities were collected from chart reviews. Univariate logistic regression was 
used to define factors that are predictive of ER usage. Significant covariates were then 
used in multivariate backward stepwise logistic regression model to predict ER visits.
Results: Number of GP visits(OR = 1.6, p=0.003), diabetes(OR = 1.7, p=0.016), 
coronary artery disease(OR = 2.5, p=0.001), below knee amputation(OR = 4.3, p=0.037), 
and number of comorbidities(OR = 1.35, p=0.001) significantly predict ER visits. Number 
of transplant clinic visits does not significantly decreased ER visits(p=0.32). By multivariate 
backward stepwise logistic regression, number of GP visits(OR = 1.5, p=0.007) and coronary 
artery disease(OR = 2.1, p=0.011) remain significantly predictive of ER usage.
Conclusions: This single center study showed that KTX recipients with more 
comorbidities have increased ER usage, particularly coronary artery disease, despite higher 
frequency of GP visits. However, kidney transplant recipients with more ER usage are not 
seen more frequently by our transplant clinic. The results suggest that KTX recipients with 
higher comorbidity burden may need to be followed more closely by transplant clinics, 
rather than relying on GP’s, to improve effective usage of ER visits.
1.    Unterman S, Zimmerman M, Tyo C, et al. A descriptive analysis of 1251 solid 
organ transplant visits to the emergency department. West JEM 2009; 10: 48.
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Stroke Predictors and Outcome in Renal Transplant Recipients 
Mark Duncan Findlay,1,2 Peter C. Thomson,2 Patrick B. Mark.1,2  1Univ of 
Glasgow, Glasgow, United Kingdom; 2Glasgow Renal and Transplant Unit, 
Glasgow, United Kingdom.
Background: End-Stage renal disease is associated with a high incidence of 
cerebrovascular disease. Conventional risk factors do not always apply & established 
preventive strategies may be ineffective. The incidence, predictors & outcomes following 
stroke in those with a functioning renal transplant is not well described.
Methods: All adult patients with a renal transplant attending Glasgow Renal and 
Transplant Unit between 1st Jan 2007 and 31st Dec 2012 were identified using the electronic 
patient record. Clinical, demographic & laboratory data were collected including presence 
of diabetes, cardio- or cerebrovascular disease (CeVD), atrial fibrillation, deprivation, 
serum renal and bone chemistry and use of immune suppressants. Stroke was identified 
via discharge codes, cerebral imaging or death certification. Independent predictors of 
stroke were identified via multivariable regression analysis. Fatality & causes of death 
are presented.
Results: 636 patients were identified, mean age 38 years (SD 12.9). 60.5% were male 
and 9.1% had AF. During follow-up 7.1% received a transplant as first RRT modality. 24 
patients experienced a stroke during 3455 patient years of follow-up. 83.3% were ischemic. 
Stroke incidence was 6.9/1000 patient years for all stroke and 3.76/1000 patient years for 
first stroke. A stepwise backward regression revealed predictors of stroke as older age (HR 
1.05, p=0.025) and previous CeVD (HR 18.16, p<0.001). Significant independent predictors 
for first stroke were age, diabetes and AF (p<0.05). There were no cases of SAH in PCKD. 
AF associated with time to stroke (p=0.003), but there was no detectable benefit from use 
of warfarin. 134 died during follow-up. 62.5% deaths followed stroke with 7, 28 and 365 
day fatality of 20.8, 25 and 45.8%. Cardiovascular (75%) or malignancy (13%) were the 
cause of death in most cases.
Conclusions: Renal transplant recipients have a high incidence of stroke and poor 
outcome following stroke. Risk factors include prior CeVD, age, diabetes and AF. Although 
AF associated with time to stroke, the role of warfarin in prevention is poorly defined, 
requiring further study.
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FR-PO1046
Factors Influencing Racial Disparities in Renal Transplantation Outcomes 
Sumit Mohan,1 Barry I. Freedman,2 William Mark Brown,2 Stephen O. Pastan,3 
Ajay K. Israni,4 David P. Schladt,5 Robert S. Gaston,6 R. Bray,3 Amber M. 
Reeves-Daniel,2 Bruce A. Julian,6 Jasmin Divers.2  1Columbia Univ; 2Wake 
Forest School of Medicine; 3Emory Univ; 4Univ of Minnesota; 5Minneapolis 
Medical Research Foundation; 6Univ of Alabama at Birmingham.
Background: Kidney transplants from African American (AA) deceased donors have 
worse outcomes than kidneys procured from donors of other ethnic groups; deceased-
donor kidney transplants (DDKTs) engrafted into AAs fare worse than kidneys placed 
into recipients of other ethnic groups. The role of biological and environmental factors in 
these disparities remains unclear. We sought to identify factors contributing to these ethnic 
differences in AA and European American (EA) recipients of kidneys from AA and EA 
donors in a study using donor-matched design to eliminate donor-specific confounding 
effects.
Methods: We compared allograft survival of DDKTs in 4 types of donor/recipient 
pairs (TDRP) (AA/AA, AA/EA, EA/AA and EA/EA). Models were fitted using a mixed 
effect Cox model with particular focus on effect modifiers of the TDRP association with 
allograft survival.
Results: We identified 669 AA and 3,383 EA donors resulting in 669 AA/AA, 669 AA/
EA 3,383 EA/AA and 3,383 EA/EA DDKTs. In agreement with previously reported trends, 
AA donors were more likely to be younger, male, hypertensive, and with higher serum 
creatinine, while EA recipients were more likely to be employed (46 and 45% vs. 37 and 
33%) and less likely to experience delayed allograft function (DGF) (19 and 18% vs. 28 
and 23%). Adjusted analyses controlling for donor and recipient characteristics identified 
strong interaction effects between the TDRP and incidence of DGF (P=0.009) and between 
the TDRP and employment status (P=0.04). Observed hazard ratios varied from 0.9 for an 
employed (EA/EA) pair without DGF to 4.3 for an unemployed (AA/AA) pair with DGF.
Conclusions: Ethnic differences in employment status and incidence of DGF were 
the strongest effect modifiers of the association between the TDRP and allograft survival 
for DDKTs. These differences partially explain the observed racial disparity in outcomes 
for DDKTs.
Funding: Other NIH Support - NIH RO1 DK070941 (BIF), NIH RO1 DK084149 
(BIF), NIH
RO1 MD009055 (JD, BIF), NIH/NIAD Genomics of Transplantation 5U19-
AI070119 (AKI)
FR-PO1047
Renal Transplantation in Bardet-Biedl Syndrome  Robert M. Haws,1 Aditya 
Joshi,1 Siddharth A. Shah,3 Omar M.A.A. Alkandari,4 Martin A. Turman.2  1Dept 
of Pediatrics, Marshfield Clinic, Marshfield, :I; 2Dept of Pediatrics, Univ of 
Oklahoma Health Sciences Center, Oklahoma City, OK; 3Dept of Pediatric 
Nephrology, Univ of Louisville, Louisville, KY; 4Dept of Pediatrics, Mubarak 
Al-Kabeer Hospital & Hamid Al-Essa Transplant Center, Safat, Kuwait.
Background: Bardet-Biedl syndrome (BBS) is a rare, multisystemic genetic 
disorder frequently associated with chronic kidney disease (CKD). Data regarding renal 
transplantation (RT) in BBS is lacking and reports tend to highlight complications. We 
report RT outcomes in the largest BBS cohort examined to date.
Methods: An international BBS registry was interrogated to identify individuals that 
had undergone RT and capture age, gender, body mass index (BMI), transplant and patient 
survival, donor source, and comorbidities.
Results: RT was performed in 19/171 (11%) registry subjects (mean age 9 y; range 
2-25 y). RT patients were younger (9 vs. 17.9 y, p <0.05) and more likely to be female (82% 
vs. 50%). Deceased donors provided 12/21 kidneys; one patient received a combined liver/
renal transplant. Two patients that underwent RT in the 1980s and died at <10 y of age were 
excluded from further analysis. Patient and kidney survival is shown. 
Thrombosis and infection resulted in graft loss in the first year in 1 patient with 2 
kidneys. One patient died awaiting a second RT. Acute reversible rejection in the first 
year occurred in 1/17 kidneys. Diabetes, hypertension, and obesity were present in 18%, 
71%, and 88% of subjects, respectively. Malignancy was not observed (mean follow-up 
9.8 y; range 1-21 y). BMI was increased compared to age-matched BBS patients without 
RT (42.2 vs. 35.2, p < 0.05).
Conclusions: Outcomes following RT in patients with BBS is favorable. Female 
predominance raises questions regarding gender as a potential modifying factor impacting 
CKD prevalence.
Funding: Private Foundation Support
FR-PO1048
Kidney Transplant Recipient Hospital Readmission: Examination of 
Discharge-Level Factors  Michelle L. Lubetzky, Maria Ajaimy, Layla Kamal, 
Graciela De Boccardo, Enver Akalin.  Transplantation, Montefiore, Bronx, NY.
Background: Early rehospitalization after kidney transplantation (KTx) is common 
and is considered a quality metric. Few studies have examined preventability or discharge 
factors associated with early rehospitalization.
Methods: We performed a single-center, retrospective cohort study between 2011-2015 
of adult KTx recipients. The primary outcome was at least one readmission within 30 days 
after discharge. Secondary outcomes were reason for readmission, potential for process 
improvement to reduce readmission, and all-cause graft failure.
Results: Of 462 KTx, 31.4% were readmitted within 30 days of discharge. The reason 
for readmission was surgical in 20.1%. Of those with non-surgical reasons, 21.7% were from 
infection, 20.9% graft dysfunction, 21.7% gastrointestinal, 21.7% metabolic, and 13.9% 
other. Readmission was significantly associated with all-cause graft failure (p=0.006). The 
assessment of preventability showed that the reason for readmission was present at the time 
of discharge in 11.7%, additional hospital resources may have abrogated the readmission 
in 15.8%, and 12.4 % could have been managed as outpatient. On univariate analysis, risk 
factors for rehospitalization were: presence of comorbidities (p=0.03), complication during 
hospitalization (p<0.001), discharge electrolyte abnormalities (p<0.001) and kidney function 
at discharge (p=0.003), Table 1. On multivariate analysis, the presence of 3 comorbidities 
pre-KTx (aOR 2.01 95% CI 1.84-3.86), electrolyte abnormalities at discharge (aOR 1.77 
CI 1.17-2.69), delayed graft function (aOR 1.65 95% CI 1-2.7), and post KTx complication 
(aOR 1.7 95%CI 1.1-2.61) were associated with increased risk of readmission
Conclusions: Early readmission is associated with worse graft survival. Many 
readmissions may be preventable and review of process improvement may reduce early 
readmission after KTx.
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FR-PO1049
Kidney Transplant Outcomes for Patients with Amyloidosis – A United 
Network for Organ Sharing Database Analysis  Ali Khalil, Tim E. Taber, 
Muhammad Ahmad Mujtaba, Muhammad S. Yaqub, Asif A. Sharfuddin. 
Medicine/Neph, Indiana Univ, Indianapolis, IN.
Background: Outcomes of patients with Amyloidosis who receive a kidney transplant 
have not been extensively studied. We examined UNOS database for outcomes of such 
recipients.
Methods: UNOS database was queried for recipients with code “3016” which 
corresponds to “ Amyloidosis”. Duration of study period was Nov 1987 to Dec 2014.
Results: A total of 625 recipients were identified as in the table.
Variable Result
Mean Age at time of transplant (yrs) SD 54.8±11.1
Mean Donor Age 40±15.1
Median Time On Wait List (days)(range) 261(0-2706)
Caucasian/African American/Hispanic/Other (%) 80.5/7.2/9.1/3.2
Deceased/Living (%) 56.5/43.5
M/F (%) 62.4/37.6
On Dialysis at time of transplant (%) 80.2
Mean BMI (SD) 25.7±4.8
Diabetes (%) 6.3
Repeat Kidney Transplant (%) 3.8
PRA >80 (%) 3.6
Zero Mismatch (%) 8.6
Blood Type A/AB/B/O (%) 40.7/5.3/12.5/41.6
ECD Donor/DCD (%) 9.6/2.9
Multi-Organ Transplant (%)
- Heart(n)
- Liver(n)
- Panc(n)
6.6
- 21
- 23
- 2
Delayed Graft Function (%) 14.6
Serum Creatinine (mg/dL) at discharge (SD) 2.3±2.1
Treated for Rejection within 6mo (%) 11.2
Treated for Rejection within 1 yr (%) 12.8
Death With Functioning Graft (%) 28.3
Unadjusted 1 yr/3yr/5yr/10 yr Graft Survival (%) 87.5/79.3/71.2/58.2
Actual Patient Survival 1yr/3 yr/5yr/10 yr 91.0/83.0/75.8/61.2
After excluding multi-organ transplants, the 1 year unadjusted graft survival was 88.6% 
and the 1 year patient survival was. 92.1 %. Kaplan Meier Survival Curves are in the Figure.
Conclusions: Although 1 year graft and patient survival of kidney transplants in 
recipients with Amyloidosis is inferior to standard outcomes, long-term outcomes are not 
remarkably different. Careful selection of this population can lead to satisfactory outcomes. 
To our knowledge this is the first and largest report on the outcomes of these patients from 
the US national database.
FR-PO1050
Early Experience with the New Kidney Allocation System  Allan Massie, 
Dorry L. Segev.  Johns Hopkins.
Background: On December 3, 2014, major changes to deceased donor kidney 
allocation were implemented under the new Kidney Allocation System (KAS).
Methods: Using national registry data, we compared changes in rate of DDKT 
among adult kidney-only waitlist registrants 1/2011-3/2015 pre vs post-KAS via Poisson 
regression, adjusting for age, sex, race, ABO blood type, calendar year, calculated panel 
reactive antibody (CPRA), and wait time. We compared donor service area-level geographic 
disparity pre vs post-KAS using multilevel Poisson regression and median incidence ratio 
ratio (MIRR). We also compared CPRA of DDKT recipients pre vs post-KAS, and incidence 
of delayed graft function (DGF).
Results: Pre-KAS, access to DDKT was poorer for women (IRR=0.91 0.92 0.94), African-
Americans (AAs) (IRR=0.86 0.88 0.90), and Hispanics (IRR=0.77 0.79 0.81, all p<0.01). Access 
was best for patients of ABO type AB (IRR vs O=2.19 2.29 2.39, p<0.01) and worst for ABO 
type B (IRR vs O=2.19 2.29 2.39, p<0.01). KAS was associated with no change in overall 
DDKT access (p=0.7), but with improved access for AAs (IRR=1.09 1.16 1.24, interaction 
p<0.001) and patients of ABO type AB (IRR=1.11 1.29 1.50, interaction p=0.001). Geographic 
disparity declined post-KAS (MIRR=1.76 pre-KAS, 1.64 post-KAS). Median CPRA at 
transplant was 0 both pre and post-KAS; the proportion of recipients with CPRA 80-99 
decreased from 13.6% to 10.1% (p<0.001), but the proportion with CPRA>99 rose from 
1.6% to 14.0% (p<0.001, Figure 1).
DGF incidence increased from 26.5% pre-KAS to 31.6% post-KAS (chi2 p<0.001); 
in a multilevel (center-level) model, DGF increased 37% (OR=1.21 1.37 1.55, p<0.001).
Conclusions: After recent changes to kidney allocation, DDKT access improved 
for AA patients and geographic disparity declined. Women and Hispanic patients are 
still disadvantaged, and disparity by ABO type worsened. The proportion of recipients 
with CPRA>99 rose dramatically. Increase in DGF may suggest risk of poorer long-term 
outcomes.
Funding: NIDDK Support
FR-PO1051
Kidney Transplantation Tourism: High Risk and Bad Outcome for the 
Recipients  Amgad E. El Agroudy.  Internal Medicine Dept, College of Medicine 
and Medical Sciences, Arabian Gulf Univ, Manama, Bahrain.
Background: While the ethical aspects of transplant tourism have received much 
attention recently, less has been written about the medical safety of this practice. We 
retrospectively evaluated the outcomes of patients who purchased organs internationally 
and presented to our center for follow-up care.
Methods: We report the outcome parameters of 270 local recipients of unrelated 
kidney (URT) vendor transplants presenting to our institute between 1986 and 2014. Their 
outcome was compared with 123 recipients of living-related donor transplants matched for 
age, gender and transplant duration done in our center as controls (RT).
Results: Age of  unrelated recipients was 42.6 ± 13.4 years with Male % of 68. The 
country of transplant was mainly in Philippines (n = 85), Pakistan (n = 56), India (n = 
57), Iran (n = 40) and Egypt (n= 25). Comparison of commercial recipients with controls 
showed high co morbidities (P = 0.01) with hepatitis-C (n=2 vs. 0) and hepatitis-B (n=2 
vs. 0) and cytomegalovirus (n=4 vs. 1). Donor age was 25.9 ± 3.8 vs. 34.6 ± 8.6 years (P 
= 0.0001) and 90.4% were male. Biologic agents induction in 74 (27.4%) vs. 123 (100%) 
(P = 0.00001), acute rejections in 65 (24.1%) vs. 26 (21.1%) (P = 0.7), while recurrent 
rejection in 13 (4.8%) vs. 1 (0.8%) (P = 0.04), surgical complications including lymphocele 
16 (5.9%) vs. 0 (0%) (P = 0.0001), ureteral obstruction 7 (2.6%) vs. 0 (0%) (P = 0.007), 
hematoma 4 (1.5%) vs. 1 (1.1%) (P = 0.06) and recurrent urinary tract infection 18 (9.9%) 
vs. 6 (6.8%) (P = 0.3). Overall 1- and 10-year  for graft survival was 91% and 22% vs. 
98% and 44% and for patient survival 96% and 70% vs. 98% and 78% in URT and RT, 
respectively (P = 0.001).
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Conclusions: Although recent developments increased success in renal transplantation, 
receiving a kidney from a paid living donor at a commercial transplant center still carries 
great risks for the recipient.
FR-PO1052
The Negative Effect of First Transplant Nephrectomy for Second 
Transplant Outcome  Masaki Muramatsu,1,2 Michael Sheaff,3 Arun Gupta,4 
Atsushi Aikawa,2 Carmelo Puliatti,1 Muhammad M. Yaqoob.1  1Nephrology 
and Transplantation, The Royal London Hospital, London, United Kingdom; 
2Nephrology, Toho Univ Faculty of Medicine, Tokyo, Japan; 3Cellular Pathology, 
The Royal London Hospital, London, United Kingdom; 4Clinical Transplant 
Laboratory, The Royal London Hospital, London, United Kingdom.
Background: The impact of failed renal allograft nephrectomy on the outcome of 
retransplant is unclear. This single center study was conducted to address this question.
Methods: We analyzed 93 patients who received a 2nd transplant at The Royal London 
Hospital between November 1994 and January 2015. 59 patients did not receive primary 
transplant nephrectomy (TNx) and had failed allograft in-situ at the time of second graft 
(group A) whilst 34 patients underwent TNx prior to second graft (group B). 2nd transplant 
survival was the primary end point. Sensitization, waiting time for 2nd graft, graft function 
and rejections were secondary end points.
Results: Group A patients had significant longer graft survival than group B (100.6 
months vs 40.2 months, p<0.001). Waiting time from primary graft loss to second transplant 
in group A was shorter than group B (36.7 months vs 59.1 months, p=0.013). In total, 35 
patients had pre-formed anti-HLA antibodies (low titer). Group B had significantly higher 
rate of pre-formed ant-HLA antibodies than group A (50.0% vs 29.3%, p=0.047). The rate of 
HLA class I in group B was also significantly higher than that in group A (47.1% vs 25.7%, 
p=0.038). Group B had numerically higher rate of acute rejection than group A (32.4% vs 
15.3%, p=0.053). eGFR between both groups did not differ until 3 years post-transplant. In 
group A, 2nd graft survival rates at 6month, 1, 3 and 5 years were 94.9%, 93.0%, 87.0% and 
82.3%, and were significantly better group B (73.3%, 70.0%, 60.6% and 46.8%, p<0.001). 
On multivariate analysis, waiting time for second transplant, TNx, second transplant donor 
age and delayed graft function were independently associated with second graft survival. 
TNx had highest hazard ratio (2.83, 95% CI 1.22-6.67, p=0.015).
Conclusions: Prior TNx is associated with inferior 2nd renal graft survival in this 
observational study and calls for an urgent randomized control trial.
FR-PO1053
Induction Agent Use, Mortality and Acute Rejection in Older KT Recipients 
Mara McAdams-DeMarco, Xun Luo, Babak Orandi, Dorry L. Segev.  Johns 
Hopkins.
Background: Induction agents are commonly used as an initial intensive 
immunosuppression after kidney transplantation (KT) to prevent acute organ rejection; this 
practice is mostly off label. Little is known about induction agent use in older KT recipients.
Methods: Data on 19,546 older KT recipients (2005-2013) was ascertained from 
the Scientific Registry of Transplant Recipients. Induction agents were classified as 
thymoglobulin/ATG, IL-2, or other induction agents. The risk of mortality was estimated 
using a Cox Proportional Hazards model (hazard ratio (HR)) adjusting for all recipient 
and KT factors (age, sex, race, BMI, peak PRA, history of diabetes, years on dialysis) and 
KT factors (HCV, HLA mismatches, cold ischemia time, donor type, donor age, and donor 
sex). The relative risk (RR) of 1 year acute rejection was estimated using modified Poisson 
regression adjusting for all recipient and KT factors.
Results: The mean age was 69 (SD=3.8 years), 36% female, 19% black and 27% 
live donor recipients. There is an increasing utilization by year of induction agents, with 
84% use in older recipients. Compared to those who did not receive induction, the risk of 
mortality for older recipients was decreased for those who received thymoglobulin/ATG 
(HR=0.86, 95%CI:0.79-0.94), IL-2 induction agents (HR=0.89, 95%CI:0.81-0.97), and 
other induction agents (HR=0.85, 95%CI:0.75-0.97). Additionally, compared to those who 
did not receive induction, the risk of 1 year rejection for older recipients was increased for 
those who received IL-2 induction agents (HR=1.36, 95%CI:1.15-1.61), as well as other 
induction agents (HR=1.27, 95%CI:1.03-1.57) but not thymoglobulin/ATG (HR=1.06, 
95%CI:0.90-1.25).
Conclusions: For older KT recipients, there is an increasing trend in the use of 
induction agents and a decreased risk of mortality regardless of the type of induction 
agent used. However, there is little evidence for a protective effect of induction agent use 
for 1 year acute rejection.
Funding: Other NIH Support - NIA, Private Foundation Support
FR-PO1054
Immunosuppression and the Elderly – Can They Take It?  Mariana C. Chiles, 
Shefali Patel, Sumit Mohan, Russell J. Crew.  Columbia Univ, New York, NY.
Background: The aging immune system has fewer naïve T cells, more memory T 
cells, and less T cell receptor variability. Older transplant patients tend to have more 
comborbidities and less functional reserve. This combination makes them more difficult 
to immunosuppress with higher risk of infection, and potentially increased mortality from 
rejection treatment.
Methods: In order to determine the impact of rejection treatment on outcomes 
in our transplant recipients >70 years of age, we reviewed the outcomes of patients 
transplanted at our center from 1/2009-12/2013. Induction regimens varied; maintenance 
immunosuppression consisted of tacrolimus, mycophenolate, and rapid steroid withdrawal.
Results: During this time period, we transplanted 110 over 70 years of age. Of these, 
27 patients had rejection—24 ACR, 1 combined AMR/ACR, 1 AMR, 1AMR followed by 
ACR (see table). 11 of these patients received Tcell depleting agents, the rest received IV 
steroids +/- IVIg. There was no difference in age, race, donor type, prior transplant, or 
induction therapy between the two groups. Mean creatinine was higher in the rejection 
group. However, treatment appeared to stabilize function- the rate of decline in estimated 
GFR after rejection treatment was no different between groups. Within 6 months of rejection 
treatment, there were 12 infectious complications, only 3 of which required hospitalization 
(urosepsis-2, CMV-1). There were no differences in rates of BK viremia, CMV viremia, 
graft survival, or mortality. 7 of the 27 patients died at some point after rejection. only one 
was related to infection >1 year later and not related to treatment.
Conclusions: Among our >70 patients, rejection treatment appeared well tolerated 
with few complications requiring hospitalizations and no treatment related mortalities. In 
addition, it appeared that treatment stabilized function in the majority of patients.
FR-PO1055
Mortality After Kidney Allograft Failure and Return to Dialysis 
Amarpali Brar,1 Edem Nguamon Timpo,1 Rahul M. Jindal,3 Nabil Sumrani,2 
Fasika M. Tedla,1 Moro O. Salifu.1  1Medicine, SUNY Downstate Medical 
Center, Brooklyn, NY; 2Surgery, SUNY Downstate Medical Center, Brooklyn, 
NY; 3Surgery, Uniformed Services Univ of Health Sciences, Bethesda, MD.
Background: Our hypothesis was that kidney allograft failure (KAF) and return to 
dialysis (RTD) results in greater mortality versus patients with end-stage renal disease 
(ESRD). We also sought to identify variables associated with mortality after KAF.
Methods: We used an incident cohort of patients from the United States Renal Data 
System who initiated any form of dialysis between Jan 2003 and Dec 2008 after KAF. We 
followed patients until retransplantation, death or Sept 2009. Multivariable Cox analysis 
was used for statistical associations.
Results: 7,156 patients were followed for a mean of 30.8 ± 22.6 months. 3,622 (50.6%) 
patients died; main causes of death cardiac (47.0 %), infectious (17.5%), other (16.4%) and 
metabolic/endocrine (7.9%) causes. Predictors of all-cause mortality included age at KAF 
[hazard ratio (HR)= 1.03, 95% confidence interval (CI) 1.03-1.04], diabetes (DM) as cause 
of kidney failure (HR= 1.52, CI 1.3-1.8), congestive heart failure [CHF] (HR= 1.19, CI 
1.04-1.36), peripheral arterial disease [PAD] (HR= 1.23, CI 1.04-1.55), stroke (HR= 1.27, 
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CI 1.05-1.55), employment (HR= 0.80, CI 0.67-0.96), BMI (HR = 0.98, CI 0.97-0.99) and 
serum albumin (HR= 0.82, CI 0.75-0.90). Mortality was higher in those with either DM or 
CHF, and increased further in those with PAD (P=<0.0001).
Gender, number of transplants, donor type (deceased, living), ESRD duration prior 
to transplant, tobacco use, drug or alcohol abuse and erythropoietin use did not predict 
all-cause mortality.
Conclusions: DM, CHF and PAD are associated with increased mortality after KAF 
and RTD. Prevention and early management of these conditions may increase survival. 
Prospective studies are needed to confirm our findings.
Funding: Private Foundation Support
FR-PO1056
Current Trends in Waiting List of Kidney Transplantation and Mortality 
in Asian: A National Population-Based Cohort Study Using the Korean 
Network for Organ Sharing (KONOS) Database  Kyung Don Yoo, Sunhwa 
Lee, Jung Nam An, Yun Kyu Oh, Chun Soo Lim, Yon Su Kim, Jung Pyo Lee. 
Seoul National Univ College of Medicine.
Background: Kidney transplantation has been increasing, globally. However, the 
clinical outcome of wait-listed patients for deceased donor kidney transplantation has not 
been well described in Asian patients with end-stage renal disease (ESRD).
Methods: We reviewed the detailed trends of wait-listed patients and conducted survival 
analysis in kidney transplant recipients using KONOS (The Korean Network for Organ 
Sharing) database which is a complete enumeration survey. We compared the outcomes 
according to the transplant era as followings: 2000~2004, 2005~2009, 2010~2014.
Results: From 2000 to 2014, a total of 34,843 patients registered in the waiting list, and 
5,164 patients received transplantation from deceased donor. The proportion of deceased 
donor kidney transplantation has increased up to 45.9% in 2013 from 4.6% in 2000. The 
number of waiting list for kidney transplantation has increased continually more than 3,000 
ESRD patients per year. The mean waiting time of deceased donor kidney transplantation 
was 54.9 months and has been getting longer. A total of 18,687 patients were remained 
on the waiting list until Jan 2015. Recently, diabetic nephropathy was the leading cause 
of primary disease on the waiting list, and the mean age of new registrants was getting 
older. The crude annual mortality rate during waiting time was 8.4%. The survival analysis 
revealed that there was no difference of patient survival according to the transplant era in 
kidney transplant recipients. However, the cumulative survival rate of the recently registered 
wait-listed patients was significantly improved even though they were older and had more 
proportion of diabetes (P<0.001, HR 0.51 95% CI 0.46-0.57).
Conclusions: In Korea, deceased donor kidney transplantation has increased. Donor 
organ is still seriously insufficient, therefore, it is necessary to encourage organ donation. 
In addition, more meticulous management needs to be provided to wait-listed patients.
FR-PO1057
Factors Affecting Mortality During Waiting Time for Kidney 
Transplantation: A Nationwide Population-Based Cohort Study Using the 
Korean Network for Organ Sharing (KONOS) Database  Sunhwa Lee,1 
Kyung Don Yoo,1 Jung Nam An,1 Yun Kyu Oh,2 Chun Soo Lim,2 Yon Su Kim,1 
Jung Pyo Lee.2  1Div of Nephrology, Dept of Internal Medicine, Seoul National 
Univ Hospital; 2Dept of Internal Medicine, Seoul National Univ Boramae 
Medical Center.
Background: Longer waiting times for kidney transplant have been suggested to be 
more deleterious than shorter waiting times. We analyzed the impact of waiting time on 
the post-transplant outcome and investigated risk factors for mortality during waiting time 
based on complete enumeration survey in Korea.
Methods: We analyzed all persons over 18-years-old deceased donor kidney transplant 
cases enrolled in Korean Network for Organ Sharing (KONOS) data between Jan 2000 to 
Jan 2015. The primary end point was all cause of death after enrollment.
Results: Of the 24,296 waiting-listed dialysis subjects, 5,255 patients including 588 re-
transplant cases received kidney transplantation from deceased donor with median waiting 
time of 4.5 years. Ten year overall survival was 81.3% in kidney transplant recipients, 
whereas 68.1% in dialysis patients. Unlike previously known data, the effect of waiting 
time on mortality after transplantation was insignificant. During waiting time, however, 
various demographic and clinical factors are associated with increased mortality. Diabetic 
patients are more likely to die before transplantation (HR 2.25, 95%CI 1.37-3.70, P=0.001). 
Aging is another significant risk factor for mortality. Only 56% of people aged 65 survive 
after 10 year of waiting, whereas 86% of people aged 35. Men are more likely to die than 
women during waiting time (HR 1.22, 1.13-1.31, P<0.001). Moreover, Patients with Rh 
negative blood type shows higher mortality rate than those with Rh positive (HR 1.60, 
1.06-2.42, P=0.024). Pre-transplant experienced patients, however, showed better survival 
during waiting time (HR 0.63, 0.46-0.86, P=0.003).
Conclusions: Longer waiting times on dialysis do not affect survival after 
transplantation although transplant itself shows better overall survival. It should be 
emphasized to have more attention to the patients who are diabetic, old, men, or Rh negative 
with higher risk for mortality during waiting time.
FR-PO1058
Normal Saline versus Lower-Chloride Solutions for Kidney Transplantation 
Susan Wan,1,2 Matthew A. Roberts,3 Peter F. Mount.1  1Dept of Nephrology, 
Austin Health, Melbourne, Victoria, Australia; 2Central Clinical School, Univ 
of Sydney, Sydney, New South Wales, Australia; 3Eastern Health Clinical School, 
Monash Univ, Box Hill, Victoria, Australia.
Background: The ideal intravenous (IV) fluid for kidney transplantation (KTx) has not 
been defined, despite the common use of normal saline (NS) in the perioperative period. 
The high chloride content of NS is associated with an increased risk of hyperchloraemic 
metabolic acidosis, which may increase the risk of hyperkalaemia and delayed graft 
function (DGF). Balanced electrolyte solutions (BES) have a lower chloride content, which 
may decrease this risk and avoid the need for dialysis due to hyperkalaemia. Randomised 
controlled trials (RCTs) have used biochemical outcomes to compare fluids and have 
been underpowered to address patient-centred outcomes such as DGF. We systematically 
reviewed the effect of BES versus NS on DGF, hyperkalaemia and acid-base status in 
KTx recipients.
Methods: We searched the Cochrane Renal Group’s Specialised Register to 24th 
March 2015. We included RCTs of KTx recipients that compared perioperative IV lower-
chloride solutions to NS. Two independent investigators assessed studies for eligibility 
and risk of bias. Data were extracted using standardised forms and pooled according to 
a published protocol.
Results: Six studies (477 participants) were included in the review. All participants were 
adult KTx recipients and 70% received live-donor KTx. The overall risk of bias was low 
for selection bias and unclear for remaining domains. There was no difference in the risk of 
DGF (RR 1.03, 95%CI 0.62–1.70, P=0.91) or hyperkalaemia (RR 0.48, 95%CI 0.04–6.10, 
P=0.57) for participants who received BES compared to NS. Compared to NS, BES were 
associated with higher blood pH (mean difference pH 0.07, 95%CI 0.05–0.09, P<0.00001), 
higher serum bicarbonate (mean difference HCO3 3.04mEq/L, 95%CI 2.13–3.94mEq/L, 
P<0.00001) and lower serum chloride (mean difference chloride -9.93mmol/L, 95%CI 
-19.96–0.11mmol/L, P=0.05).
Conclusions: Intraoperative balanced electrolyte solutions are associated with less 
hyperchloraemic metabolic acidosis compared to normal saline. However, these data do 
not support their use to reduce clinical events.
FR-PO1059
Risk Factors for Delayed Graft Function in Kidney Transplantation 
Marcos A. Meniconi,1 Vitoria C. Vilela,1 J. Medina-Pestana,1 Miguel Cendoroglo 
Neto,1,2 Miguel A Goes.1,2  1Nephrology Div, Federal Univ of Sao Paulo, Sao 
Paulo, SP, Brazil; 2Nephrology Div, Hospital Israelita Albert Einstein, Sao 
Paulo, SP, Brazil.
Background: Renal failure persisting after transplantation necessitating dialysis within 
the first week is called delayed graft function (DGF). Objective:To assess the impact of 
erythropoietin usage on DGF after renal transplantation.
Methods: A total of 196 maintenance hemodialysis patients who underwent renal 
transplantation at one center (Hospital do Rim) were prospectively analyzed pre and 
post-renal transplantation. Data on demographics, ESRD etiology, pre-transplantation 
hemodialysis, recombinant human erythropoietin (rHuEPO) use, type of donor kidney 
and immunosuppression regimen were reported. Two-sample t test were used to compare 
differences between two groups (DGF versus non-DGF groups) and X2 to analyze 
categorical variables. Binary logistic regression was used to determine the impact of 
factors on outcome-DGF.
Results: The mean time duration on maintenance hemodialysis was 18+6 months. The 
main causes of ESRD were diabetes (37%) and hypertension (15%) followed by chronic 
glomerulonephritis (9%). There were transplants from deceased-donor kidneys (47%), living 
unrelated kidney donation (43%) and living related donors (10%). 41patients necessitated 
dialysis within the first week after renal transplantation (DGF group). We observed that 
131 patients (67%) used recombinant human erythropoietin until one week before renal 
transplantation. We observed that DGF group was older (39+15; p=0.007), higher cold 
ischemia time (23+10h, 12+10h; p<0.001), longer time on dialysis (4+4, 2+1 yr; p=0.001) 
and higher rHEPO dose (4930+447, 1658+844 IU; p<0.001). DGF group had higher use of 
rHuEPO (p<0.001). Cold ischemia time (p =<0.001) was an independent predictor of DGF.
Conclusions: This study shows that rHuEPO was not associated with DGF-protection 
in renal transplant patients. Cold ischemia time is an independent predictor of DGF.
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FR-PO1060
Outcomes of Kidney Transplant Recipients from Donation After Circulatory 
Death Donors without Pre-Agonal Heparin Administration  Layla Kamal, 
Joel Lindower, Maria Ajaimy, Michelle L. Lubetzky, Graciela De Boccardo, 
Enver Akalin, Liise K. Kayler.  Montefiore-(instein Center for Transplantation.
Background: Protocols of organ donation after circulatory death (DCD) are 
considerably varied. Heparin administration during the pre-agonal phase has been 
recommended to improve organ perfusion and prevent blood clots; however some protocols 
avoid heparin before verification of death based on legal or professional concerns. We 
assessed outcomes of kidney transplant recipients who received DCD kidneys recovered 
with and without heparin.
Methods: We retrospectively evaluated recipients of kidney transplants between 2011 
and 2014 from controlled DCD donors who received (n=23) or did not receive (n=29) 
pre-agonal heparin.
Results: All kidneys underwent machine perfusion. No Heparin donors had a similar 
kidney donor profile index but were more likely to have mild histologic changes, elevated 
terminal machine perfusion resistive index, and to be imported from non-local donor 
service areas compared to the Heparin donors. Recipients of no Heparin kidneys were more 
likely to be female, sensitized, prior solid organ recipients, and to receive thymoglobulin 
induction but were less likely to have diabetes. None of these differences reached statistical 
significance. Post-transplantation, 1 patient died early due to a cardiac event (no Heparin 
group). Graft failure occurred in 2 patients in the no Heparin group (one each of sepsis/
intraparenchymal venous thrombosis and chronic histologic changes suggestive of donor 
disease) and 1 patient in the Heparin group (renal artery thrombosis). Between group 
differences were small in terms of delayed graft function, 6-month acute rejection, and 
estimated GFR at 3, 6, and 12 months. 
Conclusions: Our findings suggest that DCD kidneys recovered without pre-agonal 
heparin are not at increased risk for primary non-function or thrombosis.
FR-PO1061
Effects of Dopamine Donor Pretreatment on Graft Function After Kidney 
Transplantation: Five-Year Follow-Up of a Randomized Controlled Trial 
Urs Benck,1 Bernhard K. Krämer,1 Peter Schnuelle.2  1V. Medical Clinic, Univ 
Medical Center Mannheim, Mannheim, Germany; 2Nephrology, Center for 
Renal Diseases, Weinheim, Germany.
Background: [For the study Group]: A previous multicenter randomized controlled 
trial reported reduced dialysis requirements after kidney transplantation with dopamine 
donor pretreatment. Data on long-term outcomes are needed.
Methods: We calculated five-year graft survival from follow-ups at 60 European 
centers. We analyzed intention-to-treat and on-study-medication and produced survival 
estimates as tertiles of dopamine exposure because infusion times varied by treatment arm 
(range 0-1,929 min). Recipients with functioning grafts at three months were analyzed 
separately to differentiate early events from long-term consequences of the trial intervention.
Results: Follow-up was complete in 99.2%. Overall graft survival was 72.6 vs. 
68.7%, (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.61-1.19; p=0.35), and 
death-censored graft survival was 83.3 vs. 80.4%, (HR 0.84, 95%CI 0.54-1.29; p=0.42) in 
the treatment and control arms, respectively. The HR decreased to 0.46 (95%CI 0.23-0.94; 
p=0.03) in recipients with functioning grafts at three months, whose donor had received 
dopamine >270 min. It remained significant after adjusting for donor age (HR 1.05, 95%CI 
1.02-1.08; p=0.001), delayed graft function (HR 2.05, 95%CI 1.12-3.73; p=0.02), biopsy-
proven rejection (HR 2.13, 95%CI 1.16-3.93; p=0.02), and repeat transplants (HR 2.49, 
95%CI 1.19-5.20; p=0.02). There were no differences of graft survival on intention-to-treat.
Conclusions: Dopamine administered for >270 min provided a long-term graft survival 
advantage independent of early events after Transplantation.
FR-PO1062
Does Calcineurin Inhibitor Timing Matter? Single Center Experience 
with En-Bloc Kidney Transplantation  Maya Campara,1 Oksana A. Kucher,1 
Sanjeev Akkina,2 Ignatius Yun-Sang Tang.2  1Pharmacy Practice, Univ of Illinois 
at Chicago; 2Medicine, Nephrology, Univ of Illinois at Chicago.
Background: En-bloc kidney transplantation (KTx) has excellent outcomes. To 
minimize vascular complications and nephrotoxicity, calcineurin inhibitor (CNI) therapy 
is often delayed. The purpose of our study is to investigate the impact of CNI initiation 
timing on 1-year graft outcomes.
Methods: This is a single-center, retrospective review of adult en-bloc KTx between 
2001 and 2013. Timing of CNI initiation was decided by the operating surgeon. Patients 
were divided into two groups, those that received CNI therapy early (≤48 hours) or delayed 
(>48 hours) posttransplant. The primary objective was to compare one year estimated 
glomerular filtration rate (eGFR) between the groups. Secondary outcomes included graft 
and patient survival, CNI levels, incidence of delayed graft function (DGF), rejection and 
graft failure rates.
Results: Twenty-one en-bloc KTx recipients were included in the analysis. Ten patients 
received CNI therapy within 48 postoperative hours (Early CNI Group). There was no 
difference in age, race, gender, PRA, cause of ESRD or BMI between the groups. Only 50% 
of Early CNI patients received lymphocyte depleting therapy vs. 100% in the Delayed CNI 
group (p = ns). In the Early CNI Group, 3 patients were on cyclosporine; all other patients 
received tacrolimus and mycophenolate maintenance. There was no difference in eGFR 
between groups at one year or at any other time points. Comparable therapeutic tacrolimus 
trough was observed at 5, 10 and 30 days posttransplant. There was no difference in DGF 
or rejection incidence. In the delayed CNI group, one patient died of sepsis at 6 months.
Conclusions: Timing of CNI initiation had no impact on one year graft function and 
patient survival.
Early CNI (n = 10) Delayed CNI (n = 11)
FK506 trough POD-5, ng/ml 5.75+/-2.65 7.34+/-4.9
FK506 trough POD-10, ng/ml 11.5+/- 4.9 12.1+/-7.5
FK506 trough POD-30, ng/ml 9.3+/-1.4 9.9+/-3.7
eGFR POD-30 Days, ml/
min/m2 59.7+/-22.3 50.9+/-25.7
eGFR POD-365 Days, ml/
min/m2 84.9+/-27.8 80.5+/-21.4
Rejection 1st year, n(%) 2(20) 3(27)
BPAR, n(%) 1(10) 1(9)
FK506-tacrolimus; POD-postoperative day; BPAR-biopsy proven acute rejection 
FR-PO1063
Reduction of Pediatric Renal Transplantation Vascular Thrombosis Rates 
Utilizing Low Dose Heparin Infusion  Philip D. Acott,1,2 James B. Tee,1,2 
Philip Wornell,1,2 John F.S. Crocker.1,2  1Pediatrics, Dalhousie Univ, Halifax, 
NS, Canada; 2Pediatrics, IWK Health Center, Halifax, NS, Canada.
Background: Pediatric renal allograft thrombosis rates are 4-10% and often result in 
allograft loss. Thrombotic risk factors are smaller native vessel size, deceased donor source 
(DD), delayed renal allograft function, acute rejection, and small centre size (<50 transplants/
decade). In our pediatric program from 1971 – 1992, 5 of 69 consecutive renal transplants 
(7.2%) were lost to vascular thrombosis.This study assesses if low dose continuous heparin 
reduces the risk and outcome of thrombosis in pediatric renal transplants.
Methods: Over 22 years (1993-2015), 44 of 100 consecutive children post renal 
transplant received low dose continuous heparin (10 units/kg/hour) for 1 week for thrombotic 
risk: 1) age < 6yr (n=24); 2) laboratory profile of hypercoagulability (n=10); 3) oliguric 
delayed function (n=5); 4) surgical complications with venous or arterial anastomosis or 
double artery (n=4); or 5) patient history of access thrombosis or vasculitis (n=1). Renal 
scans were obtained on days 1, 3, 5 and when clinical deterioration occurred.
Results: Only 2 thrombotic events were noted which did not cause graft loss: 1) 
2yr LRD transplant- venous thrombosis immediately post-op on heparin with successful 
thrombectomy at 2hr and allograft recovery; 2) 17yr DD double renal artery allograft arterial 
thrombosis of smaller inferior renal artery on day 10 (heparin stopped day 7). One patient 
on heparin infusion required laparotomy 3hrs after surgery for thrombosis external to the 
anastomosis. One patient not on heparin also required laparotomy in the first 24hrs post-op 
for hematoma evacuation.One patient in each group had primary non-function/surgical loss 
with removal of the kidney within the first 3 days post transplant. Graft survival at 1yr was 
96% andno allograft was lost due to thrombotic complications.
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Conclusions: Identification of pediatric patients with who are at high risk of thrombosis 
post renal transplant appears warranted. We achieved a low thrombosis rate and no 
thrombotic organ loss, despite a high proportion of high-risk patients < 6yr, utilizing low 
dose continuous heparin for 1 week post transplant.
FR-PO1064
The Influence of Induction Immunosuppressive Therapies and Diabetes 
on Graft Loss After Kidney Transplant  Hosam A. Farag,1 Nasrollah 
Ghahramani,1 Tarek Alhamad.1  1Public Health Dept, Penn State College of 
Medicine, Hershey, PA; 2Nephrology Dept, Penn State College of Medicine, 
Hershey, PA; 3Public Health Dept, Penn State College of Medicine, Hershey, 
PA; 4Nephrology Dept, Washington Univ, St. Louis, MO.
Background: Induction therapy plays a significant role to reduce the rate of acute 
rejection in kidney transplant (KT). Understanding differences in outcomes associated 
with induction agents may lead to improvement in long-term care. Our objectives were 
to examine the influence of various induction therapies and diabetes on graft and patient 
survival after KT.
Methods: We used the 2000-2013 United Network for Organ Sharing (UNOS) data 
to evaluate the effectiveness of induction therapies and diabetes on graft and patient 
survival after KT. The patients were divided into four groups based on induction therapy: 
Basiliximab (n=24,484), alemtuzumab (n=3,321), rabbit anti-thymocyte globulin (r-ATG) 
(n=54,974) and daclizumab (n=13,358). Also the patients were divided into four groups 
based on diabetic status: non-diabetic (n=192,333), type1 diabetes (n=11,863), type 2 
diabetes (n=43,543)and new onset of diabetes (n=10,509). The main outcome were the 
risk of graft loss and death at 1,3,5,10 years. Cox proportional hazards model was used to 
estimate the hazard ratios.
Results: Graft loss was significantly higher in alemtuzumab group (HR=1.171 ; P= 
0.002) and rabbit anti-thymocyte globulin group (HR=1.109 ; P< 0.0001) versus basiliximab 
group. Daclizumab group showed significantly lower risk for graft loss (HR=0.902%; P< 
0.0001) than basiliximab. Death was significantly higher in rabbit anti-thymocyte globulin 
group (HR=1.075 ; P< 0.0094) versus basiliximab group. Daclizumab group showed 
significantly lower risk for death (HR=0.850 ; P< 0.0001) than basiliximab group. Graft 
loss was significantly higher in type 2 diabetes (HR=1.451 ; P< 0.0001).
Conclusions: Induction immunosuppressive therapies and diabetic status play 
significant role in long-term graft and patient survival. Basiliximab and daclizumab as 
IL-2 RA receptor antagonists have better long-term graft and patient survival outcomes.
FR-PO1065
Does Induction Type Influence Outcomes in Kidney Transplant Recipients 
at Different Phases of Hepatitis B Infection?  Kalathil K. Sureshkumar, 
Richard J. Marcus, Bhavna Chopra.  Nephrology and Hypertension, Allegheny 
General Hospital, Pittsburgh, PA.
Background: Host response to hepatitis B virus (HBV) infection is variable with some 
patients progressing to chronic liver disease. Immunosuppression associated with kidney 
transplantation in such patients may increase the risk of disease progression. We aimed to 
analyze the impact of potent depleting vs. non-depleting antibody induction on the outcomes 
in kidney transplant recipients (KTRs) at different serological stages of HBV infection.
Methods: Using UNOS database, we identified adult KTRs from 2001 to 2011 who at 
the time of transplantation were in one of the 3 serological stages of HBV infection:HBsAg+/
HBcAb-; HBsAg+/HBcAb+ and HBsAg-/HBcAb+. All patients received peri-operative 
induction followed by calcineurine inhibitor/mycophenolate mofetil-based maintenance 
with/without steroids. Using multivariate Cox model, graft and patient survivals were 
compared for depleting (antithymocyte globulin or alemtuzumab) vs. non-depleting 
(basiliximab or daclizumab) antibody induction among the 3 HBV serological groups. 
Donor, recipient and transplant related confounders including lamivudine therapy were 
adjusted in the model.
Results: Adjusted graft and patient survivals for depleting vs. non-depleting induction 
among the 3 groups are shown in the table. 
HBsAg+/HBcAb- 
group 
(depleting=652; non-
depleting =446)
HBsAg+/HBcAb+ 
(depleting = 250; non-
depleting = 216) 
HBsAg-/HBcAb+ 
(depleting = 3562; non-
depleting = 2555)
Outcome HR 95% CI HR 95% CI HR 95% CI
Overall 
graft 
survival
0.97 0.78-1.26 0.81 0.55-1.18 0.96 0.86-1.05
Death-
censored 
graft 
survival
1.20 0.83-1.60 0.59 0.32-1.12 1.00 0.88-1.14
Patient 
survival 0.92 0.66-1.30 0.95 0.60-1.49 0.92 0.80-1.05
All p-values non-significant 
Conclusions: Our study did not show adverse graft and patient survivals associated 
with depleting as compared to non-depleting antibody induction in KTRs with either 
HBsAg+/HBcAb- (early infection), HBsAg+/HBcAb+ (inactive carrier or immune tolerant) 
or HBsAg-/HBcAb+ (clearing infection) sero-status. These findings support a practice of 
choosing induction type based on the immunological risk in such recipients rather than the 
serological status following HBV infection.
FR-PO1066
Health Economic Analysis of Rabbit Antithymocyte Globulin 
(Thymoglobulin) versus Basiliximab (Simulect) in Renal Transplantation 
– A German perspective  Friedrich Thaiss,1 Thomas Benzing,2 John Reitan,3 
Thomas Paivanas,4 Meghan E. Gallagher,5 Michael Sean Wiesener,6 Nikolai 
Zink.6  1Univ. Hospital, Nephrology, Hamburg, Germany; 2Univ. Hospital, 
Nephrology, Cologne, Germany; 3RJM Group, Crown Point; 4TAP & A, 
Annandale; 5Sanofi, Cambridge; 6Univ. Hospital, Nephrology, Erlangen-
Nuernberg, Germany.
Background: Kidney transplantation is now accepted as a proven therapeutic modality 
prompting a greater need to understand the cost-effectiveness of different treatment 
approaches.
Methods: The primary objective of this study was to quantify the economic 
consequences of acute rejection and adverse events in patients undergoing cadaveric 
kidney transplantation and receiving ATG (Thymoglobulin - Thymo) compared with those 
receiving basiliximab (Simulect - Sim). Health economic data were collected according 
to reimbursement calculations from 3 German sites in an existing database (Brennan et 
al NEJM, 2006).
Results: Based on the clinical data from the Brennan trial, the study quantified current 
data and changes in treatment patterns. Results demonstrate that at 12 months the cost 
of the Thymo-regimen is €5,753 more than that of the Sim-regimen. However, costs of 
delayed graft function, nonfatal graft failure events and post-graft failure dialysis are lower 
among Thymo treated patients. Thymo treated patients incurred higher graft maintenance 
costs, consistent with their longer graft survival. In total the associated cost-offset from 
lower rejection events with Thymo offset the added cost from drug treatment and therefore 
Thymo is a more cost-efficient resource vs Sim due to cost-avoidance. To further evaluate 
differences between the two groups we considered quality-adjusted life year differences. 
The Thymo cohort is projected to enjoy 405,714/ QALY after 1 year. After a decade, the 
Thymo cohort is projected to cost 332,232 Euros less than the Simulect cohort while 
enjoying 10.8 more QALYs.
Conclusions: This analysis was intended to provide information that should be 
considered when weighing the costs and benefits of two immunosuppressive regimens and 
to investigate if treatment changes might result in more cost-effective care.
Funding: Pharmaceutical Company Support - Sanofi and RJM
FR-PO1067
Design and Rationale of Athena Study: A 12-Month Study Evaluating 
Everolimus versus Standard Regimen in De Novo Renal Transplant 
Recipients-Baseline Data  Friedrich Thaiss,1 Claudia Sommerer,1 Barbara 
M. Suwelack,1 Duska Dragun,1 Ingeborg A. Hauser,1 Peter Schenker,1 Daniel 
Baeumer,2 Björn Nashan.1  1Athena Study Group; 2Novartis Pharma Germany.
Background: Long-term use of standard calcineurin inhibitor (CNI) post-kidney 
transplant (KTx) is associated with an increased risk for malignancies, cardiovascular 
disease, and renal failure. Previous studies have shown everolimus (EVR) to allow CNI 
reduction and thereby preserve renal function without affecting efficacy. ATHENA study 
evaluates the renal function comparing EVR with reduced CNI exposure (tacrolimus [TAC] 
or cyclosporine A [CsA]) vs a standard treatment protocol with mycophenolic acid (MPA) 
and TAC in de novo (day 0) KTx recipients (KTxR).
Methods: This is a 12-month (M), multi-centre, open-label, prospective study in 
KTxR (³18 years) receiving renal allografts from deceased or living donors. Patients were 
randomised prior to Tx to one of three treatment arms (1:1:1): TAC+MPA+steroids (n=204) 
or EVR+TAC+steroids (n=204) or EVR+CsA+steroids (n=204) (all with basiliximab). The 
primary objective is to demonstrate non-inferiority in renal function (eGFR, Nankivell) in 
one of the EVR arms vs TAC+MPA+steroids arm at M12 post-KTx. Secondary objectives 
are treatment failure (BPAR, graft loss or death) at M12 post-KTx.
Results: Study recruitment is completed in Germany and France. A total of 658 
patients were enrolled, of which 614 patients were randomised. To-date, baseline data was 
available for 367 treated patients (TAC+MPA, 125; EVR+TAC, 116; EVR+CsA, 126); of 
which 66% were male (65%, 67%, and 66%, respectively). The mean age was 54 years 
(TAC+MPA, 55 years; EVR+TAC, 54 years; EVR+CsA, 53 years). At baseline mean BMI 
was 26.8 kg/m2 (TAC+MPA, 26.7 kg/m2; EVR+TAC, 26.7 kg/m2; EVR+CsA, 26.8 kg/m2). 
Overall, 18% patients received allograft from living donor (TAC+MPA, 18%; EVR+TAC, 
17%; EVR+CsA, 20%). The mean HLA mismatch was 2.8 (TAC+MPA, 2.6; EVR+TAC, 
2.8; EVR+CsA, 3.0) The preliminary results of this ongoing trial are expected in 2016.
Conclusions: ATHENA is the largest European renal transplant study and the first 
study evaluating the non-inferiority of renal function as a primary objective in a de novo 
EVR-based immunosuppressive protocol.
Funding: Pharmaceutical Company Support - Novartis Pharma Germany
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FR-PO1068
Thymoglobulin Induction Therapy; Results for 5 Years – Improving the 
Survival of Renal Allograft and Patient  Virginia Ibarra Pedroza, Benjamin 
Gomez-Navarro.  Nephrology and Transplantation, Centro Medico Nacional 
de Occidente, Guadalajara, Jalisco, Mexico.
Background: The factor that impacts the survival of renal allograft is the presence 
of acute rejection. In our city, using Thymoglobuline has offered to patients at high 
immunological risk, and through the years has sought to reduce adverse events use. The 
objective is to evaluate the frequency of acute rejection during the last 5 years in patients 
receiving Thymoglobuline induction.
Methods: An ambispective cohort, patients transplanted in UMAE HE-CMNO, Jalisco, 
Mexico is included in the period June 2010 to June 2014 who received received induction 
therapy with Thymoglobulin. Was recorded the frequency ofacute rejection, the frequency of 
infections, use of Filgrastim(rG-CSF), graft loss and death at 12 months of transplantation.
Results: A 370 patients were included,which received initial doses of Thymoglobulin 
0.6mg/kg-1.5mg/kg. In 2013, by multivariate analysis Thymoglobuline dose that was 
associated with a lower incidence of acute rejection was analyzed and found that 1mg/
kg for 4 days (cumulative dose 4mg/kg) is a protective factor for the occurrence of acute 
rejection (IC 95%; 0.11- 0.60, OR 3.7, p= <0.001), for this reason almost patients received 
this dose. In 2010, the rate of rejection was 16%, and actually is 7.8% (p<0.05); 
Infections disease was reduced about 30%. Currently few patients use of rG-CSF 
because leukopenia- neutropenia, lost the renal graft or die during the first year.
2010 2011 2012 2013 2014 
Infetions (%) 62 42 48 34 32 
Use of rG-CSF (%) 16 15 13 9.4 4.5 
Graft loss (%) 8 8 5.6 3.7 2.2 
Death (%) 8 3.7 4.5 2.8 0 
Conclusions: Interestingly, in ourhospital, we observed a lower rate of acute rejection 
and improved patient survival and allograft. Apparently finding the right dose in our patients 
has allowed thymoglobulin induction is safe and minor complications.
FR-PO1069
Randomized Trial of Tacrolimus/Everolimus versus Tacrolimus/Enteric-
Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection 
and Chronic Allograft Injury in Adult, Primary Kidney Transplantation 
Giselle Guerra,1 Jeffrey J. Gaynor,2 David Roth,1 Warren L. Kupin,1 Adela D. 
Mattiazzi,1 Michael J. Goldstein,2 Linda J. Chen,2 George William Burke,2 
Gaetano Ciancio.2  1Dept of Medicine, Miami Transplant Inst, Miami, FL; 2Dept 
of Surgery, Miami Transplant Inst, Miami, FL.
Background: It was of interest to determine whether everolimus(EVL) might reduce 
the incidence of biopsy-proven acute rejection(BPAR) during the first 12mo post-kidney 
transplant.
Methods: We performed a single-center, open-label randomized trial comparing two 
maintenance immunosuppression regimens: TAC(tacrolimus)/EVL(Group A) vs. TAC/
EC-MPS(enteric coated mycophenolate mofetil)(Group B). In both treatment arms, dual 
induction therapy (anti-thymocyte globulin plus basiliximab) was given along with planned 
early corticosteroid withdrawal.
Results: Among 30 eligible adult participants(15 per treatment arm), median follow-up 
was 11mo(range: 3-20mo). Mean TAC levels were 5-8ng/ml in both arms; mean EVL level 
in Group A was 4-6ng/ml. One patient in Group A vs. 3 patients in Group B experienced 
BPAR - actuarial estimates at 12mo were 10%+9% vs. 20%+10%, respectively(P=.31). All 
3 BPAR’s in Group A occurred prior to 6mo vs. the single BPAR in Group B occurring after 
6mo (logrank P=.09 during the first 6mo post-transplant). A slight trend for more favorable 
renal function(eGFR) was also observed in Group A at 1-3mo post-transplant (P=.06, 
.10, and .18, respectively). No graft failures or deaths have been observed. Regarding the 
incidence of NODAT, a slight trend against Group A was observed (2/15 vs. 0/15 in Group 
B, P=.13), and higher mean cholesterol and triglyceride levels also occurred in Group A 
during 2-12mo(P<.10 at various times).
Conclusions: Although a relatively favorable performance for the experimental 
maintenance regimen of TAC/EVL in terms of a low BPAR rate during the first 12mo 
post-transplant was observed, it may occur at the expense of possibly higher rates of 
NODAT and lipidemia.
FR-PO1070
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 
24-Month Results from the ELEVATE Study  Johan W. De Fijter, Hallvard 
Holdaas, Patricia M. Lopez, Cesar Escrig, Zailong Wang, Josep M. Cruzado, 
Markus van der Giet.  For the ELEVATE Study.
Background: Long-term therapy with calcineurin inhibitors (CNIs) is associated with 
nephrotoxicity i.e., glomerulosclerosis and interstitial fibrosis (IF).We present the 24 month 
results from the ELEVATE study (NCT01114529), which compared an early conversion to 
everolimus (EVR) vs standard CNI in renal transplant recipients (RTxR).
Methods: ELEVATE, a 24M, multicenter, open-label trial, randomized de novo RTxRs 
10–14 weeks post-Tx to convert from CNI to EVR (n=360; C0 6–10 ng/mL) or standard 
CNI (n=357; C0: TAC 5–10 ng/mL, CsA 100–250 ng/mL); all received enteric-coated 
mycophenolate sodium and steroids. Primary endpoint was change in eGFR (MDRD4) 
from RND to M12. Main secondary endpoint a composite efficacy of treated biopsy-proven 
acute rejection (tBPAR; Banff ≥IB), graft loss, or death and safety.
Results: At M12, the clinical benefit observed in eGFR did not achieve statistical 
significance (1.70, 95% CI: -0.53, 3.93, p=0.134) whilst eGFR at M24 for EVR was 
significantly better (p<0.006). The composite efficacy endpoint was comparable at M12 
& M24. Overall acute rejection rates were very low with more tBPAR in EVR, but mild 
in severity (Banff IA & IB). In both the groups, number of patients with de novo DSAs 
at M12 or M24 was low and unrelated to outcomes. At M24, rate of CAN (IF/TA) was 
significantly higher in the CNI versus EVR (35.1 vs 26.7%, p=0.029).
Conclusions: Early conversion to EVR at 3 months vs continued CNIs better preserved 
renal function with comparable overall efficacy and safety up to 2-years. 
Funding: Pharmaceutical Company Support - Novartis
FR-PO1071
Early Conversion from Cyclosporine to Everolimus following Living-
Donor Kidney Transplantation: Outcomes at Five Years Post-Transplant 
in the Randomized ZEUS Trial: A Post-Hoc Analysis  Ingeborg A. Hauser,1 
Frank Lehner,1 Wolfgang Arns,1 Klemens Budde,1 Ute Eisenberger,2 Rudolf 
P. Wuthrich,2 Petra Reinke,1 Rolf A. Stahl,1 Anja Susanne Mühlfeld,1 Heiner 
H. Wolters,1 Barbara M. Suwelack,1 Katharina M. Heller,1 Martina Porstner,3 
Oliver Witzke,1 Claudia Sommerer.1  1ZEUS Study Group, Germany; 2ZEUS 
Study Group, Switzerland; 3Novartis Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living-
donation subgroup of kidney de novo transplant recipients after conversion to an everolimus 
(EVR) based regimen and withdrawal of calcineurin inhibitor therapy.
Methods: Post hoc subgroup analysis from the prospective, open-label, controlled, 
multi-center study ZEUS. 300 renal transplant (Tx) patients were randomized at month (mo) 
4.5 post Tx to either receive EVR plus enteric coated-mycophenolate sodium (EC-MPS ) 
or cyclosporine (CsA) plus EC-MPS regimen. Of these were 80 living donation recipients 
(EVR group n=42; CsA group n=38). Patients could enter an observational follow-up (FU) 
period where outcome on patients’ safety and efficacy was recorded until mo 60 post Tx.
Results: Adjusted eGFR (Nankivell) in living-donation subpopulation at mo 60 was 
67.2 (95% CI [62.5, 71.9]) mL/min/1.73m2 in EVR vs 60.8 (95% CI [56.0, 65.6]) mL/
min/1.73m2 in CsA patients, resulting in a difference of +6.4mL/min/1.73m2 in favor of 
EVR patients (p=0.031, ANCOVA). Unadjusted mean eGFR after 5 years was 69.5 ml/
min for EVR vs 60.6 ml/min for CsA (p=0.006, Wilcoxon). BPARs during FU since mo12 
occurred in 4 patients of the EVR and 3 of the CsA group, all BANFF grade IA except one 
BANFF grade IIA among EVR patients. From randomization to mo 60 one death occurred 
in CsA living-donor recipients, two in the EVR living-donation subgroup; one graft loss 
occurred in the EVR, none in the CsA group. Overall safety profile was similar between 
both treatment groups.
Conclusions: The presented analysis shows that EVR-based regimen with early 
elimination of CNI-therapy in living-donor kidney transplant recipients is associated with a 
significant benefit on renal function maintained over 5 years post Tx without compromising 
safety and efficacy.
Funding: Pharmaceutical Company Support - Novartis Pharma GmbH
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FR-PO1072
Co-Expression of RORgt and IFN-Gamma in Regulatory T Cells of Long-
Term Sirolimus-Converted Kidney Transplant Recipients  Opas Traitanon, 
Ekamol Tantisattamo, Mohammed Javeed Ansari, Lorenzo G. Gallon.  Medicine-
Nephrology, Northwestern Univ, Chicago, IL.
Background: Tacrolimus(TAC) and Sirolimus(SRL) are commonly used 
immunosuppressive drugs in kidney transplantation. SRL has been shown to induce the 
expansion of regulatory T cells in post-transplant recipients converted from TAC to SRL.
Methods: This study included 84 renal transplant recipients from a randomized trial of 
SRL conversion(n=55) or TAC maintenance(n=29). The conversion started at 12 months 
post-transplant. PBMC were collected at 0(baseline), 6, 12, 24, 36 and 48 months post-
randomization. T cell subpopulations were analyzed by flow cytometry.
Results: At baseline, frequencies of CD4+25hiFoxp3+ T cells were similar in both groups 
(0.63±0.06(SRL) VS 0.66±0.12(TAC) % of Lymphocytes, p=0.79). SRL conversion led 
to a significant increase in CD4+25hiFoxp3+ T cells at 6, 12 and 24 months post conversion 
with highest frequencies observed at 12 months post-conversion (2.23±0.23 (SRL) VS 
0.68±0.12 (TAC) %, p<0.01). However, we observed a decline of CD4+25hiFoxp3+ T 
cells started at 24 months and the differences were no longer significant compared to the 
TAC group at 36 and 48 months post-conversion (1.41±0.60 (SRL) VS 1.07±0.44 (TAC) 
%, p=0.24). Intracellular staining for Interferon Gamma (IFN-γ), Interleukin 17 (IL-17) 
and RAR-related orphan receptor gamma 2 (RORgt) showed no difference at 24 months. 
However, at 48 months, we found that PMA-stimulated CD4+CD5hiFoxp3+ T cells in SRL-
converted group had more percentage of cells that co-expressed IFN-γ and RORgt which 
are Th1 and Th17 markers respectively.
Conclusions: Switching from TAC to SRL results in an expansion of CD4+25hiFoxp3+ 
T cells which peaked at 12 months post-conversion but no significant frequency differences 
were observed at 48 months follow-up and we observed more percentage of regulatory T 
cells that co-expressed IFN-γ and RORgt in the SRL group.
FR-PO1073
Pulmonary Complications in Kidney Transplant Recipients: Role of 
Everolimus  Gianni Cappelli, Andrea Solazzo, Fabio Nava, Decenzio M. 
Bonucchi.  Nephrology Dialysis & Renal Transplant Unit, Univ Hospital of 
Modena, Modena, Italy.
Background: Kidney transplant recipients are at higher risk to develop pulmonary 
complications as drug related side-effects.
Methods: 500 kidney transplanted patients were retrospectively analyzed for pulmonary 
complications based on chest RX and HRCT, BAL, oximetry and clinical data. Results 
were classified as parenchymal, interstitial and neoplastic complications.
Results: We found 168 pulmonary complications in 161 pts (32%): 137 parenchimal 
pneumonia, 29 interstitial lung diseases (IP) and 2 cancers. Most pneumonia were 
bacterial, 96 cases (70%) required hospitalization. IP were from infections in 13 cases 
(45%) and Pneumocystis jirovecii was present in 42,85 %; 16 cases of IP (55%) resulted 
as drug-induced IP (DI-IP); all IP and cancer cases required hospitalization. According to 
antirejection protocols DI-IP occurred in 7 pts (43,7%) while on triple regimen [steroids, 
Everolimus (EVL) and Cyclosporine (CyA)] and in 7 pts on double regimen (steroid and 
mTORi: Sirolimus or EVL) (43,7%). In IP cases EVL (through concentration: EVLTLC) 
and CyA (2-hour concentration: CyAC2) levels were higher than in patients in the same 
regimen but with no-IP: EVL (ng/mL) 9.84 vs 6.85 and CyA (ng/mL) 303.97 vs 298.56; 
using the combined blood levels of both drugs (EverolimusTLC + (CyAC2/100) there is a 
significant difference between pts groups: 12.88±1,61 vs 9.83±1,91. Applying ROC analysis 
for optimal model to detect risk of developing IP using EVL or the sum of both drugs we 
obtained a ROC-AUC respectively of 0.9082 (p=0.0028) and 0.8622 (p=0.0081) and a 
threshold value of 9,03 ng/ml or 11,41ng/ml.
Conclusions: Pulmonary side-effects are frequently drug related and a relationship of 
IP to EVL concentration is obtained. Based on ROC analysis pts on EVL/CyA combined 
protocol show a risk of IP when EVL concentration is >9.03 ng/ml or the summatory of 
both drugs is >11.41 ng/ml and support the use of this formula for better prevention of IP 
in clinical practice.
FR-PO1074
High Doses of M-TOR Inhibitors May Induce Pulmonary Pro-Fibrotic 
Effects in Renal Transplant Recipients: Result of a Translational 
Comparative Research Approach Between Everolimus versus Tacrolimus 
Gianluigi Zaza,1 Valentina Masola,1 Simona Granata,1 Gloria Bellin,1 Maurizio 
Onisto,2 Giovanni Gambaro,3 Antonio Lupo.1  1Renal Unit, Dept of Medicine, 
Univ of Verona, Italy; 2Dept of Biomedical Sciences, Univ of Padova, Italy; 
3Div of Nephrology and Dialysis, Columbus-Gemelli Hospital Catholic Univ, 
School of Medicine Rome, Italy.
Background: Pulmonary fibrosis is a quite frequent adverse effect occurring in 
mTOR-I-treated renal transplant (RT) recipients. It has been suggested that epithelial to 
mesenchymal transition (EMT) in airway cells may determine this condition. However, 
the exact biological machinery involved is not completely clarified.
Methods: We performed a translational study. First we analyzed the in vivo pulmonary 
pro-fibrotic potential of Everolimus (EVE) by computing a pulmonary fibrosis index 
score (PFIS), obtained by using several computerized tomography, hemogasanalytic and 
spirometric parameters, in 13 RT patients in EVE treatment and 13 patients treated with 
Advagraf (ADV). Subsequently, we carried out an in vitro study in which we assessed 
whether EVE at low- (5, 10 nM) or high-dosage (100 nM) or Tacrolimus (5 nM, 500 nM 
e 5 µM) was able to induce EMT in bronchial epithelial cells (Nuli-1) and human type 
II pneumocyte-derived A549 cells. Additionally, microarray analysis was performed to 
identify new elements involved in this complex machinery.
Results: In the in vivo part of the study, we found that the PFIS was higher in 
EVE-treated patients compared to those treated with ADV (mean±SD 2.58±1.83 versus 
1.21±1.25). This effect was positively correlated to the trough levels (TL) in EVE-treated 
patients (R2=0.35). The higher PFIS score was measured in patients treated with EVE 
that reached a TL≥6. Interestingly, in vitro, only very high doses of EVE were able to 
induce up-regulation of alpha-SMA, Fibronectin and Vimentin at gene and protein level 
in A549. No effects were seen in Nuli-1. Interestingly, microarray analysis confirmed the 
above-mentioned results.
Conclusions: All togheter, our data suggested that only very high doses of EVE may 
induce pulmonary fibrosis and that this effect could be mediated by EMT in pnemocyte cells.
FR-PO1075
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal 
Transplant Patients: 48 Months Follow-Up Results of the HERAKLES Trial 
Wolfgang Arns,1 Volker Kliem,1 Claudia Sommerer,1 Johannes Jacobi,1 Bruno 
Vogt,2 Ingeborg A. Hauser,1 Petra Reinke,1 Rolf A. Stahl,1 Thomas Rath,1 Martina 
Porstner,3 Martin G. Zeier,1 Frank Lehner,1 Klemens Budde,1 Oliver Witzke.1 
1HERAKLES Study Group, Germany; 2HERAKLES Study Group, Switzerland; 
3Novartis Pharma, Germany.
Background: To compare safety and efficacy of 3 different immunosuppressive 
regimen at month (mo) 48 after kidney transplantation (KTx).
Methods: 802 patients (pts) were included in this 1 year, prospective, open-label, 
randomized, controlled multi-center study with observational follow-up (FU) to mo 60 
post Tx. After induction therapy all pts received cyclosporine A (CsA), enteric-coated 
mycophenolate sodium(EC-MPS) and steroids. 3 mo post Tx, 499 pts were randomized 
1:1:1 to either a) continue standard CsA(100-180ng/ml)+EC-MPS(n=166) (STD) or convert 
b) to a calcineurin inhibitor (CNI)-free regimen with everolimus (EVR) (5-10ng/ml) + 
EC-MPS (n=171) or c) to a CNI-reduced regimen with EVR (3-8ng/ml) + reduced CsA 
(50-75ng/ml; n=162). All pts continued on steroids. At time of mo 48 FU interims-analysis 
data were available from 110(73%) STD, 117(79%) CNI-free and 111(76%) CNI-low 
treated pts of the FU ITT population.
Results: From randomization to mo 48 BPAR was reported in 19/151(13%) STD, 
24/149(16%) CNI-free and in 23/147 (16%) CNI-reduced pts (ITT; p=ns). 5 deaths (3%) 
occurred in STD, 3(2%) in CNI-free and 6(4%) in the CNI-reduced group. 9(6%) graft 
losses were observed in the STD, 6(4%) in the CNI-free and 2(1%) in the CNI-reduced 
group. Composite failure (BPAR, death, graft loss, loss to FU) occurred in 32(21 %) STD, 
36(24%) CNI-free and in 39(27%) CNI-reduced treated pts. Premature discontinuation 
due to AEs was reported for 5(3%) of STD, 5(3%) of CNI-free and 1(1%) of CNI-reduced 
patients (safety-population) since mo 12 to 48. eGFR (Nankivell, LOCF) was significantly 
improved by +6.8mL/min in favor of the CNI-free regimen at mo 48 (ITT;p=0.02).
Conclusions: Mo48 results from HERAKLES show that immunosuppressive regimen 
using EVR with reduced-dose or without CNI-exposure reflect an efficacious and safe 
therapeutic approach offering the opportunity for an individualized immunosuppression 
to minimize CNI-exposure.
Funding: Pharmaceutical Company Support - Novartis Pharma
FR-PO1076
SparTacus: Multicentre, Prospective Randomised Study Comparing 
Tacrolimus Hexal® versus Prograf® Based Regimen in De Novo Renal 
Transplant Recipients  Wolfgang Arns,1 Thomas Rath,1 Lars C. Rump,1 
Klemens Budde,1 Daniel Baeumer,2 Peter Schenker.1  1Spartacus Study Group; 
2Novartis Pharma Germany.
Background: In a transplant (Tx) setting, studies evaluating pharmacokinetic (PK) 
parameters and therapeutic equivalence of generic tacrolimus vs the reference drug are 
lacking. SparTacus (NCT01649427) study was designed to compare PK profile of tacrolimus 
hexal® with prograf® in renal Tx recipients (RTxR).
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Methods: In this prospective, two-phase open-label study, 76 de novo RTxR were 
randomised to receive tacrolimus hexal® (n = 35) or prograf® (n = 41), both in combination 
with enteric-coated mycophenolate sodium + corticosteroids + basiliximab induction 
therapy. Starting dose of tacrolimus was 0.15 mg/kg/day, adjusted to target trough levels 
(C0) of 8–12 ng/mL from Tx to month (M) 1; 5–10 ng/mL up to M3; and 5–8 ng/mL up 
to M6. Primary objective of the study in phase I was to demonstrate comparable PK (ratio 
of AUC0-12h one month period) of tac. hexal® vs prograf®.Here we present the PK results 
of the first month.
Results: At M1, the dose-normalised tacrolimus 12-h-AUC (h/10^3XL) was 
comparable between tac. hexal® vs prograf® (adjusted log-transformed LS mean, 2.9 vs 
3.0; difference, 0.076; 90% CI: –0.169, 0.321, p = 0.605; adjusted back-transformed LS 
mean, 19.0 vs 20.5; ratio, 1.079; 90% CI: 0.844, 1.378, p = 0.605). LS mean value for Cmax 
(1/10^3XL) and mean 12 h tacrolimus C0 (mg/L) at M1 were comparable between tac. 
hexal® vs prograf® (Cmax, 1.1 vs 1.2; difference, 0.150; 90% CI: –0.134, 0.435; p = 0.377; 
C0, 12.2 vs 11.1, respectively). Of 76 patients, 40 (PK-Set 40 pts.) to date completed 6-M 
treatment; tac. hexal®, n = 19; prograf®, n = 21. At M6, tacrolimus hexal® vs prograf® 
had a comparable incidence of composite events (ITT, n=76) (5.7% vs 9.8%, p = 0.681) 
and its individual components (BPAR [5.7% vs 7.3%], graft loss [0.0% vs 2.4%], death 
[0.0% vs 2.4%]). Incidence adverse events (AEs, SAE) were comparable (AEs: 97.1 % vs 
100%; serious AEs: 37.1% and 42.1%).
Conclusions: Tacrolimus hexal® has a PK profile similar to that of prograf®, with 
comparable efficacy and safety in de novo RTxR.
Funding: Pharmaceutical Company Support - Novartis Pharma Germany
FR-PO1077
Monitoring of Ciclosporin by NFAT-Regulated Gene Expression Reduces 
the Cardiovascular Risk – The CIS Trial  Claudia Sommerer,1 Janina Brocke,1 
Stefan Meuer,2 Martin G. Zeier,1 Thomas Giese.2  1Nephrology, Univ Hospital, 
Heidelberg, Germany; 2Immunology, Univ Hospital, Heidelberg, Germany.
Background: Adequate monitoring tools are required to optimize the immunosuppressive 
therapy of an individual patient. A new pharmacodynamic monitoring tool has been 
established to measure directly the functional effect of ciclosporin A (CsA) in an individual 
patient. This is the first randomized controlled study comparing standard pharmacokinetic 
monitoring by CsA trough (C0) levels to pharmacodynamic monitoring by NFAT-regulated 
gene expression.
Methods: Stable renal allograft recipients were included in this 6-month, prospective, 
open-label, randomized, controlled study. All patients received triple immunosuppression 
(CsA, MPA, steroids). Patients were randomized 1:1 to either continue a) CsA therapy 
monitored by CsA C0 (80-150ng/ml) or b) CsA therapy monitored by NFAT-regulated gene 
expression (15-30%). The expression of the NFAT-regulated genes (IL2, IFNγ, GM-CSF) 
were determined by qRT-PCR at CsA C0 and C2. The cardiovascular risk was assessed by 
change of pulse wave velocity (PWV) from baseline to month 6.
Results: 55 patients were enrolled (35 male; Age 51.5±12.9y; time after transplantation 
69.8±73.7m). CsA dose was 96±25ng/mL in the NFAT-group and 93±22ng/mL in the 
standard-group. Residual NFAT-regulated gene expression was 13±9%. Patients monitored 
by the pharmacodynamic assay with NFAT-regulated gene expression showed a significant 
decline in PWV from baseline to month 6 compared to the standard group (-1.68±2.02 
vs. 0.38±1.42 m/s, p<0.0001). Renal function was stable in both study cohorts. An acute 
rejection episode occurred in one patient of the NFAT-group who refused to increase CsA 
dose according to results of NFAT regulated gene expression.
Conclusions: Renal allograft recipients on CsA therapy monitored by the residual 
NFAT-regulated gene expression showed a significantly better cardiovascular risk assessed 
by PWV compared to patients on standard CsA C0 monitoring. NFAT-regulated gene 
expression proved in this first randomized controlled trial as an efficacious and safe approach 
to individualize CsA therapy with the opportunity to improve the cardiovascular risk profile.
FR-PO1078
Follow-Up Results of HERAKLES Trial on Three Different Treatment 
Regimen and Switching Off Behaviour in De Novo Renal Transplant 
Patients After 4 Years  Claudia Sommerer,1 Oliver Witzke,1 Johannes Jacobi,1 
Wolfgang Arns,1 Bruno Vogt,2 Petra Reinke,1 Ingeborg A. Hauser,1 Rolf A. 
Stahl,1 Thomas Rath,1 Martina Porstner,3 Frank Lehner,1 Volker Kliem,1 Klemens 
Budde,1 Martin G. Zeier.1  1HERAKLES Study Group, Germany; 2HERAKLES 
Study Group, Switzerland; 3Novartis Pharma, Germany.
Background: To compare switching off 3 different immunosuppressive (IS) regimen 
4 years after renal transplantation (Tx).
Methods: 802 patients (pts) were included in this prospective, open-label, randomized, 
controlled multi-center study with observational follow-up (FU) to month (mo) 60 post 
Tx. All pts received cyclosporine A (CsA), enteric-coated mycophenolate sodium (EC-
MPS) and steroids; at 3 mo post Tx 499 pts were randomized 1:1:1 to either a) continue 
standard CsA (100-180ng/ml) +EC-MPS(n=166) (STD) or convert b) to a calcineurin 
inhibitor (CNI)-free regimen with everolimus (EVR) (5-10ng/ml) + EC-MPS(n=171) or 
c) to a CNI-reduced regimen with EVR (3-8ng/ml) + reduced CsA (50-75ng/ml;n=162). 
All pts continued on steroids.
Results: At 48 mo post Tx, 40% CNI-free, 30% CNI-reduced and 55% of STD treated 
pts were still on their initial assigned treatment and available for mo 48 analysis. Drop-out 
frequency among FU ITT population from randomization to mo 48 was 17%,15% and 
14% for STD, CNI-free and CNI-reduced groups, respectively. Premature discontinuation 
due to AEs occurred in 5(3%) of STD, 5(3%) of CNI-free and 1(1%) of CNI-reduced pts 
(safety-population) from mo 12 to 48. The CsA trough levels in CNI-reduced group were 
in the higher end of target levels (50–75 ng/mL) in non-switcher population; whereas in 
switcher population they were beyond the target levels. In non-switcher population, eGFR 
(Nankivell) was significantly improved by +13.7 mL/min in favor of CNI-free regimen 
at mo 48 (p<0.001).
Conclusions: Mo 48 HERAKLES results show that IS regimen using EVR with 
reduced-dose or without CNI-exposure reflect an efficacious and safe therapeutic approach 
offering the opportunity for an individualized IS to minimize CNI-exposure. Drop-out 
rates over 4 years post Tx showed relative similar adherence rates between groups. Pts 
that never switched off the assigned CNI-free regimen reached a markedly improved GRF.
Funding: Pharmaceutical Company Support - Novartis Pharma
FR-PO1079
Intensified Dosing of Mycophenolate Mofetil Is Associated with Slower 
Progression of Chronic Renal Allograft Injury – Results from a Randomized 
Controlled Trial  Mladen Knotek,1 Miha Arnol,2 Jadranka Buturovic-Ponikvar,2 
Danica Galessic Ljubanovic,5 Nika Kojc.3  1Dept of Medicine, Renal Div, Univ 
of Zagreb Medical School, Merkur Univ Hospital, Zagreb, Croatia; 2Dept 
of Nephrology, Univ Medical Centre Ljubljana, Ljubljana, Slovenia; 3Inst of 
Pathology, Univ of Ljubljana Medical Faculty, Ljubljana, Slovenia; 4Dept of 
Pathology, Dubrava Univ Hospital, Univ of Zagreb Medical School, Zagreb, 
Croatia; 5Univ of Zagreb School of Medicine, Dubrava Univ Hospital.
Background: Interstitial fibrosis (ci) is a major histological predictor of long-term 
graft outcome. This randomized controlled trial (NCT01860183) was designed to evaluate 
the effect of intensified mycophenolate mofetil (MMF) dosing on progression of ci during 
the first year post kidney transplant (KT).
Methods: Immunologically low-risk KT recipients were randomized on MMF 3g/d, or 
2g/d during the first year post KT. Immunosuppression consisted of basiliximab induction, 
with tacrolimus, MMF ± steroids. Protocol biopsies were performed at implantation, and 
at 12 months post KT and were scored according to the Banff. Progression of ci (Dci) 
was calculated as ci12-ci0. MMF dose was calculated as an average dose at 1, 3, 6 and 12 
months. Difference in Dci with respect to MMF dose was analyzed in an ITT population 
using one-way ANOVA.
Results: Here we report interim results from patients who completed 12 month 
follow-up by June 1st 2015. Patient and KT data are were similar in MMF 3g and MMF 2g 
group, except for average MMF dose, which was higher in the 3g group (2697.1±321.6 
vs. 1745.5±359.0 g, p<0.001). In an overall study population ci progressed during first 12 
months post KT from 0.45±0.51 (ci0) to 1.41±0.87 (ci12) (p<0.001). Dci was lower in 
the MMF 3 g group (0.60±0.74) as compared with MMF 2g group (1.36±0.93; p=0.021). 
Serum creatinine at 1 year was similar in both MMF groups (116.5±25.0 vs. 115.1±33.7; 
p=0.899). Incidence of acute rejection was similar and no significant differences were seen 
in common adverse events between both groups.
Conclusions: Intensified dosing of MMF (3g daily) during the first posttransplant 
year in a tacrolimus-based regimen may be associated with slower progression of chronic 
allograft injury.
Funding: Government Support - Non-U.S.
FR-PO1080
Safe Conversion from Tacrolimus to Belatacept in Kidney Transplant 
Recipients with Allograft Dysfunction  Anil Regmi, Dhiren Kumar, Hasan 
Fattah, Anne L. King, Pamela Kimball, Ankur Atal Gupta, Gaurav Gupta. 
Virginia Commonwealth Univ, Richmond, VA.
Background: Belatacept might be an alternative to Calcineurin Inhibitors (CNI) to 
avoid short and long-term nephrotoxicity. Prior data on low immunologic risk de-novo 
kidney transplant recipients (KTxp) with stable graft function switched from a CNI 
to belatacept demonstrated improved renal function. There is minimal data on the use 
of belatacept for sensitized patients and those with impaired graft function [estimated 
glomerular filtration rate (GFR) <35].
Methods: EBV seropositive patients were converted to belatacept from tacrolimus 
for biopsy proven presumed acute CNI toxicity and/or interstitial fibrosis/tubular atrophy. 
Belatacept was initiated based upon prior published protocol (Grinyo et al., Transpl Int. 
2012 Oct). Mycophenolate dose was increased from baseline dose of 1-2g/d to a dose of 
2-3g/d to minimize risk of rejection.
Results: Seventeen (mean age=46±10 years) patients were switched from tac to 
belatacept at a median of 4 months post-KTxp. A majority were African-American (13/17; 
76%) and received deceased donor KTxp (76%). Seven patients (41%) were sensitized 
(median PRA=31%; range=0-99%). Renal function improved significantly from a peak 
mean GFR of 28±12 ml/min/1.73m2 to an GFR of 42±16ml/min/1.73m2 (p=0.001) at 
a median follow-up of 15 (range=7-30) months post-conversion. Surveillance biopsies 
performed in 7/17 patients did not show rejection or worsening of chronicity. No evidence 
of de-novo donor specific antibody (DSA) was noted in 16/17 (94%) patients. One patient 
with pre-existing DSA and stable creatinine had rising DSA after a viral infection. A biopsy 
showed subclinical antibody-mediated rejection. There were no cases of BK viremia, CMV 
disease or malignancies.
Conclusions: In this first study on KTxp patients with significantly reduced GFR we 
report remarkable improvement in renal function in patients converted from tacrolimus 
to belatacept with acute CNI toxicity and chronic allograft fibrosis without a significant 
concurrent increase in risk of rejection, worsening chronicity and DSA. Further studies 
with protocol biopsies are needed to ensure safety and wider applicability of this approach.
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FR-PO1081
Home Infusion of Belatacept in Kidney Transplant Recipients 
Flavio Vincenti,1 M. Abouljoud,2 JH Helderman,3 R. Zhang,4 K. Calderon,5 S. 
Chen,5 SG Rizk,5 D. Gerber.6  1Univ of California, San Francisco; 2Henry Ford 
Hospital, Detroit; 3Vanderbilt Univ, Nashville; 4Tulane Univ Hospital and Clinic, 
New Orleans; 5BMS, Lawrenceville; 6Univ of North Carolina, Chapel Hill.
Background: Belatacept (bela) is an IV administered selective T-cell co-stimulation 
blocker approved for preventing organ rejection in EBV-positive adult kidney transplant 
recipients. The logistics of IV maintenance therapy are challenging for some pts/clinicians; 
the safety of home infusion has not been well described. Phase 2/3 study participants could 
have received home infusion of bela under certain circumstances. Here, we compare the 
safety of bela infused in the home vs a facility.
Methods: Pts in the 008 (BENEFIT/NCT00256750), 027 (BENEFIT-EXT/
NCT00114777), 010 (NCT00402168), and 034 (NCT00455013) studies were eligible to 
receive bela home infusion if the site sought IRB approval and if the pt lived ³2 hrs from 
the site and had been exposed to bela for >28 wks in 008 or 027, >16 wks in 010, or >6 
wks in 034. 008 and 027 compared bela with CsA regimens with basiliximab induction. In 
010, pts receiving a stable CNI regimen were switched to a bela regimen. 034 compared 
bela with tacrolimus steroid-sparing regimens under thymoglobulin induction. Rate and 
time to pre-specified peri-infusional AEs and peri-infusional serious AEs were recorded 
in pts who received bela in the home (N=66) or in a facility (N=672).
Results: Pts administered bela in the home received a median of 32.5 (range, 1–61) 
infusions. No pre-specified or serious peri-infusional AE was reported, including in the 
034 study.
Conclusions: No pt (irrespective of steroid use) receiving home infusion of bela 
had a pre-specified or serious peri-infusional AE. These data suggest that bela was safely 
administered in the home.
Funding: Pharmaceutical Company Support - Bristol-Myers Squibb
FR-PO1082
Optimizing the Immunosuppression Regimen with Belatacept 
David Wojciechowski,1 Sindhu Chandran,2 Flavio Vincenti.2  1MGH; 2UCSF.
Background: Belatacept with basiliximab induction plus maintenance MMF/
corticosteroids is associated with a higher 3-year eGFR compared to cyclosporine but 
a higher 1-year incidence of acute rejection. In an attempt to optimize the belatacept 
immunosuppression regimen we investigated the safety and efficacy of a novel combination 
utilizing belatacept with rATG induction (3 mg/kg) and maintenance everolimus ± 
corticosteroids.
Methods: Retrospective single center analysis of the first 33 patients to receive our 
belatacept regimen compared to a historical control group of 66 patients matched for 
donor type, KDPI, ESRD cause, CIT, and corticosteroid protocol who met our belatacept 
criteria (EBV seropositive and low immunologic risk [first transplant, no DSA ≥500 MFI, 
cPRA £30%]) but received basiliximab induction with maintenance tacrolimus/MMF ± 
corticosteroids. We compared the 6-month eGFR and the rates of rejection and infection 
between the groups.
Results: Demographic and transplant characteristics were similar. Mean tacrolimus 
trough (SD) at months 3 and 6 were 8.7 (2.5) and 8.4 (2.8), respectively. Mean everolimus 
trough (SD) at months 3 and 6 were 5.5 (2.6) and 5.3 (2.6), respectively. Eleven patients 
didn’t tolerate everolimus and were placed on MMF. Rejection occurred in 3 belatacept 
(1 of each: type 1a, type 1b and type 2b) and 1 tacrolimus patient (type 2a) (P=0.07). The 
belatacept rejections occurred in patients who didn’t tolerate everolimus and occurred after 
everolimus was discontinued. By month 6 two grafts were lost in the tacrolimus group with 
a 100% patient survival for both groups. eGFR at month 6 for belatacept and tacrolimus 
treated patients was 61.9 (15.3) and 60.1 (21.2), respectively (P=0.51). The incidence of 
CMV infection, BK viremia, and UTI was similar between the groups.
Conclusions: The findings suggest that a belatacept regimen with limited T cell 
depletion and an mTORi can maximize efficacy and maintain safety. These results of 
a synergistic effect of costimulation blockade and mTOR inhibition are consistent with 
experimental studies and phase 2 data. A larger prospective trial is warranted to fully 
evaluate this approach.
Funding: Pharmaceutical Company Support - BMS
FR-PO1083
A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant 
Recipients Converted from Cyclosporine or Standard Release Tacrolimus 
to Once-Daily Prolonged Release Tacrolimus  Soo young Kim,1 Joung wook 
Yang,1 Ye na Kim,1 Ho Sik Shin,1 Ji-hwan Kim,2 Yeon soon Jung,1 Hark Rim,1 
Bong geon Chun,3 Hyun yul Rhew.4  1Internal Medicine, Kosin Univ College 
of Medicine, Busan, Republic of Korea; 2Internal Medicine, Good GangAn 
Hospital, Busan, Republic of Korea; 3Pathology, Kosin Univ College of 
Medicine, Busan, Republic of Korea; 4Urology, Kosin Univ College of Medicine.
Background: New-onset diabetes after transplantation may be associated with the use 
of tacrolimus (Tac) causing impaired insulin release or reduced insulin sensitivity. And, 
dyslipidemia commonly occurred after transplantation. Such effects in insulin sensitivity 
and lipid profile have not been studied in renal transplant recipients receiving traditional 
twice-daily tacrolimus (TacBID) or cyclosporine and then compared to the new once-daily 
prolonged release formulation of tacrolimus (TacOD).
Methods: We performed an observational prospective study of 15 stable non-diabetic 
renal transplant recipients on change in insulin sensitivity and lipid profile in renal transplant 
recipients converted from cyclosporine or standard release tacrolimus to once-daily 
prolonged release tacrolimus. We evaluated the level of HbA1c,total cholesterol, HDL, 
LDL, TG, apolipoprotein A1, apolipoprotein B, serum creatinine, fasting plasma glucose, 
fasting insulin and HOMA-β at base line, two and four months. To analyze differences in 
parameter, we performed a t-test in both groups (cyclosporine to TacOD conversion group/
TacBID to TacOD conversion group), and GLM-repeated measures ANOVA. HOMA- β 
= (360 X Fasting insulin)/(Fasting glucoe-63) HOMA-IR(insulin resistance) = (Fasting 
glucose X Fasting insulin)/405.
Results: At baseline, parametes were not different in both groups (cyclosporine to 
TacOD conversion group/TacBID to TacOD conversion group). In GLM-repeated measures 
ANOVA, the result did not showed and any change in insulin sensitivity and lipid profile 
after conversion at baseline, two and four months.
Conclusions: Conversion from standard TacBID or cyclosporine to TacOD is safe. In 
spite of a reduced Tac exposure, there was no change in insulin sensitivity and lipid profile 
in renal transplant recipients.
FR-PO1084
Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal 
Transplant Patients  Zhoutao Xie, Hong Jiang, Jianghua Chen.  The First 
Affiliated Hospital, College of Medicine, Zhejiang Univ, China.
Background: Tacrolimus and ciclosporin A (CsA)are widely used to protect graft 
function after renal transplantation. The aim of the present study is to determine that whether 
CYP3A5*A and CYP3A5*G genotype is a predictive index of tacrolimus dose requirement, 
and even the selection accordance of tacrolimus or CsA treatment.
Methods: We tested archival peripheral blood of 218 kidney recipients for CYP3A5 
genotyping with PCR-SSP. The doses and blood concentrations of tacrolimus and CsA for 
recipients were measured at day7, 1st month , 3rd month,6th month and 12th month after 
renal transplantation, as well as hepatic and renal function. In addition, we also observed 
the incident of acute rejection happening on these participants.
Results: 123 patients took tacrolimus treatment and 95 patients took CsA treatment 
after renal transplantation.In tacrolimus treatment group, genotype CYP3A5*GG was 
associated with low tacrolimus dose-adjusted concentration after transplantation, showing 
lower acute rejection rate compared to CYP3A5*AA/AG group but with no significant 
difference (P=0.154).In CsA treatment group, there was no significant difference in acute 
rejection rates between CYP3A5*AA/AG and CYP3A5*GG(P=0.494) with no difference 
in dose-adjusted concentration as well. For CYP3A5*GG patients, tacrolimus treatment 
cause lower acute rejection rate than CsA treatment (P=0.030), taking shorter time to get 
a stable immune situation than CsA treatment. For CYP3A5*AA/AG patients, tacrolimus 
treatment cause similar acute rejection rate with CsA treatment ( P=0.982), but took longer 
time to get a stable immune situation than CsA treatment. What’s more, tacrolimus treatment 
costs much than CsA treatment.
Conclusions: These results indicate that CYP3A5*AA/AG carriers need higher 
tacrolimus dose than CYP3A5*GG homozygote to achieve the target blood concentration. 
CYP3A5*GG carriers preferred to tacrolimus treatment and CYP3A5*AA/AG carriers 
preferred to CsA treatment depended on the incomes. CYP3A5 genotyping is a new approach 
for detecting tacrolimus dose requirement and a predictive index for the tacrolimus or CsA 
treatment selection in the kidney recipients.
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FR-PO1085
Intrapatient Tacrolimus Level Variability in Pediatric Kidney Recipients 
Predicts Allograft Loss After Transfer to Adult Care  Hilda E. Fernandez,1 
Sandra Amaral,2 Pamela A. Shaw,3 Roy D. Bloom,3 Alden Michael Doyle,4 Sumit 
Mohan,1 Susan L. Furth.2  1Columbia Univ; 2CHOP; 3PENN; 4Hahnemann Univ.
Background: Allograft loss is especially common in 17-24 year olds and is associated 
with non-adherence around the time that transplant care is transferred from the pediatric 
to adult setting. We explored whether coefficient of variation of tacrolimus (CV TAC) 
levels prior to transfer, as a marker of non-adherence, predicted allograft loss in a cohort 
of pediatric kidney recipients transferring to adult transplant centers.
Methods: Retrospective cohort of transplant recipients at Children’s Hospital of 
Philadelphia transplanted 1999 to 2011 who transferred care to University of Pennsylvania 
or Hahnemann University Hospital, identified by chart review. CV TAC was calculated as 
SD divided by mean TAC over 12 mos. Date of transfer was defined as the last pediatric 
visit. We compared pre-transfer TAC CV in those that subsequently lost their graft to those 
that did not (t-test).
Results: 24 of 65 subjects had sufficient data for analysis. Median age at transplant 
was 15.9y (8.5-18.9). The cohort was primarily male (66%), White (77%), had CAKUT 
(8%), and 46% had LRKT. Median age at transfer was 20y (17.4-22.1). Four patients had 
allograft loss within 365 days post-transfer. Pre-transfer CV TAC for subjects with allograft 
loss post-transfer (n=4) was significantly higher as compared to subjects without allograft 
loss (n=20) (49.4% vs 26.2%, p = 0.0275).
Conclusions: CV TAC may aid in identifying patients at risk for allograft loss post-
transfer. Future analysis will investigate the effect of race, age at transfer, rejection, de 
novo DSA pre-transfer that may also help predict adolescent kidney transplant recipients 
at risk for allograft loss following transfer to adult transplant centers.
Funding: Other NIH Support - NIH Kidney Disease Epidemiology T32 Minority 
Supplement
FR-PO1086
High Tacrolimus Level Variability in the Early Post-Transplant Period 
Is Associated with Reduced Patients and Graft Survival After Kidney 
Transplantation  Benaya Rozen-zvi,1 Avry Chagnac,1 Ruth Rahamimov.1,2 
1Nephrology and Hypertension, Rabin Medical Center, Petach-Tikva, Israel; 
2Organ Transplantation, Rabin Mrdical Center, Petach-Tikva, Israel.
Background: The effect of Tacrolimus levels variability in the early period after kidney 
transplantation was not properly studied. We sought to evaluate whether increased drug 
level variability is associated with reduced graft survival and evaluated the relative effect 
of exposure to high and low drug levels.
Methods: We screened the Rabin Medical Center registry database for adult 
patients from 2001 to 2013 that were treated with tacrolimus, micophenolate mofetil and 
corticosteroids and had at least 6 values of drug level during the first six months after the 
transplantation. Variability was defined as the time average of the absolute value of the 
difference from the mean and this value was divided by the mean to get the variability index. 
Univariate and mulivariate Cox proportional hazard model was used with the combination 
of death and graft failure as composite outcome.
Results: We identified 803 patients who met the inclusion criteria, ninety eight (12.2%) 
of them reached the end point during median follow up time of 3.7 years (range 0.5 to 
12.9 years). Increased variability index was associated with increased hazard of death or 
graft failure by univariate (Hazard Ratio (HR) 1.029 per 1%, 95% Confidence Interval 
(CI) 1.006-1.052, p=0.013) and multivariate models (HR 1.036 per 1%, 95% CI 1.01-
1.062, p=0.006). Variability was still significantly associated with reduced graft survival 
after introducing acute rejection into the model (HR 1.038 per 1%, 95% CI 1.008-1.056, 
p=0.008). Introducing exposure to levels above 15 ng/ml into the model didn’t change the 
association between variability index and the composite outcome while introducing exposure 
to levels below 5 ng/ml eliminated the association and made it non-significant (p=0.18).
Conclusions: High variability index in the first six month after kidney transplantation 
is associated with increased mortality and graft loss. This association is, probably, mediated 
by exposure to low drug levels.
FR-PO1087
Decision Tree Analysis of Renal Transplantation Recipients Outcomes: A 
Single Center Data Mining  Jingyi Zhou, Jianghua Chen.  Kidney Disease 
Center, The First Affiliated Hospital, College of Medicine, Zhejiang Univ, 
Hangzhou, China.
Background: Results from former literature on factors influencing renal transplant 
outcomes are quite confusion and few include factors influencing outcomes of rejection 
cases. This study was intended to get the factors in order and to provide reliable predictive 
models for clinical practice with decision tree analysis, and attempted to discuss about 
decision tree integrated with renal transplant database to fulfill the dynamic model growth 
and to serve personal medical care in big data era.
Methods: Renal transplant recipients registering between May 1988 and April 2014 
in Kidney Center of the First Affiliated Hospital of Zhejiang University were included. 
Living state, rejection state, state post rejection and overall outcomes were analyzed by 
decision tree.
Results: Totally 3921 cases were included. The loss-to-follow rate is 9.7%. With 
survival rate as the object, we got the most important factor, steroids (P < 0.01). Patients in 
the following factor combination showed the highest survival rate: steroids, mycophenolate 
mofetil (MMF), stenting, warm ischemic time (WIT) ≤6.5min, cold ischemic time (CIT) 
£300min, and aspartate aminotransferase (AST) 6 months post operation£34U/L (survival 
rate 100%, 305 cases). Patients had the lowest acute rejection rate when in the factor 
combination: steroids, antihuman thymocyte globulin or basiliximab induction, no blood 
transfusion history and female (0%, 83). Patients with acute rejection were regarded as a 
new database. The patients who took steroids and received stents shows similar outcomes 
with patients who had no rejection. Important factors that could be intervened for long-term 
outcomes included stenting, statins, steroids, etc.
Conclusions: Decision tree analysis is an outstanding choice for risk stratification, 
prognosis prediction and dynamic follow-up. Immunosuppression therapy was regarded 
as the most important factor for renal transplant recipients’ survival, rejection and other 
outcomes. Factors should be considered in combination for each specific patient.
FR-PO1088
Comparison of Clinical Outcome Between ABO Incompatible and 
Compatible Spousal Donor Kidney Transplantations  Ji Hyun Yu,1 Byung 
ha Chung,1 Bum soon Choi,1 Curie Ahn,2 Sung-joo Kim,5 Chul Woo Yang.1 
1Transplantation Research Center, Internal Medicine, Nephrology, Seoul St. 
Mary’s Hospital, Seoul, Republic of Korea; 2Transplantation Center, Seoul 
National Univ Hospital, Seoul, Republic of Korea; 3Surgery, Severance 
Hospital, Yonsei Univ College of Medicine, Seoul, Republic of Korea; 4Organ 
Transplantation Center, Busan Paik Hospital, Inje Univ School of Medicine, 
Busan, Republic of Korea; 5Surgery, Samsung Medical Center, Sungkyunkwan 
Univ School of Medicine, Seoul, Republic of Korea.
Background: Spousal donor is an important source to overcome shortage of living 
donor in kidney transplantations (KTs). We aimed to compare the clinical outcomes in 
ABO incompatible KT (ABOi-KT) to those of ABO compatible KT (ABOc-KT) from 
spousal donors.
Methods: We analyzed 580 KTs from spousal donors among 3043 living donors KTs 
registered in the Korean Organ Transplantation Registry. Clinical outcome between ABOi-
KT and ABOc-KT were compared by episodes of acute rejection (AR), graft function, 
grafts and patients survival rates.
Results: The proportion of spousal donors in ABOi-KT was higher than that of ABOc-
KT (40.9% vs. 21.4 %, P < 0.001). The biopsy proven AR -free survival rate in ABOi-KT 
was comparable to ABOc-KT (79.7% vs. 82.3%, P=0.188). The renal allograft function 
showed no difference until 36 months after KT. The 3-year graft survival (92.5% vs. 95.7%), 
and patient survival (96.4% vs. 98.5%) were not significantly different between ABOi-KT 
and ABOc-KT groups (P > 0.05, respectively). Multivariate analysis revealed that ABOi-KT 
from spousal donors did not affect the graft, patient survival and BPAR-free survival rate.
Conclusions: The results of our study show that the ABOi spousal donor is an important 
source of living donor, and can be a good alternative of overcoming donor organ shortage.
FR-PO1089
3-Year Outcomes After ABO Incompatible Kidney Transplantation without 
Steroids  Shefali Patel, Mariana C. Chiles, Sumit Mohan, Russell J. Crew. 
Columbia Univ, New York, NY.
Background: Early steroid withdrawal paired antibody induction therapy provides 
comparable outcomes to steroid maintenance patients. However, ABOi transplantation is 
considered higher immunologic risk, and it unclear if a steroid free regimen is appropriate 
for this population.
Methods: We performed 40 ABOi transplants with pre-transplant plasmapheresis(PP) 
with IVIG to an isohemagglutinin titer £1:16 and 2 post-txp PP/IVIG treatments, 
immunosuppression with tacrolimus, mycophenolate, and intraoperative rituximab (375mg/
m^2). Prior to 2008, patients received an IL-2 receptor blocker, and prednisone tapered to 
5 mg by 6 months. After 2008, induction included Thymoglobulin® (6 mg/kg in 4 divided 
doses) and steroid withdrawal by postop day #3. Patients underwent protocol biopsies at 
predefined intervals. We compared outcomes at 3 years between those who had and had 
not received maintenance steroids.
Results: 24 patients received maintenance steroids and 16 underwent rapid steroid 
withdrawal. There were no differences in sex, starting isohemagglutinin titer, or blood 
group mismatch between the groups. Antibody mediated rejection was more common in the 
steroid maintenance group (41% vs 31%) as was cellular rejection (50% vs 47%), though 
not significantly different. At 3 years, renal function was similar between those with and 
without steroids- eGFR 46±25 cc/min vs 52±15 cc/min, respectively. Approximately 50% 
of patients underwent protocol biopsy at 3 years. There were no differences in the degrees 
of interstitial fibrosis, glomerulosclerosis, or transplant glomerulopathy between groups. 
Graft survival, patient survival, and infectious complications were also similar.
Conclusions: Even in higher immunologic risk ABOi transplant recipients, rapid 
steroid withdrawal appears to provide similar medium term results as steroid maintenance 
therapy without the longterm side effects.
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FR-PO1090
Three Year Outcome of a Pioneer ABOi Renal Transplant Programme in 
Malaysia  Si-Yen Tan,1 Mohan Rao,2 Eng-Thye Koh.2  1Medicine, Prince Court 
Medical Centre, Kuala Lumpur, WP, Malaysia; 2Surgery, Prince Court Medical 
Centre, Kuala Lumpur, WP, Malaysia.
Background: ABO incompatible (ABOi) renal transplantation increases organ donor 
pool and is an option for patients with no blood group compatible donors. We report here 
results of a pioneer ABOi renal transplant programme in Malaysia which was first established 
in Prince Court Medical Centre in 2011.
Methods: Ten patients entered into our ABOi programme between July 2011 and 
December 2013. Data were analyzed to determine the number of therapeutic plasma 
exchange (TPE) and/or immunoadsorption (IA) with Glycosorb columns to achieve target 
pre transplant ABO antibody titres of < 1:16 and ABO titres post transplant. Graft function 
and rejection rates together with graft and patient survival at 3 years were also determined.
Results: Median baseline ABO titres was 1:128 and all patients achieved target pre 
transplant ABO titres of < 1:16 after a median of 4 TPE and/or IA. Median follow up 
was 32 months with all patients maintaining ABO titres of < 1:16 at follow up with no 
protocol post transplant TPE/IA. There was 1 case (10%) of acute cellular rejection at one 
year which was reversed with steroids but none had antibody mediated rejection. Patient 
and graft survival was 100% at 3 years with current median serum creatinine 108umol/L.
Conclusions: The results of our pioneer ABOi renal transplant programme with graft 
and patient survival of 100% at 3 years is extremely encouraging and suggest that graft 
and patient outcome is similar to ABO compatible renal transplants. The use of ABO 
incompatible donors may effectively increase organ donor pools especially in countries 
where both cadaver and living related kidney transplant rates remain poor. Our results also 
suggest that national ABOi renal transplant programmes may be effectively introduced and 
led by a private medical centre to complement and support more established renal transplant 
programmes in government institutions which are now beginning to perform their own 
ABOi renal transplants in light of our success.
Funding: Clinical Revenue Support
FR-PO1091
Improved Graft Outcome After Blood Transfusion: Still in Effect? 
Gowrie Balasubramaniam,1 Arun Gupta,2 Neil Ashman,2 Raj Thuraisingham.2 
1Dept of Medicine, Southend Univ Hospital, Southend, Essex, United Kingdom; 
2Dept of Nephrology and Transplantation, Barts and The Royal London Hospital, 
London, United Kingdom.
Background: Blood transfusions can lead to sensitisation in potential transplant 
patients. We previously quantified the risk of sensitisation from transfusion per se by 
looking at a cohort of male patients on the transplant waiting list and ascertaining the 
transfusion history from electronic records and questionaires. Prior to standard triple 
immunosuppression, transfusions were associated with overall better graft outcome possibly 
by a tolerogenic effect or by selecting non-sensitisers. The majority of patients who were 
transfused do not become sensitised, we wanted to characterise graft outcome in this group.
Methods: We obtained graft outcome information on the original cohort of patients. 
Data was collected prospectively as part of routine surveillance.
Results: 100 out of the initial 126 male patients were transplanted. 10 were excluded 
from further analysis due to death or graft loss in the immediate post-transplant period. 11 
of remaining 90 patients were DSA prior to transplantation, 8 also had a history of previous 
blood transfusion. 4 of the 8 patients with a previous blood transfusion and DSA had a 
rejection episode (2 AMR and 2 ACR). Of the remaining 79 patients who were DSA negative 
prior to transplantation, 26 had a previous transfusion (TR+ DSA-) and 53 did not have a 
history of transfusion (TR- DSA-). Comparison between the two groups is shown in (table 1).
TR+ DSA- TR- DSA-
Rejection rate
ACR
AMR
2/26
2
0
15/53
12
3
Recipient age 50.1 ± 11.5 48.2 ± 9.9
Donor age 49.0 ± 13.2 45.1 ± 14.4
Donor type
LT
HB
NHB
2
13
11
10
28
15
CIT 768.1 ± 284.5 730 ± 368.6
Immunosuppression 
Induction
ATG
IL-2 agent
Campath
Maintenance
Cya, MMF, Pred
FK, MMF, Pred
FK, Aza, Pred
FK, Pred
11
15
0
23
3
0
0
17
35
1
50
0
2
1
Conclusions: Lack of sensitisation with a history of leuco-depleted transfusion is 
associated with a lower risk of rejection post-transplantation. This suggest that previous 
mechanisms of transfusion tolerance or “non-sensitisers” are still relevant in the modern 
immunosuppression era.
FR-PO1092
Geriatric Renal Transplantation in Deceased Donor Showed Compatibile 
Clinical Outomes to Younger Recipients  Hyungjin Cho, Eunhye Shin, 
Hyosang Kim, Su-Kil Park.  Dept of Internal Medicine, Div of Nephrology, 
Asan Medical Center, Seoul, Republic of Korea.
Background: According to USRDS annaul report, while 50.3% of patients who 
start hemodialysis were aged over 65 years, only 19.3% of patients who underwent 
renaltransplantation was aged over 65 years. Elderly ESRD patients still are not underwent 
renal transplantation as much as younger recipients. There were many previous studies 
about geriatric renal transplantation outcome in white, however data in Asain were limited. 
The aim of this study is analysis of geriatric kidney transplanation outcome in Korea.
Methods: From May 1993 to December 2013, kidney transplantations performed in 
Asan medical center were retrospectively reviewed. Recipients younger than 20 years and 
who underwent other organ transplantation were excluded. Binary logistic regression was 
used for evaluating risk factors of graft failure before half-life. Half life of kidney allograft 
was defined as 10 years according to previous study.
Results: Regardless of donor type, there is no statistically significant difference in death 
censored graft survival between geriatric population and younger recipients. 
Multivariate analysis of deceased donor recipients revealed that recipients aged over 
60 years was not a significant risk factor for graft failure before half-life. 
univariate analysis Multivaiate analysis 
p Hazard ratio 95% CI p
Hazard 
ratio 95% CI
+ 60 years 0.604 1.263 0.522-3.056 
Female 0.219 0.767 0.503-1.171
Cold ischemic time 0.655 1.000 0.999-1.001
Donor age 0.031 1.018 1.002-1.035 0.036 1.017 1.001-1.033 
Re-transplantation 0.531 1.272 0.599-2.705
Diabetes mellitus 0.002 2.841 1.475-5.473
Hypertension 0.931 0.959 0.376-2.447
HLA DR mismatch 0.932 1.035 0.473-2.266
Dialysis before 
transplantation 0.382 2.085 0.402-10.826
Conclusions: Renal transplantation in geriatric population can be encouraged in 
Asain ESRD patients.
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FR-PO1093
Long-Term Survival and the Associated Risk Factors for Death in Patients 
(pts) with Kidney Transplantation (Tx)  Tanja Abeling,1 Irina Scheffner,1 
Verena Broecker,2 Michael Mengel,3 Hermann G. Haller,1 Anke Schwarz,1 
Wilfried Gwinner.1  1Hannover Medical School, Germany; 2Cambridge Univ, 
United Kingdom; 3Univ of Alberta, Canada.
Background: Deaths over a period of up to 10 years (yrs) and the related risk factors 
were studied in Tx pts with protocol biopsies (Bx) (total observation: 4805 patient-yrs).
Methods: 892 pts with kidney Tx in 2000-2007 were included. Protocol Bx were 
taken at 6 weeks, 3 and 6 months post-Tx (n=2251). 862 Bx for cause were taken in the 
1st year and 262 thereafter. Lost-to follow-up was negligible (n=15). All acute rejections 
and clinical borderline cases in protocol Bx were treated.
Results: Patient and graft survival was 80% at 5 yrs and 68% at 10 yrs. Patient survival 
was 92% at 5 yrs and 82% at 10 yrs. 99 deaths occurred, relating to infection (24%), 
cardiovascular disease (15%), malignancy (16%), other specified causes (8%). Deaths were 
less in living-donor or kidney/pancreas Tx and more frequent for extended donor criteria-Tx. 
A three-level multivariate Cox regression model was created in a stepwise fashion, using 
significantly different variables from the pre-Tx, peri-operative, and long-term post-Tx 
period between survivors and deceased pts. Pre-Tx variables in the final model included 
recipient age, HLA-DR mismatches, diabetes, coronary heart disease, heart failure, and 
peripheral arterial disease. A significant peri-operative variable was cold ischemia time. In 
the long-term course, variables for death included increased loss of graft function, urinary 
tract infection, and higher PTH levels. Compared to the survivors, deceased pts received 
more therapies for rejection seen in protocol Bx (0.30 vs. 0.43 per patient) and in Bx for 
cause (0.29 vs. 0.34 per patient), however, this was not a significant factor in the final 
model. Also, the proportion of anti-rejection treatments was not higher in pts who died 
from infections, compared to pts dying from other causes. Concordance of the final model 
was 0.79; 200-fold bootstrapping confirmed its applicability.
Conclusions: Based on these results a tool is presented that readily allows risk 
calculation and stratification of individual pts, as a pre-requisite for individualized and 
optimal pre- and post-Tx care.
Funding: Government Support - Non-U.S.
FR-PO1094
Causes of Death-Censored Kidney Allograft Failure: A Matched Case-
Control Study of 340 Kidney Allograft Recipients  Mohamad M. Alkadi,1 Jim 
Kim,2 Choli Hartono,1 Thangamani Muthukumar,1 Meredith J. Aull.1  1Medicine, 
Weill Cornell Medical College, New York, NY; 2Surgery, Weill Cornell Medical 
College, New York, NY.
Background: Causes of kidney allograft failure in the current era of immunosuppression 
have not been clearly defined.
Methods: We did a matched case-control study of death-censored allograft failures 
among the 1672 adult kidney transplants at our center between 11/2001 and 12/2011. The 
cases and controls were matched 1:1 for age, donor type and year of transplant. We reviewed 
the charts and used the last available biopsy diagnosis for each case to determine the cause 
of graft failure. We divided the causes of graft failure into 8 categories; (i) acute rejection, 
(ii) transplant glomerulopathy, (iii) IF/TA, (iv) glomerular diseases, (v) BK nephropathy, 
(vi) others/unclassified, (vii) surgical and (viii) medical causes. We used conditional logistic 
regression analysis to determine the odds ratio.
Results: We identified 175 graft losses during the study period and matched 170 
of them (cases) 1:1, with 170 controls. There was no statistically significant differences 
between cases and controls in terms of donor sex, recipient sex, donor race, recipient race, 
number of transplants, induction therapy or maintenance therapy. 86% of patients received 
antithymocyte globulin induction. The median follow up in the cases and controls was 22 
months and 56.5 months, respectively. 72% of cases had a biopsy done within 12 months 
of graft failure. The proportion of cases and controls in the 8 diagnostic categories and 
their respective conditional odds ratio is shown in the table below. 
Conclusions: In the modern era of immunosuppression, allo-immune rejection and 
auto-immune glomerular disease continue to be significant factors associated with graft 
failure.
FR-PO1095
Effect of Simultaneous Native Nephrectomy on the Outcome of Kidney 
Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease 
Jeong Ho Kim, Bum soon Choi, Cheol Whee Park, Chul Woo Yang, Yong-Soo 
Kim, Byung ha Chung.  Internal Medicine, Seoul St. Mary’s Hospital, Seoul, 
Korea.
Background: End stage renal disease (ESRD) patients with autosomal dominant 
polycystic kidney disease (ADPKD) required native nephrectomy because of limited space 
for renal allograft. However, the appropriate timing for nephrectomy and also its effect on 
allograftand patient survival has not been fully investigated.
Methods: We retrospectively analyzed 41 kidney transplant recipients with ADPKD 
in whom transplantation was done either simultaneously, after or without native 
nephrectomy at Seoul St. Mary’s hospital between January 1987 and February 2014. We 
divided patients into 2 groups; simultaneous nephrectomy group (group A, n=13), after 
or without nephrectomy group (group B, n=28) and compared the perioperative outcome, 
post-transplant complications, allograft survival rate.
Results: The mean operative time was significantly longer in group A than group B 
(6.48 ± 1.84 vs. 5.27±0.84 hours; P = .048). The mean intraoperative blood transfusions 
was also significantly more needed in group A than B (3.66±3.43 vs. 0.75 ±0.26 units; P 
= .018). However, there were no differences in the incidence of acute rejection andother 
complications such as post-operative bleeding, infectious complication between the two 
groups (P > .05, for all).The graft survival rate also did not differ between the two groups 
(P > .05).
Conclusions: Our study suggests that the complication rates were acceptable and 
there was no significant negative impact on graft survival rate when native nephrectomy 
was done during kidney transplantation in ADPKD patients with ESRD. Therefore, if 
native nephrectomy is needed in ADPKD for kidney transplantation it can be done safely 
during transplantation.
FR-PO1096
Predictors of Renal Function Change After Kidney Transplantation 
Yoshifumi Hamasaki,1 Kent Doi,2 Akihiko Matsumoto,3 Daigoro Hirohama,1 
Nobuhiko Sato,1 Daisuke Katagiri,1 Rei Isshiki,1 Wakako Kawarazaki,1 Eisei 
Noiri,1 Masaomi Nangaku.1  1Nephrology and Endocrinology, The Univ of Tokyo, 
Tokyo, Japan; 2Emergency and Critical Care Medicine, The Univ of Tokyo, 
Tokyo, Japan; 3Urology, The Univ of Tokyo, Tokyo, Japan.
Background: Several perioperative factors including histological findings of allograft 
biopsy are known to be associated with graft function and graft survival after kidney 
transplantation (KT). Urinary L-type fatty acid binding protein (uL-FABP) was reported to 
be correlated with serum creatinine, serum cystatin C, and estimated glomerular filtration 
rate (eGFR) in a cross sectional study evaluating post-KT patients. It is unclear what factors 
in post-KT period predict the longitudinal change of renal function.
Methods: The data from post-KT patients followed at The University of Tokyo Hospital 
were collected retrospectively. Patients followed-up less than 6 months after KT were 
excluded. To identify predictors of the longitudinal change of renal function, we analyzed 
data including clinical parameters measured at each outpatient visit. The primary outcome 
was determined as the change of eGFR during 6 months period.
Results: 32 post-KT recipients were analyzed in this study. Age and eGFR at baseline 
of these patients were 51.3 ± 12.7 years old and 41.2 ± 16.1 ml/min/1.73m2 (mean ± SD), 
respectively. The duration from KT to collection of clinical parameters was 6.8 ± 7.3 years 
(mean ± SD). Changes of eGFR were evaluated 6 months after. When patients were divided 
into two groups with (N = 15) and without (N = 17) eGFR decline after 6 months, uL-FABP 
and urinary protein were significantly higher in the eGFR decline group (uL-FABP; 11.6 
vs 5.1 mg/ml, and urinary protein; 272.7 vs 97.2 mg/gCr, respectively). On ROC analysis, 
uL-FABP and urinary protein predicted eGFR decline after 6 months (AUC [95%CI] = 
0.78 [0.60-0.96] and 0.70 [0.51-0.89], respectively). On multiple regression analysis, 
uL-FABP and urinary protein were significantly correlated with the absolute and relative 
eGFR changes during 6 months observation period.
Conclusions: uL-FABP and urinary protein measured at outpatient clinic can predict 
the change of renal function of post-KT patients.
FR-PO1097
Plasma Proenkephalin and Poor Long-Term Outcome in Renal Transplant 
Recipients  Lyanne M. Kieneker,1 Joachim Struck,2 Ron T. Gansevoort,1 Michel 
M. Joosten,1 Rudolf A. de Boer,3 Oliver Hartmann,2 Stephan J.L. Bakker.1 
1Nephrology, UMC Groningen, Netherlands; 2Sphingotec GmbH, Germany; 
3Cardiology, UMC Groningen, Netherlands.
Background: Enkephalins are well-known endogenous opioid peptides. Recent 
evidence indicates that they are not only involved in regulation of pain, but also in 
homeostasis of the immune system and the circulation. Proenkephalin (pro-ENK) is stable 
in plasma and has been established as reliable surrogate marker for unstable enkephalins. 
Recent studies found associations of pro-ENK with acute kidney injury and prognosis 
after myocardial infarction. We aimed to investigate whether pro-ENK could be linked to 
chronic kidney injury and poor long-term outcome in renal transplant recipients (RTR).
Methods: We included 664 RTR who were 8.1±7.6 years after transplantation. Plasma 
levels of pro-ENK were measured with a double monoclonal sandwich immunoassay.
Results: Mean age was 53±13 years, 56% was male, estimated glomerular filtration 
rate (eGFR) 49 ml/min/1.73m2 (interquartile range [IQR]: 37-64 ml/min/1.73m2) and 
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urinary albumin excretion (UAE) 40 mg/24h (IQR: 10-196 mg/24h). Median pro-ENK 
was 110 pmol/L (IQR: 85-148 pmol/L). Pro-ENK was correlated with both eGFR (r=-
0.73, P<0.001) and UAE (r=0.35, P<0.001). During a median follow-up of 3.1 years (IQR: 
2.7-3.9 years), 45 RTR developed graft failure and 76 died. Pro-ENK was both associated 
with increased risk of graft failure (hazard ratio per standard deviation increment of the 
logarithm of pro-ENK, 2.76; 95% confidence interval, 1.69-4.53) and all-cause mortality 
(1.83; 1.24-2.69), independent of age, sex, eGFR, and UAE. These associations remained 
materially unchanged after additional adjustment for body mass index, alcohol consumption, 
smoking, systolic blood pressure, antihypertensive drug use, use of calcinurin inhibitors, 
and high-density lipoprotein.
Conclusions: High concentrations of pro-ENK are linked to chronic kidney injury as 
reflected by correlations with eGFR and UAE. In addition, pro-ENK was independently 
associated with increased risk of graft failure and mortality in RTR. Pro-ENK is an 
interesting new biomarker which may aid in early identification of RTR at risk for late 
graft failure and premature mortality.
Funding: Private Foundation Support
FR-PO1098
Serum Albumin Level Has Association with Both Graft Failure and 
Mortality in Kidney Transplant Recipients  Hee Jung Jeon,1 Soyon Rhee,1 
Eunjung Kim,1 Jung Pyo Lee,2 Ja-Ryong Koo.1  1Dept of Internal Medicine, 
Hallym Univ of College of Medicine, Seoul, Republic of Korea; 2Dept of Internal 
Medicine, Seoul National Univ Boramae Medical Center, Seoul, Republic of 
Korea.
Background: The studies concerned the association between post-transplant serum 
albumin concentration and post-transplant outcomes in kidney transplant recipients 
(KTRs) are scarce.
Methods: To evaluate the impact of serum albumin level on graft and patient survival, 
we performed a retrospective multi-center cohort study in Seoul National University 
Hospital, Asan Medical Center, and Kangdong Sacred Heart Hospital. A total of 2815 
KTRs who underwent renal transplantation from Jan 1997 to Jan 2012 were classified 
into two groups according to the level of serum albumin at 1 year after transplantation 
(higher albumin group, ≥4.0 g/dL, n=1978 vs. lower albumin group, <4.0 g/dL, n=837). 
The Cox proportional hazard model was adjusted with age and gender of recipient, donor 
type, age of donor, diabetes mellitus, and estimated glomerular filtration rate (eGFR) at 1 
year after transplantation.
Results: The mean age of the recipients was 41.7±11.3 (range, 18-73) years, and 
59.1% were male. The rate of graft failure was higher in lower albumin group compared to 
higher albumin group (Hazard ratio [HR] 1.840, 95% confidence interval [CI] 1.367-2.477, 
P<0.001), even though eGFR at 1 year after transplantation was not different between the 
two groups (61.7±19.8 vs. 62.1±15.8 mL/min, P=0.615). Both all-cause mortality and 
non-cardiovascular mortality rates were higher in lower albumin group (HR 2.227, 95% CI 
1.258-3.943, P=0.006, and HR 2.784, 95% CI 1.254-6.179, P=0.012, respectively). Every 
1.0 g/dL higher serum albumin concentration was associated with 69.2% lower all-cause 
mortality (HR 0.308, 95% CI 0.196-0.483, P<0.001).
Conclusions: Serum albumin level at 1 year after transplantation is a prognostic factor 
for graft failure and patients’ mortality in KTRs. Therefore, evaluation and management 
for hypoalbuminemia should be considered to improve outcomes in KTRs.
FR-PO1099
Brain Effects of Renal Transplantation: Association Between Cognition 
and White Matter Integrity  Aditi Gupta,1 Rebecca J. Lepping,2 David K. 
Johnson,3 Alan S.L. Yu,1 William M. Brooks,2 Jeffrey M. Burns.3  1Kidney Inst; 
2Hoglund Brain Imaging Center; 3KU Alzheimer’s Disease Center; 4Univ of 
Kansas Medical Center.
Background: Cognitive impairment is present in up to 87% patients with end stage 
renal disease (ESRD). Magnetic resonance imaging (MRI) using diffusion tensor imaging 
(DTI) shows lower fractional anisotropy (FA) values in these patients. FA values measure 
structural integrity of white matter and are associated with cognitive impairment. In this 
study we examine the effect of renal transplantation on cognitive function and determine 
whether changes in white matter integrity underlie the observed cognitive changes.
Methods: Adults with ESRD were recruited from the renal transplant waiting list. 
Subjects were evaluated before transplantation and 3 months after transplantation with 
neuropsychological (NP) tests and a brain MRI. Two-tailed paired t-test was used to analyze 
changes in NP tests and FA values before and after transplantation.Pearson correlation 
coefficients were calculated.
Results: Two hundred patients were screened and eighteen enrolled. Ten subjects, 57±11 
years of age have been transplanted and have completed the study. After transplantation, 
there was a significant improvement in NP tests for memory and executive function.
Test Pre-Transplant Post-Transplant P value
Logical Memory I 10.5±4.6 13.9±4.5 0.011
Logical Memory II 8.5±5.2 13±4.8 0.007
Stroop color 68.9±16 74.9±14.5 0.028
Digit Symbol 43.3±11 48±11.5 0.002
There was a significant increase in the FA values in the body of corpus callosum 
(P=0.017), forceps minor (P=0.058) and left cingulate gyrus (P=0.002). Furthermore, the 
improvement in NP tests positively correlated with the increase in FA values in these tracts.
Conclusions: Memory and executive function improve after renal transplantation. FA, 
a DTI metric representing white matter integrity also increases in brain regions important 
for these functions. This study provides insight into the neural mechanisms underlying 
cognitive impairment in ESRD and its improvement after transplantation.
FR-PO1100
Pre-Kidney Transplant Left Ventricular Ejection Fraction, Long-Term 
Allograft Function, and Survival  Asjad Sardar, Maha A. Mohamed, Arjang 
Djamali, Sandesh Parajuli, Didier A. Mandelbrot, Brad C. Astor.  Div of 
Nephrology, Univ of Wisconsin Hospitals and Clinics, Madison, WI.
Background: End stage kidney disease patients with low left ventricular ejection 
fraction (LVEF) are considered high risk for poor outcomes following kidney transplantation 
(KT). No consensus exists on the level of systolic dysfunction below which patients are at 
increased risk of unfavorable allograft outcomes.
Methods: We studied 387 KT patients transplanted from 1/02 to 12/09 who underwent 
pre-transplant invasive and non-invasive cardiac assessment of LVEF. Outcomes included 
Delayed graft function (DGF), allograft survival, patient survival and allograft function. 
LVEF N DGF Patient Survival
Graft 
Survival Mean Difference and (95% CI) in Cr
OR 
(95% 
CI)
HR (95% 
CI)
HR (95% 
CI) 1 Year 3 Years 5 Years
<45% 36
1.66 
(0.44, 
6.26)
1.03 
(0.43, 
2.49)
0.99 
(0.47, 
2.02)
-0.10 
(-0.66, 
-0.64) 
-0.41 
(-1.0, 
0.21)
-0.1 (0.66, 
0.64) 
45-60% 215
1.29 
(0.56, 
2.94)
0.78 
(0.43, 
1.42)
0.89 
(0.57, 
1.40)
0.01 
(0.13, 
0.15) 
-0.22 
(-0.56, 
0.11) 
0.07 
(-0.30, 
0.44) 
>60% 136 Ref Ref Ref Ref Ref Ref
P-trend 0.42 0.81 0.80 0.70 0.12 0.86
CI: Confidence Interval, Ref: Reference 
Data adjusted for age, sex,race,PRA,Duration of RRT,DM,CAD,LVH and Induction Therapy. 
Associations between different LVEF values.
Results: A total of 136 (35.1%) patients had LVEF > 60%, 215 (55.5%) had LVEF 
between 45-60% and 36 (9.3%) had LVEF <45% before KT. Patients with low EF were 
more likely to have DM,CAD,LVH and longer duration of dialysis. During median follow 
up of 4.4 years there were 122 graft losses including 71 deaths. 73 patients (18.9%) had 
DGF. There was no significant difference in rate of DGF, serum creatinine, allograft 
survival and patient survival.
Conclusions: Low LVEF does not appear to significantly effect patient and allograft 
survival and function, suggesting that patients with low LVEF should not be excluded 
from transplantation.
FR-PO1101
Progression of Coronary Artery Calcification in Renal Transplant 
Recipients – A Follow-Up of 7 Years  Sibel Gulcicek, Nurhan Seyahi.  Dept 
of Internal Medicine, Div of Nephrology, Istanbul Univ, Cerrahpasa Medical 
Faculty, Istanbul, Turkey.
Background: In the general population coronary artery calcification (CAC) and its 
progression is associated with cardiovascular and all cause mortality.We conducted a study 
to determine the progression of CAC in renal transplant recipients; we also examined 
the factors associated with progression and the impact of the analytic methods used to 
determine CAC progression.
Methods: We used multi-detector computed tomography to examine CAC in 113 
prevalent renal transplant recipients, who did not have a documented cardiovascular disease. 
A baseline and a follow-up scan were performed and changes in CAC scores were evaluated 
in each patient individually, to calculate the incidence of CAC progression. Univariate 
and Multivariate logistic regression analysis was used to evaluate the determinants of 
CAC progression.
Results: Baseline CAC prevalence was 34.5 % and the mean CAC score was 47.08 
± 135.25. At follow-up scan that was performed after an average of 6.9 ± 0.5 years, CAC 
prevalence increased to 47.6% and the mean CAC score to 140.18 ± 332.11. Progression of 
individual CAC score was found between 32.7 and 34.5 %, depending on the method used 
to define progression (Hokanson and Sevrukov). In patients with baseline CAC, median 
annualized rate of CAC progression was 13.8. Based on univariate analysis, age, presence of 
baseline CAC, high baseline CAC score, high body mass index were significantly associated 
with CAC progression defined according to both the Hokanson and Sevrukov methods. 
Moreover, HDL cholesterol level were significantly associated with CAC progression when 
progression was defined according to Hokanson’s method and donor type, high triglyceride 
levels and systolic blood pressure were significantly associated with CAC progression 
according to Sevrukov’s method.Based on multivariate analysis baseline CAC and high 
triglyceride were the independent determinants of CAC progression.
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Conclusions: Progression of CAC is the usual evolution pattern of CAC in renal 
transplant recipients. Beside baseline CAC, high triglyceride level were also associated 
with progression of CAC.
Funding: Clinical Revenue Support
FR-PO1102
Adiponectin Fractions Influence the Development of Cardiovascular 
Disease in Japanese Renal Transplant Recipients  Hiroki Adachi, Yuki 
Matsui, Norifumi Hayashi, Keiji Fujimoto, Junko Imura, Hideki Yamaya, 
Hitoshi Yokoyama.  Div of Nephrology, Kanazawa Medical Univ, Uchinada, 
Ishikawa, Japan.
Background: Although the risk for morbidity and mortality has been studied in subjects 
with renal transplantation (RTx), a few study has investigated the role of adiponectin 
(ADPN) for cardiovascular disease (CVD) in RTx recipients.
Methods: We studied 57 adult RTx subjects (39 males, 18 females; 10 cadaveric 
donors) with at least three years of allograft survival (median 251 months). We examined 
clinical backgrounds such as treated drugs, blood pressure (BP, mmHg), body mass index 
(BMI), and blood chemistry including cholesterol (total, LDL-C, HDL-C), glucose, glycated 
hemoglobin (HbA1c), and serum high- and low-molecular-weight(HMW-/LMW-) ADPN 
fractions with regard to the associations of the visceral and subcutaneous fat areas on CT 
scan. We also analyzed the associations of CVD and post-transplant diabetes mellitus 
(PTDM) with ADPN fractions and the fat areas.
Results: The visceral fat area was inversely correlated with serum HMW- and LMW-
ADPN levels (r=-0.400, p=0.002 and r=-0.296, p=0.025, respectively). Furthermore, 
the visceral fat area was inversely correlated with the HMW ratio and positively with 
the LMW-ADPN ratio (r=-0.444, p<0.001 and r=0.467, p<0.001, respectively), but no 
significant correlation was noted between the subcutaneous fat area and the ADPN ratio. 
On multiple regression analysis, eGFR and the visceral fat area were significant reducing 
factors of HMW-ADPN levels, and the alteration of eGFR was identified as an increasing 
factor of HMW-ADPN levels. Patients with CVD had larger visceral fat area (p=0.004), 
lower HMW-ADPN ratio (p=0.022) and higher LMW-ADPN ratio (p=0.049), but not in 
the subcutaneous fat area. On multiple logistic analysis, the higher HMW-ADPN ratio and 
statin treatment were identified as reducing factors of the development of CVD, but the 
LDL-C level was an aggravating factor. Moreover, the higher LMW-ADPN ratio and the 
visceral fat area were aggravating factors of PTDM.
Conclusions: Even in Japanese renal transplant recipients, visceral fat area and ADPN 
fractions were significant factors for the development of both CVD and PTDM.
Funding: Government Support - Non-U.S.
FR-PO1103
Obesity Before Renal Transplantation: Is Bariatric Surgery the Solution? 
Ian Thomas, Jeffrey J. Gaynor, David Roth, Warren L. Kupin, Linda J. Chen, 
George William Burke, Michael J. Goldstein, Gaetano Ciancio, Giselle Guerra, 
Tameka Joseph.  Univ of Miami, Miami, FL.
Background: Post transplant outcomes, in obese chronic kidney disease (CKD) 
patients having bariatric surgery (BS) as a bridge to renal transplantation, have not been 
widely reported.
Methods: The database at our center of renal transplant recipients having BS prior 
to transplant from was reviewed. Control group: all obese renal transplant recipients not 
having BS with body mass index (BMI) greater than 37 at time of transplant. BMI, patient 
and graft survival, time on wait-list, acute rejections and infections requiring hospitalization 
were compared between both groups. Immunosuppressant drug levels were assessed in 
both groups.
Results: 11 patients had BS prior to transplant. There were 25 obese controls. Median 
follow up post transplant was 12 months (range 2 to 39 months) in BS group versus 63 
months (range 48 to 75 months) in the controls. There were no deaths in the BS group but 
5 deaths among controls, of which 4 had functioning grafts at time of death. No significant 
difference in patient survival was found (P = 0.18). There were 2 graft losses in the BS 
group versus 6 in the controls (P = 0.77), 4 of which were due to death with functioning 
grafts. Death-censored graft survival was borderline worse in the BS group (P = 0.05). 
Rejections were more frequent in the BS group. 4/11 patients had acute rejections in the 
BS group versus 3/25 in the control group (P = 0.01). Tacrolimus levels were at target in 
cases seen in BS group except in 1 patient who was non-adherent. Tacrolimus levels were 
lower in cases of rejection seen in the controls. There were no significant differences in 
time on waitlist, BMI prior to BS or mean eGFR at 6 months (60.6 in BS and 64.8 mL/
min/1.73 m2 in controls). However, the rate of infections was significantly higher in the 
BS group, 9/11 versus 10/25 in the control group (P = 0.02).
Conclusions: Despite possible increased transplant candidacy in obese CKD patients 
having BS, higher rejection rates and inferior death-censored graft survival compared to 
matched controls seen in this study suggest that vigilance is mandatory. Further investigation 
is required.
FR-PO1104
Association Between Serum Magnesium Level and the Risk of New-Onset 
Diabetes After Renal Transplantation in Korea  Hoon Yu, Hyungjin Cho, 
Eunhye Shin, Su-Kil Park.  Div of Nephrology, Asan Medical Center, Univ of 
Ulsan College of Medicine.
Background: New onset diabetes mellitus after transplantation (NODAT) is a serious 
complication following renal transplantation. Association between serum magnesium level 
and new-onset diabetes after renal transplantation is controversial. The aim of this study 
was to identify the association between serum magnesium level and the development of 
NODAT in Korea.
Methods: The recipients who underwent living donor kidney transplantation between 
January 2009 and April 2012 were reviewed. Diagnosis of NODAT is defined by American 
diabetes association criteria. Serum magnesium level were measured at pretransplant, 3 
days, 7days and 3 months posttransplant. Univariated and logistic regression analysis were 
performed to examine the association between serum magnesium level and NODAT at 1 
year posttransplant.
Results: Total 419 patients were enrolled. NODAT was diagnosed in 85(20%) patients. 
Mean magnesium level at 3 and 7 days after transplantation was significantly lower in 
patients who diagnosed with NODAT. On logistic regression analysis, Age >40, Obesity, 
pretransplant glucose were associated with NODAT. However, there is a no association 
between serum magnesium and NODAT. 
Table 1. Risk factors of new-onset diabetes - univariate analysis
Non-NODAT NODAT P-value
Number of patients (%) 334 (80) 85 (20)
Age, years 40.83± 10.52 47.82±10.75 <0.001
Sex, male (%) 117 (53) 53 (62) 0.143
Family history of Diabetes (%) 50 (15) 21 (24.7) 0.036
Tacrolimus (%) 230 (68.9) 59 (69.4) 1.000
Cyclosporine (%) 104 (31.1) 26 (30.6) 1.000
Mycophenolate mofetil (%) 273 (81.7) 64 (75.3) 0.181
Azathioprine (%) 30 (9.0) 11 (12.9) 0.306
Corticosteroids (%) 315 (94.3) 83 (97.6) 0.273
Imparied fasting glucose, pretransplant 12 (3.6) 11 (12.9) 0.002
Glucose, pretransplant 88.7±10.4 96.7±13.5 <0.001
Obesity, pretransplant 51 (15.3) 35 (41.2) <0.001
Mg, pretransplant 2.17±0.35 2.22±0.34 0.201
Mg, 3 days 1.77±0.20 1.83±0.23 0.026
Mg, 7 days 1.77±0.20 1.82±0.23 0.037
Conclusions: A lower magnesium level at posttransplant may be associated with 
NODAT after renal transplantation in Korea.
FR-PO1105
Is NODAT Really Associated with Acute Rejection in Kidney Only 
Transplantation?  Rosa M. Montero,1 Florence R. Delaney,2 Manohursingh 
Runglall,2 Paula Mobillo,3 Syed K. Hasan,2 Paramit Chowdhury,1 Maria P. 
Hernandez-Fuentes.2,3  1Nephrology & Transplantation, Guy’s & St Thomas’ 
NHS Foundation Trust, London, United Kingdom; 2NIHR Comprehensive 
Biomedical Research Centre at Guy’s and St Thomas’  NHS Foundation Trust in 
partnership with King’s College London and King’s College Hospital, London, 
United Kingdom; 3MRC Centre for Transplantation, DTIMB, King’s College, 
London, United Kingdom; 4King’s Clinical Trials Unit, Biostatistics Dept, 
King’s College, London, United Kingdom; 5Nephrology & Transplantation, 
King’s College Hospital NHS Foundation Trust, London, United Kingdom; 
6Nephrology & Transplantation, East Kent Hospitals Univ NHS Foundation 
Trust, London, United Kingdom.
Background: Previous reports suggest an association with New Onset Diabetes 
After Transplantation (NODAT) and rejection however it is unclear whether this effect 
is secondary to hyperglycaemia or a result of previous episodes of treated rejection. This 
observational study aims to determine the association between acute rejection(AR) and 
NODAT.
Methods: 381 renal transplant recipients(RTR) from the KALIBRE study were 
analysed. Clinical details and laboratory results were collected in this cohort from 2010-
2014. Episodes of AR were identified by renal transplant biopsies;Banff 2009 Categories 
2&4 and 3 that were treatment responsive. NODAT was defined as HbA1C>6.5% 3months 
post renal transplant. Cox’s regression proportional hazards was used for survival analysis.
Results: 381 RTRs (39%female, 64%white, 39%non-white, Age at transplant 
range:17-75). 47 patients were diagnosed with NODAT (13.1%) and 93 (24.4%) with AR. 
17/47 (36.2%) patients with NODAT had AR. Rejection free survival in NODAT group 
was significantly lower than patients without NODAT (p=0.036 HR 1.75). Mean tacrolimus 
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levels between rejectors and non-rejectors were not significantly different (10.1 and 10.3 
ng/mL means, respectively). T1DM and T2DM combined did not increase the rates of 
rejection in the cohort.
Conclusions: An association between NODAT and AR has been observed that was 
independent of tacrolimus levels. RTRs with diabetes mellitus did not have the same effect 
on AR rates suggesting a different underlying mechanism specific to NODAT rather than 
just hyperglycaemia.
Funding: Other NIH Support - 
1. Guy’s & St Thomas’ Charity, Gran number R090782 (Title: Clinical Validation 
of non-invasive peripheral biomarkers to predict and diagnose rejection following renal 
transplantation. 
2. National Institute for Health Research (NIHR) Biomedical Research Centre based 
at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London
3. GSTT Kidney Patient Association
4. Quest Diagnostics
FR-PO1106
Insulin Resistance: Is It a Risk Factor for Left Ventricular Hypertrophy in 
Pediatric Renal Transplant Recipients?  Lale Sever, Nur Canpolat, Gulseren 
Pehlivan, Salim Caliskan.  Pediatric Nephrology, Istanbul Univ Cerrahpasa 
Faculty of Medicine, Istanbul, Turkey.
Background: Renal transplantation reverses uremia-related risk factors for 
cardiovascular disease; however, immunosuppressive therapy causes metabolic 
abnormalities such as insulin resistance, hyperglycemia and dyslipidemia.The aim of the 
present study was to evaluate the effects of these metabolic abnormalities as a risk factor 
for left ventricular hypertrophy in pediatric renal transplant recipients.
Methods: This is a retrospective study involving 31 renal transplanted children and 
adolescents (19 male; age 4-20 years) and 19 healthy controls. Anthropometric indices, 
office blood pressure (BP) and laboratory measurements and also left ventricular mass 
index (LVMI) at the same time were recorded from the patients’ file.The homeostasis 
model assessment of insulin resistance (HOMA-IR) was calculated. Insulin resistance 
was defined as a HOMA-IR ≥ 2.5. Dyslipidemia was defined as HDL-C<40 mg/dL, and/
or LDL-C >130 mg/dL, and/or TG >150 mg/dL.
Results: Age at transplantation was 12.4±4.4 years with a median follow-up of 
27 months. One patient received pre-emptive transplantation, 25 were on PD and 5 
on HD before transplantation; 25 patients received a kidney from living donor. Triple 
immunosuppressive therapy was used in all patients, except two who were not using steroids 
at time of the enrolment. Patients had significantly higher BMI-SDS, fasting glucose, 
fasting insulin, HOMA-IR and TG as well as lower HDL-C levels than controls (p<0.05 
for all). Nine patients (29%) had insulin resistance; 11 (42%) were dyslipidemic; and 15 
(56%) were hypertensive. LVMI was significantly higher in the patients than the controls 
(40.0±9.1 vs. 25.8±5.71; p<0.001); left ventricular hypertrophy was noted in 11 patients 
(48%). LVMI was correlated only with indexed diastolic BP (r=0.433, p=0.039), however, 
not with any of the lipid parameters or HOMA-IR.HOMA-IR was correlated with only 
BMI (r=0.381, p=0.035). There was no association between HOMA-IR and steroid doses.
Conclusions: Although insulin resistance and dyslipidemia are prevalent in pediatric 
renal transplant recipients, hypertension appears to be the main risk factor for left ventricular 
hypertrophy.
FR-PO1107
Mediterranean Type Diet Is Associated with Low Risk of New-Onset 
Diabetes and Mortality After Renal Transplantation  Maryse Osté,1 Eva 
Corpeleijn,1 Gerjan Navis,1 Charlotte A. Keyzer,1 Sabita Soedamah-muthu,2 Else 
van den Berg,1 Daan Kromhout,1,2 Stephan J.L. Bakker.1  1Univ of Groningen; 
2Univ of Wageningen, Netherlands.
Background: The incidence of new-onset diabetes after transplantation (NODAT) and 
cardiovascular events leading to premature mortality is high in renal transplant recipients 
(RTR). We hypothesized that a Mediterranean type diet protects against development of 
NODAT and premature mortality in RTR.
Methods: In a prospective cohort study consisting of 707 adult stable RTR with a 
functioning graft for > 1 year, dietary intake at baseline was assessed with a 177 item 
validated food frequency questionnaire. Patients were divided into two categories, low 
resemblance (0-4 points) and high resemblance (5-9 points), based on a 9-point score 
according to the degree that their dietary pattern resembles that of a Mediterranean type diet. 
RTR with missing dietary data, diabetes mellitus at baseline or who underwent combined 
pancreas-kidney transplantation were excluded from analyses, leaving 474 RTR. Cox 
multivariable regression analyses were used to study the association of the Mediterranean 
diet with the development of NODAT and mortality.
Results: In total 474 RTR (56,8% men) were included with a mean ± SD age of 51.5 
± 13.2 years. At baseline, 256 (54%) had a high resemblance to that of a Mediterranean 
type diet. During median follow-up of 3.8 (interquartile range [IQR], 3.0-4.6) years from 
baseline, 28 (6%) developed NODAT and 52 (11%) patients died. RTR with ≥ 5 points 
were both significantly associated with a lower risk of developing NODAT (hazard ratio 
[HR], 0.43; 95% confidence interval [CI], 0.20-0.94; P=0.04) and mortality (HR, 0.54; 
95% CI, 0.31-0.95, P=0.03), both adjusted for age and sex. The results of multivariable 
analyses, in which we adjusted for potential confounders including total energy intake, 
physical activity and smoking status, did not materially change the results of the analyses 
adjusted for age and sex.
Conclusions: Dietary habits that resemble the Mediterranean type diet may protect 
against NODAT and mortality after kidney transplantation. More attention should be directed 
to the nutritional habits of renal transplant recipients.
FR-PO1108
Parathyroidectomy for Tertiary Hyperparathyroidism in Kidney Transplant 
Recipients  Brian M. Zwecker,1 Zahra Deen,1 Sreedhar A. Mandayam,1 Luan 
D. Truong,2 A. Osama Gaber,2 Emad H. Asham,2 Dana M. Hong,2 Venkat 
Ramanathan.1  1Nephrology, Baylor College of Medicine; 2Transplant, Houston 
Methodist Hospital.
Background: Secondary hyperparathyroidism associated with ESRD improves after 
kidney transplantation (KT) in most patients. However, in some patients, high PTH persists 
post-KT to cause a tertiary hyperparathyroidism (ThPT) state, leading to hypercalcemia 
and worsening post-transplant bone disease. New calcimimetic drugs are often denied by 
insurance post-KT leaving few options for physicians.
Methods: In this retrospective study, we identified kidney transplant recipients between 
2008 and 2013 who underwent parathyroidectomy (PTx) for ThPT.
Results: We identified 26 (2.5%) patients who underwent PTx, out of 1001 patients 
who underwent KT at our center. Pre-surgery mean calcium and iPTH levels were 10.4±1.3 
mg/dl and 508±404 pg/ml respectively. Post-KT, median time to PTx was 482 days (Q1,Q3: 
225,909); 65% underwent PTx greater than one-year post-KT. PTx indications included 
persistent hypercalcemia despite medical therapy (62%) and worsening osteoporosis 
(42%). Sestamibi scan showed hyperplasia and adenoma in 50% and 34% respectively. 
However, surgical pathology showed hypercellular parathyroid tissue in 25/26 (96%) 
patients. Predictive value of the Sestamibi scan was poor (Cohen’s kappa index 0.1). PTx 
complications included hypocalcemia (19%), transient renal failure (12%), and temporary 
nerve paresis (4%). There was no deleterious effect on long-term allograft function after 
PTx: compared with baseline values, serum creatinine was identical at 1 month (1.3±0.5 
vs. 1.3±0.6, NS) and 1 year (1.3±0.8 vs. 1.3±0.6 p=NS). Seven patients had follow up post-
surgical DEXA scans revealing an improvement in femur bone mass by 7.5%.
Conclusions: In one of the largest case series, we have shown that (a) Parathyroidectomy 
is required for tertiary hyperparathyroidism to treat hypercalcemia refractory to medical 
therapy and worsening osteoporosis (b) Sestamibi scan is inaccurate in differentiating 
between hyperplasia and adenoma and (c) Parathyroidectomy is well tolerated with no 
long-term deleterious effect on allograft function.
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SA-PO001
Intra-Abdominal Hypertension and Renal Dysfunction in Pregnancy 
Wonngarm Kittanamongkolchai,1 Elliott G. Richards,2 Mari Charisse B. 
Trinidad,2 Wendy White,2 Vesna D. Garovic.1  1Nephrology, Mayo Clinic, 
Rochester, MN; 2Maternal Fetal Medicine, Mayo Clinic, Rochester, MN.
Introduction: The effects of high intra-abdominal pressure(IAP) on renal function 
have been known for over a century. However, the diagnosis of peripartum intra-abdominal 
hypertension(IAH)/abdominal compartment syndrome(ACS) is challenging due to the lack 
of well-established normative values of IAP in pregnancy.
Case Description: A 32 year old obese primigravida with a twin pregnancy at 33 
weeks gestation was admitted for intractable nausea and vomiting. She was oliguric and 
unresponsive to IV fluid. Her blood pressure was normal. Cr increased from a baseline 
of 0.5 to 0.9 mg/dL. Urinalysis was bland. A FeNa obtained after fluid resuscitation was 
0.02%. Renal ultrasound showed patent renal vessels and no hydronephrosis. A diuretic was 
given with slight improvement in urine output. IAP measured by an intravesical catheter 
was 35 mmHg, and abdominal perfusion pressure(APP) (difference between mean arterial 
pressure and IAP) was 46 mmHg(normal > 50-60mmHg). She was suspected to have IAH/
ACS and was closely monitored. 2 days later, she developed hypertension, an increase 
in liver transaminases, and proteinuria. The decision was made to proceed with delivery 
due to severe preeclampsia. IAP measured immediately after C-section decreased to 18 
mmHg, and it was 7 mmHg prior to dismissal. Urine output increased to 2.5 L per day and 
Cr declined to 0.7 mg/dL after delivery.
Discussion: Animal and human studies indicate that oliguria and acute kidney injury are 
frequent consequences of IAH/ACS, and can be present at relatively low levels of IAP. In 
our case, the IAP of 35 mmHg was quite extreme compared to IAP of 4-28 mmHg observed 
in cohort studies of peripartum patients. We suspected that obesity and twin pregnancy 
contributed to the extreme IAH. Her APP was significantly low and restoration of renal 
function was readily observed after reduction of IAP. Our case may support the theory that 
IAH plays a role in preeclampsia, as it developed after IAH was detected. Renal dysfunction 
from IAH is probably underrecognized as IAP is not routinely measured. Further study is 
needed to elucidate the impact of IAH in pregnancy.
SA-PO002
Diabetes, Deafness and Renal Disease – A Case Report  Iolanda Godinho, 
Joana Gameiro, Noélia Lopez Santos, Sofia C.A. Jorge, Fernando Abreu, Estela 
Nogueira, Maria Alice Fortes, Jose António Lopes, Patricio Aguiar, Dolores 
López Presa, António Gomes da costa.  Hospital Santa Maria, Lisboa, Portugal.
Introduction: Deafness and kidney disease as well as diabetes and kidney disease are 
associations of which the Nephrologist is well aware. However, the concomitance of the 
three is not as usual, neither is a family history of these diseases.
Case Description: We present the case of a 47-year-old woman with non-nephrotic 
proteinuria, no haematuria, normal renal function, slowly progressive bilateral sensorineural 
hearing loss and recently diagnosed diabetes and maculopathy and a maternal family history 
of deafness, diabetes and renal disease. The patient progressed with increasing proteinuria 
despite antiproteinuric measures and a renal biopsy was performed, revealing Focal and 
Segmental Glomerulosclerosis (FSGS). Alport syndrome and Fabry disease investigation 
was negative. Facing the personal and maternal family history, the mitochondrial 
mutation m3243A>G was pursued and identified in heteroplasmy and maternally 
inherited diabetes and deafness (MIDD) with renal involvement as FSGS diagnosed. 
Renal biopsy ultrastructural study is ongoing. While waiting the etiologic investigation 
because of symptomatic nephrosis the patient was started on prednisolone 1mg/kg/d with 
no antiproteinuric response and with side effects causing her to interrupt this medication.
Discussion: Mitochondrial diseases constitute a group of rare diseases in which renal 
involvement is uncommon, although possible. This is the case with MIDD, in which 
patients present with non-insulin dependent diabetes and sensorineural hearing loss, which 
may be accompanied by other manifestations as cardiomyopathies or maculopathy. Renal 
involvement is possible, mostly as tubulointerstitial nephritis or less frequently presenting 
as glomerulopathy, namely FSGS. In this type of FSGS, the proteinuria is usually non-
nephrotic, with scarce response to antiproteinuric measures, and slow progression to chronic 
kidney disease. The association of FSGS with mitochondrial diseases is not well known to 
the nephrologic community. Its timely diagnosis is particularly important to avoid exposure 
to ineffective and toxic immunossupression.
SA-PO003
Chronic Inflammatory Demyelinating Polyneuropathy Associated with 
Advanced Focal Segmental Glomerular Sclerosis  Albert Ndzengu,1 Rada 
Petrinjac-Nneadic,2 Lekha K. George,1 Elvira Gosmanova.1  1Nephrology, 
UTHSC, Memphis, TN; 2Neurology, Tri-State Neurology, PLLC, Memphis, TN.
Introduction: Chronic demyelinating polyneuropathy (CIDP) is rarely reported in 
patients with nephrotic syndrome (NS). CIDP tends to manifest concomitantly with NS. 
We report a case of CIDP developing at a time of focal segmental glomerular sclerosis 
(FSGS) progression to ESRD and mimicking uremic neuropathy.
Case Description: A 23-yo male with NS due to biopsy proven 1ry collapsing FSGS 
and serum creatinine (SCr) 1mg/dL was initiated on oral prednisone and lisinopril. He was 
lost to follow up and returned 1.5 years later complaining on burning pain and numbness 
in both feet for 4 weeks. Physical exam was normal except for unsteady gait, inability to 
perform tandem gait, decreased sensation from feet to upper legs, depressed Achilles and 
ankle flexor reflexes. Laboratory tests showed SCr 44mg/dL, hyperkalemia, metabolic 
acidosis, normocytic anemia, and normal creatinine phosphokinase. A diagnosis of ESRD 
due to progression of untreated FSGS was made and dialysis was started. CT head and 
MRI spine were normal. Cerebrospinal fluid had protein of 74 mg/dL and 1WBC/µL. 
Electromyography (EMG) showed absent compound muscle action potential (CMAP) 
and F-waves in both peroneal and tibial nerves, active denervation in tibialis anterior, 
gastrocnemius and extensor digitorum brevis muscles, and prolonged distal latencies and 
motor conduction velocity with normal amplitude of CMAP on both arms. Sensory nerves 
action potentials on sural and peroneal nerves were absent with prolongation of peak 
latencies on other nerves. The constellation of clinical, EMG and normal inflammatory, 
infectious and autoimmune laboratory markers was consistent with diagnosis of CIDP. 
Plasmapheresis was performed with partial improvement of neurological symptoms and 
was followed by intravenous immunoglobulin infusion as a maintenance therapy.
Discussion: CIDP should be considered in patients presenting with peripheral 
neuropathy and history of FSGS. Correct diagnosis of CIDP is critical as untreated CIDP 
leads to inability to walk. Autoimmune mechanisms may be responsible for CIDP and 
glomerular damage in FSGS but remain to be proven.
SA-PO004
Alloimmune Membranous Nephropathy in Fabry Disease  Zubin T. Lathara,1 
Josephine M. Ambruzs,2 Eric P. Cohen.1  1Medicine, Medical College of 
Wisconsin, Milwaukee, WI; 2Pathology, Nephropath, Little Rock, AR.
Introduction: Use of enzyme replacement therapies may cause allo-reactivity that 
causes illness superimposed on the primary disease.
Case Description: A 20 year old male with Fabry disease developed proteinuria. He 
has the 3.1 kb alu-alu deletion including exon 2. His most recent agalactosidase serum 
enzyme activity was low at 0.8 nmol/hour/ml (normal 6.2 to 18.6). He has chronic arthralgia 
and abdominal pain. He has been on treatment with agalsidase beta enzyme since age 
10. His medications also include cholecalciferol, dicyclomine, and carbamazepine. He 
has had infusion reactions with back pain and painful diarrhea. He was premature at 32 
weeks gestation. His dizygotic twin sister has no manifestations of Fabry disease. His 
maternal grandfather has Fabry disease and is on dialysis. On exam, his blood pressure 
was 127/67 mmHg. There was minimal peripheral edema. Urinalysis showed small blood, 
100 mg/dl protein, 0-2 wbc, 0-2 rbc, and free fat. His serum creatinine was 0.78 mg/dl. 
He had 1 gram of urine protein per gram of urine creatinine. His proteinuria had ranged 
from 1.3 to 2.9 gram/gram over the preceding four months. Serological testing showed a 
negative RPR, negative tests for hepatitis B and C, and an antinuclear antibody of 1:640 
titer. A kidney biopsy showed Fabry disease and superimposed membranous nephropathy. 
Lisinopril 2.5 mg/day was started. Rheumatological evaluation showed no evidence of lupus 
erythematosus. The most recent urine protein to creatinine ratio was 0.71 gram/gram, with 
a serum creatinine was 0.8 mg/dl.
His kidney biopsy stained positive for anti-agalsidase, but normal control kidney did 
not. He had anti-agalsidase antibodies in his serum that did not block agalsidase activity. 
Immunofluorescence for the phospholipase A2 receptor (PLA2r) was negative within the 
glomeruli and his serum did not have antibodies to PLA2r.
Discussion: Enzyme replacement therapies may lead to allo-reactivity. Membranous 
nephropathy has been described in three such patients but not in Fabry disease. Its 
occurrence may change the therapy of the primary disease and force specific treatment of 
the membranous nephropathy.
Funding: Veterans Administration Support, Clinical Revenue Support
SA-PO005
Silicone Implant Associated Acute Kidney Injury in a Male Transgender 
Patient  Frank J. O Brien, Brian Y. Young.  Div of Nephrology, Santa Clara 
Valley Medical Center, San Jose, CA.
Introduction: Obstructive kidney disease secondary to nephrolithiasis is a well-
described cause of acute kidney injury. Stone formation is often due to dietary or metabolic 
factors, often no predisposing factors are found. We describe a rare case of obstructive acute 
kidney injury associated with hypercalciuria and hypercalcemia in a 32-year-old transgender 
patient. Patient was found to have granulomatous disease associated with silicone implants.
Case Description: 32-year-old male to female transgender patient presented to our 
institution with fatigue. Routine labs showed creatinine 11 mg/dl, BUN 140 mg/dl, K 7 
mmol/L. She was emergently dialyzed, and imaging showed obstructing ureteric calculi, 
requiring bilateral stent insertion. Patient had a history of silicone implants to hip, buttocks 
and thigh 5 years previous. These were inserted by a non health care professional. There 
was no history of calcium product ingestion or hormonal therapy use. Diagnostic work 
up for nephrolithiasis revealed; 24 hour urinary calcium 866 mg/24 hours, serum calcium 
12.5mg/dl, ionized calcium 1.7 mmol/L. Other 24-hour urine values were normal. ACE 
level was 216 units/L. CXR was normal. PTH and malignancy work up was negative. 
CT abdomen revealed subcutaneous edema in lower back/gluteal area, around the sites 
of previous silicone implants, and inguinal lymphadenopathy. Subsequent gallium scan 
showed tracer uptake around inguinal area, buttock and hips, consistent with granulomatous 
activity around silicone implants. Excisional lymph node biopsy revealed foreign body 
type giant cells consistent with granulomatous disease. Empty vacuoles were noted within 
the giant cell cytoplasm consistent with silicone induced granulomas. Hypercalcemia was 
managed with calcitonin and intravenous fluids and definitive therapy with prednisone was 
commenced when diagnosis was made.
Discussion: Hypercalcemia due to silicone implant associated granulomatous disease 
is a rare, but important presentation. Our patient developed symptoms years after initial 
implant insertion. With the growing prevalence of cosmetic surgery, particularly in the 
transgender community, physicians need to be increasingly aware of the associated long 
term complications.
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SA-PO006
Isolated Diplopia Caused by Calcineurin Inhibitor Therapy in a Patient with 
Idiopathic Membranous Nephropathy  Nader S. Bahri, Ashwani K. Gupta. 
Nephrology and Hypertension, Univ of Florida, Jacksonville, FL.
Introduction: Neurotoxicity is a common side effect of treatment with calcineurin 
inhibitors. Tremors are frequently reported as the most common manifestation. Variable 
presentations can include headaches, seizures, visual hallucinations or blindness. Sixth nerve 
palsy has been reported in previous cases of bone marrow and cardiac transplant patients 
receiving calcineurin inhibitors. In many of these previously reported cases, the drug was 
administered intravenously and very high drug levels were found.
Case Description: 42 year-old Caucasian female with biopsy proven idiopathic 
membranous nephropathy (iMGN) who was being treated with tacrolimus and prednisone 
for nephrotic syndrome. Her tacrolimus levels were maintained between 6-8 ng/mL. Her 
urine protein/creatinine ratio of 8 gm/gm was successfully reduced to less than 1 gm/gm 
with therapy. She continued to be in complete remission but after 3 months of therapy she 
presented with diplopia. The diplopia was binocular and vertical. The patient was seen for 
an ophthalmologic evaluation. Her visual acuity was 20/20. Pupils were equal and reactive 
to light and accommodation. No nystagmus was observed. Visual fields and color vision 
was also normal in both eyes. Assay for Acetyl-choline receptor antibody was negative. 
The patient remained compliant with her medications despite the side effects. At this time 
she was switched to low dose Cyclosporin (CyA) in anticipation that similar side effects 
may not be observed. Trough CyA levels were 44 ng/mL and 59 ng/mL on two occasions 
but her symptoms did not resolve. A consultation with neuro-ophthalmology was sought 
and the patient was instructed to discontinue CyA. The symptoms completely resolved 4 
days after stopping CyA.
Discussion: This is the first reported case of isolated diplopia secondary to calcineurin 
inhibitors in low doses for treatment of iMGN. Monitoring of serum concentrations of 
these drugs has not been correlated with toxicity. The mean duration to onset of symptoms 
can be as much as 70 days suggesting accumulation of the drug in the central nervous 
system plays a role. Recognition of this condition is important for prompt diagnosis and 
appropriate management.
SA-PO007
Bilateral Renal Artery Stenosis in a Patient Treated with Nilotinib for 
Chronic Myeloid Leukemia  Omar M. Shahateet, Milos N. Budisavljevic. 
Medical Univ of South Carolina.
Introduction: The use of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 
oncoprotein has been successful in chronic myeloid leukemia (CML). Nilotinib is a 
second generation TKI designed and used to overcome deficiencies of imatinib such as 
resistance or intolerance. Nilotinib also received approval in chronic phase (CP)-CML for 
superior response rate and less progression to blast crisis compared to imatinib. Reports 
suggest peripheral artery disease (PAD) as an adverse drug reaction associated with the 
use of nilotinib. We describe a case of bilateral renal artery stenosis in a patient treated 
with nilotinib.
Case Description: A 45 year old Caucasian male diagnosed with BCR-ABL positive 
CML at age 31. He was treated with Hydrea followed by Gleevec and was in complete 
remission (CR) for 4 years when he developed ALL transformation necessitating 
chemotherapy and peripheral blood stem cell transplantation. He was in CR for 5 years 
being maintained on dasatinib which was switched to nolitinib due to intolerance from GI 
upset. He developed worsening creatinine and high blood pressure after being on nilotinib 
for 2 years. His blood pressure was 170/90, heart rate of 64/min. The remainder of his 
physical exam was unremarkable for cardiovascular, pulmonary or abdominal findings, 
including bruits. Creatinine 2.7mg/dl. CT angiogram revealed 70% stenosis of the right 
and occulsion of the left renal artery with atrophic left kidney.
Discussion: Renal artery stenosis (RAS) is common in elderly patients. RAS due to 
fibromuscular dysplasia in the renal artery is most commonly observed in younger women. 
Recent data suggest that nilotinib bind to discoidin domain receptor 1 (DDR1) which has 
been implicated in plaque formation in atherosclerosis. Nilotinib blocks the receptor kinase 
KIT which regulates histamine and heparine release. This depresses vascular repair system 
and predisposes to arterostenotic events.
SA-PO008
A Case of Minimal Change Disease After the Administration of Anti 
RANKL Monoclonal Antibody  Keisuke Horikoshi, Norihiko Sakai, Yasuyuki 
Shinozaki, Shinji Kitajima, Akinori Hara, Yasunori Iwata, Miho Shimizu, 
Kengo Furuichi, Takashi Wada.  Div of Nephrology, Kanazawa Univ Hospital, 
Kanazawa, Ishikawa, Japan.
Introduction: Receptor activator of nuclear factor kappa B (RANK)-RANK 
ligand (RANKL) has emerged as an important regulator of bone mineral density and 
microarchitecture. In addition to that, recent study has revealed that RANK-RANKL may 
contribute to the podocyte survival signal after its injury. Here we report a case that RANKL 
inhibition might contribute to the onset of nephrotic syndrome.
Case Description: A 59-year-old male without any episodes of proteinuria was given 
denosumab, a fully human monoclonal antibody to RANKL to treat osteoporosis. Two weeks 
after its administration, he showed bilateral pretibial edema. Laboratory tests revealed that 
he had microscopic hematuria, severe proteinuria (15g/gCr), hypoproteinemia (4.0g/dL) and 
hypoalbuminemia (1.5g/dL). The proteinuria selectivity index was below 0.1, indicating 
that he had selective proteinuria. Based on the results, he was diagnosed to have nephrotic 
syndrome. Renal biopsy showed minor glomerular abnormality with less tubulointerstitial 
damage, indicating minimal change disease (MCD). Taken altogether, glucocorticoid 
therapy of prednisolone 50 mg/day had started. After four weeks of treatment, the level of 
urinary protein was still high (4.1g/gCr), but it decreased gradually to the range of partial 
remission (1.2g/gCr) with another 8 weeks treatment of prednisolone.
Discussion: This may be a rare case to report the association of RANKL inhibition 
with MCD. The responsiveness to glucocorticoid therapy was not good enough to promptly 
induce complete remission, suggesting that podocyte injury due to RANKL inhibition could 
be responsible at least in part for MCD in this case.
SA-PO009
Eculizumab in Management of Thrombotic Lesions in Kidney Allograft of 
Patient with Anti-Phospholipid Syndrome  Anju Yadav, Ravi Sunderkrishnan, 
Andres Rodrigo Caero.  Nephrology, Thomas Jefferson Univ Hospital, 
Philadelphia, PA.
Introduction: Thrombotic microangiopathy (TMA) is one of the hallmark vascular 
lesions of anti-phospholipid syndrome (APLS). These lesions are at high risk of recurrence 
after kidney transplantation. The complement pathway is thought to be active in this 
process by deposition and by presence of apoptotic and vascular cell markers on sequential 
transplant biopsies. Eculizumab is a humanized anti-C5 monoclonal antibody which has 
been used in atypical hemolytic uremic syndrome. Recently, there have been reports of 
use of Eculizumab in transplant patients with APLS/ TMA.
Case Description: We present a case of a 58 year old Caucasian man with history 
of systemic lupus erythematosus, APLS on warfarin, hypertension, rheumatoid arthritis, 
transient ischemic attack, coronary artery disease with triple vessel bypass, chronic kidney 
disease stage 5 for which he received pre-emptive living unrelated kidney transplant. After 
an uneventful post-transplant course, he was discharged on warfarin. He presented to the 
hospital 4 days later, with acute renal failure, pain over the graft and sub-therapeutic INR. A 
perinephric collection was drained. Cytomegalovirus and BK polyoma viremia were ruled 
out. Transplant kidney biopsy, revealed TMA with segmental necrosis and small vessel fibrin 
thrombi and no acute rejection. High dose steroids along with aggressive anticoagulation 
were started. He received two sessions of plasmapharesis. After meningococcal meningitis 
immunization, Eculizumab 900mg/week was started. After 4 doses, Eculizumab was 
changed to 1200mg/two weeks. Creatinine trended down from 7.3 to 3.0 mg/dl and 
dialysis was stopped after 7 sessions. He was positive for IgG anticardiolipin, beta-2 
glycoprotein, and lupus anticoagulant and was started on daily aspirin and warfarin with 
INR goal of 2.5-3.5.
Discussion: Treatment with Eculizumab and plasmapheresis resulted in a relatively 
rapid and dramatic improvement of graft function in our patient and should be considered 
in difficult to manage TMA/APLS in transplant patients. Its use permits a safer approach 
of controlling the complement final common pathway.
SA-PO010
Transient Gestational Diabetes Insipidus in a Patient with Pre-Eclampsia 
Anju Yadav, Ravi Sunderkrishnan, Andres Rodrigo Caero.  Dept of Nephrology, 
Thomas Jefferson Univ Hospital, Philadelphia, PA.
Introduction: Diabetes insipidus (DI) is manifestation of post pituitary insufficiency 
characterized by polyuria and hypotonic urine. DI can be neurophyseal, nephrogenic, 
polydispsia related or gestational (GDI). L-deamino-8-d-arginine- vasopressin (DDAVP) 
is a vasopressin analogue which had higher and prolonged anti-diuretic activity with no 
effects on smooth muscle. An increase in urine osmolality by at least 50% following 
administration of DDAVP is diagnostic of disorder.
Case Description: We present a case of 22-year-old African American primigravida 
woman with no past medical history, in 32nd week of pregnancy, admitted with pre-
eclampsia with no liver injury. On admission, blood pressures were between 140-165/60-
79mmHg. After an uneventful delivery she had urine output ranging 6-9 liters along 
with polydipsia. Both of these were present all through out her third trimester. On exam 
there was no evidence of volume overload or dehydration. Labs were sodium 137mEq/L, 
Potassium 2.8mEq/L, Alb 3.0mg/dl, TSH 4.16, urea nitrogen <0.3, creatinine 0.4, serum 
osmolality 284, urine osmolality 141, spot urine protein creatinine ratio of 0.8. With one 
dose of sub-cutaneous DDAVP increased urine osmolality to 385 within 24hrs. Oral DDAVP 
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doses were titrated based on clinical response and labs. Hypokalemia was managed with 
oral repletion and resolved later. On discharge urine osmolality increased up to 523 with 
2 liters urine output and no excessive thirst.
Discussion: GDI is attributed to decreased thirst threshold, secretion of vasopressinase 
from placental cells (cystine amino-peptidase) along with reduced vasopressin secretory 
capacity, increased degradation of vasopressin by placenta derived vasopressinase, decreased 
responsiveness to vasopressin by physiologically increased prostaglandin E2 activity in 
kidney and polyuria with hypokalemia renders collecting ducts resistant to vasopressin. 
Subclinical DI can manifests itself under the influence of physiological pregnancy changes. 
DDAVP is the only treatment, as it is not degraded by vasopressinase. Timely diagnosis with 
high index of suspicion can help with appropriate management and shorter length of stay.
SA-PO011
A Case Report of Baclofen Toxicity in a Hemodialysis Patient  Sweta Carpenter, 
Sandeep Aggarwal.  Nephrology and Hypertension, Drexel Univ.
Introduction: The dangers of baclofen toxicity in patients with advanced kidney 
disease and in particular patients on dialysis remain underappreciated by many physicians.
Case Description: We present a case of a 64 year old male who developed an 
uncommon case of altered mental status during his hospitalization. His medical history 
included ESRD for which he was receiving in-center hemodialysis, diabetes and 
hypertension. He initially presented to the hospital with complaints of shortness of breath 
and hiccups. His shortness of breath was attributed to volume overload and resolved with 
two consecutive days of dialysis with fluid removal. For his intractable hiccups, he was 
started on baclofen. During his hospitalization, he became lethargic and was unable to 
move his lower extremities. Laboratory data including serum sodium, potassium, glucose, 
calcium, BUN, phosphorus, liver transaminases, thyroid function tests, troponins, infectious 
work up and ammonia levels were unremarkable. Neuroimaging, including CT head and 
brain MRI, were unchanged from previous studies and revealed moderate diffuse cerebral 
atrophy. An EEG was also performed and did not suggest signs of epileptic activity. Further 
investigation revealed that he had received a total of 20 mg of baclofen over 2 days. After 
other etiologies were ruled out, we determined that he may have suffered from baclofen 
induced encephalopathy.  His baclofen was stopped and he was prescribed daily sessions of 
hemodialysis for three days with the intent of clearing baclofen. He was dialyzed for 4 hours 
during each dialysis session with a high flux dialyzer. After his first session of dialysis, the 
patient was more alert and would follow simple commands. At 3 days, the patient’s mental 
status returned to baseline and he was able to move his extremities.
Discussion: Although the kinetics of baclofen elimination during hemodialysis are not 
well understood, this case demonstrates the resolution of baclofen induced encephalopathy 
with frequent and consecutive dialysis. Furthermore, we hope this case raises awareness 
among physicians of the toxic effects that baclofen can cause in dialysis patients.
SA-PO012
Utility of Hemodialysis in Urea Cycle Disorders  Chintan Shah, Zeinab M. 
Tamam, Inder Patel, Yahya M. Osman Malik, Nashat Burhan Imran.  Wayne 
State Univ.
Introduction: Urea cycle disorders (UCDs) are rare pediatric diseases but partial 
enzyme deficiency can persist throughout adulthood. Little has been published about the 
role of hemodialysis in addressing the acute complications of UCDs in adulthood. Catabolic 
states are well known trigger factors for the life-threatening acute hyperammonemia.
Case Description: We are reporting a 32-year old male patient with history of partial 
ornithine transcarbamylase deficiency diagnosed at age of 6 months. He presented with 
altered mental status due to acute hyperammonemia (108mcg/dl). He was treated with a 
pre-specified protocol (infusion of Na Phenylacetate/benzoate and Arginine HCl, fasting 
for 36 hours along with intravenous administration of lipids and glucose followed by 
protein restricted diet of 35 grams per day and Na phenyl butyrate & L-citrulline). This 
decreased Ammonia level to 34mcg/dl. Later, patient underwent a procedure and was kept 
NPO without intravenous calorie supplements and developed fever. Due to both of these 
catabolic states, he developed a second acute hyperammonemia (270mcg/dl). He was treated 
with the same protocol which was successful initially but due to worsening infection his 
ammonia continued to worsen regardless of the treatment (258mcg/dl) and developed 
tonic clonic seizure requiring intubation and mechanical ventilation. He was promptly 
started on a 7.5-hour hemodialysis session followed by a 5-hour session in following day. 
He was kept on CVVHD during the second night. Ammonia level decreased to 0 mcg/dl 
and patient regained consciousness.
Discussion: Partial Ornithine transcarbamylase deficiency is a very rare disorder 
among adults and its complications can be life-threatening like cerebral edema and 
herniation. Prompt dialysis is indicated as an emergency treatment or after failure of 
medical management to prevent such complications. Given the molecular characteristics 
of ammonia, prolonged (>5hours) hemodialysis sessions are more effective. Subsequent 
continuous modalities might be required as a maintenance to prevent the potenital rebound 
elevation. Discontinuation of dialysis is a clinical judgment after considering resolution of 
both the life-threatening condition and the catabolic event.
SA-PO013
Treatment of Atypical Hemolytic Uremic Syndrome Early in Pregnancy 
with Eculizumab  Rahul N. Pawar,1 Savneek S. Chugh,1 Amy R. Patel,1 Prachi 
Kale.2  1Nephrology, Westchester Medical Center, New York; 2Internal Medicine, 
Westchester Medical Center.
Introduction: Atypical Hemolytic Uremic syndrome (aHUS) is known to cause acute 
thrombotic microangiopathy (TMA) in pregnancy with adverse maternal and fetal outcomes. 
A French study showed that aHUS usually occurs postpartum when activity of placental 
related complement regulatory proteins decreases. We present a case of a young lady early 
in pregnancy with severe thrombocytopenia and acute renal failure suspicious for TTP, but 
later diagnosed with aHUS, which improved with eculizumab.
A 30 year old G11P5A5L5 10 weeks pregnant with a past medical history of 5 first 
trimester miscarriages presents with nausea, vomiting and watery diarrhea whose labs 
show a hemoglobin (Hgb) 7.8 g/dL, platelet (PLT) count 15K/uL, BUN 65 mg/dL, and 
serum creatinine 2.44 mg/dL along with a LDH of 1,847 U/L, haptoglobin <8 mg/dL, and 
albumin 3.2 g/dL. Liver function tests (LFTs) and coagulation studies were normal. She was 
suspected to have TTP and transferred to our tertiary medical center. Urinalysis revealed 
3+ protein and 3+ blood. Blood smear showed schistocytes. A diagnosis of TMA was 
made and plasmapheresis was started. Serologies for lupus and anti-phospholipid antibody 
syndrome were negative and LFTs remained normal, ruling out HELLP. The ADAMTS-13 
activity level was noted to be 129%. Renal function declined requiring the initiation of 
hemodialysis(HD). On the basis of ongoing hemolytic anemia with thrombocytopenia, 
renal failure and a negative ADAMTS-13, she was started on Eculizumab. After 2 doses, 
her renal function and urine output improved and HD was stopped. At discharge, her Hgb 
was 8.5 g/dL, PLT 150 K/uL, and BUN/creatinine 23/1.84 with the plan to receive monthly 
eculizumab infusions.
Discussion: aHUS is caused by activation of the complement system due a genetic 
deficiency of its regulatory proteins, specifically complement factor H, factor I, and/
or membrane cofactor protein. It can lead to TMA causing multi-organ failure and the 
potential for death if not managed in time. Pregnancy can cause aHUS in any trimester. 
One should maintain a low suspicion for aHUS in a pregnant patient with prompt initiation 
of eculizimab to prevent negative outcomes.
SA-PO014
I’ve Got a Fever and the Only Prescription Is More Colchicine: Familial 
Mediterranean Fever Related Pauci-Immune Glomerulonephritis 
Ashvin Baru, Anam Khan, Celia A. Peña, Rajeev Raghavan.  Nephrology, Baylor 
College of Medicine, Houston, TX.
Introduction: Relatively few renal manifestations have been detected in Familial 
Mediterranean Fever (FMF). We present a case of biopsy proven pauci-immune 
glomerulonephritis (GN) in a patient with clinically diagnosed FMF and review past 
treatments of pauci-immune GN in FMF patients.
Case Description: We present an interesting case of a 22 year old man who had 
suffered for nearly seven years a constellation of symptoms including fever, nausea, 
vomiting, abdominal pain, arthralgias, chest pain, and an erythematous rash consistent with 
a clinical diagnosis of Familial Mediterranean Fever. He had a normal serum creatinine 
of 1.0 mg/dL which peaked at 2.0 mg/dL. Repeated urinalysis indicated 6-10 RBCs per 
high powered field (phf) and 6-21 WBCs phf. Laboratory testing revealed only an elevated 
C-reactive protein. A kidney biopsy was performed which revealed 41% of the total 
glomeruli globally sclerosed and 54 % of the viable glomeruli with active crescents and 
25% interstitial fibrosis with tubular atrophy. Immunofluorescence revealed minimal C3 
staining. This was consistent with Pauci-Immune Glomerulonephritis or ANCA negative 
GN. He was treated with Colchicine, pulse steroids, and maintained with mycophenolate 
mofetil as detection for mutations in the MEFV gene in the diagnosis of FMF is ongoing. 
He has had no relapse of his FMF with initiation of colchicine and now has had resolution 
of his hematuria, proteinuria, and acute kidney injury.
Discussion: In the literature, there is minimal knowledge about the renal manifestations 
of Familial Mediterranean Fever and fewer documented reports on the treatment protocols 
for ANCA negative vasculitis in FMF. We were able to treat ANCA negative vasculitis in 
a patient with FMF with only pulse steroids and maintenance immunosuppression with 
mycophenolate mofetil with great response.
SA-PO015
Stress of Surgery – Is It Just Mental or Can It Be Renal as Well? 
Mitul Natu Patel, Maria M. Picken, Kavitha Vellanki.  Nephrology, Loyola Univ 
Medical Center, Maywood, IL.
Introduction: Waldenstrom’s macroglobulinemia (WM) is a rare clinicopathological 
disorder with a reported annual incidence of 3 per million people. It is characterized by Ig 
M monoclonal gammopathy in the blood and lymphoplasmacytic lymphoma in the bone 
marrow. Clinical manifestations are non-specific and generally related to Ig M infiltration 
of hematopoietic tissues. While deposits of Ig M in the glomerular basement membrane 
may be seen, renal failure per se is unusual. Here, we present a unique case of recurrent 
episodes of acute kidney injury (AKI) post-operatively in a patient with underlying WM 
with spontaneous recovery each time.
Case Description: 75 year old woman with WM, hypertension, obstructive sleep apnea 
and paroxysmal atrial fibrillation presented for an elective surgery for lumbar stenosis to 
our center. Her post-operative course was fairly uncomplicated and she was transferred 
to rehabilitation floor on day 3. She had gradual worsening of lower extremity swelling 
and shortness of breath and repeat labs showed a serum creatinine of 3.32 mg/dl (0.94 
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mg/dl, 5 days prior) and renal service was consulted for AKI. She had a prior episode 
of AKI with knee replacement in 2008, dialysis dependent for 33 days with subsequent 
spontaneous recovery. Further work up revealed fairly active urine sediment with new 
onset 24 hour urine protein of 3.3 grams. C3 was normal, C4 < 5 mg/dl, cryoglobulin was 
positive, rheumatoid factor of < 20 ug/dl, serum Ig M were elevated at 646 mg/dl (normal 
46-304 mg/dl) and serum immunofixation showed an abnormal restricted band between 
the beta and gamma regions. Kidney biopsy showed strongly PAS positive hyaline-like 
precipitates in the glomerular capillaries with immunofluorescence strongly positive (3+) 
for IgM and lambda light chains. There were abundant, confluent electron dense deposits 
in the mesangium and subendothelial space. Her symptoms improved with diuresis and 
she refused any other major intervention. Renal function eventually improved with serum 
creatinine of 1.2 mg/dl at the time of discharge.
Discussion: In conclusion, we believe the stress of surgery precipitated intraglomeruli 
deposition of Ig M leading to AKI with spontaneous resolution thereafter.
SA-PO016
New Causes of Secondary Hyperparathyroidism: Unforeseen Effects of New 
Drugs on the PTH-Calcium Axis  Muthanna M. Saraireh, Harold M. Szerlip. 
Nephrology, Baylor Univ Medical Center, Dallas, TX.
Introduction: Calcium homeostasis is a function of the interplay between GI 
absorption, renal excretion and bone resorption. Although numerous effectors control 
these processes, PTH is primarily responsible. PTH affects the kidney and bone through 
PTH receptor 1. In the kidney PTH decreases phosphorus reabsorption, increases 
calcium reabsorption and stimulates 1-hydroxylation of vitamin D. In the bone PTH 
up-regulates expression of RANKL and decreases expression of osteoprotegrin. This 
process increases RANKL binding to RANK on osteoclast precursors stimulating them to 
become osteoclasts that increase bone resorption. New drugs that inhibit RANK are used 
to treat osteoporosis and bone metastases. We describe two patients treated with recently 
developed chemotherapeutic agents who developed severe hypocalcemia, and secondary 
hyperparathyroidism with hypophosphatemia due to renal PO4 wasting . We hypothesize 
that these drugs inhibit RANK.
Case Description: Case 1: A 72 y/o woman with metatstatic leiomyosarcoma received 
Trabactedin, an experimental agent which interacts with DNA. She subsequently complained 
of weakness. Labs are shown. Case 2: A 73 y/o man with ALL positive for BCR-ABL was 
tarted on the tyrosine kinase inhibitor Dasatanib. He subsequently developed the laboratory 
abnormalities shown.
Ionized 
calcium Pi Urine Ca FePi
25-Vit 
D
1,25-
Vit D PTH
patient 1 0.84 mmol/L
0.9 mg/
dl < 5 mg/dl 44%
33 ng/
ml
110 pg/
ml
832 pg/
ml
patient 2 0.95 mmol/L
1.3 mg/
dl < 5 mg/dl 46%
32 ng/
ml
101 pg/
ml
509 pg/
ml
Creatinine was 0.7 mg/dl in patient 1 and 0.8 mg/dl in patient 2
Discussion: Both patients developed secondary hyperparathyroidism. The renal 
effects of PTH appeared to be intact with increased calcium resorption, phosphorous 
excretion and hydroxylation of 25-Vitamin D. The effects of PTH on bone resorption, 
however, appeared blunted. Because PTH acts on both kidney and bone through the same 
receptor, we believe that this represents a post receptor phenomena involving the RANKL/
osteoprotegrin system. The tyrosine kinase inhibitor, Imatinib, has been shown to decrease 
bone resorption through a similar mechanism. As new drugs are developed it is important 
to recognize potential untoward effects.
Funding: Clinical Revenue Support
SA-PO017
Connection or Coincidence: Behçet’s Disease and Focal Segmental 
Glomerulosclerosis with Nephrotic Syndrome  Deanne Leonard, Cherise M. 
Cortese, Xochiquetzal J. Geiger, Nabeel Aslam.  Mayo Clinic, Jacksonville, FL.
Introduction: Behçet’s Disease (BD) often presents with aphthous and genital 
ulcers, uveitis, and erythema nodosum. Rarely, renal amyloidosis, IgA nephropathy and 
crescentic glomerulonephritis result. Here we present a case of nephrotic syndrome from 
focal segmental glomerulosclerosis (FSGS) in a patient with BD with evidence to suggest 
a direct connection.
Case Description: 49 y/o female with history of hypertension and BD on etanercept, 
colchicine and carvedilol. Following a recent prednisone taper, she developed oral ulcers, 
uveitis, pathergy reaction and proteinuria. Physical exam: Blood pressure: 170/90, aphthous 
ulcer, uveitis, and 3+ bilateral leg edema. Laboratory data: serum albumin 3.3 g/dL, total 
cholesterol 282mg/dL, serum creatinine 1.1 mg/dL. Urinalysis: 3+ proteinuria, 10 RBC/
hpf and a random protein:creatinine ratio of 8.5. Normal complement levels, DS-DNA, 
SS-A, SS-B, Sm Ab, RNP Ab, Scl 70 ab, and Jo Ab. Renal biopsy: Light microscopy: focal 
segmental lesions. Immunofluorescence: IgM trace mesangial granular staining, consistent 
with immunoglobulin trapping. IgG, IgA, C3, C1q, kappa, and lambda: negative. Electron 
microscopy: near total visceral epithelial cell foot process effacement with villous formation.
Treatment included losartan and prednisone 1 mg/kg/day which resulted in resolution 
of edema and reduction of protein to creatinine ratio to 0.14 along with resolution of oral 
ulcers and uveitis.
Discussion: At present, there is no proven correlation between BD and FSGS with 
nephrotic syndrome. Our patient presented with BD flare coinciding with the development 
of nephrotic syndrome both of which improved simultaneously with steroids suggesting 
a direct connection. Therefore, the clinician should be aware of this possible link and 
screen accordingly for proteinuria both qualitatively and quantitatively to detect early renal 
involvement in patients with BD.
SA-PO018
Reversal of Dialysis-Dependent Renal Failure and Nephrotic Syndrome after 
Conservative Therapy in an Adult with Proliferative Glomerulonephritis 
with C3-Dominant Deposition  Eriko Takehara,1 Shintaro Mandai,2 Shinichi 
Uchida.2  1Dept of Nephrology, Shuuwa General Hospital, Saitama, Japan; 
2Dept of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo 
Medical and Dental Univ, Tokyo, Japan.
Introduction: C3 glomerulonephritis (C3GN) is a recently described entity in a 
reclassification of membranoproliferative glomerulonephritis, characterized by isolated or 
predominant glomerular C3 deposits. Although abnormalities in the alternative pathway 
are known to be involved in the pathogenesis, efficient therapeutic approaches have yet 
to be established.
Case Description: In December 2012, a 55 year-old man was admitted with rapidly 
progressive glomerulonephritis and nephrotic syndrome. In May 2011, his serum 
creatinine(SCr) was 0.63mg/dl. Seven weeks previously, he was admitted to another 
hospital with hemorrhagic gastric ulcer accompanied by renal failure (SCr 4.61 mg/dL, 
urinary protein 15 g/gCr, and moderate hematuria), in the absence of preceding infection. At 
admission to our hospital, SCr increased to 7.60 mg/dL. ANCA, anti-nuclear antibody, and 
decrease in complement factors were absent. A renal biopsy specimen showed crescentic 
and endocapillary proliferative GN with dominant C3 and trace IgG. Conservative therapy 
was started, given the repeated hemorrhagic ulcer, and decreased rate of renal function 
decline. Hemodialysis was initiated on hospital day 20 because of oliguria, but was ceased 
on day 60 with recovery of kidney function. SCr decreased to 1.2 mg/dL, and urinary 
protein decreased to <1 g/gCr. One year after discharge, he developed nephrotic-range 
proteinuria, and the second renal biopsy revealed the increased sclerotic glomeruli and 
fibrous crescents with isolated C3 deposits.
Discussion: To our knowledge, this report is the first to describe reversal of dialysis-
dependent renal failure after conservative therapy in a C3GN patient. Similarly to the present 
case, the histological morphology and clinical presentation infrequently mimic the picture of 
postinfectious GN, although the transient recovery is usually partial. A novel classification 
of such cases among C3GN may be needed to avoid an unbeneficial immunosuppression.
SA-PO019
Optical Coherence Tomography and En Face Retinal Findings in 
Membranoproliferative Glomerulonephritis Type 2  Paula Delegrego Borba, 
João Rafael De oliveira dias, Eduardo Amorim Novais, Andre Romano, Gianna 
Mastroianni-kirsztajn, Rubens Belfort De mattos.  Ophtalmology and Visual 
Sciences Dept, Univ Federal de Sao Paulo - UNIFESP, Sao Paulo, Brazil; 
Nephrology Dept, Univ Federal de Sao Paulo - UNIFESP, Sao Paulo, Brazil.
Introduction: Membranoproliferative glomerulonephritis type 2 (MPGN II) is a 
condition with electron dense deposits in the glomerule basal membrane that usually 
affects youngsters of 5-15 years old. Patients may have assymptomatic retinal drusen-like 
deposits but 10% of cases may have choroidal neovascularization that leads to visual loss. 
We evaluated patients with a high-speed spectral-domain optical coherence tomography 
(SD-OCT) device and en face OCT imaging of the retina.
Case Description: Four eyes of 2 patients with MPGN II were scanned using a high-
speed 840-nm-wavelength SD-OCT (RTVue XR Avanti; Optovue, Inc, Fremont, USA). 
The split-spectrum amplitude-decorrelation angiography algorithm was used to detect 
blood flow. Fluorescein angiography (FA) (HRA System, Heidelberg Engineering) images 
were obtained in search for drusen-like deposits in the Bruch membrane or choroidal 
neovascularization.
Both patients (female, 34 years old and male, 25 years old) had best corrected visual 
acuity of 20/20 in both eyes, unremarkable anterior biomicroscopy, RPE mobilization and 
macular drusen-like deposits.There was no choroidal neovascularization at the FA. En face 
OCT showed hyporeflective dots with a hyperreflective ring at the RPE that corresponds 
to drusen-like deposits underneath the RPE and dilated choroidal image.
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Discussion: MPGN II may cause drusen and choroidal neovascularization. Eye 
examination is useful to diagnose visually threatening complications. The newer high-speed 
spectral-domain optical coherence tomography instrument may define the precise location 
of the drusen-like deposits when using En face OCT.
SA-PO020
Severe Hyponatremia following the Treatment of Pulmonary Strongyloides 
Stercoralis Infection  Renu Regunathan-Shenk, Wooin Ahn, Sumit Mohan. 
Nephrology, New York Presbyterian-Columbia Univ Medical Center, New 
York, NY.
Introduction: Strongyloides sterocoralis is a soil transmitted nematode which can cause 
serious infection in immunocompromised patients through skin penetration. The helminth 
can cause abdominal and pulmonary symptoms and can continue to autoinfect patients if 
untreated. It has been infrequently reported to cause hyponatremia which resolves with 
treatment of the infection.
Case Description: A 59-year-old Dominican man with a history of single lung 
transplant and chronic abdominal pain was admitted for treatment of pulmonary 
strongyloides infection found on routine outpatient bronchoscopy. On admission he was 
found to have an E. Coli bacteremia which was attributed to gastrointestinal translocation. 
The patient was started on ivermectin (15 mg/day orally) and piperacillin tazobactam (4.5 
grams every 8 hours intravenously in 5% dextrose solution). He developed a rapid decline 
in his serum sodium concentration from 135 mmol/L prior to admission to 109 mmol/L on 
hospital day 5. Physical exam at this time was notable for euvolemic appearance, lethargy, 
and inattention. Laboratory evaluation confirmed a hypo-osmolar hyponatremia with 
elevated urine osmolality (576mOsm/kg) consistent with Syndrome of Inappropriate ADH 
Secretion (SIADH). Thyroid studies and cerebral fluid studies were unremarkable. He was 
treated with hypertonic saline and desmopressin until he achieved normonatremia. He has 
been continued on weekly ivermectin treatment, daily salt tablets, and furosemide tablets.
Discussion: Strongyloides stercoralis induced SIADH in an under-recognized cause of 
euvolemic hyponatremia, especially in patients who have traveled to endemic areas or who 
are immunocompromised. Prior case reports have shown resolution of hyponatremia with 
strongyloides treatment, however we present a patient who worsened after bronchoscopy 
and initiation of ivermectin. We propose that this may have occurred due to increased 
systemic parasite exposure after the bronchoscopy procedure.
SA-PO021
A Case of Disseminated HSV Infection in PD Patient with Bullous 
Pemphigoid  Yujiro Machida,1 Kentaro Fujii,1 Ayumi Yoshifuji,1 Naoki 
Washida,1 Hirobumi Tokuyama,1 Matsuhiko Hayashi,2 Shu Wakino,1 Hiroshi 
Itoh.1  1Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan; 
2Apheresis and Dialysis Center, Keio Univ School of Medicine, Tokyo, Japan.
Introduction: Patients with end stage renal disease (ESRD) are affected by various 
infections with high mortality because of the immunodeficiency. We report a rare case of 
disseminated Herpes simplex virus (HSV) infection in peritoneal dialysis (PD) patient, 
who was treated with high-dose steroid for bullous pemphigoid (BP).
Case Description: A 72-year-old man under the treatment with PD for 2 months for 
ESRD caused by nephrosclerosis was admitted to our hospital because of blisters and 
ulceration on his whole body for two weeks. He had had BP and been treated with 60 mg 
of prednisolone. Twenty-nine days after the admission, peritoneal fluid became yellowish-
brown and peritonitis was suspected from the elevation of inflammatory markers. Though the 
cell count of peritoneal fluid was within the normal range, multinuclear, frosted glass-formed 
cells were detected in PD fluid, which indicated HSV pritonitis. Serum HSV-DNA elevated 
to 6x105 copies and he was diagnosed as disseminated HSV infection. After 200 mg of 
Acyclovir daily was administered, he had a severe disturbance of consciousness. Although 
differential diagnosis between acyclovir encephalopathy and HSV encephalitis was 
difficult, the results of spinal fluid tap and head MRI concluded acyclovir encephalopathy. 
Introduction of hemodialysis recovered his consciousness. HSV-DNA was decreased, 
although he developed multiple complications of hemophagocytic syndrome, bacterial 
infection and invasive pulmonary aspergillus, and died 56 days after hospitalization.
Discussion: We experienced a rare case of disseminated HSV infection and PD-related 
HSV peritonitis. The combination of immunodeficient factors of ESRD, high-dose steroid 
and BP contributed to the severe immune-compromised state and disseminated HSV 
infection. Since an early diagnosis determines the prognosis of disseminated HSV infection, 
cell pathology in peritoneal fluid would assist preemptive therapy.
SA-PO022
Use of Rituximab in Goodpasture’s Disease with Pulmonary Hemorrhage 
Scherly Leon, Vadim Abramov, Farouk Talakshi, Mary C. Mallappallil, Moro 
O. Salifu.  Medicine, Renal Div, Downstate Medical Center, Brooklyn, NY.
Introduction: Goodpasture’s syndrome (GPS)or anti-GBM disease is a rare 
autoimmune disease, where pathogenic autoantibodies deposit in the basement membrane. 
It presents with rapidly progressive glomerulonephritis, with or without pulmonary 
hemorrhage. The current standard treatment of Anti-GBM disease is immunosuppression 
to reduce antibody production and plasmapheresis to remove existing antibodies in 
circulation. Rituximab, a monoclonal antibody directed against CD-20 antigen present 
on B-lymphocytes, approved for various B-cell lymphoproliferative diseases has been 
used in ANCA associated vasculitis with success; however it’s use in anti-GBM disease 
is scarce and data regarding safety and efficacy is lacking. We report use of Rituximab in 
the treatment of GPS with pulmonary hemorrhage.
Case Description: A 35 year-old man presented in 2012 with two week history of 
nausea, vomiting, intermittent fevers and dark urine. Laboratory findings were creatinine 
18 mg/dl, potassium 6.1 mmol/L, Hgb 11.6 g/dL, and platelet count 288 x 103 per µL. 
Urinalysis showed nephritic urine sediment. Serology test including ANCA was negative. 
Anti-GBM antibodies levels were greater than 8 with peak 27. CT chest with pulmonary 
hemorrhage. He was given pulse dose steroids and initiated on dialysis. Renal biopsy was 
consistent with GPS (crescentic GN linear anti-GBM on IF). Plasmapheresis was initiated 
and patient received four doses of Rituximab. Anti-GBM level on discharge from hospital 
was 2.9. Since initial presentation, patient had two admissions to the hospital in 2014 and 
2015 with undetectable Anti-GBM levels.
Discussion: Patients with anti-GBM renal disease have high mortality, especially 
when pulmonary involvement is present. The use of steroid, immunosuppressives and 
plasmapheresis alone or in combination has led to a significant improvement of both patient 
survival and clinical symptoms. Anti-GBM disease is a rare fulminant disease, data regarding 
the safety and efficacy of alternative therapies are lacking. There are few reported cases 
of anti-GBM disease treated with rituximab. We present a case of anti-GBM disease with 
pulmonary hemorrhage successfully treated with Rituximab.
SA-PO023
A Rare Case of Aluminum Toxicity  Khurram Saleem, Khaled Boobes, Yazan 
M. Alia, Muhammad H. Hasan, Jennifer A. Tuazon.  Nephrology, Northwestern 
Memorial Hospital, Chicago, IL.
Introduction: Aluminum toxicity was initially described in encephalopathic patients 
with renal failure, overdosing of aluminum-based phosphate binders and attributed 
to contamination of water used for dialysis treatments. Use of alum irrigation for the 
treatment of refractory hemorrhagic cystitis was first reported in 1982. It was described as 
a safer alternative to formalin bladder irrigation. We report a case of bladder perforation 
after alum irrigation, leading to intra-peritoneal aluminum exposure. Our patient expired 
despite chelation and renal replacement therapy. Her serum aluminum concentration is the 
highest reported level to date.
Case Description: 67 year old female with cervical cancer, admitted for urosepsis, 
was noted to have hematuria and urinary retention. Her catheter was changed due to clot 
obstruction and bladder irrigated with saline. Following day continuous bladder irrigation 
was instituted for persistent hematuria. She underwent cystoscopy with fulguration for 
persistent hematuria secondary to radiation cystitis. Her CBI resumed with alum irrigant. 
Overnight, alum irrigant was placed on a pump for infusion. Hours later, patient transferred 
to ICU for hypotension. CT abdomen revealed free intraperitoneal air, large volume of 
new fluid, air around bladder suspicious for bladder perforation, and absence of contrast 
outside of the bowel. Bilateral percutaneous nephrostomy performed for urinary diversion 
and to evacuate free fluid. Aluminum levels were drawn. Patient was intubated, placed on 
vasopressors. Had non-gap metabolic acidosis and worsening renal function, concerning 
for aluminum toxicity due to intra-abdominal bladder perforation in the setting of alum 
irrigation. Deferoxamine was started and CVVH for acidosis. However patient developed 
refractory shock, and expired. Shortly before her death, aluminum level resulted 163.7mcg/L 
(normal 0 to 20mcg/L). Subsequent levels peaked at 1455.2mcg/L.
Discussion: We report systemic absorption of alum-containing irrigant following 
bladder perforation. Large aluminum load to the peritoneum resulted in systemic 
toxicity,multi-organ failure and death. Chelation therapy and CVVH were inadequate. We 
report the highest serum aluminum level to date.
SA-PO024
Primary Glioblastoma Multiforme in a Renal Transplant Patient 
Hermes Garcia-Sanchez, Arshad Ali, Stephen O. Pastan.  Nephrology, Emory 
Univ, Atlanta, GA.
Introduction: Glioblastoma multiforme is the most common and most aggressive 
malignant primary Brain tumor in humans, involving glial cells and accounting for 52% 
of all functional tissue brain tumor cases and 20% of all intracranial tumors. Incidence of 
2–3 cases per 100,000. The principal neoplasm involving the CNS of transplant recipients 
is non-Hodgkin lymphoma while glial tumours are rarely described.
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Case Description: We describe 54 year old Male with a history of Deceased 
Donor Renal transplant in 1999 whose kidney disease was secondary to Hypertensive 
nephrosclerosis. Donor information is not available. The patient had been in his usual state 
of health until one week prior to presentation, when he started feeling weak and became 
confused, reason for hospitalization.
An MRI brain confirmed a large mass measuring 5.4 x 2.9 cms ,in the corpus 
callosal splenium and second lesion 8 x9 mm, in the left parietal region. He had a biopsy 
done which revealed a GBM. Neurosurgery was consulted and mass was found to be 
unresectable. Neuro-Oncology was consulted and he was advised radiation therapy and 
possible chemotherapy, however he decided to seek second opinion. His Post transplant 
period has been remarkable for a borderline rejection with donor specific antibodies, treated 
with plasmapheresis and IVIG. His immunosuppressant medications were Cyclosporine , 
Mycophenolate mofetil and prednisone.
Discussion: Review of the literature indicates that gliomas do not seem appear in an 
early post-transplant period. These tumors have been reported mostly after 4–20 years from 
renal transplantation. Increased risk of tumour occurrence may be related immunological 
disorders such as HIV, and also to the administration of immunosuppressive drugs. Few 
studies have shown that cyclosporine may induce phenotypic changes in different tumoural 
and normal line cells and may play a role in modulating the neoplastic course. There seems to 
be the existence of a relationship between glioblastoma development and kidney transplant, 
but this association needs to be studied further. With increasing life expectancy of transplant 
recipients, evaluation of the risk of serious complications such as glial tumors is necessary.
SA-PO025
Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy 
Venkata Buddharaju, Rajat Lamba, Savneek S. Chugh, Rahul N. Pawar, Rudrick 
V. Ledesma, Praveen N. Chander.  Nephrology, Westchester Medical Center, 
Valhalla, NY.
Introduction: Thrombotic microangiopathy (TMA) is a pathological process involving 
thrombocytopenia, microangiopathic hemolytic anemia and microvascular occlusion 
particularly the kidney and brain. Eculizumab, a complement C5 inhibitor, has been used 
to successfully treat cases of atypical HUS but its use has not been widely reported in drug 
induced TMA. We report a case of Gemcitabine induced TMA treated with Eculizumab.
Case Description: A 68 y/o male with h/o hypertension, Diabetes mellitus, CKD 
with a baseline Cr 1.9, Prostrate Ca. s/p Whipple procedure, receiving gemcitabine as neo 
adjuvant chemotherapy was sent to the hospital for worsening creatinine, 20 lbs. weight 
gain and worsening pedal edema over the duration of one month. On admission, he was in 
hypertensive urgency with BP 235/110. Labs showed Hb 9, platelet 201, Na 136, K 5.4, 
Cl 114, HCO3 18, BUN 53 and Cr of 3.0. Urinalysis showed 3+ blood and 4+ protein. 
Further workup revealed normal complements, negative ANA, ANCA, hepatitis panel and 
HIV serology, elevated LDH and low haptoglobin. Occasional schistocytes were noted on 
the peripheral smear. Renal ultrasound showedmildly echogenic kidneys. Urine protein/
creatinine ratio was 7.5.A renal biopsy was performed, which showed TMA, clinically 
suspected to be secondary to gemcitabine. The patient was started on Eculizumab regimen 
but renal function deteriorated requiring RRT. After 3 months of therapy, his LDH and 
haptoglobin have improved but he is still on Dialysis.
Discussion: The mechanism of chemotherapy induced TMA is presumed to be a 
dose dependent direct endothelial injury rather than deficient ADAMTS 13 activity or 
complement dysfunction. So, Therapeutic plasma exchange is usually not recommended. 
There are rare case reports of Gemcitabine induced TMA that improved with TPE. This 
indicates that patients who do get TMA while on Gemcitabine likely have some complement 
dysfunction or a serum factor induced by Gemcitabine that is responsible for endothelial 
injury. There might be a role for Eculizumab in underlying complement dysregulation in 
chemotherapy induced TMA, which needs further studies.
SA-PO026
Improvement of Renal Function with Treatment of Hypothyroidism 
Ibrahim M. El-Ali, Ana Claudia Onuchic, Ruchir D. Trivedi.  Dept of Medicine, 
Div of Nephrology, Univ of Connecticut School of Medicine, Farmington, CT.
Introduction: Association of subclinical hypothyroidism and chronic kidney disease 
is increasingly being recognized. Early data suggests improvement in renal function with 
thyroid hormone replacement in patients with clinical and subclinical hypothyroidism. 
We present a case of dramatic improvement of renal function upon successful treatment 
of hypothyroidism.
Case Description: 33 y/o AA male with past medical history of nasopharyngeal 
carcinoma and cisplatin nephropathy (baseline creatinine 2.4 mg/dL)presents with sustained 
elevation of creatinine kinase (CK). No improvement was noted after stopping statin and 
reported intense exercise regimen. No detectable urine myoglobin. CK remained about 
40,000 IU/L, with gradual worsening of creatinine up to a peak of 3.2 mg/dL. Work up 
revealed primary hypothyroidism with TSH 117 uU/ml (N=.34 - 5.6) and Free T4 < 0.4 ng/
dL. Muscle biopsy showed type ll muscle fiber atrophy and loss which can be correlated 
with biochemical lack of L-thyroxine. The patient was started on levothyroxine replacement 
and within days demonstrated improvement in CK and Scr. Seven weeks after initiation 
of therapy there is ongoing improvement in CK, TSH and Scr to levels of 3271 IU/L, 15.4 
uU/ml, and 1.9 mg/dL.
Discussion: Experimental evidence suggests that hypothyroidism is associated with 
changes in renal function and decrease nephron mass. Similarly, hyperthyroidism can 
result in glomerular hypertrophy by enhanced expression of renin mRNA. Hypothyroidism 
blunts compensatory hypertrophy after unilateral nephrectomy in remnant kidney 
models. Developmentally, thyroid hormone also has important role in tubular function 
including maturation and density of many tubular transporters. We demonstrate continued 
improvement in renal function upon thyroid hormone replacement. Subclinical and overt 
hypothyroidism may be under recognized in CKD and ESRD. Further studies are needed 
to understand these complex interactions.
SA-PO027
A Case of Rapidly Progressive C3 Glomerulonephritis  Aala Jaberi, Jean M. 
Francis, Craig E. Gordon.  Nephrology, Boston Medical Center, Boston, MA.
Introduction: C3 glomerulonephritis (C3GN) is a rare glomerular disease,characterized 
by predominant C3 deposition within the glomerulus. It is thought to be caused by 
uncontrolled activation of the alternative complement pathway . Eculizumab, a humanized 
monoclonal C5 antibody, has advanced the treatment of complement mediated diseases 
such as complement-mediated hemolytic uremic syndrome ,and has emerged recently as 
a treatment option for C3GN.
Case Description: A 74 year old retired software engineer with history of atrial 
flutter,and nephrolithiasis was transferred to our center with 2 weeks history of sore throat, 
fatigue, fever and rigors. Laboratory studies were significant for WBC 19U/L with left shift, 
platelets 40,000/UL, and serum creatinine 2.2 mg/dl, which rapidly increased to 11 mg/dl 
over 4 days. Blood cultures grew Streptococcus pyogenes. Further tests revealed a high ASO 
titre at 800, ANA 1:160, and low C3 and C4. Hemodialysis was started for uremic symptoms 
and a kidney biopsy was performed. The biopsy revealed an acute glomerulonephritis 
with C3 predominance, with tubulointerstitial nephritis, there were also features of post 
infectious GN evident by subepthelial humps. Intravenous Methylprednisolone was started 
but he remained dialysis dependent. With the consideration that the infection likely induced 
unregulated activation of the alternative complement pathway. We started eculizumab 900 
mg . Patient received a total of six hemodialysis treatments . After 1 dose of eculizumab, 
the serum creatinine plateaued without dialysis treatment at 3.9 mg/dl, dialysis treatment 
was discontinued and plan was made to continue weekly infusions of eculizumab.
Discussion: Disorders of alternative complement pathway regulation are becoming 
increasingly recognized. There are no proven therapies for C3GN, but targeting terminal 
complement is an attractive approach given the known causes of C3GN. There are few 
reported cases of the benefit of eculizumab in C3GN and often describe the agent’s efficacy 
earlier in the course. This case represents a unique instance of effective treatment of dialysis-
dependent C3GN with early restoration of renal function.
SA-PO028
Nephrotic Syndrome After Scorpion Sting  Boju Sangeetha Lakshmi, 
Chaitanya Vemuri, Anil Kumar Cheni Venkata, Ram R, Siva Kumar 
Vishnubhotla.  Dept of Nephrology, Sri Venkateswara Inst of Medical Sciences, 
Tirupati, Andhra Pradesh, India.
Introduction: Scorpion venom is a water soluble, anti-genic and heterogeneous 
mixture.The reported incidence of scorpion sting in India is 0.6%. Scorpion sting resulting 
in acute renal failure has been reported in the past, but not the nephrotic syndrome.
Case Description: A 49-year-old gentleman, non-diabetic and not a hypertensive, 
presented with history of scorpion sting over the fourth digit of the left hand. Patient had 
immediate intense local pain, swelling and redness. Within one hour he had hypersalivation, 
sweating, vomiting and diarrhoea. After three days, the patient complained insidious onset 
of abdominal distension, followed by paedal oedema and facial puffiness over next one 
week. There was no history of oliguria, dysuria and haematuria. Investigations revelead 
serum creatinine: 2.9 mg/dL, 24 hour urine protein was: 9.90 g. He was subjected to renal 
biopsy at that institute.The diagnosis was minimal change with acute tubular necrosis.He 
presented to our institute with breathlessness and ansarca. On examination BP 140/90mmHg 
and bilateral crackles on auscutation. Serum creatinine:7.0 mg/dL, blood urea:148 mg/
dL, total serum proteins: 5.5 g/dL, serum albumin: 2.5 g/dL, total cholesterol: 237 mg/dL, 
triglycerides: 182 mg/dL, haemoglobin: 12.0 g/dL and 24 hour protein: 2872 mg. He was 
dialyzed for three sessions and subjected to renal biopsy and diagnosed to have minimal 
change disease and acute tubular necrosis, thepatient was continued on dialysis. Urine 
output improved after three more weeks. Serum creatininestabilizedto2.0 mg/dL after 
eight weeks of scorpion sting.
Discussion: The scorpion venom is composed of varying concentration of neurotoxin, 
cardiotoxin, nephrotoxin, haemolytic toxin, phosphodiesterase, phospholipases, 
hyaluronidases, glycosaminoglycons, histamine, serotonins, and tryptophan and cytokine 
releasers. Acute renal failure after scorpion sting is reported but nephrotic syndrome is not 
reported.We report a patient of nephrotic syndrome after scorpion sting.The lacunae in the 
present knowledge linking scorpion sting venom with nephrotic syndrome would only be 
repleted with publications of similar reports.
SA-PO029
Diffuse Crystals Accumulation in the Proximal Tubules, Podocytes, and 
Interstitial Histiocytes of a Patient with a Multiple Myeloma  Satoshi Hara,1 
Kiyoaki Ito,1 Kazunori Yamada,1 Ryoichi Miyazaki,2 Mitsuhiro Kawano.1 
1Rheumatology, Kanazawa Univ Graduate School of Medicine, Kanazawa, 
Ishikawa, Japan; 2Internal Medicine, Fujita Memorial Hospital, Fukui, Japan.
Introduction: Light chain proximal tubulopathy with crystals formation is a rare 
condition, accompanied by paraproteinemia. In particular, observation of crystal inclusions 
in the podocytes has seldom been reported. We present a distinct case that revealed diffuse 
crystal inclusions in a variety of kidney cells of a multiple myeloma (MM) patient, including 
the proximal tubular cells, podocytes, and interstitial histiocytes.
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Case Description: A 66-year-old Japanese woman was admitted to our hospital 
and diagnosed with gradual deteriorated kidney function (serum creatinine, 2.0 mg/
dL), proteinuria (urinary protein, 1.3 g/d), and mild hematuria (urinary red blood cells, 
10-19/hpf). Urinary b2-microglobulin was notably elevated (117,700 mg/L); however, 
Fanconi’s syndrome was not detected. Elevated serum IgG levels (IgG 2,559 mg/dL) with 
IgA and IgM suppression were confirmed, and serum immunoelectrophoresis revealed 
monoclonal IgG-κ. Examination of kidney biopsies revealed crystal inclusions in the 
proximal tubules, podocytes, and interstitial histiocytes. The crystals tested negative for 
eosin, periodic-acid Schiff, and trichrome staining. No segmental glomerulosclerosis 
was observed. Immunofluorescence staining of both κ and Ȝ was negative. Similarly, 
immunohistochemistry, using an antigen retrieval method, failed to detect either κ or Ȝ. 
Transmission electron microscopy revealed highly electron dense crystals that diffusely 
accumulated in the proximal tubules, podocytes, and interstitial histiocytes. By bone 
marrow biopsy, the patient diagnosed as MM. Bortezomib treatment attenuated kidney 
dysfunction and proteinuria. Sequential DNA analysis confirmed that the patient had Vκ 
subgroup I restriction.
Discussion: Monoclonal light chains are internalized into the lysosomes of proximal 
tubular cells by receptor-mediated endocytosis, where they form protease resistant crystals. 
Our case suggests that podocytes can engulf crystals in a similar manner, despite lacking 
the receptors found on proximal tubular cells.
SA-PO030
Erythematous Skin Rash and Gastrointestinal Bleeding as Presenting 
Features of ANCA Negative Pauci-Immune Glomerulonephritis 
Anusha Lakshmi Badveli, Chanchal Kumar Jana.  Internal Medicine, R.G. Kar 
Medical College and Hospital, Kolkata, West Bengal, India.
Introduction: Pauci-immune glomerulonephritis (PGN) is one of the common 
causes of RPGN. In most patients with PGN, circulating antineutrophil cytoplasmic 
autoantibody(ANCA) is present, however 10% of the patients are ANCA-negative. Usually 
extra renal manifestations in ANCA negative PGN are rare, but the case reported here is a 
rare presentation having skin rash and gastrointestinal (GI) manifestations.
Case Description: A 50-year-old female was admitted with low-grade intermittent 
fever, erythematous maculopapular rash all over the body and asymmetrical arthralgia 
involving large and small joints for about 3 months. She had one-week history of pain 
abdomen and melena followed by decreased urine output and generalized edema. 
On examination BP 156/94 mmHg, Birmingham Vasculitis Activity Score of 23/63. 
Investigations: Hb 9.9 g/dL, serum creatinine 4.0 mg/dL, urinalysis - protein ++, RBC 2-3/
hpf, 24 hour urinary protein 4.75gm/day. Serum uric acid & C3 were normal. Serum ANA, 
pANCA, cANCA, and RA factor were negative. Skin biopsy for IgG, IgM, IgA, C3, C1q 
was negative. USG showed normal sized kidneys. Renal biopsy: Light microscopy showed 
segmental fibrinoid necrosis and early cellular crescents with mild increase in cellularity of 
mesangial matrix. Immunofluorescence: IgG, IgM, IgA, C3, C1q, kappa and lambda chains 
were negative. Diagnosis of ANCA negative pauci-immune GN with crescents was made 
and patient was started on systemic steroids and cyclophosphamide pulse therapy. Patient 
improved symptomatically and creatinine levels gradually declined.
Discussion: Patients with ANCA negative PGN rarely present with skin and GI 
manifestations. In a study done in China comparing clinical features of ANCA negative 
patients only 7% were found to have GI manifestations and 17.9% had skin rash. These 
patients were treated similarly to ANCA-positive patients, although no study has focused 
specifically on the treatment of ANCA-negative patients. Such patients could be easily 
confused as other forms of systemic vasculitis and therefore early identification and prompt 
treatment could prevent many life threatening complications and improve prognosis.
SA-PO031
A Case of ANCA-Associated Nephritis Mainly Localized to the 
Tubulointerstitial Area, Successfully Treated by Steroid Therapy 
Tomo Nakajima, Yosuke Nakagawa, Takuya Isegawa, Masahiro Koizumi, 
Masafumi Fukagawa.  Div of Nephrology, Endocrinology and Metabolism, 
Tokai Univ School of Medicine, Isehara, Kanagawa, Japan.
Introduction: The typical pathological findings of antineutrophil cytoplasmic antibody 
(ANCA)-associated nephritis consist of extracapillary proliferation and necrotizing 
crescent formation. Nevertheless, a few cases of ANCA-associated nephritis, in which the 
tubulointerstitial area was mainly affected, are reported. Here, we present such a case of 
ANCA-associated tubulointerstitial nephritis, and review its characteristics compared to 
ANCA-associated glomerulonephritis.
Case Description: A 74 year-old generally healthy female developed bilateral hearing 
loss, and thereafter suffered from persistent fever. With a diagnosis of bacterial pneumonia, 
she was admitted to another hospital and treated with several broad-spectrum antibiotics 
without improvement. Four weeks later, she was referred to our hospital. On admission, 
weight loss and peripheral numbness and weakness was noted in addition to advanced 
hearing loss and fever. Serum creatinine level was elevated to 3.5 mg/dl, while urinalysis 
revealed mild proteinuria with few red blood cells and no cast in the sediment. Sinusitis and 
alveolar hemorrhage were observed by CT scan. Immunological tests demonstrated positive 
myeloperoxidase (MPO)-ANCA (104 U/ml). In view of multiple organ involvements, 
ANCA-associated vasculitis was suspected. Renal biopsy showed diffuse interstitial 
infiltrates and remarkable vasculitis in small arteries and capillaries with only a small number 
of crescentic glomeruli, which was consistent with ANCA-associated tubulointerstitial 
nephritis. Steroid therapy ameliorated not only kidney dysfunction, but also hearing loss.
Discussion: In an atypical case of ANCA-associated nephritis with near normal 
urinalysis, we need to consider the possibility of tubulointerstitial nephritis.
SA-PO032
Treatment of Severe Resistant Idiopathic Membranous Glomerulopathy with 
Adrenocorticotropic Hormone Gel: A Case Report  Blaithin A. McMahon,1 
Adam R. Berliner.2  1Div of Nephrology, Johns Hopkins School of Medicine, 
Baltimore, MD; 2Nephrology Center of Maryland, Baltimore, MD.
Introduction: Idiopathic membranous glomerulonephritis is a frequent cause of 
nephrotic syndrome. Therapy is based on Ponticelli protocol or other immunosuppressive 
therapies. Adrenocorticotropic hormone has been used with some success for the treatment 
of resistant idiopathic membranous nephropathy. We present here a case of a 39 year old 
Caucasian man presenting with severe resistant idiopathic membranous glomerulonephritis 
who encountered only a partial response with cyclosporine but had a complete remission 
with single therapy corticotropin.
Case Description: Medical history included chronic kidney disease stage IIIA and 
hypertension. He attended a work-associated physical examination that revealed proteinuria 
and subsequent 24hr urine collection revealed 18g of proteinuria. His physical examination 
was notable for stage 3 hypertension, no chest, cardiac or abdominal abnormalities. He had 
bilateral +2 pitting edema to the knees. Renal biopsy showed thickened capillary walls with 
spikes and holes in the glomerular basement and subepithelial deposits. All inflammatory 
and infectious serological studies were negative. Treatment included corticosteroids and 
cyclosporine 100mg twice daily. His glomerular filtration rate was 58 ml/min per 1.73/
m2. His proteinuria improved from 18g to 5g over an eight week period after initiation 
of cyclosporine, however, five months later he relapsed to 10g and later to 15.9g. After 
stopping his cyclosporine, his proteinuria worsened to 20g/24hr urine collection. Magnetic 
resonance imaging of his renal veins were negative for thrombus. PLA2 receptor antibody 
testing was negative. At our institution, he was treated with corticotropin (ATHACAR H.P.) 
80 unit/mL injectable gel subcutaneously twice weekly. A complete remission was achieved 
within 12 months. Patient characteristics and clinical course is reviewed.
Discussion: Randomized controlled trials are needed to evaluate the therapeutic efficacy 
of corticotropin for resistant idiopathic membranous glomerulonephritis.
SA-PO033
HCV-Related Cryoglobulinemic Glomerulonephritis and B Cell 
Lymphoma: Early Antiviral Therapy Crucial  Sixto G. Giusti, Ivo Lukitsch. 
Nephrology, Ochsner Clinic Foundation, New Orleans.
Introduction: Untreated chronic Hepatitis C Virus (HCV) infection often leads 
to a spectrum of severe extra hepatic manifestations related to B cell dysregulation, 
which include cryoglobulinemia, renal diseases, and lymphoproliferative disorders. 
Type I membranoproliferative glomerulonephritis (GN) associated with type II mixed 
cryoglobulinemia is the most common HCV related kidney disease, with membranous 
nephropathy and MPGN without cryoglobulinemia being less frequent.
Case Description: A 58 year-old Caucasian man with history of hypertension, recent 
biopsy proven membranous nephropathy, and treatment naïve chronic HCV infection 
Genotype 3a diagnosed 5 yrs ago, presented with complaints of intermittent vasculitis 
rash in his legs for a year as well as worsening paresthesias of his palms and soles. Initial 
evaluation showed microscopic hematuria, red blood cell casts, 1.2 grams of proteinuria, 
and serum creatinine (SCR) of 1.0 mg/dL. Serum C4 was low, and serum positive for 
type II cryoglobulins. Repeat kidney biopsy was showed a diffuse proliferative GN 
with characteristics of cryoglobulinemic GN. The patient was referred to hepatology for 
antiviral treatment, which was delayed due to myocardial infarction requiring bypass 
surgery. During this time he developed worsening renal function (SCR of 3 mg/dL) with 
increase in proteinuria to 2-3 gm prompting the decision for immunosuppressive therapy. 
Rituximab (1 gm) was administered and he was started on ledipasvir 90 mg/sofosbuvir 400 
mg with prompt viral response and an improvement of renal function (SCR 1.6). Weeks 
after, he presented with AKI and diffuse alveolar hemorrhage and was treated with high 
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dose steroids, plasma exchanges, and a second dose of Rituximab, with clinical and renal 
improvement. One month after discharge, he was re admitted with ARDS and diagnosed 
with B-cell lymphoma.
Discussion: There is a paucity of data on anti-HCV therapy in patients with renal 
failure often resulting in a delay of antiviral therapy. Immunomodulatory therapies may 
provide transient improvement of symptoms but bear the risk of significant adverse 
reactions. Early initiation of antiviral therapy is vital in order to prevent spectrum of HCV 
related complications.
SA-PO034
A Case of Membranous Nephropathy with an Adjacent Smooth Muscle Cell 
Tumor  Laith Al-Rabadi,1 Cathryn J. Byrne-Dugan,2 Stanley D. Crittenden,1 
Helmut G. Rennke,2 Laurence H. Beck.1  1Boston Medical Center; 2Brigham 
and Women’s Hospital.
Introduction: Different stromal tumors can occur in the kidney and potentially skew 
the true extent of parenchymal injury induced by different glomerular diseases. Most of 
these stromal tumors are benign. The value of renal biopsy in assessing interstitial sequalae 
may be compromised by the mass effect of the infiltrating tumor cells.
Case Description: We describe a case of a 65 year old male patient, with a history 
of primary membranous nephropathy 20 years ago. He had initially been treated with the 
Pontocelli protocol with favorable response. He continued to be in remission until a few 
months prior to presentation when he developed anasarca. His 24 hour urine collection 
revealed 8 grams of protein, and creatinine was 1.8 mg/dl. The decision was made for the 
patient to undergo a kidney biopsy which confirmed recurrence of primary membranous 
nephropathy with positive staining for PLA2R. It also revealed advanced chronic changes 
that included focal global glomerulosclerosis (87%) in addition to interstitial fibrosis 80%. 
However, adjacent to this atrophic area, there was a tumor of spindle-shaped cells with 
smooth muscle characteristics. There was no atypia or mitosis and no clear capsule but 
the tumor cells appeared to infiltrate and surround the tubules and vasculature. This was 
labeled by the pathologist as a fragment of a smooth muscle cell tumor of undetermined 
malignant potential. The possibility of leiomyosarcoma could not be ruled out. MRI 
abdomen and pelvis did not show any evidence of extra renal involvement. The possibility 
of the parenchymal tissue being significantly influenced by its close proximity to the tumor 
prompted us to pursue another renal biopsy from the other kidney. Surprisingly, repeat 
biopsy showed only 15% of tubular atrophy and interstitial fibrosis. The patient was initiated 
on Rituximab and tolerated two courses of treatment. He achieved partial remission with 
UPCR less than 3 gram with stable Cr at 1.8 mg/dl.
Discussion: Coexistence of smooth muscle tumors and membranous nephropathy is 
rare. The extent of parenchymal involvement should be confirmed, with repeat biopsy, 
when there are concerns about tissue distortion by neighboring tumor.
SA-PO035
Freezing Point: Sjögren’s Disease Leads to Cryoglobulin Induced 
Membranoproliferative Glomerulonephritis  Manuel A. Fernandez Palmer, 
Roberto L. Collazo-Maldonado.  Nephrology, Methodist Dallas Medical Center, 
Dallas, TX.
Introduction: Sj|gren’s disease is chronic autoimmune inflammatory disorder mainly 
affecting salivary and lacrimal glands but rarely it can present with systemic manifestations 
including kidney involvement.The kidney manifestations may incluye hypokalemic RTA, 
interstitial disease and rarely MPGN.
Case Description: This is a 30 year old woman with no medical history who 
arrived to ER complaining of a three day history of SOB and increasing edema on lower 
extremities.She denied toxic habits. Review of systems positive for lower extremity rash 
in the preceding weeks.P/E was pertinent for elevated BP at 159/90 mmHg, 94% O2Sat 
on NC at 2LPM, bibasilar crackles with decreased breath sounds at bases and lower 
extremity pitting edema.Labs showed HGB of 10 g/dL, creatinine of 1.32 mg/dL with 
normal electrolyte,albumin levels 3.4 mg/dL,UA with proteinuria and hematuria, and a 
BNP that was markedly elevated.CXR showed pulmonary edema and bilateral moderate 
pleural effusions.Patient was admitted and workup performed, including CTwhich was 
negative,lower extremity Doppler that was negative for DVT.Creatinine increased to 
2.6 and proteinuria was quantified at 4 g/24hrs.Serologic work up was negative except 
for low Complement levels,along with a positive rheumatoid factor, positive anti-SSa.
Clinical presentation and labs consistent with a diagnosis of Primary Sjögren’s disease. 
Cryoglobulin levels where negative but kidney biopsy was performed and results consistent 
with Membranoproliferative Glomerulonephritis with intra capillary thrombi highly 
suggestive of cryoglobulins.Patient was started on high dose steroids and received five 
plasma exchanges. Afterwards, Rituximab 375 mg/m2 was administered at weekly intervals 
times four. At the time of discharge creatinine had stabilized at 0.95 mg/dl.
Discussion: Despite being rare, Sjögren’s Disease can lead to cryoglobulin formation 
and subsequent deposition in different tissues of the body.  Nephrologists must consider 
this rare complication when evaluating patients with proteinuria, especially when there is 
worsening renal function and other systemic symptoms.
SA-PO036
Postinfectious Glomerulonephritis Associated with Escherichia coli 
Infection Caused by Transuretheral Prostatectomy  Eleni Chelioti, Alexia 
Papalexandrou, Evdokia Efthimiou, Maria Sotiraki, Ioannis Xatzis, Maria 
Tsilivigou.  Dept of  Nephrology, General Hospital of Piraeus, Athens, Greece.
Introduction: Postinfectious glomerulonephritis (PIGN) is an immune-mediated 
glomerulonephritis(GN) caused by non-renal bacterial infection. In adults, PIGN is more 
common in immunocompromised patients, particularly diabetics. The major site of infection 
is the skin, followed by the lungs and the urinary tract. In terms of causative agents, 
Staphylococcusis the most common cause in elderly people, followed by Streptococcus. 
Gram-negative bacteria, including Escherichia coli (E. coli), are responsible for up to 
10% of cases of adult PIGN and 5% of cases in the elderly. We report a patient with PIGN 
associated with E. coli infection caused by transuretheral prostatectomy.
Case Description: A 76-year-old Caucasian man with a history of coronary artery 
disease and recent transuretheral prostatectomy was admitted with complaint of fever, and 
uremic symptomatology that necessitated dialysis therapy. Blood and urinary cultures were 
positive forE. coli and resumed antibiotic therapy. After one week, he was afebrile, without 
amelioration of renal function and with signs of glomerular involvement:urine red blood 
cells= 20-40/HPF, 24-hour urine proteins=1.7g. Immunological analyses were neg-ative, 
except for decreased C4.The diagnostic approach led to a renal biopsy that findings were 
consistent with PIGN: endocapillary proliferative and exudative GN on LM; C3-dominant 
glomerular staining on IF and hump-shaped subepithelial deposits on EM. After urinary 
tract infection was controlled by antibiotic therapy, oral methylprednisolone was initiated, 
and the patient’s renal function and nefritic syndrome subsequently gradually improved.
Discussion: For a diagnosis of PIGN, at least three of the following five criteria must 
be satisfied: 1)clinical or laboratory evidence of an infection preceding the onset of GN 2)
decreased serum complement levels 3)endocapillary proliferative and exudative GN on LM 
4)C3-dominant or co-dominant glomerular staining on IF and 5) hump-shaped subepithelial 
deposits on EM. In the present case, all criteria were met. Moreover, recently reported that 
rarely, E. coli , also cause this type of GN.
SA-PO037
A Patient Presenting with Thrombotic Thrombocytopenic Purpura-
Hemolytic Uremic Syndrome and Leptospirosis  Ali Veysel Kara,2 Yasar 
Yildirim,2 Zülfükar Yilmaz,2 Melike Elif Celik,2 Erdal Bodakci,2 Ali Kemal 
Kadiroglu,2 Mehmet Emin Yilmaz.2  1Nephrology, Dicle Univ, Diyarbakir, 
Turkey; 2Internal Medicine, Dicle Univ, Diyarbakir, Turkey.
Introduction: There are very rare case reports in the literature about leptospirosis in 
association with TTP-HUS. We present a case report of TTP-HUS syndrome in a patient 
with leptospirosis.
Case Description: A 27 years old female patient was was transferred to our clinic 
due to progressive deterioration in the general status and kidney functions. On admission, 
she was oriented and cooperated. She had blood pressure of 130/65 mmHg, heart rate of 
90/min, temperature of 38.3 C and respiratory rate of 25/min. Patient had no urine output. 
There is minimal swelling on the dorsum of right hand of the patient. When we detailed 
history about this finding, she remembered that she saw mice in her working place in the 
night shift. Peripheral blood smear showed large numbers of fragmented red blood cells. 
Disseminated intravascular coagulation panel was normal. Viral hepatitis markers and 
serological tests for anti-nuclear anticore , anti-double stranded DNA and also Toxoplasma, 
Rubella, Cytomegalovirus, Herpes panel were all negative. C3 and C4 levels were normal. 
There was no reproduction in the blood cultures. ADAMS 13 level was reported as normal. 
Plasmapheresis was initiated immediately with the preliminary diagnosis of TTP/HUS. 
Also patient was empirically treated with antibiotics and on the 3rd day of treatment ; 
doxycycline 200 mg orally per day was added to therapy because of the positive result 
of Leptospira IgM ELISA test. After 14 days of antibiotherapy and a total of 10 sessions 
of plasmapheresis, patient general status improved and laboratory findings come to near 
normal levels. Patient was discharged with the normal laboratory findings.
Discussion: In conclusion; leptospirosis and TTP-HUS can present with the same 
clinical findings and differential diagnosis is crucial to initiate the right treatment. Also, it 
is important to consider co-occurrence or association of these two disease in the light of 
patient’s history and laboratory findings although there are very rare reports in the literature.
SA-PO038
For the Eye Altering, Alters the All  Marie-Angélique De Scheerder, Anne 
Marie Bogaert.  Internal Medicine, UZ Gent, Gent, Belgium; Nephrology, Sint-
Elisabethziekenhuis, Zottegem, Belgium.
Introduction: We describe the case of a 26-year-old African female that was treated 
successfully with belimumab in a case of severe membranous lupus nephritis, resistant 
to first line therapy.
Case Description: She presented initially with chronic dacryoadenitis and screening 
showed nephrotic range proteinuria. Biopsy of the kidney confirmed the diagnosis of 
membranous lupus nephritis. Clinical features (joint pain, dacryoadenitis and lupus nephritis) 
in combination with serology (positive anti-DNA antibodies, hypocomplementemia) 
confirmed diagnosis of systemic lupus erythematosus(SLE). Treatment was initiated with 
glucocorticosteroids (GCS), mycophenolate mofetil (MMF) and Hydroxychloroquine 
sulphate (Plaquenil®). Tacrolimus was associated but no effect was observed with the 
proteinuria remaining in nephrotic range and secondary effects of the GCS becoming a 
real concern. Patient was started on add-on belimumab with quasi-immediate effect on the 
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proteinuria, making it possible to decrease dosage of the other immunosuppressants and 
gradually stop them, even the GCS. Patient is now in complete remission after 2 years of 
treatment with no signs of relapse after stopping additional medication.
Discussion: Belimumab is indicated in treatment of seropositive active SLE in addition 
to standard therapy, when lack of clinical improvement despite optimal standard therapy. 
Two large, phase 3, multicenter, prospective, randomized, controlled trials (BLISS-52 and 
BLISS-76) compared belimumab with placebo in patients with SLE who were receiving 
standard therapies. Both studies showed significant improvement in SRI (Systemic Lupus 
Erythematosus Responder Index) with 10mg/kg of belimumab as compared with placebo. 
A phase 3 study (BLISS-LN) is recruiting patients with lupus nephritis since these post-hoc 
analysis of the BLISS trials suggest that belimumab may offer renal benefit in patients 
with SLE. The treatment is so far not recommended in these cases. We can conclude that 
our case shows excellent results of belimumab in lupus nephritis with persistent nephrotic 
range proteinuria under conventional treatment. Alternatives are scarce and mostly limited 
due to toxic effects and by failure to control disease.
SA-PO039
Overlap Syndrome or Drug Reaction?  Varun Gaur, Michael T. Eadon, Jesus 
H. Dominguez.  Medicine, Indiana Univ, Indianapolis, IN.
Introduction: The overlap of ANCA-Associated Vasculitis (AAV) with other 
autoimmune diseases is well known. However, the association of AAV with the use of 
TNF-α antagonists in Rheumatoid Arthritis (RA) patients is less understood.
Case Description: A 44 y/o white female with RA had prior treatment with 
methotrexate (3 yr), adalimumab (2 yr) and etanercept (2 yr). She concluded all DMARD 
therapy 3 yr prior to presentation (PTP), and then her RA flared 5 months PTP. After 
initiation of leflunomide and steroids, she had partial resolution. Two weeks PTP, she 
received golimumab for onset of severe neurological manifestations including right foot 
drop, distal extremity numbness, and a right 4th digit ischemic lesion. Upon presentation, 
she was admitted with persistence of these symptoms. Her serum creatinine increased from 
0.9 (mg/dl) to 1.4 with 2 gm proteinuria. Her urinalysis had hematuria and serology was 
positive for PR3-positive cANCA. Her renal function deteriorated with a peak creatinine of 
6.7, necessitating intermittent dialysis. A biopsy revealed pauci-immune diffuse necrotizing 
and crescentic glomerulonephritis consistent with AAV. She received pulse solumedrol, 
cytoxan, and plasma exchange. Her neurological symptoms improved after a month of 
therapy. After 6 weeks, she did not require dialysis and her serum creatinine was 2.4.
Discussion: We present a case of a patient previously treated with TNF-α inhibitors 
who then developed PR3-positive AAV years later. An association between AAV and RA 
has been described and RA may precede AAV by up to 8 years. Different theories explain 
this association. One reason may be the common genetic predispositions to autoimmunity, 
involving HLA or PTPN22 genes, reported in a series of both RA and AAV.A second 
theory suggests TNF antagonists may predispose one to develop secondary autoimmunity. 
In our case, the patient discontinued DMARDs 3 yr PTP, although had recently received 
Leflunomide and Golimumab. There are no reports that associate leflunamide use with 
AAV and only one case report suggests an association of golimumab with AAV. Our case 
highlights the need to further understand the importance of AAV in RA patients, and the 
potential role of TNF inhibitors on the development of AAV.
SA-PO040
Pauci Immune Crescentic Glomerulonephritis in a Patient with T-Cell 
Lymphoma and Argyria  Tamer Rezk, James J. Penton, Mark Alan Little, John 
Cunningham, Alan D. Salama.  Centre for Nephrology, Royal Free Hospital, 
London, United Kingdom.
Introduction: Silver is a transition metal element with a range of industrial and 
ornamental uses and is known to be toxic when ingested in significant amounts. Silver 
exposure causing argyria (skin deposition) and argyrosis (eye deposition) is well-recognised 
but the renal consequences of silver toxicity are poorly understood.
Case Description: A 47 year old woman with a T-cell lymphoma who refused 
conventional chemotherapy for 18 months but self-medicated with a remedy containing 
colloidal silver was admitted with acute dialysis-dependent kidney injury. The serum silver 
concentration was strikingly elevated at 127.1 nmol/l (reference value <2.8 nmol/l). Kidney 
biopsy demonstrated a pauci-immune crescentic glomerulonephritis and glomerular tufts 
with fine, dark, granular material scattered within the mesangium and along the glomerular 
basement membrane (GBM). Electron microscopy confirmed the presence of electrondense 
granules in the mesangium and along and within the GBM. 
Electron probe microanalysis demonstrated that these granules contained predominantly 
silver. The patient recovered independent renal function following immunosuppression 
with cyclophosphamide and steroids.
Discussion: Crescentic glomerulonephritis results from disruption of the GBM which 
may be induced by immune complexes or by cellular mediators. However our patient 
had no autoantibodies, and no deposited immunoproteins. Our case therefore represents 
a pauci-immune crescentic glomerulonephritis with intense silver deposition along the 
GBM. Between 5-10% cases of pauci-immune glomerulonephritis are ANCA negative. The 
pathogenesis in these cases may be related to other autoantibodies (such as anti-endothelial 
antibodies) or to direct leukocyte-induced GBM damage via soluble mediators, which in 
this case we believe was due to a combination of T cell lymphoma and argyria.
SA-PO041
PR3-ANCA Vasculitis following Influenza Vaccination  Karim El Hachem, 
Eduardo J. Zouain, Isha Gupta, Steven D. Smith.  Nephrology, Mount Sinai- St 
Luke’s Hospital, New York, NY.
Introduction: Influenza vaccination has been associated with the development of 
autoantibodies and autoimmune rheumatic disease. We report a case of PR3-ANCA 
associated vasculitis following influenza vaccination.
Case Description: The patient is a 45 year old Hispanic male with no known medical 
history who presented with subacute onset pleuritic chest pain and shortness of breath. Four 
weeks prior to presentation, he had received his annual injectable influenza vaccine and 
reports feeling weak since. On presentation, he was hemodynamically stable. His exam 
was notable for bibasilar crackles. He had positive Rheumatoid Factor. His CT chest was 
notable for multiple ground glass nodules at the right upper lobe. His creatinine was 1.64 
mg/dL. His urine albumin to creatinine ratio was 225 mg/gm creatinine and his urine protein 
to creatinine ratio was 500 mg/gm creatinine. He had 25-30 RBC/hpf with no dysmorphic 
RBCs. He had strongly positive PR3-ANCA antibody (>8 AI). His kidney biopsy revealed 
acute focal segmental necrotizing crescentic GN, pauci-immune type.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
634A
J Am Soc Nephrol 26: 2015 Fellows Case Reports - V Poster/Saturday
The patient was treated with pulse IV methylprednisolone and Rituximab 375mg/m2 
weekly for four doses. Three months following induction therapy his creatinine improved 
from a peak of 3.6mg/dL to 1.4 mg/dL. His CT findings and hematuria resolved. His PR3-
ANCA slowly decreased and became negative 6 months after induction.
Discussion: This patient’s presentation with lung nodules on chest CT, necrotizing 
crescentic GN on kidney biopsy and high serum level of PR3-ANCA support a diagnosis 
of Granulomatosis with Polyangiitis with a strong temporal relationship to vaccination 
against influenza. This is the 9th case of ANCA associated vasculitis following influenza 
vaccination reported in the literature. Clinicians should be aware of the possible association 
between systemic vasculitis and influenza vaccination.
SA-PO042
C3 Glomerulonephritis Associated with Monoclonal Gammopathy 
Aumyot Prongdong,1 Weeraporn Srisung,1 Mustafa G. Aly,1 Irfan Warraich,2 
Faisal Jamal.1  1Nephrology, Texas Tech Univ Health Sciences Center, Lubbock, 
TX; 2Pathology, Texas Tech Univ Health Sciences Center, Lubbock, TX.
Introduction: A case of C3 glomerulonephritis associated with monoclonal 
gammopathy responding effectually with immunosuppressive therapy.
Case Description: The patient is a 65 year-old Hispanic female who presented with 
lower extremity edema and dyspnea. She had acute kidney injury with nephritic urinary 
sediments. C3 and C4 were low. Hepatitis B & C profile, ANA, ANCA, anti-GBM and 
SPEP were within normal limits. There was a faint monoclonal band in the gamma region 
on UPEP. Kidney biopsy was consistent with membranoproliferative glomerulonephritis 
(MPGN), of an undetermined etiology. Patient was readmitted with similar complaints 
and a rapidly declining renal function. Repeated UPEP showed a significant IGG kappa 
monoclonal protein and an elevated serum free light chain with kappa/lambda ratio of 2.52. 
Bone marrow biopsy revealed atypical plasmacytosis without overt myeloma. Repeated 
kidney biopsy showed global proliferative changes along with splitting of glomerular 
basement membrane. C3 deposits were seen on immunofluorescence. No reactivity was 
seen for IgA, IgG, IgM, C1q, C4, fibrinogen and albumin. Electron microscopy showed 
subendothelial and mesangial immune complex deposits.
Diagnosis was determined as C3 glomerulonephritis associated with monoclonal 
gammopathy. Patient was successfully treated with pulse glucocorticoids followed by 
oral glucocorticoids and mycophenolate mofetil. C5b-9 was elevated whereas factor H, 
C3 nephritic factor, and factor B were within normal limits.
Discussion: C3 glomerulonephritis is related to dysregulation of alternative pathway 
of complement (AP) that can be associated with monoclonal gammopathy. Treatment of 
underlying monoclonal gammopathy may be of benefit in such a situation. Genetic studies 
for dysregulation of AP might be helpful.
SA-PO043
Late-Onset Fabry Disease with a R112H GLA Mutation and Mild Increase 
in Plasma Globotriaosylsphingosine  Akifumi Onishi,1 Reika Takemoto,2 
Tsutomu Hiromasa,2 Hidetoshi Kagawa,2 Hiroki Maruyama,3 Ichiei Narita,3 
Hitoshi Sugiyama,1 Jun Wada.1  1Okayama Univ Graduate School, Okayama, 
Japan; 2Himeji Red Cross Hospital, Himeji, Japan; 3Niigata Univ Graduate 
School, Niigata, Japan.
Introduction: Fabry disease (FD), a lysosomal storage disorder caused by 
α-galactosidase A (GLA) gene variants, has a heterogeneous phenotype. GLA variants can 
lead to a late-onset and non-classical phenotype. We herein describe a 42-year-old patient 
with FD diagnosed by a renal biopsy exhibiting a R112H GLA mutation and a mild increase 
in plasma globotriaosylsphingosine (Lyso-Gb3).
Case Description: A 42-year-old Japanese male was referred to our hospital due to 
proteinuria. He had never experienced neuropathic pain, cutaneous angiokeratomas, or 
hypohidrosis. He had no family history of FD. At 32 years of age, positivity for urinary 
protein was noted on a health checkup. Thereafter, his urinary protein was annually positive, 
however, it was untreated because he had no other symptoms. The urinary protein was 
0.62 g/gCr, serum creatinine 1.27 mg/dL, and the eGFR 51 mL/min/1.73m2. Microscopic 
findings of a renal biopsy showed foamy change and numerous lamellar inclusions in the 
cytoplasm of podocytes. A significantly low level of leukocyte GLA activity (1.0 nmol/mgP/
hr), normal level of plasma globotriaosylceramide (Gb3) (2.7 mg/ml), mildly high level of 
plasma Lyso-Gb3 (4.1 ng/ml), and the c335G>A, p.R112H mutation of GLA were found. 
He was diagnosed with late-onset FD without signs of the classical symptoms, cardiac 
hypertrophy or cerebrovascular disorder. He began taking enzyme replacement therapy of 
agalsidase beta every 2 weeks, and his renal function has remained stable for 8 months.
Discussion: FD patients with the R112H GLA mutation do not exhibit classical 
symptoms and are considered to have a late-onset phenotype (Clin Genet 2014) with higher 
plasma Lyso-Gb3 levels than healthy subjects (PLoS One 2015). Undiagnosed FD patients 
may exist because their symptoms are restricted to proteinuria alone, as shown in this case. 
Further familial examination will help us elucidate this case as sporadic or familial FD to 
make an earlier diagnosis and treatment.
SA-PO044
Another Enemy for Kidneys: Synthetic Cannabinoids  Alper Alp,1 Hakan 
Akdam,2 Aysegul Ormeci,3 Ibrahim Meteoglu,3 Alparslan Unsal,4 Yavuz 
Yenicerioglu.2  1Nephrology, Van Region Education and Research Hospital, 
Van, Turkey; 2Nephrology, Adnan Menderes Univ, School of Medicine, Aydin, 
Turkey; 3Pathology, Adnan Menderes Univ, School of Medicine, Aydin, Turkey; 
4Radiology, Adnan Menderes Univ, School of Medicine, Aydin, Turkey.
Introduction: Synthetic cannabinoids(SC) are widely used especially among 
young population.These substances have various physiological,metabolic and 
psyhciatric(addictive) effects.In last few decades SC related acute kidney injury(SC-RAKI) 
is pronounced more often.
Case Description: A 20-yo man without a medical history presented to ED with 
abdominal discomfort,nausea and vomiting for 3-4 days.On physical examination;arterial 
tension was 150/60 mm/Hg,HR 86/min,without orthostatic signs.He denied any 
nephrotoxic drug use,OTC medication or contrast media exposure.He has been a synthetic 
cannabinoid(Bonzai)smoker for last 2 weeks.On admission he was oliguric and 
creatinine was 7.71mg/dl with normal creatinine kinase levels.Urinary analyse revealed 
pH 5,5,protein +,leu 3,ery 1.Renal ultrasound showed normal size kidneys with 
increased echogenities,without hydronephrosis.Intermittent hemodialysis therapy was 
started.Autoimmune antibodies were negative.Renal biopsy revealed acute interstitial 
nephritis with increased mesangial matrix.Vascular structures were normal,no specific 
immunohistochemistry staining was detected.
After 6 sessions of HD his urinary output increased and creatinine levels regressed 
without a specific therapy.24-h urinary proteinuria was 529,2mg/d.On the 11th day of 
hospitalisation his creatinine level was 0.6mg/dl.
Discussion: SC-RAKI is usually reported as a consequence of prerenal conditions 
or rhabdomyolysis.In general renal histopathology reveals acute tubular necrosis.
However,rarely these patients may present with interstitial nephritis.In our case complete 
cure of the patient without specific therapy was quite interesting.
SA-PO045
A Unique Case of Granulomatous Acute Interstitial Nephritis from 
Ipilimumab  Kenneth Ralto,1 Seymour Rosen,2 Melanie P. Hoenig.1 
1Nephrology, Beth Israel Deaconess Medical Center, Boston, MA; 2Pathology, 
Beth Israel Deaconess Medical Center, Boston, MA.
Introduction: Ipilimumab is a CTLA-4 inhibitor which is used for the treatment of 
melanoma. We report a case of granulomatous interstitial nephritis due to ipilimumab, 
which developed after the first dose and featured a prominent component of granulomatous 
vasculitis.
Case Description: A 70 year old man with stage IV melanoma presented with low grade 
fevers and malaise. He was found to have acute kidney injury with a creatinine of 6.0 mg/dL. 
Two months earlier, he had received a single dose of ipilimumab at which time his creatinine 
was 0.9 mg/dL. Laboratory data was notable for the absence of eosinophilia. Urinalysis 
showed 5-10 WBCs/hpf and many hyaline casts. A renal biopsy showed granulomatous 
interstitial nephritis with a component of granulomatous vasculitis (figure: H&E, Masson 
trichrome). He was treated with high-dose prednisone, which resulted in improvement of 
his renal function without the need for hemodialysis. After ten weeks of steroid therapy, 
his creatinine had decreased to 1.6 mg/dL.
Discussion: Ipilimumab is a potent activator of T cells and can interfere with the 
immune system’s tolerance of self-antigens. This drug is known to cause a variety of 
immune-related adverse events including hypophysitis, hepatitis, colitis and dermatitis. 
Interstitial nephritis is a rare diagnosis, but has been reported to occur after exposure to 
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ipilimumab. Additionally, there have been reports of a sarcoidal-type response involving the 
lung and skin. This injury pattern is typified by angiocentric non-necrotizing well formed 
granulomas. Steroid therapy is effective at treating these immune-related adverse events 
and does not appear to impair the antineoplastic effects of ipilimumab. With the increasing 
use of immune-modulating antibodies for treatment of malignancies, it is important to be 
aware of this potential complication.
SA-PO046
Severe Rhabdomyolysis Secondary to Adenovirus Infection  Daniel Tseytlin,1 
Sharon E. Maynard.2  1Dept of Medicine, Lehigh Valley Health Network, 
Allentown, PA; 2Div of Nephrology, Lehigh Valley Health Network, Allentown, PA.
Introduction: A 38-year-old male presented with renal failure in the setting of a flu-
like illness. Urinalysis showed myoglobinuria and granular casts. His CPK was markedly 
elevated. He is diagnosed with rhabdomyolysis from adenovirus and requires hemodialysis.
Case Description: A 38-year-old AA male presented to the ER with a 4-day history 
of weakness, subjective fever, and diffuse myalgias as well as recent left eye viral 
conjunctivitis. He noted dark urine and poor urine output. On arrival to the ER his vitals 
were stable. He had full muscle strength and no neuro deficits. He was oliguric. His SCr 5.04, 
CPK 1,149,533 despite volume resuscitation including bicarb-containing fluid. He required 
HD. Workup was positive for adenovirus. Muscle biopsy was deferred in setting of known 
cause. He required 4 weeks of HD and was able to come off with impaired GFR of 67.
Discussion: Two cases of rhabdomyolysis from adenovirus have been reported. Most 
commonly manifests as a febrile illness with pharyngitis. Management strategies have been 
adopted from studies on crush injury victims. Early volume resuscitation is recommended to 
mitigate renal failure. Despite the theoretical benefits of bicarbonate-containing resuscitation 
fluids, no consensus exists. Adenoviral infection can lead to rhabdomyolysis with severe 
acute kidney injury. Respiratory viral panel should be included in workup of rhabdomyolysis 
when no other cause is evident. Treatment relies on supportive care, intravenous fluid 
resuscitation, and hemodialysis in cases of severe renal failure.
Serum Parameter Day 1 Day 2 Day 3
Day 17 
(discharge 
day)
Day 64 
(outpt f/u 
off dialysis)
Sodium (mmol/L) 125 124 122 136 137
Potassium (mmol/L) 4.7 7.3 6.7 4.2 4.1
Chloride (mmol/L) 89 83 84 104 102
Bicarbonate (mmol/L) 17 20 26 24 26
BUN (mmol/L) 40 52 58 40 17
Creatinine (mg/dL) 5.04 5.79 8.50 9.52 1.32
Albumin (g/dL) 3.3 4.3
Anion Gap 19 17 12 9
CPK (U/L) 857,200 360,000 1,149,533 245
Phosphorus (mg/dL) 14.4 >16 14.6 3.5
Calcium (mg/dL) 5 <5 8.2 9.4
Ionized Calcium 
(direct) <2.24
Magnesium (mg/dL) 2.8 2.9 2.9 1.7
AST (U/L) 3,107
ALT (U/L) 279
Lactate (mmol/L) 3.1 2.1 1.5
SA-PO047
Acute Respiratory Distress Syndrome and Posterior Reversible 
Encephalopathy  Syndrome fo l lowing  Ri tux imab Therapy 
Eoin D. O Sullivan,1 Katrina E. Wardrope,1 Lynn Manson,2 Wendy Metcalfe.1 
1Dept of Renal Medicine, Royal Infirmary of (dinburgh, (dinburgh, United 
Kingdom; 2Scottish Blood Transfusion Service, Royal Infirmary of (dinburgh, 
Edinburgh, United Kingdom.
Introduction: The anti CD20 monoclonal antibody Rituximab is an increasingly used 
therapy in modern medicine. It is associated with rare but potentially serious adverse events, 
notably Posterior Reversible Encephalopathy Syndrome (PRES), and Acute Respiratory 
Distress Syndrome (ARDS).
Case Description:  A 60 year-old female was admitted with symptoms of peripheral 
oedema, arthralgia and mucosal bleeding. She was noted to have a widespread vasculitic 
rash, nephrotic range proteinuria and new acute kidney injury. Renal biopsy demonstrated 
mesangiocapillary glomerulonephritis with multifocal extraglomerular necrotising 
vasculitis, in keeping with cryoglobulinemia. She was commenced on plasma exchange, 
prednisolone and Rituximab. 2 days after the initial dose of Rituximab she developed acute 
respiratory distress and was found to be in florid pulmonary oedema. This was managed with 
ultrafiltration, furosemide and oxygen therapy. She received a second dose of Rituximab 1 
week later, and rapidly developed tonic-clonic seizures,a further episode of flash pulmonary 
oedema, encephalopathy and hyperreflexia. MRI brain revealed subcortical white matter 
high T2 and FLAIR signal in the occipital and posterior parietal lobes consistent with PRES. 
She received no further Rituximab. Her cryoglobulin levels remained detectable despite 
alternate day plasma exchange for 2 weeks, prompting the initiation of cyclophosphamide. 
Following 1 dose of cyclophosphamide the cryoglobulin titre fell to undetectable levels. 
All reported cases of PRES and ARDS were identified and are presented as a review.
Discussion: There are 7 reported cases of PRES complicating rituximab use. The 
onset of PRES occurred from immediately to 21 days after administration. All patients 
recovered completely, and rituximab was reintroduced in half of the cases. Mean recovery 
time was 4 days, and an additional risk factor was present in 5 cases. The occurrence of 
ARDS in association with rituximab is rare, only 3 confirmed cases exist . ARDS may 
occur as a delayed reaction.
SA-PO048
Atypical Hemolytic Uremic Syndrome Associated with Rituximab 
Kristina Angela Rathmell, Shilpa Gadde.  Nephrology, Tulane, New Orleans, LA.
Introduction: Hemolytic uremic syndrome (HUS) is classified as a thrombotic 
microangiopathies (TMA). Atypical HUS (aHUS) occurs in 0.5 to 2 per million population 
per year, 50% progress to end-stage renal disease (ESRD), and 25% may die in the acute 
phase. Atypical HUS is linked to uncontrolled activation of the complement system. A 
variety of genetic abnormalities of the alternative pathway of complement have been 
described in aHUS, occurring in 60% of cases. aHUS is diagnosis when toxin producing 
bacterial infections, ADAMTS13 deficiency, and systemic-associated diseases are all 
excluded.
Case Description: A 57 year-old woman with a history of dermatomyositis and 
associated interstitial lung disease (ILD) was being treated for her ILD with Rituximab. 
She presented with altered mental status, shortness of breath, and fatigue after receiving 
an infusion of Rituximab. She was noted on physical exam to have peripheral edema and 
crackles on lung exam. On laboratory evaluation, her creatinine was 4.5 (baseline 1), 
hemoglobin 7, and platelets 20 with schistocytes on peripheral smear and a low C3 and C4. 
ADAMTS13 showed normal activity. She was initially treated with high dose steroids and 
plasmapharesis. She was started on Eculizumab. She required hemodialysis. Renal biopsy 
showed thrombi consistent with thrombotic microangiopathy as well as mild acute tubular 
necrosis. She is still hemodialysis dependent.
Discussion: Overall outcomes of this rare diagnosis vary widely. Initial treatment 
is usually plasmapheresis and corticosteroids. Confirmed aHUS is usually treated with 
Eculizumab. Our unique case entertains Rituximab, a monoclonal antibody, as a possible 
trigger for aHUS. Knowing the mechanism of action of Rituximab, it is possible it mediated 
a complement imbalance. More investigation is needed to determine Rituximab’s causality 
in inducing aHUS. Given the increasing use of Rituximab for various autoimmune 
conditions and malignancies it will be notable to see if more cases like this arise. 1. Noris 
M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687. 
2. Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic 
syndrome: Causes and short-term course. Am J Kidney Dis. 2004;43: 976-982.
SA-PO049
Acute Renal Failure Associated with Parenchymal Involvement of Lambda-
Restricted Neoplastic Plasma Cells  Mark C. Sievert, Amanda K. Hall, 
Mazdak A. Khalighi, Josephine Abraham.  Div of Nephrology, Univ of Utah, 
Salt Lake City, UT.
Introduction: The pathogenesis of renal disease in multiple myeloma (MM) is 
diverse, but biopsies show that cast nephropathy, light chain amyloidosis and monoclonal 
Ig deposition are most often responsible. Renal function often correlates to the degree of 
cellular injury, not the degree of cast burden, amyloidosis or light chain deposition and direct 
involvement by plasma cells is rare. We present a case of diffuse interstitial involvement 
by neoplastic plasma cells, contributing to renal failure.
Case Description: A 70-year-old male with MM presented with acute renal failure. He 
was diagnosed with IgG lambda myeloma 8 years prior but refused therapy until 7 months 
ago. He failed CyBorD (M-protein remained at 9g/dl) prior to staring Carfilzomib-Revlimid. 
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On day 8 of therapy he was admitted with a Cr of 3.4, acutely elevated from 1.7. He denied 
hematuria, oliguria, fevers, edema or NSAID use. Renal ultrasound was without obstruction. 
He underwent renal biopsy. Pathology revealed diffuse interstitial involvement by lambda-
restricted neoplastic plasma cells and minimal cast nephropathy, but no significant interstitial 
fibrosis, tubular atrophy or monoclonal deposition disease. Congo red studies were negative 
for amyloid. There were no features of TMA. Chemotherapy was resumed. 
CD138 IHC stain showing plasma cells.
Discussion: Kidney disease with MM is common but it is rare to see involvement 
of plasma cells in the renal parenchyma. Several review articles list renal parenchymal 
involvement of plasma cells as a cause of renal failure and, to our knowledge, one case report 
suggests the same. It is unknown the extent to which parenchymal involvement by plasma 
cells contributes to the pathogenesis of renal failure. To our knowledge, this is one of only 
several cases of renal failure that can be attributed to neoplastic plasma cell involvement.
SA-PO050
AL Amyloidosis with Rapidly Progressive Renal Failure and Massive 
Liver Involvement: A Case Report  Matteo Floris,1 Maura Conti,1 Riccardo 
Cao,1 Anna Maria Asunis,2 Elisabetta Tamponi,2 Alice Atzeni,1 Patrizia Melis,1 
Gianfranco Pili,1 Valeria Matta,1 Nicola Lepori,1 Doloretta Piras,1 Andrea 
Angioi,1 Antonello Pani.1  1Nephrology, G. Brotzu Hosp, Italy; 2Pathology, G. 
Brotzu Hosp, Italy.
Introduction: AL amyloidosis is a plasma cell disorder clinically dominated by 
organized deposits of light chains, mainly in renal and cardiac tissues. Although hepatic 
disease is described, clinical manifestations are usually mild and frequently undetected. 
We report a severe case of AL amyloidosis with a massive hepatic involvement and rapidly 
progressive renal failure (RPRF).
Case Description: One month before coming to our attention, a 67 year old male 
was admitted to another institution for ascites and scrotal edema. Past medical history 
included hypertension, previous hepatitis B virus infection and estimated daily alcohol 
intake of 60g. Renal function was normal(serum creatinine[SCr]0.7 mg/dl),while hepatic 
lysis indexes were moderately positive. A serum monoclonal component IgA kappa (0.21 
g/dl) was detected and the bone marrow aspirate showed 10% plasma cell infiltration. 
Hepatic ultrasound showed hepatomogaly and portal hypertension. Final diagnosis was 
compensated alcoholic liver disease. After discharged, nephrotic syndrome(NS) (albumin 
2.4 g/dl, proteinuria 12 g/24h), RPRF (SCr 1.6 mg/dl) and cholestasis appeared (ALP 1359 
IU/L, GGT 462 IU/L, AST-ALT normal).The patient was admitted to our institution and renal 
biopsy was performed revealing AL amyloidosis, with prominent IgA(+) and Kappa(++) 
mesangial deposits, coherently with the serology. The hepatic disease was rediscussed, and 
the liver biopsy revealed coarse deposits of amyloid as for the kidney. Other organs, heart 
included, appear to be spared at the time. In accordance with hematologists, a CyBorD based 
regimen was started. Due to worsening kidney dysfunction, hemodialysis was initiated.
Discussion: This case highlights a rare presentation of AL amyloidosis with severe 
renal and hepatic involvement. Liver amyloidosis should be suspected in any patient with 
NS and unexplained cholestasis. Therefore, renal and hepatic biopsies should be considered 
when the clinical diagnosis is obscure, especially if rapid evolution to multiorgan failure 
is documented.
SA-PO051
Pulmonary-Renal Syndrome: A Rare Case  Joana Gameiro,1 Sofia C.A. 
Jorge,1 Miguel Bigotte Vieira,1 Estela Nogueira,1 Maria Alice Fortes,1 Helena 
Sousa Viana,2 Fernanda Carvalho,2 Jose António Lopes,1 Antonio Gomes Da 
Costa.1  1Service of Nephrology and Kidney Transplantation, Hospital Santa 
Maria, Portugal; 2Service of Nephrology, Hospital Curry Cabral, Portugal.
Introduction: Pulmonary-renal sindrome (PRS) is characterized by acute renal and 
pulmonary involvement of immunological or non-immunological causes.
Case Description: A 35-year-old African woman with 6-month history of edema, 
bilateral arthralgias in her knees, shoulders and hands, creatinemia 2,6mg/dL and nephrotic 
proteinuria referred to Portugal for medical care presenting with bilateral erythematous 
non pruriginous macular lesions in both thighs. Investigation confirmed renal failure 
(creatinemia 7mg/dL), nephrotic proteinuria (4.7g/24h), haematuria, hypoalbuminemia, 
hyperlipidemia, normal sized kidneys with increased parenchymal echogenicity. She 
began hemodialysis and was transferred to ICU due to pulmonary hemorrhage requiring 
mechanical ventilation. Plasmapheresis and intravenous high-dose steroids were started. 
Pneumococal pneumonia was also diagnosed and began antibiotic. Imunologic and 
serologic tests were negative or normal range. Serum protein electrophoresis showed 
hypogamaglobulinemia. Echocardiogram revealed type II diastolic dysfunction. Renal 
biopsy showed nodular glomerulosclerosis. Investigation of haematological disease revealed 
serum kappa light chain band and urine Bence Jones kappa. Free kappa light chains, 
serum kappa/lambda ratio and serum Beta-2-microglobulin were elevated. Bone marrow 
biopsy and aspirate showed 10% monoclonal plasmocytosis. No lytic lesions or masses 
were detected. Immunofluorescence of the renal biopsy revealed linear staining for kappa 
light chains along the tubular basement membrane and scarcer in the glomeruly. Electron 
microscopy is underway. Multiple myeloma was diagnosed and started chemotherapy 
with Bortezomib. Although there was mantained remission of pulmonary hemorrhage she 
remained on dialysis.
Discussion: Light chain deposits disease (LCDD) should be considered in the 
differential diagnosis of PRS. Renal involvement is typical in LCDD with nodular 
glomerulosclerosis as the common pathologic finding. Pulmonary haemorrage is unsual 
and might suggest coexistence of fibrillary glomerulonephritis.
SA-PO052
Acute Cadriorenal Syndome as a Presenting Symptoms for Scleroderma 
Renal Crisis  Muhammad H. Hasan, Khurram Saleem, Khaled Boobes, Yazan 
M. Alia, Sadaf S. Khan.  Nephrology and Hypertension, Northwestern Univ, 
Chicago, IL.
Introduction: Systemic scleroderma is known to have renal manifistations including 
scleroderma renal crisis. Acute decompensated heart failure was not descrined in the 
literature as the presenting symptom.
Case Description: 50 year-old female with benign past history was diagnosed with 
new acute decompensated diastolic heart failure and hypertension 160/89 and acute kidney 
injury with elevated serum creatinin (SCr) 2.6 mg/dL from normal kidney function 2 months 
prior. Right heart catheterization showed elevated right heart pressures. Endomyocardial 
biopsy showed small vessel vasculitis. Urinalysis was bland. Renal ultrasound was 
unremarkable. Renal artery Duplex showed high resistant signals with low velocity. 
Sunsequent immunology screen showed elevated antinuclear antibodies >1:1280, elevated 
RNA Polymerase III >80 and normal C3 and C4. Renal biopsy showed changes consistent 
with systemic sclerosis; the glumeruli were ischemic in general and one was sclerosed, the 
arteriols were with marked walls thickening and swelling of the intima, some undergone 
occlusive changes with onion skinning of their walls, while others undergone focal fibrinoid 
necrosis, the tubules were with  mild to moderate atrophy, the interstitium was diffusely 
scarred, with mild to moderate focal and scattered cellular  of lymphocytes. (biopsy). 
Retrospectively, the patient reported skin tightening noticed 6 months prior to admission. 
Blood pressure was controlled with nicardipine drip, captopril, diuretics and bosentan. SCr 
peaked up to 6.72 mg/dL but renal replacement therapy was avoided. She was discharged 
on bosentan, amlodpine and lisinopril. SCr improved to 1.78 mg/dL after 8 months.
Discussion: Scleroderma renal crisis can present as acute cardiorenal syndrome.
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SA-PO053
Dent’s Disease: An X-Linked Tubulopathy  Sambhavi Krishnamoorthy, 
Tingting Li.  Renal Div, Washington Univ in St. Louis, Saint Louis, MO.
Introduction: Dent’s disease is an X-linked recessive disorder of the proximal tubule 
characterized by low-molecular weight proteinuria, hypercalciuria, nephrocalcinosis/
nephrolithiasis, and progressive renal failure. This disorder is caused by mutations in either 
the CLCN5 gene, or less commonly the OCRL1 gene, leading to disruption of tubular 
endocytosis and the characteristic clinical findings.
Case Description: We describe an interesting case of a 24 year old Caucasian male 
with a longstanding history of excessive thirst and polyuria. He had no known history of 
renal disease. He denied history of urinary tract infections, nephrolithiasis, or NSAID use. 
Physical examination was unremarkable. Laboratory data showed a serum creatinine of 1.6. 
Hemoglobin A1c was normal. Urinalysis showed 2+ blood and 2+ protein. Urine osmolality 
was 277 msosm/kg. A 24 hour urine collection showed proteinuria of 1.7 g/day. ANA, 
ANCA, and hepatitis panel were all negative. Renal ultrasound showed multiple bilateral 
renal calculi and nephrocalcinosis. Further testing showed a daily urinary calcium excretion 
of 735 mg, phosphate 2150 mg and sodium 257 mg. His urine beta microglobulin level was 
significantly elevated at 29817 mcg/L. The presence of significant low molecular weight 
proteinuria, hypercalciuria, hyperphosphaturia, nephrolithiasis/nephrocalcinosis, hematuria/
subnephrotic proteinuria, and chronic kidney disease fulfilled criteria for the diagnosis of 
Dent’s disease. No obvious X-linked pattern had been noted in his family history. Further 
genetic testing is pending at this time. On initiating hydrochlorothiazide, urinary calcium 
excretion reduced by 50%. Polyuria, which we attributed to nephrogenic diabetes insipidus 
in the setting of nephrocalcinosis, also improved significantly with the thiazide.
Discussion: This case report highlights the importance of recognizing this rare X-linked 
tubulopathy when presenting in adulthood. Commercially available genetic testing can 
be utilized for supporting the diagnosis and for appropriate genetic counseling for family 
members. The treatment focuses on reducing urinary calcium excretion and formation 
of nephrocalcinosis/nephrolithiasis with the ultimate goal of slowing progression to end 
stage renal disease.
SA-PO054
Phlegmasia Cerulean Dolens: Complication of Femoral Vein Catheterization 
Chaitanya Vemuri, Boju Sangeetha lakshmi, Hari Krishna Reddy Mogili, Ram 
R, Siva Kumar Vishnubhotla.  Dept of Nephrology, Sri Venkateswara Inst of 
Medical Sciences, Tirupati, Andhra Pradesh, India.
Introduction: There are three manifestations of acute massive venous thrombosis 
and obstruction of the venous drainage of an extremity. They are phlegmasia alba dolens, 
phlegmasia cerulean dolens (PCD) and venous gangrene.
Case Description: We present a 55-year-old hypertensive,presented with paedal 
oedema and breathlessness. About a month ago, she fell down and had dislocation of left 
patella. She was treated with a plaster cast and immobilization for 3 weeks. Her serum 
creatinine was 8.8 mg/dL. She was initiated on haemodialysis via two single lumen catheters 
placed in left femoral vein. The femoral vein catheters were removed after third session 
of haemodialysis. On fourth day, the patient complained pain and blue discolouration of 
left toes. Examination revealed that the left lower limb was swollen, discoloured and cold 
up to ankle joint. The left dorsalispedis and posterior tibial arteries were not palpable. 
Within next 12 hours, the signs extended to upper one-third of left leg and there were blebs.
Doppler revealed thrombosis of left common, external iliac,femoral,popliteal,anterior,p
osterior tibial vein and superficial veins.The left lower limb was elevated and anticoagulation 
was started but blebs increased and limb became blue. Below knee amputation of left 
lower limb was performed.
Discussion: The causative factor in phlegmasia is massive thrombosis and occlusion 
of major venous channels.Perkins et al reported that in 10 percent of patients no cause is 
found.It is common in women between fifth and sixth decades of age.Swelling, pain and 
cyanosis are the triad of PCD.Amputation rates are 12-50%.In our patient the effect of 
immobilization is compounded by femoral vein catheterization. PCD after femoral vein 
catheterization for haemodialysis has not been reported yet.
SA-PO055
Successful Treatment of Ischemic Hand Ulcer by Paclitaxel Coated 
Balloon  Jie Cui,1 Fengyong Liu,2 Zubin Irani.3  1Nephrology, Massachusetts 
General Hospital, Boston, MA; 2Interventional Radiology, Chinese People’s 
Liberation Army General Hospital, Beijing, China; 3Div of Vascular Imaging 
and Intervention, Massachusetts General Hospital, Boston, MA, China.
Introduction: Hand ischemia is a common complication in end stage renal disease 
(ESRD) patients. Steal syndrome from dialysis access is the most common cause of ischemic 
hand and is usually treated with banding procedure. However, exclusion of peripheral 
arterial disease (PAD) prior to banding is crucial.
Case Description: A 74 year-old women with history of ESRD due to diabetes 
mellitus on hemodialysis presented to access clinic for right hand ulcer. She had a right side 
brachiobasilic graft placement 3 years ago and has been dialyzed through this graft without 
any issues. However, 3 months prior to the presentation, she started to notice severe right 
hand pain, especially during dialysis treatment. Four weeks ago, she developed an ulcer 
in the 2nd finger of her right hand.
Given the concerns for steal syndrome, she was referred for a banding procedure. On 
physical exam, the graft had good thrill and bruits. Right radial artery pulse was very weak. 
A black ulcer was noticed on the 2nd finger of the right hand. Decreased sensation in the 
1st , 2nd and 3rd fingers of the right hand. Fistulogram was performed which demonstrated 
occluded lesion in the proximal right radial artery, which was recanalized and angioplastied 
with 2mm, 3mm and 4mm balloon. However, at one-month clinic follow up, her ulcer only 
had minimal improvement. Repeat arteriogram showed moderate radial artery stenosis, 
which was angioplastied with 4mm paclitaxel coated-angioplasty balloon. The ulcer healed 
completely 1 month later.
Discussion: Paclitaxel coated balloon was recently approved by FDA to treat PAD in 
the lower extremities. This case report showed upper extremity PAD can also be treated 
successfully with paclitaxel coated angioplasty balloon.
SA-PO056
Minimal Change Disease Associated with Invasive Ductal Carcinoma of the 
Breast: A Case Report and Literature Review  Siddhesh R. Lotlikar,2 Julian D. 
Rose,1 Soumya Patnaik,2 Supakanya Wongrakpanich,2 Mary Carolina Rodriguez 
Ziccardi,2 Mark S. Morginstin,2 Rasib Raja,2 Eric J. Bloom.2  1Sidney Kimmel 
Medical College; 2Albert Einstein Medical Center, Philadelphia.
Introduction: A tenth of malignancies have been associated with nephrotic syndrome, 
the diagnosis of which may precede the detection of cancer. In an adult with Minimal 
Change Disease (MCD), paraneoplastic etiology should be explored. Here, we describe a 
rare case of MCD associated with breast cancer.
Case Description: Our patient is a 72-year-old Caucasian female who presented with 
bilateral lower extremity edema for 1 week. Home medications were notable for occasional 
Diclofenac use. Urinalysis on admission showed nephrotic-range proteinuria. MCD was 
suspected and confirmed on renal biopsy. CT ruled out lymphoma and thymoma. MCD 
was presumed secondary to Diclofenac use and she was discharged on daily prednisone 
with instructions to avoid NSAIDs. Two months later, she presented with a pulmonary 
embolus and CT showed concerning breast changes. Biopsy confirmed a stage IIIc invasive 
ductal adenocarcinoma. She was tapered off steroids, continued on furosemide and started 
on Paclitaxel.
Discussion: Breast cancer mainly causes antibody-mediated paraneoplastic syndromes. 
Yet, studies have shown intratumoral IFN-α expression correlates with induction of 
autoreactive T-cells, presenting a route for breast cancer to cause a T-cell mediated process 
such as MCD. Our patient had no lymphoma or thymoma and the lack of evidence of AIN 
and failure of improvement on discontinuation of NSAIDs argue against NSAID-induced 
MCD. The relationship of MCD with breast carcinoma is reinforced by her improved 
proteinuria with chemotherapy.
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Time MCD dx 1 month after dx
1.5 months 
after dx
1 week 
after first 
chemo 
(week 1)
2nd cycle 
of chemo 
(week 2)
3rd cycle 
of chemo 
(week 3)
1 week 
after 3rd 
cycle of 
chemo
Urine 
Protein 
(mg/dl)
1270.1 1773.4 1407.3 55 35.8 10.6 0
SA-PO057
A Case of Donor-Derived Enterococcal Pyelonephritis in an HIV-Positive 
Kidney Transplant Recipient  Akshatha Rao,1 Shilpa A. Chaudhari,2 Dong 
Heun Lee,2 Karthik M. Ranganna,1 Alden Michael Doyle.1  1Div of Nephrology, 
Drexel Univ, Philadelphia; 2Divison of Infectious Disease, Drexel Univ, 
Philadelphia.
Introduction: Donor-derived infections are an unusual but recognized complication of 
solid organ transplantation. Between 2005-2011, there were 118 reported donor bacterial 
infections, of which 34 recipients had confirmed transmission of infection and 9 deaths due 
to donor derived bacterial infections. Herein, we describe a unique case of donor-derived 
enterococcal pyelonephritis in a kidney transplant recipient with HIV infection.
Case Description: 47 year old male with history of HIV infection (CD4 -534 cells/
mm3, VL<20 copies), ESRD on peritoneal dialysis, hypertension had deceased donor kidney 
transplantation. Post-op patient was given 1 dose of cefazolin as surgical prophylaxis. 
Basiliximab and intravenous immunoglobulin was used for induction therapy. Patient was 
started on tacrolimus, mycophenolate mofetil and prednisone for maintenance therapy. 
POD#3 we were notified by organ procurement organization (OPO) that donor urine 
culture grew >100,000 colonies /ml of Enterococcus faecalis. Our patient was started on 
intravenous ampicillin to complete a total of 6 days antibiotic course. POD #17 patient 
was readmitted to the hospital with urinary retention and elevated serum creatinine 2.2.
Renal ultrasound showed no hydronephrosis. Urinalysis showed 2+ leukocyte esterase, 
WBC 11-20, with occasional bacteria. Blood and urine culture grew Enterococcus faecalis 
that had same susceptibility pattern of that from donor kidney. Patient was started on 
intravenous ampicillin to complete a total of 14 days. Serum creatinine improved with 
treatment.
Discussion: There is no clear consensus on treatment regimens for donor-derived 
infections. This case demonstrates transmission of donor-derived enterococcal infection 
despite timely initiation of appropriate antimicrobial therapy. Because of increased morbidity 
and mortality associated with post-transplant infection extended duration of antimicrobial 
therapy should be considered in these patients.
SA-PO058
Peritoneal Dialysis: A Better Modality of Renal Replacement Therapy 
for Liver Cirrhotics with End Stage Renal Disease?  Akshatha Rao, Sweta 
Carpenter, Alden Michael Doyle.  Divison of Nephrology, Drexel Univ, 
Philalphia.
Introduction: Managing patients with end stage liver disease associated with portal 
hypertension, ascites and end- stage kidney disease requiring renal replacement therapy 
is challenging for a number of reasons including chronic hypotension, poor nutrition, 
coagulopathy, high infection rates, and encephalopathy.  It is difficult to assess accurate 
dry weights because of the large variation patient weights depending on how much ascites 
they have at the time of dialysis, with weight fluctuations in excess of 10 kg.  There is also 
a reluctance on the part of the transplant community to utilize PD because of the perception 
that these patients may not be able to go on to receive a successful liver transplant.
Case Description: Herein, we report our experience with 5 consecutive patients with 
decompensated cirrhosis who progressed to ESKD and required dialysis support.  One 
patient did not tolerate HD and was switched to PD, the other 3 started with de novo PD.  In 
each case, the patients were admitted to hospital for PD catheter placement with a surgeon 
experienced with patients who had advanced liver disease and stayed in the hospital for 
initial recovery period with IV albumin to support blood pressure.  By our protocol, ascites 
fluid was drained in the OR and then drained each morning for the next 2 weeks before 
dialysis was initiated. Blood pressures ranged from 80/50-110/65 mmHg, patients remained 
asymptomatic. All patients received oral midodrine for BP support.
Adequate ultrafiltration achieved and edema improved. Serum albumin was monitored 
at regular intervals, ranged from 2.5-3. One patient had peritonitis from time of surgery, 
which was treated successfully; no other cases of peritonitis were noted.
Discussion: We suggest that PD should be considered in selected patients who have 
ascites and end-stage kidney disease.  Further research is warranted regarding long term 
outcomes and potential effects of PD on the ability for these patients to get transplanted.
SA-PO059
Focal Segmental Glomerulosclerosis Presenting Concurrently with 
Chromophobe Renal Cell Carcinoma  Itunu O. Owoyemi, Denise J. Thomson, 
Hiren J. Joshi, M.J. Barchman.  Nephrology, East Carolina Univ/Vidant Medical 
Center, Greenville, NC.
Introduction: Chromophobe renal cell carcinoma (CHRCC) is a rare variant of RCC 
with distinct histochemical, ultrastructural and genetic characteristics. CHRCC accounts 
for approximately 4% of all kidney neoplasms. Glomerulopathies are often diagnosed in 
patient with malignances, particularly hematological cancers with membranous nephropathy 
being the most common variety. We present a case of resistant hypertension in a young 
adult male found to have focal glomerulosclerosis (FSGS) with concurrent CHRCC. This 
case highlights the association and emphasis of screening for secondary hypertension in 
resistant patients, early referral and the pitfalls of percutaneous biopsy for solid renal masses.
Case Description: A 34 year old Nigerian male initially presented to the Internal 
Medicine clinic to establish care in 2011. His past medical history was significant for 
hypertension and gross hematuria. He was subsequently referred to Nephrology due 
to persistent microalbuminuria, hematuria and passage of blood clots in his urine. On 
presentation to Nephrology, he was found to have nephrotic range proteinuria. Renal 
ultrasound was significant for several lesions in the right kidney with the largest measuring 
3 cm. Percutaneous renal biopsy performed for proteinuria revealed focal segmental 
glomerulosclerosis with moderate tubulointersitial scarring. He initiated on steroids however 
he was lost to follow up for approximately 9 months. Upon return, his renal lesions were 
readdressed with an MRI of the abdomen which could not exclude multiple solid masses 
in the right kidney. A subsequent ultrasound-guided fine needle aspiration and core biopsy 
of the right kidney lesion diagnosed chromophobe renal cell carcinoma. He underwent a 
right nephrectomy with biopsy result negative for metastasis.
Discussion: We were able to unravel this unique finding of FSGS co-presenting 
with chromophobe renal cell carcinoma. The prevalence of FSGS in RCC has not been 
established with precision. This case highlights the importance of timely evaluation of 
secondary hypertension and biopsy of suspicious renal masses.
SA-PO060
A Case of Peritoneal Dialysis Patient with Unknown Membrane-Like 
Structure Covering Intestinal Tract  Yu Honda, Nanae Matsuo, Yudo Tanno, 
Yasuyuki Nakada, Taketo Uchiyama, Izumi Yamamoto, Ichiro Ohkido, Keitaro 
Yokoyama, Takashi Yokoo.  Div of Nephrology and Hypertension, Dept of 
Internal Medicine, Jikei Univ School of Medicine, Minato-ku, Tokyo, Japan.
Introduction: A 24-year-old male developed end-stage renal disease (ESRD) and 
was initially started on hemodialysis (HD). Since he had found difficulty to continue HD 
because of disdialysis syndrome, he switched to the combination therapy with peritoneal 
dialysis (PD) and weekly HD on 17years of dialysis duration. Seven years later, he was 
converted to HD alone.He had no episode of peritonitis. He had no episode of ileus and was 
not diagnosed with encapsulating peritoneal sclerosis (EPS). Generally the macroscopic 
appearance of EPS is the whole bowel trapped in a thick, tough peritoneal cocoon. Since 
his PD duration was long, laparoscopy was performed when his PD catheter was removed. 
We found his agglomerated small intestine was coated with thin membrane-like structure. 
It was soft, elastic and easy to separate from intestine. 
We performed biopsies of the structure. Surprisingly its histology looked like the 
normal peritoneum. On the surface of the biopsy, a single layer of mesothelial cells was 
present. There are no apparent fibrosis (thickening) and sclerosis. This case suggests that 
his peritoneum-like membrane might be the very early stage of sclerosing capsule of EPS. 
Since little has been known about transition from a normal state to EPS through pre-EPS 
state, this case is valuable to identify one part of the mechanisms of EPS. We report this 
rare case with some literature review.
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SA-PO061
Abdominal Compartment Syndrome: An Overlooked Culprit of 
Acute Kidney Injury in Immediate Post-Liver Transplantation 
Ekamol Tantisattamo,1 Praveen Ratanasrimetha,2 Siwadon Pitukweerakul.3 
1Nephrology, Northwestern Univ; 2Faculty of Medicine Siriraj Hospital, Mahidol 
Univ, Bangkok, Thailand; 3Presence St. Francis Hospital, Evaston.
Introduction: Acute kidney injury (AKI) is a common complication after liver 
transplantation and often times, dialysis is required. Abdominal compartment syndrome 
(ACS) is a treatable cause of prerenal AKI without dialysis needed.
Case Description: A 60-year-old man with HCV and alcoholic cirrhosis underwent an 
OLT. He had massive blood loss during the uncomplicated operation and required massive 
transfusion and fluid resuscitation. Postoperatively, renal function initially was stable at the 
baseline serum creatinine(SCr) of 0.8 mg/dL. However, hemoglobin dropped from 9.1 to 5.7 
g/dL and tacrolimus level elevated up to 53 ng/mL on postoperative day(POD)4. SCr rose 
up to 1.3 mg/dL and urine output(UOP) decreased on POD7. Renal function continued to 
decline with a peak BUN and SCr of 120 and 2.73 mg/dL on POD14, respectively(Figure 
1). Dialysis was initially planned. However, he had progressively increased ascites with 
markedly tense abdomen. Bladder pressure revealed intraabdominal hypertension (IAH) 
with the pressure of 20 mmHg. FENa and FEurea were 0.7% and 21%, respectively. Therefore, 
abdominal paracentesis was performed with an 8 L of yellowish clear ascitis fluid removed. 
UOP significantly increased shortly after paracentesis. SCr had trended down and dialysis 
was not required.
Discussion: Our patient presented with prerenal AKI secondary to perioperative 
hypovolemia concomitant with supratherapeutic tacrolimus level. Massive blood 
transfusion and fluid resuscitation in the setting of major abdominal surgery caused IAH 
and subsequently ACS contributing to worsening prerenal AKI. Bladder pressure is a 
bedside diagnostic tool to detect IAH. AKI could be reversed and dialysis could be avoided 
by abdominal paracentesis.
SA-PO062
Rasburicase: A Salvage Strategy to Prevent Renal Allograft Loss in Acute on 
Chronic Urate Nephropathy  Ekamol Tantisattamo,1 Praveen Ratanasrimetha,2 
Siwadon Pitukweerakul.3  1Nephrology, Northwestern Univ; 2Faculty of Medicine 
Siriraj Hospital, Mahidol Univ, Bangkok, Thailand; 3Presence St. Francis 
Hospital, Evaston.
Introduction: Chronic hyperuricemia can lead to chronic kidney disease (CKD) and 
acute on chronic hyperuricemia potentially causes renal failure. Rasburicase is an effective 
uric lowering agent indicated for the treatment of acute hyperuricemia especially in tumor 
lysis syndrome. We report a case of kidney transplant recipient with acute hyperuricemia-
related acute kidney injury (AKI) which was resolved with rasburicase.
Case Description: A 51-year-old man with ESRD secondary to type 2 diabetes 
status post renal transplant was admitted with diffuse muscle cramping. Maintenance 
immunosuppression included cyclosporine (CsA) and mycophenolate mofetil. The baseline 
serum creatinine (SCr) was 2.5 mg/dL after 2 episodes of borderline changes detected from 
transplant renal biopsy at 1 and 2 years posttransplant, respectively. However, over the past 
9 months, SCr had gradually trended up to 4.4 mg/dL. He had asymptomatic hyperuricemia 
with a serum uric acid of 9.1–12.5 mg/dL. Two days after admission, he developed severe 
pain on the right first metatarsal joint presumed from acute gouty arthritis which responded 
to oral prednisone. However, SCr continued rising up to 4.8 mg/dL. Urinalysis showed 
a pH of 6 and Sp.Gr. of 1.011. Serum and urine BK virus were undetectable. Transplant 
renal ultrasound was unremarkable. Serum uric acid was markedly elevated up to 17.7 
mg/dL. Given worsening renal function in the setting of acute hyperuricemia, rasburicase 
was initiated. Serum uric acid had been decreased to 8.1 and 4.5 mg/dL within 20 and 30 
hours, respectively and SCr returned to the baseline of 2.5 mg/dL.
Discussion: Our patient presented with AKI on CKD in the setting of symptomatic 
acute on chronic hyperuricemia. Acute hyperuricemia leads to AKI which was resolved by 
rapidly lowering uric acid level with rasburicase. AKI in the patient with underlying chronic 
hyperuricemia should raise a suspicion for acute hyperuricemia-related AKI. Rasburicase 
should be considered as a salvage therapy to avoid renal allograft loss.
SA-PO063
The Effect of Taurine on Haemodialysis Filtration in Patients with Chronic 
Heart Failure: A Case Study  Shunji Shiohira,1,2 Kosaku Nitta,1 Ken Tsuchiya.1 
1Dept of Medicine IV, Tokyo Women’s Medical Univ, Shinjuku, Tokyo, Japan; 
2Dept of Blood Purification, Joban Hospital, IZaki, Fukushima, Japan.
Introduction: Taurine, an important factor in the living body, is essential for 
cardiovascular function and development and function of skeletal muscle, retina and 
central nervous system. In the present study, its effect on cardiovascular function was 
specifically taken into consideration. In haemodialysis filtration (HDF) patients, the effect 
of taurine on patients with chronic heart failure (CHF), in whom dry weight was difficult 
to control, was evaluated.
Case Description: All patients who were subjected to regular HDF for 4 h three times 
per week at Joban hospital in this study. Patients with chronic heart failure, in whom dry 
weight was difficult to control (n = 4), were included in the evaluation of clinical status. 
X-ray and echocardiography were determined before and after taurine treatment.
Almost all cases were taking nitric acid, warfarin, anti-platelet and vasopressor. Because 
vital signs were unstable in chronic heart failure, all cases withheld antihypertensive drugs 
during HDF. For unstable vital signs during HDF, pulmonary congestion was chronically 
recognized.After taurine was started, vital signs stabilized and lowering of dry weight was 
possible. In addition, X-ray and cardiac diastolic failure on echocardiography improved.
Discussion: Taurine was effective for CHF patients on HDF in whom dry weight was 
difficult to control in spite of various medications.
SA-PO064
Immune Complex MPGN Associated with Hashimoto’s Thyroiditis in a 
Young Female  Samuel Chakola, Iris J. Lee, Jean Lee, Xu Zeng, Duncan B. 
Johnstone, Lleras A. Samuels.  Nephrology, Temple Univ, Philadelphia, PA.
Introduction: Glomerular disease associated with Hashimoto’s Thyroiditis 
(HT) is a rare occurrence infrequently reported in the literature. We present a case of 
membranoproliferative glomerulonephritis (MPGN) that was thought initially to be due 
to systemic lupus erythematous (SLE) in a young woman.
Case Description: A 38 year old female presented in 2013 with leg edema and two 
grams of proteinuria. Creatinine (Cr) was 1.3 mg/dl. Of note, her thyroid function tests were 
consistent with severe hypothyroidism, with a TSH of 129 IU/ml and thyroid peroxidase 
and thyroglobulin antibodies >900 IU/ml. Serologic workup for hepatitis B, C and HIV 
and complements were negative. She had a history of Raynaud’s but did not fulfill clinical 
and immunological criteria for SLE. Kidney biopsy was consistent with immune complex 
MPGN with immunofluorescence positive for IgG and C3 only. Patient was non- compliant 
with thyroid replacement therapy and was lost to follow-up. She reappeared in 2015 with 
arthralgias, dyspnea, and leg edema. Her Cr had worsened to 1.7 mg/dl with 16 gram 
proteinuria. She was found to have a pericardial effusion. TSH was 174 IU/ml. Repeated 
testing for SLE was negative and a repeat renal biopsy demonstrated an immune complex 
mediated MPGN with minimal staining for full house immunoglobulins. She was placed on 
thyroxine hormone and also initiated on mycophenolate mofetil, given that both her thyroid 
and renal disease appeared to be driven by an autoimmune antibody mediated process.
Discussion: HT, immune complex MPGN and clinical findings in our patient were 
initially thought to be due to SLE however patient failed to fulfill any immunologic criteria 
for SLE. HT is rarely associated with MPGN and specific mechanisms remain unclear. 
Proteinuria in glomerular disease associated with HT is not correlated with levels of thyroid 
hormone. However, deposition of thyroglobulin and thyroid-peroxidase antibodies has been 
found in the kidney in HT. This supports the theory of an autoimmune basis for MPGN in HT, 
and reinforces that immunosuppression may be required to adequately treat both diseases.
SA-PO065
Hypervitaminosis D – A Rare Complication of PJP in a Transplant Patient 
Khaled Boobes, Khurram Saleem, Yazan M. Alia, Muhammad H. Hasan, 
Aneesha A. Shetty, Mohammed Javeed Ansari.  Nephrology, Northwestern 
Univ/Norhwestern Memorial Hospital, Chicago, IL.
Introduction: Pneumocystis Jiroveci Pneumonia (PJP) is a known complication in 
immunocompromised hosts including transplant recipients, usually in the first six months 
of transplant. Hypercalcemia (HCa) is not a classic symptom of the disease. We present a 
case of a patient with simultaneous kidney and pancreas transplantation nineteen years ago 
who presented with PJP and developed HCa (highest value 14.8mg/dl [8.3-10.5] mg/dl). 
Parathyroid Hormone (PTH) was appropriately suppressed with a level of (6; [12-88] pg/
ml). 1,25-(OH) vitamin D concentration was elevated (123; [18-72] pg/ml). After treatment 
with trimethoprim-sulfamethoxazole her Calcium concentration returned to normal along 
with PTH and 1,25-(OH) vitamin D. It is thought that, like other granulomatous disease-
induced HCa, it is likely that endogenous extrarenal production of 1-alpha-hydroxylase by 
activated macrophages and by interferon-gamma involved in granuloma formation results in 
increased conversion from 25-(OH) vitamin D to 1,25-(OH) vitamin D and, consequently, 
in HCa and suppression of PTH secretion. Although only few cases of PJP-associated 
HCa have been reported to date, it is possible that this association is more frequent than 
previously thought. Hypercalcemia in transplant recipients with pulmonary symptoms 
must raise suspicion of PJP.
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SA-PO066
A Rare Case of Tubulointerstitial Nephritis Associated with Primary 
Biliary Cirrhosis  Jatinder K. Hothi,1 Jingyin Yan,1 William F. Glass.2  1Dept 
of Nephrology, Baylor College of Medicine, Houston, TX; 2Dept of Nephrology, 
Baylor College of Medicine, Houston, TX; 3Dept of Pathology, Univ of Texas 
Health Science Center, Houston, TX.
Introduction: Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease 
characterized by positive antimitochondrial antibodies (AMA), immune-mediated epithelial 
damage of small bile ducts, which leads to liver cirrhosis as the disease advances. In 
addition to liver injury, other autoimmune diseases, such as Sjögren’s syndrome and 
Raynaud’s syndrome, are reported in approximately 2-20% patients with PBC. However, 
the association of PBC and renal injury is rarely documented.
Case Description: Here we present a case of tubulointerstitial nephritis (TIN) in a 
patient with PBC. A 35-year-old female with past medical history of PBC developed sub-
nephrotic range proteinuria and chronic kidney disease stage 3. A renal biopsy showed 
moderate to severe renal cortical and focal medullary tubulointerstitial inflammation with 
infiltration of lymphocytes, plasma cells and occasional eosinophils, as well as significant 
tubulitis.
The patient was treated with a short course of oral prednisone and her renal function 
improved.
Discussion: This case highlights a very rare cause of TIN and suggests that steroid 
therapy is effective in this setting.
SA-PO067
Plasma Exchange as AdjunctiveTherapy for Crescentic IgA Nephropathy 
Jicheng Lv, Xinfang Xie, Fude Zhou, Minghui Zhao, Hong Zhang.  Renal Div, 
Peking Univ Inst of Nephrology.
Introduction: Recent KDIGO guidelines recommend an aggressive immunosuppressive 
therapy in patients with crescentic IgA nephropathy (CreIgAN). While large cohort study 
from our center suggest that even with such a therapy, the 1- and 5-year renal survival 
rates remained low at 65% and 28%, respectively. Especially patients who present with 
serum creatinine (SCr)>580umol/L hardly recovered from dialysis. In this study we aim 
to evaluate the efficacy of plasma exchange(PE) in severe CreIgAN.
Case Description: In this pilot study we give PE as adjunctive therapy to patients with 
severe CreIgAN on the back of high dose steroids and cyclophosphamide. Severe CreIgAN 
is defined as diffuse crescent forming with kidney failure that needs dialysis or presents 
kidney function declining even with high dose steroids and cyclophosphamide therapy.
Overall ten patients with severe cresentic IgA nephropathy received PE from 2011 
to 2015. 
Pa-
tients Age Gender
Dialy-
sis 
Scr
(ȝmmol/ L)
Crescents
(%)
Course 
of PE
Pulse of 
steroids
Follow-up 
months
1 57 M Y 1087 61 7 Y 40
2 64 M Y 580 55 6 N 37
3 26 M Y 756 67 6 Y 6
4 24 M Y 710 81 10 Y 6
5 58 M Y 881 90 5 N 15
6 23 M N 449 85 7 Y 6
7 39 M N 394 85 6 Y 6
8 66 F Y 775 89 7 N 6
9 40 F N 253 54 7 Y 8
10 44 M Y 589 43 10 Y 1
Y: yes, N: No 
Among them 7 patients reached dialysis at presentation with serum creatinine 
(768±176mmol/L). Another 3 cases showed progressively kidney decline even after an 
aggressive immunosuppressive therapy. Patients received 5-10 PEs. After a mean 13 month 
follow-up, 4 of the 7 patients who had dialysis successfully recovered from dialysis, One 
of the 3 patients with persistent kidney progression showed serum creatinine decline.
No severe adverse event was observed during the follow-up.
Discussion: Plasma exchange as adjunctive therapy may achieve benefit for patients 
with severe crescentic IgAN.
SA-PO068
Fibrillary Glomerulonephritis Associated with Demyelinating 
Polyneuropathy  Sixto G. Giusti, Pradeep Vaitla, Jorge C. Garces.  Nephrology, 
Ochsner Clinic Foundation, New Orleans.
Introduction: Fibrillary glomerulonephritis (FGN) is characterized by nonbranching 
randomly arranged fibrils along the mesangium and glomerular capillary walls that do not 
stain for Congo red, have a diameter of 16-24 nm, and usually show polyclonal IgG, C3, 
and light chain deposition by immunofluorescence. Found in ≤ 1% of native renal biopsies, 
FGN is usually idiopathic, although some cases are associated with malignancy, monoclonal 
gammopathy, and autoimmune diseases. Association of FGN with demyelinating neuropathy 
has been rarely described.
Case Description: A 38-year-old Indian man with 3-year history of hypertension and 
10-month history of end stage renal disease attributed to hypertension, presented to our 
institution with a 3-week history of progressive, bilateral lower extremity weakness. During 
his hospital stay, he was diagnosed with non-infectious pleural and pericardial effusions. 
Lab work revealed normal Anti nuclear antibody, anti double stranded DNA antibody, 
serum complements, anti nuclear cytoplasmic antibodies. Serologies for hepatitis and 
human immune deficiency virus were negative. Electromyography revealed demyelinating 
sensorimotor polyneuropathy. Chest, abdomen and pelvis imaging was unrevealing for 
malignancy. No monoclonal peaks on serum and urine electrophoresis or immunofixation. 
Fat pad biopsy negative for amyloid. Bone marrow biopsy showed 60% cellularity with tri 
lineage hematopoietic activity, no B cell clonality or T cell aberrancy. He was started on 
high dose steroids with gradual improvements of weakness. Renal biopsy showed findings 
of chronic FGN with IgG4 dominant deposition. 44 of 48 glomeruli were globally sclerosed 
with 80% fibrosis and no activity. Sural nerve biopsy results are still pending.
Discussion: FGN is a rare and leads to ESRD in the majority of cases. There are very 
few cases describing FGN in association with demyelinating polyneuropathy without 
associated plasma cell dyscrasias. Although FGN renal prognosis remains poor, early 
identification is important as it may help identify an underlying malignancy or systemic 
autoimmune disorder with potential for treatment. FGN may be a precursor for future 
lymphoproliferative disorder.
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SA-PO069
Acute Inflammatory Polyarthritis following Kidney Transplantation 
Paul P. Maraj.  Nephrology, Baylor College of Medicine, Houston, TX.
Introduction: An acute inflammatory polyarthritis develops one month after deceased 
donor kidney transplantation in a 54 year old male. He had no prior diagnosis of any form of 
arthritis, crystalline, inflammatory or otherwise. Following workup he was diagnosed with 
Rheumatoid arthritis and improved with an increased dose of steroids. To date there are no 
case reports which describes rheumatoid arthritis precipitated by kidney transplantation. 
This case report describes this unique clinical scenario and the dilemmas with diagnosis.
Case Description: 54 year old man with a medical history of end stage renal disease 
secondary to hypertensive nephrosclerosis who underwent deceased donor kidney transplant 
one month prior is admitted for joint pains. During kidney transplantation he had induction 
with thymoglobulin, plasmapheresis and rituximab as per institutional protocol for positive 
DSA. Maintenance immunotherapy consisted of tacrolimus, mycophenolate mofetil and 
prednisone taper dose. Following transplantation he was asymptomatic until one month 
after transplantation when he developed bilateral shoulder pains which then migrated to 
elbows and wrist; this was associated with significant morning stiffness and malaise. Xrays 
which were negative for bony abnormalities, MRI wrist revealed small to moderate joint 
effusion. Fluid analysis was negative for septic arthritis and crystals. Serum uric acid was 
within normal limits. Autoimmune workup negative including ANA, C3, C4. Rheumatoid 
factor was positive to titer 1:4, anti CCP was significantly positive at>250. He was treated 
with oral steroids which resulted in resolution of his symptoms.
Discussion: To date there have been no reports of rheumatoid arthritis in the immediate 
post-transplant period. There have been reports of an acute inflammatory syndrome related 
to mycophenolate use which improved on discontinuation, anti-CCP titers were unknown 
in these cases. Mycophenolate was continued in this patient and his symptoms did not 
recur after steroid taper making a reaction to mycophenolate less likely. Anti CCP is very 
specific for diagnosis of rheumatoid arthritis but its validity post transplant is unknown. The 
temporal relation with transplantation also raises the possibility of a drug induced reaction.
SA-PO070
IgM Nephropathy: A Neglected Pathology of Nephrotic Syndrome 
Krystahl Z. Andujar, Carlos Antonio Cortes Sanchez, Hector R. Cordova. 
Medical Service, VA Caribbean Healthcare System, San Juan, PR.
Introduction: IgM nephropathy is defined by the presence of immunoglobulin M 
(IgM) as the dominant immunoglobulin in the mesangium of the glomeruli in a diffuse 
and global distribution. Clinically, a poor response to steroids distinguishes this disease 
from Minimal Change Disease.
Case Description: An 80-year-old man with past history of Hypertension, Alzheimer’s 
dementia, and benign prostatic hypertrophy complained of progressive shortness of breath 
associated with severe bilateral lower extremity edema and decreased urine output. Vital 
signs revealed blood pressure of 171/77mmHg. Lung auscultation was remarkable for 
bibasilar rales. The patient had anasarca. Laboratory tests showed serum creatinine at 
2.2mg/dL (baseline of 1.2mg/dL), BUN of 36mg/dL and albumin of 2.2g/dL. Urinalysis 
showed microscopic hematuria and proteinuria (> 500 mg/dl). Renal sonogram revealed 
normal kidney size without hydronephrosis or nephrolithiasis. The 24-hour urinary protein 
excretion was 6.7gms/day. Serum creatinine rose to 7.7mg/dL a week later. Kidney biopsy 
was performed and steroid pulse therapy was started. Hemodialysis was initiated. Renal 
biopsy results showed mild increase in mesangial matrix and interstitial fibrosis. Sections 
stained for IgG, IgA, albumin C1q and kappa and lambda light chains were negative. 
Staining for IgM showed granular deposits in the mesangial areas compatible with a 
diagnosis of IgM Nephropathy. Hemodialysis was discontinued after two sessions since the 
patient had rapid recovery of kidney function after the 3 day steroid pulse therapy. Steroid 
therapy was tapered and eventually discontinued. Three months later, 24 hour urinary 
protein excretion was normal and the serum creatinine was 1.6mg/dl.
Discussion: Patients with IgM Nephropathy are less likely to respond to 
immunosuppressive agents. The presence of mesangial IgM deposits and intersttitial fibrosis 
entails a worse prognosis. However, in our case, the patient had a prompt response to 
steroid therapy with resolution of the nephrotric syndrome and recovery of renal function.
Funding: Veterans Administration Support
SA-PO071
Renal Infarct from Traumatic Renal Artery Dissection  Eduardo J. Zouain, 
Isha Gupta, Karim El Hachem, Germaine Z. Chan, Steven D. Smith.  Nephrology 
Dept, Mt. Sinai St. Luke’s Hospital and Icahn School of Medicine at Mt. Sinai, 
New York, NY.
Introduction: Renal infarction is an uncommon condition associated with a 
thromboembolic event (i.e.: related to atrial fibrillation), hypercoagulable state, renal artery 
dissection or fibromuscular dysplasia.
Case Description: A 26 y/o male with no significant PMHx presented with left flank 
pain for 3 days. The pain was described as 10/10 and associated with intermittent nausea. 
He fell from his motorcycle onto his left side 2 weeks prior. On exam there was a healing 
laceration over the left knee and tenderness to palpation over the left lower quadrant and L 
flank. The remainder of his exam including blood pressure was unremarkable. Blood work 
was pertinent for a WBC of 13.3K/uL and an elevated CRP of 2.5mg/dl. Urinalysis was 
positive for 30mg/dl protein, and trace blood with 5 RBC/HPF. A basic metabolic panel 
was normal with a creatinine of 1.1mg/dl. After a non-contrast CT a CT angiogram of the 
L renal artery was performed.
Discussion: Renal infarcts are characterized by acute onset of flank or generalized 
abdominal pain, nausea, vomiting, and occasionally fever and hypertension. Elevated WBC, 
CRP and LDH have also been associated. Renal artery dissection secondary to trauma is 
rare and has been associated with anatomical variations and acceleration/deceleration 
injury leading to intimal tearing. The two goals of treatment are organ preservation 
and improvement of renovascular hypertension. The treatment options include surgical 
reconstruction, endovascular repair, or conservative treatment. Our patient was initially 
placed on empiric anticoagulation with heparin. After hypercoagulable disorder, vasculitis, 
and embolic source was ruled out, anticoagulation was stopped. The patient was discharged 
on conservative treatment.
SA-PO072
Persistent Fever in a Patient with Wünderlich Syndrome  Marijeta Pekez,1 
Kshitij Thakur.1  1Dept of Medicine, Crozer Chester Medical Center, Upland, 
PA; 2Clinical Renal Associates, Crozer Chester Medical Center, Upland, PA.
Introduction: Wünderlich syndrome is spontaneous, nontraumatic renal hemorrhage 
confined to the subcapsular and perirenal space. We present a case of a patient with a 
Wünderlich syndrome complicated by renal abscess.
Case Description: Patient was a 43 year old male who presented with nausea and 
generalized weakness, found to have sepsis secondary to urinary source. Ultrasound obtained 
during work up showed a old right perinephric hematoma. Patient continued to be febrile 
despite IV antibiotics. Repeat imaging with CT scan showed large abscess in place of the 
previously described subcapsular hematoma. Successful CT-guided drainage of the abscess 
led to marked improvement and resolution of fever.
Discussion: Wünderlich syndrome is secondary to neoplastic and non-neoplastic 
causes. It usually presents as mild flank pain, flank tenderness, or hematuria. Depending 
on blood loss, symptoms, of hypovolemic shock may develop. Treatment varies according 
to severity, ranging from monitoring of the hematoma to nephrectomy. Our case is 
interesting since Wünderlich syndrome provided a nidus for infection and eventual abscess 
formation causing persistent fevers and flank pain with preserved hemodynamic stability. 
It demonstrated the need for CT imaging in order to fully appreciate the extent of the 
hemorrhage which in this case converted into an abscess. In the right clinical scenario, 
Wünderlich syndrome should be evaluated as a possible factor in infectious presentations.
SA-PO073
Gaucher’s Disease and Lupus, Two Diseases in the Same Scope? 
Ana Pocinho Pimentel, Ana Cabrita, Teresa M. Jeronimo, Joana Vidinha, Viriato 
J.V. Santos, Pedro L. Neves.  Nephrology, Centro Hospitalar do Algarve, Faro, 
Portugal.
Introduction: Gaucher’s disease is a rare inherited lysosome storage disease caused 
by genetic mutations that encodes for glucocerebrosidase enzyme. It’s deficiency leads to 
glucocerebroside (GC) accumulation in mononuclear macrophage system, including liver, 
spleen and bone marrow. Kidney involvement is usually rare. Systemic lupus erythematosus 
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(SLE) is an autoimmune disorder where similarly, sphingolipid accumulation occurs when 
there is glomerular disease.The authors describe a case of a woman with both Gaucher’s 
disease type 1 and SLE.
Case Description: A 32-year-old woman with Gaucher’s disease diagnosed at 17 
years old, having velaglucerase, presented several clinical clues suggesting SLE. Months 
later started presenting face and limbs edema and hypertension. She was admitted with 
microcytic and hypochromic anemia, 77000 platelets, creatinine serum levels of 1.38mg/
dL and hypocalcemia. The urinalysis showed hematoproteinuria and proteinuria of 7628mg 
in the 24h urine collection. The patient had positive anti-nuclear antibodies, Anti-Sjögren’s 
syndrome-related antigen and negative anti-double stranded DNA antibodies, anti-neutrophil 
cytoplasmic antibodies, viral serologies. Both complement levels were low. A kidney 
biopsy was performed.
It has been suggested that progressive accumulation of GC may trigger macrophage 
activation resulting in enhanced cytokine secretion and subsequent clonal B-cell expansion 
leading to chronic stimulation of the immune system. GC changes natural killer T cell 
function, a regulatory lymphocyte that have a role in infectious, neoplastic and inflammatory 
processes, therefore having a potential role in inducing other autoimmune disease. NKT 
lymphocytes are considered to be a link between innate and adaptive immune responses 
and were shown to have a role in a number of immune-mediated disorders. In an animal 
model of SLE, a selective reduction in NKT cells precedes the development of autoimmune 
phenomena.
Discussion: This case highlights a possible immunologic proximity between Gaucher’s 
disease and SLE, bringing up the already existing doubt that the defects in lipid metabolism, 
could contribute to the development of autoimmunity.
SA-PO074
Chronic Periaortitis, a Known Cause of Obstructive Uropathy 
Margaret Duffy,1 Smita Mahendrakar,1 Mandeep Samra,1 Michael Yudd.2 
1Nephrology, Rutgers-New Jersey Medical School, Newark, NJ; 2Nephrology, 
East Orange Veterans Administration Hospital, East Orange, NJ.
Case Description: A 59 year-old man with hypertension presented with one week 
of gradually decreasing urine output, nausea, generalized weakness, and vague dull left 
lower quadrant pain with radiation to the left flank. He was afebrile with blood pressure of 
170/90 mmHg, pulse of 79 beats per minute, respiratory rate of 16 breaths per minute, and 
oxygen saturation of 98% on room air. His abdominal exam was unremarkable except for 
non-tender scrotal swelling bilaterally. Laboratory studies were notable for the following 
values: WBC 12.1 x 109 /L, BUN 62mg/dL, SCr 13.8mg/dL (baseline SCr 1.1mg/dL), 
ESR 57mm/hr, CRP 67mg/dL, U/A clear, yellow, specific gravity 1.01, pH 6, moderate 
blood, negative protein, leukocyte esterase, or nitrites. A renal ultrasound showed moderate 
hydronephrosis with patent renal arteries and veins bilaterally. CT of the abdomen and pelvis 
revealedmoderate bilateral hydronephrosis, an abdominal aortic aneurysm (3.6cm), and a 
periaortic soft tissue mass measuring 2 cm in diameter with associated ureteral obstruction. 
There was no inguinal iliac lymphadenopathy or suggestion of discrete malignancy. Based 
on combined clinical and radiographic evidence the patient was diagnosed with chronic 
periaortitis and retroperitoneal fibrosis. He was started on mycophenalate mofetil and 
prednisone taper with complete resolution of symptoms within 6 months.
Discussion: Retroperitoneal fibrosis (RPF) is a relatively rare condition characterized by 
the presence of fibrosis and inflammation of the retroperitoneal tissues that often surrounds 
the ureters and other abdominal organs and can lead to renal failure in advanced cases. Our 
case demonstrates the importance of considering RPF as an etiology of flank pain and renal 
failure as medical treatment is effective in reversing obstructive uropathy.
SA-PO075
IgA Nephropathy in HIV Positive Patient with Acute Kidney Injury 
Giovanna Y. Arteaga Muller,1 Lilia Maria Rizo Topete,1 Elisa Maria Guerrero 
Gonzalez,1 Concepcion Sanchez Martinez,1 Jesus Cruz Valdez,1 Gabriela 
Alarcón-Galván.2  1Nephrology, Univ Hospital José E. González UANL, 
Monterrey, Mexico; 2Anatomic Pathology, Univ Hospital José E. González 
UANL, Monterrey, Mexico.
Introduction: Acute kidney injury is common in patients with HIV, being 
prerenal variety the predominant etiology. Among the intrinsic causes are thrombotic 
microangiopathy, the antiretroviral drugs associated and the immune complexes associated 
(3.5%-10%) being the collapsing focal segmental glomerulosclerosis the most frequently 
found.
Case Description: Male 41 year old, with use of cocaine, marijuana, benzodiazepines 
tattoos and high-risk sexual behavior, diagnosed with HIV nine years ago, treated with 
antiretrovirals which suspended two years ago. Begins 3 months before with malaise, a 
week prior to his admission presented progressive dyspnea on moderate to high stresses 
accompanied by productive cough and fever. Chest radiography showed fine interstitial 
infiltrate, compatible with pneumocystis jiroveci, laboratories: Hb9.4g/dl, creat.3.0 mg/dl, 
BUN30 mg/dl, urine protein 4.79g/24 hrs, the urinalysis reported reddish urine, with granular 
casts, hematuria and pyuria. Hepatitis B, Hepatitis C, CMV and tuberculosis tests were all 
negative and the renal ultrasonography was normal. Renal biopsy revealed IgA nephropathy. 
Direct immunoflourescence technique (400X).Mesangial granular staining (4+) for 
IgA. Early treatment with anti-proteinuric general measures and prednisone improved 
renal function with a decreased in creatinine to 1.3mg/dl.
Discussion: The immune complexes associated nephropathy in patients with HIV 
is more common due to the start of antiretroviral therapy, however IgA nephropathy 
remains uncommon in this patients. In our patient the indication for renal biopsy was the 
erythrocyturia and the proteinuria in nephrotic range. Early detection and treatment can 
prevent progression to ESRD.
SA-PO076
Ketorolac Induced Mesangiolysis: A Clinical Example of Anti-Thy 1.1 
Model of Mesangio-Proliferative Glomerulonephritis  Fatima Khalid.  Dept 
of Medicine, Univ of Rochester School of Medicine, Rochester, NY.
Introduction: NSAIDS are known cause of acute kidney injury, but do not usually 
cause glomerulonephritis. We share an unusual presentation of glomerulonephritis after 
only one dose of ketorolac. No renal biopsy findings in acute ketorolac-related acute kidney 
injury appear to have been published based on an Ovid literature search.
Case Description: This is a 42 year old male with past medical history of nephrolithiasis 
and urethral stricture, who presented to the hospital for a cystoscopy procedure. The patient 
had urinary obstruction after the procedure and developed oliguric acute kidney injury with 
serum creatinine of 3.1 mg/dl (baseline 0.8 mg/dl). Of note, the patient also received one 
dose of ketorolac during the procedure. Urinalysis showed 2+ blood with many red blood 
cells, and 9 grams of proteinuria as TP/creatinine ratio. Lab work demonstrated high LDH, 
low haptoglobin but stable hematocrit and platelet count. Peripheral smear did not reveal 
schistocytes. Urine microscopy showed RBC casts. Renal ultrasound showed normal sized 
kidneys with no hydronephrosis. Kidney biopsy showed acute tubule-interstitial nephritis 
with tubular necrosis and mesangiolysis. Electron microscopy showed patent capillary loops 
with focal epithelial foot process effacement, visceral epithelial cells with cytoplasmic 
vacuolization, dilated capillaries with endothelial apoptosis and mesangial lysis. Glomerular 
basement membrane thickness was increased. There was evidence of acute tubular injury. 
No electron dense deposits, thrombi or crescents were identified. Immunofluorescence of 
glomeruli was negative. The patient remained oliguric and required renal replacement for 
short term followed by full recovery of renal function.
Discussion: Renal toxicity of ketorolac has been described, and appears generally to be 
reversible, but could lead to glomerulonephritis in a rare setting. The pathological findings 
in the glomeruli resemble those described in experimental animals with Thy-1 induced 
glomerulonephritis treated with rofecoxib(COX-2 inhibitors). In this model, glomerular 
disease is initiated by immune-mediated mesangial cell damage, resulting in mesangiolysis.
SA-PO077
Disseminated Cytomegalovirus Disease in Induction Treatment with 
Mycophenolate Mofetil in a Lupus Nephritis Patient  Ana Pocinho Pimentel, 
Joana Vidinha, Teresa M. Jeronimo, Ana Cabrita, Ana Paula Silva, Pedro L. 
Neves.  Nephrology, Centro Hospitalar do Algarve, Faro, Portugal.
Introduction: Mycophenolate mofetil (MMF) is an immunosuppressive agent 
that exerts relatively selective antiproliferative effects on T and B lymphocytes and is 
increasingly being associated with higher incidence of tissue-invasive cytomegalovirus 
(CMV) disease in transplant receivers and other immune-mediated diseases. The 
case presented is a patient who developed CMV enteritis while receiving MMF and 
corticosteroids for lupus nephritis (LN).
Case Description: 59 year-old man with LN class IV G(a) + V under MMF (2,5g/day) 
and prednisolone (60mg/day) when started having weight loss, diarrhea, nauseas, dysphagia 
and haematochezia. The blood count showed severe anemia and leucopenia. Comprehensive 
chemistry profile revealed PCr 2.7mg/dL improving proteinuria from 11.7 to 2g/day and 
normal urinary sediment. CMV serology IgM came positive (PCR CMV: 834 copies/mL). 
Immunology tests were negative. Upper endoscopy and colonoscopy were performed. 
Biopsies showed CMV infection signs and esophageal candidiasis. MMF was tapered to 
1g/day and prednisolone to 20mg/day. The patient was started on intravenous ganciclovir 
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and fluconazole, with favorable clinical response. Proteinuria then worsened to 7,9g/day. 
Renal biopsy was repeated showing relapse of LN class V. Renal function improved PCr 
1.6mg/dL having 2g MMF and prophylactic oral valganciclovir.
CMV virus directly infects the bowel causing mucosal erosions or ulcerations. We can 
only find little evidence that CMV disease explains the gastrointestinal adverse event profile 
associated with MMF but we bring up again the hypothesis that high local concentrations of 
MMF have a direct toxic effect on cells of the small intestine, causing gastrointestinal upset.
Data on the incidence of CMV disease with the MMF induction protocol for LN are scarce.
Discussion: Similarly to transplant recipients receiving MMF, LN patients presenting 
gastrointestinal upset demand exclusion of CMV infection. This report highlights the 
importance of clinical follow-up of lupus patients with GI symptoms undergoing intense 
immunosuppression and accurate serological and histological diagnosis.
SA-PO078
Cryoglobulinemic Nephropathy with Successful Childbirth After Recurrent 
Episodes of Nephrotic Syndrome During Pregnancy  Miho Karube, Shinya 
Kaname, Kazuhito Fukuoka, Hideki Shimizu, Yoshinori Komagata, Yoshihiro 
Arimura.  The First Dept of Internal Medicine, Kyorin Univ School of Medicine, 
6-20-2 Shinkawa Mitaka-city, Tokyo, Japan.
Introduction: It is unknown whether pregnancy affects clinical course of 
cryoglobulinemic nephropathy and how to treat pregnant patients complicated with it.
Case Description: A 35-year-old woman was admitted to our hospital because 
of massive proteinuria that developed during the third pregnancy. The previous two 
pregnancies had been terminated for similar episodes of nephrotic syndrome. No history 
of hypertension was observed, but during the course she presented cryoglobulinemia, a 
high titer of RF and low serum complements. The renal biopsy performed 10 days after the 
third termination revealed MPGN-like lesions with lobulation in glomeruli, double contour 
of GBM, endotheliosis, and moderate mesangial cell proliferation. Immunofluorescence 
study showed IgG, IgA, IgM, C3, C4, and C1q all positive mainly along the glomerular 
capillaries, and subendothelial deposits were confirmed by EM, thus she was diagnosed 
as cryoglobulinemic nephropathy. Because the histological findings of repeated renal 
biopsy were not improved two months after the disappearance of proteinuria, treatment 
with 30 mg/day of PSL was started, followed bv intravenous cyclophosphamide 6 times 
and plasma exchange, since she had a desire for baby. Finally at the fourth pregnancy, she 
bore a healthy baby weighing 2,342g on vaginal delivery at 36 weeks despite of recurrent 
appearance of nephrotic syndrome. After delivery, she was given 30 mg/day of PSL and 
proteinuria subsided.
Discussion: We experienced a rare case of type III cryoglobulinemic nephropathy that 
repeatedly developed nephrotic syndrome during pregnancy, but finally bore a baby after 
immunosuppressive therapy. Although the pathogenesis of pregnancy-induced exacerbation 
of cryoglobulinemic nephropathy was not clear in this patient, aggressive treatment may 
have been helpful for ameliorating it, leading to successful delivery.
SA-PO079
Renal Recurrence of Acute Lymphatic Leukemia  Anna Bertram,1 Jan H. 
Braesen,2 Ansgar Reising.1  1Nephrology and Hypertensiology, Hannover 
Medical School, Hannover, Germany; 2Pathology, Hannover Medical School, 
Hannover, Germany.
Introduction: Renal complications of hematologic neoplasia can be therapy- or 
neoplasia-associated. We report a case of acute kidney injury (AKI) in the long term 
follow-up of a patient with acute lymphatic leukemia (ALL).
Case Description: The 42y old patient was diagnosed with ALL in 2009 and treated 
according to recommendations with chemotherapy and peripheral blood stem cell 
transplantation. In 2012, extramedullary ALL recurrence in his right knee was treated with 
irradiation. Starting from September 2014, molecular markers of minimal recurrence without 
evidence of lymphoblasts were found in bone marrow biopsies, and the patient received 
donor lymphocytes to induce graft vs. host reaction. In December 2014, ramipril was started 
for newly diagnosed hypertension, after which creatinine increased within several days 
to 290µmol/L. Because of this association, we suspected renal artery stenosis, toxic AKI, 
or acute interstitial nephritis. Ultrasound revealed diffusely swollen and dense kidneys 
(Fig.1A). Renal artery stenosis could be excluded, but - untypical for interstitial nephritis 
- segmental arteries seemed compressed. Kidney biopsy revealed ALL recurrence with 
extensive lymphoblast infiltration. DOTA-CXCR4-PET-CT confirmed diffuse infiltration 
of both kidneys (Fig.1B) without bone marrow affection. After starting chemotherapy, 
creatinine rapidly ameliorated. Ultrasound and PET-CT-controls 10 weeks after starting 
therapy confirmed good treatment response (Fig.1C-D). 
Discussion: This exceptional case of isolated renal ALL recurrence highlights the 
importance of early evaluation with ultrasound and biopsy in patients with hematologic 
neoplasia and AKI. An empiric treatment for suspected interstitial nephritis would have 
delayed chemotherapy and thereby endangered the patient.
SA-PO080
A Rare Cause of Acute Kidney Injury in Non-Renal Solid Organ 
Transplantation  Sameer Gupta, Wasay Humayun, Ramapriya Sinnakirouchenan, 
Liliana Osadchuk.  Nephrology, Medical College of Wisconsin, Milwaukee, WI.
Introduction: Acute kidney injury (AKI) is a frequent complication of non-renal solid 
organ transplantation (SOT). Here we report a case of rapidly progressive renal failure 
leading to end stage renal disease (ESRD) due to acute oxalate nephropathy (AON) in a 
patient with non-renal SOT.
Case Description: A 63 year old female with past history of pulmonary fibrosis status 
post bilateral lung transplant, obesity status post Roux en Y gastric bypass (RYGB) surgery, 
and hypertension presented with worsening kidney function with BUN and creatinine of 55 
mg/dl and 6.18 mg/dl respectively. She had normal kidney function with serum creatinine 
of 0.5mg/dl prior to transplant 8 months ago. Induction regimen included Basiliximab 
followed by tacrolimus, prednisone and mycophenolate (MMF) as maintenance therapy. 
Ensuing transplantation, she had multiple episodes of AKI attributed to calcineurin inhibitor 
(CNI) toxicity and hypovolemia from MMF and clostridium difficile associated diarrhea. 
Her average tacrolimus trough level was 12 ng/ml. Several urinalyses showed acute tubular 
necrosis casts. Renal ultrasound revealed bilateral echogenic small kidneys compared to 
normal kidney size prior to transplant. Her kidney biopsy unexpectedly revealed oxalate 
nephropathy. She is currently on hemodialysis.
Discussion: AON has been poorly described in patients with RYGB surgery and SOT. 
In our patient with prior RYGB, chronic diarrhea, and numerous antibiotics unveiled AON. 
This superimposed with CNI toxicity resulted in rapid progression to ESRD. Antibiotic 
use depletes colonization of oxalate consuming bacteria (Oxalobacter formigenes). This 
combined with fatty acid malabsorption from prior RYGB increases colonic oxalate 
absorption resulting in hyperoxaluria. Diarrhea causes hypovolemia and metabolic acidosis 
leading to low urinary pH and hypocitraturia promoting calcium oxalate crystallization. 
Additional steps should be taken for SOT patients with RYGB, like diet modification, 
probiotic use, citrate supplementation, administration of fatty acid binding agents, and 
monitoring for hyperoxaluria. High suspicion for AON in patients with risk factors may 
lead to early diagnosis and treatment.
SA-PO081
Paraneoplastic Membranous Nephropathy and Myelodysplastic Syndrome 
– A Rare Combination  Krishna K.R. Manda, Madhuri Manne, Dagmar Klinger. 
Renal Medicine, Univ of Massachusetts Medical School, Worcester, MA.
Introduction: We report a case of Membranous Nephropathy(MN) seen in association 
with Myelodysplastic Syndrome(MDS). This occurrence is rare and only 3 cases have been 
reported in literature previously. Up to 5-20% of adults with MN have been reported to have 
most commonly a solid tumor and less frequently, a hematologic malignancy.
Case Description: Our patient is a 58 y/o man who has chronic kidney disease of 
unclear etiology with serum creatinine(SCr) of 1.3 and MDS. He was admitted with 
acute kidney injury in the setting of pneumonia and had nephrotic range proteinuria 
along with dysmorphic red blood cells on the urinary sediment. Renal biopsy showed 
MN with relatively recent immune complex deposition. There was no colocalization of 
IgG4 membranous deposits with phospholipase A2 receptor. He was hospitalized again 
with pancytopenia, marked inflammatory markers and infectious complications. Although 
bone marrow biopsy was not diagnostic, this syndrome was diagnosed as hemophagocytic 
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lymphohistiocytosis by clinical criteria and therapy was initiated with high-dose steroids and 
etoposide. During the hospitalization SCr peaked to 4 but did not require renal replacement 
therapy. Following this treatment SCr improved to 0.7.
Discussion: MN is the most common cause of the nephrotic syndrome in nondiabetic 
adults. Histologic change on light microscopy is glomerular basement membrane thickening 
with little or no cellular proliferation. Patients without known cancer who are diagnosed 
with MN should undergo age-appropriate cancer screening and this could be life saving. 
MDS, a group of heterogeneous hematopoietic stem cell disorders, are characterized by 
abnormal bone marrow differentiation & maturation, morphologically and functionally 
changed progenitors and a variable risk of evolution to acute leukemia. Paraneoplastic 
Glomerulonephritis(PGN), a rare secondary cause of glomerulonephritis and a complication 
of cancer remains a challenge to both nephrologists and oncologists. Studies to identify 
diagnostic biomarkers of PGN in blood, urine, or kidney biopsy samples by use of proteomic 
or other approaches are critically needed to facilitate the early diagnosis of this disease.
SA-PO082
Eculizumab in Gemcitabine Induced Atypical Hemolytic Uremic Syndrome 
aHUS  Mohit Gupta, Rupesh Raina, Natthavat Tanphaichitr.  Dept of Nephrology, 
Akron General Medical Center, Cleveland, OH.
Introduction: HUS (aHUS) is caused by endothelial damage due uncontrolled 
activation of complement system. Gemcitabine a nucleoside analog induced HUS (GiHUS) 
is rare. We report a patient with unresectable, locally advanced pancreatic cancer who 
developed a HUS after 1 months of gemcitabine.
Case Description: A 64 year-old female was diagnosed with 4 cm mass adenocarcinoma 
of the pancreatic head, after extensive evaluation of recurrent abdominal associated with 
clay colored stool. She underwent three cycles of gemcitabine at 1,000 mg/square meter. 
Her condition deteriorated over the following 1 weeks and developed microangiopathic 
hemolysis, rapidly declining renal function with proteinuria and hematuria, and renal biopsy 
of the last dose. Other markers of hemolysis namely LDH and bilirubin had dramatic 
improvement after 2 treatment of Eculizumab.
Pt was consequently treated with Eculizumab for management of atypical HUS. She 
received 1 dose of Eculizumab IV every week after which she was transitioned to once 
monthly for a total of nine doses. Pt’s Creatinine Clearance was closely monitored and 
had significantly improved from 14 mL/min at the time of onset to 60 mL/min by the time 
of the last dose. Other markers of hemolysis namely LDH and bilirubin had dramatic 
improvement after 2 treatment of Eculizumab.
Discussion: HUS associated with gemcitabine is quite rare and no consistent risk 
factors have been Identified. Conventional treatment with hemodialysis, or corticosteroids 
or plasmaphresis as minimal response.The rapid clinical response to eculizumab supports 
the concept that GiHUS might involve aberrant and autonomous complement activation. 
The dramatic resolution of symptoms after eculizumab administration suggests that 
chemothearpy induce aHUS is an area deserving further careful investigation of therapeutic 
complement blockade.
SA-PO083
A Case of Rapidly Progressive Idiopathic Mempranoproliferative 
Glomerulonephritis Effectively Treated with High-Dose Steroid Therapy 
Bernice Kim, Kyung Soo Kim.  Div of Nephrology, Dept of Internal Medicine, 
Dongguk Univ Ilsan Hospital, Goyang, Republic of Korea.
Introduction: Membranoproliferative glomerulonephritis (MPGN) is an uncommon 
kidney disorder which can be idiopathic or secondary in etiology. As diagnostic methods 
improved over time, secondary cause of MPGN is increasingly defined and the truly 
idiopathic form is now a very rare condition. Because of the rarity of idiopathic MPGN, 
treatment guidance is based mainly on case series and the natural history of the disease 
is unclear. We present a case of rapidly progressive idiopathic MPGN effectively treated 
with high-dose steroid.
Case Description: A 73-year-old male was admitted because of subtrochanteric 
fracture. On admission, he had normal kidney function with serum creatinine (sCr) level 
of 1.02 mg/dL. 5 days after the operation of fracture, he was referred to the nephrology 
department due to abruptly increased level of sCr. On postoperative day 10, despite adequate 
intravenous hydration, he became anuric and sCr rose to 4.40 mg/dL requiring hemodialysis. 
Serum C3 level was low (38mg/dL). Kidney biopsy revealed mesangiocapillary 
proliferation, duplication of the glomerular basement membranes, subendothelial deposits 
and predominant C3 immunofluorescent staining suggestive of MPGN type I. Secondary 
causes such as infection, autoimmune disease, monoclonal gammopathy, neoplasia, 
complement dysregulation were excluded. He was diagnosed as idiopathic MPGN type I 
and high dose steroid therapy (40mg/day of prednisolone) was initiated. After 17 days of 
therapy, urine output was increased and dialysis was discontinued accordingly. Prednisolone 
was gradually tapered to 5mg over 1 month and he was discharged with sCr of 1.39 mg/dL.
Discussion: The early trials of the treatment of idiopathic MPGN have given 
inconsistent results, and should be interpreted with great caution since many of the reports 
likely included cases of secondary MPGN. The clinical presentation of MPGN is variable, 
from benign and slowly progressive to rapidly progressive, and different therapeutic 
approach should be applied in regard of the disease course. Studies are needed to identify 
the natural course and effective treatment of MPGN.
SA-PO084
A Case of Advanced IgG4 Related Tubulointerstitial Nephritis Complicating 
Multiple Lymphadenopathy and Intrathoracic Nodule, Mimicking 
Malignant Lymphoma  Shigeto Horita, Hiroshi Fujii, Yuhei Fujisawa, 
Satoshi Hara, Yasunori Suzuki, Kazunori Yamada, Mitsuhiro Kawano.  Div 
of Rheumatology, Kanazawa Univ Graduate School of Medicine, Kanazawa, 
Ishikawa, Japan.
Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a systemic 
inflammatory disorder characterized by mass-forming lesions with IgG4-producing plasma 
cells. We describe a patient with IgG4-RD associated with advanced tubulointerstitial 
nephritis, membranous nephropathy, and multiple lymphadenopathy, mimicking malignant 
lymphoma.
Case Description: Four months prior to this admission, an 81-year-old male 
experienced anorexia and weight loss. Enhanced CT revealed gastric cancer, intrathoracic 
nodule, multiple defects of contrast medium in the kidneys and abdominal periaortitis. The 
patient’s serum Cr level was 1.1 mg/dl and IgG4 level was 390 mg/dl. One month prior to 
this admission, the patient had received gastrectomy. After gastrectomy, decreased renal 
function (Cr 2.09 mg/dl), elevation of IgG4, and hypocomplementemia were detected. 
A renal biopsy showed marked infiltration by IgG4-positive plasma cells, spiking and 
bubbling on PAM staining, and granular deposits of IgG on immunofluorescent staining. 
The patient was diagnosed with IgG4 related tubulointerstitial nephritis and membranous 
nephropathy. PET showed accumulation of fluorodeoxyglucose in the submandibular glands, 
lymph nodes, kidneys, abdominal aorta and prostate, which were hard to distinguish from 
malignant lymphoma. Biopsy of the largest lymph nodes in the axilla and intrathoracic 
nodule showed reactive lymphadenopathy with IgG4 positive plasma cell infiltration. One 
month after starting prednisolone (25 mg/day), Cr level was partially decreased to 1.1mg/
dl and, the size of the lymph nodes and intrathoracic nodule reduced.
Discussion: Findings of IgG4-RD often mimic those of malignancies, so the 
differentiation of malignancies from IgG4-RD is important. In this regard, pathological 
findings of the affected organs are important to make the correct diagnosis. As severe renal 
dysfunction might develop during a several month period, IgG4-related kidney disease 
should be considered as a cause of renal dysfunction of unknown origin, especially in 
elderly men.
SA-PO085
Presence of PLA-2R Autoantibodies in a Patient with Clinical and 
Histopathological Evidence Suggestive of Secondary Membranous 
Nephropathy  Kristen P. Tamura, Niti Madan.  Nephrology, UC Davis Medical 
Center, Sacramento, CA.
Introduction: Differentiating between secondary membranous and idiopathic 
membranous nephropathy (IMN) is based on histopathology showing proliferative features 
in mesangium, full-house staining pattern, electron dense deposits in the mesangium and 
tubular basement membrane . Phospholipase A2 receptor (PLA2R) has been identified is a 
major target antigen involved in IMN pathogenesis. We describe here a patient with clinical 
history and histopathology suggestive of secondary membranous and positive anti-PLA2R 
antibody suggestive of IMN.
Case Description: A 56 year old Caucasian man with history of colon tubular adenoma, 
NHL- status post chemotherapy and radiation 30 years back, hypothyroidism presented with 
new- onset nephrotic-range proteinuria. He was not taking any medications and physical 
exam noted generalized edema. Laboratory exam as noted in table 1. 
Proteinuria in 
24 hrs Creatinine Albumin
Anti-PLA2R 
IFA titres
At Diagnosis 9 gms 0.85 mg/dL 1.8 g/dL 1:1000
6 months of conservative 
therapy 11 gms 1.3 mg/dL 1.6 g/dL
3 months of Ponticelli 
regimen 7.3 gms 1.5 mg/dL 2.2 g/dL 1:20
A renal biopsy showed variable-sized electron dense deposits in subepithelial,intra
membranous,mesangial and paramesangial locations. This finding strongly suggested a 
secondary etiology for the membranous nephropathy. Workup for infectious,autoimmune 
and neoplastic causes of membranous nephropathy was negative. Proteinuria worsened to 
11 g/24h despite six months of conservative therapy with lisinopril and low protein diet. 
Additional labs obtained came back positive for PLA2R autoantibodies (IFA 1:1000,ELISA 
976.6 RU/ml). Kidney stained positive for PLA2R glomerular deposits suggesting IMN. 
The patient was then treated with a modified Ponticelli protocol using alternating monthly 
prednisone and oral cyclophosphamide (2 mg/kg/d) for six months. After three months, 
proteinuria , albumin and edema improved.
Discussion: Relying on histopathologic differences to distinguish between idiopathic 
and secondary membranous nephropathy may lead to incorrect diagnosis and delay in 
treatment.The presence of circulating and tissue PLA2R autoantibodies may be more 
reliable in diagnosing IMN than histopathology.
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SA-PO086
Silent Malakoplakia in a Recipient of Kidney-Pancreas Transplant 
Diagnosed on Surveillance Biopsy of Kidney Allograft: A Patient-Centered 
Approach to Treatment of Malakoplakia  Jun Shoji,1 Ravinder K. Wali.2  1Dept 
of Kidney Disease and Hypertension, George Washington Univ, Washington, 
DC; 2Inova Transplant Center, Inova Fairfax Hospital, Falls Church, VA.
Introduction: Malakoplakia is an inflammatory disease leading to chronic morbidity 
and organ dysfunction. It was originally described in association with genitourinary 
tract infections with coliform bacteria and can manifest as acute pyelonephritis, acute or 
chronic renal failure, or renal mass. We present a case of a 40-year-old female recipient of 
simultaneous pancreas-kidney transplant who developed an acute rise in serum creatinine 
without apparent cause and found to have malakoplakia on kidney allograft biopsy. 
Patient-centered treatment resulted in reversal of allograft dysfunction and resolution of 
histological features of malakoplakia.
Case Description: 40-year-old Caucasian female with type 1 diabetes mellitus and 
end-stage renal disease on peritoneal dialysis underwent SPK transplant. After induction 
with thymoglobulin, she was maintained on tacrolimus and mycophenolate mofetil. Two 
months later, she was treated for acute T-cell mediated rejection (Banff Grade IA) with 
thymoglobulin. Serum creatinine returned to baseline and maintenance prednisone was 
added to her regimen. Her posttransplant course was complicated by multiple infections 
including parvovirus B19 infection, primary CMV infection, two episodes of urinary tract 
infections, and influenza A pneumonia. Due to an increase in serum creatinine without 
apparent cause, a kidney allograft biopsy was performed which revealed lesions consistent 
with malakoplakia.
Discussion: Treatment of malakoplakia in kidney transplant recipients is not well 
established but include surgical resection and use of antimicrobial agents. In the era of 
cyclosporine and azathioprine, it was speculated that the use of azathioprine may be 
associated with the development of malakoplakia. Discontinuation of azathioprine was 
shown to restore bactericidal activity of mononuclear cells. This case report illustrates 
that in the era of immunosuppression with tacrolimus and mycophenolate mofetil, the 
maintenance therapy with tacrolimus may be continued while treating for malakoplakia.
SA-PO087
Common Weight Loss Medication Pill “Qsymia” Causing Hypokalemia and 
Renal Tubular Acidosis  Jyotsana Thakkar, Mala Sachdeva.  Div of Nephrology, 
North Shore -LIJ School of Medicine, Great Neck, NY.
Introduction: The obesity epidemic is growing. Aside from the traditional diet and 
exercise, weight loss pills are more commonly prescribed. Qsymia is one such weight loss 
pill consisting of topiramate and phentermine. We report potentially life threatening side 
effects of Qsymia causing severe hypokalemia, proximal renal tubular acidosis (pRTA), 
and cardiac dysrhythmia.
Case Description: A 68 year old female with history of hypertension presented with 
complaints of tingling of her left arm and jaw of one day duration. Her home medications 
included Aspirin and Hyzaar (Losartan and Hydrochlorothiazide). She had self discontinued 
the Hyzaar five days prior to presentation. Patient was recently started on the weight loss 
medication “Qsymia” three months prior. She denied any alcohol use. On initial presentation, 
she was noted to be in atrial fibrillation (HR 150s) and hypotensive (BP 84/43 mmHg) 
requiring cardioversion. Subsequent cardiac catherization and echocardiogram were 
unremarkable. Initial lab data showed severe hypokalemia-2.4 mmol/L, creatinine 1.08 mg/
dL, bicarbonate 22 mmol/L, phosphorus 2.1 mg/dL, magnesium 2.2 mg/dL, and calcium 
8.9 mg/dL. Urinalysis showed pH 8 with glucosuria. Urine Lytes showed potassium 38 
mmol/L, chloride 43 mmol/dL, and sodium 141 mmol/L.
It was suggested that patient’s clinical presentation and electrolyte disorders were 
due to the weight loss medication, and Qsymia was discontinued. Qsymia was approved 
by FDA in 2012 for weight loss. Most common side effects reported include paresthesia, 
dizziness, insomnia, constipation and dry mouth. In the U.S., drug label contains warnings 
for increased heart rate. Topiramate is known to cause pRTA. Our patient had mild acidosis, 
hypophosphatemia and glucosuria which we believe was a result of an early pRTA, induced 
by topiramate. Although hydrochlorothiazide is known to cause hypokalemia, our patient 
was not taking the medication for five days.
Discussion: Weight loss medications are now being more commonly used to treat 
obesity. Prescribers should be aware of the potential nephrotoxic side effects of Qsymia. 
Monitoring serum potassium and bicarbonate levels regularly should be taken into 
consideration.
SA-PO088
Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy 
Venkata Buddharaju, Liga Yusvirazi, Anastasios Papanagnou, Savneek S. Chugh, 
Rahul N. Pawar.  Nephrology, Westchester Medical Center, Valhalla, NY.
Introduction: Thrombotic microangiopathy (TMA) describes a pathological process of 
microvascular thrombosis, consumptive thrombocytopenia and microangiopathic hemolytic 
anemia, leading to end-organ ischemia and infarction affecting particularly the kidney and 
brain. TMA is a pathological feature of a number of clinical disorders including Hemolytic 
uremic syndrome (HUS) and atypical HUS. Rare but important, TMA may also occur in 
malignancy, connective tissue disease, malignant hypertension, and renal transplantation 
(rejection or drug toxicity). We present a rare case where patient developed AKI from TMA 
but found to have plasma cell dyscrasia as possible underlying etiology.
Case Description: A 42 y/o man with h/o myopathy, questionable mixed connective 
tissue disorder on prednisone and cellcept, Pulmonary Hypertension on home oxygen, 
CHF with preserved EF and Anemia requiring multiple transfusions went to an outside 
hospital with SOB and pedal edema found to have AKI with serum creatinine of 4 and 2+ 
proteinuria.  Serologies were negative except for anti-RNP and ESR; with no improvement 
in renal function the patient had a renal biopsy which showed TMA, mild fibrosis and 
atherosclerosis. The patient was Started on RRT and then transferred to Westchester medical 
center for treatment with Eculizimab for atypical HUS. After reviewing the labs we ordered 
Serum and urine protein electrophoresis which showed monoclonal Ig M spike, the patient 
underwent bone marrow biopsy which showed Plasmacytoma with 18% Plasma cells. 
The patient’s renal function improved in the hospital stay and stabilized with creatinine of 
around 2.0 mg/dl, but unfortunately the patient had a severe sepsis and passed away before 
initiation of management for Multiple myeloma.
Discussion: Multiple Myeloma accounts for 10% of hematological malignancies. 
Atleast 50% of patients with MM have evidence renal insufficiency and more than 80% 
have proteinuria. Multiple myeloma can present as has wide range of renal manifestations 
including myeloma cast nephropathy, Immune deposition disease, CKD Fanconi syndrome. 
Though rare Multiple myeloma can cause TMA and the Pathogenesis still remains unclear.
SA-PO089
Drug-Induced Acute Interstitial Nephritis Managed with Early and 
Aggressive Steroid Therapy  Radhika Vemuri, Abhilash Koratala, Keerti K. 
Bhanushali, William L. Clapp, Saraswathi Gopal.  Nephrology, Univ of Florida, 
Gainesville.
Introduction: Pantoprazole (PPZ), a Proton Pump Inhibitor, is known to cause acute 
interstitial nephritis (AIN). We report a case of PPZ induced AIN in a young adult with 
just 3 doses of drug exposure.
Case Description: A 21 year old Asian American male with no past medical history 
was sent to the hospital by his Internist for elevated serum creatinine (Scr). He had nausea 
and abdominal pain 3 weeks earlier and was prescribed PPZ, which he took for 3 days. He 
denied use of any other medications including herbal supplements and NSAIDs. Laboratory 
data showed BUN of 82 mg/dL , Scr 15 mg/dL (baseline 0.6) , bicarbonate of 15 mmol/L 
and no serum osmolar gap.Urinalysis showed sterile pyuria with no eosinophils , glycosuria 
with normal blood glucose , mild proteinuria (900mg/24 hrs). Serum and urine toxicology, 
protein electrophoresis, auto-immune work up were unremarkable. A Renal biopsy revealed 
diffuse expansion of the interstitium due to accumulation of cellular infiltrates consisting of 
lymphocytes, plasma cells and eosinophils with accompanying tubulitis consistent with AIN. 
He received pulse steroids for 3 days and was continued on prednisone 1mg/kg/day 
with a plan to taper over 8-12 weeks .He required a few sessions of renal replacement 
therapy before his renal function started to recover, 6 weeks later his Scr was 1.4 mg/dl.
Discussion: Any drug can cause AIN, although the categories of antibiotics, diuretics 
and NSAIDs are most commonly implicated. Drug-induced AIN is not dose dependent, 
and recurrence can occur with a second exposure to the same or a related drug. The data on 
time of initiation, dosage and duration of steroids in drug induced AIN is limited due to lack 
of randomized control trials. On review of literature and our experience, we conclude that 
stopping the culprit agent and early steroid use confers better prognosis in drug induced AIN.
SA-PO090
Metastatic Sarcomatoid Carcinoma of Urothelial Origin in Failed Renal 
Allograft  Venkata Buddharaju, Rajat Lamba, Daniel G. Glicklich.  Nephrology, 
Westchester Medical Center, Valhalla, NY.
Introduction: Renal cell carcinomas are more common in ESRD than the general 
population and renal transplant patients with enhanced longevity may be at particular risk. 
Sarcomatoid renal cell carcinoma represents 1-15% of all renal cell carcinomas but has 
been very rarely described in renal allograft. The median age at diagnosis is 60years with 
45-77% of patients with locally advanced or metastatic disease at the time of diagnosis. 
We describe a case sarcomatoid tumor of urothelial origin in a transplanted renal allograft.
Case Description: A 54 y/o man with ESRD from polycystic kidney disease, HTN, 
aortic dissection repair, mechanical AVR, paroxysmal Afib, who had 2 failed renal 
transplants in the past and was on dialysis for past 12 years, was admitted for left lower 
quadrant pain, fever and leukocytosis for which he was started on vancomycin and 
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aztreonam. On imagine, he was found to have a mass around the left transplant kidney, 
ascites, omental caking, retroperitoneal lymphadenopathy and heterogeneous liver lesions. 
Retroperitoenal lymph node biopsy and ascitic fluid cytology was negative for malignant 
cells. Left kidney mass could not be biopsied because of technical difficulties and he had 
biopsy of the liver lesions which showed sarcomatoid tumor. He developed respiratory 
failure and septic shock requiring pressor support and expired. An autopsy was performed 
which showed Metastatic Sarcomatoiid carcinioma of urothelial origin.
Discussion: Malignancy in post transplant is related to direct effects of immune-
suppressants as well as their effects to suppress immune surveillance and to stimulate the 
activation of oncogenic viruses. It is generally recommended that patients on the active 
transplant list and renal transplant recipients be screened every several years for renal 
tumors. However after allograft failure, it is unclear how often to do cancer screening 
tests. Although in this particular case it is unclear whether screening would have made a 
difference in outcome, we recommend routine screening for renal cell carcinoma even if 
the renal allograft has failed.
SA-PO091
Parathyroidectomy on a Patient with Sickle Cell Disease and End Stage 
Renal Disease  Farouk Talakshi, Mary C. Mallappallil, David Kau, Moro O. 
Salifu.  Suny Downstate Medical Center, Brooklyn, NY.
Introduction: Patients with End Stage Renal Disease (ESRD) can develop elevated 
parathyroid hormone (PTH) levels with hypercalcemia. Some fail or cannot tolerate medical 
therapy. They eventually require parathyroidectomy. Tertiary hyperparathyroidism (3HPTH) 
is the autonomous function of the parathyroid gland due to increased mass. Our case is 
unique as there are no reported cases of tertiary hyperparathyroidism in sickle cell patient, 
where symptoms of renal osteodystrophy mask vaso-occlusive crisis which improved 
with parathyroidectomy. 25 year old man with sickle cell disease, ESRD on hemodialysis 
since 2012, (3HPT), presents after many admissions for sickle cell pain crisis. Cause of 
ESRD was unknown but attributed to sickle cell nephropathy. Current admission for knee 
pain, imaging of which showed “sclerotic appearance of the bones, likely due to renal 
osteodystrophy”. Intact PTH (iPTH) consistently > 4000 pg/mL, and patient non adherent to 
cinacalcet, agreed to parathyroidectomy after many admissions for presumed vasoocclusive 
crisis. CT neck:”moderately enhancing foci inferior to the left and right thyroid lobes, and 
superior to the left thyroid lobe, could be compatible with parathyroid adenomas. “Sestamibi 
scan:”equivocal slow washout focus in region of right lower pole of thyroid gland extending 
posteriorly. Suspicious for but not definitive for parathyroid adenoma”.On the day prior 
to surgery, iPTH =4078 pg/mL with serum calcium (Ca)=10.3 mg/dl. Immediately after 
surgery, iPTH=265 pg/mL with Ca=8.9 mg/dl. The first day after surgery, iPTH=36 pg/
mL with Ca=7.6 mg/dl. Patient admitted for 3 weeks due to his requirement of intravenous 
calcium and daily hemodialysis. Since discharge, patient has had fewer admissions for pain. 
He has however, remained hypocalcemic and is on 5 grams of calcium carbonate, 4 mcg 
of doxercalciferol, and is dialyzed with a 3 mEq/L calcium bath.
Discussion: 3PTH is common in ESRD patients that can leave them debilitated. Those 
who fail medical therapy may benefit from resection. In sickle cell disease symptoms of 
3PTH was masked by vaso-occlusive crises and could be distinguished by marked reduction 
in symptoms after resection.
SA-PO092
Synthetic Cannabinoid (SC) in End Stage Renal Disease  Chyi Chyi Chong,1 
Pallavi D. Shirsat,1 Ramesh Marahatta,1 Neville R. Dossabhoy.1,2  1LSU Health 
Science Center, Shreveport; 2VA Medical Center, Shreveport.
Introduction: Synthetic cannabinoid (SC) are drugs of abuse especially among 
young adults. They are affordable, widely available and mostly importantly undetectable 
by standard urine toxicology screen. The avoidance of detection in the urine contributes 
to their allure and abuse.  Acute kidney injury (AKI) related to synthetic cannabinoids has 
been reported. However, effect of synthetic marijuana in end stage renal disease (ESRD) 
patients remains unknown.
Case Description: We present a case of severe high anion gap metabolic acidosis 
(HAGMA) with acute respiratory failure in an ESRD patient. A 37-year-old African 
American female with ESRD, hepatitis C and hypertension was found smoking synthetic 
marijuana under a tree, and in a confused state. Upon arrival to the emergency room, 
patient was severely hypertensive with blood pressure of 230/140 mmHg, and subsequently 
developed acute respiratory failure requiring intubation. Chest x-ray showed bilateral 
pulmonary edema. Laboratory data revealed: WBC 18K/uL, Na 138 mEq/L, K 3.6 mEq/L, 
Cl 104 mEq/L, CO2 10 mEq/L, Anion Gap 24. On Blood Gas: pH 6.95, pCO2 42 mmHg, 
pO2 73 mmHg, HCO3 8.3 mmHg. Urine drug screen was positive for benzodiazepine and 
cannabinoid. Patient required emergent hemodialysis for severe high anion gap metabolic 
acidosis. Patient required dialysis consecutively for 2 days and anion gap metabolic acidosis 
resolved. She was also successfully extubated on third day of admission.
Discussion: Synthetic Cannabinoids are sold under different trade names and the exact 
compounds contained in these products change frequently and are frequently unknown. 
Therefore, risks and adverse consequences of consuming synthetic cannabinoids are 
unpredictable and can be deadly. Acute tubular necrosis and interstitial nephritis are most 
common findings for patients who developed synthetic cannabinoid related AKI. Treatment 
is supportive management. However, effects on ESRD patients remain unknown. Our 
patient developed (HAGMA), which could very well be related to synthetic marijuana use. 
Physicians should be aware of designer drugs use in ESRD patients.
SA-PO093
Focal Segmental Glomerulosclerosis Associated with Cocaine Abuse: A Case 
Report  Teg Marcos Veiga, Nathalia K.N. Alecrim, André Luiz De Andrade 
Araújo, Gisele Vajgel Fernandes, Luis H.B.C. Sette, Lucila Maria Valente, 
Maria Alina G.M. Cavalcante.  Nephrology, Univ Federal de Pernambuco, 
Recife, Pernambuco, Brazil.
Introduction: Cocaine exists in two major forms: cocaine hydrochloride and 
alkaloidal freebase (crack). Cocaine abuse causes many well recognized systemic adverse 
effects and acute kidney injury is usually due to rhabdomiolysis, malignant hypertension 
with thrombotic microangiopathy and renal infarction. In addition, it has been described 
ANCA-positive vasculitis induced by levamisole-adulterated cocaine causing nephrotic 
syndrome. We report a case of focal segmental glomerulosclerosis in a patient with history 
of cocaine use.
Case Description: A 49 year-old man of admixture race presented with progressive 
edema and dyspnea for the past five months. Lab tests showed Scr 7.0 mg/dL (baseline: 
0.9 mg/dL), hypoalbuminemia, hypercholesterolemia and nephrotic range proteinuria 
(13g/24h). The patient had started using illicit drugs (marihuana and crack) three months 
before the symptoms begun. There was no sign of infection or hypovolemia. All serologic 
tests were normal or negative, including complement, antinuclear antibodies, anti-DNA 
antibody, c-ANCA, p-ANCA, hepatitis B and C, HIV, syphilis and there was no evidence of 
monoclonal serum spike. Renal ultrasound was normal. The patient underwent hemodialysis 
and received metylprednisolone. Renal biopsy showed 13 glomeruli, 6 globally sclerotic 
and 5 with segmental sclerosis and synechiae of the glomerular tuff, tubular atrophy and 
moderate intersticial fibrosis. Imunofluorescence was negative. There was no recovery 
of renal function.
Discussion: Although it has been described nephrotic syndrome due to ANCA-positive 
vasculitis induced by levamisole-adulterated cocaine, we have reported a case that showed 
association between the use of cocaine and focal segmental glomerulosclerosis.
SA-PO094
A Rare Case of Tumor Lysis Syndrome in a Patient with Angiosarcoma 
Bilal J. Alturkmani,1 Michael A. Mao,2 Edward T. Casey.2  1Alfaisal Univ, 
Riyadh, Saudi Arabia; 2The Div of Nephrology and Hypertension, Mayo Clinic, 
Rochester, MN.
Introduction: To report a rare case of tumor lysis syndrome (TLS) developing in a 
patient with angiosarcoma and metastasis to the liver.
Case Description: A 63-year-old male presented to his primary care physician 
complaining of fatigue, night sweats, fever, and newly developed RUQ pain. An ultrasound 
of the abdomen revealed hepatic lesions and a subsequent CT scan showed two large 
masses in the liver and a mass in the pancreas. A liver biopsy was obtained and findings 
were consistent with metastatic angiosarcoma and he was therefore initiated on palliative 
chemotherapy. The patient then presented to his local hospital with abdominal pain and 
abdominal bruises. His hemoglobin was 4.9 g/dL and he was found to be bleeding from 
the liver biopsy site. He was transferred to our institution for embolization in setting of 
intra-abdominal bleeding and multiorgan dysfunction. His clinical presentation, along with 
laboratory findings, was consistent with anuric renal failure secondary to TLS. 
Table 1
Laboratory Values Three days prior to hospitalization
On admission to 
Mayo Reference Ranges, Units
Creatinine 1.4 2.7 [0.8-1.3], mg/dL
Potassium 4.3 6.6 [3.6-5.2], mmol/L
Uric Acid - 16.3 [3.7-8.0], mg/dL
Calcium 8.2 - [8.9-10.1], mg/dL
Ionized Calcium - 4.29 [4.65-5.30], mg/dL
Phosphorus - 8.4 [2.5-4.5], mg/dL
The patient was initiated on allopurinol, rasburicase, and continuous veno-venous 
hemofiltration (CVVH). He progressively deteriorated during his 11-day hospital course 
with recurrent episodes of arrhythmia, persistent encephalopathy, continued mechanical 
ventilator and hemodialysis dependence, and refractory septic shock with candidemia. The 
family elected for comfort care and the patient expired the next day.
Discussion: TLS is a constellation of laboratory and/or clinical manifestations that can 
arise either spontaneously or secondary to cancer treatments. Patients with hematological 
malignancies have a higher tendency to develop this syndrome due to the rapid turnover 
of cell growth and death. However, patients with solid tumors occasionally present with 
TLS. To our knowledge, this is the first case report of TLS associated with angiosarcoma.
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SA-PO095
Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: 
A Case Report  Alejandro Pepen Romero,1 James Drakakis,1 Joseph Mattana.1 
1Nephrology Dept, Winthrop Univ Hospital, Mineola, NY; 2Pathology Dept, 
Columbia Univ, New York, NY.
Introduction: ALECT2 amyloidosis is a frequent form of systemic amyloidosis, 
represents 2.7-10% of all cases of renal amyloidosis. Most patients are elderly who presents 
with chronic renal insufficiency and bland urinary sediment.
Case Description: We report a 76-year-old Egyptian male who presented after a recent 
hospitalization for self limited gastroenteritis and severe acute renal failure presumed 
secondary to acute tubular necrosis. Due to non-improving renal function and uremic 
symptoms, renal biopsy was done and showed patchy Interstitial amyloidosis deposits that 
did not stain for IgG, IgM, IgA, Kappa, Lambda chains or Amyloid A; sample was sent to 
Mayo Clinic where Liquid chromatography tandem mass spectrometry detected a peptide 
profile consistent with ALECT2 Amyloidosis.
Discussion: This case suggests that ALECT2 Amyloid can present with bland 
urianalysis and non-nephrotic range proteinuria in elderly patients.
SA-PO096
Monitoring Disease Activity in ANCA Associated Vasculitis (AAV): A 
Case for Activated Circulating Monocytes?  Florian Gunnar Scurt,1 Leon 
Brian Schubert,1 Noemi Rose Emma Doll,1 Marius Früh,1 Tobias Hölscher,2 
Andreas Jeron,2 Dunja Bruder,2 Peter R. Mertens,1 Christos D. Chatzikyrkou.1 
1Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke 
Univ Magdeburg; 2Inst of Microbiology, Otto von Guericke Univ Magdeburg.
Introduction: We are still in need for more reliable markers to monitor disease 
activity in AAV.
Case Description: The clinical course of a patient with therapy refractory AAV is 
presented .
Disease activity was assessed by means of the BVAS and VDI score and by serial 
measurements of the CD19/CD20 cell count and the MPO titer. The last renal flare was 
on 11/2014 and was corroborated by renal biopsy. Monocyte subsets were also identified 
by flow cytometry with the use of the surface markers CD 14, CD 16 CCR2 and CxCR3. 
The expression of different proteins reflecting antigen presentation or activation status as 
well as scavenger receptor and toll like receptor functions was quantified in the monocyte 
subpopulations. Blood samples of a healthy individual were used as controls. Results of 
the antigen presentation marker HLA-DR and the monocyte activation marker CD 11b 
are presented here.
Renal and pulmonary disease progressed despite the use of an impressive 
immunosuppressive therapy. The CD19/CD20 cell count and the MPO titer did not predict 
relapse. The intermediate CD14++CD16+CCR2lowCXCR1+ monocyte subpopulation 
was increased but expressed less of the HLA-DR protein. The CD11b antigen expression 
was reduced in the classical monocyte subpopulation CD14++CD16-CCR2highCXCR1-, 
whereas no differences in the HLA-DR and CD 11b expression were observed in the non-
classical monocyte subpopulation CD14+CD16+CCR2lowCXCR1high.
Discussion: There appear to be functional alterations in the different monocyte 
subpopulations during relapse of AAV. Their pathophysiological significance remains to 
be elucidated.
SA-PO097
A Case of Rhabdomyolysis Induced AKI with Two Questions: Serum 
Myoglobin versus CPK and the Potential Role for Rasburicase 
Mehdi Nouri kolouri.  Nephrology, Baylor College of Medicine, Houston, TX.
Introduction: Rhabdomyolysis induced AKI is a common scenario. The mechanisms 
include myoglobin and uric acid crystal induced tubular injury. The role of uric acid lowering 
agents in such condition remains to be defined. Here we describe such a case, in which 
uric acid lowering agent successfully lowered uric acid level and possibly contributed to 
renal function recovery. In this case CPK level was not high enough to justify AKI and a 
very high serum myoglobin level established the diagnosis.
Case Description: a 37 years old man without known history was brought to ER with 
agitation and delusional/combative behavior. Vital signs included temp=100.4, BP=165/85, 
RR=32/min and PR=120/min. On examination, he was mildly volume depleted. He was 
found to have AKI with BUN=76, Cr=4, K=6.7 and metabolic acidosis. Urine toxicology 
was positive for amphetamines. CPK level was 4200 U/L and uric acid level was 21 mg/
dL. Supportive management including aggressive IV fluids was initiated for amphetamine 
toxicity with resultant rhabdomyolysis. Urine exam showed several coarse granular casts. 
Serial CPK levels were not high enough to justify AKI. However serum myoglobin level was 
very high at >20000 ng/mL and confirmed severe rhabdomyolysis. one session of dialysis 
was done due to persistent metabolic acidosis and hyperkalemia. However uric acid level 
remained high at same range. We used a dose of Rasburicase at 3 mg which reduced uric 
acid level to 5.5 six hours later. After few days, renal function and clinical status started to 
improve and he was discharged in stable condition.
Discussion: There may be a therapeutic/prophylactic role for uric acid lowering agents 
in rhabdomyolysis induced AKI. In our case, Rasburicase successfully lowered uric acid 
level after it had remained high post-dialysis. Similar results have been reported in the past, 
however further research is needed in the future. Besides, Although AKI in rhabdomyolysis 
is usually seen with CPK levels>20000, our patient had much lower levels and a very high 
serum myoglobin established the diagnosis of severe rhabdomyolysis. Serum myoglobin 
is more accurate to determine the severity of rhabdomyolysis and predict the risk of AKI.
SA-PO098
Exploring the Utility of Albuminuria  Saman Sarani,1 Ruchika Bhasin,1 
Afsaneh Haftbaradaran,1 Golriz Jafari,1 P.T. T. Pham,2 P.C. Pham.1  1Div of 
Nephrology and Hypertension, Olive View-UCLA Medical Center, Sylmar, CA; 
2Kidney Transplant, UCLA Medical Center, Los Angeles, CA.
Introduction: Patients with underlying glomerular diseases often present with acute 
kidney injury from either acute tubular necrosis (ATN) due to hemodynamic compromise 
such as diuretic overuse versus exacerbation of underlying disease. The clinician is 
often faced with the difficult decision to either provide fluids and supportive care vs. 
intensification of immunosuppressive therapy. Whereas proteinuria associated with ATN 
is presumably predominantly non-albumin protein, proteinuria associated with glomerular 
disease exacerbation is predominantly albuminuria. We follow a case with biopsy proven 
minimal change disease and concurrent ATN and evaluate sequential urine albumin to 
creatinine (MAC) ratio to protein to creatinine (PCR) ratio MAC/PCR over the course of 
treatment for changes.
Case Description: A 63 year old Hispanic male presented with anasarca and blood 
pressure 214/104 mm Hg. Routine evaluation was significant for a serum creatinine (SCr) 
of 1.4 mg/dl, peaked at 1.77 mg/dl, PCR of 12.8 g/g Cr, and MAC of 7.9 g/gCr. Physical 
examination was significant for anasarca. There was no lymphadenopathy noted. Routine 
proteinuria evaluation for hepatitis B and C, RPR, HIV, C3, C4, CH50, ANCA, serum free 
light chains, serum and urine protein electrophoresis and immunofixation were negative. A 
kidney biopsy performed revealed minimal change disease with evidence of marked ATN. 
Patient was treated with a course of prednisone at 1m/kg/day tapered over a 6 month period. 
Patient went into full remission without any complications. Over the course of disease, 
sequential MAC/PCR was noted to increase as PCR and SCr decreased. Presentation: 
Scr 1.44-1.77, MAC=7.9 g/g Cr, PCR=12.8 g/gCr, MAC/PCR=0.62; 2-month follow-up: 
Scr 1.3, MAC=1.6, PCR=1.7, MAC/PCR=0.95; 3-month follow-up: Scr 1.3, MAC=1.4, 
PCR=0.8, MAC/PCR=1.6.
Discussion: The current case indicates that a higher degree of albuminuria relative to 
proteinuria is noted with eventual resolution of ATN. We suggest that MAC/PCR may be 
used as a marker of associated ATN complicating underlying GN. Further studies are needed.
SA-PO099
Idiopathic Eosinophilic Peritonitis After Peritonial Dialysis Catheter 
Placement  Nader S. Bahri, Charles W. Heilig.  Nephrology and Hypertension, 
Univ of Florida, Jacksonville, FL.
Introduction: Idiopathic Eosinophilic peritonitis (IEP) typically occurs soon after 
initiation Peritoneal Dialysis (PD) with variable presentation mimicking bacterial or fungal 
peritonitis. The main etiology of IEP is unclear and many have speculated that it represents an 
allergic reaction to possible plasticizers in the PD bags or catheter or an eosinophilic reaction 
to the solutions, methods of catheter placement or air exchanges during the exchanges.
Case Description: 42 year-old AAF with ESRD from T2DM and hypertension in 
9/2009 was started on hemodialysis (HD) via fistula. She underwent PD training and 
started CAPD on 9/18/2010 with Baxter Ultra bag dextrose solution after laparoscopic 
placement of Quinton Curl PD catheter on 9/2/2010. During follow on 9/30/2010 cloudy 
PD fluid recognized. The patient didn’t have any symptoms of abdominal pain, nausea, 
vomiting, constipation, diarrhea or fatigue. Vital signs were stable .Physical exam didn’t 
show any evidence of site infection or abdominal tenderness and no skin allergic reaction. 
There were no new medications or no current antibiotic therapy since placement of PD 
catheter. PD fluid cell count showed total WBC count of 480/mm³ with 49% eosinophil 
and 1% neutrophil. Gram stain and all bacterial, fungal and AFB cultures were negative. 
CBC showed normal WBC count of 9900/ mm³ with 8.9% eosinophilia. The patient kept 
on PD with close follow ups. empiric antibiotics were discontinued. Repeat PD fluid cell 
count showed total of WBC 327/ mm³ with 20% eosinophil and 6% neutrophil with all 
repeated- cultures negative. AT this point the patient has switched to HD on 11/04/2010 via 
available fistula and PD catheter was kept in place. By 12/28/2010 a sample of peritoneal 
fluid obtained which showed declining of WBC count to 123/mm³ with 7% eosinophil with 
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complete resolution of eosinophilia while the patient was on HD. In 3/28/2011, the patient 
resumed PD via same catheter and same solution, follow up PD fluid sample on 4/07/2011 
showed normal WBC count and 4% eosinophil.
Discussion: Our case suggests IEP was a transient reaction to the catheter placement 
rather than a reaction to the PD set or solution.
SA-PO100
Post Renal Transplant Follow Up in Focal Segmental Glomerulosclerosis 
with 24 Hour Urine Protein Collection – Traditional and True 
Ravinder Pal S. Bhatti, Manisha Singh, Lakshmi P. Nadimpalli, Sameh R. 
Abul-Ezz.  Nephrology, Univ of Arkansas for Medical Sciences, Little Rock, AR.
Introduction: Random Urine Protein Creatinine Ratio (PCR) is commonly used to 
estimate proteinuria compared to 24 hour urine protein measurement (24-UP). However, 
there are concerns over the diagnostic accuracy and reliability of such an approach in post-
transplant setting. We present a case of post-transplant focal segmental glomerulosclerosis 
(FSGS) illustrating this.
Case Description: A 39 year old male with primary FSGS, on peritoneal dialysis for 
4 years received a cadaveric kidney transplant. His panel reactive antibody was 0% and 
HLA cross-match was negative. Peri-operative course was uneventful. Given the history 
of FSGS, PCR was monitored. By post-op day 5, serum creatinine had decreased from 7.3 
mg/dl to 3.2 mg/dl and PCR from 4.3 to 2.8. However, his 24-UP came back 8 g, which 
was markedly different. 
Early recurrence of FSGS was diagnosed. A biopsy was withheld to avoid delay in 
timely management and risk of bleeding with plasmapheresis which was immediately 
initiated. He was switched from tacrolimus to cyclosporine. He required plasmapheresis 
for 5 weeks and had satisfactory recovery in the ensuing months.
Discussion: Logistics have led to the widespread use of PCR in follow-up of kidney 
transplant recipients. However changing creatinine excretion with recovering renal function, 
lower precision with heavier proteinuria, and limited data on accuracy compared to 24-UP, 
potentially limit its utility at detecting early post-transplant recurrence of FSGS. Our case 
highlights marked discordance between the PCR and 24-UP, detection of which allowed 
a timely change in management. We conclude that it is prudent to monitor proteinuria by 
timed urine collection in preference to random PCR in the immediate post-transplant setting 
for recipients with primary FSGS.
SA-PO101
Donor Kidney Lithiasis: A Case of Throwing Out the Baby with the 
Bathwater?  Ravinder Pal S. Bhatti,1 Sameh R. Abul-Ezz,1 Lakshmi P. 
Nadimpalli,1 Gary Wickens Barone.2  1Nephrology; 2Transplant Surgery, Univ 
of Arkansas for Medical Sciences, Little Rock, AR.
Introduction: Cadaveric kidneys account for a majority of transplants in the United 
States. However, only 10% of waitlisted patients receive one annually, making optimal 
utilization critical. Donor nephrolithiasis represent a small yet significant proportion of 
kidneys discarded. We present a patient who received such a kidney which otherwise 
could have been discarded.
Case Description: The donor was a healthy 31 year old female who suffered anoxic 
brain injury in a motor vehicle accident. Her CT abdomen showed 2 stones in the right 
kidney as represented in the figure’s inset. The kidney became available to us on a regional 
list after it was declined locally due to concerns over kidney quality. Our recipient was a 50 
year old female with hypertensive nephropathy, on hemodialysis for the past 2 years. Her 
panel reactive antibody was 90% and HLA cross match was negative. Intra-operatively, 
a large stone measuring 2 cm was identified in the hilum of the donor kidney and was 
extracted via pyelotomy. A smaller middle calyceal stone was localized by fluoroscopy 
and successfully removed by irrigation. 
There were no perioperative complications and the recipient had excellent immediate 
graft function. Her creatinine progressively improved by time of discharge, remaining 
normal in subsequent months.
Discussion: The new kidney allocation policy aims to address organ shortage by 
reducing donor and graft survival mismatch. Traditionally, donor hemodynamics, age, 
serum creatinine and histopathology have influenced decisions on accepting a kidney. The 
perceived quality and utilization techniques widely vary for deceased donor kidneys with 
lithiasis. Our case illustrates how this can lead to non-acceptance of an otherwise healthy 
kidney, which can be transplanted with a favorable outcome.
SA-PO102
A Peritoneal Dialysis Catheter Leak Complicated by Burkholderia Gladioli 
Peritonitis  Ravinder Pal S. Bhatti, Dumitru Rotaru.  Nephrology, Univ of 
Arkansas for Medical Sciences, Little Rock, AR.
Introduction: Dialysate leaks can occur any time after peritoneal dialysis (PD) catheter 
placement. Early leaks usually manifest as an exit site leak, though may also present with 
air in the PD catheter. Leaks increase the risk for exit site infections (ESI) and peritonitis. 
We present such a patient developing peritonitis with an unusual pathogen.
Case Description: A 74 year old male who had been on Continuous Cycling Peritoneal 
Dialysis for 3 years, presented with exit site erythema a week after trying to push in an 
extruded cuff. Prophylactic antibiotics were started but he declined surgery. The ESI recurred 
soon after completing 3 weeks of antibiotics. He agreed to catheter replacement with an 
exit site change. He was started on low volume exchanges. Two weeks later, he noted air 
bubbles in the PD catheter upon draining. 
A small pinhole was found at the exit site, suspected to be from a sharp injury during 
dressing change. He was planned for surgical revision but soon started having turbid 
drainage. Instilled dialysate was cultured, broad spectrum intravenous antibiotics were 
started and he was switched to hemodialysis. During surgery, the damaged catheter was 
spliced to new tubing proximal to the exit site. The cultures grew Burkholderia Gladioli 
by now. PD was resumed the next day. The peritonitis resolved during the 3 weeks of 
antibiotics. He continued PD uneventfully over ensuing months.
Discussion: A rare observation, air in a PD catheter is almost pathognomic of a dialysate 
leak. Our case highlights several key points in such a scenario. Firstly, use of sharps is 
a major risk factor and should be discouraged. Secondly, an increased risk of peritonitis 
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including by rare pathogens warrants appropriate antibiotic prophylaxis and lastly a more 
limited approach than catheter exchange may be used even for leaks close to exit sites 
based on the location and local experience.
SA-PO103
Enteric Hyperoxaluria Related to Celiac Disease Causing Acute Kidney 
Injury After Kidney Transplantation  Ashvin Baru, Venkat Ramanathan. 
Nephrology, Baylor College of Medicine, Houston, TX.
Introduction: Acute kidney injury (AKI) after kidney transplantation can occur from 
myriad of causes. We present an interesting case of a young woman with history of Celiac 
disease who developed AKI and biopsy-proven oxalate nephropathy within 3 months post-
transplantation, as a result of enteric hyperoxaluria associated with gluten noncompliance.
Case Description: A 35 year-old woman with type 1 diabetes mellitus, and celiac 
disease underwent living unrelated kidney transplantation for ESRD related to biopsy-
proven diabetic nephropathy. Her original renal ultrasound did not show nephrocalcinosis. 
After transplantation, nadir serum creatinine was 1.0 mg/dL. Three months later, she 
presented with six-day history of diarrhea and AKI. Serum creatinine peaked at 2.6 mg/
dL. Since volume replacement did not improve her allograft function and she had high 
panel reactive antibody levels pre-transplant, a kidney biopsy was performed that showed 
acute tubular injury with significant oxalate crystalline deposits. Initial serum oxalate level 
was undetectable, but 24-hour urine oxalate excretion was elevated at 98 mg/dL. Pending 
gene testing, she was treated with intravenous fluids, low oxalate diet, gluten free diet, 
vitamin B6, oral alkali and calcium carbonate. Subsequent gene testing did not reveal gene 
mutation in the oxalate pathway. Her urine output was maintained between 3 to 4L per day. 
With strict gluten avoidance and low oxalate diet, urine alkalinization and oral calcium, 
her allograft function has improved to baseline.
Discussion: Celiac disease exacerbation and subsequent malabsorption can lead to 
significant gut oxalate absorption and hyperoxaluria. Resulting oxalate nephropathy is a 
rare cause of AKI after kidney transplantation.
SA-PO104
Unusual Presentation of Tumor Related Membranous Nephropathy 
Tahir Zaman,1 Frederic Clayton,2 Josephine Abraham.1  1Nephrology, Univ of 
Utah, Salt Lake City, UT; 2Pathology, Univ of Utah, Salt Lake City, UT.
Introduction: The literature is laden with evidence of several solid tumors causing 
secondary membranous nephropathy. It is also described in the literature that solid tumors 
could also ANA positivity.1
Case Description: A 62-year-old male with a history of hypertension presented with 
oliguric renal failure following an episode of gastroenteritis. History was unremarkable 
with patient denying smoking or other vices. Urine analysis revealed rare dysmorphic 
RBC’s and minimal proteinuria (spot protein/creatinine ratio 0.5 gms). Serologic workup 
revealed +PR3 (ANCA negative) and abnormal Kappa/Lamda Ratio thus renal biopsy was 
performed, which revealed membranous nephropathy and acute tubular necrosis (ATN). 
Immunofluorescence was positive for C3, IgG, though negative for PLA-2R, IgA and 
C1q. ANA was strongly positive (1:10240 speckled pattern), HIV serology was negative. 
Sublingular mass was found which revealed squamous cell carcinoma. Bone marrow biopsy 
revealed smoldering multiple myeloma. The patient’s ATN resolved and he subsequently 
underwent left partial glossectomy. His cancer was staged at T2N0 and he is undergoing 
chemotherapy and radiation therapy.
Sublingular mass.
Discussion: Secondary membranous nephropathy has a known association with solid 
tumors. The positive ANA raised the concern of concomitant connective tissue disease 
but C1q negativity on the biopsy made this diagnosis unlikely. Ultimately treatment of the 
underlying condition is paramount. 1. Imai, H. et al. Nucleolar antigens and autoantibodies 
in hepatocellular carcinoma and other malignancies. Am. J. Pathol. 140, 859–70 (1992).
SA-PO105
A Case of Severe Adrenal Insufficiency due to Long-Term Glucocorticoid 
Administration for Pediatric Nephrotic Syndrome  Yuko Fujii,1 Akira 
Ashida,1 Hideki Matsumura,1 Akihiko Shirasu,1 Hyogo Nkakura,1 Motoshi 
Hattori,2 Hiroshi Tamai.1  1Pediatrics, Osaka Medical College, Takatsuki, 
Osaka, Japan; 2Pediatric Nephrology, Tokyo Women’s Medical Univ, Shinjyuku, 
Tokyo, Japan.
Introduction: One of the adverse effects of long-term glucocorticoid therapy in 
supra-physiologic doses is suppression of the hypothalamic-pituitary-adrenal axis, 
although symptomatic adrenal insufficiency is considered to be an unusual complication 
of glucocorticoid therapy for nephrotic syndrome in pediatric patients. Here we describe 
a case of secondary adrenal insufficiency due to long-term glucocorticoid therapy for 
steroid-dependent nephrotic syndrome.
Case Description: A 12-year-old boy who had developed steroid-dependent nephrotic 
syndrome at the age of 2 years had been treated repeatedly with corticosteroid, cyclosporine 
and mizoribine. On relapse of the disease at 4 years of age, the nephrotic syndrome 
had been resistant to steroid therapy including 2 mg/kg prednisolone and 4 courses of 
methylprednisolone pulse therapy, but had responded to additional cyclophosphamide 
therapy at 7 months after relapse onset. During tapering of the glucocorticoid therapy, the 
patient had shown various symptoms, including general fatigue, facial edema, decreased 
urine volume, appetite loss, and dizziness from the age of 5 years. At that time, the basal 
value of cortisol was not detectable and a rapid ACTH loading test elicited a low response. 
In the CRH and insulin loading test, the basal value of ACTH was not detectable and an 
over-response of ACTH was demonstrated. Therefore the patient was diagnosed as having 
glucocorticoid-induced hypothalamic adrenal insufficiency and treated with cyclosporine, 
a decreased dose of prednisolone, and hydrocortisone supplementation. The serum ACTH 
and cortisol values increased gradually. An insulin loading test at the age of 12 years 
demonstrated normal responses of the ACTH and cortisol levels.
Discussion: The very long-term nature of the therapy for this patient with idiopathic 
nephrotic syndrome resulted in glucocorticoid-induced adrenal insufficiency. Periodic 
evaluation of adrenal function and re-evaluation of the treatment is important for patients 
with nephrotic syndrome receiving steroid therapy.
SA-PO106
Henoch-Schönlein Purpura in Adult, from a Clinical Case  Miguel Goncalves, 
Pedro Vieira, Jose Duraes, Luis Resende, Nuno Rosa, Jose Alves Teixeira, Gil 
Silva.  Nephrology, Hospital Dr. Nélio Mendonça, Funchal, Portugal.
Introduction: Henoch-Schönlein purpura is a small vessel vasculitis mediated 
by IgA-immune complex deposition with multisystemic involvement. Rare in adults, 
is characterized by purpura, arthralgias, abdominal pain, and renal involvement. Viral 
infections have been reported as triggers.
Case Description: The authors present the case of a 25 years old male, without 
relevant medical history, admitted to the Nephrology Department in May 2014 by severe 
hypertension, renal failure (creatinine 6.7mg/dL), erythrocyturia and proteinuria. Renal 
ultrasound was normal. Renal biopsy revealed IgAnephropathy (M1E1S1T2). Our 
investigation revealed chronic hepatitis B virus (HBV) of vertical transmission origin 
(viral load 150 IU/mL). Corticosteroid therapy was started, with slight improvement 
in renal function. He was readmitted 2 months later by asthenia, epistaxis, weight loss, 
pallor, generalized edema, ascites, and oral and nasal ulcers. Laboratory tests revealed 
hemoglobin 9.2g/dL, creatinine 4,3mg/dL, normal transaminases, albumin 20g/L, urinary 
spot protein:creatinine ratio 1300mg/g, hypocomplementemia, negative p-ANCAs, 
c-ANCAs and cryoglobulins, HBV load 379.980IU/mL. During hospitalization the patient 
initiated progressive pancytopenia, diffuse abdominal pain, generalized skin purpura and 
fever (with no identifiable infectious origin and interpreted as immunologic). We made 
clinical diagnosis of Henoch-Schönlein purpura and started with cyclophosphamide and 
entecavir. A few days later appeared hypoxemia and oliguria, requiring urgent dialysis. 
Cranial CT scan showed microangiopathic leukoencephalopathy of unspecified etiology and 
alveolar hemorrhage in chest CT scan. Due to life threatning multisystemic involvement 
we started methylprednisolone pulses, intravenous immunoglobulin and plasmapheresis. 
Patient completely recovered, but remained dependent on dialysis. 6 monthly cycles of 
cyclophosphamide were maintained, with no signs of recurrence.
Discussion: We emphasize the rare severe multisystemic involvement of a Henoch-
Schönlein purpura in an adult, the onset of the disease with exacerbation of viral infection, 
and the therapeutic challenge of an HBV patient with an vasculitis.
SA-PO107
Rare Etiology for Chronic Kidney Disease: Bronchiectasis Related 
Secondary Amyloidosis  Alper Alp,1 Hakan Akdam,2 Aysegul Ormeci,3 
Ibrahim Meteoglu,3 Alparslan Unsal,4 Yavuz Yenicerioglu.2  1Nephrology, Van 
Education and Research Hospital, Van, Turkey; 2Nephrology, Adnan Menderes 
Univ, School of Medicine, Aydin, Turkey; 3Pathology, Adnan Menderes Univ, 
School of Medicine, Aydin, Turkey; 4Radiology, Adnan Menderes Univ, School 
of Medicine, Aydin, Turkey.
Introduction: Here we present an elderly patient with a known posttuberculosis-
bronchiectasis.Nephrotic-range proteinuria and renal failure was detected.Renal biopsy 
revealed AA amyloidosis.Tuberculosis and tuberculosis related systemic disorders still have 
clinical impact in nephrology practice especially in developing countries.
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Case Description: A 67 yo man was referred to our hospital with renal failure and 
proteinuria.PMH was remarkable for tuberculosis(41 years ago) and posttuberculosis-
bronchiectasis for long years.On physical examination pretibial edema was evident.Chest 
X-ray,thorax CT revealed left sided total bronchiectasis and pulmonary nodules.Malignancy 
was excluded with PET/CT and bronchoscopy.On admission biochemical tests;urea: 
220mg/dl,creatinine: 5.86mg/dl,potassium: 4.8mmol/L,GFR 10.3ml/min/1.73m2,ANA 
1/100 positivity(cytoplasmic).Renal ultrasonography revealed bilateral echogenic kidneys 
with normal size and shape.24 hour urinary proteinuria,albuminuria was 7924 was mg/
dl,4789mg/dl,respectively.Renal biopsy was compatible with AA amyloidosis(segmental 
homogeneous deposits of amyloid in the glomeruli and interstitium.Immunohistochemistry 
was positive for staining of AA amyloid.There was no immunofluorescen staining with 
IgG-A-M,C3,fibrinogen.
Tunnelled catheter was placed and hemodialysis was started.
Discussion: FMF and rheumatological disorders are the leading causes of amyloid 
AA in Turkey.However other rarely seen etiologies should not be missed in clinical 
practice.Secondary amyloidosis as a multisystemic disease has a high mortality risk.Renal 
manifestations include nephrotic syndrome and renal failure.
SA-PO108
Sunitinib Induced Acute Renal Failure and Nephrotic Syndrome in a Patient 
with Metastatic Neuroendocrine Tumor: A Case Report and Review of 
the Literature  Srijita Mukherjee,1 Carla L. Ellis.2  1Nephrology, Emory Univ 
Hospital and School of Medicine, Atlanta, GA; 2Pathology, Emory Univ Hospital 
and School of Medicine, Atlanta, GA.
Introduction: Sunitinib is a chemotherapeutic agent used to treat advanced 
malignancies via inhibition of tyrosine kinase phosphorylation. We present a case of 
sunitinib induced acute renal failure with nephrotic syndrome, occurring within one week 
of initiation for persistent carcinoid syndrome secondary to hepatic metastasis of a primary 
small intestinal neuroendocrine tumor.
Case Description: A 63 year old man with metastatic neuroendocrine tumor was 
initiated on sunitinib to treat persistent carcinoid syndrome despite initial therapy. Within 
one week of initiation, he developed new onset peripheral edema, 20 pound weight gain 
and acute renal failure with nephrotic range proteinuria. Baseline creatinine was 1.0, and 
on presentation, had increased to 3.0. There were over 10 grams of proteinuria on urine 
protein to creatinine ratio. Sunitinib was discontinued, but renal failure progressed, with 
peak creatinine of 7.1 prior to starting hemodialysis. A kidney biopsy was performed, which 
showed diffuse podocyte foot process effacement, focal global glomerulosclerosis and acute 
tubular injury. The patient remains dialysis dependent as of this report.
Discussion: Literature review reveals reports that vary both in time to onset and degree 
of resolution of renal disease after initiation and discontinuation of sunitinib therapy, 
respectively. Renal pathology also varies, including acute tubular necrosis, acute interstitial 
nephritis, diffuse podocyte foot process effacement and thrombotic microangiopathy. Our 
patient developed a greater severity of renal failure than most reported, including a higher 
peak serum creatinine, longer duration of renal replacement therapy and current lack of 
renal recovery. To our knowledge, this is also the first report of the onset of renal failure in 
the specific clinical scenario described. Given the near immediate adverse effect of sunitinib 
in our patient, we recommend monitoring of creatinine and urine protein at baseline and 
within the first three to five days of medication initiation.
SA-PO109
Cryoglobulinemic Glomerulonephritis After Successful Treatment of 
Hepatitis C  Nupur Gupta, Chad A. Zarse, Allon N. Friedman.  Nephrology, 
IU School of Medicine, IN.
Introduction: The optimal treatment of cryoglobulinemic glomerulonephritis (GN) in 
the setting of Hepatitis C (Hep C) with sustained viral response (SVR) is unknown. Only 
expert opinion obtained from case reports provide guidance to the clinician. Some reports 
suggest treatment with Rituximab may be beneficial.
Case Description: 58yo male with h/o treated Hep C currently with an undetectable 
viral load, gastric ulcer, anemia, and HTN presented to clinic for evaluation of CKD. Hep 
C was initially diagnosed when he was found to have leukocytoclastic vasculitis on a skin 
biopsy of skin rash. Labs were positive for serum cryoglobulins, rheumatoid factor, low 
C4, and Hep C viral load. Renal function was normal and he was successfully treated for 
cryoglobulinemic vasculitis due to Hep C with interferon alpha, telaprevir and ribavirin and 
achieved a SVR. He presented 1 year later with renal insufficiency (creatinine -2.2 mg/dL) 
and 500mg proteinuria. He had intermittent flares of vasculitis. SPEP revealed IgM kappa 
monoclonal with negative UPEP. C4 was low and cryoglobulins remained positive. Kidney 
biopsy showed immune complex GN with organized deposits. Bone marrow biopsy was 
negative for lymphoproliferative disease. He was diagnosed with cryoglobulinemic GN with 
SVR. Initially, he was treated with prednisone followed by Rituximab and plasmapheresis. 
He failed the treatment and was started on hemodialysis.
Discussion: Cryoglobulinemic GN is frequently due to Hep C but is rare in patients 
achieving a SVR. In our case an underlying B cell lymphoma was ruled out and it was 
felt that B cell immune dysregulation due to Hep C was the culprit, in part due to prior 
published cases. However, in our case treatment with rituximab and plasmapheresis was 
unsuccessful. It remains possible, as others have demonstrated, that the virus may persist 
within the liver, macrophages, lymphocytes, and even kidney. The pathological basis for 
persistent vasculitis in setting of a SVR requires further study so that targeted and more 
effective treatment strategies can be designed.
SA-PO110
Diagnostic Intrapartum Dilemma: Distinguishing Glomerulonephritis from 
Preeclampsia in Pregnancy  Suzanne L. Katsanos, Fernanda Payan Schober, 
William Franklin Pendergraft, Volker Nickeleit, JulieAnne G. McGregor, 
Harsharan Kaur Singh.  UNC Kidney Center, Chapel Hill, NC.
Introduction: Distinguishing glomerular disease from preeclampsia intrapartum can 
be challenging due to overlap of clinical findings. Unfortunately, this diagnostic dilemma 
can result in unwarranted early delivery. Here we present 5 cases of glomerulonephritis 
(GN) complicating pregnancy.
Case Description: 3 patients (ages 22, 31 and 33) presented during pregnancy with 
proteinuria, dysmorphic hematuria and, in 2 cases, acute kidney injury. In all 3 cases, the 
concern for preeclampsia prompted induction of labor (IOL), and postpartum kidney biopsy 
showed IgA nephropathy. 2 patients were treated with steroids and ACE inhibitors (ACEI) 
with improvement in proteinuria. The one with the most severe kidney dysfunction was 
treated with cyclophosphamide (CYC). Unfortunately, she became dialysis-dependent 1 
month postpartum. The fourth patient (age 20) presented with HELLP syndrome at 25 
weeks and underwent IOL. 5 months post-partum, she developed clinical symptoms of 
lupus in the setting of proteinuria, dysmorphic hematuria and persistent kidney dysfunction. 
Kidney biopsy showed diffuse proliferative lupus nephritis, which was treated with IV 
CYC. Unfortunately, she continued to have renal dysfunction despite treatment. The fifth 
patient (age 37) had minimal change disease (MCD) and was in remission at the time of 
pregnancy. She did well on cyclosporine until 25 weeks gestation when she developed 
hypertension, edema, and nephrotic-range proteinuria. It was unclear whether this 
represented preeclampsia or a MCD flare so she underwent IOL. Subsequent placental 
pathology failed to show signs of preeclampsia. She was treated postpartum with steroids 
and ACEI and re-entered remission.
Discussion: Here we show that pregnancy can aggravate (as in the case of our patient 
with MCD) or unmask (as in the other 4 cases) underlying glomerular disease. Diagnosis 
can be delayed due to risks related to kidney biopsy during pregnancy, and treatment is 
complicated by safety concerns for the developing fetus. Further work is needed to identify 
meaningful mechanisms to accurately differentiate preeclampsia from GN during pregnancy.
SA-PO111
A Case of Rapidly Progressive Glomerulonephritis Associated with 
Metastatic Lung Cancer  Eduardo J. D. de Sa Carneiro Filho, Victor Longo 
Silva, Lilian Cordeiro, Veronica T. Costa e Silva, Elerson Costalonga.  Univ of 
São Paulo, Nephrology Division, São Paulo, Brazil.
Introduction: Several solid malignancies have been associated with glomerular 
diseases. Rapidly progressive glomerulonephritis (rPGn) has been reported in association in 
particular with renal cell carcinoma and lung cancers. We report a case of rPGn associated 
with metastatic lung cancer treated with chemotherapeutic agents.
Case Description: A 57-year-old male with metastatic epidermoid lung cancer, treated 
previously with paclitaxel plus carboplatin, cisplatin plus gemcitabine and four cycles 
of docetaxel, was admitted with dysuria and hematuria for last 1 week. Upon physical 
examination: edema of the lower limbs. Laboratory results demonstrated normal liver 
function, positive anti-Hbc, negative HbsAg and anti-Hbs, hemoglobin 6,5 g/dL, serum 
creatinine of 3,78 mg/dL (baseline 1,5), C3 154 mg/dL, C4 24,8 mg/dL, negative cANCA. 
Urinalysis showed proteinuria (>1 g/L), more than 100 leukocytes per field and more than 
100 red cells even after antibiotic treatment for presumed urinary infection. Due to persistent 
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proteinuria (3,7g/24h), evidence of dysmorphic hematuria and worsening of renal function 
(Cr 4,1 mg/dL), he received methylprednisolone 1g for three days and renal biopsy was 
proposed. It revealed pauci-immune crescentic glomerulonephritis. Immunofluorescence 
showed mesangial deposition of C3 (3+) and lambda chains (1+). Treatment was followed 
by monthly i.v. cyclophosphamide and proteinuria decreased to 0.87 g/24h. cANCA became 
positive (1/160) 4 months after diagnosis.
Discussion: Membranous nephropathy is the most commonly reported glomerulopathy 
especially with pulmonary cancer, but several reports suggest an association between rPGn 
and malignancies. The increased risk for malignancy has been confirmed in a retrospective 
review of 200 patients with ANCA-associated vasculitis, demonstrating a significantly 
increased relative risk (6.02) compared with age-matched controls. Biava et al reported 
seven cases of rPGn associated with a coexisting nonrenal malignancy (6 carcinomas and 
1 lymphoma). The pathogenetic mechanisms by which neoplasms lead to the development 
of ANCA-associated vasculitis and rPGn are largely unknown.
SA-PO112
A Case of Encapsulating Sclerosing Peritonitis in a Type I Diabetic on 
Peritoneal Dialysis  Zachary Freestone, Josephine Abraham, Akram M. 
Shaaban.  Nephrology, Univ of Utah, Salt Lake City, UT.
Introduction: Encapsulating sclerosing peritonitis (ESP) is a rare disorder associated 
with PD. It is characterized by peritoneal fibrosis and encasement of the bowel. Symptoms 
associated with ESP are non-specific and may be attributed to other etiologies. Abdominal 
imaging is required to evaluate ESP and diagnostic confirmation is achieved by laparoscopy. 
ESP should be considered in patients on peritoneal dialysis with symptoms involving the 
gastrointestinal tract, weight loss, or inadequate solute clearance.
Case Description: A 34 year old Caucasian male on PD presented to the clinic 
with complaints of nausea and abdominal pain. He had a history of type I DM, ESRD, 
neuropathy, and gastroparesis. He was started on PD 8 years ago and has had 3 prior 
episodes of peritonitis. The patient appeared ill and malnourished. His abdomen was soft 
on examination and non-tender to palpation. An abdominal x-ray indicated that he had 
calcification in the abdomen and pelvis. CT imaging showed calcification of the parietal 
peritoneum, abdominal cavity, omentum, and bowel. The patient underwent exploratory 
laparotomy with simultaneous PD catheter removal. The visual examination revealed a 
brown, inflamed rind encompassing the peritoneum, omentum, bowel, and colon. Peritoneal 
dialysis was discontinued and the patient was transitioned to hemodialysis.
Discussion: Encapsulating sclerosing peritonitis (ESP) is a condition associated with 
peritoneal dialysis. Its presenting symptoms are often non-specific and may be attributed to 
other causes. Abdominal imaging is necessary to evaluate for suspected ESP, CT being the 
preferred method. ESP is characterized by peritoneal thickening and fibrosis that encases 
the bowel. Treatment includes cessation of PD with transfer to hemodialysis and bowel 
rest. Other attempted treatments of this disease have included steroids and total enterolysis.
SA-PO113
Acute Kidney Injury from Enterovescical Fistula Secondary to Squamous 
Cell Carcinoma of Bladder  Eleni Chelioti, Evdokia Efthimiou, Alexia 
Papalexandrou, Maria Sotiraki, Ioannis Xatzis, Maria Tsilivigou.  Dept of 
Nephrology, General Hospital of Piraeus, Athens, Greece.
Introduction: Squamous cell carcinoma (SCC) of the bladder is a relatively rare tumor. 
Predisposing factor is chronic irritation of the bladder by urinary infection, calculi and 
long-term indwelling catheterization. Enterovescical fistula (EVF) usually has flow from 
intestine to the bladder and commonly manifests with recurrent urinary tract infections(UTI), 
fecaluria and pneumaturia. We report a case with SCC of bladder who developed EVF, 
leading to acute kidney injury(AKI).
Case Description: A 56 year old Caucasian female with hypertension, diabetes mellitus 
and recurrent UTI was admitted in a uremic state that necessitated the immediate start of 
hemodialysis. Further clinical and laboratory findingsrevealed hematuria, pyuria,bacteriuria 
and fecaluria after placing a Foley catheter. Ultrasound scan of the abdomen showedtwo 
kidneys of normal size and parenchymal thickness. CT scan of the abdomen and pelvis 
showed a markedly contracted and nodular bladder with a large bladder wall defect and 
the Foley catheter extending through the bladder wall into a small bowel loop. A diagnosis 
of EVF with reverse flow from the bladder to intestine was made. She subsequently 
underwent to a long surgery with total cystectomy, a ileo-hemicolectomy and creation of 
an ileal conduct. Histopathology examination of specimens revealed SCC of bladder and 
metastasis in the colon.After surgical intervention,she became hemodialysis dependent, 
refused further therapy and she is well 6 months later.
Discussion: In the western world SCC represent less than 5% of all bladder tumors. 
There are no specific diagnostic tests and it is usually diagnosed in advanced stage. Although 
distant metastasis is infrequentbut the prognosis is poor and most patients die. In our case 
the only proved predisposing factor is chronic irritation of the bladder by UTI. EVF rarely 
can have reverse flow leading to urine excretion via GI tract in patients with diminished 
bladder capacity. The diverted urine stimulates metabolic disorders causing AKI.
SA-PO114
Postoperative Bilateral Ureteroenteric and Enterovesicular Fistulas 
Complicated by Hydronephrosis and Ursosepis  Ayaa M. Zarm, Muner 
Mohamed, Rohini Chawla, Sunithi Krishnan, Richard E. Seguritan, Vinay N. 
Kikkeri.  Medicine/Nephrology Div, Richmond Univ Medical Center, Staten 
Island, NY.
Introduction: Lower urinary tract fistulas are serious complications of abdominopelvic 
surgeries, often resulting in poor outcomes.
Case Description: This is a case of a 65-year-old man with a history of colorectal 
cancer who underwent colon resection with colostomy placement, chemotherapy and 
radiotherapy. The patient was admitted with signs and symptoms of Urosepsis with MDR 
Klebsiella and oliguric acute kidney injury. CT abdomen/pelvis demonstrated moderate 
bilateral hydronephrosis and hydroureter with cystitis and inflammatory changes within the 
pelvis. Patient was noted to have minimal urinary output after a Foley catheter placement 
and worsening renal failure due to which a bilateral percutaneous nephrostomy catheter was 
placed by Interventional Radiology. During this procedure, the patient was found to have 
bilateral Ureteroenteric and Enterovesicular fistulas (Figure 1, 2) with associated cystitis.
In order to confirm the diagnosis of these bilateral ureteroenteric fistulas, a sample of 
colostomy fluid was checked for Creatinine levels. The Creatinine level from the colostomy 
fluid was equivalent to the urine creatinine level hence confirming the diagnosis. Patient 
was further treated with intravesical Polymyxin for cystitis.
Discussion: Lower urinary tract infections are a serious complications in patients 
undergoing abdominopelvic surgeries. However, they are mainly associated with patients 
undergoing chemotherapy and radiation therapy for colorectal malignancies. These 
complications can be lethal and have a very poor prognosis.
SA-PO115
Clinicopathological Feature of a Patient with IgD-Lambda Type Multiple 
Myeloma Showing Kidney Involvement  Kaori Yamaguchi,1 Toshiya 
Okumura,1 Kengo Furuichi,2 Takashi Wada,2 Yasunori Iwata,2 Taichiro Minami.1 
1Nephrology, Tonami City Hospital, Tonami, Toyama, Japan; 2Nephrology, 
Kanazawa Univ, Kanazawa, Ishikawa, Japan.
Introduction: Kidney involvement sometimes occurs in patients with multiple 
myeloma (MM). MM associated kidney diseases encompass diverse manifestations, 
such as cast nephropathy, amyloidosis and immunoglobulin deposition disease. Since 
the frequency of IgD type MM is relatively low, renal manifestation, especially, renal 
pathology has not been fully understood. Here, we repots the autopsy case of IgD type 
MM with kidney involvement.
Case Description: A 81 years old women admitted the hospital because of systemic 
pain and appetite loss. Laboratory data showed serum Cr 5.14 mg/dl, urea nitrogen 57.2 
mg/dl and corrected Ca 16mg/dl. Urine protein was 1+ with dipstic analysis and 9.7 g/gCr. 
Serological test revealed a monoclonal IgD-lambda chain. Proliferated plasma cells with the 
positivity of IgD-lambda chain was increased (16%) in bone marrow. After the Ca lowering 
therapy, dexamethasone (20mg/day X 4days) was administrated to the patient. While serum 
levels of IgD was decreased by the therapy, renal function deteriorated, requiring dialysis. 
She died of infection at 64 day after admission. Autopsy specimen of kidney showed cast 
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formation in tubular lumens with severe tubular atrophy. Cell accumulation and fibrotic 
lesion were also detected in interstitium. Mesangial matrix was mildly expanded in 
glomeruli. Amyloid deposition was not observed.
Discussion: Herein, we showed clinical course and renal pathology of the patient with 
IgD-lambda type MM. Although steroid pulse therapy decreased serum levels of IgD, renal 
function did not improve. Renal pathology showed cast nephropathy, interstitial fibrosis 
and cell infiltration. The renal manifestation of IgD type MM requires further investigation.
SA-PO116
Sunitinib-Induced Nephrotic Syndrome and Acute Kidney Injury in a 
Malignant Insulinoma Patient: A Case Report  Wakana Shoda, Naofumi 
Yui, Shotaro Naito, Soichiro Iimori, Koichiro Susa, Takayasu Mori, Naohiro 
Nomura, Eisei Sohara, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida. 
Dept of Nephrology, Tokyo Medical and Dental Univ, Bunkyo, Tokyo, Japan.
Introduction: Sunitinib, a tyrosine kinase inhibitor targeting vascular endothelial 
growth factor receptors (VEGFR), has been proven to be effective in the treatment of several 
types of cancer, including pancreatic neuroendocrine tumors. However, its risk of renal 
complications, such as proteinuria, renal dysfunction, and hypertension, are underestimated.
Case Description: A 71 year-old man with malignant insulinoma treated on sunitinib 
for six months, developed proteinuria, acute kidney injury and hypertension. Kidney 
biopsy showed thrombotic microangiopathy (TMA) like lesions such as double contoure, 
edematous endothelial cells and microaneurysms, suggesting injuries induced by sunitinib. 
Decreased VEGF expression in podocytes was demonstrated by immunohistochemistry, 
supporting the diagnosis. Sunitinib was discontinued and partial remission of the renal 
complication was achieved in two weeks. However, the patient mandatorily needed to 
restart sunitinib because of poor control of blood glucose level due to pancreatic cancer 
exacerbation. By reducing the dose of sunitinib and administering losartan concurrently, 
the patient was able to maintain stable renal function with serum creatinine level of 1.4 
mg/dl and urinary protein level under 1.0g/day.
Discussion: VEGF blockade by sunitinib is featured by adverse effects including 
hypertension and renal injury. In the present case, renal injury partially improved after 
discontinuing sunitinib. Reducing the dosage of sunitinib and administering losartan made 
it possible to restart sunitinib treatment while controlling its renal side effects. VEGF, 
which is expressed and secreted by podocytes, is an important factor for development and 
maintenance of glomerular endothelium. Renal biopsy in this case showed down regulation 
of VEGF in podocytes. Although the mechanism of renal dysfunction and proteinuria caused 
by anti-VEGF therapy is not well elucidated, the findings of this case might provide insights 
into the mechanism of renal toxicity by sunitinib.
SA-PO117
Liver-Kidney versus Liver Transplant Alone: Decision Making in the 
Operating Room  Ekamol Tantisattamo,1 Siwadon Pitukweerakul,2 Praveen 
Ratanasrimetha.3  1Nephrology, Northwestern Univ; 2Presence St. Francis 
Hospital, Evaston; 3Faculty of Medicine Siriraj Hospital, Mahidol Univ, 
Bangkok, Thailand.
Introduction: Acute kidney injury (AKI) is a common complication of decompensated 
chronic liver disease and hepatorenal syndrome (HRS) is one of the leading causes. Liver 
transplantation (LT) is a definitive treatment for HRS; however, simultaneous liver-kidney 
transplantation (SLK) is pursued due to the severity of preoperative AKI with uncertainty 
of postoperative renal recovery.
Case Description: A 60-year-old Caucasian woman with ESLD due to alcoholic 
cirrhosis had been readmitted twice over 2.5 months with AKI from HRS. Even though, 
she was treated with albumin, midodrine, and octreotide, serum creatinine (SCr) had been 
elevated from the initial baseline of 1 mg/dL and had never returned to the baseline. Instead, 
it was worse every times she had AKI (Figure 1). After the last episodes of AKI, SCr had 
been stable at 2.5 mg/dL and she was listed for SLK. One week later, she was offered for 
SLK. After the LT, she started making a significant amount of urine immediately; therefore, 
the kidney was not transplanted and transferred to other potential kidney transplant recipient 
in another transplant center. Postoperatively, SCr had trended down to 1.1 mg/dL.
Discussion: Even though, our patient had recurrent episodes of AKI from HRS 
and persistently elevated SCr even <3 months period, it was thought that the chance of 
meaningful renal recovery was small and SLK was initially planned. Fortunately, her 
renal function was recovery immediately after the LT alone. Preoperative evaluation for 
SLK versus LT alone sometimes becomes uncertainly. Intraoperative finding of signs of 
renal recovery after LT is crucial as it can avoid unnecessarily kidney transplantation and 
provide an opportunity to utilize kidney organ to other potential kidney transplant recipients.
SA-PO118
Is Portopulmonary Hypertension Patient a Good Candidate for Liver 
Transplantation?  Ekamol Tantisattamo,1 Praveen Ratanasrimetha,2 Siwadon 
Pitukweerakul.3  1Nephrology, Northwestern Univ; 2Faculty of Medicine Siriraj 
Hospital, Mahidol Univ, Bangkok, Thailand; 3Presence St. Francis Hospital, 
Evaston.
Introduction: Portopulmonary hypertension (PPH) is one of the most feared 
complications of end-stage liver disease (ESLD). Liver transplantation (LT) may reverse 
this complication with uncertain outcomes. We report a case of ESLD women complicated 
by severe pulmonary arterial hypertension (PAH) secondary to PPH and acute kidney injury 
(AKI) who had prolonged pre- and post-operative simultaneous liver-kidney transplantation 
(SLK) with partial liver improvement, un-meaningful renal recovery, and bed bound with 
reconditioning.
Case Description: A 48-year-old woman with ESLD from cryptogenic cirrhosis 
complicated by portal hypertension, PAH-related to PPH and sarcoidosis presented with 
AKI requiring CRRT. She was treated with treprostinil, sildenafil, and ambrisentan until 
suitable for SLK. Postoperatively, liver and renal allografts worked well and PA pressure 
was decreased. However, she still required treprostinil and dieresis to control PAH and 
volume status. After 5 months of ICU stay, she developed severe deconditioning and 
malnutrition. She had AKI with SCr of 0.5 mg/dL up to 1 mg/dL over 3 weeks. Calculated 
average clearance from 24-hour urine collection was 15 ml/min. Transplant renal allograft 
biopsy revealed moderate ATN and borderline changes. Diuretic dose was decreased 
and SCr was improved to 0.7 mg/dL. She still required treprostinil as well as intensive 
rehabilitation and nutritional supplementation. She remains in ICU for the majority of the 
time posttransplantation.
Discussion: PPH is one of the challenging scenarios for ESLD requiring LT. 
Reversibility from PPH after LT is uncertainty. It is still a dilemma in managing this difficult 
situation between LT to prolong life with poor quality and conservative management. LT 
is a life-saving surgery but may not always reverse a severe complication of ESLD such 
PPH and thus prolongs no postoperative quality of life. Therefore, LT in such a complex 
underlying condition needs to be individualized.
SA-PO119
Flash Pulmonary Oedema in Renal Artery Stenosis: An Indication for 
Stenting?  Elise Chua, Martine David, Neil Chapman.  Medicine, Imperial 
College, United Kingdom.
Introduction: Renal artery stenosis (RAS) is an unusual but potentially treatable 
cause of flash pulmonary oedema. Although national guidelines recommend percutaneous 
revascularization (level of evidence B), we present a case of recurrent flash pulmonary 
oedema which suggests a need for further evidence to support use of revascularization 
therapy in elderly patients with multiple comorbidities.
Case Description: A 78 year old woman presented with a fourth episode of sudden onset 
dyspnoea in 4 months. Her medical history included CAD, AF, hypertension (HTN) and 
severe pulmonary HTN due to heart failure with preserved ejection fraction (HFPEF). On 
admission, there were bilateral respiratory crackles and pulmonary congestion on chest XR. 
BP was 164/95, creatinine 110umol/L, eGFR 42. Echocardiogram showed concentric LVH, 
preserved EF and raised PAP. Because of recurrent symptoms despite apparently adequate 
medical management of HFPEF, she underwent CT angiography which revealed bilateral 
ostial RAS (70% right, 40% left). Following multidisciplinary team discussion, bilateral 
balloon angioplasty with stent insertion was performed with radiologically successful 
results and she was discharged on rivaroxaban for stroke prevention. Since then, she has 
had no further episodes of pulmonary oedema. However, renal function has deteriorated 
post-procedure (max creatinine 226umol/L, eGFR 18 at 6 weeks; no evidence of in-stent 
thrombosis) and she has diuretic-resistant pedal oedema severely impacting quality of life.
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Discussion: This case highlights the importance of recognizing RAS as a cause of flash 
pulmonary oedema, especially in bilateral disease due to lack of compensatory mechanisms. 
Observational studies and case series have demonstrated that angioplasty +/- stenting 
reduces the incidence of flash pulmonary oedema. However, there is limited literature to 
guide management (eg. on risks and benefits of unilateral vs. bilateral intervention, degree 
of stenosis) and limited experience in the elderly in whom comorbidities may increase the 
risks of procedural complications such as deterioration of renal function due to contrast 
nephropathy and/or cholesterol emboli.
SA-PO120
Complement Mediated Hemolytic Uremic Syndrome Secondary to SLE 
Aala Jaberi, Jean M. Francis, Craig E. Gordon.  Nephrology, Boston Medical 
Center, Boston, MA.
Introduction: Complement-mediated hemolytic uremic syndrome (CM-HUS) is a 
life-threatening disease. Rapid diagnosis and early treatment impact patient outcomes. 
CM-HUS is often caused by defects in the complement regulatory system leading to 
uncontrolled activation of the alternative complement pathway, resulting in systemic 
thrombotic microangiopathy (TMA).
Case Description: 64-year-old female with well-controlled HIV on HAART, presented 
with new pancytopenia, thrombocytopenia and acute kidney injury. On examination she had 
no neurological symptoms and no diarrhea. Preliminary blood tests revealed WBC 2.9K/
UL, hemoglobin 6.6g/dl, platelets 64 K/UL, and serum creatinine at 4.0 mg/dl. LDH was 
elevated at 600U/L, haptoglobin was undetectable, with Coombs test negative. Peripheral 
blood smear revealed numerous schistocytes. Further work up revealed an elevated ANA 
(>1:2560), and hypocomplementemia. Anti-Smith antibody elevated at >8. These laboratory 
studies and the presence of lymphadenopathy and pancytopenia established a diagnosis of 
SLE. Patient received pulse methylprednisolone, but creatinine increased to 6 mg/dl . A 
kidney biopsy revealed TMA. The patient was treated with plasma exchange but developed 
uremia and was started on hemodialysis. Neither renal function nor hemolysis improved. 
In the absence of anti phospholipid antibody, normal ADAMTS13 level and activity, 
well-controlled HIV, and in the presence of positive serologies for SLE with complement 
consumption, the diagnosis of CM-HUS secondary to SLE was the most explanation of the 
patients’ presentation, a decision was made to treat with eculizumab. Patient received one 
treatment,with no immediate improvement in her renal disease or hematologic parameters. 
Unfortunately her clinical status deteriorated and patient opted to be made comfort measures 
only and ultimately expired.
Discussion: This case emphasizes the importance of early consideration of CM-HUS 
as well as prompt initiation of treatment to block terminal complement upon recognition of 
the syndrome. As clinicians, this class of diseases is challenging and complicated, requiring 
our rapid attention to aid timely identification and rapid management.
SA-PO121
Idiopathic Nodular Glomerulosclerosis Presenting with Nephrotic Range 
Proteinuria and Normal Renal Function  Hassan E. Osman, Dany H. Issa. 
Dept of Internal Medicine - Div of Nephrology, Saint Louis Univ, Saint Louis, MO.
Introduction: Idiopathic Nodular Glomerulosclerosis (ING) is a well-established but 
uncommon entity that has been described in 1985 by Chan JY et Al. It is common in older 
white men with history of long-standing hypertension, obesity, and smoking and typically 
presents with renal Insufficiency & Nephrotic Range Proteinuria. Multiple reports and 
meta-analyses of patients with ING demonstrate an average creatinine > 2.0 mg/dl and 
progressive kidney dysfunction leading to ESRD.
Case Description: We report a case of a 57 year old Caucasian obese female who 
presented with edema and heavy proteinuria (9 grams/day). She is a 40-pack year smoker 
with long-standing hypertension with variable control. Serum Creatinine on presentation was 
0.7 mg/dl. Hba1c was 6.0% and fasting/random sugars never met criteria for overt Diabetes 
Mellitus. Urine showed 3-10 rbcs/hpf and none where dysmorphic with an otherwise bland 
urine sediment. She had a negative work up for paraproteinemias and all other causes of 
proteinuria. Kidney biopsy showed Class III nodular sclerosis (KW lesions) and moderate 
atherosclerosis by light microscopy. Immunofluorescence and Congo red staining were 
negative while EM showed ultra-structural features of Diabetic Nephropathy.
Treatment with diuretics and ACE-Inhibitor lead to improvement in volume status and 
proteinuria. Nine-months into follow up renal function remain stable.
Discussion: Our case illustrates that Idiopathic Nodular Sclerosis is not limited to male 
gender and can occur in the setting of preserved renal function, contrary to the common 
observation revealed in previous case reports. 
References (among other reviewed data) include:
[1] Clin Exp Nephrol. 2014 Dec;18(6):865-75. doi: 10.1007/s10157-013-0929-y. 
Epub 2014 Jan 10.
[2] Diabetes Care. 1985 Jul-Aug;8(4):385-90.
SA-PO122
Hemofiltration Reinfusion Aequilibrium Can Be an Answer to Malnutrition 
and Hypotension in Dialysis  Nicoletta Pertica.  Dept of Nephrology, Verona 
Hospital (AOUI VR), Verona, Italy.
Introduction: We analyze the impact of A-HFR on intradialytic tolerance, nutritional 
status and on the clinical condition of two malnourished patients of our dialysis center.
Case Description: We performed an observational study for 12 months on 2 patients 
shifted toA-HFR caused to dialysis intolerance towards other methods.We monitored Blood 
Gas (pre and post treatment),clinical,biochemical, and dialitic data. Patient 1 62 years old 
man: on dialysis since 2008, suffering from malnutrition and anorexia due to cerebellar 
stroke (BMI 15.8) with intra and interdialytic hypotension. On February 2014 he started 
IDPN (IntraDialytic Parental Nutrition) + HDF online without any clinical improvement. 
On June 2014 he shifted to A-HFR+IDPN with improved hemodynamics control, weight 
(10% compared to its initial), nutritional and inflammatory indexes. In addition, he improved 
his quality of life with disappearance of hypotensive episodes and reduced consumption 
of EPO. Patient 2 44 years old Woman: kidney-panceas transplanted, on dialysis since 
2011. In 2012 she started an antibiotic therapy for curing a pulmonary TBC, burdened by 
malnutrition and severe peripheral neuropathy with persistent hypotension, also during 
dialysis. In 2013 she shifted to A-HFR and improvements regarding bodyweight, blood 
pressure, inflammatory markers and peripheral neuropathy were observed.
Discussion: A-HFR has dynamic profiles of ultrafiltration and conductivity of 
the dialysate: this aspect creates an iso-osmolar dialysate, ensuring a better periferical 
refilling and improving compliance during the dialysis treatment. This is due to the use of 
biosensors. A-HFR also reduces the Amino acids loss.This report has numerical limitations 
but provides encouraging data on the use of AHFR in malnutrition and disequilibrium 
syndromes. This experience underlines the importance of further efforts towards customized 
dialysis procedures.
SA-PO123
Monoclonal Gammopathy of Renal Significance: The Significance Is 
Not Always Unknown  Umair S. Ahmed.  Nephrology, West Virginia Univ, 
Morgantown, WV; Nephrology, West Virginia Univ, Morgantown, WV.
Introduction: Membranoproliferative glomerulonephritis (MPGN) is a pattern of 
glomerular injury noted on microscopy. It is less commonly associated with monoclonal 
gammopathies, including monoclonal gammopathy of unknown significance (MGUS).
Case Description: Patient is a 67 years old female, with a history of rheumatoid 
arthritis, on Methotrexate, who presented to an outside facility with progressively worsening 
fatigue for four months. Investigations showed pancytopenia, following which she was 
transferred to our hospital for further management. On arrival at our hospital, patient was 
noted to have an acute kidney injury. A random urine protein/creatinine ratio showed 5.5 gm 
proteinuria. Serum protein electrophoresis showed a monoclonal spike, with an Ig M kappa 
clone. Immunoglobulin (Ig) G was low at 161 mg/dl, while Ig M was increased at 378 mg/
dl. Bone marrow biopsy done showed 5 % plasma cells, with no morphological features 
of a plasma cell neoplasm, leukemia or lymphoma. Kidney biopsy done showed MPGN, 
with positive immunofluorescence for IgM, C3, kappa, along with large subendothelial and 
mesangial deposits. Both C3 and C4 were low. Work up was negative for hepatitis B and C. 
Serum cryoglobulin levels were normal. No evidence of lupus was noted. Infectious work 
up was also unremarkable. Patient was diagnosed as having MGUS by the hematology 
service. MPGN was assessed to be secondary to MGUS in the absence of other possible 
etiologies. Patient was started on high dose steroids for 3 days followed by a taper, along with 
intravenous Rituximab 375 mg/m2 weekly for 4 weeks. Due to worsening renal functions 
patient was started on hemodialysis. Unfortunately due to lack of renal recovery, patient 
was declared as having end stage renal disease.
Discussion: MGUS is the most common plasma cell disorder and may be a precursor 
for myeloma. It is characterized by a lack of end organ damage. A small subset of 
patients, however, may rarely have renal involvement, with MPGN being noted on renal 
biopsy. MGUS can therefore be associated with morbidity and mortality, and therefore its 
significance may not always be unknown.
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SA-PO124
A Case of Chronic Unilateral Hematuria Treated by Segmental Renal 
Artery Embolization  Hansae Kim,1 Joon Seok Oh,2 Yong Ki Park,2 Dongyeol 
Lee.1  1Nephrology, Bongseng Memorial Hospital, Busan, Korea; 2Nephrology, 
Dongrae Bongseng Memorial Hospital, Korea.
Introduction: Chronic unilateral hematuria is characterized by intermittent or 
continuous hematuria that cannot be diagnosed using standard radiologic and hematologic 
methods. Unilateral hematuria is probably a benign condition that seldom requires surgical 
treatment, but some cases were managed with partial or total nephrectomy. Recently, a 
variety of treatments, including the ureteroscopic interventions have been attempted if the 
bleeding focus is identified. However, if not identified on ureteroscopy, surgical treatment 
has been considered a priority. We report the case of treatment of chronic unilateral hematuria 
with segmental renal artery embolization.
Case Description: We experienced a case of chronic unilateral hematuria in a 
42-year-old woman who was admitted to our hospital due to intermittent gross hematuria 
and anemia for 31 months. About 29 and 19 months ago she already underwent CT scan, 
renal angiography, and renal biopsy at other tertiary hospitals, but didn’t found any other 
specific abnormalities repeatedly except some blood clots in left renal pelvis on ureteroscopy. 
She underwent CT urography, renal arteriography, cystoscopy and ureteroscopy again. 
Ureteroscopic findings only showed bleeding in the upper third of left renal calyces but 
definite bleeding focus could not be identified. Thus we decided to manage with segmental 
renal artery embolization than partial nephrectomy to minimize the reduction in renal 
function and to reduce operational risk. The superior and superoanterior segmental renal 
arteries were successfully embolized with 3mm coils and gelatin sponge. Gross hematuria 
disappeared on the 4th day after the procedure, microscopic hematuria disappeared on the 
5th day. In 11th day, infarction in the upper third portion of left kidney was confirmed on 
CT scan. In 13th day, the patient was discharged. Thereafter serial urinalysis showed no 
hematuria.
Discussion: Patients with chronic unilateral hematuria often require surgical or 
upper urinary tract endoscopic procedures. Segmental renal artery embolization will be 
a better treatment for patients unable to identify the bleeding focus on the upper urinary 
tract endoscopy.
SA-PO125
An Unusual Cause of Acute Kidney Injury in a Patient Several Months 
Post Renal Transplant  Sweta Carpenter, Karthik M. Ranganna.  Nephrology, 
Drexel Univ.
Introduction: Urinary anastomosis leaks after kidney transplants are no longer 
a common phenomenon. Due to advancements in reconstruction techniques, urologic 
complications after renal transplant are now reported to occur in only 2-2.5% of patients. 
If a urinary anastomotic leak were to develop, it frequently occurs within one month of the 
transplant and is usually due to technical error or ischemia to the ureter.
Case Description: We present a case of a 60 year male with a history of a living 
unrelated kidney transplant who developed acute kidney injury 5 months after transplant. 
He had a baseline creatinine of 1.5-1.7 mg/dL and initially presented to the hospital with 
fevers and a creatinine of 2.96 mg/dL. A fungal urinary tract infection with Candida 
Albicans was deemed the culprit of his symptoms and so he was promptly started on 
fluconazole with only a slight improvement in his creatinine. A renal ultrasound of the 
allograft revealed that the patient had a 7x5 cm perinephric fluid collection. A perinephric 
drain was placed in the collection and culture of the fluid grew Candida Albicans. The large 
amount of perinephric drainage led to concerns of an anatomic urinary leak. Further testing 
on the perinephric fluid showed similar levels of creatinine in the perinephric fluid and the 
patient’s urine. Cystoscopy later revealed that the patient had a large ureteral anastomotic 
leak. He underwent a percutaneous nephrostomy tube and nephroureteral stent placement. 
The patient’s perinephric fluid collection subsequently resolved and he was discharged 
home with a creatinine of 1.47 mg/dL.
Discussion: Improvements in surgical techniques have decreased but not eliminated 
the incidence of anatomic surgical complications. Urinary anastomotic leaks are a rare but 
serious complication of kidney transplantation. This case highlights the need for diligence in 
diagnosing such a leak and favorable outcomes with prompt treatment. Since urinary leaks 
are uncommon months after kidney transplant, a question could be raised about the possible 
causative association between the fungal urinary tract infection and the anastomotic leak.
SA-PO126
Early Onset Kidney Stone Formation in Severe Ulcerative Colitis: 
Prevention Better Than Cure  Akshatha Rao, Rozina B. Ali, Ziauddin Ahmed. 
Div of Nephrology, Drexel Univ, Philadelphia.
Introduction: Incidence of kidney stones is higher in patients with inflammatory 
bowel disease (IBD) than in general population. Studies using screening ultrasound showed 
38% of Crohn’s disease and 37% of Ulcerative Colitis(UC) patients had asymptomatic 
renal calculi mostly calcium oxalate and or uric acid stones. Active inflammation was the 
important risk factor for renal calculi.
Case Description: In our case report we describe a 40 year old male with no significant 
past medical history except newly diagnosed ulcerative colitis with severe pancolitis on 
colonoscopy 3 months ago. His pancolitis was treated with steroids and Infliximab therapy 
with significant improvement of his symptoms. Subsequently patient was readmitted to 
the hospital with severe abdominal pain, radiating from loin to groin. CT abdomen and 
pelvis showed multiple bilateral kidney stones, largest measuring 7mm, and a 5mm stone 
at the ureterovesical junction on the left with hydronephrosis. His serum creatinine (SCr) 
increased from 1.2 to 4 mg/dl.
Patient underwent cystoscopy, left retrograde pyelogram for renal stone extraction 
and stent placement with improvement of creatinine. A 24-hour urine collection 4 weeks 
after the acute episode showed high normal urinary calcium and oxalate excretion and low 
citrate excretion. A repeat 24 hour collection 8 weeks after the remission of UC showed 
normal both calcium and oxalate excretion but citrate excretion remained low and urine 
of pH 6.5. Patient was told to increase fluid intake to 3L /day and potassium citrate was 
added to his regimen.
Discussion: This case suggests that stone formation may be an early phenomenon 
in UC. We think there might be a benefit in obtaining 24-hour urine collection for stone 
analysis following diagnsois of IBD, as this may help us identify patients at increased risk 
of stone formation. Early simple intervention like increasing fluid intake may prevent stone 
formation. Benefits from empiric treatment with potassium citrate are not well known. 
Further studies need to be done for the better understanding and preventing renal stones 
formation in patients with active and severe IBD.
SA-PO127
Bilateral Renal Artery Stenosis due to Takayasu Arteritis Complicated 
by Complete Renal Artery Occlusion with Complete Spontaneous Renal 
Recovery  Saifullah Kazi, Ghulam Akbar, Paul Robbins.  Nephrology, Lankenau 
Medical Center, Wynnewood, PA.
Introduction: 53 year old female who had established diagnosis of severe bilateral 
renal artery stenosis from unknown cause, admitted for elective repair of the aortic root 
aneurysm and aortic valve replacement for severe aortic regurgitation developing acute 
renal failure from complete renal artery occlusion post operatively due to ischemic insult 
followed by spontaneous recovery.
Case Description: 53 year old female with past medical history of multiple CVA and 
negative embolic workup, presented with syncope at an outside hospital. Workup with 
echocardiogram revealed severe aortic regurgitation. CT angiogram revealed multiple 
small ulcerations within the aorta starting from ascending aorta until iliac artery bifurcation 
with severe stenosis of superior mesenteric artery, celiac artery and bilateral renal arteries. 
Her serum creatinine was at 0.9 and an ultrasound revealed right and left kidnies size to 
be at 11.4cm and 9.4cm respectively. Her serologies for vasculitis were negative. She 
underwent elective repair of the aortic root and aortic valve. Immediately in post operative 
period, patient became anuric due to complete occlusion of the right renal artery based on 
CT angiogram. She was taken to catheterization laboratory with unsuccessful attempt to 
open right renal artery. She was started on hemodialysis next day. A week later, reattempt 
to open right renal artery was again unsuccessful. She was placed on prednisone as her 
biopsy revealed Takayasu Arteritis. After 2 weeks into her course, patient started to have 
spontaneous recovery with renal function and she was taken off the hemodialysis.
Discussion: Renal artery stenosis as a manifestation of systemic vasculitis is rare. With 
an aggressive surgical approach, combined with glucocorticoid therapy, mortality due to 
Takayasu arteritis is less than 10%. In our patient, it is most likely that slow progression of 
renal artery stenosis occurred over time with an acute embolic occlusion postoperatively. 
However, her best functioning kidney on right side likely had spontaneous recovery 
after ischemia based on renal angiograms and potential benefit of steroids by reducing 
inflammation.
SA-PO128
A Case of Kidney Dysfunction and Visual Loss  Patrick Kosciuk,1 Muhammad 
Sohaib Karim,1 Micah R. Chan,1 Anthony Krentz.2  1Div of Nephrology, Univ 
of Wisconsin School of Medicine and Public Health; 2PreventionGenetics.
Introduction: Senior-Loken syndrome is a rare hereditary nephronophthisis (ophtho-
renal syndrome) often presenting with autosomal recessive inheritance, a reduction in 
urinary concentrating ability with bland urinary sediment, and chronic tubulointerstitial 
nephritis with typical progression to end-stage renal disease (ESRD) in individuals younger 
than 20 years old. It was first described in 1961 by Senior et al., and Loken et al.
Case Description: A 29 year old male and his seeing eye dog presented to the kidney 
clinic with uncontrolled hypertension, creatinine of 2.6mg/dl and a history of Leber 
congenital amaurosis since the age of four. Physical exam was unremarkable other than 
nystagmus and severe visual impairment with 5-degree visual field and 20/300 acuity. 
Patient was currently pursuing his PhD via braille and did not appear to have any mental 
impairment. . Family history was remarkable for a healthy sister in her 20s, a paternal uncle 
who passed away from renal failure in his 20s, and his paternal cousin (son of his deceased 
uncle) who had been born with hearing loss. Further evaluation was undertaken, which 
revealed normal electrolytes, unremarkable UA (notably with specific gravity <1.005 and 
absence of proteinuria, hematuria, leukocyte esterase, nitrates, and pyuria), but findings of 
minimal proteinuria (urine protein to creatinine ratio of 0.55). A renal ultrasound revealed 
a 12.4 cm R and 12.6cm L kidney with multiple cysts. Taking into account the history of 
renal dysfunction, visual impairment and renal cysts, patient was referred to a geneticist. 
Genetic studies revealed two autosomal recessive heterozygous mutations in the IQCB1 
gene. A frameshift mutation was seen in c.424_425 del ITT resulting in premature protein 
mutation. Another chromosomal mutation was found as a nonsense mutation in IQCB1 as 
c.1090C>T. This was consistent with a diagnosis of Senior-Loken syndrome.
Discussion: There is no specific treatment for Senior-Loken Syndrome. Uniform 
progression to ESRD is inevitable, and patients are often good renal transplant candidates 
as there is no recurrence of the disease.
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SA-PO129
Clostridium Difficile Associated Peritonitis in a Patient on Peritoneal 
Dialysis  Dimpu M. Patel, Gaurav Jain.  Nephrology, Univ of Alabama at 
Birmingham, Birmingham, AL.
Introduction: Culture negative infectious peritonitis (CNP) is a common and serious 
complication in peritoneal dialysis (PD) patients. It is usually a result of samples failing 
to reach the threshold of microbiological detection, recent antibiotic exposure, or simply 
unusual organisms not routinely tested for. Clostridium difficile (C. diff) infections have 
become more frequent, and more refractory to treatment, and dialysis patients are often 
affected by C diff secondary to repeated exposure to antibiotics, as well as hospitalizations. 
C diff infection should be considered in the differential for CNP in dialysis patients.
Case Description: A 41 AA male on PD since 2012 presented to PD unit with 
complaints of abdominal pain and cloudy fluid. He was started on intraperitoneal antibiotics 
(Vancomycin and Ceftazidime) as an outpatient, though his symptoms of abdominal pain 
worsened requiring a hospital admission within 48 hrs of onset of symptoms. He complained 
of non-bloody diarrhea for 12 hrs on the day of admission. On exam, he was diffusely 
tender in his abdomen, with no guarding/rigidity. Lab data was significant for peritoneal 
fluid WBC count of 7,130 with 85% polys and he was continued on broad-spectrum IV 
antibiotics. Stool C diff toxin resulted positive on day 2 of hospitalization and he was 
started on IV metronidazole. His abdominal pain persisted, and a recheck of PD fluid cell 
counts on Day 3 revealed a WBC count of 17,671 with 79% polys. The PD fluid cultures 
from the PD unit as well as the hospital were negative for any growth. Microbiology lab 
was asked to check his PD fluid for C diff, and the C diff PCR from the PD fluid was 
positive. The vancomycin and ceftazidime were stopped, and oral vancomycin added to 
the metronidazole. His abdominal pain and diarrhea both improved and he was discharged 
to complete a 14 day course of PO metronidazole and vancomycin.
Discussion: Our case study describes culture negative peritonitis in a patient with C 
diff diarrhea that did not respond to broad spectrum IV antibiotics. This prompted further 
investigation of C. difficile peritonitis that was confirmed on lab testing. This case highlights 
the importance of suspecting C diff peritonitis in PD patients with CNP.
SA-PO130
Adequacy of Australian Nephrology Training  Nicholas A. Gray,1 Thomas 
Joseph Beaton,1 Rathika Krishnasamy,1 Nigel David Toussaint,3 Richard K.S 
Phoon.2  1Renal Unit, Sunshine Coast Hospital and Health Service, Nambour, 
Queensland, Australia; 2Renal Unit, Westmead Hospital, Westmead, New South 
Wales, Australia; 3Renal Unit, Royal Melbourne Hospital, Parkville, Victoria, 
Australia.
Background: There has been an increase in the number of doctors training in 
nephrology in Australia. This study aimed to assess the adequacy of nephrology training 
by measuring self-determined competency and skill relevance among recently graduated 
nephrologists.
Methods: A survey was developed by the Nephrology Advanced Training Committee 
of the Royal Australasian College of Physicians. The survey was administered on-line in 
2015 via the annual subscription to the Australian and New Zealand Society of Nephrology. 
Nephrologists who were awarded Fellowship after 2002 were invited to participate.
Results: 113 of a 306 eligible Fellows (37%) completed the survey. 8 respondents had 
trained overseas and were excluded. Median age was 41 years (interquartile range 37-44) and 
63% were male. Medical school was completed in Australia (59%), India (15%), and New 
Zealand (7%). 35% received at least some training in a rural area and 25% were qualified 
in another specialty (mainly internal medicine). 56% had completed and 21% commenced 
a higher degree. Higher degrees were undertaken for career development (43%) and desire 
for a research career (30%). Respondents indicated good training and competency in most 
clinical skills that were relevant to their practice. Training in home hemodialysis (37%) 
and living kidney donor assessment (51%) were considered less adequate, despite these 
areas being considered very relevant to practice. There was a greater mismatch identified 
between training and importance of skills for management and research. This included 
inadequate training in managing complaints (82%), managing a private practice (98%), 
health system knowledge (86%) and regulations (93%), medical directorship (94%), ethics 
approval (76%), research funding (88%), and quality assurance (73%).
Conclusions: Nephrology training in Australia meets the clinical needs of new 
specialists. Similar to findings in USA, training in management and research was considered 
insufficient for the practices of new specialists and should be addressed in updates of the 
curriculum.
SA-PO131
Pediatric Nephrology Workforce and Training: An International 
Perspective  Dorey A. Glenn,1 Adam R. Weinstein,2 Maria E. Ferris.3  1Univ of 
North Carolina at Chapel Hill; 2Dartmouth Hitchcock Medical Center; 3Univ 
of North Carolina at Chapel Hill.
Background: There is a shortage of pediatric nephrology providers in a number of areas 
around the world. We sought to determine pediatric nephrologists’ perspectives on this issue.
Methods: A voluntary web-based survey was deployed via the Qualtrics™ survey 
engine. Members of the International Pediatric Nephrology Association responded 
anonymously to questions about their geographic location, time spent on training, practice 
setting, and impressions on local workforce challenges and opportunities.
Results: The number of responses to date was 38, representing 21 countries from all 
continents. Six percent of the respondents treat both children and adults. The number of 
years required to train in pediatric nephrology was reported as: 2 years (35%), 3 years 
(58%) and 4 years (8%). Nearly 80% of practices were associated with academic settings. 
Sub-specialty training programs are reported in 63% of the respondents’ institutions and 
50% of those with training programs stated that it was difficult or very difficult to recruit 
trainees. Forty two percent of the respondents stated that it was difficult or very difficult to 
find a job after training. The themes most frequently cited on qualitative analysis include 
low availability and interest in the field by trainees, poor compensation, demanding schedule 
and competing family demands.
Conclusions: In this preliminary study of an international cohort of pediatric 
nephrologists, our data suggests a perception of a decreased pediatric nephrology workforce. 
There is also a perceived shortage of available positions in the field. Further data collection 
on workforce issues as it pertains to country-related factors is needed.
SA-PO132
Take Guessing Out of Milestone Ratings – Simplify the Evaluation 
System to Easily Achieve the Next Accreditation System (NAS) Report 
Samantha J. Thompson, Laura J. Maursetter.  Div of Nephrology, Univ of 
Wisconsin School of Medicine and Public Health, Madison, WI.
Background: In an effort to translate into competency-based training, the ACGME has 
developed 24 milestones specific to fellowship. While the milestones are comprehensive, 
it is challenging to determine an individual’s rating through faculty evaluations; many 
of whom are untrained in this system. We aimed to create a simple scoring system that 
translates the milestones into observable nephrology activities that can be completed daily 
on a handheld device.
Methods: For each nephrology rotation, a list of 5-10 frequent activities was developed. 
For every activity, a description for the five levels of competency was written to standardize 
the score. The activities were mapped to 1-4 NAS milestones. The evaluations were built 
in Google Forms and delivered daily to supervising faculty members. Using a four-click 
system, the observer can submit a fellow evaluation with most done on mobile devices. 
If faculty members wish to express a narrative, a free-text response box is provided for 
comments.
Results: Of the 914 possible evaluations over a nine-month period of time 727 
evaluations were returned. This provided data points to distinguish scores among all fellows 
in all of the NAS milestones.
In Clinical Competency Committee meetings thus far, 1 of 276 scores have been 
adjusted from the scores provided by the evaluation system.
Conclusions: This is an easy to use scoring system that has resulted in immediate 
feedback that is activity-specific and feed into NAS milestones easily and effectively. By 
translating the evaluation system into specific activities that any nephrologist can observe, 
a robust amount of valuable data has been obtained. The 4-click system has yielded an 
excellent response rate with more narrative comments than were previously obtained with 
monthly evaluations.
SA-PO133
American Society of Nephrology In-Training Exam for Fellows 2010-2014: 
Scoring and Item Statistics  Suzanne M. Norby,1 Troy J. Plumb,2 Nancy Day 
Adams,3 Ryan Russell,4 Mitchell H. Rosner,5 Mark G. Parker.6  1Mayo Clinic; 
2Univ of Nebraska Medical Center; 3Univ of Connecticut Health Center; 
4American Society of Nephrology; 5Univ of Virginia School of Medicine; 6Maine 
Medical Center.
Background: Since 2009, the American Society of Nephrology (ASN) In-Training 
Exam (ITE) has been administered annually to fellows. This study reports 2010-2014 
overall scale scores, item difficulty, item discrimination, and reliability.
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Methods: ITE annual reports provided by the National Board of Medical Examiners 
were reviewed and summarized.
Results: Scale score for all was 480±104 (mean ± SD); 1st-year fellows (Y1, n=2,020) 
445±96, 2nd-year (Y2, n=2,005) 515±100, and 3rd-year and higher (n=112) 509±113. 
Standard error of the mean ranged 41-45. The 2010 ITE had 150 core items only. 2011 
and 2012 ITE had separate 20-item urinalysis and renal pathology modules administered 
to Y1 and Y2 respectively (not included in total test statistics). In 2013 and 2014, all 
completed two 10-item modules on these topics (included in statistics). A mean of 6.6 
core items (4.4%) were deleted per year after adjudicating items with high difficulty or 
negative discrimination. Content areas aligned with American Board of Internal Medicine 
Certification Exam: General Aspects of Chronic Kidney Disease (CKD), Glomerular/
Vascular (G/V), Tubulointerstitial/Cystic (TI/C), Acute Renal Failure/ICU Nephrology 
(ARF/ICU), Kidney Transplant, Hypertension, Sodium/Water (Na/H20), Acid-Base/
Potassium (A-B/K), Mineral Metabolism (MM), and Clinical Pharmacology (CP), plus 
Ethics. Though examinee abilities typically vary yearly, overall total test average p value 
was 0.67. ARF/ICU, Na/H20, MM, and CP tended to be less difficult (average p value 
0.7) and TI/C more difficult (average p value 0.58). Total test mean item discrimination 
biserial correlation averaged 0.21, highest for A-B/K (0.28) and lowest for CKD (0.18). 
Total test reliability (α) averaged 0.81; highest for G/V (0.46) and lowest for TI/C (0.25).
Conclusions: As expected, scale scores were higher for Y2 than Y1 fellows. Over 95% 
of administered items were scored; among those, mean item difficulty, item discrimination, 
and reliability varied among content areas.
Funding: Private Foundation Support
SA-PO134
What Are We Doing? A Survey of U.S. Nephrology Fellowship Program 
Directors  Scott E. Liebman, Mahrukh Rizvi, Catherine A. Moore, Rebeca D. 
Monk.  Medicine- Nephrology Div, Univ of Rochester, Rochester, NY.
Background: Recent years have seen a decrease in Nephrology fellowship applicants. 
Long work hours may be partially responsible, and may affect the educational mission of 
the fellowship. Our survey addresses fellow work load and educational experiences to 
further explore these issues.
Methods: We distributed a survey for nephrology program directors via the Training 
Program Directors’ website. The survey addressed fellows’ service load and the scope of 
educational activities offered by the fellowship.
Results: 57 out of 147 programs responded (39%). Most are 2 years long, with a mean 
of 7 fellows, and are “front loaded”- 64% require ≥ 7 months of inpatient service during year 
one. Inpatient services are usually (93%) covered by one fellow with significant resident 
involvement. NP’s and PA’s help cover about 15% of services. The busiest services have 
about 21-25 patients, although 13% of programs averaged ≥ 26 patients. At their busiest, 
these services have more than 30 patients, occasionally surpassing 50 patients. About one 
quarter of programs cap the number of patients and/or notes for which a fellow is responsible. 
Night call is most often divided equally among all years. Weeknight call is typically one 
night at time (74%) covering a single hospital (66%). Fellows in the call rotation typically 
cover ≥ 10 nights over a three month period and ≥ 1 week-end a month. Most fellows do 
one weekly half day clinic, averaging 4-6 patients per session with a faculty: fellow ratio 
typically £2:1. Clinic structure is not usually modified during fellows’ inpatient service. 
Longitudinal coverage of HD and PD patients is provided by 82% and 61% of program 
respectively. Educational conferences ranged from 2-6 hours per week. Faculty didactic 
teaching varies from < 1 hour a week to 5 hours per week; one hour is typical. Fellows usually 
give 2-6 formal presentations yearly, although in some programs this is significantly more.
Conclusions: Our survey underscores the large variety in work load, practice patterns 
and frequency of educational conferences at different institutions and provides a framework 
to help address the service/education balance during nephrology fellowship.
SA-PO135
Perceptions of Nephrology Among Internal Medicine Residents 
Michael N. Daniels,1 Ivan E. Porter,2 Nabeel Aslam,2 Deepika Jain,1 Charity 
Curtis,3 Hope Kincaid,3 Sharon E. Maynard.1  1Div of Nephrology, Lehigh Valley 
Health Network/ Univ of South Florida, Allentown, PA; 2Div of Nephrology and 
Hypertension, Mayo Clinic College of Medicine, Jacksonville, FL; 3Network 
2ffice of Research and Innovation, Lehigh 9alley Health NetZork/ Univ of 
South Florida, Allentown, PA.
Background: As interest in nephrology declines, we sought to identify factors 
influencing career interest among internal medicine (IM) residents.
Methods: This is a repeated cross-sectional survey of IM residents to assess perceptions 
of nephrology and the impact of these perceptions on career decisions. All categorical 
internal medicine residents at two institutions were invited to participate in 2012, prior 
to the initiation of a nephrology fellowship program (Group 1); and in 2015, three years 
following initiation of a nephrology fellowship program (Group 2).
Results: 131 of 156 residents (84.0%) completed the survey. A total of 14.8% (19/131) 
of residents indicated an interest in a nephrology career, with 6.25% (8/131) indicating 
Nephrology as their first choice. Cardiology (21.1%) and Hospitalist (12.5%) were the 
most popular career choices. The presence of a Nephrology Fellowship program did not 
increase resident career interest in nephrology (14.5% in Group 1 vs. 15.1% in Group 
2). Residents’ perceptions of nephrology were not significantly different in Group 1 vs. 
Group 2. Negative perceptions of nephrology most commonly endorsed by residents 
were: renal pathophysiology is too complex (22.9%), poor preparation in medical school 
(22.14%), few opportunities for procedures (26.7%), long work hours (24.4%), and long 
hours/burdensome call for nephrology fellows (27.5%). The majority of residents (83.2%) 
reported exposure to positive role models in nephrology. Experiences cited as having a high 
impact on career choice included: mentors/role models in the field (71.65% of residents) 
and rotations during residency (57.14%).
Conclusions: The presence of a nephrology fellowship program had no effect on IM 
residents’ interest in nephrology careers. Residents endorsed several negative perceptions 
of nephrology which may affect career choice.
SA-PO136
Insight into the Declining Interest in Nephrology  Sherry Mansour, Yeunjung 
Kim, Mark A. Perazella.  Nephrology, Yale School of Medicine, New Haven, CT.
Background: The decline of interest in nephrology is very concerning with an 
increasing number of unfilled fellowship spots every year. Identifying the reasons behind 
such decline is crucial to reverse this trend and preserve the future nephrology workforce. 
Several surveys have attempted to isolate this problem but none targeted US IM residents. 
We present the results of a survey targeting IM residents.
Methods: A web-based survey was conducted using survey monkey. 10 questions 
designed to help understand the reasons behind the decline of interest in nephrology were 
utilized. The survey link along with recruitment letter and consent form were sent to all US 
IM residency programs. Email addresses were obtained from the Alliance for Academic 
Internal Medicine website.
Results: 531 residents responded to the survey. 81% of those who completed the survey 
answered “No” to the question asking if they had interest in nephrology. The most common 
reason cited was a disheartening patient population, followed by salary, work hours &amp; 
lack of understanding. 50.9% found nephrology “difficult” with the most challenging 
topics being glomerulonephritis (GN), acid/base &amp; transplant. The respondents noted 
that exposure to interventional nephrology; transplant &amp; GN might increase their 
nephrology interest. Of those interested, more exposure to GNs during residency was felt 
to likely reinforce their interest.
Conclusions: These survey results demonstrate that most IM residents aren’t interested 
in nephrology and that restructuring of nephrology electives in residency programs to include 
enhanced exposure to GNs, transplant, and nephrology procedures might increase interest. 
Nephrology rotations are primarily an inpatient experience with exposure to critically ill 
AKI patients or complicated ESRD patients with significant recidivism. This experience 
leads to the perception that the nephrology population is disheartening. Since this is the 
most common reason why residents lack interest, changing the structure of nephrology 
electives in IM residencies to allow for more outpatient exposure with emphasis on GNs 
and transplant might be crucial for enhancing interest in nephrology fellowship training 
and a career in this subspecialty.
SA-PO137
Challenges and Opportunities in the Training and Retaining of Nephrology 
Workforce in Developing Countries: A Review of the Current Trends and 
Implications for Optimal Kidney Disease Care  Julius Oluoch Okel,1 Bilal 
Qarni,1 Timothy Olusegun Olanrewaju,2 Aminu K. Bello.1  1Univ of Alberta, 
Canada; 2Univ of Ilorin, Nigeria.
Background: Nephrology education has undergone rapid advancement leading 
to the development of comprehensive curricula and standards towards a high quality 
patient-centered care. These standards are often lacking on issues critical to the practice 
of nephrology in developing countries.
Methods: We evaluated nephrology training programs within the context of the 
healthcare systems across 25 upper-middle and high income countries to identify best 
practices and opportunities for adoption in developing nations. We further reviewed training 
guidelines from the major professional societies (ISN, major national societies) on content 
and process of training. Data were obtained from multiple sources (government reports, 
published literature, and websites of professional/licensing authorities, World Federation 
for Medical Education (WFME) and its Regional branches. The WFME 3-set of Global 
Standards on medical education at all levels were applied in evaluating training programs 
on the domains of training process, assessment, and evaluation.
Results: We found 5 key thematic problems with the current training model in 
developing countries that included 1)an emphasis on factual information, memory and 
recall (core knowledge content), 2) absence of needs assessment and evaluation, 3)structure 
and organization of training is a product of established tradition than of evidence and not 
in congruent with health system changes and dynamics, 4) a didactic and opportunistic 
instructional model with other core areas of competencies (professionalism, collaboration, 
advocacy, managerial skills and of scholarship are not formally taught, and 5) application 
of summative rather than formative assessment methods.
Conclusions: There are similarities and differences in structure, content and process 
of training programs across both developed and developing countries. The results have 
implications for re-design of training programs in the developing world for quality education 
and better clinical care delivery in patients with kidney diseases addressing local needs 
and priorities.
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SA-PO138
Creating and Enhancing Interest in Nephrology Careers:  A Novel 
Nephrology Elective Experience for Medical Students  Hitesh H. Shah, 
Kenar D. Jhaveri.  Nephrology, Hofstra North Shore-LIJ School of Medicine, 
Great Neck, NY.
Background: Interest in nephrology careers continues to decline in the United States 
(US). The type of nephrology elective that US medical students experience may play an 
important role in creating and enhancing interest in nephrology careers.
Methods: At our institution, we created a novel 4-week nephrology elective experience 
for medical students. Our redesigned elective included both 2-week inpatient (IP) and 
2-week outpatient (OP) nephrology experiences. The OP rotation included 10 half-days 
of various nephrology clinic experiences, 2 half-days of immediate post-transplant clinic, 
1 half-day of kidney donor evaluation clinic, 2 half-days of peritoneal dialysis clinic and 3 
half-days of outpatient hemodialysis unit rounding. The redesigned elective also included 
education conferences. From 7/2012 to 2/2015, nine 4th year medical students (all from 
different US medical schools) completed our redesigned nephrology elective. To evaluate 
the novel elective experience, all medical students were asked to complete an anonymous 
on-line survey upon completion of their rotation.
Results: All students responded to our survey. All reported adequate OP nephrology 
exposure during their elective. 89% had worked with 1 or 2 faculty members during the IP 
setting. In comparison, 78% were exposed to at least 4 different faculty members during 
the OP experiences. All students had interacted with at least 3 fellows. All reported that 
the elective experience enhanced their exposure and knowledge in nephrology and that 
they would recommend this elective to other medical students. They also thought that this 
elective structure provided them with a better insight into what nephrologists do in practice. 
78% reported that this elective experience created an interest in nephrology career. 56% 
responded that they would consider nephrology as one of their 3 top career choices as a 
result of this elective experience.
Conclusions: We believe that the restructured nephrology elective provides the 
medical student with a much needed and realistic exposure to nephrology careers. Based 
on our experience, we recommend all training programs to consider this elective structure 
for medical students.
SA-PO139
Journal Publication of Nephrology Fellows Case Report Presentations at 
ASN Kidney Week 2012-2013  Hitesh H. Shah,1 Nairuti H. Shah,2 Rushang 
Parikh,3 Kenar D. Jhaveri.1  1Nephrology, Hofstra North Shore-LIJ School of 
Medicine, Great Neck, NY; 2Colgate Univ, NY; 3SUNY Upstate Medical Univ, NY.
Background: The inception of the fellows case report (CR) category at the ASN 
Kidney Week (KW) occurred in the year 2012. However, the number and types of CR 
abstracts accepted for presentation at ASN KW 2012-2013 is not known. Peer-reviewed 
journal publication (PR-JP) of these previously presented CR abstracts at ASN KW is 
also not known.
Methods: All previously accepted fellows CR abstracts from ASN KW 2012-2013 were 
reviewed and further categorized as follows: glomerular diseases (GN), tubulointerstitial 
diseases (TIN), acute kidney injury (AKI), fluid-electrolyte and acid-base disorders (FE-
AB), dialysis (D), kidney transplant (KT), genetic disorders (GD), mineral diseases (MD), 
and other (O) cases. To determine the PR-JP rate of these CR abstracts, a literature (PubMed) 
search was performed in May 2015.
Results: A total of 415 abstracts were presented in the fellows CR category at the 
ASN KW 2012-2013. Compared to KW 2012, there was a 7.5% increase in CR abstract 
presentations at KW 2013. Over these previous two KW meetings, nearly one-third (31.6%) 
were GN related case presentations. The remaining abstracts were FE-AB (15.2%), AKI 
(14.4%), KT (11.8%), D (11.8%), TIN (5%), MD (4%), O (4%), and GD (2.2%) related 
presentations. Compared to KW 2012, there was increase in GN related presentations (from 
55 to 76) at KW 2013. So far, only 72 (17.3%) out of the 415 abstracts have been published 
as papers in peer-reviewed journals. One abstract was published as a letter to the editor 
format. Of those that were published, 31.5% were GN related case reports. Interestingly, 
22% of these journal publications did not list the lead author of the KW CR abstract as the 
primary author of the paper.
Conclusions: Based on our study, it seems that there is an increased interest among 
fellows to present CR abstracts at ASN KW. Nearly one-third were GN related case 
presentations. However, so far, less than one-fifth of the fellows CR abstracts presented 
at KW 2012-13 have been published in peer-reviewed journals. Reasons for this low 
publication rate is not known. Measures to enhance CR publications need to be considered.
SA-PO140
Analysis of Published Medical Student Related Nephrology Medical 
Education Research  Sarah D. Bayefsky,1 Hitesh H. Shah,1,2 Kenar D. Jhaveri.1,2 
1Hofstra NSLIJ School of Medicine; 2Nephrology, Hofstra NSLIJ School of 
Medicine.
Background: Undergraduate (medical student) related medical education research in 
nephrology is not well studied. This analysis aims to assess the rigor of the studies describing 
teaching methods used in medical student education in nephrology.
Methods: A review of the English literature on nephrology education of medical 
students was conducted on two major online academic search engines (PubMed and ERIC). 
References of the papers discovered in this search were also reviewed. Conference abstracts 
were not investigated. The empirical studies were categorized by subject within nephrology. 
The research design of each study was then recorded.
Results: 26 original studies were found in which a method of teaching nephrology to 
medical students was described. The studies dated from 1977 to 2015. The focus of these 
teaching experiences was as follows: anatomy (3.3%), physiology (23.3%), pathophysiology 
(26.7%), pathology(10%), treatment (20%), and general nephrology (16.7%). 4 of the 
pathophysiology studies were also classified under other categories, so there were 30 
total topics. The papers were also categorized into types of assessments, with two papers 
containing two different types of studies for a total of 28 types of assessment. 14.2% 
had either no assessment of the educational experience or had a description too vague 
to categorize it; 3.6% involved a questionnaire about the existing educational approach 
before a novel method was implemented; 57.1% involved surveys or questionnaires after a 
practice was carried out; 7.1% assessed the method both before and after; 10.7% were case 
studies or ethnography; and 7.1% included a randomized controlled trial. The randomized 
controlled trials involved teaching techniques focused on the pathophysiology of renal 
disease. Overall, students responded positively to teaching that is interactive.
Conclusions: Rigor is lacking in most studies done in medical student education 
research in nephrology. Over 50% of the studies done had a survey-based design. More 
randomized controlled trials are needed to assess reliably the effectiveness of the educational 
techniques in nephrology medical education research.
SA-PO141
Participation in the Open, Online, Twitter-Based, Nephrology Journal Club, 
NephJC  Joel Topf,1 Matthew A. Sparks,3 Edgar V. Lerma,2 Thomas Oates,6 Paul 
J. Phelan,5 Francesco Iannuzzella,7 Swapnil Hiremath.4  1St. John Providence 
Hospital, Detroit, MI; 2UIC-Advocate Christ Medical Center, OakLawn, IL; 
3Duke, Durham, NC; 4Univ of Ottawa, ON, Canada; 5Royal Infirmary of 
Edinburgh, United Kingdom; 6Imperial NHS Trust, London, United Kingdom; 
7Arcispedale Maria Nuova, IRCCS, Reggio Emilia, Italy.
Background: We established an online nephrology journal club, NephJC, in April 2014 
that meets twice monthly to discuss emerging research and clinical practice guidelines. 
We invite content experts and manuscript authors to the discussion. The meeting occurs 
on the public forum Twitter, allowing any interested individual to join. The purpose of 
NephJC is to provide a recurring, academically-minded event on Twitter to help establish 
this communication channel as one for serious nephrology discourse. In addition, online 
journal clubs are becoming a critical route for post publication peer review. In order to 
assess the impact of NephJC we reviewed participation in the discussions over the first year.
Methods: We searched the Symplur analytics database for all tweets with the hashtag 
#NephJC from March 16, 2014 to June 2, 2015. We measured the numbers of participants, 
number of tweets and assessed participation over the first 27 NephJC sessions.
Results: From April 29th to June 2nd, 2015, 27 topics were discussed. 27 Chats were 
at 9PM Eastern for the Americas and starting Dec 18, 2014 a Europe and Africa chat was 
added at 8PM GMT. 10 GMT chats have been held, generally one day after the American 
chat. 1,022 Twitter accounts have used the hashtag #NephJC a total of 14,891 times. The 
median journal club chat has 41.5 (IQR 30.5-56.5) participants and 353.5 (IQR 268.5-633.5) 
tweets. The number of participants and tweets increased over time (P<0.01). The addition of 
the GMT chat was responsible for some of that growth (median number of tweets increased 
from 273 to 662.5, P<0.001, participants from 35 to 60.5, P<0.001).
Conclusions: NephJC has established itself as an integral part of the online digital 
mentorship curricula. The sustained usage and growth in participation of NephJC 
demonstrates the positive value of Twitter in medical education.
SA-PO142
Three Years’ Experience with the Online Educational Game, NephMadness 
Joel Topf,1 Kenar D. Jhaveri,3 Edgar V. Lerma,5 Warren L. Kupin,4 Paul J. 
Phelan,6 Matthew A. Sparks.2  1St. John Providence Hospital, Detroit, MI; 2Duke, 
Durham, NC; 3Hofstra NSLIJ School of Medicine, New York, NY; 4Univ of Miami 
Miller School of Medicine, Miami, FL; 5UIC/ Advocate Christ Medical Center, 
OakLawn, IL; 6Royal Infirmary of (dinburgh, United Kingdom.
Background: NephMadness is an educational project that leverages social media and 
Free Open Access Medical Education (FOAMed) to highlight advances and important issues 
in nephrology. NephMadness 2015 was the third year of this project.
Methods: The curriculum takes the form of an online game that mimics the NCAA 
basketball tournament, March Madness. Participants attempt to predict the winners of 
hypothetical contests between nephrology concepts. The NephMadness field consists of 64 
concepts from 8 different domains of nephrology: cardiorenal, onconephrology, nutrition, 
obstetrics, infectious disease, vascular surgery, genetics, and critical care. The theme for 
2015 was nephrology’s interaction with other specialties of medicine. The editorial content 
was created by a team of nephrologists with experience in social media. Additionally, content 
experts assisted in building the field (selection committee) and fact-checked the editorial 
content. A blue ribbon panel of nephrologists determined the winners of each match-up. 
Engagement in the contest was assessed by participation, website traffic and use of the 
hashtag #NephMadness on Twitter.
Results: There were 342 entries in NephMadness (25% increase over 2014) 
representing 26 countries with three quarters from the US. Gender breakdown was 31% 
female, 69% male. 46% of the contestants were attendings, 24% fellows, 10% residents 
and 9% medical students. The hashtag #NephMadness was tweeted 4,297 times (190% 
increase) by 401 people (144% increase) between Jan 16 and June 16. Web traffic to the 
hosting site was triple its monthly average and included the single highest traffic day ever.
Conclusions: NephMadness is increasing engagement on three unique metrics. We 
believe this indicates that pairing social media with freely available, expert-generated 
content can stimulate interest in nephrology.
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SA-PO143
Awareness of AKI in Low Resource Settings: A Global Survey 
Joseph Lunyera,1 Kajiru Kilonzo,2 Andrew J.P. Lewington,3 Karen E. Yeates,4 
Fredric O. Finkelstein.5  1Duke Univ; 2KCMC; 3Leeds Teaching Hospitals; 
4Queen’s Univ; 5Yale Univ.
Background: The ISN has set a goal of eliminating preventable deaths from AKI 
by 2025—the “0X25” initiative. However, there is limited awareness of the challenges 
presented by AKI in terms of diagnosis, treatment and management in low resource 
settings (LRS).
Methods: We reached out to nephrologists working in LRS using a web-based 
instrument of 18 questions. Responders were asked what strategies should be considered 
to increase the awareness of AKI in LRS and recommend approaches to heighten this 
awareness. 26 respondents were from 5 WHO world regions, including 54% from Africa.
Results: The major barriers to raising awareness cited by all were inadequate training, 
shortage of adequately trained health workers and lack of awareness of the significance 
of AKI by healthcare workers, government officials and the general public. Additional 
factors cited were limited patient access to health facilities, limited diagnostic and 
treatment facilities, lack of support for AKI programs, lack of clinical practice guidelines 
for AKI, poor communication systems, limited research funding and lack of linkages of 
AKI programs to other health projects. Health centers (HCs) were broken down into rural, 
district and regional HCs. Supplies available for diagnosis (serum creatinine and BUN) 
and management (IV fluids, antibiotics, anti-venom) of AKI are limited in rural HCs. All 
noted that hemodialysis services were available but only in selected, large urban centers. 
Peritoneal dialysis was limited to regional HCs.
Conclusions: Increasing the awareness of AKI in local, district, and regional 
HCs requires a multi-faceted approach, reaching out to government officials, hospital 
administrators, physicians, nurses, local health care workers, community leaders, 
international organizations and the general public. The success of this initiative involves 
the development of meaningful and targeted educational programs, training materials, and 
treatment guidelines tailored to the local situations. Alliances will need to be formed with 
governmental agencies, non-profit organizations and global health programs. Support needs 
to be provided for additional research programs.
SA-PO144
Acute Kidney Injury Education to Nursing and Assistant Health Care Staff 
Mansoor N. Ali.  Renal Medicine, Calderdale and Huddersfield Hospitals NHS 
Foundation Trust, United Kingdom.
Background: Acute Kidney injury (AKI) is a global healthcare problem. It carries 
significant mortality and incurs heavy costs to the National Health Service. Extensive 
work has been done recently both at undergraduate and postgraduate level to ensure front 
line medical staff have better understanding in managing AKI. One such important area 
of focus involves the need for training nursing and assistant healthcare staffs who care for 
patients presenting with AKI. 
Purpose of the study: To gauge the understanding of AKI amongst nursing and 
healthcare assistants working on busy acute medical admissions unit.
Methods: The anonymous questionnaire was aimed at the nursing and assistant health 
care staff working on the admissions unit at two large district hospitals. The length of time 
since qualification ranged from few weeks to 16 years. The questionnaire was followed 
by planned teaching, simulation training and workshop sessions. The process was carried 
out within a period of 2 months.
Results: The Questionnaire was completed by 50 staff members. It included series of 
questions aimed at defining and managing AKI from a nursing perspective. 24 out of 50 were 
able to define AKI. Only 5 out of 50, have never cared for patients with AKI. Not all were 
aware of the symptoms of AKI; common answers given by 40 respondents were “reduction 
in urine output” and “dehydration.” All participants answered “yes” to monitoring urine 
output and understood the significance of fluid monitoring but all admitted more needed 
to be done to ensure accurate documentation in the patient’s notes. Other questions asked 
were if nurses check patient’s blood results on the system server to which most replied 
“no” and if medications were regularly reviewed during drug rounds. Surprisingly, not all 
were aware of nephrotoxic medications and only 20 respondents would regularly review 
drug charts in the context of renal failure.
Conclusions: The questionnaire and the training sessions identified lack of better 
understanding of AKI and its management. There needs to be a stronger emphasis on the 
introduction of AKI and its management during their training years and development of 
mandatory online e-learning modules.
SA-PO145
Evaluation and Management of Acute Kidney Injury – A Trainee Survey 
Savio M. Kumar, Prabhat Singh, Priya S. Srivastava, Adedeji Sodeinde, 
Charuhas V. Thakar.  Nephrology, Univ of Cincinnati.
Background: Aki occurs in 1-in-3 hospitalized patients, and majority of those are 
managed by non-nephrology specialties, including trainees.
Methods: The renal fellowship program designed an online anonymous survey, 
distributed to trainees (students, residents, fellows), to understand their level of knowledge in 
recognition and management of AKI. 37 questions were classified into following categories: 
knowledge of guidelines; prognostic factors; and drug safety. Results are represented as 
aggregate proportions.
Results: 104 trainees responded to the online survey; 50% were male, 84% US medical 
graduates and 70% were residents/fellows. 50% were affiliated to medical specialties; 
and 53% had spent at least one elective in nephrology. In terms of AKI definition: 51% 
use serum creatinine (SCr) as the most important factor to diagnose AKI, whereas 20% 
use urine output. Majority (76.1%) agreed that rise of 0.3 mg/dl or 1.5 times of baseline 
SCr was clinically relevant, in concordance with current guidelines. RIFLE criteria were 
most commonly used (42%), followed by KDIGO (13%); and 90% agreed that guidelines 
help in standardization, and management of patients. 85% concurred that AKI impacts 
short and long-term outcomes, however, majority (60%) felt dialysis requirement was the 
most important clinical predictor of outcome. Majority (67%) felt that early involvement 
of nephrology services is helpful in AKI management; 66% sought nephrology input to 
determine the cause of AKI/co-management, and 7% viewed nephrology role purely for 
procedural delivery of dialysis. As for drug safety, 89% reported to pay attention to renal 
function while drug dosing, but 70% felt that this was the responsibility of either pharmacy 
or ordering team. In terms of follow-up 61% of subjects felt that follow-up was only needed 
in moderate to severe AKI cases or in non-recovery; 86% preferred that in < 30 days, and 
64% preferred that to be with primary care.
Conclusions: Most of the trainees displayed good knowledge of AKI guidelines 
(RIFLE), seek timely nephrology involvement and view it to be beneficial. More work 
needs to be done in terms of improving knowledge/practice about drug safety and follow-
up care in AKI.
SA-PO146
Adherence to Care Bundles for AKI – Challenges in Supporting Education 
and Measuring Compliance  Melanie Louise Sully, Christopher J. Mulgrew. 
Renal Medicine, Royal Devon & Exeter Hospital, Exeter, Devon, United 
Kingdom.
Background: AKI typically occurs as a consequence of intercurrent illness in patients 
with multiple comorbidities and risk factors. The use of clinical guidelines to assist medical 
and nursing staff in AKI management has been adopted by most secondary care institutions 
in the UK. We have previously presented our use of e-alerts for AKI as a prompt to improve 
AKI care (Mulgrew et al, ASN, 2013). Clinical guidelines were prompted by the e-alert 
and widely publicised to staff.
Methods: In a model similar to the NHS Safety Thermometer, snapshots of compliance 
with 6 key elements of the AKI guidelines on 4 medical wards was measured by identifying 
patients from AKI e-alerts. These included documentation of AKI, medication review, 
clinical assessment and ongoing investigation/monitoring. Awareness was supported by an 
AKI Education nursing team, working with medical and nursing staff. Monthly compliance 
was assessed over a period of one year.
Results: Mean compliance for all elements of the guidelines improved from 52% to 
69% over the year. Significant variability was seen, often associated with notable workforce 
challenges such as new medical staff or periods of increased activity.
Variability in compliance with individual elements of the care bundle also existed in 
different clinical areas. Analysis allowed for targeted support and education to clinical teams.
Conclusions: Supporting medical and nursing teams to manage AKI in secondary care 
in order to prevent progression and treat promptly remains challenging. A number of external 
factors frequently impact upon adherence to guidelines and support needs to be planned in 
order to continue to maintain high standards and optimise patient care. The use of a Safety 
Thermometer, allowing performance to be analysed and comparisons made between clinial 
areas, may continue to be useful in improving performance and patient outcomes in AKI.
SA-PO147
Internal Medicine Residents Knowledge of Vein Preservation in Chronic 
Kidney Disease Patients  Sandesh Joshi, Jamie Alton Green, Maria C. 
Bermudez.  Nephrology, Geisinger Medical Center, Danville, PA.
Background: Vein preservation is important among CKD patients for future 
arteriovenous fistula potential. House staff plays critical role in managing these patient 
population and preserving their vein for future arteriovenous fistula. Their knowledge and 
current practices directly affects the outcome for vein preservation among these patients.
Methods: We conducted a survey among 44 internal medicine residents to understand 
their baseline knowledge and current practices regarding vein preservation. The survey 
was conducted at Geisinger Medical center, Danville,PA.
Results: 44 residents were included in the survey. Only 6.8% (3) were able to correctly 
identify patient population, on whom we should avoid particular arm for IV draws, BP 
measurements, peripherally access or peripherally inserted central catheters. Two-third 
(27) answered non-dominant arm to avoid for these procedure and 13.5% (6) responded 
side does not matter. 81.8 %( 36) answered that nephrology should be consulted prior to 
peripherally inserted central catheters placement for CKD 4 patient. 93.1 %( 41) answered 
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correctly that peripherally inserted central catheters can damage peripheral veins .52 %( 23) 
knew alternative of PICC line was tunneled internal jugular catheter, however 34 %( 15) 
answered tunneled subclavian catheter as an alternative. 55 %( 24) did not know preferred 
site for peripheral access, blood draws. 63 %( 28) has never written orders for nurse to 
request to avoid particular arm for IV draws, BP measurements in advanced CKD patients 
or patients on HD, 90%(31) have never requested a bedside sign to avoid particular arm 
for these patients.
Conclusions: Baseline knowledge was poor regarding vein preservation in CKD 
patients and very few residents have engaged in practices to preserve veins. More resident 
education is needed to engage them in vein preservation for CKD patients.
SA-PO148
Vascular Access and Transplant Referral Rates in CKD: An Ongoing 
Performance Improvement Project for Nephrology Fellows  Nardos Belayneh, 
Anuj Regmi, Jusmin Patel, Divakar Jammalamadaka, Elias Ugwu, Noble 
Iwuagwu, John Jason White, N. Stanley Nahman, Lu Y. Huber.  Medicine, 
Georgia Regents Univ.
Background: Referral for vascular access (Ac) and kidney transplantation (Tx) 
are important management facets of CKD. We previously conducted a performance 
improvement project assessing Ac and Tx referral rates (RR) in CKD patients from 
the Nephrology fellows’ clinics. Following an educational intervention, there was an 
improvement in transplant RR (JASN 25:786A, 2014). To evaluate the sustainability of 
this initiative, we conducted a follow-up analysis.
Methods: This performance improvement project was conducted in 3 phases at the 
Charlie Norwood VAMC; Phase 1 (baseline, 1/1-4/30, 2013), Phase 2 (post-intervention, 
8/1-11/30, 2013) and Phase 3 (follow-up, 1/1- 4/30, 2015). Data extraction was conducted 
by three, 2-fellow teams, each reviewing the other’s RR for all patients seen in the previous 
4-month period. The analysis was sorted by eGFR (ml/min/1.73m2): for eGFR<15, both Ac 
and Tx RR were recorded. In addition, Tx RR for eGFR 15-20 was documented.
Results: 1114 total records were reviewed (349, 361, and 404 for Phases 1, 2 and 3, 
respectively). Table 1 indicates the number of patients and RR in those with GFR<20. RR 
for Ac through all 3 phases were steady at 72-73%. Tx RR were improved after intervention 
and were sustained in Phase 3.
Table 1. Referral in patients with GFR <20 in different study phases. Results presented as number 
of patients (%)
Phase 1 Phase 2 Phase 3
GFR 
15-20 GFR<15
GFR 
15-20 GFR<15
GFR 
15-20 GFR<15
N 79 36 30 22 18 29
Transplant referral 9 (11%) 18 (50%) 11 (37%) 15 (67%) 8 (44%) 19 (66%)
Vascular Access 
referral - 26 (72%) - 16 (73%) - 21 (72%)
Conclusions: Referral rates for kidney transplantation by Nephrology fellows 
improved after a chart review and educational intervention were performed. Vascular access 
referrals from this study remained stable. This work suggests that outpatient performance 
improvement projects conducted by Nephrology fellows confer peer review accountability 
for outpatient practice habits, heightens trainee awareness of key referral issues, and appears 
to help sustain or improve referral rates for vascular access and kidney transplantation.
SA-PO149
Impact of Standardized Electronic Documentation in an Academic 
Nephrology Setting  Leslie P. Wong,1 Emilio D. Poggio.1,2  1Nephrology and 
Hypertension, Cleveland Clinic, Cleveland, OH; 2Transplant Center, Cleveland 
Clinic, Cleveland, OH.
Background: Reimbursement depends on documentation and billing based on 
complexity of care. Academic nephrologists are under pressure to improve productivity 
measured by revenue and relative-value based units (RVUs). Incorrect documentation or 
billing may result in loss of revenue and RVUs despite services having been provided. 
Standardized electronic templates were introduced in an academic nephrology setting to 
help address this issue.
Methods: Standardized templates based on Medicare 1997 Guidelines were introduced 
in July 2014 for all inpatient nephrology encounters. A training presentation was provided 
to teach nephrologists proper use of the templates. 73,314 inpatient charges submitted by 
22 academic nephrologists between January 2012 and March 2015 were reviewed. Data 
included the current procedural terminology (CPT) code specifying the type of service, the 
identity of the nephrologist and any adjustments made by the coding department. Adjusted 
charges were accompanied by the reason for adjustment, the corrected CPT code and a 
revenue change based upon Medicare reimbursement. RVUs were calculated using the 
Medicare National Physician Fee Schedule.
Results: Before July 2014, 6.2% of charges were adjusted compared to only 2.8% 
after July 2014. The mean work RVU loss per adjustment decreased from 1.15 to 1.00 
(p<0.01). The mean revenue loss per adjustment improved from $270.88 to $229.56 
(p<0.01). Multivariate regression identified factors associated with worse productivity 
adjustments: encounters before July 2014, more than 10 years of academic experience 
and transplant nephrology (all p-values <0.01). Factors associated with improvement in 
adjustments were encounters after July 2014, ICU encounters and less than 10 years of 
academic experience (all p-values <0.01).
Conclusions: Standardized templates led to significant reductions in revenue/work 
RVU losses per encounter at a large academic nephrology center. Nephrologists with more 
than 10 years of academic experience and transplant nephrologists performed worse than 
their peers. Efforts to improve documentation and billing may have important implications 
for academic nephrologists.
SA-PO150
Nephrology Documentation and Billing Educational Needs at an Academic 
Medical Center  Leslie P. Wong,1 Emilio D. Poggio.1,2  1Nephrology and 
Hypertension, Cleveland Clinic, Cleveland, OH; 2Transplant Center, Cleveland 
Clinic, Cleveland, OH.
Background: Reimbursement in nephrology depends on accurate documentation and 
billing. Academic nephrologists are under increasing pressure to meet financial productivity 
targets. An analysis of nephrology reimbursement was performed at an academic medical 
center to find deficiencies and identify targets for education.
Methods: 75,097 inpatient nephrology encounters by 22 nephrologists from January 
2012 and March 2015 were reviewed. Data included the current procedural terminology 
(CPT) code specifying the type of service and any charge adjustments made by the coding 
department. Adjusted charges were accompanied by the reason for adjustment, the corrected 
CPT code and a gross revenue adjustment based upon Medicare reimbursement. Relative 
value units (RVUs) were calculated using the Medicare National Physician Fee Schedule. 
Multivariate regression analysis was performed to identify factors associated with RVU 
adjustments.
Results: 5615 (7.5%) of encounters were adjusted by coders. 3832 (68%) were due 
to incorrect documentation or billing and 1683 (32%) were due to services performed but 
not billed by nephrologists. For submitted charges, revenue was reduced by $995,976 
and 4227 work RVUs as a result of incorrect documentation or billing. The potential 
loss of revenue from unbilled services was $693,014 and 2823 work RVUs. Inadequate 
documentation of physical exam (p=0.01) and inadequate documentation of supervision 
of medical students/residents/fellows (p<0.01) were independently associated with RVU 
adjustments. Incorrect charge selection, duplicate charges, competing charges from another 
nephrologist and conflicting discharge/observation/post-operative care CPTs were also 
independently associated with RVU adjustments (p<0.01).
Conclusions: There was a substantial loss in gross revenue and work RVUs due to 
incorrect documentation and billing in an academic nephrology setting. These reductions 
in reimbursement and productivity might be avoided through better physician education 
and training. Specific targets include documentation of physical exam and supervision 
of trainees, correct CPT charge selection and ensuring all services performed are billed.
SA-PO151
Reaching Renal Goals – A Quality Improvement Project  Mihran V. Naljayan, 
Oksana I. Nimkevych, Vecheslav Fedorchenco, Sara Jacob Coulon, Kimberly 
Cox Fremin, Zohayr M. Al Shaial.  Medicine, LSUHSC School of Medicine, 
New Orleans, LA.
Background: The purpose of this study was to improve our patient care in a renal 
clinic at a large university hospital by using three of the core competencies- patient care, 
systems based practice, and practice based learning and improvement.
Methods: A check-out sheet was developed and given to all trainees in the nephrology 
clinic. Data was collected for 174 visits over 6 months. Data include age, gender, eGFR, 
and CKD stage. Each patient’s blood pressure, hemoglobin, phosphorus, Vitamin D, 
PTH, bicarbonate, and the extent of renal replacement therapy planning were acquired 
and further analyzed to determine whether nephrology goals were met based on KDOQI/
KDIGO guidelines.
Results: Achievements in goals for CKD 3-5 as per KDIGO/KDOQI guidelines 
based on a percentage value of the patients seen each month. Data are from April to 
October. Hemoglobin of >10 g/dL were met in 64%, 64%, 67%, 78&, 90%, 96% and 83%, 
respectively. Blood pressure of <140/90 mmHg (or <130/80) were met in 52%, 64%, 45%, 
67%, 68%, 54% and 71%, respectively. Vitamin D of ³30 ng/mL were met in 36%, 36%, 
78%, 30%, 41%, 48% and 47%, respectively. PTH of ≤ 150 were met in 52%, 27%, 67%, 
44%, 63%, 68% and 71%, respectively. Proteinuria (<300 mg/day) were met in 12%, 9%, 
22%, 26%, 53%, 80%, and 55%. Phosphorus of ≤ 5.5 mg/dL were met in 76%, 73%, 89%, 
85%, 81%, 88% and 96%, respectively. Attending renal education classes were met in 40%, 
73%, 56%, 41%, 50%, 59% and 42% respectively. 
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Conclusions: Our project was helpful in educating trainees in the treatment goals 
and guidelines for patients in the renal clinic and standardized an approach to patient care. 
Overall, the results show a trend towards improvement in all goal areas except for renal 
education. This study did not account for patients who were new to our clinic and therefore 
had never received renal education previously.
SA-PO152
A Simulation Exercise to Assess Renal Replacement Therapy and Kidney 
Biopsy Communication Skills  Lisa K. Prince,1 Maura A. Watson,1 Anna 
M. Howle,2 Christina M. Yuan.1  1Nephrology, Walter Reed National Military 
Medical Center, Bethesda, MD; 2Medical Simulation, Walter Reed National 
Military Medical Center, Bethesda, MD.
Background: We piloted a nephrology-specific “Breaking Bad News” simulation to 
assess Interpersonal Communication Skills and Professionalism during renal replacement 
therapy (RRT) and kidney biopsy (Bx) counseling. Assessment tools were a 9-point Likert 
Mini-Clinical Examination Exercise (Mini-CEX) adapted for RRT and Bx counseling, 
and the Essential Elements of Communication-Global Rating Scale 2005 (EEC-GRS).
Methods: There were three cases: 1) a middle-aged woman with polycystic kidney 
disease and CKD5, 2) a critically-ill elderly man with AKI whose wife was his surrogate 
decision maker, and 3) a previously healthy soldier with nephrotic syndrome. There were 
5 nephrology fellow examinees. One patient actor performed for each case, assessing 
each examinee with the EEC-GRS. One faculty assessed all examinees for one case using 
the EEC-GRS and mini-CEX. Encounters lasted 15 minutes, followed by 5 minutes for 
examinee counseling by the actor and faculty.
Results: Post-simulation, 3/3 faculty surveyed felt that the exercise met objectives, 
and was an excellent assessment tool. 4/5 examinees felt the exercise was “good” and met 
objectives. 5/5 felt that simulation time was too short to assess communication skills. 2/5 
felt that a mini-CEX assessing a real patient encounter was superior. Median examinee 
EEC-GRS performance assessed by actors and faculty was 4 (range 3-5). Median mini-
CEX performance was 6 (range 5-9).
Conclusions: Based on feedback, the original mini-CEX was too detailed for a 
15-minute encounter, and was simplified. Instructions now stress that, because of encounter 
brevity, counseling is unlikely to be completed, and completion is not required for 
satisfactory grading. A second set of scenarios was developed to permit a yearly simulation 
in a two-year cycle. We plan to test the revised simulation in a larger group of nephrology 
fellows within the next year. The views expressed are those of the authors and do not 
reflect the official policy of the Department of the Army, the Department of the Navy, the 
Department of Defense or the United States Government.
Funding: Other U.S. Government Support
SA-PO153
Implementation of KDIGO CKD Guidelines Leads to Decreased Diagnosis 
of CKD  Heather M. Mascio, Deepti S. Moon, Ryan J. Altenburg, Lisa K. Prince, 
Dustin J. Little.  Nephrology Service, Walter Reed National Military Medical 
Center, Bethesda, MD.
Background: Estimated glomerular filtration rate (eGFR) is used to diagnose and 
classify CKD.The accuracy of creatinine-based eGFR(eGFR-Creat)is inferior to eGFR 
calculated using multiple renal filtration markers. CKD guidelines suggest using serum 
creatinine and serum cystatin C to evaluate for CKD in select patients, but methods for, 
and results of guideline implementation have not been reported.
Methods: We reviewed new patient nephrology clinic encounters for a three 
month period to establish baseline guideline adherence. Combined creatinine/cystatin 
CeGFR(eGFR-CreatCysC)was considered indicated in patients with eGFR-Creat 45-59ml/
min/1.73m2 and no albuminuria,urine sediment abnormalities, or other markers of kidney 
damage. Consultation review was modified such that a nephrologist reviewed every referral 
request,with the option of ordering labs to be obtained prior to a clinic visit. During a 
six-month implementation period, guideline awareness was targeted via didactics, signs 
posted in exam rooms, and “cystatin C–just check it” t-shirts. Seven months of charts were 
reviewed following the intervention period, and pre and post-intervention adherence was 
compared using Fisher’s exact test. Patients with eGFR-CreatCysC≥ 60mL/min/1.73m2 
were considered to have no evidence of CKD. Inpatients for whom eGFR-CreatCysC 
was obtained,mean eGFR-Creat and eGFR-CreatCysC were compared using paired t test.
Results: Guideline adherence was significantly higher in the post-intervention 
compared to the pre-intervention period (testing obtained in 30 of 40 (75%) vs.12 of 32 
(37.5%)indicated cases; p =0.002).Mean eGFR-CreatCysC was significantly higher than 
eGFR-Creat (77.3± 15.3vs.58.3 ±9.1mL/min/1.73m2; p<0.001). eGFR-CreatCysC was 
≥60mL/min/1.73m2 in85.3% of cases.
Conclusions: By modifying our consult review process and raising awareness among 
nephrology providers, we significantly increased implementation of eGFR-CreatCysC 
guidelines and determined that the vast majority of tested patients had no evidence of CKD. 
Our results suggest testing as suggested in the guidelines has the potential to markedly 
decrease the number of inaccurate CKD diagnoses.
SA-PO154
Improving Pathology Curriculum for Nephrology Fellows  Enrica Fung,1 
Orlando Camacho,1 Michelle M. O’Shaughnessy,1 Adetokunbo A. Taiwo,1 
Gabriela Velez,1 Neeraja Kambham,2 Timothy W. Meyer.1,3  1Nephrology, 
Stanford; 2Pathology, Stanford; 3Nephrology, VA Palo Alto.
Background: Stanford fellows were previously exposed to renal pathology through 
attendance at monthly hour-long “biopsy conferences” where faculty and fellows discussed 
difficult cases; and informal quarterly “fellows-only conferences” where fellows asked 
pathologists questions on core topics. Our project sought to improve fellows’ education 
in renal pathology.
Methods: Twelve first to third year fellows participated in this project. Two renal 
pathologists led five orderly review sessions, dedicated to fellows only: 1. Common renal 
pathology; 2. Primary glomerulonephritis; 3. Secondary glomerulonephritis; 4. Plasma 
cell dyscracia-related renal disease; 5. Renal transplant pathology. Second year fellows 
helped in preparation of teaching material. Fellows were encouraged to ask questions. 
Participants completed a survey to measure their satisfaction with renal pathology 
teaching and their confidence in interpreting renal biopsies before and after this project. 
Five 10-question pre-session quizzes and a comprehensive 40-question post-project final 
measured knowledge acquisition.
Results: Prior to our project, 55% of fellows felt “somewhat satisfied” to “satisfied” 
with the current pathology conferences, and 10% of fellows felt “somewhat confident” in 
their abilities to interpret biopsy findings. Most fellows (83%) viewed renal pathology to 
be an “important” or “very important” part of their overall nephrology training. After the 
project, 100% of fellows felt “somewhat satisfied” to “very satisfied” with the project, and 
60% of fellows felt “somewhat confident” in their abilities to interpret biopsy findings. To 
date, fellows answered 63% of quiz questions correctly prior to the project and 60% of 
final questions correctly after the project.
Conclusions: Survey of nephrology fellows revealed poor confidence in interpreting 
renal pathology prior to our project despite perceived importance of the topic. To date, post 
project evaluation suggested improved confidence in renal pathology but lack of significant 
change in knowledge base. This may be due to issues with knowledge acquisition, inter-test 
comparability or instruction method.
SA-PO155
Improving the Communication Skills of Nephrology Fellows by Utilizing 
MBTI Training  Anna Marie Burgner, Julia Lewis.  Vanderbilt Univ School 
of Medicine, Nashville, TN.
Background: Communication skills can both positively and negatively affect the 
patient-physician relationship. Although many things impact successful communications, 
individuals’ personality types affect the way they communicate and the way they interpret 
the communications of others. It has been suggested that a lack of understanding of the basic 
difference between personality types contributes to poor communication and unsuccessful 
interactions. Nephrologists work in a unique environment in the dialysis unit with a complex 
interdisciplinary team and a “captured” audience of anywhere from 10-40 patients in a 
single room. In the dialysis unit, communication between the multi-disciplinary team and 
the patients and between the multidisciplinary team’s individual members impacts the 
successful achievement of dialysis outcomes.
Methods: Eleven nephrology fellows underwent a curriculum designed to increase 
their awareness of their own Myers Briggs Type Indicator (MBTI) personality preferences, 
their knowledge of the different basic personality preferences, and how those differences 
impact communication. Knowledge of the MBTI preferences was tested pre-intervention, 
immediately post intervention, and 8 weeks post intervention. Communication skills were 
measured prior to the intervention and 8 weeks post intervention by dialysis nurses observing 
fellow-real patient interactions. Fellows were also asked to describe how they used their 
knowledge at 8 weeks post intervention.
Results: The intervention led to a sustained increase in the nephrology fellows’ MBTI 
personality preference knowledge. At 8 weeks post intervention, fellows reported utilizing 
their personality preference knowledge to improve their communication with their patients 
as well as with members of their team. However, nephrology fellows’ communication skills, 
as measured by the Kalamazoo Essential Elements Communication Checklist Adapted 
(KEECC-A), did not change.
Conclusions: Although training in MBTI personality preferences led to a significant, 
sustained increase in MBTI knowledge and fellows continued to report utilizing their 
knowledge at 8 weeks post intervention, there was no change in their measurable 
communication skills utilizing nurse observations.
SA-PO156
Lung Ultrasound: A New Skill for Nephrologists for Volume Overload 
Quantification in End Stage Renal Disease Patients on Hemodialysis 
Marc M. Saad, Wissam Mansour, Elias Moussaly, Jeanne Kamal, Boutros 
Karam, Cara Brown, Monica Kapoor, Elie El-Charabaty, Suzanne E. El Sayegh. 
Internal Medicine/Nephrology, Staten Island Univ Hospital, Staten Island, NY.
Background: Many methods have been tried to assess the volume status in patients on 
hemodialysis (HD). While the estimated dry weight is still the only method widely used, 
it is often inaccurate and poses a clinical challenge. Pulmonary congestion detected as B 
lines on ultrasound (BLUS) is rising as a novel parameter for assessing volume status; we 
evaluate the accuracy and reliability of measuring BLUS performed by residents following 
a short training course.
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Methods: Residents underwent a 3 hour course under the supervision of ultrasound-
fellowship trained Emergency Physicians (EP). The course included a didactic section, a 
simulation hands-on training, and an Objective Structured Clinical Examination prior to 
enrolling the trainees as investigators; Residents performed lung ultrasound (LU) on ESRD 
patients post HD sessions in a supine position over 28 intercostal windows. They obtained 
at each window a 6s clip that were reviewed by 2 blinded EP. BLUS were summed up 
categorizing patients into different classes of pulmonary congestion:mild (0-14), moderate 
(15-30) and severe (>30).
Results: A total of 81 ESRD patients on HD were scanned. 71.6% were males; mean 
age 59.74 years, mean BMI 28.59±5.62 kg/m2 ; mean test duration was 15 min. The B-lines 
score found by the study investigators and EPs was 15.8±21.3 and 12.06±21 respectively. 
The difference was 3.77±16.8 (0.0475). When categorized into the 3 classes, there was no 
significant difference between both classification (0.085), and were in moderate agreement-
kappa 0.56 [0.42-0.71].
Conclusions: B-lines visualized on bedside LU can provide a reliable and quantifiable 
assessment for lung congestion. Our study shows that a short training course can render 
novice users of ultrasound capable of performing this quick evaluation. This can aid in 
objectively assessing volume overload in a timely manner in HD patients who present a 
unique clinical challenge. LU has emerged as a new technic, readily available at bedside, 
providing immediate results, yet is an easily learned skill.
SA-PO157
Renal Pathology: What We Think and What Is  Ambarish Athavale, Kalyani 
Perumal, Peter D. Hart, Amit J. Joshi, Albert M. Osei.  Nephrology, John H. 
Stroger Jr. Hospital of Cook County, Chicago, IL.
Background: Percutaneous kidney biopsy is the gold standard for diagnosis of 
kidney disease but is underutilized due to wariness of complications. Based on clinical and 
laboratory data, Nephrologists try to predict the renal pathology (clinical gestalt). However, 
no study has compared the diagnostic accuracy of the clinical gestalt with the kidney biopsy 
result. Aim: To compare pre-biopsy diagnosis (PBD) by Nephrologist with final histologic 
diagnosis. To assess if accuracy of PBD improves with increasing years in clinical practice.
Methods: Division of Nephrology at Stroger Hospital of Cook County conducts a 
monthly biopsy conference. Three case summaries are presented followed by discussion 
and presentation of the biopsy findings. Between September 2014 and April 2015, using 
a structured form Fellows and Nephrologists were asked to provide their top diagnosis 
for each case and this was compared with the actual histologic diagnosis. All physicians 
apart from the primary Nephrologist were blinded to the diagnosis. The study was deemed 
exempt by IRB.
Results: 23 cases were discussed in the biopsy conference involving 13 unique 
diagnoses and 286 unique responses were obtained. Overall diagnostic accuracy was 
53.49% (153/286); Fellows (52.5%) and Nephrologists (54.36%). Diagnostic accuracy for 
nephrologists was 100% for ANCA vasculitis and Minimal Change Disease (MCD) and 
86% for Diabetes but < 50% for stages of Lupus and other seronegative GNs.
Biopsy Diagnosis Pre-biopsy diagnostic accuracy (%)
ANCA vasculitis 100
MCD 100
DM 86
Lupus class II 80
Amyloid 57.14
Lupus class III +V 50
Idiopathic Membranous 45.45
HIVAN 42.85
IgA 38.46
Lupus class V 33.33
HTN 33.33
Fibrillary GN 25
Normal 0
Nephrologists with > 10 years’ experience tended to more accurately predict the 
diagnosis than those with < 10 years’ experience (64.4 vs. 48.3%, p=0.07).
Conclusions: Nephrologists more accurately diagnosed ANCA vasculitis, MCD & 
Diabetes by clinical gestalt, but were less accurate for stages of lupus and other seronegative 
GNs. Regardless of training and experience kidney biopsy is still the diagnostic tool of 
choice in patients with kidney disease.
SA-PO158
Out-Patient Clinic Based Multidisciplinary Patients’ Education for 
Advanced DM Nephropathy Is Effective and Efficient for Reducing ESRD 
Fumika Taki, Takuya Fujimaru, Masataka Hasegawa, Miyuki Futatsuyama, 
Yuki Heath, Masahiko Nagahama, Yasuhiro Komatsu.  Nephrology, St. Lukes’ 
International Hospital, Tokyo, Japan.
Background: Diabetes Mellitus (DM) is the most common etiology of CKD. Patients 
educations for these patients are known to be important, however, effectiveness and 
efficiency of them are still unclear. We established multidisciplinary out-patient clinic 
based education system, specialized for advanced diabetes nephropathy, and assessed 
their clinical outcomes.
Methods: Education system were started from May 2012, in St. Lukes’ International 
Hospital. Tokyo, Japan. All CKD patients with DM were asked to meet nurse and dietitian, 
before seeing physicians, on every visit of the CKD clinic. Nurse and dietitian give the 
specific advices for each patients, within 15 minutes, by using our original short text or 
materials. Initiation of renal replacement therapy (RRT) were assessed for the primary 
end point, comorbidity, HbA1c, eGFR, type of RRT were also analyzed, retrospectively.
Results: From May 2012 to March 2015, total 372 individual patients were participated. 
Their baseline eGFR were 36.5±12.5ml/min, mean age 65.5±13.2 y.o. and 68% of them were 
male. Two hundred and ninety seven, 82% of patients were educated and their average of 
frequency of education was 4.3±2.1 times/year. Comparison of educated and non-educated 
groups, baseline eGFR, HbA1c or other comorbid did not differ. However, preservation 
of renal function were better in educated group ; delta eGFR: Educated vs. Non-educated: 
-3.26±1.21 vs. -8.2±3.25 ml/min/1.73m2 /year, P=0.04, T-Test. More, incidence of ESRD 
is lower in educated group ; Initiation of Dialysis: Educated vs. Non-educated: 9.4% vs. 
33.3%, P=0.033, Chi-Square test. Furthermore, in non-educated group, none of the patient 
selected peritoneal dialysis or transplants for the RRT.
Conclusions: Our out-patient clinic based education system is simple and useful for 
diabetic CKD patients for reducing ESRD.
SA-PO159
Our Stories Our Way: Creation of a Digital Story CKD Educational 
Intervention  Stacey Jolly,1 Marcia Oleary,2 Ashwini R. Sehgal.3  1General 
Internal Medicine, Cleveland Clinic, Cleveland, OH; 2Missouri Breaks 
Industries Research Inc, Eagle Butte, SD; 3Center for Reducing Health 
Disparities, MetroHealth Medical Center, Cleveland, OH.
Background: Chronic Kidney Disease and End Stage Renal Disease disproportionately 
affects American Indian communities, yet there are few culturally appropriate educational 
interventions for this population.
Methods: Digital storytelling combines first person narrative with digital images and 
music and can be done with a community-based, learner-centered approach. With these 
digital tools, people create personal narratives that are powerfully compelling, emotionally 
engaging, and provide another view or perspective on a topic. We recruited 10 men and 
women with diverse life experiences related to health and kidney disease from an American 
Indian community to create digital stories. Each participant was mailed a pre-workshop 
information sheet about digital storytelling and were encouraged to bring pictures.
Results: We held a 3 ½ day digital story workshop with our partner nDigiDreams, 
LLC in Nov 2013 at a tribal college. Participants, their family members, and research staff 
worked together with the facilitators to create their personal digital story related to health 
and kidney disease in their words. A total of 10 digital stories were created. The process 
encompassed four areas: develop story idea, gather media such as pictures and music, 
record the voice parts/edit the digital story, and share or screen the digital stories among the 
group. Five stories about life on dialysis, having a kidney transplant, and making changes 
to control diabetes were selected to be in the final DVD.
Conclusions: We created a unique educational tool in the form of digital stories. The 
DVD has been used in an ongoing pilot observational educational trial looking at the impact 
on chronic kidney disease knowledge and health behaviors among American Indians.
Funding: NIDDK Support
SA-PO160
The Effect of Nephrology Specialty Clinics on Patient Care and Trainee 
Experiences  Frederick H. Kuo, Rajeev Raghavan, Wolfgang C. Winkelmayer, 
Jose Jesus Perez.  Dept of Medicine-Nephrology, Baylor College of Medicine, 
Houston, TX.
Background: As medicine evolves, there has been a trend towards the creation of 
special clinics which streamline care in hopes of improving patient survival through 
clinical trials and increased time with “super-specialists”. From a trainee perspective, a 
Nephrology clinic focused on a particular disease affords fellows a unique perspective on 
disease pathophysiology and treatment and can be a wonderful tool to recruit residents or 
students into Nephrology. We hypothesized that a majority of Nephrology training programs 
across the US utilize such subspecialty clinics, and we aimed to characterize the patient 
and trainee experience by conducting a nationwide survey.
Methods: An e-mail detailing the study’s aims and an anonymous 7-question online 
survey were sent to the 139 program directors of ACGME-accredited nephrology fellowship 
programs in July 2014.
Results: 54 of 139 program directors (39%) replied. We found Transplant clinics to 
be the most common subspecialty clinic (83%), followed by Stone clinic (63%), Advanced 
CKD clinic (50%), and Glomerulonephritis clinic (38%). Transplant clinics were oldest 
on average, with 67% in existence for over 10 years. Less common clinics included those 
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for lupus, polycystic kidney disease, and genetics. Regarding patient compliance within 
specialty clinics, 40% indicated no change, 40% improved, and 20% much improved. On 
patient satisfaction, 32% indicated no change, 49% improved, and 19% much improved. No 
respondents perceived decreased patient compliance or satisfaction. Trainees participated 
in 98% of specialty clinics with a 91% satisfaction rate; 29% were very satisfied. 45% of 
specialty clinics had ongoing research projects, with an average of 5.5 research projects 
in those clinics.
Conclusions: Subspecialty clinics can be an invaluable tool for both trainees and 
patients; both groups reported high satisfaction levels. These clinics also enable research 
by providing an established database of patients with specific disease processes. Access 
to such information is essential to quality research and may streamline the development 
of key clinical trials.
SA-PO161
The Impact of a Patient Education Program on Chronic Kidney Disease 
Patients’ Plans to Initiate Dialysis – Prospective Study (2012-2014) 
Abdallah Guerraoui, Hallonet Patrick, Agnes Caillette-Beaudoin.  Néphrologie-
Dialyse, Calydial, Vienne, France.
Background: The distribution of renal replacement therapy (RRT) modalities among 
patients varies from country to country, and is often influenced by non-medical factors. In 
our department, patients progressing towards end-stage renal disease (ESRD) go through a 
structured Pre-Dialysis Education Program (PDEP). This PDEP is conceived with patients 
association and nursing educator.
Methods: Forty nine patients with CKD who were receiving care in a multidisciplinary 
predialysis clinic (mean age 73.5, 63% men). The participants are accompanied by family 
membres.They have an initial educational evaluation, followed by two workshops in 
groups and a final educational evaluation. The workshops are carried out in groups of 6 
to 10 patients. The PDEP consisted of: (1) psychosocial assessment, (2) education about 
dialysis and choice of modalities, (3) counseling sessions with patient, family membres, 
(4) education about dietetic and dialysis.
Results: - Choice of the substitution method at the end of the workshops: 61% 
peritoneal dialysis, 18% haemodialysis and 21% absence of choice. - 94% of the patients 
began the substitution treatment with a chosen modality. - 100% Satisfaction of the patients, 
26% decrease of the anxiety. (p<0,0005), 25% (p< 0,0001) increase in the consent for 
the treatment, 61% increase in the engagement in the treatment (patient ready to receive 
treatment) (p<0,00001), 47% increase knowledge of RRT(p< 0,00001).
Conclusions: Most studies dealing with the pre-dialysis information show a balanced 
choice of the RRT, but only 50% of the patients actually begin DP. Our workshops of help 
and assistance to the choice enable to significantly reduce the anxiety linked to the dialysis 
and thus increase the adherence and engagement for the chosen method RRT. A two-phase 
educational intervention can increase the proportion of patients who intend to initiate 
dialysis with self-care dialysis. In our centre offering all treatment RRT modalities, a high 
percentage of patients exposed to a structured PDEP start with a self-care RRT modality.
SA-PO162
Frequency of Use of Social Media in CKD Patients on Hemodialysis: Pilot 
Study in Ecuador  Fabian A. Ortiz-Herbener,1 Juan Carlos Calderon,2 Walter 
Morquecho,3 Julio Israel Merino,3 Byron Josué Haz,2 Ivan Manuel Cherrez.2,3 
1Inst Ecuatoriano de Diálisis y Transplantes, Guayaquil, Guayas, Ecuador; 
2Respiralab, Guayaquil, Guayas, Ecuador; 3School of Medicine, Univ de 
Especialidades Espíritu Santo, Samborondón, Guayas, Ecuador.
Background: CKD on dialysis is defined as <15% of kidney function. In Latin America, 
461 per million are on dialysis. Region is the third largest Internet user. Social Media 
includes communications spread electronically, shared by individuals and discussed by a 
committed population. Hispanic Americans with CKD used it, to inform and be informed, 
and for supporting each others.
Methods: Observational, cross sectional, pilot study. Patients were recruited in dialysis 
center in Guayaquil. Survey included demographical and clinical items, Charlson score and 
4 questions about frequency of use of social media were included. Also, questions about 
obtaining information; and interest in receiving or asking physician questions related to 
illness in social media. Frequencies and mean (SD) were employed. Chi-square, ANOVA 
and M-W U was used for comparisons. Also, Cronbach were calculated.
Results: 34 patients participated, with mean age of 56.5 (SD 16.3), mean years on 
dialysis of 3.9 (SD 4). 52.9% were women. Comorbidity’s rate was very high (82.4%). 
70.6% of patients believed that dialysis control symptoms of disease. 11.8% hadn´t 
got cellular-phone neither Internet. 61.8% hadn´t got SMS. Almost half of patients had 
smartphones. Women had a high comorbidity (41.2%), p>0.05. Around 30.0% reported 
using SMS, Facebook, YouTube, email an Internet at least once a week. 46.7% use Internet 
as principal source of information, YouTube (20.0%) and email (16.7%). 40.0% of patients 
reported high interest in receiving information by SMS, Facebook (33.3%) and email 
(26.6%). 33.3% reported high interest in asking by SMS, email (26.7%) and Facebook 
(20.0%). Finally, 43.5% reported interest in receiving information and asking by whatsapp. 
Conbrach was 0.884.
Conclusions: Internet use is very common for searching information related to disease. 
Whatsapp, SMS, Facebook and email were reported as new tools for providing illness related 
information to the patient. The survey had a good reliability and consistency.
SA-PO163
The Impact of Predialysis Education on Patient Understanding, 
Preparedness, and Decisional Conflict Regarding Renal Replacement 
Therapy Options  Syed Amir Hamid Ali Shah,1 Ion D. Bucaloiu,1 Amanda 
Young,2 Jamie Alton Green.1  1Nephrology, Geisinger Medical Center, Danville, 
PA; 2Center for Health Research, Geisinger Medical Center, Danville, PA.
Background: Predialysis education is recommended to prepare patients with advanced 
chronic kidney disease (CKD) for initiation of renal replacement therapy; however, the 
impact of various approaches on medical decision-making is unknown.
Methods: We surveyed 91 advanced CKD patients before and after a 2-hour nurse led 
group education class to assess patient understanding of renal replacement therapy options 
(1=poor to 5=excellent), preparedness to make a decision (1=not at all to 5= very prepared), 
and decisional conflict using a validated scale (0=no decisional conflict to 100=extremely 
high). The class included a combination of direct verbal instruction and video presentation, 
tailored to patients with a variety of health literacy and sociodemographic backgrounds. 
Content included the advantages/disadvantages of hemodialysis (HD), peritoneal dialysis 
(PD), transplant, and conservative management.
Results: Mean age was 66, 58% male, 94% white, 44% had a high school or lower 
level of education, and 46% had low health literacy. Mean level of understanding increased 
significantly for all modalities pre-post (2.02 vs. 4.10 for HD, 1.95 vs. 4.14 for PD, 2.35 vs. 
4.15 for transplant, and 2.10 vs. 4.12 for conservative management; all p<0.001). Decision 
preparedness also increased significantly from 2.44 to 3.50 (p<0.001). Improvements were 
similar regardless of age, gender, educational level, or health literacy. At the end of the class, 
overall decisional conflict was low (median score 10; IQR 0, 20). Equal proportions of 
patients preferred HD (24%) or PD (22%), compared with transplant (12%) and conservative 
management (4%), yet nearly (30%) of patients remained unsure of their decision.
Conclusions: Despite significant improvements in patient understanding and 
preparedness about renal replacement therapy options, a substantial number of patients 
remain unsure of their decision after routine predialysis education. Additional decision 
supporting interventions may be needed to improve decision-making in advanced CKD 
patients.
SA-PO164
Chronic Kidney Disease Knowledge Among English and Non-English 
Speakers  Anushya Jeyabalan, Pranav S. Garimella, Lesley Inker.  Nephrology, 
Tufts Medical Center, Boston, MA.
Background: Patient education regarding CKD is an important part of pre-dialysis 
care. While educational interventions have also shown to improve clinical outcomes among 
dialysis patients, there is little information however, on health literacy in CKD populations.
Methods: We performed a cross-sectional survey of patients identifying themselves 
as primarily English or Chinese (Cantonese or Mandarin) speakers visiting an outpatient 
nephrology clinic at a single tertiary hospital. A validated Kidney Knowledge Survey 
(KiKS) that has been used to assess CKD knowledge in previous studies was translated 
into Chinese and then self-administered in English or Chinese. All patients had at least 1 
prior visit with a nephrologist.
Results: 102 participants completed the survey of which 70 were English speakers and 
32 were Chinese speakers. Chinese speakers were older, more likely to have less than high 
school education and had a greater prevalence of diabetes (Table). Estimated glomerular 
filtration (eGFR) and urine albumin creatinine ratio were not different between groups. 
Mean KiKS score was lower in Chinese speakers compared to English speakers (11.9 vs. 
17.2, p=0.001). Chinese speakers scored lower in all domains of the KiKS; general kidney 
knowledge (6.2 vs. 4.5), knowledge of kidney function (5.5 vs. 4.0) and knowledge of 
symptoms (5.4 vs. 3.7).
Conclusions: While our results for CKD knowledge among English speakers are 
comparable to previously published data (mean score 18.6), scores among non-English 
speaking CKD patients is lower than English speakers. Whether this finding is associated 
with differences in care management and clinical outcome needs to be evaluated. 
Furthermore, educational material and programs may need to be tailored to specific 
populations to improve health literacy.
SA-PO165
Follow-Up with Doppler Ultrasound of Asymptomatic Arteriovenous Fistula 
(AVF) After Renal Biopsy (RB)  Maite Rivera,1 Saul Enrique Pampa,1 Virginia 
López de la Manzanara Pérez,2 Victor Burguera,1 Nuria Rodriguez Mendiola,1 
Cristina Galeano,1 Ingrid Viviana Raoch Michaels,1 Rodrigo Hernandez Loyola,1 
Fernando Liano.1  1Nephrology, Hospital Univ Ramon y Cajal.UAH, Madrid, 
Spain; 2Nephrology, Hospital Univ San Carlos, Madrid.
Background: RB is an essential percutaneous technique in Nephrology that entails 
major and minor complications, one being the AVF which is usually asymptomatic and 
underdiagnosed because of the absence of routine Doppler examination post RB. We 
analyzed the natural history of asymptomatic AVF post RB of native kidney (NK) and 
transplanted (RT) detected by Doppler examination following RB.
Methods: We analyzed the presence of AVF on 327 RB between January 2011 and 
December 2014 included in our database. 47 (14%) RB developed AVF detected by 
Doppler ultrasound performed at 24h post RB. We studied the following data: AVF size 
and its relation to the needle caliber and time to spontaneous closure and its relationship to 
the AVF size. All RB were real-time ultrasound-guided RB performed with a biopsy gun 
(Acecut Tsk, Japan), the RT caliber 16G and 14G in the NK.
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Results: 45 AVF were asymptomatic (96%), whereas 2 (4.2%) had to be embolized by 
their large size. Of the 45 asymptomatic AVF, 28 were of RT (62.2%). 69% were male. AVF 
28 (62%) were followed until its closure with Doppler. 75% sized <1cm and corresponded 
to RT (16 G-needle). We noticed that the 50% of AVF had closed at 3 months post RB at 
an average of 49 days. AVF with a size between 1.1 and 1.9 cm (17.7% of the total) took 
longer time to close (mean 67 days). Among the 17 patients without follow-up five had 
died, 3 lost the renal graft and 9 were lost in the evolution. Seven of the 9 patients without 
follow-up were studied by Doppler after contacting them by phone, 28 months post-biopsy. 
In the seven AVF had spontaneously closed.
Conclusions: Contrary to published, AVF after RB is a frequent complication but 
asymptomatic and rarely requires surgery. All asymptomatic AVF closed spontaneously. 
The size of AVF were related with the caliber of the needle and with the time to close. No 
AVF grew in evolution. The routine use of Doppler following RB is essential to identify 
and standardizing management of AVF.
SA-PO166
The Role of Post Biopsy Ultrasound in Predicting Complications After 
Percutaneous Renal Biopsy of Native Kidneys  Umar Hayat, Hafiz I. Ahmad, 
Syed Rizwan Bokhari, Syed A. Khalid.  Dept of Nephrology, Allama Iqbal 
Medical College/ Jinnah Hospital Lahore, Lahore, Pakistan.
Background: The percutaneous renal biopsy (PRB) of native kidneys has been an 
essential tool in the diagnosis and management of renal diseases. Despite all advances, 
clinically evident bleeding complications do occur in up to 30% of patients after PRB of 
native kidneys. Traditionally patients are kept under observation for 24 hours after the 
procedure. An earlier investigation to anticipate the likelihood of complications will help to 
reduce the length of stay for these patients and thus the resource burden. Post PRB ultrasound 
has been studied for this purpose. We conducted a study to evaluate the role of early post 
PRB ultrasound to predict procedure related complications in our patient population.
Methods: 46 patients undergoing renal biopsy at department of Nephrology, Jinnah 
Hospital were considered for this study. Renal biopsy was performed using a 16-gauge 
automated core biopsy needle. After the biopsy, patients were closely monitored in recovery 
room and after 1 hour, the biopsied kidney was examined by ultrasound. These patients were 
admitted and were kept under observation to assess any complications for next 23 hours.
Results: Of these 46 patients, 24 (52%) were males with mean age 39 (16 to 60 years). 
More than 3 cm hematoma was seen in 2 (4.3%) patients at 1 hour post biopsy ultrasound 
scan. Of these 2 patients, only 1(2%) patient had major complications including hypotension, 
decrease in hemoglobin etc. Thus 45 (97.8%) patients had uneventful recovery. Sensitivity of 
more than 3 cm hematoma formation at 1 hour post biopsy in predicting major complications 
was 100% with specificity of 97.7%.
Conclusions: Our study showed that the frequency of major complications was 
minimal in patients without >3 cm hematoma formation at one hour post-PRB. Post-PRB 
ultrasound is a non-invasive, accurate diagnostic tool in predicting procedure related 
major complications.
SA-PO167
A Multidisciplinary Clinic for Children with Lupus Nephritis (LN) – A 
Step Towards Personalized Medicine?  Nicole A. Hayde,1 Tamar Rubinstein,2 
Janice Berthe Desir,1 Dawn Wahezi,2 Katherine Steigerwald,2 Beatrice Goilav.1 
1Pediatric Nephrology, Children¶s Hospital at Montefiore, Albert (instein 
College of Medicine, Bronx, NY; 2Pediatric Rheumatology, Children’s Hospital 
at Montefiore, Albert (instein College of Medicine, Bronx, NY.
Background: Most children with SLE develop LN, which significantly worsens 
morbidity and mortality. Progression to ESRD occurs in 5-10%. Early diagnosis and 
treatment improve long-term outcomes, thus prompt evaluation is essential. Therefore, a 
combined pediatric nephrology/rheumatology clinic (LN Clinic) was started in 2013. The 
primary aim was to evaluate the number of days between onset of proteinuria (first-am 
urine p/c >0.2) and performance of a renal biopsy (bx) for SLE patients (pts), pre- and 
post-establishment of the LN Clinic. We aimed for a 20% reduction in time to renal bx 
within 2yr of establishment of this clinic. The secondary aim was a reduction of steps in 
the referral process.
Methods: SLE pts with an outpt renal bx were identified by an EMR query. Pts were 
selected if a bx was performed within 5yr pre or 16mo post establishment of the LN clinic. 
Our sample selection was cross-referenced with an established lupus registry. A chart review 
provided the date of proteinuria onset, disease activity markers, and LN class. Pts diagnosed 
in the inpt setting were excluded. A process map determined the number of steps occurring 
between new-onset proteinuria and first evaluation by a nephrologist.
Results: We show that pre LN clinic, the median number of days between onset of 
proteinuria and renal bx was 51 (IQR=25–83.5d), compared to 34 (IQR=14–48d) post 
(p=0.057). This is a 33% decrease in time. There was a negative association between 
amount of proteinuria and days to bx (r=-0.5826, p<0.001). There was no association 
between hematuria or markers of disease activity and days to bx. There was also no 
association between LN class and days to bx. Pre LN clinic, a referral required 10 steps, 
which was reduced to 6.
Conclusions: The LN clinic has resulted in earlier renal bx and fewer steps in the referral 
process. For pts with proliferative LN, this translates to earlier initiation of treatment and 
a chance at improved outcome.
SA-PO168
Antidepressant Efficacy and Safety Observations: USRDS ACTIVE-
ADIPOSE Study  Nancy G. Kutner,1 Rebecca H. Zhang,1 Yijian Huang,1 C. 
Barrett Bowling.1,2  1Emory Univ, Atlanta, GA; 2Atlanta VA Medical Ctr.
Background: Although depression is a prominent issue, depression management in 
advanced CKD and ESRD patients is not well understood. Antidepressant medications are 
the most frequent therapy, but efficacy and safety data are limited (Hedayati et al. 2012).
Methods: The primary exposure of interest was use of antidepressant medications 
among 771 maintenance hemodialysis (MHD) patients ages 20-92 in 14 outpatient clinics 
who were enrolled 2009-2011 in the ACTIVE-ADIPOSE special study (median ESRD 
treatment 3.2 years). Gender distribution and ESRD etiology were similar to the overall 
MHD population, but the proportion non-white and younger than age 65 was higher in 
the study cohort. Medication efficacy was defined by participants’ scores (<18 vs. 18+) on 
the Center for Epidemiologic Studies-Depression (CES-D) scale (Hedayati et al. 2006). 
Adjusted odds for recent falls observed in association with antidepressant use and CES-D 
score provided an indicator of safety.
Results: Antidepressants were prescribed for 15% of study participants. 40% of those 
with prescribed antidepressants had an elevated CES-D score, suggesting lack of drug 
efficacy. Efficacy did not appear to vary by patients’ age or vintage, but more whites had 
elevated CES-D scores. Recent falls were more frequent among patients on antidepressants 
with elevated CES-D score (adjusted odds ratio 2.27 [1.05, 4.90], p = 0.04, compared with 
patients not on antidepressants and CES-D score <18). Fall risk was similar across type of 
prescribed antidepressant (SSRI, atypical, and tricyclic drugs). 
Conclusions: Efficacy of antidepressant medications was unclear for 40% of those 
with these drugs prescribed, and safety hazard was suggested by increased fall risk. 
Continued evaluation of nonpharmacologic as well as pharmacologic options for depression 
management in MHD patients, the focus of a current PCORI trial, is important.
Funding: NIDDK Support
SA-PO169
Sofosbuvir Use in Patients with Hepatitis C Virus Infection and Severe 
Chronic Kidney Disease  Alberto J. Sabucedo, Marie Essie Antoine, Delvis 
Jorge, Aileen Andreu, Fernando E. Pedraza, Maria Del Pilar Hernandez, Lennox 
Jeffers, Marco A. LadinoAvellaneda.  Dept of Medicine. Divs of Nephrology and 
Hepatology, Miami VA Medical Center/Univ of Miami, Miami, FL.
Background: Chronic hepatitis C virus (HCV) infection is a major health problem. 
The use of new direct acting antiviral (DAA) based regimens has been shown to provide 
a high sustained virologic response with less adverse reactions compared to interferon-
ribavarin regimens. The American Association for Study of Liver Diseases recommends 
expert consultation on patients with eGFR less than 30 mL/min because safety and efficacy 
data are not available on these patient populations. We propose that these DAAs are safe 
to use in patients with advanced kidney disease.
Methods: A total of 23 patients with HCV and estimated glomerular filtration rate 
(eGFR) less than 45 ml/min were treated with sofosbuvir and simeprevir, dose of sofosbuvir 
was adjusted to 200 mg PO daily or 400 mg PO every other day for patients with eGFR less 
than 30 ml/min by Hepatology and Nephrology services. These patients were monitored 
closely by both services.
Results: A cohort of 23 HCV positive patients had the following descriptive statistics, 
20 males (87%) and 3 females (13%). 15 patients had Genotype 1a (65%), 7 patients had 
Genotype 1b (31%) and 1 patient had Genotype 2b (4%). 3 patients (13%) had End Stage 
Kidney Disease (ESKD) and were on hemodialysis, 9 patients (39%) had Chronic Kidney 
Disease grade IV (CKD IV - eGFR <30 ml/min) and 11 patients (48%) had Chronic Kidney 
Disease grade IIIB (CKD IIIB - eGFR <45 ml/min) The HCV viral load of the 23 patients 
(100%) had a statistically significant decrease as the therapy progressed through completion 
with a statistically significant T-test with a p < 0.05. No side effects were present on the 
patients during DAA therapy. Patients with CKD grades IIIB and IV on DAA treatment 
had a preserved kidney function by the end of therapy.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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Conclusions: Sofosbuvir is safe and effective in patients with Hepatitis C Virus 
infection and severe Chronic Kidney Disease, co-management and close monitoring by 
Hepatology and Nephrology is imperative due to the lack of data in safety and efficacy.
SA-PO170
Enoxaparin as Bridging Therapy in Veterans with Advanced Kidney Disease 
Chai L. Low, Renae A. Minnema.  Pharmacy, VA San Diego Healthcare system, 
San Diego, CA.
Background: Patients with CrCl < 30ml/min on anticoagulation require temporary 
bridging perioperatively. Low-molecular weight heparins (LMWH) have longer half-lives 
and predictable anticoagulant effect but require anti- Xa monitoring in CKD. This study 
aims to evaluate the safety and efficacy of lovenox as a bridge therapy in patients with 
CrCl< 30ml/min.
Methods: A retrospective study was conducted from Jan 1, 2012 to Dec 1, 2014. 
Patients with CrCl < 30 mL/min, received enoxaparin 1 mg/kg/day as a bridge therapy to 
warfarin, and had at least one anti-Xa level checked were included in the study. Patients 
were excluded if they had major bleeding or thromboembolism in previous 3 months 
before enoxaparin, history of bleeding disorders, or used enoxaparin for other indications. 
A dosing nomogram was used to guide dosage adjustment to keep anti-Xa levels within 
the target range (0.5 -1.0 mcg/ml). The primary outcomes are # of minor/major bleeds and 
thromboembolic events. The proportion of anti-Xa levels within goal range was assessed. 
Descriptive statistics were used to compare outcomes to the literature.
Results: 12 patients met inclusion and exclusion criteria. The mean age was 62.4 ± 
11.9 years, 91.7% were male, 58% were diabetic and 46% had congestive heart failure. 
50% were on both warfarin and aspirin. The mean treatment duration of enoxaparin was 
11.4 ± 4.6 days, the average CrCl was 17.6 ± 4.5 mL/min. A total of 19 anti-Xa levels 
were included for analysiss. There were 2 (16.7%) bleeding events, 1 (8.3%) major and 1 
(8.3%) minor bleed. None of the patients developed thromboembolic complications. The 
most common adverse event was bruising at the injection site that did not lead to any early 
discontinuations of therapy. Seventeen of the anti-Xa levels (89.4 %) were in the target range.
Conclusions: Majority (83.3 %) of patients had minimal or no adverse events and none 
with thromboembolic outcomes. In patients with bleeds, no correlation was seen with the 
anti-Xa levels. The dosing protocol is effective, with 89.4 % of anti-Xa levels within goal 
range. The results of this study support the safety and efficacy of the enoxaparin dosing 
protocol as a bridge therapy perioperatively in patients with CKD.
Funding: Veterans Administration Support
SA-PO171
Thiopurine Methyltransferase (TPMT) Genotyping to Predict 
Myelosuppression Risk in Chinese Patients with Nephropathy  Xuemei Li, 
Jie Ma.  Nephrology, Peking Union Medical College Hospital, Beijing, China.
Background: Pharmacogenetic study in nephritis is mainly focused ongenes involved 
in the metabolism of Azathioprine (AZA).Use of AZA is limited by its toxicity. Variants in 
theThiopurine S-methyltransferase(TPMT)have been associated with AZA toxicity. The 
aimofthis study was to determine the contribution of TPMT variantsin the development of 
AZA-relatedmyelosuppression in Chinese patients  with nephropathy.
Methods: Variants associated with the decrease of enzymeactivity in TPMT genes 
were genotypedin 4nephritis patients treated with AZA, andcorrelated with the clinical 
response and development ofadverse drug reactions in a retrospective case-control study.
Three commom mutation alleles of TPMT [TPMT* 3A ( G460A/A719G) , TPMT* 3B( 
G460A) , TPMT* 3C ( A719G)]were detected by polymerase chain reaction-high resolution 
melting and sequencing in 12 patients , included 4 patients with myelotoxicity and 8 patients 
without myelotoxicity.
Results: Genotypic analysis showed only one of the 4 patients with myelotoxicity was 
detected TPMT *3C polymorphisms, no TPMT*2, *3A, *3B or *3C polymorphisms were 
detected in any of the 11 patients.
Conclusions: Single-nucleotide polymorphisms of TPMT could not explain the 
azathioprine-related adverse events.
SA-PO172
Lanthanum Carbonate - Induced  Granulomatous  Gastr i t i s 
Francesco Iannuzzella,1 Loredana De Marco,2 Sonia Pasquali.1  1Dept of 
Internal Medicine, Nephrology and Dialysis Unit, Arcispedale Santa Maria 
Nuova, IRCCS, Reggio Emilia, Italy; 2Dept of Human Pathology, Arcispedale 
Santa Maria Nuova, IRCCS, Reggio Emilia.
Background: Long-standing non-calcium based phosphate binders administration has 
been recently associated with a number of different gastroduodenal lesions. We describe 
a rare case of lanthanum carbonate-induced granulomatous gastritis.
Methods: A 58-year-old woman was admitted to our hospital because of nausea, 
vomiting, and progressive weight loss. Because of a well-known stage 5 chronic kidney 
disease, she was started on peritoneal dialysis. About one month later, CAPD was well-
tolerated with an adequate dialysis dose. Nevertheless, she continued to complain of 
nausea, vomiting and dyspepsia. A gastroscopy revealed chronic gastritis with superficial 
erosions and an histopathology consisting of non-necrotizing, sarcoid-like granulomas 
with aggregates of multinucleated giant cells. Orange cristalloid material was seen within 
granulomas. Special stains for fungus and mycobacteria were negative. Her previous 
medical history was only significant for hypertension and type 2 diabetes mellitus. Physical 
examination was unremarkable. A chest X-ray was normal. A tubercolin skin test was 
negative. ANCA titres was negative and serum angiotensin converting enzyme (ACE) 
level was in the laboratory reference range. At the time of our evaluation, she had been 
receiving lanthanum carbonate 1 g bid for about 6 months.
Conclusions: At the best of our knowledge, so far, only 7 cases have been described 
in the literature. 
The histopathologic picture in our patient was compatible with a lanthanum carbonate-
induced gastritis with some peculiar characteristics: a granulomatous reaction and the 
appearance of lanthanum carbonate crystals not only within histiocytes/multinuceated giant 
cells but also inside the cytoplasm of the epithelial glandular cells.
SA-PO173
Relative Incidence of Adverse Events with Ferumoxytol versus Other 
Intravenous Iron Products in Non-Dialysis-Dependent Chronic Kidney 
Disease  Eric D. Weinhandl, David T. Gilbertson, Allan J. Collins.  Chronic 
Disease Research Group, Minneapolis Medical Research Foundation, 
Minneapolis, MN.
Background: All intravenous (IV) iron products confer risk of hypersensitivity 
reaction (HSR). The relative safety of ferumoxytol versus other IV iron products is not 
established. We used Medicare claims to assess relative safety of ferumoxytol versus other 
IV iron products in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients.
Methods: We analyzed a 20% sample of Medicare Parts A and B claims in 2009-2012. 
Patients received a first dose of IV iron between Jan 1, 2010, and Nov 30, 2012, and had 
diagnosed NDD-CKD without IV iron treatment during the 1 year before first dose. For each 
ferumoxytol user, we identified 1 propensity score-matched control who used another IV 
iron product; the score included demographics, comorbidity, and concomitant IV medication. 
Patients were followed until change in IV iron product, end stage renal disease, death, or 
Dec 15, 2012. With Cox regression stratified by matched pair and cumulative number 
of prior IV iron doses, we assessed relative incidence of anaphylaxis, HSR symptoms, 
hypotension, emergency room (ER) visit, hospitalization, and death within 1 day of first 
dose and within 1 day of each subsequent dose.
Results: We identified 7358 ferumoxytol users and 7358 matched controls. Baseline 
characteristics were balanced across groups. There were too few cases of anaphylaxis and 
death to permit comparisons. However, after first dose, hazard ratios (ferumoxytol users 
vs. matched controls) were 0.90 (95% confidence interval, 0.80-1.01) for HSR symptoms, 
1.06 (0.66-1.72) for hypotension, 0.72 (0.55-0.94) for ER visit, and 0.78 (0.60-1.02) for 
hospitalization. After subsequent doses, corresponding hazard ratios were 1.07 (0.90-1.27) 
for HSR symptoms, 0.91 (0.50-1.67) for hypotension, and 0.86 (0.64-1.15) for ER visit, 
and 0.97 (0.70-1.35) for hospitalization.
Conclusions: Relative to other IV iron products, ferumoxytol was not associated 
with excess risk of adverse events in NDD-CKD patients, following both first dose and 
subsequent doses. The incidence of anaphylaxis and death was very low in ferumoxytol 
users and matched controls.
SA-PO174
Efficacy, Safety and Pill Burden of Sucroferric Oxyhydroxide, an Iron-
Based Phosphate Binder, Over 52 Weeks in African American Dialysis 
Patients  Stuart M. Sprague,1 Anjay Rastogi,2 Markus Ketteler,3 Adrian 
C. Covic,4 Jürgen Floege,5 Viatcheslav Rakov,6 Llera Armando Samuels.7 
1NorthShore Univ Health System, Chicago; 2Univ of California; 3Coburg 
Clinic and KfH-Dialysis Center, Germany; 4’Gr.T. Popa’ Univ of Medicine and 
Pharmacy, Romania; 5RWTH Univ Hospital Aachen, Germany; 6Vifor Pharma; 
7Temple Univ, Philadelphia.
Background: A post hoc analysis of data from a randomized, open-label, Phase 3 
study and its extension investigated the efficacy and safety of the iron-based phosphate 
binder sucroferric oxyhydroxide (SFOH; VELPHORO®) vs sevelamer carbonate (SEV; 
Renvela®) in African American dialysis patients.
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Methods: Overall, 1059 patients were randomized to SFOH (1.0–3.0 g/day; n=710) 
or SEV (2.4–14.4 g/day; n=349) for 12 weeks’ dose titration then 12 weeks’ maintenance. 
Eligible patients enrolled in a 28-week extension study.
Results: Of the 549 patients who completed the extension study, 100 were African 
American patients, equally distributed between the treatment groups despite the 2:1 
randomization (n=48, SFOH; n=52, SEV). Serum phosphorus decreased rapidly and to a 
similar extent with SFOH and SEV, and remained relatively constant thereafter (Table). 
Mean ± standard deviation number of tablets/day was lower for SFOH (3.4 ± 1.35) vs SEV 
(7.6 ± 2.92) over 52 weeks. The incidence of serious or severe treatment emergent adverse 
events and deaths were similar in both treatment groups. Gastrointestinal-related disorders 
were the most frequently observed adverse events for SFOH and SEV.
Conclusions: SFOH efficacy was maintained long-term, with a lower pill burden than 
SEV and similar safety profile, in African American dialysis patients. Post hoc results reflect 
those from the overall study population.
Funding: Pharmaceutical Company Support - Vifor Pharma
SA-PO175
Intergrated Dialysis Unit Module and Module Compartment Structure 
Stanley Shao-Ying Lee,1 Ming-cheng Wang.2  1Chi-Hsien Hemodialysis Center, 
Taiwan; 2College of Medicine, National Cheng Kung Univ, Tainan, Taiwan.
Background: Conventional set-up of hemodialysis (HD) center requires intensive 
manpower and tedious workload due to the intricate fluid and electricity layouts, and 
the fixed partitions structure. It is vital to design an integrated module considering rapid 
assembly, patient privacy and easy access to the fluid pipes and electricity lines for routine 
maintenance.
Methods: The Integrated Dialysis Partition System was designed for HD center. To 
ensure patient privacy, an easy-assembled partitions with a herringbone seating arrangement 
was used to position the HD seats partially and equally askew in one direction. The mobile 
modules of fluid pipes and electricity lines allow easy access for routine maintenance. 
Eighty uremic patients were enrolled to examine the differences between conventional and 
new HD unit in terms of psychological adjustment including depression, anxiety, mood, 
and illness intrusiveness.
Results: The state-of-the-art HD center with 40 seats could be established within 
one day.
For the entire patients, BDI scores were significantly higher when dialyzed in the 
conventional HD unit (M = 13.3 :t 0.9) than in the new HD unit with integrated dialysis 
partition system (M = 10.3 :t 1.2; t = 1.95, p = 0.014). In the conventional HD unit, patients 
recorded higher anxiety and lesser positive mood. There were no significant differences 
regarding negative mood or illness intrusiveness.
Conclusions: The intergrated dialysis unit module allows for rapid assembly, easy 
pipeline maintenance, and improved patients’ quality of life.
SA-PO176
Safety and Adherence in End Stage Renal Disease Patients on Chronic 
Hemodialysis  Kamran Karimi, Yezina T. Nigatu, Catherine Miranda, Keri 
Fico, Leonard A. Arbeit, Nand K. Wadhwa.  Nephrology, Stony Brook Univ 
Medical Center, Stony Brook, NY.
Background: Missed hemodialysis and abbreviated hemodialysis sessions are common 
in end stage renal disease patients on maintenance hemodialysis. Dialysis non-adherence has 
been associated with increased mortality and morbidity in chronic hemodialysis patients.
Our quality assessment performance improvement data revealed that on an average 15% 
of patients missed and abbreviated hemodialysis (HD) sessions over a period of 6 months.
Methods: We evaluated patients’ perception about missed and abbreviated sessions, 
and safety during HD sessions at our dialysis center. A questionnaire regarding patients’ 
views about missed, abbreviated and safe hemodialysis sessions using a visual analog 
scale (0-100 mm, where 0 means ‘No’ and 100 means ‘Yes’) was conducted in-person by a 
nephrology fellow or a social worker on all HD patients. Data are presented as (mean ± SD).
Results: Ninety patients participated in the survey. Sixty eight (75.6%) patients with 
a mean score of 78+ 29.6 felt like coming for their HD sessions during the last one month. 
Fifteen of 89 (16.9%) did not know why they came for HD sessions. Twenty seven percent 
came because they wanted to live while 18% came because they did not want to die. Eighty 
nine (98.9%) patients with a mean score of 94.5 + 17.3 felt safe during the HD sessions. 
Seventeen (18.9%) patients indicated missing the HD sessions. Thirty six of 83 (43.4%) 
patients with a mean score of 71 + 37.6 wanted to miss HD sessions during the last one 
month.Fifteen of 89 (16.9%) signed against medical advice for the abbreviated HD sessions 
during the last one month.
Conclusions: Data suggest that safety of HD sessions does not appear to be a factor 
for missing HD sessions. Lack of patients’ understanding of importance of HD treatments 
as well as lack of their active participation likely leads to non-adherence and abbreviation 
to HD sessions. The safety of HD treatment was not the core issue behind increasing 
patients’ absenteeism. Active patients’ participation and individualization of HD sessions 
may improve adherence to HD sessions.
SA-PO177
Validation of a Tool to Assess Nursing Workload in Hemodialysis 
Clara Bohm,1 Brett M. Hiebert,1 Joe A. Bueti,1 Jan Schneider.2  1Univ of 
Manitoba; 2Winnipeg Regional Health Authority.
Background: Patient classification scales (PCS) to assess nursing workload predict 
staffing needs and facilitate transparency in assignments resulting in improved work 
environment, patient safety and quality of care. Few validated PCS tools exist for 
hemodialysis (HD). This study validates a point-of-care PCS developed for in-centre HD 
at a Canadian tertiary care centre.
Methods: Using LEAN framework, from Sept 1, 2013 to Mar 1, 2014 at the Health 
Sciences Centre in Winnipeg, Canada, iterative consultations with stakeholders resulted 
in creation of a PCS consisting of 9 domains and 67 subdomains. At each HD session 
between April 7-21, 2014, bedside HD nurses completed both a visual analogue scale 
(VAS), which assessed general level of nursing care required, and the PCS tool. Karnofsky 
scale and time-series studies were completed in 50 and 28 randomly selected HD patients, 
respectively. Analysis: Internal consistency and reliability were assessed using Cronbach’s 
alpha and Intraclass Correlation Coefficient (ICC), respectively. Multi-trait multi-method 
analysis (MTMM) determined item homogeneity. Spearman’s correlation of PCS with VAS, 
Karnofsky Score and time-series studies assessed criterion and predictive validity. Linear 
regression was performed to determine the association of each subdomain with PCS score.
Results: PCS and VAS data for 1640 HD sessions (380 patients) was obtained. 
PCS Score VAS Score Karnofsky Score Time Series 
Mean (SD) 10.7 (5) 3.7 (1.9) 66 (14.4) 89 min (48)
N 380 380 50 27
PCS correlated well with VAS (0.769). Correlation of PCS with Karnofsky scale and 
time-series studies was -0.56 and 0.39, respectively. ICC was 65%. MTMM identified 
4 subdomains never used and 2 which were redundant. Linear regression identified 
16 subdomains with minimal contribution to overall PCS score. Reconsultation with 
stakeholders resulted in a revised 41-item PCS tool. Correlation between the revised tool 
and VAS, Karnofsky score and time-series was similar to the original model (0.77, -0.51 
and 0.316, respectively).
Conclusions: Preliminary results suggest excellent reliability and validity of this 
PCS tool. Validation studies at other HD centres with expanded time-series and reliability 
studies continue.
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SA-PO178
Feasibility of a Hemodialysis Safety Checklist for Nurses and Patients 
Samuel A. Silver,1 Alison Thomas,1 Andrea Rathe,1 Pamela L. Robinson,1 Ron 
Wald,1 Chaim Bell,2 Ziv Harel.1  1Nephrology, St. Michael’s Hosp, Toronto, ON, 
Canada; 2Medicine, Mt.Sinai Hosp, Toronto, ON, Canada.
Background: In 4% of ESRD patient deaths, the cause of death is a result of a 
preventable hemodialysis complication. These include errors related to communication, 
organization and human factors. We recently developed a hemodialysis safety checklist 
(Hemo Pause) to be completed by nurses and patients at specified intervals throughout a 
hemodialysis session, with the goal to improve dialysis unit safety culture. Our objective 
was to determine the feasibility of using Hemo Pause during every hemodialysis session 
for 3 months.
Methods: We conducted a single center, prospective time series study. A convenience 
sample of 14 nurses and 22 prevalent in-center hemodialysis patients participated. All 
participants were trained in the administration of Hemo Pause, completed the checklist at 
every hemodialysis session for 3 months and were free to suggest checklist modifications 
consistent with quality improvement methodology. The primary outcome was Hemo Pause 
completion, which was determined weekly using the percentage of checklists in the patient 
chart with all 17 items assessed. We also measured Hemo Pause acceptability using local 
patient safety surveys.
Results: There were 799 hemodialysis treatments pre-intervention and 757 post-
intervention. The checklist was completed for 556 of 757 (73%) treatments. The most 
common reasons for non-completion were the availability of nursing staff trained in Hemo 
Pause and patient admission to hospital. Among hemodialysis nurses, 93% (13/14) agreed 
that Hemo Pause was easy to use and 79% (11/14) agreed it should be expanded to other 
patients. Among hemodialysis patients, 73% (16/22) agreed that Hemo Pause made them 
feel safer and should be expanded to other patients. Negative comments by nurses or patients 
occurred on 4% (7/200) of survey responses.
Conclusions: A hemodialysis safety checklist (Hemo Pause) was acceptable to both 
nurses and patients over a 3 month period. Our next step is to spread Hemo Pause locally, 
and conduct a mixed methods study to determine mechanisms by which Hemo Pause may 
improve safety culture, patient engagement, and reduce adverse events.
Funding: Government Support - Non-U.S.
SA-PO179
Community-Based Parenteral Anti-Infective Therapy (COPAT) for ESRD 
Patients  Evamaria Anvari, Reza Anvari, Laura Ferreira Provenzano, Juan C. 
Calle.  Nephrology, Cleveland Clinic Foundation, Cleveland, OH.
Background: Infections are the leading cause of hospital admissions for patients 
with ESRD. The majority will need to continue antimicrobial therapy when discharged. 
Community-based parenteral anti-infective therapy (COPAT) refers to the practice of 
administrating antimicrobial therapy in the outpatient setting. It requires a multidisciplinary 
and the goals are to improve outcomes, reduce toxicity, drug resistance, and decrease hospital 
stay. ESRD patients have the advantage that IV antibiotics can be given at their dialysis 
units. The downfall is that every outpatient dialysis provider has their own policies for 
the approval of IV/IP therapy. Patients are frequently discharged with an order to continue 
therapy but it is not continued, leading to adverse outcomes.
Methods: We investigated the policies from the main dialysis providers in our 
community.
Results: 
Fresenius Medical Care Davita Centers for Dialysis Care
IV/IP drugs 
in unit
Vancomycin, Ceftazidime 
Cefazolin, Gentamycin
Vancomycin, Ceftazidime, 
Cefazolin, Gentamycin
Vancomycin, Cefalzolin, 
Gentamicin, Tobramycin 
(IP), Ceftazidime (IP)
IV/IP drugs in 
formulary 
Amikacin, Tobracycin, 
Ceftriazone, Cefepime, 
Meropenem, Daptomycin, 
Aztreonam, Ampicillin, 
Levofloxacin, 
Amphoteracin B, 
Fluconazol, Ganciclovir, 
Pentamidine
-Any other medication 
needs pre-approval
-Daptomycin will not be 
approved
Any other antimicrobial 
drug will beapproved
Time for drug 
arrival 24-48 hrs.
-Pre-approval 24-48 hrs.
-Day after approval 48 hrs.
Requirement Hospital order
-ID consult
-Organism with sensitivity
-Rational for using other 
antimicrobial
Hospital order
IP drugs Receive in unit
-Loading dose in unit and 
continue self-administer
-Drugs orderd Monday 
- Thursday will arrive at 
their home the following 
day
-If ordered after 3PM 
Friday it will arrive 
Monday
Loading dose in the unit 
and are given a 5-7 day 
supply to self-administer
Home Hemo Dialyze in center for therapy
Dialyze in center for 
therapy or trained to self-
administer
Dialyze in center for 
therapy
Conclusions: Readmissions and complicated infections in ESRD patients can be 
prevented if the multidisciplinary team coordinates care with the outpatient dialysis unit 
before discharge.
SA-PO180
Rapid Response and Cardiac Arrests in In-Patient Hemodialysis - A 
Retrospective Review  Justin Chen,1 Ladan Golestaneh,1,2 Lewis Ari Eisen.1,3 
1Albert Einstein College of Medicine, Bronx, NY; 2Nephrology, Montefiore 
Medical Center, Bronx, NY; 3Critical Care, Montefiore Medical Center, Bronx, 
NY.
Background: Patients with renal dysfunction requiring hemodialysis are known to be at 
increased mortality and morbidity risk. Few studies have examined rapid response (RR) and 
cardiac arrest (CA) events in inpatient hemodialysis. The purpose of this study is to evaluate 
patient characteristics and predictive factors of RR and CA in inpatient hemodialysis units.
Methods: A retrospective review of all available RR/CA events in two separate 
hospitals over a 3-year period was performed. Charts were reviewed for abnormalities 
in vital signs or laboratory values during hemodialysis sessions and for a 24-hour period 
prior to RR/CA events.
Results: In total, 16 RR and 13 CAC events were recorded for 26 unique patients 
(average age 64±16 years). Of the 29 total RR/CA events, 9 events resulted in survival 
<24 hours (31%). Common medical comorbidities included hypertension (92%), diabetes 
(73%), chronic heart failure (50%), and coronary artery disease (50%). The most common 
inciting factors for RR/CA activation were altered mental status (72%), systolic blood 
pressure < 90 (45%), and respiratory distress (31%). Vital sign abnormalities identified 
prior to hemodialysis included need for supplemental oxygen (72%), respiratory rate > 20 
(34%), and systolic blood pressure < 90 (3%). Vital sign abnormalities identified during 
hemodialysis included systolic blood pressure < 90 (34%) and heart rate < 40 (3%). Of 
those with labs available, the most common lab abnormalities included low hemoglobin 
and hematocrit (100%), elevated direct bilirubin (71%), elevated troponin-T (62.5%), and 
elevated PT (60%).
Conclusions: Our data suggest there are characteristics amongst patients undergoing 
inpatient hemodialysis that predispose them to RR/CA events. Simple, objective measures 
such as requirement for supplemental oxygen and abnormal vital signs may be important 
indicators that patients are at risk for serious adverse events. Knowledge of these factors 
can aid in decision-making regarding pursuit of dialysis and lead to the study of strategies 
to prevent patient harm.
SA-PO181
Monitoring of Protective Levels of Hepatitis B Antibody Titre in Pre-Dialysis 
and Dialysis Patients  Ravindra Mukkunda, Zahra Jabir.  Renal Medicine, 
Doncaster and Bassetlaw NHS Foundation Trust, Doncaster, Yorkshire, United 
Kingdom.
Background: Patients on dialysis are at risk of hepatitis B virus infection. Hence it is 
widely recommended to vaccinate chronic kidney disease (CKD) patients who might need 
renal replacement therapy. Antibody titre of >10iu/L is generally regarded as protective 
against Hepatitis B infection. The frequency of antibody level monitoring remains unclear. 
Once adequate antibody response achieved levels would wane with time. We monitored 
antibody levels in pre-dialysis and dialysis patients who achieved antibody response of 
>100iu/L, yearly for 2 years in order to explore the sustainability of the levels.
Methods: We selected 112 predialysis and dialysis patients who had Hepatitis B 
antibody response of >100 iu/L and has had antibody titres checked subsequently for 2 
consecutive years. Results analysed retrospectively to see how long the protective antibody 
levels lasted.
Results: Total number of patients who had antibody response of >100 iu/L from 2007 
to 2015 was 112 from our dataset at Doncaster Royal Infirmary Renal Unit. Of these 34% 
(38) of patients had hepatitis B antibody titres checked for 2 consecutive years. Patients 
maintaining antibody level of atleast >10iu/L for 2 years or more were 95%(36 out of the 38).
Conclusions: The outcome of this study confirms that protective antibody levels 
(>10iu/L) are maintained in 95% of those monitored for 2 years. This result reiterates the 
need for more robust evidence to inform nephrologists about the appropriate frequency of 
antibody monitoring in CKD patients.
SA-PO182
Improving Emergency Room (ER) to Dialysis Flow in a Busy Inner City 
ER  Anjali Acharya,1 Cherryll Moore,2 Raymond Mcclinton,1 Naheed Ansari,1 
Bonnie Carnes.2  1Nephrology, Jacobi Medical Center/Albert Einstein College 
of Medicine, Bronx, NY; 2Nephrology, Atlantic Dialysis, Queens, NY.
Background: Delays in access to hemodialysis during hospitalization are not 
uncommon and negatively impact on quality of patient care and lead to avoidable 
complications and unnecessary hospitalizations. Triple Aim is a sought after goal for health 
organizations to optimize health system performance. We hoped to target one of the three 
components which is to improve the experience of care.
Methods: The objective was to ensure initiation of dialysis for all non- emergent 
patients within four hours of ER triage. We analyzed retrospectively in a 8 week observation 
period, Electronic Medical Record (EMR) data on all hemodialysis patients >18 years of age 
presenting to the ER, with emphasis on time from triage to initiation of dialysis (TID). We 
also analyzed factors contributing to delays in dialysis initiation. Data were collected daily 
on each patient and tabulated weekly. We instituted two measures to address the obstacles. 
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These were-i) educating the ER staff about timeliness of informing the renal team and ii) the 
second was to institute a tracking system to systematically gather detailed data on patient 
transport metrics such a time to patient pick up from initial contact with the transport office.
Results: Baseline data revealed average TID from triage was 8 hours. Two major 
contributory factors identified were late notification by ER to renal team and delays in 
transport. By instituting measures targeting these, we were able to achieve being able 
to provide dialysis within 4 hours of triage in over 80% of our non-urgent hemodialysis 
patients.
Conclusions: We were able to improve the patient experience and care with simple 
measures. This has a positive impact on patient safety by minimizing late treatments and 
staff fatigue. Though Triple Aim is a goal at the population and health care delivery level, 
we believe processes can be implemented at a local level that align with the CMS goals of 
triple aim. In today’s environment it is incumbent upon us to make efforts to innovate for 
better patient care and to minimize health care costs.
SA-PO183
Quality Improvement Project in Dialysis: Improving Access to Dialysis for 
Patients Presenting to the Emergency Room (ER)  Nikulkumar Chaudhari,1 
Bonnie Carnes,2 Cherryll Moore,2 Roshni Upputalla,1 Parikshit Thakur,1 Naheed 
Ansari,1 Anjali Acharya.1  1Nephrology, Jacobi Medical Center/Albert Einstein 
College of Medicine, Bronx, NY; 2Nephrology, Atlantic Dialysis, Queens, NY.
Background: Hemodialysis patients presenting to the emergency room are a vulnerable 
patient population. Majority of them have significant comorbid conditions. Delays in 
evaluation and institution of dialysis are common in busy emergency rooms. We undertook 
a project to improve quality of patient care as well as the patient experience with a goal 
to provide timely dialysis.
Methods: We analyzed baseline data from electronic medical record (EMR) pertaining 
to all hemodialysis patients presenting to the ER in a specified 8 week period. After brain 
storming within the team we identified a few factors that were seen as obstacles in providing 
timely dialysis. One of them was the time from patient triage to notification of the renal 
team. We instituted an educational program with the ER staff with focus on the timeliness 
of informing the renal team, establishing “triage to renal team notification time” of less 
than 30 minutes as a meaningful metric. Data was collected at pre and post intervention. 
The objective was to meet this goal >80% of the time over the 2 month intervention period.
Results: There was a positive impact on the triage to renal notification time. The 
percentage of timely notifications as defined, rose to >85% from a baseline of <25% and 
this effect was sustained over the 8 weeks. Most patient notifications happened within 10 
minutes of triage.
Conclusions: A simple intervention on educating the ER staff made a significant impact 
on timely evaluation of dialysis patients presenting to the ER. There was an observable 
positive impact on patient experience. We view this as a simple first step in optimizing 
patient care and experience towards a seamless journey through the hospitalization. Simple 
innovative steps such as this could contribute to cost control by avoiding /minimizing 
dialysis treatments during off hours. In addition it could help mitigate staff fatigue and 
treatment errors thus improving patient safety.
SA-PO184
Diagnostic Reference Values for Cerebrospinal Fluid May Not Be Useful 
in Haemodialysis Patients Suspected of Having Central Nervous System 
Infection  Thomas Oates, Damien Ashby.  Imperial NHS Trust, London, United 
Kingdom.
Background: Invasive investigations in haemodialysis (HD) patients can be associated 
with complications due to bleeding, and standard diagnostic tests, such as pleural fluid 
biochemistry, have been shown to be of limited value in this patient group. As a result, 
we examined the utility of cerebrospinal fluid (CSF) analysis in HD patients suspected of 
central nervous system (CNS) infection.
Methods: We used electronic records to retrospectively examine laboratory data from 
HD patients who had CSF analysis in a 5 year period. All patients were initially suspected of 
having a CNS infection but relevant culture and polymerase chain reaction tests ultimately 
proved negative for bacterial, mycobacterial, fungal or viral infections in all cases.
Results: 30 CSF samples from 29 patients were identified in the study period. 
CSF protein concentration was available for 16 samples (median 0.40g/L, range 0.19-
1.06g/L, corrected for number of red cells in sample) and paired CSF and plasma glucose 
concentrations, allowing calculation of CSF:serum glucose ratio, for 25 samples (median 
ratio 0.58, range 0.21-1.40). Using the accepted normal CSF protein concentration of 0.23 
to 0.38 g/L (see Figure shaded region), 8 out of 16 samples showed an elevated protein 
concentration suggesting CNS infection. Additionally, 13 out of 25 samples had a CSF:serum 
glucose ratio of less than the normal value of 0.6 (see Figure horizontal line) which is also 
suggestive of CNS infection.
Conclusions: CSF biochemistry is frequently used in the diagnosis of CNS infection. 
Our preliminary results suggest CSF protein and glucose concentrations should be 
interpreted with caution in HD patients and may not add diagnostic information in suspected 
CNS infection. We are currently investigating the hypothesis that CSF biochemistry may 
be influenced by duration of chronic kidney disease and HD vintage.
Funding: Clinical Revenue Support
SA-PO185
Continuous Renal Replacement Therapy (CRRT) and Hypoglycemia: A 
Retrospective Study on Patients Undergoing CRRT and Development of 
Hypoglycemia in Diabetic and Non-Diabetic Individuals  Mamtha Balla,1 
Adam Lyons,1 Mary C. Naglak,1 Doron Schneider,1 Robert A. Sirota.2  1Internal 
Medicine, Abington Jefferson Health, WillowGrove, PA; 2HTN Nephrology 
Associates, Abington Jefferson Health, WillowGrove, PA.
Background: Hypoglycemia is a little known complication of CRRT. There are no 
studies available to evaluate the prevalence or intensity of hypoglycemia during CRRT. 
This study attempts to determine the frequency, timing, and severity of hypoglycemia as 
a complication of CRRT in diabetic and non-diabetic patients in the intensive care unit.
Methods: This was a retrospective observational study to assess the effect of CRRT 
on plasma glucose in diabetic and non-diabetic individuals who were admitted to Abington 
Jefferson Health. A chart review was used to complete a detailed data collection form for 
patients who underwent CRRT for several diagnosis (sepsis, medication overdose, acute 
renal failure) in 2013 and 2014 who met the selection criteria. Hypoglycemia is defined as 
Blood sugar less than 70mg/dl. Dialysate contained 100mg/dl glucose.
Results: After reviewing the charts for 218 CRRT events in 119 patients admitted to 
Abington Jefferson Health, 100 patients were studied based on selection criteria. The mean 
age of the study population was 66.3 + 15.3 years. Thirty-six of the 100 patients studied 
had hypoglycemia during CRRT. The number of episodes was as follows: 14/36 (38.9%) 
had one episode, 7/36 (19.4%) had two, 7/36 (19.4%) had three and 5/36 (13.9%) had five 
episodes (mean number of episodes was 2.7±1.9). Hypoglycemia occurred on average 
9.9±6.1 hours from start of CRRT. Patients who had hypoglycemia during CRRT were 
more likely to have it again after CRRT (53%; 19/36) (p<0.0005). Of the 36 patients with 
hypoglycemia, 78% (28/36) had sepsis vs. 22% (8/36) who did not have sepsis but had 
hypoglycemia (p>0.05). No association was found between development of hypoglycemia 
and history of diabetes and CKD.
Conclusions: Our study showed that hypoglycemia is a frequent complication during 
CRRT. In order to prevent hypoglycemia from being under-recognized protocols including 
frequent blood glucose monitoring during CRRT should be in place.
SA-PO186
The Safety of Intravenous Hydration for the Prevention of Contrast Induced 
Nephropathy  Yvonne R.P. de Waal,1 Corinne E.A. Balemans,1 Marc A.G.J. 
Ten Dam,2 Louis J.M. Reichert,3 Jack F. Wetzels.1  1Nephrology, Radboud Univ 
Medical Center, Nijmegen, Netherlands; 2Nephrology, Canisius Wilhelmina 
Hospital, Nijmegen, Netherlands; 3Nephrology, Rijnstate Hospital, Arnhem, 
Netherlands.
Background: Contrast-induced nephropathy (CIN) is associated with marked morbidity 
and mortality. To prevent CIN, current guidelines advise intravenous hydration in high risk 
patients. Thus far, the possible side effects of hydration have received little attention. We 
evaluated the incidence of (serious) adverse events ((S)AEs) after intravenous hydration.
Methods: In a retrospective study we analyzed the incidence of (S)AEs after 
intravenous hydration in two Dutch hospitals. In one hospital (Rijnstate Hospital Arnhem) 
we evaluated all AEs related to hydration. In the other hospital (CWZ Nijmegen) the analysis 
was limited to SAEs, i.e. those necessitating prolonged hospital stay. Patient and outcome 
characteristics were retrieved from the hospital records.
Results: In the Rijnstate Hospital Arnhem we evaluated 233 records of patients 
hydrated in the period from February till July 2013. AEs occurred in 18 patients (8%). The 
most common AE was overhydration, which occurred in 11 patients (5%) and necessitated 
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prolonged hospitalisation in 4 (2%). Admission to the coronary care unit was needed in one 
patient. Almost all patients with overhydration (91%) had pre-existent cardiac disease and 
used diuretics. Infusion related AEs also occurred, like extravasation and phlebitis, in one 
case leading to S. Aureus bacteremia. In the CWZ Nijmegen we evaluated 257 medical 
records of patients hydrated from May 2013 till January 2014. Prolonged hospitalisation 
due to overhydration was necessary in 10 patients (4%).
Conclusions: Our study demonstrates that overhydration is a common adverse event 
after intravenous hydration and necessitates prolonged hospital stay in 2-4% of patients. 
These data provide arguments against routine hydration in patients with moderate increased 
risk of CIN. Patients with pre-existent cardiac disease are most prone to overhydration. 
However, these patients are also at highest risk for the development of CIN. Risk and 
benefits must be weighed when choosing strategies to prevent CIN.
SA-PO187
Cystatin C in Predicting Cardiorenal Syndrome Type 1 and Mortality in 
Patients with Acutely Decompensated Heart Failure with Preserved Renal 
Function  Carlos Federico Varela,1 Ivan Constantin,2 Gustavo Cristian Greloni,1 
Griselda Bratti,1 German Barrera Hugalde,1 Cesar Belziti,2 Rodolfo Pizarro,2 
Guillermo Javier Rosa diez.1  1Nephrology, Hospital Italiano de Buenos Aires, 
Buenos Aires, Argentina; 2Cardiology, Hospital Italiano de Buenos Aires, 
Buenos Aires, Argentina.
Background: Cardiorenal Syndrome type 1 (CRS 1) is defined as a worsening renal 
function that complicates acutely decompensated heart failure (ADHF). These patients 
experience higher mortality and morbidity. Serum creatinine (SC) is slow to reflect 
changes in kidney function. Cystatin C (Cys C) has emerged as a novel biomarker with 
a stronger correlation with cardiovascular disease than SC. The aim of our study was to 
evaluate Cys C in predicting CRS 1 and outcomes in patients admitted with ADHF and 
preserved renal function.
Methods: We conducted an observational and prospective study. We included patients 
above 18-years old with ADHF with preserved renal function defined as a SC below 1.3 
mg/dL. We excluded patients with heart valvular disease and acute coronary syndrome. 
Cys C blood samples were collected on admission. We defined CRS 1 as a rise in creatinine 
by 0.3 mg/dL or more during five days.
Results: 166 patients aging 85 median (IQR 77-89) years old were enrolled. The 
incidence of CRS 1 was 29.7 %, with an in-hospital mortality of 3.1 %, and a total mortality 
(TM) of 24.4 %. The median follow-up was 193 days. Cys C was significantly higher in 
patients with CRS 1 compared to those without (1.72±0.58 vs1.51±0.41, p=0.03) and predict 
TM but did not predict in-hospital mortality (1.69± vs 1.57±0.48, p=0.58) or readmission 
(1.47±0.4 vs 1.6±0.5, p=0.58). In the multivariable analysis Cys C was an independent 
predictor of mortality (OR 3.31, IC1.38-7.93) while SC at admission was not (OR 0.48, IC 
0.05-3.48). The area under the receiver-operating characteristic curve of Cys C for CRS 1 
was 0.60 and for TM was 0.65. The best cutoff value was 1.6 mg/dL for both end points. 
It had a sensitivity and specificity of 61.2 % and 60.3 % for CRS 1, and 61.5 % and 62 
% for TM, respectively.
Conclusions: Above a cut-off value of 1.6 mg/dL, Cys C predicts CRS 1 and mortality 
in patients admitted with ADHF with preserved renal function.
SA-PO188
Is Cystatin C a Better Biomarker of AKI in ICU to Compare NGAL? 
Itir Yegenaga, Fatih Kamis.  Internal Medicine, Kocaeli Univ Medical School, 
Kocaeli, Izmit, Turkey.
Background: Serum creatinine levels can be affected with many variable factors. 
We concluded that better bio-marker is needed to recognize AKI as early as possible. We 
studied Cystatin C (CysC) and Neutrophyl Gelatinase Associated Lipocalin (NGAL) in 
ICU patients to determine which is more predictable.
Methods: Hundred and eighty three (85 male; mean age: 65) critically ill patient with 
no previous chronic renal failure history were included to this study. Clinical, laboratory 
evaluations were noted and blood was taken in 48 hours for CysC and NGAL and followed 
for 7 days, if they meet the RIFLE criteria.
Results: CysC and NGAL values for every stages RIFLE and serum CysC value were 
significant only for RIFLE-L stages (p=0.25) but not urinary CysC. NGAL in serum and 
also in urine were significantly different in RIFLE-I,F. Biomarkers were compared when 
fulfilled the RIFLE criteria in first 48 hour and following 3-7days to non-AKI values .
S-CysC
mean+/- SD U-CycC
S-NGAL
Median(25-75)
U-NGAL
Median(25-75)
(1) No-AKI
N:122 30.42+/- 10.17
* 7.38+/-2.58 75.69(53.76-91.58)* 17.98(8.72-39.25)*
(2)AKI in 48 h
N:14 32.23 +/- 9.70 6.78+/-1.65 95.28(67.98-110.90) 21.74(19.99-50.52)
*
(3) AKI in 3-7 
days
N:15
31.40+/- 13.45 7.74+/-2.42 123.68(90.89-166.31) 12.32(24.59-96.63)*
(4)AKI in 
7days
N:32
40.75 +/-13.38* 7.74+/-1.82 136.38(117.96-220.54)* 66.06(59.39-75.17)
*
(1-4) P<0.001 p=0.714 (1-3) p=0.028(1-4) p<0.001
(1-3)p=0.23
(1-4) p<0.001
(2-4) p=0.040
While sNGAL and u NGAL were significantly different between these two groups. 
Serum CysC level was related to mortality (figure 1)(AUC-ROC 0.68 CI; 0.575-0.733).
Conclusions: In our cohort NGAL obtained in 48 hours is more predictable biomarker 
than CysC for early AKI diagnosis following 7 days. But CysC levels were fairly predictive 
for mortality.
SA-PO189
The Effect of Point of Care (POC) Creatinine/eGFR Measurement on the 
Incidence of Contrast-Induced Acute Kidney Injury (CI-AKI) following 
Primary Percutaneous Coronary Intervention (PPCI) for the Treatment 
of ST Elevation Myocardial Infarction (STEMI)  Firas Al-Janabi, Shah 
MohdNazri, John R. Davies, Thomas Roger Keeble, Ellie Gudde.  Interventional 
Cardiology, Essex Cardiothoracic Centre, Basildon, Essex, United Kingdom.
Background: Contrast-induced acute kidney injury (CI-AKI) is a predictor of mortality, 
morbidity and length of hospital stay. During STEMI treatment with primary percutaneous 
coronary intervention (PPCI) there are a number of predictors of AKI including existing 
renal dysfunction (eGFR < 60) and contrast volume used.
Methods: A retrospective audit over 6 months at the Essex Cardiothoracic Centre 
identified 348 patients who had presented with STEMI and had PPCI. These patients formed 
the standard care control group. Prospectively 131 consecutive patients presenting with 
STEMI and under-going PPCI had a point of care creatinine measurement (STATSENSOR, 
Nova Biomedical). A comparison in rates of AKI was made between the two groups.
Results: In the standard care group, 9.7% of patients with normal renal function and 
26.6% of patients with impaired renal function developed AKI. When creatinine was 
measured pre-PPCI, 8% of patients with normal renal function and 16.1% of patients 
with renal impairment developed AKI, a 39.5% reduction in AKI in those with renal 
dysfunction in the POC creatinine group. The average contrast volume in the standard care 
group was 159 ml, compared to 117.5ml when renal function was found to be impaired 
(eGFR < 60) pre-PPCI. 186ml was used on average in the POC group when creatinine 
was found to be normal.
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Conclusions: Measuring the POC creatinine of 131 patients presenting with STEMI 
and undergoing PPCI reduces the rates of AKI by 39.5% in those with renal dysfunction. 
This appears to be mediated in part by a reduction in contrast volume in those patients 
identified with renal dysfunction (117.5ml) compared to normal renal function (186 ml).
Funding: Pharmaceutical Company Support - Nova Biomedical
SA-PO190
Serum Creatinine Variability Predicts Progression to CKD4 
Carlos E. Palant,1,2 Lakhmir S. Chawla,1,2 Ping Li,1,2 Paul L. Kimmel,2,3 
Charles Faselis,1,2 Richard Amdur.1,2  1Medicine, Washington DC VA Medical 
Center, Washington, DC; 2Medicine, George Washington Univ Medical School, 
Washington, DC; 3NIDDK, National Insts of Health, Bethesda, MD.
Background: Pre-dialysis patients have high serum creatinine (SC) variability. SC 
variability is associated with high death rates. We examined the association between SC 
variability and CKD progression in a large cohort of US veterans with a wide range of 
baseline eGFR.
Methods: VA patients admitted 10/1999 - 12/2005 with at least 4 months with SC and 
initial eGFR>30 ml/min/1.73 m2 (using CKD-EPI) were selected. Autoregression-based 
slope was computed for each patient using monthly peak SC. SC variability was root 
mean-square residual of peak SC readings from the regression line. CKD4-date was the 
first date when eGFR permanently fell below 30 ml/min/1.73 m2. Logistic regression was 
used to predict CKD4 using: initial eGFR, SC variability, SC slope, age, race, sex, months 
with SC readings, and comorbidities (DM, CAD, PNE, MI, angina, AKI, COPD, CHF). 
Kaplan-Meier (KM) analysis was used to examine time from first admission to entry into 
CKD4, stratified by SC variability quartile and baseline eGFR, and Cox regression was 
used to adjust survival estimates for the covariates above.
Results: Of 342,086 patients, 36,108 (10.6%) reached CKD4. The logistic model had 
strong prediction accuracy (c=.94) with sensitivity and specificity both .86. SC variability 
was strongly associated with entry into CKD4 (adjusted OR 3.79 [3.67-3.91], p<.001). 
Time to CKD4 differed by level of SC variability in KM (p<.0001; Figure) and Cox (HR 
1.34 [1.31-1.36], p<.0001).
Conclusions: SC variability is strongly independently associated with rate of decline 
in renal function, at all baseline eGFR levels, after accounting for covariates, and is an 
important risk factor for entry into CKD4.
Funding: Veterans Administration Support
SA-PO191
Assessment of Methods Used to Substitute for Missing Preadmission 
Creatinine Values in the Diagnosis and Staging of Acute Kidney Injury 
Amelie Bernier-Jean, Anatolie Duca, Francois Madore, Remi Goupil, Stephan 
Troyanov, Josee Bouchard.  Nephrology, Hopital du Sacre-Coeur de Montreal, 
Canada.
Background: Missing preadmission serum creatinine values (SCr) are a common 
obstacle to the diagnosis and staging of acute kidney injury (AKI). As a workaround, 
the KDIGO guidelines suggest using a baseline SCr computed from the MDRD formula 
assuming a baseline estimated glomerular filtration rate (eGFR) of 75 ml/min per 1.73m2. 
We hypothesized that surrogates for preadmission SCr will misclassify AKI incidence and 
severity when compared to a known preadmission SCr.
Methods: Over a 12-month period, we performed a retrospective single-center study 
of critically ill patients with known preadmission SCr to identify the most accurate method 
to estimate baseline SCr for AKI diagnosis and staging (KDIGO criteria). We assessed 
three surrogate methods: 1) the first hospital admission SCr, 2) the minimal SCr after 
ICU admission and 3) SCr computed for a eGFR of 75 ml/min per 1.73 m2 using MDRD.
Results: Of 1001 randomly selected patients, a preadmission SCr was available for 498 
and 14 were excluded for requiring acute renal replacement therapy. Median age was 67 
(IQR 58-76), 60% were male and 98% were Caucasian or Asian. The median time between 
SCr measurement and admission was 116 (IQR 78-179) days. AKI incidence according 
to preadmission SCr was 24.8%. We reported in table 1 the AKI incidence, sensitivity, 
specificity and kappa values for each surrogate method.
N=484 AKI incidence (%) SEN SPE Kappa
Known baseline creatinine 120 (24.8) - - -
Hospital admission creatinine 93 (19.2) 75.0 99.2 0.80
Minimal creatinine 227 (46.9) 99.2 70.3 0.54
MDRD GFR 75ml/min/m2 131 (27.1) 91.7 94.2 0.83
For AKI staging, we found the following kappa values: 0.75 using the first SCr upon 
admission, 0.43 using the minimal SCr, and 0.66 using the computed MDRD eGFR of 
75ml/min per 1.73m2.
Conclusions: In our cohort, the MDRD computed SCr for a eGFR of 75 ml/min 
per 1.73m2 was the best surrogate method for diagnosing AKI. Using the minimal SCr 
significantly overestimated the incidence of AKI. Concerning AKI staging, the first hospital 
admission SCr was the most accurate method.
SA-PO192
Fluid Balance and Oliguria in Early AKI Diagnosis After Liver Transplant 
Camila Lima,1 Luciana Haddad,2 Luiz M. Malbouisson,3 Luiz Augusto Carneiro 
D’Albuquerque,2 Etienne Macedo.1  1Nephrology, Univ of Sao Paulo, Brazil; 
2Gastrointestinal Surgery, Univ of Sao Paulo, Brazil; 3Anesthesiology, Univ of 
Sao Paulo, Brazil.
Background: AKI is a frequent complication of liver transplant (LT), associated with 
increased morbidity and mortality. Early diagnosis can translate into secondary preventive 
measures and improve outcomes. We hypothesized that adjusting Scr for positive fluid 
balance (FB) and applying urine output(UO) criterion would improve timing of AKI 
diagnosis. In addition, we investigate whereas sequential assessment of urinary biochemistry 
after LT can improve prediction of early post-operative AKI development.
Methods: In a prospective cohort study, we recorded UO, FB and labs of patients 
undergoing LT. We assessed urine and blood biochemistry perioperative (before induction 
of anesthesia, after portal reperfusion, 6, 18, 24 hours after surgery). AKI diagnosis was 
based on UO and the sCr KDIGO criterion before and after correcting scr for FB (Scr 
adjusted), using the formula: ((weight*0,6)+(FB)/(weight*0,6).
Results: Fifty-five patients >18 years undergoing LT from Jun13 to Oct14 were included 
in the analysis. twenty-seven percent (15) of patients developed AKI based on Scr criterion 
within 48h of surgery (early AKI). By adjusting Scr for fluid balance 38%(21) patients were 
classified as early AKI. Applying the UO criterion, 43patients were classified exclusively 
by this criterion as early AKI. All patient showed a decline in FeNa and the FeU after portal 
reperfusion. Patients developing early AKI had a higher decline and maintained lower 
levels for 24h. FeUreia values were significantly different 6 hours after surgery in early 
AKI patients. Patients with early AKI based on both criteria or exclusively by UO had a 
higher mortality and longer ICU and hospital stay than non-AKI patients.
Conclusions: Applying UO criteria and adjusting Scr for FB can help in the early 
identification of patients developing AKI after liver transplant. Tubular function assessment 
could be utilized along with biomarkers of kidney injury to identify patients with increased 
risk of developing AKI. Standardized approach for early AKI diagnosis in high-risk patients 
could improve outcomes.
Funding: Other U.S. Government Support
SA-PO193
Renal Angina Index a Practical Tool to Identify Patients at Increased Risk 
of Acute Kidney Injury  Rolando Claure-Del Granado,1 Andrea Pero,1 Josee 
Bouchard,2 Ravindra L. Mehta.3  1IIBISMED, Univ Mayor de San Simon, School 
of Medicine, Bolivia; 2Hospital du Sacre-Coer de Montreal, Canada; 3Univ of 
California San Diego Medical Center.
Background: Reliable prediction of acute kidney injury (AKI) has the potential to 
optimize treatment. Recently Goldstein SL et al. proposed an empiric clinical model of renal 
angina using patient demographic factors and early signs of injury to identify critically-ill 
children who would be at higher risk of AKI. We test the hypotheses that in a cohort of 
adult critically-ill patients, a modified renal angina index (RAI) will identify patients at 
high risk of developing AKI, and could be related to in-hospital mortality.
Methods: We included 124 consecutive patients admitted to our medical ICU. We 
measured serum creatinine (sCr) every 24 h for 7 consecutive days after ICU admission. 
RAI was calculated at ICU admission (day 1) and 24 h after (day 2) using the following 
formula: Risk level (vasopressors and invasive mechanical ventilation = 5; diabetes 
mellitus = 3; and sepsis = 1) X Injury level (decreases in eGFR: no change=1, 0-24.9%=2, 
25-49.9%=4, and ≥50%=8). The composite range of the RAI is therefore: 1, 2, 3, 4, 5, 6, 
8, 10, 12, 20, 24, and 40. We analyzed the value of a RAI score ≥8 to predict subsequent 
AKI (after 48 h, day 3) and survival.
Results: We identified 50(40.3%) patients with AKI (KDIGO guidelines sCr criteria), 
and 74(59.7%) patients who did not develop AKI. Patients with a RAI ≥8 were at higher 
risk of developing AKI within 7 days of follow-up (RR 1.64 95% CI 1.31–2.05; p<0.0001). 
A RAI ≥8 at ICU admission (day 1) and 24 h after admission (day 2) was able to identify 
individuals who developed AKI (day 3-7) with an AUC of 0.861 (95% CI 0.777-0.945); p < 
0.0001 and an AUC of 0.891 (95% CI 0.815-0.966); p < 0.0001, respectively. No difference 
was found in terms of 28 day in-hospital mortality in patients with a RAI ≥8 vs a RAI ≤8.
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Conclusions: The RAI provides a clinically feasible methodology to identify critically-
ill patients at high risk of developing AKI before a rise in sCr occurs. This tool would permit 
the early identification of AKI to initiate preventive and treatment strategies minimizing 
extension of kidney injury.
SA-PO194
The Renal Angina Index Identifies Patients at High-Risk of Acute Kidney 
Injury – Analysis from AWARE: A Prospective Multinational Study of 
AKI in Critically Ill Children  Rajit K. Basu,1,2 Ahmad Kaddourah,1,2 Stuart 
Goldstein.1,2  1Pediatrics, Center for Acute Care Nephrology, Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH; 2On Behalf of the AWARE 
Study Investigators, Multinational Pediatric ICU.
Background: We conducted a global, prospective observational study of critically ill 
children to study the epidemiology of pediatric acute kidney injury (AKI). We analyzed 
the discrimination of the renal angina index for prediction of AKI and patient outcomes.
Methods: Data from 32 centers (5 continents, data collection for 3 consecutive months 
in 2014) from children (aged 3 months to 25 years) admitted to a pediatric intensive care unit 
were analyzed. The renal angina index (RAI) was calculated on the day of admission (Day 
0) as previously described. A cut-off of > 8 on Day 0 was used to determine fulfillment or 
absence of renal angina (RA+ vs. RA-). The primary outcome was the presence of severe 
AKI on Day 3, defined by change in serum creatinine from baseline using KDIGO stage 
2-3 criteria (Day 3 AKI). Other patient outcomes were assessed at 28 days.
Results: 9.6% (501/5231) of children were RA+ on Day 0. The area-under-curve 
receiver operating characteristic of the Day 0 RAI for Day 3-AKI was 0.797 (95% confidence 
interval 0.759-0.836). RA+ was associated with a higher net fluid balance on Day 3 than 
RA- (p<0.001). Compared to RA-, Day 0 RA+ was associated with prolonged duration of 
mechanical ventilation, longer length of stay, increased use of extracorporeal therapies, 
and higher incidence of mortality.
Conclusions: In AWARE, the largest prospective multi-center epidemiologic 
assessment of AKI in critically ill children, we demonstrate the ability of the renal angina 
index to identify patients at high risk of AKI, three days in advance. Fulfillment of renal 
angina early in the ICU course is associated with poor patient outcome.
SA-PO195
Phase Angle and Extracellular Hypervolemia, as a Prognostic Markers in 
Acute Kidney Injury  Francisco Javier Lavilla, Maria Jose Molina Higueras, 
Diana Lopez Espinosa, Pelayo Moiron Fdez-Felechosa, Nuria Garcia-Fernandez, 
Paloma L. Martin Moreno, Pedro Errasti.  Nephrology, Clínica Univ de Navarra, 
Pamplona, Navarra, Spain.
Background: The bioelectrical impedance analysis (BIA) is a noninvasive and painless 
technique and easy to perform , which is used for determining body composition . Can offer 
information about membrane cell integrity, volemia and clinical status. We evaluate use of 
BIA and two bioelectrical parameters (Phase angle –PA-, and extracelular/intracelular watter 
ratio –ECW/ICW- ) as a prognostic markers in acute kidney injury (AKI).
Methods: We include a cohort of 83 patients (mean age 64 years SD 1.8, and male 
72.3 %) with AKI and BIA. We evaluate clinical prognostic index (individual severity 
index –ISI-), inflammatory and protein metabolism analitical parameters (C-reactive protein, 
albumin, prealbumin) and chronic health index (Karnofsky –K-).
Results: Exitus 14.5%. PA and ECW/ICW was associated with prognosis in AKI. 
ISI CRP Alb PreAlb K
PA r=-0.228, p=0.038
r=0.250, 
p=0.027
r=0.369, 
p=0.006 NS
r=0.516, 
p<0.001
ECW/ICW r=-0.271, p=0.001
r=0.248, 
p=0.004 NS
r=-0.410, 
p=0.008
r=-0.253, 
p=0.003
PA: PHASE ANGLE ECW/ICW: EXTRACELLULAR/INTRACELLULAR WATTER RATIO. 
ISI: INDIVIDUAL SEVERITY INDEX. CRP: C-REACTIVE PROTEIN. Alb: ALBUMIN. PreAlb: 
PREALBUMIN. K: KARNOFSKY.
PA was associated with protective risk mortality OR 0.425, p=0.007, CI 95% 0.229-
0.780 and ECW/ICW with risk mortality OR 2.247 CI 95% 1.266-3.98. The AUC with 
PA was 0.770 (p=0.003, CI 95% 0.652-0.888) and with ECW/ICW was 0.778 (p=0.001, 
CI 95% 0.678- 0.879).
Conclusions: BIA is a useful technique to evaluate AKI. Lower PA and higher ECW/
ICW are associated with worse prognosis in AKI. There are relation with inflammatory and 
proteín metabolism status, and with health clinical status prior to the event.
SA-PO196
Preoperative Renal Resistive Index Predicts the Risk of Acute Kidney Injury 
in Patients Undergoing Cardiac Surgery  Daniel P. Olsson Hertzberg,1 Ulrik 
Sartipy,2 Martin Holzmann.1  1Dept of Medicine, Karolinska Inst, Stockholm, 
Sweden; 2Dept of Anesthesiology, Surgical Services and Intensive Care Medicine, 
Karolinska Univ Hospital, Stockholm, Sweden; 3Dept of Molecular Medicine 
and Surgery, Karolinska Inst, Stockholm, Sweden.
Background: Previous studies have indicated that Renal Resistive Index (RRI), an 
ultrasound-based measurement, can predict AKI in a variety of settings. To our knowledge, 
there are no studies investigating the predictive value of preoperative RRI and the risk of 
AKI in cardiac surgery patients. The aim of this study was to investigate whether an elevated 
preoperative RRI predicts AKI in a general cardiac surgery population.
Methods: Patients undergoing elective cardiac surgery were included prospectively 
between September 21, 2014 and April 22, 2015 at the Karolinska University Hospital. RRI 
was measured the day before surgery. An elevated RRI was defined as >0.7. The outcome 
AKI was defined as an absolute increase in post- compared to preoperative serum creatinine 
by 0.3 mg/dL (>26µmol/L) or a relative increase by >50%. The odds ratio for AKI was 
calculated by logistic regression in patients with a RRI >0.7 versus those with a RRI ≤ 0.7.
Results: 98 patients were included. In patients with a RRI £0.7, 6 (15%) patients 
developed AKI, compared to 19 (33%) in patients with a RRI >0.7. The mean increase 
in postoperative serum increase in patients with RRI £0.7 was 0.12 mg/dL (11 µmol/L) 
compared to 0.34 mg/dL (30 µmol/L) in those with RRI >0.7 (P=0.03). The odds ratio 
for developing AKI in patients with a RRI >0.7 compared to those with a RRI £0.7 was 
2.76 (0.99-7.71).
Conclusions: We found that patients with an elevated RRI before cardiac surgery 
had an increased risk of developing AKI postoperatively. RRI might be a valuable tool for 
identifying patients with an increased risk of developing AKI connected to cardiac surgery.
SA-PO197
Development of a Postoperative Risk Stratification Tool via Bayesian Model 
Averaging for Acute Kidney Injury After Cardiac Surgery  Allison Meisner,1 
Kathleen F. Kerr,1 Heather Thiessen Philbrook,2 Francis Perry Wilson,3 Amit 
X. Garg,2 Michael Shlipak,4 Peter Kavsak,5 Richard P. Whitlock,5 Steven G. 
Coca,6 Chirag R. Parikh.3  1Univ of Washington, Seattle, WA; 2Western Univ, 
ON, Canada; 3Yale School of Medicine, New Haven, CT; 4UCSF; 5McMaster 
Univ, ON, Canada; 6Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Acute kidney injury (AKI) is a frequent complication of cardiac surgery. 
We sought predictive combinations of biomarkers measured 0-6 hours after surgery, 
potentially in combination with cardiopulmonary bypass (CPB) time (to account for the 
degree of insult).
Methods: The primary endpoint was sustained mild AKI, defined as an increase of 50% 
or more in serum creatinine over preoperative levels lasting at least two days during the 
hospital stay. Severe AKI (secondary endpoint) was defined as a serum creatinine increase 
of 100% or more or dialysis during hospitalization. Data were from a cohort of 1219 adults 
undergoing cardiac surgery at 6 medical centers; among these, 117 developed sustained 
mild AKI and 60 developed severe AKI. We considered CPB time and 22 biomarkers as 
candidate predictors. We used Bayesian Model Averaging (BMA) methods to develop 
center-adjusted combinations for sustained mild AKI by (1) maximizing the posterior model 
probability and (2) retaining predictors with posterior variable probabilities above 0.5.
Results: The maximum posterior model probability combination included plasma 
NT-proBNP, plasma h-FABP and change in serum creatinine; the median probability 
combination additionally included plasma IL-6. The center-adjusted, optimism-corrected 
AUCs for these combinations were 0.80 (95% CI: 0.78, 0.88) and 0.81 (0.77, 0.88), 
respectively, for predicting sustained mild AKI, and were 0.81 (0.77, 0.90) and 0.83 (0.76, 
0.90), respectively, for predicting severe AKI. For these data, the BMA methods yielded 
combinations with predictive capacity comparable to that achieved by standard frequentist 
methods but with smaller models.
Conclusions: Pending external validation, the identified combinations could be used 
to identify individuals at high risk of AKI immediately after cardiac surgery and could 
facilitate clinical trials of renoprotective agents.
Funding: Other NIH Support - RO1HL085757
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SA-PO198
Low Pre-Operative Serum Bicarbonate Levels Predict Acute Kidney Injury 
After Cardiac Surgery  Jong Hyun Jhee, Kyoung Sook Park, Hyung Jung Oh, 
Seung Hyeok Han, Tae-Hyun Yoo, Jung Tak Park.  Dept of Internal Medicine, 
Yonsei Univ College of Medicine, Seoul, Korea.
Background: Low serum bicarbonate levels are known to be risk factors for renal 
function deterioration in chronic kidney injury patients. However, it is not well known 
whether preoperative low serum bicarbonate levels are associated with the development 
of acute kidney injury (AKI) in patients who undergo cardiac surgery. Therefore, clinical 
implications of preoperative serum bicarbonate levels on AKI occurrence after cardiac 
surgery were evaluated.
Methods: The patients who underwent coronary artery bypass or valve surgery at 
Yonsei University Health System from January 2013 to December 2014 were enrolled. The 
patients were categorized into three groups according to pre-operative serum bicarbonate 
levels (group 1 <23 mEq/L, group 2 23-24 mEq/L, group 3 >24 mEq/L). Multivariate 
logistic regression analysis was performed to determine the effect of pre-operative serum 
bicarbonate levels on development of AKI at 48 hours after cardiac surgery.
Results: Among 452 patients, 228 patients (26.1%) developed AKI at 48 hours after 
cardiac surgery. Incidence of AKI was higher in group 1 (34.6%) than group 2 (26.3%) 
and group 3 (39.0%) (P <0.001). The duration of post-operative intensive care unit (ICU) 
stay was longer in AKI patients (AKI vs. non-AKI, 6.2 vs. 2.7 days, P<0.001). In addition, 
post-operative ICU stay was longer in the low pre-operative serum bicarbonate level groups 
[group 1 (4.4 days), group 2 (3.6 days), group 3 (3.3 days), P<0.001]. In multivariate logistic 
regression analysis, low pre-operative serum bicarbonate levels were significantly associated 
with post-operative AKI development even after adjusting for age, sex, hypertension, 
diabetes mellitus, operation type, hemoglobin, and glomerular filtration rate (group 3 as 
reference, odds ratio=2.36, 95% confidence interval=1.57-3.54, P<0.001).
Conclusions: Low serum bicarbonate levels were associated with higher incidence of 
AKI and prolonged ICU stay. Correction of low serum bicarbonate levels before cardiac 
surgery may reduce the risk of AKI development.
SA-PO199
Admission Hyperuricemia Increases the Risk of Acute Kidney Injury in 
Hospitalized Patients  Wisit Cheungpasitporn,1 Charat Thongprayoon,2 Stephen 
B. Erickson.1  1Nephrology and Hypertension, Mayo Clinic, Rochester, MN; 
2Internal Medicine, Bassett Medical Center, Cooperstown, NY.
Background: The association between elevated admission serum uric acid and risk 
of in-hospital acute kidney injury (AKI) is limited. The aim of this study was to assess 
the risk of developing AKI in all hospitalized patients with various admission serum uric 
acid (SUA) levels.
Methods: This is a single-center retrospective study conducted at a tertiary referral 
hospital. All hospitalized adult patients who had admission SUA available from January 
2011 through December 2013 were analyzed in this study. Admission SUA was categorized 
based on its distribution into six groups (less than 3.4, 3.4 to 4.5, 4.5 to 5.8, 5.8 to 7.6, 7.6 
to 9.4, and greater than 9.4 mg/dL). The primary outcome was in-hospital AKI occurring 
after hospital admission. Logistic regression analysis was performed to obtain the odds 
ratio of AKI of various admission SUA levels using the most common SUA level reference 
range (5.8 to 7.6 mg/dL) as the reference group.
Results: Of 1,435 patients enrolled, AKI occurred in 263 patients (18%). The incidence 
of AKI and need for dialysis was increased in patients with higher admission SUA levels. 
After adjusting for potential confounders, SUA greater than 9.4 mg/dL was associated 
with an increased risk of developing AKI with odds ratios of 1.79 (95% CI 1.13-2.82). 
Conversely, admission SUA of less than 3.4 mg/dL and 3.4 to 4.5 mg/dL were associated 
with decreased risk of developing AKI with odds ratios of 0.38 (95% CI 0.17-0.75) and of 
0.50 (95% CI 0.28-0.87) respectively.
Conclusions: Elevated admission SUA was associated with an increased risk for 
in-hospital AKI.
SA-PO200
Hypoalbuminemia Is a Strong Risk Factor for Acute Kidney Injury 
Progression in Elderly Patients in Intensive Care Unit  Yu Kurata,1 Keita 
Hirano,2 Fumio Omata,3 Yasuhiro Komatsu.2  1Div of Nephrology, Mitsui 
Memorial Hospital, Chiyoda-ku, Tokyo, Japan; 2Div of Nephrology, St. 
Luke’s International Hospital, Chuo-ku, Tokyo, Japan; 3Center for Clinical 
Epidemiology, St. Luke’s International Hospital, Chuo-ku, Tokyo, Japan.
Background: Population aging is a global issue; especially, Japan is experiencing 
rapid aging, at a faster speed than any other developed country, and those aged 65 or older 
comprised 25.9% of Japan’s population as of September 2014. Previous studies showed 
elderly patients are at high risk for developing acute kidney injury (AKI). AKI is also a 
common clinical syndrome in the ICU setting, but its clinical presentation varies from 
mild to severe. Predicting whether AKI progress or not is difficult but can guide clinical 
decision making. The aim of the present study is to elucidate risk factors of AKI progression 
among elderly patients in ICU.
Methods: A retrospective study of patients age 65 and older developed AKI during 
ICU stay between January 2004 and September 2013. AKI was defined as increase in 
serum creatinine (sCr) of ³1.5 times baseline. The primary outcome was the progression 
to AKIN stage 3 (increase in sCr of 3 times over baseline or need for renal replacement 
therapy (RRT)) within 14 days after AKI development. Prerenal AKI, postrenal AKI, and 
AKIN Stage 3 at diagnosis of AKI are excluded; prerenal AKI is diagnosed when serum 
BUN-to-creatinine ratio is ≥ 20 and postrenal AKI is diagnosed based on clinical situation.
Results: 418 patients were included. The mean of age was 80.6 ± 8.2 years, baseline 
sCr 0.89 ± 0.40 mg/dl, and baseline eGFR 66.1 ± 32.3 ml/min/1.73m2. Among 418 patients, 
77 (18.4%) experienced AKI progression and 83 (19.9%) died. Of the 77 patients with 
AKI progression, 25 (6.0%) patients received RRT. AKIN stage 2 at diagnosis (OR=2.33, 
95%CI=1.23-4.36), RAS inhibitor use (OR=2.84, 95%CI=1.33-5.93), bacteremia (OR=1.69, 
95%CI=0.89-3.14), hypoalbuminemia (OR=5.10, 95%CI=2.94-9.06) were risk factors for 
AKI progression.
Conclusions: Hypoalbuminemia is a strong risk factor for AKI progression in older 
patients in ICU. Further study is needed to evaluate whether correction of hypoalbuminemia 
could prevent AKI progression or not.
SA-PO201
Impact of Preexisting Serum Prealbumin on All-Cause Mortality in 
Community-Acquired and Post-Operative Acute Kidney Injury Patients 
Yanfang Zou,1 Dan Wen,1 Jingyuan Xie,1 Xiaonong Chen,1 Wen Zhang,1 Nan 
Chen.1  1Nephrology, Ruijin Hospital, Shanghai, China; 2Nephrology, Ruijin 
Hospital; 3Nephrology, Ruijin Hospital.
Background: To explore the impact of pre-existing prealbumin concentration on all-
cause mortality in AKI (acute kidney disease, AKI) patients.
Methods: From 2000 to 2010, 477 patients diagnosed with community-acquired AKI 
(CA-AKI) and treated in the Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong 
University were enrolled in the CA-AKI group. 138 patients diagnosed with AKI after 
cardiac operations were enrolled in the post-operative AKI (PO-AKI) group. Data were 
collected at the time point of AKI onset and one year after the discharge.
Results: Patients with CA-AKI were younger than PO-AKI patients. Compared with 
PO-AKI patients, more patients in CA-AKI group suffered from chronic kidney disease, 
obesity and hyperlipidemia and less patients with cerebrovascular disease (CVD), anemia, 
shock, arrhythmia and so on. Risks for CA-AKI were atherosclerosis, CVD, arrhythmia, 
multiple organ dysfunction syndrome (MODS) and usage of vasoactive agents, and for 
PO-AKI were elderly age, arrhythmia and RRT(renal replacement therapy, RRT)-requiring. 
A higher level of preexisting serum prealbumin (PA) lead to better outcome in CA-AKI(HR 
0.92, 95%CI 0.85-1.00)and PO-AKI group(0.91, 95%CI 0.84-0.99). In CA-AKI group, 
cumulative survival rate of patients in normal PA group(PA>20mg/dL) was higher than that 
in lower PA(PA£20mg/dL) group (95.4% vs 88.3%, P=0.031). Similarly, in PO-AKI group, 
normal PA level was associated with a higher survival rate (74.1% vs 47.6%, P=0.019).
Conclusions: A significant difference was detected between CA-AKI group and PO-
AKI in general characteristics, comorbidities, laboratory examinations, outcome, and risks. 
Patients with PA>20mg/dL showed better survival rate.
Funding: Government Support - Non-U.S.
SA-PO202
Usefulness of Serum Ischemia-Modified Albumin Levels to Predict Dialysis 
Reqirement in Patients with Acute Renal Injury  Mehmet Uzun, Harun Akar. 
Internal Medicine, Izmir Tepecik Education and Research Hospital, Turkey.
Background: Ischemia-modified albumin is a promising biomarker for early diagnosis 
of diseases related with ischemia.  Ischemia leads to modification in albumin molecule by 
reducing its binding to cobalt. The aim of this study was to evaluate the levels of ischemia-
modified albumin in patients with acute kidney injury (AKI).
Methods: Serum levels of ischemia-modified albumin were estimated  in 51 patients 
with AKI.
Results: The mean age of 28 female and 23 male patients were 65.39±15.28 and 
70.11±15.25, respectively. Levels of IMA were found to be high in 75.5 % of the patients 
( >400) and were found to be normal in 25.5 % of the patients ( <400). Kaplan-Meier 
survival analysis showed that the survival was not different between IMA groups. Urine 
amounts were significantly different between IMA groups. The urine volume was lower 
in patients with higher IMA levels ( >400).
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Conclusions: In the present study, the levels of IMA were found to be significantly 
higher who needed hemodialysis treatment. IMA levels do not predict mortality.Taking 
these results together, serum IMA levels might give an idea about dialysis requirement in 
patients with AKI. More studies with larger sample groups may help to establish the role 
of IMA on decisions regarding dialysis initiation.
SA-PO203
Urinary TIMP-2 and IGFBP7 Elevate Early After Vancomycin 
Administration in Critically Ill Patients Who Develop AKI  Maria Ostermann,1 
Lui G. Forni,2 Lakhmir S. Chawla,3 Jing Shi,4 Kianoush Banaei-Kashani,5 John 
A. Kellum.6  1King’s College London, London; 2Royal Surrey County Hospital, 
Guilford; 3George Washington Univ, Washington; 4Walker Bioscience, Carlsbad; 
5Mayo Clinic, Rochester; 6Univ of Pittsburgh, Pittsburgh.
Background: We previously validated a biomarker combination of tissue inhibitor of 
metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) 
for risk stratification of acute kidney injury (AKI).1 A cutoff of 0.3 (ng/ml)2/1000 for 
[TIMP-2]•[IGFBP7] indicated AKI stage 2-3 at least 24h prior to serum creatinine.2 We 
also showed that nephrotoxic drug use was common in patients developing AKI and that 
the [TIMP-2]•[IGFBP7] test could have identified patients earlier.3 In this sub-analysis of 
the Sapphire study1, we examined the temporal changes in [TIMP-2]•[IGFBP7] following 
vancomycin.
Methods: We identified patients who received vancomycin and grouped them according 
to their maximum KDIGO AKI stage within 3 days of 1st dose of vancomycin. We calculated 
the median daily [TIMP-2]•[IGFBP7] value from day prior to 1st dose of vancomycin until 
5 days after. A bootstrap analysis was used to calculate 1-sided p-values for comparison 
to the 0.3 (ng/mL)2/1000 cutoff.
Results: 249 patients received at least 1 dose of vancomycin. 137 (55%) developed AKI 
within 3 days [AKI 1 (n=81), AKI 2 (n=44), AKI 3 (n=12)]. In patients without AKI or with 
AKI 1, median [TIMP-2]•[IGFBP7] values were £0.3 (ng/mL)2/1000 for all time points. 
In patients with AKI 2-3, median [TIMP-2]•[IGFBP7] values were significantly elevated 
on the day of the 1st vancomycin dose and remained elevated for the following 2 days.
Conclusions: In patients with AKI 2-3 after vancomycin administration, urinary 
[TIMP-2]•[IGFBP7] was significantly elevated on the first 2 days after the 1st dose. These 
biomarkers have the potential to improve management in patients receiving vancomycin.
Funding: Pharmaceutical Company Support - Astute Medical
SA-PO204
Peri-Operative Serum IL-33 Concentrations in Matched AKI and Non-
AKI Patients Undergoing Cardiac Surgery  Charles L. Edelstein,1 Heather 
Thiessen Philbrook,2 Jay L. Koyner,3 Michael Shlipak,4 Steven G. Coca,2 Chirag 
R. Parikh.2  1Univ Colorado Denver; 2Yale Univ; 3Univ Chicago; 4UCSF.
Background: Endothelial cell damage and death in the nephron is an early feature of 
AKI. Damage–associated molecular patterns (DAMPS) are endogenous molecules released 
by damaged cells including endothelial cells. IL-33, a DAMP, has been shown to be present 
in blood vessels in the kidney and released into the blood, but not the urine, in cisplatin-
induced AKI in mice before the increase in serum creatinine. We sought to determine 
whether serum IL-33 levels are a biomarker of AKI in humans in a nested case-control study.
Methods: Perioperative plasma samples were obtained from patients enrolled in the 
TRIBE-AKI cohort. 35 cases of AKIN Stage 2 AKI or higher within the first 4 post-op 
days were matched to 70 controls with no AKI by pre-op GFR, age, sex, site and cohort. 
Blood samples were available pre-op, day 1 (0-6 hours), days 2 and 3. Serum IL-33 was 
measured by ELISA.
Results: The pre and post-operative levels of IL-33 are shown in Table 1. Using a 
mixed model accounting for the matching in the data, the first post-operative value of 
IL-33 was significantly different (p=0.005) between cases and controls after adjusting for 
pre-op values. There was a non-significant trend towards higher IL-33 levels on day 2.
Time 
point
Cases Mean 
(SD)
Cases 
Median 
(P25,P75)
Controls 
Mean (SD)
Controls 
Median 
(P25, P75)
P
Pre-op Actual 1082 (2174) 155 (0,516) 1160 (2214) 58 (0, 641) 0.87
Day 1 Actual 1452(2131) 331 (71, 1922) 1172(2094) 72 (0,759) 0.048
Day 1
Delta 
from 
pre
355(926) 0 (-63, 202) 12(759) -5 (-166, 0)
Day 2 Actual 1591(2082) 315 (34, 2731) 1272(2236)
158 (0, 
905) 0.08
Day 2
Delta 
from 
pre
456(1252) 0 (-97, 592) 111(1069) 0 (-163, 5)
Day 3 Actual 1367(2098) 413 (12, 1391) 1383(2294)
135 (0, 
1170) 0.38
Day 3
Delta 
from 
pre
282(1402) 0 (-152, 382) 222(1190) 0 (-82,30)
Conclusions: Immediate post-operative serum IL-33 concentrations were higher in 
matched AKI cases compared to non-AKI controls. Further studies are needed to clarify 
the role of serum IL-33 in human AKI.
Funding: NIDDK Support SA-PO205
First Post-Operative Urinary Kidney Injury Biomarkers and Association 
with the Duration of AKI in the TRIBE-AKI Cohort  Steven G. Coca, Girish 
N. Nadkarni, Amit X. Garg, Jay L. Koyner, Heather Thiessen Philbrook, Eric 
Mcarthur, Michael Shlipak, Chirag R. Parikh.  TRIBE-AKI Consortium.
Background: We previously demonstrated AKI duration improves risk-stratification 
for AKI prognosis in addition to the magnitude of serum creatinine rise. We evaluated 
whether kidney injury biomarkers within 6 hours after cardiac surgery associate with 
post-operative AKI duration.
Methods: We included 1199 adults undergoing cardiac surgery in TRIBE-AKI cohort 
that survived to discharge and examined association between five urinary biomarkers: 
neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury 
molecule-1 (KIM-1), liver fatty acid binding protein (L-FABP) and albumin with duration 
of serum creatinine-based AKIN criteria for AKI (0 (no AKI), 1-2, 3-6, ≥7 days).
Results: Overall, 406 (34%) patients had AKI, of which 48 had stage 2/3 AKI. Of 
358 with stage 1 AKI, 115 (32.1%) had AKI duration >3 days. An additional 41 (85%) 
with stage 2/3 AKI had duration of >3 days. Concentrations of all biomarkers increased 
with AKI duration and each log increase in biomarker was independently associated with 
greater odds of longer duration category (IL-18 OR 1.25, 95% CI 1.16-1.35; KIM-1: 1.36, 
95%CI 1.21-1.52; albumin 1.21, 95% CI 1.10-1.33; L-FABP 1.14, 95% CI 1.07-1.21; 
NGAL 1.10, 95% CI 1.03-1.17).
Biomarkers 
at 0-6 hours 
AKI Duration in days 
0 (No AKI)
(n=788)
1-2
(n=250)
3-6
(n=118)
>7
(n=38)
Urine IL-18 (pg/mL) 9.3 (3.6-27.9) 15.8 (5.9-82.4)
23.1 (6.0-
88.9)
45.9 (16.6-
188.6)
Urine NGAL (ng/mL) 8.4 (3.3-32.8) 14.1 (5.2-79.9)
15.0 (5.6-
86.3)
26.5 (10.3-
418.3)
Urine KIM-1 (ng/mL) 0.4 (0.1-0.8) 0.5 (0.2-1.0) 0.7 (0.3-1.5) 1.0 (0.7-2.2)
Urine LFABP (ng/mL) 16.0 (3.3-79.0)
21.2 (6.4-
178.7)
34.0 (6.6-
183.3)
61.1 (13.9-
371.9)
Urine Albumin (mg/L) 12.5 (6.4-30.8)
18.0 (7.9-
53.7)
20.0 (9.0-
61.3) 43.3 (19.0-70.4)
Conclusions: While most patients in the TRIBE-AKI Cohort experienced stage 1 AKI 
when classified by peak serum creatinine increase, one-third of those have duration of AKI 
of >3 days. Elevated urinary kidney injury biomarker within 6 hours of surgery may help 
in identifying of patients at risk for longer AKI duration, which may serve as a reliable 
metric for drug development trials.
Funding: Other NIH Support - NHLBI
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SA-PO206
Urinary Biomarker Evaluation in Cancer Patients Receiving Cisplatin 
Blessy George,1 Amandla Roque- Atilano,2 Cara A. Chang,2 Nickie L. Johnston,2 
Madeleine Gomez,2 Lucas Ellison,2 Xia Wen,1 Lauren Aleksunes,1 Daniel 
Bowles,2 Cindy L. O’Bryant,2 Melanie S. Joy.2  1School of Pharmacy, Rutgers 
Univ, NJ; 2Schools of Pharmacy and Medicine, Univ of Colorado, CO.
Background: The study explored the time dependency of urinary biomarker changes 
and correlations between the biomarkers and traditional markers of kidney injury in a 
cohort of patients receiving cisplatin.
Methods: Urine was obtained at 1)baseline, 2)Day 3 and 3)Day 10 from patients (n=42) 
receiving cisplatin (³25 mg/m2). Urinary kidney injury molecule-1 (Kim-1), calbindin, beta-2 
microglobulin (B2M), clusterin, monocyte chemoattractant protein-1 (MCP-1), cystatin C, 
trefoil factor 3 (TFF3), tissue inhibitor of metalloproteinase 2 (TIMP2), and insulin growth 
factor binding protein 7 (IGFBP7) were measured with multiplex or ELISA.
Results: 
Mean±SEM Baseline Day 3 Day 10
Kim-1 (ng/mL) 0.42±0.1A,B 0.77±0.1 0.97±0.2
Calbindin (ng/mL) 59.0±13.8B 70.1±12.2C 544±163
B2M (ng/mL) 144±39.1A 502±71.8C 185±41.5
Clusterin (ng/mL) 42.0±23.5B 27.7±8.5 52.9±16.1
MCP-1 (ng/mL) 0.62±0.2B 0.45±0.1 1.0±0.23
Cystatin C (ng/mL) 39.5±7.7 77.3±22.8 64.9±19.0
TFF3 (ng/mL) 865±154B 1441±202 1616±264
TIMP2 (ng/mL) 2.2±0.5 2.3±0.6 3.2±0.7
IGFBP7 (pg/mL) 2931±484 2357±514C 4650±561
Albumin (ng/mL) 11,038±2067B 15,958±2442 24,373±4232
A: baseline vs. Day 3 p<0.05, B: baseline vs. Day 10 p<0.05, C: Day 3 vs Day 10 p<0.05 
The biomarker-GFR correlations were: TFF3 (r: -0.2590), B2M (r: -0.2017), Kim-1 
(r: -0.1758), MCP-1 (r: -1390), cystatin C (r: -0.0936), IGFBP7 (r: -0.0764), clusterin 
(r: -0.0767), calbindin (r: -0.0647), and TIMP2 (r: -0.0619). The biomarker-albumin 
correlations were: calbindin (r: 0.7813), TFF3 (r: 0.5949), clusterin (r: 0.5869), Kim-1 
(r: 0.3186), TIMP2 (r: 0.3016), MCP-1 (r: 0.2340), IGFBP7 (r: 0.2217), cystatin C (r: 
0.1375), and B2M (r: 0.1149).
Conclusions: Urinary biomarkers display time dependent increases post cisplatin 
and exhibit variable degrees of correlation with GFR and urinary albumin. TFF3 had high 
concordance with both GFR and urinary albumin, which may be a favorable characteristic.
Funding: NIDDK Support
SA-PO207
Prediction of Long-Term Renal Outcomes in AKI Survivors by Urinary 
Biomarkers  Rei Isshiki,1 Kent Doi,2 Maki Sumida,1 Yoshifumi Hamasaki,1 
Naoki Yahagi,2 Masaomi Nangaku,1 Eisei Noiri.1  1Nephrology and 
Endocrinology, Univ Hospital, Univ of Tokyo, Tokyo, Japan; 2Emergency and 
Critical Care Medicine, Univ Hospital, Univ of Tokyo, Tokyo, Japan.
Background: Although several epidemiological studies suggested that acute kidney 
injury (AKI) increases the risk of chronic kidney disease (CKD) development and 
progression, it is still unclear whether any AKI biomarker can predict long-term renal 
outcomes in AKI survivors. This study was aimed to evaluate the performance of urinary 
biomarkers for long-term renal outcome prediction.
Methods: We conducted an observational study examining the association of three 
urinary biomarkers measured at ICU admission [L-type fatty acid-binding protein (L-FABP), 
neutrophil gelatinase-associated lipocalin (NGAL), and N-acetyl-β-D-glucosaminidase 
(NAG)] with CKD progression after discharge without major adverse kidney events 
(MAKE). MAKE were determined with death, incident dialysis dependency, or 50% 
reduction of eGFR at hospital discharge. Two different long-term renal outcomes were 
defined as follows; 30% reduction of eGFR or incident end-stage renal disease within two 
years after hospital discharge (Outcome 1) and halving of eGFR or incident end-stage renal 
disease in three years (Outcome 2).
Results: Among all the enrolled 495 patients, 393 patients discharged from the 
hospital without MAKE. Of them, 173 patients were followed up for two years after ICU 
discharge and 63 patients (36.4%) were positive for long-term renal outcomes (Outcome 
1). A step-wise logistic regression analysis demonstrated that only urinary NGAL showed a 
significant association. For Outcome 2, 26 of 159 followed-up patients (16.4%) were positive 
and urinary L-FABP and NGAL were significantly associated with CKD progression in a 
univariate logistic regression analysis.
Conclusions: Urinary biomarkers measured at ICU admission were significantly 
associated with long-term renal outcomes after hospital discharge in MAKE-free AKI 
survivors.
SA-PO208
Significance of Serial Measurement of Acute Kidney Biomarker in Intensive 
Care Unit  Rei Isshiki,1 Kent Doi,2 Maki Sumida,1 Naoki Yahagi,2 Masaomi 
Nangaku,1 Eisei Noiri.1  1Nephrology and Endocrinology, Univ Hospital, Univ 
of Tokyo, Tokyo, Japan; 2Emergency and Critical Care Medicine, Univ Hospital, 
Univ of Tokyo, Tokyo, Japan.
Background: AKI biomarkers have been developed with the concept of earlier 
detection of kidney damage than serum creatinine. However, single time point measurement 
appears not to provide sufficient information for detecting and predicting AKI in ICU 
patients who frequently suffer from multiple and transient/persistent renal insults. This 
study was aimed to evaluate whether serial measurement enables to predict AKI progression 
and recovery in these patients.
Methods: Serial measurements of AKI biomarkers including plasma and urinary 
NGAL, urinary L-FABP, and urinary NAG at ICU admission (day 1) and 24 hr after (day 
2) were conducted in adult critically ill patients who were treated in a mixed ICU.
Results: Among the enrolled 272 patients, 33 were determined as newly developed 
AKI after ICU admission, 64 showed worsening of kidney function and 63 recovered from 
AKI. ROC analysis showed that biomarkers at day 2 showed no significantly additional 
benefit in predicting these three AKI outcomes compared with those measured at day 
1. However, net reclassification improvement (NRI) analysis demonstrated adding AKI 
biomarkers at day 2 to the clinical model consisted of clinical variables and biomarker at 
day 1 significantly improved prediction of these AKI outcomes.
Newly AKI Worsening AKI Recoveryof AKI
AUC-
ROC
Continuous 
NRI
AUC-
ROC
Continuous 
NRI
AUC-
ROC
Continu-
ous NRI
Clinical model 
+D1uNGAL 0.89 0.86 0.78
+D2uNGAL 0.92 0.92 (0.59 to 1.26)* 0.91
0.60 (0.33 
to 0.88)* 0.80
0.39 
(0.042 to 
0.73)*
Clinical model 
+D1plNGAL 0.85 0.85 0.79
+D2plNGAL 0.87 0.74 (0.39 to 1.092)* 0.87
0.61 (0.33 
to 0.88)* 0.79
0.13 
(-0.22 to 
0.48)
Clinical model 
+D1uL-FABP 0.89 0.87 0.79
+D2uL-FABP 0.89 0.63 (0.26 to 0.99)* 0.88
0.51 (0.23 
to 0.79)* 0.82
0.42 
(0.0077 to 
0.076)*
Clinical model 
+D1uNAG 0.87 0.86 0.79
+D2uNAG 0.89 0.85 (0.52 to 1.19)* 0.87
0.32 
(0.0030 to 
0.60)*
0.79
-0.031 
(-0.38 to 
0.32)
Conclusions: Serial measurement of AKI biomarkers involved in clinical models could 
contribute to prediction of AKI outcomes in a heterogeneous cohort of adult mixed ICU.
SA-PO209
Role of Carbonyl Stress Revisited in Pathogenesis of Tropical Acute Kidney 
Injury  Pinaki Mukhopadhyay.  Nephrology, NRS Medical College, Kolkata, 
West Bengal, India.
Background: Malaria and snake bite are two common causes of Acute Kidney Injury 
(AKI) in tropics with lot of morbidity and mortality. The aim of this study was to (I)
evaluate the carbonyl and oxidative stress in these group and their pathogenesis link and 
(II)prognostic predictability of carbonyl and oxidative stress marker in this AKI.
Methods: All cases of falciparum malaria mediated AKI (FMAKI) (n=50),confirmed 
by antigen and/or in peripheral blood smear and snake bite mediated AKI(SAKI) (n=58) 
were included. AKI was calculated as per RIFLE criteria. Demographical, clinical and 
biochemical data were analysed and were followed from hospitalization to discharge/
death. Oxidative and carbonyl stress markers [advanced oxidation protein product (AOPP), 
advanced glycation end product (AGE), pentosidine, dityrosine, thiobarbituric acid reactive 
substance (TBARS) and methyl glyoxal (MG)] were measured consecutively according 
to standard protocol. Predictive importance was assessed from trend analysis, receiver 
operated characteristic(ROC) curve analyses and multiple logistic regression with AKI 
as positive response.
Results: The Oxidative stress index(OSI) of FMAKI patients were 1.89 higher than 
controls.The TBARS, MG level were 6.49 and 5.56 times higher indicating a significant 
carbonyl stress in these patients. AOPP level was 2.33 times higher indicating proteins being 
highly insulted in FMAKI.Similarly in SAKI,significantly elevated total oxidant stress with 
decreased total antioxidant stress leads to net oxidative stress in SAKI patients depicted by 
increased OSI values (p<0.001). MG was increased by 3.48 times (p<0.001).Only AOPP 
(p=0.001) and MG (p=0.004) were found to be significantly elevated in expired patients 
than the survived indicating their predictive power for adverse outcome. At univariate level, 
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all parameters can differentiate between AKI and the non-AKI group. At multivariate level, 
methylglyoxal, AOPP and dityrosine appeared to be independent predictor of AKI in snake 
bite and malaria infected patients (p<0.05).
Conclusions: 1.MG,the carbonyl stress marker along with oxidative stress are 
significantly raised and possibly linked to the pathogenesis of AKI. 2.MG and AOPP can 
be used as a surrogate marker in these tropical AKI.
SA-PO210
Prediction of Short-Term and Long-Term Outcomes of AKI-Based on 
Plasma NGAL  Karina Soto,1,3 Fernando Pereira,1 Liliana Maria goncalves 
Cunha,1 Iola Pinto,2 Ana Luisa Papoila,3 Prasad Devarajan.4  1Nephrology, 
Hospital Fernando Fonseca; 2Inst Superior de Engenharia de Lisboa; 3Nova 
Medical School/FCM, Univ Nova de Lisboa, Portugal; 4Nephrology, Cincinnati 
Children’s Hospital Medical Center, OH.
Background: We have previously shown a good performance of Plasma NGAL 
(pNGAL) as an AKI biomarker in emergency settings. Now we investigated a new AKI 
classification based on pNGAL for prediction of kidney dysfunction at discharge and at 
the end of follow-up.
Methods: Patients from a previous study at ED were followed for >5y. During the 
index hospitalization, 21% were AKI (based on SCr), 26% transient azotemia, 51% normal 
function and 2.4% stable CKD. All patients had SCr and pNGAL meassured at 0, 6,12, 24 
and 48H of admission. A new AKI classification based on pNGAL levels (AKIpNGAL+) 
defined AKI as pNGAL=>110 ng/mL (cut-off by GAMS). A multivariable logistic and cox 
regression models were applied.
Results: Of 599 patients admitted, 97.8% were available at discharge and 54.4% 
at last follow-up. At admission 42.6% were reclassified as AKIpNGAL+ whereas only 
21.7% were based on SCr. . All significant clinical variables were included in multivariable 
analysis at discharge.
Variables OR 95% CI
AKIpNGAL+ 4.2 2.3-7.6
Age 1.1 1.0-1.1
CVD 1.2 1.2-3.2
DM 1.5 1.5-4.0
p<0.001 all unless CVD=0.007 
Having pNGAL>110 at ED corresponded to 4-fold increased odds for eGFR<60 mL/
min (p<0.001 ROC-AUC 0.82). The cumulative incidence of CKD showed that most of 
AKIpNGAL+ developed CKD at 60 mo (the highest proportion 77%) (figure 1)  HR for 
CKD: 2.4 for patients AKIpNGAL+ in long-term (p<0.001 ROC AUC 0.74) NRI 56.3 
and IDI 0.03.
Conclusions: Patients who were AKIpNGAL+ had significant lost kidney function 
at discharge and more than 2-fold risk of developing CKD in long-term evolution. Plasma 
NGAL is a useful tool for CKD prediction, independent of serum creatinine.
SA-PO211
The Use of Novel Serum and Urinary Biomarkers to Predict the 
Development of Hepatorenal Syndrome in Patients with Advanced Cirrhosis 
Desmond Y.H. Yap,1 Wai Kay Seto,1 James Yy Fung,1 See-Ching Chan,2 Siu-Ho 
Chok,2 Man-Fung Yuen,1 Daniel Tak Mao Chan.1  1Medicine, The Univ of Hong 
Kong, Hong Kong, Hong Kong; 2Surgery, The Univ of Hong Kong, Hong Kong, 
Hong Kong.
Background: Hepatorenal syndrome (HRS) is associated with high mortality rates in 
advanced cirrhotic patients without liver transplantation. Prediction of the development 
of HRS remains difficult.
Methods: We prospectively recruited patients with Child’s B or C cirrhosis and 
followed them at 2-week intervals 12 weeks or until HRS developed. Serum cystatin C 
(CysC), serum Neutrophil Gelatinase-Associated Lipocalin (NGAL), serum IL-18, urine 
kidney injury molecule-1 (KIM-1) and urine liver-type fatty acid binding protein (LFABP) 
were measured at recruitment (Baseline).
Results: 43 patients were included. 12 developed HRS at 7.3±5.1 weeks from Baseline. 
Patients who developed HRS had higher Baseline levels of serum CysC (1.42±0.51 mg/L 
vs. 1.07±0.50 mg/L, p=0.021), serum NGAL (129.10±68.66 ng/mL vs. 72.84±48.91 ng/mL, 
p=0.025), serum IL-18 (759.91±477.05 mIU/mL vs. 358.13±153.00 mIU/mL, p=0.001), 
urine KIM-1 and LFABP (3.64±3.34 ng/mL vs. 1.18±1.68 ng/mL and 10.17±8.37 ng/mL 
vs. 3.28±4.20 ng/mL, p=0.023 and 0.035 respectively) when compared to patients who 
did not develop HRS. The cut-off and positive and negative predictive values for HRS 
were shown in Table 1.
Cut-off 
Value AUC 95%CI
PPV 
(%)
NPV 
(%) P-value
Baseline serum Cystatin 
C (mg/L) 0.899 0.748
0.572-
0.924 52.4 90.9 0.021
Baseline serum NGAL 
(ng/mL) 90.47 0.756
0.592-
0.939 72.7 75.0 0.025
Baseline serum IL-18 
(mIU/mL) 442.84 0.858
0.708-
1.000 73.3 92.9 0.001
Baseline urine KIM-1 
(ng/mL) 1.499 0.785
0.607-
0.963 75.0 84.2 0.008
Baseline urine LFABP 
(ng/mL) 3.398 0.765
0.578-
0.949 54.5 86.7 0.035
Serum NGAL and IL-18 and urinary KIM-1 at Baseline were significantly associated 
with the development of HRS (OR 1.017, 95%CI 1.001-1.033, p=0.035; OR 1.007, 95%CI 
1.002-1.013, p=0.012; OR 1.003, 95%CI 1.009-2.237, p=0.045, respectively).
Conclusions: Serum IL-18 and NGAL and urinary KIM-1 could serve as biomarkers 
to predict HRS in patients with advanced cirrhosis.
Funding: Private Foundation Support
SA-PO212
Robust Risk Assessment of Acute Kidney Injury After Acute Myocardial 
Infarction Using the Novel Biomarker C-Terminal Fragment of Agrin (CAF) 
Spyridon Arampatzis,1 George Chalikias,2 Vasileios Devetzis,1 Stefan Hettwer,3 
Dimitros Tziakas,2 Uyen Huynh-do.1  1Nephrology, Hypertension and Clinical 
Pharmacology, Uni. Hospital Bern, Inselspital, Switzerland; 2Cardiology, 
Democritus Univ of Thrace, Greece; 3Neurotune AG, Switzerland.
Background: Acute kidney injury (AKI) complicating acute myocardial infarction 
(AMI) increases subsequent morbidity and mortality. The objective of this study was to 
validate c-terminal fragment of agrin (CAF) as a novel AKI biomarker in patients with AMI.
Methods: 403 consecutive patients with AMI were enrolled, samples were collected 
at presentation for serum (sCAF), urine (uCAF) CAF, neutrophil gelatinase-associated 
lipocalin (NGAL), interleukin-18 (IL-18) and cystatin-C analysis. The presence of AKI 
was evaluated at 48 hours post admission and at discharge.
Results: The incidence of AKI was 6.7%-14.6% depending on time-point and criteria 
used and increased across quartiles of uCAF (x2:10.99, p<0.001). Both uCAF and sCAF 
significantly correlated with serum creatinine on admission (r=0.233, p<0.001 & r=0.175, 
p<0.001), at 48 hours (r=0.263, p<0.001 & r=0.226, p<0.001) and with peak creatinine as 
well (r=0.317, p<0.001 & r=0.225, p<0.001). The predictive accuracy for AKI of uCAF 
was good (AUC:0.630, 95%CI:0.552-0.708) and slightly better as that of urine NGAL 
(AUC:0.616, 95%CI:0.540-0.692, uCAF vs. uNGAL p=0.733), whereas that of sCAF was 
moderate (AUC:0.587, 95%CI:0.509-0.666). A uCAF value of 1033pM is suggested to 
have the best discriminating ability. The sensitivity of uCAF was 37% and the specificity 
85% (NPV: 89%, PPV: 30%). Univariate analysis showed a strong association of uCAF 
with AKI incidence (OR:1.45, 95%CI:1.15-1.82, p=0.002) which remained significant even 
after adjustment for several confounders (OR:1.35, 95%CI:1.05-1.74).
Conclusions: Urine CAF analysis allows a robust risk stratification of AKI after AMI 
and thus optimized management in such patients.
Funding: Government Support - Non-U.S.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
675A
J Am Soc Nephrol 26: 2015 AKI: Clinical - Biomarkers/Epidemiology Poster/Saturday
SA-PO213
At Myeloma Diagnosis, Age and Free Light Chain Level Predict Renal 
Function and These Factors with Free Light Chain Response Predict Renal 
Outcome  Punit Yadav,1,2 Mark Trehane Drayson,1,2 Mark Cook,1,2 Jennifer H. 
Pinney,1 Hannah V. Giles,2 Yu sandar Aung,1,2 Paul Cockwell.1,2  1Univ Hospital 
Birmingham, UK; 2Univ of Birmingham, UK.
Background: Elevated involved immunoglobulin free light chain (FLC) is a major 
cause of renal impairment (RI) in myeloma. Relationships between presentation and post-
induction (PI) renal function and serum FLC levels are not established.
Methods: We used central laboratory data from the MRC Myeloma IX trial which 
compared bisphosphonate and thalidomide-based therapies. Patients were divided into 3 
eGFR categories: eGFR ≥60 ml/min, normal renal function; eGFR 30-59 ml/min, mild-
moderate RI; eGFR <30 ml/min, severe RI. Linear regression and Logistic regression 
modelling were used to explore independent determinants of renal function.
Results: 52.8% had an eGFR ≥60 ml/min; 37.3% had an eGFR 30-59 ml/min and 9.8% 
had an eGFR <30 ml/min. Median eGFR in patients with involved ȜFLC was significantly 
lower than those with κFLC (58 [IQR 42-77] vs 63 [IQR 46-80]; P=0.01). Median eGFR 
for light chain only myeloma (LCO) was also significantly lower than those with IgG and 
IgA myeloma (49 [IQR 28-78] vs 62 [IQR 47-79] vs 63.5 [IQR 42.2-82.0] respectively; 
P<0.0001). Patients with a difference between involved and uninvolved FLC (dFLC) 
≥500 mg/L had a lower eGFR compared to those with dFLC 100-499 mg/L and dFLC 
<100 mg/L (52 [IQR 35-72] vs 66 [IQR 52.0- 82.2] vs 67 [IQR 54.2-82.0] respectively; 
P<0.0001). A dFLC level of 700 mg/L was the optimal cut-off value for prediction of 
severe RI, with an AUC of 0.80. Factors associated with eGFR at presentation were: age, 
log10 dFLC, male gender and LCO myeloma. On censoring those with dFLC <700mg/L; 
age and log10 dFLC were still associated with eGFR at presentation but not male gender 
and LCO myeloma. Factors that were independently associated with RI at PI were: age 
(odds ratio [OR] 1.033, P=0.041); presentation eGFR (OR 0.93, P<0.0001) and attainment 
of ³VGPR (very good partial response) compared to <PR (partial response) serum FLC 
response (OR 0.52, P=0.005).
Conclusions: Age and serum FLC level predict eGFR at presentation and age, 
presentation eGFR, and serum FLC response predict PI renal outcome.
SA-PO214
Urinary Biomarkers Improve the Prediction and Prognostic Assessment 
of Acute Kidney Injury in Critically Ill Patients  Patrick T. Murray, Teresa 
Martin, Eoin J. Cotter.  UCD Clinical Research Centre, School of Medicine, 
Univ College Dublin, Dublin, Ireland.
Background: Acute kidney injury (AKI) is common in intensive care unit (ICU) 
patients, and is diagnosed late by serum creatinine. New biomarkers may permit earlier 
detection and better management.
Methods: All patients admitted to the ICUs of two university hospitals were screened 
for this prospective cohort study. Clinical information and urine were collected on admission 
and daily for 7 days. Urine biomarkers analysed were neutrophil gelatinase-associated 
lipocalin (NGAL), α- and ʌ- glutathione-S-transferases (GSTs), kidney injury molecule-1 
(KIM-1), liver fatty acid binding protein (L-FABP), creatinine, and albumin. AKI was 
defined by modified KDIGO criteria, using ICU admission creatinine as reference. 
Values were compared between those who did or did not develop AKI or 30d adverse 
clinical outcomes (RRT or death). ROC curves were generated for prediction of AKI and 
outcomes by a clinical score (including age, gender, serum creatinine & urea, urine output) 
and urine biomarker values on admission. In patients developing AKI, ROC curves were 
similarly generated for the prediction of clinical outcomes with values obtained at time 
of AKI diagnosis.
Results: 659 patients were enrolled;181 patients (27%) developed AKI within 7d of ICU 
admission. AKI stages at diagnosis were:Stg1(n=81,45%),Stg2(n=17,9%),Stg3(n=83,46%). 
On admission, addition of a panel of AKI biomarkers significantly but modestly improved 
prediction of AKI developing within the first 48h in ICU (AUC±SD: 0.79±0.12), compared 
to clinical score alone (0.77±0.11;p=0.0001). AKI biomarkers similarly improved the 
prediction of AKI developing within the first 7d (0.73±0.15), compared to clinical score 
alone (0.69±0.07;p=0.0003); and marginally improved the prediction of 30d RRT or death 
(0.7±0.1 vs 0.69±0.1;p=0.05). In patients developing AKI, AKI biomarkers at the time of 
diagnosis significantly improved prediction of 30d adverse clinical outcomes (RRT or 
death): 0.77±0.19, compared to clinical score alone (0.68±0.13;p=0.01).
Conclusions: Urinary biomarkers combined with standard clinical tests improved 
prediction of AKI and outcomes in ICU patients, on admission and at AKI diagnosis.
Funding: Pharmaceutical Company Support - Support-in-kind from Abbott Labs and 
Argutus/EKF Diagnostics (assay kits).
Irish Government support: Health Research Board and Dublin Centre for Clinical 
Research, Government Support - Non-U.S.
SA-PO215
Association of Growth Factor Biomarkers with Acute Kidney Injury 
and Long-Term Mortality in Adults following Cardiac Surgery 
William R. Zhang, Richard P. Whitlock, Heather Thiessen Philbrook, Eric 
Mcarthur, Amit X. Garg, Steven G. Coca, Peter Kavsak, Chirag R. Parikh. 
TRIBE-AKI Consortium.
Background: Following the structural damage and functional impairment from acute 
kidney injury (AKI), the kidney undergoes a coordinated process of repair involving 
regenerative growth factors. We conducted an ancillary analysis of a large, prospective 
study of adults undergoing cardiac surgery to investigate the utility of epidermal growth 
factor (EGF) and vascular endothelial growth factor (VEGF) in predicting kidney injury 
and mortality.
Methods: Patients undergoing cardiac surgery at high risk for AKI were enrolled at 
six academic centers. AKI was defined as a doubling in serum creatinine from baseline 
or receiving acute dialysis during the hospital stay. Postoperative plasma levels of EGF, 
VEGF, and a combination model of the two growth factors were evaluated for association 
with outcomes of AKI or long-term, all-cause mortality at a mean follow-up of 3 years.
Results: First postoperative and peak plasma EGF were not associated with AKI. 
Elevated peak plasma VEGF was independently associated with increased risk of AKI 
(adjusted odds ratio [OR] 7.4, 95% confidence interval [CI]: 1.1-47.9). Elevated first 
postoperative EGF was inversely associated with a lower risk of mortality (adjusted 
HR=0.67; 95% CI: 0.47-0.97). Elevated first postoperative VEGF was likewise associated 
with a lower risk of mortality (unadjusted HR=0.36; 95% CI: 0.16-0.82), though the 
association was attenuated following adjustment (adjusted HR=0.36; 95% CI: 0.15-1.04). 
When assessed conjointly, elevated levels of first postoperative EGF and VEGF together 
were independently associated with a lower risk of mortality (adjusted HR=0.28; 95% 
CI: 0.11-0.72).
Conclusions: Postoperatively, EGF and VEGF are released in response to AKI, and 
their concentrations were inversely associated with long-term mortality. These growth 
factors may serve as biomarkers of long-term outcomes in adults undergoing cardiac surgery.
Funding: Other NIH Support - R01HL085757
SA-PO216
Procalcitonin as a Predictor of AKI in Patients with Sepsis  Jonathan Chavez,1 
Maria de la luz Alcantar Vallin,1 Guillermo Garcia-Garcia,1 Luis Arnoldo 
Muñoz.2  1Nephrology Service, Hospital Civil de Guadalajara, Guadalajara, 
Mexico; 2Internal Medicine, Hospital Civil de Guadalajara, Guadalajara, 
Mexico.
Background: Sepsis is a common cause of AKI. Identifying patients at risk for AKI 
could improve clinical outcomes. Procalcitonin (PCT) reflects accurately the presence of 
sepsis and its severity. We evaluated the role of PCT as predictor of AKI in septic patients.
Methods: Cross-sectional study of 72 septic patients between January to December 
2014. Patients with SCr ³1.5 mg/dl before admission, ESRD patients and those with 
autoimmune comorbidity were excluded. PCT, Scr, urea, and WBC were measured on 
admission, and at 24 h and 48 h of hospitalization. X2 and t-test were used when appropriate. 
A ROC curve for PCT value on admission as well as the area under the curve (AUC), 
the standard AUC error, and sensitivity and specificity of PCT values were determined.
Results: Patients’ mean age was 50.8 y (18-79); 37 (51.4%) were women. 18 (25%) 
patients had PCT value at <0.5 ng / mL (negative) and 54 (75%) ³0.5 ng / mL (positive) on 
admission. Forty-two (58.3%) patients developed AKI, 19 (45.2%) KDIGO 1, 12 (28.6%) 
KDIGO 2, and 11 (26.2%) KDIGO 3. Of the 42 patients who developed AKI , 37 (88.1%) 
had a positive value of PCT at admission (p <0.01, OR 5.659, 95% CI 1.738 to 18.425). 
The ROC PCT presented an AUC of 0.75 (p <0.0001, 95% CI 0.639 to 0.862). The cutoff of 
2.565 ng / mL of PCT had the highest validity for predicting AKI with an SE of 61.9%, one 
SP of 80%, a PPV of 44.52%, 56.18% NPV, LR + LR of 0.80 and 0.77, respectively. Fig. 1
Conclusions: We found a significant association between levels of PCT and 
development of AKI in patients with sepsis. A cutoff PCT value of 2,565 ng /mL on 
admission had the highest validity for predicting AKI. Early recognition of septic patients 
at risk for AKI with PCT could improve clinical outcomes in this population.
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SA-PO217
Elevated Erythropoietin Concentration in AKI Is Associated with IGFBP-1 
Rather Than Hemoglobin  Tetsushi Yamashita, Eisei Noiri, Yoshifumi 
Hamasaki, Naoki Yahagi, Masaomi Nangaku, Kent Doi.  The Univ of Tokyo, 
Tokyo, Japan.
Background: EPO expression will be increased by hypoxia in the kidney and hypoxic 
injury plays a crucial role in pathogenesis of AKI. However, little is known about blood 
EPO levels in critically ill patients complicated with AKI.
Methods: This study prospectively enrolled 98 adult critically ill patients who admitted 
to the adult mixed ICU. We measured plasma EPO and also measured plasma IGFBP-1 as 
a hypoxic marker, which is produced mainly by liver, and plasma NGAL and urinary NAG 
as renal damage biomarkers on ICU admission.      This study was conducted to evaluate 
whether plasma EPO levels in AKI patients. was regulated by other factors than anemia.
Results: AKI occurred in 42 (42.9%) patients. Significantly higher plasma EPO in the 
AKI group was detected compared with the non-AKI group (16.13 [9.87–28.47] mIU/mL 
versus 27.81 [10.16–106.02] mIU/mL, p<0.05). Plasma EPO concentration was strongly 
and negatively correlated with hemoglobin in the non-AKI group but not in the AKI group.
In AKI group, plasma IGFBP-1 was strongly and positively correlated with plasma 
EPO. Multiple logistic regression analysis revealed plasma EPO in the AKI group was 
significantly associated only with plasma IGFBP-1 and complication of diabetes mellitus.
Conclusions: EPO production in AKI was enhanced by not anemia but systemic 
hypoxic stimuli evaluated by IGFBP-1, indicating unknown independent pathway of renal 
EPO production in AKI.
Funding: Government Support - Non-U.S.
SA-PO218
Predictive Value of Plasma Neutrophil Gelatinase-Associated Lipocalin 
(NGAL) to Distinguish Prerenal AKI to Other Causes of AKI  Chae Ho Lim, 
Young-Il Jo.  Div of Nephrology, Dept of Internal Medicine, Konkuk Univ 
Medical Center, Gwangjin-gu, Seoul, Republic of Korea; Div of Nephrology, 
Dept of Internal Medicine, Konkuk Univ Medical Center, Gwangjin-gu, Seoul, 
Republic of Korea.
Background: Plasma Neutrophil gelatinase-associated lipocalin (NGAL) is a promising 
biomarker for acute kidney injury, but it’s role for distingushing prerenal AKI from other 
causes are not well known. The aim of this study was to evaluate the predictive value of 
plasma NGAL to distinguish prerenal AKI to other causes of AKI.
Methods: We reviewed all NGAL test from December 26, 2011to February 28,2015 
in Konkuk University Medical cencer ( Seoul, Republic of Korea) and subtract patients 
who taken factional excretion of sodium(FENa) test at the same time. Patients were first 
grouped with Acute Kidney Injury Network (AKIN) stages and evaluated it’s diagnostic 
role for AKI and second divided with prerenal AKI and other causes of AKI.
Results: Total 5814 NGAL test were done from December 26, 2011to February 28,2015 
in Konkuk University Medical center, and 495 patients taken FENa test at the same time.
Conclusions: Plasma NGAL had a predictive value for diagnosing AKI but it itself had 
a limited value for distinguishing prerenal AKI from other causes of AKI.
SA-PO219
Neutrophil/Lymphocyte Ratio for Early Detection of Acute Kidney Injury 
(AKI) in Patients Admitted to the Emergency Room  Mohsen Abu Alfeilat, 
Itzchak N. Slotki, Linda Shavit.  Adult Nephrology, Shaare Zedek Medical 
Center, Jerusalem, Israel.
Background: Neutrophil to lymphocyte ratio (NLR) is a readily available biomarker of 
systemic inflammation. Several studies have provided evidence of an association between 
elevated NLR and adverse outcomes in a variety of medical and surgical conditions, 
including CKD. In this study, we evaluated the predictive capacity of single Emergency 
Room (ER) measurement of NLR for early diagnosis of acute kidney injury (AKI).
Methods: We prospectively studied 294 patients aged 71.6 ± 17. NLR was measured at 
presentation to the ER.AKI was defined as a new-onset 1.5-fold or more increase in serum 
creatinine or a 25% decrease in estimated GFR sustained for at least 3 days despite volume 
resuscitation. The primary outcome was AKI. Secondary outcome was in-hospital mortality.
Results: 36 patients (12.2%) developed AKI and 26 (9%) died. Mean NLR was 
significantly higher in AKI compare to non-AKI patients (11.7 ± 15.2 vs 6.45± 7.19, 
p=0.048). A multivariate model adjusted for age, gender, blood pressure, and plasma 
albumin levels confirmed that NLR is higher in AKI patients (p=0.048). Receiver operating 
characteristics curve revealed AUC 0.715 (95% CI 0.63-0.8) sensitivity 0.78, specificity 
0.65, OR 6.423 (CI, 2.659 to 16.026) for a cutoff value of NLR 5.5. The association between 
NLR and in hospital mortality was not statistically significant (p = 0.92).
Conclusions: Single ER measurement of NLR can be a useful tool for early diagnosis 
of AKI. This finding is particularly important in light of the widespread availability and 
low cost of NLR, especially compared with other biomarkers currently under study in the 
context of AKI.
SA-PO220
Urine Klotho in Human AKI  Javier A. Neyra,1 Xilong Li,2 Beverley 
Adams-Huet,2,3 Carolina De La Flor,3 Ming Chang Hu,3 Robert D. Toto,1,2 Orson 
W. Moe.1,3  1Nephrology, UT Southwestern; 2Clinical Sciences, UT Southwestern; 
3Mineral Metabolism, UT Southwestern, Dallas, TX.
Background: AKI is associated with increased morbidity and carries increased risk 
for subsequent CKD. Klotho deficiency has been observed in experimental AKI and low 
Klotho post-AKI is associated with progression to CKD in rodents. We report the first 
study of Klotho in human AKI.
Methods: We conducted a prospective study of 29 AKI patients and 29 controls without 
AKI in the ICU setting. We excluded patients with baseline eGFR<60 or kidney transplant. 
Urine samples were obtained within 24h of peak serum creatinine (SCr) or at RRT initiation 
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in AKI cases, and within 24h of ICU admission in frequency-matched controls. AKI was 
defined by KDIGO criteria. Longitudinal data from AKI cases were obtained throughout 
hospital stay. Renal recovery was defined as the ratio of follow-up SCr/baseline SCr £1.5. 
Urine Klotho was measured by immunoprecipitation-immunoblot. Mixed-effects linear 
models were constructed to assess longitudinal trends of Klotho in AKI survivors.
Results: Mean (SD) age was 58 (17) years, 62% were men and 75% white. Patients 
with AKI had higher critical illness scores than controls without AKI. Five (17.2%) patients 
died and 8 (27.6%) required RRT in the AKI group. Only 3.5% patients died in the control 
group. Urine Klotho adjusted by urine creatinine (uKlotho/Cr) was significantly lower 
in AKI cases than in controls, median 10 [IQR 4–20] vs 28 [14–52] fmol/mg, p=0.003. 
Furthermore, uKlotho/Cr significantly increased with time in patients that exhibited renal 
recovery (n=7, ∆+216%, p=0.05) but not in those that did not (n=7,∆+8%, p=0.91), median 
follow-up 24 days.
Conclusions: uKlotho/Cr is significantly lower in patients with AKI when compared 
to ICU controls without AKI. uKlotho/Cr recovered only in patients that recovered kidney 
function. Klotho may serve as a prognostic marker for AKI recovery.
Funding: Other NIH Support - University of Texas Southwestern Medical Center 
O’Brien Kidney Research Core Center (NIH, P30 DK079328-06) and the National 
Center for Advancing Translational Sciences of the National Institutes of Health (NIH, 
UL1TR001105).
SA-PO221
Biomarkers of Acute Kidney Injury in Children Treated with Cisplatin 
Kelly Mcmahon,1 Shahrad Rod Rassekh,2 Kirk Raymond Schultz,2 Maury N. 
Pinsk,3 Tom D. Blydt-Hansen,2 Cherry Mammen,2 Ross T. Tsuyuki,3 Prasad 
Devarajan,4 Michael Zappitelli.1  1McGill U, Montreal; 2U British Columbia, 
Vancouver; 3U Alberta, Edmonton, Canada; 4Cincinnati Children’s Hosp, 
Cincinnati.
Background: Cisplatin(CisP) causes acute kidney injury(AKI) and may cause chronic 
kidney disease(CKD). Biomarkers(BioM) may allow early AKI diagnosis and treatment. 
Applying BioM to Long-Term Effects in Child/Adolescent Cancer Treatment(ABLE) is a 
Canadian study of cancer treatment toxicities, including nephrotoxicity. We study BioM 
of child CisP treatment for early and late renal outcome prediction. This analysis evaluates 
neutrophil gelatinase-associated lipocalin(NGAL), kidney injury molecule-1(KIM-1) and 
serum Cystatin C(CysC) with CisP therapy in the first 1/3 of subjects.
Methods: Ongoing, 8-site, prospective cohort of 150 children receiving CisP. Excluded: 
severe CKD. Protocol includes 2 “acute” visits[AV] around CisP infusion(pre, post, 
discharge urine/blood) for serum creatinine(SCr), CysC, urine NGAL, KIM-1. Outcomes: 
AKI (Kidney Disease Improving Global Outcomes[KDIGO] SCr criteria; AKI by National 
Cancer Institute(NCI) criteria(based on serum electrolytes).
Results: Data available in 44/60 (mean±SD age 7±6yrs; AV1/AV2 hospital stay 
16±27/12±26 days; 55% male). AV1: 11% KDIGO AKI, 46% NCI AKI, 50% with either. 
AV2: 14% KDIGO AKI, 72% NCI AKI, 75% with either. BioM drop immediately post-
CisP (n=25), followed by a rise at discharge.
A similar pattern is seen in AKI and non-AKI groups and when expressing BioM/
urine creatinine(not shown).
Conclusions: This is a novel study of AKI BioM excretion in CisP-AKI. NCI-AKI is 
more common than SCr-AKI. The immediate BioM drop post-CisP may be related to injury 
protection from high fluid rate and/or urinary alkalinization peri-CisP. Our larger sample 
size will allow to further characterize BioM excretion and evaluate BioM associations with 
AKI definition and outcomes.
Funding: Government Support - Non-U.S.
SA-PO222
Elevated Renal Injury Biomarkers Fall Transiently After Stenting in 
Human Atherosclerotic Renal Artery Stenosis (ARAS)  Wei Wang,1,2 Ahmed 
Saad,1 Sandra Herrmann,1 Alfonso Eirin,1 Hui Tang,1 Lilach O. Lerman,1 
Stephen C. Textor.1  1Nephrology and Hypertension, Mayo Clinic, Rochester, 
MN; 2Nephrology, Dalian Municipal Central Hospital, Dalian, Liaoning, China.
Background: ARAS reduces blood flow and perfusion pressures to the post-stenotic 
kidney (STK), ultimately producing inflammatory injury. The aim of our study was to 
identify and track renal injury biomarkers for 24 hours and 3 months after combined CT 
imaging and stent revascularization.
Methods: 12 patients with severe ARAS scheduled for revascularization for clinical 
indications were enrolled in a 3 day inpatient and restudied 3 months later. All subjects 
maintained ACE/ARB Rx and fixed Na+ intake, and were compared with Essential 
Hypertensives(EH) (n=12) undergoing the same biomarkers and imaging studies. 
Glomerular filtration rate (GFR) was measured by iothalamate clearance, blood flow and 
perfusion by Multidetector Computerized Tomography (MDCT) and NGAL, MCP-1, IL-
10, TNF-α, KIM-1, IGFBP7 and TIMP-2 in renal vein and peripheral blood/IVC samples 
every 6 hours for 24 hours and after 3 months.
Results: Kidney perfusion, whole kidney blood flow, single kidney iothalamate 
GFR were reduced in the STKs compared to kidneys from EH and increased after stent 
revascularization.
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Basal renal biomarkers were higher in ARAS than in EH. MCP-1 and IGFBP7 fell 
immediately then rose by 6 hours, while NGAL remained below baseline for 24 hours. All 
biomarkers rose to or above baseline by 3 months, despite increased STK GFR.
Conclusions: Renal biomarkers were universally elevated as compared to EH. Despite 
intense contrast exposure and renal artery stenting, our results demonstrate transient 
reductions during the 24 hours after revascularization in ARVD, before returning to sustained 
elevations by 3 months. These data reinforce ongoing inflammatory injury in ARVD despite 
restoration of blood flow to stenotic kidneys.
SA-PO223
Comparison of Urinary Angiotensinogen Level Between Septic and 
Dehydrated AKI  Hiroyuki Suzuki, Eri Muso.  Dept of Nephrology, Kitano 
Hospital, Osaka, Japan.
Background: Increasing evidences have suggested that urinary (U) angiotensinogen 
(ATG) is one of potential biomarkers related with severity of chronic kidney diseases 
(CKD). Recently, in addition to CKD, U-AGT has been reported to be a useful prognostic 
biomarker in acute kidney injury (AKI) especially after cardiac surgery, however, little is 
known about U-AGT in AKI due to other etiologies. In this study, we measured U- AGT 
in patients with pre-renal (dehydration) and renal (sepsis) AKI.
Methods: Fifteen patients who were hospitalized due to sepsis, and 6 patients who had 
AKI due to dehydration were included in the study. The patients included 13 women and 
8 men with a mean age of 71.4 yr (range 41 to 94 yr). U-ATG levels were measured when 
sepsis or AKI was diagnosed and compared with clinical parameters and other known urinary 
renal injury biomarkers such as urinary liver-type fatty acid-binding protein (L-FABP), 
b2-microglobuline (MG), and NAG.
Results: Among 15 patients with sepsis, 7 were diagnosed as AKI. The number of cases 
in each AKIN stage from I, to III were 4, 1, and 2 in sepsis, and 3, 1, and 2 in dehydration, 
respectively. No patients have died from AKI. During AKI, peak Cre levels were 1.79mg/
dl (238% increase) in sepsis group, and 2.88mg/dl (213%) in dehydration group. U-ATG 
in sepsis with AKI (84297±70397 ng AngI Eq/gCr) were significantly higher than in sepsis 
without AKI (12598 ±8916 ng AngI Eq/gCr) and dehydration group (14960±6771 ng AngI 
Eq/gCr). Among urinary markers, in sepsis group, U-ATG were strongly correlated with 
U-ß2MG (r=0.914, p<0.01). U-NAG (r=0.552, p=0.033) and L-FABP (r=0.594, p=0.020) 
were also correlated with U-ATG. In contrast, in dehydration group, U-ATG were not 
correlated with U-ß2MG, NAG, nor with L-FABP. In comparison with the severity of 
AKI and the levels of U-ATG , in sepsis group, ∆Cre (peak – basal Cre) were positively 
correlated with U-ATG significantly (r=0.716, p=0.003). On the contrary, in dehydration 
group, U-ATG tended to decrease as maximum Cre increased.
Conclusions: Apparent difference of dynamism between in AKI due to septis and 
dehydration indicates that U-ATG could be a potent biomarker to distinguish renal from 
pre-renal AKI, before developing to CKD.
SA-PO224
AKI Development Upon SIRS Is Associated with Platelet Activation, 
Possibly Triggered by Mitochondrial DNA Derived from Damaged 
Cells  Marcel Jansen,1 Wilco P. Pulskens,2 Diba Emal,1 Sandrine Florquin,1 
Joris J. Roelofs,1 Jaklien Leemans.1  1Nephrology, Academic Medical Center, 
Amsterdam, Netherlands; 2Nephrology, Radboud Univ Medical Center, 
Nijmegen, Netherlands.
Background: Multiple inflammatory pathways are activated by non-infectious agents 
during Systemic inflammatory response syndrome (SIRS) leading to collateral damage, 
including the development of acute kidney injury (AKI). Pattern recognition receptors 
(PRRs) of the innate immune system sense Damage-Associated Molecular Patterns 
(DAMPs) leading to an immune response. Components of mitochondria e.g. unmethylated 
CpG-enriched mitochondrial DNA (mtDNA) that leak upon cell injury, are a source of 
DAMP. Platelets express several PRRs and play an important role in innate immunity. To 
date, it is unclear which intrinsic factors trigger the onset of SIRS and associated AKI. 
We investigated the role of mtDNA during systemic inflammation and AKI and the role 
of platelets herein.
Methods: Human platelets were stimulated with mitochondrial DNA, genomic DNA 
or unmethylated CpG-enriched oligonucleotides (CpG ODN). Platelet activation was 
measured with FACS. In a single centre prospective observational study we included 37 
patients diagnosed and classified for the onset of SIRS with or without the development of 
AKI that were admitted to the ICU. As a control we included (n=25) patients after elective 
major surgery without a diagnosis of either SIRS or AKI. Blood and urine samples were 
isolated and processed. Free circulating plasma and urinary mtDNA was determined by 
RT-PCR. Inflammatory mediators and PF4 in urine were measured using specific ELISA.
Results: Mitochondrial DNA, but not genomic DNA triggered platelet activation. 
Unmethylated CpG ODN, dose dependently stimulated platelet activation. Compared 
to ICU-controls, critically ill patients with SIRS demonstrated elevated levels of plasma 
and urinary mtDNA and proinflammatory cytokines. Compared to SIRS patients without 
AKI, the patients with AKI displayed elevated levels of urinary PF4 –indicative of platelet 
activation.
Conclusions: The development of AKI in critically ill patients is associated with 
platelet activation, possibly triggered by mitochondrial DNA.
SA-PO225
Invaders in the Night: Sleep Apnea and Sub-Clinical Renal Injury 
Aaron A. Rampersad,1 Shahab Bozorgmehri,1 Areef Ishani,2,3 I. David 
Weiner,1,4 Satish P. Ramachandrarao,5 Rebecca Beyth,1,4 Muna T. Canales.1,4 
1Univ of Florida, Gainesville, FL; 2Minneapolis VAMC; 3Univ of Minnesota, 
Minneapolis, MN; 4Malcom-Randall VAMC, Gainesville, FL; 5Univ of 
California, San Diego, CA.
Background: Sleep apnea is common in patients with CKD. We postulated that sleep 
apnea may cause renal injury through repeated ischemia-reperfusion. The current study 
correlated overnight changes in urinary excretion of renal injury biomarkers with severity 
of sleep apnea.
Methods: 39 consecutive participants in the SNORE Study, a longitudinal study of 
sleep apnea and kidney function decline, underwent overnight sleep study and provided spot 
urine samples before and after sleep. We measured urinary NGAL, L-FABP, KIM-1, and 
urinary cystatin-c levels, and correlated differences between AM and PM levels (AM-PM) 
with severity of sleep apnea or hypoxia. Sleep apnea was defined by the apnea-hypopnea 
index (AHI, events/hour); hypoxia was % total sleep time <90% SaO2 (%TST90). Data 
were log-transformed to normalize distribution.
Results: Patient characteristics: Mean age, 73.6±8.4 years; 90% male; 87% Caucasian, 
13% black; BMI, 29.4± 4.2 kg/m2; MDRD eGFR, 34.3±8.1 ml/min/1.73m2; Median urinary 
albumin/creatinine ratio, 46 mg/g Cr [IQR 9-357 mg/g Cr]. 69% had sleep apnea (AHI≥5); 
median AHI, 10 [IQR 2-23]; median %TST90, 15 [IQR3-22] with 34% %TST90³10%. 
Higher %TST90 was correlated with higher AM KIM-1 values (r=0.40, p=0.01) and 
greater increase in urinary KIM-1 (AM-PM) (r=0.32, p=0.04). None of the remaining 
biomarkers correlated with %TST90. Also, none of the overnight urinary biomarker 
changes correlated with AHI.
Conclusions: The correlation of KIM-1 with hypoxia suggests that SA may contribute 
to CKD through ischemic renal injury. Future studies with larger sample size and in non-
CKD populations are needed to further test this hypothesis.
Funding: Other NIH Support - DK079337 UAB-UCSD O’Brien Center, Veterans 
Administration Support
SA-PO226
Body Mass Index and Acute Kidney Injury in Hospitalized Patients 
Yan Lun Allen Liu, Milind Nikam, Lee Ying Yeoh.  Dept of Medicine, Khoo 
Teck Puat Hospital, Singapore.
Background: Acute kidney injury (AKI) is common in hospital settings. The 
association between AKI and Body Mass Index (BMI) in general hospitalized patients is 
not known. This study is to explore the incidence of AKI and the impact of BMI on AKI 
in hospitalized patients.
Methods: This was a single centre, retrospective, case-control study. All patients aged 
21 or above under in-hospital care from January to December 2013 were recruited for 
analysis. We calculated the incidence of AKI according to the Kidney Disease: Improving 
Global Outcomes (KDIGO) criteria among different BMI groups (underweight [BMI < 18], 
normal [BMI 18-23], overweight [BMI 23-25] and obese [BMI > 25]), and then analyzed 
the risks of developing AKI within and between groups. Baseline creatinine was defined by 
the most recent value obtained in hospital up to 12 months before admission. If no previous 
serum creatinine was available, the lowest serum creatinine during hospitalization was used 
instead. If only one serum creatinine result was known during hospital stay, the baseline 
creatinine was estimated by the use of simplified Modification of Diet in Renal Disease 
(MDRD) formula (assuming a glomerular filtration rate [GFR] of 75 ml/min per 1.73 m2).
Results: A total of 12567 patients were recruited for analysis. Mean age was 62.5 
± 18.5 years. Male patients constituted 53.8% of the study population. 61.9% were 
Chinese ethnicity. There were 2656 patients suffered from AKI (21.1% of the whole study 
population), among which 10.7%, 6.1% and 4.4% had stage 1, 2 and 3 AKI respectively. 
Underweight patients (BMI < 18) had statistical significantly more stage 1 AKI than the 
rest of the population, while patients with BMI ≤ 25 had more stage 2 AKI (stage 1 AKI 
for underweight, normal, overweight and obese patients was 15%, 10.2%, 9.4% and 
10.3% respectively; stage 2 AKI, 7.6%, 6.3%, 6.4% and 5.2% respectively). There was no 
difference in frequency of stage 3 AKI among different BMI groups.
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Conclusions: Preliminary results revealed underweight hospitalized patients had 
increased risks of developing stage 1 AKI. Stage 2 AKI was more commonly seen in patients 
with BMI ≤ 25. BMI status was not associated with the development of severe AKI (stage 3).
SA-PO227
Hypermagnesemia as a Risk Factor for the Mortality in Intensive Care 
Unit Patients with Acute Kidney Injury  Shunichi Shibazaki,1 Makoto Araki,1 
Kohei Miura,1 Daijo Inaguma.2  1Dept of Nephrology, Suwa Central Hospital, 
Chino, Nagano, Japan; 2Dept of Nephrology, Nagoya Daini Red Cross Hospital, 
Nagoya, Aichi, Japan.
Background: We need an easily measured biomarkers predicting for the mortality 
in acute kidney injury (AKI) because of high mortality rate. Therefore, we paid attention 
for serum magnesium (sMg) levels which reflects the renal tubular damage, and study the 
relationship sMg and prognosis in intensive care unit (ICU) patients with AKI.
Methods: A cohort study was conducted by collecting data from January to December 
2014 in Nagoya Daini Red Cross Hospital. According to sMg at ICU 1st day, three groups 
were divided; low Mg group(sMg <1.8mg/dL), normal Mg group (1.8mg/dL £sMg <2.6mg/
dL), and high Mg group (sMg ³2.6mg/dL). AKI was defined as serum creatinine (sCr) abrupt 
(within 7 days) increase to ³1.5 times baseline or sCr increase by ≥ 0.3mg/dL The primary 
endpoint was 28 days morality after ICU admission. The secondary endpoint was the renal 
recovery rate, the renal replacement therapy (RRT) induction rate, and the transition rate to 
maintenance dialysis. Renal recovery was defined as an absence of AKI.
Results: Out of 1614 ICU patients, 200 patients were included. The number of each 
groups are following; low Mg group was 55, normal Mg group was 115, and high Mg group 
was 30. The mortality was higher in high Mg group than in other Mg group (p =0.011). 
A multivariate analysis identified high Mg group as an independent risk factor for the 
mortality (p =0.041). High Mg group had 2.39-fold increased odds of mortality against 
normal Mg group (95% CI 1.04 -5.50). Kaplan-Meier curves showed the high Mg group 
was associated with higher mortality.
There was no significant association between each groups and the secondary endpoints.
Conclusions: Hypermagnesemia is an independent risk factor for the mortality in 
ICU patients with AKI.
SA-PO228
Gemcitabine-Induced Thrombotic Microangiopathy (TMA): A Report 
from the French Pharmacovigilance Network  Noemie Jourde-chiche,1 
Florence Daviet,1 Frank Rouby,2 Bertrand Gondouin,1 Marion Sallée,1 Julie 
Moussi-Frances,1 Stephane Burtey,1 Pascale Poullin,3 Bertrand Dussol,1 Joelle 
Micallef.2  1Nephrology, Aix-Marseille Univ, Marseille, France; 2Pharmacology 
and Pharmacovigilance, Aix-Marseille Univ, Marseille, France; 3Hemapheresis, 
Aix-Marseille Univ, Marseille, France.
Background: Gemcitabine is a chemotherapy which use can be limited by renal 
adverse events, in particular thrombotic microangiopathy (TMA). This study evaluated 
the occurrence of gemcitabine-induced TMA, and described therapeutic strategies and 
outcomes.
Methods: All spontaneous reports of TMA attributed to gemcitabine in the French 
Pharmacovigilance Network database, between January 2000 and May 2015, were reviewed 
using a standardized questionnaire.
Results: 81 cases of TMA were reported in 48 male (59%) and 33 female (41%), 
with a median age of 63.5 yrs (range 39-87). Gemcitabine was prescribed for pancreatic 
(58%), pulmonary (15%), breast (8%), biliary tract (6%), urinary tract (5%), uterine (3%), 
testicular (1%) or liver (1%) cancers, or T lymphoma (3%). TMA occurred after a median 
of 7 months (range 0.2-60), and a median cumulative dose of 21.8g (range 1.1-48.6). Main 
symptoms were hypertension (51%), diffuse edema and/or congestive heart failure (42%), 
acute renal failure (86%), thrombocytopenia (67%), hemolytic anemia (86%). Median 
creatinine level was 1.8 mg/dL (range 0.8-17). In 6 patients, renal TMA was biopsy-proven. 
Renal replacement therapy was required in 10 (12%) patients, plasma exchanges (PEx) 
were performed in 17 (21%), 8 (10%) received fresh frozen plasma infusions, 9 (11%) 
corticosteroids, and 3 (4%) eculizumab (after PEx failure). Evolution data were available 
for 59 (73%) patients, among which the 17 treated with PEx. Hematological and renal 
remission was achieved in 35% with PEx versus 50% without, hematological remission 
without renal improvement in 18% with versus 26%, and no improvement was observed in 
47% with versus 24% without PEx. Only one patient improved with eculizumab.
Conclusions: Gemcitabine treatment can be associated with TMA and severe renal 
adverse effects. The benefit of plasma exchange or eculizumab in this setting remains 
uncertain.
SA-PO229
Contribution of Drugs versus Risk Factors in Drug-Induced Renal Injury 
Celina D. Cepeda,1 Linda Awdishu,1 Etienne Macedo,1 Dinna Cruz,1 Stuart 
Goldstein,2 Jorge Cerda,3 David T. Selewski,4 Michael Zappitelli,5 Andrew J.P. 
Lewington,7 Ravindra L. Mehta.1  1Nephrology, Univ of California San Diego, 
San Diego, CA; 2Nephrology, Univ of Cincinnati, Cincinnati, OH; 3Nephrology, 
Albany Medical College, Albany, NY; 4Nephrology, Univ of Michigan, Ann Arbor, 
MI; 5Nephrology, Univ of Montreal, Montreal, QC, Canada; 6Nephrology, Cares 
Hospital India, Hyderbad, India; 7Nephrology, St. James’s Univ Hospital, Leeds, 
London, United Kingdom.
Background: Drug-induced renal injury (DIRI) is an increasing cause of acute kidney 
injury (AKI). Attribution of DIRI requires consideration of the drug exposure, the number 
of drugs involved and underlying or concomitant risk factors (RF). We hypothesized that 
underlying RF would influence attribution of DIRI.
Methods: The drug induced renal injury (DIRECT) study is an ongoing prospective 
multicenter study evaluating genetic determinants of DIRI. Each enrolled case was 
adjudicated for causality by two independent nephrologists. We analyzed the first 
consecutive 86 adult and pediatric AKI cases. We evaluated the percent agreement, kappa 
statistic, and contribution of each drug (in setting of multidrug injury) and AKI RF.
Results: Adjudicators agreed 87.2% (n=75) had DIRI. For non-DIRI cases, causality 
could not be established because of competing AKI RF. RF contributed to AKI in 86% 
of adults and 70% of children. Adjudicators disagreed on the percent attribution for each 
drug in 52%. For DIRI cases, inter-rater agreement on percentage attributed to drug 1 was 
48% with kappa=0.239 (p=0.001). For non-DIRI cases, inter-rater agreement for drug 1 
was 81.8% and RF attribution was 80%.
Percent Attribution of Drugs versus Risk Factors
DIRI 
n=75
Percentage attributed to 
drug
Number of cases agreed 
upon 
Percentage distribution for 
risk factors 
No agreement 39 30 (10-50)
0-25% 1 65 (60-65)
26-50% 20 40 (12.5-50)
51-75% 2 40
76-100% 13 0 (0-20)
Conclusions: Underlying RF are common in DIRI associated AKI. Causality 
assessment in DIRI is complex due to difficulty in determining the attribution of drug and 
RF. CAT for DIRI should incorporate AKI RF and their interaction with drugs.
Funding: Private Foundation Support
SA-PO230
Reduced Incidence of Post-Operative Acute Kidney Injury After 
Cardiovascular Surgery  Dadi Helgason,1 Þórir E. Long,1 Sólveig Helgadóttir,2 
Tomas Gudbjartsson,3,6 Gisli H. Sigurdsson,2,6 Martin I. Sigurdsson,2,4 Olafur S. 
Indridason.5  1Dept of Medicine; 2Dept of Anesthesia and Intensive Care; 3Dept 
of Cardiothoracic Surgery, Landspitali, Reykjavik; 4Dept of Anesthesia, Brigam 
and Women´s Hospital, Boston; 5Div of Nephrology, Landspitali; 6Faculty of 
Medicine, Univ of Iceland, Reykjavik, Iceland.
Background: Acute kidney injury (AKI) is a serious complication of cardiac surgery. 
The aim of this study was to examine time trends in incidence and survival of patients 
diagnosed with AKI following cardiac and thoracic aorta surgery.
Methods: This was a retrospective study of all heart and thoracic aorta operations 
performed on adults in Iceland from 2007 to 2014. AKI was diagnosed according to the 
KDIGO criteria based on serum creatinine values in the electronic database of the clinical 
laboratory at our institution. Survival status was verified at Statistics Iceland. The incidence 
of AKI and its outcome was compared between the first and second half of the 8 year study 
period using Chi squared and the Kaplan Meier method. Outcome between AKI and non-
AKI patients was compared by propensity score matching (1:2, non-replacement matching).
Results: A total of 2224 patients underwent 2502 operations during the study period, of 
which 28.4% were acute operations. Median (range) age at operation was 67 (18-97) years 
and 70.7% of patients were men. AKI occurred after 417 operations (16.7%). Of these 302 
(12.1%), 69 (2.8%) and 46 (1.8%) were of stage 1, 2 and 3, respectively. Incidence of AKI 
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decreased from 19.2% in the first period to 14.5% in the second period (p=0.002). Survival 
of AKI patients at 30 days and 1 year did not differ between time periods, being 82.6% vs 
83.8% and 79.5% vs 76.8%, respectively (p>0.10). Survival was worse for patients with 
AKI compared with the propensity score matched control cohort, both at 30 days (86.1% 
vs, 96.5%, p=0.0001) and at 1 year postoperatively (81.2% vs. 91.5%, p=0.0001).
Conclusions: The incidence of AKI following cardiac and thoracic aorta surgery is 
decreasing. Nevertheless it still affects one in seven patients and even though most patients 
have mild AKI, it is associated with increased mortality which remains unchanged over 
the past decade. Funding: Private Foundation Support
SA-PO231
Acute Kidney Injury in Patients with Chronic Kidney Disease: Aetiology 
and Survival Comparisons to Non-Acute Kidney Injury Chronic Kidney 
Disease Population  Akib Khan,1 James Ritchie,2 Smeeta Sinha.3  1Senior House 
2fficer, Imperial NHS Foundation Trust, London, United Kingdom; 2Renal 
Medicine, Univ of Manchester, Manchester, United Kingdom; 3Nephrology, 
Salford Royal Foundation Trust, Salford, United Kingdom.
Background: AKI, described by an acute (hours to days) fall in kidney function, is 
associated with significant morbidity and mortality. Poor outcomes exist when AKI is 
superimposed on CKD, a disease involving structural or functional renal abnormalities in 
a chronic setting (>3 months). We present a single-centre prospective observational study; 
retrospectively analysed. We determine the factors surrounding AKI on CKD. Aetiology, 
length of stay, specialist review and medication data were examined. We compare AKI on 
CKD patients’ survival to matched non-AKI CKD patients.
Methods: CRISIS database CKD patients matching inclusion criteria treated at Salford 
Royal Foundation Trust were studied (n=542). A 2.0-3.0 and >3.0 times serum creatinine 
increase from last measurement was used to define Acute Kidney Injury Network stages 
2 (n=17) and 3 (n=10) events respectively. Controls were matched by age, eGFR and 
blood pressure. Logistic Regression, Cox-Hazard Ratio and Kaplan-Meier Survival Plots 
were used.
Results: Aetiological factors associated with AKI included sepsis (48.1%), 
drug-induced (29.6%) and dehydration (25.9%). Septic-AKI had a 1.405 odds ratio 
(95%CI:0.099-19.936,p=0.801) of death compared to non-septic events. Hazard ratio for 
death due to AKI on CKD compared to non-AKI CKD was 1.77 (95%CI:0.72-4.33,p=0.207). 
Kaplan-Meier survival function clearly demonstrates this.
Conclusions: Aetiology of AKI in our patient group was similar to that seen in non-
CKD studies. There was a clear trend towards increased all-cause mortality in patients 
with AKI on CKD in comparison to non-AKI CKD patients. Renal function decline rate 
following AKI on CKD should be explored in the future.
SA-PO232
Prospective Study of Incidence and Early Detection of Acute Renal Failure 
in Preterm Babies in a Tertiary Center in South India  Indira Agarwal, 
Nithya Ponmudi, Anil K. Kuruvilla, Vijayakumar Theophilus-Sunder. 
Pediatric Nephrology, Christian Medical College, Vellore, Tamil Nadu, 
India; Neonatology, Christian Medical College, Vellore, Tamil Nadu, India; 
Nephrology, Christian Medical College, Vellore, Tamil Nadu, India.
Background: Preterm babies are at risk for ischemia, hypovolemia and hypotension 
and thus vulnerable to Acute kidney injury (AKI). We aimed to study the incidence and 
predisposing factors for AKI in preterm babies and to assess the usefulness of urinary 
NGAL as a predictor of kidney injury.
Methods: Babies born < 32 weeks+6 weeks were recruited; those with abnormal 
antenatal renal scans and major congenital anomalies were excluded. Weekly monitoring 
of urine output, clinical progress, interventions, ventilation, unexpected events and use 
of nephrotoxic drugs was done. Serum creatinine and urine NGAL was collected at 72 
hours of age and weekly thereafter. Descriptive statistics using mean+/- SD for continuous 
variables, ANOVA and chi square test / Fishers exact test for categorical variables and Risk 
factor analysis using log binomial was performed.
Results: Of the 4823 live births, 80 fulfilled inclusion criteria (10.14%).The incidence 
of AKI was 12.6%.The risk factors included oligoanuria, PDA, nephrotoxic drugs, low 
Apgar, mechanical ventilation, CPAP and abnormal antenatal scans. Urine NGAL was 
estimated in 31 babies. It rose earlier and was significantly elevated in those on mechanical 
ventilation by week 2 while Creatinine rose only by week 3.
NGAL was inversely proportionate to gestational age and birth-weight. Both NGAL 
rise and creatinine were higher in babies with AKI associated with NSAIDS, umbilical 
lines and asphyxia.
Conclusions: NGAL holds promise as an early marker of AKI and a non invasive test 
for serial monitoring of renal function in preterm babies. A study with a larger sample size 
is required to establish reference values for NGAL in preterm babies.
SA-PO233
Acute Kidney Injury Electronic Alerts in Primary Care  Conor Patrick Moran,1 
Ying C. Kuan,1 Patrick Lm Lynch,2 Francis Mccarroll.1  1Dept of Nephrology, 
Altnagelvin Hospital, Londonderry, United Kingdom; 2Dept of Clinical 
Chemistry, Altnagelvin Hospital, Londonderry, United Kingdom.
Background: Acute Kidney Injury, (AKI), is common with a variably reported 
mortality, (15-60%). A UK national audit reported that up to 30% of cases were avoidable 
and that as much as 43-61% of post-admission AKI experienced an unacceptable delay 
in recognition. AKI is regarded as the remit of Secondary Care and there have been few 
studies examining Community Acquired AKI, (CA-AKI). Guidelines have recommended 
the use of electronic alerts (e-alerts) for AKI detection in both Primary and Secondary care. 
We examined the incidence and mortality of CA-AKI.
Methods: We introduced AKI e-alerts with accompanying e-guidance in late October 
2014 and prospectively collected data on the patients identified with severe AKI in Primary, 
(n=121), and Secondary care, (n=110), environments. Data collection was carried out for 
3 months. The demographics of both cohorts were compared.
Results: Median age, (74.5 years vs. 75 years), gender distribution, (M:F: 48% / 52% 
vs. 44.5% / 55.5%), and median time to death, (8 days vs. 11 days), were comparable. 44 
Alerts were from Primary Care and 77 from Emergency Department. Of the Primary Care 
Alerts, 20 patients were subsequently admitted. Of those who were not, 3 died within 30 
days, (1. Died at 5 days, 2. Died at 8 days, 3. Died at 21 days). Despite this, Community-
acquired AKI was associated with a 30-day mortality of 10.7%. Hospital-acquired AKI, 
(HA-AKI), was associated with a 28.2% 30-day mortality, (p=<0.001). Sub-group analysis 
showed Primary care alert associated with 13.64% mortality and Primary Care alerts with 
9.76%, (p=<0.001). Median Age at Death; CA-AKI 80 years. Median time to death; CA-
AKI 5 days, HA-AKI 11 days.
Conclusions: AKI is common and associated with a significant morbidity and mortality. 
CA-AKI is common opportunities at diagnosis and intervention are often missed with grave 
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consequences. Appropriate management of CA-AKI could help reduce the economic and 
physical burden associated with AKI and reduce the long-term burden of CKD. Further 
work is required to expand the role of AKI e-Alerts in Primary Care.
SA-PO234
Acute Kidney Injury Causes and Outcome: A Single Center Experience 
from Sudan  Dalia Elrashid M Yousif,1,2 Maha Farah,2 Len A. Usvyat,3,4 Roberto 
Pecoits-Filho,1 Peter Kotanko.3  1PUCPR, Curitiba, PR, Brazil; 2Nephrology, 
SOBA Univ Hospital, Khartoum, Sudan; 3Renal Research Inst, New York, NY; 
4Fresenius Medical Care, Bad Homburg, Germany.
Background: Acute kidney injury (AKI) is a challenging problem in Africa—a 
diverse continent with regards to population and financial and medical resources. There 
are no reliable statistics about the incidence of AKI in Africa. Based on sporadic regional 
publications the incidence has been estimated at 150 per million population. In addition to 
infectious diseases; toxins play a major etiologic role in AKI.
Methods: In this study we analyzed data from Omer Belail Renal Center in Soba 
University Hospital, Sudan, a tertiary referral center with a catchment area of 3 million 
citizens. All hemodialysis (HD) patients treated for AKI in the period between 1/1/2013 
and 12/31/ 2014 were included in the study.
Results: Out of 520 hemodialysis patients we identified 69 patients with AKI; 39 
(56.5%) were males. The mean±SD age was 40.5±17.4 years. Serum creatinine and 
blood urea levels on admission were 14.7±6.7 and 245±125 mg/dl, respectively. Serum 
creatinine and blood urea levels at discharge were 2.5±2.1 and 53±32 mg/dl, respectively. 
29 patients (42%) experienced recovery of normal renal function; the recorded mortality 
was 13 %. AKI causes.
Acute tubular necrosis 15 (21.7%)
Obstructive uropathy 10 (14.5%)
Glomerulonehritis 7 (10.1%)
Acute interstitial nephritis 6 (8.7%)
Sepsis 6 (8.7%)
Snake bite 5 (7.2%)
Hair dye poisoning 4 (5.8%)
Hemolytic uremic syndrome 3 (4.3%)
Fluid depletion 1 (1.4%)
Others 12 (17.4%)
Conclusions: AKI has become increasingly prevalent in developing countries, and is 
associated with severe morbidity and mortality. Many causes of AKI can be prevented by 
interventions at the individual, community, and regional levels. Efforts should be directed to 
eradicate causes of AKI, expedite diagnosis, and aggressively manage pre-renal conditions 
and specific infections.
SA-PO235
Usefullness of Presepsin, Procalcitonin and IL6 as a Biomarkers of Adverse 
Renal Outcome and Mortality After Cardiac Surgery  Alessandra Brocca, 
Grazia Maria Virzì, Maria Jimena Mucino-Bermejo, Davide Giavarina, Massimo 
de Cal, Claudio Ronco.  S Bortolo Hospital, Vicenza.
Background: Cardiac surgery (CS) is now possible in increasingly high-risk patients 
(pts): accurate evaluation of surgical risk is crucial. Mortality and negative impact on 
distant organs must be evaluated. In a large number of clinical scenarios, biomarkers have 
been proven to be reliable tools in clinical settings either for single a single biomarker 
or a biomarker panels. Presepsin has been reported to be useful for stratifying mortality 
risk among septic pts in the ICU and thus it may also be helpful in many different clinical 
situations. Procalcitonin is related to the development of postoperative complications. 
IL6 is considered to be a major mediator of the acute phase response to cardiopulmonary 
bypass. The main aim of this study is to assess the usefulness of Presepsin, Procalcitonin 
and IL6 as a biomarkers in predicting mortality and negative renal outcome among CS pts.
Methods: Observational single center study that includes 122 adult CS pts. Blood 
samples were collected at the second day after surgery. Presepsin was tested by the 
PATHFAST Immunoanalyzer system, Procalcitonin by BRAHMS PCT sensitive KRYPTOR 
and IL6 by ELISA assay. A p-value of <0.05 was considered statistically significant.
Results: We observed that Presespin and IL6 are better predictors of inhospital 
(AUC=0.831 and 0.819), 30-day (AUC=0.723 and 0.785) and global mortality (AUC=0.759 
and 0.793) than Procalcitonin (p<0.05). Pts with worse renal outcome (defined as AKI, 
change on CKD stage or need for CRRT) have significantly higher Presepsin and 
Procalcitonin levels (p<0.05). IL6 is not significantly different in pts with adverse renal 
outcome compare whit those without.
Conclusions: Presepsin and IL6 levels correlate with the risk of death better than 
Procalcitonin. Higher Presepsin and Procalcitonin levels are associated with adverse renal 
outcomes in this population. It is possible that a combination of these three biomarker in 
an inflammatory multi-biomarker panel as opposed to a single biomarker should betaken 
as “add-value” rather than a “unique-predicting” data.
Funding: Private Foundation Support
SA-PO236
Allopurinol Attenuates Rhabdomyolysis-Induced Acute Kidney Injury: 
Renal and Muscular Protection  Pedro H.F. Gois, Daniele Canale, Rildo A. 
Volpini, Daniela Ferreira, Mariana Veras, Maria H.M. Shimizu, Antonio C. 
Seguro.  Univ of São Paulo.
Background: Myoglobinuric acute kidney injury(AKI) is the most severe complication 
of rhabdomyolysis.Aim:To evaluate the efficacy of allopurinol(Allo) on rhabdomyolysis-
induced AKI.
Methods: Male Wistar rats were injected intramuscularly with 5ml/Kg body 
weight(BW) of either 50% glycerol(Gly) or 0.9% saline(S).Five groups were studied:
S(n=5),S+Allo(n=6),Gly(n=7),Gly+Allo(n=7),Gly+ivAllo(n=7).S+Allo and Gly+Allo 
rats received Allo(300mg/L) in drinking water 7 days prior to and for 24h after Gly/S 
injection.Gly+ivAllo: intravenous Allo(50mg/Kg BW) 30’ after Gly injection and 300mg/L 
in drinking water thereafter.
Results: Gly rats showed markedly reduced glomerular filtration rate(GFR,inulin 
clearance) associated with renal vasoconstriction,renal tubular damage,increased oxidative 
stress,apoptosis and inflammation.Allo treatment ameliorated all these alterations.Allo 
reduced muscular oxidative stress and accelerated its recovery.
S S+Allo Gly Gly+Allo
GFR(mL/
min/100gBW) 1.12±0.03 1.02±0.05 0.49±0.04
ace 0.78±0.08af
RBF(3h)mL/min 6.6±0.3 6.7±0.2 3.8±0.3ace 5.3±0.5
Plasma 
TBARS(nmol/mL) 1.4±0.2 1.1±0.2 6.8±1.0
ace 3.7±0.8
Muscular TBARS 0.9±0.1 0.8±0.1 1.6±0.2ace 0.8±0.1
Renal MnSOD(%) 100±2 113±27 311±55ace 126±25
Renal 
Caspase-3(%) 100±8 103±6 158±18
bce 67±5
CPK(3h)mg/dL 467±75 298±31 13.101±2.388ae 11.265±2.100ae
CPK(24h) 374±37 398±50 917±358ace 358±45
TIS 0.06±0.01 0.22±0.05 1.48±0.13ad 0.81±0.17ae
Intrarenal 
Lymphocytes 7±1 6±1 27±2
ace 13±2bf
Muscular Injury 
Score 0 0 2.2±0.2
ade 1.5±0.2ae
ap<0.001,bp<0.01vs.SF;cp<0.001,dp<0.01vs.Gly+Allo;ep<0.001,fp<0.01vs.SF+Allo.
Therapeutic Allo also improved GFR(0.78±0.06),renal blood flow(RBF)
(6.5±0.3),plasma TBARS(1.2±0.3) and tubular injury score(TIS)(0.89±0.17).
Conclusions: Prophylactic and therapeutic Allo attenuates Gly-induced AKI by 
reducing oxidative stress (systemic, muscular and renal),inflammation and apoptosis.It may 
represent a new therapeutic approach for rhabdomyolysis and myoglobinuric AKI.(FAPESP)
Funding: Government Support - Non-U.S.
SA-PO237
Cell Cycle Progression in the Early Phase of Septic Kidney  Daisuke Nakano, 
Akira Nishiyama.  Dept of Pharmacology, Kagawa Univ, Kagawa, Japan.
Background: The recovery of renal function after acute kidney injury (AKI) is likely 
controlled by proliferation of survived tubular cells in damaged nephrons containing cell 
death or sloughing. However, recent studies revealed that AKI concomitant with sepsis 
had significantly less tubular cell death than other forms of AKI, such as ischemic- and 
drug-induced AKI. It has not been examined whether septic AKI accelerates tubular cell 
proliferation in the condition with less cell death. In the present study, we examined the 
time-course changes in tubular cell proliferation after sepsis.
Methods: Lipopolysaccharide (LPS) and cecum ligation and puncture (CLP) model 
were used to induce sepsis in mice. Cell cycle progression was assessed by intravital imaging 
of Tg(FucciG1)#596Bsi (Fucci) mice, which express monomeric Kusabira-Orange2 in G1/0 
phase cells, and immunohistochemistry for Ki67 or bromodeoxyuridine in young (8-12 
weeks of age) and old (18-20 months of age) C57Bl/6 mice.
Results: Fucci mice (8 weeks of age) showed an increase in G1/0 to S transition of 
tubular cell cycle in the early phase of sepsis (within 2 hours in LPS and 4 hours in CLP). 
Ki67 and bromodeoxyuridine staining were increased only in young mice (Ki67+ cell 
number: 1.5±0.1 fold increase in both LPS and CLP mice compared to normal control), not 
in old mice (Ki67+ cell number: 0.8±0.1 fold in LPS mice and 1.0±0.1 fold in CLP mice 
compared to the control) at a similar time course observed in Fucci mice. Etoposide, an anti-
cancer drug, abolished the cell proliferation after LPS injection in young mice. Importantly, 
old mice or etoposide-treated young mice showed much worse AKI as compared to young 
mice at 24h after sepsis. Moreover, mice lacking p21, a cyclin-dependent kinase inhibitor, 
showed a marked increase in Ki67+ cells after LPS (2.2±0.1 fold increase vs. WT mice).
Conclusions: These results indicate that sepsis induces tubular cell proliferation in the 
early-phase of septic kidney. This situation may be a compensatory mechanism against the 
development of AKI since the frequency of cell proliferation is inversely correlated with 
the severity of sepsis. Moreover, cell senescence may worsen this compensation leading 
to an increased risk of AKI.
Funding: Government Support - Non-U.S.
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SA-PO238
Hepcidin Mitigates Endotoxin-Induced AKI  Yogesh M. Scindia, Paromita 
Dey, Sundararaman Swaminathan.  Medicine, Univ of Virginia, Charlottesville, VA.
Background: Sepsis is a common cause of acute kidney injury (AKI). Sepsis-associated 
inflammation induces hypoferremia and thereby limits iron availability to pathogens. It has 
been shown that hepcidin-induced degradation of ferroportin and consequent iron restriction 
are key for this hypoferremic state. Since, iron has been implicated in the pathogenesis of 
both sepsis and AKI, we hypothesized that hepcidin pretreatment would mitigate bacterial 
endotoxin-induced AKI.
Methods:    C57BL/6 were treated with saline or 50 mg of hepcidin, 24 hours prior 
to LPS (Escherichia coli O111:B4) injection (6.5 mg/kg). Renal function, injury and 
inflammatory markers were examined up to 24 hours post LPS injection. Mouse glomerular 
endothelial cells (MGEC) were cultured with 100 ng/mL LPS for 6 hours after treating 
them with and without 1 mg/mL hepcidin for 12 hours.
Results: Kidney function (as measured by serum BUN) significantly declined 2 hours 
post LPS injection and progressively deteriorated for 24 hours. This was prevented by 
hepcidin treatment (BUN: LPS; 83.55 Vs Hepcidin + LPS; 32.33, p < 0.001). Renal NGAL 
expression paralleled the changes in BUN (NGAL: LPS; 6.74 Vs Hepcidin + LPS; 0.78, p < 
0.001. Hepcidin treatment also reduced early systemic TNF alpha production following LPS 
injection (TNF alpha: LPS; 2266 Vs Hepcidin + LPS; 1248, p < 0.01). The ultra-structural 
morphology of the glomeruli revealed extensive loss of endothelial fenestrae and epithelial 
mitochondria in LPS treated mice, which was prevented by hepcidin treatment. However, 
MGEC cultures treated with or without hepcidin up-regulated endothelin gene to similar 
levels after stimulation with LPS.
Conclusions: Our results demonstrate a novel protective role of hepcidin in endotoxin-
mediated AKI, which is largely exerted through down regulation of systemic cytokine 
production.
Funding: NIDDK Support
SA-PO239
ELK-B Peptide Prevents Renal Histological Damage and Mortality in Septic 
Mice  Ana C. Souza,1 Irina Baranova,2 Jonathan Street,1 Xuzhen Hu,1 Peter S.T. 
Yuen,1 Robert A. Star.1  1Kidney Diseases Branch, NIDDK, NIH, Bethesda, MD; 
2Clinical Center, NIH, Bethesda, MD.
Background: Targeting SR-BI/II and CD36 receptors with L-37pA, an antagonist 
peptide, reduced multi-organ failure, peritoneal bacterial counts, and increased survival from 
6 to 27% in antibiotic-treated mice subjected to cecal ligation and puncture (CLP)-induced 
sepsis (J Immunol. 2012). We tested ELK-B, a peptide more specific to the CD36 receptor.
Methods: Because the free peptide was toxic, ELK-B was formulated with micellar 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine. For survival study, animals were 
randomized into two groups: CLP (N=16) and CLP+ELK-B (15 mg/kg, N=15). A blinded 
observer administered treatments every 12h until death or until euthanized per protocol. 
For acute studies, 10 mice/group were subjected to CLP+saline (CLP) or CLP+ELK-B; 
saline or ELK-B was administered IV 0 and 6h after CLP. 18h post-CLP mice were 
euthanized for peritoneal lavage, and blood/organs collection. Serum creatinine (Cr) was 
measured by HPLC, BUN by colorimetry, and AST, ALT by an autoanalyzer. PAS-stained 
kidney sections were scored for renal tubular damage. Peritoneal bacterial cell counts were 
expressed per mouse. Caspase-3 IHC was performed on spleens. Data were analyzed by 
ANOVA and log-rank test.
Results: ELK-B significantly increased survival: all CLP+vehicle mice died by 78h, 
whereas 31% of ELK-B treated mice were still alive at 7 days. The survival curves did not 
diverge until 36h. At 18h (before survival curves diverged), ELK-B did not alter Cr (sham, 
CLP, CLP+ELK-B= 0.07±0.01, 0.30±0.06, and 0.21±0.06 mg/dl); BUN, AST, or ALT. 
ELK-B significantly reduced tubular damage (p<0.001 vs sham; p<0.01 vs CLP+ELK-B). 
Spleen caspase-3 +cells were increased 18X in CLP and 6.8X in CLP+ELK-B but not 
statistically different. Log peritoneal bacterial counts were decreased 2X in CLP+ELK-B 
(p<0.05).
Conclusions: ELK-B reduced 7 day mortality and 18h renal histological damage after 
sepsis. However, it did not alter other biochemical outcomes at 18h. This suggests that it 
may act late in sepsis, perhaps by increasing bacterial killing.
Funding: NIDDK Support
SA-PO240
Renal Ischemic Preconditioning Protects against Septic Acute Kidney 
Injury via miR-21  Ping Jia,1 Yi Fang,1 Mingyu Liang,2 Xiaoqiang Ding.1  1Dept 
of Nephrology, Zhongshan Hospital, Fudan Univ, Shanghai, China; 2Dept of 
Physiology, Medical College of Wisconsin, Milwaukee, WI.
Background: Septic acute kidney injury(AKI) is one of the most common and 
life-threatening complications in critically ill patients, and there is no approved effective 
treatment. We have showen ischemic preconditioning upregulates miR-21, provides 
renoprotection against subsequent ischemia reperfusion injury. Here we studied the effects 
of ischemic preconditioning on septic AKI and its mechanism.
Methods: Bilateral renal pedicles were clamped for 15 min in mice 24 h before 
the induction of septic AKI, and septic AKI was induced by intraperitoneal injection of 
lipopolysaccharide. The effects of renal ischemic preconditioning on LPS-induced AKI were 
investigated, including changes of renal function, histology, inflammation and apoptosis 
in kidneys. The role of microRNA, miR-21, in renal protection conferred by the ischemic 
preconditioning was examined using in vivo knockdown of miR-21 and miR-21 signaling 
pathways were analyzed.
Results: We observed that renal ischemic preconditioning provided morphological 
and functional renoprotection, characterized by attenuation of renal tubular damage, 
cell apoptosis, and a reduction in inflammation in circulation. Furthermore, we found 
that renal ischemic preconditioning significantly upregulated the expression of miR-21 
in kidneys, suppressed proinflammatory factor PDCD4 expression and NF-κB activity, 
increased IL-10 production. Meanwhile, renal ischemic preconditioning also suppressed 
the expression of PTEN which is a proapoptotic protein, activating Akt signaling pathway, 
subsequently increasing the expression of Bcl-2 and inhibiting Caspase-3. A locked nucleic 
acid-modified anti-miR-21, given before renal ischemic preconditioning, knocked down 
miR-21 effectively, and upregulated its target effector PTEN expression, resulting in increase 
of apoptosis, exacerbated LPS-induced AKI.
Conclusions: Our findings domenstrate that renal ischemic preconditioning protects 
against LPS-induced AKI, and miR-21 coordinates its downstream signaling to reducing 
cell apoptosis and circulatory inflammation, contributing to renal protection.
SA-PO241
Remote Ischemic Preconditioning Protects against Contrast-Induced 
Nephropathy via Renalase Induced by TNFα/NFκB Pathway  Feng Wang, 
Zeyuan Lu, Jianyong Yin, Guangyuan Zhang, Niansong Wang.  Nephrology, 
Shanghai Jiao Tong Univ Affiliated Sixth People¶s Hospital, Shanghai, China.
Background: Renalase is a flavin adenine dinucleotide-dependent amine oxidase which 
has recently been suggested to be a reno-protective molecule. Herein we suggested that 
renalase expression induced by circulatory TNF-α which was evoked by remote ischemic 
preconditioning (rIPC) play a key role in contrast-induced nephropathy(CIN) protection.
Methods: CIN model was setup by Ioversol intravenous injection to SD rats. Limbs 
ischemic preconditioning was carried out 24 hours before CIN inducing. TNF-α blocking, 
NF-κB blocking, HIF blocking and renalase blocking were performed respectively. TNF-α 
administration was also performed as rIPC mimic. Renal injury, kidney oxidative stress, 
renal function, renalase expression, and circulating TNF-α after IPC were assessed. HK2 
exposure to TNF-α and its blocker were studied and renalase expression was assessed.
Results: Reduced tubular injury, decreased oxidative stress and improved renal function 
were observed in CIN rats following rIPC. The therapeutic effects could be neutralized 
by renalase blocking. Renalase expression was significantly up-regulated after rIPC. rIPC 
induced renalase expression could be abolished by TNF-α blocking or NFκB blocking but 
not HIF blocking. Up-regulated renalase triggered by TNF-α could also be blocked by 
NFκB both in vivo and in vitro.
Conclusions: Renalase expression which mediated by TNFα/NFκB pathway played 
an essential role in reno-protection of rIPC for CIN.
Funding: Government Support - Non-U.S.
SA-PO242
DNA Methylation in Cisplatin-Induced Acute Kidney Injury 
Chunyuan Guo,1,2 Xiao Xiao,1,2 Qingqing Wei,1,2 Zheng Dong.1,2  1Cellular 
Biology and Anatomy, Georgia Regents Univ, Augusta, GA; 2Charlie Norwood 
VA Medical Center, Augusta, GA.
Background: DNA methylation is a major epigenetic modification, which plays 
an important role in regulating gene transcription without changing primary nucleotide 
sequence. DNA methylation has been implicated in major diseases, such as cancer. 
However, the changes of DNA methylation in kidney diseases, such as cisplatin-induced 
nephrotoxicity, remain unclear.
Methods: We determined the global DNA methylation changes in cisplatin-induced 
AKI by reduced representation bisulfite sequencing (RRBS) using kidney cortex from mice 
treated with cisplatin. We also established proximal tubule-specific DNMT1 (PT-DNMT1) 
knockout mice to determine the role of DNA methylation in cisplatin-induced AKI.
Results: Totally 1.5 and 1.9 millions of CpG sites were analyzed in the control and 
cisplatin treated kidney samples, respectively. Compared with control, cisplatin-treated 
samples showed aberrant DNA methylation changes, resulting in the identification of 236 
differentially methylated regions (DMRs). Further analysis identified 15 genes that contained 
DMRs at 5’ end regulatory promoter region or 5’ UTR. To determine the pathological 
role of DNA methylation, we established the PT-DNMT1 model, in which the DNA 
methyltransferase 1 gene was specifically deleted from kidney proximal tubules. Compared 
with wide type mice, PT-DNMT1 knockout mice showed higher necrotic tubular damage at 
4 day after cisplatin injection. Although BUN did not show difference between wide type 
and knockout mice, serum creatinine was increased in knockout mice treated with cisplatin.
Conclusions: Cisplatin induced significant changes in DNA methylation in kidney 
tissues, which may contribute to gene regulation and related kidney injury.
Funding: NIDDK Support, Veterans Administration Support
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Blockade of KCa3.1 Potassium Channels Protects against Cisplatin-Induced 
Acute Kidney Injury  Cheng-Lung Chen,1 Li-Heng Pao.1,2,3,4  1Graduate Inst of 
Life Sciences; 2School of Pharmacy, National Defense Medical Center, Taipei, 
Taiwan; 3Graduate Inst of Health-Industry Technology; 4Research Center for 
Industry of Human Ecology, Chang Gung Univ of Science and Technology, 
Taoyuan, Taiwan.
Background: Anti-tumor efficacy of cisplatin chemotherapy is mainly limited by its 
toxicity to normal tissues, particularly the kidney toxicity. Tubular apoptotic cell death 
significantly contributes to the pathogenesis of cisplatin-induced acute kidney injury (AKI). 
KCa3.1, a calcium-activated potassium channel, has been reported to participate in cell 
apoptosis. However, the involvement of KCa3.1 in cisplatin-induced AKI is unknown.
Methods: We examined KCa3.1 mediates cispaltin-induced tubular apoptotic cell 
death in vitro, as well as the development of cisplatin-induced AKI in KCa3.1-/- and 
pharmacological blockade mouse models in vivo.
Results: Cisplatin treatment triggered an early induction in KCa3.1 expression, which 
is associated with apoptotic cell death in HK-2 cells, as well as with the development of 
renal tubular damage and cell apoptosis in mice. By treating with highly selective blocker 
TRAM-34, we found KCa3.1 inhibition suppressed cisplatin-induced apoptotic cell death in 
HK-2 cells. In the in vivo study, KCa3.1 deficiency reduced renal function loss, renal tubular 
damage and apoptotic marker caspase-3 inducution in kidneys after cisplatin administration 
in KCa3.1-/- mice. Pharmacological blockade of KCa3.1 by TRAM-34 similarly attenuated 
cisplatin-induced AKI in mice. Furthermore, we dissected the underlying mechanisms in 
which KCa3.1 blocking reduces cisplatin-induced apoptosis. We found KCa3.1 inhibition 
attenuated the cytochrome c release and the increase of intrinsic apoptotic mediator Bax, 
Bak and caspase-9 after cisplatin treatment. We also found KCa3.1 blocking inhibited 
cisplatin-induced the increase of ER stress mediator caspase-12, which is independent of 
calcium-dependent protease m-calpain activation.
Conclusions: Blockade of KCa3.1 protects against cisplatin-induced AKI through 
the attenuation of tubular apoptotic cell death by interference with intrinsic apoptotic 
and ER stress-related mediators, and that provides a potential target for the prevention of 
cisplatin-induced AKI.
Funding: Government Support - Non-U.S.
SA-PO244
Bax Mimotope Therapy: Effective Treatment for Ischemic Acute Kidney 
Injury (AKI)  Zhiyong Wang, Ryan M. Mulhern, Andrea Havasi, Ramon 
G. Bonegio, Steven C. Borkan.  Renal Section, Boston Univ Medical Center, 
Boston, MA.
Background: Ischemic AKI causes renal cell death partly by Bax-mediated apoptosis. 
Recent studies show that Bax requires the chaperone nucleosphosmin (NPM) for 
mitochondrial targeting and apoptosis. We propose that a mimotope that interferes with 
Bax-NPM interaction is an effective treatment for ischemic AKI.
Methods: To assess mimotope efficacy, 2 mg control or therapeutic Bax mimotope 
was administered by a single tail vein injection in 6-week old B6 mice either before or 
after renal ischemia caused by 22 min of bilateral renal pedicle clamping, an insult that 
produces severe AKI. BUN/Cr, histologic injury score, caspase 3 activity, Bax activation 
and Bax-NPM interaction were compared in each experimental group at the above time 
points (n = 8 each group).
Results: Compared to control, Bax mimotope administration 15 min before or 15 min, 
1, 2 or 3 hr after ischemia significantly improved renal function. No protection was observed 
if Bax mimotope exposure was delayed for 4 or more hours after ischemia. Although 12% 
of controls died of AKI, only 2% of animals died in the Bax mimotope groups. Despite 
equivalent Bax activation in both groups, the Bax mimotope improved histologic injury 
score, reduced caspase 3 activation and decreased Bax-NPM interaction as assessed by 
co-immunoprecipitation.
Conclusions: Selective interference of Bax-NPM interaction with a Bax mimotope 
within several hours of acute ischemia improves survival, significantly reduces the severity 
of AKI (lower BUN and Cr), decreases histologic injury score and inhibits Bax-mediated 
apoptosis downstream of Bax activation.
Funding: NIDDK Support
SA-PO245
Role of AMPK in Aristolochic Acid-Induced Acute Kidney Injury 
Anne-Emilie Decleves,1 Inès Jadot,2 Vanessa Colombaro,2 Eric De prez,1 Isabelle 
Habsch,2 Kumar Sharma,3 Nathalie Caron,2 Joelle L. Nortier.1  1Free Univ of 
Brussels; 2Univ of Namur; 3Univ of California, San Diego.
Background: Experimental aristolochic Acid nephropathy (AAN) is a pertinent 
model of tubulo-interstitial nephritis characterized by an early phase of acute kidney injury 
(AKI) leading to progressive fibrosis and chronic kidney disease (CKD). Here, the present 
model was used to determine the role of AMPK in renal outcome and its involvement in 
the AKI-to-CKD transition.
Methods: C57BL/6J male mice were randomly subjected to i.p. injection of either 
sterile saline solution, AA, AA+AICAR (the specific AMPK activator) for 4 days. Mice 
were then euthanized either at day 5 or day 20.
Results: AA-treated mice displayed loss of renal function, as reflected by significant 
increases in plasma creatinine level and proteinuria at days 5 and 20. In addition, impairment 
of tubular cells was also observed by the significant increase in urinary excretion of 
lysosomal enzyme N-acetyl-ß-D-glucosaminidase in AA-treated mice. These changes were 
prevented by AICAR treatment. To further determine the role of AMPK in AA-induced 
oxidative stress, Nox1, 2 and 4 were investigated at the mRNA levels. No changes were 
observed for Nox1 and 4. However, Nox2 was significantly increased in AA-treated mice 
while this rise was prevented by AICAR treatment at day 5 but not at day 20. Moreover, 
the urinary hydrogen peroxide level, a stable product of ROS production, was significantly 
higher after AA intoxication and reduced with AICAR. Regarding inflammation, AA mice 
exhibited a significant increase in MCP-1 mRNA level. This rise was only prevented by 
AICAR at day 5. Finally, at day 5, there was no significant macrophage infiltration with 
AICAR while at day 20, this significant increase was not prevented by AICAR.
Conclusions:  These findings show a beneficial effect of AMPK in AA-induced AKI. 
In view of these data, we suggest that chronic AICAR treatment is necessary for complete 
nephroprotection and recovery. The activation of AMPK represents a potential strategy to 
prevent the transition from AKI-to-CKD.
Funding: Government Support - Non-U.S.
SA-PO246
Nrf2 Activation in Tubular Cells Prevents Progression of AKI to CKD 
Masahiro Nezu,1,2,3 Tomokazu Souma,1,2,3 Sadayoshi Ito,2 Norio Suzuki,3 
Masayuki Yamamoto.1  1Dept of Medical Biochemistry, Tohoku Univ Graduate 
School of Medicine, Sendai, Miyagi, Japan; 2Div of Nephrology, Endocrinology, 
and Vascular Medicine, Tohoku Univ Graduate School of Medicine, Sendai, 
Miyagi, Japan; 3Div of Interdisciplinary Medical Science, Tohoku Univ Graduate 
School of Medicine, Sendai, Miyagi, Japan.
Background: Acute kidney injury (AKI) is one of the major risk factors for chronic 
kidney disease (CKD). Reactive oxygen species are generated by ischemia-reperfusion 
injury (IRI) during transition of AKI to CKD, and oxidative stress contributes to defects 
of renal tubular cells. Nrf2 is a master transcription factor for cellular defense against 
oxidative stress, and an E3 ubiquitin ligase subunit Keap1 negatively regulates Nrf2 activity. 
Here, we evaluated protective roles of the Keap1-Nrf2 system in AKI-to-CKD transition.
Methods: Unilateral ischemia reperfusion injury (UIRI) was performed to induce rodent 
model of AKI-to-CKD. Hypomorphic Keap1 knockdown mutant (KKD) and tubular-specific 
Keap1-null mutant (TKO) mice were used for genetic activation of Nrf2. A Keap1 inhibitor 
CDDO-Im was used for pharmacological activation of Nrf2.
Results: Remaining tubular areas at 14 days after UIRI were 64%, 51% and 34% in 
KKD, TKO and wild-type mice, respectively compared with their contralateral kidneys. 
CDDO-Im treatmetne after UIRI to wild type mice also protected againtst tubular defects 
(CDDO-Im, 63%). Nrf2-induceible antioxidant genes (Nqo1, Hmox1, Gclc, Gclm, and 
Srxn1) were transiently up-regulated in 3-6 hours after UIRI in wild-type kidneys, while 
both genetic and pharmacological activation of Nrf2 maintained expression of these genes 
at high levels throughout the observation period.
Conclusions: Activation of Nrf2 alleviates IRI-induced tubular loss through enhancing 
the antioxidant response system. Nrf2 inducers are one of prospective therapeutic candidates 
for preventing AKI-to-CKD transition.
Funding: Pharmaceutical Company Support - Chugai Pharmaceutical Co.
SA-PO247
Acute Kidney Injury in the Rat Is Prevented by Pirfenidone 
Ixchel Quetzaliztli Lima Posada,1 Francesco Fontana,1,3 Nathan Berman,1,2 
Gianni Cappelli,3 Norma Bobadilla.1  1Inst de Investigaciones Biomédicas, 
UNAM e Inst Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 
Mexico, Mexico; 2Univ Panamericana, Mexico, Mexico; 3Univ degli studi di 
Modena e Reggio Emilia, Modena, Italy.
Background: Pirfenidone (PFN)  is an orally active small molecule which acts mainly 
through an anti-fibrotic effect, but also possesses antioxidant and anti-inflammatory 
properties.This study was designed to evaluate the effect of the prophylactic treatment 
with PFN on acute kidney injury (AKI) due to bilateral renal ischemia (I/R) in the rat.
Methods: We studied three groups of rats: 1) sham operated (S) 2) rats undergone 
20 min of ischemia and 24-h of reperfusion and, 3) rats treated with PFN (700 mg/kg), 
24-h before ischemia (I/R+PFN). Serum creatinine, creatinine clearance (CrC) protein 
excretion, urinary levels of Hsp72 (UHsp72V) and nitrates and nitrites (UNO2/NO3V) 
were assessed. Mean arterial pressure (MAP) and renal blood flow (RBF) were recorded 
24-h after surgery. Tubular injury (TI) was evaluated in fixed kidneys by counting the cast 
number and the number of injured tubules per field.
Results: As expected, the I/R group showed a reduction in CrCl (I/R 0.22 ± 0.04 vs. 
S 0.36 ± 0.06 ml/min/100 g BW; p<0.05), urinary output (I/R 20±9.5 vs. S 32.7±19.3 ml/
day; p<0.05), RBF (I/R 1.08 ± 0.37 vs. S 1.53±0.17 ml/min/100 g BW; p<0.05), and a 
significant increase in UHsp72V assessed by Western blot. Extensive TI was evidenced by 
histological analysis. These alterations were associated with a decrease in UNO2/NO3V (I/R 
3.1±1.3 vs. S 5.4±2.5 mmol/24-h). In contrast, I/R+PFN group showed restoration of CrCl 
(I 0.33± .04 ml/min/100g BW; p<0.05), urinary output (47.5 ± 5.7 ml/day; p<0.05), RBF 
(1.51±0.15 ml/min/100g weight; p<0.05). The levels of urinary Hsp72 were undetectable 
or very low and the histological signs of TI were significantly reduced. Interestingly, UNO2/
NO3V was completely recovered (7.05±0.78 mmol/24-h; p<0.05).
Conclusions: Our results revealed that pre-treatment with PFN prevents AKI in the rat. 
Part of its renoprotective effects seems to be related with the restoration of NO production. 
These findings suggest that PFN could be a promising tool in the prevention of AKI.
Funding: Government Support - Non-U.S.
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HDAC8 Plays a Critical Role in the Epigenetic Activation of Fibroblasts and 
the Pathogenesis of Renal Fibrosis  Scott R. Manson, Qiusha Guo, Katelynn 
H. Moore, Paul F. Austin.  Dept of Surgery, Div of Urology, Washington Univ, 
St. Louis, MO.
Background: The development of renal fibrosis is associated with changes in the 
expression of approximately 10% of the genome, suggesting widespread transcriptional 
dysregulation. Nonetheless, the roles of critical epigenetic pathways in disease progression 
remain poorly understood. Here, we examine the biological and therapeutic importance 
of histone deacetylases (HDACs) in the function of fibroblasts and the pathogenesis of 
renal fibrosis.
Methods: Renal fibrosis was modeled in vitro by treatment of NRK-49F fibroblasts 
with the pro-fibrotic cytokine TGF-β and in vivo in mice by unilateral ureteral obstruction 
(UUO). The role of HDAC proteins was assessed by treatment with the broad spectrum 
HDAC inhibitor Trichostatin A (TSA) and the HDAC8-specific inhibitor PCI-34051. 
The translational relevance of these findings was assessed in patients who underwent a 
nephrectomy following UPJ obstruction.
Results: UUO leads to a 6.1-fold increase in HDAC8 expression that localizes 
specifically to myofibroblasts. In NRK-49F cells, treatment with PCI-34051 promotes 
myofibroblast differentiation and apoptosis, but suppresses proliferation and matrix 
synthesis. These findings extend to the injured kidney in vivo, where HDAC inhibition 
results in a 41.6% decrease in COLIA1 and a 61.6% decrease in α-SMA. Furthermore, 
there is a 77.9% decrease in the interstitial proliferative response, a 43.0% decrease in 
myofibroblast number, and a 31.1% decrease in renal fibrosis. Finally, the development of 
renal fibrosis in patients with obstructive kidney disease is associated with a 32.1% increase 
in the number of HDAC8-positive cells.
Conclusions: Together, these findings demonstrate that HDAC8 plays a critical role 
in regulating fibroblast activation. Treatment with HDAC inhibitors is also an effective 
therapeutic approach to reverse the epigenetic changes associated with the pathogenesis 
of renal fibrosis. Finally, since an increase in HDAC8 expression occurs in patients during 
disease progression, HDAC8-targeted therapies have therapeutic potential for the treatment 
of chronic kidney disease.
Funding: NIDDK Support, Private Foundation Support
SA-PO249
Reciprocal Effects of HDAC1 and HDAC2 Deletion on Renal Ischemia-
Reperfusion Injury  David Dean Aufhauser,1 Zhonglin Wang,1 Guanghui Ge,1 
Tricia Bhatti,2 Wayne W. Hancock,2,3 Matthew H. Levine.1  1Surgery, Hospital 
of the Univ of Pennsylvania and the Children’s Hospital of Philadelphia, 
Philadelphia, PA; 2Pathology and Laboratory Medicine, The Children’s Hospital 
of Philadelphia, Philadelphia, PA; 3Pathology and Laboratory Medicine, 
Hospital of the Univ of Pennsylvania, Philadelphia, PA.
Background: Histone/protein deacetylases proteins (HDACs) have been implicated 
in renal ischemia-reperfusion injury (IRI). HDACs 1 and 2 are highly homologous Class 
I HDACs thought to have similar function.
Methods: This study included wild type C57BL/6 (B6) and inducible HDAC1- or 
2- gene deleted mice (HDAC1KO and HDAC2KO). Renal-specific or extra-renal gene 
deletion was achieved with transplantation, native nephrectomy, and subsequent gene 
deletion. Warm IRI consisted of unilateral clamping of the renal pedicle and contralateral 
nephrectomy. Cold IRI was achieved through procurement, controlled interval of cold 
storage, and transplantation.
Results: HDAC1KO mice had impaired renal IRI tolerance compared to controls with 
higher BUN levels (p<0.01; Figure 1A) and increased fibrosis post-injury. HDAC2KO mice 
had improved early renal function (p<0.01; Figure 1B) and decreased fibrosis (p<0.01) 
compared to controls and tolerated extended periods of ischemia. In transplant models, renal-
specific HDAC2KO mice had superior IRI tolerance with less renal impairment (p<0.01) 
and decreased fibrosis (p<0.01) compared to extra-renal HDAC2KO and controls. After 
transplantation with 18 hours of cold ischemia, HDAC2KO donor kidneys had improved 
BUN (p=0.02) and survival compared to controls.
Conclusions: HDAC1 and 2 have reciprocal effects on murine renal IRI tolerance, 
with HDAC1 deletion increasing vulnerability and HDAC2 deletion providing protection. 
The effect of HDAC2 deletion is profound, is intrinsic to the kidney, and extends to cold 
ischemia and renal transplantation.
Funding: NIDDK Support
SA-PO250
Renoprotective Effect of Long Acting Thioredoxin by Modulating 
Oxidative Stress and Macrophage Migration Inhibitory Factor against 
Rhabdomyolysis-Associated Acute Kidney Injury  Hiroshi Watanabe,1 Kento 
Nishida,1 Masafumi Fukagawa,2 Toru Maruyama.1  1Dept of Biopharmaceutics, 
Graduate School of Pharmaceutical Sciences, Kumamoto Univ, Kumamoto, 
Japan; 2Div of Nephrology, Endocrinology and Metabolism, Tokai Univ School 
of Medicine, Kanagawa, Japan.
Background: Rhabdomyolysis-associated acute kidney injury (AKI) is a serious 
life-threatening condition. As such, more effective strategies are needed for its prevention 
and treatment. Although thioredoxin-1 (Trx) possesses superior biological activities, such 
as anti-oxidative and anti-inflammatory effect via the modulating macrophage migration 
inhibitory factor (MIF), its short blood retention limits the therapeutic application. To 
overcome this, we engineered long acting Trx by genetically fused with human serum 
albumin (HSA-Trx), and examined its renoprotective effect against glycerol-induced AKI.
Methods: HSA-Trx was prepared by using Pichia expression system. The mouse 
model of rhabdomyolysis-associated AKI was induced by the administration of a 50% 
glycerol solution.
Results: An intravenous HSA-Trx pre-treatment attenuated the glycerol-induced 
decline in renal function, compared to a PBS, HSA or Trx alone. HSA-Trx caused a 
reduction in the tubular injuries and in the number of apoptosis-positive tubular cells. Renal 
superoxide, 8-hydroxy deoxyguanosine, nitrotyrosine and the plasma Cys34-cysteinylated 
albumin were clearly suppressed by the HSA-Trx treatment. Prior to decreasing TNF-α and 
IL-6, HSA-Trx suppressed an increase of plasma MIF level. In LLC-PK1 cells, HSA-Trx 
decreased the level of reactive oxygen species and lactate dehydrogenase release induced 
by myoglobin. HSA-Trx treatment resulted in a threefold increase in the survival of lethal 
glycerol-treated mice. The post-administration of HSA-Trx at 1 and 3 hr after glycerol 
injection exerted a significant renoprotective effect.
Conclusions: HSA-Trx, a long acting Trx, has potential for use in the prevention 
and treatment of rhabdomyolysis-associated AKI via its extended effects of modulating 
oxidative stress and MIF.
SA-PO251
Selective Endothelin-A Receptor Antagonism Prevents the Progression of 
Acute Kidney Injury to Chronic Kidney Disease  Neeraj Dhaun.  Queen’s 
Medical Research Inst, Univ of Edinburgh, Edinburgh, United Kingdom.
Background: AKI is common and associated with significant morbidity and mortality. 
AKI often progresses to CKDand endothelin-1 (ET-1) contributes to this. We hypothesized 
that therapeutic administration of selective ETA receptor antagonism would protect from 
the transition of AKI to CKD.
Methods: 28 FVB mice underwent prolonged (50min) unilateral ischemia-reperfusion 
injury (IRI) with 28d recovery. 14 mice received daily selective ETA antagonism (sitaxentan) 
starting 24h after IRI. We assessed blood pressure (BP) via telemetry, vascular function, 
renal injury and measures of the ET system.
Results: Systolic BP increased by ~5mmHg after IRI and was associated with vascular 
dysfunction in both resistance and conduit vessels. Sitaxentan partly prevented both of 
these. At 28d after IRI kidney weight was reduced (-55%) and associated with significant 
macrophage infiltration and fibrosis compared to the contralateral control kidney. Mice 
treated with sitaxentan had normal kidney weight, reduced macrophage infiltration and 
less fibrosis: IRI kidney vs. control kidney vs. IRI kidney with sitaxentan: F4/80 stain/high 
power field: 2.5vs.0.2vs.0.8%; picosirius red stain/high power field: 8.6vs.0.48vs.3.1%. For 
both macrophage infiltration and fibrosis, p<0.05 for IRIvs.control and for IRIvs.IRI with 
sitaxentan, p=ns for control vs. IRI with sitaxentan. Furthermore, an up-regulation of both the 
ETA (28-fold) and ETB (2-fold) receptors as well as pre-pro-ET-1 (10-fold) mRNA was seen 
in both the cortex and medulla of the IRI kidney relative to control. With sitaxentan treatment 
ETA/ETB receptor and pre-pro-ET-1 mRNA remained similar to baseline levels. Finally, 
renal ET-1 production increased following IRI and this was prevented by ETA receptor 
antagonism (fractional excretion of ET-1: IRIvs.IRI with sitaxentan: 47vs.16%, p<0.05).
Conclusions: In an in vivo model of AKI progressing to CKD, ETA receptor antagonism 
reduced BP and vascular dysfunction and prevented progression of renal injury and 
ET system activation after AKI. Therefore, selective ETA receptor antagonism offers a 
potentially novel therapy for AKI. Translational studies are now warranted.
SA-PO252
Inhibition of Vascular Adhesion Protein-1 Suppresses Neutrophil 
Infiltration and Preserves Renal Function in the Rat Model of Renal 
Ischemia–Reperfusion Injury  Shinji Tanaka, Tetsuhiro Tanaka, Reiko Inagi, 
Masaomi Nangaku.  Div of Nephrology and Endocrinology, The Univ of Tokyo 
Graduate School of Medicine, Tokyo, Japan.
Background: Vascular adhesion protein-1 (VAP-1) is an adhesin expressed in 
endothelial cells. With its unique properties as an ectoenzyme which catalyzes oxidative 
deamination of primary amines, VAP-1 plays a critical role in leukocyte trafficking. In light 
of a growing body of evidence that VAP-1 controls inflammation in various organs, such 
as the liver and the lung, we examined the effect of VAP-1 inhibition in the rat model of 
renal ischemia–reperfusion injury.
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Methods: Rats were subjected to left renal ischemia for 45 min after right nephrectomy, 
followed by reperfusion for 48 h. A specific VAP-1 inhibitor, RTU-1096 (R-Tech Ueno, 
Tokyo, Japan), or vehicle was administered to rats since 7 days before the surgery (mixed 
with feed, 40 mg/kg/day).
Results: Immunofluorescence studies suggested that VAP-1 is expressed not only in 
endothelial cells of peritubular capillaries but also in interstitial cells of non-endothelial 
lineage. In vitro, higher mRNA expression of VAP-1 was confirmed in cultured pericytes. 
In vivo, VAP-1 enzyme activity in the whole kidney was unaffected by the surgery, but 
following VAP-1 inhibition by RTU-1096 (0.9±0.1 vs. 7.0±1.3 pmol/mg protein/min), 
renal function was significantly better preserved as compared to the vehicle group (BUN: 
69±6 vs. 139±15 mg/dL, Cr: 1.4±0.1 vs. 2.5±0.2 mg/dL; p<0.01), which was accompanied 
by amelioration in histological tubular injury and decreased KIM-1 mRNA levels. 
Immunohistochemical analysis revealed a significantly decreased number of neutrophils 
in the corticomedullary junction in the drug group, whereas the number of macrophages 
was similar. VAP-1 inhibition resulted in significantly lower mRNA levels of CXCL1 and 
CXCL2 in the kidney without affecting chemokines involved in macrophage recruitment, 
such as MCP-1, or major adhesion molecules, VCAM-1 and ICAM-1.
Conclusions: These data suggest that VAP-1 plays an important role in renal ischemia–
reperfusion injuries by controlling neutrophil infiltration, and offer a promising view that 
its inhibition can be a novel therapeutic target in ischemic acute kidney injury.
Funding: Government Support - Non-U.S.
SA-PO253
Kim-1 Overexpressing Transgenic Zebrafish Identify mTOR as an Effector 
of Kim-1-Mediated Kidney Injury in Fish and Mice  Wenqing Yin, Said 
Movahedi naini, Dirk M. Hentschel, Benjamin D. Humphreys, Joseph V. 
Bonventre.  Renal Div, Brigham and Women’s Hospital, Boston, MA.
Background: Mammalian kidney injury molecule 1 (KIM-1), an epithelial phagocytic 
receptor, is markedly upregulated in the proximal tubule in various forms of acute and 
chronic kidney injury in humans and many other species. Here, we characterized the 
zebrafish Kim family to consist of Kim-1, Kim-3 and Kim-4. By genetically expressing 
constitutive or tamoxifen-induced Kim-1 in zebrafish kidney tubules, we identified mTOR 
as an effector in Kim-1-mediated kidney injury. We then validated mTOR as a therapeutic 
target for kidney injury and fibrosis in KIM-1 overexpressing transgenic mice.
Methods: We created two transgenic zebrafish models of Kim-1 overexpression in 
nephrons employing the cdh17 promoter. One model utilized a constitutively active promoter 
while the other utilized a tamoxifen-induced Cre-ERT2 recombinase to express Kim-1 in 
nephrons in a temporally-controlled manner. The role of mTOR signaling was evaluated 
using the inhibitor rapamycin. Zebrafish GFR was determined using the elimination rate 
of fluorescein-labeled dextran.
Results: Kim-1 was markedly upregulated after gentamicin-induced kidney injury and 
had conserved phagocytic activity in zebrafish. Both constitutive and tamoxifen-induced 
expression of Kim-1 in zebrafish kidney tubules resulted in shedding of the tubule brush 
border, reduced GFR, pericardial edema and increased mortality rate. Kim-1-induced kidney 
injury was associated with inhibition of growth of adult fish. Kim-1 expression led to mTOR 
pathway activation, and inhibition of this pathway with rapamycin increased survival. mTOR 
pathway inhibition in KIM-1 overexpressing transgenic mice also significantly reduced 
serum creatinine, proteinuria, tubular injury and kidney inflammation.
Conclusions: Persistent Kim-1 expression resulted in chronic kidney damage and 
growth impairment in zebrafish. Kim-1-mediated kidney tubular injury was mediated 
by the mTOR signaling pathway. This observation in zebrafish predicted the role of the 
mTOR pathway and therapeutic efficacy of rapamycin to protect the mouse kidney against 
KIM-1-mediated kidney injury and fibrosis.
Funding: NIDDK Support
SA-PO254
Treg and ILC2 Contribute to IL233 (a Novel Fusion Cytokine)-Mediated 
Protection in AKI  Marta Stremska,1 Liping Huang,1 Sheethal Jose,1 Amandeep 
Bajwa,1 Diane L. Rosin,1,2 Mark D. Okusa,1 Rahul Sharma.1  1CIIR, Univ of 
Virginia, Charlottesville, VA; 2Dept of Pharmacology, Univ of Virginia.
Background: Inflammation is an early event in AKI and studies have shown regulatory 
T cell (Treg)-mediated protection in inflammation driven injuries. Since we found that 
interleukin (IL)-2 upregulates IL-33 receptor-ST2 on CD4 T-cells, we hypothesized that 
IL-2 and IL-33 cooperate to expand endogenous Tregs. Indeed, a proportion of Tregs 
constitutively expressed ST2 and IL-33 contributed to promote Tregs. IL-2 and IL-33 
in combination or as IL233 fusion cytokine, but not alone protected mice from IRI, with 
IL233 being more efficient than the combination.
Methods: We designed a fusion cytokine (IL233) containing the activities of IL-2 
and IL-33 for better targeting of Tregs. The cytokines were expressed in E.coli, purified to 
homogeneity and tested in a mouse model of ischemia reperfusion injury (IRI). C57BL/6 
male mice were pretreated (ip) with different doses of cytokines prior to 26 min of bilateral 
ischemia and 24 hours of reperfusion. Kidneys were characterized for function, acute tubular 
necrosis and the profile of infiltrating cells.
Results: IL-2 and IL-33 in combination or as IL233 fusion cytokine, but not alone 
protected mice from IRI, with IL233 being more efficient. Our data suggests that the IL233 
treatment first increases splenic levels of Tregs followed by their mobilization. Since both 
IL-2 and IL-33 also promote Th2 response, an increase in IL-4 and IL-5, and a decrease 
in Th1 cytokines IFNγ and TNFα was seen, indicating a shift towards a protective Th2 
response. Protected mice had a higher proportion of innate lymphoid cells 2 (ILC2) in the 
blood and the kidneys. Neutrophil infiltration in the kidneys was significantly lowered in 
IL233 treated mice. Treg adoptive transfer studies revealed higher degree of protection in 
mice injected with Tregs obtained from mice pretreated with IL233. Adoptive transfer of 
ILC2, pretreated with IL233 also protected against IRI. In vitro experiments with IL233 
pre-treated Tregs revealed their higher suppressive function.
Conclusions: Thus, IL233 cytokine attenuates kidney inflammation to protect from 
IRI and bears strong potential to be a therapeutic agent for AKI.
Funding: NIDDK Support
SA-PO255
Vagus Nerve Stimulation (VNS) Protects Kidneys from Ischemia-
Reperfusion Injury Through Alpha 7 Nicotinic Acetylcholine Receptor 
(α7nAChR) Expressing Splenocytes  Tsuyoshi Inoue,1 Chikara Abe,2 Stefan 
Moscalu,1 Liping Huang,1 Hong Ye,1 Diane L. Rosin,1,2 Patrice G. Guyenet,2 
Mark D. Okusa.1  1Depts of Medicine, Univ of Virginia Health System; 2Depts 
of Pharmacology, Univ of Virginia Health System, Charlottesville, VA.
Background: The nervous and immune systems interact in complex ways to maintain 
homeostasis and respond to stress or injury. The inflammatory reflex referred to as the 
cholinergic anti-inflammatory pathZay CAP modulates innate and adaptive immunity, 
and modulation of the reflex by VNS is effective in inflammatory disease models. The effect 
of VNS on AKI has never been examined. Experimental activation of vagal efferent fibers 
suppresses inflammation in a manner that depends on α7nAChR in the CAP. However, the 
site of the essential α7nAChR was not established.
Methods: We applied electrical VNS (5 Hz, 50 µA for 10 min) 24 hr prior to kidney 
IRI and assessed kidney injury by evaluating plasma creatinine (PCr, mg/dl), kidney Kim-1 
mRNA expression and histology (H&E). The effect of VNS on IRI was assessed by: a) 
prior splenectomy and b) adoptive transfer of splenocytes from VNS-stimulated mice to 
recipient mice subjected to IRI.
Results: VNS applied 24 hr prior to IRI markedly attenuated IRI. VNS reduced the 
IRI-induced increase in PCr by 65% (P<0.01) and Kim-1 mRNA expression in whole 
kidney by >70% (P<0.01). H&E–stained kidney sections confirmed the functional data. 
When splenectomy was performed 7 d before VNS and IRI, the protection by VNS was 
abolished. Adoptive transfer of splenocytes from VNS-treated mice to recipient mice 
subjected to IRI provided greater protection than splenocytes from mice who received 
sham VNS stimulation (PCr: 0.41 and 1.54 (P<0.001) for VNS- and sham VNS-treated 
splenocytes, respectively). To evaluate the role of α7nAChR, VNS was initiated 24 hr prior 
to IRI in α7nAChR knock out (α7KO) and WT mice. Compared to the protective effect of 
VNS on IRI in WT mice, no protection was observed in α7KO mice. In addition, recipient 
mice were protected (PCr) from IRI if they received splenocytes from VNS-treated WT 
mice (0.41) but not from VNS-treated α7KO mice (1.57, P<0.001).
Conclusions: VNS-induced protection from IRI is consistent with activation of the 
CAP.
SA-PO256
Elevations of Intraglomerular Pressure Exacerbate Ischemia Reperfusion 
Injury-Induced Acute Kidney Injury  Jie Zhang, Lei Wang, Shaohui Wang, 
Gensheng Zhang, Jin Wei, Ruisheng Liu, Kay-Pong D. Yip.  Molecular 
Pharmacology & Physiology, Univ of South Florida, Tampa, FL.
Background: The physiological and pathophysiological mechanisms of renal ischemia 
reperfusion (IR)-induced acute renal injury (AKI) are complex and have not been elucidated. 
We sought to determine whether intraglomerular hydrostatic pressure (Pg) during the 
ischemic phase plays a critical role in IR-induced AKI.
Methods: AKI was induced in three groups of C57BL/6J mice at 37° C with IR by 
18 min of bilateral clamping of renal arteries (RA), pedicles (RP), and pedicles plus pre-
clamping of ureters 20 min before ischemia (PU). Free flow proximal tubular pressure (Pf) 
was measured with servo-nulling method during ischemia. Pf was used as an index of Pg.
Results: We found that mean Pf was higher in PU mice (48.9±7.5 mmHg) than in 
RP mice (34.6±3.6 mmHg). The RA mice had lower Pf (1.6±1.2 mmHg) when compared 
to Sham operated mice (9.54±2.2 mmHg). In separate experiments, the renal injury was 
determined 24 hours after IR in these mice. Plasma creatinine was significantly increased 
in all three groups compared with sham-operated group. The mean plasma creatinine were 
2.1±0.07 mg/dl, 1.85±0.08 mg/dl, and 0.45±0.7 mg/dl for PU, PR and RA, respectively. 
The mean plasma Kidney Injury Molecule-1(KIM-1) levels were 2761±493 pg/ml in PU, 
1548±220 pg/ml in RP and 734±234 pg/ml in RA group, respectively. Histology by PAS 
staining showed that all AKI mice had a significant increase in renal tubular necrosis 
compared with sham-operated mice. However, there were more tubular necrosis in the 
cortex, medulla or cortex-medulla junction area in PU mice (3.1±1.3%, 34.1±8.5% and 
54.4±6.9%) than in RP mice (1.2±0.5%, 23.0±9.2% and 50.1±12.7%). RA mice had the 
least tubular necrosis (0.23±0.1%, 8.9±4.5% and 31.7±10.2%).
Conclusions: We found that RA mice had lowest intraglomerular pressure and renal 
injury and that PU mice had highest intraglomerular pressure and most severe renal injury. 
These data indicate that elevations of intraglomerular and tubular pressure exacerbate IR-
induced AKI. Intraglomerular and tubular pressure may be a novel therapeutic target for AKI.
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SA-PO257
GFR in Conscious Mice After Sepsis: Role of Tubuloglomerular Feedback 
Jonathan Street, Yuning George Huang, Peter S.T. Yuen, Robert A. Star.  NIDDK, 
Bethesda, MD.
Background: Reabsorption of glomerular filtrate by the tubules is an energy intensive 
process. During sepsis the ability of the tubules to meet this energy demand may be 
impaired. To prevent renal salt wasting during sepsis it is hypothesized that activation of 
tubuloglomerular feedback reduces GFR and subsequently the metabolic demand on the 
tubules – “acute renal success”. Mice without tubuloglomerular feedback should maintain 
higher levels of GFR. In conscious mice we detected early changes in GFR using a novel 
transcutaneous measurement of a fluorescent filtration marker. Because adenosine 1a 
receptor (A1aR) signaling is required for tubuloglomerular feedback we directly measured 
GFR following sepsis in A1aR knockout mice.
Methods: Sepsis was induced in male A1aR knockout mice and littermate controls 
by cecal ligation and puncture. GFR was monitored in awake mice for 5 hours by 
plasma disappearance of FITC-Sinistrin, injected at 0 and 90 minutes after surgery, and 
its transcutaneous fluorescence measured by a miniaturized fluorimeter attached to the 
mouse back.
Results: The baseline GFR was similar in A1aR WT and KO mice. In WT mice, 
GFR was stable during the first hour following induction of sepsis. GFR slowly declined 
over hour two, and then fell rapidly to <10 % of normal and remained low for 5 hours. In 
contrast, the GFR was lower in KO mice than in WT mice in the first hour following sepsis 
(p=0.0226), then fell gradually to 27% of normal, with a smaller decrease observed after 
2 hours compared to WT mice (p=0.0286).
Conclusions: In mice lacking tubuloglomerular feedback, unexpectedly, GFR begins 
to decrease earlier after sepsis suggesting impaired autoregulation. The sudden decrease 
in GFR in WT mice at 2 hours after induction of sepsis does not occur in A1aR KO mice. 
Tubuloglomerular feedback modestly supports, not suppresses, GFR in the first hour 
following sepsis, and only later acts to suppress GFR.
Funding: NIDDK Support
SA-PO258
Renal Functional Reserve May Be Inferred from Variation of Renal 
Resistive Index: Preliminary Evidence  Sara Samoni,1,2 Federico Nalesso,2 
Gianluca Villa,2 Silvia De Rosa,2 Ilaria Petrucci,1 Massimo de Cal,2 Fiorenza 
Ferrari,2 Alessandra Brendolan,2 Mario Meola,1 Claudio Ronco.2  1Sant’Anna 
School of Advanced Studies, Pisa; 2IRRIV, Vicenza.
Background: The increase of glomerular filtration rate(GFR)after a protein load 
represents the renal functional reserve(RFR).Mechanical abdominal stress(MAS),through 
the compression of renal arteries and the consequent reduction of renal blood flow,can 
activate the autoregulation mechanism to maintain glomerular perfusion.Both phenomena 
are related to the afferent vasodilation,which can be displayed by the drop of renal resistive 
index(RI)measured by colorDoppler.We hypothesized that the variation of RI during MAS 
may predict the RFR.
Methods: In 15 healthy volunteers,MAS was performed through the application of a 
saline bag on abdominal wall.According to the performed dose-response curve,we used bags 
which weigh 10% of subject’s BW.We recorded RI in mesorenal interlobar arteries each min 
for the 10 min of MAS.The RI reduction was defined by the difference between baseline 
RI and the lowest RI reached during MAS and expressed as percentage reduction(pDRI).
RFR was measured through a standardized protein loading test.Spearman’s correlation was 
applied to evaluate if pDRI correlates with RFR.
Results: We enrolled 9M and 6F with a median age of 30(24-57)yrs old.The median 
baseline CrCl was 99.2(70.3-132.8)ml/min/1.73m2.The RFR ranged between 11.55%and 
134.66%with a median value of 38.55%.The median baseline RI was 0.60(0.50-0.67)while 
pDRI ranged between 13.33%and 29.23%with a median value of 20%.The correlation 
between pDRI and RFR was 80.71%(p<0.001).According to physiology,RFR and pDRI may 
not be directly proportional;indeed,while ranges of RFR may widely broaden,pDRI should 
reach a plateau value.For this reason,we analyzed the linear regression model between pDRI 
and logarithm(ln)of RFR.According to this model,we found that an increase in pDRI was 
associated to an increase in the ln of RFR(coef0.10,p<0.001,95%CI:0.06;0.15,R20.66).
Conclusions: Our results suggest that the variation of RI during MAS is an indirect 
measure of RFR,putting the bases for the development of a stress test that could be used 
for a rapid screen of RFR before potentially nephrotoxic procedures.
SA-PO259
5-Aminolevulinic Acid Attenuates Rhabdomyolysis-Induced Acute Kidney 
Injury in Mice  Atsushi Uchida, Minoru Satoh, Tamaki Sasaki, Naoki Kashihara. 
Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, 
Japan.
Background: Rhabdomyolysis often occurs after severe skeletal muscle injury, 
and high mortality have been reported with the acute kidney injury (AKI) that develops 
subsequently. Thus, the establishment of effective prevention and treatment is a pressing 
problem. 5-Aminolevulinic acid (ALA) is the naturally occurring metabolic precursor 
of heme, and serves as protein material related to energy production. Previous study 
demonstrated that ALA has the potential to prevent cisplatin-induced AKI via the induction 
of heme oxygenase (HO)-1, and prevention of tubular apoptosis. We hypothesize that 
ALA plays a renoprotective role via the induction of HO-1 and anti-apoptotic pathway in 
rhabdomyolysis-induced AKI.
Methods: Male C57BL/6 mice were used.Rhabdomyolysis-induced AKI was induced 
by intramuscular injection of glycerol (50%) 5 ml/kg bw. ALA (30 mg/kg) was administrated 
at 24 hr before or 24 hr after glycerol administration. These mice were sacrificed at 72 h 
after glycerol injection, and the blood and renal tissues were harvested. In vitro experiment, 
human proximal tubule cells were stimulated by 100 uM hemin to induce apoptosis. Cells 
were incubated for 24 hr with or without 1 mM ALA. Apoptotic cells were examined by 
TUNEL staining and caspase-3 expression.
Results: In vivo experiments, serum creatinine, blood urea nitrogen and urine NGAL 
excretion were increased in glycerol-injected group compared with saline-injected control 
group. ALA significantly reduced these changes in both pre and post treatment. ALA also 
ameliorated glycerol-induced morphological tubular damages. HO-1 level was increased 
in glycerol-injected group and further up-regulated by ALA treatment. ALA significantly 
attenuated macrophage infiltration and pro-inflammatory cytokine (IL-1beta and TNFα) 
expression. In vitro experiments, TUNEL-positive cells and caspase-3 expression were 
increased by hemin and were significantly reduced by ALA co-treatment.
Conclusions: ALA has renoprotective effects in glycerol-injected AKI. ALA is already 
used for tumor diagnosis in human. So the safety of the drug is proved in clinical use. ALA 
treatment may be a new therapeutic target in rhabdomyolysis-induced AKI.
SA-PO260
Ferroptosis as a Cause of Proximal Tubule Injury  Joel M. Weinberg,1,2 
Andreas Linkermann.3  1Nephrology, VA Healthcare System Ann Arbor, Ann 
Arbor, MI; 2Nephrology, Univ of Michigan, Ann Arbor, MI; 3Nephrology, 
Christian Albrechts Univ, Kiel, Germany.
Background: ‘Ferroptosis’ has recently been described as a form of iron-dependent, 
lipid peroxidation-mediated cell death with a distinct injury pattern relative to other forms of 
necrosis and there is evidence that it contributes to AKI in vivo (PNAS 111:16835,2014, Nat. 
Cell Biol. 16:1180,2014). Here, we have refined approaches to study ferroptosis in freshly 
isolated proximal tubules (PT) and assessed new agents being developed to ameliorate it.
Methods: Freshly isolated rabbit (R) and mouse (M) PT were treated with either 
tert-butylhydroperoxide (tBHP, 5 mM) or hydroxyquinoline + ferrous ammonium sulfate 
(HQ+Fe,10 uM each) followed by incubation for 120 min, then measurement of LDH 
release, malondialdehyde (MDA) production, mitochondrial membrane potential, and GSH.
Results: tBHP and HQ+Fe induced progressive LDH release that was more severe 
in M PTs (for HQ+Fe: R60’-35.5±6.8%, R120’-51.4±9.0%; M60’-72.1±2.6%, M120’-
87.4±3.25%). These changes were accompanied by 5 fold increases of MDA levels and 
GSH depletion. LDH release and MDA production were iron and NAPH oxidase (Nox)-
dependent since they were blocked by deferoxamine or the Nox1/4 inhibitor GKT 137831. 
Fer-1, the prototypical ferroptosis inhibitor that emerged from chemical library screening, 
strongly alleviated both forms of injury and associated MDA production at concentrations 
of 0.1 to 2 uM as did a panel of 23 other ferrostatin analogs with potencies similar to those 
seen in isolated non-renal cell systems. Interestingly, the lipophilic antioxidant, diphenyl-
p-phenylenediamine (DPPD), was even more potent than the highly active ferrostatins. 
Ferrostatins were not effective against acute cell killing and energetic deficits induced by 
hypoxia/reoxygenation, indicating that the benefit seen during in vivo ischemia/reperfusion 
does not target that phase of injury.
Conclusions: Ferroptosis is strongly expressed in fully differentiated PTs, is suppressed 
by both newly developed ferrostatins and the classical lipophilic antioxidant, DPPD, and 
is an injury process that can be targeted to alleviate AKI.
Funding: Veterans Administration Support
SA-PO261
Identification and Characterization of IGFBP7 and TIMP2 Expression 
in Human Proximal and Distal Tubule Cells  David R. Emlet,1 Nuria M. 
Pastor-Soler,2 Allison L. Marciszyn,2 Xiaoyan Wen,1 Jacob K. Volpe,1 John 
A. Kellum.1,2  11Center for Critical Care Nephrology, Dept of Critical Care 
Medicine, Univ of Pittsburgh, Pittsburgh, PA; 2Renal Electrolyte Div, Dept of 
Medicine, Univ of Pittsburgh, Pittsburgh, PA.
Background: IGFBP7 and TIMP2 have been identified as biomarkers for Acute Kidney 
Injury (AKI), but little is known regarding any role in the pathogenesis of the disease. To 
study this question we established primary cell culture models of human proximal and 
distal tubule epithelial cells.
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Methods: The cortex of human kidneys were dissociated and viable cells cultured. 
Proximal and distal tubule epithelial cells (PTECs and DTECs) were isolated with antibodies 
against CD13 and CD227 using the Dynabead pan-mouse IgG system. Isolated cells were 
cultured on transwell supports and characterized by immunoblot and immunofluorescence.
Results: CD13 isolated cells were positive for the PTEC markers Gamma Glutamyl 
Transpeptidase and Aquaporin-1. CD227 isolated cells were negative for GGT and AQP1 
but positive for the distal tubule markers CD227 and E-cadherin. Microscopy demonstrated 
that both PTECs and DTECs formed tight junction monolayers with a low percentage of 
cells in cycle as identified by Ki-67. Analysis of conditioned media demonstrated that 
these cells can indeed express and secrete IGFBP7 and TIMP2. Importantly, we identified 
a preferential expression of IGFBP7 in PTECs and of TIMP2 in DTECs. Furthermore, we 
discovered evidence suggesting that TIMP2 is primarily secreted across the apical surface, 
while the majority of IGFBP7 is secreted across the basolateral surface. Despite this, we also 
found evidence to suggest that some IGFBP7 can be secreted apically, primarily in PTECs.
Conclusions: We have developed human cell culture model systems of PTECs and 
DTECs for the cellular/molecular analysis of AKI. We confirmed that IGFBP7 and TIMP2 
can be expressed and secreted by these cells, and we have identified differential expression 
and secretion of these proteins across cell types and spatially within cells. These systems 
and knowledge will now allow for investigation of the potential role of these biomarkers 
in the molecular etiology of AKI.
Funding: Pharmaceutical Company Support - Astute Medical
SA-PO262
Klotho and S100A8/A9 as Discriminative Markers Between Pre-Renal and 
Intrinsic AKI  Ji Yong Jung,1 Ae Jin Kim,1 Eul Sik Jung,1 Byoungho Choi,1 
Yun Jung Oh,2 Chungsik Lee,2 Han Ro,1 Jae Hyun Chang,1 Hyun Hee Lee,1 
Wookyung Chung.1  1Div of Nephrology, Dept of Internal Medicine, Gachon 
Univ Gil Medical Center, Incheon, Republic of Korea; 2Div of Nephrology, Dept 
of Internal Medicine, Cheju Halla General Hospital, Jeju, Republic of Korea.
Background: Early detection and accurate differentiation of the cause of acute kidney 
injury (AKI) may improve the prognosis of the patient. However, to date, there are few 
reliable biomarkers for the discrimination of pre-renal and intrinsic AKI. The purpose of 
this study was to determine whether AKI is associated with an altered level of klotho and 
S100A8/A9 (an endogenous toll-like receptor 4 ligand), and NGAL (neutrophil gelatinase-
associated lipocalin) protein that may contribute to differentiate between pre-renal and 
intrinsic AKI.
Methods: Volume depleted pre-renal AKI model was induced by Male Sprague-Dawley 
rat were fed a low-salt diet (0.03%) without water 96hr before two times at intraperitoneal 
(IP) injection of furosemide (20 mg/kg) at 24hr intervals. In contrast, cisplatin-induced 
intrinsic AKI model were given by a single IP injection of cisplatin (5 mg/kg). All animals 
were euthanized 72hr after first IP injection. We also performed a proof of concept cross-
sectional study to measure serum and urinary biomarkers in 77 hospitalized patients with 
established AKI.
Results: Compared with intrinsic AKI group, pre-renal AKI group caused a marked 
depression of urinary klotho level (13.21 ± 17.32 vs. 72.97 ± 17.96 pg/ml; P = 0.002). In 
addition, intrinsic AKI group caused a marked elevation of S100A8/A9 level than those 
of pre-renal AKI group (2629.97 ± 598.05 ng/ml vs. 685.09 ± 111.65 ng/ml; P = 0.002 
in serum; 3361.11 ± 250.86 ng/ml vs. 741.72 ± 101.96 ng/ml; P = 0.003 in urine). Serum 
and urinary NGAL showed no difference between pre-renal and intrinsic AKI group. 
The proof of concept study with hospitalized AKI patients also demonstrated decreased 
urinary klotho in pre-renal AKI patients and increased urinary S100A8/A9 concentrations 
in intrinsic AKI patients.
Conclusions: The attenuation of urinary klotho and increment of urinary S100A8/A9 
may contribute to discriminate the pre-renal AKI and intrinsic AKI.
Funding: Pharmaceutical Company Support - Fresenius Medical Care Korea
SA-PO263
Release of Extra Cellular DNA Contributes to Renal Ischemia Reperfusion 
Injury Through Platelet Activation and Formation of Neutrophil 
Extracellular Traps  Marcel Jansen, Diba Emal, Sandrine Florquin, Joris J. 
Roelofs.  Pathology, Academic Medical Center Amsterdam, Amsterdam, Noord-
Holland, Netherlands.
Background: Renal ischemia reperfusion injury (I/R) results from a complex interplay 
between coagulation and inflammation, resulting in tissue damage. It has been shown that 
platelet inhibition protects from I/R. How platelets are activated upon renal I/R is not entirely 
known. In this study we investigate renal cell death, extracellular DNA release and neutrophil 
extracellular traps (NETs) as potential triggers for platelet activation and renal I/R injury.
Methods: We stimulated platelets with necrotic renal cells in presence or absence of 
deoxyribonuclease 1 (DNase1). Platelet activation and platelet-leukocyte formation were 
measured by FACS. We stimulated granulocytes with activated platelets and measured 
DNA release –indicative of NET formation. Vice versa we stimulated platelets with NETs 
and measured PF4 release. Mice were subjected to renal I/R and treated with DNAse1 or 
vehicle, and sacrificed after 1 day. As marker for NET formation in tissue we stained renal 
tissue for citrullinated histone H3 and granulocyte marker Ly6G. In blood we measured 
Platelet Factor 4 (PF4), DNA, creatinine and urea.
Results: Supernatant from necrotic renal cells stimulated platelet activation and 
platelet-leukocyte complex formation and incubation with DNase1 reduced platelet 
activation. Activated platelets generated NETs in vitro and, vice versa, NETs stimulated 
platelet activation ex vivo. Mice subjected to renal I/R showed a significant increase of 
extracellular DNA and PF4 levels in the circulation. Treatment with DNase1 improved 
renal function upon I/R. Immunostainings revealed presence of NETs in renal tissue after 
I/R. DNase1 treatment resulted in a trend towards fewer NETs and granulocytes in tissue.
Conclusions: Both DNA from necrotic kidney cells and NETs activate platelets, which 
in their turn cause further NET formation, leading to a vicious triad in the pathogenesis 
of I/R injury. Treatment with DNase1 may have therapeutic benefits in the context of 
renal I/R injury.
SA-PO264
The Role of Senescence of Bone Marrow Cells in Acute Kidney Injury 
Myung-Gyu Kim,1 Sung Yoon Lim,1 Jihyun Yang,1 Young Ju Na,1 So-Young 
Lee,2 Sang-Kyung Jo,1 Won-Yong Cho.1  1Dept of Internal Medicine, Korea 
Univ Anam Hospital, Seoul, Republic of Korea; 2Dept of Internal Medicine, 
Eulji Univ Hospital, Seoul, Republic of Korea.
Background: There have been considerable growth in older population and age-related 
kidney disease in the world. It was demonstrated that the impairment in the potentiality to 
repair and regenerate of renal resident cells is a hallmark of biological processes associated 
with aging. However, the impact of senescence of bone marrow derived cells (BMDC) on 
kidney injury is not known. Here, we investigated the role of senescence of BMDC in the 
development and progression of ischemic acute kidney injury (AKI).
Methods: Seven wk-old female mice were sublethally irradiated and reconstituted with 
bone marrow from 12-mo-old (old-to-young, old BMT) or 7-wk-old (young to young, young 
BMT) mice. Then we performed renal ischemia reperfusion injury (IRI) in old or young 
BMT mice, and functional, histological kidney damage and inflammation were compared.
Results: The Y chromosome was detected in peripheral blood of BMT mice indicating 
successful reconstitution of female mice with male bone marrow. Although the population 
of immune cells in spleen between young and old BMT mice was not significantly different, 
old BMT mice showed less renal functional deterioration and histological damage after 
IRI. This was associated with less infiltration of F4/80 macrophages and lower level 
of tissue cytokine (IL-12). In vitro study with BMDCs also revealed that LPS-induced 
cytokine productions (IFN-r, MCP-1 and IL-10) were significantly suppressed in old BM 
cells than young BM cells.
Conclusions: Our data shows that senescence of BMDC could affect susceptibility 
and response to renal ischemic injury possibly via immune modulatory effect. A better 
understanding of these processes may help us to develop new strategies that are specifically 
tailored for treatment of the elderly population.
SA-PO265
Optimal Transplantation Timing of Mesenchymal Stem Cell in Rat Model 
of Renal Ischemia Reperfusion Injury  Xiaoyan Liu,1 Xiaofang Yu,1,2 Jieru 
Cai,1 Xiaoqiang Ding.1,2  1Kidney and Dialysis Inst of Shanghai, Shanghai, 
China; 2Div of Nephrology, Fudan Univ Zhongshan Hospital, Shanghai, China.
Background: To investigate whether timing of mesenchymal stem cells (MSCs) 
transplantation can determine the survival and therapeutic potential of MSCs in ischemic 
kidney.
Methods: The model of renal IRI was induced by the release of bilateral renal pedicle 
clamps following 60 min of occlusion. Six rats per group were sacrificed per time point, 
at 0h, 1h, 12h, 24h, 48h, 72h and 1 week post-I/R respectively. Passage 3 rat MSCs were 
cultured with different time points kidney homogenate supernatants. After reperfusion, 
CM-Dil-labeled MSCs or vehicles only were administered through the carotid artery of 
the animals 1h before reperfusion(-1h) and immediately(0h), 12h, 24h after reperfusion. 
The animals were sacrificed 48h after reperfusion and 24h after MSCs transplantation.
Results: The serum creatinine level peaked at 24h of reflow(470.6±41.65mmol/l, 
P<0.05) and NGAL peaked at 12h(7607±1066 pg/ml, P<0.05).The highest expression 
of inflammatory factor was in 12h and 24h groups, and the lower was in -1h, 0h and 1w 
groups. In vitro, there was lower cell apoptosis and higher proliferation in -1h and 0h 
groups compared with other groups. Significant kidney function and histological damage 
improvement was observed after the treatment of MSCs in -1h and 0h groups. Meanwhile, 
the expression of proinflammatory factor significantly decreased and anti-inflammatory 
factor significantly decreased in -1h and 0h groups compared with other point time groups 
and control group. In addition, we also observed more obvious inhibition of renal tubular 
cell apoptosis and promotion of proliferation in -1h and 0h groups compared with other 
groups. Consistent with the improvement above, the viability of implanted MSCs also 
increased in -1h and 0h groups.
Conclusions: MSCs transplantation 1h before reperfusion or immediately after 
reperfusion produces the most dramatic improvement in renal function and morphology 
in rat model of renal I/R injury. It is the optimal timing to transplant MSCs in IRI before 
the inflammatory response is established.
Funding: Government Support - Non-U.S.
SA-PO266
Reno-Protective Role of Par1b in Acute Kidney Injury  Abhijeet Pal,1 Natalie S. 
Uy,1 James M. Pullman,2 Zhongfang Du,1 Kimberly J. Reidy.1  1Pediatric Nephrology, 
Children’s Hospital at Montefiore, Montefiore Medical Center/ Albert Einstein Medical 
College, Bronx, NY; 2Pathology, Montefiore Medical Center/ Albert Einstein Medical 
College, Bronx, NY. Background: Partitoning defective Par1 (aka MARK) is a member 
of the Par polarity protein family and that localizes to the basolateral aspect of renal 
tubular cells. Defects in apico-basal polarity and cell-cell adhesion occur in acute kidney 
Injury (AKI). Mammalian homologues Par1a and 1b are serine threonine kinases that 
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are functionally redundant on kinase assays. We have identified a role for Par1a/1b in 
glomerular and proximal tubular development in mice associated with downregulation of 
Notch signaling. We hypothesized that Par1a/1b would contribute to renal epithelial repair 
in the setting of acute kidney injury.
Methods: Expression of Par1a/1b and Notch signaling was examined using western 
blotting and immunostaining in mouse models of tubular injury and human kidney tissue 
(leftover from clinically indicated renal biopsy). Proximal tubular injury was induced by 
in wild-type(WT) and Par1b knockout mice by injecting cisplatin (30mg/Kg, ip) or folic 
acid (250 mg/kg, ip). The degree of histological damage was assessed by light microscopy.
Results: Par1a/1b proteins are highly expressed in developing mouse kidneys and 
down regulated in the adult. Increased basolateral Par1a/b expression was observed after 
cisplatin/folic acid injury in the wild type mice compared to untreated controls. More severe 
dilated tubular injury was observed in the cisplatin and folic acid injured Par1b knockout 
vs WT mice. Preliminary data indicate that Notch ligand Jag1 expression was increased 
in cisplatin treated wild-type mice but not Par1b-/- mice. In human biopsy samples, we 
identified tubular expression of Par1a and 1b.
Conclusions: Our data demonstrates that Par1 proteins has a reno-protective role in 
tubular injury. Further studies of the mechanisms of this effect and interaction with Notch 
signaling are ongoing.
Funding: NIDDK Support
SA-PO267
Small Heat Shock Protein Beta-1 (HSPB1) Is Upregulated and Regulates 
Mitophagy and Apoptosis of Renal Tubular Cells in Acute Kidney Injury 
Tatsuki Matsumoto, Kazu Hamada-Ode, Yoshiko Shimamura, Koji Ogata, 
Kosuke Inoue, Taro Horino, Yoshinori Taniguchi, Shimpei Fujimoto, Yoshio 
Terada.  Dept of Endocrinology, Metabolism and Nephrology, Kochi Medical 
School, Kochi Univ, Nankoku, Kochi, Japan.
Background: Heat shock protein beta-1 (HSPB1, also known as HSP27) is a small 
heat shock protein involved in many cellular processes and reportedly protects cells against 
oxidative stress. Autophagy protects cells from many types of stress and is thought to play 
a key role in preventing stress in acute kidney injury (AKI). However, little is known about 
the role of HSPB1 in autophagy and apoptosis in the pathogenesis of AKI.
Methods: We used a rat ischemia/reperfusion AKI model and cultured renal tubular 
cells as an in vitro model. To elucidate the regulation of HSPB1, we evaluated the promoter 
activity and expression of HSPB1 in normal rat kidney (NRK)-52E cells in the presence of 
H2O2. To examine the regulation of autophagy by HSPB1, we established NRK-light chain 
3 (NRK-LC3) cells that were stably transfected with a fusion protein of green fluorescent 
protein and LC3.
Results: The results of immunohistological examination showed that HSPB1 was 
expressed in proximal tubule cells after AKI. Real-time quantitative reverse transcription-
polymerase chain reaction and western blot analysis showed that HSPB1 mRNA and protein 
expression were upregulated 6–72 h and 12–72 h, respectively, after ischemia/reperfusion 
injury. HSPB1 promoter activity as well as mRNA and protein expression indicated dose-
dependent induction by H2O2. HSPB1 overexpression-induced autophagy in NRK-LC3 cells 
under normoxic conditions was confirmed with confocal microscopy, which revealed the 
presence of LC3-positive granules. Furthermore, H2O2-induced autophagy was inhibited 
by the transfection of small interfering RNAs for HSPB1. Overexpression of HSPB1 
reduced BAX activation and H2O2-induced apoptosis, as measured by caspase 3 activity and 
terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling assay.
Conclusions: These results indicate that HSPB1 upregulation plays a role in the 
pathophysiology of AKI.
SA-PO268
Developing a More Clinically Relevant Mouse Model of Cisplatin-Induced 
Acute Kidney Injury  Cierra Sharp, Mark A. Doll, Tess Dupre, Deanna L. Siow, 
Parag P. Shah, Levi J. Beverly, Leah J. Siskind.  Univ of Louisville, Louisville, KY.
Background: Cisplatin, a commonly used chemotherapeutic for the treatment of many 
solid cancers is known to induce acute kidney injury (AKI) in 30% of patients. Patients that 
develop cisplatin-induced kidney toxicity must either have the dose severely reduced or be 
switched to an alternative therapy to prevent long-term renal damage. In many cases the 
alternative therapy may be less effective at treating the tumor. Due to cisplatin’s complex 
nephrotoxic mechanism of action, the development of renoprotective agents remains a 
challenge. Currently there are no FDA approved drugs for the protection of cisplatin-
induced AKI. The standard mouse model of cisplatin-induced AKI is a single high dose of 
cisplatin (10-30 mg/kg), and animals are sacrificed 72h after injection. This model does not 
accurately represent the clinical dosing regimen, which involves repeated dosing of cisplatin.
Methods: In this study we compared the standard single dose model to a new multiple 
dose model where mice received lower doses of cisplatin once a week for 4 weeks. We 
measured and compared indicators of kidney function (KIM-1, NGAL, BUN, and Serum 
Creatinine) as well as inflammatory cytokines and chemokines (i.e. TNFα, IL6, CXCL1, 
MCP-1). Indicators of apoptosis and cell death were measured as well as indicators of 
fibrosis (i.e. TGF-β, CTGF, BMP-7, and Sirius Red staining).
Results: In comparing the results of the single and multiple dose models, BUN 
values were similar, suggesting a comparable loss of kidney function. However, KIM-1 
and NGAL were reduced by roughly 10-fold and 100-fold, respectively. Inflammation 
was also decreased in this model with TNFα, IL6 and IL1-β reduced by 4, 10 and 5-fold, 
respectively. Fibrosis was nearly non-existent in the single dose model; however, the 
multiple dosing model showed a significant increase in fibrosis. Also, expression of PAI-1, 
a mediator of fibrosis was significantly increased in the multiple dosing model compared 
to the single dose model.
Conclusions: Taken together, we propose that the multiple dosing model is a more 
relevant model for the discovery of renoprotective agents in the prevention/treatment of 
cisplatin-induced AKI.
Funding: NIDDK Support
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Genetic Knock Out of CHOP Protects against Ischemia-Mediated 
Acute Kidney Injury  Rachel Carlisle, Elise Brimble, Jeffrey G. Dickhout. 
Nephrology, St. Josephs’s Healthcare Hamilton and McMaster Univ, Hamilton, 
ON, Canada.
Background: Acute kidney injury (AKI), a major cause of morbidity and mortality in 
North America, is characterized by a sudden increase in serum creatinine. Renal ischemia, 
a common cause of AKI, induces endoplasmic reticulum (ER) stress and activates the 
unfolded protein response. This leads to a subsequent upregulation in the expression of 
the pro-apoptotic gene, CHOP. Transgenic knock out of CHOP inhibits ER stress-mediated 
acute tubular necrosis, implicating CHOP in the pathogenesis of AKI.
Methods: Bilateral renal ischemia/reperfusion (I/R) was performed in mice, using 
atraumatic vessel clamps, and confirmed via colour change (red to dark purple) of the 
kidney. Surgeries were performed on C57BL/6 mice to determine the appropriate time 
point to cause significant renal damage. Various time points for renal ischemia were 
examined, between 25-55 mins, with 48-72 h of recovery. I/R surgeries were subsequently 
performed on C57BL/6 and CHOP knock out mice. Ischemia was induced for 55 mins, and 
mice recovered for 48 h. Plasma creatinine was measured using an enzymatic assay, and 
kidneys were stained to analyze renal damage. Imaging of the kidneys was focused on the 
juxtamedullary region, as this area is the most vulnerable to ischemic damage.
Results: Creatinine levels increased in response to I/R surgery in both wild type 
and CHOP knock out mice; however, creatinine levels from CHOP knock out mice 
were significantly lower than from wild type mice. Stained kidney sections confirm 
renal protection in CHOP knock out mice, demonstrating reduced cellular damage and 
vacuolization in kidneys from these animals.
Conclusions: These results suggest that CHOP plays a significant role in ischemia-
mediated renal injury, and attenuating its expression may provide new therapeutic strategies 
to protect against AKI.
SA-PO270
The Protective Role of Doxycycline for Cisplatin-Induced AKI by Its Anti-
Inflammatory and Anti-Oxidative Effects  Terumasa Nakagawa,1 Yutaka 
Kakizoe,1 Yoshikazu Miyasato,1 Teruhiko Mizumoto,1 Manabu Hayata,1 Yuichiro 
Izumi,1 Takashige Kuwabara,1 Taku Miyoshi,1 Masataka Adachi,1 Kenichiro 
Kitamura,2 Masashi Mukoyama.1  1Nephrology, Kumamoto Univ Graduate 
School of Medical Sciences, Kumamoto, Japan; 2Internal Medicine III, Univ 
of Yamanashi Faculty of Medicine, Yamanashi, Japan.
Background: Cisplatin (CDDP) is a chemotherapeutic drug widely used for the 
treatment of solid tumors. However, its nephrotoxicity is the major dose-limiting factor. 
Doxycycline (Dox) is a tetracycline antibiotic commonly used in a variety of infections, but 
several other properties have been suggested such as an anticancer effect or the inhibition 
of matrix metalloproteinase (MMP). In this study, we investigated whether Dox exerts the 
protective effects on CDDP-induced acute kidney injury(AKI).
Methods: Ten-week-old male C57BL/6J mice were divided into following four groups: 
1) Control, 2) Dox (2mg/ml in drinking water), 3) CDDP (25 mg/kg, intraperitoneally) 
and 4) CDDP+DOX. After 7 days pretreatment with Dox, CDDP was administrated, and 
animals were sacrificed 3 days later. BUN and serum creatinine (Cr) were measured and renal 
histological changes as well as, inflammation, and oxidative stress markers were evaluated. 
MMP and serine protease activities in the kidney tissue were accessed with zymography.
Results: No apparent adverse effects were observed in Dox group. Dox did not affect 
mRNA expression of transporters for CDDP (OCT-1, OCT-2 and MATE1) in the renal 
tubules. CDDP caused severe tubular damages along with elevated BUN and Cr levels. 
It also increased mRNA expression of inflammatory and profibrotic molecules, together 
with enhanced oxidative stress in the kidney. Dox alleviated significantly those detrimental 
changes (Cr: Control, 0.13±0.01; Dox, 0.13±0.03; CDDP, 1.04±0.20;and CDDP+Dox, 
0.30±0.12 mg/dL). Moreover, Dox suppressed the activities of MMP-2 and 9 as well as 
serine proteases, which were enhanced by CDDP in the kidney tissue.
Conclusions: Dox mitigated CDDP-induced AKI through its pleiotropic effects, i.e., 
anti-inflammatory, anti-oxidative and enzyme-inhibiting effects. Our results suggest that 
Dox could become a new strategy for the prevention of CDDP-induced nephrotoxicity 
in humans.
Funding: Government Support - Non-U.S.
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SA-PO271
Involvement of Indoxyl Sulfate in Exacerbated Susceptibility of 
Streptozotocin (STZ)-Induced Diabetic Rat Kidney to Ischemia/
Reperfusion-Induced Acute Kidney Injury (AKI)  Yuna Shimokawa,1 
Naoko Oyama,1 Takashige Kuwabara,2 Masashi Mukoyama,2 Hirofumi Jono,1,3 
Hideyuki Saito.1,3  1Clinical Pharmaceutical Sciences, Kumamoto Univ School of 
Pharmacy, Kumamoto, Japan; 2Nephrology, Kumamoto Univ Graduate School 
of Medical Sciences, Kumamoto, Kumamoto, Japan; 3Pharmacy, Kumamoto 
Univ Hospital, Kumamoto, Japan.
Background: Diabetes mellitus (DM) is one of the potential risk factors in progression 
of acute and chronic kidney failures. In patients with DM, AKI tends to be severer and the 
restoration delays compared to that in non-DM patients. However, the precise mechanism is 
unclear. Indoxyl sulfate (IS) is a representative oxidative stress-inducible uremic toxin and 
involved in the progression of renal failures. In this study, we examined the toxicological 
involvement of IS in ischemic AKI in DM rats.
Methods: STZ-induced DM rats and nondiabetic rats without STZ treatment (non-
DM) were subjected to 20 min of renal ischemia/reperfusion (I/R), and the development 
of renal injury in DM and non-DM rats were compared. An oral indole adsorbent AST-120 
was orally administered to rats (2.5 g/kg) at 24 h, 1 h before and 24 h after I/R. Serum and 
kidney tissues were collected at 48 h following I/R.
Results: In DM ischemic AKI group, serum creatinine (SCr) (4.3-fold vs non-DM 
ischemic rats) and BUN (7.0-fold) were increased. The kidney of DM rats with I/R exhibited 
severetubular injury compared to that of non-DM rats with I/R in association with a marked 
increase in serum Kim-1 level (25-fold). Hydroperoxide (1.7-fold) and IS levels in serum 
(14.7-fold) and kidney (5.8-fold) were also elevated. Immunoblot analysis revealed that renal 
expression of organic anion transporters rOAT1/rOAT3 mediating renal excretion of IS were 
significantly downregulated. AST-120 treatment prevented the increases in SCr and BUN, 
and renal tubular injury in DM rats with I/R, in association with the reduction of serum and 
renal IS levels.The downregulation of rOAT1/rOAT3 was restored by AST-120 treatment.
Conclusions: In conclusions, DM could be a pivotal factor in progression of ischemic 
AKI, and AST-120-removable uremic toxin(s) including IS could play a toxico-physiological 
role as a mediator in the DM-exacerbated ischemic AKI.
Funding: Government Support - Non-U.S.
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Discoidin Domain Receptor 1 Is a Key Mediator of the Ischemia-
Reperfusion Induced Renal Injury  Aude Dorison, Yi-chun Xu-dubois, 
Christos E. Chadjichristos, Eric Rondeau, Christos Chatziantoniou, Jean-claude 
Dussaule.  UMRS 1155, INSERM, Paris, France.
Background: Discoidin Domain Receptor 1 (DDR1) is a non-integrin collagen receptor, 
expressed by different cell types in the kidney, which displays tyrosine-kinase activity.
We have previously demonstrated that a de novo expression of DDR1 in target cells was 
driving renal inflammation and fibrosis in different models of chronic kidney disease. The 
aim of our study was to investigate whether DDR1 participates in the pathophysiological 
mechanisms of ischemia/reperfusion (I/R), a model of acute renal injury.
Methods: To this end, male mice subjected to I/R were injected either with 
oligodeoxynucleotide (ODN) antisense sequences directed against DDR1 (AS, n=8) or 
with scrambled sequences (SCR, n=7). Mice were sacrificed after 24h and parameters of 
renal function, structure and inflammation were measured.
Results: DDR1 protein expression was strongly induced in proximal tubular cells after 
I/R and this expression was inhibited by the AS administration. Increased uremia (BUN) 
showed impaired renal function in SCR+I/R animals, whereas AS treatment lowered 
BUN levels. In addition, histological damage such as brush border alterations and tubular 
necrosis were significantly decreased and E-cadherin protein expression was preserved in 
AS+I/R mice. Kim-1, NGAL, vimentin and VCAM-1 mRNA expressions were increased 
in SCR+I/R compared to controls and significantly decreased in mice treated with AS. 
Moreover, the AS-induced inhibition of DDR1 was accompanied by decreased T-lymphocyte 
infiltration and mRNA expressions of TNFα, MCP1, IL-1β, IL-6 and TGFβ.
Interestingly, DDR1 staining performed on transplant patient biopsies with a delayed 
graft function showed a strong expression of DDR1 which was associated with the severity 
of tubular necrosis and vimentin expression.
Conclusions: DDR1 inhibition protects mice from the I/R-induced histological damage, 
inflammation and loss of renal function. DDR1 overexpression plays a deleterious role 
in this model of kidney injury, thus reinforcing the interest to develop agents capable of 
specifically blocking the function of this receptor.
Funding: Government Support - Non-U.S.
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Heat Shock Factor 1 and Crystallin-αB in Cisplatin-induced Renal Tubular 
Cell Apoptosis and Nephrotoxicity  Qiang Lou,1,2 Zheng Dong.2  1Medical 
College of Henan Univ, Kaifeng, Henan, China; 2Dept of Cellular Biology and 
Anatomy, Georgia Regents Univ, Augusta, GA.
Background: Cisplatin, a wildly used chemotherapy drug, induces nephrotoxicity that 
is characterized by renal tubular cell death. In response to toxic stress, renal tubular cells 
may activate cytoprotective mechanisms, such as the expression of heat shock proteins. 
However, the heat shock response during cisplatin nephrotoxicity is largely unclear. The 
present study analyzed the heat shock response during cisplatin treatment of renal tubular 
cells in vitro and mice in vivo, and examined the relevant regulatory mechanisms.
Methods: For in vivo study, male C57BL/6 mice were given a single intraperitoneal 
injection of cisplatin. In vitro, cultured renal proximal tubular cells (RPTC) were incubated 
with cisplatin. To determine the role of heat shock factor 1 (HSF1), HSF1 was knocked 
down by stable transfection of specific shRNAs.
Results: In RPTC, cisplatin induced a rapid expression of HSF1 and specific heat 
shock proteins, including Hsp70, Hsp27, and Crystallin-αB. The induction of these 
proteins was transient and decreased at late time points of cisplatin treatment. Similar 
changes were verified in kidney tissues following cisplatin injection, whereas Hsp90 
did not change significantly. Knockdown of HSF1 decreased Crystallin-αB expression 
and increased RPTC apoptosis. Interestingly, p38 activation was enhanced in these cells. 
Moreover, inhibition of p38 with SB203580 markedly inhibited cisplatin-induced apoptosis 
in HSF1-knockdown cells.
Conclusions: Induction of HSF1 is a cytoprotective response during cisplatin 
nephrotoxicity. Crystallin-αB appears to be a key heat shock protein induced by HSF1 for 
its protective effect. Heat shock response may regulate or co-operate with other signaling 
pathways, such as p38, to regulate tubular cell apoptosis.
Funding: NIDDK Support, Veterans Administration Support
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The Effect of the Cytoplasmic Domain of Tissue Factor in Contributing to 
Renal Ischemic Reperfusion Injury Is Both Protease Activated Recptor-1 
(PAR-1) and Strain Dependent  Jonathan H. Erlich,1,3 Sean E. Kennedy,1,2 
Joseph J. Murphy,1 Calum Wai Kit Chong.1  1Dept of Medicine, Univ of New 
South Wales, Randwick, Australia; 2Dept of Nephrology, Sydney Childrens 
Hospital, Randwick, NSW, Australia; 3Dept of Nephrology, Prince of Wales 
Hospital, Randwick, NSW, Australia.
Background: The cytoplasmic domain of tissue factor plays a role in cell signaling and 
regulation of angiogenesis and inflammation. It may do this both by regulating intracellular 
signaling and via modulating protease activated receptor signaling. Previously we have 
shown that mice on a mixed genetic background deficient (MGB) in the cytoplasmic 
domain of tissue factor (TFdeltact/deltact) mice developed serve renal injury. TFdeltact/deltact have 
increasedcytokine and PAR-1 expression. We further investigated the importance of 
increased PAR-1 signaling and the strain background of the mice.
Methods: Mice WT or TFdeltact/deltact on MGB or mice backcrossed onto CB7BL6 mice 
background underwent 25 min bilateral warm ischemia and 24 reperfusion. Renal function 
was assessed by serum cretainine and renal injury was further assessed by histology and 
expression of inflammatory mediators form renal tissue. The role of PAR-1 was assessed 
using the inhibitor SCH79797.
Results: TFdeltact/deltact mice on the MGB developed more severe injury at 24 than WTon 
a similar genetic background. These mice developed greater PAR-1 mRNA expression and 
treatment of these mice with the PAR-1 inhibitor reduced injury similar to PAR-1 deficient 
mice. In contrast the effect of TF cytoplasmic depletion was not seen in mice on C57BL6 
background. These mice had similar PAR-1 induction to that observed in WT C57BL6. 
WT mice with a MGB had lesser renal injury and lower basal PAR-1 expression than WT 
C57BL6 mice. TFdeltact/deltact mice on MGB having simialr basal PAR-1 expression and much 
greater inducible PAR-1 expression( 5 fold compared to 2.8 fold for WT). TFdeltact/deltact on a 
C57bL6background had similar renal injury and PAR-1 induction to WT mice.
Conclusions: The cytoplasmic domain of TF may contribute to renal IR injury be 
regulating PAR-1 expression. The role of the TF cytoplasmic domain in regulating renal 
injury is genetic background dependent.
SA-PO275
Protective Effects of Endonuclease Inhibitors on Cisplatin-Induced Acute 
Kidney Injury  Dae Song Jang,1 Tariq Fahmi,1 Todd Fite,1 Narsimha Reddy 
Penthala,3 Dolapo Taiwo Odeniyi,1 Alena Savenka,1 Peter A. Crooks,3 Sudhir V. 
Shah,1,2 Alexei G. Basnakian.1,2  1Univ of Arkansas for Medical Sciences, Dept 
of Pharmacology and Toxicology, Little Rock, AR; 2Central Arkansas Veterans 
Healthcare System, Div of Nephrology, Little Rock, AR; 3Univ of Arkansas for 
Medical Sciences, COP Pharmaceutical Science, Little Rock, AR.
Background: Cisplatin is one of the most commonly used and the most nephrotoxic 
anticancer drugs. Acute kidney injury induced by cisplatin cannot be overcome and may 
lead to chronic kidney failure. Our previous studies showed that genetic inactivation of 
two kidney apoptotic endonucleases, DNase I and EndoG, was partially protective against 
tubular epithelial cell death induced by cisplatin. Until very recently, pharmaceutically 
meaningful inhibitors of the endonucleases, which would be non-toxic and effective in 
vivo, were not available.
Methods: This study was aimed to determine if the two new endonuclease inhibitors 
recently identified by us, IG-17 (1,3-phenylene-bis-aminoguanidine hydrochloride) for 
DNase I and PNR-3-82 (5-((1-(2-naphthoyl)-5-methoxy-1H-indol-3-yl)methylene)-2-
thioxodihy dropyrimidine-4,6(1H,5H)-dione) for EndoG, could ameliorate cisplatin toxicity 
to kidney tubular epithelial cells in vitro and in vivo.
Results: In vitro experiments using NRK-52E cells showed that the compounds are 
able to suppress endonuclease activity inside the cells provide partial protection against 
cisplatin toxicity measured using LDH release assay and TUNEL, and are non-toxic at 
the used concentrations. The inhibitors were found to markedly suppress the total-body 
endonuclease activity in mice at the dose of 5 mg/kg administered subcutaneously, and were 
non-toxic up to 25 mg/kg as measured using 14 blood plasma markers of organ toxicities.
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Conclusions: Importantly, cisplatin-induced kidney injury was functionally (creatinine) 
and structurally (acute tubular necrosis, TUNEL) reduced by the administration of the 
inhibitors (5 mg/kg) in mice suggesting their potential therapeutic value.
Funding: NIDDK Support, Other U.S. Government Support, Veterans Administration 
Support
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Involvement of CYLD as a Regulatory Factor in Fibrotic Response 
of Ischemic AKI Kidney and Hypoxic HK-2 Cells  Go Yoneda,1 Naoki 
Suenaga,1 Nozomi Yabuuchi,1 Kazuhiko Nishi,2 Hirofumi Jono,1,3 Hideyuki 
Saito.1,3  1Clinical Pharmaceutical Sciences, Kumamoto Univ Graduate School 
of Pharmaceutical Sciences, Kumamoto, Japan; 2Hemodialysis and Apheresis, 
Kumamoto Univ Hospital, Kumamoto, Japan; 3Pharmacy, Kumamoto Univ 
Hospital, Kumamoto, Japan.
Background: Cylindromatosis (CYLD), a tumor suppressor, regulates various signaling 
pathways by acting as a deubiquitinating enzyme. Recent studies have revealed that CYLD 
is associated with not only tumors, but also chronic inflammatory diseases, such as tissue 
fibrosis. It is well-documented that tissue fibrosis is common hallmark of chronic kidney 
disease (CKD), and CKD progresses toward end-stage renal disease through renal fibrosis. 
However, the molecular pathogenesis of renal fibrosis is not fully uncovered yet. In this 
study, we elucidated the roles of CYLD in renal fibrosis by using in vivo and in vitro models.
Methods: We generated model mice of ischemia/reperfusion (I/R)-induced acute 
kidney injury (AKI) and hypoxic human kidney (HK)-2 cells. CYLD expression in kidney 
tissue and HK-2 cells was determined by immunoblot analysis. Fibrosis gene expression 
of PAI-1, CTGF and COL1A1 were examined by RT-PCR.
Results: In I/R-induced AKI mice, serum creatinine (SCr) and BUN were elevated 
2 days after I/R treatment, and renal fibrosis was induced 28 days after I/R treatment. In 
those kidney tissues of I/R-AKI mice, CYLD protein expression was markedly decreased 
(0.4-fold) in a time-dependent manner. Interestingly, fibrosis gene expression (PAI-1: 
12-fold, CTGF: 2.5-fold, COL1A1: 4-fold) was significantly increased in response to the 
CYLD down-regulation. In HK-2 cells, siRNA knockdown of CYLD gene expression 
significantly increased the PAI-1 gene expression (12-fold). Moreover, CYLD mRNA 
expression was significantly suppressed (0.5-fold) under hypoxic condition, an important 
factor of CKD progression, whereas the PAI-1 gene expression (2-fold) was elevated in 
HK-2 cells. These results suggested that CYLD could play a pathological role in regulating 
renal fibrotic response.
Conclusions: In conclusion, CYLD may be a novel regulatory factor involved in 
renal fibrosis and its down-regulation may trigger fibrosis under ischemic and/or hypoxic 
conditions.
Funding: Government Support - Non-U.S.
SA-PO277
Attenuation of Renal Fibrosis After Unilateral Ischemia Reperfusion May 
Require a Multi-Target Approach  Nathalie Le Clef,1 Bruce L. Riser,2 Patrick 
C. D’Haese,1 Benjamin Arthur Vervaet.1  1Laboratory of Pathophysiology, Univ 
of Antwerp, Wilrijk, Antwerpen, Belgium; 2BLR Bio LLC, WI.
Background: Acute kidney injury (AKI) is an important risk factor of chronic kidney 
disease (CKD). We optimized a mouse model of AKI to CKD by unilateral ischemia-
reperfusion (UIRI) with development of renal fibrosis. To validate this model for use in 
therapeutic intervention studies, 3 experimental treatments were tested: administration of 
1) recombinant human CCN3 (CCN2/CTGF antagonist), 2) TGFb1 neutralizing antibody 
(1D11) or 3) dexamethasone (corticosteroid).
Methods: Male C57Bl/6 mice underwent 21 min of unilateral ischemia-reperfusion 
(UIRI) at 36°C body temperature. 8 treatment groups (n>4/group, ip) were included: 
dexamethasone (10 mg/kg, daily), vehicle (PBS, daily), rhCCN3 (5 µg/kg, daily), vehicle 
(PBS, daily), antibody to TGFβ (0.5 mg/kg, every other day), vehicle (PBS, every other 
day), an untreated UIRI group and a sham group. Three weeks after UIRI renal fibrotic 
outcome was determined by gene expression analysis (qPCR) of collagen I, TGFβ, CTGF, 
CCN3, PAI-1 and TNFα.
Results: UIRI induced a ~40% reduction in renal mass. Treatment with rhCCN3, 
anti-TGFβ or dexamethasone did not attenuate this reduction. UIRI induces significant 
upregulation of the fibrosis-related genes. rhCCN3 treatment had no effect on gene 
expression. Anti-TGFβ antibody treatment induced significantly less upregulation of 
TGFβ and CCN3 gene expression, however, vehicle also reduced TGFβ expression. 
Dexamethasone treatment induced significantly less upregulation of collagen I and CCN2/
CTGF gene expression and a trend towards higher CCN3 upregulation.
Conclusions: Despite the earlier proven benefits of TGFβ antagonism and CCN3 
treatment on the development of fibrosis, neither treatment (at doses demonstrated to 
be effective in more mild injury models) showed effect in the UIRI model. Broad anti-
inflammatory suppression by dexamethasone attenuated fibrotic gene expression. We 
speculate that the natural course of renal demise after UIRI is very robust and highly likely 
to require a multi-target approach. Whether some combination of the therapies tested here 
could have efficacy in this model remains to be determined.
Funding: Government Support - Non-U.S.
SA-PO278
The Effect of Oxygen and Hypothermic Therapy on the Prevention of Acute 
Kidney Injury  Sang H. Woo,1 Cholawat Pacharinsak.2  1Medicine, Thomas 
Jefferson Univ, Philadelphia, PA; 2Dept of Comparative Medicine, Stanford Univ.
Background: There is no effective therapy for acute kidney injury. The effect of oxygen, 
hypothermic therapy delivered through urinary tract on the treatment of acute kidney injury 
has not be known. This pilot study was performed as a proof of concept of a catheter-based 
oxygen and hypothermic oxygen therapy in preventing and treating acute kidney injury.
Methods: Rats (n=6) were used for the experiment. Three rats were used to compare 
oxygen therapy and control. The other three rats were used to compare hypothermic 
oxygen therapy and control. Oxygen was cooled for hypothermic oxygen therapy before 
it was delivered to the kidney. Right kidneys received treatment (oxygen or hypothermic 
oxygen) and left kidneys were used for control. After a catheter was placed in a bladder, 
oxygen (or cooled oxygen) was delivered to the right kidney from the bladder through the 
catheter for five minutes for pretreatment before clamping. Both right and left renal arteries 
were clamped for 30-45 mins to induce acute kidney injury. Only right kidneys continued 
to receive oxygen or hypothermic oxygen during the clamping of renal arteries. The 
kidneys were extracted after the induction of acute kidney injury with the clamping. Gross 
examination of both kidneys during the clamping and after the extraction was performed.
Results: Gross examination of kidneys demonstrated less ischemic changes of kidneys 
treated with oxygen or hypothermic oxygen during and after the induction of acute kidney 
injury. As shown in Figure 1, right kidneys that received oxygen therapy or hypothermic 
oxygen therapy showed less ischemic changes on gross examination during the clamping 
and after extraction.
Conclusions: This pilot study shows novel methods for the prevention and treatment of 
acute kidney injury. Further study is necessary to investigate the benefits of catheter based 
oxygen and hypothermic therapy in the prevention and treatment of acute kidney injury.
SA-PO279
MicroRNA-17 Is Induced via P53 to Protect against Renal Ischemia-
Reperfusion Injury by Targeting Death Receptor 6  Jielu Hao,1,2 Qingqing 
Wei,2 Changlin Mei,1 Zheng Dong.2  1Nephrology, Shanghai Changzheng 
Hospital, Shanghai, China; 2Cellular Biology and Anatomy, Georgia Regents 
Univ, Augusta, GA.
Background: Ischemia-reperfusion injury is the critical cause of acute kidney injury 
(AKI) in clinical settings, which unavoidably develops into chronic kidney disease (CKD) 
due to lack of understanding of mechanism and effective therapies. In the present study, 
we investigated the role of microRNA-17 (miR-17) regulation in kidney against damage 
in ischemia-reperfusion injury.
Methods: Renal ischemia-reperfusion was induced in C57 mice by bilateral clamping 
of renal arteries, followed by releasing of the clamps. BUN and serum creatinine were 
measured to indicate the loss of renal function. In vitro, rat kidney proximal tubular cells 
(RPTC) were treated with hypoxia (1% oxygen). To test the effect of miR-17, anti-miR-17-
LNA and miR-17 mimic were transfected before hypoxia. The change of p53 and DR6 were 
detected by Western blot. Pifithrin-α and dominant-negative p53 were used to determine 
the role of P53 in miR-17 expression.
Results: By real time PCR, we identified that miR-17 was significantly increased 
in kidney tissues after 30 minutes of bilateral renal ischemia and 12h-48h reperfusion. 
In the moderate injury model of 25 minutes of ischemia, miR-17 was induced at day 
1 and the induction lasted for a week. In vitro, hypoxia also induced miR-17 in RPTC 
cells. Functionally, miR-17 mimic reduced apoptosis and caspase activation, whereas 
anti- miR-17-LNA increased apoptosis during hypoxia, suggesting a cytoprotective role 
of miR-17. Blockade of p53 with pifithrin-α or a dominant-negative mutant led to the 
suppression of miR-17 induction in hypoxia, supporting a role of p53 in this inductive 
response. Bioinformatics analysis predicted Death receptor 6 (DR6) as a target of miR-17. 
In line with this, we showed that the expression of DR6 was inhibited by miR-17 mimic, 
in contrast, increased by anti-miR-17-LNA.
Conclusions: MiR-17 is one of the microRNAs that are induced significantly during 
renal ischemia-reperfusion. MiR-17 induction is mediated by p53 and, upon induction, it 
may suppress downstream target genes, such as DR-6, to protect kidney cells and tissues 
from injury.
Funding: NIDDK Support, Veterans Administration Support, Government Support 
- Non-U.S.
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SA-PO280
Proximal Tubule-Derived CSF-1 Mediates Expansion and Polarization of 
Renal Macrophages/Dendritic Cells and Recovery in Acute Kidney Injury 
Yinqiu Wang, Bing Yao, Raymond C. Harris, Ming-Zhi Zhang.  Medicine, 
Vanderbilt Univ, Nashville, TN.
Background: Colony-stimulating factor-1 (CSF-1)-mediated renal macrophage 
expansion and polarization play an essential role in recovery from acute kidney injury 
in ischemia/reperfusion (I/R)-injury and selective apoptotic proximal tubule injury in 
transgenic mice expressing the human diphtheria toxin receptor (DTR) and exposed to 
DT (DTR-AKI). In the kidney, a major site of CSF-1 production is in proximal tubular 
epithelial cells.
Methods: Male DTR mice with CSF-1f/f (wild type) or with γ-GT-Cre:CSF-1f/f (CSF-1 
KO in renal proximal tubule) were used for DTR-AKI and for I/R injury (30 min of ischemia 
and contralateral nephrectomy).
Results: CSF-1 expression in the proximal tubule and its deletion in CSF-1 KO 
mice were confirmed with immunostaining. Six days after DTR-AKI, activation of the 
CSF-1 receptor (p-c-fms) was markedly attenuated in both renal tubules and interstitial 
cells, including macrophages (F4/80 and p-c-fms dual positive cells). Flow cytometry 
and qPCR indicated fewer renal macrophages/dendritic cells and reduced mRNA levels 
of M2 phenotype markers (CD206, IL-4Rα, TGF-β and 15-LOX) in CSF-1 KO mice 6 
days after DT injection. Although selective proximal tubule CSF-1 deletion did not affect 
the severity of kidney injury, it delayed renal functional recovery, in association with 
increased oxidative stress, increased secondary necrosis (HMGB1 expression) and severe 
tubulointerstitial fibrosis, with increased Picro-sirius red staining of fibrillary collagen 
and increased profibrotic and fibrotic components (α-SMA, CTGF, fibronectin, collagen I 
and IV). Selective proximal tubule CSF-1 deletion also led to delayed functional recovery 
after I/R injury, with decreased mRNA levels of M2 phenotype markers in isolated renal 
macrophages/dendritic cells and more severe renal fibrosis. In both I/R injury and DTR-
AKI, selective proximal CSF-1 deletion had minimal effects on the expression of M1 
phenotype markers.
Conclusions: These studies demonstrate that proximal tubule is a major source of 
CSF-1 that mediates the expansion and polarization of renal macrophages/dendritic cells 
that play an essential role in recovery following AKI.
Funding: NIDDK Support
SA-PO281
Ablation of Myo-Inositol Oxygenase Protects against Cisplatin-Induced 
Acute Kidney Injury by Inhibiting p53 Activation  Rajesh K. Dutta, Yashpal 
S. Kanwar.  Dept of Pathology, Northwestern Univ, Chicago, IL.
Background: MIOX is a renal tubular enzyme. Its role in the pathogenesis of diabetic 
nephropathy is currently being investigated. Conceivably, it modulates redox imbalance 
and apoptosis in tubular cells in diabetes via modulation of glucuronate-xylulose (G-X) 
pathway. However, its role in acute kidney injury (AKI) is unknown.
Methods: In this study we used both MIOX-over-expressing transgenic and MIOX 
null mice to elucidate its role in a model of cisplatin induced AKI.
Results: We observed severe cisplatin-induced proximal tubular injury in MIOX 
transgenic and protection in null mice compared to wild type mice. In transgenic mice 
an increased serum creatinine and urea levels, caspases-3 activity and tubular apoptosis 
along with marked deterioration of tubular morphology was observed. Renal injury was 
remarkably less in null mice compared to wild type mice. Cisplatin treatment led to p53 
activation in wild type and MIOX transgenic mice, whereas minimal p53 activation was 
observed in MIOX null mice. Likewise, we noted that cisplatin induces mTOR pathway 
in both wild type and MIOX transgenic mice while such an effect was not observed in 
MIOX null mice. Treatment with mTOR inhibitor, rapamycin, prevented cisplatin-induced 
MIOX expression, p53 activation and deterioration of tubular morphology in control mice. 
In vitro studies revealed significantly high levels of ROS generation, caspases-3 activity 
and apoptosis in MIOX over-expressing cells compared to control cells transfected with 
empty vector following cisplatin treatment.
Conceivably, this was attributed to the accentuated induction of GX-pathway and its 
associated myriad enzyme system.
Conclusions: Overall this study suggest that MIOX is a mediator of cisplatin induced 
AKI via activation of G-X-ROS-p53 pathway, and genetic deletion of MIOX protects the 
kidney tubules from cisplatin induced renal injury.
Funding: NIDDK Support
SA-PO282
Precision Medicine for AKI: Novel RNA Labeling Technique Demonstrates 
Unique Transcriptional and Cellular Responses in Different Injury Models 
Katherine Xu,1 Tian Shen,1 Alexandra Jacunski,1 Paul Rosenstiel,1 Neal A. 
Paragas,2 Jonathan M. Barasch.1  1Columbia; 2Univ of Washington.
Background: The clarity brought to CKD patients by Precision Medicine has not been 
applied to AKI, which is currently defined by the rise of a single analyte, the Pcreatinine 
(Pcr).
Methods: To identify specific molecular responses we investigated 3 models: (i) 
ischemia (10min bilateral pedicle clamping), (ii) volume depletion (72 hr water deprivation 
which matched the Pcr of the ischemic model) and (iii) a model of cystitis (small volume 
UPEC inoculation). We generated a novel technique of cell and time-specific Cre mediated 
in-vivo RNA labeling to purify specific RNA species directly from the kidney.
Results: We analyzed RNA pools from the entire Collecting Duct (CD) and its 
subset Intercalated Cells (IC). We found a robust genetic response of CD to volume 
depletion (94.5% of the induced genes) but a limited genetic response to ischemia (3.2% 
of induced genes) with very little overlap (2.3%). In contrast, the IC subset demonstrated 
a greater response to ischemia (62% of the induced genes) compared to volume depletion 
(32% of induced genes) and only 6% of the genes were shared. Remarkably, the IC cell 
population demonstrated an overwhelming specific response to cystitis (95% of induced 
genes). Region specific laser capture microdissection validated the cellular distinctions: 
ischemia and volume depletion induced different transcriptional changes in different cells 
with limited overlap. Moreover, functional analyses demonstrated activation of different 
molecular pathways, and different secreted proteins. Testing the urine of 100 Emergency 
Department patients revealed five new candidate biomarkers that distinguished ischemia 
and volume depletion.
Conclusions: We found that despite identical Pcr, ischemia and volume depletion 
targeted different regions, cell types and genes with limited overlapping genetic responses: 
the CD responded robustly to volume depletion while the IC were unique sensors of 
ischemia and infection. These data demonstrate that while Pcr can not distinguish between 
models of injury, the specific responses of the nephron provide Precision AKI diagnoses.
Funding: NIDDK Support, Private Foundation Support
SA-PO283
Calcium Oxalate Crystal-Induced Acute Kidney Injury Involves Ripk3-Mlkl 
Mediated Tubular Cell Necroptosis  Hans J. Anders,1 Jyaysi Desai,1 Santhosh 
Kumar Vr,1 Jonathan Nicodemos Eberhard,1 Dana Thomasova,1 Simone Romoli,1 
Andreas Linkermann,2 Shrikant R. Mulay.1  1Ludwig Maximillians Univ, Munich, 
Germany; 2Christian-Albrechts-Univ, Kiel, Germany.
Background: Crystalline nephropathy (CN) & nephro-/urolithiasis involves crystal-
induced renal inflammation via NLRP3 inflammasome (Mulay et al, JCI 2013), but the 
mode of direct crystal cytotoxicity remains elusive. The aim of the study was to investigate 
mechanisms of crystal cytotoxicity in kidney.
Methods: All in vivo experiments were approved by the local government authorities. 
Acute oxalate nephropathy (AON) was induced by i.p. injection of sodium oxalate (NaOx) 
(100mg/kg) and 3% NaOx in drinking water for 24hr. IHC, EM, RT-PCR, MTT assay, PI 
stain and multicolour FACS were used for data analysis.
Results: We found that crystals of calcium oxalate (CaOx), monosodium urate, calcium 
pyrophosphate dehydrate & cystine trigger caspase-independent necrosis of mouse tubular 
cells, human kidney cells & human renal progenitor cells. Pretreatment with RIPK1 inhibitor 
necrostatin-1 (Nec-1), MLKL inhibitor & RNA interference of RIPK3 or MLKL blocked 
crystal cytotoxicity. Consistently, deficiency of RIPK3 or MLKL protected mice from 
AON (e.g. plasma creatinine, BUN, tubular injury score, renal KIM-1 & ʌ-GST mRNA 
expression, neutrophil count and TUNEL+ve cells) despite similar crystal deposition. 
I.p. injection of crystals induced neutrophil recruitment into peritoneal cavity, which was 
unaffected by Nec-1 as was crystal injection into air pouches at the back of mice. However, 
Nec-1 significantly reduced microvascular permeability & leukocyte extravasation from 
post-ischemic cremaster muscles. Thus RIPK1 signaling per se does not affect neutrophil 
recruitment. Next, we found that AON was significantly reduced in Tnfr1-deficient mice, 
with no additive effects with concomitant Tnfr-2 deficiency. Thus, TNFR1 signaling 
activates RIPK3-dependent necroptosis in this model. Finally, etanercept, TNFR inhibitor 
R-7050 & Nec-1 protected mice from AON.
Conclusions: Crystal-cytotoxicity involves TNFR1-RIPK1-RIPK3-MLKL pathway. 
All components of this pathway represent novel molecular targets for therapeutic 
interventions to limit CN.
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SA-PO284
Allopurinol Protects against Rhabdomyolysis and Acute Kidney Injury 
Induced by a Membrane Protein (Lp25) from Pathogenic Leptospires 
Antonio C. Seguro,1 Daniele Canale,1 Patricia A. Abreu,2 Denize Monaris,2 
Tatiana B. Gotti,2 Larissa R. Matos,2 Thales de Brito,1 Pedro H F Gois,1 Antonio 
J. Magaldi.1  1Nephrology, Hospital das Clínicas FMUSP, São Paulo, Brazil; 
2Lab. de Bacteriologia, Inst Butantan, São Paulo, Brazil.
Background: Acute kidney injury (AKI) in leptospirosis is frequently nonoliguric, 
hypo or normokalemic. Higher serum potassium levels, elevated creatine phosphokinase 
(CPK) associated with maximum serum creatinine level were observed in nonsurvivor 
patients suggesting that rhabdomyolysis contributes to more severe AKI in leptospirosis. 
Previous study from our group demonstrated that Lp25, a protein membrane from pathogenic 
Leptospires, was responsible for hyperkalemic AKI induced by rhabdomyolysis in guinea 
pig. Recent studies suggest that Allopurinol (Allo) protects individuals from exercise-
induced rhabdomyolysis. The aim of this study was to evaluate the effect of Allo on guinea 
pigs injected with Lp25.
Methods: Three groups of guinea pigs were studied:1- Sham (phosphate-buffered 
solution);2- Lp25;3- Lp25+Allo. One mL of PBS and Lp25 (400µg of Lp25/mL) were 
intraperitoneally injected for 4 days. Lp25+Allo received Allo (300mg/L) in drinking 
water during this time. On the 5th day, animals were placed in metabolic cages for 12 
hour urine collection. We measured urinary volume (Ur V/12h), creatinine clearance (ml/
min/100gBW), serum potassium (mEq/L), CPK (U/L), uric acid (mg/dL), phosphate (mg/
dL).Data are mean±SEM.
Results: Lp25 induced hyperkalemia, rhabdomyolysis (elevated CPK, uric acid, 
phosphate) and oliguric AKI. Allo ameliorated CrCl, serum potassium, CPK and uric acid.
Cr Cl Ur V K CPK Uric acid P
Sham 
(n=7) 1.10± 0.18 25.1± 4.9 4.8± 0.3 897± 277 1.08± 0.19 6,9± 0.3
Lp25 
(n=8) 0.48± 0.05
 b 11.1± 
1.8 a 6.8± 0.5 
a 2852± 495 a 4.15± 0.48 b 9.3± 0.6 a
Lp25+ 
Allo 
(n=6)
0.91± 0.14 d 17.0± 3.7 5.1± 0.6 c 1331± 374 c 0.47± 0.07 d 8.4± 0.5
a p<0.05, b p<0.01 vs. Sham; c p<0.05, d p<0.001 vs. Lp25
Conclusions: These data demonstrate that Allo attenuates rhabdomyolysis and AKI 
induced by Lp25 in guinea pigs. This may represent a new therapeutic approach for AKI 
in patients with leptospirosis. (CNPq, FAPESP).
SA-PO285
Conventional Autophagy Regulates the Degradation of AQP2 in 
Hypokalemia  Wan-Young Kim,1 Sun-ah Nam,1 Yumi Kim,1 Arum Choi,1 Yong 
kyun Kim,2 Jin Kim.1  1Anatomy and Cell Death Disease Research Center, 
The Catholic Univ of Korea, Seoul, Korea; 2Internal Medicine and Cell Death 
Disease Research Center, The Catholic Univ of Korea, Buchoen, Korea.
Background: Autophagy is a catabolic pathway utilized to maintain a balance among 
the synthesis, degradation, and recycling of cellular component, thereby playing a role 
in homeostasis. Abundance of AQP2 is regulated through balance between production 
by tralation and removal by degradation. Although AQP2 degradation is supposed to be 
occurred via lysosomal or proteasomal degradation, the precise mechanisms still remain 
unknown. It has been known that prolonged hypokalemia causes vasopressin-resistant 
polyuria and induces autophagy especially in principal cells (PC) of collecting duct.
Methods: To investigate the role of autophagy in the degradation of AQP2, we 
generated AQP2-cre;Atg7f/f mice, in which Atg7, an essential gene for mammalian 
autophagy, was selectively inactivated in PCs. Hypokalemia was induced by K+-depleted 
diet for 2 weeks.
Results: In control AQP2-cre;Atg7f/f mice, the distribution pattern of AQP2 was not 
different from Atg7f/f mice. Immunolabeling of pS261-AQP2 was localized mostly subapical 
and punctate in appearance in the PCs. In contrast to pS261-AQP2, immunolabeling of 
pS256-AQP2 was localized mainly at the apical plasma membrane and subapical domains. 
In hypokalemic Atg7f/f mice, the abundance of pS261-AQP2 was significantly reduced and 
redistributed to intracellular vesicles, and co-localized with LC3-positive vacuoles. In 
hypokalemic AQP2-cre;Atg7f/f mice, there was a decrease of convertion of LC3-I to LC3-II 
and a marked accumulation of p62 selectively in PCs. Rab9 protein, an essential molecule 
for alternative autophagy pathway, and Rab9-positive vacuoles were markedly increased. 
Interestingly, pS261-AQP2 was distributed throughout the cytoplasm and not co-localized 
with Rab9- or LC3-positive vacuoles in the PCs of AQP2-cre;Atg7f/f mice. There was no 
difference in localization of pS256-AQP2 at the plasma membrane from each genotype.
Conclusions: These results suggest that down regulation of AQP2 in hypokalemia could 
in part be caused by degradation of pS261-AQP2 in PCs through a LC3/Atg7-dependent 
conventional autophagy pathway.
Funding: Government Support - Non-U.S.
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Early Autophagy Precedes Angiotensin II-Induced Podocyte Apoptosis 
Tae-Sun Ha.  Pediatrics, Chungbuk National Univ, Cheongju, Chungbuk, Korea.
Background: Autophagy is a highly regulated catabolic process that is involved in the 
turnover of unwanted cellular materials, on the other hand, apoptosis removes damaged or 
unwanted cells. Therefore, autophagy and apoptosis constitute the two processes through 
which injured/aged cells or organelles are eliminated. Angiotensin II (Ang II) induces 
podocyte injury resulting in apoptosis in vitro and in vivo. However, the relationship 
between autophagy and apoptosis in Ang II-induced podocytes is not elucidated and the 
role of Ang II-induced autophagy in podocyte survival remains unclear. We investigated 
the sequential relationship between autophagy and apoptosis in Ang II-induced podocytes.
Methods: Mouse podocytes were incubated in media containing various concentrations 
of Ang II and at different incubation times. The changes of podocyte autophagy and 
apoptosis were observed by electron microscopy, confocal imaging, Western blotting, 
and FACS assay according to the presence of Ang II. Results: Ang II-treated podocytes 
showed an increase in autophagosomes compared with control cells at early phase in a 
dose-dependent manner. This pro-autophagic effect of Ang IIwas inhibited by pretreatment 
with 3-methyladenine, an inhibitor of PI3-kinase class III. Ang IIalso enhanced podocyte 
expression of autophagic proteins such as LC3-II and beclin-1. Atg5 siRNA further reduced 
the expression of LC3-II and cleaved caspase-3 suppressed by Ang II at 12 hrs. However, 
Atg5 siRNA did not affect the expression of Atg5, LC3-II, and cleaved caspase-3 in the 
presence of Ang II at 24 hrs. Thereafter, Ang II induced podocyte apoptosis significantly in 
concentration- and time-dependent manners in FACS assays. LY294002 and Atg5 siRNA 
further increased podocyte apoptosis induced by Ang II. Therefore, high concentrations 
of Ang II induced apoptosis, while autophagy response decreased, which implicated that 
autophagy preceded apoptosis for cytoprotection in angiotensin II-induced podocyte injury.
Conclusions: We suggest that Ang II induced autophagy in mouse podocytes prior to 
apoptosis as an early adaptive cytoprotective mechanism for podocyte survival after Ang 
II treatment and the imbalance between autophagy and apoptosis causes podocyte injury.
Funding: Government Support - Non-U.S.
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Emodin Ameliorates Cisplatin-Induced Renal Tubular Cell Apoptosis 
Through Activation of Autophagy  Hong Liu,1 Wei Sun,1 Yigang Wan,2 
Liubao Gu.3  1Dept of Nephrology, Affiliated Hospital of Nanjing Univ of 
Chinese Medicine, Nanjing, China; 2Nanjing Drum Tower Hospital, The 
Affiliated Hospital of Nanjing Univ Medical School, Nanjing, China; 3Center 
for Diabetes Care, Education and Research, Jiangsu Province Inst of Geriatrics, 
Nanjing, China.
Background: Autophagy plays a key role in regulating cell survival. Emodin can 
ameliorate cisplatin-related nephrotoxicity. Thus, we explored the effects and mechanisms 
of emodin on cisplatin-induced apoptosis in NRK-52E cells by activation of autophagy.
Methods: NRK-52E cells were treated with cisplatin with or without emodin, cell 
morphology and expressions of cleaved Caspase-3 and autophagy makers LC3 I/II, were 
detected. Red fluorescent protein-LC3 (RFP-LC3) plasmid was transiently transfected 
into NRK-52E cells, and changes of RFP-LC3 fluorescent particles were observed by 
fluorescence microscopy. The level of LC3 was tested after treated with Bafilomycin 
A1 and mTOR inhibitor rapamycin. Besides, morphological changes of apoptotic cells 
were observed and cell death was evaluated by FACS analysis. Finally, AMPK/mTOR 
signaling pathway related proteins were detected. Further, changes of cell morphology 
and the level of cleaved Caspase-3 were detected after the addition of compound C, which 
is an AMPK inhibitor.
Results: Emodin improved cisplatin-induced cell shape change, cell viability and 
caspase 3 cleavage. This protective effect of emdoin was associated with increased LC3 
conversion and occurrence of RFP-LC3 punctate structures. Further studies revealed that 
the suppressive effect of emodin on cisplatin-induced apoptosis could be abolished by 
suppression of autophage with bafilomycin A1 and mimicked by activation of autophagy 
with rapamycin. Additionally, AMPK/mTOR signaling pathway was important for the 
induction of autophagy and inhibition of apoptosis.
Conclusions: Induction of autophagy could be an important mechanism by which 
emodin protected renal tubular cells against cisplatin-induced cell injury, and the potentially 
mechanism of emodin-induced autophagy may be attributed to the activation of AMPK 
and inhibiting mTOR signaling pathway. Emodin may have a therapeutic potential in the 
prevention of cisplatin-induced nephrotoxicity.
Funding: Government Support - Non-U.S.
SA-PO288
Autophagy in Renal Tubular Epithelial Cells Plays a Protective Role in 
Renal Fibrosis  Yong Kyun Kim,1 Sun-Ah Nam,2 Wan-Young Kim,2 Arum Choi,2 
Yumi Kim,2 Ho Cheol Song,1 Jin Kim.2  1Dept of Internal Medicine, College 
of Medicine, The Catholic Univ of Korea, Seoul, Korea; 2Dept of Anatomy and 
Cell Death Disease Research Center, College of Medicine, The Catholic Univ 
of Korea, Seoul, Korea.
Background: Renal tubulointerstitial fibrosis (TIF) is the final common pathway 
of various renal injuries. Autophagy is a cellular process of degradation of damaged 
cytoplasmic components and regulates cell death or proliferation. Recent studies reported 
that autophagy has protective role in renal TIF. However, the mechanism of autophagy 
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regulating fibrosis is not fully understood. In this study, we investigated the proposed 
mechanisms of autophagy in renal TIF induced by UUO by using conditional knockout 
mice in which Atg7 is genetically ablated specifically in tubular epithelial cell (TEC).
Methods: Atg7-floxed mice were crossed with Ksp-Cre mice to generate TEC-
specific Atg7 knockout mice (Atg7f/fl;Ksp-Cre+). Unilateral ureteral obstruction (UUO) 
was performed. We examine the expression of epithelial-mesenchymal transition (EMT) 
markers. The expression of TGF-β, plasminogen activator inhibitor 1 (PAI-1) and p62 as 
the regulators of EMT were examined. We determined apoptosis and proliferation of TECs 
and the expression of c-Myc as a regulator of cell apoptosis and proliferation.
Results: In vitro, TGF-β treatment induced autophagy. In vivo, TEC-specific Atg7 
deletion enhanced renal TIF after UUO. TEC-specific Atg7 deletion increase expression 
of TGF- β and enhance tubular EMT (decrease E-cadherin and increase α-smooth muscle 
antibody and vimentin) after UUO.In electron microscopy,TEC-specific Atg7 deletion 
results in ultrastructural alterations of TEC after UUO. TEC-specific Atg7 deletion increase 
expression of PAI-1, P62 after UUO. TEC-specific Atg7 deletion enhanced apoptosis and 
proliferation of TECs after UUO. The expression of c-Myc was significantly increased 
mice with TEC-specific Atg7 deletion after UUO.
Conclusions: Our data suggest that autophagy regulate EMT through TGF-β, PAI-1 
and P62 during renal TIF. Autophagy also regulates apoptosis and proliferation of TECs 
through the expression of c-Myc during renal TIF. Autophagy could represent a therapeutic 
target for renal TIF.
SA-PO289
Partial De-Differentiation of Parietal Epithelial Cells Caused by Reduced 
Expression of Sirt1 and Concomitant Increased Expression of p21 and 
CD133 in Diabetic Nephropathy  Kazuhiro Hasegawa, Shu Wakino, Hiroshi 
Itoh.  Keio Univ.
Background: We have previously reported the role of proximal tubular Sirt1 in 
diabetic nephropathy (DN). Parietal epithelial cells (PECs) and their cellular metabolism 
reportedly play a pivotal role in kidney. Sirt1 is a key energy sensor, whereas DN disrupts 
energy metabolism.
Methods: Thus, we examined the effect of Sirt1 expression in PECs on DN.
Results: In two DN murine models including streptozotocin-treated and db/db mice, 
expression of Sirt1 in proximal tubules and PECs was decreased at 8 weeks after the onset 
of DN, corresponding to the early stage of DN. Sirt1 expression was also downregulated in 
podocytes at 24 weeks. We further investigated the changes in PECs at 8 weeks. No change 
was found in the number of PECs. The morphology of all PECs showed hypertrophy, 
and some PECs contained autophagic vesicles, especially in the periphery or the border of 
the plasma membrane at basolateral sides.
HG treatment of cultured PECs resulted in significant reductions in cell proliferation 
and migration, while increasing the production of extracellular and basement membrane 
components such as type IV collagen. We performed DNA microarray, confirmatory real-
time PCR, and immunofluoresence, revealing that an increase in Glut1 (glucose transporter) 
expression promoted influx of high amounts of glucose into PECs, which led to a reduction 
in Sirt1 expression and lysine acetylation-mediated activation of p21. Among the main 
molecular markers of precursor cells, including CD24, CD44, and CD133, only CD133 
showed remarkable elevation, indicating that the decrease in Sirt1 expression caused the 
partial de-differentiation of PECs.
Conclusions: Sirt1 may be a promising target for protection against DN-induced de-
differentiation of PECs, which would prevent not only hypertrophy of PECs but also the 
concomitant thickening of the basement membrane of Bowman’s capsule.
SA-PO290
APOL1 Variants are Critical to Induce Vitamin D Receptor (VDR) Down 
Regulation in Dedifferentiated Podocytes  Shabirul Haque,1 Ashwani 
Malhotra,1 Karl Leon Skorecki,2 Pravin C. Singhal.1  1Medicine, Hofstra North 
Shore LIJ Medical School, Great Neck, NY; 2Medicine, Rambam Health Care 
Campus, Haifa, Israel.
Background: African Americans carrying APOL1 variants (Vs) are prone to develop 
HIV-associated nephropathy (HIVAN). Recently, vitamin D receptor (VDR) has been 
reported to play a critical role in the development of HIVAN. We hypothesized that HIV-
induced dedifferentiation of podocytes is the first hit but to accelerate the injury a sustained 
second hit is needed and may be the sustained down regulation of VDR. Down regulation of 
VDR has been reported to activate renin angiotensin system in kidney cells. HIV-induced 
low VDR status in kidney cells has been shown to contribute to the progression of HIVAN. 
We asked whether APOL1 variants would be contributing to accelerate podocyte injury 
in HIV milieu through down regulation of VDR. In the present study, we evaluated the 
effect of APOL1 variants on podocyte VDR expression both in differentiated (DPs) and 
dedifferentiated podocytes (DDPs).
Methods: RNAs were extracted from human podocytes (both DPs and DDPs) stably 
expressing vector, G0, G1 and G2. cDNAs were amplified with a specific VDR primer 
specific. Vector, G0, G1 and G2 expressing DPs and DDPs were infected with HIV followed 
by Western blotting and probing for SNAIL (a transcriptor of VDR). Additionally, the effects 
of APOL1 variants were evaluated on glycosylation and methylation status of SNAIL.
Results: DDPs expressing G1 and G2 displayed moderate decrease in VDR mRNA 
expression, whereas, G0 expressing DDPs displayed only mild decrease in VDR expression. 
There was no alteration in VDR mRNA expression in DPs expressing either G0 or G1/
G2. Vector-expressing DPs and DDPs did not reveal any expression of SNAIL. On the 
other hand, G0 and G1/G2 expressing DPs and DDPs displayed moderate expression of 
SNAIL. HIV further enhanced SNAIL expression by DPs and DDPs expressing G1/G2.
Conclusions: We conclude that APOL1 modulates VDR expression in DDPs only. 
Since HIVAN occurs in APOL1 variants only, presence of APOL1 variants seems to be 
critical to sustain HIV-induced podocyte injury.
SA-PO291
Post-Transcriptional and Post-Translation Status of APOL1 (G0) and Its 
Variants (G1and G2) in Podocytes and 293T Cells Post-Transcriptional 
and Post-Translation Status of APOL1 (G0) and Its Variants (G1and G2) 
in Podocytes and 293T Cells  Shabirul Haque,1 Xiqian Lan,1 Gauri P. Patil,1 
Amrita Kaur Chawla,1 Ashwani Malhotra,1 Karl Leon Skorecki,2 Pravin C. 
Singhal.1  1Medicine, Hofstra North Shore LIJ Medical School, Great Neck, 
NY; 2Mediciine, Rambam Health Care Campus, Haifa, Israel.
Background: APOL1 gene variants have been reported to contribute to higher 
prevalence of kidney diseases in African Americans. APOL1 gene is known to contribute 
to kidney cell injury but the mechanisms involved are not clear. Interestingly, renal biopsy 
specimens in kidney disease patients with of APOL1 variants displayed lower podocyte 
expression of APOL1. However, the involved mechanism for lower APOL1 expression 
in these patients is not clear. Gene sequence alterations/mutations hamper either mRNA 
transcription stability or defects in protein translation. We hypothesized that mutation in 
APOL1 would lead to modulation of protein expression in podocytes.
Methods: Protein blots of human podocytes (HPs) stably expressing vector, APOL1G0, 
APOL1G1 and APOL1G2 were probed for APOL1 and reprobed for acitn. RNAs were 
extracted with HPs expressing Vec, G0, G1 and G2 and cDNA were amplified with APOL1 
specific primer. 293 T cells were transfected with equal amount of plasmids (vector, G0, 
G1, and G2) for 48 hours. Protein blots were probed for APOL1 and reprobed for actin. To 
evaluate stability/decay rate of APOL1 mRNA, APOL1/APOL1variants expressing HPs 
were pulsed with actinomycinD and RNAs were harvested at different time points (0.0, 
0.5, 1.0, 3.0, 8.0, and 24 hours) by Trizol method.
Results: APOL1 variants (G1/G2) expressing HPs displayed lower expression of 
APOL1 when compared APOL1G0. 293 T cells also displayed lower expression of G1 and 
G2. However, there was no difference in mRNA expression in APOL1G0 and APL1G1/
G2 expressing cells. Stability/decay kinetic assay revealed that variants (G1 and G2) of 
APOL1 mRNA decayed in an accelerated mode (more than 35%) during ½ to 24 hours 
after actinomycin D exposure.
Conclusions: These findings suggest that APOL1 variants protein instability may 
be related to loss/decay of variants APOL1 mRNA or to some extent defects in protein 
translation/stability.
Funding: NIDDK Support
SA-PO292
HIV Promotes NLRP3 Inflammasome Complex Activation in HIVAN 
Shabirul Haque, Xiqian Lan, Amrita Kaur Chawla, Rivka Lederman, Rabani 
Bharara, Ramachandra prasanna Bongu, Ashwani Malhotra, Pravin C. Singhal. 
Medicine, Hofstra North Shore LIJ Medical School, Great Neck, NY.
Background: Dysregulated growth and loss of podocytes are important features of 
HIV-associated nephropathy (HIVAN). In a recent report, HIV induced programmed cell 
death in T cells has been implicated to pyroptosis as a consequence to inflammasome 
formation. We hypothesized HIV would also be promoting podocyte loss through the 
induction of pyroptosis. We evaluated the role of HIV in podocyte NOD-like receptor 
family, pyrin domain containing (NLRP) 3 protein complexes (inflammasomes) formation 
both in vitro and in vivo.
Methods: Renal cortical sections of control and Tg26 (HIVAN) mice (n=4) were 
labeled for inflammasome molecular markers (IMMs; NLRP3, ASC, cleaved caspase-1 
and IL-1β). Protein blots of renal tissues of control and Tg26 mice were also probed for 
IMMS and actin (n=11). Protein blots of empty vector (EV) - and NL4-3 (HIV)-transduced 
human podocytes (HPs) were probed for IMMs and actin (n=4). EV/HPs and HIV/HPs 
were evaluated for pyroptosis by PI staining under a fluorescence microscope as well as 
by FACS analysis. Effect of Tempol (SOD mimetic), caspase-1 inhibitors, and glyburide 
(an inhibitor of K-efflux inhibitor was evaluated on HIV induced podocyte pyroptosis by 
morphologic assay and FACS analysis.
Results: Renal cortical sections of HIV-transgenic mice (Tg26) displayed increased 
podocyte expression IMMs. Renal tissues of Tg26 mice also displayed enhanced mRNA 
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expressions as well as protein expressions of IMMs. Serum from Tg26 mice showed higher 
levels of IL-1β. HIV promoted pyroptosis in podocytes in a dose as well as time dependent 
manner. Since caspase-1 inhibitor not only attenuated podocyte expressions of caspase-1 
and IL1β in addition to protection against pyroptosis; this would confirm that HIV induced 
podocyte injury was mediated by caspase-1 activated complexes. Interestingly, HIV-induced 
podocyte pyroptosis could be partially inhibited by tempol as well as by glyburide.
Conclusions: These findings indicate that generation of reactive oxygen species and 
potassium efflux contributed to HIV-induced pyroptosis in podocytes.
SA-PO293
Urinary Cytochrome C (Cyto C) Detects Subliminal Injury and Correlates 
with Apoptosis in Acute (AKI) and Acute on Chronic Kidney Disease 
(A-CKD)  Lena Succar,1 Philip Peake,1 Zoltan H. Endre.1  1Prince of Wales 
Hospital and Clinical School, Univ of New South Wales, Sydney, NSW, Australia; 
2Prince of Wales Hospital and Clinical School, Univ of New South Wales, Sydney, 
NSW, Australia; 3Prince of Wales Hospital and Clinical School, Univ of New 
South Wales, Sydney, NSW, Australia.
Background: Mitochondrial Cyto C is a potentially specific biomarker of apoptotic 
kidney injury in AKI. We investigated urinary Cyto C in detecting subliminal kidney injury 
(histological injury without an increase serum creatinine, sCr) in two models of A-CKD.
Methods: In male Sprague Dawley rats (i) adenine-CKD was induced by diet 
supplementation with 0.025% adenine, days (d) 0 to 28 and monitored until d56 (n=8). 
On d56, AKI was induced in rats by a subnephrotoxic (2mg/kg; n=8) or nephrotoxic 
(4mg/kg; n=8) cisplatin (Cis) dose ip and monitored to d63 (n=8 in matched controls). 
(ii) Aristolochic-acid nephropathy (AAN) induced by AA-1 (10m/kg) ip for five days and 
monitored to d21 (n=6) or d42 (n=6) then given 2mg/kg (n=6) or 4mg/kg (n=6) Cis and 
monitored to d28 and d49 respectively. Cyto C was measured by ELISA. Tubulointerstitial 
damage (TID) and TUNEL were quantified on d63.
Results: Cyto C levels increased in subliminal AAN (d1 to d7) and adenine-CKD 
(d3 to 21) without change in sCr, but increased in both CKD groups after 2mg/kg and 
4mg/kg Cis dose in controls. In AAN, Cyto C levels increased progressively (d22 to d28) 
after Cis exceeding controls given 4mg/kg whereasCyto C was lower after Cis on d42 to 
d49. Regardless of Ci dose, Cyto C increased in controls and adenine-CKD. A-CKD rats 
displayed diffuse medullary and cortical TID with positive TUNEL staining while injury in 
CKD alone was largely in outer medulla. In ANN peak Cyto C,72 hours post Cis, correlated 
significantly with outer medullary (Spearman R=0.86*)and cortical apoptosis (R=0.81*). In 
adenine fed rats, Cyto Ccorrelated only with medullary apoptosis (R=0.79*). sCr correlated 
only with severe diffuse cortical TID (R=0.94*) (*P<0.05).
Conclusions: Cyto C detected subliminal injury and correlated strongly with outer 
medullary apoptosis in A-CKD, which alone did not increase sCr. Cyto C is a useful 
biomarker for early detection of apoptotic kidney injury.
SA-PO294
Assessment of Graphene Toxicity to Kidney Tubular Epithelial Cells and 
Cell Spheroids Using DNase Activity Probe  Tariq Fahmi,1 Zeid A. Nima,2 
Julietta Sargsyan,1 Alexandru S. Biris,2 Alexei G. Basnakian.1  1Pharmacology 
and Toxicology, Univ of Arkansas for Medical Sciences, Little Rock, AR; 2Univ 
of Arkansas at Little Rock, Center for Integrative Nanotechnology Sciences, 
Little Rock, AR.
Background: Recently invented nanomaterial, graphene, consists of monomolecular 
carbon sheets, which are extremely strong, light and flexible. It will be used widely because 
of its versatility. However, little is known about its potential for being a toxicant and 
environmental hazard, and methods to study graphene toxicity are not established. Kidney 
is one of the primary organs for the assessment of nanomaterial toxicity. We hypothesized 
that graphene induces nephrotoxicity mainly through DNA destruction, and measuring of 
DNase activity by using near infrared fluorescence (NIRF) DNase activity probe would 
be a reliable tool for assessing graphene cytotoxicity.
Methods: Non-modified graphene (50 µg/ml) exposed with cultured rat kidney tubular 
epithelial NRK-52E cells induced TUNEL-type DNA fragmentation usually associated with 
cytotoxicity. Raman spectroscopy showed the TUNEL-positive cells have significantly 
higher graphene content than TUNEL-negative cells. DNase activity was quantified in 
live cells using the oligonucleotide-based NIRF probe. Quantitative immunocytochemistry 
(qICC) was then used to measure apoptotic DNases such as caspase-activated DNase 
(CAD), endonuclease G (EndoG), and DNase I, and the marker of oxidative stress, heme 
oxygenase-1 (HO-1).
Results: The NIRF fluorescence and all of the above qICC markers were induced in 
NRK-52E cells by graphene exposure. In addition, a 50% colocalization of HO-1 with 
DNase activity was observed suggesting a possible link between oxidative stress and the 
DNases. Furthermore, we developed kidney spheroids (mini-kidneys) model by culturing 
NRK-52E cells using 3D hanging drop method, and tested the graphene toxicity in this 
model by measuring the DNase activity using the NIRF probe. The result showed a strong 
dose-dependent increase of DNase activity induced by graphene.
Conclusions: Measuring of DNase activity by using NIRF probe in combination 
with TUNEL assay and qICC are appropriate tools for assessment of graphene toxicity.
Funding: NIDDK Support, Other U.S. Government Support, Veterans Administration 
Support
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Identification of a Novel Bidirectional Regulatory Mechanism Involving 
AKT/β-Catenin and Anillin That Drives Podocyte Proliferation 
Gentzon Hall,1,3,4 Jose A. Gomez,1 Brandon M. Lane,2,4 Guanghong Wu,4 Himani 
Vaidya,4 Robert F. Spurney,1,3 Rasheed A. Gbadegesin.2,3,4  1Internal Medicine, 
Duke Univ; 2Pediatrics, Duke Univ; 3Nephrology, Duke Univ; 4Duke Molecular 
Physiology Inst, Duke Univ.
Background: Mutations of the F-actin binding protein Anillin (ANLN) have been shown 
to cause familial FSGS. Although ANLN is a suspected modulator of phosphoinositol-3 
kinase (PI-3K) signaling, specific interactions with PI-3K pathway intermediates and the 
role of these interactions in the pathogenesis of FSGS remains unknown.
Methods: siRNA-mediated gene knockdown studies, immunoblot and proliferation 
assays were performed by standard methods in conditionally immortalized human 
podocytes (CIHP) to examine the effects of ANLN depletion on PI-3K pathway signaling 
in podocytes. CIHP lines stably expressing tGFP-vector control or tGFP-ANLNWT were 
established via lentiviral transduction to characterize the effects of ANLN overexpression 
on PI-3K signaling in podocytes.
Results: We evaluated the effect of ANLN overexpression and targeted ANLN 
knockdown (KD) on AKT activation in podocytes. Additionally, we explored the effects of 
pharmacologic inhibition of AKT on ANLN expression in podocytes. Finally, we examined 
the role of AKT-mediated activation of β-Catenin via the direct phosphorylation of serine 
552 in podocyte ANLN expression. We determined that ANLN overexpression significantly 
attenuated AKT activation. Conversely, ANLN KD significantly enhanced AKT activation 
and upregulated AKT-mediated phosphorylation/activation of β-Catenin at serine 552. 
Pharmacologic inhibition of AKT also inhibited basal podocyte proliferation. Finally, we 
demonstrated that pharmacologic inhibition and targeted gene knock down of β-Catenin 
significantly attenuated podocyte ANLN expression.
Conclusions: These findings elucidate a novel mechanism of reciprocal regulation 
involving AKT/β-Catenin signaling and ANLN which may provide valuable insights into 
the role of ANLN in the pathogenesis of FSGS and other proliferative podocytopathies.
SA-PO296
Akt Mediates Cell Survival in Proteinuric States  Elif Erkan, Jian Gao, 
Sam Z. Coffey.  Pediatrics, Cincinnati Children’s Hospital Medical Center, 
Cincinnati, OH.
Background: The degree of proteinuria correlates with progression in association 
with tubulointerstitial injury in glomerulonephritis. High concentrations of albumin in 
the glomerular filtrate results in apoptosis. Protein kinase B (Akt) is a serine/threonine 
kinase involved in multiple signaling events including cell survival. We hypothesize that 
down regulation of survival protein, protein kinase B (Akt) triggers tubular apoptosis in 
proteinuric states.
Methods: We utilized in-vitro and in-vivo model of albumin overload. Human kidney 
proximal tubule epithelial cells (HKC-8) are exposed to 10mg/ml albumin for 24-hours to 
induce apoptosis. C57BL/6C mice are exposed to 10mg/g of intraperitoneal(ip) albumin 
injections for 6 weeks to induce albuminuria. Fluorometric caspase-3 assay and TUNEL 
staining were utilized to asses apoptosis. Protein expression was assessed by Western 
blotting and immunofluorescence. Kidney sections from bigenic (Fyn-/-Cd2ap+/-) mice 
model of FSGS and patients with FSGS were evaluated for apoptosis and Akt expression.
Results: Albumin overload in-vivo and in-vitro resulted in proximal tubule epithelial 
cell apoptosis in association with down regulation of pser473 Akt and Thr-308 Akt 
expression. Furthermore mice model of FSGS and patient kidney biopsies confirmed down 
regulation of tubular pser473 Akt expression in association with apoptosis. Overexpression 
of Akt by a constitutively active mutant ameliorated the albumin induced apoptosis where as 
chemical inhibition of Akt by of MK2206 enhanced albumin induced apoptosis in HKC-8 
cells. Phosphorylation of downstream targets of Akt, transcriptional factors forkhead family 
Foxo1 and 3 is inhibited in association with apoptosis in response to albumin overload.
Conclusions: Down regulation of Akt expression in proteinuric states results in 
tubular apoptosis which is a precursor to tubular atrophy. We postulate that decreased 
Akt phosphorylation of Foxo proteins allow them to translocate to nucleus and induce 
apoptotic gene expression. Therapeutic interventions directed to increase Akt expression 
in tubular epithelial cells can serve to prevent tubulointerstitial injury by inducing cell 
survival in proteinuric states.
Funding: NIDDK Support, Pharmaceutical Company Support - Malincrodt
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Altered Protein Kinase Signalling Causes Major Phenotypical 
Changes in Renal Cells from Patients with Nephropathic Cystinosis 
Ekaterina A. Ivanova,1 Fanny Oliveira Arcolino,1 Maria Pia Rastaldi,2 Lambertus 
P.W.J. Van den Heuvel,1 Elena N. Levtchenko.1  1Pediatric Nephrology, UZ 
Leuven, KU Leuven, Leuven, Belgium; 2IRCCS Policlinico, Milano, Italy.
Background: Cystinosis is caused by mutations affecting the lysosomal cystine 
transporter cystinosin and results in lysosomal cystine accumulation. Cystinosis causes 
proximal tubular dysfunction, but also glomerular damage, which is present starting from 
early age. Current therapy of cystinosis is based on cystine-lowering cysteamine treatment, 
which greatly improves the prognosis, but does not cure the Fanconi syndrome and fails 
to prevent kidney damage in the majority of patients. It is therefore likely that, apart from 
the transporter function, cystinosin is implicated in other important cellular processes. We 
have investigated the mTORC-Akt signalling cascade in cystinosin-deficient renal cells. 
Akt kinase lies at the crossroads of cellular signalling regulating cytoskeleton, motility, 
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response to stress and survival, and is a target of mTORC2 and an upstream activator of 
mTORC1. mTORC1 is the master regulator of autophagy and metabolism. mTORC1 and 
2 are also implicated in the regulation of cytoskeleton and cell motility.
Methods: Using conditionally immortalized proximal tubular epithelial cells (PTECs) 
and podocytes originating from cystinosis patients and healthy donors, we performed 
biochemical and microscopic analysis of phosphorylation and activation of protein kinases 
in response to various stimuli.
Results: Phosphorylation of Akt1 and 2 was increased in cystinosis podocytes and 
PTEC in response to nutrient/growth factor replenishment and wounding of cellular 
monolayer. In podocytes, such increased phosphorylation, was associated with altered 
cytoskeleton, disturbed focal adhesion sites and increased motility. Treatment with specific 
Akt inhibitor demonstrated a prominent decrease of motility and Akt phosphorylation. 
mTORC1 activation in response to nutrient replenishment was delayed in cystinosis PTECs 
accompanied with abnormal subcellular distribution of the kinase complex, as revealed by 
antibody staining of mTOR.
Conclusions: We demonstrate that cystinosin dysfunction is associated with disturbed 
signalling of protein kinases mTORC1 and Akt1 and 2.
Funding: Private Foundation Support
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Interstitial Pericytes Decrease in Aged Mouse Kidneys  Anna Maria Stefanska,1 
Diana G. Eng,1 Natalya V. Kaverina,1 Jeremy Stuart Duffield,2 Jeffrey W. Pippin,1 
Stuart J. Shankland.1  1Div of Nephrology, Dept of Medicine, Univ of Washington, 
Seattle, WA; 2Biogen Idec, Cambridge, MA.
Background: With increasing age, the kidney undergoes characteristic changes in the 
glomerular and tubule-interstitial compartments, which are ultimately accompanied by 
reduced kidney function. Studies have shown age-related loss of peritubular vessels. Normal 
peritubular vessel tone, function and survival depend on neighboring pericytes. Pericyte 
detachment leads to vascular damage, which can be accompanied by their differentiation 
to fibroblasts and myofibroblasts, a state that favors matrix production.
Methods: To better understand the fate of pericytes in the aged kidney, 27-month-old 
mice were studied. Picrosirius red staining was performed to evaluate kidney fibrosis. 
Histological sections were stained against endothelial antigen CD31 together with pericyte 
markers PDGFRß and NG2. Additionally, immunoreactivity of myofibroblast marker aSMA 
was assessed together with pericytes.
Results: Compared to 3 month-old young adult mice, aged kidneys showed a substantial 
decrease in capillaries, identified by CD31 staining, in both cortex and medulla. This was 
accompanied by a marked decrease in surrounding NG2+/ PDGFRß+ pericytes. This decrease 
was more pronounced in the medulla. Capillaries devoid of pericytes were typically dilated 
in aged mice. Aged kidneys were also characterized by interstitial fibrosis due to increased 
collagen-I and -III staining. This was accompanied by an increase in the number of pericytes 
that acquired a pro-fibrotic phenotype, identified by increased PDGFRß+/ aSMA+ staining.
Conclusions: These findings are consistent with the decline in kidney interstitial 
pericytes as a critical step in the development of changes to the peritubular vasculature 
with aging, and accompanying fibrosis.
Funding: Other NIH Support - R24 DK094768-01, R01 DK093493-02
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Interactions of Urotensin II and Mitophagy in Diabetic Nephropathy and 
Its Implications on Drug Design  Guan-Jong Chen, Fei Wu, Ai-hua Zhang. 
Dept of Nephrology, Peking Univ Third Hospital, Beijing, China.
Background: Urotensin II (UII), an important vasoactive neuropeptide, and the 
processes of mitophagy have been considered as possible therapeutic targets for treating 
diabetic nephropathy (DN). The present study is to define the interaction between UII and 
the process of mitophagy under the setting of DN.
Methods: Immunohistochemistry and western blot analysis were conducted on the 
protein extracts harvested from the kidney tissues of DN mice that were induced eighteen 
weeks after the injection of streptozotocin. For in-vitro cell experiment, HK-2 cells were 
cultured and treated with different concentrations of UII (10-7-10-9 mol/L) for 12 h and 3-MA 
treatment was used as a negative control. The cell protein extracts were then analyzed by 
western blot. For immunohistochemistry and western blot analysis, BNIP3 was used as 
a marker for mitophagy.
Results: Immunohistochemistry and western blot analysis results of the animal renal 
extracts show that the expressions of UII and BNIP3, marker of mitophagy, are upregulated 
for DN kidney compared to that of controls. In-vitro cell experiment results also demonstrate 
UII can upregualte BNIP3. Our data indicates that UII expression is positively associated 
with the expression of BNIP3.
Conclusions: Our results indicate that UII expression can upregulate mitophagy in DN. 
Past studies already demonstrate that mitophagy can have a therapeutic role in DN. Our 
study carries the implication that UII and its effect on the process of mitophagy presents 
potential opportunities for developing novel treatments for DN.
Funding: Government Support - Non-U.S.
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Reduction in CTGF Leads to Increased Proliferation Through Influences on 
Claudin-1 and Extracellular Matrix Protein Spondin 2  Leighton R. James, 
Yongxin Gao.  Medicine, Univ of Florida, Jacksonville, FL.
Background: Accumulation of extracellular matrix is a characteristic feature of diabetic 
kidney disease. We have recently demonstrated that connective tissue growth factor (CTGF) 
mediate increases in extracellular matrix production, proteinuria and scarring in mice. In 
addition, CTGF may have anti-proliferative properties. In specific human neoplasm (breast, 
colon), increased CTGF have been linked to reduced proliferation, improved response to 
therapy and prognosis but data is not consistent. On the other hand, metastatic melanoma 
progression correlates with CTGF levels and inhibition of CTGF reduces invasion and 
migration.
Methods: To define a possible role for CTGF in proliferation, embryonic fibroblasts 
(MEF) generated from wild-type and a previously reported CTGF knock mice line were 
studied. Expression array (Illumina) was used to identify changes in gene expression in 
MEF. Protein expression was assessed by Immuno-blotting. Inhibitors of MAPK (SP600126, 
SB203580 and U0126) were used to assess role of MAPK in glucose-mediated CTGF 
expression by cultured MEF.
Results: CTGF gene disruption lead to enhanced proliferation (3-fold) in CTGF 
knockout cells compared with wildtype cells. Reduced CTGF led to 50% decreased 
expression of the gene for the extracellular protein, procollagen 4, alpha 2 (Col4a2; 
confirmed at protein level)) in association with 2.8-fold increased expression of cluadin-1, a 
member of the tight junction proteins. In addition, there was a 3.2-fold increased expression 
of spondin-2 and a 1.6-fold increased expression of Secreted protein, acidic and rich in 
cysteine-like 1 (SPARCL1). Immunoblotting confirmed the observation for claudin 1. 
Glucose induced CTGF expression (2-3 fold) was attenuated by inhibitors of p38MAPK 
and JNK, but unaffected by inhibition of ERK (p42/44 MAPK).
Conclusions: In MEF, CTGF gene disruption leads to increased proliferation and 
altered matrix protein linked to increased expression of claudin 1 and other extracellular 
protein. Secondly, glucose-induced CTGF level is mediated by MAPK (p38 and JNK). 
Targeted alteration in CTGF along with one or more of these extracellular protein may 
offer new approahes to manage glomerulosclerosis.
Funding: Private Foundation Support, Clinical Revenue Support
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miR21 Upregulates YY1 to Increase Renal Cell Apoptosis in Diabetes 
Adam Kosti,1,2 Sitai Liang,1,2 Samy L. Habib.1,2  1Geriatric Research, Education 
and Clinical CTR, South Texas Veterans Health System, San Antonio, TX; 
2Cellular and Structural Biology, The Univ of Texas Health Science Center, 
San Antonio, TX.
Background: The regulation of miRNAs in response to hyperglycemia that contributes 
to the pathogenesis of kidney disease has been underscored.
Methods: In the current study, we investigated the role of miR21 in regulation of cells 
apoptosis in human renal proximal tubular cells (Hk2) cells exposed to high glucose and 
in type II diabetes mouse model.
Results: Cells pretreated with either miR21 inhibitor or antisense before exposed to HG 
resulted in decrease YY1 expression and decrease cleavage of caspase 3. Nuclear extracts 
from Hk2 cells exposed to high glucose for 48hrs showed increase in binding of YY1 to 
the miR21 promoter element in nuclear extracts of cells by EMSA. On the other hand, 
pretreatment with miR21 inhibitor or antisense significantly decrease the binding of miR21 
to YY1 in nuclear extracts of cells grown in NG or treated with HG. The DNA-protein 
complexes were significantly decreased in the presence of the YY1 antibody, indicating 
that YY1 is indeed a component of these complexes. Transfected the cells with promoter/
reporter construct of miR21 showed significant increase in miR21 promoter activity in 
cells exposed to HG while cells pretreated with miR21 inhibitor reverse the effect of HG. 
In addition, significant increase in the percentage of TUNEL-positive tubular cells stained 
in the kidney sections of dbdb mice compared to kidney sections of the wild type mice. 
Quantitation of miR21 by real-time PCR showed significant increase miR21 levels in 
kidney of diabetic mice (db/db) compared to kidneys from wild type mice. Immunostaining 
analysis of miR21 showed that majority of miR21 staining within the tubular cells and 
glomerular compartments.
Conclusions: In summary, expose renal cells to HG and increase hyperglycemia in 
kidney of diabetic mice resulted in significant increase in miR21. Increase binding of YY1 
to miR21 under HG condition suggesting the important role of miR21 in regulating YY1 to 
increase cell apoptosis. The data provide a novel role of miR21 as a target for controlling 
renal cell death that induced by hyperglycemia during diabetic nephropathy.
Funding: Veterans Administration Support
SA-PO302
The Role of miR-302 and Let7 in Macrophage Polarization  Thomas K. Dodd, 
John Crean, Letizia De Chiara, Orina Belton.  Diabetic Complications and 
Reneal Disease, Univ College Dublin, Dublin, Ireland.
Background: Recent advances in the pathogenicity of renal injury highlighted the 
critical role of the immune system in the onset and resolution of disease. Monocytes canto 
differentiate along two pathways: pro-inflammatory (MI) due to the secretion of cytokines 
such as IL-6 and a pro-resolution attributable to the secretion of cytokines such as IL-10. 
Banerjee et al. have suggested that the ratio of M1 and M2 macrophages is controlled by 
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interplay between two micro RNAs, miR302 and Let7. We have recently shown that the 
silenced targets of miR302 and Let 7 are the TGFβ type II and type I receptors respectively 
and hypothesize that this circuitry plays a critical role in macrophage differentiation.
Methods: The pro-resolving lipid mediator, conjugated linoleic acid (CLA), inhibits the 
acquisition of a pro-inflammatory macrophage phenotype by priming monocytes towards an 
anti-inflammatory M2 phenotype. To identify pathways associated with this phenotype we 
performed proteomic analysis of THP-1s treated with CLA. Exosomes were isolated from 
urine samples taken from patients with renal injury and analyzed for miRNA expression. 
Renal cells were transduced with miR-302 and let7 virus. TGFβ receptor expression and 
signaling was analyzed by Western blot. Additionally, Thp-1 cells were transduced with 
miR302 and let7 and their effect on macrophage differentiation assessed for expression 
of CD68 and CD206.
Results: Bioinformatic and Western blot analysis revealed enrichment of the TGFβ 
signaling pathway in THP-1 cells treated with CLA. miR302 expression was increased in 
the urine of patients compared to controls. Cells transduced with miR302 and Let7 displayed 
low levels of expression of the TGFβ type 2 and type 1 receptors respectively and dampened 
Smad3 phosphorylation. miR302 and let7 prevented renal epithelial cell dedifferentiation. 
THP-1 cells transduced with both miRs demonstrated similarly enhanced plasticity.
Conclusions: miR302 and let7 have potential injury resolving roles in renal disease. 
Manipulation of this circuitry results in enhanced cell plasticity. In vitro studies suggest 
that this results in the generation of pro-resolution cellular phenotypes in both resident 
cells and macrophages.
SA-PO303
Dopamine D2 Receptor Regulates Wnt3/β-Catenin Signaling and Apoptosis 
in Human Renal Proximal Tubule Cells  Fei Han,1 Prasad Konkalmatt,2 
Jianghua Chen,1 Pedro A. Jose,2 Ines Armando.2  1Kidney Disease Center, First 
Affiliated Hospital, College of Medicine, Zhejiang Univ, Hangzhou, Zhejiang, 
China; 2Dept of Medicine, School of Medicine, Univ of Maryland, Baltimore, MD.
Background: Dopamine D2 receptor (D2R) in the kidney has a direct role in regulating 
renal inflammation and injury, and blood pressure. Some common single nucleotide 
polymorphisms (D2R SNPs; rs 6276, 6277, and 1800497) in the human DRD2 gene are 
associated with decreased D2R expression and function.
Methods: We measured apoptosis and activation of Wnt3/β-catenin signaling pathway 
in human renal proximal tubule cells (RPTC) carrying these D2R SNPs (RPTC-D2R SNPs), 
and in RPTC carrying D2R wild type (RPTC-D2R WT).
Results: RPTC-D2R SNPs showed increased apoptosis compared with RPTC-D2R 
WT(11± 0.8% vs 2.3±0.4% TUNEL positive cells, P<0.01). We found that Wnt3 expression 
was increased in RPTC-D2R SNPs in comparison with RPTC-D2R WT (mRNA: 2.6±0.35 
vs 1±0.11 fold; P<0.05; protein: 133±4% vs 100±5%; p<0.05). RPTC-D2R SNPs showed 
activated Wnt3/β-catenin signaling pathway demonstrated by decreased β-catenin 
phosphorylation (64±4% vs 100±8%; P<0.05) and increased expression of downstream pro-
apoptotic factors Bax (136±4.6% vs 100±5%, P<0.05) and FasL (128±5.6% vs 100±6.5%, 
P<0.05). Silencing D2R in RPTC-D2R WT increased Wnt3 expression, decreased β-catenin 
phosphorylation and increased expression of Bax and FasL. In contrast treatment of 
RPTC-D2R WT with a D2R agonist (quinpirole,1µM, 24h) or transfection of RPTC-D2R 
SNPs with a DRD2 which restored D2R expression decreased Wnt3 expression, increased 
β-catenin phosphorylation and decreased Bax and FasL expression. Moreover Wnt3 
silencing in RPTC-D2R SNPs increased β-catenin phosphorylation (132±5% vs100±9%, 
P<0.05), decreased Bax (68±2.5% vs100±9%, P<0.05) and FasL (70±3% vs100±9%, 
P<0.05) expression and reduced the number of apoptotic cells (6±1.0% vs12± 0.9% 
TUNEL positive cells, P<0.01).
Conclusions: D2R protect cells from apoptosis by regulating the Wnt3/β-catenin 
pathway. These results may have clinical relevance for subjects bearing D2R SNPs.
SA-PO304
Effect of Omega-3 Fatty Acids on Nrf-2 Expression and Its Regulation in 
Cyclosporine Induced Rat Model  Won Suk An,1 Eu Gene Jeong,1 Hansae 
Kim,2 Dongyeol Lee,2 Yun Jung Oh,3 Su Mi Lee,1 Sung Hyun Son,4 Young Ki 
Son,1 Seong Eun Kim.1  1Dept of Internal Medicine, Dong-A Univ Hospital, 
Busan, Republic of Korea; 2Dept of Internal Medicine, Bong Seng Memorial 
Hospital, Busan, Republic of Korea; 3Dept of Internal Medicine, Cheju Halla 
General Hospital, Cheju, Republic of Korea; 4Dept of Internal Medicine, BHS 
Han Seo Hospital, Busan, Republic of Korea.
Background: Cyclosporine (CsA)-induced kidney injury is characterized by kidney 
dysfunction with inflammatory cell infiltrations, apoptosis, and fibrosis. Although Nrf-2 
regulates antioxidant and anti-inflammatory process in kidney injury model, it is not clear 
omega-3 fatty acid (FA) role on Nrf-2 expression. The aim of this study is to investigate 
whether omega-3 FA affects the Nrf-2 expression and has anti-inflammatroy, anti-apoptotic, 
and anti-fibrotic processes in CsA-induced nephropathy.
Methods: Male Sprague-Dawley rats fed a low-sodium diet were divided into three 
treatment groups: control (0.9% saline injection; n=5), CsA (15 mg/kg/day by subcutaneous 
injection; n=6), CsA with Omega-3 FA (300 mg/kg/day by gastric gavage; n=6). Kidney 
function was measured at the end of 4 weeks. The expression of Ik-b, ED-1, transforming 
growth factor-b1 (TGF-b1), α-smooth muscle actin (α-SMA), E-cadherin, Smads for 
inflammation and fibrosis, caspase-3, caspase-7, and BAX/Bcl-2 ratio for apoptosis, and 
Nrf-2 were examined by western blot analysis.
Results: Kidney function was decreased in CsA-treated rats compared with control. 
Compared with control, CsA group significantly upregulated ED-1 protein expression 
and Ik-b. Omega-3 FA supplementation attenuated increased ED-1 expression and Ik-B. 
We found that caspase-3, caspase-7, Bax/Bcl2 ratio, TGF-b1, Smad-2/3 and Smad-4 
were activated in CsA group and that omega-3 FA prevented these activation related with 
apoptosis and fibrosis. The expression of Nrf-2 was decreased in CsA-treated rats but Nrf-2 
was increased by omega-3 FA.
Conclusions: We suggest that Nrf-2 is one of potential mediator induced by omega-3 
FA supplementation attenuating inflammatory pathway, fibrotic process and apoptosis. 
Further studies are necessary to elucidate cross-talks between Nrf2 expression and related 
signals of omega-3 FA.
SA-PO305
The Role of High Mobility Group Box 1 in Renal Epithelial Cell Survival 
During Hypertonic Stress  Michael M. Yeboah,1 Marla A. Chesnik,1 Hayley 
Lund,2 Kevin R. Regner,1 David L. Mattson.2  1Div of Nephrology, Medical 
College of Wisconsin, Milwaukee, WI; 2Dept of Physiology, Medical College 
of Wisconsin, Milwaukee, WI.
Background: High mobility group box 1 (HMGB1) is a ubiquitous and evolutionarily 
conserved, DNA-binding protein and is characterized as an alarmin or damage associated 
molecular pattern because of the ability of extracellular HMGB1 to trigger an inflammatory 
response when it binds to its putative receptors, including RAGE, TLR2 and TLR4. New 
and emerging evidence suggest that intracellular HMGB1 is involved with numerous cell 
survival functions. The aim of this study was to examine the functional role of HMGB1 
in tubular epithelial cells during hypertonic stress.
Methods: In vivo, 2 groups of Dahl Salt sensitive rats were placed on high salt diet 
(4% NaCl, n=5/group) and were treated with either daily intraperitoneal injection of a 
HMGB1 inhibitor (glycyrrhizic acid) or a vehicle for 3 weeks while their blood pressure 
was monitored by telemetry. In vitro, NRK52E cells were incubated in control medium 
(332 mOsmol/kg) or hypertonic medium that contained NaCl (500 or 600 mOsmol/kg) 
for 6 hours in the presence or absence of the HMGB1 inhibitor. In other experiments, cells 
were transfected with scrambled siRNA or siRNA against HMGB1 and were exposed to 
control medium or hypertonic medium.
Results: Following exposure to a high salt diet, pharmacologic inhibition of HMGB1 
resulted in more severe kidney damage as assessed by the percentage outer medullary 
area with tubular dilatation and protein casts, when compared with vehicle-treated rats. 
Inhibition of HMGB1 was associated with a significant increase in tubular cell apoptosis 
in comparison to vehicle treatment on TUNEL staining. Also, inhibition of HMGB1 led to 
significantly higher urinary albumin excretion and blood pressure at day 21 compared with 
vehicle treatment. Exposure of NRK52E cells to hypertonic medium resulted in increased 
expression and release of HMGB1 from the cells. Both pharmacologic inhibition and siRNA-
mediated knock-down of HMGB1 led to reduced cell viability as determined by MTT assay.
Conclusions: HMGB1 plays an important role in renal tubular epithelial cell survival 
during hypertonic stress.
SA-PO306
KIM-1-Mediated Phagocytosis Defines a New Mechanistic Paradigm for 
Kidney Epithelial Cells, which Involves Autophagy and Anti-Inflammatory 
Antigen Presentation  Craig R. Brooks, Melissa Y. Yeung, Takaharu Ichimura, 
Joseph V. Bonventre.  Renal Div, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA.
Background: The expression of kidney injury molecule-1 (KIM-1), the protein most 
upregulated with proximal tubule cell (PTC) injury, transforms PTCs into semi-professional 
phagocytes. The processing of phagocytosed cells to the lysosome can determine the 
immunogenicity of antigens derived from the phagosomal cargo. Here we compare the 
phagocytic processing of KIM-1-expressing PTCs to that of professional phagocytes and 
establish distinct mechanisms.
Methods: LLC-PK1 cells expressing KIM-1 were exposed to apoptotic cells. LC3 
localization to the phagosome, phagosomal acidification and degradation were measured 
by live cell imaging, phagosome isolation and western blotting. NADPH oxidase (NOX) 
activity was blocked with diphenyleneiodonium and reactive oxygen species (ROS) 
were measured with fluorescent probes. MHC presentation was measured in primary 
PTCs directly using specific antibodies by flow cytometry. Functional implications were 
determined by activation of CD4+ and CD8+ T cells.
Results: KIM-1 binds to and induces phagocytosis of apoptotic cells within ~5-30 min, 
similar to professional phagocytes. Following uptake, however, PTCs process phagosomes 
more slowly than professional phagocytes, with delayed phagosomal acidification and 
phagosome degradation (4-12 hrs vs 1-2 hrs). Mechanistically, PTCs do not upregulate 
NOX-induced production of ROS, a process necessary for efficient acidification and 
degradation of the phagosome. LC3 associated phagocytosis (LAP), an important NOX-
dependent feature of professional phagocytic function, is not observed in PTCs. PTCs 
instead induce canonical autophagy to clear phagocytosed debris. Delayed phagosomal 
processing and increased autophagy result in increased PTC antigen presentation and 
decreased T cell activation.
Conclusions: Autophagy plays a critical role in KIM-1-mediated phagocytosis in 
PTCs, distinguishing the epithelial cell process from the mechanism used by professional 
phagocytes. The PTC has evolved a distinct process which leads to anti-inflammatory 
antigen presentation which is beneficial in acute kidney injury.
Funding: NIDDK Support
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SA-PO307
Apoptotic Cells Activate AMPK and Inhibit Proximal Tubular Cell (PTC) 
Growth without Change in Intracellular Energy Stores  Philip Speigel,1 
Snezana Vujicic,1 Lanfei Feng,1 Natalia O. Litbarg,1 Vimal Patel,1 Wilfred 
Lieberthal,2 Jerrold S. Levine.1  1Nephrology, Univ of Illinois at Chicago, 
Chicago, IL; 2Nephrology, Stony Brook Univ Medical Center, Stony Brook, NY.
Background: Apoptosis plays an indispensable role in the maintenance and 
development of tissues. We have shown that receptor-mediated recognition of apoptotic 
target cells by viable kidney PTCs inhibits the proliferation and survival of these viable 
PTCs. Here, we examined the effect of apoptotic target cells on PTC cell growth (cell size 
during G1 phase of cell cycle).
Methods: We used BU.MPT cells, a conditionally immortalized PTC line, as 
responder cells. BU.MPT cells, induced to undergo apoptosis in several ways, were used 
as apoptotic targets.
Results: Apoptotic cells potently activated AMP-activated protein kinase (AMPK), 
a highly sensitive sensor of intracellular energy stores. AMPK activation led to 
decreased activity of its downstream target, ribosomal protein p70 S6 kinase (p70S6K) 
and concomitant inhibition of cell growth. Importantly, these events occurred without 
detectable change in intracellular levels of AMP, ADP, or ATP. Inhibition of AMPK, either 
pharmacologically by compound C or molecularly by shRNA, diminished the effects of 
apoptotic targets, and largely restored p70S6K activity and cell size to normal levels. 
Apoptotic targets also inhibited Akt, a second signaling pathway regulating cell growth. 
Expression of a constitutively active Akt construct partially relieved cell growth inhibition, 
but was less effective than inhibition of AMPK. Inhibition of cell growth by apoptotic 
targets was dependent on physical interaction between apoptotic targets and PTCs, but 
independent of phagocytosis.
Conclusions: We conclude that receptor-mediated recognition of apoptotic targets 
mimics the effects of intracellular energy depletion, activating AMPK and inhibiting 
PTC cell growth. By acting as sentinels of environmental change, apoptotic death may 
enable nearby viable cells, especially non-migratory epithelial cells, to monitor and adapt 
to local stresses.
Funding: Clinical Revenue Support
SA-PO308
The Effect of Uremia on Cardiac Autophagy  William White, Steven Michael 
Harwood, Petros Andrikopoulos, Muhammad M. Yaqoob.  William Harvey 
Research Inst, Barts & The London School of Medicine & Dentistry, Queen 
Mary Univ of London, London, United Kingdom.
Background: Autophagy is the process by which cells remove and recycle unwanted 
structures, contributing to intracellular homeostasis and energy production. Cardiac 
autophagy has a role in ischemia protection and ventricular remodelling, and decreasing 
autophagy is central to aging. Evidence suggests these processes are disordered in CKD. We 
have previously demonstrated that autophagy may be down-regulated at a transcriptional 
level in uremic hearts, and now present data concerning cardiac autophagic-protein 
expression (LC3, p62) and senescence marker p53 in models of uremia.
Methods: In Vitro Rat cardiac myoblast cells (H9C2) were cultured in the presence 
of indoxyl sulphate (IS) to simulate a uremic milieu, for 24 or 48 h, with or without 25 
mM chloroquine (CQ, a late-stage autophagy inhibitor) for the last 6h. Cells were lysed 
and underwent immunoblotting for LC3B and p62. In Vivo Rats were rendered uremic 
using an adenine diet (controls given normal feed), fasted for 24 h (to control for calorie 
intake) and given 10 mg/kg IP CQ prior to sacrifice. Cardiac tissues were homogenised 
and immunoblotted for LC3B, p62 and p53.
Results: In Vitro At 24 and 48 h the amount of LC3BII (a marker of autophagic flux) 
expressed increased with IS in a dose-dependent manner with and without CQ. At 48 h p62 
expression decreased with IS in the absence of CQ, but increased in its presence. In Vivo 
setting LC3BII and p62 expression increased in the uremic hearts in line with the in vitro 
data. Interestingly p53 expression was increased in the uremic group.
Conclusions: Uremia appears to stimulate autophagy in cardiac tissues at the protein 
level, in contrast to our autophagy transcriptome data. Previous authors have found that 
changes in autophagic activity are not always mirrored at a transcriptional level. Interestingly 
p53 expression was greater in uremia, suggesting an increase in senescence, which we are 
currently investigating. Changes in autophagy activity and senescence in uremic hearts may 
contribute to the pathogenesis of uremic cardiomyopathy, and provide targets for therapy.
SA-PO309
Decorin Potentially Alleviates TGF-β1 Induced Podocyte Injury by 
Inactivating mTORC1 and Increasing Autophagy  Xing Mao, Zhigang 
Zhang, Huijuan Wu.  Dept of Pathology, Shanghai Medical College, Fudan 
Univ, Shanghai, China.
Background: TGF-β1 is the major factor mediating podocytes injury during 
mesangialoproliferative glomerulonephritis (MsPGN), manifested by decreased autophagy, 
cytoskeleton relocation and increased apoptosis. Decorin (DCN), mainly secreted by 
mesangial cells (MCs) in glomuruli, is a natural antagonist of TGF-β1 and has been shown 
to induce autophagy via Peg3 and Vps34. However, the mechanism underlying the aberrant 
autophagy in injured podocytes of MsPGN and the possible effect of DCN/TGF-β1 axis 
on the crosstalk of MCs and podocytes are still not clear.
Methods: We used immunohistochemistry(IHC) to detect p-smad2 and LC3 in rat 
anti-Thy1.1 nephritis, and TGF-β1 in human nephritis. Then we treated podocytes with 
TGF-β1 or DCN and detected the expression of Vps34, p-S6K1(Thr389), TGF-β1, p62 
and LC3 by western blot.
Results: In this study, we firstly found increased p-smad2 and decreased LC3 by IHC in 
podocytes of rat anti-Thy1.1 nephritis with obvious proteinuria, and consistently, increased 
TGF-β1 staining in human nephritis featured by MCs proliferation and proteinuria. Then 
we treated podocytes by TGF-β1 (20ng/ml) for 1, 3, 6 and 12h, and found decreased protein 
expression of Vps34 and increased p-S6K1(Thr389) representing mTORC1 signaling, 
accompanied by increased P62 and decreased LC3II/Iratio. However, treatment of mouse 
soluble DCN (6.25nM or 100nM) for 1, 3, 6 and 12h on podocytes led to an increased 
protein expression of Peg3, decreased p-S6K1(Thr389) , decreased P62 and increased 
LC3II/I ratio. Moreover, it also decreased TGF-β1 in podocytes.
Conclusions: These results showed that TGF-β1 evoked an activation of mTORC1 
signaling and the abortion of macroautophagy in podocytes, whereas DCN downregulated 
TGF-β1 protein expression, and thus inactivate mTORC1 signaling and induce autophagy 
on podocytes, indicating DCN may have a potential in alleviating TGF-β1 induced podocyte 
injury in MsPGN.
Funding: Government Support - Non-U.S.
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Albumin Endocytosis in the Proximal Tubule Causes Accumulation of 
Dysfunctional Mitochondria  Angela Nolin, Ryan M. Mulhern, Ramon G. 
Bonegio, Zhiyong Wang, Steven C. Borkan, John H. Schwartz, Andrea Havasi. 
Renal, Boston Univ Medical Center, Boston, MA.
Background: Proteinuria is a major risk factor for chronic kidney disease progression. 
Furthermore, exposure of proximal tubular epithelial cells (PTEC) to excess albumin 
promotes tubular atrophy and fibrosis, key predictors of progressive organ dysfunction. 
The mechanism by which protein exposure causes tubular cell injury is uncertain. We 
hypothesize that albumin endocytosis causes tubular cell injury by inhibiting autophagy, 
including mitophagy, resulting in an accumulation of dysfunctional mitochondria leading 
to enhanced ROS production, mitochondrial and cellular injury.
Methods: The effect of proteinuria was examined both in in vivo and in vitro 
experiments. Proteinuria was induced in mice by injection of a sheep nephrotoxic serum 
that causes acute immune-complex glomerulonephritis with massive proteinuria by 24-48 
hrs. In Vitro, to mimic nephrotic glomerular filtrate, PTECs were exposed to albumin. 
Autophagy was assessed in tissue samples from mice and primary PTECs. Steady state 
LC3-II, an autophagy marker was quantified by immunoblot. Autophagosomes (APs) 
were visualized in cell culture using fluorescent markers and in renal cortical tissue 
using immunohistochemistry. Mitochondrial respiration was measured in primary cells. 
Mitochondrial morphology and colocalization with autophagosomes were imaged 
using confocal microscopy. Reactive oxygen species production was measured using a 
2’,7’-dichlorofluorescin diacetate assay.
Results: Exposure to excess albumin induced defective autophagy and mitophagy in 
vitro. In renal cortices, proteinuria decreased both the number of LC3-II positive APs and 
the amount of LC3-II detected in cell lysates. Albumin-exposed cells accumulated damaged 
mitochondria with altered mitochondrial function and morphology. Albumin exposure 
caused mitochondrial dysfunction as evidenced by decreased oxygen consumption rate 
from coupled ATP production. Increasing albumin exposure time caused an increase in 
ROS production.
Conclusions:    Dysfunctional autophagy caused by proteinuria likely contributes to 
tubular cell toxicity leading to renal progression.
Funding: NIDDK Support, Private Foundation Support
SA-PO311
Association Between a Marker of Aging and Cardiovascular Pathology in 
End-Stage Renal Disease Patients  Karin Luttropp,1 Dagmara Mcguinness,2 
Abdul Rashid Tony Qureshi,3 Hannes Olauson,3 Annika Wernerson,3 Louise 
Nordfors,3 Jonaz Ripsweden,4 Peter F. Barany,3 Peter Stenvinkel.3  1Dept of 
Molecular Medicine and Surgery, Karolinska Inst, Stockholm, Sweden; 2Inst of 
Cancer Sciences, Univ of Glasgow, Glasgow, United Kingdom; 3Dept of Clinical 
Science, Intervention and Technology, Div of Renal Medicine, Karolinska Inst, 
Stockholm, Sweden; 4Dept of Clinical Science, Intervention and Technology, 
Div of Radiology, Karolinska Inst, Stockholm, Sweden.
Background: Patients with chronic kidney disease (CKD) display a progeric phenotype, 
with a high incidence of cardiovascular disease (CVD) and vascular calcification (VC). 
The process of VC is complex, and has been linked to apoptosis. A potential contributor 
to the calcification process is the pro-apoptotic factor cyclin-dependent kinase inhibitor 
2A (CDKN2A). This study aims to investigate possible associations between CDKN2A 
expression, VC and CVD in a CKD population.
Methods: CDKN2A expression was determined in epigastric arteries (n=43) from 
patients with end-stage renal disease (ESRD) undergoing living donor renal transplantation 
(RTx). All arteries were scored for degree of calcification in percent. Coronary artery 
calcification (CAC) score was also obtained.
Results: The arterial expression of CDKN2A was significantly associated with VC 
(p=0.01, ȡ=0.4), CVD (p=0.0002), CAC score (p=0.008, ȡ=0.5) and diabetes mellitus 
(p<0.05). In addition, arterial CDKN2A expression was associated with MGP (p=0.007, 
ȡ=0.4) and RUNX2 (p=0.046, ȡ=0.3) expression in artery, both of which are involved in 
osteogenic transformation of vascular smooth muscle cells.
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Conclusions: These findings provide evidence that cell senescence and apoptosis are 
important in the development of VC and CVD in the uremic milieu, and further strengthen 
the hypothesis that comorbidities present in CKD could be caused by a premature ageing 
process. Attempts to ameliorate any progeric process in this patient group is therefore of 
great interest.
Funding: Private Foundation Support, Government Support - Non-U.S.
SA-PO312
Role of RTN1-A in Mediating Tubular Cell Injury Induced by Albumin 
Overload  Ying Fan,1 Wenzhen Xiao,2 Peter Y. Chuang,2 Kim Lee,2 Niansong 
Wang,1 John C. He.2  1Dept of Nephrology, Shanghai Jiao Tong Univ Affiliated 
Sixth People’s Hospital, Shanghai, China; 2Dept of Nephrology, Icahn School 
of Medicine at Mount Sinai, New York, NY.
Background: We performed mRNA sequencing in the kidneys from the murine model 
of HIV-associated nephropathy and identified an association between the expression of an 
endoplasmic reticulum (ER)-associated protein reticulon-1, RTN1, and the severity of kidney 
disease. Of the three known RTN1 isoforms, only RTN1A protein expression was increased 
in kidneys of multiple murine models and patients with kidney disease. Interestingly, both 
mRNA and protein expression of RTN1-A in the kidneys correlated inversely with estimated 
glomerular filtration rate (eGFR) in patients with diabetic kidney disease.
Methods: To determine how RTN1-A mediates the progression of kidney disease, we 
studied the role of RTN1-A in HK2 cells treated with or without human serum albumin 
(HSA) at different concentrations. Then, we studied the role of RTN1-A in vivo by 
generating a protein overload mouse model in both wild-type and RTN1-A knockdown mice.
Results: HSA induced both ER stress markers (GRP78 and CHOP) and apoptosis 
in HK2 cells. However, treatment with 4-PBA (inhibitor of ER stress) or knockdown of 
RTN1-A expression attenuated HSA-induced ER stress/apoptosis in HK2 cells. These data 
suggest that RTN1-A mediate HSA-induced ER stress and apoptosis of kidney tubular 
cells. To determine the effect of albumin overload on tubular injury in vivo, we generated 
tubular cell-specific RTN1-A shRNA knockdown mice, in which RTN1-A expression was 
reduced by 80%. Then, we inject BSA intraperitoneally in these RTN1-A knockdown 
mice and their control littermates to generate albumin overload mouse model. Mice with 
BSA injection developed significant proteinuria in both knockdown and wild-type mice. 
However, RTN1-A knockdown mice developed less tubulointerstitial injury than wild-type 
mice. Also, there was less apoptosis and lower expression of ER-stress markers in tubular 
cells of RTN1-A knockdown mice than wild-type mice.
Conclusions: These data suggest that RTN1-A likely mediates proteinuria-induced 
tubular cell injury and progression of kidney disease through ER stress and apoptosis.
Funding: NIDDK Support
SA-PO313
Inhibition of Caspase-1, but Not of Caspase-3, Ameliorates Diabetic 
Nephropathy: Does Apoptosis Play a Role in Diabetic Kidney Disease? 
Fabian Bock,1,2 Khurrum Shahzad,1,3 Moh’d Mohanad Ahmad Al-Dabet,1 Shrey 
Kohli,1 Hongjie Wang,1,4 Ihsan Khan Gadi,1 Satish Ranjan,1 Peter Nawroth,1,2 
Madhusudhan Thati,1 Berend Heinrich Isermann.1  1Inst of Clinical Pathology 
and Pathobiochemistry, Otto-von-Guericke-Univ Magdeburg, Magdeburg, 
Sachsen-Anhalt, Germany; 2Dept of Internal Medicine I and Clinical Chemistry, 
Univ of Heidelberg, Heidelberg, Baden-Württemberg, Germany; 3Khayaban-e-
Jamia Punjab, Univ of Health Sciences, Lahore, Pakistan; 4Dept of Cardiology, 
Huazhong Univ of Science and Technology, Wuhan, China.
Background: Glomerular apoptosis is thought to contribute to diabetic nephropathy 
(dNP), but insights into its pathogenetic relevance in dNP are incomplete.
Methods: Here we employed two partially distinct caspase inhibitors in db/db mice: 
M-920 (inhibiting caspases-1,-3,-4,-5,-6,-7) and CIX (inhibiting caspases-3,-6,-7,-8,-10). 
The nephromine database was interrogated for glomerular expression of apoptosis and 
inflammasome markers in human dNP. In vitro glucose stimulated podocytes were used. 
Findings were validated in caspase-1 and caspase-3 deficient mice.
Results: Both M-920 and CIX reduced glomerular cell death and caspase-3 and -7 
activity, but only M-920 ameliorated dNP. Nephroprotection by M-920 was associated 
with reduced renal caspase-1 and inflammasome activity. Glomerular expression of 
inflammasome markers (NLRP3, CASP1, IL18, ASC), but not of apoptosis markers 
(CASP3, CASP7, PARP1), was significantly elevated in patients with dNP compared to 
non-diabetic controls. Markers of inflammasome activation (Nlrp3, caspase-1 cleavage) 
precede those of apoptosis activation (caspase-3,-7, and PARP cleavage) in glucose stressed 
podocytes in vitro. Finally, caspase-3 deficiency in mice does not protect from dNP, while 
both homozygous and hemizygous caspase-1 deficiency is protective.
Conclusions: Manifestation of diabetic nephropathy is independent of caspase-3 
dependent cell death (apoptosis), but requires caspase-1 activation in mice. These data 
support a critical role of caspase-1 dependent inflammasome activation in dNP. Targeting 
the inflammasome may be superior to targeting apoptotsis.
SA-PO314
Endothelial Autophagy Is Essential for Vascular Lipid Homeostasis 
Kumiko Torisu,1,3 Subodh Verma,2 Takehiro Torisu,1,3 Krishna K. Singh,2 Toren 
Finkel.1  1Center for Molecular Medicine, National Heart, Lung, and Blood Inst, 
NIH, Bethesda, MD; 2Div of Cardiac Surgery, St. Michael’s Hospital, Univ of 
Toronto, Toronto, ON, Canada; 3Graduate School of Medical Sciences, Kyushu 
Univ, Fukuoka, Japan.
Background: Caridiovascular disease is one of the common complications in chronic 
kidney diseases. It is known that autophagy plays a critical role in the course of kidney 
diseases. The resulting cardiovascular diseases are presumably regulated by autophagy. 
However the physiological role of autophagy in the vascular endothelial cells remains 
poorly understood.
Methods: Using human umblical vein endothelial cells (HUVECs), induction of 
autophagy by ox-LDL, and uptaking or transcytosis of LDL are analyzed. To inhibit 
autophagy pharmacologically, chroloquine is used. The essential autophagy gene, Atg7 
shRNA-mediated knockdown are performed to inhibit autophagy genetically. To assess an 
acute and chronic in vivo model of lipid exposure, we generated endothelial specific Atg7 
knockout in ApoE deficient mice (Atg7endo/ApoE KO).
Results: Ox-LDL induced autophagosome formation in HUVECs. Moreover, native or 
ox-LDL appeared to be engulfed within autophagosomes by live cell imaging and electron 
microscopy. Atg7 knockdown or pharmacological inhibition of autophagy resulted in higher 
accumulation of intracellular LDL, suggesting that in vascular endothelial cells, autophagy 
is one of the degradation machinery of excess lipids. As an acute model of lipid exposure 
in vivo, Atg7endo/apoE mice showed longer retention of ox-LDL within the retina after 
infusion of DiI ox-LDL. In a chronic model of lipid excess, we analyzed atherosclerois in 
ApoE KO or Atg7endo/ApoE KO mice. Atg7endo/ApoE KO mice demonstrated markedly 
increased atherosclerosis.
Conclusions: In endothelial cells, autophagy appears to play a critical role in regulating 
excess intracellular lipids. Moreover, in both acute and chronic in vivo model, endothelial 
autophagy is essential to attenuate LDL accumulation within endothelial layer. Prevention 
of the decline in autophagy flux accompanied by kidney diseases pharmacologically might 
be beneficial to treat atherosclerotic diseases.
SA-PO315
Targeted Mutations at the p66 Locus Antagonize Stem Cell Aging 
and Delay Expression of Senescent Phenotypes in Diabetic Kidneys 
Himanshu Vashistha,1 Antonio G. Jimenez,1 Sixto G. Giusti,1 Allyson E. Bradley,1 
Ashwani Malhotra,2 Pravin C. Singhal,2 Leonard G. Meggs.1  1Nephrology, 
ITR, Ochsner Health System, New Orleans, LA; 2Nephrology, Feinstein Inst for 
Medical Research,North Shore Long Island Jewish Health System, New York, NY.
Background: Senescence has important implications for the biologic function of tissue 
stem cells, which maintain tissue homeostasis by replacement of old or dying cells and 
via the repair of tissue injury. The p66 longevity gene plays a key role in the activation of 
gene programs that induce senescent and apoptotic phenotypes. We hypothesize gene base 
strategies targeting p66 will delay or prevent stem cell senescence and premature aging 
phenotypes in diabetic kidneys.
Methods: Mesenchymal stem cells (MSCs) were isolated from kidneys of p66 KO 
mouse (p66 KO-MSCs) using established methods and plated in high glucose (HG) 
containing media. Microarray was used to profile secreted factors expressed by MSCs. 
p66 KO diabetic mice were generated to evaluate survival of MSCs in diabetic kidneys, 
glomerulosclerosis, interstitial fibrosis and tubular atrophy. Confocal imaging and 
immunofluorescent staining was used to identify MSCs, podocytes, renal tubular cells and 
to detect senescent protein p16INK4a and proliferation marker Ki-67.
Results: Cultured p66 KO-MSCs at HG escape entry to senescent and apoptotic 
programs and display enhanced secretion of IGF-1, VEGF and HGF. Microarray detected 
unexpected cross talk between p66 and Wnt regulatory genes that antagonize senescence. 
Kidney sections from p66 KO diabetic mice show increased numbers of MSCs in glomeruli 
and tubules, with barely detectable histologic markers of aging and near normal urine 
albumin excretion. Kidney nuclei staining (+) for Ki-67 was upregulated, whereasp16INK4a 
was downregulated.
Conclusions: These findings suggest a genetic link between p66 longevity gene, stem 
cell aging and senescent phenotype(s) in diabetic kidneys.
Funding: Private Foundation Support
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The Full Time Course and Localization of mTOR Activation in 
Compensatory Renal Hypertrophy  Jinxian Xu,1 Meichu Cheng,1 Jianchun 
Chen,2 Jian-Kang Chen.1  1Cellular Biology & Anatomy and Medicine, Georgia 
Regents Univ, Augusta, GA; 2Medicine, Vanderbilt Univ, Nashville, TN.
Background: Previous studies documented an essential role for mTOR activation in 
mediating compensatory renal hypertrophy induced by unilateral nephrectomy (UNX) but 
the time course and localization of the mTOR activation are unclear.
Methods: 8-week-old male FVB/NJ mice were subjected to right UNX or sham surgery, 
followed by sacrifice at different time points to collect left kidney and determine the time 
course and localization of mTOR activation by immunoblotting and immunofluorescence 
staining for phospho-S6K1 and phospho-rpS6, along with nephron segment-specific 
markers.
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Results: In this inbred mouse strain, UNX induced 8.27 ± 0.93% renal hypertrophy 
within 24 h. The hypertrophy continued to rise up to 12.74 ± 3.32%, 39.78 ± 7.06%, 45.56 
± 7.72%, 45.92 ± 2.80%, 49.13 ± 2.09%, and 50.26 ± 9.87% by 48 hours, 1 week, 2 weeks, 
1 month, 3 months, and 4-7 months, respectively. Thus, the hypertrophy is complete within 
3-4 months, with ~50% hypertrophy on average. Immunoblotting indicated that UNX 
increased T389-phosphorylated S6K1 within 3 min, indicating mTOR activation, but had 
no effect on Akt, TSC2, AMPK, or ERK1 and ERK2 phosphorylation in the remaining 
kidney at any time points examined. The mTOR activity peaked at 24 h, remained at the 
plateau level even after 48 h, declined but still activated by 1 month, and returned to the 
basal level by 3 months after UNX. Immunofluorescence staining visualized the most 
prominent mTOR activation in the cytoplasm of LTL-positive tubules in response to UNX, 
although the basal mTOR activity in the kidney of sham-operated control mice was largely 
confined in THP-, calbindin-, and DBA-positive tubules, with very little in LTL-positive 
tubules. n=5-6 mice for each group and time point.
Conclusions: This is the first report on the full time course of dynamic mTOR activation 
and the first demonstration that UNX-induced mTOR activation is primarily localized 
in the proximal tubules of the remaining kidney. The present study also indicates that 
compensatory renal hypertrophy largely occurs within 1 week but is not complete until 
3-4 months after UNX.
Funding: NIDDK Support
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EGF Dependent Regulation of VEGF-A Secretion by Proximal Tubule 
Cells  Diana Zepeda-Orozco,1 Hsiang M. Wen,1 Nandita S. Raikwar,2 Christie 
P. Thomas.2  1Pediatrics, Univ of Iowa, Iowa City, IA; 2Internal Medicine, Univ 
of Iowa, Iowa City, IA.
Background: Vascular endothelial growth factor A (VEGF-A) plays a critical role in 
peritubular capillary development by promoting vasculogenesis and angiogenesis. It is now 
recognized that there is increased expression of VEGF-A by proximal tubular epithelial cells 
in ischemia reperfusion injury and in chronic tubulointerstitial injury. Although hypoxia is 
known to increase the expression of VEGF-A in proximal tubular epithelial cells in vitro 
and in vivo, the mechanisms regulating VEGF-A secretion by proximal tubule epithelial 
cells in normoxia has not been established.
Methods: We utilized HK2 cells, an immortalized human proximal tubule cell line, to 
characterize the epidermal growth factor (EGF)-dependent regulation of VEGF-A secretion 
by proximal tubular epithelial cells.
Results: EGF increases HIF1-a expression, stimulates VEGF-A secretion and promotes 
proliferation of HK2 cells under normoxic conditions. HIF1-a knockdown decreases 
EGF-dependent VEGF-A secretion indicating that the EGF effect is at least partly HIF1-a 
dependent even in normoxia. EGF stimulates HIF1-a and VEGF-A via activation of the 
EGF receptor and upregulation of mTOR and p42/44 MAPK pathways. P42/44 MAPK 
inhibition significantly downregulates HIF1-a dependent VEGF-A secretion and cell 
proliferation. Although mTOR inhibition reduces HIF1-a, it upregulates MAPK with a 
very modest reduction of VEGF-A secretion indicating that mTOR and p42/44 MAPK 
may act via parallel pathways in VEGF-A regulation. Finally, we demonstrate that the 
EGF-stimulated proliferation of HK2 cells is reduced by VEGF Receptor 2 (VEGFR2) 
blocker indicating that EGF stimulates proximal tubular cell proliferation via the secretion 
of VEGF and the activation of the VEGFR2 receptor.
Conclusions: EGF stimulates VEGF-A secretion via activation of the EGF receptor, 
and stimulation of HIF1-a. EGF stimulates proliferation of HK2 cells via the secretion 
of VEGF-A indicating that VEGF is an autocrine proximal tubular epithelial cell growth 
factor. The effects of EGF on HIF1-a, and VEGF-A in HK2 cells are modulated by complex 
crosstalk between p42/44 MAPK and mTOR pathways.
SA-PO318
Selective Regulation of a Novel Truncated CCN3 Protein by TGFb1 in 
Human Tubule Epithelial Cells  Matthew Pottle,1 Bruce L. Riser,2 Mark E. 
Dockrell.1  1SWT Inst for Renal Research, London, United Kingdom; 2BLR 
Bio, WI.
Background: CCN3 is a member of the matricellular CCN family of proteins along with 
the structurally similar CCN2/CTGF, a powerful fibrotic agent, but recent work supports 
our hypothesis that CCN2 and 3 act in opposition to each other regulating fibrosis. In renal 
cell carcinoma tubular expression of CCN3 is reduced in patients with cancer. TGFb1 has 
been shown to counter regulate the expression of CCN2 and CCN3 in the vertebral nucleus 
pulposus and in mesangial cells. We have previously characterised TGFb1 induction of 
CCN2 in proximal tubule epithelial cells (PTEC); here we investigate the expression of 
CCN3 in primary human PTEC and its potential regulation by TGFβ.
Methods: Primary human PTEC were cultured on collagen IV in supplemented 
medium. At 80% confluence cells were treated with TGFβ-1 (0.25 -2.5 ng/ml) for 24 & 48h, 
medium was collected and cells lysed. Equal amounts of lysate were subjected to PAGE 
and Western blotting then probed with antibodies (Ab) to the C-terminal, N-terminal and 
hinge region of CCN3, as well as the hinge region of CCN2/CTGF.
Results: Under control conditions the anti-CCN3 hinge Ab revealed the expression in 
PTEC of the 51KDa full-length protein as well as a 39KDa isoform. The antibodies to the 
respective termini detected bands of approximately 23-28KDa. The C-terminal ab did not 
detect the 39KDa band. The antibody to the N-terminal detected proteins of approximately 
45KDa as well as the 39KDa form. Treatment with TGFβ for 24h had no effect on the 
51KDa protein but significantly inhibited the expression of the 39KDa.
Conclusions: At a concentration that induces CCN2/CTGF expression in PTEC, 
TGFβ does not regulate the expression of full length CCN3. However, it does reduce the 
expression of a truncated form apparently lacking the CT domain. The characteristics of 
this smaller protein are not consistent with any known splice variants and may represent an 
intracellularly cleaved form regulated by TGFb1. The lack of the CT domain would change 
the 3 dimensional conformation of the protein, inhibit its binding to various integrins and 
potentially remove the ability of the molecule to inhibit cell proliferation.
SA-PO319
Deletion of TGF-Beta Receptor in Renal Proximal Tubule Cells Impairs 
HGF Signaling  Stellor Nlandu Khodo,2 Leslie S. Gewin.1,2  1Research, 
Tennessee Valley Veterans Affairs, Nashville, TN; 2Medicine, Div of Nephrology, 
Vanderbilt Univ, Nashville, TN.
Background: The growth factors TGF-beta and HGF have antagonistic and synergistic 
interactions that govern renal development and response to injury. We previously showed 
that TGF-beta worsens the epithelial response to acute renal injury, so we postulated that 
epithelial TGF-beta signaling may inhibit responsiveness to HGF, a growth factor that 
mediates beneficial effects following epithelial injury.
Methods: To address how TGF-beta signaling alters epithelial responsiveness to HGF, 
we generated proximal tubule (PT) cells with the TGF-beta type 2 receptor, necessary 
for all signaling, either intact (TbRIIfl/fl) or deleted in vitro with adeno-Cre (TbRII-/-). 
Responsiveness to HGF was assessed by receptor (cMet) phosphorylation, and the biological 
relevance of altered HGF signaling was determined by branching morphogenesis studies 
in 3D gels and migration assays.
Results: TbRII-/- PT cells had increased tubular branching and impaired migration 
compared to cells with the receptor intact. Unexpectedly, PT cells lacking TbRII had 
impaired response to HGF in both branching morphogenesis and migration assays compared 
to TbRIIfl/fl cells. Consistent with this, TbRII-/- PT cells had impaired cMet phosphorylation 
associated with reduced membrane expression of cMet and transcriptional downregulation 
of the HGF receptor. Notch signaling, a known inducer of cMet transcription, was increased 
in cells with TbRII intact, and Notch inhibition by gamma-secretase equalized the responses 
to HGF by PT cells with and without the receptor.
Conclusions: PT cells lacking TbRII have impaired responsiveness to HGF signaling, 
and this effect is due to reduced Notch-mediated cMet transcription. Thus, efforts to block 
TGF-beta signaling may inadvertently inhibit signaling pathways of other growth factors 
such as HGF.
Funding: Veterans Administration Support
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Enhancement of HGF-Induced Tubulogenesis by Endothelial Cell-Derived 
GDNF  Masao Nakasatomi, Akito Maeshima, Shunsuke Takahashi, Hidekazu 
Ikeuchi, Toru Sakairi, Yoriaki Kaneko, Keiju Hiromura, Yoshihisa Nojima.  Dept 
of Medicine and Clinical Science, Gunma Univ Graduate School of Medicine, 
Maebashi, Gunma, Japan.
Background: Renal proximal tubular epithelium can regenerate itself after a variety of 
insults. However, the microenvironment that regulates regeneration process of renal tubules 
after injury remains unclear. We previously established an in vitro 3D tubulogenesis assay 
which at least partly mimics in vivo regeneration processes of renal tubules after injury 
(Am J Physiol Renal Physiol: 301: F387-95, 2011). Utilizing this system, the endothelial 
cell-derived factors that regulate tubular formation was examined.
Methods: Human renal proximal tubular epithelial cells (RPTEC) were cultured 
in gels (type I collagen/matrigel mixture) in the presece of HGF with or without human 
umbilical vein endothelial cells (HUVEC) using Transwell filter system. The signaling 
pathways activated by co-culture with HUVEC in tubular structures were examined using 
phospho-receprtor tyrosine kinase (RTK) array.
Results: HGF, a potent renotropic factor, induced aquaporin-1-positive tubular 
structures with microvilli, suggesting that these structures are morphologically equivalent 
to renal tubules in vivo. When co-cultured with HUVEC, HGF-induced tubular formation 
was significantly enhanced. Tubulogenic effect of HGF was also enhanced in the presence 
of HUVEC-conditioned media (HUVEC-CM), but not in the presence of VEGF, basic FGF 
or PDGF. Co-culture with HUVEC did not induce tubular structures in the absence of HGF. 
RTK array revealed that phosphorylation of RET (GDNF receptor) was markedly enhanced 
in tubular structures cultured with HUVEC-CM compared to those without HUVEC-CM. 
HUVEC produces GDNF and RPTEC expresses both RET and GFR alpha1 (co-receptor). 
HGF-induced tubular formation was significantly enhanced by addition of GDNF.
Conclusions: These data indicate that endothelial cell-derived GDNF potentiates 
tubulogenic action of HGF in a paracrine manner. GDNF-RET signaling may play a 
role in the crosstalk between renal tubules and surrounding endothelium during tubular 
regeneration after injury.
SA-PO321
Massive Formation of Ang(1-7) from AngII(1-8) Is Largely ACE2 
Independent  Peter Daniel Serfozo, Jan A. Wysocki, Minghao Ye, Daniel 
Batlle.  Div of Nephrology, Northwestern Univ - Feinberg School of Medicine, 
Chicago, IL.
Background: AngII(1-8) degrading mechanisms are complex including cleavage 
by aminopeptidases that form AngIII and carboxypeptidases like ACE2 and 
Prolylcarboxypeptidase (PRCP) that cleave Phenylalanine to form Ang(1-7). The relative 
importance of these peptidases to the formation of Ang(1-7) is unknown but ACE2 has been 
assumed to be the main Ang(1-7) forming enzyme resulting from cleavage of AngII(1-8). 
We tested the hypothesis that Ang(1-7) formation largely occurs independently of ACE2.
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Methods: After acute AngII(1-8) infusion to WT mice plasma concentrations 
of AngII(1-8), Ang(1-7) and Ang(1-5) were measured by LC-MS/MS. Additional 
measurements of Ang(1-7) by RIA and ELISA were performed for confirmatory purposes. 
Plasma ACE2 and PRCP activity in WT mice was measured using a fluorogenic substrate.
Results: Following AngII(1-8) infusion to WT mice plasma Ang(1-7) levels measured 
by MS were extremely high. Similarly high levels were also found when this peptide was 
measured by RIA and ELISA (Table).
AngII(1-8) Ang(1-7)
MS 244 ± 21 pg/ml 766 ± 199 pg/ml
RIA n.a. 1527 ± 240 pg/ml
ELISA 1012 ± 223 pg/ml 1137 ± 394 pg/ml
In an ACE2 KO line there was no significant difference in Ang(1-7) levels as compared 
to WT mice and the levels of ACE2 activity in plasma of WT mice were low. Moreover, 
activity of PRCP, another Ang(1-7) forming enzyme is very low at the normal plasma pH. 
We therefore hypothesize that Ang(1-7) formation after AngII(1-8) infusion must be largely 
ACE2 and PRCP independent. To give further support for this hypothesis, we infused a 
different set of mice with AngII(1-8) in the presence of recombinant murine ACE2 or 
ACE2 + MLN, a specific inhibitor. Under all these conditions the levels of Ang(1-7) were 
massively increased and therefore unaccountable only by the conversion of AngII(1-8) to 
Ang(1-7) by ACE2 cleavage.
Conclusions: Formation of Ang(1-7) during AngII(1-8) infusion is massive and largely 
ACE2 independent. The increase in Ang(1-7) after AngII(1-8) infusion suggests the presence 
of unknown Ang(1-7) forming enzymes that are very active in plasma.
Funding: NIDDK Support
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HIF1a and HIF2-Induced Erythropoietin Production Along the Nephron 
Yuichiro Izumi,1 Yukiko Yasuoka,2 Yushi Nakayama,1 Hideki Inoue,1 Masashi 
Mukoyama,1 Katsumasa Kawahara,2 Hiroshi Nonoguchi.3  1Nephrology, 
Kumamoto Univ Graduate School of Medical Science, Kumamoto, Japan; 
2Physiology, Kitasato Univ School of Medicine, Sagamihara, Kanagawa, Japan; 
3Internal Medicine, Kitasatro Univ Medical Center, Kitamoto, Saitama, Japan.
Background: Kidney peritubular interstitial cells produce erythropoietin (Epo) in 
response to hypoxia and/or anemia. By using in situ hybridization method, we have shown 
that Epo is also produced by the cortical nephron segments (mainly in PCT, DCT and CCD) 
in control and/or hypoxic conditions (Nagai, et al, 2014). The use of renin-angiotensin-
aldosterone inhibitor has been suggested to exacerbate anemia in chronic kidney disease, 
suggesting aldosterone-regulated erythropoietin production.
Methods: To characterize the molecular machineries for Epo production in renal 
tubules, we examined the mRNA expressions of HIF1α, HIF2α, PHD2, mineralocorticoid 
receptor (MR) and EGF-receptor (EGFR) along the nephron in basal condition. Each 
nephron segment from SD rats was microdissected in the presence of ribonucleoside 
vanadyl complexes. After the extraction of RNA, mRNA expression was measured using 
RT-PCR and real-time PCR.
Results: Epo mRNA expression was confirmed in whole nephron segments by RT-PCR 
in basal condition. The expressions of HIF1α, HIF 2α and PHD2 mRNAs were detected 
in whole nephron segments both in RT-PCR and real time PCR. The largest expression 
of HIF2α mRNA was observed in PCT. HIF2α mRNA expression was larger than HIF1α 
mRNA expression in most segments (∆∆CT relative to GAPDH). MR and EGFR mRNAs 
expression was observed not only in distal but also in proximal tubules.
Conclusions: The results suggest the presence of HIF2a induced-Epo roduction in renal 
tubules. The presence of MR in whole nephron segments suggest that aldosterone may have 
physiological effects for Epo production not only in distal but also in proximal tubules.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Cytokine Response of Primary Human Mesangial Cells Is LPS Strain 
Dependent  Margaret M. O’Neill, Carine Boustany, Steven S. Pullen. 
CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma. Inc, 
Ridgefield, CT.
Background: LPS stimulation of Toll-like receptor 4 (TLR4) induces the release of 
proinflammatory cytokines which activate potent immune responses. LPS is an important 
structural component of the outer membrane of Gram-negative bacteria and consists of three 
parts: lipid A, a core oligosaccharide, and an O side chain. It has been studied extensively 
in models of inflammation with E.coli 0111:B4 most often referenced in the literature. 
The antigenicity of LPS varies from strain to strain depending on the composition its O 
side chain. A comparative study was designed to identify the optimal strain to be used for 
LPS-stimulated release of proinflammatory mediators from primary human mesangial 
cells (HMC).
Methods: HMC were stimulated with 7 strains of LPS and 24 hour supernatants were 
analyzed for production of inflammatory mediators (IL-1β, IL-6, IL-8, TNF-α and MCP-1). 
Culture supernatants were assessed with MSD kits ProInflammatory 4-Plex II and MCP-
1. TLR4 antagonists EX00076824 a small molecule and FHAN_2014062 an antibody 
were tested to evaluate inhibition of LPS activity in HMC using 3 LPS strains with most 
pronounced inflammatory effects.
Results: LPS induced strain-dependent increases in IL-6, IL-8, and MCP1 in HMC, 
while there was no effect on IL-1β and TNF-α. When compared to controls, IL-6 production 
was significantly (p<0.05) increased: E.coli 0111:B4 (25X), LPS-EB (10X), E.coli K12 
(44X), E.coli 055.B5 (8X), S.Minnesota (99X), S.typhosa (18X) and P.gingivitis (6X). All 
strains induced IL-8 and MCP-1 except for E.coli 055.B5 (no IL-8) and P.gingivitis (no IL-8 
or MCP-1). Both TLR4 antagonists blocked LPS induced production of IL-6, IL-8, and 
MCP-1 in a dose dependent manner. IC50 values for both inhibitors (EX00076824: 30-60nM; 
FHAN_2014062: 800-2700ng/ml) were consistent across LPS strains and analyte detected.
Conclusions: In this study we demonstrate that LPS-stimulated release of inflammatory 
mediators in HMC is strain dependent, and can be blocked using TLR4 antagonists. These 
data highlight the importance of identifying the most effective LPS strain in a cell type of 
interest, prior to initiating pharmacology studies.
Funding: Pharmaceutical Company Support - Boehringer Ingelheim Pharmaceuticals 
Inc.
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Effect of Angiotensin II Type 1 Receptor Blocker on 12-Lipoxygenase 
Activity and Slit Diaphragm Protein Nephrin and P-Cadherin Expression in 
Type 2 Diabetic Rat Glomeruli  Wan-ning Wang, Yuanyuan Zhang, Hongzhao 
Xu, Fu-zhe Ma, Tao Sun, Hang Yuan, Mindan Sun, Zhong-gao Xu.  Nephrology, 
The First Hospital of Jilin Univ, Changchun, Jilin, China.
Background: 12-lipoxygenase (12-LO) and angiotensin II(Ang II) interaction plays an 
important role in the development of diabetic nephropathy (DN), in which proteinuria was 
thought to be associated with decreased expression of glomerular slit diaphragm protein 
nephrin and P-cadherin. However, it is unclear whether Ang II type 1 receptor blocker 
(ARB) regulates 12-LO activity and slit diaphragm protein expression in type 2 diabetic 
rat glomeruli and hence was investigated in this study.
Methods: Podocytes and glomeruli isolated from rats were used in this study. The 
12-LO product 12(S)-HETE and Ang II wereinfused to rats by osmotic mini-pump. Rats 
fed high fat diet received low dose streptozotocin to make type 2 diabetes. Glomeruli 
were isolated with sieving method and classified into small glomeruli (SG, on the 75mm 
sieve) and large glomeruli (LG, on the 125mm sieve). ELISA, RT-PCR and Western blot 
for related targets were performed respectively.
Results: Ang II increased 12(S)-HETE levels in podocytes and glomeruli. Direct 
infusion of rats with 12(S)-HETE and Ang II significantly decreased LG nephrin, but 
increased SG nephrin expression compared to control. The glomerular P-cadherin expression 
was reduced after Ang II and 12(S)-HETE treatment and there was no difference between 
LG and SG. ARB did not affect blood glucose levels but completely attenuated increases 
in 12(S)-HETE content, AT1 expression and proteinuria induced by diabetes. Nephrin 
protein expression was significantly reduced in diabetic LG but increased in diabetic SG 
compared to control. P-cadherin expression was decreased in both diabetic LG and SG. 
These abnormalities were partially but significantly prevented by ARB treatment.
Conclusions: ARB could amelioratethe progression of DN via upregulation of 
glomerular nephrin and P-cadherin expression through inhibition of 12-LO activation in 
type 2 DN rat.
Funding: Government Support - Non-U.S.
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APOL1 Risk Variants and HIV Stimulate Induction of PDGF-β Receptor 
in Podocytes  Xiqian Lan,1 Hongxiu Wen,1 Ashwani Malhotra,1 Karl Leon 
Skorecki,1 Pravin C. Singhal.1  1Medicine, Hofstra North Shore LIJ Medical 
School, Great Neck, NY; 2Medicine, Rambam Health Care Campus, Haifa, Israel.
Background: Clinical reports demonstrated that two coding sequence variants (G1 
and G2) in the APOL1 gene are responsible for the higher percentage of kidney disease in 
African Americans. This disparity between patients with APOL1 variants versus wild type 
APOL1 increases by 10 fold for the development of HIVAN in patients of HIV infection 
who are not on antiviral therapy. Podocytes do not express platelet-derived growth factor 
(PDGF) receptors constitutively. Nonetheless, in experimental animal models, podocyte 
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upregulated expression of PDGFs manifested as progressive glomerulonephritis. We 
hypothesized that APOL1 risk variants and HIV carry potential for the induction of the 
activation of the PDGF pathway in podocytes.
Methods: To determine the effect of APOL1 and APOL1 variants expression, stably 
expressing Vector, APOL1G0, APL1G1, or APOL1G2 human podocyte (HP) cell lines were 
developed. To evaluate the effect of HIV expression, pseudo type HIV (NL4-3) or empty 
vector (control) virus was transduced into APOL1G0/HPs, APOL1G1/HPs and APOL1G2/
HPs. After 48 h, RNAs were extracted. cDNAs were amplified with specific primers for 
PDGF-A, PDGF-B, PDGF-C, PDGF-D, and PDGFRβ.
Results: HIV transduction significantly increased the expression of PDGF-A, PDGF-B, 
PDGF-C, PDGF-D, and PDGFRβ in podocytes.G0/HPs, G1/HPs, and G2/HPs with or 
without HIV transduction did not display any change in the expression of PDGF-B, PDGF-C, 
or PDGF-D, when compared with vector; whereas, G2/HPs in HIV milieu displayed 
enhanced expression of PDGF-A. Interestingly, both G1/HPs and G2/HPs displayed 10 
fold increase in PDGFRβ expression when compared to vector/HPs or G0/HPs.
Conclusions: These findings indicate that PDGFs and their receptor PDGFRβ can be 
induced by HIV and APOL1 risk variants. The present study could lead to new therapeutic 
targets for HIVAN.
Funding: NIDDK Support
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Assessment of Urinary Liver Type Fatty Acid Binding Protein in 
Patients of Type 2 Diabetes Mellitus with Early Chronic Kidney Disease 
Om Prakash Kalra,1 Mohit Garg,1 Ashok Kumar Tripathi,2 Sunil Agarwal.1 
1Medicine, UCMS & GTB Hospital, Delhi, India; 2Biochemistry, UCMS & 
GTB Hospital, Delhi, India.
Background: Diabetes mellitus is the most common cause of chronic kidney disease 
(CKD) worldwide. Various markers are being indentified which can detect nephropathy at an 
earlier stage. Both glomerular and tubular injury play an important role in etiopathogenesis 
of diabetic nephropathy (DN) and tubular damage preceeds glomerular damage. Tubular 
markers like urinary neutrophil-gelatin associated lipocalin, urinary liver-type fatty acid 
binding protein (L-FABP) and kidney injury molecule-1 are newer markers for early 
kidney injury. In the present study, we assessed the role of urinary L-FABP as a tubular 
injury marker in DN.
Methods: This was a case control, cross sectional study. Eighty four subjects in the age 
group 30–60 years of either sex were taken and were divided into three groups: Group I: 
Healthy controls (n=28) Group II: Type 2 diabetes patients with normoalbuminuria (n=28) 
Group III: Type 2 diabetes patients with micro/macroalbuminuria (n=28). Detailed history, 
physical examination, liver and kidney function tests, urine albumin creatinine ratio (ACR) 
was done. Urinary L-FABP was measured by ELISA (CMIC, Tokyo).
Results: The urinary ACR levels were comparable in group I and II. Subjects in 
Group III had significantly elevated ACR values. Levels of urinary L-FABP were higher 
in subjects of group II and III when compared with group I. Values of L-FABP were also 
higher in group III compared to group II. There was a significant positive correlation found 
between urinary ACR and urinary L-FABP levels. A significant negative correlation was 
found between urinary L-FABP and eGFR.
Conclusions: Levels of urinary L-FABP are markedly increased in patients of diabetic 
nephropathy as compared to healthy controls. Levels were also increased in diabetes patients 
with normoalbuminuria suggesting early tubular injury in these patients. This suggests that 
urinary L-FABP may be a promising early marker for detection of diabetic nephropathy.
SA-PO327
Neuropilin1 Regulates Pericyte Behavior in Postnatal Kidney 
Monika Lucyna Wnuk, Regula Buergy, Werner A. Graber, Valentin Djonov. 
Inst of Anatomy, Univ of Bern, Bern, Switzerland.
Background: Neuropilin1 (Nrp1) is a transmembrane co-receptor implicated in the 
regulation of endothelial cell migration during angiogenesis. In the adult kidney, Nrp1 is 
however expressed not only by endothelium but also by pericytes including peritubular 
pericytes and mesangial cells.
Methods: In order to precisely address the role of Nrp1 in postnatal kidney, two 
complementary mouse models were used; in the first one, Nrp1 was deleted specifically 
in pericytes with tamoxifen-inducible NG2Cre line and in the second approach, Nrp1 
was blocked with neutralizing antibody (Genentech). In both models, tamoxifen/antibody 
treatment started at P21.
Results: Mutant mice showed mild proteinuria and/or hematuria at 3 months of age 
with Nrp1 excision efficiency being around 30% based on colocalization level between 
Nrp1 and PDGFRb. Kidney histology revealed that it was primarily glomerular basement 
membrane (GBM) that was affected; mutant mice presented thickened, folded GBM with 
relatively intact podocyte foot process and endothelial fenestrations. The expression of 
genes encoding GBM proteins was examined and the deregulation of nidogen1 could 
be confirmed on protein level. Mutant mice showed additionally dilated capillaries with 
increased glomerular capillary surface area. Interestingly, these mice had also a tendency 
for fewer renin stained glomeruli as compared to Cre- controls. Furthermore, mutants had 
more BrdU-positive interstitial cells. Consistently, mice treated with anti-Nrp1 neutralizing 
antibody showed hematuria, mild mesangial expansion and GBM abnormalities including 
nidogen1 deregulation. Interestingly, in both models, male but not female mice were 
primarily affected. In vitro experiments with primary mesangial human and mouse cell 
lines showed increased cell proliferation, abnormal spreading and actin reorganization in 
Nrp1 knock down cells.
Conclusions: This study shows a novel role of Nrp1 in adult kidney pericytes. Future 
experiments with kidney challange models and measurement of blood pressure will help 
to further clarify these interesting findings.
Funding: Government Support - Non-U.S.
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Development of a Spontaneous, Reproducible and Treatable Kidney 
Fibrosis Model  Jessica Marie Overstreet, Ming-Zhi Zhang, Raymond C. Harris. 
Medicine, Vanderbilt Univ, Nashville, TN.
Background: Kidney fibrosis in chronic kidney diseases causes gradual loss of kidney 
functionality. Currently, only a few kidney fibrotic models are available. New kidney fibrotic 
models are needed. Since our previous studies indicated that activation of epidermal growth 
factor receptor (EGFR) contributes to the development of renal fibrosis, we have developed 
a model with selective overactivation of proximal tubule EGFR.
Methods: B6D2 transgenic mice with selective overexpression of an EGFR ligand, 
human heparin-binding EGF (hHB-EGF) in renal proximal tubule, were generated. Male 
C57/BL6 homozygous hHB-EGF mice received vehicle (water) or erlotinib (80 mg/kg/
day) by daily gastric gavage from 4 to 14 weeks of age.
Results: Kidney cortical hHB-EGF mRNA and protein levels were dramatically higher 
in homozygous hHB-EGF mice than in heterozygous mice. Profound renal interstitial 
fibrosis was found in both B6D2 and C57/BL6 homozygous hHB-EGF mice, but not in 
heterozygous mice, as indicated by histology and increased levels of the pro-fibrotic and 
fibrotic components (CTGF, α-SMA, collagen I and IV). Homozygous hHB-EGF mouse 
kidneys also exhibited increased oxidative stress and infiltration of both macrophages and 
T-lymphocytes. Interstitial fibrosis appeared as early as 4 weeks old. Homozygous hHB-
EGF mice had increased kidney EGFR activation (increased phosphorylation of EGFR) and 
activation of downstream signaling, p-ERK and p-AKT. In addition, there was markedly 
increased p-Smad 2/3. p-EGFR, p-ERK, and p-Smad 2/3 were all primarily localized to 
proximal epithelial cells, indicating that hHB-EGF-mediated EGFR activation in proximal 
epithelial cells is the primary event in the development of interstitial fibrosis. Treatment 
with erlotinib, an inhibitor of EGFR tyrosine kinase activity, inhibited EGFR signaling 
pathways and attenuated the development of renal interstitial fibrosis.
Conclusions: These studies suggest that ligand-mediated EGFR activation in renal 
proximal tubule epithelial cells leads to spontaneous, reproducible, and treatable renal 
interstitial fibrosis. Therefore, homozygous HB-EGF mice may be a useful renal fibrosis 
model to test the effectiveness of anti-fibrotic agents.
Funding: NIDDK Support
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LPA-LPA1 Signaling Regulates Fibroblast Proliferation and Myofibroblast 
Differentiation Dependent on Epithelial Cell-Fibroblast Interaction 
Norihiko Sakai, Yasutaka Kamikawa, Akihiro Sagara, Yasuyuki Shinozaki, 
Shinji Kitajima, Akinori Hara, Yasunori Iwata, Miho Shimizu, Kengo Furuichi, 
Takashi Wada.  Div of Nephrology, Kanazawa Univ, Kanazawa, Japan.
Background: Renal fibrosis is a common pathway of progressive renal diseases, 
resulting in renal failure regardless of its cause. The accumulation of fibroblasts and 
myofibroblasts has been recognized as a hallmark of renal fibrosis. However, the precise 
mechanisms driving it remain to be determined. We have previously found the lipid mediator 
lysophosphatidic acid (LPA) and one of its receptors, LPA1, stimulates peritoneal mesothelial 
cells to induce fibroblast proliferation through connective tissue growth factor (CTGF) 
production, suggesting the involvement of epithelial cell-fibroblast interaction regulated 
by LPA-LPA1 signaling in the pathogenesis of organ fibrosis.
Methods: In this study, we focused on the effects of LPA-LPA1 signaling on the 
interaction between renal tubular epithelial cells (RTEC) and renal fibroblasts (RFB).
Results: The stimulation with LPA induced CTGF expression in both RTEC and RFB 
in a time- and dose-dependent manner. The induction of CTGF in both cells was suppressed 
by the treatment with LPA1 antagonist (AM095). In addition to that, LPA-induced CTGF 
expression in both cells was diminished by the treatment with Rho inhibitor (C3 toxin) 
and Rho kinase inhibitor (Y27632). In both cells, LPA enhanced the nuclear translocation 
of myocardin-related transcription factor (MRTF)-A/B and the transcriptional activity 
of MRTF-serum response factor (SRF), whereas Y27632 treatment inhibited those. The 
inhibition of MRTF-A/B-SRF pathway by the treatment with siRNA or a chemical inhibitor 
suppressed CTGF expression in response to LPA. Finally, CTGF derived from RTEC or RFB 
enhanced the proliferation of RFB and the expression of alpha smooth muscle actin in RFB.
Conclusions: In conclusion, LPA-LPA1 signaling regulates epithelial cell-fibroblast 
interaction to induce fibroblast proliferation and differentiation into myofibroblasts through 
CTGF production dependent on Rho/Rho kinase/MRTF/SRF pathway.
Funding: Government Support - Non-U.S.
SA-PO330
TWEAK/Fn14 Signaling Promotes Kidney Disease by Driving Myofibroblast 
Activation, Inflammation and Vascular Instability  Ivan G. Gomez,1 Allie 
M. Roach,1 Gamze Karaca,1 Linda Burkly,1 Jeremy Stuart Duffield.1  1Research 
& Development, Biogen, Cambridge, MA; 2Medicine, Univ of Washington, 
Seattle, WA.
Background: We identified Fibroblast growth factor-inducible 14 (Fn14) as a receptor 
on pericytes, which is strongly upregulated as they differentiate into myofibroblasts in 
vivo in kidney disease. TNF-related weak inducer of apoptosis (TWEAK), a TNF-family 
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cytokine produced predominantly by myeloid leukocytes has been reported to activate NFκB 
signaling via Fn14. We discovered that NFκB signaling was activated in myofibroblasts 
in vivo and hypothesized that TWEAK/Fn14 signaling might be an important driver of 
pathological myofibroblasts in kidney disease.
Results: Fn14 deficiency ameliorates myofibroblast appearance, fibrosis and 
microvascular injury in the UUO model. TWEAK activates primary murine cultured kidney 
pericytes through Fn14, inducing proliferation, migration, myofibroblast differentiation 
and production of pro-inflammatory mediators. In addition, TWEAK/Fn14 signaling 
further activates established pathological myofibroblast cultures. Transcriptional profiling 
of TWEAK-stimulated myofibroblasts supports its multifaceted role and has identified 
TWEAK-response genes, including inflammatory, matrix pathways and vascular 
destabilizing pathways. TWEAK stimulates non-canonical NFκB pathway, an interferon 
response, as well as ERK signaling in myofibroblasts.Non-canonical NFκB downstream 
signaling plays a vital role in myofibroblast responses to TWEAK. The importance of 
TWEAK signaling in disease progression was evaluated in the mouse Alport model of 
chronic kidney disease. Anti-TWEAK antibodies preserve organ function and significantly 
attenuate disease progression.
Conclusions: These findings suggest that targeting the TNF superfamily TWEAK/
Fn14 pathway is an approach to modulate myofibroblast activation and a novel way to 
block both inflammatory and fibrotic aspects of chronic kidney disease.
Funding: Pharmaceutical Company Support - Biogen
SA-PO331
Deregulation of Hippo-TAZ Pathway During Renal Injury Promotes 
Fibrotic Phenotype  Rohan Samarakoon,1 Lucas Falke,2 Roel Goldschmeding,2 
Paul J. Higgins.1  1Center for Cell Biology and Cancer Research, Albany Medical 
Center, Albany, NY; 2Dept of Pathology, Univ Medical Center Utrecht, Utrecht, 
Netherlands.
Background: Hippo pathway is the principal regulator of organ size. Transcriptional 
co-activator with PDZ-binding motif (TAZ), a nuclear transducer of Hippo pathway, is 
activated by loss of cellular polarity, tensional forces and soluble factors. TAZ has been 
implicated in the progression of lung fibrosis and cancer. However, role of Hippo-TAZ 
pathway in chronic kidney disease (CKD) is unknown.
Methods: We utilized three mouse models of renal injury [ureteral ligation (UUO), 
aristolochic acid nephropathy (AAN), streptozotocin (STZ)-driven diabetic nephropahty] 
and TAZ genetic manipulation in HK-2 tubular epithelial cells and NRK-49F renal 
fibroblasts to investigate role of TAZ in renal fibrosis.
Results: TAZ is activated [as evident by increased nuclear accumulation (4-fold) and 
expression (2.5-fold) at both in the tubular and interstitial cells and decreased TAZSer89 
phosphorylation] in the UUO kidney compared to contralateral controls. TAZ expression 
is also upregulated in AAN and streptozotocin (STZ)-induced renal diabetic injury models. 
TAZ activation correlated with increased pSMAD3 in the fibrotic kidney. TGF-beta1 and 
Angiotensin II stimulation, moreover, promoted TAZ and pSMAD3 nuclear entry in HK-2 
cells suggesting that these cytokines likely disable core Hippo signaling. TAZ stable gene 
silencing in HK-2 cells, indeed, suppressed TGF-beta1 and Angiotensin II induced CTGF, 
PAI-1 and fibronectin expression. Stable TAZ overexpression in HK-2 cells promoted 
epithelial dedifferentiation and proliferative arrest.
Conclusions: Activated during renal injury, TAZ is a novel profibotic effector of 
TGF-beta1 and Angiotensin II induced phenotypic responses. TAZ nuclear accumulation 
in response to TGF-beta1 and Angiotensin II is suggestive of cross-talk among Hippo 
pathway and these cytokines.
Funding: Other NIH Support - GM057242
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Design and Characterisation of Novel BMP Agonists and Antagonists 
Daniel Crean, Satnam Surae, Finian Martin, Catherine Godson.  UCD; UCD; 
UCD.
Background: We have previously reported a role for the Bone Morphogenetic Protein 
[BMP] antagonist Gremlin as a driver of diabetic nephropathy and fibrosis in both kidney and 
lung. Bone Morphogenetic Proteins are integral regulators of bone and organ development. 
BMPs are secreted proteins and signal by associating with membrane bound receptors. The 
activity of BMP agonists is modulated by a family of secreted protein antagonists, including 
Noggin, Crossveinless-2 and Gremlin that limit BMP-receptor association by binding to 
the ligand and thereby inhibiting receptor binding.
Methods: We have analysed BMP-receptor and BMP-antagonist interactions using a 
newly designed automated pipeline, Protein Complex Tool (PCT). Co-crystal structures of 
the BMP-BMP receptor and the BMP-antagonist complexes were submitted to PCT and in 
silico alanine substitution scans were performed to calculate the free energy contribution of 
each BMP-2, or BMP-7, residue to the stability of the complexes with receptors, BMPRIa 
(BMP-2 only) and ActRIIa, and antagonists, Crossveinless-2 (BMP-2 only) and Noggin 
(BMP-7 only).
Results: The free energy calculations identified the key contributions of BMP residues 
to both binding events and suggested mutations that might generate super-agonist and 
dominant negative molecules. Further in silico analysis was performed by mutating each 
residue to each of the other 19 amino acids. From this we identified potential super-agonist 
and dominant negative mutations for both BMP-2: L51V and N102T (super-agonists) and 
S88G and L92D (dominant negatives), and BMP-7: E60T, D119I, I124A and K127E (super-
agonists) and F117E and V122D (dominant negatives). The super-agonists will bind and 
activate receptor but will be resistant to binding by antagonist; in contrast, the dominant 
negatives, bind antagonist but not receptor.
Conclusions: Data will be presented from our investigations of these molecules as 
potential therapeutic leads for treating fibrotic diseases including DN.
Funding: Pharmaceutical Company Support - ROCHE
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Engineered Growth Factors to Treat Acute Kidney Injury  Shawdee Eshghi, 
Kris Kuchenbecker, Tim Stowe, Matt Onsum.  Silver Creek Pharmaceuticals, 
San Francisco, CA.
Background: Acute kidney injury remains a major unmet medical need and economic 
burden. Currently there are no therapies that act directly on damaged kidney cells to promote 
survival. At Silver Creek Pharmaceuticals, we are engineering a new class of therapeutics 
called Smart Growth Factors that act selectively on damaged kidney cells to safely deliver 
pro-survival signals and restore kidney function.
Methods: We harness the potent pro-survival and mitogenic signaling of growth factors 
and engineer more desirable drug-like properties, including extended half-life and cell type-
specific targeting. Our first SGF, designed to reduce cardiomyocyte death following acute 
myocardial infarction, has shown positive pre-clinical efficacy and is being prepared for an 
Investigational New Drug application. We are now designing an SGF to treat acute kidney 
injury, where apoptosis of proximal tubule cells is a leading mechanism of pathology. We 
developed an in vitro model of tubule cell apoptosis using hypoxia to screen wild type 
growth factors for the ability to restore cell viability and promote proliferation. We then 
used computational models to design SGFs that could maximize pro-survival signaling 
and targeting in damaged kidney tubule cells.
Results: SGF variants were built, expressed and purified in-house, and screened for 
their ability to activate prosurvival and proliferative signals selectively in damaged cells 
using the in vitro hypoxia model. SGFs with favorable rescue ability, selectivity and 
pharmacokinetics will be tested in a rodent AKI model using bilateral ischemia.
Conclusions: Smart growth factors have the potential to transform the treatment 
of acute kidney injury, but safely delivering potent pro-survival and mitogenic signals 
specifically to damaged cells, hopefully leading to better outcomes for this patient 
population.
SA-PO334
Loss of the Podocyte Glucocorticoid Receptor Exacerbates Proteinuria 
Julie Goodwin,1 Xuefei Tian,2 Shuta Ishibe.2  1Pediatrics, Yale Univ School of 
Medicine, New Haven, CT; 2Internal Medicine, Yale Univ School of Medicine, 
New Haven, CT.
Background: Nephrotic syndrome is one of the most common renal diseases in 
children and podocyte foot process effacement is its histologic hallmark. Glucocorticoids 
(GC) are the mainstay of treatment. Podocytes express the glucocorticoid receptor (GR) 
and new evidence suggests that podocyte-specific GC effects may be central to controlling 
proteinuria.
Methods: Mice with knockout of GR in podocytes were generated by crossing GR fl/fl 
mice with podocin Cre mice. Proteinuria was induced using both a systemic stimulus (LPS) 
and a renal-specific insult (nephrotoxic serum (NTS)). Urine protein/creatinine ratios, serum 
albumin and GBM morphology were assessed in both controls and knockout animals. In 
vitro, wound healing assays and analysis of stress fiber formation after stimulation with LPS 
in the presence or absence of dexamethasone (DEX) were performed in primary podocytes 
isolated from animals of both genotypes.
Results: Podocyte GR knockout mice did not have a phenotype at baseline. Their 
weight, serum creatinine, serum albumin, urine protein/creatinine ratios and foot process 
diameter were similar to controls. When challenged with low-dose LPS (12.5 mg/kg, IP), 
knockout mice developed significantly more proteinuria (2.11 ± 0.77 vs. 0.60 ± 0.21, p<0.05, 
n=5/group ) than did controls. Knockout mice also showed greater foot process effacement 
by EM after LPS (855 ± 157 nm vs. 466 ± 8 nm, p<0.05, n=5/group) compared to controls. 
When mice were treated with NTS, similar results were noted. In vitro, GR knockout 
podocytes showed fewer and more disorganized stress fiber formation and impaired wound 
healing after LPS treatment compared to control podocytes. Administration of DEX could 
rescue the in vitro phenotype in control, but not GR knockout, podocytes.
Conclusions: These results demonstrate that (1) loss of podocyte GR exacerbates 
proteinuria in two different models in vivo, (2) podocytes lacking GR are more intolerant 
to injury, and (3) DEX administration ameliorates cellular injury in control, but not GR-
deficient, podocytes. We conclude that podocyte GR plays a key role in maintaining the 
integrity of the slit diaphragm after injury.
Funding: NIDDK Support
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Deletion of Inositol-Requiring Enzyme-1α in Podocytes Disrupts 
Glomerular Capillary Integrity and Autophagy  Daniel Robert Kaufman,1 
Joan Papillon,2 Takao Iwawaki,3 Andrey V. Cybulsky.1,2  1Physiology, McGill 
Univ, Montreal, QC, Canada; 2Medicine, McGill Univ, Montreal, QC, Canada; 
3Medicine, Gunma Univ, Maebashi, Japan.
Background: Inositol-requiring enzyme-1α (IRE1α) is an endoplasmic reticulum 
(ER)-transmembrane endoribonuclease-kinase, which plays an essential function in 
extraembryonic tissues during normal development, and is activated during ER stress. IRE1α 
may be involved in upregulating genes associated with the unfolded protein response and 
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ER-associated degradation, as well as in the activation of c-Jun N-terminal kinase (JNK)-
1, and induction of apoptosis and autophagy. In this study, we address the functional role 
of IRE1α in podocytes.
Methods: Podocyte-specific IRE1α knockout (KO) mice were produced by breeding 
mice with loxP sites surrounding exons 20-21 with podocin (NPHS2)-Cre mice. LoxP-
mediated excision in glomeruli was confirmed with PCR.
Results: In male mice, deletion of IRE1α in podocytes resulted in albuminuria 
beginning at 5 months of age, and worsening with time. Electron microscopy revealed focal 
podocyte foot process effacement in 9 month old male KO mice, as well as microvillous 
transformation of podocyte plasma membranes and cytosolic vacuolation. By light 
microscopy, glomerular cross-sectional area (an indicator of hypertrophy) was greater in KO 
males, compared with control, and capillary lumens occupied a higher fractional area of KO 
glomeruli, suggesting formation of aneurysms. By immunofluorescence microscopy, WT1-
positive cells per glomerulus were comparable in KO and control males. Immunoblotting 
showed reduced LC3B-2 expression and JNK-1 phosphorylation in KO glomeruli, in 
keeping with reduced autophagy. There was also a reduction in nephrin maturation in KO 
glomeruli, suggesting impaired ER function. Finally, expression of IRE1α or IRE1α K599A 
(dominant inhibitor) in cultured COS-1 kidney cells did not affect ERAD, as monitored by 
the degradation of the CD3∆ ERAD reporter.
Conclusions: Podocyte-specific deletion of IRE1α leads to albuminuria and 
morphologic evidence of podocyte injury. Thus, IRE1α is essential to the maintenance of 
podocyte integrity as mice age. The mechanism may, at least in part, relate to disruption 
of autophagy in podocytes.
Funding: Government Support - Non-U.S.
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Consistent Downregulation of Autophagy Gene Atg12 Through 
MicroRNA-192 in Diabetic Nephropathy  Supriya Deshpande,1 Mitsuo Kato,1 
Mei Wang,1 Rama Natarajan.1  1City of Hope; 2City of Hope; 3City of Hope.
Background: Autophagy (Atg) plays a key role in the pathogenesis of kidney diseases, 
however its role in Diabetic Nephropathy (DN), and particularly in mesangial cells (MC) is 
not clear. TGF-b1, a key player in the pathogenesis of DN, regulates expression of various 
microRNAs (miRs) including miR-192. Also, several miRs regulate expression of various 
Atg genes. We hypothesized that miR-192 plays an important role in Atg regulation in DN.
Methods: Atg gene expression was analyzed in type-2 diabetic (db/db) and in STZ- 
injected type-1 diabetic mice. To analyze the role of miR-192 in Atg regulation, STZ-injected 
mice were treated with control locked-nucleic-acid (LNA) oligonucleotides (oligos) or LNA 
oligos targeting miR-192 (anti-miR-192-LNA), and Atg gene expression was analyzed in 
kidneys. Atg gene expression was also analyzed in kidneys of WT and STZ-injected miR-192 
knock-out (KO) mice. The effect of TGF-b1 on Atg gene expression and GFP-RFP-LC3 
puncta formation was analyzed using mouse MC (MMC).
Results: Expression of several Atg genes was decreased in kidneys of type-1 and type-2 
diabetic mice compared to controls. Treatment with LNA-anti-miR-192 reversed the effect 
of diabetes on some of the Atg genes. Further, Atg gene expression was not affected in 
kidneys of diabetic miR-192-KO mice compared to controls. In vitro studies using MMC 
treated with TGF-β also showed a decrease in Atg gene expression compared to control. 
Transfection of MMC with miR-192 mimic oligos decreased expression of certain Atg 
genes. In addition, transfection of MMC with a GFP-RFP-LC3 plasmid decreased the 
average number of RFP-LC3 puncta/cell following TGF-β treatment, and this effect was 
reversed in MMC from miR-192-KO mice. Of all Atg genes analyzed, Atg12 expression 
was consistently decreased in these mouse models, and its decrease was reversed by anti-
miR-192 LNA oligos as well as in miR-192-KO mice.
Conclusions: These results demonstrate that consistent downregulation of Atg12 
through miR-192 contributes to an overall decrease in autophagy and subsequent increase 
in cellular hypertrophy in response to TGF-b1 in MC and in glomeruli of diabetic mice 
leading to DN.
SA-PO337
mTOR Dependent Regulation of the Podocyte Metabolic Profile 
Tillmann Bork, Wei Liang, Tobias B. Huber.  Renal Div, Univ Hospital Freiburg, 
Freiburg, Baden-Wuerttemberg, Germany.
Background: Podocytes play a critical role in the formation and maintenance of the 
kidney filtration barrier. Previously we have highlighted the role of mTOR signaling as 
regulator of podocyte adaption, differentiation and size-control. However, the eventual 
link between podocyte size control and the regulation of podocyte metabolism by mTOR 
remained elusive.
Methods: Mice models of mTOR hyperactivation (Tsc1 PcKO) and mTOR loss of 
function (Raptor PcKO) were crossed to a Tomato/eGFP reporter line to efficiently isolate 
podocytes for primary cell culture studies. Mitochondrial respiration and ATP synthesis were 
assessed using Seahorse bioanalyzer with specific inhibitors of glycolysis and ß-oxidation.
Results: Lipids are the main source for ATP synthesis due to oxidative phosphorylation 
in podocytes. Anerobic glycolysis is the dominating pathway to use glucose. Active mTOR 
signaling pathway massively enhances basal metabolic activity and the capacity for oxidative 
phosphorylation as well as anaerobic glycolysis.
Conclusions: Podocyte metabolism relies on ß-oxidation of lipids and anerobic 
glycolysis. mTOR signaling regulates metabolic activity without affecting the preferences 
for the used metabolic pathways. Targeting the predominant metabolic pathways of 
podocytes might help to ameliorate diabetic nephropathy or podocyte ageing.
Funding: Government Support - Non-U.S.
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Derlin-2 Knockout Mice Unravel an Essential Role for Protein Dislocation 
in Podocytes  Guohui Ren, Kwi Hye Koh, Jing Li, Changli Wei, Mehmet 
M. Altintas, Jochen Reiser.  Dept of Medicine, Rush Univ Medical Center, 
Chicago, IL.
Background: Protein quality control represents a balance between chaperone-assisted 
folding and removal of misfolded proteins from the endoplasmic reticulum (ER). Disturbed 
balance results in ER stress in podocytes that is associated with cellular injury. Derlin-2, a 
component that nucleates cellular dislocation machinery, has been identified as an important 
element in skeletal and matrix producing cells.
Methods: Western blot and immunofluorescence staining were used for detection of 
protein expression. Derlin-2 knockdown or overexpression in podocytes was achieved 
with transduction of lentivirus containing shRNA or cDNA. Podocyte-specific Derlin-2 
knockout mice were generated by crossing Derlin-2-floxed mice with podocin-Cre mice. 
Autophagy was detected with the conversion of LC3-I to LC3-II. Activation of caspase-12 
was measured by cleavage of procaspase-12.
Results: Derlin-2 was expressed in both mouse and human podocytes. Derlin-2 
deficiency in podocytes could be compensated for by inositol-requiring enzyme 1 (IRE1) 
induced autophagy at baseline conditions. However, in situations with induced ER stress 
owed to adriamycin (ADR) or other compounds, the compensatory response of autophagy 
was overwhelmed. Meanwhile, caspase-12 mediated apoptosis pathway was activated, and 
severe cellular injury ensued, leading to heavy proteinuria in podocyte-specific Derlin-2 
knockout mice, as compared with wild type C57BL/6J control mice. In contrast, Derlin-2 
overexpression in vitro attenuated podocyte injury. Derlin-2 expression was induced in 
podocytes of patients during focal segmental glomerulosclerosis (FSGS) and diabetic 
nephropathy (DN) as well as in ADR nephropathy in BALB/cJ mice, streptozotocin (STZ)-
induced diabetic mice and BTBR ob/ob DN mice.
Conclusions: Podocytes like osteocytes and chondrocytes emerge from mesenchyme 
and belong to a group of cells that employ Derlin-2 to guarantee protein quality and minimize 
ER stress for cellular homeostasis. Overexpression of Derlin-2 may be a mechanism to 
rescue damaged podocytes. Induction of Derlin-2 expression in vivo may have applications 
for prevention and therapy of glomerular diseases.
SA-PO339
Protein O-GlcNAcylation Is Essential for Normal Podocyte Structure and 
Function  Shinya Ono,1 Mako Yasuda,1 Shinji Kume,1 Osamu Sekine,1 Jun 
Nakazawa,1 Hisazumi Araki,1 Masami Kanasaki,1 Shin-ichi Araki,1 Daisuke 
Koya,2 Masakazu Haneda,3 Takashi Uzu,1 Hiroshi Maegawa.1  1Dept of Medicine, 
Shiga Univ of Medical Science, Otsu, Shiga, Japan; 2Div of Diabetology & 
Endocrinology, Kanazawa Medical Univ, Kahoku-Gun, Ishikawa, Japan; 3Div 
of Metabolism and Biosystemic Science, Asahikawa Medical Univ, Asahikawa, 
Hokkaido, Japan.
Background: Post-translational modification is essential for normal cell function. The 
addition of O-linked β-N-acetylglucosamine (O-GlcNAcylation) to proteins is a form of 
post-translational modification and serves as a nutrient/stress sensor for modulating cell 
functions. However, little is known about the role of O-GlcNAcylation in podocyte function.
Methods: O-GlcNAc transferase (OGT) is a critical enzyme for O-GlcNAcylation 
in mammals, and resides on the X chromosome. To examine the physiological role of 
O-GlcNAcylation in podocytes, we analyzed the renal phenotype of male podocyte-specific 
Ogt-knockout (Podo-OGTKO) mice, which were generated by crossbreeding Ogt-floxed 
mice with podocyte-specific Cre mice.
Results: O-GlcNAcylation was immunohistochemically observed in the nuclei of 
podocytes in wild-type mice, but was completely absent in Podo-OGTKO mice. Podo-
OGTKO mice showed normal birth rate and growth up to 32 weeks of age. Proteinuria 
was first apparent at 8 weeks of age and increased with age up to 32 weeks. Scanning 
transmission electron microscopy showed disruption of podocyte foot processes in Podo-
OGTKO mice after 8 weeks of age. Immunofluorescence showed podocin to have a punctate 
distribution in Podo-OGTKO podocytes and to be at a reduced level compared with wild-
type mice. Furthermore, the numbers of podocytes in 16-week-old Podo-OGTKO mice were 
significantly decreased compared with wild-type mice. Finally, severe glomerular sclerosis 
with tubulointerstitial damage was observed in Podo-OGTKO mice at 32 weeks of age.
Conclusions: O-GlcNAcylation of intracellular proteins by OGT is necessary to 
maintain podocyte numbers and normal foot process structure. Our results provide new 
insight into podocyte biology.
SA-PO340
Identification of Novel Gene Products That Regulate Podocyte Function 
Davide Pietro Cina,1,2 Chengjin Li,3 Jason Moffat,4 Susan E. Quaggin.1,2  1Div 
of Nephrology, Northwestern Univ, Chicago, IL; 2Feinberg Cardiovascular 
Research Inst, Northwestern Univ, Chicago, IL; 3Tannenbaum-Lunenfeld 
Research Inst, Mount Sinai Hospital, Torontto, ON, Canada; 4Donnelly Centre 
and Banting and Best Dept of Medical Research, Univ of Toronto, Toronto, 
ON, Canada.
Background: Podocyte function is linked to the organization of its cytoskeleton and 
adhesion to the glomerular basement membrane. To identify genes that regulate podocyte 
function, we designed an in vitro genome-wide screen for factors involved in podocyte 
adhesion to fibronectin, an integrin mediated pathway, or sFLT1/Fc, a heparin sensitive 
pathway, using a pooled 90000 shRNA library.
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Methods: A pool of knockdown podocytes was generated using this library and plated 
on both substrates for one hour followed by separation of the adherent and floating fractions 
and deconvolution by illumina sequencing. We developed a stringent method for statistical 
analysis and ‘hit’ determination and performed a small-scale validation of this method by 
interrogating top candidate genes individually. We also performed a larger scale validation 
using a secondary, focused pooled Cas9 mediated knockout screen.
Results: We identified 121 genes that increased adhesion to fibronectin and 145 genes 
that increased adhesion to sFLT1/Fc. We also identified 66 genes that decreased adhesion 
to fibronectin and 106 genes that decreased adhesion to sFLT1/Fc. DPH1, DPH2, DPH3 
and DPH4 were in the top ten hits for increased adhesion to both fibronectin and sFLT1/
Fc. Stable podocyte knockdown lines for these genes displayed increased adhesion to both 
substrates. We also generated Cas9 mediated podocyte knockout lines for DPH1, DPH2 
and DPH3, which displayed increased adhesion and a spreading defect.
Conclusions: We have developed a novel method for identifying genes that regulate 
podocyte function. Future work will investigate how DPH1, DPH2 and DPH3 regulate 
podocyte adhesion, and select novel candidate genes that decrease podocyte adhesion. This 
unbiased approach will yield a list of genes that broadens our understanding of podocyte 
physiology and the disease states that perturb this system resulting in kidney disease.
Funding: Government Support - Non-U.S.
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Targeted Deletion of Drp1 in Podocytes Mitigates Mitochondrial 
Remodeling and Progression of Diabetic Nephropathy  Bernard A. Ayanga,1 
Yin Wang,1 Shawn S. Badal,1 Farhad R. Danesh.1,3  1Section of Nephrology, Univ 
of Texas MD Anderson Cancer Center, Houston, TX; 2Div of Nephrology, Baylor 
College of Medicine, Houston, TX; 3Dept of Pharmacology, Baylor College of 
Medicine, Houston, TX.
Background: Diabetic nephropathy (DN) is the most common cause of end-stage 
kidney disease in the United States. Recent evidence, from our lab and others, suggests that 
mitochondrial fission may be linked to the pathogenesis of DN and little is known on how 
mitochondrial fission contributes to the development of DN. Mitochondrial dynamics is 
regulated by at least three dynamin-related GTPases, including Opa1, mitofusin, and Drp1. 
Drp1 is an evolutionary conserved protein whose loss results in elongated mitochondria. 
We have previously reported that Rock1-mediated Drp1 activation leads to increased 
mitochondrial fragmentation and podocyte apoptosis. We hypothesized that attenuation of 
Drp1 expression and activity in podocytes may ameliorate features of DN.
Methods: To investigate the role of Drp1 in podocytes, we deployed a genetic and 
pharmacological approach using a model of Type 2 diabetes (LepRdb). First, we crossed 
conditional Drp1 (db/m;Drp1flox/flox) mice with a Podocyte-specific tamoxifen, inducible Cre 
recombinase to generate diabetic, db/db;Pod-Drp1f/f mice. Second, we employed the Drp1 
GTPase activity inhibitor, Mdivi-1, to pharmacologically assess the therapeutic potential 
of targeting Drp1 in diabetic mice.
Results: Both podocyte-specific, Drp1-/- and pharmacological inhibition of Drp1 by 
Mdivi-1 in diabetic mice exhibited significantly attenuated albuminuria, mesangial matrix 
expansion, increased podocyte numbers, reduced podocyte foot process effacement and 
attenuated glomerular basement membrane thickening. Ultrastructure analysis revealed 
significantly elongated mitochondria in Drp1-/- diabetic mice compared to non-induced 
diabetic controls. Consistent with our in vivo observations, Mdivi-1 treatment attenuated 
high glucose induced mitochondrial fission, apoptosis and mitochondrial ROS production 
in podocytes.
Conclusions: Our Data Suggest that Drp1 as a key regulator of mitochondrial dynamics 
in podocytes, and point to Drp1 as a potential therapeutic target in DN.
Funding: NIDDK Support
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A Lack of eNOS Leads to Mitochondrial Injury in the Podocytes 
Shuko Ueda,1,2 Shota Ozawa,1,3 Kiyoshi Mori,1 Katsuhiko Asanuma,1 Motoko 
Yanagita,1,4 Shunya Uchida,2 Takahiko Nakagawa.1  1TMK Project, Medical 
Innovation Center, Kyoto Univ Graduates School of Medicine, Kyoto, Japan; 
2Teikyo Univ School of Medicine, Tokyo, Japan; 3Pharmacology Research 
Laboratories II, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan; 
4Nephrology, Kyoto Univ Graduate School of Medicine, Kyoto, Japan.
Background: Endothelial nitric oxide synthase deficiency was shown to accelerate 
the progression of glomerular injury in several types of renal disease, but the role of eNOS 
to podocyte integrity remains unclear.
Methods: In order to examine the role of eNOS in the podocytes, cell morphology and 
mitochondria were examined by using adult male eNOS knockout mice.
Results: A lack of eNOS caused the glomerular hypertrophy in occasionally 
accompany with mesangiolysis and glomerular sclerosis. Urinary albumin excretion was 
also significantly increased in the eNOS knockout mice compared to the wild type mice. 
Ultrastructural analysis showed that the injured podocytes exhibited the enlarged lysosomes, 
microvillus formation, pseudocysts and foot process effacement. An increase in oxidative 
stress was also associated with podocyte injury. With respect to mitochondria, its number 
was elevated while its size was reduced, suggesting that mitochondrial fragmentation 
was induced in the podocytes due to eNOS deficiency. While the expressions of several 
mitochondrial proteins were not altered, the D-17 mutation in mitochondrial DNA was 
significantly induced in the kidney of eNOSKO mice. Mitochondrial function was also 
likely impaired by eNOS deficiency as ATP level was significantly reduced in renal cortex 
of eNOSKO mice. Furthermore, the primary podocytes from eNOSKO mice exhibited the 
impairment of mitochondrial respiration. Consistently, conditioned medium derived from 
cultured glomerular endothelial cells lacking NO caused a greater degree of mitochondrial 
fragmentation and an increase in mitochondrial oxidative stress in the cultured podocytes 
while such alterations was rescued by an NO donor.
Conclusions: These data suggest that eNOS may be necessary to maintain podocyte 
integrity, especially mitochondrial function.
SA-PO343
Cytosolic Phospholipase A2 Alpha Regulates G1 Progression Through 
Modulating Forkhead Box Protein O1 Activity  Said Movahedi naini,1 
Gabriel Choukroun,2 Dirk M. Hentschel,1 Joseph V. Bonventre.1  1Brigham 
and Women Hospital, Renal Division, Boston, MA; 2Amiens Southern Hospital, 
Renal Division, Amiens, Picardie, France.
Background: Mesangial cell (MC) proliferation is characteristic of a number of chronic 
progressive glomerular diseases. cPLA2α is expressed in MCs and plays a role in cellular 
proliferation, however the mechanisms involved remain unclear. Here, we show for the 
first time a novel regulatory role for cPLA2α in the regulation of G1 phase of the cell cycle 
that is conserved in zebrafish and mammals.
Methods: Mouse embryonic fibroblasts (MEFs) and MCs were derived from cpla2α-/- 
mice. cPLA2α was knocked down in zebrafish using morpholinos (MOs). Cell cycle 
progression was assessed by flow cytometry in zebrafish larvae and in G0 synchronized cells 
after stimulation with PDGF. S phase population was assessed in zebrafish and MEFs by 
BrdU pulse studies. Analysis of the phosphorylation of proteins was carried out by western 
blot assays using phosphospecific antibodies.
Results: We identified two zebrafish cpla2α genes, termed zcpla2aa and zcpla2ab, with 
conserved phospholipase activity. In zebrafish and MCs cPLA2α promotes G1 progression 
via its phospholipase activity and through PGE2 production. PGE2 through the PI3’-K/AKT 
pathway, promotes FOXO1 phosphorylation and FOXO1 nuclear export. This, in turn, 
inactivates FOXO1 resulting in upregulation of cyclin D1 and downregulation of p27Kip1, 
thus promoting G1 progression. These data indicate an evolutionary conserved mechanism 
between lower vertebrates and mammals. Further, using pharmacological inhibitors, we 
show that cPLA2α, RAF/MEK/ERK, and PI3’-K/AKT signaling pathways cooperatively 
regulate G1 progression in response to mitogenic stimulation.
Conclusions: cPLA2α is a critical effector of the G1 phase of the cell cycle through 
its phospholipase activity. Pharmacological targeting of this enzyme may have important 
therapeutic benefits in disease mechanisms that involve excessive cell proliferation including 
progressive acute and chronic glomerulonephritis.
Funding: NIDDK Support
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Podocyte Specific Glycogen Synthase Kinase 3 Is Critical for Neonatal 
Survival and for Renal Function in Maturity  Jenny Hurcombe,1 Abigail 
Charlotte Lay,1 Gavin Iain Welsh,1 Peter W. Mathieson,1 Satish Patel,2 Susan 
E. Quaggin,3 James R. Woodgett,2 Richard Coward.1  1Academic Renal Unit, 
Univ of Bristol, Bristol, United Kingdom; 2Samuel Lunenfeld Research Inst, 
Univ of Toronto, Toronto, ON, Canada; 3Feinburg School of Medicine, North 
Western Univ, Chicago, IL.
Background: GSK3 is a multi-functional serine/threonine kinase existing as two 
distinct but related isoforms: α and β. Knockout mouse models suggest that the GSK3 
isoforms have different and cell type specific functions. This study aims to examine the 
importance of GSK3 in the podocyte.
Methods: We have used Cre/LoxP technology to generate mice with podocyte-specific 
ablation of GSK3α and/or GSK3β in development (using the podocin cre driver) and in 
maturity (using the doxycycline inducible podocin RtTA – tet-o-cre driver).
Results: Mice developmentally lacking either GSK3α or GSK3β specifically in the 
podocyte are viable with normal life span (up to 2 years) and normal renal histology. In 
contrast, mice null for both GSK3 isoforms, born at normal Mendelian frequency, die at 
10-16 days with massive albuminuria and acidosis. These mice have vacuolated glomeruli 
and glomerulosclerosis. Knockout of GSK3α and β after full glomerular development, at 
4 weeks of age, also results in significant renal disease which develops within 2 weeks 
of knockdown. It consists of significant albuminuria with renal failure in some mice. 
Furthermore, there is evidence of a crescentic proliferative glomerulopathy, together with 
massive fibrosis and glomerulosclerosis. Mechanistically the wnt signalling pathway is 
up-regulated and β-catenin activated throughout the kidney. Contemporaneous knockdown 
of β-catenin in the developmental model dramatically improves albuminuria and renal 
histology but not acidosis or survival indicating the involvement of other pathways. These 
are currently being investigated through a glomerular transcriptomic approach.
Conclusions: Podocyte specific GSK3 is critical for glomerular and renal function in 
development and full maturity. Loss of single isoforms can be compensated throughout 
life but loss of both is catastrophic.
Funding: Government Support - Non-U.S.
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Podocyte Oxidative Stress Coupled with Ubiquitin C-Terminal Hydrolase 
Deletion Exacerbates Renal Damage  Naomi C. Read,1,2 Chet E. Holterman,2 
Douglas A. Gray,2 Chris R. Kennedy.1,2  1Cellular and Molecular Medicine, 
Univ of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Inst, Ottawa, 
ON, Canada.
Background: Ubiquitin C-terminal hydrolase L1 (UCHL1) may promote antioxidation 
by hydrolyzing ubiquitin-thioester bonds on glutathione (GSH) thereby protecting GSH 
from degradation. Podocyte UCHL1 is upregulated in diseased glomeruli where it may 
maintain redox balance. UCHL1-deleted mice overexpressing podocyte-specific NOX5 
should exhibit exacerbated glomerular damage due to unregulated oxidative stress.
Methods: COS7 cells were infected with AdGFP or AdNOX5 and UCHL1 levels 
determined by immunoblot. UCHL1 mRNA was quantified by qPCR. UCHL1+/- and 
NOX5pod+ mice were crossed to generate NOX5pod+/UCHL1-/- mice. Albuminuria (ACR) 
was measured by ELISA. Renal mass was normalized to tibia length. Glomerular filtration 
rate (GFR) was assessed by FITC-Inulin. Immunofluorescence with anti-PCNA and 
anti-renin was performed on renal sections. Blood pressure was determined by tail cuff 
plethysmography.
Results: UCHL1 protein increased 1.9-fold in COS7 cells infected with AdNOX5 vs. 
AdGFP-infected controls. Similarly, glomeruli from 12-week-old NOX5pod+ mice showed 
limited UCHL1 mRNA induction (1.5-fold). ACR increased in NOX5pod+/UCHL1-/- mice at 
12 weeks (40ug/mg) but not in nonTG, UCHL1-/- and NOX5pod+/UCHL1-/- mice (24, 28 and 
25ug/mg). Renal mass was reduced by 10% in both UCHL1-/- and NOX5pod+/UCHL1-/- mice 
as compared to nonTG mice. Interestingly, GFR was elevated in NOX5pod+, UCHL1-/- and 
NOX5pod+/UCHL1-/- mice (283, 362 and 352ul/min) vs. nonTG (198ul/min). In UCHL1-/- 
mice regardless of NOX5 expression, hypercellularity was evident in the juxtaglomerular 
region. However, no differences were found in renin or PCNA expression, suggesting 
that the increased GFR is independent of the renin-angiotensin system. Blood pressure 
increased in NOX5pod+/UCHL1-/- mice (121mmHg vs. 113 and 109mmHg for nonTG and 
UCHL1-/- mice), but was not different from NOX5pod+ mice (127mmHg) at 12 weeks.
Conclusions: UCHL1-null mice have altered renal function and mass. When 
intercrossed with NOX5pod+ mice, UCHL1 deletion combined with unchecked oxidative 
stress promotes filtration barrier damage.
Funding: Private Foundation Support
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Apolipoprotein L1 Has Diverse RNA and Protein Isoforms and APOL1-B3 
Activates Pro-Inflammatory Signaling  Hidefumi Wakashiu, Jeffrey B. Kopp. 
Kidney Disease Branch, NIDDK, NIH, Bethesda, MD.
Background: Genetic variants apolipoprotein L1 (APOL1), present in individuals of 
recent African descent, are strongly associated with glomerular disease, but the molecular 
mechanisms have not been clarified. APOL1 mRNAs have seven exons, and produce splice 
variants which are predicted to code for distinct protein isoforms (A, B3 and C). However, 
it is unknown which isoforms drive glomerular disease.
Methods:   We examined mRNA expression by TA cloning and determined protein 
localization using immunofluorescence (IF) of FLAG-tagged APOL1 in stably transfected 
cells. Mitochondrial fractions were isolated using a detergent-based method.
Results:   Using RNA from human podocytes we cloned a new APOL1 splice variant 
(B3) that lacks exon 4, which contains the signal sequence of APOL1. APOL1-B3 was 
specifically recognized by APOL1-B antibody raised in rabbits immunized to exon 2. 
APOL1-B3 was absent from human serum, but was present in podocytes. Both endogenous 
and transfected APOL1-B3 partially co-localized with mitochondria in IF study and were 
detected in mitochondrial fractions by Western blot using either anti-FLAG antibody and 
APOL1-B antibody. By immunoprecipitation, APOL1-B3 was associated with NLRP12, 
which is a regulator of pro-inflammatory signaling. IL-1 receptor signaling was enhanced 
in APOL1-B3 stably transfected HeLa cells, and over-expressed NLRP12 overcame the 
enhancement of IL-1 receptor signaling by APOL1-B3.
Conclusions: APOL1 mRNA splicing produces multiple protein isoforms including A, 
B3 and C. APOL1-B3 was associated with NLRP12 and enhanced IL-1 receptor signaling. 
APOL1 nephropathies may be driven by podocyte inflammation and the TLR and IL-1 
receptor signaling pathways may be therapeutic targets.
Funding: NIDDK Support
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TNFα Mediated NFAT Activation Causes Podocyte Cholesterol 
Accumulation in FSGS  Christopher E. Pedigo,1,2 Farah Leclercq,1,2 Matthias 
Kretzler,3 Sebastian Martini,3 Alla Mitrofanova,1,2,4 Ximena A. Morales,1,2 
Christian Faul,1,2 Alexis J. Sloan,1,2 George William Burke,4 Alessia Fornoni,1,2 
Sandra M. Merscher.1,2  1Nephrology, U of Miami; 2Katz Drug Discovery Center, 
U of Miami; 3U of Michigan; 4Surgery, U of Miami.
Background: Focal Segmental Glomerulosclerosis (FSGS) is the most common cause 
of glomerulonephritis in the US and podocyte injury is associated with the development 
of albuminuria. Tumor Necrosis Factor alpha (TNFα) levels are increased in a subset of 
patients with FSGS and TNFα alters ATP-Binding Cassette A1 (ABCA1) expression in 
association with altered cholesterol homeostasis. Treatment strategies for FSGS patients 
include cyclosporine A (CsA) which directly influences podocyte Nuclear Factor of 
Activated T-Cells (NFAT) activation. However a potential link between TNFα-NFAT-
ABCA1-Cholesterol has not been established. We hypothesized that TNFα causes NFAT 
mediated lipid dependent podocyte apoptosis in FSGS.
Methods: Differentiated human podocytes were cultured in the presence of TNFa 
(100ng/ml). Caspase 3 activity was determined in human podocytes. Cyclodextrin (CD) 
was utilized to deplete cholesterol.
Results: FSGS sera treated podocytes demonstrated increased TNFα expression. 
Increased TNFα expression correlated with reduced ABCA1 expression in glomerular 
biopsies from FSGS patients. TNFα treatment of podocytes increased NFAT promoter 
luciferase activity and RCAN1 mRNA expression. Inhibition with CsA an upstream 
activator of NFAT prevented downregulation of ABCA1 and increased Caspase 3 activity. 
TNFα administration in mice caused glomerular NFAT activation and albuminuria that 
was prevented by CsA. Mice overexpressing podocyte specific constitutively active 
NFAT developed albuminuria and kidney cholesterol accumulation that was prevented by 
cholesterol depletion with CD.
Conclusions: TNFα expression is increased in glomeruli of patients with FSGS 
and in podocytes treated with sera from patients with FSGS. TNFα treatment of human 
podocytes causes NFAT activation leading to reduced ABCA1 expression and cholesterol 
accumulation in association with podocyte apoptosis. Our data suggest that treatments 
targeting the TNFα-NFAT-ABCA1-cholesterol axis may prevent podocyte injury in FSGS.
Funding: NIDDK Support, Pharmaceutical Company Support - Hoffman La Roche
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Insulin Receptor Isoform A Is Implicated in Podocyte Injury in 
Diabetic Kidney Disease  Alla Mitrofanova,1,2 Ximena A. Morales,1 Mayrin 
Correa-Medina,1 Christopher E. Pedigo,1 Farah Leclercq,1 George William 
Burke,2 Sandra M. Merscher,1 Alessia Fornoni.1  1Katz Family Drug Discovery 
Center, Div of Nephrology & Hypertension, Univ of Miami, FL; 2Dept of Surgery, 
Univ of Miami, FL.
Background: Disruption of physiological insulin signaling occurs in podocytes in 
experimental diabetic kidney disease (DKD). Two isoforms of insulin receptor (IR) have 
been described that either lack (IRA) or contain (IRB) the 12 amino acids encoded by 
exon 11. IRA signals primarily through p70S6 kinase and IRB signals primarily through 
AKT. Podocytes are dependent on functional lipid rafts and associated protein caveolin-1 
(Cav1) for proper signaling and survival. We have recently shown sphingomyelin-
phosphodiesterase-acid-like-3b (SMPDL3b), which regulates the activity of acid-
sphingomyelinase in podocyte lipid rafts, is upregulated in DKD and may contribute to 
podocyte injury. We tested the hypothesis that SMPDL3b overexpression suppresses IRB 
signaling and facilitates IRA signaling leading to podocyte hypertrophy and apoptosis.
Methods: Podocytes were treated with insulin (0.1 or 1 nM, 30 min) and samples 
were used for Western blot analysis. Co-immunoprecipitation experiments (Co-IP) were 
performed in HEK cells, transfected with 1ug of GFP- or FLAG-SMPDL3b, FLAG-IRA, 
FLAG-IRB, GFP-Cav1 plasmid. Apoptosis analysis was measured using Caspase-3 
Fluorometric Assay kit. Cell surface area was measured by confocal microscopy (OPERA 
XL).
Results: Podocytes overexpressing SMPDL3b (OE) showed significant increase 
of IRB/IRA mRNA expression ratio compared to control podocytes (CT) (1.00±0.00 
and 0.74±0.05, p<0.05). Co-IP demonstrated that both IRA and IRB interact with Cav1. 
SMPDL3b overexpression augmented IRA/Cav1 interaction and suppressed IRB/Cav1 
interaction. OE podocytes showed bigger cell surface area compared to CT (2778.0±246.5 
and 2171.0±54.7, p<0.05). Insulin stimulation had no effect on the caspase-3 activity in 
CT podocytes while it induced apoptosis in OE cells (1.19±0.08 and 2.14±0.32, p<0.05).
Conclusions: Our data suggest SMPDL3b overexpression in human podocytes impairs 
IRB signaling leading to increased apoptosis and augments IRA signaling resulting in 
cell hypertrophy.
Funding: NIDDK Support, Other NIH Support - The study is supported by NIH 
DK090316, NIH/NIDDK 5U24DX076169
SA-PO349
Cyclodextrin Improves Renal Function in Experimental Alport Syndrome 
Ximena A. Morales,1,2 Alla Mitrofanova,1,2,3 Christopher E. Pedigo,1,2 Judith T. 
Molina David,1,2 Mayrin Correa-Medina,1,2 Farah Leclercq,1,2 Javier T. Varona 
Santos,1,2 Gloria Michelle Ducasa,1,2 Sandra M. Merscher,1,2 Alessia Fornoni.1,2 
1Div of Nephrology and Hypertension, Dep of Medicine, Univ of Miami, Miami, 
FL; 2Peggy and Harold Katz Family Drug Discovery Center, Univ of Miami, 
Miami, FL; 3Dep of Surgery, Univ of Miami, Miami, FL.
Background: Alport syndrome (AS) is an inherited disease caused by gene mutations 
involved in collagen type IV biosynthesis. No treatments are currently available for AS. 
2-hydroxypropyl-β-cyclodextrin (CD) is a cholesterol depleting agent that is now in clinical 
trials for treating Niemann-Pick disease type C. We have recently reported that CD protects 
in experimental DKD by reducing cholesterol dependent podocyte damage. We hypothesized 
that CD improves renal function in an experimental model of AS.
Methods: Collagen Col4a3 knockout (KO) mice were used as a model for AS. Four-
week-old Col4a3 (KO) and wild type (WT) female mice were injected subcutaneously with 
CD (4000 mg/kg) or vehicle (0.9% Saline solution), 3 times per week for 3 weeks. Four 
groups were analyzed: WT+vehicle (n=4), WT+CD (n=5), KO+vehicle (n=6), and KO+CD 
(n=4). Body weight and ACR (albumin/creatinine ratio) from urine were determined weekly. 
Serum creatinine and blood urea nitrogen (BUN) were analyzed by mass spectroscopy 
and ELISA respectively at treatment initiation and at sacrifice. Perfused kidneys and skin 
samples at the site of injection were collected for histological analysis (H&E, PAS) and 
for Oil Red O (ORO) Staining.
Results: H&E staining showed no toxicity at the site of CD injections. No body 
weight changes were observed during treatment. CD administration reduced glomerular 
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ORO staining and prevented the development of mesangial expansion in KO+CD group 
compared to KO+Vehicle. A significant reduction in ACR was observed after 3 weeks 
of CD treatment in KO+CD compared to KO+Vehicle mice (p<0.001), accompanied by 
a trend in reduced serum creatinine. CD treatment did not affect ACR, renal function or 
mesangial expansion in WT mice.
Conclusions: Based on these results, we conclude that CD improves renal function in a 
mouse model for AS and could be a new therapeutic strategy for the treatment of AS patients.
Funding: NIDDK Support, Pharmaceutical Company Support - Hoffman La Roche
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The Glomerular Matrisome in Alport Syndrome Is Altered prior to the 
Onset of Albuminuria  Michael J. Randles,1,2 Sophie C. Collinson,1 Jeffrey H. 
Miner,3 Rachel Lennon.1,2  1Wellcome Trust Centre for Cell-Matrix Research, 
Faculty of Life Sciences, Univ of Manchester, Manchester, United Kingdom; 
2Inst of Human Development, Faculty of Medical & Human Sciences, Univ of 
Manchester, Manchester, United Kingdom; 3Renal Div, Washington Univ School 
of Medicine, St. Louis, MO.
Background: Alport Syndrome is caused by genetic defects in COL4A3, COL4A4 or 
COL4A5, but despite this knowledge there are currently no targeted therapies. We aimed 
to build our basic understanding about the glomerular extracellular matrix (ECM) in Alport 
syndrome and performed global analysis of composition and ultrastructural imaging in 
the Col4a3-/- mouse.
Methods: Cellular and extracellular matrix (ECM) fractions from wild type and 
Col4a3-/- glomeruli at 6 and 16 weeks of age were analysed by mass spectrometry (MS) 
and imaged using serial block face-scanning electron microscopy (SBF-SEM).
Results: MS analysis revealed moderate changes in the composition of glomerular 
ECM at 6 weeks, even prior to the onset of barrier dysfunction. These included complete 
absence of type IV collagen a3, α4, α5 and upregulation of type IV collagen a1, a2, α6 and 
type VI collagen. At 16 weeks more dramatic changes were detected including elevated 
type IV collagen a1, a2, fibronectin, type I collagen, laminin a2 and fibrinogen chains. 
Global and pathway analysis of cellular fractions indicated changes in actin regulating 
proteins at 6 weeks and mitochondrial dysfunction at 16 weeks. SBFSEM demonstrated 
thickened and irregular glomerular basement membranes with evidence of podocyte 
protrusions into this ECM.
Conclusions: Our data demonstrate that Alport syndrome progresses with distinct 
early changes in ECM followed by more profound ECM accumulation, disruption and 
mitochondrial dysfunction. Enhanced understanding about the pathways that control 
podocyte cell-matrix adhesion may ultimately inform therapeutic strategies to correct or 
repair glomerular barrier function in Alport syndrome.
Funding: Private Foundation Support
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Creation and Analysis of Mouse Models of Human Nephrotic Syndrome 
Caused by the Laminin b2 (LAMB2) S80R Mutation  Steven Daniel Funk, 
Jeffrey H. Miner.  Renal Div, Washington Univ School of Medicine, St. Louis, MO.
Background: Most cases of congenital nephrotic syndrome in the first year of life 
are caused by mutations in 4 genes expressed in podocytes: NPHS1, NPHS2, WT1, and 
LAMB2. LAMB2 encodes laminin b2, a glomerular basement membrane component 
critical for glomerular filtration. We previously created transgenic mice using the nephrin 
promoter to study missense mutations discovered in patients with congenital nephrotic 
syndrome, including R246Q and C321R, which inhibit laminin-521 secretion and/or 
induce podocyte ER stress. Here we aimed to characterize a new mutation (S80R) in the 
LAMB2 polymerization domain that was discovered in a delayed nephrotic syndrome 
patient; this delay suggests that chronic dysfunction in glomerular filtration may be the 
pathogenic mechanism.
Methods: In our first approach the S80R mutation was engineered into the rat laminin 
b2 cDNA and placed under the control of the nephrin promoter; this construct was used to 
make transgenic mice expressing LAMB2-S80R in podocytes on the Lamb2-/- background. 
In a second approach, we utilized CRISPR/Cas9 and homologous recombination to “knock-
in” the S80R point mutation into the endogenous Lamb2 gene.
Results: Several transgenic mouse lines were characterized as very high, high, and 
low/mosaic LAMB2-S80R-expressing mouse lines. Surprisingly, high S80R expressers 
did not exhibit albuminuria up to 1 year of age. The low/mosaic expressers exhibited 
persistent, low level albuminuria that never progressed into the nephrotic range or overt 
kidney disease. These observations suggested to us that unregulated transgene expression 
may compensate for what could be only a mildly pathogenic mutation. We then used 
CRISPR/Cas9 technology in zygotes to generate LAMB2-S80R knock-in mice that will 
better mimic endogenous expression of the mutant protein, as in the patient. These are 
currently being bred for analysis.
Conclusions: The LAMB2-S80R mutation seems to be mild vs. other LAMB2 
mutations. S80 is in the laminin N-terminal (LN) domain important for laminin polymer 
formation. High transgene expression may compensate for S80R-induced polymerization 
defects, which will be avoided with CRISPR/Cas9-induced, S80R knock-in mutants.
Funding: NIDDK Support
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Differential Roles of Cell Surface Proteoglycans in Podocyte-Glomerular 
Basement Membrane Adhesion  Angela C. DiPoto-Brahmbhatt, Deborah J. 
McCarthy, Kevin J. McCarthy.  Pathology and Translational Pathobiology, 
LSU Health Sciences Center-Shreveport, Shreveport, LA.
Background: Cell surface proteoglycans (PG), via their heparan sulfate (HS) chains, 
work in a cooperative fashion alongside integrins to mediate podocyte (POD)-glomerular 
basement membrane (GBM) interactions. Results of our previous studies have shown 
that complete loss of HS at the POD cell surface leads to the development of foot process 
effacement. Since POD have at least two cell surface HS PG’s that are capable of mediating 
such interactions, the purpose of this study was to determine the effects of selective deletion 
of the cell surface PG, syndecan-1 (Sdc1) or syndecan-4 (Sdc4) on POD in vivo.
Methods: Frozen tissue sections of kidneys from wild-type (WT), Sdc1, or Sdc4 
knockout (KO) mice were immunostained with antibodies against the core proteins of 
Sdc1 and Sdc4, HS (antibody HS4C3), synaptopodin (SYN), nephrin, and α-actinin-4. 
To determine the potential for loss of anionic charge associated with HS, 500µm sections 
of unfixed kidneys were labeled with polyethylenimine (PEI) followed by fixation and 
processing for transmission electron microscopy.
Results: TEM studies showed that the GBMs of both Sdc1 and 4 KO mice had GBM 
irregularities, the POD in Sdc4KO mice showing moderate foot process effacement. 
Immunostaining for HS did not show differences in staining intensity for HS between Sdc1 
and Sdc4KO mice. However, PEI labeling showed that the GBMs in Sdc4 KO mice had 
larger aggregates of PEI than those found in the GBM of Sdc1KO mice. Immunostaining 
showed that a compensatory increase in Sdc4 expression in Sdc1KO glomeruli or Sdc1 
expression in Sdc4KO glomeruli did not occur. The glomeruli of Sdc1 KO mice showed 
disruption of nephrin organization compared to Sdc4 and WT mice. Immunostaining for 
α-actinin-4 in both Sdc1KO and Sdc4KO glomeruli was also disrupted compared to control.
Conclusions: The data show that disruption of either Sdc1 or Sdc4 interactions with 
the GBM does affect the manner by which POD interact with the GBM. Although loss of 
Sdc4 was associated with the development of foot process effacement, the loss of either 
Sdc1 or Sdc4 have effects on POD cytoskeletal organization.
Funding: NIDDK Support
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ERM Protein Activation by CLIC4 in Glomerular Endothelial Cells 
Abass Almomany,1 Mahtab Tavasoli,1 Laiji Li,1 John C. Edwards,2 Barbara J. 
Ballermann.1  1Medicine, Univ of Alberta, Edmonton, AB, Canada; 2Internal 
Medicine, St. Louis Univ, St. Louis, MO.
Background: We reported (J. Cell Sci. 2014, 127:5164) that the podocyte-predominant 
CLIC5A stimulates PI[4,5]P2 production and consequent ERM (ezrin, radixin, moesin) 
protein phosphorylation (pERM). Activated ERMs link membrane-spanning proteins 
to cortical actin, and inactive ERMs are unstable. CLIC4, homologous to CLIC5A, is 
expressed at high levels in glomerular and peritubular capillary endothelial cells (EC), 
and in proximal tubule brush border and basolateral membranes. CLIC4 deficient mice 
(CLIC4-/-) have fewer glomeruli and a lower peritubular capillary density than wild-type 
mice (BMC Nephrology 2014, 15:54). Here, we explored whether CLIC4 regulates ERM 
protein activation, similar to CLIC5A.
Methods: Confocal immunofluorescence (cIF) microscopy was used to visualize 
CLIC4 and moesin kidney sections. Western blot analysis (WB) was used to study total 
and cytoskeletal fractions from isolated mouse glomeruli and cultured human glomerular 
EC cells. In cultured human glomerular EC, CLIC4 was silenced with CLIC4-specific 
siRNA ± CLIC4 cDNA rescue.
Results: By cIF CLIC4 co-localized exquisitely with moesin in mouse glomerular 
EC. WB showed that CLIC4 is absent from CLIC4-/- glomerular lysates, and that the ratio 
of pERM : tubulin is lower in CLIC4-/- than in CLIC4+/+ glomeruli (1.28 ± 0.11 vs. 2.26 ± 
0.30, respectively, p < 0.01, mean ± SD, n=3). Total ERM protein was also reduced, and 
much less ERM protein was observed in the cytoskeletal fraction of CLIC4-/-, compared 
to CLIC4+/+ glomeruli. In cultured human glomerular EC, CLIC4 siRNA reduced CLIC4 
protein by >90% and resulted in ERM protein dephosphorylation and dissociation 
from the cytoskeleton, all rescued by over-expression of CLIC4. CLIC4-induced ERM 
phosphorylation was abolished by PLC activation with m-3M3FBS, indicating that PI[4,5]
P2 dependence.
Conclusions: Hence, CLIC4 co-localizes with moesin in glomerular EC in vivo. 
Like CLIC5A, CLIC4 promotes ERM phosphorylation in a PI[4,5]P2-dependent fashion. 
We speculate that defective ERM phosphorylation may be responsible, in part, for the 
morphological and physiological abnormalities in CLIC4-/- mice.
SA-PO354
Vascular Glycocalyx Syndecan (SDC) 4 Loss Coincides with Albuminuria 
in Diabetic Nephropathy (DN)  Raina D. Ramnath, Amy Russell, Rebecca R. 
Foster, Gavin Iain Welsh, Andy Salmon, Simon C. Satchell.  Academic Renal 
Unit, Univ of Bristol, Bristol, United Kingdom.
Background: The endothelial glycocalyx is a critical determinant of vascular health 
and a key regulator of vascular permeability. Increasing evidence points to disruption of 
the endothelial glycocalyx as a contributor to development of albuminuria (albumin in the 
urine) and eventually DN. TNFα which is important in the development of microvascular 
disease in diabetes caused a disruption of the glomerular endothelial cells (GEnC) 
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glycocalyx through shedding of SDC4 and heparan sulphate (HS). We seek to investigate 
the role of vascular endothelial glycocalyx in DN and determine the mechanisms involved 
in its disruption in DN.
Methods: DN was induced in DBA2J mice by giving daily intraperitoneal injection of 
streptozotocin (STZ) at 50mg/kg for 5 days. The mice became hyperglycemic at 2 weeks 
and significantly albuminuric at 8 weeks post STZ injection.
Results: In DN, SDC4 protein expression was significantly decreased in isolated 
glomeruli. This was accompanied by a corresponding increase in SDC4 in the circulation 
and in the urine, suggesting shedding of vascular glycocalyx SDC4. An increase in SDC4 
shedding causes a positive feedback mechanism resulting in an increase in SDC4 mRNA 
synthesis in isolated glomeruli and GEnC. The glycocalyx SDC4 disruption coincides 
with albuminuria, strongly suggesting that vascular glycocalyx SDC4 damage is likely to 
contribute to albuminuria in DN. There was a significant elevation in gelatinase matrix 
metalloproteinase (MMP)2 in glomeruli in DN, suggesting that MMP2 could mediate 
SDC4 shedding. My in vitro data in human GEnC showed that gelatinase MMP9 was 
upregulated and resulted in the shedding of SDC4 and HS. This resulted in an increase in 
BSA permeability across the monolayer.
Conclusions: MMP2,9-mediated shedding of SDC4 is likely to contribute to vascular 
endothelial glycocalyx disruption and albuminuria observed in DN.Potential therapies 
targeted at glycocalyx protection will be of benefit not only in DN but also in ameliorating 
systemic vascular disease in diabetes.
Funding: Private Foundation Support
SA-PO355
Blood Cell Velocities in Glomerular Capillaries Measured by 2-Photon In 
Vivo Microscopy Reveal Heterogeneous Blood-Flow  Deianira Pedoto,1,2 
Eugenio Gutierrez,3 Luca Bordoni,1 Sara Damiano,2 Francesco Trepiccione,2 
Giovambattista Capasso,2,4 Sebastian Frische.1  1Dept of Biomedicine, Aarhus 
Univ, Aarhus, Denmark; 2Dept of Cardio-Thoracic and Respiratory Science, 
Second Univ of Naples, Napoli, Italy; 3Center for Functionally Integrative 
Neuroscience, Aarhus Univ, Aarhus, Denmark; 4Biogem, Ariano Irpino, Italy.
Background: Theoretical models have shown that the blood-flow within a glomerulus 
may be heterogeneous and that flow heterogeneity may affect the ultrafiltration coefficient 
and thus GFR. The aim of this study is to provide experimental data to test these model 
predictions by measuring glomerular capillary flow velocities by in vivo 2-photon 
microscopy.
Methods: Male Munich-Wistar rats were intubated, anesthetized with isoflurane, and 
mechanically ventilated. Blood pressure and heart-rate were monitored. The left kidney 
was externalized and the rat placed in the 2-photon microscope. Blood plasma was labeled 
by i.v. injection of 70 kD TexasRed-Dextran. Longitudinal lines in the lumen of capillaries 
in superficial glomeruli were scanned at a frequency of >700 Hz. The axial movement of 
single blood cells was measured. 308 different capillaries were analyzed in 17 glomeruli 
from 5 different rats.
Results: Blood cell velocity was 2.99 µm/ms +/- 0.54. A Gaussian distribution and a 
Gamma-distribution were fitted to data from 13 glomeruli in which >12 capillaries were 
studied. C2-tests (α=0.05) showed 5 of 13 datasets not to follow a Gaussian distribution and 
1 of 13 not to follow a Gamma-distribution. The data from all 308 capillaries normalized 
to the mean of the respective glomerulus did not follow a Gaussian distribution (P<0.05). 
The Gamma-distribution allows an asymmetrical distribution around the mean and provided 
the best description.
Conclusions: This study provides experimental evidence of heterogeneity and 
an asymmetric distribution of blood cell velocity in glomerular capillaries. This new 
experimental evidence calls for refinement of current models of glomerular blood flow 
heterogeneity and invokes the possibility to investigate the potential regulatory control 
of the ultrafiltration coefficient by regulation of capillary flow heterogeneity, e.g. by the 
action of mesangial cells.
Funding: Government Support - Non-U.S.
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Assessment of Exosomes Derived from Mesangial Cells Stimulated with 
High Glucose  Antonio S. Novaes,1 Fernanda Teixeira Borges,1 Marcos Dias,2 
Mirian A. Boim.1  1Medicine, Federal Univ of Sao Paulo, Sao Paulo, SP, Brazil; 
2CIPE - Centro Internacional de Pesquisa, A.C. Camargo Cancer Center, Sao 
Paulo, SP, Brazil.
Background: Exosomes and microvesicles (MV) are extracellular vesicles (EV) that 
play a key role in the intercellular communication and they have been recently involved in 
many physiological and pathological conditions. EV released by cells contains substances 
that can modify the function of other target cells. The content of this vesicles include 
proteins and nucleic acids such as microRNAs (miRNA). This study aimed to ascertain 
whether high glucose can modify the cargo of the human mesangial cell (HMC)-derived EV.
Methods: EV secreted from HMC were purified by ultracentrifugation serum-free 
medium and analyzed by electron microscopy. The vesicles size/concentration ratio was 
determined by the particle tracking using a nanoparticles analyzer (NanoSigth) and the 
characterization of the exosomes was performed by the presence of a specific marker 
CD63. Since mesangial cells are an important intrarenal source of the renin angiotensin 
system (RAS) components, we evaluated the presence angiotensinogen in the exosomes, by 
Western Blot. The exosomes obtained from control (C-Ex) and HG exposed HMC (HG-Ex) 
were used to evaluate whether they are able to modify the function of target control HMC. 
Exosomes were added to the culture medium and 24 hr after, the expression of fibronectin 
mRNA was estimated by real time PCR.
Results: The vesicles had a mean size of 140 nm and expressed the CD63, specific 
for exosomes.The amount and size of exosomes were not modified by stimulation with 
high glucose. It was observed the presence of angiotensinogen in the exosomes, and it was 
increased in the exosomes derived from HG stimulated HMC. Interestingly, the expression 
levels of fibronectin was higher in control HCM treated with HG-Ex compared with those 
treated with C-Ex, indicating that HG-Ex can modify the function of normal HMC.
Conclusions: In conclusion, the exosomes derived from HG stimulated HMC were 
able to induce fibronectin production in target control cells, and suggest that the intercellular 
communication through the exosomes may have pathophysiological implications in the 
diabetic kidney.
Funding: Government Support - Non-U.S.
SA-PO357
Axl Receptor Tyrosine Kinase Is Involved in Proliferation of Human 
Mesangial Cells Activated by PDGF  Qi Bian,1,2 Joshua Charles Anderson,1 
Xianwen Zhang,1 Zhi Qiang Huang,1 Kerstin Ebefors,4 Jenny C. Nystrom,4 
Stacy D. Hall,1 Bruce A. Julian,1 Christopher D. Willey,1 Jan Novak.1  1Univ of 
Alabama at Birmingham, Birmingham, AL; 2Changhai Hospital, Second Military 
Medical Univ, Shanghai, China; 3Univ of Gothenburg, Sweden.
Background: Proliferation of mesangial cells (MC) is an important feature in many 
glomerular diseases, including IgA nephropathy (IgAN). Platelet-derived growth factor 
(PDGF) is a potent stimulator of MC, activating multiple signaling pathways associated 
with proliferation of MC. Our global kinomic profiling revealed that activity of multiple 
kinases in MC increased after PDGF stimulation, including tyrosine kinase Axl. As there is 
limited information on the association of PDGF signaling and activation of Axl in human 
MC, we studied details of Axl involvement in human MC stimulated by PDGF.
Methods: MC were obtained from a commercial source or isolated from biopsy 
specimens of patients with IgAN or other glomerular diseases. Quiescent primary human MC 
were stimulated by PDGF AB in the presence or absence of different inhibitors. MC lysates 
were analyzed by global tyrosine-kinome profiling using PamStation®12 platform and 
Western blotting. MC proliferation was measured by BrdU incorporation. The expression 
and distribution of Axl in MC were assessed by immunofluorescence.
Results: Tyrosine-kinome profiling indicated that PDGF AB increased Tyro3, Abl, 
and Ltk kinase activities. Further data analyses predicted Axl as one of the key upstream 
kinases activated in PDGF-AB-stimulated MC. We found that Axl was expressed in all 
tested primary human MC. PDGF AB stimulated proliferation of MCs; this effect was 
inhibited by Axl-specific inhibitor R428. Signaling studies revealed that PDGF AB increased 
phosphorylation of multiple signaling proteins, including Axl, PDGFR-β, Akt1, and ERK1/2. 
R428 significantly inhibited phosphorylation of Axl and Akt1, and, to a lesser extent, also 
of ERK1/2 and PDGFR-β. MEK1/2 inhibitor U0126 and PI3K inhibitor LY294002 did 
not affect phosphorylation of Axl.
Conclusions: Axl is involved in PDGF-induced proliferation of cultured MC through 
multiple signaling pathways. Targeting Axl may provide a new therapeutic strategy for 
IgAN.
SA-PO358
Different Effects and Mechanisms of Prostaglandin E2 Receptor Subtypes 
EP2 and EP4 in TGF-β1 Induced Mesangial Cell Injury  Chen Xiao Lan,1 
Yuan Li.2  1Affiliated Hospital of Nantong Univ; 2Affiliated Hospital of Nantong 
Univ.
Background: To study effects of prostaglandin E2 receptor subtypes 2 and 4 (EP2 and 
EP4) in mesangial cell injury by transforming growth factor -β1 (TGF-β1) and relevant 
signal pathways.
Methods: 1. The primary cultures of EP2 gene knockout (EP2-/-), EP4 gene knockout 
(EP4flox/flox) and wild type (WT) mice mesangial cells were established; 2. grouping: 
A: ① WT; ② WT +TGF-β1; B: ③ EP2-/-; ④ EP2-/- + TGF-β1; C: ⑤ EP4flox/
flox + AD-CRE (EP4KO); ⑥ EP4flox/flox + AD-CRE (EP4KO) + TGF-β1; Group ⑤ 
and ⑥ respectively take EP4flox/flox+AD-GFP (EP4KO) and EP4flox/flox + AD-GFP 
(EP4KO) +TGF-β1 as control; 3. the level of PGE2 ,cAMP ,the PKA activity of mesangial 
cell was tested ; PKA (H89) and ERK (PD98059) inhibitors were used to interdict PKA 
activity and ERK pathway in WT mesangial cell; EP2 or EP4 receptor agonist were used 
to pretreat WT MCs.
Results: 1. After TGF-β1 stimulation, expression of FN and CTGF increased; the 
expression of FN and CTGF in Group EP2KO increased; the expression of FN and CTGF 
in EP4KO decreased; 3. after TGF-β1 stimulation, the Smad3 phosphorylation level in 
EP2KO increased; while the Smad3 phosphorylation level markedly decreased in EP4KO; 
4. the PGE2 level of WT mesangial cell increased at 12h after TGF-β treatment; 5. the 
cAMP content in EP2KO was less than that of the control; PKA activity obviously declined; 
the cAMP content has no obvious changes in EP4KO; after stimulation with TGF-β1, the 
PKA activity increased; 6. ERK inhibitor blocks the function caused by agonist EP4; while 
PKA inhibitor block the inhibition function of agonist EP2.
Conclusions: EP2 and EP4 have different regulating effects on injury and renal 
fibrosis of mesangial cells: EP2 receptor mediated PGE2 induced up-regulation of the 
level of cAMP and PKA activity, so as to inhibit transduction effects of TGF-β1/Smad3 
pathway and reduced the occurrence of injury and fibrosis of mesangial cell; while EP4 may 
coordinate the promotional effect of mesangial cell injury induced by TGF-β1 by activating 
phosphorylation ERK pathway, resulting in regulating effects different from that of EP2.
Funding: Government Support - Non-U.S.
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Mesenchymal Stem Cells in the Repair of the Damaged Mesangium: A Step 
by Step Ultrastructural Account of the Events Taking Place  Jiamin Teng. 
Pathology and Transitional Pathobiology, Louisiana State Univ Health Sciences 
Center, Shreveport, LA.
Background: Not much is known about repairing the damaged mesangium. The 
use of mesenchymal stem cells (MSCs) to repair the injured mesangium is a rather novel 
concept. The present study aimed at analyzing the entire process using transmission electron 
microscopy in an effort to better understand the various steps involved.
Methods: Mesangial cells (MCs) cultured single layer in dish (2D) and on Matrigel 
(3D), MCs were first cultured to confluent and quiescent for 48 hours. Then they were 
incubated with glomerulopathic light chains (GLCs) (10 ug/ml) purified from the urine 
of patients with renal biopsy-proven light chain-related amyloidosis (AL-Am) (n=3) and 
light chain deposition disease (LCDD) (n=3) for 4 days and subsequently labeled MSCs 
were added. Samples were collected 10 days after the introduction of the MSCs (day 14) 
and processed for light and transmission electron microscopy.
Results: MCs revealed evidence of direct damage by the GLCs including apoptosis with 
apoptotic bodies released. MSCs identified and migrate to areas where cellular damage was 
present. When MSCs became activated they acquired a “macrophage” phenotype. They then 
became active in phagocytosing cell debris, apoptotic bodies damaged extracellular matrix 
and non-extracellular matrix material. Their process of cleaning the damaged mesangium 
resulted in MSCs full of cellular debris and eventually disposing of the internalized material. 
After performing this function, they proceeded to differentiate into mature MCs.
Conclusions: MSCs actively clean the injured mesangium by phagositosing apoptotic 
cells and other material.  They do so by transforming into a macrophage phenotype. Once 
the cleaning process is completed, they differentiate into MCs acquiring their characteristic 
smooth muscle morphology and functional properties. .The entire sequence of events was 
documented by transmission electron microscopy providing an added dimension to the 
understanding of MSCs in the repair of the damaged mesangium.
Funding: Private Foundation Support
SA-PO360
Characterization of Circulating APOL1 Complexes and Their Kidney 
Distribution in African Americans  Lijun Ma, Allison Weckerle, James A. 
Snipes, Dongmei Cheng, Abraham K. Gebre, Mariana Murea, Gregory A. 
Hawkins, John S. Parks, Barry I. Freedman.  Wake Forest School of Medicine.
Background: The apolipoprotein L1 gene (APOL1) G1 and G2 renal-risk variants 
associate with non-diabetic nephropathy and cardiovascular disease in African Americans 
(AAs). Although substantial APOL1 protein is present in the circulation, with enrichment 
in podocytes compared to other renal cells, little is known about circulating APOL1 protein.
Methods: Total serum APOL1 levels were examined by Western blot in a cohort 
of healthy AAs who had a 1st degree relative with kidney disease. APOL1 protein 
complexes were isolated from fast protein liquid chromatography (FPLC) peak fractions 
and characterized by proteomic analyses. Results were subsequently verified by co-
immunoprecipitation and Western blot.
Results: No significant differences were detected in serum APOL1 protein 
concentration based on APOL1 genotypes. However, serum APOL1 protein binds to other 
protein complexes. Non-denaturing gradient gel electrophoresis and FPLC demonstrated 
that serum APOL1 protein existed in two non-overlapping peaks (12.2nm and 20.0nm 
in diameter, respectively). The smaller complex was labeled complex A and the larger 
complex B. Density gradient ultracentrifugation and agarose gel electrophoresis confirmed 
that neither APOL1 protein complex was associated with HDL or LDL cholesterol. The 
exposure of APOL1 complex A surface epitopes appeared to be altered by G1/G2 renal-risk 
variants based on avidity to a specific monoclonal antibody from a non-G1/G2 associated 
immunogen (p=0.01). APOA1, haptoglobin-related protein (HPR), and complement C3 
were present in APOL1 complex A. APOA1, HPR, IgM, and fibronectin were present in 
APOL1 complex B. In APOL1 complex A, HPR-α was more abundant in those with G1 
and G2 renal-risk variants, relative to G0 (GENMOD p=0.04, total N=12). Serum HPR-α 
was only present in APOL1 complexes. Small amounts of HPR protein were detected 
in renal tubule cells but not glomeruli, whereas HPR mRNA was absent in the kidney.
Conclusions: Results provide unique insights on the composition of circulating APOL1 
complexes. The role of circulating APOL1 in kidney and cardiovascular disease in AAs 
requires further investigation.
Funding: NIDDK Support
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Deep Mapping of the Native Mouse Podocyte Proteome  Markus M. Rinschen,1 
Florian Grahammer,2 Tobias B. Huber,2 Thomas Benzing.1  1Internal Medicine, 
Univ Hospital Cologne, Cologne, Germany; 2Internal Medicine, Univ Hospital 
Freiburg, Freiburg, Germany.
Background: The entity of proteins expressed within a podocyte is still not known.
Methods: We performed mass spectrometry based absolute and relative quantification 
of the proteome of FACS-sorted native mouse podocytes.
Results: We resolved the podocyte proteome at a near-comprehensive resolution (more 
than 8000 identified proteins). Absolute copy numbers of proteins correlated with copy 
numbers obtained from deep-sequencing transcriptomic analysis. The dataset indicates 
agreement between transcriptome and proteome regarding expression of proteins which 
are mutated in hereditary forms of proteinuria and FSGS in humans. 541 proteins were 
enriched within podocytes at very high ratios and significance. This study suggests that 
the podocyte is not only target to inflammatory stimuli such as TNFalpha and IFNgamma, 
but also several unanticipated other stimuli. In addition, this study delineates podocyte 
enriched tyrosine kinases, a few of these are drugable. Protein domains significantly 
enriched in podocyte proteins comprise not only PDZ and Fn3 domains, but also i-set 
domain, an adhesion domain. The majority of podocyte specific proteins also stain positive 
for glomeruli in human samples, with a weak correlation between staining intensity and 
absolute protein abundance measured by MS/MS.
Conclusions: This initial, near comprehensive draft of the podocyte proteome reveals 
untapped molecules and mechanisms. This dataset will be of benefit to understand podocyte 
physiology, pathobiology and develop potential therapeutic strategies.
SA-PO362
Maternal Obesity Is a Significant Risk Factor for the Development of 
Diabetic Nephropathy  Sarah J. Glastras,1 Rachel Teh,1 Michael Chi-Ho Tsang,2 
Hui Chen,2 Amgad Sawiris,1 Carol A. Pollock,1 Sonia Saad.1  1Dept of Medicine, 
Kolling Inst, Univ of Sydney; 2Univ of Technology, Sydney.
Background: Our previous studies have shown that maternal obesity is associated 
with increased renal injury in offspring. We hypothesised that a second-hit such as diabetes 
may further exacerbate diabetic nephropathy in offspring exposed to maternal obesity.
Methods: Female C57Bl6 mice were fed either normal or high-fat diet (HFD) for 6 
weeks prior to pregnancy, during pregnancy and weaning and their offspring were weaned 
to chow diet or HFD. At Week 8, the male offspring were randomized to streptozotocin 
(STZ) 55mg/kg/day for five consecutive days, 100 mg/kg once only or placebo. Weight 
and glucose levels were tested fortnightly. 24 h urine collection was performed at Week 
20 and 30. The kidneys were harvested at Week 32.The renal structure was observed. 
Gene expression levels of profibrotic, inflammatory and oxidative stress markers were 
measured by real time PCR and confirmed with protein quantification with Western blot 
and/or immunohistochemistry.
Results: Offspring of obese mothers had increased fat deposition. Diabetic offspring had 
reduced weight gain, hyperglycaemia, glycosuria and microalbuminuria. Urinary albumin 
measurements were highest in diabetic offspring of obese mothers exposed to 5 doses of 
STZ. The kidneys of the offspring exposed to maternal obesity and induced with diabetes 
had increased structural damage, renal fibrosis and increased inflammatory changes and 
markers of oxidative stress when compared to the kidneys of diabetic offspring of normal 
weight mothers. There was significant intrarenal lipid deposition in obese offspring, 
exacerbated by maternal obesity and diabetes.
Conclusions: Offspring exposure to maternal obesity accelerates the severity of 
damage to the kidney caused by diabetes. Fetal programming of renal inflammation and 
oxidative stress may be a key component to the accelerated risk. Offspring diet has a 
powerful effect on renal outcome.
Funding: Government Support - Non-U.S.
SA-PO363
Leucine-Rich Glycoprotein 1 : A Candidate Biomarker for Early Renal 
Function Decline in Type 2 Diabetes  Sona Haku,1,2 Kouichi Tamura,1 Jennifer 
W. Xu,2 Carla Cavallin,2 Hiromichi Wakui,1 Kengo Azushima,1 Kazushi Uneda,1 
Ryu Kobayashi,1 Kotaro Haruhara,1 Michael S. Simonson,2 Satoshi Umemura.1 
1Dept of Medical Science and Cardiorenal Medicine, Yokohama City Univ 
Graduate School of Medicine, Yokohama, Kanagawa, Japan; 2Dept of Medicine, 
Div of Nephrology and Hypertension, Univ Hospitals Case Medical Center and 
Case Western Reserve Univ School of Medicine, Cleveland, OH.
Background: Biomarkers that identify patients with type 2 diabetes and early renal 
function decline may improve our ability to intervene and slow progression to end-stage 
renal disease. In a Phase I preclinical exploratory study, we tested whether leucine rich 
glycoprotein-1 (LRG1), a candidate biomarker discovered in db/db mice, would identify 
patients with early decline in renal function.
Methods: Patients with type 2 diabetes were recruited into training (n=56) and 
independent, non-overlapping test (n=37) groups (median baseline eGFR = 80.3 + 29.5 ml/
min/1.73m2). LRG1 was measured in spot urine collections by ELISA, and performance was 
assessed as area under the receiver operating characteristic curve (AUC) with adjustment 
for clinical covariates of DKD.
Results: Urine LRG1 was associated inversely with eGFR (r = -0.546, P<0.001) and 
positively with ACR (r = 0.283, P = 0.034). The AUC of LRG1 for identifying participants 
with baseline eGFR 90 – 60 was 0.815 + 0.103; in contrast, the AUC of the albumin/
creatinine ratio was 0.465 + 0.093 (P < 0.01 versus LRG1). Adjustment for age, sex, race, 
duration of diabetes, and HbA1c did not alter the AUC for LRG1, and these results were 
replicated in the test group. In participants with eGFR >= to 60 ml/min/1.73m2 at baseline, 
LRG1 predicted a 5-year outcome of eGFR < 60 or ESRD better than ACR (0.702 ± 0.085, 
P < 0.01 versus ACR, 0.520 ± 0.119).
Conclusions: Taken together, these results suggest LRG1 may identify patients with 
early renal function decline more accurately than ACR. Evaluation of LRG1 in prospective 
cohort studies of type 2 diabetes may lead to a better biomarker for identifying and 
monitoring DKD.
Funding: Other NIH Support - NIH RO1 DK 096549
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A Longitudinal Study on Kidney Function, Pathology, and Multiple Urinary 
Biomarkers in ZSF1 Rat Model of Type II Diabetic Nephropathy  Zhi Su, 
Deborah Widomski, Marian T. Namovic, Diana L. Donnelly-Roberts, Laura 
Leys, Katherine Salte, Arthur L. Nikkel, Lauren Olson, Ji Ma, Timothy A. 
Esbenshade, Steve McGaraughty.  Renal Discovery, Abbvie, North Chicago, IL.
Background: Obese ZSF1 rats display many clinical features of human type II diabetic 
nephropathy (DN). To further understand this model and to identify relevant biomarkers 
of disease progression, we followed the development of DN by measuring glomerular 
filtration rate (mGFR), histopathology, and a variety of urinary and tissue biomarkers 
over 24 weeks after uninephrectomy (Unx). Correlations between mGFR and individual 
urinary biomarkers were assessed.
Methods: Male rats (9-week old) underwent either a sham or Unx (right kidney) surgery 
and were fed a high carbohydrate diet. GFR was measured by transdermal clearance of 
FITC-sinistrin. Urine samples were collected once every 2-4 weeks for biomarker analysis, 
and renal tissue was examined for collagen deposition as well as for the levels of key 
inflammatory and fibrotic genes.
Results: Kidney hyperfiltration was observed (2-3 fold increase in mGFR) in obese 
rats 2-week after surgery lasting until week 4. The mGFR subsequently declined over 
time in these rats and was 2-fold lower than control rats by end of study. Compared to 
lean rats, obese rats also demonstrated time-dependent increases in urinary excretion of 
protein, KIM-1, L-FABP, NGAL, Cystatin C, Clusterin, Beta2-microglobulin, alpha1-acid 
glycoprotein, VEGF, MCP-1, TIMP-1, Collagen IV, TGF-b1, and TGF-b2. A significant 
correlation was found between mGFR and a number of urinary biomarkers (L-FABP, KIM-
1, TIMP-1, Clusterin, Cystatin C, and TGF-b2). Kidney fibrosis was significantly elevated 
by week 12 post surgery and continued to expand in the following weeks. Unx increased 
the weight and glomerulosclerosis of the remaining kidney and accelerated the decline of 
mGFR in obese rats during late weeks of observation.
Conclusions: ZSF1 rats showed a progressive increase of fibrosis and loss of mGFR 
over the 24-week study. A number of urinary biomarkers demonstrated a strong inverse 
correlation with the time-dependent changes in mGFR. Additionally, Unx significantly 
increased glomerulosclerosis and loss of GFR in obese rats.
SA-PO365
Haptoglobin 2-2 Genotype Is Associated with Decreased Levels of Vitamin 
D Receptor (VDR), Klotho and Accelerated Renal Apoptosis in Mice and 
Humans Diabetic Nephropathy  Farid M. Nakhoul,2 Farber Evgeny,2 Nadia 
Thawho,1 Andy Levy,3 Inbal Dahan.1  1Diabetic Nephropathy Lab, Baruch-Padeh 
Poriya M. Center, Lower Galilee, Israel; 2Nephrology, Faculty of Medicine In 
Galilee Bar Ilan Univ, Israel; 3Vascular Medicine, Technion, Haifa.
Background: Haptoglobin (Hp) is an antioxidant protein by its ability to binds 
free hemoglobin (Hb) and prevents heme-iron mediated oxidation. Diabetic mice & 
humans with different Hp genotype (1-1, 2-2) have a different susceptibility to developed 
Diabetic Nephropathy (DN) due to impaired Hb clearance and increased iron deposits 
in the lysosomes of the kidney proximal tubules (PCT). This leading to increased renal 
oxidative stress and cell damage. Our study proposed a molecular mechanism explaining 
the influence of Hp genotype, klotho expression on 1-α hydroxylase and active vitamin 
D/VDR in DN patients.
Methods: Slides from kidney biopsies of DN patients and mice with different Hp 
genotype (1-1, 2-2) were subjected to Immunohistochemistry staining of iron modified with 
DAB method, klotho, active caspase 3, vitamin D receptor (VDR) and 1-α hydroxylase, 
using specific antibodies. Blood samples to Haptoglobin test and ELISA assays.
Results: There were significant increased in iron deposits in the renal PCT of Hp2-2 DM 
patients. In the PCT of Hp 2-2 mice and patients there was a significant increase expression 
of active caspase-3 staining that was accompanied with decrease renal expression‹ of VDR, 
1α hydroxylase and klotho levels.
Conclusions: Hp 2-2 genotype associated with increased iron deposits and high 
levels of PCT apoptosis Decreased levels of the anti oxidant klotho and VDR in the 
renal PCT.  We propose a molecular mechanism explaining the influence of Hp genotype 
and klotho expression on renal PCT apoptosis in DN patients. These results provide new 
insights into the role of Klotho and VDR expression on the pathogenesis of DN in 
patients with Hp2-2 genotype.
SA-PO366
Resistance Exercise Training Prevents Kidney Hypertrophy and Increases 
the Biogenesis Mitochondrial in Diabetic Rats  Luciana Jorge,1 Kleiton 
Augusto Santos Silva,1 Rafael Luiz,1 Rodolfo Rosseto Rampaso,1 Janaina Paulini 
Aguiar,2 Nestor Schor.1  1Nephrology, Federal Univ of Sao Paulo, Sao Paulo, 
Brazil; 2Molecular Biology, Univ of Utah, Salt Lake City, UT.
Background: Diabetic nephropathy(DN) is a progressive complication arising 
from diabetes. kidney cell response to injury includes cell division, cell hypertrophy and 
apoptosis. Increasing evidence indicates that the disruption of mitochondrial bioenergetics 
and structural change in the kidney may be important in the development and progression 
of DN. Therefore, is fundamental the understand of a non pharmacological intervention as 
exercise training to prevent those complications. We investigated the effect of resistance 
training(RT) on the DN pathogenesis.
Methods: Male Wistar rats were divided into:control(C),control trained(CT),diabetic(D) 
and diabetic trained (DT). DM was induced by STZ. Trained groups were submitted to 
a resistance exercise training on Ladder climb (8wk). Urinary volume and proteinuria 
were evaluated.Tissue weight/tibial lenght ratio was used as kidney hypertrophic index. 
Expression of P-Akt,P-Mtor,P-AMPK and MFN2 protein was evaluated by western blotting.
Results: RT improved renal parameters in DT group show a decreased urinary vo
lume(D=160;DT=120;C=13;CT=14ml),proteinuria(D=45;DT=32;C=18;CT=7 mg/24h)
(p<0.05).Diabetes resulted in increased hypertrophic index (50%)and RT prevented 
it.Renal expression of PAMPK and MFN2 was reduced in D group and RT normalized this 
expression(p<0.05). Moreover, the renal expression of PAKT and PmTOR were increased 
in the DM and the RT influence on it(p<0.05). Histological analysis showed glomerular 
hypertrophy in D and RT prevent this complication.
Conclusions: RT attenuated progression of diabetic nephropathy; Those improvements 
could be a result of increased AMPK/MFN2 pathway, an important pathway to biogenesis 
mitochondrial; and inhibition of AKT/mTOR pathway, responsible for hypertrophic 
response, demonstrating that those complications were prevented by exercise training. 
Ours findings demonstrated that RT is an important approach to avoid, both molecular 
and functional complications in diabetic kidney.Funds from FAPESP,CNPq and CAPES.
SA-PO367
Aerobic Exercise Training Improves Proteinuria and Renal Inflammatory 
Factors in Rats with Diabetic Nephropathy  Rodolfo Rosseto Rampaso, Rafael 
Luiz, Kleiton Augusto Santos Silva, Luciana Jorge, Edson Andrade Pessoa, 
Mario luis Ribeiro Cesaretti, Nestor Schor.  Nephrology, UNIFESP, SP, Brazil.
Background: The objective of this study was to evaluate the effects of aerobic exercise 
training in controlling the progression of diabetic nephropathy, inflammatory factors, and 
its possible renoprotective effects.
Methods: Adult male Wistar rats/4 groups, n=8/group: Sedentary controls (C-SED), 
Diabetes+Sedentary (DM-SED), Diabetes+Exercise (DM-EXE) and control exercise 
(C-EXE). Diabetes was induced with STZ,50 mg/kg iv. The exercise training were conducted 
on a treadmill 60min/day, 5 days/week/8 weeks. Weekly certain, maximal exercise test(set 
at 65-70% of MEtest). Glycemia after post 24 education(24 glycemiapt), MEtest, creatinine 
clearance/BW(CrCl/BW), arterial pressure(AP), proteinuria(uProt), renal inflammatory 
factors IL-6, IL-10 and TNF-α were measured. Data as mean ± SD.
Results: 
C-SED DM-SED DM-EXE EXE
glycemiapt 
(mg/dl) 103±2.03 551±7.03*& 491±5.50*& 83±2.57
uProt ( mg/24h) 17±0.88 46±2.05 *#& 18±0.72 16±0.99
CrCL/ (ml/min/
BW) 5.65±0.66 5.02±0.43 4.19±0.37 4.21±0.29
AP (mmHg) 122±1.89 133.88±1.79*#& 122±1.35 121±2.11
Weight (g) 455±6.00 236±14.41*#& 324±9.34*& 387±8.71
MEtest (m/min) 23.2±0.49#& 19.5±0.57*#& 35.1±0.97 37.5±0.57
IL-6 (pg/ml) 541±98 993±40*#& 768±74*& 391±22
IL-10 (pg/ml) 545±86 876±34*#& 654±31*& 453±28
TNF-α (pg/ml) 3.05±0.4 5.18±0.76*#& 4.08±0.22*& 2.32±0.51
P<0.05:*VS C-SED #VS DM EXE &VS C- EXE
Conclusions: Reductions in blood glucose and AP ~11% comparing DM-EXE vs 
DM-SED. The DM-EXE controlled weight loss ~40% compared to DM-SED, but did 
not prevent change in CrCl/BW with this protocol. However, the effect was surprisingly 
observed EXE reduction in both excretion through uProt ~60% and ~25% in MD-
inflammatory factors comparing SED vs DM-EXE. Therefore, preliminary data suggests 
that aerobic exercise can reduce proteinuria and inflammatory factors in diabetic animals 
and hence reduce the potential effects caused by diabetic nephropathy and could reduce 
the progression of renal failure.
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SA-PO368
Inhibition of miR-25 Processing Mediated by Mecp2 Phosphorylated 
by HIPK2 Can Upregulate NOX4 in Early Diabetic Nephropathy 
Hyung Jung Oh, Mitsuo Kato, Supriya Deshpande, Mei Wang, Linda L. Lanting, 
Rama Natarajan.  Diabetes and Metabolism, Beckman Research Inst of City of 
Hope, Duarte, CA.
Background: Altered microRNA (miR) levels play key roles in the pathogenesis of 
diabetic nephropathy (DN), but it is unclear if miR processing is involved. Phosphorylated 
methyl-CpG binding protein2 (p-MeCP2), known to act as a transcriptional repressor, was 
recently reported to suppress the processing of several miRs. Homeo-domain interacting 
protein kinase2 (HIPK2) can bind to and phosphorylate MeCP2. However, it is not 
known if MeCP2 and HIPK2 are involved in processing and expression of candidate 
miRs involved in DN.
Methods: p-MeCP2 and HIPK2 staining in kidney sections from 4-week streptozotocin 
(STZ) injected diabetic and control mice, was studied by immunohistochemistry. Protein, 
mRNA and miR levels were examined by Western blotting (WB) or RT-qPCRs in TGF-b1- 
or high glucose (HG)-treated mouse mesangial cells (MMCs).
Results: p-MeCP2 and HIPK2 immunostaining, and their protein levels were 
significantly higher in renal glomeruli (but not cortex) of STZ mice than control. Moreover, 
Seven in Absentia Homolog 1 (SIAH1), which mediates proteasomal degradation of HIPK2, 
was decreased in STZ mice compared with control. Among several regulated miRs, miR-25 
and -93 levels were significantly decreased in STZ mice relative to control. The precursors 
of miR-25 and -93 were also significantly decreased in STZ mice, while conversely, NADPH 
oxidase4 (NOX4), a target of miR-25 that is associated with renal fibrosis and DN, was 
significantly increased in STZ mice. Protein levels of p-MeCP2 and HIPK2 were also 
increased in vitro in TGF-β- or HG-treated MMCs compared to control. Moreover, mRNA 
levels of the genes mentioned above in vivo were similarly regulated in MMCs in vitro, 
although only miR-25 and its precursor were significantly decreased in the treated MMCs.
Conclusions: NOX4, a target of miR-25, can be upregulated due to downregulation of 
miR-25. This occurs via impairment of miR-25 processing by p-MeCP2 phosphorylated by 
HIPK2 which is stabilized by decrease of SIAH1 in diabetes. These results reveal a novel 
mechanism for downregulation of key protective miRs during DN progression.
SA-PO369
Ursolic Acid Attenuated High Glucose Induced Podocyte Injury by 
Increasing Autophagy Level via Inhibition of miR-21 Expression and PTEN/
Akt/mTOR Pathway  Qiuling Fan.  Nephrology, The First Hospital of China 
Medical Univ, Shenyang, Liaoning, China.
Background: Autophagy played an important role in maintanining podocyte 
homeostasis. The defective autophagy might contributed to podocyte dysfunction under 
high glucose condition. In this study, we investigated the effects of ursolic acid (UA) on 
autophagy and injury of podocyte cultured with high glucose condition.
Methods:  Conditionally immortalized murine podocyte were cultured in high glucose, 
the effect of PI3K inhibitor LY294002 and ursolic acid treatment would be observed. The 
autophagic inhibitor 3-MA was used to assess the effect of ursolic acid on autophagy in 
podocyte. The miR-21 expression was detected using RT-qPCR. The activation of PTEN-
PI3K/Akt/mTOR pathway, expression of autophagy-associated protein and podocyte 
associated protein were determined by western blot. Immunofluorescence staining showed 
the expression of podocyte associated protein and endogenous accumulation of LC3.
Autophagosomes were observed using electron microscopy.
Results:  In the high glucose condition, high basal level of autophagy in podocyte 
became defective and defective autophagy facilitated the podocyte injury. miR-21 expression 
was upregulated, PTEN level was downregulated, PI3K/Akt/mTOR pathway was activated 
in podocyte cultured with high glucose. Ursolic acid and LY294002 can reduced podocyte 
injury by increasing autophagy level via inhibition of PI3K/Akt/mTOR pathway. However, 
LY294002 did not affect the expression of miR-21 and PTEN. Ursolic acid inhibited miR-
21 expression and upregulated PTEN level. Downregulation of autophagy with 3-MA 
significantly suppressed the protective effect of ursolic acid on podocyte.
Conclusions: These data suggested that podocyte injury is associated with defective 
autophagy level under high glucose condition. Ursolic acid could reduce podocyte injury 
by increasing autophagy level via inhibition of miR-21 expression and PTEN/Akt/mTOR 
pathway.
SA-PO370
Hyperglycemic Memory in DN: Effects of Epigenetic Changes of SHP-1 
in Podocytes  Farah Lizotte, Benoit Denhez, Andréanne Guay, Pedro Miguel 
Geraldes.  Medecine, Univ ok Sherbrooke, Sherbrooke, QC, Canada.
Background: Previous animal and clinical observation suggested that disruption of 
normal insulin actions is a part of the etiology of diabetic nephropathy (DN). Although, 
intensive blood glucose control reduced the development of DN, the EDIC study showed 
that, if not started early, it is not sufficient to prevent DN progression. This hyperglycemic 
memory phenomenon can be explained by epigenetic changes. Our previous studies 
demonstrated that SHP-1, a protein tyrosine phosphatase, is elevated in renal cortex of 
type 1 diabetic mice (Akita) causing insulin unresponsiveness and DN. We hypothesize 
that epigenetics changes lead to persistent increase of SHP-1 expression despite systemic 
glucose normalization that triggers to hyperglycemic memory in DN.
Methods: The persistent expression of SHP-1 in vivo that contribute to hyperglycemic 
memory effect was evaluated using diabetic Akita (DM) mice treated with insulin implants 
after 4 months of diabetes. Mouse podocytes were cultured in normal (5.6 mM; NG), high 
glucose concentrations (25 mM; HG) or HG prior returning glucose levels to NG for an 
addition 24-48h (HG+NG).
Results: Urinary albuminuria secretion, GFR, mesangial cell expansion and collagen 
IV expression were measured and were significantly increased by 2.3 fold, 64%, 58% and 
40%, respectively in DM mice compared to non-DM mice and remained elevated despite 
glucose normalization with insulin implants. SHP-1 expression was increased by 2 fold 
in renal cortex of DM and DM mice treated with insulin implants. Elevated expression of 
SHP-1 mRNA, protein and phosphatase activity in HG conditions remained increased in 
spite returning glucose concentration to NG and associated with insulin actions inhibitions. 
Evaluation of histone modifications showed that monomethylation of the H3K4 (me1), 
which is associated with enhanced gene activity, in the promoter region of SHP-1 was 
increased in HG and remained elevated after returning to NG concentration.
Conclusions: In conclusion, hyperglycemia induces epigenetic changes on SHP-1 
promoter causing persistent expression and elevated activity of SHP-1 leading to podocyte 
unresponsiveness to insulin and DN.
Funding: Government Support - Non-U.S.
SA-PO371
Targeting the Polycomb Repressive Complex Chromatin Remodeling 
Machinery for Therapeutic Benefit in Diabetic Nephropathy 
Letizia De Chiara, Hayley Beaton, Catherine Godson, John Crean.  UCD School 
of Biomolecular and Biomedical Science, Diabetes Complications Research 
Centre, Univ College Dublin, Dublin, Ireland.
Background: Diabetic Nephropathy (DN) manifests as renal microvascular 
abnormalities, mesangial sclerosis and tubulointerstitial fibrosis as a result of longstanding 
hyperglycaemia. Emerging evidence indicates that multiple factors involved in the aetiology 
of diabetes can alter epigenetic mechanisms and regulate susceptibility to microvascular 
complications.
Methods: Immunoprecipitation, ChIP, Western Blot, miR302 overexpression, 
luciferase assay.
Results: We have previously identified SMAD3 and EZH2 as part of a context 
dependent switch enhancing complex that regulates cell fate during fibrotic processes. 
Here we describe the further characterisation of this interaction and delineate its potential 
pathogenic significance. Comparative analysis of gene expression data from patients, 
animals and cell models of diabetic kidney disease revealed a subset of genes that are 
potentially regulated by the interaction between Smad3 and EZH2, including critical 
regulators of epithelial fate such as E-Cadherin. Endogenous immunoprecipitation and 
luciferase assays performed in renal epithelial cells demonstrated that SMAD3 directly binds 
and recruits EZH2 to the E-Cadherin promoter causing its down-regulation during Epithelial 
to Mesenchymal Transition. We further demonstrated that this interaction is disrupted by 
mutating SMAD3 protein sequence. Perturbation of the interaction between SMAD3 and 
EZH2 was facilitated by viral overexpression of miR302. Human renal mesangial cells 
transduced with mir302 undergo profound changes in gene expression exhibiting de novo 
expression of SNAIL and EZH2 and start to express de novo E-Cadherin.
Conclusions: Our results suggest that SMAD3 and EZH2 control the repression of 
E-Cadherin during DN, opening the possibility for therapeutic manipulation of this nexus 
during the progression of renal disease. Understanding the processes through which 
dynamic epigenetic silencing is controlled in adults cells will allow us to address the 
epigenetic state of acquired disease and whether original states, regenerative in nature, 
can be restored with therapy. 
Funding: Government Support - Non-U.S.
SA-PO372
Effects of DPPIV Inhibitor versus Combined Treatment with DPPIV 
Inhibitor and ARB on Renal Function in Type 2 Diabetic Mice 
Hye Sook Min,1 Jin Joo Cha,1 Sung Jin Kim,2 Kitae Kim,1 Jung Eun Kim,1 
Jungyeon Ghee,1 Ji Eun Lee,3 Hyunwook Kim,3 Jee Young Han,4 Young 
Sun Kang,1 Dae R. Cha.1  1Internal Medicine, Korea Univ Ansan Hospital; 
2Nephrology, Sam Hospital, Anyang; 3Internal Medicine, Wonkwang Univ 
Sanbon Hospital; 4Pathology, Inha Univ, Incheon, Republic of Korea.
Background: Recent evidence has shown that DPPIV is involved in all steps leading 
to renal fibrosis, such as inflammatory response, cell apoptosis and fibrosis. The aim of our 
study was to investigate the mechanism and effects of DPPIV inhibitor (DA1229) alone 
and combined treatment with DPPIV inhibitor and ARB (LC158809) on renal injury in 
db/db mice.
Methods: The mice were divided into five groups as follows: non-diabetic db/m mice 
(control), untreated db/db mice, db/db mice treated with DA1229 (300mg/kg/d), db/db mice 
treated with LC158809 (1.5mg/kg/d) and db/db mice combined treatment with DA1229 
and LC158809 for 12 weeks.
Results: 12week HbA1c level was significantly decreased in combined treatment group. 
Oxidative stress markers were not different from each other. Activity of serum DPPIV 
was significantly reduced with DA1229. 24h albuminuria significantly decreased with 
LC158809 treatment at 8 weeks and with DA1229 at 12 weeks in diabetic mice. However, 
no additive effect on albuminuria was observed with combined treatment. Administration 
of DA1229 or LC158809 significantly decreased accumulation of ECM protein, TLR4 and 
NOX4 expressions in glomeruli. No additive effects were observed in combined treatment 
group. Urinary excretion of nephrin was increased in diabetic mice and was decreased in 
combined treatment with DA1229 and LC158809. In vitro, DPPIV was expressed on the 
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podocyte membrane and its expression was activated by angiotensin-II. Nephrin expression 
in cultured podocyte was attenuated by high glucose and angiotensin-II. This attenuation 
was recovered with DA1229 treatment, but not with other DPPIV inhibitors.
Conclusions: Our data suggest that renoprotective effects of DA1229 in experimental 
diabetic mice might be associated with protective effect of podocyte injury. DA1229 might 
be a potential therapeutic agent to slow the progression of diabetic nephropathy.
SA-PO373
PBI-4425, a Novel Anti-Inflammatory/Fibrotic Compound, Improves 
Kidney Function and Structure in the Diabetic db/db Mouse Model 
Brigitte Grouix, Kathy Hince, François Sarra-Bournet, Liette Gervais, Alexandra 
Felton, Alexandre Laverdure, William Gagnon, Martin Leduc, Lilianne Geerts, 
Pierre Laurin, Lyne Gagnon.  ProMetic BioSciences Inc., Laval, QC, Canada.
Background: Kidney disease associated with diabetes mellitus is a major health 
problem worldwide. Glomerular injury plays a pivotal role in the development of diabetic 
nephropathy. PBI-4425 possesses a pleiotropic mechanism of action with anti-inflammatory, 
antioxidant and anti-fibrotic properties. The aim of this study was to investigate the 
protective effect of PBI-4425 on kidney function and structure in uninephrectomized 
(NX) diabetic (db/db) mice.
Methods: Total nephrectomy of the right kidney was performed on day 0 and animals 
were treated with vehicle or PBI-4425 (100 mg/kg, oral once a day) from day 1 through 
105. Kidney function (GFR), kidney mesangium lesions, modulation of gene expression, 
and serum cytokines were investigated.
Results: GFR assessed by inulin clearance was significantly reduced in NX-db/db mice 
compared to NX-C57BL/6 negative control mice, and PBI-4425 treatment significantly 
improved GFR. As shown by PAS staining, NX-db/db mice had larger glomeruli with 
increased mesangial matrix. Mesangium lesions scores were significantly reduced by PBI-
4425 treatment. Gene expression of inflammation, fibrosis, oxidative stress, and extracellular 
matrix remodeling markers were assessed. Kidney MCP-1, IL-6, Collagen I, iNOS, MMP2, 
and Timp1 mRNA expression were markedly increased in NX-db/db mice, and PBI-4425 
treatment induced a significant decrease of these markers. Glomerular response to injury 
was accompanied by activation of kidney development-related genes, such as glomerular 
epithelial protein 1 (GLEPP1); expression of GLEPP1 was significantly increased in NX-
db/db mice, and restored to the negative control level following treatment with PBI-4425. 
Moreover, PBI-4425 significantly reduced serum pro-inflammatory cytokines IL-1β, IL-6, 
IL-12(p70), as well as TH9-type pro-inflammatory cytokine IL-9.
Conclusions: These results suggest that PBI-4425 offers the potential as a novel 
therapy for diabetic nephropathy by improving kidney function and structure, and reducing 
pro-inflammatory and pro-fibrotic markers.
SA-PO374
The Effect of Nox Inhibitor APX-15 on Diabetic Kidney Disease 
Jin Joo Cha,1 Hye Sook Min,1 Kitae Kim,1 Jung Eun Kim,1 Jungyeon Ghee,1 
Hyunwook Kim,2 Ji Eun Lee,2 Jee Young Han,3 Young Sun Kang,1 Dae R. 
Cha.1  1Internal Medicine, Korea Univ Medical College Ansan Hospital, Ansan, 
Republic of Korea; 2Internal Medicine, Wonkwang Univ Medical College Sanbon 
Hospital, Gunpo, Republic of Korea; 3Pathology, Inha Univ College of Medicine, 
Incheon, Republic of Korea.
Background: Excess reactive oxygen species generated by NADPH oxidases (Nox) 
have been implicated in the inflammatory and fibrotic processes of chronic kidney disease. 
Recent studies have suggested the importance of renal Nox in the progression of diabetic 
nephropathy. Therefore, we investigated the effect of a novel NOX-inhibitor APX-15 on 
diabetic nephropathy in an experimental model of type 2 diabetic mice.
Methods: 8 to 10 week old db/m and db/db mice were treated with APX-15 for 12 
weeks. APX-15 was administered by oral gavage at a dose of 60mg/kg/day. To compare the 
effects of APX-15 with a selective Nox inhibitor, db/db mice were treated with GKT136901 
according to same protocol.
Results: APX-15 significantly improved insulin resistance in diabetic mice similar to 
GKT136901. Oxidative stress measured by plasma 8-isoprostane level was decreased in 
APX-15 group compared to diabetic control. All lipid profiles, both in plasma and tissues 
(kidney, fat, liver) improved with Nox inhibition. Nox mRNA expressions in adipose 
tissue (Nox1, Nox2) and in kidney tissue (Nox4) were downregulated and Nox protein 
expressions were decreased with APX-15. 24 hour urinary albumin excretion was reduced 
and creatinine clearance was preserved with APX-15. In diabetic kidney, structural changes 
were notably attenuated with APX-15. Importantly, mesangial expansion was significantly 
improved with APX-15, but not with GSK 136901. Kidney PAI-1 and TGF-β expressions 
were decreased and nephrin expression increased in both APX-15 and GKT136901 groups 
compared to diabetic control. Additionally, F4/80 infiltrations in the adipose tissue and the 
kidney were decreased with APX-15.
Conclusions: Our findings suggest that APX-15 may have a better renoprotective 
effect compared to selective inhibitor GKT136901 in experimental animal model of 
diabetic nephropathy. Broad Nox inhibition with APX-15 might be a promising therapy 
for diabetic nephropathy.
SA-PO375
Metabolomics Reveals a Key Role for Fumarate in Mediating NOX4 Activity 
in Diabetic Kidney Disease  Young-Hyun You,1 Rintaro Saito,2 Kumar Sharma.3 
1Medicine, UCSD, La Jolla, CA; 2Medicine, UCSD, La Jolla, CA; 3Medicine, 
UCSD, La Jolla, CA.
Background: The NADPH oxidase isoform NOX4 has been linked with diabetic 
kidney disease (DKD), however a mechanistic understanding of the downstream effects 
of NOX4 remains to be established.
Methods: To clarify the role of increased NOX4, we examined the role of NOX4 
in the podocyte-specific NOX4 transgenic mouse. We also treated F1 Akita (DBA/2J × 
C57BL/6J- Ins2Akita) mice with food pellets containing GKT137831, a NOX1/4 inhibitor 
from week 12 to week 28, and examined the effectiveness of treatment with the NOX1/4 
inhibitor on the development of chronic kidney disease (CKD) and on the urine metabolome 
in a model of progressive DKD.
Results: Podocyte-specific induction of NOX4 in vivo was sufficient to recapitulate 
the characteristic glomerular changes noted with DKD, including glomerular hypertrophy, 
mesangial matrix accumulation, GBM thickening, albuminuria, and podocyte dropout. 
Intervention with a NOX1/4 inhibitor reduced albuminuria, glomerular hypertrophy, and 
mesangial matrix accumulation in the F1 Akita model of DKD. Metabolomic analysis 
from the mouse studies revealed that TCA related urinary metabolites were increased in 
DKD however fumarate levels were uniquely reduced by the NOX4 inhibitor. TCA cycle 
enzyme fumarate hydratase (FH) reduction has been linked to regulating urine fumarate and 
indeed, FH was reduced in the diabetic kidney (in mice and human tissue) and the Nox4 
inhibitor increased FH levels. Induction of Nox4 both in vitro and in the podocyte-specific 
NOX4transgenic mouse led to reduced FH levels. The potential role of fumarate to DKD 
was demonstrated as fumarate was found to stimulate ER stress, matrix gene expression 
and regulate HIF-1α andTGF-b.
Conclusions: Our data suggest that NOX4 is a major mediator of glomerular 
dysfunction with diabetes and renal FH is a key enzyme regulated in DKD and targeted 
by NOX4. Fumarate is a key link that connects metabolic pathways to DKD pathogenesis 
and may have application to monitor renal NOX4 activity.
Funding: Other NIH Support - NIH (UO1DK076133 and DP3DK094352)
SA-PO376
The Prostaglandin E2 EP3 Receptor Regulates Diet Induced Obesity 
Ryan Patrick Ceddia,2 Richard M. Breyer.1  1Div of Nephrology and 
Hypertension, Dept of Veterans Affairs and Vanderbilt Univ, Nashville, TN; 
2Dept of Pharmacology, Vanderbilt Univ, Nashville, TN.
Background: Obesity is associated with a number of co-morbidities including diabetes, 
dyslipidemia and nonalcoholic fatty liver disease. Deletion of the PGE2 E-prostanoid (EP) 
3 receptor in mice has been shown to alter feeding patterns and increase food consumption.
Methods: To further characterize the effects PGE2-EP3 signaling on diabetes in a 
setting of diet induced obesity, EP3-/- mice were fed a high-fat diet (HFD; 45% calories 
from fat) or a control diet (10% calories from fat).
Results: Though no differences in body weight were observed in mice fed control 
diet, when fed a HFD, EP3-/- mice became heavier relative to EP3+/+ mice (41.1±1.10 vs. 
32.6±0.98 g; P<0.0001). EP3-/- mice fed HFD had increased epididymal fat mass (1407±177 
vs. 2401±167 mg; P<0.0001) and adipocyte size (6350±375 vs. 4330±469 µM2; P=0.0005) 
compared to HFD fed EP3+/+ mice; paradoxically a relative decrease in both epididymal 
fat pad mass (P < 0.0001) and adipocyte size (P=0.0055) was observed in the heaviest 
EP3-/- mice. EP3-/- mice had increased macrophage infiltration (P<0.0001) and necrosis (P 
< 0.0001) in epididymal fat pads as compared to EP3+/+ mice. Adipocytes isolated from 
EP3-/- mice lacked PGE2-evoked inhibition of isoproterenol-stimulated lipolysis compared 
to EP3+/+ (1 nM ISO, ±100nM PGE2; EP3+/+: 10.2±1.14 vs. 4.4±1.84, P = 0.0036; EP3-/-: 
11.8±1.20 vs. 10.3±0.68 nmol glycerol/10,000 cells, P>0.9999). EP3-/- mice fed HFD had 
ectopic lipid accumulation in skeletal muscle (7.5±1.24 vs. 17.7±1.82 mg triglyceride/
mg; P<0.0001) and liver (14.6±2.83 vs. 78.5±13.0 mg triglyceride/mg; P<0.0001), with 
evidence of hepatic steatosis. When fed HFD, EP3-/- mice became hyperglycemic (107±8.80 
vs. 158±7.14 mg/dl; P<0.0001) and hyperinsulinemic (0.598±0.079 vs. 1.55±0.241 ng/
ml; P<0.0001) when compared to EP3+/+ fed HFD, demonstrating a more severe insulin 
resistance phenotype in EP3-/- (4.77±0.931 vs. 18.1±3.50 HOMA-IR; P<0.0001).
Conclusions: These results demonstrate that when fed a HFD, EP3-/- mice have 
abnormal lipid distribution, developing excessive ectopic lipid accumulation and associated 
insulin resistance.
Funding: NIDDK Support, Veterans Administration Support
SA-PO377
Resveratrol Activates Renal Expressions of Adiponectin Receptor 1 and 2 
in db/db Mice  Yaeni Kim, Ji Hee Lim, Min Young Kim, Hyung Wook Kim, 
Cheol Whee Park.  Div of Nephrology, Dept of Internal Medicine, College of 
Medicine, The Catholic Univ of Korea, Seoul, Republic of Korea.
Background: Adiponectin is an adipocyte-derived adipokine that binds to adiponectin 
receptors (AdipoR) and exhibits antidiabetic effects via activation of AMPK and PPAR-α. 
Our previous study investigated the renoprotective role of resveratrol by decreasing 
lipotoxicity and inhibiting mesangial cell glucotoxicity in a manner dependent on the 
AMPK-SIRT1-PGC1α axis in diabetic mouse model. The common pathway shared by both 
substances instigated us to explore the favorable effect of resveratrol on renal physiology 
through the activation of AdipoR.
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Methods: Male db/db mice at 8 weeks of age were fed resveratrol (20 mg/kg/day) via 
gavage for 12 weeks. Serum, urine and renal tissue were obtained to analyze for changes 
in metabolic parameters, molecular levels and renal structure.
Results: Resveratrol treatment showed favorable effects on albuminuria, glomerular 
matrix expansion and inflammatory cell infiltration. Increased expressions of AdipoR1 and 
AdipoR2 were observed with increases in phosphorylated AMPK and PPAR-α level. It 
also ameliorated free fatty acid and triacylglycerol accumulation in the kidney which was 
related to increases in the phosphorylation of AMPK and the activation of SIRT1-PGC-
1α signaling and of the key downstream effectors, the PPARα-Forkhead box O (FoxO)1/
FoxO3a-oestrogen-related receptor (ERR)-1α- sterol regulatory element-binding protein 
1 (SREBP1)/acetyl coenzyme A carboxylase (ACC). Furthermore, resveratrol increased 
eNOS phosphorylation and Bcl-2/Bax ratio which were associated with decreased apoptotic 
cells and oxidative stress as reflected by renal 8-hydroxy-deoxyguanosine (8-OH-dG) and 
urinary 8-OH-dG and isoprostane concentrations. Resveratrol prevented high-glucose-
induced oxidative stress and apoptosis in cultured human glomerular endothelial cells 
(HGECs) through activation of both AdipoR and subsequent phosphorylation of AMPK 
and the downstream effectors.
Conclusions: In conclusion, our results suggest that resveratrol exerts its renoprotective 
effects through activation of both AdipoR which prevent lipotoxicity related apoptosis and 
oxidative stress in the kidney.
SA-PO378
Oral Treatment with PBI-4547, a Novel Anti-Diabetic and Anti-Fibrotic 
Compound, Ameliorates Kidney Function and Glomerular Integrity in the 
Diabetic db/db Mouse Model  Martin Leduc, Brigitte Grouix, Kathy Hince, 
Alexandra Felton, François Sarra-Bournet, Liette Gervais, William Gagnon, 
Alexandre Laverdure, Mikaël Tremblay, Marie-Pier Cloutier, Pierre Laurin, 
Lyne Gagnon.  ProMetic BioSciences Inc., Laval, QC, Canada.
Background: Diabetic nephropathy is the most common complication of longstanding 
diabetes affecting up to 30% of all diabetic patients, and is the main cause of end-stage 
kidney disease. This study examined the long-term nephroprotective effects of PBI-4547 
in uninephrectomized (NX) diabetic (db/db) mice, a model of type 2 diabetes.
Methods: Total nephrectomy of the right kidney was performed on day 0 and animals 
were treated with vehicle or PBI-4547 (10 and 50 mg/kg, oral once a day) from day 1 through 
105. Kidney function (GFR) and structure (mesangium lesions, glomerular integrity), 
regulation of pro-inflammatory/fibrotic gene expression in the kidney, as well as serum 
pro-inflammatory cytokine levels were examined.
Results: Kidney function assessed by GFR was significantly reduced in NX-db/
db mice compared to NX-C57BL/6 negative control animals, and PBI-4547 treatment 
significantly improved GFR in NX-db/db mice. As shown by PAS staining, mesangial matrix 
accumulation/expansion was prominent in NX-db/db mice compared to the negative control, 
but was significantly suppressed in PBI-4547-treated NX-db/db mice. Moreover, qPCR 
analysis of the expression of MCP-1, IL-6, Collagen I, MMP2, Timp1, and iNOS showed 
that PBI-4547 downregulated diabetes-induced inflammation, fibrosis, oxidative stress, and 
extracellular matrix remodeling in the kidney. Expression of GLEPP1 was significantly 
increased in NX-db/db mice, and restored to the negative control level following treatment 
with PBI-4547. Serum levels of cytokines were measured (multiplex panel). Early/innate 
TNF-α, IL-1β, and IL-6 cytokines were markedly reduced by PBI-4547, as well as TH1-
type IL-12p70, IFNγ, IL-2 cytokines, and TH2-type IL-4, IL-5, IL-13 cytokines. TH9-type 
pro-inflammatory cytokine IL-9 was also decreased.
Conclusions: These results suggest that PBI-4547 is a potential novel therapy for 
diabetic nephropathy by improving kidney function and structure, and reducing pro-
inflammatory and pro-fibrotic markers.
SA-PO379
Prostaglandin E2 Receptor 3 (EP3) Inhibits Vasopressin-Stimulated Water 
Reabsorption and Contributes to Diabetic Renal Dysfunction in Mice 
Ramzi Hassouneh, Rania Nasrallah, Joe A. Zimpelmann, Kevin D. Burns, 
Richard L. Hébert.  Kidney Research Centre, Cellular and Molecular Medicine, 
Univ of Ottawa, Ottawa, ON, Canada.
Background: The early renal manifestations of diabetes are polyuria and reduced urine 
osmolality (Uosm), and when sustained long-term lead to nephropathy. We propose that 
these processes are mediated through the interaction of prostaglandin E2 (PGE2) acting 
via EP3 and the anti-diuretic hormone, vasopressin (VP).
Methods: Global EP3-/- and wild-type (WT) 8wk male C57BL6 mice were injected 
with vehicle or streptozotocin (STZ) and analyzed after 12wks. Glomerular filtration rate 
(GFR) was measured by inulin clearance. Aquaporin (AQ) 1/2 and cyclooxygenase-2 (COX-
2) were assessed by Western blotting. PAS stain was done to assess renal injury on paraffin 
sections. 24hr urinary VP excretion rate was quantified. Cortical collecting ducts (CCD) were 
microdissected for in vitro perfusion and stimulated with VP and sulprostone (SLP; EP3/1 
agonist). 3H-inulin was used as a volume marker to measure net water reabsorption (Jv).
Results: EP3-/- STZ show decreased polyuria, hyperfiltration, CCD injury, and VP 
levels compared to STZ. EP3-/- STZ show increased Uosm compared to STZ. Cortex 
AQP2 and medulla AQP1/2 are decreased by 50% in STZ and restored to control levels in 
EP3-/- STZ. Cortex and medulla COX-2 was increased up to 2-fold in STZ, and attenuated 
in EP3-/- STZ (n=5, P<0.05). VP increased Jv in all groups, and SLP reversed this effect 
only in WT and STZ. See table. 
Conclusions: Despite elevated VP levels in STZ, the CCD response to VP stimulation 
was no different than in WT, while SLP inhibited VP-induced Jv in both groups. In the 
absence of EP3, the VP-induced Jv was unchanged by SLP, confirming the importance of 
EP3 in this process. During diabetes, EP3 inhibition of VP-induced Jv may lead to polyuria 
and a sustained increase of VP, which may be injurious to the kidney.
Funding: Government Support - Non-U.S.
SA-PO380
Effects of Diuretics on SGLT2 Inhibitor-Induced Changes in Blood 
Pressure and Natriuresis in Obese Rats Suffering from the Metabolic 
Syndrome  Akira Nishiyama, Daisuke Nakano, Wararat Kittikulsuth.  Dept of 
Pharamacology, Kagawa Univ Medical School, Kagawa, Japan.
Background: Experiments were carried out to investigate whether diuretics 
(hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose 
co-transporter 2  (SGLT2) inhibitor on glucose metabolism, blood pressure and rate of 
urinary excretion of sodium in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp).
Methods:    Male 13-week-old SHRcp were treated with: (i) vehicle; (ii) the SGLT2 
inhibitor luseogliflozin (10 mg/kg/day, p.o.); (iii) diuretics (hydrochlorothiazide; 10 mg/
kg/day + furosemide; 5 mg/kg/day, p.o.); or (iv) luseogliflozin + diuretics for 5 weeks (n = 
5–8 for each group). Blood pressure and glucose metabolism were evaluated by a telemetry 
system and oral glucose tolerance test, respectively.
Results:    Vehicle-treated SHRcp developed non-dipper type hypertension (dark- vs. 
light-period mean arterial pressure (MAP): 148.6±0.7 and 148.0±0.7 mmHg, respectively, 
P=0.2) and insulin resistance. Compared with vehicle-treated animals, luseogliflozin-treated 
rats showed an approximately 4000-fold increase in urinary excretion of glucose and 
improved glucose metabolism. Luseogliflozin also significantly decreased blood pressure 
and converted the circadian rhythm of blood pressure from a non-dipper to dipper pattern 
(dark- vs. light-period MAP: 138.0±1.6 and 132.0±1.3 mmHg, respectively, P<0.01), 
which were associated with a significant increase in urinary excretion of sodium. Addition 
of diuretics did not influence luseogliflozin-induced improvement of glucose metabolism 
and circadian rhythm of blood pressure in SHRcp.
Conclusions: These data suggest that a SGLT2 inhibitor elicits its beneficial effects 
on glucose metabolism and hypertension in subjects with metabolic syndrome undergoing 
treatment with diuretics.
Funding: Other NIH Support - the Japan Society for the Promotion of Science (JSPS) 
Grants-in-Aid for Scientific Research (KAKENHI), Pharmaceutical Company Support - 
Taisho-Toyama Pharm.
SA-PO381
SGLT2 Inhibition Slows the Progression of Diabetic Nephropathy in the db/
db Mice  Li Tang, Yuanyuan Wu, Yufeng Huang.  Fibrosis Research Laboratory, 
Div of Nephropathy, Univ of Utah, Salt Lake City, UT.
Background: It has been shown that SGLT2 inhibitor not only enhanced renal glucose 
excretion and lowered blood glucose (BG) but also reduced albuminuria in patients with 
Type 2 diabetes (T2DM). However, the renoprotective effect of SGLT2 inhibition in 
diabetes has not fully established.
Methods: This study sought to determine whether dapagliflozin, a selective SGLT2 
inhibitor, could slow the progression of glomerulosclerosis in the uninephrectomized db/
db mouse, a model of T2DM.
Results: Untreated uninephrectomized db/db mice developed progressive albuminuria 
and glomerulosclerosis between wks 18 and 22, associated with increased renal expression 
of TGFß1, PAI-1, type IV collagen and fibronectin. Treatment with dapagliflozin (1mg/
kg/d) via gel diet from wks 18 to 22 did not affect body weight but reduced BG (from 
573.53±21.73 to 371.14±55.02 mg/dL, P<0.05) and HbA1c levels. Of note, treatment with 
dapagliflozin arrested the increases in albuminuria and markers of glomerulosclerosis seen 
in db/db mice between wks 18 to 22. Renal expressions of NF-κBp67, MCP-1, Nox4, 
Nox2, and p47phox and urine TBARS levels, the markers of renal inflammation and 
oxidative stress, were increased during disease progression in db/db mice. Treatment with 
dapagliflozin reduced these markers. In addition, db/db mice had markedly increased daily 
water intake, urine output, urinary sodium and potassium excretion but decreased urinary 
osmolality. Dapagliflozin had no effects on these measurements. Interestingly, dapagliflozin 
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ameliorated diabetes-induced glomerular hyperfiltration determined by elevated creatinine 
clearance rates (2.44±0.55 ml/min in treated db/db vs. 3.72±0.63 ml/min in db/db) and 
caused a significant reduction in renal RAS activity determined by urinary aldosterone 
levels (45.5±4.93 vs. 60.9±4.01, µg/24h, P<0.05).
Conclusions: These results suggest that SGLT2 inhibitor not only reduces albuminuria 
but also slows the progression of the glomerulosclerosis resulting from T2DM by improving 
hyperglycemia and renal inflammation and oxidative stress. Decreasing glomerular 
hyperfiltration and negatively regulating renal RAS activity by SGLT2 inhibitor may be 
also renoprotective.
Funding: Pharmaceutical Company Support - AstraZeneca R&D
SA-PO382
Effect of SGLT2 Inhibitor Ipragliflozin on Urinary Na Excretion and Body 
Fluid Volume  Takahiro Masuda,1 Yuko Watanabe,1 Minami Watanabe,1 Keiko 
Fukuda,1 Akira Onishi,3 Hermann Koepsell,2 Volker Vallon,3 Daisuke Nagata.1 
1Div of Nephrology, Deparment of Medicine, Jichi Medical Univ, Shimotsuke, 
Tochigi, Japan; 2Univ of Würzburg, Germany; 3Univ of California and VA San 
Diego Healthcare System, San Diego, CA.
Background: Sodium-glucose cotransporter (SGLT) 2 inhibitors are new antidiabetic 
drugs that increase urinary glucose excretion (UGE) by inhibiting renal SGLT2. SGLT2 
inhibitors may induce body fluid reduction due to the increase in urine volume and Na 
excretion, but the details remain unclear.
Methods: Spontaneously Diabetic Torii (DM) rat, a non-obese type 2 diabetic model 
was used in this study. At the onset of diabetes (blood glucose ≥ 250 mg/dl), DM rats and 
age-matched Sprague-Dawley (non-DM) rats were separated to vehicle (Veh) and 0.01% 
(in diet) Ipragliflozin (Ipra) group, respectively. After 8 weeks, bioimpedance spectroscopy 
(ImpediVet) for the assessment of total body water, urine collection and blood tests were 
performed.
Results: Renal membrane protein expression of SGLT2 was significantly higher in 
DM rats compared with non-DM rats. Ipra enhanced the expression of SGLT2 in non-DM 
rats, but not in DM rats. Ipra did not change plasma glucose in non-DM rats (Veh 172±11 
vs. Ipra 158±5 mg/dl, P=0.12), but significantly decreased in DM rats (681±21 vs. 361±22 
mg/dl,* P<0.05). Ipra increased fractional glucose excretion in non-DM rats (0.3±0.2 vs 
31.3±2.1 %*) and DM rats (31.5±1.7 vs. 52.9±3.2 %*). In non-DM rats, Ipra increased 
urine volume (36±7 vs. 61±5 ml/day*), UGE (0.03±0.01 vs. 4.8±0.2 g/day*), urinary Na 
excretion (3.0±0.4 vs. 4.2±0.3 mEq/day*), food intake (31±1 vs. 34±1 g/day*) and fluid 
intake (61±9 vs. 87±8 ml/day*). These parameters were higher in DM rats than in non-DM 
rats, but Ipra did not significantly change these parameters. Total body water (related to 
body weight) and fluid balance (fluid intake-urine volume) were similar among the 4 groups.
Conclusions: SGLT2 inhibition did not induce sustained changes in body fluid volume 
in DM or non-DM rats. In non-DM rats given Ipragliflozin, the increase in fluid intake 
might maintain fluid balance in response to the osmotic diuresis whereas the natriuresis is 
likely due to greater food intake.
Funding: Government Support - Non-U.S.
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Up-Regulated Sglt2 Reduces Proximal Tubular Sirt1 and Augments Renal 
Gluconeogenesis in Early Stage Diabetic Nephropathy  Hiroyuki Umino, 
Kazuhiro Hasegawa, Shu Wakino, Hiroshi Itoh.  Keio Univ.
Background: We previously reported that high glucose (HG) decreases proximal 
tubule (PT) Sirt1 prior to decreasing glomerular Sirt1, which leads to a disruption of 
tubule-podocyte communication in diabetic nephropathy (DN) (Nat Med 2013). Protein 
expression levels of Sglt2 are elevated to compensate for the increased demand for glucose 
uptake in DN, which causes a rise in intracellular HG in PT. Here, we investigated whether 
Sglt2-mediated HG down-regulates PT Sirt1.
Methods: Cultured PTs (HK2) were cultivated on a two-chamber-system consisting 
of an upper chamber equivalent to the ureteral lumen on the apical side of PTs and a lower 
chamber corresponding to the vascular lumen on the basolateral side of PTs. PTs were 
cultured with combinations of normal glucose (NG) or HG in each chamber to determine the 
polarity of HG that affects Sglt2 and Sirt1 expression. We also administered a Sglt2 inhibitor 
(canagliflozin) to 8-week-old db/db mice and analyzed the Sglt2 and Sirt1 expression.
Results: HG in the lower chamber increased Sglt2 and decreased Sirt1 expression, but 
HG in the upper chamber had no effect. Thus, high blood sugar (BS), but not glucosuria 
regulates Sglt2 and Sirt1. Furthermore, in db/db mice, high BS also elevated Sglt2 and 
lowered Sirt1 expression in PTs, as confirmed by immunofluorescence and immunoelectron 
microscopy, and reduced deacetylation of Foxa2, a Sirt1 target. Decreased Sirt1 expression 
led to an increase in Foxa2 acetylation, which induces gluconeogenesis. Results from 
DNA microarrays and confirmatory real-time PCR using laser-microdissected db/db PTs 
showed an increase in Pck1 and G6Pase in concert with Sglt2 upregulation and Sirt1 
downregulation. However, Sglt2 inhibitors blocked these changes.
Conclusions: Increased Sglt2 expression, already seen in the early stage of DN, 
forms a vicious cycle whereby both exogenous HG, mediated by a Sglt2-induced influx 
of BS, and endogenous HG, generated by Foxa2-induced renal gluconeogenesis, reduce 
PT Sirt1 levels. Decreased Sirt1 acetylates and activates Foxa2, further promoting renal 
gluconeogenesis, which accelerates this cycle. However, Sglt2 inhibitors can block the 
HG-induced reduction in Sirt1 levels and prevent DN progression.
SA-PO384
Characterization of Aged Mice Lacking SGLT2  Yiling Fu, Falk Bernhard 
Batz, Akira Onishi, Aleksandra Novikov, Panai Song, Volker Vallon.  Div of 
Nephrology, UC San Diego & VA San Diego Healthcare System, La Jolla, CA.
Background: SGLT2 inhibitors have recently been approved in type 2 diabetes and 
long-term clinical trials are ongoing to further establish efficacy and safety. Humans with 
familial renal glycosuria due to mutations in SGLT2 do not show signs of general renal 
tubular dysfunction or other pathological changes, and they seem to have normal life 
expectancies. Here we compared the phenotype of non-diabetic aged male mice (at 24 
months) that lack SGLT2 (Sglt2-/-) with their wild-type littermates (WT).
Methods: In awake mice, blood pressure (BP) and heart rate (HR) was measured 
by an automatic tail-cuff system and GFR by FITC-inulin plasma eliminations kinetics.
Results: Out of initially 11 Sglt2-/- and 14 WT, 2 mice per genotype died for unknown 
reasons before reaching an age of 24 months; thus 9 Sglt2-/- and 12 WT mice were analyzed. 
Consistent with results previously reported in young adult mice (3-5 months): aged Sglt2-
/- and WT showed similar body weight (33.6±0.6 vs 32.1±0.9 g), blood glucose (105±6 vs 
116±10 mg/dl), and GFR (329±36 vs. 370±20 µl/min); Sglt2-/- had higher urinary glucose 
excretion (381±71 vs 5±1 µmol/mg creatinine) associated with higher intake of food 
(3.8±0.1 vs 3.2±0.1 g/day) and fluid (8.9±0.2 vs 5.1±0.1 ml/day) and smaller adipocytes 
in subcutaneous and epididymal fat tissue (4790±446 vs 6348±130 and 8093±890 vs 
11811±778 µm2)(each P<0.01); urine pH was similar (6.2±0.1 vs 6.5±0.2) and no bacterial 
growth detected in bladder urine. Different from previous findings in young adult mice: 
aged Sglt2-/- had modestly higher kidney weight (15.4±0.9 vs 12.6±0.4 µg/g body wt), BP 
(105±2 vs 95±1 mm Hg) and HR (660±7 vs 625±9 1/min) than WT and lower hematocrit 
(38.1±1.0 vs 41.3±0.4% (each P<0.01).
Conclusions: Aged Sglt2-/- mice show many of the expected phenotypes previously 
observed in young adult mice, and have preserved GFR and no evidence for ascending 
bacterial infections. An increase in kidney weight has previously been reported in 7.5 
months old Sglt2-/- mice. Further analyses aim to better understand the latter findings and 
the observed modest changes in BP and hematocrit.
Funding: NIDDK Support
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Renal Secretion of the SGLT2 Inhibitor Empagliflozin and Rightward Shift 
in Its Glucosuric Response Curve in Mice Lacking OAT3  Yiling Fu,1 Akira 
Onishi,1 Panai Song,1 Falk Bernhard Batz,1 Eric W. Mayoux,2 Volker Vallon.1 
1Div of Nephrology, UC San Diego & VA San Diego Healthcare System, La 
Jolla, CA; 2Boehringer Ingelheim, Biberach, Germany.
Background: SGLT2 inhibitors, like empagliflozin (EMPA), may reach their target 
in the brush border of the early proximal tubule through nephron filtration and tubular 
secretion. The organic anion transporter OAT3 in the basolateral membrane of the proximal 
tubule contributes to secretion.
Methods: Renal 3H-inulin clearance studies were performed in wild-type (WT) mice to 
characterize the renal handling of EMPA. EMPA was given in diet for 3 weeks (~30mg/[kg 
body wt x day]) ± i.p. bolus (10 mg/kg 1 hr before study)). EMPA was determined by LC/
MS/MS. Mean fractional protein binding of empagliflozin in mouse plasma is constant over 
a wide range (up to >=50µM) at 88.1 +/- 0.5%. b) Metabolic cage studies were performed 
in mice lacking OAT3 and WT littermates; EMPA (0.3-30 mg/kg) or vehicle was applied 
i.p. together with an oral water load (30 ml/g bw) and the urine quantitatively collected 
over 3 hours to determine the glucosuric response.
Results: Comparing freely filtered and excreted amounts of EMPA revealed a fractional 
renal excretion of ~300-500 % for free plasma concentrations in the range of 1-2 nM (with 
chronic application in diet, which is close to the IC50 for mouse SGLT2) to 20-22 nM (with 
additional bolus application), indicating that 2/3 or more of the renal excretion of EMPA 
derived from renal secretion. B) OAT3-/- showed a small but significant rightward shift in 
the glucosuria response curve to EMPA (ED50 ~6 vs. 3 mg/kg in WT; with significantly 
lower glucosuria at 1, 3, and 10 mg/kg (P<0.05), whereas vehicle/0.3 mg/kg and 30 mg/kg 
induced similar minimal and maximal glucosuria, respectively)(n=9-19/dose).
Conclusions: The SGLT2 inhibitor empagliflozin is secreted by the kidney; this may 
involve OAT3 in the early proximal tubule whose activity is a determinant of the acute 
glucosuric effect of EMPA.
Funding: NIDDK Support, Pharmaceutical Company Support - Boehringer Ingelheim
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SGLT Inhibition Significantly Increases Oxygen Consumption of the 
Medullary Thick Ascending: A Modeling Study  Anita T. Layton,1 Volker 
Vallon,2 Aurelie Edwards.3  1Mathematics, Duke Univ, Durham, NC; 2Medicine 
and Pharmacology, Univ of California San Diego, La Jolla, CA; 3Centre 
National de la Recherche ScientifiTue, Paris, France.
Background: The objective of this study was to investigate how changes in sodium 
reabsorption in the proximal tubule affect oxygen (O2) consumption and the metabolic 
efficiency of the nephron.
Methods: To do so, we developed a detailed mathematical model of solute transport 
in a short-loop nephron of the rat kidney. Glucose is reabsorbed via sodium-glucose 
cotransporters (SGLTs) in the proximal tubule, which expresses the isoform SGLT2 in S1-
S2 and the isoform SGLT1 in S3. We used the model to investigate the effect of inhibiting 
SGLT2, a novel treatment for reducing proximal tubule glucose uptake in diabetes, on renal 
Na+ transport and renal oxygen consumption (QO2).
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Results: Inhibiting SGLT2 shifts Na+ transport to downstream nephron segments, 
possibly increasing their QO2. Of particular concerns are the S3 segment and medullary 
thick ascending limb (mTAL), which are at risk for hypoxic injury. Dual SGLT1-SGLT2 
inhibition protects the S3 segment, but could further reduce mTAL oxygenation. Model 
simulations suggest that SGLT2 inhibition substantially increases S3 QO2. Together with 
elevated membrane expression of Na-K-Cl cotransporter (NKCC2), SGLT2 inhibition also 
increases mTAL QO2. Additionally, we used the model to determine the optimal combination 
of SGLT1 and SGLT2 inhibition, in terms of suppressing tubular glucose uptake and 
maintaining sufficiently low S3 and mTAL QO2.
Conclusions: In conclusion, SGLT inhibition significantly increases oxygen 
consumption of the mTAL. This research was supported in part by NIH grant DK-89066.
Funding: NIDDK Support
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SGLT2 Expression Is Increased in Human Diabetic Nephropathy: 
SGLT2 Inhibition Decreases Renal Lipid Metabolism, Inflammation 
and the Development of Nephropathy in Diabetic Mice  Xiaoxin Wang,1 
Jonathan Levi,2 Yuhuan Luo,1 Evgenia Dobrinskikh,1 Almut Grenz,1 Michal 
Herman-Edelstein,3 Uzi Gafter,3 Avry Chagnac,3 Hermann Koepsell,4 Jeffrey 
B. Kopp,2 A. Rosenberg,2 Moshe Levi.1  1Univ of Colorado Denver; 2NIDDK; 
3Rabin Medical Center; 4Univ of Wurzburg.
Background: The renal sodium gradient dependent glucose transport protein SGLT2 
expression is increased in renal biopsies from human subjects with diabetic nephropathy.
Methods: To determine the potential mechanisms of beneficial effects of SGLT2 
inhibition in progression of diabetic renal disease we treated db/db mice with a selective 
SGLT2 inhibitor.
Results: We found that SGLT2 inhibition caused marked decreases in systolic blood 
pressure, kidney weight/body weight ratio, urinary albumin (745±36 mg/g in db/db vs. 
207±5 mg/g in treated db/db, p<0.001) and urinary thiobarbituric acid-reacting substances 
(TBARS). SGLT2 inhibition also a) prevented renal lipid accumulation via inhibition of 
LPK, SCD-1 and DGAT1, key enzymes that mediate fatty acid and triglyceride synthesis, b) 
decreased inflammation via inhibition of CD68 macrophage accumulation, and expression of 
p65, TLR4, MCP-1 and OPN, and c) increased CD73 and decreased adenosine A receptors 
Adora1, Adora2a, and Adora2b mRNA. These effects were associated with prevention of 
mesangial expansion, accumulation of extracellular matrix proteins fibronectin and type 
IV collagen, as well as loss of podocyte markers WT1 and synaptopodin, as determined 
by quantitative immunofluorescence microscopy.
Conclusions: In summary, our study showed that SGLT2 inhibition modulates renal 
lipid metabolism and inflammation and prevents the development of nephropathy in db/
db mice.
Funding: Pharmaceutical Company Support - J&J
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Loss of Angiotensin-Converting Enzyme 2 Alters Glomerular Strucutre 
in Non Obese Diabetic Mice  Heleia Roca-Ho,1 Marta Riera,1 Marta Rebull,1 
Javier Gimeno,2 Julio Pascual,1 Maria Jose Soler.1  1Nephrology, Hospital del 
Mar-Inst Hospital del Mar d’Investigacions Mèdiques, Barcelona; 2Pathology, 
Hospital del Mar, Barcelona.
Background: ACE2 has been shown to play an important role in diabetic nephropathy 
(DN). We studied renal morphology and kidney function in non-obese diabetic(NOD) female 
mice (with spontaneous autoimmune diabetes) carrying a deletion on ace2 gene(NOD.
ACE2-/-) and NOD.ACE2+/+ after 30days of diabetes (DOD). Non obese resistant strain 
(NOR.ACE2-/- and NOR.ACE2+/+) was used as control mice.
Methods: To evaluate kidney function urinary excretion of albumin(UAE) and 
glomerular filtration rate(GFR) were calculated.UAE was determined on spot urine 
collections. GFR was measured using clearance kinetics of plasma FITC-inulin after 75min 
of a single bolus injection on conscious mice (N=6-13 animals/group). Paraffin embedded 
kidney sections were obtained. 20glomeruli were randomly selected for each animal. To 
assess renal morphology, PAS staining was performed. The extent of extracellular mesangial 
matrix was identified by PAS-positive material in the glomerulus and factored by the 
glomerular tuft area. Area calculations were performed using ImageJ software. To assess 
podocyte number in glomerular tuft, WT-1 staining was performed.
Results: NOD.ACE2-/- mice showed glomerular area increase, mesangial matrix 
expansion and podocyte loss as compared to NOR.ACE2-/- age matched mice. UAE was 
increased in both diabetic NOD mice, without differences among them. Interestingly, GRF 
was found decreased in NOD.ACE2-/- showing a tendency for GFR decrease as compared 
to NOD.ACE2+/+.
Conclusions: Glomerular hypertrophy, mesangial matrix expansion and podocyte 
loss were found in female NOD.ACE2-/- after30DOD.GFR values showed mild decrease 
in NOD.ACE2-/- compared to NOD.ACE2+/+ mice. Our results suggest that ACE2 deletion 
worsens kidney injury in diabetic NOD mice.
SA-PO389
Ace2 Deficiency Accentuated AngII-Induced Hypertension and 
Albuminuria in Diabetic Mice  Sergi Clotet-Freixas, Maria Jose Soler, Marta 
Rebull, Julio Pascual, Marta Riera.  Nephrology, Hospital del Mar-Inst Hospital 
del Mar d’Investigacions Mèdiques, Barcelona, Spain.
Background: AngiotensinII (AngII) promote renal vasoconstriction, albuminuria, 
fibrosis, apoptosis and inflammation. ACE2 deficiency exacerbates hypertension in AngII-
infused male mice. However, the effect of ACE2 deletion on diabetic and AngII-infused 
female mice has not been previously studied.
Methods: We evaluated the effect of AngII infusion in age matched C57BL/6 wild-
type (WT) and ACE2KO streptozotocin(STZ)-induced female mice and their respective 
non-diabetic controls. At week 8 of follow-up, mice were anesthetized and minipumps for 
AngII infusion (ANGII) were surgically implanted. Sham-operated (SHAM) mice were used 
as control groups. Study groups: WT-Control(CONT) + SHAM, WT-CONT + ANGII, WT-
Diabetic(DB) + SHAM, WT-DB + ANGII, ACE2KO-CONT + SHAM, ACE2KO-CONT 
+ ANGII, ACE2KO-DB + SHAM, ACE2KO-DB + ANGII. Blood glucose, body weight, 
kidney weight/body weight (KW/BW), heart weight /body weight (HW/BW), systolic blood 
pressure (SBP) and urinary albumin excretion (UAE) were studied.
Results: Hyperglycemia and reduced BW were observed in all groups given STZ. 
ACE2 deletion and AngII infusion supposed a modest decrease in body weight in control 
and diabetic mice. Both, SHAM and AngII-infusedACE2KO diabetic mice showed higher 
KW/BW as compared to WT.AngII infusion significantly augmented HW/BW and SBP 
in control and diabetic ACE2KO mice as compared to non-infused mice. Diabetes and 
AngII infusion were accompanied by increased UAE in all groups. This increase was more 
pronounced in ACE2KO mice. Within AngII-infused groups, ACE2KO-CONT + ANGII 
and ACE2KO-DB + ANGII showed significantly higher HW/KW, SBP and UAE than 
WT-CONT + ANGII and WT-DB+ANGII.
Conclusions: Loss of ACE2 accentuated renal hypertrophy and AngII-induced 
hypertension, albuminuria and cardiac hypertrophy in diabetic female mice.
Funding: Government Support - Non-U.S.
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Global ACE2 Deficiency Worsens Glomerular Cell Proliferation but Does 
Not Affect GFR in Diabetic Mice  Jan A. Wysocki,1 Minghao Ye,1 Yashpal S. 
Kanwar,1 Agnes B. Fogo,2 Daniel Batlle.1  1Northwestern Univ; 2Vanderbilt Univ.
Background: Alterations in ACE2 have been described in rodent models of diabetic 
kidney disease and in humans with type 2 diabetes where glomerular ACE2 expression 
has been found to be decreased similar to findings in diabetic db/db mice. At the tubular 
level however, ACE2 is increased. To examine the impact of ACE2 deficiency on kidney 
pathology we developed a model of type 2 diabetes with global ACE2 deficiency. The effect 
of STZ-induced diabetes on kidney pathology was also examined in ACE2KO mice with 
two different genetic backgrounds.
Methods: ACE2 deficient db/db mice were generated and backcrossed to the BLKS 
genetic background for at least 6 generations. The effect of ACE2-deficiency was also 
studied in WT and ACE2KO mice (C57BL6/J and FVB/N genetic backgrounds) that were 
rendered diabetic using STZ (2x150mg/kg).
Results: In ACE2 deficient db/db mice, there was a modest but significant reduction 
in podocyte count (10.3±0.2 vs. 11.1±0.1, p<0.05) and an increase in glomerular cellularity 
(1.81±0.13 vs. 1.06±0.11, p<0.001, respectively) but neither GFR (3.0±0.4 vs. 2.4±0.3ul/
min/g) nor albumin excretion were significantly different from db/db WT controls. ACE2-
deficient db/db mice also exhibited Lacis cell hyperplasia, increase in polar cells and foci of 
glomerular sclerosis. Glomerular cellularity was significantly increased also in mice with 
STZ-induced diabetes on the FVB/N but not in the C57BL6/J background as compared to 
their respective diabetic WT counterparts.
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Conclusions: Genetic ACE2 ablation worsens glomerular hypercellularity in diabetic 
mice whereas GFR and ACR are not significantly altered and other markers of glomerular 
pathology are minimally affected.
Funding: NIDDK Support, Private Foundation Support
SA-PO391
Blood Pressure-Independent Amelioration of Glomerulosclerosis in 
Diabetic Rats Treated with Dual AT1Receptor-Neprilysin Inhibition versus 
AT1Receptor Blockade Alone  Lodi C.W. Roksnoer,1 Richard Van Veghel,1 
Marian Clahsen - van Groningen,3 René De Vries,1 Ingrid M. Garrelds,1 
Usha M. Bhaggoe,1 Jeanette M. Van Gool,1 Edith C.H. Friesema,1 Frank P.J. 
Leijten,1 Ewout J. Hoorn,2 Alexander H. Danser,1 Wendy W. Batenburg.1  1Div. 
Pharmacology and Vascular Medicine, Dept Internal Medicine, Erasmus MC, 
Rotterdam, Netherlands; 2Div. Nephrology, Dept Internal Medicine, Erasmus 
MC, Rotterdam, Netherlands; 3Dept Pathology, Erasmus MC, Rotterdam, 
Netherlands.
Background: Dual AT1 receptor-neprilysin inhibition (ARNI) has recently been 
shown to exert beneficial effects on blood pressure (BP), NT-proBNP, and estimated GFR 
in heart failure patients, compared with AT1 receptor blockade (ARB) alone. Neprilysin is 
upregulated in epineural arterioles of diabetic rats. We hypothesized that ARNI improves 
cardiac and kidney parameters in diabetic TGR(mREN2)27 rats, a model displaying 
angiotensin II-mediated hypertension.
Methods: Rats were made diabetic with streptozotocin, for 5 or 12 weeks. In the final 
3 weeks rats were treated with vehicle, the ARB irbesartan (15mg/kg.day) or irbesartan 
(15mg/kg.day) + the neprilysin inhibitor thiorphan (0.1mg/kg.day; ARNI). BP was measured 
by telemetry in the 5-week group only.
Results: Baseline mean arterial BP (MAP) was 157±5mmHg. ARB and ARNI lowered 
MAP identically over the 3-week period, reaching a maximum reduction of ~50mmHg 
around day 7. Heart weight/tibia length ratio in 12-week diabetic rats was 17±9% lower after 
ARNI treatment vs. ARB treatment (P<0.05). Proteinuria and albuminuria were observed 
from 8 weeks of diabetes onwards. ARNI reduced proteinuria more strongly than ARB 
(-78% vs. -49%, P<0.05), and a similar trend was seen for albuminuria. Kidneys of ARNI-
treated rats showed less focal segmental glomerulosclerosis than those of ARB-treated rats. 
At the end of the study, no differences between ARNI- and ARB-treated rats were found 
regarding diuresis, natriuresis, plasma endothelin-1, vascular reactivity (acetylcholine and 
endothelin-1 responses), or kidney sodium transporters.
Conclusions: ARNI reduces proteinuria, focal segmental glomerulosclerosis, and 
cardiac hypertrophy in diabetic TGR(mREN2)27 rats more strongly than ARB, and this 
occurs in a blood pressure-independent manner.
SA-PO392
Collateral Effects of Atrasentan on Renin-Angiotensin System 
Lidia Anguiano, Marta Riera, Marta Rebull, Julio Pascual, Maria Jose Soler. 
Nephrology, Hospital del Mar-Inst Hospital del Mar d’Investigacions Mèdiques, 
Barcelona, Spain.
Background: Endothelin-1 is a vasoconstrictor peptide that has been shown to be 
increased in diabetic kidney disease. In kidney cortex from obese diabetic mice ACE2 
activity is increased whereas ACE activity is decreased. Objective: study the effect of 
atrasentan, an antagonist of type A endothelin receptor, on renin-angiotensin system (RAS) 
in obese diabetic mice(db/db) and its respective controls(db/m).
Methods: Diabetic groups: vehicle (VehDB), 10mg/kg/day atrasentan (10DB), 25mg/
kg/day atrasentan (25DB), 50mg/kg/day atrasentan (50DB). Non-diabetic groups: vehicle 
(VehCONT), 10mg/kg/day atrasentan (10CONT). Animals were included in the study at 
12weeks of life and treated for 16weeks. Systolic (SBP) and diastolic (DBP) blood pressure 
and ACE2 and ACE enzymatic activities in serum and kidney were analyzed.
Results: See table. Atrasentan therapy significantly decreased SBP and DBP in non-
diabetic mice. Circulating and renal ACE2 activities were significantly increased in VehDB 
mice as compared to VehCONT. Atrasentan treatment at 25 and 50mg/kg/day reduced 
circulating and renal ACE2 activities. Circulating and renal ACE activities were decreased 
in VehDB as compared to VehCONT, with no modulation by atrasentan treatment.
Conclusions: Atrasentan prevented the increase of circulating and renal ACE2 in 
diabetes, indicating a collateral effect by RAS modulation. These results suggest that the 
beneficial effect of atrasentan in diabetic nephropathy may be related with endothelin 
blockade and its effect in the non-classic RAS pathway.
SA-PO393
P16ink4a Expression Is Increased via 12-Lipoxygenase in High Glucose-
Stimulated Glomerular Mesangial Cells and Type 2 Diabetic Glomeruli 
Yuanyuan Zhang, Fu-zhe Ma, Tao Sun, Wan-ning Wang, Hang Yuan, Zhong-gao 
Xu.  Nephrology, The First Hospital of Jilin Univ, Changchun, Jilin, China.
Background: Arachidonic acid-metabolizing enzyme 12-lipoxygenase (12-LO) 
is involved in glomerular hypertrophy of diabetic nephropathy (DN), in which cyclin-
dependent kinase inhibitors (CKIs) play important roles. However, it is unclear whether 
12-LO regulates the expression of the CKI p16ink4a in DN.
Methods: Primary glomerular mesangial cells (MCs) and glomeruli isolated from rats 
were used in this study. The rats were fed a high-fat diet and given low-dose streptozotocin 
to induce type 2 diabetes. The 12-LO product 12(S)-hydroxyeicosatetraenoic acid [12(S)-
HETE] was infused through an osmotic minipump. Enzyme-linked immunosorbent assay, 
Western blot, and morphometric analyses were performed.
Results: High glucose (HG) increased p16ink4a protein expression in MCs, but this 
increase was prevented by the 12-LO inhibitor cinnamyl-3,4-dihydroxy-α-cynanocinnamate 
(CDC). The levels of p-p38MAPK and p16ink4a in MCs were significantly elevated after 
12(S)-HETE treatment, whereas the p38MAPK inhibitor SB203580 prevented these 
increments. Compared with levels in control MCs, marked increases in p38MAPK 
activation and p16ink4aexpression were observed in MCs plated on collagen IV, while CDC 
treatment prevented these changes. Subcutaneous injection of CDC did not affect glucose 
levels but completely attenuated the diabetes-related increases in 12(S)-HETE content, 
p16ink4a expression, p-p38MAPK levels, glomerular volume, and kidney/body weight ratio. 
Compared with levels in controls, p16ink4a and p-p38MAPK in the glomeruli derived from 
12(S)-HETE-treated rats were significantly increased.
Conclusions: 12-LO-p38MAPK mediates the upregulation of p16ink4a in HG-stimulated 
MCs and type 2 diabetic glomeruli, and new therapies aimed at 12-LO inhibition might be 
beneficial in ameliorating diabetes-induced glomerular hypertrophy.
SA-PO394
The Effect and Mechanism of Probucol on Diabetic Nephropathy 
Tubulointerstitial Injury via Down-Regulating P66Shc  Shi-kun Yang,1 
Xiaoxuan Xu,1 Chun Hu,1 Li Xiao,1 Fuyou Liu,1 Lin Sun.1  1Dept of Nephrology, 
Kidney Inst of Central South Univ, Changsha, Hunan Province, China; 2Dept 
of Nephrology, Kidney Inst of Central South Univ, Changsha, Hunan Province, 
China.
Background: P66Shc induce mitochondrial ROS overproduction and lead to renal 
oxidative stress. Probucol has the renal protective effect on the progression of DN. However, 
the mechanism remains poorly understood.
Methods: ICR mices were divided into control (n=10), DN (n=10), probucol (10mg/
kg/d) group (n=10), DMSO group (n=10). The DN model was induced by injection of 
STZ (40mg/kg body weight) . Probucol was intraperitoneally injected to the mice every 
other day for 12 weeks after the model was built. Renal lesions and the expression of 
SIRT1, P300, AcH3, P66Shc, FN were detected by HE, Masson staining, TUNEL, DHE, 
immunohistochemistry and western-blot respectively.In addition, HK-2 cells were incubated 
with different concentrations of D-glucose (5, 30mM) with or without probucol, 1mM 
AICAR or 20uM Dorsomorphin or1uM EX-527 . The expression of P66Shc, SIRT1, P300, 
AcH3, AMPK, p-AMPK in HK-2 cells were detected by realtime-PCR,Western-blot and 
immunoflurescence assays. In addition, chromatin immunoprecipitation (ChIP) assay was 
used for determining the effect of probucol on acetylation of histone of P66Shc gene.
Results: Compared to control, the reduced ECM protin and renal tubular damage 
were observed in DN mice after treated by probucol. It also decraesed the expressions 
of P300, P66Shc, FN in the kidney of DN mices. In addition, Probucol can reduce the 
level of serum creatinine levels, attenuate renal ROS levels and apoptosis ,while boost 
the expressions of p-AMPK and SIRT1. Furthermore, pretreatment with the selective 
AMPK inhibitor Dorsomorphin or SIRT1 inhibitor EX-527 could block the inhibitory 
efficiencies of probucol. The ChIP analysis showed that probucol treatment could decrease 
the acetylation of histone H3 in p66Shc gene promoter regions (-535 bp to -276 bp) in 
HK-2 cells induced by high glucose.
Conclusions: Probucol could epigenetically suppress the expression of P66Shc through 
AMPK-SIRT1-AcH3 pathway, then ameliorate the apoptosis and oxidative injury in HK-2 
cells induced by high glucose.
Funding: Government Support - Non-U.S.
SA-PO395
Macrophages in Type 2 Diabetic Nephropathy  Celine Klessens, Malu 
Zandbergen, Ron Wolterbeek, Jan A. Bruijn, Ton J. Rabelink, Ingeborg M. 
Bajema, Daphne Thomas-ijpelaar.  Leiden Univ Medical Center.
Background: Inflammation seems to play a role in type 2 diabetic nephropathy (DN). 
Therefore, novel therapies focus on inhibition of inflammation to inhibit renal failure in 
DN. Interstitial macrophages are present in progressive interstitial lesions, however, the 
role of glomerular macrophages in the development of diabetic glomerular damage remains 
incompletely understood. In this study we investigated the accumulation of macrophages 
in glomeruli and interstitium of humans with various stages of DN.
Methods: Kidney samples obtained at autopsy of type 2 diabetes patients (N=88) 
with histologically proven DN were stained with CD68 and CD163, as global and M2 
macrophage markers. As controls, renal autopsy samples of 5 non-diabetic and 18 diabetic 
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patients without DN were used. Macrophages in 50 glomeruli per sample were counted. 
Interstitial macrophages were counted semi-quantitatively. Glomerular and interstitial 
macrophages were correlated to histological and clinical parameters.
Results: Glomerular CD68+ and CD163+ cells were present in all stages of DN 
according to the histopathological class and did not differ between classes, but the 
accumulation varied widely. The mean influx of glomerular CD68+ cells over the classes 
was 4.2 (range 0-19) and the mean influx of glomerular CD163+ cells was 2.1 (range 
0-14.74). The mean ratio of CD163/68+ cells amounted 0.5. Glomerular macrophages 
were also present in the control groups. Renal function was associated with the number 
of CD68+ cells and CD163+ cells were significantly associated with histological lesions. 
Interstitial macrophages significantly correlated with clinical parameters like GFR stage 
and albuminuria.
Conclusions: We showed that macrophages (including anti inflammatory CD163 
+ macrophages) are present in all stages of DN both in the glomerulus and interstitium. 
Correlation between clinical data and interstitial macrophages indicates that interstitial 
inflammation probably influences the progression of DN. In addition, presence of glomerular 
macrophages in early diabetic nephropathy suggests that they influence the glomerular 
diabetic damage as well. Therefore, therapies targeting macrophages might be a useful 
novel therapy in DN.
SA-PO396
Activation of CXCL16/CXCR6 Pathway by Inflammation Accelerates the 
Progression of Diabetic Nephropathy  Zebo Hu, Kun Ling Ma, Yang Zhang, 
Wu Yu, Bi-Cheng Liu.  Inst of Nephrology, Southeast Univ, Nanjing City, Jiang 
Su Province, China.
Background: Diabetic nephropathy(DN)was considered as a chronic inflammatory 
disease. Inflammation plays critical roles in the progression of DN. This study investigated 
the role of CXC chemokine ligand 16 (CXCL16)/CXC chemokine receptor 6 (CXCR6) 
pathway in DN under inflammatory stress and explored its potential mechanisms modulated 
by purinergic receptor P2X ligand-gated ion channel 7 (P2RX7).
Methods: Diabetic db/db mice were randomly divided into two groups: db/db, and 
db/db+casein for eight weeks. Casein was subcutaneously injected to induce chronic 
inflammation. The morphological change of renal pathology and ultra-microstructure were 
checked by pathological staining and electron microscopy. Lipid accumulation in kidneys 
was observed by Filiping staining and quantitative assay of intracellular free cholesterol. 
The expression of CXCL16/CXCR6 pathway, inflammatory cytokine, and fibrotic index 
related molecules were detected by immunohistochemistry, immunofluorescent staining, 
and Western Blot.
Results: The 24-hour urinary protein, tubulointerstitial injury, inflammatory cell 
infiltration, and the protein expression of monocyte chemotactic protein 1(MCP-1), tumor 
necrosis factor α (TNFα), CD68, a-Smooth muscle actin (α-SMA), and fibronectin (FN)
in kidneys of db/db+casein mice were significantly increased compared with the db/db 
mice. Furthermore, there was significant lipid accumulation, increased protein expression 
of CXCL16 and CXCR6 and decreased disintegrin and metalloproteinase-10(ADAM10) 
expression in kidneys of db/db+casein mice compared with db/db mice, accompanied 
with increased P2X7R expression. Further analysis demonstrated that there was a positive 
correlation between P2X7R and CXCL16 expression.
Conclusions: Inflammation accelerates tubulointerstitial injury in DN partly through 
the activation of CXCL16/CXCR6 pathway, which may facilitate inflammation induction 
and lipid accumulaton in cells. The P2X7R pathway may be involved in the activation of 
CXCL16/CXCR6 pathway.
SA-PO397
Albumin Glycation Induces Structural Changes That Reduce Proximal 
Tubule FcRn-Albumin Binding and Reclamation  Mark C. Wagner,1 Jered 
Myslinski,1 Shiv Pratap Singh Yadav,3 George Rhodes,1 Ruben M. Sandoval,1 
Sudhanshu Kumar,1 Sarah E. Wean,1 Fnu Ashish,3 Bruce A. Molitoris.1,2 
1Nephrology Div, Dept of Medicine, Indiana Univ School of Medicine, 
Indianapolis, IN; 2Cellular & Integrative Physiology, Indiana Univ School of 
Medicine, Indianapolis, IN; 3CSIR-Inst of Microbial Technology, Chandigarh, 
India.
Background: Diabetic nephropathy remains the leading cause of chronic kidney 
disease (CKD) and ESRD. It results in increased albumin glycation and this is believed to 
be involved in proximal tubule cell injury and the pathophysiology of interstitial fibrosis 
and CKD progression.
Methods: To understand the mechanisms we have addressed specific in vitro albumin 
modifications and their impact on albumin-FcRn binding since proximal tubule FcRn is 
necessary for transcytosis and reclamation of filtered albumin.
Results: Those studies showed markedly reduced binding to FcRn when albumin 
was glycated proportional to the level of glycation. To address the mechanism for reduced 
binding we used SAXS analysis and molecular modeling to determine structural changes. 
SAXS data analysis revealed significant shape changes occur to albumin upon glycation 
which affected its binding affinity to FcRn.Our prediction would be that albumins with 
weaker FcRn binding would have more rapid serum clearance implying increased Pt 
catabolism via lysosomal degradation. Prior to evaluating modified albumin, control albumin 
was labeled with multiple fluorophores to determine conjugation ratios and dyes that retained 
normal pH dependent FcRn binding and would thus permit accurate serum clearance to 
be evaluated. The results agreed with our prediction and we are presently evaluating the 
serum clearance for the glycated albumins that have been conjugated to a fluorescent probe.
Conclusions: The data indicate modifications to albumin lead to structural alterations 
resulting in reduced PT pH dependent FcRn binding, which alters lysosomal catabolism 
leading to transcytosis and reclamation resulting in a shorter serum half life and may mediate 
the enhanced interstitial inflammation and fibrosis in diabetic nephropathy.
Funding: NIDDK Support
SA-PO398
The Efects of Glucagon-Like-Peptide-1 and Vitamin D on Inflammatory 
and Histological Changes of Diabetic Nephropathy in db/db Mice 
Yael Einbinder,1,2 Sydney Benchetrit,1,2 Tali Zitman-Gal.1  1Renal Physiology 
Laboratory, Dept of Nephrology and Hypertension, Meir Medical Center, Kfar 
Saba, Israel; 2Sackler Faculty of Medicine, Tel Aviv Univ, Tel Aviv, Israel.
Background: Glucagon-like-peptide-1 is a gut incretin hormone that stimulates insulin 
secretion and may affect the inflammatory pathways involved in type 2 diabetes mellitus 
(DM). Calcitriol plays an important role in renal, endothelial, and cardiovascular protection. 
We evaluated the anti-inflammatory and histological effects of GLP-1 and calcitriol in a 
db/db mice diabetic model.
Methods: C57BL/6 (WT) and BKS.Cg-Dock7m +/+ Leprdb/db (db/db) mice were 
randomized to: a) WT mice; b) db/db mice (diabetic control group); c) db/db mice+GLP-1 
analog (100 nmol/kg); and d) db/db mice+GLP-1 analog +calcitriol (250 ng/kg). Blood 
glucose levels and weight were evaluated weekly. At the end of the14-week treatment, 
kidneys were perfused and removed for protein analysis and histology.
Results: Blood glucose levels and weight were significantly higher in db/db mice 
compared to control WT mice. Blood glucose level was non-significantly lower in the db/
db GLP-1 group compared to untreated db/db mice (460.5±83.2 mg/dl vs. 526.3±33.3 mg/
dl). GLP-1 treatment significantly up-regulated eNOS protein expression and significantly 
down-regulated p65 protein expression compared to the db/db control group. Vitamin D 
did not further improve the beneficial effect observed on protein expression. Kidney VDR 
protein expression increased only in the vitamin D group compared to the db/db control 
group. Kidney histology demonstrated beneficial effect of GLP-1 treatment on golmerular 
hypertrophy in db/db mice at 26 weeks of age but had no significant effect on the severity 
of mesangial expansion.
Conclusions: In the experimental model of diabetic nephropathy (db/db mice), GLP-
1analog treatment improved the protein expression involved in the inflammatory response 
and significantly ameliorated the glomerular hypertrophy seen in the diabetic control group.
Funding: Private Foundation Support
SA-PO399
Mineral Metabolism and Interleukin-6: Predictive Risk Factors for 
Left Ventricular Hypertrophy in Patients with Diabetic Nephropathy 
Teresa M. Jeronimo,1 André Fragoso,1 Filipa Brito Mendes,1 Ana Paula Silva,1,2 
Ana Pocinho Pimentel,1 Nelson Tavares,3 Pedro L. Neves.1,2  1Nephrology, 
Centro Hospitalar do Algarve, Faro, Portugal; 2Dept of Biomedical Sciences 
and Medicine, Univ of Algarve, Faro, Portugal; 3Cardiology, Centro Hospitalar 
do Algarve, Faro, Portugal.
Background: Left ventricular hypertrophy (LVH) is an important risk factor for 
cardiovascular disease in patients with diabetic nephropathy (DN) and is an independent 
predictor of mortality in patients with chronic kidney disease (CKD). The aim of this study 
was to evaluate the predictive risk factors of LVH in a population of patients with DN.
Methods: The authors analysed the relationship of LVH with gender, body mass 
index (BMI), systolic blood pressure (SBP), estimated glomerular filtration rate (eGFR), 
albumin, cholesterol, hemoglobin (Hb), calcium, phosphorus, parathyroid hormone (PTH), 
urine albumin-to-creatinine ratio (UACR), interleukin-6 (IL-6), hemoglobin A1c (HbA1c) 
and insulin resistance (HOMA-IR). Descriptive statistics, Student’s t-test and logistic 
regression model were used.
Results: In a cross-sectional study were included 119 type 2 diabetic patients with 
CKD stages 3 and 4. Patients with LVH had significant lower values of eGFR and albumin, 
higher levels of UACR, HOMA-IR and IL-6. Phosphorus (odd ratio (OR) = 0.602 (1.075-
4.414), p = 0.038), PTH (OR = 1.009 (1.098-3.000), p = 0.004) and IL-6 (OR = 1.264 
(1.863-6.719), p = 0.0001) were independently related with LVH. 
Variable Adjusted OR (95% CI) p-Value
Gender -1.012 (0.064-2.076) 0.255
Age 0.032 (0.890-1.053) 0.455
BMI 0.170 (0.969-1.448) 0.098
SBP -0.008 (0.944-1.043) 0.757
eGFR -0.026 (0.930-1.021) 0.279
Albumin -0.021 (0.137-7.012) 0.983
Hb 0.242 (0.770-2.106) 0.347
Phosphorus 0.602 (1.075 -4.414) 0.038
iPTH 1.009 (1.098-3.000) 0.044
UACR -0.001 (0.993-1.006) 0.865
HOMA-IR 0.422 (0.746-3.114) 0.247
IL-6 1.264 (1.863-6.719) 0.0001
Multivariate logistic regression model — risk factors of LVH.
Conclusions: Phosphorus, PTH and IL-6 were independent risk factors of LVH in our 
diabetic population with CKD stages 3 and 4.
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SA-PO400
Far-Infrared Therapy Retrieves Pancreatic Beta Cell Function and Survival 
in a Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mouse Model 
Yung-Ho Hsu,1 Tso Hsiao Chen,2 Cheng-hsien Chen.1,2  1Div of Nephrology, 
Dept of Internal Medicine, Shuang Ho Hospital, Taipei Medical Univ, Taipei, 
Taiwan; 2Div of Nephrology, Dept of Internal Medicine, Wan Fang Hospital, 
Taipei Medical Univ, Taipei, Taiwan.
Background: In diabetes, the apoptotic cell death of insulin-producing beta cells 
leads to insulin deficiency. Recently, we found low-temperature far-infrared (FIR) 
irradiation increased proliferation and survival of human umbilical vein endothelial cells 
via promyelocytic leukaemia zinc finger protein (PLZF)-mediated PI3K/Akt activation.
Methods: In this study, we investigate the protective effects of FIR on pancreatic beta 
cell function and survival in the nicotinamide (NA) and streptozotocin (STZ)-induced type 
II diabetic mouse model. ells via promyelocytic leukaemia zinc finger protein (PLZF)-
mediated PI3K/Akt activation.
Results: The present study showed that FIR therapy decreased non-fasting blood 
glucose levels and increase blood insulin levels in diabetic mice in a dose-dependent manner. 
Immunohistochemistry staining revealed that FIR therapy retrieved insulin production of 
pancreatic beta cells in diabetic mice. But the influence of FIR on blood glucose and insulin 
levels was not found in NA/STZ-treated PLZF-knockout mice. We also used the insulin-
secreting beta cell line RIN-m5f to investigate the protective effects of FIR in vitro. FIR 
irradiation promoted cell proliferation and inhibited STZ-induced apoptosis in RIN-m5f 
cells. FIR also induced PLZF nuclear translocation and increased PI3K expression and 
Akt phosphorylation in RIN-m5f cells. PLZF siRNA transfection inhibited the influence 
of FIR on RIN-m5f cells.
Conclusions: Our data suggest that FIR therapy retrieves pancreatic beta cell function 
and survival in diabetic mice via a PLZF-mediated pathway.
SA-PO401
Transgenic Mice Overexpressing Human CD39 (ENTPD1) Are 
Protected from High-Fat Diet-Induced Obesity and Insulin Resistance 
Anna U. Brandes,1 Yue Zhang,1 Kristina M. Heiney,1 Simon C. Robson,2 
Bellamkonda K. Kishore.1  1Internal Medicine, Univ of Utah & VA Med Ctr, 
Salt Lake City, UT; 2Internal Medicine, BIDMC, Harvard Univ, Boston, MA.
Background: CD39 is a vascular ecto-nucleotidase that sequentially hydrolyzes 
extracellular ATP to ADP and AMP, thus terminating P2 receptor signaling. Previously 
we reported that deletion of Cd39 results in hepatic insulin resistance (IR). We also found 
that deletion of ATP/UTP activated P2Y2-R confers significant protection against high-fat 
diet (HFD)-induced obesity and IR. Hence, we hypothesized that global overexpression of 
human CD39 (hCD39), which decreases the availability of extracellular nucleotides should 
attenuate development of HFD-induced obesity and IR.
Methods: Groups of age-matched adult wild type C57/Bl6 (WT) and syngeneic 
transgenic (TG) mice globally overexpressing hCD39 were fed regular diet (10% calories 
as fat; n = 5) or HFD (60% calories as fat; n = 7) with free access to food and water for 10 
weeks. Body weights (BW), food and water consumption and urine output were monitored 
periodically. Glucose tolerance (GTT) and insulin sensitivity (IST) tests were conducted 
between 8 to 10 weeks.
Results: In response to HFD feeding, both genotypes showed significant increases 
in BW over the experimental period as compared to their counter parts fed regular diet. 
However, the gain in BW was significantly less in TG vs. WT mice (mean 21.5 ± 0.3 
vs. 15.3 ± 2.0 g, n = 7, p = 0.005). There were no significant differences between the 
genotypes in the amount of food consumed, nor was there evidence of steatorrhea indicating 
malabsorption. Fasting blood glucose levels in HFD fed TG mice were 2-fold higher vs. 
WT mice (179 ± 12 vs. 88 ± 5 mg/dL, n = 7, p = 0.0001). When fed HFD, both genotypes 
exhibited glucose intolerance, but this was less severe in TG mice. In parallel, insulin 
sensitivity was significantly better in HFD-fed TG vs. WT mice.
Conclusions: Our results demonstrate that overexpression of hCD39 confers significant 
protection against the development of HFD-induced obesity and IR, and thus validating 
the proposition that dominantly deleterious roles are played by extracellular nucleotides 
in metabolic homeostasis.
Funding: Veterans Administration Support
SA-PO402
Mass Spectrometry Imaging Reveals a Role for Glomerular Sphingomyelin 
to Suppress AMPK Activity by Stimulating ATP Production in Mesangial 
Cells  Satoshi Miyamoto,1,2,3 Cheng-Chih Hsu,4 Gregory Hamm,5 Manjula 
Darshi,1,2 Jonathan Stauber,5 Pieter Dorrestein,1,4 Kumar Sharma.1,2,3  1Inst of 
Metabolomic Medicine, Univ of California San Diego, La Jolla, CA; 2Center 
for Renal Translational Medicine, Univ of California San Diego, La Jolla, CA; 
3Veterans Affairs San Diego Healthcare System, La Jolla, CA; 4Therapeutic 
Discovery Mass Spectrometry Center, Univ of California San Diego, La Jolla, 
CA; 5ImaBiotech, MS Imaging Dept, Lille, France.
Background: We have recently shown that the ATP/AMP ratio is increased in the 
glomeruli in a mouse model of type 1 diabetes by matrix-assisted laser desorption/ionization 
mass spectrometry imaging (MALDI-MSI) and may be the basis for reduced AMP-activated 
protein kinase (AMPK) in diabetic glomeruli. Here, we applied MALDI-MSI to identify a 
key molecule involved in the regulation of glomerular ATP.
Methods: For MALDI-MSI, 23 weeks-aged male diabetic Akita (C57BL/6J-Ins2Akita) 
(A), wild type mice (W), and a normal human kidney (H) were used. For cell culture study, 
murine mesangial cells (MMCs) were treated with sphingomyelin(d18:1/16:0) (SM)-
containing liposomes (SL), control liposomes (CL) and vehicle. For ATP measurements, 
MMCs were transfected with sphingomyelin synthase (SMS)1, 2 or control siRNA before 
treatment with liposomes.
Results: By MALDI-MSI, we found that SM(d18:1/16:0) was preferentially distributed 
in the glomeruli in W and H. Importantly, we found that SM is more abundant in glomeruli 
of A compared with W, and associated with increased SMS1 and 2 in the glomeruli 
(p<0.05). SL stimulated ATP production in MMCs compared with CL (p<0.01), and 
was inhibited by siRNA based inhibition of SMSs. AMPKα activity and PGC1α protein 
expression were significantly reduced by SL (p<0.05). In addition, SL increased glucose 
consumption and lactate production in high glucose conditions (p<0.05) suggesting a role 
for enhanced glycolysis.
Conclusions: We demonstrate using MALDI-MSI that the accumulation of glomerular 
SM in type 1 diabetic mice is associated with increased ATP in glomeruli and may contribute 
to reduced AMPK activity in diabetes. These findings suggest that reduction of SM may 
lead to novel therapeutic targets for the treatment of diabetic kidney disease.
Funding: NIDDK Support, Other NIH Support - DP3DK094352-01, Veterans 
Administration Support
SA-PO403
Chronic Hyperglycemia Activates Authophagy Through an Increased 
Lysine-63 Linked Ubiquitination: A Candidate Mechanism in the 
Progression of Tubular Damage in Diabetic Nephropathy  Paola Pontrelli, 
Annarita Oranger, Mariagrazia Barozzino, Francesca Conserva, Massimo 
Papale, Matteo Accetturo, Maria Teresa Rocchetti, Giuseppe Castellano, Loreto 
Gesualdo.  Dept of Emergency and Organ Transplant, Nephrology Unit, Univ 
of Bari, Italy.
Background: Chronic hyperglycemia, a key pathogenic factor of diabetic nephropathy 
(DN), can alters autophagy whose role in tubular cells under hyperglycemic conditions (HG) 
remains unclear. We reported that lysine63-ubiquitination (K63-Ub) plays a key role in 
the progression of tubular damage in DN; moreover K63-Ub promotes protein autophagic 
clearance. Aim of our study was to: evaluate the HG effect in modulating autophagy in 
tubular cells (HK2); evaluate in vivo the autophagy state in patients with diabetes without 
renal damage and in different DN classes; investigate the K63-Ub role in the modulation 
of tubular cells autophagy.
Methods: K63-Ub was inhibited in HK2 under HG (30mM) by UBE2v1 silencing, 
E2 enzyme involved in K63-Ub, or by NSC697923 inhibitor. The expression of the 
authophagic factor LC3 was detected by western blotting and confocal microscopy. 
Immunohistochemistry (IHC) and immunofluorescence (IF) were performed on kidney 
biopsies of 3 control patients, 3 diabetic, 9 DN (classes IIb, III and IV).
Results: HK2 showed a significant increase in LC3 protein after 24h of HG. UBE2v1 
silencing completely abolished LC3 induced protein expression after 24h of HG. Confocal 
microscopy showed the reduction of autophagic vesicles induced by HG in the presence of 
the K63-Ub inhibitor (NSC697923). IHC on kidney biopsies revealed an increased tubular 
expression of LC3 in diabetic patients vs controls, that persists in all DN classes and class 
IV patients showed cytoplasmic accumulation of fused-vesicles. The same tubules with 
activated autophagy, expressed K63-Ub proteins both in diabetic and in DN patients (IF).
Conclusions: In conclusion, our data demonstrate that chronic hyperglycemia induces 
an increase in autophagy, linked to the accumulation of K63 ubiquitinated proteins. However, 
uncontrolled autophagy levels could lead to tubular damage through the generation of 
intracellular vesicles, bringing to the progression of renal damage in DN patients.
SA-PO404
Abstract Withdrawn 
SA-PO405
Complexome Profiling of Mitochondrial Respiratory Chain Proteins from 
Podocytes of Diabetic Mice  Zengchun Ye, Shawn S. Badal, Daniel L. Galvan, 
Jianyin Long, Farhad R. Danesh.  Section of Nephrology, The Univ of Texas MD 
Anderson Cancer Center, Houston, TX.
Background: Mitochondria play essential roles in many aspects of biology, and 
their dysfunction has been linked to diverse diseases, including diabetic nephropathy 
(DN). Central to proper mitochondrial function is oxidative phosphorylation (OXPHOS), 
coordinated by respiratory chain complexes encoded by both nuclear and mitochondrial 
genomes. Whether alterations in specific OXPHOS complex protein expression/activity 
contribute to mitochondrial dysfunction in DN remain largely unknown.
Methods: To asses complexome profiles, mitochondria were isolated from 
podocytes of16-week-olddiabetic (db/db) and nondiabetic (db/m) mice. Blue Native Gel 
Electrophoresis (BNE) was coupled with quantitative mass spectrometry (nano-HPLC/ESI/
MS/MS) to identify known and unknown macromolecular protein complexes.
Results: We identified a total of 1216 mitochondrial proteins. Complexome 
profilingrevealed mitochondrial complexes I and III to be markedly reduced in podocytes 
of db/db compared to controls. Consistent with MS results, Complex I activity was 
significantly reduced in podocytes of db/db mice compared to controls. Importantly, we 
found that the protein expression levels of Ndufb2, Ndufb3 and Ndufb8, all components 
of complex I, were significantly reduced in podocytes of db/db mice. We further validated 
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our initial results and found that the podocyte-derived mitochondria from diabetic db/db 
mice display markedly reduced message and protein expression levels of Ndufb8. These 
changes are coincident with significantly decreased Complex I activity from analogously 
isolated and processed mitochondria derived from db/db mice.
Conclusions: Our study uncovers a previously unrecognized role of complex I in 
the pathogenesis of DN. We propose that deficiencies in components of complex I may 
disrupt complex I assembly, eventually reducing mitochondrial oxidative metabolism of 
podocytes in diabetic kidney disease. Further genetic studies are currently underway in 
our laboratory to establish the value and limitations of using Ndufb8 transgenic mice in 
experimental models of diabetes as a model for targeting mitochondrial dysfunction in DN.
Funding: NIDDK Support
SA-PO406
Hyperglycemia and Hyperinsulinemia Increased Cell Proliferation and 
Regulated DNA Damage/Repair Pathways in Type II Diabetic (db/db) 
Mouse  Samy L. Habib,1,2 Sitai Liang.1,2  1Geriatric Research, Education 
and Clinical CTR, South Texas Veterans Health System, San Antonio, TX; 
2Cellular and Structural Biology, The Univ of Texas Health Science Center, 
San Antonio, TX.
Background: The mechanisms by which hyperglycemia and/or hyperinsulinemia 
activate cell proliferation to regulate the DNA damage/repair pathways and increase renal 
cell damage in diabetes remain unclear.
Methods: In the current study, we investigated the role of hyperglycemia and 
hyperinsulinemia in regulating cell survival and cell proliferation to regulate the DNA 
damage/repair pathways the in type II diabetic (db/db) mouse.
Results:    Significant increase in proteinuria, albuminuria, creatinine in 24h urine 
as well as in serum insulin was detected in db/db mice compared to wild type mice. Cell 
proliferation was measured by Ki67 staining and PCNA expression in kidney sections of 
diabetic and wild type mice. Data showed significant increase of Ki67 staining and protein 
expression of PCNA in kidney of diabetic mice compared to wild type mice. The activity 
of survival kinase Akt (measured by phospho-Akt at Ser473) was significantly increased 
and associated with increased activation of mTORC1 (measured by phosphor-p70S6K at 
Thr389) in kidney cortex of db/db mice compared to wild type mice by Western blot analysis. 
DNA repair OGG1 and the transcription factor regulates OGG1 (Nrf2) were significantly 
decreased and associated with increased in oxidative DNA damage (8-oxodG) in kidney 
homogenate from db/db mice compared to wild type mice. Gel shift analysis shows 
reduction of Nrf2 binding to OGG1 promoter in nuclear extracts of kidney homogenate 
of db/db mice compared to wild type mice. A portion of the DNA-protein complexes was 
significantly decreased in the presence of the Nrf2 antibody indicating that Nrf2 is indeed 
a component of these complexes.
Conclusions: In summary, our data provide a novel mechanism of increase renal 
cell damage through decrease binding of Nfr2 to the OGG1 promoter and consequence 
deficiency in DNA repair that lead to accumulate DNA damage and lead to renal 
complications under hyperglycemia and hyperinsulinemia condition in diabetic mice.
Funding: Veterans Administration Support
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Spleen Tyrosine Kinase Activation Promotes the Progression of Diabetic 
Nephropathy in the Early Stage  Fei Liu.  Nephrology, West China Hospital 
of Sichuan Univ, Chengdu, Sichuan, China.
Background: Inflammation triggered by metabolic disorder has played an important 
role in the pathogenesis of diabetic nephropathy (DN) in the early stage.The inflammatory 
cytokines binding to immunoglobulin G Fc receptors (FcgRs) in the surface of cell contribute 
to the progression of inflammation. It was found in our previous study that there was an 
increased expression of FcgRs with an immunoreceptor tyrosine-based activation motif 
(ITAM-FcgRs) in the kidney of diabetic CRP-Tg mouse induced by streptozotocin (STZ). 
It was also observed that ITAM-FcgRs were increased and spleen tyrosine kinase (SYK) 
were activated in rat glomerular mesangial cells (GMC) cultured with high glucose. SYK 
is a cytoplasmic nonreceptor tyrosine kinase and plays critical role in intracellular signal 
transduction of ITAM-FcgRs. It has been established that activated SYK signal cascade 
leads to the pro-inflammatory cytokines production in antibody-dependent kidney disease. 
However, the role of SYK in the progression of DN remains unclear. The present study 
investigated the potential role of SYK activation in the early stage of DN.
Methods: Diabetes was induced by STZ in Sprague Dawley (SD) rats for assessment 
of kidney injury at 2, 4, 8weeks by real-time PCR, immunohistochemistry and western 
blot analysis. In vitro, the pathogenic effect of SYK was observe.
Results: Compared with control, urinary albuminexcretion significantly increased 
in diabetic SD rats at 2, 4 and 8 weeks after STZ injection. Renal inflammation has been 
developed with enhanced infiltration of macrophages and T cells, and upregulation of pro-
inflammatory cytokines (IL-1β, TNFα) in diabetic rats. Enhanced renal inflammation in 
diabetic rats caused the increase of SYK phosphorylation and the over-activation of nuclear 
factor κB (NF-κB) signaling pathway. In vitro, high glucose significantly upregulated pro-
inflammatory cytokines (IL-1β, TNFα) via SYK cascade, which further promoted high 
glucose-mediated renal inflammation.
Conclusions: These findings suggested that SYK may be as “signal switch” to activate 
NF-κB signaling pathway and promote the progression of renal injury in the early stage 
of DN.
Funding: Government Support - Non-U.S.
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Smooth Muscle Specific Heavy Chain Ferritin Knockout Mice as a 
Model of Obesity  Vyvyca Walker, Bo Chen, Reny Joseph, Anupam Agarwal. 
Nephrology Research and Training Center, Div of Nephrology, Univ of Alabama 
at Birmingham, Birmingham, AL.
Background: Ferritin, consisting of heavy (H) and light (L) chain subunits, is a highly 
conserved ubiquitous protein that safely sequesters iron in a non-toxic form. During the 
course of our studies to evaluate the role of heavy chain ferritin (FtH) in a model of vascular 
calcification in CKD, we generated a transgenic mouse using the cre-lox system with 
smooth muscle cell-specific deletion of FtH (FtHSM22-/-). Serendipitously, we discovered the 
FtHSM22-/- mice gained more weight compared to control “floxed” FtH mice and exhibited 
features resembling metabolic syndrome.
Methods: To characterize FtHSM22-/- mice as a model of obesity, male FtHSM22-/- mice 
and FtHSM22+/+ control mice were individually housed from 6-28 weeks of age to monitor 
weight, food intake, and body composition utilizing quantitative magnetic resonance (QMR) 
imaging. Protein analysis was performed on skeletal muscle and fat to determine expression 
levels of insulin signaling mediators and iron regulators. RNA analysis of inflammatory 
markers expressed in white fat was also performed.
Results: At 28 weeks old, FtHSM22-/- mice gained more weight (30.58g ± 2.02 vs. 
27.72g ± 1.06 controls) during the observation period and consumed significantly more 
food starting at 20 weeks of age than the controls. QMR studies revealed that FtHSM22-/- 
mice had slightly more fat, lean and water mass compared to controls. Protein analyses 
of skeletal muscle and white fat revealed a loss of GLUT4 expression and iron trafficking 
proteins, respectively, in transgenic mice. Moreover, there was an increase in tissue iron 
concentration and gene expression of TNFα in the fat tissue of FtHSM22-/- mice compared 
to controls. Interestingly, review of publically available microarray data sets (NCBI, GEO 
data set GDS3876) derived from human samples suggest a significant (~1.5 fold) increase 
in FtH gene expression in obese individuals compared to lean controls.
Conclusions: Over a third of the adults in the United States are obese. Obesity 
predisposes individuals to other health risks, including CKD, diabetes, stroke, and 
cardiovascular disease. Our studies provide a novel mouse model for obesity.
Funding: NIDDK Support, Veterans Administration Support
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The Induction and Role of p53 in Tubular Cell Apoptosis During High 
Glucose Treatment and Diabetes  Lin Li,1,2 Zhengwei Ma,1 Changlin Mei,2 
Zheng Dong.1  1Dept of Cellular Biology and Anatomy, Georgia Regents Univ, 
Augusta, GA; 2Dept of Nephrology, Shanghai Changzheng Hospital, 2nd Military 
Medical Unversity of PLA, Shanghai, China.
Background: p53, known as a tumor suppressor, plays a crucial role in the cellular 
response to various stresses. P53 has been implicated in diabetic kidney disease but its role 
remains unclear and controversial.
Methods: Kidneys from Akita mice and STZ-treated diabetic mice were collected for 
in vivo studies. In vitro, renal proximal tubular cells (RPTC) with or without p53 dominant 
negative (p53-DN) were cultured in medium containing 5.5 mM or 30 mM glucose. 
Apoptosis was evaluated by morphologic observation, TUNEL, and flow cytometric 
analysis. The cells were also fractionated to investigate the subcellular redistributions of 
Bax and cytochrome c. The expression of p53, phosphorylated-p53 and apoptosis-related 
proteins were examined by western blot, immunohistochemistry/immunocytochemistry 
and immunofluorescence.
Results: Apoptosis was detected in renal tubules within a few weeks of diabetes, 
which was accompanied by p53/p-p53 expression. In cultured RPTC cells, high glucose 
induced apoptosis and p53. In these cells, there were Bax translocation to the mitochondria 
and cytochrome c release. Interestingly, these changes and apoptosis were attenuate in 
p53-DN cells. Consistently, they were also suppressed by pifithrin-α, a pharmacological 
inhibitor of p53.
Conclusions: These results suggest that p53 may be an upstream mediator of tubular 
cell apoptosis during high glucose treatment and in diabetic kidneys. P53 is induced under 
these conditions and may activate the mitochondrial pathway of apoptosis.
Funding: NIDDK Support, Veterans Administration Support, Government Support 
- Non-U.S.
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Mechano-Growth Factor Regulates mTOR and Other Growth Factor 
Expression in Mouse Mesangial Cells, Enhancing Cell Proliferation 
and Extracellular Matrix Production: Implications for Diabetic 
Glomerulosclerosis  Yongxin Gao, Leighton R. James, Charles W. Heilig. 
Medicine, Univ of Florida College of Medicine-Jacksonville, Jacksonville, FL.
Background: MGF-S mesangial cells (MC) overexpress Mechano-Growth Factor 
protein 13.2-fold, with increased GLUT1, glucose uptake, cell proliferation and extracellular 
matrix (ECM). Here we examined mTOR expression and downstream S6 kinase 
activation, VEGF and TGF beta1 in our MGF-EV empty vector control MC, MGF-S MC 
overexpressing MGF, and MGF-AS MC with suppressed MGF.
Methods: Western analyses for selected proteins in cultured MGF-EV, MGF-S and 
MGF-AS were performed with specific antibodies and band densities normalized to 
endogenous beta-tubulin. 3H2-Deoxyglucose (3H2-DOG) uptake rates were determined 
as we have previously published. P<.05 was considered significant in statistical analyses.
Results: MGF-S exhibited persistent stimulation of VEGF expression 1.6-fold the 
MGF-EV control. mTOR expression increased 7.7-fold vs MGF-EV, leading to activation 
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of S6 kinase ( phospho-S6 kinase) protein 8.7-fold. This increase in mTOR and active S6 
kinase correlated with an increased proliferation rate of MGF-S vs. MGF-EV. MGF-AS 
had suppressed mTOR by 69%, but suppressed active S6 kinase by an insignificant amount. 
VEGF expression was suppressed 60% in MGF-AS vs MGF-EV. TGF beta1 protein was 
increased 1.8-fold in MGF-S, and reduced 46% in MGF-AS. GLUT1 protein in MGF-S 
was increased 7.2-fold, with a 10.6-fold increased 3H2-DOG uptake rate. In contrast, 3H2-
DOG uptake was suppressed 85% in MGF-AS vs. MGF-EV. In MGF-S, Type IV collagen 
(Col-IV) was increased 4.2-fold.
Conclusions: MGF-S MC demonstrate increased mTOR with S6 kinase activation, 
consistent with their enhanced proliferation rate, while the increased VEGF and TGF beta1 
promote Col-IV protein expression. Overexpression of MGF in MC to mimic events in 
diabetic glomeruli recreates many features of high glucose-exposed MC. MGF-AS MC 
demonstrate a role for MGF in basal VEGF and TGF beta1 expression.
Funding: Pharmaceutical Company Support - Dialysis Clinics Inc.
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High Fat and High Sucrose Diet Induce Steatohepatitis That Is Dependent 
on Fructokinase  Takuji Ishimoto,1 Miguel A. Lanaspa,2 Shoichi Maruyama,1 
Richard J. Johnson.2  1Nephrology, Nagoya Univ of Graduate School of Medicine, 
Nagoya, Aichi, Japan; 2Renal Diseases and Hypertension, Univ of Colorado 
Denver, Aurora, CO.
Background: High fructose intake from added sugars, which are high in Western diet, 
correlates with the epidemic rise in obesity, metabolic syndrome, nonalcoholic fatty liver 
disease, and chronic kidney disease. However, the interaction of fructose with high fat 
intake, which is also rich in Western diet, remains unclear. Here we tested the interaction 
between fructose and fat, and determined whether if this was dependent on a primary 
enzyme in fructose metabolism, fructokinase.
Methods: Wild type mice and fructokinase knockout mice (C57BL6/J background, 
male) were assigned to one of three groups (n = 8–9) respectively, matching mean body 
weight among the groups. Mice had free access to tap water, and a low fat (11%, LFD), 
high fat (36%, HFD) or high fat (36%) and high sucrose (30%) diet (HFHSD) for 15 weeks. 
Urine samples were collected at 13 weeks using metabolic cages. At 15 week, blood was 
withdrawn, and tissues including kidney and liver were taken after 6 h fasting.
Results: Both wild type mice fed HFD and fructokinase knockout mice fed HFD 
developed obesity with mild hepatic steatosis without hepatic inflammation compared 
to mice fed LFD. In contrast, wild type mice fed HFHSD developed more severe hepatic 
steatosis and low grade inflammation and fibrosis in pathological analysis, but not in 
fructokinase knockout mice. Increased CD68, TNF-alpha, MCP-1, alpha-smooth muscle 
actin, and collagen I and TIMP1 expression were found in wild type mice fed HFHSD. 
These changes were prevented in the fructokinase knockout mice. Meanwhile, there was no 
significant change of urinary protein and urinary NGAL, and no apparent renal pathological 
change among groups.
Conclusions: This study demonstrated an additive effect of high fat and high sucrose 
diet on the development of hepatic fat accumulation. Furthermore, the combination of 
sucrose with high fat diet may induce steatohepatitis. These results indicates the important 
role of fructose in the development of fatty liver and nonalcoholic steatohepatitis.
Funding: NIDDK Support
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The Succinate Receptor 1 Contributes to Obesity-Induced Type II Diabetes 
and Chronic Kidney Disease  Peter M.T. Deen,1 Claudia Carmone,1 Janna A. 
Van diepen,3 Joris Hubertus Robben,1 Ana Carolina Ariza,1 Olivier Devuyst,2 
Rinke Stienstra.3  1Physiology, Radboud Univ Medical Center, Nijmegen, 
Netherlands; 2Physiology, Univ of Zürich, Zürich, Switzerland; 3Internal 
Medicine, Radboud Univ Medical Center, Nijmegen, Netherlands.
Background: Cell stress-induced release of mitochondrial succinate and activation of 
its SUCNR1 receptor in the macula densa is essential for type I diabetes mellitus (T1DM)-
related renin release and hypertension. Obesity-induced T2DM and Chronic Kidney 
Disease (CKD) are aggravated by hypertension and go with cell stress in adipose/kidney 
tissue and macrophages, which express SUCNR1. Here we tested the role of SUCNR1 in 
obesity-induced T2DM and CKD.
Methods: Wild-type (wt) and SUCNR1-/- mice were fed a low fat diet (LFD; 10%) 
or high (H) FD (60%). At different weeks, mice were weighed, and subjected to metabolic 
cages (electrolyte measurements), glucose tolerance tests (GTT). Mice were sacrificed and 
blood and tissues collected.
Results: Blood succinate was increased in diabetic patients versus healthy controls. 
Isolated adipose tissue of wt and SUCNR1-/- mice revealed increased succinate release 
with hypoxia or high glucose. 16 weeks LFD/HFD showed similar body, adipose tissue and 
kidneys weight gain for both HFD groups, but liver and heart weight gain was reduced in 
HFD SUCNR1-/- versus wt mice. Starving glucose levels were similarly increased in both 
HFD groups, but SUCNR1-/- mice had a better GTT response. Inflammatory signals and 
macrophage infiltration was higher in adipose tissue of wt than SUCNR1-/- HFD mice. 
Bone marrow derived cells of SUCNR1-/- mice migrated less efficient towards chemotaxic 
signals from diabetic/hypoxic 3T3 cells. Blood sodium and urine volumes were similarly 
decreased and eGFR increased in both HFD groups versus LFD controls. However, only 
HFD wt mice showed albuminuria, elevated collagen IV expression, and some increase in 
inflammatory gene expression in the kidney.
Conclusions: SUCNR1-mediated chemotaxis of macrophages to affected adipose 
tissue and, possibly, increased SUCNR1-mediated hypertension, contributes to obesity-
induced T2DM and CKD development. If similar in humans, the SUCNR1 may form a 
novel therapeutic target for T2DM and CKD.
Funding: Government Support - Non-U.S.
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Fluoxetine Disrupts E-Cadherin-Mediated Cell Adhesion and Calcium 
Homeostasis in Pancreatic β Cells  Yun-wen Chen,1 Huang-Yu Chang.1 
1Pharmacology, National Cheng Kung Univ, Tainan, Taiwan; 2Pharmacology, 
National Cheng Kung Univ, Tainan, Taiwan.
Background: Major depressive disorder (MDD) is a common psychiatric illness and 
it affects as many as 840 million people.MDD and Type 2 diabetes (T2D) are disorders 
with mutual risk factors identified in prevalence study reports. Antidepressant treatment 
could be another critical factor affecting the bidirectional associations between MDD and 
T2D. Long-term use of selective serotonin reuptake inhibitors (SSRIs), the most commonly 
prescribed class of antidepressants, is associated with an increased risk of developing T2D. 
E-cadherin mediated cell-cell adhesion has been linked to diseases such as cancer and 
diabetes. Loss of cell-cell adhesion in beta cells decreases insulin secretion.
Methods: Here we examine the effects of the SSRI fluoxetine (Prozac®) on beta 
cell function employing MIN6 cells, a mouse beta cell line, to elucidate the underlying 
molecular mechanisms.
Results: We showed that fluoxetine treatment significantly reduced glucose stimulated 
insulin secretion (GSIS). We found that fluoxetine has no effect on the total expression 
of E-cadherin, but decreased the surface of E-cadherin. Moreover, fluoxetine triggered 
E-cadherin accumulating in cytosol, mainly localized in Golgi, not in endoplasmic reticulum 
(ER). Our immunohistochemistry showed that reduction cell surface E-cadherin is due to 
increased endocytosis. Moreover, ER calcium release and the activation of store-operated 
calcium entry (SOCE) were suppressed by fluoxetine .
Conclusions: Taken together, the results suggested that the impairment of E-cadherin 
and calcium homeostasis may be underlying mechanisms by which fluoxetine caused the 
reduction of GSIS in pancreatic beta cells.
Funding: Government Support - Non-U.S.
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Involvement of Ischemic Condition in the Pathophysiology of Renal 
Damages in Obesity-Induced Kidney Injury  Koji Futatsugi, Hirobumi 
Tokuyama, Makiko Naitoh, Shu Wakino, Hiroshi Itoh.  Internal Medicine, Keio 
Univ School of Medicine, Tokyo, Japan.
Background: We have reported hypertrophic proximal tubules in obese mice which 
implies an inefficient oxygen supply in this area (Obesity Int, 2012). We examined whether 
hypoxic condition in proximal tubules are involved the pathogenesis of obesity-induced 
renal injury. We also test the hypothesis that this injury can be ameliorated by molecular 
intervention of prolyl hydroxylase domains (PHDs), sensors for tissue oxygen levels that 
is a crucial molecule for tissue response to hypoxia.
Methods: Tissue hypoxic conditions were assessed by pimonidasole immunostaining. 
Peritubular capillaries (PTCs) were evaluated by counting CD34 stained vessels.Tamoxifen 
(Tam)-inducible proximal tubules-specific PHD2 deficient mice were created by crossing 
PHD2flox/flox mice and Tam-inducible N-myc downstream-regulated gene-1-Cre mice on 
C57BL/6J backgrounds.These inducible conditional knock out (CKO) miceand their 
wild-type littermates (WT) were fed a high fat diet (HFD) or a low fat diet (LFD) for 
12 weeks. The expressions of PHD2 and VEGF were measured by real-time PCR and 
immunohistochemistry.
Results: The WT mice on HFDmanifested renal histological changes, including 
cellular enlargement of proximal tubules and a rarefaction of PTCs, which were consistent 
with more hypoxic area in proximal tubules than in WT mice on LFD. Urinary albumin 
and NGAL excretion were higher in HFD-fed mice, indicating ischemic tissue damage in 
proximal tubular area.However, expression of either PHD2 or VEGF was unchanged in 
HFD-fed WT mice, suggesting the lack of hypoxic tissue response in HFD-fed WT.Injecting 
Tam to HFD-fed CKO mice downregulated PHD2 in proximal tubules, increased VEGF 
expression, increased the number of PTCs, decreased hypoxic area, and attenuated proximal 
tubular damages and albuminuria.
Conclusions: Hypoxic condition due to enlarged cell with vascular rarefaction is 
evident in the proximal tubular area of obese mice whereas tissue reaction to hypoxic 
damages failed to properly compensate. The early reduction of PHD2 specifically in the 
proximal areamay constitute a novel strategy againstthe progression process from an early 
stage of obesity-induced kidney injury.
SA-PO415
Herbal Mixture of Radix Puerariae and Fructus Crataegi Prevents Renal 
Injury in Type 2 Diabetes via Inhibition of AKT/PI3K  Zhengyue Chen.1,2 
1Runliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, 
Ningbo Univ, Ningbo, China; 2Div of Nephrology, Ningbo Urology and 
Nephrology Hospital, School of Medicine, Ningbo Univ, Ningbo, China.
Background: It has been reported recently that radix puerariae (RP) is one of the best 
herbal medicines for metabolic diseases, as it has pronounced anti-oxidative effects and helps 
improving insulin resistance and lowering blood sugar and lipids levels. Fructus crataegi 
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(FC) also possesses strong antioxidant activity in vitro. The present study was designed to 
investigate whether RP and FC together (RPFC) can prevent renal injury through a diabetic 
rat model generated by a high-fat diet and a low-dose streptozotocin (STZ).
Methods: A Type 2Diabetic model was generated by feeding rats with high fat diet 
followed by injecting a low dose of STZ. Rats were randomly divided into five groups: 
normal, high fat diet, diabetes mellitus, high fat diet plus RPFC prevention, and diabetes 
mellitus plus RPFC prevention. RPFC was given to rats daily by intragastric gavage for 
3 weeks. The rats were monitored for body weight, blood glucose, oral glucose tolerance, 
blood insulin and lipids, serum creatinine and urea nitrogen, urinary protein. Renal 
pathological changes were examined with hematoxylin and eosin staining, periodic acid 
schiff staining, and Masson trichrome staining. The mRNA and protein levels of α-smooth 
muscle actin (α-SMA) and collagen IV in the kidney were detected by RT-PCR, Western 
blot and immunohistochemical staining. The levels of PI3K and AKT were determined 
by Western blot.
Results: Rats treated with RPFC showed reduced 24 h urinary protein excretion and 
decreased blood glucose level compared with corresponding vehicle treated rats, but RPFC 
prevention did not affect blood lipids. Glomerulus mesangial matrix expansion, renal 
capsule constriction, and renal tubular epithelial cell edema were less severe following 
RPFC prevention. Moreover, RPFC prevention markedly reduced protein levels of PI3K, 
AKT, α-SMA and collagen IV in the kidney of diabetic rats.
Conclusions: Combined prevention with RPFC may inhibit the PI3K/AKT pathway 
in the kidney, thereby preventing renal injury in diabetic rats.
Funding: Private Foundation Support
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High Protein Diet Markedly Accelerates Diabetic Nephropathy Whilst 
Nephrectomy Has Minor Effects in the BTBR ob/ob Mouse Model 
Anna Granqvist,1 Karin Nelander,2 Ann-katrin Andersson,1 Gerhard Bottcher,3 
Magnus Soderberg,3 Anette E. Ericsson.1  1Dept of Bioscience; 2Discovery 
Sciences; 3DSM Pathology Sciences, AstraZeneca R&D, Mölndal, Sweden.
Background: There is a need for better mouse models that resemble the features of 
diabetic nephropathy (DN). The obese diabetic BTBRob/ob mouse was recently shown to 
mimic key features of human DN including progressive proteinuria and glomerular lesions.
Methods: In an attempt to enhance the progression of renal disease further we 
challenged the model through unilateral nephrectomy (performed at 7 weeks of age) or 
supplementation with high protein content diet (40%, from 10 weeks of age).
Results: BTBRob/ob mice exhibited hyperinsulinemia and hyperglycemia with 
elevated HbA1c. The urinary albumin excretion rate (AER) was increased 33-fold in 
intact and 34-fold in nephrectomised BTBRob/ob at 20 weeks age whereas high protein 
diet increased AER 332-fold in BTBRob/ob at 18 weeks age compared with lean controls. 
Plasma creatinine level was lower in intact (median 3.2 µM) and nephrectomised (median 
2.9 µM) BTBRob/ob compared with lean controls (median 7.2 µM ) at 20 weeks. At 
18 weeks age high protein treated BTBRob/ob also had lower creatinine (median 3.2 
µM) indicative of hyperfiltration. Morphological assessment of glomeruli demonstrated 
notable mesangial matrix expansion in BTBRob/ob mice at 20 weeks, which was slightly 
increased by nephrectomy. High protein diet (up to 24 weeks of age) resulted in a significant 
aggravation of renal pathology, with increased mesangial expansion as well as subcapsular 
and interstitial fibrosis. Moreover, the high protein diet increased GBM thickness and 
decreased the number of podocyte slits per mm GBM.
Conclusions: In conclusion, the BTBRob/ob mouse demonstrated renal injury with 
marked albuminuria and glomerular morphological alterations. Disease progression was 
not significantly advanced by nephrectomy and maintained an intact capacity of filtration 
comparable to lean mice. Using high protein content diet appears to be a straightforward 
method to aggravate BTBR ob/ob pathology, which enables new end points for efficacy 
studies and shortens cycle times.
Funding: Pharmaceutical Company Support - AstraZeneca
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Insulin Stimulates Renal Proximal Tubule Sodium Transport in Overt Type 
2 Diabetic Nephropathy  Motonobu Nakamura,1 Nobuhiko Sato,1 Masashi 
Suzuki,1 Atsushi Suzuki,1 Haruki Kume,2 Yukio Homma,2 George Seki,3 Shoko 
Horita.1  1Nephrology, The Univ of Tokyo Hospital, Bunkyoku, Tokyo, Japan; 
2Urology, The Univ of Tokyo Hospital, Bunkyoku, Tokyo, Japan; 3Internal 
Medicine, Yaizu City Hospital, Yaizu, Shizuoka, Japan.
Background: We have previously shown that the insulin receptor substrate (IRS) 
2-dependent stimulatory effect of insulin on renal proximal tubule (PT) transport is 
preserved in insulin resistant humans without nephropathy, facilitating hypertension in 
metabolic syndrome (Kidney Int 87:535-42, 2015). Whether this stimulatory effect of insulin 
is preserved in type 2 diabetes (T2D) with overt nephropathy remains to be determined.
Methods: Cell pH measurement with BCECF was performed to estimate the activity of 
Na-HCO3 cotransporter (NBCe1) in isolated PTs from 55 week-old OLETF rats. Compared 
to control LETO rats, OLETF rats showed extensive mesangial expansion (glomerular 
injury score 1.6 vs 3.3) and overt proteinuria (1.5 vs 34 mg/mg Creat). NBCe1 activity 
was also determined in a T2D patient with renal carcinoma who had decreased eGFR (39.2 
ml/min/1.73m2), massive proteinuria (2.5 g/g Creat), and histological changes compatible 
with overt diabetic nephropathy.
Results: The basal NBCe1 activities of OLETF rats and the patient were comparable 
to those of respective non-diabetic control rats and humans. Furthermore, 10-8 M insulin 
markedly stimulated the NBCe1 activity by 65 % and 104% in OLETF rats and the patient, 
respectively. While the expression of insulin receptor was moderately reduced by 15%, 
the expression of IRS1 was severely reduced by 80% in kidney cortex of OLETF rats. 
However, the expression of IRS2 was completely preserved in kidney cortex of OLETF rats. 
Insulin-mediated Akt phosphorylation was also preserved in kidney cortex of OLETF rats.
Conclusions: These data indicate that insulin can induce sodium retention via its effect 
on PT transport even in T2D with overt nephropathy, which may at least partially explain 
increased cardiovascular risk and volume expansion occasionally associated with intensive 
glycemic control in T2D CKD patients. On the other hand, the reduced expression of IRS1 
in PT could be relevant to enhanced renal gluconeogenesis in T2D.
Funding: Government Support - Non-U.S.
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Modulation of Akt/AS160 Phosphorylation Mediates Insulin Resistance 
in a Rat Model of Metabolic Syndrome  E. Chepchumba K. Yego, Katherine 
Kam, Sharma S. Prabhakar.  Internal Medicine, Texas Tech Univ Health Science 
Center, Lubbock, TX.
Background: Insulin resistance is the underlying pathophysiologic hallmark of 
metabolic syndrome (MS) which is most often associated with obesity. While adipokines 
and inflammatory cytokines have been incriminated in the insulin resistance of MS, the 
exact underlying mechanisms and signaling processes have not been defined. The current 
study assessed the molecular mechanisms of insulin signaling in the skeletal muscle in ZSF1 
rats which have leptin receptor mutation and phenotypically manifest MS.
Methods: Obese ZSF1 rats were maintained from the 8th week and sacrificed at 24 or 
32 weeks and fed on high calorie high fat diet (Purina 5008) while control rats (lean ZSF 
and SD) were fed normal rat chow. Body weights and water intake were monitored weekly 
and blood and urine samples were obtained at 8 weeks and at the time of sacrifice for 
chemistry analysis. Skeletal muscle and fat tissue were also harvested and homogenates were 
examined for the expression of proteins involved in insulin signaling such as adiponectin 
and its receptor, insulin receptor substrate 1 (IRS1), Akt and AS160 by western blots.
Results: The obese ZSF1 rats showed full blown MS with obesity, hyperlipidemia, 
hypertension and hyperglycemia while the lean ZSF and SD rats were normoglycemic. 
The expression of GLUT 4 was decreased in both skeletal muscle and fat tissue of obese 
rats. Studies done previously in our lab demonstrated that compared to non-diabetic rats, 
plasma adiponectin levels were lower in obese ZSF rats and adiponectin expression was 
decreased in fat tissue but not in skeletal muscle. The expression of adiponectin receptor 1 
and insulin substrate receptor1 (IRS1) were similar in all rats. Furthermore, the expression 
of phosphorylated Akt and AS160 were reduced by 74% and 38% in diabetic obese ZSF1 
rats compared to non-diabetic controls.
Conclusions: Our results demonstrate that while GLUT4 expression in insulin sensitive 
tissues is decreased in obesity mediated diabetes, several intermediary steps in insulin 
signaling are unaltered. However the most consistent finding was reduced phospho Akt/
AS160, which could be a major determinant of insulin resistance in obesity.
Funding: Private Foundation Support
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Murine Recombinant ACE2 Reduces Renal Fibrosis in Experimental 
Alport Syndrome (AS)  Eun Hui Bae,4 Ana Konvalinka,1 Fei Fang,1 Xiaohua 
Zhou,1 Vanessa R. Williams,1 John Tran,1 Xuewen Song,1 Shao-Ling Zhang,2 
Rohan John,1 Vaibhav B. Patel,3 Gavin Oudit,3 York P. Pei,1 James W. Scholey.1 
1Univ of Toronto; 2Univ of Montreal; 3Univ of Alberta; 4Chonnam National 
Univ Medical School.
Background: ACE2 is a monocarboxypeptidasein the renin angiotensin systemthat 
catalyzes the breakdown of angiotensin II (AngII) to angiotensin-(1-7) (Ang1-7). We have 
reported that ACE2 expression and activity in kidney are reduced in experimental Alport 
Syndrom (AS) but the impact of this finding on disease progression has not been studied.
Methods: Accordingly, we evaluated the effects of murine recombinant ACE2 
(mrACE2) treatment in Col4A3-/- mice, a model of AS characterized by proteinuria and 
progressive renal injury. mrACE2 (0.5 mg/kg/day)was administered from 4 -7 weeks of 
agevia osmotic mini-pump.
Results: Treatment with mrACE2 led to an increased urinary ACE2 excretion, 
reduced renal AngII level and a correspondingly increased Ang1-7 level in 7-week-old 
Col4A3-/- mice. Pathological structural changes and albuminuria in the mutant mice were 
both attenuated by mrACE2 administration. mrACE2 ameliorated kidney fibrosis in 
Col4A3-/- mice as shown by decreased expression of profibrotic genes, less accumulation of 
extracellular matrix proteins and inhibition of the TGF-β signaling activation. Further, the 
increases in proinflammatory cytokine expression, macrophage infiltration, inflammatory 
signaling pathway activation and heme oxygenase-1 (HO-1) level in Col4A3-/- mice were 
also reduced by mrACE2 treatment. Lastly, mrACE2 influenced the turnover of renal 
ACE2, as it suppressed the expression of TNF-α converting enzyme (TACE), a negative 
regulator of ACE2.
Conclusions: In summary, treatment with mrACE2 alters angiotensin peptide 
metabolism in the kidneys of Col4A3-/- mice and attenuates the progression of AS 
nephropathy.
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Blockade of CDK9 and Smad3/4 Signaling Reduces Renal Fibrosis in 
Mice with Unilateral Ureteral Obstruction  Jinhua Li,1 Xinli Qu,1 Xiaoyun 
Jiang,2 John F. Bertram,1 David J. Nikolic-Paterson.3  1Dept of Anatomy and 
Developmental Biology, Monash Univ, Clayton, Vic, Australia; 2Dept of 
Pediatrics, The First Affiliated Hospital of Sun Yat-Sen Univ, Guangzhou, 
Guangdong, China; 3Dept of Medicine, Monash Medical Centre, Monash Univ, 
Clayton, Vic, Australia.
Background: TGF-b1/Smad signalling plays a central role in the pathogenesis of 
renal fibrosis. Smad3 and Smad4 are pro-fibrotic, while Smad2 is anti-fibrotic. However, 
these Smads form heterogeneous complexes the functions of which are poorly understood. 
This study investigated Smad complexes in renal fibrosis in mouse unilateral ureteric 
obstruction (UUO).
Methods: UUO was established in wild type mice, mice heterozygous or homozygous 
for Smad3 and/or Smad4 (Smad3/4+/-, Smad3-/- , Smad4-/-). siRNA was used to knock down 
CDK9. CDK9 activity and Smad3 c-terminal phosphorylation was inhibited by a specific 
CDK9 inhibitor or a Smad3 inhibitor in cultured mouse renal fibroblasts and in UUO.
Results: Smad3/4+/- mice exhibited substantial protection from renal fibrosis on day 7 
UUO, whereas Smad2/3+/- or Smad2/4+/- mice showed only modest protection. Formation 
of Smad3/Smad4/CDK9 complexes was an early event following UUO in wild type 
mice, which involved nuclear phosphorylation of the linker regions of Smad3. Smad3 or 
Smad4 deficiency significantly decreased the formation of Smad4/CDK9 or Smad3/CDK9 
complex, Smad3 linker phosphorylation as well as renal fibrosis but at different degrees. 
In vitro, TGF-b1 stimulation of collagen I promoter activity involved formation of Smad3/
Smad4/CDK9 complexes, and over-expression of each component gave additive increases 
in collagen promoter activity. A CDK9 inhibitor or CDK9 siRNA significantly reduced 
TGF-b1-induced interaction between Smad3 and Smad4, Smad3 linker phosphorylation 
and fibrotic response in mouse renal fibroblasts. Co-administration of the CDK9 inhibitor 
and the specific Smad3 inhibitor achieved better protection from TGF-b1-induced fibrotic 
response in vitro and renal interstitial fibrosis in UUO.
Conclusions: Our studies suggest that the formation of Smad3/Smad4/CDK9 complex 
drive renal fibrosis in the UUO model. Formation of this complex represents a novel target 
for anti-fibrotic therapies.
Funding: Government Support - Non-U.S.
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Genetic Activation of Nrf2 Signaling Protects against Chronic Kidney 
Disease  Roderick J. Tan,1 Dionysios V. Chartoumpekis,3 Dong Zhou,2 Brittney 
M. Rush,1 Haiyan Fu,2 Thomas W. Kensler,3 Youhua Liu.2  1Medicine, Univ of 
Pittsburgh, Pittsburgh, PA; 2Pathology, Univ of Pittsburgh, Pittsburgh, PA; 
3Pharmacology, Univ of Pittsburgh, Pittsburgh, PA.
Background: The Keap1/Nrf2 pathway is upregulated in kidney injury, leading to the 
expression of an array of cytoprotective genes with antioxidant, anti-inflammatory, and 
detoxifying roles. Keap1 inhibits Nrf2 by sequestering it in the cytoplasm. During oxidative/
electrophilic stress, Keap1 undergoes conformational change that renders it inactive and 
Nrf2 accumulates and enters the nucleus to upregulate target genes. Pharmacologic inducers 
of this pathway (e.g. CDDO-Me) have harmful off-target effects. Therefore, more specific 
study of the Keap1/Nrf2 pathway with genetic approaches is necessary to determine its 
therapeutic potential in chronic kidney disease (CKD).
Methods: Keap1 hypomorphic (HM) mice have lower Keap1 expression and increased 
Nrf2 activity. We subjected HM and wild-type (WT) mice to two models of CKD: unilateral 
ischemia followed by 10 days of reperfusion (IR); and unilateral ureteral obstruction 
(UUO). Kidney injury was assessed with serum creatinine, histology, western blotting and 
quantitative real-time PCR (qPCR) for injury markers.
Results: Compared to WT, HM mice had increased expression of numerous Nrf2-
regulated genes after injury. In IR injury, HM mice were significantly protected from 
developing CKD, demonstrating decreased serum creatinine and renal fibrotic lesions 
compared to WT mice. Furthermore, HM mice had lower levels of fibronectin, α-smooth 
muscle actin, and TGF-β. Inflammation was also suppressed in HM mice, as was pathologic 
β-catenin signaling, which is known to play a role in CKD progression. Similar results 
were obtained in the UUO model.
Conclusions: Most studies on the Keap1/Nrf2 pathway examine acute kidney injury 
or utilize pharmacologic agents with off-target effects. We demonstrate here that genetic 
enhancement of the Nrf2 pathway is protective in two models of CKD in mice, due to 
increased expression of cytoprotective genes as well as downregulation of β-catenin 
signaling. These studies suggest that the Keap1/Nrf2 pathway should remain a promising 
target in CKD treatment.
Funding: NIDDK Support, Private Foundation Support
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Early and Late Treatment with PBI-4050, an Orally Active Anti-Fibrotic 
Agent, Reduces Fibrosis and Increases Survival of 5/6-Nephrectomized 
Rats  Lyne Gagnon, François Sarra-Bournet, Lilianne Geerts, Brigitte Grouix, 
Jean-Simon Duceppe, Boulos Zacharie, Pierre Laurin.  ProMetic BioSciences 
Inc., Laval, QC, Canada.
Background: PBI-4050, a first-in-class orally active compound which is currently in 
clinical phase Ib/II in CKD patients, displays anti-fibrotic activities via a novel mechanism 
of action. In a double-blind ascending dose (400 to 2400 mg) clinical phase I, PBI-4050 
was found to be safe and well tolerated up to 2400 mg without any significant side effect. 
The aim of this study was to investigate the effect of early (Day 21) and late (Day 84) 
treatment of PBI-4050 on 5/6-nephrectomized rats.
Methods: Sprague-Dawley rats were partially nephrectomized (2/3 of the left kidney) 
on day 0. On day 7 the right kidney was removed. Oral treatment with PBI-4050 (200 mg/
kg, once a day) or vehicle was initiated at day 21 or at day 84, following randomization 
based on their glomerular filtration rate (GFR) results. GFR was measured at day 21 or day 
84 and assessed every 3 weeks up to day 190 (early) or day 128 (late).
Results: Early treatment with PBI-4050 resulted in a significant improvement (up to 
threefold relative to control) in GFR. It also significantly reduced proteinuria. Histological 
lesion scores of kidney were also significantly (p<0.05) decreased in PBI-4050-treated rats 
(2.7 ± 1.5) compared to control (3.9 ± 1.4), as determined by HPE, PAS and Masson’s 
trichrome staining. Early treatment with PBI-4050 induced a significant reduction of urine 
MCP-1 level. Furthermore, early treatment with PBI-4050 reduced the overexpression of 
fibrotic (TGF-b1, collagen I and α-SMA), pro-fibrotic cytokines (IL-23p19 and IL-6), 
remodeling (MMP2, SPARC and fibronectin), and oxidative stress (iNOS) markers. Late 
treatment with PBI-4050 resulted in mild improvement of GFR and serum creatinine level 
(reduction of 50 mmol/L) but most importantly in an increase in survival (55% non-treated 
versus 80% with late treatment) at day 128.
Conclusions: These results suggest that PBI-4050 offers the potential as a novel therapy 
for chronic kidney disease by reduction of fibrosis and may potentially improve residual 
kidney function in patients with end-stage renal failure.
SA-PO423
Targeting Cardiorenal Connectors Reduces Renal and Cardiac Fibrosis in 
Experimental Chronic Renocardiac Failure  Nynke R. Oosterhuis,1 Lennart G. 
Bongartz,1 Branko Braam,3 Marianne C. Verhaar,1 Roel Goldschmeding,1 Carlo 
A. Gaillard,2 Jaap A. Joles.1  1UMC Utrecht, Netherlands; 2UMC Groningen, 
Netherlands; 3Univ of Alberta, Edmonton, Canada.
Background: Cardiorenal connectors (CRC) play a major role in progression of organ 
damage in renocardiac failure (subtotal nephrectomy (SNX) followed by coronary ligation 
(CL)). We hypothesized that simultaneous inhibition of all CRC would be most effective 
in reducing cardiorenal fibrosis and functional decline.
Methods: In rats subtotal nephrectomy was followed by coronary ligation (wk 8) 
[Bongartz, AJP, 2012]. In wk 11 we administered losartan (RAS), or PDTC, tempol and 
moldisomine (Inflammation-NO/ROS) or all of these plus metoprolol (all-CRC) until wk 16.
Results: Tubulo-interstitial (TI) fibrosis decreased in all treated groups (fig 1A). 
However, renal function was not significantly affected by any treatment. Systolic dysfunction 
stabilized in all treated groups, but declined further in vehicle-treated rats (fig 1B). Cardiac 
fibrosis improved in all treated groups without significant additive effect of targeting all 
CRC (fig 1C). TI and cardiac fibrosis correlated (fig 1D). Only all-CRC reduced MAP. 
Diastolic hemodynamics and ventricular and cardiomyocyte size were not affected by any 
treatment. Reducing TI injury and renal and cardiac CTGF mRNA expression was most 
effective by targeting all CRC.
Conclusions: Pharmacological targeting of cardiorenal connectors in this model of 
chronic renocardiac syndrome ameliorated the severity of cardiac and renal fibrosis and 
prevented further decline in systolic dysfunction. 
SA-PO424
Fibroblast Growth Factor 23 Is Synthesised Locally by Renal Proximal 
Tubular Cells and May Be Pro-Fibrotic  Edward Robert Smith,1 Sven-Jean 
Tan,1,2 Stephen G. Holt,1,2 Tim Hewitson.1,2  1Dept of Nephrology, The Royal 
Melbourne Hospital, Melbourne, Victoria, Australia; 2Dept of Medicine (RMH), 
The Univ of Melbourne, Melbourne, Victoria, Australia.
Background: Physiologically, FGF23 synthesis occurs predominantly in bone and 
regulates mineral handling in the kidney. In Chronic Kidney Disease, circulating levels 
become grossly elevated and are strongly predictive of disease progression, yet changes 
in FGF23 are not explained by increased osteocytic synthesis. Since extra-osseous FGF23 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
722A
J Am Soc Nephrol 26: 2015 Proteinuria, Fibrosis, and Their Modulators Poster/Saturday
production is observed in diseased heart and vascular tissue, and is associated with the 
activation of pro-fibrotic cascades, the involvement of renal FGF23 synthesis and potential 
fibrinogenic effects warranted investigation.
Methods: Kidneys were harvested from FVB mice at day 0 or after 3 or 9 days post-
unilateral ureteric obstruction (UUO) (n=6). Paraffin-embedded sections were stained for 
FGF23 and with lectins to identify specific nephron segments. Total RNA was extracted 
from whole kidney tissue and laser-capture microdissected glomerular and tubular regions, 
and analysed by qPCR. Rat renal fibroblasts were cultured with exogenous recombinant 
human FGF23 and stained for α-smooth muscle actin (aSMA) to assess myofibroblast 
differentiation.
Results: Generalisedlow-level FGF23 protein staining was observed in proximal 
tubules at day 0, with more intense focal staining at days 3 and 9 post-UUO. Local 
FGF23 synthesis was confirmed by qPCR of whole kidney extracts, and specifically, in 
microdissected proximal tubular cells, but not glomeruli. Normalised FGF23 expression 
increased 11-fold in day 3 UUO relative to day 0 (both p<0.01). Treatment of rat UUO 
fibroblasts with 10ng/mL FGF23 resulted in 4-fold increase in aSMA staining over 72h, 
equivalent to the effect of 1ng/ml transforming growth factor-b1 (both p<0.01).
Conclusions: Local renal FGF23 synthesis in proximal tubular cells is enhanced by 
tubulointerstitial injury and may augment myofibroblast differentiation.
Funding: Private Foundation Support, Clinical Revenue Support
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Quantitating Intracellular Oxygen Tension in Kidney by Phosphorescence 
Lifetime Measurement  Yosuke Hirakawa,1 Imari Mimura,1 Toshitada 
Yoshihara,2 Mako Kamiya,1,3 Yasuteru Urano,1,4,5 Seiji Tobita,2 Masaomi 
Nangaku.1  1Graduate School of Medicine, The Univ of Tokyo, 7-3-1 Hongo, 
Bunkyo-ku, Tokyo, Japan; 2Dept of Chemistry and Chemical Biology, Gunma 
Univ, 1-5-1 Tenjincho, Kiryu, Gunma, Japan; 3PRESTO, Japan Science and 
Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama, Japan; 4Graduate 
School of Pharmaceutical Sciences, The Univ of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 
Tokyo, Japan; 5CREST, Japan Science and Technology Agency, 4-1-8 Honcho, 
Kawaguchi, Saitama, Japan.
Background: Hypoxia plays critical roles in the progression of chronic kidney disease, 
since intracellular reactions to hypoxia depend on intracellular oxygen (O2) tension. 
However, existing techniques to detect intracellular hypoxia cannot quantify O2 tension.
Methods: Phosphorescence lifetime (PL) measurement is reported to be useful 
to quantitate O2 tension in vivo, however, most phosphorescent probes distribute 
extracellularly. Here we used BTPDM1, a lipophilic phosphorescent probe, to quantitate 
intracellular hypoxia in the kidney. We measured PL in Human Kidney 2 (HK-2) cells and 
murine kidney after BTPDM1 administration.
Results: We first made a calibration curve between PL and partial pressure of O2 (pO2) 
in HK-2 cells. Then we confirmed that BTPDM1 distributed in tubular cells in vivo. Next 
we measured PL of the murine kidney in normal condition, renal ischemia, hypoxemia 
and anemia. PL were calculated to be 1.8±0.2µs, 4.0±0.3µs, 2.8±0.2µs, 2.2±0.2µs, 
respectively. We also investigated chronic kidney damaged model mice of 7 days after 30 
minutes unilateral ischemia-reperfusion (I/R) injury of kidney. PL of I/R injured kidney 
was longer than contralateral kidney (2.2±0.2µs vs 1.8±0.1µs). We also found an increase 
in pimonidazole adduct protein and a decrease in peritubular capillary density in I/R injured 
kidneys. We quantitated in vivo intracellular pO2 by extrapolating the calibration curve in 
HK-2 cells. The intracellular pO2 of normal kidney tubule was estimated to be 50mmHg, 
which was compatible with published value obtained by needle O2 electrode.
Conclusions: Our novel technique allowed accurate estimation of intracellular O2 
tension of the normal and diseased kidney in vivo for the first time.
SA-PO426
Resveratrol Increases Expression of Heme Oxygenase-1 via Nrf2 Signaling 
to Ameliorate Renal Damage by Anti-Complement, Anti-Oxidative, and 
Anti-Apoptotic Effects in a Murine Model of Membranous Nephropathy 
Chia-chao Wu,1,2 Kuo-cheng Lu.3  1Div of Nephrology, Dept of Medicine, Tri-
Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 
2Dept and Graduate Inst of Microbiology and Immunology, National Defense 
Medical Center, Taipei, Taiwan; 3Dept of Medicine, Cardinal Tien Hospital, 
School of Medicine, Fu Jen Catholic Univ, New Taipei City, Taiwan.
Background: Idiopathic membranous nephropathy (MN) is an autoimmune-mediated 
glomerulonephritis and a common cause of nephrotic syndrome in adults. There are limited 
available treatments for MN. We assessed the efficacy of resveratrol (RSV) therapy for 
treatment of MN in a murine model of this disease.
Methods: Murine MN was experimentally induced by cationic bovine serum albumin, 
with phosphate-buffered saline used in control mice. MN mice were untreated or given 
RSV. Disease severity and pathogenesis was assessed by determination of metabolic and 
histopathology profiles, lymphocyte subsets, immunoglobulin production, oxidative stress, 
apoptosis, production of heme oxygenase-1 (HO1) and signalings.
Results: MN mice given RSV had significantly reduced proteinuria and a marked 
amelioration of glomerular lesions. RSV also significantly attenuated immunofluorescent 
staining of C3 in the kidney. RSV treatment also reduced the production of reactive oxygen 
species, cell apoptosis, and upregulated heme oxygenase 1 (HO1). Inhibition of HO1 with 
tin protoporphyrin IX partially reversed the renoprotective effects of RSV. We show that 
concentration-dependent induction of HO-1 in E11 podocytes as RSV added. Nrf2 but 
not AMPK1/2 protein level can be upregulated by RSV. We find that an induction of Nrf2 
exists at the HO-1 promoter regions segment #3 and #4 when RSV added. The Nrf2-specific 
siRNA attenuated the induction of HO1 mRNA by RSV. It suggests that increased Nrf2 at 
the HO1 promoter leads to elevated HO1 expression when RSV is exposed.
Conclusions: Our results show that RSV increased the expression of HO1 and 
ameliorated the effects of membranous nephropathy in a mouse model due to its anti-
complement, anti-oxidative, and anti-apoptotic effects. RSV appears to have potential as 
a treatment for MN.
Funding: Government Support - Non-U.S.
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FVB Os/+ Mesangial Cells Exhibit Enhanced mTOR and Growth 
Factor Expression, Modeling the FVB Os/+ Glomerulosclerosis Mouse 
Yongxin Gao, Charles W. Heilig.  Medicine, Univ of Florida College of 
Medicine-Jacksonville, Jacksonville, FL.
Background: We previously reported Fvb Os/+ mice which exhibit rapidly progressive 
glomerulosclerosis beginning within the first 2 weeks after birth. Here we examine primary 
culture mesangial cells (MC) from FVB Os/+ mice and FVB +/+ control mice to examine 
the phenotype of FVB Os/+ MC and identify cellular mechanisms which may contribute 
to glomerulosclerosis (GS) in vivo. FVB Os/+ MC have excess ECM production.
Methods: Primary culture MC were studied between passages 5 -12. Western analyses 
were performed with specific antibodies against selected proteins to examine mTOR, 
phospho-S6 Kinase, and growth factor expression important to excess extracellular matrix 
(ECM) production. GLUT1 glucose transporter expression and 3H2-deoxyglucose uptake 
rates were also determined. P<.05 was considered significant for statistical analyses.
Results: GLUT1 and glucose uptake rate were both increased >2-fold in FVB Os/+ 
MC vs. FVB +/+ control MC, consistent with their increases in FVB 0s/+ glomeruli. FVB 
Os/+ MC exhibited slowed proliferation consistent with the Os mutation. FVB Os/+ MC 
also had increased VEGF (1.6-fold) and TGF beta1 (2.7-fold), which likely contribute to 
the excess ECM production of these cells. The increased VEGF in vitro simulates increased 
VEGF in FVB Os/+ glomeruli in vivo. MGF was increased in FVB Os/+ MC (2.7-fold), 
mimicking increased glomerular MGF in vivo. We previously found MGF stimulates VEGF 
and TGFß1 in MC. FVB Os/+ MC carry the Os mutation which impairs cell division, 
explaining their slow proliferation. Consistent with this, phospho-ERK1/2 was reduced 
66%. In spite of increased mTOR (3.8-fold) and downstream phospho-S6 kinase (5.2-fold), 
the cells could not proliferate normally.
Conclusions: FVB Os/+ MC exhibit growth factor expression simulating glomerular 
growth factor expression in vivo in these mice. MGF expression is increased both in 
glomeruli in vivo and MC in vitro. MGF is a stimulus to VEGF and TGFbeta1 expression 
as observed here. These growth factors are associated with excess ECM production in 
FVB Os/+ MC, despite suppressed Erk1/2, indicating another pathway is important to 
excessive ECM production.
Funding: Pharmaceutical Company Support - Dialysis Clinics Inc.
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Role of Sodium-Glucose Linked Cotransporter-2 Inhibitor in the Kidneys 
of Salt Sensitive Hypertension  Mikako Hisamichi,1 Atsuko Ikemori,1,2 
Takeshi Sugaya,1 Kenjiro Kimura,3 Yugo Shibagaki.1  1Div of Nephrology 
and Hypertension, Dept of Internal Medicine, St. Marianna Univ School of 
Medicine, Kawasaki, Japan; 2Dept of Anatomy, St. Marianna Univ School 
of Medicine, Kawasaki, Japan; 3Dept of Internal Medicine, Tokyo Takanawa 
Hospital, Tokyo, Japan.
Background: Sodium-glucose linked cotransporter-2 (SGLT2) is expressed in the 
apical side of the proximal tubules and can transport not only glucose but also sodium. 
Because salt is an aggravated factor for the salt sensitive hypertensive renal injury model, 
SGLT2 expression may be related to the the progression of renal injury due to salt sensitive 
hypertension. The aim of this study is to reveal the role of SGLT2 inhibitor in angiotensin 
II (AII) induced renal injury.
Methods: Male C57/BL6 wild-type mice were divided into three groups: The Ang II 
group was systemically infused with Ang II for 16 days. The SGLT2 inhibitor (SGLT2-I) 
group was given an oral dose of the dapagliflozin SGLT2 inhibitor of 1mg/kg/daily in 
addition to an injection of Ang II. The control group was injected with a vehicle.
Results: In both the Ang II and the SGLT2-I groups, the degree of hypertension, the 
glycemic levels in blood and the body weight were similar. Renal gene expressions of 
angiotensinogen and SGLT2 significantly increased in both the AII and the SGLT2-I groups 
than the control group. Renal gene expression of the angiotensinogen in the SGLT2 inhibitor 
group tended to be lower than that in the AII group. The degree of macrophage infiltration 
and urinary albumin levels tended to be lower in the SGLT2-I group than in the AII group. 
These results suggested that SGLT2 inhibitor may attenuate the renal damage due to salt 
sensitive hypertension via inhibiting the activation of renal renin angiotensin system.
Conclusions: In conclusion, SGLT2 inhibitor may be a useful treatment of hypertensive 
renal disease.
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The Renoprotective Effect of Nuclear 1 Factor Related Factor 2 (Nrf2) 
Activator, Bardoxolone Methyl, in Aldosterone and High Salt-Induced 
Renal Injury  Mikako Hisamichi,1 Atsuko Ikemori,1,2 Takeshi Sugaya,1 
Kenjiro Kimura,3 Yugo Shibagaki.1  1Div of Nephrology and Hypertension, 
Dept of Internal Medicine, St. Marianna Univ School of Medicine, Kawasaki, 
Kanagawa, Japan; 2Dept of Anatomy, St. Marianna Univ School of Medicine, 
Kawasaki, Kanagawa, Japan; 3Dept of Internal Medicine, Tokyo Takanawa 
Hospital, Tokyo, Japan.
Background: Activation of nuclear 1 factor related factor 2 (Nrf2) is reported to have 
anti-oxidant and anti-inflammatory effects. In the aldosterone (Ald) and high salt-induced 
renal injury model using mice, we previously reported that severe tubulointerstitial damage 
was provoked by oxidative stress. The aim of this study is to reveal the renoprotective effect 
of the Nrf2 activator in this model.
Methods: To evaluate the degree of tubulointerstitial damage using the urinary liver 
type fatty acid binding protein (L-FABP), known as a biomarker of the tubulointerstitial 
damage, we used human L-FABP chromosomal transgenic (L-FABP+/-) mice. Male 
L-FABP+/- mice were divided into three groups: The Ald group received systemic aldosterone 
infusions via an osmotic minipump and were given 1% NaCl water for 14 days. The Ald-
Nrf2 group wasgiven Bardoxolone Methyl of the Nrf2 activator intraperitoneallyat a dose 
of 10mg/kg/daily in addition to an injection of aldosterone and salt. The control group 
was given only a vehicle.
Results: The gene expression of MCP-1, the gene expression of RANTES, the gene 
expression of collagen typeIand type III and the degree of macrophage infiltration were 
significantly greater in the kidneys of the Ald group compared to those in the control, and 
renal inflammatory reaction and renal fibrosis were significantly attenuated in the Ald-
Nrf2 group. The degree of renal hL-FABP gene expression and urinary hL-FABP levels 
increased in the Ald group compared to the control and decreased in the Ald-Nrf2 group.
Conclusions: The Nrf2 activator, Bardoxolone Methyl, could attenuate renal oxidative 
stress induced by aldosterone and high salt, and consequently, renal inflammatory reaction 
and the production of renal collagen were prevented. Bardoxolone Methyl may be a useful 
treatment for renal disease.
SA-PO430
Detection of Mesangial Tissue Transglutaminase Activity in Human 
Kidney Biopsy Specimens  Kazuo Takahashi,1,2,6 Tomohiro Mizuno,1,2 Takanori 
Onouchi,1 Shin’ichi Akiyama,1,3 Hideki Tatsukawa,4 Mamoru Kusaka,1 Tadashi 
Nagamatsu,2 Yutaka Tsutsumi,1 Shoichi Maruyama,3 Hiroshi Kitamura,5 
Jan Novak,6 Kiyotaka Hitomi,4 Yukio Yuzawa.1  1Fujita Health Univ School 
of Medicine, Toyoake, Aichi, Japan; 2Meijo Univ, Nagoya, Aichi, Japan; 
3Nagoya Univ Graduate School of Medicine, Nagoya, Aichi, Japan; 4Nagoya 
Univ Graduate School of Pharmaceutical Sciences, Nagoya, Aichi, Japan; 
5NHO Chiba-East Hospital, Chiba, Japan; 6Univ of Alabama at Birmingham, 
Birmingham, AL.
Background: Tissue transglutaminase (TG2) is a protein-cross-linking enzyme that 
plays an important role in tubulointerstitial fibrosis in animal models of chronic kidney 
disease and diabetic nephropathy. However, its pathological significance in human 
glomerular diseases remains unclear. TG2 transforms into catalytically active TG2 through 
conformational changes. Thus, it is crucial to detect catalytically active TG2 to assess the 
role of TG2 in human biopsy samples.
Methods: A total of 241 renal biopsy specimens obtained between January 2010 and 
December 2013 were assessed for TG2 activity by immunofluorescence microscopy with 
FITC-labeled highly reactive TG2 substrate peptides.
Results: Thirty-five of 65 (56%) patients with IgAN, 23 of 40 (58%) patients with 
lupus nephritis (LN), and 7 of 11 (64%) patients with secondary IgAN, including 8 IgA 
vasculitis patients, exhibited mesangial TG2 activity. In contrast, only 7 of 125 (6%) 
patients with other kidney diseases showed mesangial TG2 activity. IgAN patients with 
mesangial TG2 activity had higher levels of proteinuria (1.2 vs. 0.5 g/day, P< 0.01) and a 
higher mesangial score defined by the Oxford classification (0.53 vs. 0.38, P= 0.03) than 
those without mesangial TG2 activity. LN patients with mesangial TG2 activity showed 
higher presence of hematuria more than 20/hpf (39% vs. 0%, P< 0.001) and had histological 
evidence of active lesions more frequently than patients without mesangial TG2 activity 
(83% vs. 35%, P< 0.001).
Conclusions: Immune-complex mediated glomerulonephritis such as IgAN, LN, and 
IgA vasculitis frequently have the active form of TG2 in the mesangial area. This assay 
for mesangial TG2 activity may represent a useful new diagnostic test.
Funding: Pharmaceutical Company Support - Kyowa Hakko Kirin Co., 
Otsuka Pharmaceutical Co., Baxter, Chugai Pharmaceutical Co., Mitsubishi Tanabe 
Pharmaceutical Co., Government Support - Non-U.S.
SA-PO431
Renoprotective Effect of Xanthine Oxidoreductase Inhibitor, Topiroxostat, 
in Hyperuricemic-Induced Renal Injury  Atsuko Ikemori,1,2 Takeshi Sugaya,2 
Mikako Hisamichi,2 Kenjiro Kimura,2 Yugo Shibagaki.2  1Dept of Anatomy, 
St. Marianna Univ School of Medicine, Kawasaki, Japan; 2Div of Nephrology 
and Hypertension, Dept of Internal Medicine, St. Marianna Univ School of 
Medicine, Kawasaki, Japan; 3Dept of Internal Medicine, Tokyo Takanawa 
Hospital, Tokyo, Japan.
Background: Hyperuricemia is known to be a risk factor of chronic kidney disease. The 
aim of this study is to reveal the effect of xanthine oxidoreductase inhibitor, Topiroxostat 
in a model of hyperuricemic renal disease provoked by adenine-containing diet.
Methods: To evaluate the degree of tubulointerstitial damage using urinary liver type 
fatty acid binding protein (L-FABP) known as a biomarker of the tubulointerstitial damage, 
we used human L-FABP chromosomal transgenic (Tg) mice. Male Tgmice (n=24) were 
fed a 0.2% w/w adenine-containing diet. Two weeks later from the start of the diet, renal 
dysfunction of these mice were confirmed and were divided into the four groups: the adenine 
group was given only the diet containing adenine. The Febuxostat (Feb) group and the 
Topiroxostat high (Top-H) or low (Top-L) groups were given the diet containing each Feb 
(3mg/kg), Top-H (3mg/kg), Top-L (1mg/kg) in addition to adenine for another 2 weeks. 
Thereafter, adenine-containing diet was stopped, only each medication was continued for 
additional 2 weeks and the kidneys in each group were removed.
Results: Renal dysfunction, the degree of macrophage infiltration, tubulointerstitial 
damage and renal fibrosis were significantly attenuated in the kidneys of the Feb, the Top-L 
and the Top-H groups compared to those in the adenine group. Serum uric acid levels and 
renal xanthine oxidoreductase activity in the Feb, the Top-L and the Top-H groups were 
significantly lower than those in the adenine group. Those levels in the Top-H group were 
significantly lower than those in the Feb group. Urinary excretion levels of L-FABP in 
both the Top-H and Top-L groups were significantly lower than those in both the adenine 
and Feb groups.
Conclusions: In conclusion, Topiroxostat attenuated the renal damage induced by 
hyperuricemia and may be a useful treatment for hyperuricemic renal damage.
Funding: Private Foundation Support
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Accumulation of Indoxyl Sulfate in Renal Tubular Cells Aggravates Kidney 
Injury in Rats with 5/6 Nephrectomy  Ayano Konagai, Kaori Kikuchi, Ayako 
Fujieda, Sumie Goto, Hiroko Iijima, Yoshiharu Itoh.  Pharmaceuticals Division, 
Kureha Corporation, Tokyo, Japan.
Background: Indoxyl sulfate (IS), a representative uremic toxin, is detected in renal 
tubular cells of CKD patients and 5/6 nephrectomized rats administrated with IS. It has 
been suggested that the retention of IS is induced through organic anion transporters 
in the basolateral membrane of renal tubular epithelial cells and this retention leads to 
nephrotoxicity. However, the mechanism for IS accumulation in renal tubules remains 
unclear. To reveal the correlation between IS accumulation and renal dysfunction in 
5/6 nephrectomized rats, we investigated the expression of transporters in the apical or 
basolateral membrane and of markers for renal injury, and a content of IS in renal tubular 
epithelial cells using a novel antibody against IS.
Methods: To study the serum concentration of IS, we used high-performance liquid 
chromatography (HPLC) and our newly developed enzyme-linked immunosorbent assay 
(ELISA). The renal sections from the rats were stained with the antibody for IS. The 
expression of the transporters in renal tubular cells and the markers for renal injury such 
as Kidney Injury Molecule-1 (KIM-1) were detected by immunohistochemistry.
Results: Serum level of IS was identified to be increased in the 5/6 nephrectomized 
rats compared to the normal rats by the newly ELISA. The new system could sensitively 
detect the low concentration of IS. The value determined by ELISA is in a good correlation 
with HPLC. Immunohistochemistry showed a significant IS staining in renal sections of the 
model rats. We found the presence of IS in hypertrophic tubular cells, where the expression 
of a transporter in the apical membrane mediating IS secretion was decreased, while the 
expression of a transporter in the basolateral membrane was retained. KIM-1, the marker for 
early kidney injury, was highly expressed in some tubules, but not in the IS positive cells.
Conclusions: Our findings suggest that IS is accumulated in renal tubular cells at the 
later stage of renal injury due to unbalance expression of transporters between in the apical 
membrane and in the basolateral membrane, and this accumulation aggravates kidney injury.
Funding: Pharmaceutical Company Support - KUREHA corporation
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IL-15 as a Potential New Therapeutic Treatment for Renal Fibrosis 
L. Lecru,1 A. Devocelle,1 V. Le coz,1 C. Gallerne,1 S. Ferlicot,2 A. Durrbach,1 
P. Eid,1 B. Azzarone,1 H. Francois,1 J. Giron-michel.1  1UMRS Inserm 1197, 
Villejuif, France; 2Bicetre Hospital, Kremlin-Bicetre, France.
Background: The human epithelial cells of various tissues produce interleukine-15 
(IL-15), which acts not only on immune cells, but also on epithelial cells, mainly via its 
anti-apoptotic action. Thus, human and mouse renal tubular epithelial cells (RPTEC) 
constitutively secrete IL-15. Our group recently reported that IL-15 preserves epithelial 
phenotype in human kidney tubular cells since IL-15 is sufficient to inhibit EMT 
commitment of RPTEC. Therefore, the goal of our study is to explore the renoprotective 
potential of IL-15 in vitro and in vivo in renal fibrosis.
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Methods: Our study sought to examine if IL-15 could inhibit EMT in tubular epithelial 
cells in vitro and therefore ameliorate tubulointerstitial fibrosis using the unilateral ureteral 
obstruction model (UUO) in mice. We also analyzed IL-15 expression in various human 
nephropathies.
Results: IL-15 expression decreased in human renal disease and in mice during 
UUO (p<0.05, n=19). IL-15 treatment coupled with its soluble receptor (IL-15/IL-15Rα), 
prevents interstitial fibrosis during UUO (10.7 ± 1.1% in control group, vs 8.2 ± 0.7% 
in IL-15 treated mice and 6.4 ± 0.6% in IL-15/IL-15Rα treated mice, p<0.01, n=7 mice/
group), quantified by Sirius Red and Western Blot, through two different mechanisms. We 
first found a reduction of macrophages infiltration associated with a decrease of MCP1 
expression in IL-15 and IL-15/IL-15Rα treated mice (p<0.05, n=7 mice/group). IL-15 also 
reduced TGFb1-induced EMT in vitro on RPTEC and tubular cell line (HK2) (p<0.05). 
This protective effect of IL15 acted through Snail inhibition and C-Jun activation (p <0.05). 
Furthermore, we found a direct inhibition of IL-15 on collagen synthesis, in both HK2 
(collagen IV) and myofibroblasts (collagen I and III).
Conclusions: In conclusion, IL-15 can attenuate TGFb1-induced EMT by acting 
directly through a reduction of collagen synthesis, both on myofibroblast, the main effector 
of fibrosis, and tubular cell. IL-15 also modulates macrophages infiltration in vivo in UUO. 
Therefore IL-15 could be a novel therapeutic player in renal diseases.
SA-PO434
Loss of the Vascular Class 3 Semaphorin, Semaphorin 3G, Leads to 
Attenuated Fibrosis and Reduced Tubular Injury by Unilareral Ureteral 
Obstruction in Mice  Kana Ide,1 Yoshiro Maezawa,1 Shintaro Ide,1 Christer 
Betsholtz,2 Minoru Takemoto,1 Koutaro Yokote.1  1Clinical Cell Biology and 
Medicine, Chiba Univ Graduate School of Medicine, Chiba, Japan; 2Dept of 
Immunology, Genetics and Pathology, Uppsala Univ, Uppsala, Sweden.
Background: Chronic kidney disease (CKD) is a large social health issue, affecting 
10-16% of the adults worldwide. In advanced stage of CKD, tubulointerstitial fibrosis 
occurs and promotes renal failure. Although a number of cell types and secretary factors 
are known to be involved in the formation of renal fibrosis, its precise mechanisms are still 
unclear. Semaphorin 3G (Sema3G) belongs to a class 3 family of secreted semaphorin. 
Class 3 semaphorins binds to neuropillin receptors and plexin coreceptors, showing various 
biological functions in neural development, angiogenesis, immunological response, and 
tumorigenesis. In the kidney, Sema3G is expressed in podocytes and endothelial cells of 
extraglomerular blood vessels. However, its role in renal fibrosis is still unknown.
Methods: To understand the role of Sema3G in renal fibrosis, Sema3G knockout mice 
and control mice are subjected to unilateral ureteral obstruction (UUO).
Results: Histologically, UUO kidneys does not show obvious difference between 
controls and Sema3G KO. However, although mRNA expression of Tgfb and Snail, a 
key regulator of Tgfb-induced fibrosis, increases by UUO in controls, these increases are 
attenuated in Sema3G KO UUO kidneys (for Tgfb, 55% suppression compared to controls, 
P<0.01). In addition, mRNA expression of Acta2 and Fibronectin, and serum BUN level 
tend to be reduced in Sema3G KO after UUO. Expressions of inflammatory markers do not 
show a consistent tendency. Interestingly, increase of a tubular injury marker, Kim-1, after 
UUO is largely suppressed in Sema3G KO mice (77% suppression compared to controls, 
P<0.05 at day3,95% suppression, P<0.01 at day7), suggesting that Sema3G KO mice are 
protected from tubular injury.
Conclusions: Together, these data demonstrate that endothelial Sema3G acts on 
adjacent tubular/interstitial cells and promotes fibrosis by UUO. Identification of the 
mechanism of this interaction would provide new therapeutic targets for CKD and renal 
fibrosis.
Funding: Government Support - Non-U.S.
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Leukemia Inhibitory Factor Attenuates Tubulointerstitial Fibrosis in 
Unilateral Ureter Obstruction  Sebastian Alexander Potthoff, Fabian Srugies, 
Lars C. Rump, Ivo Quack.  Nephrology, Medical Faculty - Heinrich Heine Univ 
Duesseldorf, Duesseldorf, Germany.
Background: Tubulointerstitial fibrosis is common in chronic kidney disease which 
is often sustained by chronic inflammation. CD4+ T-cells play an important role in 
immune response in kidney disease. Leukemia inhibitory factor (LIF), a member of the 
Interleukin 6 family, and Interleukin 6 (IL-6) play a crucial role in regulating the balance 
between Th17- and regulatory T-cells (Treg): LIF augments expression of forkhead-box-P3 
(Foxp3) leading to Treg, IL-6 induces RAR-related orphan receptor gamma (RORyt) 
driving Th17 lineage development. Dysregulation or overproduction of Th17 cells result 
in sustained inflammation. Here, we investigate how LIF influences renal inflammation 
and tubulointerstitial fibrosis in unilateral ureter obstruction (UUO).
Methods: 6-8-week old male C57BL/6 mice were treated intraperitoneally daily either 
with LIF (10µg/kgBW; n=7) or PBS (control; n=8) starting 2 days prior to UUO. At day 
10 after UUO, kidneys, spleen and paraaortal lymphnodes were extracted.
Results: qPCR from tissue lysates of obstructed kidneys (OB) revealed that NFκB 
and RANTES as well as collagen1 and TGF-ß were significantly downregulated in LIF 
treated mice. There was no significant difference between IL17a, IL-1b, MCP1, IL-6, 
TNFα, PAI1 and PDGFR1. Accordingly, expression of MCP1, NFκB, RANTES and TNFα 
in the paraaortal lymphnodes were reduced by LIF. IL-1b and IL-6 expression tended to 
be reduced by LIF but failed to reach statistical significance. CD3+ cells accumulated 
in obstructed kidneys. LIF significantly reduced renal infiltration of CD3+ cells (OB vs. 
OB+LIF: 144±6 vs. 115±8; p<0.01) and F4/80+ cells. LIF treatment significantly reduced 
tubulointerstitial fibrosis in obstructed kidneys assessed by Sirius Red morphometry (OB 
vs. OB+LIF: 10.3±2.4 vs. 5.1±1.2 %-area; p<0.05) and collagen1 Western Blot analysis 
(OB vs. OB+LIF: 0.77±0.12 vs. 0.32±0.09 arbitrary units; p<0.01).
Conclusions: These data confirm the critical role of inflammation in UUO. LIF 
treatment significantly attenuates tubulointerstitial fibrosis by inhibiting pro-inflammatory 
pathways and T-cell infiltration indicating a possible future treatment option.
Funding: Clinical Revenue Support
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Dendritic Cell-Specific Shp-1-Knockout Mice Spontaneously Develop 
Unique Glomerulo- and Tubulointerstitial Nephritis  Mitsuharu Watanabe,1 
Keiju Hiromura,1 Yoriaki Kaneko,1 Masato Kinoshita,1 Yuko Ohishi,1 Toru 
Sakairi,1 Hidekazu Ikeuchi,1 Akito Maeshima,1 Hiroshi Ohnishi,2 Takashi 
Matozaki,3 Yoshihisa Nojima.1  1Dept of Medicine and Clinical Science, Gunma 
Univ Graduate School of Medicine, Japan; 2Dept of Laboratory Sciences, 
Gunma Univ Graduate School of Health Sciences, Japan; 3Div of Molecular and 
Cellular Signaling, Dept of Biochemistry and Molecular, Kobe Univ Graduate 
School of Medicine, Japan.
Background: Src homology 2 domain-containing protein tyrosine phosphatase-1 
(Shp-1) is a nonreceptor-type protein tyrosine phosphatase, which is highly expressed in 
hematopoietic cells. We have previously reported that dendritic cell (DC)-specific Shp-1 
conditional knockout mice (CKO) spontaneously developed pneumonitis and nephritis at 
around 40 wks of age, together with anti-dsDNA antibody (J Immunol. 2012; 188, 5397). 
In the current study, we further characterize the renal lesions in the CKO mice.
Methods: CKO mice were generated by mating Shp-1-flox mice and CD11c-Cre mice. 
Mice were sacrificed at 8, 20, and 40 wks or later.
Results: Compared to control mice, CKO mice showed significantly higher serum 
creatinine at 40 wks or later. Anti-dsDNA antibody was detected at low levels at 8 wks and 
markedly elevated at 20 and 40 wks. At 40 wks, CKO mice showed severe proliferative 
glomerulonephritis and tubulointerstitial nephritis by light microscopy with mesangial IgG 
and C3 depositions by IF staining. Electron microscopy revealed electron dense depositions 
in mesangial area, but few in subendothelial or subepithelial area. Immunohistochemical 
staining showed marked accumulation of DCs (CD11c+), macrophages (F4/80+) and helper 
T cells (CD4+) at periglomerular and tubulointerstitial area. Infiltration of numerous DCs 
was also observed within glomeruli. Flow cytometric analysis of the CKO kidney showed 
the inflammatory cells increased with increasing age. Despite the prominent morphological 
changes, there was no significant increase of albuminuria, even at 40 wks.
Conclusions: The DC-specific ablation of Shp-1 in mice resulted in development of 
unique autoimmune glomerulo- and tubulointerstitial nephritis, which is distinct from typical 
lupus nephritis characterized by wire-loop lesions and heavy proteinuria.
Funding: Government Support - Non-U.S.
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TLR4 Mutant Mice Are Protected from Renal Fibrosis following Folic Acid 
Injection  Ana C. Souza,1 Irina Baranova,2 Alexander V. Bocharov,2 Jonathan 
Street,1 Xuzhen Hu,1 Kenneth J. Wilkins,1 Peter S.T. Yuen,1 Robert A. Star.1 
1Kidney Diseases Branch, NIDDK, NIH, Bethesda, MD; 2Clinical Center, NIH, 
Bethesda, MD.
Background: Local renal inflammation contributes to interstitial fibrosis (IF). Toll-
like receptor 4 (TLR4) drives inflammation/ inflammasome and is expressed on renal 
epithelial cells (RECs). In the folic acid (FA) model of renal fibrosis there is an acute 
phase of acute tubular damage and a later phase of IF. To evaluate the role of TLR4 in 
renal inflammation-fibrosis, we analyzed the degree of inflammation that is dependent on 
TLR4 in RECs from WT or TLR4 mutant mice subjected to LPS. We further compared IF 
following FA injection in both strains.
Methods: Primary cultures of RECs isolated from WT or TLR4 mutant mice were 
incubated for 20h with increasing doses of LPS. Supernatant IL-6 was measured by ELISA. 
Total RNA was extracted, and RTqPCR performed for IL-6, IL-1β, NLRP3, and GAPDH. 
Results were normalized by protein content. Exact stratified Wilcoxon test was used for 
differences. In vivo, FA (250 mg/kg IP) was given to 9 wk old TLR4 WT or mutant mice 
(N=16/group). Day 2 BUN was used as an AKI marker. Mice with [day 2:baseline BUN] 
ratio above 1.5 were included. At day 14, mice were euthanized and kidneys harvested 
for IF by Masson trichrome stain. Changes in IF (after adjusting for day 2 log BUN) were 
analyzed by regression analysis.
Results: LPS dose-dependently increased IL-6 secretion in TLR4 WT RECs , but TLR4 
mutant RECs secreted very low levels of IL-6, and IL-6 mRNA expression was 7-fold lower 
than WT cells. TLR4 mutant RECs expressed less NLRP3 (2-fold), and IL-1β (40-fold). 
Day2 log BUN was not different between the groups at day 2, and correlated with day 14 
IF (p<0.01). After adjustment for day2 log BUN, TLR4 mutant mice were protected from 
IF at day 14 (p=0.014). Renal mRNA expression of IL-6, TNF-α, and TGF-β were not 
different between the strains at day 14.
Conclusions: In vitro, TLR4 signaling can stimulate inflammasomes and inflammatory 
cytokine production RECs. In vivo, although TLR4 is not required for the acute phase injury, 
the TLR4-mutant is protected from interstitial fibrosis, potentially via reduced sensitivity 
to DAMPs released after acute injury.
Funding: NIDDK Support
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A New Mouse Model of Glomerular Foam Cell Accumulation in Disease 
Minseob Eom, Kelly L. Hudkins, Anna Batorsky, Charles E. Alpers.  Dept of 
Pathology, Univ of Washington School of Medicine, Seattle, WA.
Background: Foam cells are lipid-laden cells of monocyte/macrophage origin which 
have a key role in the development of atherosclerosis. Similar foam cells are found in 
human kidney biopsies in various diseases (e.g. tip and cellular variants of focal segmental 
glomerulosclerosis (FSGS), diabetic nephropathy, and the interstitium in nephrotic states). 
The pathophysiologic significance of foam cells in the kidney is poorly understood, in part 
due to lack of good animal models. We sought to develop a robust animal model for foam 
cell accumulation in the kidney to test their pathogenic significance.
Methods: Six-week old apolipoprotein E (Apo E)-null C57BL/6 mice were divided 
into two groups. Group 1: Mice were gavaged daily with 1% hydropropyl methyl cellulose 
with 0.1% tween 80 (HPMC-Tween) (10ml/kg) for 30 days. Group 2: Untreated age-
matched controls. Each organ including kidney was harvested for histologic evaluation. 
Immunohistochemical stains (IHC) for Mac2 were performed to quantify the state of 
monocyte/macrophage infiltration and urinalysis was conducted to calculate the urine 
albumin-creatinine ratio (ACR) and total albumin excretion.
Results: IHC for Mac2 revealed that 83.76% of glomeruli were infiltrated by foam cells 
in the HPMC-Tween treated group. Most showed several foam cells in each glomerulus. 
Neither FSGS nor mesangiolysis nor interstitial foam cell accumulation developed in 
the treated mice despite the prominent glomerular foam cells. Additionally, there was 
no significant difference in ACR between treated group and control group, although the 
treated mice revealed a trend of higher urine ACR, compared with pre-treatment urine.
Conclusions: Treated mice developed widespread glomerular foam cells. FSGS, 
mesangiolysis, or interstitial changes that are features of human renal foam cell injury did not 
develop within the limited 30 day observation period during which foam cells accumulated. 
We speculate affected mice may not have had sufficient time to develop sclerosis. Apo E 
null mice treated with HPMC-Tween has potential to be a good animal model for the studies 
of the tip and cellular variants of FSGS, for which no good mouse models currently exist.
Funding: Pharmaceutical Company Support - Genzyme
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Aberrant Methylated DNA Regions Lead to Low Activation of CD4+ T 
Cells with a Consequent  Imbalance of the Th1/Th2 Polarization in IgA 
Nephropathy Patients  Fabio Sallustio,1,2,3 Grazia Serino,1 Alessandra Dalla 
Gassa,4 Claudia Curci,3 Giuseppe De Palma,3 Barbara Banelli,5 Gianluigi Zaza,4 
Massimo Romani,5 Francesco Paolo Schena,1,3 Sharon N. Cox.1  1DETO, Univ of 
Bari, Bari, Italy; 2DiSTeBA, Univ del Salento, Lecce, Italy; 3Consorzio Carso, 
Valenzano, Italy; 4Dept of Medicine, Univ of Verona, Verona, Italy; 5IST, IRCCS 
San Martino, Genova, Italy.
Background: The immunoglobulin A nephropathy (IgAN) pathogenesis has a strong 
genetic component. In this setting, also the DNA methylation could be an important factor 
influencing the pathology. Aim of our study was the identification of abnormally methylated 
regions in CD4+T cells of IgAN patients.
Methods: A genome-wide screening of the DNA methylation CD4+T cells from 6 IgAN 
patients and 6 healthy subjects (HS) was performed. Differentially methylated regions have 
been validated on 40 samples of IgAN and HS by pyrosequencing and functional studies by 
5-aza-2’-deoxycytidine and MSP-RT-PCR. The gene expression was verified by RT-PCR. 
Activation of CD4+T cells was studied by BrdU proliferation assays and IL2 and IL4 ELISA.
Results: We found 161 tiling regions, 12 promoters, 12 genes and 5 CpG islands 
differentially methylated. Three regions differentially methylated included genes 
involved in the response and proliferation of CD4+ T cells. In particular, we identified 
an hypermethylated region containing the gene codifying for the miR-886 precursor and 
two hypomethylated regions containing TRIM27 and DUSP3 genes involved in the T cell 
receptor (TCR) signaling. We showed that these genes were dysregulated due to the aberrant 
methylation in IgAN patients. Moreover, we demonstrated that the hypermethylation of 
miR-886 precursor led to a decreased CD4+ T cell proliferation following TCR stimulation 
and to an over-expression of the TGFβ, also regulated by the miR-886 precursor.
Conclusions: We describe, for the first time, some DNA regions abnormally methylated 
in IgAN patients, some of which including genes involved in the TCR signalling and CD4+ 
T cell response and proliferation. These abnormalities led to a reduced activation of CD4+ 
T cells with a consequent T helper cell imbalance. These findings may play an important 
role in the pathogenesis of IgAN.
SA-PO440
5-Aza-2-Deoxycytidine Reduces Nephrotoxic Nephritis and DNA 
Cytosine Methylation in Nephritic Glomeruli and Macrophages In Vitro 
Thomas Oates,1 Stephen Paul McAdoo,2 Charles D. Pusey,2 H. Terence Cook,2 
Enrico Petretto.3  1Imperial NHS Trust, London, United Kingdom; 2Imperial 
College London, London, United Kingdom; 3MRC Clinical Sciences Centre, 
London, United Kingdom.
Background: Nephrotoxic nephritis (NTN) is a macrophage dependent rat model 
of crescentic glomerulonephritis (CRGN). We investigated whether DNA cytosine 
methylation could determine dysregulation of macrophage activity and contribute to CRGN 
susceptibility, by examining the effect of 5-aza-2’-deoxycytidine (DAC), an inhibitor of 
DNA methylation, on NTN phenotypes and DNA methylation in both nephritic glomeruli 
and bone marrow derived macrophages.
Methods: NTN was induced in male WKY rats. 6 rats were treated with intra 
peritoneal DAC and 6 controls with vehicle only. Treatment was given every three days 
prior to sacrifice at 10 days and then NTN phenotypes assayed. The effect of DAC on 
DNA methylation was examined by multiplexed PCR sequencing of bisulfite converted 
DNA in both nephritic glomeruli from NTN animals, and in WKY bone marrow derived 
macrophages treated in vitro with DAC.
Results: DAC treated animals had fewer glomerular crescents, less proteinuria and 
less glomerular macrophage infiltration (ED1 staining).
DNA methylation in nephritic glomeruli was decreased across 200 cytosine bases 
in DAC treated samples compared to controls (P = 0.049, Wilcoxon rank sum test). This 
decrease was driven by 39 cytosines that showed demethylation in DAC treated animals. In 
vitro sequencing in macrophages showed diverse methylation changes after DAC treatment 
depending on length of exposure and dose.
Conclusions: These experiments show that DAC treatment had a protective effect 
on NTN phenotypes in WKY rats with a reduction in DNA cytosine methylation in both 
nephritic glomeruli and macrophages. These results suggest that DNA methylation may 
be involved in the pathogenesis of CRGN and may represent a target for intervention.
Funding: Government Support - Non-U.S.
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Macrophages Present an Essential Source of Anti-Inflammatory Annexin A1 
Signals During the Course of Acute Anti-Thy-1.1 Nephritis  Robert Labes,1 
Philipp Dittert,1 Sebastian Bachmann,1 Alexander Paliege.1,2  1Dept of Anatomy, 
Charité - Universitätsmedizin Berlin, Berlin, Germany; 2Dept of Nephrology, 
Charité - Universitätsmedizin Berlin, Berlin, Germany.
Background: Macrophage subpopulations exert distinctive effects during inflammatory 
kidney disease and may either aggravate kidney damage or foster renal repair. The anti-
inflammatory protein annexin A1 (AnxA1) has been shown to shift macrophage polarization 
towards the anti-inflammatory M2 phenotype. Cellular sources and regulation of intrinsic 
AnxA1 signals during renal inflammation remain to be elucidated.
Methods: Adult Wistar rats were injected with anti-Thy-1.1 antibody to induce 
mesangioproliferative glomerulonephritis and examined after 24h (initiation phase), 5d 
(proliferation phase), and 15d (resolution phase). Regulation of AnxA1 was studied by 
qPCR and immunohistochemistry. AnxA1+ cells were characterized by triple labelling 
immunofluorescence using antibodies against CD68 for monocytes and macrophages, and 
CD206 for macrophages with M2 polarization. Quantification of immunoreactive cells was 
performed by cell counting on confocal micrographs.
Results: Induction of anti-Thy-1.1 nephritis caused a rapid increase of renal AnxA1 
mRNA levels (24h: +92±16%; 5d: +128±19%; 15d: +78±33% relative to controls; p<.05). 
Quantitative image analysis revealed a pronounced interstitial accumulation of total, and 
CD206+ M2 macrophages at d5 (+150±40% and +260±29%; p<.05) and d15 (+378±43% 
and +600±100%; p<.05) as compared to controls. Triple labelling studies revealed elevated 
numbers of CD68+/CD206+/AnxA1+ interstitial M2 macrophages at d5 and d15 as 
compared to controls (+240±27% and +450±80%; p<.05). CD68+/CD206-/AnxA1+ 
macrophages were increased to a lesser extent (d15: +270±47% relative to controls; p<0.05).
Conclusions: In conclusion, we have shown that AnxA1 expression and protein 
abundance are significantly increased during the course of anti-Thy-1.1 nephritis. 
Accumulation of CD206+/AnxA1+ and CD206-/AnxA1+ macrophages at d15 suggests 
that these cells present a relevant source for anti-inflammatory AnxA1 signals during 
the resolution phase of renal inflammation. Further studies are needed to establish the 
characteristics of these cells.
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SA-PO442
Reduced Mitochondrial Energy Production in the Kidney Induces Focal 
Segmental Glomerulosclerosis in Low-Birth-Weight Rats at Adulthood 
Toshiyuki Imasawa.  Kidney Center, National Hospital Organization Chiba-East 
Hospital, Chiba-City, Chiba, Japan.
Background: Intraglomerular hypertension has been linked with the pathogenesis of 
focal segmental glomerulosclerosis (FSGS) lesions in low-birth-weight (LBW) -related 
nephropathy, which is associated with a decreased number of nephrons. However, other 
mechanisms may participate in the pathogenesis of LBW-related nephropathy. Here, we 
investigated innate factors that could induce LBW-related nephropathy at adulthood.
Methods: LBW rats (N = 7) were obtained by intraperitoneally injecting pregnant rats 
with dexamethasone. Normal-birth-weight (NBW) rats (N = 7) were obtained by saline 
injection. At 4 weeks of age, the left kidney was removed and used for histological analysis 
and quantitative proteomics (label-free LC-MS). At 9 weeks of age, the right kidney was 
histologically analyzed.
Results: At 4 weeks of age, glomerular numbers in LBW rats were significantly lower 
than NBW rats (p < 0.01) . However, there were no sclerotic lesions, and neither group 
showed any other pathological changes at this age. At 9 weeks of age, FSGS lesions were 
observed in 7.4% of glomeruli in LBW rats, but only 0.5% of glomeruli had lesions in 
NBW rats. The pathological changes in LBW rats at 9 weeks of age resembled that of 
human LBW-related nephropathy. Quantitative proteomics using the renal cortex from 
4-week-old rats revealed that 685 proteins decreased in LBW rats compared with NBW 
rats, and among them, 97 proteins (14.2%) were mitochondrial proteins. In such reduced 
mitochondrial proteins, 12 subunits of OXPHOS, especially of complex III and V, and 15 
enzymes of TCA cycle were significantly decreased in LBW rat cortexes (p < 0.05). Western 
blotting revealed the reduced expression of p-AMPK, NRF-1, and TFAM, which are master 
regulators of mitochondrial biogenesis, in LBW rats at 4 weeks of age.
Conclusions: This is the first report to investigate the innate suppression of 
mitochondrial energy production in LBW animals. We have shown that in addition to 
intraglomerular hypertension, innate defects to mitochondrial energy production should 
induce the formation of FSGS lesions in LBW-related nephropathy at adulthood.
SA-PO443
Chronic Hypoxia Does Not Activate Innate Immunity Neither Promotes 
Kidney Injury in Normal Rats or Undergoing Renal Ablation 5/6 
Lisienny C.T. Rempel, Gizely C.S. Moreira, Thalita F. Nascimento, Camilla 
Fanelli, Orestes Foresto-Neto, Simone C.A. Arias, Viviane D. Faustino, Claudia 
R. Sena, Vivian L. Viana, Victor F. Avila, Denise M. Malheiros, Niels O.S. 
Camara, Clarice K. Fujihara, Roberto Zatz.  Univ of Sao Paulo, Brazil.
Background: Tissue hypoxia (Hyp) is thought to influence the pathogenesis of chronic 
kidney disease (CKD), but direct evidence that prolonged exposure to tissue Hyp initiates 
or aggravates CKD is lacking. We tested this hypothesis by chronically exposing to Hyp 
normal rats and rats with 5/6 nephrectomy (Nx). In addition, we investigated whether such 
effect of Hyp would involve activation of innate immunity.
Methods: Adult male Munich-Wistar rats underwent Nx (n=30) or sham surgery (S, 
n=19). Seven S (Snor) and 13 Nx (Nxnor) rats remained in normoxia, while 12 S rats (Shyp) 
and 17 Nx rats (Nxhyp) were kept in a normobaric Hyp chamber (12% O2). Results at 8 
weeks (BW, body weight, g; Hb, hemoglobin, g/dL; TCP, tail-cuff pressure, mmHg; Ualb/
Ucr, urine albumin/creatinine; KW/BW, kidney/body weight; GSI, glomerulosclerosis 
index; %INT, % cortical interstitium; MØ, interstitial macrophages, cells/mm2; renal IL-1β 
(pg/g); and TLR-4 (2-∆∆Ct).
Results: 
Snor Shyp Nxnor Nxhyp
BW 307±8 285±7b 280±6a 271±6
Hb 15.6±0.2 18.1±0.6b 14.1±0.4 16.6±0.5b
TCP 143±2 139±3 195±7a 182±5a
Ualb/Ucr 0.2±0.1 0.2±0.1 4.9±1.3a 3.7±0.6a
KW/BW 0.5±0.0 0.4±0.0 0.5±0.0 0.4±0.0b
GSI 0.3±0.3 0.3±0.1 9.9±4.9a 3.3±0.9ab
%INT 0.6±0.2 0.1±0.1 8.4±1.8a 4.6±1.2ab
MØ 9±3 11±2 76±6a 38±7ab
IL-1β 2.1±0.5 1.6±0.3 8.8±2.6a 4.4±1.2b
TLR-4 1.03±0.12 0.93±0.08 2.69±0.30a 2.15±0.16ab
Mean ± SE, ap <0.05 vs. respective S, bp <0.05 vs respective Nor.
Exposure to Hyp increased Hb in both S and Nx, but led to no injury or elevation of 
the renal content of IL-1β or TLR-4 in S. Unexpectedly, Hyp attenuated IL-1β, TLR-4, 
Mĭ, GSI and %INT in Nx.
Conclusions: We found no evidence that chronic Hyp initiates or worsens CKD. 
Chronic Hyp may be even renoprotective by unclear mechanisms, perhaps involving 
adaptive molecules. FAPESP/CNPq.
Funding: Government Support - Non-U.S.
SA-PO444
Methylation Decreases Expression of Erythropoietin in Fibrosing Kidney 
Disease  Ching-chin Yang,1 Yu-ting Chang,1 Szu Yu Pan,2 Yu-hsiang Chou,1 
Yung-ming Chen,2 Shuei-Liong Lin.1,2  1Physiology, National Taiwan Univ 
College of Medicine, Taipei, Taiwan; 2Internal Medicine, National Taiwan Univ 
Hospital, Taipei, Taiwan.
Background: Renal erythropoietin-producing cells remain in atrophic kidneys and are 
capable of producing erythropoietin in dialysis patients who take the stabilizer of hypoxia-
inducible factors. The mechanism of decreased response of renal erythropoietin-producing 
cells to anemic stimulation in chronic kidney disease remains unclear.
Methods: We use genetically modified mice who report pericytes/myofibroblasts 
and express pericyte-specific Cre recombinase to perform in vivo study. We also isolate 
pericytes/myofibroblasts from these mice for in vitro analysis of epigenetic modification 
and erythropoietin expression.
Results: Here we show that Foxd1+ progenitor-derived;Col1a1-GFP+;PDGFRbeta+ 
kidney pericytes are erythropoietin-producing cells regulated by hypoxia-inducible factor 
2 alpha but decrease such a function upon their transition to myofibroblasts in fibrosing 
kidney disease. Hypermethylation of erythropoietin 5’-untranslated region is demonstrated 
and associated with decreased expression of erythropoietin in kidney myofibroblasts. 
Demethylation with 5-azacytidine or knockdown of upregulated DNA methyltransferase 
1 in kidney myofibroblasts is found to increase expression of erythropoietin in fibrosing 
kidney disease.
Conclusions: These studies demonstrate that epigenetic modifications may provide a 
molecular basis for decreased response of renal erythropoietin-producing cells to anemic 
stimulation in fibrosing kidney disease.
Funding: Government Support - Non-U.S.
SA-PO445
Multiparametric Magnetic Resonance Imaging for Assessing Renal 
Histopathology in a Mouse Model of CKD  Gunnar Schley,1 Jutta Janke,2 
Kai-Uwe Eckardt,1 Tobias Bäuerle,2 Carsten Willam.1  1Nephrology and 
Hypertension, Univ of Erlangen-Nuremberg, Erlangen, Germany; 2Radiology, 
Univ of Erlangen-Nuremberg, Erlangen, Germany.
Background: Multiparametric magnetic resonance imaging (MRI) allows non-invasive 
assessment of renal pathologies, especially in patients with chronic kidney disease (CKD) 
as is does not require contrast agent administration. We aimed to establish an imaging 
protocol for multiparametric MRI in an experimental CKD mouse model and correlate 
radiological and histopathological parameters.
Methods: CKD was induced in male C57BL/6 mice (n=8) by feeding an adenine-
supplemented diet for 3 weeks resulting in deposition of dihydroxyadenine crystals, tubular 
dilation, capillary loss, tubulointerstitial inflammation and fibrosis. Untreated animals 
(n=8) served as controls. Kidneys were fixed in paraformaldehyde and subjected to MRI 
in a 7-Tesla scanner ex vivo. Volumetry of renal cortex and medulla was performed on T2 
weighted sequences. MRI parameters (apparent diffusion coefficient (ADC), fractional 
anisotropy (FA), T1, T2, T2* relaxation times) were determined for 3 regions of interest 
placed manually in the cortex and outer medulla, compared between CKD and controls 
kidneys and correlated with (immuno-)histological analyses for crystal density, tissue 
cellularity, tubular dilation, inflammatory infiltration, fibrosis, and vascularization.
Results: CKD resulted in significant volumetric augmentation of the medulla. T1 times 
did not differ in control and diseased kidneys, T2 and T2* times were significantly increased 
in both cortex and medulla, whereas ADC was increased only in the cortex of diseased 
kidneys in comparison to controls. In contrast, FA was significantly reduced in diseased 
cortex and medulla. T2 time correlated with the relative area of fibrosis (Spearman’s rho 0.71 
for cortex, 0.79 for medulla), infiltrated macrophages (0.69, 0.81), and tubular lumen (0.74).
Conclusions: Multiparametric MRI enabled characterization and diagnosis of chronic 
changes in the presented CKD model and showed correlation of T2 times with fibrosis, 
inflammatory infiltration, and tubular dilation. These results may help to broaden our 
understanding of MRI findings in CKD patients.
SA-PO446
Nuclear Magnetic Resonance Based Metabonomic Profiles Produced by 
Aristolochic Acids: Comparison with Well-Known Tubulotoxic Agents 
Marilyn Duquesne,1,2 Nordinn Rabai,1 Anne-Emilie Decleves,2 Coulon 
Françoise,3 Eric De prez,2 Jean-Marie Colet,1 Joelle L. Nortier.2  1Lab Human 
Biology & Toxicology, UMONS; 2Lab Experimental Nephrology, ULB; 3Lab 
Histology, UMONS.
Background: Aristolochic acids (AA) are powerful nephrotoxic and carcinogenetic 
products derived from Aristolochiaceae responsible for acute to chronic renal failure 
and urothelial cancer complications in countries using traditional herbal medicine. Early 
detection of renal tubular injury could be useful in individuals at risk of exposure to AA.
Methods: The Consortium of Metabonomic in Toxicicology (COMET) has developed 
predictive models of renal toxicity based on the NMR-based metabonomic evaluation of 
urine and serum samples collected from rats acutely exposed to various well characterized 
nephrotoxicants. Using this COMET protocol, we studied the metabonomic urine profile of 
rats exposed to one sc injection of AA I or II at different dosages (75, 100mg/kg). We then 
compared it to those obtained with 3 molecules known for their toxicity on the proximal 
tubule, i.e ifosfamide (Ifo: 7, 70mg/kg), gentamicin (Genta: 40, 400mg/kg) and cisplatin 
(Cis: 0.5, 5mg/kg), respectively.
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Results: Metabonomic results obtained in AA rats demonstrated a urinary increase in 
metabolites involved in osmoregulation (taurine, betaine, glycine), cell death (lactate) and 
in reabsorptive capacity of the tubular epithelium (glucose), and a significant reduction 
of Krebs’s cycle components (alpha-ketoglutarate, succinate, citrate), suggesting a 
mitochondrial injury. The comparison of these AA profiles with those obtained with Ifo, 
Genta and Cis revealed close similarities in 2D plots. However, the 3D modelization 
approach showed very close score plots shared by AA, Ifo and Cis and a different behaviour 
exhibited by Genta samples.
Conclusions: This metabonomic study confirms the mode of action of AA towards the 
proximal tubule and provides an original signature of induced mitochondrial insult. This 
approach could bring new insight in understanding the toxicity pathways of AA within 
the kidney. Moreover, it could be a useful tool of noninvasive screening in populations at 
risk of AA intoxication.
SA-PO447
Establishment of a 3-Step Method to Obtain the Absolute Number of 
Nephrons in Mice  Xiaogang Chu, Jian-Kang Chen.  Depts of Cellular Biology 
& Anatomy and Medicine, Georgia Regents Univ, Augusta, GA.
Background: Low nephron number is implicated in hypertension and kidney disease. 
Existing methods to determine nephron number have various limitations. While using the 
Cre reporter mice expressing membrane-Tomato/membrane-Green fluorescent protein (mT/
mG) for other studies, we fortuitously noticed that the Tomato fluorescence remarkably 
visualized all glomeruli in the kidneys, which prompted us to establish a 3-step (Separate-
Press-Count) method to obtain the exact nephron number in mice.
Methods: One homozygous mT/mG mouse ($232, available from the Jackson 
Laboratory, Stock Number: 007576) was bred with FVB/NJ mice. This produced ~11 
heterozygous pups per litter. After the pups reached 6 weeks of age, they were weighed 
and euthanized. Each kidney was decapsulated, weighed, and bluntly separated into 35-45 
pieces (1-2 mm3 each) using forceps with non-serrated but blunted tips. Each piece was 
pressed between a microscope slide with grids and a coverslip, followed by counting of 
every single glomerulus under a fluorescence microscopy.
Results: The nephron number in male mice ranged from 10421 to 15577 (mean = 12977 
± 2136) for left kidney and 10374 to 15691 (mean = 13271 ± 2414) for right kidney (n=6) 
while that of female mice ranged from 13890 to 16277 (mean = 15184 ± 993) for left kidney 
and 14547 to 16165 (mean = 15555 ± 741) for right kidney (n=5). Thus, the mean total 
nephron number in male mice (25562 ± 4530) is lower than that of female mice (30739 ± 
1443). This is still true when expressed as mean nephron number per gram of body weight 
(N/gBwt): male 1025 ± 179 vs. female 1362 ± 90; n=5-6, p<0.01). 5/6 nephrectomy (Nx) 
in male mice decreased N/gBwt down to 156 ± 17, increased blood pressure (BP) up to 
142 ± 7 mmHg, elevated BUN level up to 292 ± 7 mg/dl, and caused 37.5% mice to die 
within 2 weeks while the remaining 5/6Nx mice with >241 N/gBwt had 130 ± 8 mmHg 
BP and 73 ± 25 mg/dl BUN and were still alive even 4 weeks after 5/6 Nx.
Conclusions: We have established a new simple method to count the absolute nephron 
number and are using it to define the minimum of nephrons per gram of body weight that 
can maintain the normal blood pressure and kidney function in mice.
Funding: NIDDK Support
SA-PO448
New Aspects on the Difference in Permeability Between Proteins and 
Polysaccharides in the Glomerular Filtration Barrier  Carl Mikael Öberg,1 
Joseph J. Groszek,2 William Henry Fissell,2 Bengt Rippe.1  1Dept of Nephrology, 
Lund Univ, Lund, Skane, Sweden; 2Nephrology and Hypertension, Vanderbilt 
Univ, Nashville, TN.
Background: One of the many unresolved questions regarding the permeability of the 
glomerular filtration barrier (GFB) is the reason behind the marked difference in permeability 
between albumin and polysaccharide probe molecules such as Ficoll. The difference in 
sieving coefficients between albumin and a Ficoll molecule of the same molecular size 
(~36 Å) is ~2-3 orders of magnitude. Although this large difference in permeability has 
been attributed mainly to charge effects, we have previously shown that this would require 
a supraphysiological amount of charge on the filtration barrier, being about ~10 times more 
than the charge on the albumin molecule (~0.02 C/m²).
Methods: The classic heteroporous model by Deen, Bridges, Brenner and Myers (Deen 
et al, AJP Renal Physiology, 1985) was extended by introducing size distributions on the 
solute molecules, making them flexible in their conformation. Experimental sieving data 
for Ficoll, both from the rat glomerulus and from precision-made nanopore membranes, 
were analyzed using the model. The variation in solute size was quantified in terms of the 
geometric standard deviation (gSD) of the solute size distribution. The (mode) solute radius 
was assumed to be equal to the SE-radius and the pore size distribution gSD was set to unity.
Results: For the glomerulus (n=7), a gSD for the Ficoll size-distribution of 1.16 (± 0.01) 
was obtained, along with a small pore radius of 36.1 Å (± 0.5 Å) and a large pore radius 
of 152 Å (± 7 Å). For the nanopore membranes (n=16), a gSD of 1.24 (± 0.01) was found.
Conclusions: In the current study, we show, for the first time, that a variation of only 
~15-17% in the size of the molecule is sufficient to explain the difference in permeability 
between albumin and Ficoll. In addition, we show that the effects of applying a size-
distribution on the solute molecule are only evident when the molecular size is close to 
the size of the selective elements of the barrier. This is well in line with experimental data, 
both from the GFB and from synthetic membranes.
Funding: Private Foundation Support, Government Support - Non-U.S.
SA-PO449
Rapid MicroRNA Isothermal Amplification and Detection in Urine for 
Nephrotic Syndrome and Other Renal Disease Biomarker Discovery 
Kathrin Gassei, Chandramohan Ishwad, Jacqueline Ho, Abhay N. Vats. 
Pediatrics, Childrens Hospital of Pittsburgh, Pittsburgh, PA.
Background: MicroRNAs play an important role in renal development and are being 
explored as biomarkers for several renal diseases including nephrotic syndrome (NS). 
However, miRNA detection assays can be expensive, laborious, and time consuming. 
We have been developing a fast and reliable assay for microRNAs in urine and report a 
novel isothermal amplification method. We tested this method [ called cross hybridization 
amplification (CHAMP)] for detection of miR-30a-5p in urine of patients with NS and 
controls.
Methods: We designed two 20-25 nt  primers and a probe specific for miR-30a-5p. 
Primers were labeled with either Biotin or Digoxigenin on the 3’-end. Synthetic miR targets 
were developed for miR-30a, miR30b and Let7 microRNAs. Amplification required, Bst 
DNA polymerase enzyme, and incubation at 65°C for 30-60 min. Assay optimization 
was performed on urine samples spiked with synthetic miR constructs. Amplification and 
detection was performed with real-time PCR; gel electrophoresis and later flow devices.
Results: CHAMP was able to amplify and detect miR30a-5p in 60 minutes or less. The 
primers / probe were specific for miR30a and did not amplify mir30b or let7 microRNA . 
Appropriate melting curves were obtained for mir30a only. Amplicons were also detected 
by UV transillumination. The incorporation of Biotin and Digoxigenin in primers allowed 
the detection on lateral fl ow strips also. The presence of urine did not inhibit the reaction, 
and unprocessed urine could be used, without the need for RNA isolation. The de-identified 
urinary samples of 3 patients with steroid resistant NS had mir30a levels that were upto 
200 fold higher than controls.
Conclusions: A novel isothermal amplification method (CHAMP) can be used for 
paid microRNA detection in human urine. It allowed a rapid, sensitive, and highly specifi 
c amplification and detection of miRNA and is much easier and more cost effective than 
qPCR or microarray. CHAMP could detect miR-30a-5p, with sensitivity similar to qPCR, 
without the need for RNA isolation and could be used for biomarker discovery based on 
micrRNA studies for NS and other renal diseases.
Funding: Other NIH Support - NIAID
SA-PO450
Dominant Negative Etv Expression in Metanephric Mesenchyme 
Reduces Nephron Endowment: A Model of Low Nephron Number CKD 
Susanne V. Fleig, Flavia G. Machado, Benjamin D. Humphreys.  Brigham and 
Women’s Hospital, Boston.
Background: The role of etv4 expression in the ureteric bud during kidney development 
has been established; however etv4 is also expressed in the metanephric mesenchyme. We 
asked what role Etv4 plays during nephrogenesis.
Methods: To inhibit etv4 function in the metanephric mesenchyme, we crossed mice 
with a loxP-flanked dominant-negative etv4 (R26-LoxP-DN-Etv4+/+) with metanephric 
mesenchyme-specific six2-cre mice (Six2-TGC (tg/+)); cre-negative littermates served as 
control.
Results: Six2cre-DN-Etv4 mice express DN-etv4 in the nephron progenitor population 
starting dpc10.5. Cre-positive mice have lower body weight and fail to thrive. At four weeks, 
they have a reduced nephron number (24.4 ±2.4 vs. 86.8 ±6.9 glomeruli/section, p<0.0001). 
They develop kidney failure (at 4 weeks: BUN 103.8±17.8mg/dl vs. 14.1±1.8mg/dl, p < 
0.001) and proteinuria (21.29±7.23g Albumin/g Creatinine vs. 0.14±0.03g Albumin/g 
Creatinine in urine, p<0.05). Their kidneys show all features of chronic kidney failure 
(protein casts, glomerulosclerosis, fibrosis) and they die at 3-5 weeks of kidney failure.
Conclusions: Etv4 expression in the metanephric mesenchyme is required for normal 
kidney development, and expression of DN-Etv4 in the six2+ population leads to defective 
kidney development with reduced nephron number and progressive chronic kidney failure 
at 3-5 weeks of age. Titration of DN-Etv4 expression in metanephric mesenchyme may 
provide a novel genetic model for low nephron endowment and progressive CKD.
Funding: NIDDK Support
SA-PO451
NO Depletion by L-NAME Causes Increases in Rat Glomerular 
Permeability In Vivo – Reversal with Tempol and L-Arginine, but Not with 
the Potent NO-Donor DEA-NONOate  Bengt Rippe, Julia Dolinina, Kristinn 
Sverrisson, Anna Rippe.  Dept of Nephrology, Lund Univ, Lund, Sweden.
Background: There is increasing evidence that the permeability of the glomerular 
filtration barrier (GFB) is regulated by a balance between the bioavailability of nitric oxide 
(NO) and the presence of reactive oxygen species (ROS). It has been postulated that normal 
or moderately elevated NO levels protect the GFB from permeability increases, while ROS, 
through reducing the bioavailability of NO, have the opposite effect.
Methods: In anaesthetized Wistar rats, the left ureter was cannulated for urine 
collection, while simultaneously blood access was achieved. To test the tentative antagonism 
between NO and ROS, rats were systemically infused with either L-NAME (6 mg/kg/min) 
or L-NAME together with the superoxide scavenger tempol (1 mg/kg/min), or L-NAME 
together with L-arginine (290 mg/kg/min). Furthermore, we tested whether the potent 
NO donator, DEA-NONOate, could reverse the permeability effects of L-NAME. To 
measure glomerular sieving coefficients (ș) to Ficoll, rats were infused with fluorescein 
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isothiocyanate (FITC)-Ficoll 70/400 (mol.radius 10-80Å). Plasma and urine samples were 
analyzed by high performance size exclusion chromatography (HPSEC) for determination 
of ș for Ficoll repeatedly during up to 2 hours.
Results: L-NAME increased ș for Ficoll70Å from 2.27 (± 1.30) x 10-5 to 8.59 (± 2.06) 
x 10-5 (n=6; p<0.05) in 15 min. Tempol (n=6) completely abrogated these increases in 
glomerular permeability, the ș Ficoll70Å being 7.0 (± 2.1) x 10-6 at 15 min, which was also 
seen with L-arginine. However, DEA-NONOate did not reverse the permeability effects 
following L-NAME.
Conclusions: NO depletion in vivo by L-NAME caused increases in glomerular 
permeability, which could be reversed by either the ROS antagonist, tempol, or by 
L-arginine. By contrast, the potent NO-donor, DEA-NONOate, did not ameliorate the 
permeability effects of L-NAME. It is concluded that moderate levels of elevated NO 
production act to protect the permeability of the GFB, whereas very high levels of NO, 
as predicted following systemic DEA-NONOate infusion, may actually be detrimental 
to the GFB.
Funding: Government Support - Non-U.S.
SA-PO452
Down-Regulation Of Renal Tubular Wnt/β-Catenin Signaling Induces 
Tubular Cell Death in Proteinuric Nephropathy  Dickson W.L. Wong, Wai 
Han Yiu, Hao-Jia Wu, Ruixi Li, Kam Wa Chan, Joseph C.K. Leung, Loretta 
Y.Y. Chan, Kar Neng Lai, Sydney C.W. Tang.  Dept of Medicine, The Univ of 
Hong Kong/ Queen Mary Hosptial, Hong Kong.
Background: Persistent proteinuria from any causes is closely associated with chronic 
kidney disease (CKD) progression. Excessive transglomerular protein trafficking impacts 
on renal tubular cell injury by triggering tubular cell death. Studies on the role of Wnt/β-
catenin signalling in different forms of CKD have yielded discrepant results.
Methods: β-catenin expression was measured in control/ human serum albumin (HSA)-
treated human kidney 2 (HK-2) cells and kidney cortical lysates of protein-overloaded mice 
given 4- or 8- week BSA injection by Western blotting and IHC staining. Genetic knockdown 
of β-catenin in HK-2 cells was achieved using siRNA transfection. Apoptotic phenotypes 
were evaluated by qPCR, Western blotting, IHC staining/ activity assay and TUNEL assay.
Results: Upon 4-dayHSA stimulation, protein levels of active nuclear β-catenin in 
HK-2 cells declined by 67%±0.04 (p<0.05) versus control. Simultaneously, Bax/Bcl-2 
gene expression ratio increased significantly. HSA treatment with or without β-catenin 
siRNA transfection in HK-2 cells up-regulated Bax/Bcl-2 gene expression ratio by 
116%±0.2 (<0.05) and 52%±0.2 (p<0.05), respectively. Similarly, TUNEL and caspase-3 
activity was also increased by silencing β-catenin. In protein-overloaded mice, dynamic 
expression of tubular β-catenin was observed, with up-regulation (by 88 %±0.2 vs. control 
animals; p<0.05) at the early stage (4 weeks after BSA injection) and abrogation (24%±0.2; 
p<0.05) in the late phase (8 weeks after BSA injection). UACR decreased during renal 
tubular β-catenin overexpression but increased thereafter as tubular β-catenin levels came 
down. Elevated apoptotic phenotypes were evident in the later phase and associated with 
up-regulation of NGAL and KIM-1 genetic expressions.
Conclusions: Protein-overload promotes renal tubular apoptosis via abrogation of 
Wnt/β-catenin signalling in vitro and in vivo. Funding supports: Hong Kong Society of 
Nephrology Research Grant (2013), and the National Basic Research Program of China 
973 program no. 2012CB517600 (no. 2012CB517606).
SA-PO453
Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption 
of the Endothelial Glycocalyx  Marjolein Garsen,1 Olivia Lenoir,2 Angelique 
Rops,1 Henry Dijkman,3 Brigith Willemsen,3 Ton J. Rabelink,4 Jo H.M. Berden,1 
Pierre-Louis Tharaux,2 Johan Van der vlag.1  1Nephrology, Radboud Univ 
Medical Center, Nijmegen, Netherlands; 2Paris Cardiovascular Research 
Centre, Inst de la Santé et de la Recherche Médicale, Paris, France; 3Pathology, 
Radboud Univ Medical Center, Nijmegen, Netherlands; 4Nephrology, Leiden 
Univ Medical Center, Leiden, Netherlands.
Background: Diabetic nephropathy (DN) is the leading cause of chronic kidney 
disease in the Western world. Recently, endothelin receptor antagonists (ERAs) have 
emerged as a novel treatment for DN, but the mechanism underlying the protective effect 
of ERAs remains unknown. We previously showed that heparanase (HPSE), a heparan 
sulfate (HS)-specific endoglucuronidase, is essential for the development of DN. Loss of 
HS expression has been associated with the development of proteinuria. We hypothesize 
that endothelin-1 signals via HPSE.
Methods: In this study we evaluate the effects of endothelin-1 on HPSE expression 
and function in vitro and in vivo.
Results: Endothelin-1 induced HPSE expression in cultured mouse podocytes. 
Moreover, culture supernatant of endothelin-1-stimulated podocytes increased 
transendothelial albumin passage, which is HPSE-dependent. Experimental type 1 
diabetes in wild type (WT) mice revealed proteinuria and renal damage, accompanied 
with an increased glomerular HPSE expression and a reduced glomerular HS expression. 
Proteinuria and renal damage were reduced in the diabetic podocyte-specific endothelin 
receptor knockout (podETRKO) mice, which showed a normal HPSE and HS expression. 
Importantly, glycocalyx thickness was reduced after induction of diabetes in the WT mice, 
but preserved in the diabetic podETRKO mice.
Conclusions: Our data show that endothelin-1 induces HPSE expression in the 
podocyte in experimental DN. Furthermore, these results suggest that HPSE cleaves HS 
in the endothelial glycocalyx, which results in a reduced glycocalyx thickness and the 
development of proteinuria.
SA-PO454
Endothelin-1 Increases Glomerular Permeability in Sickle Cell Mice 
Malgorzata Kasztan,1 Chiao-Wang Sun,2 David M. Pollock.1  1Cardia-Renal 
Physiology&Medicine, Univ of Alabama at Birmingham, Birmingham, 
AL; 2Biochemistry&Molecular Biology, Univ of Alabama at Birmingham, 
Birmingham, AL.
Background: Sickle cell disease (SCD) leads to nephropathy manifested by increased 
glomerular permeability (Palb) and albuminuria/proteinuria. The endothelium-derived 
peptide, endothelin-1 (ET-1), with its powerful vasoconstrictor and pro-inflammatory effects 
mediated primarily through ETA receptors, is elevated in SCD patients and may contribute 
to the development of sickle cell glomerulopathy. Therefore, the aim of the study was to 
determine whether ET-1 contributes to increased glomerular permeability to albumin in 
SCD and if ETA receptors blockade ameliorates glomerular damage. Furthermore, because 
our preliminary studies showed sex differences in the vasoconstrictor response to ET-1 in 
sickle cell mice the study was designed to determine if sex differences exist in this response.
Methods: Experiments utilized 12 week old humanized sickle cell mice (HbSS) 
and genetic controls (HbAA) recently developed by the Townes’ lab. Ambrisentan (ETA 
antagonist), A-182086 (ETA/B antagonist) or vehicle was administrated via drinking water 
(10mg/kg/day) for 2 weeks. Glomeruli were isolated for direct permeability measurements 
as a volume response of glomerular capillaries to an oncopressive medium generated by 
defined concentrations of albumin.
Results: Palb was significantly higher in glomeruli from sickle mice (both in males 
and females) than control mice (0.50±0.07 and 0.47±0.06 vs. 0.13±0.02 and 0.10±0.2, 
respectively). Ambrisentan treatment significantly reduced the elevated Palb in glomeruli 
from male (0.24±0.05 vs. 0.50±0.07) and female (0.20±0.03 vs. 0.47±0.06) HbSS mice. 
ETA/B receptors antagonism with A-182086 also significantly decreased the Palb in glomeruli 
from male (0.28±0.06 vs. 0.50±0.07) and female (0.24±0.03 vs. 0.47±0.06) HbSS mice. 
Treatment with both antagonists did not alter Palb in HbAA mice.
Conclusions: These data support the hypothesis that ET-1 may play an important role in 
the development of sickle cell nephropathy and support the use of chronic ETA antagonism 
as a prospective treatment for sickle cell nephropathy.
Funding: Other NIH Support - NIH/NHLBI (U01 HL117684-01)
SA-PO455
Longitudinal Transcutaneous Glomerular Filtration Rate (GFR) After 
Uninephrectomy (UNx) in Mice  Hiroshi Kojima, Jonathan Street, Ana C. 
Souza, Peter S.T. Yuen, Robert A. Star.  Renal Diagnostics and Therapeutics 
Unit, NIDDK, NIH, Bethesda, MD.
Background: Glomerular filtration rate is a universally accepted measure of global 
kidney function. Serum filtration markers such as serum creatinine, BUN, or cystatin C 
have confounding factors, and measuring clearance of “inert” markers requires blood 
and urine collection, which can be cumbersome in unstable, oliguric patients, and small 
animals. A new non-invasive method using fluorescently-labeled Sinistrin and a miniaturized 
fluorescence detector can non-invasively detect plasma disappearance in conscious mice. To 
determine if the assumptions for plasma disappearance are met, we tested the method in a 
classic mouse uninephrectomy model with a predictable change (50%) then slow recovery.
Methods: Young male CD-1 mice underwent left UNx at Day 0. Transcutaneous 
measurement of GFR was performed every 3-4 days until Day 18. Under isofluorane 
anesthesia, a depilatory was applied to the back, and a miniaturized fluorescence detector 
(NIC-Kidney; Mannheim Pharma & Diagnostics GmbH, Mannheim, Germany) was fixed 
on the exposed skin using a double-sided adhesive patch. After background signal was 
obtained, FITC-Sinistrin was injected intravenously. Data acquisition lasted 60 min. After 
removing injection artifacts, GFR was calculated using the half-life derived from the rate 
constant of the single exponential elimination phase of fluorescence-time curve.
Results: All fluorescence measurements decayed as a single exponential, consistent 
with a stable, single components model and a stable GFR during the time of measurement. 
Assuming that GFR declined 50% immediately after UNx, GFR gradually increased until 
8 days post-UNx, when it plateaued at 75% of normal function.
Conclusions: FITC-Sinistrin plasma disappearance follows single component kinetics 
at baseline and after UNx, allowing calculation of GFR by single pool kinetics. This 
technology can easily detect renal hyperfiltration early after UNx.
Funding: NIDDK Support
SA-PO456
CHOP Deficiency Impedes Progressive CKD by Inhibiting Proteinuria 
Zahraa Mohammed-Ali,1 Chao Lu,2 Jeffrey G. Dickhout.1,2  1Medicine, McMaster 
Univ, Hamilton, ON, Canada; 2St. Joseph’s Healthcare Hamilton, Hamilton, 
ON, Canada.
Background: Endoplasmic reticulum (ER) stress occurs due to the accumulation of 
misfolded proteins in the ER and is associated with proteinuria in chronic kidney disease 
(CKD). CHOP (GADD153/DDIT3) is a pro-apoptotic transcription factor that is upregulated 
during ER stress. Increased expression of CHOP has been shown in biopsies of patients 
with membranous nephropathy and membranoproliferative glomerulonephritis. CHOP 
deficiency protects against oxidative stress, albuminuria and inflammation in mouse models 
of acute kidney injury and diabetic nephropathy. Therefore, we hypothesized that CHOP 
deficiency would influence the development of CKD.
Methods: Our model of CKD combines a uninephrectomy and subcutaneous 
implantation of a slow release deoxycorticosterone acetate (DOCA) pellet and Angiotensin 
(Ang) II osmotic infusion pump in C57BL/6 male mice. Mice were also given 1% sodium 
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chloride in their drinking water. Mice with total CHOP knockdown were used to test the 
role of CHOP in CKD development. CKD was assessed using blood pressure and 24h 
total urinary protein and albumin measurements. On day 21 post-implantation, mice were 
sacrificed and PAS staining was used to evaluate renal intertubular cast formation and 
glomerular damage.
Results: In response to the CKD model, both CHOP-/- and wild type (WT) mice 
experienced significant increases in systolic and diastolic blood pressure. However, 
CHOP-/- mice showed significantly lower proteinuria and albuminuria. In addition, CHOP 
deficiency significantly decreased intertubular cast formation and glomerular damage in 
response to the model compared to WT.
Conclusions: CHOP deficiency resulted in a decrease in proteinuria and renal 
tissue damage. Along with inducing apoptosis, CHOP has been shown to interact with 
inflammatory pathways resulting in NFκB activation. Further tests will evaluate the effect 
of CHOP deficiency on inflammatory, fibrotic and apoptotic response in our model. Our 
findings could lead to the development novel therapeutics to halt the progression of CKD. 
Funding: Government Support – MOP-133484.
Funding: Government Support - Non-U.S.
SA-PO457
Caveolin-1 Is Crucial in the Pathogenesis and Progression of Light Chain 
Deposition Disease but Not in Al-Amyloidosis  Jiamin Teng.  Pathology 
and Transitional Pathobiology, Louisiana State Univ Health Sciences Center, 
Shreveport, LA.
Background: In-vitro models of glomerulopathic light chains (GLCs), including light 
chain deposition disease (LCDD) and light chain amyloidosis (AL-Am) have provided 
solid platforms to study the pathogenesis of these disorders and how initiation / progression 
takes place. C-fos and NF-κB have been found to be important signaling mechanisms in the 
initiation phase of these two disorders. The role of caveolin-1 in the initiation / progression 
phases was explored in this study using human and mouse caveolin-1 knock-out (KO) and 
wild type (WT) mesangial cells (MCs).
Methods: Human and Caveolin-1 KO and WT mouse MCs were grown on dishes 
(2D) and Matrigel (3D),  and incubated with GLCs 10 µg/ml purified from the urine of 
renal biopsy-proven patients with LCDD and AL-Am. Downstream effects were tested by 
determining whether c-fos and NF-κB cytoplasmic to nuclear signal translocation occurred 
and analyzing the presence / absence and amounts of amyloid fibril formation in AL-Am 
and determining amounts of extracellular matrix production in LCDD.
Results: When LCDD GLCs were incubated with caveolin-1 KO cells, no c-fos or NF-
κB cytoplasmic to nuclear migration occurred and there was no increase in the extracellular 
matrix. In contrast, normal translocation was observed with WT caveolin-1 MCs. In contrast, 
signal translocation for c-fos or NF-κB was unaffected and similar amounts of amyloid fibril 
formation occurred when WT and caveolin-1 KO MCs were incubated with AL-Am GLCs.
Conclusions: Caveolin-1 (through activation of c-fos and NF-κB) plays a crucial role 
in signaling in LCDD and subsequent downstream effects. The absence of caveolin-1 at the 
surface of MCs abolishes downstream effects in LCDD but not in AL-Am. While amyloid 
production still occurs when MCs are incubated with Am-AL GLCs, the production of excess 
extracellular matrix is abolished when LCDD GLCs are incubated with caveolin-1 KO MCs.
Funding: Private Foundation Support
SA-PO458
Inhibition of TRPC6 Channels Protects against Renal Fibrosis 
Yueh-lin Wu,1,2 Jian Xie,2 Chou-Long Huang.2  1Taipei Medical Univ Hospital, 
Taiwan; 2UT southwestern Medical Center, Dallas, TX.
Background: Fibrosis is an important process of tissue repair, yet excess leads to 
organ failure. Transformation of fibroblasts into myofibroblasts is a critical step in fibrosis 
and requires activation of multiple new genes. Ca2+-permeable TRPC3/6 channels contain 
NFAT response element in the promoter such that increased Ca2+ entry via TRPC3/6 may, 
by activating calcineurin/NFAT nuclear signaling cascade, lead to positive feedforward 
amplification and un-remitting gene expression. We test the hypothesis that TRPC6 is 
critical for fibroblast-myofibroblast transformation in kidney fibrosis and inhibition of 
TRPC6 may ameliorate fibrosis.
Methods: Wild type (WT) and Trpc6-null mice (129 SvJ) underwent unilateral ureteric 
obstruction (UUO) on left kidney and sham operation on contralateral kidney. Ten days after 
surgery, kidneys were harvested for histological analysis of fibrosis by trichrome staining 
and for measurement of mRNA expression by quantitative real-time PCR. In separate 
experiments, WT mice underwent UUO and received injection of TRPC3/6 inhibitor BTP2 
(2 mg/kg daily by i.p.) or vehicle for 7 days.
Results: UUO induced a >20-fold increase in mRNA for Trpc6 in UUO kidney vs 
contralateral sham kidney in WT mice. mRNA for collagen-1, vimentin, cTGF, TGF-b1, 
and matrix metalloproteases MMP-2 and MMP-9 as well as area for fibrosis measured by 
trichrome staining were also markedly increased in UUO vs sham kidney. Deletion of Trpc6 
resulted in a significant reduction in fibrosis and blunted the increase in mRNA expression 
of collagen-1, vimentin, cTGF, TGF-b1, MMP-2, and MMP-9 in UUO kidney relative to 
those in WT mice. Trpc6 deletion did not alter the basal gene expression in sham kidney. 
Compared to vehicle-treated mice, BTP2 treatment also markedly decreased the measured 
area of fibrosis and attenuated the increase in expression of fibrosis and pro-fibrotic gene 
markers in UUO kidney. As in results from Trpc6 deletion, inhibition of TRPC6 by BTP2 
had no effect on sham kidney.
Conclusions: Activation of TRPC6 may be critical for myofibroblast transformation 
in fibrosis. TRPC6 may be a new potential pharmacologic target in treating renal fibrosis.
SA-PO459
Histone Methyltransferase EZH2: A Novel Therapeutic Target for Renal 
Fibrosis  Xiaoxu Zhou, Murugavel Ponnusamy, Evelyn Tolbert, George P. 
Bayliss, Shougang Zhuang.  Dept of Medicine, Rhode Island Hospital and 
Alpert Medical School, Brown Univ, Providence, RI.
Background: EZH2 (Enhancer of Zeste Homolog 2) is a methyltransferase that 
induces histone H3 lysine 27 trimethylation (H3K27me3) and functions as an oncogenic 
factor in many cancer types. However, its role in renal fibrogenesis remains to be explored.
Methods: In this study, we studied the role EZH2 in the activation of cultured renal 
interstitial fibroblasts and development of renal fibrosis in a murine model of unilateral 
ureteral obstruction as well as mechanisms involved.
Results: Our results showed that EZH2 and H3K27me3 were highly expressed in 
the cultured renal fibroblasts and the fibrotic kidney from mice with unilateral ureteral 
obstruction. Pharmacological inhibition of EZH2 with 3-deazaneplanocin A(3-DZNeP) 
and GSK126, or silencing of EZH2 with its specific siRNA, inhibited serum- and TGFb1-
induced activation of renal interstitial fibroblasts in vitro. Administration of 3-DZNeP 
abrogated deposition of extracellular matrix proteins and expression of a-SMA in the 
obstructed kidney. Mechanistically, 3-DZNeP inhibited expression of type I TGFb receptor 
and phosphorylation of Smad3, along with preservation of Smad-7 expression. 3-DZNeP 
was also effective in blocking phosphorylation of the EGF and PDGFb receptors, and 
suppressing activation of STAT3 and ERK1/2 signaling pathways in the injured kidney. 
Moreover, 3-DZNeP treatment abolished injury-induced renal expression of avb6 intergin, 
Notch1 and Notch3. Finally, EZH2 inhibition increased expression of PTEN, a protein 
tyrosine phosphatase associated with dephosphorylation of multiple tyrosine kinase 
receptors, in the kidney after ureteral ligation.
Conclusions: This study has identified EZH2 as an important epigenetic regulator of 
renal fibrosis and suggested that it could be a novel target for therapeutic interference in 
chronic kidney disease.
Funding: NIDDK Support
SA-PO460
Targeting PHD2 for the Treatment of Anemia and Interstitial Fibrosis in 
Chronic Kidney Disease  Raechel Peralta, Xiaokun Xiao, Melanie Katz, Shuling 
Guo, Gene Hung, Sue Murray.  Antisense Drug Discovery, Isis Pharmaceuticals, 
Inc., Carlsbad, CA.
Background: Anemia is a common manifestation of chronic kidney disease (CKD) 
and is associated with cardiovascular disease. The predominant cause of anemia in CKD 
is erythropoietin (EPO) deficiency. EPO is a hormone produced primarily by adult kidneys 
and is essential for the production of red blood cells. It has been shown in many animal 
models that EPO protects the kidney against interstitial fibrosis. Prolyl hydroxylase 
domain protein 2 (PHD2) is a primary regulator of hypoxia-inducible factors (HIFs) 
that regulate genes involved in cellular adaptation to reduced oxygen availability. When 
PHD2 is reduced, HIFa is stabilized and upregulates several genes to promote survival 
in low-oxygen conditions. Systemic PHD2 inactivation has been found to increase renal 
EPO production and stimulate red blood cell synthesis, which can improve anemia in CKD 
patients (Minamishima et al, Science 2010).
Results: Using antisense oligonucleotides (ASOs) designed against the PHD2 mRNA, 
we have demonstrated a 60% reduction of kidney PHD2 expression after 4 weeks of 
treatment (50 mpk/wk) compared to the saline group. In addition, we observed increases 
of EPO mRNA expression in the kidney interstitial fibroblasts by RT-PCR (~550-fold) 
and by in-situ analysis. We sought to demonstrate an improvement in anemia and renal 
fibrosis using our PHD2 ASO. We developed an adenine-induced mouse model of CKD 
that demonstrates severe anemia and interstitial fibrosis. After simultaneous administration 
of the 0.2% adenine diet and the PHD2 ASO (12 mpk/wk) for 12 weeks, we observed 
significant increases in kidney EPO mRNA (~35-fold) and plasma EPO levels (~12-fold) 
compared to the control ASO group. Histological analysis showed improved fibrosis based 
on reduced Sirius Red staining. There were also improvements in anemia based on whole 
blood analysis of hemoglobin and hematocrit levels.
Conclusions: These data indicate that reducing PHD2 with ASOs may be a viable 
option for treating CKD patients with severe anemia and renal fibrosis.
Funding: Pharmaceutical Company Support - Isis Pharmaceuticals, Inc.
SA-PO461
Fibronectin Assembly Mediates KIM-1 Induced TGFβ-Dependent Kidney 
Fibrosis  Venkata Sabbisetti, Cuiyan Xin, Sandhya Padmanabhan, Bhargavi 
Chandrasekar, Akinwande A. Akinfolarin, Joseph V. Bonventre.  Dept of 
Medicine, Renal Div, Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA.
Background:  Cell-extracellular matrix interactions play a crucial role in kidney 
fibrosis. Localized activation of TGFβ is critical for exertion of its cellular effects. Kidney 
Injury Molecule-1 (KIM-1) is upregulated in dedifferentiated proximal tubular cells (PTECs) 
following kidney injury and has been shown to induce kidney fibrosis in vivo. Here, we 
report that KIM-1 mediates fibrosis by up-regulating the critical components of the TGFb 
activation machinery including fibronectin and corresponding integrin receptors. In vivo, 
blocking fibronectin assembly reduces kidney fibrosis.
Methods: Full-length KIM-1 or the KIM-1 mutant was overexpressed in LLC-PK1 
and HEK cell lines and fibronectin and integrin levels were evaluated. Active TGFbwas 
measured using a bioassay. Mice were subjected to ischemia/reperfusion injury (IRI) or 
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unilateral ureteral obstruction (UUO). In the UUO model, mice were treated with fibronectin 
blocking peptide or control peptide to evaluate the effects of inhibition of fibronectin 
assembly on fibrosis.
Results: KIM-1 expressing PTECs produced significantly increased levels of fibronectin 
and fibronectin receptors. These increases were abrogated when phosphotyrosine-350 of 
KIM-1 was mutated or KIM-1 was deleted. KIM-1 expressing cells displayed higher levels 
of total and activated TGFβ as compared to control cells. In vivo, KIM-1 expressing tubular 
epithelial cells were characterized by high fibronectin staining after ischemia/reperfusion 
injury or UUO. Blocking fibronectin assembly with a blocking peptide decreased fibrosis 
in the UUO model.
Conclusions: KIM-1 induced localized activation of TGFbthrough up-regulation of 
TGFβ, fibronectin and integrin receptors. Blocking fibronectin assembly reduced fibrosis 
in response to UUO in vivo. This mechanism can contribute to the fibrosis associated with 
chronic expression of KIM-1 and may be a common feature of chronic kidney disease. 
Blocking fibronectin assembly may be therapeutically beneficial to prevent or reduce 
kidney fibrosis.
Funding: NIDDK Support
SA-PO462
Complement Modulation by C1-Inhibitor Hampered Pericyte (PC) to 
Myofibroblast Trans-Differentiation (TDF) and Vascular Rarefaction in 
Ischemia/Reperfusion (I/R) Injury  Giuseppe Castellano,1 Rossana Franzin,1 
Chiara Divella,1 Alessandra Stasi,1 Angelica Intini,1 Margherita Gigante,1 
Marco Fiorentino,1 G. Lucarelli,1 M. Battaglia,1 Giuseppe Grandaliano,2 Loreto 
Gesualdo.1  1Nephrology and Urology Unit, Univ of Bari; 2Dept Medical and 
Surgical Science, Univ of Foggia, Italy.
Background: Preservation of endothelium-Pericyte (PC) interaction is critical to 
counteract renal fibrosis during chronic kidney disease; no data are available on PC 
involvement in AKI. We investigated whether Complement might modulate PC activation 
in I/R.
Methods: Ten pigs underwent to 30 min of renal warm I, followed by 24h of R. Five 
pigs were treated with C1-Inhibitor (C1-Inh, 500U/Kg). Biopsies were analyzed by IHC and 
IF for PDGFRβ, Caspase3 and aSMA. FACS, AnnV-IP and IF were performed on human 
PC (PDGFRβ+ cells) stimulated with C5a (1x10-7M) for 24h in vitro.
Results: I/R injury induced PC to myofibroblasts TDF by reducing PDGFRβ without PC 
apoptosis (PDGFRβ+/Caspase3-) in vivo. TDF was accompanied by a significant decrease in 
capillary lumen area (Fig1A %T0:11.3±2.1;T24:3.9±2.3; p<0.05) and aSMA up regulation 
(Fig1B). C1-Inh preserved PDGFRβ expression in PC and restored peritubular capillary area 
(T24C1-Inh: 12.06±3.5 vs T24). In accordance, C5a induced PC proliferation and Collagen I 
production without apoptosis (Ann V-) in vitro. C5a induced PC to myofibroblasts TDF, with 
PDGFRβ down-regulation (Fig1C. %Bas: 15.2±3.6; C5a:3.6±2.3; TGFβ:2.08±1.04,p<0.05) 
and remodeling of aSMA-stress fibers, with contractile phenotype. Finally, C5a significantly 
up-regulated Id2 factor in PC, which is pivotal for cellular de-differentiation. 
Conclusions: Complement might contribute to PC to Myofibroblasts TDF in I/R injury, 
leading to vascular rarefaction and renal fibrosis. C1-Inh may be an effective strategy to 
prevent fibrosis development in transplanted kidney.
SA-PO463
Establishment of a Novel Mouse Strain to Trace Erythropoietin Producing 
Cells at Desired Time Points  Keiichi Kaneko, Motoko Yanagita.  Nephrology, 
Kyoto Univ, Kyoto, Japan.
Background: We previously reported that resident fibroblasts including Erythropoietin 
(Epo)-producing cells were lineage-labeled with myelin protein zero-Cre mouse strain 
and transdifferentiated into myofibroblasts during fibrosis with concomitant loss of Epo 
production. However, the previous method could not distinguish between Epo-producing 
cells and other resident fibroblasts and the behavior of Epo-producing cells remains unclear. 
Recently, Epo-Cre mice were generated which enabled the lineage tracing of the cells with 
the history of Epo production. Using the mouse strain, the transdifferentiation of Epo-Cre 
labeled cells into myofibroblasts during fibrosis has been demonstrated. Because Epo-Cre 
mice labeled the cells with the history of Epo production from fetal period to adult life, we 
tried to narrow down the period of labeling and to trace the certain cell population with the 
current Epo-producing ability at desired time points.
Methods: We generated a novel mouse strain in which inducible form of Cre is 
knocked-in at the locus of Epo gene (Epo-CreERT2 mice). Epo-CreERT2 mice were crossed with 
R26tdTomato mice. Tamoxifen was administered to activate inducible form of Cre, CreERT2.
Results: Epo-CreERT2 labeled cells were located in the interstitium of the cortical and 
corticomedullary region of the kidney, and the numbers were increased with the induction 
of anemia. Epo-CreERT2 labeled cells expressed PDGFRβ and CD73, suggesting that Epo-
CreERT2 labeled cells are resident fibroblasts and are likely to be Epo-producing cells. After 
unilateral ureteral obstruction (UUO), Epo-CreERT2 labeled cells transdifferentiated into 
myofibroblasts. The ratio of Epo-CreERT2 labeled cells transdifferentiated into myofibroblasts 
was 68 % at day 3 and 86 % at day 5 of UUO. The numbers of Epo-CreERT2 labeled cells 
were increased 1.9-fold at day 3 and 2.1-fold at day 5 of UUO.
Conclusions: We generated a novel mouse strain and succeeded in labeling Epo-
producing cells at desired time points. We demonstrated that Epo-producing cells 
transdifferentiated into myofibroblasts and were increased in fibrotic kidney. We aim 
to elucidate the mechanism of injury and repair of Epo-producing cells with this strain, 
Epo-CreERT2 mice.
SA-PO464
Role of PI3 Kinase γ in Recruitment of Bone Marrow-Derived Fibroblasts 
and Development of Renal Fibrosis  Yuanbo Wu, Hua Liang, William E. Mitch, 
Yanlin Wang.  Medicine, Baylor College of Medicine, Houston, TX.
Background: Renal fibrosis is a prominent pathological feature of chronic kidney 
disease leading to progressive loss of renal function. Although activated fibroblasts are 
responsible for the production and deposition of the extracellular matrix, the origin of 
activated fibroblasts mediating renal fibrosis remains debatable. Recent studies have shown 
bone marrow-derived fibroblasts contributed significantly to the pathogenesis of renal 
fibrosis. We have previously shown that CXCL16 plays a critical role in recruiting bone 
marrow-derived fibroblasts into kidney. However, the signaling mechanisms are not known. 
In the present study, we examined the role of PI3 kinase γ (PI3Kγ) in the recruitment of 
bone marrow-derived fibroblasts and development of renal fibrosis.
Methods: We examined the role of PI3Kγ in the recruitment of bone marrow-derived 
fibroblasts and the development of fibrosis using a mouse model of folic acid-induced 
nephropathy in wild-type (WT) and PI3Kγ-knockout (KO) mice in vivo and migration of 
cultured mouse monocyte treated with CXCL16 in vitro.
Results: Compared with WT mice, PI3Kγ-KO mice exhibited significant preservation 
of kidney function as measured by serum urea nitrogen and displayed significantly fewer 
bone marrow-derived fibroblasts dual positive for CD45 and PDGFR-β in the kidney 2 weeks 
after folic acid treatment. Furthermore, PI3Kγ-KO mice exhibited fewer α-smooth muscle 
actin (α-SMA) positive myofibroblasts and expressed less α-SMA protein in the kidney 
following folic acid treatment. Consistent with these findings, PI3Kγ deficiency significantly 
reduced total collagen deposition and suppressed expression of extracellular matrix proteins 
(collagen I and fibronectin). In cultured mouse monocytes, CXCL16 activated PI3Kγ and 
induced transwell migration, which was abolished in the absence of PI3Kγ.
Conclusions: These data indicate that PI3Kγ plays a pivotal role in recruiting bone 
marrow-derived fibroblasts into the kidney and developing renal fibrosis. Inhibition of 
PI3Kγ signaling may represent a novel therapeutic strategy for chronic kidney disease.
Funding: NIDDK Support
SA-PO465
Inhibition of K-Ras prior to Induction of Acute Kidney Reduces Long-Term 
Progression to Chronic Kidney Disease in a Murine Model of Aristolochic 
Acid Nephropathy  Sujit Kumar Saha, Bruce M. Hendry, Claire C. Sharpe. 
Dept of Renal Sciences, King’s College London, London, United Kingdom.
Background: Acute kidney injury (AKI) is recognised to be an early harbinger of 
chronic kidney disease (CKD). We have previously shown that K-Ras expression and 
activation are up-regulated in renal fibrosis and reducing K-Ras expression can prevent 
scarring. In this study our aim was to test whether transiently reducing K-Ras expression 
in the peri-AKI period can reduce progression to CKD.
Methods: CD1 mice received i.p. injections of either 3.5mg/kg Aristolochic Acid 
(AA) or normal saline on Day 1 and on Day 5. A treatment group were also given a single 
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subcutaneous injection of 100mg/kg of mouse K-Ras antisense oligonucleotide (ASO) 2 
days prior to the first AA injection. A vehicle group was given a subcutaneous injection 
of saline 2 days prior to the first AA injection. Renal function at multiple time points was 
assessed through a blood urea nitrogen (BUN) assay. The degree of fibrosis was ascertained 
through Picrosirius Red (PSR) and Masson Trichrome (MT) staining to quantify collagen 
deposition. The expression of K-Ras was determined by Q-PCR.
Results: CD1 mice given AA suffered an AKI with a 4.6 fold rise in BUN at Day 12 
that returned to baseline by Day 30. However by Day 80, the AA mice had a 57% higher 
BUN than control mice, demonstrating later onset CKD. AA mice treated with mouse K-Ras 
ASO pre-AKI suffered a similar AKI but BUN at Day 80 was 48% lower than untreated 
AA mice and was comparable with healthy controls. PSR and MT staining demonstrated 
a 5 fold increase in collagen deposition by Day 80 in AA mice which was reduced by 30% 
in ASO-treated animals. K-Ras expression was consistently unregulated in the untreated 
AA mice throughout the chronic phase but the transient treatment with ASO prior to the 
acute injury resulted in normalisation of K-Ras mRNA by Day 80.
Conclusions: Transiently reducing K-Ras expression in the peri-AKI period in a 
murine model of aristolochic acid nephropathy reduces downstream fibrosis and prevents 
the decline in renal excretory function. Targeting K-Ras may provide a future therapeutic 
option for preventing renal fibrosis and CKD following AKI.
SA-PO466
Non-Osmotic Sodium Storage Affects Glomerular Endothelial Cell 
Permeability  Rik Hg Olde Engberink,1 Peter Ochodnicky,2 Simon C. Satchell,3 
Ed van Bavel,4 Liffert Vogt.1  1Nephrology, AMC, Amsterdam, Netherlands; 
2Pathology, AMC, Amsterdam, Netherlands; 3Renal Unit, Univ of Bristol, Bristol, 
United Kingdom; 4Biomedical Engineering and Physics, AMC, Amsterdam, 
Netherlands.
Background: High dietary NaCl intake may affect glomerular permeability via pressure 
effects or via direct effects. In this respect, the Na+ buffering capacity of heparan sulfate 
glycosaminoglycans (HS-GAGs) in the endothelial surface layer (ESL) is of interest. The 
objective of this study is to investigate the interplay between Na+ and HS-GAGs and their 
effects on glomerular permeability.
Methods: Human glomerular endothelial cell (GEnCi) permeability to macromolecules 
was tested by measuring FITC-labeled albumin passage. Electrical resistance of a GEnCi 
monolayer, reflecting ESL Na+ content, was assessed with the ECIS® system at 4000 Hz. 
We studied the expression of gene coding enzymes involved in heparan sulfate (EXT-1, 
EXT-2) and chondroitin sulfate (CHSY) synthesis using real-time qPCR. Measurements 
were performed at different NaCl concentrations (125/150/175 mM ± HS degradation 
enzyme heparinise, 0.7 U/mL). We added mannitol to keep osmolality constant.
Results: Relative to 125 mM, EXT-1 and EXT-2 expression was higher after stimulation 
with 150 mM NaCl while CHSY expression remained unchanged (Fig A). Albumin 
permeability decreased after 2 and 5-d stimulation with 150 and 175 mM NaCl (Fig B). 
ECIS experiments showed that NaCl addition led to a concentration-dependent decrease 
in resistance (Fig C). NaCl did not alter resistance in the absence of cells. Heparinase 
increased resistance when added to 125 and 150 mM NaCl (Fig D). Mannitol did not alter 
permeability or resistance. 
Conclusions: High NaCl stimulates HS-GAG synthesis of the glomerular endothelium, 
which may facilitate more Na+ binding. Subsequent higher ESL Na+ content may seal the 
glomerular barrier as suggested by both lower permeability and lower resistance.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Precision-Cut Human Kidney Slices as a Model to Elucidate the Pathogenesis 
of Renal Fibrosis  Elisabeth G.D. Stribos,1,2 Theerut Luangmonkong,2 
Annemarie Leliveld,4 Igle J. de Jong,4 Willem Van Son,1 Jan-luuk Hillebrands,3 
Marc Maj Seelen,1 Harry Van Goor,3 Peter Olinga,2 Henricus A.M. Mutsaers.2 
1Dept of Internal Medicine, Div of Nephrology, Univ of Groningen, Univ 
Medical Center Groningen, Netherlands; 2Dept of Pharmaceutical Technology 
and Biopharmacy, Univ of Groningen, Netherlands; 3Dept of Pathology and 
Medical Biology, Div of Pathology, Univ of Groningen, Univ Medical Center 
Groningen, Netherlands; 4Dept of Urology, Univ of Groningen, Univ Medical 
Center Groningen, Netherlands.
Background: Renal fibrosis is a major problem in chronic kidney disease and chronic 
renal transplant failure. Unraveling the mechanisms underlying the initiation and progression 
of renal fibrosis is of key importance to identify new therapeutic targets. However, suitable 
human ex vivo models for renal fibrosis are lacking. Here, we explored precision-cut human 
kidney slices (PCKS) as a model for human renal disease.
Methods: PCKS were prepared from human cortical kidney tissue obtained from 
tumor-nephrectomies and cultured up to 96h. Morphology, cell viability (ATP levels, LDH 
leakage) and metabolic functionality (UDP-glucuronosyltransferase and transporter activity) 
were determined to assess PCKS integrity. Furthermore, inflammation- and fibrosis-related 
gene expression was characterized. To validate the model, renal fibrogenesis was induced 
using transforming-growth factor b1 (TGF-b1).
Results: Preparation of PCKS induced an inflammatory tissue response, while long-
term incubation (96h) induced fibrogenesis as seen by increased expression of collagen 
type 1a1 (COL1A1) and fibronectin (FN1). Importantly, PCKS remained functional for 
more than 48h as evidenced by active glucuronidation and phenolsulfonphthalein uptake. 
Moreover, treatment with TGF-b1 augmented fibrosis, as illustrated by at least 1.8-fold 
increase of multiple fibrosis markers including COL1A1, FN1, plasminogen activator 
inhibitor-1 and α-smooth muscle actin.
Conclusions: After extensive characterization, PCKS appear to be an excellent model 
to investigate renal pathology e.g. renal fibrosis. Moreover, the human origin of PCKS 
makes this ex vivo model very suitable for translational research.
SA-PO468
Centrality of Bone Marrow-Derived Fibroblasts in Magnetic Resonance 
Imaging Contrast-Induced Systemic Fibrosis  Viktor Drel,2 Catherine Do,2 
Chunyan Tan,2 Brent Wagner.1,2  1South Texas Veterans Health Care System, 
San Antonio, TX; 2Dept of Medicine, Univ of Texas Health Science Center at 
San Antonio, San Antonio, TX.
Background: So–called “nephrogenic” systemic fibrosis is a ghastly sclerotic condition 
that occurs only in conditions of low renal function (acute kidney injury or severe chronic 
kidney disease) and gadolinium–based contrast exposure. Nothing is known about the 
pathobiology.
Methods: Experiments were designed to test if bone marrow from magnetic resonance 
imaging contrast–treated donors is stimulated to induce fibrosis, and to what degree these 
cells can be primed to home to affected organs. Male Fisher 344 rats that express human 
placental alkaline phosphatase (hPAP) were divided into two groups; one served as control, 
the other treated with pharmaceutical–grade gadodiamide (Omniscan, General Electric) 
2.5 mol/kg IP daily, aiming for 20 doses over 4 weeks or evidence of systemic fibrosis. 
Rats with 5/6 nephrectomies were lethally–irradiated (900 Rad) followed by salvage bone 
marrow transplant from the control or contrast–treated donors. After an engraftment period, 
these recipients were divided into control and contrast–treated groups.
Results: Regardless of bone marrow source, contrast–treated recipients demonstrated 
severe skin fibrosis. Fibronectin was similarly increased by immunofluorescence and 
immunoblot, but a synergistic effect evident in recipients of contrast–treated animals. The 
fibroblast precursor (“fibrocyte”) markers, CD45RO and procollagen I, were increased 
in the contrast–treated recipients. Recipients of marrow from contrast–treated donors 
demonstrated greater dermal CD34 without histologic evidence of fibrosis.
Conclusions: Bone marrow from contrast–treated animals did not induce systemic 
fibrosis, therefore target organs (such as the skin) appear central to the process. However, 
given the synergistic effect, “primed” fibroblast precursors do have an increased affinity for 
diseased lesions. Clinically, this may explain why repeat administrations of gadolinium–
based contrast correlate with chronicity.
Funding: NIDDK Support, Veterans Administration Support
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SOCS2 Plays No Major Role in the Mouse Remnant Kidney Model of 
Fibrosis  Yael Segev,1 Muhamed Assadi,1 Ralph Rabkin,2,3 Daniel Landau.1,4 
1Microbiology and Immunology, Ben Gurion Univ, Beer Sheva, Israel; 2Research 
Inst, Veterans Administration Hospital, Palo Alto, CA; 3Medicine, Stanford Univ, 
CA; 4Pediatrics B, Schneider Children’s Medical Center, Petach Tikva, Israel.
Background: SOCS2, a key negative regulator of GH stimulated JAK/STAT5 signaling, 
is overexpressed in muscle, bone and liver of uremic rats and is presumably a cause of 
uremic GH resistance and growth retardation. SOCS2 deficient mice are GH sensitive, 
exhibit gigantism and accumulate collagen in skin, trachea and lungs (Reiser K et al, AJP 
2004). Since GH overexpression in mice causes renal fibrosis, we tested whether SOCS2 
deletion, by increasing GH sensitivity, accelerates remnant kidney fibrosis.
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Methods: Four-week old SOCS2 deficient mice (high growth - HG strain) and normal 
wild-type mice (N) underwent 5/6 nephrectomy (CRF) or sham operation (SO), forming 
4groups: SO-N, SO-HG, CRF-N, CRF-HG. Mice were sacrificed after 3 weeks. IP bovine 
GH was given 30 min before sacrifice.
Results: Weight gain was reduced significantly in CRF-N versus SO-N. In contrast, 
growth of CRF-HG increased significantly versus both CRF-N and SO-N. Kidney SOCS2 
mRNA, absent in HG mice, was significantly increased in CRF-N Vs SO-N. The degree of 
renal insufficiency was similar in CRF-N and CRF-HG mice. TGF-β and type IV collagen 
mRNA levels were increased to the same extent in SO-HG, CRF-HG and CRF-N Vs SO-
N. Renal GH receptor mRNA levels were decreased in both CRF groups. GH stimulated 
STAT5 phosphorylation increased in SO-HG Vs SO-N, decreased in CRF-N Vs SO-N and 
increased in CRF-HG Vs CRF-N. IL6, SOCS3 mRNA and phospho-STAT3 levels increased 
similarly in both CRF groups Vs SO controls.
Conclusions: GH induced STAT5 signaling is depressed in remnant kidneys of 
CRF-N mice but is increased in non-uremic and uremic SOCS2 deficient mutants. Levels 
of fibrosis-related genes rose similarly in CRF-HG and CRF-N, despite absence of SOCS2 
expression in CRF-HG mice. This suggests that SOCS2 does not play a central role in 
remnant kidney fibrosis. On the other hand, IL6 and its mediators phospho-STAT3 and 
SOCS3, were elevated in CRF-HG and CRF-N mice suggesting that inflammation may 
play a role in remnant kidney fibrosis.
Funding: Veterans Administration Support, Government Support - Non-U.S.
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β-arrestin2, Downstream of Angiotensin II Type 1 Receptor Biased Signaling 
Pathway, Plays an Important Role in Renal Fibrosis  Yan-Dao Wang, Chen 
Yu.  Dept of Nephrology, Tongji Hospital, Tongji Univ, Shanghai, China.
Background: Expect G protein signaling pathway, it is now considered that there is 
also a β-arrestin pathway in the downstream of G protein-coupled receptors (GPCRs); 
angiotensin II type 1 receptor (AT1R) belongs to GPCRs and angiotensin II (AngII) is 
a bi-stimulus to both G protein pathway and β-arrestin pathway;it is important to known 
which downstream pathway involving in AngII-AT1R-induced renal fibrosis. In this study, 
we used β-arrestin biased agonist SII ([1-sar, 4, 8-ile]-angiotensin II) to study β-arrestin 
pathway in renal fibrosis.
Methods: The model of unilateral ureteral obstruction (UUO) was used in vivo, and 
rat kidney fibroblast cell line (NRK-49F) was treated with SII in vitro.
Results: 1) SII induced the binding of β-arrestin2 with AT1R, not β-arrestin1. 2) 
SII increased the synthesis of collagen I and fibronectin in NRK-49F. Transfection of 
β-arrestin2 siRNA abolished the effect of SII on the accumulation of ECM. Overexpression 
of β-arrestin2 increased SII-induced ECM synthesis. 3) Candesartan pretreatment abolished 
collagen I and fibronectin up-regulation induced by SII in NRK-49F. 4) These effects were 
blocked in the presence of ERK1/2 blocker (PD98059). Transfection of siRNA targeting 
β-arrestin2 inhibited SII-induced ERK phosphorylation. Overexpression of β-arrestin2 
enhanced SII-induced ERK1/2 phosphorylation. 5) The mRNA and protein levels of 
β-arrestin2 were significantly upregulated in the UUO model.
Conclusions: Our results suggested that AT1R downstream β-arrestin2 pathway, not 
β-arrestin1, might play a key role in renal fibrosis by forming complexes of β-arrestin2 and 
AT1R, inducing ERK1/2 phosphorylation and increasing ECM accumulation.
Funding: Government Support - Non-U.S.
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Deletion of ATR, a Master Molecule of DNA Damage Response, in the 
Proximal Tubule Exacerbates Kidney Injury and Increases Fibrosis 
Seiji Kishi,1,2 Takaharu Ichimura,1,2 Ryuji Morizane,1,2 Joseph V. Bonventre.1,2,3 
1Renal Div, Dept of Medicine, Brigham and Women’s Hospital, Boston, MA; 
2Harvard Medical School, Boston, MA; 3Harvard Stem Cell Inst, Cambridge, MA.
Background: Impaired response of cells to DNA damage can cause cellular senescence. 
We have previously implicated the DNA damage response of renal proximal tubule 
cell (RPTC) in progressive kidney injury and fibrosis. The purpose of this study was to 
investigate the role of Ataxia telangiectasia and Rad3-related (ATR), a master molecule 
of the DNA damage checkpoint, in kidney injury and fibrosis.
Methods: RPTC-specific conditional ATR knockout (ATRRPTC-/-) mice were generated 
by crossing ATR floxed (ATRfl/fl) mice , ATR+/– mice and tamoxifen-inducible (SLC34a1-
CreERT2) mice. We evaluated the role of ATR in susceptibility to cisplatin nephrotoxicity, 
unilateral ureteral obstruction (UUO) and renal ischemia/reperfusion injury (IRI).
Results: Four days after cisplatin injection, ATRRPTC-/- mice had increased kidney 
histological damage, increased Kidney Injury Molecule-1 (KIM-1) expression and decreased 
renal function compared with wild-type mice. Within the first 5 days, 34% of ATRRPTC-/- mice 
died, while no WT mice died. Increased DNA damage and the number of apoptotic cells 
were also found in ATRRPTC-/- mice. At 7 days after UUO, when compared with wild-type 
mice, ATRRPTC-/- mice exhibited increased kidney histological damage, KIM-1 expression, 
DNA damage markers, and number of apoptotic cells. ATR deletion resulted in increased 
expression of fibrosis-related genes and increased kidney fibrosis. After IRI there was worse 
kidney function on day 3 and day 7 in ATRRPTC-/- mice and increased interstitial fibrosis 4 
weeks after IRI. Expression of p21, a marker of senescence, was significantly increased in 
ATRRPTC-/- mice in each of the three models of injury.
Conclusions: ATR activation in the RPTC represents a protective response in acute 
and chronic kidney disease of various etiologies.
Funding: NIDDK Support
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Role of Heparanase in Renal Epithelial-Mesenchymal Transition Induced 
by Ischemia/Reperfusion  Valentina Masola,1 Gianluigi Zaza,1 Giovanni 
Gambaro,2 Maurizio Onisto,3 Gloria Bellin,1 Gisella Vischini,2 Iyad Khamaysi,4 
Antonio Lupo,1 Israel Vlodavsky,5 Zaid Abassi.5  1Renal Unit, Dept of Medicine, 
Verona, Italy; 2Columbus-Gemelli Hospital Catholic Univ, Roma, Italy; 3Univ 
of Padova, Padova, Italy; 4Rambam Medical Center, Israel; 5Technion, Israel.
Background: Ischemia/reperfusion (I/R) activates epithelial-mesenchymal transition 
(EMT) of tubular cells, thus leading to organ fibrosis. Heparanase (HPSE) controls the 
EMT induced by FGF2 and TGFb. The aim of this study was to evaluate whether HPSE 
modulates the EMT induced by I/R.
Methods: Tubular cells (HK-2) wt and stably silenced for HPSE were subjected to 24h 
of hypoxia and 6h of reoxygenation. The cells were also treated with SST0001 (Sigma-Tau 
Research Switzerland SA), an inhibitor of HPSE. The I/R injury has been reproduced in 
vivo by clamping the renal arteries for 30 min in transgenic mice over-expressing HPSE 
(HPSE-tg) and their wt mice. Mice were sacrificed after 48 and 72 h. Gene and protein 
immunoreactivity of EMT markers (α-SMA, VIM, FN and TGF-β) were evaluated by 
real-time PCR, WB and IF; histology was assessed by PAS staining.
Results: In vitro; I/R increased the expression of EMT-markers in wt tubular cells but 
not in HPSE-silenced cells. Similarly, the inhibition of HPSE with SST0001 (Sigma-Tau 
Research Switzerland SA) in wt cells prevented the development of I/R induced EMT. In-
vivo; I/R induced acute tubular necrosis, which was more profound in HPSE-tg than their 
wt animals. In wt mice I/R-injury increased glomerular and tubular HPSE expression, but 
did not induce the EMT-markers. In contrast, I/R in HPSE-tg mice remarkably induced 
the expression of EMT-markers already after 72h.
Conclusions: HPSE is as a crucial factor for the development of EMT induced by I/R. 
HPSE inhibition may therefore constitute a possible therapeutic approach for the prevention 
of fibrosis in organ transplantation.
Funding: Government Support - Non-U.S.
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Hydrogen Sulfide Deficiency in the Kidney and Brain in Aging Mice 
Hak Joo Lee,1,2 Kavitha lakshmi Satara natarajan,4 Meenalakshmi M. 
Mariappan,1 Denis Feliers,1 Jeffrey L. Barnes,1,2 Goutam Ghosh-Choudhury,1,2 
Christopher G. Kevil,3 Balakuntalam S. Kasinath.1,2  1Medicine, MC7882, Univ of 
Texas Health Science Center, San Antonio, TX; 2Medicine, South Texas Veterans 
Health Care System, San Antonio, TX; 3Pathology, Louisiana State Univ, 
Shreveport, LA; 4Oklahoma Medical Research Foundation, Oklahoma City, OK.
Background: Hydrogen sulfide (H2S) is constitutively synthesized by cystathionine 
γ lyase (CSE) and cystathionine β synthase (CBS). It regulates GFR and tubular transport 
in the kidney and NMDA receptors in the brain. H2S activates AMPK to inhibit mTORC1 
and abrogate matrix protein increment in high glucose treated renal cells (Lee, JBC, 2012). 
Since mTORC1 is implicated in aging, we surveyed the status of H2S relative to mTORC1 
in the organs of aging mice.
Methods: C57B6 mice, immunoblotting, H2S generation and content assays, 
histopathology, cell culture.
Results: The renal and cerebral CSE and CBS expression, H2S content and generation 
were reduced in old mice (26-32 mos old, n=6 mice) compared to young mice (4-6 mos 
old, n=8 mice); such changes were not seen in the heart or the skeletal muscle. Old mice 
showed increase in renal collagens I, III, fibronectin, parenchymal fibrosis, albuminuria, 
and rise in serum cystatin C. Signaling analysis showed that aging was associated with 
renal and cerebral activation of Akt, reduced phosphorylation of AMPK, and activation of 
mTORC1 manifest as increase in the phosphorylation of p70S6 kinase and 4E-BP1. Since 
insulin has been implicated in the aging process, we examined insulin regulation of CSE 
and CBS in renal proximal tubular epithelial (MCT) cells; insulin rapidly reduced CSE 
and CBS expression and decreased H2S generation. Insulin also promoted the synthesis 
of fibronectin matrix protein in MCT cells.
Conclusions: Our data show for the first time that the aging kidney and cerebrum 
share similar changes in H2S metabolism associated with reduced AMPK activity leading 
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to mTORC1 activation; these pathways could be related to age related changes including 
fibrosis. Insulin may mediate reduction in CBS, CSE and H2S and contribute to matrix 
accumulation in the aging kidney.
Funding: Other NIH Support - NIA, Veterans Administration Support
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The Role of Ergothioneine/OCTN1 in CKD  Yasuyuki Shinozaki,1 Kengo 
Furuichi,1 Shinji Kitajima,1 Akinori Hara,1 Yasunori Iwata,1 Norihiko Sakai,1 
Miho Shimizu,1 Takashi Wada.1,2  1Div of Nephrology, Kanazawa Univ Hospital, 
Kanazawa, Ishikawa, Japan; 2Dept of Laboratory Medicine, Kanazawa Univ, 
Kanazawa, Ishikawa, Japan.
Background: Chronic kidney disease (CKD) is a strong risk factor for end stage kidney 
disease, and closely complicates with other organ damages.  Organic cation transporter 1 
(OCTN1) is known as a specific transporter for ergothioneine (ERGO).  ERGO is reported 
to have a strong antioxidant effect.  We hypothesized that OCTN1 function and the reduction 
of ERGO were closely related to the progression of CKD.
Methods: To evaluate the effects of OCTN1 function in CKD, everted sac method was 
used in CKD model or control mice.  Furthermore, the pathological changes and oxidative 
stress in the kidney of OCTN1-/- or OCTN1+/+ were evaluated in the CKD model mice. 
Moreover, the amount of ERGO in red blood cells of was measured in CKD patients.
Results: The uptake of ERGO in everted sac significantly decreased in CKD mice 
than control mice.  Interstitial fibrosis, that evaluated by azan stain, sirius red stain, and the 
content of hydroxyproline of injured kidney, was significantly advanced in OCTN1-/- CKD 
mice.  Moreover, oxidative stress, that assessed by the number of 4-HNE stain positive 
cell, was exaggerated in OCTN1-/- CKD mice (WT 26.4±9.7, KO 73.8±37.4/mm2>, 
p<0.05).  Correspondingly, the total antioxidant capacity decreased in OCTN1-/- CKD mice. 
The concentration of ERGO in red blood cells decreased accompanied with CKD stage 
(G3b:30.0±4.4mg/mL, G4:25.8±5.6mg/mL, G5:14.8±8.1mg/mL, ESKD:5.1±3.9mg/mL).
Conclusions: The uptake of ERGO through OCTN1 decreased in CKD.  The reduction 
of ERGO in CKD may participate in oxidative stress and progression of kidney injury.
SA-PO475
SIRT2-MDM2 Signaling Attributes to Fibroblasts Activation but Not 
Tubular Epithelial-Mesenchymal Transition During Tubulointerstitial 
Fibrosis  Chun Zhang, Renyu You, Hua Su.  Nephrology, Huazhong Univ of 
Science and Technology, Wuhan, Hubei, China.
Background: Renal resident fibroblasts and tubular epithelial cells are the main sources 
for extracellular matrix producing myofibroblasts during tubulointerstitial fibrosis (TIF). 
Histone deacetylases (HDAC) inhibitors are shown to have an antifibrogenic effect in skin, 
liver and lung. Sirtuin 2 (SIRT2), belonging to class III HDAC, mediates p53 deacetylation 
and subsequently sensitizes the sequestration of p53 by MDM2, thereby resulting in a p53 
reduction and cell cycle progression. Up to now it is unclear the role of SIRT2 and its 
association with MDM2 during renal fibrosis.
Methods: Unilateral Ureteral Obstruction (UUO) animal model was constructed on 
B57CL/6 mice. In vitro study cultured tubular epithelial cell line NRK-52E (TEC) and renal 
fibroblast cell line NRK-49F were employed. The expression of SIRT2 and MDM2 was 
regulated by its pharmacologic inhibitors or transfection of Lentiviral shRNA.
Results: It showed the protein level of SIRT2 was elevated markedly in UUO mice 
as well as the fibroblasts treated with TGF-b1. Nevertheless, in TECs the abundance of 
SIRT2 was not altered under TGF-b1 exposure. Additionally, AGK2, a specific SIRT2 
inhibitor, attenuated the severity of TIF in UUO mice and the fibroblast activation 
triggered by TGF-b1. Next in fibroblast we found MDM2, a p53 inhibitor, was upregulated 
simultaneously under TGF-b1 stimulation. Interestingly, the increased MDM2 level can 
be minimized by pharmacologic or genetic blocking of SIRT2 which was not interfered 
by Nutlin-3 (an inhibitor of the interaction between MDM2 and p53). Thus, it indicated 
SIRT2 regulating MDM2 was p53 independent. Moreover, genetic deletion of MDM2 by 
shRNA transfection didn’t affect the expression of SIRT2, although which could alleviate 
fibroblast activation.
Conclusions: Our current study suggests that besides p53, SIRT2 also could modulate 
MDM2 during fibroblasts activation, and targeting SIRT2-MDM2 signaling may be a 
potential strategy for the treatment of renal fibrosis.
Funding: Government Support - Non-U.S.
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The Role of cPLA2 in Experimental Renal Fibrosis  John Ross Montford, 
Allison M.B. Lehman, Raphael A. Nemenoff, Seth B. Furgeson.  Div of Renal 
Disease and Hypertension, UC Denver School of Medicine, Aurora, CO.
Background: Chronic kidney disease (CKD) is characterized by progressive renal 
fibrosis involving poorly defined signaling events between renal epithelial cells, fibroblasts, 
and inflammatory cells. Cytosolic phospholipase A2 (cPLA2) is abundant in renal epithelium 
and inflammatory cells and serves as the rate-limiting enzyme in eicosanoid production. 
Since eicosanoids regulate many biological processes important in renal injury, we aimed 
to investigate the role of cPLA2 in the progression of renal fibrosis in a mouse model.
Methods: Wild type (WT) and cPLA2 globally deficient (KO) C57BL/6 mice were 
subjected to unilateral ureteral obstruction (UUO). In separate experiments WT mice were 
lethally irradiated and transplanted with either WT bone marrow or cPLA2-deficient bone 
marrow. We then performed UUO 5-6 weeks after bone marrow transplantation. After UUO, 
we collected uninjured and injured kidneys for RNA, protein, flow cytometry, and histologic 
analysis, and preparation of single cell suspensions for flow cytometry.
Results: Compared with WT, cPLA2 KO animals had a 1.5-2.0 fold increase in 
histologic fibrosis at 14 days after UUO. In addition, the KO animals had elevated levels of 
mRNA for matrix proteins such as collagen and fibronectin, pro-fibrotic chemokines such 
as fractalkine, and inflammatory markers such as MCP-1 after UUO as compared with WT 
animals at 7 days. By flow cytometry, cPLA2 KO animals had significantly more infiltration 
of CD45+, CD11b positive-Ly6C negative cells than WT animals after UUO. Additionally, 
adoptive bone marrow transplant from cPLA2 KO mice into WT mice yielded worsening 
of histologic fibrosis after UUO as compared with transplants derived from WT animals.
Conclusions: Depletion of cPLA2 and/or its products, predominantly from circulating 
myeloid cells, contribute to the development of experimental fibrosis using a UUO model 
in mice.
Funding: Other NIH Support - 1 F32 DK104475-0
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Delayed Administration of Suramin Attenuates Peritoneal Fibrosis in Rats 
Chongxiang Xiong,1 Na Liu,2 Shougang Zhuang.1  1Dept of Medicine, Rhode 
Island Hospital and Alpert Medical School, Providence, RI; 2Dept of Nephrology, 
Shanghai East Hospital, Tongji Univ School of Medicine, Shanghai, China.
Background: Peritoneal fibrosis is one of the most serious complications in patients 
with peritoneal dialysis (PD) and lacks effective treatments. Our recent study showed that 
treatment with suramin, a compound that inhibits the interaction of multiple cytokines 
and growth factors with their receptors, attenuated the development of peritoneal fibrosis 
in a model of peritoneal fibrosis induced by chlorhexidine gluconate (CG). In the current 
study, we further assessed the therapeutic effect of suramin on the progression of peritoneal 
fibrosis in this model.
Methods: Rats were given a daily intraperitoneal injection of chlorhexidine gluconate 
(CG) for 3 weeks to induce peritoneal fibrosis followed by weekly administration of suramin 
at 20 mg/kg for an additional one or two weeks before kidneys were harvested.
Results: Delayed administration of suramin attenuated peritoneal membrane thickening 
and collagen fibril deposition occurred after CG exposure. Suramin was also effective in 
reducing CG-induced expression of a-smooth muscle actin, fibronectin and collagen I. 
Injury to the peritoneal membrane resulted in increased phosphorylation of Smad-3, a 
prominent mediator in transforming growth factor –b signaling, and epidermal growth 
factor receptor (EGFR), a key tyrosine kinase receptor associated with peritoneal fibrosis; 
suramin treatment blocked their phosphorylation. Similarly, suramin reduced CG-induced 
phosphorylation of transducer and activator of transcription-3 (STAT3) and extracellular 
signal-regulated kinase 1 and 2 (ERK1/2), two molecules that mediate profibrotic signal 
transduction. Moreover, delayed application of suramin suppressed CG-induced expression 
of several inflammatory cytokines in fibrotic peritoneum.
Conclusions: Our results indicate that suramin treatment inhibits the progression 
of peritoneal fibrosis via a mechanism involved in suppression of TGF-b1 and EGFR 
signaling pathways, and suggest that suramin holds a therapeutic potential for treatment 
of peritoneal fibrosis.
SA-PO478
MDM2 Mediates Tubulointerstitial Fibrosis and Fibroblasts Activation 
via p53-Independent Pathway  Hua Su, Chen Ye, Chun Zhang.  Nephrology, 
Huazhong Univ of Science and Technology, Wuhan, Hubei, China.
Background: MDM2 is an E3 ubiquitin ligase which plays essential roles in 
podocytes and tubular epithelial cells injury or repair by regulating cell cycle and mediating 
inflammatory process. MDM2 exerts its pathophysiological effects via p53 dependent or 
independent pathway. However whether MDM2 is implicated in tubulointerstitial fibrosis 
(TIF) and fibroblasts activation is still unknown.
Methods: Patients with TIF (secondary glomerulonephritis and interstitial nephritis 
were excluded) were enrolled in this study and Unilateral Ureteral Obstruction (UUO) 
animal model was constructed on B57CL/6 mice. In vitro study cultured renal fibroblast 
cell line NRK-49F was employed. The expression of MDM2 and Notch1 was regulated 
by its pharmacologic inhibitors or transfection of Lentiviral shRNA. PYR-41 was used as 
an inhibitor of ubiquitin E1 activating enzyme.
Results: Here, we found the abundance of interstitial MDM2 was increased in patients 
with TIF as well as UUO mice. And interstitial MDM2 mainly originated from (myo)
fibroblast. In vitro the expression of MDM2 was upregulated with fibroblasts activation 
under TGF-b1 stimulation, which was minimized by MDM2 knocking down but not by 
MDM2-p53 pathway inhibitor---Nutlin-3. Consistently, in UUO mice Nutlin-3 treatment 
cannot alleviate the interstitial fibrosis. Interestingly, we found Notch1, a molecule positively 
or negatively affecting the processes of proliferation, differentiation and apoptosis in a 
context-dependent manner, was reduced in cultured fibroblast treated with TGF-b1 which 
could be reversed by either genetic deletion of MDM2 or ubiquitin E1 activating enzyme 
inhibitor. Moreover, although pharmacologic or genetic blocking Notch1 signaling could 
trigger fibroblast activation it did not affect MDM2’s abundance.
Conclusions: Our current study suggests that MDM2-Notch1 signaling pathway, not 
the classic MDM2-p53 pathway, is involved in fibroblast activation in an ubiquitination 
dependent manner during tubulointerstitial fibrosis.
Funding: Government Support - Non-U.S.
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Biomarkers of Collagen Type III and VI Turnover Can Predict 
Poor Recovery of Kidney Function in Kidney Transplant Recipients 
Daniel Guldager Kring Rasmussen,1,2 Signe Holm Nielsen,1 Federica Genovese,1 
Morten Asser Karsdal,1 Shengqiang Xia,2 Martin Tepel.2  1Nordic Bioscience, 
Denmark; 2Univ of Southern Denmark, Denmark.
Background: Allograft dysfunction is a common complication after renal 
transplantation (Tx). The turnover of extracellular matrix proteins, collagen type III and 
type VI, contributes to renal repair mechanisms which accompany allograft dysfunction. 
Distorted turnover may lead to progressive fibrosis and to loss of renal function. The 
objective of our study was to evaluate the role of specific collagen type III and type VI 
cleavage fragments for early allograft dysfunction after kidney Tx.
Methods: 171 incident patients, receiving a kidney allograft were enrolled at Odense 
University Hospital. Plasma and urine samples were collected at the first postoperative 
days. C3M and Pro-C6 were measured in samples using novel ELISAs. Early allograft 
dysfunction was defined as eGFR less than 30 mL per minute per 1.72m² 29 days after 
Tx. The relative change of plasma creatinine (RCPC) is the difference between plasma 
creatinine (pCrea) on the preoperative and first postoperative day divided by preoperative 
pCrea. Follow-up data on pCrea from a subset of patients was available at 6- and 12 months.
Results: Plasma Pro-C6 (pPro-C6) levels were significantly different in patients 
who received a deceased donor (DD), living donor (LD) and AB0 incompatible (AB0) 
donor kidney (p<0.001). pPro-C6 had a negative correlation with eGFR 29 days post-Tx 
(p<0.0001, r=-0.35) and a positive correlation with pCrea at 6- (p=0.0001, r=0.31) and 12 
months (p=0.0001, r=0.32). With a cut-off of 0.3 for the RCPC, ROC curves showed that 
plasma Pro-C6 predicted allograft dysfunction (p<0.0001, AUC=0.898). uC3M levels were 
not significantly different in patients receiving a DD, LD and AB0 donor kidney. uC3M 
levels showed a negative correlation with plasma creatinine at 6- (p<0.0001, r=-0.37) and 
12 months post-Tx (p<0.0001, r=-0.35). Plasma C3M was associated with plasma CRP 
(p<0.0001, r=0.62).
Conclusions: The study indicates that specific collagen type III and type VI cleavage 
fragments, i.e. C3M and Pro-C6, are both markers for early and late allograft dysfunction 
after kidney Tx, and reflect the underlying pathophysiology.
SA-PO480
Inhibitory Effect of Proximal Tubular Cells-Derived Neuropilin-1 in TGF 
Beta Signaling Pathway  Rui Cheng, Xuemin He, Symon Ma, Jian-xing Ma. 
Physiology, Univ of Oklahoma Health Sciences Center, Oklahoma CIty, OK.
Background: Neuropilin-1 (NRP-1)is a co-receptor protein for multiple growth factors 
including class 3 smaphorins, VEGF, PDGF and TGF-β, and promotes signaling pathway 
involved in tumor growth, axonal chemorepellents, angiogenesis and liver fibrosis. In 
contrast, its function in the renal fibrosis has not been defined.
Methods: Primary renal proximal tubular cells (MRPTC) were cultured from Nrp-1flox/flox 
mice. After infection of Nrp-1flox/flox cells with adenovirus expressing Cre resulted in NRP1 
Knock-out (Nrp-1-/-) in the primary cells. Human proximal tubular cell line HKC-8, MEF 
cells and 3T3-L1 cells were used in this study. TGF-β-driven promoter transcriptional 
activity was measured by luciferase assay.
Results: NRP-1 was down-regulated by TGF-β in HKC8 and up-regulated in MEF cells 
and 3T3-L1 cells, suggesting the different regulation mechanisms and functions of NRP-
1 between proximal tubular cells and fibroblasts. Over-expression of NRP-1 suppressed 
TGF-β-induced phosphorylation of Smad2/3 and expression levels of fibronectin. HKC-8 
cells over-expressing NRP-1 showed significantly decreased levels of both TGF-β receptor 
I and receptor II. The Nrp-1-/- cells showed higher TGF-β-induced Smad2/3 transcriptional 
activities and expression of fibronectin in Nrp-1flox/flox MRPTCs, compared with control 
adenovirus-infected Nrp-1flox/flox MRPTCs.
Conclusions: Proximal tubular cells-derived NRP1 inhibits the TGF beta signaling 
pathway. NRP1 functions are cell type-specific in the kidney.
Funding: Other NIH Support - R01EY012231
SA-PO481
The cAMP-epac Pathway Regulates Renal Fibrosis by Promoting 
Mitochondrial Biogenesis of Tubular Epithelial Cell  Lei Jiang, Junwei Yang. 
Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical Univ, 
Nanjing, Jiangsu, China.
Background: As a universal second messenger, cAMP inhibits the formation of 
extracellular matrix in tissue fibrosis. Mitochondrial dysfunction is an early event in real 
fibrosis, but how it leads to kidney fibrosis and how it is regulated is unclear. In this paper, we 
investigated the role of cAMP-epac pathway in mitochondrial biogenesis and renal fibrosis.
Methods: Animal models of renal fibrosis was induced by unilateral ureteral obstruction 
(UUO), chronic Ang II infusion and adriamycin administration. cAMP was given to CD1 
mice under UUO by tail vein injection. Rolipram was injected intraperitoneally in CD-1 
mice under UUO. A primary tubular epithelial cell (PTC) culture from normal CD-1 mice 
renal cortex was used. Rolipram, PKA activator, epac activator, PDE4b siRNA, epac 
siRNA were given to PTC respectively with TGF-b1 stimulation. ATP kit and NAD+/
NADH kit were used to evaluate the mitochondrial function. Real-time PCR was used to 
detect mitochondrial DNA (mtDNA) expression. The morphology of mitochondria was 
observed by electron microscope.
Results: 1.The level of cAMP was decreased in the fibrotic kidney; 2.PDE4b were 
upregulated obviously in the kidney under UUO, and the epac not PKA were responsed 
to fibrosis; 3. Upregulation cAMP by giving PDE inhibitor (rolipram) or cAMP could 
ameliorate the renal fibrosis and protect mitochondrial structure; 4.Rolipram could stabilize 
PGC-1a expression and block the mitochondrial dysfunction induced by UUO; 5.TGF-b1 
could induced the downregulation of cAMP in PTC. Increasing the level of cAMP in PTC 
by rolipram, PDE 4b siRNA, epac acitivator or epac siRNA could reduce the damage of 
PTC under TGF-b1 sitimulation; 6.Rolipram could restore PGC-1a expression, reduce 
the mtDNA damage and protect the mitochondrial function and structure of PTC under 
TGF-b1 stimulation.
Conclusions: cAMP-epac pathway is involved in renal fibrosis. Increased cAMP level 
blocks the progress of renal fibrosis. cAMP promotes mitochondrial biogenesis and restores 
mitochondrial structure and function of tubular epithelial cell.
Funding: Government Support - Non-U.S.
SA-PO482
Endothelial Cell Thymosin β4 Knock Down Ameliorates Kidney 
Fibrosis by Reducing Endothelial to Mesenchymal Transition (EndoMT) 
Jianyong Zhong,1,2 Haichun Yang,1 Agnes B. Fogo.1  1Dept of Pathology, 
Microbiology and Immunology, Vanderbilt Univ; 2Div of Pediatric Nephrology, 
Vanderbilt Univ, Nashville, TN.
Background: Thymosin β4 (Tβ4) is a G-actin sequestering protein with effects on 
angiogenesis, cell migration and matrix. Our previous data showed that exogenous Tβ4 
treatment ameliorated matrix accumulation at day 14 after unilateral ureteral obstruction 
(UUO). In this study, we investigated whether knockdown of Tb4 only on endothelial cells 
has effects on renal fibrosis.
Methods: We generated inducible endothelial cell Tβ4 knockdown mouse (Tβ4 KD) 
by mating Tb4 shRNA loxp mice with SCL Cre mice. SCL Cre negative mice were used as 
control (Cont). Tamoxifen was administrated to induce Tβ4 knockdown (×5, qod, from-8d). 
Mice were sacrificed at 14 days after UUO.
Results: Peritubular capillary density, assessed by CD31 staining, was significantly 
decreased in Tβ4 KD mice (Tβ4 KD 2.39±0.11 vs. Cont 3.20±0.08 %, P<0.001). Peritubular 
capillary permeability, measured by injecting Evans blue dye in vivo and assessing 
extravasated dye in the kidney, also was reduced in Tβ4 KD mice (Tβ4 KD 107.01±5.49 
vs. Cont 161.85±16.32 mg/g KW, P<0.05). Tβ4 KD had significantly decreased collagen 
I, accessed by IHC, vs Cont (Tβ4 KD 15.24±0.57 vs. Cont 17.68±0.71 %, P<0.05), but 
no significant change in Sirius red positive area (Tβ4 KD 0.91±0.03 vs. Cont 1.14±0.15 
%) or total collagen (Tβ4 KD 48.06±5.01 vs. Cont 53.50±2.34 mg/mg). Tβ4 KD had less 
EndoMT (α-SMA+ and CD31+ double positive cells/high power: Tβ4 KD 1.20±0.11 vs. 
Cont 1.74±0.17 P<0.05).
Conclusions: We conclude that endothelial cell thymosin β4 knockdown results in 
impaired peritubular capillary number and function, with reduced collagen I protein in 
UUO. We speculate that Tβ4 KD in endothelial cells may change endothelial function 
and modulate EndoMT.
Funding: NIDDK Support
SA-PO483
Endostatin and Transglutaminase 2 Are Geronic Proteins Involved in 
Fibrosis of Aging Kidney  Chi Hua Sarah Lin,1 Jun Chen,1 Gail V.W. Johnson,2 
Arthur J.l. Cooper,1 Zhongtao Zhang,1 Julianne Feola,2 Jonathan Shein,1 Heli 
Ruotsalainen,3 Taina Pihlajaniemi,3 Michael S. Goligorsky.1  1New York Medical 
College; 2Univ of Rochester; 3Univ of Oulu, Finland.
Background: Endostatin (EST), the C-terminal fragment of collagen XVIII and a 
potent anti-angiogenic factor, is highly enriched in aging kidneys. It has also been recently 
described as an interactive partner of another profibrogenic factor, transglutaminase 2 (TG2), 
an enzyme cross-linking extracellular matrix proteins. We inquire the possible direct or 
auxiliary role they may play in the development of renal tubulointerstitial fibrosis of aging.
Methods: Studies were conducted in young and aging wild type mice, mice 
overexpressing EST and mice kidney of subcapsular injection of TG2 or EST.
Results: In wild type mice, aging kidneys exhibited 2-4-fold increase in TG2 paralleled 
by the increased cross-linking of extracellular matrix proteins and striped fibrosis. Ex vivo 
aortic rings embedded in matrigel supplemented with TG2 showed suppressed angiogenesis 
and proteolytic degradation. Injection of TG2 in the intact kidney produces increased cross-
linking within 48h. Transgenic miceoverexpressing EST showed renal interstitial fibrosis 
already at the young age, suggesting that EST may contributes to interstitial fibrosis in the 
aging kidney. Moreover, a month-long delivery of EST peptide via implanted minipumps 
to young mice also showed increased renal fibrosis, which became more robust when 
superimposed on the early “wound healing” phase of folic acid (FA)-induced nephropathy, 
a “second hit” model. Upregulation of TG2 and impaired renal function were also apparent 
in kidneys of mice with EST peptide delivery in combination with FA-induced nephropathy. 
Moreover, subcapsular injection of TG2 or EST increased the proportion of kidney-resident 
cells prematurely senescent.
Conclusions: These studies allow us to conclude that kidney fibrosis in aging may 
represent a natural outcome of deregulated EST and TG2, but more likely it appears to 
be a result of cumulative renal stresses occurring on the background of elevated geronic 
proteins, EST and TG2.
Funding: NIDDK Support
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Angiopoietin-1 Deficiency Increases Tubulointerstitial Fibrosis 
Krishnapriya Loganathan,1 Susan E. Quaggin,2 Marie Jeansson.1  1Dept of 
Immunology, Genetics and Pathology, Uppsala Univ, Uppsala, Sweden; 
2Feinberg School of Medicine, Northwestern Univ, Chicago, IL.
Background: Renal tubulointerstitial fibrosis is predictive of progressive decline in 
kidney function, independent of underlying disease. It is characterized by an increase in 
aSMA+ fibroblasts, myofibroblasts that produce collagen. Identification of factors that 
regulate the fibrotic response are excellent candidate targets for treatment of kidney diseases. 
We previously showed that loss of Angiopoietin-1 (Angpt1) in adult mice predisposes to 
fibrosis in wound healing and diabetic nephropathy. Angpt1 acts through the Tie2 tyrosine-
kinase receptor expressed on endothelial cells and a subset of myeloid cells. Here, we test 
the hypothesis that loss of Angpt1-Tie2 signaling destabilizes endothelial cells and results 
in an increased fibrotic response.
Methods: To investigate the role of Angpt1 in renal fibrosis we utilized Angpt1 
conditional knockout mice in experimental models of renal fibrosis, including unilateral 
ureter obstruction (UUO) and ischemia/reperfusion injury. Gene and protein regulation 
of fibrotic markers were investigated at different time points. We also performed lineage 
tagging experiments using Tie2-Cre and LysM-Cre to better understand the contribution 
of Tie2+ cells and macrophages to the myofibroblast population in UUO.
Results: Angpt1 deficient mice showed a significant (p<0.01) increase in fibrotic area 
3days after UUO, 9.7±0.45%, compared to controls, 7.9±0.24%. At the same time point, 
there was a trend (n.s) towards an increased number of myofibroblasts per field from 
15.4±1.8 in controls to 20.1±4.1 in Angpt1 deficient mice. Ischemia/reperfusion experiments 
are ongoing. In our lineage tagging experiment we found that 18.5±0.03% of myofibroblasts 
came from the Tie2-lineage whereas the LysM lineage contributed minimally, 2.4±0.005%.
Conclusions: Our results suggest that loss of Angpt1-Tie2 signaling increases 
tubulointerstitial fibrosis as seen by the increased expression of fibrosis markers in Angpt1 
deficient mice. Ongoing work is designed to use other models of fibrosis and to elucidate 
the mechanism(s).
Funding: Government Support - Non-U.S.
SA-PO485
Inter-Alpha-Inhibitor Heavy Chain5 Interactions Control Fibroblast: 
Myofibroblast Differentiation  John Martin, Timothy Bowen, Soma Meran, 
Aled O. Phillips, Robert Steadman.  Nephrology, Cardiff Univ, Cardiff, Wales, 
United Kingdom.
Background: Fibroblasts are central to CKD through their Transforming Growth 
Factor-β1 (TGF-β1)-triggered phenotypic transition into contractile, α-smooth muscle actin 
(α-sma)-positive myofibroblasts. Transition is dependent on an increase in the synthesis 
and accumulation of a pericellular matrix of hyaluronan (HA) and the HA-dependent 
co-localisation of CD44 with EGFR. Interactions of HA with hyaladherins, such as inter-
alpha-inhibitor (IαI) and the protein product of Tumour necrosis factor-stimulated gene 6 
(TSG-6) aid the assembly of this matrix and are also essential for the phenotypic activation 
of fibroblasts. The mechanisms controlling this effect, however, are not known and are 
the subject of this study.
Methods: Fibroblasts were incubated for 72 h with 10ng/ml TGF-β1 to become 
myofibroblasts. RT-QPCR was used to assess mRNA, siRNA was used to knockdown mRNA 
expression, immunocytochemistry and SDSPAGE:Western Blotting assessed protein levels.
Results: Following TGF-β1 treatment, TSG-6 and α-sma, had different kinetics of 
induction. Using siCD44 or EGFR inhibitor AG1478 to interfere with the CD44/EGFR-
dependent signal initiation prevented differentiation but had no effect on TSG6 expression. 
TSG-6, however, was essential for differentiation and using monoclonal antibody A38, 
HA-oligosaccharides, Cobalt, or siBikunin to interfere with the activity of TSG6, all 
prevented phenotypic change. These results suggested that it was the TSG6/IaI heavy chain 
(HC) interaction that was necessary for the effect. HC5 was shown to be the principal HC 
expressed in these cells. HC5 was released by hyaluronidase treatment of the fibroblast cell 
surface and siCD44, siTSG6 and siBikunin all inhibited the expression of HC5 protein. 
Finally, HC5 could be deleted on the cell by specific siRNA and this resulted in antagonism 
of phenotypic change, confirming its role in myofibroblast differentiation.
Conclusions: The mechanisms regulating TSG-6 and HA synthesis, during TGF-
β1-dependent induction of myofibroblasts are distinct. TSG-6, however, contributes to 
the pro-fibrotic response through its catalytic transfer of IαI HC5 to HA leading to the 
subsequent induction of phenotypic change.
Funding: Private Foundation Support
SA-PO486
Role of IL-4 Receptor α in Bone Marrow-Derived Fibroblast Activation 
and Renal Fibrosis  Hua Liang, Yuanbo Wu, Yanlin Wang.  Medicine, Baylor 
College of Medicine, Houston, TX.
Background: Renal fibrosis is a common pathway leading to progression of chronic 
kidney diseases. We and others have shown that bone marrow-derived fibroblasts contribute 
significantly to the pathogenesis of renal fibrosis. However, the signaling mechanisms 
underlying the activation of bone marrow-derived fibroblasts in the kidney are incompletely 
understood. We have found that IL-4 and its receptor α (IL4Rα) are induced in the kidney 
during the development of renal fibrosis. However, little is known about the role of IL-4Rα 
in the activation of bone marrow-derived fibroblasts and the development of renal fibrosis.
Methods: We examined the role of IL-4Rα in the activation of bone marrow-derived 
fibroblasts and the development of renal fibrosis using a mouse model of folic acid-induced 
nephropathy and cultured bone marrow monocytes treated with IL-4.
Results: Compared with wild-type (WT) mice, IL4Rα-knockout (KO) mice exhibited 
significant preservation of kidney function as measured by serum urea nitrogen and 
accumulated significantly fewer bone marrow-derived fibroblasts dual positive for CD45 and 
PDGFR-β in the kidney 2 weeks after folic acid treatment. Furthermore, IL4Rα-KO mice 
exhibited fewer α-smooth muscle actin (α-SMA) positive myofibroblasts and expressed less 
α-SMA protein in the kidney following folic acid treatment. Consistent with these findings, 
IL4Rα deficiency significantly reduced total collagen deposition and suppressed expression 
of extracellular matrix proteins (collagen I and fibronectin). In cultured bone marrow 
monocytes, IL-4 activated STAT6 and induced expression of α-SMA and extracellular 
matrix proteins, which was abolished in the absence of IL4Rα.
Conclusions: Our results have demonstrated that IL4Rα plays an important role in 
the activation of bone marrow-derived fibroblasts and the development of renal fibrosis. 
These results indicate that IL4Rα signaling may represent a novel therapeutic target for 
chronic kidney disease.
Funding: NIDDK Support
SA-PO487
Role of Scaffolding Protein JLP in Preventing Renal Fibrosis in Obstructive 
Nephropathy  Qiang Fu, Qi Yan, Qin Zhang, Guohua Ding, Huiming Wang. 
Renmin Hospital of Wuhan Univ.
Background: Renal fibrosis is a common pathologic lesion in the end stage of various 
progressive kidney diseases, and is characterized by interstitial inflammation, proliferation 
of myofibroblasts, and progressive accumulation of extracellular matrix(ECM). The JNK-
associated leucine zipper protein (JLP) is a crucial scaffolding protein in signals transduction 
and molecular trafficking. JLP has been found expressed in mouse tissues of brain, lung, 
spleen, testis, and kidney. We reported here, for the first time, the effects of  JLP deficiency 
on the progression of renal fibrosis in mice model of unilateral ureteral obstruction (UUO).
Methods: lp Wild type (jlp+/+) and jlp deficient (jlp-/-) mice were divided into four 
groups,: jlp+/+- and jlp-/--sham-operated groups, jlp+/+- and jlp-/--unilateral ureteral obstruction 
(UUO)-operated groups (jlp-/-- UUO group and jlp+/+- UUO group). Mice were sacrificed at 
the days of 7 and 14 to evaluate the fibrosis by Masson and H&E staining. The expression 
of transforming growth factor-b1 (TGF-b1), α-smooth muscle actin (α-SMA), collagen 
I(COL-I), and collagen III (COL-III) were assayed by immunohistochemistry staining.
Results: One week after the surgery, more collagen deposition was observed in the 
renal interstitial area in jlp-/-- UUO group than in jlp+/+- UUO group. Similar to that, the 
expression of COL-I and COL-III were significantly increased in the kidney cortices in 
jlp-/-- UUO-operated groups. The expression of TGF-b1 and α-SMA was also significantly 
higher in jlp -/-- UUO-operated group than in jlp+/+- UUO group.
Conclusions: Scaffolding protein JLP is critical in preventing renal fibrosis through 
the  mechanism of inhibition TGF-b1 expression and myo-fibroblast induction.
Funding: Government Support - Non-U.S.
SA-PO488
HGF-Producing Cell Sheet Suppress Renal Fibrosis Induced by Unilateral 
Uretic Obstruction in a Rat  Masatoshi Oka,1 Sachiko Sekiya,2 Ryoichi 
Sakiyama,2 Kosaku Nitta,1 Tatsuya Shimizu.2  1Nephrology, Tokyo Women’s 
Medical Univ, Shinjuku, Tokyo, Japan; 2Tokyo Women’s Medical Univ Inst 
of Advanced Biomedical Engineering and Sciences, Shinjuku, Tokyo, Japan.
Background: Tubulointerstitial fibrosis is a typical pathological finding in chronic 
kidney disease (CKD) and is associated with the progression of renal dysfunction. Recently 
several studies reported to suppress renal fibrosis by transplantation of cells expressing 
several growth factor, for example EGF, HGF. Cell sheet transplantation is a methodology 
of cell therapy for regenerative medicine. This technology demonstrated high effective 
therapy for diseases in other organs, such as cornea, periodontium, esophagus and heart. In 
this study, we performed to suppress renal fibrosis by local and sustained administration of 
hepatocyte growth factor (HGF) with HGF-producing cell sheet (HGF sheet) transplantation.
Methods: Human mesothelial cells transfected human HGF gene by lipofection were 
cultured on temperature-responsive dish for 4 days. When temperature reduced,  these 
HGF-producing cells were detached from dishes as cell sheet without enzyme-treated. 
We performed unilateral ureteric obstruction (UUO) in nude rat and transplanted the HGF 
sheet immediately. To compare HGF sheet transplantation with intermittent administration 
of HGF protein, we also injected HGF protein from tail vein every 24 hours for UUO rat 
(HGF i.v.). The kidney volume after operation measured with CT every 7 days for 4 weeks.
Results: One week after operation, histologically the positive area of collagen and 
smooth muscle actin in kidney transplanted HGF sheet was significantly less compared to 
that in HGF i.v. kidney. Moreover, the kidney volume treated HGF sheet with UUO was 
significantly less compared to control 4 weeks after operation.  And it maintained thick cortex 
tissues with a lot of glomeruli, tubules and microvessels in the kidney treated HGF sheet.
Conclusions: Local and sustained HGF administration with HGF sheet strongly 
suppressed renal fibrosis induced by UUO in a rat. Our results suggested that cell sheet 
therapy may be a promising strategy for renal disease.
Funding: Government Support - Non-U.S.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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Extracellular Matrix Modulates Macrophage Phenotype Profile 
Astgik Petrosyan,1 Stefano Da Sacco,2 Sargis Sedrakyan,2 Giuseppe Orlando,3 
Matthew Edward Thornton,1 Brendan Grubbs,1 Roger E. De Filippo,1,2 Laura 
Perin.1,2  1Univ of Southern California; 2Children’s Hospital Los Angeles; 3Wake 
Forest School of Medicine.
Background: It is known that macrophages play an important role in kidney damage 
and resolution. An increase in macrophages phenotype type 1 (M1) is known to promote 
scar formation while an increase in macrophage phenotype type 2 (M2) leads to pro-
healing processes. However little is known on how the extracellular matrix (ECM) can 
direct macrophages toward a specific phenotype acquisition during development, tissue 
homeostasis and disease.
Methods: Using established protocols we decellularized human adult healthy, adult 
diseased, and fetal kidneys; monocytes were seeded on the different ECMs and macrophage 
phenotype switch after 24hrs and 5 days was assessed. Macrophage maturation was tested 
by evaluating release of IL-10, IFN-γ, TNF-α and IL-4 in the culture media along with 
qRT-PCR and immunocytochemistry to evaluate expression of M1 (CD80 and CD86) and 
M2 (CD163, CD16, CD14 and CD200R) phenotypes.
Results: We observed that monocytes cultured on ECMs were able to mature into 
macrophages and present an increase in M1 marker (CD80) on diseased ECM, an increase in 
M2 markers (CD163, CD200R) on healthy ECM, and an increase in anti-inflammatory M2 
marker (CD16) on fetal ECM, after 24hrs. After 5 days of co-culture there was an overall 
decrease in gene expression for all markers followed by an increase in media secretion of 
IL-10 on diseased ECM vs healthy and fetal ECM. Additionally after 5 days higher number 
of seeded monocytes appear to adhere onto the adult ECM vs the fetal ECM. IFN-γ, IL-4 or 
CD64 expression was not detected during 24hrs and 5 days. Monocytes capacity to mature 
into macrophages was confirmed in vitro by administration of phorbol myristate acetate 
(PMA) and 1,25-dihydroxy vitamin D3 with LPS.
Conclusions: This preliminary work suggests that the ECM has the capacity to modulate 
macrophage phenotype and might contribute to disease progression. Additionally, this 
model may be used to investigate mechanisms of ECM-dependent macrophage activation 
during renal disease and regeneration.
SA-PO490
High Salt Diet Induces Blood Pressure Independent Tubulointerstitial 
Remodeling and Lymphangiogenesis in Rat Kidney  Ryanne S. Hijmans, 
Saleh Yazdani, Gerjan Navis, Jacob van den Born.  Nephrology, Univ Medical 
Center Groningen, Groningen, Netherlands.
Background: In chronic kidney disease (CKD), proteinuria is an important cause of 
tubular activation and progressive tubulointerstitial damage. It has been shown that high salt 
(HS) intake can aggravate this renal damage. Although earlier studies mainly focused on 
the blood pressure dependent (BP) effects of sodium on the kidney, recent studies suggest 
there is a BP independent route as well. A HS diet has been shown to store Na+ in the skin 
and as a result of binding of Na+ to proteoglycans, the influx of macrophages stimulates 
the secretion of vascular endothelial growth factor C (VEGF-C). Macrophage-derived 
VEGF-C has been shown to induce lymphangiogenesis (LA) in the skin. As LA has a 
role in inflammatory remodeling, we hypothesize that HS diet exerts its BP independent 
effects on the kidney by inducing LA and renal tubulointerstitial (TI) remodeling. We 
tested this hypothesis in normal rats, to avoid interference with TI remodeling due to the 
primary renal disorder.
Methods: Male Wistar rats (n=15) were randomly assigned to one of three study 
groups. Two groups (both n=5) received a high salt diet of 8% salt, while the control group 
(n=5) had a normal rat diet. After 2 weeks, one of the two groups on a high salt diet was 
sacrificed, and the other groups were sacrificed at 4 weeks. The kidneys were stained and 
quantified for lymphangiogenic, fibrotic and inflammatory markers.
Results: Rats with HS intake showed an increased number of lymph vessels compared 
to their controls at week 4 (p<0,06). ED1+ macrophages also increased in the HS group 
at week 4 (p<0.06). There was a significant increase of myofibroblasts (α-SMA) after 4 
weeks in the HS group (p<0,02). Except for week 1 (p<0,05), the HS groups showed no 
significant BP differences with their controls at 2, 3 and 4 weeks.
Conclusions: We showed that high salt intake induces tubulointerstitial 
lymphangiogenesis, inflammation and profibrotic changes in rat kidneys, even when the 
BP is not significantly different between the groups. This finding supports our hypothesis that 
HS intake has BP independent effects next to it’s well known BP dependent effects in CKD.
SA-PO491
Genetic and Epigenetic Analysis of the MicroRNA-200 Family for 
Association with End Stage Renal Disease  Laura Jane Smyth,1 Gareth J. 
McKay,1 Alexander P. Maxwell,1,2 A.J. McKnight.1  1Centre for Public Health, 
Queen’s Univ of Belfast, Belfast, Northern Ireland, United Kingdom; 2Regional 
Nephrology Unit, Belfast City Hospital, Belfast, Northern Ireland, United 
Kingdom.
Background: DNA methylation and miRNA profiles are associated with complex 
disease and are altered in uremic patients. We evaluated CpG sites, gene expression and 
SNPs of the miRNA-200 family and their target genes, including exploration of relevant 
methylation quantitative trait loci (meQTLs).
Methods: Quantitative DNA methylation was extracted from existing epigenome-wide 
association data (Illumina’s 450K Methylation array) for individuals with and without 
kidney disease (n=407). Following stringent quality control, a total of 14 significant CpG 
sites were identified within the miRNA-200 family, the most significant of which was 
cg23651812 (MIR429, P=4.1x10-45). The top 20 predicted target genes were determined 
using miRDB for each miRNA (MIR141, MIR200A, MIR200B, MIR200C and MIR429). 
Target genes had 308 CpG sites with methylation data; the most significant for MIR429 
were cg11686204 in ELL2 and cg19038462 in ZEB1 (P=4.2x10-48). RNA-Seq analysis was 
performed on renal transplant recipients and healthy controls using the Ion Proton™. RNA 
was selectively depleted for ribosomal RNA and up to 40 million reads were gained per 
sample. Differential methylation status was associated with expression of miRNA and their 
corresponding gene targets. Genome-wide SNP data (n=561,233 SNPs; 372 individuals) 
from the Illumina 660K array was analysed in PLINK with QTL methylation data from 
the individual miRNA (n=14) and their target genes (n=308) CpG sites.
Results: No genome-wide significant cis-meQTLs were identified for the miRNAs. 
Two cis-meQTLs were identified for ZEB2 (rs10200550 and rs4347890), a target gene for 
MIR429. Genome-wide significant results (n=476 SNPs) were obtained for 67 target genes 
(maximum P=9.98x10-32). These genes may influence miRNA regulation.
Conclusions: CD36, the top-ranked gene, has previously been linked to kidney disease 
where it is suggested that it has a prominent role in the development of renal fibrosis. We 
have provided a genomic map of the miRNA-200 family using novel data in order to assist 
in determining its association with ESRD.
Funding: Private Foundation Support
SA-PO492
A MicroRNA Signature of Epithelial–Mesenchymal Transition in 
Progression of Chronic Renal Disease  Ali Ramezani,1 Joseph M. Devaney,2 
Akshay Roy-Chaudhury,1 Richard Scott,2 Sara Karandish,1 Susan Knoblach,2 
Jeffrey B. Kopp,3 Dominic S. Raj.1  1Div of Renal Diseases and Hypertension, 
George Washington Univ, Washington, DC; 2Center for Genetic Medicine 
Research, CNMC, Washington, DC; 3NIDDK, NIH, Bethesda, MD.
Background: Irrespective of the diverse initial causes, progression of CKD is 
characterized by increasing tubulointerstitial fibrosis. There is a great need for accurate, 
noninvasive biomarkers for early detection of fibrosis in the kidney and the progression of 
kidney disease. Recent evidence suggests that miRNAs participate in the fibrotic process 
in the kidney. The aim of this study was to examine the urinary and circulatory miRNA 
expression profiles regulating the EMT and whether they are reflected by parallel changes 
in the pro-fibrotic factors and the progression of kidney disease.
Methods: Blood and urine samples were obtained from 28 patients with CKD. Patients 
were divided into two groups according to their GFR: GFR<30 and GFR>30. Plasma and 
urinary levels of two biomarkers of fibrosis, collagens III (PIIINP) and IV, were measured. 
To analyze the involvement of miRNAs in kidney fibrosis, the plasma and urinary miRNA 
expression profiles of the patients were analyzed.
Results: Plasma and urine PIIINP and CIV levels were significantly increased in 
patients with GFR<30. Furthermore, miRNA expression profile of the patients showed 
58 downregulated and 60 upregulated miRNAs in urine, and 51 downregulated and 61 
upregulated miRNAs in the plasma of the patients with GFR<30 compared with GFR>30. 
A panel of 4 urine and 6 plasma miRNAs was identified which not only distinguished 
patients with GFR<30 from GFR>30, but their altered expression were also implicated in 
the phenotypic changes that occur during EMT and fibrosis. The altered expression levels 
of these miRNAs were validated in a tubular epithelial cell line, and studies are underway 
to validate their expression in vivo, in the Alb/TGFβ mouse model.
Conclusions: Plasma and urinary miRNAs are reliable, noninvasive, and inexpensive 
markers for CKD fibrosis and progression. These miRNA panels warrant study in larger 
cohorts since plasma- and urine-based assays could provide a more feasible and safer 
screening compared to biopsy.
Funding: NIDDK Support
SA-PO493
The PR3 Receptor CD177 Is Controlled by Epigenetic Mechanisms 
Claudia Eulenberg,1 Sylvia Bähring,1 Friedrich C. Luft,1 Ralph Kettritz.2 
1Charité-Buch, Experimental and Clinical Research Center, Berlin, Germany; 
2Nephrology and Intensive Care Medicine, ECRC, Berlin, Germany.
Background: Proteinase 3 is the major ANCA antigen in granulomatosis with 
polyangiitis (GPA). PR3-ANCA binding to membrane-PR3 (mPR3) is a key event for 
neutrophil activation and vascular damage. The neutrophil-specific CD177 receptor enables 
mPR3high expression on a neutrophil subset (CD177pos/mPR3high). ANCA patients show a 
higher percentage of CD177pos/mPR3high neutrophils compared to healthies, the higher 
the percentage, the worse the prognosis. We reported previously that CD177 protein and 
mRNA expression is restricted to CD177pos/mPR3high neutrophils with a random monoallelic 
mRNA expression pattern. We hypothesized that epigenetic mechanisms control CD177 
gene expression.
Methods: Haplotype analysis, genome-wide methylation analysis, chromatin 
immunoprecipitation (ChIP) analysis and CD177 expression studies were performed in 
neutrophils and HeLa cells.
Results: Methylation analysis on CD177neg and –pos neutrophils revealed three CpGs in 
the potential CD177 promotor that were methylated in CD177neg, but not in CD177pos cells 
(p<0.001; n=6). ChIP identified an enrichment of the H3K4me3 mark (euchromatin) in the 
predicted CD177 promotor region in CD177pos neutrophils (p<0.05; n=4). This putative 
promotor region contains a TATA box and binding sites for several transcription factors, 
including the AP1 family. We established a HeLa cell model that recapitulates the neutrophil 
situation. We observed CD177 mRNA in PMA-treated HeLa cells. HeLa cells also had 
euchromatin in the promotor region and CD177 mRNA followed a monoallelic expression 
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pattern. CD177 mRNA expression was upregulated when we transfected HeLa cells with 
the AP1 family members c-Jun, c-Fos and c-Ets1. The same AP1 family members bound 
the putative CD177 promotor region by ChIP experiments in HeLa and neutrophils. HeLa 
cell treatment with the demethylation agent 5-aza-2’-deoxycytidine led to a biallelic CD177 
gene expression. Reporter assays in HeLa cells will further characterize the epigenetic and 
transcriptional CD177 regulation.
Conclusions: Our data strongly implicate epigenetic mechanisms that are responsible 
for the generation of distinct CD177/mPR3 subsets.
Funding: Government Support - Non-U.S.
SA-PO494
Application of Human Kidney RNA-seq Expression Quantitative Trait 
Loci in Chronic Kidney Disease  Yi-An Ko, Frank S. Chinga, Nora Ledo, 
Katalin Susztak.  Renal Electrolyte and Hypertension Div, Perelman School of 
Medicine, Univ of Pennsylvania, Philadelphia, PA.
Background: There are more than 5 million sequence variants in humans. Somegenetic 
variations influence transcript levels and therefore have the ability to interfere with cell 
and organ function. Such genetic variants are called expression quantitative trait loci 
(eQTL). The goal of our study was identify such functionally important genetic variants 
at the genome-wide level.
Methods: This analysis requires the collection of large number of human tissue 
samples with genotype and transcript level data. Here we used 99 human kidney samples 
of Central European descents.RNAseq and genotype data was normalized and genotype 
data was imputed using 1,000 Genome reference data. The association between genotype 
and transcript levels was performed using Matrix eQTL software and was limited to cis-
eQTLs where the genetic variant and transcript levels were within 2 megabases distance.
Results: We identified 164 significant target genes (we call these eGenes) and 
7590 significant SNPs (eSNPs) that passed the threshold for statistical significance after 
multiple testing correction using adjusted p-values<1.0E-10. Next we compared variants 
that influence gene expression in the kidney to those that have been published for other 
organs using the publicly available Genotype-Tissue Expression project (GTEx). Of the 
164 eGenes,103 were common between the kidney and other organs, indicating that there 
are cell type specific and cell type independent eGenes. Using kidney specific epigenome 
maps, we found that eSNPs were enriched on kidney specific regulatory elements, including 
promoters and enhancers. We also found a significantly greater overlap between kidney 
eGenes and polymorphisms that are associated with CKD development, compared to 
other traits (digestive, nervous, immune system diseases, hematological measurement, 
cardiovascular, and metabolic disease).
Conclusions:    We identified transcript level changes associated with genotypic 
variations. These results can highlight kidney specific regulatory elements and may also help 
to identify target genes for polymorphisms associated with kidney function related traits.
Funding: Other NIH Support - NIH Roadmap Epigenomics Program 
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RNA Sequencing Reveals Tumor Necrosis Factor α Inducible Protein 6 
(TNFAIP6) as a Potential Single Gene Classifier of Renal Cell Carcinoma 
Oystein Solberg Eikrem,1 Christian Beisland,1 Andreas Scherer,2 Arnar Flatberg,3 
Trude Skogstrand,1 Lea Landolt,1 Sabine Leh,1 Karin Margrethe Hjelle,1 Vidar 
Beisvag,3 Hans-Peter Marti.1  1Dept of Clinical Medicine, Univ of Bergen, 
Bergen, Norway; 2Spheromics, Kontiolahti, Finland; 3Dept of Cancer Research 
and Molecular Medicine, Univ of Science and Technology, Trondheim, Norway.
Background: The recent release of a new library preparation kit improved the cDNA 
library quality from formalin-fixed, paraffin-embedded (FFPE) tissues. In this study we 
demonstrate the feasibility of next generation sequencing (NGS) of mRNA obtained from 
FFPE tissues as compared with RNAlater® stored tissues.
Methods: Paired biopsies from tumorous and adjacent non-tumorous tissue of 16 
patients with ccRCC were either FFPE or stored in RNAlater® (Qiagen) for £1 year. 
Total RNA was extracted utilizing the miRNeasy FFPE kit and the miRNeasy micro kit 
(Qiagen). Sequencing libraries were prepared using the TruSeq RNA Access Library Prep 
Kit® (Illumina).
Results: The average expression of detected transcripts in both FFPE and RNAlater® 
datasets correlated with R2=0.97, and the log2 fold changes of the transcripts which are 
significantly altered in both datasets (n=1106) correlated with R2=0.94. A classifier model 
with TNFAIP6 was developed for the FFPE dataset with a specificity of 100% and sensitivity 
of 94%; ROC AUC=0.99 (Fig. 1A); only one normal sample was misclassified due to a 
small admixture of cancer tissue. Classifier validation in an Affymetrix microarray dataset 
obtained from GEO (GSE53757) showed TNFAIP6 up-regulation in all tumor stages with 
both sensitivity and specificity of 94%; ROC AUC=0.98 (Fig. 1B).
Conclusions: We describe a potential single gene classifier for ccRCC. Furthermore, 
NGS in FFPE tissues is feasible and correlates well withRNAlater® stored tissues. Thus, 
our studies open up novel diagnostic possibilities on archival renal biopsies.
Funding: Government Support - Non-U.S.
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Gene Expression Based Dissection of Chronic Kidney Disease Traits 
Pazit Beckerman, Katalin Susztak.  Renal, Electrolyte and Hypertension Dept, 
Univ of Pennsylvania, Philadelphia, PA.
Background: Chronic kidney disease (CKD) is a progressive decline in kidney 
function. There are several manifestations of CKD including glomerular function change, 
albuminuria, glomerulosclerosis, tubulointerstitial fibrosis and metabolic changes. These 
traits are strongly correlated but the question remains whether they are driven by identical 
mechanisms.
Methods: We conducted genome wide transcript level analysis of 95 microdissected 
human kidney tubule samples. We used transcript level changes as quantitative traits to 
dissect underlying mechanisms. These samples included subjects with normal eGFR with 
or without diabetes (DM) or hypertension (HTN), and diseased kidney samples with low 
eGFR, fibrosis and sclerosis, with or without DM or HTN.
Results: We identified 1430 transcripts with significant linear correlation with eGFR. 
Pathway analysis indicated significant enrichment for inflammation and metabolism related 
pathways. Subgroup analysis indicated enrichment for TGFβ and Wnt signaling and ECM 
receptor interactions only in earlier CKD stages. Our analysis identified 1606 transcripts 
that correlated with fibrosis and 1803 transcripts correlated with glomerulosclerosis. 
Similar to the clinical overlap between eGFR and fibrosis, we found that 78% of transcripts 
were identical. Transcripts that showed correlation with fibrosis but not with eGFR were 
enriched for inflammation related pathways. On the other hand, metabolism related genes 
correlated with eGFR but not with fibrosis. There were significant differences between 
male and female samples as well.
Conclusions: Our transcriptome-based dissection method highlights the relatedness 
of eGFR and kidney fibrosis, but also indicates potential differences in the underlying 
mechanisms of the two processes.
Funding: NIDDK Support
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Early-Onset, Severe Forms of Hypertension and Cardiovascular 
Complications Are Associated with APOL1 G1/G2 Susceptibility Alleles 
in African Americans  Girish N. Nadkarni, Geneviève Galarneau, Stephen 
B. Ellis, Rajiv Nadukuru, Stuart Scott, Laura Rassmussen Torvik, Abel Kho, 
Geoffrey Hayes, Jennifer Pacheco, Rex L. Chisholm, Joshua C. Denny, Dan 
M. Roden, Eimear Kenny, Erwin P. Bottinger.  Electronic Medical Records and 
Genomics (eMERGE) Network.
Background: Apolipoprotein L1 (APOL1) susceptibility alleles have been associated 
with kidney disease progression and ESRD in hypertensive African Ancestry (AA) 
populations. We explored whether these APOL1 alleles are associated with blood pressure-
related traits in AA enrolled in the electronic medical records and genomics (eMERGE) 
Network.
Methods: Study populations included the Mount Sinai BioMe biobank discovery(dis) 
cohort(n=5,213) and three EMR-linked biobank replication(rep) cohorts, including 
Vanderbilt BioVU (n=2,889), Northwestern NUgene (n=613), and Mount Sinai BioMe 
(n=1,655). APOL1 single nucleotide polymorphisms (SNPs) rs73885319, rs71785313 and 
rs60910145 were genotyped in BioMe samples and imputed in BioVU and NUgene samples 
to determine APOL1 G1 and G2 risk alleles. Longitudinal phenotypic data were extracted 
from EMRs. Linear regression models & meta-analyses (METAL) were performed with 
age, sex, mean BMI, and eGFR as covariates.
Results: Compared with carriers of [0 or 1] APOL1 G1/G2 risk alleles, carriers of [2] 
risk alleles were diagnosed with hypertension a mean of 2.5 years (95%CI 1.9-2.9 yrs) 
earlier in life (Pdis=0.04, Prep=3x10-4; Cox hazard); manifested 2-3 mmHg higher systolic 
BP(SBP) in younger AA (age 20–39) (Pdis=0.07, Prep=0.04); and were exposed to more 
antihypertensive medication classes (Pdis=0.11; Prep=3x10-4). Carriers of [2] risk alleles 
were more likely to manifest concentric left ventricular hypertrophy by echocardiogram 
(OR(95%CI)=1.52(1.14-2.02); P<0.01) and hemorrhagic cerebrovascular accidents 
(OR(95%CI)=2.42(1.01-5.97); P=0.05).
Conclusions: APOL1 G1/G2 susceptibility alleles are associated with early-onset, 
more severe form(s) of hypertension & with hypertensive complications hemorrhagic stroke 
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and concentric LVH independent of kidney function & BMI. These results may warrant a 
shift from kidney-intrinsic to systemic vascular pathomechanisms attributable to APOL1 
G1/G2 susceptibility alleles.
Funding: Other NIH Support - NHGRI
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Apolipoprotein L1 (APOL1) Gene Variants and Incident Proteinuria: 
Results from the African American Study of Kidney Disease and 
Hypertension (AASK)  Teresa K. Chen,1 Carmen A. Peralta,2 Lawrence J. 
Appel,3 Michael J. Choi,1 Michelle M. Estrella.1  1Nephrology, Johns Hopkins 
Univ; 2Nephrology, Univ of California San Francisco; 3Medicine, Johns 
Hopkins Univ.
Background: APOL1 gene variants are associated with kidney function decline. 
Whether these same gene variants are associated with incident proteinuria in the context 
of pre-existing chronic kidney disease (CKD) is unknown.
Methods: Using the trial and cohort phases of AASK (median follow-up of 6.8 years, 
maximum follow-up of 12.2 years), we evaluated participants who had hypertension-
attributed CKD and who did not have proteinuria at baseline. Cox proportional hazards 
models were used to estimate the relative hazard of incident proteinuria (defined as a 
doubling of urine protein-to-creatinine ratio and UP/Cr ³0.22), comparing APOL1 high-
risk genotype (2 risk alleles) vs. low-risk genotypes (0-1 risk alleles). We adjusted for 
age, gender, baseline GFR, percentage of European ancestry, randomized blood pressure 
goal (usual vs. low), and randomized blood pressure drug (ramipril vs. metoprolol vs. 
amlodipine). Effect modification by randomized trial interventions and dietary sodium 
intake (as estimated by 24-hour urine sodium) was assessed.
Results: Of the 480 participants included in our study, 17% (n=82) had the APOL1 
high-risk genotype. Individuals with the APOL1 high-risk genotype were 83% more likely 
to develop incident proteinuria compared to those with the low-risk genotypes (adjusted 
HR: 1.83; 95% CI: 1.36 to 2.47; p<0.001). The association between APOL1 and incident 
proteinuria was not modified by randomized blood pressure goal, randomized blood pressure 
drug, or dietary sodium intake (p-interaction>0.05 for each).
Conclusions: Among African-Americans with CKD attributed to hypertension but 
without baseline proteinuria, high-risk variants of APOL1 are associated with a greater 
risk of incident proteinuria.
Funding: NIDDK Support, Pharmaceutical Company Support - The AASK trial 
and cohort were also supported by the following pharmaceutical companies: King 
Pharmaceuticals, Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia, 
and Upjohn.
SA-PO499
African Ancestry Specific Alleles Confer Chronic Kidney Disease Risk in 
U.S. Hispanics  Nora Franceschini,1 Adrienne M. Stilp,6 Michael F. Flessner,2 
Carmen A. Peralta,3 Sylvia E. Rosas,4 Cathy C. Laurie,6 Holly J. Kramer.5 
1Epidemiology, Univ of North Carolina, Chapel Hill, NC; 2National Insts of 
Health, Bethesda, MD; 3Univ of San Francisco, San Francisco, CA; 4Harvard 
Univ, Boston, MA; 5Loyola Univ, Maywood, IL; 6Univ of Washington, Seattle, 
WA.
Background: Hispanics are a heterogeneous group with varying genetic ancestry. 
African ancestry can differ in Hispanics by country of origin, and its proportion relates to 
their risk of chronic kidney disease (CKD).
Methods: We examined the association of African ancestry population-specific risk 
alleles (APOL1 and HBB rs334 related sickle cell anemia) with CKD in 11,921 Hispanics, 
aged 18-74 years, recruited in a community-based study in four US centers. APOL1 G1/
G2 alleles were genotyped and rs334 alleles were imputed (rsq=0.83). CKD was defined 
as an increased urine albumin to creatinine ratio (UACR) (≥ 17 mg/g in men and ³25 mg/g 
in women), reduced estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 based 
on serum creatinine/cystatin C CKD-EPI equation, or presence of reduced eGFR or an 
increased UACR. Analyses used generalized linear mixed models that accounted for the 
sampling strategy and family relatedness, age, sex, diabetes, systolic blood pressure and 
anti-hypertensive medications, and stratified by Hispanic background.
Results: There were 41% men, and mean age was 46 (SD =14). The prevalence of 
increased UACR was 14%, reduced eGFR was 4%, and combined CKD outcomes was 16%. 
Caribbean Hispanics (Cuban, Dominican, Puerto Rican, N=5348) had higher prevalence of 
2 APOL1 risk alleles (1% vs 0.1%) and rs334 allele (2% vs. 0.7%) compared to Mainland 
Hispanics (Central American, Mexican, South American, N=6,539). APOL1 alleles were 
associated with increased UACR (p=10-4) and the composite CKD outcome (p=10-4), and 
rs334 was associated with same outcomes (UACR, p=10-7; CKD composite outcome, 
p=10-7) among Caribbeans only.
Conclusions: African-specific alleles are associated with CKD in Hispanics, but 
associations vary by Hispanic background. Medical care providers should be aware of the 
impact of these genetic variants for CKD risk in Hispanics.
Funding: Other NIH Support - R21HL123677, 1R01ES021367, 1R01HL118305-
01A1
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Role of Klotho Genetic Polymorphisms in Salt-Sensitivity: A Link Between 
Salt and Aging?  Chiara Lanzani, Lorena Citterio, Elena Brioni, Simona Delli 
Carpini, Marco Simonini, Guido Gatti, Elisabetta Messaggio, Paolo Manunta. 
Nephrology and Hypertension, San Raffaele Hospital, Milan, Italy.
Background: Previous data in transgenic mice showed that one-half klotho deficiency 
resulted in extensive premature aging, increased salt sensitivity and caused salt-sensitive 
hypertension. Recent gene expression study confirmed the expression oh Klotho in renal 
distal tubular cells. The aim of this study is to evaluate the role of Klotho polymorphisms 
in salt sensitivity hypertension.
Methods: Design: study of pressure-natriuresis relationship in essential hypertensive 
patients, never treated before, naive (NHP) by Acute salt load (NaLoad: 310 mMol in 2 h 
iv) and low salt diet (Low SD: <100 mEq/die for 15 days). Methods: 580 NHP underwent 
Naload, whereas 137 NHP were compliant to lowSD protocol (of 324 enrolled).
Results: GWA analysis identified 32 SNPs in Klotho gene (restricted to 15 with tagging 
r²=0,80). Six of these resulted significantly associated to BP variation after Naload and 
LowSD. The effect of intron 2 and 3 SNPs genotype on SBP variation after Naload and 
LowSD are reported in the (figure 1) confirming the similar effect in the two manoeuvres.
Conclusions: These results are the first demonstration of the role of Klotho gene in 
salt homeostasis and hypertension development and suggest that Klotho polymorphisms 
affect sodium renal tubular excretion. If confirmed these results propose Klotho as key 
gene in salt sensitivity and aging.
Funding: Government Support - Non-U.S.
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Associations Between the Reticulon 1 Gene (RTN1) and End-Stage Kidney 
Disease  Jason A. Bonomo,1 Nicholette D. Palmer,1 Ying Fan,2 John C. He,2 
Donald W. Bowden,1 Barry I. Freedman.3  1Center for Genomics & Personalized 
Medicine Research, Wake Forest School of Medicine; 2Dept of Internal Medicine, 
Section on Nephrology, Mount Sinai School of Medicine; 3Dept of Internal 
Medicine, Section on Nephrology, Wake Forest School of Medicine.
Background: RTN1 encodes endoplasmic reticulum stress proteins that have recently 
been associated with chronic kidney disease. We sought to determine if genetic variants 
within RTN1 were associated with end-stage renal disease (ESRD) in African Americans 
(AAs) and European Americans (EAs) with diabetic (T2D-ESRD) and non-diabetic forms 
of ESRD.
Methods: We examined the RTN1 gene region using a published AA T2D-ESRD 
genome-wide association study (Discovery study; n=922 cases, n=861 controls). Seven 
single nucleotide polymorphisms (SNPs) with p<0.05 were identified and genotyped in 
replication samples of AAs with T2D-ESRD (n=1,312) and controls (n=774), as well as 
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EAs with T2D-ESRD (n=604) and controls (n=1030). SNPs were also investigated in AAs 
with non-T2D ESRD (n=1,459 AA) and T2D in the absence of ESRD (n=500 AAs, n=620 
EAs). Data were adjusted for age, gender, admixture, and the APOL1 alleles, if applicable.
Results: The top RTN1 SNPs from the Discovery study underwent replication testing 
in independent case-control samples of AAs with T2D-ESRD. Replication was observed 
with three variants and a combined T2D-ESRD analysis (Discovery + Replication study) in 
AAs yielded p=0.015–3.0x10-4 with OR=0.67-0.77 thus showing protection with the minor 
allele. One SNP, rs12434215, replicated association in EAs with T2D-ESRD (p=0.019, 
OR=0.69). Nominal associations were observed for SNPs rs12431381 and rs12434215 
with non-T2D ESRD in AAs (p=0.014–0.015, OR=0.77). A combined AA all-cause ESRD 
analysis (n=3,800 cases, n=1,803 controls) demonstrated associations with rs12434215 
(p=6.7x10-4, OR=0.73) and rs12431381 (p=7.5x10-4, OR=0.75). Minimal evidence of 
association between these three SNPs and T2D alone was observed in both AAs and EAs.
Conclusions: These data provides genetic evidence of association between RTN1 and 
ESRD in AAs and EAs. Further studies are needed to clarify the signal.
Funding: NIDDK Support
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Interaction of Risk Alleles in Japanese Idiopathic Membranous 
Nephropathy  Kenjiro Honda,1 Myo Thiri,2 Koji Okamoto,3 Kent Doi,1 Hodaka 
Suzuki,4 Tsuyoshi Watanabe,4 Masaomi Nangaku,1 Katsushi Tokunaga,2 Eisei 
Noiri.1  1Nephrology and Endocrinology, The Univ of Tokyo, Tokyo, Japan; 2Dept 
of Human Genetics, Graduate School of Medicine, The Univ of Tokyo, Tokyo, 
Japan; 3Kidney Section, NIDDK/NIH, Bethesda, MD; 4Depts of Nephrology and 
Hypertension, Fukushima Medical Univ, Fukushima, Japan.
Background: Recent studies have reported the association of risk alleles of PLA2R1 
and HLA-DQA1 with idiopathic membranous nephropathy (IMN) in the European and 
Chinese populations. However, both close association of the risk alleles and interaction 
between risk alleles of PLA2R1 and HLA from high-resolution HLA typing among Japanese 
IMN patients has not been investigated.
Methods: Samples of Japanese biopsy-proven IMN patients (N = 183) and healthy 
control subjects (N = 620) were collected. Fifteen common variants were selected within 
PLA2R1 gene. High-resolution association analysis of single nucleotide polymorphisms 
(SNPs) within PLA2R1 and HLA alleles in HLA-A, B, C, DRB1, DQB1 and DPB1 was 
performed using 53 IMN cases and 420 controls. The significant associations discovered 
in the first sample set were validated by the second set that comprised of 130 IMN cases 
and 200 controls.
Results: The strong associations HLA-DRB1*15:01 (P=7.72 x 10-5, OR=2.9) and 
HLA-DQB1*06:02 (P=5.12 x 10-4, OR=2.6) were observed. Additionally, HLA-Cw*07:04 
and HLA-DRB1*16:02 showed nominal association with IMN, while HLA-B*07:02, HLA-
DRB1*04:05 and HLA-DQB1*04:01 were inversely associated with IMN. The associations 
did not remain significant after correction for multiple comparisons. In combined data 
analysis, HLA-DRB1*15:01 and HLA-DQB1*06:02 showed stronger association with 
IMN. In single locus analysis of PLA2R1, seven SNPs showed strong associations with 
IMN. Interaction analysis between HLA alleles and PLA2R1 variants revealed high odds 
ratio for IMN with both risk alleles.
Conclusions: The associations of PLA2R1 and HLA polymorphisms were identified 
in Japanese IMN patients. Moreover, PLA2R1 risk alleles and HLA risk haplotype showed 
additive effects that were stronger than individual odds ratios, indicating the importance 
of interaction of these two genes in the development of IMN.
SA-PO503
Relationship Between rs3760106 Variation of PRKCB1 Gene and End-Stage 
Renal Disease in Type 2 Diabetes Mellitus in Chinese  Limei Liu,1 Xiaoxu 
Ge,1 Langen Zhuang,1 Ming Li,1 Rong Zhang,1 Feng Wang,2 Niansong Wang.2 
1Dept of (ndocrinology and Metabolism, Shanghai Jiao Tong Univ Affiliated 
Sixth People’s Hospital; 2Dept of Nephrology, Shanghai Jiao Tong Univ Affiliated 
Sixth People’s Hospital, Shanghai, China.
Background: To explore the relationship between rs3760106 (C/T) variation of 
protein kinase C-β gene (PRKCB1) and end stage renal disease (ESRD) in type 2 Diabetes 
mellitus (T2DM) in Chinese.
Methods: 602 type 2 diabetes patients of Shanghai Han origin were recruited, which 
were divided into DN-ESRD group (n=274) with end-stage renal disease (ESRD) of 
diabetic nephropathy (DN) and DN-0 group (n=328) without diabetic nephropathy (DN-0). 
Taqman PCR assay was used to detect the genotypes of rs3760106 variation of PRKCB1 
gene. Genotypic and allelic frequencies and clinical characteristics were compared between 
two groups, including DN-0 and DN-ESRD groups as well as genotypic groups in DN-0 
or DN-ESRD group.
Results: Three genotypes (CC, CT and TT) of rs3760106 were detected. The 
distribution of the three genotypes of type 2 diabetes patients was in accordance with 
Hardy-Weinberg equilibrium. There were significant differences in both genotypic and 
allelic frequencies between DN-0 and DN-ESRD groups (p < 0.05 for each). The frequencies 
of CT+TT genotype and T allele in DN-ESRD group were significantly higher than those 
in DN-0 group (p < 0.05 for each). Patients with risk allele T (i.e. CT and TT genotypes) 
were at significantly higher risk of developing ESRD (OR = 2.14, 95% CI, 1.18-3.87, p 
<0.05). After adjusting for confounding variables, i.e., sex, onset age of diabetes and BMI 
with multi-factorial logistic regression model, this odds ratio (OR) remained significant 
[OR=1.94 (95% CI, 1.04-3.64)]. Moreover, compared with patients carrying CC genotype, 
those with CT+TT genotype had significantly higher fasting plasma glucose (FPG) level 
in DN-0 group (p < 0.05) or had an increasing tendency in DN-ESRD group (p >0.05).
Conclusions: PRKCB1 gene rs3760106 (C/T) is significantly associated with 
development of ESRD and T allele carriers are at higher risk of developing ESRD than 
those CC carriers in T2DM in Han Chinese of Shanghai.
Funding: Government Support - Non-U.S.
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The First Genome-Wide Association Study of Diabetic Nephropathy in 
Korean Type II Diabetes Patients  Byeongwoo Kim,1 Yeong Hoon Kim,1 
Sang Ho Lee,2 Sunwoo Kang.1  1Dept of Nephrology, Inje Univ, Busan Paik 
Hospital, Busan, Korea; 2Dept of Nephrology, College of Medicine, Kyung Hee 
Univ, Seoul, Korea.
Background: It has been suggested that genetic susceptibility plays an important role 
in the pathogenesis of diabetic nephropathy. Recently, several genome wide association 
studies (GWASs) suggested that specific polymorphisms of candidate genes were associated 
with susceptibility to diabetic nephropathy. However, there was weak point in contents of 
GWAS DNA chip for GWAS. In fact, previous contents of GWAS DNA chip were fixed 
and did not cover SNPs in exon region and promoter region. In present study, we used the 
Axiom™ Genome-Wide Human Assay. The contents of assay are selected by researcher 
and useful to investigate association between several candidate SNPs and specific diseases.
Methods: To investigate whether specific polymorphisms are involved in the 
development of the diabetic nephropathy, 87 diabetic nephropathy patients and 104 diabetic 
controls in Korean with type II diabetes were studied. We firstly selected 47,777 genes of 
homo sapiens in NCBI gene database and searched the SNPs in dbSNP database. And the 
criteria for selection exonic SNPs, promoter SNPs, and intron SNPs in each gene were 
following: (1) SNPs with > 10% minor allele frequency (MAF), (2) >0.1 heterozygosity, 
(3) known genotype frequencies of SNPs in Asian population, (4) SNPs studied in previous 
study, and (5) unknown SNPs. Finally we selected 378,707 SNPs. Logistic regression 
models were performed to determine odds ratio (OR), 95% confidence interval (CI), and 
P value. The analysis were analysis using Helixtree program.
Results: Among 378,707 SNPs, three SNPs (rs3214159 in ABCC8 gene, rs3747636 in 
PIK3C2B gene, and rs3765156 in PIK3C2B gene) showed strongly significant association 
with diabetic nephropathy (p<0.00001).
Conclusions: These results suggest that these significant SNPs may be useful to 
investigate the development of diabetic nephropathy.
Funding: Clinical Revenue Support
SA-PO505
An Efficient and Comprehensive Strategy for Genetic Diagnostics of All 
Hereditary Kidney Diseases  Lisbeth Silva,1 M. Lara Besada-Cerecedo,1 
Olaya Lamas-Gonzalez,1 Patricia Regueiro Casuso,1 Ana Barcia de la Iglesia,1 
Beatriz Sobrino,2 Jorge Amigo,2 Francisco Barros Angueira,2 Angel Carracedo,2 
Candido Diaz Rodriguez,1 Miguel A. Garcia-Gonzalez.1  1Group of Genetics and 
Developmental Biology of Renal Diseases, Dept of Nephrology, Univ Hospital 
Complex and Health Research Inst of Santiago de Compostela (IDIS), Santiago 
de Compostela, A Coruña, Spain; 2Galician Public Foundation of Genomic 
Medicine, Santiago de Compostela, A Coruña, Spain.
Background: Sanger is a traditional and reliable method for sequencing, but next 
generation sequencing (NGS) has improved genetic diagnosis in a time and cost effective 
manner. We established and validated a NGS strategy for all hereditary kidney diseases, 
and compared it with traditional and NGS exome sequencing technologies.
Methods: Based in clinical classification and population prevalence, we generated 
four panels and test them in 318 patients with renal disease during 2 years of routine 
clinical assistance: (1) Panel for common cystic disease (8 genes, 129 patients); (2) Panel 
for common, rare and ultra-rare cystic diseases (72 genes, 48 patients); (3) Panel for 
glomerular disease (26 genes, 89 patients) and (4) Panel for tubule/interstitial disease (36 
genes, 52 patients).
Results: This strategy has shown greater gene coverage, sensibility and specificity 
considering pseudogenes, compared to two independent NGS exome sequencing strategies 
(ampliseq n=2 and sureselect n=115). Also, we have developed a bioinformatics algorithm 
and generated an in-house database identifying a total of 6945 genomic variants (248 
frameshift- and 66 nonframeshift- insertion/deletion/substitutions, 44 stopgain; 102 
splicing, 807 nonsynonymous SNV, 592 synonymous SNV and 39326 non coding variants) 
that we have used to classify and re-classify considering every single genetic variant 
described into the literature. We have identify genetic interaction as the most common 
lack of positive genetic diagnosis and the major mechanism of phenotypic inter- and 
intra-familial variability.
Conclusions: Here we describe a novel strategy to anticipate disease and provide 
complete genetic information for clinical decision-making, in a time- and cost-efficient 
manner.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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SA-PO506
Exome Sequencing as Diagnostic Tool in Daily Clinical Nephrology Practice 
Ilse M. Rood,1,2 Dorien Lugtenberg,1,2 Elisabeth A.M. Cornelissen,1 Jeroen 
Schoots,1 Nicole Van De Kar,1 Michiel F. Schreuder,1 Linda Koster-Kamphuis,1 
Jeroen Deegens,1 Julia M. Hofstra,1 Tom Nijenhuis,1 Jack F. Wetzels,1 Ronald 
Roepman,1 Ernie M.H.F. Bongers.1  1Radboud Center Renal Disorders, 
RadboudUMC, Nijmegen, Netherlands; 2Shared first author.
Background: Next generation sequencing, e.g. exome sequencing (ES), is currently 
the state of the art technique to identify mutations in genetic diseases. We developed a 
workflow for implication of ES in daily clinical practice for patients with a suspected 
hereditary kidney disease. The aim of this study was to analyze the diagnostic yield of 
this approach in clinical practice.
Methods: We developed a two-tier analysis, in which the first step is a kidney disease 
gene panel to screen for pathogenic variants in 187 genes, minimizing the change of 
coincidental findings. If causative mutations are not identified (first step), the complete 
exome data set was analyzed after additional written informed consent. We analyzed the 
diagnostic yield of this approach.
Results: From Jun. 2013 till Jan. 2015 we included 74 unrelated patients with kidney 
disease, defined as glomerular disease (n=34), cystic renal disease (n=16), electrolyte 
disorders (n=11), renal insufficiency of unknown cause (n=4) and other (n=9). The kidney 
disease gene panel revealed pathogenic mutations in 11 cases (15%), and likely pathogenic 
variants in 12 other cases (16%), necessitating follow-up studies. Further analysis of the 
complete exome data set in 19 patients, revealed candidate genes in 6 patients that are 
under investigation. In addition, copy number variation analysis revealed a pathogenic 
deletion in 2 patients (in one patient another pathogenic mutation was also identified in step 
one). There was 1 coincidental finding necessitating follow up for coloncarcinoma. In 23 
patients open exome analysis is currently ongoing. Nine patients refused further analysis.
Conclusions: Currently, in 30 out of 74 patients (41%) (likely) causative mutations 
or new candidate genes were identified. We conclude that diagnostic exome sequencing is 
a powerful tool for detecting causative mutations in daily clinical practice without having 
the limitations of other gene testing approaches (single gene testing/targeted sequencing).
SA-PO507
Atypical Hemolytic Uremic Syndrome Targeted Re-Sequencing Study 
in a South Italian Cohort of Patients  Matteo Accetturo,1 Anna Zito,1 E.D. 
Stea,1 Maddalena Gigante,2 Paola Pontrelli,1 S. Diella,2 Giuseppe Castellano,1 
M. Giordano,3 L. Santangelo,3 Loreto Gesualdo.1  1Emergency and Organ 
Transplants, Nephrology Unit, Univ of Bari, Italy; 2Medical and Surgical 
Sciences, Nephrology Unit, Univ of Foggia, Italy; 3Giovanni XXIII Hospital, 
Italy.
Background: Atypical hemolytic uremic syndrome (aHUS) is a multifactorial disease 
due to autoimmune or genetic factors leading to deregulated alternative complement pathway 
activation. At present 12 genes are associated to aHUS, however 30-50% of patients lack 
mutations in these genes resulting in still partially obscure genotype-phenotype correlations.
Methods: We enrolled 20 aHUS patients and 2 relatives from Apulia Region, Italy. 
We performed targeted parallel re-sequencing of the 12 known genes plus ADAMTS13, 
integrated in the panel for genetic diagnostic routine screening. We analyzed the genotypes, 
investigating the overlapping with other alternative complement pathway disorders, such 
as C3 glomerulopathy, Age-related Macular Degeneration (AMD) and drusen. We selected 
patients for their history of sporadic aHUS. Target enrichment was performed using an 
Illumina TruSeq Custom Amplicon panel. Sequencing was performed on Illumina MiSeq 
Desktop Sequencer. All variants were evaluated for their pathogenicity according to CADD, 
Sift and Polyphen algorithms.
Results: We identified 30 missense and one nonsense variants in known aHUS genes, 
plus seven missense variants in ADAMTS13. Several combined variants were identified 
which might explain the different phenotypic nuances of our patients, as well as, in some 
cases, their signs of other Complement-related diseases. We evidenced that different 
combination of variants together with different triggering factors result in a phenotypic 
spectrum encompassing all the Complement-related disease range. Additionally, in 
presence of some combinations, also other underlying pathologies can act as a triggering 
background for aHUS.
Conclusions: Our data suggest that (i) ADAMTS13 gene should be routinely sequenced 
for aHUS (ii) the overlapping with other complement-related diseases is considerable. 
Mutations should therefore be analyzed in combination, and the high-throughput strategy 
is the only feasible in this scenario.
SA-PO508
Whole Exome Sequencing (WES) Revealed Underlying Complexity in 
Genetic Studies of Familial IgA Nephropathy (fIgAN)  Xuewen Song,1 
Nicole M. Roslin,2 Meng Yi Xu,1 Kairong Wang,1 Jannel Liu,1 Bushra Joarder,1 
Amirreza Haghighi,1 Melody Ren,1 Mitchell Li Cheong Man,1 Joseph C.K. 
Leung,3 Sydney C.W. Tang,3 Kar Neng Lai,3 Andrew D. Paterson,2 Florent 
Soubrier,4 York P. Pei.1  1Div of Nephrology, Univ Health Network, Toronto, 
ON, Canada; 2Program in Genetics and Genomic Biology, Hospital for Sick 
Children, Toronto, ON, Canada; 3Div of Nephrology, The Univ of Hong Kong, 
Hong Kong, China; 4INSERM, Univ Pierre et Marie Curie Paris 06 (UPMC), 
Paris, France.
Background: Diagnosis of familial glomerular diseases may be confounded by non-
specific clinical (i.e. hematuria and proteinuria) and/or pathological findings. Indeed, a 
recent study of familial focal segmental glomerulosclerosis (FSGS) has identified COL4A3 
and COL4A4 mutations in ~10% of study families [Kidney Int 86:1253-59, 2014]. In the 
course of studying a cohort of fIgAN, we unexpectedly identified pathogenic mutations in 
13 families with non-IgAN glomerular diseases.
Methods: We performed whole exome sequencing (WES) in 109 patients from 54 
families all with at least 2 biopsy-proven cases.
Results: Our WES study identified heterozygous/hemizygous pathogenic COL4A3 
(c.1504+1G>A; p.G291R; p.G695R; p.G1054E; p.G1286R), COL4A4 (p.Q970X; 
p.G1508A), and COL4A5 (p.G48R; p.G325R) mutations in 9 families with fIgAN. These 
mutations occurred at the canonical splice junction or conserved glycine residues and 
segregated in all affected subjects within family. In two multiplex families, co-existence 
of thin basement membrane disease (TBMD) with IgAN was also observed in the biopsied 
subjects in retrospect. Additionally, putative heterozygous pathogenic variants were found 
in 3 families in the known genes for FSGS (ACTN4, c.398-2A>G), CFHR5 nephropathy 
(CFHR5, p.C449fs), and membranous nephropathy (PLA2R1, p.C192G) and homozygous 
mutation in one family in another known gene for FSGS (ADCK4, p.S246N).
Conclusions: The presence of other glomerular diseases may confound the diagnosis 
of fIgAN in some putatively affected subjects ascertained based on urinary findings or 
even kidney biopsy. Due to its high prevalence in the general population, TBMD may 
be an important cause of phenocopy that can confound genetic linkage studies in fIgAN.
SA-PO509
Disease Gene Discovery for Familial IgA Nephropathy (fIgAN) by Whole 
Exome Sequencing (WES)  Xuewen Song,1 Nicole M. Roslin,2 Meng Yi Xu,1 
Kairong Wang,1 Jannel Liu,1 Bushra Joarder,1 Amirreza Haghighi,1 Melody Ren,1 
Mitchell Li Cheong Man,1 Joseph C.K. Leung,3 Sydney C.W. Tang,3 Kar Neng 
Lai,3 Andrew D. Paterson,2 Florent Soubrier,4 York P. Pei.1  1Div of Nephrology, 
Univ Health Network, Toronto, ON, Canada; 2Program in Genetics and Genomic 
Biology, Hospital for Sick Children, Toronto, ON, Canada; 3Div of Nephrology, 
The Univ of Hong Kong, Hong Kong, China; 4INSERM, Univ Pierre et Marie 
Curie Paris 06 (UPMC), Paris, France.
Background: IgAN is the most common primary glomerular disease worldwide. 
Genome-wide linkage scans have identified multiple susceptibility loci for fIgAN but no 
disease gene has yet been identified.
Methods: To identify susceptibility genes for fIgAN, we performed WES in 109 
patients from 54 families all with >2 biopsy-proven cases and putatively affected members 
ascertained with persistent hematuria/proteinuria. In 3 multiplex families each with >5 
affected cases, we also performed genome-wide linkage scans under a dominant model 
and focused WES on regions with suggestive linkage. Standard algorithms for sequence 
alignment, base calling, and QC filtering were applied to identify rare (MAF<1%) 
deleterious variants of high (i.e. protein-truncating) and moderate (i.e. inframe indels and 
deleterious non-synonymous missense variants predicted by PolyPhen-2, Sift, Mutation 
Assessor, CADD_phred, PhylopPMam_avg, and PhylopVert100_avg) impact.
Results: Overall, 99.8% of the targeted exome were covered with a mean depth of 100x. 
We examined 19 regions with LOD >1 in 3 multiplex families and ~3,000 immunologic 
candidate genes. We identified 26 candidate genes (i.e. IFIH1, CD33, MSH6, ERAP2, 
FUT2, MMRN1, MINA, OAS1, TLR1, RNASEL, MARCO, THADA, BTN1A1, PTPRK, 
RELT, ERCC1, ASB4, LCP1, HK3, ASH1L, LTB, FES, MPO, GP1BA, BACH2, and EMP3), 
each with rare deleterious variants affecting 2 or 3 unrelated families.
Conclusions: Our results suggest extensive genetic heterogeneity in fIgAN with 
many disease genes each contributing to a small proportion of cases. Future studies 
with expanded sample size will aid selection of the most promising candidate genes for 
functional studies. Identification of disease genes for fIgAN has the potential to improve 
diagnosis and treatment.
Funding: Government Support - Non-U.S.
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SA-PO510
Discovery of New Risk Gene Loci in IgA Nephropathy: Genome-Wide 
Human Assay  Kyung-Hwan Jeong, Tae Won Lee, Sang Ho Lee, Se Yun Kim, 
Jin Sug Kim, Shin Yeong Lee, Chun-Gyoo Ihm.  Internal Medicine, KyungHee 
Univ School of Medicine.
Background: IgA nephropathy(IgAN) is the most common form of glomerulonephritis 
in Korea. The etiology of IgAN is complex with high genetic heterogeneity. Several genome 
wide association studies(GWAS) suggested that specific polymorphisms of candidate genes 
were associated with susceptibility to IgAN. However, previous contents of GWAS DNA 
chip were fixed and did not cover SNPs in exon region and promoter region.
Methods: We used the Axiom™ Genome-Wide Human Assay by Affymetrix. The 
contents of assay are useful to investigate association between several candidate SNPs 
and specific diseases. We firstly selected 47,777 genes of homo sapiens in NCBI gene 
database and searched the SNPs in dbSNP database. And the criteria for selection exonic, 
promoter, and intron SNPs in each gene were following: SNPs with>10% minor allele 
frequency, >0.1 heterozygosity, known genotype frequencies of SNPs in Asians, SNPs 
studied in previous study, and unknown SNPs. Logistic regression models were performed 
to determine odds ratio(OR), 95% confidence interval(CI), and P value. The analysis was 
using Helix tree program.
Results: To investigate whether specific polymorphisms are involved in the development 
of the IgAN, 182biopsy confirmed IgAN patients and 455 healthy controls were studied. We 
selected 378,707 SNPs. We carried out genome wide genotyping on customized Axiom™ 
Genome-Wide Human Assay Among 378,707 SNPs, 19SNPs showed strongly significant 
association with IgAN(p<0.00001). We identified at rs201580039,rs12219125 and 
rs55730189 that implicated the genes encoding KLF14(Kruppel-like factor14,7q32.3,OR 
8.04,p=4.95x10-7), intergenic region at chromosome 10(OR0.24,p=1.72x10-5and unc-51 like 
autophagy activating kinase 2(ULK2,17p11.2,OR 8.44, p=3.61x10-5) as susceptibility genes. 
To validate the previous reported susceptibility SNPs of IgAN , we selected and genotyped 
19 SNPs. rs660895 of HLA-DRB1 and rs2856717 of HLA-DQB1 were significantly 
different between two groups.
Conclusions: These results suggest that these significant SNPs may be useful to 
investigate the development of IgAN.
SA-PO511
Mannan-Binding Lectin 2 Polymorphisms Were Associated with 
Progression of IgA Nephropathy  Yan Ouyang, Jingyuan Xie, Meng Yang, 
Xiaoyan Zhang, Xiaoxia Pan, Weiming Wang, Nan Chen.  Nephrology Dept, 
Ruijin Hospital, Shanghai Jiao Tong Univ, School of Medicine, Shanghai, China.
Background: Our aim is to evaluate whether MBL2 polymorphism associates with 
progression of IgA nephropathy (IgAN).
Methods: Patients with Primary lgAN were retrospectively recruitd from 2009 to 2013. 
Renal specimen was semi-quantitative scored according to the Oxford scoring system. 
Whole coding and promoter regions of MBL2 were sequenced in 101 patients. Then 3 SNPs 
(rs11003125, rs7096206 and rs7095891) in promoter and 1 SNP (rs1800450) in exon1 of 
MBL2 were genotyped in other 185 patients by Sanger sequencing. The associations of 
the 4 SNPs with patients’ clinical, pathological and prognostic parameters were analyzed. 
Serum MBL level was measured by ELISA.
Results: A total Of 286 patients were enrolled, mean age at time of biopsy was 
36.37±12.1 years. ESRD was found in 29 patients (10.1%) after a mean follow-up time of 
34.80 months. Among the 4 SNPs, only rs1800450, coding the 54th amino acid of MBL, 
significantly increased the risk of ESRD. More patients with rs1800450-AA (27.3%) 
progressed to ESRD compared to patients with GA genotype (15.5%) [P=0.326] or GG 
genotype (6.8%) [P=0.015]. Then all patients were divided into GG group (n=191), GA 
group (n = 84) and AA group (n=11) based upon genotypes of rs1800450. There were 
no differences of demographic, clinical and pathological parameters at time of biopsy, 
except for proteinuria (P =0.028). Interestingly, serum MBL levels in patients with AA 
genotype (median 0ng/ml) were significant lower than GA genotype (median 243.28ng/
ml) [P<0.001] and GG genotype (median 1033.03ng/ml) [P<0.001]. Kaplan-Meier survival 
analysis showed that mean survival time of AA group (38.90±5.68 months) was significant 
shorter than GG group (66.01±1.9months) [P=0.173] and GA group (56.37±2.62 months) 
[P<0.001].Finally, AA independently increased the risk of ESRD (AA vs GG+GA, 
HR=26.73, 95%CI 4.92-145.30, P<0.001) after adjusted by sex, age and clinical indicators 
by COX regression analysis.
Conclusions: IgAN patients with rs1800450-A allele have a higher risk of disease 
progression probably as a result of lower MBL levels in these patients, which may increase 
the risk of infection.
SA-PO512
ARHGAP32 as a Candidate Gene for Primary Focal Segmental Glomerulo-
sclerosis  Guisen Li, Li Wang.  Nephrology, Sichuan Academy of Medical 
Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China.
Background: Focal and segmental glomerulosclerosis (FSGS) is one of common 
causes of end-stage renal disease worldwide. Previous studies showed that genetic factor 
played an important role in the pathogenesis of FSGS. The purpose of this study was to 
identify the candidategene of FSGS in Chinese familial FSGS.
Methods: Total 21 individuals of a FSGS pedigree were involved in this study. 
Firstly, we screened the known causal mutations of ACTN4, TRPC6, and INF2gene in this 
pedigree. Then we conducted a genome wide scan for linkage study. And DNA of four 
members were assayed by whole exome sequencing. The data were filtrated according to 
the 1000 Genomes Project, ESP6500 and dbSNPinformation, and database with 69 exome 
sequencing project (without kidney diseases). By PCR sequencing methods, we detected 
candidate causal mutation. And then, we tested the mutation in other 97 sporadic FSGS 
patients and 96 normal controls.
Results: No mutation was detected from those exons of INF2, ACTN4 and TRPC6 in 
the FSGS pedigree. 8 loci suggested for linkage were identified, and the maximum two-
point parametric LOD score of 1.69 was marked by D5S2115. A mutation (c.C1213G, 
p.L405V) of ARHGAP32 gene was identified by combination with exome sequencing, 
genome-wide scan, function prediction of coding proteins. A new mutation (c.A3559G, 
p.T1187A)of ARHGAP32 gene was detected in one sporadicFSGS patient from 97 cases 
and 96 controls. The ARHGAP32 expression was detected in the glomeruli and tubule.
Conclusions: We found a candidate mutation of ARHGAP32gene for primary FSGS 
by combination with whole genome linkage analysisandwhole exome sequencing.
SA-PO513
Targeted Sequencing in Adults with Focal Segmental Glomerulosclerosis 
Konstantinos Koutroutsos,1 Jana Vandrovcova,2 Thomas M. Connor,1,2 H. 
Terence Cook,2 Marina Loucaidou,1 Tim Aitman.3  1West London Renal and 
Transplant Centre, Imperial College NHS Trust, United Kingdom; 2Imperial 
College London, United Kingdom; 3Inst of Genetics & Molecular Medicine, 
Univ of Edinburgh, United Kingdom.
Background: Multiple genes underlying focal segmental glomerulosclerosis (FSGS) 
and/or steroid resistant nephrotic syndrome (SRNS) have been identified. We aimed to 
investigate the distribution of gene mutations in adult patients with FSGS by targeted 
sequencing.
Methods: 94 adults with familial or sporadic FSGS were recruited through a single 
renal unit in England. The mean age at diagnosis was 46.4, and 61 were male. Ethnicity: 
42 Caucasian, 24 Afro-Caribbean, 24 South Asian. History of familial renal disease (14), 
recurrent FSGS in a renal transplant (21). DNA was extracted from whole blood or saliva 
using standard protocols. An Illumina TruSeq Custom Amplicon Targeted Next Generation 
sequencing (NGS) panel was designed covering 21 genes for FSGS. NGS sequencing was 
performed on the MiSeq v3 system. Data were analysed using our standard Mendelian 
disease pipeline and all variants were confirmed by Sanger sequencing.
Results: 19 rare, non-synonymous coding variants were identified, affecting 16 
individuals, including 3 with a family history and 4 with recurrent disease. 14 variants 
were heterozygous dominant, 3 compound heterozygous, and 2 X-linked recessive. Known 
pathogenic mutations included TRPC6 N143S and NPHS2 R229Q. Control variants 
were accurately identified in INF2 R214H, NPHS2 V180M, and MYH9 R1932fs. Other 
variants included ACTN4 (1), CD2AP (4), INF2 (1), ITGB4 (3), MYH9 (3), NPHS2 (2), 
NFX5 (2), TRPC6 (2), and WT1 (3); of these 13 were predicted to be pathogenic by SIFT 
and/or Polyphen2.
Conclusions: We have shown a high frequency of potentially pathogenic variants in 
our adult population with FSGS. We did not see enrichment for mutation carriers in those 
with a documented family history or recurrent disease. Targeted NGS allows rapid and 
inexpensive identification of these gene mutations.
Funding: Government Support - Non-U.S.
SA-PO514
Family Risk of Acute Kidney Injury  Olafur S. Indridason,1 Snaevar 
Sigurdsson,2 Þórir E. Long,3 Gisli H. Sigurdsson,4,6 Martin I. Sigurdsson.4,5  1Div 
of Nephrology, Landspitali; 2Decode Genetics, Reykjavik; 3Dept of Medicine; 
4Dept of Anesthesia, Landspitali - The National Univ Hospital of Iceland; 
5Faculty of Medicine, Univ of Iceland, Reykjavik, Iceland; 6Dept of Anesthesia, 
Perioperative and Pain Medicine, Brigham and Women´s Hospital, Boston, MA.
Background: Previous studies indicate that certain genetic variants may predispose 
to acute kidney injury (AKI) in critically ill patients but global assessment of heritability 
and an unbiased genome-wide assessment of acute kidney injury is lacking. The purpose 
of this study was to assess the familiality of AKI to support a common genetic background.
Methods: We used data from the clinical laboratory at Landspitali – The National 
University Hospital of Iceland to find all serum creatinine (SCr) measurements over 20 
years. We identified each patients highest SCr value and a baseline SCr within the preceding 
6 months, defining AKI as a 50% increase in SCr compared to baseline (highest/baseline 
SCr>1.5). Patients with ESRD and diseases known to result in AKI were excluded. To assess 
the familial relationship between individuals, we used the Icelandic Genealogy Database 
that contains reliable genealogy information on the entire Icelandic nation dating back to 
the year 1650. Familiality of AKI was assessed by calculating the risk ratio of AKI in 1-5th 
degree relatives of AKI patients, and significance assessed by comparing the risk ratio to 
the risk ratio in 1000 randomly selected control groups.
Results: We identified 12.807 individuals with AKI. There was a significantly increased 
risk of AKI in the relatives of AKI patients with 1st-degree relative risk ratio (RR) of 1.26, 
2nd-degree relative RR of 1.08, 3rd-degree relative RR of 1.12 (p<0.001 for all). The risk 
ratio was even higher for the most severe AKI (highest/baseline SCR>3.0), where 1st-degree 
relative RR was 1.36 (p=0.006), 2nd-degree relative RR was 1.18 (p=0.067) and 3rd-degree 
relative RR was 1.14 (p=0.06).
Conclusions: Our results suggest a genetic component in the development of AKI and 
given the relationship between relative risk and the power to map disease genes by linkage 
analysis, GWAS studies might yield positive results.
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SA-PO515
Premature Death in First Degree Relatives of End Stage Renal Disease 
Patients  Rannveig Skrunes,1,2 Einar Svarstad,1,2 Anna Reisaeter,3 Hans-Peter 
Marti,1,2 Bjorn Egil Vikse.2,4  1Dept of Medicine, Haukeland Univ Hospital, 
Bergen, Norway; 2Dept of Clinical Medicine, Univ of Bergen, Bergen, Norway; 
3Dept of Transplantation Medicine, Rikshospitalet Oslo Univ Hospital, Oslo, 
Norway; 4Dept of Medicine, Haugesund Hospital, Haugesund, Norway.
Background: Increased risk of end stage renal disease (ESRD) and death in Norwegian 
living kidney donors has been reported. The majority of donors were related to the recipient. 
The present study investigates risk of death in first degree relatives of ESRD patients.
Methods: The Norwegian Population Registry has since 1960 registered all Norwegian 
Citizens. Sibling data are complete for most individuals since 1953. The National Cause 
of Death Registry has registered causes of death since 1969 and the Norwegian Renal 
Registry has registered all individuals with ESRD since 1980. The registries were linked. 
All citizens born in Norway with at least one registered first degree relative were included. 
A cohort-design was used, ESRD in a first degree relative was the main exposure variable 
and death and causes of death were the main outcome variables. Adjusted hazard ratios 
(aHR) were calculated using Cox regression analysis.
Results: 5,217,568 individuals were included, 27,650 had at least one relative with 
ESRD. 844,407 died during follow-up. aHR for death was 1.14 (95% CI 1.10-1.17) in 
individuals with a relative with ESRD compared to those without a relative with ESRD. 
Excluding known hereditary renal disease, aHR decreased to 1.12 (95% CI 1.09-1.16). 
Cardiovascular death aHR was 1.15 (95% CI 1.10-1.21), of which cerebrovascular death 
1.34 (95% CI 1.22-1.47). aHR for death due to non-hereditary renal/ureteric disease was 
2.32 (95% CI 1.84-2.94) with renal failure 1.80 (95% CI 1.26-2.56) and primary renal 
disease 5.88 (95% CI 4.04-8.56) as main contributors. Compared to individuals without a 
relative with ESRD, death occurred 9 years earlier in individuals who died before the age 
of 50 and 1 year earlier in individuals who died at age 70.
Conclusions: ESRD in first degree relatives was associated with premature death. Death 
due to cardiovascular- and non-hereditary renal diseases increased the most.
Funding: Government Support - Non-U.S.
SA-PO516
Identifying Genetic Predictors of Skin Cancer in Renal Transplant 
Populations  Caragh P. Stapleton,1 Mark Mccormack,1 Dervla M. Connaughton,2 
Paul J. Phelan,3 Gianpiero Cavalleri,1 Peter J. Conlon.2  1Dept of Molecular 
and Cellular Therapeutics, Royal College of Surgeons, Dublin 2, Dublin, 
Ireland; 2Kidney Centre, Beaumont Hospital, Dublin 9, Dublin, Ireland; 3Dept 
of Nephrology, Royal Infirmary of (dinburgh, (dinburgh, NHS Lothian, United 
Kingdom.
Background: Renal-transplant recipients have a 33-fold increased risk of developing 
non-melanoma skin cancer relative to an age-matched non-transplanted individual. Some of 
this risk can be attributed to factors such as type of immunosuppressant treatment, however 
much of the risk remains unaccounted for. In this study we set out to map germline genetic 
variations influencing the development of skin cancer in our cohort of 325 renal-transplant 
recipients, using a genome-wide association study (GWAS) and candidate gene study design.
Methods: Both logistic regression and survival analysis was applied in our GWAS. 
Survival analysis was used in our candidate gene study. Multiple robust genetic loci for 
skin cancer in non-transplant populations have been identified via large GWAS. These 
genetic predictors of skin cancer (n=21) identified from non-transplant populations were 
examined to see if they have a higher effect size in renal-transplant recipients compared 
to the general population.
Results: For the candidate SNP analysis, a nominally significant association was 
found with a SNP in the MC1R gene (p= 0.0157). The variant was found to have the same 
direction of affect as described in the original study and the odds ratio was higher. The 
presence of one or more copies of the minor allele caused a significant decrease in time to 
develop skin cancer post renal transplantation (hazard ratio = 2.06). We found a significant 
association in our GWAS between time to developing skin cancer post transplantation and 
a variant in SPOCK1 (p = 4x10-8). We found that heterozygote individuals developed skin 
cancer 7 times faster than wild type homozygotes.
Conclusions: Associations were found between time to developing skin cancer post-
transplantation and the genes MC1R and SPOCK1. We will be carrying out further testing 
in other cohorts for validation of results. This work is funded by Irish Research Council 
for Science, Engineering and Technology.
Funding: Government Support - Non-U.S.
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Genetic Variants in ANCA-Associated Vasculitis: A Meta-Analysis 
Chinar Rahmattulla,1 Antien Mooyaart,1 Daphne Van Hooven,1 Jan W. 
Schoones,1 Jan A. Bruijn,1 Olaf Dekkers,1,2 European Vasculitis Genetics 
Consortium,3 Ingeborg M. Bajema.1  1Leiden Univ Medical Center; 2Aarhus 
Univ Hospital.
Background: Genetic factors may influence the pathogenic pathways leading to anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We performed a 
meta-analysis to determine the genetic variants most likely associated with AAV and 
investigated whether diagnostic and serological subtypes within AAV have distinct genetic 
backgrounds.
Methods: Studies investigating the association between genetic variants and AAV in 
humans were searched in PubMed, Embase, and Web of Science. All variants significantly 
associated with AAV in at least one study and investigated in at least two studies were 
included. Additionally, data on these genetic variants from the largest GWAS in AAV were 
included to increase the validity of this meta-analysis.
Results: The literature search yielded 5180 articles. Fifty-three articles investigating 
55 genetic variants were included, 31 of which remained associated with AAV in a meta-
analysis. These genetic variants were in or near the following genes: SERPINA1, CD226, 
CTLA-4, HLA-B, HLA-DP, HLA-DQ, HLA-DR, HSD17B8, IRF5, PTPN22, RING1/RXRB, 
RXRB, and TLR9. Moreover, we identified genetic distinctions between granulomatosis with 
polyangiitis and microscopic polyangiitis and between proteinase 3 ANCA vasculitis and 
myeloperoxidase ANCA vasculitis. In 79% of the genetic variants, subdivision based on 
ANCA serotype resulted in higher odds ratios than subdivision based on clinical diagnosis.
Conclusions: This meta-analysis identified 31 genetic variants associated with AAV, 
supporting a role for alpha-1-antitrypsin, the major histocompatibility complex system, 
and several distinct inflammatory processes in AAV pathogenesis. Our results indicate that 
subdivision of AAV based on ANCA serotype has a stronger genetic basis than subdivision 
based on clinical diagnosis.
SA-PO518
Meta-Analyses of Genetic Associations in New Onset Diabetes After 
Kidney Transplantation  Katherine A. Benson,1 A.J. McKnight,1 Alexander P. 
Maxwell.1,2  1Centre for Public Health, Queen’s Univ Belfast, Belfast, Northern 
Ireland, United Kingdom; 2Regional Nephrology Unit, Belfast City Hospital, 
Belfast, Northern Ireland, United Kingdom.
Background: New-onset diabetes after transplantation (NODAT) is a serious 
complication following solid organ transplant. There is evidence of a genetic contribution to 
this disease and we have previously identified genetic risk factors associated with NODAT 
following kidney transplantation. These meta-analyses examine the pooled effect of genetic 
variants associated with NODAT in kidney transplant populations.
Methods: Relevant articles investigating the association between genetic markers 
and NODAT were identified by means of a database search of PubMed, Web of Science 
and Google Scholar from 1945 to 2015. Variants replicated in a minimum of three studies 
were included for analysis. Data was analysed using a random effects model in Review 
Manager 5.3. The association between identified variants and NODAT was calculated at 
the per-study allele level, where original studies were concordant with Hardy-Weinberg 
Equilibrium, to generate overall significance values and effect sizes.
Results: Our literature search returned 4,147 citations. Of the 36 eligible articles 
identified, 18 genetic variants from 13 genes were included for analysis. Of these, three 
were significantly associated with NODAT by meta-analysis at the 5% level of significance; 
TCF7L2 rs7903146 p=0.01 OR=1.41, 95%CI=1.07-1.85 (n=2967 individuals), CDKAL1 
rs10946398 p=0.006 OR=1.43, 95% CI=1.11-1.85, (n=696 individuals), and KCNQ1 
rs2237892 p=0.0007 OR=0.70, 95% CI=0.54-0.91, (n=1270 individuals).
Conclusions: These meta-analyses identified three genetic variants statistically 
associated with NODAT. Ideally, these variants should be assessed in less heterogeneous 
studies with larger numbers of kidney transplant recipients with a carefully defined 
NODAT phenotype.
Funding: Private Foundation Support
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New Prioritization and Burden Analyses of Rare Variants in 208 Candidate 
Genes Are Questioning the Pathogenicity of Previously CAKUT-Associated 
Genetic Variants  Nayia Nicolaou,1 Sara L. Pulit,1 Isaac J. Nijman,1 Albertien M. 
van Eerde,1 Ernie M.H.F. Bongers,2 Rachel H. Giles,3 Nine V. Knoers,1 Kirsten 
Y. Renkema.1  1Medical Genetics, UMC Utrecht, Utrecht, Netherlands; 2Human 
Genetics, Radboudumc, Nijmegen, Netherlands; 3Nephrology and Hypertension, 
UMC Utrecht, Utrecht, Netherlands.
Background: The leading cause of end-stage renal disease in children is attributed to 
congenital anomalies of the kidney and urinary tract (CAKUT). Familial clustering and 
mouse models support the presence of monogenic causes. Genetic testing is insufficient 
as it mainly focuses on HNF1B and PAX2 mutations that are thought to explain CAKUT 
in 5-15% of patients.
Methods: To identify novel, potentially pathogenic variants in additional genes, 
we designed a panel of genes identified from studies on familial forms of isolated or 
syndromic CAKUT and genes suggested by in vitro and in vivo CAKUT models. The coding 
exons of 208 genes were analyzed in 453 patients with CAKUT using next-generation 
sequencing. Rare truncating, splice-site variants and non-synonymous variants, predicted 
to be deleterious and conserved, were prioritized as the most promising variants to have 
an effect on CAKUT.
Results: Previously reported disease-causing mutations were detected. Five variants 
were fully penetrant causal mutations that improved diagnosis. We prioritized 148 candidate 
variants in 151 patients, found in 82 genes, for follow up studies. Using a burden test, we 
found no significant excess of rare variants in any of the genes in our cohort compared 
to controls.
Conclusions: Thus, in a study that represents the largest set of genes analyzed in 
CAKUT patients to date, the contribution of previously implicated genes to CAKUT 
risk is significantly smaller than expected and the disease may be more complex than 
previously assumed.
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Comparison of Genetic Associations with Different Definitions of CKD 
Progression in Children  Matthias Wuttke,1 Elke Wuehl,2 Li Luo,3 Jayanta 
Gupta,4 Bradley Warady,5 Susan L. Furth,6 Anna Kottgen,1 Franz S. Schaefer,2 
Craig S. Wong.3  1Freiburg Univ, Germany; 2Heidelberg Univ, Germany; 3Univ 
New Mexico; 4Texas Tech Univ; 5Children’s Mercy, Kansas City; 6CHOP, Univ 
Pennsylvania.
Background: The PediGFR Consortium aims to identify genetic factors associated 
with pediatric chronic kidney disease (CKD) progression. The optimal definition of CKD 
progression for testing is unclear. To address this question, we performed genome-wide 
association studies (GWAS) of two different definitions of CKD progression, slope of the 
annual change in estimated GFR (eGFR) versus time-to-event (TTE).
Methods: There were >8 million genotyped and imputed markers from 1,122 patients. 
The calculation of slope was based on 2-41 eGFR values per patient. TTE was a combined 
primary endpoint of dialysis, transplant, 50% GFR loss or GFR <5 ml/min/1.73m2. 
Respectively, cox proportional hazards and linear regressions were used for the GWAS 
of TTE and slope. Both analyses were adjusted for age, sex, principal components and 
baseline eGFR. For each definition, data were meta-analyzed from five study-/ancestry-
specific groups in PediGFR.
Results: For TTE, follow-up time was 1.66-5.0 years (IQR) and an event rate of 34%. 
For slope, mean slope was -4.2 ml/min/1.73m2. For comparison, we focused on SNPs 
present in all five groups with a minor allele frequency >0.05, and I2<50%. For TTE, 6 
genomic regions contained one or more of such SNPs with p<1E-6, one of which reached 
genome-wide significance (p<5E-8). Hazard ratios per risk allele ranged from 1.58-1.97. For 
slope, there were 3 regions with p<1E-6, one of which reached genome-wide significance. 
All of the 6 TTE variants were nominally associated with slope (one-sided p<0.05), whereas 
2 of the 3 slope variants were nominally associated with TTE. None of the loci with p<1E-6 
overlapped between the two definitions.
Conclusions: Genetic variants associated with CKD progression differed based on 
the definition of the phenotype. GWAS of TTE identified more loci at p<1E-6 than slope 
and these were biologically more plausible based on current knowledge of kidney disease. 
However, the number of genome-wide significant loci was the same.
Funding: NIDDK Support, Private Foundation Support
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New Candidate Genetic Loci Associated with Pediatric Proteinuria in 
the CKiD Cohort  Sophie Limou,1 Derek Ng,2 Kimberly J. Reidy,3 Robert 
Woroniecki,4 Susan L. Furth,5 Bradley Warady,6 Craig S. Wong,7 Jeffrey B. 
Kopp,8 Cheryl Ann Winkler,1 Frederick J. Kaskel.3  1Leidos Biomedical Research, 
Inc / NCI-Frederick National Laboratory; 2Johns Hopkins Bloomberg School 
of Public Health; 3Children¶s Hospital at Montefiore/ Albert (instein College of 
Medicine; 4Stony Brook Univ Hospital; 5Children’s Hospital of Pennsylvania; 
6Children’s Mercy Hospital; 7Univ of New Mexico; 8NIDDK, NIH.
Background: Proteinuria is an early marker for chronic kidney disease in adults and 
children. Here, we sought to identify genetic variants associated with baseline proteinuria 
in African American children diagnosed with chronic kidney disease from the CKiD cohort.
Methods: We genotyped 140 CKiD participants using the Illumina HumanExome 
beadchip v1.2 comprising over 250,000 markers, including putative functional exonic 
variants that were implicated in common metabolic disorders. 81,460 SNPs passed quality 
control and were tested for association with baseline proteinuria in 129 children with chronic 
kidney disease by linear regressions adjusted for age, gender, and the first five eigenvectors 
from the population stratification analysis.
Results: We identified several genetic loci that were significantly associated with 
proteinuria (P£10-8), as well as new candidate loci (10-5<P<10-8). Among the top hits, we 
notably revealed kidney-expressed genes that were previously associated with the TGFβ 
pathway, renal homeostasis, IgA nephropathy, congenital kidney disease, and vascular 
integrity (e.g. VAV3, STRA6, and HDAC7).
Conclusions: Our study emphasizes the power of unbiased large genetic screenings 
to discover new factors associated with pediatric kidney conditions. These new results 
warrant independent replication and functional validation.
Funding: NIDDK Support, Other NIH Support - NCI Contract HHSN261200800001E
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Genotype-Phenotype Analysis in Pediatric Patients with WT1 
Glomerulopathy  Eujin Park,1 Yo Han Ahn,1 Hee Gyung Kang,1,2 Hye Won 
Park,3 IL-Soo Ha,1 Hae Il Cheong.1,2  1Dept of Pediatrics, Seoul National Univ 
Children’s Hospital, Seoul, Korea; 2Research Coordination Center for Rare 
Diseases, Seoul National Univ Hospital, Seoul, Korea; 3Dept of Pediatrics, 
Seoul National Univ Bundang Hospital, Seongnam, Korea.
Background: The WT1 gene plays an essential role in urogenital and kidney 
development and its mutations manifest two different types of glomerulopathies, Denys-
Drash syndrome (DDS) and Frasier syndrome (FS). In this multicenter retrospective cohort 
study, genotype-phenotype correlations in Korean pediatric patients with WT1 mutations 
were analyzed.
Methods: During the period from 2001 to 2015, WT1 mutations were detected in a 
total of 23 children by genetic screening.
Results: The patients were grouped into FS (n=10, having a mutation in intron 9) and 
DDS (n=13, having an exon mutation). Nine (69%) DDS patients presented as congenital 
(CNS) or infantile nephrotic syndrome (INS), while 7 (70%) FS patients presented as 
steroid-resistant focal segmental glomerulosclerosis. Interestingly, monozygotic twin 
patients with DDS presented as end-stage renal disease (ESRD) without any previous 
history of glomerulopathy. Progression to ESRD was noted in 11 (85%) DDS patients at the 
median age of 0.22 (interquartile range [IQR], 0.07-1.65) years and in 5 (50%) FS patients 
at age 9.30 (3.25-16.50) years. Five (38%) DDS patients died at age 0.59 (0.27~2.29) years. 
Disorder of sexual development (DSD) was accompanied in 8 (62%) DDS and 7 (70%) FS 
patients. Three (13%) patients (2 with DDS and 1 with FS) had diaphragmatic defect/hernia. 
Five (22%) and six (26%) patients underwent prophylactic nephrectomy and gonadectomy, 
respectively. Among the rest of the patients, Wilms tumor and gonaldoblastoma developed 
in 3 DDS patients and 1 FS patient, respectively.
Conclusions: The clinical manifestations and disease course of the Korean patients with 
WT1 glomerulopathy were mostly same as those of previous reports. Of note, patients with 
WT1 mutations may manifest atypically, i.e., chronic kidney disease without any preceding 
history of significant proteinuria and/or NS. DSD is common in both in FS and DDS and is 
a useful diagnostic clue. Prophylactic nephrectomy/gonadectomy is strongly recommended.
SA-PO523
Age of the NPHS2 p. V260E Mutation, a Cause of Childhood Steroid 
Resistant Focal Segmental Glomerulosclerosis, in the Ancestral Population 
of Black Africans in Durban, South Africa  George W. Nelson,1 Rajendra 
Bhimma,2 Sophie Limou,1 Jeffrey B. Kopp,3 Cheryl Ann Winkler.1  1FNLCR, 
NCI, Frederick, MD; 2Univ of KwaZulu-Natal, Durban, South Africa; 3NIDDK, 
NIH.
Background: A study of 44 children with sporadic steroid resistant nephrotic syndrome 
(SRNS) with focal segmental glomerulosclerosis (FSGS) histology, in Durban, South Africa, 
revealed that 30% carried two copies of a missense mutation, p. V260E, in the podocin 
gene, NPHS2. This mutation has previously been reported as recessively associated with 
FSGS in consanguineous families in regions at one time in the Omani empire, suggesting 
spread with this empire. We speculated that the children in our study might be cryptically 
related from common descent from a recent ancestor.
Methods: Inheritance of the V260E mutation from two parents with a common 
ancestor will result in a region of homozygosity surrounding the locus, indicating the 
overlap of extended haplotypes preserved around the locus. To test for this we genotyped 
10 individuals homozygous for the mutation, and 74 individuals homozygous for the wild 
type variant, with the Illumina exome chip. After QC, this chip provided 1674 markers 
within 20 megabases (Mb) ofV260E. To predict the distribution of lengths of homozygous 
regions around the locus as a function of the number of generations between parents and 
their common ancestor carrying the mutation, we performed 10,000 coalescence simulations 
of recombination in each generation for n generations from 6 to 48.
Results: Plotting heterozygous and homozygous loci in the region surrounding V260E 
clearly showed regions of homozygosity around the locus. 8 of the 10 individuals had 
segments of homozygosity from 1.9 to 3.6 mB. This distribution of lengths is inconsistent 
with a common ancestor within the last 20 generations.
Conclusions: Cryptic consanguinity does not explain the presence of homozygosity 
for NPHS2 V260E among Durban children with SR-FSGS. The indicated age of the 
mutation is inconsistent with introduction by the Omani Empire, which spread in East 
Africa beginning in the 1690s.
Funding: Other NIH Support - grant HHSN 261200800001E
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Genetic Markers Associated with Hemoglobin in the PediGFR Consortium 
Meredith A. Atkinson,1 Anna Kottgen,2 Elke Wuehl,3 Craig S. Wong,4 Matthias 
Wuttke,2 Franz S. Schaefer,3 Bradley Warady,5 Susan L. Furth.6  1Johns Hopkins 
Univ; 2Univ of Freiburg; 3Heidelberg Univ; 4Univ of New Mexico; 5Univ of 
Missouri-Kansas City; 6Univ of Pennsylvania.
Background: Genome-wide association studies have identified genetic variants 
associated with erythrocyte traits, but associations in children with CKD have not been 
studied. Our goal was to identify whether single nucleotide polymorphisms (SNPs) are 
associated with hemoglobin (Hgb) decline in progressive CKD in children.
Methods: Longitudinal analysis of genotype and Hgb in 1,141 European (n=806) 
or Turkish (n=335) children in the Pediatric Investigation for Genetic Factors Linked 
to Renal Progression (PediGFR) consortium. With a candidate marker approach, linear 
mixed-effect modeling for Hgb regressed on time and genotype of 24 previously reported 
SNPs was performed, stratified by ethnicity. Bonferroni correction was used to account 
for multiple comparisons.
Results: In Europeans, a nominally significant association between SNPs on the RCL1 
(p=0.03), BCL11A (p<0.001), RTBDN (p=0.006), and TFR2 (p=0.007) genes and increased 
risk for Hgb decline over time was noted. Among Turks, a significant association was seen 
with SNPs on the RCL1 (p=0.03), KIT (p=0.006), BCL11A (p<0.001), RTBDN (p=0.006), 
CD164 (p=0.031) and HBS1L/MYP (p=0.031) genes. The RCL1 gene has been associated 
with MCH. The TFR2 and HBS1L/MYB genes are associated with Hgb; TFR2 mediates 
cellular iron uptake and HBS1L/MYB is a quantitative trait locus controlling fetal Hgb. 
The KIT, BCL11A, RTBDN, and CD164 genes are associated with MCV, and have roles in 
hematopoiesis (KIT and CD164), persistence of fetal Hgb (BCL11A) and retinoid binding 
(RTBDN). After Bonferroni correction, only the SNP on BCL11A remained significantly 
associated with Hgb in Europeans and Turks, with marginal significance for SNPs on 
RTBDN and TFR2 in Europeans and on KIT and RTBDN in Turks.
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Conclusions: We confirmed the association of selected genetic variants with decline 
in Hgb in children with progressive CKD, with differential effects by ethnicity at specific 
loci. Clarification of the genes involved in susceptibility to anemia has the potential to 
identify new therapeutic targets.
Funding: NIDDK Support
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Cell-Free Hemoglobin and HMOX1 in Sickle Cell Nephropathy 
Santosh Saraf,1 Xu Zhang,1 Binal N. Shah,1 Krishnamurthy P. Gudehithlu,2 
Jose A.L. Arruda,1 Ashok K. Singh,2 Victor R. Gordeuk.1  1Medicine, Univ of 
Illinois at Chicago, Chicago, IL; 2Nephrology, John H. Stroger, Jr Hospital of 
Cook County, Chicago, IL.
Background: Chronic kidney disease (CKD) is observed in over 50% of adults with 
sickle cell disease (SCD) and hemoglobinuria, a consequence of intravascular hemolysis, is 
independently associated with CKD stage and its progression. In this study we investigate 
the mechanistic role of hemoglobinuria and HMOX1, the rate limiting enzyme for heme 
metabolism, in SCD nephropathy.
Methods: Urinary tubular (kidney injury molecule-1, KIM-1) and glomerular (nephrin) 
biomarkers of injury were measured in 32 SCD patients by ELISA from the University 
of Illinois at Chicago (UIC). We then cultured human kidney-2 (HK2) tubular cells with 
lyophilized hemoglobin (L-Hb) to determine biological responses and expression of 
candidate genes. We examined the association of CKD with 11 tag SNPs and the GT-repeat 
polymorphism in HMOX1 in 247 UIC SCD patients and in a separate replication cohort 
(Walk-PHaSST) of 482 SCD patients.
Results: Urine KIM-1 correlated with increasing urine cell-free hemoglobin 
concentration (P=0.003), while urine nephrin levels did not. HK2 culture studies showed 
increasing KIM-1 concentrations in the culture medium (P=0.01), decreasing HK2 cell 
viability (P=0.01), increased HMOX1 expression (P=0.0001) and protein concentration 
(P<0.0001) with incremental concentrations of L-Hb. We identified a SNP in HMOX1 
(rs743811, MAF=0.14) that was significantly associated with CKD stage (OR 2.8, 
P=0.0003) and CKD stage ³3 (OR 3.0, P=0.02) in the UIC cohort and with ESRD (OR 
9.8, P=0.0004) and CKD stage ³3 (OR 2.3, P=0.04) in our replication cohort. UIC SCD 
patients with £25 GT-repeats in the promoter region of HMOX1, known to be associated 
with increased HMOX1 inducibility and activity, had higher estimated glomerular filtration 
rate (eGFR)(β=9.2, P=0.01).
Conclusions: Cell-free hemoglobin contributes to sickle cell nephropathy through renal 
tubular injury. A tag-SNP in HMOX1, rs743811, was associated with kidney disease and the 
presence of shorter (GT)n repeats correlated with increasing eGFR, raising the possibility 
that altered HMOX1 activity has a critical role in SCD-nephropathy.
SA-PO526
Telomere Attrition Is Associated with Renal Replacement Therapy and 
Immunosuppressive Treatment in End-Stage Renal Disease Patients 
Karin Luttropp,1 Louise Nordfors,2 Dagmara Mcguinness,3 Abdul Rashid Tony 
Qureshi,2 Peter F. Barany,2 Peter Stenvinkel.2  1Dept of Molecular Medicine 
and Surgery, Karolinska Inst, Stockholm, Sweden; 2Dept of Clinical Science, 
Intervention and Technology, Karolinska Inst, Stockholm, Sweden; 3Inst of 
Cancer Sciences, Univ of Glasgow, Glasgow, United Kingdom.
Background: Telomere attrition is a feature of ageing and is accelerated by renal 
disease. The effects of renal replacement therapy (RRT) and immunosuppressants on 
telomere length and attrition are unknown. We therefore investigated changes in telomere 
length during 12 months of RRT and effects of immunosuppressants.
Methods: Telomere length was measured in whole blood DNA from 47 renal 
transplantation (RTx) and 49 dialysis patients. Data were collected at baseline and after 12 
months of RRT. Telomere length determination was performed by qPCR using a Roche Light 
Cycler LC480. The relative T/S ratio (repeat copy number to single gene copy number) was 
determined in relation to the control DNA sample. Non-parametric statistical tests were used.
Results: RTx patients had a greater telomere attrition than dialysis patients (p=0.008), 
despite no significant differences in telomere length at baseline or after 12 months. 
RTx patients were divided into those receiving azathioprine (n=11) and those receiving 
mycophenolate (n=32). Mycophenolate-treated patients had greater telomere attrition than 
patients receiving azathioprine (p=0.007), although telomere length at baseline and after 
12 months was not significantly different.
Conclusions: RTx patients have a greater telomere attrition than dialysis patients 
over the course of 12 months; this may reflect an increased stress associated with the 
transplantation procedure itself as opposed to dialysis treatment. This raises questions 
regarding the potential risk of accelerated ageing in RTx, which is commonly considered 
by be a superior form of RRT. In addition, mycophenolate-treated patients show greater 
telomere attrition than azathioprine-treated patients. This is currently being investigated 
further, as it could have clinical implications on the choice of treatment regimen.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Differences in Susceptibility to Cisplatin Nephrotoxicity Among 8 Mouse 
Strains  Gabor Bodonyi-Kovacs, Rosa Chan, Thu H. Le.  Renal Div, Univ of 
Virginia, Charlottesville, VA.
Background: Cisplatin is a widely used chemotherapeutic agent with remarkable 
efficacy, but its use is limited by significant nephrotoxicity. Significant differences in 
susceptibility to nephrotoxicity among individual patients have been noted, but predicting 
those at risk remains a challenge. To begin to identify genes that play a role in susceptibility 
to cisplatin nephrotoxicity (CPN), we set out to determine differences in CPN among 8 
genetically distinct founder mouse strains of the Collaborative Cross: A/J, C57BL/6J, 129S1/
SvImJ, NOD/ShiLtJ, NZO/HlLtJCAST/EiJ,PWK/PhJ, and WSB/EiJ.
Methods: 10-14 week old male mice received ip. injection of 25 mg/kg cisplatin and 
serum was collected 72 hours later prior to sacrifice. Serum urea nitrogen (BUN) was 
measured for the 8 strains using a nonenzymatic, colorimetric kit (Arbor Assays) and 
analyzed by one way ANOVA and two sided t-test. Serum creatinine was measured using 
an enzymatic, colorimetric kit (Crystal Chem) and analyzed by a two sided t-test for the 2 
strains that showed the largest difference in BUN.
Results: The 8 strains differed significantly in their serum BUN values (p=0.042). The 
number of animals in each group, and the mean and SD of BUN (mg/dl) were as follows: 
C57BL/6J (n=4) 188.6±9.2, CAST/EiJ (n=3) 207.9±32.7, NOD/ShiLtJ (n=5) 236.7±93.0, 
PWK/PhJ (n=4) 240.9±27.2, WSB/EiJ (n=5) 254.1±51.6, A/J (n=5) 267.6±62.3, NZO/
HlLtJ (n=5) 290.0±50.7,129S1/SvImJ (n=4) 319.5 ±28.3. The biggest differences were 
seen between the C57BL/6J and 129S1/SvImJ strains, (p = 0.0001). In direct comparison 
the serum creatinine was significantly different between C57BL/6J (n=10) and 129S1/
SvImJ (n=9) strains, (p=0.0047) (Figure 1).
Conclusions: Crosses from “susceptible” and “resistant” mouse strains may enable 
identification of novel genetic determinants governing individual susceptibility to CPN.
Funding: Other NIH Support - T32
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The PAX2-Related SNP rs11190739 Is Associated with Accelerated Loss of 
GFR in Diabetes Mellitus  Paul R. Goodyer,1 Melanie Cosgrove,1 James C. 
Engert.2  1Pediatric Nephrology, Research Inst of McGill Univ Health Centre, 
Montreal, QC, Canada; 2Genetics, McGill Univ, Montreal, QC, Canada.
Background: In embryonic kidney, PAX2 is crucial for optimal branching of the 
ureteric bud and final nephron number. Previous studies show that common polymorphic 
variants of the PAX2 gene are associated with a 10% decrease in newborn kidney size. 
Brenner proposed that individuals with suboptimal nephron number might have accelerated 
loss of GFR in the setting of acquired renal disease in adulthood.
Methods: We used PLINK software to test for an association between PAX2 SNPs and 
reduced GFR among Caucasians (N=225) entered into the FIND (“Family Investigation of 
Nephropathy and Diabetes”) cohort available through dbGaP. This cohort of adult diabetics 
consisted of 175 Afro-American, 225 European-American and 257 Mexican Americans 
with eGFR data 15-25 years after onset of diabetes. Association testing that incorporated 
a genomic inflation factor, as well as gender and duration as covariates was used. To test 
Brenner’s hypothesis, we tested this PAX2 SNP for an additional association with subtle 
newborn renal hypoplasia among 225 healthy Caucasian newborns from Montreal. Kidney 
volume was measured by ultrasonography within the first 3 days of life.
Results: We identified a SNP (rs11190739) in the FIND cohort (MAF=6.5%) that was 
associated with a 15% decrease in GFR exclusively among European-American diabetics 
with one or more minor alleles (p=0.022). eGFR (ml/min/1.73m2) in European Americans 
was 70.71 for GG individuals, 61.64 for GT, and 41.9 for TT. No association was found 
between the rs11190739 SNP and eGFR among Afro-American and Mexican-American 
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subjects. Among healthy Montreal newborns, this same PAX2 SNP (rs11190739) was 
associated with a 10.2% decrease in newborn combined kidney volume in 14.6% of babies 
who were heterozygous for this common variant (p=0.036).
Conclusions: Our study provides the first evidence that a common PAX2 variant 
associated with newborn renal hypoplasia is also associated with decreased eGFR among 
Caucasians with diabetes mellitus for 15-25 years.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Cefepime Dosing in Modeled Critically Ill Patients Receiving SHIFT 
Hemofiltration or Hemodialysis Renal Replacement Therapies 
Katherine N. Gharibian, Susan J. Lewis, Bruce A. Mueller.  College of Pharmacy, 
Univ of Michigan, Ann Arbor, MI.
Background: Cefepime is an antibiotic commonly used in the ICU where acute 
kidney injury (AKI) is prevalent. SHIFT therapy, a 6-12 hour renal replacement therapy 
(RRT), also referred to as Prolonged Intermittent Renal Replacement Therapy (PIRRT) 
or Slow Low Efficiency Daily Dialysis (SLEDD), is increasingly utilized to help treat 
AKI. However, dosing information for cefepime in critically ill patients receiving SHIFT 
therapy is currently lacking.
Methods: Using previously-published pharmacokinetic (PK) data and a PK model 
developed for critically ill patients receiving SHIFT RRT, a series of 5000-subject Monte 
Carlo simulations were performed for 18 cefepime regimens in 8 scenarios with varying 
duration (8 & 10 hr), effluent rate (4 & 5 L/hr), modality (HF/HD), and time of SHIFT 
relative to cefepime doses. Cefepime regimens were evaluated on the probability of attaining 
a free drug concentration equal to at least the minimum inhibitory concentration (MIC)×4 
for ≥60% of the dosing interval during the first 48 hours of therapy. Optimal regimens 
yielded a probability of target attainment (PTA) ≥90% for MIC values ≤8 mg/L using the 
smallest total daily dose.
Results: Cefepime 1 g q6 hours with a 2 g loading dose was the only regimen to yield a 
PTA ≥90% in all 8 SHIFT settings while limiting the total daily maintenance dose to 4 g. This 
dosing regimen resulted in 48-hour mean trough concentrations >32 mg/L in most subjects. 
Conclusions: In PK models of critically-ill subjects receiving 8 or 10 hours of SHIFT 
RRT, a cefepime dose of 1 g q6 hours with a 2 g loading dose yielded pharmacodynamic 
target attainment for >90% of the population.
Funding: Pharmaceutical Company Support - NxStage Medical, Inc.
SA-PO530
Identification of Optimal Ceftazidime Dosing Regimens in Modeled 
Critically Ill Patients Receiving SHIFT Renal Replacement Therapy 
Katherine N. Gharibian, Susan J. Lewis, Bruce A. Mueller.  College of Pharmacy, 
Univ of Michigan, Ann Arbor, MI.
Background: Ceftazidime is an antibiotic commonly used in critically ill patients. 
Ceftazidime doses of 2 g every 12 hours have been recommended for continuous renal 
replacement therapies (CRRT), however, no studies have evaluated the optimal dose in 
patients receiving SHIFT Therapy (NxStage Medical), a 6-12 hr RRT commonly referred 
to as Prolonged Intermittent Renal Replacement Therapy (PIRRT) or Slow Low Efficiency 
Daily Dialysis (SLEDD).
Methods: Pharmacokinetic (PK) data compiled from previously-published studies 
were used to develop models for critically ill patients receiving intermittent hemofiltration 
(HF) or hemodialysis (HD). Eight models were developed to account for the variability in 
settings including duration (8 & 10 hr), effluent rate (4 & 5 L/hr), modality (HF/HD), and 
time of SHIFT relative to ceftazidime dose. Using a series of 5000-subject Monte Carlo 
simulations, 12 ceftazidime regimens were applied to each model and evaluated for the 
probability of attaining free drug concentrations equal to or greater than the minimum 
inhibitory concentration (MIC)×4 for ≥70% of the dosing interval during the first 48 hours 
of therapy. Optimal regimens yielded a probability of target attainment (PTA) ≥90% for 
MIC values ≤8 mg/L, the MIC for Pseudomonas aeruginosa.
Results: Ceftazidime administered in 4 g total daily doses (2 g q12 hours; 1 g q6 hours) 
yielded a PTA ≥90% in all 8 RRT models. Continuous infusion of the drug (3 g continuous 
infusion with a 2 g loading dose) achieved similar PTA values. 
Conclusions: Published ceftazidime CRRT doses (2 g every 12 hours) yielded 90% 
PTA in modeled critically ill patients receiving 8 or 10 hours of SHIFT RRT. Future studies 
should validate these findings in the clinical setting.
Funding: Pharmaceutical Company Support - NxStage Medical, Inc.
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Use of Monte Carlo Simulation to Determine Optimal Meropenem 
Regimens in Patients Receiving SHIFT Renal Replacement Therapy 
Susan J. Lewis, Katherine N. Gharibian, Bruce A. Mueller.  College of Pharmacy, 
Univ of Michigan, MI.
Background: Current antibiotic dosing regimens often result in subtherapeutic 
concentrations in critically ill patients, but scant pharmacokinetic (PK) data exist to support 
antibiotic dosing. This study applied Monte Carlo simulations (MCS) to determine the initial 
meropenem regimen to treat critically ill patients receiving SHIFT Renal Replacement 
Therapy (RRT), a daily prolonged intermittent RRT.
Methods: Body weight & PK parameter [non-renal clearance, free fraction, volume 
of distribution & extraction coefficients] estimates with variability were obtained from 
relevant published studies. Values were randomly selected from the log-Gaussian 
distribution within the assigned limits to vary individual free meropenem concentration 
profiles. MCS were performed for 13 meropenem regimens including weight-based and 
pre- & post-SHIFT dosing, in 4 different SHIFT settings (4L/hour x 10 hours or 5L/hour 
x 8 hours in hemodialysis or hemofiltration) occurring either at the beginning of or 14-16 
hours after meropenem infusion. Probability of target attainment (PTA) was evaluated 
using a pharmacodynamic target of ≥ 40% free meropenem concentrations above 4 times 
of the minimum inhibitor concentration (fT≥4xMIC) for Pseudomonas aeruginosa (2 µg/
mL) for the first 48 hours of therapy. A ≥ 90% of PTA with the smallest daily dose was 
defined as optimal.
Results: Meropenem regimens using ³2g/day attained ≥ 90% PTA. Meropenem 1g 
q12h and 1g given pre- & post-SHIFT were optimal regimens for all SHIFT settings. 
Weight-based regimens did not yield better target attainment than fixed-dose regimens.
Conclusions: This simulation indicates that meropenem regimens using 2g/day should 
be used initially to treat critically ill patients receiving 8 or 10 hour SHIFT RRT. These 
results warrant clinical validation.
Funding: Pharmaceutical Company Support - NxStage Medical Inc.
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SA-PO532
Evaluation of Piperacillin/Tazobactam Regimens in Patients with SHIFT 
Renal Replacement Therapy  Susan J. Lewis,1 Katherine N. Gharibian,1 Ashita 
J. Tolwani,2 William Henry Fissell,3 Bruce A. Mueller.1  1College of Pharmacy, 
Univ of Michigan, MI; 2Univ of Alabama, AL; 3Vanderbilt Univ, TN.
Background: SHIFT Renal Replacement Therapy (RRT) is a prolonged intermittent 
RRT to treat critically ill patients with acute kidney injury, but lack of antibiotic 
pharmacokinetic (PK) data in this RRT limits its utility. This study evaluated probability 
of target attainment (PTA) of piperacillin/tazobactam regimens recommended in critically 
ill patients receiving SHIFT RRT, using Monte Carlo Simulations (MCS).
Methods: Mathematical PK models were constructed using literature-derived 
demographic/PK data with known variability. Four daily-SHIFT settings (hemofiltration 
or hemodialysis with effluent rates of 5L/hour x 8 hours or 4L/hour x 10 hours) occurring 
at 2 different times relative to drug dose were modeled. PTA of 13 piperacillin regimens 
(2-4g q6-8h) and 3 tazobactam regimens (0.5g q6h) with intermittent or prolonged infusion 
(4-hour or continuous) were evaluated. MCS generated free drug concentration profiles for 
each regimen in the 5,000 virtual patients. Pharmacodynamic targets were ≥ 50% of time 
free piperacillin concentrations above 4x the minimum inhibitory concentration (MIC) of 
Pseudomonas aeruginosa (16 µg/mL) and ≥ 50% of time free tazobactam concentrations 
above corresponding threshold (4 µg/mL) for the initial 48 hour-therapy. The optimal 
regimen required ≥ 90% of PTA for both agents.
Results: The attainment of≥ 90% of PTA required piperacillin 16g/day and tazobactam 
2g/day in all SHIFT settings. Prolonged infusion was not superior to intermittent infusion 
to yield better PTA in patients receiving SHIFT RRT. 
Conclusions: Piperacillin/tazobactam 4.5g q6h is recommended for critically ill 
patients receiving 8 or 10 hour SHIFT RRT. These PK simulation results need to be 
clinically validated.
Funding: Pharmaceutical Company Support - NxStage Medical Inc.
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Beta-Blocker Dialyzability in Chronic Hemodialysis Patients  Alvin Tieu,1 
Thomas Velenosi,1 Andrew S. Kucey,1 Laura Elisabeth Mccuaig,1 Matthew 
A. Weir,1 Brad Urquhart.1,2  1Dept of Physiology and Pharmacology, Schulich 
School of Medicine and Dentistry, London, ON, Canada; 2Dept of Medicine, 
Div of Nephrology, Western Univ, London, ON, Canada.
Background: There is a paucity of data available to describe beta-blocker dialyzability. 
Of the available information, most were obtained prior to implementation of high-flux 
dialysis membranes. This study aims to characterize the dialyzability of four of the 
most commonly prescribed beta-blockers in patients undergoing conventional high-flux 
hemodialysis (HD). Based on physiochemical properties, we hypothesize atenolol and 
metoprolol to be extensively removed by HD, while bisoprolol and carvedilol to be 
poorly dialyzed.
Methods: HD patients from the London Health Sciences Centre were recruited for a 
pharmacokinetic, crossover study. Atenolol (50mg), bisoprolol (5mg), carvedilol (6.25mg) 
and metoprolol (50mg) were administered separately to each patient over four hemodialysis 
sessions. Arterial and venous blood samples and total spent dialysate were collected. Beta-
blocker concentrations were measured by mass spectrometry, and dialytic clearance was 
determined by the dialyzer and recovery clearance methods.
Results: Following dialysis, 6.78 mg of atenolol, 0.66 mg of bisoprolol, 0.02 mg of 
carvedilol, and 1.53 mg of metoprolol were recovered in spent dialysate. These amounts of 
dialyzed beta-blockers were applied in the recovery clearance method to produce dialytic 
clearance values of 124.0, 91.5, 1.3, and 150.2 mL/min for atenolol, bisoprolol, carvedilol, 
and metoprolol, respectively.
Conclusions: Beta-blocker efficacy can be hindered if substantial dialytic clearance 
occurs. Accordingly, atenolol and metoprolol were extensively cleared by HD, while 
carvedilol displayed low dialyzability. Contrary to previous literature, our data suggests 
moderate dialyzability for bisoprolol. With recent studies indicating heightened mortality 
risk in HD patients prescribed highly-dialyzable beta-blockers, drug dialyzability data is 
critically important to optimize pharmacotherapy in HD patients. Definitive characterization 
of beta-blocker dialyzability can allow for determination of post-dialysis supplemental drug 
doses, or alternative drug therapies.
Funding: Government Support - Non-U.S.
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Rituximab Exhibits Altered Pharmacokinetics in Patients with Membranous 
Nephropathy  Uma R. Fogueri,1 Wisit Cheungpasitporn,2 David Bourne,1 
Fernando C. Fervenza,2 Melanie S. Joy.1  1Schools of Pharmacy and Medicine, 
Univ of Colorado, Aurora, CO; 2Div of Nephrology and Hypertension, Mayo 
Clinic, Rochester, MN.
Background: Rituximab (RTX) is an anti-CD20 antibody used in the treatment of 
glomerular diseases including membranous nephropathy (MN). There is little information 
about the pharmacokinetics of therapeutic proteins, including RTX in patients with 
glomerular diseases. The study evaluated rituximab pharmacokinetics in patients with MN 
from a pilot investigation(Fervenza et.al, 2010).
Methods: Patients with MN (n=20) received 4 RTX weekly IV infusions (375mg/m2), 
with a repeat of the identical treatment at 6 months. Patient baseline characteristics were: 
gender (17M/3F), age (49±13 y), BSA (2.22±0.24 m2), urinary protein excretion (11.3±4.1 
g/d), creatinine clearance (72±33 mL/min). Pharmacokinetic analysis was performed using 
rituximab plasma concentrations. Comparisons of pharmacokinetic parameters were made 
between the MN patients and published data from other populations.
Results: The MN population had a favorable reduction in urinary protein excretion 
3 months after each RTX treatment course (7339±4114 mg/day and 4131±3441 mg/day, 
respectively), while creatinine clearance values were similar to baseline (72±31 mL/min 
and 82±37 mL/min, respectively). Patients with MN exhibited a shortened half-life (T1/2), 
greater volume of distribution (Vd), and enhanced clearance of RTX vs. previous reports 
in other patient populations. These characteristics resulted in an exposure (AUC) that was 
significantly reduced in patients with MN. 
Membranous 
Nephropathy (N=20)
Follicular Lymphoma 
(N=22)
Autoimmune 
Disorders (N=14)
T1/2 (h) 231±143 513 (248-705) 484 (292-859)
Clearance(mL/hr) 29.6±9.5 11.2 (8.4-17.8) 14.5 (8.4-26.2)
Vd (mL) 9722±6877 3850 (3432-4686) 4642 (2266-5786)
AUC (mg h/mL) 31.4±12.7 73.6 (46.3-98.2) 56.9 (31.5-98.2)
Conclusions: The pharmacokinetics of RTX in patients with MN are significantly 
altered compared to published data from cancer and autoimmune populations. These 
results suggest shorter T1/2 and lower exposures to RTX in MN may necessitate higher 
doses and/or changes to dosing frequency in order to elicit an optimal therapeutic effect.
SA-PO535
Eculizumab Treatment Efficiently Prevents C5 Cleavage without C5a 
Generation In Vivo  Elena Volokhina,1 Grethe Bergseth,2 Nicole Van De 
Kar,1 Lambertus P.W.J. Van den Heuvel,1 Tom Eirik Mollnes.2  1Radboud Univ 
Medical Center, Nijmegen, Netherlands; 2Nordland Hospital, Bodø, Norway.
Background: The C5 inhibitor eculizumab has been successfully used to treat atypical 
hemolytic uremic syndrome (aHUS), however, available data on pharmacodynamics of this 
medication are limited. Recently, increased generation of C5a in a single patient with HELLP 
syndrome treated with eculizumab has been reported. Since this observation was unexpected, 
we aimed to reproduce these data and search for possible explanations for the findings.
Methods: Levels of C5a were analyzed in EDTA plasma samples of aHUS (n=3) 
patients using three commercial ELISA kits, one of the kits was also used in the HELLP 
study and other two kits were included as controls. The samples were collected before the 
first eculizumab dose and then at various time points during treatment.
Results: In line with the report on HELLP patient, the C5a values, measured by one 
of the commercial ELISA kits, increased significantly in all aHUS patients after the first 
eculizumab dose as compared to the values obtained before treatment (p=0.016). C5a 
remained elevated throughout the treatment period. Such increase could not be reproduced 
by using another two commonly available commercial kits. When eculizumab was added 
in vitro to normal human serum prior to activation, no generation of C5a was measured 
by all used kits.
Conclusions: Our data indicate that existing commercial assays require validation 
for specificity before being used to monitor effect of eculizumab, especially in clinical 
laboratory practice. This example illustrates how false conclusions can be drawn when 
based on results from one single commercial assay not satisfactorily validated for the 
purpose it is used.
Funding: Government Support - Non-U.S.
SA-PO536
Sensitive, Reliable and Easy-Performed Laboratory Monitoring 
of Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome 
Elena Volokhina,1 Nicole Van De Kar,1 Grethe Bergseth,2 Thea J. Van der 
velden,1 Jack F. Wetzels,1 Lambertus P.W.J. Van den Heuvel,1 Tom Eirik 
Mollnes.2  1Radboud Univ Medical Center, Nijmegen, Netherlands; 2Nordland 
Hospital, Bodø, Norway.
Background: Atypical hemolytic uremic syndrome is a severe renal illness caused 
by complement dysregulation. Treatment with the complement C5 inhibitor eculizumab 
is effective, but associated with high costs. Laboratory monitoring of these patients with 
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respect to complement function has not been standardized. The aim of this study was to 
evaluate novel complement functional assays for their application in routine follow-up of 
eculizumab-treated patients.
Methods: Complement activity in serum samples was analyzed using Wieslab® 
complement screen assay. The presence of eculizumab-C5 complexes in serum, EDTA 
plasma samples and in urine was measured using ELISA. Levels of sC5b-9 in urine were 
measured using electroluminescent epitope assay.
Results: First, we documented that the Wieslab® complement screen assay showed a 
sensitivity of 1-2% of C5 activity by adding purified C5 or normal human serum to a C5 
deficient serum. Second, we found that all the patient samples obtained during the standard 
treatment course, were completely blocked for terminal complement pathway activity. 
Moreover, complement remained fully blocked when intervals between the eculizumab 
infusions were extended to four weeks. Levels of complexes between eculizumab and C5 
were inversely correlated to the complement activity (p=0.01). Third, titrating serum from 
eculizumab-treated patients into normal serum, revealed that eculizumab was present in 
excess up to four weeks after infusion. Finally, we showed that increased urine sC5b-9 
disappeared after eculizumab treatment.
Conclusions: We demonstrate sensitive, reliable and easy-performed assays to monitor 
eculizumab-treated patients, which can be used to design individual dosage regimens.
Funding: Government Support - Non-U.S.
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Dose Exposure Relationship of AKB-6548 Is Independent of the Level 
of Renal Function  Akshay Buch, Bradley J. Maroni, Charlotte S. Hartman. 
Akebia Therapeutics, Inc., Cambridge, MA.
Background: AKB-6548 is a novel, once-daily, oral hypoxia-inducible factor prolyl-
hydroxylase inhibitor (HIF-PHI) in development for the treatment of anemia in non-
dialysis dependent (NDD) and dialysis dependent (DD) chronic kidney disease (CKD). 
Studies in NDD-CKD patients have shown AKB-6548 produces physiologic increases in 
erythropoietin, enhances iron mobilization, and produces a dose dependent increase in 
hemoglobin levels.
Methods: The pharmacokinetics (PK) of AKB-6548 have been evaluated in single and 
multiple dose studies in healthy volunteers and CKD patients (NDD-CKD and DD-CKD) 
over a broad range of dose levels. An analysis of results across studies was conducted to 
assess the potential impact of renal function on selecting the dose levels and dosing regimen 
in CKD patients. The analyses evaluated dose-linearity in drug exposure, clearance routes of 
AKB-6548 and its metabolites, as well as the impact of CKD severity and the hemodialysis 
procedure on drug disposition.
Results: In healthy volunteers, AKB-6548 demonstrated dose linearity and 
proportionality over single doses of 80-1200 mg and multiple doses of 500-900 mg/
day. The PK parameters of AKB-6548 in healthy volunteers, NDD-CKD and DD-CKD 
patients were similar except for a slightly longer half-life with declining renal function 
(4.7 hr., 7.9 hr. and 9.1 hr., respectively). A mass balance study (using 14C- labeled drug) in 
healthy volunteers demonstrated both renal and fecal routes of parent drug and metabolite 
clearance, supporting use of AKB-6548 in CKD patients without significant differences 
in drug exposure. Moreover, AKB-6548 was minimally cleared by the hemodialysis 
procedure and the PK parameters were similar whether AKB-6548 was administered prior 
to or following dialysis.
Conclusions: The results demonstrate a linear dose-exposure relationship for AKB-
6548 over a wide range of doses and support the utility of once-daily dosing and similar 
dose levels across the spectrum of CKD severity.
Funding: Pharmaceutical Company Support - Akebia Therapeutics
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Nonclinical Pharmacokinetics and Toxicokinetics of RG-012, an Inhibitor 
of MicroRNA-21 Being Investigated for Treatment of Alport Syndrome 
John Stewart Grundy,1 Kai Liu,1 Steven Neben,1 Cindy L. Berman,2 Deidre 
Mackenna,1 Neil W. Gibson.1  1Regulus Therapeutics, San Diego, CA; 2Berman 
Consulting, Wayland, MA.
Background: RG-012 is a single-stranded chemically modified oligonucleotide 
being developed to treat patients with Alport syndrome, which is characterized by loss of 
renal function associated with defects in specific collagen genes expressed in the kidney 
glomerular basement membrane. RG-012 inhibits miR-21, a microRNA target known to 
have increased expression in context of kidney stress and associated with renal dysfunction.
Methods: In vitro pharmacokinetic (PK) evaluations of RG-012 conducted during 
preclinical development included: plasma protein binding, metabolic stability in whole 
blood and liver lysates, and CYP450 inhibition/induction potential in cryopreserved human 
hepatocytes. In vivo PK and toxicokinetic (TK) properties of RG-012, and its major active 
metabolite (RG0005), were determined upon subcutaneous dosing of RG-012 in a set of 
nonclinical PK, pharmacology, and safety studies in CD-1, SV129, and COL4A3 mice 
(6.25–450 mg/kg/week) and cynomolgus monkeys (10–225 mg/kg/week).
Results: Both RG-012 and RG0005 were highly bound (≥98%) to proteins in plasma 
from mice, monkeys, and humans. RG0005 was the only major degradation product seen 
in whole blood and liver lysates from all three species. RG-012 exhibited little to no 
potential to inhibit or induce CYP450 enzymes. Upon administration of RG-012, PK and 
TK properties of RG-012 and RG0005 were consistent across all nonclinical species and 
were characterized by rapid absorption, dose-dependent plasma exposure, rapid plasma 
clearance due mainly to extensive tissue distribution, and subsequent slow tissue elimination 
(half-lives in liver and kidney of ~2–3 weeks). Comparison of plasma and tissue exposure 
levels (RG-012+RG0005 combined) seen at the NOAEL in cynomolgus monkeys, the most 
clinically relevant toxicological species, with those achieved at pharmacologically active 
dose regimens (ED50 and ED90) in a COL4A3 mutant mouse model, indicates a therapeutic 
index (TI) ranging from 3.4 to 25.4.
Conclusions: In conclusion, favorable nonclinical PK/TK properties and TI of RG-012 
support initial clinical testing.
Funding: Pharmaceutical Company Support - Regulus Therapeutics
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Novel Methodology for Assessing Inhibition of MicroRNA-21 by RG-012, 
a MicroRNA Therapeutic in Development for the Treatment of Kidney 
Dysfunction in Patients with Alport Syndrome  John Rolf Androsavich, 
Xueqing Liu, Shweta Pandya, Deidre Mackenna.  Regulus Therapeutics, San 
Diego, CA.
Background: microRNA-21 (miR-21) is upregulated in animals models with kidney 
dysfunction and also in patients with chronic kidney disease (CKD). RG-012 is a miR-21 
inhibitor entering clinical development for treatment of CKD in Alport syndrome (AS) 
patients. RG-012 demonstrates activity both as a monotherapy and in combination with the 
ACE inhibitor ramipril in the Col4A3 deficient mutant mouse model of AS.
Methods: Two distinct methods have been developed to evaluate the ability of RG-012 
to inhibit miR-21 in preclinical studies – the polysome shift assay (PSA) and alterations 
in the expression of miR-21 target mRNAs. The PSA measures direct target inhibition 
at the level of the physical interaction between microRNA and messenger RNA targets. 
C57Bl/6 mice were treated subcutaneously with RG-012 at doses ranging from 0.1 to 100 
mg/kg. Tissue homogenates were separated using sucrose gradient ultracentrifugation, with 
microRNAs associating with messenger RNA targets in the heavier polysome fraction. The 
ability of RG-012 to displace the target miR-21 from the polysome containing fraction was 
used to assess direct target engagement.
Results: RG-012 demonstrated dose dependent displacement of miR-21 from 
polysomes in both liver and kidney with a maximum effect reached at dose levels that are 
efficacious in the Col4A3 mouse models. Loss of miR-21 from the polysomes was specific 
as levels of Let-7a, a control microRNA to which RG-012 has no complementarity, were 
unaffected. In the liver, target engagement was also assessed using mRNA derepression of 
a set of confirmed miR-21 target genes. Here, target gene derepression strongly correlated 
with polysome displacement. This comparison was not possible in kidney, however, because 
target genes are not regulated in kidneys in the absence of stress.
Conclusions: RG-012 directly and specifically inhibits miR-21 resulting in its 
displacement from actively translating polysome complexes and subsequent derepression 
of messenger RNA targets.
Funding: Pharmaceutical Company Support - Regulus Therapeutics
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Tacrolimus Pharmacokinetics in Nephrotic Stage  Mara Medeiros,1 
Saul Valverde,1 Luis Velasquez-Jones,1 Ana M. Hernández,1 Gilberto 
Castañeda-Hernández,2 Guido Filler.3  1Hospital Infantil de México Federico 
Gómez, Mexico; 2CINVESTAV, IPN, Mexico; 3Children’s Hospital, Univ of 
Western Ontario, Canada.
Background: While tacrolimus (Tac) therapy is not first-line therapy for childhood 
nephrotic syndrome, it is often used instead of cyclosporine to ameliorate the side effects. 
The pharmacokinetics of Tac can be influenced by many conditions, and it has a high plasma 
protein binding. The Tac pharmacokinetics during relapse and remission of childhood 
nephrotic syndrome have not been well described.
Methods: We performed 14 pharmacokinetic (PK) profiles (with measurements 
before and 0.5, 1, 2, 4 and 12 hours post intake) in 7 children with steroid-resistant 
nephrotic syndrome (SRNS) during relapse and in remission. These data were compared 
with historical PK data of 161 PK profiles in 87 pediatric renal transplant recipients with 
measurements before, 0.5,1,1.5,2,3,4,6,8 and 12 hours post intake. Tac levels were measured 
using the Abbott Tacro II assay. We used descriptive statistics to generate percentiles and 
compared these with the SRNS patients. We also compared the PK profiles during relapse 
and remission.
Results: Median age of SRNS patients was 3.2 years. Tacrolimus dose, biochemical 
values and pharmacokinetics parameters are shown in Table 1. Values as median and 
interquartile range. 
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Baseline Week 1 Week 16 P value*
Serum albumin (mg/dL) 2.1 (1.4, 2.9) 2.6 (2.4, 3.5) 3.7 (3.6, 3.7) 0.008
Proteinuria (mg/m2/h) 54.5 (28.5, 168) 22 (5, 30) 4.5 (0.46, 30) 0.01
Cholesterol (mg/dL) 281 (229, 506) 286 (236, 383) 165 (137,191) 0.0003
Triglycerides (mg/dL) 182 (115, 430) 173 (120, 276) 90 (49, 126) 0.02
eGFR (ml/min/1.73m2) 114 (92, 349) 92 (91, 130) 85 (73, 120) 0.02
Tacrolimus dose mg/kg/day 0.11 (0.08, 0.12)
0.13 (0.08, 
0.15) 0.81
Tacrolimus C0h (mg/dL) 7.9 (3.8, 10.2) 5.3 (3.6, 11.3) 1.0
AUC/Dose (ng*h/ml/mg) 1858 (625, 3172)
3823 (1212, 
4790) 0.07
Cmax/Dose [(ng/mL)/[mg/
kg/d)] 131 (93, 240) 188 (135, 330) 0.21
Tmax (h) 1 (1, 2) 0.5 (0.5, 2) 0.58
t ½ (h) 9.2 (6.1, 11.3) 8 (6, 12.8) 0.57
The PK profiles were well within the percentiles of the transplant children.
Conclusions: Tac PK profiles are not different in children with nephrotic syndrome 
during relapse and remission.
Funding: Government Support - Non-U.S.
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Clinical and Genetic Determinants of Longitudinal Dose-Corrected CNI 
Exposure in Children After Renal Transplantation  Noel Knops,1 Elena N. 
Levtchenko,1 Dirk R. Kuypers.2  1Pediatric Nephrology, Univ Hospitals Leuven, 
Leuven, Belgium; 2Nephrology, Univ Hospitals Leuven, Leuven, Belgium.
Background: Calcineurin-inhibitors (CNI) have a narrow therapeutic index and 
dosing is difficult due to inter- and intra-individual variation in pharmacokinetics (PK). 
Polymorphisms in genes involved in drug metabolism can play a critical role in individual 
exposure. Data concerning long-term CNI exposure in relation to dose in children are 
scarce and in general based upon trough levels. We present the longitudinal follow up of 
12-hour CNI PK in relation to dose, clinical and genetic factors in a cohort pediatric renal 
allograft recipients.
Methods: Retrospective single center study in subjects after renal transplantation 
(age 0-20 yrs) with annual PK assessments (6-point AUC0-12hr) for tacrolimus (Tac) or 
cyclosporine (CsA). Clinical and laboratory data were retrieved. Analysis of polymorphisms 
in CYP3A4, CYP3A5, CYP3A7, POR and ABCB1 was performed.
Results: We collected 180 “full” AUCs for Tac, 56 for CsA in 51 kids. Mean age at 
Tx: 9.9 yrs(1-19); FU after Tx: 4.6 yrs (0-16). Dose-corr. exposure (AUC/ dose in mg/
kg) increased with age: 854 (mean) in <5 yrs to 2702 >15yrs); 817 to 1787 ng*hr/ml per 
mg/kg in Tac and CsA resp. (p< 0.01). Correction for dose per m2 body surface (BS) 
demonstrated stable dose-corr. exposure for ages <15 yrs, and was higher only for >15 
yrs (Tac: <5yrs-15 yrs: 44 (95%CI: 40-48) >15yrs: 73.4 ng hr/ml per mg/m2; CsA: 40 (CI 
36-44) vs. 52. CYP3A5 genotype was an important co-determinant of dose-corr. exposure 
for Tac (2.1 higher dose-req. in *1 vs *3/3), but not for CsA. *1 carriers had an attenuated 
increase in dose-corr.exposure into adulthood (27 vs. 39 in >15yrs; *3/3: 48 vs. 82 resp.)
Conclusions: Dose-corr exposure according to BS, in contrast to bodyweight, 
demonstrates stable CNI dose requirements in children <15 yrs. Polymorphisms in CYP3A5 
are important for individual Tac dose requirements and modify the effect of age. CsA is 
not affected by CYP3A5. Our data suggest that CNI dosing per m2 in children after renal 
transplantation would be less prone to variation in exposure with age and thus preferred. 
CYP3A5 genotype only aids in predicting Tac dose requirements.
Funding: Government Support - Non-U.S.
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Sex and Race Influences on Tacrolimus Pharmacokinetics in Renal 
Transplant Recipients  Kathleen M. Tornatore,1,3 Calvin J. Meaney,1 Joseph 
D. Consiglio,2 Gregory E. Wilding,2 Shirley Shwu-Shiow Chang,3 Rocco C. 
Venuto.3  1NYS Center of Excellence in Bioinformatics & Life Science; Pharmacy, 
School of Pharmacy & Pharmaceutical Sciences; 2Biostatistics, School of 
Public Health; 3Medicine, School of Medicine & Biomedical Sciences; Univ 
at Buffalo, Buffalo, NY.
Background: Tacrolimus (TAC) is the primary calcineurin inhibitor in 
immunosuppressive regimens for renal transplant recipients(RTR) and exhibits 
notable interpatient variability in pharmacokinetics(PK) necessitating therapeutic drug 
monitoring(TDM). There are limited data that characterize sex and race influences on 
TAC PK.
Methods: During a 12-hour PK study, we evaluated steady-state TAC trough (C0), area 
under the concentration time curve 0-12 hours (AUC 0-12) normalized for dose, apparent 
clearance(CL) and total body weight(TBW) normalized CL using non-compartmental 
analysis. 65 stable African American (AA) and Caucasians (C) females(F) and males(M) 
who were greater than 6 months post-transplant and receiving TAC and mycophenolic 
acid were enrolled. TAC dosage was adjusted using C0 range of 4-9 ng/ml. TAC adverse 
effects(AE) were evaluated using standardized assessments to generate a cumulative AE 
score(CAE).
Results: The clinical and PK parameters are summarized below. Total and weight-
normalized CL were most rapid with lower dose-normalized AUC in AAF compared to 
other RTR. Higher CAE was found in female RTR. No sex-race differences were noted 
for C0 in spite of higher TAC doses in AA. 
Mean(SD) AAF[n=13] AAM[n=20] CF[n=16] CM[n=16] P Value
eGFR[ml/
min/1.73m2] 49.9(17.7) 57.4(13.4) 49.8(11.5) 64.4(16.2) 0.019
TAC dose[mg] 5.0(1.7) 3.7(1.6) 2.7(1.2) 2.2(0.7) <0.001
TAC C 0[ng/ml] 7.2(1.8) 7.3(1.9) 6.7(1.7) 6.2(1.2) NS
Apparent CL[L/
hr] 40.0(16.8) 28.2(13.3) 22.2(8.9) 21.3(6.7) 0.0003
CL/TBW 0.47(0.23) 0.34(0.20) 0.32(0.15) 0.23(0.07) 0.005
AUC 0-12/
Dose[ng.hr/
ml/mg]
29.6(12.5) 44.9(25.5) 54.6(25.9) 51.7(16.8) 0.001
CAE Score 0.21(0.06) 0.09(0.06) 0.16(0.09) 0.13(0.06) <0.001
Conclusions: Sex-race differences in TAC PK contribute to differential dosing 
requirements in AA vs C. A more individualized approach to chronic TAC immunosuppression 
integrating sex-race with TDM and a standardized adverse effect assessment may benefit 
RTR.
Funding: NIDDK Support, Pharmaceutical Company Support - Astellas Scientific 
and Medical Affairs, Inc
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Sex and ABCB1 Haplotype Associations with Tacrolimus Pharmacokinetics 
in Renal Transplant Recipients  Kathleen M. Tornatore,1,3 Daniel Brazeau,2 
Calvin J. Meaney,1 Louise M. Cooper,1 Rocco C. Venuto.3  1NYS Center of 
Excellence in Bioinformatics & Life Science; Pharmacy, School of Pharmacy 
& Pharmaceutical Sciences; 2GAP-Core Facility; Schools of Pharmacy & 
Medicine, Univ of New England, Portland, ME; 3Medicine, ECMC, School of 
Medicine;  Univ at Buffalo, Buffalo, NY.
Background: Tacrolimus (TAC) is the mainstay calcineurin inhibitor for 
immunosuppression in renal transplant recipients (RTR). TAC exhibits interpatient 
variability in pharmacokinetics (PK) attributed primarily to CYP 3A5 isoenzymes and 
P-glycoprotein (Pgp). Pgp is encoded by the ABCB1 gene. The common single nucleotide 
polymorphisms (SNP): 1236C>T (rs1128503), c.2677G>T/A (rs2032582), and c.3435C>T 
(rs1045642) have conflicting associations to TAC PK. This study objective evaluated these 
common SNP as haplotypes in relation to TAC PK.
Methods: During a 12-hr PK study, trough (C0), apparent clearance (CL) and lean 
body weight (LBW) normalized CL were determined in 29 female and 36 male African 
American (AA) and Caucasian (C) stable RTR greater than 6 months post-transplant 
receiving TAC and mycophenolic acid. TAC dosage was adjusted to C0 range of 4-9 ng/ml. 
The ABCB1 SNPs: c.1236C>T (rs1128503), c.2677G>T/A (rs2032582), and c.3435C>T 
(rs1045642) were assessed. ABCB1 haplotype associations comparing the primary variant 
TTT to CGC [wild-type (WT)] relative to TAC PK were computed using the THESIAS 
program with sex sub-analysis.
Results: TAC C0 ranged from 5-10 ng/ml with no difference between groups in spite 
of higher doses in AA (P<0.0001). Significant associations of TTT to TAC dose, CL and 
CL/LBW were noted with sex sub-analysis and summarized as Phenotypic Mean with 
Confidence Interval (CI) of WT compared to variant  in table. These data suggest RTR with 
TTT variant received lower doses and had slower TAC CL relative to sex.
Mean[SD]
CGC[WT] Phenotypic 
Mean[CI]
TTT- Phenotypic 
Mean[CI] P Value
TAC Dose[mg] 2.4[1.7-3.2] 1.6[0.7-2.5] 0.029
Apparent CL[L/hr] 20.4[14.5-26.3] 13.9[7.9-20.1] 0.023
CL/LBW 0.48[0.37-0.60] 0.35[0.23-0.47] 0.022
Conclusions: The ABCB1 haplotypes provide important insight into interpatient 
variability in TAC PK post renal transplant and the role of P-gp that is also influenced by sex.
Funding: NIDDK Support, Pharmaceutical Company Support - Astellas Scientific 
and Medical Affairs, INC
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Pharmacokinetics and Pharmacodynamics of Tacrolimus, and NFAT 
Regulated Gene Expression in Kidney Transplant Patients  Frieder Keller. 
Univ Hospital, Ulm, Germany.
Background: Suppression of genes that are regulated by the nuclear factor of activated 
T-cells (NFAT) is an effect of calcineurin inhibitors. We correlated the pharmacodynamics 
to the pharmacokinetics of tacrolimus.
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Methods: This study was undertaken in the University Hospitals of Ulm (Frieder 
Keller) and Heidelberg (Claudia Sommerer, Thomas Giese, Martin Zeier). Tacrolimus 
trough concentrations (Ctrough) and 1.5 – 2 hours later the peak concentrations (Cpeak) 
were measured by LCMS. Simultaneously, the NFAT trough effect (Etrough) and the nadir 
effect (Enadir) were determined. The pharmacokinetic half-life (T1/2) was estimated from 
peak (Cpeak) and trough concentrations (Ctrough) considering the time distance between 
steady-state peak and troughs (10.5 – 10 hours). The pharmacodynamic concentration 
producing the half-maximum effect (CE50) and the Hill coefficient (H) were estimated 
from trough effect (Etrough) at trough concentrations and from nadir effect (Enadir) at 
peak concentrations. The two equations were solved by numerical iteration for an estimate 
of the two unknown parameters (CE50, H).
Results: A total of 10 stable kidney transplant patients were included. The median age 
was 58 years and the median serum creatinine was 306 mcmol/l. The pharmacokinetics 
of tacrolimus were estimated with T1/2 = 11 hours, Cl/F = 64 l/h and Vd/F = 480 l. The 
median value for NFAT was 89% (Etrough) of normal gene expression, and the nadir effect 
was 43% (Enadir) representing the strongest immunosuppression of basal gene expression. 
The pharmacodynamics of tacrolimus were estimated with CE50 = 7.7 ng/ml and the Hill 
coefficient with H = 4.6, respectively.
Conclusions: While on triple immunosuppression, the NFAT pharmacodynamics 
indicate a low concentration producing the half-maximum effect and a high Hill coefficient. 
These findings suggest a narrow trough-to-peak target concentration range of 4.0-to-9.5 
ng/ml for tacrolimus.
SA-PO545
2-Sample Iohexol Plasma Clearance: The Clear Choice for Measuring 
Kidney Function in Rats  Mandy E. Turner,1 Kimberly J. Laverty,1 Martin 
Kaufmann,1 Glenville Jones,1 Rachel M. Holden,2 Michael A. Adams.1 
1Biomedical and Molecular Sciences, Queen’s Univ, Kingston, ON, Canada; 
2School of Medicine, Queen’s Univ, Kingston, ON, Canada.
Background: The lack of simple and sensitive tools for longitudinal kidney function 
assessment in rodent models has impeded analysis of CKD onset and progression and the 
impact of interventions. This study evaluates 2-sample plasma clearance (pCl) of iohexol, 
a radio-contrast agent, compared to previously validated inulin pCl in rats to estimate GFR.
Methods: Progressive CKD was induced with a 0.25% adenine diet in male Sprague-
Dawley rats (N=8). Following serial tail vein injections of iohexol (51.92 mg/kg) and 
FITC-inulin (2.5 µL/kg of 5% solution), 12 saphenous blood samples were taken from 
conscious rats over 5 hours, weekly (control, 5 weeks of adenine). Plasma creatinine was 
measured via the Jaffrey method, FITC-inulin via fluorometry, and iohexol via UPLC-MS. 
Two reference methods for pCl calculation were used: a 2-compartment model(2 COM) 
and trapezoidal approximation(TRA) of area under the curve.
Results: Reference methods of inulin PCl agreed well with iohexol pCl. 
Reference 
Clearance
Comparative 
Clearance R
2 %Bias/Precision 15% Accuracy
INU TRA
IHX 2-COM 0.86 6.0±16.9 62.6
IHX TRA 0.93 3.9±10.9 81.4
IHX 1-COM 0.93 6.8±13.3 69.8
Cre 0.53
INU 2-COM
IHX 2-COM 0.93 15.3±12.7 46.5
IHX TRA 0.96 13.2±12.3 48.8
IHX 1-COM 0.96 16.2±10.1 51.2
Cre 0.58
pCl of iohexol and inulin was significantly decreased, compared to baseline, after one 
week (p<0.005), whereas plasma creatinine concentration was not significantly elevated 
until the third week (p=0.02). Characterization of a 1-compartment model using 2-samples 
was employed: samples at 30 and 90 min post injection yielded high agreement (R2=0.98) 
and no significant bias.
Conclusions: Iohexol pCl sensitively and accurately measures an early decline in 
kidney function, especially compared to creatinine. The 2-sample method for assessing 
kidney function is straightforward and is therefore suitable for large rat cohorts. This 
approach will both enable detection of early kidney disease and facilitate concise 
interpretation of results derived from pre-clinical studies.
Funding: Government Support - Non-U.S.
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Renal Nitrate Clearance in Chronic Kidney Disease  Mark Gilchrist,1 Jennifer 
Williams,2 Richard D’Souza,2 Miranda J. Smallwood,1 Lindsay Hayman,1 Angela 
C. Shore,1 Paul G. Winyard,1 Nigel Benjamin.3  1NIHR Exeter Clinical Research 
Facility, Univ of Exeter, Exeter, United Kingdom; 2Renal Unit, Royal Devon and 
Exeter Hospital Foundation Trust, Exeter, United Kingdom; 3Horizon Inst, South 
Devon Healthcare Foundation Trust, Torquay, United Kingdom.
Background: Endogenously synthesised nitric oxide(NO) is rapidly oxidised to nitrite 
and nitrate. These oxidation products can be recycled back into nitric oxide via a complex 
entero-salivary pathway, thus preserving NO activity. It has previously been shown that 
60% of circulating nitrate is excreted in the urine in 48 hours with the fate of the remainder 
unknown. 24hour urinary nitrate excretion is often used to estimate total body nitric oxide 
synthesis rates. It is not known what effect declining GFR has on renal nitrate clearance.
Methods: 27 subjects, 14M,13F, median age 70 (range 27-74years) with CKD-EPI 
eGFR between 9 and 89 were recruited. Following 24hrs low nitrate diet plasma nitrate 
concentration and 24 hour urinary nitrate excretion were measured to determine renal 
nitrate clearance using a microplate spectrophotemetric method.
Results: There was a statistically significant correlation between renal nitrate clearance 
and eGFR: Pearson r = 0.748, p<0.0001. There was no relationship between plasma nitrate 
concentration and eGFR, p=0.239, or between plasma nitrate concentration and renal 
nitrate clearance, p=0.547.
Conclusions: As plasma nitrate concentration is unchanged despite diminished renal 
nitrate clearance at lower eGFRs, we suggest that non-renal clearance is responsible for a 
greater proportion of nitrate elimination as GFR falls. We conclude that 24 hour urinary 
nitrate excretion cannot be considered a reliable measure of total body nitric oxide synthesis 
in CKD. Elucidating the non-renal pathways of loss of the NO storage molecule, nitrate, 
may lead to novel therapeutic strategies in CKD and cardiovascular disease.
SA-PO547
The Pharmacodynamic Effect of Tenapanor Is Most Pronounced when 
Administered Before Food in Healthy Volunteers  David P. Rosenbaum,1 
Mikael Knutsson,2 Maria Leonsson Zachrisson,2 Susanne Johansson.2  1Ardelyx 
Inc., Fremont, CA; 2AstraZeneca R&D, Mölndal, Sweden.
Background: Tenapanor (AZD1722), a small molecule with minimal systemic 
availability, is an inhibitor of the Na+/H+ exchanger NHE3. Tenapanor acts locally in the 
gut to reduce absorption of sodium (Na) and phosphate. This study evaluated the effect of 
food intake on the pharmacodynamics of tenapanor.
Methods: In this open-label, 3-way crossover study (NCT02226783), 18 healthy 
adults (mean age±SD, 35±11 years; 14 men) completed a randomized sequence of 4-day 
treatments with tenapanor hydrochloride 15 mg bid: before food (5–10 min before breakfast 
and dinner); after food (30 min after the start of breakfast and dinner); and at fasting (1 
h before breakfast, and 3 h after dinner/1 h before an evening snack). There was a 2-day 
washout between treatments. All participants received the same meals on the same study 
days; diet was standardized for Na content.
Results: Stool Na content was higher for tenapanor taken before food than for after 
food or at fasting, with least-squares mean differences significant in both cases (Table). 
Differences in urinary Na were not significant. The difference in stool phosphorus (P) 
content was significant for tenapanor taken before food versus at fasting. The difference 
in urinary P was significant for administration before food or after food versus at fasting. 
Stool frequency and consistency were similar across treatments, and there were slightly 
higher stool weights for administration before or after food, compared with at fasting. There 
were no serious AEs or discontinuations due to AEs. 
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Conclusions: The pharmacodynamic effect of tenapanor, as judged by stool Na content, 
was greatest when tenapanor was taken before food. This supports taking tenapanor before 
meals in future trials.
Funding: Pharmaceutical Company Support - AstraZeneca
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Triferic Does Not Induce Non-Transferrin Bound Iron or Labile Plasma 
Iron: In-Vivo/In-Vitro Correlation  Raymond D. Pratt,1 Dorine W. Swinkels,2 
Carrie D. Guss,1 Ajay Gupta.1  1R&D, Rockwell Medical Inc., Wixom, MI; 
2Radboud Univ Medical Center, Nijmegen, Netherlands.
Background: Triferic is a complex iron salt approved for administration via 
hemodialysate to maintain hemoglobin in patients with CKD 5HD. Triferic crosses the 
dialyzer membrane and binds to transferrin during hemodialysis replacing the obligatory 
iron losses in HD patients. Serum iron and transferrin saturation (TSAT) values rise after 
HD and return to the baseline by the start of the next dialysis session.
Methods: A pharmacokinetic (PK) study in healthy volunteers administered up to 
10 mg of Triferic iron over 4 hours and up to 20 mg Triferic iron over 12 hours assessed 
the PK of serum total iron (sFe-total) and transferrin bound iron (TBI). An in-vitro study 
assessed labile plasma iron (LPI). Triferic iron was added to plasma like medium (40 
mg/mL human serum albumin) at a concentration range of 0 to 112 mg/dL . In addition, 
Triferic was added to 5 different human plasma’s (TSAT, range 10 - 46%; total iron binding 
capacity (TIBC), mean: 374 mg/dL, range: 342-446 mg/dL) across a concentration span 
up to and exceeding 100% TSAT. LPI was measured in the presence of 40 mM ascorbate 
using dihydrorhodamine (DHR)-123 in the presence of 50 mM deferiprone (DFO) to detect 
iron- catalyzed radical generation.
Results: In the human PK study, sFe-total and TBI showed an identical PK profile. 
Non-transferrin bound iron (NTBI), calculated as the difference between SFe-total and 
TBI, showed no dose dependent increase up to a TSAT of 100%. In plasma like medium, 
LPI increased with increasing concentrations of Triferic iron. When Triferic was added to 
human plasma, there was a small increase in LPI observed when iron concentrations were 
less than 100% TSAT. The mean magnitude of LPI (expressed in concentration units) at 
approximately 100% TSAT was 5.35 mg/dL (mean 1.4% of the total iron concentration). 
Once 100% TSAT was exceeded, the LPI increased rapidly.
Conclusions: Triferic rapidly donates iron to transferrin in vivo and in vitro. In vivo, 
at TSAT less than 100%, NTBI was minimal. In vitro, the LPI results confirm the lack of 
redox active iron in plasma until the plasma TIBC is exceeded.
Funding: Pharmaceutical Company Support - Rockwell Medical Inc.
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Impact of Tubular Luminal H+/Organic Cation Antiporter, MATE, on 
Imatinib-Induced Fluid Retention  Moto Kajiwara,1,2 Satohiro Masuda.1 
1Dept of Pharmacy, Kyushu Univ Hospital, Fukuoka, Japan; 2Dept of Research 
and Development of Next Generation Medicine, Kyushu Univ, Fukuoka, Japan.
Background:   A tyrosine kinase inihibitor, imatinib (IMA) is the first class agent 
against chronic myeloid leukemia. Although little is known about mechanism involved, 
more than 50% of imatinb-treated patients suffering from edema. In vitro study reported 
that clinical blood level of IMA inhibits multidrug and toxin extrusion (MATE, SLC47A)-
mediated transport of metformine, a hypoglycemic drug. MATE is highly expressed in the 
brush border membrane of proximal tubular cells mediating the efflux of organic cations, 
such as metformin, monoamines. The renal dopaminergic system is likely responsible for 
regulating >50% of net renal salt and water excretion when salt intake increases. In this 
study, we test a hypothesized that IMA prevents natriuresis by inhibiting MATE-mediated 
dopamine (DA) secretion into tubule lumen and consequently causes edema.
Methods:   C57BL/6 wild type mice (WT) and Mate1 knockout mice (KO) were used. 
Sodium levels in the urine of mice were measured using an ion-selective electrode. Urinary 
DA concentration was measured with a liquid chromatography-tandem mass spectrometry.
Results:   To determine whether IMA inhibits dopamine uptake by MATE, we examined 
[3H]DA uptake in HEK293 cells transiently expressed human (h) MATE1, hMATE2-K, 
and mouse (m) MATE1 in the presence of various concentration of IMA. Uptakes of [3H]
DA by those cells were inhibited by IMA in a concentration dependent manner with IC50 
values (µM) of 1.1, 13.8, and 100.6, respectively. In vivo acute saline-loading experiments 
were performed to examine inhibitory effect of IMA on urinary DA secretion in WT. In 
IMA-treated WT, the amount of urinary DA and urinary sodium were decreased to 42% and 
27% of that observed in vehicle-treated WT, respectively. Consistently, urinary dopamine 
was almost undetectable in KO. Furthermore, fraction water weight in mice body was 
significantly increased in IMA-treated WT compared to vehicle-treated WT (P<0.05).
Conclusions:   IMA prevents natriuresis by inhibiting MATE-mediated DA secretion 
into tubule lumen and consequently causes edema.
Funding: Government Support - Non-U.S.
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Optimizing Between-Patient Variability in Response to Renoprotective 
Drugs: Meta-Analysis of Rotation Trials  Sergei Petrykiv,1 Dick de Zeeuw,1 
Frederik I. Persson,2 Peter Rossing,2,3 Hans-Henrik Parving,3 Gozewijn Dirk 
Laverman,1 Hiddo Jan Lambers Heerspink.1  1Univ Medical Center, Groningen, 
Netherlands; 2Steno Diabetes Center, Gentofte, Denmark; 3Univ Copenhagen, 
Denmark.
Background: Individual response to albuminuria lowering intervention is highly 
variable between patients. To investigate whether uptitrating the dose of drug, changing the 
mode of intervention (with similar or different drug classes), or lowering dietary sodium 
intake improves individual response variability, we meta-analyzed individual responses 
to different modes of anti-albuminuric intervention in non-diabetic and diabetic patients.
Methods: Randomized rotation trials were analyzed to assess correlation of patient-
specific responses (n=216 patients) to anti-albuminuric interventions. Included studies 
(N=20) compared the anti-albuminuric effect of uptitrating the dose of intervention in the 
RAS (RASi) (N=10 comparisons) and NSAIDs (N=1), rotation within the same class of 
RASi (e.g. ACEi to ARB; N=5) or NSAIDs (N=1), rotation between RASi and NSAIDs 
(N=2), and rotation from high to low sodium intake during RASi (N=1). A two stage meta-
analysis was performed. First, deeming reression was conducted in each study to assess 
correlation in response. Individual study results were then meta-analyzed. Albuminuria 
was measured in 24-hr urine samples.
Results: The albuminuria response to one dose of RASi or NSAID positively correlated 
with the response to a higher dose of RASi or NSAID, rotation within the same class of 
RASi or NSAIDs, rotation between RASi and NSAIDS, and rotation from high to low salt 
intake. Correlations were consistent in diabetic and non-diabetic patients. 
Correlation P-value
Uptitration dose of RASi or NSAID 0.73 <0.01
Rotation within class of RASi or NSAID 0.54 <0.01
Rotation between RASi and NSAIDs 0.44 <0.01
Rotation high to low salt intake 0.48 <0.01
Conclusions: The correlations observed in this study indicate that patients poorly 
responding to one dose or mode of albuminuria lowering intervention also respond poorly 
to other doses or modes of intervention in the RAS. Whether other drugs targeting pathways 
beyond the RAS improve individual response variability requires further study.
SA-PO551
Acute Kidney Injury Serum Upregulates Hepatic Transcription of 
Cytochrome P450 3A4 and 3A5  Katie Lane,1 John Dixon,1 Ekram Nabi,2 
Barbara J. Philips,1 Iain Macphee,3 Mark E. Dockrell.2  1Critical Care, St. 
George’s Univ of London, United Kingdom; 2South West Thames Inst for Renal 
Research, United Kingdom; 3Renal Medicine, St. George’s Univ of London, 
United Kingdom.
Background: Hepatic drug metabolism by cytochrome P450 3A (CYP) is reduced 
in end stage kidney disease (ESKD) and acute kidney injury (AKI). The underlying 
mechanisms are uncertain. Previously we reported suppression of CYP3A4 mRNA 
transcription when human hepatocytes (HepG2) were exposed to serum from ESKD patients 
compared to healthy adults. CYP3A4 and 5 protein concentrations were unchanged. We 
now investigate whether serum from patients with AKI elicits similar results.
Methods: Serum was collected from critically ill adults with varying AKI severity. 
Sera from KDIGO 0 (n=15) and KDIGO 3 (n=16) AKI patients were applied individually to 
HepG2s for 24 h, when cells were lysed. CYP3A4 and 3A5 gene expression was examined 
by RT-qPCR. CYP3A4 and CYP3A5 protein expression was examined by Western blotting. 
The sera were also applied to HepG2 in a pooled fashion, alongside pooled sera from adults 
with ESKD prior to hemodialysis (n=10) and healthy adults (n=6), to allow comparison 
with previous data.
Results: AKI serum exposure doubled CYP3A4 gene expression compared to No AKI 
serum (p=0.0055 individual and p=0.003 pooled). AKI serum CYP3A5 mRNA increased 
approx. 25% compared to No AKI serum (p=0.11 individual and p=0.0098 pooled).
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CYP3A4 and 3A5 protein concentrations did not differ after exposure to AKI or No 
AKI sera (p=0.35, p=0.43).
Conclusions: In contrast to ESKD, hepatocyte exposure to AKI serum upregulates 
CYP3A4 and CYP3A5 transcription compared to No AKI serum. CYP3A4 and 3A5 protein 
concentrations were unchanged. Further serum analysis will determine whether differences 
in inflammatory profiles may be responsible. The results underscore the need to view drug 
metabolism in AKI as distinct from that in ESKD.
Funding: Private Foundation Support
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The Effect of Gut-Derived Uremic Toxins on the Expression of Hepatic 
Drug Metabolizing Enzymes in Chronic Kidney Disease  Thomas Velenosi, 
Alvin Tieu, Andrew S. Kucey, David A. Feere, Brad Urquhart.  Physiology and 
Pharmacology, Univ of Western Ontario, London, ON, Canada.
Background: Hepatic drug metabolism is altered in patients with chronic kidney 
disease (CKD). Previous studies suggest that uremic toxins affect drug metabolizing 
enzymes in CKD. We hypothesize that gut-derived uremic toxins are involved in the 
downregulation of hepatic drug metabolizing enzymes and that removal of gut-derived 
uremic toxins by AST-120 will recover hepatic CYP3A and CYP2C enzyme function and 
expression in rats with CKD.
Methods: Huh7 human hepatoma cells were treated with various uremic toxins as 
well as a cocktail of all uremic toxins. Chronic kidney disease was induced in male Wistar 
rats using 0.5% adenine supplemented into rat chow. Control rats were pair-fed to CKD 
animals. After 5 weeks, control and CKD animals were further divided and received 8% 
AST-120 or a control diet. Rats were sacrificed 8 weeks after initiation of the study and 
plasma and liver tissue were obtained.
Results: Indoxyl sulfate caused a concentration-dependent decrease in Huh7 CYP3A4 
expression with an IC50 value of 179.8 ± 20.1 µM. In CKD rats, gut-derived uremic toxins: 
indoxyl sulfate, p-cresyl sulfate and hippuric acid were significantly increased 4.8-fold, 
11.8-fold and 3-fold; respectively, compared to controls. Animals with CKD treated with 
AST-120 had indoxyl sulfate, p-cresyl sulfate and hippuric acid levels significantly lower 
than CKD animals and similar to control animals. Hepatic CYP3A2 mRNA expression was 
significantly decreased by 90% in rats with CKD (P<0.05); however, rats with CKD given 
AST-120 had a 25% recovery in CYP3A2 mRNA expression. Rats with CKD had decreased 
hepatic CYP2C11 mRNA expression that was not recovered by AST-120.
Conclusions: Uremic concentrations of indoxyl sulfate decreased CYP3A4 mRNA 
expression in Huh7 cells. AST-120 given to rats with CKD reduced indoxyl sulfate, p-cresyl 
sulfate and hippuric acid levels similar to control levels. Hepatic CYP3A2 mRNA expression 
was decreased in CKD and partially recovered by AST-120. AST-120 did not affect the 
downregulation of CYP2C11 in rats with CKD. Therefore, gut-derived uremic toxins may 
partially mediate the downregulation of hepatic CYP3A in CKD.
SA-PO553
The Effect of AST-120 on Hepatic and Intestinal Drug Transporter 
Expression in Chronic Kidney Disease  Andrew S. Kucey,1 Thomas Velenosi,1 
Alvin Tieu,1 Stephanie E. Nevison,1 Brad Urquhart.1,2  1Dept of Physiology 
and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, 
Canada; 2Lawson Health Research Inst, London, ON, Canada.
Background: Chronic kidney disease (CKD) is the progressive decline in renal 
function over time. There is a marked reduction in both renal and non-renal drug clearance 
in CKD. AST-120 is an oral adsorbent that promotes the elimination of gut-derived toxins 
that accumulate in CKD due to impaired clearance. It is hypothesized that there will be 
a reduction in the expression of drug transporters in CKD conditions. AST-120 will help 
recover drug transporter expression in CKD by decreasing uremic toxins that accumulate 
in CKD.
Methods: In vivo: CKD was induced in Wistar rats by treatment with adenine (0.7%) 
in standard rodent chow for 7 weeks. Treatment groups received AST-120 in the final 3 
weeks to decrease the concentration of uremic toxins. Expression of hepatic and intestinal 
transporters were determined by real-time PCR. In vitro: Using the human hepatoma cell 
line Huh7, specific uremic toxins (e.g. indoxyl sulfate, p-cresyl sulfate, CMPF) will be 
tested to see if they directly impair rosuvastatin transport. Rosuvastatin uptake will be 
measured with ultra-performance liquid chromatography coupled to mass spectrometry.
Results: Preliminary results have shown that OATP2 expression is decreased by 
25% in CKD rat livers compared to control. Treatment with AST-120 causes a significant 
reduction in the plasma concentration of the uremic toxins indoxyl sulfate and p-cresyl 
sulfate. AST-120 treatment restores OATP2 expression to control levels.
Conclusions: Decreased hepatic OATP2 expression in CKD will result in reduced 
clearance of substrate drugs. This could lead to toxicity if a lowered dose is not administered. 
On average a CKD patient will be co-prescribed 10 different drugs. Clarifying the impact 
of CKD on drug transporter expression and activity will help guide dosing in this patient 
population.
SA-PO554
Patient Characteristics and Genetics Contribute to Kidney Function After 
Cisplatin Therapy  Cara A. Chang,1 Nickie L. Johnston,1 Madeleine Gomez,1 
Lucas Ellison,1 Lauren Aleksunes,2 Steven R. Kleeberger,3 Daniel Bowles,1 
Cindy L. O’Bryant,1 Melanie S. Joy.1  1Skaggs Schools of Pharmacy and 
Medicine, Univ of Colorado, Aurora, CO; 2Ernest Mario School of Pharmacy, 
Rutgers Univ, NJ; 3NIEHS.
Background: It is known that kidney function can decline after a single dose of 
cisplatin necessitating alternate chemotherapeutic regimens. The current study explored the 
contribution of patient characteristics and polymorphisms in drug metabolism and transport 
genes relevant to cisplatin kidney disposition on changes to renal function.
Methods: Blood (5mL) was obtained from patients (n=206) who received cisplatin. 
Genotyping assessments included candidate SNPs in kidney uptake and efflux transporters 
(SLC22A2, ABCC2, SLC47A1) and metabolism pathways (GSTA1, GSTP1, GGT1). 
Genotyping was performed using QuantStudio multiplex assays and coded [0(wt/wt), 
1(wt/var), or 2(var/var)]. Glomerular filtration rate (GFR, mL/min/1.73m2) and changes 
from pre-cisplatin to the time just prior to the second dose were calculated. Univariate and 
multivariate analyses were performed using patient characteristics and genotyping results.
Results: Patient demographics (mean±sd) included: age 53±14 y, weight 80±20 kg, 
BSA 1.9±0.3, Caucasian 90%, gender (50%M/50%F), and cisplatin dose (65±23 mg/m2). 
Specific patient characteristics that significantly (p<0.05) contributed to a beneficial effect 
on GFR were non-Caucasian race, baseline GFR, and non-fractionated cisplatin dosing. 
Genetic variant in GSTP1/GST pi-1 variant (rs1695) and wildtypes in SLC22A2/OCT2 
(rs2279463 and rs3127573) significantly (p<0.05) contributed to a beneficial effect on 
GFR. Variables retained in the final model (R2 25.25%, P<0.0001) were: Change in GFR 
= 38.983 - 0.1714 (weight) – 0.3685 (baseline GFR) + 5.893 (GSTP1; rs1695).
Conclusions: The results from this study demonstrate the combined role of patient 
characteristics and genetic variants in drug disposition genes on changes to GFR secondary 
to cisplatin. Appropriate risk stratification based on patient characteristics and genetics may 
be used to apply precision medicine to reduce the risk of kidney injury from cisplatin and 
potentially other nephrotoxins.
Funding: NIDDK Support
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Influence of Genetic Variations in Fcγ Receptors (FcgR) and Cytochrome 
P450 (CYP450) Enzymes on Treatment Outcomes in ANCA-Associated 
Vasculitis (AAV)  Divya Indrakanti,1 Rodrigo Cartin-ceba,2 Gary S. Hoffman,3 
Cees Kallenberg,4 Carol Langford,3 Peter A. Merkel,5 Paul Monach,6 Robert 
Spiera,7 E. William St. Clair,8 Ulrich Specks,2 John H. Stone,9 Daniel J. 
Birmingham,1 Brad H. Rovin.1  1The Ohio State Univ Wexner Medical Center, 
Columbus, OH; 2Mayo Clinic and Foundation; 3Cleveland Clinic Foundation; 
4Univ of Groningen, Netherlands; 5Univ of Pennsylvania; 6Boston Univ School 
of Medicine; 7Hospital for Special Surgery; 8Duke Univ Medical Center; 
9Massachusetts General Hospital.
Background: The Rituximab in AAV (RAVE) trial compared rituximab (RTX) to 
cyclophosphamide (CYC) for the treatment of AAV. Using the RAVE cohort we investigated 
whether known single nucleotide polymorphisms (SNPs) in FcgR or CYP450 enzyme genes 
were associated with the response to RTX and CYC treatment, respectively.
Methods: SNPs for FcgR (FcgRIIA 491G>A, FcgRIIB 695T>C, FcgRIIIA 559T>G) 
and CYP450 (CYP2B6 1459 C>T, CYP2C19 681 G>A) were analyzed by direct sequencing 
of PCR-amplified genomic DNA. Each SNP was tested as a predictor of the primary 
outcome, complete remission at 6 months, using logistic regression including the covariates 
baseline BVAS/WG, ANCA type, and new versus relapsing disease. The association of 
these SNPs with the trial’s secondary outcomes, including time to complete remission, 
time to relapse, and time to B-cell reconstitution, were analyzed by Kaplan-Meier and 
Cox proportional hazard ratios.
Results: No significant associations were identified between FcgRIIA, FcgRIIB, 
FcgRIIIA, CYP2B6 or CYP2C19 SNPs and the primary outcome. However, the 491AA 
genotype of FcgRIIA was associated with a shorter time (183± 47 versus 241± 114 days) 
to complete remission (n=52, p<0.001) in the entire cohort.
Conclusions: None of the SNPs tested influenced response to treatment with RTX or 
CYC in AAV. The finding that FcgRIIA 491 G>A was associated with a shorter time to 
complete with both RTX and CYC implies FcgRIIA may be involved in disease pathogenesis 
and response to therapy.
Funding: Pharmaceutical Company Support - Genentech
SA-PO556
The GSTA1 Polymorphism and Cyclophosphamide Therapy Outcomes in 
Lupus Nephritis Patients  Na Hong Wang, Jun Xue.  Nephrology, Nephrology, 
Shanghai, China.
Background: Pulsed low-dose cyclophosphamide (CTX) therapy has become the 
most effective approaches in improving the clinical outcomes of lupus nephritis (LN) 
patients. However, variations in CTX therapeutic outcomes in LN patients are incompletely 
understood.
Methods: We investigated the contributions of known allelic variants in CYP2B6, 
CYP2C19, CYP3A5, GSTA1,GSTP1, ABCC1 and ABCC4 genes to CTX therapy outcomes 
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in LN patients.Pharmacokinetics of CTX and 4-hydroxycyclophosphamide (4OHCTX) 
were obtained from 22 patients randomly enrolled from 77 LN patients and applied to 
explore the mechanism.
Results: GSTA1, one of detoxification enzymes to CTX, gene polymorphism could 
greatly influence the therapeutic outcome to CTX treatment in these 77 LN patients. LN 
patients with a GSTA1*A mutation (CT heterozygous) had a risk of none-response (P 
=0.005). 
Genotype No. of patients response No. of patients none-response P
CYP2B6*4
AA(n=38)
GA/GG(n=39)
33
29
5
10 0.25
CYP2C19
GG(n=31)
GA/AA(n=46)
24
38
7
8 0.57
CYP3A5
GA/AA (n=40)
GG(n=37)
35
27
5
10 0.15
ABCC1/MRP1
CT/TT(n=63)
CC(n=14)
50
12
13
2 0.73
ABCC1/MRP1
GG(n=67)
GT(n=10)
52
10
15
0 0.20
ABCC4/MRP4
GG(n=35)
GT/TT(n=42)
28
34
7
8 1
GSTA1*A
CC(n=59)
CT(n=18)
52
10
7
8 0.005**
GSTA1*B
GG(n=60)
GA/AA(n=17)
50
12
10
5 0.30
GSTP1
AA(n=45)
GA/GG(n=32)
38
24
7
8 0.39
Pharmacokinetics data indicated that patients with a GSTA1*A heterozygous variant 
had a lower exposure to 4OHCTXcompared to wild-type patients (12.8(9.8, 19.5) h*mg/L 
vs.27.5 (18.1, 32.8) h*mg/L, P =0.023), but not CTX. And clinical efficacy was significantly 
related to higher exposure to 4OHCTX, P =0.038).
Conclusions: LN patients with GSTA1*A heterozygous genotypes had poor CTX 
treatment response due to less exposure to activated 4OHCTX. A pharmacogenomic 
approach using the GSTA1 SNP may be useful for predicting clinical efficacy to CTX 
therapy in LN patients, and facilitating individualized therapy.
SA-PO557
Effect of Growth Factors on Bone Mineralization in Health and CKD 
Nadine Khouzam,1 Renata C. Pereira,1 Isidro B. Salusky,1 Richard E. Bowen,2 
Katherine Wesseling-Perry.1  1Pediatrics, David Geffen School of Medicine at 
UCLA, Los Angeles, CA; 2Orthopedic Surgery, David Geffen School of Medicine 
at UCLA, Los Angeles, CA, United Kingdom.
Background: Children with chronic kidney disease (CKD) develop unexplained 
resistance to PTH and GH. Moreover, bone expression of FGF23 is very high in CKD. 
Data suggest that FGF23 may directly suppress osteoblast maturation and mineralization 
in mice (Weng JBMR 2009); however, it is not known whether excess expression of this 
hormone has direct effects on bone cells in CKD. We have previously demonstrated that 
primary osteoblasts isolated from patients with CKD have defects in maturation and 
mineralization, even when removed from the uremic milieu. We thus hypothesized that 
CKD-mediated alterations in osteoblast maturation may contribute to a blunted response 
to growth factors in pediatric CKD.
Methods: Human osteoblasts isolated from 3 patients with CKD and 3 normal controls 
were grown to confluence and induced to mineralize. Cells were treated twice weekly 
with fresh media and 100 nm of PTH, 200ng/mL of IGF1 or 10ng/mL of FGF23 for 0, 
2 and 4 weeks. Cell density and mineralization were assessed by staining parallel wells 
with crystal violet and alizarin red respectively and quantified using spectrophotometry. 
Results were expressed as the mean (+ SE) in optic density. A mixed model was used to 
test differences in proliferation between CKD cells and healthy controls and between 
hormone dosages over time.
Results: Cells from CKD patients mineralized at a slower rate than cells from normal 
controls (p<0.05). The addition of growth factors did not have a significant effect on the 
rate of mineralization for the sample size used.
Conclusions: Diminished mineralization is present in CKD; as previously demonstrated 
in pediatric patients. Further studies are required to assess whether PTH, IGF1 and FGF23 
have an effect on mineralization of human osteoblasts.
SA-PO558
CKD Induces Intrinsic Alterations in Osteoblast Response to 1,25D 
Renata C. Pereira,1 Nadine Khouzam,1 Richard E. Bowen,2 Isidro B. Salusky,2 
Katherine Wesseling-Perry.1  1Pediatrics, David Geffen School of Medicine at 
UCLA, Los Angeles, CA; 2Orthopedics, David Geffen School of Medicine at 
UCLA, Los Angeles, CA.
Background: Skeletal mineralization defects are common in pediatric CKD patients. 
In vivo 1,25(OH)2vitamin D (1,25D), the only currently approved therapy for the treatment 
of 2oHPT in children, fails to normalize skeletal mineralization in these patients. We have 
recently demonstrated that primary osteoblasts obtained from patients with CKD have 
altered proliferation, differentiation and mineralization characteristics, suggesting that 
CKD results in intrinsic changes to osteoblast biology, independent of circulating mineral 
ion and hormone concentrations.
Methods: To evaluate the interaction between CKD and 1,25D therapy on osteoblast 
maturation and mineralization, primary human osteoblasts from 3 healthy controls, 3 
pediatric dialysis patients with low bone turnover (adynamic bone) and 3 pediatric patients 
with high bone turnover (2oHPT) were cultured under pro-mineralizing conditions consisting 
of 10mM β-glycerolphosphate and 100 ug/ml ascorbic acid in the presence of 1,25D at 1, 
10, and 100 nM. After 2, 3, and 4 weeks of growth under mineralizing conditions, cells were 
washed with PBS, fixed with 10% formalin, and stained with2% Alizarin Red S. The amount 
of mineral content was assessed by measuring absorption of acetic acid-extracted Alizarin 
Red S dye (at 405 nm) normalized by live cell concentration (as assessed by absorption 
(at 570 nm) of methanol-extracted Crystal Violet staining obtained from parallel cultures).
Results: 1,25D treatment decreased proliferation and increased mineralization; 
however, high concentrations were required in cells from CKD patients (Figure).
Conclusions: CKD induces osteoblast resistance to 1,25D.
Funding: NIDDK Support, Private Foundation Support
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SA-PO559
Fourier Transform Infrared Spectroscopy Crystallinity Indices in Bone 
from Patients with ADPKD  Renata C. Pereira,1 Berenice Y. Gitomer,2 Isidro 
B. Salusky,1 Diana George,2 Jason W. Stoneback,3 Karen B. King,3 Myles S. 
Wolf,4 Michel Chonchol.2  1Pediatrics, UCLA, Los Angeles, CA; 2Medicine, 
Univ of Colorado, Aurora, CO; 3Orthopaedics, Univ of Colorado, Aurora, CO; 
4Nephrology, Northwestern Univ, Chicago, IL.
Background: We have previously shown that patients with autosomal dominant 
polycystic kidney disease (ADPKD) and normal kidney function have a low bone turnover 
state. This is coupled with increased expression of fibroblast growth factor 23, dentin matrix 
protein 1 and osteopontin in bone compared to healthy controls. To further characterize the 
bone defect in ADPKD fourier transform infrared (FTIR) spectroscopy was undertaken.
Methods: ADPKD patients with an average eGFR 111 ml/min/1.73m2 and normal 
parathyroid hormone levels underwent standard tetracycline double labeling prior to 
transiliac crest bone biopsy. FTIR imaging was performed on bone sections from 6 ADPKD 
patients and 6 age and sex matched healthy historical controls.
Results: The mean (SD) age and eGFR of ADPKD patients were 29±4 yrs and 115 
mL/min/1.73m2, respectively. The sex distribution was 5 males and 1 female. Crystallinity 
a measure of the size of mineral crystals and the degree of order within the crystals was 
obtained by FTIR and differed significantly between ADPKD and control samples. The 
differences were more pronounced in the cortices (1.22 vs. 1.19; p = 0.03) than in the 
trabeculae (1.19 vs. 1.17; p= 0.48). There were no significant differences in heterogeneity 
of crystallinity, mineral/matrix, carbonate/mineral, collagen maturity (cross links) or acid 
phosphate substitution between ADPKD and historical control samples.
Conclusions: We describe for the first time a significant difference in the chemical 
composition of cortical bone measured by FTIR in patients with ADPKD when compared 
to historical control bone samples. Bone crystallinity has been associated with bone strength 
and stiffness, it is thus intriguing to hypothesize that the observed changes may impact bone 
quality and expression of bone proteins in ADPKD. Future studies that also assess bone 
strength and elasticity will be required to more fully investigate bone quality in ADPKD.
Funding: NIDDK Support
SA-PO560
Late Onset Avascular Osteonecrosis in Renal Transplant Recipients 
Spyridon Arampatzis, Anita Maurer, Vasileios Devetzis, Uyen Huynh-do. 
Nephrology, Hypertension and Clinical Pharmacology, Uni. Hospital Bern, 
Inselspital, Bern, Switzerland.
Background: Avascular osteonecrosis (AO) after renal transplantation (RT) is a 
debilitating skeletal complication. In most studies patients with AO presented within the 
first 24 months after RT. In order to determine the prevalence and therapeutic outcome 
of late onset AO (³24 months after RT) we conducted a single-center retrospective study 
based on radiological/histological confirmed cases.
Methods: We conducted a single-center retrospective study among our RTR with a 
clinical diagnosis of AO over the past two decades. We evaluated 70 cases with a AO. In 46 
patients AO was radiological/histological confirmed and all relevant clinical, radiological 
and laboratory data were extracted and analyzed.
Results: The average follow-up time was 14 (±8) years after the first RT. The prevalence 
of AO was 5.4%. Overall, 41 patients showed AO of the femoral head, 23 bilateral AO of 
the femoral head, 5 of the knee and 5 of other locations, while 43 patients were symptomatic 
at time of diagnosis. In our cohort 71% presented late onset (³24 months) AO after RT. 
On average, AO was diagnosed 90 months after RT (SD±78). Furthermore, RTR with late 
onset were younger at the time of first RT (39±15 years, p<0.01) than the ones with early 
onset (53±14). A considerably higher cumulative dose of prednisone was administered to 
patients with late onset of AO prior to their first AO (21±11g vs. early onset 4±1g, p-value 
<0.001) and a higher percentage of late onset RTR received corticosteroids even prior to 
their first RT (48%) compared to the group of early onset (15%; p=0.038). Overall, 34% 
of the patients presented with an advanced stage of AO Ficat III or IV at first diagnosis of 
AO and 57% needed total hip arthroplasty.
Conclusions: Late onset avascular necrosis represent a corticosteroid related 
complication, with a particularly high prevalence among young RTR and is associated 
with significant morbidity. The majority of AO patients have a bilateral manifestation and 
present with advance structural femur failure resulting in hip replacement.
SA-PO561
Indoxyl Sulfate Exacerbates Low Bone Turnover Induced by 
Parathyroidectomy in Rats  Junya Hirata,1 Kazuya Hirai,1 Hirobumi Asai,1 
Masaki Inada,2 Chisato Miyaura,2 Hideyuki Yamato,1 Mie Watanabe-Akanuma.1 
1Kureha Corporation, Tokyo, Japan; 2Tokyo Univ of Agriculture and Technology, 
Tokyo, Japan.
Background: Low-turnover bone disease is one of the bone abnormalities observed 
in chronic kidney disease (CKD) patients and recognized to be associated with low serum 
parathyroid hormone (PTH) level and skeletal resistance to PTH. Indoxyl sulfate (IS) is a 
representative uremic toxin that accumulates in the blood as renal dysfunction progresses 
in CKD patients. In order to examine whether IS exacerbates low bone turnover, we 
produced rats with low bone turnover by parathyroidectomy (PTX) and fed these rats a 
diet containing indole, a precursor of IS, to elevate blood IS level from indole metabolism.
Methods: Male SD rats were underwent PTX. From 2 weeks after PTX, the rats 
were fed a diet containing 0.5% indole (w/w) for 4 weeks. Serum IS levels and bone 
metabolism related markers were examined periodically. After the end of indole treatment, 
histomorphometric analyses in the secondary spongiosa of the femur and measurement of 
bone mineral density of the tibia were performed.
Results: Histomorphometric analyses revealed significant decreases in both bone 
formation-related parameters (mineralized surface/ bone surface, bone formation rate/ bone 
surface) and bone resorption-related parameters (eroded surface/ bone surface, osteoclast 
surface/ bone surface) in PTX rats. In indole-treated PTX rats, further decreases in bone 
formation-related parameters were observed. On the other hand, there were no decreases in 
bone resorption-related parameters in indole-treated PTX rats when compared to the PTX 
rats. Serum IS levels in indole-treated PTX rats were elevated during the indole treatment 
period and the levels were similar to those in CKD and dialysis patients.
Conclusions: IS exacerbates low bone turnover through inhibition of bone formation 
by mechanisms unrelated to skeletal resistance to PTH in rats. Our data suggest that IS 
may be one of the uremic toxins that contribute to progression of low-turnover bone 
disease in patients with CKD or on dialysis whose serum IS levels are elevated because 
of renal dysfunction.
SA-PO562
Changes of Marrow Adipocyte Away from Bone Surface After 
Parathyroidectomy in Patients with Secondary Hyperparathyroidism 
Aiji Yajima, Ken Tsuchiya, Kosaku Nitta.  Medicine, Tokyo Women’s Medical 
Univ, Tokyo, Japan.
Background: We’ve already reported that marrow adipocytes proliferated around 
bone surface after parathyroidectomy for secondary hyperparathyroidism. However, fibrous 
volume was reduced near bone surface where adipocytes proliferated after the surgery. 
In addition, adipocytes may be associated with bone remodeling, because adipocytes 
suppress the function of osteoblasts. Therefore, the parameters of marrow adipocyte, 
which are away from bone surface were histomorphometrically measured before and after 
parathyroidectomy for secondary hyperparathyroidism.
Methods: Sixteen hemodialysis (HD) patients suffering from secondary 
hyperparathyroidism (Age; 58.4 ± 8.4 years, HD duration; 14.3 ± 6.8 years ) were treated 
by total parathyroidectomy with immediate autotransplantation (parathyroidectomy) 
and received iliac bone biopsies before and at 1 week (n=4) and at 4 weeks (n=10) after 
parathyroidectomy. Adipocyte volume per marrow volume (Fa.V/Ma.V;%), adipocyte 
number per marrow volume (N.Fa/Ma.V;N/mm2), and mean adipocyte volume (Fa.V/N.
Fa (×10-3) mm2/N) were obtained in the area away from bone surface. If there are so many 
artifacts in bone marrow, the bone samples were excluded from this research.
Results: Serum intact parathyroid hormone (i-PTH) level was decreased from 1268.8 
± 459.6 to 18.5 ± 7.9 pg/mL. Fa.V/Ma.V was siginificantly increased from 22.4 ± 6.3 to 
30.9 ± 8.1 % (P<0.001), N.Fa/Ma.V was also increased from 183.3 ± 48.1 to 217.7 ± 47.1 
N/mm2 (P<0.001), and Fa.V/N.Fa was not changed (1626.9 ± 418.5 to 1668.7 ± 548.1 (× 
10-3) mm2/N) after parathyroidectomy.
Conclusions: The facts substantiate that an acute reduction of PTH induced an increase 
of adipogenesis. As reported previously, osteoblast surface transiently increased at 1 week 
after parathyroidectomy, but it acutely decreased at 4 weeks after the surgery. Thease findings 
mean that undifferentiated stem cells went to the adipogenesis after the acute reduction of 
PTH in patients receiving HD.
Funding: Private Foundation Support
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Evaluation of Marrow Adiposity in Patients Pre and Post-Kidney 
Transplantation: Comparison Between Bone Histomorphometry 
Mariel Jose Hernandez,1 Luciene dos Reis,2 Igor Marques,2 Fellype C. Barreto,3 
Elias David-Neto,4 Rosa M.A. Moyses,2,5 Ezequiel R. Bellorin-Font,1 Vanda 
Jorgetti.2  1Nephrology Div, Univ Central de Venezuela, Caracas, Venezuela; 
2Nephrology Div, Univ de Sao Paulo, Sao Paulo, Brazil; 3Medical School, 
Pontifícia Univ Católica, Curitiba, Brazil; 4Urology Div, Univ de Sao Paulo, 
Sao Paulo, Brazil; 5UNINOVE.
Background: The osteoblasts (Obs) and adipocytes (Ads) derive from the mesenchymal 
cells (MSCs). An imbalance in the differentiation of Obs and Ads could be decisive to 
preserve the integrity of bone. We analyzed bone histomorphometry and marrow adiposity 
in bone biopsies from patients before and after kidney transplantation (KT).
Methods: We compared biochemical parameters and bone histomorphometry data 
from 23 patients, before and one year after KT, under standard immunosuppressive therapy 
including glucocorticoids. Adipocytes area (Ad.Ar/T.Ar,%), number (N.Ad/B.Pm,n/mm), 
and the ratio adipocytes/active osteoblasts (N.Ad/N.AcOb), and adipocytes/total osteoblasts 
(N.Ad/N.TOb) indexes were measured.
Results: Our patients were young (42.3±2.6 years) and mostly male (14). One year 
after KT, PTH levels (515.6±424.1 vs. 96± 137.1), bone alkaline phosphatase (98.2±63.9 
vs. 37.4± 26.6) and sclerostin (1.1±0.8 vs. 0.5± 0.1) decreased significantly. A significant 
increase in Ad.Ar/T.Ar (24.3±11.6 vs. 30.6±10.5), N.Ad/B.Pm (37.3±20.6 vs. 47.9±25), 
N.Ad/N.AcOb (240.4±657.6 vs. 674.6±1192.4) and N.Ad/N.TOb (128.2±362.3 vs. 
230.5±642.4) and a decreased osteoblast number/tissue area (22.8±21.9 vs. 5.3±2.8) was 
observed. In the post-transplant biopsies significant correlation was found between N.Ad/N.
TOb and PTH (r=-0.48), trabecular number -Tb.N (r=-0.29) and mineral apposition rate 
(r=-0.23); as well as between Ad.Ar/T.Ar and bone volume (r=-0.36) and between N.Ad/B.
Pm and Tb.N (r=-0.72).
Conclusions: KT improved biochemical findings related to bone mineral disease, 
however, this condition is also clearly associated with an inverse relationship of the bone 
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mass and osteogenic cellularity with marrow adiposity, compromising dynamic parameters. 
MSCs differentiation is competitively balanced; mechanisms that promote one cell fate 
actively suppress mechanisms that induce the alternative.
SA-PO564
High Marrow Adiposity Is Associated with Low Turnover Bone Disease in 
Peritoneal Dialysis Patients  Fellype C. Barreto,1 Rodrigo Azevedo de Oliveira,5 
Mariel Jose Hernandez,6 Ana Clara Simões Flórido Almeida,1 Luciene dos 
Reis,2 Aluizio B. Carvalho,3 Vanda Jorgetti,2 Rosa M.A. Moyses.2,4  1Pontificia 
Univ Católica do Paraná; 2Univ de São Paulo; 3Univ Federal de São Paulo; 
4Univ Nove de Julho, UNINOVE; 5Univ Federal do Rio Grande do Norte; 
6Univ de Caracas.
Background: Marrow adiposity has been implicated in the pathogenesis of bone 
disorders, such as osteoporosis and bone fragility. We sought to investigate the relationship 
between marrow adiposity and renal osteodysthrophy in peritoneal dialysis patients.
Methods: We analyzed transiliac bone biopsy specimens from 41 peritoneal dialysis 
patients (age:50.3±10.2 yrs) by quantitative histomorphometry to asses bone and marrow 
adipocyte parameters. Selected biochemical parameters, such as serum markers of bone 
turnover and sclerostin, were measured.
Results: Adipocyte area (Ad.Ar), perimeter (Ad.Pm) and percentage of adipocyte 
volume per marrow volume (Ad.V/Ma.V) correlated positively with age. Diabetic patients 
had higher marrow adiposity than non diabetic patients (Ad.V/Ma.V= 50±14 vs 39±12%; 
P=0.009; Ad.Ar=0.19±0.06 vs 0.15±0.05 mm2;P=0.02). Ad.V/Ma.V demonstrated inverse 
association with bone specific alkaline phosphatase (r= -0.32;P=0.04) and direct relationship 
with sclerostin (r=0.38;P=0.01). No association was found between marrow adiposity and 
dynamic bone hystomorphometric parameters. Interestingly, patients with Ad.V/Ma.V > 
41% (median) presented higher percentage of low turnover bone disease (P=0.04) as well 
as significantly lower bone specific alkaline phosphatase (39.5±27.3 vs 65.3± 28.9 U/L; 
P=0.006) and higher sclerostin (2.3±0.97 vs 1.6±0.97 ng/mL ;P=0.02) levels than patients 
below the median.
Conclusions: Increased marrow adiposity seems to be associated to lower osteoblast 
activity and to low turnover bone disease in peritoneal dialysis patients. The higher marrow 
fat in diabetic and aged patients might expose them to an increased risk for fracture. Further 
studies are required to understand the possible contribution of marrow adiposity to the 
pathogenesis of renal osteodysthrophy.
Funding: Government Support - Non-U.S.
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Role of Wnt10b Signaling in Cinacalcet-Induced Bone Anabolic Effects 
Cai-Mei Zheng,1,2 Yung-Ho Hsu,1,2 Yuh-feng Lin,1,2 Jia-Fwu Shyu,1,3 Kuo-cheng 
Lu.1,4  1Graduate Inst of Clinical Medicine, Taipei Medical Univ, Taipei City, 
Taiwan; 2Dept of Nephrology, Shuang Ho Hospital, New Taipei City, Taiwan; 
3Biology and Anatomy, National Defense Medical Center, Taipei City, Taiwan; 
4Dept of Medicine, Cardinal-Tien Hospital, New Taipei City, Taiwan.
Background: Chronic kidney disease-mineral bone disorders (CKD-MBD) is important 
for osteoporosis and bone fractures in CKD patients. Since calcium receptor plays an 
important role in osteoclast differentiation, we assume that calcimimetic agents(cinacalcet) 
might have a role in bone remodeling.
Methods: Bone marrow mononuclear cells isolated from rat femur and tibia were 
induced into osteoclasts by M-CSF and RANKL treatments. Osteoclasts were treated 
with different doses of cinacalcet. Untreated osteoclasts used as control. The release of 
Clastokine Wnt10b was measured by ELISA and Western blot. Alizarin red staining was 
used to evaluate mineralization of osteoblasts co-cultured with osteoclasts. Fluo-4 AM 
stain was used to determine intracellular calcium changes. Cinacalcet treated and untreated 
CKD animal models (5/6 nephrectomy) were used to analyse the changes in clastokines 
and bone mineral density.
Results: In osteoclasts, cinacalcet decrease the TRAP stain reaction. However, 
ELISA analysis showed increases of Wnt10b expression in supernatant collected from the 
cinacalcet-treated osteoclasts. Pretreatment of Wnt10b secretion inhibitor, C-59, blocked 
the increase of Wnt10b induced by cinacalcet. Western blot analysis showed an increase 
intracellular Wnt10b in the cinacalcet-treated osteoclasts. Culture of osteoblasts with 
the cinacalcet-treated osteoclasts supernatant showed an increase of mineralization as 
indicated by alizarin red staining. Intracellular calcium staining is increased in cinacalcet-
treated osteoclasts, which demonstrated its effect on osteoclast Wnt 10b release is through 
intracellular calcium oscillation. Clastokines and bone mineral density (BMD) changes are 
also noted in CKD rats before and after cinacalcet treatment.
Conclusions: Cinacalcet decrease osteoclastic activity, but increase the secretion 
of Wnt10b through intracellular calcium oscillation. Cinacalcet also related with certain 
clastokine and BMD changes in CKD animals.
SA-PO566
Changes of Osteocyte Number in Micropetrosis Area After Treatment of 
Secondary Hyperparathyroidism  Aiji Yajima, Ken Tsuchiya, Kosaku Nitta. 
Medicine, Tokyo Women’s Medical Univ, Tokyo, Japan.
Background: Osteocyte number decreased after total parathyroidectomy with 
immediate autotransplantation (parathyroidectomy) for secondary hyperparathyroidism 
in hemodialysis (HD) patients (JBMR 2010). Osteocyte number in micropetrosis area 
and in the other area was measured before and after parathyroidectomt and treatment with 
cinacalcet hydrochloride (HCL).
Methods: Thirteen HD patients received parathyroidectomy and transiliac bone 
biopsies before and at 3-9 weeks after parathyroidectomy (Group I). And eight HD 
patients with secondary hyperparathyroidism were treated by cinacalcet HCL and received 
bone biopsies before and at 1 year after the treatment (Group II). Osteocyte number in 
micropetrosis area (N.Ot/Mp.V;N/mm2) and in the other area (N.Ot/(BV-Mp.V);N/mm2) 
were measured before and after the treatment.
Results: Serum intact parathyroid hormone (i-PTH) levels decrease from 1186.5 
± 768.3 to 24.8 ± 8.1 pg/ml after parathyroidectomy. N.Ot/Mp.V was decreased from 
159.8 ± 71.2 to 110.1 ± 87.3 N/mm2 (P<0.001), and N.Ot/(BV-Mp.V) was not changed 
(from 236.1 ± 69.3 to 262.2 ± 79.3 N/mm2 ) after parathyroidectomy (Group I). Serum 
i-PTH levels decrease from 903.6 ± 503.0 to 212.7 ± 98.1 pg/ml after the treatment with 
cinacalcet HCL. N.Ot/Mp.V was not changed in both mictropetrosis area (100.1 ± 68.2 
to 99.6 ± 76.1 N/mm2 ) and in the other area (from 240.1 ± 56.3 to 279.6 ± 88.6 N/mm2 ) 
after the treatment (Group II).
Conclusions: Cinacalcet HCL did not reduce osteocyte number in both micropetrosis 
area and in the other area, suggesting that this agent improves bone quality by maintaining 
osteocytic perilacunar/canalicular system. Parathyroidectomy reduces osteocyte number 
in only the micropetrosis area.
Funding: Private Foundation Support
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Trabecular Bone Score in Kidney Transplant Recipients  Kyla Lynn Naylor,1 
Lisa M. Lix,2 Didier Hans,3 Amit X. Garg,1,4,5 David N. Rush,2 William Leslie.2 
1Western Univ; 2Univ of Manitoba; 3Lausanne Univ Hospital; 4London Health 
Sciences Centre; 5Inst for Clinical Evaluative Sciences.
Background: Kidney transplant recipients have altered bone mineral metabolism and 
are at a higher risk of fracture compared to the general population. There is conflicting 
evidence regarding the ability of bone mineral density (BMD) to accurately predict 
fracture. Trabecular bone score (TBS) is a texture measure derived from dual energy x-ray 
absorptiometry (DXA) lumbar spine images which provides information independent of 
BMD. We assessed TBS in kidney transplant recipients.
Methods: We included 327 kidney transplant recipients from Manitoba, Canada, 
who received a post-transplant DXA (median 106 days post-transplant). We matched 
each kidney transplant recipient (mean age 45 years, 39% men) to three controls from 
the general population (matched on age, sex, and date of DXA). Lumbar spine (L1-L4) 
DXA images were used to derive TBS. Non-traumatic incident fracture (excluding hand, 
foot, and craniofacial) (n=31) were assessed during a mean follow-up of 6.6 years. We 
used logistic regression to determine predictors of TBS and hazard ratios per standard 
deviation decrease in TBS to express the gradient of risk for fracture prediction using Cox 
proportional hazards regression.
Results: Compared to the general population, kidney transplant recipients had a 
significantly lower lumbar spine TBS (1.41 ± 0.13 versus 1.37 ± 0.13, p<0.001). Multiple 
logistic regression revealed reduced TBS (lowest versus highest tertile) in kidney transplant 
recipients compared to the general population (adjusted odds ratio, 2.13 95% confidence 
interval [CI] 1.47-3.07). TBS predicted fractures in kidney transplant recipients independent 
of the Fracture Risk Assessment (FRAX) score and spine BMD (adjusted hazard ratio per 
standard deviation decrease in TBS 1.57, 95% CI 1.07-2.29).
Conclusions: Kidney transplant recipients had abnormal bone texture as assessed 
by TBS. Lumbar spine TBS was able to predict incident fractures in kidney transplant 
recipients and may provide novel insights into skeletal fragility in this unique population.
SA-PO568
Low Bone Turnover Disease Is Prevalent 1 Year After Successful Renal 
Transplantation: A Cross-Sectional Bone Biopsy Study  Pieter Evenepoel,1 
Patrick C. D’Haese,2 Liesbeth Viaene,1 Geert J. Behets.2  1Nephrology, Univ 
Hospitals Leuven, Leuven, Belgium; 2Pathophysiology, Univ of Antwerp, 
Antwerp, Belgium.
Background: Studies evaluating bone histomorphometry in renal transplant recipients 
are scanty and so far hampered by small sample size and heterogeneity.
Methods: We evaluated bone histomorphometry (according to TMV classification), 
laboratory parameters of mineral metabolism (including biPTH, FGF23, sclerostin, 
OPG, sRANKL), biomarkers of bone formation (bsAP) and bone resorption (TRAP5b, 
NTX), and inflammation (IL6) in an unselected cohort of 60 renal transplant recipients 
(44 males, age 56±12 yrs) 1 year after successful transplantation (NCT01886950). 
Standard immunosuppressive regimen consisted of steroids, a calcineurin inhibitor and 
mycophenolate mofetil. Mean cumulative methylprednisolone dose at 1 year was 1.7 g/d.
Results: Sixty-five % of the patients presented with disturbances in at least one 
of the TMV parameters. High, normal and low bone turnover disease were observed 
in 1.7, 45.0, and 53.3 % of renal transplant recipients , respectively. Mineralization 
was delayed in 17.0 % and bone volume was low in 15.0 %. Patients with persistent 
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hypercalcemic hyperparathyroidism (n=4, 7%) showed either low or normal bone turnover. 
Hypophosphatemia was present in 11%. Vitamin D stores were sufficient in 52% (median 
HydroxyvitaminD 32 ng/ml) . Spearman correlation revealed significant correlations 
between bone formation rate and biomarkers of bone formation & resorption (direct: bsAP: 
r0.36, p=0.01; TRAP5b: r0.40, p<0.01; NTX:r0.38, p<0.01) and inflammation (inverse: Il6: 
r-0.51, p<0.001), but not with mineral metabolism hormones (PTH, FGF23, sclerostin).
Conclusions: Low bone turnover disease is the most prevalent bone disease in renal 
transplant recipients 1 year after successful renal transplantation. Additional studies are 
required to clarify underlying pathophysiological mechanisms. PTH, FGF23 and sclerostin 
do not correlate with histomorphometric parameters and circulating biomarkers of bone 
turnover.
SA-PO569
Sclerostin Bone Expression and Blood Levels in Patients with Chronic 
Kidney Disease Stages 2-5  Florence Lima, Marie-Claude M. Faugere, 
Hanna W. Mawad, Hartmut H. Malluche.  Div of Nephrology, Bone & Mineral 
Metabolism, Univ of Kentucky, Lexington, KY.
Background: Sclerostin (Scl) produced by osteocytes (ocy) was found to be increased 
in blood in early stages of CKD patients (pts) with renal osteodystrophy (ROD). The aim 
of this study was to establish when blood scl levels and bone expression are increased and 
how they progress with worsening CKD.
Methods: Fifty pts underwent anterior iliac crest biopsies and blood was drawn at time 
of biopsy. Kidney function was determined by creatinine clearance using MDRD calculation. 
There were: 11 CKD-2, 16 CKD-3, 9 CKD 4-5 pts, and 14 healthy aged-matched controls. 
Scl concentrations in blood were determined by ELISA and scl expression in bone was 
determined in undecalcified bone sections by measuring number of ocy exhibiting positive 
scl immunostaining. Measurements were done separately in cortical and cancellous bone. 
Bone sections were also evaluated by histomorphometry for turnover, mineralization and 
volume.
Results: Blood scl levels were significantly greater in CKD compared to controls with 
no differences between stages (P<0.01). 
Bone scl expression was significantly higher in cortex of CKD 2-5 pts compared to 
controls (P<0.01). Scl expression was significantly greater in cortical than in cancellous bone 
in CKD. In cancellous bone scl expression was higher in CKD; this reached significance 
in CKD-3 (Figure 1). 
Scl expression in cortical and cancellous bone correlated with serum scl (rho=0.30, 0.40, 
rsp; P<0.05). Serum scl correlated negatively with bone formation, activation frequency and 
osteoblast number (rho=-0.33, -0.38, -0.43, rsp; P<0.05). Scl in bone correlated negatively 
with trabecular thickness (rho=-0.51; P<0.05), osteoblast and osteoclast surface, and erosion 
depth (rho=-0.50, -0.52, -0.55, rsp; P<0.01).
Conclusions: These findings ascribe a potential role to scl in the pathogenesis and 
management of ROD.
Funding: NIDDK Support, Private Foundation Support
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Single Timepoint and Longitudinal Serum Sclerostin Levels as Mortality 
Predictors in Prevalent Dialysis Patients  Lotte Lips,1 Camiel L.M. de Roij 
van Zuijdewijn,1 Marc G. Vervloet,1 Peter J. Blankestijn,2 Denis Fouque,4 
Solenne Pelletier,4 Pieter M. Ter Wee,1 Menso Jan Nubé,1 Muriel P. Grooteman.1 
1Nephrology, VU Univ Medical Center, Amsterdam, Netherlands; 2Nephrology, 
Univ Medical Center Utrecht, Utrecht, Netherlands; 3Internal Medicine, 
Maasstad Hospital, Rotterdam, Netherlands; 4Nephrology, Centre Hospitalier 
Univ de Lyon, Pierre Benite, France.
Background: Currently, data are conflicting whether high serum Sclerostin 
(sScl) levels, a 22kDa-sized glycoprotein inhibiting bone formation, are positively or 
negatively associated with mortality. Its concentration may change over time. Therefore, 
we investigated whether longitudinal sScl levels predict mortality better than a single 
measurement.
Methods: A post-hoc analysis on data from the CONTRAST study was performed, 
a RCT comparing online postdilution hemodiafiltration to hemodialysis in prevalent 
dialysis patients. sScl was measured in a subset of patients. Patients were eligible for 
analysis if a baseline (T0) and a 6 months (T6) sScl value were available. Hazard ratios 
(HRs) were calculated within quartiles for sScl level at T0, T6 and for DsScl. All-cause 
mortality was used as end point. As the interaction between dialysis modality and DsScl 
was non-significant (p>0.1), pooled estimates are reported. To correct for multiple testing, 
a two-sided p-value <0.01 was considered statistically significant.
Results: Out of 714 patients, 341 were available for analysis. Baseline characteristics 
between these groups did not differ. Median sScl at T0, T6 and DsScl was 136.3 pmol/L 
(interquartile range [IQR] 98.7-186.1), 134.0 pmol/L (IQR 100.4-183.0) and 0 pmol/L 
(IQR -25 to 15), respectively. sScl values at baseline and T6 were negatively associated 
with mortality (adjusted HRs highest versus lowest quartile 0.49 [95% CI 0.30-0.81] and 
0.48 [95% CI 0.29-0.82], respectively). However, we found no association between DsScl 
and mortality.
Conclusions: A single timepoint sScl is inversely associated with mortality in our 
cohort of dialysis patients. sScl change over a six month period does not predict mortality.
SA-PO571
Variation of PTH and Bone Biomarkers in Hemodialysis Patients 
Pierre Delanaye,1 Xavier Warling,1 Martial Moonen,1 Nicole Simone Smelten,1 
Hans Pottel,2 Jean-marie H. Krzesinski,1 Etienne Cavalier.1  1Univ of Liège, 
Belgium; 2Univ of Leuven, KULAK.
Background: Bone turnover must be monitored in dialysis patients. KDIGO guidelines 
suggest to measure and follow-up both parathormone (PTH) and bone-specific alkaline 
phosphatase (b-ALP). Also underlined by the KDIGO, clinical decision should be based on 
variations (or slopes) (∆, in%) of these biomarkers, more than on isolated concentrations. In 
this work, we studied the correlation between DPTH and ∆ of different bone biomarkers: 
P1NP, CTX, TRAP-5b, osteocalcin and sclerostin. ∆ were studied at different timings, 
namely 6 weeks (T6W), 6 months (T6M) and 1 year (T1Y).
Methods: We have prospectively followed the variations of these biomarkers over one 
year in patients from 3 independent dialysis centers at T6W (n=123), T6M (n=108) and 
T1Y (n=93). We analyzed DPTH with ∆ of bone biomarkers by univariate linear regression. 
We also categorized patients according to variations reaching the critical difference of the 
biomarkers at one year. These results were analyzed by Mantel-Haenszel c² test.
Results: At T6W, a significant correlation was only found between DPTH and ∆CTX 
(r=0.38, p<0.0001). At 6M, a significant correlation was found between DPTH and ∆CTX 
(r=0.38, p<0.0001) and Dosteocalcin (r=0.27, p=0.0049). At T1Y, a significant correlation 
was found between DPTH and ∆CTX (r=0.47, p<0.0001), DP1NP (r=0.4, p<0.0001), Db-
ALP (r=0.29, p=0.0054) and Dosteocalcin (r=0.36, p=0.0004). No correlation was found at 
T1Y neither between DPTH and DTRAP-5b nor Dsclerostin. The same conclusions were 
reached when variations reaching the critical differences were considered. Correlations 
between DPTH and Dbone biomarkers were particularly poor in patients with low PTH 
levels (as defined by the KDIGO) at baseline. Conclusions remained the same if analysis 
was restricted to the 93 patients who completed the study.
Conclusions: A concordance between variations of PTH on one hand and variations 
of CTX, b-ALP, osteoclacin and P1NP on the other hand can be observed in dialysis 
patients, but only after a long follow-up (at least one year). Variation of bone biomarkers 
need repeated measures and must not be analyzed on a too short period.
SA-PO572
Intereukin-1 Inhibition, Chronic Kidney Disease-Mineral and Bone 
Disorder (CKD-MBD), and Physical Function  Kristen L. Nowak,1 Adriana 
Hung,2,3 Talat Alp Ikizler,2 Heather Farmer,1 Natjalie Salas,2 Rafia I. Chaudhry,2 
Andrew N. Hoofnagle,4 Gerard John Smits,1 Michel Chonchol.1  1Univ of 
Colorado Denver; 2Vanderbilt Univ; 3VA Tennessee Valley Healthcare System; 
4Univ of Washington.
Background: Epidemiologic studies have suggested a possible link of chronic 
systemic inflammation with vitamin D deficiency, intact parathyroid hormone (iPTH), and 
fibroblast growth factor 23 (FGF23) excess, which are a central features of CKD-MBD. 
Declining renal function is also associated with worsening physical function, which may be 
explained by systemic inflammation, CKD-MBD, or both. We hypothesized that inhibiting 
inflammation with an interleukin-1 (IL-1) trap would improve vitamin D deficiency, iPTH 
and FGF23 excess, as well as physical function in patients with moderate-to-severe CKD.
Methods: In a two-site, double-blind trial, 42 patients with stage 3-4 CKD were 
randomized to receive either the IL-1 trap rilonacept (160 mg/week) or placebo for 12 weeks. 
The following CKD-MBD markers were assessed in serum before and after the intervention: 
calcium, phosphorus, 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D 
(1,25(OH)2D), iPTH, and iFGF23. A battery of tests was also administered in a sub-group 
(n=22) to assess multiple domains of physical function (endurance, locomotion, dexterity, 
balance, strength, and fatigue).
Results: Participants were 63±11 years of age, 24% female, 29% Hispanic, mean 
eGFR 38±13 ml/min/1.73m2, and mean high sensitivity C-reactive protein (hsCRP) 4.7±4.2 
mg/L. Rilonacept effectively reduced systemic inflammation, as evidenced by reduced 
hsCRP levels (p<0.01). There was no change in serum calcium, phosphorus, 25(OH)D, 
1,25(OH)2D, iPTH, or FGF23 levels (p³0.41) with IL-1 inhibition. Similarly, rilonacept did 
not alter locomotion, dexterity, balance, strength, or fatigue (p³0.22 ). However, endurance 
(400m walk time) tended to be reduced in the rilonacept (-29 sec) as compared to placebo 
(-6 sec; p=0.059).
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Conclusions: 12 weeks of IL-1 inhibition did not improve circulating markers of 
CKD-MBD or physical function (although it tended to improve endurance). These results 
support that inflammation does not directly mediate CKD-MBD or select domains of 
physical function.
Funding: Veterans Administration Support, Pharmaceutical Company Support - 
Regeneron Pharmaceuticals, Inc., Private Foundation Support
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Serum Metabolomic Profiling and CKD-MBD: A New Tool for Bone 
Turnover Evaluation  Aline Lourenco Baptista,1 Kallyandra Padilha,2 Pamella 
Araujo Malagrino,2 Gabriela Venturini,2 Ana Carolina de Mattos Zeri,3 Janaina 
Silva Martins,4 Rodrigo Azevedo de Oliveira,5 Geuza Dutra,6 Luciene dos Reis,1 
Vanda Jorgetti,1 Alexandre Costa Pereira,2 Rosa M.A. Moyses.1,6  1Nephrology, 
USP; 2Molecular Cardiology, INCOR, USP; 3LNBio, CNPEM; 4UEM; 5UFRN; 
6Master Degree Program, UNINOVE, Brazil.
Background: Bone biopsy still is the gold standard to assess bone turnover in CKD 
patients and serum biomarkers are not able to replace histomorphometry. Recently, 
metabolomics has emerged as a new technique that could potentially improve disease 
diagnoses and the understanding of pathophysiology. However, as this approach has never 
been tested in the CKD-MBD scenario we investigated whether a serum metabolomic 
profile could help us to better predict bone turnover in CKD patients.
Methods: Serum and bone histomorphometry data from hemodialysis (HD, n=51) and 
peritoneal dialysis patients (PD, n=40) were analyzed. They were classified as high (HT, 
49.4%) or low turnover (LT). Metabolomic analysis was done through MRI spectroscopy, 
followed by identification and quantification of metabolites and PLS-DA. As HD had a 
completely different metabolome of PD group, we analyzed them separately. In addition, 
we selected the main metabolites found in each group and searched for the metabolic 
pathways involved.
Results: The difference between LT and HT was explained by 12 metabolites in HD and 
8 in PD (p = 0.03 and 0.01, respectively). ROC curve analysis showed that parathormone 
and alkaline phosphatase were the best predictors for HT, whereas glycerol and glucose 
were the best predictors for LT in HD and PD, respectively. The main canonical pathways 
involved were glycine degradation, tyrosine biosynthesis IV and phenylalanine degradation 
I in HD and creatine-phosphate biosynthesis, pyruvate fermentation to lactate and AMPK 
signaling in PD group.
Conclusions: In this preliminary analysis, we identified new metabolites that might 
be used as biomarkers of bone turnover. Moreover, the differences in metabolome 
between the two dialysis modalities and the different metabolic pathways suggest that 
the pathophysiological mechanisms involved in the modulation of bone turnover in these 
patients might be different.
Funding: Government Support - Non-U.S.
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Deletion of the Gene Encoding the Transient Receptor Potential Canonical 
Type 1 (TRPC1) Channel Produces Hyperparathyroidism, Low Calcitonin 
(CaT), Hypercalcemia, but Hypocalciuria and Enhanced Bone Mass: 
Evidence for the Role of TRPC1 in Regulating Intracellular Ca ([Ca2+]i]) 
in Target Cells  Bonnie Eby,1 Alexander Lau,1 Lindsay J. Barron,1 Marybeth 
Humphrey,1 Leonidas Tsiokas,2 Kai Lau.1,3  1Medicine, Univ of Oklahoma, 
Oklahoma City, OK; 2Cell Biology, Univ of Oklahoma, Oklahoma City, OK; 
3Medicine, VA Medical Center, Oklahoma City, OK.
Background: We recently showed that TRPC1 deficiency impairs store-operated 
Ca entry (SOCE), reduces [Ca2+]i], stimulates PTH and causes hypercalcemia. We here 
evaluated the potential mechanism & consequence.
Methods: We studied male TRPC1 wild-type & null mice by metabolic, clearance 
(Cl), & micro-CT techniqes. PTH, 1,25 di(OH) vit D (1, 25 D), & CaT were measured by 
mouse ELISA. We analyzed Ca & P (by published methods) & creatinine (Cre) by HPLC.
Results: Hypercalcemia in null mice emerged at 2 mon & lasted through 21 mon, 
when last checked. Serum Ca was high in fed & fasted null mice (10.1 vs. 9.4 mg%), 
excluding gut hyperabsorption. In pg/ml, [PTH] was higher in the null (598 vs. 402), [1,25 
D] (301 vs. 308) similar & CaT lower (2.2 vs 2.8). P (6.6 vs. 6.5 mg%) was similar. At 7 
mon, femur (105 vs. 84 mg) & hind limb (189 vs. 151 mg) were heavier, but the latter was 
shorter (34.5 vs. 35.7 mm), implying higher bone density in the null. Urine Ca (1.2 vs 2.2 
mg/d), CaCl (14 vs. 26 ml/min) & urine Ca:Cre (1.8 vs. 3.1) were reduced. At 16 mon, urine 
OH-proline, absolute (400 vs. 734 mg/d) or ratioed to Cre (0.54 vs 0.96), was reduced. At 
19 mon, on micro-CT, proximal tibia of null mice had 80 % more bone volume to tissue 
volume, 37% more trabecular number, 25 % less trabecular spacing, & 3-fold increase in 
trabecular connectivity density.
Conclusions: 1. TRPC1 deficiency impairs SOCE, reduces [Ca2+]i, stimulates PTH, and 
inhibits calcitonin in their respective glands, producing hypercalcemia independent of 1,25 
D or P. 2. Lack of TRPC1 channels produces hypocalciuria in the kidney & reduced bone 
resoprtion and skeletal PTH resistance in osteoclasts. 3. Our data support the critical role of 
TRPC1 channels in regulating [Ca2+]i in the many cells where it is ubiquitously expressed.
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Role of the Sodium/Calcium Exchanger NCX1 in Osteoclasts 
Giuseppe Albano,1,3,4 Candice Stoudmann,2,4 Willy Hofstetter,3 Olivier 
Bonny,2,4 Daniel G. Fuster.1,3,4  1Div of Nephrology, Hypertension and Clinical 
Pharmacology, Univ of Bern, Bern, Switzerland; 2Inst of Pharmacology and 
Toxicology, Univ of Lausanne, Lausanne, Switzerland; 3Dept of Clinial Research, 
Univ of Bern, Bern, Switzerland; 4NCCR Kidney.CH, Univ of Zürich, Zürich, 
Switzerland.
Background: Previous studies demonstrated that inhibition or siRNA-mediated knock-
down of sodium/calcium exchanger 1 (NCX1) in osteoclasts decreases bone resorption in 
vitro, indicating a critical role of NCX1 in osteoclast-mediated bone resorption.
Methods: To test the role of NCX1 in osteoclasts in vivo, we generated mice with 
osteoclast-specific deletion of NCX1 (NCX1DOC/DOC). For this purpose, mice with a floxed 
exon 11 of NCX1 were crossed with mice expressing Cre-recombinase under the influence 
of the osteoclast specific cathepsin K promoter.
Results: Osteoclasts differentiated from NCX1DOC/DOC mice displayed an 80-90 % 
reduction of NCX1 protein compared to wild-type mice. NCX1 expression was unaltered 
in extraosseus tissues in NCX1DOC/DOC mice. NCX2 and NCX3 were present at low levels 
in wild-type osteoclasts and not upregulated in NCX1DOC/DOC osteoclasts. In vitro RANKL 
stimulation of bone marrow cells isolated from wild-type and NCX1DOC/DOC mice yielded 
no differences in osteoclast development and resorptive activity. In addition, at 3 months 
of age, structural parameters of bone, quantified by high-resolution microcomputed 
tomography, were not different in NCX1DOC/DOC mice compared to wild-type littermates. To 
stimulate osteoclast-mediated bone resorption, we performed surgical ovarectomy (OVX) 
in 12 week old female mice, but OVX-induced bone loss over 12 weeks was similar in 
WT and NCX1DOC/DOC mice. 
Interestingly, however, at 6 months of age, female NCX1DOC/DOC mice had significantly 
higher bone volume whereas male NCX1DOC/DOC mice displayed reduced bone volume 
compared to wild-type mice.
Conclusions: Our data indicate that genetically induced deficiency of NCX1 in 
osteoclast-precursors and mature osteoclasts does not affect osteoclast differentiation and 
bone resorption in vitro. However, NCX1DOC/DOC mice display an age- and sex-specific 
phenotype. Additional studies are needed to unveil the underlying mechanisms.
Funding: Government Support - Non-U.S.
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The Impact of a Previously Created AV-Fistula on Radial Bone Mineral 
Density Measurements in Renal Transplant Recipients  Spyridon Arampatzis, 
Vasileios Devetzis, Uyen Huynh-do.  Neprhrology, Hypertension and Clinical 
Pharmacology, Uni. Hospital of Bern, Inselspital, Bern, Switzerland.
Background: The arteriovenous-fistula (AVF) of the distal radius often remain patent 
after transplantation. Distal radius is the typical site for peripheral DXA measurements in 
renal transplant recipients (RTR). Since no data exist concerning the impact of a previously 
created AVF on peripheral bone characteristics in RTR we evaluated the effect of AVF on 
bone mineral density (BMD) as mirrored by contralateral differences between forearms 
and explored the densitometric correlation of distal radius with the tibia as an alternative 
peripheral measurement site.
Methods: This cross sectional study included 40 renal transplant recipients (RTR) and 
40 chronic kidney disease (CKD) patients matched for age, gender and BMI. In addition to 
relevant demographic, biochemical and clinical aspects we assessed bone characteristics 
of both forearms, femoral neck and tibia by DXA.
Results: The CKD patients without any AVF, displayed no significant discrepancies 
concerning BMD in both forearms. In RTR BMD was significantly lower in the AVF 
forearm in comparison to the contralateral non AVF forearm. This observation was evident 
at all measured subregions of the AVF radius sides, i.e. at the 1/3 radius (0.710±0.103 vs. 
0.727±0.104, p=0.003), ultradistal radius (0.424±0.085 vs. 0.444±0.080, p=0.007) and 
total radius (0.571±0.090 vs. 0.589±0.090, p=0.001) as well. This significant side-to-side 
difference was 7.5% at the 1/3 radius, 7.2% at the total radius, and 7.0% at the ultradistal 
radius, respectively. The BMD intersite analysis between radius and distal tibial showed 
a strong and highly significant correlation (r= 0.7346-0.875) between corresponding 
peripheral sites.
Conclusions: In conclusion, a previously placed AVF in RTR exerts a negative impact 
on the ipsilateral radius resulting in significant side-to-side BMD differences. A strong 
densitometric association exist between peripheral sites and thus DXA measurements at 
the tibia can be considered as a valuable alternative site to radius. Longitudinal studies are 
needed in order to replicated these findings by incorporating methods with higher bone 
density definition.
SA-PO577
Cortical Bone Analysis in Pre-Dialysis Patients: A Comparison with 
a Dialysis Population  Catarina Carvalho,1 Juliana Magalhães,1 Ricardo 
Neto,1 Luciano Pereira,1 Teresa Adragao,2 Joao M. Frazao.1  1Nephrology 
and Infectiology Research and Development Group, INEB, Porto, Portugal; 
2Nephrology, Hospital Santa Cruz, Lisboa, Portugal.
Background: ROD presents early in CKD pts. Bone biopsy is the gold-standard 
diagnostic tool. Cortical bone represents 80% of human bone and is the major determinant 
of bone strength.
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Methods: We evaluated cortical bone histomorphometry in 13 CKD stage 3 and 4 pts, (9 
male, age 65.1±10.4, eGFR 23.3±8.3ml/min/m2, who underwent trans-iliac bone biopsy and 
compared them to 13 dialysis pts (9 male, 11 on HD, age 52.15±10.2, 55.3±17.6 mo in RRT).
Results: Biochemical values and external cortical bone parameters of both groups 
shown in table 
Pre-dialysis Dialysis p value
PTHi (pg/ml) 157.8±85.9 283.2±187.5 0.038
Ca (mg/dL) 9.6±0.4 9.0±0.6 0.009
Pi (mg/dL) 3.6±0.8 4.8±2.2 0.087
External Cortical
Po (%) 12.5±7.9 12.6±6.6 0.973
CtTh (ȝm) 635.6±323.2 384.6±170.5 0.023
OnMS/BS (%) 3.0±5.6 4.1±4.3 0.593
OnBFR/BS (ȝm3/ȝm2/y) 1.8±2.4 15.0±15.4 0.025
OnOS/BS (%) 23.5±9.4 26.2±10.0 0.506
OnES/BS (%) 9.2±4.5 7.0±8.8 0.463
OnOTh (ȝm) 6.8±2.3 9.9±5.0 0.067
OnAjAR (ȝm3/ȝm2/day) 0.02±0.03 0.15±0.15 0.023
Dialysis pts compared to the pre-dialysis population showed more deranged cortical 
bone, with decreased cortical thickness, increased osteonal bone formation rate and 
adjusted apposition rate. In this pre-dialysis population, external cortical porosity positively 
correlated with both trabecular bone volume and osteoid volume (respectively, r=0.70 and 
0.76, p=0.016 and p=0.006). External cortical osteonal BFR correlated negatively with 
S-calcium (r=-0.88, p=0.021) and positively with trabecular thickness (r=0.88, p=0.021). 
These findings were not observed in internal cortical suggesting that this is more stable 
to PTH effects.
Conclusions: In pre-dialysis pts, our findings support that PTH has a modulating effect 
on both trabecular and cortical bone. As renal disease progresses cortical thinning is more 
pronounced, eventually contributing to the higher fracture rate. Understanding cortical 
abnormalities may have implications in the treatment of CKD-MBD.
SA-PO578
Chronic Kidney Disease Severity Is Independently Associated with 
Deficient Bone Mineralization, Hip Fracture and Post-Fracture Mortality 
Farsad Afshinnia,1 Robert J. Ackermann,1 Ka kit Wong,1 Baskaran Sundaram,2 
Panduranga S. Rao,1 Subramaniam Pennathur.1  1Univ of Michigan; 2Thomas 
Jefferson Univ.
Background: While decreased bone mineral density (BMD) is associated with fracture 
in non-chronic kidney disease (CKD) subjects, its utility in CKD has been questioned 
because of associated renal osteodystrophy. In this study, we aim (a) to estimate prevalence 
of decreased BMD by CKD severity in a large tertiary care academic medical center (b) 
test whether CKD severity is independently associated with hip fracture and decreased hip 
BMD, and (c) ascertain if CKD increases mortality following hip fracture.
Methods: This study is a retrospective cohort of 25109 patients with bone densitometry, 
clinical and lab values from 2001 to 2013 at the University of Michigan. Deficient 
mineralization (DM) is defined as BMD£2.5 standard deviation (SD) below the mean 
peak bone mass of young, healthy adults. Clinical outcomes are all-cause mortality and 
hip fracture. Logistic regression was used to assess the risk associated with fracture. Cox 
survival model was used to assess risk of all-cause mortality by stage of CKD in hip fracture.
Results: Mean age was 61 years (SD=14). There were 4700 males (18.7%) and 23215 
(92.5%) were Caucasian. There were 20507, 4226, 293, and 83 patients with eGFR≥60, 
30-59, 15-29, and <15 mL/min, respectively. There was a graded increase in prevalence 
of DM at total hip from 6.4% in eGFR≥60 to 27.7% in eGFR<15 mL/min (P<0.001). Hip 
fracture was observed in 544 patients of which 122 (22.4%) died during follow up. Hip 
fracture ranged from 1.9% in eGFR≥60 to 9.6% in eGFR<15 mL/min (P<0.001). CKD 
stage 4 and 5 was independently associated with 2.2 folds higher odds of DM (95% CI: 
1.6-3.0, P<0.001) and 1.7 folds higher odds of hip fracture (95% CI: 1.0%-2.7%, P=0.044) 
as compared to eGFR≥60. In an age and co-morbidity adjusted Cox model, risk of mortality 
following hip fracture was 6.5-fold (95% CI: 1.8-23.3, P=0.004) higher in eGFR<15 
compared to eGFR>60 mL/min.
Conclusions: This study highlights utility of BMD to predict fracture in CKD, 
underscores the burden of DM on outcomes, and reveals independent higher mortality 
after hip fracture in end stage kidney disease.
SA-PO579
Chronic Hyponatremia Is a Novel Risk Factor for Hip Fracture in Chronic 
Kidney Disease-Mineral Bone Disease  Sagar U. Nigwekar,1 Andrew S. 
Allegretti,1 Julia Beth Wenger,1 Juan Carlos Ayus,2 Ravi I. Thadhani,1 Ishir Bhan.1 
1Massachusetts General Hospital; 2Renal Consultants of Houston.
Background: Risk factors that make skeleton more fragile in chronic kidney disease 
(CKD) are uncertain. Considering recently reported direct effects of sodium depletion on 
bone health, we investigated chronic persistent hyponatremia (CPH) as a novel risk factor 
for hip fractures caused by CKD-mineral bone disease (CKD-MBD).
Methods: Cases for this multi-center case-control study were elderly (>65 years) 
patients with CKD (eGFR <60 ml/min) with a new hip fracture. Controls (CKD patients 
with no hip fracture) were matched to cases on age, sex, race and comparative health. 
Primary exposure was serum sodium <135 mEq/L on at least 2 occasions ≥ 90 days apart 
within one year preceding hip fracture for cases and within the first year of study entry for 
controls (CPH90). Secondary exposure definitions were hyponatremia on at least 1 occasion 
(H1) and hyponatremia on at least 2 occasions ≥ 180 days apart (CPH180). Variables for 
multivariable logistic regression analyses were identified using stepwise selection.
Results: We analyzed 1,236 cases and 4,515 controls. Mean age of all patients was 84 
± 9 years, 87% were whites, and 39% were females. Serum calcium, phosphate, parathyroid 
hormone and 25-hydroxy vitamin D levels were similar between cases and controls. 
Prevalence of CPH90 (21.2 vs. 9.9%, P<0.001), CPH180 (15.5 vs. 6.5%, P<0.001) and H1 
(52.7 vs. 41.1%, P<0.001) were higher in cases compared to controls. In analyses adjusted 
for falls, tobacco use, osteoporosis, eGFR, body mass index, heart failure and medications, 
CPH90 and CPH180 were associated with increased risk of hip fracture but H1 was not.
Conclusions: CPH is a risk factor for hip fractures caused by CKD-MBD. Mechanistic 
studies are needed to investigate the effects of CPH on bone turnover, mineralization and 
volume in CKD.
Funding: Private Foundation Support
SA-PO580
Follicle Stimulating Hormone Is Associated with Low Bone Mineral Density 
in Women in Hemodialysis  Priscila Preciado, Enrique Rojas-Campos, Alfonso 
M. Cueto-Manzano, Benjamin Gomez-Navarro.  Unidad Investigación Médica 
en Enfermedades Renales, IMSS, Guadalajara, Jalisco, Mexico.
Background: CKD-BMD associated to sexual hormonal status have not been well 
evaluated. Aim:Assess the association between female hormones (FSH and estradiol) and 
bone mineral density (BMD) in women in hemodialysis (HD).
Methods: Cross-sectional study in 46 women (20-60 years), at least 3 months in HD 
in a tertiary care setting between Jan-Jul 2014. Pregnant patients or with steroid medication 
were excluded. Physical examination and blood markers of sexual hormonal and mineral-
bone status were done. A bone densitometry of lumbar spine and non-dominant femur was 
performed; the results were classified as normal, osteopenia and osteoporosis.
Results: 5 had osteoporosis and 5 had osteopenia in the lumbar spine. In the femur, 
2 had osteoporosis and 18 had osteopenia. Comparisons are shown in Table. BMD in 
lumbar spine was associated to FSH (R2 0.27; P<0.0001), FSH (OR -0.52 [-0.02 - -0.008]; 
p<0.0001), on the other hand BMD in femur (R2 0.30; p =0.001), FSH (OR -0.34 [-0.01 - 
-0.001]; p=0.02), and CRP were significantly associated (OR -0.32 [-0.02 - -0.001]; P=0.03) 
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L1 – L4 Normal (N 36) Abnormal (N 10) p value 
Age (years) 30 ± 8 44 ± 12 <0.0001
Phosphorus (mg/dl) 5.9(4.9-7.7) 5.6 (5.3-5.9) 0.53
Calcium (mg/dl) 9.1 (8.0-9.6) 9.3 (9.0-9.6) 0.40
Alkaline phosphatase (U/l) 233 (121-435) 131 (93-232) 0.16
PTHi (pg/ml) 795 (446-1064) 164 (112-456) 0.001
Estradiol (pg/ml) 114 (79-244.4) 71 (54 -98) 0.03
FSH (pg/ml) 4.8 (4-8.5) 66.07 (7.3-136.4) 0.001
C Reactive protein (mg/l) 4.0 (3-9.4) 6.3 (3.0-33.3) 0.62
FEMUR Normal (26) Abnormal (20) p value
Age (years) 31.0 ± 8.4 35.7 ± 12.6 0.18
Phosphorus (mg/dl) 6.2 (4.87-7.7) 5.4 (5.24-6.3) 0.29
Calcium (mg/dl) 8.9 (8-9.4) 9.4 (9-9.62) 0.03
Alkaline phosphatase (U/l) 163 (97-316) 223.5 (109-509) 0.38
PTHi (pg/ml) 756 (349-958) 591 (166-1011) 0.67
Estradiol (pg/ml) 133.9 (92.2-244.4) 82.6 (57.4-178.8) 0.14
FSH (pg/ml) 4.78 (4.03-9.13) 7.01 (4.46-5.50) 0.20
C Reactive protein (mg/l) 3.1 (3-7.0) 7.8 (3-32.1) 0.02
Conclusions: In women in HD, the higher levels of FSH predicts lower BMD in 
the lumbar spine, while in the femoral region higher FSH and CRP predicts lower BMD.
SA-PO581
Time Averaged Intact Parathyroid Hormone Concentration as a Risk Factor 
For Hip Fractures in Patients on Dialysis  Steven Fishbane,1 Azzour Hazzan,1 
Kenar D. Jhaveri,1 Lin Ma,2 Eduardo K. Lacson.2  1Div of Nephrology, Hofstra 
North Shore-LIJ School of Medicine, Great Neck, NY; 2Fresenius Medical Care, 
North America, Waltham, MA.
Background: Recent studies found the incidence of hip fractures has increased greatly 
in patients on dialysis. Most of the increase occurred in patients with characteristics typical 
of bone frailty, where oversuppression of intact parathyroid hormone (iPTH) could be 
harmful. Since recent studies have not addressed clinical risk factors, we studied time-
averaged iPTH as a risk factor for hip fractures.
Methods: 142,407 prevalent patients of Fresenius Medical Care had hip fractures 
identified by ICD-9 codes. Four cohorts were constructed: observation periods 2001-2003, 
2004-2006, 2007-2009, 2010-2012. For each, the prior year was used to measure exposure. 
Risks for fractures were analyzed for each cohort and for the combined cohorts. Three 
models for risk adjustment were created: Case Mix CM-adjusted: age, gender, race, dialysis 
vintage, and diabetic status, CM+Lab adjusted and CM+Lab+Med adjusted.
Results: For the combined cohorts, unadjusted analyses indicated higher hip fracture 
risk with with lower iPTH (p<0.0001), lower calcium (p=0.003), lower phosphate 
(p<0.0001) and lower IV vitamin D (p<0.0001). In the fully adjusted model the two lowest 
iPTH quartiles were significantly associated with greater risk of fractures (HR 1.2, 95% 
CI 1.01-1.44, p=0.03 for lowest quartile, iPTH < 181 pg/ml). Similarly the lowest quartile 
for calcium was associated with greater risk (< 8.7 mg/dl, HR 1.00-1.37, p=0.04). Serum 
phosphate and iv vitamin D were no longer associated with risk in the fully adjusted model.
Conclusions: In conclusion, we found that that lower time-averaged iPTH and calcium 
were associated with a greater risk for hip fracture in dialysis patients.
Funding: Clinical Revenue Support
SA-PO582
The Discriminative Ability of Three Fracture Risk Assessment Tools in 
Hemodiaylysis Patients  Ying Qian, An jin Chang, Xiaonong Chen, Nan Chen. 
Dept of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiaotong Univ School 
of Medicine, Shanghai, China.
Background: The present study aimed to explore factors associated with fractures 
among hemodialysis patients, and assess the ability of the World Health Organization’s 
fracture risk assessment tool (FRAX) compared with bone mineral density (BMD) and 
OSTA to discriminate fracture status.
Methods: We enrolled 118 hemodialysis patients in this cross-sectional study. 
Parameters including serum calcium, phosphate, intact parathyroid hormone, 25 hydroxy 
vitamin D, alkaline phosphatase were analyzed. Clinical characteristics were also collected. 
BMD values were tested using dual-energy X-ray absorptiometry at the lumbar spine and 
hip region. OSTA and FRAX scores were calculated using formula or through the FRAX 
website. Factors associated with fractures were examined. Discriminative ability of BMD, 
OSTA and FRAX (non-BMD model and BMD model) in fracture status was assessed with 
receiver operator characteristic curves (ROC) analysis.
Results: There were 16 (13.56%) fractures in 118 hemodialysis patients. Patients 
with fractures were significantly older and more osteoporosis. All BMD parameters at 
hip region (including femoral neck, femoral shaft, and total hip) were notably lower in 
fracture group than in non-fracture group ( 0.74 (0.65~0.87) vs 0.82 (0.74~0.96); 0.88 
(0.77~1.01) vs 0.99 (0.86~1.14); 0.80 (0.66~0.88) vs 0.88 (0.78~1.00)). There was no 
difference in clinical characteristics or blood biochemistry levels between the two groups. 
Areas under ROC curves of BMD, OSTA, FRAX1 (non-BMD model) and FRAX2 (BMD 
model) were 0.692 (95% CI: 0.600 to 0.774 ), 0.654 ( 95% CI: 0.561 to 0.739 ), 0.917 
(95% CI:0.851 to 0.960), and 0.851 (95% CI:0.773 to 0.910), respectively. Either FRAX1 
or FRAX2 performed better than BMD and OSTA at identifying patients with fractures (P 
< 0.05). But FRAX2 performed no better than FRAX1 (P>0.05). The best cutoff values 
were 0.91, -3, 7.2%, 3.4%.
Conclusions: Among hemodialysis patients, age and BMD at hip are associated with 
fracture. FRAX performs better than BMD and OSTA in discriminating fracture status, 
suggesting its usefulness of fracture risk prediction in hemodialysis patients.
Funding: Government Support - Non-U.S.
SA-PO583
Teriparatide for Low Bone Mass in Hemodialysis Patients  Rikako Hiramatsu, 
Yoshifumi Ubara, Junichi Hoshino, Kenmei Takaichi.  Nephrology Center, 
Toranomon Hospital, Tokyo, Japan.
Background: Fracture rates in dialysis patients are extremely higher than general 
population. Recently the prevalence of low turnover has greatly increased in dialysis 
population. Teriparatide would be also beneficial for low turnover dialysis patients with low 
bone mass. However, there have been only a few reports describing the use of teriparatide 
in dialysis patients.
Methods: Design This was a prospective, single-center, observational study. 
Hemodialysis patients with low iPTH ( iPTH<60 pg/mL) coexisting low bone mass 
determined by lumbar spine (LS) or /and femoral neck (FN) T-score<-2.5 with DXA 
were eligible and subcutaneous recombinant human PTH1-34 (20 µg teriparatide; Forteo) 
was injected 3 times per week at the end of each hemodialysis sessions. We analyzed 
the following parameters, including serum Ca, P, albumin, ALP, iPTH and bone 
metabolic makers including iP1NP, BAP, OC, and TRACP-5b at baseline and following 
teriparatide. BMD at LS and FN were measured at baseline, 6, 18 months after treatment. 
Pharmacokinetics After the of 24 th administration of teriparatide, we measured the serum 
teriparatide acetate concentrations.
Results: Five patients (median age; 72 yeas old,median hemodialysis periods; 24 
years) were included.After teriparatide injection, BMD of LS as well as FN at 6 months 
significantly increased from 0.67±0.18 to 0.68±0.19 g/cm2 and from 0.44±0.08 to 0.48±0.07 
g/cm2 , respectively. Corrected Ca levels significantly decreased at 3 and 6 months with 
increases in endogenous iPTH in response to lowering of serum Ca. As for bone metabolic 
markers, percent changes of serum BAP and serum iP1NP levels significantly increased 
at 3 and 6 months. Conversely, serum TRACP-5b decreased after injection. Throughout 
this study, there were no fractures. Pharmacokinetics result is shown in Figure 1. There 
was a peak at 30 minutes at 157.2 pg/mL, and then it rapidly decreased to undetectable 
level at 240 minutes.
Conclusions: In conclusion, treatment with teriparatide, the dose was 20 µg 3 times/
week, which is smaller than the suggested dose for non dialysis patients, led to increase 
of BMD at LS and FN. Our data on pharmacokinetic of teriparatide suggested that we can 
use this agent in normal dose in dialysis patients.
SA-PO584
Restless Leg Syndrome in Hemodialysis Patients: Possible Relationship with 
Mineral and Bone Metabolism  Precil Diego Miranda de Menezes Neves,1 
Ramaiane Aparecida Bridi,1 Rosa M.A. Moyses,1,2 Rosilene M. Elias.1 
1Nephrology Div, Univ of São Paulo, São Paulo, Brazil; 2Nephrology Div, Univ 
Nove de Julho - UNINOVE, São Paulo, Brazil.
Background: Restless legs syndrome (RLS) is a movement sleep disorder that is 
common among patients on hemodialysis (HD) and is associated with cardiovascular 
morbidity and mortality. The physiopathology of this syndrome is not completely 
understood, and CKD-MBD may be implicated. We aimed to evaluate the prevalence 
of RLS in patients on hemodialysis, testing the relationship with CKD-MBD markers.
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Methods: Prevalence and severity of RLS were assessed using the International RLS 
Study Group (IRLSSG) rating scale.
Results: Of the 101 patients (53.5% women) included, RLS was observed in 29 
patients (28.7%), with mild, moderate, severe and very severe presentation in 1, 12, 13 e 3 
patients, respectively. RLS was more frequent among women (62% vs 38%, p=0.04), and 
was associated to high phosphate-P (6.0 ± 1.7 vs 5.2 ± 1.7mg/dl, 0.048), lower transferrin 
saturation-TS (32 ± 16% vs. 46 ± 29%, p=0.019) and a tendency toward high parathyroid 
hormone-PTH [529 (190, 1017) pg/ml vs. 305 (143, 546) pg/ml, p=0.054]. Logistic 
regression showed that female gender (HR=2.8, p=0.039), P (HR=1.4, p=0.042) and TS 
(HR=0.9, p=0.033) were independently associated to RLS. As 22.8% of patients were 
already submitted to parathyroidectomy, we further categorized PTH as ≥ or <500pg/ml. 
This new variable was modeled in another regression model, which came out independently 
associated to a high risk of RLS (HR 3.0, p=0.027). We also compared patients with RLS 
severe/very severe to those with RLS mild/moderate. The first group presented higher P, 
and lower serum albumin, iron, and ionic calcium. Finally, multivariable regression showed 
that severity score was dependent on P and vit D insufficiency (r2= 0.37).
Conclusions: Besides all traditional risk factor for RLS already described in the general 
population, CKD-MBD seems to play a role in the pathophysiology of this syndrome in 
HD patients. It is plausible that the relationship between RLS and CKD-MBD contribute 
to the increased mortality risk observed in these patients.
SA-PO585
Vascular Smooth Muscle Cells from CKD Rats Have Increased Intracellular 
Calcium  Chad A. Zarse,1 Mikaela Lee Mckenney,2 Stacey L. Dineen,2 Rebecca 
S. Bruning,2 Michael Sturek,2 Neal X. Chen,1 Sharon M. Moe.1,3  1Nephrology, 
IU School of Medicine; 2Physiology, IU School of Medicine; 3Roudebush VAMC, 
Indianapolis, IN.
Background: CKD vascular smooth muscle cells (VSMC) exhibit phenotypic plasticity 
which promotes calcification and increases cardiovascular risk. Changes in intracellular 
calcium (iCa) as CKD progresses may regulate transcription of genes requisite for this 
process. This study examined iCa homeostasis in early and advanced CKD.
Methods: We studied VSMC freshly isolated from 10 week normal Sprague Dawley 
(SD) and CKD Cy/+ rats and 35 week normal SD, CKD Cy/+ (~15% nl function), and 
CKD rats treated with 3% calcium gluconate. (n=6-8 per group). Intracellular calcium 
was measured with Fura-2 using a ratiometric approach (F360/F380 nm). Basal iCa, 
sarcoplasmic reticulum (SR) store release, and store-operated calcium entry (SOCE) was 
assessed. Expression of common calcium regulatory proteins NCX1 and SERCA2a was 
examined by Western Blot. Results were compared by ANOVA.
Results: Basal iCa levels were lower in 10 week CKD VSMCs compared to NL 
(0.76±0.02 vs. 0.66±02, p<0.05) however increased 1.5-fold by 35 weeks to become 
greater than NL (0.98±0.01 CKD, 0.81±0.02 NL, 0.90±0.04 CKD+Ca, p<0.05). SR store 
release was greater in CKD VSMCs at both 10 weeks (0.45±0.02 vs. 0.37±0.02, p<0.05) 
and 35 weeks (0.62±0.02 CKD, 0.44±0.03 NL, 0.50±0.03 CKD+Ca, p<0.05). At 10 weeks, 
SERCA2a expression was greater in CKD rats in part explaining the lower basal iCa levels, 
however, at 35 weeks SERCA2a and NCX1 were both decreased in CKD rats, consistent 
with higher iCa levels. There was no difference in SOCE at 10 weeks but by 35 weeks was 
increased in the CKD+Ca cohort (p<0.05) with a trend toward significance in the CKD 
cohort (p=0.08), also consistent with higher observed basal iCa levels.
Conclusions: Basal iCa, SR store release, and SOCE increases with progressive CKD 
at least in part due to changes in expression of the common calcium regulatory proteins 
SERCA2a and NCX1. The increase in iCa is likely a key mechanism in our previous 
observations that CKD VSMCs display an osteogenic phenotype, which is known to 
worsen cardiovascular outcomes.
Funding: Other NIH Support - NIAMS, NHLBI, Veterans Administration Support, 
Pharmaceutical Company Support - 2013-2014 Sanofi Nephrology Fellowship Award
SA-PO586
The Role and Mechanism of Nrf2/HO-1 Pathway in Oxidative Stress-
Induced Vascular Calcification in End-Stage Renal Disease In Vitro 
Li Wang.  Nephrology, Sichuan Academy of Medical Sciences & Sichuan 
Provincial People’s Hospital, Chengdu, Sichuan, China.
Background: To investigate the mechanism of Nrf2/HO-1 pathway in oxidative 
stress(OS)-induced vascular calcificationin in end-stage renal disease(ESRD) in vitro, and 
to explore a new target for the intervention of vascular calcification in ESRD.
Methods: 1. Rat aortic vascular smooth muscle cells(RASMCs) were cultured and 
divided into 4 groups: the complete medium cultured group, the calcification medium 
cultured group, the group of complete medium cultured for 42h and then sulforaphane (SFN) 
cultured for 6h, the group of complete medium cultured for 46h and then H2O2 cultured for 
2h. Detect nuclear Nrf2 expression in each group by western blot. 2. 4 groups of RASMCs 
were cultured: the calcification medium cultured group, the group of H2O2 pretreated for 
2h and then calcification medium cultured, the group of SFN pretreated for 6h and then 
calcification medium cultured, the group of SFN pretreated for 6h and H2O2 pretreated for 
another 2h, and then calcification medium cultured. Detect the expression of intracellular 
reactive oxygen species (ROS) by using DCFH-DA probe, and the expression of Nrf2, 
Heme Oxygenase (HO-1), Runt-related transcription factor 2(Runx2) by western blot.
Results: 1.Nrf2 expression in nuclear was enhanced after SFN and H2O2 stimulation. 
2. The expression of Nrf2,Runx2 and ROS,but not HO-1, were induced by calcification 
medium in a time-dependent manner. 3. ROS was significantly reduced after H2O2, SFN, 
SFN + H2O2 pretreated, and decreased gradually with incubation time (P<0.05). 4. The 
expression of Nrf2 and HO-1 were induced by SFN, and the expression of Runx2 was 
inhibited in calcification medium. 5. The expression of Nrf2, HO-1, Runx2 could be induced 
by H2O2, but the expression of Runx2-induced calcification medium decreased gradually 
within incubation time after H2O2 or SFN + H2O2 pretreated.
Conclusions: The calcification in RASMCs is associated with the overexpression 
of endogenous ROS. Overexpression of Runx2 induced by endogenous ROS, but not 
exogenous ROS, may be inhibited or attenuated by the activated Nrf2/HO-1 pathway.
SA-PO587
Matrix Vesicles from Calcifying Vascular Smooth Muscle Cells (VSMC) 
Have Different MicroRNA (miRNA) Expression from Non-Calcifying 
VSMC  Neal X. Chen,1 Sarath Chandra Janga,2 Kalisha O’Neill,1 Manjunath 
Siddappa,2 Jeanette N. Mcclintick,3 Sharon M. Moe.1,4  1Nephrology; 2Biohealth 
Informatics; 3Medical and Molecular Genetics, Indiana Univ; 4Roudebush 
VAMC, Indianapolis.
Background: Treating VSMC with high phosphorus induces the production of 
calcifying matrix vesicles (CaMV) that initiate mineralization within the extracellular matrix 
of VSMC. MV are similar to exosomes which are known to contain miRNA important in 
cell-cell communication. We hypothesized that the miRNA expression profile in calcifying 
MVs (CaMV) would differ from non-calcifying MV (CTLMV) isolated from CKD rats.
Methods: VSMC from CKD rats (n=3) were incubated with control media or high-
phosphorus (calcifying media) and MV isolated. Total RNA was isolated from CaMV or 
CtlMV, miRNA quantified, and MiRNA array was performed using GeneChip miRNA 3.0 
Array. We analyzed the miRNA on array that changed at least 2 fold in the comparison 
groups with a p value of < 0.01 and false discovery rate of < 20%. Bioinformatic target 
gene prediction was performed using Targetscan and Miranda. CTLMV or calcifying MV 
were also co-cultured with VSMC to assess the change in calcification.
Results: CaMV increase calcification when added to VSMC compared to CTLMV. 
The arrays demonstrated 33 increased miRNAs and 17 decreased miRNAs in CaMV vs 
CTLMV. Real time PCR confirmed the miR-30c expression, known to regulate vascular 
calcification, is increased in CaMV vs CTLMV. Additional regulatory miRNA identified 
via target prediction analysis followed by functional enrichment yielded multiple miRNA-
mRNA networks. Narrowing the analyses to only those RNA controlled by at least 3 
miRNAs identified important miRNAs, including cell signaling pathways known to be 
involved in vascular calcification: Decreased expression of miRNAs (Ca vs. CTL) that 
would upregulate target genes involved in PI3 kinase signaling. In contrast, increased 
miRNA expression in CaMV vs. CTLMV would lead to downregulation of several signaling 
pathways including MAPK, RAS, mTOR and FOXO.
Conclusions: Calcifying MV contain different miRNAs compared to CTLMV. 
MiRNAs contained in calcifying MV may be transferred to other VSMC and regulate 
signaling pathways involved in vascular calcification.
Funding: Other NIH Support - NIH R01AR058005, Veterans Administration Support
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The Precedence of the Reduced Osteopontin Expression and the Increased 
Calcium Phosphate Nanoparticle to the Calcification by Phosphate Load 
with Normal Fasting Glucose in Human Vascular Smooth Muscle Cells 
Masanori Tokumoto,1 Shunsuke Yamada,1,2 Kazuhiko Tsuruya,3 Takanari 
Kitazono,2 Hiroaki Ooboshi.1  1Div of Internal Medicine, Fukuoka Dental 
College, Fukuoka, Japan; 2Dept of Medicine and Clinical Science, Graduate 
School of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 3Integrated Therapy 
for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu 
Univ, Fukuoka, Japan.
Background: It is well-known that vascular calcification (VC) develops in diabetes 
mellitus patients. On the other hand, malnutrition is also reported to induce VC. Thus, we 
examined how glucose load affects phosphate (P)-induced calcification in human vascular 
smooth muscle cells (hVSMC).
Methods: We added P of 1, 1.5, or 2.0 mM in the culture media (DMEM) of hVSMC 
with normal fasting or high glucose (HG) (100 or 450 mg/dl), although hVSMC are usually 
cultured with HG. The degree of calcification, the content of calcium P nanoparticle (CPP) 
in the media, and the expression of both the intrinsic calcification inhibitors and the chondro-
osteogenic differentiation markers were examined at Day 1, 7, and 14.
Results: Regardless of P load amount, the degree of calcification was severer with 
normal fasting glucose at Day 7 and 14. At Day 7, the mRNA expression of Sox9, a 
chondrogenic differentiation marker, increased by P load and was higher with normal 
fasting glucose. The content of calcification correlated significantly with the SOX9 mRNA 
expression at Day 7. At Day 1, the content of CPP increased by P load, and was higher 
with normal fasting glucose. The SOX9 mRNA expression at Day 7 correlated significantly 
with the content of CPP at Day 1. At Day 1, the mRNA expression of osteopontin (OPN), 
a calcification inhibitor, decreased by P load and was less with normal fasting glucose. 
Moreover, it negatively correlated with the content of CPP at Day 1 and the correlation was 
more intensive with normal fasting glucose. There was no significant change in the mRNA 
expression of chondro-osteogenic differentiation markers at Day 1.
Conclusions: In conclusion, P load with normal fasting glucose reduced OPN 
expression and induced the formation of CPP, followed by the chondrogenic differentiation 
and calcification in hVSMC.
Funding: Pharmaceutical Company Support - Kyowa Hokko Kirin, Government 
Support - Non-U.S.
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SA-PO589
VCAM - 1 and TNF Alpha Induce Vascular Calcification In Vitro 
Kevin Willy, Ralf Schindler, Daniel Zickler.  Dept of Nephrology and Internal 
Intensive Care Medicine, Charité Univ Medicine, Berlin.
Background: VCAM, TNF alpha and soluble TNF alpha receptor 1 (sTNFR1) are 
elevated in patients with chronic kidney disease (CKD). In previous clinical trials with 
high cut-off dialysis plasma levels of these molecules and in vitro vascular calcification 
were lowered. Here we assessed the role of sTNFr 1 and VCAM on in vitro calcification.
Methods: In human vascular smooth muscle cells (VSCMs) vascular calcification 
was induced by osteogenic medium (OM). VCAM , TNF-α and sTNFR1 were added. 
Calcification was quantified by alkaline phosphatase staining and alizarin red staining. 
Calcification was then normalized to WST – 8.
Results: VCAM enhances vascular calcification in vitro in a dose-dependent 
manner (p<0,0001). TNF-α –induced calcification was effectively inhibited by sTNFR1 
(50% reduction of the initial level; p<0,0001). sTNFr1 alone does not promote vascular 
calcification. 
VCAM concentration: 0,001 - 10 µg/mL.
Conclusions: VCAM and TNF alpha promote vascular calcification in vitro. 
Their elimination with high cut-off dialysis or their pharmacological blockade may be 
advantageous in regard to vascular calcification in CKD.
Funding: Pharmaceutical Company Support - Gambro  GmbH, Government Support 
- Non-U.S.
SA-PO590
The Triplehelical Collagen Analog (GPO)10 Affects Calcifications of 
Vascular Smooth Muscle Cells in a Concentration Dependent Manner 
Uwe Querfeld,1,2 Nadja Kretzschmar,2 Christian Freise.1,2  1Pediatric Nephrology, 
Charité, Berlin, Germany; 2Center for Cardiovascular Research, Charité, 
Berlin, Germany.
Background: Extensive remodeling of the extracellular matrix and the trans-
differentiation of vascular smooth muscle cells (VSMC) contribute to the pathogenesis 
of vascular calcifications in patients with chronic kidney disease (CKD). Matrix 
metalloptoteinases (MMPs) are proteolytic enzymes that impact on both of these processes 
and, thus, represent potential therapeutic targets. We have previously shown that the 
synthetic collagen analog (Gly-Pro-Hyp)10 - (GPO)10 –impacts the substrate binding and the 
enzymatic activity/stability of the gelatinases MMP-2 and -9 in a concentration dependent 
manner [1]. Aim of this study was therefore to investigate potential regulatory functions of 
(GPO)10 in an in- vitro model of arteriosclerotic VSMC calcification.
Methods: Calcifications of murine VSMC were induced by a calcification medium 
(CM) containing elevated concentrations of calcium and phosphorus with or without the 
presence of different (GPO)10-concentrations. VSMC calcifications were quantified by 
measuring calcium depositions and ALP-release in the cultures. Effects on MMP-activities 
were determined by specific substrate assays.
Results: CM-treated VSMC exhibit strong calcifications compared to control. Low 
(GPO)10 concentrations (50-70 nM) massively enhanced calcifications of VSMC and were 
accompanied by elevated gelatinase activities in VSMC supernatants. In contrast, higher 
concentrations of (GPO)10 (680 nM) blocked CM-induced calcifications of VSMC and 
reduced gelatinolytic activities in culture supernatants.
Conclusions: Considering the important function of MMP-2 and -9 in VSMC 
calcification [2], the collagen peptide (GPO)10 on the one hand indirectly impacts the VSMC 
calcification by modulating MMP activities. On the other hand, direct effects of (GPO)10 e.g. 
by interaction with collagen receptors might simulate a “healthy” vessel matrix, which will 
be investigated in future studies. [1] Ruehl, M., et al., Fibrogenesis Tissue Repair., 2011. 
4(1): p. 1. [2] JASN 25: 2014 (SA-OR062, p.95A; TH-PO555, p.233A; FR-PO833, p.562A).
Funding: Private Foundation Support
SA-PO591
Protective Effects of Epigallocatechin Gallate (EGCG) on Vascular 
Calcification In Vitro and In Vivo  Uwe Querfeld,1,2 Karoline Websky,2 
Christian Freise,2 Kerstin Sommer,2 Ursula Schulz,2 Veronika Bobb.2  1Pediatric 
Nephrology, Charité, Berlin, Germany; 2Center for Cardiovascular Research, 
Charité, Berlin, Germany.
Background: Vascular calcifications are common in patients with chronic kidney 
disease (CKD). Our preliminary studies indicate that inhibition of matrix metalloproteinases 
(MMP)-2 and -9 suppresses the development of arterial calcification in uremic rats. 
Epigallocatechin gallate (EGCG), a polyphenol ingredient of green tea, has strong 
antiinflammatory properties and inhibitory effects on MMPs. We therefore investigated 
potential protective effects of EGCG on calcium uptake of vascular smooth muscle cells 
(VSMC) in vitro and in an animal model of uremia-associated arteriosclerosis in vivo.
Methods: In vitro, calcifications of murine VSMCs were induced by a high phosphate 
(HP)-medium and cells were treated with different EGCG-concentrations (20-100µg/
ml). VSMC calcifications were quantified using the ortho-cresolphthalein-method and 
proteolytic activities of MMP-2 and -9 in VSMC supernatants were determined by gelatin 
zymographies. C57BL/6 mice were 5/6-nephrectomized and arterial calcifications were 
induced by calcitriol (1µg/kg body weight) and a HP-diet (2% phosphate). One cohort (n=10) 
was additionally administrated 0.02% EGCG in drinking water. Animals were sacrificed 
after 2 weeks of treatment and aortic calcifications were quantified after von Kossa-staining.
Results: In-vitro, EGCG provoked a dose-dependent decrease of HP-induced 
calcification (up to 85%) of VSMCs and of proteolytic MMP-2 and -9 activities. In vivo, 
all calcitriol-treated mice had severe arterial calcifications, involving 50% of the arterial 
wall after only 2 weeks of treatment. EGCG had no significant inhibitory effect on the 
development of vascular calcifications.
Conclusions: In this “negative experimental trial”, EGCG had no beneficial effect in the 
chosen animal model, which (considering the rapid development of calcifications) may have 
been too aggressive, thus overriding potential protective effects of EGCG.Encouraged by 
the positive in vitro results, the effects of EGCG and other polyphenols should nonetheless 
be further investigated in other animal models of uremia-associated arteriosclerosis.
Funding: Private Foundation Support, Clinical Revenue Support
SA-PO592
Mechanism of Calcification by Iron Stimulation in Vascular Smooth Muscle 
Cells  Sayuri Kawada,1 Yasuyuki Nagasawa,1 Mutsuki Kawabe,2 Aritoshi Kida,1 
Mana Yahiro,1 Tomoko Kimura,1 Kiyoko Yamamoto,1 Masayoshi Nanami,1 
Yukiko Hasuike,1 Takahiro Kuragano,1 Keiji Nakasho,2 Hideki Ohyama,2 Takeshi 
Nakanishi.1  1Dept of Internal Medicine, Div of Kidney and Dialysis, Hyogo 
College of Medicine, Nishinomiya, Hyogo, Japan; 2Dept of Pathology, Hyogo 
College of Medicine, Nishinomiya, Hyogo, Japan.
Background:  In CKD patients, atherosclerosis is one of important key factors which 
determine their prognosis. It was reported the calcification induced by TNF-alpha was related 
with iron in HUVEC cells by our group. TTo reveal the relationship between calcification 
in vascular media and iron stimulation using vascular smooth muscle cells.
Methods: The aorta smooth muscle cells were cultured for three weeks. At day 0, 
we changed the usual culture medium to calcification medium, and TNF-alpha and iron 
were added to the calcification medium. Calcification in each condition was confirmed by 
Alizarin staining. And to reveal early mechanism to enhance the calcification by iron and 
TNF-alpha stimulation, we compared the gene expression profile between each condition 
in day 1 and day 3 using microarray analysis. We confirmed gene expression of cytokine 
which had increased in microarray analysis by real-time PCR.
Results: We confirmed both iron and TNF-alpha stimulation enhanced calcification 
by Alizarin Staining. Moreover, both iron and TNF-alpha stimulation at the same time 
enhanced calcification more strongly than single stimulation. We picked up a cytokine 
which had increased with both iron and TNF-alpha stimulation in the microarray analysis 
as similar as the Alizarin Staining result had shown. We confirmed gene expression of 
this cytokine by real-time PCR. Gene expression was increased at day1 by stimulation of 
iron(5.8±3.0 fold change vs control), TNF-alpha (7.8±1.9 fold change vs control) ,and both 
stimulation(53.1±27.1fold change vs control),synergistically.
Conclusions: Iron stimulation enhanced calcification in vascular smooth muscle cells 
along with TNF-alpha stimulation. The possibility was suggested that this gene change 
from the early stage participated in the mechanism that iron promoted blood vessel media 
calcification.
Funding: Clinical Revenue Support, Government Support - Non-U.S.
SA-PO593
Kidney Injury/Repair Stimulates Vascular Disease Through Activin and 
Systemic Wnt Inhibition  Matthew James Williams, Olga A. Agapova, Yifu 
Fang, Toshifumi Sugatani, Carmen M. Halabi, Keith A. Hruska.  Pediatrics, 
Nephrology, Washington Univ School of Medicine, Saint Louis, MO.
Background: We show that the vascular effects of CKD are an interplay of Wnt 
inhibition and activin induced modulation of Activin receptor (ActRIIA) function resulting 
in a stimulation of atherosclerosis and vascular calcification.
Methods: CKD with elevated activin and Wnt inhibitors, especially Dkk1, was induced 
in the mouse models for vascular calcification, lineage tracing, and Alport’s. Activin, 
Dkk1, ActRIIA, psmad 2/3, aklotho and collagen levels were measured by Elisa, RT-PCR 
and westerns. Vascular smooth muscle cell (VSMC) function was measured by pressure 
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induced arterial dilatation in situ. Cell lineage tracing was performed in Rosa-tdT mice 
bred to endothelial specific Tie2-Cre mice. Mice harboring Rosa-tdT express tomato red 
in cells harboring Cre recombinase.
Results: Circulating activin and Dkk1 levels were increased while aklotho levels were 
decreased by CKD. In diseased kidneys, activin was expressed in myofibroblasts, and 
activin receptor, ActRIIA, signaling through Smad 3 was increased. An ActRIIA ligand 
trap, RAP-011, inhibited renal pSmad 3, ColA1 expression, urinary protein levels, and 
Dkk1 levels, and increased tubular epithelial klotho levels. In the vasculature, CKD 
decreased VSMC ActRIIA protein levels, and ActRIIA signaling was decreased along with 
decreased VSMC differentiation and function. The ActRIIA ligand trap increased VSMC 
differentiation and inhibited osteoblastic transition and atherosclerotic calcification. In 
the circulation, the ActRIIA ligand trap decreased Dkk1 levels. CKD induced expression 
of tomato red in cells of the adventia after two weeks of femoral artery injury in Tek-Cre/
Rosa-tdT CKD mice compared to Tek-Cre/Rosa-tdT mice with normal kidney function.
Conclusions: CKD increased circulating free activin levels, decreased VSMC function, 
stimulated aortic osteoblastic transition and atherosclerotic calcification. Decreasing 
effects of elevated activin in CKD with an ActRIIA ligand trap, inhibited Smad dependent 
renal fibrosis, blocked aortic osteoblastic transition, increased VSMC differentiation and 
decreased vascular calcification.
Funding: NIDDK Support, Pharmaceutical Company Support - Celgene
SA-PO594
Transient Azotemic Episode Exacerbates Vascular Calcification in Adenine-
Induced Uremic Rats  Daisuke Mori,1 Isao Matsui,1 Akihiro Shimomura,2 
Yasuo Kusunoki,1 Sayoko Yonemoto,1 Masamitsu Senda,1 Yusuke Sakaguchi,1 
Takayuki Hamano,2 Yoshitaka Isaka,1 Hiromi Rakugi.1  1Geriatric Medicine 
and Nephrology, Osaka Univ Graduate School of Medicine, Suita, Japan; 
2Comprehensive Kidney Disease Research, Osaka Univ Graduate School of 
Medicine, Suita, Japan.
Background: Urea, the final metabolite of amino acids in the body, can carbamylate 
proteins at lysine residues, and thereby modifies characteristics of proteins irreversibly. 
Several studies have revealed that functions of proteins are impaired by carbamylation. 
Acute kidney injury (AKI) is a representative pathological condition that elevates serum 
urea temporarily. Although AKI is not a perpetual condition, it is well-known that AKI 
increases subsequent risk of cardiovascular diseases through yet-unknown mechanisms.
Methods: We evaluated the effects of transiently elevated serum urea on vascular 
calcification (VC). Male Sprague-Dawley rats at age 9 weeks were divided randomly into 
two groups: cellulose-preload + adenine diet (group C+A) and urea-preload + adenine 
diet (group U+A). Urea-preloaded group received 10% urea diet from 9 to 13 weeks of 
age. Cellulose served as a control for urea. After one week of urea-washout period, all rats 
received 0.75% adenine-containing diet up to 19 weeks of age.
Results: Serum urea levels were 15.87 ± 2.96 mg/dL in cellulose-preloaded group and 
39.20 ± 3.74 mg/dL in urea-preloaded group at the end of the preload period. Serum urea 
levels in urea-preloaded group were normalized to 14.73 ± 1.28 mg/dL during the washout 
period. At age 19 weeks, rats in group U+A developed severer VC in comparison with the rats 
in group C+A. Serum creatinine, urea nitrogen, calcium, phosphate, magnesium, albumin, 
and body weight were not different between the two groups at age 19 weeks. Western blot 
analysis of the aorta revealed that dietary preload of urea increased carbamylated protein.
Conclusions: Preload of urea exacerbated VC in adenine-induced uremic rats. Protein 
carbamylation might link urea-preload to VC.
SA-PO595
SNF472 Inhibits Cardiovascular Calcification in Uremic Rats  Joan Perelló,1,2 
Carolina Salcedo,1 Ellen Neven,3 Geert J. Behets,3 Pieter H. Joubert,1 Patrick 
C. D’Haese,3 Miquel D. Ferrer.1  1R	D Dept, Laboratoris Sanifit, Palma, Illes 
Balears, Spain; 2Laboratory of Renal Lithiasis Research, Univ of Balearic 
Islands, Palma, Illes Balears, Spain; 3Laboratory of Pathophysiology, Univ of 
Antwerp, Antwerp, Belgium.
Background: SNF472, an intravenous (i.v.) formulation of phytate, has been shown 
to inhibit cardiovascular calcification (CVC) in non-uremic conditions. We investigated 
the pharmacokinetics (PK) and efficacy (inhibition of CVC) of i.v. SNF472 in control 
and uremic rats.
Methods: The first part of the study was performed with 10 male Wistar rats in which 
uremia was induced by 10 daily oral (p.o.) administrations of 600 mg/kg adenine followed 
by p.o. administrations of 300 ng/kg α-calcidol on days 11 and 13. Ten animals received 
10 mg/kg and ten animals 50 mg/kg of SNF472 daily as 4-hour i.v. infusions. Blood was 
collected at days 1 (controls) and 14 (uremic) and plasma SNF472 concentrations were 
measured at different time points. In an efficacy study uremia was induced as above whilst 
α-calcidol was administered 3 times/week from day 11 to day 19. Twelve rats received daily 
4-hour i.v. infusions of 50 mg/kg SNF472 and twelve rats received saline from day 0 to 
day 19. At day 19 all surviving animals were sacrificed and blood and tissue samples were 
collected to measure SNF472 plasma levels as well as calcium content in aorta and heart.
Results: Steady state was reached at 60 minutes in control animals receiving 50 mg/kg 
SNF472 but not in those receiving 10 mg/kg. Steady state was reached in uremic animals, 
but with exposures between 3 and 7 times lower than in controls. All the animals in the 
efficacy study developed uremia as a consequence of the high-dose adenine administration. 
The exposure to SNF472 in uremic animals was distinctly lower (5-fold for Cmax). 
SNF472 treatment resulted in a significant reduction in CVC of 80 and 88% in aorta and 
heart, respectively.
Conclusions: Daily SNF472 4 hour infusions of 50 mg/kg inhibit the development 
of CVC by up to 88% in a rat adenine model of uremia. These results support further 
investigation of SNF472 in the treatment of CVC in patients with calcification-related 
disorders such as calciphylaxis and ESRD patients.
Funding: Pharmaceutical Company Support - Laboratoris Sanifit S.L.
SA-PO596
Enzyme Therapy for Vascular Calcification  W. Charles O’Neill,1 Kelly E. 
Manning,1 Koba A. Lomashvili,1 Nelson Hsia,2 Peychii Lee,2 Francis T. Danehy,2 
Kim L. Askew,2 Anthony G. Quinn.2  1Renal Div, Emory Univ School of Medicine, 
Atlanta, GA; 2Synageva Biopharma, Lexington, MA.
Background: Pyrophosphate (PPi) is a key endogenous inhibitor of hydroxyapatite 
formation that circulates at levels sufficient to prevent vascular calcification. PPi is produced 
from extracellular ATP by the ectoenzyme, nucleotide pyrophosphatase pyrophosphorylase 
1 (NPP1) and deficiency of this enzyme produces severe fatal medial arterial calcification 
in humans. Mice lacking NPP1 have undetectable plasma PPi and also develop arterial 
calcification. We examined whether exogenous NPP1 can increase plasma PPi and prevent 
vascular calcification in these mice.
Methods: Recombinant proteins containing the extracellular portion of human 
ENPP1 fused to human IgG1 Fc (ENPP1-Fc) were created and injected into two mouse 
models of NPP1 deficiency (Enpp1-/- and Enpp1asj/asj ). NPP1 activity was measured by 
conversion of [32P]ATP to 32PPi with separation by thin-layer chromatography. Plasma PPi 
was measured by a radiometric enzyme assay using UDP-[14C]glucose and UDP-glucose 
pyrophosphorylase.
Results: Intravenous injection of NPP1-Fc (6 mg/kg) into Enpp1-/- mice increased 
plasma NPP1 activity to a peak of 160 +/- 10% of normal at 4 hours with a decline to 70 
+/- 5% of normal by 72 hours. There was no increase in aortic NPP1. Plasma PPi followed 
a similar pattern, with a peak of 2.2 +/- 0.6 uM at 4 hours declining to 0.21 +/- 0.04 uM at 
72 hours (normal: 2.18 +/- 0.33 uM). With subcutaneous injection, plasma NPP1 was 110 
+/- 13% of normal and plasma [PPi] was 0.38 +/- 0.14 uM after 48 hours. Subcutaneous 
injection every 48 hr reduced aortic calcium content 86 +/- 5% (p<0.001) after 18 days in 
Enpp1-/- mice fed a high phosphorus diet, and improved survival at 10 weeks from 15% to 
50% (p<0.001) in Enpp1asj/asj mice fed a high phosphorus, low magnesium diet.
Conclusions: Administration of NPP1 in NPP1-deficient mice produces an increase 
in circulating PPi that is sufficient to prevent vascular calcification and increase survival. 
The ability of Enpp1 fusion proteins to raise PPi levels and inhibit tissue calcification 
supports the potential to reduce vascular calcification in other calcification-prone states.
Funding: Pharmaceutical Company Support - Synageva Biopharma
SA-PO597
The Risk of Medial Arterial Calcification in Early Chronic Kidney Disease 
W. Charles O’Neill,1 Kum Hyun Han,1,2 Arshad Ali,1 Ansley O’Neill,1 Kelly 
E. Manning.1  1Renal Div, Emory Univ, Atlanta, GA; 2Internal Medicine, Dept 
of Internal Medicine, Inje Univ College of Medicine, Ilsan Paik Hospital, 
Goyang, Korea.
Background: Medial arterial calcification is common in advanced chronic kidney 
disease (CKD) but whether this risk begins in early CKD is unknown. There is also 
concern that possible benefits of vitamin D and calcium in this group may be offset by 
potential induction of vascular calcification. We have previously shown that breast arterial 
calcification is a readily available and specific marker of medial arterial calcification and 
that its prevalence is increased in advanced CKD.
Methods: From a computerized search of medical records, 446 women with CKD and 
mammograms were randomly selected. After exclusion of women with renal transplants or 
other stages of CKD, history of warfarin use, or non-screening mammograms, 333 women 
with CKD 3 (MDRD formula) were identified and individually matched by age and diabetes 
status to women with an estimated GFR >90 ml/min/1.73 m2. Digital mammograms were 
visually inspected for arterial calcification.
Results: Mean age was 69.5 +/- 0.6 (range: 44-91), mean eGFR was 49.5 +/- 0.4 ml/
min/1.73 m2, 20.1% had diabetes, 31.5% were receiving calcium supplements, 31.3% 
were receiving vitamin D (> 1000 units/d), and 1.8% were receiving an active form of 
vitamin D. Controls had a mean eGFR of 104.1 +/- 0.7 ml/min/1.73 m2. The prevalence 
of arterial calcification was the same in CKD 3 patients (35.1%) and controls (33.3%). 
Dividing the CKD 3 patients by different thresholds of serum creatinine yielded similar 
results. There was no difference in calcification between patients taking or not taking 
calcium supplements (36.2% vs. 34.6%), vitamin D (36.2% vs. 34.6%), or both (30% vs. 
32.5% with neither). In a logistic regression, only age was a significant determinant of 
arterial calcification (p<0.0001).
Conclusions: The prevalence of medial arterial calcification is not increased in women 
with stage 3 CKD, indicating that the risk begins at stage 4 CKD. Supplementation of 
calcium or vitamin D does not increase the risk of medial arterial calcification in these 
patients.
Funding: Clinical Revenue Support
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SA-PO598
Deoxycholic Acid (DCA), a Metabolite of Circulating Bile Acids, and 
Coronary Vascular Calcifications in Chronic Kidney Disease (CKD) 
Makoto Miyazaki,1 Shinobu Miyazaki-anzai,1 Audrey L. Keenan,1 Kristen L. 
Nowak,1 Jessica B. Kendrick,1 Geoffrey A. Block,2 Michel Chonchol.1  1Univ 
of Colorado Denver; 2Denver Nephrology.
Background: Our group has previously shown that DCA, a metabolite of circulating 
cholic acid, induces vascular mineralization and osteogenic differentiation in animal models 
and that circulating levels of DCA are elevated in patients with CKD.  We investigated 
whether increased DCA serum levels are associated with an increase risk for higher 
coronary artery calcification (CAC) volumes and lower lumbar bone mineral density 
(BMD) in CKD patients.
Methods: We used stored baseline serum samples in 112 patients with moderate to 
advanced CKD (eGFR= 20-45 mL/min/1.73m2) who participated in a randomized-controlled 
study to examine the effects of phosphate binders on vascular calcification. Circulating 
DCA levels were assayed using liquid-chromatography-tandem mass spectrometry (LC-
MS/MS). CAC volume was obtained using GE-Imatron C150 scanner and lumbar BMD 
was determined using abdominal computed tomography scans with a calibrated phantom 
of known density. Linear regression models were used to examine the cross-sectional 
association between DCA with CAC volume and lumbar BMD.
Results: Participant characteristics were as follows: mean age, 68±11 years; 50% 
women; 10% black; mean eGFR, 32±8 mL/min/1.73m2; and median DCA 58.4 (IQR 29-
112) ng/mL. After adjusting for demographics, co-existing illness, body mass index, eGFR 
and circulating markers of CKD-MBD including serum calcium, phosphorus, vitamin D, 
parathyroid hormone and fibroblast growth factor 23, an increase serum DCA level > 58 
ng/mL positively associate with CAC volume (ß: 494.84 ± 238.82; p=0.03) and negatively 
associated with BMD (ß: - 20.35± 9.56; p=0.03).
Conclusions: Higher serum levels of DCA in patients with stage III and IV CKD is 
independently associated with higher CAC volume and lower lumbar BMD. Larger cohort 
studies are needed to confirm these findings.
Funding: NIDDK Support, Other NIH Support - NHLBI
SA-PO599
Fibroblast Growth Factor 23 and Fetuin A Levels in Pre-Dialysis Stage 4-5 
Chronic Kidney Disease Patients with Aortic Calcification: A Case Control 
Study  Vijayakumar Theophilus-Sunder, Anna T. Valson, Vinoi George David, 
Santosh Varughese, Tamilarasi Veerasamy.  Dept of Nephrology, Christian 
Medical College, Vellore, Tamil Nadu, India.
Background: Vascular calcification (VC) contributes to the increased cardiovascular 
mortality seen in CKD. However, not everyone with advanced CKD develops VC, indicating 
that circulating levels of factors that modulate VC may play a role in determining individual 
susceptibility towards VC. We aimed to examine this hypothesis by measuring the levels 
of FGF-23 and Fetuin-A in a group of pre-dialysis CKD Stage 4-5 patients who had 
documented abdominal aortic calcification (AAC) and an age, gender and eGFR matched 
group of patients who did not have AAC.
Methods: Out of a pre-existing cohort of 710 patients with CKD Stage 4-5, 28 patients 
with AAC (Group 1, cases) were compared with an equal number of age, gender and eGFR 
matched patients without AAC (Group 2, controls) with respect to their demographic and 
biochemical parameters, including FGF-23 and Fetuin-A. AAC was assessed by lateral 
abdominal X ray, while Fetuin-A and intact FGF-23 were estimated by ELISA in serum.
Results: Groups 1 and 2 were matched for age (mean age 57.7 and 57.8 years 
respectively, p = 0.938), gender (84.6% males in both groups) and eGFR (median eGFR 
14.5 and 13.1 respectively, p = 0.826), and were not significantly different with respect 
to risk factors for AAC such as presence and duration of diabetes, hypertension, smoking 
and obesity. Levels of calcium, phosphorus, PTH, 25 (OH) vitamin D, serum cholesterol, 
triglycerides, HDL and LDL were also comparable between the two groups. However, 
median FGF23 levels were significantly higher in Group 1 [25.2, (Q1= 14, Q3=34.2)] 
compared to Group 2 [12.1 (Q1 = 6.6, Q3 = 14.1), n = < 0.001]. Median Fetuin-A levels 
were also significantly higher in Group 1 [5.5 (Q1=4.4, Q3=6.5)] compared to Group 2 
[4.1 (Q1 = 3.6, Q3 = 5.7, n = 0.034).
Conclusions: Pre-dialysis patients with Stage 4-5 CKD with AAC, had higher FGF-
23 and Fetuin-A levels compared to age, gender and eGFR matched patients who did not 
have AAC. The nature and mechanism of this association between elevated FGF23 and 
Fetuin-A levels and AAC requires further exploration.
SA-PO600
Lack of Association Between Serum Osteoprotegerin, Osteopontin and 
Fetuin-A Levels and the Longitudinal Changes in Arterial Stiffness in CKD 
Patients Undergoing Renin-Angiotensin System Blockade  Cecilie Lyngsø,1 
Marie Frimodt-Moller,2 Marianne Rix,2 Anne-Lise Kamper,2 Svend Strandgaard,1 
Arne Høj Nielsen,1 Allan Flyvbjerg,3 Mette Bjerre.3  1Dept of Nephrology, Herlev 
Hospital, Herlev, Copenhagen, Denmark; 2Dept of Nephrology, Rigshospitalet, 
Copenhagen, Denmark; 3The Medical Research Laboratory, Dept of Clinical 
Medicine, Aarhus Univ, Aarhus, Denmark.
Background: Osteoprotegerin (OPG), osteopontin (OPN) and fetuin-A, have been 
suggested to participate in the accelerated development of arteriosclerosis seen in patients 
with chronic kidney disease (CKD). We have previously shown that measures of vascular 
stiffness were significantly reduced after 24 weeks of treatment with renin-angiotensin 
system (RAS) blocking agents. The aim of this longitudinal post hoc study was to investigate 
whether serum levels of OPG, OPN and fetuin-A were associated with these same changes 
in markers of arterial stiffness found in CKD patients treated with RAS blocking agents.
Methods: Serum OPG, OPN and fetuin-A levels were measured in 57 patients with 
CKD stage 3-5, mean eGFR 29 ml/min, as a post hoc analysis of data acquired during a 
24-week controlled trial in which patients were randomized to treatment with 16 weeks of 
monotherapy with either enalapril or candesartan followed by 8 weeks of dual blockade. 
Serum levels were obtained upon study entry and after 16 and 24 weeks of RAS blocking 
therapy and compared to aortic pulse-wave velocity and augmentation index.
Results: Except for a significant correlation between OPG and central pulse pressure 
(p < 0.05), serum levels of OPG, OPN and fetuin-A did not correlate to markers of vascular 
stiffness. There were no significant changes in serum levels of OPG, OPN and fetuin-A 
when monotherapy with enalapril or candesartan was compared to dual blockade.
Conclusions: The present results do not corroborate the use of OPG, OPN and fetuin-A 
as surrogate markers for vascular stiffness in patients with CKD.
SA-PO601
Hyperuricemia Is Significantly Associated with Coronary Artery 
Calcification and Vascular Stiffness in Asymptomatic Subjects Undergoing 
General Health Examination  Ah Ran Choi, Hae Yeul Park, Seok-Hyung Kim, 
Hoon Young Choi, Sung-Kyu Ha, Hyeong Cheon Park.  Nephrology, Gangnam 
Severance Hospital, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Recent studies suggest that hyperuricemia may be associated with 
increased adverse cardiovascular events even in healthy subjects. Quantity of coronary artery 
calcium (CAC) correlates with atherosclerotic plaque burden and increased cardiovascular 
events. This study aimed to determine the relationship between serum uric acid level(sUA) 
and brachial-ankle pulse wave velocity (ba-PWV), coronary artery calcium score (CACS) 
as well as other traditional cardiovascular risk factors in asymptomatic subjects.
Methods: We consecutively enrolled 4,703 asymptomatic subjects who underwent 
ba-PWV and coronary CT angiography as part of a general health examination. A high ba-
PWV group, those having increased vascular stiffness, was defined as ba-PWV greater than 
1497.5 cm/s (75th percentile). The subjects were stratified into four groups according to sUA.
Results: Mean age of enrolled subject was 52.8 ± 9.4 years, 61 % of the study 
participants were male. Eight point four percent of the study participants showed CACS 
greater than 100. The adjusted odds ratio (OR, 95% confidence interval) for the presence 
of high ba-PWV in the second to fourth sUA quartile vs. first sUA quartile was 1.45 (1.137-
1.840, P<0.003), 1.42 (1.081-1.866 P<0.012), 1.66 (1.246-2.218, P<0.001), respectively 
after adjusting for age, gender, diabetes, hypertension, smoking, body mass index (BMI), 
estimated glomerular filtration (eGFR), fasting blood sugar (FBS) and calculated LDL. 
Moreover, subjects with CACS greater than 100 also showed that fourth quartile of sUA 
was associated with high ba-PWV compared with the first quartile of sUA [OR 2.4, (1.65-
3.47, P<0.001)]. Multivariate linear regression analysis demonstrated that old age, male, 
hypertension, diabetes, BMI, FBS, eGFR and sUA were significantly associated with mean 
ba-PWV and log transformed CACS.
Conclusions: Our results show that sUA is an independent risk factor for increased 
vascular stiffness and coronary atherosclerosis in asymptomatic adults undergoing health 
examination.
SA-PO602
Abdominal Aortic Calcification Score on Plain Radiograph as a Predictor 
of Coronary Artery Calcification Score on Computed Tomography and 
T-Score on BMD in Dialysis Patients  Eu Gene Jeong,1 Su Mi Lee,1 Young 
Ki Son,1 Dongyeol Lee,2 Hansae Kim,2 Sung Hyun Son.3  1Dept of Internal 
Medicine, Dong A Univ Hospital, Busan, Republic of Korea; 2Dept of Internal 
Medicine, Bong Seng Memorial Hospital, Busan, Republic of Korea; 3Dept of 
Internal Medicine, BHS Han Seo Hospital, Busan, Republic of Korea.
Background: Not only coronary artery calcification scores (CACS) on computed 
tomography (CT) but also several VC scores on plain radiographs can predict cardiovascular 
events. However, there is no study about the correlation between CACS on CT and VC 
scores of several sites on plain radiographs. Therefore, we evaluated which VC scores among 
several VC scores on plain radiographs are a predictor of CACS on CT in dialysis patients. 
We also investigated the association between VC scores and bone mineral density (BMD).
Methods: We conducted this single center cross-sectional study from March 2013 to 
September 2014. We checked the plain radiographs of the feet, hands, pelvis, and lateral 
lumbar spine and estimated the VC scores. CACS on CT and BMD were evaluated. We 
defined severe CACS as CACS > 1000. FGF-23, fetuin-A, osteoprotegerin (OPG) and 
receptor activator of NF-κB ligand (RANKL) were analyzed with ELISA.
Results: The mean ages of 61 patients including 38 hemodialysis(HD) and 23 peritoneal 
dialysis(PD) patients were 58.6±10.2 years. The prevalence rate of significant VC was 75.4% 
and prevalence rate of severe CACS was 26.2%. The OPG levels were higher in patients 
with severe CACS(p=0.019) and significant VC(p=0.009). Patients with AAC score≥5 had 
lower T score of wrist and hip than patients with AAC score<5. CACS is positively correlated 
with AAC score(r=0.639, p< 0.001), VC score of the hands and pelvis (r=0.494, p< 0.001). 
AAC score is negatively correlated with T score of wrist(right: r=-0.286, p=0.027) and 
hip(right: r=-0.259, p=0.045)on BMD. AAC score(B=59.4, C.I.=18.3-100.6, p=0.006) and 
VC score of the hands and pelvis(B=225.8, C.I.=69.7-381.8, p= 0.006)on plain radiographs 
were independently associated with CACS on CT.
Conclusions: AAC score among several VC scores on plain radiographs is the most 
reliable predictor of CACS on CT and T score on BMD in dialysis patients.
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SA-PO603
Total Body Multislice Computed Tomography as a Gold Standard of 
Vascular Calcification  Nadia Martin Alemany,1 Xoana Barros,1 Jordi Calabia,1 
Juan Baños.2  1Nephrology, Univ Hospital Dr Josep Trueta, Girona, Spain; 
2Radiology, Inst de Diagnostic per la Imatge (IDI), Girona, Spain.
Background: Vascular calcification (VC) is a marker of cardiovascular risk in CKD 
patients. Imbalance of calcium-phosphate parameters and secondary hyperparathyroidism 
(sHP) has been proposed as inductors of VC. Traditionally VC has been evaluated with 
Kauppila, Adragao and coronary Agatston scores but they are limited to restricted body 
areas and may underestimate total VC. We proposed a new method to assess VC in CKD 
patients with mild sHP based on total body multislice computed tomography (MSCT) 
without contrast.
Methods: Multicenter transversal study which included incident dialysis patients 
with mild sHP (PTH >150pg/dL) after signed informed consent. Kauppila and Adragao 
scores were determinate on abdominal and pelvis/hand X-ray, respectively. Total body area 
calcification (cm2) was measured by MSCT. Patients with a total calcified area of >150 
cm2 were considered calcified. Sensibility and specificity of Kauppila and Adragao scores 
were calculated considering total calcified body area > 150 cm2 as reference.
Results: We enrolled 22 patients (13 hemodialysis / 9 peritoneal dialysis), 45% 
diabetics, 62±15 years old. Mean±SD were: phosphorus 4.6±1.5mg/dl, calcium 
9.21±0.44mg/dL and parathyroid hormone 278±132pg/dL.They presented mean Kauppila 
score of 6.9±6.9, Adragao score of 2±3.7 and total calcified area of 112.6±196.7cm2. 77% 
patients were calcified, considering positive if overall calcified area was >150cm2. Diabetics 
and those with previous cardiovascular events had higher total body calcified area, whereas 
gender and type of dialysis didn’t demonstrate any influence on calcification. Sensibility 
of Kauppila and Adragao scores were 70% and 30% respectively, whereas specificity of 
both of them was 100%.
Conclusions: It is possible to evaluate the overall body calcified area in patients with 
ESRD by multislice computed tomography, which could be considered as a potential gold 
standard of global vascular calcification in those patients.
SA-PO604
Comparison of Mineral Metabolic Markers and Therapy in Chronic 
Hemodialysis Patients with Different Degree of Abdominal Aortic 
Calcification Score  Manja Antonic,1 Saska Lampreht,1 Zeljka Veceric Haler,2 
Jakob Gubensek,2 Andrej Drozg.1  1Dept of Nephrology and Dialysis, General 
Hospital, Celje, Slovenia; 2Dept of Nephrology, Univ Medical Centre, Ljubljana, 
Slovenia.
Background: The correlations of vascular calcifications with different markers of 
CKD-MBD and also its therapy are not always consistent across the studies and cross-
sectional associations are favoured over long-term analyses. We therefore aimed to evaluate 
laboratory markers and therapy load over a longer period in chronic hemodialysis patients 
with different severity of abdominal aortic calcification (AAC).
Methods: In hemodialysis patients AAC was determined by lateral lumbar radiography 
and quantified by Kauppila score. Patients were divided in two groups according to median 
AAC score of the whole group. Mean active vitamin D and cinacalcet intake for last 4 years 
and calcium carbonate for last 10 years (or whole dialysis vintage for those on dialysis 
for shorter time) and mean mineral metabolism markers (Ca, P, iPTH, CaxP product and 
alkaline phosphatase (AF) for last 4 years) were compared between the groups.
Results: 20 patients with high AAC score were significantly older (72±9 vs. 59±15 
years, p=0.003) and more often diabetic (15% vs. 2%, p=0.04) compared to 19 patients 
with low score, but there was no difference in dialysis vintage (6.4±4.8 vs. 5.3±4.2 years, 
p=0.44) or presence of cardiovascular disease. We found no difference in mean calcium 
carbonate dose (4.1±1.6 vs. 4.4±1.9 g/day, p=0.59) or mean cinacalcet dose (21±26 vs. 
12±17 mg/day, p=0.18), but significantly higher mean calcitriol-equivalent dose of active 
vitamin D (1.7±0.8 vs. 0.9±0.8 mg/week, p=0.03). There was no significant difference in 
Ca, CaxP product, iPTH or AF, but P was significantly higher (1.6±0.2 vs. 1.4±0.3 mmol/l, 
p=0.03) in group with high AAC score.
Conclusions: In patients with higher AAC score higher mean active vitamin D dose 
and higher phosphate levels over a long period of time were found in addition to older age 
and more diabetes. We find this retrospective analysis important because treatment and 
laboratory values were evaluated over a prolonged period.
SA-PO605
Influence of the Bone Mineral Disorder on Vascular Calcification Occurrence 
and Progression in Hemodialysis Patients  João Henrique Castro,1 Pasqual 
Barretti,1 Janaina Silva Martins,2 Rogerio Carvalho Oliveira.1  1Medical Clinic, 
Faculdade de Medicina de Botucatu, Botucatu, Sao Paulo, Brazil; 2Medical 
Clinic, Univ Estadual de Maringa, Maringa, Parana, Brazil.
Background: Cardiovascular disease is the main cause of death in hemodialysis 
patients; vascular calcification (VC) is common among them. The main objective of this 
study was to evaluate the influence of bone mineral disorders in VC and its progression 
in a prospective cohort of patients. Secondarily, we intend to identify clinical, laboratory 
and nutritional predictors of the presence and progression of VC.
Methods: Adult patients undergoing HD for ≥90 days were included. At the beginning 
of and after 12 months Kaupilla and Adragão methods were used to determin the VC score 
(VCS); and clinical, hormonal, inflammatory, biochemical, and nutritional markers were 
measured. Bone biopsy and histomorphometric analysis were performed at the beginning 
of follow up.
Results: Sixty patients completed the study; of them 41.7 % were male, 43.4% diabetic, 
and the mean age was 56. 7±13.8 years. At the beginning of the follow-up, 75% of the 
patients exhibited VC. Age > 60 years (Odds ratio=50.2, 95%CI= 4.1-618,4, p=0.002), 
FGF23 levels > 3000 Ru/ml (Odds ratio=5.7, 95%CI= 1,00-329, p=0.05), and serum fetuin A 
>673 g/l (Odds ratio=7.34, 95%CI= 1,26-43,7, p=0.03) were independent predictors of VC. 
Regarding VC progression age > 60 years (Odds ratio=4.3, 95%CI= 1.003-18.5, p=0.049), 
serum fetuin A >673 g/l (Odds ratio=6.4, 95% CI= 1.47-27.9, p=0.01), no use of statins 
(Odds ratio=5.6, 95%CI= 1.13-28.1, p=0.03) were the only independent predictors. Bone 
turnover and histomorphometric findings were not associate with VC and its progression.
Conclusions: The present study reinforces the role of age, FGF23 levels, use of 
statins on the VC process and arises a paradoxical effect of serum fetuinA on VC and its 
progression, which deserves new and more specific investigations.
SA-PO606
Low Bone Mineral Density of Lower Extremities Associates with Coronary 
Calcification Score in End-Stage Renal Disease Patients  Zhimin Chen,1 Abdul 
Rashid Tony Qureshi,1 Bengt Lindholm,1 Hannes Olauson,1 Peter F. Barany,1 
Lars Wennberg,2 Jonaz Ripsweden,3 Peter Stenvinkel.1  1Renal Medicine & 
Baxter Novum, Karolinska Inst, Stockholm, Sweden; 2Transplantation Surgery, 
Karolinska Inst, Stockholm, Sweden; 3Radiology, Karolinska Inst, Stockholm, 
Sweden.
Background: Kidney transplantation (Rtx) corrects many abnormalities in uremia but 
mineral and bone disorders and cardiovascular disease often persevere. We investigated 
associations between low bone mineral density (BMD) and coronary artery calcification 
(CAC) in patients (pts) with end stage renal disease (ESRD) undergoing living donor Rtx.
Methods: In 40 pts (aged 44 ± 13 years; 60% male) undergoing living donor Rtx, BMD 
measurements were made before (n=19), close to (n=40) and after (n=13) RtX and CAC 
measurements (n=34) were also made close to RtX. BMD was assessed by dual-energy 
X-ray absorptiometry (DXA) and CAC by computed tomography. We investigated the 
associations between BMD and CAC (measured at the same time). Logistic regression 
models were adjusted for age, gender and diabetes.
Results: Altogether 32 % (11/34) pts had CAC Agatston score ≥ 100. CAC associated 
with age (rho = 0.46, p < 0.01) and diabetes (rho = 0.57, p < 0.001). At baseline, there 
were significant associations between CAC and BMD of upper extremities (rho= -0.49, p 
< 0.01), BMD of lower extremities (rho = -0.66, p < 0.001) and BMD of femoral neck (rho 
= -0.58, p < 0.001). In multivariate analysis adjusted for age, gender and diabetes, BMD 
of lower extremities remained as significantly lower in pts with CAC scores ≥ 100 (p< 
0.05). No significant differences were seen between values of BMD obtained -2.0 [-4.4, 
-1.1] years before Rtx (n=19) as compared to BMD obtained close to Rtx at -0.1 [-0.7, 0.6] 
years (n=40) or 2.1 [1.1, 3.3] years after (n=13) RTx. Sex-stratified analyses also showed 
no significant differences in BMD before, close to and after RTx.
Conclusions: BMD of lower extremities is associated with CAC in ESRD pts 
undergoing living donor Rtx. No significant changes in BMD were found when comparing 
values before, close to and after RTx. Further studies are required to elucidate the 
mechanism(s) linking BMD to CAC score in ESRD pts.
Funding: Pharmaceutical Company Support - Baxter, Government Support - Non-
U.S.
SA-PO607
Association of Vascular Calcification Biomarkers with Peripheral Arterial 
Disease in Hemodialysis Patients  Steven Menez,1 Michelle M. Estrella,1 Esther 
D. Kim,2 Lucy A. Meoni,1 Kunihiro Matsushita,1 Pranav S. Garimella,3 Stephen 
M. Sozio,1 Rulan S. Parekh,1,2 Bernard G. Jaar.1  1Medicine, Johns Hopkins Univ, 
Baltimore, MD; 2Medicine, Univ of Toronto, Toronto, ON, Canada; 3Medicine, 
Tufts Univ, Boston, MA.
Background: Vascular calcification is common in ESRD patients. We evaluated 
whether the vascular calcification biomarkers, namely osteoprotegerin (OPG), fetuin A, 
and matrix Gla protein (MGP) are associated with PAD among incident hemodialysis 
(HD) patients in the Predictors of Arrhythmia and Cardiovascular Events (PACE) study.
Methods: We performed a cross-sectional analysis among 402 participants in whom 
these biomarkers were measured at baseline. We defined PAD as ABI <0.9 or >1.4 and or a 
documentation in the medical record at study entry. Using multivariable logistic regression 
we evaluated the association of OPG, fetuin A and MGP with prevalent PAD. Sensitivity 
analysis was performed in persons who had PAD defined only by medical records.
Results: PAD was prevalent in 28% (n=111) of the cohort. Mean age was 55 years, 
72% were black. 60% were ever smokers, 58% had diabetes, 37% had coronary artery 
disease, and 69% hypercholesterolemia. The median OPG and MGP levels were 10.1 
pmol/L and 1412 pM, respectively; the mean fetuin A level was 0.51 g/L. Adjusting for 
age, gender, race, Charlson co-morbidity index, smoking, diastolic blood pressure, mean 
serum phosphate, and mean dialysate calcium concentration, 1 pmol/L higher OPG was 
associated with 1.07-fold increased odds of PAD. There was no association of fetuin A 
or MGP with PAD. In sensitivity analysis, the association of OPG and odds of PAD was 
similar to the main results.
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Association of Vascular Calcification Biomarkers with Odds of PAD
Unadjusted OR (95% CI) Adjusted OR (95% CI)
OPG, per 1 pmol/L higher 1.06 (1.02-1.11) 1.07 (1.01-1.13)
Fetuin A, per 1 g/L higher 0.88 (0.24-3.26) 1.25 (0.27-5.81)
MGP, per 1-log pM higher 0.98 (0.75-1.28) 0.91 (0.66-1.25)
Conclusions: In this population of incident HD patients at high risk of PAD, OPG 
was significantly associated with odds of PAD. Whether the elevation of OPG is causal 
to the development of PAD or whether it serves as a marker of disease severity needs to 
be explored.
Funding: NIDDK Support
SA-PO608
Association of Metabolic Syndrome with Aortic Arch Calcification and 
Outcome in Non-Diabetic Peritoneal Dialysis Patients  Cheng Chia Lee,1,2 
Kun-Hua Tu,1,2 Ya-chung Tian,1,2 Ming-Yang Chang,1,2 Chih-Wei Yang.1,2  1Dept 
of Nephrology, Kidney Research Center, Chang Gung Memorial Hospital, 
Taoyuan, Taiwan; 2Chang Gung Univ, College of Medicine, Taoyuan, Taiwan.
Background: Vascular calcification (VC) is now recognized as an important risk 
factor for mortality in dialysis patients. Previous studies have shown conflicting results 
regarding the association of the metabolic syndrome (MetS) and mortality in patients on 
peritoneal dialysis (PD). Despite the controversial definition of MetS in PD patients, the 
association between MetS and the presence and severity of VC in the non-diabetic PD 
patients remained unknown.
Methods: We enrolled 277 non-diabetic PD patients into this study. Posterior-anterior 
chest X-ray were assessed for the aortic arch calcification (AoAC). Frequency of different 
components and their constellation as MetS were determined according to the modified Adult 
Treatment Panel III criteria. Using multinomial logistic regression, the factors determine 
baseline AoAC were analyzed. We used Kaplan Meier analysis to assess the impact of 
MetS on both mortality and technique failure.
Results: Mean age was 48.4 ± 13 years and 43.1% (n=118) had metabolic syndrome.179 
patients were classified as no visible calcification (AoAC grade 0), 51 patients as mild 
calcification (AoAC grade 1), and 47 patients as moderate to severe calcification (AoAC 
grade 2+ 3). The adjusted odds ratio for AoAC grade 1 was 3.03 (95% CI: 1.34-6.84) 
and for AoAC grade 2+3 was 6.25 (95% CI: 2.26-17.27) among patients with MetS as 
compared with those without MetS. Multivariate linear regression analysis showed that 
MetS (P <0.001) was independent risk factor for higher inflammation, as denoted by high 
sensitivity C-reactive protein. Over a mean of 45.9 months of follow-up, 34 patients died. 
Kaplan Meier analysis demonstrated that the incidence of mortality and technique failure 
does not differ in patients with and without MetS.
Conclusions: MetS was independently associated with the presence and severity 
of AoAC but cannot predict mortality or technique failure in non-diabetic PD patients. 
Nevertheless, non-diabetic PD Patients with MetS warrant more aggressive risk factor 
management to reduce the risk of VC.
SA-PO609
Increased Peripheral Arterial Calcification in Patients Receiving Warfarin 
Kum Hyun Han,2 W. Charles O’Neill.1  1Renal Div, Emory Univ, Atlanta, 
GA; 2Internal Medicine, Inje Univ College of Medicine, Ilsan Paik Hospital, 
Goyang, Korea.
Background: Matrix gla-protein is a vitamin K-dependent inhibitor of vascular 
calcification, and genetic deficiency or inhibition with warfarin produces medial vascular 
calcification in animals, raising concerns that warfarin may promote vascular calcification 
in humans. We recently showed that warfarin use is associated with increased breast arterial 
calcification but whether this is reflective of other arteries or occurs in men as well is unclear. 
Therefore, we compared the prevalence of calcification in peripheral arteries in patients 
with and without warfarin therapy.
Methods: A random sample from a computerized search of medical records yielded 
430 patients with x-rays performed during or after warfarin therapy. Each was matched 
to a patient without warfarin exposure based on age and diabetes. Patients with warfarin 
exposure <1 month, history of ESRD, or serum creatinine > 2.0 were excluded. X-rays 
were reviewed visually for arterial calcification.
Results: Mean age was 66.9 + 0.8, 41% were males, and 34% had diabetes. The 
indication for warfarin was atrial fibrillation in 45% and venous thrombosis or embolism 
in 44%, and mean duration of warfarin was 4.8 yrs (range: 1 month to 38 yrs). 68% were 
on warfarin at the time of the x-ray and the remainder had been off warfarin for a mean of 
2.4 yrs (range: 1 day to 25 yrs). Serum calcium was slightly lower (9.04 +/- 0.03 vs. 9.17 
+/- 0.03, p=0.0005) in the warfarin patient but serum creatinine and phosphorus did not 
differ. Prevalence of arterial calcification was 44% greater in warfarin patients (30.2% vs. 
20.9%, p=0.0023) but not on x-rays performed prior to warfarin (26.4% vs. 22.4%, n=156), 
indicating that the increase was due specifically to the warfarin and not to underlying disease 
or other patient characteristics. The increase in calcification was seen only after >5 yrs 
of warfarin and only in the ankle and foot. It was similar in men and women and greatest 
(2.4-fold) in patients under age 60 (15% vs. 6.3 %, p=0.04).
Conclusions: Warfarin use is associated with lower extremity arterial calcification 
in both men and women independent of age, diabetes, and other patient characteristics.
Funding: Clinical Revenue Support
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Matrix Gla Protein and Vascular Calcification in Patients with End Stage 
Renal Disease  Hannes Olauson,1 Christian L. Meuwese,1 Karin Luttropp,1 
Annika Wernerson,1 Peter F. Barany,1 Cees Vermeer,2 Peter Stenvinkel.1 
1CLINTEC, Karolinska Inst, Sweden; 2VitaK, Maastricht Univ, Netherlands.
Background: Vascular calcification (VC) is a common and severe consequence of 
end-stage renal disease (ESRD). Matrix Gla protein (MGP) is a calcification inhibitor 
expressed by the vasculature that counteracts the development of VC.
Methods: In 84 ESRD patients undergoing LD-Tx at Karolinska University Hospital, 
biopsies from the inferior epigastric artery were obtained during surgery. Vascular 
calcification was assessed by von Kossa staining both by manual scoring (0-3) and by 
semi-automated analysis (%). Total uncarboxylated MGP (t-ucMGP) and dephospho-
uncarboxylated MGP (dp-ucMGP) were measured in plasma. Tissue MGP expression was 
quantified in arterial biopsies by TaqMan rtPCR. DNA methylation of the MGP gene was 
assessed in peripheral blood from 12 ESRD patients and 12 healthy controls.
Results: 50 patients (59.5%) had low VC scores (0 and 1) and 34 (40.5%) patients high 
VC scores (2 and 3). Plasma levels of dp-ucMGP were higher in patients with high VC 
scores compared to patients with low VC scores (2214 [1413-2995] vs. 1701 [1275-2233] 
pmol/L, p<0.05) and also associated with calcification (%) (Fig 1A: β [95%CI]: 26 [7 to 
45] p<0.01). Additionally, calcification (%) associated with arterial expression of MGP (Fig 
1B: β [95%CI]: 0.04 [0.02 to 0.06] p<0.0001). t-ucMGP levels were not associated with 
measures of VC. DNA methylation of the MGP gene was significantly lower in patients 
with ESRD compared to healthy controls (adjusted p<0.01). 
Conclusions: Tissue and plasma levels of dp-ucMGP were higher in patients with VC 
versus those without, possibly indicating a compensatory up-regulation of MGP to prevent 
further progress. The observation that the methylation of the MGP gene was lower in ESRD 
than in controls suggests that the altered expression could be due to epigenetic regulation.
Funding: Government Support - Non-U.S.
SA-PO611
A Nationally Representative Case Control Study of Calciphylaxis Risk 
Factors  Sagar U. Nigwekar,1 Sophia Zhao,1,2 Julia Beth Wenger,1 Franklin 
W. Maddux,2 Jeffrey L. Hymes,2 Ravi I. Thadhani,1 Kevin Chan.1,2  1MGH; 
2Fresenius Medical Care North America.
Background: Prior studies evaluating calciphylaxis risk factors suffer from sample 
size limitations and none examine whether characteristics at dialysis initiation predict 
calciphylaxis risk.
Methods: Data for this matched case control study were derived from hemodialysis 
(HD) population at the Fresenius Medical Care North America (FMCNA). Cases were 
identified from FMCNA calciphylaxis prospective database. Controls (HD patients without 
calciphylaxis) were matched to cases on age, sex, and race. Data on variables at HD 
initiation were abstracted. Variables for multivariable logistic regression analyses were 
identified using stepwise selection.
Results: We analyzed 1,025 calciphylaxis cases (52% biopsy-confirmed) and 2,050 
controls. Body mass index, diabetes mellitus (DM), serum parathyroid hormone (PTH) 
level, use of warfarin and phosphate binders were higher whereas serum calcium and active 
vitamin D use were lower at HD initiation in cases compared to controls.
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Cases (n=1,025) Controls (n=2,050) P value
Age,years 54±14 54±14 NA
Sex, female % 67 67 NA
Race, white % 49 49 NA
BMI, kg/m2 36.3±9.9 30.3±8.5 <0.001
DM, % 61.2 44.4 <0.001
Albumin-corected calcium, mg/dL 8.6±1.3 8.8±1.0 <0.001
Phosphrous, mg/dL 5.1±2.3 4.9±1.7 0.18
PTH, pg/mL (median, IQR) 339 (153, 658) 288 (129, 523) <0.001
Albumin, g/dL 3.3±0.8 3.5±0.6 <0.001
Warfarin, % 23.3 7.4 <0.001
Active vitamin D, % 70.8 80.9 <0.001
Cinacalcet, % 7.2 4.3 0.06
Phosphate binder, % 65.5 58.5 0.04
Statin, % 44.3 38.0 0.67
Insulin injections, % 25.6 15.5 <0.001
No significant differences were noted for serum phosphorous, dialysate calcium, use of 
statins and cinacalcet. In DM subgroup, insulin injection use was more common in cases. 
In multivariable analyses, obesity (OR: 2.55, 95% CI: 1.82-3.59), DM (OR: 2.63, 95% 
CI: 1.88-3.69), use of warfarin (OR: 3.60, 95% CI: 2.40-5.41) and insulin injections (OR: 
1.29, 95% CI: 1.07-1.89) were associated with higher risk. Similar results were noted in 
analyses restricted to biopsy-confirmed cases.
Conclusions: Obese, diabetic HD patients treated with insulin injections or warfarin 
are at high risk for calciphylaxis.
Funding: Private Foundation Support
SA-PO612
Calciphylaxis Quality Improvement Project and Case Series  Rohan V. Mehta, 
Jean Luc Franck, Jason Cobb.  Renal Div, Emory Univ, Atlanta, GA.
Background: Calciphylaxis (Calcific Uremic Arteriolopathy) is a serious condition 
characterized by extended length of stays and multiple hospital admissions. The treatment 
of calciphylaxis can become a burden on the healthcare system especially with the demands 
on hospital systems to become more efficient.The lengths of stay & 30-day readmission 
rates are becoming a measure of hospital quality.We developed a multidisciplinary team 
including nephrologists, hospitalists, dermatologists, hospital administration, nurses, 
wound care staff, social workers, dieticians, and palliative care.The purpose of the team is 
to improve the quality of care of our calciphylaxis patients.In development of this quality 
improvement project we began by examining our baseline patient population.We are 
reporting our baseline data as a case-series.
Methods: Retrospective chart review of calciphylaxis patients from 2001-2014 in our 
single center hospital which includes academic and community physicians.Baseline data 
reported included age, calcium, phosphorus, PTH, albumin, hemoglobin, creatinine, BUN, 
and the use of warfarin. Treatment options, the length of stay, and number of admissions 
were reported.
Results: In 20 reported patients, 19 were African-American. Average age was 61 
years old. Average calcium levels of 8.8 mg/dl and phosphorus of 5.5 mg/dl. The average 
PTH was 573, albumin 2.75 gm/dl, hemoglobin of 10.4 gm/dl BUN of 42, and creatinine 
6.5 md/dl. 13 patients received hyperbaric oxygen treatment, 9 patients received sodium 
thiosulfate infusions, and 6 patients received cinacalcet. 11 patients were using warfarin 
for medical conditions including atrial fibrillation and deep venous thrombosis.The average 
length of stay was 45 days and 3 admissions per patient.
Conclusions: We reported one of the largest single center and predominant African-
American calciphylaxis case series.In comparison to other reported calciphylaxis series our 
average PTH was lower and a high percentage of our patients were using warfarin at time 
of diagnosis.Future tasks include testing if the multidisciplinary quality improvement team 
interventions can improve our patient quality of care and hospital goals such as reductions 
in length of stay and 30-day readmission rates.
SA-PO613
Calciphylaxis – A Multi-Interventional Treatment Regimen Including 
Vitamin K Supplementation Might Reduce Mortality in Chronic Kidney 
Disease Patients  Daniel A. Hochfellner,1 Barbara Binder,2 Werner Ribitsch,1 
Alexander R. Rosenkranz,1 Gernot Schilcher.1  1Clinical Div of Nephrology, 
Dept of Internal Medicine, Medical Univ of Graz, Graz, Austria; 2Dept of 
Dermatology, Medical Univ of Graz, Graz, Austria.
Background: Calciphylaxis is a rare disease predominantly affecting patients with 
chronic kidney disease (CKD) with a high mortality mainly due to wound infection. 
Recently, multimodal therapy schemes including sodium thiosulfate (STS) have been 
established. The role of a standardized Vitamin K supplementation remains unclear.
Methods: In a retrospective study we evaluated the impact of a standardized, multi-
interventional treatment regimen on the mortality of calciphylaxis patients treated at 
the Clinical Department of Nephrology, Medical University of Graz, Austria between 
January 2009 and February 2014. Patients were treated with STS, dermatological wound 
management and high dose supplementation of vitamin K1 (Phytomenadion 30mg/week). 
The primary endpoint was mortality compared to the present literature. Secondary endpoints 
included gender distribution, number of biopsy proven cases, analysis of triggering events 
and time from event to diagnosis. Data were collected from medical records.
Results: 20 patients with newly diagnosed Calciphylaxis at different CKD stages (CKD 
5, n= 15; CKD 4, n= 3; CKD 3, n= 1; no CKD, n= 1;) were included. The mortality was 
25% versus 52% compared to recent literature. Gender distribution and amount of biopsy 
proven cases were comparable to other retrospective studies. 12 patients (60%) had a known 
preceding event such as trauma possibly having triggered development of calciphylaxis. 
The period from event to diagnosis was 103±94 days. 19 patients (95%) received STS. In 
contrast to other multimodal therapeutic concepts 95% (19) of our patients additionally 
received high dose vitamin K supplementation.
Conclusions: In our cohort calciphylaxis was associated with a markedly reduced 
mortality as compared to published outcome data. We hypothesize that supraphysiological 
supplementation of vitamin K in addition to thiosulfate therapy and our multi-interventional 
treatment regimen play an important role in the treatment of calciphylaxis.
SA-PO614
The German Calciphylaxis Registry  Vincent Brandenburg,1 Jürgen Floege,2 
Joanna Korbiel,1 Markus Ketteler.3  1Cardiology, RWTH Aachen Univ Hospital, 
Aachen, Germany; 2Nephrology, RWTH Aachen Univ Hospital, Aachen, 
Germany; 3Nephrology, Klinikum Coburg, Coburg, Germany.
Background: Calciphylaxis (CUA) is a rare disease and for patients a devastating 
condition associated with high morbidity and mortality. CUA is characterised by painful, 
ischemic, partly necrotic skin ulcerations. Pathomorphologically, media calcification 
of cutaneous arterioles and extracellular matrix remodelling are the hallmarks of CUA. 
Epidemiology and risk factors are incompletely understood. Referring patients to specialized 
units is limited due to high disease burden.
Methods: Therefore, we established an internet-based observational registry in 2006 
(www.calciphylaxie.de) to allow online notification for pts with CUA. The registry includes 
a comprehensive data base with 71 parameters concerning patient and laboratory data, 
clinical background and presentation as well as therapeutic strategies. The diagnosis of 
CUA is made on clinical and/or histological grounds by the referring physician.
Results: Until Febr 2015 n=253 patients with CUA have been recorded (~ 30 pts/
year at constant rate) with a median delay of 28 days after onset: 99% Caucasians, 60% 
females; 76% HD and 10% PD patients; median age 66 (IQR 61-76) years. Co-medication 
at the time of diagnosis: 75% ESA, 51% vitamin K antagonists (VKA). Skin biopsy was 
done in 45%, prior PTex in 12%; major skin lesion in 80% at the legs. Median lab data 
upon diagnosis of CUA: Alk Phos 113 U/L (IQR 86 - 167); PTH 173 ng/L (IQR 73-390), 
total calcium 2.20 mmol/L (IQR 2.04-2.36), phosphorus 1.62 mmol/L (IQR 1.28-2.00). 
Among the most frequently recorded therapeutic procedures were: surgical necrosectomy 
(plus antibiotics), intensifying dialysis modality, reduction of calcium supply, i.v. sodium-
thiosulfat application. Survival was analyzed in a subgroup of 91 pts: Median survival time 
was 516 days after online notification.
Conclusions: CUA is a rare disease among ESRD pts with high mortality. Therapeutic 
strategies vary significantly among centers; EBM guidelines are absent. VKA usage appears 
to be risk factor for CUA in ESRD pts. The German CUA registry is a valuable tool to 
collect data and may become a basis for a European registry (EuCalNet).
Funding: Pharmaceutical Company Support - Sanofi, Amgen
SA-PO615
Evaluation of the Effects of Sodium Thiosulfate Treatment on Calciphylaxis 
Pain  Guillermo Ortiz, Joshua Wibecan, Julia Beth Wenger, Ravi I. Thadhani, 
Sagar U. Nigwekar.  Nephrology Div, Massachusetts General Hospital, Boston, MA.
Background: Intravenous sodium thiosulfate (STS) is commonly prescribed to treat 
calciphylaxis, a highly fatal disease that presents with excruciating painful skin lesions. 
Anecdotal reports suggest that STS may improve calciphylaxis associated pain (CAP) within 
2 weeks of initiation; however, systematic evaluation of effects of STS on CAP is lacking.
Methods: This observational study included 22 patients with biopsy-confirmed 
calciphylaxis who were hospitalized at our center for ≥ 2 weeks during 2012-2014 for 
newly diagnosed calciphylaxis and were treated with STS. Medical records were reviewed 
to abstract clinical data including CAP severity (0-10 scale) and analgesic use. CAP scores 
at baseline, 1-week, and 2-week time-points were noted and classified into mild (1-3), 
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moderate (4-6), and severe (7-10) categories. Responders were patients who reported ≥ 30% 
improvement in CAP severity score from baseline during the first 2 weeks of treatment. 
Predictors of response and association between CAP response during the first 2 weeks of 
STS treatment and 6-month outcomes (skin lesion status, mortality) were examined in 
univariate logistic regression analyses.
Results: Median age was 60 years (Range: 52-67), 59% were males, 95% were whites, 
55% were on dialysis, 36% had chronic kidney disease not requiring dialysis, and 9% had 
normal kidney function. Median duration between lesion appearance and STS initiation 
was 12 weeks (Range: 6-19). There was a trend toward decrease in severe CAP from 
baseline to 2-weeks (figure 1) despite steady doses of opiate medications. No significant 
predictors of CAP response were observed and CAP improvement at 2-weeks did not 
predict 6-month outcomes.
Conclusions: A large prospective trial is needed to ascertain the effects of STS on CAP.
SA-PO616
Long-Term Impact of Strict Blood Pressure Control During CKD on 
Mortality Risk After ESRD  Elaine Ku,1 Lawrence J. Appel,2 Jennifer J. 
Gassman,2 Miroslaw Smogorzewski,2 Mark J. Sarnak,3 David V. Glidden,1 
Chi-yuan Hsu.1  1UCSF; 2AASK; 3Tufts.
Background: In extended follow-up of the Modification of Diet in Renal Disease 
(MDRD) study, we reported that strict BP control did not lower risk of ESRD but associated 
with lower mortality risk after ESRD (HR 0.72 [95% CI 0.58–0.89]) (Ku KI 2015). To 
further address this issue, we conducted parallel analyses in the African American Study of 
Kidney Disease (AASK) and post-hoc pooled analyses of AASK and MDRD.
Methods: AASK randomized 1094 persons with CKD attributed to hypertension 
to strict (mean arterial pressure [MAP] <92) versus usual BP control (MAP <102-107 
mmHg) between 1995-2001. We ascertained death and ESRD status through 6/2012 via 
US Renal Data System (USRDS) and Social Security Death Index for 1067 enrollees with 
non-missing identifiers.
Results: In extended AASK follow-up, 397 cases of ESRD and 475 deaths (208 after 
ESRD) occurred. The risk for ESRD was 0.94 (95% confidence interval [CI] 0.77-1.14), 
overall mortality risk was 0.92 (95% CI 0.77-1.10), and risk for death after ESRD onset 
was 0.92 (95% CI 0.70-1.20) comparing strict versus usual BP arms. Thus, the CI for 
death after ESRD was wider and included the prior MDRD estimate. In pooled MDRD/
AASK analysis (N=1907), the corresponding risk for ESRD (1024 cases) was 0.90 (95% 
CI 0.80-1.02), overall mortality (N=920) was 0.87 (0.76-0.99), and risk for death after 
ESRD (N=532) was 0.78 (95% CI 0.75-0.92).
Conclusions: Although AASK analyses did not achieve conventional statistical 
significance for outcomes of interest, potentially due to inadequate power, pooled results 
demonstrated a continued association between strict BP control and lower mortality risk after 
ESRD. These data provide the most persuasive evidence to date that aggressive management 
of BP prior to ESRD may have a persistent benefit after ESRD onset.
Funding: NIDDK Support
SA-PO617
Obesity, Renin-Angiotensin System Blockade, and Chronic Kidney 
Disease: A Population-Based Cohort Study  Jordana B. Cohen, Alisa J. 
Stephens-Shields, Michelle Denburg, Amanda Hyre Anderson, Raymond R. 
Townsend, Peter P. Reese.  Univ of Pennsylvania, Philadelphia, PA.
Background: Obesity substantially increases the risk of the development and 
progression of chronic kidney disease. Adipose tissue expresses all of the components 
of the renin-angiotensin system (RAS), which is an important contributing factor to the 
high prevalence of hypertension in obese patients, and drives renal hyperfiltration and 
subsequent glomerular injury.
Methods: We performed a retrospective cohort study using The Health Improvement 
Network, a primary care database with comprehensive demographic, laboratory, and 
pharmacologic data from patients in the United Kingdom. We evaluated the effect of time-
updated exposure to RAS blockade versus all other antihypertensive medications in obese, 
hypertensive, non-diabetic patients with normal or mildly reduced kidney function using 
a Cox proportional hazards model as estimated by pooled logistic regression to assess the 
hazards of developing a 50% reduction in estimated glomerular filtration rate (eGFR) or 
end stage renal disease. In addition to adjusting for baseline comorbidities including age, 
gender, socioeconomic status, cardiovascular disease, and body mass index (BMI), we 
adjusted for time-varying covariates including systolic blood pressure (SBP), number of 
antihypertensive medications, use of mineralocorticoid antagonists, and eGFR.
Results: There were 219,701 patients that met inclusion criteria, with a median 4.9 
years of follow-up. Median baseline eGFR was 72.6 mL/min/1.73m2, median SBP was 
146 mmHg, and median BMI was 32.8 kg/m2. 59% of patients were on RAS blockade at 
baseline, and 69% of patients were on it for at least half the duration of follow-up. Taking 
into account time-updated exposure, there was a significantly reduced hazard of adverse 
renal outcomes in patients treated with RAS blockade compared to those treated with other 
antihypertensive medications (HR 0.93, p<0.01).
Conclusions: This study, conducted in a large real-world cohort of patients with detailed 
and time-updated data about blood pressure treatment, provides important evidence that RAS 
blockade may protect against deterioration in renal function among obese, hypertensive, 
non-diabetic patients.
Funding: NIDDK Support
SA-PO618
Distribution and Prognostic Value of Central Blood Pressure in Chronic 
Kidney Disease  Yun Jung Oh,1 Su Mi Lee,2 Ji Yong Jung,3 So Mi Kim,4 
Chungsik Lee.1  1Dept of Internal Medicine, Cheju Halla General Hospital, Jeju, 
Republic of Korea; 2Dept of Internal Medicine, Dong-A Univ Hospital, Busan, 
Republic of Korea; 3Dept of Internal Medicine, Gacheon Univ Gil Hospital, 
Incheon, Republic of Korea; 4Dept of Internal Medicine, Jeju National Univ 
Hospital, Jeju, Republic of Korea.
Background: Central blood pressure (CBP) has been shown to be a better predictor 
for cardiovascular events and target organ damages than brachial blood pressure. However, 
little is known about comparative values of CBP and brachial BP in chronic kidney disease 
(CKD) population. We investigated the distribution of CBP and evaluated the comparative 
values of CBP and brachial BP for the prediction of renal progression in both CKD and 
non-CKD population.
Methods: We conduct this study using data from 868 subjects who underwent CBP 
measurement by the radial artery tonometric method between 2009 and 2013. Demographic 
and clinical characteristics were obtained from a review of the medical records at the time 
of CBP measurement. The outcome was renal progression defined as decline of estimated 
glomerular filtration rate greater than 30% of baseline during the follow-up.
Results: In overall, estimated central systolic BP (cSBP) was higher than brachial 
systolic BP (bSBP). The cSBP was significantly increased with age in non-CKD group, but 
such a correlation was not observed in CKD group. In CKD population, high cSBP group 
with greater than mean cSBP value (³150mmHg) had significantly increased probability 
of renal progression (P=0.016), while high bSBP (³140mmHg) group did not predict the 
outcome (P=0.370). In contrast, the predictor of renal progression was high bSBP not cSBP 
in non-CKD population. In Cox analysis adjusted for covariates, high cSBP remained 
a predictor of renal progression in CKD population (HR 5.408; 95% CI 1.008-29.030; 
P=0.049), whereas high bSBP was not a significant predictor in non-CKD population (HR 
2.893; 95% CI 0.786-10.650; P=0.110).
Conclusions: The CBP had different correlation with age and clinical significance 
according to presence or absence of CKD, and the high cSBP was strong independent 
predictor of kidney disease progression in CKD patients.
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SA-PO619
Clinical Characteristics and Outcomes Associated with Resistant 
Hypertension in a Large Cohort of U.S. Veterans  Csaba P. Kovesdy,1,2 Miklos 
Zsolt Molnar,2 Adriana Hung,3 Jun Ling Lu,2 John J. Sim,4 Robert B. Canada,2 
Elvira Gosmanova,2 Fridtjof Thomas,2 Kamyar Kalantar-Zadeh.5  1VA Medical 
Center, Memphis, TN; 2Univ of Tennessee Health Science Center, Memphis, 
TN; 3VA Medical Center, Nashville, TN; 4Kaiser Permanente, CA; 5Univ of 
California, Irvine, CA.
Background: The prevalence of true resistant hypertension (RH), the characteristics 
of patients with RH and its association with clinical outcomes is unclear.
Methods: From 2,398,778 patients with essential HTN, we identified 95,334 (4%) 
with RH, defined as: Failure to achieve BP<140/90 mmHg with >=3 antihypertensives 
(one being a thiazide diuretic) or success with >=4 drugs; excluding measurements when 
pain score was >5, when interfering medications were prescribed and excluding those with 
confounding conditions (CKD, secondary HTN, sleep apnea, urinary obstruction, adrenal, 
thyroid and parathyroid over-activity). We examined associations with mortality, incident 
CKD, ESRD, steeper slopes of eGFR, incident coronary heart disease (CHD) and stroke in 
Cox models and logistic regression models adjusted for demographic and socioeconomic 
factors, comorbidities, BP, and antihypertensives.
Results: The mean SBP/DBP in RH and non-RH patients were 148±22/81±14 vs. 
137±19/78±12 mmHg. Compared to non-RH, patients with RH were older (64±11 vs. 
62±13), more likely to be black (25 vs. 17%) and had a higher prevalence of DM and CVD. 
Crude mortality was similar and the incidence of the renal and cardiovascular end points 
was higher in RH. After full adjustment the risk of CHD and stroke associated with RH 
remained significant, but the risk of renal outcomes was reversed (Figure).
Conclusions: RH is relatively infrequent (4%) among patients with essential HTN, 
and is associated with older age and a higher comorbidity burden. Patients with RH have 
a higher risk of incident CHD and stroke.
Funding: NIDDK Support, Veterans Administration Support
SA-PO620
Association of Components of Body Mass Index with Treatment-
Resistant Hypertension in Men and Women with Chronic Kidney Disease 
Toshiyuki Aoki,1 Yasushi Ohashi,1 Reibin Tai,1 Kiyoto Koibuchi,2 Atsushi 
Aikawa,1 Ken Sakai.1  1Nephrology, Toho Univ School of Medicine, Ohta-ku, 
Tokyo, Japan; 2Nephrology, Saiseikai Eastern Hospital, Yokohama, Kanagawa, 
Japan.
Background: Treatment-resistant hypertension is a risk for cardiovascular disease and 
end-stage renal disease. However, the appropriate clinical management strategies remain 
unclear in patients with CKD. Our objective is to investigate the association of components 
of body mass index (BMI) with treatment-resistant hypertension in patients with CKD.
Methods: Body fluid composition was measured in 310 patients with CKD from 2005 
to 2014, and BMI was separated into 3 components – (a) free water mass consisting of 
muscle, fat, and minerals, (b) intracellular water (ICW), and (c) extracellular water (ECW). 
Treatment-resistant hypertension was defined as an office BP of ³130/80 mmHg, despite 
receiving ³3 antihypertensives including diuretics, or ≥4 drugs usage. The main outcomes 
were adverse renal outcomes, as defined by a decline of 50% or more from baseline GFR 
or initiation of renal replacement therapy and cardiovascular events.
Results: The prevalence of treatment-resistant hypertension were 69 male patients 
(35.4%) and 19 females (16.5%). Patients with treatment-resistant hypertension were more 
likely to be diabetic, have a higher BMI, GFR, and proteinuria, and to be older especially in 
women. In the components of BMI, those in men and women tended to have higher ECW 
content and free water mass, respectively. Higher ECW contents in men and diabetes in 
relation to higher free water mass in women were independently caused treatment-resistant 
hypertension. Compared with patients with no treatment-resistant hypertension during a 
median 743-day follow-up, those with treatment-resistant hypertension had worse adverse 
renal outcomes (16.2 vs. 6.1 per 100 patient-years, P < 0.001) and cardiovascular events 
(5.0 vs. 1.6 per 100 patient-years, P < 0.001).
Conclusions: Treatment-resistant hypertension is associated with diabetes in relation 
to higher free water mass in women and higher ECW in men, which exhibits adverse renal 
outcomes and cardiovascular events. These findings emphasize the importance of adequate 
weight and volume status.
SA-PO621
Adherence Assessment in Resistant Hypertension: A Comparison 
Between Pill Count and Direct Method of High Performance Liquid 
Chromatography Analysis in Urine  Patricia Cardoso Alarcon Hori, Silvana 
de Barros, Indira Fernandes Braga Azam, Andrea Pio de Abreu, Andrea Cassia 
Perreira Sforsin, Vanusa Barbosa Pinto, Decio Mion Junior, Giovanio Vieira 
da Silva.  Nephrology and Pharmacy, General Hospital of Sao Paulo Univ, 
Sao Paulo, Brazil.
Background: Poor adherence to antihypertensive therapy is one of possible causes 
of resistant hypertension. Pill count is currently considered the standard for assessing 
drug adherence, but as an indirect method, it is inaccurate. The aim of this study was to 
compare the pill count with the direct method of toxicological urine screening in patients 
with resistant hypertension.
Methods: Patients with resistant hypertension criteria were included: office blood 
pressure (BP) above goal (systolic BP> 140mmHg and/or diastolic BP> 90mmHg) taking 
3 or more antihypertensive agents of different classes, one of them diuretic, or office BP 
below goal taking 4 or more classes. Adherence was assessed by direct method of high 
performance liquid chromatography analysis for antihypertensive drugs or their metabolites 
in 4 different urine samples, with 30-day interval between them. Simultaneously, pill count 
was also performed. Patient was considered adherent by direct method if it was found every 
prescribed agents in at least 3 urine samples. Regarding pill count, patient was considered 
adherent if he consumed at least 90% of prescribed agents.
Results: 18 patients were selected: 78% women, age 57.5 ± 5.7 years, body mass 
index 29.3 ± 3.6 kg/m2, office mean BP 151/88 ± 20/15 mmHg and 24 hours mean BP by 
ambulatory blood pressure monitoring 132/85 ± 21/12 mmHg. The average number of 
antihypertensive agents prescribed was 4.8 ± 0.8 classes per patient. 3 (17%) and 2 (11%) 
patients were considered adherent by direct method and pill count, respectively. However, 
the agreement between methods was poor (Kappa correlation coefficient -0.15).
Conclusions: Adherence to therapy in patients with resistant hypertension was very 
low in both methods. There was no agreement between pill count and direct method. 
The best method to assess adherence in resistant hypertension is yet to be determined. 
Supported by FAPESP, CNPq.
Funding: Government Support - Non-U.S.
SA-PO622
Plasma Renalase Concentration Before and After Radiofrequency Renal 
Denervation in Patients with Resistant Hypertension: Preliminary Results 
Marcin Adamczak,1 Beata Czerwienska,1 Maciej T. Wybraniec,2 Michal 
Lelek,2 Katarzyna T. Mizia-Stec,2 Andrzej Wiecek.1  1Dept of Nephrology, 
Transplantation and Internal Medicine, Medical Univ of Silesia, Katowice, 
Poland; 21st  Dept of Cardiology, Medical Univ of Silesia, Katowice, Poland.
Background: Renalase is a catecholamine-metabolizing enzyme produced by proximal 
tubular cells in kidney which is supposed to be involved in blood pressure regulation. The 
aim of the study was to evaluate plasma renalase concentration after radiofrequency renal 
denervation (RDN) in patients with resistant arterial hypertension (HTN).
Methods: 19 patients (10 men; median age 56 (48; 57) years; BMI 30.9±4.4 kg/m2 
and eGFR 89±17.7 ml/min/1.73 m2) with resistant HTN were enrolled in the study. In all 
patient plasma renalase concentration was measured before and 1, 3, 6 and 12 months after 
RDN by ELISA method (Cloud-Clone Corp, Houston, USA).
Results: A significant decrease of both office systolic and diastolic blood pressure 6 
months after RDN was found (192 ± 31 vs. 177 ± 28 mmHg, p=0.03; 113 ± 23 vs. 99 ± 21 
mmHg, p=0.002, respectively). One and 3 months after RDN plasma renalase concentration 
decreased significantly, with a subsequent return to values comparable with baseline at 6- 
and 12-month follow-up (median of 22100 vs. 18550 vs. 17600 vs. 20750 vs. 20500 ng/
ml respectively; Friedman analysis of variance p=0.054).
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Conclusions: 1. RDN leads to the temporary decrease of plasma renalase concentration 
in patients with HTN. 2. Lower plasma renalase concentrations seems to be a counteract 
reaction to the antihypertensive effects of RDN.
Funding: Government Support - Non-U.S.
SA-PO623
A Non-Vascular Treatment for Resistant Hypertension  Richard R. Heuser,1 
Adam Gold.2  1Cardiology, St. Luke’s Medical Center, Phoenix, AZ; 2Verve 
Medical, Scottsdale, AZ.
Background: Systematic arterial hypertension remains the most common and important 
risk factor for cardiovascular and renal disease. A safe and effective medical device effecting 
a significant and immediate fall in arterial BP addresses an unmet clinical need. Early 
clinical experience with the Verve non-vascular device causes an immediate BP drop in 
patients with resistant hypertension.
Methods: In humans, there is a greater abundance of efferent compared with afferent 
nerve fibers and the afferent nerves are much less abundant in general and are much less 
abundant as one goes away from the aorta. In contrast to the widespread distribution of 
EFFERENT Sympathetic nerve fibers in the kidney, the majority of the AFFERENT Renal 
Sensory nerves are located in the renal pelvic area. With our first generation device, we 
treated patients with resistant hypertension. Four patients with resistant hypertension were 
treated. They had immediate blood pressure drop (Systolic Mean 44mmHg, Diastolic 
Mean 13mmHg), which was maintained for 3 months. Because of the possibility of 
calyceal damage noted in follow-up in our animal model, we have redesigned the probe 
and shortened the duration of therapy.
Results: In over two dozen animals, it appears that we get a similar histopathologic 
results with our first generation probe without late pelvic or calyceal damage. In our first 
clinical application of this helical probe, there also is an immediate blood pressure drop.
Conclusions: Unlike other renal denervation treatments, the Verve natural orifice 
approach appears to treat the afferent nerves and results in an immediate blood pressure 
drop. More patients will need to undergo treatment to confirm these encouraging results. We 
will present our first series of resistant hypertensive patients treated with the helical device.
SA-PO624
Microparticles Cause Preeclampsia and Kidney Injury by Activation of 
Inflammasome in the Placenta  Shrey Kohli, Berend Heinrich Isermann. 
Inst of Clinical Chemistry and Pathobiochemistry, Otto Von Guericke Univ, 
Magdeburg, Germany.
Background: Preeclampsia is a hypertensive disorder of pregnancy associated 
with high morbidity and mortality. Hallmarks of preeclampsia are endothelial damage 
and functional (e.g. proteinuria) and morphological renal aberrations. The only known 
remedy against this is the delivery of the placenta. Cell derived microparticles (MP) of 
different origins are elevated in preeclampsia but their mechanistic relevance is unknown. 
Preeclampsia is also associated with a pro-inflammatory condition but there are meager 
mechanistic insights into this as well.
Methods: To address these questions MP (endothelial or platelet derived) were 
injected into C57/Bl6 pregnant mice and the pregnancy outcome (embryonic survival 
and growth, placenta morphology) was studied. Morphology of the kidney was studied 
using PAS staining and electron microscopy. Proteinuria was studied as a measure of renal 
dysfunction. To address mechanistic questions, inflammasome activation by MP in placenta 
and trophoblast cells was studied using western blotting and immunohistochemistry. Human 
trophoblast derived cells and placentas from pregnancies complicated with pre-eclampsia 
were also studied for activation of inflammasome. NLRP3 and Casp-1 KO mice were 
used to rescue the mice from disease conditions and establish causality of the mechanism.
Results: MP caused preeclampsia associated with fetal loss and embryonic growth 
restriction in mice. This was associated with renal damage indicated by proteinuria, 
glomerular enlargement, thickness of glomerular basement membrane, and podocyte 
effacement in the kidney. Human and mouse placenta analysis indicated inflammasome 
activation seen by elevated expression of NLRP3, cleaved casp-1 and IL-1β. The pregnancy 
outcome and renal function was rescued in NLRP3 and Casp-1 KO mice.
Conclusions: Our results establish that MP are causative of preeclampsia, fetal 
death, embryonic growth restriction, and renal injury. These pathogenic effects of MP are 
mechanistically linked with inflammasome activation in the placenta.
Funding: Government Support - Non-U.S.
SA-PO625
Short Term Sequela of Preeclampsia  Michael Yannik Girsberger,1 Irene 
Mathilde Hoesli,2 Michael Dickenmann.1  1Clinic for Transplantation 
Immunology and Nephrology, Univ Hospital Basel, Basel, Baselstadt, 
Switzerland; 2Dept of Gynaecology and Obstetrics, Univ Hospital Basel, Basel, 
Baselstadt, Switzerland.
Background: Data on sequela in the first year after preeclampsia are scarce. We 
investigated kidney function, blood pressure, proteinuria and urine sediment in women 
with preeclampsia six month after delivery.
Methods: From January 2007 to July 2014 all women with preeclampsia and 6-moths 
follow up at the university hospital Basel were prospectively analysed. Preeclampsia 
was defined as new onset of hypertension (³140/90 mmHg) or worsening hypertension 
and either proteinuria or signs of end-organ dysfunction. Hypertension was defined as a 
blood pressure (BP) ³140/90 or the use of antihypertensive medication. Proteinuria was 
defined as a protein-to-creatinine ratio in a spot urine > 11 mg/mmol. Urine sediment was 
evaluated by a nephrologist.
Results: 202 women were included. Baseline characteristics are shown in Table 1 and 
follow up data are shown in Figure 1. The mean time of the follow up visit was 172 days 
(+/- 39.6) after delivery. The mean blood pressure at follow up was 124/76 mmHg (+/- 
14/11, range 116-182/63-110) and the mean serum-creatinine was 61.8 umol/l (+/- 11.6). 
Mean estimated glomerular filtration rate (CKD-EPI) was 110.7 mml/min/1.73m2 (range 
59.7-142.4 mml/min/1.73m2). No active urine sediment (e.g. signs of glomerulonephritis) 
was observed. 
Onset Gestational Week 36+1.75 (+/- 3.9)
Gravida 1.75 (+/- 1.16)
Para 1.41 (+/- 0.78)
Multiple pregnancy (twins, triplets) (27/202) 13.4%
Diabetes before pregnancy (4/201) 1.99%
Gestational diabetes (19/202) 9.4%
Previous hypertension (16/202) 7.9%
HELLP (40/198) 20.2%
Eclampsia (4/198) 2.0%
Severe Preeclampsia (132/197) 67%
Acute Kidney Injury (17/197) 8.6%
Chronic kidney disease (4/201) 1.99%
Conclusions: The findings stress the importance of a close follow up to identify those 
women who need further care.
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SA-PO626
Preeclampsia: Long-Term Effects on Pediatric Neurologic Disability 
Alberto Tejedor Jorge, Clara Nicolas, Patrocinio Rodríguez Benítez, Olga 
Arroyo, Maria Silva, Laura Matesanz, Carmela Mercurio, Manuel Sánchez 
Luna.  Hospital General Univ Gregorio Marañón.
Background: Preeclampsia affects up to 10% of pregnancies worldwide and is 
one of the main causes of fetal morbidity and mortality. Although it has been linked to 
developmental delay, its long-term effects on neurologic development in children have yet 
to be sufficiently quantified. Our aim is to evaluate whether the preeclampsia’s severity 
and the therapeutic options used to manage it correlate to the degree of developmental 
delay in these infants.
Methods: This is an observational and descriptive study performed on a population 
of 96 women who were diagnosed with preeclampsia at Hospital General Universitario 
Gregorio Marañón between 2007 and 2014, and their 111 children. To evaluate the 
mother, we gathered data pertaining to her medical history, renal function markers, and 
medical management of the preeclampsia. To assess the children, we collected fetal 
growth measurements, acute fetal distress markers and main diagnoses at birth. We used 
the Pediatric Disability Inventory in its computerized adaptive test version (PEDI-CAT) 
to study neurologic development, and the TNO-AZL Preschool children Quality of Life 
(TAPQOL) to estimate health-related quality of life.
Results: Early-onset and more severe preeclampsias were associated with higher 
preterm birth and perinatal mortality rates. Preeclampsias with a greater impact on maternal 
organ function showed a clear correlation to higher periventricular-intraventricular 
hemorrhage rates in the newborn. In terms of neurologic development, PEDI-CAT 
percentiles were consistently lower in the Social/Cognitive domain than in other areas. 
Lower Social/Cognitive percentiles were associated to both lower maternal IgG levels and 
presence of necrotizing enterocolitis during the neonatal period.
Conclusions: Early-onset preeclampsias have a greater negative impact on both 
maternal renal function and fetal morbimortality. A connection between preeclampsia and 
poor social/cognitive outcomes exists that warrants further research, as does the possible 
link between between preeclampsia, immunity, and autistic features.
SA-PO627
Do Hypertension Providers Inquire About Hypertension in Pregnancy? 
Andrea G. Kattah, Vesna D. Garovic.  Div of Nephrology and Hypertension, 
Mayo Clinic, Rochester, MN.
Background: Hypertensive pregnancy disorders are increasingly recognized as a risk 
factor for future hypertension and cardiovascular disease. However, knowledge of this risk 
may be inadequate among internal medicine providers.
Methods: We reviewed all new consults in a 2-month period in a hypertension 
subspecialty clinic. We determined the frequency with which providers documented a 
reproductive history, a history of hypertension in pregnancy and known cardiovascular 
risk factors. We also studied whether there were differences according to gender and level 
of training of the provider (consultants vs. residents/fellows) using the chi-square test.
Results: There were 102 consults for hypertension in the study period. The majority 
of consults were by consultants, 55/102 (53.9%), and 23/102 (22.6%) were by female 
providers. A reproductive history, including number of pregnancies, infertility and/or intent 
of pregnancy, were documented in 37/102 (36.3%) of notes. Chart review revealed that 
85/102 (83.3%) of women had live births, but it was documented in only 31 (36.5%) of notes. 
Female providers were more likely to document pregnancies (57.9% vs. 30.3%, p=0.03). 
Of the women who had live births, 15/85 (17.7%) of providers inquired about hypertension 
in pregnancy and 12/85 (14.1%) inquired about preeclampsia. Other hypertension and 
cardiovascular risk factor documentation by level of training are shown below.
Risk Factor, n(%) Resident/Fellow (n=47)
Consultant 
(n=55) P-value
Dietary issues 29 (62%) 32 (58%) 0.72
Alcohol Use 37 (79%) 36 (55%) 0.94
Illicit Drug Use 16 (34%) 2 (4%) <0.0001
Smoking 41 (87%) 47 (85%) 0.79
Exercise 27 (58%) 29 (53%) 0.71
Medication-related effects 32 (68%) 31(56%) 0.23
Family History of Hypertension 43 (92%) 38 (69%) 0.005
Renal Disease 44 (94%) 41 (75%) 0.01
Dyslipidemia 17 (36%) 25 (46%) 0.34
Diabetes 22 (47%) 25 (46%) 0.89
Obstructive Sleep Apnea 22 (47%) 21 (38%) 0.38
Hypertension in Pregnancy* 5/36 (14%) 10/49 (20%) 0.44
Preeclampsia* 5/36 (14%) 7/49 (14%) 0.96
*Only in women with live births 
Conclusions: Hypertension specialists rarely document a reproductive history or a 
history of hypertension in pregnancy, irrespective of level of training. Female providers 
were more likely to document pregnancies.
SA-PO628
Accuracy of a Spot Urine Protein-to-Creatinine Ratio in Preeclampsia 
Roshni Upputalla,1 Juliet Mushi,2 Mary King,2 Belinda Bun Jim,1 Anjali 
Acharya.1  1Nephrology, Jacobi Medical Center/Albert Einstein College of 
Medicine, Bronx, NY; 2Obstetrics, Jacobi Medical Center/Albert Einstein 
College of Medicine, Bronx, NY.
Background: Correlation between a 24 hour urinary protein excretion with a spot urine 
protein-creatinine (SP/Cr) ratio in patients with preeclampsia is unclear. Moreover, urinary 
creatinine excretion is greater in populations such as Africans and non-white Hispanics. 
We studied the correlation of the SP/Cr ratio with a 24 hour urine protein measurement 
in this minority population.
Methods: ICD-9 codes of 642.4, 642.5, 642.6, 642.7 representing mild pre-eclampsia 
to eclampsia were used for data collection. Only 110 women with both 24 urinary protein 
collection and (SP/Cr) were included in the analysis. Correlation between SP/Cr and 24-hour 
protein excretion was assessed by Spearman correlation coefficient. The sensitivity and 
specificity of the SP/Cr ratio at various cut-offs for the prediction of significant proteinuria 
were estimated with a 95% confidence interval, using the 24-hour urine collection as gold 
standard. Receiver operating characteristic (ROC) curve analysis was used to determine 
the best discriminator values of the (SP/Cr) to predict proteinuria above 300 mg/ 24 hr. A 
P value of 0.05 or< was significant.
Results: The median SP/Cr ratio was 0.30 (interquartile range (IQR) 0.3) while the 
median 24 hour urine protein was 316.5 mg (IQR 286.8). The overall Spearman correlation 
was 0.48 (P= .0001). and 0.63 (P = 0.05), 0.59 ( P= .01), and 0.45 (P= .0001) for the 1st, 2nd, 
and 3rd trimesters respectively. At the cut-off value of 0.15 for SP/Cr, the sensitivity and 
specificity were 91.8% and 75.5% respectively. The cut-off SP/Cr ratio 0.25 was identified 
as the best threshold to detect a 24 hour protein excretion of 300 mg with a sensitivity and 
specificity of 75% and 59% respectively. The area under the curve (AUC) by the ROC 
curve analysis was found to be 0.69.
Conclusions: Even in a minority, inner city population we found significant correlation 
between the 24 hour protein excretion and the SP/Cr ratio, especially in the 2nd and 3rd 
trimesters of preeclamptics. Our findings are in line with the literature despite a minority 
patient population.
SA-PO629
Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using 
Tacrolimus  Arthur David Moes, Dennis Alexander Hesselink, Anton H. Van 
den Meiracker, Robert Zietse, Ewout J. Hoorn.  Internal Medicine, Erasmus 
Medical Center, Rotterdam, Netherlands.
Background: Hypertension after kidney transplantation is common and associated 
with poorer graft and recipient outcomes. Recently, we and others showed that tacrolimus 
activates the thiazide-sensitive sodium chloride cotransporter to cause hypertension. 
This suggests that thiazide diuretics may be especially effective drugs in this context, but 
prospective data are lacking.
Methods: We conducted a non-inferiority crossover trial to compare chlorthalidone 
(CT, 12.5-25 mg) with amlodipine (AML, 5-10 mg). Patients were invited for ambulatory 
blood pressure measurement (ABPM) if office BP >140/90 mmHg. Other criteria included 
eGFR >30 ml/min, proteinuria < 1 g, and no use of glucocorticoids. The treatment periods 
were randomized, lasted 8 weeks (allowing dose titration after 2 weeks), and were separated 
by a 2-week wash-out. Background anti-hypertensive drugs were allowed except for other 
diuretics.
Results: 71 patients underwent initial ABPM of whom 45 patients (63%) with average 
wake SBP >140 mmHg were enrolled (median 2.6 years after transplantation). 38 patients 
completed the study (5 patients stopped during CT mainly due to electrolyte disorders vs. 
2 during AML, p=0.4). CT and AML both markedly reduced ABPM after 8 weeks (151/85 
± 11/9 to 141/81 ± 12/9 mmHg vs. 151/84 ± 13/9 to 138/79 ± 14/7 mmHg). There was no 
statistical difference in blood pressure response between the two drugs (p=0.3 by 2-way 
ANOVA). Dose titration rates were similar (42% for CT vs. 37% for AML, p=0.8). CT 
decreased eGFR (53 ± 17 to 46 ± 15 ml/min), whereas amlodipine increased it (50 ± 16 to 
53 ± 17 ml/min, P<0.001). The first post-CT eGFR returned to baseline (51 ± 17 ml/min). 
Treatment with CT resulted in less proteinuria (median 14 vs. 19 mg/mmol, p=0.03) and less 
edema (8 vs. 31%, p=0.02). Regression analysis showed that a higher aldosterone to renin 
ratio, lower baseline serum potassium, and higher baseline serum bicarbonate predicted a 
better anti-hypertensive response to CT.
Conclusions: Thiazide diuretics effectively lower blood pressure in kidney transplant 
recipients using tacrolimus. Thiazides were especially effective in patients with more 
aldosterone effect.
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SA-PO630
The Detrimental Effects of Beta-Blockers on Central Hemodynamic 
Parameters: A Propensity Score Analysis  Remi Goupil,1 Dominique Dupuis,1 
Stephan Troyanov,1 Francois Madore,1 Mohsen Agharazii.2  1Hopital du Sacre-
Coeur de Montreal, Montreal, QC, Canada; 2CHU de Québec, Hotel-Dieu de 
Quebec, Quebec City, QC, Canada.
Background: Central blood pressure (BP) and aortic stiffness are better predictors 
of the cardiovascular burden than peripheral BP. Beta-blockers (BB) are known to reduce 
central BP to a lesser extent than peripheral BP, a hypothesized consequence of heart rate 
(HR) reduction. Therefore, the association between BB use, HR and central hemodynamics 
indices were studied in the treated hypertensive participants of the CARTaGENE study.
Methods: Using propensity score analyses, BB users (n=605) were matched to controls 
having similar clinical characteristics with (Model 1) and without (Model 2) adjustment 
for HR. This resulted in 457 and 510 pairs with adequate balance, except for a different 
HR in Model 2 (62.5 ± 10.5 vs. 70.4 ± 11.5 bpm, p<0.001).
Results: In Model 1, the difference between peripheral and central systolic BP 
(DSBP) was 8.3 mmHg (IQR 5.8, 11.6) with BB compared to 9.7 mmHg (7.1, 13.5) 
without (p<0.001), indicating that for any given peripheral BP, BB use resulted in higher 
central systolic BP. Pulse pressure amplification, augmentation index and augmented 
pressure were also less favorable with the use of BB. The different HR in Model 2 further 
increased the detrimental DSBP observed with BB to 7.9 (5.6, 11.0) vs. 10.6 (8.1, 14.3) 
without (p<0.001) and was associated with a higher central pulse pressure (46.5 ± 13.0 
vs. 43.3 ± 11.3, p<0.001).
Model 1 Model 2 
Parameters No beta-blocker 
Beta-
blocker p-value 
No beta-
blocker 
Beta-
blocker p-value 
Central SBP 120 ± 15 121 ± 16 0.67 118 ± 15 121 ± 17 0.006
ΔSBP 9.7 (7.1-13.5)
8.3 (5.8-
11.6) <0.001
10.6 (8.1-
14.3)
7.9 (5.6-
11.0) <0.001
Central PP 45 ± 11 46 ± 13 0.45 43 ± 11 47 ± 13 <0.001
PP amplification 1.3 (1.2-1.3)
1.2 (1.1-
1.3) <0.001 1.3 (1.2-1.4)
1.2 (1.1-
1.3) <0.001
Augmentation 
Index 29 ± 11 31 ± 11 0.005 27 ± 11 31 ± 10 <0.001
Augmented 
pressure 13 (9-17) 13 (9-19) <0.001 11 (7-16) 14 (9-20) <0.001
Conclusions: This study shows that the unfavorable central hemodynamic profile of 
BB has both a HR-dependent and a HR-independent component.
Funding: Government Support - Non-U.S.
SA-PO631
Risk of Development of Dementia During Treatment of Hypertension with 
Different Calcium Channel Blockers  Leonid Feldman,1,2 Shai Efrati,1,2 Ilia 
Beberashvili,1,2 Shlomo Vinker,2,3 Michal Shani.2,3  1Assaf Herofeh Medical 
Center, Israel; 2Tel Aviv Univ, Israel; 3Clalit Health Services, Israel.
Background: Arterial hypertension (HTN) is proved to be a risk factor for development 
of dementia. Medical treatment of HTN may decrease the risk of dementia. Experimental 
study pointed to the possibility of difference between different calcium channel blockers 
(CCB) in their neuro-protective effect. The aim of our study was to evaluate the risk of 
dementia during treatment of HTN with one of three different CCBs.
Methods: This is a retrospective cohort study based on electronic database of Clalit 
Health Services, Central District. Study period was 11 years (2002-2012). Inclusion criteria: 
age 40-75, diagnosis of HTN without diagnosis of “Dementia” at the starting point, minimal 
duration of treatment > 30 months with single specific CCB. New diagnosis of dementia was 
established according to appearance of its diagnostic code in the chronic diseases register 
or prescription of medication for its treatment – whatever occurred first.
Results: 15,664 patients were included in the study: 3,884 were treated with amlodipine, 
2,062 - with nifedipine, 609 – with lercanidipine and 9,109 never received CCBs. The mean 
age was 60.7 years, 52.9% were females and the mean baseline creatinine was 1.0 mg/dL. 
13.4% of patients died during the study period. Dementia developed in 765 (4.9%) patients. 
Adjusted HR of dementia in patients treated with amlodipine, nifedipine and lercanidipine 
was 0.60 (p<0.001), 0.89 (NS) and 0.90 (NS).
Conclusions: Treatment of arterial hypertension with amlodipine may be associated 
with decreased risk of development of dementia in comparison to treatment without CCBs.
SA-PO632
The Association Between Antihypertensive Agents and Postural Blood 
Pressure Response Using Beat-to-Beat Data: Results from the Irish 
Longitudinal Study on Ageing  Mark N. Canney,1,2 Matthew Dl O’Connell,1 
Catriona M. Murphy,1 Mark Alan Little,2 Conall M. O’Seaghdha,3 Rose Anne 
M. Kenny.1  1The Irish Longitudinal Study on Ageing, Trinity College Dublin; 
2Trinity Health Kidney Centre, Tallaght Hospital Dublin; 3Dept of Nephrology, 
Beaumont Hospital Dublin.
Background: Beat-to-beat blood pressure (BP) measurements provide a dynamic 
picture of BP behavior during postural change. Impaired BP stabilization after standing is 
associated with substantial morbidity and mortality. We aimed to define the relationship 
between class of antihypertensive drug and BP stabilization during an active stand.
Methods: Cross-sectional analysis from The Irish Longitudinal Study on Ageing, 
a nationally representative cohort study of 8175 adults ≥50 years. Beat-to-beat BP was 
recorded in participants undergoing an active stand test. We defined grade 1 hypertension 
according to European Society of Cardiology criteria (systolic BP [SBP] 140-159mmHg 
± diastolic BP [DBP] 90-99mmHg). Orthostatic hypotension (OH) was defined as a drop 
in SBP ³20mmHg ± DBP ³10mmHg. Outcomes were sustained OH (OH throughout the 
test) and impaired BP stabilization (OH at each 10-second (s) interval during the test [total 
110s]). Outcomes were assessed using logistic regression models adjusted for potential 
confounding variables.
Results: A total of 536 participants with self-report hypertension were receiving 
monotherapy with a renin-angiotensin-aldosterone-system inhibitor (317), betablocker (89), 
calcium channel blocker (89) or diuretic (41). Betablockers were associated with increased 
odds of sustained OH vs untreated grade 1 hypertension (OR 3.4, 95% CI 1.9-6.0). This 
was evident from 20s (OR 2.3, 95% 1.4-3.7) and remained statistically significant at 110s 
(OR 2.8, 95% CI 1.6-4.9). Multivariable adjustment did not attenuate the association. No 
significant association was detected among the other drug classes.
Conclusions: In older hypertensive adults betablocker monotherapy was associated 
with a >3-fold increased odds of OH compared to subjects with untreated grade 1 
hypertension. The effect was evident from 20s after standing and was sustained. This 
should inform decision-making regarding appropriate choice of antihypertensive agent 
in older adults.
SA-PO633
Effect of Vitamin D on 24 Hour Ambulatory Blood Pressure: A Randomized, 
Double-Blind, Placebo-Controlled Clinical Trial  Ciaran Joseph McMullan,1 
Lea Borgi,1 Gary C. Curhan,1 Naomi D.L. Fisher,2 John P. Forman.1  1Renal Div, 
Brigham and Women’s Hospital, Boston, MA; 2Endocrine Div, Brigham and 
Women’s Hospital, Boston, MA.
Background: Lower levels of 25-hydroxyvitamin D (25[OH]D) have been associated 
with an increased risk of hypertension in prospective cohort studies, suggesting that 
vitamin D might be a modifiable target for the prevention of hypertension. Vitamin D 
supplementation has also been shown to decrease clinic blood pressure (BP) in some studies.
Methods: We performed a randomized, double-blind, placebo-controlled trial of 
nonhypertensive participants with body mass index ³25, and 25[OH]D£20ng/mL; subjects 
were randomized to receive either ergocalciferol 50,000 units or placebo, once a week for 
8 weeks. Mean 24 hour BP was measured using 24 hour ABPM at baseline and 8 weeks 
after starting the study.
Results: By the end of the trial, 29 and 27 participants randomized to receive vitamin 
D and placebo, respectively, had adequate 24 hour ABPM at both baseline and at 8 weeks. 
Mean vitamin D levels increased from 14.9 to 30.3 ng/mL in the intervention group and from 
14.4 to 17.4 ng/mL in the placebo group. Vitamin D supplementation did not lower BP at 8 
weeks; 24 hour systolic BP changed from 120±10 to 122±8 mmHg in the intervention group 
(p-value=0.29), and from 124±8 to 125±10mmHg in the placebo group (p-value=0.38), 
with a treatment effect p-value of 0.92.
Conclusions: In this randomized, double-blind, placebo-controlled trial of overweight/
obese normotensive individuals, there was no improvement in mean 24 hour blood pressure 
after repletion of vitamin D. These findings are not consistent with vitamin D being a 
modifiable target for prevention of hypertension.
Funding: NIDDK Support
SA-PO634
Effect of Uric Acid Lowering on Intrinsic Renal and Systemic Renin 
Angiotensin System Activity: A Randomized, Double-Blind, Placebo-
Controlled Clinical Trial  Ciaran Joseph McMullan,1 Lea Borgi,1 Gary C. 
Curhan,1 Naomi D.L. Fisher,2 John P. Forman.1  1Renal Div, Brigham and 
Women’s Hosptial, Boston, MA; 2Endocrine Div, Brigham and Women’s Hosptial, 
Boston, MA.
Background: Higher levels of uric acid have been associated with an increased activity 
of the renin angiotensin system (RAS) in animal models of hypertension and kidney disease. 
Similarly, individuals with high levels of circulating uric acid have increased renal specific 
RAS activity measured using renal plasma flow (RPF).  However, the effect of lowering 
serum uric acid on RAS activity in humans is unknown.
Methods: We performed a randomized, double-blind, placebo-controlled trial analyzing 
the Modifiable Effectors of Renin System Activation Treatment Evaluation (MODERATE). 
Normotensive individuals with body mass index (BMI) ³25 and uric acid level ≥ 5.0 mg/
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dL were randomized to receive either allopurinol 300/600mg, probenecid 500/1000mg, 
or placebo daily for 8 weeks. Renal specific and systemic RAS activity was measured at 
baseline and 8 weeks after starting the study.
Results: By the end of the trial, 36, 30 and 41 participants randomized to receive 
probenecid, allopurinol and placebo, had RAS measurements at baseline and 8 weeks, 
respectively.  Uric acid levels changed from a mean of 5.9, 5.6 and 5.6 mg/dL to 3.9, 3.9 
and 5.7 mg/dL in the probenecid, allopurinol and placebo groups, respectively. Renal 
specific RAS, measured by change in RPF to captopril in high sodium balance, was not 
improved after uric acid lowering: RPF response to captopril changed from 42.6±38.8 at 
baseline to 45.3±43.9 mL/min at 8 weeks with probenecid (p-value=0.26), from 40.5±34.9 
to 35.1±29.8 mL/min with allopurinol (p-value=0.23), and 37.3±46.9 to 35.9±26.2 mL/
min with placebo (p-value=0.70). Similarly, changes in plasma renin activity and plasma 
angiotensin II levels did not significant change with treatment.
Conclusions: In contrast to animal experiments and observational studies, this 
randomized, double-blind, placebo-controlled trial found that lowering uric acid had no 
effect on renal specific or systemic RAS activity.
Funding: NIDDK Support
SA-PO635
Effect of Vitamin D Supplementation on Intrinsic Renal and Systemic 
Renin Angiotensin System Activity: A Randomized, Double-Blind, 
Placebo-Controlled Clinical Trial  Ciaran Joseph McMullan,1 Lea Borgi,1 
Gary C. Curhan,1 Naomi D.L. Fisher,2 John P. Forman.1  1Renal Div, Brigham 
and Women’s Hospital, Boston, MA; 2Endocrine Div, Brigham and Women’s 
Hospital, Boston, MA.
Background: Disruption of vitamin D signalling in rodents causes activation of the 
renin angiotensin system (RAS). In humans lower circulating 25[OH]D is associated with 
increased renal specific RAS activity (measured using renal plasma flow [RPF]); in addition, 
a small, open label, uncontrolled study found that vitamin D supplementation decreased 
renal specific RAS activity. However, the effect of vitamin D supplementation on the 
RAS in humans with vitamin D deficiency has never been examined in a rigorous manner.
Methods: We performed a randomized, double-blind, placebo-controlled trial of 
normotensive individuals with body mass index ³25 and vitamin D deficiency (25[OH]D 
£20ng/mL); subjects were assigned to receive either ergocalciferol 50,000 units or placebo, 
once a week for 8 weeks. Renal specific (assessed by RPF response to captopril in high 
sodium balance) and systemic RAS activity (plasma renin activity [PRA] and angiotensin 
II levels [AngII]) were measured at baseline and 8 weeks after starting the study.
Results: By the end of the trial, 43 and 41 participants allocated to receive vitamin D 
and placebo, completed the study with measurement of renal and systemic RAS activity. 
Mean vitamin D levels increased from 14.9 to 30.3 ng/mL in the ergocalciferol group and 
from 14.4 to 17.4 ng/mL in the placebo group. Renal specific RAS did not significantly 
change after vitamin D repletion: the RPF response to captopril was 33.9±56.1 mL/min 
at baseline and 35.7±47.7 mL/min at 8 weeks in the ergocalciferol group (p-value=0.26); 
and was 37.3±46.9 mL/min at baseline and 35.9±26.2 mL/min at 8 weeks in the placebo 
group (p-value=0.70), with a treatment effect p-value of 0.27. Similarly, vitamin D 
supplementation had no effect on PRA or AngII levels.
Conclusions: In contrast to animal experiments, observational studies, and open-label 
uncontrolled interventions, this randomized, double-blind, placebo-controlled trial found 
no effect of vitamin D supplementation on RAS activity in vitamin D deficient individuals.
Funding: NIDDK Support
SA-PO636
Comparison of Office Orthostatic Blood Pressure and 24-Hour Ambulatory 
Blood Pressure Measurements in the Prediction of Autonomic Dysfunction 
Girish Singhania, Rajesh Mohandas, Kawther Farouk Alquadan, Abhilash 
Koratala, A. Ahsan Ejaz.  Nephrology, Univ of Florida, Gainesville, FL.
Background: Evaluation of orthostatic hypotension (OH) may involve office 
orthostatic blood pressure (BPOH) measurements, 24-hour ambulatory BP (ABP) and 
autonomic reflex screen (ARS). We investigated the predictive performance of BPOH and 
the variables of ABP, i.e., reversal of circadian pattern (RCP), postprandial hypotension 
(PPH) and noncompensatory heart rate variability (HRV), to predict autonomic dysfunction 
as measured by the AUC of the ROC curves.
Methods: Data from previously published study were analyzed. Ninety-four patients 
were included for analysis. BPOH, RCP, PPH, HRV were investigated for the presence 
or absence of autonomic dysfunction. Autonomic dysfunction was defined as a CASS 
(composite autonomic scoring system) score of ³1. Comparisons of the AUCs of the ROC 
curves of the candidate parameters were performed.
Results: ROCs of candidate parameters are shown in Fig. 1.
The diagnostic performance to predict autonomic dysfunction for HRV was superior 
to PPH. Both were superior to RCP. RCP was a better predictor of autonomic dysfunction 
than office BPOH.
Conclusions: Our data suggests that ABP is a reliable, simple and inexpensive predictor 
of autonomic dysfunction in routine clinical practice.
SA-PO637
Factors Predicting Long Term Renal Prognosis in Malignant Nephrosclerosis 
Peng Xia, Jiaxin Lang, Yubing Wen, Mingxi Li, Hang Li, Xuemei Li, Xuewang 
Li, Limeng Chen.  Nephrology, Peking Union Medical College Hospital, 
Beijing, China.
Background: This study investigated correlations between kidney pathology and 
Renin-Angiotensin System(RAS) activation, RAS inhibitor response and prognosis of 
malignant hypertensive nephrosclerosis(MHN) patients.
Methods: This retrospective cohort study included 82 essential MHN patients 
from Jan.2003 to Oct.2014 with renal biopsy followed up to May2015. Pathology were 
evaluated by two pathologists independently. Localized renin expression and peritubular 
capillaries(PTC) area were evaluated by IHC staining of renin and CD34. Renal replacement 
therapy, kidney transplant and death were defined as the primary end point.
Results: 87.8% of patients were male with mean age of 34.7±8.8ys. Clinical 
data showed highest blood pressure(BP)226.6±25.7/152.2±22.0mmHg, serum 
creatinine(Scr)5.31±3.79mg/dl,  proteinuria2.06±1.83g/d(n=68) and mean 
eGFR21.3±15.1ml/min.1.73m2. Glomerular Sclerosis Index, tubular atrophy and interstitial 
fibrosis were 1.51±0.51, 63.7±18.3% and64.0±18.3%. MHN patients has a lower PTC 
proportion (2.27±0.74%(n=35),3.75±0.79%(n=17), P<0.001) and a higher renin-positive 
juxtaglomerular apparatus ratio(35.1±17.8%,(n=35),21.2±15.0%(n=17),P=0.008) 
comparing with glomerular minimal lesion patients. Tubularinterstitial lesions correlated 
with Scr(r=0.547,P<0.001), eGFR(r=-0.574,P<0.001) and proteinuria(r=0.447,P<0.001). 
PTC area correlated with Scr(r=-0.675,P<0.001,n=35) and eGFR(r=0.648,P<0.001,n=35). 
90.4%patients received RAS inhibitors which was associated with improvements in BP
(136.7±9.9/86.8±8.2mmHg,P<0.001),Scr(4.06±2.74mg/dL,P<0.001) and proteinuria 
(2.26±1.89vs.1.26±0.86g/d,n=45,P<0.001). After 54.1±36.6 months follow up, 1-year 
and 5-year cumulative renal survival rates were 93%and 65%. RAS inhibitors, BP control 
and eGFR over 30ml/min·1.73m2 correlated with longer renal survival by Kaplan-Meier 
analysis. Cox regression identified RAS inhibitors(RR=0.24,95%CI(0.09,0.62),P=0.004) 
and CKD stages(RR=4.72,95%CI (1.71,13.03),P=0.003) as independent factors predicting 
renal outcome.
Conclusions: MHN patients had localized activation of renin and less PTC area. 
RAS inhibitors benefited patients in BP control, eGFR improvements and long-term renal 
outcome.
Funding: Government Support - Non-U.S.
SA-PO638
Office Blood Pressure Monitoring: A Novel Tool for Evaluating Blood 
Pressure in Children (and Adults)  Gianluigi Ardissino,1 Paolo Marchetto,1 
Francesca Tel,1 Sara Testa,1 Ilaria Possenti,1 Michela Perrone,1 Luciano 
Sangaletti,1 Amelia Ballarino,1 Stefani Rotondo,1 Silvia Ghiglia,1 Franco De 
luca,2 Patrizia Salice.1  1Pediatric Nephrology and Cardiology, Fondazione 
IRCCS Ca’ Granda Policlinico, Milan, Italy; 2Pediatric Cardiology, Policlinico 
Univ, Messina, Italy.
Background: Blood pressure measurement (BPM) is a common procedure in clinical 
practice but in children (C) obtaining reliable values can be challenging. Casual office 
BPM, the standard of care, is all but accurate and ABPM may be difficult to perform or 
even misleading.
Methods: Office Blood Pressure Monitoring (OBPM) was developed at our Center 
in 2010 for evaluating BP in C with serial and automated BPM (³10 in at least 30 min) 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
772A
J Am Soc Nephrol 26: 2015 Hypertension: Clinical Poster/Saturday
with a standard oscillometric device. BP values are uploaded in a software to calculate the 
coefficient of variation (CV) after having excluded outlier values (<5th and >95th centile 
of the recorded values).
Results: Since 2010 a total of 402 OBPMs have been performed but only the 282 in 
110 C (59% Males) aged <18 yrs old (IQR 4.8-12.1) with a CV <10% for both syst and 
diast BP were considered for the analysis. The table compares BP as measured by OBPM 
with a single BPM (1st and 3rd) and with the mean of the 3 initial measurements (*: p<0.01 
vs. others BPMs with student’s t test for paired data and c2). 
Systolic Diastolic Patient BP class No. (%)
Mean Z score ± sd Normotensive Border-line Hypertensive
1st BP 1.92±1.40 1.62±1.27 70 (24.8) 26 (9.2) 186 (66.0)
2nd BP 1.75±1.40 1.51±1.20 72 (25.5) 36 (12.8) 174 (61.7)
1st, 2nd and 3rd BP 
(mean) 1.81±1.31 1.55±1.15 75 (26.6) 30 (10.6) 177 (62.8)
OBPM 1.69±1.30* 1.48±1.12* 88 (31.2) 37 (13.1) 157 (55.7)*
Conclusions: OBPM provides significantly lower BP values, leading to a diagnosis of 
poor BP control in a smaller number of patients (-10%). Given the lack of a gold standard, 
the present analysis doesn’t demonstrate that OBPM is more reliable then standard 
procedures however serial BPM have the potential of reducing measurement biases and 
white coat effect. We recommend the routine use of OBPM for measuring BP in C at risk 
of hypertension rather then relying upon few measurements.
SA-PO639
A Simple Prediction Score for Incident Hypertension in a Korean Population 
Jong-Hwan Jung, Sung Kwang Park, Won Kim, Kyung Pyo Kang, Sik Lee. 
Dept of Internal Medicine, Chonbuk National Univ Medical School, Jeonju, 
Republic of Korea.
Background: We aimed to develop a simple prediction model for incident hypertension 
that could help to prevent or delay the onset of hypertension for some patients who did not 
experience hypertension yet.
Methods: The Korean Genome and Epidemiology Study was used for the model 
development (n=3533) and internal validation (n=1698). Hypertension was defined when 
either the systolic and diastolic blood pressures (SBP, DBP) were 140 and 90 mmHg or 
higher or being treated with antihypertensive medications.
Results: SBP, age and DBP, parental hypertension, obesity, high density lipoprotein 
(HDL), current smoking and fasting glucose were significantly associated with incident 
hypertension. Integer scores were assigned to variables based on the magnitude of 
associations SBP (-2 to 5), age and DBP (-2 to 5), parental hypertension (2), obesity (2), 
low HDL (2), current smoking (2) and high fasting glucose (2).  
b (se) Adjusted OR (95% CI)
Assigned 
score 
Systolic blood pressure
SBP <110 -0.6 (0.2) 0.55 (0.36-0.85) -2
110 ≤ SBP < 115 1 0
115 ≤ SBP < 120 0.6 (0.2) 1.87 (1.25-2.81) 2
120 ≤ SBP < 125 0.9 (0.2) 2.43 (1.61-3.67) 3
125 ≤ SBP < 130 1.1 (0.2) 2.87 (1.85-4.44) 4
130 ≤ SBP 1.3 (0.2) 3.64 (2.32-5.71) 5
Age and Diastolic blood pressure
age 40-50 and DBP ≤ 70 -0.8 (0.3) 0.45 (0.27-0.75) -2
age 50-60 and DBP 70-80 1 0
age 60-70 and (DBP ≤ 70 or DBP 70-80) 0.4 (0.2) 1.44 (1.03-2.00) 2
age 40-50 and DBP ≥ 80 0.9 (0.2) 2.51 (1.65-3.81) 3
age 50-60 and DBP ≥ 80 1.1 (0.2) 3.10 (1.94-4.95) 4
age 60-70 and DBP ≥ 80 1.3 (0.3) 3.53 (2.12-5.88) 5
Parental hypertension 0.4 (0.2) 1.41 (1.05-1.89) 2
Obesity 0.4 (0.1) 1.46 (1.13-1.89) 2
HDL < 40mg/dl 0.2 (0.1) 1.29 (1.01-1.66) 2
Fasting glucose ≥ 126mg/dl 0.6 (0.3) 1.84 (1.03-3.28) 2
Smoking 0.4 (0.1) 1.54 (1.14-2.09) 2
Based on the Youden index, 5 or greater defined a high risk with 76% sensitivity, 72% 
specificity, 27% positive predictive value and 96% negative predictive value.
Conclusions: This prediction algorithm, weighted towards common modifiable 
variables, showed good performance characteristics in a Korean population.
SA-PO640
Hemodynamics and Cardiovascular Autonomic Efficiency During  Blood 
Pressure Variations in Hemodialysis  Dan Sapoznikov, Rebecca Backenroth, 
Dvora Rubinger.  Nephrology and Hypertension Services, Hadassah Univ 
Medical Center, Jerusalem, Israel.
Background: Chronic hemodialysis (HD) is associated with hemodynamic instability 
and with reduced cardiovascular autonomic efficiency (CaE).
Methods: To define hemodynamic changes associated with intradialytic blood pressure 
variations, beat-to-beat systolic blood pressure (SBP) and interbeat interval (IBI) monitoring 
using Finometer device and Beatscope software was performed during HD sessions in 
69 non-diabetic patients (Pts), age 56±15 y. Cardiac output (CO) and total peripheral 
resistance (TPR) were calculated using the Modelflow simulation method. Differences in 
variability indices during SBP periods, 10% above (high) or below (low ) the mean SBP 
were considered representative of CaE.
Results: During low to high SBP periods, two patterns of changes were noted: increased 
CO and decreased TPR (18 Pts,TPRĻ), and relatively stable CO with increased TPR (51 
Pts, TPR↑). Low frequency (LF) range variability of SBP and IBI, CO and TPR (median 
and interquartile ranges) were:
TPRĻ TPR↑
Low-high SBP p Low-high SBP p
SBP (mmHg) 109(33)-146(28) 0.001 114(25)-159(31) 0.001
IBI (ms) 830(235)-844(226) NS 808 (158)-827(177) NS
sd IBI (ms)^ 26(14)-22(10) NS 23 (17)-24(22) NS
LF SBP (mmHg2/Hz) 132(140)-146(102) NS 127(123)-99(160) NS
LF IBI(ms2/Hz) 1706(1894)-1118(1593) NS 1014(2480)-1589(3757) NS
CO (L/min) 4.20(1.64)-5.95(2.81) 0.001 6.19 (1.90)-6.32(1.41) NS
TPR(mmHg.s/ml) 1.160(0.359)-0.922(0.412) 0.001
0.808 (0.196)-
1.046(0.443) 0.001
^sd: standard deviation 
The proportion of Pts with intradialytic hypotension (56%) was significantly higher 
in TPRĻ than in TPR↑ (28%, p=0.036), while TPR changes were directly correlated with 
post dialysis SBP (r=0.453, p=0.001) and with sd IBI (r=0.357, p=0.003) in all Pts. There 
were no differences between groups in other variables.
Conclusions: 1.CaE resetting during HD may be associated with predominant CO 
and/or TPR variations; the latter are significantly correlated to sd IBI, a strong marker of 
autonomic activity. 2.Intradialytic hemodynamics may be different in hypotension-prone 
Pts. These observations are relevant to the pathogenesis of intradialytic hemodynamic 
instability and of postdialysis hypertension.
SA-PO641
Antihypertensive Medications and Blood Pressure Control in Chronic 
Kidney Disease: A Cross-Sectional Analysis from the German Chronic 
Kidney Disease (GCKD) Study  Karl F. Hilgers,1 Matthias Schmid,2 Silvia 
Huebner,1 Martin Busch,3 Seema Baid-Agrawal,4 Anna Kottgen,5 Georg 
Schlieper,6 Claudia Sommerer,7 Gunter B. Wolf, MHBA,3 Kai-Uwe Eckardt.1 
1Univ Hospital Erlangen; 2Univ of Bonn; 3Univ Hospital Jena; 4Charite Medical 
Univ; 5Univ of Freiburg; 6RWTH Univ Hospital; 7Univ Hospital Heidelberg, 
Germany.
Background: We reported low rates of blood pressure (BP) control in a large 
German cohort of patients with chronic kidney disease (CKD). Here, we analyzed the 
antihypertensive drug therapy to assess the prevalence of resistant hypertension, and to 
determine associations with control of BP.
Methods: The German Chronic Kidney Disease (GCKD) study is a prospective 
observational cohort study which enrolled 5217 patients with CKD in Germany. Inclusion 
criteria were an estimated glomerular filtration rate (eGFR) of 30-60 mL/min×1.73 m2 
or overt proteinuria. At enrollment, office BP was measured by trained study nurses, and 
information on medications was collected from patients.
Results: Office BP was obtained from 5181 participants, 4958 (95 %) were classified 
as hypertensive (>= 140/90 mmHg or use of antihypertensive medication). In 2410 (49 
%) hypertensive patients, BP was controlled (defined as < 140/90 mmHg). Inhibitors of 
the renin-angiotensin system (RAS; ACE inhibitors, sartans and aliskiren) were the most 
frequently used antihypertensives (87.4 % of participants), followed by diuretics (61.6 %), 
beta-blockers (57.7 %) and calcium channel blockers (39.6 %). 81.4 % of hypertensive 
participants received 2 or more different antihypertensive substances. Of the patients with 
uncontrolled hypertension, 49.9 % met the definition of resistant hypertension (uncontrolled 
despite 3 or more antihypertensive substances, including a diuretic). In multivariate analysis, 
RAS inhibitors were associated with better control of BP (odds ratio 1.48, p<0.001), as 
were diuretics (odds ratio 1.16, p=0.036).
Conclusions: Resistant hypertension was present in 49.9% of CKD patients whose BP 
was not controlled. RAS inhibitors were widely used and associated with better odds for 
controlled BP whereas the use of diuretics was less frequent than expected.
Funding: Private Foundation Support, Government Support - Non-U.S.
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SA-PO642
Associations Between Cystatin C Based eGFR, Ambulatory Blood Pressure 
Parameters, and in-Clinic versus Ambulatory Blood Pressure Agreement 
in Older Community-Living Adults  Tyler Woodell, Jan M. Hughes-Austin, 
Tiffany Tran, Atul Malhotra, Joseph A. Abdelmalek, Dena E. Rifkin.  UC San 
Diego.
Background: Although CKD IV-V has been associated with abnormal ambulatory 
blood pressure (ABPM) patterns, the associations with milder CKD have not been 
determined. We examined the relationship between mild chronic kidney disease (measured 
by cystatin C-based eGFR) and abnormal ABPM (including nocturnal dipping) in healthy 
older adults. Further, we assessed agreement between clinic and ambulatory blood pressure 
monitoring.
Methods: 334 older community-living adults had clinic BP and 24-hour ABPM 
measured. Serum cystatin C levels were used to calculate eGFRcys using the CKD-EPI 
equation. Multiple linear regression was performed to examine associations between eGFR < 
60 ml/min/1.73m2 (CKDcys) and ABPM parameters. Bland-Altman analysis was performed 
to evaluate agreement between clinic and ambulatory measurements.
Results: Average age was 72. Average eGFRcys was 78 ± 20, and 60 individuals with 
CKDcys. Compared to those without CKDcys, individuals with CKDcys were older, more 
likely to have clinic-based hypertension and less likely to be dippers. After multivariate 
analysis, the presence of CKDcys was significantly associated with lower mean ambulatory 
diastolic blood pressure (DBP) (-2 mm Hg, p = 0.048), but not with nocturnal dipping or 
other ABPM parameters. Analyses using creatinine-based eGFR yielded similar results. 
Clinic systolic blood pressure (SBP) significantly overestimated mean wake time ambulatory 
SBP; mean difference was 11 mmHg for those without CKDcys (95% limits of agreement 
-14 to 35 mmHg) and 14 mmHg for those with CKDcys (95% limits of agreement -13 
to 41 mmHg); there was no statistically significant effect modification by CKD status.
Conclusions: In older community-living adults, mild CKD as detected by cystatin C 
was associated with lower ambulatory DBP, but not with dipping status. This result is in 
contrast to findings with more advanced CKD in other studies and suggests that abnormal 
ABPM may only emerge at more advanced stages of CKD. The presence of CKD did not 
affect interpretation of clinic vs. ABPM pressures, although accuracy of clinic SBP was 
poor in this older cohort.
Funding: NIDDK Support
SA-PO643
Serum MicroRNA Biomarkers for Obese Children with Hypertension 
Scott Saint-Amour,1 Santosh Kumar Patnaik,2 Sudha Garimella.1  1Pediatric 
Nephrology, Univ at Buffalo, Buffalo, NY; 2Cardiothoracic Lab, RPCI, Buffalo, NY.
Background: Childhood obesity is a major health problem and 30% of obese children 
may develop hypertension.There is no clinical method to identify high risk obese children 
before they develop hypertension. MicroRNAs are non-coding RNAs that are implicated in 
pathways of inflammation and vascular injury.There has been no characterization of miRNA 
profiles of obese children with hypertension. This study aims to characterize miRNA profiles 
as a first step toward evaluating miRNAs as biomarkers for obesity-related hypertension.
Methods: 39 patients ages 3-21 were placed in four cohorts based on presence or absence 
of obesity and hypertension.Total serum RNA was isolated using miRCURYBiofluids kit 
Exiqon®, and examined for miRNAs by RT-PCR. Cq values were normalized by the global 
mean method. Rates of false discovery(FDR) arising from multiple testing were assessed 
from P values with the Benjamini-Hochberg method.
Results: 69 of 179 examined miRNAs were detected in all samples. MiRNA 
measurements were globally reduced in sera of obese normotensive Vs. controls. Four 
miRNAs were identified as differentially expressed between these two groups at FDR 
<10%, whereas no miRNA was identified as differentially expressed between controls and 
hypertensive obese. Tukey plots of miRNAs in the cohorts are shown.
Conclusions: Serum levels of four miRNAs appear to be reduced in patients with 
obesity alone, but not in those with obesity and hypertension. While it is possible that 
serum miRNA differences were because of variables such as serum lipid content and 
medications, our study suggests that serum miRNAs have utility in detecting hypertension 
risk in obese children. This should be validated in a larger study, and the biomarker value 
of the serum miRNAs correlated with ambulatory blood pressure monitoring data as well 
as left ventricular hypertrophy.
Funding: Pharmaceutical Company Support - Roswell Park Cancer Institute Support 
to Dr. Sai Yendamuri in the Cardiothoracic Lab at RPCI was used for this study.
SA-PO644
Effect of Prenatal and Childhood Lead Exposure on Blood Pressure at 4 
Years of Age Alison P. Sanders,1 Katherine Svensson,1 Chitra Amarasiriwardena,1 
Priyanka Basnet,1 Ivan Pantic,2 Adriana Mercado-Garcia,3 Lourdes Schnaas,2 
Andrea A. Baccarelli,4 Martha M. Tellez-Rojo,3 Chris Gennings,1 Lisa M. Satlin,1 
Robert O. Wright.1  1Icahn School of Medicine at Mount Sinai; 2National Inst 
of Perinatology; 3National Inst of Public Health; 4Harvard T.H. Chan School 
of Public Health.
Background: Prenatal lead (Pb) exposure occurs during a susceptible period of renal 
development and may program later life cardiovascular and renal disease.
Methods: Systolic and diastolic blood pressure (SBP and DBP) was obtained using an 
automated oscillometer from 397 children at 4 years of age in the PROGRESS cohort located 
in Mexico City. Maternal blood samples were previously collected at the 2nd trimester 
(2T), 3rd trimester (3T), and at delivery and children’s blood samples were collected at 
birth (cord blood), 1 year, and 2 years of age. Blood lead levels (BLLs) were analyzed via 
inductively coupled plasma-mass spectrometry. We performed linear regression to examine 
the associations between longitudinal BLLs and children’s SBP, DBP, and pulse pressure 
(mSBP-µDBP) adjusting for child’s age, sex, body mass index, maternal education and 
environmental tobacco smoke.
Results: Maternal 2T BLLs ranged between 0.7 and 18.8 mg/dL, and 89 (22%) 
prenatal BLLs were above the CDC guideline level of 5 mg/dL. Increased 2T and 3T 
BLLs were associated with decreased pulse pressure (p<0.05) and modestly associated 
with increased DBP (p=0.1).
No significant associations were observed for childhood BLLs and BP. Stratification 
by sex showed that the effect of prenatal Pb (2T and 3T) on decreased pulse pressure was 
significant only among females.
Conclusions: Prenatal Pb exposure may contribute to subclinical changes in the 
developing kidney or cardiovascular system leading to elevated BP in childhood. Future 
studies will assess if the contributions of early life Pb exposure to BP outcomes persist 
at later life stages.
Funding: Other NIH Support - Supported by grants from the NIEHS P42ES016454; 
R01ES013744; R01ES021357; R01ES020268; P30ES023515.
SA-PO645
Smoking, Microalbuminuria and Renal Function in Essential Never 
Treated Hypertensive Patients  Dimitrios Petras,1 Vanessa Tzamou,3 
Athanasios Bramos,4 Panagiota E. Giannou,1 Stella-Maria Kyvelou,3 Eva 
Karpanou,2 Gregory Vyssoulis.3  1Nephrology Dept, Hippokration Hospital, 
Athens, Greece; 21st Cardiology Clinic, Onassis Cardiac Surgery Center, 
Athens, Greece; 3Hypertensive Unit, 1st Cardiology Clinic, Univ of Athens, 
Hippokration Hospital, Athens, Greece; 4Microbiology Dept, Hippokration 
Hospital, Athens, Greece.
Background: The aim of the present study was to identify possible differences 
depending on patient’s individual smoking history with renal function and microalbuminuria 
in essential never treated hypertensive patients.
Methods: The study included 6100 consecutive patients with essential hypertension. 
In each patient the smoking status has been assessed by means of a standard questionnaire. 
Each patient had renal profile work up including microalbumin levels, albumin creatinine 
ratio in 24h urine collection (ACR) and 24h creatinine clearance.
Results: The study population was divided according to the smoking status in three 
groups: Smokers (n=2350), Ex-smokers (n=663) and Non-smokers (n=3121). Microalbumin 
and ACR were significantly higher in smokers compared to ex-smokers and non-smokers 
[(26.3±24.3 vs 23.6±21.7 vs 22.0±20.0, p<0.0001), (31.5±30.2 vs 28.8±29.3 vs 27.4±27.2, 
p<0.0001), respectively]. There was no significant difference in creatinine clearance among 
the three groups of smokers (p=NS) 
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Parameters Smokers (n=2350)
Ex Smokers 
(n=663)
Non Smokers 
(n=3121) p
Micoralbumin (mg/dl) 26.3±24.3 23.6±21.7 22.0±20.0 0.0001
ACR 31.5±30.2 28.8±29.3 27.4±27.2 0.0001
24h creatinine clearance 122±37.8 121.4±37.1 121.4±36.8 0.914
SBP (mmHg) 162.7±10.3 164.4±9.7 162.4±10.6 0.0001
DPB (mmHg) 101.6±7.2 100.1±8.3 99.6±7.9 0.0001
Age (years) 51.3±12.7 57.1±12.8 55.1±14.2 0.0001
N (males) 1321 437 1506 0.0001
Conclusions: In conclusion, in this retrospective large cohort study of essential never 
treated hypertensive patients there is a clear association that active smoking is associated 
with higher microalbumin and ACR levels in these patients.
SA-PO646
Comparison of Salt Taste Thresholds and Salty Usage Behaviors Between 
Myanmar and Korean Adults  Hyungjin Cho.1  1Div of Nephrology, Dept of 
Internal Medicine, College of Medicine, Univ of Ulsan, Asan Medical Center, 
Seoul, Republic of Korea; 2Div of Nephrology, Dept of Internal Medicine, Jeju 
National Univ Hospital, Jeju, Republic of Korea.
Background: Excessive oral salt intake can induce hypertension. According to previous 
studies, prevalence of hypertension is higher in Myanmar than Korea. We postulated that 
Myanmar adult had higher salt taste thresholds and eat much saltier food. The aim of 
this study is comparing of salt taste thresholds and salt usage behavior scores between 
Myanmar and Korean adults.
Methods: This cross sectional study enrolled the patients who visited volunteer medical 
service clinic at Ansung in Korea and Hlegu and Bago in Myanmar in August 2014. We 
measured vital signs, height and weight of each patient and evaluate detection threshold, 
recognition threshold, salt preference. All patients took urinalysis and checked spot urine 
Na. They also filled up the salt usage behavior questionnaire.
Results: Total 131 patients were enrolled and 64 of them were Myanmarese and 67 
were Koreans. Blood pressure was significantly higher in Myanmar adults than Koreans. 
Detection threshold, recognition threshold, salt preference, spot urine sodium and salt usage 
behavior score was also higher in Myanmarese than Koreans.
Myanmar (n=64) Korea (n=67)
Detection threshold (%)*** 0.102±0.108 0.046±0.026
Recognition threshold (%)** 0.174±0.163 0.103±0.115
Salt preference (%)** 0.44±0.16 0.37±0.10
Spot urine sodium (mg/dL)** 157.7±84.3 117.0±62.1
Salt usage behavior score* 11.4±2.5 10.4±2.4
*p<0.05, **p<0.01, ***p<0.001
We calculated correlation coefficient between spot urine Na and other parameters that 
related to salt intake. The salt preference, salt usage behavior score and detection threshold 
significantly correlated with the spot UNa.
Conclusions: All parameters related to salt intake, such as detection thresholds, the 
recognition thresholds, salt preference, salt usage behavior score and spot urine sodium 
concentration, of Myanmarese were significantly higher than those of Korean.
SA-PO647
Relationship Between Circadian Rhythm of Blood Pressure and Intrarenal 
Arteriolosclerosis  Keiji Kono, Hideki Fujii, Kentaro Nakai, Shunsuke Goto, 
Shinichi Nishi.  Div of Nephrology and Kidney Center, Kobe Univ Graduate 
School of Medicine, Kobe, Japan.
Background: Hypertension (HT) is a common complication in chronic kidney disease 
(CKD) patients. CKD patients often have circadian rhythm disorder of blood pressure 
(BP). However, the relationship between circadian BP pattern and intrarenal damage 
remains unclear.
Methods: Ninety patients with glomerulonephritis were included in this study. Patients 
with diabetes mellitus and prescription for antihypertensive agents were excluded. Clinic 
BP (CBP) and 24-h ambulatory BP (ABP) measurements were performed in all the study 
patients, and who were divided into the following four groups; normotension (NT), 
white coat hypertension (WHT), masked HT (MHT) and sustained HT (SHT). As renal 
histopathological assessments, we evaluated the percents of sclerotic glomeruli (SG) and 
interstitial fibrosis (IF), and classified the degrees of intimal thickening of intra-lobular 
arteries (ILA) and arteriolar hyalinosis (AH) into four grades (none, mild, moderate, severe) 
in each biopsy specimen.
Results: The prevalence of NT, WHT, MHT and SHT was 60.0%, 3.3%, 23.3% and 
13.4%, respectively. In comparison of circadian BP pattern, all-day HT was most prevalent 
in the SHT group, and nocturnal HT was most prevalent in the MHT group. SG and IF 
were significantly severe in the SHT group compared to the NT group. As for intrarenal 
vascular lesions, the MHT and SHT groups had more severe AH compared to the NT and 
WHT groups, whereas ILA was comparable between all the four groups. Furthermore, we 
investigated the relationship between intrarenal vascular lesions and clinical characteristics. 
ILA was significantly correlated with age and renal function, whereas AH was significantly 
correlated with age, sex, smoking, total cholesterol, HT based on ABP (ABPHT) and HT 
based on CBP (CBPHT). In multivariate analysis, ILA was significantly correlated with 
only age, and AH was significantly correlated with age and ABPHT.
Conclusions: Our findings suggest that intrarenal AH was markedly severe not only in 
the SHT group, but also in the MHT group. Careful ABP monitoring should be recommended 
in patients with glomerulonephritis.
SA-PO648
Association of Inpatient versus Outpatient Systolic Blood Pressure with All-
Cause Mortality in Patients with Normal Estimated Glomerular Filtration 
Rate  Osita W. Okechukwu,1 Miklos Zsolt Molnar,1 Praveen Kumar Potukuchi,1 
Jun Ling Lu,1 Fridtjof Thomas,1 Kamyar Kalantar-Zadeh,2 Csaba P. Kovesdy.1,3 
1Univ of Tennessee Health Science Center, Memphis, TN; 2Univ of California, 
Irvine, CA; 3VA Medical Center, Memphis, TN.
Background: Hypertension is associated with worse outcomes, and its treatment of 
improves mortality and cardiovascular disease. Hospitalized patients undergo frequent 
BP measurements, and hence hospitalization is an opportunity to diagnose and treat 
hypertension. However, it is unclear if BP measured as inpatient is associated with outcomes.
Methods: From 3,499,271 US veterans with normal eGFR, we identified 1,113,515 
patients with inpatient and outpatient SBP recordings. We examined the association of 
baseline outpatient SBP, and baseline inpatient SBP (defined as the SBP obtained on the 
first day of the first hospitalization following cohort entry) with all-cause mortality in Cox 
proportional hazards analyses. Models included both in- and outpatient SBP and their 
interaction terms, and were adjusted for age, gender, race, eGFR, comorbidities, socio-
economic factors, and antihypertensives.
Results: Low SBP was associated with higher mortality in both settings, but much 
more so inpatients (Figure). Outpatient SBP >140-149 mmHg was associated with linearly 
higher mortality (hazard ratio (95%CI) for SBP ³170 mmHg: 1.22 (1.16-1.29), p<0.001), 
but with less increase in mortality in the inpatient setting, which was only present for SBP 
³170 mmHg (HR (95%CI) for SBP ³170 mmHg: 1.08 (1.02-1.14)). 
Conclusions: SBP shows markedly different associations in the outpatient vs inpatient 
setting, with higher blood pressures in the inpatient setting conferring less mortality risk 
compared to the outpatient setting. Until randomized controlled clinical trials are done, 
caution is warranted when treating hypertension in hospitalized patients.
Funding: NIDDK Support, Veterans Administration Support
SA-PO649
Fibroblast Growth Factor 23 and Sodium-Volume Regulation: FGF23-
Response to Sodium Restriction in Essential Hypertensive Subjects and 
to Long Term Extracellular Volume Reduction in Hemodialysis Patients 
Francesca Mallamaci, Patrizia Pizzini, Daniela Leonardis, Sebastiano Cutrupi, 
Rocco Tripepi, Giovanni Tripepi, Carmine Zoccali.  Clin. Epid. and Physiopath. 
of Renal Dis. and Hypert. & Nephrology, Dialysis, and Transplantation Unit, 
CNR-IFC & Azienda Ospedaliera, Reggio Calabria, Italy.
Background: Dietary sodium load causes volume expansion and hypertension in 
mouse models of FGF23 and αKlotho deficiency. FGF23 also associates with ultrafiltration 
volume in cross-sectional analyses in hemodialysis (HD) patients (pts) further implicating 
this bone hormone in extracellular volume regulation.
Methods: 32 uncomplicated essential hypertensives were randomized to a 2-weeks 
high sodium diet (200mmol/day) or to a 2-weeks low sodium diet (10-20 mmol/day). After 
1 week wash out, these treatments were crossed-over. At the end of each diet-period, pts 
underwent 24h urine sodium, 24h ABPM and serum intact FGF23 measurements. The 
FGF23 response to UF intensification was assessed in 52 hypertensive HD pts. FGF23 
and standardized BP measurements were performed at baseline and after 6 months of UF 
intensification.
Results: In essential hypertensives, PRA and aldosterone (P<0.01) rose during low 
sodium. However, FGF23 remained unmodified [low sodium: median 36.2 pg/mL, inter-
quartile range (IQR):32.4-44.0; high sodium:33.9 pg/mL, IQR:29.5-41.0; P=0.18]. Changes 
in FGF23 were unrelated to systolic and diastolic ABPM, heart rate, PRA and aldosterone 
changes. In hypertensive HD pts, baseline FGF23 was 4062 pg/ml (IQR: 1381-12571). BP 
during the longitudinal study fell from 144 to 139 mmHg (P=0.02) along with a parallel 
decline in dry body weight (BW)(from 63.7 to 62.8 Kg) but FGF23 remained unchanged 
(3688 pg/mL, IQR: 1372-14117,P=0.30). Changes in FGF23 were unrelated (P=0.90) with 
ongoing changes in dry BW.
Conclusions: Changes in sodium intake that potently activate the renin-aldosterone 
system do not alter FGF23 in essential hypertensives. Similarly, extracellular volume 
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reduction by UF intensification does not materially influence FGF23 in hypertensive HD 
pts. These findings suggest that FGF23 is unlikely to play a role in the response to changes 
in sodium intake in human hypertension.
Funding: Government Support - Non-U.S.
SA-PO650
Association of Urinary Albumin Excretion and Salt-Sensitivity of Blood 
Pressure: Genetic Epidemiology Network of Salt Sensitivity (GenSalt) Study 
Jing Chen,1,2 L. Lee Hamm,1 Chung-shiuan Chen,2 Kevin K. Wu,2 L. Gabriel 
Navar,1 Jiang He.2,1  1Medicine, Tulane School of Medicine, New Orleans, LA; 
2Epidemiology, Tulane School of Public Health and Tropical Medicine, New 
Orleans, LA.
Background: Albuminuria is a marker of early kidney injury and associated with risk 
of hypertension, cardiovascular disease, end-stage renal disease, and premature death. 
However, it is unknown whether urinary albumin excretion is associated with salt- and 
potassium-sensitivity.
Methods: We investigated the association between urinary albumin excretion and 
salt- and potassium-sensitivity of blood pressure (BP) among GenSalt study participants. 
The GenSalt dietary intervention consisted of a 7-day low sodium diet (51.3 mmol sodium/
day), 7-day high-sodium diet (307.8 mmol sodium/day), and 7-day high-sodium diet 
with potassium supplementation (307.8 mmol sodium/day and 60 mmol potassium/day). 
Twenty-four hour urinary albumin excretion was estimated at baseline and at the end of 
each intervention from 100 randomly selected GenSalt participants.
Results: Urinary albumin-to-creatinine ratio (ACR, mg/g) was significantly reduced 
during low-sodium and potassium-supplementation interventions to 2.26 (1.11, 4.61) and 
2.10 (1.46, 4.26), respectively, from a baseline ratio of 2.97 (1.20, 6.40) and increased during 
the high-sodium intervention to 3.23 (2.15, 5.73) with P for group difference=0.005. One 
standard deviation higher of baseline log-transformed ACR (2.23 mg/g) was significantly 
associated with 1.5 (95% CI 0.3, 2.7) mm Hg higher in mean arterial BP (P=0.01) from 
low-sodium to high-sodium intervention (salt-sensitivity) but not statistically significantly 
associated with potassium-sensitivity after adjusting for confounding factors.
Conclusions: These data indicate that urinary albumin excretion may be associated 
with BP salt-sensitivity.
SA-PO651
Effects of Nephrectomy on Blood Pressure and Its Circadian Rhythm 
Naro Ohashi,1 Sayaka Ishigaki,1 Shinsuke Isobe,1 Takayuki Tsuji,1 Akihiko Kato,2 
Hideo Yasuda.1  1Internal Medicine 1, Hamamatsu Univ School of Medicine, 
Hamamatsu, Japan; 2Blood Purification Unit, Hamamatsu Univ School of 
Medicine, Hamamatsu, Japan.
Background: Intrarenal renin-angiotensin system (RAS) activation causes disturbance 
of sodium excretion from the kidney by increasing sodium reabsorption in the tubulus, with 
resultant blood pressure (BP) elevation and nocturnal hypertension. However, the effects 
of nephrectomy on BP and its circadian rhythm have not been clarified in the patients who 
have various renal functions.
Methods: We investigated 25 nephrectomized patients [17 men and 8 women, age: 
61.3±14.7 years, chronic kidney disease stage 1 in 3 patients, stage 2 in 7, stage 3 in 5, 
stage 4 in 1 and stage 5 in 9 (hemodialysis in 8 and peritoneal dialysis in 1)]. Body weight 
(BW), circulating RAS [plasma renin activity (PRA) and plasma angiotensin II (AngII)] 
and 24-h ambulatory BP monitoring (ABPM) were examined before and after nephrectomy. 
We divided the daytime and nighttime for 24-h ABPM using sleep and waking times. Renal 
function [estimated glomerular filtration rate (eGFR)] was evaluated in non-dialysis patients.
Results: In non-dialysis patients,eGFR after nephrectomy was significantly decreased 
compared with that before nephrectomy (before nephrectomy, 67.8±23.1 ml/min/1.73m2 and 
after nephrectomy, 47.9±16.5 ml/min/1.73m2; p<0.01). There were no significant differences 
in the levels of BW, BPs during daytime, nighttime and 24-h periods, and circulating RAS 
before and after nephrectomy. However, night-to-day (N/D) ratio of systolic BP (SBP) was 
significantly increased after nephrectomy compared with that before nephrectomy (before 
nephrectomy, 93.0±6.7% and after nephrectomy, 97.4±7.5%; p=0.032), and the patterns 
of circadian BP rhythm were also significantly changed before and after nephrectomy 
(p=0.021). Namely, dipper pattern decreased and nondipper and riser patterns increased after 
nephrectomy. On the other hand, no significant findings were found in N/D ratio of SBP 
and the patterns of circadian BP rhythm in dialysis patients before and after nephrectomy.
Conclusions: Nephrectomy has effects on nocturnal hypertension due to the decrease 
of renal sodium filtration ability, but not absolute values of BP.
Funding: Government Support - Non-U.S.
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Association of Urinary Dopamine and Norepinephrine Excretion with Salt- 
and Potassium-Sensitivity of Blood Pressure  Jing Chen,1,2 L. Lee Hamm,1 
Chung-shiuan Chen,2 Kevin K. Wu,2 L. Gabriel Navar,1 Jiang He.2,1  1Medicien, 
Tulane School  of Medicine, New Orleans, LA; 2Epidemiology, Tulane School 
of Public Health and Tropical Medicine, New Orleans, LA.
Background: Dopamine and norepinephrine may play an important role in regulating 
sodium and potassium reabsorption in the proximal tubules. It is unknown, however, if 
urinary dopamine and norepinephrine excretion are associated with salt- and potassium-
sensitivity of blood pressure (BP).
Methods: We investigated the association of urinary dopamine and norepinephrine with 
BP salt- and potassium-sensitivity among Genetic Epidemiology Network of Salt Sensitivity 
(GenSalt) study participants. The GenSalt dietary intervention consisted of a 7-day low 
sodium diet (51.3 mmol sodium/day), 7-day high-sodium diet (307.8 mmol sodium/day), 
and 7-day high-sodium diet with potassium supplementation (307.8 mmol sodium/day 
and 60 mmol potassium/day). Twenty-four hour urinary dopamine and norepinephrine 
were estimated at baseline and at the end of each intervention in 100 randomly selected 
GenSalt participants.
Results: Urinary dopamine (µg/24-h) was significantly (p=0.01) reduced from baseline 
(191.5±124.2) during high-sodium (157.2±143.2) and high-sodium and potassium-
supplementation (149.9±139.7) interventions. Likewise, urinary norepinephrine (µg/24-h) 
was significantly (p<0.0001) reduced from baseline (38.6±24.3) during high-sodium 
(24.5±21.4) and high-sodium and potassium supplementation (24.6±24.1) interventions. In 
addition, one standard deviation higher in urinary dopamine concentration (124.2 µg/24-h) 
was associated with 1.5 (-2.5, -0.6) mm Hg of mean arterial BP reduction from high-sodium 
to high-sodium plus potassium supplementation (p=0.001). One standard deviation higher 
in urinary norepinephrine concentration (24.3 µg/24-h) was associated with 1.4 (0.2, 2.6) 
mm Hg mean arterial BP increase from low-sodium to high-sodium (p=0.02) and 2.2 (-3.1, 
-1.3) mm Hg mean arterial BP reduction from high-sodium to high-sodium plus potassium 
supplementation (p<0.0001).
Conclusions: These data indicate that urinary excretion of dopamine and norepinephrine 
may play a role in BP salt- and potassium-sensitivity.
Funding: Other NIH Support - NHLBI and the National Center for Research 
Resources, National Institutes of Health, Bethesda, MD.
SA-PO653
Difference of Impact on Cardio-Ankle Vascular Index Among Various Blood 
Pressure Indexes in Patients with Non-Diabetic Chronic Kidney Disease 
Hideo Okonogi, Tetsuya Kawamura, Akira Fukui, Shinya Yokote, Nobuo Tsuboi, 
Yoichi Miyazaki, Makoto Ogura, Takashi Yokoo.  Div of Nephrology and 
Hypertension, Dept of Internal Medicine, The Jikei Univ School of Medicine, 
Tokyo, Japan.
Background: Several studies reported that pulse pressure (PP) is the predictor of 
heart and kidney risks. On the other hand, arterial stiffness negatively correlates with renal 
function, and is the predictor of all causes mortality and mainly cardiovascular events in 
chronic kidney disease (CKD). Cardio-ankle vascular index (CAVI) is a non-invasive 
indicator of arterial stiffness, and is not influenced by the blood pressure (BP) at the time 
of examination. Therefore, we examined the relationship between various BP indexes and 
CAVI in patients with non-diabetic CKD.
Methods: Fifty-nine patients with non-diabetic CKD, who were diagnosed by first time 
biopsy, were included. Relationships between various BP indexes and CAVI were analyzed. 
Then receiver-operating characteristic (ROC) analysis for diagnosis of the presence of high 
arterial stiffness (CAVI≥9, suggesting the presence of arterial sclerosis) were analyzed.
Results: As a result, systolic BP (SBP) and PP significantly correlated with CAVI 
(r=0.433, p<0.01 and r=0.624, p<0.01, respectively), while diastolic BP (DBP) and mean 
BP (MBP) did not correlate with CAVI. The ROC curves for diagnosis of the presence of 
high arterial stiffness by each BP index showed that SBP, DBP, MBP and PP had an area 
under the ROC curve (AUC) value of 0.786 (p<0.01), 0.425, 0.614 and 0.906 (p<0.01), 
respectively. Then, by two-graph ROC analysis, the threshold values of SBP and PP were 
obtained as 132.4mmHg (sensitivity 71%, specificity 71%) and 55.5mmHg (sensitivity 
82%, specificity 82%), respectively.
Conclusions: These results indicated that PP has the most strong impact on arterial 
stiffness among various BP indexes. PP may affect renal function and cardiovascular risk 
via increase in arterial stiffness.
SA-PO654
Uric Acid Levels Are Associated with Peripheral but Not Central Blood 
Pressure Parameters in Normotensive Individuals  Pierre-Luc Lavoie, 
Stephan Troyanov, Francois Madore, Remi Goupil.  Nephrology, Hopital du 
Sacre-Coeur de Montreal, Montreal, QC, Canada.
Background: Uric acid is increasingly recognised as a risk factor for cardiovascular 
disease. Whether this could be explained by changes in peripheral or central blood pressure 
(BP) profiles remains controversial. The aim of this study was to assess the association 
of uric acid levels with peripheral and central hemodynamic parameters in untreated 
normotensive individuals.
Methods: Of 20,004 CARTaGENE participants, 8,420 were normotensive individuals 
not treated for hyperuricemia or hypertension with valid pulse wave analysis (46.9% male, 
52.6 yo). The associations between uric acid levels and peripheral systolic BP (SBP), pulse 
pressure (PP) central systolic BP (cSBP), central PP (cPP), pulse pressure amplification 
(PPA), augmentation index (AIx) and augmented pressure (AP) were tested with linear 
regressions.
Results: In univariate analyses, uric acid levels were significantly associated with 
all parameters. In contrast, in multivariate analyses, only SBP and cSBP remained 
independently associated with uric acid levels. As cSBP is usually highly dependent of 
SBP, it was further adjusted for peripheral BP, where it was not independently associated 
with uric acid levels (β coefficient -0.003, p=0.51). 
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Univariate Multivariate a
Parameters b β coefficient c p-value β coefficient c p-value
SBP 0.260 <0.001 0.062 <0.001
PP 0.108 <0.001 -0.004 0.77
cSBP 0.167 <0.001 0.068 <0.001
cPP -0.027 0.013 0.002 0.89
PPA 0.236 <0.001 -0.005 0.65
AIx -0.272 <0.001 0.002 0.85
AP -0.210 <0.001 0.006 0.60
a adjusted for gender, age, BMI, diabetes, cardiovascular disease, smoking history, eGFR, fasting 
glucose, total cholesterol, HDL, TSH, and heart rate. 
b PPA expressed in 0.01 unit and AIx in %. All others in mmHg. 
c expressed per 10 umol/L of serum uric acid.
Conclusions: In normotensive individuals, uric acid levels were independently 
associated with SBP, but not with other hemodynamic parameters. Whether the increased 
risks associated with uric acid levels are explained by these parameters remains uncertain 
and needs further study.
Funding: Government Support - Non-U.S.
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Blood Pressure Trajectory and Events in the Cardiovascular Health Study 
Christopher C. Smitson,1 Rebecca Scherzer,1 Michael Shlipak,1 Mark J. Sarnak,2 
Michelle Odden,3 Carmen A. Peralta.1  1UCSF; 2Tufts; 3OSU.
Background: The association of blood pressure (BP) trajectories with clinical events 
in elders is not well established. The importance of integrating trajectories of systolic (SBP) 
and diastolic (DBP) is not known.
Methods: Among 4,067 participants in the Cardiovascular Health Study, we used 
repeated measures from the first 7 years to identify discrete trajectories of SBP, DBP and 
joint SBP/DBP by latent class analysis. We evaluated independent associations of BP 
trajectory with all-cause mortality, incident CVD (myocardial infarction, cardiac arrest, 
stroke or CVD death), and heart failure using multivariable Cox models with follow up 
beginning after 7th year (median follow-up 9.3 years).
Results: Mean age at 7th year was 78. Considering SBP or DBP separately, trajectory 
groups were primarily determined by baseline BP, and these were not independently 
associated with outcomes (all p>0.05). In contrast, three distinct groups were identified 
using joint SBP/DBP: (1) concordant increasing, (2) discordant (stable SBP and decreasing 
DBP), and (3) concordant decreasing. Compared with a concordant increasing, a concordant 
decreasing and discordant trajectory had increased risk of death. Concordant decreasing was 
also associated with increased risk for incident CVD and HF, compared with concordant 
increasing. Findings did not differ when we stratified by use of antihypertensives. 
Event Rate 
per 1000 PY
Multivariable 
Analysis 
HR (95% CI)
Mortality
Concordant Increasing (n=1838) 60.6 (57.1, 64.4) 1 [reference]
Discordant (n=1109) 62.2 (57.6, 67.2) 1.16 (1.03, 1.31)
Concordant Decreasing (n=1120) 83.9 (78.2, 90.1) 1.20 (1.06, 1.36)
Incident CVD
Concordant Increasing (n=1332) 24.0 (21.4, 26.9) 1 [reference]
Discordant (n=779) 25.2 (21.8, 29.2) 1.16 (0.93, 1.44)
Concordant Decreasing (n=726) 30.6 (26.5, 35.4) 1.26 (1.01, 1.58)
Incident HF
Concordant Increasing (n=1689) 32.3 (29.5, 35.3) 1 [reference]
Discordant (n=998) 32.6 (29.0, 36.7) 1.00 (0.84, 1.20)
Concordant Decreasing (n=946) 42.2 (37.7, 47.3) 1.18 (0.99, 1.42)
Conclusions: Among community-dwelling elders, distinct BP trajectories were 
identified integrating SBP and DBP. Decreasing BP is associated with higher risk for 
adverse outcomes.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Serum Uric Acid and Vascular Stiffness in African Americans with 
Hypertension  Rajesh Mohandas,1,2 Xuerong Wen,2 Jogiraju V. Tantravahi,1,2 
Titte Srinivas,3 Richard J. Johnson,4 Mark S. Segal.1,2  1Nephrology and 
Hypertension Section, North Florida/South Georgia Veterans Health System, 
Gainesville, FL; 2Div of Nephrology, Hypertension & Transplantation, Univ of 
Florida, Gainesville, FL; 3Div of Nephrology, Medical Univ of South Carolina, 
Charleston, SC; 4Div of Renal Diseases and Hypertension, Univ of Colorado, 
Denver, CO.
Background: Elevated serum uric acid levels as well as vascular stiffness is associated 
with hypertension and cardiovascular (CV) disease. However, how uric acid affects vascular 
stiffness is not known. We examined the relationship between uric acid and vascular stiffness 
in a cohort of African American men and women with well-controlled hypertension.
Methods: 120 African-Americans with controlled hypertension were randomized in a 
double-blind, placebo controlled study to allopurinol (300mg/dl) or placebo for 4 weeks. 
Vascular stiffness was assessed by augmentation index at baseline and at 4 weeks after 
allopurinol therapy. Uric acid was characterized as low or high (>7 mg/dL in men and > 
6 mg/dL in women).
Results: The mean age was 48.7 ± 8.73 years and majority of the participants were 
women (71%). Augmentation index was negatively correlated with uric acid at baseline 
(R= -0.24 p=0.009). The high uric group as compared to the low uric acid group, had a 
lower augmentation index (9.07 ± 5.52 vs. 11.22 ± 5.23 p=0.03) while the mean BP (119 
/75 vs 118/75), age (48.7 vs 48.6), and endothelial function as measured by endoPAT (2.2 
vs. 2.2) were similar . With allopurinol therapy there was a drop in uric acid by 2.23 ± 1.4 
mg/dl as compared to placebo -0.15 ± 0.9 mg/dl but there were no significant changes in 
vascular stiffness or endothelial function.
Conclusions: In African Americans with hypertension uric acid is negatively associated 
with vascular stiffness and short-term therapy with allopurinol does not alter vascular 
stiffness. These changes are not explained by endothelial function. The mechanistic basis of 
how uric acid may be protective against vascular stiffness may explain the many conflicting 
studies on the contribution of uric acid to cardiovascular risk and merits further investigation.
Funding: Other NIH Support - NHLBI R01HL079352
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The Impact of Renin-Angiotensin System Blockers on Renal Sodium 
Handling: An Analysis of CARTaGENE  Catherine Delmas-Frenette, Stephan 
Troyanov, Josee Bouchard, Francois Madore, Remi Goupil.  Nephrology, Hopital 
du Sacre-Coeur de Montreal, Montreal, QC, Canada.
Background: Renin-angiotensin system blockers (RASB) reduce the effects of 
angiotensin II, and subsequently aldosterone, leading to vasodilation and natriuresis. 
The magnitude of the RASB-induced natriuresis compared to diuretics and other anti-
hypertensive agents remains uncertain.
Methods: We identified patients treated for hypertension from the prospective 
CARTaGENE cohort, a random sample of the Quebec population aged 40 to 69, who had 
available urinary sodium levels. We compared the fractional excretion of sodium (FeNa) 
between patients on beta-blockers or calcium channel blockers without diuretics (Group 
1), on RASB without diuretics (Group 2) and on diuretics (Group 3) with ANOVA and a 
general linear model adjusting for age, gender, estimated glomerular filtration rate (eGFR), 
diabetes and peripheral mean arterial pressure (pMAP).
Results: Of the 3828 individuals with treated self-declared hypertension, 155 had 
urinary measurements. Of these 61% were male, their mean age was 59±8 years, 23% had 
diabetes and the eGFR and pMAP were 85±14 ml/min/1.73m2 and 93±11 mmHg. Groups 
1, 2 and 3 included 42, 72 and 41 patients, respectively. In unadjusted analyses, patients 
in Group 1 (0.67±0.33) had lower FeNa than Group 2 (1.02±0.51, p=0.001) and Group 
3 (1.25±0.70, p<0.001), while Group 2 had lower FeNa compared to Group 3 (p=0.029). 
In the adjusted analysis, Group 2 still had higher FeNa than Group 1, but the results were 
similar to Group 3. 
Treatment Adjusted FeNa(95% CI)
p-value
(vs Group 1)
p-value
(vs Group 2)
Group 1 (beta-
blockers and 
calcium channel 
blockers)
0.75 (0.59-0.92) - - 
Group 2 (RASB) 1.01 (0.88-1.13) 0.049 - 
Group 3 (diuretics) 1.19 (1.03-1.36) 0.001 0.22 
Conclusions: After adjustment for important covariables, RASB therapy is associated 
with a natriuresis similar to diuretics and greater than other antihypertensive drugs in 
hypertensive patients. Whether the degree of natriuresis parallels the blood pressure response 
to these agents remains to be determined.
Funding: Government Support - Non-U.S.
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Urine Mitochondrial-DNA Copy Number Identifies Renal Injury in Severe 
Renovascular Disease  Alfonso Eirin,1 Ahmed Saad,1 Sandra Herrmann,1 
Hui Tang,1 Amir Lerman,2 Stephen C. Textor,1 Lilach O. Lerman.1,2  1Divs of 
Nephrology and Hypertension, Mayo Clinic; 2Cardiovascular Diseases, Mayo 
Clinic, Rochester, MN.
Background: We have previously demonstrated that mitochondrial injury contributes 
to renal dysfunction in swine renovascular disease (RVD), but its implications in human 
RVD remain unknown. Fragments of the mitochondrial genome released from dying cells 
are considered surrogate markers of mitochondrial injury. We hypothesized that RVD 
would be associated with increased urine mitochondrial DNA (mtDNA) copy numbers.
Methods: We prospectively measured urinary copy numbers of the mtDNA genes 
COX3 and ND1 by quantitative real-time PCR in essential hypertensive (EH), moderate 
RVD, and severe RVD patients (based on ultrasound criteria and evident loss of functional 
tissue), during constant sodium intake and anti-hypertensive regimens, and compared them 
with healthy volunteers (HV). Systemic levels of the kidney injury molecule neutrophil 
gelatinase-associated lipocalin (NGAL) were measured by ELISA.
Results: Blood pressure was similarly elevated in EH and RVD, yet serum creatinine 
and NGAL were higher and estimated glomerular filtration rate (eGFR) lower in RVD 
versus HV and EH (Table). Urinary COX3 and ND1 were higher in EH and moderate 
RVD compared to HV, and further elevated in patients with severe RVD (Figure). In RVD 
patients, urinary COX3 and ND1 directly correlated with NGAL (R²=0.18, p=0.02 and 
R²=0.37, p<0.001), proteinuria (R²=0.33, p<0.001 and R²=0.53, p<0.001), and serum 
creatinine (R²=0.27, p=0.002 and R²=0.16, p<0.02) levels, and inversely with eGFR (R²=-
0.11, p=0.05 and R²=-0.13, p<0.04, respectively).
Conclusions: We found progressive increments in urinary mitochondrial injury markers 
with increased severity of RVD, implicating mitochondrial injury in kidney damage in 
human RVD. Mitochondria might represent a novel therapeutic target in RVD. 
Funding: NIDDK Support, Other NIH Support - DK100081
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Association Between Urinary Big Angiotensin-25 and Microalbuminuria 
in Hypertensive Patients  Yasuhiro Yamashita,1 Sayaka Nagata,1 Yuji Sato,2 
Kazuo Kitamura,1 Shouichi Fujimoto.3  1Div of Circulatory and Body Fluid 
Regulation, Dept of Internal Medicine, Faculty of Medicine, Univ of Miyazaki, 
Miyazaki, Japan; 2Dialysis Div, Univ of Miyazaki Hospital, Miyazaki, Japan; 
3Dept of Hemovascular Medicine and Artificial 2rgans, Faculty of Medicine, 
Univ of Miyazaki, Miyazaki, Japan.
Background: In hypertensive patients, albuminuria is a predictive factor for 
cardiovascular events. Recently, a newly glycosylated angiotensin-related peptide, Big 
angiotensin-25 (Bang-25), was isolated from human urine (Nagata et al. Biochem Biophys 
Res Commun 2013), and it was localized to podocytes in kidney tissue. Bang-25 may be 
involved in the renin-independent pathway for localized angiotensin II generation, and can 
contribute to diagnosis in organ disorders. Using cross-sectional data, we investigated the 
relationship between urinary Bang-25 and albuminuria in hypertensive patients.
Methods: We examined the data of 408 hypertensive patients (male 50.5%; mean age 
70±10 years, BMI 25±3.7 kg/m2, diabetes mellitus 38.0%, and eGFR 72±17 ml/min/1.73m2). 
We evaluated urinary albumin/creatinine ratio (ACR) and we measured urinary Bang-25 
by specific AlphaLISA immunoassay. The association between urinary Bang-25/creatinine 
ratio and microalbuminuria was analyzed by a multivariate logistic method.
Results: Thirty patients were excluded because of macroalbuminuria (ACR³300 mg/
gCr). Of 378 patients, 96 had microalbuminuria (30≤ACR<300 mg/gCr). Patients were 
then divided by quartiles of Bang-25/creatinine ratio. Older patients, females, lower 
hemoglobin, lower uric acid, and higher HDL were more prominent in higher Bang-25/
creatinine quartiles. After adjusting for age, sex, eGFR, and presence of diabetes, the odds 
ratios (95% confidence intervals) for microalbuminuria per quartile, calculated using 
multivariate logistic analysis, were as follows: Q1, reference; Q2, 0.72 (0.33-1.54); Q3, 
0.99 (0.49-2.01); and Q4, 2.05 (1.01-4.14).
Conclusions: Higher urinary Bang-25/creatinine quartile was significantly associated 
with microalbuminuria in hypertensive patients. As Bang-25 is localized to podocytes, it 
may play some role in the development of albuminuria.
SA-PO660
Independent Association of Vitamin D on Endothelial Function: A 
Randomized, Double-Blind, Placebo-Controlled Clinical Trial  Lea Borgi,1 
Ciaran Joseph McMullan,1 Gary C. Curhan,1 Naomi D.L. Fisher,2 John 
P. Forman.1  1Nephrology, Brigham and Women’s Hospital, Boston, MA; 
2Endocrinology, Brigham and Women’s Hospital, Boston, MA.
Background: In nonhypertensive individuals, lower levels of 25-hydroxyvitamin D 
(25[OH]D) have been associated with an increased risk of hypertension, and vitamin D 
deficiency has been associated with endothelial dysfunction in such individuals. However, 
the effect of vitamin D supplementation on endothelial dysfunction in nonhypertensive 
individuals has not been examined in a rigorous fashion.
Methods: In this randomized, double-blind, placebo-controlled trial of nonhypertensive, 
nondiabetic overweight or obese individuals with vitamin D deficiency (body mass index 
[BMI] ³25 and 25[OH]D£20ng/mL), we assigned subjects to receive either ergocalciferol 
(50,000 units) or matching placebo, once a week for 8 weeks. Our primary outcome was 
endothelial-dependent vasodilation (EDV) measured by brachial artery ultrasound at 
baseline and 8 weeks post-randomization.
Results: By the end of the trial, 46 and 47 participants were allocated to receive 
ergocalciferol and placebo, respectively. Mean 25(OH)D levels increased from 14.9 to 30.3 
in the vitamin D group and 14.4 to 17.4 in the placebo. EDV did not change significantly 
with either vitamin D repletion (from 6.3±3.6% at baseline to 6.1±4.6% at 8 weeks; 
p-value=0.78) or placebo (7.9±4.7% to 6.8±4.7%; p=0.17). The treatment effect p-value 
(comparing the 8-week change with ergocalciferol to the change with placebo) was 0.35.
Conclusions: In this randomized, double-blind, placebo-controlled trial, there was no 
improvement in endothelial function (measured as EDV) after repletion of vitamin D in 
overweight/obese non-hypertensive individuals.
Funding: NIDDK Support
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Secondary Hypertension, Primary Hyperaldosteronism, and Renal Cell 
Carcinoma  Nicole Piero,1 Krishnanath Gaitonde,1,2 Charuhas V. Thakar.1,2 
1Cincinnati VA Medical Center; 2Univ of Cincinnati.
Background: Primary hyperaldosteronism (PH) is the most common cause of 
secondary hypertension. Renal cell carcinoma (RCC) can cause secondary hypertension, but 
as a renin-mediated process. We describe 5 cases referred for evaluation of PH (uncontrolled 
hypertension and hypokalemia), incidentally diagnosed with RCC, and the potential role 
of RCC as a renin-independent mechanism for hypertension.
Methods: At the initial renal visit, average blood pressure (BP) was 167/87 mmHg, 
with an average of 4 BP meds (no aldosterone blockers). Average serum levels of potassium, 
sodium and bicarbonate were 3.1, 143 and 30 mmol/L respectively. Average plasma 
renin activity (PRA) was 0.12 ng/ml/hr, average serum aldosterone (sAldo) was 16.6 
ng/dL, with a mean sAldo:PRA of 143.6. In 24-hour urine analysis, aldosterone ranged 
from 11.8 to 30.2 ng/dL and sodium ranged 82-226 mmol/24 hours. All patients required 
1 or 2 aldosterone blocking agents to achieve an average BP of 134/75 mmHg. Upon 
imaging, 4/5 had adrenal adenomas and all 5 patients had incidental solid renal masses 
with radiological characteristics of RCC. To date, 3/5 have had renal masses treated with 
partial/total nephrectomy or cryotherapy; all have confirmed pathology of RCC. All those 
undergoing RCC treatment were had improved BP with 2/3 having reduced therapy. At 
presentation these 3 patients had an average BP of 159/87 mmHg and were on an average 
of 4.6 BP meds; between 5 and 9 months after RCC treatment BP was 133/75 mmHg on 
average of 4 BP meds; 2/3 able to eliminate aldosterone blockade. 2/3 patients treated for 
RCC had follow-up biochemical assessment. sAldo:PRA normalized in the patient with 
partial nephrectomy; whereas it remained elevated in patient treated with cryotherapy.
Conclusions: To our knowledge this is the first case series describing a possible renin-
independent, aldosterone-mediated mechanism for secondary hypertension associated 
with RCC. Although presence of adrenal and renal tumors has been reported, this series 
describes a physiological link between the two. Whether RCC leads to maladaptive sterol 
pathways leading to an aldosterone-like action in mediating hypertension requires detailed 
analysis of RCC tumors.
SA-PO662
Effect of Uric Acid Lowering Agents on Endothelial Function: A 
Randomized, Double-Blind, Placebo-Controlled Clinical Trial  Lea Borgi,1 
Ciaran Joseph McMullan,1 Gary C. Curhan,1 Naomi D.L. Fisher,2 John 
P. Forman.1  1Nephrology, Brigham and Women’s Hospital, Boston, MA; 
2Endocrinology, Brigham and Women’s Hospital, Boston, MA.
Background: In nonhypertensive individuals, higher levels of serum uric acid have 
been associated with an increased risk of hypertension, and elevated serum uric acid has 
been associated with endothelial dysfunction in such individuals. However, the effect of 
lowering serum uric acid on endothelial dysfunction in nonhypertensive individuals has 
not been examined thoroughly.
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Methods: In this randomized, double-blind, placebo-controlled trial of nonhypertensive, 
nondiabetic overweight or obese individuals with elevated serum uric acid (body mass 
index [BMI] ³25 and serum uric acid≥5mg/dL), we assigned subjects to receive one of the 
following: allopurinol 300mg daily for 4 weeks followed by 600mg daily for 4 weeks; 
probenecid 500mg daily for 4 weeks then 1000mg daily for 4 weeks; or matching placebo. 
Our primary outcome was endothelial-dependent vasodilation (EDV) measured by brachial 
artery ultrasound at baseline and 8 weeks post-randomization.
Results: By the end of the trial, 43, 44 and 47 participants were allocated to receive 
probenecid, allopurinol and placebo, respectively. Mean serum uric acid levels decreased 
from 5.9 to 3.6 mg/dL in the probenecid group, from 5.6 to 2.9 mg/dL in the allopurinol 
group, and were unchanged in the placebo group (5.6 to 5.7 mg/dL). EDV did not 
change significantly with either probenecid (from 7.6±5.1% at baseline to 8.4±5.2% at 
8 weeks; p-value=0.39), allopurinol (from 7.4±6.0% at baseline to 5.9±4.6% at 8 weeks; 
p-value=0.09) or placebo (6.8±3.8% to 7.1±4.9%; p=0.66).
Conclusions: In this randomized, double-blind, placebo-controlled trial, there was no 
improvement in endothelial function (measured as EDV) after lowering serum uric acid in 
overweight/obese non-hypertensive individuals.
Funding: NIDDK Support
SA-PO663
Azelnidipine Can Restore the Deceleration Capacity of Heart Rate 
Variability (DC) In CKD Patients with Preceding Treatment with ARB 
Michio Fukuda,1 Toshiyuki Miura,1 Yoshiaki Ogiyama,1 Ryo Sato,1 Daisuke 
Fuwa,1 Hiroyuki Ito,1 Tetsuhei Matsuoka,1 Yukako Isobe-Sasaki,1 Ken Kiyono,2 
Yoshiharu Yamamoto,3 Junichiro Hayano,1 Nobuyuki Ohte.1  1Nagoya City Univ; 
2Osaka Univ; 3Tokyo Univ.
Background: Recently, we have hypothesized that DC, novel measure of cardiac 
vagal modulations, is also attributable to sympathetic nerve activities. Azelnidipine was 
reported to decrease non-Gaussianity index of HRV (l25s), which can serve as a marker of 
sympathetic cardiac overdrive.
Methods: In 43 hypertensive patients with CKD under treatment with an angiotensin 
receptor blocker (ARB), we tested whether 8-week add-on administration of azelnidipine can 
increase DC. DC was calculated by Bauer’s signal processing technique of phase-rectified 
signal averaging. For reference, the power of high frequency (HF, 0.15–0.40 Hz) obtained 
from frequency measure of HRV was examined as a conventional indicator of vagal activity.
Results: DC increased (6.17 ± 1.84 to 6.55 ± 1.85, p=0.002) and l25s decreased (0.56 
± 0.15 to 0.50 ± 0.12, p=0.001), while no significant changes were observed in other HR 
variability measures including HF (p=0.9). Change in DC correlated inversely with the 
change in l25s decreased (r=-0.38, p=0.01), but not with the change in HF (p=0.8).
Conclusions: Our findings are consistent with the thesis that DC is not a simple 
measure of vagal activity but a product of complex interplay between sympathetic and 
vagal nerve activities.
SA-PO664
Elevated Levels of Podocyte Derived Urinary Microparticles in Angiotensin 
II Induced Hypertension  Uta Erdbruegger, Christine Rudy, Sylvia Cechova, 
Rosa Chan, Joseph C. Gigliotti, Thu H. Le.  Div of Nephrology and HTN, Univ 
of Virginia Health System, Charlottesville.
Background: Early and non-invasive biomarkers of kidney damage are needed to 
identify hypertensive patients at risk for kidney damage. Urinary micropaticles (uMPs) 
have gained significant attention as potential novel biomarkers for kidney damage, and 
have already been identified in pre-albuminuric diabetic glomerular injury. These vesicles 
are less than 1 micron in size and carry markers of the parent cell. We hypothesized that 
podocyte derived uMPs are elevated in angiotensin II-induced hypertension (HTN).
Methods: Wild-type mice were treated with AII (400ng/kg/min) via mini-osmotic 
pumps. Untreated WT mice served as controls. Blood pressure was measured with tail-cuff 
manometry. 24 hour urines were collected after 5 days of AII treatment. Enumeration and 
phenotyping of MPs was done of podocyte culture supernatant and urine. UMP levels were 
normalized to urinary creatinine concentration. Podocalyxin(Pcal), podoplanin (Ppla) and 
annexin 5 (AV) were used as surface markers.
Results: Pcal and Ppla positive MPs as well as AV positive and negative MPs were 
detectable in supernatant from primary podocyte cultures. Compared to untreated controls 
(n=3), AII treated mice (n=2) had an increase in systolic blood pressure (SBP) by 33 mmHG 
(p=0.02). Despite similar urinary albumin/creatinine ratios between groups, there was a 
trend of higher levels of total numbers of Pcal and Ppla positive MPs in hypertensive mice 
compared to untreated (see Figure1). In addition, AV negative but Ppla and Pcal positive 
MPs were also numerically higher in hypertensive mice compared to AV positive uMPs. 
Conclusions: In conclusion, podocyte derived urinary MPs are detectable in AII HTN. 
These findings need to be confirmed in a larger group of animals. Urinary MPs can be 
potential marker for kidney end-organ damage in HTN.
Funding: Clinical Revenue Support
SA-PO665
Blood Pressure Lowering Effects of Sulodexide Depend on Albuminuria 
Severity  Rik Hg Olde Engberink,1 Hiddo Jan Lambers Heerspink,2 Dick de 
Zeeuw,2 Liffert Vogt.1  1Nephrology, AMC, Amsterdam, Netherlands; 2Clinical 
Pharmacy and Pharmacology, UMCG, Groningen, Netherlands.
Background: Diabetic patients have a thinner endothelial surface layer (ESL), 
especially when macroalbuminuria is present. Sulodexide, a mixture of glycosaminoglycans 
(GAGs), increases ESL thickness. Previous data indicate that the ESL is pivotal for BP 
regulation. In this study, we assessed whether the BP reducing effect of sulodexide is 
modified by albuminuria severity (a surrogate for the ESL) in type 2 diabetic patients.
Methods: In a post-hoc analysis of the randomized, double-blind, placebo-controlled 
Sun-MACRO trial, including type 2 diabetic patients with macroalbuminuria and maximal 
angiotensin II receptor blocker therapy, we studied the BP effects of sulodexide 200 mg/d. 
We stratified patients in baseline urinary albumin-creatinine ratio (UACR) tertiles. We 
used ANCOVA to study whether baseline UACR modified the 3-month SBP changes of 
sulodexide.
Results: Data of 843 patients were available for analysis. Baseline BP was 138/73 
mmHg. At 3 months, mean (SEM) SBP change was -0.9 (±0.9) and +1.7 (±0.9) mmHg 
in the sulodexide and placebo arm, respectively (p=0.037). The SBP reduction was most 
pronounced in the highest UACR tertile (-1.6 (±1.5) vs 2.9 (±1.6) mmHg; p=0.042). 
Treatment (p=0.015), baseline SBP (p<0.001), heart rate (p=0.007) and UACR (p=0.007) 
were associated with SBP change. We found an interaction between treatment and UACR 
(p=0.047), indicating that sulodexide and placebo differently affected SBP at various UACR 
levels. Age, eGFR, BMI, Hba1c and lipid profile (i.e., factors influencing ESL thickness) 
did not modify the treatment effect. The BP differences persisted during the first year of 
follow-up (p=0.047). 
Conclusions: The BP reducing potency of sulodexide is modified by albuminuria 
severity in type 2 diabetes, indicating that ESL restoration may represent a new target for 
BP treatment in these patients.
Funding: Private Foundation Support, Government Support - Non-U.S.
SA-PO666
Under-Diagnosis of Hypertension in a Large Cohort of Overweight/Obese 
Adolescents  Brian William Sykes, Divya G. Moodalbail, Christopher J. LaRosa, 
Joshua Zaritsky.  Nephrology, Nemours/A.I. duPont Hospital, Wilmington, DE.
Background: The obesity epidemic in children is strongly associated with increasing 
prevalence of childhood hypertension (htn) along with heightened risk for cardiovascular 
morbidity and mortality in adulthood.  Therefore we assessed the identification of htn in 
overweight/obese adolescents cared for by a large healthcare system utilizing an EMR 
system.
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Methods: We performed a retrospective study of patients (pts) in the Nemours Health 
Care System, aged 12-17 years, with a BMI > 85%ile, and >3 documented BPs > 120/80 
in the outpatient setting, between 1/2010 and 12/2014. Pts with established diagnosis of 
htn (ICD-9 codes 401.XX – 405.XX), renal or heart disease were excluded.
Results: Of the 6604 distinct pts identified, only 255 (3.8%) received a diagnosis of htn 
during the study period, while 6,349 (96.2%) were undiagnosed. Pts who were undiagnosed 
had lower BMIs and BPs and were less likely to be African American or have Medicaid 
and were seen less by Nephrology, Cardiology or Weight management subspecialties 
compared with those diagnosed with htn (table). Additionally undiagnosed pts had fewer 
abnormal BPs and had a longer interval between their 1st and 3rd abnormal BP compared 
with those diagnosed with htn. 
Conclusions: In this large cohort of overweight/obese adolescents with htn, the vast 
majority of pts were undiagnosed and not referred to subspecialists who manage BP 
monitoring and treatment. Thus it is crucial that future efforts focus on improving detection 
and early recognition of htn in order to reduce cardiovascular morbidity and mortality in 
this at-risk population.
SA-PO667
Multidisciplinary Selection of Angioplasty Indications in Atheromatous 
Renal Artery Stenosis Leads to an Improvement in Blood Pressure, Drug 
Sensitivity and Renal Function  Thomas Fournier,1 Florence Sens,1 Olivier 
Rouviere,2 Antoine Millon,3 Laurent Juillard.1  1Nephrology, Hôpital E.Herriot, 
Hospices Civils de Lyon, Lyon, France; 2Radiology, Hôpital E.Herriot, Hospices 
Civils de Lyon, Lyon, France; 3Vascular Surgery, Hôpital E.Herriot, Hospices 
Civils de Lyon, Lyon, France.
Background: Angioplasty as treatment of atheromatous renal artery stenosis (ARAS) 
is controversial since 3 large randomised trials (CORAL, ASTRAL, STAR) failed to prove 
the superiority of percutaneous renal artery angioplasty and stenting (PTRAS) over medical 
treatment alone (MT). However, since population selection was questionable among other 
bias, the extrapolation of these results in clinical practice is uncertain.
Methods: ARAS cases were discussed during bi-monthly multidisciplinary meetings 
gathering nephrologists, radiologists and vascular surgeons from April 2013 to February 
2015. For every patient, we compiled clinical, biological and radiological data. We then 
recorded blood pressure (BP), renal function and treatment evolution after a one-year 
follow-up.
Results: During 23 months, 52 cases were discussed. Mean age was 69 years. Two 
thirds of patients had at least 3 cardiovascular risk factors. Mean BP was 161/77 mmHg, 
despite the use of 2.5 ± 1.1 anti-hypertensive drugs. CKD-EPI was 53mL/min/1,73m2. 
31% of patients had a history of pulmonary edema. Collective decisions were PTRAS 
for 21 patients (40%), MT for 28 patients (54%) and surgery for 3 patients (6%). PTRAS 
and MT groups were initially comparable (blood pressure, renal function, treatment, 
comorbidities). In the PTRAS group, a significant improvement at 1 year was observed for 
BP control (systolic -22.6 +/- 29.3 mmHg; diastolic -10.1 +/- 12.9 mmHg), antihypertensive 
drug number (-0.8 +/- 0,94) and creatinin (-18.3 +/- 35.4 µmol/L). In the MT group, these 
improvements were not observed.
Conclusions: The significant improvement observed in the PTRAS could be explained 
by a better selection of patients who could benefit from PTRAS, based on radiologic data 
analysis and systematic multidisciplinary approach. Multidisciplinary identification of 
PTRAS indications leads to a better BP control, a reduction in anti-hypertensive drugs use 
and an improvement in renal function.
SA-PO668
Comparison of Control Rates Among Recommended Drug Selection 
Strategies for Initial Therapy of Hypertension  Kamel A. Gharaibeh,1 Stephen 
T. Turner,1 Arlene B. Chapman,3 Rhonda M. Cooper-DeHoff,2 Julie A. Johnson,2 
Gary L. Schwartz.1  1Nephrology and Hypertension, Mayo Clinic, MN; 2College 
of Pharmacy, Univ of Florida, FL; 3Nephrology, Univ of Chicago, IL.
Background: Thiazide diuretics (TD) are recommended for initial therapy of 
hypertension (HTN). In addition to this TD for all, other recommended strategies for 
initial drug selection are based on age/race (A/R) criteria or on measures of plasma renin 
activity (PRA). It is uncertain which of these 3 strategies achieves the highest control rate 
with monotherapy in stage-I HTN.
Methods: Blood pressure (BP) responses from the Pharmacogenomic Evaluation of 
Antihypertensive Responses (PEAR) study were used to estimate control rates for each of 
the 3 strategies: (i) TD (hydrochlorothiazide) for all, (ii) TD for all black subjects and for 
white subjects aged ≥50 years and a renin-angiotensin system (RAS) blocker (atenolol) for 
whites aged <50 years (A/R strategy) or (iii) TD for suppressed PRA < 0.6 ng/ml/h and a 
RAS blocker for non-suppressed PRA ≥ 0.6ng/ml/h regardless of age or race (PRA strategy). 
In PEAR, adults with stage 1 HTN were treated with either hydrochlorothiazide (n=148 
black and 218 white subjects) or with atenolol (n=146 black and 221 white subjects). BP 
response was assessed in the clinic and by 24-hour ambulatory BP (ABP).
Results: Overall, the PRA strategy was associated with the highest control rate 
compared to the other strategies: clinic BP: 48.9% with PRA strategy, 40.8% with A/R 
strategy (P=0.0004) and 31.7% with the TD strategy (P<0.0001); ABP: 61.3% with PRA 
strategy, 51.6% with A/R strategy (P<0.0001) and 43.9% with TD strategy (P<0.0001). This 
was also true for each racial subgroup: clinic BP: in whites: 50.3% with PRA strategy, 40.6% 
with A/R strategy, P=0.002 and 25.4% with the TD strategy P<0.0001; in blacks: 46.7% 
with PRA strategy, and 41.1% for the other 2 strategies, P=0.08, ABP: in whites 63.5% with 
PRA strategy, 50.9% with A/R strategy, P<0.0001 and 38.2% with TD strategy, P<0.0001; 
in blacks 57.9% with the PRA strategy, and 52.6% with the other 2 strategies P=0.099.
Conclusions: Compared to TD or A/R, the PRA strategy for initial drug selection in 
stage I HTN was associated with the highest control rate.
Funding: Other NIH Support - PEAR was supported by the National Institute of 
Health Pharmacogenomic Research Network grant (U01 GM074492) and the National 
Center for Advancing Translational Sciences under the award number UL1 TR000064 
(University of Florida), UL1 TR000454 (Emory University), and UL1 TR000135 (Mayo 
Clinic). PEAR was also supported by funds from the Mayo Foundation
SA-PO669
Primary Hyperaldosteronism: An Inner City Hypertension Clinic 
Experience!  Ewalola A. Ijaduola, Srijan Shrestha, Islamiyat J. Babs 
animashaun, Jeffrey D. Wallach, Sudhanshu Jain.  Nephrology, Harlem Hospital 
Center, New York, NY.
Background: Primary Hyperaldosteronism (PA) has historically been regarded as a 
rare disorder. Recent studies have shown a widely variable prevalence. We screened for 
PA in the Hypertension(HTN) Clinic at Harlem Hospital in patients with predominantly 
African-American and Hispanic ethnicities.
Methods: Retrospective cross-sectional study of patients seen at Harlem HTN 
Clinic between January 2008 to November 2013. The inclusion criteria were patients 
seen with completed aldosterone and renin levels. The exclusion criteria were patients 
on spironolactone prior to the laboratory studies or with incomplete data. Prevalence 
was measured as number of patients with both an Aldosterone/Renin ratio >20 and an 
Aldosterone level >15ng/dl as a ratio of total number of patients tested.
Results: A total of 268 patients who had plasma aldosterone and renin activity obtained 
was reviewed. Of these, 8 patients had incomplete data and were excluded. 220 of the 
remaining 260 patients in the study were black, while 40 patients were Hispanic. Notably, 
43/260, or 16.5% of the patients were found to have met biochemical criteria for PA. About 
half, 22/43 or 51% of the patients had CAT Scans showing adrenal adenomas. Additionally, 
one patient had bilateral enlarged adrenal glands consistent with adrenal hyperplasia, 10 
had CAT scans with no evidence of an adrenal mass, while the remaining 10 patients had 
no abdominal imaging. In the 43 patients who met biochemical criteria for PA, 34 patients 
were black, 16 of which (47%) had CT evidence of adrenal adenoma while 1 patient had 
bilateral hyperplasia. Of the 9 Hispanic patients, 6 (67%) had CT evidence of adrenal 
adenoma. Overall, the prevalence of PA was 34/220 (15.4%) in African-American patients 
and 9/40 (22.5%) in Hispanic patients.
Conclusions: Our study suggests a higher than anticipated prevalence of PA in African-
American and Hispanic patients in Harlem, NYC, based on selective screening with plasma 
aldosterone and plasma renin activity. In addition adrenal adenomas were present by CT 
scan in at least 50% of cases, potentially treatable with surgery. Thus,adequate screening 
of patients for PA is essential, especially in minorities.
SA-PO670
HIV-2 and Chronic Kidney Diseases (French HIV-2 Cohort ANRS CO5) 
Jerome Tourret,3,4 Aissatou Paye,1 Marine Naudin,1 Roland Tubiana,3,4,5 Philippe 
Genet,6 Diane Descamps,2,7,8 Francoise Brun-Vezinet,2 Catherine Fagard,1 
Genevieve Chene,1 Sophie Matheron,2,7,8 The french Anrs co5 cohort.1  1INSERM 
U897, Univ Bordeaux, France; 2AP-HP Hôpital Bichat, France; 3AP-HP 
Hôpital Pitié Salpêtrière, France; 4UPMC, Univ Paris 06, France; 5INSERM 
UMR 1136, France; 6Hôpital Argenteuil, France; 7Univ Paris Diderot, France; 
8IAME, INSERM UMR 1137, France.
Background: The link between HIV-2 and chronic kidney diseases (CKD) has not 
been studied. We describe the prevalence of CKD and their risk factors in people living 
with HIV-2.
Methods: All patients included in the HIV-2 French national cohort with 2 creatinine 
measurements at least 3 months apart were included. Glomerular filtration rate was estimated 
by MDRD formula and used to categorize CKD according to the NKF classification. Risk 
factors were determined by uni and multivariate analyses using a Cox model which included 
the main known risk factors for CKD and the main characteristics of HIV infection.
Results: Out of 1048 patients, 737 had 2 creatinine measurements. Their characteristics 
did not significantly differ from those of the total cohort: mean age (SD) was 50 (11) years, 
62% of the patients were females, and 80.1% originated from sub-Saharan countries. On 
average, HIV-2 infection was diagnosed 12.8 (6.8) years before last creatinine measurement. 
Prevalence of CKD stage ³2 was 39.8% and that of chronic kidney failure (stages ³3) was 
7.2%. Univariate analysis revealed that age (HR=1.06, p<10-4), HIV stage (HR=3.1, p<10-4 
for CDC stage C), HIV-2 plasma viral load (HR=1.9 for each increment of log10 (copies/
ml), p<10-3), and CD4 count (HR=3.12, p<10-2 if <100/mm3) were risk factors for chronic 
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kidney failure. HIV stage A (HR=0.3, p<10-4) had a protective effect. Multivariate analysis 
revealed that age (HR=1.05, p=0.002) and CDC stage A (HR=0.35, p=0.01) were risk and 
protecting factors, respectively.
Conclusions: The prevalence of CKD in this very large cohort of people living with 
HIV-2 seems to be comparable to what is known in literature for people living with HIV-1. 
HIV-2 infection parameters determine most of the kidney risk. The role of ARV exposition 
remains to be taken into account.
Funding: Government Support - Non-U.S.
SA-PO671
Effect of Nephropathy on the Frequency of Cardiac Dysautonomia in HIV 
Patients  Syed Rizwan Bokhari,1 Syed Hunain Riaz,2 Qurrat-ul-ain Abid,2 Hafiz 
I. Ahmad,1 Muhammad Zaman Khan Assir,2 Fahmina Ashfaq,2 Kashif Saleem.2 
1Dept of Nephrology, Allama Iqbal Medical College/ Jinnah Hospital, Lahore, 
Pakistan; 2HIV Clinic, Jinnah Hospital, Lahore, Pakistan.
Background: Dysfunction of autonomic nervous system including Cardiac 
Dysautonomia (CD) is seen in a variety of conditions like diabetes mellitus, adrenal 
insufficiency and renal failure. CD is well documented in patients with renal dysfunction/
CKD. Prevalence of renal dysfunction (HIV Nephropathy) is high in our population of HIV 
positive patients, but the effect of HIV nephropathy on the frequency of CD has not been 
previously studied. We conducted this study to determine the effect of HIV Nephropathy 
on the frequency of CD.
Methods: This cross sectional study was conducted at HIV Clinic in collaboration 
with the Department of Nephrology Jinnah Hospital Lahore. A total of 47 HIV positive 
patients were enrolled; 13 (28%) with nephropathy and 34 (72%) without nephropathy. 
Patients underwent 5 tests for cardiac autonomic dysfunction including resting tachycardia, 
abnormal heart rate response to deep breathing, abnormal Valsalva ratio, abnormal 30:15 
ratio and postural hypotension. Patients with 2 or more abnormal tests were considered 
positive for CD.
Results: Of 47 patients, 39(83%) were male, 5(11%) female and 3(6%) were 
transgender with median age of 31 years (range 19-56 years). The median CD4 count was 
339 (range 39-797) and 96% (n=45) patients were on highly active anti-retroviral therapy 
(HAART). The median duration of HIV was 12 months (range 1-56) and median duration 
of HAART was 11 months (range 0-49). CD was seen in 42 (89%) patients. Seventeen 
(36.2%) patients had 2, 18(38.3%) had 3, 6 (12.8%) had 4 and 1 (2%) had 5 abnormal 
tests. The frequency of CD was comparable among patients with and without nephropathy 
[92% (12 out of 13) vs 88% (30 out of 34), respectively; p value=1]. The presence of CD 
had no correlation with CD4 count, degree of renal impairment, treatment regimen and 
duration on HAART.
Conclusions: There was high frequency of CD in our population of HIV patients 
and it was independent of presence or absence of nephropathy, CD4 count and duration 
of anti-retroviral therapy.
SA-PO672
Glomerular Filtration Rate Estimating Equations Using Beta-Trace Protein 
and Beta-2 Microglobulin in Chronic Kidney Disease  Lesley Inker, Hocine 
Tighiouart, Josef Coresh, Meredith C. Foster, Amanda Hyre Anderson, Gerald 
J. Beck, Gabriel Contreras, Tom Greene, Amy Karger, John W. Kusek, James 
P. Lash, Julia Lewis, Jeffrey R. Schelling, Sankar D. Navaneethan, James H. 
Sondheimer, Tariq Shafi, Andrew S. Levey.  Chronic Kidney Disease Biomarkers 
Consortium.
Background: Beta-trace protein (BTP) and beta-2-microglobulin (B2M), like cystatin 
C (Cys), are novel serum filtration markers that have stronger associations with adverse 
outcomes than serum creatinine (Cr). However, comparisons of BTP and B2M to Cr 
and Cys as filtration markers are limited by the absence of rigorously developed GFR 
estimating equations.
Methods: Using a pooled database of three populations with CKD (N=3551, mean 
measured GFR using iothalamate [mGFR] 48 ml/min/1.73m2), we developed equations 
to estimate mGFR using Cr, Cys, BTP or B2M. Equations were developed in 2/3 of the 
population and tested in the remaining 1/3.
Results: The table shows the coefficients included in each equation and the performance 
of the equations in the validation dataset compared to established CKD-EPI Cr-Cys 
equations. 
Performance of GFR estimating equations in the validation dataset
Description IQR(95%CI) 1-P30(%)(95%CI)
BTP age, sex* 15.0 (14.1, 15.9) 23.6 (21.3, 26.1)
B2M* 12.9 (12.2, 13.8) 18.4 (16.2, 20.8)
BTP-B2M* 12.1 (11.4, 13.0) 15.5 (13.3, 17.7)
CKD-EPI Cr age, sex, race* 11.6 (10.9, 12.4) 16.4 (14.2, 18.6)
CKD-EPI Cys age, sex* 11.4 (10.6, 12.4) 16.9 (14.9, 19.1)
CKD-EPI Cr-Cys age, sex, 
race 9.3 (8.7, 10.1) 11.3 (9.5, 13.2)
Average of CKD-EPI Cr-Cys 
+ BTP-B2M 10.2 (9.5, 11.0) 9.6 (8.0, 11.4)
IQR, interquartile range of mGFR-eGFR. 1-P30,% of estimates >30% of mGFR. Bias is not shown 
as it is expected to be near zero, since both the development and the validation dataset are random 
samples of the total dataset. *p<0.001 for difference of 1-P30 from CKD-EPI Cr-Cys equation
Conclusions: BTP and B2M are less influenced by age, sex and race than Cr or Cys 
but did not improve precision (IQR) or errors (1-P30), even when averaged with Cr-
Cys equation. CKD-EPI BTP and B2M equations provide tools for future study in their 
associations with mGFR and risk and adverse outcomes, but further study is required 
before clinical use.
Funding: NIDDK Support, Other NIH Support - This work is supported by  NIDDK 
R01DK097020; NIDDK U01DK085689 - Chronic Kidney Disease Biomarkers 
Consortium (Drs. Coresh, Levey and Inker); NIDDK U01DK045388 and the 
NCMHHD M01RR00071 - AASK Study;  NIDDK U01DK35073 - MDRD Study; and 
cooperative agreements from NIDDK (U01DK060990, U01DK060984, U01DK061022, 
U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902) 
and supported in part by the following institutional Clinical Translational Science Awards 
(CTSA) and other National Institutes of Health grants: University of Pennsylvania NIH/
NCATS UL1TR000003, K01DK092353, and K24DK002651, Johns Hopkins University 
UL1TR000424, University of Maryland General Clinical Research Center (GCRC) M01 
RR16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 
from the National Center for Advancing Translational Sciences (NCATS) component 
of the National Institutes of Health and NIH roadmap for Medical Research, Michigan 
Institute for Clinical and Health Research (MICHR) UL1TR000433, University of 
Illinois at Chicago CTSA UL1RR029879, Tulane University Translational Research in 
Hypertension and Renal Biology P30GM103337, Kaiser Permanente NIH/NCRR UCSF-
CTSI UL1 RR-024131 - CRIC Study. Dr. Shafi is supported by National Institute of 
Diabetes and Digestive and Kidney Diseases grant K23 DK083514. Dr. Kusek works 
at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)., 
Pharmaceutical Company Support - Dr. Inker reports funding to Tufts Medical Center for 
research and contracts with the National Institutes of Health, National Kidney Foundation, 
Pharmalink AB and Gilead Sciences, a consulting agreement with Otsuka, and has 
a provisional patent [Coresh, Inker and Levey] filed 8/15/2014 - Precise estimation of 
glomerular filtration rate from multiple biomarkers (licensing under negotiation).  Dr. 
Levey reports funding to Tufts Medical Center for research and contracts with the 
National Institutes of Health, National Kidney Foundation, Amgen, Pharmalink AB, 
Gilead Sciences, and has a provisional patent [Coresh, Inker and Levey] filed 8/15/2014 
- Precise estimation of glomerular filtration rate from multiple biomarkers (licensing 
under negotiation).  Dr. Coresh has a provisional patent [Coresh, Inker and Levey] filed 
8/15/2014 - Precise estimation of glomerular filtration rate from multiple biomarkers 
(licensing under negotiation).  Dr. Greene is a consultant for Jansen Pharmaceuticals and 
Pfizer, and reports grants from Nephrogenix, Keryx biopharmaceuticals, and Genkyotex 
S. A.
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Estimation of Glomerular Filtration Rate  P.C. Pham,1 Ruchika Bhasin,1 
Afsaneh Haftbaradaran,1 Eileen C. McCann,1 Solomon C. Huang,1 Saman 
Sarani,1 Anita Kamarzarian,1 Golriz Jafari,1 P.T. T. Pham.2  1Div of Nephrology 
and Hypertension, Olive View-UCLA Medical Center, Sylmar, CA; 2Kidney 
Transplant, UCLA Medical Center, Los Angeles, CA.
Background: Estimations of glomerular filtration rates (GFR) based on routine 24 
hour urine collections have been replaced by relatively accurate equations derived from 
large epidemiological studies. Nonetheless, equations including Modification Diet in 
Renal disease-4 and 6 variables (MDRD-4, -6) and Chronic Kidney Disease-Epidemiology 
Collaboration (CKD-EPI) are known to have wider variations in predicting GFR among 
patients with relatively good kidney function. As renal clearance of any solute is dependent 
on its presence in the plasma and not whole blood, we suspect that varying hemoglobin/
hematocrit (Hct) may play an important role in the actual clearance of solutes. We aim 
to determine if adding the plasma factor PF (1 - Hct/100) to MDRD-4, -6, or CKD-EPI 
equations can improve the accuracy of determining actual GFR.
Methods: This is a retrospective pilot study where the most recent 200 existing 24-
hour urine collections obtained with creatinine concentrations as recorded by the Olive 
View-UCLA Medical laboratory are collected for analysis. Only 24-hour urine collections 
with concurrent measurements of complete blood count and chemistry 7 are included. To 
minimize poor 24 hour collections, only samples with urine creatinine ranging between 
15-25 mg/kg body weight/day are used. PF is added as an inverse multiplication factor to 
MDRD-4 and 6-variables and CKD-EPI equations to assess for variations when correlated 
with actual 24 hour urine collections.
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Results: 90 out 200 samples met inclusion criteria. Albeit small, when each of the 
aforementioned equation was adjusted for PF, R2 variation improved. MDRD-4: unadjusted 
R2=0.836 to adjusted R2 = 0.853, MDRD-6, R2=0.811 to 0.813, CKD-epi, R2=0.746 to 0.747.
Conclusions: Adding PF to MDRD-4, MDRD-6, and CKD-EPI equations reduced 
variations when correlated to 24 hour urine collections. Of interest, PF appears to improve 
MDRD (derived for CKD patients where anemia is prevalent) variations better than CKD-
EPI. Large-scale reevaluation of eGFR estimates with consideration for PF is warranted.
SA-PO674
Interest of Cystatin C in the Evaluation of Glomerular Filtration 
Rate in Type 2 Cardio-Renal Syndrome  Delphine Kervella,1,3 Sandrine 
Lemoine,2,3 Florence Sens,1,3 Eric Pouliquen,1,3 Laurence Dubourg,2,3 Fitsum 
Guebre-egziabher,1,3 Laurent Juillard.1,3  1Nephrology, Hôpital Edouard Heriot, 
Hospices Civils de Lyon, Lyon, France; 2Renal Function, Hôpital Edouard 
Heriot, Hospices Civils de Lyon, Lyon, France; 3Univ Claude Bernard Lyon 
1, Lyon, France.
Background: In patients suffering from type 2 cardio-renal syndrome (CRS2), 
glomerular filtration rate (GFR) is overestimated with creatinine based formulae, leading 
to the misclassification of these patients in chronic kidney disease stages. As cystatin C is 
less dependent from muscle mass than creatinine, the aim of this study was to determine 
if estimation of GFR based on cystatin C offers a better evaluation of renal function than 
creatinine-based estimations in patients with CRS2.
Methods: GFR measured by Inulin clearance (measured GFR, mGFR) in 50 patients 
with CRS2 was compared to estimations of GFR (eGFR) with CKD EPI (Chronic Kidney 
Disease Epidemiology Collaboration) formulae based on creatinine (CKD EPI), cystatin 
(CKD EPICYST) and cystatin and creatinine (CKD EPICYST-CREAT). We calculated absolute 
bias (eGFR-mGFR) and accuracy 30% for each formula.
Results: Mean mGFR is 26.5±11.5 mL/min/1.73 m². eGFR are 41.5±20, 32±15 and 
35±14.5 mL/min/1.73 m² with CKD EPI, CKDEPICYST and CKD EPICYST-CREAT respectively .
These values of eGFR are significantly different from mGFR. Mean absolute bias are 
15.4, 5.7 and 8.8 mL/min/1.73 m² and accuracies 30% are 30%, 68% and 48% respectively. 
The accuracy of CKD EPICYST is significantly higher than the accuracy of CKD EPI.
Conclusions: Glomerular filtration rate is strongly overestimated with creatinine-based 
CKD EPI formula in CRS2 patients as previously described. CKD EPI formula based on 
cystatin C offers a better evaluation of GFR in this population. The high prevalence of 
malnutrition in this population can explain these results.
SA-PO675
Creatinine Level in Capillary Blood: A New Tool for Instant Estimation 
of Glomerular Filtration Rate  Maurice Laville,1 Solenne Pelletier,2 Denis 
Fouque.1  1Nephrologie, Univ de Lyon, Pierre Benite, France; 2Nephrologie, 
Hospices Civils de Lyon, Pierre Benite, France.
Background: Serum creatinine is the most used endogenous marker to estimate 
glomerular filtration rate (eGFR) in clinical practice. A handheld device (StatSensor®, 
Nova Biomedicals) allows to measure creatinine level in capillary blood. The aim of the 
study was to assess the accuracy of GFR values (eGFR) estimated from capillary blood 
creatinine level (CBCr), as compared with GFR values simultaneously measured by a gold 
standard method (mGFR) in patients with CKD.
Methods: The study included 79 adult patients (36 men, 43 women) who underwent 
renal function tests. The consent form contained information on the procedure and on the 
later use of the information for research. Inulin clearance was performed using a continuous 
infusion of inulin, and urine collections by periods of 30 min. Blood tests were done in the 
middle of each period of urine collection. Measurements of polyfructosan concentrations 
were performed using an enzymatic method. Inulin clearance was calculated in each period 
to obtain the average, and normalized to 1.73 m2 body surface area. A drop of capillary 
blood was collected from a finger simultaneous to the first and the last blood sampling for 
inulin measurement. The drops were deposited on a test strip including enzyme reagents 
and inserted into the SatSensor® device. Reading was done at 30 sec. eGFR was calculated 
from CBCr with the CKD-EPI equation and the average of the 2 values was taken as eGFR. 
To assess the performance of CBCr-derived eGFR, the mean absolute bias (eGFR - mGFR) 
and the correlation coefficient (R2)were calculated.
Results: Mean age was 54 ±17 years, and mean BMI was 25± 5 kg/m2.Mean value of 
mGFR was 61 ±27 ml/min/1.73 m2. Mean bias was -5.2 ml/min/1.73 m2. On correlation 
analysis, there was no significant difference between the 2 methods (correlation coefficient 
0.86 [0,7;1,01].
Conclusions: Estimation of GFR using instant measurement of capillary blood 
creatinine level and CKD-EPI formula provides consistent results as compared with a 
gold standard method for GFR measurement, and could be used for screening and self-
assessment purposes.
Funding: Clinical Revenue Support
SA-PO676
Renal Function Estimated with Different Formulae and Mortality in the 
INCIPE Cohort: Results After 8 Years Follow-up  Pietro Manuel Ferraro,1 
Antonio Lupo,2 Giovanni Gambaro.1  1Div of Nephrology, Catholic Univ of the 
Sacred Heart, Rome, Italy; 2Div of Nephrology, Univ of Verona, Verona, Italy.
Background: Chronic kidney disease is a known risk factor for adverse outcomes. Its 
presence and severity is usually ascertained with formulae to estimate renal function based 
on serum creatinine and/or cystatin C. We analyzed whether renal function estimated with 
different formulae has a differential association with mortality.
Methods: The INCIPE cohort is a sample of the Italian population enrolled in 2006-07, 
with follow-up data available up to 2014. CKD stages were defined as GFR ≥90, 89-60, 
59-45 and <45 mL/min based on the following formulae: Cockcroft-Gault (CG), Cockcroft-
Gault normalized to body surface area (nCG), abbreviated MDRD (MDRD), 6-variables 
MDRD (MDRD-6), CKD-EPI calculated with serum creatinine (EPI-Cr), with serum 
cystatin C (EPI-Cys), and with both serum creatinine and cystatin C (EPI-CrCys). CKD 
stage was then included in a Cox proportional hazards model together with age, body mass 
index, sex, high blood pressure, diabetes, dyslipidemia, previous cardiovascular disease, 
smoking status and albuminuria. Harrell’s c statistics with 95% confidence intervals (CI) 
were then calculated and compared for each formula.
Results: The final sample included 2,916 participants, all caucasians, 47.4% males, 
with an average age at enrollment of 59.9±11.4 years. Participants contributed a total of 
22,514 person-years of follow-up (median follow-up 7.9 years) during which 198 death 
events occurred. Overall, the models were highly predictive of mortality 
Harrell’s c 95% CI
CG 0.818 0.788, 0.848
nCG 0.818 0.788, 0.848
MDRD 0.820 0.791, 0.849
MDRD-6 0.819 0.789, 0.848
EPI-Cr 0.818 0.789, 0.848
EPI-Cys 0.826 0.797, 0.856
EPI-CrCys 0.821 0.791, 0.850
The GFR-Cys model performed significantly better than MDRD-6 (difference 
in c-statistics of 0.008, 95% CI 0.001, 0.015; p=0.034), whereas all the other models 
performed similarly.
Conclusions: Our study suggests that CKD defined with the CKD-EPI cystatin C 
formula shows a better prediction of mortality after accounting for a large number of 
potential risk factors.
SA-PO677
Do the BIS Equations Better Predict Death in Older Women? 
Muna T. Canales,1,2 Terri L. Blackwell,3 Areef Ishani,4,5 Brent C. Taylor,4 
Allyson Hart,6 Rebecca Beyth,1,2 Kristine E. Ensrud.4,5  1Malcom-Randall 
VAMC; 2Univ of Florida; 3California Pacific Medical Center; 4Minneapolis VA 
Health Care System; 5Univ of Minnesota; 6Hennepin County Medical Center, 
Minneapolis, MN.
Background: KDIGO 2012 guidelines recommend use of the CKD-EPI equations to 
estimate GFR except when there are alternate equations that may perform better for certain 
populations such as older adults. The BIS equations were specifically developed in an aged 
population, but their performance when compared to the CKD-EPI equations to predict 
mortality in older adults is unclear.
Methods: We conducted a prospective study of 1289 community-dwelling elderly 
women (≥72 years old) enrolled in the Study of Osteoporotic Fractures (SOF) who had 
both serum cystatin-C(cysc) and creatinine(SCr) measured at Year 10(1992-1994). We 
used Cox proportional hazards regression and net reclassification improvement(NRI) to 
compare the ability of the BIS2 (cysc & SCr-based), CKD-EPIcr,cysc, BIS1 (SCr-based), and 
CKD-EPIcr expressed as 4 eGFR categories (≥75, 60-74, 45-59, <45) to predict death. For 
NRI analyses, reference equations were CKD-EPIcr,cysc for BIS2 and CKD-EPIcr for BIS1.
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Results: The mean age was 79.5±4.6 years; 89% were white. Mean BMI was 27±5 kg/
m2. Mean follow-up time was 9±4 years. % eGFR<60 was: CKD-EPIcycs,cr 33%, BIS2 48%, 
CKD-EPIcr 24% and BIS1 49%. When compared to eGFR≥75 and after adjustment for age, 
race, BMI, HTN & DM, eGFR<45 by BIS2 was associated with a 2.1-fold greater risk of 
death (95% CI 1.5-3.0) vs 1.9-fold for eGFR <45 by CKD-EPIcr,cysc (95%CI 1.5-2.5); BIS1 
eGFR<45 was associated with a 1.6-fold greater risk of death (95% CI 1.1-2.1) vs 1.8-fold 
for eGFR <45 by CKD-EPIcr (95% CI 1.4,2.4; p trend <0.001 across categories for each 
equation). In category-based NRI analyses neither of the BIS definitions materially changed 
discrimination of mortality risk when compared to CKD-EPI equations.
Conclusions: In this cohort of older community-dwelling women, the BIS equations 
identified a greater proportion of participants as having CKD. With respect to mortality 
risk prediction, the BIS equations did not perform better than current CKD-EPI equations 
recommended by KDIGO 2012.
Funding: Other NIH Support - NIA, Veterans Administration Support
SA-PO678
Canine Chronic Kidney Disease: New Protein Biomarkers and 
Treatment with Human Umbilical Cord Mesenchymal Stem Cells 
Camila Eleuterio Rodrigues,1 Jose Manuel Condor Capcha,1 Talita R. Sanches,1 
Douglas Caragelasco,2 Cinthia Martorelli,2 Fernanda Chacar,2 Priscila Queiroz 
Gouveia,1 Irene L. Noronha,1 Marcia Kogika,2 Lucia Andrade.1  1Div of 
Nephrology, School of Medicine; 2Dept of Veterinary Internal Medicine, Univ 
of Sao Paulo, Brazil.
Background: There are few strategies to prevent the progression of renal disease 
in humans or animals. In canine chronic kidney disease (cCKD), as in human CKD, 
proteinuria correlates with CKD progression, although there are no established urinary 
protein biomarkers. cCKD has become more common, dogs routinely being euthanized upon 
reaching the advanced stages. Mesenchymal stem cells (MSCs) have proven renoprotective 
in rodent CKD models. Here, we aim to characterize the roles that urinary excretion of 
albumin (Alb), Tamm-Horsfall protein (THP), vitamin D-binding protein (VDBP) and 
retinol-binding protein (RBP) play in cCKD and to determine whether human umbilical 
cord MSC (huMSC) administration slows its progression.
Methods: We performed Western blotting for urinary exosomal expression of Alb, 
THP, VDBP and RBP in cCKD stage 1-4 dogs (n=10/stage) and control dogs (n=10). 
We evaluated huMSC phenotypes with flow cytometry and immunocytochemistry. We 
randomized CKD stage 3 dogs to receive i.v.-injected placebo (n=5) or 106 huMSC/kg (n=6). 
We measured serum creatinine (SCr), serum urea (SUr) and the urinary protein:creatinine 
ratio (UPC) monthly for a year.
Results: Alb, THP, VDBP and RBP correlated significantly with cCKD progression. 
Over the study period, UPC decreased in treated dogs (2 excluded for external causes) 
and increased in control dogs (-25.46±29.63 vs. 81.93±25.56%, p<0.05); SCr and SUr did 
not differ between the groups (183.6±236.2 vs. 32.02±68.69 and 48.3±31.7 vs. 45.3±62.2%, 
respectively); treated dogs presented less proteinuria.
Conclusions: Our findings broaden perspectives for CKD treatment. Supported by 
FAPESP.
SA-PO679
Validation of the Urine Total Protein-To-Creatinine Ratio-Based 
Chronic Kidney Disease Risk Classification: A Secondary Analysis 
Hiroyuki Yamamoto,1 Kyoko Yamamoto,1,2 Yutaro Nishi,1 Kyoko Takeda,1 
Hiroko Izumo,1 Yasuhiro Komatsu.1  1St. Luke’s Int’l Hospital, Tokyo, Japan; 
2Tohoku Univ Graduate School of Medicine, Sendai, Japan.
Background: The most recent Japanese chronic kidney disease (CKD) guideline states 
that patients without diabetes should be classified using the total urine protein-to-creatinine 
ratio (PCR) instead of the urine albumin-to-creatinine ratio (ACR); however, validation of 
the PCR is still required. This study was conducted to validate the PCR-based CKD risk 
classification compared with the ACR-based classification and to explore more accurate 
methods for classification, focusing on relatively early CKD patients.
Methods: We conducted a secondary analysis using two previous datasets with 
diabetic or cardiovascular patients who were classified into CKD stages A1-A2 and G1-
G3b. We assessed the CKD stage and risk classification of each patient according to the 
estimated glomerular filtration rate and the ACR- or PCR-based classification method. 
Then, various candidate PCR values were utilized as the cut-off values between stages 
A1 and A2. Cohen’s kappa statistics were calculated to evaluate the agreement between 
each classification method.
Results: In total, 860 patients (131 from the diabetic clinic and 729 from the 
cardiovascular clinic) were enrolled. Using the cut-off value recommended in the current 
guideline (PCR 0.15 g/gCr), the misclassification rates in these populations were 26.0% 
and 16.6%, respectively; the misclassifications were primarily caused by underestimation. 
The kappa statistics achieved 0.56 (95% confidence interval, 0.45-0.69) and 0.72 (0.67-
0.76), respectively. Using PCR values of 0.08-0.10 g/gCr as the cut-off value improved 
the misclassification rates and kappa values.
Conclusions: Current PCR-based CKD classification method leads to underestimation 
of risk classification in outpatient setting.
Funding: Private Foundation Support
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Beta-Trace Protein as Renal Marker in Older Adults – Results from the 
Berlin Initiative Study  Natalie Ebert,1 Olga Jakob,2 Jan Bartel,3 Markus van der 
Giet,1 Mirjam Schuchardt,1 Christine A. White,4 Elke Schaeffner.1  1Nephrology, 
Charité, Berlin, Germany; 2Epidemiology and Biostatistics, Charité, Berlin, 
Germany; 3Labor Limbach, Heidelberg, Germany; 4Nephrology, Queen’s 
Hospital, Kingston, ON, Canada.
Background: It has been shown that GFR estimation based on b-Trace Protein (BTP), a 
relatively novel biomarker, is reliable and might serve as an alternative in kidney transplant 
recipients. Whether BTP-based eGFR equations can be applied in older adults is not known.
Methods: BTP has been analysed by immunonephelometry with N-Latex® bTP Assay 
on a BN ProSpec® System, Siemens, Germany. Analysis was done in 570 participants of the 
Berlin Initiative Study (mean age: 78.5 yrs) who underwent iohexol clearance measurement 
(mean mGFR: 60.3 mL/min/1.73m2). The following 3 currently available eGFR equations 
were used: Pöge (BTP): GFR = 47.17 ×BTP-0.7933, Pöge (BTP/Crea): GFR = 974.31 × 
BTP-0.2594 × creatinine-0.647 and White (BTP/Crea): GFR=167.8 × BTP-0.758 × creatinine-0.204 
× (0.871 if female). Comparison of BTP estimating equations with mGFR was done for 
determination of bias (mGFR-eGFR), precision (SD) and accuracy (P10, P30).
Results: The boxplot includes median and eGFR range calculated with the 3 GFR-
equations. Mean eGFR was 100,3 for Pöge (BTP), 62,7 for Pöge (BTP/Crea) and 86,2ml/
min/1.73m2 for White (BTP/Crea). 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
783A
J Am Soc Nephrol 26: 2015 CKD: Estimating Equations, Incidence, Prevalence, Special Populations Poster/Saturday
Table 1 shows bias, precision and accuracy for all 3 equations compared to mGFR. 
Mean Bias
(ml/
min/1.73m2)
SD of 
Differences
Mean 
Percentage 
Bias 
(%)
SD of 
perc. 
Bias
P10 
(%)
P30 
(%)
Pöge, BTP 40.0 15.5 71.4 32.4 1.2 5.8
Pöge, BTP/
Crea 2.40 10.4 6.68 18.6 45.0 87.9
White, 
BTP/Crea 25.9 13.0 46.0 24.4 3.3 25.7
Conclusions: Currently available eGFR equations that were developed for adult kidney 
transplant recipients are not applicable in non-transplanted elderly patients. Further research 
is necessary to evaluate whether BTP is a useful renal marker for older adults.
Funding: Private Foundation Support
SA-PO681
Galectin-3, Possible Useful Biomaker in Predicting Chronic Kidney Disease 
in Hepatitis C Positive Patients  Hany Refaat, Haitham Ezzat, Amr Mohab. 
Nephrology Dept, Ain Shams Univ, Cairo, Egypt.
Background: Galectin-3, a profibrotic mediator, is involved in mechanisms of 
tubulointerstitial fibrosis and CKD progression. Data regarding its predictive value of CKD 
development in Hepatitis C patients is scarce.
Methods: In this Cohort study, we measured the level of Galectin-3 in the sera of 
80 Hepatitis C positive patients. Patients were stratified into two groups: Forty hepatitis 
C positive patients with normal kidney function (Group I), and 40 hepatitis C positive 
patients with CKD (Group II). Galectin-3 concentration was also measured in 10 healthy 
individuals, as a control group (Group III). Other laboratory investigations were done which 
included hemoglobin level, serum creatinine, eGFR by MDRD equation, ALT, AST, INR, 
serum albumin, serum bilirubin and CRP titre. We correlated galectin-3 concentrations 
with demographic and biochemical parameters in all groups.
Results:  30 females (33.3%) and 60 males (66.7%) were included in the study with 
mean age 47.6±5.3 years.Plasma levels of Galectin-3 were highest in group II (22.1±5 ng/
ml) when compared to group I (15 ±2.4 ng/ml) and group III (9.7±2.5 ng/ml) (p<0.001). 
Also CRP titre was highest in group II (10.1±1.5 mg/L), when compared to group I and III 
(2.5±0.9 mg/L and 2.3±1.1 mg/L respectively) (p<0.001). There was positive correlation 
between Galectin-3 level and CRP titre in both group I and II (p<0.001). Moreover, in 
group II, Galectin-3 level was positively correlated with serum creatinine (p<0.001), 
while inversely correlated with eGFR (p<0.001). There was no correlation between serum 
Galectin-3 level, and INR, ALT, AST and serum albumin in both group I and II.
Conclusions: In hepatitis C positive patients, galectin-3 concentrations increased with 
progressive renal impairment. Galectin-3 levels were not correlated with liver functions, 
suggesting the predictive value of galection-3 for CKD development in hepatitis C positive 
patients.
SA-PO682
Chronic Kidney Disease: Long Term Prevalence Trends and Influence of 
Modifiable Risk Factors  Stein I. Hallan,1 Marius Altern Øvrehus,2 Solfrid 
Romundstad,2 Dena E. Rifkin,1 Arnulf Langhammer,2 Joachim H. Ix.1  1UCSD, 
La Jolla, CA; 2Faculty of Medicine, NTNU, Trondheim, Norway.
Background: Prevalence of chronic kidney disease (CKD) is high worldwide, and it 
has been increasing in the US. However, less strict treatment goals for hypertension have 
recently been suggested despite increasing prevalence of obesity and diabetes.We aimed 
to determine whether CKD prevalence is increasing in Norway, evaluating the influence 
of changing prevalence of CKD risk factors on CKD prevalence, and compared findings 
to corresponding US data.
Methods: We included general population based participants from the Nord-Trøndelag 
Health Studies (HUNT), Norway: 65237 from HUNT2 (1994-96) and and 50586 from 
HUNT3 (2006-08). eGFR and u-ACR based on fresh blood and 3 urine samples were used 
to diagnose CKD. Thorough quality-control and comparisons of methods over time excluded 
analytical drift. We used attendance weights used to avoid responder bias.
Results: Total CKD prevalence remained stable in Norway 1996-2007 (11.3%- 
11.1%, p=0.42) but increased in subjects >75 years (36.6%-39.3%, p=0.014). eGFR <60 
ml/min/1.73m2 increased (4.5%-4.8%, p=0.033) while albuminuria >30mg/g decreased 
(7.9%-7.4%, p=0.034). The most important contributors were a strong blood pressure 
decline during this 10 years period, more physical activity and lower cholesterol; without 
these improvements 2.8, 0.7 and 0.6 percentage-point higher CKD prevalence would have 
been expected, respectively. In contrast, the prevalence of diabetes and obesity increased 
moderately, but diabetics received more intensive preventive therapy, and the proportion of 
diabetic patients with CKD decreased substantially (33.4%-28.6%, p=0.002). In contrast, 
published US data indicate a stronger increase in obesity and diabetes, and physical activity 
was low and not improving. Access to effective care was also suboptimal for a substantial 
group of the population.
Conclusions: In contrast to the US where CKD prevalence has been increasing, it 
remained stable over a 10 year period in Norway, likely due to substantial improvements in 
blood pressure, lipids and physical activity despite modestly increasing diabetes and obesity.
Funding: NIDDK Support
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Natural Progression of Chronic Kidney Disease in Optimally Managed 
Patients on the Maximum Conservative Management Pathway 
Suzanne H. Forbes, Kieran Mccafferty, Muhammad M. Yaqoob.  Nephrology, 
Royal London Hospital.
Background: The natural progression of advanced chronic kidney disease (CKD)/
end-stage renal disease (ESRD) managed in a specialist palliative care nephrology clinic 
setting is unknown.
Methods: We conducted an observational study of all patients with advanced CKD 
undergoing predialysis counselling between 2009-2014 in a single UK center. All patients 
who opted for conservative management were followed up prospectively in a specialist 
conservative care clinic and their clinical phenotype and renal outcomes recorded. Change 
in eGFR was noted in those patients whose eGFR was<10, with 2 or more serum creatinine 
estimations taken more than 2 months apart.
Results: We prospectively studied 354 patients with median length of follow-up 452 
days (165-769). Median eGFR at referral was 8ml/min (7-9). Demographics are shown. 
Age 78 (73-84)
Gender M - 62%F - 38%
Diabetes Yes - 62%No - 38%
Ethnicity
Caucasian - 39%
South Asian - 37%
Black - 14%
Other - 10%
Cause of CKD
Diabetes - 38%
Renovascular (including hypertension) - 24%
Urological - 9%
GN - 5%
Other - 4%
Unknown - 20%
Previous Modality
Nephrology/Low Clearance Clinic - 92%
Failing Transplant - 2%
Unknown to Service - 6%
Death (n) 209
Cause of Death n (%)
Cardiac - 16 (8)
Sepsis - 13 (6)
Stroke - 2 (1)
Unknown - 38 (18)
Other - 12 (6)
Age at Death 80 (75 - 85) 
Time to Death (days) 276 (103 - 555)
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Fall in eGFR in ml/min/year was 3.9 (1.8-8). Neither baseline eGFR (p=0.13) nor 
presence of diabetes (p=0.72) affected this rate of decline. Time to death from eGFR 
10ml/min was 276 days.
Conclusions: In this first longitudinal study of conservatively treated patients with 
advanced CKD, variable rate of decline of eGFR ranging between 1.8-8ml/year led to death 
of 55% of the cohort within the median follow up period of 15 months. Reassuringly the 
majority of patients died at their preferred place of terminal care (home/hospice) and were 
registered as deaths due to ESRD. Over 50% of patient’s eGFR decline was less than 4 
ml/min per year which could translate into a life expectancy of >1 year without dialysis in 
these exceedingly frail individuals. Prospective study is ongoing to determine the quality 
of life of these patients treated conservatively.
SA-PO684
Estimating County-Level Prevalence of Chronic Kidney Disease (CKD) in 
the United States  Sai Hurrish Dharmarajan,1 Jennifer L. Bragg-Gresham,1 Hal 
Morgenstern,1 Yi Li,1 Neil R. Powe,2 Delphine S. Tuot,2 Deborah Rolka,3 Sharon 
Saydah,3 Rajiv Saran.1  1Univ of Michigan, Ann Arbor, MI; 2Univ of California, 
San Francisco, CA; 3Centers for Disease Control and Prevention, Atlanta, GA.
Background: The prevalence of adult CKD in the US, estimated from 2005-2012 
national survey data, is about 13%; however, those surveys are not designed to provide 
estimates for small regions. Applying a Bayesian multi-level model (BMLM), we estimated 
adult CKD prevalence in US counties using national and state surveys.
Methods: Data on self-reported CKD and risk-factors were obtained from (i) the 
National Health and Nutrition Examination Survey (NHANES 2005-2012; n=20,831), and 
(ii) the Behavior Risk Factor Surveillance System (BRFSS 2011; n=506,467); NHANES 
also provided CKD laboratory data. CKD was defined as estimated glomerular filtration rate 
15-60 ml/min/1.73m2 or urinary albumin-to-creatinine ratio >30mg/g. As BRFSS does not 
include laboratory data, CKD for each person in the BRFSS was multiply imputed using 
a logistic regression model trained on NHANES data. A BMLM that effectively borrows 
information from neighboring counties was then fit to each imputed dataset to produce 
10 sets of county-level estimates of CKD prevalence. These estimates were combined to 
obtain a final prevalence estimate for each county.
Results: Estimated county-level prevalence of CKD ranged from 12.3 to 27.8% 
(median: 18.8%) in 2011 (see map). 
The standard deviation of these estimates ranged from 0.8 to 7%, and the coefficient 
of variation ranged from 5 to 32% of the estimate, suggesting good statistical precision.
Conclusions: We believe this is the first attempt to estimate CKD prevalence in U.S. 
ccounties. Our approach yields estimates with improved statistical precision for small 
counties, and is being used to study geographic variation in CKD burden across the U.S.
Funding: Other U.S. Government Support
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Overall CKD Prevalence in the U.S. Has Stabilized in Recent Years 
Daniel P. Murphy,1 Charles E. McCulloch,1 Feng Lin,1 Tanushree Banerjee,1 
Jennifer L. Bragg-Gresham,2 Mark Eberhardt,3 Meda E. Pavkov,3 Rajiv Saran,2 
Neil R. Powe,1 Chi-yuan Hsu.1  1UCSF [Drs. CY Hsu and NR Powe are Co-
Senior Authors]; 2Univ of Michigan; 3CDC.
Background: ESRD incidence rates in the U.S. have stabilized recently. We sought 
to better understand trends in CKD prevalence since 2003-2004.
Methods: We examined data on adults from the National Health and Nutrition 
Examination Surveys from 1988 through 2012. We determined prevalence of stage 3-4 
CKD (CKD-EPI equation eGFR 15-59 mL/min/1.73m2) overall and by age, sex, race, and 
diabetes strata. We examined crude prevalence and adjusted prevalence for age, sex, race, 
and diabetes mellitus (diagnosed and undiagnosed). Restricted cubic splines were used to 
model trends. The years 2003-4 (last years with published literature) were compared to 
2011-12 (most recent years of available data).
Results: Consistent with the published literature, we saw a rise in CKD prevalence 
from the late 1990s to the early 2000s. But since around 2003-4, adjusted and unadjusted 
prevalence of CKD have stabilized (Figure). This temporal trend was observed across 
age (p for interaction=0.11), sex (p=0.61) and racial-ethnic subgroups (p=0.07; although 
the trend in non-Hispanic blacks appeared to differ); and did not differ by diabetes status 
(p=0.17). There was no difference in overall stage 3-4 CKD prevalence comparing 2003-4 
and 2011-12 (p=0.25). Similar trends were seen with an expanded definition of CKD to 
include persons with higher eGFRs but albuminuria or used the MDRD equation.
Conclusions: Over the last decade in the U.S., there has been stabilization in the overall 
prevalence of stage 3-4 CKD, with a possible exception in blacks. This is contrast to what 
has been reported by prior studies analyzing older data but consistent with the observed 
stabilization of overall ESRD incidence. Efforts should be continued to implement reno-
protective measures, especially in blacks.
Funding: NIDDK Support, Other U.S. Government Support, Private Foundation 
Support
SA-PO686
Global Prevalence of Chronic Kidney Disease Categories 3-5 – A Systematic 
Review  Tazeen H. Jafar,1 Pryseley Nkouibert Assam,1,2 Fahad Javaid Siddiqui,1 
Shreyasee S. Pradhan,1 Edwin S.Y. Chan.2  1Duke-NUS Graduate Medical 
School, Singapore; 2Singapore Clinical Research Inst.
Background: Chronic kidney disease (CKD) has become a leading contributor to 
the global burden of disease. We performed a systematic review of published studies to 
estimate the global prevalence of CKD categories 3-5 defined by estimated glomerular 
filtration rate (eGFR) less than 60 ml/min/m2.
Methods: PubMed, EMBASE and Scopus were searched for studies published in 
English from 2003 to 2013 reporting prevalence of CKD categories 3-5 in the general 
population. Studies were included if they (1) sampled from the general adult population, 
(2) assessed CKD using CKD-EPI or MDRD Study equations; (3) not on renal replacement 
therapy.
Results: A total of 13,081 studies were considered, of which 566 studies from 54 
countries assessed prevalence of CKD, and 284 studies were in unselected general 
population. The global prevalence of CKD accounting for clustering among all adults aged 
20 years or older are shown in table below 
CKD Category (C) Countries Studies
CKD 
Prevalence
(95% CI)
Expected Number of 
Individuals with CKD 
(Millions) (95% CI)
C 3 to 5 (eGFR <60 ml/
min/1.73m2) 41 264
7.0 (5.2 to 
9.3) 335.0 (249.0 to 446.0)
C 3 to 5 (20 to 65 yrs) 29 66 3.9 (2.1 to 7.2) 154.4 (80.0 to 289.0)
C 3 to 5 (65 + yrs) 25 58 28.9 (19.3 to 41.1) 229.6 (154.4 to 328.0)
C 3 only (eGFR 30-59 
ml/min/1.73m2) 27 86
6.2 (4.2 to 
9.3) 332.8 (220.9 to 446.0)
C 4 only (eGFR 15-29 
ml/min/1.73m2) 18 50
0.3 (0.2 to 
0.4) 14.4 (11.5 to 17.2)
C 5 only (eGFR <15 
ml/min/1.73m2) 15 29
0.1 (0.1 to 
0.2) 5.2 (3.8 to 7.2)
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Figure shows the association of age with CKD categories 3-5. Sensitivity analysis 
revealed consistent CKD prevalence (6.9%) for all 566 studies.
Conclusions: Clinically significant CKD is high both in younger and older adults 
globally. Our findings call for institution of urgent public health efforts for CKD prevention 
and management.
SA-PO687
Prevalence of Chronic Kidney Disease with Diabetes and Glomerulonephritis 
in China  Luxia Zhang, Jinwei Wang, Ming Hui Zhao.  Renal Div, Dept of 
Medicine, Peking Univ First Hospital, Beijing, China.
Background: Diabetes is the leading cause of end stage kidney disease worldwide, 
while glomerulonephritis is thought to be the predominant cause in developing countries. 
However, the surging prevalence of diabetes in developing countries such as China may 
have substantial impact on the spectrum of chronic kidney disease.
Methods: A national in-patient database involving 19.5 million patient-records 
was used. Diagnoses of chronic kidney disease with diabetes (DM-CKD) as well as 
with glomerulonephritis (GN-CKD) were extracted from International Classification of 
Diseases-10 codes of the discharge diagnoses. Furthermore, a general population-based, 
national representative sample of 47 204 participants was used. Identification of DM-
CKD and GN-CKD was based on laboratory tests and the questionnaire inquiring about 
medical history. Then the prevalence of DM-CKD and GN-CKD was compared among 
both hospitalized population and general population.
Results: Among 19.5 million hospitalized patients, 1.19% and 0.79% were identified 
as with DM-CKD and with GN-CKD, respectively. Compared with GN-CKD, DM-CKD 
was associated with 7.2% (95% confidence interval [CI] 6.4-8.0%), 5.4% (95%CI 4.7-
6.0%) and 59% (95%CI 46-73%) increase of costs, length-of-stay and in-hospital mortality, 
respectively. For general population, the prevalence of GN-CKD is also exceeded by that 
of DM-CKD at 0.84% (95%CI 0.68-1.00%) and 1.23% (95% CI 1.06-1.41%), respectively. 
The estimated number of DM-CKD patients in China was 20.1 million.
Conclusions: Our study indicates that DM-CKD surpassed GN-CKD in both 
hospitalized population and general population, which marked a transition of kidney 
disease spectrum in China. Furthermore, DM-CKD is associated with substantial increased 
healthcare resources utilization and increased risk of in-hospital mortality.
Funding: Government Support - Non-U.S.
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Prevalence of Chronic Kidney Disease on the U.S.-Mexico Border: Role 
of Acculturation  Jonathan Michael Starkey,1 Kristina Vatcheva,2 Susan P. 
Fisher-Hoch,2 Joseph B. Mccormick.2  1Inst for Translational Sciences, Univ 
of Texas Medical Branch, Galveston, TX; 2Univ of Texas School of Public 
Health, Houston, TX.
Background: Mexican-Americans are the dominant Hispanic group in the US and 
face significant health disparities, including end-stage renal disease, diabetes and obesity. 
We characterize the quantity and associations of chronic kidney disease (CKD) in Cameron 
County, TX where almost 90% of the population is Hispanic and is predominantly zero or 
first generation Mexican-American.
Methods: The Cameron County Hispanic Cohort (CCHC) is a random sample of 
the Hispanic population on the southernmost point along the US-Mexico border. 1,777 
participants with baseline serum creatinine measurements from 2003-2014 are included in 
this cross-sectional study. The glomerular filtration rate (eGFR) is estimated from serum 
creatinine and CKD is defined as eGFR < 60 mL/min/1.73 m2 . The weighted prevalence 
of CKD is estimated. A multivariate model of factors associated with CKD outcome.
Results: The prevalence of CKD is 6.0% in the CCHC and estimates the prevalence 
in Cameron County, TX. Stratified by gender, the prevalence in men and women is 6.9% 
and 4.9%, respectively. Multivariate analysis reveals significant associations of country of 
birth (OR 2.14, 95% CI [1.02, 4.46] for those born in the US), hypertriglyceridemia (OR 
2.72, 95% CI [1.41, 5.239]) and granulocyte count (OR 1.345, 95% CI [1.058, 1.708]) with 
CKD status after adjusting for age, gender, diabetes status, cardiovascular disease history, 
hypertension, smoking history, obesity, LDL and statin use.
Conclusions: The prevalence of CKD in the CCHC is higher than previous national 
estimates in Hispanics or Mexican-Americans. The data suggest that acculturation, 
triglycerides and inflammation are associated with CKD in Hispanics living on the US-
Mexico border. More research is needed in Mexican-Americans to investigate CKD in this 
growing minority population.
Funding: Other NIH Support - K22 LM011869-01A1, National Library of Medicine 
(NLM) Starkey, Jonathan M (PI)
MD000170 P20 funded from the National Center on Minority Health and Health 
disparities (NCMHD) McCormick, Joseph (PI), and the Centers for Clinical and 
Translational Science Award UL1 TR000371 from the National Center for Advancing 
Translational Science (NCATS)
Clinical and Translational Science Award (UL1TR000071)
SA-PO689
Validation of the Kidney Failure Risk Equation in Manitoba  Reid Whitlock,1,2 
Paul Komenda,1,2,3 Claudio Rigatto,1,2,3 Allison Dart,1,3,4 Joe A. Bueti,3,4 Randy 
Walld,1 Navdeep Tangri.1,2,3  1Community Health Sciences, Univ of Manitoba, 
Winnipeg, MB, Canada; 2Nephrology, Seven Oaks Hospital, Winnipeg, MB, 
Canada; 3Medicine, Univ of Manitoba, Winnipeg, MB, Canada; 4Nephrology, 
Health Science Centre, Winnipeg, MB, Canada.
Background: Patients with chronic kidney disease (CKD) are at risk for progression 
to kidney failure. We previously developed the Kidney Failure Risk Equation (KFRE) to 
predict the progression of CKD to kidney failure in patients referred to nephrologists. This 
study aims to validate the KFRE in an unreferred population in Manitoba, and to determine 
risk thresholds for clinical decision-making.
Methods: We included patients from the Diagnostic Services of Manitoba database with 
an eGFR < 60 ml/min/1.73 m2 and a urinary albumin creatinine ratio measured between 
October 1, 2006 – March 31, 2007. Five year kidney failure risk was predicted using the 
4-variable KFRE and compared with treated kidney failure events from the Manitoba Renal 
Program database. Sensitivity and specificity for KFRE thresholds (3% and 10% over 5 
years) were then compared to eGFR thresholds (30 and 45 ml/min/1.73m2).
Results: 1,512 patients were included and 151 developed kidney failure over the 
5-year follow-up period. The 4-variable KFRE more accurately predicted kidney failure 
when compared to eGFR alone (AUROCs 0.90 [95% confidence interval (CI) 0.88-0.92] 
for KFRE vs. 0.78 [95% CI 0.74-0.83] for eGFR). At a risk threshold of 3 % over 5 years, 
the KFRE had a sensitivity of 97 % and a specificity of 62 %.
Conclusions: The KFRE is highly accurate at predicting 5-year risk of kidney failure 
in a population based sample of Manitobans with CKD Stages 3 to 5. Integration of the 
4-variable KFRE into laboratory information systems should be considered.
Funding: Private Foundation Support
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A Risk Prediction Model of End-Stage Renal Disease in Type 1 Diabetes Using 
Urine MCP-1 as an Alternative Biomarker of ACR  Masayuki Yamanouchi, 
Monika A. Niewczas, Natalia Z. Nowak, Andrzej S. Krolewski.  Genetics & 
Epidemiology, Joslin Diabetes Center, Boston, MA.
Background: There is a great need to develop risk prediction models to recruit patients 
at high risk of end-stage renal disease (ESRD) for clinical trials in patients with type 1 
diabetes. We developed two models to predict progression of CKD 3 and 4 to ESRD in 5 
years in patients with type 1 diabetes: “ACR model” that consists of patient’s age, eGFR, 
HbA1c and ACR, and “Urine MCP-1 model” that consists of the same markers but replacing 
ACR with urine MCP-1.
Methods: We identified 285 patients with type 1 diabetes and impaired renal function 
(eGFR: 15-60 ml/min/1.73m2) from Joslin Proteinuria Cohort that was followed for 7 to 
18 years to ascertain ESRD. We focused on the events within 5 years from enrollment. For 
the ACR model, the Cox model identified four baseline variables: age, eGFR, ACR, and 
HbA1c for the final model. For the urine MCP-1 model, urine MCP-1, age, eGFR and HbA1c 
were identified by the Cox model. Assigned point scores corresponded to each coefficient.
Results: 5-year risk of ESRD in the study group was 40.5%. In the ACR model, the 
variable with highest magnitude was eGFR<30, 4 points; followed by ACR >300, 2 points; 
HbA1c >7.5, 1 point; and age <45 years, 1 point, while in the urine MCP-1 model, the 
variable with highest magnitude was eGFR<30, 2 points; followed by urine MCP-1 >545, 
1 point; HbA1c >7.5, 1 point; and age <45 years, 1 point. The model with urine MCP-1 
performed almost equal to the model with ACR (C statistic of 0.702 (0.556-0.831) vs. 
0.719 (0.574-0.845)). Although the number of patients who developed ESRD in the high 
risk group in the urine MCP-1 model is smaller than in the ACR model, the incident rate 
of ESRD in the high risk group in the urine MCP-1 model was much higher than in the 
ACR model (291/1000 vs. 196/1000, p<0.001).
Conclusions: Using the risk score with urine MCP-1, we can identify a subgroup of 
patients at very high risk of ESRD.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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SA-PO691
A Reliable Formula to Estimate 24-h Urine Sodium Excretion from Morning 
Fasting Urine in Patients with Chronic Kidney Disease  Se Yun Kim,1 Ho 
Jun Chin,2 Sejoong Kim,2 Dong Ki Kim,3 Suhnggwon Kim,3 Jung Hwan Park,4 
Sung Joon Shin,5 Bum Soon Choi,6 Chun Soo Lim,7 Sang Ho Lee.1  1Kyung 
Hee Univ Hospital, Seoul, Korea; 2Seoul National Univ Bundang Hospital, 
Seong-Nam, Korea; 3Seoul National Univ Hospital, Seoul, Korea; 4KonKuk 
Univ Hospital, Seoul, Korea; 5Dongguk Univ Ilsan Hospital, Goyang, Korea; 
6Seoul St. Mary’s Hospital, Seoul, Korea; 7Seoul National Univ Baramae Medical 
Center, Seoul, Korea.
Background: Estimated 24 hour urine sodium excretion based on spot urine has been 
proposed to replace 24 hour urine collection in epidemiologic studies. However, estimated 
sodium excretion has not been verified whether it is useful in patients with chronic kidney 
disease (CKD) as well as in interventional study. The aim is to evaluate the estimated sodium 
excretion in prospective low salt diet education study (ESPECIAL) cohort.
Methods: New formula was developed from baseline data of 228 CKD patients of 
ESPECIAL cohort using a multivariate linear regression and compared with previous three 
formulas from healthy population (Kawasaki, INTERSALT, Tanaka) and one from CKD 
patients (Nerbass) for the prediction of 24 hour sodium excretion after ARB treatment and 
low salt diet education.
Results: Among previous reported formulas, the estimation by Tanaka’s formula 
showed the smallest bias (estmated 144.3±46.5 vs. measured 154.1±69.6 mEq/day), but 
weak correlation (r=0.34). We developed new formula with improved bias (estimated 
154.0±39.7 mEq/day) and correlation (r=0.56). New formula also showed the best 
correlation (r=0.57) with smallest bias (estimated ± mEq/day) even after ARB treatment, 
which did not showed significant change of measured sodium excretion(156.3±70.6 mEq/
day). Intensive low salt diet education elicited the significant decrease of measured sodium 
excretion (121.2±59.4 mEq/day). Although new formula also showed best correlation, any 
of formulas did not predict the amount of the decrease of measured sodium excretion.
Conclusions: We developed more reliable formula for estimating urine sodium 
excretion for CKD patients. However, our data suggests estimated sodium excretion could 
be applied for epidemiological study rather than low salt intervention study.
SA-PO692
Evaluation of Glycated Albumin for Glycemic Monitoring in Diabetic 
Nephropathy  Yang Fei, Ying Fan, Yumei Liu, Niansong Wang.  Dept of 
Nephrology and Rheumatology, Shanghai Jiaotong Univ Affiliated the Sixth 
Hospital, Shanghai, China.
Background: Glycated albumin(GA) has been now widely used for the evaluation of 
blood glucose in diabetic nephropathy(DN) patients. However, the effect of proteinuria on 
GA should be taken into account, especially in patients with advanced DN.
Methods: A total of 621 diabetic nephropathy patients from year 2009 to 2014 were 
enrolled in the study. According to the 24h urinary protein(UP) output, subjects were 
divided into 3 groups defined as (1) microalbuminuia: UP=30-300mg/24h, (2) moderate 
albuminuria: UP=300-1000mg/24h, (3) macroalbuminuia: UP>1000mg/24h).
Results: In all DN patients, the related factors of GA were fasting blood glucose(FBG), 
postprandial blood glucose(PBG), body mass index (BMI) and 24h UP. The multivariate 
regression equation was GA = 0.254FBG + 0.347PBG-0.341 BMI-1.306UP, (R2=0.375). 
There was no correlation between GA and 24h UP in DN patients with micro or moderate 
albuminuria. However, GA was found to be much lower and negatively correlated 
with 24h UP in DN patients with macroalbuminuria. Therefore, adjusted GA (adjGA) 
was applied for those subjects, taking 24h UP, serum albumin (SA) and the ratio of 
normal albumin metabolism days to total albumin metabolism days into account. 
adjGA=mGA×(1+3.75×UP/SA). As a result, GA value was increased after adjustment 
in DN macroalbuminua group. The adjGA was also found only correlated with FBG and 
PBG, and had no relation with 24h UP and SA.
Conclusions: In diabetic nephropathy patients, blood glucose, serum albumin and 24h 
urinary protein output may serve as important factors for the evaluation of GA on glycemic 
level. GA tended to be underestimated in DN patients with macroalbuminuria. The adjGA 
may be a better way to objectively evaluate glycemic status in patients with advanced DN.
SA-PO693
Fat Mass, Lean Body Mass and Serum Filtration Markers in Adults in the 
United States: The National Health and Nutrition Examination Survey 
(NHANES)  Meredith C. Foster,1 Julie K. Bower,2 Josef Coresh,3 Roger A. 
Fielding,4 Lesley Inker,1 Andrew S. Levey.1  1Tufts Medical Center; 2The Ohio 
State Univ; 3Johns Hopkins Univ; 4Tufts Univ.
Background: Established serum filtration markers are influenced by body composition 
(creatinine by muscle mass, cystatin C by fat mass) but limited data exist evaluating 
associations of these markers with body composition assessed using a gold-standard 
measurement approach. Our aim was to examine the association of body composition 
quantified using dual energy X-ray absorptiometry (DXA) with serum creatinine and 
cystatin C in US adults.
Methods: We conducted a cross-sectional analysis in 4378 adults age 18+ years from 
NHANES 1999-2002. Body composition included total lean mass and total fat mass; 
body mass index (BMI, kg/m2) was included for comparison. Associations of natural log-
transformed creatinine and cystatin C with body composition measures were evaluated 
using multivariable linear regression, stratified by age. Analyses were weighted to account 
for the NHANES design with multiple imputation for missing DXA data.
Results: Lean mass was associated with higher serum creatinine in in all age groups 
whereas higher fat mass was associated with higher creatinine in adults age 65+ (Table). 
Lean mass and fat mass were associated with higher serum cystatin C across all age 
groups; associations of lean mass with cystatin C were not significant with additional 
adjustment for fat mass.
Conclusions: Fat mass and lean mass are differentially associated with creatinine 
and cystatin C in US adults. Findings in younger adults suggest that observed associations 
may reflect the impact of body composition rather than kidney function on serum marker 
levels. Further work is needed to determine how the observed associations are influenced 
by GFR and body composition simultaneously and the impact of fat and lean mass on 
CKD prevalence estimates.
Funding: Private Foundation Support
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Associations of the Levels of Kidney Function with Protein-Energy Wasting 
Syndrome Are Independent of Serum CRP and Bicarbonate  Xiaorui Chen,1 
G. Wei,1 Robert E. Boucher,1 Dominique Ferranti,1 Michel Chonchol,3 Kalani 
L. Raphael,1 Srini Beddhu.1,2  1U of Utah; 2VA SLC; 3UC Denver.
Background: Inflammation and metabolic acidosis are putative causative factors of 
protein-energy wasting (PEW) in CKD. Therefore, we examined whether serum CRP and 
bicarbonate levels attenuate the associations of CKD with PEW in 11,834 adult (age > 
20 yrs) participants in the 1999-2004 National Health and Nutrition Examination Survey 
(NHANES).
Methods: PEW syndrome was defined as the presence of at least one criterion in two 
out of three categories: serum chemistry (albumin < 3.25 g/dl or cholesterol < 100 mg/
dl), body weight (BMI < 20 kg/m2 or unintentional wt loss > 10% over 1 yr), and muscle 
mass (body fat % < 10% or MAMC < 10% of 50th percentile of reference population). 
Using eGFR 60 to 89 ml/min/1.73 m2 as the reference, the odds of PEW in ≥ 90, 45-59 
and < 45 ml/min/1.73 m2 groups were examined in logistic regression models using svy 
suite in STATA 13.
Results: Mean age was 46.0 yrs, 50.3% were male, 9.5% were black. The prevalence 
of PEW syndrome had a U shaped association with the level of kidney function.
Compared to the reference group, both eGFR ≥ 90 and < 45 groups had nearly two-
fold increased odds of PEW. This was not attenuated after adjusting for serum CRP or 
bicarbonate. 
eGFR (ml/min/1.73m2)
PEW syndrome OR (95% CI)
Model 1* Model 2$
60 – 89.9 Ref Ref
≥ 90 1.95 (1.41, 2.68) 1.86 (1.36, 2.55)
45 – 59.9 1.11 (0.70, 1.76) 1.17 (0.72, 1.90)
<45 2.09 (1.05, 4.13) 2.33 (1.10, 4.97)
* adjusted for age, gender, race, education, smoking, alcohol use, MI, CHF, stroke, diabetes, lung 
disease and cancer 
$ Above + serum CRP and serum bicarbonate
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Conclusions: PEW syndrome is highly prevalent in those with lower kidney function. 
This appears independent of inflammation and serum bicarbonate. Further studies are 
warranted to determine the mechanism of PEW syndrome in the CKD population.
Funding: NIDDK Support
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Awareness and Perceived Risk of CKD Among African American Patients 
with CKD  Raquel C. Greer,1 Yang Liu,1 Jessica M. Ameling,1 Deidra C. Crews,1 
Patti Ephraim,1 Lisa A. Cooper,1 L. Ebony Boulware.2  1Johns Hopkins Univ; 
2Duke Univ.
Background: African Americans (AAs) are disproportionately affected by CKD with 
greater prevalence of advanced disease and poorer control of CKD risk factors. Patients’ 
awareness of CKD may facilitate engagement in self-management behaviors to modify 
CKD risks.
Methods: As part of a baseline assessment for a randomized controlled trial, we 
characterized CKD awareness and perceived risk of CKD among AAs with uncontrolled 
hypertension and CKD (eGFR 15-60 ml/min/1.73m2 or UACR³30mg/g). We assessed 
patients’ self-reported CKD awareness (“Do you have a kidney problem or chronic kidney 
disease?”; yes or no response) and degree of perceived likelihood (“How likely do you 
think it is that you could develop kidney problems or kidney failure in the next 10 years?”; 
not likely versus slightly, moderately, or very likely response) and perceived concern of 
developing CKD (“How concerned are you about developing kidney problems in the next 
10 years?”; not concerned versus slightly, moderately, or very concerned response). We 
constructed multivariable models to assess patient characteristics independently associated 
with patients’ CKD awareness and perceived CKD risks.
Results: Among 52 AA patients with CKD, the mean age was 58 years, 67% were 
female, 67% had diabetes, 15% had coronary artery disease, 40% had eGFR<60 and 60% 
had albuminuria alone. The majority (n=37, 71%) of patients were not aware of their CKD. 
Among these, 27% (n=10) considered themselves unlikely to develop CKD and 19% (n=7) 
were not concerned about developing CKD. CKD awareness was greater among patients 
with an eGFR<60 (vs. eGFR≥60) (adjusted percentages (AP) [95% CI]: 50% [19-81%] 
and 19% [reference], respectively; p=0.05. Conversely, patients with diabetes reported less 
CKD awareness than those without diabetes (AP [95% CI]: 53% [reference] and 10% [2-
38%], respectively; p=0.008). Perceived risk of CKD did not vary by patient characteristics.
Conclusions: Among AA patients with uncontrolled hypertension and CKD, awareness 
of CKD was low, with some patients unconcerned about developing CKD in the future. 
Strategies to improve recognition of CKD risks among AAs at high CKD risk are needed.
Funding: NIDDK Support, Other NIH Support - NHLBI
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Discussions About CKD Between African Americans with High CKD Risks 
and Their Primary Care Physicians  Raquel C. Greer,1 Debra L. Roter,1 Yang 
Liu,1 Jessica M. Ameling,1 Deidra C. Crews,1 Patti Ephraim,1 Lisa A. Cooper,1 
L. Ebony Boulware.2  1Johns Hopkins Univ; 2Duke Univ.
Background: Routine primary care visits provide an important opportunity for primary 
care physicians (PCPs) to discuss CKD risk modification with patients at high risk, but the 
frequency of patient-physician discussions about CKD is unknown.
Methods: In a randomized controlled trial of African American (AA) patients with 
uncontrolled hypertension, we analyzed audio-recorded encounters between patients and 
their PCPs using the Roter Interaction Analysis System to characterize the occurrence of 
CKD discussions (e.g., discussion of kidney disease, eGFR, creatinine, or albuminuria) and 
patient-physician communication patterns (e.g., patient-centeredness, the degree to which 
the discussion focused on the patient’s psychosocial and lifestyle context) during routine 
primary care visits. In multivariable logistic regression models, we assessed patient, visit, 
and communication characteristics independently associated with the presence of CKD 
discussions among all patients and among those with CKD (eGFR<60ml/min/1.73m2 or 
UACR³30mg/g).
Results: Among 124 patients, the mean age was 58 years, 69% were female, 48% had 
diabetes, 35% had CKD (mean eGFR 83). The average visit length was 22 minutes. Patients 
and PCPs discussed CKD in 47% of visits and discussions more frequently occurred among 
patients with CKD (vs. without CKD) (66% and 36% respectively, p=0.002). Discussions 
were less common [Odds Ratio (95% CI)] in visits of patients ≥ age 60 (vs. <60) [0.3 
(0.1-0.8)] or with higher eGFR [0.96 (0.95-0.98), per ml/min/1.73m2], and more common 
when visits were more (vs. less) patient-centered [2.4 (1.0-5.8)] or when diabetes was (vs. 
was not) discussed [3.7 (1.5-9.4)]. Patient gender, comorbid disease, and visit length did 
not predict discussions. Among patients with CKD (n=44), CKD discussions were also less 
common among patients ≥ age 60 [0.1 (0.2-0.9)] or with higher eGFR [0.96 (0.92-1.0)].
Conclusions: AA patients at high risk of CKD and their PCPs discussed CKD in 
fewer than half of routine primary care visits. Efforts to improve the occurrence of CKD 
discussions during routine primary care encounters are needed.
Funding: NIDDK Support, Other NIH Support - NHLBI
SA-PO697
Primary Care Utilization Is Associated with Reduced Mortality Among 
Older Adults With CKD  Raquel C. Greer,1 Hsien-Yen Chang,1 Gerard Fenton 
Anderson,1 Bernard G. Jaar,1 Craig Pollack,1 Nae-Yuh Wang,1 Lawrence J. 
Appel,1 L. Ebony Boulware.2  1Johns Hopkins Univ; 2Duke Univ.
Background: Routine primary care visits provide opportunities to identify and manage 
patients’ CKD risk factors and to provide preventative care. It is unclear how primary care 
utilization impacts clinical outcomes among older adults with CKD.
Methods: We quantified the association between primary care utilization and ESRD 
incidence or mortality among older US adults with CKD (in 2005-2006) using Medicare 
claims.   We assessed (in 2006) patients’ primary care utilization (no visit vs. at least 
one), other care utilization (nephrology care [no visit vs. at least one], the total number 
of ambulatory evaluation and management (E &M) visits with any type of provider), 
and patients’ comorbid conditions and sociodemographics.  We used standard and cause-
specific (accounting for competing risk of death) Cox proportional hazard models overall 
and stratified by age (65-74, 75-84, or ≥ 85 years) to estimate hazard ratios (HRs) for 
ESRD or mortality.
Results: Among 106,765 patients, most (79%) had at least one primary care visit in 
2006, and 21% had at least one nephrology visit. The median number of ambulatory E&M 
visits was 10. Compared to patients with no primary care visits, patients with at least one 
visit were younger (78 vs. 80 mean years, p<0.001), less likely African American (10 vs. 
14%, p<0.001), and had a greater prevalence of diabetes (46 vs. 42%, p<0.001), hypertension 
(88 vs. 78%, p<0.001), or coronary artery disease (74 vs. 72%, p<0.001). Over 4 years 
of follow-up, 4,264 patients developed ESRD and 45,059 died. Primary care utilization 
was not associated with ESRD incidence. However, compared to patients with no primary 
care visits, patients with at least one visit had a lower risk of death [HR (95%CI): 0.73 
(0.72-0.75)] overall and in age stratified models.
Conclusions: Primary care utilization was not associated with lower ESRD risk, but it 
was associated with a lower risk of death among older adults with CKD. Efforts to improve 
the engagement of primary care providers in the care of patients with CKD represent an 
important strategy to improve the health of this high risk population.
Funding: NIDDK Support
SA-PO698
Routine Use of Health Care Among High-Risk African Americans at Risk 
of CKD  Clarissa Jonas Diamantidis,1 Nrupen Anjan Bhavsar,1 Julia J. Scialla,1 
Clemontina A. Davenport,1 Rasheeda K. Hall,1 Crystal C. Tyson,1 Mario Sims,3 
Tara Smith Strigo,1 Neil R. Powe,2 L. Ebony Boulware.1  1Medicine, Duke 
Univ, Durham, NC; 2Medicine, UCSF, San Francisco, CA; 3Medicine, Univ of 
Mississippi Medical Center, Jackson, MS.
Background: Engagement in routine health care (RHC) is a key strategy to decrease 
health inequities among African Americans (AAs) at high risk of developing CKD or CKD 
complications. We examined demographic, attitudinal and socio-cultural factors associated 
with RHC among high-risk AAs at risk of CKD incidence or progression.
Methods: We quantified the prevalence of RHC (physical exam <1 year prior) use 
among AA Jackson Heart Study (JHS) baseline participants (from 2000-2004) with 
hypertension (HTN) or diabetes. We identified demographic, attitudinal (e.g., perceived 
discrimination, anger and hostility, stress, trust in health providers) and educational 
(i.e., CKD awareness) factors independently associated with RHC use. Those missing 
demographic or attitudinal data were excluded.
Results: Of 5301 JHS participants, 1152 met inclusion criteria. Most (n=909, 79%) 
reported RHC use. Rates of RHC were similar in those with and without CKD (22% vs. 
23%). Participants not using RHC (vs. using) were more likely to be < 55 years of age 
(51% vs 37%), male (43% vs. 30%), without HTN (9% vs. 5%), tobacco users (38% vs. 
29%), and uninsured (14% vs. 9%), all p<0.05. Participants not using RHC less frequently 
reported trust in their health provider (80% vs. 95%), more frequently reported difficulty 
obtaining health services (17% vs. 8%), and less frequently reported provider satisfaction 
(91% vs. 98%), all p<0.05. In multivariable models, not using RHC was associated with 
age <55 (OR 1.75 [95% CI 1.25-2.5], male sex (OR 1.55 [1.12-2.16]), < HS diploma (OR 
1.63 [1.12-2.34]), no HTN (OR 2.14 [1.13-4.1]), lower provider trust (OR 3.27, [1.61-6.65]) 
and less anger and hostility (OR 1.53, [1.1-2.1]).
Conclusions: Among high-risk AAs in the JHS, younger participants and males were 
less likely to use RHC. Those with low trust were also less likely to use RHC. Efforts to 
address health risks among high-risk AAs should target those using less RHC and consider 
attitudinal barriers to RHC.
SA-PO699
Development of a Question Prompt Sheet for Patients with Chronic Kidney 
Disease  Swati Lederer,1,2 Michael J. Fischer,1,2 Howard S. Gordon,1,2 Anuradha 
Wadhwa,2 Subhash Popli,2 Elisa J. Gordon.2,3  1Jesse Brown VAMC and Univ 
of Illinois, Chicago, IL; 2Hines VA Hospital, Hines, IL; 3Northwestern Univ, 
Chicago, IL.
Background: Patients with chronic kidney disease (CKD) commonly have unmet 
information needs. Greater patient participation in healthcare discussions can address these 
needs, and is associated with improved health outcomes. A question prompt sheet (QPS), a 
list of questions to prompt discussion, has been shown to increase patient participation in 
other chronic disease discussions; however, no QPS has been developed for CKD patients.
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Methods: We conducted a 2-phase cross-sectional study involving semi-structured 
telephone interviews to develop a QPS targeted to patients with moderate CKD. Patients 
with an estimated glomerular filtration rate <60ml/min/1.73m2, on dialysis, or with a 
transplant were recruited from a single VA nephrology clinic. Phase 1 interviews included 
17 open-ended questions assessing patients’ CKD information needs. Responses were 
qualitatively analyzed to generate an initial 67-item QPS. Phase 2 participants reviewed a 
pre-mailed QPS to rate the importance of asking each question on a 5-point Likert scale, 
provide open-ended feedback, and rate their willingness to use a CKD-QPS. Question item 
responses were analyzed to refine and reduce QPS questions.
Results: A total of 76 patients completed interviews (phase 1: n=32, phase 2: n=44). 
Most were male (96%), non-Hispanic white (68%), and mean age was 66 years. Patients 
desired more information about CKD, particularly regarding self-care techniques, dialysis/
transplant, and CKD complications. The final QPS tool included 37-questions divided 
into 10 CKD subtopics (i.e., CKD definitions, causes, impact, monitoring, labs, self-care, 
treatment, dialysis, transplant, managing comorbid conditions). Most patients (91%) 
reported being ‘completely’ or ‘very’ willing to use a CKD-QPS in future doctor visits.
Conclusions: CKD patients have unmet information needs and wish to use a CKD-QPS. 
Further research is needed to assess whether our CKD-QPS effectively addresses patients’ 
information needs, enhances doctor-patient communication, and improves health outcomes.
Funding: Veterans Administration Support
SA-PO700
Medication Burden and Safety in Veterans with Chronic Kidney Disease 
Swati Lederer,1,2 Michael J. Fischer,1,2 Zhiping Huo,2 Katie Suda,2 Kevin 
Stroupe.2  1Jesse Brown VAMC and Univ of Illinois Hospital, Chicago, IL; 
2Hines VA Hospital, Hines, IL.
Background: Veterans are at exceptionally high risk for chronic kidney disease (CKD) 
and other chronic health conditions. Pharmacologic treatments are a core aspect of CKD 
disease management. We characterized medication burden and safety and their relationship 
to CKD severity among elderly Veterans.
Methods: Using national VA databases, we included all female and a random 10% 
sample of male VA healthcare users who were >65 years old. We characterized the average 
number of medications, frequency of contraindicated medications, and occurrence of 
concerning drug-drug interactions. CKD was defined by estimated glomerular filtration rate 
(eGFR) in 2008 and classified according to conventional eGFR-based severity groups. A 
non-CKD comparison was used (eGFR >=60 ml/min/1.73m2). Medications were identified 
in calendar year 2009 from VA utilization data and Medicare Part D claims.
Results: Among a final cohort of 96,317 Veterans, 47% had CKD (mean age=79.8, 
male=81%, non-black=93%, hypertensive=90%, diabetic=33%). Mean medication number 
increased with CKD severity: 8.5(eGFR >=60), 9.6 (eGFR 30-59), 11.7 (eGFR15-29), 
12.5 (eGFR <15). After adjusting for demographic characteristics, CKD stage 3, 4, 
and 5 took 1.3, 3, and 3.6 more medications, respectively, compared to the non-CKD 
group (p-value<0.0001). Contraindicated medications were often prescribed to patients 
with an eGFR<30ml/min/1.73m2 and included bisphosphonates (5%) and nonsteroidal 
anti-inflammatory drugs (4%). Concerning drug-drug interactions with an eGFR<60ml/
min/1.73m2 included: sedatives-opioids (3.8%), ace inhibitor-angiotensin receptor blocker 
(1.6%), statins-diltiazem or verapamil (5.1%).
Conclusions: Greater severity of CKD was independently associated with an increasing 
number of medications among elderly Veterans. Medications that were contraindicated 
in CKD and concerning drug-drug interactions were commonly prescribed. Increased 
awareness and interventions are needed to improve medication management and safety 
in Veterans with CKD.
Funding: Veterans Administration Support
SA-PO701
Illicit Drug Use and Chronic Kidney Disease in an Urban Population 
Tessa Kimberly Novick,1 Anika Alvanzo,1 Yang Liu,1 Alan B. Zonderman,2 
Deidra C. Crews.1  1Johns Hopkins Univ, Baltimore, MD; 2National Inst on 
Aging, NIH, Baltimore, MD.
Background: Opioid and cocaine use have been associated with risk of ESRD in 
retrospective studies, however, the association of illicit drug use with chronic kidney disease 
(CKD) has not been well-examined in prospective studies. Our objective was to determine 
the association of illicit drug use with reduced kidney function, albuminuria and rapid 
kidney function decline (KFD) among a cohort of urban-dwelling adults.
Methods: Our study included 2,286 Healthy Aging in Neighborhoods of Diversity 
across the Life Span (HANDLS) study participants who are community-dwelling African 
American and white adults from 12 neighborhoods in Baltimore MD. We used logistic 
regression to examine whether opioid or cocaine use (defined as ≥ 5 lifetime uses of either 
drug) was associated with baseline reduced eGFR (<60 ml/min/1.73m2 by CKD-EPI), 
baseline albuminuria (albumin-to-creatinine ratio >30mg/g) or rapid KFD (eGFR decline 
of >3% per year over a median of 4.7 years of follow up).
Results: Participants’ mean age was 48 years, 57% were African American, 15% 
reported opioid use, and 22% reported cocaine use. Those reporting illicit drug use (opioid or 
cocaine) were more likely to be male, African American, living in poverty and/or uninsured; 
and tobacco use, problem drinking, and hepatitis B and/or C infection were more prevalent 
among illicit drug users than non-users (P <0.01 for all variables). Our adjusted models 
included those variables above, and age, diabetes and hypertension. A total of 5.3% of illicit 
drug users had reduced eGFR compared to 5.0% of non-users (NS). A total of 5.9% of illicit 
drug users died during follow-up compared to 3.8% of non-users (P 0.03). 
Outcome N for analysis N events
Opioid Users vs Non 
Opioid Users
Adjusted Odds Ratio 
(95% CI)
Cocaine Users vs Non 
Cocaine Users
Adjusted Odds Ratio 
(95% CI)
Reduced eGFR 2286 115 2.7 (1.5, 4.9) 1.4 (0.9, 2.3)
Albuminuria 1652 190 1.2 (0.8, 1.7) 1.8 (1.3, 2.5)
Rapid KFD 1665 245 0.9 (0.6, 1.3) 0.9 (0.7, 1.3)
Conclusions: Illicit drug use was associated with prevalent reduced eGFR and 
albuminuria, but not rapid KFD. Illicit drug use may be an important risk factor for CKD 
in urban populations.
Funding: NIDDK Support, Other NIH Support - Intramural study of the National 
Institute on Aging
SA-PO702
A Tailored, Interactive Mobile Health Communication Application for 
Patients with Chronic Kidney Disease: Development and Feasibility 
Assessment  Yali Cao.  Nephrology, China-Japan Friendship Hospital, Beijing, 
China.
Background: Chronic kidney disease (CKD) is an increasingly common chronic 
condition whose prognosis can be improved by patient involvement and self-management. 
Patient involvement can be fostered by web-based Interactive Mobile Health Communication 
Applications (IMHCAs) combining health information with decision support, social support 
and/or behavior change support. Tailoring content and tone of IMHCAs to the individual 
patient’s needs might improve their effectiveness.
Methods: A tailored, IMHCAs was developed by collaborative profession 
(nephrologist, nurse, research fellow, web developer). The effectiveness and usage of 
the tailored IMHCA were tested against the control arm without access to this IHCA in a 
small–scale single-blinded randomized trial. The content covers information on CKD, its 
complications and sequelae, and its treatment options including health behavior and dietary 
guidance. In the intervention group the content is delivered in dialogue form, tailored to 
relevant patient characteristics (the stage of CKD and the Etiology). Eighty patients (forty 
patients at each arm) with stage 3-5 CKD were enrolled in the study. The data were collected 
directly after the first visit, and at 3-month follow-up.
Results: There were no difference between the two groups as to the age, gender, 
CKD stage and blood pressure. Three months after system use, participants using the 
tailored system displayed significantly more knowledge(P=0.001), better blood pressure 
compliance rate (P=0.02) and improved dietary behavior, mainly regarding low protein 
and enough calories (P=0.003).
Conclusions: This is the first tailored IMHCAs in China. Our data demonstrated that 
implementation of IMHCAs into standard practice is feasible.Suggested developments will 
augment reported strengths to inform ongoing testing in the wider China network of units.
Funding: Government Support - Non-U.S.
SA-PO703
Evaluation of Clinical Pharmacy Services in the Management of Kidney 
Disease  Calantha K. Yon, Chai L. Low.  Pharmacy, Veterans Affairs San Diego 
Healthcare System, San Diego, CA.
Background: Chronic kidney disease (CKD) and end stage renal disease (ESRD) place 
a significant burden on healthcare systems and is the focus of national health initiatives. 
Management of CKD requires a multidisciplinary approach to maximize outcomes. 
Studies support the impact of clinical pharmacists (CP) in medication management, but 
studies demonstrating the significance of a CP as part of a multidisciplinary approach to 
management of AKI and CKD/ESRD are lacking. This study evaluates the effectiveness 
of pharmacy services in the setting of a multidisciplinary approach to the management of 
AKI and CKD/ESRD.
Methods:  Interventions by a CP in the inpatient setting were collected from 12/1/2010 
to 11/1/2011 as part of Nephrology Consults. Interventions were categorized as: drug 
interaction, dose/frequency adjustment, untreated diagnosis, adverse reactions, duplication 
of therapy, and other. Cost avoidance from these interventions were calculated. Outpatient 
pharmacy patient encounters were monitored from 1/1/2008 to 12/31/2014 as patient visits 
or interventions in hemodialysis (HD), peritoneal dialysis (PD), erythropoietin stimulating 
agent (ESA) clinic, and renal access clinic. CPs were involved in the management of anemia, 
hypertension, immunizations, mineral bone disease, transplant, dialysis related infections, 
pharmacokinetic drug monitoring, medication reconciliation and patient counseling.
Results: Most of the 440 inpatient interventions were dose adjustments for renal 
function and medication therapy for untreated diagnoses during AKI. Inpatient interventions 
by a CP resulted in $706,911 in cost avoidance. HD and PD encounters by a CP increased 
from 241 in 2008 to over 1,400 since 2011. Patient visits in the ESA/anemia clinic increased 
from 185 in 2008 to near 300 in 2014. Encounters in the renal access clinic increased from 
19 in 2008 to near 300 in 2014.
Conclusions: The expansion of pharmacy services in nephrology at Veterans Affairs 
San Diego Healthcare System has resulted in the improvement in the quality of care provided 
to patients with AKI, CKD or ESRD with significant cost avoidance. Clinical pharmacists 
play a significant role in the multidisciplinary approach to the management of CKD/ESRD.
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SA-PO704
Views and Practice Patterns of Dialysis Medical Directors Towards 
End-of-Life Decision Making for Patients with End-Stage Renal Disease 
Enrica Fung,1 Nathan Samuel Slesnick,2 Manjula Kurella Tamura,1,3 Brigitte 
Schiller.2  1Stanford Univ, Palo Alto, CA; 2Satellite Healthcare, San Jose, CA; 
3Geriatric Research and Education Clinical Center, Veterans Affairs, Palo 
Alto, CA.
Background: Nephrologists frequently engage in end-of-life decision making for 
patients with end-stage renal disease (ESRD). Patients with ESRD report infrequent 
end-of-life discussions and nephrology trainees report feeling unprepared for end-of-life 
decision making, but the views of dialysis medical directors have not been studied. Our 
objective is to understand dialysis medical directors’ views and practice patterns on end-of 
life decision making for patients with ESRD.
Methods: We administered questionnaires to dialysis medical directors during medical 
director meetings of three different dialysis organizations in 2013. Survey questions 
corresponded to recommendations from the Renal Physicians Association clinical practice 
guidelines on initiation and withdrawal of dialysis.
Results: There were 121 medical director respondents from 28 states. The majority 
of respondents felt “very prepared” (66%) or “somewhat prepared” (29%) to participate 
in end-of-life decisions and most (80%) endorsed a model of shared decision-making. 
If asked to do so, 70% of the respondents provided prognostic information “often” or 
“nearly always”. For patients with a poor prognosis, 36% of respondents would offer a 
time-limited trial of dialysis “often” or “nearly always”, while 56% of respondents would 
suggest withdrawal from dialysis “often” or “nearly always” for those with a poor prognosis 
currently receiving dialysis therapy. Patient resistance and fear of taking away hope were 
the most commonly cited barriers to end-of-life discussions.
Conclusions: Views and reported practice patterns of medical directors are consistent 
with clinical practice guidelines for end-of-life decision making for patients with ESRD 
but inconsistent with patient perceptions.
Funding: NIDDK Support
SA-PO705
Emergency Department Utilization Among United States ESRD Patients 
Brendan P. Lovasik, Rebecca H. Zhang, Taylor A. Melanson, Stephen O. Pastan, 
Rachel E. Patzer.  Emory Univ, Atlanta, GA.
Background: Single center studies suggest that ESRD patients have a high rate of 
emergency department (ED) utilization, with 0.9-2.4 ED visits/patient-year. Prior studies 
show that ESRD is a stronger risk factor for ED use than heart failure, lung disease, or cancer. 
However, ED utilization among a national ESRD patient population has not been examined.
Methods: We examined a cohort of 788,162 incident adult ESRD patients in the 
United States Renal Data System from 2005-2011. ED utilization was identified using CPT 
codes 99281-5 (Severity Levels 1-5) and 99291 (Critical Care) by American College of 
Emergency Physicians guidelines. ED and hospital admission, diagnosis, and procedures 
were obtained from the USRDS and Medicare Physician/Supplier and Inpatient databases 
for Medicare Part A/B claims.
Results: In the first year of ESRD diagnosis, 1,143,372 ED visits were observed for 
480,176 unique ESRD patients. 77% of ESRD patients used the ED within the first ESRD 
year at an average of 2.69 ED visits/patient-year. The national range was 1 to 172 ED visits 
per year with median 2 visits (interquartile range 1-4 visits) and 95th percentile 8 visits.
The top 5% of patients accounted for 80.4% of ED visits, and 7 patients utilized the ED 
over 100 times in their first ESRD year. Nearly half (46.0%) of ED visits were coded as a 
Severity Level 5, with 9.6% coded as Critical Care emergencies. 15.4% of ESRD patients 
in the ED were admitted to the hospital, with vascular access infection, pneumonia, and 
congestive heart failure as most common indications.
Conclusions: This study is the first to our knowledge to describe ED utilization in a 
national sample of ESRD patients. Compared to the national average, ESRD patients have 
higher ED use (2.69 vs. 0.4) and hospital admission rates (15.4 vs. 11.9%). Comprehensive 
understanding of ED utilization will aid development of outpatient and ED interventions.
SA-PO706
Impact of Evidence-Based Clinical Care on Major Adverse Clinical Events 
in Patients with Clinically Significant Proteinuria: A Population-Based 
Retrospective Cohort Study  Julius Oluoch Okel,1 Bilal Qarni,1 Timothy 
Olusegun Olanrewaju,2 Aminu K. Bello.1  1Univ of Alberta; 2Univ of Ilorin, 
Nigeria.
Background: Proteinuria is an important prognostic marker for cardiovascular (CV) 
and renal events. Most studies of quality of care (QoC) in chronic kidney disease (CKD) 
have focused on other markers for risk stratification and outcomes. We hypothesized that in 
proteinuric CKD, markers of good quality care will be associated with lower risk of adverse 
clinical outcomes (all-cause mortality, all-cause hospitalization, CV and renal outcomes).
Methods: We used a population-based cohort of patients with significant proteinuria 
(albumin:creatinine ratio (ACR) ≥60 mg/mmol, protein:creatinine ratio (PCR) ³100 mg/
mmol or protein ³3+ on dipstick) to evaluate current patterns of evidence-based care and 
association with outcomes. Markers of good quality care were defined as nephrology 
referral, relevant laboratory testing and appropriate medication use (ACEi/ARBs; statins). 
Participants were followed from their index date until March 2009 for outcomes of all-cause 
mortality, hospitalization, CV and renal events.The associations between quality of care 
markers and outcomes were estimated using Cox proportional hazards models.
Results: Of the 71, 660 with atleast 1 or 2 proteinuria measurements, 16,204 (22.6%) 
had significant proteinuria. At follow-up, receipt of good quality care [1) timely referral, 
2)HbA1c testing, 3)use of ACEi/ARBs and 4) use of statins] was associated with reduced 
risk of mortality: 0.67 (0.59-0.75), 0.52 (0.46-0.59), 0.68 (0.62-0.74), and 0.63 (0.57-0.69), 
and all-cause hospitalization: 0.85 (0.69-0.93), 0.65 (0.59-0.72), 0.93 (0.87-0.99), and 0.82 
(0.77-0.88) respectively. There were no statistically significant associations with the risk 
of CV and renal events.
Conclusions: This study examined the link between evidence-based treatment and 
clinical outcomes in an especially high-risk population with CKD. Good quality care 
impact on mortality risk and reduced risk of hospitalization. The impact of QoC on renal 
and cardiovascular events is less clear. The findings would justify future interventions to 
increase uptake of such treatments in patients with proteinuric CKD.
SA-PO707
APOL1 Risk Alleles and Risks of Cardiovascular Disease in Children with 
Focal Segmental Glomerulosclerosis (FSGS)  Robert Woroniecki,1 Derek Ng,2 
Sophie Limou,3 Cheryl Ann Winkler,3 Kimberly J. Reidy,4 Mark Mitsnefes,5 
Craig S. Wong,6 Bradley Warady,7 Susan L. Furth,8 Jeffrey B. Kopp,9 Frederick 
J. Kaskel.4  1Stony Brook Children’s Hospital, Stony Brook, NY; 2Johns Hopkins 
Bloomberg School of Public Health, Baltimore, NY; 3NCI, NIH, FNL, Frederick, 
MD; 4(instein/Children¶s Hospital at Montefiore, Bronx, NY; 5Cincinnati 
Children’s Hospital, Cincinnati, OH; 6Univ of New Mexico, Albuquerque, 
NM; 7Children’s Mercy Hospital, Kansas City, MO; 8Univ of Pennsylvania, 
Philadelphia, PA; 9NIDDK, NIH, Bethesda, MD.
Background: APOL1 renal risk alleles are a major cause of glomerular disease in 
African Americans (AA). It is controversial as to whether individuals with high risk 
(HR) APOL1 genotypes (2 risk alleles) are at risk for atherosclerotic heart disease, and 
association with left ventricular hypertrophy (LVH) has not been explored. It is unclear 
whether children with focal segmental glomerulosclerosis (FSGS) and HR APOL1 are at 
increased cardiovascular risk.
Methods: Self-identified AA children with FSGS in CKiD study cohort were genotyped 
for APOL1 renal risk variants: G1 (rs73885319, S342G) and G2 (rs71785313, NY388-389 
deletion), and compared to non-AA children with FSGS; none with HR.
Results: Of 79 children with FSGS, 36 were non-AA, and 25 were AA with HR 
APOL1. Compared to non-AA, children with HR APOL1 developed FSGS at a later age, 
11.5 (IQR: 9.5, 12.5) vs 6 (IQR: 2.5, 11) years, p=0.005. There were no differences in GFR, 
hemoglobin, iPTH, calcium-phosphate product, or CRP. HR APOL1 subjects had a higher 
prevalence of uncontrolled hypertension (52% vs 28%, p=0.06) and a lower prevalence of 
nephrotic range proteinuria (13% vs 43%, p=0.02). Subjects with HR APOL1 had higher left 
ventricular mass index (41 [28, 53] vs 30 [27, 33] g/m2.7, p=0.01) and a higher prevalence 
of LVH (53% vs 12%, p=0.009) compared to non-AA children with FSGS.
Conclusions: Children with FSGS and HR APOL1 have later onset kidney disease 
and are at higher risk for cardiovascular disease than non-AA.
Funding: NIDDK Support, Private Foundation Support
SA-PO708
Trends in Burden of Out-of-Pocket Expenses in United States Adults with 
Kidney Disease from 2002-2011  Mukoso N. Ozieh,1 Kinfe Gebreegziabher 
Bishu,2 Clara E. Dismuke,2 Leonard Egede.2  1Nephrology, MUSC; 2Center 
for Health Disparities Research, Internal Medicine, MUSC, Charleston, SC.
Background: High out-of-pocket (OOP) burden negatively impacts healthcare access 
and outcomes. Studies examining high OOP burden in the general population exists however 
no studies has examined OOP healthcare burden in people with kidney disease (KD). This 
study examined trends in high OOP healthcare in people with KD while concurrently 
evaluating the impact of insurance status and income category on high OOP burden.
Methods: We analyzed 2,966 adults aged 18-64 years with kidney disease using 
the Medical Expenditure Panel Survey-MEPS. Individuals with KD were identified with 
Clinical Classification Codes: 156 - nephritis, nephrosis, renal sclerosis; 157 - acute and 
unspecified renal failure; 158 - chronic renal failure; 160 - calculus or urinary tract and; 161 
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- other diseases of kidney and ureters. OOP burden was calculated by dividing total family 
OOP spending on healthcare in a given year by the family’s self-reported pretax income 
for that year. A person with KD is considered to have high OOP burden if the family total 
OOP spending on healthcare exceeds 10% of the family income. We used t-test to examine 
the mean changes from the bench mark year (2002/2003) to the subsequent time periods.
Results: Mean annual total family OOP spending was highest for prescription drugs 
over the years. Compared to the privately and publicly insured, uninsured status in people 
with KD was associated with high mean annual total family OOP spending. Of the 2,966 
adults with KD, 19% faced a high OOP burden from 2002-2011. Overall, the proportion 
of people with high OOP fell by 10 percentage points from 2002/2003 to 2010/2010. The 
proportion of poor/near poor people and uninsured with high OOP was as high as 52% and 
30% respectively in 2002/2003 but fell to about 25% and 27% respectively in 2010/2011.
Conclusions: Trends in high OOP burden in people with KD has decreased over time 
however people with kidney disease in the US still experience high OOP burden. Policies 
to reduce high OOP in people with KD could significantly impact KD outcomes.
SA-PO709
Health Disparities and Increased Risk of Developing End Stage Renal 
Disease in Patients with Chronic Kidney Disease  Alejandro Pepen Romero, 
Ritika Sharma, Candace D. Grant, Ronak Patel, Monika Wadhwani, Vladimir 
Liberman, Shanza Mujeeb, Sairah Sharif, Shayan Shirazian, Nobuyuki (Bill) 
Miyawaki, Joseph Mattana.  Medicine, Winthrop-Univ Hospital, Mineola, NY.
Background: Health disparities occur in groups of people that experience suboptimal 
health care based on their social, economic, and/or environmental disadvantage.  Identifying 
how these disparities affect the risk of chronic kidney disease (CKD) progression to end 
stage renal disease (ESRD) can hopefully lead to a reduction in these health inequities and 
improve clinical outcomes for all CKD patients. We examined health disparities and the 
risk of ESRD using patient-specific and community-specific variables.
Methods: We studied a cross-section of 623 patients with stage 3 and 4 CKD and 
estimated their 2- and 5-year risk of ESRD using the method of Tangri et al. (JAMA 2011; 
305:1553–1559). The U.S. Census Bureau Community Survey was used to obtain patient 
zip code-specific data including percent foreign born, percent below the poverty level, 
median household income, and percentage graduating high school.  We did a multivariable 
generalized linear analysis on the outcome variables of the 2 and 5 year risk of ESRD.
Results: Lower household income was associated with a higher risk of ESRD at 2 and 
5 years (p<0.05).  There was a trend towards a higher risk of ESRD amongst patients from 
zip codes with higher poverty rates and lower education levels.   Being single, including 
by divorce and separation but not by being widowed, was associated with a significantly 
higher risk of ESRD.  We also found that patients on Medicaid and patients with private 
insurance or self pay had a significantly higher ESRD risk compared to those on Medicare.
Conclusions: Our findings suggest that there are substantial health disparities related 
to CKD and the risk of ESRD.  Some of these disparities are patient-specific but others 
appear to be related to variables associated with the community where they reside.  This 
suggests that evaluation of patient-specific as well as community-specific variables might 
help to better individualize CKD care and improve our ability to identify and treat the 
patient at increased risk of developing ESRD.
SA-PO710
Impact of Timely AV Fistula Placement on Resource Utilization After 
Initiation of Dialysis  Edwin J. Anand,1 Kabir Jalal,3 Laura L. Argauer,2 Brian 
M. Murray,1 Pradeep Arora,4 Rocco C. Venuto.1  1Medicine, SUNY at Buffalo, 
Buffalo, NY; 2Computer Task Group, Buffalo, NY; 3Epidemiology, SUNY at 
Buffalo, Buffalo, NY; 4Medicine, VA Medical Center, Buffalo, NY.
Background: Maintenance dialysis is ideally initiated in the outpatient setting with a 
permanent access. This requires advance planning and of care between nephrologists, and 
access surgeons. The costs associated with ‘crash’ initiation of dialysis is anticipated to 
be high. In this observational study, we studied the hospitalization rates and costs of care 
in the 12 months following dialysis initiation between patients who started dialysis in an 
ideal manner versus sub optimally.
Methods: Claims and laboratory data from a large, regional insurance company 
covering half a million patients between January 2001 and May 2014 were reviewed. 
32,121 patients were identified to have CKD (at least one eGFR <60 ml/min/1.73 m2). Of 
these, 422 patients developed ESRD during the observed period. We defined a ‘crash’ if 
the first instance of dialysis was in an inpatient setting, provided they had atleast one eGFR 
value indicative of CKD before their first dialysis. Univariate and multivariate analyses 
were performed to analyze the effect of ‘crash’ on hospitalization and costs for 12 months 
following initial dialysis.
Results: 422 patients were started on dialysis in the above period. 257 patients (61%) 
had a crash start of dialysis. 86 patients (20%) had a fistula prior to dialysis. Compared 
to patients who did not crash, patients who crashed were older (p <0.0001), had a higher 
hospitalization rate in the one year period (p=0.0089). Multivariate analysis confirmed 
that patients who crashed had a significantly higher hospitalization rate in the one year 
following dialysis (p=0.0067). Patients with a fistula in place prior to dialysis experienced 
fewer hospitalizations (p=0.0377). Cost in the first year was also higher in patients who 
had a ‘crash’ without a fistula (p=0.0181). The cost advantage of having a fistula decreased 
with increasing age (0.0402).
Conclusions: Dialysis ‘crash’ results in increased morbidity and resource utilization. 
Coordination of care and timely access creation should reduce hospitalization and costs.
SA-PO711
DASH Diet Accordant Foods in the Homes of Urban African Americans 
at Risk for CKD  Deidra C. Crews,1 Yang Liu,1 Edgar R. Miller,1 Patti 
Ephraim,1 Jessica M. Ameling,1 Kimberly Gudzune,1 Lisa A. Cooper,1 L. Ebony 
Boulware.1,2  1Johns Hopkins U., Baltimore, MD; 2Duke U., Baltimore, MD.
Background: The Dietary Approaches to Stop Hypertension (DASH) diet is 
recommended for the treatment of hypertension, especially among African Americans 
(AAs). Many barriers may hinder urban AAs from following the DASH diet, putting them 
at increased risk of poor health outcomes, including CKD.
Methods: In a randomized trial of urban AAs with uncontrolled hypertension, we 
assessed (via interview and home inspection) the presence of DASH diet accordant foods 
and full-sized kitchen appliances needed to prepare DASH meals. We examined factors 
associated with having DASH diet accordant foods or needed appliances using logistic 
models adjusted for age, sex, food insecurity (skipping meals due to lack of money), 
income, literacy, diabetes, obesity, CKD (eGFR<60 or albuminuria) and comorbid disease 
(Charlson Index).
Results: Among 159 participants, mean age was 57 yrs and 74% were female. Only 
14.5% had 5 of the DASH food categories in their homes (fruits, vegetables, low fat dairy, 
whole grains, plant proteins). Over 80% had full-sized ovens and refrigerators.
DASH Accordant Foods in Home N (%) Participants 
Fresh or frozen vegetables 131 (82%)
Fresh or frozen fruits 93 (58%)
Low fat dairy 48 (30%)
Whole grains 102 (64%) 
Plant proteins 129 (81%)
Participants with CKD (vs without) had lower odds of having fresh fruits (adjusted 
odds ratio, 95% confidence interval: 0.40, 0.18-0.86). Younger age (yr increments) and 
annual income <30K (vs ≥30K) were associated with lower odds of having whole grains 
(0.96, 0.93-0.99 and 0.28, 0.11-0.72, respectively). Younger age was associated with lower 
odds of having plant proteins (0.94, 0.90-0.99). Persons with low literacy (<3rd grade level 
versus higher) had lower odds of having an oven (0.15, 0.04-0.52) and lower odds of a 
full-sized refrigerator in their homes (0.12, 0.02-0.59).
Conclusions: The homes of urban AAs at high risk for CKD were often lacking either 
foods or needed appliances required for DASH meals. The lack of these items was associated 
with CKD, younger age, low income and/or low literacy. Interventions to improve DASH 
adherence in this high-risk group should consider these factors.
Funding: NIDDK Support, Other NIH Support - NHBLI
SA-PO712
ABCD of CKD Management Among Internal Medicine Residents: Are 
Interactive Workshops and Web-Based Tools Useful?  Swati Arora, Richard 
J. Marcus, Khaled Nashar, Bhavna Chopra, Jia Zhang, Gargi Davda, Emad 
Sedki, James B. Reilly, Kalathil K. Sureshkumar.  Nephrology and Hypertension, 
Allegheny General Hospital, Pittsburgh, PA.
Background: Chronic Kidney Disease (CKD) is under-recognized and suboptimally 
managed especially in primary care setting. We aimed to evaluate the impact of interactive 
workshops and web-based tools in improving CKD management among internal medicine 
residents.
Methods: A pre-test assessed knowledge in areas of CKD diagnosis, anemia (A), bone-
mineral disease (B), control of BP (C) and degree of proteinuria (D). Interactive workshop 
on ABCD of CKD lasting 90-minutes was conducted over 5 weeks along with access to 
self-developed online CKD management resource (www.nephromania.com). Post-test was 
conducted at workshop conclusion and 12 weeks later. Assessment for post-intervention 
CKD care improvement was done through chart review.
Results: Among 98 participating residents, 25% utilized the online resource and 62% 
found it very helpful with majority bookmarking it on smart phones. KDOQI guidelines 
awareness, recognition of CKD diagnosis and complications were respectively 22%, 70% 
and 75% on pre-test, 98%, 93% and 90% on immediate post-test (P<0.001), declining 
to 86%, 77% and 74% at 12-weeks. Aggregate scores are shown in Figure 1A. Practice 
patterns measured through chart-review (n=94) to assess compliance with CKD guidelines 
over next 3 months failed to show change (figure1B). 
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Conclusions: Our study showed effectiveness of targeted interactive workshops to 
improve recognition of CKD and its complications. Intelectualizing the taught concepts by 
residents did not translate to improved patient care. Declining retention of core concepts at 
12-week testing indicates the need for ongoing reinforcement sessions. Continued education 
including online resourses utilization is warranted as opposed to annual core-lectures 
provided by most training programs.
SA-PO713
Evaluating Progress of Healthy People 2020 Chronic Kidney Disease 
Objectives: Are We There Yet?  Asel Ryskulova,1 Lawrence Agodoa,2 Paul 
W. Eggers,2 Kevin C. Abbott.2  1NCHS, CDC; 2NIDDK, NIH.
Background: Chronic Kidney Disease (CKD) is a significant public health problem 
in the U.S. and a major source of disability, poor quality of life, and premature death for 
those afflicted. CKD and End-Stage Renal Disease (ESRD), the final stage of the CKD, 
exact a high economic price. In 2012 ESRD costs exceeded $49 billion dollars including 
34 billion (about 20%) of total Medicare expenditures. An estimated 11.5% of adults ages 
20 or older had physiological evidence of CKD determined from data collected through 
the 2001-06 National Health and Nutrition Examination Survey (NHANES). Each year in 
the United States, more than 115,000 people are diagnosed with ESRD.
Methods: Reflecting the importance of CKD, 24 CKD objectives area were included in 
the Healthy People 2020 (HP2020) national health goals to reduce new cases of CKD and 
related complications, disability, death, and economic costs. CKD objectives are focused on 
improving cardiovascular care in patients with CKD; increasing the proportion of patients 
with CKD and diabetes who received recommended evaluation and treatment; reducing 
death rate and percentage of U.S. population with CKD; and increasing CKD awareness 
in persons with impaired renal function. All CKD objectives are measurable, having at 
least one data point from national data systems including the NHANES, National Death 
Index, and U.S. Renal Data System.
Results: In 2015, 14 objectives had met their target (n=9) or showed improvement 
(n=5). Six objectives showed little or no significant change. Two objectives: increase the 
proportion of persons with diabetes and CKD who received recommended medical treatment 
with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and 
increase the proportion of patients receiving a kidney transplant within 3 years of ESRD, 
moved away from the target. The remaining 2 objectives were not evaluated as they were 
informational with no target set. Disparities persisted by sex, race/ethnicity, and SES status.
Conclusions: The presentation will cover the most recent national and state data for 
selected CKD objectives and provide an overview of the HP2020 and data search using 
the HP2020 website.
SA-PO714
Telenephrology for the Remote Management of Chronic Kidney Disease 
(CKD): A Retrospective Cohort Study  Rajeev Rohatgi,1,2 Judy K. Tan,2 Anita 
Mehrotra.2  1Medicine, James J. Peters VAMC, Bronx, NY; 2Medicine, Icahn 
School of Medicine, New York, NY.
Background: Veterans with CKD who live in the Hudson Valley Veterans Affair 
Medical Center (HVVAMC) catchment area travel to the Bronx VAMC for nephrology 
care. Analysis of the no-show and cancellation frequencies for these renal appointments 
exceeded 50%, likely due to the distance between HVVAMC and the Bronx (60 miles).
Methods: We hypothesized that patients managed via a telenephrology service, where 
patients visit their local VA and are evaluated remotely via videoconference by a Bronx 
VA nephrologist, would exhibit comparable clinical outcomes and visit compliance as 
in-person renal care. In a retrospective observational study, the clinical outcomes of CKD 
patients enrolled in telenephrology (n=117) and the Bronx VA nephrology clinic (n=121) 
from 2008-14 were compared.
Results: Characteristics of the groups were similar (initial creatinine [Cr], eGFR, 
distribution of CKD stage, urine protein) except for race and probable cause of CKD. Prior 
to the telenephrology service, 53.1% of scheduled visits of HVVAMC patients to the Bronx 
VAMC renal clinic were either cancelled or “no-shows” and this was reduced to nearly half 
(29.2%) after instituting telenephrology (p<0.001). Moreover, the frequency of attending 
appointments was greater in the telenephrology (70.8%) vs. Bronx VA cohort (61.8%) 
which was driven by a greater frequency of cancelled visits in the Bronx VA (27.9%) vs. 
the telenephrology group (15.8%). The incidence of a composite outcome of doubling of 
Cr, ESRD and/or death was similar between both groups (Figure 1). The change in blood 
pressure and eGFR from baseline to 1 year was also similar.
Conclusions: Telenephrology is not inferior to in-person care for the management 
of CKD and may be superior for visit compliance. Application of this technology is a 
promising method to deliver care to CKD patients.
Funding: Veterans Administration Support
SA-PO715
Engaging Urban African Americans at Risk for CKD in Discussions About 
Their Diet  Deidra C. Crews,1 Debra L. Roter,1 Raquel C. Greer,1 Yang Liu,1 
Patti Ephraim,1 Jessica M. Ameling,1 Kimberly Gudzune,1 Lisa A. Cooper,1 L. 
Ebony Boulware.1,2  1Johns Hopkins U., Baltimore, MD; 2Duke U., Durham, NC.
Background: Patient-physician discussions about diet are recommended in primary 
care to decrease patients’ health risks, including CKD. However, little is known about the 
frequency of diet discussions or factors influencing them among African Americans (AAs) 
at increased CKD risk.
Methods: In a randomized trial of urban AAs with uncontrolled hypertension, we 
audio-recorded patients’ routine visits with their primary care physicians (PCPs) at the first 
visit following enrollment. We transcribed audio recordings, and quantified the frequency of 
patient-physician discussions about diet during visits. We marked transcripts for discussions 
of 36 dietary terms (e.g. sodium, weight, sweets). We also assessed patterns of patient-
physician communication, including patient centeredness (degree to which the discussion 
focused on the patient’s psychosocial and lifestyle context), during each encounter using 
the Roter Interaction Analysis System. We identified factors independently associated with 
discussions of diet using logistic regression.
Results: Among 127 participants, mean age was 58 years and 70% were female. 
Average PCP visit lasted 25 minutes. Diet was discussed in 73% of visits, but only included 
discussion of the Dietary Approaches to Stop Hypertension (DASH) diet in 12%, weight/
obesity in 36%, and cholesterol in 39% of visits. Independent predictors of diet discussions 
(odds ratio, 95% confidence interval) were patient centeredness score ratio (7.5, 1.3-41.9), 
annual income (3.8, 1.4-10.5 comparing ≥10k vs <10k), and visit length (1.07, 1.02-1.1 
for each minute increment). Patient age, gender, literacy, comorbid disease burden, obesity, 
diabetes nor CKD status predicted discussions.
Conclusions: Discussions of diet in primary care were frequent, and they were more 
likely to occur when visits were longer, were centered on patient priorities, and were attended 
by patients with incomes ≥10k. Diet discussions focused on various topics, but infrequently 
on the recommended DASH diet or other key aspects of dietary modification. Improvements 
in the content of diet discussions among African Americans at risk for CKD may be needed.
Funding: NIDDK Support, Other NIH Support - NHLBI
SA-PO716
Tele-Nephrolog: A Feasible Way to Improve Access to Care for 
Patients with Kidney Disease Who Reside in Underserved Areas 
Marco A. Ladino Avellaneda, Desiree Garcia, Joslyn Wiley, Jose M. 
Cardona-Guzman, Alejandro Valdes, Alberto J. Sabucedo, Roberto J. Echeverri. 
Dept of Medicine/Div of Nephrology, Miami VAMC/Univ of Miami, Miami, FL.
Background: The Miami VA Healthcare System serves veterans in three South 
Florida counties: Miami-Dade, Broward and Monroe, with an estimated veteran 
population of 175,000. To overcome geographical barriers and facilitate the access to 
nephrology evaluations, we implemented Provider-Patient Tele-Nephrology using secured 
videoconferencing.
Methods: A retrospective and descriptive study design was used to evaluate the effect 
of the Tele-Nephrology clinic intervention. Multiple clinical indicators were included in 
the analysis: blood pressure control, stabilization of the renal function and electrolyte/
metabolic control. 101 patients that were evaluated in the clinic between 2013-2015 were 
included and the indicators were collected retrospectively.
Results: 101 patients were included, 95% male (n=96) and 5% female (n=5). The mean 
age was 65.5 years. 50 patients had Chronic Kidney Disease (CKD) stage III (49.5%), 14 
patients had CKD stage IV (13%0, 8 patients had CKD stage II (7.9%). A one-way analysis 
of variance analysis (ANOVA) between subjects was conducted and showed that the effect 
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of the Tele-Nephrology clinic interventionon reducing blood pressure was statistically 
significant (systolic blood pressure P-value <0.0001). Renal function stabilized but the 
creatinine changes over time were not statistically significant (P-value: 0.50). 
The potassium showed a significant improvement in this sample (P-value: 0.0076). 
Phosphorous and bicarbonate did not show a statistically significant improvement (p-value 
0.79 and 0.91).
Conclusions: With the tele-nephrology clinic intervention we were able to effectively 
improve blood pressure and stabilize renal function in patients with kidney disease who 
reside in underserved areas.
SA-PO717
Impact of Exercise Counseling on Physical Function in Chronic Kidney 
Disease  Clara Bohm,1 Mara McAdams-DeMarco,2 Navdeep Tangri,1 Brett M. 
Hiebert,1 Leroy J. Storsley,1 Lawrence J. Cheskin,2 Claudio Rigatto.1  1Univ of 
Manitoba; 2Johns Hopkins Univ.
Background: Few studies have investigated the effect of exercise counseling on 
physical function (PF) in chronic kidney disease (CKD). Using retrospective, quasi-
experimental pretest-posttest non-equivalent control group design, this study investigated 
the effect of attending a real-world exercise counseling clinic (ECC) on PF in individuals 
with CKD.
Methods: Individuals with any stage of CKD registered with the Manitoba Renal 
Program from Jan. 1, 2011 to Dec 1, 2014 were eligible for inclusion. The exposed group 
(EC) included individuals who attended ECC. The control group (CG) included individuals 
who did not attend ECC, but participated in an observational frailty study. Primary Outcome: 
Change in Short Physical Performance Battery score (SPPB) at 1 year. Ranging from 0-12, 
lower SPPB represents worse PF. Secondary Outcomes: Change in health-related quality 
of life (HRQOL) at 1 year using EQ5D-3L; 2. Change in physical activity (PA) at 1 year 
using HAP and PASE. Analysis: Mann Whitney U, Independent T and Chi-square tests 
used for group comparisons.
Results: Of 194 individuals in EC and 216 in CG eligible for 1-year follow-up, 73 
(37%) in EC and 72 (33%) in CG were assessed. At baseline, mean age was lower in EC (60 
years) as compared to CG (68 years); p<0.01. Median SPPB scores at baseline and follow-
up were significantly different between groups, but change in SPPB over time was not. 
Group N Baseline SPPB (IQR) Follow-up SPPB (IQR)
Mean Change in SPPB 
(SD)
EC 73 11 (9-12) 11 (9-12) -0.2 (2.0)
CG 72 10 (8-11) 9 (6-11) -0.6 (2.2)
P-value p = 0.01 p = 0.01 p = 0.32
Subgroup analysis of individuals with eGFR < 30 ml/min or on dialysis reduced the 
differences in age and SPPB between groups, but demonstrated no significant difference 
to change in SPPB over time. HRQOL did not change significantly between groups. 
Proportion of individuals with improved PA over 1-year was 36% and 38% in EC and 
CG, respectively (p=0.82).
Conclusions: In this study, an exercise counseling clinic had no significant effect 
physical function as measured by SPPB at 1-year, suggesting that exercise counseling 
alone is inadequate to improve physical function in CKD.
SA-PO718
Ideal and Actual Support of Renal Replacement Therapy Modality 
Selection Patients with Chronic Kidney Disease: A Nationwide Survey in 
Japan  Shiho Kosaka,1 Shinichi Nishi,2 Yugo Shibagaki,3 Junichi Hoshino,4 
Kazuo Takahashi,5 Yukiko Katagiri,1 Chika Murayama,1 Yuka Funaki.1  1Sophia 
Univ, Tokyo, Japan; 2Kobe Univ Graduate School of Medicine, Kobe, Japan; 
3St. Marianna Univ Hospital, Kawasaki, Japan; 4Toranomon Hospital, Tokyo, 
Japan; 5Fujita Health Univ School of Medicine, Toyoake, Japan.
Background: Optimal renal replacement therapy (RRT) selection supports for chronic 
kidney disease (CKD) patients are essential to improving post-therapy outcomes. We aimed 
to investigate how and when modality selection supports for patients with CKD are used 
by nephrologists in Japan, through a nationwide questionnaire survey of nephrologists.
Methods: A questionnaire was mailed to 1903 board-certified nephrologists of Japanese 
Society of Nephrology. Questionnaireitems targeting support for modality selection 
examined the following points: establishment of an RRT modality selection (RRT-MS) 
clinic, ideal and actual disease stage at which RRT-MS explanation is discussed, timing of 
RRT initiation, and type of specialist discussing RRT-MS with patients.
Results: The valid response rate was 12.3% (234/1903). Ninety-four out of 234 
responding nephrologists (40.9%) had clinics dedicated to RRT-MS. Modality selection was 
most frequently discussed at CKD stage 4 (53.0%), stage 3b (22.8%), and stage 3a (13.4%). 
Nephrologists considered stage 3b (32.5%), stage 3a (19.5%), most ideal for discussing 
RRT-MS; a significant difference was therefore found between ideal and actual timing of 
RRT-MS discussion. Timing (by eGFR) of access placement of hemodialysis (HD) and 
peritoneal dialysis (PD) was significantly earlier in patients of RRT-MS clinics than in those 
of conventional clinics (HD, 12.3/14.1; PD, 12.6/14.9 mL/min/1.73 m2). Regarding types 
of specialists, nurses most frequently supported patients in RRT-MS (67.1%); however, 
this may be partly explained by the fact that nephrologists are required to commit more 
specialiststo supporting patients for RRT-MS.
Conclusions:  A gap between ideal and actual timing of discussion of RRT-MSwith 
patients in Japan was identified.  To promote appropriate timing of RRT-MS among CKD 
patients, early and multidisciplinary support systems should be structured.
Funding: Government Support - Non-U.S.
SA-PO719
Primary Care Physicians’ Perceived Barriers and Facilitators to Care of 
Older Adults with Kidney Failure Not on Dialysis  Helen Tam-Tham, Brenda 
Hemmelgarn, Chandra Mary Thomas, Karen Fruetel, Robert R. Quinn, Kathryn 
M. King-Shier.  Univ of Calgary, AB, Canada.
Background: Primary care physicians are important care providers for older adults 
with kidney failure, but how they perceive and practice conservative (non-dialysis) care 
has not been studied. We undertook a qualitative study to describe barriers, facilitators, 
and possible enhancements of conservative care in the community for these older adults.
Methods: Semi-structured telephone interviews were conducted with primary care 
physicians from southern Alberta, Canada. Participants were identified by a snowball 
sampling strategy and purposively sampled based on sex, age, and rural/urban location 
of clinical practice. All participants managed at least 1 patient ≥75 years with kidney 
failure (eGFR <15ml/min/1.73m2 for at least 3 months, not on dialysis) over the past year. 
Transcripts were analyzed thematically by conventional content analysis.
Results: Twenty-seven primary care physicians participated in this study (55.6% of 
participants were male, 55.6% of participants were aged 40 to 60 years, and 51.9% of 
participants practiced in the primary care setting for greater than 20 years). Perceived barriers 
to conservative care included: managing expectations of kidney failure for patients and their 
families, optimizing medical management of conservative care, and negotiating provider 
roles and responsibilities of co-management. Facilitators for care included: establishing 
patient and their family expectations of care early, preserving continuity of care, and utilizing 
a multidisciplinary team approach. Primary care physicians also identified suggestions for 
enhancement of conservative care in the community, including direct telephone access by 
primary care physicians to conservative care clinicians, treatment decision aids for patients 
and their families, and a conservative care clinical pathway for primary care providers.
Conclusions: We found important barriers and facilitators to conservative care by 
primary care physicians in the community. Further investigation of potential strategies that 
remove barriers and enable facilitators is required to improve the quality of conservative 
care in the community.
Funding: Government Support - Non-U.S.
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SA-PO720
Asking Patients If They Are Aware of Their Chronic Kidney Disease: Does 
the Question Matter?  Delphine S. Tuot, Yunnuo Zhu, Alexandra Velasquez, 
Juan Maciel Espinoza, Celia Mendez, Tanushree Banerjee, Chi-yuan Hsu, Neil 
R. Powe.  Univ of California San Francisco.
Background: Awareness of chronic kidney disease (CKD) is low, even among patients 
with advanced disease. Increasing awareness to 11.7% is a Healthy People 2020 goal. The 
National Health and Nutrition Examination Survey (NHANES) measures CKD awareness 
using the question “Have you ever been told by a doctor or other health professional that you 
had weak or failing kidneys (excluding kidney stones, bladder infections, or incontinence)?” 
The framing of this question may influence responses. We sought to compare its sensitivity/
specificity to different questions as well as to awareness of other chronic conditions.
Methods: We administered a questionnaire to 220 English, Spanish and Cantonese-
speaking adults who received primary care in a public healthcare delivery system. We 
obtained demographic data, screened for health literacy and ascertained patient awareness 
about chronic health conditions, including CKD, diabetes, hypertension and hyperlipidemia. 
CKD awareness was measured using the NHANES question and additional ones, asking if 
patients had been told about “kidney disease”, “protein in the urine”, “kidney problem”, or 
“kidney damage”. Health conditions were verified by medical record review.
Results: In our diverse study population (9.6% White, 40.5% Black, 36.4% Hispanic, 
12.0% Asian), mean age was 58, mean eGFR was 47 ml/min/1.73m2 and 47% had low 
health literacy. Sensitivities of each CKD awareness question were: 26.7% for “kidney 
damage”, 28.0% for “kidney disease”, 33.5% weak or failing kidneys” (NAHNES), 36.2% 
for “protein in the urine” and 40.6% for “kidney problem”. Specificities ranged from 88.2% 
to 97.7%. Combining all 5 questions yielded a sensitivity of 61.1% and a specificity of 
79.6%. This was comparable to awareness of hyperlipidemia (68.8%) but was lower than 
awareness for hypertension and diabetes (89.6% and 94.3% respectively). Sensitivities 
were lower in patients with low health literacy.
Conclusions: CKD awareness is low compared to other chronic diseases. Nevertheless, 
by using more sensitive combinations of questions to ascertain CKD awareness, we have 
likely reached the Healthy People 2020 goal.
Funding: NIDDK Support
SA-PO721
The Effects of Age and Symptoms on Recommendations to Initiate Dialysis 
Michael Walsh, Rajnish Mehrotra, Carmel M. Hawley, Marcello Tonelli, Clare 
I. Castledine, Stephen P. McDonald, Peter Margetts, Darin Treleaven, Vicki 
Levidiotis, K. Scott Brimble.  McMaster Univ.
Background: The extent to which patient characteristics influence Nephrologists’ 
recommendations regarding initiation is unclear. We conducted an international survey to 
examine the effect of country on recommendations to initiate dialysis.
Methods: Nephrologists from Australia, Canada, New Zealand, the UK and the US were 
surveyed by email. The survey included clinical vignettes that varied patient characteristics. 
The recipient scored the likelihood they would recommend initiating dialysis on an 8-point 
modified Likert scale anchored at 1 (definitely would not) and 8 (definitely would). Results 
were analysed using mixed-effects regression.
Results: 771 nephrologists were included. The degree to which patient age was 
associated with recommending dialysis varied by country (p<0.001 for interaction) (Figure 
1). For a given level of GFR, only nephrologists from Canada (p<0.001) and the US 
(p<0.001) were more likely to recommend dialysis for patients age 75 than those aged 45. 
Conversely, nephrologists from Australia (p<0.001), New Zealand (p<0.001) and the UK 
(p=0.003) were less likely to recommend dialysis for patients aged 90 than those age 45. 
All nephrologists were more likely to recommend dialysis as symptoms increased but this 
association was less pronounced in the US and Australia (p<0.001 for interaction). Patient 
comorbidities, nephrologists’ years in practice, and practice type were not associated with 
recommendations. 
Conclusions: For patients at a given eGFR, other characteristics such as age and 
symptom burden influence nephrologists’ recommendations to initiate dialysis but the 
extent of this influence differed substantially between nephrologists in different countries. 
Further research is required to understand the effect of these differences on patients and 
health systems.
SA-PO722
The Association of Community Health Indicators with Late Nephrology 
Referral in Patients Reaching End-Stage Renal Disease in the U.S. 
Jung-Im Shin, Mari Palta, Micah R. Chan, Brad C. Astor.  Univ of Wisconsin 
School of Medicine and Public Health, Madison, WI.
Background: Late nephrology referral in patients reaching end-stage renal disease 
(ESRD) is associated with inadequate preparation for dialysis and poorer clinical outcomes 
after renal replacement therapy (RRT). Previous studies have focused on individual-level 
factors to identify patients at higher risk of late nephrology referral. Environmental 
and socioeconomic conditions of communities in which patients live may also impact 
nephrology referral patterns.
Methods: We assessed the association of community health indicators with late 
nephrology referral in 587,574 patients reaching ESRD, using the data from United 
States Renal Data System (USRDS) from 2005-2012. An overall community health risk 
score was calculated using 35 community-level factors based on 1) health outcomes, 2) 
health behaviors, 3) access and quality of care, 4) socioeconomic factors, and 5) physical 
environment, using County Health Rankings data from University of Wisconsin Population 
Health Institute. Late nephrology referral was defined as the first encounter with a 
nephrologist occurring < 6 months before RRT initiation. Multilevel logistic regression 
models adjusted for individual characteristics, including demographics, cause of ESRD, 
body mass index, comorbidities, and insurance and employment status.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
794A
J Am Soc Nephrol 26: 2015 CKD: Health Services, Disparities, and Prevention Poster/Saturday
Results: The prevalence of late nephrology referral was 47.8%. A significant dose-
response relationship of community risk score with late nephrology referral was found, 
with an adjusted odds ratio of 1.52 (95% CI: 1.36-1.71) for the highest versus lowest risk 
communities.
Conclusions: Higher community risk is significantly associated with late nephrology 
referral, independent of individual-level factors. Community risk may be an important 
consideration for developing interventions to improve access to pre-ESRD nephrology care.
SA-PO723
Assessment of Quality of Care Received by Patients with Predialytic 
Chronic Kidney Disease Seen at a Philippine General Medicine Out-Patient 
Clinic – Experience at a Government Training Hospital  Rizza Ann B. Lio. 
Section of Nephrology, Univ of the Philippines-Philippine General Hospital, 
Manila, Philippines.
Background: In a country with limited access to dialysis and transplantation such as 
the Philippines, it is imperative to recognize patients with early stage CKD and aggressively 
intervene in a timely fashion to prevent ESRD and death. The objective of this study is 
to evaluate the quality of care (QoC) of patients with predialytic CKD seen at a general 
medicine clinic.
Methods: This was a retrospective study which reviewed the medical records of 276 
patients with CKD Stages 3-4 who have at least 1 year of consult. Patients who were 
admitted for critical illness, and are on dialysis were excluded. For each QoC parameter, 
percentage of patients who received the appropriate care were reported. For the QoC 
correlates, Mann-Whitney U Test, Kruskal-Wallis Test or regression analysis was done.
Results: The mean QoC score for this study is 58.36% (± 23.7%) and the average 
annual GFR decline is 3.92 mL/min/1.73m2. 
Percentage Achieved 
CKD Monitoring
Diagnosis 72.83
Staging 39.13
Monitoring of GFR 97.10 
Monitoring of Proteinuria 54.35
Cardiovascular Care
BP Control 70.29
Glycemic Control 69.6
Dietary Modification
Salt Restriction 82.25
Protein Restriction 30.43
Anemia Monitoring 51.81
Metabolic Bone Disease
Baseline Calcium 66.67
Baseline Phosphate 44.93
Baseline Alkaline Phosphatase 10.51
Acidosis 70
Drug Safety 83.33
Nephrology Referral 55.47
TOTAL 58.36
In majority of patients, physicians failed to deliver CKD-specific management strategies 
such as proteinuria monitoring, protein restriction, anemia and metabolic bone disease 
recognition. Nephrology comanagement is associated with a better quality of care (85.9 
vs. 48.6, p <0.001) and a lower GFR decline (1.64 vs. 4.7 mL/min/1.73m2; p <0.001).
Conclusions: The study confirmed that there are significant gaps and challenges as 
well as opportunities for improvement in the delivery of quality health care to our patients. 
There is a need for education to improve the knowledge of primary care physicians in 
CKD management in consideration to the limited number of nephrologists in the country.
SA-PO724
Chronic Kidney Disease (CKD) Patients’ Understanding of Renal 
Replacement Therapy (RRT) Options: Early Findings from the U.S. CKD 
Outcomes and Practice Patterns Study (CKDopps)  Laura H. Mariani,1,2 
Charlotte Tu,1 Brian Bieber,1 Elodie Speyer,1 Jarcy Zee,1 Hal Morgenstern,2 
Benedicte Stengel,3 Bruce M. Robinson,1 Francesca Tentori.1,4  1Arbor Research 
Collaborative for Health, Ann Arbor, MI; 2Univ of Michigan, Ann Arbor, MI; 
3Inserm UMR1018, France; 4Vanderbilt Univ, Nashville, TN.
Background: Current KDIGO guidelines indicate that kidney failure patients should 
receive information on all RRT modalities, including conservative management.Even when 
education is provided, patients’ understanding of such a complex topic may be limited. We 
report the perspective of US participants in the first year of CKDopps.
Methods: CKDopps is a new international prospective cohort study that enrolls 
adult advanced CKD patients in national samples of nephrology clinics in the US, Brazil, 
France, and Germany and follows patients through the dialysis transition period. As of early 
2015, 245 US participants with eGFR<30 mL/min/1.73m2 completed a self-administered 
questionnaire including their understanding of, education on, and preferences for RRT 
options.
Results: The median age of patients was 71; 43% were male and 57% had diabetes. 66% 
of patients reported they received no education about treatment options for kidney failure; 
20% said they received one-on-one education; and 14% participated in a class. 34% recalled 
that in-center hemodialysis (HD) was discussed as a treatment option, and less than 25% 
recalled their doctor discussing peritoneal dialysis, home HD, conservative management, 
or transplantation. 58% of participants reported they did not know if transplantation was 
an option for them. Nearly 3 out of 5 participants did not know what RRT option they 
would choose if their kidneys failed.
Conclusions: Understanding of RRT options was poor among CKDopps participants 
in the US. Though the responses may not necessarily reflect information that was actually 
provided by their nephrology clinic teams, our results indicate that current educational 
strategies fail to adequately communicate key messages on RRT.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), Japanese 
Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private Foundation 
Support
SA-PO725
Statin Prescribing Among U.S. Ambulatory Outpatient Visits for Patients 
with CKD  William A. Janes,1 Talar Markossian,1 David J. Leehey,2 Benjamin 
Ling,1 Nicholas Burge,2 Vinod K. Bansal,1 Julia Koval,1 Ivan Pacold,1 Kevin 
Stroupe,2 Holly J. Kramer.1  1Loyola Univ Chicago; 2Hines VA Medical Center.
Background: Approximately 1 in 3 adults with CKD is at high risk of developing 
cardiovascular disease (CVD). Recent lipid management guidelines agree that statins 
alone should be used for CVD prevention via lipid lowering. However, lack of congruent 
recommendations for statin use in adults with CKD may lead to low utilization of statins 
in this population at high risk for CVD.
Methods: Outpatient visit data during years 2006 to 2010 were obtained from the 
National Ambulatory Medical Care Survey to determine the frequency of statin prescriptions 
among outpatient visits for adults age ≥50 years with non-dialysis stage 1-5 CKD based 
on ICD9 codes. Drug type (particular statin or other cholesterol lowering drugs type) was 
determined by the generic code recorded in the survey data. The analysis accounted for the 
complex survey design and utilized the sampling weight, cluster and strata statements so 
that results are generalizable to US outpatient ambulatory visits during years 2006-2010.
Results: A total of 2262 visits were included with patients being 48% white, 54% 
male and mean age of 69.6 years. 52% visits were covered by Medicare. Overall, 43% 
and 31.5% of visits for non dialysis CKD stage 3-5 and stages 1-2, respectively, included 
a statin prescription with simvastatin being the most commonly prescribed statin. Table 
1 shows the prevalence of statin prescription in all patients with non-dialysis dependent 
CKD by provider type for the outpatient visit. 
Clinician Type
% Visits (standard error) with Statin Prescribing 
for Adults age ≥50 years with non-dialysis CKD by 
prescriber type
Internal Medicine/Family Practice 35.6 (0.05)
Cardiology 46.8 (0.10)
Nephrology 45.4 (0.13)
Advanced Nurse Practitioner 40.6 (0.16)
Physician Assistant 7.7 (0.04)
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
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Conclusions: These results suggest that the rate of prescription of statins in CKD 
patients is suboptimal and differs by the provider who cares for the patient with CKD. 
Lack of CVD preventive care may impact overall CVD risk in patients with non-dialysis 
dependent CKD.
SA-PO726
Patients’ Knowledge of Their Chronic Kidney Disease Stage and 
Education About Kidney Failure Prevention – The CKD-REIN Cohort 
Benedicte Stengel,1 Celine Lange,2 Briançon Serge,2 Luc Frimat,3 Denis 
Fouque,4 Maurice Laville,4 Christian Jacquelinet,2 Bruce M. Robinson,5 Ziad 
Massy,1,6 Christian Combe.7  1Inserm U1018-CESP UVSQ, Villejuif; 2Agence 
Biomedecine; 3CHU Nancy; 4CHU Lyon; 5Arbor Research Collaborative for 
Health, Ann Arbor; 6A.Paré - APHP; 7CHU Bordeaux, France.
Background: Patient knowledge about their CKD stage and how to prevent kidney 
failure is important to reduce ERSD risk through better adherance to treatment and lifestyle 
changes. We report primary findings about CKD knowledge among patients seen by 
nephrologists in France.
Methods: We used baseline data from the CKD-REIN study, a prospective cohort of 
patients with CKD stage 3 and 4 in a national sample of 40 nephrology clinics. Information 
was collected from patient interview and self-administered questionnaire.Comparisons 
between stages were adjusted for age and gender.
Results: Median age was 68[60-76] and 56% were men. About 80% reported knowledge 
that their kidney function was low. Patients were more likely to know their creatinine level 
(~40%) than GFR or CKD stage. For each question, knowledge increased slightly from 
stage 3 to stage 4. Education about how to prevent kidney failure was uncommon (£10%)
Answers Stage 3 Stage 4 p
Patient Interview n=1,107 n=925 
Has a doctor ever told you your kidney 
fonction was low? Yes 77% 82% 0.002
Do you know your creatinine level ? Yes 39% 43% 0.04
Do you know your GFR level ? Yes 18% 27% <0.001
Do you know your CKD stage ? Yes 32% 34% 0.1
Patient questionnaire n=944 n=749 
Have you attended a class or received 
one-on-one education about the 
prevention of kidney failure?
Yes, a class
Yes, one-on-one
4%
4%
10%
9% <0.001
During the past year, how many times 
have you see the nephrologist ?
None
1 or 2
≥3 times
2%
72%
26%
2%
48%
50%
<0.001
Conclusions: Most CKD patients seen by nephrologists are aware that they have low 
kidney function, but their knowledge of disease severity is low. Very few received education 
about prevention of kidney failure. While the precise impact of these gaps in knowledge 
on CKD outcomes requires further investigation, the findings highlight the need to more 
effectively educate CKD patients about its potentially serious consequences.
Funding: Pharmaceutical Company Support - Amgen, Baxter, Fresenius, GSK, Lilly, 
MSD, Sanofi, Government Support - Non-U.S.
SA-PO727
The Cost-Effectiveness of Primary Screening for Chronic Kidney Disease 
in Rural and Remote First Nations  Thomas W. Ferguson,1 Navdeep Tangri,1,2 
Matthew T. James,3 Zhi Tan,3 Claudio Rigatto,1,2 Paul Komenda.1,2  1Community 
Health Sciences, Univ of Manitoba, Winnipeg, MB, Canada; 2Medicine, Univ 
of Manitoba, Winnipeg, MB, Canada; 3Medicine, Univ of Calgary, Calgary, 
AL, Canada.
Background: Chronic Kidney Disease (CKD) is a risk factor for cardiovascular 
disease, early mortality, and kidney failure. We have shown that the burden of CKD in 
First Nations (FN) populations in Manitoba is similar to that in diabetic and hypertensive 
populations. The cost-effectiveness of screening for CKD and subsequent treatment in FN 
or other high-risk indigenous populations has not yet been described.
Methods: We constructed a Markov model comparing screening in adult FN (age 
18+) for CKD by both proteinuria and estimated glomerular filtration rate (eGFR) to usual 
care from the perspective of the publicly funded Canadian health care payer. Patients were 
assigned an initial risk classification based on urine albumin-to-creatinine ratio and eGFR 
using the Kidney Disease Improving Global Outcomes (KDIGO) heat map. We obtained 
screening tests results on 1346 adult participants from the First Nations Community 
Based Screening to Improve Kidney Health and Prevent Dialysis (FINISHED) initiative. 
Our analysis was further stratified into communities accessible by road and communities 
accessed by air travel. Our primary outcome of interest was the incremental cost per 
quality-adjusted life-year (QALY).
Results: Overall crude prevalence of CKD in FN was 26.7%. Screening for CKD was 
associated with an ICER of $33,500/QALY in comparison to usual care. Restricting the 
model to screening in the remotest air access communities (prevalence of CKD 36.0%), 
this ratio fell to an ICER of $16,180/QALY. In less remote road access communities (CKD 
prevalence 18.4%) this ICER was $63,780/QALY. Primary model drivers included the cost 
of dialysis, assumed treatment effectiveness, and rates of progression towards kidney failure.
Conclusions: Targeted screening for CKD in rural and remote First Nations is likely 
cost-effective (< 50,000/QALY). These findings may be translatable to other high-risk 
indigenous groups with elevated rates of CKD and kidney failure and warrant further 
research.
SA-PO728
Getting a Diagnosis of Chronic Kidney Disease: Despite Fears, Patients 
Want to Know Early  Julie A. Wright Nunes,1 Meghan Roney,2 Eve Kerr,3 
Akinlolu O. Ojo,1 Angela Fagerlin.1,2,3  1Internal Medicine, Univ of Michigan, 
Ann Arbor, MI; 2Center for Bioethics and Social Sciences in Medicine, Univ of 
Michigan, Ann Arbor, MI; 3Center for Clinical Management Research, VA Ann 
Arbor Healthcare System, Ann Arbor, MI.
Background: Little is known about patient perspectives related to getting a diagnosis 
of chronic kidney disease (CKD). This information could help providers optimize diagnosis 
messaging at the point of care.
Methods: Using root/cause analysis and quality function deployment we conducted 
semi-structured patient interviews. Adult patients with established non-dialysis CKD were 
interviewed between January-October 2014. Interviews were audiotaped and transcribed. 
Content analysis was done with Dedoose, a qualitative software package.
Results: 49 patients completed interviews. Mean (SD) age was 63 (14) years, 50% 
were male, 80% were Caucasian and 84% had CKD Stage 3-5. Key themes emerged 
from a total of 786 statements: 1) Reaction to diagnosis (160 statements) 2) Barriers to 
accepting diagnosis (61 statements) and 3) Expectations of diagnosis communication (122 
statements). 45% of patients felt fearful after getting a CKD diagnosis - most often related 
to perceived threats of future dialysis and death. Barriers to diagnosis acceptance included 
disbelief because of lack of symptoms and lack of prior familiarity with CKD. Despite 
fear and denial the majority of patients (63%) desired early diagnosis communication by 
their providers, i.e. at earliest stages of identification. Consistent terminology and disease 
explanations by providers across the care continuum were perceived as critical to effective 
communication and diagnosis delivery, yet patients expressed frustration at inconsistent 
terminology/explanations.
Conclusions: Our findings emphasize that patients learning of a CKD diagnosis can 
experience fear, but they also prefer early communication of diagnosis. More work is needed 
to set uniform diagnosis terminology for patients with CKD across the care continuum.
Funding: NIDDK Support
SA-PO729
The Impact of Chronic Kidney Disease on Household Income: Does Health 
Affect Wealth?  Rachael L. Morton,1,3 Alan Cass,2 Borislava N. Mihaylova.3 
1Univ Sydney, Australia; 2Charles Darwin Univ, Australia; 3Univ Oxford, United 
Kingdom; 4On behalf of SHARP Collaborators.
Background: The impact of progressive chronic kidney disease (CKD) on household 
income is unclear. We sought to determine whether CKD severity and non-fatal adverse 
events were associated with a fall into poverty.
Methods: Prospective cohort study among participants with moderate-to-severe CKD 
randomized into the Study of Heart and Renal Protection (SHARP) with information on 
household income at study entry and study end (median follow-up 5 years). Household 
income recorded as: High (> twice the participating country median); Medium-high (> 
the median, but < twice the median); Medium-low (< the median, but > half the median); 
and Low (< half the median income, i.e. poverty). Logistic regression models with socio-
demographic factors, smoking, prior diseases, severity of CKD, income category at entry 
and incident non-fatal events (myocardial infarction, stroke, incident cancer, initiation of 
dialysis, kidney transplantation) were used to determine a fall into poverty, defined as a 
move into the lowest household income category.
Results: 2914 SHARP participants were included in the analysis; 933 of these were 
in poverty at screening and a further 436 (22% of the remaining) moved into poverty by 
study end. In addition to black ethnicity, low educational attainment, single adult household 
and low income category at baseline, CKD severity was a significant predictor of a fall 
into poverty.
Those who received kidney transplant were less likely to fall into poverty (OR 0.48, 
95%CI 0.31-0.72). Non-fatal adverse events were not significantly associated with a fall 
into poverty.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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Conclusions: Patients in advanced stages of CKD are at an increased risk of falling 
into financial hardship. Kidney transplantation may have a role in reducing the risks of 
household poverty due to CKD.
Funding: Government Support - Non-U.S.
SA-PO730
Healthcare Expenditures for Non-Dialysis Dependent Kidney Disease 
Compared to Other Chronic Diseases  Christina Small,1 Holly J. Kramer,1 
Karen A. Griffin,1 David J. Leehey,1 Vinod K. Bansal,1 Kavitha Vellanki,1 Talar 
Markossian.1  1Loyola Univ Chicago; 2Hines VA Medical Center.
Background: There is a paucity of literature comparing the expenditures of kidney 
disease with other common costly chronic diseases in the United States. Our study compares 
the U.S. healthcare expenditures of non-dialysis dependent kidney diseases to several 
other chronic conditions.
Methods: This study used the 2012 Medical Conditions and Consolidated Data files 
from the Medical Expenditure Panel Survey administered by the Agency for Healthcare 
Research and Quality. Analyses included adults age ≥ 21 years with one of the following 
conditions: kidney disease, stroke, cancer, or a combination of the three (multichronic). 
Non-dialysis dependent kidney disease included any ICD9 code for kidney related conditions 
while chronic kidney disease (CKD) included only ICD9 code “585”. Analyses of calculated 
healthcare expenditures accounted for the complex survey design and incorporated the 
sampling weights so that estimates represent healthcare expenditures for the 2012 adult U.S. 
population (~313.4 million). Out of pocket healthcare expenditure burden was defined as the 
ratio of out of pocket healthcare expenditure to total person-level income for the year 2012.
Results: The mean age for non-dialysis dependent kidney disease and CKD was 56.5 
and 65.9 years, respectively. Table 1 shows the median total and out of pocket healthcare 
expenditure values and mean out of pocket healthcare expenditure burden for kidney 
disease, CKD and other chronic conditions. 
Chronic 
Condition
Median Out of Pocket 
Expenditures, $ 
(range)
Median Total Expenditures 
$(range)
Mean Out 
of Pocket 
Expenditures 
Burden %
CKD 862 (38-13,915) 22, 919 (1,782-189,893) 9.5
Any kidney 
disease 795 (0-42,034) 6,351 (0-262,189) 5.0
Cancer 760 (0-54,698) 8, 528 (0-147,533) 5.2
Stroke 790 (0-79, 313) 7,606 (0-212, 886) 5.2
Multiple 
Chronic 
Conditions
824 (2-5,711) 16, 323 (992-276, 047) 6.0
Conclusions: Healthcare expenditures including out of pocket costs are higher for 
non-dialysis dependent CKD compared to other chronic medical conditions. Policy efforts 
should focus on reducing the healthcare cost burden for patients with kidney disease.
SA-PO731
Smartphone-Based Self-Management System for Chronic Kidney Disease: 
Results from a Single Centre Prospective Trial  Stephanie W. Ong,1,2 Sarbjit 
Vanita Jassal,1 Akib Uddin,3 Kelly Min,1 Joseph A. Cafazzo,3 Alexander G. 
Logan.1  1Nephrology, Univ Health Network, Toronto, ON, Canada; 2Pharmacy, 
Univ Health Network, Toronto, ON, Canada; 3Centre of Global eHealth 
Innovation, Univ Health Network, Toronto, ON, Canada.
Background: Following user-centric design principles we developed a smartphone-
based self-management support system for patients with advanced CKD. The patient 
interface focuses on 4 behavioral elements over which they have direct control: monitoring 
BP at home, self-assessment of symptoms, managing medications and tracking laboratory 
results. The main objectives of this 6-month prospective study were to determine 
acceptability,measured by system adoption and adherence, and assess effectiveness by 
measuring pre and post changes in BP,medications, labs and self-management behaviors.
Methods: We tested the mobile app system in 10 renal clinics at a single academic 
renal center in Toronto. The 47 enrolled patients were instructed at a regular clinic visit 
on the use of the mobile app.The clinical team independently received information on the 
mobile app system’s operation.
Results: 61% of participants were non-smartphone owners. All had more than one 
chronic condition and on average were on 10 to 15 medications. Most were over the age of 
50 with the greatest representation in the age group 55-64. >80% of the users achieved more 
than the recommended 80% adherence rate to mobile app use.27% with normal clinic BP 
readings were discovered to have ‘masked’ hypertension on home BP monitoring. By the 
end of the study the SBP fell by 6.8 ± 20.4 mm Hg (p<0.05) and DBP, by 0.9 ± 9.1 mmHg. 
Out of 250 medication reviews,49% required intervention from the clinical team, such as 
altering drug dosing. Due to the short study duration and infrequency of lab testing,there 
were no changes in pre and post laboratory test results. On exit, patients and clinicians felt 
the mobile app helped engage and empower patients in their CKD care.
Conclusions: The mobile app was acceptable and suggests improvements in BP 
management and medication error prevention. This offers early evidence to supporting 
innovative use of mobile technology in CKD management and strongly support evaluating 
its use in a larger clinical.
SA-PO732
Potentially Preventable Hospitalization Among Patients with Chronic 
Kidney Disease and High Inpatient Use  Paul E. Ronksley, Braden J. Manns, 
Marcello Tonelli, James Wick, Brenda Hemmelgarn.  Univ of Calgary, Calgary, 
AB, Canada.
Background: While prior studies have observed high rates of hospitalization among 
patients with chronic kidney disease (CKD), little attention has been given to those with high 
inpatient use. We explored clinical characteristics, patterns of hospital use, and potentially 
preventable acute care encounters among hospitalized patients with CKD.
Methods: We identified all adults (³18 years) with an eGFR<60 mL/min/1.73m2 in 
Alberta, Canada between Jan 1 and Dec 31, 2009, excluding those with prior kidney failure. 
Patients with CKD were linked to administrative data to capture clinical characteristics and 
frequency of hospital encounters, and followed until death or end of study (Dec 31, 2012). 
Patients with 1 or more hospital encounters were categorized into 3 groups: persistent high 
use (upper 5% of inpatient use (³3 encounters/yr) in 2 or more years), episodic high use 
(upper 5% in 1 year only), or non-high use (lower 95% in all years). Within each group we 
described patient characteristics and calculated the proportion of potentially preventable 
hospitalizations as defined by 4 CKD-specific ambulatory care sensitive conditions (ACSC); 
heart failure, hyperkalemia, volume overload, malignant hypertension.
Results: During a median follow-up of 3 years, 57007 patients had 118671 
hospitalizations of which 1.7% of patients were persistent high users of hospital services, 
12.3% episodic high users, and 86.0% non-high users. Persistent high users were often 
younger, male, First Nations, living in rural areas, and had higher levels of comorbidity 
compared to episodic and non-high use groups. Overall, 24804 (20.9%) CKD-related 
ACSC encounters were observed in the cohort. The proportion of ACSC encounters were 
higher in persistent high users (29.1%) compared to episodic (27.3%) and non-high users 
(17.3%) (p<0.01). The majority of the encounters were attributed to heart failure and 
hyperkalemia in all groups.
Conclusions: A substantial proportion of hospitalizations among patients with CKD 
and high inpatient use are ACSC-related. These findings suggest opportunities to reduce 
inpatient use and cost by focusing on strategies to improve community-based care for this 
subset of patients.
SA-PO733
Effect of Increased Blood Pressure Variability on Neurocognition in 
Children with Chronic Kidney Disease  Marc Lande,1 Susan R. Mendley,2 
Matthew Matheson,2 S. Shinnar,2 Arlene C. Gerson,2 Joshua A. Samuels,2 
Bradley Warady,2 Susan L. Furth,2 Stephen R. Hooper.2  1Univ of Rochester; 
2CKiD Investigators.
Background: Increased blood pressure variability (BPV) is associated with lower 
neurocognitive test (NCT) performance in adults. We previously studied children with 
chronic kidney disease (CKD), who are at risk for cognitive dysfunction and increased 
BPV. However, little is known about the impact of increased BPV on cognition in children 
with CKD.
Methods: Children 6-18 years enrolled in the prospective NIH-sponsored Chronic 
Kidney Disease in Children (CKiD) study had NCT including WASI Matrix Reasoning, 
parent BRIEF, CPT-II, Digit Span, and Verbal Fluency. Casual BP visit-to-visit BPV was 
assessed by SD (BPV-SD) and average real variability (ARV), and 24-hour ambulatory 
BP monitoring by SD of wake and sleep periods. For unadjusted analyses, test scores of 
the subjects with BPV in the upper tertile were compared to that of subjects in the lower 
tertile. Multiple linear regressions were used to evaluate the relation between BPV and NCT 
scores, adjusting for BP index, sex, age, maternal education, race, BMI %ile, estimated 
GFR, % of life with CKD, nephrotic proteinuria, and low birth weight.
Results: Depending on the task, 121- 511 subjects had both BP and NCT results 
available. In unadjusted analysis, subjects with increased visit-to-visit systolic BPV scored 
lower on Verbal Category Switching (3rd vs 1st tertile of BPV-SD, 8.4 ± 2.7 vs 9.8 ± 3.0, 
p = 0.004; of ARV, 8.6 ± 3.0 vs 9.7 ± 2.5, p = 0.009). There was no effect of increased 
visit-to-visit BPV or ambulatory BPV on any other task. In adjusted analyses, increased 
visit-to-visit systolic BPV remained significantly associated with lower Verbal Category 
Switching scores for BPV-SD (β=-0.28, 95% CI:-1.34, -0.15) and there was a trend for 
ARV (β =-5.7, 95%CI:-1.16, 0.03).
Conclusions: Increased visit-to-visit systolic BPV was independently associated with 
decreased Verbal Category Switching scores in children with CKD. These results suggest 
that children with CKD may have difficulties with set shifting that are related, in part, to 
increased BPV. Further study is needed to determine the significance of this isolated result.
Funding: Other NIH Support - NHLBI
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SA-PO734
Rapid Post-Transplant Improvement of HRQOL in Older Kidney 
Recipients  Kristian Heldal,1,2 Kjersti Lønning,2,3 Tomm Bernklev,2,4 Nanna von 
der Lippe,2 Anna Reisaeter,3 Anders Hartmann,2,3 Marit helen Andersen,3 Karsten 
Midtvedt.3  1Clinic of Internal Medicine, Telemark Hospital, Skien, Norway; 2Inst 
of Clinical Medicine, Faculty of Medicine, Univ of Oslo, Oslo, Norway; 3Clinic 
of Cancer, Surgery and Transplantation, Oslo Univ Hospital, Rikshospitalet, 
Oslo, Norway; 4Research Unit, Telemark Hospital, Skien, Norway.
Background: It is widely accepted that health-related quality of life (HRQOL) is 
significantly compromised in patients with ESRD. In adults, kidney transplantation (KTx) 
is known to improve HRQOL. In older recipients there is a lack of studies measuring the 
effect of KTx on HRQOL. The aim of this study was to measure HRQOL longitudinally 
in enlisted patients >65 years of age, from pre-transplant and until 6 months after KTx.
Methods: Patients >65 years listed for transplantation at our centre were asked to 
complete the SF36 questionnaire at enlisting and thereafter every 6 months until KTx. Post 
transplant, the patients received a new SF36 form after 10 weeks and 6 months.
Results: A total of 180 patients have been included from Jan 2013. Mean age at enlisting 
was 70.6 years (65.0-81.8) and 68% were male. By the end of May 2015, 100 patients were 
transplanted and 59 of them had completed both pre- and post-transplant questionnaires. 
Mean time from completing the first pre-tx questionnaire to transplantation was five months. 
When comparing the scores for the last SF36 pre-tx with 6 months post-tx, there was a 
statistical significant increase of the mean scores for GH (53-71), PF (68-74), BP (64-78), 
VT (53-71) and MH (79-85). There was also a tendency towards improved scores for RP 
and RE, while the SF score was unchanged.
Conclusions: Our preliminary findings indicate that older patients report a significant 
improved HRQOL measured by SF36 already 10 weeks after KTx and the status remains 
stable after 6 months. Longer follow-up is warranted.
Funding: Government Support - Non-U.S.
SA-PO735
L-Carnitine Improves Cognitive and Renal Functions in a Rat Model of 
Chronic Kidney Disease  Zaher Anis Armaly,2 Adel Rafik Jabbour,1 Avi Avital.3 
1Dept of Nephrology, Bar Ilan Univ, E.M.M.S. Hospital, Nazareth, Israel; 2Dept 
of Biochemical Laboratory, E.M.M.S. Hospital, Nazareth, Israel; 3Behavioral 
Neuroscience Lab, Dept of Physiology, Rappaport Faculty of Medicine, Technion 
and The Emek Medical Center, Haifa, Israel.
Background: Over the past decade, the prevalence of chronic kidney disease (CKD) 
has reached epidemic proportions. L-Carnitine, considered as the “gatekeeper” responsible 
for admitting long chain fatty acids into mitochondria. L-Carnitine synthesis and turnover 
are regulated mainly by the kidney and its levels inversely correlate with serum creatinine 
(SCr) of normal subjects and CKD patients. Previous studies showed that L-Carnitine 
administration to elderly improves and preserves cognitive function. Yet, there are no clinical 
intervention studies that investigated the effect of L- Carnitine administration on cognitive 
impairment evidenced in CKD patients.Thus, we investigated the effects of L-Carnitine 
treatment on renal function and cognitive performance in a rat model of progressive CKD.
Methods: Animals were subjected to right unilateral nephrectomy combined with 2/3 
of left kidney ligation. Sham operated rats served as controls. Following 14-days recovery 
period, animals were randomly assigned into two treatment conditions: treatment with 
saline (sham n=7; CKD n=9) or L-Carnitine (250 mg/kg) (sham+car n=7 ; CKD+car;n=8) 
by daily intraperitoneal injections, for 8 consecutive weeks. Then all rats were sacrificed, 
blood samples and remnant kidney were collected, for biochemical and histological analysis, 
respectively.Two way shuttle avoidance test was used to assess the effects of CKD and 
L-Carnitine treatment on cognitive-related behavior.
Results: We found that all CKD animals exhibited renal dysfunction, as indicated by 
elevated sSCr, BUN, and histopathological abnormalities. L-Carnitine treatment of CKD 
rats significantly reduced SCr and BUN, attenuated renal hypertrophy and decreased renal 
tissue damage. In addition, in the two way shuttle avoidance learning, CKD animals showed 
cognitive impairment which recovered by the administration of L-Carnitine.
Conclusions: Administration of L-Carnitine in a rat model of CKD, significantly 
improved cognitive and renal functions.
SA-PO736
Being a Relative to Patients with Chronic Kidney Disease – Experiences 
of Participation in Care and Treatment  Hanne Agnholt,1 Jette Kristiansen,2 
Mona Kyndi Pedersen.3  1Dept of Nephrology, Aalborg Univ Hospital, Aalborg, 
Denmark; 2Univ College of Northern Denmark, Aalborg, Denmark; 3Clinic for 
Internal Medicine, Aalborg Univ Hospital, Aalborg, Denmark.
Background: Studies concerning the lives of patients with chronic kidney disease have 
focused on the patients, and not the relatives. However, relatives share and are affected 
by the same consequences as the patient with regard to changes in everyday life, roles in 
the family and mutual relationship. The purpose of the study was to gain insight into and 
understanding of the needs of the relatives of patients with chronic kidney disease with 
regard to their ability to provide support in everyday life, and the expectations of the 
relatives of participation in care and treatment.
Methods: A qualitative study based on four focus group interviews with four to eight 
relatives in each group (in total 27 relatives). The groups were formed according to the 
age and gender of the relatives as well as their relation to the adult patient with chronic 
kidney disease.
Results: The study demonstrated how relatives provide substantial support to the 
patient both in everyday life and in care and treatment. In relation to the patient, it was a 
constant challenge for relatives to find the balance between supporting and taking over. 
They expressed a need for recognition by both the close relations and the health care 
professionals as well as a need for sharing their experiences with other relatives in the 
same situation. The analysis identified six themes: 1. Different needs and possibilities 
for support and participation. 2. Finding balance between disease and everyday life. 3. 
Emotional pressure. 4. The importance of recognition. 5. Need for regaining energy, and 
6. Collaborating with health care professionals.
Conclusions: When collaborating with the relatives with regard to care for patients 
with chronic kidney disease, the health care professionals should actively recognize the 
patient support that the relatives already provide in everyday life. Initiatives of participation 
in care and treatment should be based on collaboration and the needs, expectations and 
possibilities of both the patient and the relatives.
SA-PO737
CKD(3-5) Affects Endurance, Strength, Balance and Fine Motor Skills 
which Are Not Detectable by Questionnaire  Naomi D. Clyne,1 Matthias 
Hellberg,1 Peter Hoglund.2  1Clinical Sciences Lund, Nephrology, Lund Univ, 
Lund, Sweden; 2Laboratory Medicine, Clinical Pharmacology, Lund Univ, 
Lund, Sweden.
Background: Physical functions are impaired in dialysis patients. It is unclear which 
functions are affected and how they decline in the course of CKD. This study investigated 
the effects of declining GFR (CKD 3-5) on measured physical functions, self perceived 
physical functioning and well-being.
Methods: In this cross sectional analysis 101 patients (40 women, 61 men; mean age: 
67±13 years, median GFR: 21 (9-41) ml/min/1.73m2) were tested with 6 Minutes Walk 
(6-MWT), Isometric Quadriceps Strength (IQS), Functional Reach (FR) and Picking-up 
(PUT). Self perceived physical functioning and well-being were assessed by KDQOL-SFTM. 
GFR was measured with Iohexolclearance and comorbidity by Davies´index. Multivariable 
linear regression analyses were employed including the following explanatory variables: 
GFR, age, sex, comorbidity and the interaction between sex and age.
Results: Significant associations were found between decline in GFR and endurance 
(6-MWT; p=0.039), strength (IQS; p=0.035), balance (FR; p=0.024) and fine motor skills 
(PUT; p=0.015) as well as by the patients’ perceived domains in the KDQOL-SFTM of 
effects- (p=0.023) and burden (p=0.016) of kidney disease and social support (p=0.006) 
after having taken the explanatory variables into account. There were significant associations 
between the KDQOL-SFTM domains role physical and emotional well-being and 6-MWT 
(p=0.018; p=0.018, respectively) and IQS (p=0.005; p=0.045, respectively), but these were 
dependent on age, sex and comorbidity and not driven by GFR.
Conclusions: Physical functions comprising endurance, strength, balance and fine 
motor skills were impaired relatively early in the course of CKD (3b-5), seemed to progress 
with declining GFR and could be detected by easy to perform physical function tests. The 
relationship between self perceived physical functioning and well being, respectively, with 
measured endurance and strength, respectively, were driven by age, sex and comorbidity but 
not by decline in GFR. The only domains that descriminated for GFR associated infuelnce 
were effects- and burden of kidney disease and social support.
SA-PO738
The Prevalence of Cognitive Impairment in Chinese Peritoneal Dialysis 
Patients  Chi-bon Leung, Cheuk-Chun Szeto.  Dept of Medicine and 
Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong.
Background: Cognitive impairment is common amongst patients with chronic kidney 
disease and may be associated with excessive morbidity in dialysis patients. This study 
determines the prevalence and risk factors of cognitive impairment in Chinese peritoneal 
dialysis (PD) patients.
Methods: We studied 178 prevalence PD patients (103 males). Cognitive impairment 
was screened by the 10-item Abbreviated Mental Test (AMT) questionnaire. We also 
determined patients’ comorbidity load, dialysis adequacy, residual renal function, nutritional 
status, and degree of frailty.
Results: The mean age was 60.7 ± 11.7 years; vintage of dialysis 42.5 ± 44.1 months. 
Average AMT score was 9.3 ± 1.3. The AMT score is closely associated with age (r = 
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-0.398, p < 0.0001). AMT score also has a modest but significant correlation with Charlson’s 
comorbidity index (r = -0.192, p = 0.010), subjective global assessment score (r = 0.153, p 
= 0.041), malnutrition inflammation score (r = -0.212, p = 0.004), serum albumin level (r 
= 0.184, p = 0.024), and frailty index (r = -0.199, p = 0.008), but not with vintage of PD, 
dialysis adequacy, or residual renal function. When defined as a AMT score <7, 14 patients 
(7.9%) had cognitive impairment.
Conclusions: Cognitive impairment is not uncommon amongst Chinese PD patients. 
Frailty and malnutrition are the major risk factors of cognitive impairment in our cohort, 
while comorbidity load and dialysis adequacy have little effect.
Funding: Government Support - Non-U.S.
SA-PO739
Neurocognitive Functioning and Association with Clinical Outcomes in 
Adults with End-Stage Kidney Disease: The COGNITIVE-HD Study 
Giovanni F.M. Strippoli.1,2,3,4  1On behalf of the COGNITIVE-HD Study 
Investigators*; 2Diaverum Medical Scientific 2ffice; 3Univ of Bari; 4Univ of 
Sydney.
Background: Cognitive impairment and neurocognitive disorder have been associated 
with increased mortality in the general population. Whether dialysis patients have specific 
patterns of cognitive dysfunction, or whether cognitive function is associated with activities 
of daily living and durability of dialysis treatment remain poorly understood.
Methods: The COGNITIVE-HD study will provide detailed neuropsychological 
assessments of cognitive function among hemodialysis patients to characterize age- and 
education-adjusted prevalence and patterns of cognitive impairment and the associations 
with physical and social functioning and clinical outcomes including cardiovascular events 
at 12 months. The COGNITIVE-HD study is a prospective, longitudinal, population study 
of 751 adults conducted in 20 dialysis centers in Italy. A detailed battery of comprehensive 
testing for executive function, visuospatial function, language, learning and memory, 
personality traits, and complex attention has been carried out by a trained psychologist 
at baseline to assess for presence of cognitive impairment and to evaluate the pattern of 
cognitive deficits, and any association between cognitive impairment and activities of 
daily living.
Results: Preliminary analyses have been conducted on the Mini Mental State 
Examination (MMSE) evaluation of cognitive function among 702 participants (mean 
age 68.2 years, 60% men). 50% had normal cognitive function (MMSE score 27-30), 
22% had mild cognitive impairment (score 26-24). 198 patients (28%) had MMSE results 
compatible with dementia (score <24), of whom 51%, 48% and 1% had mild, moderate 
and severe impairment respectively.
Conclusions: The COGNITIVE-HD is a population-based study of cognitive function 
involving dialysis patients that has the potential to inform candidate interventions for 
treatment trials of cognitive impairment in the setting of advanced kidney disease. *List of 
study investigators: S Palmer, M Ruospo, A Iurillo, V Saglimbene, P Natale, O Barulli, L 
Gargano, AM Murgo, C Loy, JC Craig, DW Johnson, M Tonelli, J Hegbrant, C Wollheim, 
G Logroscino and GFM Strippoli.
SA-PO740
Lower Renal Function Predicts Poorer Performance in Specific Domains of 
Neurocognitive Function in Older Hypertensive Men  Stephen L. Seliger,1,2 
Jason Kisser,3 Jamie Giffuni,2 Leslie I. Katzel,1,2 Shari R. Waldstein.3  1Medicine, 
U Maryland Sch Medicine; 2GRECC, VA Maryland Healthcare System; 
3Psychology, U Maryland Baltimore Co.
Background: CKD has been associated with lower cognitive performance, especially in 
older adults. However, the specific pattern of functional deficits is uncertain, and many prior 
reports have not accounted for common vascular risk factors of ageing such as hypertension.
Methods: We tested neurocognitive functions using a multi-item test battery among 
older (60+) community-dwelling hypertensive males with stage 2-4 CKD (n=108) and 
without CKD (n=68). Subjects were free of stroke and dementia. GFR was estimated 
using the MDRD equation. Multiple linear regression was used to compare those with 
and without CKD, and to estimate associations of eGFR and proteinuria with cognitive 
functions, adjusting for demographics and potential confounders (education, depression, 
blood pressure, hemoglobin, fasting glucose, smoking, alcohol use, and BMI).
Results: Mean age was 69.1±7.4 years, mean SBP 134+/-18 mm Hg, and 47% were 
African-American; mean eGFR was 42.9.±14.5cc/min/1.73m2 among those with CKD. 
Among all subjects, lower eGFR was linearly associated with worse performance on tests of 
attention, non-verbal memory, visuospatial ability, manual dexterity, and language fluency 
after multivariable adjustment (Table). In contrast, those with stage 2-4 CKD as a group 
did not differ from controls in cognitive performance after adjustment for confounders, 
nor was proteinuria correlated with cognitive test performance.
Conclusions: Among older men, those with primarily mild-moderate CKD and HTN 
do not have lower cognitive function compared to hypertensive controls after accounting 
for common cognitive risk factors. However, across a range of GFR, lower renal function 
is associated with worse performance in specific domains of cognitive function.
Funding: NIDDK Support, Veterans Administration Support
SA-PO741
Neurocognitive Function and Psychiatric Disorder in Children with Chronic 
Kidney Disease from the KNOW-Ped CKD Cohort Study (Korean Cohort 
Study for Outcome in Patients with Pediatric Chronic Kidney Disease) 
Kyoung Hee Han,1 Eujin Park,2 Yo Han Ahn,2 Seong Heon Kim,3 Joo Hoon 
Lee,4 Young Seo Park,4 Hee Gyung Kang,2 Hae Il Cheong,2 Curie Ahn,5 Il-Soo 
Ha.2  1Dept of Pediatrics, Jeju National Univ School of Medicine, Jeju, Republic 
of Korea; 2Dept of Pediatrics, Seoul National Univ Children’s Hospital, Seoul, 
Republic of Korea; 3Dept of Pediatrics, Pusan National Univ Children’s 
Hospital, Yangsan, Republic of Korea; 4Dept of Pediatrics, Asan Medical Center, 
Univ of Ulsan College of Medicine, Seoul, Republic of Korea; 5Dept of Internal 
Medicine, Seoul National Univ Hospital, Seoul, Republic of Korea.
Background: We determined whether pediatric chronic kidney disease (CKD) is 
associated with neurocognitive impairment and psychiatric disorder from the KNOW-
PedCKD cohort study in Korea.
Methods: A total of 322 children (M:F 218:104) enrolled from seven major pediatric 
nephrology centers of Korea from July 2010 to December 2013 were the subject of this 
study. Neurocognitive function and psychiatric status of pediatric CKD patients were 
evaluated using Wechsler intelligence scale for children, Child Behavior Checklist, ADHD 
Rating Scale-IV, State-Trait Anxiety Inventory, Child Depression Inventory and Parental 
bonding instrument-Korean version.
Results: Verbal, performance and full scale IQ were lower in younger age and 
congenital anomalies of the kidney and urinary tract as a cause of CKD. More than 10 
percent of school-age children with CKD presented significant emotional distress including 
somatization (15%), attention problems (15%) and anxiety (12%). Impact of progression 
of CKD on their neurocognitive function and psychiatric status will be investigated in 
KNOW-PedCKD as follow-up study.
Conclusions: In young patients with CKD and those with multiple congenital 
problems in addition to CKD suffer from low intelligence and psychiatric disorder. 
Pediatric CKD patients with low intelligence and psychiatric disorder need close attention 
and developmental training techniques. Acknowledgement. This work was supported by 
the Research Program funded by the Korea Centers for Disease Control and Prevention 
(2013E3301600, 2013E33081601).
Funding: Government Support - Non-U.S.
SA-PO742
Awareness of Kidney Disease Is Associated with Depressive Symptoms: 
NHANES 2005-2010  Shayan Shirazian, Robert Diep, Joseph Mattana, Ritika 
Sharma, Rose Calixte.  Winthrop Univ Hospital.
Background: Depressive symptoms are common in patients with chronic kidney 
disease (CKD). The purpose of this study was to define variables associated with depressive 
symptoms in patients with CKD including awareness of CKD diagnosis.
Methods: We used data from the National Health and Nutrition Examination Surveys 
(NHANES) 2005-2010. Non-pregnant subjects age >20 with CKD stage 1-4, who completed 
both an awareness of kidney disease questionnaire and a Patient Health Questionnaire (PHQ-
9) were included. Three outcome groups were defined: 1) minimal depressive symptoms 
(PHQ-9 score 0-4), subthreshold depressive symptoms (PHQ-9 score 5-14) and severe 
depressive symptoms (PHQ-9 score > 14). All analyses were performed with appropriate 
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weighting. Chi-square and unpaired t-tests defined significant differences between outcome 
groups. Multivariable logistic regression defined variables independently associated with 
subthreshold depressive symptoms. Significance was defined as p£0.05.
Results: Of the 2500 subjects with CKD that met study criteria, 21.8% had subthreshold 
depressive symptoms and 3.3% had severe depressive symptoms. Multivariable predictors 
of subthreshold depressive symptoms included female gender, lower education, lower 
income, single marital status, Mexican and Black race, diabetes, elevated diastolic blood 
pressure, smoking, cardiovascular comorbidity and awareness of kidney disease. 6.4% 
of subjects were aware they had CKD. CKD awareness was significantly associated with 
subthreshold, but not severe, depressive symptoms in univariable analysis (OR 1.76, CI 
1.10-2.80). In multivariable analysis, the association between awareness of CKD and 
subthreshold depressive symptoms remained significant (p=0.05). There was a significant 
interaction between awareness and stage 1 CKD on subthreshold depressive symptoms 
(OR 8.25, CI 2.24-30.63), and between awareness and female gender on subthreshold 
depressive symptoms (OR 2.19, CI 1.09-4.38).
Conclusions: Awareness of kidney disease is significantly associated with subthreshold 
depressive symptoms. This association is possibly mediated by distress caused by CKD 
diagnosis. Increased psychosocial support, especially in early stages of CKD, may be 
warranted.
SA-PO743
Vitamin D Deficiency Is Significantly Associated with Depression in Chronic 
Kidney Disease Patients  Jong Hyun Jhee, Sul A. Lee, Hyung Jung Oh, Jung 
Tak Park, Seung Hyeok Han, Shin-Wook Kang, Tae-Hyun Yoo.  Dept of Internal 
Medicine, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Recent studies have reported significant associations between vitamin D 
deficiency and depression in the general population. Although both vitamin D deficiency and 
depression are common features in chronic kidney disease (CKD) patients, the association 
between these two prevalent factors in this patient population remains poorly elucidated. 
Therefore, the association between vitamin D deficiency and depression in CKD patients 
was investigated.
Methods: The data from the Korean National Health and Nutritional Examination 
Survey between 2010 and 2012 were used. A total of 495 patients with estimated glomerular 
filtration rate ≤60 mL/min/1.73m2 were enrolled. Vitamin D deficiency was defined as 
25-hydroxyvitamin D3 [25(OH)D3] levels £10 ng/mL. Patients were dichotomized by the 
presence of vitamin D deficiency. Depression was determined by the EuroQOL-5D (EQ5D) 
questionnaire. Independent association between vitamin D deficiency and depression was 
evaluated by multivariate logistic regression analysis.
Results: The mean age was 71.2±9.3 years, and 257 patients (51.9%) were female. The 
median 25(OH)D3 levels were 17.9 (13.9-22.7) ng/mL. The prevalence of depression in 
CKD patients was higher compared to the general population (14.3% vs. 11.1%, P=0.031). 
In addition, the prevalence of depression was significantly higher in patients with vitamin 
D deficiency than those without vitamin D deficiency (27.0% vs. 13.3%, P=0.022). 
Multivariate logistic regression analysis showed that vitamin D deficiency was a significantly 
independent predictor of depression after adjusting for age, sex, alcohol, body mass index, 
hypertension, diabetes mellitus, anemia, suicidal idea, EQ5D index, and serum parathyroid 
hormone levels (odds ratio=6.27, 95% confidence interval=1.57-25.05, P=0.009).
Conclusions: Depression was highly prevalent in CKD patients. Vitamin D deficiency 
was a significantly independent predictor of depression in CKD patients. Therefore, 
determining vitamin D levels might be helpful to predict depression in these patients.
SA-PO744
Comparison of Prevalence and Predictors of Fatigue in Advanced Chronic 
Kidney Disease and Cancer Patients  Manisha Jhamb,1 Sanah Parvez,2 Khaled 
Abdel-Kader,3 Mark L. Unruh,2 Jennifer L. Steel.1  1Univ of Pittsburgh; 2Univ 
of New Mexico; 3Vanderbilt Univ.
Background: Although >50% of patients with advanced CKD report fatigue, its 
presence, predictors and consequences are under-appreciated by renal providers. We 
compared the symptom burden among CKD/ESRD patients to those with advanced 
hepatobiliary cancer (CA).
Methods: In 237 patients with advanced kidney disease (35% CKD stage 4-5, 65% 
ESRD) and 606 with advanced CA, patient-reported symptoms and health-related quality 
of life (HRQOL) were assessed using validated fatigue, pain, sleep quality, depression 
and HRQOL questionnaires. Chi-square and ANOVA were used to test between group 
differences and linear regression was employed to test predictors of fatigue.
Results: In unadjusted analyses, CKD patients reported statistically (but not clinically) 
less fatigue, similarly poor sleep quality, and significantly lower prevalence of depression 
and pain as compared to CA patients. Lower levels of fatigue were strongly associated 
with higher HRQOL in both groups (r=0.80, p<0.001 in CKD; r=0.67, p<0.001 in CA). 
Depression was significantly associated with higher levels of fatigue for both groups 
(p<0.001 for both). Poor sleep quality was associated with higher fatigue in both groups 
(r= -0.40, p<0.001 in CKD; r= -0.27, p<0.001 in CA). Similarly, in both groups, more pain 
was associated with higher fatigue (r=0.41, p<0.001 for MOS SF-36 pain score in CKD; 
r= -0.48, p<0.001 for BPI in CA). Using linear regression, and including those factors 
significantly associated with fatigue, 29% of the variance in CKD and 31% in CA cohort 
was explained by depression, sleep and pain.
Conclusions: Patients with advanced CKD experienced similar levels of fatigue and 
poor sleep quality as those with advanced CA. Sleep, depression, and pain were significant 
predictors of fatigue in these chronically ill patients.
Funding: NIDDK Support, Other NIH Support - National Cancer Institute 
K07CA118576; R21CA127046; and R01CA176809, Private Foundation Support
SA-PO745
Urinary Incontinence Is Common Among Adults with Chronic Kidney 
Disease (CKD) and May Impact Patient Compliance with Diuretics 
Mitul Natu Patel, David J. Leehey, Kavitha Vellanki, Vinod K. Bansal, Julia 
Koval, Linda Brubaker, Neelam Balasubramanian, Jasmin Sandhu, Anuradha 
Wadhwa, Holly J. Kramer.  Nephrology, Loyola Univ Medical Center, Maywood, IL.
Background: Urgency urinary incontinence (UUI) is a stigmatized condition that 
may be common among adults with CKD due to the older age and high prevalence of 
comorbidities (obesity and diabetes) that increase risk for UUI in this population. Diuretics, 
which are commonly used for hypertension management, may exacerbate UUI symptoms. 
However, the impact of UUI on diuretic compliance has not been previously assessed in 
adults with CKD.
Methods: This pilot study recruited 89 adults with non-dialysis dependent stage 3-5 
CKD who are prescribed diuretics for hypertension management. All participants provided 
written informed consent. Study participants completed the Morisky Medication Adherence 
Scale (MMAS), a validated questionnaire for hypertension medication compliance with 
scores ranging from 0 (poor adherence) to 11 (excellent adherence). Participants were asked 
“Do you ever avoid taking the diuretic (water pill) because it increases the urge to urinate 
or because it makes you urinate before reaching the toilet?” Information on UUI prevalence 
and nocturia was collected using standardized, validated questions for urinary symptoms.
Results: The mean age of the participants was 71 years, 54% were male and 71% were 
white. Overall, UUI was present in 44%, and 93% reported nocturia (waking at night to 
urinate) and 33% reported severe nocturia (waking 3 or more times to urinate). Overall 
17% reported ever not taking their diuretic due to urinary urgency and this was significantly 
more frequent among those with UUI vs. those without UUI (32% vs. 6%; P = 0.002). 
Compared to patients who do not avoid diuretics, patients who reported ever avoiding 
diuretics showed significantly lower median values of medication adherence scores (7.0 
vs. 10.0; P< 0.001) and were less likely to to have a blood pressure < 140/90 mmHg at the 
clinic visit (53% vs. 72%; P < 0.05).
Conclusions: UUI is common among older adults with CKD and may negatively 
impact compliance with diuretics and blood pressure management.
SA-PO746
Validation of a Patient-Perceived Symptom Score for Chronic Kidney 
Disease  Stephanie A. Brown,1 Freya Tyrer,2 Amy L. Clarke,1 Laetitia H. 
Lloyd-Davies,1 Andrew G. Stein,3 Carolyn Tarrant,2 Alice C. Smith.1  1Leicester 
Kidney Exercise Team, Univ of Leicester, Leicester, United Kingdom; 2Dept of 
Health Sciences, Univ of Leicester, United Kingdom; 3Univ Hospitals of Coventry 
and Warwickshire, United Kingdom.
Background:   Chronic Kidney Disease (CKD) is associated with a range of symptoms, 
even at relatively early stages. There is increasing recognition of the importance of the 
patient symptom experience for clinical management and quality of life, but validated 
symptom scores are lacking. We have refined and validated an existing draft CKD symptom 
questionnaire listing 11 common renal symptoms plus lines for additional symptoms not 
included in the list.
Methods:   Validation was undertaken in 4 phases. In Phase 1, 219 patients with 
CKD1-5 not requiring renal replacement completed the draft questionnaire to identify the 
most common symptoms in this population. Phase 2 explored cognitive validity via semi-
structured interviews with 11 patients, after which the draft questionnaire was refined. Phase 
3 was a focus group with 5 patients, to review and further refine the updated questionnaire. 
Phase 4 was content validity testing: the questionnaire was sent to 16 external expert 
clinicians for assessment of relevance, clarity and comprehensiveness.
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Results:   Phase 1 identified 13 common symptoms, and Phases 2 and 3 confirmed 
symptom selection and refined the wording used to describe them. The symptom descriptions 
finalised were: itching, sleep disturbance/insomnia, loss of appetite, feeling tired, pain 
in bones/joints, poor concentration/mental alertness, loss of libdo/erectile dysfunction, 
loss of muscle strength/power, shortness of breath, cramp/muscle stiffness, restless legs/
difficulty keeping legs still,  need to urinate more often, feeling cold. In Phase 4, 14 of 16 
experts responded (87.5%). 10 of the 13 symptoms had “excellent” or “good” evaluation 
scores, and the content validity index of the whole questionnaire was 0.81, falling within 
the recommended threshold.
Conclusions:   This work has provided a new, validated symptom score for the early/
pre-dialysis CKD population, which can be used as a patient reported outcome measure in 
both clinical management and research.
Funding: Private Foundation Support
SA-PO747
Impact of Psychosocial Factors in Advanced Chronic Kidney Disease on 
Wait-Listing for Transplantation  Sanjeev Akkina, James P. Lash, Jason 
Roy, Boyang Chai, Michael J. Fischer, L. Lee Hamm, Peter D. Hart, Chi-yuan 
Hsu, Yonghong Huan, Anne M. Huml, Radhakrishna Reddy Kallem, Manjula 
Kurella Tamura, Anna C. Porter, Ana C. Ricardo, Sylvia E. Rosas, Raymond R. 
Townsend, Peter P. Reese, Meera Nair Harhay.  CRIC Study Group Investigators.
Background: Transplantation (Tx) is generally regarded as the best option for renal 
replacement therapy. However, few patients with CKD are listed for Tx when eligible. We 
examined the association between psychosocial factors in patients with advanced CKD 
and wait-listing for kidney Tx.
Methods: The study population includes 803 individuals with an eGFR of less than 
or equal to 20mL/min/1.73m2 (advanced CKD) in the Chronic Renal Insufficiency Cohort 
study. The primary predictors were health related quality of life (HRQOL) and depressive 
symptoms assessed within 24 months prior to reaching the eGFR inclusion criteria using 
the Kidney Disease QOL (KDQOL)-36 survey and the Beck Depression Inventory (BDI), 
respectively. The primary composite outcome was wait-listing or transplantation (WLT). 
Cox proportional hazards models were used to examine the association between low HRQOL 
(³1 SD below the cohort mean) and BDI (³11) with WLT.
Results: Of the 803 subjects, 380 (47%) were wait-listed including 120 that proceeded 
to Tx. Compared to individuals who were not WLT, those in the WLT group were more 
likely to be younger, male, have no history of cardiovascular disease, and have proteinuria 
> 300mg/day (p <0.01). After adjustment for demographic and clinical variables, a low 
Mental Component Summary (MCS) score was associated with a lower likelihood of WLT 
(Table). There was no association between the BDI or other QOL measures with WLT. 
Predictor Adjusted Model (HR, 95% CI)
BDI ≥ 11 0.88 (0.69-1.12)
KDQOL (≥1 SD below the cohort mean)
-Mental Component Summary 0.73 (0.56-0.95)
-Physical Component Summary 0.92 (0.69-1.24)
-Symptoms/Problems 0.97 (0.71-1.32)
-Burden of Kidney Disease 0.82 (0.61-1.09)
-Effect of Kidney Disease on Daily Life 0.94 (0.69-1.28)
Conclusions: Lower MCS scores were associated with lower likelihood of WLT. 
Further work is needed to evaluate the impact of poor mental QOL in advanced CKD and 
how it might influence wait-listing.
Funding: NIDDK Support
SA-PO748
Perspectives on Pregnancy in Women with Chronic Kidney Disease 
Allison Tong,1 Mark A. Brown,2 Wolfgang C. Winkelmayer,3 Jonathan C. Craig,1 
Shilpa Jesudason.4  1The Univ of Sydney; 2St. George Hospital; 3Baylor College 
of Medicine; 4Royal Adelaide Hospital.
Background: Women with chronic kidney disease (CKD) often have difficulty 
achieving pregnancy, and are at increased risk of adverse pregnancy outcomes. Given the 
medical, ethical and emotional complexities of pregnancy in CKD, the clinical approach 
should involve explicit consideration of women’s values; of which there are sparse data. 
We aimed to describe the beliefs, values, and experiences of pregnancy in women with 
CKD, to inform pre-pregnancy counseling and pregnancy care.
Methods: Semi-structured interviews were conducted with 41 women aged 22-56 
years with advanced chronic kidney disease, from two renal units in Australia. Transcripts 
were analyzed thematically.
Results: Six themes were identified: bodily failure (conscious of fragility, noxious self, 
critical timing, suspended in limbo); devastating loss (denied motherhood, disempowered 
by medical catastrophizing, resolving grief, barriers to parenthood alternatives, social 
jealousy); intransigent guilt (disappointing partners, fear of genetic transmission, respecting 
donor sacrifice, medical judgment); rationalizing consequential risks (choosing survival, 
avoiding fetal harm, responding to family protectiveness, compromising health, decisional 
ownership, unjustifiable gamble); strengthening resolve (hope and opportunity, medical 
assurance, resolute determination, reticent hope); and reorientating focus (valuing life, 
gratitude in hindsight).
Conclusions: Decisions surrounding pregnancy in the context of chronic kidney disease 
require women to confront uncertainties about their own survival, disease progression, 
guilt towards their family and kidney donor, the outcomes of their offspring, and genetic 
transmission. Communicating the medical risks of pregnancy to women with chronic 
kidney disease must be carefully balanced with their values of autonomy, hope, security 
and family. Informed and shared decision making that is sensitive to women’s priorities 
as identified in this study can contribute to improved pregnancy, health and psychosocial 
outcomes in this vulnerable population.
SA-PO749
Nrf2 Activator, Resveratrol, Ameliorates Aging-Related Progressive Renal 
Injury  Eun Nim Kim, In-Ae Jang, Ji Hee Lim, Min Young Kim, Byung Ha 
Chung, Cheol Whee Park, Chul Woo Yang, Yong-Soo Kim, Yoonsik Chang, 
Bum Soon Choi.  Div of Nephrology, Dept of Internal Medicine, College of 
Medicine, The Catholic Univ of Korea, Seoul, Republic of Korea.
Background: The senescence markers of kidney have been shown to cause many 
changes in the energy metabolism. Two important issues in aging kidney are mitochondria 
dysfunction and oxidative stress. Nrf2 activator, Resveratrol may prevent inflammation 
and oxidative stress by activating SIRT1 and Nrf2. We examined that Resveratrol can 
potentially ameliorates the cellular condition, such as renal injury due to cell oxidative 
stress and mitochondria dysfunction caused by aging.
Methods: Male 19-month-old C57/BL6 mice were used in this study. Resveratrol 
(0.04%) was provided to old mice for 6month. We compared histological change, oxidative 
stress, and aging-related protein expression in the kidneys between Resveratrol treated 
old-mice group (RSV) and vehicle old-mice group (VH).
Results: In our study, expression of Nrf2 in nuclear (1 ± 0.1 fold vs. 2 ± 0.4 fold; p 
< 0.01 vs. VH) was increased in RSV. Expression of SIRT1 (1 ± 0.2 fold vs. 1.31 ± 0.11 
fold; p < 0.05 vs. VH) was increased in RSV. p-AMPK/Total AMPK ratio expression (1 
± 0.1 fold vs. 1.79 ± 0.2 fold; p < 0.01 vs. VH) was increased in RSV compared with VH. 
RSV group displayed decreased albuminuria and Creatinine clearance increased with RSV. 
There were decreases in mesangial volume, tubulointerstitial fibrosis and collagen IV in 
RSV. Immunohistochemistry of F4/80 expression in glomerulus and tubule were decreased 
in RSV compared with VH. Also, TGF-β was decreased in RSV. Urine isoprostane and 
8-OHdG excretion decreased with aging. Antioxidant enzyme, HO-1 (1 ± 0.08 fold vs. 
1.6 ± 0.1 fold; p < 0.001 vs. VH) and NQO-1 (1 ± 0.06 fold vs. 1.3 ± 0.1 fold; p < 0.01 vs. 
VH) were increased in RSV compared with VH.
Conclusions: These results suggest that activation of Nrf2 may benefit aging-related 
renal injury related with SIRT1 and AMPK activation by reducing oxidative stress. 
Pharmacologically targeting Nrf2 signaling molecules may reduce the pathologic changes 
of aging in the kidney.
SA-PO750
Dual Agonist of Nuclear Hormone Receptor Farnesoid X Receptor and 
G Protein Coupled Receptor TGR5 Exhibits Calorie Restriction Mimetic 
Effects in Aging Mice  Xiaoxin Wang,1 Evgenia Dobrinskikh,1 Yuhuan 
Luo,1 Luciano Adorini,2 Moshe Levi.1  1Univ of Colorado Denver; 2Intercept 
Pharmceutical Company.
Background: Previous studies have shown that calorie restriction (CR) in mice and in 
rats prevent age-related proteinuria and glomerulosclerosis. We have observed an age-related 
decrease in renal nuclear hormone receptor farnesoid X receptor (FXR; NR1H4), and G 
protein-coupled receptor TGR5 (GPBAR1 or GPR131) expression. In contrast, renal FXR 
and TGR5 expression are increased by CR in the aging mice. FXR and TGR5 expression 
are also increased in the long-lived Ames dwarf mouse. The purpose of the present study 
was to determine if activation of FXR and TGR5 in the kidneys of ad lib fed aging mice 
have similar effects to CR.
Methods: We studied 5 month old ad lib fed, 24 month old ad lib fed, 22 months old ad 
lib fed mice treated with the dual FXR/TGR5 agonist INT-767 for 2 months, and compared 
them to lifelong 24 month old CR mice.
Results: Treatment of 22 month old ad lib fed aging mice with FXR/TGR5 dual 
agonist INT-767 for 2 months decreases albuminuria, TGF-β expression, and fibronectin 
accumulation in aging mice. INT-767 stimulates mitochondrial biogenesis, increases 
mitochondrial DNA content, and mitochondrial transcription factors Nrf-1 and Tfam in the 
aging kidney. INT-767 also increases the expression of SIRT1, PGC-1α, and ERRα mRNA, 
as well as PGC-1α and SIRT3 protein abundance. INT-767 activation of the mitochondrial 
NAD-dependent deacetylase SIRT3 restores its targets MCAD and acetyl-IDH2 to normal 
levels, which are important for regulation of mitochondrial fatty acid β-oxidation as well 
as mitochondrial redox status. Furthermore, INT-767 increased expression of NAMPT and 
Nrk1, enzymes involved in synthesis of sirtuins substrate NAD.
Conclusions: Our results therefore indicate that activation of FXR and TGR5 in the 
aging kidney reverses most of the age-related changes and the effects of FXR and TGR5 
are similar to beneficial effects achieved by lifelong CR.
Funding: NIDDK Support
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SA-PO751
ESRD in Nonagenarians in the United States, 1995 Through 2010 
Donal J. Sexton, Scott Reule, Robert N. Foley.  Medicine, Univ of Minnesota, 
Minneapolis, MN.
Background: Patients in their 90’s are increasingly being considered for maintenance 
dialysis, comprehensive epidemiological data could help with decision making.
Methods: We used US census data and data for patients who initiated maintenance 
dialysis between 1995 and 2010 (N=1,557,117) to examine trends in ESRD for those aged 
90 to 99 years (N=14,289).
Results: The rate of ESRD in 1995-1996 was 0.6 per million per year in those 
aged 90-99 years respectively. Standardized incidence ratios (SIRs) rose between 1995 
and 2010 both overall (SIR 2.8), and individually in males (2.89), females (2.7) white 
(3.1) African American (1.93) and other races (2.43). Median survival was 10.7 months. 
“Unspecified renal failure” was the most common reported cause of ESRD (62.6%), 
followed by “diabetes mellitus type 2” (15.89%), “ATN without recovery” 3.47%, “GN 
(not histologically examined)” 3.18%, “renal artery stenosis” 2.44% and other 12.44%. 
Causes of death included; Cardiac deaths 42.4%, Infection 12.07%, Withdrawal of dialysis/
Uremia 10.16%, Stroke/Intracranial Hemorrhage 3%, Cachexia 2.99%, Cancer 2.45%, Other 
12.03% and Unknown 14.89 %. Mortality fell over time, AHR (95% CI) 0.79 (0.72, 0.87) 
in 2009-2010 vs 1995-1996. Factors associated with a higher likelihood of death included; 
ischemic heart disease (AHR 1.13), AV graft (AHR 1.36 vs AV fistula), or venous catheter 
for hemodialysis vascular access (AHR 1.7 vs AV fistula), shorter pre-dialysis nephrology 
care (AHR 1.37), higher eGFR at dialysis initiation (AHR 1.13), serum albumin < 3.5 g/dl 
(AHR 1.34), cerebrovascular disease (AHR 1.21), peripheral vascular disease (AHR 1.14), 
cancer (AHR 1.08), inability to ambulate (1.43) or transfer (1.59), “ATN without recovery” 
as primary cause of ESRD (AHR 1.11 vs “renal failure not specified”).
Conclusions: ESRD in nonagenarians has risen over the period of observation in the 
United States. Rising prevalence may be attributable not only to rising incidence but to 
falling mortality also.
SA-PO752
Impact of Geriatric Multi-Morbidity Versus Medical Multi-Morbidity 
on Quality of Life in Older CKD Patients  Christine Liu,1,2 Jamie Giffuni,3 
Kieran Reid,2 Leslie I. Katzel,3 Stephen L. Seliger,3 Daniel E. Weiner,2 Roger 
A. Fielding.2  1Boston Univ, Boston, MA; 2Tufts Univ, Boston, MA; 3Univ of 
Maryland, Baltimore, MD.
Background: Geriatric conditions are constellations of signs and symptoms not 
always linked to a disease, such as cognitive impairment and fatigue; geriatric conditions 
are associated with worse quality of life (QoL). Older adults with CKD are likely to have 
geriatric multi-morbidity (GM), defined as ³2 geriatric conditions. Medical multi-morbidity 
(MM) is also common in this population and affects QoL. We compared the impact of GM 
to MM on QoL in older CKD patients.
Methods: We used baseline data from an ongoing trial of excercise in persons ≥55 
years with stage 3b-4 CKD. For GM, persons were defined with 1) cognitive impairment 
if Montreal Cognitive Assessment <26; 2) poor physical function if Short Physical 
Performance Battery ≤7; 3) dizziness as reported by Memorial Symptom Assessment Scale; 
4) fatigue if responded ≥”good bit of time” to feeling worn out on Short Form-36 (SF-36); 
and 5) chronic pain if ≥”moderate” pain on SF-36. For MM, hypertension, diabetes, CAD, 
and COPD were self-reported, and depression was defined as Beck Depression Inventory 
³15. QoL was measured with the SF-36. Linear regression adjusting for age, sex, race, site, 
BMI, and eGFR was utilized.
Results: Of 72 persons (31% women, mean age 68.6±7.8 years, mean eGFR 33.3±9.8 
ml/min/1.73m2), 49% (35) had GM and 76% (55) had MM. GM was associated with lower 
scores in all SF-36 subdomains (all p< 0.05). MM was associated with lower scores in two 
SF-36 subdomains (both p<0.05).
Conclusions: In older adults with CKD, geriatric multi-morbidity is common and 
likely affects QoL.
Standardized βs of the associations of geriatric multi-morbidity and medical multi-morbidity 
with SF-36 
SF-36 subdomain Geriatric multi-morbidity P value
Medical multi-
morbidity P value
Physical functioning -0.519 <0.001 -0.185 0.09
Role-physical -0.489 <0.001 -0.060 0.61
Bodily pain -0.650 <0.001 -0.025 0.81
General health -0.451 <0.001 -0.259 0.02
Vitality -0.524 <0.001 -0.136 0.25
Social functioning -0.503 <0.001 -0.077 0.49
Role-emotional -0.289 0.02 -0.257 0.05
Mental health -0.353 0.07 -0.106 0.41
Funding: Private Foundation Support
SA-PO753
A Survey of Provider Knowledge, Attitude, and Practices Surrounding 
Conservative Management for Patients with Advanced Chronic Kidney 
Disease  Sanah Parvez,1 Khaled Abdel-Kader,2 V. Shane Pankratz,1 Mi-Kyung 
Song,3 Mark L. Unruh.1  1Div of Nephrology, Univ of New Mexico; 2Div of 
Nephrology, Vanderbilt Univ; 3Adult and Geriatric Health Div, School of 
Nursing, Univ of North Carolina.
Background: Despite the potential benefits of conservative management (CM), 
discussing CM as a viable treatment option rarely occurs. Several factors might contribute 
to this but no studies in the U.S. have described them. The purpose of this survey was to 
describe nephrologists’ (NEPHs) and primary care providers’ (PCPs) knowledge, attitudes, 
and practices of CM for patients with advanced CKD.
Methods: We developed a survey based on the relevant literature to include items 
assessing knowledge, attitudes, and self-reported practices of CM for patients with advanced 
CKD. We then conducted a web-based cross sectional survey between April and May 2015. 
We used the American Medical Association’s Physician Masterfile to identify NEPH and 
PCPs practicing in the U.S.
Results: 431 (67.6% NEPHs, 32.4% PCPs) providers completed the survey. The 
respondents were, on average, white, predominantly male, and in their 30s and 40s. A 
majority of both PCP (83.5%) and NEPH respondents (78.2%) reported that they were 
likely to discuss CM with their older advanced CKD patients. Self-reported number of 
patients managed conservatively was at least >11 patients for 30.6% NEPHs and 49.2% 
of PCPs. As shown in the figure where a higher percent demonstrates a lower barrier, the 
major barriers to CM discussions identified by NEPHs and PCPs significantly differed. 
There were significant differences in knowledge across the groups with PCPs reporting 
significantly more uncertainty about survival rates with CM.
Conclusions: Both NEPH and PCP are comfortable with discussing CM with their 
patients. PCPs have less certainty regarding patient selection for CM and report feeling 
less informed about outcomes of CM.
Funding: Pharmaceutical Company Support - DCI Inc
SA-PO754
Which Therapeutic Project for Elderly Reaching ESRD? Patient’s 
Characteristics and Outcomes  Coraline Fafin,1 Cécile Couchoud,2 Cecile 
M. Vigneau,3 Olivier Moranne.1  1Nephrology, CHU Nice, Nice, France; 2REIN 
Registry, Agence de Biomédecine, St. Denis La Plaine, France; 3Nephrology, 
CHU Pontchaillon, Rennes, France.
Background: The KDIGO guidelines recommend referral for planning RRT in people 
at risk of kidney failure. Treatment without dialysis in ESRD patient is another therapeutic 
option especially in elderly. The objective of our study is to describe the therapeutic 
projects declared by nephrologist and associated patient’s characteristics and outcomes 
in a prospective design.
Methods: 573 patients over 75 y/o (82±5 y/o) with eGFR below 20 (14 ± 4) were 
included by nephrologists in 2009 and followed 4 yrs (Moranne et al 2012). At baseline, 
we recorded social, clinical characteristics and therapeutic project declared by nephrologist. 
The first project was considered at the second visit as Postponed decision about dialysis 
(STAB), decision to start Dialysis when required (DIAL), Non-dialysis made by nephrologist 
(NDne) or at patient’s request (NDpt). During follow-up, we evaluated the dialysis start and 
death before dialysis and compared patient’s characteristics and incidence of these events 
according to the therapeutic projects.
Results: The therapeutic project was STAB in 234 patients (41%), DIAL in 216 pts 
(38%), NDne in 66 (12%) and NDpt in 55 (10%). Patients were older in ND group, with 
more women for NDpt and more comorbidities for NDne (dementia, active malignancy, 
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CVD, less physical autonomy). After 4 yrs follow-up, the number of death before dialysis 
and dialysis start were 10%/85% for DIAL, 42%/34% for STAB, 67%/20% for NDpt and 
95%/2% for NDne respectively. There was significantly more emergency start for the NDpt 
group starting nevertheless dialysis. In all groups, the main reasons declared by nephrologist 
to start dialysis were: eGFR level, fluid overload and weight lost.
Conclusions: In this population, we observed many patients with stable conditions and 
high risk mortality which anyway raises the issue of dialysis options and care organization. 
Although some patients expressed their willingness not to start dialysis at one point or 
another, it could nonetheless occur but with worst condition. On the contrary, if the dialysis 
option isn’t retain by the nephrologists, it will not occur.
Funding: Pharmaceutical Company Support - Roche, Baxter, Amgen, Freseinus, 
MSD, Shire
Agence de Biomedecine; Société Francophone de Dialyse, Government Support - 
Non-U.S.
SA-PO755
Specific Prognosis Factors of Death and Dialysis Start for Elderly Patients 
Reaching ESRD in the Prospective PSPA Cohort Study  Coraline Fafin,1 
Cécile Couchoud,2 Cecile M. Vigneau,3 Olivier Moranne.1  1Nephrology, CHU 
Nice, Nice, France; 2Agence deBiomedecine, REIN, St Denis de la Plaine, 
France; 3Nephrology, CHU Pontchaillon, Rennes, France.
Background: The death before dialysis start is high in elderly patients reaching ESRD 
and the treatment without dialysis is another option. We need to better predict the outcomes 
of this specific population and identify prognosis factors to improve strategies of care. The 
objective of our study is the identification of prognosis factors of dialysis start or death 
before dialysis in a multicenter prospective cohort of elderly reaching ESRD.
Methods: 573 patients over 75 y/o (82±5 y/o) and with eGFR below 20 (eGFR14 ± 
4 mL/min/1.73m²) were included by nephrologist in 2009-10 (Moranne et al 2012). At 
baseline, we recorded social and clinical characteristics, laboratory test and medications. 
Information about death or dialysis status is available for all patients after 4 years follow-
up. Prognosis factors for dialysis start or death before dialysis were quantified with 
subdistribution hazard ratios using proportional hazard regression models constructed 
according to Fine and Gray to take account competiting risks.
Results: After 4 yrs follow-up, 274 patients (48%) started dialysis and 223 (39%) died. 
Compared to patient still alive without dialysis, the variables independently associated 
with higher risk of death prior to dialysis are: higher age, male, diabetes, lower eGFR, 
behavioural disorder, less mobility, cerebrovascular disease, cardiac heart failure, active 
malignancy and anemia. The variables associated to higher probability of dialysis start are: 
lower age, male, lower eGFR, high blood pressure, hyperphosphatemia, higher proteinuria, 
chronic respiratory disease, cerebrovascular disease and less behavioural disorder or active 
malignancy.
Conclusions: We observed a higher probability of dialysis start than death before 
dialysis in this population of elderlies included by nephrologists. We identified specific 
prognosis factors that could discriminate the risk of starting dialysis or died before dialysis 
to help organisation of the CKD 5 care in elderly patients.
Funding: Pharmaceutical Company Support - roche baxter amgen freseinus msd shire
SA-PO756
Ageing and Decreased GFR: A 1,249,388 Elderly Population-Based Study 
Regina C.R.M. Abdulkader,1 Emmanuel A. Burdmann,1 Yeda Aparecida Oliveira 
Duarte,2 Maria Lucia Lebrao,2 Dirce M.T. Zanetta.2  1Div of Nephrology, Univ 
of Sao Paulo Medical School, Sao Paulo, SP, Brazil; 2Epidemiology, School of 
Public Health of the Univ of Sao Paulo, Sao Paulo, SP, Brazil.
Background: GFR decreases with ageing and so a low GFR in old people might occur 
due to a physiologic process instead of being a mark of disease. However, comorbidities 
can superimpose on this process, and reduce GFR by a pathologic course. This study aims 
to assess the frequency of isolated low GFR without coincident diseases in a geriatric 
population in a developing country megalopolis.
Methods: A multistage cluster sampling (1,353 inhabitants) was used in order to obtain 
a sample representative of the elderly population of São Paulo megalopolis (1,249,388 
inhabitants aged ≥60 years). Participants answered a survey on socio-demographic factors 
and health and had urine and blood samples collected. GFR < 60 ml/min/1.73m2 (estimated 
by the abbreviated MDRD equation) was defined as low and presence of hematuria or 
proteinuria as kidney damage. Data are presented as weighted proportion or means and 
standard errors. Comparisons were made by chi-square with Rao-Scott correction or t-test.
Results: Individuals with GFR < 60 (19.8%) were older (75 ± 1 vs. 69 ± 1 y, p<0.001), 
had lower education level, more hypertension, diabetes and cardio-vascular disease and 
more kidney damage (35% vs 15%, p<0.001), when compared with the group with GFR 
≥ 60. In the low GFR group only 25% of the individuals had no simultaneous diseases 
and no kidney damage.
Conclusions: Low GFR was associated with kidney damage and/or coincident chronic 
diseases that might affect the kidneys in this population. These data strongly suggest that 
in this group of geriatric individuals low GFR is indicative of renal disease. Funding: 
Government Support - Non-U.S (FAPESP, Ministério da Saúde, Brasil).
Funding: Government Support - Non-U.S.
SA-PO757
Indoxyl Sulfate, a Representative Uremic Toxin, Suppresses Myogenic 
Differentiation: Implication in Uremic Sarcopenia  Chih-Kang Chiang,1,2 
Un Iong Ao,1 Yuan-Siao Chen,1,2 Shing-Hwa Liu.1  1Inst of Toxicology, College 
of Medicine, National Taiwan Univ, Taipei, Taiwan; 2Depts of Integrated 
Diagnostics and Therapeutics and Internal Medicine, College of Medicine, 
National Taiwan Univ, Taipei, Taiwan.
Background: Sarcopenia (or muscle wasting) is a common feature of the uremic 
phenotype and predisposes this vulnerable patient population to increased risk of comorbid 
complications, poor quality of life, frailty and premature death. Accumulation of uremic 
toxin would be the most significant difference between health and uremic subjects. We 
hypothesized that indoxyl sulfate (IS), a representative protein-bound uremic toxin, might 
disturb skeletal myotube differentiation and contribute to sarcopenia in uremic patients.
Methods: The mouse myoblast cell line C2C12 was applied to evaluate myotube 
differentiation and signaling. Cell viability evaluated by MTT assay. Cell morphology was 
observed by microscope. Hematoxylin and eosin staining morphologically analyzed the 
multinucleated myotube formation. The expressions of myogenic differentiation markers 
and related signaling proteins were determined by Western blotting.
Results: We first investigated the non-lethal concentration of IS by MTT assay, 
and found IS level less than 1mM without significant cellular toxicity as compared with 
control group. In order to development the protocol, we confirmed myotubes were visibly 
formed throughout 4 days of differentiation first. IS significantly attenuated the number 
of myotubes and the percentage of mature myotubes. Furthermore, IS significantly and 
dose-dependently decreased the expression of MyoD, Myogenin and myosin heavy 
chain, which is the representative markers of slow and fast myofiber phenotype, both in 
translational and transcriptional level. The molecular signals of myotube differentiation 
were also disturbed by IS treatment.
Conclusions: These findings suggest that IS, a uremic toxin, dysregulates myotube 
differentiation in C2C12 cells. This is the first time to provide additional evidence that 
IS might contribute to the development of sarcopenia in uremic patients. Further explore 
wound give the light to provide potential therapeutics in uremic sarcopenia.
Funding: Other NIH Support - MOST in Taiwan
SA-PO758
Attitudes, Experiences and Perspectives of Elderly Kidney Transplant 
Recipients: Thematic Synthesis of Qualitative Research  Jule Pinter,1 Camilla 
Sara Hanson,1 Jonathan C. Craig,1 Jeremy R. Chapman,1 Klemens Budde,2 
Fabian Halleck,2 Allison Tong.1  1Univ of Sydney; 2Charité - Universitätsmedizin 
Berlin.
Background: Kidney transplantation offers improved survival and quality of life 
in an increasing number of elderly patients with end-stage kidney disease. However, 
elderly kidney transplant recipients may face unique challenges due to a higher burden 
of comorbidity, greater cumulative risk of immunosuppression-related complications, 
and increasing frailty. We aimed to describe the perspectives of elderly kidney transplant 
recipients.
Methods: Electronic databases were searched to April 2015. Thematic synthesis was 
used to analyze the findings.
Results: 41 studies involving more than 120 kidney transplant recipients aged 60 yrs 
and over were included (29 studies did not specify number of patients aged ≥ 60 yrs). We 
identified 6 themes. Regaining strength and vitality meant valuing the marked physical 
and psychosocial improvements in daily functioning and life participation. Extending life 
was the willingness to accept an organ, including an extended criteria kidney, to prolong 
survival. Debt of gratitude entailed a need to be consciously appreciative towards their 
donor whilst knowing they were unable to repay their sacrifice. Moral responsibility of 
maintaining health motivated adherence to medication and lifestyle recommendations 
out of an ethical duty to protect their gift and prolong graft survival. Disillusionment with 
transplant reflected disappointment and exasperation at having to contend with side effects 
and adverse events such as cancer, and residual physical limitations. Finality of treatment 
option reflected an acute awareness that their current transplant may be their last and some 
would not return to dialysis if the transplant failed.
Conclusions: Kidney transplantation reverses deterioration of functioning and well-
being that patients experienced whilst on dialysis. However, elderly transplant recipients 
may have anxieties about debilitating adverse events, comorbidities, and a sense of 
vulnerability that the current transplant may be their last. Addressing these concerns in 
the care of elderly kidney transplant recipients may improve treatment outcomes in this 
growing population.
SA-PO759
New Perspectives on the Evolution of Quality of Life and Depression Among 
Hemodialysis Patients  Christiane Hegedus Karam, Nadia Guimaraes-Souza, 
Adriano Luiz Ammirati, Maria C.C. Andreoli, Thais Nemoto Matsui, Fabiana 
Dias Carneiro, Rosana Cardoso, Ana Merzel Kernkraut, Bento C. Santos. 
Nephrology, Hospital Albert Einstein, São Paulo, Brazil.
Background: Hemodialysis is the most common treatment for patients with chronic 
kidney disease. Five to 22% of those also have a psychiatric condition. The objective of 
this study was to evaluate the quality of live perception and depression symptoms in three 
groups of age (<65, 65-75, e >65 y.o.).
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Methods: This was a retrospective observational study. Clinical and social demographic 
data were collected from clinical records. The Kidney Disease Quality of Life and Beck 
depression inventory were used to assess quality of life and depression symptoms.
Results: 104 patients were included. 68.3% were man, 71.2% married, 91.3% 
Caucasian and 44.2% were in productive life period. A relation between quality of life-
score and time in dialysis was observed (p=0.0118, CI -0.0023; 0.0003). Patients younger 
than 65 y.o. showed more favorable results, such as general health perceptions, emotional 
well-being, energy/fatigue, pain and dialysis staff encouragement. Patients between 65 to 
75 y.o. showed lower energy/fatigue index (11.98; CI -22.93; -1.02) and a reduction of 
18.97-points (IC -33.97; -3.98) for emotional well-being. A 15.04-point (CI -27.21; -2.87) 
and a 14.78-point (-26.46; -3.10) reduction, for patients between 65-75 y.o. and for older 
than 75 years, respectively, was observed in physical function. Burden of kidney disease 
had a reduction of 13.29 (-25.40; -1.18) and sexual function reduced 69% (27%; 87%) in 
65-75 y.o. patients. Patients older than 75 years had a significant increase in quality of social 
interaction (17%; CI: 1%;36%) and an increase of 16% (CI 3% -30%) in social support. 
Depression correlated with time in hemodialysis (p = 0.0007; CI 0.14%; 0.55%). For each 
month an increase of 0.35% on depression symptoms was found.
Conclusions: For patients younger than 65 years hemodialysis treatment represents a 
rehabilitation possibility. Patients over 75 years had significant increase on social support 
and social interaction. Patients 65 to 75 y.o. had worse perception of quality of life.
SA-PO760
Fibroblast Growth Factor 23 and the Risk of Infection-Related 
Hospitalization in Older Adults: The Cardiovascular Health Study 
Kristen L. Nowak,1 Traci M. Bartz,2 Lorien S. Dalrymple,3 Joachim H. Ix,4 Ian 
H. De Boer,2 Bryan R. Kestenbaum,2 Michael Shlipak,5 Pranav S. Garimella,6 
Michel Chonchol.1  1Univ of Colorado Denver; 2Univ of Washington; 3Univ 
of California Davis; 4Univ of California San Diego; 5Univ of California San 
Francisco; 6Tufts Medical Center.
Background: Fibroblast growth factor 23 (FGF23) may inhibit 25-hydroxyvitamin-
D-1α-hydroxylase (CYP27B1) in monocytes. We hypothesized that higher circulating 
FGF23 would lead to an increase in serious infection risk because FGF23 decreases the 
intracrine production of 1,25-dihydroxyvitamin D (1,25(OH)2D), which consequently 
reduces production of cathelicidins.
Methods: Plasma C-terminal FGF23 concentrations were measured in 3141 
Cardiovascular Health Study participants. Cox proportional-hazards models were used to 
examine the association between FGF23 levels and the first infection-related hospitalization 
(multivariable models adjusted for demographics, co-existing illnesses, body mass index, 
tobacco use, albumin, estimated glomerular filtration rate, urine albumin creatinine ratio, 
C-reactive protein, and IL-6). We tested whether associations differed by the presence of 
chronic kidney disease (CKD) (eGFR; >60 [n=2309] or ≤60 ml/min/1.73m2 [n=832]).
Results: Participants were 78±5 years, 60% females, and the median serum FGF23 
level was 70 [IQR 53, 99] pg/mL. During a median follow-up of 15.7 years, 1162 (37%) 
had an infection-related hospitalization. In the adjusted models, participants in the highest 
quartile of FG23 (compared to the lowest) had a higher risk of infection (hazard ratio [HR] 
1.33; 95% confidence interval [95% CI], 1.10-1.60). The association was stronger for those 
participants with CKD (HR 1.27; 95% CI 1.11-1.46 per doubling of FGF23) than in those 
without CKD (HR 1.07; 95% CI 0.98-1.17 per doubling of FGF23; p-value for interaction: 
0.06).  The addition of serum calcium, phosphorus, vitamin D and PTH into the statistical 
models did not attenuate these associations.
Conclusions: In ambulatory elders, higher serum FGF23 levels were independently 
associated with the risk of first infection-related hospitalization. This association appeared 
stronger in the setting of CKD.
SA-PO761
Characteristic of the Elderly Patients in the Chronic Renal Insufficiency 
Standards Implementation Study (CRISIS) Cohort Compared to Their 
Younger Cohort A Descriptive Analysis  Maharajan Raman, Darren Green, 
James Ritchie, Thilini Nishani Abeygunaratne, Smeeta Sinha, Philip A. Kalra. 
Renal Medicine, Salford Royal NHS Foundation Trust, Salford, Manchester, 
United Kingdom.
Background: CKD in the Elderly is associated with high mortality and slower rate of 
progression to ESRD. Identifying the characteristics of this phenotype and modifying their 
risk may reduce the burden of death but this can be challenging due to the heterogeneity 
of the disease in this group.
Methods: The CRISIS cohort of 2706 participants was divided into four groups based 
on their age. Descriptive statistical analysis was performed using SPSS and in between 
group significance was calculated using one way ANOVA or Chi-Square test.
Results: Essential characteristics of the cohort are shown in the table below. 
<55years 55- <65years
65- 
<75years >75years P value
Number 644 507 823 732
Age*(years)
Male(%)
Current Smoker(%)
43.2± 8.9
56.4
19.7
60.5± 2.8
63.9
15
70± 2.8
64
12.2
80.2± 3.7
64.5
5.2
0.000
-
-
Systolic Blood 
Pressure* 131.6± 22.9 138.2± 22.4 141.2± 23.6
141.59± 
25.7 0.000
eGFR(ml/min/1.73m2)*
Urine PCR(mg/mmol)*
35.9± 19.0
119.4± 
201.5
34± 17.7
89.8± 189.4
32± 16.4
70.3± 147
28.7± 13.2
55.7± 113.8
0.000
0.000
Primary Renal 
Disease(%)
Hypertension
ARVD
Diabetes
Obstructive Uropathy
Glomerulonephritis
Pyelonephritis
APKD
Other
Unknown
5.3
3
14.8
0.8
25.8
12
12.6
17.4
8.2
10.1
7.5
20.1
1.4
20.7
4.7
5.1
17.9
12.4
14.1
14.8
19.9
1.3
12.4
4
2.6
15.9
14.8
19.9
21
13.3
2
7.5
2.9
1.1
11.7
20.5
Medications(%)
1. RAS Blockade
Dual
Single
None
2. Beta Blocker
3. Calcium Channel 
Blocker
4. Statin
5. No Blood Thinners
9.6
61
27
31.8
45
44.6
71.4
9.5
54.6
34.7
36.5
56.4
62.1
52.5
4.9
57.1
37.7 
42.3
56.5
70.2
41.2
3.4
50
45.6
40
54.2
61.6
32.9
Renal Replacement 
Therapy(%) 32.1 20.8 14.3 6.6 0.000
Death(%) 11.1 21.8 42.2 52.5 0.000
Co-Morbidity(%)
>1 Vascular co-
morbidity
>1 Non-Vascular co-
morbidity
Diabetes
3.3
2.8
19.2
12.2
7
37.2
19.8
5.5
39
22.6
7.7
33.2
0.000
0.001
0.000
*mean±SD
Conclusions: The group aged >75 years had the highest incidence of death and 
accumulation of co-morbidities . We aim to develop a risk prediction model to identify the 
characteristics of this phenotype, which may help in modifying their risk.
SA-PO762
Muscle Strength Rather Than Muscle Mass Is More Important in 
Evaluating Physical Function in Elderly Patients with Predialysis 
Chronic Kidney Disease  Yasuhiro Taki,1 Koji Hiraki,2 Keita Uehara,1 Hiroo 
Kawarazaki,1 Tsutomu Sakurada,1 Yugo Shibagaki.1  1Dept of Nephrology and 
Hypertension, St. Marianna School of Medicine, Kawasaki, Kanagawa, Japan; 
2Dept of Rehabilitation Medicine, St. Marianna School of Medicine, Kawasaki, 
Kanagawa, Japan.
Background: Recently, physical function has been reported to be strongly associated 
with prognosis of patients with chronic kidney disease (CKD). Sarcopenia is well described 
in CKD patients on dialysis especially of the elderly and is known to be associated with 
reduced physical function, but whether this is the case in elderly predialysis CKD is 
undetermined.
Methods: We enrolled consecutive 85 elderly patients (age over 60) with predialysis 
CKD (estimated GFR:eGFR < 60 ml/min/1.73m2)in outpatient nephrology clinic at St 
Marianna University Hospital. We evaluated kidney functional parameters, muscle mass by 
bioimpedance, muscle strength by dynamometer (hand grip, knee extension) and 4-meter 
walking speed in these participants.
Results: Average age was 74 years old, 76% were men, 33% had diabetes mellitus 
(DM) and average eGFR was 28.6ml/min/1.73m2. Patients were divided into those with 
eGFR<30 or >30. After adjustment for age, gender and history of DM, hand grip strength 
(–4.36, 95%CI;-0.85~-7.85), knee extension strength (-5.62, 95%CI;-2.28~-8.97) and 
4-meter walking speed (-0.12, 95%CI;-0.02~-0.22) were significantly reduced in those with 
eGFR<30. However, there was no difference in muscle mass (-0.23, 95%CI;-0.68~0.23).
Conclusions: In conclusion, muscle strength and walking speed but not muscle mass 
declined along with progression of CKD. Thus, it seemed more important to check muscle 
strength and walking speed rather than muscle mass when evaluating physical function in 
elderly patients with predialysis CKD.
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SA-PO763
Lower Muscle Endurance, Strength and Quality Are Associated with 
Greater Risk of Functional Limitations in Older Adults with CKD 
Baback Roshanravan,1 Kushang V. Patel,3 Linda F. Fried,2 Ian H. De Boer,1 
Cassianne Robinson-Cohen,1 Anne B. Newman,2 Bryan R. Kestenbaum.1 
1Medicine/Nephrology, Kidney Research Inst - Univ Washington, Seattle, WA; 
2Univ of Pittsburgh, Pittsburgh, PA; 3Univ of Washington, Seattle, WA.
Background: Chronic kidney disease is associated with inflammation and insulin 
resistance contributing to fatigue and muscle weakness. The association of muscle 
endurance, strength, and quality with functional limitation among persons with CKD is 
unknown.
Methods: We studied 186 participants with eGFRcys<60 at the year 3 Health ABC 
visit. Participants were excluded if unable to complete >90% of quadriceps isokinetic fatigue 
testing. Quadriceps endurance was defined by total work using isokinetic dynamometer. 
Quadriceps strength was measuring by isometric torque. Leg lean mass (leglm) was 
measured using DXA. Muscle quality was defined by specific work (work/leglm) and 
specific torque (torque/leglm). Outcome was incident persistent severe lower extremity 
limitation (PSLL) based on 2 consecutive reports of having a lot of difficulty or inability 
to walk 1/4 mile or climb 10 steps without resting. We used competing risks regression.
Results: Participants had a mean age 76.2 ±3yrs, eGFRcys of 49.2 ±10. None had 
mobility disability. There were 82 PSLL events over a median 6 years. After adjustment 
each 1-SD lower quadriceps isokinetic work and isometric maximal torque were associated 
with a 1.38 fold (95% CI 1.04, 1.85, P=0.028) and 1.43 fold (95% CI 1.01, 2.03 P=0.045) 
greater risk of PSLL, respectively. Leg lean mass was not associated with PSLL (P=0.12). 
Unadjusted SHR Adjusted SHR
Isokinetic Work (Joules) 1.26 (0.99, 1.61) 1.38 (1.04, 1.85)*
Specific work (Joules/kg) 1.32 (1.06, 1.64)* 1.38 (1.09, 1.76)+
Isometric Torque (N*m) 1.37 (1.04, 1.79)* 1.43 (1.01, 2.03)*
Specific Torque (N*m/kg) 1.46 (1.10, 1.94)+ 1.42 (1.04, 1.93)*
Per 1-SD difference
Adjusted for demographics, comorbidity, activity, cognitive function, statins & bicarbonate, ±leg 
lean mass
*P<0.05, +P<0.01
Conclusions: Among older adults with CKD free of mobility disability, lower muscle 
endurance, strength, and quality are independently associated with greater risk of severe 
lower extremity limitation.
Funding: NIDDK Support, Other NIH Support - NIDDK K23DK099442
Health ABC study funded by NIA
SA-PO764
Efficacy and Safety of Exercise Training in Patients with Predialysis Chronic 
Kidney Disease  Yugo Shibagaki,1 Koji Hiraki,2 Takashi Yasuda,1 Kenjiro 
Kimura.1  1Div of Nephrology and Hypertension, St. Marianna Univ; 2Div of 
Rehabilitation, St. Marianna Univ.
Background: Efficacy and safety of exercise training has not been well studied in 
patients with predialysis chronic kidney disease (CKD). Since we have reported in elderly 
patients with predialysis CKD that there was a significant reduction in muscle strength and 
short-term exercise did not damage kidney, we conducted a randomized controlled trial to 
elucidate the long-term efficacy and safety of exercise in this population.
Methods: Study design was a randomized controlled trial. Thirty six male elderly 
patients with CKD stage 3-4 seen at the outpatient nephrology clinic at St. Marianna 
University Hospital agreed to participate in the study with written informed consent. We 
randomly divided them into intervention (I) group and control (C) group. Patients with I 
group were adised to walk fast for 30 minutes a day or 10,000 foot steps a day and was 
trained to do muscle training for upper/lower extremities at every clinic visit for 12 months. 
Patients with C group did not received exercise advice. Both groups received conventional 
drug therapy for CKD and were checked the daily foot steps by pedometer. Primary outcome 
was the change in estimated glomerular filtration rate (eGFR) and secondary outcomes 
were the changes in muscle strengths by dynamometer (hand grip and knee extension).
Results: There were no difference in baseline characteristics (demographic, kidney 
functional parameter, hemoglobin and serum albumin level) with average age of 68.7±6.8 
years and eGFR of 39.0±11.6 ml/min/1.73m2. Change in eGFR were not different at 12 
months among both groups . Muscle strength in knee extension increased in I group 
(0.65±0.17kgf to 0.70±0.17kgf in knee extension) but not in C group (0.66±0.15 to 
0.62±0.13kgf) (0.65±0.17kgf to 0.70±0.17kgf in knee extension) but not in C group 
(0.66±0.15 to 0.62±0.13kgf), which showed statistically significant difference. Change in 
muscle strength in hand grip also showed the difference between the groups.
Conclusions: Only the advise on exercise training could increase the physical activity 
and muscle strength without compromising kidney function in the elderly patients with 
predialysis CKD.
SA-PO765
Determinants of Impaired Cardiorespiratory Fitness in Older Adults with 
CKD  Stephen L. Seliger,1,2 Jamie Giffuni,2 Roger A. Fielding,3 Eamon F. 
Fleming,3 Christine Liu,4,6 Leslie I. Katzel,1,2 Kieran Reid,3 Sushrut S. Waikar,5 
Andrew M. Well,6 Daniel E. Weiner.3  1Medicine, U Maryland Sch of Medicine; 
2GRECC, VA Maryland Healthcare System; 3Tufts Univ Sch of Medicine; 
4Boston Univ Sch of Medicine; 5Brigham and Women’s Hospital; 6Emory Univ 
School of Medicine.
Background: Chronic Kidney Disease (CKD) may be associated with impaired 
cardiorespiratory fitness (CRF). We examined methods of estimating CRF in CKD and 
identified factors associated with CRF.
Methods: We measured peak aerobic capacity (VO2peak) using a modified Graded 
Exercise Treadmill Test (GXT) in 71 older adults with CKD stage 3b-4 in an ongoing 
exercise clinical trial. GFR was estimated with the CKD-Epi equation. Linear regression 
was used to examine factors associated with VO2peak. Resting VO2 was measured prior 
to GXT in seated position. Metabolic Equivalents of Task (MET, oxygen consumption 
during exercise relative to rest) was estimated at peak exercise based on GXT stage and 
compared to actual achieved METS.
Results: Mean age was 68.4±7.7 years, with 61% African-Americans, 30% women; 
mean eGFR was 33±11 ml/min/1.73m2 and mean Hb 12.3±1.6 g/dL. Mean VO2peak was 
17.4±5.4 ml/kg/min, which was 31±17% lower than expected based on normative values 
(p<0.001). In a multivariate model including demographics and co-morbidity, lower 
hemoglobin - but not GFR - was associated with lower VO2peak (Table). Albuminuria did 
not correlate with VO2peak.
Covariate Standardized β p-value
Age -0.25 0.005
African-American 0.08 0.3
Male 0.41 <.001
Diabetes 0.01 0.9
Cardiac Disease -0.25 .002
Body Mass Index -0.47 <.001
GFR 0.09 0.3
Hemoglobin 0.19 0.025
Estimated METS: Mean achieved METS was 5.6±1.8. Although there was low bias 
for estimated vs. achieved METs (mean difference, -0.45), precision and accuracy were 
poor, with only 35% of predicted values within 1 MET of achieved values, and nearly one 
third of estimated values >30% different from achieved.
Conclusions: Among older adults with CKD stage, CRF as reflected by VO2peak is 
markedly impaired. Lower hemoglobin, obesity, and prevalent cardiac disease are associated 
with worse aerobic capacity. The use of estimated METS during treadmill testing poorly 
estimates actual aerobic capacity.
Funding: NIDDK Support, Veterans Administration Support
SA-PO766
Access to Kidney Transplantation and Outcomes of Those Listed for Kidney 
Transplant in Elderly  Pritika Shrivastava, Ankit Sakhuja, Diane M. Cibrik, 
Abhijit S. Naik.  Div of Transplant Nephrology, U Michigan, Ann Arbor, MI.
Background: Data suggests that patients above 70 years of age (>70 y.o.) with ESRD 
derive a benefit from kidney transplant (KT). We report our single center experience of 
access to transplant and outcomes for those >70 y.o. listed for KT. We used the number 
of evaluations in a year and rate of acceptance after evaluation as surrogate markers for 
KT access in elderly.
Methods: We assessed the rate of acceptance for KT and its trends over the years for 
those >70 y. o. between 2000-2014. Linear regression was used to assess trends over time. 
Differences in rates of listing stratified by diabetes status, KT rates among those approved for 
listing by diabetes status and mortality among those transplanted vs waitlisted was assessed.
Results: Over 15 year period, we evaluated 612 elderly patients (pts). 25.3% of 
those evaluated were approved to be listed for transplant. There were 9 patients who 
were evaluated twice of those 5 were approved for listing the second time and two got 
transplanted. There was 300% increase in annual evaluation of the elderly from year 2000 to 
2014 and trend towards increased acceptance rate of those evaluated (slope=+0.82, p=0.12). 
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The acceptance rate was lower in diabetics compared to non-diabetics (18.2% vs 
32.0%; p=0.001). 38.0% of listed pts have been transplanted and the rate of transplant did 
not differ by diabetes status. Of those transplanted 59.3% had living donors. Mortality 
among those transplanted was 64.4% in comparison to 87.3% of those waitlisted (p=0.001).
Conclusions: Only a fourth of those >70 evaluated for KT were accepted for listing, 
though there has been some improvement in the acceptance rate for listing over time. 
Acceptance rate was significantly lower among elderly diabetics. Mortality though improved 
remained significantly high for transplant vs waitlisted patients.
SA-PO767
P-Cystatin C Improves GFR Estimation in Older People  Karin Werner,1 
Anders G. Christensson,2 Mats Pihlsgård,1 Sölve Elmståhl.1  1Dept of Geriatrics, 
Lund Univ, Malmo, Sweden; 2Dept of Nephrology and Transplantation, Lund 
Univ, Malmo, Sweden.
Background: There is a need for validation of commonly used cystatin C and creatinine 
based formulas for eGFR (estimated glomerular filtration rate) in the older segment of the 
general population for all levels of kidney function.
Methods: Markers used for eGFR estimation were P-Cystatin C and P-Creatinine. 
Measured GFR (mGFR) adjusted to body surface area was performed by a single sample 
iohexol clearance in 112 participants, aged 70-100 years old from the population-based 
cohort “Good Aging in Skåne”. The participants were selected to cover a wide range of 
kidney function and to obtain an even distribution regarding sex and age. The timing of the 
sample depended on eGFR (eGFR >50, 25-50, and >25 at 4, 7, and 24 hours respectively). 
Formulas using both markers (CKD EPI combined, Lund-Malmo combined, BIS2), only 
creatinine (CKD EPI creatinine, MDRD) and only cystatin C (CKD EPI cystatin C) were 
compared. The analysis included bias (median difference: mGFR-eGFR), precision (IQR: 
interquartile range of the differences), accuracy (P30: percentage of estimates ±30% of 
mGFR) as well as accuracy (P30) above and below mGFR 45.
Results: There were 57 women and 55 men. Mean age was 82 years and mean GFR 
55 ml/min per 1.73m2. Results are presented in the table. 
eGFR CKD-EPI comb
Lund-
Malmo BIS2
CKD-EPI 
creatinine MDRD
CKD-EPI 
cystatin C
Median difference 
(ml/min per 
1.73m2)
3.3 4.2 6.1 -0.5 2.9 6.1
IQR (ml/min per 
1.73m2) 7.9 8.4 12.6 10.5 11.6 8.8
% P30 96 95 94 86 84 93
% P30 mGFR>45 99 96 93 92 91 92
% P30 mGFR<45 92 92 95 73 70 95
Conclusions: All the formulas that include cystatin C performed well in this Swedish 
cohort with a mean age above 80. This confirms that it is safe to use either of those formulas 
in our older patients across a wide spectrum of kidney function. However, the formulas 
based solely on creatinine are not reliable enough below GFR 45. Further sub-analysis can 
demonstrate detailed performance for males and females respectively, for all CKD-stages 
and for smaller age-intervals.
Funding: Government Support - Non-U.S.
SA-PO768
Factors Associated with Early Death After Dialysis Initiation Among Elderly 
CKD Patients  Fahad Saeed, Susana Arrigain, Jesse D. Schold, Joseph V. Nally, 
Sankar D. Navaneethan.  Nephrology, Cleveland Clinic.
Background: There are limited studies examining prognosis for elderly CKD patients 
following dialysis initiation. Herein, we evaluated the factors associated with poor one year 
survival after dialysis initiation among elderly CKD patients at our institution.
Methods: We studied 621 CKD patients≥65 years from an EMR based CKD registry 
linked to the USRDS data. We retrospectively analyzed factors associated with one year 
mortality after dialysis initiation including: age, sex, race, presence of diabetes, hypertension, 
BMI, stroke, CHF, COPD, malignancy, peripheral vascular disease , depression, alcohol 
use, smoking, presence of AVF, pre-dialysis serum albumin and potassium.
Results: In our study, 224 (36%) patients died within the first year of dialysis initiation. 
Results from the Cox proportional model showed that older age and CHF were associated 
with early deaths, while higher albumin, presence of AVF and HTN were associated with 
a lower hazard of early death.
Conclusions: CHF and older age in the pre-dialysis setting are associated with higher 
1-year mortality after dialysis initiation. These prognostic data need to be presented to 
geriatric CKD patients while discussing renal replacement therapy options. 
Table. Multivariable Cox model of 1 year mortality among elderly CKD patients
Parameter Hazard Ratio (95%CI)
Age per 1 year increase 1.05 (1.03, 1.07)
Male sex vs. female 1.16 (0.87, 1.55)
African American vs. not 0.82 (0.58, 1.16)
Smoke
no Ref
Yes 1.15 (0.64, 2.07)
Missing 1.26 (0.67, 2.36)
BMI
<18.5 kg/m2 2.22 (0.85, 5.76)
18.5-25 kg/m2 Ref
25-29.9 kg/m2 0.74 (0.52, 1.06)
30+ kg/m2 0.87 (0.60, 1.27)
Missing BMI 0.44 (0.22, 0.88)
Diabetes mellitus 1.18 (0.86, 1.63)
Hypertension 0.71 (0.45, 1.11)
Cerebrovascular disease 0.96 (0.64, 1.42)
COPD 0.82 (0.44, 1.53)
CHF 1.76 (1.27, 2.45)
CAD 1.00 (0.72, 1.39)
Malignancy 1.20 (0.86, 1.67)
PVD 0.65 (0.32, 1.29)
Alcohol use
No Ref
Yes 0.73 (0.52, 1.04)
Missing 0.98 (0.57, 1.69)
Depression 0.69 (0.37, 1.30)
Albumin (g/dl) per 1 unit increase 0.75 (0.59, 0.96)
Potassium (meq/l) per 1 unit increase 0.92 (0.74, 1.13)
AVF access
No AVF Ref
AVF present 0.35 (0.20, 0.61)
Missing 0.72 (0.45, 1.16)
SA-PO769
Differential Significance of Prognostic Factors for 6-Month and 3-Year 
Mortality in Elderly Patients on Hemodialysis  Koji Harada,1 Azusa 
Izumiya,1 Tomohiro Kawamura,1 Juri Tsukahara,1 Koichi Sumida,1 Yukinari 
Yamaguchi,1 Yasuhiro Akai.2  1Dept of Nephrology, Rakuwakai-Otowa Hospital, 
Yamashina, Kyoto, Japan; 2Center for Postgraduate Training, Nara Medical 
Univ, Kashihara, Nara, Japan.
Background: As the population of elderly people has been growing, the number 
of older chronic kidney disease patients commencing renal replacement therapy (RRT) 
is increasing. The survival advantage of RRT may be counterbalanced by the burden of 
treatment and its negative effect on quality of life in the elderly, and old age is no longer 
seen as a contraindication to RRT. Therefore, it is important to evaluate survival factors in 
this population. We conducted this study to investigate prognostic factors for mortality in 
elderly patients starting hemodialysis (HD) for end-stage renal disease (ESRD).
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Methods: This is a single-center, retrospective cohort study from January 2009 to 
December 2014. In total, 90 ESRD patients commencing HD were enrolled. All the patients 
were aged 65 years or older. Six-month and 3-year survival rates and prognostic factors 
for mortality were evaluated.
Results: The mean follow-up period was 21.7±18.3 months. The 6-month and 3-year 
survival rate were 94.0% and 66.9%, respectively. Age, unplanned initiation of HD, presence 
of heart failure, high value of estimated GFR on starting HD, Charlson comorbidity index 
(CCI), and Eastern Cooperative Oncology Group Performance Status scale (ECOG-PS) were 
associated with 3-year mortality, whereas only the presence of heart failure and ECOG-PS 
were significant predictors of 6-month mortality. There was no significant difference in 
6-month mortality rate between patients aged ≥ 80 and < 80. On the other hand, 3-year 
mortality rate of ≥ 80 year-old patients was significantly higher than that of < 80 (≥ 80: 
53.3% vs < 80: 14.2%, p = 0.0004).
Conclusions: There is a variation of significance among different prognostic factors 
according to the duration of life after starting hemodialysis. The presence of heart failure 
and ECOG-PS predicted short-term mortality among elderly ESRD patients starting HD. 
These results might help clinical decision making when nephrologists consider commencing 
HD for elderly ESRD patients.
SA-PO770
Cumulative Cardiovascular Polypharmacy Is Associated with the Risk of 
Geriatric Acute Kidney Injury  Chia-Ter Chao,1 Hung-Bin Tsai.2  1Dept of 
Medicine, National Taiwan Univ Hospital Jin-Shan Branch, New Taipei City, 
Taiwan; 2Dept of Traumatology, National Taiwan Univ Hospital, Taipei, Taiwan.
Background: Polypharmacy is common in the elderly due to multiple morbidities. 
However, the effect of polypharmacy on renal outcomes is rarely recognized. We 
investigated the effect of cardiovascular polypharmacy on acute kidney injury (AKI) in 
elderly patients.
Methods: We used the Taiwan National Health Insurance PharmaCloud system to 
investigate the relationship between cumulative cardiovascular medications in the 3 months 
prior to admission and risk of AKI in the elderly at admission to general wards. Community-
dwelling elderly patients (>60 years) were prospectively enrolled and classified according 
to the number of pre-admission cardiovascular medications. Cardiovascular polypharmacy 
was defined as use of 2 or more relevant medications.
Results: We enrolled 152 patients, 48% with AKI (based upon Kidney Disease 
Improving Global Outcomes [KDIGO] classification) and 64% with cardiovascular 
polypharmacy. The incidence of AKI was higher in patients taking more cardiovascular 
medications (0 drugs: 33%; 1 drug: 50%; 2 drugs: 57%; 3 or more: 60%; p = 0.048). 
Patients with higher KDIGO grades also took more cardiovascular medications (p = 0.04).
Multiple regression analysis showed that patients who used 1 or more cardiovascular 
medications had increased risk of AKI at admission (1 drug: odds ratio [OR] = 1.63, p = 0.2; 
2 drugs: OR = 4.74, p = 0.03; 3 or more drugs: OR = 5.92, p = 0.02), and that cardiovascular 
polypharmacy increased the risk of AKI (OR 2.58; p = 0.02). Each additional cardiovascular 
medication increased the risk for AKI by 30%.
Conclusions: We found that elderly patients taking more cardiovascular medications 
had increased risk for adverse renal events. Interventions that reduce polypharmacy may 
be able to reduce the incidence of geriatric AKI.
SA-PO771
Low Bicarbonate Associates with Higher Mortality Independent of pH in 
Healthy Older Individuals: The Health, Aging, and Body Composition Study 
Kalani L. Raphael,1 Rachel A. Murphy,2 Michael Shlipak,3 Suzanne Satterfield,4 
Hunter K. Huston,1 Anthony Sebastian,3 Deborah Sellmeyer,5 Kushang V. Patel,6 
Anne B. Newman,7 Mark J. Sarnak,8 Joachim H. Ix,9 Linda F. Fried.7  1Univ of 
Utah; 2Univ of British Columbia; 3Univ of California San Francisco; 4Univ of 
Tennessee; 5Johns Hopkins Univ; 6Univ of Washington; 7Univ of Pittsburgh; 
8Tufts Medical Center; 9Univ of California San Diego.
Background: Low serum [HCO3-] associates with higher mortality in CKD. The 
purpose of this study is to determine if [HCO3-] associates with all-cause mortality 
independent of systemic pH in healthy older persons.
Methods: Data were analyzed from the Health, Aging, and Body Composition Study, 
an observational study of black and white adults aged 70-79 years followed from 1997-2014. 
Arterialized venous blood gas measurements were obtained in 2,287 individuals. Participants 
were grouped into one of 3 [HCO3-] categories: <23.0 (low), 23.0-27.9 (reference group), 
and ³28.0 mEq/L (high). Mortality hazard ratios (HR) in the low and high [HCO3-] groups 
were compared to the reference group using Cox models adjusted for demographics, eGFR, 
albuminuria, COPD, smoking, and pH. Multiplicative interaction terms tested whether CKD 
status modified the relationship between [HCO3-] categories and mortality.
Results: The mean age was 76 years, 51% were female, and 38% were black. The mean 
pH was 7.41, mean [HCO3-] was 25.1 mEq/L, 11% had low and 10% had high [HCO3-]. 
The mean eGFR was 82.1 ml/min/1.73m2; 12% had CKD. During follow-up (mean 10.3 
years), 1,326 (58%) participants died. The adjusted all-cause mortality HR was 1.24 (95% 
CI, 1.02-1.49) in the low [HCO3-] category and 1.03 (95% CI, 0.84-1.26) in the high [HCO3-
] category compared to the reference group. CKD status did not modify the association 
between [HCO3-] and mortality (p=0.74).
Conclusions: Healthy older persons with low [HCO3-] have higher mortality risk than 
those with normal [HCO3-] independent of pH and potential confounders. High [HCO3-] 
does not associate with higher mortality. The potential health benefits of normalizing low 
[HCO3-] in generally healthy older persons should be investigated.
Funding: Other NIH Support - National Institutes on Aging and National Institute of 
Nursing Research, Veterans Administration Support, Private Foundation Support
SA-PO772
Low Urinary Creatinine Excretion Is a Valid Surrogate for Frailty in 
Patients with Advanced Chronic Kidney Disease  Harmke Polinder-Bos,1 
Hakan Nacak,2 Friedo W. Dekker,2 Stephan J.L. Bakker,1 Carlo A. Gaillard,1 
Ron T. Gansevoort.1  1Internal Medicine, Univ Medical Center Groningen, 
Groningen, Netherlands; 2Epidemiology, Leiden Univ Medical Center, Leiden, 
Netherlands.
Background: Muscle wasting is a key component of frailty, which is highly prevalent in 
advanced stages of chronic kidney disease (CKD). Whether low urinary creatinine excretion 
(UCrE), a marker of low muscle mass, is a valid surrogate for frailty in this population 
is unknown. We studied cross-sectional associations between frailty and a low UCrE in 
patients with CKD stages 4 and 5 (not on dialysis).
Methods: 2748 healthy individuals of the general population were included to define 
low UCrE. Low UCrE was defined as height-indexed UCrE below the age- and sex-
specific 5th percentile. In a CKD population including 320 and 967 participants of the resp. 
PREPARE-2 and NECOSAD studies, associations of frailty, the individual components 
that define frailty, and frailty-associated variables with low UCrE were evaluated using 
multivariate logistic and linear regression models. Frailty was defined as a composite 
construct including self-reported poor physical functioning, exhaustion, low physical 
activity, and underweight.
Results: In the general population with a median age of 46 years, median UCrE was 
9.8 mmol/day for women and 14.3 mmol/day for men, compared to 7.0 mmol/day and 
9.5 mmol/day in CKD patients, respectively. In the CKD patients with a median age of 
63 years, low UCrE was found in 38%. Frailty, and the individual components that define 
frailty, were associated with a low UCrE, independent of comorbidities (OR frailty = 2.19 
[1.28-3.77], p=0.005). Of the frailty-associated variables, lower hemoglobin and albumin 
levels, and higher parathyroid hormone levels were associated with low UCrE. Adjustment 
for GFR attenuated the associations of frailty, and the individual components that define 
frailty with low UCrE, except for underweight.
Conclusions: Low UCrE is a valid surrogate for frailty, independent of comorbidities. 
Low UCrE is strongly determined by a lower kidney function, suggesting that reduced 
kidney function induces changes in muscle mass and performance leading to frailty.
SA-PO773
Oral Anticoagulation and Kidney Function in Elderly  Antonios Douros,1 
Elke Schaeffner,2 Olga Jakob,3 Reinhold Kreutz,1 Natalie Ebert.2  1Clinical 
Pharmacolology, Charité; 2Nephrology, Charité; 3Clinical Epidemiology, 
Charité.
Background: In the past years new oral anticoagulants (NOACs) were approved 
expanding our pharmacological arsenal. Data on their utilization in elderly compared to 
vitamin K antagonists (VKA) are scarce and the impact of kidney function (KF) on NOAC 
use in a population with declining glomerular filtration rate (GFR) is of great interest. The 
present study investigates anticoagulant use and KF in people ≥ 70 years.
Methods: Individuals included in the analysis were participants of the Berlin Initiative 
Study (BIS). BIS is a population-based prospective cohort study initiated in 2009 in Berlin, 
Germany, to evaluate KF in people ≥ 70 years. Medication was assessed through personal 
interviews and coded using the Anatomical Therapeutic Chemical Classification System. 
For GFR estimation we used the CKD-EPIcr equation. Predictor analysis was conducted 
via logistic regression.
Results: Figure 1 illustrates the percentage of drug use for the three NOACs and 
phenprocoumon, the most common VKA in Germany, over the course of 4 years. 
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Table 1 shows the characteristics of patients for each oral anticoagulant group during 
the 4-year follow-up visit (01/2014-04/2015). 
Phenprocoumon
(n=153)
Dabigatran
(n=14)
Rivaroxaban
(n=46)
Apixaban
(n=12)
Age mean±SD 
(years) 84±6 87±4 84±5 85±5
Female sex n (%) 62 (41) 4 (29) 24 (52) 9 (75)
eGFRCKD-EPI < 60ml/
min/1.73m2 n (%) 64 (42) 3 (21) 16 (35) 5 (42)
Myocardial 
infarction n (%) 27 (18) 3 (21) 8 (18) 1 (9)
Stroke n (%) 17 (11) 3 (21) 0 (0) 2 (17)
The probability of dabigatran use rose with increasing age (+12%), and the probability of 
phenprocoumon use rose in case of eGFR < 60 ml/min/1.73m2 (+54%) or male sex (+82%).
Conclusions: Our data show that also in the elderly NOAC use increased over the 
past years. Characteristics such as age, sex or KF had an impact on the choice of oral 
anticoagulation.
Funding: Other NIH Support - Kuratorium für Dialyse und Nierentransplantation 
(KfH Foundation of Preventive Medicine)
SA-PO774
Can Morbidity Predict Mortality in Dialysis Patients?  Kathryn Ducharlet,1 
Vijaya Sundararajan,2 Nuala Barker,1 Jodie L. Burchell,2 Robyn G. Langham.1 
1Dept of Nephrology, St. Vincent’s Hospital, Fitzroy, Victoria, Australia; 2Dept 
of Medicine, Melbourne Univ, Fitzroy, Victoria, Australia.
Background: Symptom management and quality of life (QOL) in dialysis patients is 
increasingly important in determining treatment approach and outcome research. This study 
identified symptoms, QOL, functional status in dialysis patients, determining if symptom 
burden had an impact on mortality.
Methods: A single-centre cross-sectional study was undertaken in dialysis patients 
with median follow up time 10 months. Patients completed surveys incorporating POS-S 
renal, WHOQOL-BREF and Karnofsky Performance scale. A Log rank test determined 
the risk of death based on symptom severity.
Results: 112 patients were recruited; 67 hemodialysis, 10 home/nocturnal hemodialysis 
and 35 peritoneal dialysis patients, average age 66 years, 66% male. Patients had high 
symptom burden (median POS-S score 13 (inter-quartile range (IQR 9, 22)) and reduced 
total QOL 4 (IQR 3,4), health satisfaction 3 (IQR 2,4) and performance status 60 (IQR 
50,70). A log rank analysis was performed on 104 POS-S renal responses with 8 deaths 
during the study. A significant impact of pain, shortness of breath, nausea, mouth problems, 
drowsiness, poor mobility and skin changes on survival was found. 
Symptom Number (%) n = 112 Log rank test (Chi
2) n=104
Pain 82 (73%) 10.56*
Shortness of breath 72 (64%) 8.18*
Weakness 98 (88%) 1.62
Nausea 44 (39%) 9.54*
Vomiting 25 (22%) 9.49*
Poor appetite 58 (52%) 3.53
Constipation 62 (55%) 3.06
Mouth problems 38 (34%) 16.29**
Drowsiness 68 (61%) 8.22*
Poor mobility 76 (68%) 12.28*
Itching 70 (63%) 3.95
Difficult sleeping 89 (79%) 9.02
Restless legs 57 (51%) 8.05
Feeling anxious 62 (55%) 6.01
Feeling depressed 52 (46%) 3.13
Diarrhoea 68 (61%) 3.40
Skin Changes 28 (25%) 60.37***
*P<0.05, **P<0.01 ***P<0.001
Conclusions: This study demonstrated high symptom burden, reduced functional status 
and QOL in dialysis patients. Patients with severe pain, weakness, shortness of breath, 
nausea, mouth problems, drowsiness, poor mobility and skin changes were more likely 
associated with higher mortality risk. Symptom identification and management may help 
predict and improve patient QOL outcomes in dialysis patients.
SA-PO775
Outcomes of Cardiopulmonary Resuscitation in Maintenance Dialysis 
Patients Based on CPR Characteristics  Haris Farooq Murad, Fahad Saeed. 
Cleveland Clinic Foundation.
Background: Cardiopulmonary resuscitation (CPR) is associated with high rates of 
mortality, especially in patients with end stage renal disease (ESRD). Previous studies have 
reported an in-hospital mortality rate of up to 75% in ESRD patients undergoing CPR. 
There are no large studies to date on how individual CPR characteristics relate to the long 
term outcomes in these patients. Herein, we aimed to answer this question.
Methods: By an EMR inquiry, we identified all the adult patients (³18years) who 
had underwent CPR from January 2006 to December 2014, and then selected patients 
who were on maintenance dialysis. We conducted a chart review of CPR characteristics 
and its association with the hospital discharge survival. We studied following variables: 
initial rhythm, duration of CPR, in-hospital versus out of hospital CPR and the use of 
hypothermia protocol.
Results: We studied a total of 497 ESRD who had undergone CPR. Sixty eight percent 
of our patients had expired in the hospital post-CPR. Pulseless electrical activity (PEA) was 
the most common initial rhythm (51.4%), followed by ventricular arrhythmias (19.6%) and 
asystole (19.2%). In-hospital mortality was the highest (76.8%) for patients with asystole 
. Mortality rates at the time of discharge were 73.3% for PEA and 57.7% for patients with 
ventricular arrhythmias respectively. Fifty six percent of patients who underwent therapeutic 
hypothermia died in the hospital as compared to 68.9% of those who did not undergo a 
cooling protcol. CPR duration of greater than 10 minutes was associated with higher in-
hospital mortality (76.1%) as compared to patients who had CPR for less than 10 minutes 
(40.9%). Patients who had undergone out of hospital CPR (by paramedics or bystanders), 
72.2% died before discharge; while 68.9% of patients who underwent CPR in the hospital 
expired during the same hospitalization. The average length of stay for patients who were 
alive at discharge was 17 days.
Conclusions: CPR in dialysis patients is associated with high mortality rates.It is 
possible to predict hospital discharge survival of patients with cardio-pulmonary arrest 
based on the CPR characteristics.
SA-PO776
End of Life Care Preferences in Maintenance Dialysis Patients 
Haris Farooq Murad,1 Muhammad Adil Sardar,1 Syed Zamrak Khan,1 Sara 
N. Davison,2 Fahad Saeed.1  1Cleveland Clinic Foundation; 2Univ of Alberta.
Background: Dialysis patients have an annual mortality rate of 20-25%. A previous 
Canadian study comprising mainly of Caucasian patients has shown that patients are 
interested in active involvement in end of life care discussions and majority would want 
to know their prognosis on dialysis. In this Caucasian predominant cohort, approximately 
50% chose to be DNR. It is not known if patients’ preferences on end of life care are any 
different in a racially more diverse cohort of patients in the U.S.
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Methods: We collected data on 423 out of 440 dialysis patients from 7 dialysis facilities 
in the U.S. using self-reported questionnaires.
Results: Our study included 28.1% Caucasian and 66.7% African American patients. 
Eighty three percent of the patients felt that their QOL was an important determinant in 
guiding their future care plans, and 72.3% of patients reported that they need to have 
frequent discussions about their QOL with their nephrologist. Only 35.4% of patients 
actually get information about their health and well-being from their nephrologists. Only 
8.6% of patients had a discussion with any Physician, nurse or social worker regarding 
end of life care during the past 12 months. Notably, 74.2% of our participants reported 
that they would like to have such discussions with their health care providers. Sixty seven 
percent of the patients wished to be full code. Fifty six percent of the patients preferred to 
die at home versus 20.4% wanted to die in a hospice facility and 13.4% in a hospital. Only 
23.6% of patients knew about palliative care.
Conclusions: There is a need to have more dialogue between patients and their 
nephrologists regarding end of life care preferences, and it is necessary to develop policies 
and practices that would help address this need.
SA-PO777
“So I had No Choice”: Perceptions of Dialysis Decision-Making Among 
Older Adults  Keren Ladin,1 Daniel E. Weiner.2  1Occupational Therapy, Tufts 
Univ, Medford, MA; 2Medicine, Tufts Univ Medical School, Boston, MA.
Background: Multiple treatments are available to older patients with advanced chronic 
kidney disease. However, poor communication about available treatment options may result 
in a mismatch between patient preferences and treatment choice.
Methods: Semi-structured in-depth interviews were conducted with a purposive sample 
of 26 dialysis patients aged 65 and older at two dialysis clinics in the Greater Boston area. 
Trained researchers conducted, audiotaped and transcribed interviews. Applying grounded 
theory, interviews were and analyzed in an iterative process to identify emergent codes. 
Codes were discussed using consensus and organized into themes.
Results: Twenty-six patients participated in the interview. Mean age was 77±9 years; 
50% were men, 19% African American and 58% diabetic. Median vintage was 28 (17, 39) 
months. Four major themes with associated subthemes were identified. The first, “Deciding 
to start dialysis” revealed that only two patients conceptualized dialysis initiation as a choice. 
Patients were seldom informed of conservative management, and many had unanswered 
concerns about trade-offs among treatment choices. The second theme, “Experience with 
dialysis”, included positive and negative physical, emotional, and social consequences of 
dialysis and logistics of care. While many reported greater than anticipated levels of pain, 
fatigue, and frustration over transportation costs and time spent, others reported substantial 
benefits, including increased longevity and the ability to achieve life goals. The third theme, 
“Patient Role”, revealed patients tied self-worth to meeting clinical goals. Finally, “End-
of-life (EOL) preferences and conversations” revealed that most patients had not discussed 
EOL with their clinical team and or with loved ones.
Conclusions: Many older patients who treated with dialysis do not perceive that 
they had a choice when making their dialysis decision. Initiating dialysis may contradict 
patients’ EOL preferences, and many desire greater information and more discussions with 
clinicians. Older adults’ preferences and experiences with dialysis vary, underscoring the 
importance of patient involvement in decision-making.
SA-PO778
Improving Advance Care Planning in Elderly Outpatients with Chronic 
Kidney Disease – A Quality Improvement Initiative  Ritu K. Soni,1 Jane O. 
Schell.1,2  1Section of Palliative Care and Medical Ethics, Univ of Pittsburgh 
Medical Center, Pittsburgh, PA; 2Renal-Electrolyte Div, Univ of Pittsburgh 
Medical Center, Pittsburgh, PA.
Background: Despite a high annual mortality rate in patients with advanced chronic 
kidney disease (CKD), advance care planning (ACP) is underutilized. A minority of 
dialysis patients complete advance directives (AD). Timely ACP ensures that patients’ 
preferences for future care are respected and is associated with less intensive care at end 
of life. We sought to introduce ACP and increase documentation of AD in older outpatient 
CKD patients.
Methods: This quality improvement study was conducted over 15 weeks in older 
outpatients at the University of Pittsburgh Kidney Clinic. The intervention included training 
and supporting the CKD nurse educator to introduce and encourage ACP completion. 
Inclusion criteria were age older than 65 years and referral to the CKD education session. 
The CKD nurse educator was assigned the role of asking whether each patient had AD and 
a designated healthcare power of attorney (HPOA). The nurse additionally offered every 
eligible patient the Five Wishes AD form and documented their responses.
Results: Of the 110 patients who underwent CKD education over a period of 15 
weeks, 52 (47.2%) were eligible. Thirty-one of 52 (59.6%) patients already had AD and 
32 of 52 (61.5%) had a HPOA. Thirteen of 52 (25%) were interested in reviewing the Five 
Wishes AD form although 2 of them had already completed an AD. The AD and HPOA 
screening information was documented by the nurse educator in 59.6% and 61.5% patients 
respectively. One patient had an AD scanned in the electronic records and one patient 
requested referral to the Renal Supportive Care clinic for continuation of ACP discussions.
Conclusions: We report a successful nurse educator based quality improvement 
initiative to increase AD documentation in older nephrology outpatients. Our data suggest 
that although many of these patients have previously completed AD, these preferences are 
not documented in the medical chart. A nurse educator based intervention is effective in 
improving documentation rates of AD.
SA-PO779
Trends in Inpatient Intensive Procedures in the Last Six Months of Life 
Among Medicare Beneficiaries Treated with Maintenance Dialysis, 2000-
2011  Nwamaka Denise Eneanya,1 Susan M. Hailpern,2 Ann M. O’Hare,2 
Manjula Kurella Tamura,3 Ronit Katz,2 Yoshio N. Hall.2  1Div of Nephrology, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA; 2Kidney 
Research Inst, Univ of Washington, Seattle, WA; 3Geriatric Research and 
Education Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA.
Background: Many US dialysis patients undergo intensive procedures intended to 
prolong life such as mechanical ventilation, cardiopulmonary resuscitation or feeding tube 
placement at the very end of life. Little is known about trends over time in use of intensive 
procedures in this population.
Methods: We examined temporal trends in receipt of inpatient intensive procedures in 
the last 6 months of life by age and race among 601,942 adult Medicare beneficiaries treated 
with maintenance dialysis who died between January 1, 2000 and December 31, 2011.
Results: From 2000 to 2011, inpatient admissions during the last six months of life 
increased slightly from 89% to 90%. Among those admitted, there was a marked increased 
in the use of intensive procedures ranging from 38% in 2000 to 44% in 2011. Intensive 
procedures at the end of life were more common among black vs. white patients (50% to 
57% vs. 34% to 39%) and among younger vs. older patients (50% to 61% for those < 55 
years vs. 27% to 26% for those 85+ years).
In adjusted analyses, racial differences in receipt of intensive procedures were most 
pronounced at older ages (black vs. white aOR [95% CI]; 1.38 [1.33-1.42] in patients < 
55 years, 2.48 [2.38-2.59] in patients 85+ years).
Conclusions: From 2000 to 2011, a growing number of Medicare beneficiaries treated 
with maintenance dialysis received intensive procedures during the final months of life. 
These procedures were most common and increased most dramatically in younger patients 
while racial differences were most pronounced in older patients.
Funding: NIDDK Support
SA-PO780
Will Nephrologists Implement an Advance Directives Program in Their 
Patients? (Quality Improvement Program)  Ali Mohammed Habeeb, 
Sheldon W. Tobe.  Nephrology, Sunnybrook Health Sciences Centre, Toronto, 
ON, Canada.
Background: Mortality remains high among patients on dialysis. Advanced age and 
multiple co-morbidities are the majors predictors for increasing mortality. ADs extend 
patients’ autonomy and are the best tool to inform about a patient’s preferences for health 
care decisions when they become unable to make such decisions. Chronic dialysis patients 
have been shown to want to discuss ADs in the past.
Methods: We reviewed 215 chronic in-center hemodialysis patients at Sunnybrook 
Health Sciences Centre from March to April 2015 by the dialysis unit social workers for any 
documents related to ADs (like Living wills, Substitute Decision Maker (SDM) and CPR 
forms). Only 2 patients had ADs in their charts (1.0%). When this data has presented to the 
Nephrologists they agreed that ADs should be discussed with their patients and that this was 
a quality improvement issue. Will the staff nephrologists change their practice behaviour 
and begin to ask their hemodialysis patients about ADs and document the discussion?
Results: As part of the process to discuss Ads, the unit’s social workers distributed a 
pamphlet for the patients with simple and explicit definitions and advantages of AD and 
also provided explanations about the contents of the pamphlets. The Staff Nephrologists 
were educated about the importance and advantages of ADs in their patients and were asked 
to start discussing the issues with their patients. The Nephrologists will also be educated 
about how an AD discussion might go and how to document the results of the discussion. 
In 3 months, a review of the patients’ charts will again look for any documented ADs. We 
will also study the response of individual dialysis staff and their participation in completing 
and discussing the ADs. We will assess the potential barriers for not completing ADs by 
the dialysis unit staff and by patients and attempt to address these barriers.
Conclusions: Expected Outcome: Based on the Prochaska model we are anticipating 
the dialysis staff are now in the contemplation stage and we are aiming to observe the 
progression in their behavior to more advanced stages of behavior and try to find out what 
are the barriers that prevent the progression.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
809A
J Am Soc Nephrol 26: 2015 Dialysis: Planning for the End Is a Little Shorter Poster/Saturday
SA-PO781
Current Practice of Advance Care Planning in Australia and New Zealand 
Rachael L. Morton,1 Lucy Spencer,2 Allison Tong,1 Carol A. Pollock,1,2 Karen 
M. Detering,4 Josephine M. Clayton.1,3  1The Univ of Sydney, Australia; 2Royal 
North Shore Hospital, Australia; 3HammondCare Palliative Care Service, 
Australia; 4Austin Health, Australia; 5On behalf of Univ of Technology Sydney 
Collaborators.
Background: Recent guidelines emphasise the need to improve advance care planning 
(ACP) for patients with chronic kidney disease (CKD). Little is known about current ACP 
practice in Australian/New Zealand renal centres. We aimed to describe current practice 
and barriers to ACP from the perspective of renal clinicians.
Methods: A cross-sectional survey was administered online to nephrology nurses, 
nephrologists and social workers between May 2014 and January 2015. Survey questions 
covered the topics of experience, skills, comfort and knowledge regarding ACP, workplace 
policies and procedures concerning ACP, perceived barriers and facilitators to ACP, and 
perceived need for new CKD-specific ACP programs and materials.
Results: 375 participants completed the survey, mean age 48 years, from renal centers in 
all Australian states and territories and New Zealand. 57% indicated that ACP was performed 
in their workplace on an ad-hoc basis; 22% reported that there was a formal program; 13% 
reported that ACP hardly ever occurred; and 8% were unsure.61% reported that ACP was 
done poorly, 32% well, and 7% were unsure. Perceived barriers to ACP included patient/
family discomfort with the topic (84% of respondents), difficulty engaging families and 
lack of clinician expertise (83% each), lack of clinician time (82%), health professional 
discomfort (72%), cultural/language barriers (65%), environmental problems such as lack 
of space (61%) and lack of formal policy/procedures (60%). Whilst discouragement from 
colleagues or managers was identified as a barrier in only 19% of cases, narrative comments 
on the survey emphasised the gate-keeping role played by nephrologists.
Conclusions: ACP in Australian/New Zealand renal centres is subject to health system, 
provider and patient related barriers. Given the volunteer effect associated with online 
surveys, our study may underestimate the need for ACP support. Targeted interventions 
are needed to improve ACP in Australian and New Zealand renal centres.
Funding: Private Foundation Support
SA-PO782
Nephrology Leadership Required to Address Unmet Palliative Care Needs 
in Dialysis Centers  Alvin H. Moss,1 Stacey Culp,1 Dale Lupu,2 Cheryl Arenella,2 
Nancy C. Armistead.3  1Medicine, West Virginia Univ School of Medicine, 
Morgantown, WV; 2Daleview Associates, Silver Spring, VA; 3Mid-Atlantic Renal 
Coalition, Richmond, VA.
Background: Because of high symptom burden, numerous comorbidities, and 
shortened life expectancy, dialysis patients are increasingly recognized as appropriate 
candidates for early and continuous palliative care.
Methods: In 2013 the Coalition for Supportive Care of Kidney Patients conducted 
an online survey of dialysis professionals and administrators using ESRD Network and 
Renal Physicians Association email lists to determine perceptions about how well patient 
palliative care needs are met. Differences among disciplines were assessed by chi-squared 
testing and one-way ANOVA.
Results: The 487 respondents included 41 nephrologists, 152 nurses/physician 
assistants, 199 social workers, and 95 dialysis center administrators. There was a significant 
difference by discipline in reported unmet palliative care needs for symptom management, 
care coordination, and family bereavement support, with administrators least likely to view 
each need as unmet (all p <.02). In rating possible barriers to providing high quality palliative 
care in their centers, mean scores differed by discipline for 7 items, and nephrologists 
were most likely and administrators least likely to perceive them as barriers (all p <.05). 
“Guidelines to help with decision-making in seriously ill patients” was selected as the top 
priority for change by each discipline (37% overall, p=.47 by discipline). Nephrologists 
were most likely to be aware that a dialysis guideline already existed and to have used it 
(43.9% vs 3.3% RN/PA vs 10.6% MSW vs 8.5% administrator, p <.001).
Conclusions: Nephrologists report more unmet palliative care needs, barriers, and 
resources than the administrators who oversee dialysis centers. Because the respondents 
were self-selected, a study limitation, the results likely underestimate unmet palliative care 
needs. To better address palliative care needs, nephrologists need to lead interdisciplinary 
collaborations, including administrators, to implement palliative care pathways already 
established in evidence-based clinical practice guidelines.
SA-PO783
Hospice and Race for End-of-Life Care in U.S. Dialysis Patients 
Robert N. Foley,1 Scott Reule,1 Donal J. Sexton.2  1Div of Nephrology, Univ 
of Minnesota, Minneapolis, MN; 2Div of Medicine, National Univ of Ireland, 
Galway.
Background: While hospice use is increasingly used for end-of-life care in dialysis 
patients, we hypothesized that important racial disparities may be present.
Methods: To address this hypothesis, we examined USRDS files to characterize end-
of-life care for deaths occurring between 2006 and 2011.
Results: During this 5-year period, the proportion of deaths in hospice increased 
from 14.7% to 24.2%; grouped by age at death, the following trends were observed: < 65 
years-11.5% to 15.0%; 65 to 79 years-19.1% to 26.1%; 80-89 years-24.9% to 34.3%; ≥ 90 
years-25.9% to 39.6%. As shown in the accompanying Table, associations of hospice use 
among decedents included more recent calendar year, older age and female sex. Hospice 
use varied substantially with race: compared to whites, adjusted odds ratios of hospice use 
were 0.56, 0.56 and 0.57, respectively, in patients of African American, Native American 
and Asian race.
Conclusions: While end-of-life care in hospice settings is growing rapidly in the US, 
substantial, unexplained racial disparities exist.
Candidate Variable Comparator Adjusted Odds Ratio
Death in 2008 2006 1.18
Death in 2009 2006 1.27
Death in 2010 2006 1.39
Death in 2011 2006 1.51
Age 65-80 < 65 1.80
Age 81-90 < 65 2.52
Age ≥ 90 < 65 3.03
> 1 year on RRT ≤ 1 0.98
Female Male 1.12
Asian White 0.57
African American White 0.56
Native American White 0.56
SA-PO784
Palliative Care Perspectives of Latinos with End-Stage Renal Disease 
Lilia Cervantes,1,2 Stuart L. Linas,1,2 Stacy M. Fischer.1  1Dept of Medicine, Univ 
of Colorado, Denver, CO; 2Dept of Medicine, Denver Health and Hospital, 
Denver, CO.
Background: Latinos are the fastest growing minority and have a nearly 2-fold faster 
progression from chronic kidney disease to end-stage renal disease (ESRD). Despite the 
high symptom burden and mortality suffered by patients with ESRD, there is limited 
palliative care research and Latinos are underrepresented in existing palliative care studies. 
The purpose of our study is to provide the first description of the Latino palliative care 
perspective.
Methods: Observational descriptive survey of adult English and Spanish speaking 
Latinos with ESRD from a safety-net hospital and two private dialysis centers. We modified 
Davison’s 2010 End of Life Care Preferences and Needs Survey to include known barriers 
to palliative care in the Latino community. The survey was translated to 3rd grade Spanish 
and then back-translated to English.
Results: Participants (n=61) had a mean age of 59 years ± 12, mean Charlson 
Comorbidity Index of 6.5 ± 2.5, and a dialysis vintage mean of 43.3 months ±44.8. The 
majority (77%) spoke Spanish and reported limited understanding of hospice and palliative 
care. We found that 60 (98%) want to be informed about their prognosis and 55 (90%) 
want to be prepared and plan ahead; however, only 16 (26%) had discussed prognosis 
and only 10 (16%) had discussed end-of-life care with their nephrologist. The majority 
of participants stated that it was their doctor’s choice (68.8%) to start dialysis; however, 
few (14.7%) regret the decision to start dialysis. Participants reported a preference to have 
advance care planning conversations on a routine basis (86.8%), after starting dialysis but 
before becoming ill (85.2%), and while receiving dialysis (47.5%) or at home (37.7%). 
Participants want their family have a central role in medical decision-making (93.4%) and 
care-giving (95%).
Conclusions: Our findings provide the first description of the palliative care 
perspectives of a predominantly Mexican Latino population with ESRD. By understanding 
the palliative care perspectives and barriers experienced by Latino patients with ESRD, we 
can move toward a value-based and patient-centered model of palliative care.
Funding: Private Foundation Support
SA-PO785
Symptom Burden Amongst Latinos with End-Stage Renal Disease 
Lilia Cervantes,1,2 Stuart L. Linas,1,2 Stacy M. Fischer.1  1Dept of Medicine, Univ 
of Colorado, Denver, CO; 2Dept of Medicine, Denver Health and Hospital, 
Denver, CO.
Background: All patients with end-stage renal disease (ESRD) experience a high 
symptom burden. Although Latinos represent 19% of the US ESRD community, little 
research is available on their symptom burden. The purpose of our study was to provide the 
first description of symptom burden prevalence and severity amongst Latinos with ESRD.
Methods: Observational descriptive survey of adult English and Spanish speaking 
Latinos with ESRD from a safety-net hospital and two private dialysis centers. We used 
Davison’s ESAS-r: Renal tool which measures physical and psychological symptom distress 
and contains 11 symptom items on a Likert scale of 0-10. Moderate = 4-6 and severe = 
7-10. We asked three questions about symptom treatment preferences.
Results: Participants (n=61) had a mean age of 59 ±12 years, mean Charlson 
Comorbidity Index of 6.5 ±2.5, and a dialysis vintage mean of 43.3 ±44.8 months. The 
majority were born in Mexico (90.2%), spoke Spanish only (77%), and had a less than high 
school education (72.2%). Overall, Latinos experience a substantial symptom burden with a 
mean of 6.8 ± 2.9 symptoms of which 5.1 ±2.8 are moderate or severe symptoms. Tiredness 
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was experienced by 83.5% of patients and reported as moderate or severe by 67.2%. Pain was 
present in 65.6% and moderate or severe in 49.1%. Depression was reported by 55.7% and 
anxiety by 49.1% and moderate or severe in 49.2% and 39.3%, respectively. The majority 
(78.6%) of patients reported lack of well-being and feeling drowsy (70.5%). With respect 
to medication preferences, our cohort prefers Western Medicine (77.1%) over traditional 
curandero (22.9%) medicine and is agreeable (77.1%) to taking a few more medications 
if it meant all symptoms could be controlled. Our Latino cohort prefers (88.5%) to have 
their physical symptoms (e.g. pain, nausea) treated by nephrology staff.
Conclusions: Latinos with ESRD suffer from a debilitating symptom burden and over 
half of the symptoms are amenable to symptom directed therapy. Our findings support the 
early identification and treatment of physical symptoms by nephrology staff.
Funding: Private Foundation Support
SA-PO786
Care of the ‘Failing HD Patient’: Role of a Supportive Care Register 
Tracy Maryan, Maria Da Silva-Gane, Suresh Mathavakkannan.  Renal Unit, 
Lister Hospital, Stevenage, Hertfordshire, United Kingdom.
Background: Older dialysis patients (>70) often have significant comorbidities, 
that worsen with duration on HD. Continuation of dialysis often occurs at the expense of 
frequent illness episodes. There is a progressive decline in cognitive and physical function 
that exacerbates dialysis. We had introduced a Supportive Care Register (SCR) in 2012 to 
identify ‘failing dialysis patients’ based on their physical performance scores. We attempted 
to understand whether being on the SCR enabled better patient care when these patients 
were admitted with inter-current illnesses.
Methods: Data was collected from Patient Administration System (PAS) and Renal IT 
database in a large Tertiary (non-transplanting) Renal Unit serving a catchment population 
of 1.2 million. Data maintained in the SCR was reviewed. Total number of HD patient 
admissions to the acute renal service in 2013 were obtained with analysis of demographics, 
length of stay (LoS) and outcomes at discharge. Patients who were admitted were checked 
against the SCR entries.
Results: 287 out of the 409 total HD patients were admitted (123 F, median age 68 
years, 590 episodes) with 137 of these patients being admitted more than once. The LoS 
was 9 days. 49 patients died in 2013 (28M; 76±16 yr; vintage 60 m; LoS 18±12 p<0.05). 28 
patients died in hospital or at home/hospice following withdrawal of dialysis and institution 
of palliative care. 16 patients had died following severe acute illness. Five patients died 
at home. 18/28 patients were on the SCR and had discussions relating to ongoing and 
future dialysis therapy and advanced and preferred place of care planning prior to their 
last admission in the clinic setting. Seven patients had proceeded to discussions regarding 
resuscitation.
Conclusions: In conclusion, establishment of a SCR for dialysis patients with declining 
functional capacity and significant comorbidities allows for an early identification of 
patients at risk of physical and functional decompensation. Once identified, establishing 
a dialogue in the OP dialysis setting about future care needs and expectations allows for 
a more integrated care approach when patients decompensate to the point of being unable 
to continue dialysis.
Funding: Government Support - Non-U.S.
SA-PO787
A Descriptive Study of Home Palliative Service Utilization and Care 
Trajectory Among Patients Dying on Dialysis  Gihad E. Nesrallah,1 Stephanie 
Dixon,2 Marnie MacKinnon,3 Sarah E. Bota,2 Jade S. Hayward,2 Erin Arthurs,2 
Peter G. Blake,3 Amit X. Garg,2 Sara N. Davison.5  1Nephrology Program, 
Humber River Hospital, Toronto, ON, Canada; 2Inst for Clinical Evaluative 
Sciences, London, ON, Canada; 3Ontario Renal Network, Toronto, ON, Canada; 
4Ottawa Health Research Inst, Ottawa, ON, Canada; 5Faculty of Medicine, Univ 
of Alberta, Edmonton, AB, Canada.
Background: Palliative care service use and outcomes among Ontario’s dialysis 
recipients remain uncharacterized.
Methods: We conducted a descriptive, retrospective, cohort study of 5,507 patients 
who died while receiving or withdrawing from chronic dialysis (hemodialysis or peritoneal 
dialysis) in Ontario, between January 1, 2010 and December 31, 2012. Data sources included 
the Ontario Renal Reporting System, the Canadian Organ Replacement Register, the Home 
Care database, and other linked administrative health datasets. The date of death served as 
the index date, and we examined patterns of service use in the prior 365 days. We present 
selected measures of health service use and outcomes.
Results: Cohort characteristics at death, expressed as median (IQR) or percent of cohort 
included: 75 (16) yrs old, 3.0 (5) yrs on dialysis, 42% female, 65% had diabetes, 14 (4) 
Johns Hopkins ACG (comorbidity score). Final dialysis modality was 85% centre HD, 1% 
home HD, 4% PD, 10% missing. During the last year of life, 11.3% received at least one 
palliative care service in the home, and 17.5% withdrew from dialysis in the last 30 days 
of life. In the last 14 days of life, 44% of patients had an emergency department (ED) visit 
and 36% had an ICU visit. ED and ICU visits were less frequent among patients who had 
received home palliative services in the last year of life. Place of death was ICU in 33%, 
and acute care hospital (without ICU) in 32%, while only 3.6% of patients died at home. 
Patients with home palliative care services in the last year of life had a greater frequency 
of death at home (15 vs. 2%) compared with those who did not.
Conclusions: Home palliative care services may not be used optimally by dialysis 
patients in Ontario. Further studies are needed to understand barriers to accessing palliative 
care services and to improve service planning and delivery.
SA-PO788
Ventilator Dependent Dialysis Patients  Jack Rubin.  Los Amaeios.
Background: We have started treating ventilator dependent patients at our dialysis 
unit and wish to share our results.
Methods: Chart review was done on all ventilator dependent patients treated at our unit.
Results: All data are shown mean ± sd. To date we have treated 19 patients (8F/11M) 
aged 71 ± 14 years with a mean time on dialysis of 90 ± 102 days. These patients were 
on dialysis prior to coming to us a mean 741 ± 1046 days. Seven were started within 2 
months of their catastrophic event. Mean last available KT/V 1.5 ± 0.3, weight 152 ± 41 
pounds, dialysis time 194 ± 21 minutes, bun 90 ± 20, creatinine 4.5 ± 1.5 Hemoglobin 
9 ± 1 g%, albumin 3 ± 0.5 g%, pre-albumin 18 ± 9 mg%, calcium 9.2 ± 0.6 mg% and 
phosphorus 3.4 ± 1.3 mg%. Four patients were transferred a mean of 71 ± 54 days because 
of insurance issues. 7 are on dialysis 97 ± 137 days and 8 have died after 94 ± 95 days on 
dialysis. There were no apparent differences in the parameters listed above between those 
transferred for insurance reasons, those who died and those still receiving treatment. 7 
patients were non communicative, 7 were diabetic, 2 had a fistula and the rest catheters, 3 
had atrial fibrillation and all a history of hypertension and congestive heart failure. Deaths 
were caused by gastrointestinal bleeding (1) and sepsis (7).
Conclusions: These non verbal non communicative patients are receiving aggressive 
end-of-life care fostered in some cases by unrealistic family expectations and in other 
instances by state conservators who prefer treatment until death so that outpatient 
withdrawal of dialysis and comfort care is not a realistic option. There are two groups - 
vintage patients and new to dialysis patients with a catastrophic event. The goal should 
be to educate families on the consequences of dialysis for the patient so that they do not 
start or allow withdrawal of dialysis after a defined trial. Upon taking on treatment of this 
group of patients the dialysis unit should anticipate a lower star rating in the benchmarks 
as most are on catheters and are frequently admitted for infection, bedsores or pulmonary 
complications. To sustain these selected patients requires a dedicated staff of nurses, 
respiratory technicians and ambulance services.
SA-PO789
External Validation of a Prediction Model for 6-Months Mortality Risk 
(MR) in Patients on Hemodialysis  Adeera Levin,1,2 Brian Forzley,1 Helen 
Chiu,2 Lee Er,2 Ognjenka Djurdjev,2 Mohamud A. Karim,1 Rachel C. Carson,1 
Gaylene M. Hargrove,1 Dan J. Martinusen.3  1Dept of Medicine, Faculty of 
Medicine, UBC; 2BC Provincial Renal Agency; 3Island Health Authority, BC, 
Canada.
Background: End-Stage Renal Disease (ESRD) is associated with poor prognosis. 
Clinicians must be prepared to address end-of-life issues; hence, identifying patients at 
higher MR is recommended. We aimed to validate a 6-month MR prediction model for 
prevalent hemodialysis patients derived by Cohen et al. (2010) in a Canadian cohort and 
assess its clinical utility.
Methods: 375 prevalent dialysis patients in two regions of BC, Canada, were followed 
for 6 months. Data including serum albumin (ALB), age, peripheral vascular disease and 
dementia captured when the surprise question (SQ) was asked were used to validate the 
6-month MR model. Model performance was evaluated through discrimination, calibration 
and decision-curve analysis.
Results: The observed mortality was 13.3% at 6-months. The model had reasonable 
discrimination (c-stat=0.70) but poor calibration (slope=0.46 [95% CI: 0.24, 0.69]) in 
our data. Decision curve showed added value of the model for threshold probabilities of 
8%-20% (= 12-42% fewer false-positive death), but no more beneficial to “treat-all” for 
probability <8% and “treat-none” for probability >20%. 
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Exploratory analysis showed that only SQ (OR=2.3, 95% CI 1.05, 4.97) and ALB 
(OR=0.22, 95% CI 0.10, 0.46) were associated with 6-month MR. Simpler models appeared 
to perform equally well.
Conclusions: The existing prediction model by Cohen et al. has reasonable 
discrimination but over-estimated the number of deaths and may require recalibration of 
model coefficients. The model may guide advance care planning conversations, but caution 
is required when applying this model in clinical decisions. A simpler model may enhance 
feasibility for use. Further research is needed prior to utilizing the model to predict death.
Funding: Government Support - Non-U.S.
SA-PO790
Identifying Advanced Chronic Kidney Disease Patients with Same Survival 
Under Conservative Care versus Dialysis  Csaba P. Kovesdy,1,2 Miklos Zsolt 
Molnar,1 Jennie Jing,3 Melissa Soohoo,3 Jun Ling Lu,1 Elani Streja,3 Lawrence 
Agodoa,4 Kevin C. Abbott,4 Paul W. Eggers,4 Kamyar Kalantar-Zadeh.3  1Univ of 
Tennessee Health Science Center, Memphis, TN; 2VA Medical Center, Memphis, 
TN; 3Univ of California, Irvine, CA; 4NIH/NIDDK, Bethesda, MD.
Background: It is unclear if dialysis offers advantages over conservative care in 
certain patients with advanced CKD who do not have rapidly deteriorating kidney function.
Methods: From 659,546 US veterans with CKD we identified 9,273 who transitioned 
to dialysis, and 6,136 who reached eGFR<15 ml/min1.73m2, but did not start dialysis. 
We matched these groups for their eGFR slope and for the last eGFR prior to ESRD, and 
restricted analyses to patients with no rapid pre-ESRD progression (defined as a slope of 
-5 to <0) and pre-ESRD eGFR of 10 to 14.9. We examined all-cause mortality using time-
stratified Cox models (by 1-year increments) to account for non-proportionality of hazards.
Results: Of 1,026 veterans included in the analysis, 651 patients did not, and 375 
patients did initiate dialysis. Baseline age, gender, race, eGFR slope and last eGFR, and 
comorbidities were similar in the dialysis vs. no dialysis groups. Overall, 624 patients died 
over a median follow-up of 1.5 years. Patients on dialysis experienced lower mortality in the 
first year (HR, 95%CI: 0.25, 0.17-0.36, p<0.001) and in year 2 (0.67, 0.52-0.87, p=0.003). 
Among patients who survived at least 2 years (28% of the original cohort), the risk of death 
associated with dialysis was 28% higher but not statistically significant (1.28, 0.94-1.75, 
p=0.12) during the subsequent time period. In this latter group baseline slopes were flatter 
(-2.1(1.3) vs. -1.9(1.2)), but their other characteristics were similar to the overall cohort.
Conclusions: Among patients with eGFR 10-15 ml/min/1.73m2 and no rapid loss 
of kidney function, transition to dialysis was associated with survival advantage over a 
two year time period. However, in 28% of the patients conservative management was not 
associated with worse mortality. Better characterization of patients who may benefit from 
conservative management warrants additional studies.
Funding: NIDDK Support, Veterans Administration Support
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Enteric Dialysis – Stabilization of the Gut Microbiome using Probiotics 
and Prebiotics (Gut-Kidney Connection)  Natarajan Ranganathan,1 Eli A. 
Friedman.2  1Research and Development, Kibow Biotech Inc, Newtown Square, 
PA; 2Downstate Medical Center, State Univ of New York, Brooklyn, NY.
Background: Recent scientific evidence from the human microbiome project has 
revealed that the trillions of gut microbiome exceed the human microbiome by a factor of 
10. There are just 23,000 human genes as against the 3.3 million genes coded by the gut 
microbiome. This complex microbiome has a major role to play in health and diseases. 
Scientific evidence has shown that the imbalance in the ratio of this complex microbial 
community leads to dysbiosis a cause for various diseases. The use of beneficial microbes-
probiotics and prebiotics is generally well recognized towards digestive, gut and immune 
health. However, novel and niche application of probiotics and prebiotics as a dietary 
supplement in stabilization of Gut Microbiome towards Chronic Kidney Disease (CKD) 
is relatively new. Many independent reviews in various scientific journals have reflected 
on various topics such as gut Microbiome, its dysbiosis, impact of the altered intestinal 
characteristics including small bowel bacterial overgrowth, newer uremic toxins, adsorbent 
drugs and several observational small scale clinical studies from Kibow and many others.
Methods: “Renadyl” a synbiotic dietary supplement was studied in randomized clinical 
trials in CKD 3 and 4 and ESRD patients. Other oral therapies for removal of uremic toxins 
include the use of keto acids and charcoal sorbents.
Results: Our studies using Renadyl for “Enteric Dialysis” showed reduction in levels of 
various uremic toxins like urea and indoxyl glucuronide. Levels of CRP also decreased with 
improved quality of life.This demonstrates the potential restoration of the gut microbiome 
dysbiosis with the use of specific strains of probiotics.
Conclusions: The use of a well-researched, clinically documented and safe probiotic/
prebiotic dietary supplement formulation has the potential to safely perform continuous 
24h/7d uremic toxin removal and thus stabilize the gut Microbiome and its dysbiosis. Hence, 
the concept of “Enteric Dialysis” with continuous removal of uremic toxins may be the 
future key to providing an alternative HOPE for renal failure population.
Funding: NIDDK Support
SA-PO792
Charcoal Hemoperfusion in the Treatment of Pruritus in Cholestatic Liver 
Disease  Wonngarm Kittanamongkolchai, Ziad El-Zoghby, Nelson Leung. 
Nephrology, Mayo Clinic, Rochester, MN.
Background: Pruritus is a distressing symptom in a considerable proportion of 
cholestatic patients and few of them do not respond to conventional treatment. Charcoal 
hemoperfusion (CH) is an extracorporeal technique to eliminate albumin-bound substances 
that are accumulated during cholestasis by the passage of blood through a column containing 
activated charcoal. Several case reports have shown significant reduction of bilirubin in 
mechanical jaundice and neonatal hemolytic jaundice. However, the published data of CH 
for the treatment of resistant pruritus in cholestatic patients is scarce.
Methods: Procedure code “Charcoal hemoperfusion” was used to identify patients who 
received charcoal hemoperfusion at Mayo Clinic, Rochester from 1/1/2000 to 5/1/2015.
Results: Thirteen patients were identified. All patients had failed conservative treatment 
and 2 of them had not responded to plasmapheresis. A median of 5(1-9) sessions for a total 
of 20(1-33) hours were performed. CH resulted in a significant decrease of pruritus in 9 
patients (69%). 2 patients did not have significant relief and 2 patients did not pursue further 
treatments after having adverse reaction during the first session. Median pruritic score 
significantly decreased from 9/10 (9-10) to 4/10 (0-9) posttreatment (p=0.004). Duration 
of symptom free period ranged from 8 to 46 days (median 18 days) in 6 patients who 
returned for follow up. 6 patients (46%) experienced adverse reactions described in Table 1.
Conclusions: Charcoal hemoperfusion is an effective therapy for refractory cholestatic 
pruritus. However, the improvement is not sustainable and the short benefit should be 
balanced with the invasive nature of the therapy and the relatively common adverse 
reactions.
SA-PO793
Strict Adherence to Medicaid InterQual® Criteria Increases Adverse 
Events and Health Care Utilization in Undocumented Dialysis Patients 
S. Jawad Sher, Melissa D. Anderson, Ranjani N. Moorthi, Sharon M. Moe, 
Michael T. Eadon.  Medicine, Indiana Univ, Indianapolis, IN.
Background: Current estimates suggest there are 6000 undocumented ESRD patients 
in the US that may be ineligible for scheduled hemodialysis. To meet emergency Medicaid 
requirements, hospitals have sought creative ways to treat undocumented patients. We 
present data from an undocumented cohort as it progressed through a succession of three 
periods with different dialysis criterion.
Methods: This is a retrospective evaluation of a prospective cohort of 20 undocumented 
ESRD patients. The patients were followed over 3 consecutive periods (P1, P2, P3) each 
of 2 months duration. In P1, patients received twice weekly dialysis. In P2, patients were 
dialyzed based on strict emergent InterQual® Criteria. In P3, emergent criteria included 
long interdialytic interval as an additional justification. Adverse outcomes, utilization, and 
dialysis adequacy in P2 and P3 were compared to P1.
Results: The mean age of the cohort was 35.9 y, 30% were female, 45% were employed, 
and none were US citizens. Emergent dialysis (P2&P3) was associated with increased 
biochemical abnormalities (peak K+, mean BUN and serum bicarbonate) as compared to P1 
scheduled dialysis (P < 0.05). Emergent dialysis (P2&P3) was associated with an increase 
in nights hospitalized and ICU days (Fig1). Strict adherence to InterQual® Criteria (P2) was 
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associated with increased adverse events with a composite OR for intubation, bacteremia, 
NSTEMI, ICU admit, and death of 48 (5.9-391.2) compared to P1. P2 charge estimates 
increased from P1 ($357,501 v $202,326 per person per year, P<0.001).
Conclusions: Strict adherence to InterQual® Criteria increases adverse events and 
healthcare cost per patient. We must determine better alternatives to emergent dialysis 
which minimize cost, while maintaining dignity, safety, and quality of life.
SA-PO794
Factors Associated with Withdrawal of Care (WOC) in Maintenance 
Dialysis Patients  Fahad Saeed, Robert Butler, Jesse D. Schold.  Nephrology, 
Cleveland Clinic.
Background: There is paucity of data on factors leading to WOC in dialysis patients. 
We studied this question by using the NIS dataset, 2005-2011.
Methods: We studied the following six major primary diagnoses: MI, cardiogenic 
shock, sepsis, stroke, CPR and coma. Effect of age, sex, race, hospitals’ profit status 
and comorbidities were assessed on WOC status. We studied 836563 dialysis patients’ 
admissions,and WOC occurred in 68152 patients.
Results: Male sex, African American and Latino races, smoking, obesity, psychosis 
and anemia carried lower odds of WOC. Primary diagnoses of CPR, coma, MI, cardiogenic 
shock, and sepsis; and co-morbidities such as CHF, dementia, HTN, CA, liver disease, 
paralysis, chronic lung disease,DM, weight loss were associated with higher odds of WOC. 
Odds of WOC were increased by approximately 6 % per year of patient age.Teaching 
hospitals had higher odds while private hospitals carried lower odds of WOC status.
Conclusions: Age, non-profit hospital status, coma, metastatic malignancy and weight 
loss are the most significant factors associated with WOC among dialysis patients. These 
prognostic data should be considered while treating such patients. 
Odds Ratio Estimates
Effect Point Estimate 95 % CI P-Value
Male vs. Female 0.892 0.860-0.926 <.0001
Black vs. White 0.494 0.445-0.548 <.0001
Hispanic vs. White 0.445 0.355-0.557 <.0001
Other vs. White 0.582 0.507-0.668 <.0001
Tracheostomy 0.670 0.564-0.796 <.0001
G-tube 0.785 0.671-0.918 0.0025
CPR 1.624 1.400-1.884 <.0001
GI Bleed 1.225 1.134-1.323 <.0001
Cardiac shock 2.311 2.002-2.668 <.0001
MI 1.365 1.258-1.481 <.0001
Coma 4.850 4.025-5.843 <.0001
Sepsis 2.130 1.964-2.311 <.0001
Stroke 1.544 1.419-1.680 <.0001
Smoking 0.565 0.498-0.642 <.0001
Malnutrition 0.682 0.593-0.784 <.0001
Dementia 1.966 1.736-2.227 <.0001
Alcohol abuse 1.239 1.092-1.406 0.0009
Anemia 0.874 0.808-0.945 0.0008
CHF 1.225 1.163-1.291 <.0001
DM 0.614 0.575-0.656 <.0001
HTN 0.673 0.634-0.714 <.0001
Liver disease 1.430 1.279-1.599 <.0001
Metastatic cancer 3.334 2.988-3.719 <.0001
Obesity 0.777 0.708-0.851 <.0001
Paralysis 1.214 1.096-1.346 0.0002
Psychosis 0.863 0.763-0.976 0.0191
Cancer 2.323 2.095-2.576 <.0001
Weight loss 2.154 1.819-2.551 <.0001
Teaching hospital status 1.263 1.048-1.522 0.0140
SA-PO795
Red Cell Distribution Width and Mortalityin Incident Hemodialysis 
Patients  Tania Vashistha,1 Elani Streja,1 Miklos Zsolt Molnar,2 Connie Rhee,1 
Steven M. Brunelli,3 Hamid Moradi,1 Tae Hee Kim,1 Vanessa A. Ravel,1 Melissa 
Soohoo,1 Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2UTHSC; 
3DaVita Clinical Research.
Background: Red cell distribution width (RDW) is a measure of red blood cell size and 
variability that is often used as an indicator of iron-deficiency anemia. Although RDW has 
recently been found to be associated with mortality in the general population, few studies 
have examined this association in hemodialysis (HD) patients.
Methods: We examined the association of RDW with all-cause mortality in a cohort 
of 109,675 incident HD patients from a large dialysis organization during 2007-2011 
using Cox proportional hazards regression with adjustment for case-mix (demographics, 
comorbidities covariates) and markers of malnutrition and inflammation (MICS). RDW 
was divided into 5 categories <14.5, 14.5-<15.5, 15.5-<16.5, 16.5-<17.5, and ³17.5 %.
Results: The mean age (mean±SD) of the cohort was 63±15years old and included 44% 
females, 58% diabetics, and 31% African Americans. Higher baseline RDW was linearly 
associated with higher all-cause mortality risk in both unadjusted and fully adjusted models. 
Conclusions: Higher RDW is associated with higher mortality risk in HD patients. It 
is unclear whether RDW is a risk factor for mortality or an epiphenomenon of underlying 
biological and metabolic imbalances across RDW categories. Further studies are needed to 
confirm the findings generated from our study and to determine the mechanisms underlying 
the RDW-mortality association.
Funding: NIDDK Support
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Association of Pre-ESRD Hemoglobin with Early Post-ESRD Mortality 
Among U.S. Veterans: A Transition of Care in CKD Study  Melissa Soohoo,1 
Connie Rhee,1 Vanessa A. Ravel,1 Elani Streja,1 Jennie Jing,1 Danh V. Nguyen,1 
Csaba P. Kovesdy,2 Kamyar Kalantar-Zadeh.1  1UC Irvine; 2UTHSC.
Background: Patients with chronic kidney disease (CKD) are often afflicted with 
anemia. Previous studies have shown that low hemoglobin (HGB) is associated with 
pre-dialysis mortality in non-dialysis dependent CKD patients, yet the association of 
HGB levels in the immediate period preceding dialysis (prelude) and early post-dialysis 
mortality remains unknown. We hypothesized that lower HGB levels are associated with 
higher post-transition survival in comparison to higher HGB levels.
Methods: We investigated 18,555 US veterans who initiated dialysis between 10/2007-
9/2011 and had at least 1 HGB measurement during the 6 month prelude period before 
dialysis transition. 6 month averaged HGB was used as a continuous predictor of early post 
dialysis all-cause mortality occurring in the first 3 months after initiation using restricted 
cubic spline models and Cox proportional hazard regressions. The models were adjusted 
for age, gender, race, ethnicity, region and primary cause of ESRD.
Results: The analytic cohort was a mean±SD age of 68±11 yrs, among whom 30% 
were African-American, 7% Hispanic and 50% had diabetes as the cause of ESRD. The 
6 month prelude HGB average was 10.9±1.6 g/dL. Prelude HGB exhibited a U-shaped 
association with 3-month post-ESRD all-cause mortality; patients with a 6 month prelude 
HGB average between 10-11.5 g/dL had better survival, whereas patients with HGB 
measurements <9 g/dL or >13 g/dL had higher mortality (Figure). 
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Conclusions: HGB during the 6 month prelude period prior to dialysis initiation 
exhibited a U-shaped association with all-cause mortality in the immediate interval 
post-dialysis with the best survival when HGB was between 9 and 11 g/dL. These results 
confirm the findings of earlier clinical trials, and support current therapeutic paradigms for 
management of pre-ESRD anemia.
Funding: NIDDK Support
SA-PO797
Higher Serum Ferritin Levels are Associated with Better Survival in the 
HEMO Study  Anna Jeanette Jovanovich,1,2 Eugene J. Nuccio,2 Alfred K. 
Cheung,3,4 Tom Greene,4 Michel Chonchol.2  1Denver VA Medical Center; 2Univ 
of Colorado Denver; 3VA Salt Lake City; 4Univ of Utah.
Background: Ferritin is an important indicator of total body iron stores and has been 
shown to prevent ox-LDL-induced oxidative injury in endothelial cells. Studies regarding 
the relationship between serum ferritin levels and all-cause mortality in chronic hemodialysis 
patients are conflicting. The purpose of this study was to determine the relationship between 
higher serum ferritin levels and death among participants in the Effect of Dialysis and 
Membrane Flux in Maintenance Hemodialysis (HEMO) trial.
Methods: We studied the association of serum ferritin and iron levels with all-cause 
mortality among 1799 subjects from the HEMO trial. Cox regression models adjusted 
for important confounding variables including demographics, comorbidities, treatment 
assignment, smoking, and albumin.
Results: Mean age was 58±14 years, 56% were female, and 63% were black. Median 
(IQR) ferritin and iron levels were 249 (2-497) ng/mL and 50 (5-78) µg/dL, respectively. 
Over a mean follow-up of 2.84 years, there were 582 deaths. Among subjects with levels in 
the highest quartile compared to the lowest quartile, both ferritin and iron were significantly 
associated with reduced all-cause mortality in adjusted analyses, odds ratio (OR) 0.67 (95% 
CI, 0.46-0.97) and OR 0.60 (95% CI, 0.42-0.85), respectively.
Conclusions: Among subjects participating in the HEMO trial higher serum ferritin 
and iron levels were associated with reduced mortality. We hypothesize that ferritin may 
play an important role in protecting the endothelium from oxidative stress-induced damage.
Funding: NIDDK Support, Veterans Administration Support
SA-PO798
Anemia in Chronic Kidney Disease Patients Could Be Linked to Indoxyl 
Sulfate Levels  Denise Mafra,1 Natalia Alvarenga Borges,1 Milena Barcza 
Stockler-Pinto,2 Amanda F. Barros.2  1Medical Sciences Graduate Program, 
Federal Univ Fluminense, Brazil; 2Cardiovascular Sciences Graduate Program, 
Federal Univ Fluminense, Brazil.
Background: Indoxyl sulfate (IS) is a uremic toxin derived from the action of colon 
bacteria in dietary tryptophan. This toxin is related to many complications for chronic 
kidney disease (CKD) patients, including anemia. The aim of this study was to verify the 
relationship between IS plasma levels and anemia in hemodialysis (HD) patients.
Methods: This transversal study included 18 HD patients (50% men, 54.2 ± 11.6 yrs, 
BMI 26.3 ± 4.7kg/m2, time on dialysis 51 (30-52) months, all patients received the same 
dose erythropoietin per week). Routine laboratory parameters were measured, the total IS 
plasma levels were quantified with high-performance liquid chromatography (HPLC) and 
protein C reactive (CRP) levels analyzed by Immunoenzymatic Assay. Statistical analyzes 
were performed with SPSS version 19.0.
Results: The mean of hemoglobin was 11.0 ± 1.28 g/dL and hematocrit of 34.2 ± 3.0%. 
The mean of IS plasma levels was 23.9 (10.3 - 100.9) mg/L and CRP 3.1 (1.3 – 8.6) mg/
dL. Multivariate linear regression analysis adjusted for age, sex, time on HD, albumin, 
BMI, CRP revealed that serum hemoglobin (β = -0.62; p = 0.01) was independently and 
negatively associated with IS levels.
Conclusions: This study provided evidence that IS seems be associate with anemia in 
HD patients and therapeutic strategies in the clinical care to reduce uremic toxins levels 
may be effective to management of anemia in HD patients.
Funding: Government Support - Non-U.S.
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High Ferritin Level Above 100 Ng/Ml Is Associated with Poor Clinical 
Outcomes in Maintenance Hemodialysis Patients  Raku Son,1 Takuya 
Fujimaru,2 Takeshi Kimura,3 Masataka Hasegawa,2 Yuki Heath,2 Fumika Taki,2 
Miyuki Futatsuyama,2 Masahiko Nagahama,2 Yasuhiro Komatsu.2  1Internal 
Medicine, St. Luke’s International Hospital, Tokyo, Japan; 2Nephrology, St. 
Luke’s International Hospital, Tokyo, Japan; 3Center for Clinical Epidemiology, 
St. Luke’s International Univ, Tokyo, Japan.
Background: Ferritin is a well-known marker of iron deficiency anemia, but the target 
ferritin level in maintenance hemodialysis (MHD) patients still remains controversial 
among countries. This study is to examine the association of baseline ferritin level and 
clinical outcomes.
Methods: We retrospectively collected data of 116 patients on MHD at St Luke’s 
International Hospital for 60 months. Ferritin level above 100 ng/ml was defined as high 
ferritin (HF) group and the rest as low ferritin (LF). The primary end point was all-cause 
mortality. The secondary endpoints included cardiovascular events and positive blood 
cultures. Cox proportional hazard analysis was performed as multivariate analysis.
Results: Of the 116 patients (age 65.3±13.4, 70% of males), 29 patients belonged 
to HF and 87 to LF. During the follow-up (median 60 months, IQR 24.1-60 months), 22 
patients (18.9%, 13 in HF and 9 in LF) died. In Kaplan-Meier survival curves, HF showed 
significantly poor survival compared with LF (p= 0.02). 
After adjusting age, sex, vintage of hemodialysis and past medical history of diabetes 
mellitus, hazard ratio (HR) of HF was 2.60 (95% confidence interval 1.25-5.24, p=0.01). 
The multivariate analysis for cardiovascular events revealed a similar result with statistical 
significance (HR 2.65, 95% confidence interval 1.07-6.31, p=0.04). For positive blood 
cultures, HR of HF was 1.81, although not statistically significant (p=0.17).
Conclusions: In MHD patients, ferritin level above 100 ng/ml increases all-cause 
mortality and cardiovascular events.
SA-PO800
Erythropoietin-Stimulating Agent (ESA) Hyporesponse (ESAhr) Is 
Associated with Persistently Elevated Mortality Among Hemodialysis (HD) 
Patients  Jiacong Luo,1 Donna E. Jensen,1 Sarb Shergill,2 Bradley J. Maroni,2 
Steven M. Brunelli.1  1DaVita Clinical Research, Minneapolis, MN; 2Akebia 
Therapeutics, Cambridge, MA.
Background: Prior studies have examined the association between ESAhr and 
outcomes among HD patients. However, none has been conducted using contemporary 
data nor with a definition of ESAhr that is relevant in contemporary practice, specifically 
following 2011 changes to the US ESA labels and reimbursement policy.
Methods: We retrospectively studied a cohort of prevalent (vintage >6 months) HD 
patients from a single large provider (N=98,972) for 24 months (2012-2013). ESAhr 
was defined as 2 consecutive bimonthly hemoglobin (Hb) measures <10 g/dL with 
erythropoietin dose >7700 U/treatment. Patients were categorized as of 1Q2012 and 
followed longitudinally. Associations between ESAhr and mortality were determined using 
generalized estimating equations adjusting for baseline characteristics.
Results: At baseline, 12,361 (12.5%) patients qualified as having an ESAhr. Mean 
ESA dose was initially 3-fold greater in ESAhr than control patients and remained 2-fold 
greater by the end of study. 
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Initially, mean Hb level was approximately 1 g/dL lower among ESAhr patients and 
remained 0.4 g/dL lower through the end of study. During follow-up, ESAhr was associated 
with a greater adjusted risk of mortality vs nonESAhr (control referent). Incidence rate 
ratios (95% confidence interval) ranged from 2.24 (1.93-2.60) in the 2nd quarter to 1.48 
(1.18-1.84) in the 8th quarter.
Conclusions: Using a contemporarily relevant definition, ESAhr at a single point in 
time is potently and persistently associated with greater ESA utilization, lower Hb levels, 
and higher mortality risk.
Funding: Pharmaceutical Company Support - Akebia Therapeutics
SA-PO801
Impact of ESAs and Iron on Survival in Hemodialysis Patients: Which 
Is the Best, Which Is the Worth?  Jacques B. Rottembourg,1 Alain Guerin.2 
1Dept of Nephrology, Hôpital de la Pitié, Paris, France; 2Hemodialysis Units, 
Diaverum, Paris, France.
Background: Appropriate anemia management for Hemodialysis (HD) patients (Pts) 
is still challenging. Intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs) 
are the main thérapies, with conflicting outcomes. In the unit, pts were treated over the 
last seven years, cumulative doses of ESAs (darbepoetin alfa [DA]), converted in µg per 
session, and IV iron (iron-sucrose [IS]),converted in mg per session, were exactly constantly 
reported. Survival depending on the cumulative dose of each product and both products 
together was calculated using the Kaplan Meier methodology.
Methods: 300 incident HD pts (67% male) mean[M] (SD) age at start 59,7(16.3) 
years, were treated for 100,430 dialysis sessions [S], receiving all over 1,192,250 µg of 
DA, and 1,794,050 mg of IS. M Hb level was 11.55(0.77) g/dL, M TSAT 37.1(8.5)%, 
and M ferritin 562(322) µg/L. The M DA dose injected was 12.91(9.90) µg per S.The M 
IS dose injected was 20.91(11.57) mg per S.Expressing the separate doses of DA and IS 
received by the pts in three categories for each product, we obtained 9 categories of pts, 
depending on whether they received low, middle, or high doses of ESA and IS per S: M 
doses were [5.4(2.6), 10.8(3.3), 25.1(14.8)µg] for ESA, [12.5(4.5), 18.4(3.4), 32.3(11.9)
mg] for IV iron respectively.
Results: Survival was expressed at 1000, 2000, and 3000 days (d):
The better survival was obtained in the group of low ESA and low IV iron, the worth 
was high ESA and high IV iron. Survival is better with low ESA, whatever is the IV iron 
dose injected. High ESA dose, whatever IV iron dose is injected, seems to be worth.
Conclusions: Because the majority of patients on HD receives ESA and IV iron, 
rigorously conducted and adequately powered clinical trials studying the cumulative doses 
of ESA and IV iron, reflective of present-day practice, are greatly needed.
SA-PO802
Relationship Between Statin Prescription and Erythropoietin Stimulating 
Agent (ESA) Hyporesponsiveness in Hemodialysis (HD) Patients: Results 
from the Japan Dialysis Outcomes and Practice Patterns Study (JDOPPS) 
Takeshi Hasegawa,1,5 Junhui Zhao,2 Douglas S. Fuller,2 Brian Bieber,2 Yun Li,3 
Jarcy Zee,2 Hal Morgenstern,3 Masaomi Nangaku,4,5 Bruce M. Robinson,2 Norio 
Hanafusa.4,5  1Fukushima Medical Univ Hospital, Fukushima City, Fukushima, 
Japan; 2Arbor Research Collaborative for Health, Ann Arbor, MI; 3Univ of 
Michigan, Ann Arbor, MI; 4The Univ of Tokyo, Tokyo, Japan; 5Anemia Working 
Group of JDOPPS, Japan.
Background: Statins are widely used in HD patients and have pleiotropic anti-
inflammatory and anti-oxidative effects, but the latest guideline is advising against starting 
its use in this population.  Hypothesizing that statins could be used as adjuvant treatment 
for renal anemia, we examined the association between statin prescription (Rx) and ESA 
hyporesponsiveness (ESAHYPO) in Japanese HD patients (pts) prescribed ESAs.
Methods: We included 3,208 pts in 178 HD facilities dialyzed 3x/week for ≥4 months 
from JDOPPS phases 3-5. Statin Rx was reported at baseline. ESAHYPO was defined in 
the next 4 months as a binary indicator (mean hemoglobin (hgb) <10 g/dL and mean ESA 
dose >7,500 units/wk) and separately as ESA resistance index (ERI, mean ESA dose/
[post-dialysis body weight*mean Hgb]). We used adjusted logistic and linear regressions 
to evaluate the associations.
Results: 16.1% of pts reported statin Rx at study entry; 8.8% were classified as 
ESAHYPO during follow-up. Compared to pts without statin Rx, pts with statin Rx had 
lower odds of ESAHYPO. Similarly, ERI was lower for statin Rx vs. no statin Rx (adjusted 
mean ratio [95%CI] = 0.93[0.88, 1.00] in model 3). 
Conclusions: Our results suggest that statins may reduce ESAHYPO in HD pts. Causal 
inference is limited by the observational design and unmeasured compliance with statin 
Rx. The applicability of this finding to non-Japanese populations merits further study, as 
reported statin Rx is low in JDOPPS.
Funding: Pharmaceutical Company Support - Amgen, Kyowa Hakko Kirin, AbbVie, 
Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
BHC Medical, Janssen, Takeda, Kidney Foundation of Canada (for logistics support), 
Hexal AG, DGfN, Shire, WiNe Institute, Società Italiana di Nefrologia (SIN), PDOPPS 
Japanese Society for Peritoneal Dialysis, Fresenius Medical Care, Keryx., Private 
Foundation Support
SA-PO803
25(OH)D Deficiency Contributes to the Erythropoietin Hyporesponsiveness 
in Patients on Maintenance Hemodialysis  Pu Lei, Daqing Hong, Fei Deng, Li 
Wang.  Nephrology, Sichuan Academy of Medical Sciences & Sichuan Provincial 
People’s Hospital, Chengdu, Sichuan, China.
Background: The aim of this study was to identify the factors that contribute to 
erythropoietin hyporesponsiveness in patients on maintenance hemodialysis (MHD).
Methods: demographic data , hemoglobin, dose of erythropoetin, biochemical 
indicators and other related indicators of 80 MHD patients were collected and analyzed 
retrospectively. They were followed up for 12 moths. Erythropoietin resistance index (ERI) 
was used to evaluate the response to erythropoietin in patients on MHD.The ERI was 
calculated dividing the weekly weight-adjusted (kg) dose of ESA (IU) by the hemoglobin 
level (g/dL). Logistic regression study was used to determine the key variables which might 
be independently associated with erythropoietin hyporesponsiveness in MHD patients.
Results: Mean erythropoietin resistance index (ERI) for the entire study population 
was 16 U/kg/week/g/dl. 26% patients were erythropoietin hyporesponsive. Patients were 
divided into two groups according to ERI: ERI<25IU/week/kg/g/dl and ³25IU/week/kg/g/dl. 
In ERI³25 U/kg/week/g/dl cases, the proportion of female gender was higher, hemoglobin 
and 25(OH)D were significantly lower than that of patients with ERI<25 U/kg/week/g/dl. 
In addition, comparing with ERI<25 U/kg/week/g/dl patients, body mass index(BMI) and 
serum cholesterol were slightly lower in ERI³25 U/kg/week/g/dl patients(p=0.05). Logistic 
regression study adjusted gender, dialysis periods, BMI, Kt/v, serum cholesterol, serum 
albumin, and alkaline phosphatase, indicating an independent association between 25(OH)
D deficiency and the erythropoietin hyporesponsiveness(HR:4.590, 95%CI:1.277~16.503).
Conclusions: Erythropoietin hyporesponsiveness is prevalent among MHD patients. 
Female gender and malnutrition are associateed with erythropoietin hyporesponsiveness. 
25(OH)D deficiency is the main risk factor for erythropoietin hyporesponsiveness. 
Improving 25(OH)D deficiency and malnutrition may increase the response to erythropoietin 
treatment in MHD patients.
SA-PO804
Incidental Findings on 15 Fluorodeoxyglucose Positron Emission 
Tomography Along with Low Dose Computerized Tomography (FDG PET 
CT) Scans Among Clinically Stable Haemodialysis with Erythropoietin 
Stimulating Agent (ESA) Hypo Responsiveness (ESA-R)  Tarun Kaushik, 
Stanley Fan, Neringa Vilimiene, Muhammad M. Yaqoob.  Nephrology 
(*Contributed equally), Barts Health Cardiovascular Biological Research Unit 
and Barts Health NHS Trust, United Kingdom.
Background: Burden of comorbidities is high among hemodialysis (HD) patient. 
Underlying infective focus or occult malignancy is always of concern when clinically stable 
patients have ESA-R (ESA resistance index of ≥6.5 IU/kg body weight/Hb gm/dl per week).
Methods: Patients with similar characteristics were recruited as a part of an on-going 
clinical trial, which also included whole body FDG PET CT scan at baseline and at six 
month. Any clinically significant finding was reported to clinical team for further action. We 
were therefore in a unique position to report incidental findings in this cohort of patients.
Results: Out of total 111 scans 31% showed pathological tracer uptake including 
suspected malignancy. 2 patients with confirmed malignancy had to be suspended from 
on going living donor kidney transplant work up. 4 patients needed antibiotics and 1 had 
anti TB therapy. 7 patients needed appropriate invasive investigations for confirmatory 
diagnosis. There was no association between elevated CRP around time of scan and 
pathological tracer uptake (P=0.468) 
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Imaging Initial Follow up Total
Number of scans 62 49 111
Pathological tracer uptake 20 15 35
Suspected malignancy 9 1 (new) 10
Lung nodule 0 1
Inflammatory / infective lymphadenopathy 4 1 (old)
Colonic polyp (non malignant) 1
Infected renal cyst 1
Infected sebaceous cyst 1
Renal cell carcinoma 1
Papillary carcinoma of thyroid 1
Confirmed malignancy (new) 2 2 (old) 2
Pathological uptake (other) 11 11 22
Arthropathy 2 2
Sialadenitis 2 1
Access related infection 1 1
Gastric mucosal uptake 2 3
Lung changes 3 2
Lymphadenopathy 0 1
Other 1 1
Conclusions: This observation confirms occult disease burden among this study 
group which otherwise would have been undetected and may have seriously impacted 
patient outcome. We recommend that HD patients with ESA-R should be regarded as 
high risk and further work is needed to devise easily accessible monitoring tools as part 
of their management.
SA-PO805
Serial Hepcidin Concentrations in Incident and Prevalent Hemodialysis 
Subjects Relating to ESA Response  Michael E. Brier,1 Michael Merchant,1 
Xiaolan Zhang,2 Jonathan Himmelfarb,3 Brad H. Rovin,2 Jon B. Klein.1,4 
1Medicine, Univ of Louisville, Louisville, KY; 2Medicine, Ohio State Univ, 
Columbus, OH; 3Medicine, Univ of Washington, Seattle, WA; 4Robley Rex VA 
Medical Center, Louisville, KY.
Background: Hepcidin is a key regulator of iron metabolism and alterations in 
levels may contribute to an apparent erythropoietin (EPO) resistance. The purpose of the 
current study was to determine the effect of incident vs. prevalent subjects on hepcidin 
concentrations at a single point in time and serially up to 6 months.
Methods: We collected blood for hepcidin measurement in 257 prevalent and 33 
incident hemodialysis subjects from 2 locations (Louisville and Washington). Repeated 
blood samples were collected for up to 6 months in 66 prevalent and 33 incident subjects.A 
total of 752 hepcidin measurements were performed. Additionally we collected EPO dose, 
hemoglobin (HB), TSAT, and Ferritin. Hepcidin-25 peptide was measured by EIA (Bachem 
Group) and values are reported as ng/ml.
Results: Hepcidin concentrations in Incident subjects were higher (191±141) vs. 
Prevalent subjects (151±102, p=0.043) and in Females (n=93, 169±109) vs. Males (n=151, 
140±97, p=0.015). There was no difference by Race p=0.948 (African American n=132, 
150±106; Caucasian n=95, 151±101; Asian n=10, 154±78; Other n=7, 173±96). Forty 
five prevalent and 11 incident subjects did not require EPO (EPO naive) for anemia for 6 
months prior to Hepcidin measurement. ANOVA of hepcidin by Incident (p=0.018) and EPO 
naive (p=0.006)showed significant differences (Incident EPO Naive 156±96; Incident EPO 
206±161; Prevalent EPO Naive 97±86; Prevalent EPO 164±101). Hepcidin concentrations 
remained constant in Incident subjects for the first 6 months of dialysis (p=0.913). (Month 
1-6; 190, 153, 180, 178, 176, 166).
Conclusions: Differences in Hepcidin concentration exist between Incident and 
Prevalent hemodialysis subjects as well as Males and Females. Increased Hepcidin 
concentrations in Incident subjects are maintained for at least the first 6 months in dialysis. 
Those subjects that are naive to EPO have the lowest Hepcidin concentrations and may 
provide evidence for the usefulness of Hepcidin as a therapeutic target.
Funding: NIDDK Support
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Female Gender Is Associated with Higher Degree of Erythropoietin 
Hyporesponsiveness in Maintenance Hemodialysis Patients  Daqing Hong, 
Fei Deng, Li Wang.  Nephrology, Sichuan Academy of Medical Sciences & 
Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China.
Background: To investigate the difference of erythropoietin hyporesponsiveness 
between female and male patients.
Methods: 310 MHD patients (163 male and 147 female) were enrolled with their 
demographic information, comorbities, erythropoietin dosage, hemoglobin, dry body 
weight, ferrtin and Kt/V collected between Jan, 2014 and Mar, 2014. ERI was calculated 
to study the response to erythropoietin treatment. Covariates were analyzed to compare 
the relationship between gender and erythropoietin hyporesponsiveness.
Results: The ERI index was higher in female patients than male patients(28.8±16.0 
vs. 20.2±12.3 U/kg/week/g/dl, P<0.05) . Hb was lower and Kt/V was higher in female 
patients than in male patients(P<0.05). There were no difference in age, ferritin, and PTH 
between male and female patients(P<0.05). The mean dosage of erythropoietin was higher 
in female than in male patients(14934±6927U vs. 13353±7554U,P>0.05). Patients were 
divided into 3 groups according to the tertiles of ERI and no difference was found in PTH, 
ferritin, Kt/V and age among the three groups.
Conclusions: Female hemodialysis patients are associated with higher degree of 
erythropoietin hyporesponsiveness. Special attention must be paid to them when treatment 
strategy is made to treat anemia.
SA-PO807
Oral Vitamin C Supplementation Reduces Erythropoietin Requirement in 
Hemodialysis Patients with Functional Iron Deficiency  Tanjim Sultana, Maria 
V. DeVita, Michael F. Michelis.  Medicine, Lenox Hill Hospital, New York, NY.
Background: Functional iron deficiency (FID) is a major cause of erythropoietin (Epo) 
hyporesponsiveness and persistent anemia in dialysis patients. Vitamin C acts as a reducing 
agent and enhances mobilization of the ferrous form of iron to transferrin thus increasing 
its bioavailability. High dose intravenous vitamin C has been shown to decrease the Epo 
requirement and improve hemoglobin levels in previous studies.This route has its downside 
regarding difficulty of use, higher cost and associations with increased oxalate levels and 
inflammatory markers. Use of oral vitamin C has been limited due to the concerns of low 
bioavailability and patients compliance to medication. This study assessed the effect of 
low dose oral vitamin C on Epo dose requirements in stable hemodialysis patients with 
functional iron deficiency.
Methods: This prospective study included 22 stable hemodialysis patients with 
functional iron deficiency defined as transferrin saturation (Tsat) <30 % and ferritin levels 
of >100 mcg/L with Epo requirement of ≥ 4000 u/HD. Patients received oral vitamin C 250 
mg daily for three months. Epo dose was adjusted according to unit protocol depending on 
the hemoglobin level. Hemoglobin, iron and Tsat levels were recorded monthly. None of 
these participants received iron or renal vitamin supplementation during the study period.
Results: The mean Epo dose was reduced in fifteen participants by 867±1356u/HD 
(p=0.03). In seven responders there was 33 % reduction in Epo dose from their base line. 
No ill effects of oral vitamin C were observed. Despite adjustment of Epo dose, hemoglobin 
level was significantly increased from 10.1± 0.6 mg/dL to10.7± 0.6 mg/dL (p=0.03).There 
were no significant change in Tsat and ferritin levels.
Conclusions: Daily low dose oral vitamin C supplementation reduced Epo dose 
requirements in hemodialysis patients with functional iron deficiency. Despite concerns 
regarding oral vitamin C absorption in dialysis patients this study indicates Vitamin C is 
well tolerated and effective.
SA-PO808
The Greatly Misunderstood Erythropoietin Resistance Index  Yossi Chait,1 
Sahir Kalim,3 Joseph Horowitz,1 Christopher V. Hollot,1 Elizabeth D. Ankers,3 
Michael J. Germain,2 Ravi I. Thadhani.3  1UMass; 2WNE Renal & Transplant 
Assoc; 3MGH.
Background: The use of erythropoiesis stimulating agents (ESAs) to treat anemia in 
end stage renal disease remains controversial due to reported associations with adverse 
events. Many studies introduce so-called ESA resistance indices (ERIs) to characterize a 
patient’s resistance to ESA.
Methods: We use retrospective data from a cohort study of incident hemodialysis 
patients (n=8924). ERI is defined as average weekly erythropoietin (EPO) dose (IU) per 
kg body weight (EPOwt) per average hemoglobin (Hgb) (g/dl)) over a 3-month period. 
Linear regression was used to describe the relationship between ERI and EPOwt. Logistic 
(Cox proportional hazards) regression modelled the relationship between 1-year mortality 
(survival time) and albumin, age, and either ERI or EPOwt.
Results: ERIs were strongly linearly related with EPOwt (r=0.98) but weakly correlated 
with 1/Hgb (r=0.44). Associations between covariates and mortality based on two logistic 
regression models differing only by a single covariate, EPOwt or ERI, were almost identical 
(figure 1) ; the same was found for Cox proportional hazards models (Table 2). 
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The area under the ROC curve (AUC) was changed by <1% when covariates ERI or 
EPOwt were removed from the logistic regression model (AUC = 0.71, sensitivity = 0.66, 
specificity = 0.65.).
Conclusions: ERIs are strongly linearly related to weight-adjusted EPO doses by a 
“universal” (i.e., not patient specific) formula, hence are merely surrogates of EPO dose. 
Because true resistance must depend on both the input, (EPO) and its effect (Hgb increase 
over endogenous Hgb level), ERI appears to be a poor marker of resistance. EPO dose 
itself, even though a statistically significant covariate, does not substantially strengthen the 
association between mortality and albumin and age as assessed by logistic or Cox regression.
Funding: NIDDK Support
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Evaluation of Iron Deposition by MRI in the Heart and Liver in End 
Stage Renal Disease Patients on Hemodialysis  Rhea Bhargava,1 Ibrahim 
Saeed,3 Joseph S. Soltys,4 Omkar U. Vaidya.2  1Dept of Internal Medicine, 
Univ of Missouri- Kansas City, Kansas City, MO; 2Dept of Nephrology and 
Hypertension, Univ of Missouri- Kansas City, Kansas City, MO; 3Dept of 
Cardiovascular Diseases, Mid America Heart Inst, Saint Luke’s Hospital, 
Kansas City, MO; 4Dept of Cardioascular Imaging, Cardiovascular Imaging 
Technologies, LLC, Kansas City, MO.
Background: Anemia is highly prevalent in patients with chronic kidney disease and its 
management is one of the key components of treatment in this population. 2011 introduced 
the bundling system which led to increased use of parenteral iron to treat anemia in this 
population. There has been significant controversy regarding our current model of iron and 
whether this leads to iron overload and increased mortality.
Methods: Retrospective evaluation of patients with end-stage renal disease on 
hemodialysis who had a cardiac MRI for clinical reasons to evaluate for iron deposition 
in the heart and liver. Exclusion criteria: Porphyria cutanea tarda, chronic liver disease, 
hemochromatosis,sideroblastic anemia , thalassemia. Inclusion criteria:End stage renal 
disease and received a cardiac MRI after 3-5 years of hemodilaysis.
Results: Average total dose of venofer dose before cardiac MRI was 3500 mg. Average 
ferritin level :695 ng/ml. Average iron saturation : 34%. All patients receiving IV iron had 
hepatic iron deposition. No correlation was seen between ferritin or iron saturation and 
hepatic iron deposition. A weak relationship was noted between the total iron dose and 
hepatic iron deposition.
Conclusions: These data suggest that even though we still use iron markers like 
ferritin and iron saturation for treatment of anemia in ESRD patients,this may not have a 
correlation with iron deposition in the liver. Significant iron deposition was not noted in 
the myocardium. MRI can be a useful modality to evaluate iron overload in this population. 
Larger studies are needed to evaluate this issue and to formulate an ideal way of intravenous 
iron dosing in ESRD patient on hemodialysis.
SA-PO810
Achieved Iron Stores and Clinical Safety in a Trial of Ferric Citrate as a 
Phosphate Binder  Kausik Umanath,1 Barbara A. Greco,2 Molly Mcfadden,3 
Diana I. Jalal,4 Sean D. Barry,5 Simin Goral,6 Mohammed Sika,7 Robert M. 
Niecestro,8 Mark Koury,7 Julia Lewis,7 Tom Greene,3 Jamie P. Dwyer,7 The 
Collaborative study group.8  1Henry Ford Hosp; 2Baystate Med Ctr; 3U of Utah; 
4U of Colo; 5LSU Health; 6U of PA; 7Vanderbilt; 8CSG.
Background: Adequate Fe stores are needed for hematopoiesis in ESRD pts on ESA, 
but optimal Fe stores assuring efficacy/safety are unknown. PO Fe preparations have been 
unable to do this. In a multicenter phase 3 RCT we showed ferric citrate (FC) as a Phos 
binder ↑Fe stores and ĻIV iron/ESA use. We studied subjects’ safety in this trial based on 
achieved Fe stores.
Methods: 441 subjects randomized 2:1 to FC or non-Fe-containing active control 
were followed for 52 wks. IV iron use was at a site’s discretion while ferritin£1000 ng/
mL and TSAT£30%. Serious adverse events (SAE), ferritin and TSAT were studied using 
time-dependent Cox regression, relating trailing 3-mo running means of ferritin/TSAT to 
subsequent SAE. 1° outcome was composite of CV, ID, GI and Hepatobiliary SAE. Clinical 
classes of ferritin/TSAT were used, adjusted for age, sex, black race, DKD and prior CVD.
Results: 437 subjects were analyzable. No baseline ∆ among groups existed. TSAT 
30-50% protected against future SAE, Table 1, but not so for any ferritin category, Table 
2. Hazard ratio (HR) for 1° outcome per 10 unit ∆ in TSAT was 0.81 (0.66-0.99, p=0.045) 
with adjustment for ferritin, and HR per 400 unit ∆ in ferritin was 1.16 (0.9-1.48, p=0.23) 
with adjustment for TSAT. Sensitivity analyses, adjusted for baseline Alb and Phos, and 
introducing a 1-mo lag to address ?confounding by ferritin as acute phase reactant, showed 
no ∆ in result. 
Conclusions: TSAT 30-50% appears to be protective vs <30%. No TSAT upper limit 
was evident. There were no  SAEs at  ferritin. Fe stores across the range studied did not  risk 
at  levels, and  TSAT associated with ¯risk of ID, CV and GI SAEs.
Funding: Other U.S. Government Support, Pharmaceutical Company Support - 
Keryx Biopharmaceuticals, Inc.
SA-PO811
Paricalcitol, Klotho and Renal Anemia in Hemodialysis Patients 
Miguel Uriol Rivera,1 Sheila Cabello Pelegrin,1 Gonzalo Gómez Marqués,1 
Manuel Luque-Ramírez.2  1Nephrology, Son Espases Univ Hospital, Palma de 
Mallorca, Islas Baleares, Spain; 2Endocrinology, Ramón y Cajal Univ Hospital, 
Madrid, Spain.
Background: Low Klotho levels, a protein linked to aging, is associated with an 
increase in the eryptosis process(programmed red-cell death). Chronic Kidney Disease is 
considered as a state of Klotho deficiency. We evaluate the association between plasma 
sKlotho levels with iron and hematologic parameters, and the influence of paricalcitol on 
their changes.
Methods: Data were obtained from the MIR-EPO study (EudraCT: 2009-015511-
40). Chronic hemodialysis patients were stratified as a function of paricalcitol use(Group 
A) or not(Group B). Erythropoietin-stimulating agents (ESA) and iron supplementation 
were administered in order to maintain hemoglobin(Hb) between 10.5 and 12.0 g/dl 
and transferrin saturation(TSAT) ≥ 20%. After a 3-month titration period, sKlotho was 
measured(month 3 and 6 of follow-up) by ELISA. The changes in sKlotho from month 
3 to 6 (∆) and their associations with iron metabolism and hematologic parameters as a 
function of paricalcitol use were assessed.
Results: A total of 31 patients were evaluated(Group A: 23; Group B: 8). Intact 
parathyroid hormone(iPTH) levels and ESA doses did not change during the study. Mean 
sKlotho levels decreased at month 6 compared to month 3 in the whole group of patients(527 
vs 474 pg/ml; P=0.001). After adjustment for iPTH and globular sedimentation rate, mean 
sKlotho levels in the Group A were higher than those observed in the Group B throughout 
the study(537 versus 401 pg/ml, P=0.005). ∆ sKlotho correlated with ∆ serum iron(r:0.42, 
P=0.020) in the Group A of patients. A cubic regression model showed that ∆ sKlotho 
strongly explained ∆ serum iron in these subjects(F:9.5, R2:0.64, P=0.001). ∆ sKlotho were 
also associated with changes in iron supplementation (r: -0.47, P = 0.030) in the Group A 
of patients. In the Group B, a direct correlation between ∆ sKlotho and ∆ red blood cell 
count was found (r: 0.73, P = 0.030).
Conclusions: Soluble Klotho is associated with iron metabolism in hemodialysis 
patients. Higher soluble Klotho levels may be a novel beneficial effect of paricalcitol use 
on renal anemia.
Funding: Private Foundation Support
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Influence of the Paricalcitol on Iron Metabolism in Hemodialysis 
Patients  Miguel Uriol Rivera,1 Juan Rey Valeriano,1 Aina Obrador,1 Manuel 
Luque-Ramírez.2  1Nephrology, Son Espases Univ Hospital, Palma de Mallorca, 
Islas Baleares, Spain; 2Endocrinology, Ramón y Cajal Univ Hospital, Madrid.
Background: Interleukin-6(IL-6) and hepcidin may play a role in the pathogenesis 
of iron functional deficiency(IFD). The influence of the Paricalcitol in IFD is not known.
Methods: Data were obtained from the MIR-EPO study(EudraCT:2009-015511-40). 
Chronic hemodialysis patients were stratified as a function of paricalcitol use(Group A) 
or not(Group B). Erythropoiesis-stimulating agents(ESA) and iron supplements were 
administered in order to maintain hemoglobin(Hb) between 10.5 and 12.0 g/dl and 
transferrin saturation (TSAT)³20%. After a 3-month titration period, plasma IL-6 and 
hepcidin were measured(month 3 and 6 of follow-up) by ELISA. The changes in IL-6 and 
hepcidin levels from month 3 to 6 (∆) and their associations with iron metabolism and 
hematologic parameters as a function of paricalcitol use were assessed.
Results: A total of 31 patients were evaluated(Group A:23; Group B:8). Intact 
parathyroid hormone(iPTH) and ESA doses did not change throughout the study. We found 
no correlation between ∆IL-6 and ∆Hepcidin(r:-0.10,P=0.640). However, ∆IL-6 correlated 
with DTSAT(r:-0.40,P=0.030). After adjustment for iPTH and globular sedimentation rate, 
mean IL-6 levels in Group A were lower than in Group B(8 versus 22 pg/ml,P=0.010). IL-6 
levels decreased in the whole group of patients throughout the study, but these changes 
correlated with an increase in serum iron and TSAT only in the Group A. Hepcidin decreased 
in the whole group of patients throughout the study as well. Correlation between ∆Hepcidin 
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and ∆Hb(r:-0.49,P=0.010) was found in the whole group of patients. Interestingly, mean 
hepcidin levels were higher in Group A than in Group B(992 vs 494 pg/ml,P=0.050) during 
the study. In the Group A, ∆Hepcidin correlated with ∆Hb(r:-0.55,P=0.030).
Conclusions: IL-6 and hepcidin are likely related to different iron pools (functional and 
storage, respectively) since no correlations between their changes were found. Paricalcitol 
therapy showed an unexpected increase in iron availability for erythropoiesis that might 
be associated with changes in IL-6 and hepcidin levels.
Funding: Private Foundation Support
SA-PO813
48 Week Open Label Safety Extension Study with Ferric Citrate 
Demonstrates Favorable Safety Profile in Subjects Not on Intravenous 
Iron: A Post-Hoc Analysis  Bryce Foote, Lisa Loram, Luke S. Acree, Adam 
Schayowitz.  Keryx Biopharmaceuticals, Boston, MA.
Background: Ferric citrate (FC) is an iron-based phosphate binder approved for the 
control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The 
Phase 3 pivotal trial in subjects with ESRD demonstrated FC to effectively control serum 
phosphorus but also significantly increased serum iron parameters. This 48 –week open 
label extension study to the Phase 3 pivotal trial was conducted to demonstrate long-term 
safety of ferric citrate. The primary data have been reported previously.
Methods: Subjects from the pivotal FC RCT (NCT01191255) who completed the 
active control period and, if eligible, the placebo control period were eligible to enroll in 
the safety extension trial. 79% had a time lag between participation in the RCT and this 
trial. The primary outcome was safety as assessed by lab data and adverse events (AE). 168 
subjects enrolled. 166 received a dose of FC. The data presented are a post-hoc analysis 
of 98 of the 166 subjects that did not receive IV iron for the duration of the 48-week trial. 
Safety data regarding changes in serum iron parameters and treatment emergent AEs by 
system organ class are presented.
Results: Of the 98 subjects included in this analysis, 71 subjects were randomized to 
FC in the previous Phase 3 trial and 27 to the AC group. Table below shows the changes in 
TSAT and serum ferritin over the 48 wk period. Data presented as mean (SD). 
Time (wk) TSAT (%) Serum ferritin (ng/mL)
0 34.5 (14.1) 772 (378)
12 37.9 (16) 891 (458)
24 38.1 (15.9) 904 (450)
36 41.7 (19.1) 961 (517)
48 40.9 (19) 872 (417)
83% of subjects experienced at least one treatment emergent adverse event with the 
most common being gastrointestinal disorders (40%) and infections and infestations (37%).
Conclusions: Subjects receiving ferric citrate and no IV iron demonstrated serum 
phosphorus control over the 48 wk study period, and an increase in TSAT and serum 
ferritin. The increase in TSAT did not exceed 45% in subjects receiving ferric citrate and 
no IV iron, which might suggest that ferric citrate is absorbed but the risk of excessive 
iron absorption is low.
Funding: Pharmaceutical Company Support - Keryx Biopharmaceuticals
SA-PO814
Iron Isomaltoside: A Novel Intravenous Iron Preparation for Hemodialysis 
David Jackson, Christopher Brown, Grant Sugiura, Rachel S. Ashcroft, Ashraf 
I. Mikhail.  Nephrology, ABM Univ Health Board, United Kingdom.
Background: Diafer® (iron isomaltoside) is newly licensed in Europe for iron 
deficiency anaemia in CKD patients on dialysis. It is thought the controlled-release matrix 
minimises free iron; possibly reducing side effects. Little is known about the efficacy & 
safety of Diafer in clinical practice. This study aims to assess the impact of this novel 
formulation on anemia parameters in prevalent hemodialysis (HD) patients previously 
maintained on iron sucrose.
Methods: Data was collected for 13 months; 6 month pre-switch (iron sucrose), 1 
month crossover, & 6 month post-switch (iron isomaltoside). All patients received dialysis 
for ≥ 3 months before evaluation, excluding potential bias of iron loading doses. For both 
preparations, patients received intradialytic bolus doses of 100mg at frequencies dependant 
on individual requirements as per current practice.
Results: 
n= 51 pts Iron Sucrose Switch Iron Isomaltoside
Sig
Parameter 
Mth -6 to -1 Mth 0 Mth +1 to +6
Mean Median Mean Mean Median
Hb (g/l) 111 112 110 110 111 N
Ferritin (ng/ml) 449 447 477 459 435 N
TSAT (%) 19.5 19.0 20.4 21.2 20.0 Y
ESA (U/wk) 7868 6000 7980 7053 6000 Y
Iron (mg/mth) 202 200 186 168 200 Y
CRP (mg/l) 14 7 15 18 8 Y
The percentage of patients maitaining Hb target (100-120g/L) was 71% with iron 
sucrose & 70% with iron isomaltoside. No adverse drug reactions were observed. No 
metallic tastes were reported with Diafer administration. The CRP rise during months 1-6 
was imparted by 2 infections & 1 amputation.
Conclusions: Iron isomaltoside maintains Hb stability & adequate iron status in HD 
patients when incorporated into current practice. While these data suggest Diafer may 
reduce ESA & iron requirements, further analyses are necessary to validate these findings. 
Whether the potential to reduce labile iron with iron isomaltoside impacts on clinical 
outcomes is yet to be determined.
Funding: Government Support - Non-U.S.
SA-PO815
Low Iron Availability May Influence on Second Patency Rates of Vascular 
Access in Patients on Hemodialysis  Yukiko Hasuike, Wataru Fukao, Takeshi 
Nakanishi.  Div of Kidney and Dialysis, Dept of Internal Medicine, Hyogo 
College of Medicine, Nishinomiya, Hyogo, Japan.
Background: Vascular access (VA) is essential for the patients on HD. However, VA 
failure is often occurred even after percutaneous-transluminal angioplasty (PTA). Iron is 
important for normal vascular physiology, and insufficient iron availability can lead to 
various vascular dysfunction. The purpose of this study was to examine the factors affecting 
VA patency after PTA, including iron availability and oxidative stress.
Methods: Blood samples were taken from 281 HD patients at the PTA. Routine blood 
chemistries and factors related to iron metabolism (transferrin saturation rate (TST), ferritin), 
oxidative stress (advanced oxidation protein products (AOPP), 8OHdG, GSH/GSSG), and 
inflammation (high-sensitive CRP, interleukin-6, tumor necrosis factor-α, pentraxin-3) were 
measured. The end point of study was the re-vascularization or re-operation of VA during the 
observational period after PTA. Cox proportional hazards models for the end point was used.
Results: 133 patients (47.3%) had native arteriovenous fistula. During follow-up 
period, re-vascularization was performed in 34 patients and re-operation in 31 patients. 
The patients with VA failure had higher numbers of leukocytes and platelet, significantly 
lower TST, and a tendency of higher AOPP compared with the patients without VA failure. 
There was no significant difference in other factors between the patients with and without 
VA failure. The Kaplan-Meier analysis showed lower TST (‹20%) was associated with VA 
failure (p=0.0010, (figure 1)). 
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Cox regression analysis also revealed that lower TST (hazard ratio 2.316, 95% 
confidence interval 1.385-3.873, p=0.0014) was related to VA failure.
Conclusions: TST ‹20% was associated with the poorest event-free patency of VA after 
PTA. Low Iron availability might affect the second patency rates of VA.
SA-PO816
Triferic Has a Safety Profile Similar to Placebo: An Integrated Safety 
Analysis of Phase 2 and 3 Studies  Vivian H. Lin, Raymond D. Pratt, Carrie 
D. Guss, Ajay Gupta.  R&D, Rockwell Medical Inc, Wixom, MI.
Background: Triferic is a novel soluble iron compound delivered via the dialysate to 
prevent iron deficiency and maintain hemoglobin in CKD-HD patients.
Methods: The Triferic clinical program included 3 large placebo-controlled efficacy 
studies lasting 36 to 48 weeks (Controlled Studies), one large placebo-controlled short-term 
safety study, 3 open-label (OL) safety studies of up to 48 weeks, and 3 small controlled 
early Phase 2 studies. Patients randomized to Triferic in the 2 pivotal controlled studies 
who completed the randomized treatment and transitioned to the OL study received Triferic 
for up to 72 weeks.
Results: Exposure-adjusted most frequent adverse event rates (AE) are presented in 
the table below. 
Controlled Studies All Studies
Adverse Events Triferic Placebo All Triferic
Subjects (N)
PYE (Patient Year)
Total TEAE (N)
346
159
2089
345
161
2081
1411
780
10766
Events/100 Patient-Years of Exposure
Procedural hypotension 291.5 290.6 226.6
AVF Site Complication 35.3 39.1 39.7
Headache 34.6 21.1 33.2
Nausea 29.6 34.8 36.4
Dizziness 28.3 20.5 28.0
HD-induced Symptom 27.7 25.5 68.1
Cough 26.4 18.0 17.2
Diarrhea 25.8 31.1 33.0
Muscle Spasms 22.7 26.7 19.6
Discontinuations and exposure-adjusted AE were similar to placebo in the controlled 
studies with no increase in the OL studies. The exposure-adjusted mortality rate in the 
Controlled Triferic group was 7.9/100 PYE, compared to 7.2/100 PYE in placebo. The 
mortality rate in the All Triferic group was 6.5/100 PYE. No deaths occurred during Triferic 
administration and none were attributed to Triferic. There were no reports of anaphylaxis 
in over 100,000 individual doses of Triferic. Suspected hypersensitivity reactions, vascular 
access thrombotic events, composite cardiovascular events and systemic or serious 
infections were also similar between the Triferic and placebo groups.
Conclusions: Triferic was well tolerated in long-term controlled and OL studies. 
Triferic, administered at each treatment, maintained Hgb and iron balance compared to 
placebo. The safety profile in short and long-term studies supports a favorable benefit-risk 
profile for use as a maintenance iron therapy for CKD-HD patients.
Funding: Pharmaceutical Company Support - Rockwell Medical Inc.
SA-PO817
Structural, Physical and Functional Characterization of Ferric 
Pyrophosphate Citrate (FPC, Triferic), A Novel Iron Compound for 
Pharmaceutical Applications  Ajay Gupta,1 Garry J. Handelman,2 Raymond 
D. Pratt.1  1R&D, Rockwell Medical Inc., Wixom, MI; 2Univ Massachussetts, 
Lowell, MA.
Background: Ferric pyrophosphate citrate (FPC) is the first iron compound approved 
for parenteral administration that is not an iron-carbohydrate complex. FPC has a molecular 
mass of about 1313 Da, and high solubility of FPC in aqueous solutions allows its 
administration via the dialysate.
Methods: FPC is a complex iron salt in which Fe3+ is bound to pyrophosphate (PPi) and 
citrate by coordinate covalent bonds. Extended X-ray absorption fine structure (EXAFS) 
spectroscopy showed that the Fe in FPC is in the ferric (Fe3+) state and does not complex 
with sulfate. EXAFS analysis demonstrated that Fe forms a stable complex with 6 O atoms 
at 2.02 Å in the first coordination sphere and with 2 P and 4 C atoms at 3.22 Å and 2.98 
Å, respectively, in the second coordination sphere. FPC demonstrates stability in both the 
solid and solution forms.
Results: The uptake rate of FPC iron by human apo-transferrin was measured in vitro 
by monitoring absorbance at 471 nm. At an identical set of conditions we observed 75% 
Tf saturation in <10, 15, and >9 x 104 sec for Fe(NTA), FPC and Fe(citrate), respectively. 
We conclude that Tf loading from FPC is rapid and of similar magnitude to that from ferric 
nitriloacetic acid, but over four orders of magnitude faster than from ferric citrate. The 
observed rapid binding kinetics allows for facile Fe3+ uptake by transferrin for transport to 
the bone marrow for hemoglobin synthesis. Pharmacokinetic studies of FPC administered 
IV to healthy volunteers demonstrate dose-proportional kinetics with a t½ of approximately 
1.4 hours. No non-transferrin bound iron has been detected at TSAT levels of up to 100%.
Conclusions: FPC is a novel iron compound that is ideally suited as a maintenance 
treatment for CKD 5HD patients. FPC replaces ongoing iron losses and maintains 
hemoglobin. The small doses of iron and the lack of a carbohydrate shell contribute to the 
favorable safety profile. FPC represents a new paradigm for rational iron replacement in 
patients on chronic hemodialysis.
Funding: Pharmaceutical Company Support - Rockwell Medical Inc.
SA-PO818
Proton Pump Inhibitors and CYP2C19 Are Associated with Iron-Deficiency 
Anemia in Hemodialysis Patients: A Cross-Sectional Study  Akio Nakashima,1 
Ichiro Ohkido,1 Keitaro Yokoyama,1 Mitsuyoshi Urashima,2 Takashi Yokoo.1 
1Div of Nephrology and Hypertension, Dept of Internal Medicine, Jikei Univ 
School of Medicine, Tokyo, Japan; 2Div of Molecular Epidemiology, Jikei Univ 
School of Medicine, Tokyo, Japan.
Background: Hyporesponsiveness to erythropoiesis stimulating agents (ESA) is an 
important phenomenon in dialysis patients. As chronic proton pump inhibitor (PPI) use 
reduces gastric acid secretion, it seems possible that chronic PPI use might lead to iron 
malabsorption and anemia. In addition, PPI is mainly metabolized by cytochrome P450 
(CYP) enzymes, particularly CYP2C19, in the liver. The genotypes of CYP2C19 affect the 
pharmacokinetics and pharmacodynamics of PPI. However, there is no study investigating 
the relationship between PPI use and anemia status that includes the effect of CYP2C19 
genotype in hemodialysis patients.
Methods: This cross-sectional cohort study analyzed 1350 hemodialysis patients. DNA 
was isolated from leukocytes in peripheral blood. We used polymerase chain reactions and 
direct sequencing to analyze CYP2C19 genotypes. We analyzed anemia status with and 
without PPI usage, including the association with CYP2C19 genotypes.
Results: PPI use was associated with a significantly lower mean serum hemoglobin 
concentration. Iron and TSAT were also lower in PPI users. ESA dosage was significantly 
higher in patients receiving PPIs(mean [SD] PPI: 3685 [3288] IU/week; non-PPI: 2899 
[2734] IU/week; P<0.001), and multiple regression analysis indicated a significant 
relationship between PPI use and ESA dosage(β: 494.1 P=0.011). CYP2C19 genotypes 
were significantly associated with iron status and anemia. Multiple regression analysis 
demonstrated that CYP2C19 poor metabolizer (PM) type was significantly associated with 
ESA dosage in PPI users (β: 901.1 P=0.036).
Conclusions: In this study, we found that PPI use is associated with iron status and 
anemia in hemodialysis patients. Among the dialysis patients receiving PPIs, CYP2C19 
genotype was associated with hemoglobin levels, ESA dosage, and iron status.
SA-PO819
A 4-Week Dose Response Study of the Hypoxia Inducible Factor-Prolyl 
Hydroxylase Inhibitor GSK1278863 in Japanese Anemic Hemodialysis 
Subjects  Yukihiro Endo,1 Tomoko Kohno,1 Yukiko Imai,1 Natsumi Kawase,1 
Katsutoshi Hara,1 John J. Lepore,2 Alexander Ralph Cobitz.2  1GlaxoSmithKline, 
Tokyo, Japan; 2GlaxoSmithKline, King of Prussia, PA.
Background: Hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitors, such as 
GSK1278863, are an emerging class of oral agents for treatment of anemia associated with 
chronic kidney disease (CKD). Dose response of GSK1278863 for anemia correction in 
Japanese hemodialysis-dependent (HDD) subjects is reported.
Methods: We evaluated the relationship between GSK1278863 dose and hemoglobin 
(Hgb) response in Japanese HDD subjects with anemia of CKD in a 4-week, randomized, 
double-blind, placebo-controlled study (funded by GlaxoSmithKline). Subjects on thrice 
weekly hemodialysis for at least 8 weeks and with Hgb of 8.5-10.5 g/dL after stopping their 
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erythropoiesis stimulating agent for at least 2 weeks were randomized to placebo or to 4 mg, 
6 mg, 8 mg or 10 mg of GSK1278863 once daily. The primary endpoint was Hgb change 
from baseline at Week 4. Other endpoints included circulating levels of erythropoietin 
(EPO), vascular endothelial growth factor (VEGF) and hepcidin.
Results: A total of 97 subjects were randomized, and 86 subjects completed the study. 
Mean Hgb at baseline ranged from 9.68 g/dL to 9.92 g/dL across the treatment groups. 
After 4-week treatment, GSK1278863 produced dose-dependent increases in mean Hgb 
from baseline (placebo: -1.41 g/dL; 4 mg: -0.28 g/dL; 6 mg: -0.01 g/dL; 8 mg: 0.54 g/dL; 
10 mg: 0.97 g/dL). A posterior distribution from Bayesian four parameter Emax model 
estimated that 2.0 mg, 3.9 mg and 8.7 mg doses would, on average, lead to achieve placebo 
corrected increases in Hgb over 4 weeks of 0.5 g/dL, 1.0 g/dL and 2.0 g/dL, respectively. 
Dose-dependent increases in EPO and decreases in hepcidin were observed across the 
GSK1278863 groups, while no trends of increase in VEGF were observed in any groups. 
All AEs were reported as single instances in any treatment groups except nasopharyngitis, 
and no trends in AEs were noted. There were no deaths in the study.
Conclusions: This study demonstrated that GSK1278863 produced dose-dependent 
elevations in Hgb concentration in Japanese HDD subjects across the dose range tested.
SA-PO820
A Three-Year Study of an ESA Treatment Algorithm for Patients with Renal 
Anemia: Stable Hb Levels Obtained with Twice-Monthly Administration of 
CERA (Second Report)  Teruhiko Maeba, Shigeru Owada.  Internal Medicine, 
Asao Kidney Clinic, Kawasaki, Japan.
Background: Treatment of renal anemia in hemodialysis(HD) patients requires 
an adequate ESA dosage to maintain stable Hb levels. Guidelines in Japan recommend 
determining ESA dosage based on Hb levels measured twice a month. An algorithm for the 
administration of continuous erythropoietin receptor activator (CERA) has been prepared 
and implemented to treat patients on HD. The 2-year study results were previously reported 
during the ASN Kidney Week 2014 (TH-PO 820).
Methods: Based on the algorithm, CERA was administered for 1 year to 102 HD 
patients being treated with rHuEPO. After the 1st year, the algorithm was reviewed, 
and some cases of fluctuating Hb levels because of terminating and restarting CERA 
administration were found. Therefore, the algorithm was revised. Consequently, CERA 
administration was continued for another 2 years. The target Hb level was 10.5–11.0 g/
dl, and Hb levels, CERA dosage, Erythropoietin Resistance Index (ERI), and iron dosage 
were investigated. CERA was administered once every 2 weeks, and the dosages were 
changed within a range of 25 mg/dose based on Hb levels. The standard iron dosage was 
not changed during the evaluation period.
Results: Hb levels at the baseline and 1, 2, and 3 years after the baseline measurement 
were 10.9 and 11.1, 11.2, and 11.2 g/dl, respectively. The corresponding CERA dosages, 
administered every 2 weeks, were 62 ± 16, 38 ± 25 , 36 ± 23, and 33 ± 21 mg, respectively, 
and ERI values were 0.11 ± 0.04, 0.06 ± 0.05, 0.06 ± 0.04, and 0.06 ± 0.04, respectively. 
To reduce fluctuations in Hb levels to a possible extent, terminating CERA administration 
was avoided. Serum ferritin levels gradually decreased from 147.9 ± 122.1 at the baseline 
to 112 ± 95, 88 ± 67, and 67 ± 47 ng/ml in the 1st, 2nd and 3rd years, respectively, and 
weekly iron dosage decreased from 13± 1.5  at the baseline to 11 ± 2.6 and 11 ± 2.4 mg in 
the 2nd and 3rd years, respectively.
Conclusions: Three years of twice-monthly CERA administration, based on the 
algorithm, could maintain stable Hb levels, improve ERI, and reduce iron dosage. Twice-
monthly CERA administration based on the algorithm effectively controlled anemia in 
HD patients.
SA-PO821
Continuous Erythropoiesis Receptor Activator (CERA) for the Anemia 
of Chronic Kidney Disease (CKD): A Meta-Analysis of Randomized 
Controlled Trials  Valeria M. Saglimbene,1 Suetonia Palmer,2,3 Giovanni F.M. 
Strippoli.1,3  1Diaverum Medical Scientific 2ffice; 2Univ of Otago Christchurch; 
3Cochrane Kidney and Transplant.
Background: Targeting high hemoglobin levels with erythropoiesis-stimulating agents 
(ESA) leads to adverse effects in people with chronic kidney disease (CKD). Whether there 
are treatment differences between different ESA agents is uncertain.
Methods: We did a systematic review of randomized controlled trials evaluating 
treatment effects of CERA compared with other epoetins (darbepoetin alfa and epoetin 
alfa or beta) or placebo/no treatment, in people with any stage of CKD. We systematically 
searched Cochrane databases. Results were expressed as risk ratios (RR) and their 95% 
confidence intervals (CI) for dichotomous outcomes, and mean difference and 95% CI for 
continuous outcomes using random-effects meta-analysis.
Results: 17 studies involving 5397 participants were eligible. Studies compared CERA 
with epoetin (n=8 studies), darbepoetin (n=5), differing frequency (n=2) and dose (n=4). 
Compared to epoetin and darbepoetin CERA had similar effects on mortality, hypertension, 
need for blood transfusion and iron therapy.
Outcome Relative Risk (95% CI)
CERA vs epoetin CERA vs darbepoetin
Mortality 1.06 (0.72-1.55) 1.10 (0.73-1.65)
Hypertension 1.01 (0.86-1.18) 1.00 (0.73-1.36)
Need for blood transfusion 0.94 (0.68-1.30) 0.64 (0.30-1.37)
Iron therapy 1.03 (0.91-1.15) 0.99 (0.95-1.03)
In two studies of low-moderate risk of bias, CERA significantly improved quality of 
life as measured by SF36. Data were sparse for differing frequency of administration and 
dose. Evidence for treatment effects of CERA was absent among children and particularly 
limited for kidney transplant recipients. Studies included in this review were generally at 
high or unclear risk of bias.
Conclusions: There is no evidence that CERA has different effects on patients-centered 
outcomes compared to epoetin or darbepoetin among adults with CKD. CERA may improve 
health-related quality of life, but further high quality trials are needed. Its effects in children 
with CKD and kidney transplant recipients remains poorly understood.
SA-PO822
Risks of Long-Term Management for Anemia, Cardiovascular Disease 
(CVD) Death and Risk Factors for Heart Failure in Maintenance 
Hemodialysis  Hajime Hirano,1 Haruhito Azuma,1 Hideaki Shima.2  1Blood 
Purification Center, 2saka Medical Collage, Takatsuki, Japan; 2Nephrology, 
Osaka Medical Collage, Takatsuki, Japan.
Background: In this study, to evaluate the various outcome factors, the effects of 
improvement in anemia in patients treated with hemodialysis on the vital prognosis were 
evaluated focusing on changes after enrollment.
Methods: This retrospective study was conducted with 201 outpatients with 
hemodialysis at our Blood Purification Therapy Center and our other related hemodialysis 
facilities from March 2005 to February 2007 (24 months, 136 males and 65 females, age: 
male: 59.4 years old, female: 59.8 years old, overall: 59.5 years old). Using CVD death and 
hospitalization due to heart failure as outcomes, 2-year risk of CVD death was analyzed by 
logistic regression model with surviving patients. In addition, to assess anemia, changes 
over a long time after start of observation were evaluated.
Results: The multivariate analysis reveled 3 factors for CVD death risk including 
smoking history (OR: 9.06 [95%CI: 1.86~44.0, p=0.006]), history of ischemic heart 
disease (OR: 3.82 [95%CI: 1.19~12.25, p=0.024]) and hypercalcemia. (OR: 1.77 [95%CI: 
1.00~3.13, p=0.049]). Similarly, the risk factors for heart failure were smoking (OR:3.11 
[95%CI:0.78~12.36, p=0.101]) and history of ischemic heart disease (OR: 5.03 [95%CI: 
1.46~17.33, p=0.010]), and history of ischemic heart disease was the only significant 
variable in the final step.
Conclusions: The factors that influence the risk of CVD death included smoking, 
history of ischemic heart disease and hypercalcemia. The risk factors occurring heart failure 
included history of IHD, and it was shown that the effects of smoking and history of IHD 
on prognosis were stronger than the effects of anemia. The evaluation of changes in Hb 
over time revealed that the low Hb sustained for a long time would increase the risk. In 
addition, the risk of death was high in the high-dose rHuEPO group suggesting the risk in 
the low rHuEPO response patients.
SA-PO823
Anemia Management in ESRD Patients Admitted to the Hospital 
Priyanka Govindan, Arjun V. Sharma.  Dept of Nephrology, Univ of Washington 
Medical Center, Seattle, WA.
Background: Anemia was twice as prevalent in people with CKD (15.4%) as in the 
general population (7.6%). The prevalence of anemia increased with stage of CKD, from 
8.4% at stage 1 to 53.4% at stage 5. Anemia can be managed successfully with appropriate 
investigations and therapy in the ESRD population. The aim of the study was to see how 
appropriate the management of anemia was in our hospital in patients on dialysis and to 
identify areas for improvement.
Methods: Selected patients were those with ESRD on hemodialysis and peritoneal 
dialysis that underwent in- hospital dialysis at the University of Washington Medical Center 
from July 1st 2014 to Sep 30th 2014. The patients who had been undergoing dialysis for 
less than 12 weeks were considered to have AKI and were excluded from the analysis. In 
addition, the patients who underwent dialysis only in the Intensive Care units were excluded. 
The data was collected from the electronic medical records of the individual patient charts. 
Gender, Age, Anemia status, Lowest Hemoglobin , Iron panel, Reticulocyte count were 
noted in addition to treatment with iron, blood transfusions and ESA.
Results: A total 145 dialysis patients were identified and 65 of them had both ESRD 
and anemia. 73.86% of these patients were found to be anemic by KDIGO. Patients in the 
60-69 age range had the largest number of anemia with a total of 20 falling in this category. 
18 patients had a Hemoglobin between 7.0-7.9. Among the anemic patients 48.5% did not 
have an iron panel checked and 86.4% did not have a reticulocyte count checked. 40% of 
those with a Hb < 6 mg /dl had an iron panel checked. In patients with Hemoglobin of less 
than 11 31% were treated with ESA at least once during their hospital stay. 36.36% received 
transfusions. 50% of the patients who received blood transfusions did not have an iron panel.
Conclusions: Routine investigations for the management of anemia are being missed 
regularly. Worse anemia was associated with fewer investigations. We suspect that the 
management of anemia in patients with ESRD can be improved with more comprehensive 
labs and therapy. • We intend to follow up with an intervention involving the EMR making 
it easier to work up anemia in the hospital.
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SA-PO824
Variability in Hemoglobin (Hb) Levels in Hemodialysis (HD) Patients in the 
Current Era  David T. Gilbertson,1 Yan Hu,1 Yi Peng,1 Sarb Shergill,2 Bradley 
J. Maroni.2  1CDRG/MMRF; 2Akebia Therapeutics, Inc.
Background: Hb variability in dialysis patients has been characterized using a 
number of methods. The majority of this work occurred prior to the 2011 change in CMS 
reimbursement policy and ESA labels. We therefore examined Hb variability and patient 
demographics from current data and compared the results to those obtained prior to 
implementation of these policy changes.
Methods: We used CMS ESRD data to define a cohort of chronic HD patients who 
were alive from Apr 1 through Dec 31, 2012. Using a method from Ebben et al. (CJASN 
1:1205-1210, 2006), monthly Hb values were categorized as low (L), intermediate (I), and 
high (H), where L and H were based on monthly Hb values below or above the 25th and 
75th percentiles, respectively. Variability was then classified based on the Hb categories 
during a 6-month period, resulting in 6 categories of variability (see figure legend).
Results: The figure compares the percentage (%) of patients in each Hb variability 
group in 2004 compared to 2012. The 25th and 75th percentiles in the 2012 data were 10.2 
and 11.5. Corresponding 2004 values were 11 and 12.5. Similar % of patients were observed 
in 2004 and 2012 for the LL and IH categories. A higher % of patients was consistently 
intermediate (II) in 2012 than 2004 (9.5% vs. 6.0%), whereas a larger % was observed for 
LI and a smaller % for LH. Compared to the overall 2012 cohort, II patients were older 
(mean=65.2), and LL or HH patients were younger (mean=58.2 and 57.8). LL had the 
highest % who were black (48.8%).
Conclusions: While Hb levels have decreased during the last few years, Hb variability 
is still present. The lower % of patients in the LH group is consistent with a narrowing of 
the overall Hb distribution. Further studies are needed to assess the association of variability 
with outcomes in the current era. 
Funding: Pharmaceutical Company Support - Akebia Therapeutics, Inc.
SA-PO825
Prevalence and Predictors of Naturally Occurring Normal Hemoglobin 
Concentration in Hemodialysis Patients  Zakaria Abdulnabi, Veeda O. 
Landeras, Shalini Bumb, Abdulah Alrifai, Jay B. Wish, Peter B. De Oreo, Thomas 
H. Hostetter, Mirela A. Dobre.  Case Western Reserve Univ, Cleveland, OH.
Background: Epidemiological data and clinical observations suggest that 
erythropoietin producing cells exist even in ESRD kidneys. A small subset of ESRD patients 
have naturally occurring normal hemoglobin levels, without the use of blood transfusions 
or erythropoietin stimulating agents (ESA), but limited data exists in this field. The aim of 
this study was to evaluate the prevalence and predictors of naturally occurring hemoglobin 
concentration ≥ 12 mg/dl in hemodialysis patients.
Methods: This analysis is a retrospective chart review of ESRD patients receiving 
hemodialysis at Centers for Dialysis Care in East Cleveland, OH, from April-September 
2013. Data collected included demographics, cause of renal disease, co-morbidities, duration 
of ESRD, dialysis access, indices of dialysis adequacy, systolic blood pressure, hemoglobin 
level, PTH, albumin, calcium, phosphorus. Multivariable regression models were used to 
identify independent associations with the outcome of interest.
Results: In this cohort of 449 community dialysis patients, the prevalence of naturally 
occurring hemoglobin level ³12 mg/dL, without the use of ESA, was 5.3%, slightly higher 
than previous reports of around 2%. In unadjusted analyses, compared to ESRD patients 
with a hemoglobin level ³10 mg/dL maintained with the use of ESA, the patients with 
naturally occurring hemoglobin ³12 mg/dL were more likely to be younger, male, with 
an arteriovenous fistula, longer dialysis vintage, lower systolic blood pressure and higher 
serum albumin level. In adjusted analyses, male sex, serum albumin and systolic blood 
pressure remained statistically significantly associated with naturally occurring hemoglobin 
concentration ³12 mg/dL (OR 3.66(95%CI 1.11-12.06); 14.10(2.21– 90.11); and 0.98(0.96 
– 0.99), respectively).
Conclusions: In this sample of community dialysis patients, male sex, serum albumin 
and systolic blood pressure were the strongest predictors of naturally occurring higher 
hemoglobin concentration. Further studies to evaluate the mechanisms underlying these 
associations, including factors stimulating sites of extrarenal erythropoiesis are warranted.
Funding: NIDDK Support
SA-PO826
Estimation of Pre-Dialysis Hemoglobin Concentration Using the Crit-Line® 
Monitor  Stephan Thijssen, Hanjie Zhang, Doris H. Fuertinger, Peter Kotanko. 
Renal Research Inst, New York, NY.
Background: Pre-dialysis laboratory measurements of hemoglobin (Hb) are generally 
used for anemia management. In some clinics, bi-weekly or even weekly Hb measurements 
are performed for this purpose. The Crit-Line® Monitor (CLM) provides Hb non-invasively 
and continuously during hemodialysis (HD), but initial readings early during HD are 
systematically lower than pre-HD laboratory values due to hemodilution caused by the 
priming fluid. We present a method of correcting CLM Hb for hemodilution.
Methods: Pre-HD reference Hb (Hb_Spec) was measured by Spectra East Laboratories. 
Hb obtained by CLM (Hb_CLM) was averaged between minutes 4 and 6 after start of the 
HD treatment. The difference between the two (Hb_Spec - Hb_CLM) was estimated as 
∆Hb = (VBsal * 0.5 A (tBCLM/tB1/2Bsal) - VBUF) * HbBCLM/BV, with VBsal = amount of 
priming fluid (saline) infused at start of HD, tBcrit = time point of HbBCLM measurement 
(5 min into HD), t_1/2_sal = plasma half life of infused saline (20 min, adapted from ATC 
Consensus Statement, 2004), VBUF = cumulative ultrafiltration volume up until tBcrit, 
and BV = pre-HD blood volume (obtained by estimating post-HD BV via Nadler equation 
(using post-HD weight, sex, height), then dividing by end-HD relative blood volume and 
subtracting VBsal). Corrected HbBCLM was calculated as HbBcorr = HbBCLM + ∆Hb.
Results: 5,731 HD treatments from 952 chronic HD patients in the USA were analyzed. 
Without correction, Hb_CLM was found to be systematically lower than Hb_Spec by 
on average 0.425 g/dL (SD 0.59 g/dL). After correction for hemodilution, the difference 
(Hb_corr - Hb_Spec) was reduced to -0.068 g/dL (SD 0.59 g/dL).
Conclusions: When applying a correction for the hemodilution caused by infusion 
of the priming fluid at the start of HD, the corrected Crit-Line® Hb is nearly identical on 
average to the pre-HD Hb measured by a reference laboratory. More and more clinics are 
employing Crit-Line® Monitors for fluid and anemia management. Crit-Line® Hb corrected 
in this way may be used for anemia management, which could reduce blood draws and costs.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
SA-PO827
Hemodialysis (HD) Patients Who Can Maintain Fair Hb Level (>10g/dl) 
without Iron or Erythropoietin (Epo) Administration Showed Higher Serum 
Soluble Transferrin Receptor(sTfR) and Normal Epo, Vitamin C (VC) 
Levels  Noriko Saito,1 Kazuhide Saito,2 Tetsuo Morioka,1 Hisaki Shimada,1 Kozo 
Ikarashi,1 Yutaka Tsubata,1 Shunsuke Sakai,1 Shigeru Miyazaki.1  1Nephrology, 
Shinraku-en Hospital, Niigata, Japan; 2Urology, Niigata Univ, Niigata, Japan.
Background: HD patients have severe anemia and their Hb levels were recommended 
to be maintained at greater than 10g/dl using iron and Epo supplementation. Certain 
HD patients showed Hb levels over 10g/dl without iron or Epo. This time, we studied 
erythropoiesis and iron metabolism markers in these patients in order to analyze the 
background mechanism.
Methods: 21 HD patients who could maintain Hb level at 10g/dl and greater without 
iron or Epo for more than 3 months(G1) were enrolled in this study. 23 HD patients with 
Hb level less than 10g/dl without iron or Epo for more than 2 months(G2) and 30 healthy 
volunteer(GN) were also enrolled as control. Blood samples were collected before HD and 
Epo, hepcidin(HPC), sTfR, VC and standard hematological parameters were examined. 
The data are indicated as median(interquartile range).
Results: 1. In G1, ferritin(20(14-36) ng/ml), transferrin saturation(14(8-19)%), 
HPC(0.7(0.2-4.5)ng/ml) were significantly lower than those in both GN and G2, respectively. 
The percentage of hypochromic RBCs(%HypoHe)(2.7(1.5-4.8)%) was higher than those of 
GN and G2. 2. MCV values were not significantly different in all three groups. 3. sTfR level, 
a marker of erythropoietic activity, of G1(30.0(22.1-36.5)nmol/L) was significantly higher 
than those of GN and G2. 4. Epo level(7.3(5.1-15.2)mIU/mL), reticulocytes(12(9-15)‰) 
and VC(6.8(2.8-23.4)µg/mL) of G1 were not significantly different from those of GN, 
whereas significantly higher than those of G2, respectively. 5. In G1, negative correlation 
was revealed between VC and %HypoHe(r= -0.437, p=0.048), whereas positive correlation 
between %HypoHe and sTfR(r=0.816, p<0.001). By multivariate analysis, %HypoHe was 
the predictor of sTfR(β=0.834, p<0.001).
Conclusions: HD patients with fair Hb level revealed higher sTfR, %HypoHe and 
normal Epo, MCV, VC and low HPC levels. These results indicated that iron utilization of 
these patients was upregulated and this may participate in the maintenance of erythropoiesis.
Funding: Private Foundation Support
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SA-PO828
Acute Effects of Erythropoietin Administration on Blood Pressure in 
Dialysis Patients  Nawf Hamad Al-Gublan, Kristin M. Corapi, Ishir Bhan. 
Nephrology, Massachusetts General Hospital, Boston, MA.
Background: Erythropoiesis-stimulating agent (ESA) doses are often held in patients 
with end stage renal disease (ESRD) because of hypertension. However, missed doses 
may exacerbate anemia of chronic disease. The acute effects of ESA on blood pressure are 
unknown. We hypothesized that ESA administration during dialysis would not be associated 
with a significant change in blood pressure.
Methods: With institutional review board approval, we retrospectively reviewed the 
medical records of 100 hemodialysis patients who were admitted to our hospital between 
1/2013-4/2015. All patients in this study were prescribed, and received, ESA’s during 
dialysis. Patients were excluded if dialyzed in the ICU, received vasopressors, were treated 
for hypertensive urgency (>180/110 mmHg), initiated on hemodialysis, or only underwent 
ultrafiltration without dialysis. Blood pressure just prior to and 2 hours after ESA were 
compared using a paired t-test.
Results: The mean age was 61.6 years (±12.8), 42% were male, 66% were Caucasian, 
16% African-American, and 10% Asian. Mean change in blood pressures immediately prior 
to ESA administration and 2 hours after are summarized. 
Pre-Dialysis Just Prior to ESA
2 Hours Post 
ESA
Mean Change 
(95% CI) 
SBP 136±25 132±27 128±25 -4.5 (1.74) p=0.008
DBP 68±11 67±10 66±11 -1.2 (0.25) p=0.18 
No statistically significant increase in SBP or DBP was noted. In fact, we observed a 
significantly lower SBP 2 hours after ESA dosing. In a subgroup analysis of patients with 
an SBP > 160 immediately prior to ESA administration, an even greater decrease in SBP 
was noted 2 hours after ESA compared to a subgroup with an SBP < 160 (p=0.004). No 
significant relationship existed between dose of ESA and effect on blood pressure (SBP, 
p=0.52; DBP, p=0.95).
Conclusions: We demonstrated a decrease in systolic blood pressure 2 hours after ESA 
administration with no significant change in diastolic blood pressure. Withholding EPO 
during dialysis due to hypertension may be unnecessary.
SA-PO829
Serum Ferritin Predicts Mortality Regardless of Inflammatory and 
Nutritional Status in Incident Peritoneal Dialysis Patients  Meiyan Wu,1 
Kyoung Sook Park,2 Hyung Jung Oh,2 Jung Tak Park,2 Seung Hyeok Han,2 
Tae-Hyun Yoo,2 Shin-Wook Kang.1,2  1Severance Biomedical Science Inst, 
Brain Korea 21 PLUS, Yonsei Univ College of Medicine, Seoul, Korea; 2Dept 
of Internal Medicine, Yonsei Univ College of Medicine, Seoul, Korea.
Background: Serum ferritin levels have been proposed as a prognostic factor in 
hemodialysis (HD) patients, due to its close relationship with inflammation and malnutrition. 
Since iron supplementation methods and factors affecting nutritional status are somewhat 
different from those of HD patients, the impact of serum ferritin on clinical outcomes was 
investigated in incident peritoneal dialysis (PD) patients.
Methods: A prospective cohort of 408 PD patients from the Clinical Research Center 
for End-Stage Renal Disease was selected. Patients were divided into three groups according 
to tertiles of Ln ferritin concentrations (group 1: <4.69 ng/mL, group 2: 4.69-5.58 ng/mL, 
group 3: >5.58 ng/mL). Cox proportional hazard analysis was performed to determine the 
independent prognostic value of serum ferritin levels for all-cause mortality.
Results: The mean age was 51.2±13.2 years and 236 (57.8%) were male. During a 
median follow-up of 25 months, 46 (11.3%) patients died. Univariate Cox analysis revealed 
that the mortality risk was significantly higher in group 2 [hazard ratio (HR)=2.65, 95% 
confidence interval (CI)=1.11-6.34, P= 0.029] and group 3 (HR=3.16, 95% CI=1.33-7.48, 
P=0.009) compared to group 1. Moreover, multivariate Cox proportional hazard models 
revealed that Ln ferritin was independently associated with an increased risk of all-cause 
mortality (per 1 ng/mL increase, HR=1.94, 95% CI=1.31-2.88, P=0.001), even after 
adjustment for variables representing inflammatory and nutritional status.
Conclusions: Higher serum ferritin level was a significant independent risk factor for 
all-cause mortality regardless of systemic inflammation and nutritional status. Therefore, 
determining serum ferritin levels could be a useful marker to predict clinical outcomes in 
incident PD patients.
SA-PO830
Improving Anemia Therapy in Hemodialysis Patients: Interim Results 
of a Clinical Audit  Iain C. Macdougall,1 Antonio Sousa,2 Carlos Andrade,2 
Erika Schümann,3 Thomas Ryzlewicz,4 Franz Ferdinand Becker,4 Amelia 
Fairburn-Beech,4 William Kilgallon.4  1Renal Unit, King’s College Hospital, 
London, United Kingdom; 2Fundação Renal Portuguesa, Portalegre, Portugal; 
3Via Medis, Riesa, Germany; 4Oxyless Ltd, London, United Kingdom.
Background: An earlier pilot audit (ASN 2013, PUB200) suggested that the use of a 
novel bloodline (Oxyless), which reduces the contact between blood and air, could improve 
the efficiency of Erythropoietin Stimulating Agent (ESA) therapy by prolonging red cell 
survival. The aim of this investigation was to explore this effect in a larger population.
Methods: Patients (n=110; >18 years, HD ≥ 3 months via AV fistulae) were entered 
into a 16-month open label, single crossover audit following a 3 month Run-In. Patients 
reverted to control bloodlines (Nikkiso/Gambro) in the Crossover phase after treatment 
with Oxyless. Hemoglobin (Hb) levels, IV iron sucrose and ESA doses were reported.
Results: Data analysis was conducted on 66 patients from two clinics. Twenty six 
patients dropped out due to transplantation and intercurrent events, death (n=14) and clinic 
transfers (n=4). Hb was maintained over the Treatment phase (11.22-11.34 g/dL). Mean 
ESA doses reduced by 34% (p<0.01) at month 8, equal to 1,909 IU/week/patient. IV iron 
dose did not change significantly during the audit. 
Patients of a shorter dialysis vintage (<4 years, n=35) showed a greater reduction 
in ESA usage (-42%, p<0.01) compared with those of a longer vintage (>4 years, n=31, 
-23%). By month 11 (Crossover) ESA doses increased by 9.7 IU/week/kg; 32% of the 
reduction seen during Treatment.
Conclusions: The reduction in ESA doses observed during Treatment, and the initial 
reversal in the Crossover, suggest that this novel bloodline can improve anemia therapy in 
HD patients. The audit design increases the confidence in the data validity. These results 
could have clinical and financial benefits for HD service delivery.
Funding: Pharmaceutical Company Support - Oxyless Ltd
SA-PO831
First in Human Feasability Study Assessing the Tablo Hemodialysis System 
Luis E. Morales-Buenrostro,1 Jose Antonio Nino-Cruz,1 Javier Zúñiga-Varga,1 
Juan M. Ardavin Ituarte,1 May L. Yau,2 Luis Alvarez.3  1Dialysis Dept, Nefros 
Investigacion SC, Mexico City, DF, Mexico; 2Outset Medical Inc, San Jose, CA; 
3Palo Alto Medical Foundation, Menlo Park, CA.
Background: Self-care, at home or in-center, is a must for patients who want more 
independence and control, or have geographical or mobility constraints. Widespread 
adoption of this modality requires an easy to use dialysis machine with real-time water 
treatment capabilities. We conducted a first in human feasibility study to assess the safety 
and performance of the TABLO™ Hemodialysis System,  that may meet these requirements.
Methods: We enrolled 5 patients receiving hemodialysis 3 times/week, with a well-
functioning fistula or high-flow catheter. Primary outcomes of measure were Kt/V and 
adverse events.
Results: A total of 27 treatments in 5 patients were analyzed. Patients had the following 
characteristics: 40% female (n=2), mean age of 50 years, weighed 66 kg, height of 160 cm, 
40% (n=2) fistula, 60% (n=3) high-flow catheter, average treatment time of 183 minutes, 
average fluid removal of 0.57 L, 80% (n=4)had an unknown etiology of ESRD, and 20% 
(n=1) had hypertension. Heparin was administered in 52% of treatments. The average 
single pool Kt/V was 1.4. One patient had only one treatment and was withdrawn from 
the study due to commute issues. Subjects were monitored during dialysis treatment by 
in-center staff, per institutional protocol. Only one interdialytic event, mild headache, was 
reported. In total, 3 subjects reported cramping (n=6/27 treatments) and 1 had hypotension 
(n=1/27 treatment). There were no unanticipated adverse events, serious adverse events 
or deaths in the study.
Conclusions: The TABLO™ Hemodialysis system was safe and showed good 
performance during treatments with shorter times, minimal fluid removal and heparin 
utilization. The standards of conventional dialysis were maintained without serious adverse 
events related to the device. The incorporation of an integrated water treatment module and 
touchscreen with animated step by step instructions was extremely easy to use. This system 
will allow self-care access, both in-center and at home, in a larger number of patients.
Funding: Pharmaceutical Company Support - Outset Medical, Inc.
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SA-PO832
The Big Red Kidney Bus: Mobile Holiday Dialysis  Peter G. Kerr,1 Lesley 
Ross,1 Jo M. Fairbairn,2 Anne C. Wilson.2  1Nephrology, Monash Health, Clayton, 
Vic, Australia; 2Kidney Health Australia, South Melbourne, Vic, Australia.
Background: The availability of hospital based hemodialysis for those wishing to 
travel is scarce and often results in restricted opportunities for patients on dialysis to have 
a holiday.  The Kidney Health Australia (KHA) and Monash Health (MH) Big Red Kidney 
Bus Project (BRKB) offers patients the ability to dialyse on the BRKB whilst on holiday 
at one of a range of Victorian tourist destinations.
Methods: The aim of the BRKB Project is to provide safe, fully staffed mobile 
haemodialysis care, to enable people, their families and carers to take a break.  KHA 
owns the bus, manages the bookings and markets the BRKB nationally. MH, a regional 
health care provider oversees the clinical assessment and treatment and provides medical 
supervision, dialysis nurses and renal technicians.
The BRKB is a modified bus accommodating 3 hemodialysis machines, dialysis chairs 
and complete water treatment. Typically, holiday dialysis on the BRKB operates across 2 
sessions per day, 6 days per week duplicating the dialysis parameters of the patients’ home 
unit. The bus is driven to and parked at caravan parks around Victoria for 6-week periods, 
during which time patients may book in for dialysis sessions. Their accommodation is 
up to them to decide on – with the option of using cabins in the parks or local motels (or 
their own caravans).
Results: Since its inaugural visit in October 2014, 148 different patients have taken 
advantage of the BRKB. The bus has visited 6 sites around the State and has site bookings 
for the next 10 months.  Participating holidaymakers were overwhelmingly positive about 
the service. They found the booking system easy to use. The dialysis service on the bus was 
delivered to the standard of care experienced at their home units. The professionalism of 
the nursing staff and friendliness was commended and all participants would recommend 
the service to others in need of hemodialysis. Most had actively recommended the service 
to others.
Conclusions: The BRKB is a unique project that provides patients with the opportunity 
to dialyse on the bus while taking a much-needed holiday.
Funding: Private Foundation Support
SA-PO833
Patient and Caregiver Values, Beliefs and Experiences when Considering 
Home Dialysis as a Treatment Option: A Semi-Structured Interview Study 
Rachael C. Walker,1 Kirsten Howard,4 Rachael L. Morton,1 Suetonia Palmer,2 
Mark R. Marshall,3 Allison Tong.1  1Univ of Sydney; 2Univ of Otago; 3Middlemore 
Hospital, New Zealand; 4Univ of South Australia.
Background: Home dialysis is associated with higher quality of life and economic 
benefits to health care systems compared with facility dialysis. However, little is known 
about the decision-making process of patients when considering home dialysis as a 
treatment option.
Methods: This semi-structured interview study aimed to describe patient and caregiver 
values, beliefs and experiences when considering home dialysis, to inform policy and 
practice strategies that align with patient preferences. We conducted semi-structured 
interviews with adults with CKD Stage 4-5D (on dialysis <1 year) and their caregivers, 
treated in 3 nephrology centers in New Zealand. Transcripts were analyzed thematically.
Results: 43 patients (18 pre-dialysis, 13 peritoneal dialysis, 4 home hemodialysis and 
9 facility hemodialysis) and 9 caregivers participated. We identified 5 themes related to 
decision-making when considering home dialysis; lacking decisional power (complexity 
of information, limited exposure to home dialysis, feeling disempowered, deprived of 
choice, pressure to choose); sustaining relationships (maintaining cultural involvement, 
family influence, trusting clinicians, minimizing social isolation); reducing lifestyle 
disruption (sustaining employment, avoiding relocation, considering additional expenses, 
seeking flexible schedules, creating free time); gaining confidence in choice (guarantee 
of safety, depending on professional certainty, reassurance of peers, overcoming fears); 
and maximizing survival.
Conclusions: Patients feel disempowered when choosing home dialysis and make 
decisions that sustain their relationships, maintain lifestyle values and maximize survival. 
Confidence in their modality decision is gained by medical professional and peer support 
combined with overcoming safety concerns. Pre-dialysis programs that address these patient 
experiences may support home dialysis as a treatment option.
Funding: Pharmaceutical Company Support - Baxter Clinical Evidence Council 
research program
SA-PO834
Patient Experiences of Training and Transition to Home Hemodialysis: 
A Longitudinal Mixed Methods Study  Camilla Sara Hanson,1,2 Jeremy R. 
Chapman,3 Jonathan C. Craig,1,2 David C. Harris,3,4 Lukas K. Kairaitis,4 Mary ann 
Nicdao,4 Mary Mikaheal,4 Allison Tong.1,2  1School of Public Health, The Univ 
of Sydney, Sydney, NSW, Australia; 2Centre for Kidney Research, The Children’s 
Hospital at Westmead, Sydney, NSW, Australia; 3Centre for Transplant and 
Renal Research, Westmead Hospital, Sydney, NSW, Australia; 4Dept of Renal 
Medicine, Westmead Hospital, Sydney, NSW, Australia.
Background: Home hemodialysis (HD) can offer better survival and quality of life 
outcomes compared with in-centre HD. However, psychosocial barriers such as fears of 
needles and medical isolation may limit home HD uptake. This study aims to describe 
patients’ perspectives on training and transition to home HD; to inform strategies to 
optimize home HD programs.
Methods: Three semi-structured interviews were conducted prospectively with 20 
patients before, during and after home HD training at an Australian renal unit. The CHOICE 
satisfaction survey was administered during the first and final interview. Transcripts were 
analyzed thematically.
Results: We identified six themes: persevering despite trepidations (intimidation of 
machinery, acquiescing to fatal risks, reconciling cannulation fears, dispelling concerns of 
neglect, tolerating concessions); optimizing learning pathway (practicing problem solving, 
learning from mistakes, grasping technical complexity, minimizing cognitive overload); 
developing confidence (believing in own abilities, depending on caregiver partnership, faith 
in crisis support); interrupted transition momentum (lacking individual attention, language 
barriers, installation delays, illness and complications, acclimatizing to new conditions); 
noticing immediate gains (reclaiming normality, satisfying self-sufficiency, personalizing 
treatment regime); depleting resources and energy (exhaustion, draining financial reserves, 
imposing caregiver burden). There was no significant change in satisfaction with care after 
commencing home HD.
Conclusions: Individualized home HD training fosters confidence and competency in 
patients; however patients may face anxiety and exhaustion with medical responsibilities. 
Ensuring access to respite, medical assistance, and psychosocial support may alleviate 
treatment burdens for patients commencing home HD.
Funding: Private Foundation Support
SA-PO835
Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk 
in Incident Hemodialysis Patients  Yoshitsugu Obi,1 Elani Streja,1 Connie 
Rhee,1 Vanessa A. Ravel,1 Alpesh Amin,1 Csaba P. Kovesdy,2 Rajnish Mehrotra,3 
Kamyar Kalantar-Zadeh.1  1UC Irvine; 2UTHSC; 3UW.
Background: We have previously reported that an incremental hemodialysis regimen 
(e.g., dialysis initiation at twice weekly) was associated with more preserved residual kidney 
function over a year of dialysis therapy (WCN 2015, Cape Town). Here, we compared 
survival between the incremental vs. conventional regimen.
Methods: In a longitudinal cohort of 33,277 patients who initiated maintenance 
hemodialysis over four years (1/2007-12/2010) and survived the first year, 364 patients 
treated with the incremental regimen were matched to 4,797 patients treated with the 
conventional regimen on age, gender, race, the use of central venous catheter as blood 
access, and a history of congestive heart failure at the initiation of dialysis. The incremental 
hemodialysis regimen was associated with ~20% higher residual renal urea clearance 
(KRU) and 24-hr urine volume (UV) after 1 year of dialysis initiation. We then examined 
survival after the first year.
Results: Patients were 69±12 years old, 39% female, 13% non-Hispanic Black, and 
64% diabetic. Median KRU and UV were 4.74 (IQR, 3.23-6.65) mL/min/1.73m2 and 1,150 
(IQR, 800-1,650) mL/day, respectively. Baseline KRU and UV modified the association 
between the incremental regimen and mortality; the incremental regimen was associated 
with higher mortality in patients with KRU <3.0 mL/min/1.73m2 or UV <600 mL/day, but 
not in those with higher levels of KRU and UV.
Conclusions: Among incident hemodialysis patients with substantial RKF, incremental 
hemodialysis may be a safe transitioning regimen associated with greater preservation of 
RKF, whereas in patients without substantial RKF it should be avoided.
Funding: NIDDK Support
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SA-PO836
Seasonal Trends in Dialysis Initiation and Rising Home Dialysis: Results 
from the USRDS  Hui Liu,1 Yang Jiao,2 Douglas Lehmann,2 Richard Hirth,3 
Yi Li,2 Rajiv Saran.1  1Dept of Internal Medicine, Univ of Michigan, Ann Arbor, 
MI; 2Dept of Biostatistics, Univ of Michigan, Ann Arbor, MI; 3Dept of Health 
Management and Policy, Univ of Michigan, Ann Arbor, MI.
Background: Motivated by increasing interest in home dialysis and incentive for it 
in the bundled payment system, we examined incident trends in home dialysis use in the 
United States Renal Data System (USRDS).
Methods: Using USRDS data (2007-2013), monthly counts of all new ESRD cases 
in the US, as well as incident home hemodialysis (HHD) and incident peritoneal dialysis 
(PD) patients were tracked. Incident HHD patients were those who started HHD within 
90 days of entry into an ESRD program and incident PD patients those who started PD 
as their initial modality.
Results: In 2013, over 55% of US facilities offered only in-center HD, 24.7% both HD 
and PD and 13.5% offered HD, PD and HHD. Figure 1 shows trends in monthly ESRD and 
PD utilization in the US during 2007-2013. The incidence rate of ESRD has been stable 
since 2010, but the number of new PD starts has risen steadily since 2009 and has somewhat 
further accelerated since 2011. Figure 1 also shows a seasonal trend for new ESRD and PD 
starts: incident ESRD cases tend to peak in the first 3 months of the year, while new PD 
starts tend to peak by mid-year. Rising HHD use is evident since 2007, without seasonal 
variation. A substantial variation in the annual growth rate of PD is notable across the states.
Conclusions: We report steadily rising home dialysis use in the US, both HHD and PD, 
since 2007 and 2009, respectively. This rise predates the implementation of the bundled 
payment system in 2011, although PD use seems to be rising faster since 2011. Research into 
this seasonality in ESRD incidence and the impact of rising home dialysis use are warranted.
Funding: NIDDK Support SA-PO837
Understanding Barriers to Home-Based and Self-Care In-Center 
Hemodialysis  May L. Yau,1 Luis Alvarez,2 Michelle Carver,1 Geoffrey A. 
Block,3 Glenn Matthew Chertow.4  1Outset Medical, Inc, San Jose, CA; 2Sutter 
Health, Menlo Park, CA; 3Denver Nephrology, Denver, CO; 4Stanford School 
of Medicine, Palo Alto, CA.
Background: Despite superior outcomes and lower associated costs, few patients 
with end stage renal disease undergo selfcare (SC) or home hemodialysis (HHD). Few 
studies have examined patient and physician barriers to SC and HHD and the degree which 
innovative technology might facilitate adoption.
Methods: We surveyed 250 in-center patients (pts) receiving hemodialysis and 51 
board-certified nephrologists to identify key barriers to adoption of SC and HHD.
Results: Overall, 172 (69%) pts reported that they were “likely” or “very likely” 
(figure 1) to consider SC hemodialysis if they were properly trained on a new hemodialysis 
system designed for SC. 
Nephrologists believed that pts were capable of performing dialysis-relevant tasks, 
including: weighing themselves (98%), wiping down the chair and machine (84%), clearing 
alarms during treatment (53%), taking vital signs (46%), and cannulating vascular access 
(41%), but thought that patients would not be willing to do the same. 
Description of tasks % of patients CAPABLE to be more involved
% of patients WILLING to be 
more involved
Weigh themselves 98% 69%
Wipe chair/machine after 
treatment 84% 34%
Clear alarms during treatment 53% 31%
Take/record vitals 45% 29%
Document/monitor treatment 43% 27%
Collect supplies 41% 27%
Cannulate their access 41% 16%
Set up machine 35% 19%
Administer medications 31% 26%
Take down machine 22% 21%
Reasons that nephrologists believe pts are hesitant to pursue SC do not correspond to 
reasons reported by patients.
Conclusions: SC and HHD offer several advantages to patients and dialysis providers. 
Overcoming real and perceived barriers with new technology, and education will be required 
for these modalities to gain traction in the coming years.
Funding: Pharmaceutical Company Support - Outset Medical, Inc
SA-PO838
Dialyzer Clearance, Residual Renal Function and Middle Molecule Levels 
in Daily Dialysis  Christos Argyropoulos, Maria-Eleni Roumelioti, Mark L. 
Unruh.  Internal Medicine, Div of Nephrology, UNM-HSC, Albuquerque, NM.
Background: Beta 2 Microglobulin (B2M) has emerged as a predictor of cardiovascular 
morbidity, mortality and LVH in patients with CKD and ESRD. Daily dialysis leads to 
higher B2M removal and has been associated with improvements in LVH and mortality in 
randomized trials. It is not known how B2M levels vary with dialysis membrane clearance 
(Kd) in daily dialysis regimes.
Methods: We adopted a population kinetic model (PKM) for the intraindividual 
variability in the generation, distribution and extrarenal removal of B2M (ASN 2014,SA-
PO969). We used the PKM to simulate B2M concentrations in patients dialyzed with HF 
membranes in thrice weekly or daily sessions. For the latter we applied the intervention 
protocols for Short (SD) and Long Daily (LD) dialysis utilized in the FHN trials. The 
impact of Kd relative to residual renal function (RRF) on B2M was examined across the 
three dialysis modalities.
Results: B2M was lower in SD or LD relative to thrice weekly HF dialysis irrespective 
of RRF; the highest differences from HF (∆, 95%CI were obtained in anuric pts: 7.5, 7.4-
7.62 (SD) and LD 17.2, 17-17.4 mg/dl. The modelled average B2M relative to Kd is shown: 
There were significant interactions (p<0.001) between modality and RRF, as well as 
modality and Kd. A Kd of 60 ml/min resulted in lower B2M in LD and SD v.s. HF patients. 
Modality RRF (ml/min) ΔB2M (mg/l) KD (60 v.s 20 ml/min) LCI UCI
HF 0 6.8 6.7 7.6
SD 0 8.2 7.5 8.9 
LD 0 8.6 7.8 9.2 
The differences between lower and higher dialyzer clearances were minimal (<1.1 mg/
dl) at higher RRF irrespective of modality.
Conclusions: In simulations, higher dialyzer clearance is associated with lower 
plasma B2M in patients on daily dialysis, especially at lower levels of RRF. Whether 
these differences translate to improved cardiovascular outcomes should be confirmed in 
clinical studies.
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SA-PO839
Wessex Kidney Centre Experience of Nocturnal Home Haemodialysis Using 
the NxStage Sytem One  Venkat Gangaram, Amanda Jane Laird, Laura Hignell, 
Natalie L. Borman.  Renal Medicine, Wessex Kidney Centre, Queen Alexandra 
Hospital, Portsmouth, United Kingdom.
Background: Wessex Kidney Centre (WKC) Portsmouth established Home 
Haemodialysis (HHD) programme in 2009. In the absence of an in-house technician and 
limited capital the programme was set up using NxStage system one (NSO). WKC has 
now established a rapidly growing HHD programme using exclusively NSO, trained 97 
patients to date includes nocturnal therapy.
Results: A total of 18 patients have received NHHD with mean time of 12.3 months 
(range 1 to 31). All patients dialyse alternate nights processing 40-60 litres using dual 
needling access and a single bolus of Enoxaparin Sodium. Patients have regular transonic 
monitoring of their access and home visits. Two NHHD patients successfully dialyse alone. 
The mean age is 47.7 years (range 26 to 80), 78% male, 94% Caucasian with mean BMI 
26.9. The Access used was AV fistula 56%, AV graft 22% and CVC 22% of patients. 14 
patients changed from short daily HHD (SDHHD), 3 patients from in centre Haemodialysis 
and 1 from Peritoneal dialysis. Laboratory parameters have been favourable as shown below. 
C.Ca
Mmol/L
PO4
Mmol/L
K
Mmol/L
Hb
g/l
Alb
g/l
Ca-PO4
mmol2/L2 sKt/V
Pre-NHHD
(N=18) 2.4 1.6 4.9 11.3 35 3.8 2.44
6 months
(N=14) 2.4 1.4 4.7 12.3 36 3.3 2.57
12 months
(N=10) 2.4 1.36 4.6 12.3 36 3.0 2.50
Retention has been excellent with one patient returning to in-centre HD after 25 months 
of HHD. Two patients switched to SD HHD as it more suited to their lifestyle and five 
patients have been transplanted. Pill burden has reduced, with less or no phosphate binders 
(mean number of binders reduced from 6 to 2) and a 40 % reduction in antihypertensive 
medications after 12 months. Patients experience has been excellent with self reported 
improvements in quality of life including facilitating return to employment. A number of 
patients have successfully travelled taking their NSO both within UK and abroad.
Conclusions: In Conclusion, NHHD using NSO is a viable alternative for HHD patients 
with our data suggesting good clinical outcomes. Patients have improved quality of life 
and with less pill burden, flexibility and more opportunity to engage in social activities.
SA-PO840
Current and Future Training of Home Haemodialysis Nurses  Ruth Silverton,1 
Philippa Catherine Brown,1 Paul Laboi,1 Nicola Thomas.3  1Dept of Renal 
Medicine, York Hospital, United Kingdom; 2School of Health and Social Care, 
London South Bank Univ, United Kingdom.
Background: The UK National Institute for Health and Care Excellence recommend 
that >10% of dialysis patients be treated by home haemodialysis (HHD), however only 4.1% 
of patients in the UK are undergoing this modality. Success with HHD can be attributed to 
a supportive health policy, formal infrastructure, committed individuals and home dialysis 
experience; providing a patient-centred approach. Lack of nursing expertise is reported 
as a barrier to home dialysis for 30% of units. A 2010 survey by the Australian HOME 
network revealed insufficient resources in dialysis units to provide support and education 
to patients. A potential barrier to HHD in the UK is specific training for renal nurses on 
the facilitation of shared or self-care.
Methods: The extent of current training provision for dialysis nurses in order to educate 
patients in home therapies/shared care was evaluated via an online survey. A link to the 
survey was sent to the British Renal Society database and the survey was available online 
for 1 month. There were 63 respondents.
Results: Over 76% of respondents (n=48) had worked in renal care for >10 years, with 
a third (n=21) receiving more than 5 days of structured training in how to teach self care. 
The majority of this training (51%) was as part of an ‘in-service programme’, with just 
over half (53%) of all nurses surveyed feeling adequately prepared for educating patients. 
The preferred mode of further training was face to face at a national event (38%), with a 
quarter (n=14) citing e-learning as the preferred option.
Conclusions: Data from the survey highlights a lack of adequate, standardised training 
for HHD nurses, demonstrating the need for a structured programme that ensures up-to-date 
best practice. As a result, we plan to pilot a specific HHD training scheme that involves 
patients and carers in curriculum planning and delivery, with content including; assessment 
of patients’ learning styles, how to facilitate shared decision-making with patients, and how 
to evaluate effectiveness of the HHD programme.
SA-PO841
Daily Hemodialysis in France: Patient’s Characteristics, Trajectories, and 
Treatment Modalities  Adelaide Pladys,1,2 Sahar Bayat,1 Cécile Couchoud,3 
Cecile M. Vigneau.1,4  1French School of Public Health, Rennes, France; 2Univ 
Rennes 1, Rennes, France; 3French Biomedecine Agency, Saint Denis La Plaine, 
France; 4CHU Pontchaillou, Rennes, France.
Background: Increased weekly frequency of hemodialysis (HD) sessions should have 
positive effects on the control of several biological data of end stage renal disease patients. 
However, a recent study observed contradicting results in terms of survival compared to 
previous ones. Patients included in this study came mainly from France where knowledge 
about daily hemodialysis (DHD) practices is poor. In this context, the aim of this study 
was to describe the characteristics of French patients in DHD, the treatment modalities 
and the individual trajectory before starting such a program.
Methods: Were included all patients ³18 y/o who started DHD between 2003 and 2012 
in France. Bioclinical and treatment characteristics were extracted from the French Renal 
Epidemiology and Information Network (REIN registry) then described and compared by 
groups using Chi-square tests.
Results: 753 patients were included in the study. According to the median age (64 
years), two groups of patients were distinguished: old group (≥64 years) characterized by 
lots of comorbidities such as diabetes (48% vs 29%, p<0.0001), active malignancy (17% 
vs 10%, p<0.0001), ³1 cardio-vascular disease (80% vs 41%, p<0.0001) compared to the 
younger one (<64 years). At the 31/12/2013, 30.4% of the young patients underwent renal 
transplantation and 69% of the old ones were died. The main regimen observed was HD 
6x/week with sessions’ duration of 3 hours. Among these patients, 496 started with other 
dialysis modality before switching to DHD (sDHD) and 257 started directly with DHD 
(dDHD). Before starting DHD, 81% of sDHD patients were in HD 3x/week and 5.4% had 
³1 modality change. dDHD patients initiated DHD in urgent condition for 57% of them 
and 92.6% underwent DHD in centre.
Conclusions: DHD in France is addressed both to old patients with lots of comorbidities 
who died rapidly and to young patients in better medical conditions who accessed more 
to renal transplantation. DHD regimens are various and depend of patients’ characteristics 
and previous trajectories.
SA-PO842
In Vivo Urea Removal by Electro-Oxidation in a Wearable Dialysis Device 
Maarten Wester,1 Frank Simonis,2 Diënty Hazenbrink,1 Jaap A. Joles,1 Karin 
G. Gerritsen.1  1Nephrology and Hypertension, Univ Medical Center Utrecht, 
Utrecht, Netherlands; 2Nanodialysis BV, Oirschot, Netherlands.
Background: In EU consortium NEPHRON+ a wearable dialysis device is being 
developed that can offer prolonged dialysis by continuous regeneration of a small volume 
of dialysate. A major challenge is the removal of urea, since the daily urea production is 
high and removal by adsorption difficult. Electro-oxidation (EO) seems attractive since 
electrodes are durable, small and inexpensive. Here, we studied in vivo urea removal by 
EO in a hemodialysis model in goats.
Methods: An EO-unit containing 10 graphite electrodes for EO and sorbent beads 
for K+ and PO43- removal was incorporated in a dialysate circuit in series with activated 
carbon (AC;25g/unit). 3 Ampère (A) was applied using 1 EO-unit (1x3A;N=7) or 2 EO-units 
in parallel (2x3A;N=7). Healthy goats were instrumented with a CVC, heparinized blood 
was pumped (110mL/min) during 3hrs over a 0.2m2 Polyflux dialyzer and dialysate was 
recirculated over the EO unit in counter current direction (40mL/min for 1x3A; 2x40mL/
min and 2x70mL/min for 2x3A; total dialysate volume 100mL (1 EO-unit) or 150mL (2 
EO-units)). Urea was infused to achieve higher urea concentrations.
Results: Urea removal and clearance were 8.4±1.5mmol/h and 11.9±1.6 mL/min, 
respectively, using 1 EO unit (Fig. A,B) and remained stable during consecutive hours. Use 
of 2 units in parallel doubled the removal of urea and caused a 1.6-fold increase in urea 
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clearance. Increase of the dialysate flow did not further increase urea removal. Urea removal 
was dependent on urea plasma concentrations (Fig.1C). Limited release of ammonia/-um 
was observed (0.16±0.03 mole per removed mole of urea).
Conclusions: EO by graphite electrodes combined with AC shows promising urea 
removal in vivo. Research aimed at increasing the efficacy and biocompatibility testing 
is warranted.
SA-PO843
Unplanned “Crash” Home Dialysis Starts: Single Center Experience from a 
University Hospital in the United States  Kristen P. Tamura,1 Jose A. Morfin.2 
1Nephrology, UC Davis Medical Center, Sacramento, CA; 2Nephrology, UC 
Davis Medical Center, Sacramento, CA.
Background: There is a high incidence of starting dialysis from the hospital to the 
in-center unit, and frequently these starts are unplanned and unexpected (“crash”). To this 
end, we sought to implement an educational program to identify patients suitable for a 
home dialysis modality, unplanned home hemodialysis (UHHD) and unplanned peritoneal 
dialysis (UPD).
Methods: We performed an retrospective observational analyses on patients who 
were started on dialysis from January 2013 to April 2015 in a diverse patient population 
admitted to UC Davis Medical Center in Sacramento, CA. We devised a systematic and 
comprehensive screening educational program to provide all modality options. We identified 
patients suitable UHHD, and UPD, both which were transitioned to a home dialysis 
training program upon discharge. Clinical characteristics and outcomes were compared 
to groups who had a standard start home dialysis (SHHD, SPD) during the study period. 
Our measured outcomes include the following: average training days, interval of technique 
failure rate (patient drop out), access status and complications, infections, hospitalizations 
and mortality in the first 90 days.
Results: Preliminary results reveal the groups tended to have similar demographic 
profiles with the average age for patients starting an unplanned home dialysis 51.5 years 
of age, 60% non-white race, but with a trend toward more males at 59% compared to 
standard starts.
Group # Subject Training DaysMean
90 Days Drop 
Out
Number
180 Day 
Drop out 
Number
% Retention at 
12 months
U HHD 9 19.6* 1 02 77.7*
S HHD 27 21.8 3 2 75.7
U PD 10 9.2+ 3 0 70.0+
S PD 28 10.5 6 2 71.4
*not statistically sig.between UHHD vs SHHD 
+not statistically sig.between UPD vs SPD 
Conclusions: In this small representative sample, UHHD and UPD was a viable option 
for programs to consider for the transition of new dialysis patients from the hospital to 
the outpatient setting. We found similar outcomes in comparison to patients starting home 
dialysis training in a traditional standard way. Education and screening of home dialysis 
therapies should be promoted in the hospital setting.
SA-PO844
Quality of Life After 1 Year of Nocturnal Home Hemodialysis Is Comparable 
to Quality of Life After Renal Transplantation  Anna A. Bonenkamp,1 Franka 
E. Van reekum,1 Marianne C. Verhaar,1 Brigit C. van Jaarsveld.2  1Nephrology & 
Hypertension, Univ Medical Center Utrecht, Utrecht, Netherlands; 2Nephrology, 
VU Univ Medical Center, Amsterdam, Netherlands.
Background: Quality of life (QOL) is an important outcome measure for pts with 
ESRD. Several studies found improved QOL in Nocturnal Home Hemodialysis (NHHD) 
compared to conventional HD (CHD). There are no studies comparing QOL in NHHD 
vs Tx. Therefore, some pts on NHHD hesitate whether or not to apply for a place on the 
renal transplant (Tx) waiting list. The aim of this study is to assess the difference in QOL 
between NHHD and Tx after 1 yr of follow up.
Methods: Data were obtained from the ongoing NOCTX-study, which evaluates the 
3-yr progression of coronary atherosclerosis in pts treated with CHD, PD, NHHD and Tx. In 
this study, QOL was measured with the Kidney Disease QOL-SF questionnaire at baseline 
(<3 mo after start) and after 1 yr in NHHD (n=22; 5-7x/wk, 6-8 hr HD; all Tx-waitlisted) 
and Tx (n=30). Composite scores (Physical = PCS, Mental = MCS) and disease related 
domains were used. One yr results were analyzed with an unpaired t-test.
Results: Pts (n=52) were 50±12 yr, 67% male and median duration of RRT was 
37±31mo. Baseline characteristics were comparable between the groups. PCS was 46±9 in 
NHHD and 44±8 in Tx group at baseline; follow up PCS was 44±7 and 47±9 respectively 
(p=0.13). MCS at baseline was 53±9 vs 53±8 and 50±12 vs 52±9 after 1 yr (NS). Compared 
to NHHD, Tx-pts scored better on the domain ‘Effects of kidney disease’ (75±18 vs 
86±14 p=0.01). Sexual function had a remarkably good response rate (90%) and equal 
scores between NHHD and Tx (69±34 and 75±27 p=0.55). In other KDQOL domains no 
significance was observed.
Conclusions: This is the first study to compare QOL between Tx-pts and wait-listed 
NHHD-pts. Physical and Mental Composite Scores were similar. In disease specific 
domains, Tx and NHHD scored not significantly different except for the domain ‘Effects’. 
These data support an important role for NHHD as an alternative to renal transplantation.
Funding: Pharmaceutical Company Support - The NOCTX study is performed with 
unrestricted grants from:
Baxter Nederland B.V.
Roche Nederland BV
Amgen Nederland BV
Fresenius Medical Care Nederland
Shire Pharmaceuticals Benelux
Novartis B.V.
Wellerdieck de Goede fonds, UMC Utrecht
SA-PO845
Association of Vascular Access Type with Mortality, Hospitalization, 
and Transfer to In-Center Hemodialysis in Patients Undergoing Home 
Hemodialysis  Matthew B. Rivara,1 Melissa Soohoo,2 Elani Streja,2 Miklos 
Zsolt Molnar,3 Alfred K. Cheung,4 Ronit Katz,1 Onyebuchi A. Arah,5 Allen 
R. Nissenson,6,7 Jonathan Himmelfarb,1 Kamyar Kalantar-Zadeh,2 Rajnish 
Mehrotra.1  1Kidney Research institute, Seattle, WA; 2Harold Simmons Ctr for 
Kidney Dis Research & Epidemiology, Univ of California Irvine Med Ctr, Irvine, 
CA; 3Div of Nephrology, Univ of Tenn Health Science Ctr, Memphis, TN; 4Div of 
Nephrology, Univ of Utah, Salt Lake City, UT; 5Epidemiology, Fielding School 
of Pub Health, Los Angeles, CA; 6DaVita, Inc., El Segundo, CA; 7David Geffen 
Sch of Med at UCLA, Los Angeles, CA.
Background: In individuals undergoing in-center hemodialysis (HD), use of central 
venous catheters (CVCs) is associated with worse clinical outcomes compared to use 
of arteriovenous access.  However, it is unclear whether a similar difference in vascular 
access type risk is present in patients undergoing home HD, as these patients have higher 
dialysis treatment frequency and lower rates of exposure to sources of nosocomial infection.
Methods: We examined the associations of vascular access type with all-cause 
mortality, hospitalization, and transfer to in-center HD in patients who started home HD 
from 2007-2011 in 464 facilities in 43 states in the United States.  We analyzed the data 
using competing-risks hazards regression with vascular access type at the start of home 
HD as the primary exposure in a propensity score-matched cohort (1052 patients; 526 with 
CVC, 526 with arteriovenous access).
Results: Compared to arteriovenous access use, CVC use was associated with increased 
risk for mortality (hazard ratio [HR] 1.78; 95% confidence interval [95% CI] 1.21 to 2.61) 
and hospitalization (HR 1.38; 95% CI 1.19 to 1.59).  CVC use was not associated with 
increased risk for transfer to in-center HD (HR 1.07; 95% CI 0.81 to 1.40). The results of 
analyses in the entire unmatched cohort (2481 patients), with vascular access type modeled 
as baseline exposure at start of home HD or as a time-varying exposure, were similar.
Conclusions: In a large nationally representative cohort of home HD patients, CVC 
use was associated with increased risk for mortality and hospitalization.
Funding: NIDDK Support
SA-PO846
Time to Transplant Associates with Home Dialysis Modality  Rita Suri,1,3 
Gihad E. Nesrallah,2 Lihua Li,3 Lakshman Gunaratnam.3  1Centre de Recherche, 
Centre Hospitalier de l’Univ de Montréal, Univ of Montreal, Montreal, QC, 
Canada; 2Humber River Hospital, Toronto, ON, Canada; 3Nephrology Div, 
Western Univ, London, ON, Canada.
Background: We recently showed that prevalent end-stage renal disease patients 
starting home daily hemodialysis (DHD) have reduced cardiovascular and infection-
related hospitalization risk compared to those starting peritoneal dialysis (PD). As current 
hospitalization precludes being active on the transplant wait-list, we investigated whether 
DHD patients receiving home DHD would be more likely to be transplanted than those 
receiving PD.
Methods: We matched 2997 adults starting home daily hemodialysis (DHD) in a single 
US dialysis provider’s facilities from 2004-2011, to 2997 contemporaneous USRDS patients 
starting PD by US state and propensity-scores. Demographics, comorbidities (form 2728 
and hospitalization codes), and outcomes were ascertained from USRDS. We used Cox 
regression stratified on matched sets censoring for death, and competing risk analysis using 
Fine’s approach for stratified data, to compare times to transplantation between groups.
Results: Baseline variables were balanced between groups after matching, with 
standardized differences <10%. During 12,558 years of follow-up (mean 2.1±1.4 yrs), 514 
DHD and 428 PD patients were transplanted. DHD patients were 19% more likely to be 
transplanted than PD patients (DHD 8.2 vs PD 6.8 per 100 patient-yrs; HR 1.19, 95%CI 
1.05–1.35, p=0.012). Competing risk analysis accounting for death and follow-up losses 
yielded a HR of 1.18 (95%CI 1.04–1.33, p=0.010). Time to wait-listing did not differ 
between groups (HR 0.97, 95% CI 0.90–1.06, p=0.54), but once waitlisted, PD patients 
were significantly more likely to be permanently removed from the wait-list (PD 14.2% 
vs. DHD 10.2%, RR 1.39 (95%CI 1.09–1.78), p=0.008).
Conclusions: In this prevalent cohort, home DHD patients were more likely to be 
transplanted than matched PD patients, and less likely to be permanently removed from 
the wait-list during follow-up. Mean times to wait-listing were similar, suggesting that the 
groups were well-matched at baseline. Further study is needed on the factors responsible 
for the differential transplantation rates observed in home DHD and PD patients.
Funding: Private Foundation Support
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SA-PO847
Spectrum of Mutations in PKD1 and PKD2 Genes in 100 Unrelated Italian 
Pedigrees with ADPKD – Sanger Sequencing versus Next Generation 
Sequencing (NGS)  Maddalena Gigante,1 S. Diella,1 Matteo Accetturo,2 Paola 
Pontrelli,2 Giovanni Stallone,1 Giuseppe Grandaliano,1 Loreto Gesualdo.2  1Univ 
of Foggia, Foggia, Italy; 2DETO, Univ of Bari, Bari, Italy.
Background: ADPKD is caused by mutations in PKD1 or PKD2 genes. Although, 
clinical studies and case reports describing one or few ADPKD families have been reported 
in Italian population, to date a comprehensive molecular study is still lacking.
Methods: PKD1 and PKD2 genes were analyzed in 150 Italian ADPKD patients from 
100 unrelated pedigree - the largest Italian cohort analyzed to date in a single study - using 
Sanger sequencing and NGS. The potential pathogenicity of the newly identified variants 
was evaluated by combining different in silico methods.
Results: We identified the largest number of definitively and probable pathogenic 
mutations (n=78) reported in a single study in Italian population, achieving an overall 
detection rate of 90%. 55 mutations (52 PKD1 and 3 PKD2) have not been previously 
described, expanding the spectrum of known ADPKD mutations. We identified 12 de novo 
PKD1 mutations in sporadic patients without family history, providing a definitive diagnosis 
of ADPKD. We found the largest number of de novo mutations reported in a single study 
(15%) demonstrating, for the first time, that the prevalence of PKD1 de novo mutations 
may be underestimated. 4/32 PKD1 mutations were found in ³2 unrelated Italian patients, 
a sign of founder effect. 20 patients were analyzed by NGS: we confirm the presence of 
a nonsense PKD1 mutation and the lacking of clear pathogenic mutations in 3 patients 
previously analyzed by Sanger, and the presence of definitively/probable pathogenic 
mutations in the 17 not previously genotyped patients. All NGS results have been confirmed 
by Sanger sequencing, achieving sensitivity and specificity of 100%.
Conclusions: Our data provide important new advances in the molecular diagnostics of 
ADPKD: (i) describe for the first time new potential founder mutations in Italy; (ii) report 
the largest number of de novo mutations identified in a single study and (iii) provide a new 
NGS method with a detection rate comparable to Sanger sequencing but with significantly 
lower cost and reduced turnaround time.
Funding: Government Support - Non-U.S.
SA-PO848
The Use of Screening MR Angiography in Patient with ADPKD 
Claudine Christiaens, Ruben Poesen, Dirk R. Kuypers, Bert Bammens, Bjorn 
Meijers.  Nephrology, Univ Hospitals Leuven, Belgium.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is associated 
with the development of intracranial aneurysms and an elevated risk of hemorrhagic stroke 
(HS). It is suggested that screening MR angiography reduces the incidence of hemorrhagic 
stroke. Current screening criteria include positive aneurysmal history in relatives, 
neurological symptoms and planned major surgery. The efficacy of these screening criteria 
has, however, not been fully evaluated.
Methods: We performed a single-center retrospective analysis of all ADPKD patients 
followed at the University Hospitals Leuven, between January 1990 (date of the first MR 
angiography) and August 2014. Baseline demographics and occurrence of screening criteria, 
screening MR angiography, intracranial aneurysm and hemorrhagic stroke were evaluated.
Results: We identified 865 patients with ADPKD. Those who were seen at least three 
times (n=627, median age 51y, 49% males) were included for analysis. Mean duration of 
follow up was 11.6 years. In this cohort, current screening criteria were met in 183 ADPKD 
patients (29.2%). Of these, 136 (74.3%) had screening MR angiography. In patients with 
no MR angiography, presence of screening criteria was associated with an elevated risk 
of hemorrhagic stroke (12.8% vs. 4.0%, P 0.02). Use of MR angiography in patients with 
screening criteria was related with a lower risk of hemorrhagic stroke during follow-up 
(2.2% vs. 12.8%, P 0.01).
Conclusions: In patients with ADPKD, current screening criteria for intracranial 
aneurysm are associated with an 3-fold elevated risk for future hemorrhagic stroke and 
performing MR angiography seems effective in reducing this risk.
SA-PO849
Influence of Genotype on ADPKD Progression in the HALT PKD Cohort 
Christina M. Heyer,1 Kaleab Z. Abebe,2 Vicente E. Torres,1 Ronald D. Perrone,4 
Marie C. Hogan,1 William E. Braun,5 Godela M. Brosnahan,3 Peter G. 
Czarnecki,6 Charity G. Moore,7 Peter C. Harris,1 Dana Miskulin,4 The HALT 
PKD Investigators.8  1Mayo Clinic, Rochester, MN; 2U of Pittsburgh, Pittsburgh, 
PA; 3U of Colorado, Denver, CO; 4Tufts, Boston, MA; 5Cleveland Clinic, 
Cleveland, OH; 6Brigham and Women’s Hospital, Boston, MA; 7Carolina’s 
Health Care System, Charlotte, NC; 87 Sites.
Background: We assayed here the influence of the ADPKD disease gene (PKD1 or 
PKD2) or PKD1 mutation type (truncating or non-truncating) on the rates of renal disease 
progression over 5 years in the HALT PKD cohort.
Methods: PKD1 mutation type was divided into strength groups: truncating (MSG1), 
and more or less penetrant non-truncating (MSG2 and MSG3). Correlations were made 
between gene type/MSG and changes in eGFR or height adjusted total kidney volume 
(htTKV).
Results: PKD1 patients had a faster eGFR decline than PKD2 (3.3 vs. 1.87 ml/
min/1.73m2/yr; P<0.0001) but the rate of htTKV increase did not differ (6.44 vs. 6.81%/
yr; P=0.42). Baseline PKD1 htTKV was larger than PKD2 (733, 557ml/m; P=0.0001) and 
so PKD1 kidneys expanded to a greater extent (268, 217ml/m/5yr; P=0.0001). Rates of 
change in eGFR or htTKV did not differ between PKD1 MSG3 and MSG1 (P=0.15 and 
0.70), but MSG3 baseline kidneys were smaller relative to MSG1 and MSG2 (611, 753, 
777ml/m; P=0.004) and so the volume increase was less (221, 262, 277ml/m; P=0.004). 
PKD2 patients were less likely to reach a study endpoint (death, ESRD or 50% eGFR 
decline; P=0.0003), but there was no difference between PKD1 MSG1, 2, 3 (P=0.61). 
Patients with no mutation detected, had a slower increase in htTKV (4.84%/yr; P=0.008 
vs. PKD1). The study showed a difference in TKV increase between the low and standard 
blood pressure groups (5.6 vs. 6.6%/yr; P=0.006). The magnitude of difference was similar 
when restricted to PKD1 MSG1 (5.7 vs. 6.7%/yr; P=0.0518) or PKD1 MSG1 and 2 (5.8 
vs. 6.6%/yr; P=0.0543), but not significant in the smaller populations.
Conclusions: PKD1 MSG3 kidneys are smaller but not because they grow more slowly; 
possibly because they have less early cysts, similar to PKD2 vs. PKD1. Since genic and 
allelic effects do not alter progression rates, restricting analysis by genetic factors did not 
improve significance.
Funding: NIDDK Support
SA-PO850
Climate Temperature Affects the Age of End-Stage Kidney Disease in 
Autosomal Dominant Polycystic Kidney Disease (PKD)  Marwan M. Abbas,1 
Michael E. Bleyer,1 Elizabeth Swain,1 Kendrah O. Kidd,1 Gregory B. Russell,2 
Anthony J. Bleyer.1  1Section on Nephrology, Wake Forest School of Medicine, 
Winston-Salem, NC; 2Biostatistical Sciences, Wake Forest School of Medicine, 
Winston-Salem, NC.
Background: Vasopressin receptor 2 antagonists decrease cyst size in PKD. We 
postulated that patients in hotter climates would have more concentrated urine, and this 
would affect the age of ESRD in PKD.
Methods: We obtained demographic data and cause of ESRD on 1,332,402 individuals 
who had their first occurrence of ESRD between ages 30 and 90 between 1971 and 2012 
from the US Renal Data system (USRDS). We obtained annual mean temperatures from 
1990 to 2010 for US weather stations and linked a participant’s zip code to the nearest 
weather center. We correlated the mean age of onset of ESRD for PKD and other causes 
of ESRD with 5 degree temperature intervals. We created a multivariate model for PKD 
patients, with the dependent variable age of ESRD and independent variables race, gender, 
year starting dialysis, residual GFR at start of ESRD, annual median income by patient zip 
code, and temperature as discrete variables in 5 degree intervals.
Results: Figure 1 shows the mean age of onset of ESRD by disease. Cold and warm 
temperature extremes were associated with increasing age of ESRD for PKD, but also 
other diseases. 
Variable Type III SS F value p value
Temperature 11156 8 <0.0001
Gender 3076 18 <0.0001
Race 30783 45 <0.0001 
Median income by zip code 25287 150 <0.0001 
GFR at start of ESRD 79568 472 <0.0001 
Year starting ESRD 82317 488 <0.0001 
The multivariate model showed that temperature had a minimal effect on age of ESRD 
compared to other variables in the model.
Conclusions: There was a U-shaped relationship for age of ESRD according to 
temperature that was present in PKD and other diseases. However, in a multivariate model, 
climate temperature had a minimal effect on age of ESRD in PKD.
Funding: Clinical Revenue Support
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SA-PO851
Urinary Biomarkers and Prediction of Disease Progression in Autosomal 
Dominant Polycystic Kidney Disease  A. Lianne Messchendorp, Esther 
Meijer, Wendy Ellen Boertien, Niek F. Casteleijn, Edwin M. Spithoven, Ron 
T. Gansevoort.  Nephrology, UMCG, Groningen, Netherlands.
Background: The variable disease course of ADPKD underlines the importance of 
predicting disease progression especially since therapeutic options are now available. 
Conventional risk markers (age, gender, GFR, total kidney volume (TKV)) lack sensitivity, 
are expensive or time consuming to measure. We therefore investigated whether easy to 
measure urinary markers can predict disease progression and have additional value to 
conventional risk markers.
Methods: At baseline tubular damage and inflammatory markers were measured in 
24-hr urine; albumin, IgG, KIM1, NAG, b2MG, H-FABP, MIF, NGAL and MCP-1. Kidney 
function was estimated (eGFR by CKD-EPI) and measured (mGFR by (125)I-iothalamate), 
and TKV by MRI. Disease progression was expressed as annual change in eGFR, mGFR, 
and height-adjusted (ht)TKV. Multivariate linear regression was used to assess the predictive 
ability of the markers above conventional risk markers.
Results: Included were 104 ADPKD patients, 40±11yrs, 39% female, eGFR 77±30, 
mGFR 79±29 ml/min/1.73m2 and htTKV 852 (510-1243) mL/m. During a follow-up of 
3.8±1.2 yrs, annual change in eGFR was -3.2±3.0, in mGFR -3.0±3.0 mL/min/1.73m2 and 
in htTKV 6.2±5.9%. b2MG and MCP-1 were associated with annual change in eGFR (St. 
β=-0.23, p=0.02; St. β=-0.38, p<0.001 resp.) and mGFR (St. β=-0.24, p=0.03; St. β=-0.24, 
p=0.03 resp.), even when adjusted for conventional risk markers, but not with annual change 
in hTKV. Similar results were obtained when patients with an eGFR≥60 mL/min/1.73m2 
were selected. Combined b2MG and MCP-1 had an added predictive ability for annual 
change in eGFR (R2=0.178 vs. 0.324, p=0.008) and in mGFR (R2=0.134 vs 0.217, p=0.07). 
The best predictive model for annual change in eGFR included age, htTKV, MIF, b2MG 
and MCP-1 (R2=0.343, p=0.025), and for annual change in mGFR, gender, b2MG, NGAL 
and MCP-1 (R2=0.211, p=0.5).
Conclusions: b2MG and MCP-1 both predict disease progression, and had an added 
predictive value on top of conventional risk markers. These markers have therefore potential 
to serve as a predictive tool for clinical practice.
SA-PO852
The Novel Surrogate Marker of Autosomal Dominant Polycystic Kidney 
Disease (ADPKD) – Urinary Copeptin  Satoru Muto,1 Yan Lu,1 Haruna 
Kawano,2 Shigeo Horie.2  1Urology, Teikyo Univ School of Medicine, Tokyo, 
Japan; 2Urology, Juntendo Univ, Graduate School of Medicine, Tokyo, Japan.
Background: Experimental studies suggest a detrimental role for Arginine vasopressin 
(AVP) in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). 
Copeptin consists of the C-terminal portion of Pro-AVP and has been shown to be a reliable 
and stable substitute for circulating AVP concentration. In contrast to serum or plasma, 
urinary proteins do not undergo detectable degradation by endogenous proteases after 
voiding. It is unknown, however, whether urinary copeptin concentration are associated 
with disease severity in patients with ADPKD.
Methods: Serum and Urinary copeptin concentration were measured by immunoassay 
in ADPKD patients with CKD stage ≤ 4. We compared our measurements with clinical 
parameters including estimated Glomerular Filtration Rate (eGFR), Total Kidney Volume 
(TKV), and height-adjusted TKV (htTKV). Logarithmic transformation of all variables was 
performed to fulfill the requirement of equal distribution of the residuals.
Results: We included 50 patients in this study (24 females and 26 males; mean age: 
49.3 years).The median eGFR and TKV were 53.2 ml/min/1.73 m2 (interquartile range: 
IQR; 29.4 - 68.45) and 1138.1 ml (IQR; 814.7 - 2065.0), respectively. The median urinary 
copeptin level was 12.19 (IQR; 6.91 - 22.32) ng/ml. We could show the positive-correlation 
between u-copeptin and plasma copeptin but without significant relationship (p = 0.198). 
Although there are no significant correlations between plasma copeptin and eGFR (R = 
-0.245, p = 0.227), there are significant correlations between plasma copeptin and htTKV (R 
= 0.458, p = 0.019) and TKV (R = 0.465, p = 0.017). On the other hand, Urinary copeptin/ 
u-Cr was statistically associated with the various markers of disease severity in ADPKD 
(positively with TKV (R = 0.351, p = 0.014,), htTKV (R = 0.383, p = 0.008) and negatively 
with eGFR (R = -0.304, p = 0.036).
Conclusions: In ADPKD subjects, a higher urinary copeptin concentration is associated 
with disease progression, suggesting that urinary copeptin may be a surrogate marker to 
detect deisease severity renal prognosis in ADPKD.
SA-PO853
The Burden of Tolvaptan Treatment for Autosomal Dominant Polycystic 
Kidney Disease (ADPKD)  Satoru Muto,1 Haruna Kawano,2 Masaki Kimura,1 
Shigeo Horie.2  1Urology, Teikyo Univ School of Medicine, Tokyo, Japan; 
2Urology, Juntendo Univ, Graduate School of Medicine, Tokyo, Japan.
Background: Last year, Japan became the first country in the world to approve tolvaptan 
for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Because 
tolvaptan has powerful diuretic effect, patients have to take huge amount of water to prevent 
dehydration. We evaluated the burden of tolvaptan treatment on patients with ADPKD.
Methods: This study targeted Japanese patients with ADPKD on tolvaptan. An initial 
dose of tolvaptan was 60 mg. Estimated glomerular function rate (eGFR) and total kidney 
volume (TKV) were measured at regular intervals. The burden of tolvaptan treatment 
was evaluated by visual analog scales. Statistical analysis was performed using analysis 
of variance.
Results: We included 40 patients (male: 28, female: 12). The median age was 46.5 years 
(interquartile range: IQR 24 - 69 yr.). The median baseline eGFR was 43.4 ml/min/1.73m2 
(IQR: 26.9 – 58.8) and the median baseline TKV was 1,917 ml (IQR: 1,378 - 2,905). The 
median starting dosage of tolvaptan was 60 mg (IQR: 30 – 60) and the median treatment 
period was 8 months (IQR: 6 - 11). We observed no statistical variations in eGFR (p = 0.787) 
and TKV (p = 0.561) during treatment. There were no significant changes in VAS scores 
for general fatigue (p = 0.817), anorexia (p = 0.393), back pain (p = 0.682), and abdominal 
distention (p = 0.607) during treatment. Although analysis of variance demonstrated that 
aquaretic burden including thirst and dry skin were significantly increased after Tolvaptan 
treatment (p = 0.003), 35 % (n = 14) of patients did not completely sense thirst at al during 
treatment, and 42 % (n = 17) of patients spontaneously improved without any additional 
treatment or tolvaptan withdrawal.
Conclusions: Although analysis of variance demonstrated that aquaretic burden 
including thirst and dry skin were significantly increased after Tolvaptan treatment, almost 
third of the patients did not completely sense thirst at al from beginning of Tolvaptan 
treatment, and the remaining third part of patients spontaneously improved.
SA-PO854
Adapted PKDOC Disease Predicts Actual Progression of Autosomal 
Dominant Polycystic Kidney Disease in TEMPO3:4  Frank S. Czerwiec,1 
Jaime Blais,1 Jf Marier,2 Nathalie H. Gosselin,2 Thomas Peyret,2 Vicente E. 
Torres,3 Arlene B. Chapman,4 Berenice Y. Gitomer,5 Steven Thomas Broadbent,6 
Dana Miskulin,7 Ronald D. Perrone.7  1Otsuka PDC, Rockville, MD; 2Pharsight, 
Montreal, QC, Canada; 3Mayo Clinic, Rochester, MN; 4U. Chicago, Chicago, IL; 
5U. Colorado, Denver, CO; 6Critical Path, Tucson, AZ; 7Tufts MC, Boston, MA.
Background: The Polycystic Kidney Disease Outcomes Consortium (PKDOC) has 
submitted for FDA and EMA concurrence, the use of total kidney volume (TKV) as a 
prognostic biomarker to enrich autosomal dominant polycystic kidney disease (ADPKD) 
trials for patients likely to display progressive decline in renal function and progression 
to end-stage renal disease (ESRD). A disease progression model linking TKV growth 
(with baseline covariates of age and eGFR) to longitudinal eGFR was constructed using 
a combination of PKDOC datasets including ADPKD patients with TKV data collected 
over 30 years of follow-up.
Methods: This report uses baseline data for placebo subjects from the TEMPO 
3:4 ADPKD clinical trial to support this approach to disease progression modelling by 
comparing model predicted and observed TKV and eGFR. Simulations were performed by 
utilizing the PKDOC model with subject-specific baseline TKV and eGFR measurements 
from subjects enrolled in TEMPO 3:4.
Results: Bias (mean of the relative error) and precision (square mean of relative error) 
of TKV and eGFR were derived to assess the predictive performance of the PKDOC model. 
The model resulted in very robust predictions of TKV and eGFR with mean (95% CI) bias 
values of 2.98% (1.1-5.1) and 3.03% (1.4-4.7), respectively. Mean (95% CI) precision 
on TKV and eGFR were 42.9% (19.1-68.7) and 37.9% (34.0-43.4), respectively. The 
coefficient of determination (r2) for observed and model predicted TKV and eGFR data 
were 0.957 and 0.877, respectively.
Conclusions: The disease progression model developed with PKDOC data and 
applied to the TEMPO placebo dataset demonstrated excellent predictive power for TKV 
and eGFR. This demonstrates the utility of the disease model in prognosis and potential 
for evaluation treatment effects.
Funding: Other NIH Support - Access to NIDDK Datasets through PKDOC 
collaboration, Pharmaceutical Company Support - Otsuka Pharmaceuticals, Private 
Foundation Support
SA-PO855
Polycystic Kidney Disease Imaging Biomarkers – The Texture of Things 
to Come  Timothy L. Kline, Panagiotis Korfiatis, Marie E. Edwards, Joshua D. 
Warner, Maria V. Irazabal, Peter C. Harris, Bernard F. King, Vicente E. Torres, 
Bradley J. Erickson.  Mayo Clinic.
Background: Medical imaging is essential for polycystic kidney disease (PKD) 
diagnosis, monitoring, and outcome prediction. Research studies use total kidney volume 
(TKV) as an imaging biomarker to follow the progression of PKD. However, TKV 
overlooks underlying structural and functional complexities of the kidneys. We hypothesize 
that texture analysis may provide quantifiable measurements of renal tissue structure to 
improve patient outcome prediction.
Methods: A retrospective cohort of 20 patients (38 exams) was identified who had 
imaging prior to reaching end-stage renal disease (ESRD). Image texture features were 
generated from the baseline MR images and analysis of the correlation to known time-to-
ESRD was performed. A total of 18 texture features were computed for each MRI scan. 
The analysis workflow is shown in Fig. 1.
Results: Texture features were well correlated to time-to-ESRD and many individual 
texture features outperformed height-adjusted TKV (htTKV) as shown in Figs. 2 and 3. 
Example T2 MRIs and their corresponding energy image feature (measure of heterogeneity) 
for two different patients with markedly different times-to-ESRD are also shown for 
comparison. In addition, entropy (measure of image randomness) and gray-level non-
uniformity (measure of neighboring pixel similarities) were also found to be well correlated 
(r-values of 0.66 and 0.73, respectively).
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Conclusions: We present the first use of texture analysis for PKD assessment. Results 
are promising in terms of identifying new imaging biomarkers that correlate with disease 
progression. This approach could function as a surrogate to more difficult imaging methods 
(e.g., quantitative MRI) and costly analysis (e.g., cyst segmentation). It is likely that 
combining texture analysis with other patient data will allow for substantial improvements 
to PKD prognosis.
Funding: NIDDK Support, Other NIH Support - Research reported in this poster was 
supported by NCI grant U01 CA160045 (QIN) and the National Institute of Diabetes and 
Digestive and Kidney Diseases under NIH Grant/Award Number 5 P30 DK090728 04 
Mayo Translational PKD Center (MTPC).
SA-PO856
Accuracy of Traditional and Novel Renal Filtration Markers for Estimating 
GFR in ADPKD Patients  Stephen L. Seliger,1 Charalett E. Diggs, MSN,1 
Thomas C. Dowling,2 Robert Christenson,3 Terry J. Watnick.1  1Medicine, U 
Maryland Sch Medicine, Baltimore; 2Ferris State Univ; 3Pathology, U Maryland 
Sch Medicine, Baltimore.
Background: The best method for estimating GFR in ADPKD is unclear. Changes in 
tubular handling of filtration markers may affect estimating equation accuracy.
Methods: Among 51 adults with ADPKD and eGFR >20 cc/min/1.73m2,we 
measured GFR using iohexol plasma clearance (iGFR,) serum creatinine (SCr, IDMS-
traceable assay), Cystatin C (CysC, Dimension VISTA assay) and beta-trace protein 
(BTP, immunonephelometric assay, Siemens). We estimated GFR (eGFR) using validated 
equations based on SCr (CKD-EpiCr, MDRD), Cystatin-C (CKD-Epicys), both CysC and SCr 
(CKD-EpiCr+Cys) or SCr and BTP (White equation). We compared the bias, precision, overall 
accuracy, and classification (for iGFR<60 cc/min/1.73m2) of each estimating equation.
Results: Mean age was 51±12 years, 71% were female, 84% Caucasian, and mean 
iGFR was 68.4+/-34.2 cc/min/1.73m2. Of the 5 equations, the CKD-Epicysc had the highest 
bias (overestimating GFR), lowest precision and accuracy, and was least sensitive for 
detection of low iGFR (Table). The CKD-EpiCr and BTP/SCr-based White equations had 
least bias and highest precision. Sensitivity and specificty were not significantly different 
between the SCr- and BTP-based estimating equations. (Table) 
Performance 
Characteristic Bias Precision Accuracy 
Sensitiv-
ity
Specific-
ity
Statistic Mean Difference
Inter-quartile 
range of Dif-
ference
P301 RMSE2 for iGFR<60
CKD-EpiCr 0.8 (-4.5, 6.0) -9.2, 9.3 76.5% 18.7 84% 88%
MDRD 5.6 (-11.0, -0.2) -19.5, 4.6 76.5% 19.5 88% 85%
CKD-Epicysc 17.7 (12.2, 23.2) 2.2, 27.8 51.0% 19.1 52% 100%
CKD-EpiCr+cysc 9.0 (4.1, 13.9) -3.9, 18.2 74.5% 17.1 68% 96%
WhiteBTP+Cr -0.5 (-5.8, 4.9) -9.3, 12.3 70.6% 18.4 80% 88%
1. P30 represents proportion with of GFR estimates that are within 30% of measured GFR. 
2. Smaller values indicate higher accuracy
Conclusions: In ADPKD patients, cystatin-based GFR equations may over-estimate 
true GFR, in contrast to the lower bias observed in the general CKD population. The 
SCr-based CKD-Epi equation performed best overall among 5 equations. The utility of 
equations utilizing beta-trace protein deserves further investigation.
Funding: NIDDK Support
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Statins, ADPKD Severity and Progression in the TEMPO 3:4 ADPKD 
Clinical Trial  Vicente E. Torres,1 Ron T. Gansevoort,2 Ronald D. Perrone,3 
Olivier Devuyst,4 Arlene B. Chapman,5 Eiji Higashihara,6 Wen Zhou,7 John 
Ouyang,7 Jaime Blais,7 Frank S. Czerwiec.7  1Mayo; 2U Groningen; 3Tufts U; 
4U Zurich; 5U Chicago; 6Kyorin U; 7Otsuka.
Background: In ADPKD, low HDL and high LDL cholesterol are associated with faster 
total kidney volume (TKV) increase and eGFR decline. A randomized controlled trial (RCT) 
of pravastatin in children showed lower TKV expansion without effect on renal function.
Methods: Exploratory post-hoc analysis of TEMPO 3:4 (3-year RCT of tolvaptan 
in relatively early but progressive ADPKD, age 18-50 yrs, TKV ≥750 ml, eCrCl ≥60 ml 
per minute) to examine whether use of statins might have affected ADPKD progression. 
Linear mixed-effect models that adjust for gender, age and baseline TKV and eGFR were 
used to compare TKV and eGFR slopes between groups.
Results: Patients randomized to placebo using statins were older, had larger TKV and 
lower eGFR at baseline, and their TKV and eGFR slopes were steeper compared to statin 
nonusers (Table). Similarly, patients randomized to tolvaptan using statins were older and 
had lower eGFR, with a non-significant trend to larger TKV compared to statin non-users; 
however, there was no difference between TKV and eGFR slopes of statin users and nonusers 
randomized to tolvaptan. Statin use did not affect a composite end point of clinically relevant 
ADPKD events in the placebo (HR=1.013, P=0.91) or tolvaptan (HR=0.954, P=0.65) group. 
Placebo (n=484) Tolvaptan (n=961)
Statin use No Yes P No Yes P
N 416 68 --- 827 134 ---
Sex (% male) 51.0 57.4 0.33 49.7 62.7 0.005 
Baseline age (yrs) 38.5 40.9 <0.001 38.0 41.8 0.025
Baseline eGFR (ml/
min/1.73 m2) 83.5 73.9 <0.001 82.4 74.8 0.003
Baseline TKV (ml) 1638 1848 0.039 1678 1867 0.067
eGFR slope (ml/min/1.73 
m2/yr) 3.57 4.54 0.058 -2.74 -2.64 0.76
TKV slope (%/yr) 5.76 7.10 0.033 3.90 4.29 0.42
Conclusions: Older patients with more advanced and/or severe ADPKD are more likely 
to be treated with statins. Placebo patients using statins progressed faster; tolvaptan slowed 
progression and annulled the difference between statin users and nonusers.
Funding: Pharmaceutical Company Support - Otsuka Pharmaceutical
SA-PO858
Systems Biology of Polycystic Kidney Disease  Kelly A. George,1,2 Herve 
Husson,3 Ramya Kalyana Kumar,2 Vishal S. Vaidya,1,2 Oxana Beskrovnaya,3 
Jagesh V. Shah.1,2  1Laboratory of Systems Pharmacology, Harvard Medical 
School, Boston, MA; 2Renal Div, Brigham and Women’s Hospital, Boston, MA; 
3Genzyme Corp, Framingham, MA.
Background: Polycystic kidney disease (PKD) is a group of hereditary disease states 
characterized by cystic kidneys and often accompanied by other manifestations such as 
cystic liver and hypertension. PKD occurs in 1 in 500 people, usually resulting from a 
dominant mutation in one of two genes, PKD1 or PKD2. There are no treatments for 
PKD and it is the leading genetic cause of renal failure. Numerous studies have identified 
pathways that are misregulated in PKD but targeting these individual pathways has not led 
to a successful therapeutic intervention or molecular biomarker.
Methods: To identify potential biomarkers and develop a systems-level understanding 
of PKD, we are using transcriptomics, and quantitative proteomics and phospho-proteomics 
to evaluate the state of cystic and normal kidneys in a mouse model of PKD. Kidney cysts 
also induce injury to the surrounding tissues, confounding any analysis of the “cystic state”. 
In an effort to separate the injury signature from the cystic signature, we are also evaluating 
the state of the injured kidney using a folate model of acute kidney injury and fibrosis. 
The multi-kinase inhibitor Roscovitine has been shown to prevent cystogenesis in mouse 
models of PKD but its mechanism of action remains unknown. To gain insight into the 
mechanism(s) of Roscovitine and to identify biomarkers that change with treatment, we 
are also using the above “omic” strategies using kidneys from mice following treatment.
Results: From the transcriptomic experiments, we have a list of potential biomarker 
candidates that are currently being tested by qPCR in mouse tissue at various stages of 
disease progression. Phosphorylation at motifs for CDKs, CK1, CaMK, and others are 
reduced in kidneys treated with Roscovitine. The primary transcription factor family 
found to be suppressed with Roscovitine treatment is the E2Fs, likely a result in the loss 
of CDK signaling.
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Conclusions: These experiments will not only provide candidate biomarkers for PKD 
progression, but will also yield a deeper understanding of the state of the cystic kidney.
Funding: Pharmaceutical Company Support - Sanofi Genzyme, Private Foundation 
Support
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Prognostic Enrichment Strategies in the TEMPO 3:4 ADPKD Clinical Trial 
Maria V. Irazabal,1 Jaime Blais,2 Ronald D. Perrone,3 Ron T. Gansevoort,4 Arlene 
B. Chapman,5 Olivier Devuyst,6 Eiji Higashihara,7 Wen Zhou,2 John Ouyang,2 
Frank S. Czerwiec,2 Vicente E. Torres.1  1Mayo Clinic; 2Otsuka PDC; 3Tufts 
MC; 4UMC Groningen; 5U. Chicago; 6U. Zurich; 7Kyorin U.
Background: An image classification of ADPKD based on diffuse (class 1) vs 
asymmetric (class 2) cyst distribution along with estimated cyst growth determined by 
age and height-adjusted total kidney volume (htTKV, subclass A-E) has been proposed 
for prognostic enrichment by excluding patients with a lesser risk for progression (classes 
1A-B and 2).
Methods: This enrichment strategy was compared, post-hoc, to exclusion criteria 
used for TEMPO3:4 to examine tolvaptan effects on ADPKD progression in patients with 
early but progressive renal disease (18-50 year-old, TKV ≥750 ml, eCrCl ≥60 ml/min).
Results: 1436 TEMPO 3:4 subjects with baseline MRIs were classified, finding 
only 10% class 2 or 1B and no 1A subjects. TEMPO3:4 enriched categories 1C-E (90%) 
compared to the published cohorts (62%, Irazabal 2014 JASN). TKV and eGFR slopes 
steepened from class 1B to 1E (both P<0.001, Table).
Class: N 
(%) 2: 42 (3.1) 1B: 96 (7.4) 1C: 474 (37) 1D: 441 (34) 1E: 220 (18)
TKV eGFR TKV eGFR TKV eGFR TKV eGFR TKV eGFR
Placebo 2.48 -1.66 3.25 -2.10 5.12 -3.59 6.62 -3.89 7.75 -4.93
Tolvap-
tan 2.27 -1.34 1.23 -1.79 1.79 -2.32 3.03 -2.99 4.96 -3.46
P-value 0.88 0.75 0.023 0.64 < 0.001
< 
0.001
< 
0.001 0.007
< 
0.001
< 
0.001
Tolvaptan effects on TKV and eGFR slopes was greater in classes 1C to E. Originally, 
tolvaptan blunted TKV and eGFR slopes from 5.51% to 2.80% and from -3.70 to -2.78 ml/
min/1.73m2 per year (both P<0.001), and lowered the risk for a composite endpoint (CE) 
of clinical progression events (hazard ratio [HR] 0.87, p=0.0095, Torres 2012 NEJM). 
Removing class 1A-B and class 2 patients from the trial, marginally improved estimates of 
tolvaptan effects on TKV and eGFR slopes 5.78% to 2.91% and -3.93 to -2.82 ml/min/1.73 
m2 per year (both P<0.001), and the CE endpoint (HR 0.84, p=0.0032).
Conclusions: Prognostic enrichment strategies using kidney morphology can 
enhance ADPKD trials for rapidly progressing patients, increasing power and reducing 
costs. Refinements of imaging criteria can improve the probability of success of future 
clinical trials.
Funding: NIDDK Support
SA-PO860
Prognostic Enrichment Design in Clinical Trials for ADPKD: The HALT 
PKD A Trial  Maria V. Irazabal,1 Kaleab Z. Abebe,2 Kyongtae Ty Bae,2 Ronald 
D. Perrone,3 Arlene B. Chapman,4 Robert W. Schrier,5 Alan S.L. Yu,6 William 
E. Braun,7 Theodore I. Steinman,8 Michael F. Flessner,9 Vicente E. Torres.1,10 
1Mayo Clinic; 2U. of Pittsburgh; 3Tufts U.; 4U. of Chicago; 5U. of Colorado; 
6Kansas U.; 7Cleveland Clinic; 8Beth Israel Deaconess; 9NIH-NIDDK.
Background: Patients with mild ADPKD phenotype are less likely to be informative 
in clinical trials. An image classification into typical (diffuse cyst distribution) class 1A 
ĺ E (determined by age and height adjusted total kidney volume, (TKV) and atypical 
(asymmetric cyst distribution) class 2 has been proposed for prognostic enrichment design 
in clinical trials with recommendations to exclude class 1A and 2 and follow-up class 1B 
patients to more precisely define their risk for progression.
Methods: Post-hoc analysis of HALT-PKD A, (RCT of rigorous vs standard BP 
control on TKV increase and eGFR decline; eGFR>60 ml/min/1.73 m2) to investigate the 
performance of this classification for prognostic enrichment design.
Results: 551 participants were classified by 2 raters (98.2% agreement) into class 1A 
(6.2%), 1B (20.3%), 1C (34.1%), 1D (22.1%), 1E (11.8%), and 2 (5.4%). TKV increase 
and eGFR decline became steeper from class 1A ĺ 1E (both P<0.0001). HALT PKD A 
had shown slower TKV increase, faster eGFR decline in the first four months (F0-5) and 
marginally slower eGFR thereafter (F5-80), without a significant overall (F0-80) effect 
with rigorous BP control. To ascertain the ability to detect an effect of rigorous BP control 
in imaging classes of increasing severity, we grouped classes1A and 2 (lowest severity), 
1B and 1C (intermediate severity), and 1D and 1E (highest severity). Beneficial effects on 
TKV increase and eGFR decline were detected only in class 1D and 1E.
Conclusions: Strategies for prognostic enrichment such as the image classification 
should be used in the design of RCTs for ADPKD to increase their power and reduce 
their cost.
Funding: NIDDK Support
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Long-Term Safety Profile of Tolvaptan in Japanese ADPKD Patients 
Eiji Higashihara,1 Shigeo Horie,2 Yoshifumi Ubara,3 Satoru Muto,4 Kikuo 
Nutahara,5 Ichiei Narita,6 Tadashi Okada.7  1ADPKD Research, Kyorin Univ 
School of Medicine, Tokyo, Japan; 2Urology, Juntendo Univ Graduate School 
of Medicine, Tokyo, Japan; 3Nephrology Center, Toranomon Hospital, Tokyo, 
Japan; 4Urology, Teikyo Univ School of Medicine, Tokyo, Japan; 5Urology, 
Kyorin Univ School of Medicine, Tokyo, Japan; 6Clinical Nephrology and 
Rheumatology, Niigata Univ Graduate School of Medical and Dental Sciences, 
Niigata, Japan; 7Clinical Development, Otsuka Pharmaceutical Co., Ltd., 
Osaka, Japan.
Background: Tolvaptan was first approved in Japan for autosomal dominant polycystic 
kidney disease (ADPKD) based on results of the Tolvaptan Efficacy and Safety in 
Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 trial 
(TEMPO) to evaluate 3-year efficacy and safety. Purpose: Examine adverse drug reactions 
(ADRs) of tolvaptan for up to extended 3 years after TEMPO in Japanese ADPKD patients.
Methods: This open-label study was conducted in 135 patients participating in the 
preceding TEMPO. Doses of tolvaptan were adjusted from 60 to 120 mg/day.
Results: Main ADRs, thirst (77%), pollakiuria (57%), polyuria (38%), and 
hyperuricemia (15%) were noted during up to 3 years. In TEMPO, hepatic function-related 
ADRs were observed more frequently for tolvaptan than for placebo early during treatment. 
In this study, 8 patients (6%) experienced >3-fold increases above upper limits of normal 
serum ALT or AST 3 to 9 months after tolvaptan initiation, but all recovered after tolvaptan 
cessation. Of these 8 patients, 7 had been allocated to placebo in TEMPO. However, the 
residual one patient allocated to tolvaptan similarly had shown increased serum ALT in 
TEMPO. None of the 8 patients met Hy’s Law criteria. No ADRs besides those seen in 
TEMPO were newly observed in this study.
Conclusions: Hepatic function-related ADRs occurred early during treatment and were 
reversible. Tolvaptan was thus indicated to be a promising drug for treatment of ADPKD for 
up to 6 years while carefully monitoring ADRs including hepatic function abnormalities.
Funding: Pharmaceutical Company Support - Otsuka Pharmaceutical Co., Ltd.
SA-PO862
Pregnancy Outcome in Articipants in the HALT PKD Clinical Trials 
Arlene B. Chapman,1 Kaleab Z. Abebe,2 Marie C. Hogan,3 Charity G. Moore,2 
Susan Spillane,2 Theodore I. Steinman,4 Kyongtae Ty Bae.2  1U of Chicago; 
2U of Pittsburgh; 3Mayo Clinic; 4Beth Israel Deaconess; 5Halt Investigators.
Background: ADPKD is the most common hereditary disease. Fertility rates are not 
impaired in ADPKD women, however, preexisting hypertension and proteinuria associate 
with increased maternal and fetal complications. In the HALT PKD trials, 38 pregnancies 
occurred despite counseling and review with participants. We now present maternal and 
fetal outcomes from these pregnancies.
Methods: In a secondary analysis, data regarding maternal and fetal outcomes and 
complications of reported pregnancies were obtained including spontaenous abortions, 
delivery types and still births. Data collection relied on completion of protocol case report 
forms, followup of hospital discharge summaries and patient based reports if available.
Results: In HALT A and B, 203 and 89 women were premenopausal. In all pregnancies, 
study medications were stopped immediately or before the pregnancy began. 36 pregnancies 
occurred in 30 women with 6 experiencing 2 pregnancies. 26 women experienced 32 
pregnancies in Study A (12.8%) and 4 occured in 4 women in Study B (4.5%). In study 
A baseline TKV was 871.5+502.9 mls, and GFR was 104.3+17.5 mL/min. In Study B, 
baseline GFR was 51.6 9.3 ml/min. Information on pregnancy outcome was not available 
in 3 pregnancies (2 LTFU and 1 pregnant at the end of study). In 33 pregnancies, 58% 
resulted in a live birth (100% in HALT B). In the remainder, 7 spontaneous and 2 therapeutic 
abortions, 1 ectopic and 1 stillbirth occurred. Two C-sections, one for pre-eclampsia and 
one pre-term delivery was reported.
Conclusions: In this secondary analysis of HALT Study A and B, 10.3% of 
premenopausal women became pregnant despite ongoing counseling and informaed consent 
regarding the need to avoid becoming pregnant. A high spontaneous abortion rate was noted 
with a conservative live birth rate estimate of 58%. Pre-eclampsia, preterm delivery and 
ectopic pregnancy, all known to associate with ADPKD, occured in 9% of pregnancies. 
No direct evidence for fetal injury due to telmisartan or lisinopril exposure was noted.
Funding: NIDDK Support
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SA-PO863
Renal Concentrating Capacity and Copeptin Concentration in Patients 
with ADPKD and IgA Nephropathy with Impaired Renal Function 
Debbie Zittema, Niek F. Casteleijn, Stephan J.L. Bakker, Casper F.M. Franssen, 
Ron T. Gansevoort.  Nephrology, Univ Medical Center Groningen, Groningen, 
Netherlands.
Background: ADPKD patients have an impaired maximal urine concentrating capacity 
(Umax). Whether this is an aspecific effect of renal function impairment, or specific for 
ADPKD is yet unknown. We hypothesized that ADPKD patients have a more severely 
impaired Umax in comparison with non-ADPKD renal disease patients, which leads to an 
exaggerated vasopressin (AVP) response that may be damaging to the kidney.
Methods: 15 ADPKD (eGFR<60) and 15 IgAN patients, matched for age, sex and 
eGFR, underwent a water deprivation test to determine Umax. Urine and plasma osmolality 
(Uosm and Posm), albuminuria (ACR) and plasma copeptin (surrogate marker for AVP in 
pmol/L), were measured at baseline and after water deprivation (average 17 hours). Height 
adjusted total kidney volume (htTKV) was measured by MRI.
Results: Umax was lower in ADPKD compared with IgAN patients. Upon water 
deprivation Posm increased in ADPKD (p=0.003), but not in IgAN (p=0.1), whereas 
copeptin increased in both groups similarly (ADPKD: p=0.001; IgAN: p=0.02). Copeptin 
after water deprivation was negatively associated with Umax in both groups (ADPKD: 
R=-0.72, p=0.002; IgAN: R=-0.70, p=0.004). In ADPKD, copeptin and albuminuria were 
correlated after water deprivation (R=0.71, p=0.003), independently of eGFR or htTKV. 
Furthermore, htTKV in ADPKD was associated after water deprivation with Posm (R=0.52, 
p=0.048), copeptin (R=0.58, p=0.03) and Umax (R=-0.54, p=0.04).
ADPKD IgAN p-value
Baseline
eGFR 43±9 44±14 0.74
Posm 289±5 294±10 0.14
Uosm 378±157 498±144 0.04
Copeptin 14.0 (6.6-29.1) 11.9 (7.3-26.1) 0.98
Umax
Posm 293±6 295±10 0.51
Uosm 533±138 642±148 0.046
Copeptin 26.6 (12.8-43.0) 20.7 (10.3-43.0) 0.84
Conclusions: ADPKD patients have a lower Umax compared with IgAN patients with 
similar renal function. Remarkably, this is not accompanied with an exaggerated increase in 
AVP. Notwithstanding, ADPKD severity was associated with stronger increases in Posm, 
copeptin and albuminuria during water deprivation. This suggests that in ADPKD water 
deprivation may be deleterious and should be avoided.
Funding: Government Support - Non-U.S.
SA-PO864
Total Abdominal Organ Volume Is a Major Risk Factor for Malnutrition in 
Ambulatory Patients with Autosomal Dominant Polycystic Kidney Disease 
Hyunjin Ryu,1 Hyosang Kim,2 Hayne C. Park,3 Hyunsuk Kim,1 Kook-Hwan 
Oh,1 Young-Hwan Hwang,4 Curie Ahn.1  1Internal Medicine, Seoul National 
Univ Hospital, Seoul, Korea; 2Asan Medical Center; 3Armed Forces Capital 
Hospital, Seongnam; 4Eulji General Hospital.
Background: In Autosomal dominant polycystic kidney disease (ADPKD), 
malnutrition may develop as renal function decreases and abdominal organ volume enlarged. 
In this study, we evaluated the nutritional status of outpatient ADPKD patients by using 
subjective global assessment (SGA) and investigated the risk factors for malnutrition.
Methods: In this single center, cross sectional study, anthropometric and laboratory 
data including serum creatinine (sCr), albumin, and cholesterol were collected, and total 
kidney and liver volume were measured. Total abdominal organ volume was defined as the 
sum of total kidney and liver volume and adjusted by height (htTAV).
Results: A total of 288 patients (47.9%) were included and mean age was 48.3±12.2 
years. Mean estimated glomerular filtration rate (eGFR) was 65.3 ± 25.3 mL/min/1.73m2. 
Mean SGA score was 6.6±0.6. 168 patients (58.3%) were in chronic kidney disease stage 
1 or 2, 99 (34.4%) stage 3 and 21(7.3%) stage 4. Total 21 patients (7.3%) were mild to 
moderately malnourished (SGA 4-5) and 63 patients(21.7%) were at risk of malnutrition 
(SGA 6). There was no difference in SGA score distribution with sex. Physical scores 
related to nutritional status in total and male were age, height, weight and body mass index. 
However none of these parameters were related in female. Lower hemoglobin level and 
poor renal function were related with low SGA score in total and male but only decreased 
renal function was related in female. In contrast, higher htTAV was consistently correlated 
with lower SGA score, even in subjects with eGFR ≥ 45 mL/min/1.73m2. Subjects with 
htTAV ³2,340 ml/m showed 8.7-fold higher risk of having malnutrition, after adjusting for 
sex, age, hemoglobin, albumin and sCr.
Conclusions: Nutritional risk was detected in 30% of ambulatory patients with ADPKD 
and relatively preserved renal function. Intraabdominal organ growth in ADPKD may affect 
the nutritional status independently from the renal deterioration.
SA-PO865
Tyrosine Kinase Inhibitor Tesevatinib for Patients with Autosomal 
Dominant Polycystic Kidney Disease  Anjay Rastogi,1 Mitchell H. Rosner,2 
Irina Barash,10 Theodore I. Steinman,3 Ziad El-Zoghby,4 Saul Nurko,5 Seth 
Goldberg,6 Ashraf El-Meanawy,7 Mireille El Ters,8 Maria Roche,9 Mark S. 
Berger.9  1UCLA; 2UVA; 3Beth Israel Deaconess; 4Mayo Clinic; 5Cleveland 
Clinic; 6Washington Univ; 7Med College Wisconsin; 8KU Med Center; 9Kadmon 
Corp.; 10Mount Sinai Beth Israel.
Background: Tesevatinib (formerly KD019) inhibits both epidermal growth factor 
receptor (EGFR) and SRC. It decreases cyst growth and slows the decline in renal function 
in BPK mouse & PCK rat PKD models. In oncology trials the most common adverse events 
(AEs) were EGFR inhibitor AEs of acneiform rash and diarrhea. The 1/2-life of approx. 
60 hrs allows for schedules other than daily dosing.
Methods: This study evaluated the safety and tolerability of tesevatinib at several doses 
and schedules. Eligibility used Ravine criteria for autosomal dominant polycystic kidney 
disease (ADPKD) in patients (pts) aged 18-55 years with eGFR ≥ 50 mL/min/1.73 m2.
Results: 46 ADPKD pts were enrolled into 5 dose/schedule cohorts. At 150 mg/day, 
3/5 pts had moderate rash occurring during the first 28 days that was not tolerated and led 
to study discontinuation for 2. The tolerability of intermittent dosing schedules using 150 
mg (Mon, Wed, Fri or Mon, Thu) was improved over 150 mg/day, but 1 case of severe rash 
occurred. QTc prolongation to ≥485 ms occurred in 2 pts on 100 mg/day, and 1 pt on 150 
mg MWF. The most common AEs overall in preliminary safety data were diarrhea (36%), 
rash (33%), nausea (29%), and asymptomatic CPK increase (24%). Other AEs included 
asymptomatic mild amylase elevations (21%). 
Dose/Schedule No. Pts Gender (M) Median Age (Yrs) Median TKV (mL)
50 mg/day 9 3 39 1308
100 mg/day 8 5 37 1525
150 mg/day 5 2 41 1094
150 mg MWF 14 4 36 1344
150 mg MT 10 4 37 795
Total 46 18 38 (19-55) 1138 (411-3873)
Conclusions: Tesevatinib 150 mg in various schedules was associated with skin rash 
that was not well tolerated. A rate of QTc prolongation not acceptable for chronic use was 
associated with tesevatinib 100 mg/day. Tesevatinib 50 mg/day appears to be a well tolerated 
dose in patients with ADPKD, although some acneiform rash occurs. In order to confirm 
the safety profile at 50 mg/day, an additional 20 pts are being enrolled.
Funding: Pharmaceutical Company Support - Kadmon Corporation
SA-PO866
Retrospective Analysis of Changes in Renal Function in Patients with PKD 
and Diabetes on Metformin  Jinyu Zhang,1 Anju Yadav,2 Lawrence Ward,1 
Kenneth R. Hallows,3 JingJing Zhang.2  1Internal Medicine, Thomas Jefferson 
Univ, Philadelphia, PA; 2Renal Div, Thomas Jefferson Univ, Philadelphia, PA; 
3Renal Div, Keck School of Medicine of USC, Los Angeles, CA.
Background: Autosomal dominant polycystic kidney disease (ADPKD) affects 
approximately 600,000 Americans. The cystic fibrosis transmembrane conductance regulator 
(CFTR) chloride channel participates in secretion of cystic fluid whereas the mammalian 
target of rapamycin (mTOR) pathway drives proliferation of cyst-lining epithelial cells. 
CFTR and mTOR are both negatively regulated by AMP activated protein kinase (AMPK). 
Metformin, a commonly used diabetes medication,activates AMPK. In two mouse ADPKD 
models, metformin produced a significant decrease in kidney cystic index relative to 
controls. Therefore, metformin may provide clinical benefit in PKD patients.
Methods: IRB-approved data collection of patients with PKD and diabetes from 
office visits between 3/1/2010 and 2/28/2015 were analyzed. Estimated GFR (eGFR) was 
calculated by using CKD-EPI formula. The ACEI/ARB usage was also recorded.
Results: One-hundred forty-nine patients with PKD were identified during a 5-year 
period. Of these patients, 13 also had a diagnosis of diabetes. Of these 13 patients, 1 patient 
was lost to follow up. Four patients have had a kidney transplant with the development 
of diabetes following transplantation. Eight patients had both PKD and diabetes – 7 were 
on metformin at some time whereas 1 had never. Regarding this groupof PKD patients on 
metformin, we present data on renal function trend measured by eGFR.
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Conclusions: Renal function did not change significantly during the period that 
patients were on metformin. We will continue to observe these patients and accumulate 
more patients with PKD and diabetes but not on metformin to see if metformin is beneficial 
in PKD patients.
SA-PO867
11Beta-Dichloro Inhibits Cyst Progression in an Adult ADPKD Model 
Sorin V. Fedeles,1 Bogdan I. Fedeles,3 Yasunobu Ishikawa,1 Rachel Gallagher,1 
John M. Essigmann,3 Stefan Somlo.1,2  1Dept of Internal Medicine, Yale School 
of Medicine, New Haven, CT; 2Dept of Genetics, Yale School of Medicine, New 
Haven, CT; 3Dept of Chemistry, M.I.T., Cambridge, MA.
Background: ADPKD is the most common monogenic disorder for which no effective 
therapy exists. We have previously shown that the novel antitumor agent 11β-dichloro 
specifically induced apoptosis in Pkd1 null cells (ASN 2013 FR-OR100). Administration 
of 11β-dichloro resulted in amelioration of cystic disease in the Pkd1fl/fl;Pkhd1-Cre neonatal 
ADPKD model. In the current work we explored the pathways involved in the pro-apoptotic 
effect of 11β-dichloro and investigated whether the beneficial effect seen in the early model 
is also present in an adult inducible Pax8rtTA;TetO-cre; Pkd1fl/fl model which is more akin 
to the human disease.
Methods: Pax8rtTA;TetO-cre; Pkd1fl/fl mice were induced with doxycycline for 2 weeks 
beginning at P28. 11β-dichloro was administered by IP injection at a dose of 10 mg/kg, 3 
times a week for 12 weeks beginning from P42; At the end of treatment the kidneys were 
harvested for analysis.
Results: 11β-dichloro treated adult mice resulted in a decrease in KW/BW ratio as 
compared to vehicle injected controls (2.6±0.1 vs. 6.1±0.4); There was no difference in 
body weight between treated and control. These changes were accompanied by a decrease 
in the cystic index (29%±1.5 vs. 49%±1.4), BUN (41±2.4 vs. 83±2.7), and creatinine 
(0.18±0.007 vs. 0.37±0.02). 11β-dichloro specifically increased apoptosis in cyst-lining 
cells but not in wild-type. UPR and ROS have been implicated as potential drivers of the 
11β-dichloro-dependent pro-apoptotic phenotype. We found that upregulation of the UPR 
marker XBP1s and its transcriptional targets BiP and Erdj4 was specific to the Pkd1 null 
cells compared with wild-type, in vitro and in vivo. Treatment with 11β-dichloro increased 
mRNA levels of the antioxidant genes catalase and SOD1 specifically in the Pkd1 cystic 
kidneys and not in vehicle-treated kidneys.
Conclusions: 11β-dichloro specifically induces UPR, ROS, and apoptosis in cystic vs. 
wild-type kidneys. In an adult inducible cystic model, the compound ameliorates polycystic 
disease progression and improves kidney function.
Funding: Other U.S. Government Support, Private Foundation Support
SA-PO868
Outcomes of Combined Partial Hepatectomy and Cyst Fenestration for 
Massive Polycystic Liver Disease  Fouad T. Chebib,1 Amber Harmon,1 Maria 
V. Irazabal,1 Yeon Soon Jung,1 Marie C. Hogan,1 Patrick S. Kamath,1 Vicente 
E. Torres,1 David M. Nagorney.2  1Nephrology and Hypertension, Mayo Clinic, 
Rochester, MN; 2Dept of Surgery, Mayo Clinic.
Background: Partial hepatectomy and cyst fenestration (PHCF) selectively provides 
clinical benefit in highly symptomatic patients Polycystic Liver Disease (PLD). This study 
aims to ascertain whether the reduction in liver volume achieved by PHCF is sustained 
long-term.
Methods: Clinical data was retrieved from the electronic records in all PLD patients 
who underwent PHCF between 1985 and 2014. Preoperative Liver volumes (LV1), 
postoperative (LV2) and late follow up (LV3) were measured from MR or CT images.
Results: Among 186 patients who underwent PHCF, 91% were Caucasian women 
with ADPKD with a mean age of 49 years. Major peri-operative complications (Clavien 
III/IV) occurred in 24% of the patients. Operative mortality (<90 days) was 2.7% with one 
death from liver failure. Overall survival was 95%, 90%, 76.5% and 59% at 1, 5, 10 and 
15 years respectively. Imaging records for volumetry were unavailable in 37 patients. Of 
the remaining 149 patients, 30 patients had imaging for one LV, 65 for two LV and 54 for 
all three LV. Median LV was 6812 ml preoperatively and 2502 ml after PHCF leading to 
a median postoperative liver volume reduction of 61%.
At follow-up (mean 7.8 years), median LV was 2500 ml. Interestingly, 29 out of 
61 patients with available LV2 and LV3 showed further regression in LV upon follow 
up (median -14.8%); while the rest showed mild growth of 9.5%. Overall volumetric 
comparison of preoperative to follow-up liver imaging showed sustained liver volume 
reduction (median 60%).
Conclusions: Sustained long-term reductions in LV after PHCF can be achieved in 
selected patients with severe, highly symptomatic PLD. In our experience, liver-related 
death and subsequent liver transplantation are infrequent after PHCF.
SA-PO869
Effect of Genotype on the Severity and Volume Progression of Polycystic 
Liver Disease (PLD) in Autosomal Dominant Polycystic Kidney Disease 
(ADPKD)  Fouad T. Chebib,1 Yeon Soon Jung,2 Christina M. Heyer,1 Maria V. 
Irazabal,1 Marie C. Hogan,1 Peter C. Harris,1 Vicente E. Torres,1 Ziad El-Zoghby.1 
1Div of Nephrology, Mayo Clinic, Rochester, MN; 2Kosin U.
Background: PLD is the most common extrarenal manifestation in pts with ADPKD. 
Here we analyzed the influence of genotype and gender on the severity of PLD.
Methods: Clinical data was retrieved from electronic records in a large cohort of pts 
who were mutation screened, determined to be PKD1 or PKD2 and had available CT or 
MR liver imaging during 2000-2014 at the Mayo Clinic (n=445). Liver volumes (LV) were 
measured by stereology on axial images and adjusted to height (HtLV).
Results: Among the 445 pts, 220 (49.5%) had truncating PKD1, 153 (34.4%) 
nontruncating PKD1 and 72 (16.1%) PKD2 mutations. Compared to nontruncating PKD1 
and PKD2, pts with truncating PKD1 were younger at time of first imaging (43.6 vs 47.6 
and 50.4; p<.001), had lower median survival time to ESRD (62.4 vs 66.9 and 81.4; 
p<.001,Log-Rank), and larger kidney volumes (785 vs 614 and 548 ml/m; p<.001). LV in 
pts with PKD1 truncating, PKD1 nontruncating and PKD2 were not different (HtLV 1039, 
1076 and 1058 ml/m, respectively;p=.53). Female pts had larger HtLV compared to males 
(1104 vs 1019 ml/m; p<.001). Annualized median liver growth rates were 1.65, 1.74 and 
1.2% for truncating PKD1, nontruncating PKD1 and PKD2, respectively (p=.75). Females 
younger than 48 had higher annualized median growth rates compared to those older than 
48 (2.65 vs 0.09%;p<.001). When adjusting for age, gender and baseline LV, growth rate 
remained unaffected by the ADPKD genotype. 
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Conclusions: In contrast to the renal phenotype, ADPKD gene type or PKD1 mutation 
type were not significantly associated with the severity or growth rate of PLD in ADKPD 
pts. This finding, along with the demonstrated gender influence, indicate that modifiers 
beyond the disease gene significantly influence this phenotype.
SA-PO870
Eligibility for Renal Transcatheter Arterial Embolization in Patients 
with Autosomal Dominant Polycystic Kidney Disease  Tatsuya Suwabe, 
Yoshifumi Ubara, Junichi Hoshino, Rikako Hiramatsu, Kenmei Takaichi.  Dept 
of Nephrology, Toranomon Hospital, Tokyo, Japan.
Background: In patients with ADPKD, massive renal enlargement is a serious problem. 
Renal transcatheter arterial embolization (TAE) is effective for reducing renal volume, but 
there is large variation of its effectiveness and the reasons remain unclear. We investigated 
factors influencing the renal volume reduction rate (RVRR) for one year after TAE.
Methods: All patients with ADPKD who received renal TAE at Toranomon Hospital 
from 2006 to 2013 were enrolled. We calculated RVRR by the calculation formula (1 - 
renal volume at each time after TAE / renal volume before TAE)*100, and analyzed factors 
affecting RVRR. We also compared sequential change of large cysts (>5cm), by classified 
them into four groups as cysts with wall thickening (>4mm), cyst with acute hemorrhage, 
normal cysts, and the others.
Results: 449 patients (228 men, 221 women, mean age; 57.0 ± 9.1 years) were 
enrolled. The RVRR at 1 year after TAE ranged from 3.9 to 84.8%, and the least squares 
mean RVRR calculated using mixed model was 45.73% (95% confidence interval [95% 
CI]; 44.36 to 47.10%). Multivariate analysis using mixed model revealed that large cysts 
with wall thickening (regression coefficient: -5.830, 95% CI: -9.140 to -2.520, p=0.0006), 
age(/5years) (-0.847, -1.073 to -0.621, p<0.0001), dialysis duration(/12months) (-0.115, 
-0.193 to -0.037, p=0.0039), systolic blood pressure(/10mmHg) (0.283, 0.065 to 0.501, 
p=0.0109), and number of microcoils used for renal TAE (1.333, 0.784 to 1.882, p<0.0001) 
had a significant influence on the RVRR. Among large cysts, only cysts with wall thickening 
did not decrease in volume. Significantly more microcoils were needed to achieve complete 
renal artery occlusion in patients with younger age and less dialysis duration.
Conclusions: Cyst wall thickening had an important influence on cyst volume 
reduction. Renal TAE was more effective in patients who were younger, had shorter dialysis 
duration, or had hypertension, parameters that might be associated with cyst wall stiffness. 
Renal artery narrowing may occur in older patients or those on longer dialysis, which might 
contribute to renal TAE being less effective in these patients.
Funding: Private Foundation Support, Government Support - Non-U.S.
SA-PO871
Patient Reported Health Related Quality of Life in ADPKD: Analysis from 
OVERTURE  Dorothee Oberdhan,1 Arlene B. Chapman,2 Ronald D. Perrone,3 
Andreas L. Serra,4 Jason C. Cole,5 Wen Zhou,1 Holly Krasa,1 Jaime Blais,1 Frank 
S. Czerwiec.1  1Otsuka Pharmaceutical Development & Commercialization, 
Inc., Rockville, MD; 2Univ of Chicago, Chicago, IL; 3Tufts, Boston, MA; 4Univ 
of Zürich, Zürich, Switzerland; 5PPD, San Diego, CA.
Background: ADPKD imposes a burden on health-related quality of life (HRQoL). Few 
studies have systematically examined the impact of renal and extra-renal symptomatology 
on patient’s HRQoL. The purpose of this analysis was to capture disease specific burden 
across all disease stages while determining specificity and sensitivity of existing and new 
HRQoL instruments.
Methods: The impact of disease progression on HRQoL in 3,409 ADPKD subjects 
involved in the OVERTURE observational study were evaluated by patient report outcomes 
(PRO) questionnaires, including the ADPKD-IS, ADPKD-UIS, BPI, EQ-5D, and SF-12v2. 
HRQoL was assessed by comparing subjects in CKD2-5 to subjects in CKD1 at baseline. 
Magnitude of change of 0.2, 0.5 and 0.8 standard deviations (SD) represent small, moderate 
and large effects on HRQoL. Other measures of disease severity, including TKV, were 
assessed independently.
Results: HRQoL in ADPKD was impacted at different disease stages depending on 
the sensitivity and specificity of the PRO used. The disease-specific ADPKD-IS scale 
distinguished physical, emotional and fatigue related burden as early as CKD3. Similarly, 
the SF-12 PCS scale was able to distinguish burden by CKD3. The SF-12 MCS and EQ5D 
were not sensitive to disease progression until CKD5. The impact of disease burden prior to 
ESRD was driven by specific questions focused on physical activity, anxiety, and exhaustion. 
Subjects reported being bothered by the shape of their abdomen in an independent question 
as early as CKD3 which associated with larger kidney volumes (htTKV > 635mL/m).
Conclusions: Studies to date have had limited success in their attempt to characterize 
HRQoL in ADPKD patients by using general health surveys. Disease specific instruments 
better capture the burden experienced by patients in earlier stages of ADPKD prior to gross 
kidney enlargement and effects associated with ESRD and dialysis.
Funding: Pharmaceutical Company Support - Otsuka Pharmaceutical Development 
& Commercialization, Inc.
SA-PO872
Fibroblast Growth Factor 23, Renal Progression and Death in Patients 
with Autosomal Dominant Polycystic Kidney Disease  Michel Chonchol, 
Berenice Y. Gitomer, Xuan Cai, Tamara Isakova, Isidro B. Salusky, Renata 
C. Pereira, Myles S. Wolf.  Div of Renal Diseases and Hypertension, Univ of 
Colorado Denver.
Background: No prospective studies examined fibroblast growth factor 23 (FGF23) 
and clinical outcomes among individuals with autosomal dominant polycystic kidney 
disease (ADPKD). We tested the hypotheses that higher serum FGF23 is a risk factor for 
kidney disease progression and mortality in adults with ADPKD.
Methods: We measured intact FGF23 levels (Kainos) in stored baseline serum samples 
in 1,002 patients who participated in the HALT-PKD randomized controlled trial of two 
different blood pressure control strategies. We used Cox proportional-hazards models 
to examine the associations between continuous levels and quartiles of iFGF23 and the 
primary composite endpoint of time to a 50% reduction in estimated glomerular filtration 
rate (eGFR) from baseline, end stage renal disease (ESRD) or death.
Results: At baseline, participants had a mean age of 42 ± 10 years, mean eGFR of 
71.4 ± 26.4 mL/min/1.73m2, mean serum phosphate of 3.4 ± 0.5 mg/dL, and median 
(IQR) iFGF23 of 52.6 (38.6 – 73.7) pg/mL. During a median follow-up of 5.6 years, 226 
patients (22.6%) reached the composite endpoint. After adjusting for demographic factors, 
traditional cardiovascular risk factors, baseline eGFR, and randomized treatment group 
in Cox proportional hazards models, ascending quartiles of FGF23 were associated with 
a stepwise increased risk for the composite endpoint (HR 1.0 [reference], 1.54 [95% CI, 
0.69 - 3.47], 2.92 [CI, 1.38 - 6.19], and 3.41 [CI, 1.61 - 7.22]). Similar results were obtained 
when FGF23 was examined on a continuous scale (HR 1.94 [95% CI, 1.39 - 2.69] per 1 
SD lnFGF23 increase).
Conclusions: Higher serum FGF23 is an independent predictor of kidney disease 
progression and death in adults with ADPKD. Further studies are required to determine the 
mechanisms underlying these relationships and to test whether interventions that reduce 
FGF23 levels might be renoprotective.
Funding: NIDDK Support
SA-PO873
Natural History of Polycystic Liver Disease in the HALT ADPKD 
Cohort  Marie C. Hogan,1 Kaleab Z. Abebe,2 Susan Spillane,2 Frederic F. 
Rahbari-Oskoui,3 Godela M. Brosnahan,4 Charity G. Moore,2 Vicente E. Torres.1 
1Mayo C for the HALT PKD Study Group; 2UPitt; 3Emory; 4U Col.
Background: Although hepatomegaly in polycystic liver disease (PLD) is common, 
few studies have evaluated natural history & factors associated with progression. Goal: 
Examine change in height adjusted liver volume (htLV) & factors influencing progression 
in participants in HALT-PKD-A randomized clinical trial.
Methods: Baseline PLD group (mild (htLV<1000ml;n=240) moderate (1000-1800ml; 
n=271) & severe (>1800ml; n=28; 81% female)) & follow up htLVs, quality of life 
(QOL:SF36), influence of telmisartan (T) vs placebo (P) on progression were assessed 
(n=558, age 15-49y, eGFR > 60 ml/min). We assessed factors influencing htLVs such 
as treatment group, age, gender, genotype (in separate models) & factors influencing 
progression over time were examined using linear mixed models.
Results: Annual htLV growth rates were 0.76, 0.91,& 1.08% (P=NS) in the mild, 
moderate, & severe groups, respectively (figure 1). Neither baseline age or genotype 
associated with annual htLV increase. There were strong negative relationships of eGFR 
(p=.02) & serum albumin (p=.0003) with htLV. Prior pregnancy & higher parity (both age 
adjusted) associated with htLV but not with progression over time. Increases in HtLV were 
associated with increased rates of fatigue/weakness (p=0.003) and declines in SF-36 physical 
functioning over time (p=0.02). Progression was independent of drug assignment (T 0.89% 
vs P 1.07% p.a.;p=NS) & BP target (low 0.81 vs std. 1.15% p.a. p=NS).
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Figure 1: Mean (±SE) htTLV, parenchymal volume (htLPV) & total liver cyst volume 
(htTCV) at month in study by baseline htTLV group (<1000, 1000-1800, >1800ml).
Conclusions: HtLVs increased in HALT-A participants over time, correlated with 
fatigue/ weakness and were associated with measurable continued declines in SF36 QOL 
subdomains.
Funding: NIDDK Support, Other NIH Support - Supported by grants from the NIDDK 
(DK62402 to Dr. Schrier, DK62411 to Dr. Perrone, DK62410 to Dr. Torres, DK082230 
to Dr. Moore, DK62408 to Dr. Chapman, and DK62401 to Washington University in St. 
Louis) and the National Center for Research Resources General Clinical Research Centers 
(RR000039 to Emory University, RR000585 to the Mayo Clinic, RR000054 to Tufts 
Medical Center, RR000051 to the University of Colorado, RR023940 to the University 
of Kansas Medical Center, and RR001032 to Beth Israel Deaconess Medical Center), 
National Center for Advancing Translational Sciences Clinical and Translational Science 
Awards (RR025008 and TR000454 to Emory University, RR024150 and TR00135 to the 
Mayo Clinic, RR025752 and TR001064 to Tufts University, RR025780 and TR001082 to 
the University of Colorado, RR025758 and TR001102 to Beth Israel Deaconess Medical 
Center, RR033179 and TR000001 to the University of Kansas Medical Center, and 
RR024989 and TR000439 to Cleveland Clinic)., Private Foundation Support
SA-PO874
Towards Personalised Medicine – Treating a Renal Ciliopathy 
Shalabh Srivastava,1 Simon Ramsbottom,1 Sophie Saunier,2 Colin Miles,1 
John Andrew Sayer.1  1Nephrology, Inst of Genetic Medicine, Newcastle Univ, 
Newcastle upon Tyne, United Kingdom; 2Laboratory of Inherited Kidney 
Diseases, Imagine Inst, Paris, France.
Background: Renal ciliopathies are genetic disorders presenting with nephronophthisis, 
cystic kidneys or cystic dysplasia.Pathogenesis of ciliopathies may include altered signalling 
or defective DNA damage response. Due to the huge genetic/phenotypic variability in 
ciliopathies it is pertinent to explore the most important contributor to individual phenotypes. 
We investigated disease mechanisms of a patient with Joubert Syndrome aiming to provide 
a personalised medicine approach to treatment.
Methods: We identified a family with 2 affected siblings with a ciliopathy phenotype.
Ciliopathy gene panel sequencing followed by Sanger sequencing and segregation analysis 
was undertaken to provide a molecular genetic diagnosis. We established Human Urine 
derived Renal Epithelial Cell (HUREC) cultures from one sibling and a control. Cultured 
cells where characterised and their response to therapeutic agents quantified.
Results: The siblings exhibited a cerebro-retinal-renal phenotype with renal 
corticomedullary cyst formation and progressive renal failure. Panel sequencing followed 
by Sanger sequencing confirmed biallelic mutations in CEP290 (c.2817G>T, p.K939N; 
c.2848insC, p.Q950Pfs*6) in both affected patients. The c2817G>T is located in the last 
base of exon 25 and is predicted to lead to a splicing defect. There was no difference in 
mitosis or centriole numbers in control and proband’s cells. Control cells formed spheroids 
in 3D culture (100%) whilst the proband’s cells showed a defect in spheroid forming index 
(17%) and absent primary cilia. In the proband cells there was a rescue of spheroid forming 
index in response to treatment with hedgehog agonists SAG(smoothened agonist) (67%) 
and purmorphamine (75%) and a rescue of primary cilia.
Conclusions: In a family with a ciliopathy we have confirmed a molecular genetic 
defect in CEP290. Using HURECS we have characterised, at a personalised medicine 
scale, the cellular defect. This data suggests that renal ciliopathies may have potential 
therapeutic targets and investigation through individual HUREC based model is an exciting 
new development.
SA-PO875
Effect of Metformin on the Progression of Autosomal Dominant Polycystic 
Kidney Disease  Godela M. Brosnahan,1 Michel Chonchol,1 John R. Holmen,2 
Eugene J. Nuccio,1 Berenice Y. Gitomer.1  1Univ of Colorado; 2Intermountain 
Healthcare, Salt Lake City, UT.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a common 
inherited disorder resulting in end-stage renal disease (ESRD), without an approved 
treatment. In an animal model of ADPKD metformin therapy resulted in amelioration 
of cystic renal growth. We sought to determine whether patients with ADPKD and type 
2 diabetes treated with metformin had slower progression to ESRD than similar patients 
treated with other antidiabetic drugs.
Methods: We conducted a population-based cohort study of adult patients with ADPKD 
and type 2 diabetes between January 1/2000 and December 31/2014. We identified 322 adults 
with ADPKD and type 2 diabetes, of whom 119 were treated with metformin only and 203 
with other antidiabetic agents. Among these we identified 31 subjects treated with metformin 
only who could be matched for age, sex, race, history of hypertension and coronary artery 
disease, and baseline renal function to 31 subjects not treated with metformin. The primary 
outcomes were incident ESRD and all-cause mortality.
Results: The median age of the enrolled participants was 61 years, 45% were women. 
Approximately 74% and 26% had a history of hypertension and myocardial infarction, 
respectively. The baseline MDRD-eGFR in participants receiving and not receiving 
metformin was 49±12 and 47±14 mL/min/1.73m2 (p=0.70).After a median follow-up of 
4.5 years, incident ESRD occurred in 29% and 16% of those not exposed and exposed to 
metformin, respectively, with a OR of 2.13 (95% CI 1.10-3.46; p=0.02). Deaths occurred 
in 32% and 26% of those not exposed and exposed to metformin, with a OR of 1.37 (95% 
CI 0.5-2.47; p=0.60).
Conclusions: Metformin therapy may slow progression to ESRD in ADPKD adults 
with type 2 diabetes compared to other antidiabetic drugs. Because metformin has an 
excellent safety record, a trial to slow the progression of ADPKD in the absence of 
diabetes is warranted.
Funding: NIDDK Support
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Frequency and Reasons for Hospitalization Among ADPKD Patients with 
GFR >25 mls/min  Dana Miskulin,1 Kaleab Z. Abebe,5 Ronald D. Perrone,1 
Marie C. Hogan,2 Frederic F. Rahbari-Oskoui,3 Peter G. Czarnecki,4 Susan 
Spillane,5 Arlene B. Chapman,6 Robert W. Schrier,7 Vicente E. Torres,2 Charity 
G. Moore.5  1Tufts Medical Center, Boston; 2Mayo Clinic, Rochester; 3Emory 
Univ, Atlanta; 4Brigham and Women’s Hospital, Boston; 5Univ of Pittsburgh; 
6Univ of Chicago; 7Univ of Colorado.
Background: There is a paucity of data about the frequency and causes of 
hospitalization in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
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Methods: Information about hospitalizations was prospectively collected in the HALT-
PKD Studies, 2 multi-center trials involving people with ADPKD and GFR>60 ml/min 
(Study A) and GFR 25-60 ml/min (Study B). The primary diagnosis was designated after 
review of discharge summaries and independently adjudicated by a committee.
Results: Total patient years (ptyrs) of follow-up in the 558 Study A patients and 486 
Study B patients were 3147 and 2506. The incidence rate (IR) of all-cause hospitalization 
in Study A and B, respectively, was 67.7 and 123.3 per 1000 ptyrs, which compares to 80.3 
and 118.0 , in respective age-matched general populations (CDC/NHDS National Hospital 
Discharge Survey, 2010). The IRs in Study A and B, respectively, for cardiovascular-related 
hospitalization were 7.0 and 18.1 per 1000 ptyrs, and for ADPKD-related hospitalization 
(primary diagnosis kidney or liver cyst pain, infection or hemorrhage, pyelonephritis, 
kidney stones or cerebral aneurysm) were 12.7 and 26.7 per 1000ptyrs. The most common 
primary diagnoses are listed in the table. 
Conclusions: As compared with the respective age-matched general US populations, 
hospitalization rates were lower in ADPKD patients with GFR>60mls/min and higher in 
patients with GFR 25-60 mls/min. PKD-related complications were more common than 
cardiovascular related diagnoses as the primary reason for hospitalization in both Study 
A and B.
Funding: NIDDK Support, Private Foundation Support
SA-PO877
Effect of Statins on the Progression of Autosomal Dominant Polycystic 
Kidney Disease (the HALT PKD Investigators)  Godela M. Brosnahan,1 
Kaleab Z. Abebe,2 Frederic F. Rahbari-Oskoui,3 Charity G. Moore,2 Kyongtae 
Ty Bae,2 Robert W. Schrier,1 Jared J. Grantham.4  1Univ of Colorado; 2Univ of 
Pittsburgh; 3Emory Univ; 4Univ of Kansas.
Background: ADPKD is the most common hereditary disease resulting in end-
stage renal failure (ESRD), without an approved treatment. In a small randomized trial 
comparing pravastatin for 3 years (y) with placebo in 110 patients age 8-22 y, the statin 
group experienced a slower rate of renal enlargement. No large trial has tested the effect 
of statins in ADPKD adults.
Methods: We performed a secondary analysis of the HALT PKD trials, categorizing 
participants into 3 groups based on statin use: 1) never users, 2) less than 3 y, and 3) at 
least 3 y of use. For subjects in Study A (n=558, age 15-49 y, eGFR > 60 ml/min/1.73m2) 
we compared the percent change in height-adjusted total kidney volume (htTKV), in 
height-adjusted total liver volume (htTLV) and the rate of decline in eGFR between the 
3 statin use groups. For participants in Study B (n=486, age 18-64 y, eGFR 25-60 ml/
min/1.73m2) we compared time to composite endpoint of death, ESRD or 50% decline in 
eGFR. Follow-up was 5-8 y.
Results: In HALT Study A only 59 subjects used statins for > 3y and 37 for < 3y. There 
was no difference in the rate of annual htTKV increase (6.41%, 7.11%, 5.97%; p=NS) or 
htTLV growth (1.02%, 1.15%, 0.65%; p=NS) between the 3 groups, after controlling for 
sex, age, and treatment arms. The rate of eGFR decline was faster in group 2 (4.07 ml/
min/y) than in groups 1 and 3 (2.93 and 2.82 ml/min/y; p=0.015), after adjusting for the 
more favorable baseline characteristics of group 1 (more females, younger age, higher 
baseline eGFR). In Study B 118 subjects used statins for > 3y and 76 for < 3y. There was 
no difference in time to endpoint between the 3 groups.
Conclusions: In this secondary analysis of the HALT PKD trials,statin therapy for 3 
years did not slow the rate of renal or liver enlargement or of eGFR decline in ADPKD 
adults, but these results are limited by the small numbers of statin users in Study A, different 
statin drugs and doses, and non-randomized allocation to groups.
Funding: NIDDK Support, Other NIH Support - cooperative agreements (grants 
DK62408, DK62401, DK62410, DK62402, and DK62411, DK082230) with the National 
Institute of Diabetes and Digestive and Kidney Diseases, NIH, the National Center for 
Research Resources General Clinical Research Centers (RR000039 Emory University, 
RR00585 Mayo Clinic, RR000054 Tufts University, RR000051 University of Colorado, 
RR23940 Kansas University, and RR024296 Beth Israel Deaconess Medical Center), 
and the Centers for Translational Science Activities at the participating institutions 
(RR025008 Emory University, RR024150 Mayo Clinic, RR025752 Tufts University, 
RR025780 University of Colorado, and RR024989 Cleveland Clinic)., Pharmaceutical 
Company Support - Boehringer Ingelheim Pharmaceuticals Inc donated telmisartan and 
matched placebo, Merck & Co Inc donated lisinopril, Private Foundation Support
SA-PO878
Assessment of a Dosage-Sensitive Mutational Network for PKD in a Large 
Cohort of Patients with Early and Severe Forms of Polycystic Kidney 
Disease  Carsten Bergmann,1,2 John Devane,2 Steffen Neuber,1 Eva Decker,1 
Uyen Tran,3 Oliver Wessely,3 Elisabeth B. Ott.2  1Center for Human Genetics, 
Bioscientia, Ingelheim, Germany; 2Renal Div, Univ Hospital, Freiburg, 
Germany; 3Cellular & Molecular Medicine, Cleveland Clinic.
Background: ADPKD patients with early and severe disease manifestations only 
make up a minor proportion, but are crucial for a better understanding of PKD. Affected 
families have a high recurrence risk for babies with a severe clinical course often resulting 
in perinatal death. Especially in prenatal cases the diagnostic distinction between different 
forms of PKD and other ciliopathies can be difficult and illustrates the need for more 
comprehensive genetic testing.
Methods: An accurate genetic diagnosis is crucial for genetic counselling, prenatal 
diagnostics and the clinical management of patients. To this end, we established a sequence 
capture based NGS approach targeting 95 genes for cystic and polycystic kidney disease. 
This includes PKD1, which - due to the presence of pseudogenes - is difficult to test. As 
an additional advantage over conventional Sanger sequencing we were able to detect 
copy number variations. The biological significance of some of the detected alleles were 
subsequently tested by in vitro and in vivo studies using a range of animal models including 
zebrafish, Xenopus and mice.
Results: We analysed a cohort of 309 patients exhibiting early and severe PKD. In a 
considerable percentage of patients we did not detect just one single mutated gene/allele, 
but additional mutations in trans. Notably, this proportion increased, the more severely the 
patients were affected. The affected genes were not limited only PKD1, PKD2 or PKHD1. 
In particular, a subgroup of patients with non-syndromic disease harboured mutations in 
genes typically related to ciliopathies such as nephronophthisis, Joubert, Meckel, and 
Bardet-Biedl syndrome. Finally, we used zebrafish, Xenopus and mice to validate some of 
our findings in terms of a functionally proven dosage-sensitive network.
Conclusions: This study is the most comprehensive analysis performed so far and 
points towards a general and underestimated concept for the modification of disease gene 
expression.
SA-PO879
Determinants of Progression in Early Autosomal Dominant Polycystic 
Kidney Disease - Is It Blood Pressure or Renin-Angiotensin-System 
Blockade? The HALT PKD Trial  Godela M. Brosnahan,1 Kaleab Z. Abebe,2 
Charity G. Moore,2 Theodore I. Steinman,3 Frederic F. Rahbari-Oskoui,4 Susan 
Spillane,2 Kyongtae Ty Bae,2 Robert W. Schrier.1  1Univ of Colorado; 2Univ of 
Pittsburgh; 3Beth Israel Deaconess; 4Emory Univ.
Background: The HALT PKD Study A (558 subjects age 15-49 years, eGFR > 60 
ml/min/1.73m2) showed that intensive control of systolic blood pressure (SBP) to 95-110 
mmHg was associated with a slower rate of kidney volume growth compared to standard 
control (SBP 120-130 mmHg). It is unclear whether this result was due to lower BP per se 
or to greater blockade of the renin-angiotensin-aldosterone system (RAAS) by allowing 
higher drug doses in the low BP group.
Methods: We performed a secondary analysis of HALT PKD Study A categorizing 
participants into 3 groups based on lisinopril (L) and telmisartan (T) dosage at 4 months, 
after initial dose titration: 1) high, defined as L 40 mg + T 80 mg daily, 2) middle (everyone 
not high or low) and 3) low, defined as L < 20 mg + T < 40 mg daily. We compared the 
percent change in height-adjusted total kidney volume (htTKV) and the rate of eGFR 
decline between the 3 groups during follow-up for 5-8 years.
Results: Participants in the high dose group (n=51) were more likely male and assigned 
to the low BP arm; they had higher baseline BP and lower eGFR at 4 months than subjects 
in the mid- (n=272) and low-dose (n=165) groups.After adjustment for age, sex, genotype, 
target BP (low or standard), and eGFR at 4 months, there was no significant difference in 
the rate of kidney growth (5.63, 6.40 and 5.83%/yr) or eGFR decline (3.00, 2.94 and 3.29 
ml/min/yr) between the low, middle and high dosage groups.
Conclusions: In this secondary analysis of HALT Study A in young ADPKD adults, 
a higher dosage of RAAS blocking drugs was not associated with a slower rate of htTKV 
growth or of eGFR decline, after adjustment for allocation to intensive BP control. Low 
BP appears to be the main determinant for reducing kidney volume growth.
Funding: NIDDK Support, Other NIH Support - cooperative agreements (grants 
DK62408, DK62401, DK62410, DK62402, and DK62411, DK082230) with the National 
Institute of Diabetes and Digestive and Kidney Diseases, NIH, the National Center for 
Research Resources General Clinical Research Centers (RR000039 Emory University, 
RR00585 Mayo Clinic, RR000054 Tufts University, RR000051 University of Colorado, 
RR23940 Kansas University, and RR024296 Beth Israel Deaconess Medical Center), 
and the Centers for Translational Science Activities at the participating institutions 
(RR025008 Emory University, RR024150 Mayo Clinic, RR025752 Tufts University, 
RR025780 University of Colorado, and RR024989 Cleveland Clinic)., Pharmaceutical 
Company Support - Boehringer Ingelheim Inc donated telmisartan and matched placebo. 
Merck & Co Inc donated lisinopril., Private Foundation Support
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The Short Term Effect of Tolvaptan for CKD Stage4 Autosomal Dominant 
Polycystic Kidney Disease  Haruna Kawano,1,2 Satoru Muto,2,3 Shigeo Horie.1,2 
1Urology, Juntendo Univ Graduate School of Medicine, Tokyo, Japan; 2Urology, 
Teikyo Univ, Tokyo, Japan; 3Endowed Course for the Study of Polycystic Kidney 
Disease, Juntendo Univ Graduate School of Medicine, Tokyo, Japan.
Background: In Japan, the treatment of tolvaptan, a V2 receptor antagonist, started 
from March 2014. Indication criteria of tolvaptan for ADPKD treatment in Japan is adult 
patient with more than 750ml total kidney volume (TKV) and more than about 5%/year 
increasing rate of TKV. It is contraindication to use tolvaptan for patients with eGFR<15ml/
min/1.73m2. It is recommended to reduce dose of tolvaptan for patients with CCr<30ml/
min. However, the treatment effect for patients with CKD stage 4 is still unknown. So, 
we evaluated the short time efficacy of tolvaptan treatment for patients with CKD stage 4.
Methods: Thirteen patients (5 females and 8 males, mean age; 52.5 years) with ADPKD 
who started tolvaptan at our hospitals from April 2014 to April 2015 were analyzed in 
this study. Although our standard starting dose of tolvaptan for patients with good renal 
function is 60mg/day, we administered 15mg/day for patients with eGFR<25ml/min/1.73m2 
patients. Patients were measured eGFR and TKV at the commencement of treatment and 
at 1.5 and 6 months later.
Results: The baseline median eGFR and TKV were 21.8 ml/min/1.73m2 (range; 17.1-
28.9) and 2,810ml (range; 1.031-5,847), respectively. The change of median eGFR from 
baseline at 1.5 months and at 6 months were -0.36 ml/min/1.73m2 (p=0.39) and -1.80 ml/
min/1.73m2 (p=0.04), respectively. The change of median TKV from baseline at 1.5 months 
and at 6 months were -132ml (p=0.39) and +12ml (p=0.93), respectively. One female patient 
and one male patient temporally stopped their treatment at 3 months and at 6months because 
of their eGFR decreased to lower than 15 ml/min/1.73m2. Hepatic toxicity, hypernatremia, 
and the other severe adverse events were not detected.
Conclusions: No severe adverse events were occurred and 85% of CKD stage4 
patients could keep treatment for 6 months without CKD progression. Tolvaptan was safe 
and tolerable for ADPKD patients with CKD stage 4 in lower dose.
Funding: Pharmaceutical Company Support - Otsuka pharmaceutical Co., Ltd., 
Government Support - Non-U.S.
SA-PO881
Estimation of Total Kidney Volume in Autosomal Dominant Polycystic 
Kidney Disease  Edwin M. Spithoven,1 Maatje D.A. van Gastel,1 A. Lianne 
Messchendorp,1 Niek F. Casteleijn,1 Ron T. Gansevoort.1  1Internal Medicine, 
Nephrology, UMC Groningen; 2On behalf of the DIPAK Consortium, 
Netherlands.
Background: Measuring total kidney volume (TKV) in autosomal dominant polycystic 
kidney disease (ADPKD) by magnetic resonance image (MRI) and manual tracing is time 
consuming. Two alternative MRI methods have recently been proposed to estimate TKV 
(eTKVELLIPSOID and eTKVPANK) which require less time.
Methods: ADPKD patients with a wide range of kidney function were included, if 
they had an approved T2 weighted MRI. A test set of 10 MRIs was used for assessing 
reproducibility, 220 for cross-sectional analyses and 48 for longitudinal analyses with a 
follow-up of three years. mTKV was used to assess Irazabal risk categories, reclassification 
was calculated for eTKVELLIPSOID and eTKVPANK. Measured TKV (mTKV) was manually 
traced, eTKVELLIPSOID was calculated as advised in literature as ʌ/6 * (lengthcoronal + 
lengthsagittal)/2 * width * depth/1000 and eTKVPANK as midslice x number of slices covering 
the kidney x 0.624 or 0.637 for the left and right kidney, respectively.
Results: In the test set, intra- and inter-coefficients of variation were low; mTKV 
1.8% and 2.3%, eTKVELLIPSOID 3.9% and 6.3%, and eTKVPANK 3.0% and 3.4%. Duration 
of analyses were respectively 55, 5 and 15 minutes. In cross-sectional analyses baseline 
kidney volumes (liters) were 1.96 (1.28-2.82) for mTKV, 1.93 (1.25-2.82) for eTKVELLIPSOID 
and 1.81 (1.17-2.62) for eTKVPANK, the latter both significantly different from mTKV 
(p=0.004 and p<0.001 respectively). Bias was low and precision high for repeated 
mTKV (0.2%±3.2%), eTKVELLIPSOID (1.4%±9.2%) as well as eTKVPANK (4.6±7.6%). In 
longitudinal analyses, no significant differences were observed between percentage change 
in mTKV (16.7±17.1%) compared to change in eTKVELLIPSOID (19.3±16.1%) and eTKVPANK 
(17.8±16.1%). Both methods resulted in limited reclassification in Irazabal risk categories; 
6.7% for eTKVELLIPSOID and 9.8% for eTKVPANK.
Conclusions: Both methods to estimate TKV perform relatively well compared to 
mTKV, and detect similar changes in TKV over time. Since eTKVELLIPSOID requires less time 
than eTKVPANK, we suggest this method should be preferred in clinical care.
Funding: Private Foundation Support
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Genetic Background Radically Alters Disease Progression in the Pkd1RC/RC 
Model  Diana L. Escobar, Katharina Hopp, Cynthia J. Sieben, Peter C. Harris. 
Mayo Clinic, Rochester, MN.
Background: Studies in ADPKD patients and PKD mouse models have shown that 
genetic background influences the disease phenotype. Here, we evaluated the phenotype of 
the homozygous Pkd1: p.R3277C (RC) model in three new backgrounds: BalbC, 129S6, 
and F1 (C57BL6 X BalbC) and compared them to C57BL6.
Methods: To characterize the cystic disease burden, Pkd1RC/RC animals were inbred 
into three different strains and aged to 3 months (m). At this time point %Kidney Weight/
Body W, BUN levels, kidney cyst index were used to compare disease severity.
Results: Already at this early stage of cyst progression (3m) genetic background 
significantly affects the severity of the disease in the Pkd1RC/RC model with %KW/BW 
significantly higher in the BalbC (3.31) and 129S6 (3.12) backgrounds compared with 
F1 (1.92; P<0.0001,<0.001) or C57BL6 (1.74: both P<0.0001). However, BUN levels 
did not deviate from the physiological norm at this early stage of the disease in any of the 
backgrounds. In respect to cyst index, 129S6 (21.87%) and BalbC (19.47%) animals had a 
greater disease burden compared to F1 (3.71%; both P<0.0001) and C57BL6 (5.24%; both 
P<0.0001) animals. No significant difference was found between 129S6 and BalbC mice 
(P=0.47). Histological analysis showed a distribution of variously sized cysts in the medulla 
and cortex in BalbC and large cysts mainly in the medulla in 129S6, which contrasted with 
small cysts mainly in the cortex in F1 and C57BL6 (figure 1). Immunofluorescence at 3m 
in all backgrounds showed the majority of cyst had a collecting duct (CD) origin, however 
some cysts were negative for the nephron markers LTA-AQP1 (PT), AQP2-DBA (CD).
Conclusions: This study highlights the role of genetic background in cystic disease 
progression in the Pkd1RC/RC model. Due to the more rapid progression and severe cystic 
burden, the BalbC and 129S6 models may be more suitable for PKD pre-clinical testing.
Funding: NIDDK Support
SA-PO883
Influence of Kidney Volume on Progression to Advanced Stages of Chronic 
Kidney Disease in Autosomal Dominant Polycystic Kidney Disease 
(ADPKD)  Alan S.L. Yu,1 Jared J. Grantham,1 Arlene B. Chapman,3 Kyongtae 
Ty Bae,2 Doug Landsittel,2 Chengli Shen,2 Vicente E. Torres,4 Michal Mrug,5 
Peter C. Harris,4 Frederic F. Rahbari-Oskoui,6 Michael F. Flessner,7 William 
M. Bennett.8  1U Kansas; 2U Pittsburgh; 3U Chicago; 4Mayo Clinic; 5UAB 
Birmingham; 6Emory U; 7NIH; 8Legacy Good Samaritan Med Ctr.
Background: The Consortium for Radiologic Imaging Studies of Polycystic Kidney 
Disease III (CRISP III) is the continuation of a longitudinal cohort study of patients with 
ADPKD designed to identify predictors of CKD progression and kidney failure. Cyst 
enlargement and hence increase in kidney volume is believed to be on the causative pathway 
that leads to decline in GFR and kidney failure.
Methods: In 241 patients, height-adjusted total kidney volume (htTKV) was determined 
by MRI at baseline, and serial GFR determined by corrected iothalamate clearance and 
serum creatinine estimating equations.
Results: After a mean follow-up of 11.1 years, 59.8%, 32.1% and 21.6% of subjects 
reached CKD stage 3, 4 and 5. In multivariable logistic regression analysis, baseline htTKV 
was an independent predictor for the development of CKD stages 3, 4 and 5 by the final visit, 
after correction for age, sex, race, BMI, and baseline GFR. Similar results were obtained 
whether CKD stage was determined using iothalamate clearance, MDRD eGFR, or CKD-Epi 
eGFR. The estimated htTKV at age 18 yr was also predictive of subsequent CKD stage 3. 
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aDetermined by iothalamate GFR
bPer 100 mL/m
htTKV at baselineb htTKV at age 18 yrb
Endpointa OR (95% CI) p value OR (95% CI) p value
CKD stage 3 1.35 (1.20, 1.53) < 0.001 1.16 (1.01, 1.32) 0.026
CKD stage 4 1.33 (1.18, 1.51) < 0.001 1.05 (0.86, 1.27) 0.86
CKD stage 5 1.41 (1.23, 1.63) < 0.001 1.02 (0.81, 1.27) 0.87
Conclusions:    Kidney volume measured by MRI at a single timepoint is a powerful 
predictor for the development of advanced stages of CKD over the ensuing 11 years. 
Consistent with prior analyses, greater kidney volume is strongly associated with higher 
rates of CKD progression, further supporting the notion that cyst enlargement is the primary 
cause of GFR loss and kidney failure.
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Therapeutic Effects of the Fibrokinase Inhibitor ANG3070 in Polycystic 
Kidney Disease  Prakash Narayan, Liming Zhang, Bin Duan, Jingsong Li, 
Ping Zhou, Siobhan McCormack, Latha Paka, Itzhak D. Goldberg.  Angion 
Biomedica Corp.
Background: Aberrant receptor tyrosine kinase signaling has been implicated in cyst 
expansion, renal interstitial fibrosis, increased kidney volume and reduced renal function in 
polycystic kidney disease (PKD). We investigated the effects of a novel, orally bioavailable, 
small molecule fibrokinase inhibitor, ANG3070, in experimental PKD.
Methods: Male PCK rats (PCK/CrljCrl-pkhd1pck/Crl) were rats were randomized 
to vehicle or ANG3070 (25 mg/kg, BID, PO) at 6.5 weeks of age following confirmation 
of frank disease and sacrificed at 13.5 weeks. Age-matched male Sprague-Dawley rats 
served as wild-type controls.
Results: ANG3070 has no effect on mean arterial pressure. In PCK rats with diseased 
kidneys (figure1), randomization to ANG3070 treatment was therapeutic, reducing cystic 
index, renal interstitial fibrosis (hydroxyproline (HYP), albuminuria and other urine 
biomarkers of renal injury and serum creatinine (* p<0.05).
Conclusions: With ongoing investigational new drug enabling toxicology studies 
suggesting a large safety index, these data support the continuing development of ANG3070 
for PKD, a disease currently without cure. Supported by PR130909 and AR058041-02.
Funding: Other NIH Support - AR058041-02, Other U.S. Government Support
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Extended Follow-Up of the Consortium for Radiologic Imaging Studies 
of Polycystic Kidney Disease (CRISP III): The Predictive Value of Height 
Corrected Total Kidney Volume (htTKV) for the Future Development 
of CKD Stages 3a, 3b, 4 and 5 After Ten Years Follow-Up in Autosomal 
Dominant Polycystic Kidney Disease (ADPKD)  Arlene B. Chapman,1 
Chengli Shen,2 Alan S.L. Yu,3 Michal Mrug,4 Frederic F. Rahbari-Oskoui,5 
Vicente E. Torres,6 Jared J. Grantham,3 Michael F. Flessner,8 Kyongtae Ty 
Bae,2 Doug Landsittel,2 Peter C. Harris,6 William M. Bennett.9  1U of Chicago; 
2U of Pittsburgh; 3U of Kansas; 4Univ of Alabama Birmingham; 5Emory Univ; 
6Mayo Clinic; 7National Insts of Health; 8Legacy Good Samaritan Hospital.
Background: CRISP III is a longitudinal observational cohort study of 241 ADPKD 
individuals now extending beyond 10 years. Measures of cyst burden by magnetic resonance 
imaging (MR) provide an accurate assessment through measures of htTKV. We have shown 
previously that baseline htTKV predicts CKD stage 3 after 8 years. We now evaluate 
whether baseline htTKV can predict CKD Stage 3a,3b, 4 and 5 after 10 years of followup.
Methods: Participants underwent protocol visits including MR imaging, iothalamate 
clearance and serum creatinine measurements. Baseline htTKV was evaluated in its capacity 
to predict later CKD stages both individually and in a multivariable model that includes 
age, race, gender, and baseline iothalamate clearance. Receiver operator characteristic area 
under the curves (AUROC) were developed for reaching CKD stage 3a, 3b, 4 or 5 after a 
minimum of 10 years of followup.
Results: At 10 years, 59.8%, 32.1% and 21.6% of patients had reached CKD stage 3,4 
or 5. Baseline htTKV alone predicts CKD stage 3 in 10 years with a ROC of 0.85 and an 
optimal TKV cut point of 470 ml/m. Multivariable analysis assessing future CKD Stage 
3a, 3b, 4 and 5 at 10 years demonstrated a ROC of 0.89, 0.87, 0.90, and 0.89 respectively.
Conclusions: HtTKV is a powerful predictor of the development of all advanced 
stages of CKD within 10 years with an optimal htTKV of 470 ml/m for CKD Stage 3.
Funding: NIDDK Support
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Alterations in Renal Oxylipins in Models of Polycystic Kidney Disease: 
Potential for Cyclooxygenase Inhibition for Disease Treatment 
Harold M. Aukema,1,2 Jessay Gopuran Devassy,1,2 Md Monirujjaman,1,2 Tamio 
Yamaguchi,1,2 Amir Ravandi.3  1Human Nutritional Sciences, Univ of Manitoba, 
Winnipeg, MB, Canada; 2CCARM, St. Boniface Research Hospital Research 
Centre, Winnipeg, MB, Canada; 3Inst for Cardiovascular Sciences, St. Boniface 
Research Hospital Research Centre, Winnipeg, MB, Canada.
Background: In both the Han:SPRD-Cy rat and the pcy mouse, prostanoids formed 
via the cyclooxygenase (COX) pathway are elevated, while oxylipins produced via the 
lipoxygenase (LOX) and cytochrome P450 (CYP) pathways are reduced. Importantly, 
inhibiting the formation of the elevated COX oxylipns with selective (NS-398) or 
unselective (aspirin) COX inhibitors reduces the progression of disease in the Han:SPRD-
Cy rat, suggesting their potential use in the treatment of nephronophthisis. It is not known, 
however, whether renal oxylipins are altered in orthologous models of human polycystic 
kidney disease (PKD).
Methods: Renal oxylipins were examined in orthologous models of autosomal 
dominant (AD) and autosomal recessive (AR) PKD. Mx1Cre+Pkd1flox/flox mice (ADPKD1) 
were injected with saline or pI:pC at 5 weeks of age, and control and diseased kidneys 
were obtained at 21 weeks of age. Control and diseased kidneys from Pkd2WS25/- mice 
(ADPKD2) and PCK (ARPKD) rats were obtained at 16 weeks of age. Over 100 oxylipins 
were analyzed by LC/MS/MS.
Results: In Mx1Cre+Pkd1flox/flox mice with disease, renal levels of the COX metabolites, 
prostaglandin (PG)E2 and 6-keto-PGF1α were elevated by 35 and 59%, respectively. In 
Pkd2WS25/- mice, PGE2, 11β-PGE2, PGF2α, PGD2, and 6-keto-PGF1α were elevated in diseased 
kidneys by 43, 49, 46, 67 and 136%, respectively. In the PCK rat model of ARPKD, PGE2 
and 6-keto-PGF1α were elevated by 38 and 50%, respectively. In all three models, although 
not as consistent as the COX oxylipin changes, LOX and CYP oxylipins were generally 
lower, which is similar to findings in the Han:SPRD-Cy rat and pcy mouse.
Conclusions: The elevated renal COX oxylipins in these PKD models are consistent 
with other cystic kidney disease models. This suggests that COX inhibition with common 
drugs such as aspirin or selective COX inhibitors may be beneficial in PKD, as it is in other 
models of cystic kidney diseases.
Funding: Government Support - Non-U.S.
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Hepatorenal Fibrocystic Diseases in Children  Eujin Park,1 Yo Han Ahn,1 
Hee Gyung Kang,1,2 Hye Won Park,3 IL-Soo Ha,1 Hae Il Cheong.1,2  1Dept of 
Pediatrics, Seoul National Univ Children’s Hospital, Seoul, Korea; 2Research 
Coordination Center for Rare Diseases, Seoul National Univ Hospital, Seoul, 
Korea; 3Dept of Pediatrics, Seoul National Univ Bundang Hospital, Seongnam, 
Korea.
Background: Hepatorenal fibrocystic diseases (HRFCDs) are a group of monogenic 
disorders characterized by developmental abnormalities involving the liver and kidney. In 
this study, we performed genotype and phenotype analyses of children with HRFCDs to 
determine the distribution of underlying diseases.
Methods: A total of 36 children with HRFCDs were recruited, with genetic tests 
performed in 22 patients and 14 patients diagnosed clinically as having autosomal recessive 
polycystic kidney disease (ARPKD).
Results: In children with HRFCDs, ARPKD was the most common disease (16/36, 
44.4%) followed by nephronophthisis 13 (NPHP13, 11/36, 30.6%) and Meckel–Gruber 
syndrome type 3 (MKS3, 4/36, 11.1%). Renal function deteriorated faster in children with 
NPHP13. The main hepatic pathology was Caroli disease in the NPHP13 patients, while 
most other patients had Caroli syndrome or congenital hepatic fibrosis. Of note, three of 
four MKS3 patients had an accompanying choledochal cyst. No ARPKD patients had other 
organ involvement, while several NPHP13 patients had ocular and/or neurodevelopmental 
involvement. In contrast, all MKS3 patients had severe ocular and neurodevelopmental 
involvement.
Conclusions: NPHP13 is a major disease belonging to HRFCDs, and thorough 
evaluation of its clinical features, including kidney, liver and other organ involvement, 
may aid in the differential diagnosis of HRFCD.
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Identifying Genetic Modifiers in Severe Polycystic Liver Disease (PLD) 
by Whole Exome Sequencing (WES)  Amirreza Haghighi,1 Young-Hwan 
Hwang,2 Ning He,1 Kairong Wang,1 Winnie Y. Chan,1 Xuewen Song,1 Joost P.H. 
Drenth,3 York P. Pei.1  1Div of Nephrology, Univ of Toronto, Toronto, Canada; 
2Div of Nephrology, Eulji Univ College of Medicine, Seoul, Korea; 3Dept of 
Gastroenterology and Hepatology, Radboud Univ, Nijmegen, Netherlands.
Background: Severe PLD (sPLD) is a rare and poorly understood phenotype seen 
in ADPKD and ADPLD. Mutations of PRKCSH or SEC63 in ADPLD reduce functional 
polycystin-1 dosage by decreasing endoplasmic reticulum (ER) protein-processing and 
aggravates cystic disease severity in-vivo (Nat Genet 43: 639-647, 2011). We hypothesize 
that rare mutations in ER pathway genes may modify PLD.
Methods: We performed WES using Illumina HiSeq2000/2500 with SSV4/5 capture 
kit in 88 patients (24 affected discordant sib-pairs and 7 affected concordant sib-pairs for 
sPLD and 27 sporadic cases). All sPLD patients had a liver span >25 cm by CT/MRI or 
>3x normal liver volume. In addition to genome-wide analysis, we performed focused 
analysis on 168 ER genes. Standard algorithms for sequence alignment, base calling, and 
QC filtering were applied to identify rare deleterious variants of high and moderate impact 
as predicted by PolyPhen-2, Sift, Mutation Assessor, Mammalian and Vertebrate nucleotide-
level conservation, and Combined Annotation Dependent Depletion.
Results: Overall, we achieved a mean target coverage of 108X with 90% of targeted 
exomes having >30X read depth. We identified 4,696 rare deleterious variants that 
segregated with PLD disease severity in at least one family. From them, we found 7 non 
ER genes (TTN, DNAH10, DNAH14, HMCN2, NEB, OBSCN and ADAMTS8) with rare 
variants that segregate in 4 to 6 families each and 8 ER genes (WFS1, UGGT1, UGGT2, 
SEC24D, SEC23B, EIF2AK4, ATF6B and RPN1) with rare variants that segregate in at 
least one family and 3-4 sporadic sPLD cases.
Conclusions: Our results suggest extensive genetic heterogeneity with no one single 
gene accounting for a large proportion of sPLD cases. Future studies with expanded sample 
size will help to identify promising candidate genes for follow-up functional studies. 
Identification of genetic modifiers of sPLD has the potential to improve risk prediction 
and treatment of this unusual complication.
Funding: Private Foundation Support
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TOSCA – TuberOus SClerosis Registry to Increase Disease Awareness: 
Renal Manifestations of Tuberous Sclerosis Complex  John C. Kingswood,1 
Anna C. Jansen.2  1Sussex Kidney Unit, Royal Sussex County Hospital, Brighton, 
United Kingdom; 2Pediatric Neurology Unit, UZ Brussel, Brussel, Belgium.
Background: Renal manifestations are the most common cause of morbidity and 
mortality in adult patients with tuberous sclerosis complex (TSC). The aim of the TuberOus 
SClerosis registry to increase disease Awareness (TOSCA) is to understand the various 
manifestations of TSC. The baseline data of renal manifestations in the overall TOSCA 
cohort are presented here.
Methods: Patients diagnosed with TSC were enrolled in TOSCA from 170 sites 
across 31 countries worldwide. Patients will be followed up for up to 5 years with interim 
analysis performed every year.
Results: Baseline core data from 2093 patients were entered in the registry as of 
September 30, 2014 (cut-off date for the 2nd interim analysis). Median age at consent was 13 
years (0-71). Renal angiomyolipomas were reported in 987 (47.2%) patients. Median age at 
diagnosis of angiomyolipoma was 13 years (0-67). Of the 946 (95.8%) patients with ongoing 
renal angiomyolipomas, 396 (41.9%) had multiple and bilateral lesions, 329 (34.8%) had 
lesions > 3 cm, and 204 (21.6%) had growing lesions. Symptoms/signs associated with 
renal angiomyolipomas, reported either individually or in combination with others, were 
elevated blood pressure (48 [5.1%]), microscopic hematuria (35 [3.7%]), hemorrhage (47 
[5.0%]), impaired renal function (36 [3.8%]), and pain (51 [5.4%]). Renal angiomyolipomas 
were treated in 274 (27.8%) patients; major treatment modalities included embolization in 
98 (35.8%) and mammalian target of rapamycin (mTOR) inhibitors in 78 (28.5%) patients. 
Other renal features reported were renal malignancy (24 [1.1%]), multiple renal cysts 
(477 [22.8%]), polycystic kidneys (73 [3.5%]), and impaired renal function (43 [2.1%]).
Conclusions: The prevalence of renal angiomyolipomas of 47.2% in our cohort 
compared to 80-85% in the literature probably reflects their young mean age. Despite 
this the intervention rate was high, emphasizing the need for active surveillance. This is 
the largest cohort of patients with TSC ever reported, thus TOSCA is a powerful tool to 
delineate the natural history of TSC.
Funding: Pharmaceutical Company Support - Novartis Pharma AG
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Sirolimus Reduces Fundamentally the Vascular and/or Muscular 
Components of Angiomyolipomas and Can Be Neoadjuvant to Partial 
Nephrectomy in Tuberous Sclerosis Complex Patients with Multiple and 
Large Tumors Associated with Surgical Risk  Elieser H. Watanabe,1 Fernando 
I. Yamauchi,2 Hilton M. Leao-Filho,2 William C. Nahas,3 Luiz F. Onuchic.1 
1Nephrology, Univ of Sao Paulo, Sao Paulo, SP, Brazil; 2Radiology, Univ SP, 
Sao Paulo, SP, Brazil; 3Nephrology, Univ SP, Sao Paulo, SP, Brazil.
Background: Renal angiomiolipomas (AMLs) are commonly associated with tuberous 
sclerosis complex (TSC). Because AMLs may complicate with lethal hemorrhage, invasive 
intervention is preconized for high-risk lesions. These procedures, however, imply in 
potential loss of functional renal mass and operatory risk, particularly in TSC patients 
with multiple and bilateral involvement. Since AML pathogenesis is based on the loss of 
mTOR inhibition, clinical trials have evaluated and shown efficacy of mTOR inhibitors 
(mTORi) to reduce tumor size. Such studies, however, were not capable of proving mTORi 
long-term benefit. Given that tumor size is an independent predictor of renal function 
decline after partial nephrectomy, we hypothesized that pre-surgical treatment with mTORi 
might be beneficial.
Methods: In this retrospective study we report the effects of neoadjuvant therapy 
with the mTORi sirolimus in TSC patients with multiple/large AMLs undergoing nephron 
sparing surgery (NSS).
Results: As expected, sirolimus decreased tumor volume (-32.9±30.8%, n=22 from 9 
patients, serum level of 10.4+1.3 ng/mL; p<0.001). This reduction occurred essentially due 
to the non-fatty compartment decrease (-56.2±33.1%; p<0,001) while the fatty component 
showed no significant variation. A lower rate of early operatory complications was found 
in the treated compared to the non-treated group (0%, n=7 vs 43%, n=6; p<0,05). Such 
complications included mostly intraoperatory bleeding (75%). Long-term complication 
rates did not differ between the groups. Sirolimus was well tolerated and no serious adverse 
event was reported.
Conclusions: Our data indicate that sirolimus acts fundamentally at the vascular-
containing compartment, suggesting that it may decrease the bleeding risk. In addition to 
its potential benefit as neoadjuvant therapy for large/multiple AMLs undergoing NSS, our 
findings revealed that the use of sirolimus was safe and reduced surgical complications.
Funding: Government Support - Non-U.S.
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The ARegPKD Registry Study – Initial Clinical Characterization of an 
International ARPKD Cohort  Kathrin Ebner,1 Gema Ariceta,2 Carsten 
Bergmann,3,4 Heiko Billing,5 Reinhard Buettner,1 Ali Duzova,6 Heike Goebel,1 
Dieter Haffner,7 Thomas Illig,7 Augustina Jankauskiene,8 Djalila Mekahli,9 
Bruno Ranchin,10 Anja Christine Sander,11 Sara Testa,12 Lutz Thorsten Weber,1 
Dorota Wicher,13 Elke Wuehl,14 Franz S. Schaefer,14 Max Liebau.1  1Univ 
Hospital of Cologne, Germany; 2Univ Hospital Vall d’Hebron, Barcelona, Spain; 
3Bioscientia Center for Human Genetics, Ingelheim, Germany; 4Univ Hospital 
of Freiburg, Germany; 5Univ Hospital of Tuebingen, Germany; 6Hacettepe Univ, 
Ankara, Turkey; 7Hannover Medical School, Germany; 8Center for Pediatrics, 
Univ Hospital of Vilnius, Lithuania; 9Univ Hospital of Leuven, Belgium; 10Univ 
de Lyon, Bron, France; 11Univ of Heidelberg, Germany; 12Fondazione IRCCS 
Ca Granda Ospedale Maggiore Polic, Milano, Italy; 13The Children’s Memorial 
Health Inst, Warsaw, Poland; 14Univ Hospital of Heidelberg, Heidelberg, 
Germany.
Background: Autosomal recessive polycystic kidney disease (ARPKD) is the rare 
form of polycystic kidney disease presenting in early childhood. There is unexplained 
phenotypic heterogeneity. Current therapeutic approaches continue to be largely opinion-
based and symptomatic.
Methods: ARegPKD is an international, mostly European, pro- and retrospective, 
observational study in both pediatric and adult ARPKD patients to generate a deeply-
characterized ARPKD cohort. Using web-based questionnaires regarding patients’ clinical 
data in combination with associated biobanking and reference histology ARegPKD will 
characterize long-term ARPKD courses and set roots for future translational research.
Results: In June 2015 63 centers have registered and more than 130 patients have 
been included (57,6 % male; median age at inclusion 7,6 years; number of follow-up visits 
up to 17). Here we present data on general patient characteristics, genetic testing, renal 
and hepatic phenotype putting a special focus on the peri- and postnatal period (prenatal 
findings, ventilation modalities, sonographical findings, laboratory values).
Conclusions: ARegPKD aims to deeply characterize ARPKD patients in order to 
provide evidence base for clinical treatment decisions and contribute to the understanding 
of this severe renal disorder of early childhood.
Funding: Private Foundation Support
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The Effect of Sodium Nitrite on Central and Peripheral Hemodynamics, 
Vasoactive Hormones, GFR and Sodium Excretion in Healthy Subjects 
Jeppe B. Rosenbaek, Safa Al Therwani, Janni Majgaard Jensen, Frank H. 
Mose, Erling B. Pedersen, Jesper N. Bech.  Univ Clinic in Nephrology and 
Hypertension, Holstebro Hospital and Aarhus Univ, Denmark.
Background: Recent research has shown that sodium nitrite is readily converted to 
nitric oxide (NO) by enzymes in vivo and exerts vasodilation. Previous studies based on 
nitric oxide synthase inhibition indicates a natriuretic effect of nitric oxide. The purpose 
of the present study was to examine the effects of sodium nitrite on central and peripheral 
blood pressure, heart rate, fractional sodium excretion and GFR.
Methods: In a single blinded, crossover, placebo controlled dose-response study 12 
healthy subjects were treated, in a randomized order, with placebo (isotonic NaCl) or one 
of three doses of sodium nitrite 40, 120 or 240 mg/kg/hour for two hours. Each examination 
was preceded by 4 days standardized diet. Subjects were supine and water loaded throughout 
the day. Before, during and after sodium nitrite administration we measured diastolic, 
systolic and mean arterial blood pressure (DBP, SBP and MAP), heart rate, plasma renin, 
angiotensin II and aldosterone, GFR by chrome-EDTA clearance, fractional sodium 
excretion and urinary excretion rate of nitrite and nitrate (NOx).
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Results: Fractional sodium excretion were reduced by 0.25% 95%CI (0.02;0.47) by 
the lowest dose, 0.24% (-0.12;0.59) by the intermediate dose and 0.32% (0.06;0.59) by 
the highest dose compared to placebo. The highest dose of sodium nitrite reduced SBP 
by 4.5 mmHg (0.5;8.5), DBP by 3.8 mmHg (0.9;6.7), MAP by 4.0 mmHg (1.2;6.8) and 
increased P-renin concentration by 17.6% (2.9;32.2), P-angiotensin II by 21.8% (4.6;38.9) 
and urinary excretion rate of NOx by 95% (59;132) compared to placebo. There was no 
effect on heart rate, GFR or aldosterone.
Conclusions: In supine, water loaded subjects a two hour infusion of 240 mg/kg/
hour sodium nitrite exerts an antinatriuretic and BP lowering effect. The rise in urinary 
excretion rate of NOx suggests an increased bioavailability. The activation of the renin-
angiotensin-aldosterone system (RAAS) could either be mediated directly by nitrite/NO 
or by baroreceptor reflex. The antinatriuretic effect might, at least partially, be mediated 
by the RAAS.
Funding: Government Support - Non-U.S.
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The Spatial Destribution of Metabolites Determined by Imaging 
Mass Spectrometry in the Kidneys of Rats Treated with Furosemide 
Hyo-jung Choi, Euijung Park, Tae-Hwan Kwon.  Dept of Biochem and Cell 
Biol, Sch of Med, Kyungpook Natl Univ, Taegu, Korea.
Background: In the kidney, metabolic processes vary among the cortex (COR), 
outer medulla (OM), and inner medulla (IM), and the concentrations of metabolites are 
different according to the kidney zones. We aimed to examine the regional differences of 
the significantly changed metabolites in the kidneys of rats treated with loop diuretics by 
exploiting the matrix-assisted laser desorption/ionization (MALDI) and imaging mass 
spectrometry (IMS).
Methods: Osmotic minipumps were implanted in male Sprague-Dawley rats to deliver 
12 mg/day of furosemide (s.c.). Vehicle-treated control rats (n = 14) and furosemide-treated 
rats (furosemide rats, n = 15) were maintained in metabolic cages for 6 d on a fixed daily 
amount of rat chow (15 g/220 g bw/rat) with free access to water intake.
Results: At day 6, higher urine output (32 ± 4 vs. 9 ± 1 ml/day) and lower urine 
osmolality (546 ± 44 vs. 1,677 ± 104 mOsm/KgH2O) were observed in furosemide 
rats. Extracts of COR, OM, and IM were analyzed by UPLC/Q-TOF MS. The filtered 
peaks in UPLC/Q-TOF MS were subjected to multivariate analysis, revealing a clear 
differentiation between the two groups. UPLC-QTOF-MS identified significant changes 
of metabolites, including acetyl carnitine, betaine, carnitine, choline, dehydrocarnitine, 
and glycerophosphorylcholine (GPC). Next, significant changes of metabolites were 
also identified by IMS and MALDI-TOF/TOF, including choline compounds (choline, 
phosphocholine, phosphocholine derivatives and GPC), carnitine compounds (carnitine, 
dehydrocarnitine, aceyl carnitine and acyl carnitine) and betaine. Importantly, the spatial 
distribution and relative quantitation of identified metabolites were analyzed by IMS. 
Choline compounds were increased in COR and OM, but decreased in IM from furosemide 
rats. Carnitine compounds were increased in COR and IM in furosemide rats. Betaine and 
GPC were decreased in OM and IM in furosemide rats.
Conclusions: Taken together, IMS applied to the kidney sections successfully provides 
the spatial distribution and relative quantitation of significantly changed metabolites in the 
kidneys of furosemide rats.
Funding: Government Support - Non-U.S.
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Bicarbonate Supplementation Improves Vascular Function in Patients with 
Chronic Kidney Disease: A Pilot Study  Jessica B. Kendrick,1,2 Emily Decker,1 
Kristen L. Nowak,1 Michel Chonchol.1  1Univ of Colorado Denver, Aurora, CO; 
2Denver Health Medical Center, Denver, CO.
Background:    Metabolic acidosis, as reflected by a low serum bicarbonate level, 
is associated with increased risks of endothelial dysfunction, hypertension and death. 
Metabolic acidosis induces inflammation and endothelin-1, both of which contribute to 
vascular dysfunction. Whether alkali therapy improves vascular function in patients with 
chronic kidney disease (CKD) is unknown.
Methods:    Seven subjects (5 men and 2 women) with stage III/IV CKD and serum 
bicarbonate level: 16-22 mEq/L completed a pilot, prospective, open-label, crossover study 
of 14 weeks duration examining the effect of oral sodium bicarbonate supplementation on 
endothelial function. The primary endpoint was change in brachial artery flow mediated 
dilation between treatment and control conditions. Each period was 6 weeks in duration with 
a two-week washout period in between. Patients were treated with oral sodium bicarbonate 
tablets two to three times per day for goal serum bicarbonate of ≥ 23 mEq/L.
Results:    The mean (SE) age and eGFR was 59 (3.3) years and 21.9 (2.6) ml/
min/1.73m2, respectively. The mean (SE) serum bicarbonate level increased after sodium 
bicarbonate administration from 18.4 (0.7) mEq/L to 23.7 (0.9) mEq/L. The mean (SE) 
serum bicarbonate level did not change in the control arm. Blood pressure control was 
similar between the two conditions. Brachial artery flow-mediated dilation was 42% higher 
after 6 weeks of sodium bicarbonate replacement (3.78 ± 1.58 to 5.35 ± 1.31%) whereas it 
decreased by 14% during control conditions (3.51 + 0.53 to 3.01 + 0.91%).
Conclusions:    Bicarbonate supplementation in patients with CKD and low serum 
bicarbonate levels results in improved vascular function. Large randomized trials need 
to be performed to determine if treatment with alkali therapy can reduce cardiovascular 
disease in patients with CKD.
Funding: NIDDK Support
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Tenofovir-Related Distal Tubular Acidosis in HIV Infected Patients 
Tamara Cunha, Talita Mourao Loyola, Carlos Perez Gomes, Maurilo Leite. 
Dept of Nephrology, Federal Univ of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase 
inhibitor extensively used worldwide and is now the most prescribed drug on Highly Active 
Antiretroviral Therapy (HAART).TDF toxicity is mainly targeted at the proximal tubule, 
and in severe cases can cause Fanconi Syndrome or acute kidney injury. Despite this, there 
are no studies evaluating other types of tubular toxicity. This study evaluated the presence 
of distal renal tubular acidosis (dRTA) in HIV patients on HAART.
Methods: Sixty one HIV patients older than 18 years on treatment with HAART 
for more than 6 months and GFR estimated by CKD-EPI equation greater than 45 ml/
min/1.73m2 were evaluated. They were divided into two groups: 31 used HAART that 
included TDF and 30 used HAART with no current or previous use of TDF. They were 
submitted to fluid restriction for 12 hours and received 40mg of furosemide and 0.1mg 
of fludrocortisone, following the acidification test proposed by Walsh et al (2007).We 
measured serum bicarbonate and the following parameters: hourly urinary pH (0h to 4h) 
by potentiometry, urinary ammonium (uNH4+) by spectrophotometry and urinary titratable 
acidity (uTA) by NaOH (0h and 4h).The diagnosis of dRTA was established when the 
urinary pH was higher than 5.3 in all measurements.
Results: There was no significant difference between the groups in terms of age, gender, 
ethnicity, CD4 count or eGFR. The prevalence of dRTA was 6% in the group without TDF 
and 26% in TDF group (p=0.04). In both groups, patients without dRTA showed increase in 
uNH4+ (p=0.05 and p=0.009, respectively) and in uTA (p=0.04 and p=0.05, respectively), 
unlike patients diagnosed with dRTA that showed no significant increase neither in uNH4+ 
(p=0.44 and p=0.34, respectively) nor in uTA (p=0.52 and p=0.11, respectively). In all 
cases with dRTA, the serum bicarbonate was normal, featuring an incomplete presentation.
Conclusions: The prevalence of incomplete dRTA in patients using TDF was 
significantly higher than the group not using the drug. This is the first study suggesting 
a possible association between TDF and dRTA. Subsequent studies will be necessary to 
corroborate this hypothesis.
SA-PO896
Comparison of Acid-Base Disorder Between Patients Undergoing Ileal 
Neobaldder and Ileal Conduit  Jung-woo Noh,1 Eunjung Kim,1 Ja-Ryong 
Koo.1  1Internal Medicine, Nephrology, Hallym Univ Medical Center, Hallym 
Kidney Research Inst, Seoul, Korea; 2Internal Medicine, Nephrology, Hallym 
Univ Medical Center, Hallym Kidney Research Inst, Seoul, Korea; 3Internal 
Medicine, Nephrology, Hallym Univ Medical Center, Hallym Kidney Research 
Inst, Seoul, Korea.
Background: Since the 1980s, the orthotopic ileal neobladder(INB) has been as an 
new option by eliminating the need for a cutaneous stoma and urostomy appliances of ileal 
conduit(IC). Although this method has improved patients’ quality of life, frequent incidence 
of metabolic acidosis(MA) have been reported. We compared occurrence of MA in INB 
group to IC group, and searched for risk factors affecting MA.
Methods: We conducted a retrospective study in 95 patients who underwent radical 
cystectomy and urinary diversion from January 2001 to December 2014 at Hallym 
University Medical Center. Patients who have any illness such as severe pulmonary 
disorder, take any medication that could lead to MA and sepsis were excluded. Acid-base 
balance and renal function were compared between INB and IC groups. MA was defined 
as a venous sample bicarbonate level of less than 21 mmol/L.
Results: MA was detected in 74.2% and 69.7% within 7 days(p=0.64), and in 
31% and 14.8% at 1 month(p=0.1) after operation in INB and IC group. But cases 
on bicarbonate therapy were significantly more in INB group(p=0.02). Serum HCO3 
levels(p=0.05) and base excess(p=0.02) were significantly lower in INB group in spite 
of more cases on bicarbonate therapy. Acute kidney injury(AKI) at 1 month was higher 
in INB group(p=0.008). Serum creatinine concentrations were significantly correlated 
with bicarbonate levels. Multiple logistic analysis showed that 1 mg/dl increase of serum 
creatinine level result in a 5.38-fold higher risk of MA (95% confidence interval, 1.14-
25.3; P = 0.03). Patients without AKI, MA was detected in 13.5% in INB group, 12% in 
IC group at 1 month(p= 1.0).
Conclusions: Despite there being no statistical difference, INB group may more easily 
develop MA compared with IC group especially in patients with elevated serum creatinine 
concentrations. In addition, a close association between the serum creatinine level and the 
degree of MA was observed in both groups.
Funding: Private Foundation Support
SA-PO897
Screening for Hyperlactatemia: Relationship Between the Anion Gap and 
Serum Lactate in Hypovolemic Shock  Richard M. Treger,1,2 Tristan Grogan,2 
David Elashoff,2 Craig Anderson,3 Scott Rudkin.3  1Nephrology, VHAGLA, LA, 
CA; 2Medicine and Statistics Core, UCLA, LA, CA; 3Emergency Medicine, 
UCI, Irvine, CA.
Background: In lactic acidosis (LA), a discrepancy between the increase in serum anion 
gap (AG) and serum lactate concentration has been noted. Previous studies evaluated patients 
in the Intensive Care Unit with established LA. No study has examined the relationship 
between AG and serum lactate within the first hour of the development of LA, specifically 
the sensitivity and specificity of an elevated AG for predicting hyperlactatemia.
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Methods: Data were obtained prospectively from adult trauma patients at a single 
level 1 trauma center. Venous samples were drawn prior to initiation of intravenous fluid 
resuscitation.
Results: 117 patients with elevated serum lactate levels (>2.1 mmol/L) were included. 
The sensitivity of an elevated AG (> 10) to reveal hyperlactatemia was only 43% whereas 
specificity was 84%. Sensitivity improved if the upper limit of normal AG was lowered 
and with increasing levels of serum lactate. (Table 1). The correlation between the AG and 
serum lactate level yielded an R2 of 0.30 (p < 0.001) and the slope of this relationship was 
0.29 ± 0.58 (95% confidence interval 0.23-0.35). 
Table 1: Sensitivity and specificity from use of the AG as an indicator of hyperlactatemia for specific 
AG and lactate level thresholds 
Sensitivity/Specificity Threshold for increased lactate concentration
>2.1 >5 >8 >10
Threshold for 
Anion Gap
<6 0.92/0.25 0.96/0.15 1.00/0.14 1.00/0.14
<8 0.74/0.57 0.84/0.39 0.88/0.37 1.00/0.37
<10 0.43/0.84 0.60/0.70 0.88/0.68 1.00/0.68
<12 0.24/0.98 0.48/0.88 0.63/0.85 0.67/0.85
Conclusions: Within the first hour of the development of LA due to hypovolemic 
shock, the AG was not a sensitive indicator of an elevated serum lactate level, but it was 
fairly specific. The sensitivity and specificity of the AG as an indicator of hyperlactatemia 
is consistent with prior studies examining later stages of LA. The AG increased to a greater 
extent than the serum lactate and approximately 70% of the change in AG could not be 
explained by increases in serum lactate. Our results suggest that other anions contribute 
to the AG in LA.
SA-PO898
The ¨ Anion Gap/¨ Bicarbonate Ratio in Early Lactic Acidosis: Time 
for Another Delta?  Richard M. Treger,1,2 Tristan Grogan,2 David Elashoff,2 
Craig Anderson,3 Scott Rudkin.3  1Nephrology, VHAGLA, LA, CA; 2Medicine 
and Statistics Core, UCLA, LA, CA; 3Emergency Medicine, UCI, Irvine, CA.
Background: The ratio of ∆ anion gap and ∆ bicarbonate (∆AG/∆HCO3) is used to 
detect co-existing acid-base disorders in patients with high AG metabolic acidosis. Classic 
teaching holds that in lactic acidosis (LA), the ∆AG/∆HCO3 is 1:1 within the first 60 minutes 
of onset (despite limited human data) and subsequently rises to 1.8:1. This study examined 
the ∆AG/∆HCO3 within the first hour of the development of LA.
Methods: Data were obtained prospectively from adult trauma patients at a level 1 
trauma center. Venous samples were drawn prior to intravenous fluids.
Results: 108 patients were included. 63 patients had normal serum lactate levels 
(£2.1 mM) with a mean AG of 7.1, the value used to calculate subsequent ∆AG values. 
∆AG/∆HCO3 was calculated for 45 patients who had elevated serum lactate levels (>2.1 
mM). The mean ∆AG/∆HCO3 for all patients with elevated serum lactate levels was 1.86 
(SD 1.40). The correlation between ∆HCO3 and ∆AG showed a 95% prediction interval 
of ±6.15 (Figure 1). 
Conclusions: The mean ∆AG/∆HCO3 was 1.86 within the first hour of the development 
of LA due to hypovolemic shock, confirming a small prior human study. This contradicts 
the traditional belief that in LA the ∆AG/∆HCO3 is 1:1 within the first 60 minutes. The 
classic 1:1 stoichiometry is based on animal models (in which lactic acid is infused into 
the extracellular [EC] space, facilitating EC buffering of protons by bicarbonate), while our 
results demonstrate a higher initial ∆AG/∆HCO3 ratio in early endogenous LA in humans 
(which originates intracellularly, resulting in intracellular buffering of protons while lactate 
is predominantly distributed in the EC fluid). The wide 95% prediction interval suggests 
that ∆AG/∆HCO3 should be used cautiously in the diagnosis of mixed acid-base disorders.
SA-PO899
Blood Lactate as a Predictor for Mortality in Sepsis Patients with Lactic 
Acidosis Treated Sodium Bicarbonate: A Retrospective Analysis  Su Mi Lee,1 
Eu Gene Jeong,1 Dongyeol Lee,2 Hansae Kim,2 Sung Hyun Son,3 Yun Jung Oh,4 
Young Ki Son,1 Seong Eun Kim,1 Won Suk An.1  1Dept of Internal Medicine, 
Dong-A Univ, Busan, Republic of Korea; 2Dept of Internal Medicine, Bong Seng 
Memorial Hospital, Busan, Republic of Korea; 3Dept of Internal Medicine, BHS 
Hanseo Hospital, Busan, Republic of Korea; 4Dept of Internal Medicine, Cheju 
Halla General Hospital, Cheju, Republic of Korea.
Background: Recent studies have reported that blood lactate level in the critically 
ill patients is associated with in-hospital mortality, but the use of lactate level to monitor 
and guide therapy remains under investigation. In this study, we evaluated the efficacy of 
blood lactate level as a predictor for mortality in sepsis patients with lactic acidosis treated 
with sodium bicarbonate.
Methods: We conducted a single center analysis from May 2011 through April 2014. 
We retrospectively analyzed 109 sepsis patients with lactic acidosis treated with sodium 
bicarbonate.
Results: Among the 230 patients with lactic acidosis treated with sodium bicarbonate, 
we finally included 109 patients (47.4%) with lactic acidosis caused by sepsis. The non-
survivors had lower albumin levels (P=0.009), higher SOFA and APACHE II scores 
(P=0.002, P=0.047, respectively), and higher blood lactate level at 6 hours, 24 hours, and 
48 hours after checking the initial lactate level (P=0.002, P<0.001, P=0.001, respectively). 
In particular, decrement of at least 10% in lactate clearance for the first 6 hours, 24 hours, 
and 48 hours of treatment were more dominant in non-survivors than survivors. Lactate 
clearance at 6 hours, 24 hours, and 48 hours was significantly associated with mortality 
after adjustment for confounding variables, including age, gender, CRP, albumin, SOFA 
and APACHE II scores, ventilator care, CRRT, and use of inotropic (HR: 2.201, 95% CI: 
1.197–4.046, P=0.011; HR: 3.948, 95% CI: 1.269–12.281, P=0.018; HR: 4.970, 95% CI: 
1.679–14.710, P=0.004, respectively).
Conclusions: Serial blood lactate levels monitoring is useful in terms of predicting 
mortality rather than single initial lactate or maximum lactate levels in sepsis patients with 
lactic acidosis treated with sodium bicarbonate.
SA-PO900
D-Lactate: It’s All in the Gut  Muhammad Deen, Roohi Khan.  Dept of 
Nephrology, CHI St. Luke’s Health, Houston, TX.
Background: D-Lactic acidosis is a rare form of lactic acidosis that can occur in 
patients with short bowel syndrome.
Methods: 88 yo M with PMH significant for HTN and small bowel obstruction s/p 
sub total small bowel resection presented to the ED with complains of nausea, vomiting, 
constipation, loss of appetite, altered mental status and decreased urinary output. 
On admission: 
Vitals: Blood pressure: 115/68 mmHg, Pulse: 80/min, Temperature: 98.5 F and SpO2: 
92%. 
Examination: Distended abdomen with no peripheral edema. 
Imaging: CT abdomen revealed dilated bowel loops but no bowel obstruction or free 
air in the abdomen/pelvis. 
Labs: Na: 134mmol/L, K: 4.5mmol/L, Cl: 108mmol/L, CO2: 16mmol/L, BUN: 
45mg/dL, Creatine: 1.6mg/dL and Albumin 2.3g/dL. ABG: pH: 7.42, pCO2 : 31mmHg, 
HCO3 : 19mmHg. He was found to have anion gap metabolic acidosis with a non-anion 
gap metabolic acidosis. Venous lactate: 1.11 mmol/L (Normal 0.5- 2.2 mmol/L). Serum 
D-lactate was drawn revealing an elevation at 4.15mmol/L – thus confirming the diagnosis 
of D-lactic acidosis. 
Treatment: Patient received IV fluids with bicarb. PO Flagyl was started and constipation 
was also treated. His neurological status along with his acidosis subsequently improved. 
Diagnoses of anion gap metabolic acidosis in the setting of D-Lactic acidosis was 
made due to bacterial over growth because of his past history of small bowel resection.
Conclusions: The diagnosis of D-lactic acidosis should be promptly considered in 
patients with malabsorptive disorder such as short bowel syndrome or following a jejunoileal 
bypass especially when no other cause of anion gap metabolic acidosis is found. Diagnosis 
is confirmed by a special enzymatic test measuring serum D-Lactate. Treatment involves a 
low-carbohydrate diet, sodium bicarbonate infusion to correct acute acidemia and antibiotics 
to minimize D-lactate producing bacteria.
SA-PO901
Customized Base Solutions for Treatment of Acute Acidosis 
Thomas G. Mason,1,2 Jeffrey A. Kraut.3  1Dept of Chemistry and Biochemistry, 
Univ of California, Los Angeles, CA; 2Dept of Physics and Astronomy, Univ 
of California, Los Angeles, CA; 3Medical and Research Services VHAGLA 
Healthcare System, UCLA Membrane Biology Laboratory, and Div of 
Nephrology, VHAGLA Healthcare System and UCLA Geffen School of Medicine, 
Los Angeles, CA.
Background: Acute acidosis is associated with cell dysfunction and increased mortality. 
Intravenous administration of hypertonic sodium bicarbonate (NaHCO3) does not improve 
cellular function or clinical outcome. This is attributed to undesirable generation of CO2, 
which decreases intracellular pH, and also to undesirable osmotic stress. Thus, designing a 
base that can raise pH without generating CO2 or producing osmotic stress would address 
an unmet need.
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Methods: Theoretical modeling has been performed using Mathematica software to 
determine equilibrium ion concentrations in mixed strong-weak base solutions. If these 
solutions have a significant proportion of strong base yet lower concentration, they are 
predicted to raise blood pH without generating CO2 or producing large osmotic stress. Strong 
bases examined include disodium carbonate (Na2CO3) and sodium hydroxide (NaOH); 
these were mixed with NaHCO3. Acid-base parameters were measured in acidified canine 
blood mixed with the base solutions in a closed system using a blood gas analyzer. Treated 
blood was examined using an optical microscope.
Results: A near-isotonic base solution containing Na2CO3:NaHCO3 at a ratio of 3:1 
is predicted to raise blood pH without increasing CO2 or causing osmotic stress. Addition 
of this base to acidified blood raised blood pH while reducing CO2. By contrast, NaHCO3 
raised blood pH, but also generated CO2. Examination of red blood cells exposed to the 
former 3:1 solution revealed no evidence of osmotic stress. Mixed base solutions of NaOH 
and NaHCO3 are also promising as a lower sodium alternative.
Conclusions: Mixed strong-weak base solutions, rather than hypertonic NaHCO3, 
can raise blood pH and serum bicarbonate levels, minimize osmotic stress, and limit CO2 
generation. A 3:1 mixture of Na2CO3 : NaHCO3 well below 1 M concentration appears to 
be effective in this regard.
SA-PO902
Chloride Alterations in Hospitalized Patients: Prevalence and Outcome 
Significance  Qi Qian, Charat Thongprayoon, Wisit Cheungpasitporn.  Medicine/
Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Background: Chloride (Cl) plays a fundamental role in the maintenance of serum 
osmotic pressure, acid-base balance, and cellular health. Cl channels are expressed in almost 
all cells in the body. Dysfunctions in the Cl channel result in a broad spectrum of diseases. 
Cl alterations in hospitalized patients have not been comprehensively studied in recent years.
Methods: We conducted a retrospective study of adult (³18 years old) hospital 
admissions at Mayo Clinic over a period of three years (2011 to 2013). Patients without 
admission Cl (£24hr of admission) were excluded. Outcome measures included all-cause 
mortality, length of hospital stay and discharge disposition.
Results: 76,719 unique patients from a total of 147,358 hospital admissions were 
enrolled. 55,523 (72.4%) had repeat Cl measurements within 48 hours. Admission serum 
Cl in the range of 105-108 mmol/L was found to be optimal based on hospital mortality. 
60.6% (n=48, 999) had admission Cl<105 mmol/L, and 13% (n=11,999) >108 mmol/L. 
Cl <100 or >108 mmol/L independently predicted poor outcomes including hospital death, 
longer length of hospital stay, and being discharged to a care facility. 17.1% (n=13,089) of 
the patients had anion gap >12 mmol/L; their hospital mortality, when compared to those 
with anion gap £12 mmol/L, worsened progressively with rising Cl. Further examination 
of Cl evolution within 48 hours of admission showed Cl increase to be an independent 
predictor for hospital mortality. Further, the magnitude of Cl increase was inversely 
associated with days of patient survival.
Conclusions: Non-optimal serum Cl values are common in hospitalized patients. 
Cl alterations are independent predictors for poor clinical outcomes. Post-admission Cl 
increase not only predicted hospital mortality but also inversely correlated with length 
of patient survival. These results indicate that more attention should be paid to Cl value. 
Further prospective and randomized studies are needed to determine whether avoidance 
of post-admission Cl increase would improve patient survival.
SA-PO903
A Retrospective Review of Paediatric Patients with Bartter and Gitelman 
Syndrome  Patrick Walsh, Marc Bienias, Detlef Bockenhauer.  ICH, UCL, 
London, United Kingdom.
Background: Bartter and Gitelman syndrome are rare autosomal recessive disorders 
of renal salt handling. They are characterized by disturbed electrolyte and acid-base 
homoeostasis with potentially severe complications. Currently little is known about the 
long-term disease course and best treatment is controversial. We performed a retrospective 
case review to investigate the long-term disease course of patients with a diagnosis of 
Bartter/Gitelman syndrome.
Methods: Demographic and Laboratory data was recorded at presentation, and ages 
1,2,3,4,5,10 and 15.
Results: 42 patients with a genetic diagnosis of Bartter/Gitelman were reviewed with 
a median follow up of 7.85 years (Range 0 -18 Years).
Geno-
type
Num-
ber 
of pa-
tients
Age at Pre-
sentation
Gesta-
tional 
Age
Nephro-
calcinosis 
(% of 
patients)
GFR <90ml/
min/ 1.73m2 
at last fol-
low – up 
(Schwartz)
Albumin-
uria
(>2.5 Fe-
males
3.5 Males 
mg/mmol)
Average 
Height 
at last 
follow-up 
(Z-score)
1 6 Day 7 30.3 100 6 2 -1.2
2 10 0.8 Years 32.0 70 9 1 -1.82
3 14 2.7 Years 37.4 7 4 11 -1.28
4 1 Day 1 32.0 0 1 1 N/A
Gitel-
man 11 5 Years 39.4 9 1 0 -0.93
Bartter 1&2 presented earliest with prematurity and deranged electrolytes. All of the 
Bartter 1 patients and 70% of Bartter 2 had evidence of nephrocalcinosis on their first 
ultrasound. Hypomagnesaemia (<0.7mmol/L) was seen in 11/14 Bartter 3 and 8/11 Gitelman 
patients; Hypomagnesaemia developed over time and was seen earlier in Bartter 3 (3.8 
years) than in Gitelman (7.9 years). Obvious complications of hypokalaemia were only 
seen in one patient with Bartter 3 (despite potassium levels <2.5mmol/L in 10 patients) 
in the form of hypokalaemic paralysis; he was admitted twice at age 2 and 3 (Potassium 
1.7 & 1.5 respectively). Decreased GFR was present in all Bartter 1 and 90% of Bartter 2 
at last follow-up. 3 patients with Bartter 3 developed nephrotic range proteinuria and one 
demonstrated biopsy evidence of FSGS.
Conclusions: The overall prognosis during childhood was good. Final heights were 
within the normal range and no child developed ESRD. Albuminuria was common in 
Bartter 3, indicating the need for long-term monitoring of renal function. Interestingly, 
hypomagnesaemia is often absent at presentation and develops over time in both Bartter 
3 and Gitelman.
SA-PO904
Urine Calcium to Magnesium Ratio Aids to Diagnose Gitelman’s 
Syndrome without Hypocalciuria and Receiving Intravenous Magnesium 
Administration  Chih-Jen Cheng,1,2 Shih-Hua P. Lin,1,2 Ming-Tso Yan.2,3 
1Tri-Service General Hospital; 2National Defense Medical Center; 3Cathay 
General Hospital.
Background: Although hypocalciuria is widely used to distinguish Gitelman’s 
syndrome (GS) from Bartter syndrome (BS), several patients with GS actually have 
not hypocalciuria and may be clinically misdiagnosed as BS. Intravenous magnesium 
administration to correct hypomagnesemia, another distinct finding in GS can significantly 
enhance urine calcium excretion and unmask the preexisting hypocalciuria. Because renal 
Mg2+ wasting is characteristic in GS, we hypothesize that urine Ca2+/Mg2+ ratio may be 
superior in diagnosing GS.
Methods: One hundred forty three Taiwanese GS patients (M:F =87:56, age 25 ± 
10) with definite SLC12A3 mutations was enrolled. Nine cBS patients with CLCNKB 
mutations and 15 healthy subjects were enrolled as disease and normal control, respectively. 
Intravenous MgSO4 was administered (elemental Mg 0.35 mmol/kg) in 8 GS patients 
with hypocalciuria. Relevant blood laboratory and at least two urine collection for all 
electrolytes excretion were determined. Hypoclaciuria was defined as urine Ca/Cr ratio 
less than 0.1 mmol/mmol.
Results: Fourteen (9.8%) of 143 GS patients did not have hypocalciuria (Ca2+/Cr 
ratio 0.28 ± 0.09 mmol/mmol) and exhibited no significant difference in blood parameters 
compared with GS patients without hypocalciuria. Although their urine Ca2+/Cr ratio was 
significantly lower than that in cBS (0.51 ± 0.18 mmol/mmol), there was still overlapping 
between them. Notably, urine Ca2+/Mg2+ ratio was significantly lower in GS than cBS without 
overlap (0.46 ± 0.12 vs 1.57 ± 0.53 mmol/mmol, p< 0.001). Acute MgSO4 administration 
in GS patients markedly enhanced urine Ca2+ excretion (Ca2+/Cr ratio 0.05 ± 0.01 to 0.64 
± 0.01 mmol/mmol, p < 0.001). However, urine Ca2+/Mg2+ ratio (0.21 ± 0.01 mmol/mmol) 
remained much lower than healthy subjects (1.35 ± 0.63 mmol/mmol, p<0.001) and cBS.
Conclusions: Urine Ca2+/Mg2+ ratio may be a good index to help diagnose GS without 
hypocalciuria and even receiving intravenous Mg2+ administration.
SA-PO905
A Blunted Response to Thiazide Diuretics Is Not Specific for Patients 
with Gitelman Syndrome  Anneke Bech, Jack F. Wetzels, Tom Nijenhuis. 
Nephrology, Radboud Univ Medical Center, Nijmegen, Netherlands.
Background: In Gitelman syndrome (GS), a defective sodium-chloride co-transporter 
(NCCT) in the distal tubule classically leads to hypokalemia and hypomagnesemia. A 
challenge with thiazide diuretics, testing the functional presence of NCCT, has been 
shown to differentiate GS from Bartter syndrome (BS) and normal controls. However, the 
performance of the thiazide test in renal magnesium wasting disorders other than GS and 
BS has not been studied.
Methods: Eleven patients who presented to our clinic between 2010-2014 with renal 
magnesium wasting and in whom a thiazide test was performed were included. An abnormal 
test result is defined as a maximal change of fractional chloride excretion (∆FeCl) < 2.3% 
[Colussi 2007]. The thiazide test in eight volunteers in our clinic showed a mean maximal 
∆FeCl 3.12 ± 0.48% with the lowest value being higher than 2.3%. Additional DNA 
mutation analyses were performed.
Results: Three patients had a mutation in SLC12A3 (GS), one patient had a compound 
mutation in CLCNKB and KCNJ1 (BS), 1 patient had a mutation in FXYD2 and five patients 
had a deletion of one HNF1β allele. The patients with GS showed a blunted response, the 
patient with BS showed a normal response, the patient with a FXYD2 mutation showed 
a blunted response and the patients with HNF1β mutations showed different responses to 
thiazide diuretics.
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Mutation Maximal ¨ FeCl (%)
GS c.1315G>A, exon 10 0.12
GS c.602-16G>A, intron 4 0.18
GS 815T>C and 1670 C>T, exon 6 0.86
BS CLCNKB: c.88C >T, exon 2KCNJ1: c.1070 T>C, exon 5 6.10
FXYD2 c.115G>A 0.66
HNF1β deletion one allele 0.01
HNF1β deletion one allele 1.41
HNF1β deletion one allele 1.48
HNF1β deletion one allele 2.40
HNF1β deletion one allele 3.90
unknown diagnosis unknown 2.43
Conclusions: A blunted response to thiazide diuretics is not specific for GS and can 
also be found in other renal magnesium wasting disorders, such as caused by mutations in 
FXYD2 or HNF1β. Still, the thiazide test could prove to be a valuable tool for research and 
phenotyping patients, and increase our understanding of the pathophysiological processes 
and the interrelationship between transcription factors, transporters and ion channels.
SA-PO906
Assessment of Hydration Status by Bioimpedance Spectroscopy in 
Peritoneal and Hemodialysis Patients from a Single Center  Sara Samoni,1,2 
Luis Ignacio Bonilla,1 Carla Estremadoyro,1 Alessandra Spinelli,1 Salvador 
Roberto Lopez,1 Faeq Husain-Syed,1 Carlo Crepaldi,1 Alessandra Brendolan,1 
Claudio Ronco.1  1IRRIV, Vicenza; 2Sant’Anna School of Advanced Studies, Pisa.
Background: Fluid overload(FO)is frequent in peritoneal dialysis(PD)and 
hemodialysis(HD)pts.Despite the identified correlation between systolic blood 
pressure(SBP)and FO,some conditions,i.e.vascular stiffness and heart failure,can cause a 
significant proportion of pts to fall out from this model.Our aim was to assess the relationship 
between hydration status(HYD)and SBP in PD and HD pts.
Methods: We enrolled all DP and HD pts of our center.HYD was evaluated by 
bioimpedance spectroscopy using Body-Composition-Monitor(BCM Fresenius Medical 
Care)and expressed by the absolute delta tissue hydration(ADTH).BCM and SBP were 
measured during routine ambulatory visits in DP pts.In HD pts,measurements were done 
before the intermediate HD treatment based on a 3-treatment per week program.We 
considered normohydrated(NH),hyperhydrated(HH)and dehydrated(DH)pts with ADTH 
-1/+1,>+1,<-1,respectively.We defined normal(NSBP),high(HSBP)and low SBP(LSBP)
with values of 100-140,>140,<100mmHg,respectively.Considering both parameters,we 
subdivided the cohort into 9 groups.Continuous variables were expressed as means±SD 
for normally distributed data and compared with t-test.
Results: We enrolled 188 pts,120 DP,68 HD pts.Mean SBP was 141±18 and 
144±22mmHg,respectively.Mean ADTH was 2.2±2 in PD and 1.6±3.1L in HD pts.Among 
NSBP,the percentage of HH pts was significantly higher in PD than HD pts(p=0.04)while 
among HSBP,the HD pts were more DH than PD pts(p=0.02).
Conclusions: We found that measurement of SBP is not sensitive to assess the HYD 
in PD and HD pts.We also found that PD pts with NSBP tend to be more HH than HD pts.
We suggest that SBP should not be used alone as a marker for HYD in PD and HD pts,it 
should always be accompanied by other tools.
SA-PO907
Impact of Hydration Status, Assessed by Bioelectrical Impedance Vector 
Analysis, on Mortality in Critically Ill Patients  Sara Samoni,1,2 Valentina 
Vigo,3 Luis Ignacio Bonilla,1 Gianluca Villa,1 Silvia De Rosa,1 Federico 
Nalesso,1 Fiorenza Ferrari,1 Alessandra Brendolan,1 Carlo Donadio,3 Claudio 
Ronco.1  1IRRIV, Vicenza; 2Sant’Anna School of Advanced Studies, Pisa; 3Univ 
of Pisa, Pisa.
Background: Clinical trials have shown a positive correlation between fluid overload 
and adverse outcomes in pts admitted to intensive care unit(ICU).Currently,there is not 
a non-invasive method that can provide an accurate and timely assessment of whole 
body hydration status.Our aim was to evaluate the impact of hyperhydration,assessed 
by bioelectrical impedance vector analysis (BIVA),on ICU mortality in critically ill pts.
Methods: This is a prospective,dual-center study.We included 125 ICU pts with an ICU 
stay of 72 hrs or more.Anthropometric, medical history and laboratory data were collected.
Assessment of hydration status was performed by BIVA,using a single frequency analyzer,at 
the baseline and daily for a period of 72-120 hrs.Pts were considered normohydrated(NH)
or hyperhydrated(HH)if BIVA hydration level was 72.7%-74.3% or >74.3% of fat-free 
body mass,respectively.
Results: The logistic regression analysis performed found a significant correlation 
between ICU mortality and maximum hydration level reached in observation period,either 
in patients with or without acute kidney injury(p<0.001).
Conclusions: Our findings confirm and expand literature data about the correlation 
between hyperhydration and ICU mortality.Despite the importance of this problem,there 
are currently few methods to assess hydration status in critically ill pts.BIVA has been 
shown to be safe,non-invasive,easy to use and it may predict mortality,thus we suggest its 
routinely use in ICU pts.Randomized clinical trials are needed to define the precise role of 
BIVA in the goal-directed fluid management of critically ill pts in ICU.
SA-PO908
Sleep-Disordered Breathing Is Not Associated with Body Fluid Volume 
in Chronic Hemodialysis Patients  Takahiro Masuda,1,2 Yumi Kijima,2 Chuji 
Sekiguchi,2 Yasuharu Miyazawa,2 Eiji Kusano,3 Yasushi Asano,4 Daisuke 
Nagata.1  1Div of Nephrology, Deparment of Medicine, Jichi Medical Univ, 
Shimotsuke, Tochigi, Japan; 2Nasu-Minami Hospital, Nasukarasuyama, Tochigi, 
Japan; 3Japan Community Health Care Organization Utsunomiya Hospital, 
Utsunomiya, Japan; 4Japanese Red Cross Koga Hospital, Koga, Ibaraki, Japan.
Background: Sleep-disordered breathing (SDB), characterized by nocturnal 
intermittent hypoxia, is frequent in patients with chronic hemodialysis (CHD). Fluid 
retention may promote SDB in these patients, but the detailed information is lacking.
Methods: Eighty-eight CHD patients in Nasu-Minami Hospital and Japanese Red 
Cross Koga Hospital were included in this study (male: 62.1%, age: 68.1 ± 11.5 years, 
body mass index: 21.7 ± 3.1, duration of CHD: 5.3 ± 5.9 years, diabetes mellitus: 50.0%). 
Overnight pulse oximetry and bioimpedance spectroscopy (InBody) for the assessment of 
body composition were performed after dialysis on a dialysis day. Patients were divided 
into three groups according to 3% oxygen desaturation index (3%ODI) assessed by pulse 
oximetry: normal (3%ODI<5), mild SDB (5£3%ODI<15) and severe SDB (15£3%ODI). 
We investigated the relationship between severity of SDB and body composition including 
body fluid volume.
Results: Sixty patients (68.2%) were classified into the SDB group (mild SDB 40 
[45.5%] and severe SDB 20 [22.7%]). Fat mass (relative to body weight) in the SDB 
group was significantly higher than in the normal group (normal 24.3±8.5%, mild SDB 
29.7±8.0%, severe SDB 30.2±9.2%, P=0.018). After adjusting for age, gender, diabetes 
mellitus, hemoglobin and serum albumin in a logistic regression analysis, SDB was 
independently associated with increased fat mass (odds ratio 1.22; 95% confidence interval 
1.10–1.38: P< 0.01). Total body water, intracellular water and extracellular water were 
similar among the three groups.
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Conclusions: SDB is associated with increased fat mass, but not body fluid volume 
in CHD patients. Further studies are needed to evaluate some factors that can explain the 
high frequency of SDB in CHD.
Funding: Private Foundation Support
SA-PO909
Association Between Brain Natriuretic Peptide and Fluid Volume Imbalance 
Between Intra- and Extracellular Water in Patients with Chronic Kidney 
Disease  Yasushi Ohashi, Reibin Tai, Toshiyuki Aoki, Shizuka Kobayashi, 
Atsushi Aikawa, Ken Sakai.  Dept of Nephrology, School of Medicine, Faculty 
of Medicine, Toho Univ, Tokyo, Japan.
Background: Malnourished and elderly patients with chronic kidney disease (CKD) 
may be susceptible to a extracellular volume overload due to a decreased intracellular 
volume capacity. We assume that excessive fluid volume is redistributed on the basis of the 
baseline fluid volume balance when they are exposed to fluid accumulation.
Methods: Using bioimpedance analysis, body fluid composition was measured in 129 
patients with CKD from 2013 to 2015 and was separated into three components – (a) free 
water mass consisting of muscle, fat, and minerals, (b) intracellular water (ICW) content, 
and (c) extracellular water (ECW) content. Participants was also measured brain natriuretic 
peptide levels at the time of the body fluid composition measurement. The relationship 
between the ratio of ECW to ICW and brain natriuretic peptide was examined.
Results: Patients with higher log-transformed plasma level of brain natriuretic peptide 
was more likely to be older and have lower body mass index (BMI), glomerular filtration 
rate (GFR), and serum albumin levels and higher proteinuria. In body fluid composition 
analysis, the brain natriuretic peptide levels increased along with a decrease in all contents 
of free water mass consisting of muscle, fat, and mineral (r = -0.49, P < 0.001), ICW content 
(r = -0.34, P < 0.001), and ECW content (r = -0.25, P < 0.01). By the steeper decreased 
free water mass and ICW content than the decreased ECW content in those patients, the 
percentage of ECW in body weight increased, and the ratio of ECW to ICW had a positive 
correlation with the brain natriuretic peptide levels (r = -0.58, P < 0.001). In multivariate 
analysis, age, BMI, GFR, the ECW/ICW ratio remained independently associated with the 
brain natriuretic peptide levels.
Conclusions: Brain natriuretic peptide is elevated in leaner and elderly patients with 
fluid volume imbalance between intra- and extracellular water. Fluid volume imbalance 
between intra- and extracellular water may express a reserve capacity for fluid volume 
overload and impact on cardiac preload.
SA-PO910
Blood Volume Estimation in Hemodialysis Patients  Doris H. Fuertinger,1 
Line Malha,2 Peter Kotanko,1 David S. Goldfarb,2 Stephan Thijssen.1  1Renal 
Research Inst, New York, NY; 2New York Harbor VAMC and NYU Langone 
Medical Center, New York, NY.
Background: Anthropometric formulas used to estimate absolute blood volume 
(ABV) are generally derived from healthy subjects. Most hemodialysis (HD) patients have 
an expanded ABV prior to HD, rendering these formulas inappropriate for estimation of 
pre-HD ABV (pre-ABV). Here, we compare the performance of several ABV formulas, 
used in conjunction with Crit-Line data, for assessment of pre-ABV.
Methods: We assume that post-HD ABV is closer to normal ABV, which we calculated 
based on height, sex and post-HD weight using several published formulas. Pre-BV was 
then calculated from post-HD blood volume using pre- and post-HD Hct measured by Crit-
Line®. The calculated pre-ABV was then compared to pre-ABV measured immediately 
before HD using 131I-labeled albumin dilution.
Results: We compared 27 formulas for ABV estimation in 21 patients (Ƃ: 3, mean ± 
SD: age 59 ± 14.7 years, height: 170.7 ± 10 cm, post-HD weight: 82.2 ± 16.7 kg). None 
of the equations showed good agreement with the measured data. The Nadler formula 
yielded the most accurate results (Fig 1). As exemplified in Fig 1, the equations yield a 
systematic trend in bias, with reasonable accuracy for ABV between 5-6 L but progressive 
underestimation and increasing heteroscedasticity towards higher ABV (caused by fluid 
overloaded patients). 
Conclusions: Anthropometric equations such as the Nadler formula show reasonable 
accuracy (albeit unsatisfactory precision) for patients with close to normal end-HD ABV, 
but they fail in non-euvolemic patients. Their validity in HD patients depends on the 
patients’ fluid status, which varies widely; hence their undifferentiated use in this population 
should be discouraged. More accurate and precise estimates of ABV would require a more 
sophisticated approach incorporating fluid status information, e.g. from bioimpedance.
Funding: Pharmaceutical Company Support - Daxor Corporation
SA-PO911
Impact of Hospital-Associated Hypernatremia on Outcomes in 
an Unselected Patient Population: A Retrospective Cohort Study 
Nicolaos E. Madias, Evangelos Tsipotis, Bertrand L. Jaber.  Internal Medicine, 
St. Elizabeth’s Medical Center, Boston, MA.
Background: Although hypernatremia has been associated with an increased risk of 
adverse outcomes, the majority of available studies have examined selected populations 
questioning the generalizability of their results to unselected patients.
Methods: The discharge data of 20,072 unselected adult patients admitted to a tertiary 
care facility over a 7-year period were analyzed. Based on the crude relationship between 
[Na+] and mortality, hypernatremia was defined as [Na+] > 142 mEq/L. Patients with 
community-acquired hypernatremia (CAH) and those with hospital-acquired hypernatremia 
(HAH) were compared to patients with normonatremia at presentation ([Na+] of 138-142 
mEq/L) in terms of in-hospital mortality, length of stay (LOS), and discharge disposition. 
Furthermore, patients with CAH in whom hypernatremia worsened during hospitalization 
(HAggH) were compared to those without aggravation. Multivariable logistic and negative 
binomial regression analyses were conducted.
Results: CAH occurred in 20% of hospitalized patients and was associated with an 
adjusted odds ratio (OR) of 1.67 (95% confidence interval [CI] 1.38, 2.01) for in-hospital 
mortality, and 1.44 (95% CI 1.32, 1.56) for discharge to a short-/long-term care facility, 
and an adjusted 10% (95% CI, 7%-13%) increase in LOS. HAH developed in 25.9% of 
hospitalized patients and was associated with an adjusted OR of 3.17 (95% CI 2.45, 4.09) 
for in-hospital mortality, and 1.45 (95% CI 1.32, 1.59) for discharge to a facility, and an 
adjusted 49% (95% CI 44%, 53%) increase in LOS. HAggH developed in 8.9% of patients 
with CAH. Compared to patients with CAH and no further increase in [Na+]s, HAggH 
was associated with greater risk of in-hospital mortality (adjusted OR 1.84; 95% CI 1.32, 
2.56) and discharge to a facility (adjusted OR 1.90; 95% CI 1.49, 2.41), and an adjusted 
13% (95% CI 4%-23%) increase in LOS.
Conclusions: All forms of hypernatremia encountered in unselected hospitalized 
patients are independently associated with increased in-hospital mortality and heightened 
resource consumption.
SA-PO912
Utility of Urine/Plasma Osmolality Ratio for Assessing Volume Status in 
Hyponatremia  Sho Hasegawa, Maki Shibata, Takehiro Sugiyama, Fumihiko 
Hinoshita.  National Center for Global Health and Medicine, Tokyo, Japan.
Background: Assessing volume status is critical for managing hyponatremia. Physical 
examination (P/E) and laboratory data are often used for the assessment, but the utility of 
each parameter has not been validated in hyponatremic patients. A body composition monitor 
(BCM) uses bioimpedance spectroscopy and can quantify extracellular water (ECW) and 
volume excess or deficiency. Here, we examined which parameter is superior in assessing 
volume status of hyponatremic patients, using BCM data as the reference standard.
Methods: We enrolled hospitalized patients (n=41) with hyponatremia (<130 mEq/L) 
at our institution and conducted P/E, laboratory tests and BCM measurement. Patients with 
high plasma osmolality (>275 mOsm/kg) were excluded (n=5). We used %ECW (ratio of 
volume excess or deficiency to ECW) derived from BCM data as the reference standard 
of volume status. First, patients were divided into overhydration (%ECW>0%, n=29) and 
dehydration (%ECW<0%, n=7) groups. Clinical signs obtained from P/E and parameters 
of volume status such as serum albumin (Alb), serum uric acid (UA), urine chloride, urine/
plasma osmolality ratio (U/P Osm), UUN/BUN, BUN/creatinine, U/P creatinine, FENa, 
FEUN and FEUA were compared between the groups by Fisher’s exact test or Mann–
Whitney U–test. Next, we performed univariate and multiple linear regression analyses to 
identify associations between each parameter and %ECW.
Results: U/P Osm was significantly higher in dehydration than in overhydration 
(median: 2.0 vs 1.3, p=0.01), but other parameters and clinical signs showed no significant 
differences. Univariate regression analysis showed that Alb (β=-7.1±3.2, p=0.04), U/P 
Osm (β=-11.4±3.1, p=0.001), UUN/BUN (β=-0.3±0.1, p=0.01) and U/P creatinine (β=-
0.10±0.03, p=0.01) were associated with %ECW. Since UUN/BUN and U/P creatinine 
strongly correlated with U/P Osm, we conducted multiple regression analysis using only 
Alb and U/P Osm. Results showed that compared with Alb (β=-7.7±2.7, p=0.007), U/P 
Osm (β=-12.0±2.9, p=0.0002) was more strongly associated with %ECW.
Conclusions: U/P Osm is superior to other commonly used parameters and clinical 
signs for assessing volume status in hyponatremic patients.
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SA-PO913
Sodium Concentrations of Body Fluid Losses: A Systematic Review 
Matthew Kaptein,1 Divya Sreeramoju,2 John Kaptein,3 Elaine Kaptein.1 
1Nephrology, LAC+USC Medical Center, Los Angeles, CA; 2Medicine, Presence 
Saint Joseph Hospital-UIC, Chicago, IL; 3Southern California Permanente 
Medical Group, Los Angeles, CA.
Background: Unexplained wide ranges and discrepancies of sodium concentrations 
[Na+] have been noted for different body fluids. This has led to use of “cumulative fluid 
balance” regardless of composition, which cannot account for specific water and sodium 
requirements. Appropriate water and volume management may be facilitated by an accurate 
and detailed knowledge of water and sodium composition of body fluid losses and gains.
Methods: We performed a systematic review of [Na+] of body fluids lost in adult 
humans. Particular attention was paid to gastric fluid with high and low acid states, diarrhea 
due to different mechanisms, and peritoneal, pleural and wound fluids. Inclusion criteria 
were met for 106 full-text articles.
Results: [Na+] are fluid-specific and consistent. Mean [Na+] were statistically lower for 
acidic (mean+SD:44+12mEq/L) than for alkaline (55+13mEq/L) gastric fluid; the difference 
is not clinically relevant. [Na+] are higher for bile (184+24mEq/L) or pancreatic fluid 
(156+3mEq/L) than all other body fluids, and similar for intact small bowel (119+14mEq/L) 
and ileostomy outputs (116+25mEq/L). Specific mechanisms for diarrhea are associated 
with different [Na+]. [Na+] were significantly greater for cholera (128+18mEq/L) and 
lower for osmotic-induced (28+16mEq/L) than all other causes. Among osmotic diarrheas, 
sorbitol-induced [Na+] was higher (63+17mEq/L) than for carbohydrate malabsorption 
(43+20mEq/L), lactulose (26+19mEq/L), Idolax (16+13mEq/L) and polyethylene glycol 
(13+7mEq/L). Among secretory diarrheas [Na+] for idiopathic causes (53+22mEq/L) was 
lower than for neuroendocrine and villous tumors (75+13mEq/L) or non-osmotic laxatives 
(88+33mEq/L). Pleural, peritoneal, and edema fluid had [Na+] (137+13mEq/L) similar to 
plasma. [Na+] for sweat was 44+17mEq/L.
Conclusions: This is the first in-depth review of verifiable sodium concentrations 
of body fluids most commonly lost in hospitalized patients. We propose that these losses 
be replaced with appropriate water and sodium content of enteral and parenteral fluids to 
correct and avoid dysnatremias and perturbations of volume status.
SA-PO914
Hyponatremia in CKD: The Prevalence and Risk Factors 
Masahiko Nagahama,1 Daiki Kobayashi,2 Fumika Taki,1 Takuya Fujimaru,1 
Masataka Hasegawa,1 Yuki Heath,1 Yasuhiro Komatsu.1  1Nephrology, St. Luke’s 
International Hospital, Tokyo, Japan; 2Center for Clinical Epidemiology, St. 
Luke’s International Hospital, Tokyo, Japan.
Background: Kidney is a vital organ regulating water and sodium homeostasis, and it is 
plausible that patients with CKD are more prone to develop hyponatremia due to diminished 
urinary dilution ability, reduced solute intake, and/or medication which affects free water 
clearance. However, the prevalence and risk factors of hyponatremia among CKD patients 
have not been elucidated. The aim of the present study is to clarify the prevalence and risk 
factors contributing to hyponatremia in CKD patients.
Methods: Among 32,438 patients who visited our outpatient clinic between 2011 and 
2014, 9,388 patients met the criteria of CKD, which is defined as either eGFR ≤60 ml/
min/1.73m2 or the presence of proteinuria. Dialysis and transplant patients were excluded. 
Risk factors for hyponatremia were sought using multivariate logistic regression.
Results: Prevalence of hyponatremia (serum Na£135mEq/L) was 8% in all CKD 
patients. Among moderate and severe CKD (stage 3, 4 and 5, N=6397), the prevalence of 
hyponatremia is increased as CKD progresses.
On univariate analysis, patients developing hyponatremia in moderate and severe 
CKD were older (P<0.01), female sex (P<0.01), diabetic (P<0.01) and more likely to 
have decreased eGFR (P<0.01). Multivariate logistic regression analysis identified CKD 
stage (OR:1.7-2.4, P<0.01), diabetes (OR:1.4, P<0.01) and renin-angiotensin-aldosterone 
system (RAS) inhibitors (OR:0.68, P<0.01) as independent risk factors for hyponatremia 
in moderate and severe CKD.
Conclusions: The present study shows that the prevalence of hyponatremia was 8% 
in CKD patients, and development of hyponatremia is correlated with progression of CKD 
in moderate and severe CKD. Worsening CKD and Diabetes are risk factors, while RAS 
inhibitors are protective for hyponatremia in CKD.
SA-PO915
Mild Hyponatremia on Admission Is Associated with Sepsis and Increased 
Mortality in Patients Presenting with a Hip Fracture  Juan Carlos Ayus,4 
Armando Luis Negri,2 Michael L. Moritz,3 Nora Angelica Fuentes.1  1Hospital 
Italiano, Buenos Aires, Argentina; 2Inst de Investigaciones Metabolicas, 
Argentina; 3Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 4Renal 
Consultant’s of Houston, Houston, TX.
Background: Hyponatremia is associated with an increased risk of falls and hip 
fractures in the elderly (JAMA 281: 2299-2304, 1999). Moreover, sepsis is a frequent 
cause of death in patients with hyponatremia (AJKD 65:435-442, 2015).We assessed if 
hyponatremia on admission was associated with sepsis and increased mortality in patients 
presenting with a hip fracture.
Methods: A cohort study in adult patients admitted with a traumatic hip fracture and 
at least one serum Na performed at admission. Hyponatremic (H), Na < 135 mEq/L, and 
normonatremic (N) patients were evaluated for complications occurring within 30 days of 
surgery, length of hospital stay, readmission rate, in-hospital mortality and mortality during 
1 year follow-up. An unadjusted and adjusted odds ratio (OR) and hazard ratio (HR) were 
calculated for in-hospital mortality and 1 year mortality. Adjustments were made for age, 
gender, propensity score for hyponatremia, CVA, CHF, ischemic heart disease, arrhythmias, 
thromboembolic disease, sepsis and dementia.
Results: 1571 patients were included of whom 366 (23.2%) were hyponatremic ( Na 
132 ± 4 mmol/L vs 138 ± 3; p <0,001). Length of stay was 8 days in H vs. 7 days in N 
(p=0.053). There was in increased incidence of sepsis in hyponatremic patient, 9.8% in H 
vs. 6% in N (p<0.01) OR 1.7 (CI95%: 1.13-2.6). In-hospital mortality was significantly 
higher in H vs N patients (19.9 vs 14.7%; p= 0.016), with an un-adjusted OR of 1.45 (95% 
CI 1.07-1.96) and an adjusted OR of 1.15 (95% CI 0.84-1.6). Readmissions were 15.8% 
for H vs. 12.9% for N (p=0.14). One-year mortality was greater in H vs N patients (15.4 
vs. 6.8%; p <0.001), with an un-adjusted HR of 1.8 (95% CI 1.4-2.35) and an adjusted 
HR of 1.45 (95% CI 1.1-1.9).
Conclusions: Mild hyponatremia at admission is associated with sepsis and increased 
in-hospital and late mortality in patients presenting with a hip fracture.
SA-PO916
Characteristics of Tolvaptan Trial in Korean Patients with SIADH 
Joo-Hark Yi,1 Eunyoung Lee,1 Sang-Woong Han,1 Kyung Pyo Kang,2 Ha Yeon 
Kim,3 Soo Wan Kim,3 Hoon Young Choi,4 Sung-Kyu Ha,4 Gheun-Ho Kim,5 Yang 
Wook Kim,6 Kyung-hwan Jeong,7 Sug Kyun Shin,8 Ho-Jung Kim.1  1Hanyang 
Univ Guri Hosp.; 2Chonbuk Natl. Med. Sch.; 3Chonnam Natl. Med. Sch.; 4Yonsei 
Med. Sch.; 5Hanyang Med. Sch.; 6Kyung Hee Med. Sch.; 7Haeundae Paik Hosp.; 
8NHIS Ilsan Hosp., Republic of Korea.
Background: This clinical study, a multicenter trial in 8 tertiary hospitals in Korea, 
was carried out to evaluate changes in serum sodium (Na) during 11 days on tolvaptan 
(TLV) daily and at the 7th day after stopping TLV in SIADH patients (pts) (<135 mEq/L).
Methods: A total of 39 pts (M:F, 23:16; age, 71±11.3 yrs) without neurologic symptoms 
were studied from Jun 1, 2013 to Dec 31, 2014. All pts received 15 mg/d of TLV as the 
initial dose and then further increased to 60 mg/d as needed in the hospital.
Results: Serum Na (mEq/L) increased prominently from baseline during first 24 hrs 
(127±4.3 vs 134±3.8, p<0.01), but gradually to day 4 (134±3.8 vs 136±3.6, p<0.01), and 
then maintained a plateau until discontinuation of TLV at day 11 (137±4.5). The changes 
in serum sodium (DsNa) from the baseline were 2.8±3.3 in 4 hrs, 5.9±4.1 in 8 hrs, and 
6.8±4.2 in 24 hrs, respectively. The correlation between DsNa/24 hrs and baseline Na was 
significant (r=-0.613, p<0.01). When hyponatremia was stratified into 3 groups, mild (I, 
130-134, n=12), moderate (II, 125–129, n=18), and severe (III, £124, n=9) groups, DsNa 
in III (11.1±4.8) during first 24 hrs was significantly higher than II (6.4±2.5, p<0.05) and 
I (4.3±3.3, p<0.01). Also, those of DsNa/24 hrs ≥8 mEq/L (n=18) compared to <8 (n=21) 
had significantly lower baseline serum creatinine (0.56 vs 0.73 mg/dL), Wt (53 vs 60 kg), 
BMI (21 vs 23), and body surface area (1.54 vs 1.63) (all, p<0.05). Then, serum Na after 
discontinuation of TLV for 1 wk was similar to the baseline (127±4.3 vs 129±8.6, p=NS). 
All pts underwent successfully this trial more than 24 hrs, but 4 pts were withdrawn due 
to rapid correction (1) and nausea (3).
Conclusions: Tolvaptan is effective and well tolerated in Korean with SIADH. 
However, Korean patients, particularly those with smaller frame and severe hyponatremia 
(<125 mEq/L), could be vulnerable to rapid correction by usual initial dose of Tolvaptan 
15 mg.
Funding: Pharmaceutical Company Support - Korea Otsuka Pharmaceutical Co., Ltd.
SA-PO917
Risk Factors for the Development of Thiazide-Induced Hyponatremia 
Kyle John Laporte, Milagros Zegarra, Melissa Rohrich, William Newman. 
Fargo VAHCS, Fargo, ND.
Background: Thiazide and thiazide-like diuretics are commonly utilized for 
management of hypertension. However, thiazide diuretics are one of the most common 
causes of drug-induced hyponatremia. Previous studies have pointed to potential risk 
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factors that may lead to the development of thiazide-induced hyponatremia, but there is 
still much uncertainty surrounding their role in predisposing patients to the development of 
hyponatremia. With an increasing prevalence of hypertension, thiazide utilization will likely 
continue to increase. Thus, the ability to discern potential risk factors for the development 
thiazide-induced hyponatremia may offer significant clinical value.
Methods: A retrospective study was conducted on 450 veterans of the age >18 
years with hypertension treated with a thiazide/thiazide-like diuretic (chlorthalidone, 
hydrochlorothiazide, indapamide, metolazone) between March 2004 and November 2014 
at the Fargo VA Health Care System.
Results: 404 patients met inclusion criteria. 15 % (n=63) of patients developed 
hyponatremia during treatment period with thiazide therapy. Average time to development 
of hyponatremia was 2.6 years (+3.3) from index date. Mean Charlson comorbidity scores 
were higher for those who developed hyponatremia (4.59 vs. 2.90; p < 0.001). Incidence 
of hyponatremia was found to be higher in patients who were active tobacco users (24.8% 
vs. 11.3%; p<0.001). Although there was no significant difference in serum creatinine and 
eGFR between groups, a statistically significant difference in eGFR was found to exist 
when comparing pre-thiazide eGFR to post-hyponatremia eGFR in those who developed 
hyponatremia (71 vs. 66; p=0.030). Patients who developed hyponatremia also had a lower 
serum albumin (3.78 vs. 3.95; p=0.033), and a lower BMI (30.1 vs. 31.8; p=0.035). All 
other values obtained were similar between groups.
Conclusions: Higher comorbidity index and tobacco use are positive predictors for 
the development of hyponatremia in patients treated with thiazide/ thiazide-like diuretics.
SA-PO918
Persistent Hyponatremia at 72 Hours in Cancer Patients with Severe 
Hyponatremia Is Associated with Mortality Independent of Cancer 
Stage  Vesh Srivatana,1 Xian Wu,2 Edgar A. Jaimes,3 Ilya Glezerman.3  1Div 
of Nephrology, NYP-Weill Cornell Medical Center, New York, NY; 2Div of 
Biostatistics, Weill Cornell Medical College, New York, NY; 3Renal Service, 
Memorial Sloan Kettering Cancer Center, New York, NY.
Background: Hyponatremia is a common problem and a known independent risk factor 
for mortality in cancer patients. The impact of rate of correction of sodium on mortality is 
unknown. The study aim was to determine if the rate of correction in cancer patients with 
severe hyponatremia (Na < 120 mEq/L) is linked to 90 day mortality.
Methods: Patients with a Na < 120 mEq/L were identified from the Memorial Sloan 
Kettering Cancer Center database from June 1, 2009 until June 30, 2014. 195 patients 
were identified. 55 patients were excluded from analysis because less than 72 hours after 
admission they either died (4), had no follow up data (16), were discharged (21), or made 
comfort care (14). The final cohort consisted of 140 patients who stayed in the hospital for 
at least 72 hours and had serial measurements of serum Na.
Results: The mean initial serum Na was 116.7 ± 3.0 mEq/L, the median rate of 
correction was 6 mEq/L with interquartile range 3-9 mEq/L in the first 24 hours, and the 
overall 90 day mortality was 39.3%. No patients with Na correction >8 mEq/L in the first 
24 hours (n=54) developed osmotic demyelination syndrome. In patients who died within 
90 days, the mean serum Na at 72 hrs was 128.3 ± 4.4 mEq/L compared to 130.5 ± 4.9 
mEq/L in survivors (p<0.01). When adjusting for cancer stage and rate of correction in a 
multivariate Cox model, serum Na < 130 mEq/L at 72 hrs was independently associated 
with 90 day mortality with adjusted HR 2.62 (1.47-4.64, p<0.001).
Conclusions: Cancer patients with severe hyponatremia are at heightened risk for 
90-day mortality independent of cancer stage and rate of Na correction if their serum Na 
at 72 hrs is < 130 mEq/L. Based on this finding we recommend that cancer patients with 
severe hyponatremia should be corrected to >130 mEq/L at 72 hrs.
SA-PO919
Hyponatremia Correction Using CRRT: Does Kinetic Modeling Avoid 
Overcorrection?  Saurabh Dasgupta,1 Lenar T. Yessayan,2 Balazs Szamosfalvi,2 
Sevag Demirjian.1  1Nephrology, Cleveland Clinic, Cleveland, OH; 2Nephrology, 
Henry Ford Hospital, Detroit, MI.
Background: Hyponatremia is the most common electrolyte abnormality in inpatients. 
It must be corrected at a gradual rate of < 8 in 24 hrs to minimize the risk of central pontine 
myelinosis, which can be effectively achieved in patients with renal failure by CRRT. 
Sodium (Na) kinetic models can predict end dialysis water. A simplified single pool fixed 
volume kinetic model may be applicable when net Na generation (G) is ~0 mEq/h. Our 
goal was to measure the correlation of predicted rate of correction by the formula to that 
observed in ICU patients with hyponatremia treated with CRRT.
Methods: 66 critically ill subjects with serum Na <130 at time of CRRT initiation 
were retrospectively identified. Median age was 60, and 52% were male. The predominant 
CRRT modality was CVVHD (97%), using dialysate Na of 140 mmol/L in most patients 
(92%) with average cumulative dose of 61L, delivered over median duration of 23.2 hrs. 
Predicted Na correction in the first 24 hours was calculated using a single pool fixed volume 
kinetic model. The values were then compared to actual measured serum Na using simple 
correlation, and Bland-Altman plot.
Results: The correlation factor was calculated to be 0.49 with a p value <0.001. The 
Bland Altman plot (figure) showed a mean difference of 2 mmol/L between the observed 
and predicted delta Na values, with a trend for overestimation of Na correction as delta 
sodium levels increased. 
Conclusions: In conclusion, observed serum Na correction rates are slower than that 
predicted by the simplified Na kinetic model, and err on the side of overestimation (avoid 
overcorrection). The feasibility to verify the model with empiric data is limited because 
of practical difficulties in estimating Na generation from fluid intake and output and the 
ability to ascertain TBW in critically ill patient.
SA-PO920
Hemoglobin Level (Hb) Biases the Measurement of Plasma Sodium (Na) 
by the Direct Ion-Selective Electrode (ISE) Method  Andrea Roche-Recinos,1 
Robert H. Barth,2 Philip Goldwasser.2  1SUNY Downstate, Brooklyn, NY; 2VA 
NY Harbor Healthcare System, Brooklyn, NY; 3VA NY Harbor Healthcare 
System, Brooklyn, NY.
Background: Na is measured by indirect ISE (iNa) or direct ISE (dNa), on chemistry 
(chem) and gas panels, respectively. A spurious difference between these assays (DNa = 
iNa – dNa) can be confusing to the clinician. We recently quantified the negative effect of 
serum total protein (TP) on iNa (NDT 2015). Red cells have been suggested to interfere 
with dNa, but both positive and negative interference have been reported (Bijster 1983). 
In the present study, we examined the effect of gas panel Hb on DNa.
Methods: The data were 772 pairs of closely-timed chem and gas panels (<20 min. 
apart; median 4 min.), retrospectively collected from our critical care units, excluding 
hemolyzed/turbid samples, with 1 pair per patient. We used multivariate adjustment for 3 
known effects on DNa—TP, bicarbonate (tCO2), and the chem-gas panel glucose difference 
(∆Glu)—and polynomial contrast to test for linear and non-linear trends.
Results: Mean (±SE) values were: Hb, 11.4±0.09 g/dL; DNa, 2.3±0.08 mEq/L. DNa 
rose across Hb categories (Table); trend analysis showed only a significant linear trend 
(p<.04). By simple regression, DNa rose 0.06 mEq/L per g/dL rise in Hb (p <.05); this 
estimate of the Hb effect is confounded, however, as Hb also correlated (p<.001) with TP, 
tCO2, and ∆Glu. After adjusting for these confounders, the trend of adjusted DNa across 
the categories became clearer (Table), with, again, only the linear trend being significant 
(P<10-4). By multiple linear regression with the same covariates, DNa rose 0.15±0.03 
mEq/L per g/dL rise in Hb (p<10-6). 
Hb Category Hb mean N ΔNa, unadjusted ΔNa, adjusted
<6 5 17 1.4±0.4 1.2±0.5
6-7.9 7.2 43 1.8±0.3 1.5±0.3
8-9.9 9.1 166 2.3±0.2 1.9±0.2
10-11.9 11 240 2.4±0.1 2.4±0.1
12-13.9 12.9 185 2.4±0.2 2.6±0.2
14-15.9 14.8 82 2.5±0.3 2.8±0.2
≥16 17 39 2.6±0.3 3.1±0.3
Conclusions: Increasing Hb spuriously decreases dNa and increases DNa. A linear 
correction for this artifact can reduce the discordance between iNa and dNa, promoting 
their interchangeable use.
Funding: Veterans Administration Support
SA-PO921
HHV-6 Encephalitis Resulting in Cerebral Salt Wasting and Hyponatremia 
Jonathan A. Ducastel, Uday S. Nori.  Internal Medicine and Nephrology, Ohio 
State Univ, Columbus, OH.
Background: Hyponatremia is a common electrolyte abnormality that can be associated 
with hypo-, hyper-, or euvolemic states. Low circulating volumes secondary to extra-renal 
losses, fluid overload states, and syndrome of inappropriate ADH are some of the more 
common causes of hyponatremia. One consideration that is uncommon and often overlooked 
is cerebral salt wasting (CSW). CSW is defined as “renal loss of sodium during intracranial 
disorders leading to hyponatremia and a decrease in the extracellular fluid volume.” It 
occurs in the setting of cerebral injury, most commonly associated with subarachnoid 
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hemorrhage, but also documented with other disorders of central nervous system. The 
mechanism of CSW is not completely understood, but is believed that a cerebral injury 
can lead to impairment of the sympathetic outflow causing primary natriuresis leading to 
hypovolemia and sodium depletion.
Methods: Here we describe a case of CSW in a patient with human herpes virus-6 
(HHV-6) encephalitis. The patient was a 29 year old male with a history of AML who 
presented with increasing confusion. He was found to have hyponatremia with a sodium 
of 126 mmol/L, a urine osmolality of 615 mOsm/kg, and a urine sodium of 144 mmol/L. 
On exam, he had evidence of hypovolemia with dry mucus membranes and orthostatic 
hypotension. He was initially treated with normal saline IV fluids. He had increasing 
diuresis with fluid resuscitation, with 6 liters of urine output on hospital day 1. The patient 
was continued on IV saline with the addition of oral salt supplements and started on 
fludrocortisone for suspected CSW. His hyponatremia improved and by hospital day #5 
was 133 mmol/L. CT and MRI imaging of the head and brain were unremarkable for acute 
changes or pathology. A serum HHV-6 PCR showed 13,960 copies. He was treated with IV 
foscarnet with normalization of the serum and CSF PCR within 10 days.
Conclusions: This case is important because the diagnosis of CSW is often confused 
with SIADH, as both share similar diagnostic criteria such as elevated urine sodium 
concentration and urine osmolality. The important clinical distinction is the patient, despite 
having a hypovolemic state would have polyuria and renal sodium wasting.
SA-PO922
Association of 6-Month Pre-ESRD Potassium with Immediate Post-ESRD 
Survival: A Transition to CKD Study  Melissa Soohoo,1 Connie Rhee,1 Vanessa 
A. Ravel,1 Elani Streja,1 Jennie Jing,1 Rajiv Saran,2 Bruce M. Robinson,2 Yi Li,2 
Danh V. Nguyen,1 Csaba P. Kovesdy,3 Kamyar Kalantar-Zadeh.1  1UC Irvine; 
2UM-KECC; 3UTHSC.
Background: Previous studies of the association between serum potassium level 
and mortality in dialysis patients have suggested that a range of 4.6-5.3 mEq/L portends 
greatest survival in this population. However, the optimal potassium range in the immediate 
pre-ESRD prelude period among pre-dialysis CKD patients transitioning to ESRD is not 
known. We hypothesized that a similar pre-ESRD serum potassium range is also associated 
with higher survival in this population.
Methods: We investigated a cohort of 20,404 US veterans who initiated dialysis 
between 10/2007-9/2011 and had at least 1 potassium measurement during the last 6 month 
period before ESRD transition (6 month-prelude). We examined the association of 6 month 
averaged potassium as a continuous predictor of all-cause mortality and early post dialysis 
mortality occurring in the first 3 months after transition using restricted cubic splines and 
Cox proportional hazard models adjusted for age, gender, race, ethnicity, geographic region 
and primary cause of ESRD.
Results: The analytic cohort had a mean±SD age of 68±11 years old, among whom 
30% were African-Americans, 7% Hispanic and 50% had diabetes as the leading cause of 
ESRD. The potassium level in the prelude period was 4.5±0.6 mEq/L. Lower potassium 
levels (3.5-4.0 mEq/L) in the prelude period was associated with highest mortality in the 
first 3 months after transitioning to dialysis whereas potassium in 4.5-5.5 mEq/L range 
conferred the greatest early survival. 
Conclusions: Lower serum potassium measurements during the final months prior to 
transition to ESRD are associated with higher early mortality. Whether pre-ESRD potassium 
should be kept between 4.5 and 5.5 mEq/L in the immediate pre-dialysis transition period 
warrants additional studies.
Funding: NIDDK Support
SA-PO923
Antihypertensive Medications and the Prevalence of Hyperkalemia in 
a Large Healthcare System  Alex R. Chang,1 Yingying Sang,2 H. Lester 
Kirchner,1 Kunihiro Matsushita,2 Shoshana Ballew,2 Josef Coresh,2 Morgan 
Grams.2  1Geisinger Health System; 2Johns Hopkins Bloomberg School of 
Public Health.
Background: The association of outpatient medication use with patterns and prevalence 
of hyperkalemia has not been rigorously examined.
Methods: We evaluated the association between baseline antihypertension medications 
[angiotensin converting enzyme-inhibitors (ACEi), angiotensin receptor blockers (ARB), 
beta-blockers, loop/thiazide diuretics, and K-sparing diuretics] with the frequency and 
pattern of mild (K>5 mmol/L) and severe hyperkalemia (>6 mmol/L) over a 2 year window 
in 342,342 outpatients in the Geisinger Health System based on medication prescription 
orders. Patterns of hyperkalemia were classified as: never, transient (1-time), intermittent 
(>1-time but <50% of the time), and persistent (≥50% of the time). Analyses were adjusted 
for demographics, eGFR, systolic blood pressure, diabetes, and history of cardiovascular 
disease. Interactions between medication types with hyperkalemia risk were also tested.
Results: Potassium levels were checked >=1 time/yr in 53% of the cohort; 4% had levels 
checked >=5 times/yr. Overall, 7.4% had >=1 episode of mild hyperkalemia; 0.4% had an 
episode of severe hyperkalemia. Among the different classes of antihypertensives, K-sparing 
diuretics had the strongest associations with both mild and severe hyperkalemia, followed by 
ACEis and then beta blockers, which were associated only with mild hyperkalemia (Figure). 
ARBs had similar effect size to beta blockers but were not statistically significant. Thiazide/
loop diuretics were protective against mild hyperkalemia but not severe hyperkalemia. 
There were no consistent interactions between types of antihypertensive medication for 
risk of hyperkalemia.
Conclusions: Mild hyperkalemia is relatively common and associated with the use of 
ACEis and K-sparing diuretics but not ARBs in this single healthcare system.
Funding: Private Foundation Support
SA-PO924
Wide Range in Variation in Serum Potassium in Hyperkalemic Patients with 
CKD, Response to a Fixed 60 mEq Potassium Diet  David A. Bushinsky,1 
Martha Mayo,2 Dahlia Garza,2 Yuri Stasiv,2 Daniel J. Wilson,2 Charles Dumond,2 
Lance Berman,2 Murray Epstein.3  1Univ of Rochester; 2Relypsa, Inc; 3Univ of 
Miami.
Background: Serum K(s-K+) levels are affected by diurnal variation, fasting/feeding 
cycles, and medications. In this study we characterized the differences in inter-individual 
variation in s-K+ on a random diet prior to entry and the effect of a controlled K+ diet on 
s-K+ levels in hyperkalemic (HK) pts with CKD (stage 2-4) on stable doses of RAASi, 
during the run-in phase of a treatment trial.
Methods: A total of 27 pts with s-K+ ≥5.5 to ≤6.2 mEq/L were monitored in a clinical 
research unit. At baseline pts were fed a 60 mEq K+, 100 mEq Na+ diet. S-K+ was measured 
at baseline and at prespecified intervals for the next 72 h. We calculated individual difference 
(maximum-minimum) in s-K+ at each time point for the remaining observation period to 
determine variation in s-K+.
Results: Mean s-K+ at baseline was 5.86±0.22 mEq/L and rose to 5.94±0.17 mEq/L 
at 72 h following the start of the fixed K+ diet. Over 72 h, 6/27 pts had “low” (0.0–0.2 
mEq/L), 9/27 “moderate” (0.3–0.4 mEq/L), and 12/27 “high” (0.5–1.1 mEq/L) variation 
in s-K+. Variation in s-K+ decreased at each time point over the 72-h period of observation 
on the controlled diet (Table).
Conclusions: A wide range of inter-individual variation in s-K+ occurred in HK pts 
with CKD on RAASi who were on an uncontrolled diet prior to entry. Variation decreased 
significantly after 24 h on a 60 mEq K diet. These findings have implications for management 
of pts with HK and CKD, and for interpreting clinical trials assessing directional change 
in s-K+ with an intervention.
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Table. Variation in s-K+ (max-min) over 72 h during run-in on a 60 mEq K+ diet, n=27
Time baseline +10 h +24 h +36 h + 48 h +62 h +71 h
Mean±SD 
Δ in 
s-K+, 
mEq/L
0.44±
0.24
0.42±
0.24
0.39±
0.24
0.34±
0.24
0.29±
0.21
0.15±
0.12
0.12±
0.09
P-value* - 0.0830 0.0027 0.0001 0.0001 <0.0001 <0.0001
*Comparing values from baseline to values at +10, +24, +36, +48, +62 and +71 h via paired t-test with 
Bonferroni correction (α=.05; P ≤0.0083 is significant).
Funding: Pharmaceutical Company Support - Relypsa, Inc.
SA-PO925
Best EKG Criteria for Hyperkalemia in Chronic Hemodialysis Patients 
Muzzaffar Hussain, Jamrs R. Cook, Gregory Lee Braden.  Dept of  Medicine, 
Baystate Medical Center/Tufts Univ School of Medicine, Springfield, MA.
Background: To date the effects of hyperkalemia(HK) on the EKG of chronic 
hemodialysis(CHD) patients(pts) are inconsistent. We studied the EKGs of 128 consecutive 
CHD pts with clotted grafts or fistulas. EKGs from 46 HK pts > 5.5 mEq/L were compared 
to 82 pts with normal potassum (NK) levels < 5.5 mEq/L. Pts with RBBB or LBBB or 
cardiac events within 3 months were already excluded. There were no differences between 
HK and NK pts for dialysis duration, causes for ESRD, cardiac disease or serum levels of 
Na, Ca, HCO3, or phosphorus.
Methods: EKG analysis included: the height & width of the P waves, the T waves in 
V4 & the T waves in Lead 2, the time intervals of PR, QRS, QT, QTc, PR/QT, PR/QTc, & 
slopes of ascending & descending T waves in Lead 2 & V4. For the first time ever in HK 
CHD pts, the EKG measurements in 32 HK pts with complete data were compared to their 
NK EKGs obtained 3 to 6 months from the HK event.
Results: Univariate stats between the 46 HK & 82 NK pts showed 4 differences in 
mean values: V4 T wave height 4.0 vs 2.9 mm, Lead 2 T wave height 2.7 vs 2.0 mm, & 
the V4 T wave ascending ( .03 vs .02) and descending slopes (.04 vs .03). Multivariate 
analysis for all clinical & EKG findings between HK & NK pts found only the increased 
height of the T wave in V4 was significant, p<.05. In contrast , the EKG analysis of the 
HK pts to their NK EKGs revealed more differences: higher T wave height in V4, 5.0 vs 
3.7 mm, higher T wave height in Lead 2, 4.0 vs 2.7 mm, shorter width of T wave in V4 
, 2.4 vs 4.1 ms or Lead 2, 2.1 vs 4.1 ms , longer PR 188 vs 167 ms , & steeper slopes in 
the T waves in Lead 2 and V4. Regression analysis of the change in potassium from NK 
to HK to each EKG measurement showed that the only significant correlation was to the 
width,(r = -.433, p=.007 ) & height of the T wave in V4, r= .333, p=.03. In these HK CHD 
pts T wave tenting in V4 was now present in 56 %.
Conclusions: We conclude: 1) Comparison of a NK EKG to a HK EKG in CHD pts 
significantly helps to confirm HK EKG changes in CHD pts. 2) A shortened width and an 
increased height of the T wave in V4 are the most important HK EKG changes in CHD pts.
SA-PO926
Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in 
Chronic Kidney Disease: A Randomized Clinical Trial  Katherine Desforges, 
Laurence Lepage, Anne-Claude Dufour, Jessica Doiron, Katia Handfield, Robert 
Zoel Bell, Michel Vallee, Michel Savoie, Sylvie Perreault, Louis-Philippe Laurin, 
William Beaubien-Souligny, Vincent Pichette, Jean-Philippe Lafrance.  Hopital 
Maisonneuve-Rosemont, Montreal, QC, Canada.
Background: Hyperkalemia affects up to 10% of patients with chronic kidney disease 
(CKD). Sodium polystyrene sulfonate (SPS) has long been prescribed for this condition 
even though evidence is lacking on its efficacy for the treatment of mild hyperkalemia 
over several days.
Methods: The aim of this double-blind, randomized trial was to evaluate the efficacy of 
SPS in the treatment of mild hyperkalemia (5.0 to 5.9 mmol/L) in pre-dialysis outpatients. 
We randomly assigned 33 patients on stable medication to receive either SPS or placebo 
30g orally once a day for 7 days. Patients had to be on stable medication to be eligible for 
the study. The primary outcome was the comparison between study groups of the mean 
difference of serum potassium levels between the day following the last dose of treatment 
and baseline.
Results: The mean duration of treatment was 6.9 days. SPS was superior to placebo in 
the reduction of serum potassium levels (mean difference between groups of -1.04 mmol/L; 
95%CI: -1.37 to -0.71). A higher proportion of patients in the SPS group tended to attain 
normokalemia (defined as a serum potassium level of at least 3.5 mmol/L and less than 5.0 
mmol/L) at the end of their treatment compared to the placebo group (73% vs 38%, P=0.07). 
Patients in the group treated with SPS had an increase in hypomagnesemia, hypocalcemia, 
constipation and nausea compared to the control group.
Conclusions: SPS is superior to placebo in the treatment of mild hyperkalemia over 
seven days in CKD patients. Its use was generally well tolerated in our study population, 
but does require monitoring of gastrointestinal side effects and electrolytic disorders.
Funding: Private Foundation Support, Government Support - Non-U.S.
SA-PO927
Assessment of Systemic Absorption of Sodium Zirconium Cyclosilicate 
(ZS-9): Blood and Urine Zr Concentration in Dogs During a 9-Month Oral 
Toxicity Study  Fiona Stavros, Henrik S. Rasmussen, Bhupinder Singh, Jose 
A. Menoyo.  ZS Pharma, Inc., Coppell, TX.
Background:    Hyperkalemia (HK; potassium [K+] ≥5.1 mEq/L) is a common and 
potentially life-threatening electrolyte disorder often occurring in patients with chronic 
kidney disease, heart failure and diabetes. Sodium zirconium (Zr) cyclosilicate (ZS-9), 
a potential HK therapy, is a selective K+ ion trap containing covalently bound Zr atoms 
within an insoluble 25µm particle. Zr has a long history as an inert substance used in 
biomedical implants and dialysis, and is present in normal diets and household items. 
Systemic absorption of Zr is expected to be minimal given the low solubility and particle 
size of ZS-9. Here we present Zr concentration data from urine and whole blood samples 
from ZS-9 treated dogs to assess systemic absorption of long-term, high-dose ZS-9.
Methods:    Beagle dogs received Control (n=10/sex) or high-dose ZS-9 (2000 mg/kg/
day, n=10/sex). Blood samples were collected by venipuncture at baseline, and Weeks 6, 
13, 26, and 39. Urine samples were collected directly from the bladder at necropsy (Week 
39) and recovery (Week 43). Zr levels in Control and ZS-9 treated dogs were determined 
using inductively coupled plasma mass spectrometry with a lower limit of quantification 
(LLOQ) of 10 ng/mL (ppb) for both whole blood and urine. The analytical method was 
designed to measure the presence of both free Zr and ZS-9 bound Zr.
Results:    Zr was below the LLOQ in all dog urine samples (N=28) and in all but 
one Control group whole blood sample (N=226). The one dog in the Control group had a 
blood Zr level of 10.9 ng/mL at Week 26.  
Treatment 
Group
ZS-9 Dose Level (mg/
kg/day)
Blood Zr concentration 
>LLOQ, n (N=226)
Urine Zr 
concentration 
>LLOQ, n (N=28)
Control 0 1 0
High ZS-9 2000 0 0
Conclusions:    There was no detectable Zr or increase in Zr in blood and urine samples 
following 39 weeks of 2000 mg/kg/day ZS-9 treatment; equivalent to a human dose of 
~65 g/day. Zr was detected in one non ZS-9 treated animal. These results demonstrate an 
absence of systemic ZS-9 absorption after long-term, high-dose treatment in beagle dogs.
Funding: Pharmaceutical Company Support - ZS Pharma, Inc.
SA-PO928
Admission Hypomagnesemia Linked to Septic Shock in Patients with 
Systemic Inflammatory Response Syndrome  Wisit Cheungpasitporn,1 
Charat Thongprayoon,2 Stephen B. Erickson.1  1Nephrology and Hypertension, 
Mayo Clinic, Rochester, MN; 2Internal Medicine, Bassett Medical Center, 
Cooperstown, NY.
Background: The association between admission serum magnesium (Mg) levels and 
risk of developing septic shock in patients with systemic inflammatory response syndrome 
(SIRS) is limited. The aim of this study was to assess the risk of developing septic shock 
in hospitalized patients with SIRS with various admission Mg levels.
Methods: This is a single-center retrospective study conducted at a tertiary referral 
hospital. All hospitalized adult patients with SIRS at admission who had admission Mg 
available from January 2009 to December 2013 were analyzed in this study. Admission 
Mg was categorized based on its distribution into six groups (<1.5, 1.5 to 1.7, 1.7 to 1.9, 
1.9 to 2.1, 2.1 to 2.3, and >2.3 mg/dL). The primary outcome was septic shock occurring 
after hospital admission. Logistic regression analysis was performed to obtain the odds 
ratio of septic shock of various admission Mg levels using Mg with lowest incidence of 
shock, 2.1 to 2.3 mg/dL as the reference group.
Results: Of 2,589patients with SIRS enrolled, septic shock occurred in 236 patients 
(9.1%). The lowest incidence of septic shock was when serum Mg was within 2.1-2.3 mg/
dL. A reverse-checkmark curve emerged demonstrating higher incidences of septic shock 
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associated with both hypoMg (<2.1) and hyperMg (>2.3). After adjusting for potential 
confounders, hypoMg (<1.5 mg/dL) was associated with an increased risk of developing 
septic shock with odds ratios of 1.86 (95% CI 1.07-3.27).
Conclusions: Patients with SIRS and hypoMg (<1.5mg/dL) at the time of admission 
had increased risk of developing septic shock during hospitalization.
SA-PO929
Risk Factors for Calcium-Alkali Syndrome in Post-Surgical 
Hypoparathyroidism  Sayaka Kuroya, Masahiko Yazawa, Naoto Tominaga, 
Yugo Shibagaki.  Nephrology and Hypertension, St. Marianna Univ, Kawasaki, 
Kanagawa, Japan.
Background: Post-surgical hypoparathyroidism is a common complication of total 
thyroidectomy. Patients complicated by permanent hypoparathyroidism often require 
either or both calcium or vitamin D supplement therapy to maintain serum calcium 
levels, and long-term therapy can lead to calcium-alkali syndrome (CAS). We examined 
the incidence rate, magnitude, and risk factors of CAS in patients being treated for post-
surgical hypoparathyroidism.
Methods: We retrospectively observed 27 patients with neck tumors who had undergone 
total thyroidectomy with total parathyroidectomy without autotransplantation between 
January 2010 and October 2013 at St. Marianna University Hospital. All patients received 
calcium lactate and alfacalcidol. Medical records were reviewed for historical, clinical, 
laboratory and imaging data. Definitions were as follows: hypercalcemia, corrected serum 
calcium (cCa) ³10.0 mg/dL; acute kidney disease (AKD), either or both >50% increase in 
serum creatinine (sCr) or >35% decrease in estimated glomerular filtration rate (eGFR); 
and metabolic alkalosis, difference in serum sodium (sNa) and serum chloride (sCl) >38. 
Data were expressed as mean ± standard deviation (SD). For statistical analysis, the paired 
t test, Student’s t test, and chi-square test were used to compare two matched variables 
when appropriate. P<0.05 was considered statistically significant.
Results: Average duration between surgery and reaching peak cCa level was 392.7 ± 
403.8 days, with levels peaking at 11.1 ± 1.5 mg/dL. All patients tended to have significantly 
higher cCa and sCr levels and difference in sNa and sCl after surgery than at baseline 
(p<0.01). Nineteen patients (70.3%) had hypercalcemia, 9 (33.3%) had AKD, and 7 (36.9%) 
had CAS. Calcium lactate dosage was significantly associated with hypercalcemia and AKD 
(p<0.01). Higher doses of alfacalcidol tended to increase incidence of hypercalcemia and 
AKD, although not significantly so.
Conclusions: CAS in post-surgical hypoparathyroidism was common, and dosage of 
calcium supplement was correlated with CAS. cCa levels and kidney function should be 
closely monitored in patients with post-surgical hypoparathyroidism.
SA-PO930
Body Temperature Rise in the Cell-Free and Concentrated Ascites 
Reinfusion Therapy Is Correlated to Albumin Concentration Rather Than 
the Interleukin-6 Levels in the Ascites  Noriaki Maruyama, Masanori Abe, 
Kazuyoshi Okada.  Div of Nephrology, Hypertension and Endocrinology, Dept 
of Internal Medicine, Nihon Univ School of Medicine, Tokyo, Japan.
Background: There is a fever as a side effect of Cell-free and Concentrated Ascites 
Reinfusion Therapy (CART). Cytokines in ascites after concentration is thought to be 
involved in the generation of heat after intravenous injection. To examine the fever related 
factors, we examined the relationship between inflammatory cytokines levels, total protein 
(TP), albumin (ALB) in peritoneal fluid and the heating after intravenous injection.
Methods: In this study, we have measured interleukin-1β (IL-1β), interleukin-6 (IL-
6), TP, ALB concentration in the ascites fluid before and after concentrated, and observed 
vital changes in the patient before and after intravenous injection. A total of 8 patients with 
refractory ascites were studied.
Results: IL-1β was detected in ascites prior to concentration of the two cases, it could 
not be measured in the other specimen. IL-6 is present in high concentrations in all ascites 
before concentration (mean 4218.75 pg/mL), it was further increased after concentration 
(mean 6508.75 pg/mL). Although body temperature rise was observed after the intravenous 
injection of concentrated ascites in six out of eight, IL-6 concentration in the ascites fluid 
(r = 0.61063; P = 0.114), the total dose of IL-6 (r = 0.06755; P = 0.436), dose rate(r = 
0.2876; P = 0.244) was no obvious correlation between the body temperature rise. On the 
other hand, respectively in the TP concentration and the ALB concentration of ascites, it 
was found correlated with body temperature rise after intravenous injection. In particular, 
a strong correlation between the ALB concentration and the increase in body temperature 
was observed (r = 0.8033; P < 0.01).
Conclusions: The correlation of body temperature rise after intravenous injection and 
IL-6 is weak, while the correlation between the concentrated ALB and body temperature 
rise was very strong. From these results, we considered that any substance bound to the 
ALB or ALB itself are associated with elevated body temperature.
SA-PO931
Contrast-Related Hyponatremia: What We Could Be Missing 
Christine Joy C. Junia, Kalyani Perumal.  Internal Medicine, John H. Stroger 
Jr. Hospital, Chicago, IL.
Background: Hyponatremia is a commonly encountered electrolyte abnormality. 
Long-established algorithms outline etiology and management guiding physicians to prevent 
neurologic sequelae. Close electrolyte monitoring is emphasized in acute hyponatremia due 
to higher morbidity and mortality. Contrast-related hyponatremia is an etiology of acute 
onset hyponatremia that is not routinely monitored and may easily be missed.
Methods: A 76 year-old woman with hypertension, diabetes and chronic kidney disease 
(CKD) III, eGFR of 44 was admitted for asthma exacerbation and received beta-agonist 
nebulizers and oral prednisone. Her home medications-Amlodipine and Insulin were 
restarted. She was tachypneic and wheezing, the rest of the physical exam was normal. 
Laboratory tests on admission: Na 135 meq/L, K 4.4 meq/L, BUN 11 mg/dL, Creatinine 
1.2 mg/dL, and normal urinalysis. An elevated D-Dimer prompted evaluation with CT 
Chest with contrast Omnipaque 350 (840 mosm/kg) to rule out pulmonary embolism. 
Her symptoms improved, however her sodium dropped from 135 to 122 meq/L 48 hours 
after chest CT, creatinine 1.4 mg/dL. Work-up revealed plasma osmolality of 297 mosm/
kg, osmolal gap of 30. On the 4th and 5th hospital day, sodium levels were stable at 125 
meq/L and 124 meq/L respectively. Her sodium on Day 8 improved to 133 meq/L without 
any intervention.
Conclusions: The 2014 USRDS data reports a rise in prevalence of CKD III from 
4.5 to 6.0 percent. Primary care doctors manage 80 to 90 percent of these patients. There 
is a simultaneous rise in diagnostic imaging. Over the past decade, CT Scan use in the 
emergency departments has increased over 200-300%. There are a few case reports of 
contrast-related hyponatremia, occurring mostly in patients with advanced CKD with 
eGFR<30. A consistent finding was the acute onset and an average drop in sodium of 12 
meq/dL. Contrast hypertonicity generates a fluid shift and a dilutional effect on extracellular 
sodium. This is usually offset by osmotic diuresis that is impaired in chronic kidney 
disease. Our case highlights contrast-related acute hypertonic hyponatremia in the setting 
of mild kidney disease, a high-risk patient population that may benefit from post-diagnostic 
electrolyte monitoring.
SA-PO932
A Role for NHE3 in Renal Sodium and Acid-Base Handling in the Early 
Proximal Tubule and Further Downstream Segments  Akira Onishi,1 Yiling 
Fu,1 Panai Song,1 Meinrad Busslinger,2 Manoocher Soleimani,3 Isabelle Rubera,4 
Michel Tauc,4 Volker Vallon.1  1Div of Nephrology, UC San Diego & VA San 
Diego Healthcare System, La Jolla, CA; 2Research Inst of Molecular Pathology, 
Vienna, Austria; 3Dept of Medicine, Univ of Cincinnati, Cincinnati, OH; 4Univ 
de Nice Sophia Antipolis, Nice, France.
Background: Systemic Na+/H+ exchanger 3 (NHE3) knockout in mice lowered blood 
pressure (BP) and induced metabolic acidosis, however, the role of intestine vs kidney and 
early proximal tubules (PT) vs downstream segments is unclear.
Methods: Male mice with floxed NHE3 expressing Cre recombinase under the control 
of i) the SGLT2 promoter to knockdown NHE3 in the early PT (SGLT2-Cre/NHE3fl/fl, 
n=10) or ii) the Pax8 promoter for knockdown along the entire tubular system (Pax8-Cre/
NHE3fl/fl, n=9) were compared with corresponding Cre-negative controls (n=10 and 7). 
Blood and spot urine samples were collected, BP measured by automated tail cuff and 
arterial cannulation, and GFR by inulin clearance.
Results: Urine Na/creatinine (cr) ratios were higher in Pax8-Cre/NHE3fl/fl vs controls 
(40±5 vs 28±2, P<0.05) but not significantly different in SGLT2-Cre/NHE3fl/fl vs controls 
(31±2 vs 27±3). Urine pH and HCO3-/cr ratio were strongly increased in Pax8-Cre/NHE3fl/
fl vs controls (7.83±0.11 vs 6.44±0.22; 15.5±3.1 vs 0.55±0.34, each P<0.01), and only 
modestly higher in SGLT2-Cre/NHE3fl/fl vs controls (6.50±0.15 vs 6.12±0.13, P=0.07 
and 0.45±0.20 vs 0.14±0.03, P=0.16). Urine pH and HCO3- were significantly higher in 
Pax8-Cre/NHE3fl/fl vs. SGLT2-Cre/NHE3fl/fl (each P<0.05). Blood pH and HCO3- were 
not different between any groups. Based on the stronger phenotype, BP and GFR were 
determined in Pax8-Cre/NHE3fl/fl and their controls and found to be similar. Urine protein/
cr ratios were doubled in both knockdown mice vs their controls (Pax8-Cre: 32±3 vs 17±2; 
SGLT2-Cre: 22±2 vs 10±1, each P<0.01).
Conclusions: Tubule-specific NHE3 knockdown increased urine pH and excretion 
of sodium, HCO3- and protein without metabolic acidosis. Comparison of the Cre models 
is consistent with a role of NHE3 in urinary acidification and reabsorption of sodium and 
bicarbonate in the early PT as well as in further downstream segments.
Funding: NIDDK Support, Veterans Administration Support
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SA-PO933
Effect of NBCe1 Deletion on Renal Ammonia Metabolism  I. David Weiner,1,2 
Mary E. Handlogten,1 Gunars Osis,1 Hyun-Wook Lee,1 Jill W. Verlander.1 
1Renal Div, Univ of Florida, Gainesville, FL; 2Nephrology Section, NF/SGVHS, 
Gainesville, FL.
Background: Metabolic acidosis typically increases renal ammonia excretion, but 
people with proximal renal tubular acidosis (pRTA), despite the associated metabolic 
acidosis, do not have increased ammonia excretion. Genetic forms of human pRTA typically 
involve the proximal tubule bicarbonate transporter, NBCe1. Based on these observations, 
we postulated that NBCe1 has a role in renal ammonia metabolism that is in addition to its 
role in bicarbonate reabsorption.
Methods: We used previously reported mice with NBCe1 deletion. Because -/- 
mice have 100% mortality between d10-21, we studied mice at d8±1. Wild-type (WT), 
heterozygous (HET) and homozygous knock-out (KO) mice were generated by breeding 
HET male and female mice.
Results: Serum HCO3 was 26.4±1.0 in WT, 19.8±1.9 in HET, and 10.3±0.6 mM in KO 
mice (P<0.05). Thus, NBCe1 deletion causes metabolic acidosis at d8. Although acidosis 
normally increases ammonia excretion, NBCe1 deletion decreased spontaneous ammonia 
excretion: 275±44, 212±11 and 94±69 mmol/g creatinine in WT, HET and KO mice, 
respectively (P<0.01). Serum Na and K were unchanged. Urine pH was 5.3±0.2, 4.8±0.1 and 
4.2±0.1 in WT, HET and KO mice, respectively (P<0.01), indicating intact urine acidification 
and no ongoing HCO3 loss. NBCe1 deletion did not alter urine osmolality significantly 
(WT, 596 ± 74; HET, 693 ± 51; and, KO, 726 ± 34 mOsm/kg H2O; P=NS), which, in 
combination with intact urine acidification, suggests intact collecting duct function. The 
regulation of multiple proteins involved in ammonia metabolism was atypical of acidosis. 
NBCe1 deletion decreased expression of PDG and PEPCK and increased expression of 
the ammonia recycling enzyme, glutamine synthetase. This pattern is the exact opposite 
of that expected with acidosis. Expression of the TAL ammonia transporter, NKCC2, and 
the collecting duct ammonia transporters, Rhbg and Rhcg, was unchanged.
Conclusions: We conclude: 1) NBCe1 deletion significantly alters proximal tubule 
ammonia metabolism, leading to decreased urinary ammonia excretion; and, 2) NBCe1, in 
addition to its role in HCO3 transport, may have an important role in ammonia metabolism.
Funding: NIDDK Support, Veterans Administration Support
SA-PO934
Assessing Urine Ammonium Concentration by Urine Osmolal Gap in 
Chronic Kidney Disease  Takuya Fujimaru, Yasuhiro Komatsu, Takuya Shuo. 
Nephrology, St. Luke’s International Hospital, Tokyo, Japan.
Background: Acidemia is one of the risk factor for end stage kidney disease and 
mortality for patients with chronic kidney disease (CKD). Although ammonium is the 
crucial component of renal acid excretion, measurement of urine ammonium concentration 
(NH4+) is not routinely available in most hospital laboratories. To estimate NH4+, urine 
osmolal gap (UOG = urine osmolality – [2(Na+ + K+) + urea + glucose]) is calculated and 
the formula (NH4+ = UOG/2) has traditionally been used. However, studies evaluating it in 
CKD patients are scarce. The present study aims to assess the relationship between NH4+ 
and UOG in CKD patients.
Methods: Spot urine samples were collected from 36 patients with CKD in our hospital 
(24 males, age 41-96 years, serum creatinine 0.9-12.4 mg/dl). We measured urine pH, 
Na+, K+, Cl-, urea, glucose and NH4+. NH4+ was measured by colorimetric assay (modified 
Fujii-Okuda method). The Bland-Altman plot was used to evaluate the agreement between 
NH4+ and UOG/2.
Results: NH4+ ranged from 0.3-45.8 mmol/l (median, 6.2 mmol/l). UOG/2 correlated 
positively and significantly with NH4+ (r=0.928, p<0.0001).
The mean difference between UOG/2 and NH4+ was 4.7 mmol/l, and the 95% limits 
of agreement were -5.0 mmol/l and 9.6 mmo/l.
Conclusions: UOG is an accurate method to estimate NH4+ in CKD patients and can 
be used to assess urinary acidification ability in CKD patients.
SA-PO935
Vacuolar H+-ATPase Regulation by 14-3-3 Proteins  Nuria M. Pastor-Soler,1 
Mohammad M. Al-bataineh,3 Hui Li,1 Vivek Bhalla,2 Kenneth R. Hallows.1 
1Medicine, Div of Nephrology, Keck School of Medicine of USC, Los Angeles, 
CA; 2Medicine, Div of Nephrology, Stanford School of Medicine, Palo Alto, 
CA; 3Medicine, Renal-Electrolyte Div, U. of Pittsburgh School of Medicine, 
Pittsburgh, PA.
Background: The vacuolar proton-ATPase (V-ATPase) is highly expressed at the 
apical membrane of type A intercalated cells (ICs) in the collecting duct. This pump 
mediates proton transport across a membrane often against a gradient. Defects in V-ATPase 
function can lead to renal tubular acidosis. In kidney cells we showed that the metabolic 
sensor AMP-activated protein kinase (AMPK) phosphorylates the V-ATPase A subunit 
at Ser-384. AMPK regulates some transport proteins by inhibiting their function and 
promoting their ubiquitination and degradation. These mechanisms are likely important 
for inhibition of membrane transport during cellular metabolic stress. We noticed that Ser-
384 exists within a 14-3-3 binding motif. Dimeric 14-3-3s bind to phosphorylated sites 
on target proteins and modulate protein function. We hypothesized that phosphorylation 
by AMPK and an additional kinase modulate A subunit binding to 14-3-3 proteins and A 
subunit ubiquitination.
Methods: We used transient transfections of V-ATPase A subunit mutants in Clone C 
ICs, followed by immunoprecipitation and immunoblotting.
Results: We have preliminary evidence that phosphorylation at Ser-384 and a new 
“Site III” in the V-ATPase A subunit are required for 14-3-3 binding. For example, 14-3-3 
binding to the A subunit increased when we used a phosphomimetic mutant (Ser-to-Asp) 
at Site III compared to the WT sequence at that site, and this binding was is not dependent 
of the presence of the AMPK activator AICAR. Furthermore, AICAR increased A subunit 
ubiquitination as compared to untreated cells.
Conclusions: We propose that V-ATPase A subunit binding to 14-3-3s promotes its 
ubiquitination and degradation. These pathways are downstream of phosphorylation of the 
A subunit at Ser-384 by AMPK and at Site III by another unidentified kinase. Our results 
link downregulation of the V-ATPase to metabolic depletion in kidney epithelial cells.
Funding: NIDDK Support
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Albuminuria Enhances Renal NHE3 Expression via the Activation of 
Mitochondrial Oxidative Stress/RAS Axis  Aihua Zhang,1,2 Yibo Zhuang,1 
Guixia Ding,1 Songming Huang,1 Zhanjun Jia.1,2  1Nephrology Dept, Nanjing 
Children Hospital, Nanjing Medical Univ, Nanjing, Jiangsu, China; 2Nanjing 
Key Laboratory of  Pediatrics.
Background: Renal sodium–hydrogen exchanger 3 (NHE3) plays a known role in the 
reabsorption of bicarbonate and fluid. As a result, NHE3 is thought to be important in acid 
base balance and vascular volume homeostasis. The present study was to investigate the role 
albuminuria in regulating renal NHE3 expression as well as the underlying mechanisms.
Methods: An albumin overload mouse model was established by i.p injection of 
albumin. The mouse kidney tissues and kidney biopsy specimens from proteinuric patients 
were analyzed.
Results: Following 12-day albumin overload, we found that albuminuria increased 
NHE3 expression by 2-fold in mouse kidneys determined by Western blotting and qRT-
PCR. Considering the known role of renin-angiotensin system (RAS) in modulating renal 
sodium transporters, we examined key components of RAS and found a striking elevation 
of angiotensinogen (AGT, +2.1 folds), angiotensin converting enzyme (ACE, +3.3 folds), 
and urinary antgiotensin II (Ang II, +70%) output determined by Western blotting or 
ELISA. In proteinuric patients, we detected a 1.9-fold upregulation of NHE3 and 3-fold 
increase of ACE by immunohistochemistry in line with a 2-fold increment of urinary Ang 
II excretion. To further investigate the role of RAS in upregulating NHE3, we performed 
primary cultures of renal tubular cells and observed that albumin directly enhanced NHE3 
accompanied by stimulated AGT/ACE/Ang II cascade, which was entirely abolished by ACE 
inhibitor captopril, indicating a key role of RAS in mediating albuminuria effect on NHE3 
upregulation. More interestingly, albumin overload significantly induced mitochondrial 
oxidative stress evidenced by reduced mitochondrial superoxide dismutase (SOD2, -60%) 
and elevated ROS production. Notably, a SOD2 mimic (MnTBAP) completely normalized 
NHE3 upregulation and activated AGT/ACE/Ang II cascade in mice with albumin overload.
Conclusions: These results suggest that albuminuria is of vital importance in 
upregulating renal NHE3 expression in proteinuric patients via mitochondrial oxidative 
stress-initiated stimulation of AGT/ACE/Ang II cascade.
Funding: Government Support - Non-U.S.
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ATP6v1b1 Haploinsufficiency Lead to a Mild Incomplete Renal Tubular 
Acidosis (RTA) in Mice  Soline Bourgeois, Carsten A. Wagner.  Inst of 
Physiology, Univ of Zurich, Zurich, Switzerland.
Background: Mutations in ATP6V1B1 gene in man is considered as an autosomal 
recessive disease and lead to distal RTA by dysfunction of the B1 subunit of H-ATPase 
in type A intercalated cells. B1 subunit ablation in mouse causes also distal RTA with a 
decrease in ammonuria and alkaline urine pH.
Methods: Here we investigated on littermate mice whether ATP6v1b1+/-mice also 
develop acid-base disturbances during an acute and chronic acid challenge performed by 
0.2 M HCl added to powdered standard food.
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Results: ATP6v1b1+/+ (WT) and +/- (HET) mice exhibited no difference in their 
blood and urine parameters under baseline conditions. During the acid challenge, while 
ATP6v1b1-/- mice (KO) developed alkaline pH and low ammoniuria with hypercalciuria, 
HET mice showed no difference in their urine data over the whole acid load compared to 
WT mice. However, eventhough, HET mice did not exhibit low blood pH, as KO mice, 
they had a lower bicarbonatemia, higher chloremia and lower pCO2 compared to WT 
mice at the end of the acid challenge. Both KO and HET mice drank more than WT mice 
over the acid load with a tendency to urinate more. After 4 days of acid load, subcellular 
localization of the a4 and B2 subunits of H-ATPase were not different within the 3 strains 
of mice and WT and HET mice exhibited the same localization of B1 subunit. However, 
western blot analysis of B1 and B2 expression in renal membrane fractions revealed a 
2-fold decrease of B1 and B2 protein expression in HET mice compared to WT mice and 
no difference in the expression of B2 protein in KO mice compared to WT mice while B1 
protein was totally absent from KO kidneys.
Conclusions: In conclusion, 1) HET mice developed a mild incomplete RTA during an 
acid challenge, undetectable regarding urine parameters. The RTA is partly compensated by 
the respiration and an increase in water consumption. 2) B2 subunit does not compensate 
for the decrease in B1 expression both in HET kidney tissues and seems to be inhibited 
by acid load.
Funding: Government Support - Non-U.S.
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Bedside Rule (pCO2=HCO3+15) Is Reliable in Predicting Respiratory 
Response in Metabolic Acidosis with Bicarbonate Levels of More Than 7 
meq/L  Mohammad Kazem Fallahzadeh, Michael Emmett.  Dept of Internal 
Medicine, Baylor Univ Medical Center, Dallas, TX.
Background: There is controversy about the reliability of the bedside rule 
(pCO2=HCO3+15) in prediction of respiratory response in metabolic acidosis. The aim 
of our study was to compare the accuracy of the bedside rule with Winter’s equation in 
predicting respiratory response in metabolic acidosis.
Methods: We extracted the measured bicarbonate and pCO2 levels of 382 patients 
with metabolic acidosis from the previously published articles evaluating the respiratory 
response to metabolic acidosis. We calculated the predicted levels of pCO2 by bedside rule 
and Winter’s equation for each patient. Then we compared the accuracy of these formulas 
in predicting the respiratory response to metabolic acidosis.
Results: As demonstrated in the figure 1, the values calculated by bedside equation 
(pCO2=HCO3+15) appear to be a reliable predictor of respiratory response in HCO3 
levels of more than 7 meq/L, as compared with the line of best fit and Winter’s equation. 
Conclusions: Our results show that bedside rule (pCO2=HCO3+15) is reliable in 
predicting respiratory response in metabolic acidosis with HCO3 levels of more than 7 
meq/L.
SA-PO939
TSS-Seq Analysis of Low pH-Induced Gene Transcripts in the Intercalated 
Cells of the Collecting Ducts  Yuichiro Izumi,1 Koji Eguchi,1 Terumasa 
Nakagawa,1 Yushi Nakayama,1 Hideki Inoue,1 Yutaka Kakizoe,1 Takashige 
Kuwabara,1 Hiroshi Nonoguchi,2 Masashi Mukoyama.1  1Dept of Nephrology, 
Kumamoto Univ Graduate School of Medical Sciences, Japan; 2Dept of 
Internal Medicine and Education & Research Center, Kitasato Univ Medical 
Center, Japan.
Background: Metabolic acidosis is caused by acute and chronic kidney disease due to 
the decrease of acid excretion in the intercalated cells of the collecting duct in the kidney. 
Although the effect of acidosis on renal function has been examined in vivo, direct effect 
of low pH on the intercalated cells has not been investigated.
Methods: We employed Transcription Start Site-Sequencing (TSS-Seq) to provide 
low pH-induced gene transcripts in a rat intercalated cell line (IN-IC cells). Two biological 
replicates were used for the analysis. Cells were grown in a FBS-free DMEM/F12 overnight 
and incubated in an isotonic solution for 24h in which pH was adjusted either to 7.4 or 7.0, 
then total RNA was extracted. cDNA library for CAGE (Cap Analysis Gene Expression) 
was created. Deep sequencing was performed by Illumina HiSeq2500 sequencer. TopHut 
2 software was used to map TSS-Seq reads. RECLU was used to identify differentially 
expressed transcripts. Gene Ontology (GO) analysis was carried out using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID).
Results: 278 differentially expressed transcripts were identified. 261 transcripts 
were upregulated and 17 were downregulated. Among them, 225 upregulated and 13 
downregulated transcripts were corresponded to known protein products. GO analysis of 
Biological Processes and Molecular Functions showed 9 clusters of the GO terms with 
high enrichment score (> 1.5) such as regulation of transcription, dephosphorylation, and 
enzyme-linked receptor protein signaling pathway. The upregulated transcripts included 
Jak2, Pten, and Gsk3a, that are involved in renal fibrosis and urine concentration mechanism.
Conclusions: The results suggest that metabolic acidosis could regulate the function 
of intercalated cells and further exacerbate the renal fibrosis.
Funding: Government Support - Non-U.S.
SA-PO940
Narrowing the Gap Between the Anion Gap and the Strong Ion Gap 
Kenrick Berend,1 Andrew L. Lundquist.2  1Nephrology, St. Elisabeth Hospital, 
Willemstad, Curacao, Netherlands Antilles; 2MGH Div of Nephrology, 
Massachusetts General Hospital, Boston, MA.
Background: Despite its importance in understanding acid-base pathophysiology, 
many physicians do not understand the concept of the strong anion gap. The core of the 
Stewart acid-base approach is the “strong ion gap” (SIG). The concept of SIG is similar to 
the AG, but the main difference is that Stewart uses more strong ions and the contribution 
of albumin and phosphate are adjusted for the pH. Because SIG gives a more precise picture 
of the ion balance than the AG, one may postulate that it provides a more accurate analysis 
of acid-base disturbances. The exact differences, however, are not established. This paper 
will give insight into the difference between the anion gap and the strong anion gap and 
provide an adjusted formula for the anion gap to replace the need for the strong anion gap.
Methods: The change of the strong ion gap (SIG) and the albumin-corrected anion gap 
(AGc) were calculated at a wide range of albumin, phosphate and pH levels.
Results: At a low albumin level of 1 to 3 g/dl and decreased pH from 6.9 to 7.3, the 
contribution difference of albumin in AGc and SIG will be maximally -0.97 to 0.51 mEq/L. 
In metabolic alkalosis (pH up to 7.6) and hypoalbuminaemia (1 to 3 g/dl), the AGc differs 
less than 2 mEq/L with SIG. There is a linear relationship of the serum phosphate and the 
ionic contribution of SIG: at a pH of 6.9, the phosphateSIG is 1.66 times higher and at a 
pH of 7.6, 1.86 higher. In metabolic alkalosis and moderate hyperphosphatemia, the ionic 
contribution to the anion gap will increase, but less than 1 mEq/L.
Conclusions: SIG and AGc are almost identical across a wide range of values, 
particularly when albumin and phosphate levels are low. The pH adjusted serum phosphate 
level in the SIG is about 1.76 higher, with a confidence interval of + 0.5 mmol/L. The anion 
gap will be more precise and incorporate the major components of the SIG when using 
the equation: [Na+] - [Cl-] - [HCO32-] - 2.5 [albumin, in g/dL] – 1.76 [phosphate], with an 
arbitrarily set reference range of 1 +/- 5 meq/L.
SA-PO941
V-ATPase in Luminal Membrane of Renal Proximal Tubule Requires 
B2 Subunit and CLC-5 for Its Full Functional Activity  Nobuhiko Sato,1 
Motonobu Nakamura,1 Atsushi Suzuki,1 Masashi Suzuki,1 George Seki,2 Shoko 
Horita.1  1Nephrology, The Univ of Tokyo Hospital, Tokyo, Japan; 2Yaizu City 
Hospital, Shizuoka, Japan.
Background: Using an isolated rat proximal tubule (PT) primary culture system, we 
have previously shown that the activity of basolateral Na/HCO3 co-transporter (NBCe1) 
was preserved for 36 hours. Furthermore, gene silencing with siRNA enabled us to identify 
the signaling pathways involved in insulin-mediated NBCe1 stimulation (Nakamura M, 
Kidney Int, 2015). However, it remains unknown whether this technique is applicable to 
analysis of PT luminal transporters.
Methods: Freshly isolated mouse PT was attached to a glass coverslip with Cell-
Tak glue and the lumen was exposed with a broken glass capillary. BCECF was used to 
measure intracellular pH (pHi). While the cariporide-insensitive luminal NHE activity was 
determined by the rates of pHi decrease in response to Na removal, the bafilomycin-sensitive 
V-ATPase activity was determined by the rates of pHi recovery in Na-free solution. These 
experiments were also performed after PTs were cultured overnight in the presence of 
siRNA against V-ATPase B2 subunit or CLC-5.
Results: The luminal NHE activity was at least partially preserved in isolated PT 
primary culture (0.89+/-0.08 vs 0.45+/-0.07 pH unit/min). The hypotonicity (210 mOsm)-
stimulated V-ATPase activity was also largely preserved in PT primary culture (0.50+/-
0.05 vs 0.32+/-0.04 pH unit/min). Overnight treatment with siRNA against B2 subunit or 
CLC-5 largely suppressed the V-ATPase activity by 81% and 70%, respectively, without 
affecting the luminal NHE activity. We also confirmed that transfection of wild-type 
CLC-5 into HEK293 cells not only decreased endosomal pH as estimated by ratiometric 
VAMP2-pHluorin but also induced the plasma membrane V-ATPase activity stimulated 
by hypotonicity (0.01+/-0.01 vs 0.59+/-0.07 pH unit/min).
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Conclusions: These data revealed for the first time to our knowledge that the luminal 
V-ATPase in PT requires both B2 subunit and CLC-5 for its full functional activity. The 
requirement of CLC-5 may be a common feature of mammalian V-ATPase, either expressed 
in endosome or plasma membrane.
Funding: Government Support - Non-U.S.
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The Mechanistic Target of Rapamycin Regulates Solute Transport in Renal 
Tubules  Nasir A. Shah,1 Davide Pietro Cina,2,3 Tuncer Onay,2,3 Vera Eremina,4 
Chengjin Li,4 Aline Martin,2 Yashpal S. Kanwar,2,5 Susan E. Quaggin.2,3  1Mater 
Health Services North Queensland, James Cook Univ, Townsville, Queensland, 
Australia; 2Medicine, Div of Nephrology, Northwestern Univ, Chicago, IL; 
3Feinberg Cardiovascular Research Inst, Northwestern Univ, Chicago, IL; 
4Lunenfeld-Tanenbaum Reseawrch Inst, Mount Sinai Hospital, Toronto, ON, 
Canada; 5Pathology, Northwestern Univ, Chicago, IL, Canada.
Background: Inhibitors of the mechanistic target of rapamycin (MTOR inhibitors) 
belong to a family of drugs with potent immunosuppressive, anti-angiogenic and anti-
proliferative properties. Despite their clinical potential, their use in humans has been 
hampered by a significant incidence of proteinuria and electrolyte disturbances. Although 
some studies suggest Mtor may play a role in regulating renal solute transporter expression 
and function, the exact mechanisms underlying these changes are largely unknown.
Methods: In this study we examine the contribution of MTOR inhibition in the renal 
tubules to the development of proteinuria and electrolyte disturbances by generating an 
inducible Pax8-driven, tubule-specific Mtor knockout mouse (Mtor Pax8-iKO).
Results: Loss of Mtor in the renal tubular epithelium resulted in increased 24-hour 
urine volume, diminished urine osmolalitiy, and renal failure. Despite elevated 24-hour 
urine albumin, Ca2+, and Mg2+ Mtor Pax8-iKO mice were both hypercalcemic and 
hypermagnesemic. Histologically, Mtor Pax8-iKO mice exhibited generalized tubular 
atrophy with focal cystic dilations of the distal and cortical collecting tubules, and interstitial 
fibrosis.  Immunohistochemistry showed decreased expression of aquaporin-2 (Aqp2), 
Calbindin D 28k (Calb1), and the sodium-potassium-chloride cotransporter (Nkcc2). 
Increased expression of the transient receptor potential cation channel subfamily V member 
5 (Trpv5) was also noted.
Conclusions: Taken together, our results suggest that MTOR is a key player in 
maintaining electrolyte balance by modifying the expression, and function of solute 
transporters in the renal tubular epithelium.
SA-PO943
High Mobility Group Box 1 (HMGB1) Inhibits HCO3- Absorption in 
Medullary Thick Ascending Limb (MTAL) Through Receptor for Advanced 
Glycation End Products (RAGE)-Rho-Rock1-Mediated Inhibition of 
Basolateral Na+/H+ Exchange  Bruns A. Watts, Thampi George, David W. 
Good.  Univ TX Med Branch, Galveston, TX.
Background: HMGB1 is a damage-associated molecule that is released extracellularly 
in response to infection or injury and plays a role in mediating kidney dysfunction in sepsis 
and sterile inflammatory disorders. Recently we showed that basolateral HMGB1 inhibits 
HCO3- absorption in perfused rat MTALs through a RAGE-dependent pathway additive 
to TLR4-ERK-mediated inhibition by LPS. Here we examined signaling and transport 
mechanisms involved in inhibition by HMGB1.
Results: Inhibition of HCO3- absorption by HMGB1 was eliminated by the Rho-
associated kinase (ROCK) inhibitor Y27632 and by a specific inhibitor of Rho, the direct 
activator of ROCK. HMGB1 increased ROCK1 activity in dissected inner stripe of outer 
medulla, a preparation that accurately reproduces changes in MTAL signaling proteins. 
Activation of ROCK1 by HMGB1 was eliminated by the RAGE antagonist FPS-ZM1 and 
by inhibition of Rho. Addition of a direct Rho activator reduced basal HCO3- absorption 
rate and prevented inhibition by HMGB1. The Rho and ROCK inhibitors had no effect on 
inhibition by bath LPS. The Rho-ROCK1 pathway regulates NHE1 and we have shown that 
inhibition of NHE1 decreases MTAL HCO3- absorption secondarily through cytoskeleton-
dependent inhibition of apical NHE3. Inhibition of HCO3- absorption by HMGB1 was 
eliminated by bath amiloride, 0 Na+ bath, and the F-actin stabilizer jasplakinolide, three 
maneuvers that selectively prevent inhibition of HCO3- absorption mediated through NHE1. 
Bath amiloride and jasplakinolide did not affect inhibition by bath LPS.
Conclusions: We conclude: 1) HMGB1 inhibits HCO3- absorption in the MTAL through 
a RAGE-Rho-ROCK1 pathway coupled to inhibition of NHE1; 2) this pathway functions 
in parallel with the LPS-TLR4-ERK pathway to impair MTAL HCO3- absorption. Thus, 
during sepsis, endogenous damage-associated molecules and exogenous bacteria-associated 
molecules act directly and independently to inhibit MTAL HCO3- absorption through 
different receptor signaling and transport pathways. The RAGE-Rho-ROCK1 pathway is 
a potential target to attenuate sepsis-induced renal tubule dysfunction.
Funding: NIDDK Support
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Identification of IQGAP-1 as a Pendrin-Binding Protein in the Kidney 
Jie Xu,1 Sharon L. Barone,2 Kamyar A. Zahedi,1,2 Manoocher Soleimani.1,2 
1Center on Genetics of Transport and Epithelial Biology, Dept of Medicine, 
Univ of Cincinnati, Cincinnati, OH; 2Research Services, VA Medical Center, 
Cincinnati, OH.
Background: Networks of interacting proteins are crucial for all levels of cellular 
function.The Slc26 family of anion transporters [Slc26a3 (DRA), Slc26a5 (prestin), Slc26a6 
(PAT-1), and Slc26a9] form multi-protein complexes with cytoskeleton, anchoring proteins, 
PDZ adaptor proteins, CFTR and/or protein kinases, which impart regulatory signals on 
these isoforms. No information is available on proteins that interact with pendrin (Slc26a4).
Methods: A yeast two hybrid system was employed to screen a mouse kidney cDNA 
library with a pendrin C-terminal fragment as bait. A total of 6 × 103 interacting clones 
were identified, out of which 14 clones were confirmed to be positive when screened for 
β-gal expression. Plasmids from these clones were purified and their interaction with 
pendrin was confirmed.
Results: Our experiments identified IQGAP-1 as a pendrin C-terminus binding partner. 
IQGAP-1 is a scaffolding protein that binds and/or stabilizes ezrin, CDC42 and RAC1, 
and interacts with cytoskeletal and cell adhesion molecules. In the kidney, IQGAP-1 is 
strongly expressed in the DCT, CNT, CCD and podocytes. IQGAP-1 has also been shown 
to control tight junction formation through recruitment of claudin. Our results indicate 
that IQGAP-1 co-localizes with pendrin on the apical membrane of B-intercalated cells. 
IQGAP-1 is also detected on the basolateral membrane of A-intercalated cells in CCD. 
Functional studies in HEK293 cells demonstrated that the co-transfection of IQGAP-1 
and pendrin increased pendrin-mediated Cl-/HCO3- exchange activity by more than 60%. 
Confocal microscopy showed more abundant plasma membrane expression of pendrin in 
the presence of IQGAP-1.
Conclusions: These studies demonstrate the interaction of IQGAP-1 and pendrin in 
B-intercalated cells, as well as the stimulatory role of IQGAP-1 on pendrin activity. We 
propose that pendrin interaction with IQGAP-1 is important in the regulation of CCD 
function and physiology, and that disruption of this interaction contributes to altered pendrin 
trafficking and/or activity in pathophysiologic states.
Funding: Veterans Administration Support
SA-PO945
Regulation of Rhcg by Aldosterone in Intercalated Cells of the Collecting 
Ducts  Koji Eguchi, Yuichiro Izumi, Terumasa Nakagawa, Yushi Nakayama, 
Hideki Inoue, Yutaka Kakizoe, Takashige Kuwabara, Masashi Mukoyama. 
Dept of Nephrology, Kumamoto Univ Graduate School of Medical Sciences, 
Kumamoto, Japan.
Background: Acid-base balance is regulated by aldosterone which stimulates acid 
secretion in the intercalated cells of the collecting ducts of the kidney. Rhesus blood 
group C glycoprotein (Rhcg) is an ammonia transporter which cooperates with H+-ATPase 
to secrete H+ in the intercalated cells. In vivo experiments have shown that metabolic 
acidosis and hypokalemia, that change plasma aldosterone level, increases and decreases 
the expression of Rhcg, respectively. Direct effect of aldosterone on the regulation of Rhcg 
has not been examined.
Methods: We examined the effect of aldosterone on the regulation of Rhcg. Membrane 
fraction of the whole kidney was extracted from mice that were continuously administered 
aldosterone (40µg/body/day) or vehicle for a week. To further examine the effect of 
aldosterone on the regulation of Rhcg in the intercalated cells, mRNA, whole cell protein, 
and membrane fraction were extracted from IN-IC cells (a rat intercalated cell line) after the 
treatment with aldosterone (10-6 M) for 24 h. The Rhcg mRNA and protein expressions were 
measured by real-time PCR and Western blotting, respectively. The expression of serum 
and glucocorticoid-regulated kinase 1 (Sgk1) mRNA was also measured in IN-IC cells.
Results: Administration of aldosterone increased the expression of Rhcg protein in 
membrane fraction of the whole kidney. In IN-IC cells the expressions of Rhcg and Sgk1 
mRNAs were 1.3- and 3.2-fold greater, respectively, in cells treated with aldosterone (10-
6M) than in cells with vehicle. The expression of Rhcg protein in whole cell extract was 
not changed by the treatment with aldosterone. However, the expression of Rhcg protein 
in membrane fraction was 3.2-fold greater in cells treated with aldosterone than in cells 
with vehicle.
Conclusions: The results suggest that aldosterone regulates membrane accumulation 
of Rhcg possibly through the activation of Sgk1.
Funding: Government Support - Non-U.S.
SA-PO946
Role  of  Adenylyl  Cyclase  6  in  Regulat ion of  Urinary pH 
Søren Brandt Poulsen,1,2,3 Robert A. Fenton,3, Timo Rieg.1,2  1Dept of Medicine, 
UCSD, La Jolla, CA; 2VASDHS, San Diego, CA; 3Dept of Biomedicine, Aarhus 
Univ, Aarhus, Denmark.
Background: Adenylyl cyclase isoform 6 (AC6) is expressed in all renal tubular 
segments and catalyzes the synthesis of cAMP. We have previously reported that AC6 
knockout (AC6-/-) mice have a urinary concentration defect, a mild Bartter syndrome 
and secondary hyperparathyroidism. A recent study (Am J Physiol Renal Physiol. 
2012;303(6):F812-20) determined that cAMP can increase pendrin protein (Cl-/HCO3- 
exchanger) abundance. We therefore hypothesized that AC6-mediated cAMP formation 
was important for urinary pH regulation.
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Methods: AC6 wild-type (WT) and AC6-/- mice (n=6/genotype) were challenged with 
NaHCO3 in their drinking water for a period of 8 days. As daily fluid intake is double in 
AC6-/- mice, the NaHCO3 was reduced by 50% in this genotype (0.14 mol/l vs. 0.28 mol/l 
in WT). Urine was collected daily; blood was collected under baseline conditions and at 
the end of the 8 day experimental period. Mice were euthanized, one kidney processed for 
Western blotting (pendrin, H+-ATPase B1 subunit and NBCe1), and the other kidney was 
perfused in vivo and processed for immunohistochemistry.
Results: Baseline urinary pH was significantly lower in AC6-/- vs. WT mice (6.5±0.2 
vs. 7.7±0.2, P<0.05) which was associated with higher blood pH (7.44±0.01 vs. 7.41±0.01, 
P<0.05). At the end of the experimental period urinary pH was comparable between 
genotypes (8.3±0.4 vs. 8.3±0.4, NS) and no significant change in blood pH was observed 
(7.45±0.01 vs. 7.43±0.01, P<0.05 vs. WT). NBCe1 protein abundance was not different, 
whereas pendrin and H+-ATPase B1 subunit were 1.8 and 1.5-fold higher in AC6-/- vs. WT, 
respectively (P<0.05). The number of pendrin positive cells/mm2 (WT: 32±2 vs. AC6-/-: 
28±2) in the renal cortex was not different between genotypes.
Conclusions: Our results imply a role for AC6 in expression of pendrin and H+-ATPase 
B1 subunit and subsequently regulation of urinary pH. The increase in urinary pH in AC6-
/- mice can only be achieved, or is the consequence of, higher pendrin abundance; however, 
this effect is independent of pendrin distribution changes. Further studies are needed to 
determine the signals causing baseline differences in urinary pH.
Funding: NIDDK Support, Private Foundation Support
SA-PO947
Prediction of the Development of Delayed Graft Function Using Acute 
Kidney Injury Criteria in Deceased Donor Kidney Transplantation 
Jeong Ho Kim,1 Bum Soon Choi,1 Cheol Whee Park,1 Chul Woo Yang,1 Yong-Soo 
Kim,1 Young Soo Kim,2 Byung Ha Chung.1  1Internal Medicine, Seoul St. Mary’s 
Hospital, Seoul, Korea; 2Internal Medicine, Uijeongbu St. Mary’s Hospital, 
Uijeongbu, Korea.
Background: There is no clear consensus on the definition of acute kidney injury 
(AKI) in deceased donor. In this study, we determine the discriminative ability of the 
Kidney Disease: Improving Global Outcomes (KDIGO) compared to the Acute Kidney 
Injury Network (AKIN) criteria for the prediction of the development of delayed graft 
function (DGF) and allograft outcome in deceased donor kidney transplantation (DDKT).
Methods: We analyzed 285 kidney transplant recipients who took kidney from 228 
deceased donors. We calculated the AKI stage of deceased donor according to the AKIN 
and KDIGO criteria and compared the predictability for the development of DGF and the 
change of allograft function.
Results: For 2 classification systems, DGF developed more frequently in the AKI group 
than non-AKI group (P < .05) and allograft function assessed by the Modification of Diet 
in Renal Disease (MDRD) equation showed a significantly deteriorating pattern at 2 weeks 
and 1, 3, 6, 12 months after kidney transplantation compared to that in the non-AKI group 
(P < .05, comparison at each time point). In the Receiver-Operating Characteristic(ROC) 
curve analysis, the KDIGO criteria showed better prognostic accuracy of the prediction 
of the development of DGF compared to the AKIN criteria (area under the curve = 0.72 
versus 0.62; P < .05).
Conclusions: In DDKT, the KDIGO criteria may be more useful for predicting the 
development of DGF compared to the AKIN criteria.
SA-PO948
Impact of Cold Ischemia Time on Graft Failure and Death  Douglas F. Arbetter,1 
Mariana C. Chiles,1 Prativa Baral,1 Geoffrey K. Dube,1 Russell J. Crew,1 Heather 
K. Morris,1 Jai Radhakrishnan,1 David J. Cohen,1 Stephen O. Pastan,2 Rachel 
E. Patzer,2 Sumit Mohan.1  1Dept of Medicine, Columbia Univ College of 
Physicians & Surgeons, New York, NY; 2Dept of Medicine, Emory Univ School 
of Medicine, Atlanta, GA.
Background: Patient and graft survival post kidney transplant (KT) are influenced by 
an interaction of multiple factors, including organ quality, preservation and cold ischemia 
time (CIT). Several small studies have suggested that even small increases in CIT adversely 
impact patient and graft outcomes. In this analysis we assess the impact of increasing CIT 
on patient and graft survival in the US.
Methods: We identified 75,660 first-time adult KT recipients, who received a deceased 
donor (DD) kidney from 2000-2011 in SRTR. Pearson’s chi-square tests of independence 
and Kruskal-Wallis tests were performed to test for association between CIT and mortality, 
graft failure. Cox proportional hazard analyses, adjusting for donor factors (age, gender, 
serum creatinine, cause of death), recipient factors (age, dialysis duration, PRA status, HLA 
mismatch), machine perfusion, and specified effect measure modifiers, were performed to 
estimate the hazard of either event occurring given CIT.
Results: 60.7% of our cohort was male, and 31.4% were black. Mean age was 52.2±13.0 
years and average CIT was 18.2±9.2 hours. By univariate analysis, CIT was associated with 
an increase in risk of both death-censored graft failure and mortality (both HRs=1.006; 
p<0.0001). Adjusting for covariates and effect measure modifiers, the relationship between 
CIT and recipient mortality risk and death-censored graft failure were both attenuated 
(HR=1.000; p=0.9692 and HR=0.997; p=0.7479, respectively) suggesting that each 
additional hour of CIT did not significantly increase the risk of graft failure or death.
Conclusions: Our results suggest that increases in CIT do not adversely impact patient 
and allograft outcomes following DDKT and should not be used to decline organ offers.
SA-PO949
Impact of Hypothermic Machine Perfusion on Outcomes following Kidney 
Transplantation  Prativa Baral, Mariana C. Chiles, Douglas F. Arbetter, Russell 
J. Crew, Geoffrey K. Dube, Heather K. Morris, Hilda E. Fernandez, David J. 
Cohen, Sumit Mohan.  Columbia Univ.
Background: Patient and allograft outcomes following deceased donor kidney 
transplantation (DDKT) are thought to be influenced by the intrinsic quality of the organ at 
procurement and any superimposed subsequent injury that occurs during cold preservation 
(CP). Hypothermic machine perfusion (HMP) is used in an attempt to decrease injury 
from CP especially for organs that have extended periods of cold ischemia. We analyzed 
the impact of complete, partial or no HMP use during CP on patient and graft survival 
following DDKT.
Methods: We identified 75,660 first-time adult renal transplant recipients, who received 
a DD kidney from 2000-2011 in SRTR. Pearson’s chi-square tests of independence and 
Kruskal-Wallis tests were performed to test for association between HMP and mortality, 
graft failure, and delayed graft function (DGF). Cox analyses, adjusting for donor factors 
(age, gender, creatinine, cause of death), recipient factors (age, dialysis duration, PRA, HLA 
mismatch), CP time, and specified effect measure modifiers, were performed to estimate 
the hazard of either graft failure, or DGF occurring given HMP.
Results: On unadjusted analyses, compared to no HMP use, kidneys that received HMP 
for some or all of their CP time were less likely to experience DGF (OR=0.82, p=<.0001 & 
OR=0.77, p=<.0001) but more likely to experience allograft failure (HR=1.19, p=<.0001 & 
HR=1.20, p=<.0001, figure 1). On multivariable analyses, the use of HMP was associated 
with a lower incidence of DGF (OR=0.70, p=<.0001 & OR=0.59, p=<.0001) but continued 
to be associated with a higher risk of allograft failure even after adjusting for CIT and the 
lower DGF (HR=1.11, p= 0.023 & HR=1.26, p=0.002).
Conclusions: HMP improves short term outcomes by lowering rates of DGF but is 
associated with reduced long-term allograft survival.
SA-PO950
The Impact of Remote Ischaemic Preconditioning (RIPC) on the 
Inflammatory Response following Live Donor Kidney Transplantation 
Kristin Vibeke Veighey,1 Madhur P. Motwani,2 Jennifer Nicholas,3 Raymond 
Macallister.2  1Wessex Kidney Unit, Portsmouth Hospitals NHS Trust, United 
Kingdom; 2UCL Centre for Clinical Pharmacology & Therapeutics, Univ 
College London, United Kingdom; 3Clinical Trials Unit, London School of 
Hygiene and Tropical Medicine, United Kingdom.
Background: Ischaemia reperfusion (IR) injury at transplantation contributes to organ 
damage that limits allograft longevity. Animal studies have demonstrated a reduction in 
circulating proinflammatory cytokines following RIPC, which may contribute to tissue 
protective effects. REPAIR demonstrated a trend towards improved live donor kidney 
function following RIPC. We investigated the effects of RIPC on serum and urinary 
cytokines in this study.
Methods: 406 adult live donor/recipient pairs were recruited. Pairs were randomised 
using a factorial design to either: sham RIPC, early RIPC (immediately pre-surgery), 
late RIPC (24 hours pre-surgery) or dual RIPC. Donor and recipient received the same 
interventions (active or sham RIPC). Serum from donor and recipient and urine from 
recipients was analysed at baseline and on day 2 for pro-inflammatory cytokines IL-1ß, 
IL-6, IFN-γ and TNFα, using multiplex ELISA. All analyses were conducted using linear 
regression adjusted for baseline (pre-treatment) values of the cytokine and indicator variables 
for early and late treatment group. Cytokine values were log transformed before analysis 
to account for skewed distribution.
Results: There was no difference in the expression of serum cytokines in donor serum 
or recipient serum and urine between baseline pre-surgery and day 2 post surgery. 
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From top: TNFα, IL-1ß, IL-6, IFN-γ; graph on left = early RIPC, right = late RIPC.
Conclusions: In this large randomised trial, there was no evidence that RIPC attenuated 
the inflammatory response to transplant surgery in blood or urine.
SA-PO951
Remote Ischaemic Preconditioning (RIPC) Provides a Sustained 
Improvement in eGFR following Live Donor Kidney Transplantation: 
Four Year Follow-Up in the REPAIR Study  Kristin Vibeke Veighey,1 Jennifer 
Nicholas,2 Steven Robertson,2 Raymond Macallister.3  1Wessex Kidney Unit, 
Portsmouth Hospitals NHS Trust, United Kingdom; 2Clinical Trials Unit, London 
School of Hygiene and Tropical Medicine, United Kingdom; 3UCL Centre for 
Clinical Pharmacology & Therapeutics, Univ College London, United Kingdom.
Background: Ischaemia reperfusion (IR) injury sustained at transplantation contributes 
to organ damage that limits allograft longevity. The REnal Protection Against Ischaemic 
Reperfusion in transplantation (REPAIR) study demonstrated a weak effect of early RIPC 
on the primary outcome iohexol glomerular filtration rate (GFR) at 1 year (adjusted mean 
difference 3.08 ml/min/1.73m2; 95% CI -0·89 to 7.04; p=0.13), but stronger evidence of 
an effect on eGFR at 1 year (difference 4.98; 95% CI 1.13 to 8.29; p=0.011),reflecting a 
potentially clinically important improvement of kidney function. There was no evidence 
that late RIPC alone had any benefit at 1 year. RIPC was safe and well tolerated. We used 
data from up to 4 years follow-up to examine the medium term effects of early and late 
RIPC on eGFR.
Methods: 406 adult live donor/recipient pairs were recruited and randomised using 
a factorial design to either: sham RIPC, early RIPC (immediately pre-surgery), late RIPC 
(24 hours pre-surgery) or dual RIPC (early and late RIPC). Donor and recipient received 
the same interventions (active or sham RIPC). The primary outcome was iohexol GFR at 
12 months. eGFR up to 5 years post transplantation was an important secondary outcome.
Results: Provisional analysis of eGFR data up to 48 months suggested a sustained 
benefit of early RIPC and possible emergence of benefit of late RIPC. The mean (SD) 
55.8 (23.0) in control vs 57.4 (20.4) in early RIPC at 2 years; 51.7 (18.6) vs 57.7 (21.3) at 
3 years; and 51.8 (19.8) vs 60.5 (24.3) at 4 years. The mean (SD) in control vs late RIPC 
were 55.8 (20.4) vs 57.4 (22.9) at 2 years; 52.8 (19.8) vs 56.8 (20.5) at 3 years; and 52.4 
(21.7) vs 59.7 (22.8) at 4 years.
Conclusions: The benefit of early RIPC on eGFR that was demonstrated at 1 year 
appears to be sustained during medium-term follow up, reflecting a potentially clinically 
important improvement of kidney function.
SA-PO952
Low Expression of the Messenger RNA TLRs 2-4,9 from Peripheral Blood 
Mononuclear Cells of the Kidney Recipients May Indicate Previous Delayed 
Graft Function  Slawomir C. Zmonarski, Katarzyna Madziarska, Miroslaw 
Banasik, Maria Magott, Marian Klinger.  Nephrology and Transplantation Med., 
Medical Univ, Wroclaw, Poland.
Background: The Toll-like receptors (TLR) 2-4,9 are engaged in the pathogenesis of 
acute renal injury. Earlier studies demonstrated that 24 hrs. after transplantation (KT), the 
expression of the messenger RNA (mRNA) TLR4 of peripheral blood mononuclear cells 
(PBMC) from patients (pts) with delayed graft function (DGF+) was lower than in recipients 
of kidneys without DGF (DGF-). The aim of study was to examine whether the reduced 
expression of TLR2-4,9 mRNA is a more permanent phenomenon associated with DGF.
Methods: Each of the 151 KT pts was more than 1 month after KT (from 1 to 128 
months). Within this group: in 117 pts blood sample was taken for more than 3 months after 
KT, 45 pts experienced DGF, 13 DGF+ pts was HBcAb positive (DGF+HBc+). Control 
group (Con.) included 38 healthy volunteers. TLR2-4,9 mRNA expression (expr.) from 
PBMC was assessed by polymerase chain reaction (real-time PCR) and analyzed in terms 
of DGF and clinical course.
Results: KT DGF+ pts had generally lower TLR2-4,9 mRNA expr. than KT DGF- pts 
(TLR2: p=0,06; TLR3; p= 0,021; TLR4: p=0,07; TLR4 > 3 month after KT: p=0,032; TLR 
9 ,p= 0,027). TLR3 mRNA of DGF+HBc+ pts was: lower (p=0,046) than DGF+HBc, lower 
(p=0,013) than DGF-ATN- and lower (p=0,008) than Con. TLR9 mRNA of DGF+HBc+ 
was lower (p=0,0002) than Con. In multiple regression analysis low expr. of TLR mRNA 
2-4,9 was associated with the occurrence of DGF in the past.
Conclusions: Lower than typical expression of TLR 2-4,9 mRNA seems to be a 
permanent feature of peripheral blood mononuclear cells of the recipient of the transplanted 
kidney who experienced delayed graft function. Hepatitis B seems may be associated with 
additional decline of TLR3 and TLR9 mRNA expression. TLR3,4,9 mRNA expression could 
potentially be used as an indicator of the likelihood of delayed graft function.
Funding: Clinical Revenue Support
SA-PO953
BB3, a Hepatocyte Growth Factor-Like Small Molecule, Improves 
Outcome in Kidney Transplant Recipients with Delayed Graft Function 
Jonathan Bromberg,1 Matthew R. Weir,2 A. Osama Gaber,3 Matthew Cooper,4 
Mark Laftavi,5 Barry Browne,6 Bo Zhang,7 Prakash Narayan,7 Michael A. 
Yamin,7 Itzhak D. Goldberg,7 Weizhong Cai.7  1Div of Transplant Surgery, 
Univ of Maryland School of Medicine, Baltimore, MD; 2Div of Nephrology, 
Univ of Maryland School of Medicine, Baltimore, MD; 3The Methodist 
Hospital, Houston, TX; 4MedStar Georgetown Univ Hospital, Washington, DC; 
5Transplant Center at Erie County Medical Center, Buffalo, NY; 6BNMG, San 
Diego, CA; 7Angion Biomedica Corp, Uniondale, NY.
Background: Duration of delayed graft function (DGF) portends poor short- and long-
term renal function and graft survival. We studied the safety and efficacy of BB3, a small 
molecule with HGF-like activities, dosed starting 24 hr post-transplant (Tx) in patients 
with reduced urine output (UO) in a double-blind Phase 2 study.
Methods: Patients producing <50 cc urine/hr over 6-8 h post-Tx were randomized 
(2:1) to BB3 (2 mg/kg IV QD X 3 d) or placebo (PBO). An interim analysis was performed 
on 12 BB3- and 7 PBO-treated patients.
Results: BB3 was safe and well-tolerated. BB3 reduced the median time to produce 
1.2L UO/24 hr from > 28 d to 7.5 d, increased the % of patients reaching this UO within 
28 d from 43% to 83%, increased cumulative UO (figure), decreased median duration of 
dialysis (figure), decreased % on-dialysis days during Days 7-28 (14.2% to 7.1%) and 
during Days 14-28 (10.9% to 3.6%), reduced median SCr, reduced BUN, and shortened 
median hospital stay (7 d to 5.5 d). BB3 reduced serum CRP and NGAL. 
Conclusions: BB3 administered ~24 hours post-Tx significantly reduced severity of 
DGF in patients presenting with reduced UO. Confirmation of these results in a Phase 3 
trial may translate to improved long-term outcome, decreased Tx costs, increased use of 
marginal organs, and a shorter waitlist.
Funding: NIDDK Support, Pharmaceutical Company Support - Angion Biomedica 
Corp.
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SA-PO954
DSA Monitoring and Treatment in Kidney Transplant Recipients 
Monica Grafals,1 Alexander Gilbert,1 Olga A. Timofeeva.2  1Medstar Georgetown 
Transplant Inst, Georgetown Univ, Washington, DC; 2Histocompatibility 
Laboratory, Georgetown Univ, Washington, DC.
Background: The development of DSA monitoring is a new technique to detect 
antibodies in kidney transplant recipients. We previously showed that patients that developed 
de novo DSA (dnDSA) suffer a 35% graft loss. Because of this we have developed a protocol 
for treating patients that have developed dnDSA post kidney transplant.
Methods: Since the implementation of this treatment protocol on September 12, 
2014, there have been 9 patients that have developed dnDSA after renal transplantation. 
Results: Four of the patients that developed dnDSA were in the low risk category and 
in 3 of them the DSA has cleared. The 4th patient has a DSA against DP1 with an MFI of 
1587 that has remained stable. All of these patients have a GFR>45 cc/min. Three patients 
were in the intermediate risk category. One of them has a creatinine of 3, BK viremia and 
he has a DSA against A1 with an MFI of 3150 which has been stable. Another patient in 
this group developed CMV viremia and his DSA became negative after treatment. The 
third patient just received treatment for DSA this past month and follow up DSA is not 
available at this time. Two patients were in the high risk category and both of them received 
treatment and their GFRs are >45 cc/min and their DSAs have become undetectable and 
weak respectively.
Conclusions: Since the development of dnDSA post kidney transplant is associated 
with worse graft outcomes, implementation of treatment protocols is necessary for kidney 
transplant patients. This preliminary data shows that treatment for dnDSA with this protocol 
seems to succesfully treat the antibodies.
SA-PO955
On the Patterns of Early De Novo DSA Development in Kidney 
Transplant Recipients in the First 6 Months After Alemtuzumab Induction 
Chelsea Estrada, Yezina T Nigatu, Heesuck Suh, Frank Darras, Mersema Abate, 
Edward P. Nord.  Nephrology and Transplantation, Stony Brook Medicine, 
New York.
Background: The presence of de novo DSA (dnDSA) is associated with antibody 
mediated rejection and suboptimal graft outcomes. The incidence of dnDSA post renal 
transplant varies according to immunosuppression protocols, screening, and detection 
methods, and ranges from 5-25%. A higher incidence of dnDSA after alemtuzumab (AL) 
has been observed. We sought to characterize the expression of early dnDSA development 
after AL induction in renal transplant recipients.
Methods: Consecutive kidney transplant recipients were screened for dnDSA 
from 7/1/2014 to 4/30/2015. DnDSA was detected by single antigen beads and luminex 
technology at months 1, 2, 3 and 6. Mean Fluorescent Intensity (mfi) > 500 was considered 
positive. Induction consisted of AL with rapid steroid withdrawal, and maintenance 
immunosuppression was with tacrolimus and mycophenolate mofetil.
Results: A total of 47 renal transplants, 13 from living donors and 34 from deceased, 
were performed from 7/1/14 to 4/30/15 and followed for 5.1 +/- 2.9 months (range 1-9). 
Of these, 17 developed dnDSA (36.2%) in the first 6 months; 7 class I, 7 class II and 3 
both. Class I was detected at months 1 (6), 2 (2), 3(1) and 6 (1). Class II was detected at 
months 1 (3), 2 (3), 3(2) and 6 (2). Median class I mfi was 1,081 (range 535- 2,787), and 
class II was 2,299 (range 502- 11,301). In 9/17 (52.9%) patients (5 class I and 4 class II) 
with peak mfi < 2,500, dnDSA resolved (5) or decreased (4) without intervention. Four 
patients with class II dnDSA found at month 6 (2) and month 2 (2) with peak mfi 2,600 - 
11,000, were treated with plasmapheresis, IVIG, and rituximab, preemptively. Of these, 
2 dnDSA resolved, 1 remained high but creatinine is stable and 1 had worsening renal 
function but no evidence of AMR on biopsy. Five patients with rising dnDSA, and stable 
creatinine are being followed.
Conclusions: In this cohort, dnDSA developed in 36.2% of recipients, with the majority 
developing in months 1 and 2 (76.5%). Despite the high rate of dnDSA detection, most 
resolved or decreased without change in immunosuppression or early deleterious effects 
to graft function.
SA-PO956
Low Level Class I or II Donor HLA-specific Antibodies Do Not Correlate 
with the Concurrent Presence of Antibody Mediated Injury on Biopsy 
Chelsea Estrada, Catherine Miranda, Heesuck Suh, Frank Darras, Edward P. 
Nord, Mersema Abate.  Nephrology and Transplantation, Stony Brook Medicine, 
New York.
Background: Pre-transplant and de novo donor HLA-specific antibodies (DSA) 
have been identified as risk factors for adverse outcomes in renal transplantation, causing 
antibody-mediated graft injury and acute antibody mediated rejection (ABMR) and 
transplant glomerulopathy (TG). With improved detection techniques, DSA recognition 
is increasing but there is no consensus on the definition of DSA positivity. While low level 
pre-transplant DSA has been associated with the future occurrence of ABMR, low level 
DSA on the day of indication biopsy is of unclear significance.
Methods: All sera were tested for DSA using single antigen beads with Luminex 
technology on the day of indication renal transplant biopsy from 7/1/2015- 5/21/2015. 
DSA level <500 mfi were considered negative, between 500-1500 mfi low level and 
>1500 mfi high level. Acute ABMR and TG histology met Banff 2013 criteria. In this 
cohort, induction was with alemtuzumab and rapid steroid withdrawal, and maintenance 
immunosuppression was with tacrolimus and mycophenolate mofetil. Chi square analysis 
was used to assess the association between low and high levels of DSA and biopsy findings 
of antibody mediated injury.
Results: Fifty-three consecutive indication kidney transplant biopsies were performed 
from 7/1/2014- 5/21/2015. Of these 12 had evidence of ABMR (2 acute, 8 TG and 2 both). 
Six of the 8 patients with TG alone did not have DSA. At the time of biopsy, 12 class I (6 
low and 6 high level) and 13 class II (3 low and 10 high level) were detected. 
DSA AMR/TG n=12 (%)
No AMR/TG
n=41(5) P value
Class I Low 1(8) 5(12) 0.97
Class I High 3(25) 3(7) 0.09
Class II Low 0(0) 3(7) 0.51
Class II High 5(42) 5(12) 0.02
None 7(58) 34(83) 0.05
Conclusions: 1. The presence of high level class II DSA was significantly associated 
with the concurrent biopsy finding of antibody medicated injury. 2. Of greater significance, 
the presence of class I DSA or low level class II DSA did not correlate with pathologic 
findings.
SA-PO957
Characteristics of Kidney Transplant Candidates with and without Antibody 
against Angiotensin II Type 1 Receptor (AT1R-Ab)  Mary Carmelle Philogene,1 
S.M. Bagnasco,2 Annette M. Jackson,1 Mary S. Leffell,1 Andrea A. Zachary.1 
1Medicine, Johns Hopkins Univ, Baltimore, MD; 2Pathology, Johns Hopkins 
Univ, Baltimore, MD.
Background: In this study we sought to determine whether baseline characteristics 
of kidney transplant candidates when correlated with presence of AT1R-Ab are predictive 
of transplant outcomes.
Methods: 122 renal transplant recipients were tested for presence of AT1R-Ab using 
quantitative ELISA (CellTrend GmbH, Germany). Patient demographics were obtained 
from the hospital electronic record under an approved IRB.
Results: Patients were categorized according to AT1R-Ab levels: positive >17 Units/
ml (30%); borderline 10-17 Units/mL (34%), negative <10 Units/mL (36%). There were 
fewer females (31% versus 61%, 55%) and African Americans (14% versus 24%, 16%) 
in the AT1R-Ab >17 Units/ml group compared to the other two groups. The presence of 
AT1R-Ab has been associated with development of inflammation and fibrosis; therefore, we 
examined AT1R-Ab among patients categorized by the following diseases: IgA nephropathy, 
glomerulosclerosis, lupus nephritis, FSGS, and membranoproliferative glomerulonephritis. 
We found no correlation between these diseases and AT1R-Ab levels (38%, 29% and 
30%, respectively; p=0.7). We also found no association with diagnosis of hypertension 
and AT1R-Ab levels (16%, 17%, 18%). The most significant difference between the three 
groups was a higher percentage of positive patients among those who received more than 
one kidney transplant (78%, 22%, 45%; p= 0.001). Post transplantation, sixty-one patients 
were biopsied to investigate graft dysfunction. There were more patients in the borderline 
and positive AT1R-Ab groups who were evaluated for graft dysfunction compared to the 
negative group (65%, 54% versus 34%) although this did not reach statistical significance. 
Importantly, the AT1R-Ab positive and borderline groups had fewer HLA antibody positive 
patients compared to the AT1R-Ab negative group (54%,50%, 87%; p<0.001).
Conclusions: The only pre-transplant characteristic linked to presence of AT1R-Ab 
in patients who are being evaluated for kidney transplantation is the incidence of previous 
transplant.
Funding: Clinical Revenue Support
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SA-PO958
Effect of B-Cell Activating Factor (BAFF) Inhibition (LY2127399; 
Tabalumab) on Highly Sensitized Patients with End Stage Renal Disease 
awaiting Transplantation  Muhammad Ahmad Mujtaba,1 Wendy Komocsar,3 
Milagros D. Samaniego-Picota,4 Eric Nantz,3 Jayne Hague,3 Melissa D. 
Anderson,2 Benita K. Book,2 Nancy G. Higgins,2 Tim E. Taber.2  1Nephrology, 
Univ of Texas Medical Branch, Galveston, TX; 2Transplant Nephrology, Indiana 
Univ School of Medicine, Indianapolis, IN; 3Bio-Medicines, Eli Lilly and 
Company, Indianapolis, IN; 4Nephrology, Univ of Michigan Health System, 
Ann Arbor, MI.
Background: B cell activation factor (BAFF) is critical in B-cellmaturation. 
Inhibitionof BAFF represents an appealing target for desensitization of highly sensitized 
end stage kidney disease patients.
Methods: We conducted a Phase 2a, single-arm, open-label exploratory study 
investigating the effect of tabalumab (BAFF inhibitor) in ESRD patients with cPRAs 
>50%. The treatment period had a total duration of 24 weeks. Eighteen patients received 
tabalumab, at a dose of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg SC at 
4-week intervals for 5 more months. Patients were then followed for an additional 52 weeks. 
Blood samples were analyzed for HLA antibodies, BAFF levels, serum immunoglobulins, 
T and B cell subsets at specified time intervals during the treatment and follow-up periods. 
Pre and post treatment tonsil and bone marrow biopsies were also performed.
Results: Significant reductions in cPRAs were observed at week 16(p=0.043) and at 
week 36(p=0.004), however the absolute reductions were small (<5%). Overall factor effect 
at week 76 compared to baseline was significant (p=0.04). Mean BAFF levels increased 
during treatment, reflecting binding to tabalumab and decreased in the follow-up period 
remaining slightly above baseline at week 76. Expected changes in B cell subsets and 
reductions in immunoglobulins were observed. Two tabalumab-related serious adverse 
events occurred (pneumonia and worsening of peripheral neuropathy) while the most 
common other adverse events were injection-site pain and hypotension. Three patients 
received a matched donor cadaveric transplant during the study follow up.
Conclusions: BAFF inhibition resulted in statistically significant,but not clinically 
meaningful reduction in the cPRA from baseline.
Funding: Pharmaceutical Company Support - Eli Lilly
SA-PO959
Behavior and Impact of Donor-Specific Antibodies Before and After Kidney 
Transplant  Araminta Guichard-Romero, Lluvia A. Marino-vazquez, Mayra 
Lopez, Natalia Castelan, Adrian De santiago, Norma O. Uribe-uribe, Josefina 
Alberú, Luis E. Morales-Buenrostro.  
Background: Pre- and post-transplant DSA increases the risk for acute rejection, 
humoral rejection and graft loss. Every year a 5% of patients will develop DSA but 
other patients turn negative. It is unclear how the behavior of pre-transplant DSA under 
immunosuppression and their clinical impact is. This study evaluate the relationship between 
de novo DSA and the outcome of kidney transplantation, and whether the development of 
these antibodies is related to pre-transplant DSA status.
Methods: Prospective cohort study. From Jan/2004-Dec/2014 a total of 519 kidney 
transplant were performed. For analysis we include 412 with DSA determination plus 
negative Flow-Crossmatch (in DSA-positive cases). We classified the patients in 7 groups 
according to pre-/post-transplant DSA: 1)Neg/Neg (n=130) 2)Neg/De Novo (n=81) 3)Neg/
De Novo-Variable (multiple changes in DSA, n=32) 4)Pos/Pos (same DSA, n=12) 5)Pos/
De Novo (n=12) 6)Pos/Neg (n=8) 7)Without DSA post-transplant measure (n=137). The 
outcomes analyzed were graft and patient survival, acute rejection (AR), humoral rejection 
(AMR), and graft function by MDRD.
Results: From 412 patients, 58 patients (14.1%) had pre-transplant DSA. Patients with 
Pos/Pos or Pos/De Novo DSA had higher and earlier AR and AMR rate, followed by Neg/De 
Novo-Variable and Neg/De Novo, as you can see in the figure A) and B) respectively. For 
graft loss only those with Pos/De Novo was higher than Neg/Neg (Figure C). Interestingly, 
those who are Pos/Neg had similar outcomes than Neg/Neg.
Conclusions: Staying with the same DSA or developing De Novo-DSA after 
transplantation, regardless what the pretransplant condition was, were associated with 
development of AR, AMR, and graft loss.
SA-PO960
Course of Anti-HLA Antibodies After Induction Therapy with Rituximab 
in Renal Transplantation  Luuk Hilbrands,1 Wil Allebes,2 Martijn W.f. Van 
den hoogen,3 Irma Joosten,2 Marije C. Baas.1  1Nephrology, Radboud Univ 
Medical Center, Nijmegen, Netherlands; 2Laboratory Medicine, Radboud Univ 
Medical Center, Nijmegen, Netherlands; 3Nephrology, Erasmus Medical Center, 
Rotterdam, Netherlands.
Background: B-cell depletion protocols have shown to reduce donor-specific 
antibodies against HLA (DSA) and chronic antibody mediated rejection. We aimed to study 
the effects of rituximab as a single-agent induction therapy on the titers of pre-existent 
or de novo DSA and non-DSA after renal transplantation and relate this to rejection free 
and overall graft survival.
Methods: We collected sera in participants of a prospective double-blind randomized 
study on the efficacy and safety of the prophylactic use of one dose of rituximab, added 
to standard immunosuppressive treatment (prednisolone, tacrolimus and mycophenolate 
mofetil) in comparison with standard immunosuppressive treatment alone in renal 
transplantation (www.clinicaltrials.gov, NCT00565331).
Results: 280 patients were included (142 received placebo, 138 rituximab). Anti-HLA 
antibodies (Ab) were determined in serum taken pre-transplant and 12 and 24 months after 
transplantation. Serum was analysed pre-transplant and at 12 months from 126 placebo and 
119 rituximab treated patients. Pre-existent anti- HLA Ab were present in 24/126 (19.0%) 
patients in the placebo group and in 20/119 (16.8%) patients in the rituximab group (P<0.05). 
In the placebo and rituximab treated patients HLA class I Ab disappeared in 55.6% and 
50% and HLA class II Ab in 23.5% and 57%, respectively (P=0.06). At 12 months, 11 
(8.7%) placebo treated patients and 4 (3.4%) ritixumab treated patients (NS) developed de 
novo HLA Ab. 10/245 (4.1%) had de novo HLA class I Ab: 6 (4.8%) and 4 (3.4%) in the 
placebo and rituximab treated patients, respectively (NS). 12/245 (4.9%) had de novo HLA 
class II Ab: 9 (7.1%) in the placebo group and 3 (2.5%) in the rituximab group (P=0.09).
Conclusions: Induction therapy with rituximab compared to placebo does not 
significantly influence the course of anti-HLA Ab at 12 months, however it possibly 
decreases the levels of pre-existent class II anti-HLA Ab and inhibits the formation of de 
novo class II anti-HLA Ab.
Funding: Pharmaceutical Company Support - Roche, Astellas
SA-PO961
Benefit of Desensitization with Rituximab from the Viewpoint of Anti-A/B 
Antibody Titer and Pathological Findings in ABO-Incompatible Kidney 
Transplantation  Kazuhide Saito, Shiro Takahara, Norio Yoshimura, Atsushi 
Aikawa, Shohei Fuchinoue, Takashi Yagisawa, Kazunari Tanabe, Yoshihiko 
Watarai, Motohide Shimazu, Kunio Morozumi, Kota Takahashi.  Japan ABO-
incompatible Transplantation Committee, Japan.
Background: We conducted a multicenter prospective clinical study in ABO-
incompatible kidney transplantation (ABOi-KT) without splenectomy (UMIN000006635). 
To evaluate the benefit of desensitization with rituximab (R), we investigated the data 
of this study from the time course change of anti-A/B antibody (ab) titer and sequential 
pathological findings.
Methods: Desensitization protocol included low dose MMF and steroid started 28 
days before and CNI started a few days before surgery. R 375 mg/m2 was administered at 
day -14 and day -1. Minimum 2 sessions of plasma exchange were done for anti-A/B ab 
removal before transplant, and basiliximab was administered on day 0 and day 4. Anti-A/B 
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ab titer and eGFR were sequentially evaluated, 0 hr, 1 hr and protocol biopsies (4 weeks 
after transplant) were also sequentially performed as possible. Pathological specimens were 
centrally diagnosed by 3 pathologists.
Results: 18 pts received ABOi-KT. One-year pts and grafts survival were both 100%. 
The desensitization with R was well tolerated. Average anti-A/B ab (IgG) titer at baseline 
was 48.15x and decreased to 19.72x immediately before surgery, maintaining until the end 
of the study. In pts whose sequential pathological specimen available showed positive C4d 
deposition in 1/13 at 1 hr and 11/16(69%) at protocol biopsy. No pts developed AMR related 
to anti-A/B abs except for one who experienced AMR with anti-HLA ab (Banff 07 type II). 
Her anti-A/B ab titers were slightly higher than the others (4x-32x). Pathological findings 
included arteriosclerosis in 8, nephrocalcinosis in 1, IF/TA (grade 1) in 1 and suspicious 
CNI acute nephrotoxicity in 1. Two pts showed C4d+ without other pathological signs.
Conclusions: In this series, anti-A/B ab titers were successfully decreased and no AMR 
occurred other than 1 caused by anti-HLA ab, whereas C4d deposition was detected in 69% 
of pts by protocol biopsy. Our desensitization protocol was confirmed both pathologically 
and clinically safe and effective for ABOi-KT.
Funding: Pharmaceutical Company Support - Zen-Yaku Kogyo Pharmaceutical 
Co.Ltd.
SA-PO962
Post-Transplant BAFF Levels Do Not Predict the Development of Anti-HLA 
Antibody in Kidney Transplant Recipients  Ji Won Min,2 Bum Soon Choi,1,2 
Cheol Whee Park,1,2 Chul Woo Yang,1,2 Yong-Soo Kim,1,2 Byung Ha Chung.1,2 
1Transplant Research Center, Seoul St. Mary’s Hospital, College of Medicine, 
The Catholic Univ of Korea, Seoul, Korea; 2Div of Nephrology, Dept of Internal 
Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic Univ 
of Korea, Seoul, Korea.
Background: It is well known that pre-transplant B cell activating factor (BAFF) 
levels are associated with the development of de novo anti-HLA antibodies and also 
antibody mediated rejection post-transplant. However, the clinical significance of BAFF 
values at allograft rejection has not been determined. In this study, we investigated the 
clinical significance of pre and post-transplant BAFF levels measured when indication 
biopsy was done.
Methods: In 130 kidney transplant (KT) recipients who required allograft biopsy due 
to an increase in serum creatinine, we checked for anti-HLA antibodies using Luminex 
single antigen assay, and measured BAFF levels using ELISA kits. In 78 of these patients 
we also measured pre-transplant BAFF and anti-HLA antibody levels. We investigated 
the relationship between pre-transplant, post-transplant and delta BAFF levels and the 
occurrence of anti-HLA antibodies.
Results: Pre-transplant BAFF levels showed significant association with pre-transplant 
sensitization, represented by positive PRA, high PRA , and presence of HLA-DSA. They 
also showed positive association with early rejection (rejection within 6 months from KT). 
Post-transplant BAFF levels showed significant association with pre-transplant sensitization, 
but did not show association with anti-HLA antibodies and positive donor-specific antibodies 
at the time of biopsy. We did not find any association between post-transplant BAFF levels 
and cumulative allograft survival, allograft biopsy results, Banff scores and microvascular 
inflammation scores.
Conclusions: In conclusion, pre-transplant BAFF levels are associated with pre-
transplant sensitization and are useful in predicting allograft rejection. But post-transplant 
BAFF levels measured at the time of indicated biopsy are not associated with the appearance 
of de novo HLA-DSA, allograft rejection, biopsy findings and other allograft outcomes.
SA-PO963
Effectiveness of Bortezomib (BT) in the Treatment of Antibody Mediated 
Rejection (AMR) Among Pediatric Kidney Transplant Recipients (pKTx) 
Sarah J. Kizilbash,1 Donna J. Claes,2 Isa Ashoor,3 Ashton Chen,4 Sara E. 
Jandeska,5 Raed Bou Matar,6 Jason Misurac,7 Katherine Twombley,8 Priya 
Verghese.1  1Pediatric Nephrology, Univ of Minnesota; 2Cincinnati Children’s 
Hospital; 3Children’s Hospital New Orleans; 4Wake Forest Univ; 5Rush Univ; 
6Cleveland Clinic; 7Indiana Univ; 8Medical Univ of South Carolina.
Background: AMR has a poor prognosis despite a number of therapeutic options.  BT 
is increasingly being utilized in adults but there are limited data on its safety and efficacy 
in pKTx with AMR.
Methods: Multicenter retrospective case series including all pKTx who received 
BT for biopsy proven AMR, from 2008-2015, at 8 centers within Midwest Pediatric 
Nephrology Consortium.
Results: Twenty-four pKTx from 8 centers were treated with BT for AMR. In addition 
to BT, 75% were treated with rituximab, 79.2% with plasmapheresis and 91.7% with IVIG. 
62.5% were males, 45.8% were white, and 41.7% were African American. Two-thirds were 
deceased donor recipients, and mean age at transplant was 11.1 years (SD 5.19). Obstructive 
uropathy and dysplasia comprised 50% of the underlying diseases. At the time of transplant, 
82.2% of patients had 0.0% panel reactive antibodies. Mean estimated GFR (eGFR) prior 
to AMR was 49.6 (SD 12.1). Prevalence of donor specific antibodies (DSA) and changes 
in eGFR are shown in table 1. 
Class 1 DSA Class 2 DSA Mean eGFR (ml/min/1.73m2)
Initiation of BT 66.7% 91.7% 40.1
3 months after BT 40.0% 75.0% 37.8
6 months after BT 27.8% 76.5% 36.7
Side effects were documented in 54% of patients and most commonly included 
leukopenia, anemia, and hypertension. Less frequent side effects included hepatitis, 
headaches, vomiting, and rashes. Mean time to follow up after BT was 1.3 years (SD 
0.96). At the end of follow up, patient survival was 100% and 17/24 patients (70.8%) had 
functioning grafts.
Conclusions: BT was used to treat AMR in pKTx without life-threatening side effects. 
The 6-month patient and graft survival were excellent. The efficacy and safety of bortezomib 
for pKTx AMR should be evaluated in randomized clinical trials.
SA-PO964
Immunoadsorbtion Is Efficient in the Treatment of Late Antibody Mediated 
Rejection  Yasar Caliskan,1 Yasemin Ozluk,2 Halil Yazici,1 Aydin Turkmen,1 
Alaattin Yildiz,1 Mehmet S. Sever.1  1Div of Nephrology, Dept of Internal 
Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey; 2Dept of Pathology, 
Istanbul Faculty of Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey.
Background: Plasmapheresis (PP) with IVIG, was proposed as a useful treatment for 
antibody mediated rejection (ABMR). As an alternative to plasma exchange (PE), double 
filtration plasmapheresis (DFPP) and immunoadsorption (IA) represent an attractive 
strategy for antibody depletion. We investigated whether PE or DFPP or IA is effective in 
the treatment of late ABMR.
Methods: 40 renal tx recipients diagnosed as biopsy confirmed ABMR at a mean time 
of 70±40 months after tx were included. Patients were randomly assigned to PE (n=16) 
or DFPP (n=19) or IA with protein A (n=5). The study groups were similar regarding age, 
gender, donor type, eGFR at randomization and post-tx follow-up time. Donor specific 
antibody (DSA) was positive in 62.5% of PE, 73.6% of DPFF and 100% of IA groups 
(p=0.25), and C4d was positive in 75%, 68% and 60% (p=0.79), respectively. All patients 
received 2 g/kg IVIG and Rituximab 375 mg/m2.
Results: Tubulointerstitial scarring (ci+ct) (p=0.81), microcirculation inflammation 
(g+ptc) (p=0.38) and transplant glomerulopathy (cg) (p=0.21) scores were similar. However, 
the mean total inflammation (ti) score of IA group (2.60±0.55) was significantly higher 
than PE (1.69±0.70) and DFPP (1.79±0.71). The rates of graft loss were as follows; PE; 
13/16 (81.3%), DFPP; 10/19 (52.6%) and IA; 1/5 (25%) (p=0.03). The graft survival was 
significantly higher for IA than PE (p=0.01). There was a tendency of better graft survival 
in DFPP compared to PE group (p=0.07). Kaplan-Meier survival analysis revealed better 
overall survival for IA than for PE and DFPP (p=0.03).
Conclusions: Even though limited by small patient numbers, this trial suggests 
efficiency of IA in the treatment of late ABMR.
SA-PO965
Pre-Transplant Phospholipase A2 Receptor Autoantibody Concentration 
Is Associated with Recurrence of Membranous Nephropathy Post-Kidney 
Transplantation  Hasan Fattah,1 Gaurav Gupta,1 Dhiren Kumar,1 Luis F. 
Quintana,2 Anne L. King,1 Rivka Ayalon,3 Laurence H. Beck.3  1Nephrology, 
Virginia Commonwealth Univ, Richmond, VA; 2Nephrology, Hospital Clínic de 
Barcelona, Barcelona, Spain; 3Nephrology, Boston Univ, Boston, MA.
Background: Idiopathic membranous nephropathy (iMN) has been associated with 
anti-phospholipase A2 receptor autoantibody (PLA2R-Ab) both in the native kidneys as 
well as in the setting of recurrence (rMN) post-kidney transplant (txp). Previous studies that 
have assessed pre-txp PLA2R-Ab for the prediction of rMN have yielded variable results. 
Many of these studies have been limited by the use of variable immunosuppressive protocols 
among patients, different ELISA assays as well as method of diagnoses (surveillance vs 
indication biopsies).
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Methods: Sixteen consecutive txp patients with a history of iMN were tested for 
pre-txp PLA2R-Ab. ELISA titers (Euroimmun, NJ, USA) >14 RU/ml were considered 
positive, as per manufacturer instructions. All patients received similar post-transplant 
immunosuppression. A receiver operating characteristic (ROC) analysis was performed 
after combining data from Quintana et al. (n=21; Transplantation Feb 2015) to determine 
a PLA2R-Ab concentration which could predict rMN.
Results: Six (out of 16; 37%) patients had biopsy-proven rMN at a median of 3.2 
years post-txp. Of these, 5/6 (83%) had a positive PLA2R-Ab pre-txp with a median of 82 
RU/ml (range=31-1500). The only patient who had rMN with a negative PLA2R-Ab was 
later diagnosed with non-Hodgkin’s lymphoma. 100% (n=10) patients with no evidence 
of rMN (median follow-up=5 years) had negative PLA2R-Ab though one patient did have 
a borderline titer of 13.8 RU/ml. Patients with rMN were treated with rituximab and had 
an improvement in proteinuria from a median of 6g/d to 0.6g/d. Among the patients with 
rMN and positive PLA2R-Ab, titers fell to a median of 4 RU/ml at most recent follow-up. 
In a combined ROC analysis (n=37) a pre-txp PLA2R Ab>29 RU/ml predicted rMN with 
a sensitivity of 85% and a specificity of 92%.
Conclusions: Pre-transplant PLA2R-Ab could be a useful tool for the prediction 
of rMN. Patients with rMN in the absence of PLA2R-Ab should be screened for occult 
malignancy.
SA-PO966
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predict 
Acute Allograft Rejection  David S. Wheeler,1 Scott Blumhof,1 Manjula 
Balasubramanian,2 Janani Rangaswami.3  1Internal Medicine, Albert Einstein 
Medical Center, Philadelphia, PA; 2Pathology, Albert Einstein Medical Center, 
Philadelphia, PA; 3Delaware Valley Nephrology and Hypertension Associates, 
Philadelphia, PA.
Background: Currently, allograft biopsy is gold standard for diagnosing rejection 
however there is intense interest in identifying non-invasive biomarkers. The goal of this 
study is to determine whether the neutrophil-to-lymphocyte ratio (NLR) or the platelet-to-
lymphocyte ratio (PLR) correlate with acute allograft rejection.
Methods: This single center retrospective case-control study examined all kidney 
transplant biopsies conducted at Einstein Medical Center from Jan 2013 through Dec 
2014. Biopsies were stratified for rejection (acute cellular, borderline, negative). The NLR 
and PLR was calculated from routine laboratory studies obtained at various time points 
preceding the biopsy.
Results: Of the 102 “for cause” biopsies, 37.3% showed clear evidence of acute 
rejection and 18.6% were boarderline. NLR and PLR obtained within the week prior 
to the biopsy showed a significant reduction (4-fold and 3-fold respectively) in patients 
with acute cellular rejection. This reduction in NLR and PLR preceded the biopsy by 2-4 
weeks suggesting a rejection prodome. Interestingly, NLR at the time of boarderline biopsy 
accurately predicted rejection status on subsequent biopsy conducted within 8 weeks. 
Conclusions: NLR and PLR are highly sensitive biomarkers for acute rejection which 
become positive prior to other clinical manifestations. Furthermore, in cases of boarderline 
biospies NLR accurately predict the result of subsequent biospies. The inclusion of NLR 
and PLR could revolutionize allograft rejection evaluation by reducing the need for biopsies 
and providing additional insight in cases where the biopsy is non-diagnostic.
SA-PO967
Transitional B Cell T1/T2 Ratio Is a Prognostic Marker for Human Renal 
Allograft Deterioration  Aravind Cherukuri,1 D. Rothstein,1 Richard J. Baker.2 
1Univ of Pittsburgh; 2Univ of Leeds.
Background: Human transitional B cells (TrB) may play a significant role in auto 
and alloimmune disease. We previously showed that TrB express a high IL10:TNFα ratio 
and that this ratio fell with acute rejection. TrB are comprised of less mature T1 and more 
mature T2 cells.
Methods: We characterized the cytokine expression of T1 vs. T2 cells (identified by 
differences in CD24&CD38 expression) and investigated the utility of T1/T2 ratio as a 
biomarker for allograft deterioration (graft loss or 50% decline in eGFR).
Results: While both T1 and T2 cells expressed similar IL10, T1 cells expressed less 
TNFα and had a higher IL10:TNFα ratio. Thus T1 TrBs represent the B subset with the 
most anti-inflammatory profile. T1 cells were found to fall in rejection (resulting in lower 
T1/T2 ratio), contributing to the change in IL10:TNFα ratio. When analysed in a test set 
of 84 renal transplant patients, T1/T2 ratio was a strong predictor of allograft deterioration 
over a 5 year follow-up (ROC AUC 0.84, P<0.001). In a multivariate Cox model, T1/T2 
ratio was independently associated with allograft deterioration (HR 4.8 95% CI 1.3-17.8, 
P=0.02). T1/T2 ratio was examined 2 years post-transplant in a prospective validation set 
of 97 stable patients derived from a steroid avoidance RCT comparing alemtuzumab (n=51) 
or basiliximab induction (n=46). T1/T2 ratio was a strong predictor of outcome over the 
next 5 years (ROC AUC 0.82, P<0.001) and was independently associated with allograft 
deterioration (HR 26.6, 95% CI 3.1-227.3, P=0.003). In both the test and validation sets, 
T1/T2 ratio was a much stronger predictor of graft deterioration than traditional markers 
like eGFR (test set, eGFR ROC AUC 0.76 vs. T1/T2 ratio 0.84, Z statistic 0.97; validation 
set, eGFR ROC AUC 0.64 vs. T1/T2 0.82, Z statistic 1.92), or the detection of DSA (test 
set, DSA ROC AUC 0.68 vs. T1/T2 ratio 0.84, Z statistic 2.9; validation set, DSA ROC 
AUC 0.66 vs. T1/T2 0.82, Z statistic 2.35).
Conclusions: We demonstrate a distinct subset of TrB (T1) characterized by an anti-
inflammatory cytokine profile. A decrease in T1:T2 ratio (due to selective loss of T1 cells) 
is a strong prognostic biomarker for subsequent renal allograft deterioration.
Funding: Private Foundation Support
SA-PO968
The Pre-Transplant Ratio of T Regulatory Cells to Effector/Memory 
CD8+ T Cells Is Correlated with the Development of Acute Rejection 
Kentaro Sugisaki, Qizhi Tang, Sang-Mo Kang.  Surgery, Medical Center, Univ 
of California, San Francisco, San Francisco, CA.
Background: Acute rejection (AR) or renal allografts are a major predictor for the 
development of chronic allograft nephropathy (CAN) and subsequent graft loss. Although 
clinical risk factors for the development of AR have been identified, few techniques exist to 
individually stratify patients for the risk of AR and provide a rational basis for the tailoring 
of immunosuppression regimens. Over the past two decades, regulatory T cells (Treg) have 
been identified and subsequently shown to be critical to the prevention of autoimmunity 
as well as the prevention on organ allograft rejection in numerous models. In parallel, the 
identification of various T lymphocyte subsets has been greatly refined, allowing a more 
precise quantitation and correlation with outcomes.
Methods: We hypothesized that Treg abundance pre-transplant could predict for the 
development of acute rejection in patients undergoing de novo renal transplantation.We 
prospectively enrolled 76 renal transplant patients undergoing first transplant from August 
2013 toMarch 2014. We excluded patients undergoing second transplants, desensitization 
protocols, or involved in other clinical trials. Venous blood samples from all recipients at 
transplant date were isolated the peripheral blood mononuclear cells (PBMCs) and stored. 
We analyzed the samples in batches and normalized cell surface and intracellular staining 
using a standard control, using a NAVIOS flow cytometer (Beckman Coulter). All recipients 
were followed for a minimum of 1 year for the development of biopsy proven rejection.
Results: 12 recipients experienced AR. The pre-transplant ratio of Treg and Effector 
memory (EM) CD8 (Treg/EM CD8) T cells was significantly lower in patients who 
developed rejection, as compared to patients who did not experience rejection (45 
recipients). Other T cell subsets were not associated with the development of acute rejection.
Conclusions: Our data suggests that the pre-transplant ratio of Treg/EM CD8 T cells 
may identify patients at increased risk of AR and should encourage larger scale studies to 
validate and quantify the magnitude of risk as well as to assess covariables.
SA-PO969
The Association of Th17 Cell Phenotype with Chronic Allograft Dysfunction 
in Kidney Transplant Recipients  Byung Ha Chung, Hyunseon Kim, Chul Woo 
Yang.  Internal Medicine, Seoul St. Mary’s Hospital, Seoul, Korea.
Background: The purpose of this study is to determine the significance of the Th17 
cell pathway in the progression of chronic allograft dysfunction.
Methods: We investigated the expression of T cell phenotype in long-term stable 
kidney transplant recipients (KTRs)(LTS, n=67), chronic allograft dysfunction group 
(CAD, n=52), and also in three control groups (early stable KTRs (ES, n=28), end stage 
renal disease (ESRD, n=45), and healthy control (HC, n=26)).
Results: The percentage of Th17 cells out of CD4+ T cells and the proportion of 
IL-17 producing cells out of effector memory T cells showed a significant increase 
in the CAD group compared to the LTS group and other control groups (P < 0.05). In 
addition, The percentage of CCR4+CCR6+/CD4+ T cells and IL-17 producing cells out of 
CCR4+CCR6+CD4+ T cells was higher in the CAD group than in the LTS group (P<0.05). 
However, the percentage of Th1, Th2, and regulatory T cells did not differ significantly 
between the CAD and LTS groups (P > 0.05). Also, the serum level of IL-17, IL-33, and 
RAGE, and the expression of IL-1beta, RAGE, and HMGB1 mRNA showed an increase 
in the CAD group compared to the LTS group. Lastly, IL-17 induced acute and chronic 
injury in the human proximal renal tubular epithelial cell line in a dose-dependent manner.
Conclusions: In conclusion, we found the activation of the Th17 cell pathway in 
patients with chronic allograft dysfunction. The results of this study suggest that Th17 
pathway may have a role in the progression of chronic allograft injury.
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SA-PO970
Quantitative Characterization of T Cell Repertoires in Kidney Transplant 
Patients  Houda Alachkar,1 Martin B. Mutonga,1 Taigo Kato,1 Sowjanya Kalluri,3 
Vikas Vujjini,2 Yusuke Nakamura,2 Nada Alachkar.2  1Univ of Chicago; 2Johns 
Hopkins Univ; 3Kendall Medical Center.
Background: Acute and chronic T cell mediated rejection remains a major cause 
of kidney graft failure. Despite the significant decrease in early acute rejection due to 
current potent immunosuppressions, long-term graft survival remains unsatisfactory. Thus, 
characterization of the T cell repertoire and the kinetic of the expanded clones in transplant 
(Tx) patients may shed a light on our understanding of the T cells’ role in graft rejection.
Methods: We collected blood and urine samples from (46) patients before Tx, and at 
sequential time points post Tx and at time of T cell mediated rejection. We utilized next 
generation sequencing approach to characterize T cell receptor (TCR) repertoire. Sequencing 
using the illumina miSeq was performed on cDNA synthesized from RNA extracted from 
patients’ samples. This approach enables to track each expanded TCR clone in the graft at 
3 months post Tx, back to their first appearance in blood and urine samples obtained pre 
or 1 month post Tx. We also measured the RNA expression levels of CD8, CD4, FOXP3, 
Granzyme and Perforin in blood samples (N=43).
Results: Only patients with acute T cell mediated rejection (n=2) had TCR repertoires 
defined by the top 10 TCR clones appeared at any time point in blood, showed significant 
expansion in blood at 3 month post Tx compared with that at 1 month post Tx (P=0.01 
and 0.02). CD8, FOXP3, Granzyme and perforin RNA levels were significantly higher 
in samples obtained from patients with rejection compared to that in patients with no 
rejection (P£0.02).
Conclusions: Our study provides valuable comprehensive longitudinal analyses that 
define the kinetics of each TCR beta clone, and the changes in diversity of CDR3. This 
approach allows for identification of the expanded T cell clones that are possibly associated 
with graft rejection.
SA-PO971
Critical Apparaisal of the New Banff Criteria for Chronic Antibody-
Mediated Rejection in the Real Life Setting  Isabelle Houde, Isabelle Côté, 
Mohsen Agharazii, Sacha A. De Serres.  Renal Div, Quebec Univ Health Center, 
Laval Univ, Quebec City, QC, Canada.
Background: Significant changes in the criteria for chronic active antibody-mediated 
rejection (CAABMR) were made at the 2013 meeting, which is of major concern for clinical 
management. Here we compared the 2007 vs. 2013 criteria with regards to clinical outcomes.
Methods: Single-center, observational retrospective cohort study of all patients who 
received an indication biopsy between January 2006 and October 2014, during which EM 
evaluation, ptc scoring and C4d scoring by IH and IF was routinely performed. Patients 
were included if they met the criterion 1 for CAABMR: score cg1a>0, cg1b>0 or severe 
peritubular capillary basement membrane multilayering. GN, immune deposits, HCV+ 
status or suspicion of TTP-HUS were excluded. The endpoint was a composite of doubling 
of serum creatinine and death-censored graft loss.
Results: 123 patients were included. 18% met the full 2007 criteria, whereas an 
additional 18% fulfilled the full 2013 criteria. Only 25% of patients met the 2007 criterion 
#2-C4d, in contrast to 82% for the 2013 criterion #2-microvascular injury (MVI): 67% were 
C4d-positive and 55% were g+ptc positive, with substantial overlap. 45 patients experienced 
the endpoint at a median of 22mo post-biopsy. Overall, only a 2013 diagnosis of CAABMR 
was associated with the endpoint (adjusted HR=2.5 [1.2-5.2] for 2013 vs. HR=1.6 [0.7-3.8] 
for 2007 diagnosis). Adjusted Cox modelling revealed that the 2013 criterion #2-MVI was 
more strongly associated with the endpoint than the 2007 criterion #2-C4d (HR=4.0 [1.1-
14.1] vs. HR=2.3 [1.03-5.3]). When the 2013 criterion #2 was dissected by component, the 
C4d-component was significant (HR=2.5 [1.1-5.4]), but not the g+ptc (HR=1.1 [0.5-2.3]).
Conclusions: Compared to the 2007 criteria, applying the 2013 criteria here doubled 
the proportion of patients with CAABMR. Importantly, it improved the association with 
clinical outcomes.
SA-PO972
Tissue Expression of Aquaporine 2 Is Correlated to Urine Output 
and Allograft Function in Sensitized Kidney Transplant Patients 
Luis Eduardo Becker,1 Martin G. Zeier,1 Christian Morath.1  1Nephrology, Univ 
of Heidelberg, Germany; 2Pathology, Univ of Heidelberg, Germany.
Background: Salt and water disturbances often occur during acute kidney allograft 
dysfunction contributing to graft failure, but this condition has still been poorly investigated 
in the setting of alloreactivity. We evaluated the tissue expression of aquaporins (AQP1, 
AQP2) and of the epithelial sodium channel (ENAC) in kidney allograft biopsies from 
transplant patients with high immunological risk.
Methods: Eigthy-six kidney transplant biopsies from thirty-three sensitized patients 
were divided into three groups according to the clinical context an possible pathological 
correlates as follows: time-zero (N=9), protocol (N=9) and indication (N=68) biopsies. The 
indication biopsies were further divided into three subgroups, according to the presence or 
absence of acute tubular necrosis or acute rejection. Normal kidney tissue samples (N=6) 
served as controls. Immmunohistochemical expression of AQP1, AQP2 and ENAC was 
analyzed with assistance of an image software.
Results: We observed a significantly lower AQP1 expression in time-zero and indication 
biopsies with rejection compared to controls (7.7±2.0% and 9.1±0.6% vs. 14.3±2.9% of area 
positively stained; P=0.03 and P=0.04 respectively). AQP2 expression was significantly 
lower in patients with an indication biopsy when compared to controls and protocol biopsies 
(2.1±0.2% vs. 4.4±0.7 and 4.0±0.5% of area positively stained, P=0.05 and P=0.005, 
respectively). For ENAC, a lower expression in indication biopsies compared to controls 
was seen (P=0.04). Both AQP1 and AQP2 tissue expressions were significantly correlated 
to the urine output (r=0.45 and r=0.32; P=0.001 and P=0.02, respectively), and AQP2 was 
correlated to the MDRD-glomerular filtration rate at the time of biopsy (r=0.23; P=0.05).
Conclusions: Our findings can partially confirm previous experimental data showing 
downregulation of AQP1 expression after ischemia-reperfusion injury and during rejection. 
AQP2 downregulation seems to be rejection-independent occurring during deteriorating 
or poor kidney graft function.
SA-PO973
The Utility of Protocol Biopsy in Renal Recipients: Meta Analysis and 
Systematic Review  Guga Suri.  Kidney Disease, The First Affiliated Hospital 
of Zhejiang Univ, Hangzhou.
Background: To evaluate the value of protocol biopsy in patients after renal 
transplantation.
Methods: Searches were applied to the following electronic database:Medline, Embase 
Database, Cochrane Library. Randomized controlled trails evaluating the value of protocol 
biopsy for renal allograft recipients were included. Data were extracted independently 
by two reviewer.The risk of bias of included studies was assessed by the the Cochrane 
collaboration’s tool for assessing risk of bias.
Results: 5 RCTs were included. Long term graft loss was significantly reduced (RR 
0.40,95%CI 0.25 to 0.65, P<0.001) (figure 1) by protocol biopsy after renal transplantation.
Protocol biopsy may reduce the long term serum creatinine (WMD 38.21, 95% CI 
54.83 to 21,60, p<0.00001).For renal recipients whose basal immunosuppression is CNI 
(tacrolimus or cyclosporine), protocol biopsy can significantly improve the long term 
eGFR ( SMD 0.78, 95% CI 0.51 to 1.05, P<0.00001).However, for those whose basal 
immunosuppression is tacrolimus, this effect is not notable. Protocol biopsy seems to have 
no significant beneficial effect of reducing clinical acute rejection episodes.
Conclusions: Treatment of subclinical rejection detected by protocol biopsy can 
significantly improve the graft survival and may improve the allograft function.
SA-PO974
Longitudinal Biopsy Findings Among Children, Adolescents, and Young 
Adult Renal Transplant Recipients from a Southeastern USA Cohort 
Jonathan Alexander Miles,1 Panupong Hansrivijit,2,3 Katherine D. Westreich,3 
Evan Zeitler,3 Randal K. Detwiler,3 Maria E. Ferris.3  1East Carolina Univ, 
Greenville, NC; 2Chulalongkorn Univ, Bangkok, Thailand; 3UNC at Chapel 
Hill, Chapel Hill, NC.
Background: Longitudinal procedure history in children, adolescent, and young 
adult renal transplant recipients needs to be characterized based on their primary cause of 
end-stage renal disease (ESRD). It is known that pediatric patients are a high risk group 
for transplant failure. Elucidating potential factors for transplant failure in this group is 
important for protecting valuable renal transplants.
Methods: Clinical, demographic and pathological records of patients who received a 
renal transplant at age ≤ 30 years of age and who underwent transplant biopsies between 
2000 and 2014 at the UNC Hospitals were analyzed. This cohort was classified based on 
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the primary cause of ESRD as either glomerular or non-glomerular. Demographics, number 
of biopsies (total and adjusted for graft years), and transplant failure (rates and cause) were 
compared between the two groups.
Results: We enrolled 179 patients; 105 (58.7%) were male; 67 (38%) African American, 
92 (51%) Caucasian, and 20 (11%) other race. Their mean age at transplant was 18.7 ± 
8.2 years and 98 (55%) had a glomerular cause of ESRD. This cohort underwent a total of 
505 graft biopsies. Comparing patients with glomerular vs. non-glomerular conditions, we 
found no significant differences in cellular or humoral rejections (p=0.430); mean number 
of biopsies (3.0 ± 1.9 glomerular; 2.7±1.9 non-glomerular; p=0.289); mean number of 
biopsies per year for failed transplants (p=0.702), current functioning grafts (p=0.090); 
time to a failed transplant (p=0.476); or age at time of transplant (p=0.136).
Conclusions: In this single institution cohort of children, adolescents and young adults, 
we found no statistical differences in renal biopsy findings regarding number of biopsies and 
transplant failure. This high risk age group shows no different longitudinal graft survival 
based on primary cause of ESRD. More analysis will follow.
Funding: Private Foundation Support
SA-PO975
Prospective Study of Risk Factors and Impact of Subclinical Rejection 
(SCR) and Acute Clinical Rejection (ACR) in Renal Transplant Recipients 
Rajil B. Mehta,1 Puneet Sood,1 Aravind Cherukuri,1 Shan Shan Chen,1 Chethan 
M. Puttarajappa,1 Christine Wu,1 Nirav A. Shah,1 Parmjeet S. Randhawa,2 
Sundaram Hariharan.1  1Starzl Transplantation Inst, Univ of Pittsburgh Medical 
Center, Pittsburgh, PA; 2Dept of Pathology, Univ of Pittsburgh Medical Center, 
Pittsburgh, PA.
Background: The long term outcomes of subclinical rejection (SCR) remain unclear. 
The current study evaluated the risk factors for SCR at 3 mths and followed up renal 
function upto 1 year in pts with SCR, ACR and no rejection.
Methods: We prospectively followed 340 pts who underwent an ABO compatible 
kidney transplant between Jan 2013 and Sep 2014. Eight pts were excluded. All patients 
received induction therapy with either thymoglobulin (95%) or Basiliximab for induction, 
CNI/MPA for maintenance therapy and rapid steroid withdrawal by day 7. Protocol biopsies 
were performed 3 months post transplant. Based on this, they were divided into 4 groups. 
Grp 1 - pts with SCR; Grp 2 - pts with normal biopsy; Grp 3 - pts with ACR; Grp 4 - pts with 
no biopsy. Banff classification was followed for biopsy grading. Steroids, thymoglobulin 
and PP/IVIG were used as indicated for the treatment of rejection.
Results: 
Grp 1 (SCR) Grp 2 (Normal Bx) Grp 3 (ACR) Grp 4 (No Bx) p value
44/236 
(18.6%) 159/332 33/332 (9.9%) 96/332
Age (yrs) 50+/-16 52+/-15 48+/-15 55+/-12 0.07
Sex (M/F) 28/16 100/59 15/18 52/44 0.048
Race 
(W/O) 34/10 126/33 25/8 80/16 0.07
CIT 
(mins) 474+/-327 409+/-386 396+/-316 510+/-380 0.16
DGF 
(Y/N) 13/31 17/142 5/28 21/75 0.01
HLA mm 4.1+/-1.5 3.9+/-1.7 4.25+/-2 3.96+/-1.8 0.7
HLA DR 
mm 1.23+/-0.7 1.12+/-0.7 1.41+/-0.7 1.31+/-0.7 0.08
DSA 
(Y/N) 11/27 23/109 9/24 13/73 0.18
PRA I 6.7+/-17 6.5+/-19 7.9+/-19 14+/-37 0.13
PRA II 10.8+/-26 14.8+/-29 7.1+/-22 12.6+/-27 0.48
Cr 3m 1.52+/-0.4 1.42+/-0.5 1.69+/-0.48 1.33+/-0.46 0.0064
Cr 6m 1.52+/-0.5 1.46+/-0.5 1.54+/-0.37 1.26+/-0.42 0.012
Cr 1yr 1.6+/-0.46 1.5+/-0.77 1.66+/-0.48 1.38+/-0.63 0.20
Banff Gr 
(Bord/IA 
or >)
25/75 NA 27/73 NA
Conclusions: 1. Incidence of SCR and ACR around 3 mths was 18.6% and 9.9% 
respectively 2. Significant risk variables for SCR/ACR were female recipients and DGF 
3. No difference in renal function was noted between the groups at 1 year.
SA-PO976
Histological Scoring System Predicts Renal Outcome of Post Transplantation 
Acute Tubular Necrosis  Tobias Pieters, Lucas Falke, Tri Q. Nguyen, Marianne 
C. Verhaar, Roel Goldschmeding, Maarten B. Rookmaaker.  Nephrology and 
Pathology, UMC Utrecht, Netherlands.
Background: Acute Tubular Necrosis (ATN) is a common cause of Delayed Graft 
Function (DGF) after renal transplantation (RTX). Currently no histological model is 
available to predict renal outcome. Recovery of ATN is the result of the balance between 
damage and repair. In this study we evaluated the predictive value of immunohistochemical 
parameters of renal damage and regeneration and compared these to an accepted clinical 
prediction model for cadaveric renal transplantation.
Methods: We included 25 patients that underwent cadaveric RTX with DGF caused 
by ATN only, as shown in a renal biopsy 1 week after RTX. Biopsies were evaluated for 
histological tubular damage (atrophy, edema, casts, vacuolization), DNA damage (yH2AX 
staining) and apoptosis (cC3 staining). Regeneration was assessed by staining for stem 
cell marker CD133 and proliferation marker Ki67. Clinical parameters for renal outcome 
were collected as previously described in the Deceased Donor Score (DDS). The relation 
between these parameters and renal outcome, defined as eGFR at 6 months, was assessed 
using regression or one-way ANOVA. A corrected analysis for regenerative markers was 
performed to eliminate potential confounding by the amount of renal damage.
Results: The histological damage score significantly predicted renal outcome (R:-0.52 
P:0.01), whereas the DDS only tended to correlate with renal outcome (F:3.12 R: P:0.05). 
Neither staining for DNA damage, nor for apoptosis could predict renal outcome (R:-
0.24 P:0.91 and R:-0.16 P:0.44 respectively). In addition, the investigated parameters for 
regeneration (CD133 and Ki67) did not predict renal outcome (R:-0.25 P:0.23 and R:-0.10 
P:0.63 respectively), also not after correction for renal damage.
Conclusions: We are the first to show that histological parameters can predict renal 
outcome of post transplantation ATN. Importantly, our histological damage score correlated 
better with renal outcome than the DDS. Despite the crucial role of regeneration in recovery 
after ATN, no relation was found between stem cell marker CD133, proliferation marker 
Ki67 and renal outcome.
Funding: Pharmaceutical Company Support - Dutch Kidney Foundation
The Netherlands Institute for Regenerative Medicine
SA-PO977
Histopathological Changes and Graft Survival of Long-Term Kidney 
Allograft in Alport Syndrome: A Single-Center Experience in Japan 
Yasuyuki Nakada,1 Izumi Yamamoto,1 Akimitsu Kobayashi,1 Yudo Tanno,1 
Hiroyasu Yamamoto,1 Masayoshi Okumi,2 Hideki Ishida,2 Takashi Yokoo,1 
Kazunari Tanabe.2  1Div of Nephrology and Hypertension, Dept of Internal 
Medicine, The Jikei Univ of Medicine, Tokyo, Japan; 2Dept of Urology, Tokyo 
Women’s Medical Univ, Tokyo, Japan.
Background: Patients with Alport syndrome (AS) commonly develop progressive 
kidney dysfunction due to a hereditary type IV collagen deficiency, which results in an 
abnormality in the glomerular basement membrane (GBM). Recurrent glomerulonephritis 
does not occur in transplanted kidneys, and the allograft survival rate in these patients is 
similar to that in patients with other renal diseases. Several studies have shown that the 
type IV collagen of the GBM originates from the recipient’s bone marrow–derived cells. 
Therefore, we postulated that recurrent glomerulonephritis could occur locally and should 
influence the long-term allograft survival. In this study, we investigated graft survival and 
histopathological changes in renal allograft recipients with AS, focusing particularly on 
whether the expression of GBM type IV collagen is altered.
Methods: We collected data on the clinical characteristics of 19 renal allograft 
recipients who had been diagnosed with AS. All data were obtained from a database at the 
Department of Urology, Tokyo Women’s Medical University. Graft survival was evaluated 
using the Kaplan–Meier method and compared with a control group (n = 18). We assessed 
the double staining of a2 and α5 using frozen specimens obtained from long-term allograft 
survival samples.
Results: The graft survival rate was not statistically different between patients 
with AS and controls (log-rank p = 0.2240). Immunoreactivity to α5 antibody in four 
patients exhibiting long-term allograft survival showed strong linear positivity and 
no GBM abnormalities. In the case of chronic active antibody-mediated rejection, the 
immunoreactivity to anti-a2 antibodies increased in the mesangium and subendothelial 
space.
Conclusions: These results suggest that the GBM type IV collagen structure was 
histopathologically maintained for the long term after kidney transplantation, indicating 
better kidney graft survival in patients with AS.
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SA-PO978
Histological Assessments from Kidney Transplant Biopsies: An Explorative 
Post Hoc Analysis of ZEUS 5 Year Data  Ute Eisenberger,2 Claudia Sommerer,1 
Ingeborg A. Hauser,1 Frank Lehner,1 Rudolf P. Wuthrich,2 Petra Reinke,1 Anja 
Susanne Mühlfeld,1 Katharina M. Heller,1 Rolf A. Stahl,1 Heiner H. Wolters,1 
Klemens Budde,1 Martina Porstner,3 Oliver Witzke,1 Wolfgang Arns.1  1ZEUS 
Study Group, Germany; 2ZEUS Study Group, Switzerland; 3Novartis Pharma, 
Germany.
Background: Analysis of pathologists’ assessments and histological data allow 
for deeper insight on patient outcome when combined with investigators final clinical 
diagnoses. Here we present 5 year data from de novo kidney transplant (KTx) recipients 
after conversion to an everolimus(EVR) based regimen and withdrawal of CNI therapy 
vs. continued CNI regimen.
Methods: Post hoc analysis of histological and pathologists’ assessments from ZEUS, 
a prospective, open-label, controlled, multi-center study. At mo 4.5 post Tx 300 KTx 
patients (pts) were randomized to either EVR + enteric coated-mycophenolate sodium 
(EC-MPS; n=154) or cyclosporine (CsA) + EC-MPS (n=146). After 12mo interventional 
study, observational follow-up (FU) on pts safety and efficacy was performed until mo60 
post Tx. As per study protocol, graft core biopsies were indicated by suspected rejection 
episode. Biopsies were read and interpreted by local pathologists.
Results: Total number (nr) and mean nr of biopsies per patient performed are overall 
similar in both groups until mo60. Nr of pts with at least one rejection (as per final clinical 
diagnosis) was slightly higher in CNI group vs EVR group. Nr of pts with BPAR was higher 
in the EVR group especially due to mild, early acute rejections (mostly BANFF IA and 
IB). Nr of pts with histological evidence of chronic/sclerosing allograft nephropathy was 
similar in both groups (both 10%), C4D staining positivity was found slightly higher in 
the EVR group (11% EVR vs 7% CNI), however, pts with evidence of antibody mediated 
rejection was higher in the CNI group (2% EVR vs 4% CNI), same for CNI-induced toxicity 
lesions (16% EVR vs 23% CNI).
Conclusions: Data from histological assessments together with investigator reported 
final clinical pts outcome show that an EVR-based regimen with early elimination of 
CNI-therapy is as safe and efficacious as standard CNI-therapy offering the opportunity 
to reduce cumulative CNI-induced toxicities on the allograft.
Funding: Pharmaceutical Company Support - Novartis Pharma GmbH
SA-PO979
Endothelial Microvesicles as a Biomarker of Antibody-Mediated 
Endothelial Injury  Erik Stites,1 Moglie Le quintrec,2 Brandon Renner,1 Jennifer 
Laskowski,1 Karissa Fetrow,1 Joshua M. Thurman.1  1Univ of Colorado Health 
Sciences Center, Aurora, CO; 2Transplantation Rénale, Hôpital Lapeyronie, 
Montpelier, France.
Background: Endothelial injury and inflammation are hallmark histopathologic 
features of antibody-mediated rejection (AMR) in renal transplantation. Antibodies against 
HLA on the endothelial cells activate the complement system via the classical pathway. 
The diagnosis of AMR is dependent upon pathologic examination of renal biopsy tissue. 
A clinical need exists for a noninvasive method for diagnosing AMR. Endothelial cells 
constitutively release sub-micron vesicles called microvesicles into the circulation, but the 
release of microvesicles is altered in response to a variety of stimuli. The aim of this study 
was to evaluate the effect of antibody binding and subsequent complement activation on the 
production of endothelial microvesicles in vitro and to explore endothelial microvesicles 
from human samples as a potential biomarker of AMR in renal transplant recipients.
Methods: We have developed an in vitro model of AMR using immortalized human 
endothelial cells (HMEC-1) and a monoclonal murine antibody against human HLA class 
I molecules (W6/32). We analyzed antibody binding and complement deposition with 
immunohistochemistry and flow cytometry. Microvesicle analysis was performed using 
flow cytometry.
Results: We have shown that W6/32 antibody binds HMEC-1 cells and activates 
the classical complement pathway upon exposure to normal human serum. This leads to 
deposition of complement split products on the cell surface (analogous to C4d deposition 
in biopsies from patients with AMR) and increased release of endothelial microvesicles. 
Furthermore, anti-HLA antibody (W6/32), C3, and C4 were deposited on the surface of 
the microvesicles.
Conclusions: Our results suggest that AMR will lead to an increase in production 
of microvesicles by the renal endothelium, and AMR-associated microvesicles will have 
surface-bound IgG and C4d. We have obtained human plasma samples from renal transplant 
recipients with AMR and healthy controls, and we are currently examining the potential of 
endothelial microvesicles as a biomarker of AMR.
Funding: NIDDK Support
SA-PO980
Dual Leukocyte/Endothelial Stain for Assessment of Endocapillary 
Inflammation in the Renal Allograft  A. Rosenberg,1 Jonathan Levi,2 S.M. 
Bagnasco,1 Naima Carter-Monroe.1  1JHU; 2NIDDK.
Background: The pathologist’s assessment of renal allograft rejection relies on the 
evaluation of the pattern of involvement by inflammatory cells. The Banff criteria for renal 
allograft rejection now includes semiquantitative evaluation of inflammation involving 
peritubular capillaries (ptc), glomeruli (g), arterial intima (v), tubulitis (t), interstitium (i) and 
total renal parenchyma (ti) have been elaborated as indices of antibody (g and ptc) versus 
cell-mediated rejection (v, t, i and ti). Accurate assessment of these various compartments 
can be difficult and their reproducibility a particular challenge.
Methods: We evaluated a dual pan-leukocyte marker (LCA) and a vascular endothelial 
marker (CD34) immunohistochemical stain as an ancillary tool for evaluating intravascular 
(g and ptc) vs tubulointerstitial inflammation. Nineteen cases underwent blinded review 
of the dual stain.
Results: Overall, good concordance was present between cases originally scored g3 
and those meeting criteria on dual stain (9/10), but lesser agreement for cases originally 
scored g2 with only 1/9 (11%) meeting the same criteria on dual stain. Most cases (4/5) 
originally scored as ptc2 continued to meet criteria on dual stain, but approximately 35% 
(5/14) of cases originally scored as ptc3 met criteria for either ptc1 or ptc2 on dual stain.
Conclusions: Dual LCA/CD34 IHC aided the evaluation quantization of inflammatory 
infiltrate in renal allograft rejection, possibly allowing finer and more reproducible 
discrimination between ptc and i scores and identifying the extent of glomerulitis. 
Annotation of whole slide images will be performed to yield a quantitative metric for ptc 
on a continuous scale for comparison to the current quantized scale. Implementation in 
larger cohorts and in a consensus setting will be needed to determine improvement in the 
diagnostic and prognostic yield of the current Banff-based biopsy assessment.
Funding: NIDDK Support
SA-PO981
Intragraft Granzyme-B Is Associated with Chronic Renal Transplant 
Glomerulopathy  Narayan Prasad,1 Brijesh Yadav,1 Vikas Agarwal,1 
Dharmendra Bhadauria,1 Raj K. Sharma.1  1Nephrology, SGPGIMS, Lucknow, 
UP, India; 2Immunology, 1.
Background: Chronic transplant glomerulopathy (CTG) and Interstitial fibrosis 
and tubular atrophy (IFTA) are two major causes of chronic allograft loss. CTG is often 
associated with either C4d deposition or, circulating donor specific antibody. Pathogenesis 
of IFTA is unclear. We aimed the study to determine the role of CD3+CD8+Gzm-B+ 
Cytotoxic T cells in pathogenesis of CTG and IFTA and to determine its significance as 
peripheral blood signature of CTG.
Methods: Total 58 (CTG 20, IFTA 28 and stable functioning graft SGF 10) living 
donor renal transplant recipient were recruited. Patients were categorized into 3 group 
based on Banff’s 2007. We analyzed peripheral blood cytotoxic T cell by flow cytometry, 
Granzyme-B mRNA transcript in renal biopsy tissue by Taqman real time PCR and soluble 
Granzyme B level by ELISA.
Results: Age of patients in CTG, IFTA, and SGF group was 41.8±12.7; 36.50±8.34, 
46.28±8.65 years; post transplant period at biopsy 63.92±41.0, 51.71±3.06, 70.0±15.42 
months; Creatinine at biopsy 2.38±0.84, 2.30±0.86, 1.41±0.33 mg/dl, and daily urine 
protein 2.67±0.73, 2.22±1.96, 0.22 ±0.060 g; respectively. Peripheral blood CD3+CD8+ 
T cell frequency was 17.20±6.61% in CTG; 17.39±5.78% IFTA; and 13.20±1.02% SGF 
respectively (p=0.436). Peripheral cytotoxic T cell frequency (CD3+CD8+Gzm-B+) was 
significantly low in CTG group (12.62±1.68%), as compared to IFTA (16.44±4.09%), 
(p=0.012) and SGF 26.35±2.95% (p=0.001). Intragraft mRNA of Granzyme-B in CTG 
was 3.05 fold high as compared to SGF. In IFTA intragraft Gzm B mRNA was 2.26 fold 
high compared to SGF(p<0.001). Soluble serum Granzyme B level was significantly 
high in CTG (423.7±135.20; p<0.001),as compared to IFTA(249.5±73.05; P<0.001), and 
SGF (91.88±30.89) pg/ml. This suggests that sequestration of cytotoxic T cells into graft 
resulted in low circulating cytotoxic cells and increased intragraft Gzm-B+ cells leading 
to Granzyme-B dependent injury and CTG.
Conclusions: Low peripheral blood cytotoxic T cell (CD3+CD8+Gzm-B+) frequency 
and high intragraft mRNA transcript of Granzyme-B in CTG suggest role of cytotoxic T 
cells in CTG. Lower circulating CD3+CD8+Gzm-B+ Cytotoxic T cells can be peripheral 
blood signature for CTG.
SA-PO982
Molecular Features of Kidney Transplant Biopsies with Interstitial Fibrosis/
Tubular Atrophy in the Presence of Sterile Leukocyturia  Maria Ajaimy, 
Enver Akalin.  (instein-Montefiore Transplant Center, Albert/(instein College 
of Medicine, Bronx, NY.
Background: We hypothesized that sterile leukocyturia could reflect an increased 
intragraft immune activity and investigated gene expression profiles of transplant kidney 
biopsies of patients with sterile leukocyturia comparing to patients without leukocyteuria.
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Methods: We identified 15 normal transplant kidney biopsies without leukocyturia 
(Group I) and 33 biopsies with non-specificinterstitial fibrosis/tubular atrophy (IFTA) 
for gene expression profiling. Of the 33 biopsies with IFTA, 24 patients had no sterile 
leukocyturia (Group 2) and 9 patients had sterile leukocyturia (Group 3). Biopsies with a 
diagnosis of acute or chronic rejection, recurrent or de novo glomerular disease, or polyoma 
nephropathy were excluded. Sterile leukocyturia was defined by the presence of leukocytes 
in the urine (>10µL) without bacterial growth in urine culture. The urinalysis was done 
within 1 month before or after the biopsy. The gene expression profiles were studied by 
Affymetrix HuGene 1.0 ST expression arrays.
Results: There was no difference in terms of age, race, and sex, type of transplant, 
previous history of transplantation or acute rejection, donor characteristics, panel reactive 
antibody levels and immunosuppressive treatment between the Groups 2 and 3. Both groups 
also had similar acute and chronic Banff allograft injury scores. There was no statistically 
significant difference in gene expression profiles between the Groups 1 and 2.When Group 
3 biopsies were compared to the Group 1 and 2 biopsies, significantly increased gene 
transcripts associated with cytotoxic and regulatory T cells, and macrophages (P-value for 
significance <0.05). There was a trend towards increased interferon-gamma and rejection 
associated transcripts but no statistically significant difference in expression of B-cell or 
natural killer cell associated transcripts.
Conclusions: The biopsies of the patients with sterile leukocyturia showed increased 
expression of gene transcripts associated with T cells indicating heightened intragraft 
immune activity. Those patients might require close monitoring of their allograft function.
SA-PO983
Elevated Glomerular Mechano-Growth Factor and Vascular Endothelial 
Growth Factor in Chronic Allograft Nephropathy Is Associated with 
Activation of Erk1/2  Yongxin Gao,1 Raafat Farag Makary,2 Carmela B. 
Monteiro,2 Leighton R. James,1 Charles W. Heilig.1  1Medicine, Univ of Florida 
College of Medicine-Jacksonville, Jacksonville, FL; 2Pathology, Univ of Florida 
College of Medicine-Jacksonville, Jacksonville, FL.
Background: We previously identified increased GLUT1 glucose transporter, 
Mechano-Growth Factor (MGF) and Vascular Endothelial Growth Factor (VEGF) in human 
Chronic Allograft Nephropathy (CAN) kidneys which demonstrate glomerulosclerosis. 
Here we investigated a glomerular signaling pathway, Erk1/2, with potential to mediate 
effects of MGF and VEGF on extracellular matrix (ECM) genes. We employed IHC with 
specific antibodies to assess protein expression for MGF, VEGF and phospho-Erk1/2 (active 
Erk1/2) in human CAN kidneys vs. Normal Control kidneys.
Methods: This study involving examination of archived renal biopsy samples was 
approved by the Institutional IRB. N = 6 for each group of renal transplant - and native 
kidney biopsies. Immunolabelling of human CAN and Normal Control paraffin-mounted 
kidney sections was performed for assessment of selected proteins with specific antibodies, 
by use of immunoperoxidase staining. Scoring of glomerular immunolabelling for individual 
proteins was 0 – 4+ for semiquantitation. Data were normalized to open glomerular tuft 
area. P < .05 was considered significant in statistical analyses.
Results: Glomerular MGF protein was increased 3.9-fold in CAN kidneys vs Normal 
Control kidneys, P <.0001. Glomerular VEGF was elevated 3.0-fold in CAN vs Normal 
Control kidneys, P < .0001. Both of these growth factors have potential to signal via Erk1/2 
to ECM expression. Glomerular Erk1/2 activation (i.e. phospho - Erk1/2) was examined 
and found to be increased 4.3-fold in CAN vs Control, P<.0001.
Conclusions: Human CAN, characterized by excessive glomerular MGF and VEGF 
expression, involved enhanced activation of Erk1/2 in the glomeruli. This provides a 
mechanism by which these glucose-responsive growth factors may induce glomerular ECM 
production and glomerulosclerosis. Therefore, MGF and VEGF activation of Erk1/2 may 
contribute to progressive glomerulosclerosis and renal failure in CAN.
Funding: Pharmaceutical Company Support - Dialysis Clinics Inc.
SA-PO984
Microarray Analysis of Interstitial Fibrosis/Tubular Atrophy in Kidney 
Transplant Recipients Using Formalin-Fixed, Paraffin-Embedded Renal 
Biopsy Tissue  Sanjeev Akkina,1 Vishal K. Varma,2 Michael J. Walsh,2 Suman 
Setty.2  1Medicine/Nephrology, Univ of Illinois at Chicago, Chicago, IL; 
2Pathology, Univ of Illinois at Chicago, Chicago, IL.
Background: Interstitial fibrosis/tubular atrophy (IFTA) is a common and complex 
cause of kidney transplant failure that is difficult to predict. Early identification of 
progressive IFTA (pIFTA) may lead to alternative therapies that may attenuate irreversible 
injury. In this study, we used formalin-fixed, paraffin-embedded (FFPE) renal biopsy 
specimens with microarrays to conduct differential gene expression studies to identify 
predictors of IFTA in kidney transplant recipients.
Methods: We identified 22 individuals with multiple protocol biopsies within the first 
3 years after transplant. Glomeruli and blood vessels were removed using laser capture 
microdissection and the remaining tissue was used for mRNA extraction. Affymetrix 
Primeview arrays were prepared using standard protocols. IFTA was determined by using 
image masking in Histolab to quantify the cortical interstitial fraction. pIFTA was defined 
as a 0.5% absolute increase in the interstitial fraction per month between serial biopsies. 
Data analysis was conducted using R 3.0.2 and Bioconductor 2.22.  Significance was 
defined as an unadjusted p<5 x 10-5.
Results: Of the 22 subjects in this study, 9 had pIFTA while the remaining 13 were 
considered stable IFTA (sIFTA). At baseline, the eGFR was 60.5 vs 58.5mL/min/1.73m2 
(p=0.79) and log(Urine Albumin) was 3.44 vs. 3.17 (p=0.72) for the sIFTA and pIFTA 
groups, respectively. The baseline fibrosis was higher in the sIFTA group (18%) compared 
to the pIFTA group (13%, p=0.04). Using linear modeling, 3 of the top 6 differentially 
expressed probes at baseline were mapped to metaloothionein 1X and 2A.  Paired analysis 
of serial biopsies did not reveal any significant differences between sIFTA and pIFTA.
Conclusions: Microarray analysis of FFPE specimens show that pIFTA is associated 
with the differential expression of multiple genes prior to phenotypic changes. Prospective 
investigation of these genes is needed to determine if these are predictive of pIFTA.
Funding: Private Foundation Support
SA-PO985
Pathological Analysis for Transplant Nephrectomy – 124 Consecutive 
Cases in a Single Center Study Over 10 Years  Masaki Muramatsu,1,2 Abigail 
Lee,1 Atsushi Aikawa,2 Carmelo Puliatti,1 Muhammad M. Yaqoob,1 Michael 
Sheaff.1  1Nephrology, Transplantation and Cellular Pathology, The Royal 
London Hospital, London, United Kingdom; 2Nephrology, Toho Univ Faculty 
of Medicine, Tokyo, Japan.
Background: Transplant nephrectomy (TNx) is performed for several indications. 
This study evaluates in depth histological analysis of TNx specimen.
Methods: We identified all cases at the Royal London Hospital between 2004 and 
2014. The indication for TNx was divided into four groups: 47 cases with acute graft 
loss without significant blood flow (AGL); 44 cases of suspected ongoing rejection or 
graft intolerance syndrome (Rej/GIS); 24 cases with infection (INF); and 9 miscellaneous 
reasons (MIS). We examined the histological changes in detail and specifically looked at 
the artery, vein and ureter.
Results: AGL was less likely to have tubulointerstitial changes, but 74.5% had necrosis. 
In the AGL group, the majority of cases scored zero for t, i, ct and ci. Neutrophil rich 
arteritis at renal and small arteries was observed in 29.8% and 19.2%. Venous thrombosis 
was found in 61.7%. All cases in the Rej/GIS group showed ct3 and ci3 and 40.9% showed 
t3 and i3. Glomerulitis was observed in 52.3% and cg was detected in 75.1%. Arteritis of 
small and renal arteries was detected in 70.5% and 59.1%. C4d expression was present in 
54.1%. Nearly 70% showed ureteric inflammation. Variable cellular infiltrate comprising 
of lymphocytes, plasma cells and eosinophil were seen in all cases. In the INF group, 
66.7% (t1-3) and 79.2% (i1-3) were observed, and ct3 and ci3 were detected in 66.7%. 
Glomerulitis was rare although allograft nephropathy was detected in 62.5%. All cases 
had intimal thickening of small and renal arteries but arteritis was unusual. Lymphocyte 
and plasma cell were common at interstitium and ureter, but plasma cell, neutrophil and 
eosinophil rarely appeared at vascular lesions. In the MIS group, histological changes were 
minor.t3, i3, g1-3, arteritis and venulitis were not detected.
Conclusions: The histological changes were similar and specific within the TNx groups 
but different between the groups. A failed graft often showed substantial immunological 
response. In depth histological analysis may aid management of subsequent grafts.
SA-PO986
MiRNAs as Novel Biomarkers for Transplanted Patient’s Evolution 
Esperanza Macarena Rodriguez serrano,1 Cristina Galeano,2 Edurne Ramos,1 
Elisa Conde,1 Laura Martín-Gómez,1 Sara Gimenez-Moyano,1 Maria Laura 
Garcia-Bermejo,1 Fernando Liano.2  1Biomarkers and Therapeutic Targets Unit, 
IRYCIS; 2Nephrology, Ramon y Cajal Hospital.
Background: : Transplanted patients evolution and outcome is dependent on many 
factors including allograft function, vascular homeostasis and immunogenicity. Up to 
this moments, apart from creatinine renal biopsy, there are no quantifiable and accurate 
biomarkers to predict the evolution of the allograft and the receptor, what would enable 
clinicians to improve the transplanted patient’s management. Our group has validated a 
combination of serum miRNAs as accurate biomarkers for AKI from ischemic aetiology, 
including: miR-127, miR-101, miR-210, miR-126, miR-146a, miR-26b, miR-29a, miR-10a, 
miR-93 and miR-27a. Here we have determine the expression of these miRNA in serum 
from kidney donors and receptors and correlate this expression with clinical parameters 
of allograft evolution, including ATN development, delayed graft function, rejection and 
vascular complications.
Methods: For this purpose, serum sample from brain death donors and receptors along 
pos-transplantation period (6h, 1,2,3,4,5, 6 and 7days and 1,3,6 months) in 30 transplanted 
patients form our Hospital. After RNA extraction from serum, the combination of miRNAs 
has been determined by qRT-PCR and correlation with clinical data has been established 
using SPSS.
Results: The expression of these 10 miRNAs in serum samples from donors did not 
exhibited significant differences among them. This combination neither correlate with 
immediate delay graft function because NTA or immunological rejection. However, some 
of the miRNAs correlate with long term evolution of transplanted patients in terms of 
non-optimal graft function and they also discriminate patients with also exhibited renal 
vascular alterations.
Conclusions: In summary we have identified miRNAs that correlates with long 
term evolution of transplanted patients. These information could be useful for improve 
transplanted patient management in the context of personalized patient handling.
Funding: Other NIH Support - Fundación Mutua Madrileña de Investigación
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SA-PO987
Plasma MicroRNA 17 Host Gene Protein level Cluster and Tumor Necrosis 
Factor-Alpha (TNF-α) in Patients with Renal Transplantation: Relation 
to Allograft Function and Survival  Hayam A. El Aggan,1 Sabah Abdel 
Hady Mahmoud,2 Mohamed Mohamed Saker.1  1Internal Medicine, Faculty 
of Medicine, Alexandria, Egypt; 2Medical Biochemistry, Alexandria, Egypt.
Background: Chronic allograft dysfunction (CAD) remains the leading cause of late 
graft loss after kidney transplantation. MicroRNAs (miR) are small (19-25 nucleotides) 
noncoding RNAs that regulate gene expression of diverse biological processes. The 
polycistronic miR-17~92 cluster is comprised of six miRs and its primary transcript 
may also encode for a polypeptide of 70 amino acids designated as the miR-17 host gene 
(MIR17HG) protein. So the aim of this work was to evaluate the plasma levels of MIR17HG 
protein,an index of miR-17~92 cluster activity, and the plasma level of tumor necrosis 
factor-alpha (TNF-α) in patients with renal transplantation in relation to renal allograft 
function and survival.
Methods: This study included 45 subjects; they were divided into three groups each 
15, renal transplant patients with stable renal function (Group I), with CAD (Group II) 
and healthy subjects as controls (Group III). Quantitative determination of plasma levels 
of MIR17HG protein and TNF-α were performed using enzyme linked immunoassay 
(ELISA). Blood urea, serum creatinine and estimated glomerular filtration rate (eGFR), 
urinary albumin/urinary creatinine ratio and C-reactive protein (CRP) were done. Resistive 
index (RI) was calculated. Renal biopsy was done in patients with CAD.
Results: MIR17HG protein and TNF-alevels were significantly higher in renal 
transplant especially patients with CAD than the controls. In patients with renal 
transplantation MIR17HG protein and TNF-alevel were positively correlated with each other 
and with serum creatinine, urinary albumin/creatinine ratio and CRP and was negatively 
correlated with e-GFR. The degree of fibrosis in renal biopsy was positively correlated 
with MIR17HG protein, TNF-α levelsand RI (P<0.05).
Conclusions: MIR17HG Protein and TNF-alpha plasma levels can be served as 
circulating biomarkers for early detection of renal allograft dysfunction and follow up 
of patients with renal transplantation. They can act as a pro-fibrotic factor and denoting 
ongoing inflammation in the pathogenesis of CAD.
SA-PO988
Polymorphisms of IL17 and CXCL9 Genes, but Not AIF1 Gene, Affect 
Early Kidney Allograft Function After Transplantation  Leszek Domanski, 
Karolina Kloda, Ewa Kwiatkowska, Kazimierz Ciechanowski.  Clinical Dept 
of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical 
Univ in Szczecin, Szczecin, Poland.
Background: Kidney transplantation outcome is determined by immunological and 
non-immunological factors, both the donor and the recipient dependent. There are reports 
suggesting that AIF1, IL17 and CXCL9 genes polymorphisms might influence the post-
transplant immune response, and thus kidney function. Therefore the aim of this study 
was analysis of association between 8 AIF1, IL17 and CXC9 genes polymorphisms and 
creatinine concentrations up to 1 year after transplantation.
Methods: The study enrolled 269 Caucasian renal transplant recipients (165 males, 104 
females, mean age 47.63 ± 12.96 years). Blood samples were collected for genetic analysis 
and creatinine concentrations evaluation 1, 3, 6, and 12 months after kidney transplantation. 
The analysis regarded rs2269475, rs2736182 and rs2259571 within AIF1 gene, rs2275913 
within IL17A gene, rs2397084, rs11465553 and rs763780 within IL17F gene and rs3733236 
within CXCL9 gene. Genotyping was performed using RT-PCR and PCR-RFLP methods.
Results: Creatinine concentrations 1, 3, 6 and 12 months after transplantation differed 
between the rs2275913 within IL17A gene promoter polymorphism genotypes and were 
higher among GG homozygotes (GG vs. GA+AA p=0.03, p=0.08, p=0.06 and p=0.03 
respectively). In regard to rs2397084 IL17F gene polymorphism, creatinine concentrations 
differed between the genotypes 1, 2 and 6 months after transplantation and were higher 
among TT homozygotes (TT vs. CC p=0.02, p=0.02 and p=0.09 respectively). Creatinine 
concentrations 3, 6 and 12 months after transplantation differed between the rs3733236 
CXCL9 gene polymorphism genotypes and were higher among GG homozygotes (GG vs. 
GA +AA p=0.07, p=0.048 and p=0.02 respectively). There were no significant differences 
between the studied AIF1 gene polymorphisms genotypes.
Conclusions: Polymorphisms of IL17 and CXCL9 genes, but not AIF1 gene, affect 
early kidney function after transplantation. These preliminary results indicate that there 
is a need of genome-wide association studies scoping on genes implicated in the immune 
response after transplantation.
SA-PO989
Urinary K Cadherin Predicts Renal Allograft Dysfunction  Seema Jain,1 
Ekram Nabi,1 Sharirose Abat,2 Rajeshwar Ramkhelawon,2 Sarah Yates,1 Iain 
Macphee,2 Mysore K. Phanish,1 Mark E. Dockrell.1  1South West Thames Inst 
for Renal Research, Epsom and St Helier NHS Trust, London, United Kingdom; 
2St. George’s Univ NHS Trust, United Kingdom.
Background: Renal transplantation is currently the optimal form of renal replacement 
therapy, however graft attrition remains a problem. Current non-invasive detection methods 
are insensitive and irreversible damage has often occurred at the time of detection. This 
study investigates the relationship between urinary Albumin (Alb), Retinal Binding Protein 
(RBP), N-Acetyl-β-D-glucosaminidase (NAG) activity and a novel marker, K cadherin 
(KCAD), and graft dysfunction 12 months after implantation.
Methods: 62 renal transplant recipients were recruited into a prospective longitudinal 
study. Urine was collected 3 months after transplantation. Decline in graft function 
was defined as a greater than 5ml/min/1.73m2 fall in eGFR from 3 to 12 months after 
transplantation. Urine was analysed for NAG by enzymatic colorimetric assay, KCAD 
and RBP by in-house ELISA and Alb by immunoturbidimetry. Values were expressed after 
indexing for urinary creatinine concentration. Statistics were performed using GraphPad 
Prism 6 Linear regression analysis.
Results: 18% of patients had a decline in graft function. Of these, 64% tested positive 
for significant albuminuria (ACR>3mg/mmol), 73% for RBP, 100% for NAG and 45% 
for KCAD. Further analysis showed that NAG, RBP and Alb had high sensitivity but low 
specificity. KCAD had a sensitivity of 0.46 and a specificity of 0.75. All markers correlated 
positively with a decline in eGFR. However, KCAD had the strongest correlation (R2=0.2), 
compared with Alb (R2=0.17), NAG (R2=0.05) and RBP (R2=0.01).
Conclusions: This cohort study demonstrates that, when compared to conventional 
markers Alb, RBP and NAG, the novel marker KCAD has a higher specificity and correlation 
with patients who lose graft function after one year. The presence of the proximal tubule 
cadherin in the urine may be a prognostic indicator for patients who go on to develop chronic 
allograft dysfunction, and may occur due to the excretion of KCAD by proximal tubules in 
response to fibrogenic stimuli. Further analysis is required to evaluate this.
Funding: Private Foundation Support
SA-PO990
Detection of Endothelial Cell Specific Molecule-1 According to Allograft 
Status After Kidney Transplantation  Se Yun Kim,1 Kyung-Hwan Jeong,2 Yu 
Ho Lee,1 Tae Won Lee,2 Chun-Gyoo Ihm,2 Shin Yeong Lee,2 Yang Gyun Kim,1 
Sang Ho Lee,1 Da Wun Jeong,1 Ju-Young Moon.1  1Kyung Hee Univ Hospital 
at Gangdong; 2Kyung Hee Univ Hospital.
Background: To investigate whether urine and plasma Endothelial Cell Specific 
Molecule-1 (ESM-1) level could differentiate rejection from non-rejection in kidney 
transplantation (KTP) recipients, we compared ESM-1 levels according to allograft status.
Methods: We measured plasma and urine ESM-1 in 77 patients with underwent 
KTP. The concentration of ESM-1 was analyzed by enzyme linked immunosorbent assay 
(ELISA). According to allograft status, Groups are divided stable, long-term good survival, 
immune tolerance, acute cellular rejection (ACR), acute antibody-mediated rejection 
(AMR) and chronic AMR.
Results: Plasma ESM-1 was not significantly different between all groups according 
to allograft status (p=.424). Whereas, urine ESM-1 was significantly different between 
groups according to allograft status (p<.001). Urine ESM-1 was higher in both ACR and 
acute AMR as well as chronic AMR than stable status. Patients with acute AMR showed 
significant higher level of urine ESM-1 compared with patients with ACR (p<.05). Area 
under the curve (AUC) for differentiating acute AMR from ACR was 0.744 (p=0.01).
Conclusions: Urine ESM-1 may reflect endothelial injury of allograft and it could be 
used to differentiate the patient with acute AMR from ACR.
SA-PO991
Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients 
by Measurement of Urine BCA-1  Dajin Chen.  Kidney Disease Center, The 
First Affiliated Hospital, College of Medicine, Zhejiang Univ, P.R.China.
Background: To investigate the relationship between early-stage renal acute rejection 
and the level of BCA-1 in urine, explore the diagnostic value and noninvasive monitoring 
in early stage after transplantation by measurement of urine BCA-1.
Methods: 145 patients were enrolled between January 2006 and October 2009., 
including 49 with biopsy-proved acute rejection, 58 patients with stable renal function and 
no abnormal histological findings, 9 patients with biopsy-proven acute tubular necrosis 
and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urinary 
samples were also collected from 40 healthy controls. Urinary concentration of BCA-1 was 
determined by an enzyme-linked immunosorbent assay technique in 145 renal allograft 
recipients and 40 healthy controls.
Results: Patient with acute rejection excreted urinary BCA-1 at a significantly higher 
level (8.1±2.1, 95%CI: 3.9-12.4 pg/µmol creatine) than levels of patients with No-AR and 
healthy controls (P<0.001). Patients with acute tubular necrosis excreted urinary BCA-1 at 
a significantly lower level(2.52±0.57, 95%CI: 1.21-3.84pg/µmol creatinine)than levels of 
patients with acute rejection. ROC curve was constructed to determine the discriminatory 
power of BCA-1 levels for diagnosis of acute rejection. The area under ROC curve was 
0.881 (95%CI: 0.811-0.951), at a cut point of 0.23 pg/µmol creatine, the sensitivity was 
81.6% and the specificity was 87.9% (P<0.001). Patients with acute humoral rejection had 
significantly higher urinary BCA-1 concentration than patients with acute celluar rejection 
(24.2±6.68, 95%CI: 9.5-38.9pg/µmol creatinine vs 2.91±0.65, 95%CI: 1.6-4.22 pg/µmol 
creatinine, P=0.0002).ROC curve was constructed to determine the discriminatory power 
of BCA-1 levels for diagnosis of acute humoral rejection. The area under ROC curve was 
0.867 (95%CI: 0.725-1.005),at a cut point of 8.3 pg/µmol creatine, the sensitivity was 75% 
and the specificity was 91.9%.
Conclusions: The monitoring of BCA-1 in urine may be a new and noninvasive 
approach for detection acute rejection as well as useful to discriminate the type of rejection.
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SA-PO992
B Cell Attracting Chemokine 1 in Urine Is a Biomarker of Acute Humoral 
Rejection  Wenhan Peng, Jianghua Chen.  Kidney Disease Center, The First 
Affiliated Hospital, College of Medicine, Zhejiang Univ, Hangzhou, Zhejiang, 
China.
Background: Presently, there are no noninvasive approaches which can be directly 
applied to clinical diagnosis of acute rejection (AR) or distinguish type of rejection in renal 
transplant recipients. The aim of this study was to construct diagnostic models of biomarkers 
in urine of patients with ARor acute humoral rejection (AHR) in renal transplant recipients.
Methods: Concentration of nine biomarkers in urine of 81 patients with AR and 167 
patients with stable renal function (No-AR) was determined by ELISA technique. Firstly, 
by discriminant analysis, we screened a number of biomarkersto construct the diagnostic 
models for AR and AHR. Secondly, another 102 patients with No-AR and AR were analysed 
to test the accuracy of the diagnostic model.
Results: Four biomarkers were selected to set up the diagnostic model of AR.or No-AR. 
Based on the model of AR, 84.3% patients were correctly diagnosed. Two biomarkers were 
selected to set up the complementary diagnostic model of AR. Based on the two model of 
AR, 100% patients with No-AR and 96.3% patients with AR were correctly diagnosed. 
Only B cell attracting chemokine 1 (BCA-1) was selected for the diagnostic modelfor AHR 
or acute cellular rejection (ACR). Rejection type of 81.5% patients with AR were correctly 
classfied.Another 102 patients tested the accuracy of the diagnostic models. Diagnostic 
accuracy of AR or No-AR and AHR or ACR were 100% and 95.4% respectively.
Conclusions: Urinary BCA-1 was a valuable biomarker for determining AHR. These 
diagnostic models might directly identified AR and types of AR.
Funding: Government Support - Non-U.S.
SA-PO993
18FDG-PET/CT Imaging in Suspected Acute Renal Allograft Rejection 
Pierre Lovinfosse,2 Laurent E. Weekers,1 Catherine Bonvoisin,1 Christophe 
Bovy,1 Stéphanie M.j.g. Grosch,1 Jean-marie H. Krzesinski,1 Roland Hustinx,2 
Francois Jouret.1  1Nephrology, Univ of Liege Hospital, Liege, Belgium; 2Nuclear 
Medicine, Univ of Liege Hospital, Liege, Belgium.
Background: The diagnosis procedure for kidney transplant recipients (KTR) with 
suspected acute rejection (AR) relies on needle biopsy. Still, noninvasive tests to predict 
nonrejection would be useful to save selected patients from undergoing inessential biopsy. 
AR is associated with a recruitment of activated leukocytes into the transplant, which are 
characterized by a high metabolic activity and an increased uptake of glucose analog, 
18Fluoro-deoxy-glucose (18FDG). Thus, 18FDG-Positron emission tomography coupled with 
computed tomography (PET/CT) may help noninvasively distinguish nonrejection from AR.
Methods: From January 2013 to February 2015, we prospectively performed 32 
18FDG-PET/CT in 31 adult KTR with suspected AR who underwent a biopsy. Biopsies were 
categorized as “normal”, “borderline”, “AR” or “others” according to Banff classification. 
PET/CT imaging was performed within 201 ± 18 minutes after i.v. administration of 
3.2 ± 0.2 MBq/kg of 18FDG, before any modification of immunosuppression. The mean 
standard uptake values (SUV) of both upper and lower renal poles were measured, with 
no threshold activity.
Results: Biopsies were diagnosed as “normal”, “borderline”, “AR” or “others” in 8, 
10, 8 and 6 (including 3 polyoma-BK néphropathies) cases. AR was antibody-mediated in 
1 case, whereas Type I, II and III cellular AR were found in 5, 1 and 1 cases, respectively. 
Mean SUV reached 1.5 ± 0.2, 1.6 ± 0.3, 2.9 ± 0.8, 2.2 ± 1.2 in each category. Mean SUV 
of biopsy-proven AR was significantly higher than “normal” cases (p<0.01). No difference 
was found between “normal” vs. “borderline”, or between “AR” vs. “others” histopathology. 
Still, a positive correlation between mean SUV and acute composite (g+i+t+v+ptc) Banff 
score was found, with a coefficient of 0.70 (p<0.001). Sensitivity and specificity of 18FDG-
PET/CT in detecting pathological biospies were respectively 92.3 and 36.8, with a mean 
SUV threshold at 1.4.
Conclusions: 18FDG-PET/CT imaging may help discriminate nonrejection, thereby 
avoiding unnecessary transplant biopsy in KTR with suspected AR.
Funding: Government Support - Non-U.S.
SA-PO994
High Remnant-Like Particle-Cholesterol Is a Risk Factor of Worsening 
Graft Function in Japanese Kidney Transplant Recipients  Makoto Tsujita. 
Transplant Surgery, Nagoya Daini Red Cross Hospital, Japan.
Background: Many factors cause dyslipidemia after kidney transplantation.Low 
density lipoprotein cholesterol (LDL-C) has been focused to reduce cardiovasucular 
disease(CVD),but residual risk factors such as triglyceride(TG), remnants or small dense 
LDL-C are also important to reduce CVD. We investigated whether residual risk factors 
affected graft function in kidney transplant recipients.
Methods: This study is a retrospective cohort study at a single center. Three hundred 
and seventy seven kidney transplant recipients (male 223) in more than six months after 
transplantation were enrolled. TG, Remnant-like particle-cholesterol (RLP-C), non-high 
density lipoprotein cholesterol(HDL-C), LDL-C/apoB, eGFR(estimated glomerular 
filtration rate), Urine protein /day (UP), Body Mass Index (BMI) and other parameters 
at baseline were measured and we studied the association of residual risk factors with 
kidney fuction. DeGFR meant the difference between eGFR at baseline and eGFR 1year 
after enrollement (eGFR 1y).Data are shown as n(%), mean (SD) or median (interquartile).
Results: Patients’ characteristics of this study is shown. 
Mean age (years) was 51.0 (13.2), median vintage after kidney transplantation (months) 
was 45.0 (24.0, 81.5), and mean BMI (kg/m2)was 21.9 (3.79). DeGFR were associated 
with age (r=0.12, p=0.02), BMI (r=0.12, p=0.02), TG (r=0.12, p<0.001), UP (r=0.15, 
p=0.004), RLP-C (r=0.21, p<0.001). Multivariate analysis showed that High RLP-C was 
the associated with worsening graft function.
Conclusions: High RLP-C is a risk factor of worsening graft function in Japanese 
kidney transplant recipients.
SA-PO995
The Modification of Erythrocyte Membrane Fatty Acid Contents According 
to Kidney Transplantation: Prospective Study  Young Ki Son,1 Sung Hyun 
Son,2 Dongyeol Lee,3 Hansae Kim,3 Eu Gene Jeong,1 Su Mi Lee,1 Yun Jung 
Oh,4 Won Suk An,1 Seong Eun Kim.1  1Dept of Internal Medicine, Dong-A Univ 
Hospital, Busan, Republic of Korea; 2Dept of Internal Medicine, BHS Han Seo 
Hospital, Busan, Republic of Korea; 3Dept of Internal Medicine, Bong Seng 
Memorial Hospital, Busan, Republic of Korea; 4Dept of Internal Medicine, 
Cheju Halla General Hospital, Cheju, Republic of Korea.
Background: Modifications of erythrocyte membrane fatty acid (FA) contents may 
effect on cellular function or transmembrane receptors. The high erythrocyte membrane 
oleic acid contents are related with acute coronary syndrome. It is known that kidney 
transplanted recipients have lower cardiovascular event than dialysis patients. Therefore, 
we prospectively evaluated whether erythrocyte membrane FA contents were modified 
after kidney transplantation (KTP).
Methods: We recruited 22 kidney transplanted recipients from September 2011 through 
May 2014. Blood samples were obtained just before KTP and at 6 months after KTP. The 
erythrocyte membrane fatty acid contents were measured by gas chromatography.
Results: The mean ages were 45.3±10.9 years. The erythrocyte membrane contents 
of omega-3 FA (10.1±3.9 vs. 5.5±3.63, p <0.001), omega-6 FA (26.6±6.2 vs. 20.7±7.7, 
p=0008), arachidonic acid (11.6±4.1 vs. 7.7±4.7, p=0.001), eicosapentaenoic acid (1.4±0.7 
vs. 0.7±0.5, p <0.001), docosahexaenoic acid (2.0±0.8 vs. 1.2±1.0, p=0.001), omega-3 
index (7.9±3.2 vs. 4.1±2.7, p <0.001) were significantly higher but erythrocyte membrane 
contents of total saturated FAs (44.9±8.0 vs. 52.6±9.4, p=0.003), total monounsaturated 
FAs (17.2±1.6 vs. 19.9±2.2, p <0.001), total trans FAs (0.9±0.3 vs 1.1±0.2, p=0.011), oleic 
acid (15.7±1.5 vs. 18.0±1.9, p <0.001), and omega-6/omega-3 ratio (3.1±1.4 vs. 4.6±1.7, 
p=0.14) were significantly lower at 6 months after KTP.
Conclusions: FA contents of erythrocyte membranes including increased omega-3 FAs, 
decreased oleic acid and omega-6/omega-3 were significantly modified after KTP. These 
changes of erythrocyte membrane FA contents may effect on lower cardiovascular event 
rate in kidney transplanted recipients compared to dialysis patients and further studies are 
necessary to confirm these effects.
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SA-PO996
Diffusion Impairment Measured by Functional MRI Correlates with 
Allograft Fibrosis After Kidney Transplantation in Patients with Delayed 
Graft Function  Jan H. Braesen,1 Abedalrazag Ahmad Khalifa,1 Faikah Gueler,2 
Frank Lehner,4 Wilfried Gwinner,2 Dagmar Hartung,3 Hermann G. Haller,2 
Katja Hueper.3  1Inst for Pathology, Hannover Medical School, Hannover, 
Germany; 2Clinic for Nephrology, Hannover Medical School, Hannover; 
3Inst for Diagnostic and Interventional Radiology, Hannover Medical School, 
Hannover; 4Clinic for General, Abdominal and Transplant Surgery, Hannover 
Medical School, Hannover, Germany.
Background: Functional MRI parameters derived from diffusion weighted (DWI) 
and diffusion tensor imaging (DTI) correlate with renal fibrosis and cell infiltration in 
experimental studies. Aim of this study was to investigate these non-invasive techniques 
in patients with delayed graft function (DGF) and to correlate diffusion parameters with 
renal function and renal histology of allograft biopsies.
Methods: 33 patients with initial graft function between day 4 and 11 after kidney 
transplantation and 31 patients with DGF were examined on a 1.5 Tesla MRI. DTI and 
DWI sequences were acquired and apparent diffusion coefficient (ADC) and fractional 
anisotropy (FA) were calculated. Kidney biopsies were available in 26 patients and analysed 
for acute rejection (Banff), amount of fibrosis, inflammatory infiltrates, and tubular injury 
as well as edema.
Results: ADC was significantly reduced in patients with DGF compared to patients with 
initial function. Similarly, FA, representing the degree of directed diffusion along anatomical 
structures such as tubules, collecting ducts and vessels, was impaired in DGF patients. 
ADC and FA positively correlated with renal function (r=0.573 and r=0.53, p<0.001) and 
negatively with the amount of renal fibrosis. Diffusion parameters in DGF patients did 
not discriminate between acute rejection and tubular injury. Histological evaluation of the 
allograft biopsies did not reveal any significant differences between DGF or initial function 
in the following parameters: leukocyte infiltration (CD4, CD8, CD15, CD20, CD68), CD31 
pos. peritubular capillaries or edema (intertubular distance).
Conclusions: Functional MRI with diffusion techniques detects allograft dysfunction 
early after kidney transplantation correlating with allograft fibrosis. Biopsy is needed to 
verify rejection.
Funding: Government Support - Non-U.S.
SA-PO997
Identification of Common Biological Mechanisms of Fibrosis in Transplanted 
and Native Kidneys with Chronic Diseases  Konrad S. Famulski, Jeffery M. 
Venner, Jeff Reeve, Philip F. Halloran.  Univ of Alberta, Edmonton, AB, Canada.
Background: In both primary kidney diseases and in transplants fibrosis is caused 
by chronic progressive diseases. Hence, we hypothesised that fibrosis has fundamental 
common biological pathways in native and transplanted kidneys.
Methods: We studied the molecular associations with fibrosis in 703 kidney transplant 
indication biopsies (bx) 3 days to 35 years post-transplant. The number of bx with fibrosis 
increased with time post-transplant and most bx with ci>1 (74%) were attributable to 
time-dependent diseases (ABMR, GN, TG).
Results: By microarrays we compared bx with ci>1 to those with little or no fibrosis 
(ci£1) and determined the association strength of transcripts (p-value) for ci>1. First we 
focused on transcripts previously associated with fibrosis: immunoglobulin, mast cells and 
AKI-associated transcripts. Strongest associations with ci>1 were for immunoglobulin and 
mast cell transcripts, but not for AKI transcripts. Because time of bx post-transplant is 
highly correlated with ci, we repeated the comparison of ci>1 vs. ci£1 after correcting for 
time. This resulted in a massive reduction in association strength for the immunoglobulin 
and mast cell transcripts (from 10e-27 to 10e-9). However, AKI transcripts were now more 
strongly associated with fibrosis (from 10e-9 to 10e-18). Thus time correction emphasised 
the injury-repair response at expense of inflammation. We then analyzed the fibrosis 
associated transcripts in native kidneys (CKD). 73% of CKD transcripts overlapped with 
our transcripts. 
Ci>1/CKD overlap overrepresented pathways related to immunity, response to 
wounding and energy metabolism (Figure 1).
Conclusions: Fibrosis in transplants and native CKD is characterized by the same 
inflammatory compartment, response to injury and loss of metabolism. Some of these 
processes might be related to the duration of chronic disease.
SA-PO998
DNA Double Strand Breaks Induced Collagen Type VI Secretion of 
Glomerular Endothelial Cells in Renal Allografts  Yuki Matsui, Norifumi 
Hayashi, Junko Imura, Keiji Fujimoto, Hiroki Adachi, Hideki Yamaya, Hitoshi 
Yokoyama.  Nephrology, Kanazawa Medical Univ, Uchinada, Japan.
Background: The relationship between DNA injury and glomerular fibrosis in renal 
allografts remains unclear.
Methods: We examined renal allograft specimens from 35 patients in which DNA 
double-strand breaks and glomerular fibrosis were detected by phospho-histone H2A.X 
(γ-H2AX) expression and collagen (COL) types III, IV, and VI accumulation. We also 
examined the in vitro relationship between DNA damage and COL accumulation by 
mitomycin C (MMc)-induced DNA damage in human glomerular endothelial cells 
(HRGEc).
Results: The γ-H2AX and COL type VI, which mainly accumulated in the 
subendothelial and mesangial regions, were positively correlated with the duration of 
the post-renal transplant (RT) period (r=0.691, p<0.01; r=0.760 p<0.01, respectively). In 
multiple regression analysis, the duration of the post-RT period and cg in the Banff’07 
classification were identified as significant predictors of COL type VI accumulation 
(β value=0.699 p<0.001; 5.558, p=0.035, respectively) and γ-H2AX expression in the 
glomerular capillaries (β value 0.700,p<0.001; 2.031, p=0.011, respectively). In addition, 
the γ-H2AX-positive area was also identified as a predictor of glomerular accumulation of 
COL type VI (β value=0.439, p=0.028). In the immunochemistry examination, γ-H2AX 
was detected in most cells after 24 hours’ MMc treatment, whereas no γ-H2AX expression 
had been detected before the MMc treatment. Although COL type VI was detected around 
the nuclei of the HRGEc before the MMc treatment, it was not present there after the MMc 
treatment. COL type VI was detected in the cytoplasm of the HRGEc, which was secreted 
into the supernatant after MMc stimulation with γ-H2AX expression. The number of 
γ-H2AX (-)/COL type VI (+) cells was inversely associated with the number of γ-H2AX 
(+) /COL type VI (-) cells (r=-0.655, p<0.001) during 24 hours’ MMc treatment.
Conclusions: Our findings suggested that over the long term RT may induce DNA 
double-strand breaks and HRGEc-secreted COL type VI accumulation in the glomerular 
capillaries, which might progress to intractable glomerular fibrosis.
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SA-PO999
Imatinib Improves Interstitial Fibrosis in Deceased Donor Kidney 
Transplant: A Case Report  Ignatius Yun-Sang Tang,1 Andres M. Acosta,2 
Vishal K. Varma,2 Suman Setty.2  1Medicine, Univ of Illinois at Chicago, 
Chicago, IL; 2Pathology, Univ of Illinois at Chicago, Chicago, IL.
Background: Imatinib (IM) is an oral inhibitor of tyrosine kinases. Early short term 
PDGF inhibition with IM had been shown to prevent interstitial fibrosis and tubular 
atrophy in pre-clinical kidney transplantation (KT). We assess the effect of long term IM 
therapy on renal allograft histology in a KT recipient who received IM for gastrointestinal 
stromal tumor (GIST).
Methods: Patient is a 47 year old female with ESRD due to hypertension, s/p living 
donor KT in 2007 which failed in 2010. She was then resumed on hemodialysis. A gastric 
mucosal mass was discovered incidentally in 5/2012. Fine needle aspiration showed c-KIT 
positive spindle cells consistent with GIST. Patient received deceased donor KT in 7/2012 
with Thymoglobulin induction. Maintenance immunosuppression included tacrolimus and 
mycophenolic acid. Patient was started on IM 100mg daily on day 19 post-KT because of 
GIST. Post-KT course was complicated by biopsy proven acute tubular necrosis, requiring 
dialysis in the first month post-KT. Serum creatinine (CR) improved to 1.6mg/dl by 3 months 
post-KT when she underwent partial gastrectomy. Pathology showed low grade GIST (low 
mitotic count and low Ki67 labeling index). Surveillance KT biopsy was performed at 6 
months, 1 and 2 years post-KT. We compared the 6-month and the 2-year post-KT biopsies 
for the presence of renal cortical interstitial fibrosis using the Histolab software (Microvision 
Instruments, France). The core sections stained with Masson trichrome were scanned at 
high-resolution, and divided into individual images at 200X for quantitative analysis. The 
software program was then run to quantify fibrosis of the selected areas.
Results: The cortical fibrosis percentage was 20.17% for the 6-month biopsy and 
14.35% for the 2-year biopsy. The corresponding serum CR was 1.52mg/dl and 1.17mg/dl, 
respectively. Trough tacrolimus levels were maintained between 5 and 7ng/ml.
Conclusions: Long term low dose IM reduced cortical interstitial fibrosis in deceased 
donor KT. The role of long term IM in the prevention of interstitial fibrosis in renal allograft 
warrants further studies.
SA-PO1000
Factors Associated with Referral, Evaluation and Listing for Kidney 
Transplant: A Survey of Dialysis Patients  Eric Chang, Ming Wang, Fareeha 
Khalil, Naman Trivedi, Nasrollah Ghahramani.  Penn State Univ College of 
Medicine, Hershey, PA.
Background: Kidney transplant (KT) is the treatment of choice for most patients with 
end stage renal disease (ESRD). Disparities in referral, evaluation, listing and transplantation 
have been documented. We studied factors associated with the likelihood of referral, 
evaluation and listing for KT.
Methods: We sent flyers to 1,283 dialysis units. Of 2536 interested participants 
who fulfilled inclusion criteria, we randomly selected and invited 1400 to complete the 
questionnaire. Independent variables were demographic factors, location, and modes of 
education about KT. In multivariate analysis, we calculated odds ratios (OR) and 95% 
confidence intervals (CI) for the probability of referral, evaluation and listing for KT.
Results: Of 673 participants, 401 had been referred, 361 had been evaluated and 201 
were listed. Having received 3 or more modes of education about KT was associated with 
higher likelihood of referral (OR:5.03;CI:2.76-9.18), evaluation (OR:5.67;CI:3.23-9.96) 
and listing (OR:2.70;CI:1.43-4.18). Having attended a pre-ESRD class was associated with 
higher likelihood of referral (OR:2.20;CI:1.44-3.35) and evaluation (OR:2.47;CI:1.63-3.74). 
If the nephrologist had discussed the option of KT at least twice in previous year there was 
higher likelihood of referral (OR:2.19;CI:1.44-3.33), evaluation (OR:1.67;CI:1.10-2.53) 
and listing (OR:1.83;CI:1.19-2.80). A transplant center within 10 miles was associated 
with higher likelihood of referral (OR:1.64;CI:1.09-2.66) and listing (OR:2.17; CI:1.32-
3.57). Age > 60 was associated with lower likelihood of referral (OR:0.51;CI:0.33-0.79), 
evaluation (OR:0.46;CI:0.30-0.72) and listing (OR:0.28;CI:0.17-0.45).
Conclusions: Many factors influence the decision about KT; a process that begins with 
referral. Though difficult to change, proximity to a transplant center unsurprisingly improves 
chances for KT evaluation. Emphasis on educating patients > 60 may improve referral and 
evaluation. In this study, the quantity and diversity of educational modalities are the most 
important contributors to the referral, evaluation and subsequent listing.
Funding: NIDDK Support
SA-PO1001
Patient Navigation Program in Kidney Transplant Evaluation: A 
Randomized Study  Mohua Basu, Dawn L. Fletcher, Lisa Petgrave-nelson, 
Rachel E. Patzer.  Emory Univ, Atlanta, GA.
Background: We developed a patient navigation program in a kidney transplantation 
(KTx) clinic to improve KTx evaluation completion for patients deemed “high-risk” of 
not being placed on the KTx waiting list, based on known disparities in completion of 
KTx evaluation. We examined whether the addition of patient navigation to standard care 
was associated with a decrease in the number of days from a patient’s referral for KTx 
evaluation to KTx candidacy decision.
Methods: During evaluation scheduling at a single KTx center, patients answered 
questions from a risk assessment tool created using existing data; high-risk patients were 
randomized prior to KTx evaluation to either standard of care (control) or the additional 
assistance of a patient navigator (intervention). The patient navigator helped guide patients 
through the KTx process, serving as a point of contact and providing support and education 
from the time of referral for KTx evaluation through candidacy decision (patient approved 
for placement on waiting list or deemed “not a candidate”).
Results: From January 2013 to October 2014, 394 patients were enrolled in the study. 
Patient demographics were similar among intervention and control groups (80% Black, 
80% Medicare, 50% < age 55). A total of 311 (79%) reached candidacy decision (79% 
of intervention and 79% of control patients) and were included in preliminary analyses. 
Intervention patients reached candidacy decision a median of 8 days faster than control 
patients (119 vs. 127 days). Shorter time to decision for intervention vs. control patients 
was observed in most examined subgroups, including black (8 days) and white patients (9 
days), patients who completed high school (10 days), Medicare patients (15 days), patients 
with BMI>35 (30 days), married (11 days) and single patients (7 days), and patients < 
age 55 (19 days).
Conclusions: Preliminary results support the efficacy of a patient navigation program 
in reducing time from patient KTx referral to candidacy decision in a KTx setting. The 
use of a similar program in other KTx centers may help patients who require additional 
assistance during the KTx process complete KTx evaluation more quickly.
Funding: Private Foundation Support
SA-PO1002
Knowledge of Treatment Options in Patients Evaluated for Kidney 
Transplantation: iChoose Kidney Randomized Trial  Mohua Basu,1 
Stephen O. Pastan,1 Sumit Mohan,2 John J. Friedewald,3 Daniela P. Ladner,3 
Rachel E. Patzer.1  1Emory Univ, Atlanta, GA; 2Columbia Univ, New York, NY; 
3Northwestern Univ, Chicago, IL.
Background: Although kidney transplantation (KTx) provides a significant survival 
advantage over long-term dialysis, many end stage renal disease (ESRD) patients are not 
educated about KTx options. We developed a clinical decision tool (iChoose Kidney) to 
provide individualized risk estimates of patient survival on dialysis vs. KTx to evaluate 
whether use of the decision tool during KTx evaluation improved patient knowledge of the 
survival benefit of KTx vs. dialysis and of living vs. deceased donor KTx.
Methods: In December 2014, we began enrolling patients from three large KTx centers 
across the U.S. in a trial, where patients are randomized to usual KTx evaluation (control) 
or an appointment during which the nephrologist uses iChoose Kidney with the patient 
(intervention). Pre- and post-nephrology consultation, we surveyed patients on whether 
they believed their chance of survival was higher, lower, or the same with 1) dialysis 
vs. KTx and 2) living vs. deceased donor KTx. Improvement in knowledge was defined 
as a change from incorrect to correct post-nephrology consultation. Health literacy was 
measured using the Newest Vital Sign and categorized into low/moderate vs. high (0-3 vs. 
4-6 correct out of 6, respectively).
Results: To date, 214 patients are enrolled (target enrollment n=450). Among 106 
intervention patients, 29% improved their knowledge of the survival benefit of dialysis 
vs. KTx, vs. 19% of 108 control patients (p=0.07). Among patients with low or moderate 
literacy, 35% of intervention patients improved vs. 13% of control patients (p=0.01); this 
difference was not observed among high literacy patients (26% improved in each group). 
For knowledge of the survival benefit of living vs. deceased donor KTx, 19% of intervention 
patients improved, vs. 11% of control patients (p=0.17).
Conclusions: Preliminary results show that the use of the iChoose Kidney decision 
tool in comparing survival estimates for dialysis vs. KTx may improve patient knowledge 
of treatment outcomes during KTx evaluation, and the tool may be especially effective 
among a low-literacy population.
Funding: Private Foundation Support
SA-PO1003
Hemodialysis Social Networks Facilitate the Completion of Transplant 
Testing and Successful Kidney Transplantation  Avrum Gillespie,1,3 Alexey 
Uversky,2 Jonathan T. Hunt,1 Heather Marie Traino,3 Sarah Bauerle Bass,3 
Teri Browne,4 Zoran Obradovic.2  1Nephrology, Hypertension, and Kidney 
Transplantation, Temple Univ School of Medicine, Philadelphia, PA; 2Center 
for Biomedical Informatics, Temple Univ, Philadelphia, PA; 3School of Public 
Health, Temple Univ, Philadelphia, PA; 4School of Social Work, Univ of South 
Carolina, Columbia, SC.
Background: Hemodialysis (HD) social networks may promote access to a kidney 
transplant (KT). We set out to observe the formation of HD social networks and their 
role in completing the steps of the transplantation process in a newly formed HD clinic.
Methods: Between 8/2012 - 2/2015, 46 patients admitted to a newly formed HD 
clinic were enrolled, 63% were new to HD. Patients spoke either English (78%) or Spanish 
(22%). All eligible patients were referred for transplant evaluation and testing. Progression 
of steps towards KT was tracked. Patients were surveyed on admission and then quarterly 
using a previously validated questionnaire. Social interactions and seating were recorded, 
this data was merged with survey data and analyzed in SPSS 21.
Results: Two thirds of patients were observed to participate in social networks. There 
were no demographic differences among the patients who participated in social networks 
“social” vs. those who didn’t “non-social”. More social patients wanted a KT, 100% vs 
73.3% (p=0.008). Social patients reported talking to other patients about their health or 
KT 64.5% vs. 6.7% (p < 0.001). Social patients completed more steps, 2 steps (range 0-6) 
including 7 transplants vs 0.5 steps (range 0-3) and no transplants in the “non-social” group 
(p=0.037). In a multivariate regression analysis, only participating in a social network 
was positively associated with completing more steps (β 1.44 p = 0.028), and vintage was 
negatively associated (β -0.973, p= 0.029).
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Conclusions: In this HD clinic, patients that formed and participated in social networks 
were more likely to complete the steps and receive a kidney transplant. These findings 
emphasize the importance of HD social networks and the transfer of health information 
among patients.
Funding: Private Foundation Support
SA-PO1004
Kidney Transplant Referral Among Incident Georgia Dialysis Patients with 
and without Systemic Lupus Erythematosus: The RaDIANT Community 
Study  Laura Plantinga, Rachel E. Patzer, Sung S. Lim, Cristina Drenkard, 
Stephen O. Pastan.  Emory Univ, Atlanta, GA.
Background: Although providers often wait to transplant patients with systemic 
lupus erythematosus (SLE), shorter overall times to transplant are generally associated 
with more favorable transplant outcomes in SLE patients. We examined whether referral 
for evaluation—the first step in the often years-long process of kidney transplantation—is 
delayed in dialysis patients with SLE, relative to other dialysis patients.
Methods: United States Renal Data System data on a cohort of 18,419 incident (1/1/05-
9/30/12) adult (18-69 years) dialysis patients were linked to concurrent referral data from 
all three Georgia adult transplant centers. SLE was defined by the provider-assigned cause 
of ESRD. Logistic regression and Cox proportional hazards models were used to examine 
the associations of assigned cause and patient characteristics with preemptive referral 
(referral prior to the start of dialysis) and time from start of dialysis to referral [censored 
for death or last date of follow-up (9/30/12)], respectively.
Results: Of the 352 dialysis patients with SLE, 43 (12.2%) were preemptively 
referred—50% more often than other ESRD patients [1573/18,067 (8.7%); OR=1.5 (95% 
CI, 1.1-2.1)]. Adjustment for age rendered this association null [OR=1.1 (95% CI, 0.8-1.6)]. 
Among the 17,293 dialysis patients not preemptively referred, SLE patients were referred 
at twice the rate of other dialysis patients in crude analyses [HR=1.9 (95% CI, 1.6-2.2)] 
but not after adjustment for [HR=1.1 (95% CI, 0.9-1.2)]. Among SLE patients, black vs. 
white race was associated with lower likelihood of preemptive referral [OR=0.5 (95% CI, 
0.2-1.2)] but higher rates of referral after dialysis start [HR=1.8 (95% CI, 1.1-2.9)]. Male 
vs. female sex was associated with higher rates of referral on dialysis [HR=1.6 (1.1-2.4)].
Conclusions: Referrals for kidney transplant evaluation do not appear to be delayed 
among dialysis patients with SLE, relative to other dialysis patients of similar age. Efforts 
to increase kidney transplant access in SLE patients should focus on potential race and 
sex disparities in referral as well as potential delays in other steps of the kidney transplant 
process.
Funding: Other NIH Support - NIMHD
SA-PO1005
Association of Kidney Transplantation Referral with Other Indicators of 
Quality Care Among Incident Georgia Dialysis Patients: The RaDIANT 
Community Study  Laura Plantinga,1 Stephen O. Pastan,1 Jenna Krisher,2 Eric 
M. Gibney,3 Laura L. Mulloy,4 Rachel E. Patzer.1  1Emory Univ, Atlanta, GA; 
2Southeastern Kidney Council, Inc., Raleigh, NC; 3Piedmont Transplant Inst, 
Atlanta, GA; 4Georgia Regents Univ, Augusta, GA.
Background: Dialysis facility referral of patients for kidney transplant is a potential 
indicator of quality care. We examined whether referral within a year of dialysis start 
(1-year referral) was associated with other quality indicators among incident Georgia 
dialysis patients.
Methods: We examined a cohort of 14,120 incident (7/1/05-9/30/11; follow-up through 
9/30/12) adult (18-69 years) dialysis patients using United States Renal Data System data 
linked to concurrent referral data from all three adult Georgia kidney transplant centers. 
Multilevel, multivariable logistic regression was used to examine the association of 
1-year referral with dichotomous quality indicators [pre-ESRD nephrology care, dialysis 
modality, permanent vascular access in place at dialysis start (HD patients only), pre-
ESRD erythropoietin use, and transplant information at dialysis start], with adjustment for 
demographic and clinical variables and accounting for variation across clinics.
Results: Overall, 1-year referral was 24.8% and was higher among patients with other 
indicators of quality care: 26.0% vs. 23.8%, with vs. without pre-ESRD care (P=0.005); 
27.8% vs. 24.6%, PD vs. HD (P=0.03); 28.3% vs. 22.9%, with vs. without a permanent 
vascular access in place at HD start (P<0.001); and 27.2% vs. 16.5%, informed vs. not 
informed of transplant options at dialysis start (P<0.001). With adjustment, pre-ESRD care 
[OR=1.34 (95% CI, 1.22-1.47)], permanent vascular access in place [OR=1.54 (95% CI, 
1.41-1.70)], and transplant information at dialysis start [OR=1.63 (95% CI, 1.45-1.85)] 
remained associated with higher 1-year referral.
Conclusions: These findings suggest that patients who receive quality care in multiple 
domains are more likely to be referred for kidney transplant evaluation within a year of 
starting dialysis, independent of demographic and clinical characteristics. Interventions 
to increase transplant access should be targeted to patients whose care fails to meet other 
quality indicators.
Funding: Other NIH Support - NIMHD
SA-PO1006
Feasibility and Sustainability of the RaDIANT Community Study Among 
Georgia Dialysis Facilities  Jennifer C. Gander,1 Leighann Sauls,2 Teri Browne,3 
Laura Plantinga,1 Laura J. McPherson,1 Eric M. Gibney,4 Laura L. Mulloy,5 
Stephen O. Pastan,1 Rachel E. Patzer.1  1Emory Univ; 2Southeastern Kidney 
Council; 3Univ of South Carolina; 4Piedmont Hospital; 5Georgia Regents Univ.
Background: The Southeastern Kidney Transplant Coalition developed the 
randomized, dialysis facility-level Reducing Disparities In Access to kidNey Transplantation 
(RaDIANT) Community Study to address racial disparities and low rates of kidney 
transplantation (KTx) in Georgia. We aimed to evaluate the feasibility and sustainability 
of the RaDIANT intervention activities.
Methods: The 67 dialysis facilities that completed a 12-month intervention as part 
of the RaDIANT study consisted of 12 recommended activities intended to increase KTx 
referral, such as education and outreach activities targeting the patient, facility staff, and 
facility policy level. After the intervention, facility staff were asked to complete a 20-
item questionnaire on the helpfulness (Likert scale) of each intervention activity and the 
likelihood (yes/no) of their facility continuing the activity.
Results: A total of 86 staff (51.2% social workers) at the 67 intervention facilities 
completed the survey. The median number of the 12 intervention activities completed by 
dialysis facilities was 9 (range 0,11). Most facilities reported discussing the benefits of 
KTx at a staff orientation (86.6%), attending monthly webinars (80.7%), and developing 
a referral improvement plan (76.3%) to be helpful or very helpful. The median number of 
prescribed intervention activities the facilities reported they would continue was 2, with the 
distribution of educational brochures (41.9%), a staff orientation focused on KTx (41.9%), 
and a patient and family education session (34.9%) among the most commonly cited.
Conclusions: Dialysis facility staff perceived that RaDIANT intervention activities 
were feasible to implement, with staff education potentially being the most helpful and 
sustainable component. Sustainability may be limited to intervention components that 
were the least expensive and time intensive to implement. Additional ongoing support 
from ESRD Networks may be necessary to sustain increased KTx referrals observed in 
the RaDIANT Community Study.
Funding: Other NIH Support - The RaDIANT Community Study is funded in part by 
NIMHD Award R24MD008077
SA-PO1007
Psychosocial Differences Between Living and Deceased Donor Renal 
Transplant Recipients  Anna Bertram,1 Selma Pabst,2 Martina De zwaan,2 
Tanja Zimmermann,2 Mario Schiffer.1  1Clinic for Psychosomatics and 
Psychotherapy, Hannover Medical School, Hannover, Germany; 2Nephrology 
and Hypertensiology, Hannover Medical School, Hannover, Germany.
Background: The specific impact of living donor (LD) as compared to deceased 
donor (DD) kidney transplants on psychosocial functioning has received surprisingly 
little attention. The present study aimed to assess whether LD and DD recipients differ in 
socio-demographic variables, time since transplantation, emotional variables, knowledge 
about immunosuppressant (IS) intake, and self-reported adherence to IS.
Methods: A questionnaire study was performed among 72 LD and 169 DD recipients 
who attended the kidney transplant outpatient clinic of Hannover Medical School for a 
follow-up visit at least 1 year after transplantation. Emotional responses were assessed using 
the Hospital Anxiety and Depression Scale (HADS) and the Transplant Effect Questionnaire 
(TxEQ). Patients’ knowledge about IS intake was examined with a newly developed test 
consisting of 8 multiple choice questions, and IS adherence was measured by self-report 
(BAASIS), physicians’ estimates, IS trough level variability, and allograft rejection.
Results: Overall, LD recipients were younger and had a shorter follow-up since 
transplantation. Our results indicate that LD and DD transplantation may lead to different 
emotional responses with more feelings of guilt towards the donor and perceived 
responsibility to do well and with a generally higher anxiety level in LD recipients. LD 
recipients apparently had more knowledge about IS medication. However, they did not 
report more adherence to IS. No differences between LD and DD recipients were found 
for gender, educational level, depression, perceived social support, and allograft rejection.
Conclusions: Feelings of guilt and anxiety may be an important focus for interventions 
to improve emotional adjustment to transplantation, especially in LD recipients.
SA-PO1008
Physician-Reported Adherence with Immunosuppressants in Renal 
Transplant Patients: Prevalence, Agreement, and Correlates  Anna Bertram,2 
Selma Pabst,1 Martina De zwaan,1 Mario Schiffer.2  1Clinic for Psychosomatics 
and Psychotherapy, Hannover Medical School, Hannover, Germany; 
2Nephrology and Hypertensiology, Hannover Medical School, Hannover, 
Germany.
Background: Assessing adherence to immunosuppressants (IS) is difficult. We 
investigating (1) the prevalence of non-adherence with IS as estimated by physicians; 
(2) the agreement between the physicians’ estimated and other adherence measures; (3) 
the difference between adherent and non-adherent patients according to the physicians’ 
estimation with regard to socio-demographic variables, transplant-related variables, and 
psychological factors.
Methods: All kidney transplant patients attending the outpatient clinic for a follow-up 
visit from 11/2014 to 02/2015 were screened; 238 patients met inclusion criteria. Adherence 
with IS was assessed with several measures: 4-item Basel Assessment of Adherence to 
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Immunosuppressive Medication Scale (BAASIS) and the adherence subscale of the German 
version of the Transplant Effect Questionnaire (TxEQ) for self-reported adherence; the 
physicians were asked to estimate patients’ adherence to IS on a scale ranging from 1=very 
good to 5=very poor. Other adherence measures included rejection treatment within the 
previous 12 months and IS trough level variability in the last 13 months. Psychological 
variables were assessed with the 14-item Hospital Anxiety and Depression Scale (HADS) 
and the Questionnaire of Perceived Social Support (FSozU-7).
Results: The physicians rated 9.2% (n=22) of the patients as being non-adherent. 
There was no agreement between the physicians’ estimate of adherence and the patients’ 
self-assessment, IS trough level variability, and allograft rejection. Physicians’ ratings were 
independently related to female sex, non-German native language, higher symptoms of 
depression and anxiety, and less perceived social support.
Conclusions: Physicians might rely on observable and interactional cues including sex, 
language, and psychopathology to make inferences about an individual patient’s adherence. 
Also, overestimation of IS adherence may impede physicians’s ability to provide high 
quality care for their renal transplant patients.
SA-PO1009
Evolution Through 20 Years of the Major Kidney Transplant Program from 
Living Donor in Mexico  Edgar Solis,1 Luis Alberto Evangelista-Carrillo,1 
Enrique Rojas-Campos,2 Benjamin Gomez-Navarro.1  1Dept de Nefrologia y 
Trasplantes, IMSS, Guadalajara, Jalisco, Mexico; 2Unidad de Investigación 
Médica en Enfermedades Renales, IMSS, Guadalajara, Jalisco, Mexico.
Background: According to the National Transplant Center, in 2013 a total of 2707 
kidney transplants (KT) were performed in Mexico. Our program performed the highest 
single center number of transplants with 270 KT, mostly from living donors.
Methods: We use data collected in our registration program at Nephrology and 
Transplant Unit. All the KT in adult patients performed from January 1994-December 2014 
in CMNO were included. We also analized the last 909 kidney recipients and their serum 
creatinine at the end of first year. Successful KT was defined as a Cr <1.5 mg/dl at 1 year 
following. Grafts lost were defined as Cr >4.0 mg/dl or replacement therapy initiation.
Results: During this period 3643 KT were performed, 3236 from living donors and 
407 from cadaver donor. Of living donors, 2786 were from related donor and 450 were 
from genetically unrelated donors. The mean age of recipient was 28 years; 65% of our 
recipients were male. The evolution of the program is shown. 
Success rate of KT following 1 year was 86.8%. Only female gender and younger 
donors were statistically significant associated with succesful transplant. Graft lost during 
the first year was 3.6%. Death was 2.4% during the first year. 
Multivariate analysis for succesful transplant 
OR IC 95% p
Recipient gender 2.56 (1.26-5.13) 0.009
Donor age 1.04 (1.04-1.01) 0.002
Identical HLA 0.21 (0.12-0.21) 0.129
X2 =24.50; p <0.001 
Conclusions: Each year we are still growing the number of KT. The age of our recipients 
is diminishing and age of donors is increasing. Months before KT are also increasing lately 
reflecting the great number of ESRD patients. Recipient age, HLA mismatching, induction 
therapy use and generic drugs can explain the 13.2% of patients with Cr above 1.5 mg/dl.
SA-PO1010
The Difficult Road for Native Americans in Kidney Transplantation: 
Decreased Access and Reduced Long-Term Survival  Sarah Stith,1 Kristina 
Piorkowski,1 Fidel Barrantes.2  1Economics, Univ of New Mexico, Albuquerque, 
NM; 2Presbyterian Transplant Center, Renal Medicine Associates, Albuquerque, NM.
Background: Native Americans (NAs) have disproportionately high rates of end-stage 
renal disease, yet wait listed NAs have lower rates of kidney transplantation than other racial/
ethnic groups and worse long-term post-transplant survival outcomes than whites. This 
study evaluates these disparities across multiple medical and socioeconomic dimensions.
Methods: Using data from the Organ Procurement and Transplantation Network 
(OPTN), we evaluated wait list removal reasons and post-transplant survival rates from 
3/1/95 to 12/31/12. We use a logistic regression model, controlling for patient, donor, 
match characteristics, and center and year fixed effects, along with a Blinder-Oaxaca 
decomposition of the results.
Results: Among registered patients removed from the wait list, NAs were less likely 
to receive a transplant (odds ratio, 0.71 [95% CI, 0.64-0.80]). and more likely to die on the 
wait list (1.88 [0.89-3.94), compared to whites. NAs are less likely than whites to survive 
at least two years (odds ratio, 0.80 [95% CI, 0.70-0.92]) and at least three years (0.81 
[0.71-0.94]), but these disparities become statistically insignificant with risk adjustment.
Conclusions: NAs experience higher rates of adverse wait list removal reasons than 
other racial/ethnic groups. Among NAs who do receive transplants, short term survival 
outcomes are similar to those of whites, but longer term survival outcomes are lower. The 
decomposition of our results indicates that the disparity in three-year post-transplant survival 
between NA and whites is driven primarily by the prevalence of lower quality donors among 
NAs and a greater negative impact from such donor characteristics on survival among NA. 
NAs also tend to receive transplants at centers associated with worse outcomes and would 
benefit disproportionately from receiving transplants at better centers.
Funding: Private Foundation Support
SA-PO1011
Estimated GFR for Living Kidney Donor Evaluation  Naya Huang,1 Meredith 
C. Foster,1 Krista L. Lentine,2 Amit X. Garg,3 Emilio D. Poggio,4 Bertram L. 
Kasiske,5 Lesley Inker,1 Andrew S. Levey.1  1Div of Nephrology, Tufts Medical 
Center, Boston, MA; 2Div of Nephrology, Saint Louis Univ, MO; 3Div of 
Nephrology, Western Univ, London, ON, Canada; 4Dept of Nephrology and 
Hypertension, Glickman Urological and Kidney Inst, Cleveland Clinic, OH; 
5Dept of Medicine, Hennepin County Medical Center and Univ of Minnesota, 
Minneapolis, MN.
Background: All living kidney donor candidates undergo an evaluation of GFR. 
Guidelines recommend measured GFR(mGFR) rather than estimated GFR(eGFR), but 
measurement methods are difficult, time consuming and costly. We questioned whether 
eGFR using creatinine (eGFRcr) with or without sequential cystatin C (eGFRcr-cys) is 
sufficiently accurate to identify donor candidates with high probability that mGFR is above 
or below thresholds for clinical decision making.
Methods: We combined the pre-test probabilities for mGFR thresholds <60, <70, 
≥80 and ≥90 mL/min/1.73 m2 in varying age, sex and race groups estimated from the 
National Health and Nutrition Examination Survey (NHANES) with test performance of 
eGFR (categorical likelihood ratios [LRs] determined from the Chronic Kidney Disease 
Epidemiology Collaboration) to compute post-test probabilities of meeting a given mGFR 
threshold.
Results: Using NHANES pre-test probabilities,we found that that in some 
circumstances, eGFRcr and eGFRcr-cys provides high accuracy (post-test probability≥95%) 
in candidate donors. Using data from the Scientific Registry of Transplant Recipients, we 
demonstrated that 54% and 82% of recent donors had pre-donation eGFRcr high enough 
to assure ≥95% probability that pre-donation mGFR was ≥90 and ≥80 ml/min/1.73 m2 
respectively, suggesting a large fraction of donor candidates might not require mGFR.
Conclusions: Implementation strategies could include eGFRcr as a first test and 
possibly eGFRcr-cys as confirmatory test. If post-test probabilities are of sufficient 
magnitude, eGFR could be used to accept or reject donors without measurement of GFR. 
We will provide a web-based application.
SA-PO1012
Change of Physical Activities in Male and Female Recipients in 12 Months 
After Living Kidney Donor Transplantation  Makoto Tsujita.  Transplant 
Surgery, Nagoya Daini Red Cross Hospital, Japan.
Background: Since renal dysfunction and immunosuppressive drugs cause muscle 
degeneration, physical activities decrease in CKD, dialysis patients and transplant recipients. 
In addition, elderly kidney transplant recipients are increasing in Japan, so improving 
physical activities and increasing muscle strength and volumes are important to prevent 
fracture and fall accident.
Methods: Consecutive 58 patients (male 33) older than 40 years were enrolled in 
this study from 2012. Immunosuppression basically contains steroid, cyclosporine or 
tacrolimus, and mycophenolatemofetil or everolimus. Hypertension, hyperlipidemia, 
and osteoporosis were treated as needed. Parameters of physical activities such as hand 
grip, SMI (skeletal muscle index) and Body fat mass using by DEXA(dual-energy x ray 
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absorptiometry) , and Body mass index (BMI) were measured and compared at prior, 6, and 
12 months after kidney transplantation. Recipients were encouraged to do daily exercise 
for 30 to 60 minutes everyday.
Results: Mean age (years) were 52.3±10.0 in male, and 53.6±10.4 in female. In male 
patients, any parameter did not change after transplantation in male patients. In female 
patients, SMI improved in 12 months (p<0.005), and Hand grip also tended to increase 
without statistically difference.
Physical activities seemed unchanged after transplantion in male patients than before.
Conclusions: In male recipients, physical activities do not seem to recover in 12 months 
after kidney transplantation. More interventions and more studies are needed to increase 
physical activities and know the effect of daily exercise clinically.
SA-PO1013
Search for New Data to Predict Kidney Transplant Outcomes in the Organ 
Procurement and Transplantation Network Database  Mohamed A. Sheta,1 
Bertram L. Kasiske,2 Charles E. Alexander,3 Joseph Kim.4  1Univ of Minnesota; 
2Hennepin County Medical Center; 3Univ Health Network; 4The Living Legacy 
Foundation of Maryland.
Background: The Organ Procurement and Transplantation Network (OPTN) collects 
data used to monitor transplant program outcomes for quality assurance and regulatory 
oversight. It is imperative that the variables in the OPTN database used by the Scientific 
Registry of Transplant Recipients to determine expected outcomes after kidney transplant 
be reliable,complete,and up-to-date.
Methods: We conducted a systematic review to identify risk factors not included 
in current OPTN data that predict graft failure or mortality after kidney transplant. We 
searched for studies with:publication date between Jan 1 2000-May 1 2015; at least 
1000 subjects in one or more risk prediction models;multivariate analysis used to select 
variables predicting patient or graft survival; inclusion in the multivariate model of at least 
one risk factor collected before or at the time of transplant that is not already collected 
by OPTN;and English language. For duplicate publications we selected the most recent.
For publications with overlapping but distinct cohorts,we selected the one with the largest 
cohort.We arbitrarily limited the search to studies including 1000 participants in at least 
one risk-prediction model.Although a small single-center study may convincingly show 
that a newly described risk factor predicts outcomes at that center,there are likely major 
barriers to measuring and collecting this risk factor uniformly at every program in the US.
Results: We identified 33 studies that met inclusion criteria; 6 (18%) were single-
center, 4 (12%) were multicenter, and 23 (70%) were registry studies. Promising new 
variables included: myocardial infarction, coronary artery revascularization,atrial 
fibrillation, congestive heart failure,valvular heart disease,cerebral vascular 
accident,carotid artery revascularization,aortic aneurysm repair, ischemic leg amputation 
or revascularization,tobacco abuse, alcohol and illicit drug dependence,ZIP code,and 
socioeconomic status.
Conclusions: This review provides evidence for the new OPTN Ad Hoc Data Advisory 
Committee to update the OPTN database.
SA-PO1014
Prevalence of Mineral and Bone Disorders Among Living Kidney 
Transplant Recipients  Essam Mohammed Khedr, Amr Mohab, Haitham Ezzat. 
Nephrology Dept, Ain Shams Univ, Cairo, Egypt.
Background: Mineral and bone disorders (MBD), frequent complications of chronic 
kidney disease (CKD), occur frequently in kidney transplant recipients.Still, little is known 
about its prevalence and clinical correlates in transplanted patients.
Methods: We conducted a cross-sectional analysis of 504 stable living kidney allograft 
recipients. Detailed medical history, demographic data and routine laboratory investigations, 
including s.creatinine, s.corrected Calcium, s.Phosphorus, serum iPTH and s.Alkaline 
Phosphatase (ALP) were collected. Estimated GFR was calculated using the abbreviated 
MDRD formula. Patients were stratified into three groups based on duration of kidney 
transplantation. Group I:6 months to 1 year, group (II): from 1 to 5 years and group (III): 
more than 5years.Correlations were done between bone minerals and all laboratory results. 
We also analyzed the possible relation between various immunosuppressant drugs and bone 
minerals, serum iPTH and serum ALP.
Results: The mean age was 32±8 years in group I, 45±3.7 years in group II, and 40±5 
years in group III, with no significant difference between the three groups (p >0.05). There 
was no significant difference between the studied groups as regards results of laboratory 
parameters(p >0.05).115 patients had iPTH levels > 170 ng/dl, while 365 patients (72.4%) 
had iPTH levels >70 ng/dl. Only 24 patients had hypercalcemia, and 34 patients had 
hyperphosphatemia. We also found that 68 patients had hypophosphatemia. Serum iPTH 
and serum ALP levels were higher in group III (156±66 ng/dl, 135±54 IU respectively) when 
compared to group I (98±33.4 ng/dl,120±33 IU) and group II (138±35 ng/dl,122±60 IU) 
(p <0.001). In group I, iPTH levels were negatively correlated with eGFR (r value= -0.37, 
p <0.05). Both serum ALP and iPTH levels showed significant negative correlation with 
eGFR in groups II and III (p <0.05). In all groups, bone minerals, iPTH and serum Alkaline 
Phosphatase levels had no statistically significant relation with the immunosuppressant 
agent used (p >0.05).
Conclusions: Disturbances of bone and mineral metabolism after transplantation are 
prevalent and are strongly correlated with the kidney function and transplantation duration.
SA-PO1015
Risk of Adverse Maternal and Fetal Outcomes During Pregnancy in Living 
Kidney Donors  Jessica B. Kendrick,1,2 John R. Holmen,3 Gerard John Smits,1 
Michel Chonchol.1  1Univ of Colorado Denver, Aurora, CO; 2Denver Health 
Medical Center, Denver, CO; 3Intermountain Health Care, Salt Lake City, UT.
Background: A frequently asked question by potential kidney donors is risk of 
nephrectomies on maternal and fetal outcomes in pregnancy. Studies regarding the risks of 
living kidney donation and pregnancy outcomes are conflicting. The purpose of this study 
was to determine the risk of adverse maternal and fetal outcomes in donors vs. non-donors.
Methods: Using data from an integrated health care delivery system in Utah from 
2000 through 2014, a total of 72 women were living kidney donors that became pregnant 
after kidney donation. Using a pool of 74,105 women who were not donors, we selected 
1223 to use for matches for the living kidney donors. These women were matched 1:3 by 
age and race. Adverse pregnancy outcomes were defined as preterm delivery, delivery via 
cesarean section, preeclampsia/eclampsia, length of stay in the hospital and low birth weight 
(<2,500 g). Logistic regression analysis was used to examine the association between living 
donation and adverse outcomes.
Results: Of the living kidney donors, the mean (SD) age and mean (SD) gestational 
age at delivery was 30±5 years and 38±2 weeks, respectively. The mean (SD) length of stay 
in the hospital was 2.7 ± 2.7 days. Six cases (8%) had a history of chronic hypertension. 
Living kidney donors did not have a higher risk of preterm delivery (OR 1.82, 95% CI 
0.877-3.77), preeclampsia/eclampsia (OR 1.11, 95% CI 0.47-2.65), delivery via cesarean 
section (OR 1.51, 95% CI 0.85-2.66), length of stay > 3 days (OR 1.29, 95% CI 0.63-2.64) 
or low birth weight (OR 1.94, 95% CI 0.87-4.35) compared to non-donors.
Conclusions: Living kidney donation is not associated with a higher risk of adverse 
outcomes in pregnancy.
Funding: NIDDK Support
SA-PO1016
The Quality of Life of Parents of Pediatric Kidney Transplantation 
Yuko Hamasaki,1 Miyako Tazaki,2 Yusuke Takahashi,1 Seiichirou Shishido,1 
Atsushi Aikawa.3  1Pediatric Nephrology, Toho Univ Faculty of Medicine, Tokyo, 
Japan; 2Psychology, Toho Univ Faculty of Medicine, Tokyo, Japan; 3Nephrology, 
Toho Univ Faculty of Medicine, Tokyo, Japan.
Background: The purpose of the study is to investigate how the Quality of life (QOL) 
of parents whose child had received kidney transplantation (KT) would change by delivering 
questionnaires four times; before, one month after, three months after and one year after KT.
Methods: The QOL of thirty-one parents (30 mothers and 1 father) with a mean age 
of 38.5 years old whose child received KT at Toho University Omori Medical Center from 
May 2012 to March 2015 was measured using WHO Quality of Life (WHOQOL), Visual 
Analogue Scale (VAS), and General Health Questionnaire (GHQ). The mean age of the 
recipients was 5.8 years old (18 boys, 13 girls). Congenital anomalies of the kidney and 
urinary tract were the most frequent primary diseases (54.8%). Among them, twenty-two 
children received dialysis before KT, and nine received preemptive KT.
Results: Based on the results, the average WHOQOL scores show the QOL of parents 
decreased one month after KT (3.15) with a statistical difference compared with before KT 
(p=0.042), but increased at three months (3.40) (p=0.0073), and maintained until one year 
(3.41). The average QOL of the parents of a child with frequent infection was statistically 
lower than those without any infection (p=0.448) at three months after KT and one year 
after KT (p=0.0406). The average QOL scores of nineteen donor parents had a statistically 
higher QOL before KT then reversed at one month after KT, but became higher again at 
three months after KT.
Conclusions: The QOL of the parents would decreased one month after KT when 
infection or other problems often occurred, but increased after three month when the 
condition of recipients stabilized and maintained until one year after KT, which became 
as high as before KT.
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SA-PO1017
Disparities in Access to Renal Transplant in Puerto Rican Children 
Nilka deJesus-Gonzalez,1 Sonia M. Caraballo,1 Eduardo J. Santiago-Rodriguez,2,3 
Marta P. Suarez-Rivera,1 Melvin A. Bonilla-Felix.1  1Medical School, Pediatric 
Nephrology Div, Univ of Puerto Rico; 2Univ Central del Caribe; 3Puerto Rico 
Clinical and Translational Research Consortium.
Background: Disparities in access to renal transplant have been reported in racial 
minorities living in US. No data is available from children with ESRD living in Puerto 
Rico (PR), the largest Hispanic group in a single pediatric dialysis unit in US. We describe 
the pediatric population with ESRD in PR from 2003-2013, the renal transplant rates and 
possible barriers to receiving a graft.
Methods: Retrospective chart review of patients diagnosed with ESRD in PR from 
2003-2013. Incidence, prevalence rates, means/standard deviations (SD), medians/
interquartile range (IQR), frequencies and percentages were calculated and compared to 
national rates.
Results: From 2003-2013 99 patients, male: 52%, age:13.5yrs (8-16yrs), were 
diagnosed with ESRD . Congenital anomalies were the primary cause in 40%, and FSGS 
in 24% . Incidence of ESRD ranged from 3-14 subjects per million population/year, with 
prevalence per dialysis modality from 7-18 subjects per million population/year. 38% 
were transplanted in PR (Median age: 14yrs, IQR: 9-16), 23% from living donors. 14.1% 
received a transplant in the first year (National rate: 38%). 63% of transplanted children 
had Medicare coverage. None of 9 infants diagnosed with ESRD were transplanted during 
infancy. 46% of the children who were not transplanted stayed at our unit for a median 
time of 2 yrs (IQR: 1-3). The rest was transferred to a dialysis unit outside PR (15%) or to 
an adult facility without being transplanted (39%). 67% of these non-transplanted children 
were covered by Medicare. The mortality rate during the first year of diagnosis was 3% 
(National rate: 4%).
Conclusions: Children with ESRD in PR face striking disparities in access to renal 
transplant. Lack of pediatric transplant surgeons, geographical isolation and minimal 
living donation are potential barriers. Medicare coverage does not appear to be a factor, 
as it was similar between transplanted and non-transplanted. Interventions to reduce these 
inequities are needed.
Funding: Other NIH Support - Supported by grant 2U54MD007587 (RCMI Clinical 
and Translational Research Award, University of Puerto Rico Medical Sciences Campus) 
from the National Institute on Minority Health and Health Disparities (NIMHD), a 
component of the National Institutes of Health (NIH).
SA-PO1018
The Case against Declining Donors with Impaired Fasting Glucose 
Robert N. Foley, Naim S. Issa, Danielle M. Berglund, Arthur J. Matas, Hassan 
N. Ibrahim.  Univ of Minnesota, Mpls, MN.
Background: The definition of diabetes, impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT) have changed over time. IGF was definied in 1997 by fasting 
glucose 110-125 mg/dL and in 2003 the definition changed to fasting glucose 100-125 
mg/dL. With the introduction of this new definition, many potential donors with fasting 
blood sugar between 100-110 mg/dL have been denied donation. This is highly relevant 
as many of these are potential donors to family members with type 2 diabetes mellitus.
Methods: We assessed the risk of death, new onset diabetes, hypertension, proteinuria 
and reduced GFR (<45 and <30 ml/min/1.73m2) in 3783 kidney donors according to fasting 
blood glucose(FBG) at the time of donation spanning the period between 1963-2013.
Results: 2900 donors had a FBG <100 mg/dL, 550 with 100-109, 205 with 110-125, and 
128 donors with FBG > 126 mg/dL. Donors with IFG (100-109 mg/dL) after multivariable 
adjustment were not more likely to die, develop diabetes, proteinuria, hypertension, eGFR 
<45 ml/min/1.73m2 or eGFR <30ml/min/1.73m2 as compared to those with FBG <100 
mg/dL (Table 1). In contrast, those with FBG between 110-125 mg/dL were more likely 
to become diabetic and hypertensive but not proteinuric or reduced GFR. Those with FBG 
³126 mg/dL were more likely to die, develop DM and HTN but not suffer any adverse 
renal consequences. 
Outcome Fasting Blood Glucose (mg/dL)
100-109 110-125 ≥126
Death 1.08 (0.8-1.47 1.41 (0.91-2.18) 1.57 (1.02-2.41)*
Diabetes 1.19 (0.83-1.69) 2.07 (1.36-3.14)* 2.89 (1.8-4.64)*
HTN 1.2 (0.99-1.47) 1.61 (1.23-2.11)* 1.76 (1.26-2.44)*
Proteinuria 0.68 (0.44-1.06) 0.76 (0.41-1.41) 1.62 (0.89-2.93)
eGFR <45 ml/min 0.78 (0.43-1.43) 1.26(0.54-2.94) 1.3 (0.52 - 3.27)
eGFR <30 ml/min 0.96 (0.73-1.25) 1.31(0.87-1.96) 1.06(0.66-1.7)
* p-value <0.05 compared to FBG <100 mg/dL 
Conclusions: Excluding potential donors with a fasting glucose (100-109 mg/dL) 
should be revisited as these donors do well in the long-term.
Funding: Other NIH Support - NIH (5P01 DK013083)
SA-PO1019
Psychosocial Distress and Adherence in Adolescents Post-Kidney Transplant 
Jessica L. Stahl,1 Angela P. Presson,2 Chong Zhang,2 Raoul D. Nelson,1 Matthew 
M. Grinsell.1  1Pediatrics, Univ of Utah, Salt Lake City, UT; 2Study Design and 
Biostatistics Center, Univ of Utah, Salt Lake City, UT.
Background: Adolescents who are post-kidney transplant have comorbidities in 
medical and psychosocial arenas and high risk of non-adherence and graft loss. Limited data 
exists to describe the relationship between mental health and adherence in this population.
Methods: 22 parent-child dyads with children ages 12-17 were recruited at scheduled 
post-kidney transplant visits. They completed demographic and standardized Youth 
Outcomes questionnaires. Adherence was assessed using the standard deviation of the 
prior 1 year of tacrolimus levels and chart review for hospitalization for non-adherence. 
Descriptive statistics were used to assess the relationship of adherence to psychiatric 
diagnosis, psychosocial distress, gender, and time from transplant, as well as differences 
in parent-child reporting.
Results: Overall, 52% reported a psychiatric diagnosis, which is significant compared 
to 13% in the general adolescent population (p<0.001), with 38% evidencing elevated 
levels of psychosocial distress on self-report and 25% elevated per parent report. 68% of 
adolescents reported a different distress level than estimated by their parent. The psychiatric 
diagnosis rate was 64% in the non-adherent group and 36% in adherent adolescents. Only 
40% of the adherent group reported elevated distress versus 57% of the non-adherent 
group. There was a gender bias toward male non-adherence in this group with 100% of 
the non-adherent population being male. The mean time from transplant of non-adherent 
groups was 6.1 years versus 3.9 years in the adherent group. These differences were not 
statistically significant except as above.
Conclusions: Our population’s rate of psychiatric diagnosis was significantly elevated 
compared to community norms and also correlated with elevated psychosocial distress and 
non-adherence. Disagreement in parent and adolescent reporting was common regardless of 
adherence status. Our sample did demonstrate gender differences in non-adherent behavior 
as well. Interpretation of these results, as well as statistical significance is limited by the 
small sample size.
Funding: Other NIH Support - This investigation was supported by the University of 
Utah Study Design and Biostatistics Center, with funding in part from the National Center 
for Research Resources and the National Center for Advancing Translational Sciences, 
National Institutes of Health, through Grant 8UL1TR000105 (formerly UL1RR025764).
SA-PO1020
Post Donation Diabetes and Risk of Death and ESRD  Hassan N. Ibrahim, 
Robert N. Foley, Scott Reule, Danielle M. Berglund, Aleksandra Kukla, Naim 
S. Issa, Richard S. Spong, Arthur J. Matas.  Univ of Minnesota, Mpls, MN.
Background: We have previously shown that development of diabetes following live 
kidney donation does not result in accelerated GFR decline when compared to diabetics 
with two kidneys. Herein, we report on the development of a risk calculator for new onset 
DM in donors and address its contribution to mortality and also renal outcomes.
Methods: Donors are followed indefinitely through surveys including development 
and treatment of diabetes and renal outcomes. Risk factors for post donation diabetes were 
determined using stepwise proportional hazards regression.
Results: Development of DM was ascertained in 3874 donors with a mean follow-up of 
16±12 years. In total, 279 (7%) developed DM. Pre-donation risk factors for development 
include older age, BMI, tobacco use, and fasting serum glucose at donation, p£0.01 for 
all (Table 1a). Diabetes following donation was associated with a nearly 5 fold increase 
in proteinuria and 2 fold increase for eGFR < 30 or ESRD (Table 1b). Coefficients from 
the regression model were then used to create an individualized risk calculator. This was 
developed in 1934 donors and validated in the remaining 1934 (C-statistic 0.77). The 
cumulative risk of developing DM at 5 yearly intervals is shown in figure 1. 
Variable Adjusted Hazard Ratio p-value
1a) Pre-donation risk factors for DM
Age 1.01 (1-1.03) 0.01
BMI 1.12 (1.1-1.15) < 0.001
Tobacco use 1.37 (1.06-1.75) 0.01
Serum glucose 1.01 (1.01-1.02) < 0.001
1b) Post donation DM, mortality and ESRD
Death 0.71 (0.46-1.08) 0.11
Proteinuria 4.65 (3.28-6.59) <0.0001
eGFR <30 or RRT 2.21 (1.32-3.69) 0.0026
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Cumulative risk of DM for a typical White kidney donor.
Conclusions: Diabetes can be reasonably predicted in kidney donors using baseline 
data. Diabetes is a significant contributor to reduced GFR and proteinuria.
Funding: Other NIH Support - NIH (5P01 DK013083)
SA-PO1021
What Kind of Obesity Does Affect Kidney Function? Survey of Kidney 
Transplant Donors  Mikiko Yoshikawa, Junko Nakano, Kentaro Nakai, 
Hideki Fujii, Shinichi Nishi.  Div of Nephrology and Kidney Center, Kobe Univ 
Graduate School of Medicine, Kobe, Japan.
Background: Currently obesity is a risk for chronic kidney disease. It is also suggested 
that sarcopenia is the independent risk factor of hypertension. It is unclear whether obesity 
and body composition affect to kidney function and other prognosis of donors in our country. 
The aim of this study was to investigate the influence of body composition, the findings of 
graft biopsy and 1-year after clinical outcome.
Methods: This is a retrospective single center study of 60 living kidney transplant 
donors from 2009 to 2014. Donors are stratified according to Body Mass Index (BMI³25kg/
m2 is defined as an obesity in Japanese criteria) and skeletal muscle index (SMI) from 
the appearance of muscle on cross-sectional CT images (L3 SMI, Under 38.5cm2/m2 for 
women and 52.4 cm2/m2 for men are defined as a sarcopenia)(1). We divided donors into 
four groups; (A) Obesity negative + Sarcopenia negative (ONSN)(B) Obesity positive 
+ Sarcopenia negative (OPSN) (C) Obesity negative + Sarcopenia positive (ONSP) (D) 
Obesity positive + Sarcopenia positive (OPSP). We evaluated kidney function at donation, 
baseline kidney graft biopsy findings and clinical course 1 year-after donation.
Results: Seven patients were OPSN (11.7%), 22 patients ONSP (36.7%), and 4 patients 
OPSP (6.7%). Visceral fat area ³100 m2 ( which is defined as central obesity in Japanese 
criteria) was significantly higher in OPSP group.S-Cre at donation was significantly lower 
in OPSN and ONSP groups. In multivariate analysis of graft biopsies, BMI³25kg/m2 was a 
significant risk for small artery intimal thickenings and interstitial fibrosis/tubular atrophy. 
On the contrast, OPSP was an independent risk for global sclerosis. In multivariate analysis, 
central obesity was significantly correlated with 1-year after proteinuria. In addition, OPSP 
was a independent risk for 1-year after hypertension.
Conclusions: These results indicate obese donor already has a risk for arterial and 
interstitial damages at transplantation. In addition, central obesity and sarcopenia contribute 
to the late graft function and hypertension.[Reference] (1) Prado CM et al. Lancet Oncol 
2008; 9: 629–635.
SA-PO1022
Living Donor Remaining Function Measured by CKD-EPI Correlates with 
Remaining Kidney Volume  Asif A. Sharfuddin, Ali Khalil, Muhammad S. 
Yaqub, Tim E. Taber, Muhammad Ahmad Mujtaba.  Medicine/Neph, Indiana 
Univ.
Background: The aim of our study was to evaluate whether preserved kidney volume 
correlates with donor renal function at 2-years post-donation using the CKD-EPI eGFR 
equation.
Methods: Demographics and renal function of living donors who underwent living 
nephrectomy between January 2008 and November 2012 were reviewed. All donors 
underwent computed tomography with an estimation of kidney volumes. Preserved Kidney 
Volume (PKV) was adjusted (aPKV) to Body Surface Area.
Results: A total of 208 donors with 2 year follow up data available. Pre-donation eGFR 
(β Coef. 0.344), age (β Coef.-0.318) and aPKV (β Coef. 0.11) were found to be independent 
predictors of 2yr eGFR (p<0.001). aPKV was divided into tertiles (low/medium/high) and a 
2 year eGFR of <60ml/min was chosen as a cut off for dichotomous analysis as in Table 1.
2yr eGFR<60 2yr eGFR> 60 Total
Vol Tertile 1 (low) 44(47.8%) 24(20.7%) 68(32.7%)
Vol Tertile 2 (medium) 31(33.7%) 35(30.2%) 66(31.7%)
Vol Tertile 3 (high) 17(18.5%) 57(49.1%) 74(35.6%)
Mean aPKV (ml) 165±29 194±30*
Mean eGFR (ml/min) 52±6 76±15*
* p value < 0.001 
Mean 2yr eGFR was 57.9±12, 65±16 and 73±17 between the tertile groups (p<0.05). 
The odds ratio of having a 2yr post-donation eGFR <60 with a cutoff of median aPKV of 
194ml was 5.8 (95%CI 2.9-11.6; p<0.0001), while that of 2yr post-donation eGFR <60 
with a cutoff of < 25th percentile of aPKV of 159.9 was 5.6 (95%CI 2.7-11.22; p <0.0001). 
The odds ratio of having an eGFR <60 if the aPKV was above the 75th percentile was 0.13 
(95%CI 0.05-0.3) p<0.0001. ROC and AUC for aPKV and eGFR (CKD-EPI) of <60 were 
0.763 (CI0.69-0.82) p=0.005 as in Figure 1.
Conclusions: Our study is the first to show using CKD-EPI equation that preservation 
of residual renal function in living donors needs to take into account remaining kidney 
volume, when selecting kidneys from healthy donors.
SA-PO1023
Assessing Adherence Barriers in Pediatric Kidney Transplant Recipients 
Charles D. Varnell,1 Kristin Loiselle,2 Ahna Lh Pai,2 Avani Modi,2 David K. 
Hooper.1  1Div of Nephrology and Hypertension, Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH; 2Center for Treatment Adherence and Self-
Management, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Background: Nonadherence in pediatric kidney transplant recipients(KTRs)is 
associated with poor outcomes and poses a significant financial cost to society. Patient and 
family reported barriers to taking medications predict nonadherence, rejection, graft failure, 
and death. Despite their clinical importance and amenability to intervention, barriers to 
medication adherence are not routinely assessed in pediatric settings.
Methods: From Jan 2015 - May 2015, barriers to immunosuppressant adherence in 
KTRs were assessed using a standardized checklist of 14 common barriers. For KTRs<10 
y.o. the caregiver completed the assessment. For KTRs³10 y.o. both the patient and caregiver, 
if present, completed the assessment. Assessments were completed during routine outpatient 
clinic appointments.
Results: 36 pediatric KTRs [M(SD)age=13.14(6.43)years;56.7%male] and 50 
primary caregivers completed a barriers assessment. At least one barrier was reported by 
47% of KTRs compared to 42% of caregivers. For KTRs the most frequent barriers were 
forgetting(22%), hating the taste(13.9%) and running out of medicine(8.3%). For caregivers, 
the most frequently endorsed barriers were forgetting(20%), side effects(6.0%) and patient 
refuses to take their medication(6.0%). There was excellent concordance(96.2%) in dyads 
where both KTR and caregiver reported barriers. Assessing for barriers to adherence was 
easy to perform in practice and required<60 seconds.
Conclusions: Nearly half of all patients report at least one barrier to taking their 
immunosuppression, and there is generally consistent agreement between patient and 
caregiver perception of barriers. Standardizing the approach to assessing barriers to 
immunosuppression adherence in the clinical setting can quickly produce information 
that might be missed by the provider. Future research should evaluate the effectiveness of 
interventions delivered as part of routine medical care to overcome identified barriers and 
prevent known complications associated with nonadherence.
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SA-PO1024
A Longitudinal Follow-Up of Hispanic Living Kidney Donors 
Clarence E. Foster III,1 Pinky J. Patel,2 Hirohito Ichii,1 Madeleine V. Pahl,2 
Elani Streja,2 Jonathan R. Lakey,1 Kamyar Kalantar-Zadeh.2  1Surgery/ Div of 
Transplantation, Univ of California, Irvine, Orange, CA; 2Medicine/ Nephrology, 
Univ of California, Irvine, Orange, CA.
Background: This is a long-term follow-up of living kidney donors (LKD) in an 
ethnically diverse patient population. Hispanics are known to have an increased risk of 
developing chronic kidney disease, associated with hypertension and obesity. The hypothesis 
is Hispanic living kidney donors or uninsured living kidney donors would have poorer 
long-term outcomes secondary to lack of access to health care and secondary to the higher 
risk factors for developing chronic kidney disease .
Methods: The objectives : measure obesity, hypertension, diabetes, measure CrC, 
post-donation and compare to the pre-donation CrCl. LKD were contacted & invited 
to participate & had a questionnaire about their general health & history and physical. 
Analysis included a CBC, serum chemistry, a 24-hour urine collection to measure creatinine, 
protein and albumin. A Patient Data Visit Sheet, RAND 35 Health Questionnaire. The IRB 
approved this study.
Results: 
Demographics (N=42)
Hispanics
(23)
Non-
Hispanics
(19)
Age @ Donation, Years 
(range)
36 +/- 12
(18 to 55)
32 +/-11
(18 to 52)
41 +/- 10
(22 to 55) 0.007
Female (%) 57 43 26 NS
U.S. Citizen (%) 55 35 79 <0.0001
Health Insurance (%) 57 26 95 0.0058
Years Post-Donation 3.8(1.1 to 13.5)
3.6+/- 2.8 
(1.2 to 11.8)
4.0 +/- 3.4
(1.1 to 13.5) NS
Pre-Donation BMI, mean 25.6 27.9 24.7 0.0175
Pre-Donation GFR, ml/
min, mean 122 137 104.5 NS
Pre- and post-donation systolic and diastolic blood pressures were similar between 
Hispanics and non-Hispanic LKD. Non-Hispanic LKD had a greater decrease in systolic 
blood pressure post-donation -4.5 mmHg vs. 6 mmHg ( p-0.0378). The decrease in CrCl 
post-donation was the same in Hispanic and Non-Hispanic LKD, 33 ml/min vs. 35 ml/min. 
None of the LKD in the study had significant proteinuria or micro albuminuria.
Conclusions: Post living donor kidney donation in our ethnically diverse patients are 
not at a higher risk for developing obesity, HTN, or CKD. Overall, our LKD feel they have 
a good overall quality of life including both physical and emotional realms.
Funding: Pharmaceutical Company Support - Novartis Phamaceuticals
SA-PO1025
Predictors of Low Estimated Glomerular Filtration Rate After Living 
Kidney Donation in a Southeast Asian Population from Singapore 
Ru Yu Tan,1 John C. Allen,2 Terence Kee Yi Shern,1 Tazeen H. Jafar.2  1Dept of 
Renal Medicine, Singapore General Hospital, Singapore; 2Duke-NUS Graduate 
Medical School, Singapore.
Background: We aim to investigate patterns of change in kidney function and factors 
associated with low estimated glomerular filtration rate (eGFR) following living kidney 
donation in Southeast Asian.
Methods: We retrospectively studied living kidney donors with nephrectomy performed 
at Singapore General Hospital between 1976 and 2012. Quantile regression analysis was 
performed on pre- to post-nephrectomy percent change in CKD-EPI eGFR levels. Donors 
were grouped according to elapsed time from donation as short-term (>6 months to <5 years 
after donation), medium-term (5 to <10 years after donation), and long term (³10 years after 
donation), and compared on pre-nephrectomy demographic and clinical characteristics. 
Univariate and multivariate logistic regression were performed to evaluate predictors of 
low post-donation eGFR. A pre-nephrectomy eGFR cutpoint for prognosticating low post-
donation eGFR was obtained using ROC analysis.
Results: 174 donors, predominantly female (63.8%) and of Chinese ethnicity (73%), of 
average age 40.6 years, were recruited. Median (range) follow-up was 7.8 (0.1–33.8) years 
during which 30 donors (17%) developed low eGFR, defined as <60 ml/min/1.73m2. At 5 
years post donation, 43.1% of donors recovered to at least 75% of pre-nephrectomy eGFR 
levels, and 9.8% exhibited 100% recovery to pre-nephrectomy eGFR levels at 19.2 years, on 
average. High pre-nephrectomy eGFR was protective for risk of low post-donation eGFR, 
with a 6% reduction in risk for each unit increase in pre-nephrectomy eGFR (OR, 0.94; 
95% CI, 0.91–0.97; p=0.002). This relationship was stronger in the short-term than medium 
to long term (p=0.052). ROC analysis indicated pre-donation eGFR cutpoint of 100 ml/
min/1.73m2 for prognosticating low post-donation eGFR (sensitivity=0.80, specificity=0.61, 
PPV=0.30, and NPV=0.95); AUC (95% CI) was 0.75 (0.66–0.84).
Conclusions: In general, kidney function is well preserved following kidney donation 
in Southeast Asian donors. Pre-nephrectomy eGFR is a good predictor of post-donation 
eGFR, especially in the short-term.
SA-PO1026
Post-Kidney Transplant Follow-Up in Native American: An Opportunity 
for Improvement  Fidel Barrantes,1 Sarah Stith.2  1Presbyterian Transplant 
Center, Renal Medicine Associates, Albuquerque, NM; 2Economics, Univ of 
New Mexico, Albuquerque, NM.
Background: Native Americans have been shown to face decreased access to 
waitlisting and transplantation. We explore the possibility that Native Americans might 
face decreased access to high quality post-transplant care, especially in the long-run, 
due to a decreased general access to healthcare, as is faced by many socioeconomically 
disadvantaged minority populations.
Methods: Using data from the OPTN, we evaluated the quantity and type of post-
transplant care received by Native Americans. We compare Native American populations 
with other ethnic groups from October 1, 1987 to December 31, 2012 using multivariate 
regression analysis, controlling for time-invariant factors affecting all patients in a given 
year (year fixed effects) and time-varying factors associated with a specific transplant 
center (center fixed effects). (Standard errors are clustered at the center level to account for 
heteroskedasticity and spatial correlation among patients in a given center).
Results: Statistically significant regression results (p<0.05) indicate that Native 
Americans are less likely to receive transplant program-based aftercare than other racial/
ethnic groups (Black, White, Hispanic and Asian/Pacific Islander), opting instead to see other 
types of specialists. They also are two percentage points more likely to be lost to follow-up 
(mean=0.15), one percentage point less likely to participate in an immunosuppression-
related research study (mean=0.03), and receive 0.3 fewer follow-up visits (mean=2.2) 
than whites. They face the lowest number of follow-up visits, the lowest probability of 
participating in a research study, and the highest probability of being lost to follow-up. 
They are also 13% points less likely to work post-transplant (mean=0.35) than whites.
Conclusions: The results indicate that Native Americans have reduced access to high 
quality post-transplant care. Further research will explore how much of the disparity in 
post-transplant care is related to the high correlation between being Native American and 
poor and between being Native American and living in a rural area, especially on tribal lands.
Funding: Private Foundation Support
SA-PO1027
Medication Adherence Barrier Burden Predicts Subsequent Taking 
Adherence in Adolescent Kidney Transplant Recipients in the TAKE-IT 
Trial  Bethany J. Foster,1 Huaqing Zhao,2 Ahna Lh Pai,2 Nataliya Zelikovsky,2 
Crystal D. Holly,2 Jodi M. Smith,2 Vikas R. Dharnidharka,2 Diane Hebert,2 
Douglas G. Matsell,2 Veronique Phan,2 Susan L. Furth.2  1Pediatrics, McGill 
Univ, Montreal, QC, Canada; 2TAKE-IT Investigators.
Background: Longitudinal studies of objectively-measured medication adherence 
among high-risk adolescent kidney transplant recipients are lacking.
Methods: We aimed to determine whether the burden of perceived barriers to 
medication adherence predicted taking adherence (proportion of prescribed doses taken) 
during the subsequent 3 mo., as monitored with a multidose electronic pillbox. We evaluated 
the 126 participants of TAKE-IT with electronic adherence data available for the 3-mo. 
run-in period during which no intervention was applied. Participants (11-24 y.; ≥ 3 mo. 
post-transplant) were followed in 8 transplant centers (Canada and USA). Adherence barriers 
were assessed at baseline using the Adolescent Medication Barriers Scale (AMBS). A higher 
score indicates greater barrier burden (possible range 17-85). We used linear regression 
to estimate the association between baseline AMBS scores (total score and ingestion, 
disease adaptation, and cognitive/organization subscores) and taking adherence. Models 
also included sex, age, race, and time since transplant.
Results: 60% were male and 67% were white. Median age at baseline was 15.8 (IQR 
13.2-17.4) y. Median time since transplant was 3.1 (0.7-7.5) y. Mean±SD taking adherence 
for the interval was 87.0%±28.9. Higher barrier burden (median score 38 (IQR 30-44)) 
was significantly associated with poorer adherence: a 5 unit higher total AMBS score was 
associated with 1.5% (95% CI 0.04, 3.0) lower taking adherence. Males had 7.5% (0.8, 
14.3) lower taking adherence than females. The only subscale score significantly associated 
with taking adherence was disease adaptation: a 5 unit higher sub-score was associated 
with 3.3% (0.4, 6.2) lower taking adherence.
Conclusions: While the absolute impact of barrier burden on adherence is small, higher 
burden of perceived barriers is a significant predictor of poorer adherence. Future analyses 
of the TAKE-IT data will determine the impact of an intervention targeting individual 
barriers on objectively-measured adherence.
Funding: NIDDK Support
SA-PO1028
Pre-Procurement Iodinated Contrast Exposure Is Associated with Early 
and Late Kidney Transplant Outcomes  Fidel Barrantes,1 Sarah Stith,2 Abhijit 
S. Naik,3 Isaac E. Hall,4 Mark A. Perazella.4  1Renal Medicine Associates, 
Albuquerque, NM; 2Economics, Univ of New Mexico, Albuquerque, NM; 
3Internal Medicine, Univ of Michigan, Ann Arbor, MI; 4Internal Medicine, Yale 
Univ, New Haven, CT.
Background: Iodinated contrast can cause acute kidney injury. We sought to evaluate 
the association of iodinated contrast exposure prior to organ procurement in deceased donors 
with subsequent kidney transplant outcomes.
Methods: Using OPTN data for kidney transplants between May 2000 and December 
2012, we performed multivariate regression to model 2 different definitions of delayed graft 
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function as a function of donor exposure to coronary angiograms, controlling for time-
invariant factors affecting all patients in a given year (year fixed effects) and time-varying 
factors associated with a specific transplant center (center fixed effects with standard errors 
clustered at the center level to account for heteroskedasticity and spatial correlation among 
patients in a given center).
Results: Of 93,811 donors listed in study period, 8.5 % (8012)were exposed to 
coronary angiograms. From this group, 14 628 kidneys were transplanted. Statistically 
significant regression results (p<0.01) indicate that patients receiving organs from donors 
who received coronary angiograms are 2% points more likely to receive dialysis within 
the first week of transplant (mean=0.24) and are less likely to experience a >25% decline 
in serum creatinine in the first week of transplant (mean=0.56). These patients also face 
a 61 day shorter average graft survival time and a 1% point lower probability of 6-month 
post-transplant patient survival. At three years recipients from donors with contrast exposure 
have 2% decrease in survival rate (P=0.005).
Conclusions: This large database analysis provided statistical power to detect an 
association between donor exposure to iodinated contrast from coronary angiograms before 
organ procurement and subsequent adverse early as well as later kidney transplant outcomes. 
Further research into the effects of deceased-donor management strategies is warranted to 
expand the organ pool while decreasing adverse transplant outcomes.
Funding: Private Foundation Support
SA-PO1029
One Year Recovery After Kidney Donation: The Medical and Donor Point of 
View in a Prospective Cohort Study  Briançon Serge,1 Lucie Germain,1 Michele 
Kessler,2 Marie-Alice Macher,3 Marc Soudant,1 Marie Thuong.2  1Epidemiologie 
CIC-EC, CHU de Nancy, Nancy, France; 2Nephrology, CHU de Nancy, Nancy, 
France; 3Transplantation, Agence de la Biomedecine, Paris, France.
Background: Renal transplantation is the reference treatment for ESRD patients; the 
living donor kidney has been proven to provide better outcomes to recipients. Recovery 
of donors has been less studied and understood.
Methods: An exhaustive sample of 500 donors recruited in every French transplantation 
between October 2009 and January 2012 (T0) were followed at 3 (T1) and 12 months (T2) 
after surgery. Questionnaires investigating the donation course, quality of life (SF-36 and 
Euroqol) and recovery were sent home. Medical data were from CRISTAL register. 384 
donors participated at 3(85%) and 12months(90%). The exceptional participation rate 
reflects the high commitment of donors.
Results: Before the donation, the physical health is incredibly high especially for 
older. On average a 75 year-old donor has the PCS SF36 level of 35 year-old men in the 
general population Thre months after surgery, all outcomes exhibited decreased health 
indicators. Three quarters of the donors underwent laparoscopy, associated with less 
pulmonary complications, kidney failure, high blood pressure, persistent physical pain, 
better postoperative recovery. More than half the donors have at least one complication 
of which 8% was severe. The appearance of the scar is one of the dissatisfaction of the 
donor. One year after the donation, over 10 donors, 9 resumed work, 3 not all completely 
recovered, three still feel physical pain, .4 have not recovered their PCS pre-donation 
level, and 5 their MCS level.However their status remains better than that of the general 
population of the same age and sex. Donors are ready to do it again (98.2%) and recommend 
the donation (96%).
Conclusions: The experience alters neither the initial impetus nor the meaning 
attributed to the donation. The recommendations are to pursue the development of 
laparoscopy, to inform about and manage completely pain, to better prepare the donor to 
the surgical procedure, its risks and aftermath, including professional ones in younger, to 
perfectly plan the medical follow up with information to referee physicians.
Funding: Government Support - Non-U.S.
SA-PO1030
Discard of Deceased Donor Kidneys in the United States: The Weekend 
Effect  Sumit Mohan,1 Karl F.W. Foley,1 Mariana C. Chiles,1 Geoffrey K. Dube,1 
Russell J. Crew,1 Stephen O. Pastan,2 Rachel E. Patzer,2 David J. Cohen.1  1Dept 
of Medicine, Columbia Univ College of Physicians & Surgeons, New York, NY; 
2Dept of Medicine, Emory Univ School of Medicine, Atlanta, GA.
Background: The discard rate of deceased donor kidneys (DDK) has slowly increased 
over time. The underlying reasons remain unclear. The impact of low resource availability 
over the weekends on the acceptance of DDK for transplantation is currently unknown. We 
attempt to measure the impact of weekends on organ utilization patterns.
Methods: The majority of DDK (80%) are transplanted over the weekend and are 
procured on either Friday or Saturday (Fri-Sat). Using data from the Scientific Registry of 
Transplant Recipients (SRTR), we identified and compared all DDK procured on Fri-Sat to 
those that were procured on other days of the week. Using logistic regression we estimated 
the adjusted odds of discard for DDK over the weekend.
Results: Among the available kidneys, the Fri-Sat period was associated with lower 
procurement (89.5 vs 90.2%, p<0.001) and the procured kidneys were older (39.7±17.7 v 
39.1±17.6, p<0.001) and of lower quality (KDRI 1.33±0.49 v 1.31±0.49, p<0.001). Not 
only were Fri-Sat DDK were more likely to be discarded (18.6 vs 16.4%, p<0.001), these 
kidneys were of higher quality than those discarded during the rest of the week (KDRI 
1.82±0.57 vs 1.84±0.56, p=0.018). Fri-Sat DDK were more likely to be shared without 
payback and be transplanted at a large transplant center. After adjusting for KDRI, Fri-Sat 
DDK were 20% more likely to be discarded than kidneys procured during other times 
during the week (OR=1.20, p<0.001).
Conclusions: DDK procured on Fri-Sat are more likely to be discarded than at other 
times of the week while those that are transplanted are more likely to be shared with large 
transplant centers. Our results demonstrate the possibility that low resource availability 
on the weekends adversely impacts organ procurement, acceptance and transplantation.
SA-PO1031
Medication Adherence Barrier Burden Predicts Subsequent Adherence to 
Dosing Time Schedule in Adolescent Kidney Transplant Recipients in the 
TAKE-IT Trial  Bethany J. Foster,1 Huaqing Zhao,2 Ahna Lh Pai,2 Nataliya 
Zelikovsky,2 Crystal D. Holly,2 Jodi M. Smith,2 Vikas R. Dharnidharka,2 Diane 
Hebert,2 Lorraine E. Bell,2 Douglas G. Matsell,2 Veronique Phan,2 Susan L. 
Furth.2  1Pediatrics, McGill Univ; 2TAKE-IT Investigators.
Background: Studies of adherence to timing of medication dosing in high-risk 
adolescent kidney transplant recipients are lacking.
Methods: We aimed to determine whether the burden of perceived barriers to 
medication adherence predicted timing adherence (proportion of doses taken £1 h. before 
to £2 h. after the prescribed dosing time) during the subsequent 3 mo., as monitored with 
a multidose electronic pillbox. We evaluated the 126 participants of TAKE-IT who had 
electronic adherence data available for the 3-mo. run-in period (no intervention). Participants 
(11-24 y.; ≥ 3 mo. post-transplant) were followed in 8 centers (Canada and USA). Adherence 
barriers were assessed at baseline using the Adolescent Medication Barriers Scale (AMBS). 
A higher score indicates greater barrier burden (possible range 17-85). We used linear 
regression to estimate the association between baseline AMBS scores (total score and 
ingestion, disease adaptation, and cognitive/organization subscores) and timing adherence. 
Models also included sex, age, race, and time since transplant.
Results: 60% were male and 67% were white. Median age at baseline was 15.8 (IQR 
13.2-17.4) y. Median time since transplant was 3.1 (0.7-7.5) y. Mean±SD timing adherence 
for the interval was 82.6%±32.8. Higher barrier burden (median score 38 (IQR 30-44)) was 
significantly associated with poorer timing adherence: a 5 unit higher total AMBS score was 
associated with 2.0% (95% CI 0.4, 3.6) lower timing adherence. A 5 unit higher score was 
associated with 4.3% (1.2, 7.5) lower timing adherence for the disease adaptation sub-scale, 
and with 5.9 % (0.2, 11.6) lower timing adherence for the cognitive/organization sub-scale. 
Males had 10% (2.9, 17.6) lower timing adherence than females.
Conclusions: Higher burden of perceived barriers was a significant predictor of poorer 
timing adherence in this longitudinal study. Future analysis of the TAKE-IT data will 
determine the impact of an intervention targeting individual barriers on timing adherence.
Funding: NIDDK Support
SA-PO1032
Deceased Donor Procurement in the U.S.: Measurement of Surgical Damage 
Inflicted Upon the Procured Organ  Tim E. Taber,1 Nikole Neidlinger,2 
Muhammad Ahmad Mujtaba,3 Elling E. Eidbo,5 Anil S. Paramesh.4  1Medicine, 
Indiana Univ School of Medicine / Indiana Donor Network, Indianapolis, IN; 
2Surgery, Donor Network West, Berkley, CA; 3Medicine, UTMB Galveston, 
Galveston, TX; 4Surgery, Tulane Univ School of Medicine, New Orleans, LA; 
5Association of Organ Procurement Organizations, Vienna, VA.
Background: Deceased organ donation provides healthy allografts for the majority 
of organ transplants done in this country. While there are many factors involved in 
determining suitability of allografts for transplantation, one of the most important is careful 
procurement of the organ.
Methods: In the winter of 2013, the medical directors of the Association of Organ 
Procurement Organizations (AOPO) agreed upon a standard for organ damage sustained 
during procurement. Organ damage was classified into three tiers, from 1 – 3 with the latter 
rendering the organ non-transplantable. For 12 consecutive months starting in January of 
2014, 36 of 58 OPOs prospectively submitted quality data regarding organ damage seen 
on the procured organ. These 36 OPOs recovered 5,401 of the nation’s 8,504 deceased 
donors for calendar year 2014.
Results: A total of 9501 kidneys were procured from this cohort. Organ damage 
determined at time of procurement was as follows: 156 class 1 (non-clinically relevant 
damage); 86 class 2 (damage requiring repair prior to transplantation); 43 class 3 (kidneys 
that were damaged to the extent that they could not be transplanted).
Conclusions: Damage done to the kidney at the time of procurement rendering the 
allograft non-transplantable occurred at a rate of approximately 0.45%. Smaller organ 
procurement organizations (measured by total number of donors) were more likely to have 
higher rates of damage. Class 1 and 2 damage was more frequent than class 3 but did not 
result in loss of the allograft for transplantation. While damage done to the kidney at the 
time of procurement was rare, it did exist. Further evaluation of this issue is warranted to 
maximize the opportunity for organ transplantation.
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SA-PO1033
Short-Term Outcomes After Donor Nephrectomy in Individuals with 
Persistent Asymptomatic Non-Visible Haematuria  Ben Talbot,1 Simon K. 
Winn,2 Lubna Rashid,2 Seema Shrivastava,2 Peter A. Andrews,3 Ed Kingdon.1 
1Sussex Kidney Unit, Royal Sussex County Hospital, Brighton, United Kingdom; 
2Renal Unit, St. George’s Hospital, London, United Kingdom; 3Renal Unit, St. 
Helier Hospital, Epsom, United Kingdom.
Background: National guidelines in the United Kingdom suggest investigation to 
exclude urological disease and identify glomerular pathology in potential donors with 
persistent asymptomatic non-visible haematuria (PANVH). There is currently no guidance 
on how to proceed where abnormal immunohistochemistry (IHC) is found without 
proliferative glomerular changes or electron dense deposits (EDD).
Methods: Demographic characteristics, renal function and biopsy details were obtained 
by retrospective case note review of kidney donors in the South West Thames transplant 
network who had undergone renal biopsy for PANVH between 2008-13. Light microscopy, 
IHC and electron microscopy (EM) findings were collected and clinical outcomes analysed 
for donors and recipients.
Results: Twenty four donors with PANVH proceeded to donation.
Biopsy findings in subjects proceeding 
to donor nephrectomy (n=24)
Normal Mesangial Cellularity 24/24
Focal interstitial fibrosis or tubular 
atrophy <10% 6/24
Abnormal glomerular IHC: 15/24 Location:
IgM and C1q 11/24 Mesangial
Isolated IgM 3/24 Mesangial
Isolated C1q 1/24 Mesangial
Thin basement membrane (<250 nm) 7/21 (EM not available in 3 patients)
Mean eGFR before donation 88.2 mL/min/1.73m2 (69-117) and one year after donation 
56.2 mL/min/1.73m2 (41-77). Five recipients are not followed up locally. The remaining 
recipients (n=19) had mean eGFR beyond one year 49.9 mL/min/1.73m2 (24-82), mean 
follow up 2.9 years (1-7). 
Conclusions: Renal biopsy in potential donors with PANVH will identify mesangial 
proliferation or EDD in a minority of cases. Early outcomes in our small cohort of PANVH 
donors are favourable. Longer term follow-up of PANVH donors and recipients is being 
undertaken.
SA-PO1034
Jeevandan: Deceased Donor Transplantation Programme from a 
Developing Country  Swarnalatha Guditi.  Nephrology, NIMS, Hyderabad, 
Telangana, India.
Background: In developing country like India the prevalence of end stage organ 
disease is increasing.Though transplantation has been in practice in India, its been grossly 
inadequate in terms of actual numbers, due to a shortage of resources and organs. The only 
solution for the shortage of organs is deceased donor transplantation.
Methods: In India the Human Organs Transplantation Act,was enacted in 1994 with 
the objective of promoting and regulating the transplantation of human organs like kidney, 
liver and heart - both live as well as cadaver there was no significant increase in cadaver 
transplantation over the past two decades for various reasons. India follows “opt in” 
system and brain death declaration is not mandatory. Andhra Pradesh and Telangana are 
the two important states in India, situated on the country’s southeastern coast. It is India’s 
fourth largest state by area and fifth largest by population. Government of Andhra Pradesh, 
considering the shortage of organs and burden of end stage organ failure in the state, has 
come up with a Government Order6 called “Jeevandan” to streamline the procedure for 
facilitating and regulating the cadaver transplantations on an end-to-end basis.
Results: There were 129 deceased donations in 2 years. Male  were 93 and female 
36: female to male ratio being 1: 2.58 The mean age was 41 years (range 8 to 79). Most 
common Blood group was O in 51 (39.5%) donors followed by B in 39 (30.23%), A positive 
in 29 (22.48%) donors, and AB in 10 (07.75%) donors. Total 593 organs including minor 
organs were retrieved from 129 deceased donors; 233 kidneys, 126 livers, 7 hearts, 118 heart 
valves, 103 corneas , 5 lungs and 1 Pancreas.Total deceased donor renal transplantations 
done during this period were 24.67% . Out of 129 donors, 6.8 % kidneys and 3% livers 
were not utilized. Mean age of renal recipients was 44.07 years (range 13 to 72). There were 
26.8% females and 73.2% males, female to male ratio being 1:2.73. Among deceased donor 
renal transplant recipients, O blood group was most common, seen in 36.79% followed by 
B in 32.38%, A in 22.64% and AB in 8.17% patients.
Conclusions: Decease donor transplantation is the solution for organ shortage and 
increasing demand of organ requirement.
SA-PO1035
Deceased Directed Kidney Donations: A Three-Year Experience at a 
Single OPO  Rebecca Hurst,1 Michael D. Salvatore,1 Nikole Neidlinger.1,2 
1Donor Network West, San Ramon, CA; 2California Pacific Medical Center, 
San Francisco, CA.
Background: The UAGA allows for deceased directed organ donations. Our OPO 
has incorporated the practice of offering the option of directed donations during every 
donation discussion in response to routine donor family requests. However, facilitating 
directed donations for donor families remains a controversial topic. Opponents suggest 
that directing gifts is not only inequitable, but that it may encourage malfeasance in the 
form of organ solicitation via media or social networking campaigns or by groups who 
promote discrimination. The purpose of this research effort was to identify how many 
directed kidney requests were received and honored during a three-year period in order to 
assess the impact on our allocation scheme.
Methods: We analyzed retrospective data from our OPO for three years from 2012-
2014. We evaluated the number of directed kidney donation requests in relation to the 
overall number of donors, as well as the transplant outcomes or reasons for decline when the 
request was not honored. Relationship of donors to potential recipients was also assessed.
Results: Over the three year period, 176 of our 1,056 authorized donors had a potential 
directed donation. Of these, 80% were directed to patients on the kidney waiting list. 
However, only 16% of the attempted directed kidney donations resulted in a transplant. 
The data illuminate that incompatibility/mismatch of potential directed kidney recipients 
is the most common reason that directed kidneys are not transplanted, despite the fact that 
directed donations are allocated ahead of highly sensitized patients, mandatory shares, 
multivisceral combinations, and the like.
Conclusions: Facilitating directed donations will continue as part of our routine 
practice. Each year approximately one in six of our donor families identified potential 
recipients, but transplants from these requests remained consistently less than 2% of our 
annual total. Future studies are planned to evaluate recipient outcomes, assess donor family 
satisfaction with a recipient known to them, as well as to examine our practice in detail 
in an effort to standardize the language and timing of the directed donation discussions.
SA-PO1036
Optimal Outcomes in Pediatric Renal Transplant Recipients 
Veronica A. Taylor,1 Cassie L. Kirby,1 Jens W. Goebel,1,2 David K. Hooper.1,2 
1Cincinnati Children’s Hospital Medical Center; 2Dept of Pediatrics, Univ of 
Cincinnati College of Medicine.
Background: Pediatric kidney transplant recipients (pKTRs) experience multiple 
sequelae of their condition, yet comprehensive assessment of these is lacking in the 
literature. Our objective was to develop a composite outcome measure for pKTRs that 
considers the most common comorbidities, and to evaluate a population of pKTRs at 
specific intervals post-transplant.
Methods: We retrospectively reviewed all KTRs at our center from 10/2008 through 
2/2015. An optimal outcome composite measure was created consisting of 14 criteria 
in four domains: allograft function (CKD stage <3, urine protein/creatinine ratio < 0.5, 
absence of DSAs), histology (no or mild interstitial fibrosis and tubular atrophy, no 
transplant glomerulopathy, and no history of AMR or ACR), infection (BKV PCR <10,000, 
CMV PCR£0, no history of PTLD or symptomatic EBV) and cardiovascular (CV) health 
(triglycerides<500, LDL <130, BP <90th %ile, fasting glucose < 126, and BMI < 85th 
%ile). Patients were evaluated on these pass/fail criteria at post-transplant yrs 1, 3, 5, and 
10. Optimal outcome was defined as passing ³13/14 criteria.
Results: A total of 177 patients and their 282 clinic visits were analyzed. Of 94 patients 
who completed their 1st year, only 32 patients (34%) achieved an optimal outcome. This 
was significantly higher than at yrs 3 (8/74, 11%), 5 (13/62, 21%), and 10 (9/52, 17%) (p 
< 0.01). The top two categories in which patients failed at 1 yr were cardiovascular health 
(which remained relatively stable: ~30% at each time point) and allograft function which 
decreased from 57/93 (61%) at yr 1 to 24/62 (39%) at yr 3 (p<0.01).
Conclusions: Only 1/3 of pKTRs achieved an optimal outcome at 1 year post-transplant, 
and this fell to 1/6 of patients by 10 years. Cardiovascular health and graft function were the 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
873A
J Am Soc Nephrol 26: 2015 Transplantation: Clinical and Translational - IV Poster/Saturday
primary failure modes. Evaluation of all transplant-related outcomes at specific follow-up 
intervals will allow practitioners to assess the success of kidney transplantation and overall 
recipient health and focus clinical outcome improvement efforts.
SA-PO1037
Clinical Outcome of Elderly Living Kidney Donors: A Single-Center Study 
in Japan  Jumpei Hasegawa, Kohei Unagami, Masayoshi Okumi, Kazuya 
Omoto, Hideki Ishida, Kazunari Tanabe.  Urology, Tokyo Women’s Medical 
Univ, Tokyo, Japan.
Background:  Previous studies and current guidelines have suggested that elderly 
persons can be living kidney donors; however, reports on elderly donors >70 years old 
are limited. In order to clarify the donor safety and feasibility, we investigate the clinical 
outcomes of living kidney donors > 70 years old after nephrectomy.
Methods: We conducted a case-series study of living kidney donations involving 
48 donors aged >70 years at the time of transplantation. The kidney donations occurred 
between 2001 and 2014 at Tokyo Women’s Medical University in Tokyo, Japan. The primary 
outcomes were survival or end-stage renal disease (ESRD)-free rate and all crude event-
free rates, including cardiovascular-, infection-, ESRD-, or death-free rate. The secondary 
outcome was serum creatinine level at the end of the follow-up period.
Results: The 48 cases were followed up for a median of 4 years. The survival rate 
among the donors was 100% until the fifth year, and only two donors died during follow-
up. The ESRD-free rate was 100% during the follow-up period. The overall event-free rate 
was 100% at 1 year, 85.7% at 3 years, and 75.0% at 5 years. The mean serum creatinine 
level was 1.18 ± 0.24 mg/dL at the time of hospital discharge and did not increase (1.18 
mg/dL) at the end of follow-up.
Conclusions: Living kidney donation from elderly donors >70 years old appears to be 
a safe and acceptable option for patients requiring renal-replacement therapy.
SA-PO1038
Immunosuppressive Medication Adherence following Kidney Transplant-
ation in the Military Healthcare System  Dustin J. Little,1 Matthew Ward,2 
Robert Nee,1 Christina M. Yuan,1 Rahul M. Jindal.2  1Walter Reed National 
Military Medical Center, Bethesda, MD; 2Uniformed Services Univ of the Health 
Sciences, Bethesda, MD.
Background: Limitations on the amount and duration of Medicare coverage of 
immunosuppressive medications (ISM) may contribute to ISM non-adherence and allograft 
failure. ISM adherence has not been reported in US patients who receive these medications 
at no cost. We therefore designed a prospective cohort to investigate the incidence of ISM 
non-adherence in Military Healthcare System (MHS) beneficiaries, who receive lifelong 
post-transplant ISM at no out-of-pocket cost.
Methods: Adult MHS kidney transplant recipients who provided informed consent 
completed the Immunosuppressive Therapy Adherence Scale (ITAS) and Beck Depression 
Inventory-II (BDI-II). Chart reviews were performed to obtain demographic and clinical 
data. Perfectly adherent subjects (P) (ITAS score of 12/12), were compared to not perfectly 
adherent subjects (NP; ITAS score £11/12) using Student’s t-test and Fisher’s exact test 
where appropriate. Exact logistic regression was performed to evaluate for factors associated 
with P versus NP adherence.
Results: Forty subjects completed survey instruments. 57.5% of subjects were male, 
40% were black, 22.5% were aged <65 years, and 45% were >3 years from transplantation. 
One subject did not complete the ITAS. Mean overall ITAS score was 11.5±0.9, and 69% 
(27/39) of subjects reported P adherence. BDI-II scores were significantly lower in P vs. NP 
subjects (6.7±7.2 vs. 13.6±8.8; p=0.014). Exact LR adjusted for race, timing of transplant, 
sex, and age revealed an OR of 0.61 (0.32-0.98) for P adherence for every 5 point increase 
in BDI-II score. NP subjects were significantly more likely to have donor specific antibodies 
(DSA; 6 of 11 vs. 3 of 24; p=0.015).
Conclusions: MHS beneficiaries reported high levels of ISM adherence. Modest 
increases in BDI score associated with marked reduction in adherence, and subjects with 
NP adherence were significantly more likely to have DSA. Our results suggest that enhanced 
ISM coverage as well as prevention, identification, and treatment of depression should be 
prioritized for future study in order to improve outcomes following renal transplantation.
Funding: Other U.S. Government Support
SA-PO1039
Clinical Impact of Kidney Donor Follow-Up by Nephrologists  Hee Jin Kwon, 
Jin Hae Kim, Jee Eun Park, Subin Hwang, Jung Eun Lee, Wooseong Huh, 
Yoon-Goo Kim, Dae Joong Kim, Ha Young Oh, Hye Ryoun Jang.  Nephrology 
Div, Dept of Medicine, Samsung Medical Center, Sungkyunkwan Univ School 
of Medicine, Seoul, Republic of Korea.
Background: Compensatory and adaptive mechanisms in the remnant kidney occur 
immediately after nephrectomy. The adaptability in early postoperative period may affect 
the renal function of the remaining kidney. Since the introduction of extended criteria living 
donor system, the numbers of marginal donors with risk of new morbidities are increasing. 
The aim of this study was to evaluate the clinical impact of kidney donor follow-up by 
nephrologists at a donor clinic (DC).
Methods: Our study included 427 living kidney donors from January 2010 to December 
2014 in Samsung medical center. Nephrologist-run donor clinic was established in January 
2013. The study period was divided into pre-DC and post-DC. Primary outcomes were 
incidence of CKD and renal functional adaptability (%MDRD = post/pre eGFR X100) at 
6 months after donation. Secondary outcomes were changes in compliance and incidence 
of co-morbidities; hyperuricemia and microalbuminuria.
Results: A total of 215 and 172 donors were included in pre-DC and post-DC, 
respectively. Before donation,age, sex, proportion of hyperuricemia and microalbuminuria 
were similar. Preoperative eGFR in pre-DC was significantly higher than post-DC 
(p<.001). After donation, poor renal adaptation (post-donation eGFR at 6 months < 60% 
of preoperative eGFR) was less frequent in the post-DC period compared to the pre-DC 
period (p=.026). CKD development tended to be higher in pre-DC period. Donors in the 
post-DC period had shorter mean outpatient clinic visit intervals (p<.001), more visits within 
6 months after donation(p=.001), earlier detection of de-novo hyperuricemia (p<.001). The 
incidence and detection time of microalbuminuria were similar.
Conclusions: After establishment of kidney donor clinic operated by nephrologists, 
donors tended to show better renal adaptability andearlier diagnosis and treatment of 
hyperuricemia. In conclusion, donor clinic may be a good strategy for improvingrenal 
outcome and detecting potential risk factors of CKD in donors.
SA-PO1040
Predicting Kidney Allograft Half-Life Using a Podometric Approach 
Roger C. Wiggins, Abhijit S. Naik, Diane M. Cibrik, Jeffrey B. Hodgin, 
Farsad Afshinnia, Larysa T. Wickman, Milagros D. Samaniego-Picota.  Univ 
of Michigan.
Background: Increasing donor age is a powerful predictor of worse renal allograft 
outcome. Podocyte depletion is part of the normal aging process (Hodgin, JASN, 2015). 
Recently we showed that kidney hypertrophy that occurs at time of transition from a 2 
kidney to 1 kidney state (transplantation), leads to a 20% reduction in podocyte density and 
a 6-fold increased rate of podocyte detachment associated with transplant glomerulopathy 
and allograft failure (Yang, JASN, 2014). To test the hypothesis that podocyte depletion 
could impact allograft half-life we used a model combining age specific podocyte nuclear 
density decrease and rate of podocyte attrition after transplantation for comparison with 
actual allograft outcome data.
Methods: Podocyte density was estimated from immediate post perfusion biopsies 
from living and deceased donors or from non-diseased nephrectomy specimens. Projected 
allograft life was predicted based on modeling age-specific podocyte density and the 
observed attrition of podocytes. Observed data were drawn from the OPTN/UNOS STAR 
files as of Sept 2014, using all transplants performed between Oct 1987-June 2013. A 
“conditional” Kaplan Meier analysis using the “period” method was used to calculate 
observed half-lives at different donor ages.
Results: The podometric projected average half-life for a 40 year old donor is 15.1 
years, similar to the observed average allograft half-life (15.1 years). The projected effect 
of increasing donor age on allograft half-life from podometric measurements is similar to 
the observed effect of donor age on allograft half-life at all calculated donor ages (p=NS).
Conclusions: Quantitative podometric modeling predicts both shorter-than-expected 
average renal allograft survival and the donor age effect, compatible with the concept that 
hypertrophic processes at transplantation significantly impact half-life.
Funding: Other NIH Support - RW acknowledges the support of the National Institutes 
of Health (grants DK RO1 46073 and the University of Michigan O’Brien Kidney Core 
Center P30 DK081943). F.A. was supported by NIH grant 5T32DK7378-34., Other U.S. 
Government Support, Private Foundation Support
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SA-PO1042
Prediction of Patient Survival After Kidney Transplantation (Tx): 
Construction, Validation and Evaluation of Decision Models Using Data 
Mining Approaches  Irina Scheffner,1 Kaixun Hua,2 Dan Simovici,2 Tanja 
Abeling,1 Hermann G. Haller,1 Wilfried Gwinner.1  1Hannover Medical School, 
Germany; 2Univ of Massachusetts.
Background: Understanding the risk factors that predispose to death is important 
to deliver the most appropriate therapy to Tx patients (pts). Aim of this study is to build 
reliable decision models and to identify the relevant risk factors for death using different 
data mining approaches.
Methods: We analyzed 761 pts transplanted between 2000 and 2007 (follow-up of up 
to 10 years). Data included biopsy results, clinical & laboratory factors. After conventional 
statistical feature selection of 28 variables we build Naïve Bayesian (NB), C5.0, RPART 
and Random Forest (RF) models.
Results: Compared to C5.0 and RPART, NB and RF resulted in models with a higher 
sensitivity to predict death and a high specificity. Using different partitions for training 
and test set, NB models had a sensitivity of 62-65% and a specificity of 89-91% to predict 
death. With RF, sensitivity was 64% and specificity 96%. Because of the imbalance of the 
outcome groups (13% deceased pts) modeling was repeated with balanced datasets obtained 
by oversampling. With the balanced data, sensitivity was 82% and specificity 79% with 
NB. With RF, sensitivity was 83% and specificity of 68%. These models were externally 
validated with two separate datasets showing sensitivities of 64 and 59% and specificities 
of 86% and 78% for the NB models and sensitivities of 84 and 61% and specificities of 
60 and 65% for the RF models. Highly important variables were recipient age, pre-Tx 
diabetes mellitus, peripheral arterial and coronary heart disease, cold ischemia time, graft 
function within the first 6 weeks and annual GFR loss, and post-Tx systolic and diastolic 
blood pressure, urinary tract infections, and hyperparathyroidism. Modestly important 
variables included donor age, time on dialysis, HLA DR mismatches, delayed graft function.
Conclusions: The established models permit reliable prediction of death and survival 
and can be used to identify pts on risk. Moreover, with the identified (modifiable) risk factors 
pts can be assigned to different treatment strata to offer each patient the optimal therapy.
Funding: Government Support - Non-U.S.
SA-PO1043
The Decline of Dialysis in Northern Ireland  Kathryn E. Larmour.  Regoinal 
Nephrology Unit, Belfast City Hospital.
Background: The first session of haemodialysis in Northern Ireland (NI) was in 1959 
for acute kidney injury. There has been an inexorably rise in the prevalent dialysis population 
in the province since then, with expansion of dialysis facilities to accommodate ever 
increasing numbers. However, in addition to inferior outcomes compared to transplantation, 
there are considerable capital and recurrent costs associated with chronic haemodialysis 
provision. This study considered the impact of an expansion in the living donor (LD) 
transplant programme on dialysis in NI and the financial implications.
Methods: The prevalence dialysis population from 1999-2014 (inclusive) data were 
retrieved retrospectively from collected data. The number of LD transplants in NI patients 
is prospectively recorded. The economic impact of the changes evident in our centre were 
then evaluated.
Results: In 1999 there were 479 patients in NI receiving maintenance dialysis 
treatment. This number increased annually until a zenith of 836 in 2009. There were no 
living donor transplant procedures in 1999, from 2000-2008 there were between 4 and 
9 performed annually. There was an expansion of the LD programme thereafter, and for 
the past four years there have been between 53-60 LD transplants each year (>30 donor 
pmp). This increase has coincided in an initial plateau and then a decline in the prevalent 
dialysis population [figure 1]. The cost of maintaining a patient with end-stage renal failure 
on dialysis is £17,500 ($27,000) per patient per year for a patient on peritoneal dialysis 
and £35,000 ($54,000) per patient per year for a patient on hospital haemodialysis. The 
first year of care after a kidney transplant costs around £17,000 ($26,000) and £5,000 
($7,500) for every subsequent year. Live donor costs are approximately £9,000 ($14,000). 
Transplantation results in a cost benefit in the second and subsequent years of £25,800 
(39,500) per annum. The cost benefit of transplantation compared to dialysis over a period 
of ten years is £241,000 ($370,000).
Conclusions: A proactive approach to living donor transplantation has benefits not only 
for individual patients but in reducing the prevalent dialysis population and the healthcare 
costs associated with renal replacement therapy.
SA-PO1044
Pre-Existing Donor-Related Diabetic Nephropathy Predicts Poor Allograft 
Survival  Steven Salvatore,1 Mohamad M. Alkadi,2 Thangamani Muthukumar,2 
Surya V. Seshan.1  1Pathology, Weill Cornell Med College; 2Nephrology, Weill 
Cornell Med College.
Background: Diabetic nephropathy (DN) is the most common cause of end stage 
renal disease in the US, and in the transplant setting may play a role in long-term graft 
dysfunction. In patients without diabetes, finding features of DN in the immediate for-cause 
post-transplant biopsy may confer increase risk of allograft dysfunction.
Methods: From 2005-2014, 141 biopsies from 120 transplant patients with DN were 
studied. DN was classified as 1) donor related if present on biopsy <2 yrs from transplant 
or no diabetes in recipient, 2) recurrent if >2 yrs with history of pre-transplant DN, or 3) de 
novo in post-transplant diabetes (all >3 yrs). Clinicopathologic parameters were analyzed 
in 95 patients with adequate clinical history (25 excluded).
Results: Of 95 biopsies with features of DN, 43 were characterized as recurrent, 
17 de novo, and 35 donor-related. Biopsies with donor-related DN were done 0.5 yrs 
(0 days-3.6 yrs) post-transplant and 6 had delayed graft function. Other non-DN related 
disease was seen, likely prompting biopsy: acute tubular injury (10/35), antibody mediated 
rejection (4), acute cellular rejection (1), CNI toxicity (3), AIN (4), TMA (1) and BKV 
(1). Pathologic class of DN were: Class 1-3, Class 2a-21, Class 2b-1, Class 3-10. Class 
3 DN lesions are associated with higher proteinuria, Cr, and increased vascular sclerosis. 
13/35 donors had known diabetes with mean hemoglobin A1c of 8.5% (range 4.7-14.6%). 
DN was not listed on any pre-implantation biopsy reports. Mean follow-up times were 3.8 
yrs for donor-related, 7.8 for recurrent, and 10.3 for de novo. Despite shorter follow-up, 
transplants with donor-derived DN had significantly more failure than recurrent DN (49 v 
14%, P=.0008) or de novo DN (49 v 18%, P=.024). Recurrent and de novo DN had similar 
rates of graft loss (P=.64).
Conclusions: Despite careful screening of transplant kidney donors, donor related 
DN may be missed on pre-surgical biopsy or not effectively reported and leads to renal 
dysfunction in the early post-transplant period. Donor related DN is a significant contributor 
to early allograft loss compared to recurrent or de novo DN and predicts poor long term 
graft survival.
SA-PO1045
Maternal and Fetal Outcomes in Living Kidney Donors in Korea 
Kyung Don Yoo, Hajeong Lee, Jae Yoon Park, Eunjin Bae, Jung Pyo Lee, 
Dong Ki Kim, Kwon Wook Joo, Yon Su Kim.  Seoul National Univ College 
of Medicine.
Background: Mild elevation of blood pressure was detected after unilateral 
nephrectomy in kidney donors. Consequently, female kidney donors at risk for complications 
such as gestational hypertension caused concern. However, the impact of kidney donation 
on maternal and fetal outcomes had not been well established in Asian kidney donors.
Methods: This study included young female kidney donors under 45years old (YO) 
at the time of kidney donation in Seoul National University Hospital between 1972 and 
2014. In all, 417 female donor participants (≤45YO) were enrolled. A survey of pregnancy 
experiences was performed by medical chart abstraction and telephone poll. We additionally 
enrolled 3,608 pregnancies were enrolled as non-donor control. The questionnaires were 
approved by institutional review board in our institute.
Results: We tried to contact all of 417 female kidney donors. The thirty five donors had 
no experience of pregnancy, and finally we could have got 253 questionnaires of kidney 
donors. Donors were compared in the three groups according to pregnancy pre-,post- kidney 
donation group and non-donor control group. The proportion of predonation pregnancies 
were 82% (370cases, Mean age 38.8 years), and postdonation pregnancies were 14.0% 
(56cases, Mean age 27.2 years). In the majority of postdonation pregnancy cases were 
detected in recent years from 2007 to 2014 (72.3%). There were no differences of fetal 
outcomes such as incidence of prematurity, low-birth weight and fetal death between the 
groups. Gestational hypertension were no differences between the postdonation group 
and non-donor control group (5.4% vs. 5.8%). Donors with pregnancy after donation 
were more likely to have undergone Cesarean section (40.4%) than those with pregnancy 
before donation (21.9%).
Conclusions: This study revealed that maternal and fetal outcomes had little difference 
between the kidney donors and normal control. Further research using matched controls 
should be warranted.
SA-PO1046
Self-Monitoring Renal Function After Transplantation: A Clinical Trial 
on Safety and Usability  Céline Lianne Van lint,1 Sandra Van dijk,1 Wenxin 
Wang,2 Mark Neerincx,2 Ton Rovekamp,3 Ton J. Rabelink,1 Paul J. Van der 
boog,1 Willem-Paul Brinkman.2  1Nephrology, Leiden Univ Medical Center, 
Leiden, Netherlands; 2Faculty of Computer Science, Delft Technical Univ, Delft, 
Netherlands; 3Dept of Technology in Healthcare, Prevention and Health, TNO, 
Leiden, Netherlands.
Background: Kidney transplantation requires intensive monitoring which is 
burdensome for both patient and healthcare. With the availability of an innovative creatinine 
device, patients are enabled to monitor renal function at home. To investigate safety and 
usability of self-monitoring during the first year after transplantation an RCT was conducted.
Methods: The intervention group used a Statsensor® Xpress™ to measure creatinine 
at home during the first year post-transplantation. Measurements were registered in a web-
based system using a traffic light analogy to support interpretation of creatinine trends. 
Differences between groups regarding GFR were assessed at baseline (discharge) and at 1 
year. Creatinine trends measured at home were compared to clinically relevant increases 
(>10%) measured in the hospital laboratory. A subsample of intervention patients was 
interviewed on self-monitoring experiences.
Results: In total 119 patients were included (intervention n=64; control n=55). 
GFR did not differ between groups at baseline, nor at 1 year (72.8 and 71.1 ml/min at 1 
year for intervention and control group, respectively). For 34 out of 63 laboratory-based 
creatinine increases, sufficient home-based creatinine measurements were available for 
trend comparison. In 76% a similar trend was observed. Self-monitoring enhanced early 
detection of rejection in 3 out of 5 cases, none were missed. Satisfaction was high: 71% 
of the interviewed patients (n=26) would have liked to extend self-monitoring creatinine 
beyond 1 year.
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Conclusions: Findings suggest that self-monitoring creatinine at home can be used 
for transplant follow up. With improvement of the detection rate of relevant creatinine 
increases (e.g. by increasing measurement frequency), self-monitoring creatinine allows 
number of outpatient visits to be reduced.
Funding: Clinical Revenue Support
SA-PO1047
Comparison of Heart Rate Variability in Kidney Transplantation and 
End-Stage Renal Disease Patients on Dialysis  Lee Heeryong.  Internal 
Medicine, Bong Seng Memorial Hospital, Busan, Korea; Internal Medicine, 
Pusan National Univ Hospital, Busan, Korea.
Background: Heart rate variability (HRV) is a method for evaluation of autonomic 
nervous system activity by expressing the balance of sympathetic and parasympathetic 
tones. Some studies of HRV in patients with end-stage renal disease (ESRD) have been 
performed. However, few have examined kidney transplantation (KT) patients. Therefore, 
we investigated autonomic nervous system activity by means of HRV in patients with KT 
due to ESRD.
Methods: We compared the pattern of cardiac sympathetic and parasympathetic activity 
by time- and frequency-domain analysisof HRV with 24-h Holter monitoring of 23 KT 
and 56 dialysis patients. Patients underwent KT between January, 2008 and June,2011.
Results: The mean ages of KT and dialysis patients were 54.2 ± 12.3 and 53.7 ± 
12.6 years, respectively. The KT group showedincreased time- and frequency-domain 
HRV (including HRV index), very low frequency (VLF), means and standard deviations 
ofall normal R-R intervals for all 5-min segments of the entire recording (SDNNi), low 
frequency (LF), LF in normalized units (LFnorm), and LF to high-frequency power ratio, 
compared with the dialysis group.
HD/CAPD KTP p value
SDNN(msec) 173.8±700.0 98.0±31.8 0.017
rMSSD(msesc) 447.2±54/5 35.7±53.9 0.424
SDNNi(msec) 34.5±34.1 35.3±35.7 0.048
pNN50(%) 10.4±20.1 7.1±17.6 0.589
HRV index 10.2±5.2 14.0±4.0 0.001
HRV index, intergral of the density distribution divided by the maximum of the density 
distribution;pNN50, the percentage of adjacent R-R intervals that varied by more than 50msec;rMSSD, 
root meas square of the difference between the coupling intervals of adjacent R-R intervals;SDNN, 
standard deviation of all normal sinus R-R intervals over 24h;SDNNi, means and standard deviation of 
all normal R-R intervals for all 5-min segments of the entire recording. 
Conclusions: Autonomic tone in patients with KT is higher than that in patients with 
ESRD on dialysis.
Funding: Private Foundation Support
SA-PO1048
Physical Capacity and Function Are Associated with Body Composition, 
Cardiovascular Health and Quality of Life in Renal Transplant Recipients 
Danielle Richler-Potts, Jill Neale, Maurice Dungey, Patrick Highton, Emma L. 
Watson, Alice C. Smith.  Leicester Kidney Exercise Team, Dept of Infection, 
Immunity and Inflammation, Univ of Leicester, Leicester, United Kingdom.
Background: A renal transplant can transform the life of patients with end stage renal 
failure but cardiovascular disease remains a major cause of morbidity and mortality. Post-
transplant weight gain is common, and physical functioning often fails to improve in line 
with increased renal function. This study explored associations of physical function and 
capacity with body composition, cardiovascular status and quality of life (QoL) in renal 
transplant recipients (RTRs).
Methods: 35 stable RTRs participated (mean age 52 years (range 29-70), 66% male). 
Self-reported QoL and physical function were measured by EQ5D and Duke Activity Status 
Index (DASI) questionnaires. Physical capacity was measured by shuttle walk test (SWT), 
body composition by DXA, cardiac haemodynamic function by bioreactance (NICOM), 
and systemic inflammation by plasma IL-6 ELISA.
Results: SWT, DASI and EQ5D all showed significant correlations with percentage 
body fat (SWT: r=-0.63 p<0.001; DASI: r=-0.41 p=0.02, EQ5D r=-0.47, p=0.005) and with 
IL-6 (r=0.34 p=0.05). On the other hand, fat-free mass showed positive correlation with 
cardiac output (r=0.79) and stroke volume (r=0.81, both p<0.001), and inverse correlation 
with total peripheral resistance (r=-0.67 p<0.001).
Conclusions: This study shows that in RTRs, poor physical function and capacity 
is significantly associated with lower QoL and also with higher percentage body fat and 
systemic inflammation, both of which are important cardiovascular risk factors. An increase 
in fat-free mass was significantly associated with superior cardiac function. Taken together, 
these results suggest that weight loss is desirable for those with excess body fat, and that 
gaining muscle mass is also important. Optimising body composition through appropriate 
exercise and nutrition may therefore improve physical function and capacity and enhance 
quality of life, and also reduce the risk of cardiac-related morbidity and mortality in this 
vulnerable population.
Funding: Private Foundation Support
SA-PO1049
Pregnancy in the Renal Transplant Recipient: Pregnancy Viability and 
Effects on Graft Function  Andre Caires Alvino Lima, Cinthia Montenegro 
Teixeira, Igor Gouveia Pietrobom, Mayara Ivani de Paula, Geovana Basso, Laila 
Almeida Viana, Helio Tedesco Silva, J. Medina-Pestana.  Dept of Nephrology, 
Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
Background: Fertility in women is recovered few months after kidney transplantation. 
However, pregnancy viability and maternal complications remain unclear.
Methods: We studied data from patients from a kidney transplant center in Brazil from 
2001 to 2012. In this retrospective study, we identified all pregnant kidney transplantat 
recipient and collected clinical and laboratory data before pregnancy, every quarter and 12 
months after delivery. Each pregnancy was considered a single event.
Results: We included 36 subjects and 53 events were found. The average age 
was 28±5 years. Pregnancy occurred 4,4±3 years after transplantation. Maintenance 
immunosuppression before pregnancy was prednisone, tacrolimus and azathioprine in 
74% of the cases. The frequency of chronic hypertension was 38%, and 8% had preexisting 
proteinuria greater than 0,5g. 8 (15%) unintended termination of pregnancy (UTP) were 
observed in the first quarter and 4 (8%) occurred in the second quarter. Delivery was 
induced by medical conditions in 41% of cases. 9 (22%) premature births and 7 (17%) 
very premature births were observed. Two (5%) stillbirths and two (5%) neonatal deaths 
occurred. Maternal complications were proteinuria de novo (60%), urinary tract infection 
(23%), preeclampsia (9%) and high blood pressure (9%). During the follow-up period, two 
(6%) acute rejection and one (2%) graft loss occurred. Average baseline creatinine was 
compared with third quarter and 12 months follow-up creatinine and significant increase 
(1,17 vs. 1,46 vs. 1,59mg/dL, p<0,001) was found.
Conclusions: Although the sample is limited, the number of UTP was higher than 
the general population, with high rates of maternal complications. Besides, diagnosis 
of preeclampsia may be challenging because of the high frequency of hypertension and 
preexisting proteinuria. The sustained increase in creatinine suggests higher risk of long-term 
graft loss. Further research regarding the issue of pregnancy and kidney transplantation is 
required, in order to improve maternal safety and preserve graft function.
Funding: Private Foundation Support, Government Support - Non-U.S.
SA-PO1050
Outcomes of Twin, Triplet and Quadruplet Pregnancies in Kidney 
Transplant Recipients  Serban Constantinescu,1,2 Lisa Coscia,2 Dawn 
Armenti,2 Michael J. Moritz.2,3  1Medicine, Temple Univ School of Medicine, 
Philadelphia, PA; 2National Transplantation Pregnancy Registry (NTPR), Gift 
of Life Inst, Philadelphia, PA; 3Transplantation, Lehigh Valley Health Network, 
Allentown, PA.
Background: The purpose of this study is to analyze multiple gestation pregnancy 
outcomes reported to the National Transplantation Pregnancy Registry (NTPR) in 50 
kidney transplant recipients.
Methods: Data were collected via questionnaires, telephone interviews, and hospital 
records.
Results: Of 986 kidney recipients (1802 pregnancy outcomes) participating in the 
NTPR, there were 50 who reported 52 multiple gestations with 112 pregnancy outcomes 
(45 sets of twins, 6 sets of triplets, and 1 set of quadruplets). There were 94 live births, 11 
miscarriages, 6 stillbirths, and 1 reduction (triplet to twin pregnancy). Pregnancy occurred 
after 1st kidney transplant in 47, after a 2nd in 4, and after 3rd in 1 recipient; 14 recipients 
had a prior post-transplant live birth and 2 recipients had 2 multiple birth pregnancies. 
Use of reproductive assistance was reported for 16 conceptions (medication 5, intrauterine 
insemination 5, in vitro fertilization 4, and unspecified 2). There were no reports of rejection 
during pregnancy or postpartum (PP). Mean serum creatinine (mg/dL) was pre-pregnancy 
1.4±0.6, during pregnancy 1.4±0.5, and PP 1.4±0.5. There were 4 graft losses within 2 yrs 
PP. Mean gestational age was 32.1±4.1 wks (range 23-37.4 wks) and mean birthweight 
was 1680±652 g (range 454-3551 g). There were 11 neonatal deaths including all of the 
infants in the quadruplet pregnancy. There were 5 birth defects reported: soft cleft palate, 
hypospadias, unilateral kidney, undescended testicle, and Tetralogy of Fallot. Overall, 
the majority of the children were reported healthy and developing well at last follow-up.
Conclusions: Female kidney transplant recipients can successfully maintain a 
pregnancy with multiple gestations. Given the increase in multiple gestations with the use 
of assisted reproductive techniques and the greater risks to the resulting fetuses, heightened 
surveillance in the transplant recipient population is warranted.
Funding: Pharmaceutical Company Support - Astellas Pharma, US, Inc., Pfizer, Inc., 
and Bristol-Myers Squibb Co.
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SA-PO1051
Kidney Transplantation for End-Stage Kidney Disease After Hematopoietic 
Stem Cell Transplantation  Akihiro Tsuchimoto,1 Kosuke Masutani,1 Kei 
Kurihara,2 Hidehisa Kitada,2 Takehiro Nishiki,3 Morihito Ota,3 Masayoshi 
Okumi,4 Tomokazu Shimizu,4 Hideki Ishida,4 Kazunari Tanabe,4 Kazuhiko 
Tsuruya,1 Takanari Kitazono.1  1Medicine and Clinical Science, Kyushu Univ, 
Fukuoka, Japan; 2Surgery and Oncology, Kyushu Univ, Fukuoka, Japan; 
3Sugery, Tomishiro Central Hospital, Okinawa, Japan; 4Urology, Tokyo Women’s 
Medical Univ, Tokyo, Japan.
Background: Hematopoietic stem cell transplantation (HSCT) is associated with 
various kidney diseases. The safety of kidney transplantation (KT) for end-stage kidney 
disease (ESKD) after HSCT has not been established. In this retrospective multicenter 
study, we investigated the immunological background, immunosuppressive regimens, and 
outcome in the KT patients after HSCT.
Methods: We report our experience with 5 KT patients following HSCT: 4 patients 
received bone marrow transplantation and 1 received umbilical cord blood transplantation. 
Median age at the time of HSCT was 29 years old (ranged 13-54 years old), and ESKD 
developed after 119 months (67-307 months). The median duration of pre-transplant 
dialysis therapy was 18 months (7-69 months). In one patient, bone marrow and kidney 
were from the same donor.
Results: Median observational period was 18 (5-60) months. All patients were treated 
antibody-induction with basiliximab followed by triple immunosuppression consists of 
tacrolimus, mycophenolate mofetil and methylprednisolone. In one patient with positive 
complement dependent cytotoxicity cross match, we added rituximab, splenectomy and 
plasmapheresis. In another one patient who received KT and BMT from the same donor, 
we temporary gave immunosuppressive drugs. After KT, only one patient experienced 
subclinical acute T-cell mediated rejection and bacterial pneumonia, and the other 4 patients 
have not experienced acute rejection or severe infectious complications.
Conclusions: Previous studies of KT patients after HSCT suggested low incidence 
of rejection and stable graft function, but high mortality caused by infections, whereas 
the patients in our file revealed rare infectious complications as well as mild allograft 
rejection. Current pre- and post-transplant management contributes favorable outcome of 
KT patients after HSCT.
SA-PO1052
The Risk Factors of Chronic Kidney Disease Occurrence in Patients 
Received Liver Transplantation  Li Yuehong.  Nephrology, Tsinghua 
Changgung Hospital, Medical Center, Tsinghua Univ, Beijing, China.
Background: Analysis the risk factors of chronic kidney disease (CKD) occurrence 
in patients with liver transplantation.
Methods: 190 patients received liver transplantation followed up during 2001 to 2013 
were analyzed retrospectively. 40 patients developed CKD. The observation items included 
patients’ gender, age, primary diseases, surgical approach, preoperative complications, 
laboratory examinations (hemoglobin, albumin, creatinine, glomerular filtration rate), 
intraoperative blood loss and blood transfusion volume, postoperative complications and 
average serum calcineurin concentration (from liver transplantation to the onset of CKD). 
Clinical data of CKD occurence group were compared with the non-CKD group. Chi square 
test, t test, and logistic regression analysis were used.
Results: The incidence of CKD in patients with liver transplantation was 21.1%. Renal 
pathology included IgA nephropathy, hepatitis B virus associated nephropathy, membranous 
proliferative glomerulonephritis, focal segmental glomerular sclerosis and cryoglobulinemia 
associated renal injury. 85.7% patients had tubulointerstitial damage. Univariate analysis 
showed that preoperative renal function, hemoglobin, intraoperative blood loss and 
transfusion volume, postoperative acute kidney injury, average calcineurin concentration 
and hypertension were risk factors of CKD in patients with liver transplantation. Logistic 
regression analysis showed that preoperative glomerular filtration rate (OR=0.980, P=0.041), 
hemoglobin (OR=0.972, P=0.034), calcineurin concentration (OR=1.364,P=0.015) and 
postoperative hypertension (OR=4.833, P=0.048) were independent risk factors of CKD 
occurrence . 
Items B OR 95%CI P
eGFR -0.020 0.980 0.962-0.999 0.041
Hemoglobin -0.029 0.972 0.946-0.998 0.034
calcineurin 
concentration 0.311 1.364 1.063-1.751 0.015
postoperative 
hypertension 1.575 4.833 1.014-23.027 0.048
Risk factors of CKD occurence in patients with liver transplatation by logistic 
regression analysis.
Conclusions: The incidence of CKD in patients with liver transplantation was higher. 
Independent risk factors included preoperative glomerular filtration rate, hemoglobin, 
postoperative average calcineurin concentration and hypertension.
SA-PO1053
Pre-Transplant CKD, but Not AKI, Impacts Survival in Liver Transplant 
Recipients  Yorg Al Azzi, Girish N. Nadkarni, Vinay Nair, Thomas Schiano, 
Madhav C. Menon.  Medicine, Icahn School of Medicine, New York, NY.
Background: Chronic kidney disease (CKD) stage and duration of RRT pre-liver 
transplant (OLT) have been associated with increased risk of progression to ESRD in OLT 
recipients. Currently, allocation of dual organ transplantation (liver/kidney) is limited to 
CKD stage 4 and/or RRT > 4 weeks. The data regarding the associations of less severe 
pre-OLT AKI (RRT<4 weeks) and, of CKD stage 3, with ESRD post-OLT is unclear. We 
examined the renal outcomes of OLT recipients at our center.
Methods: We reviewed charts of OLT recipients at Mount Sinai for clinical, 
demographic, laboratory and outcome data from the medical record. We utilized 
multivariable logistic regression for analysis.
Results: We had data on 115 OLT recipients from 2008-14 (mean age 57.7 years, 66% 
male). 55/115(47%) patients developed AKI pre-transplant, most often from HRS (47%). 
Pre-existing CKD-3 was present in 26/115 patients. Pre-OLT AKI developed in 23/26 
CKD-3 patients. RRT was required in 8/26 CKD-3 patients. Mean eGFR at 1- and 2-yr 
follow-up in the CKD-3 group compared to non-CKD group were 37.4 ± 16.6 vs. 33.3 ± 
23.1(p<0.01) and 59.8 ± 20.8 vs. 62.7 ± 22.3(p<0.01) respectively. At a mean follow up of 
1.4 years post OLT, proportion of patients developing ESRD was higher in CKD3 vs. non 
CKD group (23.1% vs. 2.3%;p<0.01) Although, AKI was a significant predictor of ESRD 
(adjusting for age, sex, race, diabetes), its effect was attenuated after adjusting for CKD. 
CKD3 was the strongest predictor of ESRD (aOR 8.34; 95% CI 1.25-55.7;p=0.02) (figure 
1). Overall, patient survival at a mean of 2.4 years of follow-up was lower in CKD3 vs. 
non-CKD3 groups (76.9%vs. 91%;p=0.08).
Conclusions: Although limited by small sample size and low event rate, our analysis 
suggest that pre-OLT CKD3 may have an effect on development of ESRD post-OLT. These 
effects if generalizable in larger cohorts are important for organ allocation.
SA-PO1054
Can Acute-On-Chronic Liver Failure Classification Predict Post-Liver 
Transplant and Liver Kidney Transplant Outcomes?  Giselle Guerra,1 
Panagiotis Tryphonopoulos,2 Kalyan Bhamidimarri,2 Ian Thomas,1 Rodrigo 
Vianna.2  1Div of Nephrology, Miami Transplant Inst, Miami, FL; 2Divison of 
Transplantation, Miami Transplant Istitute, Miami, FL.
Background: Recent evidence suggests that acute on chronic liver failure (ACLF) 
stratification is more accurate than other methods in predicting short term mortality rates 
pre-transplant. There is no evidence of ACLF stratification as predictor of post- transplant 
outcomes. We analyzed if ACLF could predict patient and allograft survival in liver 
transplant recipients (LTR) or simultaneous liver kidney transplant recipients (SLKTR) 
especially if hepatorenal syndrome (HRS) is present.
Methods: A retrospective analysis was performed on 86 adult patients, 77 LTR and 
9 SLKTR transplanted in 2013. Patients were classified into different ACLF grades (0-3) 
based on their pre-transplant parameters:MELD labs ( total bilirubin, serum creatinine, 
INR), hepatic encephalopathy, ventilator dependence and the presence of shock. Patient 
and allograft survival, and kidney function (serum creatinine < 1.5 mg/dL) were analyzed 
at 6 & 12 months post-transplant between LTR and SLKTR. A further analysis between 
recipients with HRS receiving either LT or SLKT was made. SLKTR received kidney 
transplants based on current International Club of Ascites (ICA) guidelines.
Results: Demographics of LTR and SLKTR cohorts: mean age of 58 and 59 years; 
males 63% and 56%; mean MELD of 21 and 33 respectively. Recipients with HRS pre- 
transplant had mean MELDof 38 vs. 30 in the LTR and SLKTR groups respectively. 27% 
of LTR had ACLF 0-1, 11% SLKTR had ACLF 0-1; 73% of LTR had ACLF 2-3; 89% of 
SLKTR had ACLF 2-3. LTR with HRS had 100% with ACLF 2-3; SLKTR with HRS had 
83% with ACLF 2-3. One year post transplant outcomes: Patient Survival – 92% LTR, 66.7% 
SLKTR; Graft Survival – 89.6% LTR, 66.7% SLKTR; Kidney Function good – 81.8% LTR, 
33.3% SLKTR. In patients with HRS both patient and graft survival are 83.3% SLKTR 
and 75% LTR, but kidney function trended to be better in LTR (50%)vs SLKTR (33.4%).
Conclusions: Patient/graft survival and kidney function appear to trend better overall 
in LTR vs. SLKTR. However, HRS patients faired the opposite favoring SLKTR vs LTR.
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SA-PO1055
C3 Alone Is Not a Prognostic Indicator of Patient or Graft Survival in 
Post-Transplant Glomerulonephritis  Amber Hertz-Tang, Arjang Djamali, 
Brad C. Astor, Sarah E. Panzer, Weixiong Zhong, Maha A. Mohamed, Didier 
A. Mandelbrot, Sandesh Parajuli.  Nephrology, Univ of Wisconsin Hospital and 
Clinics, Madison, WI.
Background: The prognostic implications of glomerular C3 in the post-transplant 
setting are not well characterized.
Methods: We examined patient and graft outcomes in 71 kidney transplant recipients 
diagnosed with glomerulonephritis(GN). Biopsies were studied by immunofluorescence(IF) 
for glomerular C3 staining and divided into two categories, C3-positive or C3-negative. 
Primary outcomes were graft and patient survival at 3, 12, and 36 months and at last follow-
up. Serum creatinine(Cr) at last follow-up was a secondary outcome.
Results: Thirty three(46%) patients were C3-positive and 38(54%) were C3-negative. 
Mean follow up was 103 months for positive C3 and 117 months for negative C3 groups. 
There were no significant differences among groups by age, gender, type of donor, or 
prevalence of hypertension, diabetes, and hepatitis B or C. A total of 57% of C3-positive 
patients had a functioning graft at 36 months post-transplant, compared to 75.1% of C3-
negative (p=0.16). A total of 88.2% of C3 positive patients were alive at 36 months post-
transplant, compared to 85.7% of C3 negative (p=0.9). The mean serum Cr for C3 positive 
patients at 36 months was 1.59mg/dl compared to 1.71mg/dl for C3 negative (p=0.55). 
There were no significant differences in graft and patient survival between two groups.
Conclusions: There was no significant difference in patient or graft survival, or in serum 
Cr between patients with GN and C3-positive IF compared to patients with C3-negative 
IF. This suggests that the presence of C3 alone is not a prognostic indicator of patient or 
graft survival in post-transplant GN. 
Positive C3(%) Negative C3(%) P
Graft survival at 3 months 96.8 91.8 0.39
Graft survival at 12 months 74.2 80.7 0.58
Graft survival at 36 months 56.8 75.1 0.16
Graft survival at last follow up 27.3 44.7(17) 0.19
Mean serum Cr at last follow up 2.00(0.67) 2.06 ±1.30 0.88
Patient survival at 3 months 100 100 -
Patient survival at 12 months 92.6 97.2 0.41
Patient survival at 36 months 88.2 85.7 0.90
Patient survival at last follow up 75.7 65.7(25) 0.36
SA-PO1056
Pretransplant Hepatitis B Viral Infection Increased Risk of Death 
After Kidney Transplantation: A Multicenter Cohort Study in Korea 
Jin Ho Hwang,1 Jeonghwan Lee,2 Jang-Hee Cho,3 Jung Nam An,4 Chan-Duck 
Kim,3 Curie Ahn,5 Chun Soo Lim,4 Yon Su Kim,5 Young Hoon Kim,6 Jung 
Pyo Lee.4  1Internal Medicine, Chung-Ang Univ Hospital, Seoul, Republic of 
Korea; 2Internal Medicine, Hallym Univ Hangang Sacred Heart Hospital, Seoul, 
Republic of Korea; 3Internal Medicine, Kyungpook National Univ Hospital, 
Daegu, Republic of Korea; 4Internal Medicine, Seoul National Univ Boramae 
Medical Center, Seoul, Republic of Korea; 5Internal Medicine, Seoul National 
Univ College of Medicine, Seoul, Republic of Korea; 6Surgery, Ulsan Univ Seoul 
Asan Medical Center, Seoul, Republic of Korea.
Background: Outcomes in kidney transplant recipients (KTRs) with hepatitis B virus 
(HBV) have not been well evaluated. Here, we aimed to investigate the recent posttransplant 
clinical outcomes of KTRs with HBV comparing with those with hepatitis C virus (HCV) 
or seronegative patients.
Methods: Among 3885 kidney recipients from Apr. 1999 to Dec. 2011, 3490 patients 
were enrolled whose viral hepatitis serology data was available. Numbers of patients with 
HBV and hepatitis C virus (HCV) were 166 (4.8%) and 55 (1.6%).We analyzed the overall 
mortality and graft failure (GF) among patients who had taken KT.
Results: Patients with HBV showed poorer patient survival (P=0.030, adjusted 
HR=2.296, 95% CI 1.084-4.864) than KTRs without HBV. However HCV did not affect 
patient survival (P=0.763). Patients with chronic hepatitis C showed increased incidence 
of GF (P=0.015, adjusted HR=2.330, 95% CI 1.178-4.606). However, the GF of patients 
with chronic hepatitis B (CHB) was not different (P=0.066). Among causes of mortality 
of KTRs with HBV, hepatic failure was predominant (44.4%). The KTRs with HCV 
had increased incidence of acute rejection (log-rank P=0.005; crude HR=2.147, 95% CI 
1.344-3.432, P=0.001). Among KTRs with HBV, mortality was significantly correlated 
with higher grade of inflammation in pretransplant liver biopsy (P=0.007) and lower rate 
of prophylactic antiviral treatment (P=0.019).
Conclusions: The KTRs with CHB could show poor survival due to post transplantation 
hepatic complications. Continuous close monitoring and antiviral management of KTRs 
with CHB patients will be needed, even if liver function is within normal range.
SA-PO1057
Does Hepatitis B Virus Impact the Outcomes in Kidney Transplant 
Recipients? Analysis by Phases of Infection  Bhavna Chopra, Swati Arora, 
Richard J. Marcus, Sabiha M. Hussain, Khaled Nashar, Tina Y. Ko, Kalathil K. 
Sureshkumar.  Allegheny General Hospital, Pittsburgh, PA.
Background: In kidney transplant recipients (KTRs) with hepatitis B virus (HBV) 
infection, immunosuppression may increase the risk for the progression of liver disease. 
HBV may contribute to allograft disease and anti-HBV therapy can have nephrotoxic 
potential. All these factors could adversely influence graft/patient outcomes. We aimed 
to analyze the impact of different phases of HBV infection on the outcomes in KTRs.
Methods: Using OPTN/UNOS database, we selected adult KTRs from 2001 - 2011 
who received peri-operative antibody induction followed by calcineurine inhibitor/
mycophenolate mofetil maintenance along with/without steroid. The cohort was divided 
into 4 groups based on the presence/absence of hepatitis B surface antigen(HBsAg) and 
core antibody (HBcAb) at the time of transplantation: HBsAg+/HBcAb-(acute infection); 
HBsAg+/HBcAb+ (developing immune response); HBsAg-/HBcAb+ (resolving infection) 
and HBsAg-/HBcAb- (HBV naive). Graft and patient survivals were compared among 
the groups as shown in the table by using multivariate Cox model. Donor, recipient and 
transplant related confounders including lamivudine therapy were adjusted in the model.
Results: Adjusted graft and patient survival comparisons are shown in the table. 
HBsAg+/HBcAb- 
(n=1098) 
vs.
HBsAg+/HBcAb+ 
(n=467)
HBsAg+/
HBcAb+(n=467)
vs. 
HBsAg-/HBcAb+ 
(n=6117)
HBsAg-/HBcAb+ 
(n=6117)
vs. 
HBsAg-/HBcAb- 
(n=81968) 
Outcomes HR (95%CI) p HR (95%CI) p HR (95%CI) p
Death-censored 
graft suvival
0.83 (0.71-
0.98) 0.02
0.80 (0.71-
0.91) 0.002 0.97 (0.9-1.0) 0.05
Patient survival 1.06 (0.93-1.25) 0.40 1.11(1.0-1.25) 0.10
0.97 (0.91-
1.11) 0.10
Conclusions: Our findings favor delaying kidney transplantation in HBV infected 
patients until they start to develop an immune response to the virus (HBsAg+/HBcAb+ 
sero-status) and preferably till HBV infection begins to resolve (HBsAg-/HBcAb+ sero-
status) in order to optimize graft outcomes. With the availability of newer anti-viral agents, 
transplant outcomes are likely to improve further in KTRs with HBV infection.
SA-PO1058
Incidence of Hepatitis B Viral Reactivation After Kidney Transplantation 
with Rituximab Administration  Kosuke Masutani,1 Kazuya Omoto,2 
Masayoshi Okumi,2 Hidehisa Kitada,3 Tomokazu Shimizu,2 Hideki Ishida,2 
Kazunari Tanabe,2 Kazuhiko Tsuruya,1 Takanari Kitazono.1  1Medicine and 
Clinical Science, Kyushu Univ, Fukuoka, Japan; 2Urology, Tokyo Women’s 
Medical Univ, Tokyo, Japan; 3Surgery and Oncology, Kyushu Univ, Fukuoka, 
Japan.
Background: The efficacy of antiviral prophylaxis for rituximab (RIT)-associated 
hepatitis B virus (HBV) reactivation in patients with malignant lymphoma has been 
reported. However, the effect of single-dose RIT on HBV reactivation in kidney transplant 
patients with hepatitis B surface antigen-negative (HBsAg-) and hepatitis B core antigen 
antibody-positive (HBcAb+) results is unclear, and there is no evidence for the necessity 
of prophylaxis in those patients.
Methods: From 2001 through 2014, 1021 patients underwent kidney transplantation 
(KTx) at Kyushu University and Tokyo Women’s Medical University, of whom 76 (7.4%) 
had HBsAg-/HBcAb+ results. Those patients showed hepatitis C virus (HCV)-RNA-
negative, hepatitis B surface antibody-positive (HBsAb+), and HBV-DNA-negative. A 
RIT dose of 200mg/body was administered to 49 patients, and 45 patients did not receive 
prophylaxis. We monitored HBV-DNA and alanine transaminase levels every 1-3 months 
after KTx. HBV reactivation was defined as an elevation of serum HBV-DNA level ³2.1 
log copies/mL.
Results: HBV reactivation was found in 1 of 45 patients (2.2%) without prophylaxis. In 
the patient with HBV reactivation, serum HBV-DNA was detected at 6 weeks after KTx, and 
the minimum and maximum HBV-DNA levels were 2.1 and 2.6 log copies/mL, respectively. 
Although the patient was not treated with antiviral therapy, the HBV-DNA disappeared 
at 8 months after KTx. HBV reactivation was not found in the patients without RIT, and 
in the 4 patients who received both RIT and prophylaxis. Four (8.9%) of the 45 patients 
developed acute rejection, and 1 patient (2.2%) died of sepsis during the observation period.
Conclusions: The incidence of RIT-associated HBV reactivation in the HBsAg-/
HBcAb+ patients without prophylaxis was less than 5%, suggesting that low-dose RIT might 
be associated with low incidence of HBV reactivation. However, sequential monitoring of 
HBV-DNA is necessary to prevent severe de novo hepatitis.
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SA-PO1059
Direct Acting Antiviral Agents for HCV-Infected Patients Transplanted with 
a Kidney from a HCV Positive Donor  David Roth, Michael J. Goldstein, 
Warren L. Kupin, Giselle Guerra, Linda J. Chen, Adela D. Mattiazzi, Gaetano 
Ciancio, Paul Martin, George William Burke, Kalyan Bhamidimarri.  Medicine, 
Univ of Miami Miller School of Medicine, Miami, FL.
Background: The availability of direct acting antivirals (DAAs) has changed the 
treatment of hepatitis C virus (HCV) infection. The decision to treat a HCV (+) patient (pt) 
before or after transplant has important ramifications. The current study reports outcomes 
in HCV-infected pts who received a kidney from a HCV (+) donor followed by early post-
transplant treatment with DAAs.
Methods: HCV RNA (+) pts on the waiting list were consented to receive a kidney 
from a HCV (+) donor. Induction immunosuppression (IS) included thymoglobulin and 
simulect followed by maintenance IS with tacrolimus and mycophenolate mofetil. At 3 
months post-transplant sofosbuvir combined with either ledipasvir, simeprevir and/or 
ribavirin for 12 or 24 weeks was initiated.
Results: Ten pts have started DAA therapy (5 others pending); 6 blacks and 4 hispanics 
with a mean age of 49.4 yrs. No pts were HIV or HBV co-infected. All pts were treatment 
naïve, genotype 1 and non-cirrhotic. Median wait time was 30 days after consenting to 
accept a HCV (+) kidney. Viral clearance rates are shown in figure1. 
No viral relapses have occurred. Ribavarin was lowered or stopped in 2/3 pts for 
anemia. Two pts had ABMR after attaining viral clearance. Tacrolimus dose required 
upwards titration in 6 pts. from 17-400%.
Conclusions: This report describes the use of DAAs in HCV infected kidney recipients 
who received a kidney from a HCV (+) donor. Accepting a HCV (+) kidney significantly 
shortened wait time. Response to DAAs appears similar to that being reported for pts 
without kidney disease however IS dosing must be carefully monitored. This treatment 
strategy should be considered for non-cirrhotic HCV-infected pts awaiting deceased donor 
kidney transplantation.
SA-PO1060
Impact of Treatment of HCV Infection on Renal Transplant Outcome 
Sanjay K. Agarwal, Soumita Bagchi, Dipankar M. Bhowmik, Sandeep Mahajan, 
Akansha Agrawal.  Nephrology, All India Inst of Medical Sciences, New Delhi, 
Delhi, India.
Background: Impact of HCV treatment on post renal transplant outcome has not 
been reported adequately. This retrospective study was done to evaluate impact of HCV 
treatment on the post renal transplant outcome.
Methods: Adult patients on dialysis with HCV infection treated with pegylated 
interferon and subjected to renal transplant (RT) formed the study group. Untreated patients 
subjected to RT during same period served as controls. Primary end points were patient’s 
and graft survival and secondary end points were serious infections and NODAT. Factors 
which affect the outcome like age, gender, diabetes as basic disease, dialysis vintage, HBV 
co-infection, HCV genotype, viral load, liver biopsy grade and stage, induction and baseline 
immunosuppression were considered for analysis.
Results: At the time of study, 2010 RT were done in department of which 133 had HCV 
infection. 30 were treated with 68% SVR and 103 were untreated. In untreated group, there 
were more males (92% Vs 77%), less dialysis number (137 Vs 211), less HBV co-infection 
(0.9% Vs 10%), less use of Tacrolimus (13.6% Vs 30%). There was no difference in terms 
of age, diabetes, HCV genotype, viral load, liver biopsy grade and stage, use of induction, 
Mycophenolate mofetyl and duration of follow-up in two groups. With mean follow-up 
of 59 ± 22 months (range 12- 105), there was no statistically significant difference in term 
of acute rejection (23% vs. 15%), NODAT (10% vs. 16.7%) and overall serious infections 
(23% vs. 15%) between two groups. However, there were 11 deaths in untreated group (8 
sepsis related, 3 liver failure and 1 coronary artery disease) while only one death related 
to sepsis in treated group. Patients survival (97% vs. 89%) and graft survival (97% vs. 
84%) was significantly better (p<0.05) in treated group as compared to untreated group.
Conclusions: Treatment of HCV with pegylated interferon during dialysis results in 
significant improvement of patients and graft survival following transplantation as compared 
to untreated patients. There is also trend of decrease in serious infection in treated patients. 
Sepsis and liver failure are two most common cause of mortality in untreated patients.
SA-PO1061
Prospective Study of Urinary Tract Infection in Renal Allograft Recipients 
in India: Single Center Study  Sanjay K. Agarwal, Muthu kumar B, Soumita 
Bagchi.  Nephrology, All India Inst of Medical Sciences, New Delhi, India.
Background: Urinary tract infection (UTI) is common in renal transplant (RT) and 
in addition to morbidity, presumed to affects graft outcome also. Still it is least studied 
infection in RT. There is no data from India. We looked for incidence, risk factors and 
pattern of UTI in first 6 months after RT and its impact on graft function.
Methods: All RT between Dec 2013 and March 2015 were followed with urine exam 
and C/S at day 3, 7, 14, 21, 28 and then every two week till 3 months then monthly for 
another 3 months. Patients with asymptomatic bacteuria (ASB) were randomized into 
treatment and no treatment group. Treatment was done for 7-10 days as per C/S. Study 
was approved by institute review board and informed consent was taken from each subject.
Results: During the study period 180 RT were done, (4 died, 2 nephrectomy, 1 graft 
failed, 4 lost to FU); 169 were analysed. Mean age of patients was 31.4 ± 10.4 (14-56) yrs 
and 81.6% were males. Diabetes was in 3.5%, renal stone in 3.5% and 3.5% had history of 
pre-RT recurrent UTI. All were on tacrolimus, MMF and steroid. 53% received induction. 
None got anti-reflux surgery. All were on cotrimoxazol for 6 months. 49 (29%) patients 
had at least one episode of UTI; 23 symptomatic and 26 ASB. Most common UTI was 
seen at 21 days followed by 14 days post surgery. 50-60% of these were symptomatic. 
Following RT, with time, frequency of UTI went on decreasing. Of the 84 UTI episodes, 
47 (56%) were caused by E.coli followed by Klebisella (16.7%), Enterococci (12%) and 
Pseudomonas (8.3%). Of the patients who had UTI, there were more females (33% vs. 
13%), more stone disease (8.2% vs. 1.7%) and more post-operative surgical complications 
(24.5% vs. 11.7%). Of the 26 ASB, 11 were treated and 15 untreated. Of the 15 untreated 
ASB, none developed symptomatic UTI or rejection. There was no difference in serum 
creatinine between treated and untreated ASB on last follow-up.
Conclusions: In conclusion, symptomatic UTI in RT in our setting is seen in 13.6% 
patients, mostly in first month with E.coli as causative organism in half of patient. Untreated 
asymptomatic UTI does not affect graft outcome and does not lead to symptomatic UTI.
SA-PO1062
High Dose Steroid Therapy in BK Viremia Adversely Affected Long Term 
Graft Function in Kidney Transplantation  Hyosang Kim, Chung Hee Baek, 
Su-Kil Park.  Div of Nephrology, Dept of Internal Medicine, Asan Medical 
Center, Univ of Ulsan College of Medicine, Seoul, Republic of Korea.
Background: High dose steroid therapy has been tried for the management of 
confusing cases of BK nephropathy (±mixed cellular rejection). However, the eventual 
fate of renal allograft after steroid therapy in the long term is still unknown. Therefore 
we investigated the graft survival and the change of BK viral load after steroid therapy in 
patients with BK viremia.
Methods: The study population comprised 144 kidney transplant recipients with 
BK viremia (serum BK viral load>1x104 copies/mL) consecutively detected at least two 
times, followed by steroid pulse treatment between July 2004 and March 2013. Patients 
were divided into two groups based on the amount of steroid: low dose (steroid 0-2g) or 
high dose (steroid>2g).
Results: A total of 123 patients belonged to low dose group and 21 patients were 
in high dose group. There were no differences in baseline characteristics, including age, 
gender, and the rates of biopsy-proven BK nephropathy and acute rejection. Serum BK 
viral loads at the time of steroid pulse therapy were 5.38±1.10 log copies/mL in low dose 
group and 6.00±0.98 in high dose group (p=0.054). They were changed into 5.25±1.05 
and 6.14±1.45 in each group one month after steroid treatment (p=0.03) and 4.92±1.25 and 
5.86±1.74 at two months (p=0.133), respectively. From three months to one year, serum 
BK viral loads were not different from each group. Kaplan Meier analyses demonstrated 
that the incidences of further 50% decline in renal function assessed by estimated GFR 
and graft failure were significantly higher in the high dose group (p=0.004 and p=0.04, 
respectively). In multivariate regression analysis, high dose steroid treatment (p=0.002, 
HR 9.61, 95% CI 2.25-40.99) and log serum BK viral load at two months after high dose 
steroid administration (p=0.027, HR 1.72, 95% CI 1.06-2.78) were important risk factors 
of further 50% decline in renal function.
Conclusions: In kidney transplant recipients with BK viremia, high dose steroid 
therapy induced BK viral activation and subsequently resulted in poor long term graft 
function and early graft failure.
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SA-PO1063
Donor Seroreactivity Strongly Correlates with Recipient BKV-Viremia 
and Nephropathy  Herman F. Wunderink,1 Els Meijden van der,1 Caroline van 
der Blij-de Brouwer,1 Antoine Touze,2 Marko Mallat,1 Geert Haasnoot,1 Erik 
Van zwet,1 Eric Claas,1 Johan W. De Fijter,1 Aloys Kroes,1 Frans Claas,1 Joris 
I. Rotmans,1 Mariet Feltkamp.1  1Leiden Univ Medical Center, Netherlands; 
2Univ François Rabelais, France.
Background: Incidence and severity of reactivating latent infections in kidney 
transplant (KTx) recipients are difficult to predict. In case of BK polyomavirus (BKV)-
induced nephropathy, donor origin of infection is likely. Since BKV-seroreactivity reflects 
BKV-(re)activity, we hypothesized that donor BKV-seroreactivity correlates with infectivity 
and predicts BKV infection of recipients.
Methods: In a retrospective cohort of 407 living donor-recipient pairs transplanted 
between 2003 and 2013 at LUMC, pre-KTx sera from donors and recipients were tested 
for presence and intensity of BKV IgG-seroresponses. Measured seroresponses were 
compared with recipient BKV-loads (viremia) determined post-KTx and compared with 
other potential risk factors for BKV-infection.
Results: Within one year after KTx, BKV-viremia was observed in 27% of recipients. 
Baseline BKV-seroprevalence among donors (96%) and recipients (95%) was high and not 
correlated with viremia. However, a strong association was observed between the strength 
of donor BKV-seroreactivity and occurrence of both viremia and PVAN (p<0.001). Baseline 
recipient BKV-seroreactivity as such was not associated. The hazard ratio of viremia 
was almost 10-fold higher in recipients of high compared to low seroreactive donors. In 
multivariate analysis, donor seroreactivity was the strongest baseline factor associated with 
viremia and nephropathy post-KTx (p<0.001), outcompeting other described risk factors.
Conclusions: The strong association between donor BKV-seroresponse and recipient 
BKV-infection points directly to the donated kidney as the source of BKV-induced disease 
and possibly reflects the BKV allograft load. Our findings warrant further research into the 
usefulness of BKV-serological testing prior to transplantation.
Funding: Private Foundation Support
SA-PO1064
The Role of BK Viral Subtypes in BK Viral Infection After Renal 
Transplantation  Anke Schwarz,1 Silvia Linnenweber-Held,1 Hermann G. 
Haller,1 Corinna Schmitt.2  1Nephrology, Hannover Medical School, Hannover, 
Germany; 2Virology, Hannover Medical School, Hannover, Germany.
Background: Risk factors for developing BK virus (BKV) infection after renal 
transplantation are unresolved, including the role of BKV subtypes.
Methods: We report on 146 patients with viral replication in urine tested by quantitative 
PCR (Cepheid-Affigene Kit) before transplantation (29 donors and 11 recipients, 
spontaneous replication in urine) and after transplantation (106 infected recipients, routine 
recipient BKV testing). Genotyping of BKV DNA subtypes was performed. Patients with 
post-transplant BKV nephropathy or high viremia of >10000 copies/mL (n=32, group 
1) were compared to post-transplant recipients with viruria alone or with low viremia of 
<10000 copies/mL (n=43, group 2) and with donors and recipients before transplantation 
(n=40, group 3).
Results: BKV subtype Ib-1 was seen in 14 /146 (10%), subtype Ib-2 in 92/146 (63%), 
subtype II in 9/146 (6%), subtype III in 1/146 (2%), and subtype IV in 30/146 (21%) of 
all patients. Thus, subtype Ib-2 was the first and subtype IV the second in frequency of 
subtypes in all patients. Comparing the 3 groups (group 1 vs group 2 vs group 3), there was 
no stat. sign. difference in the prevalence of subtype Ib-1 (8 vs 12 vs 10%), subtype Ib-2 
( 60 vs 70 vs 60%), subtype II (3 vs 7 vs 10%), subtype III (2 vs 0 vs 0%), and subtype 
IV (27 vs 12 vs 20%). However, after transplantation, subgroup IV had a trend to be less 
prevalent in patients with viruria/ low viremia (group 2) compared to patients with BKV 
nephropathy or high viremia of >10000 copies/mL (group 1) (5/43 vs 17/63, p=0.054).
Conclusions: BKV subtype Ib-2 is the most frequent subtype in all patients of the 
three groups. In the situation after renal transplantation, patients being infected with BKV 
subtype IV could be more likely to develop BKV nephropathy or high viremia than patients 
being infected with other subtypes. This has to be investigated in larger patient groups.
SA-PO1065
Inflammation and Reconstitution Injury in Resolving Polyomavirus 
Nephropathy: Good or Bad? Insights from a Protocol Biopsy Based 
Prospective Study  Harsharan Kaur Singh, A. Gasim, Volker Nickeleit.  Div 
of Nephropathology, The Univ of North Carolina, Chapel Hill, NC.
Background: Polyomavirus nephropathy (PVN) has been extensively studied at time 
of disease onset and in index biopsies. In contrast, little is known about acute and chronic 
changes occurring during PVN resolution under low dose maintenance immunosuppression. 
Aim: Enhance understanding of resolving PVN.
Methods: From 1/2009-9/2014 423 adult renal transplants with an 8.5% incidence 
of PVN (n=37) were prospectively followed at UNC. PVN patients were monitored with 
the urinary PV-Haufen test and protocol biopsies collected in 9/37 patients when the test 
turned from positive to negative as marker for PVN resolution. Histology in index PVN 
(n=9) versus corresponding protocol biopsies (n=9) was compared; clinical, treatment and 
long-term outcome data were obtained from electronic medical records.
Results: Serum creatinine and Banff scores at time of PVN index biopsy and follow-
up protocol biopsy in Table 1. 
Serum 
Creatinine 
(median) 
mg/dl
BANFF Scores (mean)
Tubulitis - t
Interstitial 
inflamma-
tion-i
Scarring 
– ci
Tubular 
atrophy-ct
A] Index Biopsy at time 
of PVN diagnosis 1.78 1.4 1.3 0.7 0.9
B@ Follow-up Protocol 
Biopsy at time of PVN 
resolution
2.7 2.4 2.0 1.2 1.3
C@ 12 month follow-up 
post protocol biopsy 1.75
Index biopsy: 5/9 cases with PVN grade 1 and 4/9 grade 2. Treatment: reduction 
tacrolimus and/or MMF. Protocol biopsy (median 6 weeks post index, range: 4-60): 5/9 
cases resolved PVN, 4/9 residual minimal PVN; 1/9 recurrent MPGN, 3/9 acute ABMR 
or Banff type 2 definitive rejection. Anti-rejection therapy 6/9 cases with decrease in S-Cr 
in 4/6 and deterioration in 2/6; function stable in 3/9. Further 12-month follow-up: Serum 
creatinine 1.75 mg/dl (median), no graft losses.
Conclusions: Resolving PVN under ‘low-dose’ immunosuppression shows significant 
increases in Banff acute inflammation scores and S-Cr. “Bad”inflammation is in part 
secondary to acute rejection and responds to anti-rejection therapy. “Good” self limiting 
reconstitution inflammation can be postulated in 1/9 cases (10%) of resolving PVN. PVN 
results in only mild increases in chronic tissue injury.
SA-PO1066
Effectiveness of Simeprevir and Sofosbuvir in the Treatment of Hepatitis C 
Virus in Genotype 1 Post-Kidney Transplant Recipients  Karolyn S. Horn,1 
Michelle T. Martin,1 Ignatius Yun-Sang Tang.2  1Pharmacy Practice, Univ of 
Illinois at Chicago; 2Medicine, Univ of Illinois at Chicago.
Background: The 2014 American Association for the Study of Liver Diseases 
(AASLD) guidelines recommended the use of simeprevir (SMV) + sofosbuvir (SOF) for 
the treatment of liver transplant recipients with genotype (GT) 1 hepatitis C virus (HCV). 
There is a paucity of data on the treatment of other solid organ recipients. We conducted a 
retrospective, single-center analysis of kidney transplant recipients (KTRs) who received 
HCV treatment.
Methods: All KTRs who received HCV treatment with 12 weeks of SMV + SOF 
between January and November 2014 were evaluated. The primary endpoint was the 
sustained virologic response at 12 weeks after the end of treatment (SVR12). Secondary 
outcomes included HCV PCR levels, serum creatinine, urine protein/creatinine ratio, trough 
calcineurin inhibitor (CNI) levels and dose changes, and AST to platelet ratio index (APRI) 
at week 4, end of treatment (EOT), and 12 weeks post-treatment.
Results: Twelve patients met inclusion criteria: mean age of 60+5.3, 11 males, 8 African 
American, 6 GT 1a and 6 GT 1b. There were 6 liver-kidney, 4 kidney, and 2 pancreas-kidney 
transplant recipients. All but 1 patient recieved tacrolimus as their CNI. Ten of 12 patients 
(83.3%) achieved SVR12. Mean tacrolimus levels increased significantly by 1.5 ng/mL 
between week 0 and 4 (p=0.041). Five (41.7%) required a mean tacrolimus dose decrease 
of 2 mg during treatment. Nine (75%) required a mean dose increase of 2 mg between 
EOT and SVR12. The APRI scores decreased from 0.64 to 0.17 between baseline and 12 
weeks of treatment, but this is not statistically significant (p=0.216). Both serum creatinine 
and urine protein/creatinine ratio remained stable pre- and post-treatment (p=0.260 and 
p=0.973, respectively).
Conclusions: SVR12 was achieved in 83.3% of KTRs treated with SMV + SOF. 
Renal allograft function was stable during and after HCV therapy. Treatment with SMV 
+ SOF increased CNI levels during treatment. CNI dose adjustment is needed to maintain 
therapeutic levels after SMV + SOF therapy.
SA-PO1067
25-Hydroxyvitamin D Insufficiency Is Associated with Higher Risk of BK 
Virus Re-Activation After Kidney Transplantation  Nissreen Elfadawy, Stuart 
M. Flechner, Emilio D. Poggio, Brian R. Stephany, Richard A. Fatica, Jesse D. 
Schold, Sherif B. Mossad.  Cleveland Clinic.
Background: The past decade has seen increased interest in vitD, because new data 
suggest that it plays a role in the immune system. The purpose of this study was to evaluate 
the association of 25-hydroxyvitD level (25[OH]D) after kidney transplant with the risk 
of BK virus reactivation.
Methods: We identified 498 kidney transplant recipients (2007-2011) who had serum 
levels of (25[OH]D), and PTH. We evaluated the relationship between the average levels 
of 25(OH)D and PTH and BKV reactivation in blood.
Results: VitD insufficiency (25[OH]D <30 ng/mL, defined by The Endocrine Society 
Clinical Practice 2011) was observed in 377 (75%)of 498 kidney recipients after transplant. 
The VitD insufficient and sufficient groups were comparable in terms of gender, age, 
BMI, race, and immunosuppressio. VitD insuffiency was more frequent in recipients of 
cadaveric allografts (P=0.009, Fisher test). By multivariable Cox regression analysis, vitD 
insuffiency was an independent risk factor for BKV reactivation after kidney transplantation 
(HR=2.4, 95% CI 1.3-4.7, P=0.002). Moreover, vitD insuffiency was associated with 
significantly earlier onset of BKV reactivation (9 compared to 16 months, P 0.01). ROC 
analysis using logistic regression showed that 25[OH]D < 24ng/mL was predictive of BKV 
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reactivation(OR:82.9, 95% CI: 17.2–744.6, P < 0.001, AUC 0.7). VitD insufficiency was 
not associated with higher risk of CMV reactivation (17 vs 19% resp, p 0.5). The positive 
BKV group had significantly higher PTH compared to the negative group (196 vs 148 resp, 
P 0.01). No significant associations of 25[OH]D with clinical outcomes were observed in 
time-dependent or fixed-covariate Cox models.
Conclusions: Vitamin D insufficiency is a risk factor for BKV reactivation after kidney 
transplantation. D3 supplementation may help reduce BKV reactivation. 
SA-PO1068
Different Types of Cytomegalovirus DNAemia and Long-Term Outcomes 
After Renal Transplantation  Tomas Reischig,1 Martin Kacer,1 Ondrej Hes,2 
Daniel Lysak,3 Mirko Bouda.1  1Internal Medicine I, Biomedical Center, 
Charles Univ Medical School and Teaching Hospital, Pilsen, Czech Republic; 
2Pathology, Biomedical Center, Charles Univ Medical School and Teaching 
Hospital, Pilsen, Czech Republic; 3Hematooncology, Biomedical Center, Charles 
Univ Medical School and Teaching Hospital, Pilsen, Czech Republic.
Background: Although occurring very often the role of cytomegalovirus (CMV) 
DNAemia in patients managed by preemptive therapy or by universal antiviral prophylaxis 
is not established. The aim of the study was to determine the impact of different types of 
CMV DNAemia during 4 years after transplantation.
Methods: A total of 180 consecutive renal transplant recipients at risk for CMV (donor 
and/or recipient CMV seropositive) were included and followed prospectively. Universal 
prophylaxis for 3 months was given to 132 (high-dose valacyclovir, n=87; valganciclovir 
n=45) patients, 48 patients were managed by preemptive therapy. Based on CMV DNAemia 
status during the first year after transplantation patients were stratified to 1) no DNAemia, 
2) early-onset (<3 months) DNAemia, late-onset (³3 months) DNAemia, and 4) combined 
early+late-onset DNAemia groups, respectively.
Results: Early-onset, late-onset, and combined early+late-onset CMV DNAemia 
occurred in 18%, 25%, and 13% of the patients being asymptomatic in majority (91%) of 
cases. Graft survival at 4 years was inferior in patients with late-onset CMV DNAemia 
compared to patients without CMV DNAemia (73% vs. 94%, P=0.002) while no significant 
differences were observed in patients with early-onset (85%, P=0.139) or combined 
early+late-onset CMV DNAemia (96%, P=0.682). Patient survival was comparable in all 
groups. Moderate to severe interstitial fibrosis and tubular atrophy assessed by protocol 
biopsy at 36 months was not increased in early-onset (15%, P=0.05), late-onset (21%, 
P=0.180), and combined (29%, P=0.609) CMV DNAemia compared to no CMV DNAemia 
group (36%). Likewise, renal function was not different at 36 months.
Conclusions: Late-onset CMV DNAemia is a risk factor for graft loss after renal 
transplantation.
Funding: Government Support - Non-U.S.
SA-PO1069
Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the 
Prediction of Cytomegalovirus Spontaneous Clearance in High-Risk Kidney 
Transplant Recipients with Cytomegalovirus Viremia  Marine Lochouarn,1 
Sylvia Benzaken,2 Laetitia Albano,1 Elisabeth Cassuto,1 Ahmed Jeribi,1 Anne 
Caramella,3 Valerie Giordanengo,3 Ghislaine Bernard,2 Vincent L.M. Esnault,1 
Barbara Seitz-Polski.1,2  1Nephrology and Kidney Transplantation Dept, Univ 
Hospital, Nice, France, Metropolitan; 2Laboratory of Immunology, Univ 
Hospital, Nice, France, Metropolitan; 3Laboratory of Virology, Univ Hospital, 
Nice, France, Metropolitan.
Background: Cytomegalovirus (CMV) is the most common virus pathogen in kidney 
transplant recipients (KTR) and CMV disease impacts patient and graft survival. CMV-
specific CD8 T cell-mediated immunity (CMI) kinetics may help to assess the risk of CMV 
disease and to adapt preventive treatment strategies.
Methods: High risk KTR with CMV seropositive donor/seronegative recipient (D+/R-), 
were longitudinally monitored after CMV prophylaxis discontinuation and during the first 
year post-transplant for CMV viremia (WHO standardization) and CMI (QuantiFERON®-
CMV). We analyzed the ability of the CMI-test to predict subsequent spontaneous viral 
clearance in case of asymptomatic viremia after prophylaxis discontinuation or CMV 
disease recurrence after curative treatment.
Results: We enrolled 12 consecutive (D+/R-) KTR. Eleven patients developed viremia 
during follow-up. Spontaneous viral clearance occurred in 7 of 11 (63.6%) patients and 4 of 
11 (36.4%) developed CMV disease. At viremia onset, 6 of 11 (54,5%) patients had a positive 
CMI-test. In those patients, the incidence of subsequent spontaneous viral clearance was 
6 of 6 (100%) compared with only 1 of 5 (20%) among patients displaying a nonreactive 
CMI (p = 0.02). This latter patient revealed a positive CMI-test one month later. In the 4 
patients who developed CMV disease, persistence of a nonreactive CMI after treatment in 
one patient was associated with disease recurrence, while patients whose CMI-test became 
positive under treatment showed no recurrence.
Conclusions: We show for the first time that D+/R- KTR with asymptomatic viremia 
attested by WHO standardized CMV viral load monitoring after prophylaxis discontinuation 
may benefit from QuantiFERON®-CMV to predict spontaneous viral clearance or CMV 
disease.
Funding: Pharmaceutical Company Support - Cellestis GmbH, a QIAGEN company, 
Darmstadt, Germany provided equipment entity (QuantiFERON®-CMV blood collection 
tubes)
SA-PO1070
Prevalence of Double Stranded DNA (dsDNA) Viral Infections Among 
Kidney Transplant Recipients  Essy Mozaffari,1 Jay Lin,2 Melissa 
Lingohr-Smith.2  1Chimerix Inc., Mendham, NJ; 2Novosys Health, Green 
Brook, NJ.
Background: Management of immunosuppression following solid organ transplant 
is a delicate balance between preventing graft rejection and minimizing the risk of 
infection. Antimicrobial prophylaxis can decrease the risk of infection, while increased 
immunosuppression can increase these same risks. Our objective was to estimate the 
occurrence of opportunistic infections, specifically dsDNA viral infections, in kidney 
transplant recipients.
Methods: Patients who received a kidney transplant between January 2009 and 
September 2013 were identified from the Premier Hospital database using ICD-9-CM 
codes. The first transplant procedure was defined as the index event. The frequencies of 
opportunistic infections, documented by diagnostic codes, were evaluated during the first 
12 months after kidney transplant.
Results: Of patients who received kidney transplant (n=5,402; mean age: 50.8 years) 
61% were male. Most patients received transplant in urban (98%), large (≥600 beds: 61%), 
teaching hospitals (84%). During the 12 month post kidney transplant, 33% (1,800 patients) 
had a diagnostic code for ³1 opportunistic infection, and among these 25% (n=448) had 
at least one dsDNA viral infection. Among the 448 dsDNA viral infections, 81% (n=365) 
were cytomegalovirus (CMV), 8% (n=36) BK virus, and 16% (n=70) other dsDNA viral 
infections (HSV, VZV, HHV, HPV, EBV).
Conclusions: Opportunistic infections frequently result from the immunosuppression 
required following kidney transplantation. In our study, one-third of the kidney transplant 
recipients had a discharge diagnosis for at least one opportunistic infection. One of four 
opportunistic infections were classified as dsDNA viral infections, with the majority caused 
by human herpesviruses including CMV despite the common use of anti-CMV agents. Our 
study also highlights the rate of BKV-related complications, which represent an unmet need 
given the absence of therapeutic options for this dsDNA virus and the known association 
with BK-associated nephropathy.
Funding: Pharmaceutical Company Support - Chimerix Inc.
SA-PO1071
Antibiotics, Gut Microbial Diversity, and Infectious Complications in 
Kidney Transplant Recipients  Anjali Masand,1 John R. Lee,1 Thangamani 
Muthukumar,1 Darshana Dadhania,1 Lilan Ling,2 Eric Pamer,2 Manikkam 
Suthanthiran.1  1Medicine, Weill Cornell Medical College, NY, NY; 2Medicine, 
Memorial Sloan Kettering Cancer Center, NY, NY.
Background: Emerging data suggests that antibiotic usage can decrease gut microbial 
diversity and predispose patients to future bacterial complications.
Methods: We profiled serial fecal specimens by 16S rRNA deep sequencing in 26 
kidney transplant recipients. Microbial diversity was assessed using the Shannon diversity 
index in subjects exposed to antibiotics in the 1st post-transplant month and in subjects 
not exposed. Based on a higher number of infections in antibiotic-exposed subjects, we 
conducted a retrospective study of 301 consecutive kidney transplant recipients and 
evaluated antibiotic usage in the 1st month of transplantation and development of bacterial 
complications in post-transplant months 2-12.
Results: Subjects exposed to antibiotics during the 1st month of transplant had 
decreased gut microbial diversity and an increased number of infections in the 1st year 
of transplant.
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In 301 transplant recipients, the most common infections (N=255) were UTIs (61%) 
and pneumonia (9%). 74 kidney transplant recipients received antibiotics during the first 
month of transplantation (Early Abx Group) and 227 did not (No Early Abx Group). The 
Early Abx Group had a significantly higher number of infections during post-transplant 
months 2-12 than the No Early Abx Group (1.2±0.2 vs. 0.3±0.1, P<0.001, Wilcoxon rank-
sum test). Within the Early Abx Group, subjects who received anaerobic coverage had a 
significantly higher number of infections during post-transplant months 2-12 than subjects 
who did not (1.8±0.5 vs. 0.9±0.2,P=0.050).
Conclusions: Early antibiotic usage was associated with increased future bacterial 
infections in kidney transplant recipients. A decrease in gut microbial diversity is a 
biologically plausible pathogenic mechanism.
Funding: Other NIH Support - KL2 Scholars Award from the Weill Cornell Clinical 
and Translational Science Center (KL2 TR-000458)
SA-PO1072
Successful Treatment of Hepatitis C in Renal Transplant Recipients with 
Directly Acting Antiviral Agents  Michelle L. Lubetzky, Enver Akalin, Paul 
Gaglio, Graciela De Boccardo.  Transplantation, Montefiore Medical Center, 
Bronx, NY.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has 
been shown to be an independent risk factor for decreased patient and allograft survival. 
Historically treatment of HCV has been interferon-alpha based, which is associated with 
acute rejection in KTx patients. With the development of new, oral, interferon-free directly 
acting antiviral (DAA) medications, treatment of HCV in renal transplant recipients is 
possible, but limited data exists on its safety and efficacy.
Methods: We performed a retrospective review of all KTx patients at our center with 
HCV started on DAA for treatment of HCV. Any patient with at least 30 days of follow up 
was included in the analysis (n=10). Clinical data including graft function, survival, and 
response to therapy was collected.
Results: Patient demographics are in Table 1. At a median of 92 days of follow up 
(range 33, 438), all patients have undetectable viral load. Median time from KTx to treatment 
was 781 days (range 173,10404). At most recent follow up, mean creatinine is 1.48±0.51 
mg/dl and mean proteinuria is 0.47±1.07 g/day with no adverse side effects reported. No 
patients have lost their grafts or developed acute rejection, but 2 patients had detectable 
CMV. For the 8 patients on tacrolimus (Tac), there was a drop in 12-hr trough level during 
therapy (mean 6.3±2.1 ng/mL pre-treatment, and mean of 4.9±2.1ng/mL after 6 weeks of 
treatment); during treatment 3 patients had a level < 4 ng/mL. All patients with level <4 
ng/mL had dose increase and repeat level was in normal range.
Conclusions: Our data demonstrates that DAAs can be used safely and effectively in 
patients after KTx. Tac levels should be monitored closely during therapy. Longer follow 
up of KTx recipients treated for HCV is needed determine the effects treatment has on 
graft and patient survival.
SA-PO1073
A Systematic Review and Meta-Analysis of Cytomegalovirus Infection 
in Renal Transplant Recipients Receiving Alemtuzumab versus Anti-
Thymocyte Globulin for Induction Therapy  Payvand Milani, Nasrollah 
Ghahramani.  Medicine, Pennsylvania State Univ College of Medicine, Hershey, PA.
Background: Use of antibody induction for kidney transplant has improved patient 
outcomes over the past decade. One common induction agent is rabbit anti-thymocyte 
globulin (ATG), a polyclonal anti-human T-cell antibody. Alemtuzumab, a humanized 
monoclonal anti-CD52 antibody with stronger lympho-depleting properties, has been 
used as an induction agent in steroid-sparing or steroid-minimizing protocols. Like all 
immunosuppressive agents, these agents are associated with opportunistic infections, 
including cytomegalovirus (CMV). Our aim was to compare the relative risk of CMV 
infection between the two induction regimens.
Methods: We used five comprehensive search themes (CMV, ATG, alemtuzumab, 
transplant, and induction) to search electronic databases from 1980 to 2014 using PubMed 
and The Cochrane Library while also manually reviewing recent abstracts from the 
American Society of Nephrology and the American Transplant Congress meetings. Studies 
reporting the number of cases of CMV infection in patients receiving one of the two agents 
were included. The outcome was the pooled relative risk (RR) of CMV infection in the 
alemtuzumab group compared to that in the ATG group.
Results: A total of 73 studies were identified and reviewed, 64 of which were excluded 
upon initial screening. Analysis of the 9 studies (8 complete articles and 1 abstract; 1,735 
patients) showed a RR of 0.58 (95% CI: 0.31-1.07) for incidence of CMV infection 
in patients receiving alemtuzumab versus ATG. Other reported adverse effects in both 
induction groups (infections, post-transplant lymphoproliferative disorder (PTLD) and/or 
malignancy, decrease in estimated glomerular filtration rate , and post-transplant diabetes 
mellitus) were similar in both groups.
Conclusions: This study suggests that for induction therapy in kidney transplant, the 
incidence of CMV infection associated with alemtuzumab is not significantly different 
than that associated with ATG.
SA-PO1074
Occurrence and Determinants of Antibiotic Resistance in Bacteriuria After 
Kidney Transplantation  Habib Mawad, Alexandre Tavares-Brum, Claude 
Lemieux, Alain Duclos, Azemi Barama, Heloise Cardinal.  Nephrology, Centre 
Hospitalier de l’Univ de Montréal.
Background: Asymptomatic bacteriuria is often treated after kidney transplantation, 
which can result in the development of antibiotic resistance. Our aim was to assess the 
antibiotic resistance profile of gram-negative bacteriuria in our kidney transplant population, 
and to determine the factors associated with antibiotic resistance.
Methods: We performed a single center, retrospective cohort study in patients who 
received a kidney allograft at our center between January 1st, 2008 and June 1st, 2013. 
Through chart review, information on all bacteriuric episodes involving gram negative bacilli 
was collected during follow-up, which ended on June 1st, 2014. Bacteriuria was defined 
as growth exceeding 104 CFU/ml. Multivariable logistic regression using a generalized 
estimating equation (GEE) procedure was performed to identify the factors associated 
with resistance to antibiotics.
Results: Amongst the 318 patients studied, 629 bacteriuric episodes involving gram 
negative bacilli occurred in 143 patients. Resistance to TMP-SMX occurred in 336 episodes 
(53%), resistance to ciprofloxacin in 142 episodes (23%) and extended beta-lactamase 
production occurred in 30 episodes (5%). An increased risk of resistance to ciprofloxacin 
and/or extended spectrum beta lactamase production was statistically associated with the 
number of previously treated bacteriuric episodes (compared to no prior treatment, 2-4 
previous treatments (odds ratio (OR):2.29, 95%confidence interval (CI ):1.16-4.52), and ≥5 
previous treatments (OR:3.05, 95%CI:1.28-7.26) )), diabetes (OR:2.57, 95%CI:1.01-6.55), 
caucasian race (OR:0.38, 95%CI:0.16-0.91) and a longer time elapsed between bacteriuria 
and transplantation (OR:0.32, 95%CI 0.15-0.66, for episodes supervening >1 year post 
transplant versus ≤ 1 year).
Conclusions: Elevated resistance rates to TMP-SMX and ciprofloxacin were observed 
in our kidney transplant population, which can reduce the usefulness of prophylaxis with 
TMP-SMX and argue against treating asymptomatic bacteriuria, given the association we 
observed between the number of previous treatment of bacteriuric episodes and resistance 
to ciprofloxacin/ESBL production.
Funding: Government Support - Non-U.S.
SA-PO1075
Carbapenem-Sparing Antibiotic Regimens for the Treatment of Extended-
Spectrum Beta-Lactamase Producing Enterobacteriacea Infections: A 
Comparative Study  Tiffany Ebony Bias,1 Gregory Malat, PharmD,1 Akshay 
Sharma,2 Dong Heun Lee,3 Alden Michael Doyle.2  1Pharmacy, Hahnemann 
Univ Hospital, Philadelphia, PA; 2Surgery, Drexel Univ, College of Medicine, 
Philadelphia, PA; 3Infectious Diseases and HIV Medicine, Drexel Univ, College 
of Medicine, Philadelphia, PA.
Background: Extended spectrum beta lactamase producing Enterobactericaea (ESBL-
PE) has been recognized as a significant cause of mortality in solid organ transplant 
recipients. Carbapenems are considered the drug of choice for the treatment of ESBL-PE 
infections. However, antibiotic selective pressure associated with carbapenem use may 
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contribute to resistance, further stressing hospital epidemiology. Our study sought to 
compare the effectiveness of carbapenem sparing regimens to carbapenem containing 
regimens on clinical outcomes in transplant patients with ESBL-PE infections.
Methods: A retrospective, observational cohort study was conducted to evaluate adult 
patients who underwent a successful kidney transplant (defined as graft survival >30 days) 
prior to August 2014 with a ESBL-PE infection post-transplant. Patients were stratified 
into 2 cohorts according to antibiotic regimens: carbapenem-containing and carbapenem-
sparing. The outcomes of clinical cure, 30-day mortality, and recurrence were assessed.
Results: Fifty-two kidney transplant patients were included in our analysis: 29 in 
the carbapenem-sparing group and 23 in the carbapenem-containing group. Majority of 
infections were caused by Escherichia coli (46%) and Klebsiella pneumoniae (44%). The 
most common infection type was urinary tract infections (46%) followed by bloodstream 
infections (23%) and nosocomial pneumonias (15%). There was no statistically significant 
difference in clinical cure rates (91% vs. 76%, p=0.268) and 30-day mortality (24% vs. 
9%, p=0.268) in the carbapenem sparing and carbapenem containing groups respectively.
Conclusions: ESBL-PE infections pose a serious threat to transplant recipients. 
Carbapenem sparing regimens may be adequate for the treatment of ESBL-PE infections, 
while offering advantages against minimizing selective pressure.
SA-PO1076
Clinical Recurrence of Primary Glomerular Disease in Kidney 
Transplantation  Saul Enrique Pampa, Ana M. Fernandez Rodriguez, Sara 
Jimenez Alvaro, Fernando Caravaca-Fontan, Estefania Yerovi, Maria Delgado 
Yagüe, Maite Rivera, Cristina Galeano, Sandra Elias, Fernando Liano. 
Nephrology, Hospital Ramón y Cajal. UAH, Madrid.
Background: Recurrence of primary glomerular disease (PGN) in renal transplantation 
(RT) is a major cause of failure and renal allograft lost which determines the prognosis 
of the patient. We analyzed the prevalence, clinical course and survival of graft in this 
group of patients.
Methods: We conducted a retrospective analysis of 1513 renal transplants between 
January 1980 and December 2013, included in our database, medical records and biopsy 
register, collecting all patients who presented recurrence of PGN. We excluded from the 
study patients with secondary GN and those without biopsy study. Renal biopsy was 
indicated according the following criteria: impairment of renal function, proteinura>1g/
day and/or microhematuria. The analisis stadistic was SPSS version 18.
Results: 414 of 1513 RT (27%) had chronic GN as underlying disease. 317 patients 
(260 man;57 woman) were primary GN (21%). The most frequent primary GN was IgA 
nephropaty (IgAGN) n=122(38,4 %); Membranoproliferative GN (MPGN), n:90(28 %); 
Focal segmental GN(FSGS), n: 58(15,1 %); membranous GN(MGN), n: 33(10,4 %) and 
rapidly progressive GN (RPGN), n:14(4,4%). Forty(12.6%) patients with primary GN 
recurred. IgA GN (5%), FSGS (20%), MPGN (17%), MNGN(12%) and GRNP (12%). 
Three MPGN patients recurred in the second RT. The mean time of recurrence was: 48.18, 
33.2, 18 and 33.2 months respectively Patients with graft loss due to GN recurrence were: 
IgAGN (n=10;75%), MPGN (n=14;93%), FGSG(n=10,75%), MNGN(n=3,70%). No 
significant difference was observed between GN types(p=0,15) and graft survival. In the 
Kaplan Meier analysis and COX test, recurrence primary GN had low survival at 10 years 
(p: 0.002). No significant differences was observed at 20 years( p: 0.15).
Conclusions: Clinical Recurrence of primary GN is an important cause of graft loss. 
GN with most recurrence was GSF and graft lost was MPGN. We didn’t observe differences 
in graft survival between tipe of primary glomerular disease. Graft survival was higher in 
the group without recurrence at 10 years and no differences at 20 years.
SA-PO1077
Glomerular Diseases following Prednisolone Free Transplant with Low 
Dose Rituximab and ATG Induction and Protocol Biopsies  Vivek Pathak. 
Nephrology, Kovai Medical Center and Hospital, Coimbatore, Tamil-Nadu, 
India.
Background: The purpose of this study is to document the incidence of post transplant 
glomerulonephritis in a steroid free protocol and other recurrent renal diseases leading to 
graft loss.
Methods: 883 patients, who underwent renal transplantation at our institute in nine 
years and eight months since July 2005 till March 2015 were studied.Thymoglobulin was 
used for induction at a dose of 1.5mg/kgm 3 doses.Rituximab 200 mg was given before 
transplant to those patients who were considered to be at high risk for rejection.Maintenance 
immunosuppression was Tacrolimus and Mycophenolate mofetil. Prednisolone was rapidly 
discontinued by fifth post operative day. All patients underwent protocol biopsies at 3 months 
, 1 year and 5 years and indicated biopsies whenever required. The total number of biopsies 
was 2928. Discussion Our results show only 1% graft loss due to cumulative recurrent 
Glomerulonephritis at nearly 10 years.Our figures could be low due to Thymoglobulin 
induction therapy.We could prevent graft loss due to recurrent FSGS by achieving complete 
or partial remission by using Rituximab in 15/19(79%) patients.
Results: The number in glomerulonephritis group was 412 of which 158 were biospy 
proven and others suspected on clinical grounds The histologically confirmed recurrent IgA 
was seen in 23 patients and 3 lost the graft. Prednisolone was added to this group. Recurrent 
FSGS was observed in 21 patients of which 3 lost the graft.We saw 1 case each of recurrent 
DDS, DHA crystallopathy,de novo anti GBM disease and post infectious glomerulonephritis.
Conclusions: Our aggressive biopsy policy detected recurrence at a stage of urinary 
abnormalities.We use Rituximab to treat FSGS to reduce the graft loss.Unique induction 
policy probably had a protective effect and thus recurrent glomerulonephritis is lower 
then published literature.
SA-PO1078
Post-Transplant Focal Segmental Glomerulosclerosis Recurrence 
Among Patients with Native Kidney Collapsing Variant: A Single-Center 
Retrospective Cohort Study  Panupong Hansrivijit,1,2 Katherine D. Westreich,1 
Jonathan Alexander Miles,1 Evan Zeitler,1 Maria E. Ferris,1 Randal K. Detwiler.1 
1Univ of North Carolina, Chapel Hill, NC; 2Chulalongkorn Univ, Bangkok, 
Thailand.
Background: Focal segmental glomerulosclerosis (FSGS) is one of the most common 
causes of end-stage kidney disease (ESKD), and is known to recur in renal transplant 
grafts. The collapsing variant of FSGS (CvFSGS) is clinically distinct from other variants: 
it has a stronger association with African-American race, more severe proteinuria, and 
rapid progression to ESKD. The impact of native FSGS subtype on post-transplant FSGS 
recurrence rate and subtype is not known.
Methods: Clinical and pathological records were reviewed for renal transplant 
recipients at UNC between 2000 and 2014 with FSGS as the cause of ESKD. Native FSGS 
subtype was dichotomized into CvFSGS and FSGS-Other. Baseline demographics (sex, 
age, and race), and rates and subtypes of post-transplant FSGS recurrence were compared 
between the two groups.
Results: Of 879 patients reviewed, FSGS was the cause of ESKD in 101. Among this 
subgroup, mean age at time of transplant was 45±17 years; 62% male; 50% non-Hispanic 
black, 45% non-Hispanic white, and 5% Hispanic. Ten patients (10%) had CvFSGS as 
the native lesion. Over a mean follow-up time of 2.4 years, the overall rate of recurrent 
FSGS was 34%. Compared to those with native FSGS-Other, patients with native CvFSGS 
had a higher rate of post-transplant FSGS of any type (50% vs 31%, RR 1.6), and were 
also more likely to have collapsing variant as the recurrent lesion (60% vs 11%, RR 5.5). 
Native lesion (n) Recurrence n (%)
Recurrent lesion n (%)
CvFSGS FSGS-Other
CvFSGS (10) 5 (50%) 3 (60%) 2 (40%)
FSGS-Other (91) 28 (31%) 3 (11%) 25 (89%)
Total (101) 33 (34%) 6 (18%) 27 (82%)
Conclusions: In a population of predominantly black and Hispanic patients in the 
Southeastern US, native CvFSGS predicts a 60% higher post-transplant FSGS recurrence 
rate, and the recurrent lesion is likely to be CvFSGS. However, 11% of patients with 
native FSGS-Other developed de novo CvFSGS post-transplant. Further study of this 
cohort will determine the predictive power of native and recurrent CvFSGS with regard 
to clinical outcomes.
SA-PO1079
Pre-Transplant Rituximab in Recurrent Focal Segmental Glomerulosclerosis 
John Manllo,1 Dany Matar,1 Sami Alasfar,1 Jochen Reiser,2 Nada Alachkar.1 
1Johns Hopkins Univ; 2Rush Univ.
Background: Focal segmental glomerulosclerosis (FSGS) recurs in 30-40% of 
patients after kidney transplant (Tx). Rituximab was suggested to have cross-reactivity with 
podocyte sphingomyelin-phosphodiesterase-acid-like-3b (SMPDL-3b), which was found 
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to be reduced in post perfusion biopsies of kidney Tx recipients who later on developed 
recurrent (r)FSGS. However, the use of rituximab to prevent rFSGS remains controversial. 
In this study, we assessed the efficacy of pre-Tx rituximab in preventing or delaying the 
recurrence of FSGS.
Methods: We enrolled 56 adult patients, 50 with biopsy proven FSGS and 6 with a 
pre-Tx course highly suggestive of FSGS. Patients underwent kidney transplant between 
2008-2014. We compared FSGS recurrence and allograft survival between recipients who 
received rituximab and those who did not.
Results: Mean time of follow-up was 28.6 months. 24 patients received rituximab 
(table 1). 35 patients developed rFSGS, 17 (48%) of them received rituximab. Of the 21 
who did not develop recurrence, 7 patients (33%) received rituximab. This difference was 
not statistically different (p=0.26). The time from Tx to rFSGS in the patients who received 
rituximab was 9.4 ±3.4 vs 8.7 ±3.7 months in patients who did not receive rituximab 
(p=0.7). The mean and standard deviation (SD) of eGFR at the most recent follow-up in 
the patients with rFSGS who received rituximab was 42 ±28 versus 39 ±21 mL/min/1.73m2 
in those who did not received it, respectively (p=0.74). There was no difference in allograft 
survival in the two groups.
Conclusions: Our data showed that pre-transplant rituximab did not decrease the 
incidence or delayed the development of recurrent FSGS, and did not improve allograft 
survival. 
Pre-Tx 
rituximab 
(n=24)
No-rituximab 
(n=32) P-value
Mean Age at Diagnosis (SD), yrs 28.5 (±18) 33.2 (±15) 0.33
Mean Time from Dx to RRT (SD), yrs 4.8 (±5.6) 10.1 (±11.5) 0.03
Mean of cumulative dialysis duration 
(SD), yrs 4.8 (±3.8) 2.9 (±3.7) 0.07
Mean Age at current tx (SD), yrs 43 (±13) 44.8 (±13) 0.62
Male, n (%) 12 (50%) 16 (50%) 1
Prior tx, n (%) 13 (54%) 6 (18%) 0.006
ABO Incompatible Tx, n (%) 5 (20%) 3 (9%) 0.22
Allograft failure, n (%) 3(12%) 3(9%) 0.91
SA-PO1080
Role of Plasmapheresis in Post-Transplant Focal Segmental 
Glomerulosclerosis  Sami Alasfar,1 Dany Matar,2 John Manllo,1 Jochen Reiser,3 
Nada Alachkar.1  1Johns Hopkins Univ, Baltimore, MD; 2McKinsey & Company, 
Washington, DC; 3Rush Univ, Chicago, IL.
Background: Focal segmental glomerulosclerosis (FSGS) commonly recurs after 
kidney transplant(Tx). This is attributed to the presence of a circulating permeability factor 
that may be removed or diminished by plasmapheresis (PP). In this study, we assessed the 
efficacy of PP in prevention and treatment of post-Tx (r)FSGS.
Methods: We prospectively enrolled 56 Tx-patients with biopsy proven FSGS(50) or 
de novo FSGS with a pre-Tx course suggestive of FSGS(6); patients were transplanted 
between 2008-2014. We compared between the preventive and non-preventive PP groups.
Results: Mean time of follow-up was 28 months. Differences between the 2 groups 
are as following: 
Preventive 
PP(n26) No PP(n30) P
Male(n) 15 13 0.2
White(n) 17 14 0.23
Time from FSGS diagnosis to renal replacement 
initiation,y(SD) 6.1(8.6) 10.1(9.1) 0.04
Prior Tx(n) 11 8 0.21
Living donor(n) 21 12 0.008
Induction with rATG(n) 25 26 0.23
rFSGS (n) 19 16 0.12
Time to rFSGS, month(SD) 7.7(3.7) 10.5(3.5) 0.6
Mean of most recent UPC, g/g(SD) 2.7(0.5) 0.2(0.1) 0.001
rFSGS developed in 35 patients (62%); of whom preventive PP was performed in 
19. Out of the 21 cases that did not develop rFSGS, 7 received PP (P=0.1). Patients who 
received preventive PP had a shorter time from FSGS diagnosis to ESRD compared to those 
who did not [(6.1±8.6 yr vs 10.1±9.1 yr (p 0.047)]. 33 out of the 35 patients (95%) with 
rFSGS received therapeutic PP, and 24 also received anti-CD20 therapy. Only 5(15%) did 
not respond; 2 lost their grafts. Of the 28 who responded, 14 (50%) subsequently relapsed. 
71% of the relapses responded to a second course of PP; only 4 lost their grafts. Kaplan-
Meier allograft survival in both groups is shown in figure 1.
Conclusions: Preventive PP does not reduce the incidence or delay the development 
of rFSGS. However, PP remains an effective therapy for post-transplant FSGS.
SA-PO1081
Post-Transplant Thrombotic Microangiopathy: A Single Center Experience 
Cinthia Montenegro Teixeira,1 Igor Gouveia Pietrobom,1 Andre Caires 
Alvino Lima,1 Gianna Mastroianni-kirsztajn,1,2 Laila Almeida Viana,1 J. 
Medina-Pestana,1,2 Helio Tedesco Silva.1,2  1Hospital do Rim- Fundação Oswaldo 
Ramos, Sao Paulo, Brazil; 2Univ Federal de Sao Paulo, Sao Paulo, Brazil.
Background: Thrombotic microangiopathy (TMA) occurs in 1-15% of kidney 
transplant allografts and predicts poor outcomes.
Methods: We reviewed 35 cases of TMA in the kidney allograft diagnosed at our 
institution between 2011-2015.
Results: The mean age was 39±14 years with 18 (51%) women. Three (9%) patients 
were recipients of simultaneous pancreas-kidney transplant. Among the recipients of 
kidney transplant alone, 21 (66%) received deceased donor grafts. The cause of end 
stage renal disease was unknown (37%), chronic glomerulonephritis (31%), obstructive 
uropathy (11%), diabetes (9%), hemolytic uremic syndrome (3%) or others (9%). Induction 
with thymoglobulin or basiliximab was performed in 24 (63%) patients. Maintenance 
immunosuppression was prednisone (PRED), tacrolimus (TAC), and azathioprine in 
15 (43%), PRED, TAC and mycophenolate sodium in 12 (37%) and PRED, TAC and 
everolimus in 3 (9%) patients. Patients were diagnosed with TMA at a median of 71 days 
(range: 5-1645) from transplant, wherein 37% patients developed TMA within 1 month 
of transplantation and 31% after 1 year. Mean serum creatinine was 4.5±3.3 mg/dL and 
13 (47%) patients needed renal replacement therapy after TMA diagnosis. TMA was 
renal-limited in 23 (66%) patients. Concomitant acute rejection was present in 12 (34%) 
cases and cellular rejection was the most common (92%) type of rejection related to TMA. 
Cytomegalovirus infection occurred in 5 (14%) and other infections were present in 19 
(54%) patients. Following diagnosis of TMA, calcineurin inhibitor (CNI) withdrawal was 
the first step in the management of 22 (63%) patients and 8 (23%) also received fresh 
frozen plasma (FFP) and/or plasmapheresis. The mean follow-up was 375 days (range: 
2-4840); 22 (62%) patients had improvement or stabilization of renal function and 11 
patients (31%) had allograft failure.
Conclusions: High clinical suspicion is essential for early diagnosis of TMA after 
kidney transplant. Withdrawal of CNI and treatment of concomitant rejections and infections 
contribute to renal function maintenance.
Funding: Private Foundation Support
SA-PO1082
Outcome After Eculizumab Therapy to Prevent Recurrence of Atypical 
Hemolytic Uremic Syndrome: Experience in Eleven Renal Transplant 
Recipients  Charlene Levi,1,2 Veronique Fremeaux-bacchi,3,2 Anne Scemla,1 
Julien Zuber,1,2 Christophe M. Legendre,1,2 Rebecca Sberro-Soussan.1  1Dept 
of Renal Transplantation, Assistance Publique-Hôpitaux de Paris, Hôpital 
Necker, Paris, France; 2Medicine Faculty, Paris Descartes Univ, Paris, France; 
3Dept of Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Georges 
Pompidou, Paris, France.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease with a high 
recurrence rate after kidney transplantation. aHUS is associated with histological lesions 
of thrombotic microangiopathy (TMA) that mainly leads to graft loss. The successful use 
of Eculizumab (Ecu) to prevent or to treat post-transplantation aHUS recurrence has been 
scarcely reported. In this study, we describe 11 patients who received a renal transplantation 
for aHUS and who were treated by Ecu after renal transplantation.
Methods: Eleven renal transplants recipients, with aHUS on their native kidney, 
received Ecu at our center between 2010 and 2015. Nine patients received prophylactic 
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Ecu at day 0. Two were treated at time of recurrence (day 6 and 25) . We reviewed clinical, 
genetic testing and histological data, and posttransplant course. Mean follow-up was 
21,6±19 months.
Results: Five patients had at least one previous transplantation that failed secondary 
to recurrent aHUS. A genetic mutation was identified in ten patients (H factor (4) ; I factor 
(2), CFH-CFHR1 hybrid gene (1) ; C3 (1), CFHR1 deletion and anti-H-factor antibody (2)). 
There was no graft loss and mean serum creatinine was 135± 60mmol/l at last follow-up. 
No patient experienced biological TMA recurrence under treatment. We found transient 
histological lesions in the 2 patients with later Ecu introduction. Three antibody mediated 
rejections (AMR) occurred during treatment including one associated with TMA lesions.
Conclusions: These data confirm that Ecu is highly effective to prevent post-
transplantation aHUS recurrence, without graft loss and with a good renal function. 
However, Ecu doesn’t prevent AMR. The best treatment duration remains to be defined.
SA-PO1083
Recurrence of Scleroderma Renal Crisis After Renal Transplant Is 
Associated with Decreased Rates of Graft Survival and Earlier Graft 
Failure  Andrew A. Collins, Donald A. Molony.  Internal Medicine, UT Health 
Houston, Houston, TX.
Background: The recurrence of Scleroderma Renal Crisis (SRC) after renal transplant 
has been previously described though its effects on outcomes and allograft survival are 
uncertain. Prior estimates suggest a recurrence rate of 20-50% (Pham et al, American Journal 
of Transplantation 2005, 5:2565-2569). Such rates of recurrence if leading to graft failure 
will have important implications. This study was conducted to better define the probability 
of recurrence and understand its impact on allograft and patient survival.
Methods: We identified all cases of renal transplantation for patients with SRC and 
all cases of disease recurrence in the UNOS database from 1987 to 2014. We analyzed 
the impact of recurrence on graft survival and compared this to outcomes of patients with 
other renal diseases: SLE, FSGS, and HUS.
Results: 492 patients were identified as having SRC as their primary diagnosis. Of 
those, 5.28% (26) had documented disease recurrence, which was similar to those with 
SLE (2.59%), FSGS (7.38%), and HUS (8.71%). Graft failure for any reason excluding 
death occurred in 80.8% (21) of patients with recurrence, compared to 24.5% (114) of those 
without recurrence (p = 0.00). Recurrent disease accounted for 11.9% (16) of graft failures 
in SRC, compared to 6.10% in patients with SLE as the cause of ESRD, 16.4% with FSGS, 
and 20.9% with HUS. The 5 year graft survival rates were similar: 68.7%, 63.2%, 67.8%, 
and 57.1% for SRC, SLE, FSGS, and HUS, respectively. SRC recurrence was associated 
with earlier graft loss; graft failure occurred an average of 628 days sooner in the recurrence 
group compared to non-recurrence, 1072 days versus 1700 (p = 0.021). Age, gender, and 
ethnicity were not associated with an increased risk of recurrence.
Conclusions: Identification of disease recurrence after renal transplantation holds 
prognostic significance. Both the rate and timing of kidney transplant failure is made more 
severe by recurrence. Post-transplant recurrence rates for SRC appear to be similar to those 
observed with SLE, FSGS, and HUS. Monitoring for recurrence of disease in these patients 
should be part of routine measures to reduce risk of allograft failure.
SA-PO1084
Clinical Characteristics of Recurrent IgA Nephropathy within the First 
Year After Renal Transplantation: Single Center Study  Yasuhiro Otsuka, 
Daijo Inaguma, Yoshihiko Watarai, Asami Takeda.  Kidney Center, Nagoya 
Daini Red Cross Hospital, Nagoya, Japan.
Background: There are a few studies showing that the long-term allograft survival of 
patients with IgA nephropathy (IgAN) is lower than that of non-IgAN, indicating that the 
cause of lower graft survival is recurrence of IgAN. There have been no large, prospective 
studies defining the risk factors contributing to the development of recurrent IgAN, and 
preventive therapy for recurrent IgAN is unknown.
Methods: Retrospective data was collected from 2008 to 2013 on 61 consecutive 
biopsy-proven IgAN patients who underwent renal transplantation (RTx) in a single center, 
excluding one case of medication nonadherence. Protocol biopsies were obtained one hour, 
three weeks, six months and one year after RTx. Recurrent IgAN (rIgAN) is defined as 
positive for IgA in mesangial area and previously negative for IgA in immunofluorescence 
study.
Results: Of 61 patients,7 had rIgAN within the first year after renal transplantation. 
There were no significant differences between rIgAN group and NOT rIgAN group in 
recipient age (mean±SD) (39.1±18.6, 41.8±12.3)years, sex (6M;1F, 31M;23F), donor age 
(55.0±8.5, 56.3±9.8)years, diabetes mellitus (2, 8)cases, PEKT (3, 23)cases, living-related 
donor kidney (5, 33)cases, immunosuppressants, tonsillectomy before transplantation (4, 11)
cases, ABO incompatible (0, 18)cases, HLA matching, HLA alleles in recipient including 
HLA-B35, DR4, B8, DR3, serum IgA concentration (263.0±66.4, 254.4±105.0)mg/dL, and 
urinary protein (0.57±1.29, 0.07±0.13)g/day. Duration of dialysis before transplantation 
(months) was significantly shorter in rIgAN group (11.1±20.3 vs 34.9±54.9, p=0.0383, 
Fisher’s exact test). Urine occult blood was also significantly higher in rIgAN group 
(p=0.000841, Mann-Whitney U test).
Conclusions: Albeit PEKT was not risk factor for recurrence of IgAN in this study, 
short-duration dialysis before transplantation could be novel risk factor for recurrence 
of IgAN. Further analysis is needed to determine risk factors for rIgAN and to establish 
preventive therapy for rIgAN for better graft survival.
SA-PO1085
An Investigation of 13 Cases of Membranous Nephropathy of the Donor 
Origin Accidentally Detected by 0-h Renal Biopsy During Kidney 
Transplantation  Kohei Unagami,1 Masayoshi Okumi,2 Anri Sawada,1 Daisuke 
Toki,2 Taichi Kanzawa,2 Yasuyuki Sato,1 Jumpei Hasegawa,3 Kazuya Omoto,2 
Hidetoshi Ishigooka,2 Kazuma Tsujimura,2 Tomokazu Shimizu,2 Masashi Inui,2 
Hideki Ishida,2 Kazunari Tanabe,2 Kosaku Nitta.2  1Nephrology, Tokyo Women’s 
Medical Univ; 2Urology, Tokyo Women’s Medical Univ; 3Nephrology, Ohkubo 
Hospital.
Background: Membranous Nephropathy (MN) is a type of glomerulonephritis 
characterized by thickening of the glomerular basement membrane with immunoglobulin 
deposition. Proteinuria is a primary symptom, and the condition may sometimes present 
as nephrotic syndrome. MN is usually diagnosed by a renal biopsy. Therefore, without 
symptoms, such as proteinuria, hematuria or renal dysfunction, MN is rarely suspected. 
Here we describe 13 cases of MN of donor origin that were accidentally detected by 0-h 
renal biopsy, which is routinely performed at the time of kidney transplantion in our hospital.
Methods: During the period between January 1995 and April 2015, 13 cases of MN of 
donor origin were accidentally detected by 0-h renal biopsy during kidney transplantation. 
We evaluated the histopathological characteristics of these cases and the clinical course 
of donors and recipients.
Results: MN view was disappeared in 7 recipients by transplanted renal biopsy at 
1035.1 ± 776.2 days after transplantation. Three donors have past histories such as hepatitis 
B past infection, prostatic cancer, or the internal past taking of thiamazole, all of which are 
well known causes of secondary MN. In the pre-transplantation evaluation, two donors 
had hematuria, however, all donors were negative for proteinuria and had normal kidney 
function (serum Cr 0.92 ± 0.25mg/dl, eGFR 70.1 ± 20.2ml/min/1.73m2). After follow-up 
of 972.3 ± 916.5 days after operation, significant proteinuria, hematuria and decreased 
kidney function (serum Cre 1.17 ± 0.44mg/dl, eGFR 50.0 ± 20.0 ml/min/1.73m2) were 
not observed. In terms of maliginancies, one donor had undergone a prostatectomy for 
prostatic cancer before transplantation.
Conclusions: Among cases of MN of the donated kidney accidentally detected in the 
0-h renal biopsy, several donors did not have symptoms such as proteinuria and hematuria.
SA-PO1086
The Occurrence of Post-Transplant Malignancies Among Kidney 
Transplant Recipients Is Not Associated with the Level of Tacrolimus 
Exposure Over Time  Shelly Lichtenberg, Ruth Rahamimov, Avry Chagnac, 
Benaya Rozen-zvi.  Nephrology, Rabin Medical Center, Petah Tikva, Israel.
Background: Immunosuppressive therapy plays a major role in the development 
of post-transplant cancer. In this case-control study of kidney transplant recipients, we 
investigated whether the occurrence of post-transplant cancer is associated with the level 
of tacrolimus exposure over time.
Methods: We screened the Rabin Medical Center registry data base for adults who 
received kidney transplants during the years 2001 to 2014, and developed post- transplant 
nonskin cancer. Those patients were matched with controls by sex, age, type of induction 
therapy, time of transplantation and length of follow-up. All patients included in the study 
received a maintenance immunosuppression with tacrolimus, micophenolate mofetil and 
corticosteroids. Exposure to tacrolimus was estimated using all blood level values of 
tacrolimus measured until time of cancer diagnosis. The time-averaged value of tacrolimus 
blood levels was calculated as the area under the curve divided by time at 1, 6 and 12 
months after transplantation, and at the time of cancer diagnosis.
Results: 32 patients who met the inclusion criteria developed nonskin cancer. They 
were matched with 64 controls. The time-averaged tacrolimus blood level at time of cancer 
diagnosis was 7.97±1.37 ng/mL in the cancer group and 7.9±1.32 ng/mL in the control group 
(p=0.8). The time-averaged tacrolimus blood levels at 1, 6 and 12 months were 9.86±1.94 
ng/mL in the cancer and 9.98±1.9 ng/mL in the control groups (p=0.97), 9.85±2.3 ng/mL 
in the cancer and 9.97±1.14 ng/mL in the control groups (p=0.75) and 8.95±2.03 ng/mL in 
the cancer and 8.96±1.04 ng/mL in the control groups (p=0.97), respectively. By multiple 
logistic regression, only smoking status was associated with cancer. The time-averaged 
tacrolimus blood level at time of cancer diagnosis was not significantly associated with 
cancer after adjustment for this variable (Hazard ratio=1.08 per ng/mL, 95% confidence 
interval - 0.78 to 1.5, p=0.65).
Conclusions: The development of de novo nonskin cancer after kidney transplantation 
was not associated with the level of tacrolimus exposure over time.
SA-PO1087
Renal Cell Carcinoma Post Renal Transplant: The Case for Post-Transplant 
Ultrasound Surveillance  William M. Bennett, Alison M. Garre, Thomas D. 
Batiuk, Kevin M. Mcevoy, Erica Simonich.  Legacy Transplant Services, Legacy 
Good Samaritan Medical Center, Portland, OR.
Background: Following successful renal transplantation, there is an increased relative 
risk of renal cell carcinoma in retained native kidneys. Stimulated by a case of widespread 
metastatic cancer nine months after transplant with a normal pre-transplant ultrasound, we 
began routine 6-18 month post-transplant surveillance on all recipients except those with 
known autosomal dominant polycystic kidney disease.
Methods: 128 consecutive patients were entered into the study. At 6-12 months 
post-transplant.
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Results: 16 suspicious masses were detected (12.5%). Of these only 9 had evidence 
of acquired cystic disease (ACD) (four or more cysts) pre-transplant. The remainder had 
normal pre-transplant scans showing only small contracted kidneys or less than the required 
number of cysts to make a diagnosis of acquired cystic disease. We are following 14 of these 
patients with scans every 6-12 months to detect growth in newly discovered, less than 1 cm 
solid lesions. We have found 2 patients in which frank renal cell cancers were discovered. 
We have now adopted an annual screening process for all post-transplant patients at their 
one-year post-transplant visit.
Conclusions: Routine screening of native kidneys post-transplant appears critical 
to detect renal cell carcinoma at a stage early enough to achieve a cure by nephrectomy.
SA-PO1088
Non-Melanoma Skin Cancer Mortality in Kidney Transplant Recipients 
Michael Thomas Burke,1 Annie-Claire Nadeau-Fredette,1 Carmel M. Hawley,1 
Elaine M. Pascoe,4 Stephen P. McDonald,2 Sunil V. Badve,1 David W. Johnson,1 
Adele Green,3 Robert Peter Carroll,2 Nicole Isbel.1  1Dept of Renal Medicine, 
The Univ of Queensland, Princess Alexandra Hospital, Brisbane; 2Central 
Northern Adelaide Renal and Transplantation Services, Adelaide; 3Cancer and 
Population Studies Group, Queensland Inst of Medical Research, Brisbane; 
4School of Medicine, The Univ of Queensland, Brisbane.
Background: Non-melanoma skin cancer (NMSC) frequently occurs in kidney 
transplant recipients (KTRs). However, the frequency of, and risk factors for NMSC 
mortality in KTRs are poorly characterised.
Methods: Aims: To determine the proportion and predictors of fatal NMSC in KTRs. 
This cohort study included all KTRs transplanted in Australia and New Zealand between 
1980 and 2013, using Australia and New Zealand Dialysis and Transplant (ANZDATA) 
Registry data. A multivariable competing-risk survival analysis was used to calculate risk 
factors for fatal NMSC in KTRs.
Results: During the study, 21875 transplant episodes occurred in 19344 patients. Of the 
6780 patients who subsequently died, 231 (3.4%) died from NMSC. Of these, 172 (74%) 
were male, 226 (98%) were Caucasian, 219 (95%) were first graft recipients and 213 (92%) 
died with a functioning graft. Amongst first graft KTRs who died from NMSC, the mean 
age at transplantation was 48.8 +/- 13.7 years and the mean age at death was 61.8 +/- 11.1 
years. Male sex (HR 2.0, 95% CI, 1.48 -2.74); Caucasian ethnicity (HR 5.31, 95% CI, 
2.15-13.11) and pre-transplant skin cancer (HR 3.79, 95% CI, 2.38-6.04) were associated 
with NMSC mortality. Age at transplantation and multiple kidney transplants had time-
dependent associations for NMSC mortality with the 5-year post-transplant HR 1.08 per 
year (95% CI, 1.06-1.1) and 2.90 (95% CI, 1.39-6.05); and the 15-year post transplant HR 
1.03 per year (95% CI, 1.02-1.04) and 1.29 (95% CI, 0.66-2.55) respectively.
Conclusions: NMSC is an important contributor to mortality in KTRs. Risk factors for 
mortality from NMSC include male sex, Caucasian ethnicity, pre-transplant skin cancer, 
multiple kidney transplants and older age at transplantation.
SA-PO1089
NFAT-Regulated Gene Expression in Patients Developing Non-Melanoma 
Skin Cancer  Claudia Sommerer,1 Thomas Giese,2 Janina Brocke,1 Stefan 
Meuer,2 Martin G. Zeier.1  1Nephrology, Univ Hospital, Heidelberg, Germany; 
2Immunology, Univ Hospital, Heidelberg, Germany.
Background: After transplantation the risk of non-melanoma skin cancer (NMSC) is 
significantly increased. Immunosuppression with calcineurin-inhibitors (CNIs) is associated 
with the development of NMSC. Association to the individual immunosuppressive loads 
of CNIs assessed by residual NFAT-regulated gene expression was investigated in renal 
allograft recipients.
Methods: Renal allograft recipients from the Department of Nephrology, University 
Hospital Heidelberg, Germany, were included. All patients had a regular annual skin 
examination. Residual expression of NFAT-regulated genes (IL-2, IFNγ, GM-CSF) in 
PMA/ionomycin-stimulated peripheral blood was measured by quantitative real-time PCR 
at predose and 2h after Ciclosporin A (CsA) intake.
Results: 258 renal allograft recipients were enrolled (160 male, age 51±14y). Of these 
patients 75 allograft recipients developed NMSCs after renal transplantation (29.1%). The 
following NMSCs were histologically confirmed: 36 basal cell carcinoma, 34 squamous 
cell carcinoma, 33 actinic keratosis, 27 Bowen disease, 8 kerato-acanthoma. As risk 
factors to develop NMSC were identified: age 60 years, skin type (Fitzpatrick 1 and 2), 
and load of immunosuppression. NFAT-regulated gene expression was significantly lower 
in patients who developed NMSCs compared to patients without NMSCs (8.3±6.5 vs. 
12.7±12.8%, p<0.001). Squamous cell carcinoma and actinic keratosis were significantly 
associated with a high inhibition of IL-2 and IFNγ. Patients with basal cell carcinoma 
and Bowen disease showed a general low expression of NFAT-regulated gene expression. 
However, in patients with kerato-acanthoma no significant inhibition of NFAT-regulated 
gene expression could be detected.
Conclusions: The immunosuppressive load contributed to the risk of NMSCs. NFAT-
regulated gene expression was significantly inhibited in patients developing NMSCs. 
Monitoring of NFAT-regulated gene expression in CNI treated transplant recipients 
provides an individual profile of response to CNIs and is a useful tool for an individual 
immunosuppression with respect to safety and toxicity.
SA-PO1090
T Cell Immunosenescence Is a Stable and Strongly Performing Predictor 
of Recurrent Squamous Cell Carcinoma in High-Risk Renal Transplant 
Recipients  Matthew James Bottomley,1,2 Paul N. Harden,2 Kathryn J. Wood.1 
1Nuffield Dept of Surgical Sciences, Univ of 2xford, 2xford, 2xfordshire, United 
Kingdom; 2Oxford Kidney Unit, Oxford Univ Hospitals NHS Trust, Oxford, 
Oxfordshire, United Kingdom.
Background: Cutaneous squamous cell carcinoma (SCC) is a major cause of morbidity 
in renal transplant recipients (RTR). 50% of RTR develop recurrent SCC, but current 
methods to stratify this risk are limited. Screening thus represents a major healthcare burden. 
We hypothesised RTR demonstrating increased immunosenescence, associated with ageing 
and increased infection risk, would be at high risk of recurrent SCC.
Methods: RTR at high clinical risk of SCC were recruited. Predictive value of 
previously published risk equations, clinical phenotype and immunosenescence (assessed 
by CD57 expression on CD8+ T cells, using FACS) for SCC development were compared 
using Cox regression. CMV serology was assessed at enrolment.
Results: 117 RTR participated. Half had a history of previous SCC. Median follow-up 
was 594 days. CD57 expression on CD8+ T cells correlated with other established markers 
of immunosenescence. RTR who developed SCC during follow-up and had >50% CD57-
expressing CD8+ T cells (CD57hi) were 2.6 (95% CI: 1.0 – 6.7, p=0.04) times more likely to 
develop a further SCC (median time between SCC: 449 days in CD57hi cohort, not reached 
in CD57lo). Previously defined clinical risk scores provided no predictive value for SCC in 
this cohort when adjusted for age at enrolment. CD8+ T cells from CD57hi RTR displayed 
normal cytotoxic and cytokine-secreting function. CD57hi phenotype was not associated 
with greater CD4+ Treg number in peripheral blood. CMV IgG titres correlated with CD57 
percentage but CMV seropositivity was not, in itself, a predictor of SCC development. CD57 
expression was stable over a one year period and with SCC development.
Conclusions: Immunosenescence, partly driven by CMV and identified by the CD57hi 
phenotype, is a stronger predictor of SCC in high-risk RTR than previously identified 
clinical scores. Quantifying CD57 expression on CD8+ T cells may enable stratification 
of RTR at increased risk of recurrent SCC, who may benefit from increased screening and 
early reduction of immunosuppression.
Funding: Private Foundation Support
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Role of Toll-Like Receptors in Aristolochic Acid Nephrotoxicity 
Gem Batuman,1 Altaf-M Khan,1 Madlin Alzoubi,1 Vecihi Batuman.1,2  1Dept 
of Medicine, Section of Nephrology & Hypertension, Tulane Univ School of 
Medicine, New Orleans, LA; 2Dept of Veterans Affairs, SLVHCS, New Orleans, 
LA.
Background: Studies demonstrated that aristolochic acid (AA) is toxic to renal tubular 
epithelium and carcinogenic to urethral epithelium. Although the exact extent of AA 
nephropathy (AAN) is unknown, case series have been reported in throughout the world 
and it has been implicated in the etiology of Balkan endemic nephritis (BEN) suggesting 
that this is a global health problem. The precise mechanisms of AA nephrotoxicity are not 
known. We investigated the role of Toll-like receptors (TLRs) in the pathophysiology of 
AAN using human renal proximal tubule epithelial cells (RPTECs).
Methods: Confluent RPTECs were exposed to AA (30 µM – 480 µM) for 24 – 48 hr 
and cytotoxicity was measured using lactate dehydrogenase (LDH) assay. RNA and protein 
were isolated from AA-exposed and unexposed RPTECs. Real time RT-PCR was performed 
for various gene primers to evaluate the role of innate immunity in AAN development.
Results: At 240 µM after 48 hr exposure, AA induced significant toxicity in RPTECs 
as measured by LDH release in the culture medium and significant cell injury was observed 
morphologically. AA significantly increased mRNA expression of acute kidney injury 
(AKI) biomarker neutrophil gelatinase-associated lipocalin (NGAL), but at the same time 
significantly decreased the expression of another AKI biomarker kidney injury molecule 1 
(KIM-1). AA also significantly upregulated the expression of prominent AKI-related TLRs 
(TLR2, TLR4 and TLR6) and their adaptor molecules (MyD88 and TICAM-1) followed by 
the activation of pro-inflammatory cytokines (IL-6 and TNF-α) and the tumor suppressor 
protein and a biomarker for apoptosis, p53, in the down-stream signaling pathways of 
TLRs. AA also significantly upregulated expression of multi drug resistant family gene 
MDR1 in RPTECs.
Conclusions: AA is toxic to RPTECs and restricts cell growth. NGAL but not KIM-
1 could be a diagnostic biomarker for AAN. AKI prominent TLR2 and TLR4 could be 
potential candidates for therapeutic target in developing new strategies for AAN and BEN 
treatment.
PUB002
A Case of Severe Symptomatic Iatrogenic Hypermagnesemia 
Rohan V. Mehta,1 Vandana Niyyar,1 Rahul Mehta.2  1Renal Medicine, Emory, 
Atlanta, GA; 2Hospital Medicine, UVA, Charlottesville, VA.
Background: Hypermagnesemia is an uncommon but a potentially life threatening 
condition. Symptoms may develop in patients with acute kidney injury (AKI) or chronic 
kidney disease with the administration of pharmacologic dose of magnesium (Mg), and 
with use of oral laxatives or magnesium containing enemas.
Methods: A 30-year-old African American man with baseline Cr of 1, admitted for 
management of multiple fractures, subdural hemorrhage and traumatic brain injury sustained 
in a motor vehicle accident, suddenly became hypotensive and developed AKI. UOP 
declined from 2-3L/ day on admission to 700 ml over the next 24 hours. He became areflexic 
and developed ARDS, with increasing FiO2 requirements. Repeat laboratory data showed 
Cr 3.9, hemoglobin 6.9 and Mg 9.5 mg/dl. Review of his chart revealed he had received 
a total of 8.75g of magnesium citrate through enemas on the previous day. Aggressive 
resuscitation was started, including IV calcium, but he continued to require multiple pressors. 
Hypermagnesemia was presumed to be the cause of his ongoing hemodynamic instability. 
Intermittent hemodialysis was initiated for 2 hours to rapidly remove magnesium and he 
was then switched to CVVHD for continuous magnesium removal. Within 12 hours of 
RRT, pressor requirements decreased, UOP improved to 50-60 ml/hr and Mg levels ranged 
between 2-3 mg/dl. CVVHD was discontinued after 72 hrs and the patient had complete 
renal recovery to his baseline Cr of 1.
Results: Severe symptomatic hypermagnesemia can develop even with small doses of 
Mg containing laxatives. It prevents presynaptic acetylcholine release resulting in blockade 
of neuromuscular transmission. Clinical features of Mg toxicity range from delayed deep 
tendon reflexes, flaccid paralysis, respiratory failure, to hypotension, bradycardia, complete 
heart block and cardiac arrest. Management includes rapid supportive measures, fluids, 
IV calcium, loop diuretics. Urgent hemodialysis can rapidly reverse shock and respiratory 
failure preventing significant morbidity and mortality.
Conclusions: In summary, we report a case of severe hypermagnesmia, in the setting 
of AKI, presenting with shock and respiratory failure, requiring RRT.
PUB003
Ischemic and Non-Ischemic Acute Kidney Injury Cause Gut Damage 
Tao Jiang Li, Chen Yu.  Nephrology Dept, Shanghai Tongji Univ, Tongji 
Hospital, Shanghai, China; Nephrology Dept, Shanghai Tongji Univ, Tongji 
Hospital, Shanghai, China.
Background: Chronic uremia induced gut injury has been well documented in a number 
of studies. However, remote effects of acute kidney injury(AKI) on the intestine are far less 
investigated. Here we studied whether the gut also suffers damage during induction of renal 
ischemia–reperfusion in rats and compared this to bilateral nephrectomy.
Methods: To test our hypothesis, six groups of SD rats (n=6 in each group) were studied: 
1) sham operation for 6h; 2) ischemic AKI for 6h (60 min of renal pedicle clamping and 
then reperfusion for 6h); 3) bilateral nephrectomy for 6h; 4) sham operation for 24h; 5) 
ischemic AKI for 24h(60 min of renal pedicle clamping and then reperfusion for 24h); 6) 
bilateral nephrectomy for 24h. Ilium and blood were collected. The damage of gut mucosa 
was assessed by histological staining. Malondialdehyde(MDA) and apoptosis of the ilium 
were measured to determine the underlying mechanism of the AKI-induced gut injury.
Results: We found histological evidence of ilium injury following both ischemia 
and bilateral nephrectomy. MDA, an index of lipid peroxidation, increased in both the 
renal ischemia and nephrectomy groups, suggesting activation of oxidative stress. Ilium 
apoptosis,which was quantified by histone-associated DNA fragmentation enzyme-linked 
immunosorbent assay, were increased after 6 and 24 h of renal ischemia or nephrectomy .
Conclusions: Our study shows that acute kidney ischemia or renal failure activates 
oxidative stress and promotes apoptosis, and tissue damage in gut . Whether the AKI 
induced-gut injury by itself is sufficient to provoke systemic inflammatory response need 
further investigation.
Funding: Government Support - Non-U.S.
PUB004
Serum from Rats with Acute Kidney Injury Contains Reactive Oxygen 
Species Generating Activity That Causes Oxidative Stress In Vitro 
Jon D. Ahlstrom,1 Zhuma Hu,1 Nicole Molin,1 Christof Westenfelder.2  1Medicine, 
Univ of Utah and VA Medical Centers, Salt Lake City, UT; 2Physiology, Univ 
of Utah and VA Medical Centers, Salt Lake City, UT.
Background: The uremic state that is induced by Acute Kidney Injury (AKI) adversely 
affects multiple organ systems by mechanisms that are still poorly characterized, including 
through reactive oxygen species (ROS).
Methods: Serum was obtained from rats 24 hrs post ischemia/reperfusion-AKI (50 
min bilateral pedicle clamp, AKI serum), and control sera was obtained from rats 24 hrs 
following SHAM surgery (SHAM serum), or from rats 24 hrs post bilateral nephrectomy 
(NPHX serum). Serum samples were evaluated for ROS activity with the sensitive Amplex 
Red H2O2 assay. For in vitro assays, NRK cells (normal rat kidney cells, proximal tubular) 
or rat mesenchymal stem cells (MSC) were cultured in rat serum for 48 hours, and then 
assayed for gene expression, GSH levels, and oxidative stress markers.
Results: Compared to SHAM or NPHX serum, serum from rats with AKI had increased 
amplex red activity compared to SHAM and NPHX serum controls. Adding catalase to rat 
serum reduced—but did not eliminate--the ROS activity of AKI serum in a dose-dependent 
manner. The ROS generating properties of AKI serum were completely destroyed with 
strong (90°C for 1 hr) but not mild (45°C for 30 min) heat inactivation. Culturing normal 
rat kidney cells (NRK, proximal tubular) or rat mesenchymal stem cells (MSC) in 10% 
AKI serum (compared to SHAM or NPHX serum) resulted in increased oxidative stress, 
including increased anti-oxidant gene expression (HO-1, catalase), increased GSH levels, 
and increased cellular ROS activity (CMH2DCFDA and mitosox).
Conclusions: At comparable levels of azotemia (AKI vs. NPHX), AKI serum contains 
ROS generating activity that is heat labile, but that is not blocked by catalase incubation. 
These results suggest that the injured kidney releases heat-sensitive factors into the blood 
stream (likely proteins) that generate ROS and may adversely affect renal tissue and 
distant organs. The Amplex Red H2O2 assay provides a useful tool for the determination 
and mechanistic dissection of the ROS activity found in AKI serum.
Funding: Veterans Administration Support
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Properdin Deficiency Enhances Renal Ischemia Reperfusion Injury in 
Mice  Zinah Dheyaa Zwaini,1,3 Nigel J. Brunskill,1 Hans-Wilhelm Schwaeble,1 
Cordula M. Stover,1 Bin Yang.1,2,4,5  1Infection, Immunity and Inflammation, Univ 
of Leicester; 2Renal Group, Univ Hospitals of Leicester; 3College of Medicine, 
Univ of Kufa, Iraq; 4Basic Medical Research Centre, Medical school of Nantong 
Univ, China; 5Nephrology, Affiliated Hospital of Nantong Univ, China.
Background: Properdin is the only positive regulator of the alternative pathway of 
complement activation via stabilizing C3bBb convertase. Properdin has been detected 
on proximal tubular epithelial cells associating with proteinuric renal damage. Previous 
studies showed that mice with combined deficiencies of properdin (Pko), DAF and CD59, 
the negative regulators of complement activation, had less renal ischemia reperfusion 
injury (IRI) in 24 hours.
Methods: Pko mice (n=9) and their wildtype (WT) littermates (n=7) were used to 
assess the role of properdin in renal IRI. Ischaemia was induced by bilateral clamping of 
the renal pedicle for 30 minutes followed by 72-hour reperfusion using normal (n=2) and 
sham operated mice (n=4 or 5) as controls.
Results: Renal IRI was successfully induced in the WT and Pko mice with more 
prominent injury in Pko mice as evidenced in renal function. Serum creatinine was 
significantly increased after IRI compared with the sham groups, which was further increased 
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in Pko in relation to WT mice (1.78±0.29 vs.1.19±0.18, P=0.046) post IRI. Similarly, blood 
urea nitrogen in IRI mice was higher than the sham animals, with significant increase in 
Pko in comparison with WT mice .
This difference was supported by histological examination, in which Pko mice showed 
a worse score of tubulointerstitial damage than WT (2.67±0.26 vs. 1.94±0.22, P=0.025) 
post IRI.
Conclusions: This study shows, for the first time, that properdin deficiency alone 
enhances IRI shown by worsened renal function and histology. The underlying mechanisms 
for these unexpected phenotype are under present investigation.
Funding: Government Support - Non-U.S.
PUB006
Neurogenic Function of Neurons with Renal Afferents Is Altered by 
Lipopolysaccharides -LPS  Kristina Rodionova,1 Martin Ziemer,1 Tilmann 
Ditting,1 Stefan Karl,1 Sonja Heinlein,1 Peter Linz,1 Peter Reeh,3 Kerstin U. 
Amann,2 Roland Veelken.1  1Dept of Medicine 4 - Nephrology and Hypertension, 
Universitaetsklinikum Erlangen-Nuernberg, Erlangen, Bavaria, Germany; 2Dept 
of Nephropathology, Universitätsklinikum Erlangen-Nuernberg, Erlangen, 
Bavaria, Germany; 3Dept of Physiology and Pathophysiology, FAU Erlangen-
Nuernberg, Erlangen, Bavaria, Germany.
Background:  Renal afferent nerves (RNs) exert complex neurogenic 
sympathomodulatory and paracrine effects. Recently, we could demonstrate that 
lipopolycaccharide (LPS) sensitized TRPV1 receptors and increased the release of CGRP 
from afferent axons in kidney. Hence,we wanted to test the hypothesis that LPS alters firing 
patterns and acid induced inward currents in cultured neuron sample.
Methods: Dorsal root ganglion neurons (Th11-L2) of rats were incubated with LPS 
(E.coli O127/B8,20mg/l) 12h before patch clamp recordings. Inward currents were assessed 
during stimulation of TRPV1 and ASICs with protons (pH6,9 and 5,0). Current clamp 
mode was performed at physiological conditions and after 12h of LPS-incubation.Neurons 
were characterized as tonic,i.e. sustained AP firing or phasic, i.e.<5 APs in response to 
current injections.
Results: Firing patterns and currents induced by acidic superfusion were studied in 246 
neurons.Renal neurons (RNs) exhibited in 59% tonic firing pattern under control conditions.
The number of neurons with tonic response was significantly reduced by exposure to LPS 
(59%vs.42%,p<0,05).Under control conditions 70,8% of RNs exhibited both sustained 
and transient inward current, whereas 29,2% showed sustained current. LPS exposure 
significantly increased sustained,i. e. TRPV1 induced current (-793,18+/-66pA vs.-1224+/-
200pA,p<0,05) and transient, i. e. ASICs induced inward current even under subthreshold 
proton stimulation (pH6,9) and could not be enhanced further by pH5,0.
Conclusions: LPS altered the properties of neurons with renal axons in a complex way: 
while the ease of AP production was significantly deceased, the responsiveness to acidic 
milieu was increased. In how far these alterations subserve different effects (e.g. decreased 
sympathetic control, altered peptide release) in experimental sepsis needs further research.
Funding: Other NIH Support - Germany, Bavaria, Erlangen
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Protective Effect of Nitric Oxide in Aristolochic Acid-Induced Toxic Acute 
Kidney Injury  Inès Jadot,1 Anne-Emilie Decleves,2 Vanessa Colombaro,1 
Blanche Martin,1 Isabelle Habsch,1 Eric De Prez,2 Joelle L. Nortier,2 Nathalie 
Caron.1  1Molecular Physiology Research Unit - URPHYM, Faculty of Medecine, 
Univ of Namur, Namur, Belgium; 2Laboratory of Experimental Nephrology, 
Faculty of Medicine, Univ Libre de Bruxelles, Bruxelles, Belgium.
Background: Aristolochic Acid (AA) nephropathy is a pertinent example of tubulo-
interstitial (TI) nephritis characterized by an early phase of acute kidney injury (AKI) 
leading to progressive fibrosis and chronic kidney disease (CKD). Nitric oxide (NO) has 
been shown to play a critical role in the AKI-to-CKD transition. Here, the AAN model was 
used to determine the role of NO in this process, focusing on the acute phase.
Methods: C57BL/6J male mice were randomly subjected to daily i.p. injection of 
control solution or AAI (3,5mg/kg) for 4 days and L-Arginine (L-Arg; substrate for NO 
synthesis) was supplemented in drinking water (5%) until mice were euthanized, 5 days 
after the beginning of AAI injections.
Results: At day 5, AA-treated mice displayed polyuria, increased plasma creatinine 
level and proteinuria. In addition, histological analyses revealed severe proximal tubular 
cell necrosis, renal inflammation and increased oxidative stress in AA-treated mice. These 
changes were associated with a significant reduction of NO bioavailability, as attested by 
urinary NOx and cGMP levels. L-Arg supplementation in AA-treated mice significantly 
improved kidney function, as reported by a significant reduction in urine volume, plasma 
creatinine level and proteinuria. Moreover, L-Arg treatment resulted in a significant 
reduction of tubular cell necrosis, renal inflammation and oxidative stress. These were 
concomitant to normalized NO levels.
Conclusions: Our findings demonstrated that sustaining NO bioavailability due to 
L-Arg supplementation improve the renal outcome of AA-induced AKI phase. Further 
investigations are ongoing to determine whether increasing NO bioavailability can also 
prevent chronic injuries in the AAN model.
PUB008
The Study of Curcumin-Loaded Nanoparticles against Renal Ischemia-
Reperfusion Injury Function and Mechanism  Yong Xu, Lili Zhong.  Dept 
of Nephrology, Huaian Second Hospital, Huaian, Jiang Su, China.
Background: To study the effects of curcumin-loaded nanoparticles against ischemia-
reperfusion renal injury, and to investigate its mechanism.
Methods: Synthetize controlled releasing curcumin-loaded nanoparticles by 
amphilic mPEG-PCL block copolymers and cultivated renal tubular epithelial cell (cell 
line HK-2) in vitro. HK-2 cells were divided into four groups: Control group; Ischenmia 
reperfusion injurygroup(IRI group); Curcumin group(Cur group); Curcumin nanoparticle 
group(CurNP group). In each group, HK-2 cells viability was assessed by dimethyl-
thiazol-diphenyltetrazoliumbromide (MTT) tests. Apoptotic Cells were  measured by Flow 
Cytometry. H2DCF-DA was used to detect intracellular generation of ROS. BCA were used 
to detect SOD activation and the Concentration of MDA.   Protein levels of procaspase-3 
were analyzed by Western Blot.
Results: Successfullyconstructed curcumin-loaded nanoparticles by amphilicmPEG-
PCL block copolymers. We found the differences between four groups. In IRI group, cells 
viability reduced gradually, cells apoptosis was obvious, SOD activity declined, the level 
of ROS and MDA activation increased significantly, the expression of Caspase-3 was 
increased.In Cur group and CurNP group,cells viability was improved.A great reduction 
in the level of apoptosis was observed.SOD activity was improved.The level of ROS and 
MDA activation were inhibited, the expression of Caspase-3 was decreased. Compared 
with Cur group,it also showed a marked  improvement in CurNP group. Difference Had 
Statistics Meaning(P<0.05).
Conclusions: 1. Efficiently produce controlled releasing Curcumin-loaded 
nanoparticles by amphilic mPEG-PCL block copolymers.Drug loading content(DLS) and 
encapsulation efficiency(EE) were more than other peports.Data indicated that incorporated 
Cur could be slow released from the core–shellstructureof polymericnanoparticles. 2. 
CurNP can ameliorate ischemia-reperfusionrenal injury in vitro. 3. The protective effects 
of Cur-NP against ischemia-reperfusion renal injurywere involved in the suppression of 
oxidative stress reaction.
PUB009
Disruption of Polyamine Catabolism Reduces the Severity of Cisplatin 
Nephrotoxicity  Kamyar A. Zahedi,1,2 Sharon L. Barone,1,2 Marybeth 
Brooks,1 Jie Xu,1 Manoocher Soleimani.1,2  1Dept of Internal Medicine, Univ 
of Cincinnati, Cincinnati, OH; 2Research Services, Veterans Affairs Medical 
Center, Cincinnati, OH.
Background: Platinum-based drugs (e.g. cisplatin) are used for treatment of many types 
of solid organ tumors. Cisplatin crosslinks the DNA, interferes with mitosis, activates the 
DNA repair response and leads to apoptosis when repair proves impossible. The latter is 
the primary anti-tumor mechanism of cisplatin. Platinum-based drugs also cause oxidative 
cell injury, which may mediate their general toxic effects. Acute kidney injury (AKI), due 
to oxidative damage, is a major side effect of cisplatin that necessitates dose reduction 
or withdrawal from treatment thereby reducing the effectiveness of cancer therapy. We 
hypothesized that treatments that reduce the oxidative tissue damage caused by cisplatin 
lessen the severity of AKI without interfering with its anti-proliferative DNA damaging 
effects and obviate the need for dose reduction or drug withdrawal.
Methods: Cisplatin-AKI was compared in wild type and SSAT-KO mice using 
functional and molecular parameters. Mechanism of polyamine catabolism mediated-cell 
injury were assessed in cultured cells.
Results: The expression of polyamine catabolic enzymes, spermidine spermine-N1-
acetyl transferase (SSAT) and spermine oxidase (SMO) increase in the kidneys of cisplatin-
treated mice. SSAT-KO mice are protected against tissue damage and renal dysfunction 
caused by cisplatin. Using cultured cells capable of inducible expression of SSAT, the effect 
of SSAT on the induction of endoplasmic reticulum stress and unfolded protein response 
(ERS/UPR). Our results indicate that up-regulation of polyamine catabolism in general, 
and enhanced production of SSAT in particular, activated the ERS/UPR.
Conclusions: These studies suggest that polyamine catabolism is involved in the 
mediation of cisplatin-AKI. These and our previous results indicate that the activation of 
polyamine catabolism causes cell injury through both genotoxic response and ERS/UPR 
pathways. Our studies suggest that short-circuiting or neutralization of toxic products 
of polyamine catabolism can be novel therapies that reduce the severity of cisplatin 
nephrotoxicity.
Funding: Veterans Administration Support, Private Foundation Support
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PUB010
Renoprotective Effect of NADPH Oxidase 4 Inhibition in Contrast Induced 
Nephropathy  Se-Hee Yoon,1 Won Min Hwang,1 Sung-Ro Yun,1 Sukyung Lee,2 
Hee-Yeon Jung,2 Ji-Young Choi,2 Sun-Hee Park,2 Chan-Duck Kim,2 Yong-Lim 
Kim.2  1Internal Medicine, Konyang Univ, Deajeon, Korea; 2Internal Medicine, 
Kyungpook National Univ School of Medicine, Daegu, Korea.
Background: The objective of this study was to investigate the renoprotective effect 
of NADPH oxidase 4(Nox4) inhibition in contrast induced nephropathy.
Methods: HK-2 cells were incubated with iohexol (nonionic low-osmolar radiocontrast 
agent) at a concentration of 75 mg I/ml, 150mg I/ml for 2 h. Cells were pre-exposed to 
GKT137831, a selective Nox1&4 inhibitor (Genkyotex,Switzerland), for 30 min before 
exposure to iohexol. Cell viability was measured at 0, 3 and 22 h after removal of iohexol 
by ATPlite assay. Apoptosis was investigated by caspase 3/7 activity assay. Reactive 
oxygen species (ROS) production was assessed by DHE assay, NADPH oxidase activity 
by the lucigenin-enhanced chemiluminescence method, and Nox4 expression by western 
blot and real time PCR.
Results: Nox4 protein expression significantly increased at 30 min after iohexol 
exposure. GKT137831 pre-exposure showed significantly less cytotoxicity at 3h after 
removal of iohexol. Caspase 3/7 activity was significantly lower in GKT137831 pre-exposed 
cells than only iohexol exposed cells at 22 h after removal of iohexol. ROS generation 
was higher with only iohexol exposed cells compared to GKT137831 pre-exposed cells.
Conclusions: A selective Nox4 inhibition induced fewer cytotoxic effects on cultured 
HK-2 cells than iohexol along with a lower induction of Nox4-dependent ROS generation. 
This enzyme may represent a potential therapeutic target to prevent iodinated radiocontrast 
media related oxidative stress.
PUB011
Autophagy Increased in the Early Stage of Rat Acute Kidney Injury Model 
Junyi Lin,1 Xing Mao,2 Yiwen Shen,1 Huijuan Wu,2 Aimin Xue.1  1Deparment 
of Forensic Medicine, Shanghai Medical College, Fudan Unviersity, Shanghai, 
China; 2Deparment of Pathology, Shanghai Medical College, Fudan Unviersity, 
Shanghai, China.
Background: Acute kidney injury (AKI) is a major kidney disease without effective 
therapies, and thus associated with a high mortality. The pathogenesis of AKI is very 
complex and still unclear. Recently, researches have shown the induction of autophagy 
in proximal tubular cells and kidneys during AKI.In the present study, we investigated 
the role of autophagy in the pathogenesis of rat renal ischemia-reperfusion (I/R) model 
which causes AKI.
Methods: All male Sprague-Dawley rats were subjected to clamping of bilateral renal 
artery only for 25 min except sham group, and then they were randomly divided into four 
groups depended on different reperfusion time point, including 3h, 6h, 12h and 24h. The 
Sham group underwent surgical procedures without ischemia was as the control.
Results: The level of blood urea nitrogen (BUN) and serum creatinine were increased 
from 3h after I/R. By H&E staining, protein casts were found at 3h after I/R, which kept 
increasing at 6h and 12h after I/R. At 24h after I/R, we found some necrotic proximal tubules. 
Immunoblotting showed the protein level of Beclin-1 and Vps34 and the ratio of LC3 II/I 
was increased from 3h after I/R, which was confirmed by electron microscopy showing the 
formation of autophagic vacuoles in proximal tubule cells. Moreover, immunohistochemical 
staining clearly showed an increasing positive staining of Vps34 and LC3 at 3h after I/R 
compared to the control.
Conclusions: Taken together, our results demonstrate the occurrence of autophagy in 
the very early stage of rats AKI model.
Funding: Government Support - Non-U.S.
PUB012
The Previous Cardio Exercise (Exe) Normalizes Renal Function of Wistar 
Rats Subjected to Acute Kidney Injury by Ischemia, and Reperfusion 
Weslei Vicente Lima, Waldemar S. Almeida, Nestor Schor.  Nephrology, Federal 
Univ of Sao Paulo, São Paulo, Brazil.
Background: The acute kidney injury (AKI) is characterized by acute reduction of 
renal function and has a high mortality rate in hospitalized patients and in severe cases 
may progress to chronic kidney disease (CKD). The AKI by ischemia and reperfusion (I/R) 
causes tubular damage mainly in the proximal convoluted tubule, reducing mitochondrial 
activity in renal cell and increasing the reactive oxygen species (ROS). It is known that 
aerobic Exe lower blood pressure (BP), slows the heart rate (HR), improves muscle aerobic 
capacity, increases both the number and size of muscle mitochondria, however little is 
known about the effects of the previous Exe in AKI. We suspect that aerobic Exe may be 
a non-pharmacological resource in the prevention of AKI. Thus, we investigated the effect 
of previous aerobic Exe on renal injury resulting from I/R. To evaluate the effects of the 
previous aerobic Exe on renal function in Wistar rats subjected to I/R.
Methods: We used male Wistar rats with 10 week of life and they were separated 
into two groups Sham clamp (SC) and trained control clamp (TC), moreover the TC were 
subjected to a prior physical training protocol for four weeks. After completed 14 weeks 
each group were underwent acute kidney injury surgery by I/R, the rast recovering for 24 
hours after that they were placed in metabolic cages for 24 hours. We evaluate renal function 
(serum creatinina and proteinuria). Then they will be realized: renal morphological study 
by light microscopy and mitochondrial (number and size) by electron microscopy. Finally, 
we will evaluate apoptosis through caspases 3 activity.
Results: The SC group increased weight compared to the TC group (399±5vs365±5g, 
P<0.05), Proteinuria was significantly different in SC vs. TC group (25.62±4.93vs14.54±1.65 
mg/24h, P<0.05). Now the creatinina serum showed significant difference in SC vs TC 
group (0.30±0.8vs0.67±0.6 mg/dL; P<0.05). We evidenced that SC group had a damage 
renal function after 48 hours recovery.
Conclusions: The results of this study are preliminary in nature, but suggest that the 
previous aerobic Exe can be renoprotective in the model I/R.
PUB013
Angiogenin Mediates a Non-Cell Autonomous Response to Endoplasmic 
Reticulum Stress in the Kidney  Nicolas Pallet,1 Dany Anglicheau,3 Eric 
Thervet,2 Iadh Mami.1  1INSERM U1147, Paris, France; 2Nephrology, Georges 
Pompidou European Hospital, Paris, France; 3Nephrology, Necker Hospital, 
Paris, France.
Background: Endoplasmic Reticulum (ER) stress is involved in the pathophysiology 
of kidney diseases, but the molecular basis of its biological outputs remain to be established. 
Angiogenin (ANG), a secreted ribonuclease, is a previously unappreciated component of 
the mammalian stress response that acts both in cell-autonomous and non-cell autonomous 
fashions to promote tissue adaptation to injury. Whether ANG signaling is a genuine 
component of the ER stress response is currently unknown.
Methods: In the present study, we explored the molecular mechanisms by which ANG 
is secreted under ER stress, and determined how it contributes to the modulation of the 
inflammatory microenvironment.
Results: Our results indicate that i) ANG secretion is specifically induced during 
ER stress and ii) this mechanism is under the selective control of IRE1a signaling. We 
demonstrate that ANG canonical secretion is induced upon ER stress, similar to the 
proinflammatory cytokine IL-6, and as such might play an instrumental role in macrophage 
activation. These data are relevant to human disease since we identified ANG as a urinary 
marker of immune-mediated acute kidney injury.
Conclusions: Collectively, our data identify ANG as a key mediator of ER stress-
dependent inflammatory response in kidney diseases, and is a potential non-invasive 
biomarker of acute kidney injury.
PUB014
Sustained Infiltration of Th17 Cells Is Associated with Pulmonary 
Fibrosis in Rats with Salt Induced CKD Secondary to Renal Ischemia 
Purvi Mehrotra, Jason Andrieu Collett, David P. Basile.  Dept of Cellular and 
Intergrative Physiology, Indiana Univ of Medicine, Indianapolis, IN.
Background: Acute kidney injury (AKI) is associated with high mortality rates and 
is a leading cause of prolonged hospitalizations. The high risk of death is due in part to 
distant organ damage (e.g., lungs, heart, brain). It is well established that experimental 
AKI induced by renal ischemia and reperfusion (I/R) induces an increase in pulmonary 
infiltration of various immune cells like T cells as early as 24 hours post surgery, which 
may alter endothelial barrier function in the lung.   However, the long-term effect of kidney 
injury induced pulmonary inflammation on lung function and structure and function is not 
known. We hypothesize that T cells infiltrate into the lung post kidney injury with potential 
effects on pulmonary structure.
Methods: SD rats were subjected to a model of AKI-to-CKD in which rats are allowed 
to recover from unilateral I/R (40 min ischemia) for 5 weeks on standard salt diet (0.4% 
NaCl) and then subjected to contralateral UNX and 4% NaCl diet for 4 additional weeks.
Results: Consistent with prior reports, infiltration of CD4+ T cells   were detected as 
early as 24 hours post surgery in the BAL fluid, and these were shown to be predominantly 
of Th17 phenotype (63%±10.1, p³ 0.05). Interestingly, Th17 cells persisted in the lungs 
even after 5 weeks of post surgery after resolution of kidney injury (2.3X104±0.1, p³0.05), 
when compared to sham (0.53X104±0.0.3). Exposure of rats to high salt diet to hasten 
CKD further increased the number of Th17 cells in the lungs (4.1X104±0.23, p³0.05). 
There was a corresponding increase in pulmonary fibrosis in post-AKI rats on high salt 
relative to sham-controls.
Conclusions: Taken together, these data suggest that AKI leading to CKD is associated 
with pulmonary fibrosis, an activity that may be due in part to the infiltration of Th17 cells 
into the lung and influenced by dietary salt.
Funding: NIDDK Support
PUB015
Endothelial-to-Mesenchymal Transition and Endothelial Cilia in EPC-
Mediated Postischemic Kidney Protection  Daniel Patschan, Susann Patschan, 
Gerhard A. Mueller.  Clinic of Nephrology and Rheumatology, Dept of Internal 
Medicine, Göttingen, Nierdersachsen, Germany.
Background: AKI increases the risk for CKD. Ischemia induces peritubular capillary 
rarefication and interstitial fibrosis with the latter partly resulting from mesenchymal 
transition of endothelial cells (EndoMT). Endothelial cilia are mechanosensory organelles 
responsible for transmitting forces of the blood flow into the cell. Early Endothelial 
Progenitor Cells (eEPCs) have reproducibly been shown to protect mice from AKI in the 
short-term. Aim of the study was to analyze mid-term consequences of eEPC treatment of 
murine AKI. Our special interest focused on dynamics of endothelial cilia and EndoMT.
Methods: Male, 8-12 weeks old C57/Bl6N mice were subjected to unilateral renal 
ischemia (40) post-uninephrectomy. Syngeneic murine eEPCs (0.5×106) were injected once 
at the time of reperfusion. Animals were investigated 1, 4, and 6 weeks later (renal function, 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
889A
J Am Soc Nephrol 26: 2015 Publication Only 
fibrosis, EndoMT, endothelial alpha-Tubulin). Cultured mature endothelial cells (ECs) were 
exposed to a variable flow with versus without treatment with eEPC supernatant. Later (24 
h) cells were investigated for the presence of cilia, alpha-Tubulin, and EndoMT, respectively.
Results: Systemically injected eEPCs significantly improved postischemic kidney 
function at week 1 (35 and 45 minutes) and 4 (45 minutes). Interstitial fibrosis was 
significantly diminished by cell treatment at all time points as well, EndoMT was less 
pronounced at week 4 (35 minutes) and 6 (45 minutes). eEPC supernatant reduced aSMA 
expression and alpha-tubulin abundances in flow-treated cultured mature endothelial 
cells while percentages of cilium+ cells increased. The loss of peritubular capillaries was 
prevented by eEPCs. Intrarenal endothelial alpha-tubulin decreased postischemia and was 
further reduced after eEPCs. The latter effect exclusively occurred in the 35 minutes groups.
Conclusions: We conclude that eEPCs are capable of reorganizing the endothelial 
cytoskeleton in an indirect manner, ultimately resulting in stabilization of the endothelial 
ciliom. The investigation indicates an anti-mesenchymal role of endothelial cilia in the 
process of postischemic tissue fibrosis / EndoMT.
PUB016
Mediators of Kidney Recovery following Ischemia-Reperfusion Injury 
Casper Lassen, Marie Louise Vindvad Kristensen, Henrik Birn, Bente Jespersen, 
Rikke Norregaard.  Dept of Clinical Medicine, Aarhus Univ.
Background: Ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury. 
Remote ischemic conditioning (rIC) performed as brief episodes of intermittent ischemia 
and reperfusion in a distant tissue may protect the kidney against IRI. We investigated the 
renal effects of rIC applied either prior to or during ischemic kidney injury.
Methods: One week after uninephrectomy Wistar rats were randomly divided into 
4 groups; sham (n=7), IR (n=10), IR+rIPC (n=10), and IR+rIPerC (n=10). rIC consisted 
of 4 episodes of 5 min clamping of the infrarenal aorta and 5 min of release either before 
(rIPC) or during (rIPerC) 37 min of left renal artery clamping (IRI). Urine and blood were 
sampled prior to ischemia or sham operation as well as 3 and 7 days after reperfusion. At 
day 7 the kidney was harvested for purification of mRNA and protein.
Results: Three days after IRI the decline in creatinine clearance (CrCl) from baseline 
values was similar comparing the IR group (∆:-1.59 ml/min/kg [-2.55;-0.64]) to both the 
IR+rIPC group (∆:-1.19 ml/min/kg [-2.22;-0.15], p>0.99) and the IR+rIPerC group (∆:-
1.48 ml/min/kg [-2.17;-0.79], p>0.99). At day 7 all groups exposed to IRI recovered to 
baseline CrCl. This was associated with a significant up-regulation of mediators of kidney 
recovery including phosphorylated Akt, ERK1/2 and HSP27 in all 3 groups. rIC was not 
associated with any significant differences in the expression of tubular damage markers, 
inflammatory or fibrosis markers, as well as anti-oxidant enzymes following IRI (see table).
Conclusions: In our study rIC did not protect the kidney against IRI. However, from 
day 3 to day 7 after IRI all groups recovered full renal function. This was associated with 
an up-regulation of pAkt, pERK1/2 and pHSP27 at day 7. 
IR IR+rIPC IR+rIPerC
pAkt 9±1.8 12±1.6 8±1.1
pERK1/2 5±1.2 5±0.8 3±0.4
pHSP27 15±3.9 16±2.8 12±3.3
SOD2 0.6±0.0 0.7±0.0 0.6±0.0
KIM-1 972±216 1228±192 956±185
ICAM-1 5±0.5 5±0.4 6±0.4
α-SMA 2±0.5 2±0.2 2±0.3
Mean±SEM.Normalized to the sham group. All values shown are statistically different from the 
sham group
Funding: Private Foundation Support
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Effect of Double Genes Transfected Adipose-Derived Stem Cells on 
Cisplatin-induced Renal Tubular Epithelial Cells Injury  Nanmei Liu.  Jimin 
Hospital of Shanghai.
Background: To observe the effects of adipose-derived stem cells (ADSCs) transfected 
with CXCR4 and EPO gene on renal tubular epithelial cells (HKC) injury.
Methods: To construct lentivirus expression system consisting of CXCR4 and EPO 
genes and transfected the system to adipose-derived stem cells (ADSCs), which co-culture 
with the cisplatin-induced HKC for 48 and 72 hrs. CCK8 detected cell proliferation of 
HKC. Electron microscope observed the ultrastructure of HKC cells and ADSCs migration 
was assayed. Western blot detected the expression of apoptosis proteins in HKC. ELISA 
detected the expression of inflammatory cytokines in culture medium.
Results: No significant changes were observed in the morphology of ADSCs after 
gene transfection, and the multiple differentiation ability were not affected. After co-culture 
the inhibitory effect of cisplatin on HKC cell proliferation was alleviated. Compared with 
the control group, the migration index of ADSCs was increased after co-culturing with 
cisplatin-induced HKC, and the gene transfection group were increased significantly as the 
extension of the culture time, indicating that the target gene transfection can promote the 
ADSCs migration to the damaged parts. Incubation with cisplatin, HKC cells EPO-R protein 
expression decreased. After co-culturing with ADSCs, the EPO-R expression increased. 
After incubated with cisplatin, the expression of Caspase-3, Bax expression in HKC cells 
increased significantly, which mediates the apoptosis. After co-cultured with ADSCs, 
the protein expression decreased, and the transfection groups decreased more obviously. 
After incubated with cisplatin, bcl-2 expression of HKC cells decreased obviously and 
the expression increased when ADSCs were cultured, and co-transfection group was more 
obviously. After incubated with cisplatin, IL-6 and RANTES were significantly increased in 
the cisplatin group. The inflammatory factor content decreased when ADSCs were cultured, 
and decreased more obviously in gene transfection group.
Conclusions: EPO has the protective effects on the damaged cells and CXCR4 could 
promote the migration of stem cells to damage sites. Double genes transfected to ADSCs 
may enhance the protective effect on HKC cells injury.
Funding: Government Support - Non-U.S.
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The Role of Endosialin in Renal Ischemia-Reperfusion Injury  Chia-Hao Liu,1 
Fang Ling Liao,1 Shun-Yang Cheng,1 Shuei-Liong Lin.1,2  1Physiology, National 
Taiwan Univ College of Medicine, Taipei, Taiwan; 2Internal Medicine, National 
Taiwan Univ Hospital, Taipei, Taiwan.
Background: Many studies reported that Endosialin deficiency can attenuate the 
inflammation, fibrosis or growth, invasion and metastasis of tumors. It is highly expressed 
during embryonic development, but largely absent in adult tissue except kidney and uterus. 
We are intrigued by the role of endosialin in the acute kidney injury.
Methods: We performed unilateral nephrectomy and then ischemia-reperfusion injury 
to induce acute kidney injury in the endosialin-deficiency (lacZ knock-in) and littermate wild 
type mice. Plasma levels of blood urea nitrogen and creatinine were analyzed at day 2,5 and 
10 after injury. We analyzed the cells expressing endosialin, tubulointerstitial injury, and 
specific cells by X-Gal staining, Periodic acid-Schiff staining and immunohistochemistry 
respectively.
Results: Positive X-Gal staining was shown in the glomeruli, small arteries and 
interstitial cells of the kidney. The capillary density determined by CD31 staining did not 
show significant difference between endosialin-deficiency and wild type mice. Nephrectomy 
and ischemia-reperfusion injury led to marked elevation of plasma blood urea nitrogen 
and creatinine in wild type mice, however the elevation of plasma blood urea nitrogen and 
creatinine was less in endosialin-deficiency mice at day 2 after injury. Interestingly the 
protective property of endosialin deficiency was lost since day5 after injury.
Conclusions: Endosialin-deficiency can attenuate acute kidney injury induced by 
ischemia-reperfusion injury, but the protective property is lost during the repair/regenerative 
phase after acute injury. The protective property of endosialin deficiency is not related to 
capillary density which has been shown increased in previous study. Further study needs 
to delineate the mechanism underlying the protective property of endosialin deficiency and 
why the protective property is lost during repair/regenerative phase.
Funding: Government Support - Non-U.S.
PUB019
The Mechanism of β2-Adrenergic Receptor /Protein Kinase A Signal 
Transduction Pathway in Restoration of Acute Kidney Injury by 
Endothelial Progenitor Cells  Ying Zhou, Chen Yu.  Dept of Nephrology, 
Tongji Hospital, Tongji Univ, Shanghai, China.
Background: Endothelial progenitor cells (EPCs) could improve renal 
microenvironment, stimulate endothelial repair and angiogenesis, and promote AKI 
restoration. However, the molecular mechanism has not been elucidated. In this study we 
investigated the role of β2-adrenergic receptor (β2 -AR) and its downstream factors (protein 
kinase A, protein kinase B, protein kinase C) in restoration of acute kidney injury by EPCs.
Methods: The model of ischemia-reperfusion acute kidney injury (I-R AKI) was 
used in vivo, while sham operation was performed in control group. Renal tissue was got 
after 7 days. Renal histology was measured by HE staining. The expression of β2-AR was 
examined using Q-PCR and immunofluorescence staining. The specific antigens on surface 
of EPCs(CD34,CD133 and VEGFR-2) were examined by Q-PCR; while VEGFR-2 was 
examined using immunofluorescence staining too. The downstream factors (PKA, PKB, 
PKC) were measured by Q-PCR and Western blotting.
Results: Renal histology suggested acute tubular necrosis, and β2-AR was positive by 
immunofluorescence staining in I-R AKI group; while neither appeared in control group. 
The mRNA levels of CD34,VEGFR-2,β2-AR and PKA were significantly up-regulated in 
I-R AKI group than in control group(p<0.05). The protein level of PKA was significantly 
higher expressed in I-R AKI group than in control group(p=0.04); while the protein 
levels of PKB and PKC were not.According to Pearson’s correlation analysis, there were 
significant positive-correlations between VEGFR-2 and CD34(p=0.005), VEGFR-2 and 
β2-AR(p<0.05), CD34 and β2-AR(p<0.05), β2-AR and PKA(p<0.05).
Conclusions: When I-R AKI occurred, the mRNA levels of specific antigens on surface 
of EPCs(CD34 and VEGFR-2) were significantly up-regulated, which suggested that I-R 
AKI might induce EPCs homing to kidney. At the same time, the mRNA levels of β2-AR 
and PKA were significantly up-regulated, and most of them were positive-correlated, which 
suggested that β2-AR/PKA pathway may play a role in the restoration of AKI by EPCs.
Funding: Government Support - Non-U.S.
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PUB020
Alpha Lipoic Acid and Dexamethasone Counteract Contrast Media-
Induced Proximal Tubule Cell Dysfunction  Hayriye Sayarlioglu,1 Ali 
Okuyucu,2 Abdulkerim Bedir,2 Osman Salis,2 Eser Yenen.2  1Dept of Nephrology, 
Ondokuz Mayis Univ Medical Faculty, Samsun, Turkey; 2Dept of Medical 
Biochemistry, Ondokuz Mayis Univ Medical Faculty, Samsun, Turkey.
Background: Contrast medium induced nephropathy (CIN) is one of the most 
common cause of hospital-acquired acute renal failure. But its pathogenesis is unclear. In 
this study, we observed the effect of iopromide, low osmolar contrast medium, on tubular 
cells in HK-2 cell line.
Methods: We observed the effect of iopromide, low osmolar contrast medium, on 
tubular cells in HK-2 cell line. First, we examined the effects of different doses of iopromide 
(10, 20, 40 and 80 mg/mL iodine) on proliferation of HK-2 cells by the real time cell 
analyser (RTCA). According to the results of RTCA we examined whether the non-toxic 
doses of iopromide (10 and 20 mg/mL iodine) is causing of the EMT by scratch assay for 
20 h. We also observed whether alpha lipoic acid (0,5 mM) and dexamethasone (5 µg/mL) 
is preventing to EMT in this assay.
Results: We observed whether alpha lipoic acid (0,5 mM) and dexamethasone (5 
µg/mL) is preventing to EMT in this assay. Although cytotoxic effect was observed for 
iopromide with concentration of 80 mg/ml iodine, the iopromide with lower doses did not 
show any effects for HK-2 cells. In scratch assay, we observed that the non-toxic doses of 
iopromide (10 and 20 mg/mL iodine) is causing of the cell migration which an indicator 
of EMT and lipoic acid and dexamethasone prevent the cell migration 
Conclusions: In conclusions, the EMT caused by contrast medium is prevented 
or reduced by dexamethasone and lipoic acid in HK-2 cells. This result suggest that 
dexamethasone and lipoic acid may be a potential treatment to prevent the development 
of CIN in individuals with high-risk.
PUB021
Contribution of Proliferating Endothelial Cells for Endothelial Repair 
After Site Specific Endothelial Injury of the Mouse Kidney  Jan Sradnick, 
Anika Luedemann, Vladimir T. Todorov, Christian Hugo, Bernd Hohenstein. 
Div of Nephrology, Dept of Internal Medicine III, Univ Hospital CGC, Dresden, 
Germany.
Background: Our previous studies have shown that renal endothelial cell regeneration 
occurs exclusively via local mechanism. To further dissect the relevance of local mechanisms 
for endothelial repair. we now investigated the contribution of local endothelial cell 
proliferation in the kidney in our model of site selective endothelial injury (ECI).
Methods: Selective ECI was induced in 9 out of 15 mice by renal arterial perfusion 
with ConcanavalinA (ConA)/anti-ConA, while 6 mice served as sham operated controls. 
Edu (15µg/g), a marker of proliferation, was injected starting 24hours after ECI every 
12hours intraperitoneally. Kidneys were harvested on day 7 and Edu+ cells were analyzed 
using flow cytometry and histology. Endothelial cells were stained using CD31, CD105, 
CD34 and CD146 and hematopoietic cells were detected as CD45+. Inflammatory cells 
(macrophages, dendritic cells and neutrophils) were analyzed via GR1, CD11c, CD11b 
and F4/80 positivity. By histology, proliferating EC were detected as anti-ERG/EdU 
double positive cells.
Results: Significantly more EdU+ cells could be detected after ECI on day 7 (sh: 
1.2%±0.7; ECI: 7.6%±4.8). Most of those EdU+ cells were positive for CD45 (65%±8) 
and 5% (sh) up to 7% (ECI) were positive for EC surface markers. In diseased kidneys 
more endothelial cells were found (sh: 5.5%±0.7; ECI: 7.3±0.5; p<0.01). A larger amount 
of EdU+ EC was found in injured kidney (sh: 1.5%±0.8 Ø160 cells; d7: 5%±1.5 Ø630 
cells p<0.01). Histological analysis supported these findings. Glomeruli of ECI kidneys 
had more ERG/EdU+ cells (Ø sh: 0.23±0.16; d7: 1.22±0.6; p<0.01). Inflammatory cells 
in injured kidneys were slightly increased. Many macrophages (21%±13), neutrophils 
(38%±17) and dendritic cells (19%±13) were EdU+.
Conclusions: Enhanced endothelial proliferation was detected following ECI. 
Thereforey EC proliferation reflects an relevant repair mechanism following site selective 
ECI. The further investigation of EC repair will have to dissect the contribution of the 
proliferative response by adult local EC from other contributors such as local progenitor 
cells.
PUB022
Injury of Proximal Tubular Cells in Neonate Rats with Hypoxic-Ischemia 
Brain Damage  Dong Li,1 Mei Han.2  1Pediatric Dept, The Second Affilliated 
Hospital od Dalian Medical Univ, Dalian, Liaoning Province, China; 2Pediatric 
Internal Medicine Dept, Dalian Children’s Hospital, Dalian, Liaoning  Province, 
China.
Background: Proximal tubular cells play a critical role in renal injury. To investigate 
the consequence of mitochondria in renal proximal tubular cells after hypoxic-ischemia 
brain damage (HIBD) in rats and the apoptosis in it.
Methods: Neonatal (7 days old) Sprague Dawley rats were randomly divided into 
2groups: sham group and operation group (n=5 per group). The Rice method was used for 
establishment of HIBD model, proximal tubular cells Mitochondria pathology and histology 
were examined under electron microscope at 1 day, 7days, 14days and 21days after the 
hypoxic-ischemic treatment, and apoptosis was analyzed by TUNEL.
Results: After the HIBD, the mitochondria of proximal tubular cells were showed 
damage under EM, some membrane and ridges were broken, the mitochondria bodies 
were swelling, and partial crista fragmentation were observed from the 1day till 21days 
after. And the 21days was the most worst for mitochondria under EM. For the TUNEL, 
after HIBD, it showed significant increased for 1day, 7days, 14days and 21days groups 
comparing with sham group. (p<0.05).
Conclusions: After the hypoxic and ischemic brain injury of neonate rats, the 
mitochondria were damaged in proximal tubular cells, even in 21days after HIBD. And 
the apoptosis maybe one of the causes of this damage.
Funding: Government Support - Non-U.S.
PUB023
Ex-Vivo Normothermic Perfusion (EVNP) to Repair Monoethylene Glycol 
Toxicity in Human Kidneys  Ivonne Palma,1 Sasha Karan Narayan,1 Ivania 
Palma,1 Rajendra Ramsamooj,2 Junichiro Sageshima,1 Jakub Woloszyn,1 Nam 
Tran,2 Chandrashankar Santhanakrishnan,1 Richard V. Perez.1  1Surgery, Univ 
of California-Davis, Sacramento, CA; 2Pathology and Laboratory Medicine, 
Univ of California-Davis, Sacramento, CA.
Background: Monoethylene glycol (MeG), a component of radiator fluids, results in 
crystal-induced acute kidney injury, hypocalcemia and often death, if ingested. Utilization 
of kidneys from deceased donors with MeG poisoning may not be suitable for transplant. 
EVNP may be utilized to potentially assess/repair high-risk kidneys in this setting.
Methods: A pair of transplantable human kidneys from a brain dead 38 year old 
female suicide victim from MeG poisoning were discarded due extensive intratubular 
crystal deposition. The kidneys were placed on 3 hours of EVNP with leukocyte depleted 
packed red blood cells at 37°C. Oxygenation via a hollow fiber membrane oxygenator 
supplemented with parenteral nutrition/insulin. One kidney was given Furosemide (10 mg) 
at the beginning to induce diuresis and assess acute kidney injury. Hemodynamic pump 
parameters and urine output were monitored. Blood and urine samples were collected at 
the start and every 30 minutes and analyzed for pH, oxygen, electrolytes, creatinine, and 
lactate. Wedge biopsies were collected pre & post perfusion & stained with alizarin red to 
measure calcium oxylate tubular deposition.
Results: Blood flow and resistance improved over time in both kidneys. EVNP reduced 
calcium deposits compared to baseline wedge biopsies. Kidney treated with furosemide 
showed slightly better hemodynamic profile and fewer crystals after EVNP. 
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Conclusions: EVNP may have the potential to repair MeG acutely injured kidneys 
rendering them suitable for transplantation. Ex vivo administration of furosemide may be 
a useful tool to assess injured deceased donor kidneys being considered for transplantation.
PUB024
Abstract Withdrawn
PUB025
Transfusion of Red Blood Cell as Predictor of Acute Kidney Injury in 
Patients Undergoing Cardiac Surgery  Eduesley Santana-Santos, Luiz 
Aparecido Bortolotto, Ludhmila Abrahão Hajjar.  ICU-Cardiac Surgery 
Postoperative Care, Heart Inst (InCor) Inst do Coração do Hospital das Clínicas 
da Faculdade de Medicina da Univ de São Paulo, São Paulo, Brazil.
Background: The red blood cell transfusion in the perioperative period of cardiac 
surgery have been associated with acute kidney injury. Our purpose was to analyze the 
influence of transfusion of red blood cell in the incidence of acute kidney injury after 
cardiac surgery.
Methods: We performed a prospective cohort study carried out in a tertiary hospital 
specialized in Cardiology. Adult patients who had undergone elective myocardial 
revascularization surgery, valvular and aortic surgery and who had agreed to participate in 
the study were included. The primary endpoint was acute kidney injury defined by KDIGO 
criterion. Secondary outcomes was serious clinical complications defined according to the 
guidelines of the Society of Thoracic Surgeons.
Results: According to KDIGO criterion, the incidence of AKI was 46.5%. The mean 
age was 60±12 years old in the AKI group and 58±13 in the no AKI group (p=0 .145), 
and mostly male (56%). The surgical risk assessed by EuroSCORE was greater in the AKI 
Group 5 (1-25) when compared to the no AKI group 4 (2-10), (p=0.047). There were no 
differences between the groups for the secondary outcomes. The use of red blood cells in 
the perioperative period (OR=3.166, p=0.001) and the presence of prior chronic kidney 
disease (CKD) (OR=2.027, p=0.036) was associated with AKI postoperatively.
Variable OR CI (95%) p (value)
Age, years 1.486 0,990 – 1,043 0,223
Cardiac Heart Failure 2,549 0,116 – 1,247 0,110
Male gender 0,661 0,395 – 1,469 0,416
Chronic Kidney Disease 2,027 1,406 – 3,052 0,036
Red Blood Cell Trasnfusion 3,166 1.572 – 6.380 0,001
Use of Cardiopulmonary Bypass 0,841 0,308 – 2,296 0,736
During the period of hospitalization the mortality rate was 6.9%. When we compare 
the mortality rate between the groups it was 4.3% in the no AKI Group and 10% in the 
AKI Group (p=0.229).
Conclusions: In our study the use of perioperative red blood cells influenced the 
primary outcome. Patients who had used red blood cells had 3 times more risk of AKI.
Funding: Government Support - Non-U.S.
PUB026
A Picture Is Worth a Thousand Words: Simultaneous ATN, AIN, and Post 
Infectious GN  Ankur Shah,1 Rachel Criner,1 Jean Lee.2  1Internal Medicine, 
Temple Univ Hospital, Philadelphia, PA; 2Nephrology, Temple Univ Hospital, 
Philadelphia, PA.
Background: The differential diagnosis of hospital acquired acute kidney injury 
in its most general terms often is described as pre-renal, intrinsic ,or post-obstructive. 
Further differentiating the intrisnsic causes of AKI, we are given the differential of Acute 
Tubular Necrosis, Acute Interstitial Nephritis, and Glomerulonephritis. We present a case 
of a patient who presented with sepsis and developed acute kidney injury whose biopsy 
revealed a plethora of pathology.
Methods: We present a case of a 54 y/o male with a pmhx of only HTN and DJD who 
presented with leg pain and weakness for 2 weeks and hematuria found to be bacteremic 
with MSSA with L spine epidural abscess and bilateral psoas muscle abscesses. He 
developed acute kidney injury thought clinically and based on microscopy to be secondary to 
hypotensive acute tubular necrosis and was started on hemodialysis on HD6.  He was being 
treated with cefazolin and over weeks had minimal return of renal function, the differential 
diagnosis was revisited and concern for AIN from the penicillin agent was raised, the patient 
was switched to Daptomycin, but remained RRT dependent. After 25 days on hemodialysis, 
a biopsy was obtained which revealed diffuse interstitial inflammation with eosinophils, 
focal mild-moderate tubular injury with vacuolization, as well as by electron microscopy, 
subepithelial deposits but not subendothelial deposits,most of which are largely absorbed, 
including in “notch” areas. These findings are consistent with an acute post-infectious 
glomerulonephritis, resolving stage; drug induced acute interstitial inflammation, as well 
as mild-moderate focal tubular injury.
Conclusions: This case demonstrates a variety of the potential causes of AKI. The 
patients course was long and provided multiple opportunities for re-evaluation and a 
return to the differential diagnosis process. This is an excellent case for the teaching of 
the fundamentals of medicine, as the differential diagnosis is truly the instrument of the 
master clinician. This patients aberrance from the expected course prompted reevaluation 
and his pathology was staggering.
PUB027
Monitoring and Follow-Up of Acute Kidney Injury Post-Discharge: 
Retrospective Case Review Series  Kosmas Papailiadis,1 Judith H. Veis.2 
1Medicine, Washington Hospital Center, Washington, DC; 2Nephrology, 
Washington Hospital Center, Washington, DC.
Background: AKI during hospitalization increases risk of progression to CKD and 
death upon discharge. Recent KDIGO guidelines suggest patients should be evaluated 
3 months after AKI for resolution, new onset, or worsening of pre-existing CKD. We 
determined factors associated with whether patients with AKI had kidney function assessed 
3 months post-discharge.
Methods: Restrospective chart review of hospitalizations in 2013 complicated by AKI, 
who had follow-up in Ambulatory Medical Clinic to assess discharge communication; 
serum Cr, urine protein:Cr at 3 and 4-9 months; 1 year outcomes including progression to 
CKD, death and referral to nephrology.
Results: 77 inpatients with AKI (48(66%) stage 1, 9(12%) stage 2, 20(26%) stage 3; 
and 6(8%) requiring RRT) had a post-discharge visit. Of these, 51(66%) had serum Cr and 
16(21%) had urine protein:Cr checked by 3 months. For 4-9 months, 13(17%) had serum 
Cr and 5(6%) had urine protein:Cr checked; 3(4%) were deceased by 1 year. 26(34%) had 
normal kidney function pre-AKI and of this group, 10(38%) had CKD by 1 year. Of these 
26, only 5(19%) were referred to nephrology. For documentation, 54(77%) had AKI as 
a problem in the inpatient hospital summary, 42(54%) had AKI documented in the brief 
outpatient hospital summary and 29(41%) had AKI addressed in the follow-up visit. There 
was no significant association between AKI severity, need for RRT, or documentation 
with checking kidney function by 3 months nor between AKI inpatient documentation 
and addressing AKI at follow-up (p<0.05). There were significant associations between 
addressing AKI at follow-up and checking kidney function; p=0.043 and between AKI 
stage and addressing AKI at follow-up; p=0.022 and between AKI outpatient summary 
and addressing AKI at follow-up; p=0.004.
Conclusions: Outpatient follow-up of inpatient AKI is inconsistent despite evidence 
of poorer outcomes and recent guidelines which suggest the need for closer monitoring. 
Improving transitions of care through more effective documentation and streamlined 
EMRs, as well as increasing primary care physician awareness could reduce the risk of 
progression to CKD and death.
PUB028
Late Recovery of Renal Function in Atypical Hemolytic Uremic Syndrome 
(aHUS) After Eculizumab Therapy  Jeffrey D. Clement, Delin Wang, Maoyin 
Pang, Tanmay Sahai, Keith R. Bartolomei.  Roger Williams Hospital.
Methods: A 33-year-old woman with hypertension and left renal agenesis presented 
with fever and acute kidney injury with serum creatinine of 2.1 mg/dL. Initially, 
hemoglobin was 11.3 mg/dL and platelets 193,000/ul. Over the next three days platelets 
dropped to 55,000/ul and LDH rose to 770 U/L; renal function worsened. Thrombotic 
microangiopathy was suspected. Stool culture was negative. Urine protein was 6.8 g per 
24 hours. Serologic assessment, including C3, C4, ANA, ANCA, HIV, cryoglobulins, 
dsDNA, lupus anticoagulant, anticardiolipin antibodies, and β-2-glycoprotein I antibodies, 
was unremarkable. The patient was treated with cryo-poor plasma exchange and steroids. 
Hemodialysis was started for uremia. ADAMTS13 was 67% of normal. Renal biopsy 
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showed acute thrombotic microangiopathy, acute tubular injury, and moderate interstitial 
fibrosis. The presentation suggested the diagnosis of aHUS. Eculizumab, an anti-C5 
antibody, was initiated at 900 mg weekly for four weeks followed by 1200 mg every two 
weeks. Eculizumab therapy resulted in resolution of hemolysis. Dialysis was continued 
thrice weekly. Eculizumab was continued every two weeks, and LDH and platelet counts 
remained normal. Twelve months after initial presentation urine output improved and 
interdialytic weight gains were negligible. Pre-dialysis serum creatinine was 3.9 mg/dL, 
and a urine collection showed creatinine clearance of 30 ml/minute. She has remained 
off dialysis for twenty weeks, and latest serum creatinine is 3.4 mg/dL. Screening for 
complement genetic defects has been negative.
Conclusions: Experience with eculizumab is ongoing. Most patients with aHUS have a 
rapid hematologic response. If they need dialysis, then recovery of renal function is usually 
prompt; late recovery is rare. We hypothesize that sustained control of complement activation 
has eliminated the microangiopathy and allowed for vascular remodeling and tubular 
regeneration, even months later. Patients are at risk for relapse if they stop treatment. This 
case points out that the presumed genetic defect may require lifelong treatment, and that 
late recovery of renal function is possible with complement inhibition and supportive care.
PUB029
The Effectiveness of Theophylline in Preventing Cisplatin Related 
Nephrotoxicity in Patients with Cancer  Ismail Kocyigit,1 Derya Karademir,1 
Fatma Dogruel,1 Cevat Yazici,2 Aydin Unal,1 Murat H. Sipahioglu,1 Oktay 
Oymak,1 Bulent Tokgoz.1  1Nephrology, Erciyes Univ Medical School, Kayseri, 
Turkey; 2Biochemistry, Erciyes Univ Medical School, Kayseri, Turkey.
Background: Cisplatin is a potent antineoplastic agent used in treatment of many 
solid tumors. The major limiting side effect of cisplatin is nephrotoxicity. Theophylline is a 
competitive antagonist of adenosine which has antiinflammatuar activity. In this study, early 
detection of acute kidney injury with biomarkers such as neutrophil gelatinase associated 
lipocalin (NGAL) and cystatin C and investigation of the potential nephron-protective 
effects of theophylline were aimed.
Methods: Sixty patients who are planned administration of cisplatin for the first time 
were included in the study. Patients were divided into two groups as group 1 (n=30) (standard 
treatment arm) and group II (n=30) (theophylline arm). Glomerular filtration rate (GFR), 
NGAL, cystatin C were measured at 5th day in all of the patients. Also, these parameters 
were repeated measured after the administration of cisplatin, at 2nd hour, 5th and 20th days.
Results: In both groups after the administration of cisplatin, glomerular filtration rate 
(GFR) showed a significant decrease within time (p=0.006). In creatinine, in spite of the 
decline in GFR, no significant difference was observed between groups and within time. 
After 2 hours of cisplatin administration, in spite of the decline in GFR, a significant decline 
was detected in serum cystatin C (p<0.001). Urine NGAL was significantly high after 2 
hours of cisplatin administration (p<0.001). No significant difference was observed between 
groups. However, when the time*group effects were considered together, higher NGAL 
was detected in the group not receiving theophylline (p=0.025). After 5 days of cisplatin 
administration, urine protein levels were significantly higher in both groups (p<0.001).
Conclusions: Results showed that urine NGAL level is a superior biomarker compared 
to creatinine and cystatin C in the detection of early acute kidney injury. Theophylline 
was found not to bring a complete protection for the kidneys, but less nephrotoxicity was 
developed when compared to the group not receiving theophylline.
PUB030
IgA Nephropathy Presenting as RPGN After G-CSF Administration: An 
Interesting Case  Talal A. Khan,1 Ahmad Hassan,2 Agha Syed Shabbir Ali,2 
Hafiz Armaghan Saeed,2 Abdul Mateen Nagaria,1 Azka Arif.1  1Freeman Health 
System; 2Rawalpindi Medical College.
Background: IgA nephropathy is the most common form of primary glomerulonephritis 
& a major cause of ESRD in the world, its pathogenesis involves lymphocyte infiltration 
within renal interstitium as well as glomerulus. Selectins are adhesion molecules that play 
very important role in leukocytes to endothelial cell attraction. G–CSF is commonly used 
to induce neutrophil production .It induces E-selectin expression on endothelial cells & E 
selectin ligand on leukocytes. We present an interesting case of IgA nephropathy presenting 
as RPGN after G-CSF administration.
Methods: 66-year-old male with past medical history significant for T-cell leukemia 
on Cyclophosphamide(CYC) who presented with epistaxis was found to have acute 
agranulocytosis, he was admitted for further evaluation and management ,his CYC was 
held & on the day of discharge he was given 1 dose of G–CSF. He presented in 2 days 
with acute renal failure, gross hematuria & rash in his lower extremities, his creatinine 
went up from 1.3 to 5.1mg/dl. He was evaluated by nephrology service, and emergent renal 
biopsy was performed which showed rapidly progressive glomerulonephritis (RPGN) with 
IgA deposition in mesangium. Glomeruli showed diffuse mesangial hypercellularity and 
matrix increase with focal nodule formation. 3/17 Glomeruli had epithelial crescents & 
focal necrosis with fibrin deposits. The sections were stained for IgG, IgM, IgA, C3, C4, 
C1q, albumin, fibrinogen, & kappa and lambda light chains. There were mesangial granular 
deposits with IgA (3+), C3 (1+), lambda (1+); kappa was negative. The remaining stains 
showed no significant deposits. Patient underwent induction with CYC and pulse steroids, 
his creatinine improved to 1.4mg/dl.
Conclusions: The pathogenesis of IgA nephropathy involves E selectin interactions, 
which are induced by G-CSF administration. In our case development of RPGN with 
IgA nephropathy might be linked to G-CSF administration especially with the timeline 
of presentation. IgA nephropathy has not been linked to G-CSF administration before in 
adults, we suggest underlying complex genetic predisposition.
PUB031
Minute Ventilation-Targeted Adaptive Servo Ventilation Protects Renal 
Function in Acute Decompensated Heart Failure Patients  Matt Kawahara,2 
Trenton Gluck,2 Elizabeth Lee,2 Boris Arbit,1 Kathleen Sarmiento,3 Atul 
Malhotra,3 Alan S. Maisel.1  1Div of Cardiovascular Medicine, Univ of 
California, San Diego, La Jolla, CA; 2Cardiac Research, VA San Diego 
Healthcare System, La Jolla, CA; 3Div of Pulmonary and Critical Care Medicine, 
Univ of California, San Diego, La Jolla, CA.
Background: Acute kidney injury (AKI) in patients admitted for acute decompensated 
heart failure (ADHF) carries a poor prognosis. Minute ventilation-targeted adaptive servo 
ventilation (MV-ASV) therapy relieves apneas and renal hypoxia. Serum creatinine (Cr) 
and estimated glomerular filtration rate (eGFR) are markers that signal kidney injury and 
improvement of kidney function. MV-ASV may mitigate kidney injury and improve renal 
function in patients admitted with ADHF compared to standard therapy.
Methods: This is a study where twenty-one patients with ADHF were randomized to 
receive either MV-ASV therapy (S9 VPAP Adapt, ResMed Corp.) with standard care, or 
standard care alone. MV-ASV therapy was administered for a minimum of six hours per 
day for up to 5 days, or until discharge. Cr was measured daily and used to calculate eGFR.
Results: The median baseline Cr levels in the MV-ASV and standard groups were 
1.09mg/dL and 1.08mg/dL, respectively. After therapy, Cr levels were unchanged in the 
MV-ASV group and increased by 0.34 mg/dL (31.5%) in the standard care group. The 
median baseline eGFR levels in the MV-ASV and standard groups were 70.5mg/dL and 
64mg/dL, respectively. Upon completion of therapy, the eGFR levels in the treatment group 
increased by 22.5mg/dL (32%) and decreased in the control group by 15mg/dL (23%).
Conclusions: MV-ASV therapy in patients with ADHF stabilizes Cr levels during a 
period of aggressive diuresis. MV-ASV may be a valuable for renal protection and could 
improve kidney function in patients with ADHF.
Funding: Pharmaceutical Company Support - Resmed
PUB032
Evaluation of Acute Kidney Injury in Patients Continued on Renin-
Angiotensin System Blockers During Hospitalization  Numan Alabdan,1 
Elvira Gosmanova,1,2 Carrie Oliphant,1,2 Joyce E. Broyles,1,2 Pan Hu,2 Quynh 
Tran,2 Joanna Hudson.1,2  1Methodist Univ Hospital, Memphis, TN; 2Univ of 
Tennessee Health Science Center, Memphis, TN.
Background: Acute kidney injury (AKI) occurs in over 20% of hospitalized patients 
and is associated with adverse outcomes. Whether continuation of angiotensin converting 
enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) during hospitalization 
increases the risk of AKI has not been fully assessed. We evaluated the development of AKI 
and its associated risk factors in patients continued on ACEIs/ARBs in the inpatient setting.
Methods: This was a retrospective cohort study that included adult patients who were 
continued on ACEIs/ARBs within 24 hours of hospitalization. Patients who developed 
AKI within 48 hours of admission or received cancer treatment were excluded. AKI was 
defined using KDIGO criteria. Risk factors for AKI were compared between the AKI and 
non-AKI groups.
Results: Among the 184 patients included, 92 patients developed AKI (age 66±13 
yrs (mean±SD), 52% male, 54% Black). Patients with AKI had a higher baseline serum 
creatinine (1.2±0.4 vs. 1±0.4 mg/dL, p<0.001), a lower eGFR (54±10 vs. 56±7mL/
min/1.73m2, p=0.03), and were more likely to have a diagnosis of CKD (40% vs.14%, 
p<0.001), an ICU stay (44% vs. 17%, p<0.001), a surgical procedure (34% vs. 14%, 
p<0.001), hypotension (24% vs. 2%, p<0.001), and concomitant loop diuretic therapy 
(52% vs. 36%, p=0.03). The AKI group had a longer length of stay (14±11 vs. 8±3 days, 
p<0.001) and a higher rate of all cause hospital mortality (8% vs. 1%, p=0.03). Factors 
associated with a significant increase in risk of AKI in the multivariable analysis were CKD 
(OR=4.3, 95% CI 1.6-9.3, p<0.001), hypotension (OR=14.2, 95% CI 3.1-65.0, p<0.001), 
and surgical procedures (OR=3.5, 95% CI 1.6-7.9, p<0.001).
Conclusions: Continuation of ACEIs/ARBs during hospitalization may increase the 
risk of AKI in select patients. Temporary discontinuation of ACEIs/ARBs may be warranted 
during hospitalization in patients with CKD, hypotension, or planned surgical procedures.
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Serum Neutrophil Gelatinase-Associated Lipocalin: A Novel 
Biomarker for Prediction of AKI Development in Critically Ill Patients 
Magdy M. Elsharkawy, Abdel Rahman Khedr, Amr Mohab, Haitham Ezzat. 
Nephrology, Ain Shams Univ, Cairo, Egypt.
Background:  Acute kidney injury (AKI) is a frequent complication in critically ill 
patients and is associated with high morbidity and mortality; therefore, its prophylaxis, 
diagnosis and intervention positively impact patient evolution.Neutrophil gelatinase-
associated lipocalin (NGAL) is thought to be a novel biomarker of AKI of several etiologies 
and is increased in both serum and urine before the increase of serum creatinine.
Methods: A prospective cohort study was conducted on 100 critically ill patients in ICU. 
Patients were stratified into 2 groups based on AKI development. Group I which included 50 
patients who did not develop AKI, and group II which included 50 patients who developed 
AKI. AKI was defined based on acute kidney injury network (AKIN) classification.The 
Sequential Organ Failure Assessment (SOFA) scores were also calculated for all patients.
Detailed medical history, demographic data and routine laboratory investigations were 
done. Serum NGAL was measured upon admission to ICU and upon AKI development.
Results: 60 males and 40 females were included in the study with mean age 37.52 years. 
As regards risks of AKI development, 9% of patients had sepsis, 15% were dehydrated, 
11% had contrast exposure, 12% had rhabdomyolysis, 29% had shock and 24% had history 
of NSAID intake recently. On admission, there were no significant differences between 
the patients as regards s.creatinine, hemoglobin level and other laboratory parameters 
(p> 0.05). Serum levels of NGAL were significantly higher in group II, before AKI 
development, with mean value 958.5 ng/ml, when compared with group I, mean value 
272.17 ng/ml (p<0.01). Serum NGAL levels were significantly higher in group II after AKI 
development when compared with the levels before AKI development in the same group 
(1660.35 ng/ml) (p<0.01). There was no significant correlation between NGAL levels and 
AKIN classification stages.
Conclusions: In the absence of diagnostic increases in serum creatinine, NGAL detects 
patients with likely subclinical AKI who have an increased risk of adverse outcomes. 
Reassessment of AKI classification and stages should be considered.
PUB034
Does Previous CKD Affect Renal Recovery After Acute Kidney Injury? 
Maria Isabel Acosta-Ochoa, Josefina Martin, Alicia Mendiluce.  Nephrology, 
Hospital Clinico Univ, Valladolid, Spain.
Background: AKI definition includes a sharp increase of serum creatinine (SCr), 
essentially reversible. There is a lack of consensus of a standard definition of Renal 
Recovery (RR). The exact course of the repair process is subject of thorough investigation. 
Few studies have engaged in comparing rates of RR in patients with previous impaired 
vs. normal renal function.
Methods: Retrospective cohorts study, 12-months period. We defined RR as discharge 
SCr with maximum increment £25% over basal value, and non recovery as ³26%, HD 
persistence, and death. We studied 2 groups: AKI and Acute on Chronic Kidney Disease 
(AoCKD). We tested epidemiological features, Charlson Index (ChaI), and KDIGO stage. 
We plotted a Kapplan-Meier survival curve 24 moths post-discharge.
Results: 270 patients, AKI=125, AoCKD=145, clinical features and KDIGO stages: 
see table 1.
Features AKI (N=125) AoCKD (N=145) P Value
Male (%) 77 (62) 98(68) 0,30
Age (SD) 66.9 ± 15 75.4 ± 11.9 <0.001
HT (%) 96 (77) 131 (90) <0.001
DM (%) 44 (35) 70 (48) 0.003
ChI (SD) 3.8 ± 2.5 4.4 ± 2.3 <0.001
KDIGO 
Stage1 (%) 43 (34) 47 (32) 0,19
Stage2 (%) 17 (14) 16 (11) 0,52
Stage3 (%) 65 (52) 82 (57) 0,45
Results
RR (%) 44 (35) 51 (35) 0,99
HD Dependence (%) 1 (1) 7 (5) 0.05
Mortality (%) 21 (17) 38 (26) 0,06
65% were males, AoCKD were older 66,9y, worst ChaI 4,4. In AKI group 35% met RR 
criteria, 1% were HD dependent and 17% died. AoCKD group 35% recovered, 26% died, 
5% were HD dependent at discharge P=0.05. Kaplan-Meier curves show a worst survival 
in the KDIGO Stage 2 for AKI and Stage 3 in the AoCKD group.
Conclusions: In spite of older age and worst ChaI AoCKD cohort recovered similarly 
with the AKI group, except for HD dependence at discharge. The finding that KDIGO Stage 
2 means worst medium term survival for the AKI group needs further study.
PUB035
The Effect of Nebivolol on Contrast-Induced Acute Kidney Injury: A 
Meta-Analysis  Natanong Thamcharoen,1 Charat Thongprayoon,1 Wisit 
Cheungpasitporn.2  1Dept of Medicine, Bassett Medical Center and Columbia 
Univ College of Physicians and Surgeons, Cooperstown, NY; 2Div of Nephrology 
and Hypertension, Dept of Internal Medicine, Mayo Clinic, Rochester, MN.
Background: Nebivolol provides protective effect on contrast-induced acute kidney 
injury (CIAKI) in animal models. However, the reports on the efficacy of nebivolol for the 
prevention of CIAKI in human remain unclear. The objective of this meta-analysis was to 
assess the effect of nebivolol for the prevention of CIAKI.
Methods: Comprehensive literature searches were performed using MEDLINE, 
EMBASE, and Cochrane Database from inception through February 2015. Studies that 
reported relative risks, odd ratios or hazard ratios comparing the risk of CIAKI in patients 
who received nebivolol versus those who did not were included. Pooled risk ratios (RR) 
and 95% confidence interval (CI) were calculated using a random-effect, generic inverse 
variance method.
Results: Four studies (2 RCT and 2 cohort studies) with 543 patients were included 
in our analysis to assess the risk of CIAKI and the use of nebivolol. Of 543 patients with 
contrast exposures, 30 patients (5.32%) had CIAKI. Patients in the nebivolol group had an 
overall lower incidence of CIAKI (14.35%) compared to the control group (17.43%). The 
pooled RR of CIAKI in patients receiving nebivolol was 0.66 (95% CI, 0.38-1.1.15, I2 = 0).
When meta-analysis was limited only to RCTs, the pooled RR of CIAKI in patients 
receiving nebivolol was 0.79 (95% CI, 0.35-1.79, I2=0%).
Conclusions: Despite no statistical significance, there was a trend toward reduced 
CIAKI risk in patients receiving nebivolol. This finding suggests the need of further 
studies on the use of nebivolol in addition to standard IV crystalloid hydration in the 
prevention of CIAKI.
PUB036
Patients with Cardiovascular Diseases Are Susceptible to Acute Kidney 
Injury After Non-Cardiac Surgery Under Preoperative Use of Angiotensin 
Converting Enzyme Inhibitors or Angiotensin Receptor Blockers 
Miho Tagawa,1 Takayuki Hamano,2 Masaru Matsui,1 Katsuhiko Morimoto,1 
Ken-ichi Samejima,1 Yasuhiro Akai,1 Yoshihiko Saito.1  1Nara Medical Univ, 
Nara, Japan; 2Osaka Univ, Osaka, Japan.
Background: It is unknown in which subgroups of patients the preoperative use of 
angiotensin converting enzyme inhibitors(ACE-I) or angiotensin receptor blockers(ARB) 
is a predictor for acute kidney injury(AKI) after non-cardiac surgery.
Methods: This is a retrospective cohort study on patients who underwent non-cardiac 
surgery from 2007 to 2009. After exclusion of urological surgery, missing creatinine 
values, and preoperative dialysis, the data for 2,725 patients were available. The exposure 
of interest was preoperative use of ACE-I/ARB. Primary outcome was postoperative 
AKI(AKIN criteria). The odds ratio(OR) of postoperative AKI among ACE-I/ARB users 
compared to non-users was analyzed using multivariable logistic regression models, adjusted 
for the logit of propensity score for ACE-I/ARB use. P<0.1 was considered statistically 
significant for interaction.
Results: Mean(SD) age was 61(16) and estimated glomerular filtration rate was 81(24) 
ml/min/1.73m2. There were 40/460(8.7%) cases of postoperative AKI in ACE-I/ARB users 
and 97/2,265 (4.3%) in non-users. The addjusted OR of AKI were shown. 
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History of cardiovascular diseases(CVD) (either coronary artery disease, stroke, 
peripheral arterial disease, atrial fibrillation, or left ventricular ejection fraction<40%) was a 
significant effect modifier for the association of ACE-I/ARB and AKI (p for interaction 0.07). 
The OR(95% CI) of AKI among ACE-I/ARB users was 1.70(0.73-3.93) and 0.72(0.42-1.24) 
in patients with CVD and without CVD, respectively.
Conclusions: ACE-I/ARB use was associated with higher OR of AKI in patients with 
prior CVD compared to patients without, suggesting that patients with CVD are more prone 
to AKI with the use of ACE-I/ARB.
PUB037
Whole Ischemia-Reperfusion Injury: The Effect of Whole-Body Cooling on 
Renal Function  Silvia De Rosa,1 Zaccaria Ricci,3 Salvador Roberto Lopez,1 
Jose Luis Salas,1 Stefano Marcante,1 Sara Samoni,1 Massimo de Cal,1 Silvia 
Maria Pulitano,2 Massimo Antonelli,2 Raffaele Bonato,1 Claudio Ronco.1 
1IRRIV; 2Intensive Care Unit, UCSC, Rome; 3Paediatric Cardiac Intensive 
Care Unit, OBG, Rome.
Background: Hypothermia is able to reduce the risk of renal failure after renal 
ischemia-reperfusion injury in animals.In humans,Cardiac Arrest(CA),a whole-body 
ischemia-reperfusion syndrome,causes warm renal ischemia-reperfusion injury,similar to 
animal models of ischemic acute kidney injury(AKI).Induced hypothermia(IH)is a treatment 
potentially efficacious for post-ischemic injury.It is unclear what effect could have on renal 
function.The aim of the study was to investigate the development of AKI during the IH.
Methods: Between Jan2013-Mar2015,we performed a prospective observational study 
of 36comatose pts resuscitated from CA and treated with IH performed with 2differents 
surface cooling devices:1)Arctic Sun Temperature Management System(Medivance,Lo
uisvilleCO);2)Blanket.Temperature rate and trend,and the development of AKI during 
induction(0-6hrs),maintainance(24hrs),rewarming(48hrs)and normothermia(72hrs)was 
assessed with RIFLEandKDIGO criteria.
Results: Pts were enrolled and followed for the development of AKI during intensive 
care unit stay.In the induction and maintaince phases,the rate and the target temperature 
was similar;conversely,the rewarming phase was shorter with a target temperature higher 
in Blanket than in ArticSun group(458 minvs615 min;37.2°Cvs36.3).The trend and the rate 
of temperature,but also the development of AKI is showed in figure 1.
Conclusions: IH could be associated with development of AKI in the rewarming 
phase(rate 0.25 to 0.5 °C).The optimal rewarming rate is unknown.Randomized controlled 
trials are needed to determine the real effect of temperature on kidney,the optimal rewarming 
strategy and applications of this treatment for kidney in other settings.
Funding: NIDDK Support
PUB038
Decongestion-Associated Worsening Renal Function Does Not Increase 
Mortality of Patients with Acute Heart Failure  Girish Singhania, Kawther 
Farouk Alquadan, Amir Kazory.  Nephrology, Univ of Florida, Gainesville, FL.
Background: A significant subset of patients admitted for acute decompensated 
heart failure (ADHF) develop worsening renal function (WRF). While there is consistent 
data regarding the negative impact of baseline renal dysfunction on the outcomes of 
these patients, the evidence on the prognostic implication of WRF during admission for 
decongestion is less well-understood. The aim of this study is to provide a reappraisal of 
the effect of decongestion on the prognostic value of WRF in patients admitted for ADHF.
Methods: Articles cited in PubMed database from 1995 to 2015 using key 
words”congestion”, “heart failure”, “worsening renal function”, and “hemoconcentration” 
were searched. Those studies evaluating the relationship between decongestion, renal 
function, and ADHF in patients treated with diuretic-based conventional therapies were 
selected. Ultrafiltration trials were excluded. Relevant data including change in renal 
function, diuretic dose, change in weight, and mortality were extracted and compared.
Results: A total of 12,843 patients from 13 trials (9 retrospective and 4 prospective) 
with data pertaining to decongestion in ADHF patients were included in this study. The 
mean age of the patients was 67.1 years with follow up periods ranging from 60 days to 
5.3 years. Eleven studies reported development of WRF following decongestion. The 
incidence of WRF was reported to be 10 to 50.1% with weight reduction ranging from 2 
to 5.4 kg. Twelve studies did not observe any negative impact for WRF on the mortality 
of patients with ADHF unless associated with markers of persistent congestion such as 
lack of hemoconcentration.
Conclusions: Decongestion is associated with markers of fluid removal and WRF in 
the setting of ADHF. Currently available data suggest that decongestion-associated WRF 
does not result in increased mortality whereas persistent congestion is likely to be the 
driving factor for adverse outcomes in these patients. Randomized controlled trials are 
needed to confirm these findings as they could portend significant therapeutic implications 
in cardiorenal syndrome.
PUB039
A 13-Year Mayo Clinic Retrospective Study of the Syndrome of Rapid 
Onset End Stage Renal Disease (SORO-ESRD) in an Incident Hemodialysis 
Cohort  Macaulay A. Onuigbo,1,2 Nneoma Agbasi,1 LaTonya J. Hickson.3 
1Medicine, Mayo Clinic College of Medicine, Rochester, MN; 2Nephrology, 
Mayo Clinic Health System, Eau Claire, WI; 3Psychiatry Nursing, North East 
London NHS Foundation Trust, London, United Kingdom.
Background: We first described the syndrome of rapid onset end stage renal disease 
(SORO-ESRD) in 2010 - acute yet irreversible ESRD after AKI. However, its overall impact 
on ESRD outcomes in the general US ESRD population remains speculative.
Methods: A retrospective examination of SORO-ESRD among the incident Mayo 
Clinic ESRD population, 2001-2013 was completed in November 2014.
Results: 149 of 1461 (10%) incident ESRD patients had SORO-ESRD – M:F = 76:73, 
mean age 62 years (19-95), 139 (93%) native kidneys, 10 (7%) kidney transplant recipients 
(RTRs). Ninety-nine percent of SORO-ESRD patients’ initial vascular access was a dialysis 
catheter. Kidney biopsy - the commonest pathologic diagnoses were acute tubular necrosis 
(ATN) in 3 (25%) KTRs and in 7 (21%) native kidneys. Cardiac arrest was the leading 
cause of death in SORO-ESRD. 
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Conclusions: Among 1461 incident ESRD patients seen at Mayo Clinic Dialysis 
Services, Rochester, 2001-2013, 149 (10%) had SORO-ESRD. There was no gender nor age 
disparity between SORO-ESRD patients and the general ESRD cohort. Ninety-nine percent 
(99%) SORO-ESRD patients’ initial vascular access was a dialysis catheter. ATN was the 
leading pathologic diagnoses for AKI among KTRs and in native kidneys. Cardiac arrest 
was the leading cause of death in SORO-ESRD, similar to the general ESRD population. 
We conclude that SORO-ESRD contributes significantly to incident ESRD here in the 
USA both among KTRs and in native kidneys. Furthermore, it negatively impacts on the 
success of AVF-First Programs. Efforts to mitigate AKI in CKD patients must be given more 
attention and priority by practicing nephrologists in particular, and by physicians in general.
PUB040
Saline-Induced, Diuretics-Responsive Acute Renal Failure (ARF): Evidence 
that Anasarca Is Nephrotoxic and Diuresis Is Therapeutic  Grant Meltzer,1 
Kai Lau.1,2  1Nephrology, Univ of Oklahoma Health Sciences Center, Oklahoma 
City, OK; 2Medicine, VA Medical Center, Oklahoma City, OK.
Background: Recent studies showed the association of fluid overload in ARDS & 
surgical patients and increased ventilator dependency, ICU & hospital stays, short-term 
mortalities, & incidence of ARF. But a cause-and-effect relationship was unproven in 
cross-sectional observations. In grossly edematous in-patients with unexplained ARF, we 
tested the hypothesis that anasarca caused the renal failure & diuresis induced recovery.
Methods: Entry criteria were fully evaluable patients, ³3 kg weight or ³3 L fluid gain, 
≥50% acute loss of estimated creatinine clearance (CrCl) or ≥ 2 x rise in serum creatinine 
(Scre) without identifiable causes. All data were reviewed, recorded, tabulated & statistically 
analyzed, notably vital signs, weight, intake, output & lab. 36 qualified patients were 
diuresed by IV furosemide at rates keeping normotension off anti-hypertensives. Serial 
volume markers & renal responses were noted. Palliative care & hepatorenal syndrome 
were excluded.
Results: Fluid overload was due to heart failure (40%), liver failure (22%), CKD 
(16%), proteinuria (9%) & iatrogenic factors (10%). During 42 ARF episodes, mean 
weight was up 12.5 kg in 13.7d. Scre rose (4.41 vs. 1.27mg%) & CrCl fell (25 vs. 76 ml/
min). Decrements in CrCl correlated with edema weight gain (p<0.02). Over 11.9 d, 15.2 
kg of fluid were diuresed. Renal function greatly improved in 33 patients & unchanged in 
3 despite >4 kg diuresis. As an entire group, Scre fell to 1.45 mg% & CrCl rose to 67 ml/
min. Increments of CrCl also correlated with diuresis volume (p<0.04). At a diuretic rate 
of 1.5 kg/d, no adverse events occurred.
Conclusions: 1. Our data support the hypothesis for the entity of Saline-Induced, 
Diuretics-Responsive Acute Renal Failure. 2. Likely mediated by reduced cardiac output, 
venous congestion, renal interstitial edema &/or abdominal hypertension, it is analogous 
to congestive kidney failure. 3. Preventable & treatable, it could cause or aggravate ARF 
from other etiologies. 4. Diuresis in cohorts at rates & monitored as ours should be safe 
& efficacious.
Funding: NIDDK Support, Veterans Administration Support, Private Foundation 
Support
PUB041
Is RIFLE Classiifcation a Good Shot for Staging Acute on Chronic Kidney 
Disease?  Maria Isabel Acosta-Ochoa, Josefina Martin, Alicia Mendiluce. 
Nephrology, Hospital Clinico Univ, Valladolid, Spain.
Background: 8-16% of worlds population may have CKD, which is a risk factor and 
promoter of AKI. We tested the performance of RIFLE and KDIGO classifications in staging 
severity and predicting outcomes in Acute on CKD (AoCKD) individuals. KDIGO with 
a 0,3mg/dL SCr increase includes patients in stage 1 category, and includes automatically 
in stage 3 patients with peak SCr ≥4.0 mg/dL.
Methods: Retrospective cohorts study. Patients were divided in 2 groups: AKI and 
AoCKD. We collected clinical data, and classified AKI severity contrasting distribution 
strata between groups by RIFLE and KDIGO criteria. And tested the ability of both 
classifications for pred¡cting need for HD and in hospital mortality with a AUC ROC 
analysis.
Results: 270 patients were included, AKI=125, AoCKD=145. Clinical features and 
RIFLE and KDIGO stages are listed in table 1.
FEATURES AKI (N=125) AoCKD (N=145) P Value
Male (%) 77 (62) 98(68) 0,30
Age (SD) 66.9 ± 15 75.4 ± 11.9 <0.001
HT (%) 96 (77) 131 (90) <0.001
DM (%) 44 (35) 70 (48) 0.003
ChI (SD) 3.8 ± 2.5 4.4 ± 2.3 <0.001
RIFLE
No AKI (%) 21 (17) 23 (16) 0,83
Risk (%) 22 (17) 35 (24) 0,18
Injury (%) 17 (14) 44 (30) 0,001
Failure (%) 65 (52) 43 (30) <0.001
KDIGO 
Stage1 (%) 43 (34) 47 (32) 0,19
Stage2 (%) 17 (14) 16 (11) 0,52
Stage3 (%) 65 (52) 82 (57) 0,45
65% males, AoCKD individuals were older 66,9y, and had worst Charlson Index (ChaI) 
4,4. In figure 1 are shown AUC ROC curves for adverse outcomes.
Conclusions: With the KDIGO staging criteria we obtain more homogeneous 
distribution strata. With the ROC analysis neither classification performs better in predicting 
adverse outcomes. We found no practical advantage when using neither classification. In 
the noAKI (by RIFLE) stratum no adverse event was present, so by including a 0,3mg/dL 
SCr increase augments sensibility, but may be not especificity.
PUB042
Incidence of Acute Kidney Injury, Risk Factors for Acute Kidney 
Injury and Absence of Renal Recovery in Patients on Aminoglycosides 
Francois Paquette,1 Amelie Bernier-Jean,1 Veronique Brunette,1 Vincent 
Pichette,2 Helene Ammann,1 Stephan Troyanov,1 Josee Bouchard.1  1Hopital du 
Sacre-Coeur de Montreal, Canada; 2Hôpital Maisonneuve-Rosemont, Canada.
Background: The KDIGO guidelines recommended to avoid aminoglycosides (AG) 
in patients at risk or with acute kidney injury (AKI). We determined the frequency of 
administration, incidence of AKI, and risk factors for AKI and absence of renal recovery 
in patients receiving AG over the last decade.
Methods: We performed a retrospective cohort study on AG administration in two 
university-affiliated centers, and then performed a nested case-control study, pairing AG-
AKI cases to 2 controls for age and gender. AKI was defined by a 50% increase in creatinine 
after ≥5 days of AG up until 7 days after cessation of AG, and renal recovery, by a decrease 
in creatinine to within 50% of baseline creatinine over 3 weeks after cessation of AG.
Results: Between 2001 and 2015, the frequency of AG administration and drug dosing 
progressively declined. Out of 562 patients, sixty-five developed AKI attributed to AG 
(12%). In the case-control study (n=195), age was 71 (IQR 58-81) and 46% were male. 
The duration of AG administration was 10.0 (IQR 7.0-15.0) days, excluding days after AKI 
diagnosis in AKI patients. Maximal AKI stage was 1 for 55.3%, 2 for 29.2% and 3 for 15.4% 
of patients. Independent risk factors associated with AKI were concomitant vancomycin 
administration, high trough levels, heart failure, and site of infection (endocarditis and 
febrile neutropenia vs. other). Only fifty-one percent (50.8%; 33/65) of patients recovered 
their kidney function. These patients had an AKI duration of 7.0 (IQR 4.0-11.5) days. Heart 
failure was associated with a lower likelihood of renal recovery, while cancer patients more 
likely recovered their kidney function.
Conclusions: Over the last decade, the frequency of AG administration and dosing 
have progressively decreased but the incidence of AKI remained unchanged. In our cohort, 
vancomycin administration, high trough levels, heart failure, and site of infection were 
independent risk factors associated with AKI. Almost half of patients did not recover their 
kidney function, which was more often seen in patients with heart failure.
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PUB043
Prairie Continuous Renal Replacement Therapy (CRRT) Study – Outcomes 
of CRRT in a Single Canadian Tertiary Centre  Bhanu Prasad,1 Michelle 
Urbanski,2 Erwin Karreman.3  1Nephrology, Regina Qu Appelle Health Region, 
Regina, SK, Canada; 2College of Medicine, Univ of Saskatchewan, Regina, 
SK, Canada; 3Research and Performance Support, Regina Qu Appelle Health 
Region, Regina, SK, Canada.
Background: Patients with stage III Acute Kidney Injury (AKI) requiring Renal 
Replacement Therapy (RRT) have the highest short-term and long-term mortality of any 
group with AKI. Our study aimed to prospectively follow patients with stage III AKI on 
Continuous Renal Replacement Therapy(CRRT) during their hospitalization in our tertiary 
care centre from April 2013 to September 2014.
Methods: We prospectively gathered the following: date and time of hospital admission, 
transfer to ICU, and starting CRRT, creatinine at admission and at CRRT initiation, weight on 
admission and at CRRT initiation.Duration of oliguria and anuria, exposures (sepsis,critical 
illness, circulatory shock, trauma, cardiac surgery, major non cardiac surgery, nephrotoxic 
medications, and radio contrast agents) and susceptibilities (dehydration, >65 years of age, 
female,pre existing CKD), APACHE score II, Inotrope support, FiO2, ECMO. Survival on 
CRRT, in ICU and hospital survival and renal recovery was documented.
Results: Of the 2634 patients:(2201/2634)83.6% had no AKI, and (269/2634)10.2% 
had stage III AKI of whom 106/269 (40%) were started on CRRT. 8/106 died in ICU 
whilst on CRRT, 58 died after CRRT was discontinued in ICU and 4 died on the ward. 
Mean(± SD) were: Creatinine(mmol/L) 337.2 (±260.1), Norepinephrine dose 22.5 (±19.6), 
APACHE II scores 34.8 (±9.0). The prescribed CRRT dose was 35 mls/minute and the 
mean delivered dose was 34.6±2.6(SD). Survivors were younger (years)(54.5± 15.6 vs. 
62.0 ±15.4), had lower Norepinephrine dose (mcg/minute) (16.95±13.58 vs. 26.09±21.18), 
and had a shorter stay in ICU prior to starting CRRT (6:06 hours vs. 12:26 hours). Stage 
III AKI needing CRRT was associated with 62% mortality in hospital. 17/106 died within 
24 hours of initiating therapy. 5/106 patients recovered within 24 hours.
Conclusions: AKI is associated with 62% in centre mortality.16% died within 24 
hours of initiating CRRT. This raises a clinical concern of the benefit vs futility of initiating 
CRRT in specific settings.
PUB044
Urinary Liver Fatty Acid Binding Protein Predicts Acute Kidney Injury 
Associated with Abdominal Aortic Repair  Daisuke Ichikawa,1 Atsuko 
Ikemori,1 Takeshi Sugaya,1 Kenjiro Kimura,2 Yugo Shibagaki.1  1Nephrology and 
Hypertension, St. Marianna Univ School of Medicine, Kawasaki, Kanagawa, 
Japan; 2Internal Medicine, Tokyo Takanawa Hospital, Tokyo, Japan.
Background: Acute kidney injury (AKI) is common problem after cardiovascular 
surgery. AKI is usually diagnosed on the basis serum creatinine (SCr) and urinary output. 
However, SCr is of low sensitivity in patients with poor renal function. Because urinary 
liver-type fatty acid binding protein (L-FABP) reflects renal tubular injury, we evaluated 
whether perioperative changes in urinary L-FABP can predict AKI.
Methods: Subjects were 68 patients who underwent EVAR and 32 patients who 
underwent open repair. We obtained urine samples before surgery, after anesthesia induction, 
upon stent placement, at the end of surgery, 4 hours after surgery, and on postoperative day 
(POD) 1, 2, and 3 for measurement of urinary L-FABP and urinary albumin in the EVAR 
patients. We obtained urine samples before surgery, after anesthesia induction, before aortic 
cross clamping (AXC), 1 and 2 hours after AXC, at the end of surgery, and on PODs 1, 2, 
and 3 for measurement of urinary L-FABP and urinary albumin in the open repair patients. 
We obtained serum samples before surgery, immediately after surgery, and on POD 1, 2, 
and 3 for measurement of SCr.
Results: AKI developed in 5 (7.4%) EVAR patients and in 9 (28.1%) open repair 
patients. With EVAR,, urinary L-FABP was increased 4 hour after the procedure (P = 0.002), 
and it decreased but remained elevated for 3 POD (P = 0.003). With AKI, SCr increased 
(P = 0.004) and eGFR decreased (P = 0.003) by POD2. SCr and eGFR did not change 
in patients in whom AKI did not develop. With open repair, urinary L-FABP increased 
significantly to its maximum by 2 h after AXC (P = 0.008) and then decreased gradually 
over the 3 PODs (P = 0.038). The increase in urinary L-FABP was greater with open repair 
than with EVAR. ROC analysis showed urinary L-FABP to be more sensitive than SCr, 
eGFR, and urinary albumin for early detection of AKI.
Conclusions: Urinary L-FABP appears to be a sensitive biomarker of AKI in patients 
undergoing abdominal aortic surgery, especially those treated by EVAR.
PUB045
Plasma Neutrophil Gelaninase-Associated Lipocalin (NGAL) as a 
Biomarker for Acute Kidney Injury in Patients with Chronic Kidney Disease 
Ha yeon Kim, Eun Hui Bae, Soo Wan Kim, Seong Kwon Ma.  Internal Medicine, 
Chonnam National Univ Medical School, Gwangju, Korea.
Background: The aim of this study was to evaluate plasma NGAL levels as a predictor 
of early AKI in patients with with/without chronic kidney disease (CKD) and to assess 
whether plasma NGAL level could represent a useful marker of recovery in patients 
undergoing continuous renal replacement therapy (CRRT).
Methods: This single center retrospective observational study included 343 patients 
with AKI or CKD. The patients were classified into 3 groups: AKI (N=69), AKI on CKD 
(N=162), CKD (N=112). The cut-off values of NGAL was 200 ng/ml and those of cystatin-C 
was 1.0 mg/L. Study II: The retrospective observational study included 404 patients treated 
with CRRT. The patients were divide into 2 groups: renal recovery (N=120) vs. renal non-
recovery (N=284) and survivor (N=193) vs. non-survivor (N=211).
Results: The prevalence of abnormal NGAL values was 69.0 % in AKI group, 94.5 
% in AKI on CKD group and 91.8 % in CKD group. The value of NGAL was positively 
correlated with eGFR (r = 0.41, p < 0.001), and cystatin-C (r=0.45, p = 0.021). The mean 
values of follow-up NGAL were 475.9 ± 435.9 ng/ml in AKI group, 773.2 ± 370.6 ng/ml 
in AKI on CKD group, 709.4 ± 401.6 ng/ml in CKD group (p < 0.001). In AKI group, the 
difference of NGAL (baseline NGAL – follow-up NGAL) was the highest (110.8 ± 325.0 
ng/ml in AKI group, 35.7 ± 205.2 ng/ml in AKI on CKD group, 14.1 ± 201.3 ng/ml in CKD 
group, p < 0.001). In comparisons between renal recovery group and non-recovery group 
and survivors and non-survivors in CRRT patients, both baseline NGAL and follow-up 
NGAL were not different, but the difference of NGAL (baseline NGAL – follow-up NGAL) 
was increased significantly in a renal recovery and survivors group (90.6 ± 82.9 ng/ml in 
renal recovery group vs. 33.8 ± 53.7 ng/ml in renal non-recovery group, 129.8 ± 182.4 
ng/ml in survivor group vs.- 98.5 ± 162.6 in non-survivor group, p < 0.001, respectively).
Conclusions: The value of serum NGAL per se has a limitation on diagnosis of AKI 
in patients with underlying CKD. In patients treated with CRRT, hourly urine output and 
follow up of serum NGAL value may predict renal recovery and survival.
PUB046
C3 Glomerulopathy: A Pediatric Case  Luis A. Ortiz,1 Daniel Kleven,2 Harika 
Gorti.3  1Ped. Nephrology, Georgia Regents Univ, Augusta, GA; 2Pathology, 
Georgia Regents Univ, Augusta, GA; 3MCG, Georgia Regents Univ, Augusta, GA.
Background: C3 glomerulopathy (C3G) is characterized by C3 deposit in the glomeruli 
with minimal Ig deposition. C3G is described as an unregulated activation of the alternative 
complement pathway due to a genetic mutations in Factor H or I, or acquired factors such as 
C3 nephritic factor, an IgG autoantibody stabilizing C3 convertase. The pattern of the injury 
varies from mesangio-proliferative, membranoproliferative, to endocapillary proliferative 
glomerulopathy. EM finding demonstrate hump shaped sub epithelial deposits, characteristic 
of acute post-infectious glomerulonephritis (PIGN). We present a pediatric case that met 
the initial criteria for PIGN, but was diagnosed as C3G according the pathology.
Methods: 15 y/o AA/M with Thin Basement D., HTN, asthma presented with one Hx 
of sore throat, gross hematuria, facial swelling, no distal edema. Initial oliguria and high Cr. 
PE revealed periorbital edema, no pharyngeal erythema, lung clear, abdomen with no ascites. 
On admission, Hb 11.6 g, Cr:3.26mg, Albumin:2.5 gr, UA20-50 RBC, UOP: 0.37 ml/k/hr. 
Despite treatment with methylprednisolone, albumin and furosemide, his Cr. increased to 
6.48, ASO 654 UI, aDNAseB normal., CRP 12.6. Group A strep was negative for growth. 
Kidney biopsy: glomeruli w/segmental sclerosis, endocapillary infiltration of neutrophils, 
IF: extensive C3 staining with scant IgG and small fibrin deposition (focal necrosis). EM: 
large subepitelial deposits. Worsening kidney function required hemodialysis. After 6 
months, he continues on Hemodialysis.
Conclusions: Kidney biopsy with C3 dominant on IF, large subepithelial deposits on 
EM, hypocomplementemia and clinical of gross hematuria preceded by URI suggested acute 
PIGN, but this overlaps with the histological presentation of C3G of C3 dominant staining 
with scant IG deposition, subepitelial deposits and low serum C3. No resolution of AKI after 
8 weeks of presentation was unusual for PIGN, steering diagnosis towards C3G. Clinicians 
should note the high overlap between the clinical and histology of PIGN and C3G. it is 
impeprative to conduct further studies to accurately diagnose and treat patient with C3G.
PUB047
Predictors of End Stage Renal Disease in Scleroderma Renal Crisis – 
A Single Center Experience  Sumedha Dhar, Cybele Ghossein.  Div of 
Nephrology, Northwestern Univ - Feinberg School of Medicine, Chicago, IL.
Background: Scleroderma renal crisis (SRC) is one of the most acute and life-
threatening complications of systemic sclerosis (SSc). It is typically characterized by 
accelerated hypertension and acute kidney injury (AKI). Angiotensin converting enzyme 
inhibitors (ACEI) are currently the treatment of choice for this disease. Despite use of ACEI, 
50% of patients with SRC develop end stage renal disease (ESRD) which is associated with 
poor long term outcomes. Our aim was to define the clinical characteristics and outcomes 
of SRC patients admitted to our institution.
Methods: This was a retrospective chart review of all patients admitted with SRC to 
Northwestern Memorial Hospital (NMH) between the years of 1/1994 to 4/2015. ESRD 
was defined as the need for chronic dialysis during admission for SRC.
Results: There were 23 patients with a diagnosis of SRC made either clinically or by 
renal biopsy during this time period. Mean time to SRC was 1.3 years after diagnosis of SSc. 
47% of patients developed ESRD during the same admission. Development of ESRD was 
not associated with age, gender, race, anti-RNA polymerase III test positivity, intensive care 
unit (ICU) admission, prior ACEI or angiotensin receptor blocker (ARB) use, or creatinine 
on admission. ESRD was significantly associated with time to control blood pressure. 
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Not requiring HD
N = 12 (%)
Requiring HD
N = 11 (%) P value
Mean Age (yr) 57 57.36 0.95
Gender Female
Male
11 (91)
1 (8)
8 (72)
3 (27) 0.32
Race White
Afro-American
Other
8 (66)
3 (25)
1(8)
7 (63)
2 (18)
2 (18)
0.87
anti-RNA polymerase III 3 (25) 5 (45) 0.39
ICU initial admission 6 (50) 2 (18) 0.19
ACEI/ARB on admission 3 (25) 7 (63) 0.09
Mean days to start ACEI 0.9 1 0.88
Mean days to control BP 3.1 (N = 11) 5.83 (N = 6) 0.03
Normotensive on admission 2 (16) 4 (36) 0.37
Mortality 2 (16) 2 (18) 1.00
Mean Creatinine on admission 
(mg/dl) 2.04 2.95 0.07
Conclusions: SRC is a serious kidney and life threatening complication of SSc. Delay 
in blood pressure control increases risk of ESRD in SRC patients.
PUB048
Acute Kidney Injury Risk Assessment at the Hospital Front Door: What 
Is the Best Measure of Risk?  Aled O. Phillips,1 Dafydd Phillips,1 Mohamed 
Hassan,5 John Geen,2 Vikas Lodhi,6 Hemanth Bolusani,4 Gareth Roberts.3 
1Nephrology, Cardiff Univ School of Medicine, Cardiff, Wales, United Kingdom; 
2Dept of Clinical Biochemistry, Univ of South Wales, Wales, United Kingdom; 
3Dept of Medicine, Royal Gwent Hospital, Newport, Wales, United Kingdom; 
4Dept of Medicine, Univ Hospital of Wales, Cardiff, Wales, United Kingdom; 
5Dept of Medicine, Prince Charles Hospital, Merthyr Tydfil, Wales, United 
Kingdom; 6Dept of Medicine, Univ Hosptial Llandough, Cardiff, Wales, United 
Kingdom.
Background: We examined the prevalence of AKI-risk factors in the emergency 
medical unit, generated a modified risk assessment tool and tested its ability to predict AKI.
Methods: 1196 patients admitted to medical admissions units were assessed for patient 
associated AKI-risk factors. Subsequently, 898 patients were assessed for a limited number 
of fixed risk factors with the addition of hypotension and sepsis. This was correlated to 
AKI episodes.
Results: In the first cohort the prevalence of AKI risk factors was 2.1±2.0 per patient, 
with a positive relationship between age and the number of risk factors and a higher number 
of risk factors in patients ≥65yrs.  In the second cohort 12.3% presented with or developed 
AKI. Patients with AKI were older and had a higher number of AKI risk factors. In the AKI 
cohort 72% of the patients had ³2 AKI risk factors compared to 43% of the cohort with no 
AKI. When age ≥65 yrs was added as an independent risk factor 84% of those with AKI 
had ³2 AKI risk factors compared with 55% of those with no AKI.ROC analysis suggest 
that use of common patient associated known AKI risk factors performs no better than 
age alone as a predictor of AKI.
Conclusions: Detailed assessment of well established patient associated AKI-risk 
factors may not facilitate clinicians to apportion risk. This suggests that additional work is 
required to develop a more sensitive validated AKI predictive tool which would be useful 
in this clinical setting.
PUB049
Acute Kidney Injury, Requiring Renal Replacement Therapy – Incidence, 
Causes and Outcomes: One Center Experience  Elena Zakharova. 
Nephrology, City Clinical Hospital n.a. s.P. Botkin, Moscow, Russian Federation.
Background: Acute Kidney Injury (AKI) is complex condition, associated with high 
mortality and morbidity. We aimed to evaluate AKI incidence, causes, risk factors and 
outcomes in patients, managed in nephrology unit of general hospital and urgently requiring 
Renal Replacement Therapy (RRT).
Methods: Using electronic database for 2010-2014 (4531 admissions, 2257 patients), 
we searched 604 cases which met KDIGO AKI definition, and selected patients, required 
RRT.
Results: Study group included 115 patients (19% of all AKI cases), 51 (44%) male, 
64 (56%) female, median age 61 [22; 89] years. In 102 (89%) cases AKI was community 
acquired. Median serum creatinine prior to start of RRT was 981 [242; 2665] µmol/l, 37 
(32%) patients had known CKD. Causes and susceptibilities for AKI are shown in table. 
Cause/exposure n of patients %
Decreased kidney perfusion 33 29
Vasculitis 8 7
Thrombotic microangiopathy 2 2
Interstitial nephritis 8 7
Sepsis 10 9
Critical illness 7 6
Circulatory shock 3 3
Nephrotoxic drugs 6 5
Radiocontrast agents 1 1
Poisoning 2 2
Hantavirus infection 2 2
Hemolysis 2 2
Rhabdomyolysis 9 8
Cast-nephropathy 8 7
Urinary tract obstruction 14 12
Underlying conditions
Chronic kidney disease 37 32
Dehydration/volume depletion 33 29
Diabetes 9 8
Chronic heart, lung or liver disease 22 19
Multiple myeloma/lymphoma 13 11
Systemic amyloidosis 7 6
Cancer 10 9
Age over 75 18 16
76 (66%) patients partially or completely recovered kidney function, 27 (23%) were 
still dialysis-dependent after 3 month of follow-up, and 12 (10%) patients died
Conclusions: In our cohort incidence of AKI was 27%, proportion of patients requiring 
RRT constituted 19% of AKI cases. Vast majority had community acquired AKI, 1/3 
developed AKI on the top of pre-existing CKD, 16% were elder than 75 years. Main 
trigger for RRT-requiring AKI in 29% of cases was initially considered as decreased kidney 
perfusion, with volume-unresponsiveness due to severe underlying conditions, such as 
CKD, chronic heart and liver diseases, multiple myeloma, cancer, diabetes and amyloidosis. 
Other most frequent causes of AKI were sepsis, rhabdomyolysis, vasculitis, and interstitial 
nephritis. Mortality rate was 10%, ESRD developed in 23% of cases.
PUB050
Renal Manifestations in Paroxysmal Nocturnal Haemoglobinuria  Ram R,1 
Dakshinamurty Kv,2 Krishna Parasd A.3  1Nephrology, Sri Venkateswara Inst of 
Medical Sciences, Tirupati, AP, India; 2Nephrology, Mahatma Sri Ramchandra 
Centenary Memorial Hospital, Hyderabad, Telengana, India; 3General 
Medicine, NIMS, Hyderabad, India.
Background: Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired chronic 
disorder characterized by a triad of clinical features- haemolytic anaemia, pancytopenia, 
and thrombosis. Not many reports of renal involvement in PNH are available in literature.
Methods: We present a case series of PNH with renal involvement. We present the 
data of PNH patients attended to departments of General Medicine and Nephrology at 
a government run tertiary care institute in South India. The diagnosis of PNH in these 
patients during initial phase, between 1998 and 2004 was based on sucrose lysis and Ham’s 
test. After 2004, the diagnosis was based on flow cytometry to detect CD59 (MIRL), a 
glycoprotein, and CD55 (DAF) in regulation of complement action. The patient data was 
collected from 1998 to 2014.
Results: There were 13 patients of paroxysmal nocturnal haemoglobinuria in this 
period. The mean age was 37 years and the range was 16 to 68 years. There were 7 females. 
Acute renal failure was noted in 5 patients. Dialysis was performed in three of them. The 
mean serum creatinine and urea at the initiation of dialysis was 5.4 ± 0.6 mg/dL and 64.1 
± 6.1 mg/dL respectively. The median number of haemodialysis sessions done was four. 
Renal biopsy was done in four patients. The indication for the biopsy was acute renal 
failure of more than four weeks. The median number of glomeruli was 9. The tubules 
showed prominent brown granular pigment within the epithelial cells. It was confirmed as 
hemosiderin with the Perls’ Prussian blue reaction. A few deposits of hemosiderin were 
also seen within the tubular lumina.  The pathological diagnosis in these four patients was 
acute tubular necrosis secondary to hemosiderin deposition. In three patients the urinalysis 
and serum chemistry was suggestive of Fanconi syndrome.
Conclusions: In our patients, three renal manifestations of PNH were identified. They 
were acute renal failure, renal vessel thrombosis and Fanconi syndrome. Chronic renal 
failure was not identified.
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PUB051
Filling the Gaps in Acute Kidney Injury Epidemiology: A Multicenter 
Prospective Study in Amazon  Fernando de Assis Ferreira Melo,1,2 Waledya 
Araujo lopes de Melo,2 Tarcisio Andrade Souza,2 Natali Mendes,2 Luis Yu,3 
Emmanuel A. Burdmann,3 Dirce M T Zanetta.1  1Epidemiology, Univ of Sao 
Paulo, São Paulo, Brazil; 2Medicine, Federal Univ of Acre, Rio Branco, Acre, 
Brazil; 3Medicine, Univ of Sao Paulo, São Paulo, Brazil.
Background: In some areas of developing countries, infectious tropical diseases or 
animal venoms may be important causes of Acute Kidney Injury (AKI). Epidemiological 
studies of AKI incidence in these areas are scanty and prospective population-based studies 
are even scarcer.
Methods: Prospective data on all adult patients admitted in all intensive care units 
(ICU) of the Western Amazon region (600 square kilometers and 800,000 inhabitants) 
were collected for 6 months in 2014. Patients with chronic kidney disease stage 5, kidney 
transplant or ICU stay < 48 hours were excluded. AKI was diagnosed by KDIGO and 
mortality was assessed 30 days after ICU discharge. Data are presented as mean±SD or 
percent.
Results: 367 patients aged 57.8 ± 19.2 years and with 39% white were evaluated. Main 
reasons for ICU admission were postoperative (34%), hemodynamic instability (22%) and 
respiratory failure (13%), with only 1% with tropical diseases. AKI incidence was 38%, but 
was lower in postoperative patients (28% vs 43% in non-postoperative, p = 0.005). Mortality 
was higher in AKI patients (53% vs 30% in non-AKI, p <0.001). Postoperative patients 
who developed AKI had similar mortality to those non-operative (46% vs 56%, p=0.302).
Conclusions: AKI has a high incidence in ICU patients of the Western Amazon area. 
The causes of ICU admission did not differ from those seen in developed countries. The 
few number of patients with the typical tropical diseases of Amazon may be due to poor 
access to health care. The peculiar social geographical region characteristics, with rivers 
that are not navigable most of the year, long rain period that difficult access to larger cities 
and the lack of health services in diverse areas, may be associated to the present findings.
Funding: Government Support - Non-U.S.
PUB052
Uncovering Complement Mediated Thrombotic Microangiopathy: Use of 
a Real Time Genetic Assay in the Diagnosis of Atypical Hemolytic Uremic 
Syndrome  Jan C. Hofmann.  Dept of Medicine, California Pacific Medical 
Center, San Francisco, CA.
Background: Improved diagnostic tests and greater understanding of pathophysiology 
of thrombotic microangiopathy (TMA) have led to more rapid differentiation of various 
types of TMAs. While ability to rapidly diagnose TTP (ADAMTS13 activity <5-10%) has 
improved, atypical HUS (aHUS) remains diagnosis of exclusion due to poor sensitivity, 
high cost, and long turnaround time (TAT) of aHUS genetic assays. We describe a patient 
(pt) with hypothyroidism and renal insufficiency diagnosed with aHUS, using appropriate 
clinical algorithms for TMA, including “real-time” aHUS genetic assay (TAT 2-5 days).
Methods: 59 y.o. female with 1-2 week (wk) history of fatigue, anemia, 
thrombocytopenia, renal insufficiency, and recent diagnosis of hypothyroidism with changes 
in CBC and creatinine (Cr) over 3 wks: hemoglobin (hgb) 13.9 to 7.1 g/dl, platelet count 
(plt ct) 241 to 68 X 109/L, and Cr 0.71 to 1.41 mg/dl (baseline Cr 0.56, BMI 19.5). Pt’s 
CNS status normal; no other signs/symptoms of systemic thrombosis noted. Additional 
labs: haptoglobin <9 mg/dl, LDH 1942 U/L (312-618 U/L), direct coombs negative, PT/
INR/PTT/fibrinogen normal, 5-6 schistocytes/high power field, ADAMTS13 activity 79% 
(40-130%) ruling out TTP.
Results: Pt received 11 plasma exchange (PE) treatments (txs) (hospital day [HD] 
3-21). By day 4 of PE (HD 7), plt ct 197 X 109/L; despite 11 PE txs, LDH remained 
elevated (886-2123) and Cr rose to 2.72 (3.8-4.9X higher than baseline). aHUS genetic 
panel (sent HD 10, results on HD 17) revealed: positive variant in CFI gene (predicted 
to be significant, but not previously described) and heterozygous mutations for 3 CFH 
polymorphisms. Pt clinically diagnosed with aHUS, received meningococcal vaccine (HD 
20), and ciprofloxacin (2 wk course). Induction eculizumab started and PE stopped (HD 
21). After 2+ months of eculizumab, pt’s Cr normalized.
Conclusions: With development of improved genetic testing (ie, increased sensitivity 
and speed), aHUS genetic assays may represent “real-time” diagnostic tools enabling more 
rapid assessment of selected TMA cases leading to more targeted treatment.
PUB053
Oral Hydration: The Way Forward in the Prevention of Contrast-Induced 
Nephropathy  Hsu pheen Chong, Matthew L p Howse.  Nephrology, Royal 
Liverpool Univ Hospital, United Kingdom.
Background: : Contrast induced nephropathy is defined as increased serum creatinine 
of 0.5 mg/dL (44.2 mol/L), or a 25% increase of creatinine from baseline levels checked 
48 hours after exposure to iodinated contrast medium. Studies have suggested the use of 
intravenous fluids such as sodium chloride 24 hours prior to contrast exposure. However, this 
step would require the patient to be admitted prior to contrast medium exposure and incur 
extra cost for this hospital. This audit explores the use of oral hydration in the prevention 
of contrast induced nephropathy.
Methods: Using the ICE computer system, all patients who were diagnosed with Type 
2 Diabetes Mellitus and taking metformin were identified from the time period of January 
2008 until January 2014. They were then advised to stop their metformin prior to contrast 
exposure. Recommended regime for contrast prophylaxis was given which was 2 litres of 
oral fluids before and after the procedure. Patients were also given advice to get their renal 
function checked, 48 – 72 hours after contrast exposure. Their renal function pre and post 
contrast exposure was documented and any patients with a reduction of their eGFR more 
than 20% were then referred to the nephrology department for follow up.
Results: A total of 277 patients were included in this audit. The mean eGFR was 47 
ml/min/1.73m². 79% of patients had their renal function checked within 48 – 72 hours, 
15% of patients had their renal function checked after that time period and 6% of patients 
did not have their renal function rechecked at all. Only 0.7% of patients had deterioration 
of their renal function that met the criteria above. However it was important to note that, 
these patients had also other multiple co-morbidities and the exposure to contrast was not 
the sole cause to the deterioration of their renal function.
Conclusions: Oral hydration should be considered as part of the protocol for the 
prevention of contrast-induced nephropathy. This regime has reduced the need for patients 
to be admitted into hospital admission for intravenous fluids, thus reducing waiting times 
for imaging and as well as reducing hospital cost.
PUB054
Gemcitabine-Mediated Thrombotic Microangiopathy – A Rare Cause of 
Hemolytic Uremic Syndrome  Natalie M. Ertz-Archambault,1 Ibrahim Qaqish,2 
Leslie F. Thomas.2  1Internal Medicine, Mayo Clinic Arizona; 2Nephrology and 
Hypertension, Mayo Clinic Arizona.
Background: Thrombotic microangiopathy (TMA) is a pathological diagnosis 
of endothelial cell injury and microvascular thrombosis. TMA has been categorized 
in the present era as one of three distinct disease processes: 1) classical hemolytic 
uremic syndrome, 2) atypical hemolytic uremic syndrome (aHUS), and 3) thrombotic 
thrombocytopenic purpura. Our focus, aHUS, reflects an underlying aberrancy in regulation 
of the alternative complement cascade. Several genetic defects have been identified leading 
to an affinity to develop uncontrolled activation of this cascade which may commence after 
exposure to a trigger. Gemcitabine is one rare trigger described in the literature.
Methods: A 66 year-old female with locally advanced, unresectable pancreatic cancer 
who had completed 12 cycles of gemcitabine-abraxane therapy with no major oncologic 
progression of disease was hospitalized with acute kidney injury. Two months prior to 
admission, she developed hypertension, nausea, and profound cytopenias requiring platelet 
and red cell transfusion. She endured a progressive decline in renal function with a nadir 
eGFR 19 mg/mL/1.73 m2. One month prior to admission, her urinalysis reflected active 
sediment. Admission labs demonstrated microangiopathic anemia with thrombocytopenia. 
ADAMTS13 activity was normal (88%), consistent with aHUS. Renal biopsy confirmed 
subacute changes consistent with TMA. Despite discontinuation of the gemcitabine-
abraxane therapy, she continued to demonstrate progressive anemia and thrombocytopenia 
in addition to persistent proteinuria, hematuria, and impaired eGFR. The patient was 
subsequently initiated on eculizumab therapy.
Conclusions: Gemcitabine-mediated aHUS is rare and associated with a 75% mortality 
rate at four months. Previous attempts at therapy have included apheresis. However, 
current guidelines discourage apheresis in this patient population. To date, six cases of 
gemcitabine-mediated aHUS have reported the successful use of eculizumab, a terminal 
complement inhibitor.
PUB055
Intravenous Contrast Material Administration Increases Mortality in 
Patients with Acute Kidney Injury Requiring Renal Replacement Therapy 
Katsuhito Ihara, Atsuki Ohashi, Yoshito Iida, Makiko Kobayashi, Hitomi Tanaka, 
Seiji Inoshita.  Internal Medicine, Tokyo Metropolitan Bokutoh Hospital, Japan.
Background: Contrast material exposure is well known to induce acute kidney injury 
(AKI); however, it is yet unclear whether contrast material administration is related to 
the prognosis of AKI. We hypothesized that intravenous contrast material administration 
might be a poor prognostic factor for short-term mortality in AKI requiring renal placement 
therapy (RRT).
Methods: We enrolled AKI patients in our hospital, who have been prescribed 
RRT for the first time, from January 2012 to December 2013 and collected the baseline 
information and data. Patients already initiated on continuous hemodialysis or peritoneal 
dialysis, patients almost reaching end-stage kidney disease with vascular access, and 
patients admitted to our hospital with cardiopulmonary arrest were excluded. The primary 
outcome was 28 days mortality from initiation of RRT. We divided the patients into two 
groups, either with or without exposure to contrast material after admission to our hospital. 
The effect of contract material exposure was evaluated by univariate and multivariate cox 
proportional hazard ratio.
Results: One hundred and seventy patients were eligible. Seventy one percent was male, 
and mean age was 65.3 ± 14.9 years old. Mean serum creatinine was 5.5 ± 5.0 mg/dL, and 
mean urine output for six hours was 2.64 ± 2.93 mL/kg. Contrast material was administered 
in 50.6 % of the patients. Each the exposure group and non-exposure groupincluded 86 and 
84 patients, respectively, and the 28 day mortalities of each group were 55.8 % and 36.9 
%,respectively. The hazard ratio in theexposure group was 2.666 [95 % Confidence Interval 
(C.I.) 1.573-4.517] (p = 0.000) by univariate analysis. After adjustment by hypertension, 
sepsis, ischemia, and diuretics usage, which were the significantly different cofounders 
between the two groups, the hazard ratio was 1.987 [95% C.I. 1.093-3.610] (p = 0.024).
Conclusions: Our results demonstrated that intravenous contrast material administration 
is an independent risk factor for mortality in patients with AKI requiring RRT.
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Dabigatran Induced Acute Kidney Injury and Management with 
Hemodialysis  Darren W. Grabe,1,2 Syed S. Haqqie.2  1Dept of Pharmacy 
Practice, Albany College of Pharmacy and Health Sciences, Albany, NY; 2Dept 
of Medicine, Div of Nephrology and Hypertension, Albany Medical College, 
Albany, NY.
Background: A 55-year-old man with a history of A Fib, cirrhosis, portal HTN, 
esophageal varices arrives in the ED, transferred from an outside hospital following initial 
presentation with multiple episodes of hematemesis and melena. Medication regimen 
recently changed with a switch from warfarin to dabigatran 8 months prior to admission 
in order to avoid frequent INR checks.
Methods: On admission, initial blood work was obtained and revealed: Hg 6.3 g/
dL, INR 6.9, SCr 15.6 mg/dL and BUN 189 mg/dL. Patient was admitted to the intensive 
care unit for management of acute blood loss and AKI. On physical exam shows a pulse 
of 95 bpm and BP of 111/75 mmHg and mild hepatosplenomegaly, the physical exam 
was unremarkable. Dabigatran was discontinued and patient was transfused with packed 
red blood cells and fresh frozen plasma and administered vitamin K. Hemodialysis was 
initiated and continued throughout the hospital course. Kidney biopsy was performed 
and was consistent with ATN, chronic tubulointerstitial nephritis, and IgA Nephropathy 
(HAAS class I).
Results: Serum dabigatran concentration (conc) drawn on admission was 860 ng/mL. 
Following the initial emergent hemodialysis (HD) procedure, subsequent dabigratan conc. 
were determined during the second HD procedure. Predialysis and postdialysis dabigatran 
conc. were 130 ng/mL and 30 ng/mL, respectively. Pharmacokinetic parameters were 
calculated and shown in the table. 
Dabigatran pharmacokinetics while on hemodialysis
KD (h-1) t 1/2 (hrs) ClD (mL/min)
0.489 1.4 571
k=elimination rate constant; t½= half-life; D =dialytic
Over the hospital course, patient required regular HD, Hg stabilized following 
transfusion and vitamin K. Patient was stable on discharge with a serum creatinine of 5.9 
mg/dL and remained on dialysis.
Conclusions: Dabigatran induced AKI is rare. The mechanism of the insult in this 
case was unclear but acute blood loss leading to prolonged ischemic insult was largely 
contributive. Hemodialysis was successful in removing the offending agent with resolution 
of bleeding but patient remains dialysis dependent.
PUB057
Relation Between BNP And NGAL, with Bioelectrical Cardiothoracic 
Impedance Hemodynamics Parameters in Patients with Cardiorenal or 
Renocardiac Syndrome  Francisco Javier Lavilla, Maria Jose Molina Higueras, 
Nuria Garcia-Fernandez, Paloma L. Martin Moreno, Diana Lopez espinosa, 
Pelayo Moiron Fdez-Felechosa, Pedro Errasti.  Nephrology, Clinica Univ de 
Navarra, Pamplona, Navarra, Spain.
Background: Evaluate the aplication of cardiothoracic bioelectrical impedance 
(CTBIA) in the classification of patients with cardiorenal or renocardiac syndrome.
Methods: We use a cohort with 18 patients (mean age 72 years SD 2.6, males 77 
%) with cardiorenal or renocardiac syndrome. We evaluate hemodynamic parameters 
(cardiac output –CO-, cardiac output index –COI-, left ventricular work index –LVWI- and 
systemic vascular resistance index –SVRI-) with BNP (pg/ml, limits 0-100) andNGAL 
(ng/ml, limits 0-149).
Results: Mean levels of BNP were 545.71 (SD 128.8) and mean levels of NGAL were 
500.11 (SD 96.25). Only vascular resistance index was associated with NGAL (r=-0.461, 
p=0.054). Not found associations with BNP. However we classificate patients in four groups: 
Group 1 (BNP high, NGAL normal) (n=7), Group 2 (BNP high, NGAL high) (n=1), Group 
3 (BNP normal, NGAL high) (n=7) and Group 4 (BNP normal, NGAL normal) (n=3). 
The associations indicate that in Group 1 are patients with cardiac dysfunction 
(cardiorenal) and higher BNP (BNP>NGAL), with lower cardiac output and higher vascular 
resistance, and in group 3 are patients with renal dysfunction (renocardiac) and higher NGAL 
(NGAL>BNP, with higher cardiac output and lower vascular resistance. 
Table 1.
Group mean/Sd BNP pg/ml
NGAL 
ng/ml
CO
l/min
COI l/
min/m2
LVWI
Kg m/m2
SVRI dyn s 
cm-5 m2
1 1068 185.9 252 36.3 4.3 0.47 2.56 0.23 2.5 0.25 2338 245.3
2 1420 1300 4.8 2.9 2.6 1842
3 189.4 52.4 706 141 6.2 0.5 3.05 0.20 3.26 0.36 2082 206.83
4 158 49.7 177 65.3 3.03 0.20 1.53 0.08 1.73 0.12 4282 394.5
p 0.001 0.005 0.01 0.008 0.085 0.001
CO: CARDIAC OUTPUT. COI: CARDIAC OUTPUT INDEX. LVWI: LEFT VENTRICULAR 
WORK INDEX.  
SVRI: SYSTEMIC VASCULAR RESISTANCE INDEX.
Conclusions: The use of CTBIA is usseful to evaluate and classify patients with 
cardiorenal or renocardiac syndrome. There are association between vascular resistance 
and renal tubular necrosis.
PUB058
Recovery of Renal Function After Removal of Functional Causes of 
Advanced Renal Failure  Maria-Eleni Roumelioti,1 Faraz khan Luni,2 Sandeep 
Vetteth,2 Darlene Melinda Vigil,1,3 Kavitha Ganta,1,3 Deepak K. Malhotra,2 
Antonios Tzamaloukas.1,3  1Univ of New Mexico; 2Univ of Toledo; 3Raymond 
G. Murphy VA Medical Center.
Background: It is important to predict whether renal function recovers completely, 
early in the course of functional azotemia.We hypothesized that the level of renal function 
can be predicted from the early change in serum creatinine concentration ([Cr]) during 
treatment of functional azotemia.
Methods: Taking into account the changes in the body pool of Cr at diagnosis and Cr 
production during treatment, we calculated the Cr clearance (CCr) between the [Cr] levels 
in the blood sample obtained at presentation ([Cr]0) and in the first blood sample after the 
initiation of non-dialytic treatment ([Cr]1) in 6 pts, 5 men with urinary retention and a 
woman with prerenal azotemia. The calculated CCr value was used to predict [Cr] levels 
corresponding to times of subsequent [Cr] measurements. We compared the predicted [Cr] 
levels to the corresponding measured ones.
Results: The table shows [Cr]0 and [Cr]1 levels, calculated CCr values, predicted and 
measured [Cr] levels at steady state after correction of the azotemia (Cr]SS. Predicted and 
measured [Cr]SS values were close. 
Patient 1 2 3 4 5 6
[Cr]0, mg/dL 42.70 17.67 11.35 35.23 8.10 6.86
[Cr]1, mg/dL 34.70 5.58 8.97 8.11 7.77 5.16
[Cr]0 to [Cr]1 hours 3.6 14.7 2.9 12.3 3.2 5.4
CCr mL/min 45 56 59 88 34 39
Predicted [Cr]SS, mg/dL 1.97 1.24 0.99 0.99 2.41 1.48
Measured [Cr]SS, mg/dL 1.60 1.52* 1.18 0.87 2.17 1.41
*Patient 2 died while [Cr] was decreasing 
A modeling of the decline in [Cr] of patient 3 is presented in figure
(solid line: exponential decline of the [Cr] predicted by the CCr, full circles: measured 
[Cr] levels)
Conclusions: Computation of early CCr after removal of the cause of functional 
azotemia may provide estimates of post-treatment [Cr] levels reasonably close to the 
measured levels. More observations are needed.
Funding: Veterans Administration Support
PUB059
Relation of Cardiothoracic Bioelectrical Impedance Hemodynamics 
and Volemics Parameters with Acute Kidney Injury Prognosis 
Francisco Javier Lavilla, Nuria Garcia-Fernandez, Diana Lopez Espinosa, 
Paloma L. Martin Moreno, Maria Jose Molina Higueras, Pelayo Moiron 
Fdez-Felechosa, Pedro Errasti.  Nephrology, Clínica Univ de Navarra, 
Pamplona, Navarra, Spain.
Background: Evaluate the relation of hemodynamics and volemic parameters with 
cardiothoracic bioimpedance (CTBIA) and Acute Kidney Injury (AKI) prognosis.
Methods: We use a cohort of 21 patients (mean age 69 years SD 2.8, 76.2% males) 
with AKI We evaluate hemodynamic parameters (cardiac output –CO-, cardiac output index 
–COI-, left ventricular work index –LVWI- and systemic vascular resistance index –SVRI-) 
and thoracic volemic parameters (Thoracic fluid volumen -TFV-, Thoracic fluid volumen 
index –TFVI- and systolic volumen –SV-) with clinical index prognosis (severity individual 
index –ISI), analytical parameters (c-reactive protein –CRP-, prealbumin –PRALB, albumin 
–ALB-) and chronic health index (Karnofsky –K-).
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Results: Patients with lower vascular resistance and higher cardiac work have worse 
prognosis, associated with inflammatory state and thoracic hypovolemia, oliguria and higher 
renal replacement therapy requeriments. But patients with higher thoracic volumen have 
higher risk of respiratoy failure. 
Table 1.
CO
l/min
COI l/
min/m2
TFV l/
kOhm
TFVI l/
kOhm/m2
SVRI dyn s 
cm-5 m2
SV
ml
ISI r
p
0.556
0.009
0,585
0,005 ns ns
-0.483
0.026
0.383
0.087
CRP r
p ns ns
-0.392
0.097
-0.480
0,038 ns ns
Hypo. p.
YES/NO
0.019
4.3/6.5
0.009
2.3/3.3 ns ns
0.016
2992/1920
0.056
61/87
Vent.Asis.R. p.
YES/NO ns ns
0.037
33.5/50
0.064
18.3/25.8 ns ns
RRT. p.
YES/NO
0.022 
4.4/6.7
0.064 
2.4/3.2
0.016 
33./51.7
0.073 
18.3/25.6
0.181
2845/2177
0.066
62/89
CO: CARDIAC OUTPUT. COI: CARDIAC OUTPUT INDEX. TFV: THORACIC FLUID VOLUME. 
TFVI: THORACIC FLUID VOLUME INDEX. SVRI: SYSTEMIC VASCULAR RESISTANCE 
INDEX. VOLUME SYSTOLIC: VS. ISI: INDIVIDUAL SEVERITY INDEX. CRP: C-REACTIVE 
PROTEIN. HYPO: HYPOTENSION. VENT. ASIS. R: VENTILATORY ASSISTANCE 
REQUERIMENT. RRT: RENAL REPLACEMENT REQUERIMENT.
Conclusions: CTBIA can be used to evaluate prognosis and theraphy of higher risk 
AKI, as a patients with vasoplegic state (with inflammatory origen and higher multiorgan 
failure risk) or thoracic hypervolemia (with higher respiratoy failure and intubation risk).
PUB060
Abruptio Placenta as a Complement Amplifying Condition for Atypical 
Hemolytic Uremic Syndrome  Syed S. Haqqie, Amro Elshoury, Daniel Sedhom, 
Arif Asif.  Albany Medical College, Albany, NY.
Background: Endothelial injury resulting in microvascular thrombosis is the 
underlying pathology leading to target organ injury in aHUS. The syndrome is characterized 
by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic injury to 
multiple organs including the kidney. Complement amplifying conditions often lead to 
the activation of complement cascade involved in the pathogenesis of atypical HUS. In 
this report, we present 33-year-old Hispanic women with abruptio placenta at 33 weeks 
of gestation and fetal death who underwent cesarean section. Post procedure, patient 
developed microangiopathic hemolytic anemia (6.7 mg/dl), thrombocytopenia (39,000/
µL ) and renal failure necessitating initiation of hemodialysis. Fibrinogen (267 mg/dl), 
PT, PTT were normal while LDH was markedly elevated at 2670 IU/L haptoglobin was 
severely reduced at 5.8 mg/dl. Market schistocytosis was observed on peripheral smear. 
ADAMTS 13 was ordered and plasma exchange was initiated. Five sessions failed to 
show any improvement and ADAMTS 13 activity returned at 56%. Plasma therapy was 
discontinued and Eculizumab (monoclonal antibody directed against complement C5) was 
initiated for the diagnosis of aHUS. At a follow-up of two weeks patient is off dialysis with 
a serum creatinine of 3.4 mg/dl, hemoglobin of 8.8 mg/dl and platelet count of 147,000/
µL. We believe that abruptio placenta acted as a complement amplifying condition in this 
case. However, pregnancy, fetal loss and caesarean section can all serve as complement 
amplifying conditions for aHUS.
Methods: Clinical Case Report
Results: Successful outcome with Eculizumab therapy.
Conclusions: aHUS responding to Eculizumab therapy.
PUB061
Foscarnet Crystal-Induced Nephropathy in a Patient with Diminished 
Native Renal Capacity  Sadiq Ahmed,2 Patrick J. Hensley,1 Virgilius Cornea.1 
1Pathology, Univ of Kentucky; 2Nephrology, Univ of Kentucky.
Background: Drug-induced crystalline nephropathies are characterized by glomerular, 
tubular or interstitial injuries with rising creatinine, hematuria and low grade proteinuria. 
Foscarnet is a pyrophosphate analog that inhibits DNA polymerase in ganciclovir-resistant 
CMV. Tubular-interstitial damage due to Foscarnet is common but reports of crystalline-
induced nephrotoxicity are rare. We report this unique case of Foscarnet crystal-induced 
nephropathy in a patient with lymphoma and solitary functioning kidney.
Methods: A 56 year old female with history of solitary functioning left kidney with 
remote history of right kidney atrophy due to obstructive uropathy was diagnosed with 
stage IV mantel cell lymphoma. Renal function was normal prior to chemotherapy and 
stem cell transplant. This was complicated by CMV infection requiring IV Foscarnet for 
8 weeks. She developed AKI with nephrotic range proteinuria and hematuria. The patient 
was initiated on hemodialysis. Renal biopsy showed deposition of calcium crystals in 
the mesangium and interstitium characterized by short sticks with angular edges and 
birefringence on polarized light microscopy. 
Conclusions: Foscarnet crystal-induced nephropathy has been reported in a limited 
number of immunosuppressed states resulting in CMV infection, including AIDS and solid 
organ transplantation. Foscarnet is solely eliminated by glomerular filtration and renal injury 
is typically characterized by reversible tubular necrosis. Foscarnet chelates metallic ions 
and frequently complexes with ionized calcium to form a highly insoluble salt that cannot 
be filtered by the kidney. This patient’s pre-treatment renal function was adequate despite 
history of a solitary functioning kidney. Altered renal hemodynamics in the solitary kidney 
may have enhanced precipitation of Foscarnet-calcium salts despite adequate hydration.
PUB062
Comparison of Estimated Glomerular Filtration Rate (eGFR) and Kinetic 
eGFR (KeGFR) in Critically Ill Intensive Care Unit (ICU) Patients 
Rakesh Malhotra,1 Etienne Macedo,2 Josee Bouchard,3 Ravindra L. Mehta.2 
1VUMC; 2UCSD; 3Univ de Montréal.
Background: Estimation of kidney function in critically ill patients is important for 
appropriate drug dosing and therapeutic strategies. However, current GFR equations are 
not applicable when plasma serum creatinine (sCR) is rapidly changing. Chen et al (JASN 
2013) has recently proposed KeGFR formula to calculate GFR from fluctuating sCR values. 
The aim of this study was to compare KeGFR values with eGFR using the Modification 
of Diet in Renal Disease (MDRD).
Methods: We analyzed data from a cohort of 735 ICU patients screened in a prospective 
observational study on the incidence of AKI from Jun06 to Dec08 at an academic center. 
Demographic data, co-morbidities, clinical course, and laboratory parameters were recorded 
from ICU admission. We estimated KeGFR and eGFR for each patient during the first 48 
hr of ICU stay. We defined KeGFR = (SSPcr × CrCL/ Mean Pcr) × (1 - 24 × ∆ Pcr / ∆ 
Time (h) × Max ∆ Pcr/Day) and MDRD eGFR = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if 
female) × (1.212 if African American). We compared estimated GFR assessed by kinetic 
formula and MDRD GFR equation.
Results: Thirty-two patients with only one time sCR measurements were excluded from 
the analysis. In remaining 703 patients for analysis, the median age was 55 (IQR 23) years; 
62% (n=436) were men and 53% (n=373) were white. In total, 4329 eGFR and KeGFR 
measurements were performed. Estimated GFR predicted by kinetic formula declined earlier 
and remained diminished as compared to eGFR till steady state was achieved.
Conclusions: Our study highlights the overestimation of renal function by MDRD 
equation in critically ill patients with acute kidney injury (AKI). KeGFR may be more 
accurate in tracking renal function changes in AKI. Further studies are needed to confirm 
these findings.
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PUB063
Contrast Induced Nephropathy Among Hospitalized South Africans – 
Impact of Serum Albumin  Justor Banda,1 Saraladevi Naicker.1  1Faculty of 
Health Sciences, Univ of the Witwatersrand, Johannesburg, Gauteng, South 
Africa; 2Faculty of Health Sciences, Univ of the Witwatersrand, Johannesburg, 
Gauteng, South Africa.
Background: Despite ranking 3rd as cause of hospital acquired acute kidney injury 
in hospitalized patients, contrast induced nephropathy (CIN) causes significant morbidity, 
mortality and high hospital costs. In sub-Saharan Africa, information on rates of CIN is 
lacking. This study investigated the rates of CIN and influence of serum albumin on CIN.
Methods: This is an on-going prospective case controlled study conducted at Charlotte 
Maxeke Johannesburg Academic Hospital, in South Africa. In-patients undergoing contrast 
media administration in the Divisions of Radiology and Cardiology were consecutively 
recruited to the study. Ethical approval was obtained from the Human Research Ethics 
Committee of the University of the Witwatersrand. CIN was defined as serum Creatinine 
>25%µmol/l or >44µmol/l from baseline over a 48-72 hours post exposure to contrast 
media. Creatinine clearance was calculated using the CKD-EPI. The following were 
exclusion criteria; age below 18years, evidence of AKI (clinical or laboratory), ESRD and 
prior contrast media administration.
Results: Among 285 recruited hospitalized patients, a rate of CIN was 16.9%. Serum 
albumin below 35d/dl positively predicted development of CIN (RR 2.3, 95% CI 1.14-4.64, 
p=0.020). The mean album was 28.4±4.6 SD and 41±2.39 SD in the CIN and non CIN 
groups respectively. An eGFR <60ml/min was associated with a 6 fold risk of developing 
CIN (P<0.00001).
Conclusions: Rates of CIN is significantly higher in developing countries and the 
presence of hypoalbuminemia, a traditional bio-maker is significantly associated with 
development of CIN.
PUB064
A Curious Case of Evans Syndrome  Sagar R. Patel, Imara Dissanayake. 
Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA.
Background: Evans syndrome is a rare autoimmune condition in which antibodies 
attack their own RBC and platelets resulting in an hemolytic anemia (AIHA) and ITP in 
the absence of a known etiology. Both of these can occur simultaneously or sequentially. 
Although many cases are idiopathic in origin, ES has been associated with other conditions 
in half of the cases, including infections and lymphoproliferative disorders.
Methods: . A 45 year old African American male seen in ED with a Hgb of 6.4 and 
asymptomatic. The patient has a history of autoimmune hemolytic anemia (AIHA), immune 
thrombocytopenic anemia (ITP), anti-phospholipid syndrome (APS) with a previous DVT/
PE and non-compliant with warfarin. labs On admission Hgb 6.4, Plts 114,T Bil 1.3, D 
Bil 0.4, LDH 346, Haptoglobin <8. He had AKI (Cr 0.9), with new onset nephrotic range 
proteinuria. Renal US showed medical renal disease. ANA 1:160, double stranded DNA 
was negative. Anti MPO, P-ANCA, C- ANCA, antiproteinase 3, atypical P-ANCA and 
glomerular basement membrane antibody were negative. CH 50,C3 and C4 were all low. 
No cryoglobulins were detected in the blood assay. Urine Electrophoresis was negative 
for monoclonal light chains. Renal biopsy was performed and showed findings consistent 
with lupus nephritis stage 4/5. The patient was treated with PRBCs and given pulse dose 
steroids for 3 days after which his hemoglobin remained stable.
Results: ES is diagnosed in only 0.8% to 3.7% of all patients with either ITP or AIHA 
at onset. Since it is thought to be secondary to immune dysfunction, a high clinical suspicion 
should be maintained for underlying autoimmune disease. However this patient was unique, 
he did not meet the standard criteria for SLE but demonstrated lupus nephritis on biopsy. 
This has a significant implication in management, and should be treated for his underlying 
SLE which could help in reducing recurrence of Evans syndrome. He responded well to first 
line therapy with corticosteroids and did not require further acute therapy such as IVIG. 
He was started on hydroxychloroquine for SLE and referred to renal clinic for cellcept.
Conclusions: This case reflects that we should have a high suspicion for SLE and 
lymphoproliferative diseases even in asymptomatic patients with Evans Syndrome.
PUB065
Anticoagulation-Free Continuous Renal Replacement Therapy: A Single 
Center Observation  Akshatha Rao, Ziauddin Ahmed.  Div of Nephrology, 
Drexel Univ.
Background: Renal failure in the ICU setting is associated with 40-60% mortality. 
Continuous renal replacement therapy (CRRT) is used for volume and electrolyte 
management in critical care units. To avoid clotting of hemofilters, patients are routinely 
started on anticoagulation. In literature, anticoagulation has been associated with 
complications of increased risk of bleeding and metabolic or electrolyte disturbances based 
on type of anticoagulation used. We aimed to investigate the length of cartridge use and 
the association of anticoagulation.
Methods: We conducted a retrospective review of 20 ICU patients who were started 
on CRRT over a course of two months for acute renal failure. We looked at the number of 
cartridges used per day. Prescription for CRRT was dialysate flow rate of 25-35 ml/kg/hr 
and blood flow rate of 250 ml/hr. No anticoagulation was ordered initially due to bleeding 
risks in this cohort. All patients were ordered 100 ml of normal saline flushes every 4 hours.
Results: For 70% of the patients, the hemofilter cartridge lasted >24 hours. 30% of 
the patients required more than 1 filter per day, of which only 1 patient was started on 
a heparin drip for anticoagulation due to multiple filter changes. We used predilution 
replacement fluid to reduce the blood viscosity and hemoconcentration for the patients 
requiring > 2 filter changes per day. Decreased requirement of filter change was noted 
after these changes were made. Among the patients with increased filter clotting, 33% had 
femoral non-tunneled dialysis catheters and 50 % had internal jugular tunneled dialysis 
catheters. Longer duration of dialysis was associated with increased cartridge use per 
pearson correlation 0.818 (p=0.000). No documentation was made in the nursing notes to 
distinguish between vascular access problems versus filter clotting.
Conclusions: Recurrent filter clotting leads to interruption of RRT. Frequent filter 
changes is not cost effective. However anticoagulation in critical care settings poses 
multiple potential problems. There was an association between permcatheters and increased 
cartridge use.
PUB066
Rosuvastatin Has a Protective Effect against Hypertonicity-Induced Cell 
Damage  Miku Sato, Masaru Horio.  Functional Diagnostic Science, Osaka 
Univ Graduate School of Medicine, Suita, Japan.
Background: Contrast-induced nephropathy (CIN) is one of the causes of acute 
kidney injury. Some studies raised a concern that statins have protective effect against CIN. 
Hypertonic stress in renal tubular cell is a possible factor inducing cell damage in CIN. 
Reactive oxygen species (ROS) can induce apoptosis. We studied the effect of rosuvastatin 
on hypertonicity induced cell damage in MDCK cells.
Methods: Hypertonic medium was made by addition of NaCl. Rosuvastatin was 
added 24 hours before the hypertonic exposure. Cell damage was assessed by LDH activity 
in culture medium. Apoptosis was evaluated by caspase-3 activity. Content of cellular 
glutathione (GSH), an important antioxidant, was measured.
Results: Hypertonicity more than 600 mOsm showed significant cytotoxic effect in 
MDCK cells. LDH activity in culture medium of 620, 640 and 660mOsm cells increased in 
osmolality dependent manner (Figure). Low concentration (0.1 and 1.0 µM) of rosuvastatin 
had a protective effect against the hypertonicity-induced cell damage. On the other hand, 10 
µM rosuvastatin that had no significant cytotoxic effect in 300mOsm condition, stimulated 
hypertonicity induced cell damage. 
Caspase-3 activity in 660mOsm cells was 13 fold higher compared with 300mOsm 
cells. Rosuvastatin (1µM) inhibited the increase of caspase-3 activity about 50%. Cellular 
GSH contents in 300mOsm, 660mOsm and 660mOsm with rosuvastatin after 8h were not 
significantly different (35.7±11, 33.0±8.1 and 34.2±19.2 nmoles/mg protein, respectively). 
Mevalonolactone (100µM)inhibited the protective effect of rosuvastatin, suggesting the 
inhibition of HMG-CoA reductase by rosuvastatin plays an important role of the protective 
effect against hypertonicity induced cell damage.
Conclusions: Low concentration of rosuvastatin has a protective effect on 
hypertonicity-induced cell damage in MDCK cells.
Funding: Government Support - Non-U.S.
PUB067
Transcription Factor SRF Promotes Renal Fibrosis in IgA Nephropathy 
Lijie He, Shiren Sun.  Dept of Nephrology, Xijing Hospital, Xi’an, Shaanxi, 
China.
Background: The role of transcription factors SRF, which regulate CArG element 
contained genes, in IgA nephropathy is unknown.
Methods:  Here we performed expression of SRF in human IgA nephropathy tissues 
from ItoV stage and the cultured proximal tubular cells (HK-2) under hypoxia or induced 
by TGF-bcompared with control conditions.
Results:  we performed SRF expression from formalin-fixed, paraffin-embedded 
tissues from renal biopsies diagnosis as IgA nephropathy. We noted the greatest change 
in SRF expression, which was significantly higher in IgAV stage compared with early 
presenters, like IgA Ior IIstage. Furthermore, in individual biopsies, high expression of SRF 
correlated with tubulointerstitial fibrosis and low estimated GFR. Next, in vitro, we identified 
overexpression of SRF was observed in hypoxia-induced HK-2 cells. Treatment of HK-2 
with TGF-bincreased SRF expression. Lower expression of SRF suppressed expression of 
the CArG element snail1, thereby opposing TGF-β-mediated downregulation of E-cadherin.
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Conclusions:  In summary, high expression of SRF associates with increased fibrosis 
and decreased estimated GFR in IgA nephropathy in vivo, perhaps by enhancing TGF-β-
mediated downregulation of snail and E-cadherin in HK-2.
PUB068
Increased Erythrocyte Reactive Oxygen Species Production Induced by 
Indoxyl Sulfate Precedes Red Blood Cell Death  Gabriela Ferreira Dias,1 
Viktoriya Kuntsevich,2 Lia S. Nakao,3 Fellype C. Barreto,1 Stephan Thijssen,4 
Peter Kotanko,2,4 Roberto Pecoits-Filho,1 Andrea Novais Moreno-Amaral.1 
1Pontifícia Univ Católica do Paraná, Brazil; 2Icahn School of Medicine at 
Mount Sinai, New York; 3Univ Federal do Paraná, Brazil; 4Renal Research 
Inst, New York.
Background: The uremic toxin indoxyl sulfate (IS) triggers eryptosis, an event 
characterized by phosphatidylserine (PS) exposure on red blood cell (RBC). The aim of 
the present study was to evaluate whether increase in RBC reactive oxygen species (ROS) 
induced by IS precedes eryptosis.
Methods: RBC from healthy controls (HC) were incubated for 4, 12 or 24h with 
IS (free concentration 4.5 mg/L) in the presence or absence of free radicals scavenger 
N-acetylcysteine (NAC 0.5mM). Flow cytometry was employed to assess eryptosis 
(annexin-V+ binding) and ROS (DCFH-DA).
Results: Incubation of HC-RBC with IS over 4h did not trigger significant eryptosis 
compared to control cells incubated without IS (4.5±1.2% vs 3.4±0.2%). However, 12h and 
24h incubation with IS increased levels of eryptosis in a time-dependent manner (10.4±3.4% 
and 16.6±6.1, respectively). This IS-induced PS exposure on HC-RBC was inhibited in 
the presence of NAC (6.0±1.3% and 6.5±1.4%, respectively). On the other hand, ROS 
production by HC-RBC was increased even after only 4h of incubation with IS in a time-
dependent manner (14±4.2%, 22.1±5.3 and 34.8±15.8% for 4h, 12h and 24h respectively) 
when compared to control cells (4.6±2.3%, 4.2±0.5% and 5.2±8%, respectively). ROS 
production was inhibited in the presence of NAC (6.6±3.4%, 6,3±2% and 13.4±10.5%) 
demonstrating the ability of an antioxidant to reverse the oxidative stress induced by IS.
Conclusions: Taken together our results suggest that IS in a high free concentration, 
which is in accordance with reported free toxin concentration in patients, induces ROS 
production in HC-RBC that precedes PS exposure. Thus, imbalance of RBC redox status 
induced by IS appears to be an important mechanism of elevated eryptosis observed in 
CKD that consequently may contribute to renal anemia.
PUB069
Impact of Constitutive C-MIP Expression on Mouse T-Cell Proteome 
Mario Ollero,1 Pauline Vachin,1 Cerina Chhuon,2 Kélhia Sendeyo,1 Melanie 
Mangier,1 Ida Chiara Guerrera,2 André Pawlak,1 Djillali Sahali.1  1INSERM, 
U955 (Eq. 21), Créteil, France; 2Plateau Protéomes Necker, Paris, France.
Background: The protein c-mip is overexpressed in lymphocytes and podocytes of 
MCNS patients. In order to dissect its role in INS pathogenesis, we generated a transgenic 
mouse expressing c-mip in peripheral mature T-cells. We aimed to evaluate the impact of 
c-mip expression on T-cell proteome in basal and stimulating conditions.
Methods: T-cells from transgenic (Tg) and control (Wt) mice (n=3) were purified by 
negative immunoselection, and subjected to anti-CD3 and anti-CD28 stimulation, to mimic 
activation by antigen presenting cells. At 0 and 60 min post-activation, total proteins were 
extracted, trypsin digested, and peptides analyzed by nano-RSLCC Q Exactive Plus MS. 
Protein quantification was performed by a label-free approach using MaxQuant and Perseus 
softwares on three parallel technical replicates per sample.
Results: The expression levels of 2660 proteins were compared in the four conditions. 
As a result, 46 proteins were found differentially expressed between Tg and Wt as a function 
of T-cell activation (two-way ANOVA interaction, p<0.05). Among these, GO annotation 
showed a significant enrichment in proteins bearing ATPase activity. Hierarchical clustering 
by K-means algorithm displayed, most remarkably, a cluster of 14 proteins upregulated 
upon T-cell activation in Wt mice but depleted in Tg mice in the same conditions - including 
KEGG annotations for tight junction, Wnt signaling, TLR signaling, RIG-I-like receptor 
signaling, Notch signaling, spliceosome, riboflavin metabolism, and DNA replication-, and 
a cluster of 11 proteins depleted in Wt and augmented or unchanged in Tg after activation 
– involved in aminoacid and nicotinamide metabolism, proteasome, and regulation of actin 
cytoskeleton-. Studies are underway to explore the mechanisms involved.
Conclusions: c-mip overexpression exerts profound alterations in the protein 
expression pattern following T-cell activation in mice, involving diverse signaling, 
metabolic pathways and cellular functions. These results, along with other preliminary 
data obtained from the same mouse model, point at a defect in T-cell activation associated 
with c-mip expression.
Funding: Government Support - Non-U.S.
PUB070
An Investigation into the Prognosis of Nephrotic Syndrome and Regulatory 
T Cells in Elderly People  Tetsuhiko Yasuno.  Internal Medicine, Fukuoka 
Univ, Fukuoka, Japan.
Background: Peripheral blood flow cytometry analysis of nephrotic syndrome (NS) in 
children has been performed, and among T cells, regulatory T cells (Tregs) are involved in 
NS. In adults, there are reports about Tregs and ANCA-associated glomerulonephritis, and 
the nephritic inhibitory effect of Tregs has become clear. As there has been no investigation 
focusing only on NS in elderly people, we conducted the analysis in this study.
Methods: In this investigation, we examined 7 patients aged 65 years or older who had 
NS. Regarding the primary disease, 3 of these patients had membranous nephropathy, 1 had 
minimal change, 1 had immunotactoidglomerulopathy (ITG), 1 had diabetic nephropathy, 
and 1 had Lupus nephritis. Flow cytometry using peripheral blood was conducted, and 
among T cells, the percentage of Th1, Th2, Treg, and Th17 was examined.
Results: The average value of Th1 cells was 31.8%, Th2 was 4.2%, Treg was 9.3%, 
and Th17 was 2.6%. The patient with ITG had a higher percentage of Treg (19.9%), but 
this patient achieved complete remission after 2 years owing to the administration of a 
steroid and mizoribine. For the other patients, there were no distinctive features for the 
2-year prognosis.
Conclusions: The Treg value was higher for the patient with ITG. However, as only 
1 such patient was examined, it is unclear whether this was because of a disease or was 
a unique phenomenon for this patient. It is possible that peculiar T cell actions could be 
involved in elderly people, so various ailments of NS should be further investigated by 
using flow cytometry.
PUB071
Antibodies against Linear Epitopes on a3(IV)NC1 in Patients with 
Antineutrophil Cytoplasmic Antibodies Associated Vasculitis  Xiaoyu Jia,1 
Juntao Yu,2 Zhao Cui,1 Minghui Zhao.1,3  1Renal Division, Peking Univ First 
Hospital, Beijing, China; 2Academy for Advanced Interdisciplinary Studies, 
Peking Univ, Beijing, China; 3Peking-Tsinghua Center for Life Sciences, China.
Background: In a substantial number of patients with crescentic glomerulonephritis, 
both anti-glomerular basement membrane (GBM) antibodies and antineutrophil cytoplasmic 
antibodies (ANCA) are detected simultaneously. ANCA is presumed to be the initial event 
leading to the production of anti-GBM antibodies. In the present study, we investigated the 
antibodies against linear epitopes on a3 chain of type IV collagen (a3(IV)NC1) in patients 
with ANCA associated vasculitis who had no classical anti-GBM antibodies, aiming to 
reveal the mechanisms of the coexistence of the two kinds of autoantibodies.
Methods: Twenty-four overlapping linear peptides were synthesized across the whole 
sequence of a3(IV)NC1 and antibodies were detected by ELISA.
Results: We found 25/31 (80.6%) ANCA associated vasculitis patients possessing 
antibodies against linear peptides on a3(IV)NC1. These antibodies were detected from 50% 
of patients with normal renal function (Scr£133mmol/L), 70% of patients with moderate 
renal dysfunction (133mmol/L<Scr≤600mmol/L), and 94% of patients with renal failure 
(Scr>600mmol/L). Patients with more aggravated renal damage had higher frequency of 
peptide recognition (P=0.032). The highest recognition frequencies were found for peptides 
P4 (51.6%), P14 (54.8%) and P24 (54.8%), which contained the sequences that constitute 
the epitopes EA (P3) and EB (P14 and P24) on a3(IV)NC1. The level of anti-P4 antibodies 
was positively correlated with the percentage of crescents in glomeruli (r=0.764, P=0.027). 
Patients with anti-P24 antibodies had a significantly higher prevalence of renal dysfunction 
on diagnosis (88.2% vs. 42.9%, P=0.018).
Conclusions: In conclusion, antibodies against linear peptides on a3(IV)NC1 could 
be detected in patients with ANCA associated vasculitis who had no classical anti-GBM 
antibodies and were associated with clinical features.
PUB072
Urine suPAR and CD80 Levels in Patients with Focal Segmental 
Glomerulosclerosis and Minimal Change Nephrotic Syndrome 
Chang-Yien Chan, Yaochun Zhang, Wee Song Yeo, Isaac Liu, Hui Kim Yap. 
Pediatrics, National Univ of Singapore, Singapore.
Background: Recent studies suggested soluble urokinase-type plasminogen activator 
receptor (suPAR) as the plausible circulating factor in the pathogenesis of focal segmental 
glomerulosclerosis (FSGS) while patients with minimal change nephrotic syndrome 
(MCNS) were reported to have increased CD80 levels in the urine. This study aimed to 
determine the value of urine suPAR and CD80 levels in distinguishing between FSGS and 
MCNS in patients with nephrotic relapse.
Methods: Plasma and urine suPAR and CD80 levels were analyzed in 51 primary 
nephrotic patients in relapse with urine protein:creatinine ratio of >0.2g/mmol (26 MCNS, 
25 FSGS) and 24 healthy controls, using Quantikine Human uPAR Immunoassay (R&D 
Systems) and Human sCD80 Elisa kit (eBioscience). Urine were concentrated using 
centrifugal filter units with molecular weight cut-offs at 3kDa (Amicon) before quantification 
of sCD80. Urine levels of suPAR and CD80 were normalised with urine creatinine. Results 
were expressed as mean±SEM. Statistical analysis was done using Mann-Whitney test.
Results: Plasma suPAR levels in patients with FSGS (3216.8±295.2pg/ml) were 
significantly higher than controls (2330.8±207.2pg/ml) and MCNS patients in relapse 
(2178.9±196.7pg/ml) (p<0.02). Urine levels of suPAR were significantly higher in both 
MCNS (351.8±52.3pg/µmol, p=0.02) and FSGS (381.6±52.9pg/µmol, p=0.012) compared 
to control (210.4±20.2pg/µmol). There was modest correlation between suPAR levels in 
plasma and urine (Spearman’s ρ=0.509, p<0.001). We were unable to detect CD80 levels 
in plasma samples even after removal of high-abundance proteins in the plasma samples 
with the combinatorial peptide ligand library beads (ProteoMiner). Urine CD80 levels were 
2.5-fold higher in MCNS (0.31±0.13ng/µmol) compared to controls (0.13±0.03ng/µmol, 
p=0.19) and 1.6-fold compared to FSGS (0.19±0.49ng/µmol, p=0.44).
Conclusions: Our study suggested that neither urine suPAR levels nor the CD80 levels 
are useful to distinguish patients with FSGS or MCNS.
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PUB073
Effects of 1,25-Dihydroxy Vitamin D3 on Treg cells, Interleukin -17, RORgt 
in Rats with IgA Nephropathy  Hui Guo.  Div of Nephrology, 2nd Affiliated 
Hospital of Shanxi Medical Univ, Taiyuan, Shanxi, China; Div of Rheumatology, 
2nd Affiliated Hospital of Shanxi Medical Univ, Taiyuan, Shanxi, China.
Background: To investigate the relationship between Treg cells, RORgt, IL-17 and 
rats with IgA nephropathy; to explore the intervention effect of 1,25(OH)2D3 on Treg cells, 
RORgt, IL-17 expression in rats with IgA nephropathy.
Methods: We choosed Wister 52 rats, with witch 8 rats were choosed in control 
group (group E) in random, while other 44 rats were established the IgA nephropathy 
model by mucosal immune with bovine serum albumin and were divided into model 
group,1,25(OH)2D3 treated group, prednisone treatment group and prednisone +1,25(OH)2D3 
treatment group. The change of 24 hours of urinary protein, red blood cells in urine, 
creatinine and blood calcium of rats were detected. Foxp3, RORgt and IL-17 levels were 
detected by using RT-PCR, Immunohistochemistry and Westernblot.
Results: The level of RORgt, IL-17 in model groups were higher than prednisone 
treatment group, prednisone+1,25(OH)2D3 treatment group,1,25(OH)2D3 treatment group 
and control group (p<0.05). After treatment the expression of RORgt, IL-17 of each 
group were declined significantly (p<0.05). The prednisone+1,25(OH)2D3 treatment group 
declined significantly compare to prednisone treatment group and 1,25(OH)2D3 treatment 
group (p<0.05). The expression of Foxp3 decreased significantly in IgAN group. After 
treatment with 1,25(OH)2D3, the level of Foxp3 increased significantly.
Conclusions: Treg cells, IL-17 and RORgt may participate in the occurrence/
development of IgAN; 1,25(OH)2D3 may play a role in immune regulation by regulating 
the expression of Treg cells ,IL-17 and RORgt directly or indirectly.
Funding: Government Support - Non-U.S.
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MGRS, Complement and C3 Glomerulopathy  Yuzhou Zhang,1 Fernando 
C. Fervenza,2 Christopher D. Blosser,3 Peter M. Fitzpatrick,4 Dingwu Shao,1 
Niamh Kieran,3 Carla M. Nester,1 Sanjeev Sethi,2 Nicolae Leca,3 Richard J. 
Smith.1  1Carver College of Medicine, Univ of Iowa, Iowa City, IA; 2Mayo 
Clinic, Rochester, MN; 3Univ of Washington Medical Center, Seattle, WA; 4Mayo 
Clinic, Jacksonville, FL.
Background: Monoclonal gammopathy of renal significance (MGRS) implies a causal 
relationship between clonal B cell proliferation and renal disease. By definition, these 
patients do not meet criteria for overt multiple myeloma/B-cell proliferation, however 
their hematologic disorder is not of undetermined significance. Rather, it is associated 
with high morbidity secondary to renal compromise induced by circulating monoclonal 
immunoglobulins (MIg). Recently, a subset of MGRS with dominant glomerular C3 
deposition or MGRS-C3 glomerulopathy (C3G) has been reported.
Methods: Factor H (FH) autoantibodies, free light chains against FH and factor B 
(FB) autoantibodies were detected by ELISA. C3 nephritic factors were detected using 
ELISA and hemolytic-based assays.
Results: Six patients developed MGRS-C3G triggered by four different mechanisms 
of action. The first mechanism of action, identified in three patients, was an IgG form of 
MIg to FH. These FH autoantibodies compromised function of FH, the only fluid-phase 
negative regulator of the alternative pathway (AP) of complement. The second mechanism, 
identified in one patient, was a free light chain (FLC) form of MGRS against FH. The 
FLCs acted as mini autoantibodies against the N-terminus of FH and impaired cofactor 
activity. The third mechanism, also identified in one patient, was an IgG form of MIg to 
FB as FB autoantibodies, resulting in increased activity of C3 convertase (C3bBb). The 
final mechanism, identified in one patient, was an IgG form of MIg, as a C3 nephritic factor 
that bound to and stabilized C3bBb.
Conclusions: These findings highlight the variability in autoantibodies associated 
with MGRS-C3G, thus mandating a comprehensive and detailed analysis of the alternative 
pathway in these patients. Acknowledgment: We gratefully acknowledge both the clinicians 
across North America who allow us to study their patients, and the patients, whose 
participation enhances our understanding of rare complex renal diseases.
PUB075
Elucidation of Tubulo-Interstitial Injury in Chronic Kidney Ischemia by 
Use of Novel Renal Artery Coiling Model  Kentaro Fujii, Kazutoshi Miyashita, 
Hiroyuki Inoue, Aika Hagiwara, Masanori Tamaki, Masaaki Sato, Hiroshi Itoh. 
Internal Medicine, School of Medicine, Keio Univ, Tokyo, Japan.
Background: Recent studies emphasize an essential role for tubulointerstitial hypo-
perfusion in the progression of chronic kidney disease (CKD) as a common pathway to 
end stage renal disease (ESRD). However, the mechanism of renal injury needs further 
to be elucidated.
Methods: Most previous animal models which aimed to simulate renal ischemia 
have been ischemic-reperfusion injury model, which shows major characteristics of acute 
kidney injury. To elucidate the progression of kidney dysfunction with chronic ischemia, 
we developed novel renal ischemia model by setting a coil around a left renal artery of 
right hemi-nephrectomized mice and reducing the kidney bloodstream for 80 %. The coil 
was made of the titanium and the inside diameter is from 0.17 to 0.28 mm.
Results: After transient decline in renal function until post-operative day 14, slowly 
progressive renal dysfunction and elevation of N-acetyl-β-D-glucosaminidase (NAD) in 
urine were observed in the chronic renal ischemia model from post-operative day 14 to 
84. A histological observation of the ischemic kidney on post-operative day 7 revealed no 
remarkable changes from control kidneys and there are no findings of tissue injury and 
infiltration of inflammatory cells. However, the progression of tubulointerstitial fibrosis 
and the increase in the markers for apoptosis and oxidative stress were significant from 
post-operative day 28 to 84. Real-time quantitative PCR analysis in ischemic kidney 
revealed the progressive changes of the hypoxia-responsive gene expressions such as 
pyruvate dehydrogenase kinases.
Conclusions: These data suggests that the novel chronic renal ischemia model by 
coiling renal artery is an appropriate animal model for CKD, which shows a slowly 
progressive tubulointerstitial injury.
Funding: Government Support - Non-U.S.
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Dialysis Induces Morphological Changes and Eryptosis in Erythrocytes 
Grazia Maria Virzì, Sabrina Milan Manani, Anna Clementi, Alessandra Brocca, 
Massimo de Cal, Claudio Ronco.  IRRIV and Dept Nephrology Vicenza.
Background: Suicidal death of erythrocytes (eryptosis) is characterized by cell 
shrinkage, membrane blebbing, activation of proteases, and phosphatidylserine (PS) 
externalization. Exposed PS is recognized by macrophages that engulf and degrade affected 
cells. Eryptosis is a physiological mechanism under complex regulation. During their 
daily life, erythrocytes (RBCs) are exposed to several stress stressors, such as oxidative 
stress, osmotic shock, energy depletion. Eryptosis is observed in a wide range of clinical 
conditions, such as CKD, malignancy, diabetes and sepsis. The aim of this study was 
analysed cell volume and PS abundance at the RBC surface in peritoneal dialysis (PD) 
and hemodialysis (HD).
Methods: 40 PD patients, 30 HD patients and 17 healthy subjects (CTR) were included 
in the study. All measurements were made in isolated RBCs. RBC volume and morphology 
was estimated from forward scatter, PS exposure at the cell surface was estimated from 
FITC-AnnexinV binding using flow cytometric analyses.
Results: We observed that the RBCs of PD and HD patients are indeed rather 
dramatically deranged in their morphology. Furthermore, the PS externalization on the RBC 
surface was significantly higher in these groups than in CTR (PD patients: 2.6%; IQR 1.6-
3.7, HD patients: 2.2%; IQR 1.2-4.1 versus CTR: 0.8%; IQR 0.7-1.3; p=0.000001). We did 
not find significant differences in PS exposure between the PD and HD patients (p=0.47).
Conclusions: In conclusion, the percentage of eryptosis has indeed been shown to be 
significantly higher in patients on dialysis than CTR. Our data suggest that dialysis may 
induce morphological changes in erythrocytes and may lead to a significant increase in 
eryptosis, but no differences in its level were observed between PD and HD. Additional 
efforts will be required to define major eryptosis-inducing components in uremic, PD 
and patients.
Funding: Private Foundation Support
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Toll Like Receptor 2, 4 and 9 Expression Is Enhanced in Kidneys of Patients 
with Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis (AAV) 
Kim M. O’Sullivan,1 Anthony Longano,3 A. Richard Kitching,1,2 Stephen R. 
Holdsworth.1,2  1Dept of Medicine, Monash Univ, Clayton, Victoria, Australia; 
2Dept of Nephrology, Monash Health, Clayton, Victoria, Australia; 3Pathology 
Dept, Monash Health, Clayton, Victoria, Australia.
Background: Toll like receptors (TLRs) may be the possible link between infection 
and autoimmunity. This study investigates the distribution of TLR2, 4 and 9 in human 
kidney biopsies from patients with AAV (40), lupus (8) and controls (with non proliferative 
glomerular lesions, minimal change and thin membrane disease, 10).
Methods: Biopsies were examined by confocal microscopy with immunofluorescent 
staining in serial sections for the cellular distribution of TLR2, 4 and 9. Mean fluorescent 
intensity (MFI) was measured by imaging software (Image J) and was correlated with 
histopathological parameters.
Results: TLR2, 4 and 9 in the AAV group, (for both MPO and PR3 patients) had 
significantly stronger staining than controls in glomeruli (1.5 vs 13.3AU; 0.25 vs 32.0AU; 
0.7 vs 36.2AU, all P<0.05, respectively) and the interstitium (7.4 vs 63.0AU; 0.41 vs 
53.8AU; 1.6 vs 59.6 AU, all P<0.05, respectively). The lupus patients also had higher 
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expression of TLR2 (4.8AU), 4 (12.6AU) and 9 (7.3AU, P<0.05) compared with controls, 
but their staining was significantly less than that of the AAV group for all TLRs (P<0.05). 
Cellular infiltrates contained intense staining for TLR2, 4 and 9 on macrophages and 
neutrophils in both glomeruli and interstitium. TLR2 and TLR4 staining was prominent on 
both endothelial cells and podocytes, although TLR9 was particularly evident on podocytes. 
In AAV glomerular TLR4 expression correlated with the % of normal glomeruli,(r=0.48, 
P<0.05) suggesting TLR4 prominence occurs in early glomerular lesions. Glomerular TLR2 
and 9 were present concurrently in more severely affected glomeruli (r=0.71, P=0.0001). 
TLR2, 4 and 9 were prominent in all crescentic glomeruli of AAV and lupus patients.
Conclusions: This study demonstrates that TLR expression is most prominent in AAV. 
Significant expression of TLRs was evident on leukocytes and intrinsic glomerular cells. 
TLR4 is prominent in early glomerular lesions, while TLR2 and 9 correlate with severe 
glomerular lesions.
Funding: Government Support - Non-U.S.
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Podocyte CD40 Expression in Patients with Post-Transplant FSGS 
Recurrence  Rutger J. Maas,1 Brigith Willemsen,2 Henry Dijkman,2 Jeroen 
Deegens,1 Jack F. Wetzels.1  1Nephrology, Radboud Univ Medical Center, 
Nijmegen, Netherlands; 2Pathology, Radboud Univ Medical Center, Nijmegen, 
Netherlands.
Background: antibodies against CD40 were recently reported to predict post-transplant 
recurrent FSGS (rFSGS) with 78% accuracy (Delville et al. Sci Transl Med 2014). Using 
immunohistochemistry, the authors reported strong focal podocyte CD40 expression in 
glomerular lesions of two patients with rFSGS. We sought to validate this novel finding of 
podocyte CD40 expression as a potential marker of rFSGS.
Methods: we used formalin-fixed, paraffin embedded kidney tissue from five patients 
with rFSGS. Two samples were obtained from nephrectomy specimens, and three were 
needle biopsy specimens. All patients had nephrotic range proteinuria at the time of tissue 
sampling. A human tonsil was used as a positive control. For immunohistochemistry, 
four mm slides were cut and deparaffinised. After endogenous peroxidase block, antigen 
retrieval was performed by boiling in a microwave with EDTA buffer (pH 9.0). Slides were 
incubated with primary antibody mouse anti CD40 (clone 11E9, Abcam ab50849) diluted 
in PBS with 1% BSA overnight at 4°C. Detection was done with Brightvision biotin-free 
goat anti rat/rabbit/mouse poly HRP (Immunologic) and DAB as substrate.
Results: specificity and adequacy of the staining was confirmed by strong CD40 
expression in tonsillar germinal centers (Figure, panel A). In kidney samples from patients 
with rFSGS, CD40 staining was found in areas of interstitial cellular infiltration, and some 
tubular epithelial cells (Figure, panel B). However, no glomerular CD40 was detected in 
any of the rFSGS samples.
Conclusions: we could not confirm glomerular CD40 staining in rFSGS with 
immunohistochemistry. The role of CD40 antibodies in rFSGS pathogenesis needs further 
study and validation. 
Funding: Private Foundation Support
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Increased Cellular Microchimerism in Women with Systemic Lupus 
Erythematosus  Suzanne Wilhelmus,1 Malu Zandbergen,1 Emilie Rijnink,1 
Juan D. Diaz de Pool,2 Mathilde M.M. Almekinders,1 Hans J. Baelde,1 Jan A. 
Bruijn,1 Ingeborg M. Bajema.1  1Pathology, Leiden Univ Medical Center, Leiden, 
Netherlands; 2Gynaecology, Leiden Univ Medical Center, Leiden, Netherlands.
Background: Microchimerism (Mc) has been suggested to play a role in the 
development of systemic lupus erythematosus (SLE). We previously showed that Mc occurs 
twice as often in kidney biopsies of patients with lupus nephritis as in controls. Recently, it 
was demonstrated that the amount of Mc in lupus nephritis is associated with renal function 
(Arthritis Research & Therapy, 2015). Because in previous studies the Y chromosome was 
used to detect Mc, these studies were limited to detecting male Mc and the origin of the 
chimeric cells remained largely unknown. The aim of the present study was to determine 
the frequency, amount and origin of chimeric cells in SLE patients and controls, by using 
insertion-deletion polymorphisms and null alleles for the detection of Mc.
Methods: We included 11 SLE patients and 22 controls, as well as their children and 
mothers. A quantitative PCR for insertion-deletion polymorphisms and null alleles was 
used to detect Mc in peripheral blood mononuclear cells and granulocytes. The relationship 
between the presence of Mc and disease onset, disease activity and accumulated damage 
since disease onset was investigated.
Results: Mc was detected more often in SLE patients than in controls (54.4% vs 
13.6%, p=0.03), and was fetal in origin in almost all cases. The median total number of fetal 
chimeric cells was significantly higher in patients than in controls (5/106 versus 2.5/106, 
p=0.048). In 50% of SLE patients with Mc, Mc originated from multiple relatives whereas 
in controls Mc was derived from only one relative. We found no relationship between Mc 
and clinical or laboratory parameters.
Conclusions: SLE patients had Mc in peripheral blood more often than controls, and 
at higher levels. We showed that Mc was mostly fetal in origin and, in SLE patients, could 
be derived from multiple relatives. Our findings substantiate the role for Mc in autoimmune 
diseases such as SLE.
Funding: Private Foundation Support
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An Oxalate-Induced Mouse Model of CKD That Displays Common CKD 
Complications  Hans J. Anders,1 Shrikant R. Mulay,1 Jonathan Nicodemos 
Eberhard,1 Victoria Pfann,2 Julian A. Marschner,1 Simone Romoli,1 Jyaysi Desai,1 
Santhosh Kumar Vr,1 Peter S. Aronson,3 Felix Knauf.2  1Univ of Munich; 2Univ 
of Erlangen-Nürnberg; 3Yale Univ School of Medicine.
Background: Chronic kidney disease (CKD) research is limited by the lack 
of a convenient inducible C57BL/6 mouse model mimicking relevant human CKD 
complications. We have reported a high soluble oxalate diet (50 µmoles/g sodium oxalate 
mixed with virtually calcium free diet) that induces a progressive decline in glomerular 
filtration rate (GFR) reflected by increasing creatinine as well as blood urea nitrogen levels 
in C57BL/6 mice.
Methods: All in vivo experiments were approved by the local government authorities. 
Computed tomography, ultrasound and MRI were used for imaging.IHC, RT-PCR were 
used for data analysis. GFR was measured using single i.v. bolus injection of FITC sinistrin 
in conscious mice.
Results: We now demonstrate that mice fed this high soluble oxalate diet develop typical 
CKD complications such as sustained hypertension, normochromic anemia, metabolic 
acidosis, hyperphosphatemia, hyperparaphyroidism, and hyperkalemia. Renal histology 
is characterized by calcium-oxalate crystal plugs in the tubular lumen, tubular atrophy, 
interstitial fibrosis, and atubular glomeruli. This pathophysiology of CKD resembles that 
of primary hyperoxaluria type I, also in terms of renal ultrasound, computed tomography, 
and magnetic resonance imaging. The duration of feeding a high soluble oxalate diet 
determines the amount of nephron loss, interstitial fibrosis, and impaired GFR equivalent 
to different stages of CKD. This can be used to produce various levels of stable impaired 
baseline GFR, a useful way to study, for example, AKI on precedent CKD.
Conclusions: We conclude that feeding a high soluble oxalate diet is a convenient 
way to induce progressive and stable CKD with clinically established complications in 
C57BL/6 mice. This model should serve to be useful for many areas of CKD research and 
avoid surgery to induce nephron loss or renal fibrosis.
PUB081
Cyclosporine A Reduces Renal Injury Through Protecting Glomerular 
Charge Barrier in Passive Heymann Nephritis  Zilong Li, Juan Wang, Lining 
Wang.  Dept of Nephrology, First Affiliated Hospital of China Medical Univ, 
Shenyang, Liaoning, China.
Background: Cyclosporine A (CsA) has been reported to reduce proteinuria in several 
kinds of kidney diseases. Glomerular charge barrier plays an important role in preventing 
urinary protein loss. The aim of this study was to elucidate the effects of CsA on glomerular 
charge barrier in passive Heymann nephritis (PHN).
Methods: Wistar rat PHN model was established by injecting antiserum against renal 
tubular epithelial antigens (anti-Fx1A) following pre-immunization. The experiment 
included Group 1: PHN control, Group 2: PHN plus CsA treatment before anti-FxlA 
injection, Group 3: PHN plus CsA treatment for the first 7 days after injection, and Group 
4: PHN plus CsA treatment from the 8th day after injection. Serum creatinine (sCr) and 
urinary protein (uPro) were measured at the 7th and/or the 14th day. Kidney tissues were 
obtained at the 14th day and labeled with a cation tracer polyethyleneimine (PEI) to study 
the distribution of negative charges on glomerular basement membrane (GBM). Kidney 
pathological changes were investigated.
Results: PHN model was established showing proteinuria and kidney injury of 
thickened GBM, a mass deposition of immune complex (IC), and decreased density and 
disturbed distribution of negative charges along the GBM. sCr was not increased in all of 
groups. With CsA treatment, uPro was significantly declined in Group 2 and 3 at 7th day, 
and in Group 2 and 4 at 14th day. In Group 2, it showed little pathological changes in kidney 
with less IC deposition and negative charges distributed evenly. In Group 3 and 4, the 
deposition of IC was reduced, and the negative charges distribution was repaired showing 
stronger density compared to Group 1, while less regularly arranged compared to Group 2.
Conclusions: Using a rat model of PHN, CsA was able to protect glomerular charge 
barrier, which might benefit from the regulation of Ca2+ influx and reduction of IC deposition, 
thus minimizing proteinuria and renal injury.
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Absence of Caspase-1 Attenuates Adriamycin-Induced Nephropathy 
Jinghui Luo,1 Yingbao Yang,1 J. Michelle Kahlenberg,2 Tamra J. Reed,2 Stephanie 
Wylie,1 Christopher Lund O’Connor,3 Jeffrey B. Hodgin.1  1Pathology, Univ of 
Michigan, Ann Arbor, MI; 2Rheumatology, Univ of Michigan, Ann Arbor, MI; 
3Univ of Michigan, Ann Arbor, MI.
Background: Recent studies have demonstrated a pathogenic role of caspase-1 in 
mediating proteinuria-associated renal injury. As a chronic proteinuric renal disease model, 
adriamycin (ADR)-induced nephropathy (AIN) has been characterized by podocyte injury 
followed by glomerulosclerosis (GS), tubulointerstitial inflammation and fibrosis, but the 
mechanisms underlying it remain poorly understood. Based on the evidence that oxidative 
stress stimulates inflammasome activation which subsequently contributes to renal injury, 
we hypothesize that abolishing caspase-1 expression in the kidney may be protective.
Methods: Male caspase-1 knockout (KO) and wildtype (WT) mice on the BALB/c 
background were injected with ADR (10.5 mg/kg) or saline at 8-10 weeks of age. Twenty 
four-hour-urine was collected and the mice were sacrificed 14 days post the injection. 
Creatinine (Cr), triglycerides, and total cholesterol (TCH) were determined in serum, 
and histological analyses, western blot, and RT-qPCR were performed in kidney tissue.
Results: ADR triggered overexpression of caspase-1 and IL-1β in kidney tissue of 
WT mice, but not in that of KO mice. ADR induced albuminuria and GS, which was 
accompanied with decreased kidney weight/body weight ratio (Kw/Bw), and increased Cr 
and TCH levels in both KO and WT mice. Compared with WT animals, KO mice showed 
significantly lower ACR, reduced GS scores, increased Kw/Bw, and attenuated Cr levels 
(P<0.05 each). Meanwhile, elevated expression of TNF-α and INF-γ, augmented 12-LO, and 
decreased PPAR-α, SDHA, and SOD2 levels were observed in ADR-treated kidneys, and all 
these changes were shown to be significantly ameliorated in KO mice. In addition, positive 
correlation between Cr and TCH was recognized in both KO and WT ADR-treated mice.
Conclusions: Cytokine-mediated inflammatory cascade, hyperlipidemic injury, and 
impaired mitochondrial function are all responsible for ADR-induced kidney injury. 
Caspase-1 might be a potential therapeutic target in proteinuric renal disease.
Funding: NIDDK Support, Other NIH Support - ASN-Nephcure Foundation
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Glomerular HO-1 Expression Control by Hemin: Role of Hemopexin 
Maria Detsika,1 Vasileios Atsaves,1 Emanuela Tolosano,3 Pu Duann,2 Elias A. 
Lianos.1,2  1Medicine, Univ of Athens, Greece; 2Medicine, Rutgers Biomedical 
and Health Sciences, NJ; 3Molecular Biotechnology Center, Univ of Torino, Italy.
Background: Hemopexin (HPX) maintains low free heme levels in serum thus 
mitigating heme-associated cell injury. HO-1 induction also minimizes injury by degrading 
heme to CO and bile pigments. In hemolytic disorders, heme scavenging by HPX is 
overwhelmed and glomeruli may be exposed to high free heme, exceeding 200 µM. 
However, while HO-1 prominently increases in tubules, it is barely detectable in glomeruli. 
We hypothesized that this is due to presence of a HO-1 expression “threshold” above which 
HO-1 induction in glomeruli is not sustainable.
Methods: hmox1+/- rats were generated by Zinc Finger Nuclease (ZFN)-mediated HO-1 
gene disruption and rats with GEC targeted HO-1 overexpression (GECHO-1) by Sleeping 
Beauty Transposon mediated transgenesis using a nephrin promoter. Glomeruli from wild 
type (WT) or hmox1+/- or GECHO-1 rats were incubated for 18 h with 10% HPX replete 
(HPX+) or HPX-deficient (HPX-) serum obtained from HPX knock-out mice. Exogenous 
heme was added at concentrations encountered in hemolytic disorders (100-400 µM). HO-1 
protein levels were assessed by western blot.
Results: HO-1 protein was reduced by 70% in hmox1+/- and increased by 2-fold in 
GECHO-1 glomeruli. HO-1 protein levels were no different between 10% HPX+ serum vs 
serum-free media. In incubations with varying dilutions of HPX- serum (1.25, 2.5, 5, 10%) 
HO-1 levels in WT glomeruli progressively increased and were 2.5-fold higher with 10% 
HPX- serum compared to 10% HPX+ serum. Co-incubation with 10% HPX- serum and 
heme (200, 400 µM) markedly reduced HO-1. This reduction was attenuated in incubations 
with higher dilutions (2.5 %) of HPX- serum or with 10% HPX+ serum. The effect of heme 
on HO-1 levels in glomeruli incubated with HPX- serum was recapitulated in GECHO-1 
glomeruli. In contrast, heme further increased HO-1 in hmox1+/- glomeruli.
Conclusions: Heme-mediated HO-1 induction in glomeruli is limited by HO-1 
expression levels attained. This may serve to limit level of HO activity thereby preventing 
excessive heme-derived Fe++ in hemolytic disorders.
Funding: Government Support - Non-U.S.
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GEC-Targeted HO-1 Over Expression: Protective Effects in Secondary but 
Not Primary GEC Injury  Vasileios Atsaves, Maria Detsika, Elias A. Lianos. 
Medicine, Univ of Athens, Athens, Greece; Medicine, Rutgers Biomedical and 
Health Sciences, N. Brunswick, NJ.
Background: In contrast to tubular epithelial cells, induction of the cytoprotective 
enzyme, Heme Oxygenase (HO-1), in response to injury in glomerular epithelial cells 
(GEC) is limited or absent and this may increase their vulnerability to injury. We, therefore, 
explored whether targeted HO-1 over expression in GEC can protect against primary injury 
induced by puromycin aminonucleoside (PAN) or secondary injury resulting from anti-
GBM Ab induced glomerulonephritis (GN).
Methods: HO-1 over expression in GEC of Sprague-Dawley (SD) rats was achieved 
by targeting a FLAG-human(h)HO-1 sequence under the control of a murine nephrin 
promoter using transposon-mediated gene-trap insertional mutagenesis based on a Sleeping 
Beauty(SB) transposon system (SB rats). GEC-targeted over expression was validated by 
FLAG immunolocalization and by western blot. PAN-mediated GEC injury was induced 
in SD rats by a single intraperitoneal injection. GN was induced by a single intravenous 
injection of a rabbit anti-rat GBM Ab. At defined points following PAN or anti-GBM Ab 
injection, albuminuria (Ualb/Ucreat) was assessed and glomeruli were isolated to determine 
changes in HO-1 and nephrin expression (GEC integrity marker).
Results: In glomeruli from SB rats HO-1 levels (protein) increasedcompared to Wild 
type (Wt). Administration of either PAN or anti-GBM to Wt rats increased glomerular HO-1. 
In SB rats receiving PAN, HO-1 markedly decreased compared to Wt. In contrast, HO-1 
was preserved following anti-GBM Ab. Nephrin expression was markedly decreased in 
glomeruli from SB rats treated with PAN. In contrast, nephrin was preserved in glomeruli 
from SB rats treated with anti-GBM Ab. Ualb/Ucreat was significantly higher in WT 
compared to SB rats treated with anti GBM Ab. In contrast, there was no difference in 
Ualb/Ucreat between Wt and SB rats receiving PAN.
Conclusions: Augmentation of HO-1 expression in primary GEC injury is impaired. 
This could be yet another mechanism contributing to GEC vulnerability in primary 
podocytopathies.
Funding: Government Support - Non-U.S.
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Comparative Evaluation of Cellular Injury Models Based on Conditionally 
Immortalized and Primary Podocytes  Vivek C. Abraham,1 Loan N. Miller,1 
Caton Brent Putman,1 Laura Kim,2 Steve Pratt,2 Sujatha M. Gopalakrishnan,2 
Andrew J. King.1  1Renal Discovery, AbbVie, North Chicago, IL; 2High 
Throughput Screening, AbbVie, North Chicago, IL.
Background: Podocyte injury is a hallmark of proteinuric chronic kidney disease. 
The response of podocytes to injury includes cytoskeletal reorganization, oxidative stress, 
de-differentiation & detachment. The purpose of this study was to compare commonly used 
conditionally immortalized podocytes with primary podocytes, by measuring podocyte 
markers and responses to injury.
Methods: Primary human podocytes were isolated and cultured from a healthy human 
donor kidney and compared to 1) a subclone (C5) of conditionally immortalized human 
podocytes (selected based on podocyte specific gene expression) and 2) conditionally 
immortalized mouse podocytes. Cellular phenotypes and gene expression were measured 
using high content screening (HCS), qPCR and western blots. For assessment of diabetic 
serum as a stressor, serum was pooled from db/db and control mice. Differential cytotoxicity 
of db/db sera was measured by quantifying cytoskeletal integrity, cell morphology, heme 
oxygenase-1 expression and cell adhesion.
Results: C5 podocytes were benchmarked to primary human podocytes using 1) 
expression of WT-1, podocin, synaptopodin and a-smooth muscle actin and 2) cytoskeletal 
and cell cycle phenotypes. C5 cells were also evaluated by comparing gene expression 
profiles in response to TGF-b treatment. C5 podocytes were judged to be similar to 
primary human podocytes based on these analyses. Current cellular models of podocyte 
protection often use the stressors puromycin aminonucleoside and TGF-b. We demonstrate 
cytoprotection by multiple reference compounds with these insults. We have also increased 
the disease relevance of stressors by showing that serum isolated from proteinuric db/db 
mice differentially elicits podocyte injury across multiple parameters.
Conclusions: Our results validate the use of conditionally immortalized C5 podocytes 
by benchmarking against primary human podocytes. We have also enhanced the pathologic 
relevance of models of podocyte injury by incorporating key disease-relevant stressors 
and readouts.
Funding: Pharmaceutical Company Support - AbbVie
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Hypoxia Stimulates the Expression of Tissue Factor in Human Podocytes 
in Culture  Ikuyo Narita,1 Michiko Shimada,1 Reiichi Murakami,1 Masayuki 
Nakamura,1 Norio Nakamura,1 Moin Saleem,2 Peter W. Mathieson,3 Hideaki 
Yamabe,1 Ken Okumura.1  1Nephrology, Hirosaki Univ, Hirosaki, Japan; 2Renal 
Academic Unit, Univ of Bristol, Bristol, United Kingdom; 3Univ of Hong Kong, 
Hong Kong, China.
Background: Hypoxia contributes to tubulointerestitial injury, however, the effect 
on podocytes and its underlying mechanisms are less well understood. Tissue factor (TF) 
is the initiator of extrinsic coagulation pathways and is also related to various biologic 
effects such as proliferation, inflammation, and cell motilities. In this study, we tested the 
expressions of TF and tissue factor pathway inhibitor (TFPI) in the hypoxic conditions. 
We further tested the roles of known transcription factors of TF such as, nuclear factor-κB 
(NF-κB) and early growth response gene-1 (Egr-1), as well as hypoxia-inducible factor-1α 
(HIF-1α) which regulates numerous changes in hypoxia.
Methods: Conditionally immortalized human podocytes were grown at 33°C and 
differentiated at 37°C. The cells were treated in normoxic or hypoxic conditions. mRNA 
expressions of TF and TFPI were analyzed by quantitative RT-PCR, and protein levels of 
TF in the cell lysate and TFPI in the supernatant were tested by ELISA. The expression 
of TF and HIF-1α were demonstrated by immunofluorescent staining. We used siRNA for 
the temporal knockdown of HIF-1α and Egr-1, and pyrrolidine dithiocarbamate (PDTC) 
for the inhibition of NF-κB.
Results: Hypoxia increased mRNA expression of TF (6h: 2.3±0.05 fold, p<0.001, 24h: 
5.6±2.4 fold, p<0.05 ) and suppressed TFPI (6h: 0.54±0.04 fold, p<0.05, 24h: 0.24±0.06 
fold, p<0.001 ) compared with normoxia. The protein levels of TF in the cell lysate were 
increased and TFPI in the supernatant were decreased. The TF staining was enhanced in 
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the cytoplasm of podocyte. As expected, HIF-1α was strongly stained in the nuclei of 
podocytes exposed to hypoxia for 6h. The expression of TF was not affected by HIF-1α 
siRNA, and neither Egr-1 siRNA. Whereas, PDTC reduced the induction of TF by hypoxia.
Conclusions: Hypoxia upregulated the expression of TF in human podocyte NF-κB 
dependently, and HIF-1α and Egr-1 independently. These changes may be related to the 
podocyte disorders and lead to proteinuria in the hypoxic condition.
PUB087
Integrity of the Mature APOL1 Protein Is Indispensable for Its Toxicity 
Xiqian Lan,1 Hongxiu Wen,1 Ashwani Malhotra,1 Karl Leon Skorecki,2 Pravin 
C. Singhal.1  1Medicine, Hofstra North Shore LIJ Medical School, Great Neck, 
NY; 2Medicine, Rambam Health Care Campus, Haifa, Israel.
Background: Several clinical reports have demonstrated that the development of 
higher rates of non-diabetic glomerulosclerosis (GS) amongst African Americans can be 
attributed to two coding sequence variants (G1 and G2) in the APOL1 gene. Recent studies 
indicate that the gene products of these APOL1 risk variants have augmented toxicity in 
kidney cells. The APOL1 protein is composed of several functional domains, including 
signal peptide (SP), pore forming domain (PFD), membrane address domain (MAD), and 
SRA-interacting domain. However, it is not clear, which domain contributes to APOL1 
induced cellular toxicity. In case, specific domain is contributing to APOL1-induced cellular 
toxicity, it will suggest us to design therapeutic strategy to target the specific domain.
Methods: To investigate the relative contribution of each domain to cell injury, we 
constructed serial of expression vectors to delete each domain, we transfected these vectors 
into the human embryonic kidney cell line 293T, and then compared the cytotoxicity. In 
addition, we conducted studies in which APOL1 wild type (G0) was co-transfected in 
combination with G1 or G2 to see whether G0 could counteract the toxicity of the risk 
variants.
Results: The results showed that deleting the SP did not abolish the toxicity of 
APOL1, though deletion of 26 amino acid residues at the N-terminal partially decreased 
the toxicity. Deleting PFD or MAD or SRA-interacting domain abolished toxicity, while, 
overexpressing each domain alone could not cause toxicity to the host cells. Deletion of 
the G2 sites while retaining G1 sites in the risk state resulted in persistent toxicity. Either 
deletion or exchanging the BH3 domain in the PFD led to complete loss of the toxicity in 
this experimental platform. Adding G0 to either G1 or G2 did not attenuate the toxicity 
of the either moiety.
Conclusions: These findings indicate that the integrity of the mature APOL1 protein 
is critical for its toxicity.
Funding: NIDDK Support
PUB088
Human Podocyte Depletion: The Effects of Aging and Hypertension 
Victor G. Puelles,1 Luise A. Cullen-McEwen,1 Jinhua Li,1 Peter G. Kerr,2 Wendy 
E. Hoy,3 John F. Bertram.1  1Dept of Anatomy and Developmental Biology, 
Monash Univ, Melbourne, Victoria, Australia; 2Dept of Nephrology, Monash 
Medical Centre, Melbourne, Victoria, Australia; 3Centre for Chronic Disease, 
The Univ of Queensland, Brisbane, Queensland, Australia.
Background: Podocyte depletion plays a major role in the development and progression 
of glomerulosclerosis. Many kidney diseases are more common in older age, and usually 
coexist with the presence of hypertension. We hypothesize that podocyte depletion develops 
with aging and is exacerbated by the presence of hypertension.
Methods: Kidneys from 21 adult Caucasian American males without overt renal disease 
were collected at autopsy in Mississippi, USA. Subjects were categorized based only on 
age as young adults, middle-aged adults and older adults. Subjects were also categorized 
based on age and hypertension as young normotensives, older normotensives, and older 
hypertensives. Demographic data were collected from available medical records. Design-
based stereology was used to estimate individual glomerular volume (IGV), podocyte 
number and podocyte density. Data are presented as mean±SD.
Results: Glomeruli from young adults (22.0±2.7 years; n=6) were small (1.72±0.50 
x106mm3), and contained 457±97 podocytes and 278±66 podocytes per 106mm3 of 
glomerular tissue. Glomeruli from older adults (60.0±8.6 years; n=7) were larger (2.94±1.41 
x106mm3; P<0.001), contained fewer podocytes (390±105; P<0.05) and had lower podocyte 
density (156±65 podocytes per 106mm3; P<0.0001). Among normotensives, older age was 
associated with a 15% increase in IGV (P=0.28), a 12% decrease in podocyte number 
(P=0.06) and a 17% decrease in podocyte density (P<0.01). Glomeruli from hypertensives 
and normotensives contained similar numbers of podocytes, but hypertensives had larger 
glomeruli (P<0.0001) and a markedly lower podocyte density (P<0.001).
Conclusions: These findings demonstrate that both aging and hypertension are 
independent and additive contributors to podocyte depletion in this cohort of white American 
men without overt kidney disease.
PUB089
Alport Nephropathy Progression Involves Altered Glomerular Mechanical 
Properties and Activation of the Unfolded Protein Response  Addie Embry,1 
Liping Liu,1 Leslie A. Bruggeman,2 Paul A. Janmey,3 R. Tyler Miller.1  1Medicine, 
UTSW, Dallas, TX; 2Medicine, CWRU, Cleveland, OH.
Background: Tissue and cell mechanics are important factors in the development 
and maintenance of tissues but are not well defined in renal disease. We determined the 
biophysical properties of glomeruli over the course of disease in the Col4a3-/- (Alport) 
mouse.
Methods: Glomerulur EMod was measured with microindentation, gene transcript 
levels with qRT-PCR and immunofluorescence, and kidney structure with histology.
Results: Col4a3-/- kidneys have normal histology, no proteinuria, and a normal 
glomerular EMod (2,200Pa) through 2 mo of age. At approximately 4 mo, early interstitial and 
glomerular fibrosis and proteinuria appear, and the glomerular EMod decreases (~1400Pa). 
Glomerular softening is characteristic of injured glomeruli, is associated with injured 
podocytes, and could lead to capillary injury even with normal hemodynamics. By 6 mo, 
the glomeruli regain their original EMod (~ 2,200 Pa) but with increased proteinuria and 
more severe glomerular and interstitial fibrosis. By 7-8 mo, the glomerular EMod increases 
(~ 2,600 Pa) with further increases in proteinuria and glomerular and interstitial fibrosis. 
At 2 mo, glomerular transcripts for matrix and fibrotic factors (CTGF, a-SMA, filamin, 
lysyl oxidase) are increased and remain so, demonstrating early responses of cells to alter 
their mechanical environment. Transcripts associated with UPR activation (BiP, CHOP, 
grp94) are elevated, suggesting that loss of the Col4a3 chain leads to activation of the 
UPR. Tunicamycin-treated glomeruli demonstrated a markedly reduced EMod (~1100Pa), 
suggesting that UPR activation causes glomerular injury.
Conclusions: Biophysical abnormalities occur early in the course of this Alport model, 
suggest that the reduced EMod of glomeruli (increased deformability) may lead to mechanical 
injury of capillaries even with normal hemodynamic force, that cells of glomeruli respond 
by producing proteins that will reduce deformability, and that glomerular or podocyte injury 
may be attributable to activation of the UPR.
Funding: NIDDK Support, Veterans Administration Support, Private Foundation 
Support
PUB090
A New Assay to Study Podocyte (De)Differentiation  Frances Kindt, Karlhans 
Endlich, Nicole Endlich.  Anatomy and Cell Biology, Univ Medicine Greifswald, 
Greifswald, Germany.
Background: Podocytes play an essential role in the formation and maintenance of 
the glomerular filtration barrier. Glomerular disease is associated with podocyte damage, 
frequently resulting in podocyte dedifferentiation. The loss of podocyte differentiation is 
poorly understood. Moreover, there are no drugs available that could halt or even reverse 
podocyte dedifferentiation. Since podocytes of isolated glomeruli have long been known 
to spontaneously loose their highly differentiated state over time, we established an assay 
to follow dedifferentiation of living podocyte in isolated glomeruli over time.
Methods: Using magnetic separation with dynabeads, glomeruli were isolated from 
transgenic mice that express cyan fluorescence protein (CFP) under control of a nephrin 
promoter fragment (Cui et al., <em style=”font-family: ‘Times New Roman’; font-size: 
16px;”>J. Am. Soc. Nephrol.[/italic] 16: 3247-55, 2005).
Results: Isolated glomeruli were mostly free of Bowman’s capsule, exhibited minimal 
cell damage as assessed by propidium iodide, showed intact immunostaining for nephrin, and 
possessed intact interdigitating foot processes as judged by scanning electron microscopy. 
Isolated glomeruli were cultured for up to 9 d in RPMI containing 10% FBS. To quantify 
CFP fluorescence as a measure of differentiation, we recorded z-stacks of several glomeruli 
by confocal laser scanning microscopy on each day. Mean total fluorescence intensity 
per glomerulus (MFG) was calculated from z-stacks after background correction. MFG 
remained stable for 5 d. Thereafter, MFG gradually decreased to 10% of the initial value on 
day 9. Dedifferentiation of podocytes could be accelerated by treatment of isolated glomeruli 
with doxorubicin, strongly decreasing MFG within the first three days.
Conclusions: In summary, we established a new assay to study podocyte (de)
differentiation. This assay may help to understand the molecular mechanisms of the loss 
of podocyte differentiation, and may allow to screen for compounds that stabilize podocyte 
differentiation.
Funding: Government Support - Non-U.S.
PUB091
Methods to Selectively Remove Murine Endothelial Glycocalyx In Vivo 
Using Glycosaminoglycan Digesting Enzymes without Causing Non-Target 
Effects  Karen L. Onions, Anjiola Onifade, Chris R. Neal, Monica Gamez, Gavin 
Iain Welsh, Andy Salmon, Simon C. Satchell, Rebecca R. Foster.  Academic 
Renal Unit, Univ of Bristol, Bristol, United Kingdom.
Background: The endothelial glycocalyx (e-GLX) is an important component of the 
glomerular filtration barrier (GFB), damage to which increases vascular permeability and 
microalbuminuria. Jeansson and Haraldsson previously used glycosaminoglycan (GAG) 
digesting enzymes to study the role of the e-GLX in glomerular permeability. However, 
e-GLX removal was not directly quantified. The aim of this research was to confirm 
removal of systemic e-GLX and identify any non-targeted effects in the glomerular or 
coronary microcirculation.
Methods: Mice were injected I.V with chondroitinase (Ch) and hyaluronidase (Hy) 
at a high (Ch: 87 mU/g, Hy: 15U/g or low (Ch: 0.087 mU/g, Hy: 15 mU/g) dose. Mice 
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were whole body (cardiac) perfusion fixed with gluteraldehyde containing Alcian blue 
to stain the e-GLX. Transmission electron microscopy (TEM) was used to image the 
ultrastructure of the heart and glomerular microcirculation, which was quantified using 
defined parameters in ImageJ.
Results: In the heart, the low dose significantly reduced glycocalyx coverage to 62% 
compared to sham (84%) and high (87%) dose groups (p=0.0227 one way ANOVA). The 
high dose caused an increase in vesicle number within the endothelial basement membrane 
(3.3/um) compared to controls (1.2/um) (p = 0.0328 t-test). Within the parameters of this 
analysis there were no structural changes to other components of the GFB or coronary 
circulation at either enzyme concentration.
Conclusions: These results indicate that a low dose of GAG digesting enzymes targets 
systemic e-GLX loss and does not cause any non-target effects. This technique will be 
utilised to study the role of the e-GLX in glomerular permeability. Increasing understanding 
in this area will identify how e-GLX contributes to glomerular albumin permeability in 
different pathological scenarios and may highlight new therapeutic targets. This work was 
funded by the British Heart Foundation (FS/13/9/29957).
PUB092
Dietary Salt Restriction Induces New, Single Mesenchymal Stem Cell-
Derived Progenies in the Glomerulus and Proximal Tubule  Donna Ralph, 
Kengo Kidokoro, Anne Riquier-Brison, Janos Peti-Peterdi.  Physiology & 
Biophysics, Univ of Southern California, Los Angeles, CA.
Background: Salt restriction is known to slow down the progression of chronic kidney 
disease (CKD) and improve albuminuria via blood pressure-independent structural changes 
in the glomerulus, however the underlying mechanisms have been elusive. We aimed to 
track the migration and fate of individually identified resident mesenchymal stem/progenitor 
cells in the renal cortex in intact mouse kidneys.
Methods: In vivo serial multiphoton microscopy (MPM) of the same glomeruli 
over several days, and genetic cell fate tracking using histology in tamoxifen-induced 
NG2CreERT2-Confetti mice expressing either CFP/GFP/YFP/RFP were performed during 
salt deficient diet+ACE inhibition for 10 days.
Results: At baseline, a few cells belonging to the NG2 lineage (NG2+) were observed 
in a scattered pattern throughout the renal interstitium. Serial MPM showed that in response 
to salt deprivation, monochromatic (either blue/green/yellow or red) multi-cellular tracing 
units appeared at the glomerular vascular pole, mesangium, Bowman’s capsule, and in the 
proximal tubule within 10 days. Subsequent histology of NG2-Confetti mouse kidneys 
found that the highest density of NG2+ cells was in the outer medulla, and confirmed the 
presence of 3-10 cells-containing monochromatic (clonal) tracing units along the cortical 
vasculature, afferent arteriole, and within the glomerulus (including mesangial and parietal 
epithelial cells, and a very few podocytes) and the proximal tubule. Spherical or stellate-
shaped NG2+ cells were observed in the Bowman’s space and in the proximal tubule lumen 
suggesting cell migration.
Conclusions: In summary, our data are consistent with highly dynamic cellular 
remodeling of the renal interstitium, vasculature, glomerulus, and the proximal tubule by 
single progenitor cells. These results also suggest the presence of a complex nephron repair 
program which is augmented in response to salt deprivation.
Funding: NIDDK Support
PUB093
Beraprost Ameliorates Renal Function and Reduce Uremic Toxin in 
GBM Nephropathy in Rat and in Humans (Small Number Study) 
Yasuno Mukaiyama, Yuki Oba, Koichi Kikuchi, Hisato Shima, Eikan Mishima, 
Yasutoshi Akiyama, Takehiro Suzuki, Daisuke Saigusa, Sadayoshi Ito, Takaaki 
Abe.  Tohoku Univ Graduate School of Medicine.
Background: In CKD patients, the accumulation of uremic toxins exacerbates renal 
damage. Beraprost sodium (BPS) is prostacyclin analogue and is mainly used to treat 
atherosclerotic obliterans. Recently, Several reports show that BPS reduced progression 
of renal damages in CKD. To identify the reno-protective effect of BPS, we measured 
uremic solutes by capillary electrophoresis with mass spectrometry (CE-MS) in anti-GBM 
Glomerular Nephropathy(GN) rat model as well as 4 CKD patients before and 5 month 
after BPS administration.
Methods: A comprehensive and quantitative analysis of charged metabolites by 
CE-MS was performed. We obtained serum from (1) Normal rats, GBM GN rats and 
BPS-administered GBM GN rats and (2) 4 CKD patients treated with BPS. We performed 
CE-MS and a comprehensive and quantitative analysis of charged metabolites. All the 
experiments were performed under Animal and Ethical Committee approval.
Results: Among 500 organic anions and cations, 16 anionic solutes and 42 cationic 
solutes were further examined. Among the anionic solute that increased in GN rats, the 
concentration of 2 anionic solutes(Gluconate and Citrate) are ameliorated by BPS treatment. 
Among the cationic solute that increased in GN rats, the concentration of 10 cationic solutes 
(N,N-Dimetylglycine, Creatinine, Uridine, Citrulline, Creatine, Hydroxyproline, Alanine, 
Arginine, Glycine, Cystathionine) also increased in GN and all of them are reduced by 
BPS treatment. Conversely, the concentration of 8 metabolites were decreased in GN rats, 
and by BPS treatment, the reduced concentration of tryptophan recovered to the normal 
level. Well-known uremic toxins such as ADMA, SDMA and 1-metyladenosine are also 
reduced by BPS in GN rats. In addition, in humans, the serum concentration of creatinine 
and Indoxyl sulfate are reduced by BPS after 6 month administration.
Conclusions: BPS reduced uremic toxins in CKD rats and ameliorates renal dysfunction 
and the serum level of indoxyl sulfate in CKD patients. These results suggest that BPS has 
a potential to prevent the progression of CKD.
Funding: Pharmaceutical Company Support - Reserch grant from Toray
PUB094
A Novel Method to Measure Glomerular Permeability  Jin Wei, Shaohui 
Wang, Lei Wang, Gensheng Zhang, Jie Zhang, Byeong Cha, Kay-Pong D. 
Yip, Ruisheng Liu.  Molecular Pharmacology & Physiology, Univ of South 
Florida, Tampa, FL.
Background: Glomerular capillaries are relatively impermeable to proteins, but in 
certain kidney diseases, such as diabetic nephropathy, the glomerular permeability (GP) is 
increased and some of the lower molecular weight (LMW) proteins, especially albumin, are 
filtered through the glomerular barrier into the Bowman’s space. Increased GP is a hallmark 
for many kidney diseases. Proteinuria is often implicated for impaired GP. However, since 
LMW proteins can be reabsorbed by proximal tubules, proteinuria is detected only when 
the GP is significantly increased. Recently, real-time quantification of GP can be visualized 
by two-photon microscopy, but it can only be applied to superficial nephrons, where laser 
can penetrate, in Munich-Wistar rats. We developed a novel method to monitor GP in C57/
BL6 mice by using florescent lysine-fixable dextran conjugates without these limitations.
Methods: 100µl Tomato Lectin 594 (endothelial cell marker) plus 50µl 40 KD lysine-
fixable dextran 488 (fluid phase marker) were injected intravenously. The kidneys were 
removed 1 min later and put into liquid nitrogen immediately for 10 minutes followed by 
fixation with 10% Formalin on ice overnight. Then 100µm thick sections were prepared 
using a vibratome and the florescent images were collected with two-photon microscopy. 
The ratio of florescent intensity in bowman’s space over that in glomerular capillary lumen 
was used as an index of GP.
Results: In WT mice, the GP is extremely low with a ratio of 0.16±0.08%, N=6 
(figure1). In contrast, in diabetic mice induced by alloxan for 8 weeks, the GP is significantly 
increased with a ratio of 5.9±1.3%, N=6 .
Conclusions: In summary, we developed a novel and sensitive method to monitor 
changes in GP using two-photon microscopy, which can be used for rodents and bigger 
animals.
PUB095
Vasopressin Regulates the Uptake of Extracellular Vesicles by Kidney 
Collecting Duct Cells  Wilna Oosthuyzen,1 Jessica R. Ivy,1 Jonathan Street,2 
Andrea Caporali,1 David J. Webb,1 Chris Gregory,3 Matthew A. Bailey,1 James W. 
Dear.1  1Centre for Cardiovascular Science, Univ of Edinburgh, United Kingdom; 
2National Inst of Diabetes and Digestive and Kidney Diseases, National Insts 
of Health; 3MRC/Univ of Edinburgh Centre for Inflammation Research, Univ 
of Edinburgh, United Kingdom.
Background: Urine contains extracellular vesicles (ECVs) originating from the 
circulation and all cells lining the urinary tract. ECVs are a route of inter-cellular 
communication along the nephron able to transfer protein and RNA. It is not known whether 
this is a regulated process analogous to other cell-to-cell signalling systems.
Methods: Kidney cortical collecting duct cells (CCDs) were stimulated with 
desmopressin, a vasopressin analogue, and uptake of fluorescently-loaded or microRNA-
loaded ECVs was measured. In mice, fluorescently-loaded ECVs were intravenously 
injected before and after administration of the V2 antagonist, tolvaptan, and urinary ECV 
excretion was measured. By combining antibodies to nephron segment-specific proteins 
with nanoparticle tracking analysis we measured human urinary ECV excretion in central 
diabetes insipidus (DI) and after radiocontrast exposure (n=37).
Results: Desmopressin stimulated ECV uptake into CCDs via V2 receptor stimulation. 
Intra-cellular uptake of ECVs was confirmed by microRNA specific mRNA down-
regulation. Mechanistically, ECV uptake in response to desmopressin required cyclic AMP 
production, was mediated by clathrin-dependent endocytosis and was selective for ECVs 
from kidney tubular cells. In mice, basally, 2.5% of injected ECVs were recovered in urine; 
tolvaptan treatment resulted in a 5-fold increase. In DI, desmopressin reduced the excretion 
of ECVs derived from upstream glomerular and proximal tubule cells. In patients exposed 
to radiocontrast, urinary ECVs from the glomerulus were positively correlated with the 
tubular injury markers KIM-1 and NGAL.
Conclusions: Tubular ECV uptake is a specific, hormonally regulated process 
that is reduced with injury. Physiologically, ECVs are a mechanism of inter-cellular 
communication; therapeutically, ECVs represent a novel vehicle by which RNA therapy 
could be targeted for the treatment of kidney disease.
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PUB096
Systemic Hypothermia and Pro-Inflammatory Cytokines  Massimo de Cal,1 
Grazia Maria Virzì,1 Alessandra Brocca,1 Salvador Roberto Lopez,1 Jose Luis 
Salas,1 Stefano Marcante,2 Silvia De Rosa,1 Claudio Ronco.1  1Nephrology, 
S.Bortolo Hospital, Vicenza, Italy; 2ICU, S.Bortolo Hospital, Vicenza, Italy.
Background: Cytokines produced by renal tubular epithelial cells are critical factors in 
inflammatory processes of renal ischemia-reperfusion injury. Increased levels of cytokines 
have been reported after resuscitation from cardiac arrest. Pro-inflammatory cytokines, such 
as IL-1β, IL-6 and IL-18, produced in the kidney during ischemia-reperfusion injury, are 
able to contribute to the renal damage. The purpose of this investigation was to define the 
proinflammatory cytokines response after resuscitation and during extended observation 
following therapeutic hypothermia phases.
Methods: We performed a prospective observational study in 36 post-cardiac arrest 
patients treated with Induced Hypothermia (IH) with two different cooling device:1)Artic 
Sun; 2)Blanket. On Admission time and at 12, 24, and 72 hours after the start of treatment, 
blood and urine samples were collected. Plasma cytokines were measured by ELISA.
Results: During IH, we observed a decrease of IL-6, IL-1β and IL-18u levels in 
both groups, and an increase of inflammatory during rewarming phase. The results are 
showed in table. 
Variable Artic Sun (26 pts) Blanket (10 pts) p value
IL-1β Adm 18 (12-20) 27 (9-43) 0.227
12hrs 17 (13-18) 17 (9-18) 0.841
24hrs 19 (13-21) 28 (10-51) 0.179
72hrs 20 (12-24) 35 (13-53) 0.089
IL-6 Adm 102 (40-121) 79 (29-104) 0.136
12hrs 100 (28-148) 72 (12-138) 0.194 
24hrs 57 (33-77) 63 (20-112) 0.406
72hrs 59 (34-61) 67 (30-84) 0.713
IL-18u Adm 412 (363-978) 847 (189-1071) 0.749
12hrs 327 (326-365) 265 (201-327) 0.028
24hrs 348 (290-371) 140 (42-295) 0.0005 
72hrs 505 (332-538) 264 (44-337) 0.048
Conclusions: Optimal rewarming rate is unknown. Adverse effects from suboptimal 
rewarming could diminish a protective effect from hypothermia. These biomarkers may 
serve as indicator of an individual patient’s place in the injury-repair continuum. Further 
investigations are needed.
PUB097
Impact of Different I.V. Iron Preparations on Monocyte Function and 
Differentiation  Adam M. Zawada,1 Lisa H. Fell,1 Sarah Seiler,1 Martina Sester,2 
Danilo Fliser,1 Gunnar H. Heine.1  1Internal Medicine IV, Saarland Univ Medical 
Center, Homburg, Saarland, Germany; 2Dept of Transplant and Infection 
Immunology, Saarland Univ Medical Center, Homburg, Saarland, Germany.
Background: Treatment of iron deficiency with intravenous (i.v.) iron is a first-line 
strategy to improve anemia and quality of life in patients with chronic kidney disease (CKD). 
However, in vitro experiments demonstrated that certain i.v. iron preparations may have 
immunological side-effects. In the present study we now investigated substance-specific 
impacts of different i.v. iron preparations on monocytic function and differentiation.
Methods: We in vitro stimulated monocytes with different concentrations (0.133 mg/
ml, 0.266 mg/ml, 0.533 mg/ml) of iron sucrose (IS), sodium ferric gluconate (SFG), ferric 
carboxymaltose (FCM), and iron isomaltoside 1000 (IIM) and assessed monocytic adhesion 
and transmigration capacity. Monocyte differentiation into M1 and M2 macrophages and 
dendritic cells (DCs) was flow-cytometrically analyzed, and functional characteristics of 
monocyte derived cells were tested. Finally, we performed ultra-deep miRNA sequencing 
to characterize dysregulated signaling pathways in iron stimulated monocyte derived cells.
Results: IS and SFG increased monocytic adhesion, while transmigration was not 
affected by any preparation. The expression of M1 (CD40) and M2 (CD16, CD206) markers 
as well as the phagocytosis capacity were significantly reduced in IS and SFG stimulated 
macrophages. IS and SFG down-regulated CD1c and CD86 in DCs and up-regulated 
CD141 and HLA-DR. FCM affected macrophage and DC phenotype and function to a 
lesser degree, and IIM had no measurable immunological effects. In miRNA expression 
analysis we found IS to strongly dysregulate miRNAs which are linked to TLR and MAPK 
signaling pathways (e.g. miR-146b-5p, miR-155-5p).
Conclusions: Our findings demonstrate that less stable i.v. iron preparations like IS and 
SFG substance-specifically affect monocyte function and differentiation into macrophages 
and DCs in vitro. Future clinical trials should delineate in how far these observations will 
lead to clinically relevant changes in immune responses and thus affect the infection risk 
in CKD patients.
Funding: Pharmaceutical Company Support - Pharmacosmos
PUB098
The Involvement of p38 MAPK in Neutrophil Bactericidal Dysfunction of 
Hemodialysis Patients  Yasutaka Kamikawa, Shinji Kitajima, Akinori Hara, 
Norihiko Sakai, Miho Shimizu, Kengo Furuichi, Yasunori Iwata, Takashi Wada. 
Div of Nephrology, Kanazawa Univ Hospital, Kanazawa, Japan.
Background: Mortality from infection has been reported to be higher in hemodialysis 
(HD) patients than that in healthy subjects. However, the precise mechanism causing it 
remains to be investigated. Neutrophils play crucial roles in host defenses against bacterial 
infection. Therefore, we investigated the impact of neutrophil inflammatory signal on 
bactericidal function in HD patients.
Methods: Four HD patients and six healthy subjects were recruited for this study. 
None of HD patients had diabetes, cardiovascular disease and cancer. Neutrophils were 
isolated from peripheral blood by density gradient centrifugation. The purity was tested 
by flow cytometry after lactoferrin staining. Microarray analysis was performed to assess 
global gene expression in leukocytes. Neutrophil bactericidal function was evaluated by 
the growth rate of Staphylococcus aureus (S.aureus) after co-culture of it with neutrophils 
obtained from HD patients or healthy subjects. Reactive oxygen species (ROS) production 
and myeloperoxidase (MPO) activity were analyzed by fluorescence intensity.
Results: Microarray analysis showed the impairment of p38 mitogen activated protein 
kinase (MAPK) signal in neutrophils from HD patients. The growth rate of S.aureus 
was higher in HD patients than that in healthy subjects (490.1±147.1%, 144.5±49.4%, 
respectively; p<0.01) suggesting that neutrophil anti-bacterial killing function was 
dysregulated in HD patients. The levels of ROS from neutrophils after co-culture with 
S.aureus were lower in HD patients than those in healthy subjects (14.6±8.3, 32.4±15.4, 
respectively; p<0.01). On the other hand, there was no difference of MPO activity between 
both groups. To confirm the importance of p38 MAPK, we examined the effect of the 
selective pharmacological p38 MAPK inhibitor SB202190 on neutrophil bactericidal 
function. The treatment with SB202190 suppressed anti-bacterial killing function as well 
as ROS production in neutrophils.
Conclusions: Impaired of p38MAPK signaling pathway might contribute to the 
suppression of neutrophil bactericidal function in HD patients through the dysregulation 
of ROS production.
PUB099
Detached c-Abl from Nephrin Contributes to Cytoskeleton Remodeling 
in Podocytes  Yiqiong Ma, Qian Yang, Zhentong Zhong, Zhilong Ren, Wei 
Liang, Cheng Chen, Huiming Wang, Guohua Ding.  Div of Nephrology, Renmin 
Hospital of Wuhan Univ, China.
Background: Previous studies showed that nephrin is required for cytoskeleton 
remodeling in podocytes. However, its specific mechanism remains incompletely 
understood. c-Abl is a non-receptor tyrosine kinase involved in cytoskeleton regulation, 
which is a candidate of signaling proteins interacting with SH2/SH3 domains of nephrin. 
The present study evaluated whether c-Abl contributes to nephrin-dependent cytoskeleton 
remodeling of podocytes.
Methods: Colocalized expression of nephrin and c-Abl was evaluated in glomeruli of 
patients with nephrotic syndrome (NS) by double immunolabeling assays. In vitro, AngII 
was used to promote cytoskeleton remodeling of podocyte. Differentiated murine podocytes 
were exposed to Ang II (10-7M) for 24h. Cytoskeleton configuration was evaluated by 
FITC-phalloidin staining. Western blotting was performed to evaluate the expression and 
phosphorylation of nephrin and c-Abl. Colocalization of nephrin and c-Abl was determined 
by confocal microscopy and co-immunoprecipitation analysis. Co-immunoprecipitation was 
conducted in COS7 cells co-transfected with CD16-CD7-nephrin and SH2/SH3-defective 
c-Abl vectors to identify the domain of c-Abl binding with nephrin.
Results: The glomerular staining of nephrin and c-Abl indicated that the colocalization 
in patients with NS was decreased compared with that in control patients. In cultured 
podocytes, AngII treatment induced dephosphorylation of nephrin and diminished the 
interaction between nephrin and c-Abl. In addition, F-actin disruption was aggravated 
by treatment of both AngII and overexpression of c-Abl. Furthermore, the disorganized 
cytoskeleton stimulated by cytochalasin D in COS7 cells was restored by cotransfection 
with phosphorylated CD16-CD7-nephrin and c-Abl full-length constructs. Co-
immunoprecipitation showed that phosphorylated CD16-CD7-nephrin interacted with wild 
type c-Abl, not with SH2/SH3-defective c-Abl.
Conclusions: These results indicate that phosphorylated nephrin is able to recruit 
c-Abl in a SH2/SH3-dependent manner and detached c-Abl from nephrin contributed to 
cytoskeleton remodeling in podocyte.
Funding: Government Support - Non-U.S.
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PUB100
Nrf2 and NF-κB mRNA Expression in Chronic Kidney Disease: A Focus 
on Non-Dialysis Patients  Denise Mafra,1 Viviane Oliveira Leal,2 Juliana 
Saldanha,1 Milena Barcza Stockler-Pinto,3 Ludmila Fmf Cardozo,3 Felipe 
Rizzetto Santos,4 Alex Sandro Duarte Albuquerque,4 Maurilo Leite.4  1Graduate 
Program in Medical Sciences, Federal Univ Fluminense, Rio de Janeiro, Brazil; 
2Pedro Ernesto Univ Hospital, State Univ of Rio de Janeiro (UERJ), Rio de 
Janeiro, Brazil; 3Graduate Program in Cardiovascular Sciences, Federal Univ 
Fluminense, Rio de Janeiro, Brazil; 4Div of Nephrology, Federal Univ of Rio 
de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Background: Nuclear factor erythroid 2-related factor 2 (Nrf2), a regulator of genes 
encoding antioxidant and detoxifying enzymes appear to be downregulated in chronic kidney 
disease patients undergoing hemodialysis (HD). However, data regarding the expression of 
Nrf2 in non-dialysis patients are scanty. Thus, the aim of this study was to evaluate Nrf2 
and nuclear factor kappa-B (NF-κB) mRNA expression in non-dialysis patients, comparing 
with data from HD patients.
Methods: 20 non-dialysis patients, 20 HD patients and 11 healthy subjects were 
enrolled. The peripheral blood mononuclear cells were isolated and processed for the 
evaluation of NF-κB and Nrf2 expression by quantitative real-time polymerase chain 
reaction.
Results: Nrf2 mRNA was significantly higher in non-dialysis when compared to 
HD patients but similar to healthy individuals. Inversely, NF-κB mRNA was lower in 
non-dialysis when compared to HD patients and also similar to healthy individuals i.e. 
Nrf2 mRNA was positively correlated with NF-κB mRNA in non-dialysis patients 
and healthy individuals . By contrast, Nrf2 mRNA was inversely correlated with NF-κB 
mRNA in HD patients.
Conclusions: Non-dialysis patients may conserve regular homeostatic balance between 
Nrf2 and NF-κB expressions, being comparable to healthy individuals. As renal disease 
progresses to more advanced stages, an impaired Nrf2/NF-κB balance can be observed, 
as in HD patients.
Funding: Government Support - Non-U.S.
PUB101
ERK 1/2 and ERK 5 Signaling Pathways via Renin Angiotensin System 
Activation Play Differential Regulatory Roles During the Progression 
of Glomerulonephritis  Takashi Nagai,1 Maki Urushihara,1 Shuji Kondo,1 
Toshiaki Tamaki,2 Shoji Kagami.1  1Dept of Pediatrics, Inst of Biomedical 
Sciences, Tokushima Univ Graduate School, Tokushima, Japan; 2Dept of 
Pharmacology, Inst of Biomedical Sciences, Tokushima Univ Graduate School, 
Tokushima, Japan.
Background: Although extracellular signal regulated kinase (ERK)1/2 and ERK5 are 
key kinases of signaling pathway involved in various cellular functions in kidney injury, 
the mechanism between those kinase and renin-angiotensin system (RAS) activation in 
glomerulonephritis (GN) have not been fully elucidated. This study was performed to clarify 
the potential role of ERK1/2 and ERK5 via RAS activation in the pathogenesis of GN.
Methods: We examined the expression of ERK1/2 and ERK5 in rat progressive model 
of GN induced by anti-glomerular basement membrane antibodies in Wistar Kyoto rats. 
In addition, the signal transduction pathway in angiotensin II (Ang II)-induced glomerular 
pathologic alterations were investigated in primary cultured mesangial cells (MCs).
Results: GN rat developed typical cellular crescent in glomeruli on day 7 and severe 
fibrocellular crescent and glomerulosclerosis were found on day 28. Immuno-staining 
of kidneys revealed that strong expression of phospho-ERK1/2 was observed on day 7 
and phospho-ERK5 expression was markedly increased on day 28 of GN. Ang II type 
1 receptor blocker (ARB) suppressed those augmentations. Macrophage infiltration and 
PCNA positive cells were seen on day 7 and collagen type 1 expression was enhanced on 
day 28, and ARB treatment reduced these expressions. Next, cultured MCs stimulated by 
Ang II showed significantly increases in MCP-1 and collagen type 1 expression, and cell 
proliferation. While optimized PD98059 that inhibited ERK1/2 phosphorylation abolished 
the elevation of MCP-1 expression (P<0.01) and cell proliferation (P<0.01), optimized 
BIX02189 that inhibited ERK5 phosphorylation abolished the elevation of collagen type 
1 expression (P<0.01). ARB treatment attenuated these augmentations.
Conclusions: These data suggest that ERK1/2 regulates acute inflammatory reactions 
and ERK5 induces the development of chronic glomerular fibrosis during RAS activation 
in GN.
PUB102
Chinese Herbal Medicine for IgA Nephropathy, ShenPing Decoction, 
Blocks Platelet-Derived Growth Factor Signaling Pathway Activated 
by IgA1-Containing Immune Complexes in Human Mesangial Cells 
Xianwen Zhang,1,2 Zhi qiang Huang,2 Stacy D. Hall,2 Lin Wang,1 Yueyi Deng,1 
Bruce A. Julian,2 Yiping Chen,1 Jan Novak.2  1Longhua Hospital, Shanghai 
Univ of Traditional Chinese Medicine, Shanghai, China; 2Univ of Alabama at 
Birmingham, Birmingham, AL.
Background: IgA nephropathy (IgAN) is characterized by mesangial immunodeposits 
containing galactose-deficient IgA1 (Gd-IgA1) usually associated with mesangial 
proliferation and matrix expansion. There is no disease-specific therapy of IgAN, although 
a herbal medicinal prescription, ShenPing decoction (SP), has been used in China for 
decades to effectively treat IgAN. Mesangial cell proliferation in IgAN is likely induced by 
Gd-IgA1-containing immune complexes (CIC) and this process may involve activation of 
platelet-derived growth factor (PDGF) signaling pathway. We have shown previously that 
SP blocks the activation of PDGF pathway induced by PDGF. In this study, we investigated 
the effect of CIC on PDGF signaling pathway in human mesangial cells (hMC) and assessed 
the effects of SP on this pathway.
Methods: CIC were isolated from sera of IgAN patients using size-exclusion 
chromatography. Primary hMCs were incubated with PDGF or CIC for 15 min or 24 h 
with or without SP. Cellular proliferation was measured with Syto60. PDGF signaling was 
evaluated by SDS-PAGE and Western blotting.
Results: 24-h incubation with CIC increased MC proliferation and SP inhibited this 
effect. Stimulation of hMC with CIC increased phosphorylation of PDGFR and ERK1/2 
after 15 min and 24 h. PDGFR degradation was not observed in CIC-treated group, which 
is different from PDGF. SP inhibited CIC- and PDGF-induced phosphorylation and 
degradation of PDGFR.
Conclusions: CIC induced cellular proliferation of hMC and activation of PDGF 
pathway without degradation of PDGFR, a normal negative feedback observed for PDGF. 
CIC possibly caused persistent activation of PDGF pathway. SP inhibited these effects. 
These findings indicate that SP likely contains component(s) targeting the PDGF/PDGFR 
system that may play a role in the mesangial injury of IgAN.
Funding: NIDDK Support, Private Foundation Support
PUB103
Effects of Fluorofenidone on the Expression of Thioredoxin-Inter-Acting 
Protein and Thioredoxin of Human Peritoneal Mesothelial Cell in High 
Glucose and Lipopolysaccharide  Yichen Chen, Jianfei Ma.  Nephrology, The 
First Affiliated Hospital of China Medical Univ, Shenyang, China.
Background: Peritoneal dialysis is one of an important alternative therapies for end-
stage kidney disease, But the occurrence of peritoneal dialysis correlation peritonitis has 
brought great resistance for the development of peritoneal dialysis.Significance of oxidative 
stress in peritoneal dialysis related peritonitis has been paid more and more attention.In 
cells that did not receive stimulation, Txnip combined with thioredoxin, when the elevated 
ROS concentration inside the cell, the formation of the compounds are separated. After 
dissociation Trx play its functions to remove ROS, whereas Txnip participation NLRP3 
activation. Objective:To observe the effects of Fluorofenidone on the Expression of 
Txnip,Trx of HPMCs in High Glucose and Lipopolysaccharide.
Methods: The expression of Txnip and Trx mRNA was measured by real time-PCR,The 
level of Trx,Txnip,IL-6,TGF-b1 in the supernatants of HPMCs(HMrSV5) were measured 
by ELISA. Experimental groups:Control group;High glucose and LPS for different 
concentrations and different times group;Fluorofenidone intervene group.
Results: Compared with the normal control, high glucose and LPS can significantly 
increase the expression of Txnip,Trx,IL-6 and TGF-b1 in a concentration and time dependent 
manner, all have statistically significant(P<0.05).Compared with 2.5% glucose and 10mg/L 
LPS group, Fluorofenidone can reduce the expression of Txnip,IL-6 and TGF-b1, increase 
the expression of Trx, all have statistically significant (P<0.05).
Conclusions: High glucose and LPS up-regulate the expression of Txnip,Trx,in the 
protein and gene levels,and increase the expression of IL-6 and TGF-b1 .Fluorofenidone 
could reduce the increase of Txnip, IL-6 and TGF-b1, and increase the express of Trx in 
HPMCs that have been pre-treated with high glucose and LPS. Fluorofenidone have the 
effect of anti-oxidant and anti-fibrosis.
PUB104
Effects of Resveratrol on NRF2 Expression in Raw 264.7 Macrophages Cells 
and Non-Dialyzed CKD Patients  Denise Mafra,1 Juliana Saldanha,1 Milena 
Barcza Stockler-Pinto,2 Viviane Oliveira Leal,3 Denis Fouque,4 Christophe O. 
Soulage.5  1Pos-Graduate Program in Medical Sciences, Fluminense Federal 
Univ (UFF), Niterói, Rio de Janeiro, Brazil; 2Pos-Graduate Program in 
Cardiovascular Sciences, Fluminense Federal Univ (UFF), Niterói, Rio de 
Janeiro, Brazil; 3Div of Nutrition, Pedro Ernesto Univ Hospital, State Univ of 
Rio de Janeiro (UERJ), Rio de Janeiro, Brazil; 4Dept of Nephrology, Centre 
Hospitalier Lyon Sud, Univ de Lyon, Pierre Bénite, France; 5INSA de Lyon, 
CarMeN, INSERM U1060, Univ de Lyon, Villeurbanne, France.
Background: Oxidative stress and inflammation are common in CKD. Bioactive 
compounds as resveratrol may modulate the Nrf2 expression, a transcription factor that 
could up-regulate cellular antioxidant systems. The aim of this study was observe Nrf2 
expression in macrophages cells and in non-dialyzed CKD patients treated with resveratrol.
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Methods: Mouse RAW 264.7 macrophages cells were treated with 50µM of resveratrol 
in DMSO 1% (v/v). Nucleus and cytoplasm were separated. Western Blot (WB) was 
performed to quantify Nrf2. qRT-PCR was performed to evaluate Nrf2 expression. 7 non-
dialyzed CKD patients (5 women; 64.0±6.5 years; GFR 37.9±10.4mL/min) received 500mg 
of resveratrol/day for 4 weeks. qRT-PCR to evaluate Nrf2 expression was performed in 
PBMC before and after supplementation.
Results: Cells treated with resveratrol showed a significant activation of Nrf2 with an 
increase in the ratio nucleus/cytoplasm compared to control cells i.e. 
p=0.02). The same was observed in qRT-PCR (p=0.02). In patients, we observed a trend 
to increase Nrf2 expression with resveratrol supplementation (p=0.06).
Conclusions: We concluded that both cells and patients treated with resveratrol 
increased Nrf2 expression. So, we suppose that supplementation with resveratrol can lead 
to an increase in oxidative stress and inflammatory status among CKD patients.
PUB105
Mitochondrial Implications of Glycolate Metabolism in Primary 
Hyperoxaluria  Sonia Fargue, Tanecia Mitchell, John Knight, Ross P. Holmes. 
Urology, Univ of Alabama at Birmingham, Birmingham, AL.
Background: The primary hyperoxalurias (PH) are rare but severe inherited diseases 
characterized by an increased endogenous production of oxalate and calcium oxalate kidney 
stones in patients. Deficiency in alanine glyoxylate aminotransferase (AGT, deficient in 
PH1) or glyoxylate reductase (GR, deficient in PH2) have repercussions on the metabolism 
of the oxalate precursors glyoxylate and glycolate. Excessive amounts of glycolate are 
characteristic of PH1, through glyoxylate to glycolate cycling in the presence of glycolate 
oxidase (GO) and GR. Perturbations in glycolate metabolism may affect mitochondrial 
function in PH patients. The objective of this study is to assess how over-expression of 
these enzymes regulates glycolate and glyoxylate generation and mitochondrial function.
Methods: An established transformed CHO cells model was used in which cells 
express GO ± AGT or GR. Cells were incubated with glycolate or glyoxylate and the 
extracellular concentrations of oxalate and glyoxylate, and the induction of oxidative stress 
were analyzed. Cellular bioenergetics were assessed with a Seahorse XF-96 extracellular 
flux analyzer.
Results: The metabolism of glycolate by GO generated glyoxylate, oxalate and H2O2. 
Intracellular ROS were produced and cell viability was reduced. Mitochondrial respiration 
and the cellular bioenergetic reserve capacity were decreased following glycolate oxidation. 
The expression of AGT or GR reduced the untoward effects of glycolate metabolism to 
glyoxylate and oxalate.
Conclusions: The disruption of normal glycolate metabolism by GO, AGT and GR in a 
cell model causes the production of stress related metabolites and mitochondrial dysfunction. 
Limiting mitochondrial dysfunction might be a therapeutic approach in treating PH patients.
Funding: Private Foundation Support
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Effect of Fasudil on Response Oxidative Stress in High Glucose and 
Lipopolysaccharide Induced Human Peritoneal Mesothelial Cells  Ye Hu, 
Jianfei Ma.  Nephrology, The First Affiliated Hopital of ChinaMedical Univ, 
Shenyang, Liaoning Province, China.
Background: Peritoneal fibrosis is a common cause of chronic peritoneal dialysis 
patients withdrew from peritoneal dialysis.Research shows that, there are oxidative stress 
exists in peritoneal dialysis patients.Rho/Rho kinase signaling pathway is involved in 
the regulation of multiple biological process, including inflammation,oxidative stress 
and fibrosis.The transcription factor NFE2 relatedfactor is a central regulator of cellular 
antioxidant responses.Rho kinase inhibitor fasudil is a Rock inhibitor which currently used 
in clinic and experiment,it can regulate cell proliferation,migration,adhesion and movement 
at the cellular level,it also can regulate a variety of factors in inflammation,thrombogenes
is,oxidation and fibrosis at the molecular level.
Methods: By using the method of Real Time-PCR to detect the expression 
of RhoA,Rock1,Nrf2 and HO-1 mRNA;Western Blot to detect the expression of 
RhoA,Rock1,Nrf2 and HO-1 protein;.chemistry fluorescence test to detect the expression of 
ROS protein;chemical colorimetry to detect the expression of GSH-PX protein;ELISA detect 
the expression of TGF-b1 protein in the human peritoneal mesothelial cell.Experimental 
groups:Control group;High glucose and LPS for different concentrations group;Fasudil 
intervene group.
Results: Compared with the normal control, high glucose and LPS can significantly 
increase the expression of RhoA, Rock-1, ROS and TGF-b1,reduce the expression of 
Nrf2, HO-1 and GSH-PX in a concentration dependent manner, all have statistically 
significant(P<0.05).Compared with 2.5% glucose and 10mg/L LPS group, fasudil can 
reduce the expression of RhoA, Rock-1, ROS and TGF-b1, increase the expression of 
Nrf2, HO-1 and GSH-PX, all have statistically significant (P<0.05).
Conclusions: High glucose and LPS up-regulate the expression of RhoA and Rock1 
but reduce Nrf2 in the protein and gene levels,and increase the expression of ROS and 
TGF-b1 but reduce the expression of HO-1 and GSH-PX.Fasudil could reverse the increase 
of RhoA and Rock1 and the reduce of Nrf2 in HPMCs that have been pre-treated with high 
glucose and LPS,play the role of anti-oxidant and anti-fibrosis.
PUB107
Glucose Induces Mitochondrial Reactive Oxygen Species Through 
Carbonyl Stress and Respiratory Chain in Rat Peritoneal Mesothelial Cells 
Satoshi Shimada,1 Takefumi Mori,1 Yusuke Ohsaki,2 Ikuko Oba,1 Shinichi Sato,1 
Kenji Koizumi,1 Sadayoshi Ito.1  1Nephrology, Endocrinologyand Vascular 
Medicine, Graduate School for Medicine, Tohoku Univ, Sendai, Miyagi, Japan; 
2Div of Integrative Renal Replacement Therapy, Graduate School of Medicine, 
Tohoku Univ.
Background: Glucose and its degradation products (GDPs) play a major role in 
the peritoneal injury and affect peritoneal dialysis vintage. Peritoneal mesothelial cell 
dysfunction has been demonstrated to involve in peritoneal injury by glucose and GDPs. 
GDPs induced carbonyl stress has been demonstrated to induce mitochondrial dysfunction 
in several cell types. The present study was designed to determine the role of GDPs and 
respiratory chain in glucose induced mitochondrial ROS in peritoneal mesothelial cells.
Methods: Primary rat peritoneal mesothelial cells (RPMC) were isolated from Wister 
rats. Real-time mitochondrial superoxide was monitored using a specific fluorescent 
indicator Mito SOX red under fluorescence microscope equipped with temperature 
controlled chamber. RPMC was stimulated with 90 mmol/L of glucose and compared to 
those of vehicle. In separate experiments, RPMC was pre-incubated with a mitochondrial 
specific superoxide dismutase mimetic mitoTEMPO, respiratory chain inhibitor rotenone 
or carbonyl stress inhibitor pyridoxamine to determine the mechanism of glucose induced 
mitochondrial ROS production.
Results:  90 mmol/L glucose significantly increased mitochondrial superoxide 
production within 200 seconds in primary cultured RPMC (0.21±0.07 AU, n=8, P<0.05 vs 
vehicle). These responses were abolished when RPMC was pre-incubated with mitoTEMPO 
(-0.04±0.15 AU, n=5, P=0.34 vs vehicle), rotenone (0.00±0.06 AU, n=6, P=0.42 vs vehicle) 
and pyridoxamine (-0.34±0.34 AU, n=5, P=0.26 vs vehicle), indicating that mitochondrial 
superoxide production through respiratory chain and GDP.
Conclusions: The results in the present study indicate that glucose and GDP present 
in the PD effluent is responsible for oxidative stress in the peritoneal mesothelial cells 
by stimulation of mitochondrial ROS production, which could play a role in peritoneal 
function and injury during PD.
PUB108
Renal Cell Carcinoma Models: Effect of Chemopreventative Agents on the 
Carcinogenic Potential of Potassium Bromate in Human Renal Epithelial 
Cells  Ismael Obaidi, Tara McMorrow.  School of Biomolecular and Biomedical 
Science, Conway Inst, Univ College Dublin, Ireland.
Background: Renal Cell Carcinoma (RCC) is a leading cause of renal cancer 
worldwide. The cause of RCC remains unknown, with many chemicals implicated in 
its development. We have developed an in vitro model of RCC using the carcinogen, 
potassium bromate, to investigate potential prevention and possible treatment options of 
RCC. Chemoprevention is the use of different chemicals, natural or synthetic, to halt, block 
or reverse the process of carcinogenesis. It is one of the novel approaches that is being 
used to control cancer and it is a good alternative to the conventional therapies that are 
associated with a long list of side effects and limitations. These agents have antioxidant, 
anti-inflammatory, antiangiogenic effects and induce phase II enzymes, apoptosis, cell 
cycle arrest, and differentiation. They antagonize hormones and growth factor- induced 
tumor proliferation. The aim of this study was to examine the functional and mechanistic 
effects of chemopreventative agents on chemically induced RCC using human (RPTEC/ 
TERT1) renal cells and cancerous (ACHN) renal cell lines.
Methods: Morphological changes, viability and cytotoxicity assays were used to assess 
the toxicity of both the chemopreventatives and the carcinogen when RPTEC/ TERT1 
cells were exposed to them individually and in combinations. Oxidative stress was also 
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assessed by measuring the intracellular concentration of H2O2. Oxidative stress-induced 
DNA damage was estimated quantitatively by measuring 8-OHdG concentrations. Western 
blot analysis was used to detect the changes in particular oxidative stress- induced proteins.
Results: The carcinogenic effects induced by potassium bromate were reduced by the 
co-administration with all of the chemopreventative agents used. Oxidative stress markers, 
H2O2 and DNA adduct formation, were reduced.
Conclusions: The results suggest that these chemopreventative agents show significant 
potential against KBrO3-induced carcinogenicity. Further analysis is being carried out to 
understand the functional mechanisms of this chemoprevention on the cells, in particular 
on the genetic and epigenetic mechanisms involved.
Funding: Government Support - Non-U.S.
PUB109
The Podocyte as a Target for the Actions of Levamisole in Nephrotic 
Syndrome  Lulu Jiang,1 Charles Colin Thomas Hindmarch,1 Mark Rogers,1 
Peter W. Mathieson,2 Gavin Iain Welsh.1  1School of Clinical Sciences, Univ of 
Bristol; 2Univ of Hong Kong.
Background: Levamisole is an antihelminthic agent that has also been shown to be 
effective as a second line treatment for steroid-dependent or frequently-relapsing nephrotic 
syndrome (SD/FRNS) in children. Levamisole is able to decrease steroid dosages and 
reduce the relapse frequency and severity. We have recently reported the effectiveness 
of levamisole in a small cohort of adult patients and provided evidence which suggests 
that levamisole’s mode of action in SSNS is attributable to its direct effects on podocytes.
Methods: To further clarify its therapeutic effectiveness and identify the therapeutic 
targets of this drug, we have employed RNA-sequencing technology to profile transcriptome 
changes of human podocytes in response to levamisole.
Results: We have identified a number of genes which are differentially expressed in 
podocytes in reponse to levamisole. These include genes linked to the cellular interferon 
response pathways and a number which overlap with those regulated by dexamethasone 
in podocytes. These have been validated in vitro and are now being studied in animal 
models of nephrotic syndrome.
Conclusions: Together, our molecular evidence strongly supports the promising use 
of levamisole in treating nephrotic syndrome.
PUB110
The PRIMAVERA Study: A Prospective, Randomized, Multicenter Trial 
Assessing the Effect of Continuous Erythropoiesis Receptor Activator 
(C.E.R.A.) on Renal Function in Non-Anemic Patients with Chronic 
Kidney Disease (CKD)  Danilo Fliser,1 Frank Dellanna,2 Michael Koch,3 
Jochen Seufert,4 Oliver Witzke,5 Alfons Wiggenhauser,6 Ingeborg A. Hauser.7 
1Saarland Univ Medical Center, Homburg/Saar, Germany; 2DaVita Renal 
Center, Düsseldorf, Germany; 3Center of Nephrology, Mettmann, Germany; 
4Univ Hospital of Freiburg, Freiburg, Germany; 5Univ Hospital Essen, Essen, 
Germany; 6Roche Pharma AG, Grenzach-Wyhlen, Germany; 7Frankfurt Univ 
Medical Center, Frankfurt, Germany.
Background: Erythropoiesis stimulating agents (ESAs) are the mainstay of renal 
anemia management. ESAs may provide a beneficial non-hematopoietic effect on 
deterioration of kidney function in CKD, but such an effect has not been examined in a 
prospective controlled trial. PRIMAVERA is the first randomized study to assess whether 
low-dose ESA therapy can slow CKD progression in patients with near-normal hemoglobin 
levels (11–14g/dL) (NCT01194154).
Methods: PRIMAVERA was a single-blind, 2-year, multicenter trial which enrolled 
patients with type 2 diabetes or recipients of a kidney transplant, all with CKD stage 3, 
urinary albumin to creatinine ratio <3000mg/g or total urine protein <3000mg/24h. Patients 
were randomized in a 1:1 ratio to placebo or once-monthly low-dose C.E.R.A. (30-75µg 
per dose). The primary efficacy endpoint was annual change in estimated GFR using the 
abbreviated MDRD formula. Secondary efficacy endpoints were the changes from baseline 
in urinary albumin to creatinine ratio, serum cystatin C and serum creatinine. Safety 
endpoints included adverse events and discontinuation due to pre-specified adverse events.
Results: 241 patients were randomized: (139 type 2 diabetes, 102 kidney transplant 
recipients). The 2-year study was completed by 159 patients (66%).
Conclusions: The PRIMAVERA study provides the first prospective examination of a 
potential effect for low-dose ESA therapy in ameliorating kidney function decline in CKD 
patients. Analysis of the study data is planned shortly.
Funding: Pharmaceutical Company Support - Roche Pharma AG
PUB111
A New Approach to Phosphate and FGF23 Lowering: Design of the 
COMBINE Trial  Joachim H. Ix,1 Tamara Isakova,2 Stuart M. Sprague,9 Kalani 
L. Raphael,3 Jennifer J. Gassman,5 Linda F. Fried,4 Dominic S. Raj,6 Alfred 
K. Cheung,3 Andrew N. Hoofnagle,10 John W. Kusek,7 Michael F. Flessner,7 
Geoffrey A. Block,8 Myles S. Wolf,2 The pilot clinical trials in Ckd study group.7 
1UCSD; 2Northwestern; 3U of Utah; 4U of Pittsburgh; 5Cleveland Clinic; 6George 
Washington U; 7NIDDK; 8Denver Nephrology; 9Northshore; 10U Washington.
Background: Elevated serum phosphate and FGF23 are associated with CVD, CKD 
progression, and mortality in CKD. Phosphate binders inconsistently reduce phosphate 
and FGF23 levels. Nicotinamide (vitamin B3) decreases active phosphate transport by 
down regulating NaPi2b in the gut. Whether nicotinamide alone or in combination with 
binders can safely and tolerably lower phosphate and FGF23 levels in CKD is unknown.
Methods: We designed a 4 arm parallel group randomized double blind trial comparing 
lanthanum carbonate (1000mg tid), nicotinamide (750mg bid), neither, or both. Supported 
by the NIDDK CKD Pilot Clinical Trials U01, 200 participants with eGFR 20-45 ml/
min/1.72m2 recruited from 7 centers across the US will be randomized 1:1:1:1 and treated 
for 12 months. Main exclusions include phosphate < 2.8mg/dL, liver disease, anemia, 
and thrombocytopenia. The dual primary efficacy endpoints are change in phosphate and 
FGF23. Secondary endpoints are change in LV mass and renal fibrosis by MRI. Enrollment 
began in March 2015.
Results: To date, 45 persons were screened, 33 were eligible, 26 entered run-in, and 
18 were randomized. Baseline characteristics of randomized participants are shown in the 
table. Updated data will be available at presentation. 
Randomized Patients (n) 18
Age±SD 65±14
Male, n(%) 12 (67%)
Black, n(%) 5 (28%)
Diabetes, n(%) 7(44%)
eGFR±SD 30±9
Urine ACR mg/g, median (IQR) 505 (48, 905)
Serum Phosphate±SD 3.9±0.6
Serum Calcium±SD 9.5±0.4
Intact PTH, median (IQR) 104 (71, 133)
Conclusions: Simultaneous blockade of NaPi2b and intestinal phosphate binding using 
nicotinamide and binders provides a new strategy for phosphate and FGF23 lowering in 
CKD, but efficacy, safety, and tolerability are uncertain. The COMBINE trial will inform us 
about combined therapy compared to either therapy alone, and to dual placebo in CKD 3b-4.
Funding: NIDDK Support
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Sofosbuvir plus Ribavirin Combination Therapy for Hepatitis C Virus 
Infection in Hemodialyzed Patients: New Simpler, Shorter and Safer but 
Costly Option  Achour Laradi,1 Christian Pilette,2 Francois Babinet,1 Stephanie 
Lanoiselee,1 Guillaume Seret,1 Jean baptiste Pain,3 Laurent Martin,4 Gilles 
Peytavin.3  1Néphrologie-Dialyse, ECHO-CMCM -Pôle Santé Sud, Le Mans, 
France; 2Gastro-enterologie, Centre Hospitalier du Mans, Le Mans, France; 
3Laboratoire de Pharmaco-Toxicologie, Hôpital Bichat-Claude Bernard, Paris, 
France; 4Biologie, Labomaine Pôle Santé Sud, Le Mans, France.
Background: Hepatitis C virus (HCV) infection is a serious issue in hemodialyzed 
patients (HD pts) and treatment is complex and rapidly evolving with the advent of newer 
direct-acting antivirals.
Methods: We evaluated SOF given with RBV in an 86 years old male HD pt , 90 kg, on 
HD since 7 years for a diabetes- related ESRD and infected by a nosocomial transmission 
of HCV genotype 2 overseas . SOF was given at a dose of 400 mg three times a week after 
dialysis session and RBV given 200 mg daily during 12 weeks.Plasma HCV RNA values 
were measured with the COBAS Taqman HCV Test , Roche diagnostics.Safety, efficacy 
and pharmacokinetics issues were studied as well as standard laboratory tests.Sustained 
virologic response(SVR) is evaluated six months after treatment.
Results: HCV infection was associated with cirrhosis with Fibroscan staging score of 
10.3 KPa. HCV viral load at diagnosis was 7.52 log.The viral decline was < 1.18 log only 3 
weeks after treatment and négative after 1 month therapy. SVR with a value of HCV NRA 
<1.18 log occured six months after. Side effects are mainly anemia and thrombocytopenia.
No life threatening adverse event was noticed .Mean Plasma SOF values before and after HD 
session was < 1 ng /mL in accordance to the dose given.Mean Plasma value of métabolite 
007 before HD session was 2394 ng/mL and falled to 938 ng/mL after HD.
Conclusions: Treatment for 12 weeks with all-oral combination of Sofosbuvir 
and Ribavirin of our old age HD pt with HCV genotype 2 hépatitis resulted in a high 
degree of antiviral efficacy with an excellent tolerability and safety profile with a dose 
recommandation of 400 mg 3 times a week.But the very high cost ( 41000 euros ) make 
access extremely limited.A reduction of the costs is mandatory to make theses new therapies 
accessible to the majority of the patients in the world who are left untreated.
J Am Soc Nephrol 26: 2015 Publication Only
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PUB113
The Rationale for and Design of TREVI TR02: A Multicenter Randomized, 
Double-Blind, Placebo-Controlled Trial of Nalbuphine ER for the Treatment 
of Uremic Pruritus in Hemodiaysis Patients  Vandana S. Mathur,1 Michael J. 
Germain,2 Roberta Duncan,3 Thomas Sciascia.3  1MathurConsulting, Woodside, 
CA; 2Western New England Renal & Transplant Associates, PC, Hamden, MA; 
3Trevi Therapeutics, New Haven, CT.
Background: Uremic pruritus (UP) is common in hemodialysis patients, but there are 
no FDA-approved treatments or “regulatory roadmap” for the development of new drugs. 
Nevertheless, the significant quality of life (QOL) burden of chronic itching underscores 
need for treatments. The striking bilateral, non-dermatomal distribution of itching and 
perception of non-pruritogenic skin stimuli as itch suggest that UP is centrally mediated, 
like neuropathic pain. Reduction in endogenous κ/µ opioid ligand ratio is hypothesized to 
be a mechanism. Our goal was to evaluate nalbuphine ER tablet (NAL), a κ-agonist and 
µ-antagonist as a treatment for UP.
Methods: The study was powered for an α = 0.05, β = 0.9 for a group difference of 
1.5 (SD = 3.5) in worst itching numerical rating scale (NRS, 0-10): N = 120/arm (NAL 
120 mg BID, NAL 60 mg BID, and placebo BID). Patients with NRS ≥ 4.5 (moderate to 
severe pruritus) were enrolled at ~45 US and 6 EU sites.
Results: 
Key Scientific or Logistical Consideration Study Design Solution
1. Itch is subjectively perceived. Itching 
intensity and QOL were relevant endpoints.
Used patient-reported outcomes previously 
validated in UP patients including NRS and 
Skindex-10 (1° and 2° endpoints)
2. Opioid drugs require titration to minimize 
opioid side effects
To perform a blinded opioid titration with a 
self-administered oral drug, we used blister 
cards that were labeled for each study day
3. Long enough duration to demonstrate 
durability and lack of tolerance but short 
enough to avoid excessive dropouts due to 
background comorbidities.
Used an 8-week blinded treatment duration
4. Post-treatment safety Added a 2-week washout period after the blinded treatment period
5. Day-to-day variability in NRS was expected
The mean of 2 weeks of measurements at 
baseline and on treatment (Wks 7 and 8) were 
used for the calculation of the 1° endpoint.
Conclusions: The trial design overcame the challenges. Unblinded results will be 
presented.
Funding: Pharmaceutical Company Support - Trevi Therapeutics
PUB114
The Rationale and Design of Trevi TR02 Extension: A Multi-Center 
Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of 
Nalbuphine HCl Extended Release Tablets in Uremic Pruritus Patients on 
Hemodialysis  Thomas Sciascia,1 Howard Hait,2 Amale Hawi,3 Roberta Duncan,1 
Vandana S. Mathur.4  1Trevi Therapeutics, Inc., New Haven, CT; 2Edenridge 
Associates LLC, Wilmington, DE; 3Hawi Consulting, Ridgefield, CT; 4Mathur 
Consulting, Woodside, CA.
Background: Nalbuphine HCl is a mu antagonist/kappa agonist being investigated for 
the treatment of pruritus in hemodialysis patients (UP). The safety and long-term benefits 
of Nalbuphine ER in the treatment of uremic pruritus is being investigated in this ongoing 
open-label extension study.
Methods: TR02ext is a 26-week multicenter open-label extension study of a double-
blind placebo controlled study in which UP patients with a baseline NRS ≥4.5 were treated 
with Nalbuphine ER or placebo for 8 weeks followed by a 2-week washout period. At the 
end of study, patients that opt to roll over into the extension study, and have an NRS > 2 
enrolled in a 26-week Treatment Period (TP), while patients with an NRS £2 entered a 
13-week Observation Period (OP). If a patient’s itch worsened (NRS > 2) within the OP, 
they entered the TP for the remainder of the study. 
All patients on treatment were titrated between 30 mg QD-120 mg BID over a 3-4 
week period based on reported tolerability and efficacy and then maintained their dose 
until end of study. Patients whose itch intensity failed to improve during the TP were 
discontinued from treatment.
Key Scientific Considerations Study Design Solution
1. Characterize the time course of worsened 
itch intensity following 8 weeks on blinded 
study drug or placebo followed by a 2-week 
wash-out period
Separate subjects into TP and OP
2. Dose distribution of flexible dosing to 
optimize efficacy and safety
Individualized titration to understand preferred 
doses
3. Individualized titration to maximize drug 
efficacy with tolerable side effects
Up to 26 weeks of treatment with 
discontinuation of subjects who do not respond 
to treatment
Conclusions: Approximately 70% of the eligible patients who completed the blinded 
controlled study, enrolled in the extension study. Final study data will be presented once 
the study is complete.
Funding: Pharmaceutical Company Support - Trevi Therapeutics
PUB115
Assessing Treatment Safety and Efficacy of a New Patient-Centered 
Hemodialysis System  Luis Alvarez,1 Geoffrey A. Block,2 May L. Yau,3 Glenn 
Matthew Chertow.4  1Palo Alto Medical Foundation, Palo Alto, CA; 2Denver 
Nephrology, Denver, CO; 3Outset Medical, San Jose, CA; 4Stanford School of 
Medicine, Stanford, CA.
Background: Many studies designed and conducted for the evaluation of new 
technologies utilized in hemodialysis have been small, observational studies. These studies 
may have underestimated the rate of clinical symptoms yielding biased safety results.
Methods: We designed a prospective, multicenter, open-label, non-randomized, 
cross-over study where patients serve as their own control. The study was designed with 
novel approaches to ensuring accuracy of clinical symptom reporting both in the home 
and clinic settting.  Up to 50 patients will be enrolled in the study for 19 weeks and will 
use the Tablo™ Hemodialysis System for treatments 4 times/week. 
Phase Description
Run-in clinic staff administered in-center hemodialysis treatment for 1 week.
In-Center treatment clinic staff administered hemodialysis treatment for 8 weeks in-center.
In-Home transition 
device training, perform self-care dialysis for approximately 2 
weeks (1 week in-center and 1 week in-home), and 
assessment for stability in the home environment.
In-Home treatment self-care dialysis treatment for 8 weeks at home.
During each study phase, patients will record inter- and intra-dialytic symptoms 
for each treatment via questionnaire. Research staff will review all responses weekly to 
determine if an adverse event (AE) has occurred. In addition, research staff will conduct 
weekly visits to the dialysis clinic and to home to educate patients on AEs and to collect 
questionnaires. Patients will also be assessed to determine if a standardized weekly Kt/V 
of 2.1 has been achieved.
Results: Study enrollment is expected to begin in 2015 with results expected in 2016.
Conclusions: By utilizing patients to collect AE data both in-center and at home, we 
should more accurately capture AE rates due to the uniformity of the reporting mechanism. 
In terms of the clinical efficacy endpoint of the study, modelled clearance data suggests the 
majority of patients will achieve the weekly standard Kt/V target. Actual clearance data 
will be forthcoming at the completion of the trial.
Funding: Pharmaceutical Company Support - Outset Medical, Inc.
PUB116
Interim Analysis of Comprehensive CKD Education Modality Choice 
Outcomes  Andrea K. Easom,1 Dumitru Rotaru,1 Fahd Syed,1 Manisha Singh,1 
Ashutosh M. Shukla,2 Sudhir V. Shah.1  1Univ of Arkansas for Medical Sciences; 
2Unversity of Florida.
Background: Preliminary data from a study comparing telemedicine vs conventional 
CKD education is presented here. The primary aim is to see if patients are able to make a 
modality choice by the end of the third visit.
Methods: Patients are enrolled in three groups as shown in the pilot study design. 
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Each group attends 3 sessions and are given handouts or an 82 page workbook designed 
specifically for the study. They are asked about their modality choice pre-education and 
at the end of each session.
Results: To date 80 subjects have been enrolled and 32 have completed all sessions. 
After 3 sessions, 38% chose peritoneal dialysis (PD), 28% chose home hemodialysis 
(HHD), 28% chose in center hemodialysis (ICHD), 3% chose no dialysis (ND), 3% could 
not make a choice (NC) and 84% chose transplant. On enrollment, 47% made a modality 
choice with 40% choosing home modalities. At the end of 3 session, 97% were able to 
make a modality choice with 66% choosing home modalities. Of the 6 subjects who have 
completed 3 visits and started renal replacement therapy (RRT), 5 started PD and 1 had a 
pre-emptive transplant. Additionally, 4 subjects did not complete all visits: 3 started ICHD (2 
with AVFs) and 1 died. Enrollment in the telemedicine arm has been slower than expected. 
Strategies to involve community leaders and local providers were developed and are being 
implemented. Communities interested in the program have been added as telemedicine sites.
Conclusions: This preliminary data shows that at the end of 3 education sessions there 
is a significant increase in subjects being able to make a RRT choice (97% vs. 47%) and 
most chose home dialysis(66% vs. 40%). Community engagement is key to a successful 
outreach of this state-wide CKD education program. Further strategies are being developed 
to improve local involvement.
Funding: Pharmaceutical Company Support - Baxter Renal Discoveries Extramural 
Grant Program
PUB117
Determination of Oxidative Stress and Inflammation Index in Patients with 
Different Dialysis Modalities and Analysis of Related Factors  Linshan Jiao, 
Jianfei Ma.  Nephrology, The First Affiliated Hospital of China Medcial Univ, 
Shenyang, Liaoning, China.
Background: This study through the determination of serum AOPPs, GSH-PX, PTX-
3, IL-6 level in ESRD patients with different treatment groups,to explore the changes and 
influence factors of oxidative stress and inflammation in dialysis patients.
Methods: 70 cases of ESRD patients divided into three groups: 26 cases of PD 
patients,26 cases of MHD patients,18 cases of CKD5 patients.Select 14 normal persons 
as control group.Age,gender and other data of the four groups were matched.Get Serum of 
each group of subjects,using ELISA for determination of serum AOPPs, GSH-PX, PTX-3, 
IL-6 content in each group.
Results: 1.The concentration of AOPPs:PD Group(25.04±12.18) ng/ml, MHD 
group(18.46±10.47)ng/ml, CKD5 group(17.96±9.81)ng/ml,healthy group(15.73±6.68) 
ng/ml.PD group was statistically significant different with other groups (p<0.05).2.The 
concentration of GSH-PX:PD group(188.54±112.04)U/ml, MHD group(157.12± 82.47)
U/ml,CKD5 group(133.59±65.59)U/ml,healthy group(176.03±98.25)U/ml. There 
was no significant difference between the groups.3.The concentration of PTX-3:PD 
Group(9.85±5.13)ng/ml, MHD group(7.54±4.07)ng/ml, CKD5 group (6.69±3.12)ng/
ml, healthy control group(6.08±2.49)ng/ml. The PD group was statistically significant 
different with other groups(p<0.05).4.The concentration of IL-6:PD group(123.69±84.46)
ng/L, MHD group(81.17±72.48) ng/L, CKD5 group(64.92±36.92)ng/L,healthy control 
group(59.08±19.27)ng/L. The PD group was statistically significant different with other 
groups(p<0.05).5.Through Correlation analysis in PD group(P <0.05): AOPPs was 
positively correlated with PTX-3 (R=0.956, P=0.000),AOPPs was positively correlated 
with IL-6 (R=0.934, P=0.000), PTX-3 and IL-6 levels were positively correlated (R=0.939, 
P=0.000).
Conclusions: Determination of serum AOPPs, GSH-PX, PTX-3, IL-6 content in 
Experience group is significantly increased compared with the control group.The PD 
patients compared with patients in other treatment groups has more severe oxidative stress 
and microinflammation state.Oxidative stress is closely related to the state of inflammation 
in PD patients.
PUB118
Impact of Type of Referral and Dialysis Start on Clinical Outcomes and 
Final Renal Replacement Therapy in a Multicenter Integrated Care Setting 
Belen Marron,1 Janusz Ostrowski,2 Marietta Torok,3 Delia Timofte,4 Jose C. 
Divino-Filho.1  1Diaverum Home Therapies. Medical Office, Diaverum, Munich, 
Germany; 2Wloclawek Diaverum Clinic, Diaverum, Wloclawek, Poland; 
3Szeged Diaverum Clinic, Diaverum, Szeged, Hungary; 4Sema Diaverum Clinic, 
Diaverum, Bucharest, Romania.
Background: Early referral, choice of RRT modality and planned start increase patient 
survival, however international reports show disparities between desirable patterns and 
practice. Objectives: To analyze the effects of Integrated Care and education on dialysis 
start (planned vs. non-planned) and RRT modality choice.
Methods: Retrospective analysis of 547 incident patients starting dialysis in 23 HD/PD 
clinics from PL, HU and RO during 2012. Scheduled initiation of dialysis with a permanent 
vascular or peritoneal access was considered as planned start.
Results: Population: 30% DM, mean age 64 years, 84% with previous medical care of 
renal disease, 49 % late referral, 58 % unplanned start, 92% on HD as modality.37% of those 
with unplanned start had previous Nephrology follow-up. Patients (n=332) with GFR <30 
ml/min were followed up mainly by “general nephrologists” (68%) and 29% in structured 
predialysis units Modality information (80% of all patients) and general renal education 
(87%) were more frequent (p<0.001) in planned start. Half of patients were involved in 
therapy choice whereas informed and dialysis start consents were signed by 57% and 
77%. The median time from information to dialysis start was 2 months. Unplanned start 
(p£0.05) correlated with nephropathy of uncertain origin, worse clinical status, shorter time 
from information to RRT start and less PD. Patient non-compliance (36%) and unexpected 
GFR loss (19%) contributed to unplanned start. “Optimal care” defined as combination 
of Nephrology follow-up (> 3 months), modality information and planned start occurred 
in 22% of the patients.
Conclusions: Despite the high rate of late referral, information and education were 
widely provided. Unplanned start was frequent and may underlie the low frequency of PD 
choice. Measures such as implementation of structured predialysis units may facilitate 
better and timely referral and improve well-being and planning of RRT start as well as 
increased PD use.
PUB119
ATHENA: A Natural History Study to Observe Disease Progression, 
Standard of Care, and Investigate Biomarkers in Alport Syndrome Patients 
Jacqui Blem,1 Paul C. Grint,1 Victoria Pratola,1 James F. Simon.2  1Regulus 
Therapeutics Inc., San Diego, CA; 2Cleveland Clinic, Cleveland, OH.
Background: Alport syndrome (AS) is a rare genetic disorder caused by mutations 
in genes coding for type IV collagen (COL4) a3, α4 and α5 proteins leading to hematuria, 
renal failure, hearing loss and eye involvement in affected patients. Patients with COL4α5 
mutations develop end stage renal disease (ESRD). While there are currently no approved 
therapies for AS, ACE-inhibitors have been shown to delay the onset of ESRD. A better 
understanding of the decline of kidney function in AS is necessary to design clinical trials 
to enable the development of new therapeutics.
Methods: Regulus’ Natural History of Disease Study, ATHENA, is an international 
multi-center observational study designed to characterize the progression of renal 
dysfunction in up to 120 subjects that have been clinically or genetically diagnosed with 
AS with a measured GFR (mGFR) between 30-75cc/min/1.75m2. Genetic mutation analysis 
is performed at enrollment. mGFR (iohexol), 24 hour urine protein excretion and serum 
creatinine levels are measured every 3-6 months. Serum and urine biomarkers of renal stress 
(microRNAs, ADMA, TGFβ, CTGF and NGAL) will also be collected.
Results: 48 subjects with clinically or genetically diagnosed Alport syndrome have 
been enrolled to date. The population has an age range of 20 to 67 years of age and 29% 
are male. Average baseline mGFR was 54.8 cc/min/1.75m2. Ethnicity is reported at 91% 
Caucasian, 2% Hispanic or Latino, 2% African American and 5% Asian.
Conclusions: Data gathered from the ATHENA study will investigate links between 
genetic mutations, biomarkers of renal stress and disease progression in AS patients. The 
correlative data collected from the ATHENA study will provide clinically important basis 
for the design of the Phase 2 clinical proof of concept study to determine efficacy of RG-
012 (an anti-miR targeting microRNA-21) on the decline in renal function and time to 
end-stage renal disease in Alport syndrome patients.
Funding: Pharmaceutical Company Support - Regulus Therapeutics Inc., Clinical 
Revenue Support
PUB120
Health-Related Quality of Life in Dialysis Patients: Effect of Type D 
Personality  Christopher Susanto,1 Constantijn Konings,2 Jeroen Kooman.3 
1Nephrology, Elkerliek Hospital, Helmond, Netherlands; 2Nephrology, Catharina 
Hospital, Eindhoven, Netherlands; 3Nephrology, Maastricht Univ Medical 
Centre, Maastricht, Netherlands.
Background: Measurement of HRQoL is a useful tool to describe the burden of illness 
and the impact of treatment. These information’s could be essential to develop a personal 
care. Type D (distressed) personality is defined as a tendency to experience both negative 
affectivity (NA) and social inhibition (SI). The prevalence of this personality and his effect 
on HRQoL in dialysis patients are assessed.
Methods: Participants were from outpatient clinic. DS 14 was used. A score of ³10 on 
both NA and SI subscales indicates that the person has a type D personality. HRQOL was 
measured using the Dutch version of the Kidney Disease Quality of Life. Six components 
of the KDQOL were the primary end points (general health perceptions, burden of kidney 
disease, effect on daily life, cognitive function, pain, emotional welfare).
Results: 147 patients with mean age of 71.2 (±11.7). Mean time on dialysis 37 months. 
The prevalence of type D personality was 30%. HRQoL in patients with type D personality 
was lower compared with non type D. It was statistically significant in all components 
except for emotional welfare.
J Am Soc Nephrol 26: 2015 Publication Only
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NA was significantly related to all components except for emotional welfare. SI was 
found to be significantly correlated esspecially with effect on daily life 
NA SI
r p-value r p-value
Age -O.20 0.02 -0.13 0.11
Duration of RRT -0.09 0.3 -0.07 0.43
General health perception -0.28 0.001 -0.20 0.02
Burden of kidney disease -0.47 <0.001 -0.27 0.001
Effect on daily life -0.36 <0.001 -0.30 <0.001
Cognitive -0.40 <0.001 -0.26 0.002
Pain -0.29 <0.001 -0.16 0.006
Emotional welfare 0.15 0.07 -0.03 0.7
Conclusions: Type D personality may be an important determinant of individual 
differences in HRQoL and should be an important consideration in a personal care of 
dialysis patients.
PUB121
Sleep Disorder and mRNA Expression Profile of Sleep-Related Gene in 
Peripheral Blood Cells in Patients with CKD  Shinji Kitajima, Yasunori 
Iwata, Yasuyuki Shinozaki, Norihiko Sakai, Miho Shimizu, Kengo Furuichi, 
Takashi Wada.  Div of Nephrology, Kanazawa Univ Hospital, Kanazawa, Japan.
Background: Although uremic substances would be candidates involved in sleep 
disorder, detailed mechanisms remain unclear so far.  we performed polysomnographic 
analysis in CKD patients and used PBCs to examine the expression of genes related to 
sleep and wakefulness states.
Methods: Polysomnographic analysis was performed in 9 CKD patients and 6 healthy 
controls. Genes related to sleep and wakefulness were evaluated by RNA microarray in 19 
subjects, including CKD patients and control subjects.
Results: Polysomnographic analysis revealed that the duration of the rapid eye 
movement (REM)/non-REM phases during total sleep time was different between CKD 
patients and healthy controls. In mRNA microarray evaluation, hierarchial clustering 
analysis showed the different pattern of sleep related gene expression in the patients with 
HD. The mRNA expression levels of GABA receptor, noradrenaline receptor, dopamine 
receptor and histamine receptor showed an inverse correlation with renal function. 
Moreover, orexin and its receptor mRNA expression also showed an inverse correlation 
with renal function.
Conclusions: These data raise the possibility that sleep related gene expression on 
PBC in CKD/HD patients may be associated with sleep disorder.
PUB122
Potential Link Between Iron, Inflammation and FGF23 in Patients with 
Early Stages of Chronic Kidney Disease  Ewelina Lukaszyk,1 Mateusz 
Lukaszyk,2 Jolanta Malyszko.1  12nd Dept of Nephrology and Hypertension 
with Dialystis Unit, Medical Univ of Bialystok, Bialystok, Poland; 2Dept of 
Allergology and Internal Medicine, Medical Univ of Bialystok, Bialystok, 
Poland.
Background: Fibroblast growth factor 23 (FGF23) is a hormone commonly increased 
in patients witch chronic kidney disease and alike inflammation and iron deficiency is a 
known risk factor of cardiovascular outcomes and death in patients with chronic kidney 
disease (CKD). The aim of the study was to evaluate the potential link between FGF23 
concentration, novel iron status and inflammatory parameters among patients with early 
stages of CKD.
Methods: 96 patients with early stage of CKD and 54 with normal renal function were 
enrolled in the study. Standard laboratory methods were used to measure serum hemoglobin, 
fibrinogen, creatinine, iron, total iron binding capacity (TIBC) and ferritin. Intact FGF23, 
hepcidin-25, sTfR (soluble transferrin receptor), GDF-15 (growth differentiation factor-15), 
IL-6 (interleukin 6) and hsCRP (high sensitivity C-reactive protein) were measured using 
commercially available kits. Data was analyzed in different group of patients according to 
iron status (absolute and functional iron deficiency and normal iron levels).
Results: There was no difference of FGF23 concentration regarding to iron status. 
Significant correlations in patients with CKD are presented in Table. 
iFGF23
eGFR -0.49
hepcidin-25 -0.21
IL-6 0.22
GDF-15 0.31
There were no statistically significant associations between FGF23 and TSAT, ferritin 
and hsCRP. We revealed significantly higher concentrations of FGF23 in patients with 
type 2 diabetes (mean logFGF23: 4±0.5 vs 3.8±0.5, P=0.03) and with heart failure (mean 
logFGF23: 4±0.6 vs 3.8±0.5, P=0.04) in comparison to those without these diagnoses.
Conclusions: Kidney function, inflammation and iron status were the parameters 
affecting FGF23 in the early stages of CKD. Our data are paving the way for further studies 
on the role of FGF23 in cardiorenal anemia-iron deficiency syndrome, in particular in the 
early stages of CKD.
PUB123
Echocardiography and Cardiovascular Risk: What’s the Relationship in 
the Renal Transplant Recipient?  Miguel Goncalves,1 Micaela Neto,2 Pedro 
Vieira,1 Luis Resende,1 Nuno Rosa,1 Susana Gomes,2 Jose Duraes,1 Jose Alves 
Teixeira,1 Gil Silva.1  1Nephrology, Hospital Dr. Nélio Mendonça, Funchal, 
Portugal; 2Cardiology, Hospital Dr. Nélio Mendonça, Funchal, Portugal.
Background: Cardiovascular (CV) disease is the major cause of death among 
renal transplant recipients (RTR). Unlike end stage renal disease, it is unknown whether 
echocardiographic abnormalities are useful to identify RTR with high cardiovascular and 
risk of death.
Methods: Retrospective review of 107 RTR with a functioning and stable graft for 
longer than 12 months and an echocardiography performed in the last year. Risk of MACE 
and death using a CV risk calculator specific for RTR and all echocardiographic parameters 
were reviewed and analyzed.
Results: Among 107 patients (57,9% males, 50,4±13,9 years old), 7-years risk for 
MACE was >10% in 30,9% of patients and 7-years risk for death >10% in 56,1%. Left 
ventricular hypertrophy (LVH) was found in 55.1%, diastolic dysfunction in 39,3%, dilated 
left atrium (LA) in 53,3%, high pulmonary artery systolic pressure (PASP) in 29,0%, 
valvular calcifications in 22,4% and moderate to severe mitral regurgitation in 3,7%. 
Mean Ejection Fraction was 68.36±6.87%. Univariate analysis showed with statistical 
significance an increased risk of MACE in patients with LVH, diastolic dysfunction, dilated 
LA, high PASP, valvular calcifications and mitral regurgitation. Univariate analysis also 
showed statistical relationship on increased risk of death in patients with LVH, diastolic 
dysfunction, dilated LA, high PASP, valvular calcifications and mitral regurgitation. 
Multivariate analysis identified an independent association between the risk of MACE 
>10% and valvular calcifications [OR 3.499 (1.115-10.982, P=0.032)] and high PASP 
[OR 7.954 (2.412-26.238, p=0.001)]. Risk for death >10% in multivariate analysis had an 
independent association with diastolic dysfunction [OR 3.909 (1.261-12.115, p=0.018)] 
and with high PASP [OR 4.319 (1.201-15.535, p=0.025)].
Conclusions: Echocardiographic abnormalities identify RTR at increased risk of 
MACE and death. Valvular calcifications and high PASP are significant predictors of 
MACE whereas diastolic dysfunction and high PASP are significant predictors of death.
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Hemodynamic Determinants of Glomerular Filtration Rate in Pulmonary 
Hypertension: A Prospective Cohort Analysis  Laurent Bitker,1 Cecile Payet,3 
Florence Sens,1,4 Turquier Segolene,2 Antoine Duclos,3,4 Vincent Cottin,2,4 
Laurent Juillard.1,4  1Nephrology, Hospices Civils de Lyon, Lyon, France; 
2Pneumology, Hospices Civils de Lyon, Lyon, France; 3Medical Research and 
Statistics Dept, Hospices Civils de Lyon, Lyon, France; 4Univ of Lyon, Lyon, 
France.
Background: Up to date, renal dysfunction incidence and determinants remain 
unevaluated in pulmonary hypertension (PHT). We aim to assess hemodynamic and 
demographic factors associated with a decrease in glomerular filtration rate (GFR) in the 
context of PHT.
Methods: The regional competence center for PHT of Lyon (France) prospectively 
compiles demographic, hemodynamic and biological variables among newly diagnosed 
patients. We retrospectively analyzed data for patients with pulmonary arterial hypertension 
(PAH, group 1 of PHT classification) after exclusion of the following causes of PHT: 
thromboembolic, lung diseases and/or hypoxia and left heart disease. Hemodynamic 
variables from the right heart catheterization and estimated GFR (eGFR, CKD-EPI formula) 
were assessed at PAH diagnosis time.
Results: 209 patients (mean age 59.1±17.1, 63.2% women) were included from 
October 1998 to July 2012. 40.2% presented with systemic arterial hypertension (HT) 
and 12.9% with diabetes. Mean eGFR was 83.9±27.1 ml/min/1.73m2 (eGFR inferior to 60 
ml/min/1.73m2 in 18.5% of cases). Mean values of mPAP, right atrial pressure (RAP) and 
cardiac index (CI) were 43.5±12.6 mmHg, 7.8±5.3 mmHg and 2.6±0.9 L/min/1.73m2. In 
multivariate analysis, age, male gender, HT, anorectic-related PAH and a CI inferior to 2.5 
L/min/1.73m2 were associated with a significant decrease in eGFR of 1.0 ml/min/1.73m2/
year, (95% confidence interval, 0.8 to 1.2), 11.8 ml/min/1.73m2 (5.8 to 17.8), 6.6 ml/
min/1.73m2 (0.1 to 13.2), 13.4 ml/min/1.73m2 (2.3 to 24.5) and 10.1 ml/min/1.73m2 (4.4 
to 15.9). RAP were not statistically related to eGFR levels.
Conclusions: Renal dysfunction is frequent from diagnosis among PAH patients. A 
low CI is associated with a significant decrease in eGFR, whereas RAP seem unrelated. 
Equally, male gender, HT and anorectic-related PAH are correlated with a significant 
decrease in eGFR. These results should incite  renal prevention in PAH patients presenting 
these risk factors.
PUB125
Kidney Function and Cause-Specific Mortality in Drug-Treated Older 
Cardiac Patients: A 10-Year Follow-Up Study  Ellen K. Hoogeveen,1 Johanna 
M. Geleijnse,2 Daan Kromhout,2 Theo Stijnen,3 Erik Giltay.4  1Nephrology, 
LUMC, Leiden, Netherlands; 2Human Nutrition, WU, Wageningen, Netherlands; 
3Medical Statistics and Bioinformatics, LUMC, Leiden, Netherlands; 
4Psychiatry, LUMC, Leiden, Netherlands.
Background: Chronic kidney disease (CKD) is highly prevalent among older (>60y) 
cardiac patients. The relation between CKD and cause-specific mortality among older 
cardiac patients who are treated with state-of-the-art pharmacotherapy is unclear.
Methods: From 2002-2006, 60-80 years old Dutch post-myocardial infarction patients 
were enrolled in the Alpha Omega Trial and followed until death or January 2012. We 
estimated Glomerular Filtration Rate (eGFR) with serum cystatin C (cysC) and creatinine 
using the CKD-EPI equations. Kidney function was available in 4,561 (94.3%) participants 
and analyzed in relation to major causes of death using Cox models and four-knot restricted 
cubic splines.
Results: At baseline mean age was 69y, 79% were men, 21% had diabetes, 90% used 
antihypertensive drugs, 85% used statins. Patients were divided into four categories of 
eGFRcysC: ≥90 (33%; reference), 60-89 (47%), 30-59 (18%), and <30 (2%) ml/min/1.73m2. 
Median follow-up was 6.4y. During follow-up, 873 (19%) patients died, of which 370 
(42%) from cardiovascular causes, 309 (35%) from cancer, and 194 (22%) from other 
causes. The hazard ratios (95%-CI) for any death according to eGFRcysC category, after 
adjustment for major risk factors, were: 1 (reference), 1.4 (1.1-1.7), 2.9 (2.3-3.6) and 4.4 
(3.0-6.4). For cardiovascular mortality the corresponding figures were 1.6, 3.6 and 6.0, for 
cancer 1.2, 2.1 and 1.6, and for other causes 1.4, 3.1 and 6.7. Similar, but weaker, results 
were obtained with creatinine-based eGFR. 
Conclusions: We found a strong inverse graded relation between kidney function and 
mortality in drug-treated older cardiac patients, in particular due to cardiovascular and 
non-cardiovascular-non-cancer causes.
Funding: Other NIH Support - Dutch Kidney Foundation (PV41)
US National Institute of Health (NIH)
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The Association Between Serum Uric Acid and Incidence of Non-Fatal 
Stroke in a Community-Based Population: A Longitudinal Survey of a 
Nationwide Cohort in Japan  Keita Kamei,1 Kazunobu Ichikawa,1 Tsuneo 
Konta,1 Shouichi Fujimoto,2 Kunitoshi Iseki,2 Toshiki Moriyama,2 Kunihiro 
Yamagata,2 Kazuhiko Tsuruya,2 Kenjiro Kimura,2 Ichiei Narita,2 Masahide 
Kondo,2 Koichi Asahi,2 Tsuyoshi Watanabe.2  1Dept of Cardiology, Pulmonology, 
and Nephrology, Yamagata Univ School of Medicine, Yamagata, Japan; 2Steering 
Committee of Research on Design of the Comprehensive Health Care System 
for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment 
by Specific Health Checkup, Japan.
Background: Hyperuricemia is a risk for adverse renal outcomes in chronic kidney 
disease. This study investigated the effect of uric acid on incidence of non-fatal strokein 
a community-based population.
Methods: We used a nationwide database of 160,164 subjects (aged 29–74, male 
39%), participated in an annual health check, “The Specific Health Check and Guidance 
in Japan” between 2008–2010, and examined the relationship between the gender-specific 
quintiles of serum uric acid level at baseline and the 2-year incidence of non-fatal stroke.
Results: During the follow-up period 2,081 non-fatal stroke occurred (1.3%). The 
incidence of non-fatal stroke showed a significant J-shaped association with the increase 
in serum uric acid levels (P for trend <0.001, lowest [1.2%] in the 3rd quintile of uric acid 
[Q3: males 5.7–6.2 mg/dL, females 4.4–4.8 mg/dL] and highest [1.6%] in the 5th quintile 
[Q5: males ≥7.1 mg/dL, females ≥5.5 mg/dL]). After adjusting for possible confounders, 
the odds ratio for incident stroke was significantly higher in Q5, compared with Q3 (OR 
1.21, 95%CI 1.05–1.39, P = 0.007). The odds ratio of hyperuricemia (serum uric acid ≥7 
mg/dL) for incident stroke was significantly increased in total subjects (OR 1.22, 95%CI 
1.07–1.39), especially in females (OR 1.46, 95%CI 1.04–1.99) and non-hypertensive 
subjects (OR 1.34, 95%CI 1.04–1.70). In contrast, the association between serum uric 
acid levels and incident stroke was not significant in subjects with diabetes, proteinuria 
and renal insufficiency.
Conclusions: This study showed that serum uric acid level is significantly associated 
with incident non-fatal stroke and that hyperuricemia might be an independent risk for 
non-fatal stroke in the general population.
Funding: Government Support - Non-U.S.
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The Association Between Serum Calcium and Mortality in a Community-
Based Population: The Takahata Study  Sayumi Watanabe, Keita Kamei, 
Kazunobu Ichikawa, Tsuneo Konta, Isao Kubota.  Dept of Cardiology, 
Pulmonology, and Nephrology, Yamagata Univ School of Medicine, Yamagata, 
Japan.
Background: The low intake of calcium is a risk for cardiovascular events. This study 
investigated the association between serum calcium and mortality in a community-based 
population.
Methods: This study included 1,314 participants (aged 40–87, males 45%) at local 
health checkup in Takahata, Japan. We divided them into 3 groups according to the tertiles 
of serum calcium at baseline and compared the mortality during 8-year follow-up period. 
Serum calcium was corrected for serum albumin.
Results: At baseline serum calcium level was 9.8 ± 0.4 mg/dL (mean ± SD). In the 
multivariate linear regression analysis serum calcium was positively associated with serum 
sodium, potassium, phosphorus, albumin, uric acid and total cholesterol, and was negatively 
associated with serum chloride and HDL-cholesterol, and urinary beta2-microglobulin. 
During the follow-up period 62 deaths, including 14 cardiovascular deaths occurred. 
In Kaplan-Meier analysis all-cause mortality was significantly increased along with the 
decrease in serum calcium (Log-rank P = 0.03). In Cox proportional hazard analysis adjusted 
for confounders including age, gender, smoking and drinking habits, comorbidities and 
other serum electrolytes, the association of serum calcium was of borderline significance 
with all-cause mortality (HR 2.09, 95%CI [0.94–4.75], P = 0.07, low tertile [≤ 9.6 mg/dL] 
vs. high tertile [≥ 10.0 mg/dL]) and was significant with cardiovascular mortality (HR 6.33, 
95%CI [1.13–43.7], P = 0.04, low tertile vs. high tertile). In addition, there was a significant 
interaction between serum calcium and sodium on all-cause mortality (P = 0.03) and the 
association of serum calcium with the mortality was significant in the subjects with low 
serum sodium (≤ 150 mEq/L), but not high sodium.
Conclusions: This study showed that serum calcium was significantly associated with 
various environmental factors and low serum calcium was an independent predictor for the 
mortality in the general Japanese population.
Funding: Government Support - Non-U.S.
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Endothelial Dysfunction According to Classification of Serum Phosphorus 
Level within Normal Range in Chronic Kidney Disease  Shina Lee, Jung-hwa 
Ryu, Seung-Jung Kim, Dong-Ryeol Ryu, Duk-Hee Kang, Kyu Bok Choi.  Dept 
of Internal Medicine, Ewha Womans Univ Mok Dong Hospital, Seoul.
Background: Hyperphosphatemia is a important problem because of its affect on 
endothelial dysfunction as well as homeostasis of bone. Chronic kidney disease(CKD) 
patients tend to have higher serum phosphorus values than those in healthy population due 
to their positive balance of phosphorus in kidney. There are a few studies which reported 
that serum phosphorus level was correlated with endothelial function. Recently it has been 
reported the patients with higher serum phosphorus level related to the worse endothelial 
function in healthy population. Thus, the following study was carried out in an effort to 
redefine the relationship between serum phosphorus level and endothelial dysfunction to 
those on chronic kidney disease.
Methods: This is a cross-sectional study and the enrolled 85 CKD patients with 
exception of CKD stage 5 or receiving renal replacement therapy. They were subjected 
to the measurement with laser doppler flowmetry with iontophoresis, reactive hyperemia 
peripheral arterial tonometry(RH-PAT) and ankle brachial index, which represented 
endothelial function assessment.The average serum phosphorus level in patients was 
measured for the last three months including examination month. The Pearson’s correlation 
coefficient analysis and multiple regression analysis were performed to define the association 
of serum phosphorus and endothelial function.
Results: When participants were divided into four groups according to estimated GFR, 
serum phosphorus level had significant higher values in CKD stage 4. From univariate 
analysis, phosphorus level was associated with RH-PAT values(r=0.296, p=0.008). 
Multivariate analysis showed serum parathyroid hormone was independent predictor for 
endothelial dysfunction assessed with RH-PAT.
Conclusions: This study showed that serum phosphorus level may associate with 
endothelial function even in CKD. Furthermore, it is required a prospective study of larger 
population to identify the relationship between phosphorus and endothelial function and 
to establish optimal reference range of phosphorus level for protection from endothelial 
dysfunction.
PUB129
Coronary Artery Calcification in Predialysis Diabetic and Nondiabetic 
CKD Patients  Sonoo Mizuiri,1 Yoshiko Nishizawa,1 Kazuomi Yamashita,1 
Kyoka Ono,1 Mariko Asai,1 Masahiro Ishine,2 Shigehiro Doi,3 Takao Masaki,3 
Kenichiro Shigemoto,1 Satoru Harada.1  1Nephrology, Iciyokai Harada Hospital, 
Hiroshima, Japan; 2Radiology, Iciyokai Harada Hospital, Hiroshima, Japan; 
3Hiroshima Univ Hospital, Hiroshima, Japan.
Background: Risk factors for coronary artery calcification may include low vertebral 
bone mineral density (BMD), and may differ in diabetic and nondiabetic CKD patients.
Methods: We examined Agatston coronary artery calcium score (CACS), BMD of T8 
vertebra using MDCT, age, sex, presence of diabetes, hypertension, smoking history, statin 
administration, BMI, eGFR, urinary protein, blood urea, glucose, serum iron, calcium, 
phosphate, uric acid, alkaline phosphatase, albumin, LDL-cholesterol, and triglyceride in 
128 predialysis CKD patients, 82 nondiabetics, and 46 diabetics. Factors related to CACS 
were assessed by multivariate regression and logistic regression analyses using all of the 
above independent variables.
Results: Coronary artery calcification was present in 106 (82.8%) patients. Significant 
associations between CACS≥400H and age, diabetes, and statin administration were 
observed, and odds ratios were 1.1, 3.4, and 3.7, respectively, in all subjects (P<0.05). Log 
CACS showed a significant association with age, diabetes, statin administration, serum 
phosphate, and iron in all subjects (P<0.05). Mean age and eGFR were 70±14 vs. 70±9 
years (ns) and 37±20 vs. 30±19 ml/min/1.73m2 (P<0.05), in nondiabetics and diabetics, 
respectively. Serum phosphate levels were not significantly different in the both groups. 
CACS (H) was 239±411 in nondiabetics and 942±1258 in diabetics (P<0.001). Significant 
associations were observed between Log CACS and age (P<0.0001, β:0.42), statin 
administration (P<0.01, β:0.31), and serum phosphate (P<0.05, β:0.20) in nondiabetics, 
and between Log CACS and blood urea (P<0.01, β:0.55), serum iron (P<0.01, β:-0.41), age 
(P<0.01, β:0.41), BMI (P<0.05, β:0.29) and smoking history (P<0.05, β:0.29) in diabetics. 
BMD showed no association with CACS.
Conclusions: Hyperphosphatemia is a risk factor for coronary artery calcification in 
nondiabetic but not diabetic CKD patients, and an association between CACS and BMD 
of T8 vertebra was not observed.
Funding: Private Foundation Support
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Association of APOL1 Risk Variants with Cardiovascular Events Among 
HIV-Infected Individuals  Tessa Kimberly Novick, Michael J. Choi, Michelle 
M. Estrella, Mohamed G. Atta, Derek M. Fine.  Nephrology, Johns Hopins 
Hospital, Baltimore, MD.
Background: HIV+ individuals have higher risk of cardiovascular disease versus 
HIV- individuals. Recently, the APOL1 risk variants that are associated with CKD among 
African Americans were also associated with adverse cardiovascular events (CVE). Given 
the potential interaction between HIV and APOL1 variants, we examined the association 
between the APOL1 risk variants and CVE in HIV+ adults.
Methods: We conducted a cohort study among HIV+ African Americans who 
underwent clinically indicated kidney biopsies from 1996-2011 and were successfully 
genotyped for the APOL1 G1 and G2 alleles. Multivariable logistic regression was used 
to compare the high-risk (2 copies) vs. the low-risk (0/1 copy) genotype and the odds of 
CVE (diagnosis of acute myocardial infarction, percutaneous cardiac intervention, CABG 
or stroke).
Results: Of 203 individuals, 64% were male with mean age of 46 years, eGFR of 38.4 
ml/min/1.73m2, and urine protein-to-creatinine ratio (UPCR) of 4.1g/g. Mean CD4 count 
was 259 cells/mm3; only 29% had HIV RNA levels <400 cps/mL. During follow-up, 12% 
had CVE and 40% died from all causes. Individuals with the high-risk vs. low-risk genotype 
had similar odds of CVE, adjusting for age, CVD risk factors, statin and aspirin use, eGFR 
and proteinuria (OR 1.13, 95% CI: 0.34 – 3.81). Similarly, APOL1 risk genotype was not 
associated with the composite outcome of CVE and death from all causes, adjusting for 
age, CVD risk factors, statin and aspirin use, and viral suppression status (OR 1.17; 95% 
CI: 0.58-2.34).
Conclusions: There is no clear relationship between the APOL1 risk variants and CVE 
or death from all causes in adults with advanced CKD and HIV.
Funding: Other NIH Support - 5P01DK056492-13 and R01 DA026770
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Proteinuria: Is It a Therapeutic Target or Only a Cardiovascular Risk 
Marker?  Jafar Al-Said.  Internal Medicine and Nephrology, Bahrain.
Background: Studies published over the last decade had illustrated that despite the 
successful reduction in proteinuria there were either no benefit or a negative impact on 
renal and cardiovascular outcomes.
Methods: Review recent published trials, which have shown an evidence of decreased 
proteinuria and have renal and cardiovascular outcome.
Results: The following studies were identified: The IDNT; The final outcome 
revealed that although Irbisartan succeeded in lowering doubling of S. Creatinine as well 
as proteinuria, it failed to show a significant difference in CV mortality, non-fatal MI, 
heart failure, or stroke. The DIAB-HYCAR; the result confirmed a successful reduction 
in albuminuria by 14%. However, no significant difference was found on CV outcome, 
including death, non-fatal MI, stroke or heart failure. The ONTARGET, in a sub analysis; 
looking at renal outcome, including doubling S. Cr., dialysis and death, it revealed that 
although the ACE Inh. and the ARB combination had successfully reduced proteinuria, but 
it resulted in worse renal outcome. The TRANSCEND; by looking specifically at the renal 
outcome, including dialysis and doubling serum Cr., it was found that GFR had decreased. 
The AASK trial; the results did not show a positive solid endpoint associated with lowering 
proteinuria, no statistical difference was encountered. The ROADMAP; the result revealed 
that decreasing miroalbuminuria as well as blood pressure in the Olmisartan subgroup was 
not reflected in decreased cardiovascular death. The Altitude trial; decreased proteinuria 
did not show a significant evidence in the primary renal or cardiovascular composite 
endpoints. Moreover, the study was terminated prematurely because of severe decline 
in eGFR, hyperkalemia and hypotension. The VA-NEPHRON-D; The final outcome was 
not statistically different. The study was stopped prematurely because of more acute renal 
injury and hyperkalemia in the combination arm.
Conclusions: Decreased proteinuria was associated with negative cardiac and renal 
outcomes. This could be due to the effect of RAAS combination, but we have to admit that 
these repeated observations carries an evidence, at least to question our standard belief, and 
that proteinuria might not be more than a cardiac risk factor indicator.
PUB132
Prevalence of Hematuria and Associations with All-Cause and 
Cardiovascular Mortality in China  Jinwei Wang, Fang Wang, Luxia Zhang, 
Ming Hui Zhao.  Renal Div, Dept of Medicine, Peking Univ First Hospital, 
Beijing, China.
Background: Hematuria is one of the indicators of kidney damage. We aimed to 
estimate the prevalence of hematuria in China and evaluate its association with mortality 
and cardiovascular adverse outcome.
Methods: A nationally representative sample of 47,204 Chinese adults was obtained 
during the survey conducted between January 2009, and December 2012. Each participant’s 
survival status was identified through Dec 31, 2013. Causes of death in ICD code I00-I99 
were classified as cardiovascular disease. Hematuria was defined as ³3 red cells per high-
power field in microscopic examination. Subjects with pyuria and women undergoing 
menstruation were excluded from the analysis. The associations between hematuria and 
all-cause and cardiovascular mortality were studied by using the Cox regression model.
Results: The mean age of the population at baseline was 49.6±15.2 years, and 42.7% 
of the participants were male. Altogether, 2126(4.5%) of the population was detected with 
hematuria. The all-cause and cardiovascular mortality for participants with hematuria were 
3.8 and 2.6 per 1000 person-years, while those for participants without hematuria were 3.4 
and 1.3 per 1000 person-years. Hematuria was found to be significantly associated with 
increased risk of cardiovascular mortality with the multivariable adjusted hazard ratio of 
1.7 (95% confidence interval: 1.1-2.7), compared with those without hematuria. However, 
no significant associations were found between hematuria and all-cause mortality.
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Table 1. Mortality risk estimation and hazard ratios for mortality according to hematuria status
Hematuria % Events Events per 1000 person-years
Fully adjusted hazard ratio 
(95% confidence interval)
All-cause mortality
No 1.8%(805/45078) 3.4 Reference
Yes 2.0%(43/2126) 3.8 0.9(0.6,1.3)
Cardiovascular mortality
No 0.6%(285/45078) 1.3 Reference
Yes 0.9%(20/2126) 2.6 1.7(1.1,2.7)
Conclusions: Mortality, especially due to cardiovascular diseases, was greater among 
the Chinese patients with hematuria. These results suggest the possible effect of hematuria 
on cardiovascular mortality.
Funding: Government Support - Non-U.S.
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Glomerular Filtration Rate Is a Predictor of Subclinical Left 
Ventricular Diastolic Dysfunction in Patients with Rheumatoid Arthritis 
Suad Ma Hannawi, Kashif Naeem, Issa AL Salmi.  Medicine, MOH, United 
Arab Emirates; Medicine, MOH, United Arab Emirates; Medicine, The Royal 
Hospital, Oman.
Background: Rheumatoid arthritis(RA)is a systemic disease effecting primarily joints 
with subclinical kidney involvement. Subclinical cardiovascular disease(CVD)is a leading 
cause of morbidity& mortality in RA& chronic kidney disease(CKD) at early stages. Left 
ventricular diastolic dysfunction(LVDD) is a principal pathophysiologic mechanism& 
essential diagnostic indexes of HF with preserved ejection fraction(HFPEF).
Methods: Renal parameters correlated with echocardiographic findings in patients with 
RA& eGFR,as estimated(MDRD equation). Doppler echocardiography was performed by 
pulse wave Doppler with sample volume at tip of mitral valve in apical 4-chambers view. 
Peak early(E)&late(A)diastolic velocities were measured as indicator of LVED pressure. 
Assessment of peak early(E’)& late(A)diastolic mitral annular velocity was performed by 
pulsed wave tissue Doppler imaging(TDI)of lateral wall in apical 4-chamber view &to 
diagnose LVDD( E/E’>8).
Results:  Interim analysis:29(3M,26F) with RA diagnosed(ACR1988), 
aged46±12year&GFR 130±36 ml/min. Univariate regression showed a negative 
linear relationship of GFR&age(p<0.001,CI-2.77,-1.03),age@RA onset(p=0.001,CI-
2.32,-0.65),age@RA diagnosis(p=0.002,CI-02.55, -0.66),SBP(p=0.032,CI-1.51,-
0.07),ESR(p=0.005,CI-1.09,-0.21),ferritin level(p=0.008,CI-0.45,-0.08),EE’(p=0.005,
CI-20.76,-4.26). Multiple regression maintained a negative relationship between GFR& 
each of age (p=0.004,CI-2.59,-0.57)&EE(p0.04,-15.25, -0.011)&R2 was 0.54.
Conclusions: RA patient have subclinical CKD and cardiac dysfunction &eGFR 
independently & negatively correlated to LVDD with moderate correlation(0.54). E/E’ 
increased with decreasing GFR& higher than in patients GFR≥90. LVDD influenced by 
increase LV preload due CKD progression& it’s a pre-clinical predictor of future HF& 
mortality. However, milder form of LVDD may stabilize or improve& subset of patients 
may, over time, be at risk for functional deterioration. Inflammation as a major pathological 
key in RA may be underlying cause for increased subclinical kidney& VD.
PUB134
The Association Between Creatinine versus Cystatin-C-Based eGFR and 
Cardiovascular Risk Factors in Children with Chronic Kidney Disease 
Sheena Sharma,1 Ji Young Kim,2 Susan L. Furth.1  1Nephrology, Children’s 
Hospital of Philadelphia, Philadelphia, PA; 2Biostatistics Core, Clinical 
and Translational Research Center, Children’s Hospital of Philadelphia, 
Philadelphia, PA.
Background: Chronic kidney disease (CKD) is an independent risk factor for 
cardiovascular events (e.g. stroke, myocardial infarction) in adults. Children with mild-
moderate CKD have a high prevalence of cardiovascular risk factors (CRF). Higher levels 
of cystatin-C demonstrate a stronger predictive value for cardiovascular events compared 
with creatinine-based eGFR in adults. However, whether similar associations exist in 
children and young adults has yet to be determined. We hypothesize that cystatin-C-based 
eGFR will demonstrate a stronger association with CRF compared with creatinine-based 
eGFR in children and young adults.
Methods: We used cross-sectional data of 93 subjects aged 8-25 years with CKD and 
70 healthy controls. eGFR was calculated using age appropriate creatinine and cystatin-C 
based formulas. The CRF included were anemia (hemoglobin < 2 standard deviations below 
the mean), hypertriglyceridemia (>130mg/dL) and proteinuria (urine protein/ creatinine 
>0.2mg/dL or urine albumin/creatinine >30mcg/g). Multivariate analysis assessed the 
association between creatinine and cystatin based eGFR and each risk factor after adjusting 
for age, gender and race.
Results: 
CRF eGFR creatinine estimate [95% CI]
eGFR cystatin-C estimate 
[95% CI]
Hemoglobin (g/dL) 0.22 [0.15, 0.3] 0.23 [0.16, 0.31]
Triglycerides (mg/dL) -5.08 [-7.83, -2.34] -6.23 [-8.89, -3.58]
Urine protein/creatinine 
(mg/dL) -0.18 [-0.26, -0.09] -0.20 [-0.28, -0.11]
Urine albumin/creatinine 
(mcg/g) -53.03 [-69.93, -36.13] -56.45 [-72.84, -40.06]
Conclusions: These results suggest that creatinine and cystatin-based eGFR have 
similar associations with CRF.
Funding: Other U.S. Government Support
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The Influence of Selected Demographics and Clinical Factors on Left 
Ventricular Function Presented by Echocardiographic Study in Patients 
Treated with Peritoneal Dialysis  Maria Wanic-Kossowska, Krzysztof 
Pawlaczyk, Krzysztof Schwermer, Krzysztof Hoppe.  Dept of Nephrology, 
Transplantology and Internal Medicine, Poznan Univ of Medical Sciences, 
Poznan, Poland.
Background: The purpose of the study was to perform a cross-sectional analysis 
between the selected demographics including age, sex, BMI as well as peritoneal dialysis 
treatment vintage, volume of residual diuresis, presence of arterial hypertension, anemia, 
inflammatory states, malnutrition, mass of the left ventricle, problems with the contractile 
function of the left ventricle as well as decreased relaxation of the left ventricle in the group 
of patients treated with peritoneal dialysis with regard to survival prognosis.
Methods: The study was conducted on 105 patients (49 men, 56 women) treated 
with peritoneal dialysis with the average time of 36.1±23.7 months. The control group 
consisted of 30 healthy volunteers (20 women, 10 men, mean age 55.0±23.8 years). 
Based on general known vascular and cardiac risk factors the patients were divided into 
subgroups: elderly patients (>65 years of age), male, patients treated on peritoneal dialysis 
over 3 years, daily diuresis <500 ml, Kt/V<2.1, arterial hypertension, anemia, inflammatory 
states, malnutrition.
Results: Analyzing the frequency of vascular and cardiac risk factors resulting in 
inadequate echocardiogram results showed the inflammatory states were the most common 
reason for increased left ventricular mass, diastolic dysfunction of the left ventricle as well 
as decreased ejection fraction. In the model of logistical regression taking into account 
age, sex, dialysis vintage, concentration of CRP, ejection fraction of the left ventricle, left 
ventricle mass, and factoring E/A from the echocardiogram study only advanced age of 
the patient treated on peritoneal dialysis decreased survival rate.
Conclusions: Chronic low-grade inflammation and advanced age seem to be two 
most common negative prognostic factors decreasing life expectancy. Further research is 
necessary to verify the intricate relationships between demographic factors and prognosis 
in the group of patients undergoing peritoneal dialysis.
PUB136
Ankle Brachial Index and Exertional Leg Pain Among Hemodialysis 
Patients without a Clinical Diagnosis of Peripheral Arterial Disease 
Pranav S. Garimella,1 Lucia Kwak,2 Kunihiro Matsushita,2 Esther D. Kim,3 
Michelle M. Estrella,2 Stephen M. Sozio,3 Lucy A. Meoni,2 Rulan S. Parekh,4 
Bernard G. Jaar.2  1Tufts Medical Center; 2Johns Hospkins Univ; 3Univ of Toronto.
Background: Exertional leg pain is considered pathognomonic for diagnosing 
peripheral artery disease (PAD). However, patients on dialysis may have multiple 
comorbidities causing or masking leg pain, potentially precluding its use to diagnose 
PAD. Furthermore, the utility of the ankle-brachial index (ABI) to diagnose PAD in this 
population is questionable due to the presence of arterial calcification. In this context, there 
are no data on the association of leg symptoms with ABI in dialysis patients despite them 
having an extremely high burden of PAD.
Methods: We evaluated the cross-sectional association of exertional leg symptoms 
with the spectrum of ABI in 247 incident hemodialysis patients without clinical diagnosis 
of PAD enrolled in the Predictors of Arrhythmia and Cardiovascular Events (PACE) study. 
The presence of exertional leg pain was based on questionnaire and ABI was categorized as 
low (<0.90), borderline (0.90-<1.00), normal (1.00-1.39) and high (³1.4). We used logistic 
regression analysis to report odds of exertional leg pain.
Results: Mean age was 54 years, 76% were black and 51% had diabetes. The prevalence 
ofexertional leg pain was lowest in the normal ABI category and increased towards both 
ends of the spectrum. Compared to normal ABI, low ABI was associated with 2.8 fold 
higher odds of exertional leg pain, although it did not reach significance. After adjusting 
for age, gender and race this association was attenuated to 2.5 fold odds. Borderline and 
high ABI were also similarly associated with exertional leg pain. 
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ABI Proportion without exertional leg pain, (%) Unadjusted OR (95% CI) P value
<0 .9 6/12 (50%) 2.80 (0.85 - 9.18) 0.09
0.9 < to < 1.0 7/21 (33%) 1.40 (0.53 - 3.72) 0.50
1.0 < to < 1.4 39/148 (26%) ref --
> 1.4 22/66 (33%) 1.40 (0.74 - 2.62) 0.30
Conclusions: Low ABI tended to be associated with higher risk of exertional leg pain. A 
low ABI value may be useful to identify ischemic etiology of leg pain even among dialysis 
patients with high prevalence of leg symptoms due to various conditions.
Funding: NIDDK Support
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Chronic Kidney Disease Is Highly Prevalent at Emergency Department 
and Associated with Cardiovascular Comorbidity  Jolanta Malyszko,1 Anita 
Swietochowska.2  1Nephrology, Medical Univ, Bialystok, Podlaskie, Poland; 
2Emergency, Regional Hospital, Lomza, Poland.
Background: Different stages of CKD affects more than 10% of the population, 
while in high-risk patients, the incidence of 30-50% is reported. The aim of this work was 
to evaluate the prevalence of CKD in patients admitted to the non-surgical emergency 
department in one year, the impact of CKD risk factors, rate of hospitalization and mortality.
Methods: From 10500 patients admitted to ED, the group of patients with serum 
creatinine measured, i.e. 3835 (40%) patients over 18 years was selected, including 2095 
(55%) subjects over 70 years. Gender, age, medical history of hypertension, heart failure, 
ischemic heart disease, acute coronary symptoms (ACS), diabetes, inflammation, current 
medications, physical examination, laboratory results: creatinine, C-reactive protein (CRP), 
leukocyte count, hemoglobin, the alcohol level in serum, urinalysis were analyzed.
Results: 2179 patients were hospitalized (57%) mainly for cardiovascular reasons, 
remaining were discharged home. 561 (15%) were admitted to the ED more than once. 
Abnormal serum creatinine was found in 27%,while 19% have CKD stage 3 and 5% stage 
4. Active urine sediment was present in 20% of studied patients. Patients and physicians 
were unaware of this finding.A small percentage of patients were under nephrology care. 
Accumulation of risk factors such as gender, age, hypertension, diabetes, results in an 
increased prevalence of CKD. Prevalence of hypertension in the population of patients 
with CKD is high (59% vs 29% in non-CKD, p<0.001), similarly to prevalence of CAD 
(24%), DM (15%) and CHF (16%). In CKD, 30% of patients have anemia.In-hospital 
mortality was 6%. Analysis of mortality of patients admitted to the emergency department 
and then hospitalized showed that the majority of patients were over 70, with CKD 
(64%), CHF (75%), DM (35%), ACS (25%) and anemia (56%). Deaths were mainly from 
cardiovascular causes.
Conclusions: Prevalence of CKD is high in patients admitted to ED, and associated 
with mainly cardiovascular disease. Education is of utmost importance to diagnose and 
treat CKD in a timely manner and decreased cardiovascular morbidity and mortality in 
this population.
Funding: Government Support - Non-U.S.
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Predictors of In-Hospital Mortality of CKD4-6 Patients with Takotsubo 
Cardiomyopathy  Fernando Rodrigo Aguilar, Mark Abi Nader, Wen Shen, 
Serban A. Dragoi, Alex Montero, Ping Li.  Internal Medicine, Div of Nephrology, 
Medstar Georgetown Univ Hospital, Washington, DC.
Background: The pathophysiology of Takotsubo cardiomyopathy (TTC) remains 
poorly understood and little is known about the factors predicting mortality in these patients 
among those with chronic kidney disease. We aimed to study the epidemiology of TTC 
and predictors of mortality in these patients.
Methods: All patients with CKD 4 to CKD 6 (ICD9 585.4-585.6) diagnosed with 
TTC (ICD9 429.83), in the Nationwide Inpatient Sample database between 2007 and 2012, 
were compared to CKD4 -CKD6 patients without TTC. Capturing only cases undergoing 
left heart catheterization (ICD9 procedure code 32.22) and excluding those recieving stent 
(ICD9 procedure code 00.66; 36.01 - 07;00.45-00.48) as a main treatment. Both groups 
were matched, using propensity matching score for chronic conditions including diabetes 
mellitus, hypertension, hyperlipidemia, coronary artery disease, obesity, alcohol use, 
smoking, heart failure and ventricular arrhythmias. Non-cardiovascular conditions were also 
used to match individual cases. Multivariable logistic regression analysis was performed.
Results: 143 cases of TTC were diagnosed from 2007-2012 in patients having 
CKD4-6. Were  138 cases were matched (n to 1) and posteriorly analyzed. Among to 
control group, CKD 4-6 patients with TTC was more commonly diagnosed in Women 
(86.23% vs 13.77 p=1.0). Alcohol, older, smoking and anxiety, were significantly more 
prevalent in TTC group. In-hospital mortality rate was not different among both groups 
even after multivariable regression analysis.  Contrary to epidemiologic studies in the 
general population, Age, Race Stress, anxiety, smoker, Obesity and HTN did not predict 
mortality with TTC.
Conclusions: In CKD4-6 patients, TTC  does not carrya higher mortality outcome 
compared to the general CKD4-6 patients. Older CKD4-6 females, with anxiety disorder 
and smokers are at higher risk to develop TTC.
PUB139
The Importance of Evaluating Coronary Artery Disease by Multi-Director 
Row Computed Tomography in Advanced CKD  Masataka Hasegawa,1 Daiki 
Kobayashi,2 Masahiko Nagahama,1 Takuya Fujimaru,1 Yuki Heath,1 Fumika 
Taki,1 Miyuki Futatsuyama,1 Yasuhiro Komatsu.1  1Nephrology, St. Luke’s 
International Hospital, Tokyo, Japan; 2General Internal Medicine, St. Luke’s 
International Hospital, Tokyo, Japan.
Background: There is a growing body of evidence that CKD contributes to the severity 
of coronary artery disease (CAD). Although Multi-director row computed tomography 
(MDCT) provides valuable information about CAD, its use for patients with CKD is difficult 
due to the risk of contrast induced nephropathy (CIN). To our knowledge, there have been 
no studies to explore the association of CAD and advanced CKD. The objectives of this 
study are to assess the severity of CAD in advanced CKD patients by MDCT and clarify 
the association between CAD and renal function.
Methods: We retrospectively collected the data from 168 advanced CKD patients, stage 
3b to 5, who underwent MDCT angiography at St Luke’s international hospital between 
2011 and 2014. We assessed CAD by coronary artery calcification score (CASC), coronary 
plaque characteristics and number of vessel disease. Risk factors for CAD were sought 
using univariate and multivariate logistic regression.
Results: Among the 168 patients (56 females, age 60.0±17.0), 108 patients were CKD 
stage 3b, 42 patients were stage 4, and 18 patients were stage 5. No patient developed CIN 
by MDCT. On univariate analysis, patients with CASC³100 were older (P=0.003), male 
sex (P=0.011), diabetic (P=0.045), and more likely to be a smoker (P=0.014). Multivariate 
logistic regression analysis identified age (hazard ratio = 1.08, P<0.01), male sex (hazard 
ratio = 2.97, P=0.013), and CKD stage (hazard ratio = 2.58, P=0.041) as independent risk 
factors for CASC³100.
Conclusions: Coronary artery calcification is worsened significantly with decreasing 
renal function in advanced CKD. Given the high morbidity and mortality of cardiovascular 
disease in CKD, our study underscores the importance of evaluating CAD in advanced CKD.
PUB140
Cardiovascular Biomarkers and Coronary Calcification in CKD 
Patients  Joaquin Manrique,1 Diana Izquierdo,1 Patricia Restituto,2 Nuria 
Garcia-Fernandez,3 Maria Fernanda Slon,1 Diana Lopez Espinosa,3 Maria Jose 
Molina Higueras,3 Nerea Varo.2  1Servicio de Nefrologia, Complejo Hospital 
de Navarra, Pamplona, Spain; 2Servicio de Bioquimica, Clinica Univ de 
Navarra, Pamplona, Spain; 3Servicio de Nefrologia, Clinica Univ de Navarra, 
Pamplona, Spain.
Background: Cardiovascular calcification and mortality are highly prevalent in 
patients with CKD. Biomarkers can help to an early diagnose, like Osteoprotegerin (OPG)
a glycoprotein from TNF family that has been associated with cardiovascular (CV) disease. 
FGF-23, a phosphaturic protein has been linked to vascular calcification, ventricular 
hypertrophy and mortality. Coronary artery calcification (CAC) measured with Agatston 
score (AS) by CT is associated to CV disease in CKD patients.We hypothesized that OPG 
and FGF-23 are abnormally elevated in CKD and are associated CAC measured with AS.
Methods: An observational study including 138 CKD 3-5patients, and 20 control 
subjects were included. Serum FGF-23 and OPG levels were measured by ELISA and 
CAC was determined by multi-detector computed tomography (AS). Biochemical regular 
labs (sCr, Ca, P and PTHi) were measured.
Results: Compared with control subjects, CKD patients exhibited significantly 
augmented serum FGF-23 (16.2 vs 304.8pg/mL; p<0.001) and OPG levels (157.0 vs 
1711.7pmol/L; r2=0.58; p<0.001), and increased proportionally to CKD stage. FGF-
23 and OPG were correlated to PTHi and P (p<0.001) and OPG correlated with renal 
function (sCr) in non-dialysis patients(p<0.05). CKD 5 patients showed significantly 
higher coronary calcification (AS: 1344.3) compared with CKD 3 (144.3;p<0.05) or 
CKD 4 (527.7; p<0.05). FGF-23 and OPG were associated with AS (r2=0.24; p<0.05 and 
r2=0.37;p<0.001, respectively). Among CKD patients, high CAC (AS>800) compared to 
low CAC patients (AS levels<150) showed higher FGF-23 (374.9 vs 156.1; p<0.05) and 
OPG levels (2121.2 vs 1305.2; p<0.001).
Conclusions: CKD is related to high coronary artery calcification levels. FGF-23 
and OPG are higher in CKD patients and are significantly associated to coronary artery 
calcification. Further investigations are needed to determine if they could promptly assess 
increased cardiovascular risk in CKD patients.
PUB141
Rate of Kidney Function Decline and Risk of Hospitalizations  Yan Xie,1 
Benjamin Charles Bowe,1 Sumitra Balasubramanian,1 Ziyad Al-Aly.1,2  1Research 
and Development, VA Saint Louis Health Care System, Saint Louis, MO; 
2Medicine, VA Saint Louis Health Care System, Saint Louis, MO.
Background: Risk of hospitalizations is increased in patients with chronic kidney 
disease (CKD). We sought to examine the association between rate of kidney function 
decline and risk of hospitalization in a cohort of patients with early CKD.
Methods: We built a cohort of 241,274 United States veterans with an estimated 
glomerular filtration rate (eGFR) between 60 and 45 ml/min on October 1, 1999 and who 
had at least 1 additional eGFR measurement between October 2003 and September 2004. 
Patients were followed longitudinally from October 2004 until September 2013. We built 
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survival models to examine the association between rate of kidney function decline and 
risk of hospitalization, and readmission. We built linear regression models to estimate the 
length of hospital stay.
Results: Over a median follow up of 9 years (IQR 5.42 – 9.00), compared to patients 
who experienced mild eGFR decline, patients with moderate and severe eGFR decline 
exhibited an increased risk of hospitalizations HR=1.10 (CI:1.07-1.12), and HR=1.29 
(CI:1.26-1.32); respectively. The number of hospitalizations modified the association 
between rate of decline and risk of hospitalizations in that the risk was increasingly more 
pronounced with increased number of hospitalizations (p value for interaction <0.0001). 
Compared to patients with mild decline in kidney function, patients with moderate and 
severe kidney function decline had increased risk of future readmission, HR=1.16 (CI:1.10-
1.21), and HR=1.47 (CI:1.39-1.55); respectively. Among patients with severe kidney 
function decline, the risk of readmission was increasingly stronger with increased number 
of readmissions (p value for interaction < 0.0001). Compared to patients with mild decline 
in kidney function, patients with moderate and severe decline experienced an additional 
length of stay of 0.91 (CI: 0.58-1.25) and 2.82 (CI: 2.43-3.20) day/year; respectively.
Conclusions: Our findings suggest that rate of kidney function decline is associated 
with future risk of increased health care utilization.
Funding: Veterans Administration Support
PUB142
Racial Influences on the Association of Albumin and Hemoglobin in Chronic 
Kidney Disease  Divya Shankaranarayanan, Avaneesh Jakkoju, Goutham 
Gudavalli, Ziad Maurice Ashkar.  Dept of Internal Medicine, Louisiana State 
Univ, Lafayette, LA.
Background: In CKD, anemia is associated with reduced kidney function, female 
gender, diabetes, older age, African-American race(AA), iron deficiency, low albumin 
, renin-angiotensin blockade, and chronic inflammation. There is a paucity of studies 
evaluating relationship of albumin and hemoglobin(Hb) in CKD among racial groups.
Methods: Retrospective cross section design of 196 patients with CKD stages 2-5, in 
a community clinic over a 7 months period. Averages of hemoglobin, albumin, body mass 
index (bmi), and glomerular filtration rate(GFR) were obtained for each individual patient. 
Patients on dialysis and on erythropoesis-stimulating agents were excluded. Multi-linear 
regression analysis (MLR) was then done between serum albumin and hemoglobin adjusting 
for age, sex, diabetic status, GFR, bmi ,and Ace inhibitors/angiotensin receptors blockers 
intake (ACEi) among African-Americans(AA) and Caucasians(W).
Results: 51% were AA. 49% were diabetics. Mean Hb was 11.7 in AA compared 
to 12.3 in Caucasians . Mean serum albumin was also lower (3.5 AA versus 3.8 in 
W). Bmi and GFR were higher in AA (36.4 and 42.8 in AA vs 32.3 and 39.9 in W 
respectively). Using MLR , there was a statistically significant positive association between 
GFR(coefficient=0.02,p<0.001) , albumin (coefficient=0.77,p=0.002),and hemoglobin. AA 
race was negatively related to hemoglobin(coefficient= -0.68,p=0.02). When MLR was 
done separately among racial groups, there was a persistent positive relationship between 
albumin and hemoglobin among AA (coef=0.95, p=0.001). In Caucasians however there 
was no association between albumin and hemoglobin (p=0.181).
Conclusions: In CKD2-5, using multilinear regression analysis, there was a positive 
association between serum albumin and hemoglobin. This relationship occurs only in AA and 
disappears among Caucasians. It is of interest that in our sample AA had higher baseline bmi 
and GFR and lower serum albumin and hemoglobin. More needs to be done to understand 
the interplay between bmi , albumin and markers of inflammation and nutrition among 
African Americans with chronic kidney disease and their relationships to hemoglobin levels.
PUB143
Mircera Use in Chronic Kidney Disease Patients with Symptomatic Renal 
Anemia: The Real Life Setting  Sai Krishna Duraisingham, Suzanne H. Forbes, 
Muhammad M. Yaqoob.  Renal and Transplantation Medicine, Barts Health 
NHS Trust on behalf of the Mircera Audit Consortium, London, United Kingdom.
Background: Randomized controlled trials have confirmed non inferiority of Mircera 
in the management of renal anemia when compared to other erythropoietin stimulating 
agents (ESAs). Many of these trials had strict exclusion criteria which perhaps confounded 
any benefit that may be seen in an unselected cohort of patients. This multicenter audit 
assessed the outcomes of Mircera use in the real life setting.
Methods: A prospective audit was conducted by 6 UK Renal Centers between 2009 
and 2011. Demographic data, as well as hematological and biochemical parameters were 
longitudinally collected from 1000 adult patients requiring ESAs, over a 1 year period. 
A cohort of 500 patients were switched from previous ESAs to Mircera and 500 patients 
remained on their existing ESA therapy. Patients with hemoglobinopathies or malignancies 
were excluded. Achievement of target hemoglobin (Hb) as per the National Institute of 
Clinical Excellence (NICE) guidelines was ascertained as the primary objective. Hb 
variability was reviewed as a secondary objective.
Results: Demographic data confirmed both cohorts were comparable. Only 11% of 
Mircera treated patients had their Hb maintained within range (10-12g/dl) over the entire 
1 year versus 4% in the non-Mircera group (p<0.05). (If an Hb recording was out of range 
the patient was classified as ‘not maintained’). Parameters such as B12, folate and iron 
were similar in both cohorts. Hb was less variable in the Mircera group 
Conclusions: The results of this audit confirm that Mircera use in the correction of 
anemia associated with CKD is equally efficacious as other ESA therapies in this real life 
setting.Over a year period, Hb variability was noted to be reduced in the Mircera treated 
cohort suggesting a role for its use in patients with fluctuant Hb levels.
Funding: Pharmaceutical Company Support - Extramural grant: Roche Products 
Limited UK
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Latent Profiles of Patient Reported Outcomes in Nephrotic Syndrome 
Patients  Jonathan P. Troost,1 Debbie S. Gipson,1 Bryce B. Reeve,2 Patrick H. 
Nachman,2 Rasheed A. Gbadegesin,3 Jichuan Wang,4 Frank Modersitzki,5 Susan 
F. Massengill,6 John D. Mahan,7 Howard Trachtman,5 David T. Selewski.1  1Univ 
of MI; 2Univ of NC; 3Duke Univ Medical Center; 4George Washington Univ; 
5New York Univ; 6Levine Children’s Hospital; 7The Ohio State Univ.
Background: Nephrotic syndrome (NS) can significantly impair the quality of life in 
children and adults. The purpose of this study was to demonstrate the feasibility and utility 
in using a latent profile analysis (LPA), a type of cluster analysis, to identify subgroups 
of patients based on their patient reported outcomes using the Patient Reported Outcomes 
Measurement Information System® (PROMIS®) measures as well as identifying significant 
predictors of those subgroups.
Methods: Prospective data were collected on 121 children with NS from the 
PROMIS-II study. Data from 55 children and 254 adults with biopsy confirmed NS from 
the NEPTUNE cohort were used as validation. LPA was used to identify patterns and 
subgroups of patients based on PROMIS domain scores. Classification was assessed using 
entropy statistics. Generalized multinomial logit models were used to identify predictors 
of profile membership as well as transitions between profiles over time.
Results: We identified three patient reported outcome profiles (figure1) in the PROMIS-
II cohort with strong indicators of membership classification (entropy>0.86).
Initial subgroups derived from the PROMIS-II cohort were also present in NEPTUNE. 
Reaching complete proteinuria remission, reduction in symptom number, increase in 
serum albumin, and shorter disease duration were significant predictors of better quality 
of life over time.
Conclusions: LPA may be an effective tool in stratifying NS patients by quality of life. 
Profile membership changed in response to changes in disease status over time.
Funding: NIDDK Support
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Sex Hormone Status in Women with Chronic Kidney Disease: A Survey 
of Nephrologists  Sharanya Ramesh,1 Ellen Wells Seely,2 Matthew T. James,1,3 
Jayna M. Holroyd-Leduc,3 Stephen B. Wilton,3,4 Sofia B. Ahmed.1,3,4  1Medicine, 
Cumming School of Medicine; 2Brigham and Women’s Hospital; 3Community 
of Health Sciences, Univ of Calgary; 4Libin Cardiovascular Inst of Alberta.
Background: Chronic kidney disease (CKD) in women is often accompanied by 
menstrual and fertility disorders due to kidney-mediated endocrine disturbances. Whether 
this issue is recognized by nephrologists and discussed by them with their patients is 
unknown.
Methods: We electronically surveyed 111 nephrologists in Canada, identified via 
Canadian Society of Nephrology membership (39% response rate), regarding their 
impressions of sex hormone status, menstrual cycle, fertility and the role of postmenopausal 
hormone therapy (HT) in women with CKD. Responses were stratified by kidney transplant 
nephrologist status.
Results: Fourteen percent of respondents were transplant nephrologists. There were 
no differences in age or sex between transplant and non-transplant nephrologists. Ninety-
three percent of respondents agreed that kidney function has an important impact on 
regulation of sex hormones. However, only 35% reported discussing fertility, and even 
fewer (14%) reported discussing menstrual irregularities with their patients. Only 40% of 
respondents advised their patients to address these concerns with their family physician 
or an endocrinologist or gynecologist. Most of the of nephrologists responded that they do 
not know if there is a role for hormone replacement therapy in patients with CKD (48%), 
23% of nephrologists disagreed with the statement. Nephrologists did not know whether 
the potential benefits of postmenopausal hormone therapy outweighed the risks in CKD 
(51%) or if the formulation (44%), route of administration (46%), and time of HRT initiation 
(50%) play a role in the actions of postmenopausal hormone therapy.
Conclusions: While nephrologists recognize the impact of CKD on sex hormone status 
in women, few address fertility and menstrual disorders with their patients. Our survey 
highlight existing uncertainties of nephrologists about how to manage disturbances of sex 
hormones in people with CKD.
Funding: Private Foundation Support
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Clinical and Pathological Analysis of Elderly Hospitalized Patients with 
Chronic Kidney Disease  Fu-You Liu, Yinghong Liu.  Inst of Nephrology, 
the Secongd Xiangya Hospital, Central South Univ, Changsha, Hunan, China.
Background: To investigate the primary disease and to examine the pathological 
patterns of renal in elderly patients with CKD.
Methods: Medical histories,laboratory test results and renal biopsy datum were 
collected and retrospectively analyzed from 967 elderly patients with CKD.
Results: (1)The average age of 967 cases of elderly patients was 68.27 ±6.41 years 
old.The leading cause of CKD was primary glomerular diseases(37.33%),followed by 
diabetes nephropathy (23.27%) and hypertensive nephropathy (19.75%). (2) The left kidney 
was larger than the right,and kidney of male patients was larger than the female(P<0.05). 
There was a positive correlation between eGFR and the left kidney width, depth, and the 
right kidney width, depth. (3)In 75 patients who underwent renal biopsy,the most common 
renal histopathology in primary glomerular disease was membranous nephropathy (MN) 
(48.08%). In patients with MN, 88.00% presented as nephrotic syndrome. (4)The prevalence 
of hypertension was 80.66%.eGFR was negatively correlated with systolic blood pressure 
levels. (5)The anemia rate of elderly patients with CKD was77.97%.eGFR and hemoglobin 
levels were positively correlated (6) There was a positive correlation between eGFR and 
HDL-C, LDL-C, total cholesterol and triglyeride respectively . (7) Calcium-phosphorus 
metabolism were mainly hypocalcemia (27.92%) and hyperphosphatemia (54.91%) 
.eGFR was negatively related to the level of blood phosphorus and intact parathyroid 
hormone(iPTH),and positively related to blood calcium levels.
Conclusions: (1)This study shows that primary glomerular disease is still the leading 
causes of elderly patients aged 60 and above with CKD,followed by diabetes nephropathy 
and hypertensive nephropathy. (2)In elderly patients receiving renal biopsy,the most 
common renal histopathology pattern was MN in primary glomerular disease. (3)It indicated 
that high systolic blood pressure, renal atrophy,anemia,low HDL-C,hyperphosphatemia and 
secondary hyperparathyroidism may be associated with deterioration of renal function level.
Funding: Government Support - Non-U.S.
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Measurement of Breath Ammonia for Detection of Patients with Chronic 
Kidney Disease  Sebastjan Bevc,1 Evelina Mohorko,2 Mitja Kolar,2 Polonca 
Brglez,3 Andrej Holobar,3 Daniela Kniepeiss,4 Matej Podbregar,5 Nina Hojs,1 
Masa Knehtl,1 Robert Ekart,1 Radovan Hojs.1  1Univ Clinical Centre Maribor, 
Slovenia; 2Faculty of Chemistry and Chemical Engineering Maribor, Slovenia; 
3ECHO d.o.o. Slovenske Konjice, Slovenia; 4Medical Univ Graz, Austria; 5Univ 
Clinical Centre Ljubljana, Slovenia.
Background: In a healthy individual, ammonia is converted to urea in the liver 
through urea and citric acid cycles. Urea is then transported through the bloodstream to 
be excreted into the urine by the kidneys. In patients with chronic kidney disease (CKD) 
an equilibrium concentration of ammonia and urea becomes imbalanced, concentrations 
exceeding physiological values and breath ammonia can be used for detecting increased 
nitrogen-bearing wastes in the body. In our pilot study, the electrochemical sensor was 
used to measure and analyze breath ammonia in healthy volunteers and CKD patients.
Methods: Six CKD patients and eight healthy volunteers were enrolled. The mean age 
of CKD patients was 47.2 years, mean age of healthy volunteers 61.3 years. One controlled 
breath sample was given from each participant. Immediately after the sample was collected 
gas analyzer (BA-NH3, Echo, d.o.o.) was used for measuring breath ammonia in our 
participants. BA-NH3 detects breath ammonia in parts per million (ppm) and measures 
the electric current in milliamperes (mA). BA-NH3 was validated with reference gas 
concentrations prepared with a precise accredited gas mixing device (M4-1-S-220, Echo, 
d.o.o.) using calibrated mass flow controllers controlled with computer software.
Results: Mean serum creatinine in CKD patients was 455.17±294.12 µmol/L and 
62.13±7.5 µmol/L in healthy volunteers. BA-NH3 detected more ppm of ammonia in breath 
of CKD patients (mean ppm 3.32±2.19; range 1.26-6.33) comparing to healthy volunteers 
(mean ppm 0.49±0.08; range 0.38-0.64 ppm) (p=0.003) and measured higher electric 
current from breath samples of CKD patients (mean mA 4.33±0.25; range 4.10-4.67 mA) 
comparing to healthy volunteers (mean mA 4.01±0.01; range 4.00-4.03 mA) (p=0.003).
Conclusions: Results of our pilot study show that breath monitoring of ammonia can 
be an useful simple, fast and noninvasive tool for detection of kidney impairment.
PUB148
Use of Urine Biomarker-derived Clusters to Predict CKD Risk and All-
Cause Mortality in HIV+ Women  Rebecca Scherzer,1 Heather Thiessen 
Philbrook,2 Chirag R. Parikh,3 Michael R. Bennett,4 Mardge H. Cohen,5 Anjali 
Sharma,6 Mary A. Young,7 Phyllis Tien,1 Vasantha Jotwani,1 Michael Shlipak.1 
1UCSF; 2London Health Sciences Centre; 3Yale; 4Cincinnati Children’s Hospital; 
5Rush; 6Albert Einstein; 7Georgetown.
Background: Individual urine biomarkers are associated with CKD incidence and 
all-cause mortality in the setting of HIV infection, but their combined utility for prediction 
remains unknown.
Methods: We measured 8 urine biomarkers in 902 HIV+ women: NAG, KIM-1, alpha 
1 microglobulin (a1m), IL-18, NGAL, ACR, L-FABP, and AAG. A novel cluster method 
classified each participant into 3 groups using the three most distinguishing markers (NAG, 
KIM-1, and a1m). We evaluated associations of each cluster with incident CKD and all-
cause mortality, adjusting for traditional and HIV-related risk factors.
Results: Over 8 years of follow-up, 177 CKD events and 128 deaths occurred. As shown 
in the Table, incidence of CKD and mortality increased incrementally across the 3 clusters. 
After multivariable adjustment, cluster 3 remained associated with a nearly 3-fold risk of 
both outcomes compared with cluster 1. Addition of the clusters to the multivariable model 
improved discrimination for CKD (c-statistic=0.72 to 0.76, p=0.0029), but only modestly 
for mortality (c=0.79 to 0.80, p=0.099). Clusters derived with all 8 markers were no better 
for discrimination than the 3-biomarker clusters.
Conclusions: Among HIV+ women, clusters developed from 3 urine biomarkers 
moderately improved discrimination for CKD risk, but not for all-cause mortality. 
Association of biomarker-derived cluster* with incident CKD and all-cause mortality in 
HIV+ women
Incident CKD Cluster 1 n=289
Cluster 2 
n=435
Cluster 3 
n=94
Event rate 13% 21% 50%
Unadjusted Risk Ratio (95%CI) Ref 1.7 (1.2, 2.4) 3.9 (2.7, 5.6)
Adjusted Risk Ratio (95%CI) Ref 1.6 (1.1, 2.3) 2.9 (2.0, 4.3)
All-cause mortality Cluster 1 n=301
Cluster 2 
n=470
Cluster 3 
n=131
Event rate 7% 13% 34%
Unadjusted Hazard Ratio (95%CI) Ref 1.9 (1.1, 3.0) 5.4 (3.2, 9.0)
Adjusted Hazard Ratio (95%CI) Ref 1.5 (0.9, 2.5) 2.8 (1.6, 4.8)
* Clusters were derived using NAG, α1m, and KIM-1. Adjusted models control for traditional 
kidney risk factors and HIV-related risk factors.
Funding: Other NIH Support - The WIHS Kidney Aging Study is funded by 
grant 1 R01 AG034853-01A2 (PI, Shlipak), which was administered by the Northern 
California Institute for Research and Education, and with resources of the Veterans Affairs 
Medical Center, San Francisco, California. Data in this manuscript were collected by the 
Women’s Interagency HIV Study (WIHS). The contents of this publication are solely the 
responsibility of the authors and do not represent the official views of the National Institutes 
of Health (NIH). WIHS (Principal Investigators): UAB-MS WIHS (Michael Saag, 
Mirjam-Colette Kempf, and Deborah Konkle-Parker), U01-AI-103401; Atlanta WIHS 
(Ighovwerha Ofotokun and Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn 
Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), 
U01-AI-031834; Chicago WIHS (Mardge Cohen), U01-AI-034993; Metropolitan 
Washington WIHS (Mary Young), U01-AI-034994; Miami WIHS (Margaret Fischl and 
Lisa Metsch), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie 
Wofsy Women’s HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, 
and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center 
(Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS 
(Alexandra Levine and Marek Nowicki), U01-HD-032632 (WIHS I – WIHS IV). The 
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PUB149
Minimizing Erythropoietin Stimulating Agents Requirement by 
Comprehensive Clinical Care  Rachita Singh Dhull, Rossana Baracco, 
Melissa J. Gregory, Tej K. Mattoo.  Pediatric Nephrology, Children’s Hospital 
of Michigan, Detroit, MI.
Background: Anemia is a common problem in children with chronic kidney disease 
(CKD). The objective of the study was to evaluate prevalence of anemia, use of iron 
supplement and erythropoietin stimulating agents (ESA) in children with CKD stage 2-4, 
and compare the same with previous pediatric studies.
Methods: This is a retrospective chart review of children with CKD stage 2-4 (defined 
per KDOQI), aged between 1-18 years followed at Children’s Hospital of Michigan (CHM) 
in 2013. Data on transferrin saturation, hemoglobin level, use of iron supplements and 
ESA was collected.
Results: Total number of patients were 62. The mean age was 10.12 ± 5.52 years and 
27.4% were female. The main causes of CKD were renal dysplasia (20%), obstructive 
uropathy (18%), reflux nephropathy (14.5%), cystic dysplasia (13%), glomerular pathology 
(11.2%) and others (23.3%). In our cohort, 27% patients had anemia compared to 44% 
in CkiD study and 43.5% in study by Wong et al. Also, only 6.5% of CKD patients were 
on ESA, compared to 18% in Ckid study and 19.5% in study by Wong et al. Results are 
elaborated in the table below. 
CKiD 
STUDY 
(2008)
Wong et al 
(2006) CHM DATA
CKD 
STAGE
Pateints(%) 
with ane-
miaa/nb
Patients(%) 
with ane-
miac/nb
Patients 
(%)with 
anemiaa/
nb
Transferrin 
saturation 
>=20%
On iron 
supplement on ESA
2 21/39 28.57/106 7.7/13 7(53.8%) 9(69.2%) 0
3 39/217 65.8/38 27/37 24(64.8%) 21(56.7%) 0
4 73/82 93.3/15d 50/12 8(66.6%) 9(75%) 4(33.3%)
TOTAL 45/338 43.5/159 27.4/62 39(63%) 39(63%) 4(6,45%)
aAnemia as defined by hemoglobin (Hb) level < 5th percentile for age and sex according to NHANES 
III data.  
bn= number of children with CKD in that group. 
cAnemia as defined by Hb <12 g/dl or on medical management for anemia. 
dincludes children with stage 4 and 5 CKD .
Conclusions: Our CKD patients had a lower prevalence of anemia and lower use of 
ESA compared to other pediatric studies. We maintain adequate iron stores by using iron 
supplements even in children with normal hemoglobins. The administration of supplemental 
iron prior to the development of anemia in children with CKD decreases the need for ESA.
PUB150
Validation of Urinary Biomarkers for the Diagnosis of Urothelial Carcinoma 
in Patients with Chronic Kidney Disease  Chiu-Ching Huang,1 Che-yi Chou,1 
Chao-Jung Chen.2  1Kidney Inst, China Medical Univ and Hospitals, Taichung, 
Taiwan; 2Proteomics Core Laboratory, Dept of Medical Research, China 
Medical Univ, Taichung, Taiwan.
Background: Many urine biomarkers for diagnosis of urothelial carcinoma(UC) have 
been published. CKD patients are prone to have UC. Most of the studies are tested in healthy 
controls and UC patients. Whether these biomarkers are specific to diagnose UC in CKD 
patients have not been studied before. AIMS: To investigate if current urinary biomarkers 
are specific to diagnose UC in CKD patients.
Methods: This is a multicenter prospective case-control study, carried out at 7 tertiary 
medical centers in Taiwan (Taiwan UC Consortium). Subjects were healthy adults (healthy 
controls), patients with CKD but without UC (disease controls) and patients with ongoing 
UC.Urine was collected from each patient and frozen immediately after collection. We 
measured 9 urinary UC biomarkers : BLCA-1.HAI-1.HtrA1, NMP22, CYFRA21-1, 
TSCSTD2, BLCA-4, BTA and Midkine. Mann-Whitney Rank Sum Test was used for 
statistical analyses.
Results: A total of 47 UC cases, 288 CKD patients and 20 healthy controls were 
recruited. We selected 47 CKD control patients who were age, sex and CKD-staging best 
matched with 47 UC patients. Among the 9 biomarkers tested, six biomarkers,e.g.NMP22, 
CYFRA21-1, TSCSTD2, BLCA-4, BTA and Midkine showed significant increase of 
urinary concentrations in UC patients when compared to healthy controls. Nevertheless, 
only Midkine and CYFRA 21-1 had significantly increased concentrations in UC patients 
when compared to CKD controls.The other 4 UC biomarkers did not show significant 
higher concentrations in UC patients than CKD controls.
P value 
Urine biomarker Healthy controls vs. CKD controls
CKD controls vs. 
ongoing UC
Healthy controls vs. 
ongoing UC
BTA 0.023 0.420 0.175
Blca-4 0.002 0.379 <0.001
NMP22 <0.001 0.486 0.007
TACSTD2 0.005 0.265 0.001
Midkine 0.027 0.050 <0.001
CYFRA21-1 0.676 0.003 0.007
Conclusions: Among 9 urine biomarkers tested, only two showed statistically 
significant higher urinary concentrations in UC patients than matched CKD patients. 
Our findings would raise caution of interpreting urinary biomarkers for UC diagnosis in 
CKD patients.
Funding: Government Support - Non-U.S.
PUB151
Predictors for 30-Day Hospital Readmission in a Nephrology Ward 
Carla S. Moreira,1 Ligia Bessa,2 Vanda Guardado,2 Jorge Malheiro,1 Josefina S. 
Lascasas,1 António Cabrita.1  1Nephrology, Centro Hospitalar do Porto, Porto, 
Portugal; 2Nephrology, Hospital Militar de Luanda, Luanda, Angola.
Background: Rehospitalization, particularly 30-day hospital readmission is a 
growing concern in health care services. In this study we searched for predictors of 30-day 
readmissions (including emergency department visits) and 12-months hospitalization rate 
in patients admitted to a nephrology ward.
Methods: A group of 144 patients admitted to our nephrology ward from 2012 to 
2013 were randomly selected. Their medical records regarding demographic and clinical-
laboratorial data were collected. The statistical analysis was performed using univariate 
and multivariate logistic regression, and poisson regression.
Results: Median age was 66yo (IQ 56-81), with 63% of male patients. The majority 
of the patients had an emergent admission (63%) and regular hospital follow-up (55%). 
The median length of hospital stay was 7 days. The readmission rate was 23% and the 
median length until readmission was 13 days. The prevalence of chronic kidney disease 
was 89%, with 30% of these patients undergoing chronic intermittent hemodialysis 
and 11% peritoneal dialysis. The median Charlson Comorbidity Index (CCI) was 7 
points (IQ 4-11). In the univariate analysis we found a statistical significant association 
between diabetes mellitus (OR =2.45, p=0.04), lower (<3.5g/dL vs ≥ 3.5g/dL) albumin 
level (OR=8.73, p=0.006), higher (<8 vs ≥ 8) CCI score (OR=2.94, p=0.02) and 30-day 
hospital readmission. In the binary logistic regression only albumin level kept its significant 
association (OR=7.9, p=0.01), with diabetes mellitus maintaining a tendency for significance 
(OR=2.97, p=0.09). The rate of rehospitalizations at the first year adjusted for gender was 
2.6 vs 6.4 rehospitalizations/100 patients-month in the lower and higher CCI score groups, 
respectively (p=0.01). The rate of emergency department episodes adjusted for gender 
was 29 versus 75 episodes/100 patient-month in the lower and higher CCI score groups, 
respectively (p<0.001).
Conclusions: The Charlson Comorbidity Index and albumin level may be valuable 
predictors of hospital readmission risk in patients from a nephrology ward.
PUB152
Urine Protein Fragment Excretion in Diabetic Patients with Chronic Kidney 
Disease  Michele V. Clarke,1 Elif Ekinci,1,2 Nicholas J. Radcliffe,1,2 Richard 
J. MacIsaac,3 George Jerums,1 Wayne Comper.4  1Austin Health, Melbourne; 
2Univ of Melbourne, Melbourne; 3St. Vincent’s Hospital, Melbourne; 4Sal Aqua 
Diagnostics, New York.
Background: Albuminuria is an established marker for the development of diabetic 
nephropathy. Normal renal handling of albumin involves endocytosis by proximal tubule 
cells through a lysosomal pathway. This returns small albumin fragments, undetectable 
by standard clinical assays, to the tubular lumen. Albuminuria has been shown in patients 
with type 1 diabetes to be associated with an impaired degradation pathway, and urinary 
peptides have been shown to be reduced in patients with macroproteinuria. However, urine 
peptide excretion studies have not controlled for changes in estimated glomerular filtration 
rate (eGFR) in patients with diabetes.
Methods: Patients with diabetes and eGFR <60ml/min were stratified into normo- 
(<20mg/min, n=9), micro- (20-200mg/min, n=12) or macroalbuminuric (>200mg/min, n=9) 
groups. 24 hr urines were passed through a 10kDa protein filter, and the <10kDa and >10kDa 
fractions were assayed separately using the BCA protein assay to detect peptide bonds.
Results: Macroalbuminuric patients had a reduced proportion of peptide fragment 
excretion (<10kDa) compared to micro- and normoalbuminuric patients (81.1% vs 89.0%, 
p<0.05 & 96.8%, p<0.001 respectively); however there was no difference between micro- 
and normoalbuminuric groups (Figure 1). Mean fragment concentrations were lower in 
micro- and macro- groups compared to normoalbuminuric patients, (3389µg/ml and 3480µg/
ml vs 4396µg/ml) but did not reach statistical significance. 
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Conclusions: In patients with diabetes and reduced renal function, we have 
demonstrated a reduction in peptide fragment proportional excretion in macroalbuminuric 
patients. These findings are consistent with the hypothesis that albuminuria is linked to 
defects in the renal tubule resorption and fragmentation pathways.
PUB153
Chronic Kidney Disease of Uncertain Etiology: A Systematic Review 
Joseph Lunyera, Dinushika Mohottige, Megan Von Isenburg, Uptal D. Patel, 
Marc A. Jeuland, John W. Stanifer.  Duke Univ.
Background: Epidemics of chronic kidney disease of uncertain etiology (CKDu) are 
emerging around the world. Highlighting common risk factors for CKDu across various 
regions and populations may be important for health policy and public health responses.
Methods: We conducted a systematic review of the PubMed, Embase, Scopus and 
Web of Science databases to identify published studies on CKDu. Two independent authors 
reviewed all abstracts for inclusion, assessed each study for quality, and extracted the data. 
We used a vote-counting method to evaluate the exposures across all studies.
Results: We identified 2535 articles of which 25 met inclusion criteria. Eighteen (72%) 
were conducted in CKDu-endemic countries: Sri Lanka (40%), Nicaragua (20%) and El 
Salvador (12%). The other studies were from India, Japan, Australia, Mexico, Sweden, 
Tunisia and the United States. Risk factors most frequently measured were agricultural 
occupation (48%), age (48%), gender (44%), and agrochemical use (40%). Heavy metals, 
heat stress and dietary exposures were reported in studies across all geographical regions. 
In South Asia, family history, agrochemical use, and heavy metal exposures were reported 
most frequently while altitude and temperature were reported only in studies from Central 
America. Across all regions, CKDu was most frequently associated with a family history 
of CKDu, farming occupation, male gender, middle-age, snake bites and heavy metal 
exposures. Among high risk populations, CKDu prevalence was reported to be 7.3%-14.9% 
in South Asia and 13%-25.9% in Central America.
Conclusions: Studies examining etiologies of CKDu have reported many potential 
exposures that are heterogeneous and vary by region. It remains unknown whether the 
regional variation in CKDu risk factors reflects inconsistencies in measurement across 
studies or complexity in the interactions between global exposures and local factors such 
as environment, genetics, and lifestyle. Thus, to identify the causative factors of CKDu, 
one important approach could be to design consistent and comparative multi-site studies 
in high-risk populations that would provide insights into the importance of region-specific 
versus global risk factors.
PUB154
Understanding the Socio-Demographic Status of Patients Receiving Care at 
Sonar Bangla Foundation Dialysis Centers in Bangladesh: A Cross-Sectional 
Pilot Study  Tamanna M. Noyon,1 Mahmood Hussain,1,2 Imtiaz M. Islam,1,3 
Akm Monoarul Islam,1,4 Abu hena M. Kamal.1  1Sonar Bangla Foundation, 
Santa Clara, CA; 2Marketing, San Francisco State Univ, San Francisco, CA; 
3Nephrology, Good Samaritan Specialists, Kearney, NE; 4Nephrology, Rajshahi 
Medical College & Hospital, Rajshahi, Bangladesh.
Background: This study constitutes an exploratory investigation to understand the 
socio-demographic status of patients receiving care at the nine dialysis centers operated by 
Sonar Bangla Foundation (SBF) in Bangladesh. SBF is a leading non-profit organization, 
exclusively dedicated to the care of patients suffering from End-Stage Kidney Disease 
(ESKD). Although ESKD is very common, there is little to no data addressing prevalence 
of ESKD in Bangladesh. Without understanding its prevalence and the socio-demographic 
status of patients, little can be done to increase effectiveness and quantity of dialysis centers 
throughout Bangladesh. This study was launched in April 2015 and will continue throughout 
the dialysis centers’ operations.
Methods: A one-time survey is being conducted to obtain clinical and demographical 
information on all existing and new patients at SBF centers.
Results: Currently, the study reveals a large gender disparity amongst dialysis 
recipients, 1 out of 4 patients is female (n=101). The average age of male patients is 44.7 
years (SD ±12.7), while the average age of female patients is 45.3 years (SD ±14.2). 
Furthermore, patients from at least 20 different districts receive dialysis at the centers. 
The study also finds a significant positive correlation between education level and the 
frequency of dialysis received.
Conclusions: Data collected throughout this study will be incorporated into an 
expanding database, first of its kind in Bangladesh. ESKD is a devastating disease that 
forces patients to become dependent on a machine. By understanding the education level, 
financial status, distance traveled and other factors in relation to the frequency of dialysis 
received, services provided by SBF centers could be greatly improved. The study aims to 
change the quality of kidney care in Bangladesh.
PUB155
Clinical and Pathological Features of Idiopathic Membranous Nephropathy 
in Young Adults  Chenni Gao, Jing Xu, Wen Zhang, Xiaoxia Pan, Xiao Li, Nan 
Chen.  Nephrology, Ruijin Hospital, Shanghai Jiaotong Univ, Shanghai, China.
Background: Membranous nephropathy (MN) is a common pathological types in 
elderly nephrotic syndrome (NS) patients. Few researches focus on the young idiopathic 
MN population.
Methods: 583 patients hospitalized between Jan 2009 and Dec 2014 in our department, 
with biopsy-proved MN eliminating secondary causes, are enrolled. All patients were 
divided into 3 groups: 150 patients (25.1%) in young adults group (≤44 yrs), 202 (34.7%) 
in middle-aged group (45-59 yrs) and 231 (39.6%) in elderly group (≥60 yrs). We collected 
and compared their clinical and pathological data as well as therapy regimes.
Results: 310 male and 273 female enrolled. The young adults group had a lower rate of 
NS (P=0.022), higher serum albumin (P<0.01), estimated-GFR (P<0.01) and hemoglobin 
level (P<0.01), and lower fast blood glucose level (P<0.01).
young adults 
group (n=150)
middle-aged 
group (n=202)
elderly group
(n=231)
P 
value
proteinuria(g/24h) 4.7±3.8 4.6±3.9 5.1±3.4 0.271
serum albumin(g/L) 23.8±7.8 23.9±6.9 21.2±6.0 <0.01
nephrotic syndrome 73 105 143 0.022
fast blood glucose (mmol/L) 4.5±0.9 4.8±0.9 4.9±1.1 <0.01
serum creatnine(μmol/L) 64.2±175 71.0±24.8 85.2±40.5 <0.01
eGFR(ml/min/1.73m2) 124.4±31.2 102.2±29.3 83.8±25.3 <0.01
hemoglobin(g/L) 135.4±18.1 132.8±18.1 123.2±17.4 <0.01
Table 1. Clinical features in three groups
There’s no significant difference in the disease staging or immunofluorescences staining. 
However, the young adult patients had fewer mesangial, interstitial, tubular and arteriole 
lesions, and fewer inflammatory cells infiltration as well (P<0.01). For the therapy, the 
number of ACEI/ARB regime applied in the three groups was 72/95/75, while corticoid 
associated with immunosuppressive agents regime was 66/92/140 (P<0.01).
Conclusions: About a quarter of all IMN patients are young adults. They had fewer 
cardiovascular risk factors, higher serum albumin level and better renal function. Their 
pathological lesions were milder. ACEI/ARB regime is more widely applied in young 
adults patients.
PUB156
Effect of Glycemic Control on Estimated Glomerular Filtration Rate 
by Cystatin C  Masaru Horio,1 Enyu Imai,2 Yoshinari Yasuda,3 Tsuyoshi 
Watanabe,4 Hitoshi Yokoyama,5 Hirofumi Makino,6 Seiichi Matsuo.3  1Osaka 
Univ Graduate School of Medicine, Suita, Japan; 2Nakayamadera Imai Clinic, 
Takarazuka, Japan; 3Nagoya Univ Graduate School of Medicine, Nagoya, 
Japan; 4Fukushima Medical Univ, Fukushima, Japan; 5Kanazawa Medical 
Univ School of Medicine, Kanazawa, Japan; 6Okayama Univ Graduate School 
of Medicine, Okayama, Japan.
Background: Cystatin C has been proposed as an alternative marker for estimating 
glomerular filtration rate (GFR). But, some factors other than GFR affect the accuracy of 
estimated GFR (eGFR). Some studies raised a concern that poor glycemic controlmay cause 
inaccuracy of estimation of GFR. We studied the effect of glycemic control on eGFR based 
on serum cystatin C (eGFRcys).
Methods: GFR was measured by inulin clearance (Cin). Estimated GFRs were 
calculated by CKD-EPI equation (CKD-EPI) and Japanese GFR equation (J-Eq) based on 
standardized cystatin C. Glycemic control was evaluated by serum glycated albumin (GA). 
Three hundred and forty five Subjects with normal GA (12.4-16.3%) and 126 subjects with 
high GA (>16.3%) were included. Effects of age, gender, BMI, GA and serum albumin on 
eGFRcys / Cin ratio was analyzed by multiple regression analysis.
Results: Cin, eGFRcys(J-Eq) and eGFRcys (CKD-EPI) in normal GA were 57.9±34.0, 
56.1±31.7 and 57.9±33.9 ml/min/1.73m2, respectively. Cin, eGFR(J-Eq) and eGFR (CKD-
EPI) in high GA were 36.2±28.9, 36.71±27.5 and 36.7±28.5 ml/min/1.73m2, respectively. 
There was no significant difference among Cin, eGFRcys (J-Eq) and eGFRcys (CKD-EPI) 
in both subjects. Slopes (95%CI) of the regression lines with zero intercepts in subjects 
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with high GA were 0.989 (0.944-1.033) in J-Eq and 0.965 (0.922-1.009) in CKD-EPI. The 
slopes were not significantly different from 1.0, suggesting that eGFRcys performed well 
in subjects with high GA. Multiple regression analysis showed that age, gender, BMI, GA 
and serum albumin were not significant factors affecting both eGFRcys(CKD-EPI) /Cin 
and eGFRcys(J-Eq) /Cin.
Conclusions: Estimated GFR based on cystatin C performed well in subjects with 
high GA.
Funding: Government Support - Non-U.S.
PUB157
Renal Hyperfiltration and Outcome in HIV-Infected Subjects 
Gianni Cappelli,1 Elisabetta Ascione,1 Giovanni Guaraldi,2 Andrea Malagoli,2 
Elisabetta Rubbiani,1 Antonio Bellasi.3  1Univ Hospital of Modena, Nephrology 
Dialysis and Renal Transplantation Unit, Modena, Italy; 2Univ Hospital of 
Modena, Metabolic Clinic, Infectious and Tropical Diseases Unit, Modena, 
Italy; 3Azienda Ospedaliera S. Anna, Como; Dept of Health Sciences, Univ of 
Milan, Nephrology and Dialysis Unit, Como, Italy.
Background: Although highly active antiretroviral therapy (HAART) improves life 
expectancy of HIV-infected subjects, it is also associated with numerous comorbidities.
Evidence suggests that renal hyperfiltration (RHF) is associated with various lifestyles, 
clinical conditions and portends poor prognosis in the general population. We sought at 
determining prevalence of RHF and its associations with traditional and HIV-related risk 
factors as well as all-cause mortality in a large cohort of HIV-infected subjects.
Methods: Retrospective study of 3875 HIV-infected patients attending at the “Modena 
Metabolic HIV Clinic”. The Chronic Kidney Disease Epidemiology Collaboration equation 
(CKD-EPI) was used to estimate glomerular filtration rate (eGFR). Linear regression was 
used to model eGFR against age and sex. RHF was defined as eGFR with residuals above 
the 95th percentile. Anova, Chi-square, logist regression and survival analyses were used 
to identify factors and the risks associated with RHF.
Results: Overall, we investigated middle-age (44.5+7.5 years) men and women 
(male 65.1%) with preserved renal function (eGFR 94.5+17.1 ml/min/1.73 m2). RHF was 
inversely associated with age (Odds Ratio 0.93), hemoglobin (OR 0.8), WBCs (OR 0.9) 
and positively associated with HIV-infection (OR 1.07). Of interest, no association with 
HAART was noted. Over mean follow-up of 7 years, 75 persons died. RHF was associated 
with all-cause mortality independently of potential confounders (Hazard ratio: 4.17, 95%CI: 
1.81 - 9.6; p<0.001).
Conclusions: RHF is influenced by HIV infection duration independently of established 
factors and isrelated with the risk of all-cause of death. Future efforts are needed to clarify 
what are the mechanisms that link RHF with poor prognosis and if RHF modulation 
improves survival in HIV-infected subjects.
PUB158
Bioelectrical Impedance Analysis as a Screening Tool for Chronic Kidney 
Disease  Anita Saxena, Amit Gupta.  Nephrology, Sanjay Gandhi Post Graduate 
Inst of Medical Sciences, Lucknow, UP, India.
Background: Chronic Kidney Disease (CKD) has a latent period during which the 
disease is present but asymptomatic. With increasing incidence of hypertension and diabetes, 
incidence and prevalenceof CKD is on increase. Bioelectric impedance analysis (BIA) a 
noninvasive method for estimation of body composition in clinical setting but it has not 
been used for CKD screening. Purpose: To evaluate applicability of BIA as a screening 
tool for presence of kidney disease in general population with creatinine clearance and 
glomerular filtration rate (GFR).
Methods: A pilot-cross-sectional CKD screening study on randomly selected 52 
subjects from general population. Maltron BIOSCAN analyzer 915/916 was validated with 
Hume etal’s equation for estimation of total body water. BIA derived GFR was validated with 
99mTec-DTPA nuclear scan derived GFR, a study done on voluntary healthy kidney donors.
Results: There was no significant difference between total body water estimated with 
BIA and Hume etal’s equation and BIA derived GFR and DTPA nuclear scan GFR. Mean 
serum creatinine for males was 0.94 ± 0.14mg% and 0.91± 0.84mg% for females. BIA 
derived creatinine clearance was 97.39± 28.98 in males and107.60± 34.03 in females, 
GFR was 74.1±25.98 ml/min/1.73 m2in males and 65.17 ±21.14 ml/min1.73 m2 in females. 
Based on GFR subjects were classified into CKD. Out of 52 subjects 8 were in CKD stage 1 
(15.5%), 23 (44.2%) were in CKD stage 2, 18 (34.6%) were in CKD stage 3 , 1 (1.9%/1.9%) 
each in CKD stage 4 and CKD stage 5 respectively. Incidentally, 13.5% were diabetic. and 
65.8% were hypertensive. Mean blood pressure was 133.99 ±40.89/82.76 ±27.79 mmHG 
in males and 132.10 ±16.20/ 83.46± 7.85mmHG in females. Based on American Heart 
Association classification for hypertension, 19 (36%) patients had normal blood pressure, 
8 (15.5%) were in prehypertensive stage, 16 (30.7%) patients were in hypertension stage 
1, 6 (11.5%) were in hypertension stage 2 and 2 had crisis hypertension.
Conclusions: Population-based CKD screening programs can identify people with renal 
injury for early intervention. BIA can be used for screening CKD in general population. It 
can also be a routine test as 99mTec-DTPA scan for estimation of GFR.
PUB159
Design and Implementation of a Chronic Kidney Disease Prevalence Study 
in Rivas, Nicaragua  Kailey Minnings,1 Martha Mosco,2 Madeline M. Fiore,3 
Eric S. Kerns,4 Juan Jose Amador,5 Rulan S. Parekh,6 Louis D. Fiore.5  1Faculty 
of Medicine, Univ of Toronto, Toronto, ON, Canada; 2Lowering Poverty and 
Disease, Boston, MA; 3Tulane Univ, New Orleans, LA; 4Warren Alpert Medical 
School, Brown Univ, Providence, RI; 5School of Public Health, Boston Univ, 
Boston, MA; 6Hospital for Sick Children, Toronto, ON, Canada.
Background: High rates of chronic kidney disease of unknown etiology (CKDu) 
have been noted in certain populations along the Pacific coast of Central America. CKDu 
is unlike traditional CKD in that the usual underlying risk factors are not present. CKDu 
in Nicaragua has been noted to affect mainly sugarcane workers although there is a paucity 
of data for the general population.
Methods: A population based cross sectional study using a random sampling of 32 
communities was carried out in the department of Rivas in Nicaragua. Visits were conducted 
in Spanish in 2012 for screening and in 2014 for repeat evaluations. Participants were 
consented and completed a baseline questionnaire. Serum creatinine was initially screened 
using a finger stick creatinine measurement device. Repeat measurements to confirm 
CKD were performed centrally at the Centro Nacional de Diagnostico y Referencia in 
Managua using the Cobas Integra Jaffe Generation 2 assay, which has been standardized 
to the IDMS method.
Results: The study sample consisted of 1240 individuals representing 75% of adults 
living in the 533 homes visited. The refusal rate was 9.3%. The median age was 36.4 years, 
57% were female, 6.6% reported DM, and 27% reported HTN. The study cohort is slightly 
enriched for women, while young people are slightly underrepresented when compared 
to census data. Repeat measurement was done in 320 with elevated creatinine to confirm 
CKD over 2 years. The re-contact rate was 85%.
Conclusions: This cross sectional study population is representative of the general 
population of the department of Rivas in Nicaragua. Establishment of this study population 
will allow investigators to determine the prevalence of CKD in a random selection of the 
general population in both urban and rural areas of Nicaragua not previously studied.
Funding: Private Foundation Support
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Validation of the Lund Model Combining Simultaneous Cystatin C and 
Creatinine-Based eGFR  Emil Den bakker, Arend Bokenkamp.  Pediatric 
Nephrology, VU Univ Medical Center, Amsterdam, Netherlands.
Background: Estimated GFR (eGFR) based on serum creatinine (crea) and/or cystatin 
C (cys) is used to monitor GFR. Based on known limitations of either marker (muscle 
wasting for crea, corticosteroids for cys) Grubb et al have proposed the “Lund model” 
to identify such patients by calculating the difference between crea and cys-based eGFR 
(Scand J Clin Lab Invest 70 (2010): 65-70). If the difference is below a certain cut-off, the 
mean of eGFRcrea and eGFRcys is used. Otherwise a choice is made for one or the other 
as a more accurate estimate based on patient history. The aim of this study was to test the 
“Lund model” using eGFR equations from the CKiD study (Kidney Int 82 (2012): 445-53).
Methods: Retrospective analysis of 449 single injection inuline clearance (mGFR) 
studies, in which serum crea, cys and urea had been measured simultaneously. Calculation 
of eGFR using crea (CKiD1), cys (CkiD2) or crea+cys+urea (CKiD3) as well as the 
average of CKiD1 and CKiD2 (avCKiD1-2). For the Lund approach, the relative difference 
(∆CKiD1-2) between CKiD1 and CKiD2 was calculated as percentage of avCKiD1-2 and 
categorized as  >40%, 30-40%, 20-30%. If ∆CKiD1-2 was > 40%, a choice was made 
for CKiD1 (corticosteroid) or CkiD2 (neuromuscular disease, wasting, malignancy). The 
performance of the different approaches was studied using bias (mGFR minus eGFR in ml/
min/1.73m2) and accuracy (% of measurements within ±30% of mGFR).
Results: CKiD1, CKiD2 and CKiD3 had a bias of 4.6, 14.2 and 2.8 and an accuracy 
of 81.7, 80.6 and 90.4, respectively. avCKiD1-2 had a bias of 9.4 and an accuracy of 88.9. 
∆CKiD1-2 was >40% in 11.4%, 30-40% in 18.9% and 20-30% in 33.9% of the studies. The 
Lund model was applied in 51 studies with ∆CKiD1-2 >40%. In 42/51 studies, a choice 
could be made based on history (CKiD1 n=16, CKiD2 n=26). This resulted in a bias of 
10.5 and an accuracy of 86.4.
Conclusions: The various CKiD equations performed comparably to the original 
publication. The arithmetic mean between creatinine-based and cystatin C-based eGFR 
yielded similar results to the complex CKiD3 equation while the Lund model did not improve 
the diagnostic performance. This may be due to the higher bias of CKiD2.
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Evaluation of Chronic Kidney Disease Epidemiology Collaboration 
Equation (CKD-EPI), Modification of Diet in Renal Disease (MDRD) 
and Cockcroft-Gault (CG) Equations to Assess Glomerular Filtration 
Rate (GFR) in Kidney Cancer Patients  Veronica T. Costa e Silva,1 Celso 
Marialva,2 George Augusto Monteiro Lins de albuquerque,3 Renato Antunes 
Caires,1 Giuliano Betoni Guglielmetti,3 Maurício Dener Cordeiro,3 Rafael 
Ferreira Coelho,3 Elerson Costalonga,1 Eduardo J. D. de Sa Carneiro Filho,1 
Emmanuel A. Burdmann,1 William C. Nahas.3  1Cancer Inst of Sao Paulo, Univ 
of São Paulo School of Medicine, Sao Paulo, Brazil; 2Urology, Garcia de Orta 
Hospital, Lisboa, Portugal; 3Urology, Univ of Sao Paulo School of Medicine, 
Sao Paulo, Brazil.
Background: Equations used to estimate GFR were not validated in kidney cancer 
patients. The aim of this study was to assess the performance of CKD-EPI, abbreviated 
(a) MDRD and CG equation in these patients.
Methods: Prospective evaluation of 124 outpatients with kidney cancer admitted 
to treatment at São Paulo State Cancer Institute between September 2012 and February 
2015. Estimated (e) GFR was calculated using CG, aMDRD and CKD-EPI equations 
and compared to 51Cr-EDTA radioisotopic (r) clearance. The bias was given as the 
mean difference between the eGFR and rGFR values and the precision as the SD of the 
differences. Accuracy was described as the number of eGFR studies within 10 and 30% 
of the rGFR values.
Results: Patients were 59.0 ± 10.3 years old, 50.2% were women. rGFR (ml/min/1.73 
m2) was 78.7 ± 24.6 and eGFRs (ml/min/1.73 m2) using the CKD-EPI, aMDRD and CG 
(ml/min) equations were respectively 80.7 ± 22.1, 83.4 ± 25.3 and 87.8 ± 26.5. Equations 
bias is detailed on table 1.
 Mean bias of differences 
CKD-EPI aMDRD CG
Mean Bias (mL/min) 2.0 4.7 9.1
SD 21.5 21.5 24.1
p 0.306 0.017 <0.001
The accuracy of eGFR equations within 10% of rGFR were 31.4%, 27.4% and 19.4% 
with CKD-EPI, aMDRD and CG, respectively. Within 30% of rGFR, the accuracy of eGFR 
equations were 75.8%, 78.2% and 68.5% with CKD-EPI, aMDRD and CG, respectively.
Conclusions: CKD-EPI equation showed smaller bias and satisfatory accuracy when 
compared with the GFR assessed by 51Cr-EDTA in this group of kidney cancer patients.
PUB162
Correlation Between Equation for Estimating Glomerular Filtration Rate : 
CKD -EPI, Cockcroft-Gault -CG- and MDRD in Colombia  Carlos H. Mejia. 
Nephrology, Cuenta de Alto Costo, Bogota, Cundimarca, Colombia.
Background: The determination of the GFR has been recommended the calculation 
from different equation , mainly Cockcroft- Gault (CG ) or the Modification of Diet and 
Renal Disease ( MDRD ) and Chronic Kidney Disease Epidemiology Collaboration (CKD 
-EPI); we have found differences of over and underestimation of renal function by these 
equation.
Methods: Between July 1 2013 and June 30 2014 3,055,568 patients diagnosed 
with hypertension, diabetes mellitus and chronic kidney disease of all members of the 
general social security system in health in Colombia were reported. The inclusion criteria 
for this analysis was older than 18 years. Quantitative variables were described by their 
mean and standard deviation and qualitative variables using frequency distribution. They 
were compared equation pairs of CG -MDRD4, CG-CKD-EPI and CKD-EPI-MDRD by 
calculating and plotting, prediction limits for differences between pairs and the values of 
the correlation coefficients Lin-matching.
Results: 1,348,214 patients were included, 832. 129 women (61.7%). The mean age 
was 64.3 years (standard deviation (SD) 13.2), 50% of patients are 60 - 74 yo. 94% had 
diagnosis of HTA and 26% had diagnosis of DM. The mean creatinine was 0.95 mg/dl for 
population. The correlation coefficient between interclase (ICC)CG and MDRD is 0.704 
IC95%(0.703, 0.705) and limits of agreement of Bland and Altman from -31.65 to 43.83; 
ICC being CG and CKD-EPI is 0.728 CI 95% (0729-0730) and limits of agreement of 
Bland and Altman from -37.26 to 40.62 and the correlation coefficient being intraclase 
CKD-EPI and MDRD is 0.855 IC 95%(0.855, 0.856) and limits of agreement of Bland 
and Altman between -25.61 and 21.89.
Conclusions: General population studies have reported a good correlation comparison 
between MDRD and CKD -EPI, our results show a good correlation between them, rather 
than between CKD -EPI and CG .A higher GFR greater are the limits of agreement, both the 
overall analysis and analysis stages, similar findings have been observed in other reports. 
Despite some limitations MDRD4 and CKD -EPI remain the most comparable and used 
to estimate kidney function.
PUB163
Family Caregivers in Chronic Kidney Disease: A Missed Opportunity to 
Improve Overall Care  Jason Christopher George,1 Andrea Lynn Berger,2 
Christina Yule,3 Jamie Alton Green.2,4  1Dept of Medicine, Geisinger Medical 
Center, Danville, PA; 2Center for Health Research, Geisinger Medical Center, 
Danville, PA; 3Center for Clinical Innovation, Geisinger Medical Center, 
Danville, PA; 4Dept of Nephrology, Geisinger Medical Center, Danville, PA.
Background: Many patients with chronic illness rely on the assistance of loved ones 
to adequately manage their disease. While there is increased recognition of the role of 
family caregivers in end-stage renal disease, little attention has been given to this role 
among patients with chronic kidney disease (CKD) not on dialysis. The aim of this study 
was to assess CKD patients’ degree of dependency on non-professional caregivers for 
their self-management needs.
Methods: We conducted a survey-based study of 208 patients with non-dialysis 
dependent CKD stages 3-5 to identify 1) whether they receive help from an informal 
caregiver to perform health-related activities and 2) the nature of this relationship. We 
excluded patients residing in a nursing facility as well as those with an assigned formal 
caregiver, since their self-management needs are different.
Results: Mean age of participants was 72, 57% were male, 98% were white, and 
53% had a high school or lower level of education. Overall, 65% (133/205) of patients 
reported receiving help from another individual with at least one health-related task. Help 
with activities included medical decision making (51%), medication management (32%), 
scheduling medical appointments (30%), attending office visits (43%), understanding 
medical providers (23%), and activities of daily living (13%). The majority stated that 
the main person who helped them was their spouse (70%) or adult child (16%) vs. other 
family members (6%). Nearly half (46%) reported that another individual had access to 
their electronic health information through the online health portal to assist with their care.
Conclusions: A significant number of independently functioning CKD patients rely 
on the help of family members to navigate their care. Efforts are needed to acknowledge 
and support these informal caregivers in the medical management of complex patients with 
kidney disease in order to provide optimal care.
PUB164
Impacts of Chronic Kidney Disease on Other Non-Communicable Chronic 
Diseases – The Burden in the Health System of China  Luxia Zhang, Jinwei 
Wang, Ming Hui Zhao.  Renal Div, Dept of Medicine, Peking Univ First 
Hospital, Beijing, China.
Background: The spread of non-communicable diseases (NCDs) presents a global 
crisis, and accumulating evidence based on individual disease reveals that major NCDs 
including heart disease and stroke have a worse prognosis in the presence of chronic kidney 
disease (CKD). However, there is neither large-scale study quantitatively evaluating the 
burden of CKD on various NCDs, nor study comparing the burden of CKD with other 
NCDs, especially among low- and middle-income countries like China.
Methods: A national in-patient database involving 19.5 million patient-records was 
used. Diagnoses of CKD and other major NCDs, including hypertension, coronary heart 
disease, stroke, chronic obstructive pulmonary diseases, and cancer, were extracted from 
International Classification of Diseases-10 codes of the discharge diagnoses. The effect of 
CKD on costs, length-of-stay, and in-hospital mortality were analyzed for each NCD. Then 
the effect of CKD on those outcomes was compared with other major NCDs.
Results: For each NCD, the presence of CKD was associated with increased length-
of-stay and in-hospital mortality. And the costs were also increased by 0.1-20.3%, except 
for coronary heart disease and diabetes. Among those NCDs, CKD was associated with 
the highest length-of-stay, and with in-hospital mortality only lower than that of cancer.
Conclusions: Using database with large sample size and broad geographic coverage 
in China, we found that the presence of CKD was associated with substantial increased 
healthcare resources utilization and increased risk of in-hospital mortality.
Funding: Government Support - Non-U.S.
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Patient Empowerment in a Multi-Disciplinary Chronic Kidney Disease 
(CKD) Clinic  Therese T. Adamowski, Jonathan H. Segal, Julie A. Wright 
Nunes.  Internal Medicine, Univ of Michigan, Ann Arbor, MI.
Background: Existing research shows economic and health gains associated with 
multi-disciplinary CKD care, but there is little data examining associations with patient-
centric measures. We collected patient-centric measures on perceptions related to care in 
a multi-disciplinary CKD clinic.
Methods: Our multi-disciplinary CKD clinic includes a pharmacist, physician 
assistant, social worker, dietician and RN educator-with oversight by a medical doctor. 
Patients see each provider during visits. Most patients have an eGFR ≤ 40 ml/min/1.73m2. 
As part of assessing quality patients were asked to: 1. Report their level of comfort asking 
questions (“please circle the number that indicates how comfortable you feel asking your 
doctor questions about kidney disease: 1=not at all comfortable to 6=very comfortable”), 
and 2. Rate perceived confidence and empowerment in kidney care (ten questions with 
responses, 1 =not confident to 5 =confident, averaged as a summary measure of confidence 
/ empowerment).
Results: Data were available on 51 patients. The mean (SD) age was 62 (15) years. 
53% were male, 65% Caucasian, and 33% African American. Patients reported being 
comfortable asking their doctor questions, mean (SD) 5.5 (0.97). The mean (SD) of the 
confidence / empowerment measure was 4.3 (0.74). In univariate analysis, higher ratings 
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of comfort asking questions was associated with higher confidence / empowerment, β 
0.23 CI (0.04, 0.45); p=0.02. Multivariate analysis adjusted for age, sex, race and comfort 
asking questions revealed comfort asking questions was independently associated with 
higher confidence / empowerment, β 0.31 (0.09, 0.53); p=0.007. Our 10-item confidence 
/ empowerment measure showed excellent internal reliability (Cronbach alpha =0.89).
Conclusions: Patients in a multi-disciplinary CKD clinic reported being comfortable 
asking their doctor questions and rated confidence and empowerment as high. Comfort 
asking the doctor questions was positively associated with patient confidence and 
empowerment in care. More work is needed to compare patient-centric quality measures 
across care models and assess changes over time.
PUB166
Factors Affect Use of Healthcare Services Among Different Ethnicities 
Enchi K. Chang,1 Li-Li Hsiao.2  1Harvard College, Cambridge, MA; 2Renal, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
Background: Use of healthcare services by medically underserved minority 
populations varies by ethnicity and cultural factors. Healthcare providers may address 
ethnicity-specific barriers to healthcare service usage to decrease disparities in healthcare 
use. Through free community health screenings provided by the Kidney Disease Screening 
and Awareness Program (KDSAP), we seek to elucidate ethnicity-specific differences and 
sociocultural barriers to healthcare service use.
Methods: A questionnaire available in English, Chinese, and Spanish was administered 
to KDSAP participants in Massachusetts, New Jersey, and Toronto from 2012 to 2014. 
Participants were asked to provide their ethnicity, health insurance, primary care physician, 
and difficulties and alternatives to receiving care.
Results: 330 Asian, 190 African-American, 82 Hispanic, and 50 Caucasian participants 
were surveyed. Participants lacking health insurance comprised 29.1% of Asian and 
45.1% of Hispanic participants, compared with 17.3% of African-American and 8% of 
Caucasian participants. 25% of Asian and Hispanic participants reported language barriers 
with their healthcare professional, compared with 6% of African-American and Caucasian 
respondents. 50% of Asian and Hispanic participants were prevented from seeking care 
due to lack of insurance, and as an alternative, 51% of Asian participants would ignore 
the problem. African American participants without insurance primarily reported seeking 
emergency care (51%), and Hispanic participants reported seeking free clinics (40.5%) or 
emergency care (37.8%).
Conclusions: Culture and ethnicity-specific barriers to receiving care affect use of 
healthcare resources for medically underserved populations. Asian and Hispanic populations 
experience greater difficulty accessing healthcare services and are less likely to have 
health insurance compared to African-American and Caucasian populations, suggestive 
of linguistic and sociocultural barriers to healthcare for immigrant populations. Healthcare 
services targeting medically underserved populations must address ethnicity-specific 
sociocultural differences to reduce healthcare disparities between ethnic populations.
Funding: Private Foundation Support
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Trends in Access to Care in Adults with Kidney Disease, United States 2002-
2011  Mukoso N. Ozieh,1 Kinfe Gebreegziabher Bishu,2 Rebekah J. Walker,2 
Leonard Egede.2  1Nephrology, MUSC; 2Center for Health Disparities Research, 
Internal Medicine, MUSC, Charleston, SC.
Background: Access to healthcare is essential in other to attain health equity in the US. 
Studies on access to healthcare in kidney disease (KD) are scant and there are no studies 
on national trends in access to healthcare in people with KD. This study aims to evaluate 
trends in access to healthcare, prescription medication and factors associated with access 
to healthcare in people with KD.
Methods: Data on 4,399 adults with KD aged ³18 from the Medical Expenditure Panel 
Survey were analyzed. Individuals with KD were identified with Clinical Classification 
Codes: 156 - nephritis, nephrosis, renal sclerosis; 157-acute/unspecified renal failure; 
158-chronic renal failure; 160-calculus and; 161-other diseases of kidney and ureters. Access 
to healthcare was defined as having a usual provider, ability to get necessary medical care 
and no delay in getting medical care. Assess to prescription medications was defined as 
ability to get necessary prescription and no delay in getting prescription. We used unadjusted 
and adjusted logistic regression to examine factors associated with access to care overtime. 
Covariates included demographics and comorbidities.
Results: Of the 4,399 adults with KD, 81% and 97% reported having access to medical 
care and prescription medications respectively. Access to medical care was stable while 
access to prescription improved over time in people with KD. Factors associated with 
increased access to medical care were age ≥45, gender, high income and comorbidity–
hypertension while marital status, being uninsured, residential region and comorbidity–
joint pain were associated with decreased access to medical care. Factors associated with 
increased access to prescription were Hispanic race, age ≥65 and ³college degree while being 
uninsured, residential region and comorbidities – diabetes and joint pain were associated 
with decreased access to prescription medication.
Conclusions: Access to medical care has remained stable and access to prescription 
medication in people with KD has improved over time. Further studies on access to 
healthcare in people with KD compared to the overall US population are needed.
PUB168
Patient-Centered Care in United States Adults with Kidney Disease 
Mukoso N. Ozieh,1 Kinfe Gebreegziabher Bishu,2 Rebekah J. Walker,2 Leonard 
Egede.2  1Nephrology, MUSC; 2Center for Health Disparities Research, Internal 
Medicine, MUSC, Charleston, SC.
Background: Patient-centered care is a quality of personal, professional, and 
organizational relationships. There no studies on factors associated with patient-centered 
care in patients with kidney disease (KD). This study examines trends in and factors 
associated with patient-centered care (PCC) in people with KD.
Methods: Data on 3,868 adults with KD aged ³18 from the Medical Expenditure Panel 
Survey (MEPS) Household Component were analyzed. Individuals with KD were identified 
with Clinical Classification Codes: 156 - nephritis, nephrosis, renal sclerosis; 157 - acute 
and unspecified renal failure; 158 - chronic renal failure; 160 - calculus or urinary tract 
and; 161 - other diseases of kidney and ureters. Patient-centered care was ascertained if 
the usual care provider asked about prescription medications and treatments other doctors 
may give them; showed respect for medical, traditional and alternative treatments that 
the person is happy with; asked the person to help make decisions between a choice of 
treatments; presented and explained all options to the person; and spoke the persons language 
or provided translator services if person is uncomfortable speaking in English. We used 
unadjusted and adjusted poison regression to examine the association of patient-centered 
care overtime. Covariates included demographics and comorbidities.
Results: Of the 3,868 adults with KD, 3%, 7%, 22%, 63% and 4% reported a positive 
response to 1, 2, 3, 4, and 5 out 5 questions on patient-centered care respectively. Patient-
centered care was significantly reported in 2010/2011. Hispanic race was significantly 
associated with increased while residence in the west was associated with decreased patient-
centered care. Compared to 2002/2003, year 2004/2005 and 2010/2011 were significantly 
associated with increased patient-centered care in the poison regression analysis.
Conclusions: Patient-centered care in people with kidney disease has improved in 
recent years. Prospective studies examining the impact of patient-centered care on kidney 
disease outcomes especially end stage renal disease is imperative.
PUB169
Hypertension and Correlating Factors in a Minority-Rich Population 
Andrew A. Lin,1 Jennie Kuo,2 Li-Li Hsiao.2  1Harvard College, Cambridge, MA; 
2Renal, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
Background: Analysis of demographic variations in hypertension (HTN) in minority-
specific populations presents a major opportunity for understanding the factors that influence 
chronic kidney disease (CKD). This study analyzes the influence of various factors in BP 
control in a minority-rich population.
Methods: Data from 417 participants from minority populations in the Boston area 
(38.4% Asian, 37.6% Black, 8.2% Hispanic, 10.8% White, and 5.0% other races) was 
sampled via Kidney Disease Screening and Awareness Program screenings from 2012-
2014. Participants were assessed via questionnaire for awareness of their BP, healthcare/
insurance, and an assessment of their own health as well as their race, gender, age, & 
education. Participants then had their systolic (SBP) & diastolic (DBP) blood pressure 
measured, which was in turn classified according to American Heart Association guidelines 
& analyzed via T-tests & one-way ANOVA.
Results: Of the 417 participants,28.8% had normal BP, 47.2% were pre-HTN 
(130-140/80-90), 18.5% had stage I HTN (140-160/90-100), & 5.5% had stage II HTN 
(>160/100). Participants aware of their HTN had higher SBP (p<0.0001) & DBP (p=0.007) 
than those who self-reported no HTN. Men had significantly higher SBP & DBP than women 
(p=0.002, p=0.0003, respectively), & individuals with little/no education had higher SBP 
than those with college (p=0.005) or post-graduate degrees (p<0.0001). Younger age groups 
(below 30 years: mean BP 125/76) had significantly lower BP than older age groups (60-
69+ years: mean BP 136/81); p<0.0001 & p=0.037 for SBP & DBP. Notably, no significant 
differences in SBP among ethnicities emerged.
Conclusions: Our results revealed that awareness of HTN status, gender, education 
level & age influence BP variations in minority-rich communities. Services tailored to these 
factors may help reduce HTN prevalence among minorities.
Funding: Private Foundation Support
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Veterans Affairs (VA) eKidneyClinic: A Freely-Available Online Tool to 
Help Close the Chronic Kidney Disease (CKD) Patient Education Gap 
Devasmita Choudhury,1 R. Brooks Robey,2 Rosemary M. Pries,3 Dorian R. 
Schatell,4 Susan T. Crowley.5  1Medicine, Salem Veterans Affairs Medical Center, 
Salem, VA; 2Medicine, White River Junction Veterans Affairs Medical Center, 
White River Junction, VT; 3Veterans Health Education & Information Program, 
Veterans Health Administration, Durham, NC; 4MEI INC., Madison, WI; 
5Medicine, Veterans Affairs Connecticut Health Care System, West Haven, CT.
Background: Patient education remains an important tool in the management of 
CKD and end stage renal disease (ESRD)- diseases with significant patient and economic 
burden. Patient knowledge and understanding of CKD are dismal, particularly amongst 
highly-affected populations (e.g. African Americans). For Veterans with CKD, limited 
health literacy, and varied, fragmented presentation of patient education materials (PEMs) 
compound the gap in understanding CKD.
Methods: To address these deficiencies, VA developed a comprehensive web tutorial, 
VA eKidneyClinic (http://ckd.vacloud.us). This freely-available, Veteran-centered, virtual 
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PEM details at 5th grade reading level (using Flesch-Kincaid formula), basic disease process, 
nutritional, laboratory, social, pharmacy, and treatment aspects of all stages of CKD in 
written and graphical format, supplemented by video narrative vignettes. Pre- and post-
tutorial questions engage, test, and reinforce understanding through action planning. Links 
to additional Internet resources allow for further knowledge acquisition.
Results: Despite the absence of a national marketing campaign, annual web traffic 
on VA health portals featuring eKidneyClinic has tripled from 5,374 (~15/d; 01 Apr 2013 
to 31 Mar 2014) to 16,730 views (~46/d; 01 Apr 2014 to 31 Mar 2015) over the past 2 y.
Conclusions: VA eKidneyClinic provides a novel, patient-centered, readily accessible 
Internet resource to remedy knowledge gaps in Veteran CKD education. Use of VA online 
resources has progressively increased over the past 2 y. Better metrics of use and targeted 
research correlating use with clinical outcomes are needed to fully validate the utility of 
this education tool and its impact on organizational health literacy.
Funding: Veterans Administration Support
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Should All Patients with Diabetic Nephropathy Be Treated in a Joint 
Renal Diabetic Clinic?  Jonathan P. Wong, Tara Lee, Tracy Maryan, Jocelyn 
Berdeprado, Suresh Mathavakkannan.  Lister Renal Unit, United Kingdom.
Background: The natural history of diabetic nephropathy is variable. Some patients 
have rapidly declining kidney function and would benefit from close monitoring in a joint 
renal-diabetic clinic, however joint renal-diabetic clinics are not widely available in the 
UK health system. We studied outpatient attendance patterns, rate of eGFR decline and 
other clinical parameters in patients with diabetic nephropathy to determine potential need 
for development of a joint renal-diabetic clinic at our unit.
Methods: A cross-sectional survey of all patients with CKD and diabetes mellitus (DM) 
at our unit was performed. Demographic, diabetic clinic attendance and clinical parameters 
including HbA1c, BP, urine protein:creatinine ratio (uPCR) and eGFR for the previous 
5years were collected. Patients who had a rate of decline in eGFR³2ml/min/1.73m2 were 
defined as having progressive CKD.
Results: 630 CKD patients with DM attending CKD clinic at our trust were identified. 
195/630 (31%) of patients had diabetic nephropathy. 54.6% (100/195) had progressive 
CKD, but only 37% (37/100) of these patients attended a diabetic clinic. Conversely, 45.4% 
did not have progressive CKD, potentially representing a group of patients who could be 
safely monitored by general physicians. Patients with progressive diabetic nephropathy 
were more proteinuric than those with stable CKD (161 vs 46mg/mmol, p=0.004) but did 
not significantly differ in terms of age, weight, glycemic control or BP. 9.2% (58/630) 
were lost to follow-up from nephrology services, 31% (18/58) of this subset of patients 
continued to attend the diabetic clinics and 69% (40/58) were lost to follow-up from both 
diabetic and renal services.
Conclusions: Not all patients with diabetic nephropathy develop progressive CKD. 
Identifying patients (e.g. low-level proteinuria) who could be safely monitored by general 
physicians may relieve pressure on CKD clinic and reduce hospital visits for patients. 
However, many patients with progressive CKD were not being monitored in a diabetic clinic, 
potentially missing out on specialist interventions. Development of a joint diabetic-renal 
clinic could streamline care and improve management for these patients.
Funding: Clinical Revenue Support
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Leveraging Predictive Modeling to Improve the Participant Identification 
Process for Transition to Dialysis Support Programs  Meghan Martin Cockrell, 
Yanting Dong, Huyi Hines, Gilbert Haugh, Vipin Gopal, Roy Beveridge, Todd 
Prewitt.  Humana, Louisville, KY.
Background: Evidence demonstrates that renal care management is beneficial to 
patients suffering from late-stage chronic kidney disease (CKD) and end-stage renal disease 
(ESRD), especially around the time of transition to dialysis. Integrated care management 
solutions provide assessment, education, and care coordination. Engagement in these 
programs improves health outcomes, including compliance with dialysis schedules and 
vascular access, and also reduces costs.
Methods: Traditionally, patients are identified for renal care management programs 
via a qualified estimated glomerular filtration rate (eGFR) lab value of <20mL/min/1.73 
m2. However, since eGFR is not always available, there may be a gap in identifying people 
who could benefit from this type of support. A predictive model (PM) was developed to 
identify candidates for a transition to dialysis program. The PM identifies individuals with 
CKD over the prior 12 months and determines their likelihood of starting dialysis within 
the subsequent 12 months. It is based on claims, demographics, and lab and consumer data. 
To assess the effectiveness of the PM, a random portion of individuals scored in the top 2% 
most likely to transition to dialysis were referred directly to the program for
Results: Thirteen percent of people referred by the PM ultimately transitioned to 
dialysis and all were invited into a renal care management program. Seventeen percent of 
the people identified by the PM and observed to see if they would be referred by the current 
standard process ultimately transitioned to dialysis, but 27% (n=68) were never identified 
for the renal care management program. Hence, the model is effective in identifying those 
that will not get identified via the standard referral process.
Conclusions: Application of advanced predictive modeling permitted identification 
of participants who may not have otherwise had the opportunity to benefit from renal care 
management.
PUB173
Does the Kidney “Age” with Time?  Umbar Ghaffar, Page Casey Moore. 
Nephrology, UAMS, Little Rock, AR.
Background: Studies show that eGFR declines with advancing age but it is unclear 
if this is related to co-morbidities or aging per se.The objective was to study predictors of 
eGFR decline in elderly individuals with and without pre-existing CKD.
Methods: Chart review for patients >65 years of age with and without CKD at baseline 
was done over 5 years.Data regarding risk factors like proteinuria, medications, contrast 
use was obtained.Repeated measures models were used to test difference in GFR between 
CKD cases versus controls.Semi-partial correlations were used to determine factors with 
largest contribution to GFR decline.
Results: CKD cases were more likely to have DM, HTN and receiving drugs like 
diuretics and antibiotics.Age, proteinuria and IV contrast exposure were identifed as the most 
significant predictors of eGFR decline.In the CKD group, rate of GFR decline was 1.7% to 
10 % per year. In the group without preexisting CKD, GFR did not decline over 5 years.
CKD cases Controlsb
Year eGFR means % change in eGFR eGFR means
a % change in 
eGFR
2006 53.166 - 72.481 -
2007 51.104 2006-2007 3.88% 72.543
2006-2007 
-0.08%
2008 50.224 2007-2008 1.72% 67.368
2007-2008 
7.13%
2009 47.449 2008-2009 5.43% 61.982
2008-2009 
8.00%
2010 47.651 2009-2010 -0.32% 67.539
2009-2010 
-8.97%
2011 42.846 2010-2011 10.08% 71.864 2010-2011 -6.4%
Net change in 
eGFR
2006-2011 
19.41%
2006-2011 
0.85%
Table 1. Adjusted rate of decline in GFR across time 
a LS means based on repeated measures model with the following independent variables: treatment, 
time, treatment*time, age, Sex, HTN, DM, AKI, AKI type, NSAIDs, contrast and proteinuria. 
b GFR values 60 or greater were reported as ≥60 in lab reports.
Conclusions: Results suggest that GFR decline may not be attributed to aging only.
Each episode of AKI related to contrast or nephrotoxic drugs increases risk for CKD 
progression/GFR decline in elderly.Preexisting CKD is a strong predictor of GFR decline 
after adjustment for other co-morbidities.
PUB174
Oxidative Stress: Dual Pathway Induction in CKD Pathogenesis 
Grazia Maria Virzì, Alessandra Brocca, Massimo de Cal, Claudio Ronco. 
Nephrology Dept-IRRIV, San Bortolo Hospital, Vicenza, Italy.
Background: Oxidative stress is defined as the imbalance between excess formation 
and insufficient removal of highly reactive molecules (Reactive Oxygen Species-ROS and 
Reactive Nitrogen Species-RNS) that attack DNA, protein and lipids, either denaturing or 
altering their structure. The variations and the correlation of inflammation and oxidative 
stress in CKD have not been thoroughly understood. In this study, we examined the putative 
role of ROS and RNS in the pathogenesis of CKD and the interaction with inflammation.
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Methods: 25 patients with CKD(5 for each stage) and 18 healthy subjects (CTR) were 
included in the study. Determinations for IL6, Myeloperoxidase (MPO), Nitric Oxide (NO) 
and Endogenous Peroxidase Activity (EPA) were performed by ELISA. A p-value of <0.05 
was considered statistically significant.
Results: CKD patients displayed significant augmentation in circulating ROS and RNS, 
as well as expression of inflammatory cytokines, as IL6 (all, p<0.01).
CKD CTR
EPA U/L 1963.6 (1081.0-2728.6) 5,9 (2.6-9.9)
MPO pg/mL 5987.0 (3989.6-11469.8) 10.2 (6.0-19.3)
NO µM 710.1 (575.6-781.6) 13.4 (12.8-14.7)
IL6 pg/ml 59.8 (45.6-104.3) 5.9 (3.4-7.6)
There is a positive correlation between IL6 and all oxidative stress markers and an 
inversely correlation with eGFR (all, p<0.05). We divided CKD patients in CKD1-2 
(n=10) and CKD3-5 (n=15): a significant higher level of oxidative stress was observed 
in CKD3-5 (p=0.008).
Conclusions: CKD is characterized by ROS and RNS disequilibrium and inflammation 
that promote additional damage to the kidney and to distal tissues with development 
and progression of concomitant diseases. This pilot study demonstrates the significantly 
heightened presence of dual oxidative stress pathway induction in CKD patients that 
increase with the progression of CKD: each stage of CKD could be characterized by 
differing levels of ROS/RNS disequilibrium. Our findings indicate that oxidative stress is a 
potential therapeutic target, as it promotes inflammation by ROS/RNS-linked pathogenesis. 
Future research should focus on interventions that aim to reduce oxidative stress and 
inflammation in patients with various stages of CKD and slow the progression of CKD 
during its early stages.
PUB175
Comparative Biomarker Analysis Reveals Serum and Urine sTNFR1 
Correlate with eGFR and Albuminuria in Man  Diana L. Donnelly-Roberts, 
Marian T. Namovic, Mark T. Houser, Murali Gopalakrishnan, Timothy A. 
Esbenshade.  Renal Discovery, Abbvie, North Chicago, IL.
Background: It has been demonstrated that soluble tumor necrosis factor receptors 
(sTNFR1 & sTNFR2) are elevated in serum of patient cohorts with various renal disease 
etiologies with a strong association to early renal decline with or without proteinuria. The 
current study was designed to gain further insight into the relationship of renal function to 
sTNFR1 and other biomarkers (BMs) from a recently completed clinical study in high-risk 
subjects undergoing non-cardiac surgery. A subset of baseline serum and urine samples 
from patients with and without CKD (mean age of 70, 64% male, mean eGFR of 58 ml/
min/1.73 m2, and mean total urinary protein concentration 70 g/l) were evaluated to assess 
sTNFR1 and other select BMs reflective of progression of DN, CV risk, inflammation, 
fibrosis or renal injury.
Methods: Samples were selected based on medical history (DM, DN, other CKD, or 
no renal disease) and stratified for analysis based on eGFR values. All samples examined 
were from baseline/pre-dose collections prior to drug administration or surgery and analyzed 
in a blinded manner.
Results: In serum, several BMs correlated with eGFR with sTNFR1 (P <0.0001) and 
uromodulin (P=0.0004) being significant but moderate for FGF-23 (P<0.01), and ADMA 
(P<0.01). In urine, results revealed that several BMs correlated with eGFR with a strong 
significance for sTNFR1 (P <0.001) as well as for complement C9 (P=0.011) and iC3b 
(P=0.013). Significant correlations were also observed for qualified biomarkers such as 
NGAL (P<0.01), albumin (P<0.01), and cystatin C (P=0.05). sTNFR1 in urine also strongly 
correlated with albuminuria (P=0.0002) and UACR (P=<0.0001).
Conclusions: Our studies demonstrate that sTNFR1 correlates with renal functional 
decline across a wide eGFR range (22 to 116 ml/min/1.73 m2) regardless of renal disease, 
which was assessed in both serum and urine. Limitations of this preliminary study are small 
sample size and use of static eGFR values. Additional correlation analyses in longitudinal 
cohorts can shed further light into the relationships of sTNFR1 and other BMs to CKD.
Funding: Pharmaceutical Company Support - Abbvie
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The Association of Plasma Uric Acid with Renal Vascular Lesions and 
Interstitial Fibrosis in Biopsy-Confirmed Kidney Disease  Anand Srivastava,1 
Venkata Sabbisetti,1 Isaac Ely Stillman,3 Helmut G. Rennke,2 Sushrut S. Waikar.1 
1Renal Div, Brigham & Women’s Hospital, Boston, MA; 2Dept of Pathology, 
Brigham & Women’s Hospital, Boston, MA; 3Dept of Pathology, Beth Israel 
Deaconess Medical Center, Boston, MA.
Background: Elevations in plasma uric acid (PUA) have been hypothesized to play 
a pathogenic role in the development of chronic kidney disease (CKD) through multiple 
mechanisms, including mitochondrial dysfunction, oxidative stress, endothelial dysfunction, 
vascular smooth muscle proliferation, and intra-renal inflammation.
Methods: We measured PUA in plasma samples obtained from 272 patients on the 
day of native kidney biopsy at three tertiary care hospitals in Boston, MA. We compared 
PUA against measures of kidney function and pathology, including estimated glomerular 
filtration rate (eGFR) and adjudicated semi-quantitated measures of kidney pathology 
using Spearman correlation coefficients. Arterial and arteriolar sclerosis/hyalinosis were 
classified as none (1), mild (2), moderate (3), or severe (4). Fibrosis was classified as 0% 
(1), 1-10% (2), 11-25% (3), 26-50% (4), and > 50% (5) of cortical volume.
Results: The primary indications for kidney biopsy were proteinuria in 61%, hematuria 
in 33%, abnormal eGFR in 35%, and nephrotic syndrome in 14% (sum exceeds 100% due 
to multiple indications). Mean age was 51.2 + 16.0 yrs, 53% were women, 18% were black, 
and median eGFR was 50 (IQR, 30–83) ml/min/1.73m2. Median PUA was 6.3 [IQR 5.1-7.5] 
mg/dl, and was inversely correlated with eGFR (r=-0.43) and positively correlated with 
arterial sclerosis (r=0.21), arteriolar hyalinosis (r=0.23), and interstitial fibrosis (r=0.28) 
(P for all < 0.001). The associations between PUA and kidney pathology were attenuated 
and no longer statistically significant after adjustment for eGFR. Findings were generally 
consistent in subgroup analyses of those with diabetes, glomerulonephritis, vascular disease, 
and tubulointerstitial disease.
Conclusions:    We found no independent associations between PUA and semi-
quantitated measures of kidney pathology. The cross-sectional associations of PUA with 
renal vascular lesions and interstitial fibrosis appear to be confounded by eGFR.
Funding: NIDDK Support
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Association of Plasma Sphingomyelins and Ceramides with Chronic Kidney 
Disease and Glomerular Filtration Rate  Maria Lourdes Gonzalez Suarez,1 
Vesna D. Garovic,1 Norman James Haughey,2,3 Veera Venkata Ratnam Bandaru,2 
Susan Resnick,4 Luigi Ferrucci,4 Michelle M. Mielke.5  1Div of Nephrology and 
Hypertension, Mayo Clinic, Rochester, MN; 2Dept of Neurology, Johns Hopkins 
Univ School of Medicine, Baltimore, MD; 3Dept of Psychiatry, Johns Hopkins 
Univ School of Medicine, Baltimore, MD; 4Intramural Research Program, 
NIA/NIH, Baltimore, MD; 5Dept of Health Sciences Research, Mayo Clinic, 
Rochester, MN.
Background: Sphingolipids are a class of bioactive lipids linked to insulin resistance 
and diabetes. Ceramides have been implicated in acute renal failure and diabetic 
nephropathy. We cross-sectionally examined the associations of plasma ceramides and 
sphingomyelins (SM) with glomerular filtration rate (GFR) and Chronic Kidney Disease 
(CKD).
Methods: Baltimore Longitudinal Study of Aging participants (N=486) with plasma 
ceramides, SM and GFR were included (median age 63, 58% men); 23 had CKD defined 
as GFR<60 ml/min. Ceramides and SM were quantitatively measured using a HPLC-
coupled electrospray ionization tandem mass spectrometer. Logistic regression was used 
to determine the association between the log transformed sphingolipids and odds of CKD, 
adjusting for age, sex, and race. Among participants without CKD, linear regression was 
used to examine the association between the sphingolipids and GFR adjusting for age, sex, 
race, BMI, and hypertension.
Results: Higher levels of all SM were associated with increased odds of CKD: 
each log unit increase in SM C18:1 was associated with six-fold increased odds of CKD 
(OR=6.92, p=0.002). Among individuals without CKD, higher SM were also associated 
with lower GFR. This association was most pronounced among the 290 individuals without 
diabetes or pre-diabetes: each log unit increase in SM C18:1 was associated with lower 
GFR (b=-8.40, p=0.002).
Conclusions: These results suggest that elevated plasma SM are associated with CKD. 
Likewise, among those without CKD, elevated SM are associated with lower GFR.The 
cross-sectional study design limits specific conclusions on the mechanisms and temporality 
of these associations but suggests that further research is warranted.
Funding: Other NIH Support - U01 AG37526 (National Institutes of Health/National 
Institute on Aging)
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Clinical and Pathologic Predictors of Progression to End Stage Renal 
Disease following Renal Biopsy  Andrew S. Allegretti,1 Ivy A. Rosales,2 A. 
Bernard Collins,2 Nina E. Tolkoff-Rubin,2 Robert B. Colvin,2 Ishir Bhan,1 Julia 
Beth Wenger, Joshua Wibecan, Rex Neal Smith.  1Div of Nephrology, MGH, 
Boston, MA; 2Dept of Pathology, MGH, Boston, MA.
Background: The value of renal biopsy in prognosis of chronic kidney disease remains 
unclear. Irreversible, chronic changes such as interstitial fibrosis and glomerulosclerosis 
are thought to provide prognostic information. We sought to define the relative prognostic 
value of biopsy pathology and clinical factors for predicting progression to end stage 
renal disease (ESRD).
Methods: Retrospective, single center review of renal biopsies performed between 
2004-2014 in four kidney diseases. Cox regression was used to evaluate nine pathologic 
findings on light microscopy and 21 clinical variables as potential predictors of progression 
to ESRD.
Results: 231 cases were reviewed (34% IgA nephropathy, 29% focal segmental 
glomerulosclerosis, 19% tubulointersitial disease, 18% diabetic nephropathy). 83/231 
(36%) subjects progressed to ESRD within 5 years follow-up. Median estimated glomerular 
filtration rate (eGFR) at time of biopsy was 32 [IQR: 18, 54] mL/min. Median percent 
interstitial fibrosis was 20% [IQR: 10%, 40%]. In multivariable Cox regression adjusting for 
pathologic diagnosis and eGFR at the time of biopsy, independent predictors of progression 
to ESRD within 5 years of biopsy were: interstitial fibrosis > 20% (HR 1.94 [95% CI 1.09, 
3.44]; p = 0.02), presence of endocapillary inflammation (HR 2.35 [1.22, 4.53]; p = 0.01), 
presence of arteriosclerosis (HR 2.03 [1.01, 4.05]; p = 0.05), history of liver disease (HR 
1.55 [0.95, 2.53]; p = 0.08) and congestive heart failure (HR 1.85 [0.99, 3.49]; p = 0.06).
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Conclusions: Pathologic findings of interstitial fibrosis greater than 20%, endocapillary 
inflammation, and arteriosclerosis as well as a clinical history of congestive heart failure 
and liver disease were the strongest predictors of progression to ESRD.
Funding: NIDDK Support
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The Influence of Mutagenic Lactobacilli on Concentration of IS in Blood 
and the Renal Expression of Renal Fibrosis Related Factors  Yafen Jiang,1 
Yunhuan Bai,2 Fang Wang,3 Yunsheng Jiang,1 Fuyou Liu.1  1Nephrology Inst, 
Central South Univ, Changsha, Hunan, China; 2Div of Nephrology, Xuzhou 
Central Hospital; 3Ningbo Medical Treatment Center Lihuili Hospital.
Background: to observe the concentration changes of Indoxyl Sulfate( IS)in blood 
and the renal expression of renal fibrosis related factors(transforming growth factor-beta 
(TGF-beta 1) and Fibronectin( FN)after administration of mutagenic lactobacilli by oral.
Methods: 60 male SD rats aged 6 weeks were divided into 3 groups randomly: normal 
control group (Sham group, n = 20) who received SHAM operation of just incision of skin 
without kidney removed. The other two groups of rats were all renal failure models selected 
from survivals of the other 40 rats who received real operation with 5/6 of the kidney 
removed.Then 35 rats finally got were randomly divided into 2 groups:pathological control 
group(Model group)(n = 17) , administrated of 2ml Sterile Saline Solution once a day by 
gavage ,Experimental group (LB group)(n = 18) administrated of 2ml mutagenic lactobacilli 
(1.5 x108 cfu/ml) once a day by gavage.8 weeks later ,blood specimens were taken to test 
the concentration of IS by High performance liquid chromatography- fluorescence detection 
(HPLC – FLU)and urea and creatinine by automatic biochemical analyzer,while the rats 
were killed to get kidney tissues for pathological examination.
Results: the concentration of IS in the experimental group were 3.18 + / - 1.39 ug/ml 
,while 3.67 + / - 2.13 ug/ml in the Model group.two groups were significantly different(P 
< 0.05).And also Blood urea and creatinine levels were statistically dtifferent between 
two groups(P < 0.05). Both the level of renal tubular damage and renal interstitial fibrosis 
were both lessen in the experimental group whencomparing with the Model group (P < 
0.05);TGF - beta 1 and FN expression in renal tissues were also decreased.
Conclusions: Mutagenic lactobacilli can not only reduce serum concentration of IS, 
urea and creatinine in renal failure rats, but also lowering the expression of TGF - beta 1 
and FN in renal tissue.
PUB180
Lower Dietary Intake of Magnesium Is Associated with Faster Decline 
in Kidney Function: The Healthy Aging in Neighborhoods of Diversity 
Across the Life Span Study  Adrienne Tin,1 Casey Rebholz,1 Yang Liu,1 Alan 
B. Zonderman,2 Marie Kuczmarski,3 Deidra C. Crews.1  1Johns Hopkins Univ; 
2National Inst on Aging; 3Univ of Delaware.
Background: Lower dietary magnesium intake has been associated with higher 
prevalence of chronic kidney disease (CKD). We hypothesized lower dietary magnesium 
intake would be associated with more rapid decline in kidney function.
Methods: Participants with estimated glomerular filtration rate (eGFR) ≥ 60mL/
min/1.73 m2 at baseline (2004-2008) of the population-based, Healthy Aging in 
Neighborhoods of Diversity across the Life Span (HANDLS) study were followed for a 
median of 4.7 years. Baseline dietary magnesium intake was calculated from two 24-hour 
dietary recalls. eGFR was calculated from serum creatinine using the CKD-EPI equation. 
We defined rapid decline as eGFR decline ³3% per year. The association between dietary 
magnesium intake and eGFR decline was evaluated using Cox regression.
Results: Among 1,326 participants, those with lower dietary magnesium intake 
(tertile 1 vs. 3) were significantly younger (mean age of 46 vs. 49 years), more likely to be 
African-American (67% vs. 48%) and male (45% vs. 31%); had lower mean body mass 
index (BMI, 29 vs. 30 kg/m2), higher mean baseline eGFR (99 vs. 94 mL/min/1.73 m2) and 
lower prevalent diabetes (10% vs. 18%); p<0.05 for all. In the overall study population, 
eGFR was stable without any decline (mean change: 0.1 mL/min/1.73 m2), while 189 
participants experienced an eGFR decline ³3% per year. Lower dietary magnesium intake 
was associated with higher risk of eGFR decline ³3% per year (tertile 1 vs. 3, hazard ratio 
1.9, 95% confidence interval: 1.1, 3.3) adjusted for socio-demographics, baseline eGFR, 
prevalent diabetes and hypertension status, BMI, serum magnesium, total energy intake, 
and dietary intake of calcium, potassium, and phorsphous.
Conclusions: Among persons with preserved eGFR, we detected a significant 
association between lower dietary Mg intake and increased risk of rapid kidney function 
decline independent of traditional CKD risk factors. These results highlight the importance 
of magnesium intake in the overall diet for the preservation of kidney function.
Funding: NIDDK Support, Other NIH Support - NIA
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Renin-Angiotensin System: A Possible Mechanism for AKI-CKD 
Continuum  Shun-Yang Cheng, Shuei-Liong Lin, Ching-Chin Yang, Yu-Hsiang 
Chou, Fang Ling Liao, Ming-Hsuan Tsai.  Graduate Inst of Physiology, National 
Taiwan Univ.
Background: Based on many clinical observations and studies, acute kidney injury 
(AKI) was now regarded as an important risky factor causing chronic kidney disease 
(CKD). Not only does CKD lead to end-stage renal disease (ESRD), but also increases 
the risk of cardiovascular disease or even death. Clinical studies often disclose that the 
higher the AKI severity of a patient is, the more likely her/his kidneys progress into CKD. 
To this day, the mechanism underlying the progression of kidneys into CKD after AKI 
remains illusive. Since the higher severity of the AKI leads to more reduction of nephron 
numbers, we propose that activation of renin-angiotensin system (RAS) may be involved 
in the progression to CKD after recovery from AKI.
Methods: Severe AKI was induced in male adult CD-1 mice by right uni-nephrectomy 
(Nx)followed by ischemia-reperfusion injury of left kidney 2 weeks later. Drinking water 
with or without type 1 angiotensin II receptor blocker losartan or direct vasodilator 
hydralazine was administered to mice from 4 weeks after surgery. Mice with Nx only were 
served as the control. Blood pressure, urinary albumin-creatinine ratio (ACR)and plasma 
levels of creatinine were evaluated.
Results: Compared to Nx group, AKI mice showed acute rise of plasma creatinine 
levels on day 2 after Nx+IRI surgery, which decreased to baseline on day 7. Moreover, 
elevated systolic blood pressure and increased urinary ACR were noted since 4 weeks after 
Nx+IRI. During the 4-month experimental period, progressive increase of urinary ACR and 
plasma levels of creatinine were noted. On the contrary, systolic blood pressure, urinary 
ACR and plasma creatinine level were normalized in mice administered with losartan 
since 4 weeks after Nx+IRI surgery. However the increase of urinary ACR and plasma 
creatinine level were not prevented in mice administered with hydralazine despite similar 
normalization in blood pressure.
Conclusions: These data suggest that RAS activation may underlie the mechanism 
for development of CKD in mice after recovery from AKI. Future studies are needed to 
explore the effect of RAS blockade in prevention of CKD and its pression in patients 
recovered from AKI.
Funding: Government Support - Non-U.S.
PUB182
The Renal Effects of Neprilysin Inhibition in Heart Failure and 
Hypertension  Girish Singhania, Abhilash Koratala, Amir Kazory.  Nephrology, 
Univ of Florida, Gainesville, FL.
Background: Neprilysin inhibitors (NEPi) represent an emerging therapeutic option 
for treatment of hypertension (HTN)) and heart failure (HF) through enhancement of 
natriuresis. While these agents have shown promising results with regards to lowering 
blood pressure (BP) and HF events, their impact on the kidney remains largely unknown. 
The aim of this study is to evaluate the currently available evidence on the effect of NEPi 
use on kidney-related parameters in patients with HTN or HF.
Methods: A search of articles cited in PubMed database from 1995 to 2015 using key 
words “neprilysin”, “heart failure” and “hypertension” found 237 articles. Animal studies 
were excluded. Those studies containing kidney-related parameters such as serum creatinine, 
glomerular filtration rate (GFR), or BP were selected. Relevant data including changes in 
renal function, blood pressure and mortality were extracted and compared.
Results: A total of 42,487 patients from 12 randomized controlled trials with data 
pertaining to NEPi use were included (8 in HTN and 4 in HF). Seven studies used NEPi 
combined with ACE-i, 4 with ARB, and 1 with endothelin converting enzyme inhibitors. 
The follow up periods ranged between 7 days and 27 months. All studies in HTN (including 
27,401 patients) reported significantly better BP lowering effect for NEPi compared to 
control group, while 94% of the patients in the HF studies presented with improvement in 
HF events or mortality. Although change in renal function was not the primary endpoint, all 
HF studies (including 15,086 patients) showed less frequent renal impairment (expressed as 
an adverse event, incidence of worsening renal function, change in GFR, or serum creatinine) 
compared to the control group. In contrast, only 3 HTN studies (including 466 patients) 
explored the impact on renal function and reported no significant benefit.
Conclusions: Current evidence suggests that in patients with HF, NEPi can lower 
HF-related events and mortality while portending favorable impact on renal function. In 
patients with HTN, although NEPi have been shown to reduce BP, there is no conclusive 
evidence of their role in improvement of renal function in this setting.
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Underline represents presenting author.
929A
J Am Soc Nephrol 26: 2015 Publication Only 
PUB183
The Differences of Renal Protective Effect by Hyperuricemia Treatment 
Using Febuxostat in Various CKD Subgroups  Akinori Yamaguchi, Makoto 
Harada, Yosuke Yamada, Koji Hashimoto, Makoto Higuchi, Yuji Kamijo.  Dept 
of Nephrology, Shinshu Univ, Mtsumoto, Nagano, Japan.
Background: We often experience the CKD cases exhibiting the attenuation of eGFR 
decline by hyperuricemia treatment using febuxostat. However, renal protective effect by the 
hyperuricemia treatment has not yet been established. We hypothesize that the therapeutic 
response of febuxostat treatment might differ among various subgroups of CKD patients.
Methods: To investigate the difference of the therapeutic response in CKD patients, 
272 outpatients with hyperuricemia who were treated by febuxostat from May 2011 to 
March 2015 were enrolled. Patients undergoing hemodialysis and/or peritoneal dialysis 
treatment, and patients lacking essential clinical data were excluded. Finally, 178 patients 
were analyzed. Correlation coefficient between the average of serum uric acid level and 
the eGFR variation during 6 months after the treatment were statistically investigated in 
various clinical subgroups.
Results: In all patients, significant correlation between the average of serum uric acid 
levels and the eGFR variation was detected (spearman’s correlation coefficient: r=-0.163, 
p=0.019). This significant correlation was also detected in each patient groups as follows: 
male patients (n=121, r=-0.211, p=0.020), non-elderly (below 70 years old) patients 
(n=107, r=-0.261, p=0.007), patients whose systolic blood pressure were below 130 mmHg 
(n=72, r=-0.238, p=0.044), patients without dyslipidemia (n=133, r=-0.316, p=0.005) and 
non-diabetic-nephropathy patients (n=133, r=0.184, p=0.034). However, the significant 
correlation was not detected in each opposite subgroups.
Conclusions: The current study suggest that therapeutic response of febuxostat 
treatment might be well in each CKD subgroups, including male, non-elderly, non-
hypertention, non-dyslipidemia and non-diabetic-nephropathy. It is possible that various 
risk factors of atherosclerosis conceal the beneficial renal protective effects of hyperuricemia 
treatment using febuxostat.
PUB184
Urinary RBP as an Independent Predictor of “Hard Composite Outcome” 
in Albuminuric Diabetic Nephropathy  Gesiane Fernandes Tavares, Roberto 
Zatz, Silvia M. Titan.  Renal Div, Dep. Clinical Medicine, Faculty of Medicine, 
Univ of Sao Paulo, Sao Paulo, Brazil.
Background: The current search for new biomarkers in CKD is intense, with particular 
emphasis on hard end-points, such as ESRD, creatinine duplication and cardiovascular 
and overall mortality. In this analysis, we sought to evaluate which baseline clinical and 
laboratorial variables were related to ESRD/mortality in 56 patients with albuminuric 
diabetic nephropathy after mean follow-up time of 5 years.
Methods: Baseline clinical and laboratorial data of 56 participants of a clinical trial 
were evaluated as predictors of major outcomes (primary outcome, PO: ESRD, creatinine 
duplication or mortality). Mann-Whitney and chi-square tests were used for univariate 
analyses. Several univariate and multivariate COX regression models were built on the 
risk of PO. Kaplan-Meier curve and LOG rank test were also performed.
Results: PO occurred in 39 participants after a mean follow-up time of 5 years (70%). 
In univariate analyses, sex, creatinine clearance, 24h proteinuria, uRBP, urinary VEGF and 
serum TGF-beta were related to the event group. In univariate COX regression models, 
sex, proteinuria, creatinine clearance, VLDL-cholesterol, ferritin, PTH, RBP and uMCP-1, 
uVEGF and uTGF-beta were significantly associated to the risk of the PO. However, after 
adjustments for creatinine clearance and proteinuria, only uRBP and uMCP-1, uTGF-beta 
and uVEGF remained significantly associated to PO. In a stepwise model, only creatinine 
clearance (HR 0,98, 95%CI 0,97 - 1,00, P=0,06) and uRBP (HR 1,13, 95%CI 1,07 - 1,20, 
P<0,0001) were left as independent predictors of PO in this population. KM curve for 
uRBP is shown in figure 1.
Conclusions: Urinary RBP is an independent predictor of PO in albuminuric diabetic 
nephropathy. Its role as a risk biomarker should be further explored in larger studies of 
CKD patients.
Funding: Government Support - Non-U.S.
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Association Between Urinary RBP and Renal and Cardiovascular 
Risk Factors in a Population with CKD: The Progredir Study 
Maria Alice Muniz Domingos,1 Alessandra C. Goulart,2 Paulo Lotufo,2 Isabela 
M. Bensenor,2 Silvia M. Titan.1  1Renal Div, Dep. Clinical Medicine, Faculty 
of Medicine, Univ of Sao Paulo, Sao Paulo, Brazil; 2Clinical Research Center, 
Univ Hospital, Sao Paulo Univ, Sao Paulo, Brazil.
Background: Urinary RBP (uRBP) has been related to the risk of ESRD in 
glomerulonephritis and renal transplant. However, its role in CKD is not well established.
Methods: Baseline clinical and laboratorial data on 454 participants of the Progredir 
Study was analysed. uRBP was measured by an immunoenzymatic assay with monoclonal 
antibody. Descriptive data is presented according to tertiles of uRBP, and correlation 
coefficients were calculated. Several univariate and multivariate linear regression models 
were built. Lastly, binary regression models were built on the risk of presenting more 
advanced CKD (class IV+V versus class II+III).
Results: In the descriptive data, the tertiles of uRBP were significantly related to sex, 
diabetes, renal function, SBP, glycated hemoglobin, HDL, proteinuria, WHR, phosphorus, 
acidosis, albumin, pulse-wave velocity (PWV), left atrium diameter (LAD), systolic and 
diastolic left ventricular diameters and ejection fraction. These results were confirmed 
by correlation. In the univariate regression models, diabetes, SBP, WHR, renal function, 
proteinuria, phosphorus, albumin, lipids, glycated hemoglobin, PWV and echographyc 
variables remained related to uRBP. However, after adjustments, only renal function, 
proteinuria, SBP, bicarbonate and LAD remained associated to uRBP. 
Lastly, uRBP was associated to an increased risk of class IV+V CKD (OR 1,16, 95%CI 
1,08 - 1,25, p<0,0001), even after adjustments for age, sex, diabetes, proteinuria and SBP.
Conclusions: uRBP is independently related to cardiovascular risk factors in the CKD 
population. Its role as a biomarker of hard clinical end-points should be further explored.
Funding: Government Support - Non-U.S.
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Treatment of Subclinical Hypothyroidism and the Progression of Chronic 
Kidney Disease  Padmavathi Mali,1 Sudheer Muduganti.2  1Internal Medicine, 
Marshfield Clinic, Marshfield, WI; 2Nephrology, Univ of Wisconsin Hospitals 
and Clinics, Madison, WI.
Background: Evidence suggests that treatment of subclinical hypothyroidism may 
slow the progression of chronic kidney disease (CKD) and delay or prevent development of 
end stage renal disease (ESRD).The goal of this study was to provide additional evidence 
regarding the same.
Methods: Patients with subclinical hypothyroidism and CKD stages 3 or 4 were 
identified by retrospective chart review over a period of 6 years. Subjects were grouped 
based on L-thyroxine treatment. Subjects treated with L-thyroxine before first elevated 
thyroid stimulating hormone (TSH) were excluded. Index date was defined as the date 
of first L-thyroxine for treated patients. Index dates for untreated patients were assigned 
by random sampling of dates for treated patients. TSH and serum creatinine values were 
captured from the electronic medical record. Change in eGFR (glomerular filtration rate) 
over time in treated and untreated patients was assessed using a linear random coefficients 
model in the subset with two or more eGFR results spanning a period of at least 6 months, 
both before and after the index date.
Results: A total of 258 patients meeting inclusion criteria were identified; 181 were 
treated with L-thyroxine and 77 were not. Treatment initiation began after the first elevated 
TSH in the study period for 110/181 subjects. Upon analysis, before the index date, eGFR 
showed a significantly decreasing trend (p<0.001) that was not significantly different 
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between treated and untreated patients (p = 0.593). After the index date, the rate of eGFR 
change showed a significant positive change (p<0.001) toward a gradual increase, but again 
this was not significantly different between groups (p = 0.522).
Conclusions: The similar results in the two groups, regardless of L-thyroxine treatment 
status, provides no evidence that treatment of subclinical hypothyroidism influences 
progression of CKD in individuals with stage 3 or 4 disease. Although previous studies 
have suggested that treatment of subclinical hypothyroidism in this population may delay 
or prevent the progression of ESRD, our results do not support the hypothesized treatment 
benefits.
PUB187
Effect of Hyperuricemia on the Blood Pressure-Dependent Proteinuria in 
Non-Nephrotic Chronic Kidney Disease  Kentaro Kohagura,1,2 Ryo Zamami,2 
Tsuyoshi Miyagi,2 Masako Kochi,2 Yusuke Ohya.2  1Dialysis Unit, Univ Hospital 
of the Ryukyus, Nishihara-cho, Okinawa, Japan; 2Cardiovascular Medicine, 
Nephrology and Neurology, Univ of the Ryukyus, Nishihara-cho, Okinawa, 
Japan.
Background: Patients with chronic kidney disease (CKD) are suggested to be highly 
susceptible for hypertensive renal damage due to disrupted autoregulation system in afferent 
arteriole. We reported that hyperuricemia was associated with renal arteriolar hyalinosis 
in the CKD patients. However, effect of hyperuricemia on a relationship between blood 
pressure (BP) and proteinuria is unknown inCKD patients.
Methods: A total of 208 consecutive patients who underwent renal biopsy at our 
department between 2003 and 2007 were considered for the study. We excluded patients 
receiving renin angiotensin inhibitor and nephrotic CKD patients defined as serum albumin 
equal or more than 3 g/gCr, leaving us with 117 patients (57 men and 60 women) for 
analysis.Arteriolar hyalinosis were assessed by semi quantitative grading for arterioles. We 
compared the relationship between systolic BP and logarithm-transformed urine protein 
(g/gCr) in the patients with or without hyperuricemia.
Results: The mean ± standard deviation values for age, BP, estimated glomerular 
filtration rate (eGFR), and urine protein were as follows: 40± 18 years, 126 ± 20/75 ± 12 
mmHg, and 84 ± 37 ml/min/1.73 m2, and 0.9±0.8 g/gCr, respectively. In the patients with 
hyperuricemia (n=63), systolic BP was significantly correlated with log-transformed urine 
protein (r=0.43, p=0.004). In contrast, there was no significant correlation between them in 
the patients without hyperuricemia (n=53, r=0.07, p=0.60). In the multiple regression model 
(R2=0.25, p=0.01), systolic BP was significantly correlated with logarithm-transformed urine 
protein (β=0.33, p=0.02) independent of age, sex and classical risk factors in the patients 
with hyperuricemia. However, its statistical significance was disappeared after additional 
adjustment with arteriolar hyalinosis.
Conclusions: These results suggested that hyperuricemia might potentiate the 
susceptibility for hypertensive glomerular damage via disrupted autoregulation in non-
nephrotic CKD patients.
PUB188
HCV Independently Affects Kidney Function Among HIV Co-Infected 
Individuals  Maya Balamane,1 Richard A. Teran,1 Joseph G. Timpone,1 Jason 
G. Umans,2,3 Princy N. Kumar,1 Seble Kassaye.1  1Georgetown Univ Medical 
Center, Washington, DC; 2Georgetown Howard Univs Center for Clinical 
& Translational Science, Washington, DC; 3MedStar Health Research Inst, 
Hyattsville, MD.
Background: Predictors of chronic kidney disease (CKD) include increasing age, 
hypertension and diabetes. Hepatitis C (HCV) infection has also been associated with 
increased risk for CKD. We sought to determine the relative contribution of HCV vs other 
co-morbidities on kidney dysfunction among individuals with HIV.
Methods: We analysed data from HIV-positive patients enrolled in the DC HIV Clinical 
Cohort study at Georgetown University Hospital (2011-2014). Estimated glomerular 
filtration rate (eGFR) was calculated using the CKD-EPI formula. Analyses were conducted 
stratified by HCV status. Chi square, Cochran–Mantel–Haenszel and Breslow Day Test 
statistics were performed to determine factors associated with normal kidney function 
(eGFR > 90 ml/min/1.732), compared with participants with decreased kidney function, 
stage 2 and 3 (³30 eGFR ≤89) usingSAS v9.4.
Results: Among 771 participants, median age was 48, 73.4% male, 50.3% black, 
median CD4+ T cell count 546.5 cells/µL, and HIV-RNA <20 copies/mL. 93 (12.1%) had 
HCV co-infection. There was significantly higher prevalence of stage 2-3 kidney dysfunction 
with HIV/HCV co-infection than HIV mono-infection (35% vs. 19%, p=0.0016; OR, 
(95% CI) 2.2 (1.3-3.6)). Prevalence of hypertension, diabetes, hyperlipidemia and chronic 
Hepatitis B was similar between HIV and HIV/HCV co-infected groups. Presence of these 
co-morbidities was not a confounder in the increased risk for CKD with HIV/HCV, (Mantel-
Haenszel chi-square OR, (95% CI) of 2.2 (1.3-3.6) for hypertension, 2.18 (1.3-3.6) diabetes 
and 2.2 (1.3-3.6) hyperlipidemia (Breslow Day test p values<.05 for each co-morbidity.
Conclusions: We identified a strong association between HIV/HCV co-infection and 
reduced kidney function independent of co-morbidities usually associated with kidney 
dysfunction in this group with well controlled HIV. Further investigation is needed to study 
the mechanisms by which HCV affects kidney function.
Funding: Other NIH Support - Division of AIDS- NIAID
PUB189
Vitamin D Deficiency Is a Cause and a Result of Renal Dysfunction in 
Rheumatoid Arthritis  Suad Ma Hannawi, Issa AL Salmi.  Medicine, Ministry 
of Health, Duabi, United Arab Emirates.
Background: Asymptomatic kidney dysfunction is common in RA. Low vitamin 
D(VD) increases susceptibility to development of RA& disease activity. Sequential 
hydroxylations occurs in liver & kidney to form active1,25-VD & patients with 
kidney failure are often resistant to VD & suffer from 2nd hyperparathyroidism & renal 
osteodystrophy. In addition to its role in maintaining Ca&PO4 homeostasis, VD is important 
for maintaining maximum muscle strength & prevention of chronic diseases. Our objective 
is to evaluate eGFR & VD status in RA.
Methods: RA diagnosed by ACR 1988 criteria. 25-VD level obtained & GFR 
calculated by MDRD at Rheumatology clinic visit. Univariate linear regression analysis 
carried out to determine the relation between 25-VD and eGFR, other renal parameters & 
RA inflammatory markers.
Results: Interim analysis of 52 RA(47F,5M) with mean age 46±13 year(F46±12, 
M45±21). 25-VD level is 40±29 nmol/l(NR50-80)&GFR is 134±49 ml/min/m2. 
Univariate linear regression showed a negative relationship between 25-VD level & 
GFR(p=0.041,CI-0.23,-0.01), micro-albuminuria(p=0.046,CI -0.63,-0.01), CRP (p=0.01,CI 
-1.16,-0.16), neutrophil count (p= 0.03,CI -1.67,-0.11) . A positive linear relationship 
between GFR &weight (p=0.03,CI 0.06,1.04), BSA(p=0.02, CI 11, 119)& BMI(p=0.009,CI 
0.65-4.05), Ca(p=0.0.03, CI 7.24, 133.12 mmol/l).
Conclusions: Negative relationship between eGFR &25-VD, indicating a higher 25-VD 
as failure to convert to active form as GFR decreases. Extra-renal formation of active VD 
requires high level of 25-VD >78 nmol/L(30 ng/mL)& is necessary for maximal extra-renal 
production of 1,25VD. 1,25-VD is one of the most potent regulators of cellular growth & 
very effective modulator of the immune system. VD receptors are present in most cells & 
tissues in the body including activated T and B lymphocytes. Surveillance for VD deficiency, 
should be part of follow-up as it may be linked to underlying kidney dysfunction in RA. 
On the other hand, reduced VD might worsen RA & hence, increase the possibility of renal 
deterioration. VD supplementation may be needed early in management for prevention of 
kidney dysfunction & to reduce RA severity.
PUB190
Associations Between the Progression of Chronic Kidney Disease and 
Patient Demographics  Danqing Xu,1 Mark Stuart,3 Barbara Cannon,3 Chad 
Sowers,3 John W. Larkin,2 Sophia Rosen,2 Carly R. Van Zandt,4 Len A. Usvyat,2 
Yuedong Wang,1 Terry Ketchersid,2 Dugan Maddux,2 Franklin W. Maddux.2 
1Univ of California, Santa Barbara; 2Fresenius Medical Care North America; 
3Acumen Physician Solutions; 4Frenova Renal Research.
Background: It is not well known if demographic factors are related to the progression 
of chronic kidney disease (CKD). We aimed to investigate whether age, sex, race, marital 
status and geography are associated with significant changes in kidney function determined 
by linear slopes of mean annual glomerular filtration rate (GFR).
Methods: We analyzed data from 90,240 CKD patients (Pts), who had significant 
declines in GFR, in the Fresenius Medical Care CKD Data Registry. Annual average decline 
in GFR was estimated on a per pt basis using linear regression with time as the predictor and 
GFR as the outcome variable. Univariate linear models were fitted for age groups (15-30, 
31-45, 46-60, 61-75, and 76-90 years old), sex (female or male), race (African American, 
Caucasian, or other), marital status (married, unmarried) and geography (10 divisions of 
zip codes); a multiple linear regression model was utilized to investigate associations in 
mean annual GFR slope and demographics.
Results: This analysis identifies significant associations between mean annual GFR 
slope and Pt demographics. CKD Pts age 15-30 years old were found to decline faster 
in GFR versus older Pts in all other age groups (p<0.001). Males were observed to 
decline slower in GFR versus females (p<0.001). Pts with a race of “other” were seen to 
decline slower in GFR versus Pts of African American or Caucasian race (p<0.001). The 
geographical location of Pts by zip code was observed to be associated with differences in 
GFR slope (p<0.001). The marital status of Pts was not found to be related to differences 
in slopes of GFR (p=0.218).
Conclusions: This study identifies that during the progression of CKD, younger Pts 
tend to have faster declines in GFR, as compared to older Pts; males have slower declines 
in GFR, as compared to females; Pts with a race of “other” have slower declines in GFR, 
as compared to Pts of African American or Caucasian race; and declines in GFR are related 
to Pt geography.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB191
Correlation of Increased Th17 to Treg Cell Ratio with Endoplasmic 
Reticulum Stress in Chronic Kidney Disease  Ou Yan.  Kidney Dept, Second 
Affiliated Hospital of Xi’an Jitong Univ, Xi’an, Shaanxi Province.
Background: The  study aimed to investigate the relationship between the regulatory 
immune network and endoplasmic reticulum stress (ERS) in patients with different stages 
of chronic kidney disease (CKD).
Methods: A total of 91 patients diagnosed with CKD were divided into different groups 
according to the stage of disease. Routine blood and biochemical tests were performed in 
patients and in healthy controls (n = 20). The frequencies of T helper type 17 (Th17) and 
regulatory T (Treg) cells in the overall T cell population was measured by flow cytometric 
analysis. Levels of Th17 cell (IL-17) and Treg cell (IL-10) cytokines and the ERS markers 
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CHOP and GRP78were measured by ELISAin serum samples collected from controls and 
patients in the different CKD groups. Correlations between each parameter and serum 
creatinine, an indicator of renal function, were analyzed by Spearman’s rank correlation 
and regression test.
Results: CKD stage showed a positive correlation with serum creatinine level, and 
increased and decreased percentages of Th17 and Treg cells, respectively, reflected in an 
increased Th17/Treg cell ratio. Consistent with this, CKD stagewas positively correlated 
with serum concentrations of IL-17and negatively correlated with serum IL-10 levels. 
Moreover, serum levels of CHOP and GRP78 increased with advancing CKD stage. 
These correlations were most pronounced in patients in the CKD5 group, who also had the 
poorest response to hemodialysis and peritoneal dialysis treatment, compared with CKD5 
patients in the non-dialysis group.Correlation analysis showed that serum levels of CHOP 
and GRP78 were independently and positively correlated with the ratio of Th17/Treg cells.
Conclusions: We have found that an increased Th17/Treg cell ratio and increased serum 
levels of ERS markers correlate with the progression of CKD. Our results indicate that the 
interplay between regulation of the immune network and management of ERS is closely 
associated with the pathogenesis of CKD. Although hemodialysis and peritoneal dialysis 
treatment manage chronic kidney conditions and prevent further deterioration of renal 
function, they have limited effects on improving the immune disorder and relieving ERS.
Funding: Government Support - Non-U.S.
PUB192
Metabolic Phenotyping in Thin Basement Membrane Nephropathy 
Claire Boulange,1 Manuja Kaluarachchi,1 Elaine Holmes,1,2 John C. Lindon,1,2 
Joram Matthias Posma,2 Konstantinos Voskarides,3 Isavella Savva,3 Alkis Mikis 
Pierides,3 Constantinos Deltas.3  1Metabometrix Ltd, London, United Kingdom; 
2CSM, Dep of Surgery & Cancer, Imperial College London, London, United 
Kingdom; 3MMRC, Dep of Biological Sciences, Univ of Cyprus, Nicosia, Cyprus.
Background: Thin basement membrane nephropathy (TBMN) is the commonest cause 
of familial microscopic hematuria in children and adults, usually associated with benign 
clinical conditions i.e minimal proteinuria and normal renal function. In a Greek-Cypriot 
cohort of TBMN patients, 35% of patients were shown to develop ESRD by age 70-years 
while ~50% of patients over 50-years developed CKD of variable degree. 40% of TBMN 
patients inherit heterozygous mutations in the COL4A3/A4 genes. What predisposes these 
TBMN patients to an adverse outcome and chronic kidney function decline during aging is 
presently unclear. Using Metabolic phenotyping techniques (NMR and mass spectrometry) 
our study should provide new biological insights in the development of extreme conditions 
in adult TBMN patients.
Methods: Spot urine samples from 81 patients with the same founder mutation, 
COL4A3-G1334E. Patients were classed; Severe (S) (n= 55): proteinuria > 500 mg/day and 
CKD, irrespective of age. Mild (M) (n=26): normal kidney function with no proteinuria, 
regardless of age. It is expected that some will proceed to CKD on follow-up. Samples were 
analysed by 600 MHz 1H NMR spectroscopy (detecting predominantly small molecules 
>1µM) and UPLC-MS (detecting water-soluble molecules > 0.05 nM). Multivariate analysis 
(MVA) was used to elucidate class differences.
Results: MVA of M vs S samples revealed significant metabolic differences between 
the groups. From the UPLC-MS 15 MS features discriminate M and S. Among the 
discriminating metabolites discovered using NMR; citrate, glycine and creatinine were 
negatively correlated with S. Metabolite identification is ongoing, as well as application 
of additional metabolic profiling technologies.
Conclusions: Urine metabolic profiling may prove useful to classify renal disorders 
such as the M and S cases of TBMN by their specific renal metabolite signatures and lead 
to the discovery of novel molecular disease biomarker profile patterns.
Funding: Other NIH Support - The research leading to these results has received 
funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) 
under grant agreement no. 305608 (EURenOmics)
PUB193
Uric Acid and Its Association with Glomerular Filtration Decline Rate in 
an Incident Pre-Dialysis Population  Pedro Vieira, Miguel Goncalves, Gil 
Silva.  Nefrologia, Hospital Central do Funchal, Funchal, RAM, Portugal.
Background: Hyperuricemia is highly prevalent and there is cumulative evidence 
based on experimental models of its’ likely detrimental role in multiple pathologies, namely 
hypertension, vascular and renal diseases. Given hyperuricemia’s high occurrence on 
chronic kidney disease patients, we have tried to assess the association between uric acid 
basal levels (UABL) in an incident pre-dialysis population with renal function decline rate.
Methods: We have randomly selected incident patients with chronic kidney disease 
stages IV-V, referred to low clearance nephrology assessment from 2010 to 2014. We kept 
follow up until dialysis initiation, death or lost of follow-up.
Results: Sixty-six patients were selected with mean UABL of 8,15 (±2,10) mg/dl and 
a mean glomerular filtration decline rate of -4,00 (±10,81) ml/min/1,73m2/year. Of notice 
that by each unit increase in UABL an added variation of -1,41 ml/min/1,73m2/year on 
glomerular filtration decline rate was perceived (CI 95%, p= .039). Adopting a linear mixed 
model analysis on UABL’ impact on glomerular filtration decline rate, despite adjustment 
for multiple demographic confounders and comorbilities, statistical significance (p=.006) 
was conserved.
Conclusions:  High UABL were associated, with statistical significance, to enhanced 
deterioration of kidney function.
PUB194
Soluble α-Klotho in HIV-Infected Patients and Kidney Dysfunction 
Clara Dias,1 Sara Maia,1 Fernando G. Pereira,2 Pedro Pereira Campos,2 Ana Luisa 
Papoila,3 Alberto Ortiz,4,5,6,7 Sofia Pereira,1 Karina Soto.2,3  1Centro de Estudos 
de Doenças Crónicas, NOVA Medical School/Faculdade de Ciências Médicas; 
2Nephrology, Hospital Fernando Fonseca; 3Centro de Estatística e Aplicações, 
Univ de Lisboa (CEAUL), Portugal; 4Nephrology, IIS-Fundacion Jimenez Diaz, 
Madrid, Spain; REDinREN, Madrid, Spain; 5REDinREN, Madrid, Spain; 6Univ 
Autonoma de Madrid, Madrid, Spain; 7IRSIN, Madrid, Spain.
Background: Kidney disease is common among HIV-infected patients. Klotho is a new 
endocrine protein that exerts modulation of kidney solute transport and nephroprotection 
in AKI and CKD. We aim to explore whether levels of serum soluble α-Klotho are related 
with CKD progression in HIV-population.
Methods: As a part of an on-going prospective study of HIV-infected patients, a 
cross-sectional analysis was performed. Glomerular filtration rate (eGFR) was estimated 
by CKD-EPI equation being Early Kidney Disease (EKD) when <90 mL/min/1.73m2. 
Fractional excretion of phosphate (FePi) was also assessed and serum soluble α-Klotho 
was quantified by ELISA.
Results: A total of 169 HIV+ patients were included, 66% men, 75% non-Black, 55yo 
(48-62). Median values Klotho: 957 pg/mL (717-1213) and FePi: 21% (14-25). Klotho/FePi 
ratio was negatively correlated with eGFR when ≥75 mL/min/1.73m2 (Spearman r=-0.213, 
p=0.024); while the correlation was positive if eGFR<75 (Spearman r=0.410, p=0.002) 
No direct relation between Klotho and eGFR was found, while FePi was only related 
with eGFR<75 (Spearman r=-0.396, p=0.002).
Conclusions: In HIV-infected patients, the association between Klotho and CKD 
progression has only significance when normalized by FePi levels. This association differed 
in opposite directions between patients with EKD and with normal kidney function, or in 
very early CKD stages. Of note, Klotho/FePi ratio seems to be better biomarker of EKD 
than Klotho itself.
Funding: Other NIH Support - Financial support: EXPL/DTP-FTO/1792/2013; PD/
BD/105892/2014 (CGD)
PUB195
Association of hsCRP and Kidney Damage Indicators in 5667 Adults 
Receiving Physical Examination  Hao Zhang, Juan Mao, Bin Yi, Guo Xu, 
Wei Li.  The Third Xiangya Hospital of Central South Univ.
Background: Chronic kidney disease and cardiovascular disease share many risk 
factors. Injury to the vascular endothelium, measured by elevated levels of serum high-
sensitivity C-reactive protein (hsCRP), may play a role in kidney disease. We therefore 
examined the association of hsCRP with kidney damage indicators (uACR,eGFR) among 
5667 participates receiving physical examination in the Third Xiangya Hospital.
Methods: We conducted a cross-sectional analysis of 5667 adults who received healthy 
physical examinationin in 2014. Spearman correlation analysis, multiple linear regression 
and multivariable logistic regression analysis were used to analyze the correlation between 
hsCRP with uACR, eGFR. ROC curves was drawing to explore the statistically significant 
intercept point of hsCRP in predicting the occurrence of albuminuria and declining in eGFR. 
Multivariable logistic regression analysis was used to calculate the ORs for albuminuria, 
declining in eGFR according to the quartile of hsCRP levels and other risk factors.
Results: Spearman correlation analysis showed that uACR was positively correlated 
with serum hsCRP (r=0.233,p<0.01). While eGFR showed negative correlation with 
hsCRP(r=-0.135,p<0.01). Multiple linear regression analysis showed that hsCRP was 
independently correlated with uACR(B=0.205,β=0.156, P<0.01). While hsCRP did’t 
enter the multivariate linear regression model of eGFR. Multivariable logistic regression 
analysis showed that male, central obesity, hypertension, diabetes and high hsCRP levels 
were independent risk factors for albuminuria. Based on the ROC curve, the 0.85mg/L 
of hsCRP was the best numerical value to predict the risk of albuminuria. Multivariable 
logistic regression analysis showed that the risk of albuminuria significantly increased in 
male, central obesity, hypertension, or diabetes combined with high hsCRP levels.
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Conclusions: HsCRP was correlated with kidney damage indicators, and hsCRP was 
an independent risk factor of albuminuria. The 0.85mg/L of hsCRP was the best numerical 
value to predict the risk of albuminuria. Male, central obesity, hypertension, diabetes 
accompanying high serum hsCRP levels are more likely to have albuminuria.
PUB196
Serum Non-Protein Bound Homocysteine Levels Are Related with Chronic 
Kidney Disease Progression in HIV-Infected Patients  Clara Dias,1 Nelson 
Casimiro,1 Nuno Coelho,1 Ana R. Lemos,1 Pedro Pereira Campos,3 Ana Luisa 
Papoila,2 Sara Maia,1 Karina Soto,1,3 Sofia Pereira.1  1Centro de Estudos de 
Doenças Crónicas, NOVA Medical School/Faculdade de Ciências Médicas 
(NMS/FCM), Univ Nova de Lisboa; 2Centro de Estatística e Aplicações da 
Univ de Lisboa (CEAUL), NOVA Medical School/Faculdade de Ciências 
Médicas, Univ Nova de Lisboa; 3Nephrology, Hospital Fernando Fonseca, 
Lisbon, Portugal.
Background: Homocysteine (Hcys) is present in serum in two major forms: 
disulfide protein-bound (PB) (70-80%, mostly albumin) and non-protein bound (NPB) 
(20-30% combined thiol dimers + 1% thiol free). Only the NPB-fraction of Hcys is able 
to enter into the cell and accumulatesIn both kidney failure and HIV-infected patients, 
hyperhomocysteinemia is a common feature. The present study was aimed to explore the 
relation of Hcys NPB-fraction and chronic kidney disease (CKD) progression in HIV-
infected patients.
Methods: As a part of an on-going prospective study of HIV+ population, a cross-
sectional analysis was performed in a cohort of HIV-infected patients under combined 
antiretroviral therapy. Serum NPB-fraction of Hcys was quantified by HPLC with 
fluorescence detection. Glomerular filtration rate (eGFR) was estimated by CKD-EPI 
equation. The fractional excretion of phosphate (FePi) was also assessed.
Results: A total of 141 HIV-infected patients were included, 65% men, 73% non-Black, 
and 55 years old (IQR44-63). Median values of eGFR and FePi were 85 ml/min/1.73m2 
(66-95) and 19% (13-25) respectively. Univariable analysis was performed for eGFR, FePi 
and age. Only eGFR remained in the multivariable model (r=-0.332, p<0.0001).
Conclusions: Serum NPB-Hcys fraction was independently related with kidney 
dysfunction. The present data suggest that monitoring this sub-fraction of Hcys could be 
a tool for early kidney dysfunction detection in HIV-infected patients.
Funding: Other NIH Support - Financial support: EXPL/DTP-FTO/1792/2013; PD/
BD/105892/2014 (CGD)
PUB197
Diabetic Foot Ulcers and Acute Kidney Injury Are Associated with a Decline 
in Renal Function  Huda Mahmoud,1 Maarten W. Taal,1,3 Frances Game,1,3 
Laura M. Proctor,1 Heather Sherriff,1 Christina Udani Peter,1 Hana Baig,1 Faaiza 
Asma,1 Emma J. Lincoln,1 Nicholas M. Selby.1,3  1Renal Medicine, Royal Derby 
Hospital, Derby, United Kingdom; 2Diabetes, Royal Derby Hospital, United 
Kingdom; 3Div of Medical Sciences and Graduate Entry Medicine, Univ of 
Nottingham, United Kingdom.
Background: There is an increased incidence of foot ulcers in patients with diabetes 
in the period immediately prior to the initiation of chronic dialysis; this may be explained 
if chronic foot ulcers accelerate a decline in renal function. We sought to examine this 
further by describing changes in renal function associated with hospitalisation for diabetic 
foot ulcer management.
Methods: All patients admitted to our centre during 2013 with ICD10 coding for 
diabetes and a primary diagnosis of foot ulcer (L97x) were identified. Data were manually 
extracted for those with a relevant clinical episode and sufficient biochemical results from 
routine clinical care. Patients undergoing amputation were excluded. Absolute creatinine 
and eGFR (CKD-EPI) values were collected from 6 months (+/- 1 month) pre and post 
hospital admission.
Results: 95 patients were included. 67 men, median age 68 years (range 31-96). 
Renal function was worse after an admission with an active diabetic ulcer; 6 months 
prior to hospital admission the mean eGFR was 72 +/- 25 SD ml/min/1.73m2compared 
to 67+/- 27 SD ml/min/1.73m2. 6 months after admission, p=0.01. 27% of the admissions 
were associated with acute kidney injury (AKI stage 1, 2, 3: 19, 6, 1 patients respectively). 
Patients who sustained AKI during the admission had larger changes in eGFR than those 
patients without; median decline of -2ml/min/1.73m2/year(IQR 6,-11) versus -5 ml/
min/1.73m2/year(IQR 2,-28), p=0.008.
Conclusions: These data add strength to the hypothesis that an active diabetic foot 
ulcer may contribute to a decline in renal function, particularly when associated with an 
episode of AKI. This decline may also be under-estimated due to loss of muscle mass 
and subsequent over-estimation of eGFR in the post hospitalisation period. These results 
support additional prospective epidemiological and mechanistic studies to further explore 
the relationship between diabetic foot ulcers, AKI and CKD progression.
PUB198
Gender – An Additional Cardiovascular and Chronic Kidney Disease Risk 
Factor in an Apparently Healthy Population  Attilio Di Benedetto,1 Annalisa 
Ciotola,1 Fabrizio Cerino,1 Annamaria Colao,2 Daniele Marcelli,3 Bernard J. 
Canaud.3  1NephroCare Italy, Naples, Italy; 2Medicina Clinica e Chirurgia, Univ 
Federico II, Naples, Italy; 3Fresenius Medical Care, Bad Homburg, Germany.
Background: Cardiovascular disease (CVD) is on the rise, presenting significant 
societal and economic burden. Early detection of CVD and chronic kidney disease (CKD) 
risk factors may prevent related complications. We report results of a CVD and CKD risk 
factor screening program in an apparently healthy population.
Methods: Participants and spectators of the “Prevention Races” held in 2013/2014 
in Naples/Salerno (Italy) were screened for CVD and CKD risk factors by different 
specialists, including nephrologists. Parameters assessed were: systolic blood pressure 
(SBP), diastolic blood pressure (DBP), weight, height, waist circumference, BMI, and body 
composition. Lean (LTI) and Fat (FTI) tissue indexes and overhydration were evaluated 
by Body Composition Monitor (Fresenius Medical Care, Bad Homburg, Germany) using 
multi-frequency bioimpedance spectroscopy at 50 different frequencies.
Results: 701 subjects (38.5% m; 61.5% f) were evaluated. Mean age was 54.54 + 15.6 
(m) and 50.06 +15.2 (f). 3.7% m and 6.8% f had dyslipidemia; 5.9% m and 3.0% f were 
diabetic; 18.6% m and 11.4% f were hypertensive; 2.2% m and 0.7% f had heart disease; 
0% m and 3.5% f had hypothyroidism; 1.5% m and 1.2% f had CKD. Gender differences 
in SBP, DBP, overhydration, FTI, LTI and BMI are shown (Table).
Waist circumference was higher than normal (i.e. ≥88 cm for f and ³102 cm for m) in 
38.4% (m) and 51.6% (f).
Conclusions: In a large sample of apparently healthy persons, males had more CVD 
and CKD risk factors than females, such as SBP, overhydration, and FTI. In association 
with other CVD risk factors, these increase morbidity and mortality. Evaluation of body 
composition is important in the general population for identification of CVD and CKD risk.
PUB199
Potential Effect of Treatment of Metabolic Acidosis on Reducing the Risk 
of End Stage Renal Disease in Chronic Kidney Disease  Solomon Dalezman, 
Candace D. Grant, Vladimir Liberman, Alejandro Pepen Romero, Shayan 
Shirazian, Nobuyuki (Bill) Miyawaki, Joseph Mattana.  Medicine, Winthrop-
Univ Hospital, Mineola, NY.
Background: There is increasing evidence that low serum bicarbonate levels 
impact adversely on the progression of chronic kidney disease (CKD) to end stage renal 
disease (ESRD). It is plausible that treatment could result in a significant reduction in 
ESRD incidence though the potential impact in a CKD population and number needed 
to treat (NNT) are incompletely understood. We carried out the present study to estimate 
the potential impact of treatment of metabolic acidosis on the incidence of ESRD in a 
population of CKD patients.
Methods: We evaluated a cross section of 623 Stage 3 and 4 CKD patients at our 
institution. Their risk of developing ESRD at 2 and 5 years was estimated using the method 
of Tangri et al (JAMA 2011;305:1553-1559) which incorporates age, gender, eGFR, urine 
albumin to creatinine ratio, calcium, phosphorus, albumin, and bicarbonate. ESRD risk was 
then recalculated after assuming correction of all serum bicarbonate levels to 28 mEq/L.
Results: The population had a mean serum bicarbonate level of 24.3 mEq/L, with 79.5% 
having levels below 28 mEq/L. When ESRD risk was calculated following correction of low 
serum bicarbonate levels to 28 mEq/L, 16 fewer patients were predicted to develop ESRD 
at 2 years and 27 fewer at 5 years (relative risk reductions of 0.31 and 0.23 respectively). 
This effect was greatest for patients with CKD stage 4, accounting for 13 fewer ESRD 
patients predicted at 2 years and 20 fewer at 5 years. For the population as a whole, the 
NNT to prevent one case of progression from CKD to ESRD was 40 and 23 at 2 and 5 years 
respectively, while for those with CKD stage 4 the NNT was only 16 and 11.
Conclusions: Our findings suggest that in a population of CKD patients correction of 
metabolic acidosis could potentially result in a substantial reduction in the number who reach 
ESRD given the large numbers of patients with low serum bicarbonate levels. Prospective 
studies are needed to determine whether sodium bicarbonate therapy in populations of 
CKD patients could prevent many cases of ESRD.
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PUB200
The Impact of Vascular Disease on Risk of Development of End Stage Renal 
Disease in Patients with Chronic Kidney Disease  Vladimir Liberman, Sairah 
Sharif, Candace D. Grant, Alejandro Pepen Romero, Shanza Mujeeb, Nobuyuki 
(Bill) Miyawaki, Shayan Shirazian, Joseph Mattana.  Medicine, Winthrop-Univ 
Hospital, Mineola, NY.
Background: Patients with chronic kidney disease (CKD) are not only at higher risk 
for development of end stage renal disease (ESRD) but also suffer disproportionately from 
vascular disease (VD), with associated high cardiovascular mortality. VD can plausibly 
impact progression of CKD and increase the risk of ESRD. However, VD also shortens 
survival, and may therefore reduce the risk of ESRD by increasing the competing risk 
of death. In the present study we evaluated the relationship between VD and the risk of 
development of ESRD in patients with CKD.
Methods: We carried out a retrospective cross sectional study of 623 CKD patients 
and recorded demographic, clinical and laboratory variables. We divided them in two 
groups based on presence or absence of VD and stratified them into different age groups. 
We estimated the risk of ESRD progression using the method of Tangri et al (JAMA 
2011;305:1553-1559) and compared the risk levels between each group.
Results: Out of 623 patients with CKD 285 had VD (coronary artery disease and or 
peripheral vascular disease) documented in the record. Patients with VD were significantly 
older than patients with no VD (76 vs 70 years), had lower serum albumin (4.0 vs 4.1 g/
dL) and lower eGFR (33.8 vs 36.4ml/min/1.73 m2). We found that older patients with VD 
had significantly higher risk of developing ESRD. For the 70 to 79 year age group the 2 
year risk was 2.45 vs 1.50 (p=0.029) and 5 year risk was 6.80 vs 4.31 (p=0.03) in patients 
with and without VD. For patients ≥80 years the 2 year risk of developing ESRD was 
2.18 vs 1.35 (p=0.029) and 5 year risk of developing ESRD was 6.80 vs 4.31 (p=0.03).
Conclusions: Our findings suggest that older patients with VD may be at increased 
risk for the development of ESRD despite the higher competing risk of death. This may 
be partly due to shared pathophysiological mechanisms between atherosclerosis and CKD 
progression. If validated in an ongoing prospective study this finding would suggest that VD 
should be considered a risk factor predisposing to an increased risk of developing ESRD.
PUB201
Management of Renal Artery Stenosis Post-ASTRAL and CORAL: 
Outcome of Patients with Radiologically Confirmed Atherosclerotic Renal 
Artery Stenosis Treated Conservatively  Moheen Mohammed Ahmed,1 
Nicholas John Railton,2 Abdelgalil Abdelrahman Ali,1 Anthony Chan.1  1Renal 
Medicine, Mid Essex NHS Trust, Chelmsford, United Kingdom; 2Radiology, 
Mid Essex NHS Trust, Chelmsford, United Kingdom.
Background: Following the publications of ASTRAL and CORAL trials, the use of 
percutaneous renal artery angioplasty and stenting (PRAS) in the treatment of atherosclerotic 
renal artery stenosis (ARAS) has fallen dramatically. We report the outcomes of patients 
with radiologically confirmed diagnosis of ARAS who did not undergo PRAS and were 
managed medically.
Methods: Retrospective review of all patients undergoing CT/MRI angiography for 
suspected ARAS from 2008-2014 in Broomfield Hospital, Essex. Patients with more than 
>50% stenosis in a renal artery who were medically managed and did not undergo PRAS 
were included in analysis. They were followed for blood pressure control, renal events 
and mortality.
Results: 29 patients were identified, all Caucasians with a median age of 78 (49-85 
years) of which 59% were males. None underwent PRAS.They were followed up from 
diagnosis till December 2014 or date of death with a mean period of 51 months. Systolic 
BP at end of study was <140 mmHg in 48%, 140-200 in 48% and >200 in 4% of patients. 
69% were on 3 or more antihypertensives with 34% on renin angiotensin system blockade. 
20 patients were CKD 3 and 8 with CKD 4 at baseline, with 3 patients progressing from 
stage 3 to 4 and 1 to stage 5 CKD, requiring dialysis.
13 out of 29 patients were dead at the end of study.
Conclusions: From this study of patients with ARAS not indicated for PRAS, only 
a small number progressed to higher grades of CKD. Blood pressure control appeared 
adequate in a significant proportion of patients. This is in keeping with the findings from 
ASTRAL/CORAL trials and may be of significant benifit in terms of cost and reducing 
patient morbidity.
PUB202
Clinical, Laboratorial and Immunological Characteristics of Membranous 
Nephropathy in Kidney Transplantation Patients  Artur Quintiliano Silva, 
Juliana Busato Mansur, Marisa Petrucelli Doher, Gianna Mastroianni-kirsztajn. 
Dept of Nephrology, UNIFESP, Sao Paolo, Brazil.
Background: Membranous nephropathy (MN) is one of the more common causes of 
nephrotic syndrome in the adult population and may occur in the transplanted kidney. The 
goal of this study was to describe clinical and laboratorial characteristics of membranous 
nephropathy in kidney transplantation patients. A total of 41 patients was studied. The first 
proteinuria was with 48 months and time at diagnosis was 57.9 months. Eleven patients had 
a secondary cause of MN. Independently of the immunosuppressive regimen occurred MN.
Methods: The characteristics evaluated were graft survival, time to onset of 
symptoms, patient profiles, treatment evolution , time from onset of symptoms to graft 
loss, immunosuppression used before and after the diagnosis of membranous nephropathhy 
post transplant (MNPT), blockers of the renin-angiotensin-aldosterone system, proteinuria 
levels and time of biopsy x beginning of the onset of symptoms with disease progression.
Results: The mean age of the receptor was 49.4 years and 58.5% were males. The most 
common comorbidities were HBP (96.7%), dyslipidemia(22%), neoplasia (12.2%), diabetes 
(9,1%), SLE (7.3%) and hepatitis (7.3%). Induction therapy to prevent acute rejection 
during the early post transplant period was used in 9 (21.9%) patients (8 antithymocyte and 
1 basiliximab) followed up by initial imunossuppression with PRED+CNI+AZA (56.1%) 
and PRED+CNI+MPA (34.1%).The end imunossuppression was Pred+CNI+AZA (29.2%), 
Pred+CNI+MPA (41.1%).Secondary MN causes had a more benign course (graft function) 
than the primary causes. Death censored graft survival in 10 years was 58.6%.
Conclusions: About 50% of grafts which develop de novo MGN eventually fail. This 
rather poor outcome may not represent the natural history of de novo MGN per se but 
rather the consequences of associated chronic rejection. Evidence is presented that many of 
the cases of so-called de novo MGN may be a complication of transplant glomerulopathy 
rather than being caused by mechanisms totally independent from rejection. The beneficial 
effects of immunosuppression agents have not been validated.
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PUB203
Factors Influencing Initiation and Choice of Immunosuppressive Therapy 
in Primary FSGS  Louis-Philippe Laurin,1 Bethany J. Foster,4 A. Gasim,2 
Caroline J. Poulton,3 J. Charles Jennette,2 Ronald J. Falk,3 Patrick H. Nachman.3 
1Div of Nephrology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; 
2Dept of Pathology and Laboratory Medicine, Univ of North Carolina at Chapel 
Hill, Chapel Hill, NC; 3Div of Nephrology and Hypertension, Univ of North 
Carolina at Chapel Hill, Chapel Hill, NC; 4Div of Nephrology, McGill Univ 
Health Center, Montreal, QC, Canada.
Background: The treatment of patients with primary focal segmental glomerulosclerosis 
(FSGS) may include immunosuppressive therapy in patients not responding to conservative 
treatment or considered at high risk of progression to renal failure. We sought to determine 
the patient and disease characteristics associated with choice of therapy early in disease 
course.
Methods: Inception cohort of biopsy-proven patients with primary FSGS diagnosed 
between 1980 and 2012. Factors influencing choice of therapy were identified using 
multiple logistic regression; we report odds ratios (OR) with 95% confidence interval (CI).
Results: 458 patients were studied (183 on no immunosuppressives; 173 treated with 
glucocorticoids [GC] alone; 90 with calcineurin inhibitors [CNIs] ± GC; 12 with other 
immunomodulatory agents). 
No immunosuppression
N=183
Immunosuppression
N=275
Median age (yr) 48 (32-63) 36 (18-55)
Female sex (%) 48.1 49.1
Black race (%) 45.1 45.9
Median eGFR (mL/min/1.73m2) 43.8 (27.2-69.9) 62.8 (41.7-85.7)
Median proteinuria (g/d) 3.8 (2.4-6.6) 6.0 (3.5-12.0)
Tip lesion variant (OR 3.00; 95% CI 1.23-7.32), eGFR ³30 mL/min/1.73m2 (OR 1.89; 
95% CI 1.01-3.45) and hypoalbuminemia (OR 2.22 per g/dL lower; 95% CI 1.59-3.13) 
were associated with a higher likelihood of any immunosuppressive treatment. Only tip 
lesion was associated with choice of GC alone vs. CNIs (OR 0.17; 95% CI 0.05-0.53).
Conclusions: Presence of tip lesion, preserved renal function at baseline and more 
severe hypoalbuminemia are associated with immunosuppressive therapy in primary FSGS, 
but only tip variant appears to influence choice of GC alone over CNIs.
PUB204
A Performance-Enhancing Drug and Its Depressing Effects  Wajdi Bader. 
Internal Medicine, John Stroger Hospital of Cook County, Chicago, IL.
Background: Anabolic steroid use is a habit with a global 3.3% lifetime prevalence rate 
and is well known for its adverse effects on the renal, endocrine, hepatic, and hematologic 
systems. We bring a case of focal segmental glomerular sclerosis (FSGS) in a known user 
of anabolic steroids.
Methods: A previously healthy 28 year old male had presented to our hospital after 
being told he had kidney damage during a recent routine check up. On presentation, he 
complained of generalized weakness of one month’s duration; the social history was 
significant for use of Mutant Plexx, a bodybuilding supplement that contained an anabolic 
steroid, methylstebolone. On admission, his vitals were pertinent for a blood pressure of 
189/109 and a heart rate of 82. His physical exam noted a muscular male with normal 
cardiovascular, respiratory, and abdominal exams. On labs the patient had a BUN of 59, 
a creatinine of 5.6, and a hemoglobin of 13.1. A urinalysis showed 1 WBC, 2 RBCs, and 
1+ protein. Nephrology team was consulted for further workup. Urine microscopy was 
performed and showed no dysmorphic RBCs. Spot urine protein/creatinine ratio was 2.2 
grams. HIV was negative; HBsAg, HBsAb, and hepatitis C antibody were negative. Three 
days into his admission, the patient had an ultrasound guided kidney biopsy. On biopsy, 
half of the glomeruli had segmental scars, some with collapsing features. The interstitium 
had areas of fibrosis and the arteries showed mild sclerosis and arterioles with hyalinosis. 
The patient was diagnosed with collapsing FSGS secondary to anabolic steroid use; he 
was educated on control of hypertension and was advised to stop using anabolic steroids.
Conclusions: FSGS, the third most common cause of nephrotic syndrome after 
minimal change and membranous nephropathy, is usually attributed to HIV or obesity. 
The pathophysiologic cause of FSGS secondary to anabolic steroids is thought to be due to 
intraglomerular hypertension. In addition, high protein diets are known to cause an elevation 
in glomerular pressure. Collapsing FSGS is most common variant in anabolic steroid users, 
and is associated with the poorest prognosis. The treatment is discontinuation of steroid 
use and control of hypertension, preferably with an ACEi or ARB.
PUB205
Uric Acid Is Independet Risk Factor for Progression of Renal Dysfunction in 
IgA Nephropathy Female Patients  Yasuyuki Nagasawa,1 Ryohei Yamamoto,2 
Maki Shinzawa,2 Sayuri Kawada,1 Katsuyuki Nagatoya,3 Aritoshi Kida,1 Tatsuya 
Shoji,4 Yukiko Hasuike,1 Terumasa Hayashi,4 Takahiro Kuragano,1 Atsushi 
Yamauchi,3 Yoshitaka Isaka,2 Takeshi Nakanishi.1  1Dept of Internal Medicine, 
Div of Kidney and Dialysis, Hyogo College of Medicine, Nishinomiya, Hyogo, 
Japan; 2Dept of Nephrology and Geriatric Medicine, Osaka Univ, Suita, Osaka, 
Japan; 3Dept of Internal Medicine, Osaka Rousai Hospital, Sakai, Osaka, Japan; 
4Dept of Nephrology, Osaka General Hospital, Osaka, Japan.
Background: Ig A nephropathy is one of common primary glomerulonephritis. 
Hyperuricemia could be caused by reduced renal function. Therefore, it was difficult to 
distinguish hyperuicemia from the factors which promote renal dysfunction. Recently, 
several reports indicated that hyperuricemia might be independent risk factor for renal 
worsening, but there was little information about the effect of hyperuricemia itself upon 
progression of kidney diseases, especially in IgA nephropathy patients. Aim is to reveal 
effect of uric acid upon renal prognosis in IgA nephropathy patients.
Methods: This study is retrospective cohort study. Subjects were 923 IgA nephropathy 
patients who had not been treated uric acid lowering drugs, from 1001 IgA nephropathy 
patients who were diagnosed by renal biopsy, and over 15 years old in Osaka University 
Hospital, Osaka general medical center, Osaka Rosaki Hospital. Outcome was 1.5 times 
of serum creatinine. Exposure is uric acid at renal biopsy. Explanatory variables included 
sex, age, BMI, blood pressure, baseline eGFR, proteinuria, smoking status.
Results: Mean age was 34[23-46] years, proteinuria was 0.40[0.18-0.89] g/day. Uric 
acid was 6.5+-1.3mg/dl in male patients, and 4.8+-1.3mg/dl in female patients. Multivariate 
Poissaon regression analysis revealed that uric acid was significant risk for progression of 
renal disease [Hazard Ratio 1.30[1.01-1.65] UA per 1mg/dl] in female patients along with 
proteinuria(g/day) [HR 1.27[1.08-1.47],p<0.001], Creatinine (mg/dl) [HR 2.73[1.84-3.74]]. 
In male patients, uric acid was not independent risk factor.
Conclusions: Hyperuricemia is independent risk for progression of kidney disease in 
female IgA nephropathy patients.
PUB206
Long-term H.P. Acthar® Gel Treatment of Relapsing Idiopathic 
Membranous Glomerulopathy: A Case Study  Firas Marayati.  Southwest 
Kidney Inst, Gilbert, AZ.
Background: Long-term treatment with H.P. Acthar® Gel (repository corticotropin 
injection, Questcor Pharmaceuticals, Inc., Hayward, CA), an FDA-approved treatment for 
remission of proteinuria associated with nephrotic syndrome, was examined in a patient 
with biopsy-confirmed idiopathic membranous glomerulopathy (iMN).
Methods: A retrospective clinical record review examined Acthar Gel treatment over 
2 years and 8 months in a patient with iMN who received prescription-based treatment in a 
clinical practice. Outcomes included proteinuria level (mg/g), serum creatinine (SCr), serum 
albumin and treatment-related side effects. Complete remission was defined as proteinuria 
<500 mg/g. Partial remission was defined as ≥50% reduction in proteinuria from baseline 
and proteinuria 500-3500 mg/g.
Results: The 54-year-old Vietnamese patient with iMN was treated over 7 years. At 
diagnosis, the patient’s proteinuria was 8000 mg/g, SCr 0.7 mg/dL, and serum albumin 2.1 g/
dL. Initial treatment included prednisone, cyclosporine, mycophenolate mofetil, tacrolimus, 
and rituximab over 4.5 years. The patient showed partial or complete remissions followed 
by relapse. At Acthar Gel initiation, proteinuria was 3400 mg/g, SCr 0.6 mg/dL, and serum 
albumin 4.2 g/dL. The patient did not tolerate 80 U twice weekly but did tolerate 40 U 
twice weekly. At 4 months, she showed complete remission (proteinuria <150 mg/g). Dose 
reduction to 20 U twice weekly resulted in relapse 7 months later (proteinuria 2300 mg/g). 
Dose increase to 40 U twice weekly led to complete remission 4 months after that. Loss of 
insurance and cessation of Acthar Gel for 4 months led to relapse (proteinuria 7700 mg/g). 
Acthar Gel was re-started at 32 U twice weekly followed by 24 U twice weekly. Partial 
remission occurred 4 months later (proteinuria 2100 mg/g) with greater improvement at 10 
months (proteinuria 800 mg/g). The patient has maintained partial remission (proteinuria 970 
mg/g) 4 months post-therapy. Side effects over the course of Acthar Gel therapy included 
fatigue, myalgia, hyperglycemia, and weight gain.
Conclusions: Long-term treatment with H.P. Acthar Gel may help meet an important 
treatment need in patients with treatment-resistant and frequently-relapsing iMN.
Funding: Pharmaceutical Company Support - Funding for editorial support provided 
by Mallinckrodt Pharmaceuticals.
PUB207
Outcome of Steroid Dependent (SDNS) and Frequent Relapsing Nephrotic 
Syndrome (FRNS) in Children  Isabel Roberti, Shefali Vyas.  Children’s Kidney 
Center, Saint Barnabas Medical Center, Livingston, NJ.
Background: Management of SDNS and FRNS in children can be frustrating. With 
the goal of minimizing steroid toxicity while achieving a sustained remission multiple 
regimens have been used with variable resullts. We reviewed our cases of SDNS/FRNS 
who had kidney biopsy (Bx) after failing MMF, for the past 12 yrs.
Methods: Charts of children with Bx due to SDNS or FRNS (after failure of MMF) 
were reviewed. Congenital and secondary causes of NS were excluded. Demographics, 
medications, side effects and response to therapy were studied. IV cytoxan (CYP) was 
considered in non-FSGS cases with suspected non-adherence (800 mg/m2/dose monthly 
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x 3). Others received tacrolimus (TAC) (0.1mg/kg BID; trough up to 6 ng/ml). Rituximab 
(7o5mg/m2 x 2 doses IV) was given if child became TAC dependent or resistant. Response 
to therapy was classified as: complete remission (CR), partial remission (PR), infrequent 
relapse (IR)(<2/yr), failure (F).
Results: 32 children had kidney biopsy (Bx) for primary SDND/FRNS. 14 females; 
14 H, 10 AA, 6 C, 2 other race. Age at presentation: 2-14 yrs (median= 3 yrs). Bx: 15 
MCNS (4 diagnosed later with FSGS), 9 IgMN, 5 FSGS, 3 C1QN, 1 idiopathic immune 
mediated GN. All children had normal GFR at the time of the bx. 24 children received 
TAC: 21 CR (13 became TAC dependent with IR), 2 PR, 1 F; 15 received CYP: 6 CR, 9 
F (4 had initial diagnosis MCNS but later bx had FSGS); 7 received rituximab: all had 
CR (5 IR). The rates of CR were significantly higher for TAC (87.5%) and rituxan (100%) 
as CYP had a failure rate 60% (p<0.01), including 4 cases with MCNS. However, those 
who had CR from CYP didn’t have further relapses. Rate of IR among those who initially 
had CR was similar between rituximab and TAC. Follow-up time: 2-12 yrs (median= 4 
yrs), including 6 discharged due to stable CR and 3 ESRD (all with FSGS). Side effects: 
4 AKI with TAC (reversible), 2 respiratory distress/allergy in rituximab group (IV D/C). 
Late TAC resistance was seen in 3 patients.
Conclusions: Children with SDND/FRNS despite failure to respond to MMF had an 
excellent outcome. Some required sequencial use of tacrolimus and rituximab after failure 
of CYP with a rate of CR/IR >88% with minimal side effects.
PUB208
Granulomatosis with Polyangiitis (GPA) versus Sarcoidosis  Sruthi Jinna,1 
Sami S. Zarouk.2  1Internal Medicine, Beaumont Health, Royal Oak, MI; 
2Nephrology, Beaumont Health, Royal Oak, MI.
Background: An African American male was diagnosed at age 18 with GPA by 
kidney biopsy with negative serology. He was treated with intravenous cyclophosphamide 
and steroids. Four months post treatment a repeat kidney biopsy showed focal segmental 
glomerulosclerosis (FSGS). At age 25, he presented with fever, fatigue and cough for few 
weeks, chronic postnasal drip with bloody secretions, nausea, vomiting, and 40-pound 
weight loss in the last two months.
Methods: His BUN was 18 mg/dl, and creatinine 1.33 mg/dl. Urinalysis showed 3+ 
blood, 2+ protein, over 100 RBCs, 10 WBCs. Serology for Hepatitis B and C, HIV, EBV 
and CMV were negative. Antinuclear antibody, anti-neutrophil cytoplasmic antibody, anti 
dsDNA antibody, smith antibody, RNP antibody, myeloperoxidase antibody, proteinase 
3 autoantibody, anti SSA antibody, anti SSB antibody, and complement levels were 
negative. An angiotensin converting enzyme (ACE) level was 81 U/L (8-52). A chest 
Computed Tomography scan showed mediastinal, hilar lymphadenopathy, and multiple 
pulmonary nodules.
Results: Suspicion for relapsing GPA prompted renal biopsy. It showed 3 out of 13 
glomeruli with pauci-immune crescentic glomerulonephritis. There were extensive non-
caseating granulomas in the interstitium with interstitial fibrosis and associated tubular 
atrophy. No microorganisms were noted on AFB and PAS stained sections. Nasal septum 
biopsy showed non-necrotizing granulomatous inflammation. Mediastinal lymph node 
biopsy showed necrotizing granulomatous lymphadenitis. These 3 biopsy sites were 
consistent with sarcoidosis.
Conclusions: This case highlights the difficulty in differentiating between ANCA 
negative GPA versus sarcoidosis as both can cause granulomatous lesions. Glomerular 
involvement in sarcoidosis can show membranous glomerulonephritis, FSGS and rarely 
a crescentic glomerulonephritis. In our opinion, high ACE level combined with extensive 
presence of non-caseating granulomas in the nasal septum, mediastinal nodes and renal 
interstitium are more characteristic of sarcoidosis. He responded well to steroids and his 
urine sediment became inactive, which is in favor of sarcoidosis and not GPA.
PUB209
Epidemiology of  Glomerulonephrit is  in  Southern Arizona 
Benjamin Kwesi Sarsah, Irfan K. Moinuddin, Bijin Thajudeen, Amy Nicole 
Sussman, Pradeep V. Kadambi.  Nephrology, Univ of Arizona, Tucson, AZ.
Background: Knowledge about the incidence and prevalence of GN and its regional 
trends are mandatory for health care planners to adopt measures for preventing patients 
with glomerular disease from progression to dialysis. The aim of the study was to look at 
the patterns of biopsy proven non-diabetic glomerulopathy in Southern Arizona.
Methods: Renal biopsy specimens from adult patients above the age of 18 years 
with glomerular renal disease were included. Renal transplant biopsies showing 
glomerulonephritis and biopsies showing co-existing diabetic nephropathies were excluded. 
Histological diagnoses were grouped into one of the following 8 categories: minimal change 
disease, FSGS, membranous nephropathy,membrane-proliferative glomerulonephritis, 
pauci-immune glomerulonephritis, IgA nephropathy, lupus nephritis and others. 
Demographic parameters were systematically collected from the medical records archive.
Results: The most common histopathological diagnosis was FSGS followed by 
membranous nephropathy and IgA nephropathy. There was male preponderance in 
all histological variants except IgA nephropathy, lupus nephritis and pauci-immune 
glomerulonephritis. The race distribution was uneven, and all histological variants except 
minimal change disease and lupus nephritis were more commonly seen in whites. In separate 
analysis of the histological pattern in Hispanics, lupus nephritis was found to be the most 
common pathology followed by FSGS. In American Indian population the most common 
pathology was IgA nephropathy followed by FSGS. Bar diagram represents frequency of 
each glomerular disease
Conclusions: This survey highlights the histopathological patterns of glomerular 
disease in southern Arizona. The data suggest regional and ethnic variations in glomerular 
disease that may suggest genetic or environmental influence in the pathogenesis of 
glomerular diseases.
PUB210
Use of Rituximab to Induce Remission in Frequently Relapsing Pediatric 
Nephrotic Patients  Jason Peter Thomas,1 Teri L. Crumb,2 Alejandro Quiroga.2 
1Pediatrics, Helen DeVos Children’s Hospital, Grand Rapids, MI; 2Pediatric 
Nephrology, Helen DeVos Children’s Hospital, Grand Rapids, MI.
Background: Rituximab has been shown to be effective in patients with frequent 
relapsing nephrotic syndrome (NS) with a reported 82% response rate. We evaluated the 
clinical response of pediatric nephrotic patients for induction of remission following one 
dose of rituximab.
Methods: This is an IRB approved, prospective clinical research trial. Informed 
consent was obtained from each family. Four pediatric patients with NS were enrolled 
prior to their clinically indicated rituximab infusion. Urine Protein/Creatinine ratio and 
albumin blood levels were collected.
Results: Urine Protein/Creatinine ratios obtained post infusion of rituximab decreased 
between 37-93% from pre infusion levels. 50% of patients identified had resolved edema 
noted on physical exam post infusion.
Conclusions: Rituximab may be an effective agent for inducing remission for pediatric 
patients with frequently replapsing nephrotic syndrome. 50% of patients had clinical 
response on physical exam post infusion and 100% of our patients had a decrease in the 
amount of protein excreted in their urine. The use of rituximab for the induction of remission 
is a novel and innovative treatment option for children with frequently relapsing nephrotic 
syndrome, warranting further investigation.
Funding: Private Foundation Support
PUB211
Lupus Nephritis: An Exploration of Management Style  Abhishek Nandan, 
Huzaefah J. Syed, Christen Vagts, Jason M. Kidd.  Internal Medicine, Virginia 
Commonwealth Univ Medical Center, Richmond, VA.
Background: We aim to evaluate the differences and rationale behind the diagnostic 
and therapeutic approaches to proliferative lupus nephritis (LN) among nephrologists and 
rheumatologists.
Methods: A de-identified, multiple-choice survey was distributed to nephrologists 
and rheumatologists. The survey consisted of a demographic questionnaire and two case 
vignettes exploring the decision of when to biopsy, management of ISN Class III LN, and 
management of refractory ISN Class IV LN.
Results: There were 38 respondents to our survey: 12 rheumatologists and 26 
nephrologists. Work setting: 81% academic, 19% non-academic. Management of abnormal 
UA findings in an asymptomatic lupus patient: 33% of rheumatologists versus 76% of 
nephrologists chose to biopsy. Induction regimen of ISN Class III LN: 79% of all providers 
chose MMF and 21% chose IV cyclophosphamide. 
Choice of Induction Regimen in ISN Class III LN per Specialty
Mycophenolate Mofetil IV Cyclophosphamide Total
Nephrology 18 8 26
Rheumatology 12 0 12
Total 30 8 38
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Maintenance regimen of ISN Class III LN: all surveyed rheumatologists chose MMF 
as a sole maintenance agent compared to 32% of nephrologists who elected the addition 
of low-dose corticosteroids to MMF. Choice of an adjunctive agent in refractory ISN Class 
IV LN: 68% of providers chose rituximab, 14% chose tacrolimus, 5% chose CTLA-4 IgG, 
and 14% elected not to add any agents listed.
Conclusions: The results of this survey suggest a significant difference among 
rheumatologists and nephrologists on the decision to perform initial kidney biopsy and 
management of ISN Class III LN. The results suggest that perception of side effect profiles 
play an important role in the choice of therapeutics. This study emphasizes the need for a 
multi-disciplinary approach toward renal disease in lupus patients. We continue to recruit 
subjects to complete this survey.
PUB212
Maintenance of Proteinuria Treatment Response to H.P. Acthar 
Gel® in Patients with Nephrotic Syndrome: A Follow-Up Case Series 
Anupa Khastgir,1 Geoffrey S. Teehan.2  1Nephrology Practice, Oklahoma City, 
OK; 2Lankenau Medical Center, Wynnewood, PA.
Background: The duration of proteinuria response to H.P. Acthar® Gel (repository 
corticotropin injection, Mallinckrodt Brand Pharmaceuticals, Inc., Hazelwood, MO) 
treatment is not yet known. The current case series examined maintenance of proteinuria 
response in 7 patients who were included in a previously presented case series of Acthar 
Gel treatment of treatment-resistant NS in clinical practice.
Methods: Five patients with partial remission (500-3500 mg/d proteinuria and ≥50% 
reduction from baseline), 1 patient with clinical response (³30% reduction without meeting 
remission criteria), and 1 patient with clinical response and ongoing treatment following 
initial prescription-based Acthar Gel treatment for NS, and who had follow-up clinical 
care, were included. Medical charts were reviewed for proteinuria levels. Follow-up 
ranged from 2 to 19 months.
Results: Biopsy-confirmed NS etiological diagnoses included focal segmental 
glomerulosclerosis (FSGS, n=3), membranous lupus nephritis (MLN, class V, n=2), 
membranoproliferative glomerulonephritis (MPGN, n=1), and diabetic nephropathy (DN, 
n=1). 5/5 patients (2 FSGS, 2 MLN, 1 MPGN) with initial partial remission maintained 
partial remission during the follow-up period from a minimum of 2 months up to 19 months 
post-Acthar Gel treatment. The patient with MPGN and 1 with FSGS showed increased 
proteinuria with relapse at 12 months and 19 months post-treatment, respectively. The 
patient with DN received ongoing Acthar Gel treatment and maintained a proteinuria 
clinical response during the 11-month follow-up period. The patient reported fatigue but 
did not require cessation of Acthar Gel treatment. The patient with FSGS who showed 
an initial clinical response had further improved proteinuria at 2 months post-Acthar Gel 
treatment and showed partial remission at 12 months post-therapy without intervening 
immunosuppressive medications.
Conclusions: These follow-up proteinuria outcomes in 7 patients treated with H.P. 
Acthar® Gel for varied etiology NS suggest the proteinuria treatment response can be 
maintained long-term in some patients during treatment and beyond treatment cessation.
Funding: Pharmaceutical Company Support - Funding for editorial support provided 
by Mallinckrodt Pharmaceuticals.
PUB213
Pauciimmune Glomerulonephritis with Immune Deposits: A 
Clinicopathologic Outcome Study  Benjamin Kwesi Sarsah, Irfan K. 
Moinuddin, Bijin Thajudeen, Amy Nicole Sussman, Pradeep V. Kadambi. 
Nephrology, Univ of Arizona, Tucson, AZ.
Background: The clinical impact of the immune complexes in pauciimmune GN 
remains unclear. The objective of this study is to compare the clinical outcome of patients 
with pauci-immune GN and positive ANCA in the presence and absence of immune deposits 
on immunofluorescence.
Methods: Cases of pauci-immune GN were identified retrospectively from the archives 
of native renal biopsies. For inclusion in the study the cases have to meet the following 
criteria 1) should have full spectrum of histopathological analysis 2) complete follow 
up information in the chart 3) ANCA positivity 4) negative serologies 5) EM showing 
absent or scant immune deposits 6) absence of comorbidities 7) absence of co-existing 
histopathological diagnosis 8) less than 25% glomerulosclerosis. Patients’ medical records 
were reviewed for age, race, gender, parameters of renal function, treatment, and outcome.
Results: Two groups- group which had immune deposits (group 1) and group with no 
immune deposits(group 2).All patients in group 2 had complete or partial improvement in 
renal function. None of them were dialysis dependent at any stage of their treatment. On 
the contrary in group 1, four patients required hemodialysis. (36% vs 0%, p value =0.0001). 
The group with immune deposits presented with higher mean creatinine (5.10±3.27 mg/
dl vs 3.67±1.03 mg/dl, p value 0.195). Relevant demographic,lab and histologic variables 
are represented in table 1.
Variable
Positive immune 
deposits
N=11 ( group 1)
Negative immune 
deposits
N=8 ( group 2)
P value
Age (mean±SD) (years) 54.82±21.27 57.75±19.54 0.76
Gender (M/F) 4/7 2/6 0.12
Race (W/H) 6/5 7/1 0.0001
Initial creatinine mg/dl 5.11±3.27 3.67±1.03 0.19
ANCA(P/C) 9/2 7/1 0.33
Crescents (>50/<50) 4/7 3/5 0.88
TIF(mild/mod-severe) 6/5 2/6 0.0001
Type of crescents (C/CF,F) 7/4 1/7 0.0001
Conclusions: Pauciimmune GN with immune deposits has poorer prognosis compared 
to those without immune deposits. Pauciimmune GN with immune deposits likely represent 
patients with severe immune complex deposition and partial clearance of immune complex. 
These are patients who might benefit from plasmapheresis in addition to standard treatment.
PUB214
Eosinophilic Pneumonia with Renal Involvement  Gabrielle Goldet,1 Rachel 
Hung,1 Michael Sheaff.2  1Basildon and Thurrock Univ Hospital; 2Pathology, 
Barts and the London School of Medicine.
Background: Eosinophilic pulmonary renal syndromes are well established and can 
be either vasculitic or infectious in aetiology. We describe a novel case of a patient whose 
presentation could not be fitted into either category.
Methods: A fifty year old male presented with increasing weight loss, night sweats 
and shortness of breath of 3 months duration. Additionally he noted some swelling of his 
lower limbs and frothy urine. He was extensively investigated with urinalysis, blood tests, 
imaging and histopathology till a novel diagnosis was made.
Results: The patient was found to have nephrotic range proteinuria with stable renal 
function, He had multifocal consolidation on computed tomography of the lungs and 
eosiniphilic infiltrates on lung histology. A kidney biopsy revealed dense subcapsular 
inflammatory cell infiltrate including eosinophils with possible subendothelial depostits on 
light microscopy. A vasculitic screen excluded vasculitis as the underlying pathology and no 
signs of vasculitis were seen on either the lung or kidney biopsies. Additionally filiarisis was 
excluded with negative serology. The patient was treated with steroids and his pulmonary 
and systemic symptoms resolved. Unfortunately, he has been found to relapse when an 
attempt at a steroid wean was made and is thus maintained on a low dose of prednisone.
Conclusions: We describe a novel pulmonary-renal syndrome and provide an approach 
to its investigation and management. This case opens the way for further research into 
eosinophilic pulmonary-renal syndromes.
Funding: Government Support - Non-U.S.
PUB215
Role of Remission of in Idiopathic Membranous Nephropathy on Long Term 
Renal Function Outcome  Abdulkareem Alsuwaida,1 Hala M. KFoury,2 Sufia 
Husain,2 Tariq Aljohani,2 Saad S. Alobaili,1 Mohammed A. Al-Ghonaim,1 Jamal 
S. Al Wakeel.1  1College of  Medicine, King Saud Univ, Riyadh, Saudi Arabia; 
2College of Medicine, King Saud Univ, Riyadh, Saudi Arabia.
Background: Heavy proteinuria is considered a poor prognostic marker among patients 
with idiopathic Membranous Nephropathy (iMN). However, the impact of the remission 
status on the renal out come in patients with iMN is not well studied. The purpose of this 
study was to evaluate the long-term prognosis after achieving a complete or partial remission 
among patients with iMN presenting with heavy proteinuria.
Methods: In this study, 25 patients with IMN with heavy proteinuria defined as ≥ 6 
gm per day were evaluated for the effect of a partial remission (50% reduction in baseline 
proteinuria to ≤ 3 g/d and ≤ 25% increase in baseline creatinine) and complete remission 
(proteinuria ≤ 0.5 g/d and serum creatinine £123 µmol/l) on renal outcomes compared 
with patients who did not attain a remission. Worse renal outcomewas defined as doubling 
of the baseline serum creatinine value or development of end-stage renal disease at the 
last follow up.
Results: The cohort consisted of 20 men and 5 women. The median proteinuria at 
presentation was 9.4 gm per day (IQR: 6.7-12.1 gm per day) and the median of follow up 
duration was 7.0 years. The median base line creatinine was 91µmol/l (IQR: 74-98 µmol/l). 
A complete remission was attained in 7 (28%) patients, a partial remission in 12 (48%) 
patients, and no remission in 6 (24%) patients. The worse renal outcome was not observed 
in all patients who achieved complete remission, but it was seen in 16.7% of the partial 
remission group and in 66.7% of the no remission group (P value 0.14).
Conclusions: Achieving a complete or partial remission compared to no remission in 
patients with iMN is associated with a significantly better renal outcome.
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Comparison of Short- and Long-Term IgA Nephropathy Clinical Remission 
Rates Between Tonsillectomy plus Consecutive and Intermittent Steroid 
Pulse Therapies  Kazuhiro Yoshikawa, Izaya Nakaya, Karen Kato, Yuta Tezuka, 
Satoshi Kumakura, Jun Soma.  Div of Nephrology, Iwate Prefectural Central 
Hospital, Morioka, Iwate, Japan.
Background: Tonsillectomy (Tx) plus steroid pulse therapy (TSP) is widely performed 
across Japan for clinical remission (CR) of IgA nephropathy (IgAN) but treatment protocol 
lacks consensus. We used both TSP (methylprednisolone at 0.5 g/day iv for 3 days*) 
thrice/3 consecutive weeks (TSP-C) and intermittent pulse (*) thrice/6 months (TSP-I). 
Oral prednisolone (oPSL) between pulse therapies began at 0.5 mg/kg on alternate days. 
After the third pulse, oPSL was tapered over 1 and 0.5 years in TSP-C and TSP-I groups, 
respectively. Tx was performed before or during steroid therapies. We compared the effects 
of two regimens for CR.
Methods: This is a retrospective cohort study of 169 patients newly diagnosed with 
IgAN during January 2007 to December 2013 in our institute. We enrolled 90 patients we 
could follow to oPSL cessation and compared short- and long-term CR rates in both groups. 
CR was defined as urine protein < 0.3 g/gCr and urinary red blood cells < 5/high-power field.
Results: Before treatments, there were no significant clinical [TSP-C (n = 57) vs. TPS-I 
(n = 33): age, 31.0 ± 11.2 vs. 34.0 ± 11.9 years; male:female, 17:40 vs. 12:21; eGFR, 82.2 ± 
29.9 vs. 77.4 ± 28.7 mL/min; blood pressure, 121 ± 17/72 ± 12 vs. 120 ± 17/76 ± 13 mmHg; 
urinary protein, 0.41 (0.18, 1.19) vs. 0.79 (0.20,1.08) g/gCr; and positive occult blood, 91.2 
vs. 90.9%] and histological grade stratification differences between the groups. At oPSL 
cessation, short-term CR rates were equivalent between the groups [TSP-C vs. TPS-I: 68.4 
vs. 61.0%]. Long-term CR rates at 1, 2, and 3 years after oPSL cessation were equivalent 
between the groups [TSP-C vs. TPS-I: 1 year, 64.1 (n = 39) vs. 59.1% (n = 22); 2 years, 
64.0 (n = 25) vs. 80.0% (n = 10); 3 years, 73.7 (n = 19) vs. 66.7% (n = 6)]. CR continuation 
rates by Kaplan–Meier method also revealed no significant differences between the groups.
Conclusions: Tx plus either consecutive or intermittent steroid pulse therapies may be 
equally beneficial for short- and long-term IgAN CR. IgAN patients can flexibly choose 
therapies.
PUB217
Clinical Characteristics of Multiple Myeloma Patients Diagnosed by 
Nephrologist  Byoung Geun Han, Jae seok Kim, Hyeon-Cheol Park, Shinhan 
Song, Jae Won Yang, Seung-Ok Choi.  Internal Medicine, Yonsei Wonju College 
of Medicine, Wonju, Korea.
Background: Early diagnosis of multiple myeloma (MM) that is in early phase or 
has atypical presentation may be difficult. Even though MM is a hematologic malignancy, 
clinicians in different departments can make a diagnosis with a suspicious eye. In our 
department, we routinely performed protein electrophoresis in the patients with renal 
failure for the early diagnosis of MM.
Methods: We reviewed the medical records of 151 patients and examined the data of 
117 patients diagnosed with MM in our hospital between January, 2003 and December, 
2014. The patients were divided into three groups: group I presented to nephrologist prior 
to diagnosis (n=31), group II presented to hemato-oncologist directly (n=53), and group 
III presented to the other departments of our institute. The age, sex, initial symptoms, 
hematologic and biochemical parameters, and survival data were retrospectively analyzed.
Results: The main findings were anemia (n=30), renal failure (n=25), back pain 
(n=17), paraproteinemia (n=10), rib pain (n=7), mass (n=7), proteinuria (n=7), fracture 
(n=5), infection (n=4), bleeding (n=3), etc. Osteolytic bone lesion, survival rate, % of 
plasma cell in bone marrow study, Hb, platelet, CRP, serum albumin and calcium were not 
significantly different between three groups. 24 hours urine study (amount of proteinuria, 
protein-albumin ratio, protein-creatinine ratio) did not show any differences. Beta-2 
microglobulin and serum uric acid were significantly higher in group I than those in the 
other groups (p<0.05). Immunoglobulin G, total protein, globulin, and amount of serum 
M protein were significantly lower in group I than those in the other groups (p<0.05). 
Distribution of BJ protein positive patients in group I was higher (p<0.05). ISS score was 
also higher in group I (p<0.05).
Conclusions: Multiple myeloma patients diagnosed by nephrologist did not show 
typical features of disease. Low levels of total protein and globulin in the patients with 
renal failure could be a cause of delayed diagnosis of MM. We recommend the protein 
electrophoresis should be routinely performed in the patients with renal failure.
PUB218
Screening for Renal Involvement in Newly Diagnosed ANCA-Associated 
Vasculitis Patients in Clinical Practice – Differences Between Hospital 
Departments  Eline Houben,1 Willem A. Bax,1 Bastiaan Van Dam,1 Walentina 
A. Slieker,2 Gideon Verhave,1 Fenneke C.P. Frerichs,1 Erik Lars Penne.1  1Dept 
of Nephrology, MCA-Gemini Group, Alkmaar, Netherlands; 2Laboratory 
of Clinical Chemistry, Hematology and Immunology, MCA-Gemini Group, 
Alkmaar, Netherlands.
Background: Kidney involvement occurs in a majority of ANCA-associated vasculitis 
(AAV) patients and requires early and aggressive immunosuppressive therapy. The aim 
of the present study was to evaluate screening procedures for renal involvement in newly 
diagnosed AAV patients and to identify differences between hospital departments.
Methods: All AAV patients with a positive ANCA (PR3 and/or MPO) between 2005 
and 2015 in a secondary care hospital in the Netherlands were included. Patient demographic 
data and the department making the diagnosis were recorded, as well as whether or not 
a complete screening for renal involvement had been made. The latter was defined as 
assessment of serum creatinine, analysis for erythrocyturia and proteinuria within two 
weeks before or after the diagnosis AAV.
Results: We included 110 newly diagnosed AAV patients (age 62± 14 years (mean±SD); 
63% male). 81 patients (68%) had renal involvement (defined as: rise in creatinine >30%, 
³10 RBC/hpf and/or proteinuria ≥500mg/24h). Complete screening was performed in 90 
patients (82%), depending on department: Nephrology 100% (21 of 21), Internal Medicine 
88% (29 of 33), Pulmonology 68% (15 of 22), Ear Nose Throat 62% (8 of 13), other 
departments 81% (17 of 21). Of the 20 patients with incomplete screening, assessment of 
proteinuria was missing in 100% (20 of 20), erythrocyturia in 55% (11 of 20) and serum 
creatinine in 5% (1 of 20). Serum creatinine was higher in patients with complete renal 
screening (72 versus 109 µmol/l, p=0.01). Screening was completed within 2 months (n=12), 
4 years (n=3), or never (n=5). One patient was found to have erythrocyturia 6 weeks after 
the diagnosis, but had not been treated accordingly.
Conclusions: In a substantial amount of newly diagnosed AAV patients, screening for 
renal involvement was incomplete, especially in patients with a normal creatinine level 
outside the renal department. Incomplete screening may have led to suboptimal treatment 
in some patients.
PUB219
A Case Series on the Treatment of Nephrotic Syndrome with Natural 
Adrenocorticotropic Hormone Gel in an Office Setting  Marco A. Bonilla, 
Xavier F. Parada, Mario A. Henriquez.  Nephrology, Bronx Nephrology-
Hypertension, Bronx, NY.
Background: ACTH is a promising treatment for the nephrotic syndrome, associated 
with significant improvement in proteinuria and relatively few adverse effects. We present 
our experience using natural ACTH gel for nephrotic syndrome in patients with diverse 
diagnosis.
Methods: Retrospective case series of 7 Adults patients with nephrotic syndrome, 
treated with ACTH gel. Data was gathered by chart review, from the clinic EMR and paper 
based records. ACTH was given in the form of ACTHAR gel 80 USP units/ml SC twice a 
week for 6 months. Complete remission defined as stable or improved renal function with 
final proteinuria of <500 mg/day; partial remission as stable or improved renal function 
with ≥50% reduction in proteinuria and final proteinuria 500 to 3500 mg/day. Failure to 
meet this criteria was classified as treatment failure.
Results: Table 1. Outcomes
Pa-
tient Age
Gen-
der Race Diagnosis
Previ-
ous  
immu-
nosu-
presion
eGFR  
(ml/
min/1.73 
m2)
Protein-
uria pre-
ACTH  
(mg/g)
Pro-
tein-
uria 
post-
ACTH 
(mg/g)
Out-
come
1 52 M His-panic
IgA 
nephrop-
athy
None 20 1031.2 871 Fail-ure
2 52 M His-panic MGN
Pred-
nisone, 
MMF
104 1001 290 Fail-ure
3 62 F Black MGN Predni-sone 20 1010.4 295.4
Com-
plete
4 73 M His-panic
IgA 
nephrop-
athy
None 48 2540 623 Par-tial
5 47 M His-panic FSGS
Pred-
nisone, 
MMF
48 1796 1157 Fail-ure
6 39 F His-panic
IgA 
nephrop-
athy
None 94 4000 161 Com-plete
7 42 F His-panic MGN MMF 36 17578 386
Com-
plete
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Figure 1.
Conclusions: ACTH gel is an effective therapy in patients with nephrotic syndrome, 
as significant reductions in proteinuria were seen in the majority of patients, it was not 
only patients with membranous nephropathy who responded to treatment with ACTH 
but also patients who were nephrotic due to other diagnosis such as IgA nephropathy; 
this data highlights a need of further studies on natural ACTH gel in the treatment of 
nephrotic syndrome.
PUB220
Efficacy of Rituximab in Severe Lupus Nephritis in Children: A Case Series 
Julien Hogan, Véronique Baudouin, Georges Deschenes.  Pediatric Nephrology, 
Robert Debré Hospital, Paris, France.
Background: The association of cyclophosphamide or Mycophenolate Mofetil (MMF) 
with prednisolone is the treatment of reference of lupus nephritis(LN), both in adults and 
children but is associated with major side effects. Rituximab (RTX) failed to demonstrate 
an improvement of patient outcome when associate with MMF and prednisolone. However, 
recent data suggest that it might allow to spare prednisolone. We report our experience of 
the use of RTX in first LN flair in children.
Methods: We included patients treated by RTX for a first flair of LN class III to V 
between 2006 and 2014. Treatment associated methylprednisolone (500mg/m2) followed 
by RTX (1000mg/1.73m2) at day one and 15 and MMF 1200mg/m2/day. Tapered down and 
withdrawal of prednisolone was left to each physician appreciation. Complete remission 
(CR) was defined as a proteinuria over creatininuria ratio (Pu/creat) <50mg/mmol and 
normal serum creatinine and partial remission (PR) as a Pu/creat<300mg/mmol and no 
raise of creatininemia over 15% of baseline.
Results: Seven patients were included with a median follow-up of 14.0months [6.0-
69.1]. They presented with proteinuria (median 0.24g/mmol [0.05-0.71]), hematuria and 4 
out of 7 had impaired renal function (mean GFR 78.4mL/min/1.73m2 [62.6-133.6]).Three 
had a LN stage IV, three a class IV+V and one a class III+V. Median CD20 depletion time 
was 10.0 [6-25] months. Prednisolone was rapidly tapered down, the median dose were 
0.2, 0.11, 0.05 mg/kg at 3, 6 and 12 month respectively. At 3 months, two patients achieved 
CR and three PR. Patients without remission had a nephrotic range proteinuria and no 
renal failure and had LN stage III+V and IV+V. At 6 and 12 months all patients achieved 
remission. No patient experienced renal relapse, two had an infectious complication and 
one presented a mild pancreatitis.
Conclusions: A treatment combining RTX, MMF with a rapid decrease of prednisolone 
seems efficient in severe lupus nephritis. Such protocol may be of major interest in children, 
since steroids are known to have major side effects in this population. More studies are 
needed to assess the safety and the efficacy of this treatment and to evaluate the amount 
of steroids that can be spared through this strategy.
PUB221
Clinical Prognosis of Anti-Neutrophil Cytoplasmic Antibody (ANCA) 
Negative Pauci-Immune Necrotizing Crescentic Glomerulonephritis: 
A Retrospective Cohort Study in Korea  Sung Woo Lee, Seon Ha Baek, 
Shin-Young Ahn, Sejoong Kim, Ki Young Na, Dong-Wan Chae, Ho Jun Chin. 
Seoul Nation Univ Bundang Hospital.
Background: Very few studies have reported on the prognosis of anti-neutrophil 
cytoplasmic antibody (ANCA) negative pauci-immune necrotizing crescentic 
glomerulonephritis (piNCGN).
Methods: Between July 2003 and December 2013, 48 patients were diagnosed with 
piNCGN. The ANCA status was tested using indirect immunofluorescence and enzyme-
linked immunosorbent assay. The primary and secondary outcomes were 1-year renal and 
patient survival, respectively.
Results: Among the 48 patients, 6 (12.5%) had ANCA negative piNCGN, while 42 
(87.5%) had ANCA positive piNCGN. All ANCA negative piNCGN patients were male and 
showed high proportion of protein ³3 positive with dipstick test. No significant differences 
in renal pathology, clinical manifestation, or treatment were noted between the groups. 
The trend of 1-year end stage renal disease was higher for ANCA negative than ANCA 
positive piNCGN (66.7% vs. 23.8%; p=0.052). In Kaplan-Meier estimation, ANCA negative 
piNCGN showed poorer 1-year renal survival than ANCA positive piNCGN [median (95% 
CI) 9 (0.0-51.0) vs. mean (95% CI) 287.5 (244.8-330.2) days; log-rank p = 0.010]. In Cox-
proportional hazard analysis, ANCA negativity was found to be an independent factor for 
1-year renal survival with a hazard ratio (95% CI) of 10.93 (1.03-115.94) compared to 
ANCA positivity (p=0.047). In contrast, the 1-year all-cause mortality and patient survival 
did not differ depending on ANCA status.
Conclusions: Although the proportion of ANCA negative piNCGN was not high 
in our study population, poor 1-year renal survival was noted among these patients. We 
believe that particular caution should be exercised while treating ANCA negative piNCGN.
PUB222
Clinical Implication of Serum Free Light Chain in Patients with IgA 
Nephropathy  Woo Jin Jung,1 Sang Heon Song,1 Su Min Park,1 Jong Man Park,1 
Il Young Kim,1 Dong Won Lee,1 Soo Bong Lee,1 Harin Rhee,1 Eun Young Seong,1 
Ihm Soo Kwak,1 Min Jung Kim,1 Joo Hui Kim.1  1Dept of Internal Medicine, 
Pusan National Univ School of Medicine, Busan, Republic of Korea; 2Dept of 
Internal Medicine, Pusan National Univ School of Medicine, Busan, Yangsan, 
Republic of Korea.
Background: Free light chains (FLCs) are produced in excess during immunoglobulin 
synthesis by plasma cells and other cells of the B-cell lineage. Recent studies demonstrated 
that elevated polyclonal FLCs are associated with increased mortality in chronic kidneys 
disease. But little is known about the clinical implication of FLCs in patients with IgA 
nephropathy which is caused by the overproduction of an aberrant form of IgA1 and the 
activation of B-cells responding to mucosal infection. Therefore, we investigated the 
relationship between the serum levels of combined FLCs (cFLCs) and prognostic markers 
in IgA nephropathy.
Methods: This retrospective study analyzed consecutive 42 patients with biopsy-proven 
IgA nephropathy without renal function impairment (estimated glomerular filtration rate 
(eGFR) ≥ 60 ml/min/1.73m2 ) at the Pusan National University Hospital from January 2010 
to December 2013. cFLCs was defined as a sum of kappa and lambda FLCs and clinical 
and laboratory data were collected by medical records reviewing.
Results: The mean (±SD) age were 41.4 (±14.9) years and the median (inter-quartile 
range) of cFLC and urinary protein-to-creatinine ratio (uPCR) were 40.5 (32.6 – 47.8) 
mg/L and 666.3 (364.8 – 1306), respectively. In correlation analyses, log-transformed 
cFLCs was positively related to age, serum cystatin C, IgG and log-transformed uPCR, and 
negatively associated with serum albumin and hemoglobin levels. In multivariate regression 
models, increased cFLCs was significantly associated with higher log-transformed 
uPCR(β(SE)=0.0124(0.006), p=0.045) after adjusting confounding factors. However, no 
significant association of cFLCs with pathologic classification was observed.
Conclusions: The cFLC level was independently correlated with the magnitude of 
proteinuria in patients with IgA nephropathy. Further longitudinal studies are needed to 
clarify the role of cFLC as a prognostic maker in IgA nephropathy.
PUB223
Long Term Renal Outcomes in Lupus Nephritis in a Multi-Racial Asian 
Population: A Retrospective Study  Hui Zhuan Tan, Cynthia Ciwei Lim, Jason 
Choo Chon Jun, Chan Choong Meng.  Dept of Renal Medicine, Singapore 
General Hospital, Singapore, Singapore.
Background: Lupus nephritis causes significant morbidity with racial predilection 
affecting prognosis and treatment responses. We aimed to evaluate risk factors for 
progressive CKD in lupus nephritis (LN) in a multi-racial Southeast Asian population.
Methods: We retrospectively reviewed 113 consecutive patients with newly diagnosed 
biopsy-proven LN diagnosed between 10 May 2001 to 30 May 2009. Demographics, indices 
of renal function and disease activity, histopathological data and pharmacotherapy were 
evaluated. Primary endpoint was progressive chronic kidney disease (CKD) defined by 
doubling of serum creatinine or end stage renal failure.
Results: Median age was 41.6 (IQR 29.2, 51.6) years, predominantly Chinese (76.1%) 
and female (81.4%). Twelve patients (10.6%) had Class I or II LN, 13 (11.5%) Class III 
LN, 62 (54.9%) Class IV LN and 25 (22.1%) isolated Class V LN. Eight patients (7.1%) 
had mixed proliferative and membranous LN. Most patients received either angiotensin 
converting enzyme (ACE) inhibitors or angiotensin II receptor blocker (100 patients, 
88.5%). Induction immunosuppressants included glucocorticosteroids in 109 patients 
(96.5%), cyclophosphamide 26 (23.0%), mycophenolate mofetil or mycophenolate sodium 
51 (45.1%), cyclosporine 9 (8.0%), and azathioprine 14 (12.4%). Median follow up was 
79.0 (61.5, 104.0) months. One hundred and eight patients (95.6%) achieved remission, 
with complete remission in 89 patients. Among patients who achieved remission, 61 
patients had disease relapse. Thirteen patients had progressive CKD at last clinic visit, 
with ESRD occurring in 5 patients at median 12.0 (1.0, 59.5) months from biopsy. Patients 
with progressive CKD tended to be non-Chinese (53.8% vs. 20.0%, p=0.01), with higher 
serum complements [median C3 0.66 (IQR 0.48, 0.87) vs. 0.38 (0.29, 0.60), p=0.04 and 
C4 0.17 (0.12, 0.22) vs. 0.06 (0.05, 0.12), p=0.004], fewer remissions (69.2% vs. 99.0%, 
p=0.001) and more relapses (100% vs. 52.5%, p=0.005).
Conclusions: In this multi-racial Asian cohort, race, higher serum complement levels, 
failure to achieve remission and relapses were associated with poor renal outcomes in 
lupus nephritis.
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The Clinical Predictors for Outcome of Antineutrophil Cytoplasmic 
Autoantibody-Associated Vasculitis Patients with Renal Involvement 
Pu Lei, Guisen Li, Li Wang.  Nephrology, Sichuan Academy of Medical Sciences 
& Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China.
Background: Primary anti-neutrophil cytoplasmic antibody(ANCA)-associated 
vasculitis(AAV) are chronic multisystem autoimmune diseases and result in dysfunctions of 
multisystem. Renal involvement is the most common manifestation and is closely associated 
with the outcome of patients with vasculitis. We investigated the clinical determinants of 
the early mortality of patients with vasculitis-related renal injury followed up 2 years in a 
single west Chinese center to study the factors associated with patient outcome.
Methods:  A  total  of  123  consecutive  patients  with  AAV-related renal injury 
diagnosed  in  our  center  were  recruited. Clinical  and  laboratory  data  were  collected 
retrospectively. All the patients were followed up for 2 years after diagnosis. The  predictive 
values  of  variables associated  with  mortality  were  analyzed.
Results:  During 2 years follow up duration, 54 (43.9%) died, of whom 41 diedwithin 
the first 12 months after diagnosis. Compared with surviving patients, the deceased patients 
had higher BVAS scores and higher incidence of pulmonary hemorrhage. They also had 
higher serum creatinine and ESR, lower hemaglobin and complement C3, more patients 
accepting renal replacement therapy than surviving patients during hospitalization,. Higher 
BVAS scores and serum creatinine>400umol/L were the predictors of death in patient with 
AAV-related renal injury independently.
Conclusions: the incidence of early mortality in patients with AAV-related renal injury 
was higher. Prudent monitoring and therapy  should  be  given  to  patients  with active 
vasculitis and serious renal dysfunction to reduce adverse events.
PUB225
Significance of Resistive Index in Renal Arterial Ultrasonography as a 
Clinical Parameter for Tubulo-Interstitial Nephropathy  Minoru Hatano,1 
Kaori Takayanagi,1,2 Taisuke Shimizu,1 Hiroaki Hara,1 Nobuyuki Onizawa,1 
Koki Ogawa,1 Yuka Tanaka,1 Kunihiko Yasuda,1 Tomonari Ogawa,1 Akihiko 
Matsuda,1 Hajime Hasegawa.1  1Nephrology and Hypertension, Saitama Medical 
center, Saitama Medical Univ, Kawagoe, Saitama, Japan; 2Ishikawa Kinenkai 
Kawagoe Ekimae Clinic, Kawagoe, Saitama, Japan.
Background: Renal arterial ultrasonography (RA-US) has been principally applied to 
evaluate the stenosis of the renal artery and the indication of catheter intervention by the 
measurement of peak systolic velocity (PSV). Resistive index (RI) is calculated as (PSV-
EDV)/PSV, where EDV indicates end-diastolic velocity, and is reported to be related to 
the renal function. In this study, we aimed to investigate the possible clinical benefit of RI 
for the assessment of tubulo-interstitial nephropathy (TIN).
Methods: We studied 51 patients (51.6±2.3 years old) who underwent RA-US and 
sufficient laboratory tests for the analysis in the past 10 years in our hospital. PSV and 
RI were measured at both main renal arteries (RA-measurement) and intra-renal arteries 
roughly corresponding to the inter-lobular arteries (IRA-measurement). NAG index (urine 
excretion ratio of N-acetylglucosaminidase (NAG) to creatinine) was used as a conventional 
clinical parameter for the assessment of TIN.
Results: Stratified analysis by median value of RI (0.69) showed significant difference 
in eGFR in the RA-measurement (43.4±4.7 vs 60.3±4.2), but not in the IAR-measurement. In 
contrast, the analysis showed significant difference in NAG index in the IRA-measurement 
(median: 11.6 vs 5.4), but not in RA-measurement. When the patients showing NAG 
index ≥ 15, indicating advanced renal insufficiency, would be excluded from the analysis, 
NAG index significantly correlated with RI of IRA-measurement (R=0.50, p<0.05), but 
not RA-measurement. In addition, ROC analysis revealed that the cut-off value of RI to 
NAG index was 0.65.
Conclusions: In addition to the previous report showing the relevance of RI to 
the histological severity, the present study demonstrated the correlation of RI with the 
conventional parameter of TIN, NAG index. Particularly, for the assessment of TIN, RI 
value measured at intra-renal artery would be more beneficial.
PUB226
Recovery of Renal Function with Eculizumab in a Girl with Dense Deposit 
Disease and Normal Soluble C5b-9 Levels  Martin Kömhoff,1 Arjan Diepstra,2 
Marc Maj Seelen,3 Coen A. Stegeman,3 Valentina Gracchi.1  1Pediatrics, UMCG, 
Groningen, Netherlands; 2Pathology, UMCG, Netherlands; 3Nephrology, 
UMCG, Netherlands.
Background: Dense Deposit Disease (DDD) is a rare glomerulopathy characterized 
by electron-dense deposits in the glomerular basement membrane (GBM) and glomerular 
complement deposition. 50% of patients progress to ESRD and have recurrences after 
kidney transplantation. Dysregulation of the alternative complement pathway plays a key 
role in the pathogenesis. Increased soluble C5b-9 in blood is considered to predict response 
to eculizumab, an anti-C5 monoclonal antibody.
Methods: We report the case of a previously healthy 15-year-old girl who presented 
with acute kidney injury, hypertension, nephrotic syndrome (10.8 gr protein /24 hours) 
and microscopic hematuria.
Results: Biochemical (C3 &4, sC5b-9, factors H & I, C3 nephritic factor and anti-
FH) and genetic workup of the complement system (CFI, CFB, C3 and MCP) showed 
normal results, except for a slightly increased C3d and a risk allele in the CFH gene. Renal 
biopsy showed cellular crescents and electron-dense deposits in the GBM. Glomerular 
C3 and C5b-9 immunofluorescence staining was positive. Despite escalating therapy, 
including methylprednisolone pulses followed by oral prednisolone, cyclophosphamide 
and plasma exchange (PE), the renal function further deteriorated and hemodialysis was 
started. Eculizumab was administered. This led to a rapid improvement of renal function 
(discontinuation of dialysis and increase of endogenous creatinine clearance from 11 to 53 
ml/min/1.73m2). Three months later the girl is in a good clinical condition but proteinuria 
is still in the nephrotic range (3.6 gr/24 hours). Treatment with eculizumab is ongoing. Up 
to now no side effects have been observed.
Conclusions: Response to eculizumab in DDD cannot be predicted merely on the 
basis of levels of sC5b-9 in blood.
PUB227
Ten-Year Experience of IgA Nephropathy in the South East of Ireland 
Heather Martha Gunning, Sean F. Leavey, Vivian Elizabeth Abernethy, Catherine 
M. Brown.  Nephrology, Univ Hospital Waterford, Waterford, Ireland.
Background: Worldwide IgA nephropathy (IgAN) is the most common non-infectious 
glomerulonephritis1. Its presentation varies widely from asymptomatic urinalysis 
abnormalities to nephrotic syndrome and renal failure. There are few randomised 
controlled trials to guide its best management and many patients continue to be treated 
on ‘best opinion’1.
Methods: All renal biopsies undertaken in our institution between January 2005 and 
December 2014 were retrospectively reviewed and those diagnostic of IgAN were identified. 
Data collected included patient characteristics, presentation, treatment and disease course, 
serum creatinine and urinary protein creatinine (uPCR) ratio at six months and one year.
Results: 426 native renal biopsies were reviewed. IgAN was diagnosed in 65 (15%); 
51 (78%) male and 14 (22%) female. At time of biopsy median age was 39 years (IQR 19), 
median creatinine was 139umol/L (IQR 146) and median uPCR was 234mg/mmol (IQR 
334). Presenting features are detailed in table 1. 
Patient number 
(n = 65)
Percentage 
(%)
Vasculitic rash 7 11
Frank haematuria 17 26 
Nephrotic range proteinuria 25 38 
Hypertension 44 68 
Creatinine ≥ 200umol/L 19 29 
Creatinine ≥ 300umol/L 11 17 
56 (86%) received renin-angiotenisin blockade. 31 (48%) received immunosuppressive 
therapy; 19 (29%) steroids, 9 (14%) combination immunosuppression and 3 (5%) 
mycophenolate. Follow-up data at one year was available in 58 (89%), 6 were receiving 
renal replacement therapy. Median changes in creatinine and uPCR at one year are detailed 
in figure 1. 
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Conclusions: Manifestations of IgAN vary widely. The mainstay of therapy consists 
of supportive measures, which the majority of our cohort received. Immunosuppressive 
regimens are reserved for a select group, and in our cohort both mycophenolate and steroid 
based regimens yielded a reduction in proteinuria.
PUB228
Effect of Rituximab on Immunoglobulin Levels and Infection Risk in ANCA 
Associated Vasculitis  Shivani Shah,1 M-Hafizur Rahman,2 Duvuru Geetha.1 
1Div of Nephrology, Dept of Medicine, Johns Hopkins Hospital, Baltimore, 
MD; 2Bloomberg School of Public Health, Johns Hopkins Univ, Baltimore, MD.
Background: Rituximab (RTX), a B cell depleting anti-CD20 monoclonal antibody, 
is approved for treatment of ANCA associated vasculitis (AAV). Low immunoglobulin 
(Ig) levels are a consequence of RTX treatment. The association between the degree of Ig 
deficiency and infection risk is unclear in AAV patients.
Methods: AAV patients treated with RTX in a single center with available serum Ig 
measurements were included. The rates and types of infection after RTX administration 
were correlated with Ig level using correlation matrix and logistic regression analysis.
Results: Our cohort of 27 patients had a median age of 68 years, eight males, 15 GPA 
patients, and 17 with a new diagnosis of AAV. Twenty five received four doses of RTX 
375 mg/m2 weekly and two received RTX 1000 mg biweekly for two doses. Nine received 
concomitant cyclophosphamide. Twenty three patients had low serum IgG levels (<751 
mg/dL) greater than one month following RTX treatment. Ten out of these 23 developed 
infections over the median follow up time of 338 days. Pneumonia was the most common 
infection. The odds of having an infection with IgG level  ≤500 mg/dL is 3 times higher than 
with IgG level between 501-750 mg/dL, though p= 0.26. There is a significant association 
between infection and IgM level £20 mg/dL (p = 0.047). 
Odds 
Ratio SE Z p-Value 95% CI
IgM (normal ≥ 46 mg/dL, reference 
≥ 46 mg/dL)
21-45 mg/dL 1.16 1.33 0.13 0.89 0.12-10.99
≤20 mg/dL 8.17 8.64 1.99 0.047 1.103-64.94
IgG (normal ≥ 751 mg/dL, reference 
501-750 mg/dL)
≤500 mg/dL 3 2.93 1.13 0.26 0.44-20.31
Conclusions: Severely low Ig levels due to RTX therapy may increase the risk of 
infection in AAV patients, and these patients may benefit from IVIG therapy. Further 
investigation is warranted given our study is limited by small sample size, concomitant 
cyclophosphamide use, and variable timing of Ig measurement.
PUB229
Monocyte Subpopulations of Patients with Different Forms of 
Glomerulonephritis Exhibit Distinct Changes of Toll Like Receptor 
Expression  Leon Brian Schubert,1 Florian Gunnar Scurt,1 Noemi Rose emma 
Doll,1 Marius Früh,1 Tobias Hölscher,2 Andreas Jeron,2 Dunja Bruder,2 Peter 
R. Mertens,1 Christos D. Chatzikyrkou.1  1Nephrology, Hypertension, Diabetes 
and Endocrinology, Otto-von-Guericke Univ Magdeburg; 2Inst of Microbiology, 
Otto von Guericke Univ Magdeburg.
Background: We are still in need for more reliable markers to monitor disease activity 
in primary glomerulonephritis.
Methods: In patients with active primary glomerulonephritis monocyte subpopulations 
were first differentiated by flow cytometry withthe use of the surface markers CD 14, CD 
16 CCR2 and CxCR3. The expression of different proteins reflecting antigen presentation 
or activation status as well as scavenger receptor and toll like receptor functions was then 
quantified. Blood samples of healthy individuals were used as controls. Preliminary results 
regarding toll like receptors 2, 4 and 5 in a patient with treatment naïve MPO positive 
vasculitis, a patient with treatment naïve membranous glomerulonephritis and a control 
are presented here.
Results: The expression of the toll like receptors 2, 4 and 5 was lower in patients with 
primary glomerulonephritis compared to the controls. 
This was the case in all monocyte subpopulations: classical (CD14++CD16-
CCR2highCXCR1-), intermediate type 1 (CD14++CD16+CCR2highCXCR1-) 
non-classical (CD14+CD16++CCR2lowCXCR1high) and intermediate type 2 
(CD14+CD16+CCR2lowCXCR1high).
Conclusions: Toll like receptors seem to be down regulated in monocytes of patients 
with primary untreated glomerulonephritis during the active phase. The pathophysiological 
significance of these findings is unclear and remains to be elucidated.
PUB230
Lipoprotein Glomerulopathy  Hostensia M. Beng, Basema I. Dibas, Hsiao 
Ling Lai, Guillermo Hidalgo.  Pediatrics, ECU, Greenville, NC.
Background: Lipoprotein glomerulopathy has been associated with mutations in the 
Apolipoprotein E (APOE) gene. The average age of reported cases is 32 years and the 
youngest patient described to date is 4yrs old.Here we present the first case of a 3 years 
old AA male with right hemihypertrophy, malignant hypertension, severe proteinuria & 
lipoprotein glomerulopathy,with a heterozygous mutation on APO E2 gene.
Methods: 3 year old African American male presented to pediatrician complaining of 
hemihypertrophy, short stature, polydipsia &hypertension. physical examination remarkable 
for right leg soft tissue hemi hypertrophy. Echocardiogram revealed left ventricular 
hypertrophy likely secondary to chronic hypertension. Hypertension and proteinuria 
persisted despite adequate treatment. Renal US showed persistent echogenic kidneys. 
Kidney biopsy showed Lipid vacuolization of podocytes, endothelial cells, tubular epithelial 
cells, and glomerular capillary lumens. Labs & imaging studies AFP and abdominal US 
have been normal with exception of proteinuria and increased lipid profile. Patient currently 
on a trial treatment with fibric acid and dietary modification.
Results: eGFR is stable at 60 ml/min/1.73 m2, proteinuria has improved from a ratio 
of 2.1 to 0.8 mg/mg and lipid profile has significantly improved.
Conclusions: APOE is an important LDL in transporting cholesterol to the liver for 
processing. Four main alleles of the APOE gene located on chromosome 19 have been 
described and different alleles have been associated with various medical conditions.
Mutations of near the LDL bind domain of the APOE gene coexist and may be associated 
with certain kidney diseases. Renal biopsy shows lipid deposits and thrombi which results 
in glomerular damage and glomerular sclerosis. No effective preventative or curative 
treatments have been identified for apolipoprotein glomerulopathy. In our patient a trial of 
fibrates to lower cholesterol,Gemfibrozil and effective management of hypertension has 
resulted in some improvement but it is uncertain if these medication can effectively lower 
lipid and prevent long term progression of kidney disease. More research to find more 
effective treatment and management strategies of this disease in children.
PUB231
Proliferative Lupus Nephritis (LN) – 60 Month Evolution of an Argentinian 
Cohort  Gabriel Pedro Alvarez,1 Marcelo Alejandro De Rosa,2 Luis Alberto 
Touceda.1  1Hospital San Martin. La Plata, Buenos Aires; 2Univ of Buenos 
Aires, Argentina.
Background: Remission of proteinuria predicts good evolution in many glomerular 
diseases; we describe the behavior of the proteinuria, renal function and flare up in a group 
of patients with proliferative LN in a 60 month period.
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Methods: Data from 55 patients were obtained. Proteinuria and Creatinine were shown 
at 0 (time of the biopsy), 6 and 60 months; renal biopsies were classified using ISN-RPS 
2003. All patients received an induction with at least 6 gr. of cyclophosphamide plus 
prednisone and a maintenance treatment with sodium mycophenolate 1440 mg/d and low 
doses of prednisone for at least 3 years. Flares was considered in case of 50% proteinuria 
increase or an active urinary sediment.
Results: Results are in table 
Table 1
N 55 %
Age (mean) 31,2 range 18-64
Sex f/m 52/3
Bx class II 1 2
Bx class III 7 12
Bx class IV 40 72
Bx class V 1 2
Bx class V+ 
III/IV 7 12
T0 6m 60m. p
Proteinuria gr/d 
(median) 3,04 (0,2-28) 1,2 (0,1-16,6) 0,2 (0,1-3,8) ‹ 0,05
Creatinine mg/
dl (median) 0,94 (0,5-4,23) 0,9 (0,6-4,22) 0,91 (0,55-7,22) NS
Flares up 17/ 32%
Treatment 
months 36 (30-60)
Conclusions: We observed a sustained decline in proteinuria and a preservation of 
renal function in most of patients; Treatment was well tolerated and flares up were in a 
high number of patients.
PUB232
A Case Study Comparing Cyclophosphamide plus Methylprednisolone 
versus Cyclophosphamide Alone in Idiopathic Membranous Nephropathy 
Basel Jaafar Alhayki.  Dept of Nephrology and Renal Transplant, Salmaniya 
Medical Complex, Manama, Bahrain.
Background: In the treatment of high risk idiopathic membranous nephropathy the 
modified Ponticelli protocol with the use of alternative month Cyclophosphamide and 
steroid is the most used treatment protocol. The scientific bases for the use of intermittent 
alternating month Cyclophosphamide and Methylprednisolone versus Cyclophosphamide 
alone in the treatment protocol is not well established and in many studies showed that 
steroid alone has limited role in the treatment of idiopathic membranous nephropathy. 
Weather this intermittent use of Cyclophosphamide and Methylprednisolone lead to a 
fluctuating response to therapy and prolong the recovery or not need to be investigated.
Methods: This is a case study of a 26 years old male with idiopathic membranous 
nephropathy and a positive AntiPLA2R antibody who needed to be started on Modified 
Ponticelli protocol with alternative month Cyclophosphamide and Methylprednisolone 
for a persistent massive Proteinuria of 16 gram per day and who failed cyclosporine in the 
past .Initially the patient was given the six month the modified Ponticelli protocol but he 
failed to reach a complete or a partial remission with persistent Proteinuria of more than 
6 gram per day and high Anti-PLA2R antibody titer and later he was given an extra three 
months of Cyclophosphamide alone .
Results: There was a fluctuating in antibody titer during the course of therapy with 
increase Anti-PLA2R antibody titer at the end of the Methylprednisolone month and 
reduce level after the month of Cyclophosphamide use. After the start of the extra three 
months of continues Cyclophosphamide the anti-PLA2R antibody titer was reducing in 
each month and at the end of the extra three months it disappeared completely with a 
remission of the Proteinuria.
Conclusions: This case shows that the use of Cyclophosphamide is more effective 
in the treatment of idiopathic membranous nephropathy than Methylprednisolone and it 
might provide a better control of the disease activity. Future study to evaluate this with the 
use of novel biomarker like Anti-PLA2 R antibody is recommended.
PUB233
Plasma Cytokines and Chemokines Profile in Patients with Systemic 
Lupus Erythematosus: Its Potential Use as Biomarkers of Kidney Damage 
Gustavo Aroca Martinez,1,2 Lisandro Pacheco,1 Elkin Navarro Navarro,1 Yirys 
Diaz,1 Henry J. Gonzalez torres,1 Gloria Garavito,3 Eduardo Egea bermejo,3 
Eduardo I. Navarro,1 Lisneth Almendrales,1 Antonio De jesus Iglesias-Gamarra.4 
1Medicine, Univ Simón Bolívar, Barranquilla, Atlántico, Colombia; 2Nephrology, 
Clínica de la Costa, Barranquilla, Atlántico, Colombia; 3Medicine, Univ 
del Norte, Barranquilla, Atlántico, Colombia; 4Medicine, Univ Nacional de 
Colombia, Bogotá DC, Cundinamarca, Colombia.
Background: Systemic lupus erythematosus is an autoimmune disease in which the 
innate and adaptive response plays a significant roll, mainly mediated by cytokines. Lupus 
nephritis-LN-is the most severe complication associated with SLE. Objective: To identify 
differential expression of cytokines profiles and circulating chemokines in plasma of SLE 
patients with different degrees of Caribbean region.
Methods: This was a case- control study. Plasma samples from 10 patients with NL 
class-II 10 patients with NL class-III, and 30 patients with NL class-IV were analyzed. As 
a control plasma from 30 SLE patients without nephritis were used. Plasma samples were 
analyzed using the Luminex technology of 38 analytes (EGF, Eotaxin, FGF-2, Flt-3 ligand, 
Fractalkine, G- CSF, GM-CSF, GRO, IFN-a2, IFN -γ, IL-10, IL-12 (p40), IL 12(p70), 
IL-13, IL-15, IL-17, IL-1Rα, IL-1α, IL-1β, IL-2, IL 3, IL4, IL-5, IL-6, IL-7, IL-8, IL-9, 
IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, TGF-α, TNF-α, TNF-β, VEGF, 
sCD40L, RIL-2Ra) using MILLIPLEX®-MAP-Human Cytokine/Chemokine-Magnetic-
Bead-Panel-Premixed 39 Plex.
Results: Significant differences(p<0.05) was between concentrations of cytokines EGF, 
G-CSF, GM-CSF, GRO, IFN, IL4, IL8, IP10, MCP, MDC, MIP.1a, sIL2Ra,TNFb when 
SLE-patients with LN vs SLE-patients without LN were compared.
Conclusions: These preliminary data suggest that there are differences in the LN 
plasma patients level of some chemokines and proinflamatory cytokines. Results support the 
hypothesis that circulating levels in plasma samples of these molecules may be considered.
Funding: Other NIH Support - Banco de la Republica de Colombia
PUB234
Clinical Outcomes of IgA Nephropathy with Necrotizing and Crescentic 
Lesions in Inner City Hospital  Ambarish Athavale, Amit J. Joshi, Kalyani 
Perumal, Albert M. Osei, Peter D. Hart, Taha Iqbal.  Nephrology, John H Stroger 
Jr. Hospital of Cook County, Chicago, IL.
Background: IgA nephropathy is the most common cause of glomerular disease 
worldwide. Segmental necrosis and crescents are seen only in small subset of patients and 
literature regarding their clinical outcomes is sparse.
Methods: Retrospective analysis of cases with primary IgA nephropathy from Stroger 
Renal biopsy database from January 2005 to May 2015 was performed. Demographic 
and clinical information was obtained from medical charts. Study was approved by IRB.
Results: Of 66 cases of IgA nephropathy, 10 (15%) had lesions with segmental necrosis 
and/or crescents. These patients responded well to cyclophosphamide based therapy with 
improvement in creatinine and proteinuria after a mean follow up of 4.6 years. However, 
patients without vasculitic lesions had a progressive decline in renal function despite 
immunosuppressive therapy. This group had longer follow up period (mean 7.1 yrs) and 
21% required dialysis. 
With necrotizing/ 
crescentic lesions 
(n=10)
Without necrotizing/ 
crescentic lesions 
(n=56)
P value
Age (in years) 44.6 46.2
Gender (M:F %) 30:70 54:46
Ethnicity 
Hispanic or Latino 
Non Hispanic/Latino
 
5 
5
 
27 
29
S. creatinine (mg/dl) at biopsy 1.4 1.7 0.26
Estimated proteinuria at biopsy (g/g of Cr) 3.5 2.7 0.21
Prednisone(%) 90 34
Immunosuppressants(%)
Cyclophosphamide based
Others
80
70
30
23
1
99
ACEI/ARB (%) 80 81
Length of follow up (in years) 4.6 7.1 0.001
Last S. creatinine (mg/dl) 1.0 1.8 0.65
Last estimated proteinuria (g/g of Cr) 1.2 2.3 0.47
Biopsy
Mesangial hypercellularity (%) 80 73
Endocapillary proliferation (%) 50 5
Segmental sclerosis (%) 70 66
Tubular atrophy
T0<25%
T1>25%
T2 >50%
 
50
30
0
 
34
37
28
Conclusions: Patients with vasculitic lesions (necrosis and crescents) carry a favorable 
prognosis when treated with Cyclophosphamide based therapy. When applying MEST 
criteria among patients with and without vasculitic lesions, only tubular atrophy was 
predictive of future decline in renal function (p=0.007). In this cohort, 21% reached ESRD 
within a mean follow up of 7 yrs which highlights the aggressive nature of this disease 
in ethnic minorities.
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Acute Tubulo-Interstitial Nephritis (ATIN): Predicting Long Term 
Outcomes  Victoria C. Robins,1 Aravind Cherukuri,2 Padmini Prasad,1 Richard 
J. Baker.1  1SJUH; 2Pittsburgh.
Background: ATIN is a relatively common potentially reversible cause of acute 
kidney injury.It has become clear over the last 2 decades that the disease is not always 
reversible,particularly in the elderly.We present a large contemporary single centre 
retrospective series concentrating on factors that predict poor outcomes.
Methods: 62 cases retrospectively diagnosed histologically via patholgy records as 
primarily ATIN were included.An experienced histopathologist,blinded to outcomes,graded 
biopsies according to the presence,absence and degree of 8 different parameters: Interstitial 
inflammation,tubular atrophy,eosinophilia,plasma cell infiltration,chronic vascular 
lesions,hyalinosis,granulomas + oedema.Patients were classified as a poor outcome if 
eGFR(4 variable MDRD) after 12 months was less than 30ml/min/1.73m2 or they died.
Results: 62 patients with biopsy proven ATIN were identified.15 had a poor outcome.
Baseline demographics are presented in Table 1.
Good 
(eGFR>30)
Poor 
(eGFR<30) p value
n 47 15
age 56.2+/-16.8 56.6+/-19 Not significant(-)
Sex M/F 19/28 6/9 -
Creatinine:diagnosis 366+/-245 545+/-334 0.02
Creatinine:6 months 130+/-40 220+/-90 <0.0001
PCR:diagnosis 103+/-72 126+/-90 -
Treatment: prednisolone 87% 80% -
Serum eosinophil count 0.4+/-1.0 0.4+/-0.5 -
Biopsy degree of:interstitial 
Inflammation 2.1+/-0.8 2.1+/-0.7 -
tubular atrophy 1.2+/-0.4 1.3+/-0.6 -
eosinophilia 0.9+/-0.8 1.3+/- 1.0 -
plasma cell infiltation 2.0+/-0.9 2.0+/-0.8 0.03
chronic vascular lesions 1.3+/-0.5 1.6+/-0.5 -
hyalinosis 0.6+/-0.7 0.6+/-0.7 -
granulomas 0.3+/-0.6 0.9+/-1.1 0.03
oedema 0.3+/-0.5 0.5+/-0.8 -
Aetiology was difficult to definitely ascertain but consisted of drug induced, infectious, 
sarcoid or sjogrens. Parameters significantly associated with poor outcomes include higher 
creatinine at presentation & 6 months,presence of granulomas and chronic vascular lesions 
on biopsy at diagnosis.The effect of steroid treatment was difficult to assess since most 
patients were treated at the outset.
Conclusions: ATIN usually carries a good prognosis but some patients experience poor 
outcomes.Poor renal function at diagnosis and the presence of granulomas and chronic 
vascular lesions are predictive of poorer outcomes.
PUB236
Cotreatment of Olmesartan and Caterpillar Fungus Attenuate Albuminuria 
in Patients with Glomerulonephritis  Hua Zhou, Ye Zhang, Ya Li, Hairong 
Tang, Congcong Jiao, Lining Wang.  Nephrology Dept, 1st Hospital of China 
Medical Univ, Shenyang, China.
Background: Angiotensin II receptor blockers (ARBs) were demonstrated to reduce 
proteinuria since a decade ago. However, proteinuria still remains as the top of clinical 
symptoms in glomerulonephritis (GN). We aim to investigate the effect of cotreatment 
with olmesartan (Olm), an ARB and caterpillar fungus capsule (CF) on proteinuria in 
patients with GN.
Methods: 491 patients with GN were retrospectively studied. GN was diagnosed by 
moderate albuminuria and/or dysmorphic hematuria. Patients were divided into seven groups 
by treatment: 1) CF alone, 2) Olm alone, 3) other ARBs defined as non Olm ARBs, 4) all 
ARBs include Olm and other ARBs, 5) CF + Olm, 6) CF + other ARBs, and 7) CR + all 
ARBs. High blood pressure is not necessary indication for ARBs treatment. Urinary albumin 
concentration (uAlb, mg/L) were examined before and 1, 2, and 3 months of the treatment.
Results: uAlb was significantly attenuated in the groups with Olm alone, all ARBs, 
CF + Olm, and CF + all ARBs at 1 and 2 months after the treatment compared to 
pretreament (Olm alone 343±82vs 483±77, p=0.009, n=92; all ARBs 351±68vs 494±68, 
p=0.004, n=125; CF+Olm 509±81vs 853±105, P=0.0002, n=118; CF+all ARBs 544±81 
vs 836±92,P=0.0006, n=138 at 1 month. Olm alone 264±54 vs 466±107, p=0.006, n=35; 
all ARBs 295±50 vs 606±117, p=0.0003, n=58; CF+Olm 395±92 vs 814±157, P=0.001, 
n=60; CF+all ARBs 438±80 vs 902±135,P<0.0001, n=77 at 2 months). At 3 months after 
the treatment, the significant reduction of uAlb was only seen in cotreatment with CF and 
Olm/all ARBs (CF+Olm 357±141 vs 559±112, P=0.026, n=28; CF+all ARBs 368±102 
vs 631±119,P<0.019, n=41). The decrease of uAlb was not found in groups of CF alone, 
other ARBs, and CR+other ARBs (numbers of patients received other ARBs are 33, 13, 8 
and received CF+other ARBs are 21, 9, 7 at 1, 2, and 3 months, quite smaller than Olm). 
The cotreatment with CF showed an increased statistical p value.
Conclusions: Cotreatment of Olmesartan and caterpillar fungus significantly attenuated 
albuminuria in patients with GN. caterpillar fungus might be a promising agent to treat 
glomerular proteinuria via synergizing the effect of ARBs in glomerulonephritis.
Funding: Government Support - Non-U.S.
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Tubulointerstitial Involvement in Lupus Nephritis  Angela Pakozdi,1 Dev 
Pyne,1 Michael Sheaff,2 Ravindra Rajakariar.3  1Rheumatology, Barts Health 
NHS Trust, London, United Kingdom; 2Histopathology, Barts Health NHS 
Trust, London, United Kingdom; 3Nephrology, Barts Health NHS Trust, United 
Kingdom.
Background: Tubulointerstitial disease is frequent in lupus nephritis (LN), and 
interstitial infiltration, tubular atrophy and interstitial fibrosis are all independent risk factors 
for LN renal outcome. We aimed to analyze tubulointerstitial changes on a series of repeat 
renal biopsies (RB) and identify correlations with clinical variables.
Methods: Histopathological changes of 39 LN patients were analysed using the revised 
Austin’s semi-quantitative grading system of 0 to 3 (0, normal; 1, mild <25%, 2, moderate 
26-50%; 3, severe >50% of the interstitium affected). Spearman’s rank-order correlation 
was run to determine relationship between clinical variables and histological findings.
Results: We found a progression in both tubular atrophy (p=0.001) and interstitial 
scarring (p<0.001), but not in inflammatory cell infiltration by the time of RB. The mean 
total tubulointerstitial score (± SD) has progressed from 2.69 ± 2.03 to 3.78 ± 2.03 (p=0.001). 
There was a positive correlation between serum creatinine and the severity of tubular 
atrophy at time of both reference biopsy (r=0.33, p=0.048) and RB (r=0.56, p<0.001). 
Serum creatinine at time of RB showed a strong correlation with interstitial scarring 
(r=0.60, p<0.001). A trend was identified between the severity of interstitial inflammation 
on reference biopsy and the amount of tubular atrophy and interstitial scaring on RB 
(r=0.349, p=0.19; r=0.385, p=0.009). Chronicity indices (CI) also progressed by the time 
of RBs. Patients with proliferative histopathology on initial biopsy had higher CI at both 
the reference biopsy (p=0.047) and RBs (p=0.019). Treatment decisions did not seem to 
be influenced by the progression of CI (p=0.982).
Conclusions: Tubulointerstitial lesions show progression in time illustrated by our 
study using RBs, and serum creatinine level showed good correlation with the severity. 
Interstitial inflammation on reference biopsies correlated with the severity of tubular atrophy 
and interstitial scaring on repeat biopsies, suggesting a possible predictive role for damage.
PUB238
Seasonal  Variat ions  of  Renal  ANCA Associated Vascul i t is 
Juliana Bordignon Draibe, Joan Torras, Xavier Fulladosa.  Nefrology, Hospital 
Univ de Bellvitge, Barcelona, Spain.
Background: Filling the gaps in the genetic research of etiological factors related 
with ANCA associated vasculitis (AAV) is a major challenge in the current investigation. 
Descriptive and analytical epidemiological studies may improve our understanding of 
environmental influences on the disease. Seasonal variations in AAV have been previously 
described, mainly related to Wegener’s disease, showing an increased number of cases 
during the winter months. It has been hypothesized tha infection could be the underlyig 
factor for these observations. Our goal is to study seasonal variations of AAV diagnosed 
in the city of Barcelona.
Methods: Our study included 209 AAV patients diagnosed between 2001 and 2013 in 
5 different University Hospitals of Barcelona. We analyzed their medical records, including 
the date of diagnosis and the approximate date of the first symptoms in 194 patients. We 
have also analyzed data related to ANCA subtypes in each patient.
Results: Of the 209 patients, 160 (76.5%) were MPO-positive, 28 (13.3%) were PR3 
positive and 21 (10%) were ANCA negative. Regarding the onset of symptoms, we have 
found a greater number of cases in the months of January, February and March, compared 
with the rest of the year.This data correlates positively with the higher incidence of flu 
symptoms in Barcelona between 2009 and 2013.
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
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Considering the date of diagnosis we found a greater number of cases in two periods 
of the year; the months of May, June and July, and the months of October, November and 
December.
Conclusions: In our population, predominantly ANCA MPO-positive related vasculitis, 
we found a higher incidence of the disease in the winter months, being diagnosed more 
frequently in May, June and July or October, November and December. One potential 
environmental factor,influenza disease,may explain this finding.
PUB239
Mycophenolate Mofetil for the Treatment of Idiopathic Nephrotic 
Syndrome: A Meta-Analysis of Randomized Controlled Trials  Bin Zhu, 
Yongjun Wang.  Nephrology, Hangzhou Hospital of Traditional Chinese 
Medicine (Guangxing Hospital) Affiliated to Zhejiang Chinese Medical Univ, 
Hangzhou, Zhejiang, China.
Background: This meta-analysis was performed to investigate the efficacy and safety 
of mycophenolate mofetil (MMF) in treating idiopathic nephrotic syndrome.
Methods: We searched MEDLINE, EMBASE, the Cochrane Library database, the 
Database for Chinese Technical Periodicals, Wanfang, Chinese National Knowledge 
Infrastructure and the Chinese Database of Biology and Medicine for randomized controlled 
trials compared MMF with the other immunosuppressive agents for the treatment of 
idiopathic nephrotic syndrome. Weighted mean difference (WMD) and summary estimates 
of relative risk (RR) reductions with 95% CIs were calculated.
Results: We identified 36 trials that included 2007 patients, mainly on membranous 
nephropathy (MN), focal segmental glomerulosclerosis (FSGS) and refractory nephrotic 
syndrome without clearly pathological diagnosis (RNS). Overall, MMF therapy 
significantly reduced proteinuria (WMD:-462.31mg/d, CI: -219.69 to -704.92 P<0.001), 
increased the likelihood of complete remission (RR: 1.25, CI: 1.11 to 1.41, P<0.001), 
complete or partial remission (RR: 1.15, CI: 1.09 to 1.22, P<0.001) compared with the 
other immunosuppressors. The subgroup analyses shown that MMF was superior to 
cyclophosphamide in the RNS patients in reducing proteinuria, serum creatinine, relapse, 
and increasing the remission rate. In the MN patients, MMF therapy was better than 
cyclophosphamide in reducing proteinuria, increasing remission rate, whereas it was poorer 
than chloramubucil in lowering proteinuria. MMF therapy also significantly decreased 
proteinuria in FSGS compared with cyclophosphamide. MMF was safer than most of the 
other agents, particularly than cyclophosphamide.
Conclusions: MMF seems superior to the other immunosuppressive regimens for the 
treatment of idiopathic nephrotic syndrome with mild adverse effects, particularly in MN, 
FSGS and RNS. High-quality large-sample trials are still required to reliably define the 
balance of efficacy and safety.
PUB240
A Retrospective Analysis of Acute Kidney Injury in Adult-Onset Minimal 
Change Disease  Yosuke Nakagawa, Takuya Isegawa, Masahiro Koizumi, 
Masafumi Fukagawa.  Div of Nephrology, Endocrinology and Metabolism, 
Tokai Univ School of Medicine, Isehara, Kanagawa, Japan.
Background: Minimal change disease (MCD) is a major cause of primary nephrotic 
syndrome in adults, accounting for 10 to 25 percent of cases. In terms of treatment, steroid 
therapy is very effective, however in some cases an acute onset of moderate to severe 
decline in kidney function is seen, occasionally requiring transient dialysis. To the best of 
our knowledge, the risk factor for acute kidney injury (AKI) and clinical course of cases 
with AKI had not been fully elucidated.
Methods: This study isa single center, retrospective observational study. The clinical 
records of adult (older than 18 years old) who had biopsy-proven MCD and were followed 
at Tokai University Hospital from 2000 to 2015 were retrospectively reviewed. The 
diagnosis of AKI was based on KDIGO criteria, namely, serum creatinine changes ≥ 1.5 
times baseline within 7 days and a 0.3 mg/dl increase in serum creatinine within 48 hours.
Results: 57 patients were enrolled, and AKI occurred in 24 patients at presentation 
or subsequently, among whom five patients underwent hemodialysis. Patients with AKI 
showed lower level of serum albumin and higher rates of use of diuretics, renin-aldosterone 
system (RAS) inhibitors, and NSAIDs. Logistic-regression analysis showed that use of 
these drugs before presentation at our institution could predict the development of AKI 
(odds ratio, 2.8; 95% CI, 2.2 to 3.2). Furthermore, use of these drugs could determine 
the time to remission (Hazard ratio, 2.4, 95% CI, 1.8 to 3.0), as well as the initial serum 
creatinine. All cases were initially treated with steroid, and there was no difference in the 
time to remission between oral and parenteral administration of steroid.
Conclusions: There is a high incidence of AKI in adult-onset MCD. The use of several 
drugs such as diuretics could influence the onset of AKI and clinical course of MCD.
PUB241
Expression of HLA-G Molecule in Crescentic Glomerulonephritis and Its 
Clinical Significance  Guisen Li, Li Wang.  Nephrology, Sichuan Academy of 
Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan, 
China.
Background: In recent years, human leukocyte antigen-G (HLA-G) was found to 
be an important immune-regulatory molecular. Our purpose of this study is to assay the 
concentrations of serum soluble HLA-G(sHLA-G)in patients with CGN and to analyze 
its clinical significance.
Methods: 48 patients with CGN from 2009 to 2014 were involved in this study. The 
clinical data were collected, include demographic characteristics, laboratory parameters, 
pathological examinations, prognostic information and immunosuppressive therapy. 
Analyze if oliguria or anuria, serum creatinine levels, the crescent formation ratio and 
therapy would affect the prognosis of patients.22 patients with CGN, 15 patients with MCD, 
and 30 healthy adults in control group were enrolled with serum levels of sHLA-G measured 
by ELISA. The relationship between the clinical or pathological features and sHLA-G 
was studied and the value of the HLA-G in crescentic glomerulonephritis was analyzed.
Results: 3-years kidney survival rate was only 38% with one case of death. Cox 
regression analysis showed higher serum creatinine was associated with the patients with 
a poor prognosis(HR=4.04,95%Cl:1.548-10.544, P=0.004).Serum level of sHLA-G in 
CGN was significantly higher than in healthy control(2198.81 ± 1924.17pg/ml vs.1311.86 
± 448.84pg/ml, P=0.0408), while higher than in MCD, (2198.81 ± 1924.17 pg/ml vs. 
1181.33 ± 320.10 pg/ml, P=0.023).Kaplan Meier survival analysis showed elevated levels 
of HLA-G was associated with poorer patients.
Conclusions: High serum creatinine level(>5mg/dl) at admission is an independent risk 
factor for the development to be ESRD. sHLA-G was significantly elevated in the serum 
of patients with CGN, and the level of sHLA-G had relationship with the prognosis of the 
patients with CGN. sHLA-G may be used as a new biomarker in CGN with clinical value 
in the early diagnosis and prognosis.
PUB242
A Treatment of Nutcracker Syndrome Leads to a Resolution of Unexplained 
Proteinuria  Badamkhand Baatarkhuu, Raymond Raut, Winston Y. Shih, 
Panupong Lisawat.  Nephrology and Hypertension, WCHN Danbury Hospital, 
Danbury, CT.
Background: The nutcracker syndrome is rare and can be a cause of unexplained 
proteinuria. We report a case of nutcracker syndrome related proteinuria and resolution of 
the proteinuria is observed after the entrapment was surgically corrected.
Methods: This is a 22-year-old male with a history of unexplained proteinuria since 
he was 17 years old. He has moved to a new location and presented to our clinic with 
proteinuria. The patient’s initial work up at an outside hospital revealed 1.4g proteinuria 
per 24 hours. A left kidney biopsy showed mesangial hypercelluarity and preserved foot 
processes. The patient at that time was treated with prednisone, cyclosporine and lisinopril. 
His proteinuria decreased to 196 mg per 24 hours. Due to intolerance, lisinopril was stopped 
and urine protein subsequently rose. At the time of evaluation, the patient’s 24 hour urine 
protein was 700 mg and the autoimmune and infectious work up was negative. Upon 
reviewing the medical record from 2 years ago, he had inferior venacavagram as a part of 
varicocele treatment. It showed compression of the left renal vein between the aorta and 
superior mesenteric artery. Nutcracker syndrome was suspected. Subsequently, he was 
referred to vascular surgery, and underwent an open reconstructive surgery. Postoperatively 
the patient remained off lisinopril and repeated 24 hour urine protein was down to 102 mg.
Conclusions: Nutcracker syndrome can cause significant proteinuria. Although it 
is rare, an early recognition could lead to a definitive treatment, help avoid unnecessary 
medications and invasive procedure such as a kidney biopsy.
J Am Soc Nephrol 26: 2015 Publication Only
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Parvovirus B19 Immune Complex Glomerulonephritis  Beth Lynne Braunhut, 
Erika R. Bracamonte.  Pathology, Univ of Arizona College of Medicine, Tucson, AZ.
Background: A 14 year old girl underwent a cadaveric renal transplant due to end-
stage renal disease from obstructive uropathy and developed parvovirus B19 viremia and 
graft dysfunction. Renal biopsy showed de novo immune complex glomerulonephritis with 
parvovirus B19 DNA detected in renal tissue by PCR. We herein review of B19-associated 
glomerular disease.
Methods: A search of the English-language medical literature was conducted. PubMed, 
Medline, and Google scholar were used. Adult and pediatric cases were included. Sources 
included case reports and series, including prior reviews. Articles were evaluated for 
demographic data, clinical findings, laboratory data, and renal biopsy results.
Results: 67 cases were identified. 51 involved native kidneys and 16 transplants. 66 
of 67 cases had serologic evidence of B19 infection (98.5%). B19 DNA testing by PCR 
of various samples was positive in 82.9% of cases. Biopsy results were reported in 52 
cases. Of native cases, 92.5% reported a proliferative glomerulonephritis. Allografts most 
commonly showed TMA (66.7%). IF showed C3 in 84.4%, IgM in 68.8%, IgG in 62.5% 
and IgA in 40.6%. IF was negative in all transplant cases, save for our patient who showed 
IgG, IgM, C1q and C4d. EM results were reported in 24 cases with subendothelial deposits 
being most common (91.7%).
Conclusions: The findings in B19-associated glomerular disease are different in the 
native kidney versus transplant setting. In a native kidney, proliferative immune complex 
glomerulonephritis is most common. In the transplant setting, most cases showed TMA. 
The pathogenesis of this discrepancy remains unclear. To our knowledge, this is the first 
report of B19 immune complex glomerulonephritis in a renal transplant patient. Our 
patient showed findings more commonly seen in native-kidney B19 disease. We believe 
this discrepancy may be explained by insufficient immunosuppression in our patient, 
as evidenced by concurrent AMR. B19 infection in a transplant patient has practical 
implications. B19 glomerular disease represents a largely reversible form of renal injury. 
But, adverse outcomes have been reported. Management may require a balancing act with 
the risk of rejection on one hand and B19 disease on the other.
PUB244
A Case of ANA-Negative Systemic Lupus Erythematosis  Ankur Shah,1 Rachel 
Criner,1 Jean Lee.2  1Internal Medicine, Temple Univ Hospital, Philadelphia, 
PA; 2Nephrology, Temple Univ Hospital, Philadelphia, PA.
Background: Systemic Lupus Erythematosis is a chronic autoimmunse disorder 
hallmarked by several autoantibodies targeting intracellular antigens. The most sensitive 
of these antibodies is the anti-nuclear antibody. Various studies show that this antibody is 
present in 95-98% of individuals with the disorder. As methodology improves, the incidence 
of ANA-negative Lupus has been decreasing.
Methods: We report a case of a 53 year old female whose known past medical 
history included only hypertension who presented to the outpatient clinic with arthralgias, 
pancytopenia, alopecia, proteinuria and skin rash whose labwork to this point included an 
elevated ESR of 115, negative ANA, neg HIV, Hep B, and Hep C serology. She was then 
lost to followup until presenting to the hospital with anisarca and acute kidney injury. 
Her further workup confirmed a negative ANA but also revealed positive Anti-SSa, and 
anti-DsDNA as well as low titer Anti-Phospholipid. Her C3 and C4 were decreased at 
43 and 66 respectively. She had a renal biopsy performed revealing focal proliferative 
and membranous lupus nephritis, Class III/V. The patient was started on mycophenolate, 
plaquenil, and prednisone.
Conclusions: Once a byproduct of a technically variable laboratory test, the entity 
of ANA negative Lupus has been decreasing in its frequency. The adoption of the human 
epithelial substrate has brought standardization to this assay and also increased its sensitivity. 
Nonetheless, the entity still exists, and has been described before. The majority of ANA-
Negative Lupus cases will present with antibodies to cytoplasmic components – SSA or 
SSB, as did our case. ANA negative cases of SLE have been shown to have a decreased 
incidence of renal manifestations, with our case being an interesting exception. Our case 
serves as a reminder that the entity of systemic lupus erythematosis remains a clinical 
one, and that while the ACR criteria do include immunologic studies, the absence of the 
hallmark antibody does not rule out the disorder.
PUB245
Patients with Combined Membranous Nephropathy and Focal Segmental 
Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles 
with Primary Membranous Nephropathy  Qiu-hua Gu, Zhao Cui, Jing 
Huang, Gang Liu, Minghui Zhao.  Renal Div, Peking Univ First Hospital, Inst 
of Nephrology, Peking Univ, Beijing, China.
Background: Patients with combined membranous nephropathy (MN) and focal 
segmental glomerulosclerosis (FSGS) have been reported with different clinical significance. 
Investigation on the possible mechanisms of the combined glomerular lesions is necessary 
but scarce.
Methods: 20 patients with both MN and FSGS lesions were enrolled, 29 patients with 
primary MN and 27 patients with primary FSGS were used as disease controls. Clinical 
data were collected on renal biopsy and during follow-up. Circulating anti-phospholipase 
A2 receptor (PLA2R) antibody, glomerular PLA2R expression and IgG4 deposition, and 
soluble urokinase receptor (suPAR) levels were detected.
Results: We found that patients with combined lesions presented with elder age, less 
proteinuria, higher serum albumin, better renal function on biopsy, more complete remission 
after treatments and better renal outcome during follow-up. These were comparable to the 
patients with primary MN, but different from the patients with primary FSGS. Patients with 
combined lesions showed higher stages of MN, no cellular variant on FSGS classification 
and more common (100%) tubulointerstitial injury than both primary MN and primary 
FSGS patients. In the patients with combined lesions, 80% had circulating anti-PLA2R 
antibody and 68.4% had IgG4 predominant deposition in glomeruli, which were comparable 
to primary MN. No circulating antibody or IgG4 deposition was detected in primary 
FSGS patients. The patients with combined lesions had significantly lower urinary suPAR 
concentration, compared to the primary FSGS patients (315.6±302.0 vs. 691.3±1223.5pg/
umol, P=0.014), but similar to the primary MN patients (275.7±253.4pg/mmol).
Conclusions: We conclude that patients with combined MN and FSGS may share the 
same underlying pathogenesis with primary MN. The FSGS lesion might be secondary 
to primary MN.
Funding: Government Support - Non-U.S.
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Glomerulosclerosis Is Prevalent but Not Associated with Kidney Function in 
Healthy Japanese Elderly  Koji Sato, Tsukasa Naganuma, Daisuke Ichikawa, 
Sayuri Shirai, Yugo Shibagaki.  Div of Nephrology and Hypertension, St. 
Marianna Univ, Kawasaki, Kanagawa, Japan.
Background: Previous western studies have shown that global glomerulosclerosis 
(GS) is common in healthy elderly but is not associated with kidney function. We here 
conducted a study to determine whether healthy Japanese elderly, whose glomerular filtration 
rate (GFR) are much lower than that of western counterparts, have also same relationship 
among kidney function and prevalence of GS.
Methods: We analyzed 81 kidney biopsy specimens from Japanese living donors 
obtained at donor nephrectomy between 2009 and 2014. Using the 2007 Banff classification 
system, GS, tubular atrophy (TA), interstitial fibrosis (IF), and arteriosclerosis (AS) on 
kidney samples were evaluated. Donor characteristics such as age, serum creatinine (sCr), 
Cr-based estimated GFR (eGFR), proteinuria, and the prevalence of hypertension, were also 
evaluated. Data were expressed as mean ± standard deviation or median and interquartile 
range (IQR). We performed univariate and multivariate analyses to identify the relationship 
between the parameters.
Results: Average age was 59.5 ± 9.1 years, male accounted for 38 (46.9%), with sCr 
0.68 ± 0.15 mg/dl (eGFR 80.0 ± 12.9 ml/min/1.73m2), proteinuria 125.5 ± 61.0 mg/gCr, 
and hypertensive 28 (34.6%). Each kidney sample had the average of 16 glomeruli (IQR, 
12 to 23) and 1 GS (IQR, 0 to 2), so the proportion of GS among total glomeruli was 6.25% 
(IQR, 0 to 14.3). The prevalence of any GS was 65.4%, any TA, 51.9%, IF greater than 
5%, 48.1%, and any AS, 91.4%. Statistical analyses revealed that donor age was the only 
independent factor related to GS, and also to TA, IF, and AS. Among kidney biopsies of 
our 53 normotensive donors, 5 (9.4%) had more GS than the 95th percentile of the number 
of GS in western studies.
Conclusions: Although Japanese healthy adults had lower GFR and a higher number of 
GS than western counterparts, GS was still not associated with kidney function. Pathological 
significance of GS in otherwise healthy Japanese is not supported as in western counterparts.
PUB247
241 Case of Monoclonal Gammopathy with Renal Biopsy Analysis 
Yuqing Chen, Beini Lv, Yan Wang, Yu Xiaojuan, Ming Hui Zhao.  Renal 
Devision, Dept of Medicine, Peking Univ Frist Hospital, Beijing, China.
Background: Patients with monoclonal gammopathy can accompany various renal 
lesions related or unrelated to the monoclonal gammopathy. We aim to describe the renal 
lesions with monoclonal gammopathy in china.
Methods: Data of renal biopsy and clinical presentation of patients with monoclonal 
gammopathy on serum and/or urine immunofixation electrophoresis in our center from 
1999 to 2014 were collected.
Results: 241 patients met the inclusion criteria and were classified as renal disease 
related to multiple myeloma (MM) (n=18, 7.5%), monoclonal gammopathy of renal 
significance (MGRS) (n=85, 34.9%) and monoclonal gammopathy of undetermined 
significance (MGUS) (n=138, 57.4%).  Among patients with MGRS, Amyloidosis (n=69, 
28.6%) is the most common diagnosis, followed by Light Chain Deposition Disease 
(LCDD) (n=7, 2.9%), Cryoglobulinemic glomerulonephritis (n=6, 2.5%), and 56 cases 
(40.6%) received clone-responsible treatment. Among patients with MGUS, a variety 
of renal lesions were found, including membranous nephropathy (n=48, 20.2 %), IgA 
nephropathy (IgAN) (n=17, 7.05%), interstitial nephritis (n=13, 5.4%), membranous 
proliferative glomerulonephritis (MPGN) (n=9, 3.3%) and so on.
Conclusions: We analyzed the data of monoclonal gammopathy with renal biopsy in 
china for the first time. A growing number of renal diseases were found to be associated with 
monoclonal gammopathy. MGUS is the most common diagnosis of patients with monoclonal 
gammopathy, while membranous nephropathy and IgAN are most common among MGUS. 
Further work are in need to determine whether some MGUS are truly underdetermined 
or with renal significance and whether or not early treatment is in need for these patients.
Funding: Government Support - Non-U.S.
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Urine Microscopy in a Case of Acute Kidney Injury: A Report of an 
Interesting Case  Azka Arif,1 Ahmad Hassan,2 Muhammad Awais Arif,2 Hafiz 
Armaghan Saeed,2 Agha Syed Shabbir Ali,2 Abdul Mateen Nagaria,1 Talal A. 
Khan.1  1Freeman Health System; 2Rawalpindi Medical College.
Background: RBCs casts are usually present in the urine of patients presenting with 
AKI secondary to RPPGN. They are sometimes seen in patients with AIN. A single RBC 
cast seen in urine is enough to consider glomerulonephritis as underlying pathology. We 
report a case of biopsy proven Myoglobinuric AKI with urine RBC casts.
Methods: 68-year-old male presented with AMS and was found to have AKI with 
BUN of 106 mg/dL. & creatinine of 28.6 mg/dL. , He had severe hyperkalemia.His urine 
analysis showed 20-30 RBCs and 3+ Blood. His urine microscopy was done which revealed 
RBC casts, pigmented casts and renal tubular epithelial cells as reviewed by nephrologist 
on call, based on such acute presentation and positive RBC cast, glomerulonephritis was 
considered as possible etiology in addition to acute tubular necrosis and rhamdomyolysis. 
He underwent emergent hemodialysis for severe hyperkalemia and uremia, he was started on 
pulse steroids and underwent CT guided kidney biopsy.It showed extensive myoglobinuric 
ATN, with no evidence of any glomerulonephritis. His ANCA serology, complements levels, 
Anti GBM antibodies & ANA were negative. He required hemodialysis for few days and 
then recovered with residual CKD.
Conclusions: RBC casts are important component of rapid and early diagnosis of 
RPGN.RBCs in a cast are almost always pathological and marker of acute glomerular injury.
Our case represents an unusual finding of RBC casts in myoglobinuric ATN.We purpose 
extensive renal glomerular injury secondary to severe rhabdomyolysis as possible etiological 
factor.Renal tubular epithelial cells are marker for acute tubular necrosis and pigmented 
casts are usually found in rhabdomyolysis which were seen in urine microscopy in our case. 
Urine microscopy though less commonly used provides a vital & faster way of diagnosing 
etiology of AKI and it should be considered in our evaluation of acute kidney injury.
PUB249
Acute Renal Failure in Thrombotic Microangiopathy and C3 
Glomerulopathy?  Tiziana Stellato,1 Paolo Fabbrini,1 Sonia Sirtori,2 Andrea 
Stella.1,2  1Dept of Nephrology, San Gerardo Hospital, Monza, Italy; 2Univ of 
Milano Bicicca, Milan, Italy.
Background: Thrombotic microangiopathy is a rare disease characterized by arteriolar 
and capillary thrombosis with endothelial damage. Clinical manifestations include renal 
involvement such as acute renal failure associated with haematuria and proteinuria .
Methods: We report a case of a 75 years old man without past medical history that 
referred to us with oliguric acute renal failure dialysis-dipendent. Laboratory work up 
revealed creatinine of 7.5 mg/dl, prolonged activated partial thromboplastin time (aPTT) in 
order to 2.2 Ratio, normal Prothrombin time (PT), reduced C3 (65 mg/dl) with normal C4, 
VES augmented, positive low title anti-cardiolipine and anti-beta2 glicoprotein1 antibodies, 
positive LAC screening. Urinalysis showed microhaematuria and proteinuria 2.5 g/24 h, 
ANA, ANCA, antiDNA are negative.  A renal biopsy was performed and showed mesangial 
proliferative glomerulonephritis associated to thrombotic microangiopathy with sub-
endothelial and mesangial C3 deposits. Considering the clinical history, the laboristic tests 
and the biopsy result, suggestive of antiphospholipid syndrome (APS), we start treatment 
with plasma-exchange (total 4 sessions) with plasma sostitution and corticosteroids (500 
mg IV methylprednisolone for 3 days, followed by 0.5 mg/Kg/die oral prednisone). So 
we obtained rapidly recovery of diuresis that resulted in a progressive recovery of renal 
function till serum creatinine 1.4 mg/dl. The post-bioptic course was complicated by 
macrohaematuria and a formation of a pseudoaneurysm immediatly treated with selective 
embolization. Because of this complication we waited start oral anticoagulant till 7 days 
after missing macrohaematuria.
Conclusions: Acute renal failure is a reversible kidney damage that can revert with a 
specific diagnosis and treatment. Kidney biopsy was always gold standard and a combination 
treatment with multiple sessions of plasma exchange and oral and corticosteroids, even 
in presence of contrasting data in literature, may be useful in case of thrombotic micro-
angiopathy.
PUB250
Differences Between Clinical Parameters at Diagnosis and After Treatment 
in Membranous Nephropathy  Sanjana Gupta,1 Horia Stanescu,1 Kieran 
Mccafferty,2 Alan D. Salama,1 Stephen H. Powis,1 John Connolly,1 Neil Ashman,2 
Muhammad M. Yaqoob,2 Robert Kleta,1 Stephen B. Walsh.1  1UCL Centre for 
Nephrology; 2Royal London Hospital.
Background: Membranous Nephropathy is the leading cause of nephrotic syndrome 
in adults. Idiopathic (IMN) and secondary (SMN) forms exist. Clinical parameters such 
as serum creatinine (sCr), serum albumin (sAlb) and urine protein creatinine ratio (PCR) 
are important to make a diagnosis, and are used as surrogate markers for evidence of 
remission from disease.
Methods: We performed a retrospective analysis of all patients with biopsy proven 
IMN at the Royal London and Royal Free Hospitals that were under follow between 1995 
- 2015. Clinical data was collected using renal databases.
Results: We identified 240 patients with biopsy proven MN. 171 patients still had native 
renal function. 69 reached end stage renal failure (ESRF). 188 had IMN, 52 had SMN. There 
was no significant difference in age between IMN and SMN (56.8 ± 1.5 vs. 52.6 ± 1.9 years 
respectively). At the time of diagnosis, there was no difference between IMN and SMN in 
PCR (924 ± 73 vs 863 ± 154, ns) or sCr (116 ± 12 vs 101 ± 10 µmol/L, ns). At presentation 
the sAlb was significantly lower in IMN (24.9 ± 0.8 vs 28 ± 1.2 mmol/L, p=0.02). In IMN, 
treatment significantly improved the PCR (924 ± 73 to 337 ± 57, p<0.0001) and sAlb (24.9 ± 
0.8 to 39.7 ± 0.6 mmol/L, p<0.0001), but sCr significantly worsened (116 ± 12 to 123 ± 7.2 
µmol/L, p=0.017). In SMN, treatment again significantly improved the PCR (863 ± 154 to 
221 ± 36, p=0.001) and sAlb (28 ± 1.2 to 39 ± 0.8 mmol/L, p<0.0001), but sCr significantly 
worsened over the treatment period (101 ± 10 to 126 ± 12 µmol/L, p=0.0045). Of the MN 
patients who reached ESRF, the sCr was significantly worse on presentation (235 ± 42 vs 
111 ± 8 µmol/L, p<0.0001). These patients had significantly higher sAlb (30.8 ± 1.4 vs 26 
± 0.6 mmol/L, p=0.001) and accordingly PCR tended to be lower at presentation, but this 
difference failed to reach significance (628 ± 79 vs 901 ± 78, p=0.06).
Conclusions: In our cohort of patients with membranous nephropathy, sAlb is lower in 
IMN compared to SMN. Treatment improves proteinuria and albumin but does not prevent 
a decline in serum creatinine.
PUB251
An Unusual Case of Seronegative Lupus Nephritis with ANCA-Positive 
Serology  Amibahen Gandhi, Varun Malhotra, Shani C. Kotadia, Medha Joshi. 
Conemaugh Memorial Medical Center, Johnstown, PA.
Background: Seronegative lupus nephritis is a condition with renal histology typical 
for lupus nephritis without clinical and serologic evidence of systemic lupus nephritis (SLE).
Methods: Here, we report an unusual presentation of seronegative SLE diagnosed 
with kidney biopsy who does not meet any other diagnostic criteria for SLE established 
by American Rheumatism Association. Our patient was 60- year-old woman with past 
medical history of only hypothyroidism, presented with new onset of acute kidney injury 
and hypertension. Laboratory data showed BUN and creatinine of 74mg/dl and 10.3mg/dl 
respectively, hypocomplementemia and nephrotic range proteinuria and hematuria. Serology 
tests including serum ANA, anti ds DNA, anti-smith and smooth muscle antibodies, 
anticardiolipin IgG and IgM titers, C1Q binding assay were negative. HIV, hepatitis B and C 
viruses serologies were negative too. C-ANCA (0.7 U) and P-ANCA (1.5U) were positive. 
Renal biopsy showed proliferative crescentic and membranous glomerulonephritis with a 
full house immuno-fluorescence pattern with extra-glomerular tubular basement deposits 
suggestive of Lupus like glomerulonephritis. Patient required hemodialysis for her renal 
failure and was treated with oral cyclophophamide and corticosteroids. Seven months into 
treatment, patient still requires twice a week hemodialysis with only minimal recovery of 
renal function and has not yet experienced any clinical symptoms of SLE.
Conclusions: In conclusion, we present an unusual case of ANCA positive, ANA 
negative full house nephropathy. ANA negative lupus nephritis is very rare presentation 
with incidence rate of 1-5%. At this point we are not sure if in the future patient will 
develop further clinical or serological evidence of SLE and then be diagnosed as “SLE with 
positive immunological response to ANCA”. ANCA vasculitis is pauci-immune and hence 
it would be extremely unlikely and rare if it turns out that she has ANCA vasculitis with full 
house on renal immuno-florescence. The treatment and prognosis of renal-limited lupus-
like glomerulonephritis remains unclear, although limited data suggest a poor prognosis.
PUB252
Pathological and Clinical Analysis of the Kidney Puncturation Biopsy in 
1,551 Cases  Mei Li,1 Qiong-li Yin,1 Zhenda Zheng,2 Cai-Lian Cheng,3 Xun 
Liu,3 Cheng-gang Shi.3  1VIP Healthcare Center, The Third Affiliated Hospital 
of Sun Yat-sen Univ, Guangzhou; 2Cardiovascular Dept, The Third Affiliated 
Hospital of Sun Yat-sen Univ, Guangzhou; 3Nephrology Dept, The Third Affiliated 
Hospital of Sun Yat-sen Univ, Guangzhou, China.
Background: To summarize all the renal biopsy cases in the Past ten years in the Third 
Affiliated Hospital of Sun Yat-sen University;analyze the pathological type distribution,and 
their relationship with clinical manifestations.
Methods: Pathological and clinical data in 1, 551 cases with renal biopsy with complete 
clinical data were analyzed retrospectively from January 2005 to December 2014.
Results: Among 1, 551 cases, age 6-83 ( 34.81±14.28 years). including primary 
glomerular disease (63.8%) , secondary glomerular diseases(33.5%). The first third 
pathological types of primary glomerulonephritis are IgA nephropathy(38.6%), glomerular 
minor lesion(25.9%) and membranous nephropathy(MN) (19.3%). The first third 
pathological types of secondary glomerulonephritis are lupus nephritis(LN)(65.2%), 
diabetic nephropathy(DN)(8.5%) and hepatitis B virus associated glomerulonephritis(HBV-
GN)(7.3%). Acute and chronic rejection are the most common pathological type of renal 
transplantation in 26 cases. Chronic nephritis syndrome and nephrotic syndrome are the 
most common clinical manifestations. For male versus female, the ratio is 1.32:l in the 
primary glomerulonephrtis,while 0.73:1 in the secondary glomerulonephrtis.
Conclusions: Primary glomerulonephritis is still the most common form of renal 
disease,and almost in male. IgA nephropathy is the most common pathological type of 
primary glomerulonephritis followed by glomerular minor lesion.While for the secondary 
glomerulonephritis,female is more than male,and LN is the most common pathological 
type followed by DN. And Chronic nephritis syndrome is the most common clinical 
manifestations of renal biopsy.
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Iodine-123 MIBG Imaging of Renal Cell Carcinoma with Pathological 
Correlation  Ken Hiratsuka,1 Isao Kurihara,1 Sayuri Suzuki,1 Shintaro 
Yamaguchi,1 Toshiaki Monkawa,1 Koichi Suzuki,2 Hiroshi Itoh.1  1Dept 
of Internal Medicine, Keio Univ School of Medicine, Japan; 2Dept of 
Mycobacteriology, Leprosy Research Center, National Inst of Infectious 
Diseases, Japan.
Background: The incidence of renal cell carcinoma has continuously increased during 
the last fifty years. Despite the increase in number, the five year survival rate has been 
reduced by the advances in renal imaging. Chromophobe renal cell carcinoma (ChRCC) is 
an uncommon variant of RCC, accounting for approximately 5% of renal cancer. Although 
its prognosis is usually favorable, preoperative diagnosis is difficult because there is no 
marker for this variant. Here, we reported a novel method to distinguish ChRCC from 
othter RCC(especially, clear cell carcinoma).
Methods: We experienced a case of ChRCC with adrenal pheochromocytoma in a 
69-year-old Japanese female. We noticed that iodine-123 MIBG scintigraphy showed uptake 
in ChRCC in addition to pheochromocytoma; uptake was not observed in othter cases of 
clear cell carcinoma. As a candidate transporter that mediate iodine-123 uptake in ChRCC, 
we determined the expression of pendrin, a Cl-/HCO3- exchanger expressed in the kidney 
cortex. The pendrin messenger RNA (mRNA) expressions, and protein expressions were 
analyzed in 4 cases of ChRCC and 3 cases of clear cell carcinoma.
Results: The protein expression of pendrin, the candidate transporter, which related 
to iodine-123 uptake, was highly detected in ChRCC compared with clear cell carcinoma. 
Moreover, the mRNA expression was also exclusively increased in ChRCC.
Conclusions: We identified specific transporter, pendrin, which is highly expressed in 
ChRCC. Our results indicates that iodine-123 MIBG scintigraphy may be a useful tool for 
the diagnosisof ChRCC and represents a substantial advance in the diagnosis of ChRCC.
PUB254
Clinical Significance of Glomerular IgG Deposits in IgA Nephropathy 
Anthony Alvarado,1 Nicole K. Andeen,2 Sergey V. Brodsky,3 Alice Hinton,4 
Tibor Nadasdy,3 Charles E. Alpers,2 Christopher D. Blosser,5 Behzad Najafian,2 
Brad H. Rovin.1  1Faculty of Medicine, Nephrology Div, The Ohio State Univ, 
Columbus, OH; 2Pathology Dept, Univ of Washington, Seattle, WA; 3Pathology 
Dept, The Ohio State Univ, Columbus, OH; 4Div of Biostatistics, College of 
Public Health, The Ohio State Univ, Columbus, OH; 5Faculty of Medicine, 
Nephrology Div, Univ of Washington, Seattle, WA.
Background: IgAN is characterized by IgA dominant or IgA-IgG co-dominant 
mesangial immune deposits. It is not clear whether the presence of IgG in IgAN affects 
disease prognosis. We evaluated the significance of IgG co-deposits in IgAN.
Methods: Consecutive IgAN biopsies (n=80) from Ohio State University and 
University of Washington (2001-2013) were retrospectively classified into IgA only and 
IgA+IgG (IgG > trace). The presence or absence of IgG was correlated to the combined 
primary outcome of renal replacement therapy, death, OR doubling of serum creatinine 
(SCr). The change in estimated GFR (eGFR) was also assessed. Covariates were age, sex, 
race, SCr and proteinuria at biopsy, length of follow-up, treatment, Oxford score, and 
presence of crescents.
Results: This cohort was 64% male, 69% Caucasian and 14% Asian. IgA+IgG deposits 
were seen in 25 of the patients. There was no difference between IgA and IgA+IgG with 
respect to any of the covariates or between initial and follow-up proteinuria. There was a 
tendency for more endocapillary hypercellularity to be seen in IgA+IgG biopsies (p=0.08). 
The primary outcome was reached in 24 patients, 16 with IgA and 8 with IgA+IgG (p=0.82). 
Using multivariate modeling the change in eGFR over time was not different between 
IgA and IgA+IgG.
Conclusions: In this cohort of IgAN patients the presence of IgG co-deposits in the 
mesangium did not affect clinical outcomes.
PUB255
Idiopathic Cryoglobulinemic Crescenteric Glomerulonephritis – A Rare and 
Atypical Case  Pedram Joseph Kohan,1 Akshatha Rao,2 Sandeep Aggarwal.2 
1Internal Medicine, Drexel College of Medicine/Hahnemann Univ Hospital, 
Philadelphia, PA; 2Nephrology, Drexel College of Medicine/Hahnemann Univ 
Hospital, Philadelphia, PA.
Background: Cryoglobulinemic Glomerulonephritis is an rare entity, manifesting 
in middle-aged females, We report an atypical case of cryoglobulinemic cresenteric 
glomerulonephritis in an 18-year-old African American Male without an identifiable viral, 
autoimmune or lymphoproliferative etiology.
Methods: Our case is an 18 y/o AAM with no significant PMH who presented for an 
incidental hematuria and proteinuria. Patient did not complain of edema, recent illness, 
joint pains, rash, night sweats or weight loss. No history of IVDA. BP was 114/72, without 
significant physical exam findings. Urine microscopy: cellular casts and dysmorphic RBCs. 
Serum creatinine was 1.27 mg/dL. 
Renal Biopsy 
LM: crescents and endocapillary proliferation. EM showed subendothelial, 
subepithelial and paramesangium 20.5-25nm microtubular fibrils. IF: only C1q 2-3+ 
granular GBM and mesangial deposits. Labs: UPCR: 2.1 grams/day, ESR and CRP levels 
were markedly elevated. Viral hepatitis/HIV PCR, ANA, anti-DsDNA, anti-RNP,anti-smith, 
SSA/SSB, anti SM and Rh factor/CCP, C3, C4, ASO, cryocrit, SPEP/UPEP/free light chains/
Immunofixation , peripheral flow cytometrywere negative. Patient was treated with IV 
methylprednisolone pulse and rituximab with improvement of renal function and proteinuria.
Conclusions: The uniqueness of this case is underscored by a variety of factors; clinical 
presentation, laboratory, serologies, and pathology. Laboratory and serological studies 
in cryoglobulinemia generally follow a characteristic pattern, detection of circulating 
cryoglobulins, low levels of complement, viral, autoimmune or lymphoproliferative 
etiology- yet a limited number of cases have presented with normal serological results, 
similar to the case presented here.
PUB256
Development of a Clinicopathologic Kidney Biopsy Database Using 
Billing and Diagnosis Codes: A Descriptive Study  Nosayaba Enofe,1 
Anju A. Oommen,1 Jason Cobb,1 Jose E. Navarrete,1 Demilade Adedinsewo,2 
Oluwatobiloba A. Osikoya,3 Helene B. Fevrier,4 Frederic F. Rahbari-Oskoui,1 
Alton Brad Farris,5 Laura Plantinga,1 Titilayo O. Ilori.1  1Dept of Nephrology, 
Emory Univ School of Medicine, Atlanta, GA; 2Morehouse School of Medicine, 
Atlanta, GA; 3Lee Univ, Cleveland, TN; 4Dept of Epidemiology, Rollins School 
of Public Health, Emory Univ, Atlanta, GA; 5Dept of Pathology and Laboratory 
Medicine, Emory Univ School of Medicine, Atlanta, GA.
Background: A growing kidney disease population coupled with expanded use of 
electronic medical records (eMR) presents a unique opportunity for regional translational 
clinical research. We developed a comprehensive registry of all native renal biopsies at 
a major hospital in Southeastern US and described the pattern of glomerular diseases.
Methods: We identified all native percutaneous renal biopsies (n=2,245) performed 
on adults (>18) between 2000 and 2011 using CPT and ICD-9 billing codes (50200 and 
55.23).Transplant biopsies (V42.0) and cytopathology were excluded. Renal pathology 
reports were reviewed by at least two independent clinical nephrologists. Clinical, laboratory 
and demographic data were extracted and validated by independent chart review. A 
clinicopathologic diagnosis was subsequently entered. Descriptive and bivariate statistics 
were used to analyze patient characteristics at biopsy.
Results: Patients in the registry had a mean age of 44.2 years; approximately half were 
male and majority were African American (40.7%). Overall, lupus nephritis (n=278, 12.4%) 
was the most prevalent renal clinicopathologic diagnosis. Among primary glomerular 
diseases, FSGS (136, 9.2%) was the most prevalent, followed by IgA nephropathy (123, 
8.3%), membranous glomerulonephritis (GN) (69, 4.6%), membranoproliferative GN (24, 
1.6%) and minimal change disease (27, 1.8%). Diabetic nephropathy was the second most 
common secondary GN (97, 6.5%) followed by ANCA-associated vasculitis (31, 2.1%). 
Other diagnoses were all less than 2%.
Conclusions: We successfully established a kidney biopsy registry at our center, which 
will be instrumental to studying outcomes in this rare group of diseases, the most prevalent 
of which were lupus nephritis and FSGS.
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Is There Clinical Significance of IgM and Complement Staining in Idiopathic 
Focal Segmental Glomerulosclerosis  Vasantha M. Muthuppalaniappan,1 
Kieran Mccafferty,1 Michael Sheaff,2 Muhammad M. Yaqoob.1  1Nephrology, 
Barts & The London NHS Trust, London, United Kingdom; 2Pathology, Barts 
& The London NHS Trust, London, United Kingdom.
Background: Experimental evidence suggest that focal segmental glomerulosclerosis 
with complement deposits is associated with poor outcome. Whether this is transferable or 
relevant in human disease is unclear.
Methods: We performed a proof-of-concept observational study on all patients with a 
diagnosis of idiopathic focal segmental glomerulosclerosis (iFSGS) on native renal biopsies 
from January 2004 to December 2014. A total of 40 renal biopsies were identified. Clinical 
outcome data were obtained to seek an association with complement deposits (CD) and 
outcomes. Immunosuppression administered was according to the local trust policy which 
included prednisolone and cyclophophamide or calcineurin inhibitor.
Results: See Table 1 
No CD (n= 21) CD (n= 19) P
Age 43 (35-50) 39 (30.5-54.5) 0.6
Sex Male 11 (52) 7 (27) 0.35
Race Black/Asian/White 6 / 9 / 6 8 / 5 / 6 0.39
Type of lesion : Tip/Collapsing/NOS 2 / 2 / 17 3 / 0 / 16 0.34
IgM 0 (0) 18 (95) <0.0001
Immunosuppression 12 (57) 12 (63) 0.75
Baseline urine protein creatinine ratio 
(UPCR) 540 (330-1000) 1000 (560-1200) 0.07
Baseline albumin 29 (24-38) 26 (21-36) 0.47
Baseline eGFR 49 (25-71) 60 (48-81) 0.26
Change in UPCR - 370 [ -700 - (-140)] - 430 [ -790- (-260)] 0.7
Change in serum albumin 8.5 (2.3-13) 4 (0-17) 0.55
Change in eGFR 4.5 (-5.5 - 21) 4 (-15-11) 0.44
CD was present in approximately 50% of the biopsies, but there was no significant 
association between CD and baseline clinical or demographic characteristics, furthermore, 
there are no association between CD and markers of disease progression (change in 
proteinuria, serum albumin or GFR between baseline and 1 year follow up). IgM staining 
was strongly co-associated with CD.
Conclusions: Our results indicate that, unlike animal models of iFSGS; IgM and 
complement deposition does not alter outcomes. However, these findings will need to be 
confirmed in a larger study.
PUB258
A Case of Intra-Ocular Lucentis (Ranibizumab) Induced Minimal Change 
Disease  Ashwin Reddy Ganta.  Dept of Nephrology, Archbold Memorial 
Hospital, Thomasville, GA.
Background: Intrvitreal Monoclonal antibodies like Lucentis (Ranizibumab) , Eylea 
and Avastin are being increasingly used for the treatment of Wet Age related Macular 
Degeneration (wAMD) and Diabetic Macular Edema (DME) of the eye. Though the 
systemic toxicity of these VEGF  inhibitors is well known, not much is known about the 
renal toxicity profile of these agents when administered intravitreally.
Methods: A 78 y/o WM presented  with worsening shortness of breath and anasarca. 
His PMH was significant for Afib, h/o Lung Cancer s/p RLL resection 8 years ago and he 
was receiving Lucentis intravitreal shots for his AMD and had just had his 5th monthly 
dose a few days ago. His urine showed 3 + protein with some RBCs and we were consulted 
for worsening renal function with a Scr of 2.4 mg/dl , up from a baseline of 1.0 mg/dl. 
Given his h/o cancer with almost 3 gms of proteinuria, MCD (Minimal Change Disease) 
was high in the differential. Serology for HIV, SPEP, Hep C, SIEP, ANA and ANCA was 
negative . His Scr continued to worsen and reached a peak of 4.6 and he had to undergo 
Dialysis for volume overload . Renal Biopsy performed showed 9 glomeruli with  no 
evidence of IC mediated injury and MCD pattern confirmed on EM. He was started on 
high dose steroids and discharged with a diagnosis of MCD 2/2 Lucentis. He was taken off 
HD after he started showing signs of renal recovery in a few weeks and he was gradually 
tapered of Steroids over the next 4 months. His proteinuria has completely subsided and 
his Scr is back to his baseline .
Conclusions: Systemic use VEGF inhibitors and their renal toxicity is well documented. 
Now , they are currently being to treat wAMD and DME. However, there is some evidence 
that intravitreal use may result in systemic absorption, with the potential for AKI. We report 
the first case to our knowledge of a patient who developed severe AKI needing HD with 
MCD pattern of injury after 5 intravitreal injections of ranibizumab that was successfully 
treated with cessation of Lucentis and Steroids. Because of the increasing use of these agents, 
ophthalmologists and nephrologists should be aware of the associated risks.
PUB259
E c u l i z u m a b  i n  a  P a t i e n t  w i t h  L u p u s  N e p h r i t i s  a n d 
Thrombot i c  Microang iopathy:  Outcome  Af ter  One  Year 
Maria Izabel Neves de Holanda Barbosa,1 Lilian M. Pereira,2 Alicia Imada,1 
Luiz Fernando Christiani.1  1Nephrology and Kidney Transplant, Hospital 
Federal de Bonsucesso, Rio de Janeiro, Brazil; 2Pediatrics Nephrology, Univ 
Estadual de Campinas, Campinas, São Paulo, Brazil.
Background: Lupus Nephritis is a severe disease and when is associated with 
Thrombotic microangipathy the prognosis is worst.
Methods: This is a cse report of a female patient, 18 years old, with no past history 
of disease, started fever, abdominal pain and dysuria treated initially as UTI. She evolved 
with skin rash and a few days later, oligoanuria, nausea and vomiting. She was admitted 
and started hemodialysis on the same day. Initial exams showed thrombocytopenia, anemia, 
High LDH, schistocytes on blood smear, direct Coombs test negative, urinalysis with 
hematuria and proteinuria. ANA and anti DNAds were positive, ADAMST13 96%, C3 
and C4low. SLE was diagnosed and she received standard therapy with metilprednisolone 
and cyclophosphamide.She needed RBC transfusions at least twice a week. After 55 days 
of treatment, she still presented over hemolysis and anuria in hemodyalisis.
Results: We decided to start eculizumab and after one week, platelet count increased 
allowing for a renal biopsy that showed lupus nephritis class IV with thrombotic 
microangiopathy. After the third dose of eculizumab, there was improvement of anemia 
and she started to present diuresis. She was discharged from hospital one week later with 
creatinine of 2.3 mg/dL and off dialysis. After one year, she is on maintenance eculizumab 
every two weeks with low dose prednisone and mycophenolate mofetil 1per day.Creatinine 
is 1.7 mg/dL, hemoglobin 11 g/dL, normal platelet count and LDH.
Conclusions: This is a successful case of eculizumab in a patient with Lupus nephritis 
and thrombotic microangiopathy refractory to classical treatment. A putative explanation is 
that autoantibodies may have primed the endothelium, unmasking a complement defect that 
was successfully controlled by terminal complement blockade. A genetic analysis may reveal 
a mutation in regulator factors of the alternative complement pathway or auto-antibodies 
against Factor H or I. Eculizumab may be an option for the treatment of refractory lupus 
nephritis with thrombotic microangiopathy.
PUB260
Diagnostic Items for Renal and Hepatic Cyst Infection – A Delphi Survey 
Marten A. Lantinga,1 Alexander J.M. Darding,1 Rudolphe De Sevaux,1 Ron T. 
Gansevoort,2 Marie C. Hogan,3 Ahsan Alam,4 William M. Bennett,5 Chantal 
P. Bleeker-Rovers,1 Mickaël Bobot,6 Arlene B. Chapman,7 Emilie Cornec-Le 
Gall,8 Gregory T. Everson,9 Tom J.G. Gevers,1 Jose L. Gorriz,10 Ziad Hassoun,11 
Esther Meijer,2 Michal Mrug,12 Frederik Nevens,13 Luiz F. Onuchic,14 Hayne C. 
Park,15 York P. Pei,16 Giorgina B. Piccoli,17 Yves A. Pirson,11 Gopala K. Rangan,18 
Darius Soonawala,19 Roser Torra,20 Folkert W. Visser,2 Terry J. Watnick,21 
Francois Jouret,22 Nada Kanaan,11 Wim J.G. Oyen,1 Tatsuya Suwabe,23 Vicente 
E. Torres,3 Joost P.H. Drenth.1  1Radboudumc; 2UMCG; 3Mayo Clinic; 4McGill; 
5Legacy Health; 6AMU; 7Emory Med; 8CHRU; 9CU Med; 10Dr Preset Hosp; 
11UCL Saint-Luc; 12UAB; 13UZ Leuven; 14Univ São Paulo; 15SNUH; 16U of T; 
17San Luigi Gonzaga Hosp; 18WMI; 19LUMC; 20IIB Sant Pau; 21Hopkins Med; 
22ULg CHU; 23Toranomon Hosp.
Background: Diagnosis of renal and hepatic cyst infection is made on the presence 
of a positive cyst aspirate culture. If that is absent, diagnosis is made on a mix of clinical, 
biochemical, and imaging findings. The weight of these diagnostic items is uncertain, hence 
our aim to establish a set of items for cyst infection diagnosis.
Methods: We used a Delphi survey among acknowledged experts to achieve consensus 
on diagnostic items. We retrieved items from literature and physician/patient interviews. 
Items were rated on a nine-point scale in a three-round online survey. We categorized items 
by median rating (£3.4=inappropriate; 3.5-6.4=uncertain; ≥6.5=appropriate).
Results: Of 58 invited experts, 35 (60%) responded to round one (round two: 91% 
n=32; round three: 86% n=30). The final panel included 23 nephrologists, five hepatologists, 
a nuclear medicine specialist, and an infectiologist from 11 countries (male 67%, age 
47±11yrs, median clinical experience 21yrs). We identified 59 items and rated each for renal 
and hepatic cyst infection. Majority was derived from literature (n=46). Ultimately, 26 renal 
and 22 hepatic items were rated as appropriate. Remaining items were rated inappropriate 
(renal n=18; hepatic n=12) or uncertain (renal n=15; hepatic n=25).
Conclusions: We identified diagnostic items for renal and hepatic cyst infection and 
on this basis we developed a diagnostic algorithm.
Funding: Clinical Revenue Support
PUB261
The Use of Multiplex Ligation-Dependent Probe Amplification Technology 
for Genetic Analysis of the Entire PKD1 Gene and PKD2 Gene 
Tetsuhiko Yasuno.  Fukuoka Univ, Fukuoka, Japan.
Background: In common cases of autosomal dominant polycystic kidney disease 
(ADPKD), diagnosis is relatively simple using a combination of diagnostic imaging of the 
kidney and analysis of ADPKD in the patient’s family history. Therefore, in most patients 
with ADPKD, genetic testing for ADPKD is not necessary for diagnosis. However, in 
ADPKD cases where a definitive diagnosis is not obtained by imaging or living relative 
related donor is identified for kidney transplantation, genetic testing may be necessary.
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Methods: Multiplex ligation-dependent probe amplification (MLPA) kits have been 
developed for genetic analysis by MRC-Holland using proprietary MLPA technology. We 
obtained informed consent from nine patients (mean age, 45 years) and collected 8 mL 
of blood from each patient for analysis of genetic mutations in PKD1 and PKD2 genes 
using the MLPA method.
Results: In case 1 (a 39-year-old man), we found deletions in exons 3 and 39 of the 
PKD1 gene. The kidney was extracted due to enlargement and cyst infection. Dialysis 
was initiated when the patient was 39 years of age. The kidney capacity was 5013 mL. 
In case 2 (a 32-year-old woman), we found a deletion in exon 3 of the PKD1 gene. Renal 
function was maintained, and the serum creatinine level was 0.7 mg/dL.She has hope of 
the delivery. Tolvaptan does not have the safety about the dosage to a pregnant woman. 
Tolvaptan was administered after delivery.
No mutations were identified in the other subjects.
Conclusions: Genetic screening of the PKD1 and PKD2 genes using the MLPA 
method may decrease cost and labor. Indeed, the MLPA method was especially useful in 
cases exhibiting juvenile onset and rapid kidney enlargement.
PUB262
Short-Term Effects of Tolvaptan to a Body Water Balance in Patients with 
ADPKD  Minoru Makita, Saori Nishio, Junya Yamamoto, Tasuku Nakagaki, 
Tatsuya Atsumi.  Internal Medicine 2, Hokkaido Univ, Sapporo City, Hokkaido, 
Japan.
Background: In the clinical trials of Tolyaptan, reversible serum creatinine elevation 
and adverse events related to increased aquaresis were reported in some patients with 
autosomal dominant polycystic kidney disease (ADPKD). To clarify the mechanism of those 
adverse events, we preliminarily evaluated a volume statusbefore and after administration 
of tolvaptan in ADPKD patients by analysing body composition with multiple-frequency 
bioelectrical impedance analyser (InBody720®) and associating with renal function.
Methods: Nineteen ADPKD patients who started administration of tolvaptan were 
examined. Body weight and renal function were measured before (baseline) and 2 days 
(day2) after initial tolvaptan administration. Height-corrected total kidney volume (htTKV) 
were measured at baseline. Total body water (TBW), intracellular water (ICW) and 
extracellular water (ECW) [whole body, limbs and trunk, respectively], were measured 
using InBody720® at baseline and day2.
Results: The administration of tolvaptan significantly reduced body weight, eGFR, 
TBW, ICW and ECW in whole body and TBW in limbs. However, TBW in trunk were 
sustained (Table).
baseline day2 p-value
Body weight(kg) 64.0±12.5 62.1±11.8 <0.001
eGFR(ml/min/1.73m2) 53.9±27.2 51.4±24.8 0.013
TBW whole(kg) 38.2±8.1 36.0±7.4 <0.001
ECW whole(kg) 14.8±2.9 13.9±2.7 <0.001
ICW whole(kg) 23.3±5.2 22.2±4.8 <0.001
TBW trunk(kg) 16.8±3.7 16.5±3.5 0.75
ICW trunk(kg) 10.3±2.4 10.2±2.2 0.58
TBW limbs(kg) 16.9±4.3 15.7±4.1 <0.001
HtTKV at baseline correlated with rate of ICW in trunk and TBW in whole at baseline 
(r=0.39, p=0.049). There were no significant correlation between eGFR decrease and rate of 
change in body weight (r=0.02, p=0.46). Rate of TBW in limbs and TBW in whole at baseline 
correlated with rate of change in eGFR (r=0.45, p=0.028). These results suggest that cyst 
fluid might be measured as ICW by InBody720®. TBW in limbs can predict eGFR decline.
Conclusions: Measuring body water balance by InBody720® could be useful as 
predictors of htTKV and eGFR decline in short term after administration of tolvaptan in 
ADPKD patients.
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A Rare Presentation of Acute Kidney Injury: Have a Look at the Skin 
Alper Alp,1 Sarenur Esener,2 Didar Gursoy.3  1Nephrology, Van Education and 
Research Hospital, Van, Turkey; 2Dermatology, Van Education and Research 
Hospital, Van, Turkey; 3Pathology, Van Education and Research Hospital, 
Van, Turkey.
Background: Tuberous sclerosis(TS) is a multisystem,rare,genetic disorder of 
autosomal dominant inheritance which can involve different organs.Most commonly 
involved organ system is skin.We describe a case presented with periungual 
fibromas,multiple renal cysts and Shagreen patch without other features of TS.
Methods: A 33 yo woman presented with fatigue and renal failure.On physical 
examination,she had multiple non traumatic periungual fibromas in both hands and feet.
Also Shagreen patch was seen in the right lumbosacral region.
On admission biochemical tests;urea 132 mg/dl,creatinine 4,7 mg/dl,potassium 
4,7 mmol/L,pH 7,32,HCO3 18,4.Urinary output was satisfactory,no uremic symptoms 
were present.Renal ultrasonography revealed bilateral renal cysts with normal size and 
parenchymal thickness.Histopathology of the Shagreen patch revealed dense collagen 
bundles in the dermis.Due to the skin lesions and renal cysts the patient was diagnosed as 
TS.Other manifestations of TS were not present.Renal biopsy was suggested but she did 
not accept the procedure.
Conclusions: As stated in diagnostic criterias,physical examination has a strong impact 
on diagnosis of TS.Hypomelanotic macules(>3),Shagreen patch,forehead plaque,non 
traumatic periungual fibromas,adenoma sebaceum,facial angiofibromas should remind 
the physicians TS.Kidneys are involved in almost 50-80% of the adult patients.Most 
frequent renal lesions in TS are angiomyolipomas.Bilateral and multiple characteristics 
of angiomyolipomas are pathognomonic.They may progress to end stage renal disease.
However in some rare cases frank renal lesions may be absent.With a detailed inspection it 
is possible to recognize these specific dermatological signs,making the Tuberous sclerosis 
diagnosis and taking these patients under nephrological follow up.
PUB265
Use of Antidepressant Medications During the HALT-PKD Randomized 
Trials  Vicente E. Torres,1 Kaleab Z. Abebe,2 Theodore I. Steinman,3 Charity 
G. Moore,2 Ronald D. Perrone,4 Arlene B. Chapman,5 Robert W. Schrier,6 Alan 
S.L. Yu,7 William E. Braun,8 Kyongtae Ty Bae,2 Peter C. Harris,1 Charity G. 
Moore,2 Michael F. Flessner,9 The HALT PKD Investigators.10  1Mayo; 2U. 
Pittsburgh; 3BIDMC; 4Tufts U.; 5U. Chicago; 6U. Colorado; 7KS U. Med. Ctr.; 
8Cleveland Clinic; 9NIH; 10Multi-Ctr.
Background: Depression occurs in CKD more commonly than in the general 
population and is associated with poor outcomes. The use of antidepressants (ADs) has been 
associated with inappropriate release of vasopressin and hyponatremia. Since vasopressin 
is thought to aggravate the progression of ADPKD, AD use could be deleterious.
Methods: Examine the use of ADs in the participants of the HALT-PKD randomized 
clinical trials (RCTs) and whether their administration is associated with faster disease 
progression. Post-hoc analysis of two HALT-PKD RCTs (A and B) studying the effect of 
rigorous vs standard BP control (A) and of ACE inhibitor alone vs ACE inhibitor/ARB 
combination (A and B) on rates of change of TKV (A) and eGFR (A and B) in ADPKD 
patients with eGFR >60 (A) or 25-60 (B) ml/min/1.73 m2.
Results: Female used ADs more frequently than male participants (39.7% of 526 
vs 20.4% of the 518, P<0.0001). Study A used ADs as frequently as study B participants 
(31.7% and 28.4%, respectively). Participants with PKD2 mutations used ADs (42.4%) 
more frequently than those with PKD1 mutations (27.9%, P=0.0009) despite having milder 
disease. Ages of those using or not using ADs were similar. To assess the effect of ADs 
on disease progression we divided the participants into three groups, no exposure to ADs, 
exposure for less £30% and exposure for >30% of the time:
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Study AD Use
S. 
Sodium* 
(mEq/L)
Ucr/Pcr*
U. 
Sodium* 
(mEq/24 
hrs)
LnTKV 
change 
(% per 
yr)
eGFR change 
(ml/
min/1.73m2/
yr)
A None (N=381) 138.7 65.1 178.3 6.32 -2.85
A >30% (N=128) 138.4 65.9 175.1 5.81 -3.32
P-value 0.031 0.89 0.37 0.22 0.07
B None (N=348) 139.3 30.5 168.2 - -3.81
B >30% (N=112) 138.8 31.9 151.6 - -3.82
P-value 0.06 0.46 0.005 - 0.98
*Average of measurements for each participant during the trial
Conclusions: AD use, defined as >30% use, does not affect the progression of ADPKD. 
Whether a particular AD class has an effect is under evaluation.
Funding: NIDDK Support
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Dysregulation of miR-378a-3p and ADAMTS1 Gene in cpk Mice: A Model 
of ARPKD  Masashi Sato,1 Koichi Nakanishi,1 Taketsugu Hama,1 Hironobu 
Mukaiyama,1 Hiroko Togawa,1 Yuko Shima,1 Masayasu Miyajima,2 Kandai 
Nozu,3 Shizuko Nagao,4 Hisahide Takahashi,4 Kazumoto Iijima,3 Norishige 
Yoshikawa.5  1Pediatrics, Wakayama Medical Univ, Wakayama, Japan; 
2Laboratory Animal Center, Laboratory Animal Center, Wakayama, Japan; 
3Pediatrics, Kobe Univ, Kobe, Japan; 4Education and Research Center of Animal 
Model for Human Disease, Fujita Health Univ, Aichi, Japan; 5National Center 
for Child Health and Development, Tokyo, Japan.
Background: The pathophysiology of cystic epithelia in PKD is characterized by 
altered proliferative activity, a secretory rather than absorptive function, and an abnormal 
matrix microenvironment. miRNAs are clarified to be involved in PKD. However, the detail 
has not been fully investigated. We reported that cpk cystic epithelia partially share cell 
pathophysiology with colorectal carcinoma (JASN 25:414A, 2014). Recently, dysregulation 
of miR-378a-3p/ADAMTS1 axis was reported in colorectal carcinoma (Kara, et al. Gene, 
in press). ADAMTS1 is one of the ADAMTS (A Disintegrin And Metalloproteinase 
with ThromboSpondin motifs) metalloproteinase family. Elevated ADAMTS1 promotes 
pro-tumorigenic changes such as increased tumor cell proliferation and altered extra cell 
matrix environment.
Methods: To identify miRNAs that are differentially expressed between cpk and control 
kidneys, we performed miRNA microarrays, and assessed the target molecule gene and its 
product expression using real-time PCR and western blotting.
Results: miRNA microarray analysis revealed that 22 (up 4, down 18) miRNAs were 
differentially expressed (more than 4-fold) in cpk (day 21, n=7) kidneys. Of 22 miRNAs, 
miR-378a-3p was significantly downregulated in cpk (5.1-fold). Real-time PCR confirmed 
that miR-378a-3p was significantly downregulated in cpk (day 14, n=14, 5.0-fold, p=0.002; 
day 21, n=12, 9.1-fold, p<0.0001) and that one of the target molecules of miR-378a-3p, 
ADAMTS1 mRNA was significantly upregulated in cpk (day 14, n=20, 1.4-fold, p=0.01; 
day 21, n=12, 3.5-fold, p=0.0002). Western blotting showed that ADAMTS1 was increased 
in cpk (day 21, n=6, 1.8-fold, p=0.03) kidneys.
Conclusions: Results suggest that miR-378a-3p/ADAMTS1 axis is involved in cpk. 
In conclusion, this axis may be a therapeutic target in PKD.
Funding: Government Support - Non-U.S.
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Identifying and Integrating Consumer Perspectives in Clinical 
Practice Guidelines on Autosomal Dominant Polycystic Kidney Disease 
David J. Tunnicliffe,1 Allison Tong,1 Pamela Andrea Lopez-Vargas,1 Jonathan 
C. Craig,1 Gopala K. Rangan.2,3  1The Univ of Sydney, Australia; 2Westmead 
Millennium Inst, Australia; 3Westmead Hospital, Australia.
Background: Integration of consumer perspectives into clinical practice guidelines 
is widely advocated as it ensures that recommendations are relevant to all stakeholders. 
We aimed to identify consumer perspectives on topics and outcomes to include in clinical 
practice guidelines on autosomal polycystic kidney disease (ADPKD).
Methods: A workshop involving three concurrent focus groups with consumers was 
convened. Guideline topics, interventions and outcomes were identified, and integrated into 
guideline development. Thematic analysis was used to analyze the reasons for their choices.
Results: Eighteen consumers (patients with ADPKD [n=15], caregivers [n=3]) 
participated and 22 priority topics (including interventions) were identified, with most 
focused on non-pharmacological management (diet, fluid intake, physical activity, 
complementary medicine), pain management, and psychosocial care (mental health, 
counseling, cognitive and behavioral training, education, support groups). They also 
identified 27 outcomes including quality of life, progression of kidney disease, kidney 
function, cyst growth, and nephrotoxicity. Almost all topics/outcomes had already been 
identified by health professionals in the guideline working group with the exception of 
five topics/outcomes (surgical management of cysts, patient education about end-stage 
kidney disease, psychosocial impact of diagnosis, need for dialysis, knowledge). Many 
more topics (33) and outcomes (44) were identified as priorities by health professionals 
than consumers. Six themes reflected reasons for consumer choices: clarifying ambiguities, 
resolving debilitating pain, concern for family, preparedness for the future, taking control, 
and significance of impact.
Conclusions: Although there was considerable concordance between the priority topics 
and outcomes of health professionals and consumers for guidelines of ADPKD, there was 
also important discordance with consumers focused on fewer issues but particularly on 
lifestyle, psychosocial support, pain management, and quality of life and renal outcomes.
Funding: Government Support - Non-U.S.
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Urine AQP2 Is One of the Candidates for a Surrogate Maker in the 
Treatment of ADPKD Patients by Tolvaptan  Kenichi Akiyama, Toshio 
Mochizuki, Miki Nishida, Masayo Sato, Hiroshi Kataoka, Hidekazu Sugiura, 
Ken Tsuchiya, Kosaku Nitta.  Medicine IV, Tokyo Women’s Medical Univ, 
Shinjyuku, Tokyo, Japan.
Background: Tolvaptan, arginine vasopressin (AVP) V2 receptor antagonist is accepted 
for autosomal dominant polycystic kidney disease (ADPKD) patients in Japan since 2014. 
TEMPO study showed tolvaptan from 60 to 120 mg per day slowed renal cyst expansion 
and renal function decline. Tolvaptan dose is decided by preliminary study (TEMPO24 ) 
which showed the maximum dose that meet both urinary osmolality (Uosm) under 300 
mOsm/kg and patient’s tolerance. So that adequate dose for individual patient has not been 
suggested. Moreover, tolvaptan cause polyuria, thirsty, polydipsia due to aquaresis. Thus, 
it is necessary to find surrogate markers for determine the maximum effects and minimum 
side effects for long-term administration.
Methods: Seventeen ADPKD patients initiated tolvaptan of 60 mg were investigated. 
Physical data, plasma osmolality (Posm), Uosm, AVP, urine cyclic AMP (UcAMP), and 
urine AQP2 (UAQP2) were assessed. UcAMP was measured by radioimmunoassay (Yamasa 
corp.) and UAQP2 was measured by a sandwich enzyme-linked immunosorbent assay 
method (Otsuka Pharmaceutical Co. Ltd. ).
Results: After initiation of tolvaptan, average urine volume was 8621 ml/day and 
delta body weight was -1.42 kg/day on day1. One month after, AVP increased from 3±3 
to 7.3±11.2 pg/mL (p= 0.001), Uosm decreased from 367±349 to 243±436 mOsm/kg 
(p<0.001). Posm and UcAMP were not statistically associated. UAQP2 decreased from 
0.029±0.068 to 0.012±0.028 pmoL/mgCr (p<0.001). In our preliminary data (n=5), the 
serum copeptin, a precursor of vasopressin, was shown to be no consistent level.
Conclusions: It has been reported that 3% of total production of AQP2 excreted into the 
urine, it reflected directly the intracellular action of AVP. Thus, UAQP2 is likely to be one 
of surrogate markers of tolvaptan effect, moreover it could provide additional information 
of determination of individual dosage and monitoring for long-term usage.
Funding: Private Foundation Support
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Abnormalities in the Radius of Patients with Autosomal Dominant 
Polycystic Kidney Disease Measured by High-Resolution Peripheral 
Quantitative Computed-Tomography Imaging  Danielle Diarra,1 Janina M. 
Patsch,2 Claudia Schueller-Weidekamm,2 Michael Weber,2 Arastoo Nia,3 Gere 
Sunder-Plassmann.1  1Dept of Medicine III, Medical Univ of Vienna, Austria; 
2Dept of Radiology, Medical Univ of Vienna, Austria; 3Dept of Medicine II, St. 
Vincent Hospital, Medical Univ of Vienna, Austria.
Background: ADPKD is a multi-organ disorder and the most common of all cystic 
kidney diseases. Mutation of the PKD1 or -2 gene causes epi- and endothelial ciliopathies, 
which lead to the dysfunction of various organs. Animal studies show that primary cilia 
are present in osteoblasts of mice and point mutation of the osteoblastic PKD1 gene 
induces osteopenia.
Methods: In this pilot-study, we examined the bone structure in 6 ADPKD patients in 
comparison to 6 matched patients with glomerular disease (GD), both in CKD stages I-II, by 
HR-pQCT of the radius and the tibia. The aim of the study was to identify microarchitectural 
target parameters for a subsequent larger study in patients with ADPKD.
Results: Demographic data see Table 1.
Table 1.
Parameter GD Patients (controls) ADPKD Patients
Patient number 6 6
Gender (male) 3 3
Age (years) 27±6,4 26±7,6
Serum creatinine (mg/dl) 0,81±0,17 0,83±0,19
eGFR (ml/min per 1.73 m2) 109±18 108±23
We found reduced cortical and trabecular microstructural parameters by HR-pQCT, 
mainly affecting the radius. The outer trabecular density, the cortical thickness and the total 
density of the radius showed the biggest differences between the two groups, see Figure 1.
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The total density of the radius was the best parameter to distinguish between the bone 
structure of ADPKD- in comparison to GD patients (AUC=0,861).
Conclusions: We provide evidence of microstructural bone deterioration of the radius in 
patients with ADPKD. We thus hypothesize that ADPKD is associated with microstructure 
bone changes in men.
PUB270
An Accurate Formula for a Quick Estimate of Total Liver Volume in 
Polycystic Liver Disease Patients  Hedwig M.A. D’Agnolo,1 Wietske Kievit,2 
Melissa Chrispijn,1 Joost P.H. Drenth.1  1Gastroenterology and Hepatology, 
Radboud Univ Medical Center, Nijmegen, Netherlands; 2Radboud Inst for Health 
Sciences, Radboud Univ Medical Center, Nijmegen, Netherlands.
Background: Polycystic liver disease (PLD) appears in two disorders; autosomal 
dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver 
disease (ADPLD). The primary aim of treatment of PLD is reduction of total liver volume 
(TLV) as patients often suffer from hepatomegaly. The gold standard to assess TLV is 
CT volumetry which involves manual delineating of the liver outline. Unfortunately this 
is a time-consuming method (45-60 minutes per CT scan) and requires a certain level of 
expertise. An easily accessible and fast method to estimate TLV in routine clinical practice 
is needed. Therefore we aimed to develop an accurate formula for quick estimation of TLV.
Methods: We collected a cohort of PLD patients in whom CT scans were available. 
Manual delineation of TLV served as gold standard. PLD patients were distributed in 2 
cohorts, a development cohort (N=80) and a replication cohort (N=50). We measured 
anterior-posterior (AP), transverse (T) and cranial-caudal (CC) distance (in meters) of the 
liver on CT. TLVs were logarithmically transformed as data were not normally distributed. 
R2 was measured as it indicates the goodness of fit of the prediction model. The prediction 
model was tested in a replication cohort.
Results: Median liver volumes in the development and replication cohort were 4749mL 
[1084-14816] and 4684mL [1287-16746] respectively. All three diameters significantly 
correlated with TLV (p < 0.0001). Linear regression analysis resulted in the following 
formula: Logarithm of TLV = 5.240 + T*5.608+ CC*2.522+AP*6.041. Our model predicted 
TLV accurately in the development cohort (R2= 0.898). The correlation in the development 
cohort was 0.948 and validation in the replication cohort resulted in a correlation of 0.937.
Conclusions: Our model accurately and quickly (< 2 minutes) predicts TLV in PLD 
patients based on three liver dimensions.
PUB271
Clinical Significance of Urine NAG and L-FABP Excretion for the 
Assessment of ADPKD-Progression  Yoshimi Okada,1 Mai Aoyagi,1 Kaori 
Takayanagi,1,2 Takatsugu Iwashita,1 Tota Kiba,1 Tatsuro Sano,1 Kento Hirose,1 
Yuichiro Kawai,1 Ryo Yamamoto,1 Yuya Shioda,1 Yosuke Tayama,1 Hajime 
Hasegawa.1  1Nephrology and Hypertension, Saitama Medical Center, Saitama 
Medical Univ, Kawagoe, Saitama, Japan; 2Ishikawa Kinenkai Kawagoe Ekimae 
Clinic, Kawagoe, Saitama, Japan.
Background: Autosomal dominant polycystic kidney disease (ADPKD) shows various 
renal prognosis. Because the progression of renal damage in ADPKD is principally caused 
by tubulo-interstitial nephropathy (TIN), the present study focused to study the relationship 
between TIN-related clinical parameters and progression of ADPKD.
Methods: In this study, 59 ADPKD cases with consents were retrospectively analyzed. 
Average age, duration of the observation, median values of kidney volume (KV) and kidney 
growth rate (KGR), average estimated GFR (eGFR) were 50.5 yeas old, 3.4 yeas, 1423 mL 
and 1.74% growth/year, respectively. KV was calculated by using the ellipsoid formula.
Results: In all cases, KV and eGFR showed exponential correlation (R=0.47). We 
focused kidney volume (KV), kidney growth rate (KGR), eGFR, and urine excretion 
ratio of N-acetylglucosaminidase (NAG) to Cr (NAG index) for the clinical assessment 
of TIN. We stratified patients by the average or median value of the parameters mentioned 
above, and analyzed their differences in each stratified group. KV, eGFR and KGR showed 
significant difference only in the eGFR-, KV- and eGFR-stratified group. However, NAG 
index showed significant difference in both KV-stratified (median: 7.42 vs 6.09 U/mgCr) 
and eGFR-stratified (8.00±5.98 vs 3.93 U/mgCr) groups. Additionally, urine liver type fatty 
acid binding protein (L-FABP), as a biomarker of the tubular ischemia, showed significant 
difference in all stratified groups (KV: 7.29±9.98 vs 1.76±1.68, eGFR: 4.15±7.76 vs 
2.45±2.34, KGR: 4.46±7.68 vs 2.09±2.30, NAG index: 4.33±7.20 vs 1.88±2.10).
Conclusions: Progression of ADPKD has been primarily assessed by the kidney 
volume. However, the present study may show that the assessment of TIN might be more 
helpful to evaluate the severity and prognosis of ADPKD. It might be suggested that TIN-
related markers such as NAG index or L-FABP index should be actively utilize in the 
clinical management of patients with ADPKD.
PUB272
Classic and Alternative Criteria for the Diagnosis of Autosomal Dominant 
Polycystic Kidney Disease: Genetics and Disease Progression in HALT-PKD 
William E. Braun,1 Kaleab Z. Abebe,2 Arlene B. Chapman,3 Peter C. Harris,4 
Godela M. Brosnahan,5 Peter G. Czarnecki,6 Kyongtae Ty Bae,2 Charity G. 
Moore,2 Robert W. Schrier.5  1Cleveland Clinic; 2Univ of Pittsburgh; 3Univ of 
Chicago; 4Mayo Clinic; 5Univ of Colorado; 6Brigham & Women’s Hospital.
Background: The HALT-PKD trials based the diagnosis of ADPKD on classic criteria 
(CC) as well as on alternative criteria (AC) with no ADPKD family history(–FH). Patients 
with AC and genetically no mutation detected (NMD) were analyzed as a distinct subset 
(AC-NMD).
Methods: Of 959 HALT-PKD patients with genetic testing 835 (87.1%) had CC, 
and 124 (12.9%) had AC. Three groups: Alternative (AC-NMD), Classical (CC-PKD1/
PKD2 mutation),and Intermediate (combined CC-NMD + AC-PKD1/PKD2 mutation)
were compared for annual change in total kidney volume (TKV, htTKV) in early 
ADPKD (n=17, 410, 81, respectively),and eGFR in early/late ADPKD (n=17/8, 414/375, 
81/64,respectively).
Results: TKV baselines were not significantly different (P=0.66). The TKV annual 
increase was 4.21% in Alternative (AC-NMD) compared to 6.39% in Classical (CC-PKD1/
PKD2),and 6.68% in Intermediate (CC-NMD + AC-PKD1/PKD2) (lnTKV P=0.0346; 
lnhtTKV P=0.0355)and was not affected by BP level.
NMD patients were 20.2% of AC but just 5.5% of CC patients which was true in 
both early (P<.0001) and late ADPKD (P=0.0066). Annual eGFR change in early and 
late ADPKD was not significantly different in the 3 groups, and Low vs Standard BP, or 
lisinopril+telmisartan vs lisinopril+placebo, did not alter that.
Conclusions: AC-NMD (Alternative) patients with early ADPKD have a significantly 
lower annual increase in TKV/htTKV. The –FH factor in AC appears to be the clinical 
portal to a genetically complex population enriched 3.7-fold for NMD. Patients with AC-
NMD might have mosaicism, atypical mutations, or even polycystic kidney disease(s) 
other than ADPKD.
Funding: NIDDK Support
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Lifestyle Counseling in Polycystic Kidney Disease Patients  Wen-Ching Tran, 
Jonathan Chan, Chi-yuan Hsu, Meyeon Park.  UCSF.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a common 
cause of end-stage kidney disease worldwide, affecting all ethnicities. Although there is no 
cure for this condition, dietary modification and water intake may attenuate progression of 
disease, yet lifestyle counseling is not consistently implemented by providers. Furthermore, 
cardiovascular risk is high in this group, and exercise may benefit cardiovascular health. 
Patients with ADPKD often express a desire to be able to “do anything” to modify their 
disease. We designed this study to determine the prevalence of lifestyle counseling in 
nephrology clinic visits with individuals with ADPKD.
Methods: We performed a systematic chart review. Using our electronic medical 
record system, we identified patients with ADPKD whose most recent visit at UCSF with 
a nephrologist occurred during the previous six months. We reviewed the notes associated 
with these visits to assess for nephrologists’ discussion of dietary advice, water drinking 
parameters, and exercise recommendations based on documentation in clinic notes.
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Results: We identified 56 unique patient visits in the previous six months. Mean age 
was 44.6 (+/- 14.9) years. 29 (52%) were women. 28 patients had documentation of dietary 
discussions; 26 received water intake recommendations; and 8 received exercise advice. 
Only 5 patients received counseling on all 3 parameters.
Number of patients receiving counseling on X of 3 parameters (Diet, Water intake, Exercise)
0 of 3 1 of 3 2 of 3 3 of 3 Total
21 13 17 5 56
Conclusions: Prevalence of lifestyle counseling was moderate as ascertained by chart 
review of our electronic medical record. Discussion of exercise recommendations was low. 
Nephrologists could consider focusing more attention on offering lifestyle counseling to 
individuals with ADPKD.
Funding: Clinical Revenue Support
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Lipid Alterations in Murine Models of Polycystic Kidney Disease 
Christine Podrini,1,2 Isaline Rowe,2 Marco Chiaravalli,2 Alessandra Boletta.2 
1Univ Vita-Salute San Raffaele, Milan, Italy; 2Dibit San Raffaele Scientific 
Inst, Milan, Italy.
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common 
genetic disorder characterized by massive bilateral renal cyst formation. ADPKD results 
from mutation in the PKD1 or PKD2 genes, encoding Polycystin-1 (PC-1) and 2 (PC-2) 
proteins respectively. Previous studies have suggested that the mTORC1 cascade might play 
an important role in PKD. Further, mTORC1 regulates the activity of SREBP which regulate 
the expression of genes required for the synthesis of fatty acids and cholesterol. However, 
the regulation of fat synthesis in ADPKD remains poorly understood. In this study, we seek 
to understand the relationship between fatty acid regulation and defective PKD1 function.
Methods: We analyzed newborn kidneys of Ksp-Cre;Pkd1flox/- mice and detected an 
increased expression of SREPB1 and its target genes including fatty acid synthase (FAS) 
and stearoyl-CoA desaturase (SCD) when compared to control, non-cystic kidneys (Ksp-
Cre;Pkd1flox/+ or Pkd1flox/+).
Results: As expected the increased expression of SREPB1 also correlated with 
increased transcript levels of SREPB2 concomitant with an increased transcript levels for 
sterol biosynthesis mevolonate kinase (MVK) and acetyl-CoA synthetase (ACSL). Next, we 
performed a lipidomic profiling of Ksp-Cre; Pkd1flox/- kidneys compared to controls Ksp-Cre; 
Pkd1flox/+ collected at P4 using shotgun lipidomics technology. The profiles confirmed the 
alteration of some lipid classes, particularly sphingolipids and sterol esters (cholesterol). 
Of interest both have been implicated in regulating membranes trafficking and they may 
cross-talk to mTORC1 in response to altered nutrient/fatty acid signals. Notably, some of 
the lipid alterations that we observed appear to be gender-specific.
Conclusions: We are currently characterizing this aspect further and trying to determine 
which lipid alterations might be dependent and/or independent of mTORC1 upregulation.
PUB275
Reactive Hyperaemic Index in Early Disease Stages of Autosomal Dominant 
Polycystic Kidney Disease  Adebowale Olayinka Adekoya,1 Andrew J. 
Streets,1 Albert C. Ong.1  1Academic Nephrology Unit, The Medical School, 
Univ of Sheffield, Sheffield, South Yorkshire, United Kingdom; 2MRC Centre 
for Developmental and Biomedical Genetics, Univ of Sheffield, Sheffield, South 
Yorkshire, United Kingdom.
Background: ADPKD is the commonest inheritable cause of ESKD. Cardiovascular 
complications are the commonest cause of death in ADPKD. Endothelial dysfunction (ED) 
has been reported to precede CV events. In our pilot study of sixty ADPKD patients in 
the late stages of disease (CKD 3 and above), ADMA and 8 isoprostane were found to be 
increased suggesting ED. The aim of this study is to investigate ED in the ADPKD patients in 
early stages of the disease (CKD 1 and 2) and to identify factors associated with its severity.
Methods: This is a single centre cross sectional study of ADPKD patients in the early 
stages of disease. Individuals with HBP, DM, eGFR< 60ml/min/1.73m2 and sokers were 
excluded. 23 patients and 26 age, sex and eGFR matched controls were recruited. 24hr 
urine was collected for creatinine clearance and protein. Reactive hyperaemic index (RHI) 
was measured using endoPAT 2000.
Results: The mean±SD age of the patients was 40.80±14.18 years. M:F was 1:2.3. 
Patients’ mean±SD eGFR was 81.87± 18.02ml/min/1.732, creatinine clearance was 
125.75± 55.69 while SBP was 129.35 ± 7.47 mmHg.There was no significant difference 
in RHI between patients and control. Furthermore, there was no significant difference in 
cholesterol, C reactive protein, uric acid, calcium phosphate product and homocysteine 
between patients and controls (p>0.05) Conversely, there was a significant difference in 
the level of proteinuria between the patients and controls. Proteinuria and homocyteinemia 
correlate with RHI on univariate and multivariate analysis.
Conclusions: Pulse arterial tonometry as measured by RHI was not significantly 
reduced in ADPKD patients in the early stages of disease. However, increased proteinuria 
and hyperhomocysteinemia were detectable in ADPKD patients with preserved kidney 
function suggesting more subtle changes in endothelial function which may not be 
detected by RHI.
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Baseline Renal Cysts Diameter Predicts the Erithropoietin Requirement in 
Autosomal Dominant Polycystic Kidney Disease  Paolo Lentini,1 Luca Zanoli,2 
Massimo de Cal,1 Stefania Rastelli,2 Andrea Contestabile,1 Antonio Granata,3 
Roberto Dell’Aquila.1  1Nephrology, St. Bassiano Hospital, Bassano Del Grappa, 
Italy; 2Internal Medicine, Univ of Catania, Catania, Italy; 3Nephrology, St. 
Giovanni Di Dio Hospital, Agrigento, Italy.
Background: Subjects with autosomal dominant polycystic kidney disease (ADPKD) 
require classically low recombinant human erythropoietin (EPO) to reach haemoglobin 
target levels. We hypothesize that EPO requirement in subjects with ADPKD is more 
dependent to the enlargement of the cysts than the reduction of glomerular filtration rate. 
Aim: To evaluate the role of renal cyst and kidney size on EPO requirement in severe 
chronic kidney disease (stage 4-5).
Methods: A total of 35 pts with ADPKD and anaemia treated with EPO were enrolled 
(14 pts with CKD Stage 4 and 21 pts Stage 5), the mean volume (V) and diameter (D) of 
the four largest cysts and the mean antero-posterior renal diameter (AP) were prospectively 
followed-up for 18 months with computer tomography.
Results: The overall mean age was 65±14 years, male sex 57%. At baseline, AP was 
19.7±2.2cm, D 4.6±1. cm, V 749±641 cm^3. During the 18 months follow-up, rHu-EPO 
dose was 8543±6626 UI/week, and EPO/haemoglobin ratio (E/H) was 1983±1039. In a 
multivariate linear regression model, adjusted for age and sex, at baseline both AP and 
V were significantly associated with E/H; after 18 months, only V remains significantly 
associated with E/H. Baseline V (100cm^3 increase: β=115UI/g week, 95%CI 65-164, 
P<0.001) was also associated with mean E/H during follow-up and explain 42% of E/H 
variability.
Conclusions: The Cysts volume is useful to predict propectively the EPO requirement 
in ADPKD in stage 4-5 CKD.
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A Novel Method to Determine Glomerular Volume Distribution from 
Few Serial Sections on a Single Slide  Mohan C. Abraham,1 Rishi Singh,2 
Krishnamurthy P. Gudehithlu,2 Jose A.L. Arruda,1,2,3 Ashok K. Singh.1,2,3  1Div 
of Nephrology, John H Stroger Hospital, Chicago, IL; 2Hektoen Research Inst, 
Chicago, IL; 3Section of Nephrology, Univ of Illinois at Chicago, Chicago, IL.
Background: Estimating glomerular volumes is important in understanding 
pathogenesis of glomerular diseases. Some methods are convenient but give a single mean 
volume for the entire kidney and do not provide volume profiles. Methods for volume 
profiling are too laborious for routine use. We describe here a new method to obtain 
glomerular volume profiles from few serial sections. The method uses the formula, R2 = 
r12 + [(r12 - r22 – h2)/2h]2, where R is the radius of a sphere and r1 and r2 are the radii of 
two parallel circular planes cut across the sphere h distance apart.
Methods: To validate our method we compared glomerular volumes between normal 
(n=5) and STZ diabetic rats (n=4) by measuring 100 random glomeruli from each group. 
Three (or four) serial sections each 5µM apart were obtained on the same slide. Sections 
were stained with H&E and glomerular diameter was measured at four points to arrive at 
a mean diameter and radius r1. The same glomerulus was identified on the third (h = 10 
µM) (or fourth; h = 15 µM) serial section to similarly determine r2. R was calculated by 
the formula to obtain the glomerular volume (4/3 π R³).
Results: The mean glomerular volume (106 µM3) of normal rats was 1.04 ± 0.06, a 
value very close to that determined by MRI recently (Heilmann et al 2012). The mean 
glomerular volume of diabetic rats was 1.48 ± 0.06, which was 45% higher (P<0.05) than 
normal, confirming glomerular hypertrophy. While the volume distribution in normal rats 
was Gaussian, the distribution of glomerular volumes in diabetic rats was skewed towards 
higher volumes (42% glomeruli >1.4 X 106µM3 compared to 12% in normals), suggesting 
that not all glomeruli but only a population of glomeruli hypertrophied in diabetic rats.
Conclusions: Precise glomerular volumes can be conveniently determined by our 
method using a few serial sections of the kidney, making it possible to obtain glomerular 
volume distribution from experimental as well as human kidney biopsies.
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Amniotic Fluid Stem Cells Transplantation in Fetal Kidney to Regenerate 
Nephrons Loss  Kathleen Laborde,1 Sebastien Sammut,2 Mehrak Hekmati,2 
Agnieszka Anna Ksiazek,3 Benedikt Weber,3 Luc Behr.2  1Necker Hôpital-Paris5 
Univ, Paris, France; 2IMMR, Paris, France; 3Swiss Center for Regenerative 
Medecine, Univ Hospital, Zurich, Switzerland.
Background: Amniotic fluid stem cells (AFSC) harbour the potential to differentiate 
toward renal lineages and contribute to the development of primordial kidney structures. 
To investigate whether AFSC can improve prenatal renal compensatory growth, cells were 
transplanted in a model of subtotal nephrectomy (5/6NX) in the fetal sheep.
Methods: Ovine AFSC labelled with GFP were selected using c-kit. In absence of LIF, 
AFS formed embryonic bodies which cultured in an optimized medium generated a renal 
epithelial progenitor population (oAFSCd), expressing PAX-2. 5/6NX was performed at 
70 days of gestation in 10 fetal lambs; 5 were injected with oAFSCd in the kidney poles. 
Sham-operated did not received oAFSCd (SHAM, n=8). At 134 days of gestation, fetuses 
were euthanized, kidneys removed and processed.
Results: Body weight did not differ significantly among the groups and no 
morphologic abnormalities were observed, in spite of a severe reduction in amniotic fluid in 
5/6NX+oAFSCd. Compensatory renal growth of the remaining kidney was observed in all 
5/6NX, but in spite of oAFSd injection, catch-up kidney growth was similar in both 5/6NX 
groups: SHAM: 3.2±0.6;5/6NX:4.6±2.4;5/6NX+oAFSCd:5.5±1.4 KW/BW. Glomeruli 
number/section was similar in all groups: SHAM:2711±237;5/6NX:2155±694;5/6NX+o
AFSCd:1962±199. In 5/6NX+oAFSCd, GFP cells were present in renal proximal tubes, 
and proximal tubule hypertrophy was observed. 
No striking changes were observed in PAX2, WT1 or PCNA expression.
Conclusions: Transplantation of oAFSCd predifferentiated toward renal epithelial 
progenitor cells during nephrogenesis increases proximal tubule mass but has no effect on 
the number of glomeruli in the 5/6NX and do not restore fully kidney damage.
Funding: Private Foundation Support
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Low Birth Weight Impairs Renal Development and Function 
Christina M. Barnett, Michael S. Shen, Kunzah Aleem Syed, Joseph A. Zullo, 
David L. Payne, Oluwadara Nnoli, Wasan Abdulmahdi, Amy R. Patel, Tala F. 
Azar, May M. Rabadi, Brian B. Ratliff.  New York Medical College.
Background: Low birth weight (LBW) results in a significant risk to the newborn, 
with many of these babies developing acute kidney failure and dying soon after birth due to 
underdeveloped vascular and renal systems. Surviving LBW neonates are also susceptible 
to a variety of health problems later in life during adulthood including hypertension, 
diabetes and chronic kidney disease with an associated 70% increased risk of end-stage 
kidney failure.
Methods: Using a maternal malnourished mouse model, we examined the causes of 
vascular and renal underdevelopment and impaired function in the LBW neonate. Parameters 
measured in the LBW offspring included nephron development, stem cell levels, apoptosis, 
gene expression, circulating cyto-/chemokines, renal blood flow and renal function.
Results: Within 24 hours after birth, LBW male offspring had 40% reduced weight, 
while only 49% of LBW neonates survived the first week after birth. Within the first week 
after birth, LBW neonates had an up to 40% reduction in renal blood flow and elevation 
of serum creatinine up to 3.0 mg/dL. Nephrogenesis was impaired in the LBW neonates 
with a 75% reduction in renal vesicle formation and a significant downregulation of Wnt9B 
(which induces differentiation of progenitor cells into tubular epithelia) at day E17.5, which 
ultimately resulted in a 30% reduction in glomeruli at the conclusion of nephrogenesis. 
During nephrogenesis, six2-positive nephron progenitor cells were reduced by up to 70% 
in the LBW embryonic kidney, which was accompanied by 6-fold increase in apoptosis. 
At birth, the LBW neonate had significantly elevated circulating levels of proinflammatory 
IL-1beta. Using explanted embryonic kidneys, we observed IL-1beta dramatically reduces 
six2+ cell populations and their ability to aggregate and form renal vesicles during kidney 
development.
Conclusions: LBW impairs vascular and renal function due to undeveloped renal and 
vascular systems that result from enhanced IL-1beta, increased apoptosis, altered Wnt9b 
expression, and reduced six2 nephron progenitor cells in the embryonic and neonate kidney.
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Increasing Podocyte Number in Neonatal Kidney Reduced Renal Injury 
in Adulthood  Jianyong Zhong,1,2 Ji Ma,2 Taiji Matsusaka,3 Agnes B. Fogo,1 
Valentina Kon,2 Haichun Yang.1  1Pathology, Microbiology and Immunology, 
Vanderbilt Univ, Nashville, TN; 2Pediatric Nephrology, Vanderbilt Univ, 
Nashville, TN; 3Dept of Molecular Life Science, Inst of Medical Science, Tokai 
Univ School of Medicine, Isehara-shi, Kanagawa, Japan.
Background: Preterm birth increases the risk of hypertension and renal disease, which 
have been linked to decreased nephron number. We previously found that puromycin 
injection in mice at birth impairs glomerular maturation, and has renal pathology phenotype 
which is similar to that observed in human preterm births. In the present study, we tested 
the hypothesis that increasing podocyte number during glomerular maturation can rescue 
glomerular loss and thus reduce renal injury in adulthood.
Methods: We mated podocin-rtTA with TRE-SV40T mice to generate double-
transgenic mice (RS), in which podocyte proliferation can be activated by doxycycline 
(Dox). rtTA mice (R) served as controls. After a single puromycin injection, doxycycline 
was given at P1 until P8. At 12 weeks of age, mice underwent uninephrectomy (UNx) and 
were started on a high salt diet. At 14 weeks of age, angiotensin II (Ang II) was given by 
minipump for the next 8 weeks. All mice were sacrificed at week 22.
Results: At week 3, there were more WT1 positive glomerular cells in RS than R 
mice (RS 10.34±0.41 vs. R 8.15±0.58 X10-3/µm2, p<0.05), while glomeruli in superficial 
cortex were less mature (RS 2.13±0.05 vs. R 2.32±0.06, maturity scale 1-3, P<0.05). At 
week 6, glomerular number increased in RS (RS 9039.2±644.2 vs. R: 6932.1±244.7/
kidney, P<0.05). Glomerular volume and albuminuria did not differ between groups at 
week 3 and 6. At week 22, after UNx, high salt and Ang II, blood pressure, albuminuria 
and glomerular number were similar in RS and R. However, RS mice had lower KW/BW 
ratio (RS 0.976±0.143 vs. R 1.263±0.041, p<0.05) and less mesangial expansion (0-4 scale) 
(RS 0.72±0.10 vs. R 1.14±0.14, p<0.05).
Conclusions: We conclude that increasing podocyte number in developing kidney 
rescues puromycin-induced impairment of glomerular growth, which in turn reduces renal 
injury following a second hit in adulthood.
PUB281
Exploring Ciliopathies – Cep164 Tissue Expression in a Murine Model 
Simon Ramsbottom, Shalabh Srivastava, Colin Miles, John Andrew Sayer.  Inst 
of Genetic Medicine, Newcastle upon Tyne, United Kingdom.
Background: Nephronophthisis (NPHP) is the major cause of paediatric renal 
failure, yet the disease remains poorly understood, partly due to the lack of appropriate 
animal models. Joubert Syndrome (JBTS) is an inherited ciliopathy giving rise to NPHP 
and neurodevelopmental abnormalities and mutations in CEP164 are one of the known 
genetic causes. Clinical phenotypes of patients with CEP164 mutations include NPHP with 
retinal degeneration and cerebellar vermis aplasia. In cultured cells CEP164 localises to 
centrosomes as well TIP-60 postive nuclear foci, and CEP164 has an established role in 
DNA damage response signalling. However, there has been no previous documentation of 
CEP164 spatial expression during development.
Methods: We have recently acquired heterozygous Cep164 mice from the International 
Mouse Phenotyping Consortium (MRC/Harwell) (B6NTac;B6N-Cep164tm1a(EUCOMM)
Wtsi/H). We used these animals for tissue expression studies, including X-gal staining 
from heterozygote adults and whole embryos. Homozygoyte Cep164 animals had 100% 
perinatal lethality.
Results: In heterozygote Cep164 animals, specific X-gal staining representative of 
Cep164 expression was observed in all tissues examined. This included the brain (olfactory 
bulbs and cerebellum); the eyes (within the retina layers); the testis and renal tissues. In 
E13.5 embryos, staining was observed globally at a low level. Stronger staining can be 
seen in discrete regions including the developing eyes and limbs, areas undergoing high 
levels of proliferation and apoptosis, further indicating a role for Cep164 in these processes.
Conclusions: These data support a role for Cep164 in multiple organs throughout 
development and explain the wide phenotypic spectrum of JBTS mutations in man.
Funding: Government Support - Non-U.S.
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Specific Deletion of Early B Cell Factor 1 from Podocytes Does Not 
Recapitulate the Developmental Defects Observed in the Globally Deficient 
Animals but Does Provide Protection from Injury  Jackie A. Fretz, Tracy 
Nelson, Li Li.  Orthopaedics and Rehabilitation, Yale School of Medicine, 
New Haven, CT.
Background: Globally deficient mice lacking the transcription factor Ebf1 (Ebf1 
KO) are extremely sick owing to the multiple functions of Ebf1 across the body. We 
recently described a novel function of Ebf1 as an essential component of the latest stages 
of metanephric development. Mice globally deficient in Ebf1 have impaired formation of 
peripheral glomeruli and a thinned cortex. Within the kidney Ebf1 is present within multiple 
cell types including distinct tubular epithelium, interstitial pericytes, glomerular mesanguim, 
and podocytes. This investigation aimed to identify if the actions of Ebf1 in the podocyte 
were driving the developmental defects present in the global knockout.
Methods: In this study we made a specific deletion of Ebf1 within the podocytes 
using the podocin-driven cre mouse. These were mated with mice where the 3rd exon of 
Ebf1 (encoding part of the DNA-binding domain) is flanked by flox sites. This is the same 
genetic region that is excised in the global deletion model. BSA overload injury was also 
performed on 3 month old animals (100mg/kg, IP daily for 4 weeks).
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Results: Restricted deletion of Ebf1 from podocytes did not result in any observable 
developmental changes as assessed at the functional and histological level. Renal mass, 
glomerular number, and glomerular development were unchanged regardless of genotype. 
The mice were followed for up to 6 months. During this time renal function did not decline 
in the mice with podocyte-specific deletion of Ebf1, and in fact baseline proteinuria was 
reduced in Podocin-cre+, Ebf1-fl/fl animals compared to littermate controls. To examine 
if Ebf1-deficient podocytes harbored differential response to injury 3 month old animals 
were subjected to BSA-overload and exhibited reduced proteinuria.
Conclusions: Taken together these results suggest that Ebf1 regulates metanephric 
development through other cell types than the podocyte. While Ebf1 does not control 
glomerular development through its actions in the podocyte, it appears to participate in 
proper damage response by podocytes as its removal appears to be protective.
Funding: NIDDK Support
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Remote Ischemic Pre Conditioning and Pharmacological Treatment 
in  Prevention of  Renal  Damage in Experimental  Diabetes 
Marcelo Rodrigues Bacci, David Feder, Fernando Luiz Affonso Fonseca, 
Matheus Polly, Jaqueline Victoria Ciancaglini, Giuliana Petri, Guilherme 
Zaremba.  ABC Medical School, Brazil.
Background: The main features of diabetic nephropathy are glomerular 
hypertrophy,thickening of the basal membrane,tubular atrophy,interstitial fibrosis and 
nodular and focal glomerulosclerosis.Remote ischemic preconditioning(RIPC)is a procedure 
that generates a brief period of ischemia followed by reperfusion.Its role in preventing 
glomerular and tubular changes is still under debate.The aim of the study was to evaluate 
the nephroprotective effect of RIPC in a diabetic rat model.
Methods: Five groups of 10 Wistar male rats were formed:control without 
diabetes;untreated diabetes;diabetes treated with pharmacological treatment(PT);diabetes 
with RIPC and diabetes with RIPC and PT.For the induction of diabetes,alloxane was infused 
intraperitoneally at a dose of 160mg/kg.PT consisted of daily use of metformin(250mg/
kg),sitagliptin(8mg/kg)and valsartan(30mg/kg).RIPC was performed with an external 
tourniquet placed on the back leg for three 5-minute rounds alternated with the same 
rounds of reperfusion,resulting in a total duration of 30 minutes.This was performed every 
week on all mice in RIPC groups.All mice were kept in a biological cage with controlled 
temperature and humidity and routine feeding.Blood and urine samples were collected 
weekly to evaluate serum glucose,creatinine and urine glucose levels and albumin/creatinine 
urine ratio(ACR).At the end of the observation period,animals were sacrificed and their 
kidneys were biopsied for microscopic analysis.
Results: Animals subjected exclusively to PT showed a significant reduction in serum 
and urine glucose levels but these reductions were not greater in the group that underwent 
RIPC in addition to PT.There were no significant differences in creatinine level between any 
of the groups but ACR was significantly reduced in all treated animals compared to controls.
Tubular atrophy was observed in all diabetic rats and was greatest in the untreated group.
Conclusions: PT was more effective at reducing ACR and tubular atrophy than RIPC.
RIPC alone or in combination with PT did not cause the expected effect of preventing 
histological and urinary abnormalities.
Funding: Government Support - Non-U.S.
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Cross Talk Between TLR4 Signaling and Angiotensin II Induces 
Pathophysiological Changes in Human Tubular Epithelial Cells Under 
High Glucose Conditions  Jinlei Lv,1 Guohua Ding.2  1Nephrology, The First 
Affiliated Hospital of NanChang Univ, NanChang, Jiangxi, China; 2Nephrology, 
Renmin Hospital of WuHan Univ, WuHan, China.
Background: To investigate the cross talk between TLR4 and angiotensin II by observe 
the expression of TLR4 in tubular epithelial cells under high glucose conditions, and observe 
the changes of fibrogenic and inflamamatory factors in human renal tubular epithelial cells, 
revealing the innate immune pathogenesis in diabetic nephropathy.
Methods: Cells were divided into five groups after cultivated with normal glucose 
medium: 1. normal-glucose group 2. mannitol group 3. AngII group 4. high-glucose 
group(25mmol/L) 5. high-glucose+Irbesartan group, extract total RNA and total protein 
after 24 hours. Real time PCR was used to analyze the expressions of TLR4, MyD88, 
HSP47 mRNA, western blot was used to observe the expressions of TLR4, MyD88, NF-
κB, CoIV, HSP47 protein, analyse the effect of high-glucose and AngII to TLR4 / MyD88 
/ NF-κB signaling pathway.
Results: Compared with normal group, TLR4, Myd88, HSP47 mRNA and TLR4, 
Myd88, NF-κB, CoIV, HSP47 protein were highly expressed under high glucose 
condition and after AngII stimulate (p<0.01) . The expression of IL-6 and MCP-1 also 
increased (p<0.01). Compared with HG group, the expresssion of TLR4, MyD88, HSP47 
mRNA and TLR4, MyD88, NF-κB, CoIV, HSP47 in the high-glucose+Irbesartan group 
were significantly reduced (p<0.01) . The difference of above indicators between the 
negative transfected group and high-glucose group and AngII group were statistically 
significant(p>0.05). the expression of IL-6 and MCP-1 in the group that cells were 
transfected with TLR4-siRNA also reduce(p<0.01).
Conclusions: Cross talk between angiotensin II and TLR4 can up-regulate the 
expression of inflammatory factors and fibrogenic factors in HK-2 cells. Irbesartan can 
block the activation of TLR4 signaling pathway induced by high glucose and angiotensin 
II. TLR4 signaling pathway is the major pathway induce the release of inflammatory and 
fibrogenic factors in tubular epithelial cells under high glucose conditions.
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Possible Renoprotective Effects of Acetazolamide Administration in Obese 
Diabetic Mice with Nephropathy  Yushi Nakayama, Koji Eguchi, Terumasa 
Nakagawa, Tomoaki Onoue, Yuichiro Izumi, Hideki Inoue, Yutaka Kakizoe, 
Takashige Kuwabara, Masashi Mukoyama.  Dept of Nephrology, Kumamoto 
Univ Graduate School of Medical Sciences, Kumamoto, Japan.
Background: Administration of carbonic anhydrase inhibitors (CAI) is thought to 
decrease glomerular filtration rate (GFR) by activation of the tubuloglomerular feedback 
(TGF) system. Acetazolamide (ACZ), a major CAI, has been shown to decrease urinary 
albumin excretion in the patients of type 1 diabetes with nephropathy. Previously, we showed 
that ACZ treatment in mice could ameliorate the onset of diabetic nephropathy due to the 
reduction of intraglomerular pressure by activating the TGF system.
Methods: In the current study, we treated obese diabetic mice (KK-Ay/TaJcl) with 
ACZ for 14 weeks, and evaluated the long-term effects on urinary albumin excretion and 
glomerular hyperfiltration.
Results: The blood glucose levels were significantly higher in KK-Ay/TaJcl mice 
compared to the control mice (BALB/cAJc1) at 14 weeks. The blood glucose levels were 
significantly reduced in KK-Ay/TaJcl mice treated with ACZ (547±37 vs 250±75 mg/dL). 
Interestingly, urinary glucose excretion levels in the ACZ group were not significantly 
different compared to the non-treated group. Creatinine clearance was higher in KK-Ay 
mice, which was not changed by ACZ (0.73±0.07 vs 0.69±0.15ml/min) (Figure A). Urinary 
albumin excretion was reduced with ACZ treatment by 29% (Figure B). The plasma renin 
activity was not reduced by ACZ in this model.
Conclusions: These results suggest that the long-term oral treatment with ACZ may 
exert renoprotective effects in obese diabetic models with nephropathy, not due to activation 
of the TGF system but to better glycemic control.
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Inhibition of miR-34a Reduces Podocyte Apoptosis by Targeting Bcl-2 and 
Autophagy  Yang Liu,1 Ruixi Li,1 Wai Han Yiu,1 Hao-Jia Wu,1 Dickson W.L. 
Wong,1 Joseph C K Leung,1 Loretta Y.Y. Chan,1 Kar Neng Lai,1 Moin Saleem,2 
Peter W. Mathieson,1,2 Sydney C.W. Tang.1  1Dept of Medicine, The Univ of Hong 
Kong, Queen Mary Hospital, Hong Kong, China; 2Academic and Children’s 
Renal Unit, Univ of Bristol, Bristol, United Kingdom.
Background: Podocyte apoptosis is a key event in the pathogenesis of diabetic 
nephropathy. MiR-34a has been reported to be involved in cell proliferation and apoptosis, 
but its potential roles in podocytes under the diabetic condition remains unknown.
Methods: Type 2 diabetic nephropathy was established by uninephrectomy (Unx) in 
nine-week-old db/db mice. In cultured immortalized human podocytes, miR-34a was over-
expressed or knocked down by transfection with miR-34a precursor (pre-34a) or inhibitor 
(anti-34a), respectively. Podocytes were exposed to glycated human serum albumin (AGEs) 
and then examined for the expression of apoptosis and autophagy markers. The expression 
of miR-34a in mouse renal cortex and cultured podocytes were determined by quantitative 
PCR (Q-PCR) using specific Taqman miRNA assay.
Results: Compared with control group, Unx db/db mice(n=7) showed significantly 
higher expression level of miR-34a in renal cortex. In cultured human podocytes, exposure 
to AGEs also markedly increased miR-34a expression. The anti-apoptosis genes Bcl-2 and 
survivin, podocyte cytoskeleton molecule synaptopodin, tight junction protein ZO-1, as well 
as autophagy marker LC3-II, were all reduced after AGE treatment. Moreover, inhibition 
of miR-34a by transfection with anti-34a in podocytes prevented AGE-induced apoptosis 
by rescue of Bcl-2 and LC3-II expression.
Conclusions: Our data demonstrated that miR-34a is involved in podocyte injury under 
diabetic conditions. Inhibition of miR-34a in podocytes attenuates apoptosis induced by 
AGEs via enhancing expression of Bcl-2 and regulating autophagy. These results indicate 
that targeting miR-34a might be a potential therapeutic strategy for diabetic nephropathy. 
This study is supported by the National Basic Research Program of China 973 program no. 
2012CB517600 (no. 2012CB517606), Small Project Funding (project code 201309176123) 
from The University of Hong Kong, and Hong Kong Society of Nephrology Research 
Grant 2014. 
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Increased Iron Deposition Is Associated with Decreased α-Klotho and 
Vitamin D Receptor Expression in the Renal Proximal Tubules in Ob/Ob 
Mice  Farid M. Nakhoul,1 Deb Dilip,1 Inbal Dahan,2 Lei Li,1 Yan Chun Li.1 
1Dept of Medicine, Biological Sciences Div, Univ of Chicago, IL; 2Diabetic 
Nephropathy Lab, Baruch Padeh Poriya M Ctr, Lower Galilee, Israel.
Background: Diabetic nephropathy is the most common renal complication of diabetes. 
Diabetes increases oxidative stress and promotes iron deposition in proximal convolute 
tubules (PCT) of the kidney, leading to renal damage. Mutations in the LEP (ob) gene 
product lead to sever obesity and type 2 diabetes, and ob/ob mice in BTBR background 
develop severe diabetic nephropathy. Klotho and vitamin D receptor (VDR) have been 
shown to involve in renal protection against diabetic injury. The goal of this study is to 
assess the relationship between iron deposition and klotho and VDR expression in the 
kidney of ob/ob mice.
Methods: One- and three-month old ob/ob BTBR mice and ob/+ control mice were 
studied in parallel. After sacrifice, the kidneys were harvested. The expression of a-klotho, 
VDR and Cyp27b1 was examined by immunohistochemistry, Western blotting and qRT-
PCR, and iron deposition was assessed by staining with Perl’s enhanced with Dab.
Results: Compared with ob/+ mice, ob/ob BTBR mice showed increased iron 
deposition in the PCT and decreased expression of a-klotho, VDR and Cyp27b1 in the 
renal PCT and kidney lysates.
Conclusions: In ob/ob BTBR mice, increased iron deposition in the renal PCT is 
associated with a decrease in klotho expression, vitamin D hormone synthesis and VDR 
signaling in the PCT . These changes together contribute to the progression of diabetic 
renal injury in these mutant mice, and future treatments.
PUB288
Erythropietin Protects Endothelial Cells from High Glucose Induced 
Injury  Haruka Yasuda,1 Yasunori Iwata,2,3 Kengo Furuichi,3,4 Takashi Wada.1,3 
1Dept of Laboratory Medicine, Kanazawa Univ, Kanazawa, Japan; 2Div of 
Infection Control, Kanazawa Univ, Kanazawa, Japan; 3Div of Nephrology, 
Kanazawa Univ, Kanazawa, Japan; 4Div of Blood Purification, Kanazawa 
Univ, Kanazawa, Japan.
Background: Diabetic nephropathy (DN) is a major cause of end stage kidney disease 
and a strong risk factor for cardiovascular diseases. High glucose induces endothelial injury 
in vasculature, resulting in tissue injury in diabetic condition. Chronic inflammation has 
been reported to play an important role for the progression of high glucose induced cell 
injury. Growing data showed that erythropoietin (EPO) protect the tissues from some kind 
of injury, such as hypoxia and mechanical stress. However, the contribution of EPO to 
high glucose induced the aberrant immune balance remains to be explored. Therefore, we 
hypothesized that EPO modulates endothelial cells from high glucose (HG) induced injury 
via the regulation of inflammatory and anti-inflammatory balance.
Methods: To explore this possibility, we performed genome-wide transcriptome 
profiling in human umbilical vein endothelial cells (HUVEC), which were stimulated by 
high glucose (HG) with/without EPO treatment and detected the expression of inflammation 
associated genes.
Results: Hieralchial clustering and principal component analysis showed the 
different pattern of mRNA expression in HG stimulated HUVEC with/without EPO. 
While inflammatory cytokines/chemokines mRNA expression were increased by the 
HG stimulation in HUVEC, Th2 related cytokine receptors and intracellular signaling 
molecules showed the reduced mRNA expression levels. EPO treatment reduced 
inflammatory cytokines/chemokines mRNA expression and increased Th2 related cytokine 
mRNA expression levels. Real-time PCR analysis confirmed the increased expression of 
inflammatory related genes, those were decreased in HG stimulated HUVEC with EPO 
treatment. Moreover, EPO stimulation increased mRNA expression of EPO receptor and 
b-common receptor. EPO signaling affect neither cell proliferation nor cell death.
Conclusions: Taken together, EPO signaling might protect high glucose induced cell 
injury by the regulation of immune balance.
PUB289
The Possible Mechanisms of Ameliorating Diabetic Mice Renal Insulin 
Resistance by NF-κB Inhibitor Parthenolide  Xuemei Li, Baobao Wang. 
Nephrology, Peking Union Medical College Hospital, China.
Background: Diabetic nephropathy (DN) was the severe complication of Diabetes 
Mellitus (DM). The treatment of DN was limited. Insulin resistance(IR)was associated with 
diabetic complications. The concrete forms of insulin resistance in diabetic renal tissue 
lacked research. AS160 could regulate the transportation of many transporters including 
glucose transporters. In kidney, AS160 was found can regulate sodium and water channel 
protein, while its role on glucose transporters has not been reported. Glucose transporter 4 
(GLUT4) was an important effector of insulin signaling, which related to insulin resistance 
closely. Sodium glucose transporter 2 (SGLT2) and sodium glucose transporter 1(SGLT1) 
were important to promote renal tubular glucose re-absorption and were the new target 
of anti-diabetic drug. Our previous results showed NF-κB inhibitor Parthenolide (PTN) 
could improve db/db mice systemic insulin resistance and renal tissues injury. The aim of 
the study was to study the expression of AS160 and GLUT4 in diabetic kidney tissue and 
correlation between AS160 with GLUT4 and SGLT2/SGLT1.To explore whether PTN 
could improve renal IR and the possible mechanisms.
Methods: Set up db/m mice as control group, the db/db mice as diabetic nephropathy 
model group and db/db mice with PTN intervention as treatment group. The mice were 
sacrificed at week 8, 12, 16 and 20 and using blood, urine and kidney specimens for the study.
Results: 1) The db/db mice showed increased body weight, blood cholesterol, blood 
glucose and insulin, as well as glomerular hypertrophy and the increased mesangial matrix. 
PTN could improve the systemic insulin resistance and renal pathological changes of db/
db mice. 2) AS160 and p-AS160, GLUT4 were all mainly expressed in renal tubules.3)
The expression of p-AS160 and GLUT4 reduced gradually in db/db mice kidney with the 
increase of weeks.4) p-AS160 showed co-expression with part of GLUT4, but no significant 
co-expression with SGLT2/SGLT1.
Conclusions: The diabetic kidney tissue may have insulin resistance resulted from 
abnormal glucose transport by AS160 and GLUT4. The NF-κB inhibitor improved kidney 
insulin resistance may by increasing the expression of p-AS160 and GLUT4.
PUB290
Hypertension Results in Moderate Diabetic Nephropathy in a Mouse 
Model of Metabolic Syndrome  Reinout Stoop,1 Arianne van Koppen,1,2 Roel 
Goldschmeding.2  1MHR, TNO, Leiden, Netherlands; 2Pathology, UMCU, 
Utrecht, Netherlands.
Background: Diabetic nephropathy (DN) is a major complication in metabolic 
syndrome/diabetes patients. We have developed a metabolic syndrome mouse model 
characterized by non-alcoholic steatohepatitis and atherosclerosis upon high fat diet 
feeding. These animals show mild renal changes, but don’t progress to moderate DN. 
Therefore, we investigate whether inducing hypertension on top of metabolic syndrome 
leads to progression of DN.
Methods: Male LDLr-/- mice (8 wk old) received high fat (45%) + high salt (6%) diet 
for 6 wk. To induce hypertension, combinations of several pro-hypertensive components 
were used (uninephrectomy (UNX), angiotensin II (ANGII), DOCA and a vasoconstrictor) 
for an additional 10 wk. At regular intervals, systolic blood pressure (SBP), 24h diuresis 
and albumin/creatinine ratio (UACR) were assessed. 17 wk after start diet, mice were 
terminated and renal injury was scored. We used age-matched chow fed animals as controls.
Results: Cholesterol and diuresis were significantly elevated in all groups vs chow from 
wk 5 onwards. ANGII induced a 20 mmHg increase in SBP at wk 13 vs. chow. At wk 8, 
UACR was significantly increased by ANGII in combination with HFD+HS (264±303µg/
mg) and UNX+HFD+HS (438±781µg/mg) vs chow (62±24µg/mg). At wk 13, ANGII 
further elevated UACR in HFD+HS (593±737µg/mg) but decreased it in UNX+HFD+HS 
(287±263µg/mg). Combining ANGII, DOCA and L-NNA strongly induced albuminuria 
(717 ±585µg/mg) at wk 5 but also caused fatal thoracic bleedings. This group was terminated 
at wk 11. Renal injury score showed glomerular hypertrophy, mesangium expansion, nodular 
glomerulosclerosis, mild hyalinosis and micro-aneurisms.
Conclusions: We show that exposure of LDLr-/- mice to HFD+HS and ANGII induces 
hypertension and mild progressive DN, in addition to NASH and atherosclerosis in a single 
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model providing broad coverage of metabolic syndrome complications. Administration of 
additional hypertensive compounds (DOCA and L-NNA) further aggravated the model but 
also led to early fatal thoracic bleedings thus precluding further studies.
Funding: Government Support - Non-U.S.
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Autophagy Activation in Proximal Tubular Epithelial Cells in Diabetic 
Nephropathy Acts as a Renoprotective Role  Ying Xu,1 Lei Liu,2 Wei Xin,2 
Xu Zhao,2 Liyong Chen,2 Qiang Wan.3  1Renal Div, Shandong Provincial 
Hospital Affiliated to Shandong Univ, Jinan, Shandong, China; 2Shandong 
Provincial Hospital Affiliated to Shandong Univ, Jinan, Shandong, China; 
3Shandong Provincial Qianfoshan Hospital Affiliated to Shandong Univ, Jinan, 
Shandong, China.
Background: Previous studies revealed that lipotoxicity participated in epithelial-to-
mesenchymal transition (EMT) of proximal tubular epithelial cells (PTECs) under diabetic 
conditions. Based on evidences that autophagy and lipid metabolism are closely related, 
the aim of the present study was to investigate autophagy under diabetic conditions and 
its role in lipotoxicity and EMT.
Methods: HK-2 cells were cultured in normal (5.5 mmol/L glucose) and high glucose 
medium (30 mmol/L glucose). At 6h, 24h, 48h, and 96h, autophagy activity was evaluated 
by western blot of LC3I/II, Beclin1 and p62. Next, the inhibition of autophagy was achieved 
by chloroquine diphosphate (CQ), 3-methyladenine (3-MA), or Atg5 knockdown using 
siRNA transfection. Rapamycin, which is a mammalian target of rapamycin (mTOR) 
receptor specific inhibitor and a known autophagy activator, was used to induce autophagy 
in HK-2 cells. Lipid accumulation was detected by Oil-Red O staining; EMT was estimated 
by western blot of vimentin and E-cadherin.
Results: In high glucose cultured HK-2 cells, Beclin1 and LC3-II were elevated, 
while p62 was decreased. These results indicate that autophagy activity was elevated under 
diabetic conditions. Autophagy deficiency induced by autophagy inhibitors, CQ and 3-MA, 
or by Atg5 siRNA transfection exacerbated lipid accumulation and EMT. Treatment of 
rapamycin attenuated high glucose induced lipid accumulation and EMT. The Atg5 silence 
counteracted the protective effect of rapamycin.
Conclusions: In conclusion, these results demonstrate that autophagy activity in 
PTECs is elevated under diabetic conditions and the elevated autophagy activity acts as 
a renoprotective response.
Funding: Government Support - Non-U.S.
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Insulin Sensitivity Before and Six Months After Kidney Transplantation 
Morten Buus Jørgensen,1 Mads Hornum,1 Gerrit van Hall,2 Claus Bistrup,3 
Jesper Hansen,4 Bo Feldt-Rasmussen.1  1Dept of Nephrology, Rigshospitalet, 
Denmark; 2Clinical Metabolomics Core Facility, Rigshospitalet, Denmark; 
3Dept of Nephrology, Odense Univ Hospital, Denmark; 4Dept of Nephrology, 
Herlev Univ Hospital, Denmark.
Background: Severe uraemia is a known cause of insulin resistance. We aimed to 
investigate the effect of kidney transplantation (Tx) on peripheral and central insulin 
sensitivity.
Methods: Nine non-diabetic patients awaiting living related kidney Tx were examined 
prior to Tx (Pre-Tx) with an oral glucose tolerance test (OGTT) and a 3h hyperinsulinaemic 
euglycaemic clamp. The clamp was repeated six months after Tx (Post-Tx). Nine age, 
gender and BMI matched individuals with normal kidney function were examined once 
with an OGTT and clamp serving as controls (Ctrl). Endogenous glucose production 
(EGP, N = 6), glucose rate of disappearance (Gd, N = 6) and lipolysis (glycerol rate of 
appearance, N = 5) were measured in a subgroup of patients with corresponding controls 
using stable isotope tracer technique. Results are in mean mmol/kg/min [95% confidence 
interval] during the clamp.
Results: Two patients had pre-Tx prediabetes whereas all other had both normal fasting 
plasma glucose and normal glucose tolerance. The amount of glucose utilized during 
clamp was non-significantly lower in patients before Tx (Pre-Tx: 15.1 [11.2–19.0], Ctrl: 
20.2 [13.4–27.0], P = 0.17) but significantly reduced after Tx (Post-Tx: 9.8 [6.7–12.9], P 
= 0.01). The suppression of EGP were comparable before Tx (Pre-Tx: 7.0 [5.4–8.5], Ctrl: 
7.0 [1.3–12.7], P = 0.99) but was significantly impaired after Tx (Post-Tx: 9.4 [7.8–11.1], 
P = 0.04). Gd were comparable both prior to and after Tx (Pre-Tx: 18.1 [13.6–22.5], Ctrl: 
22.3 [15.1–29.5], Post-Tx: 17.1 [13.4–20.8], P > 0.22). The suppression of glycerol rate 
of appearance were comparable before Tx (Pre-Tx: 1.1 [0.9–1.4], Ctrl: 1.1 [0.6–2.1], P = 
0.96) but significantly impaired after Tx (Post-Tx: 2.0 [1.0–3.8], P = 0.04).
Conclusions: The reduced insulin sensitivity after kidney Tx is characterized by a 
central insulin resistance with impaired suppression of endogenous glucose production, 
impaired suppression of lipolysis and comparable peripheral insulin sensitivity.
Funding: Private Foundation Support
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Renal Functional and Morphological Changes Related to Obesity and 
Hyperglycemia in Göttingen Minipigs  Rikke Lindgaard Thomsen,1 Berit 
Østergaard Christoffersen,2 Trine P. Ludvigsen,2 Rikke Kaae Kirk,2 Jonas 
Kildegaard,2 Lisa Tidman Fuchs,1 Pall Leifsson,1 Henrik D. Pedersen,2 Lisbeth 
Høier Olsen.1  1Dept of Veterinary Disease Biology, Univ of Copenhagen, 
Frederiksberg, Denmark; 2Novo Nordisk A/S, Maaloev, Denmark.
Background: Obesity and diabetes, two major health problems worldwide, both lead 
to renal functional and morphological changes; with diabetic nephropathy being the leading 
cause of end-stage renal failure. A large animal model displaying human-like features of 
obesity-related and diabetic nephropathy would be very valuable to study pathogenesis 
and effects of new drug candidates on these syndromes. The aim of the present study was 
to evaluate renal function and morphology in diet-fed obese, atherosclerotic Göttingen 
minipigs with or without mild diabetes.
Methods: Male castrated Göttingen minipigs, aged 8 weeks at study start, were fed 
normal chow (n=6) or high-fat, high-cholesterol diet (n=16) for 43 weeks. Mild diabetes was 
induced in 11 pigs after 18 (n=6) and 25 (n=5) weeks of diet-feeding, using streptozotocin 
(125 mg/kg IV) preceded by nicotinamide (67 mg/kg IV). The study included two cohorts. 
Parameters of interest were: Body fat percentage (BF) estimated by dual-energy X-ray 
absorptiometry, inulin clearance (IC), kidney resistive index (RI), plasma fructosamine 
reflecting plasma glucose (FRA), plasma urea, plasma creatinine (PCr), plasma total 
cholesterol (TC), urinary protein excretion (protein (UPCr) and albumin (UACr) adjusted 
for creatinine). Glomerulus area and number of nuclei/glomerulus area were estimated post 
mortem. Influence of BF, TC and FRA on in vivo kidney function and post mortem kidney 
changes was evaluated using ANOVA with cohort as fixed covariate.
Results: BF was positively associated with urea (P<0.01), IC (P<0.05), Glomerulus 
area (P<0.001) and UPCr (P=0.05), and negatively with PCr (P<0.001). FRA was positively 
associated with UACr (P<0.05) and number of nuclei/glomerulus area (P<0.05). RI was 
not associated with BF, TC or FRA.
Conclusions: In conclusion, functional and histological renal changes were found in 
diet-fed obese, atherosclerotic Göttingen minipigs with and without mild diabetes. The 
changes were associated with obesity and hyperglycemia.
Funding: Pharmaceutical Company Support - Novo Nordisk A/S
PUB294
Activation of Toll-Like Receptors Through Fetuin-A Leads to an 
Inflammatory Response in Podocytes and Exacerbates Palmitic Acid-
Induced Cell Death  Jana Orellana,1 Kapil Dev Kampe,1 Andreas Werner 
Jehle.1  1Dept of Biomedicine, Univ Hospital Basel, Basel, Switzerland; 2Dept 
of Biomedicine, Univ Hospital Basel, Basel, Switzerland; 3Dept of Biomedicine, 
Univ Hospital Basel, Basel, Switzerland.
Background: Inflammation participates in the pathogenesis of type 2 diabetes and 
contributes to diabetic nephropathy (DN). There is growing evidence that chronic elevated 
free fatty acids (FFAs) contribute to this chronic inflammatory milieu. Studies in pancreatic 
β-cells suggest that the inflammatory response mediated by FFAs depends on toll-like 
receptor (TLR) 4 and Il-1 receptor (Il-1R). The signaling pathways of TLRs and Il-1R 
involve activation of the transcription factor nuclear factor-κB (NF- κB) which induces 
a wide range of cytokines/chemokines including monocyte-chemoattractant protein-1 
(MCP-1), and Il-1β. Here, we addressed whether fetuin-A together with FFAs leads to an 
inflammatory response in podocytes and whether this exacerbates palmitic acid-induced 
podocyte death.
Methods: Conditionally immortalized murine podocytes were used. Murine and bovine 
fetuin-A were used alone or in combination with palmitic acid complex to BSA. MCP-1 
was measured by ELISA. Podocyte death was determined by flow cytometry (annexin V 
and propidium iodide staining).
Results: Palmitic acid alone did not, but fetuin-A induced MCP-1 in podocytes and this 
was further increased by palmitic acid. The MCP-1 release was prevented by ClO95 (TLR4 
blocker). Fetuin-A or LPS exacerbated palmitic acid induced podocyte death, and CLI095 as 
well as the IL1 receptor antagonist anakinra or an anti IL1β antibody attenuated cell death.
Conclusions: Fetuin-A alone and in combination with palmitic acid leads to an 
inflammatory response in podocytes and promotes palmitic acid induced podocyte death. 
As inhibition of TLR4 as well as Il1 β prevents these effects, both pathways are promising 
targets to attenuate the progression of DN.
Funding: Other NIH Support - Swiss National Science Foundation Grants 31003A-
144112/1, Pharmaceutical Company Support - Gottfried und Julia Bangerter-Rhyner-
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IL-1β Mediates the High Glucose Induced Endothelial-to-Mesenchymal 
Transition in Human Aortic Endothelial Cells  Dongdong Zhu, Ri-ning Tang, 
Kun Ling Ma, Bi-Cheng Liu.  Zhong Da Hospital, Southeast Univ Medical 
School, Nanjing, Jiangsu.
Background: Studies have shown that endothelial-to-mesenchymal transition (EndMT) 
induced by high glucose(HG) contributed to cardiac fibrosis.Additionally, proinflammatory 
cytokine interleukin-1β (IL-1β) has been implicated as one of the dominant players in the 
development of fibrosis and diabetic heart. In vitro studies , retinal endothelial cells(ECs), 
human intestinal ECs and human dermal ECs have been reported to undergo EndMT by 
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IL-1β stimulation.Interestinly, most IL-1β immunoreactivity is localized to endothelial 
cells and interstitial macrophages in an animal model of cardiac hypertrophy .However, 
the potential role of IL-1β in high glucose induced EndMT remain unknown. Here, we 
hypothesize that IL-1β might mediate the process.
Methods: Primary human aortic endothelial cells (HAECs) were divided into three 
groups: a normal glucose (NG) group, HG group, and anti- interleukin1β antibody treated 
(HG+Anti-IL-1β) group. The concentration of IL-1β in the supernatant was detected by 
Elisa. Pathological changes were investigated using fluorescence microscopy and electron 
microscopy. Immunofluorescence staining was performed to detect the co-expression of 
CD31 and FSP1. The expressions of FSP1 and a-SMA were detected by RT-PCR and 
Western blot.
Results: The treatment of HAECs in the HG group resulted in significant increases in the 
expressions of FSP1 , aSMA and IL-1β in dose-and time-dependent manners. The incubation 
of HAECs exposure to HG resulted in a fibroblast-like phenotype, wherein increased 
microfilamentation and a roughened endoplasmic reticulum structure were observed in 
the cytoplasm. The expressions of FSP1 and a-SMA were significantly increased in the 
HG group, and these changes were inhibited by anti interleukin1antibody or Il-1bsiRNA 
treatment (P < 0.05). Double staining of the HAECs indicated a colocalization of CD31 
and FSP1, while treatment with anti-interleukin1bantibody or Il-1β siRNA attenuated the 
expression of EndMT (P < 0.05).
Conclusions: These findings suggest that IL-1β mediates the HG induced EndMT, 
which was inhibited by anti- interleukin1bantibody orIL-1β siRNA treatment.
PUB296
Serum Bilirubin and Asparagine Aminotransferase Concentrations Predict 
Loss of Renal Function in Type 2 Diabetes  Kevin M. Wheelock,1 Gudeta 
D. Fufaa,1 William Knowler,1 Madhumita Sinha,1 Frank C. Brosius,2 Robert G. 
Nelson.1  1NIDDK, Phoenix, AZ; 2Univ of Michigan, Ann Arbor, MI.
Background: Higher serum bilirubin concentration is reported to slow the progression 
of nephropathy in type 2 diabetes. We examined associations of serum bilirubin and 
asparagine aminotransferase (AST) concentrations with renal function loss (RFL) in a 
post-hoc analysis of a clinical trial of renoprotection with losartan in Pima Indians with 
type 2 diabetes (ClinicalTrials.gov number, NCT00340678).
Methods: Serum bilirubin and AST were measured at baseline in 168 subjects who 
underwent annual measurement of GFR by the urinary clearance of iothalamate. RFL was 
defined by ≥40% decline in GFR from baseline. Cox regression was used to compute hazard 
ratios (HRs) for the association of a 1 standard deviation (SD) increment in bilirubin and 
AST concentrations with RFL adjusted for age, sex, treatment group, HbA1c, GFR, and 
urinary albumin/creatinine ratio (ACR). The sum of standardized AST and bilirubin was 
standardized to create a liver index variable with mean=0, SD=1.
Results: Participants (73% female, mean age 42±11 years, bilirubin 0.6±0.2 mg/dL, 
HbA1c 9.3±2.2%, GFR 163±43 ml/min, and median AST 19 U/L (IQR=13.0-31.5 U/L), 
ACR 31 mg/g (IQR=12-77 mg/g)) were followed for a median of 7.0 years (IQR=4.5-9.9 
years); 73 subjects (43%) developed RFL. After multivariable adjustment, serum bilirubin 
(HR=1.33) and serum AST (HR=1.39) predicted RFL. The combination of these liver 
function tests provided the strongest prediction (HR=1.52).
Renal Function Loss (95% CI), P-value 
Variable Univariate Multivariate
Log AST (per SD) 1.34 (1.04-1.74), P=0.025 1.39 (1.07-1.80), P=0.015
Bilirubin (per SD) 1.30 (1.05-1.62), P=0.016 1.33 (1.05-1.67), P=0.017 
Liver index (per SD) 1.43 (1.13-1.81), P=0.003 1.52 (1.18-1.95), P=0.001 
Conclusions: Higher serum bilirubin and AST concentrations predict loss of renal 
function in Pima Indians with type 2 diabetes.
Funding: NIDDK Support
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Baseline Data from the Multinational Prospective Cohort Study in 
Patients with Type 2 Diabetes for Validation of Biomarkers (PROVALID) 
Gert J. Mayer,1 Susanne Eder,1 Laszlo Rosivall,2 Peter Voros,3 Hiddo Jan Lambers 
Heerspink,3 Dick de Zeeuw,3 Beata Czerwienska,4 Andrzej Wiecek,4 Dianne Z. 
Hillyard,5 Patrick B. Mark,5 Georg Heinze,6 Peter Rossing.7  1Internal Medicine 
IV, Medical Univ Innsbruck, Innsbruck, Austria; 2Inst of Pathophysiology, 
Semmelweis Univ, Budapest, Hungary; 3Egyesitett Szent Istvan es Szent Laszlo 
Korhaz, Budapest, Hungary; 4Dept Clinical Pharmacy and Pharmcology, Univ 
Medical Center Groningen, Groningen, Netherlands; 5Dept of Nephrology, 
Transplantation and Internal Medicine, Medical Univ Silesia, Katowice, Poland; 
6Inst of Cardiovascular and Medical Sciences, Univ of Glasgow, Glasgow, 
United Kingdom; 7Section for Clinical Biometrics, Medical Univ Vienna, Vienna, 
Austria; 8STENO Diabetes Center, Gentofte, Denmark.
Background: We recruited 4065 subjects at the primary healthcare level in Austria, 
Hungary, Netherlands, Poland and Scotland, who will be treated according to local 
practise and followed for 4 years to compare the incidence and progression of renal 
and cardiovascular disease between the countries. Additionally extensive biobanking is 
performed.
Methods: We will determine the cumulative incidence of progression of albuminuria, 
doubling of creatinine, end stage renal disease as well as fatal and not fatal cardiovascular 
events. Exclusion criteria are active malignancy and age <18 years.
Results: The mean age of the population was 62 years, mean duration of diabetes as 9.9 
years. 9% of the patients had eGFR values <45 and 22% <60 ml/min/1.73m2. Baseline data 
“lowest” country “highest” country
SBP (mmHg) 134±15 140±19
DBP (mmHg) 78±9 84±12
HbA1c (%) 6.7±1.1 7.3±1.4
eGFR<45 (%) 4 12
albuminuria (mg/day) 8 (5,26) 15 (6,40)
microalbuminuria (%) 10 26
LDL cholesterol (mg%) 91±34 118±39
We observed marked variability in treatment pattern between the countries (use of 
metformin 49-74, RAS blocking agents 59-77, β-blockers 28-59, statins 21-81%).
Conclusions: We conclude that health care practices in patients with type 2 diabetes at 
the primary level of care vary widely between European countries. Whether these differences 
affect outcome remains to be established.
Funding: Pharmaceutical Company Support - abbvie; North Chicago, Illinois, USA, 
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FGF-23 and Magnesium Are Independent Risk Factors for an Increased 
Albumin-to-Creatinine Ratio in Type 2 Diabetics with Chronic Kidney 
Disease  Filipa Brito Mendes,1 Ana Paula Silva,1,2 André Fragoso,1 Nélio Santos,1 
Teresa M. Jeronimo,1 Ana Pocinho Pimentel,1 Pedro L. Neves.1,2  1Centro 
Hospitalar do Algarve- Hospital de Faro, Portugal; 2Univ do Algarve, Portugal.
Background: Microalbuminuria is the earliest sign of glomerular involvement in 
diabetes mellitus. The multiple physiopathological mechanisms involved are complex and 
not completely understood. Recently, it appeared that fibroblast growth factor- 23 (FGF-
23) and magnesium play a role in the emergence and maintenance of albuminuria in type 
2 diabetics. The aim of this study is to investigate the role of FGF-23 and magnesium in 
relation to the urine albumin-to-creatinine ratio in type 2 diabetics with chronic kidney 
disease (CKD) stages 2-4.
Methods: In a cross-sectional study we included all eligible type 2 diabetic patients 
with CKD stages 2-4, followed in our outpatient Diabetic Kidney clinic. We included 150 
patients, f=53 m=97, with a mean age of 66.6±9.7 years (40-85) and a mean follow-up of 76 
months. We used descriptive statistics, the Student’s test, ANOVA and the chi-square test. 
We divided our population according to the urine albumin-to-creatinine ratio (GI=30-300 
mg/g and G2³300 mg/g) and compared these groups regarding the several biological and 
laboratorial parameters analyzed. We employed a multiple regression model to identify 
risk factors of increased urine albumin-to-creatinine ratio. In this model we used the urine 
albumin-to-creatinine ratio as the dependent variable and as independent ones age, duration 
of diabetes, systolic blood pressure, HgA1c, eGFR, HOMA-IR, manonaldehyde, hs-CRP 
and 1,25(OH)2D3 levels.
Results: The patients in G2 displayed a lower eGFR (p=0.0001) and magnesium 
(p=0.004) levels, as well as higher levels of FGF-23 (p=0.043) compared to patients in 
G1. In the multivariate linear regression model we found that FGF-23 (β=0.562, P=0.0001) 
and the magnesium (β=-8.916,p=0.0001) are independent risk factors for increasing the 
urine albumin-to-creatinine ratio.
Conclusions: The present study shows that a dysregulation of mineral metabolism, 
reflected by altered levels of magnesium and FGF-23, correlates with an increased urine 
albumin-to-creatinine ratio in type 2 diabetic patients with CKD stages 2-4.
PUB299
FGF-23 and Klotho Influence the Pulse Pressure in Diabetic Patients 
with Nephropathy  Ana Paula Silva,1,2 Filipa Brito Mendes,1 André Fragoso,1 
Teresa M. Jeronimo,1 Ana Pocinho Pimentel,1 Nélio Santos,1 Pedro L. Neves.1,2 
1Nephrology, Centro Hospitalar do Algarve, Faro, Portugal; 2Dept of Biomedical 
Sciences and Medicine, Univ of Algarve, Faro, Portugal.
Background: The last decade have shown that FGF23 and Klotho may have relevant 
independent actions on the renal and CV systems. They interfere with vascular functions 
and may play a role in vascular calcification, atherosclerosis and arteriolosclerosis. Their 
interactive activities may also have direct and indirect effects on interdependent renal 
and CV pathophysiology. The aim of this study is to investigate the relationship between 
FGF-23 and Klotho with pulse pressure in type 2 diabetic with chronic kidney disease 
(CKD) stages 2-3.
Methods: In a cross-sectional study we included 107 type 2 diabetic patients (67 males, 
62,6%), a mean age of 66.6 ±9.7 years and CKD stage 2-3.We used descriptive statistics, the 
Student´s t and the chi-square tests. We also divided our population according to the pulse 
pressure (G I <50 mmHg and G2 ≥ 50 mmHg), and compared these groups regarding the 
several biological and laboratorial parameters analyzed. We employed a multiple regression 
model to identify risk factors of increased pulse pressure (PP). In this model we used as 
dependent variable the pulse pressure, and as independent ones age, metabolism mineral, 
urine albumin-to-creatinine ratio, insulin resistance, oxidative stress and eGFR.
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Results: We found that G2 patients showed higher age (p=0.017), phosphorus 
(p=0.0001), iPTH (p=0.0001), urine albumin-to-creatinine ratio (p=0.001), Homa-IR 
(p=0.001), FGF-23 (p=0.0001) and OxLDL (p=0.0001) and lower levels of eGFR 
(p=0.0001), Klotho (p=0.0001) and 1.25(OH)2D3 (p=0.0001). In the multivariate linear 
regression model we found that FGF-23 (β=0.377, P=0.047) and the Klotho (β= - 0.567, 
p=0.023) are independent risk factors for increasing the pulse pressure.
Conclusions: In conclusion, in a population of type 2 diabetic with chronic kidney 
disease stages 2-3, the Klotho and FGF-23 levels are independently associated with PP. 
Further studies with more patients are warranted to confirm whether an increase in Klotho 
and a decrease in FGF-23 would reduce the PP and consequently the cardiovascular risk 
of our patients.
Funding: NIDDK Support
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Prediction of Renal Outcome in Type 2 Diabetic Dephropathy by Estimating 
GFR from a Combination of Serum Creatinine and Cystatin C  Yu Pan, Song 
Jiang, Dandan Qiu, Yu An, Yongchun Ge, Honglang Xie, Zhihong Liu.  National 
Clinical Research Center of Kidney Diseases, Research Inst of Nephrology, 
Jinling Hospital, Nanjing, Jiangsu, China.
Background: Serum cystatin C is an alternative to serum creatinine for estimating 
glomerular filtration rate (GFR), however, the utility of estimated GFR from combination of 
serum creatinine and cystatin C as marker to predict long-term renal outcome is uncertain, 
particularly in the Type 2 diabetic nephropathy (DN).
Methods: A total of 501 patients (The National Clinical Research Center of Kidney 
Diseases, 2003-2011) were recruited in prospective cohort study. Follow-up was 5-year. 
Renal outcome was defined by eGFRcre-cys<15 ml/min per 1.73m2 or renal replacement 
therapy.
Results: The distributions of standardized serum cystatin C with eGFRcre and 
eGFRcre-cys are shown in. Kaplan-Meier curves showed significantly increased renal end 
points with higher quartile of cystatin C (p <0.001) and lower eGFRcre-cys (p <0.001). 
The highest AUROCs was eGFRcre-cys in predicting the renal endpoint compared with 
eGFRcre or eGFRcys.The best cut-off value for predicting the renal endpoint was 29.28% 
decline in the 24-month, which value showed 79.6% sensitivity and 82.6% specificity. Cox 
regression models with restricted cubic splines were shows a change of -30% in eGFRcre-cys 
was associated with adjusted HRs for ESRD of 27.92 (95%CI, 3.95-197.48) over 2-year.
Conclusions: eGFRcre-cys was a precision, and accuracy marker in the predicting of 
the renal outcome and 30% decline of eGFRcre-cys over 2 years was strongly associated 
with the risk of ESRD, suggesting it could be used as an alternative end point in T2DN.
Funding: Government Support - Non-U.S.
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Prevalence and Prognostic Role of Uncontrolled Risk Factors in Diabetic 
CKD (DM-CKD) Treated in Nephrology Clinics  Roberto Minutolo,1 Michele 
Provenzano,1 Paolo Chiodini,2 Giuseppe Conte,1 Luca De Nicola.1  1Nephrology, 
Second Univ, Naples, Italy; 2Med Stat, Second Univ, Naples, Italy.
Background: Knowledge of prognosis of DM-CKD mainly derives from RCTs and 
cohorts followed in the diabetology setting. Epidemiologic features are less defined in 
patients with overt disease managed in renal clinics.
Methods: We studied 763 DM-CKD patients derived from 3 prospective cohorts that 
in 2000-2010 enrolled 2,488 CKD patients stage III-V under stable care from ≥6 months in 
40 Italian renal clinics. Endpoints were ESRD (chronic dialysis-transplant) and first major 
cardiovascular (CV) events (fatal and non fatal) assessed through 12/2014. Uncontrolled 
risk factors were defined as high blood pressure (BP>140/90 or >130/80 if proteinuria 
>0.150 g/24h), HbA1c >7.5%, hemoglobin <10.5 g/dL, serum phosphorus (P) >4.5 mg/dL, 
LDL-C ³100 or 70 mg/dL according to ESC 2012 guidelines, proteinuria (Uprot) >0.5 g/24h.
Results: HbA1c was 6.9%, (IQR 6.2-7.8), Uprot 0.5 g/24h (IQR 0.1-1.4), P 3.9±0.8 
mg/dL, Hb 12.3±1.7 g/dL and BP 142±19/78±11 mmHg. During follow-up (43 months, 
IQR 21-56), 171 ESRD and 170 CV events occurred (incidence rate 6.4 and 6.9/100 
pts/y). Multivariable Cox analyses for ESRD and CV risks (HR, 95% CI) stratified by 
cohort are in the Table.
Descriptive ESRD CV
Age, years 70±10 0.98 (0.96-0.99) 1.03 (1.02-1.05)
Males, % 57.9 1.93 (1.36-2.72) 1.36 (0.97-1.91)
Smokers, % 9.7 1.07 (0.62-1.87) 1.06 (0.60-1.88)
CV disease, % 46.7 1.56 (1.13-2.15) 1.77 (1.29-2.43)
BMI, Kg/m2 29.3±5.3 1.00 (0.97-1.03) 1.00 (0.97-1.03)
GFR-EPI, ml/min/1.73m2 31.2±14.1 0.90 (0.88-0.92) 0.97 (0.96-0.99)
High BP, % 53.1 1.30 (0.91-1.88) 1.60 (1.13-2.26)
HbA1c>7.5, % 33.0 0.78 (0.55-1.10) 1.45 (1.06-1.99)
Hemoglobin<10.5, % 13.8 1.58 (1.09-2.28) 1.43 (0.94-2.18)
LDL-C≥100-70, % 83.6 1.01 (0.66-1.56) 1.03 (0.65-1.62)
Uprot>0.5, % 49.8 1.95 (1.26-3.00) 1.07 (0.74-1.54)
P>4.5, % 18.1 1.49 (1.05-2.12) 0.92 (0.60-1.41)
Anti-RAS, % 78.6 0.98 (0.67-1.44) 1.04 (0.71-1.54)
Similar results were obtained when testing continuous variables.
Conclusions: Epidemiologic peculiarities emerge in DM-CKD patients treated in 
renal clinics. This information can be helpful to optimize risk stratification and adequately 
design RCTs.
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Serum NGAL and Cystatin C Accuracy in Early Detection of Kidney 
Dysfunction in Type 2 Diabetes  Marcelo Rodrigues Bacci, Fernando 
Luiz affonso Fonseca, Livia Yadoya Vasconcelos, Mariana Rigolo, Ross 
Rozier-Alves, Beatriz Alves.  General Practice, ABC Medical School, Brazil.
Background: Diabetic nephropathy is associated with specific histological changes.
An early detection of depletion of glomerular and tubular function can be done with 
biomarkers of diabetic disease.The aim of this study is to evaluate the accuracy of early 
kidney dysfunction biomarkers in diabetes.
Methods: Patients with diabetes were splited according to their levels of glycated 
hemoglobin(GHb):greater than 7% or below this value.Urine samples were taken to measure 
cystatin C(uCYS),uNGAL,beta-trace protein(uBTP) and albuminuria(ACR).In blood,sCYS 
sNGAL,creatinine.Patients with end stage renal disease or in dialysis were not included.
ROC curve was used to evaluate the accuracy of the markers relative to renal dysfunction 
according to their simplified MDRD estimated glomerular filtration rate(eGFR).Spearman’s 
correlation and regression models were built to evaluate the markers.
Results: Ninety patients with diabetes were recruited.The mean eGFR was 79.1ml/
min/1.73m and 76.7 in GHb> 7% group.sCYS was positively correlated with creatinine(
p<0.001),eGFR(p<0.001) and uBTP(p=0.01).The ROC curve showed value of 0.635 for 
sCYS,0621 to sNGAL and 0.660 for ACR.Urine had lower values for CYS(0.569),0.526 
for NGAL and 0.567 for uBTP.The crude logistics regression model observed a positive 
association between sCYS(p=0.01) and sNGAL(p<0.001).The linear regression model 
showed positive association with sCYS and creatinine and eGFR(p<0.001) but not with 
GHb(p=0.892).ACR showed the same parameters(p=0.005 for creatinine and 0.018 to 
eGFR).
Conclusions: In this study,a comparative panel of tubular and glomerular dysfunction 
markers was built in diabetics with eGFR>60.There was a worse performance of the 
markers in urine except for ACR that had the best value in ROC analysis.The sCYS and 
sNGAL presented the best association with worse GFR and glicemic control.In another 
study of our group uBTP had better performance to distinguish early kidney disfunction 
between diabetics and non diabetics.Finally,with worse eGFR, sNGAL, sCYS and ACR 
performed better in diabetics.A worse glycemic control was positively associated with 
sCYS and sNGAL.
PUB303
Comparison of Renal Outcome Between “Chronic Kidney Disease due to 
Diabetes” and “Chronic Kidney Disease with Diabetes” in Gonryo Study 
Toshiki Iwai,2 Mariko Miyazaki,1 Gen Yamada,1 Tae Yamamoto,1 Hiroshi 
Sato,2 Masaaki Nakayama,3 Sadayoshi Ito.1  1Nephrology, Hypertension, 
and Endocrinology, Tohoku Univ Deparment of Pharmacology, Sendai, 
Miyagi, Japan; 2Clinical Pharamacology and Therapeutics, Graduate School 
of Pharmaceutical Sciences, Tohoku Univ, Sendai, Japan; 3Kidney and 
Hypertension, Fukushima Medical Univ, Fukushima, Japan.
Background: Diabetic nephropathy (DN) is defined as chronic kidney disease (CKD) 
due to diabetes mellitus (DM) in a narrow sense. The difference is not unclear between 
DN and CKD patients of other cause but complicated DM (CKD with DM) in clinical 
outcome. This study mentioned the clinical difference and renal outcome of DN, CKD 
with DM, and CKD without DM.
Methods: This is a part of Gonryo CKD study. It is the multicenter prospective 
observational survey for 5 years. From May 2006, 4,015 patients were registered. We 
include 2,484 of them into this analysis who could classify to DN (n=249), CKD with 
DM(n=448), and CKD without DM (n=1,787). The classification was performed at 
registration by clinical finding and history of other diabetic complication such as retinopathy 
if case without kidney biopsy.
Results: The characteristics of age, gender, systolic blood pressure (SBP), and 
dyslipidemia in “DN”(66.6 y.o., male 67.9%, sBP 136.6mmHg, dyslipidemia 50.1%) and 
“CKD with DM”(58.7 y.o. male 58.7%, sBP 132.3mmHg dyslipidemia 54.4%) were similar 
compared with “CKD without DM”(50.5 y.o, male 50.5%, 129.8 mmHg, 40.1%) . For 
renal outcome analysis of each CKD stage was performed. The hazard ratio of “DN” was 
significantly higher than “CKD without DN” for end stage kidney disease (ESKD) in G3b 
7.10(2.46-20.49 95% CI), G4 2.31(1.35-3.94), G5 1.67(1.16-2.42). On the other hand, that 
of “CKD with DM” didn’t elevate in G3b 0.89(0.19-4.24 95% CI), G4 1.21(0.66-2.23), G5 
1.36(0.74-2.51) compared with “CKD without DM” . Kaplan-Meier analysis revealed G3b 
and G4 in “DN” showed significantly poor outcome. The evaluation of annual decline of 
eGFR revealed stage G3b in DN was the largest. (-3.7 ml/min/1.73m^2/year).
Conclusions: Renal risk between “CKD with DM” and “DN” was completely different. 
G3b was most important critical point in renal prognosis of DN.
Funding: Clinical Revenue Support
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Prevalence of Proteinuria, Albuminuria and Associated Factors in Obese 
Patients Undergoing Bariatric Surgery  Max R. Pommier, Gaurang P. Mavani, 
Maria V. DeVita, Michael F. Michelis, Jordan L. Rosenstock.  Dept of Medicine 
Div of Nephrology, Lenox Hill Hospital Northshore/ LIJ, NYC, NY.
Background: Obesity is associated with proteinuria. But the exact prevalence of 
proteinuria or albuminuria with and without additional risk factors in obese patients is 
unclear.
Methods: Consecutive patients undergoing bariatric surgery were included in study. 
Participating patients had a urine sample for protein creatinine ratio and albumin creatinine 
ratio prior to their surgery. We defined a positive protein to creatinine ratio as greater than 
or equal 300 mg and a positive albumin to creatinine ratio as greater than or equal to 30 
mg. Associated factors such diabetes mellitus (DM), hypertension (HTN), body mass index 
(BMI), and ACEi/ ARB use were collected.
Results: One hundred forty-three patients were included. The mean age was 43 years 
+/- 11. Twenty five percent of the patients had DM, 50% had HTN, and the mean BMI was 
44 +/- 9. The prevalence of proteinuria and albuminuria was 8.5% (95% CI 4.5- 14.4%) 
and 21% (95% CI 14- 30%) respectively. Sixty six percent of the patients with proteinuria 
had DM as did 43% of the patients with albuminuria. Eighty three percent of patients with 
proteinuria had either DM or HTN. Seventy eight percent of patients with albuminuria had 
either DM or HTN. Of patients with neither DM nor HTN (n=58), only 3.4% and 8.6% 
had proteinuria and albuminuria respectively. In contrast to patients who did not have 
proteinuria, the mean BMI was higher in those with proteinuria (44 vs. 40). However, the 
BMI did not differ between those with and without albuminuria. The BMI for diabetics 
did not differ from non-diabetics. The use of ACEI/ ARB was 33% and 30% in patients 
with proteinuria and albuminuria and 25% and 20% in those without.
Conclusions: The majority of patients with proteinuria and albuminuria had diabetes 
and/or hypertension and there was a much lower prevalence of proteinuria/albuminuria 
in patients without these risk factors. Patients who had proteinuria had a higher BMI than 
patients who did not have proteinuria, though for albuminuria the BMI did not differ.
PUB305
Plasma Uric Acid and Cardio-Renal Function in Adolescents with Type 1 
Diabetes  Yuliya Lytvyn,1 Farid H. Mahmud,2 Livia Deda,2 David B. Dunger,3 
John Eric Deanfield,4 Yesmino Elia,2 Ronnie Lok-Hang Har,1 Timothy J. 
Bradley,5 Rahim Moineddin,6 Heather N. Reich,1 James W. Scholey,1 Luc 
Mertens,5 Etienne Bertrand Sochett,2 David Cherney.1  1Nephrology, Univ Health 
Network, Univ of Toronto; 2Endocrinology, The Hospital for Sick Children, Univ 
of Toronto; 3Pediatrics, Univ of Cambridge, Cambridge, United Kingdom; 4Univ 
College Hospital, London, United Kingdom; 5Cardiology, The Hospital for Sick 
Children, Univ of Toronto; 6Family and Community Medicine, Univ of Toronto.
Background: Plasma uric acid (PUA) correlates with higher blood pressure (BP), 
lower GFR and lower renal blood flow in adults with type 1 diabetes (T1D). Our overall 
aim was to determine if similar relationships exist in adolescents with T1D, analyzed on 
the basis of low-, middle- or high- albumin to creatinine ratio (ACR) tertile within the 
normal range, compared to healthy controls (HC). We hypothesized that PUA within the 
normal range would be associated with lower GFR and higher values for BP and arterial 
stiffness in T1D adolescents but not HC.
Methods: PUA, BP, GFRcystatin C and carotid-femoral pulse wave velocity (Car-Fem 
PWV) were measured in 65 HC, 64 low-, 74 middle- and 50 high-tertile T1D participants 
from the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT).
Results: PUA was lower in T1D vs. HC (242±55 vs. 306±74mmol/L, p<0.0001). 
There were no differences in PUA between the 3 ACR tertiles. Higher PUA correlated with 
lower GFR in T1D after correcting for age, gender, HbA1C, BMI z-score, BP z-score, T1D 
duration and plasma HDL (p<0.0001). This association was not seen in HC. In the T1D 
group, PUA did not correlate with BP z-score before or after correcting for HbA1C, T1D 
duration and plasma HDL. Higher PUA correlated with higher Car-Fem PWV (r=0.18, 
p=0.018) in T1D, but not in HC. This association in T1D was abolished after correcting 
for age, gender, HbA1c, BMI z-score, T1D duration and HDL.
Conclusions: PUA correlates with lower GFR in T1D adolescents and may also 
be associated with increased arterial stiffness, despite lower PUA in T1D vs. HC. The 
presence of T1D may potentiate the hemodynamic impact of PUA, thereby modifying 
future cardio-renal risk.
PUB306
Risk Factors for Renal and Cardiovascular Events in Type 2 Diabetic 
Patients with Biopsy-Proven Nephropathy in Japan  Akinori Hara,1 Kengo 
Furuichi,1 Miho Shimizu,1 Yukio Yuzawa,2 Hiroshi Kitamura,3 Hiroshi Sato,4 
Takashi Wada.1  1Div of Nephrology, Kanazawa Univ Hospital, Japan; 2Dept of 
Nephrology, Fujita Health Univ Hospital, Japan; 3Dept of Pathology, Clinical 
Research Center, National Hospital Organization Chiba East National Hospital, 
Japan; 4Clinical Pharmacology and Therapeutics, Tohoku Univ Graduate School 
of Pharmaceutical Sciences.
Background: Standardized pathological classification is an essential tool in the 
evaluation of disease progression and/or efficacy of clinical management. In this nation-
wide, multicenter, retrospective study, we examined pathological findings as risk factors 
for renal and cardiovascular events in Japanese patients with type 2 diabetes.
Methods: Renal biopsy and clinical data were retrospectively collected from 356 
patients with type 2 diabetes in 13 centers in Japan. The mean observation period was 
76.3 months and the observation period was 2264 person-year in total. Nine glomerular 
lesions, two interstitial lesions, and two vascular lesions were classified and evaluated as 
pathological predictors.
Results: One hundred sixty nine composite renal events (dialysis and doubling of 
serum creatinine or half of estimated glomerular filtration rate (eGFR)), 94 kidney deaths 
(dialysis), 34 cardiovascular events, and 30 deaths occurred. Specific pathological risk 
factors were detected for composite renal end points, renal death, and cardiovascular 
events in normo- to microalbuminuria and preserved eGFR group (G1-3a, A1-2). Among 
them, the presence of double contour of the glomerular basement membrane/subendothelial 
space widening (SubendW) and advanced interstitial cell infiltration (ICell) were particular 
risk factors for composite renal events, and glomerulomegaly (GMeg) was a risk factor 
for cardiovascular events.
Conclusions: This study revealed that specific pathological parameters (presence of 
SubendW, ICell, and GMeg) were predictors for renal and cardiovascular events in patients 
with preserved eGFR and normo- to microalbuminuria.
Funding: Government Support - Non-U.S.
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The Effect of Carbohydrate – Blood Glucose Feedback Method with Basic 
Carbohydrate Counting for Glycemic Control in Diabetic Dialysis Patients 
Toru Hyodo.  Dialysis Center, Eijin Clinic and Kurata Hospital, Hiratsuka, 
Kanagawa, Japan.
Background: Basic carbohydrate counting (BCC), a method used in the dietary 
management of diabetes, is based on the concept that the postprandial rise in blood 
glucose levels is primarily affected by ingested carbohydrates. In this method, patients 
are instructed to eat a consistent amount of carbohydrates across their three daily meals to 
minimize fluctuations in postprandial blood glucose levels. We applied the carbohydrate 
glucose feedback method (CBGFM) with BCC for the diabetic dialysis patient whose 
HbA1c levels did not keep each favorable level only by BCC. CBGFM is to measure 
the predialysis blood glucose and show the results to patients in every dialysis session. 
Patients can estimate their carbohydrate intake balance and doses. The effect of CBGFM 
with BCC is reported in this study.
Methods: Eight diabetic patients undergoing maintenance hemodialysis (6 men and 2 
women; mean age, 64.4 ± 11.9 years; mean dialysis period, 4.0 ± 5.0 years; 2 insulin users, 
6 nonusers) were instructed in CBGFM with BCC and followed for 3 months to assess 
changes in their predialysis blood glucose (BG), hemoglobin A1c (HbA1c), Hemoglobin 
(Hb), triglycerides (TG), Potassium (K), Phosphorus (P), albumin (Alb), total cholesterol 
(T-Cho), high-density lipoprotein-Cho (HDL-Cho), low-density lipoprotein-Cho (LDL-
Cho), protein catabolic rate (PCR), dry weight (DW), body mass index (BMI), and the 
Geriatric Nutritional Risk Index (GNRI).
Results: HbA1c levels were significantly decreased from the pre-instruction values 
(P=0.0054), The GA and BG showed the tendency toward decrease, but no marked changes 
were observed for the other parameters. Pre BG: 173.1± 50.9 mg/dL Pre HbA1c: 7.0±0.4 
% Pre GA: 19.2±4.5, 3M BG: 131.5±29.5 (P=0.066), 3M: HbA1c: 6.1±0.6 (P=0.0054), 
3M GA: 17.7±2.3(P=0.111).
Conclusions: The results demonstrated that the CBGFM with BCC is a useful method 
of dietary management for glycemic control that can be applied independently of, but 
concurrently with, the control of potassium and phosphorus intake in dietary therapy for 
dialysis patients.
PUB308
The Clinical Effects of Renoprotection with DPP-4 Inhibitors 
Koichi Kanozawa, Saeko Sato, Yoshimi Okada, Hiroaki Hara, Minoru Hatano, 
Nobuyuki Onizawa, Takatsugu Iwashita, Tomonari Ogawa, Hajime Hasegawa. 
Nephrology and Hypertension, Saitama Medical Center, Saitama Medical Univ, 
Kawagoe, Saitama, Japan.
Background: Recently, not only animal models of diabetic nephropathy, but also 
non-diabetic nephropathy models, DPP-4 inhibitors(DPP-4i)was reported to have the 
renoprotective effects that improve albuminuria or tissue damage, through inhibition of 
oxidative stress, inflammation, and fibrosis. The aim of study is to clarify the mechanisms 
of renoprotective effect by DPP-4i in human diabetic nephropathy (DMN), clinically.
Methods: We gave DPP-4i (either of vildagliptin 50-100mg, alogliptin 25mg, 
teneligliptin 20-40mg) for Japanese Type 2 diabetes patients with nephronpathy. We were 
compared surrogate marker of oxidative stressandrenal injury, before and afterthree months.
Results: The administration of the DPP-4i, HbA1c was improved from 6.9±0.4 to 
6.3±0.3% (p<0.01), either 1,5-anhydro-d-glucitol (1,5AG) was increased from 11.0±6.4 
to 15.3±6.9% (p<0.01). Although eGFRcreat was no change (p=0.05), but eGFRcys was 
significantly increased from 92.1±23.8 to 96.7±21.7 ml/min/1.73m2 (p=0.03). MDA-LDL 
is an oxidative stress marker, was decreased from 128±39 to 110±34 mU/L (p<0.01), 
urinary 8OHdG was reduced from 10.8±5.3 to 8.1±4.5 ng/mgCr (p<0.01). Although log 
urinary albumin to creatinine ratio(UACR) was reduced from 1.52±0.63 to 1.36±0.64 
(p<0.01), and urinary liver-type fatty acid binding protein(L-FABP) was improved from 
8.1±8.3 to 4.5±4.6 mg/gCr ( p=0.02), but NAG and urinary b2-microglobrin(MG) were 
no change (p=0.65, 0.47). In inflammation, or fibrosis, log urinay MCP-1 was decreased 
from 2.41±0.53 to 2.12±0.32 (p<0.01), and urinary collgen IV was from 5.2±3.3 to 3.9±2.4 
mg/gCr (p<0.01). In the context of blood glucose change, strong association was observed 
between the change rate of 1,5AG and urinary 8OHdG (p<0.01), also was also associated 
with the change rate of UACR (p=0.03). On the other hand, HbA1c and these were not 
associated (p=0.31, 0.14).
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Conclusions: In DMN, DPP-4i have oxidative stress relief and renoprotective effect, by 
the improvement of short-term blood sugar fluctuations, also by oxidative stress reduction 
which independently of the improving glycemic control.
PUB309
Fibrinogen: A Potential Predictive Factor for the Progress of Diabetic 
Kidney Disease  Wenbo Zhao, Hui-qun Li, Zhenda Zheng.  The Third Affiliated 
Hospital of Sun Yat-sen Univ, Guangzhou, Guangdong.
Background: To evaluate the potential of fibrinogen as a predictor of the progress of 
proteinuria in diabetic kidney disease.
Methods: For a Cross-Sectional Study, collecting 1121 type 2 diabete patients without 
or with microalbuminuria or massive proteinuria were treated during January 2008 to 
January 2013. Proteinuria was negative in 755 cases, 285 cases i with microalbuminuria, 
and 171 cases with massive proteinuria;We analyzed the correlation factors of the 
negative protein urine group and the microalbuminuria group; the correlation factors of 
the microalbuminuria group and the massive proteinuria group. Fibrinogen levels were 
compared between three groups.
Results: Retinopathy, hypertension grading, SBP, Fibrinogen levels, serum albumin, 
serum cystatin were the related progress factors of Microalbuminuria; Diabetes course, 
retinopathy, waist to hip ratio, Fibrinogen levels, serum albumin levels, serum cystatin 
C, serum creatinine were the related progress factors of the massive proteinuria; Except 
fibrinogen, other factors had been known relating to the progress of diabetic kidney disease. 
There were differences in the levels of three groups of fibrinogen (P< 0.05), which were 
3.43 + 0.91 g/L, 4.15 + 1.31 g/L, 5.16 + 1.44 g/L.
Conclusions: Fibrinogen was a potential predictive factor for the development of 
diabetic kidney disease. The conclusion needs to be confirmed by further study.
PUB310
Interaction of HDLc, Iron, and Diabetes on Kidney Function 
Baqiyyah Conway,1 Tina Costacou,2 John M. Arthur.3  1Epidemiology, West 
Virginia Univ; 2Epidemiology, Univ of Pittsburgh; 3Univ of Arkansas for 
Medical Sciences.
Background: The effect of HDL cholesterol (HDLc) on kidney function has recently 
received attention, partly due to the finding of increased hemoglobin (hb) inside of the HDL 
protein in persons with high risk haptoglobin (hp) genotypes. Such hb w/in the HDL protein 
may lead to iron induced lipid peroxidation products. These lipid peroxidation products may 
lead to iron-induced kidney damage. We have recently shown an interaction between HDLc 
and iron w/ kidney function (eGFR) in persons with diabetes such that after controlling for 
hb, higher serum iron levels were associated w/ reduced eGFR but only in those w/ HDLc 
levels above the median for the population. Because of the diabetes-specific association 
of increased hb inside the HDL protein in those w/ high risk hp genotypes, we hypothesize 
that this interaction between HDLc and iron w/ kidney function varies by diabetes status. 
To test this hypothesis, we examined the inter-relationship between HDLc, iron, and 
diabetes status w/ eGFR in approximately 55,000 individuals in West Virginia and Ohio.
Methods: Data on adults aged ³20 years were obtained from the C8 Health Project. 
eGFR was estimated using the CKD-EPI formula. Linear regression analysis was used to 
test the relationship between HDLc, serum iron, and diabetes status, and their interactions, 
with eGFR.
Results: Mean age was 57.8 in those w/ diabetes and 45.1 in those w/out diabetes. In 
multivariable analyses controlling for age and sex, iron was positive related w/ eGFR in those 
w/ (p=0.03) and inversely in those w/out diabetes (<0.0001), while HDLc was positively 
associated w/ eGFR only in those w/out diabetes (p=0.97 in diabetes; p<0.001 in those w/o 
diabetes). As previously reported, an interaction existed between HDLc and iron in diabetes 
(p=0.04). Here we report that this relationship was even stronger in those w/out diabetes 
(interaction p=0.0008). A significant 3-way interaction existed between HDLc, serum iron, 
and diabetes status w/ eGFR (p=0.008). Controlling for hb, the interaction between iron 
and HDLc disappeared in those w/ diabetes but remained robust in those w/out diabetes.
Conclusions: The divergent relationship between iron and HDL on the eGFR by 
diabetes status needs further investigation.
PUB311
Molecular-Selective Plasma Exchange in Acute Kidney Injury due to 
Multiple Myeloma  Manabu Kanda, Satoru Sanada, Shinichi Mizuno, Shu 
Yamakage, Mitsuhiro Sato, Yoshio Taguma, Toshinobu Sato.  Nephrology, Japan 
Community Health Care Organization Sendai Hospital, Sendai, Miyagi, Japan.
Background: Benefit of plasma exchange in overall survival of patients with multiple 
myeloma (MM) remains to be determined, however, it is evident that lowering free light 
chain (FLC) reverses renal function in acute kidney injury (AKI) due to MM. High cut-off 
hemodialysis is recommended to remove FLC as an initial treatment for MM related AKI, 
which is different from traditional plasma exchange (PE) in preventing loss of large size 
molecules. As another option, we show the effect of molecular-selective plasma exchange 
to remove FLC, which enables target size removal without losing other size molecules.
Methods: A 49 year male with Bence-Jones type M protein was admitted with AKI; 
serum creatinine rose from 3.8 to 7.9mg/dL in 1 month. Past history included bone fracture 
and anemia. Serum FLC lambda was elevated to 29800 mg/dL. MM was confirmed by 
plasma cells in the bone marrow. The patient was treated with sequential molecular-selective 
plasma exchange (Evacure) and on-line HDF every other day combined with Bortezomib.
Results: PE was performed 6 times and removed 43.1% of FLC each on average 
without losing small and large size molecules.
On-line HDF removed 11.6% on average. Few, if any, rebounds were found in the 
FLC concentration between the treatments. Serum FLC level decreased to 411mg/dL 
after a series of treatments (day 14) and serum creatinine reversed to 2.7mg/dL at day 21.
Conclusions: A molecular-selective plasma separator is designed to limit the loss of 
high molecular weight substances. Using this machine, FLC can be removed effectively 
while preserving large size molecules. Moreover, the use of plasma substitute fluid can be 
reduced compared to that of conventional PE. We conclude that molecular-selective plasma 
exchange could be an effective treatment option for MM associated AKI.
PUB312
Preliminary Evaluation of a New CRRT Machine: KibouTM  Mauro Neri, 
Francesco Garzotto, Anna Lorenzin, Silvia Guggia, Alessandra Brendolan, 
Federico Nalesso, Monica Zanella, Claudio Ronco.  IRRIV and San Bortolo 
Hospital, Vicenza, Italy.
Background: KibouTM (Asahi Kasei Medical Co., Tokyo, Japan) is a new 
multifunctional automatic machine for Continuous Renal Replacement Therapy (CRRT) 
system (figure 1). 
Kibou can perform different CRRT therapies with the possibility to use only a single 
platform; in particular, modalities for both adults and pediatrics, counter-current and co-
current configuration, the use of heparin or citrate-calcium anticoagulation therapies and 
plasma exchange can be delivered(figure 1).
Methods: Based on the traditional experience of International Renal Research Institute 
of Vicenza (IRRIV), in vitro and α test evaluations of Kibou and related disposables have 
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been conducted. 12 treatments were performed. Machine’s usability and accuracy has been 
evaluated by the staff through scores table. The measurement of fluid balance accuracy 
was even performed.
Results: Based on score given by the staff (engineers, nurses and physicians), the 
machine hardware results compact and well organized, with 3 well separated compartments 
(dialysate/replacement, blood and effluent) that facilitate the preparation phase. Auto-
priming function allows short priming time. The interface is user friendly in all the modalities 
(SCUF, CVVH, CVVHD, CVVHDF, TPE both for adults and pediatrics). The measured 
fluid balance error was always lower than 0.3%. On the contrary CVVHDF pre-infusion 
and pre+post infusion are not performable. For pediatric treatment the continuity of the 
flow of blood pump need to be maintained and improved.
Conclusions: Kibou is a promising CRRT machine that can perform multiple 
continuous therapies with just one platform. In particular, we evaluated a highly accurate 
gravimetric fluid balance control system and a user friendly interface. Kibou is one of the 
first machines of the new frontier of CRRT devices: the fourth generation of CRRT machines.
PUB313
The Effect of MySleeve on Fluid Restriction Adherence in Hemodialysis 
Patients  Idowu B.I Ayoola,1 Marijke J.E. Dekker,2 Marc Schonck,2 Jeroen 
Kooman,3 Erik Korsten,1,2 Wei Chen,1 Constantijn Konings,2 Loe M. Feijs.1 
1Industrial Design, Technology Univ Eindhoven, Eindhoven, Netherlands; 
2Medicine, Div of Nephrology, Catharina Hospital Eindhoven, Eindhoven, 
Netherlands; 3Medicine, Div of Nephrology, Maastricht Univ Medical Center, 
Maastricht, Netherlands.
Background: In hemodialysis patients, non-adherence to fluid restriction is associated 
with high interdialytic weight gain (IDWG) and adverse outcomes. Monitoring drinking 
behaviour and direct feedback to the patient can lead to better adherence. We developed 
the MySleeve, a device that can be wrapped around a drinking glass to monitor fluid 
intake throughout the day. The MySleeve will also provide a subtle vibration on the glass 
when the amount drunk exceeds target. The information about drinking behaviour can be 
found in the accompanying application on a mobile phone. In this study, we investigate 
the effect of direct feedback and information to the patient on fluid restriction adherence, 
measured by the IDWG.
Methods: We will include 40 prevalent, anuric hemodialysis patients from the Catharina 
Hospital Eindhoven, The Netherlands in a randomised controlled trail. Patients in the 
intervention group are provided a MySleeve device, a mobile phone and an activity tracker. 
BCM measurements are performed weekly and IDWG will be calculated before every 
dialysis session. The patients in the control group will continue with regular hemodialysis.
Results: We expect that by providing patients insight in fluid intake, there will be an 
increase in fluid restriction adherence and an increase in activity levels and better quality 
of sleep. Due to less IDWG, patients will experience less discomfort of fluid overload.
Conclusions: Introducing a MySleeve device to provide direct insight into drinking 
behavior will help the patients to adhere to their fluid restriction, leading to less IDWG 
and better quality of life measured by daily activity and better sleep.
Funding: Private Foundation Support
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A Time and Motion Study of Erythropoiesis Stimulating Agent 
Administration in United States Dialysis Centers  Mark Stephens,1 Larry 
C. Emerson,2 Leslie A. Spry,2 John P. Caloyeras,3 Ernest R. Anderson,4 John 
Reitan,4 Akhtar Ashfaq.3  1Prima Health Analytics; 2Dialysis Center of Lincoln; 
3Amgen, Inc.; 4RJM Group.
Background: Previous research suggests that ESA administration in dialysis is a time-
consuming task and switching to less frequently dosed ESAs may offer opportunities for 
more efficient and effective patient care. This study estimated the time required for activities 
involved in the ESA process at US dialysis centers using epoetin alfa (EPO) or darbepoetin 
alfa (DPO), and examined potential time savings of switching from EPO to DPO.
Methods: Time and motion study conducted from 10/2014 to 1/2015 to assess 
activities involved and staff time required to prepare, administer and document ESA doses. 
A sample of 11 dialysis centers using either 3 times-per-week (TIW) EPO or once-weekly 
(QW) DPO were selected in pairs (one EPO, one DPO), where possible, from the same 
organization or nephrology practice to help control for anemia management protocols 
and staffing patterns. ESA-related tasks were timed by trained nurse observers. Time 
savings expected from switching from TIW EPO to QW DPO were estimated. Staff were 
interviewed about alternate patient-focused activities that could be accomplished if time 
were saved in the ESA process.
Results: 200 administrations were observed (81 DPO, 119 EPO). A mean of 2.3 (95% 
CI: 2.1-2.5) minutes per dose were required for ESA-related activities. RNs performed 95% 
of tasks; LPNs 5%. ESA process time did not vary significantly between EPO and DPO 
(>p=0.83). Staff time savings would accrue due to fewer ESA administrations using QW 
DPO: 10-20 minutes per nurse/day. For an average facility, the total monthly nurse time 
that could be re-purposed was 24 hours. Patient education, fulfillment of care plans and 
more frequent review of labs were identified as opportunities for improved care processes 
that could be implemented after conversion.
Conclusions: Switching from TIW EPO to QW DPO for anemia management in 
dialysis patients can result in time savings and opportunities to redirect nurse time towards 
activities aimed at improving patient care while still offering the ability to respond to 
changing clinical circumstances to effectively manage anemia.
Funding: Pharmaceutical Company Support - Amgen, Inc.
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Observational Study on the Use of Darbepoetin Alfa in Hemodialysis Patients 
in Central Eastern Europe – ANREG Final Analysis  Tomasz Jerzy Irzyniec,1 
Alena Parikova,2 Alexander Selyutin,3 Botond Csiky,4 Jaroslav Rosenberger,5 
Igor Rus,6 Kinga Jedynasty.7  1Dept of Nephrology/ENDO, MSW Hospital, 
Katowice, Poland; 2Dept of Nephrology, Inst for Clinical and Experimental 
Medicine, Prague, Czech Republic; 3B. Braun Atvium, Orenburg, Russian 
Federation; 4FMC Dialysis Center, Pécs, Hungary; 5Nephrology and Dialysis 
Center Fresenius, Kosice, Slovakia (Slovak Republic); 6Dept of Hemodialysis/
Nephrology, General Hospital Jesenice, Jesenice, Slovenia; 7CEE Headoffice, 
Amgen GmbH, Vienna, Austria.
Background: This study observed anemia treatment patterns in HD patients (pts) 
treated with darbepoetin alfa (DA) in clinical practice in CEE.
Methods: Multicenter observational study in HD pts treated with DA. From 2007 
to 2014, 14 cohorts were observed for 6 months (mo) each. Primary outcome: % pts 
maintaining an average Hb at >11 (cohorts 1/2 enrolled prior to label change in 02/2008) 
or 10-12 g/dL (cohorts 3-12) during mo 4-6. Secondary: conversion versus de novo pts, 
Hb trends, ESA and iron use, adverse drug reactions (ADR).
Results: Of 2923 enrolled pts (n=1101 de novo; n=1822 converted from other ESAs), 
2647 (91%) completed 6 mo of DA, 276 (9%) discontinued (155 [5%] due to death). At 
baseline (BL) 83% received iron. 
all de novo conversion
Median Hb at BL, g/dL 10.2 9.5 10.5
Median Hb at 6 mo, g/dL 11.2 11.3 11.2
% with Hb >11 or 1012 g/dL at 4-6 mo 61 61 61
% with Hb 11-12 g/dL at 4-6 mo 36 36 36
The median DA dose was 10.6 mcg/wk at mo 1 and mo 6. Approx 75% received DA 
i.v. and once weekly (84% at mo 1, 75% at mo 6). 12 ADR were reported (8 serious, 3 
fatal: intracranial hemorrhage; myocardial infarction, death).
Conclusions: Hb increased substantially in de novo and conversion pts after DA 
initiation; >60% reached target by mo 4-6 with some variation between countries.
Funding: Pharmaceutical Company Support - Amgen
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Dysutilization of Iron for Erythropoiesis Is a Significant Predictor for 
Adverse Events and Survival in Maintenance Hemodialysis Patients 
Takahiro Kuragano, Takeshi Nakanishi.  Dept of Internal Medicine Div of 
Kidney and Dialysis, Hyogo College of Medicine, Nisinomiya, Hyogo, Japan.
Background: Patient with high serum ferritin and low transferrin saturation (TSAT) 
levels could be considered as dysutilization of iron for erythropoiesis. Long-term safety 
iron administration to these patients has not been well studied.
Methods: Study design was the observational multicenter study for period of 3 years. 
In 805 patients with maintenance hemodialysis (MHD), we evaluated Hb, ferritin, TSAT 
levels in every 3 months, and high sensitive C reactive protein (hsCRP) and b2microglbulin 
(MG) levels every 6 months. We defined dysutilization of iron for erythropoiesis as the 
patients with lower TSAT (<20%) and higher ferritin (³100 ng/mL) levels. The association 
between dysutilization of iron for erythropoiesis and adverse event was investigated with 
the time dependent cox hazard model.
Results: Compared with low TSAT (≤ 20%) level, patient with normal TSAT (20-
30%) was significantly lower risk for cerebrovascular and cardiovascular disease (CCVD) 
(HR:0.25, P=0.04), and patients with higher TSAT (³30%) were significantly lower risk for 
death (HR:0.12, P=0.01). In multivariate logistic regression analysis, male, younger patients, 
without diabetes, low hsCRP, and low b2MG were selected as significant predictors of high 
TSAT, but iron administration or ferritin were not. Compared with low ferritin (<100 ng/
mL) and high TSAT (³20%), patients with high ferritin (³100ng/mL) and low TSAT (<20%) 
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(HR: 4.5, p<0.001), and with high ferritin and high TSAT (HR: 2.9, p<0.001, respectively) 
had a significantly higher risk of CCVD. Moreover, patients with high ferritin and low 
TSAT had a significantly higher risk of death (HR:5.8, p<0.001) compared with those with 
low ferritin and high TSAT.
Conclusions: Although patients with low TSAT had a significantly higher risk of 
CCVD or death, higher TSAT was not associated with iron administration or iron storages. 
Patients with high ferritin and low TSAT who were suspected as dysutilization of iron for 
erythropoiesis had a higher risk of CCVD and death. From these results, the administration 
of iron should be cautious to the patients with dysutilization of iron for erythropoiesis.
PUB317
Inflammatory and Metabolic Syndrome Biomarkers Analysis of Vascular 
Outcomes in End-Stage Renal Disease  Vinod K. Bansal,1 Patrick Sweigert,2 
Debra Hoppensteadt,2 Jennifer Saluk,2 Daneyal Syed,2 Jawed Fareed.2 
1Nephrology, Loyola Univ Medical Center, Maywood, IL; 2Pathology, Loyola 
Univ Medical Center, Maywood, IL.
Background: The relevance of some biomarkers of inflammation and metabolic 
syndrome to vascular outcomes in end stage renal disease (ESRD) is not clear. To study 
these relationships, biochip array technology method was used to profile the complex 
plasma biomarkers in the setting of various comorbid outcomes such as Stroke or Transient 
Ischemic Attack (TIA), Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF), 
and Coronary Artery Disease (CAD).
Methods: Plasma samples were collected from 83 ESRD patients (mean age 65) 
prior to hemodialysis and were profiled using biochips for metabolic and inflammatory 
biomarker levels. Inflammatory cytokine and Metabolic Syndrome arrays were used to 
profile C peptide, ferritin, insulin, leptin, resistin, TNFa, PAI-1, IL1a, IL1b, IL2, IL4, IL6, 
IL8, IL10, VEGF, EGF, IFNG, and MCP1. Retrospective review was performed to group 
patients based on history of Stroke or TIA, ACS, CHF, and CAD.
Results: Of the 83 ESRD patients, 25 (30.1%) were found to have history of Stroke/
TIA, 14 (16.9%) were found to have history of ACS, 30 (36.1%) were found to have history 
of CHF, and 39 (47.0%) were found to have history of CAD. Stroke/TIA patients were 
found to have decreased plasma IFNG levels (p=0.042) and elevated plasma resistin, IL1a, 
and leptin levels (p=0.008, 0.021, 0.026; respectively) when compared to patients without 
Stroke/TIA. ACS patients had elevated plasma IL6 levels (p=0.040) when compared to 
those without ACS. CHF patients had decreased plasma leptin levels (p=0.031) and elevated 
plasma IL1b levels (p=0.042) when compared to patients without CHF. CAD patients had 
elevated plasma IL1a levels (p=0.049) when compared to ESRD patients without CAD.
Conclusions: Profiling of multiple inflammatory and metabolic syndrome biomarkers 
may aid in the risk stratification of ESRD patients for cerebrovascular and cardiovascular 
disorders. These studies demonstrate that biomarker profiling of vascular comorbidities 
in ESRD may provide useful diagnostic and prognostic information in the management 
of ESRD patients.
PUB318
Individualized Anemia Management in Pediatric Nephrology Patients 
Adam E. Gaweda,1 Jason Misurac,2 Michael E. Brier,1 Jeffrey D. Leiser.2 
1Medicine, Univ of Louisville, Louisville, KY; 2Nephrology, Riley Hospital for 
Children at Indiana Univ, Indianapolis, IN.
Background: Anemia management in pediatric patients on dialysis poses a great 
challenge to the nephrologist. In this study, we tested the hypothesis that individualized 
approach anemia management, previously demonstrated successfully in adult patients, 
improves hemoglobin maintenance within target range in pediatric dialysis patients.
Methods: We performed prospective evaluation of Clinical Decision Support 
System “Smart Anemia Manager” (SAM) in pediatric dialysis patients at Riley Hospital 
for Children at Indiana University. SAM was implemented as a stand-alone software 
on a desktop computer used by the nurse anemia manager and connected to a database 
containing Hemoglobin (Hgb) and ESA dose data. The anemia manager was allowed to 
override dose recommendations from the system and each override was documented. The 
followup period was 10 months, including 4 month washout period. We compared the 
hemoglobin distribution within 9-12 g/dL range during 6 months immediately before SAM 
implementation and 6 months after the washout period. Only patients who received ESA 
and had at least 4 Hgb values within each period were included in the analysis.
Results: 13 patients satisfied the inclusion/exclusion criteria. The percentage of monthly 
Hgb within target range varied between 82% and 92% in 6 months prior to deployment 
of SAM and between 69% and 100% during 6 months after SAM deployment. Quarterly 
Hgb distribution varied between 86% to 87% prior to SAM deployment and 87% to 95% 
after. There was a significant decrease in low Hgb numbers after SAM deployment, but no 
change in high Hgb levels, compared to the period before SAM deployment. 
Quarter Month < 9 g/dL 9 - 12 g/dL > 12 g/dL N
Pre-SAM
Q1 Nov-13 18% 82% 0% 11
86% Dec-13 9% 91% 0% 11
Jan-14 15% 85% 0% 13
Q2 Feb-14 0% 92% 8% 13
87% Mar-14 8% 85% 8% 13
Apr-14 15% 85% 0% 13
SAM
Q3 Sep-14 8% 92% 0% 13
95% Oct-14 0% 100% 0% 13
Nov-14 8% 92% 0% 13
Q4 Dec-14 0% 100% 0% 13
87% Jan-15 8% 92% 0% 13
Feb-15 23% 69% 8% 13
Conclusions: Individualized anemia management in pediatric patients improves 
distribution of Hgb within the target range, compared to a standard population-based 
protocol approach.
Funding: NIDDK Support
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Extracorporeal Ultrafiltration Therapy for Acute Decompensated Heart 
Failure  Negiin Pourafshar, Ashkan Karimi, Amir Kazory.  Medicine, Univ of 
Florida, Gainesville, FL.
Background: There has been a renewed interest in the use of ultrafiltration (UF) for 
management of patients with acute decompensated heart failure (ADHF). While a number 
of studies reported on the efficacy of this therapy and lack of any significant adverse impact, 
the more recent trials have challenged its safety. The aim of this study is to provide a 
reappraisal of the current evidence on the use of UF in ADHF.
Methods: Articles cited in PubMed database from 2000 to 2015 using key 
words”ultrafiltration” and “heart failure” were searched. Those randomized and non-
randomized trials using recent portable devices dedicated for UF were selected. Case 
reports, and case series were excluded. Relevant data such as renal function, cardiac status, 
and weight change were extracted and compared.
Results: A total 940 patients from 15 trials (7 randomized and 8 non-randomized) 
that used dedicated UF devices were included. Eleven studies reported either no change 
or non-significant decrease in serum creatinine, while 4 found worsening renal function 
after UF therapy; these studies had included patients with more severe renal dysfunction 
at baseline. Concerning weight, a reduction of 2 to 9 Kg was reported that was similar to 
conventional therapies in 9 studies but was significantly lower with UF in 6 trials. Length 
of stay was evaluated in 5 studies, 2 of which showed a significant reduction. Three studies 
showed fewer re-hospitalizations in the UF group at 30 days, 90 days, and 1 year follow 
ups. None of the studies evaluated long-term outcomes of patients undergoing UF therapy.
Conclusions: Based on the currently available data, UF is efficient for management 
of volume overload in ADHF. However, these studies do not support any beneficial impact 
for this therapy on renal function, and suggest that it might be associated with suboptimal 
renal outcomes if used for patients with more severe renal dysfunction at baseline. Currently 
there is no data on the effect of UF on long-term outcomes of patients with ADHF. Whether 
this would translate into a lack of effect for UF on these outcomes needs to be elucidated 
by future studies.
PUB320
Ultra-Sensitive Troponin I Predictive Value in Remote Ischemic Pre 
Conditioning in Hemodialysis: A Randomized Double Blinded Clinical Trial 
Marcelo Rodrigues Bacci, Livia Yadoya Vasconcelos, Felipe R. Bruniera, Felipe 
Moreira Ferreira, Neif Murad, Antonio Carlos palandri Chagas, Fernando Luiz 
affonso Fonseca.  ABC Medical School, Brazil.
Background: Remote ischemic cardiac preconditioning(RIPC)is a procedure that 
generates a brief period of ischemia followed by reperfusion.Areas submitted to RIPC in 
the experimental ischemia models have less occurrence of necrosis.RIPC role in protecting 
myocardial ischemia during hemodialysis is not stablished yet.The aim of the study was 
to evaluate RIPC as myocardial protection evaluated by ultra sensitive I troponin in 
hemodialysis outpatients.
Methods: It is a double blind randomised trial with two groups:intervention;submitted 
to RIPC with external compression in the right arm with sphygmomanometer with 
200mm/Hg of pressure with three-5 minute rounds alternating with deflation totalling 
30 minutes and control group;without RIPC.Intervention group received RIPC in three 
consecutive hemodialysis sessions.Blood samples were taken before and after each session.
Randomization was made by a software stratified by sex and age.BUN for calculation of 
single pool Kt/v and ultra sensitive I troponin were measured to evaluate dialysis adequacy 
and myocardial injury.
Results: A total of 47 patients were randomized.About 60.8% were men and 54% 
diabetic.The mean single pool Kt/v was 1.51 in the intervention group and 1.49 in control.
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There was a trend to higher mortality in the control group(26%,p=0.09).The ultra sensitive 
troponin I measured no significant change from the time of collection:before or after 
dialysis,however it showed a high negative predictive value in all models tested.
Conclusions: The RIPC applied in 3 consecutive sessions did not demonstrate 
superiority to control therefore another study tested RIPC in 12 consecutive sessions with 
a positive result in myocardial protection with RIPC.In our study more than half of the 
patients were diabetic.Diabetic patients have a trend to show a lower response to RIPC 
because of the greater presence of collateral coronary circulation.In summary,in this model 
there was no interference of RIPC in ultra sensitive troponin I values but troponin had a 
high negative predictive value for myocardial infarction in all tested models.
Funding: Government Support - Non-U.S.
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Racial Differences in the Evolution of Subclinical Cardiovascular Disease 
from CKD to ESRD: The CRIC Study  Nisha Bansal,1 Jason Roy,2 Hsiang-Yu 
Chen,2 Alan S. Go,3 Martin Keane,4 Rajat Deo,2 Elyse Foster,5 Sankar D. 
Navaneethan,6 Jiang He,7 Mahboob Rahman,8 Mirela A. Dobre,8 John W. Kusek,9 
Michael J. Fischer,10 Emile Mohler,2 Chi-yuan Hsu.5  1UW; 2UPenn; 3KPNC; 
4Temple; 5UCSF; 6Case Western; 7Tulane; 8UH; 9NIDDK; 10UIC.
Background: Studies have reported that black incident dialysis patients have better 
survival compared with white dialysis patients, even after accounting for adverse profile of 
comorbidities among blacks. We hypothesized that differences in subclinical cardiovascular 
disease (CVD) may explain this paradox.
Methods: We studied incident dialysis patients in the CRIC study who had a research 
echocardiogram performed before and after the initiation of dialysis. Left ventricular mass 
index (LVMI) and ejection fraction (LVEF) were measured at CKD (mean eGFR 24 ml/
min/1.73 m2) and at dialysis initiation (median time after initiation 7.9 months).
Results: Of 316 participants, 74% were black and 26% were white. After initiation 
of dialysis, there were 88 deaths. In multivariable models, black (vs. white) race was 
independently associated with a 38% (95% CI: 1%, 61%) lower risk of mortality. From 
CKD to incident dialysis, mean LVEF worsened in whites (51±10% to 47±11%; p-value 
for change <0.0001) and blacks (52±9% to 48±10%; p <0.0001). LVMI trended worse in 
whites (54±16 g/m2.7 to 57 ±15 g/m2.7; p=0.1) and significantly improved in blacks (61±16 
g/m2.7 to 58±13 g/m2.7; p=0.004). Adjusting for LVMI, change in LVMI, LVEF and change 
in LVEF did not change the association between black race and lower risk of death. 
Conclusions: In CRIC, black dialysis patients had better survival than whites. This 
association was not explained by differences in subclinical CVD at incident dialysis or by 
differences in the evolution of CVD from CKD to ESRD. Further studies are needed to 
understand mechanisms underlying the differential survival by race among dialysis patients.
Funding: NIDDK Support
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Study Design and Baseline Characteristics in the “Outcome Study of 
Lanthanum Carbonate (LC) Compared with Calcium Carbonate (CC) 
in Hemodialysis (HD) Patients (LANDMARK) Study”  Hiroaki Ogata,1 
Masafumi Fukagawa,2 Hideki N. Hirakata,3 Tatsuo Kagimura,4 Tadao Akizawa.1 
1Div of Nephrology, Dept of Medicine, Showa Univ School of Medicine, Tokyo, 
Japan; 2Div of Nephrology, Endocrinology, and Metabolism, Tokai Univ School 
of Medicine, Isehara, Japan; 3Div of Nephrology and Dialysis Center, Japanese 
Red Cross Fukuoka Hospital, Fukuoka, Japan; 4Translational Research 
Informatics Center, Kobe, Japan.
Background: The LANDMARK study is planned to elucidate whether a non-calcium 
(Ca)-based phosphate (P) binder, LC treatment reduces cardiovascular (CV) mortality and 
morbidity compared with a Ca-based P binder, CC treatment in HD patients.
Methods: This is a multicenter, randomized, open-label, parallel comparative study 
between LC and CC (NCT01578200/UMIN000006815). Adult HD patients who had at 
least one of following criteria; age>65 yrs, postmenopausal women, or type 2 diabetes 
mellitus) with intact parathyroid hormone (iPTH) £240pg/mL and life expectancy ³1 years, 
were eligible. In LC group, patients initially received LC of 750mg/day or previous used 
dose and were titrated up to a maximum of 2250mg/day to achieve serum P levels of 3.5-
6.0mg/dL. In CC group, patients received CC of 3g/day or previously used dose, and were 
titrated to achieve same P range as LC group. If serum P level was not achieved within 
the target with maximum tolerated dose, non-Ca-based P binders (other than LC) could 
be also added in CC group. The primary endpoint is the CV events (CV death, non-fetal 
myocardial infarction and stroke, unstable angina, hospitalization for heart failure and 
ventricular arrhythmia) free survival time.
Results: 2309 patients were allocated to LC (N=1154) or CC group (N=1155). At 
baseline, mean age was 68.7 yrs, 40.6% were female and 51.7% were diabetes. 13.4% 
had a history of ischemic heart disease, and 13.3% had cerebrovascular disease. 8.0% had 
undergone coronary intervention procedure. Mean serum Ca, P and iPTH concentrations 
were 8.9mg/dL, 5.4mg/dL, and 122.4pg/mL, respectively. Baseline characteristics were 
well balanced between the two groups.
Conclusions: The LANDMARK study will determine whether a non-Ca-based P 
binder, LC, reduce CV mortality and morbidity in HD patients.
Funding: Pharmaceutical Company Support - Bayer Yakuhin, Ltd
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The Relationship Between Prescription of Ultrafiltration in Hemodialysis 
and Intradialytic Hypotension: A Retrospective Study of Chinese 
Hemodialysis Patients  Fei Deng, Daqing Hong, Guisen Li, Li Wang. 
Nephrology, Sichuan Academy of Medical Sciences & Sichuan Provincial 
People’s Hospital, Chengdu, Sichuan, China.
Background: Our study aims to explore the relationship between prescribed 
ultrafiltration and intradialytic hypotension (IDH)and, to demonstrate risk factors of 
intradialytic hypotension in order to reduce the incidence of relevant complications and 
improve patient prognosis.
Methods: 312 patients maintenance hemodialysis patients in our dialysis center were 
enrolled with 33224 HD/HDF treatment sessions recorded. Hypotension was defined as 
a decrease of systolic blood pressure >20mmHg or mean arterial pressure declination³10 
mmHg whether presence of hypotensive symptoms or not. ROC curve was applied to study 
the cut-off point of UF/Wt (ultrafiltration/weight) ratio for the presence of hypotension. 
Pearson analysis and logistic regression was used to study the risk factor associated with 
hypotension.
Results: The prevalence of intradialysis hypotension was 38.7%. Decrease of SBP and 
MAP positively correlated with UF/Wt and age, and negatively correlated with blood flow. 
The cut-off point of UF/Wt was 4% for all patients, diabetes and non-diabetic patients with 
AUCs of 0.575, 0.570, and 0.622 respectively. The AUC for diabetic patients was higher 
than that of non-diabetic patients (P<0.001). Multivariate logistic regression showed that 
age (OR=1.005, 95%CI: 1.004-1.007), diabetes (OR=1.209, 95%CI: 1.122-1.303), and UF/
Wt>4%(OR=1.605, 95%CI:1.532-1.682) was associated with hypotension.
Conclusions: Asymptomatic intradialytic hypotension is prevalent. Increased 
intradialytic SBP/MAP variability is associated with greater UF and UF/Wt, but is not 
associated with greater blood flow. To Chinese hemodialysis patients, UF/Wt>4% is 
sensitive and specific in predicting intradialysis hypotension, especially in patients with 
diabetes mellitus. UF/Wt>4%, diabetes mellitus and age are independent risk factors for 
asymptomatic intradialytic hypotension.
PUB324
Whole Blood Viscosity at Low Shear Rate Is Associated with Cardiovascular 
Mortality in Patients with Hemodialysis  Jong-Hwan Jung,1 Dong Hwan Lee,2 
Young I. Cho,3 Kyung Pyo Kang,1 Sik Lee,1 Sung Kwang Park,1 Won Kim.1 
1Internal Medicine, Chonbuk National Univ Medical School, Jeonju, Republic 
of Korea; 2Dept of Mechanical Design Engineering, Engineering College, 
Chonbuk National Univ, Jeonju, Republic of Korea; 3Dept of Mechanical Eng. 
and Mechanics, Drexel Univ, Philadelphia, PA.
Background: The change of whole blood viscosity (WBV) may increase risk of 
major atherosclerotic events, including congestive heart failure, myocardial infarction, and 
stroke. However, there is few report about the relationship between WBV and mortality 
rate due to atherosclerotic vascular disease. The objective of the present study was to 
investigate correlation between values of WBV at shear rates of 1, and 5 S-1 before and 
after hemodialysis in patients with end-stage renal disease (ESRD) and mortality; especially 
cardiovascular or cerebrovascular mortality.
Methods: Forty three patients with ESRD receiving maintenance hemodialysis had 
initially participated in this study. In a prospective observational study, we examined the 
effect of WBV in pre- or post-dialysis on cardiovascular or cerebrovascular mortality in 
dialysis patients for approximately 5.8 years.
Results: Twenty seven patients among total 43 patients died and 2 patients had received 
transplantation of kidney within period of this study.Cardiovascular deaths occured in 8 
patients among 27 patients, and cerebrovascular deaths occurred in 5 patients among the 
27 patients.The hazard ratios for overall survival in the patient with hemodialysis according 
to increase of predialytic diastolic WBV at low shear rate of 1 S-1 in an univariate Cox 
proportional analysis were 1.585 (95% CI, P=0.382) in the group of moderate blood 
viscosity and 2.351 (95% CI, P=0.128) in the group of high blood viscosity. However, 
pre-DBV1 was not still statistically significant after adjustment for covariates. In addition, 
the HRs for overall survival according to increase of pre-DBV5 were 1.527 and 1.930 
in each moderate and high blood viscosity group. In Kaplan-Meier’s survival analysis, 
when pre-DBV1 increased, cumulative mortality relatively showed rising tendency, but, 
unfortunately there was no statistical significance.
Conclusions: These results suggest that the diastolic low-shear WBV may impact on 
cardiovascular or cerebrovascular mortality in hemodialysis patients. New prospective and 
large-scaled studies to more exactly evaluate the correlation between WBV and mortality 
will be needed in the future.
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Survival of Patients Over 75 Years Old in a Chronic Hemodialysis Program 
Adriano Luiz Ammirati, Maria C.C. Andreoli, Fabiana Dias Carneiro, Thais 
Nemoto Matsui, Nadia Guimaraes- Souza, Bento C. Santos.  Dialysis, Albert 
Einstein Hospital, São Paulo, Brazil.
Background: The intensity of medical care for people over 75 years of age has 
increased over the past decade. In this surrounding context is increasing the number of 
individuals with this profile that has clinical indication starting renal replacement therapy. 
Published data have shown a varied patient survival after initiation of hemodialysis (HD) 
according to the presence of comorbidities.The aim of this study was to evaluate the survival 
of elderly patients with chronic kidney disease on regular HD.
Methods: From analysis of medical records was assessed the rate of survival of incident 
patients in a chronic HD program from 2000 to 2010. Demographic and clinical data were 
also collected. It was made a comparison, based on these data, among the elderly (over 75 
years old) and non-elderly groups who died.
Results: During the study period, 158 patients started HD program, 69% male and 
46% were older than 75 years. The overall mortality rates at 6 and 12 months were, 
respectively, 7.5% and 17%. Considering only the elderly, mortality rates at 6 and 12 
months were respectively 14 and 27%. The median survival of these patients was 33 months. 
Considering only patients younger than 75 years mortality rates at 6 and 12 months were, 
respectively, 2% and 8%. Comparing elderly patients with non-elderly, we observed that 
the first group had a higher proportion of diabetic and hypertensive patients and with a 
history of cardiovascular disease and cancer. Considering only the patients who died, there 
were no important significant differences in the presence and score of comorbidities, when 
the elderly was compared with the non-elderly.
Conclusions: Patients over 75 years in HD had a mortality rate two times higher than 
younger patients and the presence of comorbidities may be a contributing factor to the 
age to explain this data.
PUB326
The Difference of Cognitive Function and Brain Magnetic Resonance 
Findings Between Chronic Hemodialysis and Peritoneal Dialysis Patients 
Ke Zheng, Haiyun Wang, Xuemei Li.  Nephrology Dept, Peking Union Medical 
College Hospital, Beijing, China.
Background: Cognition decline and cerebrovascular lesions has been gradually 
realized by clinicians nowadays. But It is still not clear whether there are some difference 
in cognitive function and cerebrovascular disease between chronic hemodialysis (HD) and 
peritoneal dialysis (PD) patients.
Methods: This is a cross-sectional study in a single center. 124 HD patients and 
74 PD patients were recruited. Cognitive function was evaluated with Chinese-MMSE 
and Chinese-MoCA .MR images and MR Angiography were assessed.Demographic 
informations, Clinical features, laboratory data were collected. Results were analyzed 
with SPSS.
Results: (1) Age, gender and educational level were comparative between HD and 
PD patient. Average age was 56.2±13.2 yrs and 56.6±16.1 yrs, respectively in HD and 
PD groups.(2)Average dialysis voltage was longer in HD than PD group, 70.0±60.6 
months v.s. 40.7±35.7 months. Average blood pressure was 136.7/79.6±19.5/11.3 
v.s.138.4/76.7±21.4/11.8mmHg, Hgb was 110.9±13.7 v.s. 114.0±13.6 g/L, SCr 961.1±251.2 
v.s. 857.0±276.6 umol/L, Alb39.6±3.9 v.s. 35.4±3.8 g/L,respectively in HD and PD groups. 
SCr and Alb level was higher in HD group(P<0.05). (4) In cognitive function evaluation, HD 
compared with PD groups, MMSE score was 28.0±2.5 v.s.29.6±3.1(p=0.84), MoCA score 
was 22.7±4.4 v.s 21.1±5.7(p=0.108), respectively. (5) For the brain MR results, in severity 
of brain artery stenosis, number of cortical infarcts, lacunar infarcts,microbleeds,chronic 
hematoma and Fazeka score of brain white matter lesions, only artery stenosis is more severe 
in PD groups (P<0.05). For the two kinds of bleeding lesions, there was a more severe 
tendency in HD group, but there was a more severe tendency of two kinds of ischemic 
lesions in PD group. (5) MoCA Score was relative to SCr,and Alb, negative relative with 
age,artery stenosis,lacunar infarcts and WMLs.
Conclusions: Compared with HD patients, there was a tendency of more 
severecognitive function  decline in PD patients. Also we found a tendency of more brain 
bleeds lesions in HD patients, on the contrary, a tendency of more ischemic lesion in PD 
patients. But we need a larger sample size to prove those.
Funding: Government Support - Non-U.S.
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Paucity of Evidence for Use of Postmenopausal Hormone Therapy for 
Cardiovascular Prevention in Women with Chronic Kidney Disease: 
A Systematic Review  Sharanya Ramesh,1 Michelle C. Mann,1 Matthew T. 
James,1,2 Stephen B. Wilton,2,3 Jayna M. Holroyd-Leduc,2 Sofia B. Ahmed.1,2,3 
1Medicine, Cumming School of Medicine; 2Community Health Sciences, Univ 
of Calgary; 3Libin Cardiovascular Inst of Alberta.
Background: Women with chronic kidney disease (CKD) have low sex hormone levels 
due to kidney-mediated endocrine disturbances, and are at increased risk of cardiovascular 
adverse events. Whether postmenopausal hormone therapy (PHT) alters cardiovascular 
risk in this population is unknown. We aimed to summarize current knowledge about the 
association between use of PHT and (1) cardiovascular outcomes, and (2) established 
cardiovascular risk factors, in women with CKD.
Methods: Setting and population: Adult women with CKD (eGFR≤90 mL/
min/1.73m2) Selection Criteria for Studies: Randomized control trials and observational 
studies, studying PHT with either placebo or untreated control groups. Outcome measures: 
All-cause and cardiovascular mortality, non-fatal cardiovascular event (myocardial 
infarction, stroke), and surrogate measures of cardiovascular risk (blood pressure, serum 
lipids). 
We searched electronic bibliographic databases (MEDLINE, EMBASE, Cochrane 
Central Register of Controlled Trials) (inception to 2014 September), relevant conference 
proceedings, tables of contents of journals and review articles.
Results: Of 2928 references retrieved, 4 RCTs (N=142 patients) were identified. No 
studies reported on cardiovascular outcomes or mortality. Three studies examined the 
effect of PHT on lipid profile (mean age 60 years, all patients end-stage kidney disease on 
dialysis). Compared with placebo, PHT led to increased high density lipoprotein cholesterol 
(weighted mean difference (WMD) 0.82 mmol/L 95% CI: 0.47, 1.17), but no difference 
in low density lipoprotein (WMD -0.39 mmol/L 95% CI: -0.85, 0.07) or total cholesterol 
levels (WMD 0.11 mmol/L 95% CI: -0.23, 0.45. One study examined the effect of PHT 
on blood pressure, with PHT causing no change in blood pressure.
Conclusions: Studies examining the effect of PHT on cardiovascular outcomes in 
women with CKD are lacking. Further prospective study of the role of PHT in improving 
cardiovascular outcomes in this high-risk group is required.
Funding: Private Foundation Support
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Prevalence of Abnormal Ankle – Brachial Index in Haemodialysis Patients 
in Mexico and Its Association with Other Cardiovascular Risk Factors 
Laura E. Izguerra Ochoa, Heriberto Reyes López.  Nefrología, Regional General 
Hospital #46, Guadalajara, Jalisco, Mexico.
Background: Abnormal Anckle-Brachial index (ABI), defined as  ≤ 0.9  or ³1.3, is 
considered an independent predictor of mortality in hemodialysis patients, in other countries 
abnormal ABI is found between 35% and 80 % of hemodialysis patients. In Mexico the 
prevalence of abnormal ABI has not been reported. The aim of the study was to determine 
the frequency of abnormal ABI and its association with other cardiovascular risk factors.
Methods: Prevalent hemodialysis patients over 16 years old were included; data were 
obtained from medical records and interviews. ABI was measured by oscillometry (Model 
HEM-705CPINT) and classified as a normal result between 0.91 - 1.3 (NABI), ≤ 0.9 (LABI) 
or ³1.3 (HABI). NAVI was considered as the control group and the data were analyzed 
using descriptive and inferential statistics, using T Student and Chi2.
Results: Of the 119 patients analyzed abnormal ABI was present in 36 (30%); 10 (8.4%) 
with LABI and 26 (21.9%) with HABI. The mean age was 44.9 years, 68% were male, 
duration of dialysis of 7.1 years. In univariate analysis LABI was significantly associated 
with older age (p=0.03), smoking history (p <0.001), diabetes mellitus (DM) (p=0.04), lower 
creatinine (p <0.001) and albumin (p <0.001) and higher calcium (p <0.001); HABI was 
significantly associated with lower age (p=0.01), smoking  history (p=0.05), lower systolic 
blood pressure (SBP) (p=0.02), high levels of sodium (p=0.04) and calcium (p=0.001).  No 
association was found between abnormal ABI and history of hypertension, dyslipidemia, 
heart disease, stroke; there were no differences with the dose of calcium carbonate or 
calcitriol, the value of Kt / V, the type of vascular access and serum phosphorus.
Conclusions: Abnormal ABI was less prevalent than in other populations, among these 
HABI is the most common.  LABI was associated with older age, DM, smoking history, 
high calcium and low creatinine and albumin (probably associated with poor nutritional 
status). HABI patients were younger, with smoking history, lower SBP, high serum sodium 
and calcium levels.
PUB329
A Lower Serum Uric Acid Is Associated Not Only with All-Cause Mortality 
but Also Cardiovascular Mortality Among Patients Receiving Hemodialysis 
in Japan  Naoki Sugano,1 Yukio Maruyama,1 Keitaro Yokoyama,1 Koki Takane,1 
Yasuhito Takahashi,1 Chisa Kobayashi,1 Shinichiro Nishio,1 Daisuke Takahashi,1 
Satoshi Kidoguchi,1 Kosuke Honda,1 Norihiko Morisawa,1 Gorou Tokudome,1 
Iwao Ohno,1 Tatsuo Hosoya,1 Takashi Yokoo,1 Takashi Shigematsu,2 Kunitoshi 
Iseki,2 Ikuto Masakane.2  1Div of Nephrology and Hypertension, Dept of Internal 
Medicine, The Jikei Univ School of Medicine, Tokyo, Japan; 2Committee of 
Renal Data Registry, Japanese Society for Dialysis Therapy, Tokyo, Japan.
Background: High level of serum uric acid is prevalent in chronic kidney disease 
(CKD), however it has a controversy whether high or low serum uric acid level appears 
to be a risk factor of cardiovascular event and mortality in the patients of receiving renal 
replacement therapy.
Methods: We collected the baseline data of 222,434 patients receiving HD thrice weekly 
(males: 63.0%, 66 ±12 years, median HD vintage of 60 months, females: 68 ±13 years, 
median HD vintage of 72months) extracted from a nationwide dialysis registry at the end 
of 2011 in Japan. Then we evaluated the patient survival and development of complication 
using the registry at the end of 2012.
Results: During one-year follow-up, 18775 (8.4%) died of all causes including 8094 
(3.6%) cardiovascular death. All-cause mortality, and cardiovascular mortality were lower 
in line with the increase of baseline uric acid. In a multivariable logistic regression analysis, 
patients of the highest quartile of uric acid had lower all-cause, and cardiovascular mortality 
compared with those of the lowest quartile (males: OR, 0.745; 95% CI, 0.6753 to 0.8207, 
females: OR, 0.8333; 95% CI, 0.7206 to 0.9636, and males: OR, 0.7202; 95% CI, 0.6266 
to 0.8278, females: OR, 0.8575; 95% CI, 0.7029 to 1.0462, respectively).
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Conclusions: In this large observational cohort study, lower levels of serum uric acid 
were independently associated not only with all-cause mortality but also cardiovascular 
mortality among Japanese HD patients. Close monitoring of serum uric acid is thought to 
be necessary for the management of HD patients.
PUB330
Post Stroke Disability Deterioration and Mortality of Hospital Onset Stroke 
in Patients with and without End-Stage Renal Disease  Tomoko Usui,1 Norio 
Hanafusa,1 Hideo Yasunaga,2 Masaomi Nangaku.1  1Dept of Hemodialysis and 
Apheresis, The Univ of Tokyo Hospital, Japan; 2Dept of Clinical Epidemiology 
and Health Economics, School of Public Health, the Univ of Tokyo, Japan.
Background: Increasing evidence suggests that end-stage renal disease is associated 
with higher risk and severity of cerebrovascular disease. However, the risk factors for 
post stroke disability and mortality is not clear. We examined the association between risk 
factors including dialysis treatment and disability deterioration and mortality during the 
hospital stay of hospital onset stroke.
Methods: The Japanese Diagnosis Procedure Combination database includes 
administrative claims and discharge abstract data of about 50% of all acute-care inpatients 
in Japan. Using this database, we extracted data of inpatients age ³20 years old, hospital-
onset stroke between July 2010 and March 2013. Disability level was divided into modified 
Rankin Scale (mRS) 0-1, 2-3, 4-5, and 6 (death). Deterioration of disability was defined as 
an increase in disability level. The odds ratio (OR) for in-hospital deterioration of disability 
and mortality was calculated using a logistic regression model.
Results: Out of 26,834 patients, 593 (2.2%) had dialysis therapy. The median length 
of stay was 39 and 33 days for patients with and without dialysis, respectively. During the 
hospital stay, there were 7,655 (28.5%) disability deterioration and 3,851 (14.4%) death. The 
patients with dialysis had higher disability deterioration (47.0%) and mortality rate (31.3%) 
compared to those without. After adjustment with age, gender, BMI, mRS, Activities of Daily 
Living, smoking habits, hypertension, diabetes, dyslipidemia, atrial fibrillation, coronary 
heart disease, heart failure, peripheral arterial disease, cerebrovascular complications, 
antiplatelet, anticoagulant, and thrombolytic medications, multivariate-adjusted ORs of 
dialysis for disability deterioration was 2.88 (95%CI 2.40-3.45), and in-hospital mortality 
was 3.57 (95%CI 2.94-4.33).
Conclusions: Dialysis treatment was an independent risk factor for in-hospital disability 
deterioration and mortality of hospital onset stroke.
PUB331
Role of Bioimpedance as Tool for Fluid Management in Hemodialysis 
Patients  Maria Cecilia Recalde,1 Manuela Bello,1 Cecilia Arruabarrena,1 Alvaro 
Herou,1 Fabian Cano,2 Laura Sola.1,2  1Hemodialysis Unit, CASMU, Uruguay; 
2Preventive Medicine, Univ of the Republic, Uruguay.
Background: Fluid management in hemodialysis patients is difficult, hypertension and 
fluid overload is frequent as well as hypotensive episodes leading to cerebral and cardiac 
injury and increased mortality risk. The objective of the study is to evaluate if bioimpedance 
could be a tool to optimize fluid management in hemodialysis patients.
Methods: Patients were included after giving informed consent when fulfilled inclusion 
and exclusion criteria. Were recorded age, gender, diabetes status, dialysis vintage, body 
mass index (BMI) estimated dry weight, and mean in previous month: systolic blood 
pressure (SBP), diastolic blood pressure (DBP), interdialytic weight gain, ultrafiltration 
volume (UF VOL), hypotensive episodes and use of antihypertensive drugs. A multi-
frequency bioimpedance device (BCM Fresenius Medical Care) was used to evaluate fluid 
overload. Patients were categorized according post dialysis fluid overload and analyzed 
regarding SBP, DBP, hypotensive episodes and drugs. Data were analyzed in free software 
(epi info 7). Quantitative data were expressed as mean ± standard deviation and compared 
by t test, and categorical variables were compare by chi square. Were considered significant 
differences when p < 0.05.
Results: Fifty patients were included, 32 (64%) men, age 66.1± 13.1 years, 14 (28%) 
diabetics, and BMI 30.9 ± 9.5. Mean SBP 128 ± 13, DPB 72 ±8.0, interdialytic weight 
gain 2.1 ± 0.1 kg, and UF VOL 2.0 ± 0.9 lts. Of them 26 patients (52%) had hypotensive 
episodes, and 29 (58%) were on antihypertensive drugs. Only 5 patients had mean SPB³140, 
of which 4 were overhydrated postdialysis. None had DPB≥90. The 22 (44%) patients 
with weight below the estimated by BMC presented more frequent hypotensive episodes 
during dialysis (p<0.05), and had significant higher mean BMI (33.9 vs 27.5), UF VOL 
(2.3 vs 1.7 l) and weight gain (2.4 vs 1.7). No association was found between interdialytic 
weight gain and SPB≥ 140.
Conclusions: Obtaining tight SBP and DBP was accompanied with reduced total body 
water and frequent hypotensive episodes. Adjusting dry weight according BMC estimation 
could improve dialysis tolerance.
PUB332
Effect of Renin Angiotensin Aldosterone System Blockade on Clinical 
Outcomes in Patients with End-Stage Renal Disease: A Prospective Cohort 
Study in Korea  Kyung Don Yoo,1 Jung Pyo Lee,1 Jung Nam An,1 Yun Kyu 
Oh,1 Shin-Wook Kang,2 Chul Woo Yang,3 Yong-Lim Kim,4 Chun Soo Lim,1 
Yon Su Kim.1  1Seoul National Univ College of Medicine; 2Yonsei Univ College 
of Medicine; 3The Catholic Univ of Korea College of Medicine; 4Kyungpook 
National Univ School of Medicine.
Background: Adequate blood pressure control plays a key role in the management 
of patients with end-stage renal disease (ESRD). Although renin angiotensin aldosterone 
system (RAAS) blockade is known as the best treatment option for chronic kidney disease 
with hypertension, there is debate in the ESRD patients maintaining dialysis.
Methods: A total of 5,223 patients in the Clinical Research Center for ESRD (CRC for 
ESRD) prospective observation cohort from Aug 2008 to Dec 2014 were enrolled to this 
study. We compare overall survival and major cardiovascular event (MACE)-free survival 
between RAAS group and control group for using 1:1 propensity score matching (PSM) 
analysis. We defined the RAAS group as using ACE inhibitor or angiotensin receptor 
blocker more than 3month.
Results: Before matching, the RAAS group was younger; however, had more 
comorbidities such as diabetes and cardiovascular disease. The RAAS group had higher 
systolic blood pressure and was prescribed more number of other antihypertensive 
drugs than control group. After matching, there were no differences in age, sex, dialysis 
modalities, comorbidities and number of other antihypertensive medications. Before PSM, 
patient survival was significantly better in the RAAS group using the Gehan-Wilcoxon test 
(P=0.001), however, this difference disappeared after matching (P=0.450). Cardiovascular 
event-free survival was not different between RAAS group and control group before and 
after PSM analysis.
Conclusions: RAAS blockade did not affect all-cause mortality and MACE-free 
survival in the Korean ESRD patients. Further researches such as randomized control 
study will be needed.
PUB333
Lipidemic Profile and Sleep Apnea Syndrome in Hemodialysis Patients 
Olga Nikitidou,1 Vassilios Liakopoulos,1 Aikaterini A. Papagianni,2 Euphemia 
Daskalopoulou,3 Nicholas V. Dombros.1  1Div of Nephrology and Hypertension, 
1st Dept of Internal Medicine, AHEPA Hospital, Aristotle Univ of Thessaloniki, 
Thessaloniki, Greece; 2Dept of Nephrology, Hippokration Hospital, Aristotle 
Univ of Thessaloniki, Thessaloniki, Greece; 3Sleep Laboratory, “Aghios Pavlos” 
General Hospital, Thessaloniki, Greece.
Background: Dyslipidemia, characterized by low high density lipoprotein-HDL, 
high triglyceride-TG levels and normal levels of low density lipoprotein-LDL, is one of 
the traditional cardiovascular risk factors in hemodialysis-HD patients. On the other hand, 
sleep apnea syndrome-SAS, which is very common in this population, is one of the newest 
non-traditional cardiovascular risk factors. We investigated the impact of SAS and nocturnal 
hypoxia on the lipidemic profile of HD patients.
Methods: 37 HD patients (23 males) participated in the study. The night between 
two consecutive midweek HD sessions, they underwent an overnight polysomnography 
study. The following morning fasting blood samples were obtained and serum levels of 
total cholesterol-TC, TG, LDL, HDL, apolipoprotein A-apo A, apolipoprotein B-apo B 
and lipoprotein α-Lp (α) were measured.
Results: We investigated the correlation of the patients’ lipidemic profile with their 
characteristics [age, Body mass index-BMI, duration of HD] and their sleep parameters 
[Apnea/Hypopnea Index-AHI, Respiratory Disturbance Index-RDI, Desaturation Index-DI, 
mean and minimum SpO2, percentage of sleep time with SpO2<90%and total sleep time) 
and found that: 1) TC correlated negatively with minimum SpO2 (r=-0.454, p=0.005), 2) 
TG correlated positively with BMI (r=0.490, p=0.002) and RDI (r=0.438, p=0.007), 3) 
HDL correlated negatively with duration of HD (r=-0.350, p= 0.037) and BMI (r=-0.391, 
p=0.02), 4) apo A correlated negatively with duration of HD (r=-0.344, p=0.046), 5) Lp 
(α) correlated negatively with minimum SpO2 (r=-0.364, p=0.034) and 6) LDL and apo 
B showed no correlation.
Conclusions: The results of the present study indicate that in HD patients with SAS 
the severity of the syndrome and the nocturnal hypoxia correlates with many parameters 
of their lipidemic profile which might contribute in the augmented cardiovascular risk in 
this population.
Funding: Government Support - Non-U.S.
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Hemodynamic Changes in Maintenance Hemodialysis Patients with 
Intradialytic Hypotension  Meijuan Meng, Hong Ye, Junwei Yang.  Center 
for Kidney Disease, Second Affiliated Hospital, Nanjing Medical Univ, Nanjing, 
Jiangsu, China.
Background: Intradialytic hypotension (IDH) is a common complication in patients 
undergoing maintance hemodialysis (MHD) which leads to high mortality. This study is 
to explore the hemodynamic changes in MHD patients with IDH.
Methods: Thirty-seven patients were included in our study. IHD were defined as a 
decrease of systolic blood pressure (SBP)>20mmHg or the lowest  SBP below 90 mmHg 
during dialysis. Twenty-three patients were diagnosed with IDH. Among them, 13 were 
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asymptomatic while the other had the hypotensive symptoms, such as abdominal discomfort, 
sighing, nausea, vomiting, muscle cramps and restlessness. All of them underwent a 
noninvasive hemodynamic evaluations before, during and after dialysis.
Results: Compared to the patients without IDH, the dialysis age was longer and the 
prevalence of diabetes was higher in the patients with IDH. There were no difference in 
age, amount of ultrafiltration, pre-dialysis cardiac index (CI), systemic vascular resistance 
index (SVRI) and thoracic fluid capacity (TFC) between these two groups. During dialysis, 
CI decreased while SVRI increased gradually especially in patients with IDH. At the end of 
dialysis, ΔCI was markedly higher in patients with IDH. However, there was no significant 
difference in the change of CI, SVRI and TFC ten minutes before and after hemodialysis 
between these two groups. Meanwhile, the hemodynamic changes were analyzed in IHD 
patients with or without symptoms. It was found that there were no difference of change 
values and absolute values of CI and SVRI in these subgroups.
Conclusions: It was found that CI decreased while SVRI increased during 
hemodialysis. In the mid and later period, the CI decreased much more in patients with 
IDH. It was suggested that CI might be an indicator of IDH.
Funding: Government Support - Non-U.S.
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Dual Relationships of Serum Leptin on Heart Rate Variability in Patients 
with Stage 5 Chronic Kidney Disease  Ningning Wang, Yao Jiang, Jingjing 
Zhang, Changying Xing.  Nephrology, First Affiliated Hospital of Nanjing 
Medical Univ, Nanjing, China.
Background: Leptin regulates nutrition, bone metabolism and cardiovascular function. 
Lower heart rate variability(HRV) in chronic kidney disease(CKD) predicts higher risk of 
cardiovascular disease(CVD).Relationships between leptin and HRV in CKD is obscure.
Methods: This included cross-sectional observation and longitudinal followed-up on 
parathyroidectomy(PTX) patients.
Serum leptin/BMI is transformed using natural logarithm(lnleptin/BMI).
Results: lnleptin/BMI showed no difference between stage 5 CKD and controls. 
However, quartile 2 of lnleptin/BMI level in CKD patients prone to have higher HRV indices
Quartile 1(n=34) 2(n=33) 3(n=36) 4(n=39) P
Mean 24-h HR 
(beats/min) 87.4±12.7 79.4±11.6 81.9±10.5 81.1±9.2 0.020
Time domain 
measures
Mean NN(ms) 702.1±103.2 772.3±118.3 740.9±100.9 754.6±86.2 0.039
SDNN(ms) 72.0±33.9 78.2±33.8 73.4±24.3 73.1±22.3 0.827
SDANN(ms) 64.5±32.9 72.3±31.6 64.5±23.1 62.9±19.1 0.483
rMSSD(ms) 17.5±9.8 21.4±9.7 16.4±7.1 20.0±10.5 0.111
pNN50(%) 2.8±6.1 3.8±4.2 1.8±2.9 4.2±6.4 0.212
Frequency domain measures
ln VLF 5.3±1.1 5.6±0.9 5.5±0.8 5.5±1.0 0.609
ln LF 3.7±1.5 3.9±1.3 3.8±1.4 3.7±1.4 0.945
ln HF 2.7±1.5 2.7±2.0 2.6±1.9 2.5±2.1 0.944
ln LF/HF 0.9±0.9 1.1±1.1 1.2±0.9 1.2±1.2 0.720
Lnleptin/BMI in PTX group is correlated with serum Ca, P and PTH. Compared with 
lnleptin/BMI decreased group, lnleptin/BMI increased group has higher serum PTH before 
PTX and their HRV indices were significantly elevated after PTX.
Conclusions: Serum leptin has dual relationships with HRV and keeping its proper 
level contributes to reduce CVD in stage 5 CKD. PTX can reverse above disorders in 
severe SHPT patients.
Funding: Government Support - Non-U.S.
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Association of Geriatric Nutritional Risk Index and Responsiveness to 
Erythropoiesis-Stimulating Agent in Mortality of Chronic Hemodialysis 
Patients  Kosaku Nitta, Ken Tsuchiya.  Dept of Medicine, Tokyo Women’s 
Medical Univ, Shinjuku-ku, Tokyo, Japan.
Background: Responsiveness to erythropoiesis-stimulating agent (ESA) may be 
associated with mortality in hemodialysis (HD) patients. The aim of the present study was 
to assess the effects of geriatric nutritional risk index (GNRI) and responsiveness to ESA 
in outcome in HD patients.
Methods: The ESA resistance index (ERI) was determined as the weekly weight-
adjusted dose of ESA divided by hemoglobin concentration. Patients were divided into four 
groups by quartiles of ERI. Odds ratios were estimated using a Cox proportional model for 
the association between GNRI and ERI and mortality, adjusting for potential confounders. 
Patients were divided into four groups by quartiles of ERI.
Results: Of the 298 subjects enrolled, 51 died with 31 cardiovascular deaths during the 
follow-up period of 34.6 ± 6.1 months. The ERI was inversely correlated with the GNRI 
(r = 0.287, p <0.0001). Age, gender, serum total cholesterol, phosphorus levels, transferrin 
saturation and GNRI were independent predictors of ERI. Older age, female gender, serum 
total cholesterol, transferrin saturation and GNRI were independent predictors for ESA 
hyporesponsiveness. Receiver operating curve analyses indicated the cut off values of 
GNRI and ERI for mortality were 94.9, 13.5, respectively. When subjects were stratified 
by ERI and GNRI value into four groups, those who had low GNRI and high ERI were 
associated with the highest risk of mortality among the four groups (log-rank p <0.001).
Conclusions: high ERI and low GNRI were associated with an increased risk of 
all-cause mortality.
PUB337
A Multidisciplinary Approach Is Required to Reduce Hospitalizations 
for Cardiovascular Disease in Maintenance Hemodialysis Patients 
David L. Epstein,1,2 Thomas Parker,1,2 Daniel Levine,1,2 Jeffrey I. Silberzweig.1,2 
1Medicine, The Rogosin Inst, New York, NY; 2Medicine, Weill Cornell Medical 
College, New York, NY.
Background: Patients receiving maintenance hemodialysis have hospital admissions 
rates significantly greater than patients with other chronic diseases1. Approximately 40% 
of the hospital admissions are related to cardiovascular disease including both acute 
events and pulmonary edema1. We sought to assess the contribution of fluid weight gains 
to hospital admissions.
Methods: We compared inter-dialytic weight gains as a percentage of target weight 
and changes in blood pressure for the approximately 1200 patients receiving maintenance 
hemodialysis in our seven dialysis clinics in New York City between January and April 
2015. We compared these data to total and cardiovascular hospital admissions using t- tests.
Results: Greater relative weight gains were significantly associated with pre-treatment 
systolic blood pressure (2.7 mmHg increase in BP per 1% increase in weight; p < 0.0001) 
and hospitalizations for cardiovascular complications (p=0.03). In contrast, neither greater 
relative weight gain nor pre-treatment systolic blood pressure was significantly associated 
with all-cause hospitalization (p>0.5). The clinic with both the greatest relative weight gains 
and the highest rate of hospitalization for cardiovascular disease was without a full-time 
dietitian for the months of the study.
Conclusions: In our population of maintenance hemodialysis patients, we report 
a statistically significant association between relative weight gains, hypertension and 
hospitalization for cardiovascular disease. We suggest that this relationship may be related 
to the absence of a full-time dietitian leading to a lack of a true multidisciplinary team 
approach to fluid management in these patients. References: 1. U.S. Renal Data System: 
USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal 
Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute 
of Diabetes and Digestive and Kidney Diseases, 2012.
PUB338
Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in 
Hemodialysis Patients  Mohsen Agharazii, Karine Marquis, Catherine Fortier, 
Sacha A. De Serres, Fabrice Mac-Way.  CHU de Quebec Research Center, 
Hotel-Dieu de Quebec Hospital, Québec, QC, Canada.
Background: Ionized calcium concentrations are crucial for vascular smooth muscle 
tone and myocardial contractility. The aim of the present study was to investigate whether a 
reduction in serum calcium concentration by the calcimimetic cinacalcet can reduce aortic 
stiffness and improve diastolic dysfunction.
Methods: This is a randomized, double blinded, cross-over study comparing the effects 
of 30 mg/d of cinacalcet for 7 days to 7 days of placebo. Aortic stiffness was measured by 
determination of carotid-femoral pulse wave velocity (cf-PWV), central aortic pressure 
wave form was performed by radial tonometry using generalized transfer function, and 
cardiac function was evaluated by an echocardiogramme. Linear mixed model with fixed 
effects including period, treatment and sequence, while a random effect for the patients 
nested in sequence was used.
Results: 21 patients were enrolled. After administration of cinacalcet the total serum 
calcium decreased (2.28 ± 0.18 versus 2.15 ± 0.14 mmol/L, p<0.001), with a significant 
reduction of PTH levels as expected (558 ± 293 to 306 ± 333 ng/l, p<0.001). There were no 
significant differences in central pulse wave profile. Taking into account changes in the mean 
blood pressure, sequence, carryover and treatment effect, there was a numerically lower 
cf-PWV under cinacalcet that was not statistically significant (0.35, 95% CI -0.13 – 0.83 
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m/s, p=0.139). In 14 subjects, who underwent echocardiogramme, there were no significant 
changes in cardiac output, stroke volume and ejection fraction. However, left ventricular 
end-systolic volume (52 ± 22 versus 57 ± 25 ml (p=0.20) and end-diastolic volumes (92 ± 
35 versus 97 ± 17, p=0.08). were numerically higher under cinacalcet, but not statistically 
significant. There were no significant changes in the parameters of diastolic dysfunction.
Conclusions: In this short term study, there were no detectable effects of cinacalcet on 
aortic stiffness and diastolic dysfunction despite the expected reduction in serum calcium 
concentration. The numerically higher left ventricular volumes with cinacalcet, may need 
to be investigated. Clinical trials: NCT01250405.
Funding: Pharmaceutical Company Support - Amgen
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Kidney Transplantation and Cardiac Repolarization Descriptors 
Dimitrios J. Poulikakos,1 Debasish Banerjee,2 Marek Malik.3  1Renal, Salford 
Royal, United Kingdom; 2St. George’s Univ of London, United Kingdom; 
3Imperial College, London, United Kingdom.
Background: Selected descriptors of cardiac repolarization derived from the 
computerized analysis of electrocardiogram (ECG) can predict cardiac risk in hemodialysis 
(HD) patients. Kidney transplantation improves cardiovascular survival. The aim of the 
study was to investigate the impact of kidney transplantation on these descriptors.
Methods: The study was conducted in two phases. In phase 1, Holter ECGs were 
obtained during HD sessions and repeated 5 times at 2-weeks intervals in stable HD patients. 
The repolarisation descriptors QRS-to-T angle (TCRT) and T wave morphology dispersion 
(TMD)) were calculated in overlapping 10 second ECG segments and averaged over the 
first hour of recordings. In phase 2, continuous 1-hour ECG recordings were obtained in 
patients who received a kidney transplant minimum three months after transplantation 
and if they were stable with EGFR>30 ml/min/1.73m2. Average values of post transplant 
repolarisation descriptors were compared with average values over the first hour of HD 
using Wilcoxon test and t-test was used for baseline comparisons.
Results: In 80 HD patients in phase 1 both descriptors showed intrasubject stability 
and exhibited extreme values in subjects that suffered major arrhythmic events. During a 
period of 35.9 ±3 months 10 eligible transplanted subjects were recorded and although TMD 
and TCRT improved 7 months following kidney transplantation (see table) the difference 
did not reach statistical significance (p>0.05). However these subjects had better baseline 
TCRT and TMD values compared to the study population (TCRT 0.463 vs 0.078 p < 0.05 
and TMD 17.9 vs 32.4 p<0.05) .
Conclusions: In transplant recipients with healthier baseline repolarization profiles 
the improvement did not reach statistical significance in the early post transplant period. 
Larger studies with longer follow up are needed.
PUB340
Prognostic Significance of Cardiopulmonary Exercise Test and 6-Minute 
Walk Test in Chronic Dialysis Patients  Wioletta Dziubek,1 K. Bulinska,1 
B. Ochman,2 Ukasz Rogowski,3 Mariusz Kusztal,4 Tomasz Golebiowski,4 D. 
Markowska,1 A. Zembron-Lacny,5 Marian Klinger,4 M. Wozniewski.1  1Dept of 
Physiotherapy, Univ School of Physical Education, Wroclaw, Poland; 2Dept of 
Physical Education, Univ School of Physical Education, Wroclaw, Poland; 3Non-
Public Medical College of Wroclaw, College, Wroclaw, Poland; 4Nephrology and 
Transplantation Medicine, Wroclaw Medical Univ, Wroclaw, Poland; 5Physical 
Education, Univ of Zielona Gora, Zielona Góra, Poland.
Background: Dialysis patients (pts) are burdened by significant morbidity and 
mortality from cardiovascular causes. Identifying patients with an increased risk of ominous 
prognosis is of essential clinical relevance.The aim of the study was to evaluate prognostic 
value of cardiopulmonary exercise test (spiroergometry) and 6-minute walk test (6MWT) 
in chronic dialysis pts.
Methods: In prospective study 90 pts receiving high-flux dialysis (12h/week) were 
examined by means 6MWT and spiroergometry (VO2max,VE,VCO2, METS). After 3 years 
of follow-up data were evaluated in term to assess prognostic value of physical performance 
tests. Patients were divided into 2 groups: survivors and non-survivors (died within 3 years).
Results: Mortality at 3 years was 22.2% (20 pts) – non-survivors. They showed 
significantly lower values in cardiopulmonary exercise test and achieved shorter distance 
in 6 MWT compared to survivors – table. In multivariable analyses controlling for age, 
and sex lowed distance in 6 MWT was significantly correlated with all lower measures of 
spiroergometry (r 0.5-0.6). VO2max and 6 MWT were independently (from age) associated 
with death within 3 years.
Conclusions: Both cardiopulmonary exercise test and 6-minute walk test were able 
to differentiate survivors and non-survivors within 3 years.National Science Centre gant 
2011/03/B/NZ7/01764.
Funding: Government Support - Non-U.S.
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Adaptive Servo-Ventilator Therapy Improves the Cardiac Dysfunction 
in Hemodialysis (HD) Patients with Sleep-Disordered Breathing 
Fumiko Fukuuchi,1 Ken Tsuchiya,2 Kosaku Nitta.2  1Nephrology, Komagome 
Kyouritsu Clinic, Bunkyo-ku, Tokyo, Japan; 2Medicine IV, Tokyo Women’s 
Medical Univ, Shinjyuku-ku, Tokyo, Japan.
Background: Cardiac dysfunction is a very serious problem in HD patients. Sleep 
Disordered Breathing (SDB) is considered to cause cardiac dysfunction. Dialysis patients 
have a disordered respiratory center and a high prevalence of central apnea. Adaptive 
Servo-Ventilator (ASV) is automated modality used to treat heart failure patients with SDB, 
especially central apnea. The aim of this study is to explore the relationship between sleep 
apnea and cardiac dysfunction, and to evaluate the effects of ASV therapy in HD patients.
Methods: Sleep study was performed using a portable sleep test device (Sleeptester 
LS-300, Fukuda Denshi Co., Ltd, Japan). We measured the variables of cardiac function 
by echocardiogram. The relation between apnea index and the echocardiogram indicates 
was evaluated. We also collected baseline information on demographics, laboratory values, 
plasma BNP level, medications, and clinical conditions. ASV therapy was used in the 
patients diagnosed with severe SDB and/or central apnea. The cardiac function variables 
were evaluated in comparison to the previous year.
Results: The 27 dialysis patients (sixteen diabetics, eleven non-diabetics) are included 
in this study. Out of them, echocardiogram, SDB indications showed a connection. 
The obstructive apnea hypopnea index was related to the left ventricular posterior wall 
thickness (LVPWT) (r=0.49, p=0.02). Seven patients received ASV therapy. There has 
been improvement of overall of their cardiac function with significant increase of ejection 
fraction (p=0.02) 1 year after ASV introduction.
Conclusions: In this study, we demonstrated the efficacy of ASV therapy in 
hemodialysis patients with SDB. Near future, ASV is possible to be one of attractive 
devises for HD patients, with aging, several complications, to improve their poor prognosis.
PUB342
Endovascular Renal Denervation: Effects on Dyslipidaemia and Vascular 
Inflammation in Dialysis Patients  Neil A. Hoye,1 J. Christopher Baldi,1 David 
L. Jardine,2 John B.W. Schollum,1 Gerard T. Wilkins,1 Luke C. Wilson,1 Robert 
J. Walker.1  1Dunedin School of Medicine, Univ of Otago; 2Christchurch School 
of Medicine and Health Sciences, Univ of Otago.
Background: Endovascular renal denervation (RDN) reduces afferent and efferent 
sympathetic nerve activity. Its effects on vascular inflammation and cholesterol levels in 
dialysis patients are unknown. We hypothesized RDN would reduce sympathetic activity, 
resulting in improvement in biomarkers of vascular inflammation and dyslipidaemia.
Methods: Nine dialysis patients with uncontrolled office BP (>140/90mmHg despite 
two or more agents at maximal tolerated dosages) were recruited into this feasibility study. 
Office and ambulatory BP monitoring (ABPM) were performed at baseline, one and three 
months post RDN, along with supine muscle sympathetic nerve activity (MSNA) and 
venepuncture. Bilateral RDN was undertaken with an EnligHTNTM catheter.
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Results: Similar to previous, office systolic BP reduced and the effect on ABPM was 
attenuated. MSNA did not change, a novel finding. Despite lack of change in MSNA, 
total cholesterol:HDL ratio increased along with a falling trend in CRP and rising trend in 
albumin, all novel findings.
Baseline 1 Month 3 Months P value
Office Systolic BP (mmHg) 179±28 156±24 152±25 <0.05
Office Diastolic BP (mmHg) 90±17 76±13 82±12 0.137
Mean Systolic ABPM (mmHg) 173±19 173±23 166±24 0.544
Mean Diastolic ABPM (mmHg) 92±11 89±13 88±11 0.906
MSNA Burst Frequency (n=6) (bursts/
min) 59±12 59±15 59±13 0.872
Albumin (g/L) 38±5.0 39±6.3 41±4.6 0.068
Total Protein (g/L) 66±6.1 68±8.2 69±5.9 0.282
CRP (mg/L) 27±28 20±20 15±18 0.056
Chol (mmol/L) 4.1±0.9 4.1±1.0 4.4±1.2 0.228
HDL Chol (mmol/L) 1.2±0.3 1.2±0.2 1.1±0.2 0.388
Chol:HDL Ratio 3.6±1.1 3.5±0.9 4.1±1.1 <0.05
LDL Chol (mmol/L) 2.2±0.7 2.4±0.9 2.5±1.0 0.071
Triglycerides (mmol/L) 1.4±0.8 1.2±0.6 1.6±0.7 0.160
Conclusions: RDN in dialysis patients improves office systolic BP, impacts uraemic 
dyslipidaemia and possibly reduces vascular inflammation. Further controlled studies are 
warranted.
PUB343
Comparative Study of Non Survivors and Survivors Among Twice Weekly 
Hemodialysis Patients in India  Topoti Mukherjee, Naksha Jagannath Anchan, 
Geetha S, Gayathri Devi R.G., Avinash Ignatius, Tanmay Pandya, Vidyashankar 
Panchangam, Sylvia Paz B. Ramirez, Suresh Sankarasubbaiyan.  Nephrology, 
Davita Care India Private Limited, Chennai, Tamilnadu, India.
Background: Hemodialysis practice varies based on health system, payer practice, 
patient choice and socioeconomic environment. We analyzed the practice pattern and 
characteristics of non survivors and survivors among twice weekly hemodialysis patients 
across 9 centers in India.
Methods: Retrospective study of patients on HD between July 1, 2013 to Dec 31, 
2014. Inclusion criteria: > 30 days of HD & 1.8 - 2.3 HD sessions/week. Demographic 
characteristics, comorbidites, hospitalizations, cumulative follow up, hemoglobin, 
Albumin,Calcium and Phosphorus were compared among non survivors and survivors . 
We compared mean and proportion using Student T test and chi- square test respectively.
Results: N=255; 63.9% males. Non survivors 61 , survivors 194. Data presented as non 
survivors vs survivors: Hospitalizations: 42.6% vs 25.8% (<0.01), DM: 63.2% vs 34.5%, 
(<.01)CAD: 17.5% VS 6.4% (<.05),CVA: 1.8% vs 2.3%; HCV: 1.8% vs 10.9% (p< 0.05), 
HBV: 7% vs 1.1 % (< 0.05), HIV: 5.3% vs 3.4% 
Non survivors (n-61) Survivors (n-194)
Age 59.5 (12.5) 51.6 (14.3) <.01
Cumualtive follow up (pt yrs) 41.3pt yrs 186.8 pt yrs
Median follow up (days) 209 385
Total sessions 83.6(59) 118(74.6) <.01
Avg HD /week 1.9(0.2) 1.9(0.2) ns
S. Hb (G%) 8.9 (1.7) 9.5 (1.6) <.05
URR (%) 68.8 (5.5) 67.9 (7.9) ns
Std Kt/V 1.6 (0.30 1.7 (0.4) ns
S. Alb (g%) 3.5 (0.9) 4.0 (1.4) <.01
S. Ca (mg%) 8.4 (0.8) 8.4 (0.9) ns
S. Ph (mg%) 5.6 (1.3) 5.7 (1.6) ns
S. K (mEq/L) 5.2 (0.8) 5.3 (0.7) ns
Pre HD MAP standing 100.9(9.9) 103.4(13.5) ns
Post HD MAP standing 99.7(8.7) 103.6(28.3) ns
IDWG 3.8(1.4) 3.9(1.5) ns
UF rate 0.6(0.2) 0.6(0.2) ns
Mean hospitlalization/patient 0.6(0.9) 0.3(0.7) ns
No of hospitalizations 37 69
Non survivors were significantly older, had lower number of total sessions, lower 
albumin and Hb.
Conclusions: Non survivors were characterized by older age, higher prevalence of 
diabetes, CAD, lower Hb & Albumin. But dialysis adequacy and UF were comparable. 
Short duration of follow up may limit the ability to study other factors influencing outcomes.
PUB344
New Anticoagulant Free Strategy for Non Valvular Atrial Fibrillation in 
Hemodialysis Patients  Teresa Arcidiacono, Patrizio Mazzone, Marco Simonini, 
Donatella Spotti, Maria Teresa Sciarrone Alibrandi, Rita Quartagno, Marco 
Melandri, Stefano Tentori, Giorgio Slaviero.  San Raffaele Scientific Inst, Italy.
Background: Vascular calcification in patients with CKD-5 is associated with 
increased cardiovascular morbidity and mortality. An excessive calcification of coronary 
arteries and of aortic valve has been reported during Warfarin treatment. In addition use of 
oral anticoagulation (OAC) seems to be an important risk factor for calciphylaxis. Atrial 
fibrillation (AF) is the most frequent reason for OAC use in CKD patients.
Methods: An alternative to OAC could be the percutaneous Left Atrial Appendage 
(LAA) closure. With this technique an implantable component is permanently fixed in the 
LAA to prevent thrombus embolization. Different studies demonstrated that this procedure 
is not inferior to systemic anticoagulation with OAC in prevention of thromboembolic 
risk. We reported our clinical experience with the use of this technique in haemodialysis 
patients with non valvolar AF.
Results: In the last few months seven (7) haemodialysis patients were treated with 
percutaneous LAA closure. Bleeding and stroke risks were evaluated by HAS-BLED 
score and CHA2DS2-VASc score: HAS-BLED score was 4.5±0.58 (equal to 9%±0.11 
yearly risk of major bleeding) and CHA2DA2-VASc was 4±0.81 (equal to 4.47%±1.5 
yearly risk of stroke). This procedure was well tolerated by each patient. OAC treatment 
was interrupted after the procedure and doubled antiplatelet therapy was introduced for 
a month. At this moment median of 9 months of follow-up was archived [IQR 3-12]; no 
adverse events has been assessed.
Conclusions: To the best of our knowledge this is the first consecutive series of LAA 
closures in haemodialysis patients. This procedure represents a real clinical alternative to 
the use of coumarin derivated drugs. Our experience leads the way to the possible routinary 
use of this procedure in CKD-5D patients. As well as this procedure could be used in 
those patients with contraindications to OAC, even more this treatment should be used in 
haemodialysis population, in which the use of OAC should be avoided for both increased 
risk of life-threatening bleeding events and well known negative cardiovascular effects.
PUB345
Management of Subclinical Thyroid Dysfunction Can Reduce 
Cardiovascular Events in Patients with End-Stage Renal Disease on 
Hemodialysis  Hong Joo Lee.  Dept of Nephrology, Seoul Red Cross Hospital, 
Seoul, Republic of Korea.
Background: Normal thyroid function influences basal metabolic rate and general 
body metabolism and thyroid dysfunction is often associated with dyslipidemia and 
increased cardiovascular risk in general polulation. It is known that about 25% of patients 
with end-stage renal disease(ESRD) on hemodialysis had subclinical thyroid dysfunction. 
We investigated that subclinical hypothyroid dysfunction associate with dyslipidemia and 
cardiovascular event in hemodialysis patients. Hence, we conducted our study to elucidate 
whether subclinical thyroid dysfunction treated or not in ESRD patients.
Methods: All hemodialysis patients in Red Cross Hospital within a period of one year 
were included in the study. Thyroxine-3 (T3), free thyroxine-4 fT4, Thyroid Stimulating 
Hormone (TSH) and lipid profiles in the serum were estimated and death from all causes 
and CV events served as outcome variables over a median follow-up period of 12 months. 
Participants were divided into groups based on the thyroid function. Statistical analysis 
was carried out by using SPSS.
Results: Among the 92 cases, 28.2% of the patients were having thyroid disorder. In 
which 2.1% were of hypothyroid, 13.7% were of subclinical hypothyroid, and 0.8% were 
of hyperthyroid, 11.6% were of subclinical hyperthyroid. We observed negative correlation 
between TC & fT3. Total cholesterol was raised in hypothyroidism in comparison to 
euthyroid ESRD patients. However, thyoroid function didn’t have significant association 
with lipid profiles. Cardiovascular disease significantly often occurred in subclinical 
thyroidism patients than other group.
Conclusions: Our results show that the blood thyroid hormone level isn’t affected by 
dyslipidemia but affected by occurrence of CVD. Therefore, the management of subclinical 
hypothyroidism in hemodialysis patients should be considered.
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Effect of Altitude on All-Cause Mortality in End-Stage Kidney Disease 
Patients Ongoing Hemodialysis in Peru  Katia Bravo-Jaimes,1 Viky Y. 
Suncion,2 Jose Ernesto Rojas,3 Christian R. Mejia,4 Sandra C. Schult.5  1Medicine, 
Univ of Rochester Medical Center, Rochester, NY; 2Medicine, Jackson Memorial 
Hospital, Miami, FL; 3Inst de Investigaciones de Altura, Univ Peruana Cayetano 
Heredia, Lima, Peru; 4Asociación Médica de Investigación y Servicios en Salud, 
Lima, Peru; 5Pediatrics, Inst Nacional de Salud del Niño, Lima, Peru.
Background: Worlwide, end-stage kidney disease (ESKD) prevalence has 
tremendously risen. Previous studies suggested that receiving hemodialysis (HD) at high 
altitude confers mortality benefits; however this effect has not been proved above 2000 m 
or in developing countries.
Methods: This historical cohort study analized medical records from six HD centers of 
the Peruvian Social Security System. Adult ESKD patients who started HD between 2000 
and 2010 were included. Patients were classifed into two strata (< 2000 and > 2000 m). The 
outcome variable was death from any cause. Cox proportional hazards models were built 
for the time from first dialysis to death from any cause, stratifying by year and censoring 
patients at 5 years after first dialysis; loss to follow-up; transference to another HD center 
out of the city; renal transplantation or migration to peritoneal dialysis during follow-up.
Results: 723 patients were enrolled, including 248 women (38.2%). The mean age 
was 52.8 ±16.9 years. 166 patients lived > 2000 m (22%). In first years after follow-up, 
survival rates were lower in the group > 2000 m, however after 8 years of follow-up this 
trend reversed . Age and gender were not significantly associated to mortality at altitude 
levels > 2000 m. Patients with diabetes had higher mortality rates at > 2000 m (p=0.003), 
independently of age.
Conclusions: In Peru, patients receiving HD at high altitude do not experience mortality 
benefits. In fact, diabetics have higher mortality rates at > 2000 m. 
Funding: Private Foundation Support
PUB347
End-Stage Renal Disease in North Region of Oman/Epidemiology, 
Incidence, and Aetiology  Ruqiya Khamis Al-Za’abi,1,2 Elizabeth P. Tolmie,1 
Ann marie Rice,1 Nabil Mohsin,2 Ahmed Said Al-Busaidi.2  1Nursing and Health 
Care, Univ of Glasgow, Glasgow, United Kingdom; 2Nursing Education, Ministry 
of Health, Muscat, Sohar, Oman.
Background: The epidemiology of renal failure in Oman is scarce. There is a paucity 
of information on the size and burden of renal failure in Oman. Therefore, our research 
was conducted to measure the prevalence, incidence and death rate (epidemiology) among 
patients who have renal failure and undergo renal dialysis in four dialysis centers in the North 
of Oman; and to provide a description of the major characteristics of the studied patients.
Methods: A cross-sectional study was conducted. A proportional sample (n = 341) 
patients from four Renal Dialysis Centres (RDC) were interviewed face to face or via 
telephone using a structured questionnaire. Data collection took place between October 
and November, 2014. The incidence, prevalence and death rate are under collection until 
the end of December, 2015.
Results: Over the period January 1st, 2014 to December 31st, 2014, a total of 96 new 
patients started dialysis in the four observed RDCs. The overall incidence rate was 13 
patients per 100,000. The period prevalence for the patients undergoing renal dialysis was 
52 patients per 100, 000. The mortality rate for the same period of time was four patients 
per 100,000. Demographic data are summarized in table1. 
N %
Subjects 
Included 
Excluded
380 
341 
39
100 
89.7 
10.3
Gender 
Male 
Female
 
187 
154
 
54.8 
45.2
Ethnicity 
Omani Asian 
Omani White 
Omani Black
 
237 
55 
49
 
69.5 
16.1 
14.4
Age Groups 
0-17  
18-45 
46-64 
65-75 
>75
 
6 
102 
164 
52 
17
 
1.8 
29.9 
48.1 
15.1 
5
Marital Status 
Married 
Single 
Widowed 
Divorced
 
214 
54 
51 
22
 
62.8 
15.8 
15 
6.4
Education 
Illiterate 
Read and Write 
Primary Education 
Secondary Education 
College Degree 
Post-College
 
164 
51 
47 
58 
18 
3
 
48.1 
15 
13.7 
17 
5.3 
0.9
Employment Status 
Unemployed 
Employed
 
292 
49
 
85.6 
14.4
Conclusions: Renal failure is a burden on patients, and the health and social systems 
of Oman. The expenditure on these 380 patients in 2014 was 6.5 million dollars. However, 
to determine the size of the burden, we need a comprehensive study covering the whole 
country of Oman and we need to receive data from neighbouring countries to compare with.
Funding: Government Support - Non-U.S.
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Low Potassium Bath Protocol Experience in Hemodialysis Patients in Qatar 
Abdullah Hamad, Fadwa S. Al-Ali, Eiman Mohamed Hamid, Shaza Yousif 
Elsanoosi, Mohamed Yahya Mohamed, Hany Ezzat Ismail.  Nephrology, Fahad 
Bin Jassim, Hamad General Hospital, Doha, Qatar.
Background: Hyperkalemia is a major problem in hemodialysis (HD) patients 
affecting there morbidity and mortality. HD patients receiving low potassium (K) bath for 
hyperkalemia have double the risk of sudden cardiac death. We noticed high rate of use 
of low K dialysate due to high prevalence of hyperkalemia in our dialysis unit. We are 
studying this phenomenon.
Methods: Our study was done in the biggest out-patient HD facility in Qatar (306 
patients). We identified patients who required low K bath (based on an existing rigorous 
protocol, any K over 5.5 will be started on low K bath 1 mmol/L with checking K level 
every HD treatment till corrected) in 6 months period from 10/1/2014 to 3/31/2015. We 
collected background data in these patients and their potassium levels during that period.
Results: 62 out of 306 hemodialysis patients required low K bath continuously (5 
patients) or intermittently (57 patients). Mean age was 59.9 +/- 15 years. There were 
36 females on low K bath out of total 137 females versus 26 males out of 169 (p Value 
0.014) . 39 out of 62 were Qatari (62% versus 65% in patients not on low K bath). Table 
1 summarize number of patients on low K bath and number of low k bath HD treatments 
on monthly base versus average temperature in Doha, Qatar. 
October November Decem-ber January
Febru-
ary March
number of patients on 
low K bath 35 34 28 17 9 27
number of HD 
treatments done with 
low K bath
349 362 178 79 65 160
average temperature in 
Doha, Qatar (degree 
centigrade)
35 29 25 22 25 27
Conclusions: In a study of using low K bath in a major HD clinic in Qatar we found 
a statistically significant higher number of female patients who required low K bath than 
males. This might be attributed to dietery habits based on our dietititions experience and 
vascular access issues but further study is needed to explain these findings. There was a 
significant decrease in need for low k bath in January and February compared to other 
months both in the number of patients and HD treatments . We attributed that to combination 
of cooler weather and seasonal change in dietery habits. Further study again is needed to 
evaluate that prosepectively.
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Co-Morbidity Rather Than Clinical Practice Patterns Determines Mortality 
in an Aged Dialysis Population  An Vanacker,1 Bert Bammens,2 Bart De Moor,3 
Bart D. Maes.1  1Nephrology, AZ Delta, Roeselare, Belgium; 2Nephrology, Univ 
Hospitals, Leuven, Belgium; 3Nephrology, Jessa Hospital, Hasselt, Belgium.
Background: Hemodiafiltration (HDF), by adding convective to diffusive transport, 
is more effective in removing larger uremic retention solutes than hemodialysis (HD). As 
these solutes are thought to have a role in the accelerated cardiovascular disease of dialysis 
patients, HDF might result in lower mortality compared to HD.
Methods: All patients treated with thrice weekly HD (high-flux) or online HDF at 3 
Belgian dialysis centers for ≥ six and < 42 months were included in July 2008. Hospitalized 
patients or patients with access-related problems were excluded. The effect of HDF versus 
HD on all-cause mortality at 6 years was evaluated. Multi-variate analysis taking into 
account all relevant baseline variables was performed to determine independent predictors 
of outcome.
Results: 242 patients were included (142 male, mean age 70,9 ± 11,8 years): 84 
treated with HD, 158 with HDF. After 6 years, the incidence of all-cause mortality was 
significantly higher in HD than in HDF: 54 of 84 patients in HD-group (64,3%), 70 of 158 
patients in HDF-group (55,7%) (P = 0,04). Based on univariate associations with survival 
(*) and/or significant association with center or HD/HDF variable, following parameters 
were introduced in multivariate analysis: HD/HDF*, vintage, age*, weight, CCI*, use of 
calcium(Ca)-based and non-Ca-based phosphate (P) binders, dialysis hours/week, Qb, 
Qd, dialysate Ca concentration*, vascular access*, mean P*, Ca-P product*, hemoglobin, 
albumin*, interdialytic weight gain and center. The final multivariate model is shown in 
the table below. 
Variable HR 95% CI p-value
Age 1,03 1,01 – 1, 06 0,003
Charlson Comorbidity 
Index CCI 1,30 1,16 – 1,45 < 0,0001
Weight 0,98 0,97 – 0,99 0,02
Calcium 
concentration of 
dialysate
3,60 1,06 - 12,24 0,04
Vascular access 1,43 1,19 - 1,72 0,0002
Interdialytic weight 
gain 1,31 1,07 - 1,61 0,009
Albumin 0,38 0,39 - 0,97 0,04
Conclusions: In an aged Western dialysis population, treatment with HDF did not 
improve all-cause mortality compared to high-flux HD. Mortality seems to be determined 
by comorbidity rather than by clinical practice patterns.
PUB350
Depression Is Associated with Frailty and Malnutrition but Not Comorbidity 
Load in Chinese Peritoneal Dialysis Patients  Cheuk-Chun Szeto,1 Shin Man 
Choy.2  1Dept of Medicine & Therapeutics, The Chinese Univ of Hong Kong, 
Shatin, Hong Kong; 2Dept of Medicine & Therapeutics, Prince of Wales Hospital, 
Shatin, Hong Kong.
Background: Depression is common amongst patients with chronic kidney disease 
and is associated with excessive mortality in dialysis patients. This study determines the 
prevalence and risk factors of depression in Chinese peritoneal dialysis (PD) patients.
Methods: We studied 178 prevalence PD patients (103 males). Depression was screened 
by the 15-item self-reported Geriatric Depression Scale (GDS). We also determined 
patients’ comorbidity load, dialysis adequacy, residual renal function, nutritional status, 
and degree of frailty.
Results: The mean age was 60.7 ± 11.7 years; vintage of dialysis 42.5 ± 44.1 months. 
Average GDS score was 4.9 ± 4.4. GDS score is closely associated with the frailty score 
(r = 0.692, p < 0.0001), malnutrition inflammation score (r = 0.406, p < 0.0001), and 
subjective global assessment score (r = -0.386, p < 0.0001). GDS score also has a modest 
but significant correlation with Charlson’s comorbidity index (r = 0.164, p = 0.028) and 
serum albumin level (r = -0.192, p = 0.019), but not with patient age, vintage of PD, 
dialysis adequacy, or residual renal function. When defined as a GDS score ≥8, 50 patients 
(28.1%) had depression.
Conclusions: Depression is common amongst Chinese PD patients. Frailty and 
malnutrition are the major risk factors of depression in our cohort, while comorbidity load 
and dialysis adequacy have little effect.
Funding: Clinical Revenue Support
PUB351
Trends in Anemia Management with Darbepoetin Alfa in Patients on 
Maintenance Hemodialysis  Robert H. Yenchek,1 Anne C. Beaubrun,2 Jeffrey 
Petersen,2 David G. Dalpias,1 Alfred K. Cheung.1  1Univ of Utah, Salt Lake City, 
UT; 2Amgen, Inc., Thousand Oaks, CA.
Background: In the US, darbepoetin alfa (DA) is primarily used to treat anemia in 
patients receiving treatment in hospital-based dialysis centers. Epoetin alfa (EA) doses and 
hemoglobin (Hb) levels declined in response to recent regulatory and reimbursement events 
but little is known about trends in anemia management with DA in the US maintenance 
hemodialysis (HD) population receiving treatment in free-standing dialysis centers (FSDCs). 
We describe herein anemia management in FSDCs within the University of Utah (UU) 
Dialysis Program who switched from the use of EA to DA program-wide in 2005.
Methods: We included ~650 adults (age ³18 yrs) with 1+ months on HD between 2008-
2013 in 18 FSDCs within the UU Dialysis Program. We summarized quarterly intravenous 
DA and iron use and dose, Hb, and serum transferrin saturation (TSAT) and ferritin levels.
Results: 70-78% of patients received DA over the study period. Mean Hb levels among 
patients who received DA fell from 12.2 g/dL in 2008 before leveling around 10.3 g/dL 
from Q4 2011 to 2013 (Figure). The mean monthly DA dose was 209 mcg in Q1 2008, 
reached a peak of 256 mcg in Q1 2010, and decreased to ~105 mcg in 2013. Quarterly iron 
use rose from 52% in 2008 to 67% of patients in 2013. Iron dose also rose from 129 mg 
in Q4 2008 to 194 mg in Q4 2010, but declined to 163 mg in Q4 2013. Mean serum TSAT 
levels remained relatively constant at ~30% between 2008-2013 but serum ferritin levels 
increased from 449 ng/mL in Q1 2008 to 770 ng/mL in Q4 2013.
Conclusions: Trends in anemia management parameters among patients on HD treated 
with DA within FSDCs in the UU Dialysis program were consistent with national reports 
of patients treated with EA. 
Funding: Pharmaceutical Company Support - Amgen, Inc.
PUB352
Shorter Dialysis Session Time Was Associated with Higher Risk of 
Hospitalization and Death in Maintenance Hemodialysis Patients 
Takahiro Kuragano, Takeshi Nakanishi.  Dept of International Medicine, Div of 
Kidney and Dialysis, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Background: Recently, dialysis efficiency was dramatically improved by using super 
flux dialysis membrane. However, in the condition of the common use of high flux dialysis, 
it has not been well studied the relationship between treatment time and adverse events or 
survivals of maintenance hemodialysis (MHD) patients.
Methods: Subject: 805 patients undergoing MHD. Study design: Prospective, 
observational multi-center study of 3 years. We measured serum levels of urea nitrogen 
(UN), creatinine (Cr), b2microgroblin (MG), total protein, albumin, prealbumin, high 
sensitive C reactive protein (hCRP) every 3month. We also evaluated body mass index 
(BMI), and Kt/V. The associations between dialysis intensity and adverse events or death 
were investigated with the cox proportional hazards model for time-dependent variables.
Results: Although there was no significant correlation between pre-dialysis levels of 
b2MG or UN and adverse event or survival, high pre-dialysis Cr level was associated with 
lower risk of hospitalization (HR:0.89, P=0.003) and death (HR:0.71, P=0.002). Moreover, 
high Kt/V was also associated with lower risk for cerebrovascular and cardiovascular 
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disease (CCVD) (HR:0.37, P=0.039) and hospitalization (HR:0.55, P=0.026). There was 
no significant difference in serum levels of prealbumin, albumin, Cr, Kt/V and hCRP 
levels among 3 groups of treatment time (<4hours(h), 4-5h, >5h). On the other hand, BMI 
in the patients treated with >5h was significantly (p=0.012) higher than those of patients 
treated with <4h. In time dependent cox hazard model, the risk of hospitalization (HR:0.43, 
P=0.001) and death (HR:0.49, P=0.013) of patients treated with 4-5h were significantly 
lower than that of patients treated with <4h. Moreover, the risk of death in patients treated 
with >5h was significantly (HR:0.45, P=0.024) lower than that of treated with <4h.
Conclusions: Higher Kt/V was associated with lower risk of CCVD and hospitalization 
of MHD patients, but not pre-dialysis level of b2MG levels. Shorter dialysis session time 
was associated with higher risk of hospitalization or death than that of longer treatment time.
PUB353
A Randomized, Factorial Pilot Study to Evaluate the Feasibility of an 
Intradialytic Exercise Intervention (DIALY-SIZE!)  Stephanie E. Thompson,1 
Scott Klarenbach,1 Anita Molzahn,1 Mark Haykowsky,1 Anita Lloyd,1 Marcello 
Tonelli.2  1Univ of Alberta, Edmonton, AL, Canada; 2Univ of Calgary, Calgary, 
AB, Canada.
Background: Intradialytic exercise (IDE) is associated with improved dialysis 
adequacy and amelioration of dialysis-related symptoms. However, the uptake of IDE is 
limited by knowledge gaps on efficacy—what type of exercise to prescribe to optimize 
outcomes, and on feasibility. The results of this pilot will inform the design of a full-scale 
efficacy study evaluating two types of IDE (aerobic and resistance) and will also provide 
research users with practical information on IDE.
Methods: In this single center, randomized, factorial (2 x 2) study, chronic adult 
hemodialysis patients were randomized to one of four IDE groups: cycling, resistance, 
cycling and resistance, or stretching (an attention control). Exercise was semi-supervised 
by a kinesiologist. Outcomes focused on a priori feasibility criteria: recruitment, fidelity to 
the protocol, and participant and unit staff response to IDE. As a secondary outcome, we 
evaluated the main effect of cycling and weights each compared with control on quality of 
life and physical performance at baseline and 12-weeks. To better understand feasibility, 
we conducted interviews with users.
Results: We exceeded targeted accrual of 28 people over 12 weeks. Of 100 patients 
screened, 31 were enrolled (36 did not meet inclusion criteria, 33 declined participation); 
16% dropped out after randomization. Fidelity to the intervention was high: of 1,039 
training sessions offered, 87% were delivered. Participant response to the intervention was 
favorable: 92% of participants continued exercising after the trial. There were no crossovers 
and no reported contamination. Dialysis staff were not consistently available to assist with 
implementation, so study staff were necessary to deliver IDE. Secondary outcomes were 
not statistically significant.
Conclusions: This pilot study demonstrated feasibility of recruitment, high patient 
acceptability, and low risk of contamination. However, IDE will not be feasible in the 
long term unless dialysis staff assist with implementation. This will need to be addressed 
before executing a definitive trial.
PUB354
A Prospective Study of Routine Heparin-Free Hemodialysis (HFD) with 
Streamline® Bloodlines (SL) in a Large Tertiary Acute Care Inpatient 
Practice  Sami Safadi,1 Mary Ann Ryan,2 Amanda L. Severson,2 Fares Alahdab,3 
John J. Dillon,1 Robert C. Albright,1 Amy W. Williams,1 Marie C. Hogan.1 
1Nephrology and Hypertension, Mayo Clinic, Rochester, MN; 2Nursing, Mayo 
Clinic; 3KSP Unit, Mayo Clinic.
Background: Extracorporeal circuit (EC) anticoagulation (AC) with heparin was a key 
advancement in hemodialysis (HD). However, AC in patients at risk of bleeding remains 
a frequently encountered problem. SL bloodlines eliminate blood-air contact, and reduce 
turbulence in HD circuit. Small studies suggest that SL reduces heparin use and improves 
HD efficiency. We prospectively evaluated EC clotting rates, impact on dialysis efficiency, 
and associated risk factors in our inpatient practice.
Methods: In this complete study, we followed acute care inpatients requiring HD 
without routine EC heparin. Patients could be on ACs for other non-HD indications. All 
sessions were performed using SL and Fresenius 2008K. HD sessions were observed for 
clotting events (CE) defined as interruption of HD session, loss of HD circuit, or inability 
to return blood.
Results: 1200 HD runs were performed. Demographics & HD session characteristics 
are summarized in table 1. Overall CE rate was 5.2%. Determinants for CE were temporary 
HD catheters (OR=2.8, p<0.01), transfusions (OR=2.3, p=0.05), systemic AC (OR=0.2, 
p<0.01), & antiplatelets (OR=0.4, p<0.01). CE were associated with a lower delivered KT/V 
(diff-0.39, p<0.01). Most CE during transfusions (71%) occurred when blood products 
were given by the HD circuit.
Conclusions: We successfully adopted HFD with SL as our standard inpatient 
protocol. This protocol is feasible and safe in acute care inpatient HD. CE risk is low, 
and is associated with temporary HD catheters and transfusions. Use of antiplatelets and 
systemic AC is protective. 
Floor ICU
Patients n=173 n=201
Median age 66 yrs 63 yrs
Males 64% 61%
Caucasians 84% 88%
ESRD 75% 52%
HD sessions n=600 n=600
Median time (min) 210 213
HD Access
-Tunneled Cath 51% 57%
-AV Fistula 34% 15%
-Temp. Cath 11% 24%
-AV Graft 2% 2%
Median BFR (ml/min) 350 350
Median UF (liters) 2 2
Median KTV 1.4 1.5
Antiplatelets within 7 days 46% 61%
-Aspirin 43% 58%
AC within 7 days 25% 45%
-Heparin 16% 37%
-Warfarin 22% 39%
Transfusions 4.5% 4.5%
CE 5% 5.5%
Funding: Pharmaceutical Company Support - Medisystems, a NxStage Company
PUB355
Patterns of Oral Disease in Adults with Chronic Kidney Disease Treated 
with Long-Term Haemodialysis: A Multinational Ecological Study 
Giovanni F.M. Strippoli.1,2,3,4  1On behalf of the ORAL-D Study Investigators*; 
2Diaverum Medical Scientific Office; 3Univ of Bari; 4Univ of Sydney.
Background: Oral disease is a potentially treatable risk factor for premature death 
and impaired quality of life. However, the oral disease burden and candidate preventative 
strategies are uncertain in the dialysis setting.
Methods: ORALD was a prospective study in 4726 adults treated with hemodialysis 
in Europe and Argentina recruited from a convenience sample of 80 dialysis clinics 
within a treatment network. Oral disease was assessed using standardized WHO methods. 
Participants self-reported oral health practices and symptoms. Socio-demographic and 
clinical factors associated with oral diseases were assessed within nation states.
Results: Of 4726 eligible adults from 80 dialysis units, 4205 (88.9%) participated. 
Overall, 20.6% were edentulous (95% CI, 19.4-21.8). Participants had on average 22 (21.7-
22.2) decayed, missing or filled teeth while moderate to severe periodontitis affected 40.6% 
(38.9-42.3). Oral disease patterns varied markedly across countries. Participants in Spain, 
Poland, Italy and Hungary had the highest mean adjusted odds of edentulousness (2.31, 
1.90, 1.90, and 1.54) whilst those in Poland, Hungary, Spain and Argentina had highest 
odds of ³14 decayed, missing, and filled teeth (23.2, 12.5, 8.14, 5.23). National levels of 
tobacco consumption (R2=0.79), diabetes (R2=0.49), and child poverty (R2=0.66), were 
associated with edentulousness within countries.
Conclusions: Oral disease in adults on hemodialysis is very common, frequently severe, 
and highly variable among countries, with much of the variability unexplained by participant 
characteristics or oral practices. Given the substantial variation among countries and high 
burden of disease, strategies to improve oral health in hemodialysis patients will require 
national strategies. *List of ORAL-D Investigators: S Palmer, M Ruospo, G Wong, JC Craig, 
M Petruzzi, M De Benedittis, P Ford, DW Johnson, M Tonelli, P Natale, V Saglimbene, F 
Pellegrini, E Celia, R Gelfman, MR Leal, M Torok, A Bednarek-Skublewska, J Dulawa, 
P Stroumza, L Frantzen, D del Castillo, AG Bernat, J Hegbrant, C Wollheim, L Gargano, 
CP Bots and GFM Strippoli.
PUB356
Low Serum Albumin Is a Risk Factor for In-Hospital Mortality 
Among Hemodialysis Patients Hospitalized with Infectious Diseases: A 
Multicenter Retrospective Cohort Study in Japan  Shun Minatoguchi,1,2 
Hideaki Shimizu,1,2 Takaya Ozeki,2 Daisuke Uchida,2 Hiroo Kawarazaki,2 
Hiroki Nishiwaki,2 Takahiro Imaizumi,2 Yoshiro Fujita,1,2 Yugo Shibagaki.2 
1Nephrology, Chubu Rosai Hospital, Nagoya, Aichi, Japan; 2TOMEI Nephrology 
Group for Clinical Research, Japan.
Background: Serum albumin is the known marker of nourishment and inflammation. 
Several studies in the past have shown the relationship between low serum albumin and 
long-term mortality among dialysis patients. However, There is insufficient data on the 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
971A
J Am Soc Nephrol 26: 2015 Publication Only 
relationship between serum albumin levels and short-term mortality among chronic dialysis 
patients who are hospitalized with infectious diseases. This multicenter retrospective cohort 
study in Japan evaluated if serum albumin levels at the occurrence of infection is a risk 
factor for in-hospital mortality among hemodialysis patients.
Methods: From June 2011 to July 2013, a total of 418 hemodialysis patients who took 
blood cultures were reviewed retrospectively in five tertiary dialysis units participating the 
“TOMEI Nephrology Group for Clinical Research” study. After exclusion of 232 patients 
diagnosed with non-infectious diseases, 186 patients diagnosed with infections were 
analyzed. Patients were divided into two groups according to the serum albumin level at 
hospitalization; low serum albumin (Serum albumin<3.5g/dL) or not. Outcome measure 
was in-hospital mortality. For statistical analysis, cox proportional hazard model was used.
Results: Among 186 patients with infectious diseases, there were 117 patients 
(62.9%) in low albumin group, and 69 patients (37.1%) in normal albumin group. During 
hospitalization (median 19 days, interquartile range 10-37), 29 patients (15.5%) died; 25 of 
117 (21.4%) in low albumin group, and 4 of 69 (5.8%) in normal albumin group. The cox 
proportional hazard model verified that low serum albumin and bacteremia were associated 
with in-hospital mortality. The hazard ratio of in-hospital mortality among low albumin 
group was 4.293 (95% CI: 1.36-13.55).
Conclusions: Although low serum albumin is a known risk factor for long-term 
mortality, this study showed that low serum albumin strongly predicts short-term mortality 
among hemodialysis patients hospitalized with infectious diseases.
PUB357
Usefulness of High-Frequency Wave-Length Ultrasonography as a 
Diagnostic Tool for Carpal Tunnel Syndrome in Hemodialysis Patients 
Tadashi Yamazaki,2 Tokie Hayasaka,2 Tetsuo Saito,2 Shuichi Tsuruoka.1 
1Nephrology, Nippon Medical School, Tokyo, Japan; 2Dialysis Unit, Moka 
Hospital, Moka, Tochigi, Japan.
Background: Carpal tunnel syndrome (CTS) is a common complication in dialysis-
induced amyloidosis. In orthopedics, high-frequency wave-length ultrasonography (US) 
with improved resolution is recently used for diagnosing disorders of the upper extremities. 
We aimed to determine the value of US for diagnosing CTS in hemodialysis (HD) patients, 
through a cross-sectional analysis.
Methods: All maintenance HD patients (N = 150) at our hospital were recruited 
after providing written informed consent. Patients with apparent paralysis or pain in the 
upper extremities due to causes other than CTS were excluded. Longitudinal scan of the 
median nerve around the carpal tunnel area was performed with US (Toshiba Viamo TM, 
12-MHz probe) during HD, and the compression rate (CR) of the nerve was calculated as 
(1 - shortest diameter/longest diameter of the nerve around the carpal tunnel area). The 
CTS symptoms were evaluated with the visual-analogue scale (VAS) of pain around the 
index finger area and the quick form of the Disabilities of the Arm, Shoulder and Hand 
(Quick-DASH) questionnaire. Pinch strength was also measured. Serum C-reactive protein 
(CRP) and b2-Mg concentrations, and medical histories related to CTS or dialysis-induced 
amyloidosis were extracted from the patients’ record.
Results: Total 250 wrists from 125 patients (Mean age = 65.6±10.6 years) were studied. 
The mean CR was 11.8±0.7% and the cut-off values of CR from ROC curve for history of 
carpal tunnel release was 25.7% (sensitivity 0.80, specificity 0.91). Multivariate analysis 
revealed that CR was significantly positively correlated with dialysis career , VAS and 
Quick-DASH scale, positive Tinnel’s sign, and serum CRP and b2-Mg concentrations, 
whereas it showed a significantly negative correlation with pinch strength. Especially, 
patients with >4 years of HD and serum b2-Mg concentrations >20 mg/L showed 
significantly high CRs.
Conclusions: Measurement of CR with US is an easy and reproducible method for 
diagnosing dialysis-related CTS. The CR significantly correlated with symptoms and factors 
associated with dialysis-induced CTS.
Funding: Government Support - Non-U.S.
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Technique Failure in Korean Incident Dialysis Patients: A National 
Population-Based Study  Shina Lee,1 Hyunwook Kim,2 Seung-Jung Kim,1 
Duk-Hee Kang,1 Kyu Bok Choi,1 Dong-Ryeol Ryu.1  1Dept of Internal Medicine, 
School of Medicine, Ewha Womans Univ Mokdong Hospital, Seoul, Republic 
of Korea; 2Dept of Internal Medicine, Wonkwang Univ College of Medicine 
Sanbon Hospital, Gunpo, Republic of Korea.
Background: Technique failure is an important issue for dialysis patients. In this study, 
we aimed to analyze a detailed technique failure rate and to determine the predictors for 
technique failure in Korea.
Methods: We identified all patients who had started dialysis between January 1, 
2005 and December 31, 2008 in Korea, using the Korean Health Insurance Review and 
Assessment Service database. A total of 32,357 eligible patients [24,743 hemodialysis 
(HD) patients and 7,614 peritoneal dialysis (PD) patients] were included, and the median 
follow-up was 26.4 months.
Results: The crude incidence rates of technique failure among HD patients and PD 
patients were 3.4 and 54.1 per 1000 patient-years, respectively. When comparing technique 
survival rate between HD and PD in both Kaplan-Meyer analysis and competing risks 
analysis, it was significantly higher in patients on HD than in those on PD. However, the 
gap of technique failure incidence between HD and PD was exaggerated in Kaplan-Meier 
analysis compared to competing risks analysis. In multivariate analyses, diabetes mellitus 
and Medical aid as a crude reflection of low socioeconomic status were independent risk 
factors in both Cox proportional hazard model and Fine and Gray subdistribution model. 
In addition, cancer was independently associated with a lower risk of technique failure in 
Fine and Gray model.
Conclusions: Technique failure in PD is higher than that in HD, and it is major 
concern in patients initiating dialysis in Korea. The results of our study offer a basis for 
risk stratification and customized care for technique failure.
PUB359
Frequency of Not Achieving Target Weight in Hemodialysis Patients and 
the Reasons Behind It  Line Malha,1,2 Frank Modersitzki,1 Lada Beara Lasic.1,2 
1Internal Medicine, Div of Nephrology, New York School of Medicine, New York, 
NY; 2Internal Medicine, Div of Nephrology, New York Harbor VA Healthcare 
System, New York, NY.
Background: Volume overload and volume depletion have both been associated with 
morbidity and mortality in patients with end stage kidney disease (ESKD) on hemodialysis 
(HD). A recent study demonstrated an increased mortality risk when post HD weight is 
more than 2kg above or below the prescribed estimated dry weight (EDW) for >30% of 
HD sessions. Our aim was to determine the frequency of sessions with weight difference 
(WD)>±2kg, determine the prevalence of patients WD>±2kg for >30% of sessions and 
identify the possible reasons in our outpatient chronic HD population.
Methods: 32 outpatients on chronic HD at the New York Harbor VA Healthcare 
System in Manhattan were monitored for 2 months. Data for 631 sessions was obtained. 
Charts and HD nursing notes were reviewed every 2-4 weeks for: weight, prescribed 
EDW, ultrafiltration (UF) rate, intradialytic complications (hypotension with systolic 
BP<90, dizziness, cramping, administration of intravenous fluids). Sessions with a missing 
documented EDW or post HD weight were excluded. 502 sessions were used in the analysis.
Results: The mean WD for all sessions was 0.67±1.64 kg with a majority (83.7%) of 
HD sessions ending with post HD weight within 2kg of EDW which is consistent with the 
literature. 6 out of 31 (19.3%) patients had WD>±2kg for >30% of the evaluated sessions. 
The inability to achieve post HD weight within 2 kg of EDW was most commonly (51.2%) 
associated with an elevated UF rate (defined as >875ml/hour). Possible reasons for not 
achieving EDW also included cramps (4.9%) and hypotension (2.4%).
Conclusions: Failing to achieve EDW within 2kg range is most commonly associated 
with high UF rates, indicating high weight gains between treatments. Proposed strategies to 
continue aiming at achieving EDW while compensating for the constraints of elevated UF 
include: decreasing intradialytic weight gain, increasing treatment frequency or treatment 
time. Further studies identifying the best strategies to achieve this goal are needed.
PUB360
Comparative Effectiveness of Dialyzers: A Longitudinal Propensity Score-
Matched Study  Scott Sibbel,1 Abigail Hunt,1 Suzanne Laplante,2 Werner 
Beck,2 Mary Gellens,2 John Alan Laich,1 Steven M. Brunelli.1  1DaVita Clinical 
Research, Minneapolis, MN; 2Baxter Healthcare Corporation, Deerfield, IL.
Background: Differences in dialyzer design may affect systemic inflammation and 
extracorporeal blood sequestration and thereby impact anemia management and control. 
We evaluated the comparative effectiveness of commonly used dialyzers with respect to 
longitudinal hemoglobin (Hb) levels, and ESA and IV iron utilization.
Methods: Patients included in the analysis received hemodialysis between 01 Jan 
2009 and 31 Dec 2013 and were new users of Revaclear, Optiflux 160, or Optiflux 180 
dialyzers. Patients were followed for 1 year or until end of study or censoring for dialyzer 
switch, modality change, or loss to follow up. For each comparison, eligible patients were 
propensity score-matched 1:1 on a range of demographic, comorbidity history, and baseline 
laboratory parameters. Outcomes were assessed using generalized linear mixed models 
including fixed effects for dialyzer type, time, and their interaction term.
Results: Matched patient pairs (21,551 for Revaclear-Optiflux 160 comparison; 21,008 
for Revaclear-Optiflux 180 comparison) were assessed. ESA doses evolved differently 
over time among Revaclear patients versus both Optiflux 160 and Optiflux 180 patients 
(p interaction<0.001 for both). Differences in ESA dose were significant from month 3 
for Revaclear versus Optiflux 160 (range, 173-483 U/treatment) and at all time points for 
Revaclear versus Optiflux 180 (range, 120-392 U/treatment). Hb levels were equivalent 
between Revaclear and Optiflux patients at all times. IV iron dosing was lower for Revaclear 
patients than Optiflux 160 and 180 patients (p<0.001 for each) but differences were small 
(1-5 mg/month).
Conclusions: Use of Revaclear versus Optiflux dialyzers was associated with lower 
ESA doses, modestly lower IV iron doses, and equivalent Hb concentrations. 
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Lack of Leukocytic Response to Infections in End Stage Renal Disease 
Deepa Amberker,1 Ritesh J. Rampure,1 Mary C. Naglak,1 Harold D. Stein.2 
1Internal Medicine, Abington Jefferson Health, Abington, PA; 2Hypertenson 
Nephrology Associates, Abington Jefferson Health, PA.
Background: Patients with end stage renal disease (ESRD) on dialysis are at increased 
risk of infection resulting from a relatively immunosuppressed state. Dysfunctional 
immunity may be the result of uremia, dialyzer membrane interactions, poor nutritional 
status and impaired leukocyte responsiveness. Abnormal leukocytic response in such 
situations may result in missed diagnosis in the clinical setting as well as increased 
morbidity and mortality. The nature and magnitude of the leukocytic response to infection 
in this population has not been well characterized. This study is an attempt to assess the 
degree of leukocytosis in ESRD patients and compare it with the general population in 
the presence of an infection.
Methods: This was a retrospective study wherein all patients with ESRD on 
hemodialysis admitted to our hospital between December 2011 and December 2014 with 
any kind of infection were taken as the ESRD group and compared to others without ESRD 
or significant chronic kidney disease. Analysis of total WBC as well as percentage of 
Bandemia were compared and analyzed for statistical significance. Patients were excluded 
if on steroids, less than 18 years of age, presence of cancer, HIV, pregnancy, CKD stages 
3-5 or if sent from dialysis unit.
Results: After reviewing the medical records of approximately 600 patients admitted 
for infection, 201 patients were studied based on selection criteria, of which 100 had ESRD 
and 101 did not. Pneumonia followed by sepsis were the most common infections in both 
groups. The variables studied were as shown in following table: 
ESRD group Comparison group P-Value
Average WBC count per microliter 10, 800 15, 700 < 0.0005
No. of patients with leukocytosis 
(>11000 WBC/mcl) 32 % 87 % < 0.005
No. of patients with Bandemia (>700 
bands/mcl) 26 % 41 % 0.03
Mean neutrophil percent 78.6 % 81. 9 % 0.018
Conclusions: The results of this study demonstrate impaired leukocytic response in 
ESRD patients on dialysis with infection. Leukocytic response in this population is not 
a reliable infectious biomarker and if used clinically may lead to diagnostic error and 
potentially adverse outcomes.
PUB362
Fluid Overload Predicts Mortality Risk in Maintenance Hemodialysis 
Patients  Carlo Donadio, Valentina Vigo.  Clinical and Experimental Medicine, 
Univ of Pisa, Pisa, Italy.
Background: Maintenance hemodialysis (MHD) patients have a high mortality rate, 
mainly due to cardiovascular disease and malnutrition. The aim of this study was to evaluate 
the efficacy of the analysis of body composition by bioimpedance (BIA) to predict the 
mortality risk in hemodialysis patients.
Methods: Observational longitudinal study lasting six years on 78 prevalent MHD 
patients (68% male, mean age 65 ± 14 years; dialysis vintage 7 ± 7 years). Every two 
years, starting from the baseline, we collected clinical, laboratory and BIA data, including 
vectorial analysis (BIVA) and hydration scale, that is the hydration as percentage of lean 
body mass. We compared the BIA data of patients dead during the study period (n = 45; 
65%) with those of survivors (n = 24; 35%). The significance of the differences between 
the mean values of the two groups at the baseline was evaluated.
Results: Nine patients moved to another hemodialysis facility. The patients dead 
at different times during the six years had significantly higher values of BMI (28 ± 6 vs 
24.8 ± 3.1 kg /m2, p <0.01) and fat mass index (11.2 ± 4.1 vs 8.4 ± 2.8 kg /m², p <0.003) 
compared to the survivors, while there were no significant differences for body cell mass 
(BCM) index (7.1 ± 1.7 vs 7.9 ± 1.8 kg / m²) and serum albumin (4.1 ± 0.4 vs 4.1 ± 0.1 mg/
dl). Furthermore, deceased patients had lower values of reactance (53.5 ± 11.7 vs 67.3 ± 
13.7 Ohm, p <0.000003), phase angle (5.1 ± 0.9 vs 5.9 ± 0.8 degrees, p <0.00003) and the 
percentage of extracellular water was higher (50.6 ± 5.2 vs 46.1 ± 3.6 %, p <0.00003). Finally 
the BIVA analysis confirmed that the hydration was significantly higher in the deceased 
(73.3 ± 1.8 vs 71.2 ± 3.3 %, p <0.00006). In summary survivors had normal values of BMI 
and fat mass, a smaller reduction in BCM and less fluid overload than deceased patients.
Conclusions: The survival of HD patients is influenced by the nutritional status. In 
particular, fluid overload and decrease in muscle mass play a decisive role on survival. 
Fluid overload, low values of electrical resistance and phase angle predict mortality risk 
in MHD patients.
Funding: Government Support - Non-U.S.
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A Single Center 2-Year Experience with Haemodialysis Care in Nigeria 
Bala Waziri,1 Isah Alhaji Umar.2  1Dept of Medicine, IBB Specialist Hospital, 
Minna, Niger State, Nigeria; 2Dept of Medicine, IBB Specialist Hospital, Minna, 
Niger, Nigeria.
Background: In Nigeria, sustaining maintenance haemodialysis while awaiting renal 
transplantation is largely being hampered by high cost of care. Furthermore, the scarcity 
of dialysis units, lack of government funding or subsidy on haemodialysis have made 
survival very difficult for patients with End Stage Renal Disease in Nigeria Thus the aim 
of this study was to share our experience with the challenges of providing maintenance 
haemodialysis in a developing country.
Methods: We retrospectively reviewed records of all the patients with ESRD who 
had haemodialysis at our dialysis facility over a period of 24 months. Data on their 
demographic characteristics, etiology of Chronic Kidney Disease, types of vascular 
access for dialysis, frequency of haemodialysis, history of blood transfusion and patient 
outcomes were collected.
Results: This study included 64 patients on maintenance haemodialysis. The mean 
age was 43.9±18.1 years, and there were 39 males (60.9%) and 25 females (39.1%). The 
underlying presumed etiology of Chronic Kidney Disease were hypertension (73.4%), 
diabetes mellitus (3.1 %) chronic glomerulonephritis (1.6%) and (21.0%) was unknown.
Their mean haemoglobin level at the time of commencing dialysis was 7.2±2.2g/dl , with 
37.5 % receiving 3-4 pints of blood transfusion.The mean systolic and diastolic blood 
pressure were 169.1±37.6mmHg and 103.3±15.5mmHg respectively. A significant inverse 
correlation between haemoglobin level and serum creatinine was observed (r= ˗0.413, 
p<0.001). A predominant proportion of the patients 60(93. 8%) were dialyzed via femoral 
cannulation, while 3 (4.7%) and 1(1.6%) received dialysis through tunneled internal jugular 
catheter and A-V fistula respectively.Majority of the patients 43 (67.2% ) had less than 
thrice weekly dialysis. At the time of review, more than half of the study population 37 
(57.8%) had died, while 23 (35.9 % ) are alive and 3(4.7 % )have had kidney transplant.
Conclusions: The high mortality in this study, is likely due to a combination of 
inadequate dialysis with other predictors of cardiovascular events such as anaemia and 
uncontrolled hypertension as demonstrated in our results.
PUB364
Characteristics and Patient Survival in Nursing Home Residents on 
Maintenance Dialysis  Robert Nee,1 Lawrence Agodoa,2 Kevin C. Abbott.1 
1Nephrology, Walter Reed National Military Medical Center, Bethesda, MD; 
2NIDDK, National Insts of Health, Bethesda, MD.
Background: There is limited data on the growing nursing home (NH) population 
with end-stage renal disease (ESRD) in the United States. We evaluated the characteristics 
and predictors of mortality of NH patients on dialysis.
Methods: In this retrospective cohort study using the United States Renal Data 
System database, we identified 782,161 patients initiated on maintenance dialysis from 
January 1, 2007 through December 31, 2013, followed until 31 May 2014. Covariates 
include age, gender, race, dialysis modality, body mass index, serum albumin, indicators 
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of poor functional capacity and other co-morbid conditions from the Medical Evidence 
Form 2728. We conducted both Kaplan-Meier and adjusted Cox regression analyses with 
death as the outcome variable.
Results: 56,194 (7.18%) were identified as nursing home residents upon initiation of 
dialysis. Among NH patients, 50.53% were female, 69.92% were white, and 99.49% were 
on hemodialysis and the mean age was 71.1 ± 12.1 years. The overall incidence rates of 
death of NH vs. non-NH patients were 51.8/100 and 17.6/100 patient-years, respectively 
(p<0.001). The unadjusted 1-year mortality was 50% in NH patients (vs. 20% in non-NH 
patients, p<0.001). Adjusted Cox analysis showed that NH patients were at significantly 
higher risk of death compared to non-NH patients (adjusted hazard ratio [AHR] 1.37; 95% 
confidence interval 1.35-1.38). Within this NH cohort, age (AHR 1.02; 95% CI 1.02-1.02), 
inability to transfer (AHR 1.25; 95% CI 1.22-1.29), inability to ambulate (AHR 1.08; 95% 
CI 1.05-1.11), cancer (AHR 1.15; 95% CI 1.12-1.19) and other co-morbid conditions were 
significantly associated with death.
Conclusions: NH patients on dialysis have a high mortality rate, even when compared 
to the broader ESRD population. Further studies on modifiable risk factors of mortality 
in this particularly high-risk ESRD population are warranted. [Disclaimer: The views 
expressed in this paper are those of the authors and do not reflect the official policy of the 
Department of the Army, the Department of the Navy, the Department of Defense, or the 
United States government].
PUB365
Bicarbonate as  Nutrit ion Marker in Hemodialysis  Patient 
Louis-Michael Pellerin, Robert Zoel Bell, Jean-Philippe Lafrance, Vincent 
Pichette, Michel Vallee.  Nephrology, Hopital Maisoneuve-Rosemont, Montreal, 
QC, Canada.
Background: Protein-energy malnutrition (PEM) is prevalent in the hemodialysis 
(HD) population and is associated with a high morbidity-mortality burden.  Metabolic 
acidosis and PEM are closely related.  Protein intake, which constitutes an acid load, is an 
important factor of pH regulation in end-stage renal disease patients.  Therefore, could a 
higher bicarbonate serum level be the result of insufficient protein intake and be a useful 
marker of malnutrition?
Methods: We conducted a retrospective study in our HD service using a computer 
database with measurements obtained simultaneously for all 342 patients.  Correlation 
between pre-HD session bicarbonate, albumine, prealbumine and normalized protein 
catabolic rate (nPCR) was assessed by the use of Pearson’s and Spearman’s correlation 
test.  Subgroup analysis were realised for patients with negative C-Reactive Protein (CRP 
< 5) and patients classified as clinically stable.
Results: We found a significant, negative and moderate,  correlation between 
bicarbonate and nPCR, (spearman’s p :-0.27, p<.0001).  Subgroup analysis showed similar 
results, (spearman’s p : -0.28, p<.0001)for198clinically stable patient and (spearman’s p 
: -0.24, p<.003) for 144 patients with a negative CRP.  There was no association between 
albumin (spearman’s p :-0.06, p=0.1511) or prealbumin (spearman’s p :-0.08, p=0.1511) 
and bicarbonate in any group.
Conclusions: A higher serum level of bicarbonate is associated with a lower nPCR, 
reflecting of poor protein intake, but not with a malnutrition state define by albumin or 
prealbumin criteria. These patients are at risk to develop a clinically apparent malnutrition 
state after a prolonged period.
PUB366
Scope and Consistency of Outcomes Reported in Randomized Trials of 
Hemodialysis  Gabrielle J. Williams, Allison Tong, Jonathan C. Craig.  School 
of Public Health, Univ of Sydney, Sydney, NSW, Australia.
Background: Inconsistent outcome selection and reporting in clinical trials may 
limit their capacity to inform evidence-based decision making and the ability to combine 
findings in systematic reviews. Aim: We aimed to assess the scope and consistency of 
outcome selection and reporting in trials included in systematic reviews of interventions 
for patients on hemodialysis (HD).
Methods: The Cochrane Database of Systematic Reviews was searched from 1999 
to January 2015 for published systematic reviews of interventions for patients on chronic 
HD. The description and frequency of outcomes reported within the source randomized 
controlled trials were assessed.
Results: The 18 systematic reviews included 282 trials that reported over 518 outcomes. 
There was considerable heterogeneity among the outcomes reported. Across all trials, 320 
outcomes occurred only once, and 198 outcomes were identified twice. The five most 
common outcome domains were mortality (50 trials, 18%), blood pressure (46 trials, 16%), 
calcium (44 trials, 16%), parathyroid hormone (41 trials, 15%) and quality of life (39 trials 
[14 %]). There was considerable variation in how the domains were measured, the time at 
which they were measured, and the units and threshold changes that defined an outcome. For 
example, blood pressure was reported as pre-dialysis, post-dialysis, maximum, difference 
in pre and post dialysis, ambulatory, resting, rise, and time to restore.
Conclusions: A wide array of outcomes are reported in trials of interventions in HD, 
with large heterogeneity in timing of measurements, units of measure, and threshold changes 
that define an outcome. This highlights the need for a well-defined set of standardized core 
outcomes to improve the comparability of trial findings in meta-analysis and to provide 
greater confidence around treatment decisions for patients undergoing HD.
Funding: Government Support - Non-U.S.
PUB367
Blood Pressure and Cognitive Decline in Hemodialysis Patients 
Sarah M. Duncan,1 Hocine Tighiouart,1 David A. Drew,1 Tammy Scott,1,2 Daniel 
E. Weiner,1 Mark J. Sarnak.1  1Tufts Medical Center, Boston, MA; 2Tufts Univ, 
Boston, MA.
Background: Cognitive impairment is common in hemodialysis (HD) patients; 
however, the relationship between measures of blood pressure (BP) and longitudinal decline 
in cognitive function is unknown in this population.
Methods: 314 participants in the Cognition and Dialysis Study underwent an annual 
comprehensive battery of cognitive tests. Using principal components analysis (PCA), we 
reduced individual test results to two domain scores representing memory and executive 
function. Adjusted joint mixed models accounting for death, transplant, and drop-out were 
used to explore the association of blood pressure [systolic (SBP), diastolic (DBP) and pulse 
pressure (PP)] with change in cognitive function over time.
Results: Mean (SD) age was 63 (16) years, 47% were women, 22% were African 
American, and 44% had cardiovascular disease (CVD). Mean (SD) SBP, DBP, and PP 
were 141 (21), 73 (12) and 68 (15) mmHg, respectively. Median follow up time was 1.8 
years (IQR 1.0-3.4). Mean slopes of PCA memory and executive were 0.03 (95% CI -0.01, 
0.07) and -0.11 (95% CI -0.15, -0.06) per year, respectively. Lower DBP and higher PP 
were associated with decline in measures of both memory and executive function. There 
was no association between SBP and cognitive decline. 
Conclusions: Lower DBP and higher PP are associated with faster rate of cognitive 
decline, in particular that related to executive function. Because impairment in executive 
function is a manifestation of vascular disease and lower DBP and higher PP are associated 
with CVD in HD patients, our results suggest that cognitive decline may be mediated by 
vascular disease in this population.
Funding: NIDDK Support, Pharmaceutical Company Support - Dialysis Clinic Inc.
PUB368
High Ferritin Levels Achieved with Ferric Citrate as a Phosphate Binder 
Do Not Associate with Adverse Events  Udayan Y. Bhatt,1 Kausik Umanath,2 
Mohammed Sika,3 Mark Koury,3 Robert M. Niecestro,4 Barbara A. Greco,5 Dana 
G. Negoi,6 Ingrid J. Chang,7 Tom Greene,8 Stephen Z. Fadem,9 Molly Mcfadden,8 
Julia Lewis,3 Jamie P. Dwyer,3 The Collaborative study group.4  1Ohio State; 
2Henry Ford Hosp; 3Vanderbilt; 4CSG; 5Baystate Med Ctr; 6U of VT; 7Western 
Neph; 8U of Utah; 9Baylor College of Med.
Background: Ferric citrate (FC) as a phosphate binder increases Fe stores and reduces 
IV iron/ESA use while maintaining hemoglobin. This analysis compares effects of higher 
achieved ferritin levels in subjects on FC to those in subjects on sevelemer carbonate and/
or calcium acetate (active control, AC).
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Methods: Data were obtained from the 52-wk active control period of the FC pivotal 
trial. Subjects with a baseline ferritin ³1000ng/mL or TSAT≥50% were excluded from the 
trial. We randomized 292 subjects to FC and 149 to AC. Any subjects who developed ferritin 
level ³1500ng/mL at any time over 52wks were identified. CV, ID, and dialysis access 
related adverse events (AE) occurring at any time over the 52-week period were tabulated.
Results: 57 subjects (19.8%) in the FC group and 14 subjects (9.5%) in the AC group 
had at least a single ferritin³1500ng/mL (p=0.012) during the 52 wks. CV events including 
MI, CHF, and arrhythmias, occurred in 12.3% of the FC group compared to 21.4% AC. ID 
AEs occurred in 42.1% FC and 50% AC. Dialysis access related AE occurred in 15.7% FC 
and 42.9% AC. IV iron administration was statistically lower (p=0.003) in the FC group 
(2.95±3.57mg/wk) than the AC group (6.20±3.64mg/week), consistent with the full FC 
cohort that saw a significant reduction in IV iron use. Cumulative ESA dosing was 1016±906 
Units/wk FC and 1781±1756 Units/wk AC (p=0.256).
Conclusions: This study in the subset who developed ferritin ³1500ng/mL shows that 
fewer subjects experienced a CV, ID, or dialysis access related AE in those receiving FC vs 
AC. IV iron use was statistically lower and ESA dosing was numerically lower. As previously 
reported the majority of ferritin³1500ng/mL resolved and 90.1% were adjudicated to be 
related to IV iron and/or inflammatory AEs. This analysis, although limited by small sample 
size, supports the contention that FC is clinically useful and safe vs traditional binders.
Funding: Other U.S. Government Support, Pharmaceutical Company Support - 
Keryx Biopharmaceuticals, Inc.
PUB369
Association Between Employment Status and KDQOL Scores in Dialysis 
Patients  Duane V. Dunn,1 Deborah S. Evans,1 Elizabeth I. Jones,1 Caroline 
Hann,1 Rich Mutell,2 Allen R. Nissenson,1 Deborah A. Benner.1  1DaVita 
HealthCare Partners Inc, Denver, CO; 2Apex Health Innovations, Simi Valley, 
CA.
Background: Studies have shown that unemployment negatively impacts dialysis 
patients’ quality of life (QOL).1-3 QOL can be quantified and low scores on the Kidney 
Disease Quality of Life (KDQOL) survey are associated with poor outcomes.4 Our study 
examines employment/unemployment status and KDQOL scores.
Methods: We collected employment status data on 122,166 adult patients at a large 
dialysis organization from Nov 2014-Apr 2015. Patients were grouped as either employed 
(received pay or in training), unemployed (including retirees and those on long- or short-
term disability or Workers Compensation) or other (involved in work/activity but not paid). 
Data were matched with patients’ most recent KDQOL scores.
Results: The employed group (n=16,216) had the highest KDQOL scores in all 
categories, followed by the other (n=7936) and unemployed groups (n=98,014) [Table]. A 
clinically meaningful difference (6.8) in Physical Component Score was found between 
the employed (42.0) and unemployed (35.2) groups. This difference was greater (~10 
points) between full-time employed and Workers Compensation patients, who scored 
lowest in all categories.
Conclusions: Preliminary analysis found employment is positively associated with 
KDQOL scores among dialysis patients. More studies are needed to better understand 
whether patients with higher QOL are more likely to work or whether working contributes 
to improve QOL. References1) Lopes AA et al. Qual Life Res. 2007;16(4):545-557. 2)
Curtin RB et al. Am J Kidney Dis. 1996;27(4):533-540. 3) Kutner NG et al. Clin J Am 
Soc Nephrol. 2010;5(11):2040-2045. 4) Mapes DL et al. Kidney Int. 2003;64(1):339-349.
PUB370
Reduction of Pruritus in Hemodialysis Patients by Adjustment of Serum 
B-Type Natriuretic Peptide  Yoshio Shimizu,1 Nao Nohara,2 Eri Nomura,2 Kaori 
Yamada,2 Mayumi Matsumoto,2 Toshiki Kano,2 Yasuhiko Tomino.2  1Juntendo 
Univ Shizuoka Hospital, Izunokuni, Japan; 2Juntendo Univ, Tokyo, Japan.
Background: Pruritus reduces the quality of life (QOL) and worsens the prognosis 
in hemodialysis patients. It was reported that the neuropeptide natriuretic polypeptide B 
(Nppb; alias BNP) is a neurotransmitter of pruritus. We reported that serum BNP was a factor 
that contributed to the exacerbation of pruritus in hemodialysis patients. We determined 
whether pruritus could be reduced by controlling serum BNP.
Methods: Forty-eight patients participated in this study. (Test 1) Serum BNP was 
measured with common laboratory tests and visual analogue scale (VAS) in a single 
hemodialysis session. The factors influencing the changes of VAS during the dialysis 
session were analyzed. (Test 2) The fluid volume was strictly managed to decrease serum 
BNP level by reporting the weight gain during each dialysis session. Patients who gained 
more than 5% of the target dry weight were warned with a document and the session was 
extended until they reached the target dry weight. VAS, DLQI (Dermatology Life Quality 
Index) and an inventory survey using the KDQOL (the kidney disease quality of life short 
form, Ver.1.3) were examined once a month.
Results: (Test 1) VAS decreased significantly after dialysis. Similarly, a significant 
decrease was found in BNP. Using univariate analysis, a significant correlation was found 
in the change in serum BNP, urea nitrogen, iron and ferritin. In multivariate analysis the 
BNP change and serum iron were extracted as factors that influenced a decrease of the 
VAS. (Test 2) BNP reduced the overall mean. Monthly VAS did not decrease for the 
first two months, but after three months, a significant decrease was observed (p=0.031). 
DLQI did not correlate with the BNP at the beginning of the study, but one month later, a 
significant correlation was found between DLQI and BNP. No improvements in either a 
renal disease-specific standard or the comprehensive standard in KDQOL were observed 
as a result of the intervention.
Conclusions: It was suggested that the adjustment of serum BNP by strictly managing 
the weight reduced pruritus in hemodialysis patients but it was difficult to improve long-
term QOL.
Funding: Pharmaceutical Company Support - Novartis, Kowa, Tanabe-Mitsubishi, 
Kyowa-Kirin, Private Foundation Support
PUB371
The Mechanisms Study on Neointimal Hyperplasis of Autogenous 
Arteriovenous Fistula in Maintenance Hemodialysis Patients  Nanmei Liu. 
Jimin Hospital of Shanghai.
Background: To evaluate the influence and the possible mechanism about neointimal 
hyperplasis of autogenous internal arteriovenous fistula in hypertensive nephropathy and 
diabetic nephropathy patients which was going maintenance hemodialysis and provide 
possible theory about how to prevent from intimal hyperplasia, extend the life of AVF 
in clinic.
Methods: Collecting cephalic vein when the hemodialysis patients had the surgey 
of AVF angioplasty and reconstruction.Vascular tissues were divided into chronic 
glomerulonephritis group,hypertensive nephropathy group and diabetic nephropathy group. 
Immunohistochemistry was used to detect the expression of vascular smooth muscle actin 
(a-SMA). Selecting the control group and fistula vascular tissue which the useful life was 
12-18 months, basic fibroblast growth factor (bFGF), insulin-like growth factor 1(IGF-
1),matrix metalloproteinase2 (MMP2) and matrix metalloproteinase9 (MMP9) were to 
detect expression change by immunohistochemical staining.
Results: Compared with chronic glomerulonephritis group, intima thickness of 
hypertensive nephropathy and diabetic nephropathy were significantly increased and the 
increase was more significant in diabetic nephropathy. Hyperplasia intima was eccentric 
thickening and the hyperplasia intima showed obvious inflammatory cells infiltration and 
vacuolar degeneration. Immunohistochemical staining showed that compared with the 
group of chronic glomerulonephritis, hypertensive nephropathy and diabetic nephropathy 
groups’s a-SMA, bFGF, IGF-1 and MMP9 expression levels were significantly increased, 
expression of VEGF was significantly reduced, MMP2 was no significant change (P>0.05).
Univariate regression analysis revealed that the expression levels of a-SMA was positively 
correlated with bFGF, IGF-1 and MMP9,negatively correlated with the VEGF. AVF intimal 
hyperplasia mainly dominated by the vascular smooth muscle cells (VSMC) proliferation.
Conclusions: Hypertension and diabetes can accelerate the process of intimal 
hyperplasia, shorten the life of fistula and diabetes promote intimal hyperplasia more 
significant. This study provides a theory and therapeutic targets for the prevention and 
treatment on intimal hyperplasia of AVF in dialysis patients.
Funding: Government Support - Non-U.S.
PUB372
Association of Nutritional Status with Depression and Sleep Disorders 
in Elderly Hemodialysis Patients  Avsin Ibis,1 Emre Tutal.2  1Nephrology, 
Afyonkarahisar State Hospital, Afyonkarahisar, Turkey; 2Nephrology, Baskent 
Univ Hospital, Ankara, Turkey.
Background: The relationship between depression, sleep quality, and malnutrition 
in an elderly population in maintenance hemodialysis is very complex and not yet 
fully understood. We aimed to determine the association between nutritional status and 
psychological factors such as depression and sleep disturbance in elderly dialysis patients.
Methods: Seventy three dialysis patients (41 female, 32 male; aged, 72.5±6.0 years) 
older than 65 years of age, were enrolled in the study. Nutritional status was determined 
by Subjective Global assesment (SGA). Beck Depression Inventory (BDI) questionnaire 
was used to measure presence and degree of depression. Quality of sleep was measured 
using the Pittsburgh Sleep Quality Index (PSQI). Demographic and biochemical parameters 
and Charlson Comorbidity Index and frequency of infection in previous year period of 
all patients were recorded.
Results: In our elderly patients 15 (%20.5) had sleep disorder and 24 (%32.9) had mild 
to moderate depression and 11 (%15.1) had moderate to severe depression. According to 
SGA 48 (%65.8) patients were well-nourished and 25 (%34.2) patients had mild-moderate 
and severe malnutrition. When the well-nourished and malnourished patients were 
compared, well-nourished group had higher albumin levels (4.28±0.25 g/dL vs 3.50±0.36 
g/dL), lower CRP levels (7.51±4.23 vs 16.02±19.45), better quality of sleep (3.50±0.82 
vs 5.56±1.73) and better depression scores (8.68±2.75 vs 16.28 ±4.56) than malnourished 
group. By multivariate analysis when factors affecting nutritonal status were taken into 
account BDI (p=0.001; OR=1.79; CI, 1.26-2.56) and PSQI (p=0.022; OR=4.33; CI, 1.23-
15.2) was associated with SGA.
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Conclusions: Depression and sleep disorders are important factors influencing the 
nutritional status and could be an independent risk factors for malnutrition in elderly 
patients receiving maintenance dialysis. Psychological assessment should be mandatory 
in the follow up of these patients to identify depression and sleep disturbance because 
many of them are reversible.
PUB373
Predialysis Hyponatremia and Mortality in Elderly Patients with Incident 
Maintenance Renal Replacement  Seon Ha Baek, Sung Woo Lee, Shin-Young 
Ahn, Sejoong Kim, Ki Young Na, Dong-Wan Chae, Ho Jun Chin.  Internal 
Medicine, Seoul National Univ Bundang Hospital, Republic of Korea.
Background: Predialysis hyponatremia recently have been reported to be associated 
with mortality in incident hemodialysis patients. However, little is known about whether 
predialysis hyponatremia is associated with unfavorable outcomes in elderly patients.
Methods: We retrospectively assessed mortality in 397 (mean age 73.0 year, male/
female 226/171) patients aged ≥65 years with non-diabetic end-stage renal disease (ESRD) 
who initiated renal replacement therapy (RRT) at a tertiary university hospital between 
2000 and 2010. 1 year all-cause mortality (ACM) was analyzed in relation to predialysis 
serum sodium (sNa). We divided subjects into 3 groups according to sNa: Group1, < 
sNa 125; Group 2, sNa 125-134, Group 3, sNa ≥ 135 mEq/L. Patients with sNa levels 
>145mEq/L were excluded.
Results: The median value of sNa was 137 mEq/L (interquartile range 133-140 mEq/L). 
Chronic cormobidities including congestive heart failure (r = -0.215, P<0.001) and liver 
cirrhosis (r  = -0.174, P <0.001), late referral (r = 0.230, P <0.001), use of thiazide (r = 
-0.160, P = 0.001), lower estimated glomerular filtration rate (r = 0.152, P = 0.005) and 
albumin (r = 1.296, P = 0.002), higher white blood cell count (r = -0.136, P = 0.006) were 
associated with lower sNa levels in elderly patients after fully adjustment. One hundred and 
five (26.4%) patients had died at the 1-year follow up. Higher sNa level was associated with 
lower adjusted ACM in a continuous model (HR 0.433, 95% CI 0.261-0.718, P = 0.001). 
Group 1 had a higher mortality than normonatremia group in a categorical model (reference 
group 3, HR 5.048, P = 0.018) and mortality difference was not observed between group 
2-3 (reference group3, HR 1.511, P=0.161).
Conclusions: Predialysis hyponatremia was associated with increased 1-year mortality 
in elderly ESRD patients who initiated RRT. However, the higher mortality was only 
observed in elderly patients with severe hyponatremia (sNa < 125mEq/L). These finding 
suggested that compared to adults <65 years, other cormobidites or factors rather than sNa 
may affect mortality in elderly.
PUB374
Observation of the Correlation Between the Uremic Toxins with Clinical 
Feature in Uremia Patients  Mei Li,1 Qiong-Li Yin,1 Zhenda Zheng,2 Cai-Lian 
Cheng,3 Xun Liu,3 Cheng-Gang Shi.3  1VIP Healthcare Center, The Third 
Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, China; 2Cardiovascular 
Dept, The Third Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, China; 
3Nephrology Dept, The Third Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, 
China.
Background: To investigate the correlation between the uremic toxins with age, dialysis 
duration, and the different blood purification techniques on removal uremic toxins with 
hemodialysis (HD) and hemodiafiltration (HDF).
Methods: 72 cases of maintenance hemodialysis patients were observed, age 
28~80years(59.75±13.86), dialysis duration 4~192months ( 34.46±39.15), HD group (n 
= 50), HDF group (n = 22)( once 1~2 weeks).Before each conventional HD and HDF 
therapy, blood was sampled for small molecule water-soluble toxins BUN with automatic 
biochemical analyze, Middle molecular and macromolecular toxins (MMS) with Ultraviolet 
spectrophotometry, pentosidine(PENT) with enzyme-linked immunosorbent assay 
method(from ADL Company, USA), Protein-bound toxins, indoxyl sulfate(IS) with high 
performance liquid chromatography method.
Results: For HDF versus HD, there was no significant differences between BUN,MMS, 
pentosidine and IS.There was low positive correlation between MMS, PENT, IS and the 
age of the patients (r being 0.322, 0.263 respectively, P<0.05). MMS, PENT and IS were 
positively related with dialysis months (r being 0.406, 0.427, 0.742 respectively, P<0.05).
Conclusions: HD and HDF therapy maybe not good enough in clearing middle 
molecular toxins and protein-bound toxins, which results in their accumulation in patient’s 
body with the increase of dialysis course. It is recommended that better dialysis methods 
be adopted for patients who have received hemodialysis for a long time.
PUB375
Parathyroid Hormone Response in Chronic Hemodialysis Patients 
Converted from Intravenous Doxercalciferol to Oral Calcitriol Three Times 
a Week  Anna Jeanette Jovanovich,1,3 Annegret Howe,2 Morgan E. Marcuccilli,3 
Michel Chonchol.3  1Denver VA Medical Center; 2Fresenius Medical Care; 
3Univ of Colorado Denver.
Background: The purpose of this study was to characterize serum calcium, phosphorus 
and intact parathyroid hormone (iPTH) level response during the initial 24 weeks following 
conversion from intravenous doxercalciferol to oral calcitriol three times a week in a 
real-world setting.
Methods: Data was collected by a retrospective chart audit of end stage renal disease 
patients on hemodialysis in an outpatient chronic dialysis unit. We identified 33 chronic 
hemodialysis patients that had a record of treatment with intravenous doxercalciferol (6 
months) and conversion to oral calcitriol three times a week (6 months) between June 
2014 and May 2015 following a conversion algorithm. The change in serum calcium, 
phosphorus, and iPTH between treatment periods (intravenous doxercalciferol vs. oral 
calcitriol) was analyzed.
Results: Patient characteristics were as follows: mean age, 63±16 years; 39% women; 
and 55% black. The mean (SD) for serum calcium and phosphorus and median (IQR) serum 
iPTH during the 6 months of intravenous doxercalciferol were 8.8±0.7 mg/dL, 4.5±1.3 mg/
dL and 643 (384 to 908) pg/mL, respectively. The corresponding values after 6 months of 
oral calcitriol were 8.8±0.6 mg/dL, 4.5±1.2 mg/dL and 545 (368-812) pg/mL. None of the 
comparisons achieved statistical significance (p > 0.43 for all). 48% of participants were 
on cinacalcet during each of the treatment periods. The median (IQR) change in iPTH 
increased slightly among those patients receiving oral calcitriol and sevelamer (34 (-132 
to 147)) pg/mL while iPTH decreased among patients receiving oral calcitriol and other 
non-sevelamer binders (-102 (-294 to 155 pg/mL; p=0.17)).
Conclusions: This small retrospective study suggests that conversion from 
intravenous doxercalciferol to oral calcitriol using a conversion algorithm maintains 
iPTH within KDIGO recommended targets and does not appear to cause hypercalcemia or 
hyperphosphatemia. The clinical significance of higher iPTH values among those treated 
with oral calcitriol and sevelamer needs further study.
Funding: NIDDK Support, Veterans Administration Support
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Pregnancy and Dialysis in Chronic Kidney Disease – A Case Study 
Morgan E. Lindsay, Syed S. Haqqie, Arif Asif.  Albany Medical College.
Background: For women with underlying renal disease, pregnancy remains high risk. 
Case series have provided guidance on the interdisciplinary management of these patients. 
Herein, we report one institution’s management of five patients requiring dialysis in 
pregnancy. The present case series includes patients with chronic kidney disease secondary 
to lupus nephritis (n=2), cystinosis (n=1), malignant hypertension (n=1), and diabetic 
nephropathy (n=1) . All five patients, one of whom was on dialysis prior to pregnancy 
and the rest were CKD 5 were placed on six-times weekly dialysis upon the presentation 
with pregnancy. Three of the patients, two with Lupus and one with Malignant HTN 
delivered infants with whom they were able to discharge home after NICU stays, two 
patients one with cystinosis and one with DM delivered infants who subsequently died in 
the NICU secondary to prematurity. All 5 patients post-delivery continued on maintenance 
hemodialysis. Although improving, maternal and fetal outcomes in those with chronic 
kidney disease remain variable. Our experience adds to the growing literature on dialysis 
for chronic kidney disease in pregnancy.
Methods: Restrospective study of patients at one institution.
Results: Out of five pregnancies three had successful outcome with intensive dialysis.
Conclusions: Pregnancy is rare in dialysis patients and outcomes are generally poor. 
There are improved results with intensive dialysis and multidisciplnary approach to the 
management.
PUB377
When Shall the Advanced Chronic Kidney Disease Patients Start Dialysis? 
Lee Ying Yeoh, Sri Fairuz baizuri Saifful, Bek Choon How, Yan Lun Allen Liu, 
Milind Nikam.  Medicine, Khoo Teck Puat Hospital, Singapore.
Background: Recent guidelines suggest dialysis should be initiated when estimated 
glomerular filtration rate (eGFR) drops below 10-12ml/min. The aim of the present study 
was to analyse outcomes of those initiating dialysis at very low eGFRs.
Methods: A single center, prospective study of new ESRD patients who were initiated 
on dialysis between 2012 –2014 and dialysis was performed for >90 days. The patients 
were categorized into 2 groups according to eGFR ≤ 5 and > 5ml/min upon initiation. The 
patients with incomplete data, and those who underwent transplantation were excluded.
Results: A total of 251 patients were included with mean age of 59.0 ± 11.9 years, 
mean eGFR of 5.4 ± 2.9ml/min; 57% were males and 51.4% were Chinese. Majority started 
on hemodialysis (81.7%) and 69.7% were unplanned. The survival rate till May, 31 2015 
was 88.4%; 61% were initiated when eGFR ≤ 5 (mean 3.6±1.1 ml/min) and 39% with 
eGFR > 5 (mean 8.3 ± 2.6 ml/min). Dialysis vintage was shorter in the group with eGFR 
≤ 5 (18.5 ± 9.5 vs. 21.7 ± 11.1 months). The patients with eGFR ≤ 5 had lower Charlson 
Comorbidity Index (4.0 ± 1.3 vs. 4.7 ± 1.2), and hemodialysis was preferred (90.9% vs. 
67%). The disease burden was significantly lower in the group with eGFR ≤ 5, including 
diabetes mellitus (72.1 vs. 88.7%), ischemic heart disease (23.4% vs. 37.1%) and peripheral 
arterial disease (4.5 vs. 12.4%). However, there were trends showing that these patients 
were younger, had higher serum albumin and shorter hospitalization for index admission. 
Underlying diabetes, ischemic heart disease, modality selection and dialysis vintage 
remained significant after adjusted. Mean survival for both groups were comparable (36.3 
months, 95% CI: 34.4-38.2 vs. 34.5 months, 95% CI: 32.0-37.0). Among the patients who 
survived, 97.7% remained on their initial modality.
Conclusions: Our study suggests that the ESRD patients without significant morbidities 
may be able to delay dialysis initiation without significant short term adverse outcomes. 
Further studies are required.
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The Incidence and Type of Cancer in Patients with End-Stage Renal 
Disease: A Prospective Cohort Study for End-Stage Renal Disease in Korea 
Kyung Don Yoo,1 Hajeong Lee,1 Jung Pyo Lee,1 Dong Ki Kim,1 Shin-Wook 
Kang,2 Chul Woo Yang,3 Yong-Lim Kim,4 Chun Soo Lim,1 Kwon Wook Joo,1 
Yon Su Kim.1  1Seoul National Univ; 2Yonsei Univ; 3The Catholic Univ; 
4Kyungpook National Univ.
Background: In patients with end-stage renal disease, urinary tract kidney cancer is 
known to be higher than in the general population. However, the incidence and type of cancer 
is affected by variable factor such as age, gender, ethnic differences. Moreover, the causality 
of dialysis and cancer incidence in certain type of cancer is still needed to be clarified.
Methods: A total of 5,225 patients in the clinical research center for ESRD cohort 
were enrolled from Aug 2008 to Dec 2014. The primary outcome is to compare the cancer 
incidence rate of ESRD patients with the general population. We obtained cancer incidence 
data from National Cancer Information Center Registry in healthy counterpart.
Results: A total of 2,200 incident and 3,035 prevalent dialysis patients was included 
the analysis. The mean follow up duration was 25.6 ± 16.2 months, and 116 (2.2%) patients 
were diagnosis with cancer during the observation periods. ESRD with cancer group was 
significantly older, longer dialysis duration and more comorbidity than control group. 
The incident rate of cancer in prevalent dialysis patients was higher than those in incident 
dialysis patients (2.5% vs.1.3%, p=0.002). The proportion of primary organ was highest in 
digestive organ (33.6%) including stomach, colon. The mean time to discovery of cancer 
from dialysis initiation was 58.6 months in digestive cancer, 52.0 months in urinary tract 
cancer. The standardized incidence ratio (SIR) of overall cancer was 0.94 [95% CI: 0.72 
–1.19]. Urinary tract cancer showed the highest SIR [SIR: 4.7, 95% CI: 4.42–8.19] and 
had the second highest frequency (16.1%). Interestingly, the highest frequency (33.3%) 
of digestive organ cancer showed no difference in the incidence of cancer compare to the 
general population [SIR : 0.607, 95% CI: 0.36–0.94].
Conclusions: Further research was needed to compare the organ-specific cancer 
incidence of ESRD patients with the general population. The screening test could be 
necessary for digestive and urinary tract cancer.
PUB379
The Role of Social Support in Hemodialysis Patients  Gun Woo Kang. 
Internal Medicine, Catholic Univ of Daegu School of Medicine, Daegu, Korea.
Background: A number of patients with End-Stage Renal Disease (ESRD) have 
significant impairment in social support. Especially, the limited function of patients with 
hemodialysis (HD) prevents them from social activities and even makes them social 
withdrawal. There are few studies of the factors affecting the social support in HD patients. 
The aim of the current study was to identify the clinical and psychosocial factors including 
quality of life related to impaired social support in HD patients.
Methods: The 101 participants on HD from the Daegu Catholic University Medical 
Center were assessed from September in 2013 to September in 2014. Patients on HD for 
acute kidney injury were excluded from this study. Multidimensional Scale of Perceived 
Social support(MSPSS) was used for evaluating patients’ social support. Psychosocial 
factors including quality of life, anxiety, depression and sleep disorder were evaluated. 
Laboratory and clinical information including hemoglobin, vitamin D (25(OH)D, 
1,25(OH)2D3), albumin, Kt/V, normalized protein catabolic rate, ferritin, bone mass index, 
duration of HD were assessed. Stepwise multivariate logistic regression with backward 
selection was performed.
Results: The mean of MSPSS (social support) score was 36.8±9.3. In subgroups of 
social support, the MSPSS-family, MSPSS-friend, and MSPSS-medical team scores were 
14.79±4.28, 10.44±4.76, and 10.74±4.39, respectively. The variables showed significant 
association with social support were quality of life (r=0.332, p=0.001), depression (r=-0.290, 
p=0.003), anxiety (r=-0.372, p<0.001), and serum creatinine (r=-0.270, p=0.007). Multiple 
regression showed that quality of life (95% CI; 0.615~19.799, p=0.037) and serum creatinine 
(95% CI; -1.543~-0.319, p=0.003) were independent predictors of impaired social support.
Conclusions: This study explored the determinants of high susceptibility to the impaired 
social support in HD patients. We found that the impaired social support is associated 
with the quality of life and serum creatinine. Further study will be needed because of the 
possibility of different results depending on culture and ethnicity. As well as, we should 
consider the psychosocial interventions to improve the impaired social support.
PUB380
Use of Portable Fundoscopic Photography to Screen for Diabetic 
Retinopathy in the Hemodialysis Unit  Beckie Michael,1 Yasmin G. 
Brahmbhatt,2 Nika Bagheri,3 Laura T. Pizzi,4 Benjamin Leiby,4 Anne P. 
Murchison.3  1Marlton Nephrology and Hypertension; 2Thomas Jefferson Univ; 
3Wills Eye Hospital.
Background: Over 40% of dialysis patients have diabetes, yet only 25% get annual eye 
exams. Due to the frequency and duration of visits to dialysis centers, patients on dialysis 
likely have increased barriers to receiving eye exams and other recommended preventive 
care. This study evaluated the need for ophthalmic care, barriers to care, and prevalence 
of diabetic retinopathy (DR) in this population.
Methods: Prospective cohort study at two dialysis centers (1 urban, 1 suburban). A 
patient survey (measuring eye care utilization, barriers to eye care, and self-reported visual 
functioning) and eye screening (visual acuity test and non-mydriatic fundus photos) was 
completed for diabetics who consented to the study. Other variables were obtained from 
medical records and included demographics, duration of diabetes, co-morbidities, and 
insurance type. Descriptive analyses examined barriers to eye care and presence of DR. 
Qualitative data on satisfaction with eye screening were also obtained from both staff 
and patients.
Results: 58 patients (79.5% of diabetics at the two sites) were screened. Of the readable 
fundus photos, 50% had DR and only 10% had no ocular abnormalities. The majority (64%) 
knew diabetes can cause severe eye problems. Only 11% of patients reported that getting 
an annual eye exam is a priority. The most commonly reported barriers to eye care were 
cost (89%) and transportation difficulty (82%). Qualitative data indicated that staff and 
patients were overall very satisfied with the program.
Conclusions: There is a significant unmet need for ophthalmic care among diabetics 
receiving dialysis. Since cost and transportation were reported as main barriers to eye 
exams, providing the screening at dialysis centers could improve adherence to eye care 
thereby improving ophthalmic and other health outcomes.
Funding: Private Foundation Support
PUB381
Recent Dialysis Beginning Is a Mortality Predictor for In-Patients 
Treatment  Nadia Guimaraes- Souza, Ana C M S Ramos, Thais Nemoto 
Matsui, Adriano Luiz Ammirati, Maria C.C. Andreoli, Fabiana Dias Carneiro, 
Marisa Petrucelli Doher, Bento C. Santos.  Dialysis Center, Hospital Israelita 
Albert Einstein, Brazil.
Background: Acute kidney failure occurs in 5% of hospital admitted patients. 
Dialysis need during patients stay in hospital is associated with higher mortality risk. 
The main objective was to evaluate patients profile in our dialysis center and the impact 
in the outcomes.
Methods: Prospective observational study. A check list was applied for every patient 
originating from intensive care or in clinics who need hemodialysis section in our dialysis 
center from 2010 to 2014. Patients were older than 18 y. o. and signed a consentient term. 
For analysis purpose patients were assigned as undergoing previously dialysis (PD) or 
patients that initiated dialysis in this hospital stay (ND). The possible outcomes were: kidney 
recovering function (KRF), kidney transplantation (KT), mortality (M) and maintained 
dialysis (MD). 437 patients were included. 231 (53%) were patients PD, 47% of ND.
Results: From all patients in our follow-up 27% were from kidney transplant program 
(KTP) and 33% were from liver transplantation program (LTP). 15 % started dialysis 
with arterial-venous fistula, 14% tunneled cuffed catheter  and 51% with non-tunneled 
cuffed catheter. PD groups had more hypertension and were more likely came from KTP 
(p<0.01). ND group had significantly more C hepatitis (p<0.01) and came from LTP. In 
the outcomes we observed ND patients had higher mortality (25% vs 13%; p<0.01) and 
also significantly higher KRF (63% vs 10%; p<0.01). MD outcome was more prevalent 
in PD group (47% vs 11%; p<0.01) as expected. When risk factors for our outcomes were 
analyzed patients coming from KTP, LTP and positives for C hepatitis had significantly 
higher KRF. Mortality were similar among the groups. Hypertensive patients had worse 
outcomes. Recovery time in days was shorter in ND group (56±140 vs 148±283;p<0.01).
Conclusions: It’s well known that patients treated with chronic dialysis have an 
increased risk of death. Surprisingly we observed a higher mortality rate on the ND group. 
Hypertension is a risk factor for worse outcomes. Check list is an important tool for analyzing 
and follow patients undergoing dialysis.
PUB382
Awareness and Beliefs Towards Organ Donation in Chronic Kidney Disease 
Patients in Western India  Manish Ramesh Balwani.  Nephrology, IKDRC, 
Ahmedabad, Gujarat, India.
Background: In India, there seems to be paucity of information and awareness 
regarding organ donation in general population. The study was conducted to see the 
awareness and beliefs towards organ donation programme in chronic kidney disease 
patients in western india.
Methods: The author conducted a cross sectional study among 85 CKD patients 
to evaluate the knowledge about and attitude towards organ donation at a large tertiary 
academic hospital in western india. The author used a questionnaire that included items 
on knowledge, attitude and demographics.
Results: Age of respondents participated in study ranged from 15 to 75years. Around 
2/3rd participants were males. About eighty-two percent belonged to hindu religion. All 
were aware of term organ donation and cadaver donation. About 47% of people heard about 
organ donation through hospital or from doctor. The audiovisual media such as television 
(21%) followed by newspaper/magazines (14%) were the major source of information about 
organ donation. Strikingly, radio was not the source of information to any of the respondents 
who participated in this study, despite radio being one of the most common medium of mass 
communication in india. Fourteen percent of people heard about organ donation through a 
friend or colleague. Almost 1/3 rd of patients were unaware about any legislation regarding 
organ donation. All respondents felt that the organs should go to the needy irrespective of 
their religion. About 70% feel that medical colleges/government institutions should make 
decisions about organ donation in case of unclaimed dead bodies. About 64.70% believe 
that there is a danger that donated organs could be misused, abused or misappropriated.
Conclusions: The study shows about 64% of our participants believe that there is a 
danger that donated organs could be misused, abused or misappropriated.There seems to 
be paucity of information and awareness regarding organ donation among CKD patients. 
Mass media, religious and political leaders may be involved to maximize awareness about 
organ donation.
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Enhancing Patient Engagement in Future Clinical Trials – The Effects of 
Age and Ethnicity  Territa Santhakumaran, Kieran Mccafferty.  Renal, Royal 
London Hospital, London, United Kingdom.
Background: Increasing patient engagement from ethnic minority populations is 
crucial to the widespread applicability of research findings, but this represents a challenge 
in nephrology clinical research. Ethnicity, socio-cultural and language barriers along with 
a lack of understanding and awareness of clinical trials are potential factors that affect 
patient involvement in clinical trials.
Methods: We developed a patient survey in English, Urdu and Bengali to represent 
our ethnically diverse population in East London to explore the attitudes and understanding 
of clinical research using a 1-7 scoring system to rate various statements about research. 
The surveys were offered to all patients attending the haemodialysis and renal outpatients 
department over a 2 week period.
Results: 151 forms were completed, 143 in English, 7 in Bengali and 1 in Urdu. 
41% of forms were from patients who attended transplant clinic and 31% from patients 
who attended for haemodialysis. Overall there was a strong message that patients wanted 
more trials in nephrology and felt that taking part in trials would help them take a more 
active role in their health. They also felt there was a lack of information on how to access 
research opportunities. Of those who completed the survey there was no significant ethnicity 
differences in their attitudes and understanding of clinical research, however transplant 
patients who identified themselves as White British were significantly more likely to take 
part in the survey (p<0.02). Patients who identified themselves as Black British were 
significantly less likely to take part in the survey (p<0.02). In the dialysis cohort, patients 
who identified themselves as White British were significantly more likely to take part in 
the survey (p<0.02). Whereas patients who identified themselves as Bangladeshi were 
significantly less likely to take part in the survey (p<0.04). Age did not appear to have an 
effect on patients’ perception and understanding of clinical trials.
Conclusions: From our work it is clear that there is a patient led demand for greater 
engagement in translational research. However, challenges remain in engaging ethnic 
minority cohorts in clinical research.
Funding: Other NIH Support - National Institute for Health Research
PUB384
Deferred Educational App Personalization Increases Registration 
Completion  Daniel Schwartz,1 Chan Kruse.2  1Faculty of Medicine, Univ of 
British Columbia, Vancouver, BC, Canada; 2QxMD, Vancouver, BC, Canada.
Background: ‘Read by QxMD’ (http://qxmd.com/read) is an app that curates the 
nephrology literature and personalizes reading recommendations based on a clinician’s 
or researcher’s interests. In order to provide highly accurate recommendations, the app 
must collect content preferences such as preferred journals and topics. In addition, it 
must collect email address and personal identifiers in order to complete registration and 
offer CME. When the registration process is too onerous, mobile app users may not 
complete registration. If the registration process fails to collect necessary user data, this 
may negatively impact the educational value of the app. We hypothesized that allowing 
users to delay providing personal information until after they set their preferences would 
increase registration completion.
Methods: We randomly assigned all users registering on the Android version of Read 
to two different registration processes. In version 1, “upfront personalization”, users are 
asked to provide personal identifiers prior to setting their preferences, while in version 2, 
“deferred personalization”, users set preferences first and after this has been completed are 
asked for personal identifiers. The Leanplum SDK was used to implement and automate 
the randomization of alternate registration pathways. The primary outcome was completion 
of registration.
Results: Between April 6, 2015 and June 1, 2015, a total of 5660 users who registered 
using the Android version of ‘Read’ were randomized with 2824 users randomized to upfront 
personalization and 2836 to deferred personalization. Upfront personalization yielded a 
47.4% (95% CI 46.0 to 48.8) registration completion rate versus 50.7% (95% CI 49.0 to 
52.4) with deferred personalization (p < .05).
Conclusions: A strategy of deferred collection of personal identifiers yielded slightly 
higher completion rates. To maximize user registration when onboarding users to educational 
medical apps, consider deferring the collection of personal information until user preferences 
have been provided. Further research is required to maximize app registration when data 
requested is extensive as in ‘Read’.
PUB385
Onconephrology Abstracts Trends in ASN Kidney Week 2012-2014 
Jyotsana Thakkar, Rimda Wanchoo, Kenar D. Jhaveri.  Nephrology, Hofstra 
NSLIJ School of Medicine.
Background: Onconephrology is an emerging new specialty of nephrology. The ASN 
created a forum dedicated to the field of Onconephrology in 2011 to improve collaborative 
care for cancer patients with kidney disease. One of the aims was to allow for collaborative 
research strategies in the field of onconephrology. However, the number of onconephrology 
related abstracts accepted to be presented at ASN Kidney Week (ASN-KW) 2012-2014 
is not known.
Methods: We reviewed the abstracts presented in the ASN-KW over past 3 years from 
2012-2014 which were related to Onconephrology. Search terms used to identify abstracts 
included cancer, myeloma, chemotherapy, tumor lysis, paraneoplastic syndrome and 
hypercalcemia. They were then categorized into: basic science, chemotherapy, myeloma, 
epidemiology, electrolyte disorders, AKI, tumor lysis, GN, paraneoplastic syndromes and 
obstructive uropathy. Abstracts were also categorized based on study design.
Results: 
Figure above breaks down the total number(n) of abstracts( Y axis) in the last 3 
years presented at ASN-KW by category. There has been an increase in the number of 
onconephrology abstracts over last 3 years. A total of 175 abstracts were reviewed. In 2012, 
there were 50 onconephrology related abstracts, increased to 54 in 2013 and 71 in 2014. 
Abstracts related to basic science(16%), chemotherapy toxicities(16%), myeloma(16%) and 
epidemiology (16%) dominated most of the accepted abstracts. Of the clinical abstracts, 
> 50% were case reports, 41% were retrospective studies, 4.5% database studies and 
<1% RCT.
Conclusions: Over the last 3 years, we have seen a growing trend in the number of 
abstracts submitted in the ASN-KW related to the field of onconephrology. We suggest 
creating a separate section dedicated to onconephrology in the ASN meetings to allow for 
collaborative research and greater understanding of cancer related nephrology, leading to 
improved patient outcomes.
PUB386
Patients-Ini t iated Educat ional  Research in  a  Digi ta l  Age 
Chayakrit Krittanawong,1 Zhen Wang,2 Sakkarin Chirapongsathorn,3,4 Hua 
Ann Jenny Lu.5  1Div of Cardiovascular Disease, Mayo Clinic, Rochester, MN; 
2Dept of Healthcare Policy and Research, Mayo Clinic, Rochester, MN; 3Div 
of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; 4Div of 
Gastroenterology, Dept of Medicine, Phramongkutklao Hospital and College 
of Medicine, Royal Thai Army, Bangkok, Thailand; 5Div of Nephrology, 
Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Background: The emergence of web-based technology in the digital age has become 
popular in the healthcare industry, particularly in the educational research field. A web-based 
technology can bridge the educational gap between researchers and patients.
Methods: We aimed to develop a user-friendly interface between a virtual community 
that can be used by patients and researchers and a preliminary knowledge-building activity. 
Wikiheart is a web research environment that creates a real-time community between 
researchers and patients without geographical restrictions.
Results: Once patients have registered for free, the system allows these users to write 
their own articles or to edit other articles, which often leads to thought provoking medical 
research questions. Wikiheart also demonstrates a novel approach to population science 
that is based on huge databases with multiple cloud servers that reach the web research 
community. Nowadays Wikiheart has more than one million visitors, and serves as an 
educational web technology that provides its users with both a variety of learning methods, 
and several areas of research focus.
Conclusions: Wikiheart is an innovative web-based program for conducting educational 
research in the digital community. It is an excellent tool for researchers and patients to 
generate new hypotheses via the scientific method in an online environment.
J Am Soc Nephrol 26: 2015 Publication Only
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Detailed Subject Lines Increase Engagement with Educational Emails 
Daniel Schwartz,1 Chan Kruse,2 Stephane Boyer.2  1Faculty of Medicine, Univ 
of British Columbia, Vancouver, BC, Canada; 2QxMD, Vancouver, BC, Canada.
Background: ‘Read by QxMD’ (http://qxmd.com/read) is an educational service 
and mobile app that curates the nephrology/medical literature and personalizes reading 
recommendations based on a clinician’s or researcher’s interests. Each week, registrants 
receive an email alert that highlights the most popular medical articles in the reader’s 
clinical or research area of specialty. The content of email subject lines have been shown 
to have a significant impact on whether email is read or deleted prior to being read. 
We hypothesized that providing more details in the subject line would result in greater 
engagement with the email content.
Methods: We randomly assigned all emails sent containing the “Most Read” articles 
of the week to either a generic/consistent email subject line or a subject line that included 
the title of the most commonly read article of the week (detailed/variable). SendGrid, an 
email delivery service provider, was utilized for email delivery and to automate the subject 
line randomization. The primary outcome was email open rate. Secondary outcome was 
email click through rate.
Results: Between January 7, 2014 and May 1, 2015, a total of 1,287,442 emails were 
sent. 643,475 were generic/consistent and 643,967 were specific/variable. A specific/variable 
email subject line yielded a 70.76% (95% CI 70.68 to 70.84) open rate versus 48.85% (95% 
CI 48.76 to 48.94) with an email subject line that was generic (p < .01). A detailed/variable 
subject line did not increase click through rate as compared to a generic/consistent subject 
line, 9.87% (95% CI 9.82 to 9.92) vs 9.85% (95% CI 9.8 to 9.9) p > 0.05.
Conclusions: Including details about the content of an educational email in the subject 
line resulted in a greater email open rate but did not increase the click through rate. Further 
research is required to increase engagement with the content of educational emails provided 
by the ‘Read’ educational service.
PUB388
Teaching Ethics and EBM in the Medical School: Case Discussion as a 
Teaching Tool on End-of-Life Issues – Dialysis or Palliative Treatment in 
a 92 Year Old Patient?  Giorgina B. Piccoli,1 Laura Sacchetti,2 Laura Verze,2 
Franco Cavallo.2  1SS Nephrology, Clinical and Biological Sciences, Univ of 
Torino, Italy; 2Course of EBM and Ethics, Univ of Torino, Italy.
Background: History of Nephrology follows and influences the development 
of Bioethics and offers insights for teaching: the first Ethics Committee (the “God’s 
Committee”), brain death, the sale of organs, the limitation of resources, up to the global 
needs (as in the 0-by-25 project). Case discussion within the Medical school may be a 
useful tool to acquire bioethical skills and analytical tools.
Methods: Discussion of a clinical case: patient in his nineties, high comorbidity, good 
cognitive status (writer), GFR 10 mL / min. The case raises questions about the choice 
diet-dialysis-palliation. 50 medical students of the curricular course of ethics and EBM are 
tutored for an academic year through the collection of information from databases (Pubmed), 
web, talk with experts, tutors and teachers. The analysis is performed according to the 4 main 
ethical principles (beneficium, non maleficum, justice, autonomy) to a narrative approach.
Results: The students produces a text, here summarized: from a clinical standpoint, 
beneficium and non-maleficium suggest to postpone dialysis (intent-to-defer) with the 
start of low-protein diet (equal to or greater survival, minimal damage, favorable context). 
Distributive justice favors less expensive therapies (diet, palliation); in the context of 
individual justice, the start of dialysis, if necessary, has a role in life support. The patient, 
by consulting more doctors, has expressed his desire for autonomy. Considering the chronic 
disease, the intellectual level, a doctor-patient relationship of “shared decision making” 
is advisable. Sharing the choice improves results, reduces dropout rate of dialysis, if 
undertaken. Since the four principles of bioethics take on different priorities depending 
on the socio-cultural context, the approach to the patient will be modulated in a narrative 
than his views or religious beliefs.
Conclusions: Nephrology offers suggestions for bioethical discussion. Conversely, 
bioethics offers analytical tools for the analysis of complex decisions such as dialysis in 
the “very old”.
PUB389
SLIT2 Is Upregulated in Proximal Tubules and Urine following Folic Acid 
Induced Kidney Injury  Jonathan Street, Ana C. Souza, Xuzhen Hu, Yuning 
George Huang, Peter S.T. Yuen, Robert A. Star.  NIDDK, Bethesda, MD.
Background: SLIT2, signaling via ROBO receptors, was originally described for 
its role in neuronal guidance, and has since been linked with leukocyte chemotaxis and 
angiogenesis. As both processes might be involved in kidney injury and repair, we tested 
whether SLIT2 signaling is involved in folic acid induced kidney injury.
Methods: Eight-week old male CD-1 mice were injected i.p. with 250 mg/kg folic 
acid. Groups were euthanized 0-7, or 14 days later. Expression levels were determined 
by RT-qPCR and western blot of whole kidney lysates. Localization was determined by 
immuno-histochemistry. In a second experiment mice received folic acid and then 70 mg/kg 
i.p. recombinant human SLIT2 or vehicle on days 2, 4, and 6. On day 14 GFR was measured 
in conscious mice by transcutaneous fluorescence monitoring of FITC-Sinistrin elimination.
Results: Following folic acid injection, whole kidney SLIT2 mRNA and protein 
levels decreased two-fold by day 3, whereas SLIT2 protein increased in proximal tubule 
cells by immunohistochemistry on day 3. Expression of SLIT2 protein was observed in 
the proximal tubule derived HK-2 cell line, and urinary SLIT2 protein was increased by 
2-fold 2 to 7 days after folic acid injection, supporting tubules as a site of SLIT2 synthesis. 
In a separate experiment mice were given folic acid, then recombinant human SLIT2 i.p. 
on days 2, 4, and 6. Kidney function measured directly as GFR or indirectly via BUN 14 
days after injection was not significantly improved by SLIT2 treatment.
Conclusions: Folic acid induced injury increased expression of SLIT2 in proximal 
tubule cells followed by detection of SLIT2 in the urine, which points to SLIT2 as a 
candidate urine biomarker for tubular injury. Amelioration of injury with systemic SLIT2 
treatment was not observed, suggesting better utility as a marker than a mediator.
Funding: NIDDK Support
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Urinary Trefoil Factor 3 Is Significantly Associated with Renal Tissue 
Fibrosis in Patients with Tubulointerstitial Nephritis  Keiko Tanaka, 
Hitoshi Sugiyama, Toshio Yamanari, Ayu Akiyama, Akifumi Onishi, Masashi 
Kitagawa, Hiroshi Morinaga, Yoko Kikumoto, Tatsuyuki Inoue, Jun Wada. 
Dept of Medicine and Clinical Science, Okayama Univ Graduate School, 
Okayama, Japan.
Background: Trefoil factor 3 (TFF3) is a small peptide involved in mucosal protection. 
TFF3 is widely expressed in multiple tissues including kidney. Previous studies have 
suggested that serum and urinary TFF3 significantly increases in patients with chronic 
kidney disease and that urinary TFF3 level decreases in rats with acute kidney injury. 
However, it is unclear whether serum or urinary TFF3 is associated with human renal tissue 
injury. The aim of this study is to elucidate the relationship between serum and urinary 
TFF3 levels and the degree of renal tubulointerstitial injury.
Methods: The total study population included 52 patients (tubulointerstitial nephritis: 
31, minor glomerular abnormalities and thin basement membrane disease as controls; 21) 
who underwent renal biopsy. The serum and urinary TFF3 concentrations were determined 
by a specific ELISA. The degrees of tubulointerstitial cell infiltration and fibrosis were 
semiquantitatively graded in biopsy specimens and defined by the inflammation score and 
the fibrosis score, respectively. An immunohistochemical analysis was performed to reveal 
the localization of the TFF3 protein.
Results: The median serum and urinary TFF3 levels of the disease group were 
significantly higher than those of the controls (p=0.002 and p=0.008, respectively). A 
statistically significant positive correlation was observed between the urinary TFF3 levels 
and the renal fibrosis score in the disease group. However, there was no correlation between 
the serum or urinary TFF3 level and the renal inflammation score in disease group. TFF3-
positive cells were observed in the renal tubular epithelium.
Conclusions: The data indicate that serum and urinary TFF3 levels are significantly 
increased and, in particular, that urinary TFF3 could reflect renal tissue fibrosis in 
patients with tubulointerstitial nephritis. Further studies are required to elucidate the 
precise distribution of renal TFF3 protein and mRNA, and the mechanism underlying the 
contribution of TFF3 to renal fibrosis.
PUB391
Induction of Epithelial-to-Mesenchymal Transition and Fibrosis Signals 
via AKT and Peroxisome Proliferator-Activated Receptor Pathway in 
Renal Tubular Cells Induced by a Plasticizer Di(2-ethylhexyl) Phthalate 
Shing-Hwa Liu,1 Li-Chen Huang,1 Bo-Lin Chen,1 Chih-Kang Chiang.1,2  1Inst 
of Toxicology, College of Medicine, National Taiwan Univ, Taipei, Taiwan; 
2DIDT, NTUH, Taipei, Taiwan.
Background: Di(2-ethylhexyl)phthalate (DEHP) is a plasticizer and a probable 
endocrine disruptor. More than two million tons of DEHP were used each year worldwide. 
Recent studies have suggested that DEHP has potential adverse effects on the liver, kidney, 
and reproductive system. It could also cause carcinogenicity and developmental toxicity. 
DEHP exposure might exacerbate kidney progression. Tubular epithelial-to-mesenchymal 
transition (EMT) is recognized to play pivotal role in the process of renal fibrosis. However, 
the mechanisms of nephrotoxicity induced by DEHP remain unclear. Here, we investigated 
whether DEHP could induce renal fibrosis via EMT process.
Methods: A rat renal proximal tubular cell model (NRK-52E cells) was used to 
evaluate EMT and fibrosis signaling. Cell morphology was observed by microscope. 
Cell viability evaluated by MTT assay. The molecule signals of EMT and fibrosis were 
analyzed by flow cytometry, confocal laser scanning microscopy, immunocytochemistry, 
and Western blotting.
Results: Treatment with DEHP (5-25 µM) for 72h caused the change in renal tubular 
cell morphology shifting to spindle-like shape. DEHP did not induce cell apoptosis, but 
significantly induced G2/M cell cycle arrest. Moreover, the expressions of vimentin, 
α-SMA, and CTGF, which are the markers of the mesenchymal phenotype, were 
significantly increased. The expressions of E-cadherin, a maker of epithelial cells, was 
significantly decreased by DEHP. DEHP could also inhibit the expression of peroxisome 
proliferator-activated receptor (PPAR)α and γ. The phosphorylation of Akt and Smad 
2/3 was also significantly increased by DEHP. Notably, treatment with MK2206 (an Akt 
inhibitor) significantly inhibited DEHP-induced phosphorylation of Akt and EMT. Further 
investigation revealed that MK2206 suppressed the expression of Akt downstream proteins 
(NF-ĸB and GSK3).
Conclusions: These findings suggest that DEHP is capable of inducing the EMT process 
through AKT and PPAR signaling pathway, which may lead to renal fibrosis.
Funding: Government Support - Non-U.S.
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Src Kinase Is a Potential Therapeutic Target in Renal Fibrosis  Yanli Yan,1,2 
Murugavel Ponnusamy,2 Evelyn Tolbert,2 George P. Bayliss,2 Shougang Zhuang.2 
1Dept of Emergency Medicine, Shanghai East Hospital, Tongji Univ School of 
Medicine, Shanghai, China; 2Dept of Medicine, Rhode Island Hospital and 
Alpert Medical School, Brown Univ, Providence, RI.
Background: Increased activity of Src, a non-receptor tyrosine kinase, has been 
associated with the pathogenesis of renal tumors and some glomerular diseases, but its 
role in renal interstitial fibrosis remains elusive.
Methods: In this study,we investigated the effect of Src inhibition on renal interstitial 
fibroblast activation in vitro and renal fibrogenesis in a murine model of unilateral ureteral 
obstruction and the mechanisms involved.
Results: Exposure of cultured renal interstitial fibroblasts (NRK-49F) to PP1, a 
selective inhibitor of Src, resulted in decreased expression of α-smooth muscle actin 
(α-SMA), and fibronectin and collagen I, in response to serum- or transforming growth 
factor-b1(TGF-b1). Silencing Src with siRNA also inhibited expression of those proteins. 
Furthermore, inhibition of Src activity blocked renal fibroblast proliferation as indicated 
by a dose-dependent down-regulation of cyclin D, cyclin E and PCNA (proliferating cell 
nuclear antigen), three proteins involved in cell cycle progression and up-regulation of p21 
and p27, two major cell cycle inhibitors. In a murine model of renal interstitial fibrosis 
induced by unilateral ureteral obstruction (UUO), the active form of Src (phopsho-Src 
Tyr416) was upregulated in the fibrotic kidney, and its inactivation with PP1 reduced 
renal fibroblast activation and attenuated extracellular matrix protein deposition. Src 
inhibition also suppressed expression of TGF-bR1, activation of Smad3 and STAT3, and 
phosphorylation of epidermal growth factor receptor. Finally, PP1 treatment reduced renal 
epithelial cells arrested at G2M phase of cell cycle, a phenotype that produces profibrotic 
growth factors/cytokines, after UUO injury.
Conclusions: Our results demonstrate the importance of Src in mediating renal 
interstitial fibroblast activation and renal fibrogenesis and suggest Src as a potential 
therapeutic target for treatment of chronic renal fibrosis.
Funding: NIDDK Support
PUB393
MiRNAs as Novel Biomarkers and Therapeutic Target in Chronic Kidney 
Disease  Laura Martín-Gómez,1 Elia Aguado fraile,1 Edurne Ramos,1 Elisa 
Conde,1 Esperanza Macarena Rodriguez serrano,1 Sara Gimenez-Moyano,1 Sara 
Jimenez alvaro,2 Fernando Liano,2 Maria Laura Garcia-Bermejo.1  1Biomarkers 
and Therapeutic Targets Unit, IRYCIS, Madrid, Spain; 2Nephrology, Ramon y 
Cajal Hospital, Madrid, Spain.
Background: Statistical meta-analysis demonstrates that episodes of Acute Kidney 
Injury(AKI) eventually promote development of chronic renal damage(CKD).So far,there 
aren´t quantifiable and accurate biomarkers to predict the evolution of AKI to CKD,what 
would enable clinicians to monitor these patients.Our group has validated a combination of 
serum miRNAs as AKI biomarkers, including:miR-127,miR-101,miR-210,miR-126,miR-
146a,miR-26b,miR-29a,miR-10a,miR-93 and miR-27a. Here we have identified some 
of this miRNAs as novel biomarkers for CKD and potential new therapeutic targets for 
renal fibrosis.
Methods: For this purpose,in vitro experimental model of proximal tubular epithelial 
cells under TGFb treatment as pro-fibrotic stimulus and human samples from patients with 
established CKD(stage 1-5)have been used.
Results: We characterize in vitro model by estimation of:loss of E-cadherin 
expression,increase of α-SMA expression, expression of collagen I and fibronectin and 
activation of metalloproteinase(MMP-2 and MMP-9 ),by qRT-PCR and zymogram.
Furthermore, we have modulated miR-127 in TGFb treated cells, pre-miRs and anti-miRs 
transfection, finding that miR-127 overexpression maintains epithelial phenotype and miR-
127 blockage induces epithelia-mesenchymal transition(EMT), estimated as mentioned 
above. In addition, we have determined the expression of miRNAs combination in the serum 
of CKD patients by qRT-PCR and statistical correlations with clinical data indicate:1) miR-
127 is downregulated along CKD development;2) miR-126 and miR-26b are significant in 
diabetic nephropathy;3) miR-146 discriminates patients exhibiting dyslipidemia.
Conclusions: In summary we have identified miRNAs involved in renal fibrosis 
development as well as miRNAs correlated with CKD features,suggesting that miRNAs 
could have a potential clinical use for CKD patient’s management and they can be point 
out as novel therapeutic target in this clinical context.
Funding: Other NIH Support - Instituto de Salud Carlos III (FIS 12/00094)
PUB394
Clofarabine Induced Acute Kidney Injury  Sameer Gupta, Ramapriya 
Sinnakirouchenan, Kamlesh Reddy Kurre.  Nephrology, Medical College of 
Wisconsin, Milwaukee, WI.
Introduction: Clofarabine induced acute kidney injury (AKI) has been documented 
but the mechanism leading to AKI has not been well understood.  Here we describe a case 
of clofarabine treated relapsing ALL leading to anuric AKI and death.
Case Description: A 30 year old male with relapsing ALL was admitted to the hospital 
for AKI.  His creatinine was 1.2mg/dl 2 weeks prior to admission.  He received his first 
cycle of clofarabine at 40mg/m2  for 5 days one month ago.  On the fifth day of cycle 2 he 
was admitted for AKI with creatinine of 2.5 mg/dl. Nephrology was consulted next day 
for oliguria and creatinine elevation up to 3.3 mg/dl.  Urine microscopy revealed acute 
tubular necrosis (ATN). His hospital stay was complicated by anuria and septic shock 
necessitating continuous renal replacement therapy.  Proteinuria could not be assessed 
due to anuric AKI. After a prolonged and complicated hospital course patient expressed 
his wishes for comfort care.
Discussion: Clofarabine is approved for the treatment of relapsed or refractory ALL 
in children but is also used out of label in adults.  It acts by inhibiting DNA synthesis, the 
enzyme ribonucleotide reductase and repair and activation of mitochondrial repair processes. 
It is postulated based on animal studies and its mechanism of action that collapsing 
glomerulopathy or tubular injury alone or in combination may be the etiology. In our case, 
there is a temporal relationship between clofarabine use and AKI. 
The risk factors for clofarabine-associated AKI include older age, higher AUC (area 
under the curve) and, lower baseline GFR. While the current recommendation is a 50% 
dose reduction for renal impairment, this only applies to patients with a baseline creatinine 
clearance of 30–60 mL/min. There are currently no guidelines for those patients with 
ostensibly “normal” creatinine clearance values. 
We suggest that dosing based on baseline GFR even among patients with apparently 
normal serum creatinine deserves consideration in the future use of clofarabine. Careful 
monitoring for renal toxicity and minimizing other renal insults in older patients and those 
with lower baseline GFRs should help prevent this adverse effect.
PUB395
Orthostatic Hypotension as the Presenting Feature of Primary Systemic 
Amyloid Light-Chain (AL) Amyloidosis  Scherly Leon,1 Farouk Talakshi,1 
Rajiv A. Perinbasekar,1 Gary R. Briefel,2 Moro O. Salifu.1  1Medicine, Renal 
Div, Downstate Medical Center, Brooklyn, NY; 2Medicine, Renal  Div, Kings 
County Hospital Center, Brooklyn, NY.
Introduction: Orthostatic hypotension is a common disorder among the elderly, 
often associated with hypovolemia, adrenal insufficiency, and autonomic neuropathies. 
Primary systemic amyloid light-chain (AL) amyloidosis is a rare acquired plasma cell 
disorder. Morbidity results from extracellular depositions of amyloid fibrils in vital organs. 
Deposition of amyloid protein in the nervous system leads to autonomic neuropathy, 
resulting in orthostatic hypotension,early satiety, erectile dysfunction and intestinal motility 
dysfunction. We report a case of primary systemic amyloidosis, presenting initially as 
orthostatic hypotension.
Case Description: A 61-year-old man was admitted for orthostatic hypotension with 
syncopal episodes and proteinuria. He was well until six months prior to admission, when 
he began experiencing severe recurrent orthostatic lightheadedness, anorexia, and dysgeusia. 
He reported weight loss and periumbilical paresthesias. He had been admitted to an outside 
hospital and underwent extensive evaluation including a chest CT which revealed lung and 
liver granulomas. Fludrocortisone was started for hypotension. He noted no improvement 
and stopped fludrocortisone two weeks prior to presentation to our hospital.
Extensive evaluation of his orthostasis, including an adrenocorticotropic hormone 
stimulation study was normal. Cardiac and endocrine evaluation revealed no abnormalities. 
Laboratory exam showed serum creatinine of 0.74 mg/dL, Hgb of 10 g/dL, MCV of 90fL, 
total protein 6.4 g/dl and albumin 2.5 g/dl. A 24-hour urine protein excretion was 5g. Free 
kappa (436 mg/L) and lambda light chains (6.5 mg/L) with a ratio of 67. A monoclonal 
spike was noted on serum protein electrophoresis. Additional rheumatologic workup was 
negative. Bone marrow biopsy was consistent with multiple myeloma and congo red stain 
was positive for amyloidosis.
Discussion: The finding of heavy proteinuria in conjunction with orthostatic 
hypotension should lead one to consider the diagnosis of primary systemic (AL) amyloidosis 
in the differential diagnosis.
PUB396
Refractory Anemia Secondary to B Thalassemia in a Patient with CKD: 
Case Report  Lilia Maria Rizo Topete, Giovanna Y. Arteaga Muller, Jesus 
Cruz Valdez, Elisa Maria Guerrero Gonzalez, Concepcion Sanchez Martinez. 
Nephrology, Univ Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico.
Introduction: We present a case of a Male patient, 28 years old, Mexican, diagnosed 
with CKD of unknown etiology.
Case Description: He denies chronic diseases. Mother with SLE, Sd. Evans and 
DM.The renal sonogram showed small kidneys . Viral panel negative as immunological 
tests. The patient comes as ERC G5 with uremic syndrome. RRT starts with PD, 3 months 
after an episode of peritonitis for candida and HD was initiated. He presented hemoglobin 
of 7.5 g/dl, microcytichypochromic anemia, treated with erythropoietin 12 000 IU a week, 
oral Iron and folic acid. Months later the patient came up with anemic syndrome and 
hemoglobin of 6.6 mg/dl, 2 units of blood were transfused. He presented 3 similar episodes 
, so 6 more units were transfused. Erythropoietin exchanged for darbepoetinand. Direct 
Coombs test was negative. He did not respond to treatment, iron test was performed and 
IV iron therapy was initiated. Hematology reported aspiration and biopsy Bone marrow 
normal, with megakaryocytes, M:E ratio 2:1m without blastas. Biopsy reported hypocellular 
. Abdominal US reported normal. Hemoglobin electrophoresis was performed which 
reported increased A2 hemoglobin 
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Discussion: The B Thalassemia is a hereditary disorder of hemoglobin synthesis 
in the B-globin gene that present clinically with microcytic hypochromic anemia, 
erythropoiesis ineffective, normal reticulocyte counts or slightly elevated and high levels 
of A2 hemoglobin. In the kidneys can cause tubular injury and GFR decline. Developing 
glomerulosclerosis and fibrosis. We can not rule out that CKD is secondary to B-thalassemia, 
a genetic study would be necessary. It is an uncommon diagnosis in Latin America, but 
should be considered in patients with CKD and microcytic hypochromic anemia refractory 
to convecional treatment.
PUB397
Empirical Antifungals in Peritoneal Dialysis Patients with Bowel 
Obstruction: Time to Reconsider?  Ravinder Pal S. Bhatti, Elwaleed Elnagar, 
Dumitru Rotaru.  Nephrology, Univ of Arkansas for Medical Sciences, Little 
Rock, AR.
Introduction: Intestinal obstruction, even without perforation or ischemia, predisposes 
patients on peritoneal dialysis (PD) to peritonitis by gut commensals including fungi. Fungal 
peritonitis (FP), with (Secondary) or without (Primary) prior antibiotic use, is associated with 
increased mortality and technique failure. This raises the question of empirical antifungal 
use in PD patients with bowel obstruction. We present our experience with such a patient.
Case Description: A 74 year old male who had been on Continuous Cycling Peritoneal 
Dialysis for the past four years with his prescription being 5 exchanges of 2 liters of 1.5% 
and 2.5% dianeal with a last fill of 2 liters of icodextrin, presented with worsening abdominal 
pain. His dialysate was clear and had just 3 leucocytes. His CT abdomen showed small 
bowel obstruction (SBO) with conservative management pursued. Over the next few days, 
the SBO resolved and dialysate cell counts remained unremarkable. On day 5, he became 
hypotensive. Examination was notable for increased abdominal tenderness and a cloudy 
dialysate. Repeat dialysate studies were sent and intraperitoneal vancomycin and cefepime 
were started. Imaging suggested SBO. He responded appropriately to the antibiotics over 
the next three days with no growth on any cultures thus far. However, the dialysate grew 
yeast the next day. Fluconazole was started, later being switched to micafungin with the 
yeast identified as Candida cruzei. His Tenckhoff catheter was removed and hemodialysis 
(HD) was initiated. He completed 4 weeks of micafungin and opted to continue on HD.
Discussion: Evidence on antifungal prophylaxis while treating PD related bacterial 
peritonitis has been mixed, with the decision being individualized on a per-center basis. 
Additionally, no clear role has been defined for prophylactic antimicrobials in PD patients 
with bowel obstruction. With a high risk for both primary and secondary FP, these patient 
present a conundrum. Our case highlights this while also suggesting a role for prophylactic 
antifungals even when antibiotic exposure is brief. We conclude that it may prudent to 
provide empirical antifungal coverage in PD patients with SBO.
PUB398
Leukocytosis and Peripheral Blood Eosinophilia Are Early Signs of Acute 
Cellular Rejection of a Transplanred Kidney  Elwaleed Elnagar, Ravinder 
Pal S. Bhatti, Aziz Bakhous.  Nephrology, UAMS, Little Rock, AR.
Introduction: Leukocytosis and peripheral blood eosinophilia were well described in 
acute rejection of transplanted livers and pancreas rejection. This labarotary abnormality was 
not well evaluated in kidney allograft rejection. In this case report, we explore leukocytosis 
and peripheral blood eosinophilia as possible labaratory abnormalities preceeding ACR.
Case Description: We are presenting a 65 years old woman with a history of ESRD due 
to ADPKD, who had a DDKT in 2012. Her medications included Prednisone, Tacrolimus, 
and Mycophenolate Mofetil. She maintained a stable allograft function, with a creatinine 
of 1-1.2. She was found to have leukocytosis and peripheral blood eosinophilia. Evaluation 
for infections and malignancy was negative. 6 weeks later she was noted to have AKI. She 
complained of mild lower extremities swelling. Physical examination was unremarkable. 
Labs evaluation revealed a creatinine of 2 mg/dl, WBCs count of 15.9 k/uL, and eosinophilia. 
Renal biopsy however, showed ACR (figure1). There were abundant infiltrates with 
neutrophils and eosinophils. She was treated for ACR with return of creatinine to baseline. 
Discussion: Several reports have evaluated the predictive value of peripheral blood 
eosinophilia as a simple noninvasive diagnostic marker for ACR of transplanted livers and 
of acute pancreatic rejection. However, peripheral blood eosinophilia was not evaluated as 
a possible test predicting renal ACR. In a case report, Baradhin et al, described the etiology 
of AKI following treatment with armodafinil for narcolepsy. They indicated that both 
(AIN and ACR) has similar biopsy characteristics. However, our patient had no clinical 
features to suggest AIN, including no new medications. We conclude that leukocytosis and 
peripheral blood eosinophilia could represent signs of impending acute cellular rejection 
of transplanted kidneys.
PUB399
A Case of IgA Nephropathy in an HIV-Positive Patient  Hermes Garcia-Sanchez, 
Vandana Niyyar, Thomas E. Rogers.  Nephrology, Emory Univ, Atlanta, GA.
Introduction: IgA nephropathy has been described in patients infected with HIV. 
Though IgA levels are commonly elevated in HIV, these patients may also develop IgA 
antibodies against specific HIV antigens. Renal lesions may result from HIV antigen-specific 
immune complexes that are derived from the circulation and from in-situ complex formation.
Case Description: We present a case of a patient with HIV/AIDS, on highly active 
antiretroviral therapy (HAART), who was evaluated for microscopic hematuria and 
worsening renal function. The patient’s only complaint was early morning peri-orbital 
edema. On examination, BP was 103/72 mm Hg with a BMI 23 kg/m2. Labs showed normal 
electrolytes, serum creatinine 1.7 mg/dL (baseline 0.7mg/dL), urine protein/creatinine ratio 
of 2.5 grams/dl. Other serologies were negative. HIV VL was undetectable, and CD4 count 
was 183. Renal US showed bilateral enlarged, echogenic kidneys.
Renal biopsy revealed sclerosing glomerulopathy with IgA immune type deposits on 
immunofluorescence. The patient was initiated on an ACE inhibitor and a low salt and 
protein diet, with resolution of his proteinuria to 0.7 Grams/dL. His renal function stabilized, 
with a creatinine of 1.6 mg/dL.
Discussion: In conclusion, IgA glomerular disease arising in HIV positive patients 
has clinical and pathologic aspects similar to idiopathic IgA nephropathy. IgA nephropathy 
should be suspected in patients with HIV presenting with unexplained hematuria, and renal 
biopsy should be performed as soon as possible for early diagnosis and therapy. Current 
management recommendations are similar to those with idiopathic IgA, including ACE 
inhibitors or ARB for control of proteinuria (>1 g / day) or hypertension.
PUB400
Calcium Channel Blocker Toxicity: Management Strategies and 
Considerations  Sreesh G. Iyengar, Mark I.C. Hong, Seyed-Ali Sadjadi. 
Nephrology, Loma Linda Univ, Loma Linda, CA.
Introduction: Calcium channel blocker overdose is rare but carries a high mortality 
due to cardiovascular complications. Generally the management is supportive with use of 
vasopressors, IV fluids, cardiac pacing, and insulin therapy. There are reports of CVVHDF, 
hemodialysis or hemofiltration alone and charcoal hemoperfusion for the treatment of CCB 
overdose. Effective management strategies are needed to improve outcomes.
Case Description: Here we describe a patient who presented to the ER after a suicide 
attempt with ingestion of Norvasc. On arrival to the ER he was awake but later he was 
intubated. The patient developed acute kidney injury and became anuric. Patient was started 
on CVVHD that lasted 48 hours. Unfortunately after two days the patient continued to 
decompensate and expired.
Discussion: Amlodipine is a CCB of the dihydropyridine group acting primarily on 
vessel walls whereas the non-dihydropyridines act more on cardiac muscle and pacer 
cells. In our case it was clear Norvasc selectively took its effect on the vasculature with 
profound hypotension with preserved systolic function and no arrhythmia. The case was 
complicated with ARDS related to diffuse pulmonary edema, a well known complication 
with CCB overdose. In our case renal failure was likely related to severe hypoperfusion 
leading to ischemia. There was development combined respiratory and metabolic acidosis. 
The metabolic acidosis was attributed to renal failure but it is possible that CCB induced 
inhibition of insulin secretion leading to ketoacidosis may also have contributed. In terms 
of management of CCB overdose, if recent ingestion then GI decontamination is reasonable 
with activated charcoal or whole bowel irrigation. The use of high dose insulin therapy 
has been tried and its role may include increasing ionized calcium levels, improvement 
of hyperglycemic acidosis, and improved myocardial function. Most case reports, though 
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few, have shown little benefit from hemofiltration or hemodialysis theoretically due to high 
protein binding, high tissue distribution and rapid metabolism of the drug. One case report 
did show some promise when multiple therapies were used including IV lipid emulsion, 
CVVHDF and charcoal hemoperfusion.
PUB401
A Rare Case of IgG1-Heavy Chain Deposition Disease Using Oral 
Prednisone and Therapeutic Plasmapheresis  Sacha Baldeosingh, Madhu 
Kandarpa.  Internal Medicine, Kettering Medical Center.
Introduction: Heavy chain deposition disease (HCDD) is rare, especially without 
light chain deposition and when causing non-amyloid tissue deposits.
Case Description: A 75-year-old male with chronic kidney disease (CKD) stage 3 
(baseline creatinine 2.3mg/dL) and right single lung transplant for idiopathic pulmonary 
fibrosis in 2008 presented with extremity edema and decreased urine output. He has no 
history of diabetes or uncontrolled hypertension. Admission labs showed BUN 77 mg/
dL, creatinine 4.37 mg/dL, and subtherapeutic tacrolimus levels at 3.9 ng/mL. Urine 
protein/creatinine ratio was 6.6. A 24-hr urine protein collection revealed 5822 mg/24hr. 
Serum protein electrophoresis showed hypoalbuminemia, but no monoclonal proteins 
were identified. Urine protein electrophoresis was negative for Bence Jones proteins or 
monoclonal proteins. Urine protein concentration was 713 mg/dL, consisting of 57.8% 
albumin and 42.2% globulins. C3 and C4 complement levels were low at 46.5 mg/dL 
and 8.92 mg/dL respectively. Antinuclear antibodies (ANA), anti-streptolysin O (ASO), 
anti-neutrophil cytoplasmic antibodies (C-ANCA and P-ANCA), and cryoglobulins were 
negative. Renal ultrasound showed multiple renal cysts without hydronephrosis. Renal 
biopsy revealed nodular sclerosing glomerulopathy and IgG1-heavy chain deposition 
disease. Bone marrow biopsy was negative for multiple myeloma. The patient was placed 
on oral prednisone and therapeutic plasmapheresis in an effort to prevent further renal 
damage and delay hemodialysis. The patient underwent eight plasmapheresis treatments, 
however still required hemodialysis for fluid overload.
Discussion: HCDD is a monoclonal plasma cell proliferative disorder characterized 
by tissue deposits of heavy chain fragments which can lead to renal disease. In HCDD, 
deposits do not have a fibrillar structure and do not stain positive with Congo red such as 
with heavy-chain amyloidosis. The rarity of the disease and limited data on evidence-based 
guidelines for treatment make HCDD challenging to treat. We describe a rare case of IgG1-
HCDD with no plasma cell dyscrasia. To our knowledge, no cases have been described 
using oral prednisone and therapeutic plasmapheresis to treat HCDD renal dysfunction.
PUB402
Cocaine-Induced Vasculitis  David Agyapong.  Nephrology, Univ of New 
Mexico, Albuquerque, NM.
Introduction: An increasing number of cases of Cocaine -induced vasculitis are being 
found among cocaine users in the United States which is due to the use of Levamisole laced 
cocaine. It is estimated that about 70% of the cocaine used here in the US is contaminated 
with Levamisole.
Case Description: We describe a 65 year old male, with a 20 year history of cocaine 
abuse, who presented with a 1 month history of a progressively worsening, non-healing 
and painful rash on his trunk and extremities. He denied fever, weight loss and myalgias 
but admitted to itchiness. Examination revealed multiple tender, erythematous and 
violaceous plaques with central necrosis on the trunk and extremities. These plaques 
were found to be in different stages of healing with their size ranging from 1cm-7 cms. 
Lab investigations revealed an elevated creatinine of 2.9 mg/dL, an elevated ESR, a 
low C3, presence of Myeloperoxidase (MPO) antibody and perinuclear Anti Neutrophil 
Cytoplasmic Antibody (p- ANCA), and an absence of Antinuclear Antibody (ANA) and 
Anti Proteinase 3 (PR-3) antibody. Urine drug screen was positive for cocaine and urine 
microscopy showed dysmorphic RBCs. Skin biopsy showed thrombotic vasculopathy with 
overlying re-epithelialization. Kidney biopsy revealed focal endocapillary proliferative 
glomerulonephritis with crescents involving 10 % of glomeruli and interstitial fibrosis and 
tubular atrophy involving approximately 70% of the specimen.
•Treatment is mainly abstinence and supportive. •The clinical course of patients is 
difficult to assess due to the fact that few patients are able to abstain from cocaine use. •Our 
patient was able to abstain from cocaine use for about 30 days ,and that almost resulted 
in clinical resolution after 30 days of being cocaine-free (Fig 3.) •Although ,in the setting 
of worsening skin lesions and ongoing cocaine use ,some patients have been treated with 
anticoagulation or thrombotic vasculopathy , immunosuppresion and corticosteroids with 
varying degrees of success , robust evidence lacking.
Discussion: •With more than 2 million Americans using cocaine , occurrences of 
levamisole –induced vasculitis will increase Levamisole exposure should be included in 
the differential of patients with purpuric vasculitis , neutropenia and cocaine.
Funding: Clinical Revenue Support
PUB403
Morbidity Associated with Uremic Ascites Among Emergent Dialysis 
Patients  Shobana Sivan, Rajeev Raghavan.  Nephrology, Baylor College of 
Medicine.
Introduction: Patients with end-stage renal disease(ESRD) on emergent dialysis often 
develop complications of inadequate dialysis such as pleural effusion, ascites and pericardial 
effusion. Uremic ascites is characterized by exudative ascites with SAAG usually <1.1 and 
is diagnosed after excluding liver, cardiac, infectious and malignant causes. The incidence 
of uremic ascites in standard dialysis population was described as 0.7-20%. We believe 
that emergent dialysis patients with uremic ascites have higher morbidity and mortality.
Case Description: Total of 463 emergent dialysis patients, who were initiated on 
dialysis between July 2010 and April 2015 were analyzed. Among 36 patients with Ascites 
of any cause, 12 patients were included in the study group of uremic ascites. A cohort of 36 
patients without ascites was randomly selected for comparison. Two groups were compared 
based on demographics and morbidity indicators.
The mean age was 50 years with predominance of Hispanic male in both groups. The 
serum albumin in the uremic ascites group and the cohort group was 2.6±0.4 and 3.29±0.2 
respectively. The mean emergency center(EC) visits and hospital admissions in uremic 
ascites and cohort group were 79.6, 9 and 63.4, 5.2 respectively. Volume overload and 
abdomen pain were the major reasons for admissions in the study group. They underwent 
paracentesis and frequent dialysis during the hospital course.
Cohort Group(36) Study Group(12)
Age 50.7±3.9 50.1±
Sex 31M/5F 9M/3F
Ethnicity 91.6%(33)Hispanic 80%(10)Hispanic
Serum 
Albumin (g/dl) 3.3±0.2 2.6±0.4
EC Visits/Year 63.4 79.6
Hospital 
Admissions/Year 5.2 9
Discussion: The Emergency room visits and hospital admissions are more in emergent 
dialysis patients with the complication of uremic ascites. The serum albumin, a marker 
for increased cardio-vascular events and death is lower in these patients. We conclude 
that uremic ascites increase the morbidity and mortality in emergent dialysis population 
with ESRD. The modalities such as Continuous ambulatory peritoneal dialysis, scheduled 
outpatient dialysis and kidney transplant may prove beneficial.
PUB404
A Case of Multiple Vertebral Compression Fractures due to Glucocorticoid-
Induced Osteoporosis in a Pediatric Patient with Nephrotic Syndrome 
Akihiko Shirasu,1 Akira Ashida,1 Yuko Fujii,1 Hideki Matsumura,1 Hyogo 
Nkakura,1 Motoshi Hattori,2 Hiroshi Tamai.1  1Dept of Pediatrics, Osaka 
Medical College, Takatsuki, Osaka, Japan; 2Dept of Pediatric Nephrology, 
Tokyo Women’s Medical Univ, Tokyo, Japan.
Introduction: Glucocorticoid therapy has a number of adverse effects, among which 
osteoporosis and bone fracture are major complications. However, there are few reports of 
this condition in pediatric patients. Here we describe a pediatric case of multiple vertebral 
compression fractures due to glucocorticoid-induced osteoporosis during treatment for 
steroid-dependent nephrotic syndrome in a child.
Case Description: A 12-year-old boy was referred to our hospital for treatment of 
nephrotic syndrome with massive proteinuria and generalized edema. He was treated 
with the standard corticosteroid regimen stipulated by the International Study of Kidney 
Disease in Children (ISKDC). Although he achieved complete remission, he suffered two 
relapses of nephrotic syndrome during administration of prednisolone on alternative days. 
In the second relapse, the disease became resistant to the steroid therapy, and therefore he 
received two courses of steroid pulse therapy followed by steroid tapering concomitant 
with cyclosporine administration. Two months after the diagnosis of steroid-resistant 
nephrotic syndrome, the patient complained of back pain. Magnetic resonance imaging 
demonstrated compression fractures from the sixth thoracic vertebra to the first lumbar 
vertebra. Therefore, the steroid dosage was rapidly reduced and then withdrawn because 
he was able to maintain remission under cyclosporine therapy.
Discussion: It is necessary to evaluate the state of bone particularly the bone mineral 
density of the lumbar spine, at an early stage of treatment for nephrotic syndrome in 
children, even though the incidence of glucocorticoid-related vertebral fracture is low in 
this patient population.
PUB405
First Use of Lixelle Beta 2-Microglobulin Apheresis Column (Lixelle 
Column) for Dialysis Related Amyloidosis in the United States 
Vesh Srivatana,1 Anjali Masand,1 Jeffrey I. Silberzweig.2  1Dept of Nephrology 
and Hypertension, NYP- Weill Cornell Medical Center, New York, NY; 2Dept 
of Nephrology, The Rogosin Inst, New York, NY.
Introduction: Dialysis related amyloidosis (DRA) is a debilitating complication of 
long-term hemodialysis characterized by excess accumulation of Beta 2-microglobulin, 
which deposits as amyloid fibrils in the bones, joints, and organs of affected patients. 
The Lixelle Beta 2-microglobulin apheresis column (Lixelle column) is a recently FDA 
approved medical device that contains specialized beads that selectively remove Beta 
2-microglobulin from the blood. This device has been used successfully in Japan to relieve 
symptoms and prevent progression of DRA. We describe the anticipated first use of this 
device in the United States.
Case Description: The patient is a 65 year-old man diagnosed with end-stage renal 
disease of unknown etiology in 1968. A deceased donor renal transplant in 1969 failed 
within 6 months, and a second transplant in 1970 functioned for 3 years. He has been 
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treated by maintenance hemodialysis since 1973. In 1995, biopsies documented beta 
2-microglobulin amyloid deposits in his tongue, consistent with a diagnosis of DRA. 
Over time, it has progressed to involve his shoulders bilaterally, his hips, knees, wrists 
and most recently his colon. He has undergone bilateral total hip replacements and carpal 
tunnel release procedures. Given his extensive disease burden as a result of DRA despite 
adequate dialysis, we intend to enroll him in a post-approval study using the Lixelle column. 
Measures of disease burden will include pre- and post- treatment Beta 2-microglobulin 
levels, presence of bone cysts, and quality of life (QOL) scores.
Discussion: The Lixelle Beta 2-microglobulin apheresis column appears to increase 
the Beta 2-microglobulin reduction rate in a single dialysis session, and therefore may be 
an effective treatment option to improve symptoms and quality of life for patients with 
dialysis related amyloidosis.
PUB406
An Unusual Case of Anticoagulant-Like Nephropathy in a Non-
Anticoagulated Patient  Elyas Safar, Apurv Khanna.  Internal Medicine, Div 
of Nephrology, SUNY Upstate Medical Univ, Syracuse, NY.
Introduction: Anticoagulant-related nephropathy is a well-known cause for Acute 
Kidney Injury (AKI), which was first described in Coumadin anti-coagulated patients, 
usually with excessive anticoagulation (INR >4). It was also reported to be associated 
with other Anticoagulants such as direct thrombin inhibitor Dabigatran. We report a case 
of Anticoagulant-related Like Nephropathy in a Non-anticoagulated patient.
Case Description: A 71-year-old male was admitted to the VA medical center 
for shortness of breath and hemoptysis. Past medical history was significant for Non 
Small cell Lung Cancer, cryptogenic liver cirrhosis and COPD. CT chest, showed no 
pulmonary emboli. He was treated with Vancomycin and Zosyn for Pneumonia. The 
patient reported gross hematuria initially, which resolved spontaneously. His admission 
creatinine was 1.1 mg/dl, (baseline 0.6 mg/dl), and went up to 2.4 mg/dl. The patient had 
another episode of gross hematuria and his creatinine went up to 3.5 mg/dl. The patient 
remained non-oliguric throughout the course of his AKI. Kidney biopsy showed Tubular 
epithelial cells injury with red cell casts, but no inflammatory changes and no Immune 
complexes by Immunofluorescence. The histopathologic pattern shown by the kidney 
biopsy was consistent with Anticoagulant-related nephropathy. However, the patient 
was not anticoagulated with Coumadin, Heparin, or any other anticoagulants. His Pro-
thrombin time (PT) was 13.1 seconds (normal 9-12 seconds) and INR 1.2. His PTT was 
20.1 seconds (normal 25-34 seconds). He had a low platelets count between 55-100K/
mm3, due to liver cirrhosis.
The findings in this case, suggest a role for Thrombocytopenia in liver cirrhosis, in 
causing anticoagulant like intra-glomerular hemorrhage, which may result in an AKI.
Discussion: Thrombocytopenia and likely Platelets dysfunction in Liver cirrhosis can 
cause intra-glomerular Hemorrhage and results in Anticoagulant-like Nephropathy, even in 
the absence of excessive coagulopathy as evidenced by a normal PTT & near normal INR. 
To our knowledge, there has not been a reported case of Anticoagulant-like Nephropathy 
in Non-Anticoagulated patients.
PUB407
Smoking Related Idiopathic Nodular Glomerulosclerosis with Crescents 
Tahir Zaman,1 Frederic Clayton,2 Josephine Abraham.1  1Nephrology, Univ of 
Utah, Salt Lake City, UT; 2Pathology, Univ of Utah, Salt Lake City, UT.
Introduction: Idiopathic nodular glomerulosclerosis (ING) is a rare but important cause 
of nephrotic syndrome. There have been case series reported in the literature regarding the 
association of ING and smoking.
Case Description: A 37-year-old female with a history of rheumatoid arthritis (RA) 
presented to the hospital with cough and hemoptysis. Her RA treatment consisted of 
leflunomide, prednisone and folic acid. Her social history is pertinent for a history of 
smoking (20 pack-years). Urine analysis was with dysmorphic hematuria and proteinuria 
(spot protein/creatinine ratio 3.2gms). Serologic workup was unremarkable. Renal biopsy 
revealed nodular glomerulosclerosis with sparse crescents. Due to sparse crescents, 
hemoptysis, and AKI the patient was started on high dose steroids which exacerbated 
patient’s nephrotic syndrome. Ultimately steroids were discontinued which lead to an 
improvement in proteinuria. Smoking cessation was encouraged.
Discussion: ING with crescents has not been described in the literature. In a case 
series reported by Markowitz et al, patients with ING had renal failure with a mean sCr 
of 2.4 mg/dL and proteinuria. The main clinical predictors of progression included lack 
of angiotensin II blockade and continued smoking. 1 In retrospect, it is likely the severity 
of her intra-glomerular pressures which lead to proteinuria was exacerbated with steroid 
treatment and resolved with discontinuation.
PUB408
Thrombotic Microangiopathy Secondary to Hepatocellular Carcinoma 
Tahir Zaman,1 Frederic Clayton,2 Josephine Abraham.1  1Nephrology, Univ of 
Utah, Salt Lake City, UT; 2Pathology, Univ of Utah, Salt Lake City, UT.
Introduction: Thrombotic microangiopathy (TMA) is a microvascular occlusive 
disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia and end 
organ damage. We report a case of malignancy associated TMA.
Case Description: 65-year-old female presented with diarrhea and was noted to be 
in acute renal failure with microangiopathic hemolytic anemia and thrombocytopenia. 
Therapeutic plasma exchange was discontinued after ADAMST 13 activity was normal. 
Patient underwent colonoscopy and EGD with evidence of microthrombi in bowel wall 
concerning for TMA. 
Serologies were remarkable for negative APS, SLE, ANCA-vasculitis but Ca-125 
was 753. Stool Shiga toxin was negative. Patient was treated for atypical hemolytic 
uremic syndrome (aHUS) with weekly eculizumab. Diagnostic laparoscopy on HD 24 
with peritoneal washings were negative for malignancy. The patient died on hospital day 
25 from septic shock secondary to bowel perforation. Autopsy revealed 2.5 x 2.0 x 2.0 cm 
lesion within the liver consistent with hepatocellular carcinoma (HCC).
Discussion: TMA occurring in older patients who fail to respond to TPE should increase 
suspicion of malignancy-associated TMA. 1 HCC is a rare but known cause of malignancy-
associated TMA as noted in the literature. HCC-associated TMA is quite severe leading to 
rapid progression to a fatal outcome. 2 1. George, J. N. Systemic malignancies as a cause 
of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology 25, 
908–14 (2011). 2. Seo, D. W. et al. Hepatocellular carcinoma associated hemolytic uremic 
syndrome unrelated to chemotherapy. J. Korean Med. Sci. 9, 254–8 (1994).
PUB409
Charcot Foot Syndrome in a Nondiabetic Hemodialysis Patient 
Werner Kleophas,1,2 Sebahat Sat,1 Barbara Klein,1 Andreas Westhoff,1,2 Frank 
Dellanna,1,2 Gerd R. Hetzel.1,2  1MVZ Davita Karlstrasse, Duesseldorf, Germany; 
2Heinrich-Heine Univ, Duesseldorf, Germany.
Introduction: The prognosis is very poor for diabetic hemodialysis (HD) patients 
with foot lesions. Foot lesions are associated with risk of systemic inflammation and 
cardiovascular (CV) morbidity. Severe cases of diabetic foot with neuropathic arthropathy, 
microvascular changes from mediasclerosis, and alteration of foot architecture are known as 
Charcot Foot Syndrome (CFS). Since diabetic and nondiabetic HD patients may experience 
changes in calcium and phosphate metabolism and secondary hyperparathyroidism, the 
question arises whether CFS can occur in HD patients in the absence of diabetes.
Case Description: Presented is a decade-long case study of a male HD patient (DOB 
1961) who was treated since Dec 1999 for biopsy-proven nephrotic syndrome due to 
glomerulosclerosis. The patient began thrice weekly HD in Sept 2005 without prior treatment 
for diabetes mellitus (A1C 4.9%). In Apr 2012 he presented with a painless inflammatory 
acute foot syndrome, then presented in Apr 2013 with a planar ulceration. After conservative 
wound management, prophylactic shoes were prescribed. In clinical examination he showed 
signs of chronic CFS and arthropathic changes in ossa metatarsalia 2 and 3 with osteolysis 
and luxation of tarsometatarsal joints. Lab results indicate secondary hyperparathyroidism: 
parathyroid hormone 465 pg/mL, phosphate 6 mg/dL, and calcium 2.2 mg/dL. 
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Discussion: We believe this is the first description of chronic CFS in a nondiabetic 
HD patient. Acute CFS diagnosis is important because its symptoms (red warm skin, foot 
edema) are similar to those of phlegmon and osteomyelitis, and thus may be considered a 
differential diagnosis. Further investigations are necessary to determine whether this is an 
authentic entity of a foot syndrome, and if it’s associated with CV morbidity.
Funding: Pharmaceutical Company Support - Davita
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Crescentic Glomerulonephritis (GN) in a Lupus Patient with Normal Serum 
Creatinine – A Treatment Challenge  Venkata Buddharaju, Rishikesh Morey, 
Rudrick V. Ledesma, Savneek S. Chugh, Praveen N. Chander.  Nephrology, 
Westchester Medical Center, Elmsford, NY.
Introduction: Crescentic GN is usually manifested by features of active glomerular 
disease in the urine and by progressive rapid loss of significant renal function. SLE can 
present as predominantly crescentic GN often as Class III or IV lupus nephritis (LN) usually 
resulting in rapid deterioration of renal function requiring RRT.
Case Description: 18 y/o female recently diagnosed with SLE, on Plaquenil presented 
to ER with nausea, vomiting and epigastric pain after consuming “tiny tea” and was 
found to have serum creatinine (SCr) 4.5 mg/DL, which further increased to 4.74 with 
3+ protein (2.5g/day), 3+ blood and RBC casts on urinalysis. Other relevant lab data: 
ANA 1:600, negative dsDNA, positive RNP, anti-SM Ab and normal complements. She 
was initiated on IV fluids and SCr normalized within 2 days.Renal biopsy showed Pauci 
immune Crescentic GN, class IV-S (A/C) with minimal IF staining. The clinical course 
was complicated by seizures; the diagnostic considerations included lupus cerebritis vs. 
PRESS. She was put on valproate to be started on immunosuppression as outpatient. She 
was admitted a week later with acute liver failure due to valproate and Tylenol at which 
time she was pulsed with IV Solu-Medrol and discharged on oral steroids with a plan to 
start MMF after normalization of LFTs.
Discussion: Crescentic and focally necrotizing GN can be infrequently present 
in the spectrum of diffuse proliferative LN. Such cases are generally ANCA negative. 
Normalization of SCr after hydration in this case suggest pre renal as the likely etiology 
which poses a treatment dilemma for biopsy proven crescentic GN. While there isnot 
much literature available regarding the treatment of lupus with crescentic GN and normal 
SCr, a retrospective case series reported that even <50% crescents portend a significant 
renal risk despite clinically evident preserved renal function. We believe that intense 
immunosuppression should be used in patients with crescentic GN and preserved renal 
function, despite the absence of any controlled studies. Our patient was started on MMF 
and prednisone with improvement in proteinuria from 2.6 gm to 150 mg with normal SCr.
PUB411
Anti-Thymocyte Globulin Induced Non Cardiogenic Pulmonary Edema 
Jaya Kala, Amit Lahoti.  Nephrology, Univ of Texas MD Anderson Cancer 
Center, Houston, TX.
Introduction: Anti-Thymocyte globulin (ATG) is used in treatment of hematologic 
malignancies and solid organ transplantation. Immediate local and systemic reactions 
are known. There has been only one reported case of non cardiogenic pulmonary edema 
(NCPE) caused by ATG.
Case Description: Our patient was a 59-year-old man with Marginal Zone Lymphoma 
which had progressed to diffuse large B cell lymphoma. Despite Hyper CVAD and 
Rituximab his disease continued to progress. He received Matched Unrelated Bone marrow 
transplantation after conditioning with ATG and rituximab. The next day he was admitted 
to the ICU with respiratory distress and bilateral lung infiltrates initially thought to be 
pulmonary edema. He was started on Lasix drip but did not improve. His CVP was 5, 
and his echocardiogram showed normal ejection fraction. Based on these findings he was 
diagnosed to have NCPE. Bronchoscopy revealed pulmonary hemorrhage. His condition 
worsened and he was intubated and started on Continuous Renal replacement therapy. He 
was given additional doses of steroids but without improvement. His died due to respiratory 
failure after two days of ICU stay.
Discussion: Non cardiogenic pulmonary edema is a clinical syndrome characterized 
by presence of severe hypoxemia, bilateral alveolar infiltrates on chest radiograph without 
evidence of left atrial hypertension, fluid overload or congestive heart failure. Drug related 
NCPE is usually diagnosed after other causes of pulmonary infiltrates such as gastric 
aspiration, sepsis and pneumonia are excluded. The presence of normal echocardiogram 
and pulmonary hemorrhage within a day of administration of ATG, pulmonary infiltrates 
which did not resolve after intense attempts of volume removal indicated that the patient 
had NCPE. ATG is known to cause acute respiratory distress syndrome, alveolar hemorrhage 
and rapidly progressive interstitial fibrosis likely secondary to Cytokine release syndrome. 
Providers need to be aware of such complications as even though rare these cause increased 
morbidity and mortality. It is beneficial to give ATG infusions slowly and accompanied by 
high dose systemic steroids.
PUB412
Hypomagnesemia After Treatment with Pertuzumab  Lilian Saro-Nunez,1 
Tiffany A. Traina,2 Karen A. Cadoo,3 Teresa Gilewski,2 Ilya Glezerman.4 
1Nephrology, NYP-Weill Cornell Medical Center, New York, NY; 2Breast 
Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; 
3Gynecologic Oncology Service, Memorial Sloan Kettering Cancer Center, 
New York, NY; 4Renal Service, Memorial Sloan Kettering Cancer Center, New 
York, NY.
Introduction: Hypomagnesemia is a known side effect of epidermal growth factor 
receptor (EGFR) inhibitors such as cetuximab and panitumumab. Pertuzumab blocks HER 
(human epidermal growth factor receptor) 2 dimerization with HER3 and EGFR, and is used 
in HER2+ breast cancer. We present two cases of hypomagnesemia with pertuzumab use.
Case Description: Case 1 58 year-old woman with history of breast cancer treated with 
trastuzumab (T), docetaxel, pertuzumab (2 doses of 840mg and one dose of 420mg) and 
carboplatin (AUC6). Patient developed hypomagnesemia with serum magnesium (Mg2+) 
0.7 (1.7-2.6)mg/dl and symptomatic hypocalcemia of 5.9 (8.5-10.5)mg/dl. Since initiation 
of chemotherapy she experienced diarrhea controlled with loperamide. Fractional excretion 
of magnesium (FeMg) was 2%. Parathyroid hormone (PTH) was 309.2 (12-88)pg/ml. 
Pertuzumab and carboplatin were stopped. Mild hypomagnesemia persisted 6 months later. 
Case 2 56 year-old woman with history of breast cancer on treatment with T, paclitaxel 
and pertuzumab (one dose of 840mg and 2 doses of 420mg) was admitted with Mg2+ of 0.3 
(1.4-2.2) mEq/L and corrected calcium of 6.1mg/dl. She complained of chronic diarrhea 
which improved with loperamide and was receiving proton pump inhibitor (PPI). FeMg 
was 3%. PTH was 16.1 (12-88)pg/ml. PPI was stopped but patient received another dose 
of pertuzumab (840mg). She remained hypomagnesemic and required IV supplementation 
until her death from progression of disease 22 months later.
Discussion: Although there were other confounding factors that could have caused 
hypomagnesemia including diarrhea, PPI and carboplatin, hypocalcemia (a manifestation 
of hypomagnesemia) did not develop until patients were started on pertuzumab. Carboplatin 
has been associated with hypomagnesemia but not with the degree of hypomagnesemia 
seen in these two patients. We postulate that pertuzumab may interfere with reabsorption 
of Mg2+ similar to EGFR inhibitors.
PUB413
Acute Renal Infarction: Case Series  Yelda Deligoz bildaci,1 Rumeyza 
Kazancioglu.2  1Nephrology, Bezmialem Vakif Univ, Istanbul, Turkey; 
2Nephrology, Bezmialem Vakif Univ, Istanbul, Turkey.
Introduction: Acute renal infarction (ARI) occurs from interruption of kidney’s blood 
supply either partially or totally. Causes of renal infarction include; thromboembolism 
(usually from injured or replaced heart valves, congenital heart defects etc.) vasculitic 
disorders, trauma to the kidneys or hypercoagulable state. We present five cases of ARI 
with different etiologies.
Case Description: Description of Cases : Two female, three male, mean age 52 
(range 26-72) patients presented to the emergency department between 2013 and 2015 
in a university based hospital setting. Presenting complaint was severe flank pain lasting 
between 2 to 5 days for all of them. At initial examination all patients had costo-vertebral 
angle tenderness at the effected side. Contrast enhanced abdominal tomography was useful 
for showing renal artery occlusion and also renal infarction. Trans thoracic echocardiography 
were all normal and were not adequate in identifying patients having had heart defects, 
trans esophageal echocardiography was obviously superior in finding cases with possible 
paradoxical embolism. All patients were treated with enoxaprin therapy. During follow-up 
there was neither further complication nor kidney damage.
J Am Soc Nephrol 26: 2015 Publication Only
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
984A
Age Gender
History of 
Hyperten-
sion
trans 
thoracic 
echocar-
diography
trans esopha-
geal echocar-
diography
Initial 
creatine 
levels 
before 
treat-
ment
Follow 
up cre-
atine 
levels
CASE 1 26 FE-MALE
NEGA-
TIVE NORMAL
PATENT 
DUCTUS 
ARTERIO-
SUS
0,8 0,7
CASE 2 72 MALE POSITIVE NORMAL - 4,2 3,8
CASE 3 69 MALE POSITIVE NORMAL - 0,8 0,8
CASE 4 38 MALE NEGA-TIVE NORMAL - 0,8 0,9
CASE 5 56 FE-MALE POSITIVE NORMAL
PATENT 
DUCTUS 
ARTERIO-
SUS
0,8 0,8
Discussion: ARI usually is a hidden disease, which can easily be missed without any 
spesific suspicion for patients presenting with flank pain. It should be kept in mind that 
there is no specific biochemical test for ARI and diagnosis process must involve evaluation 
of cardiac pathologies preferably with trans esophageal echocardiography.
PUB414
Disseminated Cryptococcal Infection in a 24-Year-Old Man with Primary 
Focal Segmental Glomerulosclerosis  Judith J. Wilber,1,2,3 Caitlin Dugdale,1,2,3 
George P. Bayliss.1,2,3  1Rhode Island Hospital, Providence, RI; 2Miriam Hospital, 
Providence, RI; 3Alpert Medical School, Providence, RI.
Introduction: Focal segmental glomerulosclerosis (FSGS) is commonly treated with 
high doses of corticosteroids and calcineurin inhibitors to induce remission of proteinuria, 
however immunosuppression carries with it the risk of infection. We present here the case 
of a 24-year-old African American man following seven months of intermittent treatment 
for biopsy-proven FSGS with high-dose prednisone and cyclosporine.
Case Description: Our patient initially responded to prednisone 80 mg daily with 
proteinuria reduced to 37 mg/g from 3.5 g/g, but then suffered frequent hospitalizations 
for infection necessitating interruption of immunosuppression, now with decreased 
responsiveness to prednisone. Cyclosporine was added but interrupted after he developed 
skin findings concerning for necrotizing fasciitis. A surgical wound became infected, and he 
developed Clostridium difficile diarrhea. He was placed on ethacrynic acid and atovaquone 
because of a sulfa allergy. His albumin remained < 1.5 mg/dL. Renal function worsened, 
now with ascites requiring paracenteses and subsequently developed E coli peritonitis. 
He was admitted to our medical ICU with hypoxia seven months after initial presentation. 
Chest xray at this time demonstrated pulmonary edema versus multilobar pneumonia. 
White blood cell count was 18.5, and increased to 30.0 after beginning prednisone taper. 
Broad-spectrum antibiotics and hemodialysis were initiated with no improvement. Head 
CT after seizure demonstrated diffuse hemorrhaging. Fungal cultures were sent, and 
patient was started on empiric voriconazole. Cultures returned after he expired positive for 
Cryptococcus. Autopsy showed disseminated Cryptococcus with cause of death attributed 
to cryptococcal pneumonia.
Discussion: This case demonstrates the infectious risk of high dose immunosuppression 
in treating resistant focal segmental glomerulosclerosis and the need to balance efficacy 
of treatment against these risks.
PUB415
A Rare Case of Kidney Amyloidosis Caused by Heroin Abuse  Ravina Patel, 
Nilson D. Feliz, Roberto L. Collazo-Maldonado.  Nephrology, Dallas Methodist 
Medical Center, Dallas, TX.
Introduction: Secondary(AA)Amyloidosis nephropathy is a rare manifestation of 
IVDA.Is a condition characterized by deposition of insoluble fibrils in various organs; most 
commonly the liver and kidneys.Occurs as a result of chronic inflammatory states such as 
RA, IBD, chronic osteomyelitis,or familial Mediterranean fever.Kidney involvement in 
amyloidosis is a significant source of morbidity as it can progress to CKD.
Case Description: A 40 y/o AA man with no past medical history just 20 years of IV 
heroin abuse presented to the ED with the CC: Worsening lower extremity edema and a 
weight gained of 20 lbs. in the past few months.Patient denied any other medical problems 
or complains.On PE, afebrile, normotensive, with clear lungs, normal heart at auscultation 
and benign abdominal findings,but with 3+lower extremity edema.Multiple skin popping 
in upper and lower extremities with scaring,and no evidence of active infection.Creatinine 
0.8 mg/dL on arrival.The UA showed,>600mg/dL of protein and no hematuria.A 24 hour 
urine collection showed 35 gm of proteinuria and serum albumin 2.1g/dL. Cholesterol 
232mg/dL,LDL192 mg/dL and Trig.189mg/dL.LFT’s were normal and the rest of serologic 
workup including HIV,Hep B and C were negative.A biopsy showed a nodular increase in 
mesangial matrix material that was congophilic and stained positive with both amyloid A 
and P, consistent with AA amyloidosis.The EM, showed the presence of nonbranching fibrils 
that measure 7 and 12 nm in size.The mainstay treatment for secondary renal amyloidosis 
consists of tackling the underlying cause.In this case of heroin induced amyloidosis, the 
patient was counseled extensively about heroin cessation.Per the literature, not many other 
treatment options exist. We started him on colchicine as there are studies indicating its 
efficacy on disrupting the amyloid fibrils and decreasing progression of disease.He was 
also started on anti-coagulation and diuretics, but we were unable to start him on ACEI’s/
ARB’s due to low blood pressure.
Discussion: AA kidney amyloidosis is a rare manifestation of IVDA, especially after 
a prolonged exposure.We should always considered this diagnosis in chronic heroin users 
presenting with proteinuria.
PUB416
Addressing Fertility and Management of a Patient with PCOS and C1q 
Nephropathy  Monica Sircar,1 Ivy A. Rosales,2 Rex Neal Smith,2 A. Bernard 
Collins,1 Robert B. Colvin,2 Ravi I. Thadhani,1 Andrew L. Lundquist.1 
1Nephrology, MGH, Boston, MA; 2Pathology, MGH, Boston, MA.
Introduction: C1q nephropathy is a rare disease that can present in a variety of ways. 
We present the case of a 26 year-old female with PCOS and borderline diabetes who 
developed non-nephrotic-range proteinuria with preserved renal function who wished to 
become pregnant.
Case Description: Her serologic workup was unrevealing. She did not have any 
classical symptoms of SLE and her ANA was only mildly positive at 1:40. Biopsy of the 
kidney revealed predominant immunofluorescent staining for IgG and C1q with mesangial 
deposits of C1q. There was no clear evidence of focal segmental glomerulosclerosis to 
portend a worse prognosis. Her decision to pursue pregnancy prompted further inquiry into 
the effects of pregnancy on her renal disease.
Review of existing literature, limited as it may be, suggested that C1q autoimmunogenicity 
may be associated with normal placental growth and development in the context of hormonal 
changes.
Discussion: Therefore, interpretation of typical parameters, including urinary protein 
excretion alone, may not be sufficient in determining disease status. This case demonstrates 
the importance of renal biopsy in defining the underlying pathology in young women with 
evidence of glomerular disease who wish to become pregnant as it can help guide prognosis.
Funding: Other NIH Support - NIH T32 award
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Outcomes of Calcific Uremic Arteriolopathy (CUA) Management: An Inner 
City Tertiary Center Experience  Marwan M. Abu Minshar, Nanette S. Chua, 
Sahrish Ilyas, Najibah Rehman, Nashat Burhan Imran, Zeenat Yousuf Bhat, 
Yahya M. Osman Malik.  Nephrology, Wayne State Univ S.O.M, Detroit, MI.
Introduction: CUA is a rare, necrotizing skin condition caused by medial calcification 
of sub/cutaneous arterioles leading to tissue ischemia and eventual necrosis. It predominantly 
occurs in patients with chronic kidney disease, associated with high morbidity, mortality 
and variable outcomes-- posing a difficulty in management.
Case Description: We conducted a retrospective chart review from 2010-15. 17 patients 
were diagnosed and treated for CUA in a tertiary university center. Diagnostic methods 
and multi-disciplinary treatment included parathyroidectomy, medical management of bone 
mineral disease, standard wound care, and sodium thiosulfate. We classified outcomes as No 
Improvement, Stable, and Improvement of Lesions related to the mean Calcium-Phosphate 
product (CaXPhos). Table 1 shows patient characteristics.
Characteristics SubjectsN=17
Range
(min-max)
Gender Comorbidities 
Female 13(76.4%) — CAD 7 (41.17%)
Male 4 (23.5%) — CVA 3 (17.64%)
Ethnicity — PAD 8(47.05%)
African American 16 (94.1%) — DM 13(76.4%)
White 1 (5.9%) — HTN 17 (100%)
Mean Age 56.68 28-81 DVT/PE 7 (41.2%)
Mean PTH 1244.68 35-9262 ESRD 16(94.1%)
Mean Calcium 8.95 7.6-10.3 HD 15(93.8%)
Mean PO4 5.75 3.5-8.7 PD 1(6.2%)
CaXPO4 product 51.3 29.1-78.2 Renal Transplant 1(5.9%)
Mean Ferritin 829.7 98-1640 Biopsy Proven Dx 10(58.8%)
Mean Transferrin Sat% 29% 7-51.6 Outcome
Cincalcet use 10(58.8%) — Healing 5(29.4%)
Parathyroidectomy 1 (5.8%) — Stable 4(23.5%)
Wound Care Consult 14(82.4%) — Worsening 8(47.1%)
Sodium thiosulfate 17(100%) —
Figure 1 shows mean CaXPhos product was higher in patients with no response vs. 
those that remained stable or improved.
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Discussion: CUA management still remains multi-faceted, with unpredictable 
responses, and no definitive cure.
PUB418
A Case of Adult-Onset Segmental Membranous Glomerulonephritis 
Mao Watanabe, Toshiyuki Imasawa, Takehiko Kawaguchi, Takafumi Yamakawa, 
Maiko Nagata, Moritoshi Kadomura, Hiroshi Kitamura.  Internal Medicine, 
National Hospital Organization Chiba East Hospital, Chiba, Japan.
Introduction: Generally, adult-onset membranous glomerulonephritis (MN) has diffuse 
and global glomerular changes. We experienced a rare case of segmental MN (SMN).
Case Description: A 66 years old Japanese male was firstly noted proteinuria in an 
annual health check-up. Serum creatinine was 0.76 mg/dl, urine protein excretion was 2.1 
g/gCr, and 10-19 red blood cells/high-power field were observed in the urine sediment. A 
percutaneous renal biopsy revealed segmental spike formation on the glomerular basement 
membrane (GBM) and segmental subepithelial deposits in all glomeruli. Granular deposits 
of IgG, IgM, IgA, C3, C1q were segmentally positive with granular patterns at the same 
regions. In electron microscopy, electron dense deposits were also found segmentally. The 
glomerular tufts with deposits included inflammatory cells (mainly macrophages). Any 
autoimmune disease, malignancies, and infections were detected by further examinations. 
Because urine protein decreased less than 1g/gCr during the hospitalization, only 
temocapril hydrochloride has been prescribed from 67 years old. He has never taken 
immunosuppressive drugs. In 68 years old, because urine protein increased to 3g/gCr, the 
second renal biopsy was performed. Similarly to the first biopsy, segmental spike formation 
on GBM and segmental staining of immunoglobulins and complements were observed. 
The percentage of glomeruli with subepithelial deposits decreased to 60% (6/10) compared 
with 100% (20/20) at the first biopsy.
Discussion: Adult-onset SMN was rarely reported in spite of 30% of MN cases in 
childhood. Here, we firstly reported the sequential pathological changes of adult-onset 
SMN without any immunosuppressive therapy. We will also discuss about the pathogenesis 
about SMN.
PUB419
Hyporeninemic Hypaldosteronism with Hypokalemia: A Rare Association 
Julia Brown, Shankho Shuvro Ganguli, David J. Leehey, Kavitha Vellanki.  Dept 
of Nephrology, Loyola Univ Medical Center, Maywood, IL.
Introduction: Hyporeninemic hypoaldosteronism is characterized by diminished renin 
and aldosterone secretion, with hyperkalemia and mild hyperchloremic metabolic acidosis 
being the hallmark clinical manifestations. It is often seen in diabetic patients with mild to 
moderate renal insufficiency or in patients taking calcineurin inhibitors. Here, we describe 
a rare case of hyporeninemic hypoaldosteronism in the setting of severe hypokalemia.
Case Description: A 19 year old male with a liver transplant due to cryptogenic 
fulminant liver failure presented to our institute with nausea, emesis, and fevers. He 
was 3 months post-transplant and taking tacrolimus, mycophenolate, and prednisone for 
immunosuppression. During the hospital stay, he developed hyponatremia, hypokalemia, 
and severe orthostatic hypotension (table 1). While hyponatremia improved with hydration 
and hypokalemia with aggressive potassium supplementation, orthostatic hypotension 
persisted despite volume repletion and high dose corticosteroids. Further work up revealed 
a normal morning cortisol level of 13.8 ug/dl but very low renin and aldosterone levels 
(table 1). He was started on fludrocortisone 0.1 mg daily, which was subsequently increased 
to 0.1 mg twice daily. His serum potassium levels improved and remained stable without 
potassium supplementation. The etiology of his hyporeninemic hypoaldosteronism was 
thought to be calcineurin inhibitor use, with hypokalemia caused by persistent nausea, 
emesis, and poor oral intake.
Discussion: In conclusion, hypokalemia should not exclude work up for hyporeninemic 
hypoaldosteronism in the appropriate clinical setting. 
Time Admission Day 9 Day 17 Day 23
Serum Sodium (mm/L) 133 127 137 135
Serum Potassium (mm/L) 4.0 3.9 3.6 4.1
Serum Bicarbonate (mm/L) 19 20 23 22
Serum Chloride (mm/L) 105 99 107 106
Serum Glucose (mg/dL) 106 91 93 99
Serum Urea Nitrogen (mg/dL) 14 6 10 4
Serum Creatinine (mg/dL) 1.04 0.74 0.58 0.53
Blood Pressure Supine (mmHg) 101/66 99/52 102/68 128/74
Blood Pressure Sitting (mmHg) - 79/42 72/46 121/69
Blood Pressure Standing (mmHg) - 69/30 83/46 100/54
Plasma Renin Activity (ng/mL/h) - 0.09 0.10 0.13
Plasma Aldosterone (ng/dL) - <1 <1 <1
PUB420
A Case of Hydronephrosis due to Bilateral Retroperitoneal Fibrosis 
Zachary Freestone, Akram M. Shaaban, Josephine Abraham.  Nephrology, Univ 
of Utah, Salt Lake City, UT.
Introduction: Retroperitoneal fibrosis is characterized by inflammatory and fibrous 
retroperitoneal tissue. It is believed to be due to an exaggerated inflammatory reaction to 
aortic atherosclerosis resulting from an immunologic trigger. Retroperitoneal fibrosis can 
be classified as primary or secondary. Secondary causes include medications, malignancy, 
infection, radiotherapy, and trauma. Patients diagnosed with retroperitoneal fibrosis should 
undergo thorough evaluation for infectious causes and malignancy.
Case Description: A 55 year old male presented to the clinic with a chief complaint of 
left side flank and groin pain. He had additional symptoms of night sweats, left leg edema, 
and weight loss. He was referred to our clinic after initially presenting to the emergency 
department and receiving a CT scan of the abdomen identifying left side hydronephrosis 
and a retroperitoneal mass. His past medical history included melanoma 4 years prior and 
cutaneous follicular lymphoma of the right mandible one year prior. Repeat ultrasound 
prior to initiation of therapy showed new right sided hydronephrosis. The patient was 
started on monotherapy with prednisone 1 mg/kg/day. Imaging after initiation of therapy 
showed improvement in fibrosis with resolution of ureteral obstruction. The patient’s serum 
creatinine improved from 1.93 to 1.2 after initiation of therapy. No secondary causes of 
retroperitoneal fibrosis was identified. 
Discussion: Retroperitoneal fibrosis can present as obstruction of the ureters. It is 
often idiopathic, but secondary causes should be ruled out. Secondary causes include 
malignancy, infection, and medications. Recommended therapy includes decompression of 
obstruction if renal function is compromised. If the cause of the disease is idiopathic, then 
immunosuppressive therapy is recommended. If the disease is due to secondary causes, 
the underlying cause should be immediately addressed.
PUB421
BK Virus-Associated Uropathy: A Culprit Mimicking Mechanical Post-Renal 
Obstruction in Early Post-Kidney Transplantation  Ekamol Tantisattamo, 
Aneesha A. Shetty, Bing Ho, Mohammed Javeed Ansari.  Nephrology and 
Hypertension, Northwestern Univ.
Introduction: BK virus has a predilection towards infecting the uroepithelial cells and 
is a known but rare cause of ureteral obstruction of kidney allografts.
Case Description: A 26-year-old woman with ESRD underwent renal transplantation. 
Maintenance immunosuppression included tacrolimus(FK) and mycophenolic acid(MPA). 
FK and MPA levels were 8-16ng/mL and 2-5mg/L, respectively. Three months posttransplant, 
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she developed new onset BK viruria. One month later, she had a new onset BK viremia and 
worsening BK viruria up to 3 million and 67.5 billion copies/mL, respectively(Figure1). 
Concurrently, she had AKI with a serum creatinine(SCr) of 4mg/dL from a baseline of 
1.4mg/dL. Ultrasound showed moderate hydronephrosis(Figure 2). Allograft biopsy 
revealed acute tubular injury with negative SV40. A percutaneous nephrostomy (PCN) tube 
was placed and antegrade nephrostogram showed high-grade ureteral stricture(Figure3). 
A ureteral stent was placed. FK and MPA target levels were decreased to 5-7ng/mL and 
2-4mg/L, respectively. One week later, a repeat nephrostogram showed no obstruction and 
PCN tube was removed. SCr trended down to 1.2mg/dL. Ureteral stent was removed 6 
weeks later. BK viremia became undetectable 6 months posttransplant with low-level BK 
viruria. The high-level BK viremia but negative SV40 in the kidney biopsy in the context of 
ureteric obstruction suggested that there was extensive BK replication within the urothelium 
leading to ureteral stricture and mechanical obstruction. The obstruction improved with 
resolution of BK viremia following reduction in immunosuppression.
Discussion: Medical management of BK virus with lowering immunosuppression can 
be an effective treatment to reverse ureteral obstruction due to BK virus infection, while 
surgical intervention is used to temporarily relieve obstruction.
PUB422
Impact of Cannulation Technique on Access-Related Complications in 
Hemodialysis Patients  Shriharsha Kallahalli Jayaramu, Abhilash Koratala, 
Amir Kazory.  UFL; UFL; Div of Nephrology, Univ of Florida.
Introduction: There is growing interest in home hemodialysis therapy leading to 
increased involvement of patients in their own care. Buttonhole cannulation technique 
(BHCT) is considered a practical option for self-cannulating patients due to perceived lower 
incidence of access-related complications such as pain. The aim of this study is to provide 
a reappraisal of the current evidence on the complications of BHCT and conventional 
rope-ladder cannulation technique (RLCT) in hemodialysis patients.
Case Description: Articles cited in PubMed database from 2000 to 2015 using key 
words “hemodialysis”, “cannulation”, and “buttonhole” were searched. Original articles 
evaluating hemodialysis access cannulation techniques were reviewed; randomized 
controlled trials (RCT) were selected.Relevant data including primary outcomes and 
access-related complications (i.e. pain, infection, bleeding, and aneurysm) were extracted 
and compared.
A total of 70 articles were found, of which 6 RCT were reviewed and 5 were included 
in this study (1 duplication). There were a total of 472 patients (BHCT 227 and RLCT 
245) with follow up periods ranging from 2 to 12 months. Two studies reported more 
pain with RLCT while it was similar in 2 studies and one found more pain with BHCT. 
Importantly, there was a significant tendency for infection with BHCT compared to RLCT 
in all 4 studies that could evaluate this complication and included 73% of the patients; the 
overall rate of infection being too low in one trial to be conclusive. Bleeding complications 
were similar in 4 studies while 1 found higher risk with BHCT. Only 2 studies reported 
higher tendency for increase in the size of the access in the RLCT group while 3 did not 
evaluate this complication.
Discussion: BHCT is associated with only a modest favorable impact on access-related 
pain in hemodialysis patients while it portends a significant increased risk of infection. 
There is inconclusive data regarding the impact of cannulation technique on bleeding 
complications and aneurysmal changes. Based on the findings of the currently available 
RCT, routine use of BHCT cannot be recommended for hemodialysis patients.
PUB423
A Case of Lupus Nephritis Accompanied with Long-Term Thrombotic 
Microangiopathy  Kazuhito Fukuoka,1 Shinya Kaname,1 Yoko Yoshida,2 Hideki 
Kato,2 Masaomi Nangaku,2 Yoshihiro Arimura.1  11st Dept of Internal Medicine, 
Div of Nephrology and Collagen Disease, Kyorin Univ School of Medicine, 
Mitaka, Tokyo, Japan; 2Dept of Nephrology and Endocrinology, The Univ of 
Tokyo School of Medicine, Bunkyo-ku, Tokyo, Japan.
Introduction: Although TMA is sometimes complicated in collagen disease, the 
features and its cause are still unclear.
A 39-year-old woman with a history of lupus nephritis (class V) for 19 years was 
admitted to our hospital due to complicated microangiopathic hemolytic anemia (MHA). 
Coombs test and anti-phospholipid antibodies were both negative. Considering that SLE 
played some roles, we reinforced immunosuppressive treatment and plasma exchange, 
which was only partially effective. MHA fluctuated, and seven years later renal function 
began to decline gradually, with an exacerbation of MHA. TMA was suspected, but 
ADAMTS13 activity showed within normal ranges without anti-ADAMTS13 antibody, 
thus TTP was neglected. Serum C3 levels proved low, thus we considered the possible 
involvement of complement activation, and performed hemolysis test for sheep RBCs 
using the patient’s plasma 
(a). The results showed that hemolysis was observed with recovery by adding 
complement factor H, suggesting that complement system was activated(b). Based on 
these results, she was diagnosed as atypical HUS. Despite intensive treatment, she finally 
progressed to maintenance HD, but the findings of TMA were gradually improved. 
Two months later, we examined the hemolysis test again, showing the negative results. 
Sequence analysis of the aHUS-related genes revealed two SNPs, none of which have 
been reported before.
Discussion: Our case report shows that a SLE patient can complicate TMA caused by 
complement-mediated HUS, which may be reversed during the treatment course, suggesting 
the possible involvement of genetic predisposition and some triggering factors/conditions.
PUB424
Glomerulonephritis Crescentic Pauci-Immune ANCA Related IgA – A Case 
Report  Maria C. Piraciaba, Precil Diego Miranda de Menezes Neves, Cristiane 
B. Dias, Luis Yu, Leonardo Abreu Testagrossa, Denise M. Malheiros, Viktoria 
Woronik, Irene L. Noronha, Lectícia Jorge.  Univ de São Paulo.
Introduction: The pauci-immune crescentic glomerulonephritis (PICG) are mostly 
related to antineutrophil cytoplasmic antibodies (ANCA). IgG is detected in 80-90% of 
cases. PICG reports related to ANCA IgA are rare due to low suspicion and research of 
IgA ANCA. We report a case of PICG ANCA related IgA.
Case Description: Pacient female with 83 years, asthenia and abdominal pain for 
4 months and 10 days ago emergence of purpuric lesions in upper and lower limbs and 
trunk. Biopsy of purpuric lesion showed leukocytoclastic vasculitis with granular IgA 
deposits in the vessels of the papillary dermis. After diagnosis of Henoch-Schonlein, 
prescribed treatment with prednisone 1 mg / kg for two weeks, with drug weaning. The 
skin lesions disappeared, but the patient evolves with important asthenia. Renal biopsy, 
15 glomeruli, 7 completely sclerotic, 3 with increasing cell and 3 with increasing focal 
fibroblast. Positive immunofluorescence for Fibrinogen + 2 / + 3 in the growing, being the 
framework compatible with glomerulonephritis crescentic pauci-immune, mixed form. 
By previous cutaneous involvement with IgA deposits, requested assessment of ANCA 
IgA by immunofluorescence. As the result was positive, the patient was treated with 
methylprednisolone and mycophenolate sódico, with recovery of renal function.
Discussion: The ANCA IgA evaluation should be considered in cases where there 
PICG increased serum IgA levels.
PUB425
Acute Interstitial Nephritis Associated with Probiotic Use  Sandar Win, 
Gaurang P. Mavani, Joshua A. Schwimmer.  Div of Nephrology, Lenox Hill 
Hospital of the North Shore-LIJ Health System, New York, NY.
Introduction: Acute interstitial nephritis (AIN) is associated with a variety of 
etiologies, including infections, autoimmune conditions, and medications. Probiotics are 
over-the-counter microorganisms used for their potential health benefits, and studies show 
probiotics may have immunostimulatory and immunomodulatory effects. We report the 
first potential case of AIN associated with the use of probiotics.
Case Description: A healthy 44-year-old man was found to have a stable baseline Cr 
of 1.16 mg/dL with a measured CrCl in the normal range. 42 d later, to treat infrequent 
loose bowel movements (2x/wk), he consumed a probiotic regimen of 10 billion cells of 
Lactobacillus GG bid for 14 d. There was no diarrhea, fevers, rash, blood in the stool, or 
exposure to NSAIDs, antibiotics, herbs, or other medications. 11 d after probiotics use, 
during a routine physical, he was found to have an increase in his Cr to 1.66 mg/dL (an 
increase of .5 mg/dL in 52 d). There was no proteinuria or hematuria, and an ANA was 
negative. A renal sonogram revealed echogenic, normal-sized kidneys. His Cr remained 
1.4-1.6 mg/dL and did not return to baseline. 135 d after exposure to probiotics, a renal 
biopsy was performed. The biopsy revealed patchy tubular atrophy and interstitial fibrosis 
affecting 10% of the cortical area with a few mononuclear inflammatory cells and focal 
mild lymphocytic tubulitis, consistent with resolving AIN.
Discussion: In this case, the temporal association between the use of probiotics with 
kidney injury and the absence of other causes of AIN implicates the probiotic Lactobacillus 
GG as the etiologic agent. The mechanisms by which probiotics could potentially cause AIN 
include manipulation of intestinal microbial communities, immunomodulation, alteration of 
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responsiveness of intestinal epithelial and immune cells, and altering the immunogenicity of 
degraded enteric antigens. Given the frequent over-the-counter use of probiotics, multiple 
potential coexisting etiologies for AIN, the often indolent nature of this disease, the rarity 
of this association, and the need for a renal biopsy to establish the diagnosis, the association 
between probiotics and AIN may be under-recognized.
PUB426
Decision-Making for the Critically Ill Un-Befriended Patient  Aprajita Mattoo, 
Jennifer S. Scherer.  Nephrology, NYU School of Medicine, New York, NY.
Introduction: The “un-befriended” patient is one that lacks decision-making capacity 
& a surrogate decision-maker (SDM). Nephrologists encounter un-befriended patients often, 
yet limited literature exists to guide decision-making for these vulnerable patients. This 
case describes an organized approach to caring for a critically ill un-befriended patient.
Case Description: Mr. S was a 74 year old wheelchair bound nursing home (NH) 
resident who underwent an urgent right hemicolectomy for a perforated colon. His post-
operative course was complicated by septic shock & multi-organ failure including AKI due 
to ATN. During this time his serum Cr increased from 0.8 to 3.6 mg/dl, with a urine output 
of <50cc/day. Mr. S was obtunded & had diffuse anasarca. He lacked advance directives 
& any SDM. The primary service believed that dialysis (HD) should be withheld given 
his overall poor prognosis. The consulting renal service utilized the four-topic approach 
to ethical decision-making to guide their recommendations. An estranged sister was asked 
to partake in an inter-disciplinary team (IDT) family meeting with renal, palliative care, 
bioethics, & the primary service to explore Mr. S’s values. It was established that Mr. S 
cherished his life in the NH & would have appreciated time there even if on HD. Given 
this information, the IDT decided that a time-limited trial of HD would be reasonable. 
Before HD was needed however, Mr. S decompensated due to fungemia. The IDT agreed 
that death was imminent, even with HD. Under provisions of the NY State Family Health 
Care Decisions Act (FHCDA), it was determined to be ethically appropriate to withhold 
HD & transition Mr. S to comfort care.
Discussion: Utilizing the four-topic approach to decision-making, established legal 
policies, & an IDT, nephrologists can manage un-befriended patients within an organized, 
legally sound, & ethically sensitive framework. 
PUB427
Persistent Kidney and Alveolar Damage in Patients with Goodpasture’s 
Disease and Negative Anti-GBM Antibodies  Giovanna Y. Arteaga Muller,1 
Lilia Maria Rizo Topete,1 Elisa Maria Guerrero Gonzalez,1 Concepcion Sanchez 
Martinez,1 Jesus Cruz Valdez,1 Gabriela Alarcón-Galván.2  1Nephrology, Univ 
Hospital José E. González UANL, Monterrey, Mexico; 2Anatomic Pathology, 
Univ Hospital José E. González UANL, Monterrey, Mexico.
Introduction: Goodpasture’s disease is characterized by the presence of basement 
membrane antibodies which act against type 4 collagen in the glomerular basement 
membrane (GBM) and alveoli, it represents 20% of all crescentic glomerulonephritis.
Case Description: 21 year old woman, with anemic syndrome presenting Hb 4.33g/
dl, Cr 0.8mg/dl, receiving a red cell transfusion. Is readmitted 15 days later Hb 2.7g/dl 
and Cr 1.9 mg/dl, whereby three globular packages were transfused and she was referred 
to our hospital. On admission, the patient was hypertension, lower limb edema and gross 
hematuria, Hb 11g/dl, Cr 1.7mg/dl, negative ANA’s and ANCA’S and positive anti-GBM 
antibodies. Renal biopsy showed crescentic glomerulonephritis and linear staining deposits 
of IgG in GBM (4+). 
Direct immunoflourescence technique (400X). Linear glomerular basement membrane 
staining for IgG. 
Immunosuppresive therapy begins with methylprednisolone and CYCLOPS 
protocol.Later hemoptysis which improves with plamasferesis, negative control anti-
GBM antibodies. After presented sudden hypoxemia, bronchoscopy with abundant 
hemosiderin-laden macrophages, whereby plasmapheresis is performed again together with 
methylprednisolone, cyclophosphamide and rituximab. Currently the patient is in chronic 
hemodialysis, with negative anti-GBM antibodies.
Discussion: In patients with positive anti-GBM antibodies renal involvement may 
occur alone or associated with pulmonary hemorrhage, our patient despite having negative 
anti-GBM antibodies presented pulmonary hemorrhage. The literature recommends confirm 
the sustained absence of anti-GBM antibodies and signs of recurrence every 6 months.
PUB428
Gitelman Syndrome: Use of Dual Potassium-Sparing Agents in Refractory 
Hypokalemia  Maria Bernadette Yballe, Sandeep Aggarwal.  Div of Nephrology, 
Drexel Univ, Philadelphia, PA.
Introduction: Hypokalemia is one of the most frequently encountered electrolyte 
disturbances. Chronic hypokalemia with hypomagnesemia should prompt further 
investigation to include rare genetic disorders such as Gitelman syndrome. Despite the 
appropriate diagnosis, treatment can be challenging.
Case Description: We present a case of a 49 year-old non-hypertensive Caucasian 
female who presented to our outpatient clinic for an evaluation of her polyuria, chronic 
hypokalemia and hypomagnesemia. Her polyuria started in the first trimester of her first 
pregnancy in her 20s. She has one sibling with similar complaints, sparing her parents and 
her daughter. She complained of paresthesia and lower extremity weakness. She reports no 
diuretic use, OTC weight loss regimen, and no diarrhea. She has been on potassium and 
magnesium supplements with spironolactone without a definitive diagnosis. Despite these 
interventions, electrolytes remained abnormal with a potassium of 2.8, magnesium of <1.0, 
and a serum creatinine of 0.5 mg/dL with a renin activity of 1.78 ng/dL and aldosterone level 
of 36 ng/dL (ARR 20.2). A 24-hour urine study revealed a low urine calcium of <5.0 mg/
day consistent with Gitelman syndrome. Genetic testing revealed two distinct heterozygous 
missense autosomal recessive mutations of the SLC12A3 gene from Athena Diagnostics: c. 
1315G>A; p.Gly439Ser and c. 2221G; p.Gly741Arg. She was continued on spironolactone 
along with potassium and magnesium supplements. Despite supplementation, she often 
required hospital visits which prompted magnesium and potassium infusions. Addition 
of amiloride improved her electrolyte levels, decreasing the need for hospitalizations and 
supplementations.
Discussion: Gitelman syndrome occurs in only ~1% of the Caucasian population which 
presents as chronic, sometimes severe and symptomatic hypokalemia, hypomagnesemia, 
hypocalciuria, and normotensive aldosteronism. The existence of 2 unique recessive alleles 
inherited by two siblings makes this case even more of a rarity. Our case also demonstrates 
the effective addition of a second potassium-sparing agent such as amiloride in ameliorating 
the need for more supplementation.
PUB429
Cerebral Ethylene Glycol Toxicity Despite Prompt Renal Replacement 
Therapy  Maria Bernadette Yballe, Sandeep Aggarwal.  Div of Nephrology, 
Drexel Univ, Philadelphia, PA.
Introduction: Acute cerebral edema is a rare consequence of ethylene glycol toxicity. 
Despite prompt initiation of therapy with fomepizole and renal replacement therapy, rare 
case reports of central hypodensities on CT imaging with neurologic abnormalities have 
been reported.
Case Description: We present a case of a 38 year-old female with PMH of HTN and 
anxiety who was brought in for agitation. One hour later, the patient became obtunded with 
significant respiratory distress requiring intubation. Home medications included bupropion. 
It was unclear if she ingested any toxins but the patient did have a history of marijuana 
use. On physical examination, the patient was hypertensive 210/114 mm Hg with reactive 
pupils. She was found to have high anion gap metabolic acidosis with a pH of 6.808, a 
serum bicarbonate of 4, an osmolal gap of 68, and a lactic acid of 5.6. Levels of ethanol, 
acetaminophen, phenobarbital, salicylate, and valproic acid levels were undetectable 
while urine drug screen was only positive for THC. Head CT did not reveal any acute 
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pathology. Urine microscopy revealed multiple ovoid colorless crystals in rosette formation 
consistent with monohydrate calcium oxalate crystals. Fomepizole was immediately 
started and intermittent dialysis initiated promptly within 10 hours of ingestion. However, 
due to hemodynamic instability, RRT had to be converted to a continuous veno-venous 
hemodialysis. After 2 days, patient then experienced an acute hypertensive episode with a 
BP of 27/120 mm Hg from a radial arterial line with pinpoint pupils and a repeat head CT 
revealing cerebral hypodensities in the basal ganglia, thalami, and brainstem along with 
transtentorial and tonsillar herniation. On day 5, patient met criteria for brain death and 
was assessed for organ donation.
Discussion: Despite prompt initiation of dialysis, rare case reports of acute cerebral 
edema from ethylene glycol toxicity have been reported. It is unknown whether these 
abnormalities are due to direct cellular toxicity or deposition of crystals in the cerebral 
vasculature causing ischemia and subsequent edema and inflammation. Our case 
demonstrates a rare neurologic sequela of ethylene glycol toxicity despite appropriate 
and prompt treatment.
PUB430
E n c a p s u l a t i n g  P e r i t o n e a l  S c l e r o s i s  –  C a s e  R e p o r t s 
André Luiz De Andrade Araújo, Maria Alina G.M. Cavalcante, Amadeu 
Marinho, Teg Marcos Veiga, Luis H.B.C. Sette, Lucila Maria Valente. 
Nephrology, Univ Federal de Pernambuco, Recife, Pernambuco, Brazil.
Introduction: Encapsulating Peritoneal Sclerosis (EPS) is a rare but serious and 
potencially lethal complication in peritoneal dialysis (PD), first described in 1980. Intestinal 
obstruction, serious malnutrition and sepsis are the causes of death. This uncommom 
condition is the result of chronic abdominal inflammation of multifactorial origin.  High risk 
patients include PD for more than 8 years and with frequent peritonitis (two-hits theory). 
The exact incidence is unknown.
Case Description: We described outcomes of 6 cases followed in a referral service 
of PD between 2010 and 2015. 
Case
Gen-
der/ 
Age 
(years)
CKD 
ethiol-
ogy
Time
on PD
(years)
EPS 
related 
infec-
tious 
agent
Previ-
ous 
Perito-
nitis
(num-
ber)
Clinical 
Features
Radio-
logic 
Finds
Perito-
neal
Biopsy
Out-
come
1 F / 47 SAH 8
Can-
dida sp / 
Staphy-
lococ-
cus 
aureus 
6
Acute ab-
dominal 
obstruc-
tion + 
Bloody 
effluent
Loculat-
ed ascites 
+ Peri-
toneal 
thicken-
ing and 
calcifica-
tions
Chron-
ic peri-
tonitis 
+ Peri-
toneal 
thick-
ening 
+ 
Fibrin 
deposi-
tions
HD 
since 
2010
2 F / 47 SAH 4
Pseudo-
monas 
aerugi-
nosa
3
Partial 
bowel 
obstruc-
tion + 
Bloody 
effluent
Loculat-
ed ascites 
+ bowel 
thicken-
ing
--
HD 
at 08 
months
3 F / 18 PIGN 10
Staphy-
lococ-
cus co-
agulase 
negative
5
Partial 
bowel 
obstruc-
tion + 
pain
Moderate 
ascites + 
Peritone-
al/Bowel 
calcifica-
tion.
--
HD 
since 
2013
4 M / 68 T2DM 2,5
Esch-
erichia 
coli / 
Kleb-
siella 
oxycata.
2
Partial 
bowel 
obstruc-
tion + 
pain
High 
volume 
loculated 
ascites 
+ bowel 
tethering
--
HD 
since 
2012
5 F / 39 SLE 8
Entero-
coccus 
sp
1
Bowel 
obstruc-
tion + 
Severe 
malnutri-
tion + 
Chronic 
abdomi-
nal pain 
+ Bloody 
effluent
Perito-
neal cal-
cification 
+ bowel 
disten-
tion + 
high 
volume 
ascites
--
Death 
for 
sepsis 
after 8 
months
6 M / 53 T2DM 2,5
Strepto-
coccus 
viridans
2
Abdomi-
nal dis-
tension + 
pain
High 
volume 
unique 
perito-
neal col-
lection + 
intestinal 
coccon
--
HD 
since 
2014
SAH: Sistemic Arterial Hypertension; SLE: Sistemic Lupus Eritematous; T2DM: Type 2 Diabetes 
Mellitus; PIGN: Post Infectious Glomerulonephritis;CKD: Chronic Kidney Disease. 
Discussion: EPS is a severe event related a long term on peritoneal dialysis or severe 
cases of peritonitis.
PUB431
AM Tolvaptan to Avert Hyponatremic Seizures in a Patient with Primary 
Polydipsia and New Mildly Impaired Free Water Excretion  Amit N. Shah, 
Adam G. Winkler, Claude Bassil, Bassem H. Rouphael, Jacques A. Durr.  Div 
of Nephrology, Univ of South Florida, Tampa, FL.
Introduction: A former pilot with a history of primary polydipsia PP (past urines >6 l/
day) complained of confusion. Plasma (PNa) and urine sodium were 123 and 37 mEq/l, and 
plasma (Posm) and urine osmolalities, 251 and 207 mOsmol/kg H2O . With cessation of Prozac 
and advised fluid restriction (FR) PNa corrected. Interim Posm was 286 mOsmol/kg and urine 
SG 1.005. Following multiple surgeries (decompressive laparotomy, subtotal colectomy, 
ileostomy, feeding gastrostomy, for compartment syndrome/pancreatitis), she had a first 
hyponatremic seizure (HS). No cause for impaired free water excretion (iFWE) was found. 
Her PP made FR difficult, as she was thirsty at PNa <125 mEq/l, and caused repeat HSs.
Case Description: After her 4th seizure, we replaced FR and salt tablets with AM 
tolvaptan. This normalized PNa, abolished her recurrent HSs, and was tailored to her new 
dreadful PP-SIADH combination.
Indeed, since thirst is constant in DI but only diurnal in PP, the AM tolvaptan-induced 
daytime DI allowed her to quench her thirst without fear of HSs, since iFWE recurred only 
by hs, when the drug effect wore off, and her PP abided. She was reluctant giving up this 
diurnal/nocturnal PP-DI/SIADH, for fear of seizures.
Discussion: Given the high capacity for FWE, a syndrome of inappropriate antidiuresis 
(SIAD) or impaired diuresis-aquaresis (SIDA), due or not to ADH (SIAD/H or SIDA/H) 
must coexist in PP, for HS to occur; conversely some PP or other source of free H2O must 
exist in the ‘SIAD/H – SIDA/H’ spectrum of iFWE to cause HS, since FR alone increases 
the low PNa, and prevents HS during depot ADH in man, or chronic dDAVP infusion in rats. 
This is the first report of successful compassionate off label use of AM tolvaptan, instead 
of FR, to prevent HS in a patient where PP is the culprit. However FR instead of vaptans 
is the first line treatment of low PNa in SIADH, yet here ADH is the culprit. The fact that 
PP and SIAD/H (or iFWE state) must coexist to cause HS, and that ADH, as assessed by 
sensitive assays is rarely totally suppressed, resolves this paradox.
PUB432
Atypical Presentation of Calcium Oxalate Nephropathy  Young-Soo Song,1 
Joel M. Henderson,2 David J. Salant,1 Sandeep Ghai.1  1Renal Medicine, Boston 
Univ Medical Center, Boston, MA; 2Pathology and Laboratory Medicine, Boston 
Univ Medical Center, Boston, MA.
Introduction: Ethylene glycol ingestion can cause multi-organ dysfunction including 
acute kidney injury (AKI) and death. The diagnosis can be made based on history, a high 
anion gap metabolic acidosis with an elevated osmolar gap, oxalate crystalluria and an 
elevated ethylene glycol level. The diagnosis may be challenging with the concurrent use 
of other substances such as cocaine as it causes vasomotor AKI or ANCA vasculitis. To 
elucidate the diagnosis, a renal biopsy may be required. Herein, we present a patient with 
biopsy proven calcium oxalate nephropathy who presented with unexplained AKI likely 
related to unintentional low dose regular ethylene glycol use. She did not have any symptoms 
or classic biochemical features of ethylene glycol intoxication.
Case Description: A 57-year-old homeless woman with a history of rheumatoid 
arthritis, COPD presented with a productive cough and dysgeusia and was found to have 
a Cr of 8.9 mg/dl, elevated from a recent baseline of 0.9 mg/dL. Her anion gap was 17, 
with no other electrolyte abnormalities. Toxicology was negative for ethanol or salicylates. 
Her BP was 157/77 mm Hg and physical exam was unremarkable. Her last use of cocaine 
was 3 days prior to admission. She was initially given normal saline and maintained an 
adequate urine output, but her Cr continued to rise to 13.0 mg/dL. Urine sediment showed a 
few isomorphic RBCs only. A renal ultrasound revealed normal sized kidneys. Serological 
tests for autoimmune, post-infectious and dysproteinemic causes of AKI were normal or 
negative. Renal biopsy revealed acute tubular injury with calcium oxalate deposition. An 
in depth history did not reveal a high oxalate diet nor a medical history predisposing her 
to hyperoxaluria, however she admitted to the regular ingestion of “juiced” street alcohol. 
She did not require dialysis. Her follow-up Cr was 1.8 mg/dl two months later.
Discussion: In conclusion, a thorough history is required when encountering unknown 
AKI in patients with a history of drug abuse or homelessness, while keeping a high index 
of suspicion for drug intoxications including ethylene glycol.
PUB433
Thrombotic Microangiopathy (Hemolytic-Uremic Syndrome) Induced 
Acute Kidney Injury Associated with Brucella Infection  Thomas E. Craig, 
Jonathan G. Owen.  Dept of Medicine, Section of Nephrology and Hypertnesion, 
LSUHSC, New Orleans, LA.
Introduction: Thrombotic microangiopathies (HUS, TTP and DIC) have been 
associated with a host of infectious agents. Its association with Brucellosis is uncommon. 
We present a case of a patient who developed TMA associated with a case of Brucellosis.
Case Description: 52 year-old woman with minimal past medial history presented 
to the hospital with abdominal pain, fevers/chills and generalized body aches. History 
was significant for intermittent bloody diarrhea approximately 2 weeks prior to ED 
presentation. Physical examination revealed epigastric and right upper quadrant tenderness 
to palpation and patient was started on broad-spectrum, empiric IV antibiotic therapy with 
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Vancomycin, Piperacillin/Tazobactam, and Ciprofloxacin. Shortly thereafter, her clinical 
status deteriorated resulting in acute respiratory failure requiring intubation and mechanical 
ventilation. CBC was notable for a white blood cell count of 27,000, hemoglobin of 7.3 g/
dL and a platelet count 80,000. Other labs were notable for total bilirubin 2.3 mg/dL, LDH 
509 U/L, haptoglobin less than 10 , lactic acid 5.7 mmol/L and elevated transaminases. 
Peripheral Smear was notable to be positive for numeours schistocytes. Patients was anuric 
and Nephrology consultated to begin CRRT in setting of sepsis requiring three vasopressors. 
Patient had a rapid improvment in symptoms after initiation of sepsis protocol and was 
weaned off all vassopressors by 72 hours. Initial workup including abdominal imaging and 
blood cultures were negative for a source of infection. Patient had remarkable spontaneous 
clinical recovery and was later found to be positive for Brucellosis by immunoglobluin assay.
Discussion: Brucella infection has uncommonly been associated with the development 
of Hemolytic Uremic Syndrome. In addition, clinical course is widely variable, ranging 
from spontaneous recovery, as occurred with this patient, to disease requiring long-term 
renal replacement therapy.
PUB434
Patient with Clinical Diagnosis of Scleroderma Presenting with Sjögrens’ 
Associated Renal Disease  Aala Jaberi, Jasvinder S. Bhatia.  Nephrology, Boston 
Medical Center, Boston, MA.
Introduction: Overlap rhematologic syndromes can occur in a substantial number 
of patients with renal disease. The clinical manifestations often favor one diagnosis over 
another, which can make diagnosing and treating the renal disease very challenging.
Case Description: 69-year-old female with no known history of previous 
rheumatologic disease presented with cough, fever and AKI and was diagnosed with 
multifocal pneumonia. Initial laboratory tests revealed a creatinine level of 2.2mg/dl, and 
persistent non anion- gap metabolic acidosis. On further history, she complained of long 
standing heartburn and Raynaud’s symptoms in her fingers. Her physical exam disclosed 
telangiectasia on palms and skin thickening of the face and PIP joint. These features were 
consistent with systemic scleroderma, which prompted a rheumatologic work-up. Serologies 
were significant for a positive ANA and SSA antibody as well as hypocomplementemia. 
Urine sediment revealed many WBCs with no casts and some non-dysmorphic RBCs. A 
decision was made to proceed with kidney biopsy to identify the cause of her renal disease 
since the sediment was not supportive of Scleroderma associated renal disease. Kidney 
pathology showed acute interstitial nephritis with mild chronic changes which, when 
combined with the serologic tests, was highly suggestive of Sjögrens syndrome-associated 
renal disease. She was commenced on corticosteroid therapy and two months post-initiation, 
her renal function has stabilized.
Discussion: This case demonstrated the importance of kidney biopsy in elucidating 
a diagnosis in a challenging case of overlap syndrome. The rapid diagnosis of interstitial 
nephritis was particularly important in this patient since most cases of renal associated 
Sjögrens’ go unrecognized until significant renal dysfunction has occurred. It has been 
proposed to consider kidney biopsy findings of tubulointerstitial disease as additional 
supportive criteria in the classification of Primary Sjögren’s syndrome, which is a sentiment 
we also support.
PUB435
More Than Just Diabetic Glomerulosclerosis – “A Challenge to the 
Epidemiological Paradigm”  Juan Antonio Medaura, Jeffrey D. Wallach. 
Nephrology, Harlem Hospital Center, New York, NY.
Introduction: Acute post infectious glomerulonephritis (APIGN) most frequently 
affects children and is relatively uncommon in adults. The incidence has declined sharply 
in industrialized countries over the last 50 years. Adults with an immune compromised 
background, especially due to alcoholism and/or diabetes are at higher risk for developing 
the disease.
Case Description: A 61 year old Hispanic male with medical history of uncontrolled 
diabetes, Hypertension and chronic alcohol abuse presented to the emergency department 
due to shortness of breath and swelling of his legs since one week. Patient was afebrile, blood 
pressure 200/102 mm Hg. On exam he had clear signs of fluid overload. Pitting edema was 
seen over the lower extremities bilaterally, up to the shins. He also had an oval ulcer on his 
right leg anteriorly measuring 2 cm discharging pus. The remainder of the physical exam 
was grossly normal. Relevant laboratory results potassium of 6.4 meq/L, BUN 51 mg/dl, 
Creatinine 1.7 mg/dl (Baseline unknown) and Albumin 2.8 gr/dl. Urinalysis: protein 300 mg/ 
dl, blood MOD, WBC 61/hpf, RBC 87/hpf, Hyaline casts 7/hpf. Urine eosinophils present. 
Urine 24 Hr Protein: 6.7 gr. Wound cultures positive for Beta Hemolytic Streptococcus 
Group A. Complement C3: 19 Ch50: <10, C4:34 Antistreptolysin O:400 [<200 IU/ml] 
Anti DNAse B Titre: 967. Kidney biopsy results: acute post-infectious glomerulonephritis 
superimposed on background changes of moderate nodular diabetic glomerulosclerosis. 
Discussion: Most children with APIGN recover completely, but there is general 
agreement that the prognosis is more guarded in adults. Full recovery of renal function can 
be expected in just over half of patients, and prognosis is dismal in those with underlying 
diabetic glomerulosclerosis.
PUB436
Two Cases of Kidney Injury Induced by Anti-VEGF Therapy for Carcinoma 
Yudai Isozaki, Yosuke Nakagawa, Takuya Isegawa, Masahiro Koizumi, 
Masafumi Fukagawa.  Div of Nephrology, Endocrinology and Metabolism, 
Tokai Univ School of Medicine, Isehara, Kanagawa, Japan.
Introduction: Anti-vascular endothelial growth factor (VEGF) agents have been widely 
used in the treatment of various types of advanced-stage malignant tumor, including lung 
carcinoma and renal cell carcinoma. Although these agents are generally well tolerated, 
there are increasing reports of renal adverse events, especially proteinuri.
Case Description: Case 1: A 69 year-old male started chemotherapy including 
bevacizumab (monoclonal antibody of VEGF) with a diagnosis of advanced lung 
adenocarcinoma of left upper lobe. The completion of four-course chemotherapy resulted 
in reduction of tumor volume, and then converted to bevacizumab monotherapy. At one 
year after the start of therapy, proteinuria with renal insufficiency developed. He was 
referred to our service for further evaluation and management. Renal biopsy demonstrated 
microthrombi in the loop wall with duplication of GBM, which was consistent with 
thrombotic microangiopathy (TMA). Thereafter, with cessation of anti-VEGF agent, 
proteinuria was gradually ameliorated to less than 1.0 g/day and renal function returned to 
normal range. Case 2: A 56 year-old male with renal cell carcinoma, who had undergone 
nephrectomy with three years before, subsequently proved to have metastatic lesion in 
lumbar vertebra. He started treatment with sunitinib, a tyrosine kinase inhibitor which 
blocks the intracellular domain of the VEGF receptor. This patient had baseline renal 
insufficiency due to nephrectomy and diabetes. After the introduction of therapy, he 
exhibited progression of kidney disease with nephrotic-range proteinuria in a short time. In 
addition to the cessation of sunitinib, hemodialysis was initiated because of fluid overload. 
After several times of dialysis, urine output was gradually increased and renal function 
returned to the baseline level.
Discussion: The renal adverse effects of anti-VEGF agents are supposed to arise from 
inhibition of podocyte-endothelial VEGF signaling pathway. VEGF signaling pathway 
plays an essential part in glomerular development and endothelial maintenance. We need 
to pay attention to renal adverse effects with anti-VEGF therapy.
PUB437
Concurrent Development of Eculizumab (ECU) (Anti-C5 Antibody)-
Responsive Atypical Hemolytic Uremic Syndrome (aHUS) and Siltuximab 
(SLT) (Anti-IL-6 Antibody)-Sensitive Multicentric Castleman Disease 
(MCD): Evidence for the Pathogenic Role of Inflammatory Cytokines 
Joe Ghata,1 Abdulmawla Albirini,1 Kai Lau.1,2  1Nephrology, Univ of Oklahoma, 
Oklahoma City, OK; 2Medicine, VA Medical Center, Oklahoma City, OK.
Introduction: The literature has a few cases on the association of MCD with thrombotic 
microangiopathy (TMA), but the pathogenesis & therapy are unknown.
Case Description: We describe a 29-year-old previously healthy man initially presented 
with non-specific symptoms of what later proved to be MCD. Diagnosis was delayed due to 
explosive full-blown systemic & biopsy-proven renal TMA, producing dialysis-dependent 
ARF, severe thrombocytopenia & transfusion-dependent hemolytic anemia till eculizumab 
(ECU). The appearance of diffuse lymphadenopathy 8 weeks after acute renal failure (ARF) 
led to node-biopsy proven MCD diagnosis & therapy with SLT. We postulate MCD was 
the trigger for TMA & full resolution needs both ECU & SLT directed at the etiology.
10 d before ARF, patient had abdominal pain, treated as cholecystitis by cholecystectomy. 
Mild splenomegaly & trace ascites were overlooked. Day 7 after ARF, bilateral pleural & 
pericardial effusion & moderate ascites emerged but overlooked as serum creatinine rose 
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from 0.9 to 11.3 mg% by day 33. At this point, Hgb fell to 6 g%, platelet to 45 k/mm3, 
LDH peaked at 760, C3 down to 50 & C4 to <0.8. aHUS was diganosed by normal (nl) 
ADAMTS13 level, absent Ab & negative Shigatoxin. After 4 doses of ECU, by day 50 all 
features of TMA improved. Negative were ANA, ANCA, cryo, antiphosplipid Ab, hepatitis 
profile, SPEP, HHV 6, 8, & HIV. On day 54, diffuse large lymphadenopathy appeared on CT 
of chest & abdomen with 18.8 cm spleen & generalized anasarca & polyserositis. HS-CRP 
was up 25 x nl. [IL-6] & [VEGF] were 2-12 fold nl. Lymphadenopathy regressed 50% after 
4 & >75% after 8 doses doses of SLT. Edema fully resolved after 2 doses.
Discussion: We conclude that intense cytokine activation due to MCD played a 
pathogenic role in his aHUS, as evidenced by the precedence of splenomegaly & anasarca 
to his TMA & by the dependency of anti-IL-6 Ab for full resolution of his MCD.
Funding: NIDDK Support, Veterans Administration Support, Private Foundation 
Support
PUB438
Severe Hypercalcemia Presenting During Recovery Phase of Ischemic 
Acute Kidney Injury  Buthayna A. Dinary,1 Fazel Dinary,2 Lavinia A. Negrea.1 
1Nephrology and Hypertension, Univ Hospitals Case Medical Center, Cleveland, 
OH; 2Internal Medicine, SVCMC/CWRU, Cleveland, OH.
Introduction: AKI is frequently complicated by multiple electrolyte abnormalities, 
including hyperkalemia, hyperphosphatemia, and hypo/hypercalcemia. Hypercalcemia 
is often seen in the recovery phase of rhabdomyolysis associated AKI, can be severe 
and life-threatening. Several etiologies for delayed hypercalcemia have been proposed, 
including mobilization of calcium deposits out of the recovering muscles, secondary 
hyperparathyroidism, increase in calcitriol, and resolution of hyperphosphatemia.
Case Description: A 31 yo Caucasian male with recently diagnosed Type I DM. 
Admitted for DKA complicated by cardiac arrhythmia, cardiac arrest, respiratory failure, 
septic shock, and oligouric AKI requiring a prolonged period of renal replacement 
therapy Ultimately renal function recovered and patient was taken off dialysis. There 
was no evidence of rhabdomyolysis clinically or biochemically at any time during his 
hospitalization. He was hypocalcemic during the oliguric phase of AKI but during the 
diuretic phase he developed severe symptomatic hypercalcemia. Improved with volume 
replacement and administration of calcitonin. Hypercalcemia reached a peak of 14.1 mg/dL, 
corrected for serum albumin and urine output was as high as 3.5 liters daily. Hypercalcemia 
lasted for 3 weeks and then calcium returned back to normal levels. Plasma levels of 
25-OH and 1-25(OH)2 vitamin D were not elevated, intact parathyroid hormone level 
was appropriately suppressed, and 24-hour urine calcium was 520 mg. Immobilization 
hypercalcemia as well as mobilization of calcium from calcium deposited in various tissues 
seems to account for hypercalcemia and hypercalciuria in this case.
Discussion: Hypercalcemia is uncommon during the recovery phase of non-
rhabdomyolysis associated ATN. Unattended, it can cause severe morbidity. Fluid 
administration, calcitonin, and bisphosphonates are some of the methods used for its 
treatment.
PUB439
A Case of Hyponatremia from Adrenal Insufficiency Mimicking Siadh 
Pradeep Reddy Thodima, Rasib Raja, Siddhesh R. Lotlikar, Imara Dissanayake, 
Eric J. Bloom.  Nephrology, Albert Einstein Medical Center, Philadelphia, PA; 
Nephrology, Albert Einstein Medical Center, Philadelphia, PA; Nephrology, 
Albert Einstein Medical Center, Philadelphia, PA; Nephrology, Albert Einstein 
Medical Center, Philadelphia, PA; Nephrology, Albert Einstein Medical Center, 
Philadelphia, PA.
Introduction: A 40 yr old male with a diagnosis of nasopharyngeal carcinoma was 
admitted for dysphagia and decreased oral intake. He had severe hyponatremia with 
serum Na 126 meq/l, other labs including K -4.2, Cl- 94, HC03-26. He was euvolemic and 
normotensive. A urine panel showed Na - 122 meq/l and Uosm of 932 osm/l. He was deemed 
to have euvolemic hyponatremia from SIADH and started on fluid restriction. There was 
no improvement in hyponatremia and Una increased to 235 meq/l. He was diagnosed with 
adrenal insufficiency with a co-syntropin test. Imaging studies did not demonstrate pituitary 
invasion by nasopharyngeal carcinoma. He was started on high doses of hydrocortisone 
with rapid improvement of hyponatremia and Una dropped to 35meq/l. Hyponatremia with 
high Una (280 meq/l) recurred during hydrocortisone taper. He required prolonged high 
doses of hydrocortisone to maintain normal serum sodium level. Although there have been 
many case reports of hyponatremia with adrenal insufficiency, to the best of our knowledge 
there has been no reports of hyponatremia with very high Urine sodium ( > 200 meq/l). 
This case highlights that euvolemic hyponatremia can occur with adrenal insufficiency 
with clinical and biochemical manifestations mimicking SIADH. Adrenal insufficency 
should be considered in all cases of hyponatemia especially with very high urine sodium.
PUB440
Acute Tubulointerstitial Nephritis Preceding the Diagnosis of Multiple 
Myeloma  Alper Alp,1 Hakan Akdam,2 Aysegul Ormeci,3 Ibrahim Meteoglu,3 
Harun Akar,4 Yavuz Yenicerioglu.2  1Nephrology, Van Region Education and 
Research Hospital, Van, Turkey; 2Nephrology, Adnan Menderes Univ, School 
of Medicine, Aydin, Turkey; 3Pathology, Adnan Menderes Univ, School of 
Medicine, Aydin, Turkey; 4Internal Medicine, Nephrology, Tepecik Education 
and Research Hospital, Izmir, Turkey.
Introduction: Multiple myeloma(MM) is characterized by a neoplastic proliferation 
of monoclonal plasma cells-usually-originating in the bone marrow.Atypical presentations 
of MM is not seldom in clinical practice.The hidden signs of the disease may cause late 
diagnosis and clinicians should be suspicious and aware for this entity.However in some 
rare cases these signs may really be invisible.
Case Description: A 55 yo woman presented with confusion,oliguria and elevated 
creatinine level of 18.2 mg/dl.Hemodialysis was started acutely.Renal ultrasonography 
revealed normal size kidneys without hydronephrosis.Renal biopsy was compatible with 
acute tubulointerstitial nephritis.
Kappa and lambda light chain staining was negative.1 mg/kg metilprednisolone 
therapy was initiated and given for 1 month.No regression was observed and hemodialysis 
therapy was continued.After 2 months steroid therapy was reinitiated again but there was 
no clinical and biochemical response.On follow-up,after 7 months from renal biopsy 
hypercalcemia,anemia,high sedimentation rate,hyperglobulinemia and lytic bone lesions 
were detected.16% monoclonal plasma cells were present in bone marrow.With further 
examinations MM diagnosis was made.
Discussion: Renal biopsies revealing acute tubulointerstitial nephritis pattern which 
are unresponsive to steroid therapy should always be deeply investigated for alternative 
diagnoses.MM may have obscure presentations.
PUB441
Sleep Disturbances in an ESRD Patient Soon After Initiation on 
Hemodialysis: An Atypical Presentation of ESRD-Related Sleep Disorders 
Desiree Garcia Anton, Franco H. Cabeza Rivera, Alexandre Abreu, Marco A. 
LadinoAvellaneda.  Nephrology, Univ of Miami, Miami, FL.
Introduction: Sleep disorders including obstructive sleep apnea (OSA), restless leg 
syndrome (RLS) and insomnia are highly prevalent in ESRD patients undergoing dialysis, 
however, these remain stable or tend to improve after initiation of dialysis. There is scarce 
evidence of new-onset sleep complaints or disorders after initiation of dialysis.
Case Description: We present a case of a 64 year-old male with HTN, DM, ESRD and 
no previous sleep problems who developed insomnia, RLS, sleepwalking and other sleep 
disturbances within a month after initiation of continuous hemodialysis.  He presented to the 
primary care clinic with secondary complications from uncontrolled diabetes (neuropathy, 
retinopathy and nephropathy); he had been followed by the nephrology service for 4 years 
before requiring dialysis for uremia and volume overload. Intermittent HD was well tolerated 
during first month of treatment, achieving good metabolic clearance and volume control; 
his KT/V was 1.16, phosphorus was controlled at 4.6 mg/dl and his anemia improved to a 
hemoglobin of 9.6 mg/dL; iron was 36 mcg/dl, ferritin 135 ng/ml, and transferrin saturation 
15%. Despite clinical and laboratory improvement, disabling sleep symptoms were reported 
and he was referred to the Sleep clinic for further evaluation. On his initial actigraphy, a 
bedtime or rise time pattern was unable to be determined as it showed continuous movements 
24 hours per day for the 14 days monitored. Overnight Polysomnography (PSG) revealed 
severe OSA and periodic limb movements (PLM); there was also evidence of insomnia 
with severely reduced sleep efficiency.
Discussion: New-onset sleep problems after initiation of dialysis in patients who 
previously had no sleep complaints are an atypical presentation. The role of RRT on sleep 
disturbances in the ESRD population is unknown. We propose PSG pre and post dialysis 
initiation on advanced CKD patients to assess for differences and identify how RRT may 
be a cause of sleep disturbances.
PUB442
Reduced Serum Anion Gap due to Lithium Overdose  Tanmay Sahai,1 Josef 
Bautista.2  1Internal Medicine, Roger Williams Medical Center, Providence, RI; 
2Nephrology, Brown Univ/Rhode Island Hospital, Providence, RI.
Introduction: This case demonstrates the clinical presentation and corresponding 
laboratory results of lithium overdose as well as further discuss management of overdose 
with intermittent hemodialysis.
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Case Description: A 32-year-old man with a history of bipolar disorder came to the 
hospital with altered mental status and worsening lethargy. He was subsequently intubated 
for airway protection. Patient’s lithium level was > 20 mmol/L. CT head showed no injury. 
The rest of the toxicology screen was negative. His basic metabolic panel (including 
calcium and albumin) was within normal limits however his bicarbonate was 32 mmol/L 
and creatinine was elevated to 1.5 mg/dL. Calculated anion gap was 1 mmol/L. Serum 
osmolality was not measured at time of presentation. Patient was hemodynamically stable. 
Vigorous hydration with isotonic saline was initiated. Intermittent hemodialysis with high 
blood pump speed was initiated. Serum lithium level was checked 24 hours later and it 
fell to 2mmol/L. Intermittent hemodialysis was discontinued 24 hours later as patient was 
awake, alert and arousable with dramatic improvement in mental status. Creatinine also 
trended down to 0.9 after 48 hours. Patient was extubated 48 hours after initial presentation.
Discussion: Lithium has a narrow therapeutic window and therefore in cases of 
overdose or toxicity have many symptoms including altered levels of consciousness as 
seen in this patient. Low anion gap is a diagnostic clue to lithium intoxication however 
other causes include hyperkalemia, hypermagnesemia, and monoclonal gammopathies. 
Although serum osmolalilty was not measured in our patient, this can also be a helpful 
indicator noted in previous case reports. Elevated osmolar gaps with low anion gaps are 
useful in diagnosing lithium overdose. The standard management for lithium overdose 
is intermittent hemodialysis and maintaining water balance. The theory behind using 
intermittent hemodialysis versus continuous venovenous hemodiafiltration is that higher 
clearance of lithium can be achieved from faster blood flow rates in intermittent hemodialysis 
if it can be tolerated hemodynamically.
PUB443
Episodes of Hypertensive Crises in a Tetraplegic Dialysis Patient due to 
Catheter-Associated Endocarditis  Martin Russwurm, Joachim Hoyer, Ivica 
Grgic.  Dept of Internal Medicine and Nephrology, Philipps-Univ Marburg, 
Marburg, Germany.
Introduction: Hypertensive emergencies are a life-threatening condition associated 
with organ damage including acute heart failure, seizures and coma. Pre-existing arterial 
hypertension and non-adherence to anti-hypertensive treatment as well as volume overload 
particularly in dialysis patients are considered major triggers of HC. ESRD patients have 
a high prevalence (>70%) for hypertension and are at high risk for the development of 
cardiovascular disease and related complications. Early assessment and treatment of 
hypertensive states including HC is therefore imperative.
Case Description: Here, we report a case of a 34-year-old patient with sudden onset 
of repeated episodes of hypertensive emergencies on dialysis. The first episodes of spiking 
blood pressures of >240/120 mmHg occurred several weeks prior to admission and had 
become increasingly difficult to manage forcing early termination of dialysis sessions.
The patient had been on hemodialysis, via tunneled catheter, for one year. Laboratory 
findings showed elevated inflammation parameters. Blood cultures were positive for gram-
negative rods which were later identified as Pseudomonas aeruginosa (P.a.). We performed 
transesophageal echocardiography which showed echodense masses at the tip of the catheter 
and right cardiac atrium. Hemodialysis via an alternative vascular access instantly resulted 
in normal blood pressures during dialysis. Subsequently, the patient underwent heart surgery. 
The tunneled catheter and a large (5.2 x 3.5cm), P.a-infected thrombus were removed from 
the right atrium and the patient put on a targeted antibiotics. Following recovery, a forearm 
fistula was created and used without major complications.
Discussion: To our knowledge, there is no report in the current literature of hypertensive 
crises in direct association with CVC infection. We speculate that initiation of dialysis via 
the infected catheter may have led to transient bacteremia triggering hyptertensive episodes 
via an unclear mechanism. This case demonstrates that catheter-associated infections should 
be included in the differentials of causes and triggers of HC.
Funding: Government Support - Non-U.S.
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Adypsic Nephrogenic Diabetes Insipidus a Possibility?  Nivin Haroon, Zeenat 
Yousuf Bhat.  Dept Nephrology, Wayne State Univ, Detroit, MI.
Introduction: Adypsic diabetes insipidus (DI) is a rare syndrome where the patient 
has central DI and lack of thirst response due to presence of central lesion. We describe 
a patient who developed nephrogenic DI following a contrast exposure and acute kidney 
injury ( AKI).
Case Description: The patient is a 47 yr old African American female with significant 
past medical history of mild diabetes mellitus. Her baseline kidney function was stable 
with creatinine (Cr) < 1 and non proteinuric. She had left sided progressive inflammatory 
breast cancer. She completed 2 cycles of paclitaxel and doxorubicin and cyclophosphamide. 
During this time she was admitted to the hospital following incision and drainage of a rectal 
abscess and treated with vancomycin and zosyn. Patient had received contrast exposure 
from computed tomography imaging for the abscess. Two days later the patient started to 
have rise in Cr with level going from 0.7 to 1.5. Nephrology was consulted for the same. 
There was no overt septic shock or blood pressure fluctuation. Urine microscopy was bland 
and ultrasound showed no pathology. Acute kidney injury was possible from the contrast 
exposure due to the time line of Cr bump within 48 to 72 hour period and lack of other 
overt evidence. Along with the AKI patient was found to have rise in sodium levels. She 
was having increased urine output in the range of over 4 Liters every day. Sodium was 
going up from baseline 140 up to 152. Interestingly patient was not having increased thirst 
response. She was given desmopressin (DDAVP) challenge test with no change in the urine 
output. An MRI imaging of brain was negative for pathology. She was instructed to drink 
water to match her urine out even if not thirsty. Initially the sodium leveled off and later 
trended down along with AKI.
Discussion: The case is very unique as the contrast injury resulted in nephrogenic 
DI. The patients lack of thirst response and rise in sodium was even more peculiar as the 
DI was clearly nephrogenic due to lack of response to DDAVP. It is still unclear why the 
thirst response in this patient was affected. More studies in future will unravel the complex 
relation between thirst response and osmolarity.
PUB445
Frailty Modifies the Association Between Age and Dysnatremia in 
Community-Dwelling Adults  Amanda Jean Miller,1 Susan E. Howlett,2 
Kenneth John Rockwood,2 Karthik K. Tennankore.1  1Nephrology, Dalhousie 
Univ, Halifax, NS, Canada; 2Geriatrics, Dalhousie Univ, Halifax, NS, Canada.
Background: Frailty represents a state of increased risk to adverse health outcomes, 
reflecting some combination of increased damage and compromised repair processes. 
Dysnatremia is more common with age and can occur in many settings, suggesting that it 
may reflect not simply a specific renal problem, but a more general imbalance in damage 
and repair. The aims of this study were to establish whether frailty severity is associated 
with a higher rate of dysnatremia and to determine whether frailty explains the previously 
established association between age and dysnatremia.
Methods: The relationship between age, frailty severity and dysnatremia was 
investigated across the adult life course in 8898 respondents from the 2003-2004 and 
2005-2006 cross-sectional National Health and Nutrition Examination Survey (NHANES) 
datasets. Respondents were assigned a frailty index (FI) and assessed for dysnatremia 
(a deviation of serum sodium from the 135-144 mmol/L normal range). The coefficient 
of variation in serum sodium was used as a systems measure of the response repertoire.
Results: In the overall population, there was a significant positive association between 
increasing frailty severity and the proportion of patients with dysnatremia (chi-square 
trend p < 0.001). Increasing frailty severity was also associated with more variability in 
serum sodium. There was a significant association between advancing age and dysnatremia 
(p < 0.001); however after stratifying by frailty (FI <0.100, 0.100-0.199, 0.200-0.299, 
0.300-0.399, >=0.400), the association between increasing age and dysnatremia became 
non-significant in all categories. 
Conclusions: Increasing frailty severity is associated with dysnatremia and greater 
variability in serum sodium. Furthermore, frailty appears to modify the earlier association 
between age and dysnatremia.
PUB446
Approach to Hyponatremia in Congestive Heart Failure: A Survey of 
Canadian Physicians and Trainees  Amanda Jean Miller,1 Bonnie Kuehl,2 
Karthik K. Tennankore.1  1Nephrology, Dalhousie Univ, Halifax, NS, Canada; 
2Research, Scientific Insights Consulting Group Inc., Mississauga, ON, Canada.
Background: Hyponatremia is a complication of congestive heart failure (CHF) and 
is associated with reduced survival, however there are no consensus guidelines for the 
treatment of hyponatremia in CHF. The aim of this study was to determine the approach to 
hyponatremia in CHF amongst Canadian healthcare practitioners and trainees.
Methods: Respondents completed 15 multiple-choice style questions surrounding 
three cases of hyponatremia complicating CHF using an online survey on UKidney.com 
between December 2012-May 2013. Results were summarized as the proportion of correct/
incorrect responses among Canadian Nephrologists, Cardiologists, Internists and trainees 
in each of two domains; pathophysiology and management. Management topics included 
use of diuretic therapy, hypertonic saline, oral urea tablets, vasopressin receptor antagonists 
(vaptans) and rate of sodium correction. Correct answers were determined by an expert 
panel of Canadian Nephrologists and Cardiologists.
Results: There were 1097 responses to survey questions among 455 Canadian 
respondents. Pathophysiology governing hyponatremia in CHF was correctly identified 
in 68.7% of responses (n = 380). Overall, hyponatremia was managed inappropriately in 
43.6% of responses (n = 759). The proportion of incorrect responses among specialists 
and trainees is depicted in Figure 1. Importantly, an incorrect rate for sodium correction 
was selected 61.1% of the time (n = 211).
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Conclusions: This study highlights knowledge gaps regarding pathophysiology and 
management of hyponatremia in CHF amongst Canadian specialist physicians and trainees. 
There is a need for further education to improve the management of hyponatremia in CHF 
at a national level.
PUB447
Sorafenib Induced Hyponatremia  Elan Gorshein,1 Catherine K. Wei,1 Jasmeet 
S. Bajaj.2  1Internal Medicine, Rutgers Robert Wood Johnson Medical School, 
New Brunswick, NJ; 2Critical Care Unit, Univ Medical Center of Princeton at 
Plainsboro, Plainsboro, NJ.
Background: Sorafenib treats unresectable hepatocellular carcinoma (HCC). It is a 
multi-targeted tyrosine kinase inhibitor (TKI), which prevents tumor cell proliferation. 
For those with inoperable disease, it prolonged median survival. Nevertheless, adverse 
reactions may limit its use. Sorafenib has been associated with hyponatremia, which may 
be related to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion. We 
present a case of sorafenib induced hyponatremia.
Methods: A 58 year-old female presented with lethargy and edema. Patient 
was diagnosed with HCC 6 months earlier. She underwent transcatheter arterial 
chemoembolization and was noted on repeat imaging to have metastatic disease. Patient 
began sorafenib two weeks prior to admission, with a dose of 200 mg daily. A week later, 
the dose was increased to 200 mg twice daily. Three days later, the patient increased 
her dose to 400 mg in the AM and 200 mg in the PM. A day thereafter, patient became 
lethargic, with generalized swelling. The serum sodium was 106 mmol/L, with a baseline 
of 134 mmol/L three weeks prior to admission. Urine osmolality was 542 mOsm/kg, and 
the urine random sodium was less than 25 mEq/L. Patient’s TSH was 6.82, with a normal 
FT4. AM cortisol was measured at 20.2. Her total protein and lipid profile were normal.
Conclusions: TKI agents have improved median survival in advanced HCC disease. 
Their use, however, has been limited by adverse events. Hyponatremia has been reported 
with a rate of up to 11% in patients treated for HCC. The pathophysiology may be related 
to SIADH. TKI agents may enhance the effects or increase the action of ADH. Time to 
onset of hyponatremia may be within ten days. Our patient took sorafenib for two weeks. 
Upon admission, her serum sodium was 106. With hypertonic saline and fluid restriction, 
her sodium reached 128. Other etiologies of hyponatremia were excluded. Sorafenib was 
discontinued, and attempts at patient follow-up have been unsuccessful. However, this 
report highlights that while sorafenib has had favorable impact on advanced HCC outcomes, 
clinicians should be mindful of its adverse effects.
PUB448
Current Trends in Etiologic Factors Responsible for the Development of 
Hyponatremia in Hospitalized Patients  Sandar Win,1 Maria V. DeVita,1 Diana 
Dreyer,2 Samuel J. Wahl,2 Michael F. Michelis.1  1Nephrology, NSLIJ/Lenox Hill 
Hospital, New York, NY; 2Pathology, NSLIJ/Lenox Hill  Hospital, New York, NY.
Background: Hyponatremia remains the most common electrolyte disorder seen in 
hospitalized patients. The prevalence has been reported to vary from 5% to 15% and to be 
as high as 29.6% depending on the hospital setting.
Methods: New data were obtained on 2 separate days to evaluate the prevalence 
and etiologies of hyponatremia in hospitalized patients in a large metropolitan hospital. 
Hyponatremia was defined as less than 135mmol/L.
Results: Hyponatremia was recognized in 41 of 879 patients (4.6%). The mean serum 
sodium level in the hyponatremia group was 132.0+/-3.2 mmol/L. Eighty-five percent of 
the patients exhibited a serum sodium level of >130 mmol/L. Individuals aged 65 years old 
or greater made up 58.5% of the patients. Etiologic factors identified in the total number 
of hyponatremic patients included 9.7% with ESRD, 4.8% post op, 14.6% dehydration, 
24.3% with pulmonary disorders, 26.8% with a diagnosis of cancer. The majority of patients 
were noted, however, to be receiving related drug therapies 63.4%. They were  distributed 
between diuretic therapy (36.6%) and psychiatric drug therapy (26.8%).
Percent Distribution of Drug Therapies
Diuretics (36.6%) CNS Drugs (26.8%)
Diuretics Alone 
(17.1%)
Diuretics + CHF 
(19.5%) SSRIs (17.1%) Others (9.7%)
Conclusions: This study suggests that hyponatremia often is mild, is commonly 
associated with drug therapy, affects a significant number of younger patients, and now 
includes novel conditions such as patients receiving renal replacement therapy.
PUB449
Development of Metabolic Acidosis After Neobladder Replacement in Korea 
Shina Lee, Dong-Ryeol Ryu, Kyu Bok Choi, Duk-Hee Kang, Seung-Jung Kim. 
Dept of Internal Medicine, School of Medicine, Ewha Womans Univ, Seoul, 
Republic of Korea.
Background: Metabolic acidosis frequently develops in patients after neobladder 
replacement. However, the incidence of metabolic acidosis in patients with neobladder 
and the factors associated with the development of metabolic acidosis have not been well 
elucidated. We aimed to investigate the incidence and the potential predictors for the 
development of metabolic acidosis after neobladder replacement with intestinal segment.
Methods:  We included all patients who underwent neobladder replacement using 
intestinal segment at Mokdong Hospital between January 1, 2005 and December 31, 2014. 
Metabolic acidosis was defined as serum tCO2 below 22 mEq/L at any visit during the follow 
up period. Patients’ biologic data was presented using x2 test and student t test. Subgroups 
according to the time of metabolic acidosis occurance was further analyzed in order to 
characterize predictors for metabolic acidosis by ANOVA tests and multiple regression.
Results: Metabolic acidosis was encountered in 79.4% of patients with neobladder 
during follow up period. When patients were divided into 2 groups according 
to anion gap(AG), total CO2(18.9±2.1mEq/L vs. 20.0±1.3mEq/L, p=0.001) and 
chloride(106.6±4.9mE/L vs. 109.4±3.6mEq/L; p<0.001) were significant different between 
groups with AG>12 and AG£12 respectively. Furthermore, when patients were divided 
into 3 groups; patients with metabolic acidosis at post operative day 1; within a 14days; 
after 14days, there was significant difference of postoperative laboratory findings among 
the those subgroups.
Conclusions: Our study showed the rate of development of metabolic acidosis in 
patients underwent neobladder replacement and the difference between patients with 
metabolic acidosis and those without metabolic acidosis after neobladder replacement for 
the first time in Korea. In the future, well designed prospective study will be needed to 
prevent metabolic acidosis after neobladder replacement.
PUB450
Potassium Abnormalities and Acute Kidney Injury Are Common 
Complications After Colectomy  Lindsay M. Smith,1 Robert M. Perkins,2 
Andrea Lynn Berger,1 H. Lester Kirchner,1 Morgan Grams,3 Alex R. Chang.1 
1Geisinger Health System; 2Bayer Healthcare; 3Johns Hopkins Bloomberg 
School of Public Health.
Background: Patients undergoing colectomy may be predisposed to disturbed 
potassium homeostasis, since the colon has a role in potassium excretion, and volume 
depletion due to diarrhea occurs frequently after colectomy.
Methods: We examined the frequency of incident mild (>5 mmol/L) and severe 
hyperkalemia (>6 mmol/L), mild (<3.5 mmol/L) and severe (<2.5 mmol/L) hypokalemia, 
and inpatient AKI, stratified by estimated glomerular filtration rate (eGFR) using creatinine 
(inpatient only) and potassium (inpatient/outpatient) data from 1,762 patients who 
underwent colectomy surgery at Geisinger Health System between 2004-2013.
Results: Median age was 66 and mean baseline eGFR was 79 ml/min/1.73m2. 
Colonic conditions included inflammatory bowel disease (8%), bowel obstruction (8%), 
ischemic bowel (2%), diverticulitis (23%), and colorectal cancer (20%). During the 
surgery hospitalization, post-operative AKI occurred in 32% of patients ; mild and severe 
hyperkalemia occurred in 18% and 3% of patients. Over a median of 4.0 years post-discharge 
after colectomy, mild and severe hyperkalemia occurred at a rate of 13.4 events/100 person-
years and 1.8 events/100 person-years; mild hypokalemia and severe hypokalemia occurred 
at a rate of 15.4 events/100 person-years and 0.7 events per person-years. Rates of inpatient 
AKI after discharge were high (9.1 events/100 person-years). Risks for AKI, mild and severe 
hyperkalemia increased as eGFR declined (p values<0.001; Table).
Conclusions: Patients who undergo colectomy are at high risk for hyperkalemia, 
hypokalemia, and AKI, particularly when eGFR is decreased. Comparison to a control 
group is needed to determine whether the high incidence of hyperkalemia is related to 
removal of the colon or frequent AKI episodes.
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Identify the Causes of Chronic Hypokalemia: Importance of Urinary 
Sodium and Chloride Excretion  Chih-chien Sung,1,2 Kun-Lin Wu,1,3 Chih-Jen 
Cheng,1 Yu-Juei Hsu,1 Sung-Sen Yang,1,2 Shih-Hua P. Lin.1  1Div of Nephrology, 
Dept of Medicine, Tri-Service General Hospital, National Defense Medical 
Center, Taipei, Taiwan; 2Graduate Inst of Medical Science, National Defense 
Medical Center, Taipei, Taiwan; 3Dept of Medicine, Armed Forces Taoyuan 
General Hospital, Taoyuan, Taiwan.
Background: Chronic hypokalemia with potassium (K+) wasting from kidney or gut is 
etiologically diverse. However, the correct diagnosis of the underlying causes is still fraught 
with challenge. To identify clinical and laboratory parameters helpful for the differential 
diagnosis of chronic hypokalemia.
Methods: The patients referred for evaluation of chronic hypokalemia in a medical 
center were enrolled prospectively for five years.
Results: Ninety-nine patients with chronic hypokalemia (serum K+ 2.8 ± 0.4 mmol/L, 
duration 4.1 ± 0.9 years) were enrolled. The major presentations were dizziness, fatigue, 
palpitation, abdominal fullness and muscle weakness/tetany. The plasma renin activities 
were increased in all patients along with normal-high serum aldosterone level. The main 
imaging findings were nephrocalcinosis/renal stones (n=25). Although Gitelman’s/Bartter’s 
syndrome (n=32/13) and renal tubular acidosis (n=10) were major renal tubular disorders, 
forty-four patients were identified with anorexia/bulimia nervosa (n=24), surreptitious use 
of laxatives (n=10) and diuretics (n=10). The urinary K+ excretion rates in patients with 
renal versus non-renal tubular disorders were significantly overlapped for making the 
diagnosis alone. Of note, unparalleled urinary sodium (Na+) and chloride (Cl-) excretion 
with urinary Na+/Cl- ratio are unique to non-renal tubular disorders. Furthermore, body 
mass index, serum bicarbonate and magnesium levels, and urine pH were also helpful for 
the differential diagnosis.
Conclusions: Chronic hypokalemia due to non-renal tubular disorders is emerging and 
often clinically indistinguishable from those with renal tubular disorders. The integrative 
interpretation of urine electrolytes excretion rates, especially Na+ versus Cl-, is important 
to make a prompt and accurate diagnosis.
Funding: Private Foundation Support
PUB452
Abstract Withdrawn
PUB453
PTHrP Induced Severe Hypercalcemia Secondary to Metatstatic 
Neuroendocrine Tumor: A Case Report  Azka Arif,1 Ahmad Hassan,2 
Muhammad Awais Arif,2 Agha syed Shabbir Ali,2 Hafiz Armaghan Saeed,2 
Abdul Mateen Nagaria,1 Talal A. Khan.1  1Freeman Health System; 2Rawalpindi 
Medical College.
Background: Hypercalcemia is a common clinical problem. Most common etiology 
is hyperparathyroidism followed by malignancy. We report an interesting case of PTHrP 
induced severe hypercalcemia secondary to metatstatic neuroendocrine tumor.
Methods: 49-year-old female with history of metastatic neuroendocrine tumor 
presented to the hospital with worsening mental status. On initial evaluation she was found 
to be severely hypercalcemic with serum calcium (Ca) of 19.6 mg/dL. Her ionized Ca was 
2.45 mmol/liter. Her initial PTH level was 8.4 pg per mL. Her TSH level was 3.63 miu/
ml & CK level was 66 U/L. She was not on Lithium, Thiazide diuretics. She had normal 
renal function. She was aggressively hydrated & started on intra muscular calcitonin. She 
was also given a dose of Intravenous bisphosphonates .Her serum calcium came down 
appropriately to 8.9 mg/dL, later her serum PTHRP was reported as 78 pg per mL. Her 
25-hydroxy vitamin D level was low at 11 pg /mL, and her 1 25-hydroxy vitamin D level 
was 11 pg /mL. Her ACE level was 21 U/L. She was eventually transferred to hospice.
Conclusions: PTHrP is a normal gene product expressed in variety of neuroendocrine 
tumors .Gastrointestinal neuroendocrine tumors rarely excrete PTHrP. our case represents a 
severe form of malignant hypercalcemia secondary to hyper-secretion of PTHrP.Literature 
review showed that it was amongst the highest serum calcium reported,we did not proceed 
with renal replacement therapy initially as per family meeting. Hypercalcemia secondary 
to PTHrP production significantly increases mortality and morbidity.
PUB454
Carboplatin Induced Severe Hypomagnesemia and Concurrent 
Hypocalcemia: A Report of an Interesting Case to Elaborate Evaluation 
and Management of Hypomagnesemia: “The Forgotten Electrolyte” 
Azka Arif,1 Ahmad Hassan,2 Muhammad Awais Arif,2 Agha syed Shabbir Ali,2 
Hafiz Armaghan Saeed,2 Abdul Mateen Nagaria,1 Talal A. Khan.1  1Freeman 
Health System; 2Rawalpindi Medical College.
Background: Hypomagnesemia is commonly encountered in hospitalized patients. 
Renal wasting secondary to use of diuretics and persistent diarrhea are most important 
causes. It is one of the “forgotten” electrolytes .Many clinicians have limited awareness 
of how to accurately evaluate and manage hypomagnesemia.We report an interesting case 
of severe hypomagnesemia and hypocalcaemia secondary to carboplatin administration 
with a view point of elaborating diagnostic approach to hypomagnesemia.
Methods: 62-year-old female with history of adenocarcinoma of the lung, developed 
severe hypomagnesemia with serum magnesium (Mg) levels reported as low as 0.5 mg/
dL. She had concurrent severe hypocalcaemia with serum calcium (Ca) of 5.1 mg/dL. 
Aggressive repletion was started & further workup was done. Her urine spot Mg level 
was reported as 381 mg, her fractional excretion of Mg was calculated & it was 9%. 
She received 3 cycles of carboplatin before hospitalization She was not on any diuretics, 
PPIs & Aminoglycosides. She did not receive cetuximab as well;Urine calcium was less 
than 150mg, it was thought that she had carboplatin-induced distal nephron Mg wasting 
. Her serum PTH level was 245.5 pg/ml. Her hypercalcemia was thought to be secondary 
to PTH resistance mediated by severe hypomagnesaemia. After aggressive repletion her 
serum Mg & Ca level normalized.
Conclusions: Hypomagnesemia can be due to multiple causes,Initial step in evaluation 
involves calculating FeMg,if less than 2.5%,it is likley secondary to GI loss.If FeMg 
is>2.5% then we measure 24hour urine calcium,if its more than 250mg it is likely due to 
TAL-Mg wasting which can be secondary to loop diuretics,nephrotoxins(Aminoglycosides) 
or Familial hypomagnesemia with hypercalciuria.If less than 150mg then it is likley due to 
distal nephron Mg wasting which can be secondary to thiazides & Gitleman’s syndrome. 
Our case represents an interesting concurrent presentation of severe hypomagnesemia and 
hypocalcaemia, which was successively treated.
PUB455
Effect of Arterial PH and Bicarbonate Level on Survival of Lactic Acidosis 
Patients Treated with Sodium Bicarbonate  Dongyeol Lee,1 Hansae Kim,1 
Eu Gene Jeong,3 Su Mi Lee,3 Sung Hyun Son,2 Yong Ki Park,1 Young Ki Son,3 
Seong Eun Kim,3 Won Suk An.3  1Internal Medicine, Bong Seng Hospital, 
Busan, Korea; 2Internal Medicine, Han Seo Hospital, Busan, Korea; 3Internal 
Medicine, Dong-A Univ, Busan, Korea.
Background: Patients with lactic acidosis have high mortality rate, and higher lactate 
level is poor prognostic indicator. The correction of lactic acidosis with sodium bicarbonate 
is potentially harmful when sodium bicarbonate inappropriately was used. Therefore, we 
evaluated whether starting pH of sodium bicarbonate affect on the survival in lactic acidosis 
patients treated with sodium bicarbonate.
Methods: We conducted a single center analysis from May 2011 through April 
2014. We retrospectively analyzed 230 patients with lactic acidosis treated with sodium 
bicarbonate. Patients were divided four groups according to starting arterial pH of sodium 
bicarbonate. We analyzed arterial blood gas analysis, lactate level about 6, 12, 24, 48 hours 
after using sodium bicarbonate.
Results: The mean age of patients was 62.8 ± 15.0 years, 174 patients (75.7 %) were 
died. The non-survivals had lower albumin, hemoglobin, and CRP (P <0.001, P = 0.001, 
P = 0.003), higher SOFA and APACHE II scores (P <0.001, P <0.001), and higher blood 
lactate level at 6, 24, 48 hours, and maximum after checking the initial lactic acid levels 
(P <0.001, P <0.001, P <0.001, P <0.001). Patients with increased second lactate level 
showed high mortality (84.4 %). The mortality rate was 90 % in patients with sustained 
high lactate level at 48 hours. The mortality rate was not different according to starting point 
of sodium bicarbonate. In survival group, arterial bicarbonate level was slowly increased 
without fluctuation. However, arterial bicarbonate level showed fluctuation in non-survival 
group. The mortality rate was independently associated with arterial pH at 12 hours after 
sodium bicarbonate infusion.
Conclusions: Stably increased arterial bicarbonate without fluctuation and recovering 
arterial pH at 12 hours are important factors in patients survival treated with sodium 
bicarbonate. Therefore arterial pH and sodium bicarbonate level should be closely monitored 
especially till 48 hours, if sodium bicarbonate treatment with lactic acidosis.
PUB456
Evaluation and Management of Hyperkalemia in an Academic Medical 
Center  Jason K. Law,1 Gaurav Ghosh,2 Daniel Edmonston,1 Saif A. Muhsin,1 
Yasin Hussain,3 Miriam Chung,1,2,4 Jeffrey I. Silberzweig.1,2,4  1Dept of Medicine, 
New York-Presbyterian Hospital, New York, NY; 2Weill Cornell Medical College, 
New York, NY; 3Weill Cornell Medical College, Qatar, Doha, Qatar; 4Rogosin 
Inst, New York, NY.
Background: Hyperkalemia (K > 6.0 mmol/L) is common among hospitalized patients 
but the approach to evaluation and management is highly varied. Patients are not routinely 
evaluated for clinical effects. Decisions regarding whether and how to treat are often based 
on individual physician judgments since few evidence-based guidelines exist. Since both 
hyperkalemia and its treatments can be associated with serious adverse consequences, we 
sought to evaluate the management in our institution.
Methods: Electronic medical records were reviewed for patients in our institution 
with potassium levels greater than 6.0 mmol/L between January 1, 2012 and December 31, 
2014. Records were extracted for hyperkalemia associated symptoms and ECG findings, 
as well as interventions and outcomes.
Results: Only 2% of patients had clinical findings consistent with hyperkalemia. 
One-third of patients had ECGs performed and only 20% of those had findings consistent 
with hyperkalemia. Of patients with ECG findings consistent with hyperkalemia, only 
15% had repeat tracings performed after treatment. At least 50% of patients were treated 
with insulin and dextrose and/or calcium. One-third of patients were treated with sodium 
polystyrene sulfonate (SPS), 25% with sodium bicarbonate and 10-15% were treated with 
lactulose or furosemide. Only 25% of patients had repeat potassium levels measured within 
six hours of treatment. 
J Am Soc Nephrol 26: 2015 Publication Only
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
994A
Conclusions: Management of hyperkalemia in our institution is far from systematic. 
Most patients receive treatment without evaluation for clinical effects of hyperkalemia. 
There is no standard treatment regimen and follow up measurements of potassium and 
ECGs were rarely done.
PUB457
Treatment of Hyperkalemia with Kayexalate in an Academic Medical 
Center  Gaurav Ghosh,2 Yasin Hussain,3 Jason K. Law,1 Daniel Edmonston,1 
Saif A. Muhsin,1 Miriam Chung,1,2,4 Jeffrey I. Silberzweig.1,2,4  1Dept of Medicine, 
New York-Presbyterian Hospital, New York, NY; 2Weill Cornell Medical College, 
New York, NY; 3Weill Cornell Medical College, Qatar, Doha, Qatar; 4The 
Rogosin Inst, New York, NY.
Background: Hyperkalemia (K > 6.0 mmol/L) is a potentially life-threatening 
condition; standard treatment has included sodium polystyrene sulfonate (Kayexalate) 
since its introduction in 1958. Recent literature has questioned the benefits of this treatment 
because of the lack of proven efficacy and the risk of serious adverse effects. We evaluated 
the effectiveness of Kayexalate for treatment of patients with hyperkalemia in our institution.
Methods: Electronic medical records were reviewed for all patients in our institution 
with potassium levels > 6.0 mmol/L between January 1, 2012 and December 31, 2014. 
Records were extracted for hyperkalemia treatment and outcomes. Hyperkalemia treatments 
included albuterol, diuretics, insulin, lactulose, sodium bicarbonate, and Kayexalate. 
Comparisons between hyperkalemia treatments with Kayexalate and without Kayexalate 
were made using t-tests.
Results: One-third of patients diagnosed with hyperkalemia were treated with 
Kayexalate. Post-treatment potassium values decreased by 14.8% in treatment with 
Kayexalate, compared to 17.4% reduction in treatment combinations without Kayexalate 
(p = 0.46). No patients suffered serious adverse effects from Kayexalate treatment.
Conclusions: In our population, treatment of hyperkalemia with Kayexalate was 
common. While no adverse events of treatment were noted, there was no significant 
difference in reduction of potassium levels with it. We conclude that there is insufficient 
evidence to support routine use of Kayexalate in our population.
PUB458
The Impact of Hyponatremia on Children: Prevalence and Consequences 
During Hospitalization  Zachary Sartor, Poonam Thakore, Tetyana L. 
Vasylyeva.  Pediatrics, Texas Tech Univ Health Sciences Center, Amarillo, TX.
Background: Hyponatremia in adults is associated with increased morbidity and 
mortality, but this association has not been explored in pediatrics. The aim of this study 
is to characterize the prevalence of hyponatremia and assess its impact on the course of 
hospitalization in pediatric patients.
Methods: Patients who were admitted to the TTUHSC pediatric service at Northwest 
Texas Hospital in Amarillo, TX from January through December 2012 were considered 
for retrospective chart review. Patients were divided into 3 diagnosis groups: bronchiolitis, 
asthma exacerbation, and gastroenteritis. Other diagnoses and patients without serum 
chemistries were excluded. Age, sex, and serum sodium levels were documented. The 
number of days admitted were also recorded. Hyponatremia was defined as mild if the 
sodium was 130-135 mEq/L, moderate if 125-129 mEq/L, or severe if <125 mEq/L. 
Prevalence was calculated. Prevalence was determined to be statistically significance 
by comparing sodium levels between patients with hyponatremia and those with normal 
sodium levels. All patients were then grouped together, and length-of-stay (LOS) was 
compared between those with hyponatremia and those with normal sodium. The analysis 
for prevalence and LOS was performed using a two-tailed, unpaired t-test with a p <0.05 
used for significance.
Results: Overall, 416 patients were admitted to the inpatient service during the 
study period. After exclusion,128 patients with bronchiolitis, 137 patients with asthma 
exacerbation, and 69 patients with gastroenteritis were available for analysis. There were 
24 cases of hyponatremia in the bronchiolitis group (18.75% prevalence),8 cases in the 
asthma exacerbation group (5.84% prevalence), and 18 cases in the gastroenteritis group 
(26.09% prevalence). There was one case of moderate hyponatremia in the bronchiolitis 
group, otherwise all other cases involved mild levels of hyponatremia. LOS was increased 
for patients with hyponatremia (2.33±0.11 days versus 4.26±0.71 days, p=0.01).
Conclusions: Hyponatremia was prevalent at an overall rate of 15% during the study 
period. Hyponatremia was associated with increased hospitalization at a statistically 
significant level.
PUB459
Disorders of Plasma Sodium in Hospitalized Patients and Effect of Total 
Plasma Protein Concentration on Its Measurement  Pedro J. Labrador, Silvia 
Gonzalez S, Santiago Polanco Candelario, Elena Davin Carrero, Jesús P. Marin, 
Ines Castellano, Juan R. Gomez-Martino.  Nephrology, San Pedro de Alcantara 
Hospital, Caceres, Spain.
Background: The aim of the study was analysed the prevalence of hyponatremia in 
hospitalized patients, and the effect of total plasma protein (TPP)concentration on plasma 
sodium (Na) measurements.
Methods: We registered all biochemical analysis from in-hospital patients during 
one year. Data from age, sex, and department was recorded. Plasma Na was measured 
by an indirect ion selective electrode measuring system (Cobas 8000 analyzer, Roche 
Diagnostics). Hyponatremia was considered when plasma Na was lower than 135 mmol/L. 
Hyponatremia was classified based on plasma Na concentration. Mild hyponatremia was 
defined as 130-134 mmol/L, moderate as 125-129 mmol/L and profound as lower than 125 
mmol/L. When TPP was measured, plasma Na concentration was corrected according to: 
a) Plasma Na = indirect Na x 93 /(99.1 – (0.7 x TPP concentration)); and b) Plasma Na= 
indirect Na + 0.7 x (TPP concentration – 10).
Results: Our hospital is a 520 in-hospital beds. Plasma Na was measured in 26.904 
biochemical analytics from 6.873 patients. Median age was 67 (IQR 50-79). 55.9% were 
men. Median plasma Na measurements was 5 (IQR 2-11). Hyponatremia was present 
in 1.514 patients (22%), mild hyponatremia 1.114 (16.2%), moderate 287 (4.2%) and 
profound 113 (1.6%). Plasma Na could be corrected to TPP in 3.122 patients, using the first 
formula hyponatremia was present in 29.4% (mild 19.6%, moderate 6.8% and profound 
3%) while using the second one, 27.9% (mild 18.7%, moderate 6.4% and profound 2.8%). 
Kappa index for hyponatremia diagnostic between measured plasma Na and corrected 
to TPP was 0.7 and 0.74 (p<0.001). Hyponatremia prevalence was increased in Onco-
Haematology (49.7%), General surgery (42%), Nephrology (37.1), Pulmonary (35.1%), 
Urology (34.2%), Neonatology (32.8%), Digestology (32%), Orthopedic surgery (30.3%), 
and Internal medicine (28.4%).
Conclusions: Hyponatremia is present in one fifth of in-hospital patients. Correction 
of plasma Na concentration according to TPP concentration increase hyponatremia 
diagnostic up to 25%.
PUB460
An Unusual Cause of Hypokalemia  Mohamad A. Hanouneh,1 James F. Simon.2 
1Internal Medicine, Cleveland Clinic, Cleveland, OH; 2Glickman Urologic and 
Kidney Inst, Cleveland Clinic, Cleveland, OH.
Methods: A 59-year-old woman presented as a self-referral for a second opinion 
regarding hypokalemia.She had long-standing resistant hypertension currently treated with 
metoprolol, lisinopril and amlodipine. Four weeks ago she began experiencing hypotension.
She claimed a history of edema treated with diuretics, including metolazone stopped one 
month prior and amiloride which was stopped one week prior.She denied taking any 
furosemide in the past 2 years.She complained of occasional orthostatic symptoms.Physical 
examination revealed orthostatic hypotension and no edema.Work-up revealed normal 
free serum cortisol, elevated plasma renin activity of 36.5 ug/L/hr (0.8-5.8 ug/L/hr) and 
serum aldosterone level of 76. ng/dL (3.1-35.4 ng/dL). Adrenal glands appeared normal on 
CT.24-hour urine studies suggested renal potassium wasting (sodium 310 mmol/24 hour 
without a sodium load, potassium 38 mmol/24 hour, chloride 269 mmol/24 hour).Repeat 
chemistry done at the same time showed a serum creatinine of 2.2 mg/dL compared to 1 mg/
dL 4 weeks prior, potassium level of 3.1 mmol/L.She was admitted for acute kidney injury.
After receiving 2 liters of 0.9% saline IV, blood pressure stabilized and creatinine returned 
to 1mg/dL.She remained hypokalemic.Repeat labs after IVF showed plasma renin activity 
of 5.3 ug/L/hr and aldosterone of 15.0 ng/dL.Urine diuretic screen drawn while admitted 
was positive for furosemide, consistent with diuretic abuse .This patient’s initial complaint 
of difficult to control hypertension and hypokalemia suggested a primary disorder of the 
renin-angiotensin system.However, hypotension upon presentation conflicted with this and 
was more consistent with a tubular wasting disorder such as Bartters or Gitelman syndrome 
or diuretic abuse, the last of which was most likely in this clinical situation.Suppression 
of both renin and aldosterone secretion after IVF confirmed the initial abnormalities were 
due to volume depletion.
Conclusions: Diuretic abuse should be considered when patients present with 
hypotension and hypokalemia. This case provides a rare insight into physiologic response 
of the renin-angiotensin system to diuretic abuse and volume resuscitation.
PUB461
Hypernatremia During Hospitalization Is Associated with Increased Risk of 
Death: A Systematic Review and Meta Analysis  Yorg Al Azzi, Rabi Yacoub, 
Samira S. Farouk, Ioannis Konstantinidis, Girish N. Nadkarni, Steven G. Coca. 
Icahn School of Medicine at Mount Sinai, NY.
Background: While hyponatremia is the more common dysnatremia compared 
to hypernatremia, and hyponatremia has been independently associated with mortality 
in several studies, some analyses have suggested that hypernatremia portends a worse 
prognosis. Robust estimates regarding the excess hospital mortality associated with 
hypernatremia across different inpatient settings are lacking. We sought to quantitatively 
synthesize the available evidence.
Methods: We systematically searched PubMed, EMBASE and Cochrane Central 
through May 2015, and selected studies using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) checklist. We analyzed studies reporting risk for 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
995A
J Am Soc Nephrol 26: 2015 Publication Only 
mortality adjusted for patients’ characteristics and co-morbid conditions. We used random 
effects meta-analysis to derive pooled estimates of effect in medical, surgical and mixed 
admission settings.
Results: We evaluated 135 full text publications from 10,215 reviewed abstracts, of 
which 32 studies met the inclusion criteria (19, 13, and 5 reported aOR, proportion and 
both respectively). Patients with hypernatremia were at increased risk of hospital mortality 
(OR=2.59, 95% CI 1.5-4.47, P<0.001).
There was no difference in mortality risk between medical, surgical and mixed 
admission (P=0.9). Comparison of studies based on severity of hypernatremia revealed 
a small dose effect [(OR=2.23, 95% CI 1.64-3.04, P<0.001 for Na³145) and (OR=2.84, 
95% CI 2.02-4, P<0.001 for ³150 mg/dl]. Analysis of proportion revealed higher odds of 
mortality (OR=5.48, 95% CI 3.66-8.21, P<0.001).
Conclusions: Admission with serum Na of ³145 mg/dl is significantly associated 
with twice the odds of hospital mortality. Protocols towards increasing awareness of 
hypernatremia and studies evaluating the efficacy of early intervention are warranted.
PUB462
Clinical Features of Reported Ethylene Glycol Exposures in the United 
States  Meghan A. Jobson,1 Susan L. Hogan,1 Yichun Hu,1 Gerald A. Hladik,1 
Ronald J. Falk,1 Michael C. Beuhler,2 William Franklin Pendergraft.1  1Div of 
Nephrology and Hypertension, Dept of Medicine, UNC Kidney Center, Chapel 
Hill, NC; 2Carolinas Poison Center, Carolinas Medical Center, Charlotte, NC.
Background: Ethylene glycol is highly toxic and represents an important cause 
of poisonings worldwide. Toxicity can result in central nervous system dysfunction, 
cardiovascular compromise, elevated anion gap metabolic acidosis and acute kidney 
injury. Many states have passed laws requiring addition of the bittering agent, denatonium 
benzoate, to ethylene glycol solutions to reduce severity of exposures. The objectives of 
this study were to identify differences between unintentional and intentional exposures and 
to evaluate the utility of denatonium benzoate as a deterrent.
Methods: Using the National Poison Data System, we performed a retrospective 
analysis of reported cases of ethylene glycol exposures from January 2006 to December 
2013. Outcome classification was summed for intentionality and used as a basis for 
comparison of effect groups.
Results: There were 45,097 cases of ethylene glycol exposures resulting in 154 deaths. 
Individuals more likely to experience major effects or death were older, male, and presented 
with more severe symptoms requiring higher levels of care. Latitude and season did not 
correlate with increased exposures; however, there were more exposures in rural areas. 
Denatonium benzoate use appeared to have no effect on exposure severity or number.
Conclusions: Deaths due to ethylene glycol exposure were uncommon; however, there 
were major clinical effects and more exposures in rural areas. Addition of denatonium 
benzoate was not associated with a reduction in exposures. Alternative means to deter 
ingestion are needed. These findings suggest the need to consider replacing ethylene glycol 
with alternative and less toxic agents.
PUB463
OTC Medication Leading to Chronic Salicylate Toxicity  Muhammad Deen, 
Roohi Khan.  Nephrology, CHI St. Luke’s Health, Houston, TX.
Background: OTC medication containing salicylate leading to intoxication.
Methods: 60 YO F with PMH significant for chronic migraines, PUD s/p partial 
gastrectomy, presented to the ED with complains of nausea, vomiting, AMS, confusion and 
lethargy along with headaches, tinnitus and decreased bilateral hearing. Patient was found 
to be tachypnic, diaphoretic with respiratory alkalosis and anion gap metabolic acidosis 
with normal renal function. 
Vitals: BP 114/67mmHg, Pulse 90/min, Temp 97.6 °F, RR 22/min and SpO2 100%. 
Examination: Unremarkable examination except AMS. 
Labs: Na 133mEq/L, K 3.1 mEq/L, Cl 103 mEq/L, C02 12 mEq/L, BUN 10 mg/dl, Cr 
0.8 mg/dl, venous lactate 8 mg/dl and ethanol <10 mg/dl. VBG: pH 7.5, pCO2 13 mmHg 
and pO2 49mmHg and HCO3 11 mmHg. 
Imaging: CT head -NAF. Review of medication: Unremarkable for toxic medication. 
On further discussion with family, it was found that patient had been taking BC powder 
for her chronic headaches. Hence salicylate levels were drawn and found to be 75 mg/dl 
thus leading to the diagnoses of chronic salicylate toxicity. 
Treatment:Medical management was initiated with IV fluid containing bicarb. In the 
following days patient’s condition gradually improved and labs revealed salicylate level < 8.
Conclusions: Chronic salicylate intoxication is most common in the elderly. Increased 
toxicity in older patient often appears due to inadvertent over dosage. Dual prescribing or 
additional use of non prescription OTC salicylates are some causes of unwitting long term 
toxicity. Chronic intoxication often poses a diagnostic dilemma with atypical presentation 
mimicking other disease states. The diagnosis of salicylate intoxication should be borne 
in mind when an older patient presents with recent deterioration in ADL with no known 
cause. Plasma salicylate concentration should be measured if salicylate toxication is 
suspected, even if there is no documented history of salicylate ingestion. Chronic toxicity, 
which can occur even with marginally high salicylate concentrations is treated with drug 
withdrawal and supportive therapy. It can be averted by prescription of conservative doses 
of drugs, avoidance of concomitant use of different salicylate preparations, and therapeutic 
monitoring to guide dosage.
PUB464
Diagnostic Workup of Hyponatremia in Hospitalized Patients: Does 
Education Have an Impact?  Faraj Kargoli, Ladan Golestaneh.  Dept of 
Nephrology, Montefiore Medical Center, Bronx, NY.
Background: Hyponatremia is associated with poor outcomes. Studies show that 
hospitalized hyponatremic patients seldom get adequate diagnostic workups. This study 
tests the effects of a CME activity on physician’s behavior in the diagnostic workup of 
hyponatremia.
Methods: This is a cross sectional analysis of patients admitted to the Internal 
medicine department at Montefiore Medical Center between 05/01/2014 and 12/01/2014. 
Demographic and clinical data were collected retrospectively. Patients were included if 
they were admitted under the service of 24 hospitalist attendings. These attendings were 
chosen based on their participation in a CME activity (lecture based). This activity was 
implemented to improve hyponatremia workup as defined by the frequency of the following 
orders: serum osmolality, urine osmolality, and urine sodium. Hyponatermia was defined 
as the earliest serum sodium less than 135 meq/dL. There was further subclassification 
into three groups based on the severity: mild: 130-135 meq/dL, moderate: 125-130 meq/
dL and severe: less than 125 meq/dL. Frequency of the diagnostic orders was stratified to 
before and after the activity.
Results: There were 358 patients with hyponatremia: 176 hyponatremia admissions 
occurred before the live lectures and 182 occurred after. Average age was 63yrs ±17, average 
length of stay was 5.2 days ± 2.9. The severity of hyponatremia was 82%, 14% and 3.4% 
for mild, moderate and severe, respectively. Forty eight percent of all patients who had 
hyponatremia at admission were discharged with hyponatremia. There was an increase in 
serum sodium between admission and discharge with a mean difference of 3.06 (95%CI, 
2.6-3.5mg d/L), (P<0.0001). The frequency of all 3 orders was 3.2%, 19% and 50% in the 
cohorts, (p value <0.001). This frequency was 6% in the pre-activity cohort versus 8% 
post. More of the severely hyponatremic patients were discharged with hyponatremia than 
the mild or moderate (p<0.005).
Conclusions: Hyponatremia was underinvestigated in our cohort despite a formal 
educational exercise addressing better diagnostic workup. Further research is warranted 
to investigate the effect of CME activity on the treating physician behavior and patients 
outcomes.
Funding: Pharmaceutical Company Support - Rockpointe LLC
PUB465
Characteristics and Initial Outcomes of a Multidisciplinary Renal 
Genetics Clinic (RGC)  Andrew John Mallett,1,2,3 Helen G. Healy,1,2,3 Julie M. 
Mcgaughran,2,3,4 Melissa H. Little,3,5,6 Chirag Patel.2,3,4  1Kidney Health Service 
& Conjoint Kidney Research Laboratory, Royal Brisbane & Women’s Hospital, 
Brisbane, QLD, Australia; 2School of Medicine, The Univ of Queensland, 
Brisbane, QLD, Australia; 3Inst for Molecular Bioscience, UQ, Brisbane, QLD, 
Australia; 4Genetic Health Queensland, RBWH, Brisbane, QLD, Australia; 
5Murdoch Children’s Research Inst, Melbourne, VIC, Australia.
Background: Genetic Renal Disease (GRD) accounts for 10% of adults and 50% of 
children with end stage kidney disease. Advances in molecular genetic diagnostic testing 
and multidisciplinary renal clinic models suggest opportunities for clinical redesign. Here 
we describe the initial characteristics, experience and outcomes of the first Australian 
multidisciplinary RGC.
Methods: A retrospective audit was undertaken of the RBWH Adult Conjoint RGC 
(1st year of operation; Aug’13-Jul’14). Each encounter involved a nephrologist, clinical 
geneticist and genetic counselor.
Results: 27/48 patients (56%) encountered had a known GRD, 9/48 (19%) had a 
suspected GRD and 12/48 (25%) had an unknown GRD with positive family history 
(FHx). Patients were most commonly referred by nephrologists (66%).The most common 
GRD category & diagnosis were cystic kidney disease (49%) and Autosomal Dominant 
Tubulointerstitial Kidney Disease (25%). Extra-renal features were associated with GRD in 
26/48 (54%). During consultations differential diagnoses were explored (54%), management 
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advice provided (83%) and genetic counseling undertaken (79%). A genetic test was 
requested in 58.3%, most commonly being indicated for combined diagnostic and genetic 
counseling reasons (78.6%). Of 12 returned genetic test results, 7 were positive and 1 was 
a variant of uncertain significance. Two negative results have prompted additional genetic 
testing. Of 27 patients referred with a known GRD, 6 now have a new suspected GRD. 
The majority of those referred with either a suspected (6/9) or unknown GRD diagnosis 
(10/12) now have a new suspected or confirmed GRD.
Conclusions: These findings demonstrate the early successful operation of this RGC 
model including diagnostic and genetic counseling benefit. Future assessment of clinical 
outcomes and expansion to telehealth and paediatric settings is anticipated.
PUB466
Characteristics and Clinicopathological Analysis of Japanese 
Nephronophthisis Patients  Keisuke Sugimoto,1 Tomoki Miyazawa,1 
Takuji Enya,1 Hitomi Nishi,1 Kohei Miyazaki,1 Hidehiko Yanagida,2 Mitsuru 
Okada,1 Tsukasa Takemura.1  1Pediatrics, Kindai Univ Faculty of Medicine, 
Osakasayama, Osaka, Japan; 2Pediatrics, Sakai Hospital, Kindai Univ Faculty 
of Medicine, Sakai, Osaka, Japan.
Background: Nephronophthisis (NPHP) accounts for 4 to 5% of end-stage renal 
disease (ESRD) occurring in childhood. Disease subtypes include infantile NPH, which 
progresses to ESRD around the age of 5 years. juvenile NPH, which develops from early 
childhood to school age and usually progresses to ESRD by an age of about 13 or 14 years; 
and adolescent NPH, with development of ESRD at an average age of 19 years. Juvenile 
NPH is reported to be the most common subtype.
Methods: We investigated clinical, histologic, and genetic features in 35 Japanese 
patients clinically and histologically suspected to have NPHP, aiming to promote early 
diagnosis. We studied many exons as many as 13 NPHP genes. Since such genetic analysis 
involves significant cost and time, we also screened biopsy specimens by immunohistologic 
methods employing antibodies against relevant peptides.
Results: NPHP occurred fairly uniformly throughout Japan irrespective of region or 
gender. In 3 families, NPHP affected siblings. The median age of patients was 12.5 years. 
Renal abnormalities attributable to NPHP discovered through mass screening, such as urine 
tests in school. However, NPHP accounted for less than 50% of children with abnormal 
findings, including incidentally discovered renal dysfunction during evaluation of extrarenal 
symptoms or during routine check-ups. Typical extrarenal manifestations leaded to discovery 
including anemia and delayed physical development. The urine often showed low gravity 
specific density and low-molecular-weight proteinuria. Frequent renal histologic findings 
included cystic dilation of tubules, mainly in the medulla, and irregularity of tubular 
basement membranes. Genetically abnormalities of NPHP1 were not common, with large 
deletions frequently noted. Compound heterozygotes showing single abnormalities in each 
of NPHP1, NPHP3, NPHP4 were observed.
Conclusions: Our findings resemble those reported in Western populations.
PUB467
The Functional Role of the ARHGAP32 L405V Mutation on Cytoskeleton 
Guisen Li, Li Wang.  Nephrology, Sichuan Academy of Medical Sciences & 
Sichuan Provincial People’s Hospital, Chengdu, China.
Background: A site-directed mutagenesis for ARHGAP32 was developed to whether 
the mutation of ARHGAP32 has the effect on the related factors of cytoskeleton in vitro 
and to understand the functional role of ARHGAP32 in FSGS.
Methods: 1. (1) Blood DNA of 110 FSGS patients proved by renal biopsy  were 
sequenced and screened for the mutation of ARHGAP32. (2) Total exons sequencing 
were performed in 28 DNA samples to find out whether mutation of ARHGAP32and other 
genes were existed. 2. (1) site-directed mutagenesis primers of ARHGAP32 was designed 
and amplified by PCR, obtainding the mutations of ARHGAP32 plasmids. (2) Transform 
the wild type and mutant plasmids of ARHGAP32 into Escherichia Coli respectively, 
sequenced the plasmids to identify whether the site-directed mutagenesis of ARHGAP32 
was successful constructed. (3) Transfected the mutated plasmid of ARHGAP32 into 293T 
cells and thenverified by western blot and realtime RT-PCR. 3. (1) Detected the expression 
of ARHGAP32 in FSGS, IgAN, MN, minimal change disease and diabetic disease by IHC. 
(2) Detected the expression of CDC42 andβ-catenin by realtime RT-PCR and western 
blot in 293T cells which were transfected with the wild type and mutated plasmids of 
ARHGAP32. (3) Observed the expression of F-actin by immunofluorescence in the wild 
plasmid of ARHGAP32 and mutant type in COS7 cells.
Results: 1. (1) No mutation of ARHGAP32 was detected while 6 candidate genes 
were selected by sequencing all exons. 2. (1) ARHGAP32 gene was expressed mainly in 
glomerular in kidney tissue in all different pathologic types by IHC. (2) The expression of 
CDC42 andβ-catenin by realtime RT-PCR and western blot were no significant differences 
between the wild plasmid of ARHGAP32 and mutant type in 293T cells. (3) The distribution 
of F-actin was more significant in the wild type than that in mutant plasmid of ARHGAP32. 
It spreaded all the directions in wild type, while the distribution was scattered in mutant type.
Conclusions: 1 No mutation was detected in sporadic FSGS currently. 2 The mutation 
of ARHGAP32 had effect on the distribution of cytoskeletal protein of F-actin.
PUB468
Hyponatraemia and Fractured Neck of Femurs in a Geriatric Population: 
A Retrospective Analysis  Tamer Rezk, Krish Patel, Ashish Karir, Sashinie 
Tennekoon Jayasundera, Christine Sarah Catley, Abdelgalil Abdelrahman Ali, 
Sumith Abeygunasekara.  MEHT, United Kingdom.
Background: Hyponatraemia is the commonest electrolyte abnormality found in 
elderly hospitalized patients defined as a serum sodium concentration <135 mmol/L with 
a mean prevalence of 5%. (NDT 2003; 18: 2486). It is a risk factor for fractures due to 
unsteady gait as well as osteoporosis and bone fragility. Fractured necks of femurs (NOF) 
are a significant cause of morbidity and mortality in the elderly with an estimated 24% 
mortality at 1 year (JAMA 2001; 285: 2736).
Methods: Retrospective analysis of 501 patients from fractured NOF database from 
1/1/2014 to 31/12/2014 to identify the incidence and severity of hyponatraemia, Chronic 
Kidney Disease(CKD) Stage and mortality at 30 days and 1 year.
Results: Mean age was 83 years and M:F ratio of 1:3. Mild-moderate hyponatraemia 
was found in 48% of patients (serum sodium of 126-134mmol/L) with only 3% suffering 
with severe hyponatraemia (< 126mmol/L). 31% of patients had CKD Stage 3, 5% Stage 
4 and 2% Stage 5. 30-day and 1-year mortality was 7% and 18% respectively. Patients 
were separated into 3 groups based on natraemic status 
Natraemic status (mmol/L) 1 year survival (%)
<126 (severe) 0.643
126-134 (mild-moderate) 0.809
≥135 (normal) 0.841
Kaplan-Meier survival functions were calculated looking at 1-year mortality.
Those with hyponatraemia at the time of presentation appeared to have a worse 1-year 
survival. Log-rank test was performed. Using a chi-squared value of 3.521, a p value of 
0.172 was obtained (not significant).
Conclusions: From our analysis it is clear that nearly half of patients on admission 
with fractured NOF have at least mild hyponatraemia with evidence to suggest reduction in 
1-year survival. We propose more rigorous investigation of this subtle electrolyte disturbance 
in primary care which carries with it a significant morbidity and mortality.
PUB469
The Effect of Age on Mitochondrial Protein Levels in Rat Kidney Cortex 
and Medulla  Marianna J. Zamlauski-Tucker, Natalya Mezenina, Cameron M. 
Behringer.  Physiology & Health Science, Ball State Univ, Muncie, IN.
Background: The present study was undertaken to determine the effect of rat age on 
total protein levels in mitochondria from kidney cortex and medulla.
Methods: Young (3 months of age) and Old (22 months of age) female Lewis rats 
were used. The kidneys were harvested from anesthetized rats after being perfused with 
isotonic saline via a catheter in the abdominal aorta. The kidneys were separated into cortical 
and medullary sections and homogenized in isotonic saline. Differential centrifugation 
was used to isolate the mitochondrial pellet. The mitochondrial pellet was dissolved in 
distilled water and spun again at 10,000 rpm to isolate the mitochondrial protein pellet. 
The mitochondrial protein pellet was dissolved in 1 ml of 0.1 M sodium hydroxide. The 
protein concentration of the sodium hydroxide solution was measured using the Lowry 
Protein Assay. The protein concentration was expressed as mg protein/g kidney wet weight. 
Differences were evaluated using a Student’s t test.
Results: A significant decrease in the total mitochondrial protein level was observed 
in kidney cortex from Old rats. The total mitochondrial protein level in kidney medulla 
from Old rats was not significantly decreased.
Young (n=5) Old (n=5)
Mitochondrial Protein Cortex 2.02 ± 0.42 0.59 ±0.30 *
mg/g kidney wet wt Medulla 2.43 ±0.42 1.11 ±0.40
All data expressed as X ± SEM; * Significantly different from the Young 
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Conclusions: Total mitochondrial protein levels decrease in the cortex but not in the 
medulla of the rat kidney with age.
PUB470
Intradialytic Hemodynamic Stability and Functional Status  Zubin T. Lathara, 
Aniko Szabo, Alexis Visotcky, Dawn F. Wolfgram.  Nephrology, Medical College 
of Wisconsin, Milwaukee, WI.
Background: Prior research suggests that functional status in ESRD patients declines 
after initiation of dialysis, implicating the dialysis process in contributing to functional 
decline. We evaluated a dialysis-specific risk factor of intradialytic change in blood pressure 
(BP) in relation to changes in physical performance, a component of functional status.
Methods: We enrolled 29 dialysis patients age ≥ 50 years. Participants completed a 4m 
timed walk to measure gait speed both pre and post dialysis and a Falls Efficacy Survey, a 
measure of concern for falls. Dialytic variables included BP measurements from pre, post 
and during dialysis along with ultrafiltration rate. Demographics and comorbid data was 
collected. Analysis evaluated for association between dialytic BP variables and change in 
gait speed and score on Falls Survey. Multivariate analysis was done to adjust for age, race, 
sex, diabetes and congestive heart failure.
Results: 28 participants completed the study. The mean age was 62.7 (12.3) years. The 
majority were male (70.4%) and hypertensive (86.2%). Diabetes was present in 55.2%. 
The mean (SD) change in gait speed from pre to post dialysis was -0.1(0.1) m/s. The mean 
(SD) change in systolic and diastolic BP from pre to post dialysis was -10.6(25.8) mmHg 
and -4.6(10.5) mmHg, respectively. Participants with diabetes had greater intradialytic 
hemodynamic changes with mean (SD) change of SBP + DBP of -26.9(23.5) and -7.9(11.3) 
respectively. Univariate analysis showed that every 10mmHg decrease in systolic BP and 
every 5mmHg decrease in diastolic BP was associated with a change in gait speed of 
-0.01m/s (p = 0.02) and -0.02m/s (p = 0.01), respectively. This association was no longer 
significant in multivariate analysis, likely due to correlation of change in BP with diabetes 
status. There was no association between BP change and Falls Survey score.
Conclusions: Decline in physical performance, as measured by gait speed, can be 
seen post dialysis and is associated with hemodynamic changes during dialysis. Patients 
with diabetes may be most susceptible to hemodynamic changes. Improving dialytic 
hemodynamic stability may be a way to reduce the significant functional impairment that 
occurs post-dialysis.
Funding: Private Foundation Support
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Sirtuin1 Expression in Kidney Tissue Specimens in Patients with IgA 
Nephropathy  Cetin Ozener,2 Izzet Hakki Arikan,2 Ceren Ozcan,1 Derya Guler,2 
Serhan Tuglular,2 Deniz Filinte.3  1Internal Medicine, Marmara Univ Hospital, 
Istanbul, Turkey; 2Nephrology, Marmara Univ Hospital, Istanbul, Turkey; 
3Pathology, Marmara Univ Hospital, Istanbul, Turkey.
Background: SIRT 1 immunexpression in renalbiyopsy samples of the patients with 
IgA nephropathy were evaluated to identify the possible role of SIRT 1 on the pathogenesis 
of SIRT 1 in IgA nephropathy.
Methods: Twenty eight patients 28 patients (16 women, mean age 37±13.8 years) 
were included. Biopsy specimens of the patients were reevaluated according to Oxford 
Classification.Immunoexpression of SIRT 1, TNF-α, IL-10 and TGF-β were evaluated on 
kidney tissue specimens byimmunohistochemical staining.
Results: Older age, and higher serum creatinine and uric acid levelswere the predictors 
of a greater decline of the kidney function. There was a positive correlation between 
mesangialhypercellularity and uric acid levels. TGF-β (nuclear) and IL-10 (cytoplasmic) 
expressions were shown in 20 (%71.4) and 25 (%89.3) of the patients, respectively. 
Expression of the IL-10 was higher in patients who had a high average mesangialscore. 
Tubular and weak (1+) SIRT 1 expression was present only in 7 patients.
Age 37
±
 14
Gender(female/male) 16/12
BMI(kg/m2) 23.6
±
 2.6
Creatinine(mg/dl) 1.6
±
 1.5
Albumin(g/dl) 4.0
±
 0.6
Uric acid(mg/dl) 6.0
±
 2.2
Proteinuria(g/day) 2.4
±
 1.9
GFR(CKD-EPI)(ml/min) 74.6
±
 41.2
Hypertension,n(%) 13(46.6)
Macroscopic hematuria,n(%) 11(39.3)
Microscopic hematuria,n((%) 23(82.1)
Previous immunosuppressive therapy,n(%) 3(10.7)
Follow-up time (years) 4.8
±
 2.7
Table 1. Baseline demographic and laboratory data of thepatients (n=28)
Conclusions: A positive correlation was shown between mesangial hypercellularity 
with serum uric acid levels in the first time. These results suggest that SIRT 1does not play 
a direct role in the pathogenesis of IgAnephropathy.
Funding: NIDDK Support
PUB472
Response of Human Primary Renal Proximal Tubular Epithelial Cells to 
Different LPS Strains  Hong Wang, Margaret M. O’Neill, Carine Boustany, 
Steven S. Pullen.  CardioMetabolic Diseases Research, Boehringer Ingelheim 
Pharmaceuticals, Ridgefield, CT.
Background: Toll-like receptors are expressed on leukocytes and renal tubular 
epithelial cells where they regulate immune responses. Recent evidence has implicated 
renal TLR4 signaling in the pro-inflammatory response in diabetic nephropathy. Ligands for 
TLR4 include lipopolysaccharide (LPS) and HMGB1. We sought to explore the response 
of renal proximal tubular epithelial cells (PTEC) to different strains of LPS and HMGB1 
as well as modulation by TLR4 antagonists.
Methods: The HK-2 human proximal tubular cell line was stimulated with 3 strains 
of LPS (S. minnesota, E. coli K12, E. coli 0111:B4) and HMGB1. Primary human PTEC 
were stimulated with 5 strains of LPS (S. minnesota, E. coli 0111:B4, E. coli 055:B5, E. coli 
K12, S. typhosa)and HMGB1. Supernatants were harvested and IL-1β, IL-6, IL-8, TNFα, 
and MCP-1 were detected.TLR4 antagonists EX 76233 and EX 76824 were tested for the 
ability to modulate cytokine production induced by LPS stimulation.
Results: In HK-2 cells, LPS from E. coli 0111:B4 induced IL-6 and IL-8 production, 
whereas, S. minnesota and E. coli K12 did not stimulate cytokine production. In PTEC, IL-6 
and IL-8 production increased upon S. typhosa, and S. minnesota stimulation. Other strains 
of LPS did not stimulate production of IL-6 and IL-8 in PTEC. There was little detectable 
production of IL-1β, TNFα or MCP-1 under the conditions tested in both PTEC and HK-2 
cells. HMGB1 induced IL-8 production in PTEC whereas HK-2 cells did not produce of 
any of the cytokines or chemokines tested upon HMGB1 stimulation. The TLR4 antagonists 
EX 76824 and EX 76233 blocked cytokine production stimulated by S. typhosa in PTEC. 
EX 76824 inhibited IL-6 and IL-8 production stimulated by E. coli 0111:B4 in HK-2 cells.
Conclusions: Primary PTEC have unique responses to different strains of LPS, and this 
response profile differs from that of the HK-2 cell line. HMGB1 induced IL-8 production in 
PTEC, whereas HK-2 cells did not respond to HMGB1 stimulation. These results highlight 
a limitation of using the HK-2 cell line in lieu of primary PTEC for interrogating the role 
of TLR4 in renal inflammation.
PUB473
Assessment of Serum Transforming Growth Factor-Beta 1 in Patients with 
Diabetic Nephropathy  Om Prakash Kalra,1 Avanish Shukla,1 Ashok Kumar 
Tripathi,2 Alpana Raizada.1  1Medicine, UCMS & GTB Hospital, Delhi, India; 
2Biochemistry, UCMS & GTB Hospital, Delhi, India.
Background: Diabetes mellitus is the leading cause of chronic kidney disease (CKD) 
worldwide. The pathogenesis and initial molecular events leading to diabetic nephropathy 
are still elusive. Chronic low grade inflammation plays an important role in pathogenesis 
of diabetic nephropathy. Ubiquitous cytokines like transforming growth factor-beta 
(TGF-β) function in an autocrine or paracrine fashion to elicit extra cellular matrix (ECM) 
accumulation and cellular hypertrophy in several cell types. TGF-β may play an important 
role in the pathogenesis of diabetic nephropathy by influencing ECM accumulation.
Methods: This was a case control, cross sectional study. 75 subjects aged 30– 65 
years of either sex were recruited and divided into three groups: Group I: healthy controls 
(n=25), Group II: patients of T2DM without nephropathy (n=25), Group III: patients of 
T2DM with nephropathy(n=25). Detailed history, complete physical examination, routine 
investigations, urine albumin creatinine ratio (ACR) estimation was done. Serum levels 
of hs-CRP and TGF-b1 were estimated by ELISA.
Results: A statistically significant difference in serum TGF-b1 and hs-CRP levels was 
observed between all the 3 groups (p<0.001), where highest levels were found in group 
III and lowest in group I. A positive correlation was observed between serum TGF-b1 and 
duration of diabetes, FBS, PPBS, HbA1c levels, serum creatinine, urinary ACR and serum 
hs-CRP. Similarly serum hs-CRP levels positively correlated with the duration of diabetes, 
FBS, PPBS, HbA1c levels, serum creatinine, and urinary ACR. Serum TGF-b1 and serum 
hs-CRP showed negative correlation with eGFR.
Conclusions: Overall, TGF-b1 and hs-CRP levels were significantly higher in 
diabetics as compared to non-diabetic subjects. They were higher in diabetic subjects 
with nephropathy as compared to those without nephropathy. Serum TGF-b1 and hs-
CRP levels in diabetic subjects appear to be dependent on duration of diabetes, glycemic 
control and degree of renal dysfunction. Thus cytokines like TGF-β may play a role in the 
etiopathogenesis of diabetic nephropathy.
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PUB474
Daptomycin Antibiotic Lock Therapy for Hemodialysis Patients with 
Gram-Positive Bloodstream Infections following Use of Tunneled, 
Cuffed Hemodialysis Catheters. Retrospective Single Center Analysis 
Hung-Wen Yen, Szu-yuan Li.  Dept of Medicine, Div of Nephrology, Dept of 
Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Catheter-related blood stream infection (CRBSI) is a major complication 
in hemodialysis patients. We assessed the efficacy of systemic daptomycin (DPT) plus DPT 
antibiotic lock therapy (DPT-ALT) for catheter-salvage in patients with Gram-positive 
CRBSIs.
Methods: Study Design: Retrospective study of hemodialysis patients with tunneled, 
cuffed hemodialysis catheters. Setting & Participants: All patients were from a single 
institution in Taipei and received systemic DPT plus DPT-ALT for treatment of Gram-
positive CRBSI. Outcome: Successful resolution of CRBSI. Measurements: Resolution 
of fever within 48 h, negative result of repeated blood cultures after resolution of fever, no 
clinical evidence of CRBSI relapse, and no need for catheter removal.
Results: Fifteenhemodialysis patients received DPT-ALT for CRBSI, 9 with 
coagulase-negative Staphylococcus (CONS), 2 with methicillin-resistant Staphylococcus 
aureus (MRSA), 3 with methicillin-sensitive Staphylococcus aureus (MSSA), and 1 
with polymicrobial infections. Systemic DPT plus DPT-ALT cured 11 patients (73.3%). 
Treatment failed in all 3 MRSA cases (2 with MRSA and 1 with MRSA + Enterococcus 
faecalis). 
Characteristics and outcomes of enrolled patients (n = 15)
Variable Mean (range) or Number of patients (%)
Age, years 76.20 (46-91)
Serum albumin, mg/dL 2.88 (1.5-3.7)
Males 9 (60.0%)
Comorbid disease
Diabetes mellitus (DM) 8 (53.3%)
Coronary artery disease (CAD) 6 (40.0%)
Hematological neoplasia 1 (6.7%)
Autoimmune disease 1 (6.7%)
Metastatic infection 2 (13.3%)
Fever 15 (100.0%)
Microorganisms
CONS 9 (60.0%)
MRSA 2 (13.3%)
MSSA 3 (20.0%)
Polymicrobial infection 1 (6.7%)
Outcome
Success 11 (73.3%)
Relapse 0 (0%)
Failure 4 (26.7%)
Infection attributable mortality 4 (26.7%)
Success in Subgroup Analysis
CONS 8 (88.9%)
MRSA 0 (0%)
MSSA 3 (100%)
Conclusions: Systemic DPT plus DPT-ALT appears to be a promising treatment for 
CRBSI from CONS and MSSA, but not for MRSA CRBSI. Systemic DPT plus DPT- ALT 
should be considered for patients with CRBSIs caused by certain species.
PUB475
The Association of the Type of Vascular Access and Erythropoitin Dose 
in Maintenance Hemodialysis Patients with Targeted Hemoglobin Level 
Fangping Lu.1  1Nephrology, First Hospital of Tsinghua Univ, Beijing, China; 
2Blood Purification, Beijing Chaoyang Hospital, Beijing, China; 3Nephrology, 
The Third Hospital of Beijing Hospital, Beijing, China.
Background: Both patients with central venous catheter(CVC) and higher doses 
of erythropoitin(EPO) are at increased risk of mortality in hemodialysis patients, but 
very limited studies involved the relationship. The present retrospective study aimed to 
investigate the association between the type of vascular access and EPO dose in MHD 
patients with targeted hemoglobin level.
Methods: We selected sixty-one patients among 711 MHD patients met inclusion 
criteria from January 2014 to June 2014 from three hospitals in Beijing, China and 
compared the difference of EPO dose between arteriovenous fistula(AVF) and CVC group. 
Inclusion criteria: MHD treatment for >6 months with 3 sessions per week, at least 18 years 
of age, no malignant disease or obvious infection or active immunological disease, no 
gastrointestinal bleeding, no severe iron depletion, no blood transfusions within 3 months 
before inclusion, stable hemoglobin level(100-120g/L for consecutive 3 times within 6 
months), and unchanged vascular access and EPO adjustment for 6 months.
Results: There were 32 AVF and 29 CVC patients. There were no difference of KT/
V,serum ferritin, albumin, iPTH and CRP level between AVF and CVC patients . The mean 
total EPO dose (8793.10±2664.31vs 7039.06±3651.79 iu/week,p=0.035).Standerised mean 
EPO dosage (IU/kg body weight/week)were significant higher in CVC patients compared 
with AVF patients(160.30±58.89 vs 118.02±70.06,p=0.013. It had been associated with 
increase in total weekly erythropoietin dose by 24.9% in CVC patients.
Conclusions: The findings of this study suggest that CVC patients need more EPO 
dose compared with AVF patients within targeted hemoglobin level. It is to further illustrate 
the importance of priority of AVF .
PUB476
Trans Radial Access for Percutaneous Treatment of Arteriovenous Fistula 
Thrombus – 2 Cases  Cinthia Sobral Vieira,1 Enio Ziemiecki Junior,2 Eduardo 
Ferreira Medronha,2 Heloísa Maria Chagas Rego,2 Maurício Da Silva Telles.1 
1Hemodialysis Unit, Hospital Ernesto Dornelles, Porto Alegre, RS, Brazil; 
2Intervention Radiology Service, Hospital Ernesto Dornelles, Porto Alegre, 
RS, Brazil.
Background: Arteriovenous Fistula (AVF) is considered to be the preferential 
access for patients needing hemodialysis. It is called the “line of life” for these patients. 
Complications may occur even in autologous AVF or grafts (PTFE). Stenosis is the most 
frequent complication. Therefore thrombosis is the medical urgency. They are responsible 
for high morbidity, mortality, hospitalizations, interruption of the treatment and access 
loss. The patient must go to angiography study immediately. We want to show that 
endovascular percutaneous technique with transluminal angioplasty through trans radial 
access (TRA),results in quick recovery, particularly in AVF thrombus.
Methods: case 1: a 62 y.o. man with right medium radial AVF, for 3 y, started having 
AVF ache and missed the fistula thrill 48 h after dialysis. It took 45min. to realize the 
exam. Case 2: a 81 y.o man, with a left brachiocephalic AVF, for 5 m. visited the ER with 
gastroenteritis, dehydration and loss of fistula fremitus (less than 24 h).
Results: In these cases, TRA were used with implant of a 6Fr with high compliant 
ballon angioplasty (Conquest,Bard Peripheral Company). The AVF was recovered without 
early or later complications.
Conclusions: Besides the small number of subjects and a follow up of 4 months with 
AVF patency, the TRA technique shows to be a good alternative, promising and very useful 
for AVF recovery, even without fibrinolytics in south Brazil. Contraindications must be 
observed like: intra cardiac shunt R/L, pulmonary hypertension, infected access, surgery 
in the last 30 days. The most traditional techniques use thrombolysis by accessing directly 
the occluded vein, angioplasty or mechanical thrombectomy which demands more time 
of Rx and contrast exposition, higher costs and hospitalization. This procedure does not 
need hospitalization. The success is dependent of early diagnosis of AVF thrombus, by 
the Nephrology staff. There must be a close relationship between the staffs: Nephrology 
and Intervention Radiology.
PUB477
Incidence and Risk Factors for Catheter Related Infections (CRI) and 
Their Antibiograms in Haemodialysis Patients – A South Indian Study 
Shefali Gupta,1 Shrikara P. Mallya.2  1Microbiology, SGPGIMS, Lucknow, India; 
2Microbiology, KMC, Mangalore, India.
Background: Bacterial infections particularly Staphylococcus species  often complicate 
the vascular access in dialysis patients. This study was aimed to determine the incidence and 
associated risk factors for catheter related infections in patients on maintenance hemodialysis 
in a tertiary Hospital in South India.
Methods: Eighty-seven hemodialysis patients (56 M; 31 F) were enrolled in the study. 
After insertion of dual lumen catheter, patients were followed up till its removal. Nasal 
swabs were also collected before insertion. At each dialysis session, catheters were examined 
for any evidence of local infection or sepsis. In case of suspicion, local pus swab, blood 
culture samples and the catheter tip were sent to microbiology laboratory and patients were 
empirically administered vancomycin. Data obtained was examined for relationship of CRI 
with clinical and socio-demographic risk factors.
Results: Fifty–three  catheters (61%) showed colonization(>15 CFU). Twenty four 
(45.2%) catheter tips were found to be colonized by S. aureus, 9 (17%) by P. aeruginosa, 
5 (9%) by Acinetobacter, 4 (7.5%) by Enterobacter, 3 (5.6%) by Klebsiella, 2 (3.7%) 
each by E. coli and Citrobacter spp and one (1.9%) each by S. epidermidis, S. maltophilia 
, S. marcescens and C. albicans. Bacteremia was positive in 18(20.7%) patients and P. 
aeruginosa was the organism isolated in 7(38.8%) episodes. Staphylococcal nasal carriage 
was seen in 60 (69%) patients, and 36(41.4%) of these isolates were MRSA. Positive 
Statistically significant factors associated with CRI included history of bacteremia, presence 
of diabetes mellitus, long duration (>15 days) of catheterization and antibiotic use within 
3 months (p < 0.05 for all). However, the age, gender and staphylococcal nasal carriage 
did not correlate with increased risk of infection.
Conclusions: P. aeruginosa is the most common organism in catheter related 
bacteremia which may have a bearing on our current antibiotic policy. Also, early initiation 
of hemodialysis through fistula may help reduce the CRI rate.
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PUB478
Analysis of Risk Factors of Death in Patients of Maintenance Hemodialysis 
with Tunneled Cuffed Venous Catheter  Li Zhou, Min Shi, Ping Fu. 
Nephrology/Medicine, West China Hospital of Sichuan Univ, Chengdu, Sichuan, 
China.
Background: To analyze the causes of death in patients of maintenance hemodialysis 
with tunneled cuffed catheter,and explore the risk factors of death.
Methods: All patients of maintenance hemodialysis with tunneled cuffed venous 
catheter starting hemodialysis from January 1,2009 to December 1,2014 in West China 
hospital were included and observed till June 1,2015.The patients were divided into 
observation(death) and control group (survival).Multivariate logistic regression analysis 
was used.
Results: In total 94 hemodialysis patients who met the inclusion criteria, 24 cases died 
in the study period.The median age of dead patients was 73.4 years (51.5~96.4). The median 
time of hemodialysis was 19.20 months (3.17~56.27).Just 1 case replaced tunneled cuffed 
catheter for once. The main primary causes of renal disease were: diabetic kieney disease 
(DKD) 50.0%, chronic glomerulonephritis (CGN) 25.0%, hypertensive renal damage 
(HTN)12.5%. The main causes of death were as following: infection 29.2%, cardiovascular 
diseases (CVD) 25.0% , cerebrovascular diseases 12.5%. The median age of survival 
patients was 64.9 years (20.8~95.4). Nineteen cases replaced tunneled cuffed catheter for 
twenty three times in total. The main primary causes of renal disease were: CGN 54.3%, 
DKD 25.7%, HTN 4.3%, polycystic kidney disease 4.3%. Multivariate logistic regression 
analysis showed that elder age, infection, low serum albumin were risk factors of death. 
Replacement of tunneled cuffed catheter was not the risk factors for death.
Conclusions: The main causes of death of patients with maintenance hemodialysis 
by tunneled cuffed venous catheter were cardiovascular and cerebrovascular diseases and 
infection.Elder age, infection, lower level of serum albumin were risk factors of death in 
patients of maintenance hemodialysis with tunneled cuffed venous catheter. Replacement 
of tunneled cuffed catheter was not the risk factors for death. Funds: the National Key 
Technology R&D Program of China (No. 2011BAI10B08), ‚Cost and Evaluation System 
Study on payment revolution for patient in chronic hemodialysis with insurance of Chengdu 
City (Chengdu Municipal Medical Insurance Bureau).
Funding: Government Support - Non-U.S.
PUB479
Analysis of Vascular Access of Maintenance Hemodialysis Patients: A Single 
Center Retrospective Study  Yuan Luo, Hong Ye.  Center for Kidney Disease, 
Second Affiliated Hospital, Nanjing Medical Univ, Nanjing, Jiangsu, China.
Background: Vascular access is life line for maintenance hemodialysis patients. 
The main options for vascular access for hemodialysis patients are arteriovenous fistulas 
(AVFs), arteriovenous grafts(AVGs), and tunneled cuffed central venous catheters. Proper 
vascular access is associated with lower complications and costs, which could improve the 
survival rate. The aim of our study is to analysis the characteristics of vascular accesses of 
maintenance hemodialysis patients in our hemodialysis center.
Methods: Patients underwent maintenance hemodialysis in the blood purification 
center of our hospital from January 2010 to December 2014 were enrolled in this study. The 
demographic characteristics, duration of dialysis, types of vascular access and blood flow 
volume, as well as the patency rate of AVFs of these patients were collected and analyzed.
Results: Sixty percent of the maintenance hemodialysis patients were male and the 
mean age was 57.89±14.27 years old. More than 60% patients’ initial vascular access was 
non-tunneled central venous catheters, only 20% applied AVFs as their initial vascular 
access. Vascular access types was as follows, 87.0% for AVFs, 3.5% for AVGs and 9.5% for 
tunneled cuffed central venous catheter. The cumulative patency rate of AVFs was 86.6%. 
The duration of primary patency was 29.00 (12.00, 68.00) months and the duration of the 
cumulative patency was 37.00 (12.75, 95.25) months. Fourteen patients applied AVG as their 
vascular access, of whom thromboembolism was the main complication. AVG thrombosis 
of three patients were treated using percutaneous interventions. Among the 294 patients 
applying non-tunneled central venous catheters, 5.4% have their catheters changed for more 
than 2 times and 66.7% have their catheters on the right internal jugular vein.
Conclusions: AVF is the leading type of vascular access in our dialysis center. The 
usage of tunnel cuffed central catheters is under 10%, while the usage rate of AVGs is 
increased. Non-tunneled central venous catheter is the main option for initial dialysis patients 
and the percentage of patients who prepared their AVFs ready before dialysis is still low.
Funding: Government Support - Non-U.S.
PUB480
Exchange Technique Using Over the Guidewire from Tunneled to Tunneled 
Hemodialysis Catheter Can Be Performed without Increasing Infection and 
Compromising Catheter Long Term Patency  Hoon Suk Park, Min Seok Choi, 
Woo Jeong Kim, Sung Jun Kim, Byung Ha Chung, Hyung Wook Kim, Bum Soon 
Choi, Cheol Whee Park, Chul Woo Yang, Dong-Chan Jin.  Div of Nephrology, 
Dept of Internal Medicine, College of Medicine, The Catholic Univ, Korea.
Background: Exchange over the guidewire technique does not require time for 
hemostatsis after removal and the temporary insertion of femoral HD catheter. It can also 
avoid additional new venipuncture that may be associated with the development of central 
vein stenosis later. However, some concerns of the increased risk of infection and bleeding 
after procedure cause to follow the de novo placement of the new tunneled catheter rather 
than exchanging over the guidewire.
Methods: From March in 2009 to March in 2013, 46 cases where the exchange 
from tunneled to tunneled catheter and 310 cases with de novo catheter placement were 
respectively assigned to exchange and de novo placement groups and these 2 groups were 
compared.
Results: Compared with the de novo placement group, the exchange group over the 
guidewire had a higher hemoglobin level (10.6 ± 1.7 g/dl vs. 9.5 ± 1.6 g/dl; p < 0.001), more 
females (69.6% vs. 48.1%; p = 0.006), more ESRD rather than AKI as a cause of catheter 
insertion (95.7% vs. 74.8%; p = 0.002). Both immediate complication rate including suturing 
at exit site for bleeding control (19.6% vs. 8.7%; p = 0.02) and late one including infection 
and catheter dysfunction (37.0% vs. 21.6%; p = 0.02) were higher in the exchange group. 
However, the catheter survival rates between two groups were comparable (p = 0.58) and 
multivariate Cox regression analysis for catheter survival showed the development of late 
complication was the only risk factor (odds ratio [OR] 1.391, 95% confidence interval 
[CI]: 1.017–1.901; p = 0.039) rather than the exchange procedure was not a risk factor 
(OR 0.878, 95% CI: 0.554–1.393; p = 0.582).
Conclusions: The exchange over the guidewire from a previous tunneled catheter to 
a new one should be positively considered and performed when the new tunneled catheter 
placement is required.
PUB481
The Exchange Technique Using Previous Venotomy Site Over the Guidewire 
from Non-Tunneled to Tunneled Hemodialysis Catheter Can Be Performed 
without Compromising Catheter Long Term Patency  Woo Jeong Kim, 
Min Seok Choi, Hoon Suk Park, Sung Jun Kim, Byung Ha Chung, Hyung 
Wook Kim, Bum Soon Choi, Cheol Whee Park, Chul Woo Yang, Dong-Chan 
Jin.  Div of Nephrology, Dept of Internal Medicine, College of Medicine, The 
Catholic Univ, Korea.
Background: The exchange from non-tunneled HD catheter to tunneled one over the 
guidewire using previous venotomy does not require time for hemostasis for a new tunneled 
catheter insertion after its removal. It also does not require a new venipuncture so that it can 
prevent additional vessel wall injury. However, some concerns that it may be associated 
with the increased risk of infection and bleeding after procedure prevent its application.
Methods: From March in 2009 to March in 2013, 47 cases where the exchange from 
non-tunneled to tunneled catheter and 310 cases with de novo catheter placement were 
respectively assigned to exchange and de novo placement groups and these 2 groups were 
compared.
Results: Compared with the de novo placement group, the exchange group over the 
guidewire were younger (61 ± 16 years vs. 66 ± 14 years; p = 0.04), had a lower platelet 
count (171478 ± 115942 mm-3 vs. 207896 ± 100929 mm-3; p = 0.03), the lower incidence 
of DM (38.3% vs. 58.4%; p = 0.01), more AKI rather than ESRD as a cause of catheter 
insertion (42.6% vs. 25.2%; p = 0.02). The immediate complication rate including suturing 
at exit site for bleeding control was higher in the exchange group (19.1% vs. 8.7%; p = 
0.03), but the late complication rate including infection and catheter dysfunction was higher 
in the de novo placement group (21.6% vs. 8.5%; p = 0.04). The catheter survival rates 
between two groups were comparable (p = 0.35). Multivariate Cox regression analysis for 
catheter survival showed the development of late complication was the only risk factor 
(odds ratio [OR] 1.495, 95% confidence interval [CI]: 1.045–2.139; p = 0.028) rather than 
the exchange procedure (OR 1.715, 95% CI: 0.991–2.968; p = 0.054).
Conclusions: The exchange over the guidewire from non-tunneled to tunneled catheter 
should be positively considered and performed when the catheter replacement of non-
tunneled catheter with tunneled one is required.
PUB482
Analysis of Deep Venous Catheter-Related Infections in Hemodialysis 
Patients  Yuan Zhang, Fei Deng, Daqing Hong, Li Wang.  Nephrology, Sichuan 
Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, 
Sichuan, China.
Background: Catheter-related infections are an ever-present risk in patients undergoing 
hemodialysis, and reports from Western countries have indicated their high prevalence. 
To analyze catheter-related infection rates in patients undergoing hemodialysis at the 
East Department of Sichuan Academy of Medical Science, Sichuan Provincial People’s 
Hospital, Sichuan, China.
Methods: We cultured blood samples drawn from the catheters of 464 patients 
undergoing hemodialysis with deep venous catheters at our dialysis center between April 
2011 and August 2013. We determined the type of pathogen, if present, and performed 
antimicrobial susceptibility tests. Data are presented as means ± standard deviation (SD). 
To analyze differences between two groups, we performed the c2 test. P < 0.05 was 
considered significant.
Results: Overall, 47 patients had catheter-related infections, including 41 patients 
with femoral venous catheters (9.9% of all patients with femoral venous catheters), and 6 
had jugular venous catheters (12.0% of all patients with jugular venous catheters). There 
was no significant difference in infection rates between the two groups. Catheter blood 
cultures revealed 38 infections caused by Gram-positive bacteria, seven infections caused 
by Gram-negative bacteria, and two fungal infections. Three infections were caused by 
methicillin-resistant Staphylococcus aureus. Antimicrobial sensitivity tests revealed that 
Gram-positive bacteria were most sensitive to vancomycin, whereas Gram-negative bacteria 
were most sensitive to meropenem or imipenem.
Conclusions: The infection rates of patients with deep venous catheters undergoing 
hemodialysis were relatively high. Venous catheterization should be performed under strict 
sterile conditions, and arteriovenous fistulas should be established as early as possible.
J Am Soc Nephrol 26: 2015 Publication Only
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Utility of Arterio-Venous Fistula Flow and Doppler Ultrasound in the 
Prevention of Thrombosis of the Vascular Access  Milagros Fernandez-Lucas, 
Fernando Caravaca-Fontan, Estefania Yerovi, Maria Delgado  yagüe, Saul 
Enrique Pampa, Jose L. Teruel, Fernando Liano.  Nephrology, Hospital Univ 
Ramon y Cajal, Madrid, Spain.
Background: A Multidisciplinary Unit for attention to the vascular access was 
established in our hospital in December 2010. The main role of the nephrologist consists 
in monitoring the functioning of the vascular access by determining the artery-venous flow 
(AVF) and undertaking the doppler ultrasound. The objectives for initiating this program 
were to reduce the thrombosis rate by diagnosis and treatment of a non clinically detected 
pathology and to decrease the percentage of patients with a tunnelled catheter.
Methods: The prevalence of haemodialysis patients on 31st December 2014 was 65 
patients in the Hospital Unit and 90 patients in the Dialysis Center. In the Hospital Unit we 
supervise the functioning of the vascular access by measuring the AVF flow and we perform 
a Doppler ultrasound  study if the flow is less than 500 ml/min, if there are significant 
decreases in comparison with previous controls or if there is any clinical dysfunction. The 
Dialysis Center uses first generation methods for monitoring (increase in venous pressure, 
pump flow decrease, recirculation) and requests the Hospital Unit to undertake a Doppler 
ultrasound study whenever there is any type of dysfunction.
Results: We have observed differences in the results between both centers: 1º 
Incidence of patients with a tunnelled catheter was lower in the Hospital Unit (14 vs 22%). 
2º Thrombosis rate was 40% lower in the Hospital Unit (7,9 vs 12/100 patients-year). 3º 
Doppler ultrasound detected 25 patients with haemodynamically significant stenosis, 
confirmed by radiologic study, which were successfully treated.
Conclusions: The combined use of AVF flow measuring and Doppler ultrasound 
studies for monitoring the vascular access is an efficient method for reducing the rates of 
thrombosis and the number of tunnelled catheters due to the early detection of stenosis 
and its preventive treatment.
PUB484
Females Have Less Arteriovenous Fistula and More Grafts Compared 
to Men: Data from the Slovenian Renal Replacement Therapy Registry 
Jadranka Buturovic-Ponikvar, Jakob Gubensek, Vanja Persic, Rafael Ponikvar. 
Dept of Nephrology, Univ Medical Centre Ljubljana, Ljubljana, Slovenia.
Background: The aim of our study was to compare prevalence of arteriovenous fistula 
(AVF) and graft in female and male chronic hemodialysis (HD) patients.
Methods: Data on vascular access in prevalent HD patients on December 31, from 
2009-2013, were analyzed, in addition to sex, age, dry body weight and blood flow (QB) 
during HD, from database of the Slovenian Renal Replacement Therapy Registry. The use 
of preoperative ultrasonography mapping before AVF and graft construction in standard 
practice in the country.
Results: 
Year 2013 2012 2011 2010 2009
All HD (No) 1375 1361 1346 1375 1397
Males No 831 837 824 818 827
Males age 
(years) 64±14 64±14 63±14 63±14 63±14
Males % AVF 82.8 81.8 83.5 85.0 84.6
Males % grafts 7.0 7.1 5.0 5.5 4.5
QB (ml/min) 287±35 287±39 290±39 290±44 295±44
Females No 544 524 522 557 570
Females age 
(years) 67±16 67±15 67±15 66±15 65±15
Females % AVF 72.1 72.3 72.4 76.5 75.1
Females % 
grafts 9.2 7.9 7.5 7.5 7.7
QB (ml/min) 273±35 274±38 275±38 271±40 277±41
The difference between percentage of AVF comparing females and males is persistent 
and highly significant during the observation period (p‹0.001), with females having less 
AVF. Females had persistently slightly more grafts. Males had higher mean dry body weight 
(77.1±16 kg vs. 64.7±14.7 kg, end of 2013, p ‹0.001). Although absolute blood flow during 
HD was higher in males, females had higher blood flow when standardised to body weight 
(4.41±1.05 vs. 3.83±0.83 ml/min/kg, p<0.001, end of 2013).
Conclusions: Female chronic HD patients have significantly less arteriovenous fistula 
and slightly more grafts compared to males, with the difference being persistent during five 
years. Blood flow during HD, when standardised to body weight, was significanly higher 
in females than in males. Potential clinical consequence of higher blood flow during HD 
in females should be explored. Strategies to increase arteriovenous fistula prevalence in 
females should be explored, including potential acceptance of AVF providing lower blood 
flow during HD.
PUB485
Analysis of Early Arteriovenous Fistula/Graft Management and Coexistence 
of Dual Hemodialysis Accesses: Etiology and Clinical Implications of 
Waiting Too Long to Intervene  Neena Jube, Peter J. Mattingly, Syed S. 
Haqqie, Arif Asif.  Albany Medical College, Albany, NY.
Background: A number of patients with newly created arteriovenous fistulae (AVF) 
require tunneled dialysis catheter (TDC) for dialysis until their AVF is deemed mature. 
Although data have emphasized that the AVF maturation period is 4-6 weeks long, providers 
often wait up to 6 months hoping the AVF will eventually mature. During this maturation 
period if dialysis is required, patients frequently use TDC and can experience complications 
associated with these devices. This retrospective study evaluated 43 ESRD patients with 
a maturing AVF who were dialyzing with a coexisting TDC placed within 3 months of 
AVF creation. The patient population was divided based on dual access (DA) duration: 
DA <42 days (n=10), DA=42-90 days (n=13), and DA>90 days (n=20). An analysis of DA 
duration and follow-up visits were performed. All patients had surgical follow up at least 
once within the first 42 days of AVF placement regardless of DA duration. Additionally, 
patients with DA duration greater than 90 days were evaluated consistently by a surgeon 
during this period suggesting that prolonged DA is not due to lack of surveillance. Despite 
this, patient with DA period of greater than 42 days had increasing propensity to undergo 
avoidable exposure to the risks of prolonged TDC use (p<0.01). Specifically patients with 
DA<42 days, DA=42-90 days, and DA>90 days were unnecessarily exposed to the risks of 
dual access for an additional 2.5, 11.7, and 46 days, respectively (p<0.01). This discrepancy 
between regular surveillance and delayed TDC removal raises concerns that there is a lack 
of timely intervention after assessment. A more thorough documentation of reasons for 
prolonged TDC use and analysis of such data are required to verify this hypothesis and get 
a better idea of etiology of delayed TDC removal.
Methods: Retrospective collection of data from outpatient dialysis units on patients 
who have AVF/Graft and TDC.
Results: The delayed TDC removal in patients with AVF/Graft raises the risk of 
infection in these patients with both devices.
Conclusions: TDC should be removed at an appropriate period once AVF/Graft are 
mature enough to be used.
PUB486
Gene Methylation Profile of Human Vein Tissues Taken at the Time of 
Surgery: Correlation with AVF Maturation  Begoña Campos, Sonia Bhati, 
Nikhil Grandhi, Mario Medvedovic, Amy Pflum, Timmy C. Lee, Rino Munda, 
Prabir Roy-Chaudhury.  Univ of Cincinnati.
Background: Early arteriovenous fistula (AVF) failure remains an important cause 
of hemodialysis vascular access dysfunction and a major impediment to the Fistula First 
initiative. Despite the magnitude of the clinical problem, there are currently no effective 
therapeutic interventions for early AVF failure. In order to better understand the cellular 
and molecular mechanisms involved in early AVF failure we have evaluated the gene 
methylation profile of venous segment tissue samples obtained at the time of AVF creation. 
DNA methylation of CpG islands (regions of the genome that are rich in cytosine and 
guanine sequences), influences gene expression (turns off the gene). An increasing number 
of diverse factors are now known to epigenetically regulate genes, including stress, 
inflammation, nutrition, metabolism, drugs and infection (all of which are prominent 
in the biological milieu of patients with CKD and ESRD). In this study we compare the 
overall methylation profiles of non-maturing AVFs at 6 months as compared to AVFs that 
are able to support dialysis.
Methods: gDNA was isolated from venous segments collected at the time of AVF 
creation. Deep sequencing technologies were used to identify genes with the greatest 
differences in methylation between the two groups. Gene networks focused on inflammation, 
oxidative stress and endothelial dysfunction were evaluated. Standard bioinformatic 
techniques were used to identify/interrogate both the gene list and the network analyses.
Results: We were able to identify approximately 300 genes that were significantly 
different in the overall methylation profiles of non-maturing AVFs at 6 months as compared 
to AVFs that were able to support dialysis.
Conclusions: Our results suggest that epigenetic regulation (DNA methylation) could 
play an important role in AVF maturation, and also in the identification of novel druggable 
targets. This latter point could result in the development of novel therapies for dialysis 
vascular access dysfunction as a whole.
PUB487
Development of a Uremic Pig Model of Arteriovenous Fistula Stenosis 
(AVF): A Surgical Approach  Begoña Campos,1 Yang Wang,1 Carissa Nicole 
Lester,1 Krishnanath Gaitonde,3 Keith Louis Saum,1 Sanjay Misra,2 Prabir 
Roy-Chaudhury.1,3  1Univ of Cincinnati; 2Mayo Clinic; 3Cincinnati VA Medical 
Center.
Background: AVF stenosis remains an important cause of hemodialysis vascular access 
dysfunction for which there are no truly effective therapies. We and others have previously 
described well characterized large animal models of AVF stenosis. An important flaw in 
these models is the lack of uremia, which increasingly has been shown to play an important 
role in the pathogenesis of AVF stenosis.
Methods: Chronic renal insufficiency was created by initially removing one of the 
kidneys through a midline incision. Following this the contralateral kidney underwent a 
dissection of the pelvis in order to expose the primary, secondary and if possible tertiary 
branches of the renal vasculature. A selective ligation of the renal vasculature in the pelvis, 
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which allowed for the viability of less than 20% of the renal mass on one side was then 
performed (upper figure = a, b and c). Of note the differential blanching/mottling of the 
kidney following ligature of vessels in the renal pelvis, allows us to perform a real time 
assessment in terms of the amount of viable renal tissue. BUN and creatinine estimations 
were then made biweekly for 6 weeks.
Results: The described surgical technique has allowed us to achieve a stable creatinine 
of 4 mg/dL over a four week period (lower figure = d). This stable period of uremia will 
allow us test out the impact of “downstream uremic vascular biology” on AVF maturation.
Conclusions: We have developed a unique, innovative and surgically created pig 
model of uremia with potential logistic and financial benefits. The availability of this animal 
model will put us in a unique position to be able to tease out the relative contributions of 
hemodynamics and uremia to AVF stenosis both in our experimental pig model and also 
in CKD and ESRD patients.
PUB488
Multimedia Education Tools for Dialysis Vascular Access Monitoring 
Tushar J. Vachharajani,1 Claudia L. Poole,2 Victoria L. Cash,2 Joseph A. 
Vassalotti.3  1Nephrology, W. G. (Bill) Hefner VAMC, Salisbury, NC; 2Fistula 
First Catheter Last Workgroup Coalition, ESRD National Coordinating Center; 
3Nephrology, Icahn School of Medicine at Mount Sinai & National Kidney 
Foundation, NY.
Background: From 2005 to 2012, the Fistula First Breakthrough Initiative (FFBI) of 
the Centers for Medicare & Medicaid Services focused on improving the arteriovenous 
fistula (AVF) rate in the hemodialysis (HD) patients. Since the transition to Fistula First 
Catheter Last (FFCL) in 2013, the workgroup has created multimedia tools to help dialysis 
facilities and clinicians reduce the use of central venous catheters (CVCs) and further 
increase AVF use. The key focus for FFCL remains access planning, access monitoring, 
and prevention of access infection. Access monitoring involves use of physical examination 
(PE) and interpreting the findings whereas access surveillance involves measuring access 
blood flow or venous pressure.
Methods: Why access monitoring? PE is cheap, reproducible and easy to perform and 
implement before each HD treatment. Evidence supports PE as an effective tool to accurately 
detect access dysfunction and infection. However, in practice, PE is underutilized due to 
inadequate training and perception of it being a labor-intensive evaluation method. Access 
monitoring tools: FFCL tools are created to educate the patient and the multidisciplinary 
dialysis care team (DCT) with the ultimate goal of maintaining a functional access.
Results: Two separate toolkits available on the FFCL website (http://esrdncc.org/ffcl/) 
highlight patient-level and DCT-level education.Practical teaching guides to implement 
the evidenced-based PE include “Check Before You Connect” for CVC and “One Minute 
Check” for AV access, which target the DCT and patients. The multimedia toolkits focus on 
a “look, listen and feel” concept, are interactive and are easily accessible from any mobile 
device. Poster/handout formats are also available. The impact of these educational tools 
will be evaluated once these resources are widely utilized in clinical practice.
Conclusions: The purpose of this presentation is to achieve wider dissemination of 
these tools to narrow the gap between evidence and clinical practice.
Funding: Other U.S. Government Support
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Multimedia Access Planning Tools to Attain Catheter Freedom 
Tushar J. Vachharajani,1 Claudia L. Poole,2 Victoria L. Cash,2 Joseph A. 
Vassalotti.3  1W. G (Bill) Hefner VAMC, Salisbury, NC; 2Fistula First Catheter 
Last Workgroup Coalition, ESRD National Coordinating Center; 3Icahn School 
of Medicine at Mount Sinai & National Kidney Foundation, NY.
Background: From 2005 to 2012, the Fistula First Breakthrough Initiative (FFBI) of the 
Centers for Medicare & Medicaid Services focused on improving the arteriovenous fistula 
(AVF) rate in hemodialysis (HD) patients. Since the transition to Fistula First Catheter Last 
(FFCL) in 2013, the workgroup has created multimedia tools to help dialysis facilities and 
clinicians reduce the use of central venous catheters (CVCs) and further increase AVF use. 
The key focus for FFCL remains access planning, access monitoring (physical examination) 
and prevention of access infection.
Methods: Why the need for change? FFBI Change Concepts over the past decade 
resulted in an increase in the AVF rate in the prevalent HD population from 23% to 61% 
of eligible patients. The impact on the incident HD population has remained suboptimal, 
with >78% HD patients initiating dialysis with a tunneled CVC. Moreover, the percentage 
of patients in the prevalent HD population with CVCs in use for 90 days or longer has 
remained stagnant. Access planning tools: FFCL tools are created to educate the patient 
and the multidisciplinary dialysis care team (DCT) with the ultimate goal of achieving 
freedom from CVC. Two separate toolkits available on the FFCL website (http://esrdncc.
org/ffcl/) highlight patient-level and DCT-level education.
Results: The multimedia toolkits are interactive and easily accessible from any mobile 
device. Conventional handout/poster formats are also available. The impact of these 
educational tools will be evaluated once these resources are widely utilized in clinical 
practice. The primary goal is to develop and disseminate tools to educate and create 
awareness to increase AV fistula utilization to 68% of appropriate patients, decrease the 
use of long term catheters (≥90 days) to <10%. FFCL is currently collecting metrics on 
professionals that are aware and using these tools.
Conclusions: The purpose of this presentation is to achieve wider dissemination of 
these tools and increase awareness among patients/professionals.
PUB490
Cardiac Implantable Electronic Device Infection and Ipsilateral 
Arteriovenous Fistula in End Stage Renal Disease: Avoidance and 
Management of Complications  Stephanie Lanoiselee,1 Francois Babinet,1 
Guillaume Seret,1 Helene Loubiere,3 Achour Laradi.1  1Centre ECHO 
Nephrologie Dialyse, Le Mans, France; 2Chirurgie Vasculaire, CH Le Mans, 
Le Mans, France.
Background: Cardiovascular implantable electronic devices(CIEDs) are frequently 
utilized for management of cardiac dysrhytmias in patients(pts) with End Stage Renal 
disease(ESRD) and are associated with central venous stenosis resulting in adverse effects 
for existing or future arteriovenous fistula(AVF) with an increase risk of infection of both 
(CIEDs and AVF).We report the case of a pt with ESRD who experienced a potentially 
life-threatening complication related to his ipsilateral AVF and CIEDs.
Methods: We report the case of a 80 years-old male pt who developed a symptomatic 
unilateral left arm edema with skin lesions.He has past history of CIEDs four years ago 
and the ipsilateral implementation of a AVF 2 years after the CIEDS.He experienced 
3 angioplasies on his AVF and a repeated surgery with a persistant post-anastomotic 
anastomosis with flow reduction of 180 ml/mn. A left side chest blood collateral circulation 
was also present.A deep veinous thrombosis related to the implementation of CIEDs was 
investiguated and a left subclavian venous thrombosis was confirmed.On the meantime 
infection of the CIEDs was suspected but non confirmed. An attempt of a venous 
recanalization was unsuccessful.A closure of AVF with a plug of 14mm diameter leading 
to a complete occlusion of AVF.
Results: After the occlusion of AVF we noticed a complete régressionof the huge left 
arm edema and a total recovery of the skin lésions.The pt underwent antiobiotics therapy 
for life for the CIEDs infection with succesful results two years after initiation of treatment.
Conclusions: Although the CIEDs can provide life-savings benefits, device associated 
complications needs careful mangement and should be placed by the epicardial approach as a 
first option for pts with ESRD.It remind us that the AVF is still the Achille’s heel of dialysis.
PUB491
Weekly Beta 2 Microglobulin (B2M) Kt/V, Residual Renal Function and 
Middle Molecule Levels in Daily Dialysis  Christos Argyropoulos, Maria-Eleni 
Roumelioti, Mark L. Unruh.  Internal Medicine, Div of Nephrology, UNM-HSC, 
Albuquerque, NM.
Background: B2M and residual renal function (RRF) are predictors of cardiovascular 
morbidity, mortality and LVH in ESRD. Daily dialysis leads to higher B2M removal and 
has been associated with improvements in LVH and mortality in randomized trials. It 
is not known whether kinetic measures of middle molecule adequacy are applicable to 
daily dialysis.
Methods: We adopted a population kinetic model (PKM) for the intraindividual 
variability in generation, distribution and extrarenal removal of B2M (ASN 2014,SA-
PO969). We used the PKM to simulate B2M concentrations in 10000 patients dialyzed 
with HF membranes. We examined the intervention protocols for Short (SD), Long Daily 
(LD) and thrice weekly HF dialysis utilized in the FHN trials. Weekly B2M Kt/V was 
calculated as the sum of the Kt/V in each session. The impact of Kt/V relative to residual 
renal function (RRF) on B2M was examined across the three dialysis modalities averaging 
over the intra-individual variability of kinetic parameters and dialysis prescription.
Results: B2M was lower in SD and LD relative to HF irrespective of RRF. Given 
the variability in dialysis prescriptions there was a substantial overlap in the average Kt/V 
values between HF and SD. 
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There was a steep relationship between weekly Kt/V and B2M in all three modalities.
The steepness of this relationship was similar between HF and SD across RRF values, but 
differed for RRF>4ml/min in LD. At any given level of Kt/V the B2M level depended on 
RRF and dialysis modality.
Conclusions: Weekly B2M Kt/V, a simple measure of middle molecule dialysis 
adequacy, tracks middle molecule exposure in conventional and daily dialysis. The 
interpretation of a given Kt/V value requires knowledge of RRF in all dialysis modalities. 
Future studies should determine whether RRF, dialytic Kt/V or both are predictors of 
survival in daily dialysis.
PUB492
A Test Battery to Establish Changes in Physical Performance and Protein 
Energy Wasting in Nocturnal Hemodialysis: The DiapriFIT Study 
Manouk Dam,1 Floor Neelemaat,1 Caroline E Douma,3 Brigit C. van Jaarsveld.2 
1Nutrition and Dietetics, VU Univ Medical Center, Amsterdam, Netherlands; 
2Nephrology, VU Univ Medical Center, Amsterdam, Netherlands; 3Nephrology, 
Spaarne Gasthuis, Hoofddorp, Netherlands.
Background: Nocturnal hemodialysis (NHD) improves volume control and phosphate 
and middle molecule removal. Observational data show increases in body weight and 
protein intake upon switching to NHD. Other aspects of protein energy wasting (PEW) 
remain underexposed and also little is known about functional outcomes, such as physical 
performance and muscle strength. Therefore, the aim of this study is to investigate 
whether physical performance improves and PEW decreases in patients who change from 
conventional hemodialysis (CHD) to NHD, compared to patients who continue their 
treatment on CHD.
Methods: The DiapriFIT study plans to include 25 patients on CHD (2-4x/wk, 3-4 
hours) and 25 patients on CHD who switch to NHD (3-4x/wk, 8 hours) with 1-year physical 
performance and PEW as endpoints. They were submitted to a Visual Appetite Score (VAS), 
Handgrip Strength (HGS), upper arm circumference (UAC), Short Physical Performance 
Battery (SPPB) and 6 minute walk test (6MWT), baseline results are reported here. As in 
NHD weight increases, we tested associations of the outcome parameters with dry weight.
Results: At present, 23 patients were included, aged 58.3±16.0 years, 30.4% males, 
with a dry weight of 87.6±17.2 in males and 74.3±17.2 in females. Mean VAS was 7.3±2.3, 
HGS 22.7±9.8 kg, UAC 31.9±5.6 cm, SPPB 8.0±1.96 and 6MWT 576±328 meters. Only 
HGS and UAC were correlated with HD dry weight (r 0.43, p<0.05 for HGS, r 0.79, 
p<0.001 for UAC).
Conclusions: The DiapriFIT Study measures a great variety of parameters regarding 
physical performance and PEW. As some, but not all parameters correlate with HD dry 
weight, we expect them to differentiate between CHD and NHD during follow-up of the 
study. Other results of physical performance and PEW, such as subjective global assessment, 
physical activity-, sleep-, and QOL-questionnaires, activity monitoring, body composition 
measurement, nutritional diary, DEXA and lab tests will provide additional information on 
these patient-relevant outcomes of NHD.
Funding: Pharmaceutical Company Support - Baxter U.S.
PUB493
Anti-Thymocyte Serum Nephritis Rats Develops Augmented Circadian 
Rhythm of the Intrarenal Renin-Angiotensin System  Shinsuke Isobe, Naro 
Ohashi, Sayaka Ishigaki, Hideo Yasuda.  Internal Medicine 1, Hamamatsu Univ 
School of Medicine, Hamamatsu, Shizuoka, Japan.
Background: We reported the disturbed circadian rhythm of urinary angiotensinogen 
(AGT) excretion levels might lead to renal damage, hypertension and diurnal BP variation. 
Our purpose is to clarify the circadian rhythm of intrarenal renin-angiotensin system (RAS) 
components and its contribution to renal damage, hypertension and BP variation and to 
evaluate whether administration of RAS dependent or independent antihypertensive drug 
contributes to circadian rhythm of intrarenal RAS components.
Methods: Anti-thymocyte serum (ATS) nephritis rats were made as chronic progressive 
glomerulonephritis models (A group) and compared with control rats (C group). Other rats 
with ATS nephritis received olmesartan [angiotensin II (AngII) type 1 receptor (AT1R) 
blocker] (AO group) or hydralazine (vasodilatory drug) (AH group), respectively. Rats were 
sacrificed every 6 hour and the levels of the intrarenal RAS components were evaluated.
Results: The protein expression levels of intrarenal AGT, AngII and AT1R were 
increased in A group and peaked at the same time point as the peak of BP and urinary 
protein excretion during the rest phase. The amplitude of circadian fluctuation of these 
proteins was increased in A group compared with C group and attenuated in AO and AH 
group (Peak to trough ratio of AGT in C: 1.13, A 1.47, AO 1.24, AH 1.17, AngII in C: 1.03, 
A: 1.26, AO: 1.14, AH: 1.17 and AT1R in C: 1.36, A: 1.51, AO: 1.37, AH: 1.26). However, 
renal function, proteinuria and augmentation of intrarenal RAS components were attenuated 
only in AO group. The protein expression levels of intrarenal renin and prorenin were the 
same tendency as AGT, AngII and AT1R, though fluctuation of them was augmented in 
AO group. The protein expression levels and fluctuation of angiotensin converting enzyme 
and (pro)renin receptor were not different among groups.
Conclusions: Intrarenal AGT, AngII and AT1R proteins were increased and the 
amplitude of oscillations of these proteins was augmented in ATS nephritis rats. Furthermore, 
renal damage may be linked to the activation of the intrarenal RAS independent of amplitude 
of its oscillation and BP.
PUB494
Do KCNQ1 Channels Contribute to Control of Arterial Vascular Tone? 
Dmitry Tsvetkov,1 Lan Chen,1,2 Mario Kassmann,1 Jean-Yves Tano,1 Johanna 
Schleifenbaum,1 Jakob Völkl,3 Florian C. Lang,3 Yu Huang,4 Maik Gollasch.1 
1Experimental and Clinical Research Center (ECRC), a Joint Cooperation 
between the Charité Medical Faculty and the Max Delbrück Center for 
Molecular Medicine (MDC), Berlin, Germany; 2Xiamen Zhongshan Hospital, 
Xiamen Univ, Xiamen, Fujian Province, China; 3Dept of Physiology, Univ of 
Tübingen, Tübingen, Germany; 4School of Biomedical Sciences, Lo Kwee-Seong 
Integrated Biomedical Sciences Building, Area 39, Chinese Univ of Hong Kong, 
Hong Kong, Hong Kong.
Background: Recent data suggest that the KCNQ family of voltage activated K+ (Kv7) 
channels represents a new therapeutic target in cardiovascular disease. We used Kcnq1-/- 
mice to determine whether KCNQ1 (Kv7.1) play a role in the regulation of arterial tone.
Methods: Wire-myography, pharmacology approach and patch-clamp technics were 
used.
Results: We found that R-L3 produces similar concentration-dependent relaxations 
(EC50 ~1,4 µM) in wild-type (Kcnq1+/+) and Kcnq1-/- arteries pre-contracted with either 
phenylephrine or 60 mM KCl. This relaxation was not affected by 10 µM chromanol-B293, 
10 µM HMR1556, 30 µM XE991 or 500 µM 4-aminopyridine. Chromanol-B293 and 
HMR1556 did not affect the anti-contractile effects of perivascular adipose tissue 
(PVAT). The anti-contractile effects of PVAT were normal in Kcnq1-/- arteries. Whole-
cell recordings showed normal peak Kv currents, capacity and their blockade by XE991 
in Kcnq1 -/- VSMCs. The pan KCNQ2-5 opener retigabine lead to a similar relaxations in 
Kcnq1-/- and wild-type vessels.
Conclusions: We conclude that KCNQ1 channels are apparently not involved in 
the control of arterial tone by alpha1 adrenergic vasoconstrictors and PVAT. R-L3 is 
aninappropriate pharmacological tool for studying the function of native vascular KCNQ1 
channels in mice.
PUB495
The Role of Renal AT1 Receptor-Associated Protein in Salt-Sensitive Blood 
Pressure Regulation  Hiromichi Wakui,1 Kouichi Tamura,1 Ryu Kobayashi,1 
Kazushi Uneda,1 Masato Ohsawa,1 Toru Dejima,1 Akinobu Maeda,1 Yoshiyuki 
Toya,1 Kotaro Haruhara,2 Satoshi Umemura.1  1The Dept of Medical Science 
and Cardiorenal Medicine, Yokohama City Univ Graduate School of Medicine, 
Yokohamah, Japan; 2Div of Nephrology and Hypertension, Dept of Internal 
Medicine, Jikei Univ School of Medicine, Tokyo, Japan.
Background: The intrarenal renin-angiotensin system plays a role in the regulation of 
renal hemodynamics and the maintenance of water electrolyte balance, and is also involved 
in the pathophysiology of hypertension and target organ damages. We previously identified 
an angiotensin II type 1 receptor-associated protein (ATRAP). which interacts with the 
C-terminal domain of angiotensin II type 1 receptor (AT1R) and attenuates AT1R-mediated 
pathological responses. The present study was designed to investigate the putative functional 
role of ATRAP in the blood pressure regulation by high salt loading in vivo.
Methods: We generated transgenic mice expressing ATRAP dominantly in renal tubules 
on a C57BL/6J background. Renal ATRAP transgenic mice and their wild-type littermate 
mice on a normal salt diet at baseline were subjected to dietary high salt loading for 7 days.
Results: In renal ATRAP transgenic mice, the development of high blood pressure in 
response to high salt loading was suppressed, concomitant with a significant increase in 
urinary sodium excretion, as compared to wild-type mice.
Conclusions: These results demonstrate that renal tubule-dominant overexpression of 
ATRAP suppresses the salt-sensitive blood pressure elevation provoked by high salt loading, 
thereby suggesting ATRAP to be an interesting target in hypertension.
Funding: Private Foundation Support, Government Support - Non-U.S.
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Carbonic Anhydrase II Inactivation Confers Salt Appetite and Elicits 
Salt Sensitive Hypertension  Mujan Varasteh kia,1 Sharon L. Barone,2 Saeed 
Alshahrani,1 Marybeth Brooks,1 Kamyar A. Zahedi,1,2 Jie Xu,1 Manoocher 
Soleimani.1,2  1Center on Genetics of Transport, Dept of Medicine, Univ of 
Cincinnati, Cincinnati, OH; 2Research Services, VA Medical Center, Cincinnati, 
OH.
Background: Salt appetite or salt intake in excess of physiological needs is a major 
health problem and a risk factor in the pathogenesis of hypertension, which consequently 
can lead to heart disease and stroke. Few genetic factors are implicated in the pathogenesis 
of salt appetite.
Methods: Wild-type and CAII null mice were given a choice of regular water or 
140mM NaCl dissolved in their drinking water. Balance studies were performed and 
blood pressure was measured via the CODA tail cuff system. Western blots and Northern 
Hybridizations were performed.
Results: Our results indicate that CAII null mice display significant salt appetite as 
judged by their preference for salted water (140 mM NaCl) over regular water, when both 
options are provided. In age and gender matched mice (n=4 per each group), daily salted 
water intake was 2.89 ml in WT vs. 5.71 ml in CAII null mice, while daily regular water 
intake was 5.05 ml in WT and 3.6 ml in CAII null mice. Kidney renin expression and 
blood creatinine concentration were comparable in WT and CAII null mice. When given 
only salted water, CAII null animals showed a robust increase in their daily salt intake 
(12.21ml in CAII null vs. 7.80ml in WT mice) and urine volume (4.62ml/day in CAII 
null vs. 2.62ml/day in WT mice). Expression of sodium and water absorbing channels, 
ENaC and AQP-2, increased by ~100 to 200% in both cortex and medulla in CAII null vs. 
WT mice in response to salt intake for 10 days. Consequently, CAII null mice developed 
hypertension (systolic BP of 155 +/- 3.9 in CAII null vs. 138 +/- 3.2 in WT, p<0.003). 
The protein expression levels of ENaC in taste buds were not different between the two 
genotypes. Male CAII null mice exhibited a remarkable propensity toward salted water 
intake vs. regular water intake as compared to female null mice.
Conclusions: We propose that CAII plays an important role in regulating salt intake 
and its inactivation can cause salt appetite, specifically in male animals, and provoke salt 
sensitive hypertension.
Funding: Veterans Administration Support
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Ambulatory Blood Pressure in Chronic Kidney Disease: An International 
Collaborative Study  Paul E. Drawz,1 Luca De Nicola,2 Naohiko Fujii,3 Francis 
B. Gabbai,4 Jennifer J. Gassman,4 Satoshi Iimuro,3 Roberto Minutolo,2 Robert 
A. Phillips,4 Luis M. Ruilope,5 Raymond R. Townsend,6 Mahboob Rahman.6 
1Div of Renal Diseases & Hypertension, Univ of Minnesota; 2Italian Cohort; 
3CKD-JAC; 4AASK; 5Spanish Cohort; 6CRIC.
Background: In chronic kidney disease (CKD), ambulatory blood pressure (BP) is a 
better measure of hypertension related risk for cardiovascular disease and ESRD than clinic 
BP. The International Ambulatory Blood Pressure in Chronic Kidney Disease Collaborative 
Group is a collaboration among investigators from different countries interested in 
ambulatory BP in patients with CKD. The main aims of the research facilitated by this 
collaboration will be to evaluate: 1) the clinical and demographic characteristics associated 
with elevated ambulatory BP, 2) the prognostic role of ambulatory BP on cardiovascular 
and renal outcomes, and 3) ethnic and geographic differences in these associations.
Methods: This group will establish a large database derived from individual databases 
in the various countries to allow for powerful individual participant data meta-analyses of 
the relationship between clinical and demographic characteristics, CKD severity, ambulatory 
BP, and clinical outcomes.
Results: Investigators from 5 cohort studies have already agreed to participate. 
Characteristics of the cohorts are shown below.
Italy Spain AASK CRIC CKD-JAC
Subjects 489 4434 617 1492 1075
Age (years) 64.4 69.3 60.3 63.1 60.7
Male/Female 290 / 199 2630 / 1804 382 / 235 833 / 659 682 / 393
eGFR 44.8 45.5 43.5 46.1 28.8
Proteinuria 63%a 16%b 30%c 42%c 86%b
Diabetics 176 (36%) 1385 (31%) 63 (10%) 626 (42%) 381 (35%)
a. Urine protein >0/15g/day; b. Urine alb/Cr >30mg/g; c. Urine prot/Cr >0.22mg/mg.
Conclusions: This multi-national collaboration will provide greater insights than 
possible from within-country analyses into the etiology and consequences of high risk 
ambulatory BP profiles. This information will be instrumental in helping us design 
prospective international large scale multicenter trials aimed at reducing renal and 
cardiovascular events in patients with CKD.
PUB498
Clinical Study of Pregnancy Related Kidney Injury  Yumei Liu,1 Ying Fan,1 
Yang Fei,1 Hongda Bao,1 Yajuan Huang,2 Niansong Wang.1  1Nephrology and 
Rheumatology, Shanghai Jiao Tong Univ Affiliated Sixth People’s Hospital, 
Shanghai, China; 2Obstetrics and Gynecology, Shanghai Jiao Tong Univ 
Affiliated Sixth People’s Hospital, Shanghai, China.
Background: The diagnosis and treatment of pregnancy related kidney injury is a 
complicated clinical problem for obstetricians and nephrologists. However, information 
regarding this topic in China is insufficient.
Methods: Totally 18589 women hospitalized between August 2004 and January 2013 
from Obstetric and Nephrology Department in Shanghai Jiao Tong University Affiliated 
Sixth People’s Hospital were screened. 569 women were enrolled for the pregnancy related 
kidney injury, including 494 cases from 2008 to 2013 and 75 cases from 2004 to 2007. 
The inclusive criteria was women with a history of kidney disease or Scr >= 70mmol/L or 
proteinuria >= 0.3g/24hour before the termination of pregnancy, or the diagnosis of kidney 
disease made during or after 6-month delivery.
Results: The prevalence of pregnancy related kidney injury was 3.1%. The incidence 
of kidney injury caused by obstetric disease was 3.1%, with the most common reason for 
pre-eclampsia (88.9%). The incidence of chronic kidney disease women with pregnancy 
is 0.74%, with the most common reason for chronic glomerular nephritis (36.2%). The 
incidence of kidney disease onset related to pregnancy was 1.5%. The incidence of 
proceeding to end stage renal disease for pregnancy was 0.21%. Kidney injury in pregnant 
women with obstetric disease may be more severe than that in pregnant women with kidney 
disease (with higher maternal blood pressure and proteinuria, lower birth weight and higher 
proportion of pre-term babies, P<0.05). Most women with pregnancy related kidney injury 
underwent cesarean section (>60%). Their proportion of stillbirth, pre-term and low birth 
weight babies were higher than healthy parturient, and the proportion of follow-up was 
low (9.9%). Neonatal death rate was 0.63‰ and pare-natal death rate was 2.1‰ in all.
Conclusions: Prevalence of pregnancy related kidney injury increases due to the 
foundation of Shanghai First-Aid Center for High-risk Pregnant Women in 2007. Serum 
creatinine, proteinuria and blood pressure have different indication for maternal condition 
and pregnancy outcome.
Funding: Government Support - Non-U.S.
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A New Vasculo-Renal Marker Enhances Accuracy of Hypertensive 
Nephropathy Recognition  Arkadiusz Lubas,1 Robert Ryczek,2 Grzegorz Kade,1 
Stanislaw Niemczyk.1  1Dept of Internal Diseases, Nephrology and Dialysis, 
Military Inst of Medicine, Warsaw, Poland; 2Dept of Cardiology, Military Inst 
of Medicine, Warsaw, Poland.
Background: Latent and slow beginning of chronic kidney disease (CKD) coexisting 
with well tolerated, usually not recognized previously hypertension makes difficult to 
recognize hypertensive nephropathy (HN) from CKD of others origins. The aim of the study 
was to investigate the best marker helpful in differentiating HN from other causes of CKD.
Methods: Forty patients (4 F; 36 M; age 52,7 ±15,4) with stable CKD (CKD-EPI 
53.1 ±27.6 ml/min/1,73m2) and a history of hypertension (26 with HN) were enrolled 
in the study. Serum Creatinine (Cre), Cystatin C (Cys), NT-pro brain natriuretic peptide 
(NTproBNP), Troponin I (TNI) and urinary albumin to creatinine ratio (UACR) were 
tested. Renal function was estimated according to Cre and Cys based CKD-EPI formula. 
Echocardiographic examination, carotid Intima-Media Thickness (IMT), ABPM, Renal 
Resistive Index (RRI) were performed. Vasculo-Renal Index (VRI) was calculated as 
IMT to UACR ratio.
Results: Groups with HN and CKD of other origins did not differ in renal function 
(CKD-EPI 46.2 vs 57.1 ml/min/1,73m2; p=0.22), RRI, NTproBNP, TNI, left venticular 
(LV) ejection fraction, LV mass index and mean arterial pressure. Patients with HN were 
older (56,4 ±15,1 vs 45.9 ±14.1; p =0,039), had lower UACR (0.264 ±0.484 vs 0.814 
±0.564 mg/mg; p<0.001), but higher IMT (0.858 ±0.217 vs 0.652 ±0.180; p=0.009) and 
VRI (m. 28.8 [0.36; 1030.00] vs m. 0.78 [0.34; 12.50] p<0.0001). In ROC analysis VRI ≥ 
1.91, UACR ≤ 0.199, and IMT ≥ 0.87 could recognize HN with sensitivity of 85%, 73% 
and 62% respectively, specificity of 79%, 93% and 86%, and accuracy of 82.5%, 80% and 
70% (AUC 0.874, 0.849 and 0.749; p>0.05).
Conclusions: A new Vasculo-Renal Index recognizes HN more accurately, but UACR 
and IMT are not significantly worse.
Funding: Government Support - Non-U.S.
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Association of Percentage of Global Sclerosis with Nocturnal Blood 
Pressure and Sodium Excretion in Patients with Chronic Kidney Disease 
Hiroshi Nagae,1,2 Akihiro Tsuchimoto,2 Hisako Yoshida,2,3 Shigeru Tanaka,2 
Kosuke Masutani,2 Kazuhiko Tsuruya,2,3 Ritsuko Katafuchi,1 Kiyoshi 
Matsumura,2 Takanari Kitazono.2  1Kidney Unit, Fukuoka Higashi Medical 
Centor, Fukuoka, Japan; 2Dept of Medicine and Clinical Science, Graduate 
School of Medical Sciences, Kyushu Univ, Fukuoka; 3Dept of Integrated Therapy 
for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu 
Univ, Fukuoka, Japan.
Background: In patients with chronic kidney disease (CKD), impaired urinary sodium 
excretion (UNa) may cause nocturnal hypertension and pressure natriuresis to compensate 
for daytime sodium retention. The aim of this study was to determine the renal histological 
lesions which associated with nocturnal blood pressure (BP) and UNa in patients with CKD.
Methods: We analyzed 64 patients biopsied in our institutions from Sep 2010 to Apr 
2014 (Forty IgA nephropathy, 6 Purpura nephritis, 4 membranous nephropathy and 14 the 
others). During the same hospitalization period of renal biopsy, ambulatory BP monitoring 
and evaluation of UNa were performed simultaneously. The association of histological 
findings such as global sclerosis (%GS), arteriolar hyalinosis (%hyaline), and interstitial 
fibrosis (IF), with nocturnal BP and night/day ratio of UNa were assessed using linear 
regression analysis.
Results: Twenty three patients were male, mean age was 40.5 ± 15.9 years, and mean 
estimated glomerular filtration rate (eGFR) was 79.0 ± 28.9 mL/min/1.73m2. Both nocturnal 
BP and night/day ration of UNa positively associated with %GS, %hyaline, and IF, and 
negatively associated with eGFR. Multiple regression analysis adjusted for age, sex, eGFR, 
and usage of antihypertensive drugs showed that %GS was significantly associated with 
nocturnal systolic BP (β = 0.38, p = 0.012), nocturnal diastolic BP (β = 0.34, p = 0.031), 
and night/day ratio of UNa (β = 0.52, p = 0.005).
Conclusions: We found that night/day ratio of UNa and nocturnal BP closely related 
to the percentage of global sclerosis. These findings could be the morphological evidence 
that decrease in the number of functioning glomeruli causes increase in nocturnal UNa 
to compensate for daytime sodium retention resulting in elevation of nocturnal BP in 
patients with CKD.
PUB501
A Brief Intervention to Assign Once Daily Antihypertensive Medications 
to Morning versus Evening Dosing – A Pilot Study to Assess Feasibility 
and Efficacy in Chronic Kidney Disease Patients  Julia Chernyakov, Lisa A. 
Hillman, Paul E. Drawz.  Univ of Minnesota.
Background: Hypertension is a major risk factor for cardiovascular and renal disease. 
Evening dosing of antihypertensive medications lowers nighttime blood pressure and, at 
least in one large randomized trial, reduced risk for cardiovascular outcomes. However, 
whether evening dosing reduces adverse outcomes in patients with chronic kidney disease 
(CKD) is unknown. The purpose of this pilot study was to assess the efficacy of a brief 
pharmacist based intervention on patient adherence to an assigned time of day to take 
antihypertensive medications and the feasibility of a pragmatic randomized controlled trial.
Methods: Patients with moderate to severe CKD taking ³1 antihypertensive medication 
once daily were randomized to take one once daily antihypertensive in the morning or 
the evening. After a nephrology clinic visit, a student pharmacist reviewed participants’ 
antihypertensive medications with a focus on the one once daily study antihypertensive 
medication assigned to the morning or evening dosing arm. Study participants were 
contacted by phone three to six weeks after the clinic encounter to assess adherence.
Results: Of 99 potentially eligible patients approached in the nephrology clinic, 18 
declined to participate, 2 had medication changes that made them ineligible, and 79 were 
randomized (39 to morning dosing, 40 to evening dosing). Average (SD) age was 56.5 (14) 
years, 68% were male, and average (SD) estimated glomerular filtration rate was 36.6 (8.9) 
ml/min/1.73m2. Adherence, defined as taking the once daily medication at the time indicated 
at least 6 times in the last 7 days and not taking it at any other time during the day was 91% 
in the morning arm and 95% in the evening arm (P=0.57). The average (SD) time spent by 
the pharmacy student with each participant was 9.9 (6.1) minutes.
Conclusions: This pilot demonstrates the feasibility of a pragmatic randomized trial 
evaluating the effect of once daily nighttime dosing of antihypertensive medications on 
adverse outcomes in CKD patients. Patients were willing to participate in the study and 
adherence to the assigned timing was high in both the morning and evening dosing arms.
PUB502
Bedtime Dosing Regimen Drug Therapy for Chronic Kidney Disease 
(CKD) Patients with Hypertension: A Meta-Analysis of RCTs  Caixia Wang,1 
Xun Liu,1 Zhenda Zheng,2 Linsheng Lv,3 Shaomin Li,1 Tan-qi Lou.1  1Dept of 
Nephrology, The Third Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, 
Guangdong, China; 2Dept of Cardiology, The Third Affiliated Hospital of Sun 
Yat-sen Univ, Guangzhou, Guangdong, China; 3Operation Room, The Third 
Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, Guangdong.
Background: Chronotherapeutic formulations are defined as the purposeful timing 
of medications. Bedtime dosing regimen drug therapy on blood pressure control is used 
widely, but its clinical benefits and protection for target organs in chronic kidney disease 
(CKD) patients is not known.
Methods: Randomized controlled trials (RCTs) were searched in PUBMED, EMBASE, 
ASN-ONLINE, the Cochrane Library and the reference articles of published papers. We 
identified five RCTs, including 3706 CKD patients with hypertension. Risk ratio (RR), 
weighted mean difference (WMD) with 95% confidence intervals (CIs) were pooled using 
fixed or random-effects models.
Results: In our analysis, a significant decrease was observed in bedtime mean SBP by 
-3.76 mmHg (MD, 95% CI, [-6.81, -0.71]), while there was a significant increase in awake 
time mean SBP by 1.16 mmHg (MD, 95% CI, [0.10, 2.21]) in the bedtime dosing group. 
Compared with the routine administration drug therapy, chronotherapy resulted in a larger 
decrease by 3.55% (MD, 95% CI, [0.22, 6.88]) in the sleep-time relative decline of SBP. 
Besides, a higher decline of non-dipper BP patterns was found in the chronotherapy group 
by 0.60 (RR, 95% CI, [0.43, 0.84]). No significant differences were noted for controlled 
BP, 24h mean SDP and DBP, awake time mean DBP and sleep-time mean decline in DBP 
and HB. Evidence was insufficient in CVE and proteinuria. 
Conclusions: This meta-analysis suggests that the bedtime dosing regimen drug therapy 
benefits CKD patients in terms of hypertension especially those with non-dipper BP pattern.
Funding: Government Support - Non-U.S.
PUB503
The Impact of Glomerular Collapse in Hypertensive Emergency Patients 
Takafumi Yamakawa, Toshiyuki Imasawa, Takehiko Kawaguchi, Mao Watanabe, 
Maiko Nagata, Hiroshi Kitamura.  Dept of Internal Medicine, National Hospital 
Organization Chiba East Hospital, Chiba City, Japan.
Background: The prognosis of kidney disease with hypertensive emergency (malignant 
glomerulosclerosis) is still worse compared with benign nephrosclerosis. Here, further 
to assess the reasons of worse prognosis and to reconsider more appropriate therapy for 
malignant nephrosclerosis, we compared pathological parameters between malignant and 
benign nephrosclerosis.
Methods: 8 patients diagnosed as hypertensive emergency with acute renal failure 
were performed renal biopsies from October 2005 to May 2015. We selected all patients 
with pure benign nephrosclerosis (n=20), who were performed renal biopsies during same 
period, as controls. We compared changes in clinical and pathological data using the paired 
t-test and the Mann-Whitney U-test.
Results: All 8 patients with hypertensive emergency had characteristic pathological 
changes of malignant hypertension, such as fibrinoid necrosis, onion-skin thickening and 
edematous-appearing matrix in arterioles. These changes were never observed in benign 
nephrosclerosis. The rates of global sclerosis and segmental sclerosis had no statistical 
differences between these two groups.  Interestingly, when glomerular collapsing rate 
was counted by GCR (GCR=number of glomerular collapse/ total number of glomeruli), 
GCR scores were much higher in hypertensive emergency cases compared with those 
in benign nephrosclerosis cases (42.9 ± 23.8 vs. 6.5 ± 7.4 %; p < 0.05). These patient’s 
clinical characteristics showed a high level of plasma renin activity (PRA) (14.9 ± 5.8) 
and hypokalemia (3.5 ± 2.8). Two of 8 patients reached to end stage kidney disease 
requiring dialysis.
Conclusions: Glomerular collapse and hyper-renin mean glomerular hypoperfusion. 
Therefore, if therapy accelerate this glomerular hypoperfusion, it might affect renal 
prognosis. We should reconsider the way of therapy, such as the selection of anti-
hypertensive drugs, and the speed of declining blood pressure and volume control by 
thinking glomerular hypoperfusion.
PUB504
A Study of Early Treatment with Benazepril in SHR at Different Doses 
Qiong-li Yin,1 Mei Li,1 Cheng-gang Shi.2  1VIP Healthcare Center, The Third 
Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, China; 2Nephrology Dept, 
The Third Affiliated Hospital of Sun Yat-sen Univ, Guangzhou, China.
Background: To investigate whether early treatment with super high dosage ACEI 
can reverse glomerulosclerosis in SHR.
Methods: 30 SHRs were randomized and divided into three groups(n=10): model 
control group(M group), 10 mg·kg-1·d-1 Benazepril treatment(HT group),50 mg·kg-1·d-1 
Benazepril treatment(SHT group),10 Wistar-Kyoto rats were studied as normal control 
group(N group), placebo , 10 mg·kg-1·d-1 Benazepril and 50 mg·kg-1·d-1 Benazepril were 
given through intragastric administration starting from 0 week of the experiment, rats 
were killed until 12 week of the experiment. Blood pressure(Bp), 24 hours urinary 
protein(24hUpr) and serum creatinine(Scr) were detected in the 0, 4, 8, 12 week of the 
experiment. Renal pathology damage was evaluated with paraffin wax section of kidney 
tissue through HE, MASSON stain; the protein levels for TGF-b1 and PAI-1 were tested 
through immunohistochemicalstai-ning method.
Results: Compared with model control group, Bp, 24hUpr of HT and SHT groups 
decreased obviously (P<0.05), the protein levels for TGF-b1 and PAI-1 in kidney tissue 
of HT group and SHT group were inhibited(P<0.05), glomerular collagen deposition of 
HT group and SHT group reduced evidently (P<0.05).
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Conclusions: This study shows that high dosage ACEI and super high dosage ACEI 
all can decrease blood pressure, reduce proteinuria, depress the expressions of TGF-β and 
PAI-1 protein in SHR, and delay glomerulosclerosis. But super high dosage ACEI can not 
reverse glomerulosclerosis in SHR.
PUB505
Hemolytic Uremic Syndrome Associated with Scleroderma Renal Crisis: 
The Challenge for Timely and Accurate Diagnosis  Amro Elshoury, Syed S. 
Haqqie, Daniel Sedhom, Arif Asif.  Albany Medical Center, Albany, NY.
Background: Scleroderma renal crisis (SRC) is a rare cause of atypical hemolytic 
uremic syndrome (aHUS) and differentiating it from other causes of thrombotic 
microangiopathies can be challenging. A 53-year old Caucasian male, with no 
past medical history was found unresponsive.BP was elevated to 207/141 mm Hg. 
Skin examination showed diffuse telangiectasia and edema of his extremities with 
bilateral sclerodactly (Figure 1). Fundoscopy revealed bilateral retinal hemorrhage and 
exudates. Labs showed a hemoglobin=5gm/dl, platelet=25x103/uL, creatinine=6mg/dl, 
LDH=1122IU/L, bilirubin=1.6mg/dl, haptoglobin<5%, reticulocytic count=10.4% and 
schistocytes. ANA and anti-RNA Polymerase III antibody were positive (C3 and C4, 
coagulation profile, fibrinogen were normal; Coombs negative). CT head showed severe 
microvascular changes throughout the white matter of the cerebrum and MRI showed 
evidence of punctuate chronic micro-hemorrhages in the left thalamus and cerebellar 
tonsils. The presence of MAH, acute renal failure and thrombocytopenia raised suspicion 
for possible aHUS/TTP. Serum ADAMTS 13 was ordered. Because of the possibility of 
SRC, the patient was started on capropril. A dramatic improvement in BP, hemoglobin and 
platelets count along with the normalization of LDH and schistocytes disappearance was 
observbed. However, there was no improvement in kidney function requiring hemodialysis. 
ADAMT-13 activity returned at 40% (cut-off for TTP is <5%). Patient did not pursue 
eculizumab therapy. A significant portion of patients with Scleroderma can develop aHUS. 
In this case, hypertension might have served as a complement amplifying condition. 
Methods: Clinical presentation/course of the patient.
Results: Despite therapy with ACE inhibitors patient ended up on RRT.
Conclusions: Patient presenting with Malignent HTN and MAH was found to be in 
scleroderma crisis.
PUB506
The Impact of Neck Irradiation on Baroreceptor Reflex and Hypertension 
Amro Elshoury, Syed S. Haqqie, Daniel Sedhom, Rahim Dhanani, Arif Asif. 
Albany Medical College.
Background: Only a few studies with a very limited sample size have evaluated 
the impact of neck irradiation on baroreceptor reflex failure and blood pressure (BP) 
abnormalities. We investigated 60-patients, with head/neck cancer, who received neck 
irradiation between 2005 to 2010. IRB approval was obtained. Median for age was 61.5 
years (range 24-90 years). We used the same cohort of patients, before the received neck 
irradiation, as a control for BP.  Mean systolic BP before neck irradiation was 129.1±2.646 
mm Hg, 1-months post-neck irradiation was 121.4±2.178 mm Hg (P=0.02), 3-months post-
neck irradiation was 121.9 ± 2.180 mm Hg (P=0.04), 6-months post-neck irradiation was 
125.2 ± 2.933 mm Hg (P=0.27), 1-year post-neck irradiation was 123.4 ± 4.087 mm Hg 
(P=0.32), 2-years post-neck irradiation was 122.7 ± 3.655 mm Hg (P=0.06) and 5-years 
post-neck irradiation was 124.8±2.833 mm Hg (P=0.35). Mean diastolic  BP before neck 
irradiation was 76.28±1.802 mm Hg, 1-month post-neck irradiation was 69.88±1.585 
mm Hg (P=0.009), 3-months post-neck irradiation was (72.84±1.764 mm Hg (P=0.17), 
6-months post-neck irradiation (71.00±1.957 mm Hg, P=0.07), 1-year  post-neck irradiation 
was 72.22±2.341 mm Hg (P=0.17), 2-years post-neck irradiation was  74.09mmHg±1.757 
mmHg (P=0.47), 5-years post-neck irradiation was 70.17mmhg ± 3.131 mm Hg (P=0.16). 
Patients with head/neck cancer did not have clinically significant change in their BP after 
neck irradiation. These data do not support either acute fulminant hypertensive crisis 
or a chronic labile hypertension after neck irradiation. The study suggests that carotid 
baroreceptors might not have been damaged by radiation or baroreceptors in other locations 
might have been able to control BP.
Methods: Retrospective study of blood pressure in patients with neck radiation for 
cancer.
Results: Blood pressure before and after radiation showed no increase.
Conclusions: The study suggests that carotid baroreceptors might not have been 
damaged by radiation or baroreceptors .
PUB507
Sympathetic Nervous System Activity Reflected by Renalase and 
Catecholamines in Different Aged Patients with and without Chronic Kidney 
Disease  Edyta Zbroch,1 Dominika Maciorkowska,1 Ewa Koc-Zorawska,2 Jolanta 
Malyszko.1  12-nd Dept of Nephrology and Hypertension with Dialysis Centre, 
Medical Univ, Bialystok, Poland; 21st Dept of Nephrology and Transplantation, 
Medical Univ, Bialystok, Poland.
Background: Sympathetic nervous system activity is elevated in patients with chronic 
kidney disease (CKD) as well as in older persons. It contributes to hypertension and 
cardiovascular diseases. It is due to a reduction of catecholamines clearance and in elderly 
also to an increased sympathetic discharge from different organs. Renalase may play a role 
in the catecholamines degradation. The aim of the study was to assess the sympathetic 
nervous system activity, according to serum renalase and catecholamines concentration 
in a cohort of 211 patients with hypertension and with or without chronic kidney disease.
Methods: The study group was divided according to age below and above 65 years. 
The older persons (61) was also divided into group with (75%) and without CKD stage 5. 
The serum renalase, dopamine and norepinephrine concentration as well as pressure control, 
residual renal function rate and echocardiography were assessed.
Results: The older group had higher renalase (p=0,02) and dopamine (p<0,001) 
concentration and it was elevated in patients with CKD comparing to those without. They 
also had advanced abnormalities in echocardiography, like thicker interventricular septum 
(p=0,03) and lower ejection fraction (p<0,001) as well as CKD patients comparing to those 
without CKD – pronounced left ventricular hyperthrophy (p=0,007) and lower ejection 
fraction (p=0,004). They more often suffered from coronary artery disease. The residual 
renal function was less in older patients with CKD. The main used hypotensive drugs in 
studied group were beta-blockers. There was the significant correlation between age and 
renalase, norepinephrine and dopamine concentration.
Conclusions: The advanced aged especially combined with chronic kidney disease is 
associated with elevated renalase and dopamine level. It may reflect the sympathetic nervous 
system hyperactivity due to impaired kidney function and reduction of residual diuresis. It 
may have an impact on the development of cardiovascular complications.
PUB508
Heart Rate Variabilities During Day and Night Can Alter the Circadian 
Blood Pressure (BP) Rhythm  Toshiyuki Miura,1 Michio Fukuda,1 Yoshiaki 
Ogiyama,1 Ken Kiyono,2 Yoshiharu Yamamoto,3 Junichiro Hayano,1 Nobuyuki 
Ohte.1  1Nagoya City Univ, Japan; 2Osaka Univ, Japan; 3Tokyo Univ, Japan.
Background: We previously reported in patients with chronic kidney disease (CKD) 
that the circadian rhythms of BP and urinary sodium excretion (UNaV) were both impaired 
into non-dipper pattern as renal function deteriorated.Elevated salt-sensitivity of BP and 
inappropriate activation of the renin-angiotensin-aldosterone system and the sympathetic 
nerve system play important roles in high BP and the high incidence of cardiovascular 
diseases in patients with CKD.
Methods: In 39 patients with CKD,we analyzed HRV in 24-h electrocardiography,BP 
monitoring and urine collection,separately for daytime and nighttime. Patients,who took 
antihypertensive agents,were excluded.We evaluated the relationship between systolic blood 
pressure(SBP)and λ,HF,or UNaV. The non-Gaussianity index of HRV(l25s),which reflects the 
probability of intermittent large deviations of heart rate(HR)from the trend,and the power 
of high frequency(HF, 0.15–0.40 Hz),obtained by frequency domain analysis of HRV,was 
used as a marker of sympathetic cardiac overdrive,and as vagal nerve activity,respectively.
Results: As renal function deteriorated, 24h-λ and daytime λ increased,24h-SBP 
showed significant relationships with daytime λ(r=0.40, p=0.01) and night-time HF(r=-
0.37, p=0.02). Night/day ratios of SBP and UNaV were also elevated as GFR was reduced. 
Night/day ratios of SBP correlated inversely with night-time HF(r=-0.36, p=0.02). When 
analyzed by stepwise multiple regression analysis, the main determinants of 24h-SBP were 
24h-UNaV, daytime λ, and night-time HF. Night/day SBP ratios was determined by night/
day ratio of UNaV, rather than any HRVs.
Conclusions: Our study clearly demonstrated that as renal function deteriorated, 
sympathetic nerve activity is activated during the day, and vagal activation was impaired 
during the night, both of which can contributes to high BP in patients with CKD. However, 
non-dipper type of circadian BP rhythm was associated with the circadian UNaV rhythm 
rather than sympathetic or vagal nerve activity, even though the sympathetic activity can 
stimulate tubular sodium reabsorption.
PUB509
The Effects of the Insight Meditation Practice on Blood Pressure 
Reduction in Buddhist Exemplary People  Jutamas Vareesangthip,1 
Kriengsak Vareesangthip.2  1Dhamma Communication Div, Graduate School, 
Mahachulalongkornrajavidyalaya Univ, Bangkok, Thailand; 2Renal Div, Dept 
of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.
Background: Hypertension (HTN) is a leading risk factor for preventable 
cardiovascular disease, with over one in five adults affected worldwide. Lifestyle 
modification is a key strategy for the prevention and treatment of HTN. Stress has been 
associated with greater cardiovascular risk, and stress management is a recommended 
intervention for hypertensives. For many patients, maximal medical therapy is insufficient 
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to adequately treat refractory hypertension. Lifestyle modification remains an important 
approach in management. Buddhist meditation encompasses a variety of meditation 
techniques that aim to develop mindfulness, concentration and insight.
Methods: We aimed to study whether Buddhist Insight Meditation (IM) Practice, 
composing of Walking Meditation and Sitting Meditation, could reduce the level of blood 
pressure in Buddhist Exemplary People. 65 exemplary people were divided into 3 groups 
according to the schedule they performed IM Practice. Group 1 (n=25) performed 30 minutes 
of the Walking and 30 minutes of the Sitting Meditation, group 2 (n=20) performed 45 
minutes in each Meditation and group 3 (n=20) performed 60 minutes in each Meditation. 
Their blood pressures (BP), pulse pressures (PP) and pulses (P) were measured before and 
after Walking and Sitting Meditations.
Results: The results clearly showed that systolic BP, PP and P were significantly 
decreased after the Walking Meditation at 30-45-60 minutes. After IM Practice schedule, 
an arterial pulse has been significantly decreased in all 3 groups, PP has been significantly 
decreased in group 2 and systolic BP has been significantly reduced in group 3.
Conclusions: In conclusion, the Buddhist IM Practice could meaningfully reduce the 
sympathetic activities including systolic BP, PP and P. Therefore, this Buddhist Practice 
should be added to be one modality of the standard hypertensive treatments.
PUB510
ENaC as a Novel Mechanism for Hypertension and Volume Expansion in 
Type 2 Diabetes  Mark L. Unruh,1 V. Shane Pankratz,1 Evan C. Ray,2 Rebecca 
P. Hughey,2 Thomas R. Kleyman.2  1Div of Nephrology, Univ of New Mexico; 
2Renal-Electrolyte Div, UPMC.
Background: Renal Na retention and extracellular fluid volume expansion are 
hallmarks of nephrotic syndrome. There is evidence that this occurs even in the absence 
of activation of hormones that are known to stimulate renal Na transporters. Recent studies 
suggest that plasmin-dependent activation of ENaC may be responsible for renal Na 
retention in the setting of nephrotic syndrome. We hypothesized that the ENaC inhibitor 
amiloride would be an effective therapeutic agent in inducing a natriuresis and lowering 
blood pressure in individuals with macroscopic proteinuria.
Methods: We conducted a pilot double-blind randomized cross-over study comparing 
the effects of daily administration of either oral amiloride (10 (low dose) followed by 
20 (high dose) mg/d) or HCTZ (Na,Cl co-transporter inhibitor) to patients with type 2 
diabetes and macroscopic proteinuria. We examined safety and feasibility of amiloride by 
monitoring kidney function, adherence, blood pressure, weight, urinary Na excretion and 
serum electrolytes during diuretic administration.
Results: 9 subjects were enrolled in the trial. Systolic blood pressure (SBP) decreased 
in both treatment groups, but there was not a significant difference between HCTZ and 
amiloride (p=0.53). Amiloride treatment was associated with a 1.1±0.4 kg greater decline 
in weight (p=0.02), and a 0.78 ± 0.18 mmol/L greater increase in serum potassium 
(p=0.002) over the low dose portion of the study. 2 subjects developed acute kidney injury 
and hyperkalemia when treated with amiloride. 5 subjects had readily detectable levels 
of urinary plasminogen/plasmin, and 4 did not. Among those receiving amiloride, the 
low plasmin group experienced a change of 1.1±4.6 mmHg in SBP and the high plasmin 
group experienced a change of -13.9±8.7 mmHg, although there was insufficient evidence 
to conclude that there were differential treatment effects by high/low plasminogen status 
(p=0.113).
Conclusions: Among patients with type 2 diabetes, normal renal function, and 
proteinuria, there was suggestion of increased naturiesis for those treated with amiloride 
vs. HCTZ, however, acute kidney injury and severe hyperkalemia was a safety concern.
Funding: Private Foundation Support
PUB511
Serum Phosphorus Control and Reduced Phosphate Binder Pill Burden 
Among Hemodialysis Patients Who Switched from Sevelamer to Sucroferric 
Oxyhydroxide  Vidhya Parameswaran, Lin Ma, Linda H. Ficociello, Claudy 
Mullon, Franklin W. Maddux, Robert J. Kossmann.  Fresenius Medical Care 
North America, Waltham, MA.
Background: Clinical management of hyperphosphatemia among hemodialysis (HD) 
patients (pts) can present challenges. A retrospective database analysis was conducted to 
study the effectiveness of sucroferric oxyhydroxide (SO) among in-center HD pts who 
switched from sevelamer to SO as part of routine clinical care.
Methods: Pts who switched from sevelamer and had ³1 serum phosphorus (sPhos) 
measured during SO treatment were included. Changes in sPhos, serum calcium (sCa), 
intact parathyroid hormone (iPTH), transferrin saturation (TSAT), ferritin (FER), and 
pill burden were assessed at baseline (3-months prior to SO) and at follow-up (3-months 
during SO treatment).
Results: Pts (n=1487) were, on average, 54 years old, with dialysis vintage of 4.4 years 
and hyperphosphatemia (baseline sPhos=6.94 mg/dl). Figure shows sPhos distribution at 
baseline and follow-up. Pts with in-range sPhos (3.5-5.5 mg/dl) increased from 12% to 
20.1% (68% increase). Mean sPhos decreased from 6.94 to 6.7 mg/dl (p<0.001) and mean 
sCa decreased from 9.3 to 9.25 mg/dl (p<0.001). There was a significant decrease (4.7 
pills/day, p<0.001) in pill burden (8.5 to 3.7 pills). No significant change in iPTH levels 
was observed (626.1 to 637.6 pg/ml). TSAT and FER significantly increased (p<0.001) 
from 33.7% to 35.5% and 983.5 to 1051.4 ng/ml, respectively. In pts not receiving IV iron 
(n=149), there were no significant changes in TSAT (36.3% to 35.9%) or FER (1221.5 
to 1177.4 ng/ml).
Conclusions: HD patients who switched from sevelamer to sucroferric oxyhydroxide 
as part of routine clinical care had decreased serum phosphorus (0.24, p<0.001). There 
was a 68% increase in the number of patients with in-range serum phosphorus (p<0.001). 
Patients were prescribed 4.7 fewer pills per day (p<0.001).
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB512
An Investigation of the Inverse Relationship Between Fractional Excretion 
of Phosphate and the Tubular Maximum for Phosphate per Volume of 
Filtrate  Kenneth R. Phelps,1,2 Darius Mason.1,2,3  1Stratton VAMC, Albany, 
NY; 2Albany Medical College, Albany, NY; 3Albany College of Pharmacy and 
Health Sciences, Albany, NY.
Background: The serum P concentration ([P]s) is the sum of urinary excretion and 
tubular reabsorption rates of P per volume of filtrate (EP/Ccr and TRP/Ccr). The two ratios also 
determine fractional excretion of P (FEP) [Clin Nephrol 83:167], and EP/Ccr is approximately 
proportional to the concentration of P ([P]f) in the cortical distal nephron (CDN) [Clin 
Nephrol 82:191]. Maximal TRP/Ccr (i.e. TmP/GFR) exceeds actual TRP/Ccr when FEP is < 
20%; as FEP falls, TmP/GFR and (TmP/GFR - TRP/Ccr) rise [Clin Chim Acta 26:15]. We 
investigated these phenomena.
Methods: We measured [cr] and [P] in fasting serum (s) and urine (u), and [PTH]1-84 
(Scantibodies) and intact [FGF23] (Immutopics) in plasma from 28 subjects without renal 
or parathyroid disease. We calculated EP/Ccr as [P]u[cr]s/[cr]u, TRP/Ccr as [P]s – EP/Ccr, and 
FEP as [P]u[cr]s/[cr]u[P]. We then determined TmP/GFR from the Walton-Bijvoet nomogram. 
We performed simple linear regressions (y on x) as indicated in the table.
Results: All y-variables correlated inversely with FEP. TmP/GFR correlated directly 
with TRP/Ccr but was unrelated to EP/Ccr. Other y-variables correlated inversely with EP/Ccr 
but were unrelated to TRP/Ccr. None of the y-variables correlated with [PTH] or [FGF23]. 
x FEP, % EP/Ccr, mg/dL TRP/Ccr, mg/dL 
y R2 P R2 P R2 P
TmP/GFR, mg/dL 0.39 < 0.001 0.04 0.34 0.89 < 0.001
(TmP/GFR)/[P]s 0.83 < 0.001 0.76 < 0.001 0.05 0.27
(TmP/GFR) - TRP/
Ccr, mg/dL
0.69 < 0.001 0.56 < 0.001 0.10 0.10
(TmP/GFR)/(TRP/
Ccr)
0.62 < 0.001 0.64 < 0.001 0.01 0.60
Conclusions: Correlations of y-variables with FEP ultimately reflect correlations with 
EP/Ccr, TRP/Ccr, or both [Clin Nephrol 83:167]. As expected, TmP/GFR was closely associated 
with TRP/Ccr. The other y-variables, which depicted comparisons ofTmP/GFR to TRP/Ccr, 
were inversely related to EP/Ccr, a specific indicator of P influx and a surrogate for [P]f in the 
CDN. As [P]f fell in the CDN, the difference rose between actual and maximal P reabsorption 
in the proximal nephron. We did not identify an endocrine mediator of this interaction.
Funding: Veterans Administration Support, Pharmaceutical Company Support - 
Genzyme Corporation
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PUB513
Observational Study at the Mexican Institute for Social Security and 
Services for State Worker’s National Medical Center 20 de Noviembre 
Nephrology Department Outpatient Clinic Using Cinacalcet as Renal 
Replacement Therapy for Secondary Hyperparathyroidism Caused by 
Chronic Kidney Disease  Elvira González, Jesús Alejandro Nava Martínez, 
Juvenal Torres Pastrana.  Nephrology, CMN 20 Noviembre, Mexico, DF, Mexico; 
Nephrology, CMN 20 de Noviembre, Mexico, D.F., Mexico; Nephrology, CMN 
20 de Noviembre, Mexico, D.F., Mexico.
Background: Secondary hyperparathyroidism is a highly prevalent clinical condition 
in persons with advanced chronic kidney disease (CKD). It can be seen in the early stages 
of the disease and consists of disorders in bone metabolism.
Methods: A descriptive, retrospective observational study was done using patient 
records from the Institute for Social Security and Services for State Worker’s (ISSSTE) 
National Medical Center 20 de Noviembre Nephrology outpatient clinic, located in Mexico 
City, Mexico. 50 cases of adult patients with advanced chronic kidney disease were reviewed 
in renal replacement treatment, dperitoneal dialysis and/or hemodialysis who were managed 
with Cinacalcet for Secondary Hyperparathyroidism, with PTHi >300 pg/ml.
Results: The baseline level of serum parathyroid hormone of the 42 patients was 1371.6 
pg/ml prior to the use of cinacalcet, with a percentage reduction of 33% per month and 
6 months of treatment 55% with a mean of 1133 pg/ml and 615.48 pg/ml respectively. A 
total of 42 patients; 19 (45%) achieved targets at the end of the 6-month study. 36 patients 
underwent to scintigraphy of parathyroid gland, because they did not obtain parathyroid 
hormone decreased over 30% at the 3rd month of treatment; 5 patients showed hyperplasia 
and 11 parathyroid adenoma.
Conclusions: Cinacalcet combined with conventional treatment succeeds in reaching 
goals compared to standard treatment only. Hypocalcemia is a common side effect however 
when administered together with calcium salts and / or vitamin D or its analogues decrease 
side effects According to previous studies cinacalcet it increases the achievement of goals 
in mild hyperparathyroidism. In our study was more important for the response time in the 
RRT than the severity of hyperparathyroidism.
Funding: Government Support - Non-U.S.
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“Binder Reminders” for Persistent Hyperphosphatemia in Hemodialysis 
Patients: A Fellow’s Quality Improvement Project  Divakar Jammalamadaka, 
N. Stanley Nahman, John Jason White.  Medicine, Georgia Regents Univ, 
Augusta, GA.
Background: Despite regular quality improvement (QA) processes, control of mineral 
metabolism remains poor. One root cause is patient non-adherence to phosphate (Pho) 
binders. Evolving data suggest SMS/text reminders improve medication adherence in a 
wide range of chronic illnesses. Here, we report our initial experience with text reminders 
on Pho control in HD patients.
Methods: 40 patients with Pho > 5.5 mg/dL for 2 of last 3 months, and possessing 
cell-phones with texting capabilities were studied. We randomly assigned 20 to receive 
the phrase “Binder Reminder” at mealtimes x 7 days prior to their monthly lab draw. The 
remaining 20 received usual care. Group assignment and messaging was performed by a 
nephrology fellow, not part of the multidisciplinary team. Patients were excluded if they 
declined participation, missed any dialysis sessions during the 7 day period, or if they 
were unable to obtain their binders. Pho level after intervention was the primary outcome.
Results: After exclusions, 13 patients received the intervention and were compared to 
14 controls. Pre-intervention Pho levels were 6.81 +/- 0.88 and 6.60 +/- 0.93 mg/dL (Mean 
+/- SD) in the control and intervention groups respectively. After intervention, Pho levels 
declined in the intervention group to 6.00 +/- 1.2 mg/dL(P = 0.10). Pho also declined in the 
control group to 6.19 +/- 0.76 mg/dL. Hence there was no difference between the groups 
(P = 0.76). Each group had 8 patients with improved Pho levels, and 5 patients at goal.
Conclusions: Our initial QA project utilizing SMS/text messaging appears to have no 
effect on short-term Pho control in a group of HDs patients with chronic hyperphosphatemia. 
A major drawback is the small number of patients and the number excluded (33%). However, 
this study does provide useful preliminary data for the planning of a larger pilot project, 
highlights the importance of contemporary control groups in QA to exclude the Hawthorne 
effect, and, given its simplicity, may be a model for fellow-driven QA projects and education.
Funding: Clinical Revenue Support
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Niacin Improves Cardiac Function in Alport Mice with Progressive 
Chronic Kidney Disease and Hyperphosphatemia  Kelly Ambler,1 Evgenia 
Dobrinskikh,1 Veronica A. Hogg-Cornejo,1 Xiaoxin Wang,1 Yuhuan Luo,1 
Jason R. Stubbs,2 Moshe Levi.1  1Univ of Colorado Denver; 2Univ of Kansas 
Medical Center.
Background: Increase in serum phosphate (Pi) level (hyperphosphatemia) is a common 
clinical problem in chronic kidney disease (CKD). Systemic Pi homeostasis is balanced 
through three major mechanisms: intestinal uptake, retention or release from bone, and 
renal reabsorption. Sodium-phosphate co-transporter type 2b (NaPi2b) is a major phosphate 
transporter in the small intestine. Alport syndrome is a genetic disorder characterized by 
CKD, hearing loss and cardiac dysfunction.
Methods: By 9-10 weeks of age Alport mice, which have a mutation in a COL4A3 
gene on the SvEv129 background, develop signs of CKD and hyperphosphatemia.
Results: We have found by western blot that there is an increase in intestinal NaPi-
2b protein abundance and Everted Sac studies showed increased NaPi transport in the 
Alport Ileum compared to the WT littermate controls. Cardiac echo studies revealed that 
Alport mice have decreased ejection fraction (EF: 67±2% compared to 75±3% in the WT 
littermate) and diastolic dysfunction (mitral Doppler flow E/A ratio: 1.2±0.1 compared to 
1.6±0.1 in the WT littermate, p<0.05), which could be corrected by treatment with Niacin 
(intestinal phosphate uptake inhibitor). In the treated Alport mice EF increased to 78±2% 
(p<0.05) and E/A ratio improved to 1.3±0.1 (p<0.05). In addition, there were significant 
decreases mRNA relative expression in β-MHC (0.08±0.02 in control vs. 2.19±0.34 in 
Alport, p<0.001, vs. 0.2±0.001 in Alport+Niacin, p<0.05), PAI-1 (0.12±0.01 in control 
vs. 1.05±0.15 in Alport, p<0.05, vs. 0.15±0.05 in Alport+Niacin, p<0.05), and TGF-β 
(0.03±0.01 in control vs. 0.77±0.23 in Alport, p<0.01, vs. 0.07±0.23 in Alport+Niacin, 
p<0.01), markers of heart failure and cardiac fibrosis.
Conclusions: Inhibition of intestinal phosphate transport with Niacin therefore 
improves systolic and diastolic cardiac dysfunction in CKD.
Funding: Pharmaceutical Company Support - Daiichi Sankio
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Establishing Regulatory Networks of Phosphorus Metabolism in HD 
Patients – A New Path of Treating Hyperphosphatemia  Mengjing Wang,1 
Panpan Wang,2 Yulin Zhang,1 Li Ni,1 Minmin Zhang,1 Jing Chen.1  1Nephrology, 
Huashan Hospital, Shanghai; 2MOE Key Laboratory of Contemporary 
Anthropology, School of Life Sciences, Fudan Univ, Shanghai.
Background: The clinical efficiency of current treatment of hyperphosphatemia in 
HD varies widely on different patients. We assume that it is due to phosphorus regulation 
in vivo. In physiological conditions, phosphorus is regulated by a biological network 
consisting of interacting hormones and minerals. In HD, the networks change dramatically 
and affect serum phosphorus. This study aims to establish the regulatory networks of 
phosphorus in HD and identify the key factors that may have a causal effect on circulating 
concentrations of phosphorus.
Methods: 30 MHD patients were enrolled and divided into three groups (n=10, 
PTH£300 ng/l; n=10, 300 ng/l<PTH≤600 ng/l; n=10, PTH>600 ng/l). Predialysis blood 
samples were obtained on the mid-week dialysis day for detection of PTH, FGF23, 25(OH)
D3, Klotho, and Ca every week for 12 weeks every patient. Causal inference, a widely 
used process of concluding a causal connection, was adopted to establish the regulatory 
networks of phosphorus metabolism within different PTH levels.
Results: The networks show that when PTH<600 ng/l, FGF23 can stimulate the increase 
of serum Pi, Ca, and PTH, in turn, serum Ca and Pi can also stimulate the increase of FGF23. 
When PTH>600 ng/l, FGF23 becomes the stimulator of only serum Ca, and serum Pi has 
a positive causal effect on PTH, besides, the rise of PTH increases serum Pi level, too. So, 
serum Pi is affect by FGF23 when PTH<600 ng/l and by PTH when PTH>600 ng/l. Since 
FGF23 promotes the increase of PTH when PTH<600 ng/l, FGF23 becomes the key factor 
in disorders of phosphate metabolisms. The figures also shows that Klotho and 25(OH)D3 
may be not important in the therapy of hyperphosphatemia. 
Conclusions: Reducing FGF23 levels might contribute to the control of phosphorus.
PUB517
Evolution of Renal Calcium Excretion Throughout Chronic Kidney Disease 
Carmen Gonzalez Corvillo,1 Paula Batalha-Caetano,1 Silvia Ros-Ruiz,2 Fernando 
Vallejo Carrión,3 José G. Hervas,4 Mercedes Salgueira Lazo.1  1Nephrology, 
Hospitales Virgen Macarena-Rocio, Sevilla, Spain; 2Nephrology, Hospital 
Regional, Malaga, Spain; 3Nephrology, Hospital Puerto Real, Cadiz, Spain; 
4Nephrology, Universidad, Granada, Spain.
Background: Chronic kidney disease(CKD)patients have a normal serum calcium(Ca)
concentration until the end of renal disease(ESRD).The decrease of VitaminD levels,and 
that a percentage of patients develops hypocalcemia at ESRD,lead us to think that our 
patients have a negative Ca balance,this could justify the treatment with Ca supplements.
Objetive:analyze renal Ca excretion at different stages of CKD and the effect of the 
treatments.
Methods: Observational multicenter,retrospective and transversal study,with 
the participation of 5hospitals.63patients were included,in different stages of 
the disease(66,7%men,mean age 66years).None on renal replacement therapy.
Variables:blood,urine analysis and treatment.The sample was stratified by stage of the 
disease and urine Ca(>or<100 mg/d).
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Results: Sample:6,3%CKD1,4,8%CKD2,28,6%CKD3,38,1%CKD4 and 22,2%CKD5.
Mean serum Ca:9,47 mg/dl,mean serum phosphate(P): 3,77mg/dl.PTH level 174pg/dl,VitD 
27ng/ml.Mean Ca excretion:126mg/day.Mean P excretion:477mg/d.47%was on Ca based 
binders,22.2%on calcifediol,12.7%on calcitriol and 28.6%on paricalcitol.70%of the sample 
had Ca excretion<100mg/d.When classifying by stages of the disease,increases the amount 
of patients with Ca excretion<100 mg/d(CKD1 25%,CKD2 50%,CKD3 50%,CKD4 
80%,CKD5 83%),decreasing the mean Ca excretion.The subgroup of patients with lower 
Ca excretion had a higher PTH level(155 vs 111pg/dl)p0,05. 94%of patients treated with 
Ca based binders had a Ca excretion<100mg/d with no difference in serum Ca.Patients on 
calcifediol,paricalcitol or calcitriol had lower Ca excretion than those without treatment.
Conclusions: According to our results,patients within CKD show a decrease in renal 
Ca excretion that become exacerbated as the renal disease progresses.Supplementation with 
hypercalcemic drugs is not balanced out with the expected increase of renal Ca excretion.
Therefore,we think that CKD patients are exposed to a chronic Ca overload,sometimes 
underestimated,with the resulting negative impact in morbidity and mortality.
PUB518
Effect of Parathyroid Hormone on Serum Magnesium Level: The Neglected 
Relationship in Hemodialysis Patients with Secondary Hyperparathyroidism 
Bing Tang, Li Fang, Junwei Yang.  Center for Kidney Disease, Second Affiliated 
Hospital, Nanjing Medical Univ, Nanjing, Jiangsu, China.
Background: Chronic kidney disease–mineral and bone disorder (CKD–MBD) is 
an important complication in patients with end-stage kidney disease which is associated 
with cardiovascular morbidity and mortality. Since recent studies have shown that serum 
magnesium play an important role in secondary hyperparathyroidism, vascular calcification 
and cardiovascular mortality, the interest on magnesium (Mg) has grown.
Methods: This cross-sectional study was conducted on 111 patients with end-
stage renal disease on maintenance hemodialysis who was hospitalized for secondary 
hyperparathyroidism. The interventional study was conducted on 23 patients underwent 
total parathyroidectomy.
Results: In our study, hypermagnesaemia (>2.5mg/dl) occurs in up to 44% of 
cases and hypomagnesemia did not present. No significant correlations were found 
between serum magnesium and parathyroid hormone (r =-0.143, p = 0.134). Correlation 
analysis and logistic regression analysis suggested that the derangement of magnesium 
homeostasis was correlated with the derangement of calcium/phosphate homeostasis. 
After parathyroidectomy, serum magnesium levels dropped immediately and reached the 
lowest level at one day after surgery; however, it gradually restored three days later. The 
changes of serum magnesium after surgery was positive correlated with the changes of 
serum phosphate (r=0.558, p=0.003).
Conclusions: The effect of PTH on magnesium metabolism could not be neglected, 
especially in hemodialysis patients with secondary hyperparathyroidism. The role of 
magnesium metabolism and therapeutic strategies to achieve optimum serum magnesium 
levels in CKD-MBD should take into account the varying stages of disease development.
Funding: Government Support - Non-U.S.
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Calciphylaxis in Patient with Chronic Renal Disease Not Dialytic and 
Multiple Myeloma  Patricia Junqueira Freitas, Aline Lourenco Baptista, 
Clovis Antonio lopes Pinto, Joubert Araujo Alves, Pedro Caruso, Benedito 
Jorge Pereira, Fernanda Lemos Moura, Marina Harume Imanishe, Luis Andre 
Andrade, Germana Alves Brito.  Nephrology, AC CAMARGO, Sao Paulo, Brazil.
Background: Calciphylaxis, also known as calcifying uremic arteriolopathy, is a rare 
medical condition, which is normally diagnosed in patients with terminal CKD who are 
already in renal replacement therapy (RRT).Objective:report the presence of calciphylaxis 
in CKD, in patient with oncologic disease.
Methods: Female patient, 71 years old,caucasian, conducted to AC Camargo Hospital 
for etiological investigation of injuries in lower limbs associated with renal failure, 
hypercalcemia, anemia and astenia. Has history of hypertension and obesity. Physical 
examination: poor general state, dyspneic, respiratory and cardiovascular systems without 
changes, ulcerated lesions of necrotic center in lower limbs (FIGURE). Laboratory tests: 
Creatinine 8.8 mg/dL;Urea 169 mg/dL;K 4.1 mEq/U; HCO3:16.3 mmol/U; pH 7.29; Cai: 
1:58 mmol/U;PTH: 295 pg/ml; : 3.6mg/dL; otal Ca:12,9mg/dL;albumin 1.8g/dL.Renal 
US: regular.Parathyroid US: regular.Held biopsy(Bx) of skin:chronic inflammatory process 
sharpened with necrosis and calcification dystrophic in dermis and hypodermis.Bx of Bone 
marrow:neoplastic infiltration of plasma cells. The patient was transferred to ICU due 
septic shock of cutaneous focus, performed antibiotic therapy, hemodialysis (HD) with 
Calcium (Ca) 2.5, initiated sodium thiosulfate three times a week and cinacalcet, presenting 
improvement of the injuries. 
Conclusions: The calciphylaxis is a complex clinical entity and pathogenesis not fully 
elucidated, what makes the treatment still not uniform. It is characterized by dermal ischemic 
necrosis, of acute and progressive installation. It must be paid attention to its presence even 
in non dialytic stages of CKD as happened in the described case.
PUB520
Calcium Binders Are They All Equal? Comparaison Calcium Acetate 
(CA) versus Carbonate Calcium (CC) in CKD 5D: Multicentric Study 
Philippe Brunet,1 David Attaf,2 Laurent Juillard.3  1Nephrology - Dialyse, 
Conception Hospital, Marseille, Bouches-du-Rhône, France; 2Dialyse, 
Fresenius, Paris, IDF, France; 3Nephrology - Dialysis, Edouard Herriot 
Hospital, Lyon, Rhone, France.
Background: CA’s phosphate binder is available since 2010 in France. A monocentric 
study indicates that CA is equivalent to CC based on phosphatemia reduction while reducing 
calcium intake by 60%. This study compare CA to CC in different dialysis centers i.e 
different CKD MBD protocols.
Methods: 28 hemodialysis centers are involved. CC is switched to CA at M0 with 6 
months follow up (M0-M6). We compared MO’s biologic datas with M6’s datas.
Results: 293 patients (70+/-14 y) in 28 centers. At M6 CA dosage was 3.8 +/- 2 pills/
day. Demographic characteristics are consistent with our National French registery. At 
M6 mineral values are similar to M0 : Ph mM (1,54 +/- 0,55 vs 1,52 +/- 0,65 , NS), Ca 
mM (2,23 +/- 0,17 vs 2,21 +/- 0,15 , NS), PTH pg/ml (221 +/- 204 vs 262 +/- 217 , NS), 
Vit. D nM (75 +/- 32 vs 79 +/- 24 , NS), % pts with non calcium binder (43 vs 49 , NS), 
% pts w. Ca > 2,6 mM (2 vs 1 , NS), % pts w. Ph > 1,5 mM (39 vs 38 , NS). The only 
difference is related to a decrease of Calcium Intake (g/d) from MO (1,51 +/- 1,13) to 
M6 (0, 63 +/- 0,31 , P<0,05).
Conclusions: At M6 Calcium intake is reduced by 57% vs MO while Ph. is similar 
vs M0. Mean serum calcium is not altered. The frequency of Ca > 2.60 mM and Ph > 1.5 
mM are not modified at M6/M0. A M6 PTH and 25-OH vit D are stable. This multicenter 
study (ie different therapeutic strategies ) confirm that CA is equivalent to CC with 
a reduced Ca Intake.
Funding: Private Foundation Support
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Hemodynamic Changes in Maintenance Hemodialysis Patients with 
Hypotension After Parathyroidectomy  Meijuan Meng, Bing Tang, Hong Ye, 
Junwei Yang.  Center for Kidney Disease, Second Affiliated Hospital, Nanjing 
Medical Univ, Nanjing, Jiangsu, China.
Background:  Parathyroidectomy (PTX) is applied to treat secondary 
hyperparathyroidism in hemodialysis patients. Some patients suffered from hypotension 
after PTX althrough hypocalcemia was corrected. The aim of this study was to demonstrate 
the hemodynamic changes in hemodialysis patients after PTX.
Methods: Twelve patients were included in this study. Among them 4 have hypotension 
after PTX (Group 1) and the other have their blood pressure remained after PTX (Group 2). 
Before PTX, systolic blood pressures (SBP) of all the 12 patients were above 90 mmHg. 
Noninvasive hemodynamic evaluation was performed before, during and after dialysis.
Results: Comparing with group 2, cardiac index (CI) was higher (P=0.252) while 
systemic vascular resistance index (SVRI) was lower (P=0.05) in group 1. The mean 
thoracic fluid capacity (TFC) of the two groups were similar (P=0.424) before dialysis. 
Serum Ca, PTH, ALP, ventricular ejection fraction and vascular calcification score of 
thoracic aorta, abdominal aorta and heart valve before PTX, as well as the weight of 
the removed parathyroid glands, serum Ca, ALP, hemoglobin after PTX of the patients 
were determined. No statistical differences were found. However, the phosphorus level 
was lower in group 1 both before and after PTX. CI, SVRI and TFC were similar in both 
groups during hemodialysis.
Conclusions: Patients with hypotension after PTX have a lower systemic vascular 
resistance index and a higher cardiac index, which might be associated with serum 
phosphorus level.
Funding: Government Support - Non-U.S.
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Cost of Medications Used in the Management of Secondary 
Hyperparathyroidism (SHPT) in Patients with End Stage Renal Disease 
(ESRD)  Mark E. Bensink,1 Leigh Darryl Quarles,2 Vasily Belozeroff,1 Kerry 
Cooper,1 Jonathan D. Campbell.3  1Amgen Inc., Thousand Oaks, CA; 2Univ of 
Tennessee, Memphis, TN; 3Univ of Colorado, Aurora, CO.
Background: Management of SHPT associated with ESRD is complex, typically 
requiring combinations of medications. Eighty-two percent of the ESRD population is 
covered by Medicare with detailed drug expenditures reported annually by the US Renal 
Data System. For the remaining 18% covered by commercial health plans, drug expenditure 
information is unknown. The purpose of this study is to estimate the cost of medications 
used in the management of SHPT in ESRD patients from the US commercial health plan 
perspective.
Methods: Economic analysis with one-year time horizon to estimate per-member-
per-month (PMPM) cost for SHPT related medications: calcium and non-calcium-based 
phosphate binders, calcitriol or active vitamin D analogs, and calcimimetics. Input 
parameters include: prevalence of ESRD in commercial health plans (MarketScan®); 
medication utilization and non-adherence (IMS Health for oral medications and Outcomes 
Plus for intravenous [IV] medications); and medication wholesale acquisition costs (WAC) 
(AnalySource.com) with one-way sensitivity analysis.
Results: The total PMPM (2014 US Dollars) cost of SHPT-related medications is $0.34: 
cinacalcet $0.06, phosphate binders $0.16, oral vitamin D $0.02, and IV vitamin D $0.10. 
Results are most sensitive to variation in ESRD prevalence and cinacalcet WAC 
parameters.
Conclusions: Results indicate that the collective cost of medications for the 
management of SHPT in commercial health plans is substantial with the cost of cinacalcet 
being lower compared to phosphate binders and IV vitamin D, but higher compared to 
oral vitamin D.
Funding: Pharmaceutical Company Support - Amgen Inc.
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Medullar Compression by Bone Tumor: Case Report  Cinthia Sobral Vieira, 
Nicole D.T. Carvalho.  Nephrology Unit- Clinefro, Hospital Ernesto Dornelles, 
Porto Alegre, RS, Brazil.
Background: The presentation of vertebral tumors may have different kinds of 
manifestation. They can mimic neoplastic, inflammatory and congenital diseases. The 
following report is about a patient with a lytic bone lesion in the thoracic spine causing 
medullar compression symptoms.
Methods: A 66 years old masculine patient, with chronical renal disease in hemodialysis 
for 5 years, non-adherent to treatment or diet, had his levels of phosphor, calcium/phosphor, 
alkaline phosphatase and parathyroid hormone (PTH) elevated in the last year. He did not 
take the medication prescription: Calcitriol and Sevelamer. The patient came to the ER of a 
general hospital referring constipation and abdominal distention. During the hospitalization 
he started to refer paresthesia in inferior members with progressive march dysfunction. 
The neurological exam showed ataxic/calcaneal gait and strength reduction (4+/5+) in 
the inferior members.
Results: At first, an angiotomography study of the mesenteric vessels were made, 
thinking of the possibility of mesenteric ischemia, but the exam showed multiple lytic lesions 
in the corps of lumbar vertebras and in the hipbones, mimicking secondary implants. The 
spine MRI demonstrated one lytic bone lesion at the level of D6 and D7 causing medullar 
compression. The bone scintigraphy was suggestive of a metabolic bone disease and the 
parathyroid scintigraphy showed a hyperfunctioning tissue, in the parathyroid left pole. The 
patient was submited to a compressive laminectomy, the biopsy revealed a Brown Tumor. 
Then, it was indicated a parathyreodectomy. The pathological result showed no evidence 
of malign disease. Nowadays, the patient is still in hemodialysis, receiving calcium and 
under physiotherapy to recover muscle strength, already walking.
Conclusions: Brown Tumor or osteoclatoma is a rare bone lesion, an incidence of 1,4 
to 13% in chronic renal patient due to a secondary hyperparathyroidism and less than 5% 
in primary hyperparathyroidism. It is more frequent in women. The vertebra involvement 
is uncommon. This case report has its importance for calling attention to importance to 
include brown tumor as a differential diagnosis in compressive spines lesions especially 
in chronic renal patients.
PUB524
Rescue-Therapy with Lanthanum-Carbonate (LC) in Uncontrolled 
Hyperphosphoremia in Dialysis  Nicola Giotta, Angela maria Marino.  Dept 
of Medicine, Nephrology and Dialysis Unit, Cardinal Massaia Hospital, Asti, 
AT, Italy.
Background: Control of hyperphosphatemia in hemodialysis provides an approach 
based on changes in diet, dialysis efficiency improvement, and use of phosphate binders. 
The latter, however, in some patients do not prove effective, conditioning the indirect 
increase of mortality and morbidity of the subject on dialysis. The objective of this study 
was to evaluate the difference in efficacy of a regimen of lanthanum carbonate plus standard 
therapy (LTS) compared to standard therapy alone (TS) in the treatment of patients with 
persistent hyperphosphatemia, as rescue-therapy.
Methods: We conducted an observational study of data on consecutive patients in 
hemodialysis who have presented more than four phosphorus values greater than 6 mg/dL 
in three months. Patients treated with TS, have varied therapeutic scheme introducing LC. 
Patients treated with sevelamer have outstanding this therapy and were treated with LC. 
The data analysis has been done considering a retrospective phase (FR) of three months 
and a prospective phase (FP) of six months, for each subject analyzing the effectiveness 
of therapy before and after enrollment.
Results: In a cohort of 163 patients on hemodialysis, we have selected for the study, 
14 patients who had a mean age of about 65 years and length of dialysis than 6 years. The 
combination of LC plus TS produced a significant increase in the proportion of patients 
achieving the therapeutic targets as defined by the K/DOQI Guidelines. Reduction of 
2.12 mg / dL (-32.7%) than the average of the P phase prospective (4:55 mg/dL) than the 
retrospective phase (6.77 mg/dL), was statistically significant (p <0.001), is associated with 
the reduction of 19:21 mg2/dl2 (-32.9%) of the average value of CaxP in the prospective 
phase (39.07 mg2/dl2) compared to the retrospective phase (58.28 mg2/dl2), also statistically 
significant (p <0.001). The patients at target at the end of FP accounted for 92.31% for P 
and 100% for the CaxP, respectively vs. the 7.14% and 50% of FR.
Conclusions: The introduction of the LC-as rescue therapy in the treatment of 
hemodialysis patients with uncontrolled hyperphosphatemia resulted very effective allowing 
more easily reach the therapeutic objectives.
PUB525
Glucocorticoid-Induced Osteoporosis in Renal Patients  Gabrielle Goldet,1 
George Greenhall,2 Alan D. Salama.2  1Basildon and Thurrock Univ Hospital; 
2Royal Free Hospital, London; 3Royal Free Hospital, London.
Background: Glucocorticoid-induced osteoporosis (GIO) is associated with severe 
morbidity due to fragility fractures as well traumatic fractures and 30-50% of patients on 
long term steroids are affected by GIO. GIO is relevant in the renal context as steroids are 
widely used to treat renal disease and as part of immunosuppression in transplant. Also, 
renal patients are already at higher risk of fractures in association with renal bone disease.
Methods: We designed and undertook an audit to assess screening and management of 
GIO in nephrology outpatients in a university hospital in London, using national guidelines 
as a benchmark for our performance. We then presented the results at a local meeting, 
produced posters and leaflets on GIO to be placed in the outpatient waiting area for patients 
so as to raise awareness of this issue and provided a simple algorithm to be followed by 
clinicians in all the clinic rooms. We then re-audited after 6 months.
Results: 100 patients were audited in each audit cycle. Measures audited were a) 
whether all patients over 65 were treated with bone-sparing agents (BSA); b) whether all 
patients with documented fragility fracture were treated with BSA; c) whether all patients 
under 65 without fragility fracture underwent DXA scan; d) whether all patients with T-score 
below -2.5 were treated with BSA; e) whether all patients with T-score 0 to -1.5 underwent 
repeat DXA within 3 years; f) whether BSA was prescribed for all patients where indicated; 
g) whether all patients are managed according to national guideline (cycle 1: 29%; cycle 
2: 41%). See table for breakdown of results. 
Audit 
measure
Audit 1 
percentage 
(%)
Audit 2 proportion 
of patients meeting 
target
Audit 2 
percentage 
(%)
Audit 2 proportion 
of patients meeting 
target
a 11 1/9 9 1/11
b 0 0/0 0/1 0
c 56 48/86 61 50/82
d 13 1/8 43 3/7
e 40 8/20 75 15/20
f 19 5/26 26 8/31
g 29 29/100 41 41/100
Conclusions: Our intervention has improved performance as measured against national 
guidelines, though the rate of GIO screening remains low. Many patients could potentially 
benefit from bone protection, though larger studies would be needed to demonstrate an 
effect on fracture incidence.
Funding: Government Support - Non-U.S.
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The Kidney Stone and Increased Water Intake Trial in Steel Workers: 
Results from a Pilot Study  Hakam Gharbi,1 Yair Lotan,2 Jodi Antonelli,2 
Inmaculada Buendia Jimenez,1 Allison Ahrens Beaver,1 Aphrihl Dennis-Barrie,1 
Dendra K. Von merveldt,1 Suzie Carter,1 Adam B. Cohen,1 John Poindexter,3 
Orson W. Moe,3 Margaret S. Pearle.2  1Danone Research, Palaiseau, France; 
2Urology, Univ of Texas Southern Medical Center, Dallas, TX; 3Mineral 
Metabolism, Univ of Texas Southern Medical Center, Dallas, TX.
Background: Preventing dehydration in subjects at risk may provide a means of 
primary prevention of kidney stones. The purpose of this pilot study was to assess the 
hydration status of an at-risk group of steel plant workers based on end-of-shift (‘post-shift’) 
spot urine osmolality and 24-hour urinary stone risk parameters.
Methods: 100 volunteers were recruited from Gerdau Midlothian steel mill in Texas 
on 11/14/14 and 12/5/14. Clinical data was recorded and a post-shift spot urine sample 
was obtained for measurement of urine osmolality. In addition, participants were invited 
to submit a 24-hr urine sample within 4 weeks of enrollment.
Results: Mean age was 41 and 95% were men. The majority of subjects were white 
(75%), followed by 10% Hispanic and 9% Black. Mean body mass index was 30.1 kg/m2 
and overall 16% had past history of stone disease. Mean post-shift urine spot osmolality 
was 704.5 mOsm (169-1165 mOsm) and was >800 mOsm and >700 mOsm in 39% and 
57%, respectively. Among 59 24-hour urines samples, mean volume was 1.89 ± 0.92 l/
day, with 56% <2 liters and 17% <1 liter. Elevated levels of urinary analytes were found 
in 29% of subjects for calcium (>250mg/TV), 39% for uric acid (>700 mg/TV), 25% for 
oxalate (>45mg/TV) and 50% for sodium (>200 meq/TV).
Conclusions: The prevalence of stone disease in this population of steel workers is 
higher than the published prevalence of stone disease in the general population. A significant 
number of workers had concentrated post-shift and 24-hour urines and elevated levels of 
urinary analytes.
PUB527
Chronic Renal Pain in Medullary Sponge Kidney  Giovanni Gambaro,1 
Jackie Hirsch,2 Rocco Baccaro,1 Nicole Topilow,2 Matteo Bargagli,1 David S. 
Goldfarb,2 Pietro Manuel Ferraro.1  1Nephrology, Catholic Univ, Rome, Italy; 
2NY Univ, School of Medicine, New York, NY.
Background: MSK usually occurs with recurrent stones;less frequently it is 
asymptomatic;very rarely the main manifestation is severe chronic flank pain. Often these 
pts are accused of seeking pain medications. Because of the rarity of such a presentation it 
is not know if pain is due to intense lithogenic activity or is independent of it, something 
like a form of the “loin pain hematuria syndrome”. Three Facebook support groups exist 
for North American patients with MSK and chronic pain. Their cooperation allowed us to 
investigate chronic pain in MSK.
Methods: An ad hoc questionnaire and the Brief Pain Inventory were administered 
through a dedicated web site; 92 patients (89 females) participated after verification of 
the diagnosis of MSK (imaging and diagnosis certified by a nephrologist or urologist).
Results: Mean age of patients was 39.8y, (range 24-66). Age at onset of manifestations 
and MSK diagnosis were 23y (4-47) and 31y (7-57), respectively. Manifestations at onset 
were: flank pain (31%), reno-ureteral colic (RUC) (26%), hematuria (19%), cystitis (14%), 
pyelonephritis (10%). 71% of pts have daily pain, 76.5% have taken painkillers in the 
previous week and 69.1% needed them at the time of questionnaire administration; 58% take 
them ³1 time/day. The strong pain (5.4 in a scale from 0 to 10), jeopardizes general activities, 
mood and sleep. Only 4.6% of pts have RUC like pain; in 52.9% it is non-radiating flank 
pain with manifestations of possible UTI or stone passage (painful micturition, urgency, 
frequent urination, hematuria, fever); in 42.5% it is non-radiating lumbar pain without 
other manifestations (however only in 3 cases the pain was a unilateral flank pain). Pain 
is frequently associated with stone (67%) or sand passage (46%), hydronephrosis (42%), 
hematuria (42.4%).
Conclusions: Although in these MSK pts the chronic pain -that dominates the clinical 
manifestations - is usually associated with some of the typical symptoms of stone passage, 
in a fraction of pts this is not the case and pain is not associated with lithogenic activity. 
The etiology of this pain syndrome remains uncertain and merits investigation.
Funding: Government Support - Non-U.S.
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Difference in Vitamin D Level Between Older and Younger Kidney 
Transplant Recipients  Mohamed Amin Elesnawi, Abdullah Hamad, Fadwa S. 
Al-Ali.  Nephrology, Fahd Bin Jasim Kidney Center, Hamad General Hospital, 
Doha, Qatar.
Background: Vitamin D deficiency is more common in older than younger people. 
In kidney transplant recipients, vitamin D deficiency has a high prevalence of up to 80 % 
according to recent studies. We compared vitamin D status in older versus younger patients 
with kidney transplant.
Methods: We reviewed all available record of kidney transplant recipients that came 
to our clinic at Hamad General Hospital in Qatar between September 1st 2013 and March 
1st 2014. We recorded background data and laboratory tests. Patients divided into 2 groups 
younger and older (below and above 60 years old respectively). All patients were receiving 
vitamin D supplement.
Results: 102 patients were included. 52 patients in the younger group and 50 patients 
in the older. Age was 68.8+/-5.9 years in the older versus 41.9+/-10.4 years in the younger 
group. Table (1) compare laboratory values between the two groups. Vitamin D status 
was classified(normal above 30, mild 20-29, moderate 10-19 and severe below 10 ng/
mL) figure (1). 
Younger (<60 Years) n=52 Older (>60 years) n=50
Male/Female 25/27 42/8
vitamin d 21.2+/-16.8 ng/mL 21+/-9.93 ng/mL
calcium 2.3+/-0.16 mmol/L 2.27+/-0.12 mmol/L
phosphorus 1.14+/-0.29 mmol/L 1.22+/-0.2 mmol/L
alkaline phosphatase 90+/-39.2 u/L 74.1+/-41 u/L
intact parathyroid hormone 126+/-142 pg/mL 140.8+/-223 pg/mL
Conclusions: In a comparative study, we found that older trasnplant recipient group had 
more male patients (pValue<0.05), lower alkaline phosphatase and higher intact parathyroid 
hormone (not statistically significant) but similar vitamin D, calcium and phosphorus 
level. There was a trend towards milder vitamin D deficiency in the older group that could 
be due to better compliance with vitamin D supplement. Despite vitamin D supplement 
protocol and long sunny days in Qatar we still found high rate of vitamin D defeciency in 
transplant recipients (81.4%).
PUB529
Efficacy of Low Dose, Alternate Day Cinacalcet for Treatment of Secondary 
Hyperparathyroidism in Hemodialysis Patients: A Randomized Controlled 
Trial  Pongsathorn Gojaseni, Dolnapa Pattarathitinan, Kolasorn Pakchotanon, 
Anutra Chittinandana.  Medicine, Bhumibol Adulyadej Hospital, Royal Thai 
Air Force, Bangkok, Thailand.
Background: Secondary hyperparathyroidism (SHPT) is common in hemodialysis 
patients and has been associated with increased mortality. Cinacalcet, a modulator of 
calcium-sensing receptor, effectively reduced serum parathyroid hormone (PTH) in clinical 
studies. We tested whether prescription of low dose, alternate day cinacalcet could be an 
option for treatment of SHPT.
Methods: An open-labeled, randomized controlled trial enrolled hemodialysis 
patients with severe secondary hyperparathyroidism (intact PTH > 585 pg/ml). Patients 
were randomized to received low-dose cinacalcet (25 mg alternate day) or standard-dose 
(25 mg daily) for 16 weeks. At 8 weeks, doses of cinacalcet could be increased to achieve 
KDIGO PTH target of less than 585 pg/ml. The primary outcome was the difference in 
percentage of patients achieving KDIGO target at 16 weeks. The changes of serum iPTH, 
other biochemical data were also tested.
Results: Between July 2014 and January 2015, a total of 30 hemodialysis patients 
(15 females, 15 males) were randomly assigned to a treatment group: 16 to low-dose and 
14 to standard-dose. Baseline iPTH in low-dose and standard-dose group was 1,065.9 ± 
477.7 and 1,211 ± 466.5 pg/ml respectively (p = 0.409). During study period, 4 patients 
(2 from each group) were dropout from study due to adverse events. Intention to treat 
analysis showing that the percentage of patients who achieving KDIGO PTH target was 
not different (38.5% in low-dose group compared with 30.8% in standard-dose group, p 
= 1.0). Serum iPTH reduction during 16 weeks of study period in low-dose and standard-
dose group was 253.5 ± 316.1 and 330.6 ± 698.2 respectively (p = 0.731). The adverse 
events were not different between both groups except hypocalcemia that tend to be higher 
in standard-dose (38.5% vs 13.3%, p = 0.274).
Conclusions: Among patients with SHPT, cinacalcet 25 mg alternate day may be 
sufficient effectively decrease serum iPTH levels with low incidence of hypocalcemia. 
The role of low dose cinacalcet in SHPT should be determined in large-scale, adequately 
powered randomized controlled trials.
Funding: Government Support - Non-U.S.
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Parathormone Stability in Hemodialyzed Patients: Comparison on Non-
Centrifuged EDTA and Serum Samples with 2nd and 3rd Generation Assays 
Marie Dohet,1 Pierre Delanaye,2 Etienne Cavalier.1  1Clinical Chemistry, Univ 
of Liege, CHU Sart-Tilman, Liege, Belgium; 2Nephrology, Univ of Liege, CHU 
Sart-Tilman, Liege, Belgium.
Background: PTH stability is of importance. Many studies have shown divergent 
results between EDTA and serum, mainly linked to differences in protocols or cut-offs 
used to decipher whether PTH remained stable or not. No studies have yet compared 
PTH as measured by 2nd and 3rd generation assays on the same samples in hemodialyzed 
(HD) patients.
Methods: Five pairs of samples (EDTA and gel tubes) were obtained in 10 HD 
patients before session. One pair was centrifuged and run immediately to establish the 
“T0”. Two pairs were kept at +4°C and +25°C. They were centrifuged after 4 and 18 hours. 
Supernatant was kept at -80°C for one week. Then, all samples were measured in a single 
batch, on Roche Cobas and DiaSorin XL 2nd and 3rd generation PTH assays. Samples were 
considered as stable if 90% of subjects had a decrease lower than a total change limit (TCL) 
that takes both analytical and biological variability into consideration. All determinations 
were run in duplicates.
Results: At T0, no difference was observed between plasma and serum for any of 
the methods. PTH decreased in all samples and degradation was the same with 2nd or 3rd 
generation assays, whatever the method used. Percentages of decrease were systematically 
lower in EDTA plasma compared to serum and none of our subjects presented a decrease 
higher than the TCL with EDTA plasma. In serum, PTH was not considered as stable, but 
only when kept at 25°C for 18 hours.
Conclusions: PTH stability is of paramount importance for correct interpretation of the 
results. Many studies have tried to evaluate this stability but are not free from criticisms, 
mainly due to a poorly defined T0 and questionable acceptation limits. In this study, we 
used an unfrozen T0 and decision limits based on analytical and biological variations. 
Moreover, we tested 2nd and 3rd generation PTH on two automated platforms. Our results 
show that, if PTH is basically more stable in EDTA plasma than in serum, this advantage 
is only clinically significant when samples are stored for a long period (18h) at +25°C.
PUB531
Vitamin D Metabolism Is Incompletely Restored After Kidney 
Transplantation  Thomas F. Hiemstra,2 Stephen M.S. Ting,1 Ragada 
El-Damanawi,2 Kenneth Lim,3 Martin Kaufmann,4 Glenville Jones,4 Daniel 
Zehnder.1  1Univ of Warwick, United Kingdom; 2Univ of Cambridge, United 
Kingdom; 3Massachusetts General Hospital, Boston; 4Queen’s Univ, Kingston, 
Canada.
Background: Vitamin D deficiency is widely reported in patients with renal impairment 
and is associated with adverse outcomes. The extent and rate of recovery of vitamin D 
metabolism after kidney transplantation is uncertain.
Methods: We enrolled 175 dialysis patients (HD) listed for kidney transplantation, 
and 85 hypertensive but otherwise healthy controls (HTN). We determined blood markers 
of mineral metabolism including intact FGF23 and vitamin D metabolites at entry (or 
immediately pre-transplantation), 2 and 12 months. As a surrogate for vitamin D deficiency, 
we assessed the 25(OH)D3: 24,25(OH)2D3 ratio (D-ratio, normal 5-25).
Results: Of 175 dialysis patients, 76 were transplanted (TXR) during the study. 
TXR were younger with a lower BMI than controls. FGF23 was higher in HD patients 
than HTN at baseline, but normalised after 12 months (p=0.13). At baseline, vitamin D 
insufficiency (defined as 25(OHD <30 ng/mL) was present in 82% of subjects and did not 
differ between groups. However, vitamin D deficiency (defined as 25(OHD <10 ng/mL) was 
more common in dialysis (15% versus 4%, p=0.49). The baseline D-ratio was higher in HD 
(48, IQR 27-67) than in HTN (16, IQR 14-18, p<0.0001) patients. Transplantation resulted 
in significant reduction in D-ratio after 2 and 12 months compared to HD (p=0.0008 and 
p=0.005 respectively). The slope of D-ratio vs 25(OH)D3 increased after transplantation, 
but remained lower than for HTN controls, suggesting reduced expression or activity of 
the catabolic CYP24A1 (25-OH-D3-24-hydroxylase) in kidney failure.
Conclusions: Vitamin D insufficiency is highly prevalent in patients on dialysis and in 
hypertensive controls, and only partially resolves after kidney transplantation.
PUB532
Low Time-Averaged Serum Intact Parathyroid Hormone Level Is an 
Independent Risk Factor for Overall Mortality and Major Adverse Cardiac 
and Cerebrovascular Events in Incident Dialysis Patients  Sul A Lee,1 Mi 
Jung Lee,1 Kyoung Sook Park,1 Jong Hyun Jhee,1 Jae Eun Um,2 Meiyan Wu,2 
Hyung Jung Oh,1 Jung Tak Park,1 Seung Hyeok Han,1 Shin-Wook Kang,1,2 
Tae-Hyun Yoo.1  1Dept of Internal Medicine, Yonsei Univ College of Medicine, 
Seoul, Korea; 2Severance Biomedical Science Inst, Brain Korea 21 PLUS, Yonsei 
Univ College of Medicine, Seoul, Korea.
Background: Chronic kidney disease-mineral bone disorder (CKD-MBD) is known as 
a major risk factor for cardiovascular disease in end-stage renal disease (ESRD) patients. 
CKD-MBD is classified into low turnover and high turnover bone disease according to the 
bone dynamics, both of which are related with vascular calcification in ESRD. To evaluate 
the prognostic value of abnormal serum parathyroid hormone (PTH) levels on ESRD 
patients, we investigated the effects of time-averaged serum intact PTH (TA-iPTH) levels 
on overall mortality and major adverse cardiac and cerebrovascular events (MACCEs) in 
incident dialysis patients.
Methods: In this prospective observational study, 413 patients who started dialysis 
between January 2005 and September 2010 at Yonsei University Health System were 
enrolled. Patients were divided into three groups according to TA-iPTH levels during the 
12 months after initiation of dialysis (group 1: <65pg/ml, group 2: 65 to 300 pg/ml, group 
3: >300pg/ml). Cox regression analysis was performed to determine the prognostic value 
of TA-iPTH on overall mortality and MACCEs.
Results: The mean age was 56.5±14.5 years and 222 patients (53.8%) were male. 
During a median follow-up of 50.8 months, 49 patients (11.9%) were dead and MACCEs 
were occurred in 55 patients (13.3%). Multivariate Cox regression analysis demonstrated 
that low TA-iPTH level was an independent risk factor for both overall mortality [group 
2 as reference; group 1, hazard ratio (HR)=2.08, 95% confidence interval (CI)=1.12-3.85, 
P=0.02] and MACCEs (HR=1.88, 95% CI=1.04-3.40, P=0.04) in incident dialysis patients 
after adjusting confounding factors.
Conclusions: This study demonstrates that low TA-iPTH is an independent risk factor 
for overall mortality and MACCEs in incident dialysis patients.
PUB533
Combined Analysis of Hypercalcemia and PTH Levels as Clue to Unveil 
Persistent Transplant Hyperparathyroidism  Melani Custodio,1,2 Maria Julia 
C. L. N. Araujo,1,2 Wagner Dominguez,1 Rosa M.A. Moyses,1,3 Elias David-Neto,1 
Vanda Jorgetti.1  1Nephrology Div, Univ de Sao Paulo; 2Transplant Unit, Univ 
de Sao Paulo; 3UNINOVE, Sao Paulo, Brazil.
Background: Mineral and bone metabolism disorders in chronic kidney disease 
(CKD-MBD) are not always corrected after kidney transplantation (TxR). The persistence 
of hyperparathyroidism may have a negative impact on patient and graft outcome. 
Our objective was to evaluate the evolution off CKD-MBD and the incidence of 
hyperparathyroidism after 12 months of TxR.
Methods: In this study, we included all consecutive patients submitted to a TxR during 
the period between Jan 2010 and Dec 2014 in a University based center. We excluded 
patients with a PTH <300 pg/ml before TxR, multi-organ transplants, patients with an 
eGFR<30mL/min and those who underwent parathyroidectomy after TxR. Twelve-month 
eGFR, plasma levels of total calcium (Ca), phosphorus (P), alkaline phosphatase (AlkP), 
magnesium (Mg), parathormone (PTH), and 25-hydroxi vitamin D (25-OH vit D) were 
compared to baseline values. A PTH >100pg/mL and a total calcium >10.2mg/dL were 
considered abnormal. We defined high PTH, with or without hypercalcemia as the primary 
endpoints for the analysis.
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Results: During the observation period, 408 patients were evaluated. There was a 
significant increase in eGFR and in calcium levels 12 months after the TxR. Compared to 
the baseline, PTH, AlkP, and P significantly decreased. 25-OH Vit D did not change during 
the period. Fifteen percent of patients presented both PTH and Ca above the reference levels, 
while 37% presented isolated high PTH and 8% hypercalcemia only. Multivariate analysis 
disclosed that post-TxR hyperparathyroidism was dependent on pre-transplant PTH (OR 
1.001; CI 95%: 1.001-1.002) and Ca (OR 1.233; CI 95%: 1.036-1.468).
Conclusions: Monitoring Ca and PTH before and after TxR may be important to detect 
patients at high risk of persistent hyperparathyroidism, and to identify patients in need of 
treatment to prevent its complications.
PUB534
Predictors of FGF23 and Soluble Klotho in HIV Infection  Ruibin Wang,1 
Michael Shlipak,2 Joachim H. Ix,3 Michelle M. Estrella.1  1Johns Hopkins Univ; 
2UCSF; 3UCSD.
Background: In the general population, FGF23 and its co-receptor, soluble klotho 
(sKlotho), have been implicated in the aging process. HIV+ individuals are at higher risk 
of age-related comorbidities compared with HIV- persons. We evaluated whether FGF23 
and sKlotho levels differed by HIV status and determined clinical factors associated with 
each hormone in HIV+ men.
Methods: 384 HIV+ and 225 HIV- men in the Multicenter AIDS Cohort Study (MACS) 
were randomly selected for FGF23 and sKlotho measurements from samples stored in 
2008-2010. We compared FGF23 and sKlotho levels by HIV status, adjusted for age and 
race. Multivariable linear regression models were used to determine predictors of FGF23 
and sKlotho levels among HIV+ men.
Results: Mean age was 53y; 34% were black; and median eGFR was 90mL/min. 
99% of HIV+ men were antiretroviral-treated. FGF23 and sKlotho were not significantly 
correlated (r=-0.09). In adjusted analyses, HIV was associated with 11% (p=0.002) higher 
sKlotho but not FGF23 levels (-1%; p=0.84). Among HIV+ men, diabetes was associated 
with 30% (95% CI: 3-65%) higher FGF23, whereas HCV (-34%; 95% CI: -14%, -49%) 
and cumulative tenofovir (TDF) exposure (-4%/year; 95% CI: -1%, -7%) were associated 
with lower FGF23 levels. In contrast, only HCV was associated with higher sKlotho (21%; 
95% CI: 7%, 36%). [Figure] Neither CD4 count nor HIV RNA were associated with FGF23 
or sKlotho concentrations. 
Conclusions: HIV+ individuals had similar FGF23 but higher sKlotho levels compared 
to HIV- counterparts. Among HIV+ men, clinical predictors associated with FGF23 differed 
from those associated with sKlotho. Mechanisms by which HIV treatment and co-morbid 
conditions may impact these hormone levels need further study.
Funding: NIDDK Support, Other NIH Support - NIAID, NCI, NHLBI, NIDCD
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Response of Fibroblast Growth Factor 23 to Sodium Interventions in 
Diabetic Nephropathy and Arterial Hypertension  Jelmer K. Humalda,1 
Sarah Seiler,2 Arjan J. Kwakernaak,1 Marc G. Vervloet,3 Gerjan Navis,1 Gunnar 
H. Heine,2 Martin H. De Borst.1  1Nephrology, Univ Medical Center Groningen, 
Groningen, Netherlands; 2Nephrology and Hypertension, Saarland Univ Medical 
Center, Homburg, Germany; 3Nephrology, VU Medical Center, for NiGrAm, 
Amsterdam, Netherlands.
Background: Fibroblast growth factor 23 (FGF23) rises progressively in chronic 
kidney disease (CKD) and is associated with adverse cardiorenal outcomes. Both CKD 
patients with diabetic nephropathy (DN) and patients with hypertension are vulnerable to 
the effect of excess sodium on volume status. FGF23 putatively induces sodium retention 
by up-regulating the sodium-chloride cotransporter (NCC). We studied whether, conversely, 
intervention in sodium status affects FGF23 levels.
Methods: We performed a post-hoc analysis of a randomized controlled 2x2 cross-
over trial in 45 DN patients on background ACE-inhibition (ACEi) with four 6-week 
treatment periods with add-on hydrochlorothiazide (HCT) or placebo, combined with 
regular (RS) or low sodium (LS) diet. Plasma C-terminal FGF23 was measured by ELISA 
(Immutopics). Additionally, FGF23 was measured in 12 patients with arterial hypertension 
but without overt CKD before and after 4 hours of intravenous administration of 2 liters 
sodium-chloride 0.9%. Changes in FGF23 were assessed by Friedman’s test and Wilcoxon 
Signed Rank test as appropriate.
Results: DN patients were 65±9 years old (mean±SD). During ACEi+RS eGFR 
was 65±25 mL/min/1.73m², HbA1c 7.1±0.8% and albuminuria 649 mg/d median [1st-
3rd quartile: 230-2008 mg/d]. FGF23 levels were 94 [73–141] RU/mL . FGF23 did not 
change significantly after adding either HCT (99 [74–148] RU/mL) or low sodium diet 
(99[75–135 RU/mL]) or both HCT and low sodium diet (111 [81–160] RU/mL), P=0.15. 
The patients with arterial hypertension were 45±13 years old with an eGFR of 101±18 
mL/min/1.73m². Sodium-chloride infusion did not affect FGF23 (before: 68 [58–97] RU/
mL, after: 67 [57–77] RU/mL, P=0.4).
Conclusions: Chronic and acute changes in sodium status did not materially change 
FGF23 in DN and hypertensive patients, respectively. Our data thus do not support a direct 
feedback loop between volume status and FGF23 in diabetic nephropathy or hypertension.
PUB536
Hypocalcaemia Management Post Parathyroidectomy in Renal Patients – 
Our Experience and Change in Practice  Rajkumar Chinnadurai, Maharajan 
Raman, Constantina Chrysochou, Smeeta Sinha.  Dept of Renal Medicine, 
Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Background: Hypocalcaemia is common post parathyroidectomy in renal patients with 
secondary hyperparathyroidism due to hungry bone syndrome with an incidence as high 
as 51%. Hypocalcaemia can be prevented by effectively preloading patient with Vitamin 
D supplements and close monitoring of calcium levels post operatively. Currently there is 
no clear guidance on the preloading dose of One-alphacalcidol in literature. Our current 
practice is to preload all patients with 2 mcg one-alphacalcidol for 5 days pre operatively. 
Our aim was to study the management of hypocalcemia post parathyroidectomy in renal 
patients and factors influencing length of hospital stay (LOS). To identify if any changes 
in current practice could improve outcome.
Methods: Retrospective observational study of all renal patients who underwent 
parathyroidectomy under a single surgeon over 6 years (April 2008 to September 2014).
Data was collected from the Electronic Patient Record. Data were analysed using Stats 
direct and Fisher Exact test was used for testing statistical significance.
Results: 72% of our sample (n = 25) were male with a mean age of 54.Of the 25 
there were 13 transplant, 9 haemodialysis and 3 CKD patients. The mean hospital stay 
was 5 days shorter than quoted in the literature (5.6 Days). 3 of 25 patients were not 
preloaded.40% of our patients needed intravenous calcium replacements which was the 
main cause for increased LOS (p=0.0002). Haemodialysis patients had longer LOS than 
CKD and Transplant patients(p=0.0002), this group were more likely to not have received 
pre-loading. Those undergoing total parathyroidectomy had increased LOS compared to 
subtotal parathyroidectomy (p=0.0009). There were no surgical complications contributing 
to a delay in discharge.
Conclusions: Insufficient preloading was identified as a major risk factor for 
hypocalcaemia,which significantly increased LOS. Further to consensus between renal 
and surgical teams we have increased the preloading dose of one-alphacalcidol to 5 mcg 
for 5 days pre operatively. A follow up study is planned in 12 months to observe the 
outcome of this change.
PUB537
Links Between Urinary Phosphate Handling, FGF23 and Klotho: An 
Australian Single-Centre Cross-Sectional Study  Sven-Jean Tan,1,2 Edward 
Robert Smith,1 Stephen G. Holt,1,2 Tim Hewitson,1,2 Nigel David Toussaint.1,2 
1Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; 
2Medicine (RMH), The Univ of Melbourne, Melbourne, Victoria, Australia.
Background: Aim: To examine the links between measured phosphate parameters 
and regulators of phosphate homeostasis (fibroblast growth factor-23 [FGF23] and soluble 
α-klotho [sKl]). Background: FGF23, via the FGF-Receptor/Klotho complex, reduces 
expression of sodium-phosphate co-transporters thereby inhibiting tubular phosphate 
reabsorption. Chronic kidney disease (CKD) leads to FGF23 excess and deficiency of 
sKl. Elevated serum phosphate (sPi) results as remaining functioning nephrons are unable 
to compensate for reduction in total phosphate excretion. Complex relationships between 
these parameters in health and disease, and the impact on phosphate handling, are not 
fully understood.
Methods: Blood samples and spot and 24-hour urine were collected from patients with 
CKD (Stages 1-5) and healthy volunteers. Serum and urine biochemistry, intact FGF23 
and sKl were analysed. FGF-23 and sKl were log-transformed (Ln). Fractional excretion 
of phosphate (FEPi) and maximal tubular phosphate reabsorption (TmP) were calculated. 
Pearson correlation coefficients were used to assess correlation between phosphate handling 
and regulatory hormones.
Results: 116 participants (77 CKD and 39 controls) were recruited. 74 (63.8%) 
were male. Median (IQR) age of all participants was 61 (49-71) years. FGF23 and FEPi 
were higher, while sKl and TmP were lower, in CKD compared to controls (all p<0.005). 
Adjusting for eGFR, LnFGF23 correlated with FEPi (R=0.222, p=0.026) and sPi (R=0.268, 
p=0.007) while LnKlotho displayed robust relationships with TmP (R=0.336, p=0.001) 
and sPi (R=0.309, p=0.002). There was no association between LnFGF23 and LnKlotho.
Conclusions: Disruption of phosphate regulatory mechanisms is characteristic of 
CKD. In this small cohort, we established that FGF23 contributes to phosphate excretion. 
However, sKl may provide insight into a greater physiological role of Klotho in regulating 
TmP at a cellular level. Causal relationships should be explored further in vitro.
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Fibroblast Growth Factor 23 Can Predict the Progress of Aortic Artery 
Calcification in Dialysis Patients  Zijin Chen,1 Xiaonong Chen,1 Xiaobo 
Ma,1 Bei Ding,2 Huawei Ling,2 Nan Chen.1  1Nephrology, Ruijin Hospital, 
Shanghai Jiaotong Univ School of Medicine, Shanghai, China; 2Radiology, 
Ruijin Hospital, Shanghai Jiaotong Univ School of Medicine, Shanghai, China.
Background: To investigate the factors associated with progress of aortic artery 
calcification in maintenance haemodialysis (MHD) patients and to determine whether 
plasma FGF23 level is related to progress of aortic artery calcification.
Methods: MHD patients from Ruijin Hospital from July 1st 2011 to July 31th 2011 
were involved in our study. Follow up 36 months. Aortic artery calcification (AAC) was 
detected by a lateral lumbar X-ray plain and read by two radiologists.
Results: 120 MHD patients were enrolled and followed up for 36 months. To July 
2014, a total of 67 MHD patients finished the study. Among 67 patients, 32 were male, 
mean age 53.9±13.1 years old, mean dialysis vintage 44.1±38.1 months, median FGF23 
level 48052 (11372-35750.4)Ru/ml, LgFGF23 3.79±0.83. In July 2011, 53.7% of patients 
had visible calcification in the abdominal aorta and mean involved segment was 1.42 
with mean AAC scores(AACS) 3.96. In July 2014, 73.1% had AAC and mean involved 
segment was 2.34 with mean AACS 10.7. There are significant differences between two 
AAC involved segments and AACS (both P<0.001). Age, dialysis vintage and FGF23 
level had significant difference between AAC progress group and no AAC progress group 
(P = 0.007, <0.001 and 0.020, separately). Logistic analysis showed that the independent 
parameters associated with AAC progress were age (OR=1.114, CI:1.045-1.186) and Lg 
FGF23 (OR=3.848, CI:1.429-10.346) (P<0.001).
Conclusions: The severity of vascular calcification progress yearly in maintain 
heamodialysis patients. Age and FGF23 are independently associated with the progress of 
AAC. FGF23 level could predict the progress of AAC in MHD patients.
Funding: Government Support - Non-U.S.
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Could FGF23 Be a Regulator of Hepcidin in Liver Cells?  Justine Bacchetta, 
Nathalie Demoncheaux, David Durantel.  Hospices Civils de Lyon and INSERM, 
Univ Claude Bernard Lyon 1, Lyon, France.
Background: Hepcidin is a 25-amino-acid protein synthesized in hepatocytes and 
macrophages that acts as a post-translational inhibitor of ferroportin, the only receptor 
known to export iron from intracellular compartments to systemic circulation. Thus, higher 
hepcidin levels are associated with greater intracellular sequestration of iron, and increased 
risk of anemia. Vitamin D is an inhibitor of hepcidin expression; the working hypothesis 
is that FGF23 could be an ‘inverse’ regulator of iron metabolism in comparison to vitamin 
D, with a stimulation of hepcidin expression, an increase of intracellular ferritin and an 
inhibition of ferroportin expression on the cell membrane, leading to a further intracellular 
sequestration of iron.
Methods: Three different types of liver cells were used: HepG2, HepaRG and primary 
human hepatocytes (PHH). Cells were exposed to FGF23 (1, 10 et 100ng/mL), at different 
time points (H6, H24, H48). Cultures were performed in triplicates, and QRT-PCR in 
duplicates (StepOne Plus Real-Time PCR). Western Blots were also performed (Erk and 
Akt phosphorylation pathways, FGFR1, FGFR3, ferritin).
Results: In HepG2, even though FGFR-1 expression was found by Western blot 
analysis, FGF23 did not modify hepcidin expression by QRT-PCR, and Erk/Akt pathways 
were not activated by FGF23. In HepaRG cells, hepcidin expression was modified with 
FGF23 by QRT-PCR, i.e. increased at 6 hours and decreased at 24 hours, 
Fold change of hepcidin 
mRNA expression in 
comparison to PBS 
FGF23, 1 ng/mL FGF23, 10 ng/mL FGF23, 100 ng/mL
6 hours 1.34±0.22 * 1.53±0.18 * 1.17±0.01*
24 hours 0.68±0.12 * 0.73±0.08* 0.90±0.04
* p<0.05; Western blot analyses demonstrated the presence of FGFR1 and FGFR3, 
with an activation of the Erk pathway at 30 and 60 minutes with FGF23. However, there 
was no modification of ferritin by Western blots analysis with FGF23. In the only batch of 
PHH that was available, hepcidin expression increased at 6 and 24 hours.
Conclusions: FGF23 does not appear to play a crucial role in iron regulation in liver 
cells, even though its potential role in PHH deserves further studies.
Funding: Private Foundation Support
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Prevalence of Hyperparathyroidism and Its Correlates in a Large Cohort 
of Hemodialysis Patients  Pasquale Esposito,1 Fabio Malberti,2 Elena 
Caramella,1 Marta Calatroni,1 Edoardo La Porta,1 Marina Foramitti,2 Rosanna 
Coppo,3 Antonio Dal Canton.1  1Nephrology, Fondazione IRCCS, Pavia, Italy; 
2Nephrology, Istituti Ospitalieri di Cremona, Cremona, Italy; 3Nephrology, 
Regina Margherita Children’s Hospital, Turin, Italy.
Background: Beyond experimental setting of randomized trials, little is known 
about the occurrence of mineral bone disorders (MBD) in the real-life clinical practice of 
hemodialysis (HD). This is the reason why we designed this observational study to define the 
prevalence of hyperparathyroidism (HPT) and its correlates in a large cohort of HD patients.
Methods: We enrolled HD prevalent patients from 38 Dialysis Units collecting data 
on: clinical information, dialysis parameters, biochemical and instrumental evaluations 
and pharmacological therapy. According to the KDIGO guidelines we divided the patients 
in: patients affected by HPT (i.e. PTH> 9 the upper reference limit of each laboratory) vs 
patients on target.
Results: Out of 495 patients, 34 (6.8%- 59.9±15.5 years, 53%M) presented HPT with 
mean PTH of 1064±536 pg/ml, while 461 patients resulted OT (93.2%- 66.9±13.7 years, 
66%M), mean PTH 242±151 pg/ml (p<0.0001). HPTs were younger than OT (59.9±15 vs 
69.9±13.7 years, p=0.008), with a longer HD history (126.2±125 vs 64.3±69.4 months, 
p=0.0003). There were not significant differences in both clinical and dialysis parameters. 
Similarly, there were not differences in laboratory examination except from serum ALP that 
resulted higher in HPTs (194.8±142 vs 144.1±108 U/l OT, p=0.01). Moreover, there were 
not differences in the use of phosphate binders, whereas a significantly higher percentage 
of HPTs was taking paracalcitol and calcimetics and the prescribed vitamin D doses (both 
as calcitriol and paracalcitol) were significantly higher in HPT patients.
Conclusions: The prevalence of HPT in our population was surprisingly lower, 
compared to that reported in previous studies. This finding could be due to the general 
application of KDIGO guidelines, which recommend more permissive PTH levels compared 
with the previous K-DOQI guidelines, such as to the availability of effective drugs, probably 
used more appropriately than in the past.
PUB541
Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: 
A Meta-Analysis and Systematic Review  Qian Zhang, Jing Chen.  Div of 
Nephrology, Huashan Hospital, Fudan Univ, Shanghai, China.
Background: Vitamin D receptor activators (VDRAs) can protect against mineral 
bone disease, but they may also elevate serum creatinine and reduce glomerular filtration 
rate (GFR).
Methods: We conducted a systematic review and meta-analysis of randomized 
clinical trials (RCTs) to evaluate the effect of VDRAs on kidney function and adverse 
events. MEDLINE, EMBASE, the Cochrane Controlled Trials Register were searched for 
RCTs that evaluate vitamin D receptor activators (alfacalcidol, calcitriol, doxercalciferol, 
falecalcitriol, maxacalcitol and paricalcitol) up to March 2015.
Results: We included 31 studies, all of which were performed between 1976 and 2015, 
which enrolled 2621 patients. Patients receiving VDRAs had lower eGFR (weighted mean 
difference WMD -1.29 mL/min /1.73 m2, 95% CI -2.42– -0.17) and elevated serum creatinine 
(WMD 7.03 µmol/L, 95% CI 0.61–13.46) in sensitivity analysis excluding studies with 
dropout rate more than 30%. The VDRAs and control groups had no significant differences 
in all-cause mortality (relative risk RR 1.41, 95% CI 0.58–3.80), cardiovascular disease 
(RR 0.84, 95% CI 0.42–1.71), and severe adverse events (RR 1.15, 95% CI 0.75–1.77). 
Episodes of hypercalcemia (RR 3.29, 95% CI 2.02–5.38) were more common in the VDRAs 
group than in the control group.
Conclusions: Although administration of VDRAs slightly reduced the eGFR, all-cause 
mortality and severe adverse events were comparable between the groups. Future RCTs 
with larger sample sizes are needed to assess whether the mild reduction of eGFR is of 
clinical significance.
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Low Dose Cholecalciferol Supplementation on Serum Inflammatory 
Markers in Hemodialysis Patients with Hypovitaminosis D  Yeon Joo Lee,1 
Insun Kim,1 Eunyoung Lee,2 Joo-Hark Yi,2 Hee Joon Baek,3 Sang-Woong Han,2 
Sang sun Lee.1  1Food and Nutrition, Hanyang Univ, Seoul, Korea; 2Internal 
Medicine, Hanyang Univ Guri Hospital, Guri, Korea; 3Nutirtion, Hanyang Univ 
Seoul Hospital, Seoul, Korea.
Background: Vitamin D deficiency is common in hemodialysis(HD) patients and 
has been reported to be associated with mortality due to cardiovascular disease and an 
inflammatory response. The aim of this study was to investigate the hypothesis that low 
dose cholecalciferol supplementation improves serum 25(OH)D and 1,25(OH)2D levels, 
and reduces inflammatory markers. Moreover, it was to analyze the association of FGF-23 
and 25(OH)D levels.
Methods: This study was an one-year intervention study for hemodialysis patients 
with hypovitaminosis D (25(OH)D<30 ng/mL). During the first six months, the patients 
received 3,000 IU of cholecalciferol after each hemodialysis (9,000 IU/week), thereafter, 
they stopped taking supplements. Serum levels of 25(OH)D, 1,25(OH)2D, and other 
biological variables were measured every 3 months for one year. We investigated the 
effects of cholecalciferol supplementation on the biological variables and inflammatory 
markers. In addition, the effective factors on the levels of 25(OH)D and 1,25(OH)2D after 
cholecalciferol supplementation were assessed by multivariate regression analysis.
Results: Twenty-nine patients with hypovitaminosis D participated in our study. During 
cholecalciferol supplementation, the 25(OH)D and 1,25(OH)2D concentration significantly 
increased from baseline to six months [9.9 to 34.3 ng/mL (p<0.001) and 19.7 to 22.9 pg/
mL (p<0.05), respectively]. At 6 months, 65.5% of the patients had 25(OH)D levels within 
the target range [³30 ng/mL] with a low dose of cholecalciferol supplementation. Also 
serum calcium and phosphorus levels did not increase above the normal range. However, 
the inflammation markers, hsCRP, e-selectin, VEGF-A, were not shown significant 
improvements after taking cholecalciferol supplements. The effective factors on serum 
25(OH)D levels were BMI, baseline 1,25(OH)2D and 6 months FGF-23 concentration by 
multivariate regression analysis.
Conclusions: The low dose cholecalciferol supplementation was effective in correcting 
serum vitamin D deficiency or insufficiency and safe for hemodialysis patients. However, 
6 months of low dose cholecalciferol supplementation in these patients did not improve 
the levels of inflammatory markers.
Funding: Government Support - Non-U.S.
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The Effects of sKlotho on Left Ventricular Mass and Echocardiographic 
Changes in Patients with Chronic Kidney Disease  Marc-Sebastian Baier,1 
Lucie Bauer,1 Franziska Sandermann,1 Insa E. Emrich,1 Kathrin Untersteller,1 
Sarah Seiler,1 Vincent Brandenburg,2 Danilo Fliser,1 Gunnar H. Heine.1  1Internal 
Medicine IV - Nephrology and Hypertension, Saarland Univ Medical Center and 
Saarland Univ Faculty of Medicine, Homburg, Saarland, Germany; 2Dept of 
Internal Medicine I – Cardiology, Univ Hospital of the RWTH Aachen, Aachen, 
Nordrhein-Westfalen, Germany.
Background: Recently experimental data suggest that elevated circulating levels of 
soluble Klotho (sKlotho), which is the beyond FGF-23, may directly induce myocardial 
damage. In our prospective CARE FOR HOMe study we analyzed the effect of 
serum sKlotho levels on patients with left ventricular hypertrophy at baseline and on 
echocardiographic changes during five years of follow-up.
Methods: The ongoing CARE FOR HOMe study recruits chronic kidney disease 
G2-G4 patients. At baseline serum FGF-23 (c-terminal; Immuntopics; San Clemente; 
CA) and serum sKlotho (Immuno-Biologic Laboratories, Fujiokashi, Gunma, Japan) 
were measured in all patients. Cardiovascular and renal risk factors were evaluated by 
a questionnaire. The present analysis includes 398 patients with an echocardiography at 
baseline. 94 patients received an echocardiography after five years of follow-up according 
the American Society of Echocardiography guidelines. Moreover the echocardiography 
was done by one physician.
Results: At baseline 155 patients (40%) had a normal ventricular geometry, 134 patients 
(34%) had an apparently concentric remodelling, 61 patients (16%) had a concentric 
hypertrophy and 39 patients (10%) had an excentric hypertrophy. At the beginning of our 
study, left ventricular mass (LVMI) correlated with the following parameters: glomerula 
filtration rate (eGFR; r = -0.19; p < 0.001), serum FGF-23 (r = 0.18; p < 0.001), age (r = 
0.18; p < 0.001) and pulse pressure (r = 0.15; p < 0.001). LVMI was not correlated with 
sKlotho (r = -0.07; p = 0.183) and mean blood pressure (r = 0.10; p = 0.052).
Conclusions: In contrast to recent animal data our results show neither an association 
of sKlotho with prevalent left ventricular hypertrophy nor with LVMI changes in patients 
with chronic kidney disease.
PUB544
Cost-Minimization Analysis of Sucroferric Oxhydroxide and Sevelamer 
Carbonate in Patients on Dialysis with Secondary Hyperparathyroidism 
in Germany  Joris Van Stiphout,1 Matthias Schwenkglenks,1 Peter Braunhofer,2 
Thomas Szucs,1 Viatcheslav Rakov,2 Patricia R. Blank.1  1Univ of Basel, European 
Center of Pharmaceutical Medicine, Univ of Basel, Basel, Switzerland; 2Vifor 
Pharma, Glattbrug, Zurich, Switzerland.
Background: Many patients with chronic kidney disease (CKD) on dialysis require 
vitamin D (Vit.D) agents for managing secondary hyperparathyroidism (SHPT). It has 
been shown that the concomitant administration of oral phosphate binders (sucroferric 
oxhydroxide, SFOH or sevelamer carbonate, SEV) and Vit.D therapies might impair 
the therapeutic effect of the Vit.D due to drug-drug interaction. Based on clinical trials 
(NCT01324128/ NCT01464190), this cost-minimization analysis assessed the economic 
impact of using SFOH compared to SEV treatment with Vit.D agents from a German 
third-party payer perspective.
Methods: Costs of patients with serum phosphate concentrations ≥6.0 mg/dL receiving 
either SFOH (1.5g/day [3 tablets/day]) or SEV (6.4g/day [8 tablets/day]) were assessed. 
Due to lack of interaction, it was assumed that patients on SFOH were treated exclusively 
with oral Vit.D (calcitriol, 0.28mg/day), whereas SEV patients received intra-venous 
Vit.D agents (paricalcitol, 1.84mg/day). Costs for the administration of paricalcitol and 
for adverse events were not included.Drug acquisition costs were calculated on the basis 
of the German standard pharmacy prices (Rote Liste 2015). Uncertainties were addressed 
in one-way sensitivity analyses.
Results: Over an observation period of one year, costs for SFOH or SEV resulted in 
EUR3’416 or EUR 3’592, respectively. Annual Vit.D therapy costs yielded in EUR 209 
for calcitriol and EUR 3’306 for paricalcitol, respectively. SFOH treatment with calcitriol 
versus SEV with paricalcitol resulted in an annual cost-saving of EUR 3’273 per patient. 
The variation of drug prices by ±25% did not change the conclusion of the base-case.
Conclusions: This study provide evidence that SFOH treatment with calcitriol has an 
economic benefit compared to SEV with paricalcitol to treat German CKD patients with 
SHPT.Economicsavings might be substantial for the German health care system, but real 
world data will be needed to confirm these findings.
Funding: Pharmaceutical Company Support - Vifor Pharma. Research funding by 
Vifor Pharma via employment institution.
PUB545
Effect of Intravenous Saccharated Ferric Oxide on FGF23 Metabolism 
in Dialysis Patients  Masahiro Koizumi,1 Hirotaka Komaba,1 Yoko Takeda,2 
Masafumi Fukagawa.1  1Div of Nephrology, Endocrinology and Metabolism, 
Tokai Univ School of Medicine, Isehara, Kanagawa, Japan; 2Div of Nephrology 
and Kidney Center, Kobe Univ Graduate School of Medicine.
Background: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone, 
secreted from the bone. It has been well known that the reduction in serum phosphate 
occurs following intravenous administration of saccharated ferric oxide. A recent clinical 
study showed that both production and degradation of FGF23 is enhanced in the setting 
of iron deficiency (M Wolf. J Bone Miner Res 2013). These findings suggest that iron may 
be a key regulator of FGF23. However, its precise mechanism remains to be elucidated.
Methods: We previously reported that intravenous saccharated ferric oxide further 
increase in elevated serum FGF23 levels in hemodialysis patients with iron deficiency 
anemia, using the intact FGF23 assay that only detects the full-length protein (Am J Nephrol 
2011). In this study, we additionally examined the FGF23 levels by the C-terminal FGF 23 
assay which detects both the full-length protein and C-terminal fragments, and compared 
the results of these two assays (N = 27).
Results: We previously reported that intravenous saccharated ferric oxide further 
increase in elevated serum FGF23 levels in hemodialysis patients with iron deficiency 
anemia, using the intact FGF23 assay that only detects the full-length protein (Am J Nephrol 
2011). In this study, we additionally examined the FGF23 levels by the C-terminal FGF 23 
assay which detects both the full-length protein and C-terminal fragments, and compared 
the results of these two assays (N = 27).
Conclusions: Collectively, in hemodialysis patients with iron deficiency anemia, 
substantial amounts of C-terminal fragments of FGF23 accumulate by increase in both the 
production and the degradation. The administration of saccharated ferric oxide suppresses 
both the production and degradation, leading to increase in values by Intact FGF23 assay 
and decrease in those by C-terminal assay. Specific preparations of iron for intravenous 
use may regulate both the production and degradation of FGF23.
PUB546
Serum Levels of Sclerostin (SOST) in Renal Transplantation (Tx) 
Marzia Pasquali, Lida Tartaglione, Silverio Rotondi, Maria luisa Muci, Sandro 
Mazzaferro.  Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and 
Geriatric Sciences, Sapienza Univ, Rome, Italy.
Background: SOST, by inhibiting the Wnt pathway, suppresses osteoblasts activity 
and stimulates their apoptosis. Recent evidence has shown a role of SOST in alterations 
of bone metabolism in CKD. In CKD patients SOST serum levels are higher than in the 
general population and in HD patients SOST correlate negatively with histomorphometric 
parameters of bone turnover. Little is known about serum levels of SOST in Tx. Aim of our 
study was to evaluate serum SOST levels in Tx in whom few data are available.
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Methods: We performed a cross sectional study in 80 Tx (55±10 y.o.;49M/31W) with 
CKD stage 2-4 (eGFR 47±16 ml/min). 30 healthy subjects (34±12y.o.;eGFR95±19 ml/
min) were the control group. We evaluated in all patients SOST, Ca, Pi, PTH, FGF23 and 
Alkaline Phosphatase (AP).
Results: SOST was not different between Tx and controls (27,6±10,3vs31,0±6,0 pmol/l, 
p: n.s).The table shows the mean values of the parameters evaluated With mild vitamin D 
insufficiency (25D:26±11ng/ml), TX had normal 1,25D values, mild increment of PTH 
and Ca, and normal values of P. 
Sclerostin, 
pmol/l Cas, mg/dl
Ps, mg/
dl
A.P, U/l 
(80-
275)
PTH, 
pg/ml
25D, ng/
ml
1,25D, 
pg/ml
FGF23, 
pg/ml
27.6± 10.3 10.1± 0.8 3.0± 0.7 178± 65 59± 51 26± 11 42± 15 47.3± 28.8
Serum levels of FGF23 were increased compared to controls (47,3±28,8 vs 30,0±19,0 
pg/ml, p<.05). SOST showed a negative correlation with AP (r=-.375; p<.05) and a positive 
correlation with FGF23 (r=.236; p<.05) and 25D (r=.238; p<.05). No correlation existed 
with others parameters
Conclusions: eGFR does not seem to affect serum levels of SOST in Tx. The negative 
correlation whit AP indicates that SOST maintains its modulatory role of osteoblastic activity 
in this population. The correlation with FGF23, which is in agreement with low FGF23 in 
SOST null mice, suggests modulatory effects of both proteins on osteoblasts: direct, through 
Wnt inhibition, for SOST; indirect, through effects on 1,25D levels, for FGF23. Serum 
SOST may be an additional marker of bone metabolism, useful to understand metabolic 
pathways in normal subjects and in CRF.
PUB547
Comparison of Cholecalciferol Supplementation Dosing with a Bolus 
Dose Versus Daily Administration in Chronic Hemodialysis Patients 
Pablo Molina, Belen Vizcaino, Mercedes Gonzalez Moya, Sandra Beltrán, Marco 
Montomoli, Cristina Castro, Jose L. Gorriz, Luis M. Pallardo.  Nephrology, Dr 
Peset Univ Hospital, Valencia, Spain.
Background: The aims of this study were to assess the safety profile of bolus 
cholecalciferol supplementation and compare its effectiveness to daily oral administration 
in hemodialysis (HD) patients.
Methods: This 6-month prospective, intervention study enrolled 60 stable HD patients 
with 25-hydroxyvitamin D [25(OH)D levels] <30ng/ml, who received cholecalciferol 
25,000 IU once or twice monthly (n=30) or 700 IU daily (n=30). Differences in biochemical 
parameters, including 25(OH)D, calcium, phosphorous, parathyroid hormone(PTH), 
alkaline phosphatase and C-reactive protein levels, were analyzed monthly. Primary 
outcome was 25OH(D) level at 6 months. For safety purposes, in the subgroup of patients 
receiving the bolus regimen, biochemical parameters were also assessed on days 2,4 and 
7 after the first bolus dose.
Results: At baseline, patient and biochemical characteristics were similar in both 
groups. No changes were observed in calcium, phosphorus and 25OH(D) levels in the first 
week after the first bolus dose. Throughout the 6-month follow-up, similar responses in 
25OH(D) levels and other biochemical parameters were observed in both groups.
Parameter
Fortnightly 25,000 IU 
cholecalciferol (n=30)
Daily 700 IU cholecalciferol 
(n=30)
p-value 
between  
groups 
at month 
6
Baseline Month 6 Pre-post  p-value
Base-
line
Month 
6
Pre-post  
p-value
25(OH)D (ng/ml) 10.5 ± 6.5
22.0 ± 
6.5 <0.001
11.4 ± 
5.2
24.8 ± 
10.0 <0.001 0.195
25(OH)D status 
(n,%) 
Sufficiency 
(≥20ng/ml) 
Deficiency 
(<10ng/ml)
 
4 (13%) 
15 (50%) 
 
18 (60%) 
30 
(100%)
 
0.001 
<0.001
 
4 
(13%) 
13 
(43%)
 
20 
(67%) 
29 
(97%)
 
<0.001 
<0.001
 
0.395 
0.500
iPTH (pg/ml)
257 
(128-
318)
281 
(151-
354)
0.107
193 
(130-
266)
187 
(132-
315)
0.778 0.176
Caalb (mg/dl) 9.1 ± 0.6 9.1 ± 0.5 0.571
9.0 ± 
0.6
8.9 ± 
0.6 0.943 0.199
Phosphorous 
(mg/dl) 4.0 ± 1.4 3.8 ± 1.2 0.465
4.0 ± 
1.3
3.8 ± 
0.6 0.031 0.417
Conclusions: Supplementation of 25,000 IU fortnightly or monthly oral cholecalciferol 
seems to be safe, being equally effective for raising 25(OH)D levels than 700 IU daily 
cholecalciferol administration.
PUB548
The Prevalence of Vitamin D Deficiency Among IgA Nephropathy: A 
Cross-Section Study from One Center  Minxia Li,1 Li Yuehong,1 Guangyan 
Cai,2 Xueying Cao,2 Xiang-Mei Chen.2  1Dept of Nephrology, Beijing Tsinghua 
Changgung Hospital   Medical Center, Tsinghua Univ, Beijing, China; 2Dept of 
Nephrology, Chinese PLA General Hospital, Chinese PLA Inst of Nephrology, 
State Key Laboratory of Kidney Diseases, National Clinical Research Center 
for Kidney Diseases, Beijing, China.
Background: Low serum vitamin D concentrations have been reported in chronic 
kidney disease (CKD). Very few studies concerns vitamin D deficiency of IgA nephrology 
(IgAN) in Chinese patients. Our aim is to assess the deficiency of serum 25(OH)D 
concentrations in patients with IgAN, and to explore the possible correlated factors 
contributing to Vitamin D deficiency.
Methods: 283 patients who were come from north China and were not receiving vitamin 
D supplementation were included in this study from February 2013 and April 2014. We 
collected blood samples to determine levels of Scr, BUN, UA, serum phosphate (P) and 
calcium (Ca), iPTH, albumin, as well as urinary excretion of creatinine, protein, P and Ca 
within 24h. Electrochemiluminescence immunoassay measured total 25-hydroxyvitamin 
D. Vitamin D deficiency should be defined as a 25(OH) D of < 15 ng/ml.
Results: All of the 283 patients, 25(OH)D concentration was 10.25±6.94 ng/ml. 
Only 18.82% of the patients had a circulating 25(OH) D level greater than 15ng/ml. The 
prevalence of deficiency(<15ng/ml) were 87.2%, 72.9%, 75.0%, 85.45%, 93.1%(P=0.000) 
at different CKD stages.All the 120 IgAN patients were divided into 4 groups according 
to eGFR. The prevalence of vitamin D deficiency were higher in CKD stage 1 and 
4-5(P=0.000), but there is no difference of average 25(OH) D concentration according 
to eGFR(P=0.059). The 25(OH)D concentration was higher in IgAN patients than MN 
and DN patients. But, 24UPR in IgAN patients was lower than MN and DN patients. In 
different age, gender, season, BMI or iPTH group, 25(OH)D levels were not affected, but 
25(OH)D level was lower in ³3.5g/24h group.
Conclusions: For the IgAN patients in north China, kidney function might be related 
to vitamin D deficiency, and 24UPR may play a very important role in maintaining 25(OH) 
D serum concentrations.
PUB549
Utility of Whole Exome Sequencing in the Diagnosis of a Family with 
Apparent Mineralocorticoid Excess  Ranjit Narayanan.  Nephrology, KMCT 
Medical College, Calicut, Kerala, India.
Background: Apparent Mineralocorticoid Excess (AME) is a rare familial disorder 
with hypertension, hypokalemia, metabolic alkalosis and low plasma renin and aldosterone 
due to mutations in the 11-β-hydroxysteroid dehydrogenase-2 (HSD11B2) gene. Five 
siblings of a third degree consanguineous family with unaffected parents were evaluated 
for hypertension of juvenile onset. They had varying degrees of hypokalemia, medullary 
nephrocalcinosis, concentric left ventricular hypertrophy and renal dysfunction. Plasma 
renin and aldosterone levels were low. Given the clinical picture and autosomal recessive 
inheritance pattern, a provisional diagnosis of AME was made. 24 hour urinary cortisol 
and cortisone estimation  was unavailable. We decided to confirm the diagnosis using next 
generation gene sequencing.
Methods: Whole blood was collected from the parents and the affected members 
after informed consent. 50 ng of the isolated high quality DNA was used to prepare library 
and exome capture. Sequencing was performed using v3 reagents to generate over 49.48 
million paired end reads of 101bp. The reads were aligned to the Human genome (hg19 
build, UCSC) and was further filtered for read duplicates, recalibrated and realignment 
was performed around well-annotated Indels from the 1000 genome project using GATK 
and Picard tools. Variations were called using the GATK Unified Genotyper and analysed 
using ANNOVAR and annotated ClinVar.
Results: Analysis revealed the presence of homozygous variation p.R337C in HSD11B2 
gene annotated to be pathogenic in ClinVar and predicted to be deleterious using PROVEAN 
in the affected siblings. The variant was further validated using Sanger sequencing of the 
amplicons, confirming the diagnosis. Both parents were heterozygous for the variation. This 
variation has been reported to be associated with the similar phenotype in two independent 
studies on native American populations.
Conclusions: A homozygous mutation (p.R337C variation) in the 11HSDB2 gene was 
demonstrated in the family using whole-exome sequencing. This is the first genetically 
characterized report of AME from Indian population. Our study underscores the utility of 
using next generation sequencing in the diagnosis of rare inherited diseases.
Funding: Government Support - Non-U.S.
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Genetics of Thrombotic Microangiopathies – The Viennese TMA 
Cohort  Christof Aigner,1 Martina M. Gaggl,1 Zoltan Prohaszka,2 Raute 
Sunder-Plassmann,3 Gere Sunder-Plassmann,1 Alice Schmidt.1  1Dept of 
Medicine III, Div of Nephrology and Dialysis, Medical Univ of Vienna, Vienna, 
Austria; 2IIIrd Dept of Internal Medicine, Research Laboratory, Semmelweis 
Univ, Budapest, Hungary; 3Dept of Laboratory Medicine, Laboratory for 
Molecular Diagnostics, Medical Univ of Vienna, Vienna, Austria.
Background: Thrombotic microangiopathies (TMA) classified as hemolytic uremic 
syndrome (HUS) are characterized by acute kidney injury (AKI), mechanical hemolysis 
and thrombocytopenia, caused by an excessively activated alternative pathway of the 
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complement system. This is a result of either genetic alterations within complement factors 
and regulatory proteins or secondary causes. The aim of this study was to systematically 
investigate our cohort of patients with TMA regarding genotype and triggers of disease 
episodes.
Methods: Data were analyzed by means of patient records: Demographic and laboratory 
data, results of kidney biopsies, results of genetic sequencing of complement regulatory 
proteins, CFB, thrombomodulin (THBD) and C3, and medical history for triggering 
factors were analyzed.
Results: Out of 92 patients with TMA we classified 30 as atypical HUS (aHUS), 1 
as typical HUS, and 61 as secondary HUS. At onset of disease patients with aHUS had 
a mean age of 25 years (range: 1-47), 20 were female (67%), and 13 (43%) were kidney 
transplant recipients. First presentation of 24 patients was AKI, 3 showed hemolysis, 
2 had pre-eclampsia and 1 HELLP-syndrome. Distinct triggering factors in 20 patients 
were: infection (n=10), pregnancy (n=5), hypertension (n=2), surgery, diarrhea and renal 
transplantation (each n=1). Thirteen and 3 showed a CFH-H3 and a MCPggaac risk 
haplotype, respectively; potentially disease-causing mutations were identified in 22 patients 
(7 CFH, 6 CD46, 5 CFI, 4 C3, 2 CFB, 1 THBD; 4 of them with more than 1 mutation); 7 
showed wild-types and no data existed for 1 patient.
Conclusions: In our cohort of TMA patients we identified 30 cases of aHUS. In 22 
patients (74%) we identified a mutation within genes of the complement regulatory proteins 
or C3, whereas 7 subjects showed wild-type sequences despite presenting with a classic 
phenotype of aHUS.
PUB551
Under-Diagnosis of Alport Syndrome in First-Degree Relatives of Affected 
Individuals  Clifford E. Kashtan,1,2 Theresa F. Cassidy,1,2 Michelle N. Rheault.1,2 
1Pediatrics, Univ of Minnesota, Minneapolis, MN; 2Alport Syndrome Treatments 
and Outcomes Registry (ASTOR).
Background: Alport syndrome (AS) is an important inherited cause of progressive renal 
disease. Hematuria, the cardinal feature of AS, is highly penetrant in affected individuals. 
Urinalysis is a sensitive method for detecting AS in relatives of AS patients. This report 
describes a cohort of at-risk individuals (first-degree relatives of known AS patients) who 
underwent a first urinalysis as part of a clinical trial feasibility study.
Methods: For a study entitled “Multi-center Controlled Clinical Trials in Alport 
Syndrome - A Feasibility Study” (R21 DK91480, Clinicaltrials.gov #NCT01696253) 
conducted during 2013-14, first morning urine collection kits were sent to 104 people 
registered with ASTOR who carried a diagnosis of AS or were first-degree relatives of 
people known to have AS. 45/104 participants (43%) had been classified as unknown 
because a urinalysis had not been performed previously.
Results: 17/45 unknowns did not return the urine kit. Of the 28 who returned a urine 
kit, 11 had hematuria and 17 had normal urinalyses. Of the 11 who were reclassified from 
unknown to affected, 6 were siblings of a known affected child, 3 were sons of a known 
affected mother and 2 were mothers of known affected children. 3/11 had microalbuminuria 
(urine microalbumin:creatinine ratio > 30 mg/g); none had overt proteinuria.
Conclusions: The results are consistent with the following conclusions: 1) it is not 
unusual for first-degree relatives of known AS patients to have never been screened by 
urinalysis; 2) screening of first-degree relatives of known AS patients frequently identifies 
affected individuals (39% [11/28] of those who returned urine kits) who may benefit from 
early intervention. Early initiation of ACE-inhibitor therapy appears to slow renal disease 
progression in AS (Gross et al, Kidney Int 2012). It is recommended that treatment be 
initiated in AS patients as soon as they develop overt proteinuria (Kashtan et al, Pediatr 
Nephrol 2013; Savige et al, JASN 2013). Screening urinalyses should be performed in 
all first-degree relatives of AS patients in order to identify those who are or may become 
candidates for treatment.
Funding: NIDDK Support
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Urinary Biomarkers (UBio) Predict Renal Damage in Primary 
Hyperoxaluria (PH)  Gauri Bhutani,1 Lisa E. Vaughan,2 Felicity T. Enders,2 
Samuel Edeh,1 Andrea G. Cogal,1 Nick Voskoboev,1 Dawn S. Milliner,1 John 
C. Lieske.1  1Nephrology, Mayo Clinic, Rochester, MN; 2Biostatistics, Mayo 
Clinic, Rochester, MN.
Background: PH often results in kidney stones and CKD/ESRD. We investigated 
diverse UBio for correlations with urinary chemistries (UChem) and as predictors of 
GFR decline.
Methods: UBio (Table1) were measured in biobanked urine from PH cases and healthy 
controls. Clinical details and outcomes for PH cases were obtained from the Rare Kidney 
Stone Consortium Registry, including 24 hour UChems oxalate (Uox), calcium (UCa), 
citrate (UCit) and calculated CaOx supersaturation (CaOx SS) and proximal tubular Ox 
(PTOx= (UOx* serum Cr* 4)/ UCr). Univariate and multivariate models were used to 
compare UBio with UChem and outcomes.
Results: Urine was available from 30 cases (114 samples) and 47 controls (47 samples). 
Significant correlations were present between UChem and UBio including: U RBP, NGAL, 
MCP1, L-FABP with U Ca; U MCP1, L-FABP with U CaOx SS; L-FABP, H-FABP with 
PTOx (all P<0.05). Compared to controls NGAL was increased and OPN decreased in 
PH cases. Both NGAL and OPN independently predicted subsequent eGFR (P<0.001). 
Log (n) of Cr-corrected 
Urinary Biomarker 
Cases v/s Controls eGFR prediction for cases (coefficient [95% CI; p-value])
Odds Ratio 
(95% CI)
P-value 
(c-statistic) Univariate Multivariate 
Retinol Binding Protein 
[RBP], ug/g 1.01 (0.62-1.64) .97 (0.47)
2.96 
(-1.16,7.08; 
0.16)
Clusterin, ug/g 0.63 (0.49-0.81) <.001 (0.68) 1.38(-0.41,3.16; 0.13)
Neutrophil Gelatinase-
Associated Lipocalin 
[NGAL], ug/g
4.70 (2.76-8.00) <.001 (0.90) 1.85 (0.3,3.4; 0.02)
2.94 
(1.47,4.41; 
<0.001)
8 isoprostane [8 IP], ng/g 3.33 (1.44-7.69) .005 (0.64) 2.93 (-2.01, 7.86; 0.25)
Monocyte Chemoattractant 
Protein [MCP1], ng/g 0.59 (0.40-0.87) .007 (0.61)
1.55 (-0.47, 
3.58; 0.13)
Liver-type fatty acid 
binding protein [L-FABP], 
ug/g
1.11 (0.69-1.81) .66 (0.57)
-3.53 
(-7.61,0.54; 
0.09)
Osteopontin [OPN], ug/g 0.38 (0.22-0.66) .001 (0.84) 2.20 (0.79,3.6; 0.002)
2.82 (1.25, 
4.40; <0.001)
Heart-type fatty chain 
binding protein [H-FABP], 
ng/g
0.33 (0.18-0.59) <.001 (0.74)
0.85 
(-3.13,4.83; 
0.68)
Conclusions: In PH, specific UBio correlate with UChem and provide renal prognostic 
information. These likely reflect ongoing intrarenal pathology.
Funding: Pharmaceutical Company Support - OxThera
PUB553
Whole Exome Sequencing Identifies Advillin Mutation as a Novel Single-
Gene Cause of Nephrotic Syndrome  Jia Rao,1 Shazia Ashraf,1 Svjetlana 
Lovric,1 Weizhen Tan,1 Merlin Airik,1 Eugen Widmeier,1 Heon Yung Gee,1 
Richard P. Lifton,3,4 Friedhelm Hildebrandt.1,4  1Div of Nephrology, Boston 
Children’s Hospital, Harvard Medical School, Boston, MA; 2Dept of Pediatric 
Nephrology, Faculty of Medicine Univ of Istanbul, Istanbul, Turkey; 3Dept of 
Genetics, Yale Univ School of Medicine, New Haven, CT; 4Howard Hughes 
Medical Inst, Chevy Chase, MD.
Background: Identification of single-gene causes of steroid resistant nephrotic 
syndrome (SRNS) has furthered the understanding of its pathogenesis. However, many genes 
and disease mechanisms remain unknown. To identify additional genes that if mutated cause 
SRNS, we combined homozygosity mapping (HM) and whole human exome sequencing 
(WES) in a consanguineous families with NS.
Methods: An individual of consanguineous parents from Turkey with SRNS, deafness, 
cataract, microcephaly, and mental retardation histologically exhibited diffuse mesangial 
sclerosis. HM yielded >11 segments of homozygosity by descent with cumulative 
homozygous segments of ~200 Mb. We performed WES in this individual to identify the 
underlying single-gene disease-causing mutation.
Results: We identified a homozygous missense mutation (p.Leu425Met) in the AVIL 
(advillin) gene in an amino acid residue conserved since Ciona intestinalis. The mutation 
segregated with the affected status in this family and was absent from >6,500 European 
controls in the Exome Variant Server. AVIL (advillin) is a member of the gesolin superfamiy 
of actin binding protein. AVIL (advillin) is known to be involved in neurite outgrowth 
and morphogenesis via interaction with the cytoplasmic domain of the Type F scavenger 
receptor, SREC-I.
Conclusions: We identified mutation of AVIL (advillin) as a novel single-gene cause 
of SRNS. Further genetic and functional studies will shed light on the gesolin superfamily 
of actin binding proteins in the pathogenesis of NS and will provide further understanding 
of the disease mechanism.
PUB554
Adult-Onset Familial Thrombotic Microangiopathy and Pulmonary 
Arterial Hypertension Related to Cobalamin C Deficiency  Steven Grange,1 
Elise Artaud-Macari,1 Soumeya Bekri,3 Arnaud Francois,4 Christophe Girault,1 
Fabienne Tamion,1 Dominique Guerrot.2  1Intensive Care Unit, Rouen Univ 
Hospital, France; 2Nephrology Dept, Rouen Univ Hospital, France; 3Dept of 
Metabolic Biochemistry, Rouen Univ Hospital, France; 4Dept of Pathology, 
Rouen Univ Hospital, France.
Background: Cobalamin C (cblC) deficiency is the most frequent inherited disease of 
vitamin B12 metabolism, related to mutations in the MMACHC gene. The presentation in 
adults is dominated by neuro-psychiatric symptoms, and usually constitutes a diagnostic 
conundrum. We describe a unique presentation of cblC deficiency in 2 brothers, with the 
association of renal thrombotic microangiopathy (rTMA), atypical glomerulopathy, and 
pulmonary arterial hypertension (PAH).
Methods: An 18 year-old patient was referred for dyspnea. The investigations 
revealed stage 5 CKD, nephrotic syndrome, haemolytic anemia, and PAH. Renal histology 
showed major stenosing fibroproliferative myxoid lesions in the interlobular arteries. The 
glomeruli presented an ischemic appearance, with thickened and ribbon-like glomerular 
basement membranes. Immunofluorescence showed granular glomerular deposits of IgM, 
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without IgG or C3. Metabolic analyses showed an elevation of plasma homocysteine, 
methylmalonic acid, and propionylcarnitine concentrations. Genetic analyses found 
a compound heterozygosity in MMACHC gene, with c.271dupA and c.82-9delTTC 
mutations. The patient’s brother died at the age of 17. Autopsy revealed pulmonary capillary 
hemangiomatosis, while the kidney histology showed similar lesions to those of his brother.
Conclusions: This is the first report of late-onset rTMA, atypical glomarulopathy, 
and PAH associated with cblC deficiency. We suggest that the association of rTMA and/or 
glomerular proteinuria with PAH in children and young adults should prompt metabolic 
investigations to identify cblC deficiency, and provide early specific management including 
hydroxycobalamin, folinic acid, and betaine.
PUB555
The DS3 Scores and Quality of Life in Japanese Patients with Fabry 
Disease  Nobuhito Hirawa,1 Keisuke Yatsu,2 Sanae Saka,1 Gen Yasuda,1 Satoshi 
Umemura.2  1Dept of Nephrology and Hypertension, Yokohama City Univ 
Medical Center, Yokohama, Kanagawa, Japan; 2Dept of Medical Science and 
Cardiorenal Medicine, Yokohama City Univ Graduate School of Medicine, 
Yokohama, Kanagawa, Japan.
Background: Fabry disease (FD) is the lysosomal storage disorder, caused by 
the deficiency of lysosomal hydrolase alfa-galactosidase A activity. Various symptoms 
associated with renal disease, heart lesion and cerebrovascular disease occur in Fabry disease 
patients. Thus, the quality of life (QoL) would be alterd with the disease progressed. We 
evaluated the clinical severity and the QoL in a sample of Japanese patients with Fabry 
(FD) disease using the Disease Severity Scoring System (DS3) and the SF-36 survey in 
male and in female.
Methods: Observational cross-sectional study. The DS3 and SF-36 survey was 
administered to the patients of the hospitals, which belong to the research group of 
Kanagawa enzyme replacement therapy. Participants were treated with agalsidase-alpha 
or agalsidase-beta. Disease activity was assessed by the Disease Severity Scoring System 
(DS3). The QoL was measured by Short forum-36 (SF-36) and the Kidney Disease QoL 
Short Forum version 1.3 (KDQoL).
Results: Fifteen patients were included in the study. Mean age was 45 years (M/
F=10/5), and all patients were receiving ERT. The mean serum Cr was 2.9 mg/dl. The 
DS3 scores were follows; mean assessment score: 26.5 +/- 10.1, average domains: 10.5 
+/- 0.9. The renal domain and the cardiac domain showed relatively high score compared 
to PNS and CNS scores. The QoL scores of the FD patients were lower than those of 
general population, but the scores were better than the previous reports of FD from U.S. 
or EU. The mental component summaries of women were similar to those of the general 
population. The physical component summaries of QoL were negatively associated with 
the assessment score of DS3 (r=-0.545, p<0.05).
Conclusions: Japanese patients with FD receiving ERT had a relatively good QoL 
beyond anticipation. DS3 score is useful for assessing disease severity, and may predict 
some components of QoL.
PUB556
Two Cases of Fabry Disease in Women with Proteinuria Diagnosed 
by Molecular Analysis of α-Galactosidase A Gene and Kidney Biopsy 
Jong Oh Yang,1 Eun-Young Lee.2  1Internal Medicine, Soonchunhyang Univ, 
Cheonan, Chungcheongnam-do, Korea; 2Internal Medicine, Soonchunhyang 
Univ, Cheonan, Chungcheongnam-do, Korea.
Background: Fabry disease is a X-linked lysosomal storage disorder caused 
by deficiency of α-galactosidase A. This abnormality in enzyme results intracellular 
accumulation of globotriaosylceramide and leads to severe painful neuropathy with 
progressive renal, cardiovascular, and cerebrovascular dysfunction and early death. We 
report 52 and 55 year-old women with proteinuria and hematuria, which were proven to 
be due to Fabry disease.
Methods: A 52 and 55 year-old women was admitted to the hospital due to proteinuria. 
They denied previous histories of hypertension, diabetes mellitus, pulmonary tuberculosis, 
and hepatitis. Their sister and cousin diagnosed fabry disease. Physical examination 
revealed nonspefic findings. On admission, blood pressure 110/60 mmHg, heart rate 64/min, 
respiratory rate 16/min, body temperature 36.5°. Lungs were clear and heart was normal. 
The extremities showed no edema, cyanosis or skin rashs. The laboratory data showed the 
WBC 5650/mm3, Hb 13.2 g/dL, Platelet 212,000/mm3, BUN 10.2 mg/dL, serum creatinine 
0.7 mg/dL. Urinaylsis showed pH 5.0 SG 1.023 protein 2+ RBC 5-9/HPF WBC 5-9/HPF. 
24-hour urine protein was 533 mg. Abdomen & Pelvic CT and echocardiography were 
normal. The serologic study was normal. The kidney biopsy showed expansion of mesangial 
matrix and glomerular hypertrophy. The cytoplasm of podocytes was vaculoated, which 
consisted of multiple, variable-sized, concentric electron-dense lamellated structures, by 
electron microscopy. 
The enzyme activity for a-galactosidase in serum was 0.59 nmol/min/mg protein.
Conclusions: The patients received enzyme replacement therapy every other week. 
They had reduction in proteinuria and normal renal function.
PUB557
Intradyalisis Partial Parenteral Nutrition (IDPN) in Hemodialysis Patients 
(HDP) with Protein Caloric Malnutrition (PCM): Preliminary Results 
Susana Beatriz Asia,1 Marcela Fabiana Munizaga.1  1Servicio de Nefrologia, 
Hospital Nacional de Clínicas, Cordoba, Argentina; 2Servicio de Nefrologia, 
Hospital Nacional de Clinicas, Cordoba, Argentina.
Background: PCD is higly prevalence in HDP and predicts morbi-mortality. NPID 
is according Espen Guides (march2012) and the SMOFF formule(soja,TG,olive oil 
and fish oil), improve inflamation and lipid status.Our goal is to define the evolution of 
nutritional parameters in HDP and caracterize them for future interventions. OBJETIVE: 
To evaluate if severe PCD in HDP, improve malnutrition and inflamation markers such as 
albumine,(Alb),cholesterol (Ch), reactive C protein(RCP).
Methods: Prospective and observationa study that included 14 patients up this 
time,both sexs,age27-80 years old, in maintenance HD from a University Hospital and 
Army Hospital.Patients signed informed consent. Patients received each HD session 
and during six months,SMOF lipids 4 grs/kg/d,by IV continuous infussion. We analized 
weight, Hematocrit,Alb,Ch,TG,creatinine,RCP and Global Subjetive Valoration(GSV)
in pre HD blood samples at the beginnig,three and six months.Cuantitative demographic 
variables(age,sex,biochemic parameters)were expressed as medium ,SD and applied Student 
Wilcoxon Test and Chi Test (p:<010).
Results: fourteen patients improved weight(63,1+/-3,3vs64,9+/-3,5,p:0,351),alb(gr/
dl)(3,7+/-0,4vs3,9+/-0,1,p:0,016),TG(mg/dl)(190,1+/-26,9vs179,4+/-30,8,p:0,03)and 
RCP(mg)(28,9+/-6,7vs10,1+/-2,5,p:0,009).there were not statical significance inHto(gr/
dl)(33,3+/-1.9vs33,7+/-1.9vs33.7+/-1.7,p:0.856)CH(mg/dl)(163.9+/-15.9vs165.6+/-
13,p:0.846),creatinine(mg/dl)(7.7+/-0.7vs7.4+/-0.5,p:0.233).
Conclusions: 1- NPID is a successfull tool as partial supplementation in HDP with 
oral dietary intake.2-In spite of our sample is small,the improvement of Nutritional and 
inflammatory status, applying Internatinal Guides was observed after three months of 
treatment.3- Medical awareness about nutritional risks in HDP, is the best tool to prevent 
alteration of nutritional status 4-We´ll expand the sample.
PUB558
Association of Protein Energy Wasting with Income in Chronic Kidney 
Disease Stage 3 Patients  Anita Saxena, Amit Gupta.  Nephrology, Sanjay 
Gandhi Post Graduate Inst of Medical Sciences, Lucknow, Uttar Pradesh, India.
Background: Protein energy wasting (PEW) is a major challenge in CKD. Purpose: 
Assessment of PEW in predialysis patients at first visit to a nephrologist.
Methods: Three day dietary intake of 484 CKD stage 3 patients. Patients were divided 
in to groups based on appetite and BMI.
Results: Male and female parameters: Serum albumin 3.7±0.84/ 3.68.8±.81g/dL, total 
protein 7.02±1.27/6.94 ±1.26 g/dL, creatinine 4.68± 4.19 / 3.74±3.36 mg% creatinine 
clearance 33.22± 30.48/ 37.55±33.87 ml/minute, BMI 22.60±4.29/23.43±4.77kg/m2 
energy/kg 16.97±0.65/16.8±0.64, protein g/kg 0.65 ±0.28/0.64±0.30, carbohydrate g/kg 
2.98 ±1.54/2.98±.1.36, fat g/kg 2.98±0.23/2.79±0.22, respectively. As appetite decreased 
dietary protein and energy intake decreased significantly.
J Am Soc Nephrol 26: 2015 Publication Only
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Varible/Sex NormalN 1/126
Average
N 70/20
Poor
N 88/47
Anorexic
N 64/36
Protein g/kg /Male 0.79±.23 0.58 ± .17 0.50 ± .20 0.27 ±.17
Protein g/kg /
Female 0.79±.23 0.56 ±.16 0.48 ±.15 0.29 ±.20 
Energy cal/kg /
Male 21.57 ± 7.85 25± 3.70 12.36±4.26 6.92 ±4.36
Energy cal/kg /
Female 21.19 ±5.81 14.67 ±3.09 12.79±3.92 7.25± 3.95
Appetite was average 14.46%/4.13% poor 9.7%/18.18%, anorexic 13.2%/ 7.4% in 
males and females. Income correlated with BMI (p.000), dietary protein (p.000) energy 
(p.000) and carbohydrate (p.000). Appetite correlated with creatinine (p 0.019), dietary 
energy, protein, carbohydraate and fat (p.000) intake. BMI correlated (p0.000) with fat, 
carbohydrate, energy and creatinine clearance. Anova showed significant difference 
between appetite groups in energy, protein, fat, carbohydrate, creatinine clearance (p0.000) 
and serum albumin (p 0.025). There was significant difference in protein (p0.026) energy 
intake (p 0.000) and creatinine clearance (p0.038) between BMI groups. Based on income 
there was significant difference between groups in BMI (0.000), energy (p0.019), protein 
(p 0.031), albumin (0.001).
Conclusions: With decline in renal function, appetite worsened and nutritional intake 
decreased. Energy intake was significantly deficient. 84% patients had reduced appetite 
and 69.2% had PEW. Low income is a risk factor for PEW in CKD.
PUB559
Study on Correlation Between Serum Creatinine, Cystatin-C, Urinary 
Albumin Creatinine Ratio and Body Composition  Xuemei Li, Jie Ma. 
Nephrology, Peking Union Medical College Hospital, Beijing, China.
Background: Based on an epidemiological survey in Peking, China, to study the 
correlation between serum creatinine, Cystatin-C and urinary albumin creatinine ratio 
(ACR)and body composition.
Methods: Rresidents over the age of 35 of the Beijing Pinggu District by random 
sampling method. Laboratory test: take morning ACR, blood samples were taken for 
blood routine, kidney function.Test body composition after emptying the bladder by using 
INBODY-720 machine.Use SPSS 17.0 software for data statistical analysis, count datas 
were analysised by using multivariate linear regression .
Results: A total of 9283 people participated in the survey, which 4324 males, age 
54.7±10.7 years, 4959 females, age 53.4±11.2 years. Male: 1) Human body cell mass 
(BCM) and ACR, Cystatin-C, no correlation, was positively correlated with height (B=0.43, 
P<0.01), and serum creatinine was that positive correlation (B=.01, P<0.01) . 2) Lean body 
mass (FFM) and ACR, serum creatinine, Cystatin-C, no correlation. 3) Skeletal muscle 
content and ACR, serum creatinine, Cystatin-C, no correlation. 4) Body fat mass and ACR, 
no correlation, and Cystatin-C was positively correlated with (B=7.09, P < 0.01). Female: 
1) Human body cell mass (BCM) with height and cystatin-C, no correlation , but positively 
correlated with serum creatinine (B=0.035, P<0.01), and ACR was negative correlation 
(B=-0.005, P<0.05). 2) Lean body mass (FFM) and ACR, Cystatin-C, no correlation, and 
serum creatinine were positively related (B=0.035, P<0.01). 3) Skeletal muscle content 
and ACR, Cystatin-C, no correlation, and was positively correlated with height (B=0.031, 
P<0.01), and serum creatinine were positively related (B=0.035, P<0.01). 4) Body fat 
mass and ACR was negative correlation (B=-0.01, P<0.05) ,Cystatin-C were positively 
correlated (B=12.3, P<0.01), and age were negatively correlated (B=-0.13, P<0.01), and 
serum creatinine was negative correlation (B=-0.092, P<0.01).
Conclusions: There was a positive correlation between serum creatinine and the human 
body cell mass (BCM), lean body mass (FFM) in men, and skeletal muscle content, body 
fat weight in women, but the correlation is not strong. The blood cystatin-C and body fat 
weight was positively correlated.
PUB560
Worsening Nutritional Status Assessed Is an Independent Predictor of All-
Cause Mortality in Incident Dialysis Patients  Jong Hyun Jhee, Young Eun 
Kwon, Tae-Hyun Yoo, Shin-Wook Kang.  Dept of Internal Medicine, Yonsei 
Univ College of Medicine, Seoul, Korea.
Background: Malnutrition is closely associated with mortality in end-stage renal 
disease (ESRD) patients. However, little is known whether improvement or deterioration 
of nutritional status after dialysis initiation affects clinical outcome. This study was aimed 
to elucidate the association between the changes of subjective global assessment (SGA) 
after dialysis initiation and mortality in ESRD patients.
Methods: Data were recruited from the Clinical Research Center for ESRD cohort. 
SGA score was measured by trained investigators at the time of dialysis initiation and 
after 12 months. Nutritional status was defined as well-nourished (SGA 6-7, A), mildly to 
moderately malnourished (SGA 3-5, B), or severely malnourished (SGA 1-2, C). Severely 
malnourished patients (SGA C) were excluded due to small sample size. The patients were 
divided into four groups according to the change of SGA; group 1, A to A; group 2, B to 
A; group 3, A to B; and, group 4, B to B.
Results: A total of 911 patients were enrolled. The mean age was 54.6±14.1 years, 
554 patients (60.0%) were male. During a median follow-up duration of 30 months, 109 
patients (12.0%) died. Survival rate of group 1 was the highest, and that of group 4 was 
the lowest (group 1, 91.2%; group 4, 71.4%; P<0.001). Worsening nutritional status was 
a significant risk factor for mortality (group 3 vs. 1, HR=3.15, CI=1.51-6.54, P=0.002), 
while baseline nutritional status at dialysis initiation was not (group 1 vs. 2, P=0.063; 
group 3 vs. 4, P=0.107).
Conclusions: Improvement of nutritional status after dialysis initiation could be 
beneficial for patient outcomes regardless of baseline status, suggesting that intervention 
to improve nutritional status after dialysis initiation might be a strategy to reduce mortality 
in ESRD patients.
PUB561
Prophylactic Effect of Erythropoietin Injection to Prevent Acute Mountain 
Sickness: An Open-Label Randomized Controlled Trial  Hyungjin Cho, Soon 
Bae Kim.  Div of Nephrology, Dept of Internal Medicine, Univ of Ulsan, College 
of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Background: This study was performed to evaluate whether increasing hemoglobin 
before ascent by prophylactic erythropoietin injections prevents acute mountain sickness 
(AMS).
Methods: This open label,randomized, controlled trial involved 39 healthy volunteers 
with hemoglobin £15.5g/dL who were divided randomly into erythropoietin (n = 20) and 
control (n = 19) groups. Epoetin alpha 10,000 IU injections were given weekly for four 
consecutive weeks. On day1, and 7 days after the last injection (day 29), oxygen saturation 
(SaO2), and hemoglobin were measured. The subjects departed Seoul on day 30 and arrived 
at Annapurna base camp (ABC, 4,130 m) on day 34. AMS was diagnosed when headache 
and Lake Louise score (LLS) of ≥ 3 were present. Immediate descent criteria followed 
US Army recommendations.
Results: Two groups differ in hemoglobin levels on day 29 (15.4 ± 1.1 vs 14.2 ± 1.0 
g/dL, P = 0.001). At ABC, erythropoietin group had a significantly lower mean LLS, AMS 
incidence, and number of subjects who met immediate descent criteria. Multiple logistic 
regression analysis showed that SaO2 < 87% and control group, but not hemoglobin < 15.0 
g/dL, independently predicted satisfaction of immediate descent criteria.
Criteria EPO (n=20) Control (n=19)
HACE(ataxia) plus HAPE (PR>110) 1
HACE(ataxia) 1 0
HACE(severe lassitude) 1
Severe AMS plus HAPE (PR>110) 1 1
Severe AMS alone 4
HAPE(PR>110) 1 3
Total 3 10
*p=0.019. HACE, high altitude cerebral edema; HAPE, high altitude pulmonary edema; AMS, 
acute mountaine sickness; PR, pulse rate
Erythropoietin-related adverse effects were not observed.
Conclusions: Erythropoietin-related adverse effects were not observed. In conclusion, 
erythropoietin may be an effective prophylaxis for AMS.
Funding: Pharmaceutical Company Support - CJ pharmaceutical
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Nutritional Assessment for the Chronic Dialysis Patients with/without 
Sarcopenia  Miho Suzuki, Yuya Sakai, Ikuto Masakane.  Yabuki Hospital.
Background: A recent arising problem of chronic dialysis patients is sarcopenia 
closely related to malnutrition. Muscle loss deteriorates daily activities of dialysis patients 
and ultimately worsens the QOL and prognosis of the patients. The aim of this study was 
to clarify  the relationship between the nutritional status and sarcopenia and to analyze the 
status of nutrientintake in these patients.
Methods: 90 chronic hemodialsis patients were enrolled to the current study. (age 
62.8yrs. Men were 76%, DM 41%).Skeletal muscle mass (SMM) was estimated by 
bioelectrical impedance analysis and a low muscle mass was defined by the SMM index 
(SMI: SMM [kg] / height [m2] as > men: 7.0kg, women: 5.7kg).Muscle function was 
estimated by grip strength and walking speed as the Timed up and go test (TUG).A low grip 
strength was defined as less than 26 kg (men) or 18 kg (women). TUG less than 11 second 
was diagnosed as a low walking speed.Malunutrition was defined as by the Malnutrition-
Inflammation Score(MIS)(≥6point) , GNRI(<92) and the criteria of protein energy wasting 
(PEW).The dietary assessment was performed by the food frequency questionnaire.
Results: Sarcopenia was identified in 22% of the subjects. The sensitivity to detect 
sarcopeia was not sufficient as 35% in MIS, 50% in GNRI and 10% in PEW. In the patients 
with sarcopenia, the average of total energy intake and protein was significantly lower 
than those in non-sarcopenia, 1618±122kcal vs 2041±65kcal in energy; 52±4g vs 68±2g 
in protein. The intake of fishes and meats (110±15g vs 153±8g),beans (31±11g vs 61±6g 
),confectionery, beverages and sugar (126±77g vs 306±41g ) were significantly lower in 
sarcopenia than non-sarcopenia.
Conclusions: Malnutrition-related sarcopenia was only 10-50% among sarcopenia. 
It is important to measure muscle mass and muscle function regularly for dialysis patients 
because it is not enough to screen sarcopenia only by nutritional measurements. Sufficient 
protein and energy intake are essential for the prevention of sarcopenia. If  patients don’t 
have appetite,confectionery or a beverage or sugar may beacceptable for the prevention 
of muscle loss.
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Stomach Acid Reducers May Predict Nutritional Deficiency in Dialysis 
Patients  Klara Berta, Mihaly B. Tapolyai, Maria Faludi, Melinda Forró, Ákos 
Géza Peth?.  Dialysis, Fresenius Medical Care Semmelweis Univ, Budapest, 
Hungary.
Background: Malnutrition is a major predictor of mortality among dialysis patients. 
Malnutrition markers are thus regularly monitored in order to intervene when the nutritional 
status may decline. We investigated whether taking stomach acid reducing medications 
may indicate nutritional risk.
Methods: This is a cross sectional study of 103 patients undergoing chronic 
hemodiafiltration in Budapest, Hungary at a university hospital based dialysis unit. The 
patients’ nutritional indicators such as serum albumin, phosphorus, nPCR and whether they 
were receiving cholecalciferol replacement were examined among those who did and those 
who did not take an acid reducing agent, such as a Proton Pump Inhibitor (PPI) or H2 blocker.
Results: Six patients were excluded because data were incomplete or the patients had 
not been on dialysis for more than 2 months. Of the 96 patients 44.9% took an acid reducer 
on a regular basis. The serum albumin (3.78 ±0.02 mg/dL vs. 3.56 ±0.01 p:0.008), phosphate 
(1.88 ±0.49 mmol/L vs. 1.64 ±0.54 p:0.04) and nPCR (1.00 ±0.20 vs. 0.91 ±0.25 p: 0.06) 
were lower among PPI takers. PPI takers were much more likely to be taking cholecalciferol 
for measured 25-OH-vitamin-D deficiency (1.8% vs. 18.1% p:0.01). While PPI takers 
were older (59.7 ±16.2 years vs. 65.7 ±13.3 p:0.04), there was no difference in the two 
populations in the presence of an AV Fistula, delivered Kt/V, calcium or serum bicarbonate.
Conclusions: We conclude that taking PPI’s or H2 Blockers in dialysis patients may 
be an indicator of being at risk for malnutrition.
PUB564
Impact of the Potassium Additives on the Total Content of This Element in 
Processed Foods  Margareth Lage L. de Fornasari,1,2 Maria raquel Manhani,2 
Yvoty As Sens.1,2  1Post Graduation, Santa Casa of Sao Paulo School of Medical 
Sciences, Sao Paulo, SP, Brazil; 2Nutrition, Sao Judas Tadeu Univ, Sao Paulo, 
SP, Brazil.
Background: The additives of potassium salts are allowed in processed foods to 
preserve, to inhibit mold, to emulsify products. Patients with chronic kidney disease need 
to control the intake of potassium, and are advised for doctors and dietitians to restrict 
fresh foods and those rich in potassium. The addition of potassium to processed foods is 
permitted but frequently not specified on food labels in Brazil.The purpose of this study 
was to determine the actual potassium content of a number of products often consumed 
by end-stage renal disease patients and to compare the actual content with that estimated 
in a reference source.
Methods: Twenty-five frequently processed products consumed in the diet of end-stage 
renal patients treated at the hemodialysis unit were analyzed. The processed foods were 
milk beverages, yogurt, a type of cream cheese, margarine, tomato sauce, salad dressing, 
powdered juices, and had potassium sorbate or others potassium salts. The concentration 
of potassium (mg K/100g of food) was determined by flame photometry according to the 
Adolfo Lutz Institute methodology, and in triplicate. The comparison of the potassium 
obtained with the expected potassium was based on two national reference tables.
Results: All products had potassium-containing additives listed among their ingredients. 
The medium values of potassium (mg for 100 g or mL) for the different foods were: milk 
beverages 102.6 to125.3; type of cream cheese 80.3 to 194.4; margarine 21.6 to 37.3; tomato 
sauce 253.3 to 258.2; salad dressing 78.5 to 128.4; powdered juices 33 to 240.8. Processed 
food that had higher potassium values than the content expected from the food label were, 
milk beverages (1.6 to 2 times); type of cream cheese (0.9 to 2.1 times); salad dressing (1.6 
to 2.6 times); margarine (1.4 to 2.5 times) and powdered juices (376 to 726 times). Tomato 
sauce had less potassium values than expected levels (0.6 times).
Conclusions: Processed foods with potassium additives contain higher levels of 
potassium than those listed in reference tables.
PUB565
Differences in Eating Patterns Between Maintenance Hemodialysis Patients 
from the U.S. and the UK  Annabel Biruete,1 Brandon Kistler,1 Patrick Highton,2 
Kristin P. Wiens,3 Peter J. Fitschen,1 Alice C. Smith,2 Ken Wilund.1  1Univ of 
Illinois; 2Leicester Kidney Exercise Team, Univ of Leicester, United Kingdom; 
3Univ of Delaware.
Background: Maintenance hemodialysis (HD) patients in the United States (US) have 
poorer nutritional status and higher mortality than European patients. Patient characteristics 
and clinical practices are hypothesized to contribute to these differences. Therefore, our 
aim was to compare eating patterns between HD patients from the US and the United 
Kingdom (UK).
Methods: HD patients (US=60,UK=29) were recruited. Four 24-hour diet recalls were 
collected, two dialysis days (DD) and two on non-dialysis days (NDD) using the USDA 
5-pass method. Dietary information was entered and analyzed using diet analysis software 
and then grouped into eight food categories according to NHANES. Food security was 
assessed by the USDA 10-item survey. Statistical analysis was performed using independent 
samples t-test and Pearson’s correlations.
Results: Patients from the UK consumed more energy on DD (24.9±2.1 vs. 18.5±1.1 
kcal/kg/d;p=0.004) and NDD (24.5±1.5 vs. 20.5±1.2 kcal/kg/d;p=0.048) than US patients. 
Additionally, US patients had lower energy intake on DD than NDD (p=0.007), while there 
were no differences in UK patients (p=0.85). UK patients consumed more baked goods/
breads, whereas US patients consumed more energy from beverages, entrees, and deli 
(p=<0.05 for all). Moreover, some degree of food insecurity was more frequently observed 
in the US (54.2% vs. 10.3) and was associated with younger age (r2=-0.29,p=0.033), higher 
BMI (r2=0.41,p=0.005), higher dietary sodium (r2=0.29,p=0.03) and sugar (r2=0.27,p=0.05).
Conclusions: HD patients from the US had lower energy intake on DD and NDD 
compared to UK patients. Furthermore, US patients had lower dietary intake on DD. This 
may be in part due to US clinics’ restrictive policy on eating during dialysis. Furthermore, 
there were differences in food pattern consumption and food insecurity. These differences 
may help explain global differences in nutritional status and outcomes. Further studies are 
needed to assess the contribution of eating patterns and socioeconomic status on clinical 
outcomes in HD patients.
PUB566
Is Reverse Epidemiology in BMI of Maintenance Hemodialysis Patients 
Adaptable to the Patients without PEW?  Yuya Sakai, Miho Suzuki, Ikuto 
Masakane.  Yabuki Hospital.
Background: Reverse epidemiology has been addressed in Body mass index (BMI) 
of chronic hemodialysis patients; the lowest mortality rate in BMI 24-26 as reported by 
the Japanese Society for Dialysis Therapy. The higher BMI the lower mortality as stated 
by the Dialysis Outcomes and Practice Patterns Study. However, because these survey 
subjects included lower BMI patients with malnutrition and chronic inflammation, the 
high BMI patients’ mortality risk might have been relatively low. The optimal BMI derived 
from these epidemiological analysis may not be well indicated for the patients’ who do not 
have malnutrition and inflammation. So, we aim to study the optimal BMI of maintenance 
hemodialysis patients without Protein Energy Wasting (PEW).
Methods: 183 patients on maintenance hemodialysis patients were enrolled in the 
current study. All subjects have over 2 years of dialysis vintage and are not applicable to 
PEW and don’t have inflammation which was defined as CRP less than 0.3 mf/dL as of 
December 2009. The observation period is from December 2009 to December 2014.The 
subjects were classified into 4 groups on a BMI scale (n)(<18.5 (13),18.5≤<22 (81),22≤<25 
(47),25≤ (42)). The 5-year cumulative survival rate, the death risk factor, and each BMI 
groups’ relative mortality risk for BMI 22≤<25 group were examined.
Results: During the observation period, clinical deaths resulted in 19 patients, changing 
hospital or accidental death resulted in 22 patients. There was no significant difference in 
the crude 5-year cumulative survival rate of BMI groups. Age, diabetes mellitus, albumin 
were dependent risk factors for death. When the mortality risks were adjusted by these 3 
parameters, the mortality risk of BMI <18.5 was significantly higher than each of the 3 
BMI groups (HR 6.97, P=0.0417).The mortality risk of BMI <25 was relatively higher 
than BMI 22≤<25 group but not significant.
Conclusions: In the maintenance hemodialysis patient without PEW syndrome 
and inflammation, the patients of BMI <18.5 have a higher risk of death so they require 
nutritional management to maintain and/or achieve a BMI ³18.5. Reverse epidemiology in 
BMI was not adaptable to the Japanese dialysis patients without PEW and inflammation.
PUB567
Body Weight and Proteinuria Determine Plasma Triglycerides via Hepatic 
Syndecan-1/Heparan Sulfate in Experimental Nephrosis  Saritha Adepu,1 
Harry Van Goor,2 Gerjan Navis,1 Stephan J.L. Bakker,1 Jacob van den Born.1 
1Nephrology, Univ Med Center, Groningen, Netherlands; 2Pathology, Univ Med 
Center, Groningen, Netherlands.
Background: Dyslipidemia contributes to a high cardiovascular risk profile of 
proteinuric patients. Via its heparan sulphate (HS) side chains, hepatic syndecan-1(syn-1) is 
a major uptake receptor of remnant lipoproteins. We hypothesized that proteinuria induces 
changes in hepatic synd-1/HS metabolism leading to dyslipidemia, which is reversed by 
caloric restriction (CR).
Methods: We used the hypertensive rat MWF proteinuria model. Male rats (22 wks) 
were uni-nephrectomized and fed ad libitum (AL) food (MWF-AL; n=14), or CR (MWF-
CR; n=13, 60% of MWF-AL food intake). Wistar rats matched for sex, age, nephrectomy 
on AL food intake served as controls (W-AL; n=13). Sacrification is at 48 wks. Wistar 
control rats were sacrificed at 22 wks (Young W-AL; n=6). Body weight, blood pressure, 
plasma creatinine, cholesterol, triglycerides, and proteinuria were measured at 22 and 48 
wks. Livers were used for qRT-PCR and immunostaining. Correlation analysis was done 
by linear regression analysis.
Results: Renal aging (W-AL vs Young W-AL) was associated by mild proteinuria and 
dyslipidemia (both p<0.05). Compared to W-AL rats, at 48 wks MWF-AL rats developed 
hypertension, proteinuria, reduced creatinine clearance (all p<0.05) and comparable 
dyslipidemia. CR reversed all these parameters in MWF-CR comparable to W-AL rats 
(p<0.05). Hepatic syn-1/HS profiling revealed striking increase in syn-1 protein and altered 
HS sulfation pattern in proteinuric W-AL and MWF-AL. CR normalized syn-1 protein 
levels and increased HS sulfation. Syn-1 appeared positively (r=0.366, p<0.02) and HS 
sulfation inversely (r=-0.450, p<0.005) associated with plasma triglyceride concentrations. 
Both associations were lost after adjustment for body weight or proteinuria.
Conclusions: CR normalized hypertension, renal function, proteinuria, dyslipidemia 
and synd-1/HS in MWF rats. Regression analysis suggests that body weight and proteinuria 
reduce hepatic HS sulfation, leading to hampered TRL binding and uptake and increased 
TG values.
Funding: Government Support - Non-U.S.
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Obese Donors: The Multidisciplinary Approach in Improving Outcomes 
Giselle Guerra,1 Ian Thomas,1 Panagiotis Tryphonopoulos,2 Linda J. Chen,2 
Gaetano Ciancio.2  1Dept of Medicine, Miami Transplant Inst, Miami, FL; 2Dept 
of Surgery, Miami Transplant Inst, Miami, FL.
Background: Living donation appears safe over the years but concerns still exists 
long-term. Small analyses after unilateral nephrectomies have resulted in proteinuria 
and slight decrease in renal function (eGFR) if patient tended to be obese; thus raising a 
concern for accepting living kidney donors (LKD) with body mass index (BMI) greater 
than 30 but less than 35 Aim: Determine the outcomes of obese LKD with BMI greater 
than 30 but less than 35.
Methods: A single center retrospective analysis was performed at out transplant 
center from January 1, 2013 - November 30, 2014. LKD ages 18-65 were assessed: 1. 
Study Arm (SA): obese LKD with BMI>30 who were enrolled into a nutritional program 
and 2. Control arm (CA): non-obese living kidney donor candidates at the time of referral. 
Weight loss prior to surgery and afterwards, surgical complications, loss of kidney function 
(eGFR), and proteinuria (spot urine protein/spot urine creatinine ratio) after 6 months from 
donation were reviewed.
Results: Patient demographics - SA:15African Americans (AA), 13 Hispanics (H), 7 
White, 1 Other, 3 Unknown versus CA: 55 H; 49 Whites; 20 AA; 5 Other [figure1]. In the 
SA: 24/40 had BMI >35 at time of referral and placed in nutritional program; 8/24 dropped 
BMI to less than 35 prior to surgery and 3/24 pending surgery now; 4/24 ruled out due 
to medical issues & (9/24) were non-compliant. Surgical complications 1/8: Parasthesia. 
After donation in SA, blood pressure remained stable, 2/8 gained weight ,kidney function 
at 6 months: 47% of obese donors had a derease in eGFR at 6 months of 40% or greater. 
The mean decrease in eGFR was 33.9% in the study arm. In the control arm: 55Hispanics; 
49 Whites; 20 AA; 5 Other. 15% had a decrease in eGFR at 6 months 40% or greater and 
the mean decrease in eGFR was 28.9.
Conclusions: Obesity in living donors needs careful analysis especially in minortiy 
populations since there is a trend to have a greater loss in kidney function after donor 
nephretomy. Donation is possible but strict nutritional and guidelines and medical 
evalulation need to persist for the wellness of these patients long-term.
PUB569
The Role of Renal Pharmacist in Prescribing Immunosuppressant 
Medication for Renal Transplant Patients to Improve Safety  Israr Baig, 
Preetham Boddana.  Pharmacy Dept, Gloucestershire Hospitals NHS 
Foundation Trust, Gloucester, Gloucestershire, United Kingdom.
Background: This paper describes the safe and efficient repatriation of renal 
immunosuppressant prescribing from General Practitioners (GPs) to secondary care using 
hospital Pharmacist Independent Prescribers (PIPs).
Methods: From March 2015 the UK commissioner NHS England required all renal 
immunosuppressant medication, which was traditionally prescribed by GPs following 
nephrologists’ advice, to be prescribed by hospital renal prescribers. Gloucestershire 
hospitals NHS Foundation Trust decided to use Pharmacist Independent Prescribers to 
implement this change and provide the ongoing service using commercial Homecare 
Companies. All Patients were initially sent detailed information about the changes and asked 
to consent. On receipt of the completed consent form the PIP wrote the initial homecare 
prescription which was then processed by the pharmacy homecare team. Patients continued 
to be reviewed at regular intervals by their nephrologists. Details of these consultations 
were documented using a central renal database which included graft function, drug levels 
and communication with GPs. The Pharmacist Prescribers subsequently reviewed the renal 
database prior to generating ongoing homecare prescriptions and, when necessary, contacted 
the nephrologist for clarification and interventions.
Results: This service reconfiguration has resulted in safe and robust pathway. The 
use of Pharmacist Independent Prescribers has insured the whole pathway is efficient and 
closely monitored. Patients are satisfied with the new homecare service and clinicians value 
the pharmacists’ input. Pharmacist prescribers have made a number of interventions which 
have included patient compliance issues, changes to doses in response to serum drug levels 
and appropriate brand changes to improve cost effectiveness.
Conclusions: The use of Pharmacist Independent Prescribers to prescribe and 
manage the renal immunosuppressant homecare service at Gloucestershire Hospitals NHS 
Foundation Trust has been shown to be safe and efficient.
PUB570
Tools for Adverse Events Prevention in a Hemodialysis Facility: A Local 
Experience  Cinthia Sobral Vieira,1 Cassiana G. Prates.2  1Nephrology Service, 
Hospital Ernesto Dornelles, Porto Alegre, RS, Brazil; 2Hospital Epidemiology 
and Manager Risks Service, Hospital Ernesto Dornelles, Porto Alegre, RS, 
Brazil.
Background: After the publication “To err is human” there has been a new approach 
to prevent risks in health system. According to the International Patient Safety Goals there 
are six steps to be followed like patient identification, proper communication, right surgery 
in the right side, fall prevention, high alert medication and infection prevention. The goal 
is to show how a hemodialysis unit, for ambulatory and hospitalized patients leads with 
adverse event prevention.
Methods: This experience happens in a hemodialysis unit with 101 patients, 3 shifts 
of 4 hours. It is located in a general hospital in Porto Alegre, south Brazil.
Results: Every patient has an id badge with colored marks according to the risk 
possibilities (falls, allergies, multi resistant germ, no access condition, hypoglycemic risk). 
There are no medication facilities. There are checklists for dialysis . The staff has continued 
medical education for patient safety. There is a map risk (adverse events possibilities) and 
its approach. If it happens, a notification formulary is filled and reported to the Hospital 
Epidemiology and Manager Risks Service, that analysis the root causes. The chosen 
tool is Ishikawa diagram resulting in a plan of action. Every month, one case (not only 
hemodialysis) is discussed together with a multidisciplinary group and the hospital high 
direction. The quality patient safety indicators are evaluated, as mortality incidence (21,33 
% y); sera conversion to hepatitis C and B (0) and catheter infection (5,24% y).
Conclusions: Chronic renal patient is at high risk of advent events because of frequent 
treatment, comorbidities, many medication and the pathology consequences. Needle 
dislodgment, hematomas, lack of registration of weight and arterial pressure at the beginning 
of dialysis, more than 2 vascular access needle insertion attempts, dialysis interruption may 
occur, so the unit must be prepared to intervention. Health staff rarely reveals mistakes 
afraid of consequences and blame. It is necessary to promote the Safety Culture, stimulating 
to talk about bad events or even near miss to prevent other ones.
PUB571
Zinc Deficiency Correction and Phosphaturia in Children with CKD – A 
Pilot Study  Vladimir Belostotsky,1 Stephanie A. Atkinson,1 Michelle N. 
Rasiah,1 Steven Arora,1 Ji Cheng,1 Joanne Grimmer,2 Guido Filler.2  1Pediatrics, 
McMaster Children’s Hospital, Hamilton, ON, Canada; 2Pediatrics, Children’s 
Hospital, London Health Sciences Centre, London, ON, Canada.
Background: There are no guidelines for correction of Zinc (Zn) deficiency in Chronic 
Kidney Disease (CKD). Experimental data (Morishita 2001) suggests that Zn modulates the 
phenotype of Klotho deficient mice and this can potentially increase phosphaturia. Aims: 
To identify Zn deficiency and determine whether 3 months of oral Zn therapy normalizes 
Zn status in children with CKD. To assess feasibility of conducting a clinical trial similar to 
Morishita’s in mice and gather information on clinical outcomes and relationship between 
Zn status and correction of Zn deficiency and phosphate (P) excretion.
Methods: 40 patients (pt) 4-18 yr with primary CKD and CKD due to declining graft 
function were enrolled from 2 tertiary pediatric nephrology centers. Plasma Zn was measured 
by High Resolution Magnetic Sector Inductively Coupled Plasma Mass Spectrometry at 
baseline and 3 months with routine blood and urine parameters. Pt with Zn<11.5 mmol/L 
were treated for 3 months with Zn citrate tablets (10mg Zn/day for 4-8 yr and 20 mg/day for 
9-18 yr). Statistical analysis was done using nonparametric methods and relative risk ratio.
Results: Of 21 pt (M-13, F-8) with completed data, Zn deficiency was found in 10. 
Stages of CKD were: 2-11 pt, 3-5 pt, 4-5 pt. One pt was hyperphosphatemic. 2 Zn deficient 
pt had abdominal discomfort whilst taking Zn. Plasma Zn improved in 8 out of the 10 
treatment pt (4.4 times more frequently than in control pt) after 3 months of Zn therapy. 
Zn therapy over 3 months did not change serum P (median 1.23 mmol/L to 1.25 mmol/L) 
or its fractional excretion (median 24.08% and 21.71%).
Conclusions: Zn deficiency occurred in about 50% of CKD pt. Preliminary analysis 
indicates that 3 months of oral Zn supplementation is likely beneficial in Zn deficient pt 
but a larger sample size is required to evaluate the impact of correction of Zn deficiency 
on other metabolic parameters. Correction of Zn deficiency does not alter P excretion in 
pt with normal blood P. Similar studies are feasible to perform in hyperphosphatemic pt.
Funding: Private Foundation Support
PUB572
Proteinuria as a Marker of Severe Unilateral Ureteral Obstruction in 
Infants  Mariselis Rosa-Sanchez, Jayanthi Chandar, Wacharee Seeherunvong, 
Chryso P. Katsoufis, George N. Sfakianakis, Rafael Gosalbez, Andrew Labbie, 
Gaston E. Zilleruelo, Carolyn L. Abitbol.  Pediatric Nephrology, Nuclear 
Medicine, Pediatric Urology, Holtz Children’s Hospital/Univ of Miami, Miami, FL.
Background: Unilateral ureteral obstruction (UUO) is a common congenital anomaly in 
infants. Controversies remain regarding clinical indications for timely surgery. The objective 
was to compare the radiologic and laboratory parameters of a cohort presenting with 
significant unilateral hydronephrosis that were managed either conservatively or surgically.
Methods: This retrospective analysis included 81 infants during a 10 year period with 
high grade hydronephrosis designated by renal ultrasound. Further assessment included 
renal function by nuclear scintigraphy and proteinuria. Proteinuria was determined by 
random urine total protein to creatinine ratio (Upr/cr) and albuminuria by random urine 
albumin to creatinine ratio (Ualb/cr). Receiver operator characteristic (ROC) area under 
the curve (AUC) statistics were applied to Upr/cr and Ualb/cr ratios with determination of 
likelihood ratios (LR) for requiring surgery.
Results: In this cohort, 22/81 (27%) were operated, including 21 pyeloplasties and 
1 nephrectomy for severe UUO. Initial proteinuria was significantly greater in UUO 
patients who underwent surgery compared to those without surgery (p=0.02). ROC-AUC 
demonstrated that both Upr/cr and Ualb/cr predicted the presence of severe UUO requiring 
surgery (Upr/cr: AUC=0.71; p=0.01 and Ualb/cr: AUC=0.75;p=0.02). Upr/cr and Ualb/cr 
was similar in normal control infants and those with non-surgical UUO.
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Conclusions: Proteinuria and albuminuria were significantly elevated in UUO infants 
who required surgery compared to normal term infants and those with non-surgical UUO. 
Although both were sensitive markers of renal injury, albuminuria was superior in predicting 
the need for surgery in patients with UUO.
PUB573
High Prevalence of Glomerular Hyperfiltration in Obese Adolescents 
Anitha Ezekiel, Jennifer Therese Potonia, Pedro Anis Rahnemaye rabbani 
nourani, Samhar I. Al-Akash.  Driscoll Children’s Hospital - Kidney Center, 
Corpus Christi, TX.
Background: Glomerular hyperfiltration (GHF) has been described in diabetic and 
obese (O) adults, and usually precedes proteinuria or clinical disease, and may indicate 
underlying renal damage and chronic kidney disease (CKD). GHF is poorly studied in 
adolescent children (AC). We hypothesized that GHF is present in AC and that GFR 
correlates with the BMI.
Methods: We queried the electronic medical records from 6/2010 to 12/2013 to include 
AC 12-21 years of age with at least one serum creatinine (SCr) and BMI in the same 
encounter, and excluded pts with CKD, HTN, DM, proteinuria, or renal transplant. Pts 
were separated into 2 groups; Control (C) - BMI < 30 and O - BMI ≥ 30 kg/m2. We used 
the original Schwartz formula (OSF) to calculate GFR as our lab uses the Jaffe method to 
measure SCr. We defined GHF as GFR > 150 ml/min/1.73m2.
Results: Demographic data and results are shown in table 1.
C (control) BMI 
< 30
O (obese) BMI 
> 30 P-value
N (encounters) 730 246
Mean age - years 18.5+0.8 15.5+2.0 <0.0001
Mean BMI - kg/m2 21.7+4.1 38.4+6.8 <0.0001
Male 48% 49% NS
Prevalence of GHF (GFR 
> 150) 3% 16% 0.0001 (OR 6.2)
- Male 0 28% 0.0001
- Female
4%
5%
NS
Mean GFR A 89.6 (85-95) B 128.2 (114-141) (BMI > 30) <0.0001
C 120 (114-127) 
(BMI 30-34.9)
<0.0001 (A vs. B, 
C, D, E) 
0.01 (C vs. E)
D 130 (124-136) 
(BMI 35-39.9)
E 134 (128-141) 
(BMI > 40)
Prevalence of GFR > 130 20% 43% <0.0001 (OR 6.9)
- Male 14% 62% <0.0001 (OR 19.1)
- Female 12% 25% <0.0291 (OR 2.5)
Conclusions: Using the OSF, we showed a higher prevalence of GHF in obese AC, 
and a showed that GFR correlated with BMI. Males have a greater risk of GHF. Due to the 
increased incidence of obesity in AC, special attention needs to be paid to renal function. 
In the absence of proteinuria or signs of clinical disease, GHF may be the earliest sign of 
renal disease, and should be assessed in obese AC. The choice of GFR estimation formula 
specifically in the obese has not been well established. This study provides preliminary 
data for a prospective trial for comparison of standard GFR measurement with existing 
GFR estimation formulas to allow the use of the most appropriate formula in obese pts.
PUB574
Familial Lecithin-Cholesterol Acetyltransferase Deficiency Masquerading 
as Membranous Nephropathy in Childhood  Ania B. Koziell, Katrina 
Soderquest.  Experimental Immunobiology, King’s College London, London, 
United Kingdom.
Background: Familial Lecithin-cholesterol acetyltransferase (LCAT) deficiency is a 
rare autosomal recessive disorder of lipid metabolism characterised by severely reduced 
HDL concentrations and impaired esterification of cholesterol. It is characterised clinically 
by glomerulopathy and mild haemolytic anaemia presenting in adulthood leading to ESRD 
by the fourth decade of life through the deposition of abnormal lipoproteins in the renal 
stroma. Paediatric cases are rarely described.
Methods: 2 siblings aged 8 and 11 years presented with asymptomatic non-nephrotic 
range proteinuria detected on routine testing. There was no family history of renal disease, 
although parents were consanguineous. Initial screens revealed normal renal function 
and normal serum albumin. Other investigations demonstrated raised lipid profiles but 
in keeping with nephrotic syndrome. A renal biopsy was performed in view of escalating 
protein and albumin creatinine ratios.
Results: Renal biopsy initially demonstrated light microscopic features of membranous 
nephropathy. However, electron microscopy demonstrated inclusions that were not typical of 
the adult form of the disease but clearly lipid filled (Figure 1). Confirmation of the diagnosis 
was by demonstration of significantly reduced HDL-cholesterol, and detection of a novel 
LCAT gene missense mutation G54V as well as reduced LCAT enzyme activity on assay. 
Conclusions: LCAT deficiency may present with mild symptomatic proteinuria in 
childhood. Although rare, it should be considered in a differential in paedatric membranous 
nephropathy. The diagnosis was made on characteristic EM appearances, genetics and 
reduced enxyme activity. A trial of enzyme replacement is planned. Interestingly, the older 
sibling has higher lipids yet the younger worse renal disease opening up new hypotheses 
for how LCAT deficiency might cause renal pathology.
PUB575
Umbilical Artery Histomorphometry: Linking the Intrauterine 
Environment and Nephrogenesis  Marissa J. Defreitas, Deepan Mathur, 
Wacharee Seeherunvong, Shahnaz Duara, Salih Y. Yasin, Maria Matilde 
Rodriguez, Carolyn L. Abitbol.  Pediatric Nephrology, Pediatric Pathology, 
Neonatology, Perinatology, Univ of Miami/Holtz Children’s Hospital, Miami, FL.
Background: An adverse intrauterine environment is linked to the developmental 
origins of aortic stiffness, nephron deficit, and adult onset cardiovascular and renal disease. 
We hypothesized that umbilical artery histomorphometry(UAH), a direct extension of 
the central vascular tree, would provide insight into nephrogenesis across gestational age 
(GA)groups.
Methods: From 156 newborns enrolled in the Gerber Infant Kidney Study, a subcohort 
of 32 had umbilical cord specimens evaluated (7 term(T-S), 15 preterm singletons(PT-S) 
and 10 preterm twins(PT-T)).The umbilical cord was sectioned, stained with Trichrome 
and digitalized.Muscular(MA) and collagenous areas(CA) of the umbilical arteries were 
measured in pixels using the ImageJ1.48q software and converted to mm2. The combined 
total kidney volume(TKV) was measured by ultrasound and factored by the infants’ 
ponderal indices and BSAs.
Results: TKV/PI of T-S (6.9±1.8) and PT-S(7.5±1.9) were similar; while TKV/PI of 
PT-T was significantly less than either of the singleton groups (4.5±0.8;p<0.001). Among 
PT-S, 6(40%) were from pre-eclamptic (PE) mothers. When paired by GA to other PT-S 
not from PE mothers, they demonstrated stunted TKV/BSA (93±28 versus 122±19µm2/
m2;p=0.02). Among twin pairs, there was also a discordance in TKV/BSA (68±10 versus 
81±15 µm2/m2;p=0.04). UAH demonstrated a positive correlation with increasing %MA 
and a negative correlation with increasing %CA.
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Conclusions: UAH links an adverse and/or competitive intrauterine environment with 
nephrogenesis independent of GA. An enhanced umbilical artery muscule area reflects an 
increased renal mass while increased vascular collagen parallels decreased renal mass in 
discordant twins and singletons of PE mothers.
Funding: Private Foundation Support
PUB576
Insulin-Like Growth Factor/Growth Hormone and Insulin-Like Growth 
Factor Binding Proteins in Normal Heighted and Short Children with 
CKD  John D. Mahan,1 Rose M. Ayoob,1 Larry A. Greenbaum,2 Amira Al-Uzri,3 
Frederick J. Kaskel,4 Susan L. Furth,5 Bradley Warady.6  1Pediatrics, Nationwide 
Children’s/OSU, Columbus, OH; 2Pediatrics, Emory Univ, Atlanta, GA; 
3Pediatrics, Oregon Health & Science Univ, Portland, OR; 4Pediatrics, Albert 
Einstein COM, New York, NY; 5Pediatrics, Univ of Pennsylvania, Philadelphia, 
PA; 6Pediatrics, Children’s Mercy Hospital, Kansas City, MO.
Background: Earlier reports indicated that children with chronic kidney disease (CKD) 
have ‘normal’ Growth Hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) levels, 
suggesting that intracellular resistance and increased IGF-1 Binding Proteins (BPs) account 
for the poor growth seen in 35% of these children. We explored key growth mediators in 
subjects with CKD enrolled in the Chronic Kidney Disease in Children (CKiD) study 
with either normal height or short stature to explore potential explanatory differences in 
these two subsets.
Methods: 232 children in CKiD (206 normal height: 26 short stature; none on GH 
therapy) were matched by gender, age and GFR. Short stature = Height Standard Deviation 
Score (SDS) < -1.88. GH, IGF-1, and IGFBP-1 and 3 were determined by chemiluminometer 
and ELISA.
Results: Normal height CKD children had higher serum IGF-1/GH, higher IGF-1/
IGF-1 BP1 and similar IGF-1/IGF-1 BP3 compared to short CKD children. 
IGF-1/GH* IGF-1/IGF-1 BP1* IGF-1/IGF-1 BP 3*
Children height SDS 
< -1.88
356.7 [152.3, 
1017.2]
0.0056 [0.0012, 
0.0161] 37.91 [22.62, 56.97]
Children height SDS 
> -1.88
811.8 [168.2, 
2360.0]
0.0136 [0.0055, 
0.0582] 53.44 [35.34, 77.50]
P-value (Kruskal-
Wallis ANOVA) 0.0002 0.02 0.07
* = (median [IQR]) 
Height SDS correlated with IGF-1 in normal height children (r = 0.323), but not well 
in short children not on GH RX (r=0.046).
Conclusions: Differences in IGF-1, IGF-1/GH, and IGF-1/IGF-1BP1 may explain 
some variance in growth in CKD children. Height is more highly correlated to IGF-1 in 
normal height than short CKD children. Analyses in paired subjects may provide further 
insights in children naïve to and those on rGH to allow detection of critical thresholds that 
explain and/or predict growth in children with CKD.
Funding: NIDDK Support, Private Foundation Support
PUB577
Assessment of Cochlear Sensitivity of the Pediatric Chronic Kidney Disease 
and Hemodialysis Patients  Rahime Renda,1 Levent Renda,2 Ömer Tark Selçuk.2 
1Antalya Research and Training Hospital Pediatric Nephrology; 2Antalya 
Research and Training Hospital Otorhinolaryngology Dept.
Background: Abnormalities in auditory system are frequent in patients with chronic 
renal disease and hemodialysis. The aim of this study was to throw light on the relationship 
between cochlear sensitivity and chronic kidney disease with or without hemodialysis.
Methods: Children aged 6-18 years were evaulated in three groups; 36 nondialytic 
patients with chronic kidney disease, 16 end stage renal disease patients undergoing 
hemodialysis, and 30 age and sex-matched control subjects. Hearing outcomes were obtained 
by pure-tone audiometry and distortion product otoacoustic emissions measurements.
Results: No significant difference was found except in the both ears at 500 Hz 
frequencies between the study group and the control group. The signal/noise ratio levels 
and distortion product levels were significantly lower in the nondialytic and dialytic group 
at all frequencies. Patients with normal hearing were found to have significanly lower 
signal/noise ratios and distortion product levels than those observed in the healthy controls.
Conclusions: These results showed lower cochlear functions in the dialytic and non-
dialytic group regardless of hearing loss than in the control group. Patients with chronic 
renal disease with or without hemodialysis should be monitored periodically even if the 
hearing thresholds seem to be within normal limits.
Funding: Government Support - Non-U.S.
PUB578
Percutaneous Renal Biopsy at OPD Level  Byoung-Soo Cho,1 Yumi Choi,2 
Jin-Soon Suh.3  1TheAll Medical Hub Kidney Center, MIRAE ING Research Inst, 
Seoul, Republic of Korea; 2Dept of Pediatrics, Gwangmyeong Sung-Ae Hospital, 
Gwangmyeong-si, Gyeonggi-do, Republic of Korea; 3Dept of Pediatrics, 
College of Medicine, The Catholic Univ of Korea, Bucheon-si, Gyeonggi-do, 
Republic of Korea.
Background: Renal biopsy is a prerequisite procedure for the final diagnosis and 
to evaluate the treatment effect or to determine the prognosis, however due to serious 
complication of the procedure, should be done by nephrologist and has been perfomed 
at admission state.
Methods: Our center perfomed percutaeous renal biopsy 3,000 cases without major 
complications during last 30 years, when patients were admitted for 3days. During last 
18 months, we performed percutaneous renal biopsy at OPD level under the ultrasound 
guide (LOGIQ E9).
Results: The youngest one is 1 year old male and the oldest was 64 years old. Mean 
age was 26 years old. Male to female ratio was 3:2 Mean glomeruli numbers were 31. We 
used disposable kidney biopsy needle (TSK ACECUT). We checked ultrasound 3 times after 
renal biopsy for checking AV fistula, hematoma formation during 6 hours hospital stay. Of 
the 100 case 8 cases received follow up biopsies. Among 100 samples renal medulla was not 
detected. Two patients(2%) among 100 biopsies showed small(less than 1cm) hematomas. 
No AV fistula were detected. All patients went home 6hours after renal biopsy without 
any problems. Renal biopsy results showed IgAN(23%), Nonspecific GN(21%), Diffuse 
mesangial proliferative GN (17%),HSPN (6.7%), MGN(5.6%),FSGS (5.6%),Others were 
Alport,Lupus nephritis,DM nephropathy,MPGN type I,Thin GBM nephropathy.
Conclusions: In conclusion, percutaneous renal biopsy under the ultra-sound guide 
at OPD level with 6 hour ABR is safe and effective if perfomed at renal cortex level.
PUB579
Acute Lymphocytic Leukemia with Bilateral Renal Masses Masquerading 
as Nephroblastomatosis  Salim Aljabari, Poonam Thakore, Curtis W. Turner, 
Tetyana L. Vasylyeva.  Pediatrics, Texas Tech Univ Health Sciences Center, 
Amarillo, TX.
Background: While leukemia has a wide spectrum of presenting features, renal 
involvement at presentation of the disease is rarely seen. We are reporting a child with 
bilateral renal lesions resembling nephroblastic rests as the first and the only finding 
subsequently developing classic features of acute lymphocytic leukemia (ALL).
Methods: A 4 year old boy was presented with low grade fever and abdominal pain 
for few days. A complete blood count (CBC) and abdominal CT scan were done to rule out 
appendicitis. WBC of 8.1 K/UL,hemoglobin of 13.3 g/dL,Platelets of 170 K/UL, neutrophils 
22%,Lymphocyte of 68.9% and absolute neutrophil count of 1.8 K/UL.CT scan showed 
bilateral renal enlargement with multiple hypodense lesions in the cortical and subcortical 
regions. Blood urea nitrogen of 7 mg/dl and creatinine of 0.38 mg/dl. The patient was 
diagnosed with viral gastritis and sent home on supportive treatment. CT scan was later 
interpreted as nephroblastomatosis by pediatric radiologist as an incidental finding advised 
to follow up with the pediatric nephrologist. After 14 days he again had low grade fever 
with abdominal pain. CBC showed WBC of 3.5 k/UL,Hemoglobin of 11.1 G/DL,platelets 
count of 21 K/UL,neutrophils 6 % and lymphocyte 85% ,absolute neutrophilic count was 
351 and ESR of 71 mm/hr. The pediatric oncology service was consulted for possible 
malignancy. Peripheral blood smear showed the presence of abundant immature lymphoid 
cells representing 90 % of the total white cells. Bone marrow aspirate and biopsy,flow 
cytometry and cytogenetic studies showed early B cell leukemia. Treatment was initiated 
following the guidelines of COG AALL0932. After one week of induction therapy,the CT 
scan showed a complete interval resolution of all renal hypodense lesions.
Conclusions: Renal involvement in leukemia is challenging to diagnose due to its 
variable presentation on imaging. On CT scan, it may present as enlargement of kidneys 
(unilateral or bilateral), or a low-attenuation focal parenchymal. These focal lesions can 
be difficult to distinguish from nephroblastomatosis which has a similar radiological 
picture on CT scan.
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Modality of Treatment of Pediatric Patients with Diarrheal HUS in 
Acute Renal Failure Does Not Affect Long Term Outcome and Survival 
Sonia Solomon, Julia W. Tzeng.  Pediatrics, Valley Children’s Hospital, Madera, 
CA; Pediatrics, Univ of California, San Francisco - Fresno, Fresno, CA.
Background: Diarrheal HUS is a disease process usually resulting from infection by 
E. coli H7:0157 and leading to the development of microangiopathic hemolytic anemia, 
thrombocytopenia, and acute renal failure. Acute renal failure typically follows in five days 
from presentation, with about two-third of the patients requiring renal replacement therapy. 
Studies have demonstrated that these patients are at risk for long term renal insufficiency 
and end-stage renal disease. Indications to start dialysis and the mode of dialysis vary 
from institution to institution. There is no current study comparing which mode of dialysis, 
hemodialysis or peritoneal dialysis, has greater benefit and less complications. The aim 
of this study is to compare dialysis modalities and determine whether one modality will 
result in less complications and better outcomes.
Methods: This is single center, retrospective review. We studied a total of 102 patients 
from 1999 to 2014. We compared patients with dHUS started on PD or HD. We compared 
the number of complications and the types of complications from each modality. Long term 
outcomes were measured by each patient’s CKD staging at least one year after diagnosis. 
EGFR was calculated using the Schwartz formula. Fisher’s exact statistical test was used 
to assess statistical significance.
Results: No statistical significance was found between the modality of dialysis and 
associated complications (p=0.4). There was also no statistical significance between 
modality of dialysis and long term outcome (p=0.9). Complications of PD were catheter 
malfunction (n=6), peritonitis (n=5), and the need to switch to HD or CVVHDF (n=3). 
Complications of HD included central line infections (n=1).
Conclusions: PD and HD are equally effective in treating patients with dHUS in 
renal failure and have comparable long term outcome and risks for complications. An 
important complication to consider for patients on PD is the potential need to switch to 
HD or CVVHDF; this exposes the patient to an additional surgical procedure that may 
result in further complications. 
PUB581
Self-Reported Health Care Transition Readiness Among Mexican 
Adolescents with Chronic or End-Stage Kidney Disease  Guillermo Cantu,1 
Ana Catalina Alvarez-Elias,3 Saul Valverde,2 Maria E. Ferris,3 Mara Medeiros.2 
1Univ Panamericana, Mexico, DF, Mexico; 2Univ of North Carolina at Chapel 
Hill, NC; 3Hospital Infantil de México Federico Gómez, Mexico, DF, Mexico.
Background: 90% of pediatric patients with chronic disease live more than 20 years 
after being diagnosed. When pediatric patients are transferred to adult-focused health 
services, generally they do not have the skills and abilities to manage their disease. 
Adolescents tend to have poor adherence to treatment, and there is a period when there 
may be complications and increased morbi-mortality. Performance on self-reported health 
care transition readiness (HCTR) needs to be assessed in patients with chronic or end-stage 
kidney disease. The aim of the study was to measure self-reported HCTR using the STARx 
(Self-management and Transition to Adulthood with Rx=Treatment) Questionnaire1, among 
adolescents in the Nephrology Service at Hospital Infantil de Mexico Federico Gomez.
Methods: The Spanish version of the STARx Questionnaire was translated and back 
translated and applied to adolescents with chronic or end-stage kidney disease, in the 
outpatient nephrology department over a 9-month period. The 18-question tool diagnoses 
actions, knowledge and skills on chronic disease self-management, medications adherence 
and ability to find new health providers. Age was divided at 16 years. Student’s T-tests 
were performed and p-values of < 0.05 were considered significant.
Results: We enrolled 68 adolescents (53% males) who had a mean age of 15.75 
years (± 1.87). Patients who received hemodialysis in the past were 22 (34%). Females 
had significantly greater scores than males in the “action” category. Those who received 
hemodialysis in the past had greater knowledge about the disease (p 0.013).
Conclusions: The self-reported HCTR among Mexican adolescents with chronic or 
end-stage kidney disease differs by sex and treatment modality.
Funding: Government Support - Non-U.S.
PUB582
Italian Survey on Patients on Peritoneal Dialysis Treatment: ATENA 
Alessandro Possidoni,1 Sara Di fino,1 Flavia Caputo,2 Carlo Crepaldi,3 Roberto 
Dell’Aquila,4 Emilio Giulio Galli,5 Anna Maria Costanzo,1 Umberto Di luzio 
paparatti,1 Roberto Russo.6  1AbbVie Italy; 2H. Civico of Palermo; 3H. Civile 
San Bartolo; 4Bassano del Grappa; 5H. of Treviglio; 6H. of Bari.
Background: in Italy,there are few epidemiological data concerning the clinical 
management of patients(pt)on Peritoneal Dialysis(PD)and the impact of PD on clinical 
outcomes.
Methods: epidemiological,multicenter study with a retrospective phase(12 months)
and a prospective phase(6 months)of subjects on PD.Primary objective:evaluate 
anaemia,hypertension and mineral metabolism compared to K-DIGO and K-DOQI 
guidelines(GL).Secondary objectives:comorbidities,hospitalizations,therapeutic 
strategies,mortality and quality of life(QoL).
Results: 377 consecutive pt. were enrolled(at baseline,CAPD 50.4%/APD 
49.6%;Male 59%;mean age:67 years;dialysis duration:39.7 months).The most frequent 
comorbidities were hypertension(88%),cardiovascular diseases(CVD=56%),vascular 
diseases(25%),dyslipidaemia(25%)and diabetes II(20%).The main cause of hospitalization 
was peritonitis(27%; no death associated),followed by CVD(20%).At 6 months,anaemia–not 
corrected or not adequately corrected(Hb£11g/dl)-occurred in 30% of pt. 73% received 
ESA.Systolic value>130 mmHg and diastolic value>80 mmHg occurred in 50% and 
30% of pt,respectively.Left ventricular hypertrophy was observed in about 60% of 
echocardiograms. 25(OH)D levels were<10 ng/mL in 30% of executed tests.Secondary 
hyperparathyroidism(SHPT)occurred in 30% of pt.The drugs used to manage SHPT 
were calcitriol(36.3%),paricalcitol(29.2%),colecalciferol(23.6%) and cinacalcet(21.5%).
Considering a group of pt under therapy for a year with similar basal PTH levels,a significant 
reduction of iPTH occurred with paricalcitol(1.05 mcg/day),but not with cinacalcet(39.4 
mg/day)(p<0.001 vs p=0.626).No effect on Ca and P occurred in the paricalcitol group.At 
the end of the study,PD didn’t modify the QoL significantly.
Conclusions: hypertension and CVD are the most common comorbidities of 
PD.Peritonitis is the main cause of hospitalization.Anaemia and SHPT are frequent and 
have to be treated and monitored carefully.There are significant differences in efficacy 
between different treatment options to treat SHPT.
PUB583
Advancements in Automated Peritoneal Dialysis Cycler Technology Driving 
Improved Quality of Care  Catherine Firanek, James A. Sloand.  Global 
Medical Affairs, Baxter Healthcare, Deerfield, IL.
Background: Enhancements to APD technology directed at greater ease of use and 
health care professionals’ (HCPs) oversight of patient status may help overcome barriers 
to home dialysis. Use of connectivity to enable remote patient monitoring (RPM) and 
prescription modification may facilitate patient management, increase HCP and patient 
communication, and improve outcomes. Advancements in design may also help simplify 
APD for patients. Objective is to understand and qualify importance of enhanced graphical 
user-interfaces (GUI), voice-guided instruction, and RPM embedded into APD cycler for 
HCPs and patients.
Methods: Forty-minutetelephoneinterviews and web-based surveys, including cycler 
videos, were conducted with 214 nephrologists, 138 renal nurses, and 193 CKD patients 
from UK and US. HCPs included those in practice for >3 yrs, spending > 75% of their time 
treating patients, and experience with use of conventional cyclers. Patients included those 
considered candidates for PD or those currently on dialysis, including incenter HD, home 
HD or PD. In double-blinded study, participants compared 2 conventional cyclers and a 
cycler with new technology with information screen, enhanced GUI and clinic connectivity.
Results: On a scale of 1-7 (7 the most important), cycler features rated most important 
to nephrologists, nurses, and patients include size and portability, GUI with voice-guided 
instructions, and data connectivity/RPM. When rating each cycler on favorability of 
attributes, the cycler with new technology scored highest. Attributes of 1st conventional 
cycler scored an average of 0.5 (on a scale of -3 to 3), while attributes of the cycler with 
new technology from the same manufacturer scored an average of 2.6 (p<0.0005). The 
attributes of the 2nd conventional cycler compared to the cycler with new technology 
scored on average 1.15 and 2.3 (p<0.0005), respectively.
Conclusions: HCPs and patients identified enhanced GUI, voice guidance, and 
data connectivity allowing RPM as favorable attributes to cycler usability and patient 
management. Technological enhancements that facilitate ease of cycler use and connectivity 
may increase PD acceptance by patients and HCPs.
PUB584
A Single Center Ten-Year Experience in PD Catheter Placement 
Yorg Al Azzi, Etti Deborah Zeldis, Girish N. Nadkarni, Harry Schanzer, Jaime 
Uribarri.  Nephrology, Mount Sinai Hospital - Icahn School of Medicine, New 
York, NY.
Background: In our early implantation practice, curly tip catheters had better function 
and less migration when compared with straight catheters and as such, we for the past 10 
years have implanted almost exclusively the curly catheters. This is in disagreement with 
some current literature that favors straight catheters. Due to this discrepancy, we decided 
to review our single center experience with PD catheters over the past 10 years.
Methods: PD catheters placed over the period of 2004–2014 at our hospital were 
reviewed. Demographics, comorbidities, operative note, type of catheter, surgical approach, 
complications and overall survival were collected.
Results: 170 PD catheters were inserted during 10 years (49.7% men,mean age 
54.7 years,167 curly catheters vs 1 straight intra-peritoneal,63% placed by open surgical 
technique vs 37% by Y-Teck peritoneoscopy). Diabetes mellitus was the most common 
cause of ESRD. 60 peritonitis cases occurred during the period of observation (24 lost 
their catheter), 30 had exit site infection, 9 had a leak out of which 4 lost their catheter, 3 
had primary non-function of their catheter, 4 had hernias (1 taken off PD). There was no 
difference in hazard ratios in catheter survival after adjusting for demographics; diabetes 
status and number of previous catheter placement for overall follow up. But, looking at 
2-year catheter survival, open placement of catheters had a higher adjusted hazard ratio for 
catheter loss compared to peritoneoscopic placement (aHR 2.61; 95% CI 1.02-6.71;p=0.04) 
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Conclusions: Our single-center experience demonstrated similar PD catheter survival 
rate and a better 2-year survival for catheters placed by peritoneoscopy. Our predominant 
use of the curly PD catheters suggests no significant difference in outcome compared to 
the straight catheters.
PUB585
Peritoneal Dialysis Patients Who Switch Phosphate Binders from Sevelamer 
to Sucroferric Oxyhydroxide as Part of Routine Clinical Practice: A 
Retrospective Database Study  Linda H. Ficociello, Vidhya Parameswaran, 
Phaneth Keo, Claudy Mullon, Franklin W. Maddux, Robert J. Kossmann. 
Fresenius Medical Care North America (FMCNA), Waltham, MA.
Background: A retrospective database study on the real-world effectiveness of 
sucroferric oxyhydroxide (SO), an iron-based phosphate binder (PB), in a cohort of adult 
peritoneal dialysis (PD) patients (pts) was conducted. This analysis examines PD pts from 
that cohort who switched from sevelamer (SEV) to SO (n=183).
Methods: All pts were prescribed SO as part of routine clinical practice at FMCNA 
clinics. Pts eligible for analysis had ³1 serum phosphorus (sPhos) during SO and the most 
recent PB used during the 3 months before SO was SEV. Changes in sPhos, serum calcium 
(sCa), intact parathyroid hormone (iPTH), transferrin saturation (TSAT), ferritin (FER), 
and PB pills per day were assessed 3-months before starting SO (baseline) and 3-months 
during SO treatment (follow-up).
Results: Pts (n=183) were, on average, 53 years old with a dialysis vintage of 3.9 
years. Pts with in-range sPhos increased from 14.8% to 25.7% (74% increase). There was 
a significant reduction in sPhos (6.8 to 6.5 mg/dl,p=0.005), sCa (9.2 to 9.1 mg/dl,p=0.02), 
and PB pills per day (8.4 to 3.8 pills,p<0.001). iPTH changed minimally (544.6 to 559.8 pg/
ml,p=0.5). TSAT increased significantly (35.0 to 37.5%, p=0.02) but not FER (782.1 to 840.3 
ng/ml) when pts treated with IV iron were included; there was minimal TSAT change (35.2 
to 36.3%) and no increase in FER (823.2 to 732.9) in pts not treated with IV iron (n=77).
Conclusions: In a cohort of PD patients who switched from sevelamer to sucroferric 
oxyhydroxide as part of routine clinic practice, an increase in patients with in-range serum 
phosphorus (74%, p=0.003) and significant decreases in serum phosphorus and calcium were 
observed. Phosphate pill burden was decreased by 4.6 pills (8.4 to 3.8 pills per day, p<0.001).
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB586
Improved Serum Phosphorus Control and Decreased Phosphate Binder 
Pill Burden Amongst African American Peritoneal Dialysis Patients Taking 
Sucroferric Oxyhydroxide  Vidhya Parameswaran, Linda H. Ficociello, Claudy 
Mullon, Franklin W. Maddux, Robert J. Kossmann.  Fresenius Medical Care 
North America, Waltham, MA.
Background: This study evaluated the real world effectiveness of sucroferric 
oxyhydroxide (SO) use among peritoneal dialysis (PD) patients (pts) who self-reported 
race as Black or African American (AA).
Methods: A retrospective database analysis was conducted on a cohort of AA PD 
pts who were prescribed SO as part of standard care at FMCNA clinics. Pts had ³1 serum 
phosphorus (sPhos) measured while using SO and had been on sevelamer, calcium-based 
phosphate binders or had no phosphate binder specified prior to SO treatment. Differences 
in sPhos, pill burden(PB), serum calcium(sCa), ferritin, transferrin saturation(TSAT), and 
intact parathyroid hormone(iPTH) were noted between baseline (BL; 3 months prior to 
SO) and follow-up (SO-TX; 3 months during SO).
Results: 117 AA PD pts (mean age=50 years, dialysis vintage=4.2 years) were included. 
At BL, 37% were on sevelamer, 31% on calcium-based phosphate binders, 2% on dual 
therapy and 31% had no phosphate binder specified. Figure shows increase in pts who have 
in-range sPhos (20% to 31.6%; 58% increase). Mean sPhos decreased from 6.55-6.38 mg/
dl (p=0.06). A significant decrease in PB was observed (4.5 pills/day, p<0.001) between 
BL(8.8 pills) and SO-TX(4.3 pills). No significant differences were observed between 
BL and SO-TX for sCa (BL=9.1 mg/dl, SO-TX=9.1 mg/dl), ferritin (BL=861.9 ng/ml, 
SO-TX=870 ng/ml), TSATs (BL=34.7%, SO-TX=36.8%) and iPTH (BL=729.5 pg/ml, 
SO-TX=696.4 pg/ml). 
Conclusions: In a cohort of African American peritoneal dialysis patients who were 
prescribed sucroferric oxyhydroxide as part of routine clinical care, there was a 58% increase 
in the number of patients with serum phosphorus levels in-range (p=0.006). Furthermore, 
there was a significant reduction in pill burden (4.5 fewer pills, p<0.001).
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB587
Peritoneal Dialysis for Management of Refractory Heart Failure 
Girish Singhania, Abhilash Koratala, Amir Kazory.  Nephrology, Univ of 
Florida, Gainesville, FL.
Background: Refractory heart failure (RHF) is associated with significant morbidity 
and mortality. There is growing interest in the use of peritoneal dialysis (PD) for management 
of patients with RHF. In this study, we explored the currently available data on the safety 
and efficacy of PD in this setting.
Methods: A search of PubMed database using key words “peritoneal dialysis” and 
“heart failure” from 1985 to 2015 was performed by two of the authors independently 
and found 763 articles, from which those including at least 20 patients who had initiated 
PD for cardiac indication were selected. Relevant data on efficacy and safety such as 
changes in the quality of life and cardiac function as well as the rate of hospitalization 
were extracted and compared.
Results: Seven studies (4 prospective and 3 retrospective) met the inclusion criteria with 
a total of 398 patients and a mean age of 70.4 years. PD was associated with improvement 
in functional status (1 to 2 NYHA class reductions) in 5 of the 7 studies (not reported in 2) 
as well as an increase in the ejection fraction in 6 studies. A variety of PD regimens were 
used that in general showed efficacy in removal of fluid as suggested by notable reduction 
in patients’ weight in 6 studies by up to 8.3 kg (unavailable in 1). It was also shown to 
significantly reduce the number of days of hospitalization for acute HF in 6 studies by up 
to 90%. Five studies reported increase in responsiveness to diuretics as well as perceived 
improvement in the quality of life. The PD-related complications were found to be minimal 
in 6 studies while one reported 0.75 episode/patient/year of peritonitis.
Conclusions: Currently available evidence suggests that PD is an efficacious option 
for management of patients with RHF that can result in significant improvement in their 
functional status, hospitalization rate, and the quality of life. Based on the findings of 
these studies PD is safe in this population and its related morbidity does not replace HF-
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associated morbidity. Larger controlled trials are warranted to explore the potential impact 
of PD on the mortality of patients with RHF and to define those subgroups most likely to 
benefit from this therapy.
PUB588
Procalcitonin, Is It a Useful Biomarker for Peritoneal Dialysis Peritonitis? 
Shinhan Song, Hyeon-Cheol Park, Jae Seok Kim, Jae Won Yang, Byoung Geun 
Han, Seung-Ok Choi.  Internal Medicine, Yonsei Wonju College of Medicine, 
Wonju, Korea.
Background: Peritonitis is a common complication in peritoneal dialysis (PD). 
Procalcitonin is a peptide hormone which has been used as a biomarker for the diagnosis 
of bacterial infection. We aimed to investigate the usefulness of procalcitonin in the patients 
with PD peritonitis.
Methods: This study included 33 episodes of peritonitis in 27 patients for follow-
up period of 450 days. In addition, we collected samples of PD effluents from 7 PD 
patients without peritonitis to compare with those of peritonitis. We investigated clinical 
characteristics, serum and PD effluent levels of procalcitonin at the time of initial visit 
and discharge.
Results: The mean value of dialysis vintage of patients with peritonitis was 1774 
days, incidence of total peritonitis for period of PD maintenance; 4.3 times, interval 
from symptom onset to visit; 13.6 hours, duration of intraperitoneal antibiotic treatment; 
8.2 days, and interval from clinical improvement to recurrence; 80.7 days. Initial serum 
procalcitonin increased to 0.97 ± 3.67 ng/mL (mean ± standard deviation) compared with 
reference values (healthy <0.05, PD patients <0.30, PD peritonitis >0.50 ng/mL), and PD 
effluent procalcitonin also increased compared with in the subjects without peritonitis, but 
not significantly (0.07 ± 0.19 vs. 0.01 ± 0.01 ng/mL, p=0.503). The serum procalcitonin 
decreased to 0.33 ± 0.54 ng/mL with clinical improvement but not significantly (p=0.308), 
and the PD effluent procalcitonin also showed the decreased level of 0.03 ± 0.08 ng/mL 
but not the statistical significance (p=0.360). Pearson’s correlation analysis showed that the 
serum and PD effluent procalcitonin did not have relationships with existing inflammatory 
markers such as ESR, CRP. Lastly, procalcitonin could not predict recurrence and mortality 
of peritonitis.
Conclusions: Collectively, procalcitonin showed the tendencies corresponding to the 
clinical course of PD peritonitis, but not statistical significance. We believe that procalcitonin 
is not superior biomarker in PD peritonitis compared with other existing markers.
PUB589
Epidemiological Survey of Maintenance Peritoneal Dialysis in China 
Xiang-Mei Chen, Xueying Cao, Delong Zhao, Guangyan Cai.  Chinese PLA 
General Hospital, Chinese PLA Inst of Nephrology, State Key Laboratory of 
Kidney Diseases, National Clinical Research Center for Kidney Diseases.
Background: To analysis epidemiology and trend of peritoneal dialysis during 2011 
- 2014 in China.
Methods: Patient-reported outcome data from the peritoneal dialysis centers were 
collected online during the study.
Results: (1)By the end of 2014, there were 55373 cases of maintenance peritoneal 
dialysis patients in China, had increased by 17 % per year over this time period . The annual 
incidence rate was 5.81/100 million people.The prevalence was 34.3/100 million.(2)The 
average age was 53 years. Male to female ratio was 1.2:1. The average age at initiation 
of dialysis was about 50 years old. The average residual renal function was 3ml/min. The 
average dialysis time was 2 years. The primary causes were primary glomerular disease 
54%, diabetic nephropathy 16%, hypertensive renal damage 14%. (3)In 2014, DOR fell 
to 6.6%. TOT was 27.2 months. The death patients accounted for about 51.3% of exit 
patients. The average death age was 64.8 years. The average therapy time was more than 
28.6 months. The cause of death was the cardiovascular and cerebrovascular events.(4)
Peritoneal dialysis access was the two cuffs, no gooseneck, straight. 78% patients were 
the continuous ambulatory peritoneal dialysis patients. The therapeutic dose was 6L to 8L. 
High peritoneal transport type was the largest. (5)PD patients with hemoglobin 100g/L 
ratio was raied every year. The albumin level in plasma was greater than or equal to 35g/L 
with more than 50% patients. Serum calcium, phosphorus, parathyroid hormone level was 
improved year by year. The average Kt/V was maintained at 2.1/ weeks. Ccr could reach 
62 L/1.73m2/ weeks.
Conclusions: There is a 17% annual increase in peritoneal dialysis patients. The 
incidence and prevalence was stable. DOR and TOT improved year by year. Anemia, 
plasma albumin, calcium, phosphorus metabolism and dialysis adequacy control were 
better than before.
Funding: Government Support - Non-U.S.
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Peritoneal Dialysis Patients Who Switch from Calcium-Based Binders 
to Sucroferric Oxyhydroxide as Part of Routine Clinical Practice: A 
Retrospective Database Study  Linda H. Ficociello, Vidhya Parameswaran, 
Phaneth Keo, Claudy Mullon, Franklin W. Maddux, Robert J. Kossmann. 
Fresenius Medical Care North America (FMCNA), Waltham, MA.
Background: A retrospective database study on the real-world effectiveness of 
sucroferric oxyhydroxide (SO), an iron-based phosphate binder (PB), was conducted in 
a cohort of adult peritoneal dialysis (PD) patients (pts). This analysis examines pts who 
switched from a calcium-based phospate binder (CaPB); either calcium acetate (n=95) or 
calcium carbonate (n=35) to SO.
Methods: All pts were prescribed SO as part of routine clinical practice at FMCNA 
clinics, had ³1 serum phosphorus (sPhos) measured during SO, and the most recent PB 
used was a CaPB. Changes in sPhos, serum calcium (sCa), intact parathyroid hormone 
(iPTH), % transferrin saturation (TSAT), ferritin (FER), and PB pills per day were assessed 
3-months before starting SO (baseline) and 3-months during SO treatment (follow-up).
Results: Pts who had in-range sPhos increased from 12.5% to 22.3% (78% increase) 
between baseline and follow-up (Figure). There were significant reductions in sPhos (7.1 
to 6.8 mg/dl, p=0.004) and PB pills per day (7.4 to 3.6 pills, p<0.001). Minimal change 
in sCa (8.99 to 8.95 mg/dl, p=0.5) and iPTH (519.2 to 544.4 pg/ml, p=0.4) was observed. 
There was significant change in FER (708.5 to 788.3 ng/ml, p=0.008, but not TSAT 
(35.8 to 35.5%, p=0.8) when pts treated with IV iron were included. There was minimal 
increase in FER (733.6 to 735.0 ng/ml, p=0.98) or TSAT (38.0 to 39.1%, p=0.6) in pts not 
administered IV iron (n=43). 
Conclusions: In a cohort of PD patients who switch from calcium-based binders to 
sucroferric oxyhydroxide as part of regular clinic practice, there was a 78% increase in 
patients achieving in-range serum phosphorus (p=0.003). Additionally, phosphate binder 
pill burden was lessened from 7.4 to 3.6 pills per day (3.7 fewer pills, p<0.001).
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB591
Effects of Chlorhexidine-Impregnated Patches on Catheter Exit Site and 
Tunnel Infections in Peritoneal Dialysis Patients  Chiaki Kawabata.  General 
Internal Medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Background: Exit-site infections and tunnel infections are major causes of catheter loss 
in peritoneal dialysis (PD) patients. We studied the effects of chlorhexidine-impregnated 
patches (Biopatch), which are used as central-line dressings or drain site dressings, on PD 
catheter exit site infection and tunnel infections.
Methods: A retrospective review was conducted of 45 patients whose PD catheter 
exit site was made between January 2007 and December 2014. We compared acute exit 
site infections, chronic exit site infections, and tunnel infections of the two groups, (the 
Biopatch Group and the Non-Biopatch Group), 6 months after the exit site was created.
Results: The Biopatch was used until the exit site had healed perfectly. The mean 
time of using the Biopatch was 63±26 days. The two groups had no significant differences 
in age [49.4±12.0 years vs 52.3±16.3 years], diabetes mellitus co-morbidity or pattern of 
peritoneal dialysis. There were no statistical differences in acute exit site infections [15.4% 
vs 6.1% (p=0.27)], chronic exit site infections [0% vs 9.1% (p=0.28)] or tunnel infections 
[15.4% vs 15.2% (p=0.90)] during the 6 months.
Conclusions: Using the Biopatch until the exit site has healed perfectly does not reduce 
either exit site infections or tunnel infections.
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The UK Peritoneal Dialysis Catheter Study (UK Cath): An Ancillary 
Study to the Peritoneal Dialysis Outcomes and Practice Patterns Study 
Martin E. Wilkie,1 Simon J. Davies,2 Mark Lambie,2 Francesca Tentori,3 Jeffrey 
Perl.4  1Sheffield Kidney Inst, Sheffield Teaching Hospitals NHS FT, Sheffield, 
United Kingdom; 2Keele Univ, Keele, United Kingdom; 3Arbor Research 
Collaborative for Health, Ann Arbor, MI; 4St. Michael’s Hospital, Toronto, 
ON, Canada.
Background: Delivering high quality peritoneal dialysis (PD) access placement and 
outcomes is limited by lack of standardization of PD access definitions and events, variable 
reporting of outcomes, and a paucity of robust evidence regarding optimal PD catheter 
insertion pathway(s). The UK Renal Registry PD access audit (2013) demonstrated 82% 
catheter survival at 1 year, with considerable variation between centres. Moreover, catheter 
function at 3 months was poorer for a medical (percutaneous) compared to a surgical (open 
surgical) insertion pathway.
Methods: UK-Cath, a multi-centre prospective cohort study (1350 patients, 45 dialysis 
centres, 18 month recruitment window) will assess the outcomes associated with different 
pathways of catheter insertion, dialysis unit-level policy associated with pathway use, and 
patient-level factors (e.g. case-mix, urgent start). Health economic benefits of these pathways 
will be determined using the cohort data, enriched by additional information obtained from 
more long-term follow-up study in a subset of patients using Hospital Episode Summary 
(HES) data linkage. The study has received funding from the UK NIHR Research for Patient 
Benefit Programme, NIHR PB-PG-0613-31028. A subset of study 20 centres will contribute 
to International Peritoneal Dialysis Outcomes & Practice Patterns Study (PDOPPS) with 
the primary objective of understanding variations in PD technique failure.
Results: We will present information on study design, instrument development, 
governance mechanisms, and recruitment plan. We will discuss the impact of patient 
engagement on study design.
Conclusions: The UK Peritoneal Dialysis Catheter Study will inform dialysis units’ 
decision to either focus their efforts on improving a single surgical pathway or to practise 
a mixture of surgical and medical insertions, with the ultimate goal to improve PD catheter 
survival, patient experience and optimise health economic efficiency.
Funding: Government Support - Non-U.S.
PUB593
Preparedness for Telemedicine in Outpatient Peritoneal Dialysis 
Kana N. Miyata, Panida Ditsawanon, Tiane Dai, Sharon G. Adler, Ramanath B. 
Dukkipati, Anuja P. Shah, Lili Tong, Anne A. Ugalde, Jenny I. Shen.  Nephrology, 
Harbor UCLA Medical Center, Torrance, CA.
Background: Peritoneal dialysis (PD) is generally performed daily by patients at 
home, where questions may arise. Telemedicine has the potential to improve the delivery 
of healthcare services and outcomes for PD patients. We studied the preparedness for 
telemedicine of a PD clinic run by a large dialysis organization (LDO) serving an urban 
under-resourced population.
Methods: Adult PD patients cared for by the clinic were asked about their interest 
and ability to use VSEE® (HIPPA-compliant tool for video calls) to remotely manage 
clinical concerns about PD. We compared patient characteristics between interested and 
non-interested groups. We also assessed the clinic’s ability to implement VSEE®.
Results: Initial barriers encountered were with the LDO. These included a firewall 
that prevented video products from being loaded onto clinic computers, consent issues, 
concerns regarding unequal care potentially being provided to patients with and without 
internet access, and lack of video equipment for on-call nurses. All of these barriers were 
overcome. We then assessed interest in 56 patients. Their age (mean±standard deviation) 
was 43±13 years, 63% were male, English was the primary language for 66%, and they had 
been on PD for 3.0±3.2 years. 34 patients (61%) showed some interest in telemedicine, 16 
(29%) downloaded the software to their laptop, tablet, or cell phone, and downloading in 
process for the remaining 18 (32%). The most common reason for not being interested was 
“no device” or “no internet access at home”, which was reported by 15 patients (27%). The 
only additional difference in characteristics between the interested and non-interested groups 
was that those interested lived further away from the clinic (12.9 vs 9.3 miles, p=0.03).
Conclusions: Multiple barriers to delivering telemedicine to PD patients exist, both 
on the clinic and patient side. 61% of patients were telemedicine-ready. Future evaluations 
will determine the impact on clinically significant outcome, patient satisfaction, and clinic 
workflow in this population.
PUB594
When to Remove the Peritoneal Dialysis (PD) Catheter After Renal 
Transplantation? (RT)  Saul Enrique Pampa,1 Maite Rivera,1 Victor Burguera,1 
Fernando Caravaca-Fontan,1 Estefania Yerovi,1 Nuria Rodriguez mendiola,1 Sara 
Jimenez alvaro,1 Cristina Galeano,1 Fernando Liano.1  1Nephrology, Hospital 
Univ Ramón y Cajal, Madrid, Spain; 2Urology, Hospital Univ Ramón y Cajal, 
Madrid, Spain.
Background: There seems to be consensus that the time of removal of the peritoneal 
catheter after RT may be delayed until renal function and the patient is stabilized, but there 
are few publications about it.
Methods: We analyzed retrospectively patients on Peritoneal Dialysis Unit (PD) who 
have received a RT between May 1995 and March 2015 gathering medical history data 
relating to the peritoneal catheter removal and complications.
Results: 108 patients transplanted from PD, 32 women/76 men with a mean age at 
the time of TR 50 +/- 13 years (range 16-80) were analyzed. Two patients received RT of 
living donor and 106 of cadaver. The catheter used in all was a straight Tenckhoff with 
two cuffs . If renal therapy substitution was needed postransplantation all patients were 
treated with hemodialysis. The catheter was removed during surgery in nine patients (8%) 
due to exit or tunnel infection by Staphylococcus aureus or Pseudomonas aeruginosa. The 
withdrawal was delayed in 91 patients (84%) and 8 has not yet been removed. The average 
withdrawal time was 4.1 +/- 2.7 months. The indication of withdrawn was: stable renal 
function in 85 (93%), stable pancreatic and renal function in 4 and exit site infection in 2 
(3%). Mean creatinine at the time of removal was 2.1 mg/dl +/- 1.8 mg / dl. All catheters 
were removed surgically under local anesthesia. The mean duration of hospitalization was 
2.1 +/- 1.8 days (0-12). Four patients (3.7%) had complications during withdrawal (one 
hematoma, two hemorrhagic shock and one surgical wound infection). 15 (18%) patients 
suffered complications before withdrawal: 13 exit site infection, one peritonitis associated 
with urinary fistula and one spontaneous peritonitis.
Conclusions: In our experience the removal of the peritoneal catheter may be delayed 
until renal graft function were stabilize since the rate of complication is low compared 
with another studies.
Funding: Other NIH Support - Spanish Public Health Service
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Clinical Outcomes by Differences in Therapy Among Peritoneal Dialysis 
Patients  Hironori Nakamura, Anayama Mariko, Yasushi Makino, Masaki 
Nagasawa.  Dept of Nephrology, Shinonoi General Hospital, Nagano, Japan.
Background: Studies evaluating the outcomes of peritoneal dialysis (PD) technique 
and patient survival, including those among patients who switch from PD to hemodialysis 
(HD), are scarce.
Methods: This retrospective study screened 120 patients in whom PD was initiated 
between January 1998 and December 2012 at our hospital. Of these, patients those who 
were transferred to another hospital, those who received transplantation, or those who did 
not have follow-up data were excluded. Fifty-two patients (age, mean ± SD: 69.2 ± 12.6 
years) were included to investigate the time of survival based on PD technique and overall 
survival, including those patients who switched to HD, and to evaluate the correlation 
between survival time and pharmacotherapy at the initiation of PD.
Results: Time (in months) on PD, HD, and overall survival were 34.3 ± 30.0, 18.5 ± 
43.4, and 52.6 ± 52.3, respectively. Comparison between the APD (n = 20) and non-APD 
patients (n = 28) showed that time on PD was 45.3 ± 34.4 vs. 31.3 ± 26.0 months, time 
on HD was 39.0 ± 40.6 (n = 8) vs. 81.8 ± 72.5 (n = 8) months, and overall survival time 
was 60.9 ± 49.9 vs. 54.7 ± 55.4 months, respectively. Comparison between groups with (n 
= 41) and without use of icodextrin (n = 7) showed time on PD was 10.8 ± 6.0 vs. 41.4 ± 
30.1 months, time on HD was 49.6 ± 45.0 (n = 3) vs. 62.9 ± 65.3 (n = 13) months, and the 
survival time was 32.1 ± 41.7 vs. 61.6 ± 53.6 months. When analyzed by age groups of 
<60, 61–70, 71–80, and >81 years: time on PD (months) was 47.2 ± 38.4 (n = 14), 45.2 ± 
23.4 (n = 15), 19.8 ± 27.0 (n = 10), and 21.2 ± 19.2 (n = 13), respectively. Time on HD was 
22.8 ± 44.2 (n = 6), 14.6 ± 36.3 (n = 5), 8.7 ± 28.2 (n = 1), 26.3 ± 60.1 (n = 4), respectively; 
and survival time was 70.1 ± 52.8, 59.2 ± 41.9, 28.5 ± 39.7, and 46.7 ± 67.2 months.
Conclusions: The time on dialysis and survival time may be underestimated because 
of the exclusion of patients who are currently on dialysis. Compared with non-APD 
patients, APD patients had longer time on PD and overall survival time. Patients who 
needed icodextrin when commencing PD had shorter time on PD and overall survival time.
PUB596
Combined Markers of Protein-Energy Wasting and Inflammation Predict 
Clinical Outcomes in Incident Peritoneal Dialysis Patients  Chan Ho Kim,1 
Jung Tak Park,2 Seung Hyeok Han,2 Tae-Hyun Yoo,2 Shin-Wook Kang.2  1Internal 
Medicine, Catholic Kwandong Univ College of Medicine, Incheon, Korea; 
2Internal Medicine, College of Medicine, Yonsei Univ, Seoul, Korea.
Background: Protein-energy wasting (PEW) and chronic inflammation are not only 
common but are known as predictors of adverse clinical outcomes in end stage renal 
disease (ESRD) patients. Whether the combined values of serum albumin, high sensitivity 
C-reactive protein (hs-CRP), and body mass index (BMI) have an additive impact on 
clinical outcomes compared to each variable by itself in incident peritoneal dialysis (PD) 
patients was evaluated.
Methods: A prospective cohort of 565 incident PD patients from the Clinical Research 
Center for ESRD in Korea was selected. Patients were divided into two groups based 
on the baseline levels of albumin (≥ and <3.8 g/dL), hs-CRP (≥ and <0.45 mg/dL), and 
BMI (≥ and <23 kg/m²). Primary outcome was the composite of all-cause mortality and 
unplanned hospitalization.
Results: The mean age was 51.4 years and 60.0% were male. During a median follow-
up duration of 27 months, 50 patients (8.8%) died and unplanned hospitalization events 
occurred in 123 patients (21.8%). Univariate analysis revealed an increase in primary 
outcome risk with lower albumin and elevated hs-CRP compared to higher albumin 
and lower hs-CRP, respectively. A similar tendency was observed with lower BMI and 
primary outcome, although without statistical significance. Regarding the combination of 
these variables, Cox proportional hazards analysis revealed that patients with any two risk 
factors and all three risk factors exhibited significantly higher hazard ratios for primary 
outcome compared to patients without any single risk factor. The combination of these 
factors retained a significantly higher HR for predicting primary outcome, even after 
adjusting for other confounders.
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Conclusions: The combination of serum albumin, hs-CRP, and BMI at the time of 
PD commencement was a significant independent risk factor for the composite outcome 
of all-cause death and unplanned hospitalization in incident PD patients.
Funding: Government Support - Non-U.S.
PUB597
Single Center Experience with a Peritoneal Dialysis Cycler with Advanced 
Patient Interactive Screen: Impact on Patient Training  Lili Chan,1 Ma shelda 
Cabus-Fojas,1 Marcia A. Duffoo,1 Catherine Firanek,2 James A. Sloand,2 Jaime 
Uribarri.1  1Mount Sinai; 2Baxter.
Background: Learning proper device use and clinical concepts of care must be 
internalized by patients to successfully perform PD at home. With increasingly diverse 
patients going on PD and increasing adoption of urgent start PD, there is a need for simpler 
devices. Enhancing the learning environment with methods including visual, graphical and 
voice will improve the educational experience leaving the patient with better understanding 
of the procedure.
Methods: Automated PD training was undertaken at a university based home dialysis 
program using a novel APD device (AMIA). 5 patients were trained on the device in a 
1:1 nurse to patient ratio. The cycler provided on screen instructions using a touch screen 
interface with voice guidance, text instructions and animation. Each patient was trained 
according to standardized outlines and sequential training progression from CAPD to APD 
techniques. Training included RN demonstration followed by patient direct interaction with 
the device. Instructions were displayed on a touch screen, along with verbal and graphical 
cues. Patient training completion required consistency of error free setup.
Results: 
Patient Age (years) Gender
Etiology of 
renal disease
Incident (I)/ 
Prevalent 
(P)
Urgent (U)/ 
Routine (R)
Training 
Days
1 30 F Hypertension/NSAID I U 2
2 47 F FSGS I U 3
3 49 F Calcineurin Inhib Toxicity P-HD R 5
4 68 M FSGS P-HD R 4
5 41 F Lupus Nephi-ritis P-APD R 4
5 patients aged 30-68 yrs (mean 47), 80% female with a minimum of HS education 
completed training. Device training ranged from 2-3 days for urgent start patients and 4-5 
days in routine start patients.
Conclusions: From our experience, training times were similar or reduced using the 
AMIA cycler and allowed the ability to efficiently train urgent start patients. Observed 
advantages of the new cycler included: 1) less need for memorization 2) distinction of a 
beginner vs advanced mode 3) online alarm troubleshooting 4) presence of an air detector 
in patients’ line 5) multiple prescription capability. The step by step instructions and online 
problem solving of the new device may impact positively the efficiency and understanding 
of these patients.
PUB598
Peritoneal Dialysis-Related Peritonitis in a Single Center: 10 Years 
Experience  Patricia O. Costa, Carla M V Melo, Jordanio P. Oliveira, Flavia 
A. Nobrega, Jandson P. Oliveira, Kleyton Andrade Bastos.  Dept of Medicine, 
Federal Univ of Sergipe, Aracaju, Sergipe, Brazil.
Background: Peritonitis remains as the main Peritoneal Dialysis (PD)- related 
complication. It is estimated that it contributes directly to 20% of dropout and is related to 
16% of all deaths. This study proposes to evaluate episodes of PD-related peritonitis and 
describe its incidence, causative organisms and possible predictors in patients belonging 
to a DP program from a reference center at Aracaju-Sergipe-Brazil.
Methods: Retrospective cohort study that evaluated 565 patients who stayed for at least 
30 days in the technique, between 01/01/2003 and 12/31/2012, with a mean age of 54 ± 19 
years, 55% male, 62% less than 8 years of regular study and 88% with monthly income less 
than 5 national minimum wages. They remained in DP by an average of 713.5 ± 714.2 days. 
Since 2011, was initiated daily use of gentamicin at the exit site of the peritoneal catheter.
Results: Most patients (59%) showed no peritonitis. The global index was 1 episode 
every 27.03 months. It was recorded the lowest rate in 2012 (1 episode every 45.6 
months), while the highest were in 2003 and 2005 (1 episode every 23.2 and 22.2 months, 
respectively). S. aureus was the most prevalent germ (23%), followed by E. coli (9%) 
and Alcaligenes sp (6%). The culture was negative in 31% of cases. There was healing of 
peritonitis in 71% of cases, with better outcome in gram-positive bacteria (83%). Gram-
negative healed in 61% of cases. It identified a higher risk of peritonitis in patients with 
history of exit site infection (relative risk = 1.24; 95% confidence interval = 1.02 - 1.50; p 
<0.05). There was no significant difference between the groups, with or without peritonitis, 
in terms of sociodemographic factors.
Conclusions: Despite the bad social indicators of the study population, the incidence 
of peritonitis follows the recommendations of the International Society for Peritoneal 
Dialysis (ISPD), with a reduction of rates along the years, especially after the introduction 
of gentamicin. Similar as described by other authors, exit site infection was recognized 
as a peritonitis´ predictor, so it is extremely important to perform preventive strategies.
PUB599
Placement of Peritoneal Dialysis Catheters: Not Limited to Operating 
Rooms  Sijie Zheng,3 Todd Drasin,2 Jeanne A. Darbinian,4 Paul Dybbro,2 Neelam 
M. Bhalla.1  1Nephrology, Kaiser Permanente Northern California, Hayward, 
CA; 2Interventional Radiology, Kaiser Permanente Northern California, 
Hayward, CA; 3Nephrology, Kaiser Permanente Northern California, Oakland, 
CA; 4Div of Research, Kaiser Permanente, Oakland, CA.
Background: As of December 2012, only 7% of ESRD patients in the USA utilize 
Peritoneal Dialysis (PD) for renal replacement therapy, despite many advantages of PD 
over hemodialysis (HD). One factor leading to low PD utilization is the lack of experienced 
surgeons available to place PD catheters in a timely manner. Interventional Radiologists (IR) 
can help with catheter placement. As of December 2014, Kaiser Permanente achieved a 23% 
PD rate among its ESRD population. One factor that contributed to the high percentage of 
PD utilization is a skilled IR service in the Greater Southern Alameda Area (GSAA) that 
facilitates the placement of PD catheters in a timely manner. We report a large number of 
PD catheters placed by GSAA IR physicians from January, 2011 to December, 2013 and 
compare to PD catheters placed by laparoscopic surgeons in the nearby East Bay Area 
(EBA) and Diablo Service Area (DSA) during the same time period.
Methods: We retrospectively analyzed KPNC electronic data base from 1/1/2011 
– 12/31/2013. We extracted data from GSAA where IR placed PD catheters using an 
Advanced Image guided Percutaneous (AIP) technique. We also extracted data from the 
EBA and DSA where surgeons placed PD catheters using the Advanced Laparoscopic 
Surgical (ALS) technique.
Results: We identified 203 PD catheters placed by GSAA IR with the AIP technique 
and 316 PD catheters placed by EBA/DSA surgeons using the ALS technique. Overall, 
GSAA IR placed 39% of all PD catheters across the 3 areas during the study time period.
Conclusions: : IR placed a significant percentage of overall PD catheters in 3 areas of 
our integrated health care system. In doing so, they overcame one of the barriers to high PD 
penetration in ESRD patients. In areas where there is a shortage of skilled surgeons, one 
can consider utilizing IR to solve this problem. Currently we are studying the outcomes 
of these two approaches.
Funding: Private Foundation Support
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Body Composition and Cardiovascular Outcomes Using Continuous 
Automated Peritoneal Dialysis – A Prospective Cohort Study 
Carlos Alberto Garza, Gabriela Leal, Bernardo Moguel.  Dept of Nephrology, 
National Inst of Cardiology, Mexico City, Federal District, Mexico.
Background: Fluid overload (FO) due to compliance in Continuous Ambulatory 
Peritoneal Dialysis (CAPD) is common. Efforts to achieve dry weight and avoid 
cardiovascular outcomes (CO) are lessen from inaccurate body composition(BC) estimations 
despite best clinical assessment.
Methods: We’ll follow BC, multiple frequency bioelectrical impedance(InBody S10, 
InBody Co),standard laboratories and CO, in all new patients to continuous Automated 
Peritoneal Dialysis(APD) previously in a CAPD. Measurements at baseline (CAPD), 1 
month and every visit to the dialysis clinic thereafter (APD) for a 5 year period.
Results: These are the first data of BODY cohort study. Initial 10 subjects are 
described, 4 men and 6 women, median age 27 years(17-46), height 159.5cm(146-166), 
baseline and first follow up variables are in Table 1. Wilcoxon rank test for related samples 
was performed. We found that PD modality switch to APD, at 1 month, reflected a body 
composition transition with statistical significance (P <0.05), within the EBW/TBW ratio 
at expense of trunk compartment. Most likely from improved dialysis adherence
Variable Unit Baseline 30 days P
Weight Kilogram (K) 60.75(42.7-104.2)
58.65(45.2-
108.4) -
BMI Kg/m2 23.6(17.2-39.7) 23.4(18.6-41.3) -
Systolic pressure mmHg 152(110-175) 136(117-180) -
Diastolic pressure mmHg 97.5(64-108) 91(59-127) -
Body water (TBW) Liters(L) 31.95(22.2-45.3) 31.5(24.8-45.2) -
Extracellular water (EBW) L 12.5(9.3-17.9) 12.2(9.4-17.5) -
Intracellular water (IBW) L 19.4(12.9-27.4) 19.4(14.7-27.7) -
EBW/TBW Ratio 0.39(0.38-0.42) 0.38(0.38-0.41) P<0.05
EBW/TBW Trunk Ratio 0.39(0.38-0.42) 0.38(0.38-0.41) P<0.05
Lean Muscle K 43.5(30.1-60.6) 43(33.4-60.6) -
Body Fat K 15.5(3.3-43.6) 16.2(5.7-47.8) -
Metabolic Rate (BMR) Kcal/day 1310(1019-1679) 1298(1091-1678) -
Dialysis L 7L(2-10) 8L(8-12) P<0.05
”-”not statistically significant
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Conclusions: We consider that APD, on the ground of increased, uninterrupted and 
rigorously performed therapy, is an appropriate method to optimize FO and aim for dry 
weight in PD. Further recruitment of patients and follow up of the BODY Cohort study is 
expected to confirm this hypothesis.
Funding: Pharmaceutical Company Support - HiTec Medical
PUB601
The Changes in Bicarbonate Level and Ionized Ca/ Corrected Ca Ratio of 
Patients Receiving Peritoneal Dialysis Using Bicarbonate/Lactate-Buffered 
Solution  Emi Kimoto, Nanae Matsuo, Masamitsu Morishita, Mami Nakamura, 
Yukio Maruyama, Yasuyuki Nakada, Masatsugu Nakao, Yudo Tanno, Ichiro 
Ohkido, Hiroyasu Yamamoto, Keitaro Yokoyama, Takashi Yokoo.  Div of 
Nephrology and Hypertension, Dept of Internal Medicine, Jikei Univ School 
of Medicine, Tokyo, Japan.
Background: Recently,PD solution which contains 25mEq/L bicarbonate and 10mEq/L 
lactate (Bicarbonate/Lactate-buffered peritoneal dialysis solution; B/L solution)is developed 
in Japan. Because of high concentration of lactate (40mEq/L) of conventional peritoneal 
dialysis (PD) solution, patients have generally higher serum bicarbonate level than those 
of patients receiving hemodialysis (HD). The new B/L solution is expected not only its 
biocompatibility but also improving excess correction of acidosis. Under the metabolic 
alkalosis environment, we reported that PD patients have lower levels of ionized Ca (iCa) 
at the same corrected Ca (cCa) levels. Thus, we hypothesized that iCa / cCa ratio increased 
after switching PD solution from Lactate-buffered to B/L solution.
Methods: We recruited 28 patients (55 ± 13 years, male 82%, PD duration 42 ± 21 
months) who switched from Lactate-buffered to B/L solution, and investigated changes in 
serum bicarbonate, iCa, and cCa levels.
Results: After switching solution, serum bicarbonate decreased (26.7 ± 3.2 vs 24.8 
± 2.5, P<0.01), and cCa did not change (9.3 ± 0.5 vs 9.3 ± 0.5, P=0.63). Neither iCa nor 
iCa/cCa ratio increased significantly (1.12 ± 0.09 vs 1.11 ± 0.09, P=0.48; 0.120 ± 0.007 
vs 0.119 ± 0.0006, P=0.54, respectively).
Conclusions: Conversion to B/L solution from lactate solution was associated with 
lower serum bicarbonate. Unfortunately, iCa did not change. Further investigations are 
needed to confirm the utility of the monitoring of iCa for the management of chronic kidney 
disease - mineral and bone disorder (CKD-MBD) in PD patients.
PUB602
Road to Success: One Academic Medical Center’s Experience Building 
a Peritoneal Dialysis Clinic  Yazan M. Alia, William A. Schlueter, Erwin E. 
Morales, Maria A. Gavino, Shubhada N. Ahya, Robin E. Watson.  Nephrology, 
Northwestern Memorial Hospital, Chicago, IL.
Background: Peritoneal Dialysis (PD) is an option for renal replacement therapy. 
The US Renal Data System 2012 Annual Report states that the annual per-patient HD 
cost is approximately $87,500 whereas for PD it is $66,750. In addition, studies have 
demonstrated that some aspects of quality of life are improved in PD patients compared 
with HD patients. Despite this, PD is underutilized in the US. Northwestern Medicine’s 
PD Program was initiated in 01/2014 with 4 nephrologists and 10 patients who transferred 
from a neighboring PD Unit. From 02/2014 to 04/2015, Northwestern’s Peritoneal Dialysis 
Clinic grew to 50 peritoneal dialysis patients.
Methods: We included all patients who started on PD (or transferred to PD) in PD 
Clinic between the periods of 2/14 and 4/15. Patients excluded from this analysis stopped 
PD within this period for the following reasons: switched to HD, expired, recovered kidney 
function, or underwent transplantation.
Results: From January 2014 to April 2015, PD Clinic grew to 50 patients. The age 
range is 22-86 years and mean age is 54.4 years. Thirty-one (62%) are men. Twenty-one 
(42%) are African American, 13 (26%) are Caucasian, 11 (22%) are Hispanic, and 5 are 
of Asian descent.
Conclusions: We describe a single, academic medical center experience on growth of 
PD Clinic from 0 to 50 patients within 14 months. Obstacles to PD Clinic growth included 
lack of availability of dialysate in mid 2014 and lack of experience with Urgent Start PD. 
However, with time, both nephrologist and surgeons and medical staff grew comfortable 
with this method of dialysis initiation. Features that facilitated successful and timely growth 
are: 1-realtime options training, 2-surgeon cooperation, 3-physical proximity to CKD Clinic 
and to inpatient floors, 4-continuity of care for patient-physician from outpatient CKD 
Clinic to inpatient setting to outpatient Home Dialysis Clinic.
PUB603
Peritoneal Membrane Transport Evaluation in Peritoneal Dialysis Using 
Traditional PET, Modified PET and Mini-PET  Miguel C. Riella,4 Jacek 
Waniewski,2 Bengt Lindholm,3 Marcelo Nascimento.1  1Univ Federal do Parana, 
Curitiba, Parana, Brazil; 2Inst Biocybernetics and Biomedical Engineering, 
Warsaw, Poland; 3Baxter Novum and Renal Medicine, Karolinska Inst, 
Stockholm, Sweden; 4Pro-Renal Foundation, Curitiba, Parana, Brazil.
Background: Peritoneal equilibration test (PET) is widely used for evaluating 
peritoneal transport; however, additional methods have been described to facilitate and 
improve this evaluation. Here we compared traditional PET (PET) with two newer methods, 
mini-PET and modified PET (mod-PET), which are increasingly used to investigate 
ultrafiltration capacity and peritoneal membrane characteristics in patients undergoing 
peritoneal dialysis.
Methods: Twenty-one non-diabetic adult patients on peritoneal dialysis (PD) for >3 
months underwent: PET (2.27%; 4 h), mini-PET (3.86%; 1 h) and mod-PET (3.86%; 4 h). 
Results of dialysate to plasma concentration ratios for creatinine (D/P Cr) and sodium (D/P 
Na), and dialysate to initial glucose concentration (D/D0 glucose) at the end of each test were 
compared by analysis of variance (ANOVA), Pearson correlation and Bland-Altman test.
Results: Whereas D/P Cr was not significantly different between PET and mod-PET 
(p=0.746) there were significant differences between mini-PET and both PET (p<0.001) 
and mod-PET (p<0.001). D/P Cr for PET correlated with D/P Cr for mod-PET (r=0.387; 
p=0.009) but not with D/P Cr for mini-Pet (r=0.088; p=0.241). Bland Altman test showed 
no significant bias of D/P Cr for PET vs mod-PET (-0.029; p=0.201) but a systematic 
difference (0.206; p<0.001) of D/P Cr for PET vs mini-PET. Whereas measurements of 
D/D0 glucose and D/P Na were in general not comparable nor significantly correlated, 
ultrafiltration during PET and mini-PET were weakly correlated (r= 0.260; p=0.009).
Conclusions: These results confirm that characterization of transport status based on 
D/P Cr may not necessarily differ between conventional PET and mod-PET.
Funding: Government Support - Non-U.S.
PUB604
Low Level of Albumin Is a Risk Factor for Short-Term Mortality of PD 
Patients  Kenji Harada.  Kokura Memorial Hospital; Kokura Memorial Hospital.
Background: Mortality of HD(hemodialysis) patients are reported, but few reports 
about PD(peritoneal dialysis) patients. This study aims to investigate clinical features of 
PD patients, their prognostic risk factors, and to establish a prognostic model for predicting 
their short-term mortality(1-2 years).
Methods: We investigated the mortality about PD patients(n=269, age:65 year 
old±13.7, male/female 173/96, PD vintage within 2 years, DM:121), and the influence of 
several parameters from 2009 to 2012. The dead and the transferred HD were excluded 
within 90 days. Finally 241 patients are remained. The survival rates for one year and two 
years were 91 % and 72 %. Infection was the most causes of death(53%). We investigated 
between death and several parameters(age, sex, blood pressure, albumin, hemoglobin, 
Ca, P, whole PTH, TC) by univariate analysis with JMP12, SAS. Those physical and 
laboratory data are measured at one month after PD started. Age and level of albumin were 
correlated with death. We hypothesized that low albuminuria and malnutrition influenced 
the rate of death. We divided three categories, from group A(albumin³3.3, n=82) and 
group B(2.8£albumin<3.3, n=89), group C(albumin<2.7, n=73).Cox proportional hazards 
regression model was used to analyse prognostic risk factors and establish prognostic model.
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Results: There were significant differences between group B and A(Hazard Ratio:2.611, 
p=0.0116, 95%CI:1.232-6.009), group B and C(Hazard Ratio:6.031, p<0.001, 95%CI:2.975-
13.53), group C and A(Hazard Ratio:2.309, p=0.0029, 95%CI:1.33-4.09). In addition these 
groups were analysed by adjustment factor such as age, sex, blood pressure, hemoglobin, 
Ca, P, whole PTH, TC with multivaliable analysis. The results proved that there were tended 
to be correlation between group B and A(Hazard Ratio:1.963, p=0.09, 95%CI:0.901-4.61). 
There were significant differences between group B and C (Hazard Ratio:4.00, p=0.003, 
95%CI:1.866-9.35), group C and A(Hazard Ratio:2.037, p=0.0029, 95%CI:1.165-3.63).
Conclusions: Low level of albumin increases the mortality of PD patients gradually. 
Therefore we may decrease the mortality of PD patients by improving nutritional condition 
and infection control when PD patients are introduced.
PUB605
The Effect of Neutral pH versus Conventional Peritoneal Dialysis Solutions 
on Peritoneal Permeability  Atsushi Ueda, Kei Nagai, Toshiaki Usui, Joichi 
Usui, Kunihiro Yamagata, Chie Saito.  Univ of Tsukuba, Tsukuba, Japan.
Background: Biocompatible peritoneal dialysis (PD) solutions have been anticipated 
to reduce oxidative stress more than conventional PD solutions,however, previous reports 
suggested peritoneal permeability have not been changed. This study was undertaken 
to investigate the peritoneal transport status from PD initiation, using biocompatible or 
conventional PD solutions.
Methods: We employed retrospectively 101 patients who started PD and divided into 
three groups. Acid group was consisted of 76 patients who used only conventional low pH 
solutions, and neutral pH group was consisted of 19 patients who used only biocompatible 
neutral pH solutions during the subsequent two years. The rest of six patients used low pH 
solutions at the initial phase of PD, then switched to neutral pH solutions. The ratios of 
dialysate to plasma creatinine concentration at 4 hour (D/Pcre) in peritoneal equilibration 
test were measured at every year. We evaluated D/Pcre levels at the initiation and two years 
after between acid and neutral pH groups, and also the D/Pcre movements before and after 
switching PD solutions of the six patients.
Results: There was no significant difference on the D/Pcre values between at the start 
and two years after in the acid and neutral pH groups respectively. D/Pcre change between at 
the start and two years after in the acid group was not significant different compared to that 
of the neutral pH group. However, D/Pcre declined significantly one year after switching 
PD solutions from acid to neutral pH.
Conclusions: It was not observed obvious beneficial effects of neutral pH solutions 
on peritoneal permeability within two years PD duration. However, the transient effect in 
decreasing peritoneal permeability was found, and suggested that biocompatible solutions 
may preserve peritoneal functions compared to conventional solutions in a long time period.
PUB606
Predictive Power of Serum Cystatin C Assessing Residual Renal Function in 
Patients on Peritoneal Dialysis  Jong Man Park,1 Sang Heon Song,1 Eun Young 
Seong,1 Harin Rhee,1 Ihm Soo Kwak,1 Il Young Kim,2 Dong Won Lee,2 Soo Bong 
Lee,2 Woo Jin Jung,1 Su Min Park,1 Min Jung Kim,2 Joo Hui Kim.2  1Internal 
Medicine, Pusan National Univ Hospital, Busan, Republic of Korea; 2Internal 
Medicine, Pusan National Univ Yangsan Hospital, Yangsan, Republic of Korea.
Background: Residual renal function (RRF) is of considerable importance for 
patient survival on peritoneal dialysis. In clinical practice, the RRF is usually measured 
by assessing the urine concentrations of urea and creatinine and total urine output and the 
process is cumbersome and time consuming. Cystatin C has proposed to be used in place 
of RRF measurement. This study aims to investigate the predictive power of cystatin C in 
peritoneal dialysis patients.
Methods: This study included 54 patients on peritoneal dialysis who had evaluated 
RRF, serum cystatin C and serum creatinine. RRF was measured using the 24-hour urea–
creatinine clearance method and cystatin C based glomerular filtration rate (eGFRcysC) was 
estimated using the Hoek’s formula. RRF and cystatin C were followed up for 6 months at 
least. The rate of RRF decline and slope of serum cystatin C were assessed by regression.
Results: Patients were on peritoneal dialysis for a median of 30 months and average 
serum concentrations of cystatin C was 5.41 ± 1.06 mg/L. Among the 54 patients, sixteen was 
anuric and seven became anuric during follow up. The patients with RRF had significantly 
lower cystatin C levels (p = 0.001). RRF was correlated with cystatin C (γ = -0.687, p <0.01). 
In simple linear regression, RRF was associated with cystatin C (γ = 0.687, p <0.001), 
eGFRcysC (γ = 0.741, p <0.001) and creatinine (γ = 0.662, p <0.001). The slope of serum 
cystatin C was correlated with the rate of RRF decline (γ = 0.616, p <0.001) during follow 
up. The overall loss of RRF group had a higher level of serum cystatin C at the point of 
dialysis initiation (p = 0.017).
Conclusions: Serum cystatin C level might be convenient parameter for estimating the 
RRF and serum cystatin C at the point of dialysis initiation might be a predictive marker 
of preservation of RRF. Further studies about the cystatin C based equations are required 
to replace creatinine/urea clearance measured RRF.
PUB607
Peritoneal Dialysis: A Decade Experience at a Reference Centre in Brazil 
Patricia O. Costa, Carla M.V. Melo, Flavia A. Nobrega, Jordanio P. Oliveira, 
Jandson P. Oliveira, Kleyton Andrade Bastos.  Dept of Medicine, Federal Univ 
of Sergipe, Aracaju, Sergipe, Brazil.
Background: Peritoneal Dialysis (PD) is underutilized in most countries. The Brazilian 
prevalence is around 9%. This study aims to describe the ten years experience on PD in a 
dialysis center in Northeast of Brazil (Aracaju-Sergipe). Unlike other national programs, 
negative selection for DP is not an attribute of this dialysis unit.
Methods: Retrospective cohort study that evaluated the sociodemographic and clinical 
profiles, comorbidities, peritonitis, hospitalizations and death causes of 565 patients who 
remained in PD for at least 30 days from 01/01/2003 to 12/31/2012.
Results: Patients were mostly men (55%), living outside Sergipe’s capital (56%), had 
a mean age of 54 ± 19 years old when started on dialysis, were illiterate or had less than 4 
school years (62%) and had a family income less than 5 national minimum wages per month 
(88%). The etiology of nephropathy was identified in 54% of cases, diabetic nephropathy 
(46%) and hypertensive nephrosclerosis (22%) were the most prevalent. Hypertension 
was the main comorbidity (76%). DP was the initial dialysis modality for 53% of patients, 
mainly as an emergency (58%), and only 9% of patients had undergone predialysis care for 
at least six months. Patients remained in PD by an average of 710.5 (± 714.2) days, and 61% 
of them also underwent hemodialysis (HD) at some point during their dialysis treatment. 
676 peritoneal catheters were implanted (1.19/patient), 75% by trocar, by nephrologist, 
mostly Tenckhoff (58%). The main cause of dropout were infectious complications related 
to therapy (17%). The peritonitis index was 1 episode every 27.03 months, and S. aureus 
was the most prevalent etiological agent (22%). There were 1045 hospitalizations during 
follow up, most frequently due to infections (48%). The cause of death was identified in 
64% of cases, mostly from cardiovascular diseases (50%).
Conclusions: In this study, patients had predominantly low socioeconomic status 
and did not have access to predialysis treatment, however, peritonitis rates and catheter 
complications are similar to those reported in other international series. HD and PD are 
shown as complementary techniques.
PUB608
Implementation of Clinical Practice Guidelines on Antimicrobial 
Prophylaxis in Peritoneal Dialysis Patients  Denise Campbell,1 Fiona Brown,2 
John F. Collins,3 Jonathan C. Craig,1 Martin P. Gallagher,4 David W. Johnson,5 
Geoffrey S. Kirkland,6 Subramanian K. Kumar,7 Wai Hon Lim,8 Dwarakanathan 
Ranganathan,9 Walaa W. Saweirs,10 Germaine Wong,1 David Mudge.5  1School of 
Public Health, Univ of Sydney, Sydney, New South Wales, Australia; 2Nephrology, 
Monash Univ, Clayton, Victoria, Australia; 3Renal Medicine, Auckland City 
Hospital, Auckland, New Zealand; 4Renal and Metabolic Div, George Inst for 
Global Health, Sydney, New South Wales, Australia; 5Nephrology, Princess 
Alexandra Hospital, Woolloongabba, Queensland, Australia; 6Nephrology, 
Royal Hobart Hospital, Hobart, Tasmania, Australia; 7Renal Unit, Gosford 
Hospital, Gosford, New South Wales, Australia; 8Renal Medicine, Sir Charles 
Gairdner Hospital, Perth, Western Australia, Australia; 9Nephrology, Royal 
Brisbane & Women’s Hospital, Herston, Queensland, Australia; 10Renal Unit, 
Whangarei Hospital, Whangarei, New Zealand.
Background: Despite the existence of international guidelines, peritoneal dialysis 
(PD)-related infections vary widely across Australian and New Zealand units, with multiple 
units reporting suboptimal rates and variable practice.
Methods: The current practice and barriers to guideline uptake were evaluated in 
eight PD units located in Australia and New Zealand in 2011. A multifaceted intervention 
was developed which included case report forms, a patient diary, a ‘Preventing Peritonitis 
Checklist’, an Emergency Department flyer, a letter to the patient’s general practitioner, a 
medical card, and a poster summarizing ISPD and KHA-CARI guidelines.
Results: At baseline (1 Jan-31 Dec 2011), exit-site infection (ESI) rates ranged from 
0.06-0.53 episodes/patient-year; peritonitis from 0.31-0.86 episodes/patient-year; and 
fungal peritonitis from 0.00-0.08 episodes/patient-year. After implementation (9 Dec 
2013-8 Dec 2014), the ESI rates were 0.00-0.22 episodes/patient-year; peritonitis was 
0.29-0.49 episodes/patient-year; and fungal peritonitis was 0.00-0.14 episodes/patient-year.
Conclusions: Implementing the various tools resulted in improvement in the ESI and 
peritonitis rates but the difference was not statistically significant (P=0.15 and P=0.08). 
There was no statistically significant difference in the fungal peritonitis rate (P=0.64).
Funding: Government Support - Non-U.S.
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Survival Analysis of 326 Continuous Ambulatory Peritoneal Dialysis 
(CAPD) Patients  Hao Zhang, Liu Li, Bin Yi, Wei Li.  The Third Xiangya 
Hospital, Central South Univ, Changsha, Hunan, China.
Background: This study aimed to identify clinical outcomes and risk factors that 
may affect potential prognosis of ESRD (end-stage renal disease) patients who receiving 
continuous ambulatory peritoneal dialysis(CAPD) in Southern China.
Methods: ESRD patients who initiated CAPD between period Aug 1st 2002 to Mar 
31st 2010 in The Third Xiangya Hospital, affiliated with Central South University were 
reviewed retrospectively. Demographic data including age at initiation, gender, body mass 
index(BMI), blood pressure, primary causes of ESRD and dialysis vintage, biochemical 
data including hemoglobin (HB), serum albumin(Alb), HDL(high-density lipoprotein), 
LDL(low-density lipoprotein), TL(total cholesterol), TG(triglyceride), immunoreactive 
parathyroid hormone (iPTH), serum phosphorus , serum calcium and residual renal 
function(eGFR) were collected from medical records. Outcome of death or technique failure 
from any causes were selected. All-cause mortality and survival rate were analyzed using 
variance analysis and COX regression.
Results: A total of 326 CAPD patients(199 male and 127 female)were identified in this 
study. The mean age was 50.73±14.99 years, median dialysis vintage was 46(2-144) months. 
Primary glomerulonephritis was the most common cause of ESRD (50.6%). The overall 1- , 
3- and 5- patient survival rate were 95.4%, 79.3% and 46.2%, and 1-, 3-and 5- technique 
survival rate were 90.8%, 67.2% and 43.6%, respectively. Significant differences in age, 
BMI, hemoglobin, albumin, eGFR between groups were found. No statistical significances 
were found in gender and primary causes of ESRD. In multivariate cox regression analysis, 
patient technique survival were associated with BMI (HR=1.230(1.154-1.310), p=0.000), 
Alb (HR=0.913(0.882-0.945), p=0.000), HB (HR=0.981(0.971-0.992), p=0.000), eGFR 
(HR=0.818(0.750-0.884), p=0.000).
Conclusions: The results suggested that obesity, anemia, hypoalbuminemia, lower 
eGFR at the commencement were independent risk factors for technique survival in 
CAPD patients.
PUB610
Factors Influence the Baseline Peritoneal Transport Status  Hao Zhang, Bin 
Yi, Cuiling Hou.  The Third Xiangya Hospital, Central South Univ, Changsha, 
Hunan, China.
Background: Baseline peritoneal solute transport rate(PSTR) is an independent risk 
factor for total and cardiovascular(CV) mortality in the PD(peritoneal dialysis) population. 
The determinants of PSTR in incident PD patients are still under debate. Our objective was 
to explore the influence factors of baseline PSTR.
Methods: (1) 205 incident PD patients who had a standard peritoneal equilibration 
test(PET) within 1-3 months after commencing PD and without  peritonitis history were 
enrolled. Pre-dialysis clinical parameters and biochemical indexes were assessed. 205 
individuals were divided into two groups according to the baseline PET. High transport 
group: PET³0.65,Low transport group: PET < 0.65. (2) Pre-dialysis serum advanced 
oxidation protein products (AOPP) and dialysate AOPP, GPx, hsCRP, IL-1beta, TGF-beta1 
of 59 patients among the enrolled 205 individuals were detected.
Results: (1) High baseline PET are more likely to be male(male: 77.3% vs 52.5%, 
p = 0.001), had lower serum albumin(34.0±4.40g/L vs 35.9±4.55g/L, p=0.005) and TG 
levels(1.11±0.62 mmol/L vs 1.28±0.57mmol/L, p=0.047) compared to the low baseline 
PET. Gender (r = 0.299, p = 0.299), serum albumin(r = 0.199, p = 0.199) and TG level(r 
= 0.140, p = 0.140) are correlated with the baseline PET respectively. Multiple stepwise 
linear regression analysis shows that gender (B = 0.085, p = 0.085), serum albumin (B = 
0.005, p = 0.005)) are associated with baseline PET independently. Multivariate Logistic 
analysis showed that men (OR = 3.314, p = 0.001), hypoalbuminemia (OR = 2.552, p = 
2.552) are independent risk factors for high baseline PET.ROC curve display that when 
serum albumin < 35.8 g/L, it is likely to have a high baseline PET. (2) High baseline PET 
had a relatively high level of dialysate TGF-beta1(1.58±0.33ng/ml vs 1.75±0.30 ng/ml, 
p=0.049) than the low transport status. No statistical differences were found in serum 
AOPP and dialysate AOPP, GPx, hsCRP, IL-1beta between groups. Dialysate TGF-beta1 
(r = 0.336 ,p = 0.009) relative to the baseline PET independently.
Conclusions: (1) Male, hypoalbuminemia, high dialysate TGF-beta1 level are 
independent predictors of fast baseline PSTR. (2) When serum albumin < 35.8 g/L, it is 
likely to have a high baseline PSTR.
PUB611
Influence of Peritoneal Transport Rate in Diabetic Patients on Peritoneal 
Dialysis: A Single Center Experience in Saudi Arabia  Naveed Aslam. 
Nephrology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background: Measurement of the peritoneal membrane transport features is crucial 
for both the characterization of its functional state and for the prescription of the adequate 
dialysis dose. It has been reported that increased peritoneal transport rate (PTR) is associated 
with lower patient survival, but the influence of diabetes mellitus (DM) on the PTR is still 
controversial. The objective of this study is to describe the PTR and its correlation, in 
terms of technique and patient survival, in diabetic patients on peritoneal dialysis (PD).
Methods: In a retrospective, single-center study, we evaluated a total of 84 diabetic 
patients, newly started on PD between January 2004 and December 2010. Peritoneal 
equilibration test (PET) status was recorded and patients were classified as one of the 
following four peritoneal transport types: high (H), high average (HA), low average (LA) 
and low (L) transporters. Inflammatory and nutritional markers along with routine renal 
parameters were assessed. Withdrawal from PD and death were recorded.
Results: The average age of patients starting PD was 76.3 ± 7.2 with a prevalence of 
male gender (70%). 80% of the patients showed high peritoneal transport rate (High: 28%, 
High-Average: 52%, Low-Average: 20%, Low: 2%). The 1, 3 and 5 year patient survival 
rates were 78%, 62% and 42% respectively. Technique survival rates were 64%, 52% and 
24% respectively. Only 10% of the patients could perform their PD therapy without the 
assistance of any family member or nurses. Only 70% of the patients were on APD among 
high transporters. Albumin level and CRP were negatively associated with patient survival.
Conclusions: Our data suggest that diabetic PD patients tend to be significantly high 
peritoneal transporters with worse prognosis in terms of patient and technique survival. 
This result is similar to what several large studies had reported in the literature. For diabetic 
PD patients, PET should be carefully evaluated and accordingly the prescription of short 
dwells, which have found their natural application in APD, should be kept in mind as a 
treatment option. The high transport rate is a contributory factor in low serum albumin levels.
PUB612
Practical Experience with Acute Peritoneal Dialysis (PD) as Initial Dialysis 
Modality  Jiri Vlasak.  FMC, Sokolov, Czech Republic.
Background: Hemodialysis (HD) is the predominant renal replacement therapy (RRT) 
in new end-stage renal disease (ESDR) patients in the Czech Repubłic. One of many reasons 
for this situation is that roughly 40% patients with ESDR are “late referral”. Due to the 
lack of predialysis education, these pacients have limited knowledge about dialysis options. 
Usually, hemodialysis is performed after the central catheter placement.
Methods: Between November 2012 and April 2015, 15 patiens with urgent need 
of dialysis were successfully initiated in our center on PD as the first option treatment.
Results: In two patients, we started PD immediately after the catheter insertion and 
on the second or third day in 13 patients. Exchanges were conducted in the out-patient 
dialysis center under the constant supervision of an experienced PD nurse in the modified 
mode-supine position, small volume solutions with 1,5% of glucose, 6-8 exchanges daily, 
using automated peritoneal dialysis (APD). Only one patient was treated in the local hospital 
because of severe uremia related symptoms. Exchanges were well tolerated. We did not 
observe any early complications (leak, malfunction of the catheter, infection, bleeding etc). 
All patients were educated 2-3 weeks after the start of acute PD regimen and we observed 
a strong adherence to PD method in all 15 patients.
Conclusions: Based on our experience, acute peritoneal dialysis can be successfully 
administered under the conditions of outpatient care in the majority of ESDR patients with 
the urgent need of dialysis if three preconditions are met. First, the team of well-educated 
staff in PD, especially in APD. Second, a close cooperation with surgeon experienced in 
laparoskopically assisted puncture technique of PD catheter. Third, the ability to introduce 
the PD catheter as urgent surgery.
PUB613
Cause of  Failure in Chronic Peritoneal  Dialysis  Catheters 
Elizabeth Huerta calixto.  Nephrology, Hospital Angeles Puebla, Puebla, Mexico.
Background: One of most common treatment of end stage kidney failure is peritoneal 
dialysis. Encapsulating peritoneal sclerosis is a complication in wich the osmotic capacity 
of peritoneal barrier is lost, mainly due to infections. This patology has different clinical 
presentations that obligue to use different diagnostic and therapeutic methods.
Methods: I was a survey conducted retrospective, descriptive and cross that included 
June 1, 2008 to May 30, 2014 in nephrology deparment of Angeles Hospital.
Results: Clinical and imagine presentation in three different patients, we analyze 
each separately as well as their solutions. These include delimitation of the affected zone, 
sterilization of the cavity and it’s collapse, even the renal transplatation.
Conclusions: Different clinical presentations of the encapsulating peritoneal sclerosis 
oblige to design evaluation and treatment for each patient in particular, using all the imagine 
and laparoscopic methods.
PUB614
Take on Characteristics of Incident PD Patients in a Multicentre 
Multinational Integrated Care Setting  Belen Marron,1 Marietta Torok,2 Delia 
Timofte,3 Janusz Ostrowski,4 Jose C. Divino-Filho.1  1Diaverum Home Therapies. 
Medical Office, Diaverum, Munich, Germany; 2Szeged Diaverum Clinic, 
Diaverum, Szeged, Hungary; 3Sema Diaverum Clinic, Diaverum, Bucharest, 
Romania; 4Wloclawek Diaverum Clinic, Diaverum, Wloclawek, Poland.
Background: Our institution as a Renal Service provider is committed to integrated 
care, offering all types of RRT and focusing in patient´s choice. Objectives: To analyze HD 
and PD take on and its relationship with the type of previous referral and provided care.
Methods: Retrospective analysis of 547 incident patients starting dialysis in 23 HD/PD 
clinics in 2012. Early referral (ER) considered if patient known ≥ 3months in Nephrology, 
and scheduled initiation of dialysis with a permanent access was considered planned (P).
Results: Population: 30% diabetes, mean age 64 years, 84% with previous medical 
care of renal disease, 49 % late referral, 80% modality informed, 58 % unplanned start, 
11% PD ( 3% early switch from urgent HD). PD therapy in non-planned start applied in 
5/59 PD patients. No differences in HD/PD take on were observed for gender, diabetes, 
initial renal and predialysis follow up, at structured units or in elapsed time between early 
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follow up and dialysis start. PD patients (p=0.02) received more modality information 
than HD (92% vs. 78%) and were mainly under 50 years (p <0.001). PD incidence varied 
according with different studied groups 
Studied groups: n (% vs.col.) All patients n=547 HD n=488 PD n=59 p value
ER + P 168 (31) 133 (27) 35 (59) < 0.001
Late referral + P 63 (12) 58 (12) 5 (9)
ER + Unplanned start 113 (20) 104 (21) 9 (15)
Late referral + Unplanned start 203 (37) 193 (40) 10 (17)
Optimal care: ER + modality 
informed + P 121 (22) 96 (20) 25 (42)
Conclusions: Despite commitment to offer PD/HD as complementary treatments, PD 
incidence is still low. Optimal care provision is important to improve outcomes but also to 
involve patients in their therapy choice.
PUB615
The Adsorption Kinetics Profile of Aminoglycoside Antibiotics During 
Lixellle S-35 Cartridge Hemoperfusion  Marco Sartori,1,2 Angela Casas,1 Silvia 
De Rosa,1 Mirella Zancato,2 Leopolda Zampieri,1 Davide Giavarina,1 Claudio 
Ronco.1  1International Renal Research Inst of Vicenza, St. Bortolo Hospital, 
Vicenza, Italy; 2Dept of Pharmaceutical and Pharmacological Sciences, Univ 
of Padua, Padua, Italy.
Background: The bactericidal activity against Gram(-)mo of Tobramycin(TOB)and 
Gentamicin(GEN)is concentration-dependent.It is therefore fundamental achieving the 
maximum drug plasma levels.Lixelle S-35 cartridge is a sorbent used in dialysis-related-
amyloidosis which can modified the drug plasma levels.The aim of in vitro study was to 
evaluate the TOB and GEN adsorption removal by Lixelle S-35.
Methods: We performed mock direct hemoperfusion (DHP;QB=100ml/min;Bellco 
prototype dialysis machine)for 120 min using Lixelle S-35 cartridge.Human blood 
was diluted with fresh frozen plasma in order to achieve appropriate rheological 
characteristics(Hct 30%;650mL each bag;n=6).Blood was separately spiked with 
TOB(11.00±0.42 mg/L;n=3)and GEN(12.80±1.06mg/L;n=3)then it was circulated into 
the system.Samples were taken from arterial(Cpin)and venous(Cpout)lines at 5,10,60 
and 120 min.Sample levels were mesured by TOBR and GENT Flex methods(Siemens 
Healthcare,Newark,NJ.USA)for TOB and GEN,rispectively.The adsorption kinetics 
profiles were calculated.
Results: At the of DHP TOB and GEN levels were 7.13±0.18 and 7.20±0.90mg/L.
Ratio Cpout/Cpin rose rapidly during the first 5 min then reach plateau for both antibiotics 
as shown Fig.On mass balance analysis,the total mass of antibiotics introduced into the 
system decreased from 5.12±0.25 to 3.22±0.50 and from 6.16±0.51 to 3.32±0.41mg for TOB 
and GEN,respectively.The TOB mass adsorption was 37.20% whereas GEN was 46.20%.
Conclusions: Our in vitro study indicates an high adsorption rate for both 
aminoglicosides.This should be considered when TOB or GEN are used in pts treated 
with Lixelle S-35 cartridge.A supplemental dose may be needed to maximixed efficacy.
PUB616
Analysis of Some Aminoglycoside Antimicrobials in Human Plasma by 
HILIC-MS/MS  Shinya Omiya,1,2 Xiao-Pen Lee,2 Takeshi Kumazawa,2 Keizo 
Sato,2 Kiyoko Inui,1 Tomoaki Miyazaki,1 Yoshihiko Inoue,1 Ashio Yoshimura.1 
1Dept of Medicine, Div of Nephrology, Showa Univ Fujigaoka Hospital, 
Kanagawa, Japan; 2Dept of Legal Medicine, Showa Univ School of Medicine, 
Tokyo, Japan.
Background: Aminoglycoside(AG) antimicrobials(AMBs) have been used for a 
treatment of bacterial infections,especially by acid-fast bacteria.However,their acute 
overdose or chronic abuse can cause serious side effects,such as difficulty in hearing, 
interstitial nephritis resulting in renal failure and even sudden death from anaphylactic 
shock.In such cases,there is a great need to identify and quantify AG AMBs in the blood 
from patients or cadavers.We earlier reported an analytical procedure for nine AG AMBs 
in human serum by capillary HPLC/mass spectrometry(MS).Although this method works 
well for identification of the drug,it is semi-quantitative unless a suitable isotopic internal 
standard is used.
Methods: A simple,rapid,sensitive and quantitative method is presented for the analysis 
of six AG AMBs (streptmycin, ribostamycin, kanamycin, amikacin, dibekacin, arbekacin) 
in human plasma samples by hydrophilic interaction liquid chromatography(HILIC)-
tandem MS(MS/MS).A small volume(150ul) of plasma spiked with six drugs was diluted 
with 350ml of acetonitrile containing 0.1% formic acid.After centrifugation,100ul of the 
clear supernatant extract was directly injected into the HILIC-MS/MS,without any solvent 
evapolation and reconstitution steps.The chromatographic separation of the AG AMBs was 
achieved on Unison UK-Amino HILIC column(50mm x 3mm i.d.,particle size 3um)with a 
linear gradient elution system composed of 0.1% formic acid and acetonitrile.
Results: All drugs showed base peaks due to [M+H]+ ions by HILIC-MS with positive 
ion electropray ionization,and the product ions were produced from each [M+H]+ ion by 
HILIC-MS/MS.Quantification was made by selected reaction monitoring.The data obtained 
from actual determination of the AG antimicrobials in human plasma after their oral or 
intramuscular administration are also presesnted for validation of the methods.
Conclusions: This method would seem to be useful in clinical and forensic medicine 
because of its ability in both identification and quantification of the drugs.
PUB617
Prevalence of Chronic Musculoskeletal Pain Among Hemodialysis Patients 
Magdy M. Elsharkawy, Cherry Reda, Haitham Ezzat, Amr Mohab.  Nephrology 
Dept, Ain Shams Univ, Egypt.
Background: Chronic musculoskeletal (MS) pain is common in patients with end 
stage renal disease (ESRD) undergoing hemodialysis; however information regarding its 
frequency and prevalence is relatively scarce.
Methods: A cross-sectional study was conducted on 100 ESRD patients on maintenance 
hemodialysis 3 times per week for at least 3 months. Chronic musculoskeletal pain was 
evaluated using the VON KROFF questionnaire for grading the severity of musculoskeletal 
pain. Correlation was done between chronic MS pain and physical findings of motor and 
sensory systems examination. In addition, correlation was also done between chronic MS 
pain and serum intact Parathormone (i-PTH), serum corrected calcium, serum phosphorus, 
serum alkaline phosphatase, serum albumin & hemoglobin level.
Results: Mean age was 57.46 years. Mean dialysis duration was 3.80 years. 42% were 
females and 58% males. In our study, 37% of the patients had low disability low intensity 
of pain i.e. little affection on the daily, social & work activity(grade 1),37% of the patients 
had low disability high intensity of pain (grade 2) while 26% of them had high disability 
high intensity of pain i.e. moderate limitation of the daily, social, recreational & work 
activities (grade 3). Chronic musculoskeletal pain showed positive correlation with muscle 
state, tenderness and power (p<0.001, p<0.001, p=0.001 respectively). Grade 3 disability 
patients had the highest level of serum Ca and i-PTH which were significantly different 
from grade 1 and 2 patients (p<0.001, p=0.013 respectively).While serum albumin level 
was lowest in grade 3 patients (p=0.025).
Conclusions: Chronic MS pain is common in ESRD patients.Disturbed mineral 
metabolism is strongly associated with chronic MS pain in long-term HD patients. 
Musculoskeletal system involvement remains a common problem that limits the physical 
function of patients with ESRD.
PUB618
Practice Patterns of United States Nephrologists in Blood Pressure 
Medication Use when Transitioning Patients to Dialysis  Mary C. Mallappallil,1 
Steven Fishbane,2 Rimda Wanchoo,2 Andrea Roche-Recinos,1 Subodh J. Saggi,1 
Moro O. Salifu.1  1Internal Medicine- Div of Nephrology, SUNY Downstate 
School of Medicine, Brooklyn, NY; 2Internal Medicine -Div of Nephrology, 
Hofstra North Shore LIJ School of Medicine, Great Neck, NY.
Background: As there is no standard approach to transition a patient in chronic kidney 
disease (CKD)-5 to CKD5-Dialysis in regards to adjustment of diuretics, BP medication, 
optimal frequency of medication reconciliation (MR) and determination of dry weight 
(DW) we conducted a survey to determine how US nephrologists transition a patient from 
CKD5 to CKD5D in these aspects.
Methods: We designed an anonymous electronic survey with 39 questions and sent it 
to practicing nephrologists in the US after IRB approval.
Results: 120 US Nephrologists replied to the survey; 60% were in Nephrology for 
more than 10 years. Most (79%) used furosemide in CKD 5, (66%) used a combination of 
furosemide and metolazone. The first choice of diuretics in CKD5 was furosemide (79%), 
bumetinide (12%) and torsemide (9%) (p<0.005). In CKD5D, 45% used diuretics daily, 
29% on non-dialysis days and 26% discontinued them(p=0.02). In CKD 5, 63% would 
continueACEI or ARB. In CKD5D, 84% of responders had at least 30% of patients on 
ACEI/ARB and most (64%) would not stop these medications despite hyperkalemia. The 
majority (79%) did not change ACEI to those that were not dialyzed out. The perceived 
most effective BP medication in CKD5D in decreasing order: Nifedipine/amlodipine (36%), 
ACEI/ARB(29%), beta blockers(17%), diuretics(13%) and others(4%); (p<0.0005). Most 
responders (70%) prescribed BP medication on non-dialysis days only and 88% thought 
that high BP in the first month could be controlled with ultrafiltration. The first MR in new 
CKD5D was monthly (78%), weekly (12%) and as needed only (8%). DW was determined 
in the first week(31%) and the first month(52%). Of those surveved, 59% felt HTN in 
CKD5D hadt multiple causes.
Conclusions: Transitioning patients from CKD5 to CKD5D continues to remain 
challenging in terms of adjustment of BP medication. Variations in practice regarding the 
frequency of medication use may benefit from guidelines.
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PUB619
First Dialysis Prescription and Access Use: A Survey of United States 
Nephrologists  Mary C. Mallappallil,1 Steven Fishbane,2 Rimda Wanchoo,2 
Andrea Roche-Recinos,1 Subodh J. Saggi,1 Moro O. Salifu.1  1Internal 
Medicine-Renal Div, SUNY Downstate School of Medicine, Brooklyn, NY; 2Div 
of Nephrology, Hofstra North Shore LIJ School of Medicine, Great Neck, NY.
Background: As there is no standard approach to initiate renal replacement therapy 
in CKD5patients in regard to location of first treatment, access and dialysis prescription 
we conducted a survey of US nephrologists to better identify current practice patterns.
Methods: We created an anonymous electronic survey with 39 questions that was 
validated then approved by the IRB.Aggregate data was analyzed using descriptive statistics, 
avoiding duplicate responses.
Results: 120 US nephrologists replied to the survey, 60% were in nephrology practice 
for more than 10 years. The first hemodialysis (HD) treatment was as inpatient (22%), 
outpatient (29%) or either (49.5%). At the first HD, most nephrologists (92%) used a blood 
flow (BF)<300 mL/minute; 65% would use lower than usual dialysate flow rates (DFR) 
and 47% would use a smaller dialyzer. Ninety six percent prescribed less time than usual, 
even with blood urea nitrogen less than 100 mg/dL. About 45% replied that only 10 -50% 
of patients meeting criteria for peritoneal dialysis were actually started on this modality 
(p<0.005). Of the participants 47% noted that only 10 – 50% of patients who were eligible 
for transplant were listed, and the majority of responders (83%) noted that less than 10% of 
their patients got a preemptive transplant (p<0.0005). A patient educator was available to 
64% of the participants. First dialysis with a permanent access was noted among 30-60% 
of patients by 43% of responders and in more than 60% of patients by 22% of responders. 
Of the participants 73% replied that the majority (>60%) of their patients got vein mapping 
before access creation. The time between vein mapping and access creation was one 
week to one month (61%) and more than one month (26%), (p<0.005) . The number of 
angioplasties that were acceptable prior to primary access failure was noted as 2, (25%) 
3 (25%) or more than 4(24%).
Conclusions: There is variation in practice in several areas in regard to the initial 
dialysis session in CKD5D which may benefit from guidelines.
PUB620
How to Dialyze a Patient with Left Ventricular Assist Device in a Chronic 
Dialysis Unit? A Practical Protocol  Sadiq Ahmed,1 Debbie Baker.2  1Univ of 
Kentucky; 2Davita.
Background: To provide chronic HD treatments to ESRD patients with LVAD 
in a chronic unit in the community is a challenge and a relatively new experience for 
nephrologists. As LVADs have revolutionized the treatment of advance heart failure there 
are rising numbers of these patients developing ESRD with need for HD in the community. 
Development of a practical , simple and safe protocol is needed to dialyze these patients 
in the chronic units.
Methods: This protocol and safety check list is developed to provide routine HD 
treatment for patients with LVAD and successfully implemented in a chronic dialysis unit 
in the community setting.The special policy and procedure relevant to this protocol , safety 
check list and standing orders for the dialysis nurses were approved by the governing body 
before dialysis staffs were trained. The VAD coordinator is present during first training.
Results: This protocol is a step by step guidance for the dialysis staff. The whole process 
has 3 components. 1.A supplemental informed consent signed by the patient to cover for 
additional higher risk of HD with LVAD. 2.Guidance and check list for the dialysis staffs for 
assessments of LVAD patients with additional documentation before starting HD treatment. 
3.Standing order to be followed by staff during dialysis of LVAD patient on top of regular 
dialysis orders. # 2 and 3 covers patient assessment, verification of LVAD equipment ,power 
supplies and special hemodynamic monitoring of these patients during HD. 
LVAD check list
Presence of support person who waits in lobby after power base is connected
Fully charged extra batteries for LVAD & backup system controller
Power base unit connected to electrical outlet & Patient connected to unit
Charge nurse to review LVAD log and trends
Document Pump Flow, Pump Speed & Pulsativity index for treatment and previous day
Obtain doppler, lubricant & sphygmomanometer for every 30 minute BP check
Initiate HD
Document LVAD assesment, doppler pressure, communications with MD and VAD coordinator
Review Post weight with carge Nurse if > 1 KG above TW notify MD
Conclusions: This protocol to provide incenter HD to patients with LVAD in a chronic 
unit is simple & safe. It can be implemented in a chronic HD unit.
PUB621
Association Among Calcium, Phosphorus, and Parathyroid Hormone 
with Aortic Ring Calcification in a Cohort of Hemodialysis Patients 
Arturo Reyes Marin.  Nephrology, Hospital Juarez de Mexico, DF, Mexico.
Background: The prevalence of vascular calcification in dialytic therapy is 40-92%, 
values increased in serum levels of calcium (Ca), phosphorus (P) and parathyroid hormone 
(PTH) have been associated with high calcification progression and cardiovascular mortality. 
It has been described association among serum levels of Ca, P, Ca-P product and PTH with 
aortic ring calcification in patients with chronic renal disease (CRD). We did an observational 
and descriptive study, in the nephrology department of Hospital Juarez de Mexico, with a 
cohort of 95 hemodialysis patients, the aim of study was to evaluate the association among 
aortic ring calcification by torax radiography with the serum levels of Ca, P and PTH.
Methods: Adult patients in hemodialysis were included, patients with severe 
malnutrition, cancer and mental abnormalities were excluded. We used 2 scales (torax 
radiography), in order to assessment the aortic ring calcification and we did correlation 
coefficient among Ca, P, PTH and 2 scales. We used Pearson correlation coefficient for 
analysis and Bland-Altman test for analysis of concordance among Ca, P, PTH and 2 scales.
Results: They were 95 adult patients: 50 (52%) men and 45 (48%) women, average 
age was 40.7 years old. We found weak negative correlation between Ca and PTH (r = - 
0.28, p > 0.05)), weak positive association was found between P and PTH (r = 0.30, p > 
0.05), correlation between PTH and CaxP (r = 0.36), p > 0.05), PTH and 2 scales (r = 0.5, 
p>0.05). In the scales that we used to evaluate vascular calcification (torax radiography) 
showed high scores, however the intraclass correlation coefficient between scales and PTH, 
Ca and P (0.33) showed not statistical significance.
Conclusions: Despite that vascular calcification was high by torax radiography, the 
association among scales (torax radiography) and serum levels of Ca, P and PTH was not 
statistical significant. There are other important factors that can explain the progression 
of vascular calcification and the traditional markers for calcification: Ca, P and PTH are 
not enough for explain it.
Funding: Government Support - Non-U.S.
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β2-Microglobulin Removal: Comparison Between Lixelle S-35 Cartridge 
Coupled with High-Flux Dialysis versus Online-Hemodiafiltration 
Marco Sartori,1,2 Sara Samoni,1 Federico Nalesso,1 Alessandra Brendolan,1 
Mauro Neri,1 Francesco Garzotto,1 Silvia De Rosa,1 Mirella Zancato,2 Claudio 
Ronco.2  1International Renal Research Inst of Vicenza, St. Bortolo Hospital, 
Vicenza, Italy; 2Dept of Pharmaceutical and Pharmacological Sciences, Univ 
of Padua, Padua, Italy.
Background: Lixelle is a sorbent used to treat dialysis-related amyloidosis due to 
β2-microglobulin(β2-MG)deposit.The aim of this study was to assess the impact of Lixelle 
S-35 coupled with High-Flux Dialysis(HFD)vs online Hemodiafiltration(OL-HDF)in 2 pts.
Methods: We enrolled 2 pts with β2-MG levels over15mg/L,treated with OL-HDF.Case 
1.Male,57yrs old with BMI35.5Kg/m2.We collected samples previous and after pre/post-
reinfusion OL-HDF(n=3).Then the pt was shifted to HFD+Lixelle S-35(n= 3;QB=380mL/
min;QD=500mL/min;∆BW=2.87±0.42Kg).Case 2.Male,72yrs old,BMI26.8Kg/m2.We 
collected samples previous and after post-reinfusion OL-HDF(n=3).Then the pt was 
shifted to HFD+Lixelle S-35(n=3;QB=300mL/min;QD=500mL/min;∆BW=3.1±0.53Kg).
We compared the data obtained in each treatment.
Results: Case 1.Before and after pre/post-reinfusion OL-HDF and HFD+Lixelle S-35, 
β2-MG levels were 18.26±3.91 and 5.00±0.18, 27.34±1.45 and 7.96±0.77mg/L,respectively.
There was no difference between pre/post-reinfusion OL-HDF(71.48%)and HFD+Lixelle 
S-35(70.90%)β2-MG removal rate[RR].Case 2.Before and after post-reinfusion OL-
HDF and HFD+Lixelle S-35 β2-MG levels were 13.68±4.10 and 4.66±0.24, 17.23±1.55 
and 5.13±0.60mg/L,respectively.There was difference between post-reinfusion OL-
HDF(63.44%)and HFD+Lixelle S-35(70.09%)β2-MG removal rate.We did not observe 
any adverse reactions and/or side effects potentially related to Lixelle S-35.
Conclusions: Our preliminary results indicate that HFD+Lixelle S-35 seems to be 
more efficient in β2-MG removal than post-reinfusion OL-HDF,whereas no differences 
have been found with pre/post-reinfusion OL-HDF.More studies are needed.
Funding: Private Foundation Support
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Does Dialysis Influence Treg Cells? A Meta-Analysis  Carlotta Caprara,1 
Gilbert R. Kinsey,2 Wenjun Xin,3 Jennie Z. Ma,3 Valentina Corradi,1 Elisa 
Scalzotto,1 Francesca K. Martino,1 Mark D. Okusa,2 Mitchell H. Rosner,2 
Fiorenza Ferrari,1 Claudio Ronco.1  1International Renal Research Inst Vicenza 
(IRRIV), Dept of Nephrology, Dialysis & Transplantation, St. Bortolo Hospital, 
Vicenza, Italy; 2Medicine, Univ of Virginia, Charlottesville; 3Public Health 
Sciences, Univ of Virginia, Charlottesville.
Background: The immunological state of patients with ESRD is dysregulated.
Regulatory T (Treg) cells comprise a small proportion of the total lymphocyte population yet 
regulate key immune responses across a variety of disease settings. Contrasting results have 
been reported about the influence of dialysis on Treg cells. Our aim is to determine whether 
the available literature support a positive or negative influence of dialysis on Treg cells.
Methods: After screening 84 published studeies (PubMed and Web of Science) we 
included 10 that evaluated Treg cells in ESRD patients. Of these, 5 studies that included 
comparable healthy controls (HCs) and hemodialysis (HD) patients and used similar 
criteria for determining the percentage of Treg cells in total CD4 T cells were subjected 
to a meta-analysis.
Results: A total of 99 HD patients and 88 age-matched HCs were included in these 
5 studies. Using the fixed effect model a significant difference in the percentage of Treg 
cells in total CD4 T between HD and HCs was observed (P<0.001). The mean difference 
in Treg percentage was -2.34% in HD patients vs. HCs. Several discrepancies were noted 
between studies that may be due to the lack of consistent criteria for Treg cell identification 
and use of different typse of dialysis membranes which was not specified in all articles.
Conclusions: The available literature comparing Tregs in HD patients and HCs 
suggest HD is associated with a reduction in Tregs. A limitation is that only a few articles 
consider uremic patients (ESRD not on dialysis) as a control group for HD. Furthermore, 
no studies have investigated Treg cells in the same patient before and then after initiating 
dialysis. This type of study will be critical to understanding the influence of dialysis on 
Treg cells. Furthermore, the clinical significance of these changes in Treg cell numbers 
will need to be elucidated.
PUB624
Combination of Insulin Degludec (IDeg) and Liraglutide (Lira) (IDeg+Lira) 
Is Potentially Superior to Basal-Bolus Insulin Therapy (BB) in Hemodialysis 
(HD) Patients with Type 2 Diabetes (T2DM) – An Assessment by Continuous 
Glucose Monitoring (CGM)  Satoshi Funakoshi,1 Jyunichiro Hashiguchi,1 
Kenji Sawase,1 Osamu Sasaki,1 Hiroshi Ichinose,1 Miwa Shirahama,1 Miki 
Yano,1 Yutaka Mori,3 Takuhisa Uchino,1 Kazunori Utsunomiya,3 Yoko Obata,2 
Tomoya Nishino,2 Takashi Harada.1  1Nagasaki Kidney Center, Japan; 2Dept of 
Internal Medicine, Nagasaki Univ Graduate School of Medicine, Japan; 3Dept 
of Diabetology, Jikei Univ, Japan.
Background: During HD, plasma glucose (PG) level drops due to various factors 
including clearance gap between glucose and insulin, and then rebounds to hyperglycemic 
state after HD. Therefore, it may be difficult for conventional BB to control these 
complicated PG changes in HD patients with T2DM. Recently a free combination of any 
insulin and Lira has been approved in Japan.
Methods: Eight adults with T2DM, glycoalbumin (GA) of >20%, fasting C-peptide of 
>8 ng/ml and treated with BB including IDeg (5-74 units) + insulin lispro (5-30 units) were 
converted to daily injections of the free combination of same dose of IDeg and 0.9mg of Lira 
(IDeg+Lira), then IDeg was titrated to achieve an appropriate fasting plasma glucose level. 
Glycemic control was assessed by CGM and the mean amplitude of glycemic excursions 
(MAGE) was calculated before and after the conversion.
Results: As shown in figure 1, after 4-8 weeks of change from BB, mean both MAGE 
and PG were significantly decreased as shown in figure. Six out of 8 patients reported 
gastrointestinal adverse events, but these events were transient.
Conclusions: IDeg+Lira can potentially be superior compared with BB in controlling 
glycemic fluctuations in HD with T2DM.
Funding: Private Foundation Support
PUB625
More Nephrologist Visits Are Associated with Lower Cost of Care for 
Dialysis Patients  Hao Han, Jane Brzozowski, Sheetal Chaudhuri, John W. 
Larkin, Mahathi Mothali, Len A. Usvyat, Terry Ketchersid, Franklin W. Maddux. 
Fresenius Medical Care North America, Waltham, MA.
Background: Medicare patients with end stage renal disease (ESRD) are treated by 
nephrologists, primary care providers (PCPs), cardiologists and other specialties on a regular 
basis. We investigated the relationship of visits to these providers and total costs of care.
Methods: Medicare 100% ESRD data for patients with evidence of dialysis at any 
time during January 1, 2010 through December 31, 2011 were analyzed. Nephrologist, 
PCP and cardiologist visits were determined by specialty codes of Part B claims (including 
both in- and out-patient visits). All data was aggregated at the Metropolitan Statistical Area 
level (MSA). We computed a ratio of nephrologist visits to PCP visits per MSA as well 
as nephrologist visits to cardiologist visits per MSA during the above period (visits were 
calculated on a per patient per month basis). Total costs of care (per member per month 
[PMPM]) were determined by aggregating Medicare Part A and B costs. Comparisons of 
ratios were performed using t-tests for quartiles of PMPM for two specialty visit ratios.
Results: Claims for 368,711 patients were analyzed. Patients in the lower quartiles 
of total cost had significantly more nephrology visits relative to PCPs and cardiologists. 
Conclusions: These results indicate that higher ratios of nephrologist visits to 
cardiologist/PCP visits are significantly associated with decreased cost on a MSA level. 
Taken that nephrologist visits tend to be constant (due to the monthly capitated payment), 
these results may be reveling a “sicker” and therefore more expensive population of patients 
on a MSA level that require more medical attention from a cardiologist or PCP, likely due 
to hospitalizations. Adjustments for underlying disease should be considered.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB626
Prediction of Non-Adherence to Hemodialysis Treatment Regimens 
Yue Jiao,1 Daniel E. Geary,1 Theresa J. Hetzel,1 Sheetal Chaudhuri,1 Mahathi 
Mothali,1 Terry Ketchersid,1 Dugan Maddux,1 John W. Larkin,1 Peter Kotanko,2,3 
Brian Scott Ash,1 Len A. Usvyat,1 Franklin W. Maddux.1  1Fresenius Medical 
Care North America, Waltham, MA; 2Renal Research Inst, New York, NY; 3Icahn 
School of Medicine at Mount Sinai, New York, NY.
Background: Non-adherence with hemodialysis (HD) treatment regimens is known 
to be associated with increased morbidity and mortality. The aim of this project was to 
develop a predictive model (PM) to identify HD patients who will likely have unexcused 
no shows to routine dialysis treatments within the next week.
Methods: Using data between 1/1/2014 and 12/31/2014 from the Fresenius Medical 
Care Knowledge Center and 2014 weather data from the National Oceanic and Atmospheric 
Administration’s National Centers for Environmental Information, PMs were designed and 
developed for prediction of unexcused no shows in patients not residing in a nursing home. 
Various PMs were investigated and included the generalized linear model, partitioning 
and regression trees, artificial neural networks, and generalized additive model (GAM). 
In all, 1,554,833 records stratified in weekly intervals on 60 variables from 172,854 
patients were utilized. Variables included data on the patient’s history of unexcused no 
shows, demographics, comorbidities, laboratories, holidays, sporting events, and weather. 
A multi-tier prediction process was performed with respect to the availability of data. The 
area under the curve (AUC), sensitivities and specificities were investigated to determine 
the model with the highest performance.
Results: Best performing model had AUC of 0.87 for the multi-tier PMs utilizing a 
30% test dataset. A small pilot test on 860 patients for three weeks utilizing optimal Youden 
index as the cutoff value to predict the high probability of the unexcused no show events 
achieved an average sensitivity of 0.57 and specificity of 0.95.
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Conclusions: This pilot test of the developed modeling demonstrates that PM can 
assist in identifying patients with a high probability for unexcused missed HD treatments. 
Additional studies are needed to further analyze the potential of predictions for and 
interventions associated with reducing unexcused no show events.
Funding: Pharmaceutical Company Support - Fresenius Medical Care North America
PUB627
Factors Influencing Residual Renal Function Decrease in Hemodialysis 
Treated Patients  Fernando Caravaca-Fontan, Milagros Fernandez-Lucas, 
Jose L. Teruel, Saul Enrique Pampa, Estefania Yerovi, Maria Delgado  yagüe, 
Fernando Liano.  Nephrology, Hospital Univ Ramon y Cajal, Madrid, Spain.
Background: We have shown in previous studies that maintenance of residual renal 
function in hemodialysis treated patients is conditioned by the number of weekly sessions, 
and is better in patients who start treatment with a twice weekly schedule. The aim of this 
study is to analyse the influence of other variables in the preservation of residual renal 
function.
Methods: Of the 174 consecutive patients who started hemodialysis treatment in the 
hospital, 98 began with 2-weekly sessions (2HD group), and 76 with 3-weekly sessions 
(3HD group). Residual renal function was measured every two months (mean urea and 
creatinine clearance).
Results: Decrease in residual renal function was lower in the 2HD group (median 0.19 
vs 0.46 ml/min/month, p=0.005). In both groups the residual renal function decrease was 
higher in the patients from the transplant program than in those from predialysis: 2HD group: 
median 0.93 vs 0.17 ml/min/month, p=0.003; 3HD group: median 0.76 vs 0.32 ml/min/
month, p=0.005. Neither the initial schedule, sex or etiology of the renal disease influenced 
the decrease in residual renal function in either of the two groups of patients. Moreover 
we found no correlation between the decrease in residual renal function with age, the renal 
function at the start of dialysis or with the Charlson comorbidity index. Of the 98 patients 
who began with the 2HD schedule, 45 went on to dialysis three times a week when the 
residual renal function was less than 3 ml/min: these patients had a mean of 10±8 months 
on the 2HD schedule. The length of time on this model was not influenced either by age, 
sex, etiology of the nephropathy, comorbidity index, scheduled start or basal renal function.
Conclusions: The decrease in residual renal function in the patient treated with 
hemodialysis depends basically on the number of weekly sessions with which the dialysis 
treatment was started. Of all the variables analysed only the return to dialysis due to graft 
loss conditioned a higher decrease in residual renal function in both groups of patients.
PUB628
Circadian Blood Pressure Behaviour in Hemodialysis Patients 
Dimitrios Petras,1 Kyriakos Dimitriadis,2 Panagiota E. Giannou,1 Eirini 
Andrikou,2 Konstantinos Tsioufis.2  1Nephrology Dept, Hippokration Hospital, 
Athens, Greece; 2First Cardiology Clinic, Hippokration Hospital Univ of 
Athens, Athens, Greece.
Background: Blood pressure (BP) evaluation and management in haemodialysis (HD) 
patients is often a matter of debate. During HD hypotension as well as a paradoxical rise in 
BP may be documented. Indradialytic BP is also variable depending mostly from the weight 
gain between the HD sessions. We investigated circadian BP behavior in the setting of HD.
Methods: We studied 38 patients with ESRD (68% men, mean age 62±19 years, 52% 
hypertensive) that underwent HD three times a week in the HD unit of our hospital and 
were at their ideal dry weight. Ambulatory BP monitoring was applied one hour before 
an HD session and was set to measure BP every 30 minutes and until arrival for the next 
HD session, for a total of two subsequent 24-hour periods. Blood pressure dipping was 
defined as [(daytime systolic BP – nighttime systolic BP)/ daytime systolic BP]. Patients 
were defined as dippers if BP dipping was >10% and risers if BP dipping <0%.
Results: Body weight before and after the HD session was 78±28Kgr and 75±27mmHg 
respectively. Ambulatory systolic/diastolic BP increased not significantly from 
127±23/70±13mmHg to 130±19/71±11mmHg (p>0.05) from the first to the second 24-hour 
period. Mean dipping was 1.5±7.8% in the first day and further decreased to -0.94±6.8% in 
the second day. Accordingly, in the first 24-hour period, only 6 patients (16%) were dippers 
and reduced to 2 patient in the following day (5%). Sixteen patients (42%) and 18 patients 
(47%) were risers at the first and second 24-hour period respectively.
Conclusions: Daytime systolic BP does not substantially change during the 48-hour 
period extending from HD to HD session. Yet, prevalence of the non-dipper as well as the 
riser pattern is high and further increases during the interdialytic period. Patients with this 
BP pattern are at high risk for coronary artery disease, especially if other comorbidities 
coexist. Ambulatory BP monitoring in ESRD patients is a promising non invasive technique 
for the recognition of future heart disease.
PUB629
In Vitro Dialysability of SNF472, a Novel Inhibitor of Vascular Calcification, 
Using Conventional Hemodialysis and Hemodiafiltration  Joan Perelló,1 
Miquel Gomez Umbert,2 Nestor Yesid Rodriguez,2 Carolina Salcedo,1 Miquel 
D. Ferrer,1 Juan Manuel Buades,3 Maria del mar Perez,3 Eva Martín Becerra,4 
Francisco Maduell.2  1Sanifit, Palma, Spain; 2Nephrol. and Renal Transpl., 
Hosp. Clínic, Barcelona, Spain; 3Nephrol., Hosp. Son Llàtzer, Palma, Spain; 
4Kinrel, Madrid, Spain.
Background: SNF472 is being developed for the treatment of calciphylaxis and 
cardiovascular calcification in end stage renal disease patients on hemodialysis. The intended 
use of SNF472 is intravenous infusion during dialysis; therefore our aim was to assess its 
possible dialyzation and its effects on calcium (Ca) chelation.
Methods: Dialysability of SNF472 was assessed using online hemodiafiltration (OL-
HDF) and conventional hemodialysis (HD) systems. The interaction of SNF472 with the 
system was assessed under bypass conditions (dialysis in off-mode). One liter of heparinized 
fresh blood spiked with 8 mg/dl creatinine was introduced in a container maintained at 37 ºC 
and a one hour dialysis session was simulated. 66.6, 30 and 10 mg/L SNF472 were infused 
during the first 20 minutes of dialysis. Samples were obtained at different time points and 
creatinine, total and ionized Ca and SNF472 levels were quantified.
Results: No dialyzation of SNF472 was detected at 30 and 66.6 mg/L neither in OL-
HDF nor in HD systems. Dialyzation was measured at 10 mg/L SNF472 both in OL-HDF 
and in HD, with an estimated clearance (Cl) of 39 and 18 mL/min, respectively. Creatinine 
showed a Cl of 231 and 220 mL/min, respectively. In bypass conditions, blood Ca was 
chelated during the 20 minutes of SNF472 infusion when added at 66.6 mg/mL. However, 
when the system was switched to the dialysis mode, the Ca in the dialysis bath compensated 
the chelating effect of SNF472 and Ca levels remained unaltered.
Conclusions: SNF472 dialyses with a low Cl. SNF472 levels increase in blood during 
infusion and dialysis does not prevent from attaining potentially therapeutic levels. As 
SNF472 will be infused during the whole dialysis session, this low Cl is not expected to 
affect system exposure. The chelating effects of SNF472 on Ca are compensated by the Ca 
in the dialysis bath, so no hypocalcemia is expected. Supported by REDINREN RD012/0021 
and RETOS COLABORACIÓN RTC-2014-2460-1 grants.
Funding: Pharmaceutical Company Support - Laboratoris Sanifit, Government 
Support - Non-U.S.
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A Simple and Cost Effective Approach to Ultra-Pure Dialysate 
Anthony M. Valeri,1 Bobby C. Lee,2 John Duffy,3 Robin Ferrer,4 Ronald Villota,4 
Greg C. Riccardi,3 Edmond P. Wong.3  1Dept of Medicine, Columbia Univ, New 
York, NY; 2Dept of Pharmacy, New York-Presbyterian Hospital (Columbia), New 
York, NY; 3Dept of Biomedical Engineering, New York-Presbyterian Hospital 
(Columbia), New York, NY; 4Dept of Nursing, New York-Presbyterian Hospital 
(Columbia), New York, NY.
Background: Ultrapure dialysate has been shown to reduce inflammation and improve 
nutritional and anemia parameters in patients on chronic maintenance hemodialysis. The 
Nephros(R) DSU (Dual Stage Ultrafilter, Nephros(R) Inc, River Edge, NJ) has been shown 
to reduce bacterial counts and endotoxin levels by at least a 5-log order of magnitude.
Methods: We performed an observational trial of this filter in a hospital-based acute 
dialysis facility in the USA.
Results: There were 23 chronic stable hemodialysis outpatients treated during the 6 
months before and after the installation of the Nephros(R) filters. The mean age was 51 (range 
12-91), 61% male, predominantly Hispanic (70% Hispanic, 17% African-American, 9% 
Caucasian, 4% Asian) and 30% diabetic. Comparing data from the 6 month period after 
the installation of the filters to the preceding 6 months, there was an increase in the mean 
hemoglobin level of 0.5 gms/dL (p=0.010) with a reduction in the mean weekly darbopoietin 
dose of 14.6 mcg or 40% (P<0.001) translating to a reduction in the ESA resistance index 
(weekly ESA dose/hemoglobin level) of 1.52 (p<0.001). During this time period, indirect 
inflammatory markers showed a reduction in the mean WBC count from 7,000 to 6,600 x 
109 /L (p=0.008) and an increase in serum albumin from 3.6 to 3.7 (p=0.024). The mean 
spKt/V was unchanged during the 2 time periods (from 1.609 to 1.607, p=0.30). 
Hemoglo-
bin (gms/
dL)
Darbopoietin 
dose (mcg/
week)
ESA resis-
tance index 
(ESA/Hgb)
Pre Post Pre Post Pre Post
Mean 10.3 10.8 36.3 21.7 3.54 2.03
Interquartile 
Range 10.1-10.8
10.5-
11.1 21.5-40.0
15.9-
25.6 2.06-4.42
1.46-
2.25
p-value (post 
vs. pre) 0.010 <0.001 <0.001
Conclusions: In conclusion, the use of the Nephros® DSU filter to further reduce 
endotoxin exposure in chronic hemodialysis patients can result in improved ESA 
responsiveness and a lower ESA dose.
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Underline represents presenting author.
1035A
J Am Soc Nephrol 26: 2015 Publication Only 
PUB631
Care Delivery Models for End Stage Renal Disease: A Systematic Review 
Maria Lourdes Gonzalez Suarez,1 Priya Ramar,2 Sagar Chawla,3 LaTonya J. 
Hickson,1,2 Nilay D. Shah,2 Bjoerg Thorsteinsdottir.1,2  1Dept of Medicine, Mayo 
Clinic; 2Mayo Clinic Kern Center for the Science of Health Care Delivery, Mayo 
Clinic; 3Mayo Medical School, Mayo Clinic, Rochester, MN.
Background: Reimbursement for dialysis care has led the way for the broader 
transition to a value-based payment model. As payment policy for dialysis evolves, a better 
understanding of the evidence around care delivery models that optimize outcomes and 
increase the value of care for dialysis patients is essential. Limited evidence exists about 
which care delivery models are most effective.
Methods: Multiple databases were searched for comparative studies of care delivery 
models for ESRD published between 2000 and 2014. The intervention had to include 
>5 dialysis patients over age 18 years and receiving treatment, >6 months follow up, 
and reported patient important outcomes i.e. mortality, important clinical outcomes, 
hospitalizations and quality of life. Data was abstracted by reviewer pairs; study quality 
was evaluated using Cochrane and Newcastle-Ottawa tools.
Results: 1841 abstracts were screened, 59 full-text articles were reviewed, and 23 
studies with 87,281 patients were included for final analysis. The interventions included 
nutritional (n=4), multidisciplinary care (n=6), satellite programs (n=3), home dialysis 
(n=3), access monitoring (n=2), physician contact (n=4), and nocturnal dialysis (n=1). 
Most were observational studies of decent quality with representativeness and incomplete 
follow up being the main potential sources of bias. Two randomized studies on home 
dialysis and pharmacist care, had attrition as the main risk of bias. Most interventions 
showed positive effect raising concern of publication bias. Overall, hospitalizations were 
significantly lower in the intervention group despite large heterogeneityIRR: 0.824, 95% 
CI 0.781, 0.868,p<0.001, I2=95.6%.
Conclusions: Multiple interventions have the potential to improve the outcomes of 
dialysis patients but have not been compared in terms of safety and effectiveness. Limited 
evidence is available to inform dialysis practice redesign to adapt to new payment structures. 
Further studies are needed to define best delivery models for dialysis care.
PUB632
Symetrical Dimethylarginine (SDMA) Is Poorly Cleared by Standard 
Hemodialysis  Mirela A. Dobre,1 Peter B. De Oreo,2 Timothy W. Meyer,3 
Thomas H. Hostetter.1  1Case Western Reserve Univ; 2Centers for Dialysis Care, 
Cleveland; 3Stanford Univ School of Medicine.
Background: High SDMA levels have been associated with an increased risk for 
cardiovascular disease in patients with normal or reduced renal function. The effect of 
hemodialysis on SDMA has not been thoroughly studied.
Methods: We measured SDMA levels and its handling by hemodialysis and by the 
normal kidney in subjects with ESRD on chronic hemodialysis (n= 7) and in normal 
controls (n=6).
Results: The mean (SD) SDMA levels in ESRD were six times higher than in normal 
controls, 3.35(0.65) vs 0.53(0.25) µM, p<0.001. For comparison pre-dialysis BUN levels 
was 44.1(23.1)mg/dl in ESRD, and 14.9(3.2) mg/dl in controls. The fractional reduction 
of SDMA was significantly lower than that of urea, 47.4(11.5)%, vs 76.7(4.7)%, p<0.001; 
and the volume of distribution was much higher 58.5(14.5)L vs 35.5(10.4)L for urea. Also 
the urinary clearance of SDMA [78.2 (33.5) ml/min)] in normal individuals was higher 
than that of urea 55.2(13.7) ml/min. SDMA production rates were similar 46.7(9.4) vs 52.3 
(13.9) mmoles/day, ESRD vs normals, p>0.05.
Conclusions: In summary, SDMA circulates at high levels in hemodialysis patients 
due at least in part to its relatively high clearance by the normal kidney, relative to urea, 
and its larger volume of distribution. The latter suggests that SDMA is likely to be localized 
in the intracellular compartment, and therefore less available for clearance by standard 
hemodialysis.
Funding: NIDDK Support, Private Foundation Support
PUB633
On-Line Hemodiafiltration Is Efficient for Inflammation and Phosphorus 
Control  Nadia Guimaraes- Souza, Thais Nemoto Matsui, Adriano Luiz 
Ammirati, Maria C.C. Andreoli, Ana C M S Ramos, Fabiana Dias Carneiro, 
Bento C. Santos.  Dialysis Center, Hospital Israelita Albert Einstein, Brazil.
Background: High efficiency on-line hemodiafiltration is efficient to remove uremic 
toxins and phosphorus. Many studies had demonstrated the impact of this modality in 
mortality. The main objective of this study was to analyze the high efficiency on-line 
hemodiafiltration ability to remove phosphorus and reactive C protein.
Methods: This is a prospective study with end stage chronic kidney disease 
patients undergoing dialysis with high levels of phosphorus. High efficiency on-line 
hemodiafiltration, as described as a reposition volume higher than 22lts, was used for 
a period of at least one year of follow-up. Beta-2- microglobulin, pre dialysis urea, post 
dialysis urea, reactive C protein, hemoglobin and phosphorus were collect from patients 
before starting on-line hemodiafiltration treatment and every month.
Results: Patients included in this study were 54.45±16.75 years old; they were on 
hemodialysis for at least for one year. 58% had hypertension or coronarypathy. Hemodialysis 
dose as single pool Kt/V were significantly higher (1.21±0.20 vs 1.36±0.16; p<0.001) and 
this difference was kept for all follow-up. In six months of high efficiency hemodiafiltration 
we also found a decrease on phosphorus levels (7.9±2.4 vs 7.3±2.01 p<0.001) in one 
year follow up, phosphorus levels were still significantly lower than in the conventional 
hemodialysis (7.3±2.01 vs 5.6±2.03 p=0.001). We also observed a decline in the need 
for erythroietin doses in six months (p=0.04) associated with a higher hemoglobin levels 
(p<0.001). Reactive C protein showed significantly lower levels after six months of online 
hemodiafiltration (p=0.004).
Conclusions: High efficiency on-line hemodiafiltration is an efficient method of 
reduction of reactive C protein and may reduce costs due to reduced doses of erythropoietin 
analogous.
PUB634
On-Line  Hemodiaf i l t rat ion  Fi l ters  a  Comparat ive  Study 
Nadia Guimaraes- Souza, Adriano Luiz Ammirati, Thais Nemoto Matsui, Maria 
C.C. Andreoli, Fabiana Dias Carneiro, Ana C M S Ramos, Bento C. Santos. 
Dialysis Center, Hospital Israelita Albert Einstein, Brazil.
Background: High efficiency on-line hemodiafiltration is the best method for middle 
molecules and phosphorus remotion. Many studies had demonstrated the efficiency of 
this method in mortality reduction. The main objective of this study was to compare the 
three filters available for on-line HDF comparing the ability to remove urea, phosphorus 
and beta-2-microglobulin.
Methods: Prospective cross-over study including four patients and three available filters 
for hemodiafiltration. All section of on-line hemodiafiltration was made with high efficiency 
(23-25lt). Filters HDF 100, FX100 e HDF80COR were compared. Urea, phosphorus and 
beta-2 microglobulin were collected before and after first use of each filter A reduction 
ratio was calculated to compare the treatments.
Results: 76% of patients were man, the middle age (61.3±5), 76% of patients were 
diabetics and had peripheral neuropathy and 34% had coronarypathy. FX100 filter showed 
significantly higher dialysis dose compared to FX80COR (p=0.03); the same was observed 
for urea reduction ratio(p=0.04). Beta-2-micrglobulin and phosphorus reduction ratio were 
similar between all filters.
Conclusions: FX100 and HDF100 filter were similar for urea remotion ratio. There 
were no differences for other molecules.
PUB635
Satisfaction of Patients on Dialysis Unit  Jorge Nicolas Abdala.  Nephrology, 
Militar Hospital, Cordoba, Capital, Argentina.
Background: The assesment of the nsatisfaction of patients in Dialysis, is a useful 
tool to meet patient needs; axis on which the care serevice is based.In turn it allows to 
identify the deficient áreas.
Methods: Objetive 1) To know the views of patients aboute the service that is offered in 
each of the áreas of focus. 2) To analyze the profile of satisfactionof patients they expressed 
their overall dissatisfaction. Prospective, descriptive study conducted at the Dialysisi 
Unit of the Military Hospital Córdoba, conducted between 15/11/2014 to 15/12/2014. 
Inclusión criteria: All patients attending the service, wich received some form of dialysisi 
(hemodialysis-DP) in the period. Exclusión criteria: a) diagnosos of cognitive dementia, b) 
Carryng less tan three month of treatment c) not be psychological and physical conditions to 
answer the survey. A qualitative survey, structured ajar, applied voluntary and anonymous.
Results: 95 surveys of the total population comprised 111 patients were taken; of wich 
85 are for patients undergoing henodialysis and 10 patients on CAPD. By studying the 
“General Satisfaction” in all aspect of the service that is offered to the patients responses they 
were largely positive, 80 % of the sample expressed feeling satisfied, while 20 % responded 
negatively. The results denote that carriers are those who receive the worst assessment by 
patients. The ambient temperatura for both dialysis room to the waiting room appears as 
an aspect also of disagreement. The most valued aspect is the power receiduring treatment, 
both the quality and quantity as well as the attention of the professionals: technical, medical 
and social worked, in that order.
Conclusions: 1. As a managment tool, it should be rated as positive aspects stimulate 
and work on correcting the negative aspects. 2. The level of dissatisfaction is directly related 
to dialysis treatment time of the patient, the longer, higher degree of dissatisfaction. 3. It is 
advisable conduct regular surveys on the degree of patient satisfaction Dialysis, and that 
will help improve their quality of life.
PUB636
Correlation Between Calcium Phosphorus Product and Hypertension 
in ESRD Patients on Maintenance Hemodialysis  Shoaib Islam,1 Hafiz I. 
Ahmad,1 Syed Rizwan Bokhari,1 Arif Asif.2  1Dept of Nephrology, Allama Iqbal 
Medical College/ Jinnah Hospital, Lahore, Pakistan; 2Div of Nephrology and 
Hypertension, Albany Medical College, Albany, NY.
Background: Increased levels of serum calcium, phosphorous and product of serum 
calcium and phosphorus (Ca x P) in end stage renal disease ( ESRD) patients has been 
shown to be associated with increased mean arterial blood pressure (MAP). The available 
data is limited and no study has been done in Pakistan. We conducted a cross sectional 
study to determine the correlation between mean arterial blood pressure (MAP) and serum 
calcium-phosphorous product in our ESRD patients on hemodialysis.
Methods: Blood Pressure of all the prevalent ESRD patients in a single dialysis 
center was recorded and mean arterial blood pressure (MAP) was calculated pre and post 
dialysis. All patients were clinically euvolemic. Serum calcium and phosphorous levels 
were measured and Calcium-phosphorus product (CaxP) was calculated. The product above 
50 and the MAP above 93 were taken as high.
J Am Soc Nephrol 26: 2015 Publication Only
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Results: Of the 60 ESRD patients, 35(58.3%) were males with mean age was 39.5±5 
years. High CaxP product was seen in 18 (30%) patients with high pre-dialysis MAP in 8 
(44%) and high post-dialysis MAP in 4 (22% ) patients respectively. Of 42 (70%) patients 
with CaxP product below 50 high pre-dialysis MAP was seen in 31(73%) and high post 
dialysis MAP was seen in 29 (69%) patients.
Conclusions: This study showed that high CaxP product (>50) is not correlated with 
high pre and post-dialysis MAP. The results are not consistent with earlier studies done in 
developed countries. Larger studies are needed to re-evaluate these findings.
PUB637
Behaviour of Ankle-Brachial Index During Hemodialysis: Effect of 
Calcium Dialysate Concentration  Zaida Noemy Cabrera Jimenez,1 Rosa M.A. 
Moyses,1,2 Bruno C. Silva,1 Luciene dos Reis,1 Wagner Dominguez,1 Fabiana 
Graciolli,1 Rosilene M. Elias.1  1Nephrology, Univ of Sao Paulo, Sao Paulo, SP, 
Brazil; 2Univ Nove de Julho- UNINOVE, Sao Paulo, SP, Brazil.
Background: Ankle-brachial index (ABI) is a simple way to access cardiovascular 
risk. Both low (<0.9) and high (>1.3) ABI are associated with increased mortality risk in 
patients on hemodialysis (HD). However, little is known regarding the acute variation of 
ABI (from pre to post hemodialysis), and also whether the calcium dialysate content [Ca] 
may interfere with this variability. We aimed to investigate the impact of [Ca] 3.5 vs. 2.5 
on the variability of ABI during HD.
Methods: Incident patients on HD for up to 90days were included. ABI was evaluated 
pre- and post-HD in the midweek session of two consecutive weeks with [Ca] 3.5 and 
2.5, respectively. Biochemical variables, electrical bioimpedance and non-invasive 
hemodynamic (Finapress®) were assessed.
Results: 17 patients (10 men) aged 42 ± 17 years were included. ABI pre- and post-
HD with [Ca] 3.5 and 2.5 were 1.2 ± 0.1, 1.1 ± 0.1, 1.1 ± 0.2, and 1.2 ± 0.1, respectively. 
Although the mean ABI values were within normal range, there was a great variability in 
the ABI, such that in 9 patients it increased using [Ca] 3.5, with 5 patients (29%) changing 
classification while in 6 patients it increased using [Ca] 2.5 with 3 patients (18%) changing 
classification. A [Ca] 3.5 was associated with an increase in serum calcium and a decrease in 
parathyroid hormone, while during a [Ca] 2.5 occurred a more pronounced blood pressure 
drop and consequent raise of peripheral arterial resistance. As the ultrafiltration rate was 
similar with [Ca] 3.5 and 2.5, there was no difference in total, extra- and intracellular water 
removal. ABI correlated with pre HD serum aldosterone (r= -0.515, p=0.002). Multiple 
regression analysis revealed that pre HD aldosterone and also a [Ca] were independently 
associated with the delta of ABI during dialysis, even adjusting for cardiac debit and 
ultrafiltration rate.
Conclusions: ABI presents great variability during a conventional HD. However, 
whether an acute decrease in ABI by using a [Ca] 2.5 may impact the long-term mortality 
deserves further investigation.
PUB638
Variation in the Intracranial Pressure During Hemodialysis in a Patient 
with Subdural Hematoma on Propofol  Rhea Bhargava,1 Omkar U. Vaidya.1,2 
1Dept of Internal Medicine, Univ of Missouri- Kansas City, Kansas City, MO; 
2Dept of Nephrology and Hypertension, Univ of Missouri- Kansas City, Kansas 
City, MO; 3Dept of Critical Care, Saint Lukes Hospital, Kansas City, MO.
Background: Dialysis disequilibrium syndrome (DDS) is a rare but potentially serious 
complication of hemodialysis. Pathophysiology of this disorder is explained by the ‘reverse 
urea effect’. This can be difficult to detect in patients in the neuro-intensive care unit given 
their compromised CNS status. However it is imperative to diagnose DDS especially in 
this population as intracranial pressure (ICP) instability during hemodialysis can lead to 
micro circulatory defects.
Methods: 60 y/o male with ESRD admitted for left frontal subdural hematoma, 
underwent evacuation with ventricular drain placement. He was intubated and sedated. 
BP 142/69 mmHg, Pulse 122 bpm, Temp of 37.3 °C, RR of 34 and SpO2 100%. The 
remaining physical examination was unremarkable. Hemodialysis (HD) was performed 
on 3 contiguous days. ICP and the changes in cerebral perfusion pressure (CPP) were 
monitored every 15 minutes during hemodialysis. Sedation with propofol which was started 
on Day1, was weaned off completely by the session on day three. The patient seized after 
the 3rd hemodialysis session. CT scan of the head was unremarkable. He was eventually 
discharged on day 14 and made full recovery.
Results: ICP and CPP during hemodialysis decreased in the first 30 minutes and 
maximum variation was between 45-120 minutes. Peak ICP pressure during HD: Day 1: 
5 mmHg; Day 2: 15 mmHg and Day 3: 25 mm Hg. Maximum change in CPP from basline 
during HD: Day1: 20 mm Hg; Day 2: 22mm Hg and Day 3: 47 mmHg.
Conclusions: ICP monitoring during hemodialysis is a useful modality to identify 
neurological complications in patients who have undergone neurosurgical interventions. 
Propofol along with being a sedative can lower ICP and hence prevent or mask the effects 
of hemodialysis on ICP. In the present case, net change in CPP could have led to seizure 
activity on the 3rd day of hemodialysis.
PUB639
Characterization of T Regulatory Type 1 (Tr1) Cells in Naïve and 
Transplanted Non-Human Primates  Ruichao Yu, Makoto Tonsho, Philip 
Spencer, Sibylle Bernard-stoecklin, Gilles Benichou, Joren Madsen.  Center 
for Transplantation Sciences, Harvard Medical School, Massachusetts General 
Hospital, Boston, MA.
Background: T regulatory Type 1 (Tr1) cells are peripheral CD4+FoxP3- regulatory T 
cells expressing CD49b and LAG-3 in mice and humans. Mouse Tr1 cells inhibit antigen-
presenting cell (APC) activation via secretion of IL-10 and TGF-β and via cell-contact 
dependent mechanisms mediated through their expression of programmed cell death (PD)-1. 
However, the phenotype and functions of Tr1 cells non-human primates are still unknown.
Methods: Mononuclear cells were isolated from the peripheral blood of cynomolgus 
monkeys(PBMCs). First, co-expression of CD49b and LAG-3 was compared among bona 
fide CD4+CD25highFoxP3+ Tregs and CD4+CD25-Foxp3-using flow cytometry. Second, 
cytokines(IL-10, TGF-β, IFN-γ, IL-4, IL-17 etc.,) were processed after polyclonal activation 
via anti-CD3/CD28 Ab-coated beads. Next, we compared PD-L1 and CD45RO expression 
by Tr1 cells collected from the PBMCs of naïve monkeys, monkeys undergoing rejection 
of kidney allografts and monkeys which have been rendered tolerant of kidney allografts 
via donor mixed hematopoietic chimerism induction and leukocyte costimulation blockade.
Results: In cynomolgus monkeys, CD49b and LAG-3 were co-expressed on 
CD4+CD25-Foxp3- Tr1lymphocytes but not on CD4+FoxP3+Tregs. After polyclonal 
activation via anti-CD3/CD28 Ab-coated beads, virtually all Tr1 cells secreted high levels 
of IL-10 anti-inflammatory cytokine but no pro-inflammatory IFN-γ or IL-17 cytokines. We 
observed a significant expansion of Tr1 cells expressing a memory phenotype (CD45RO) 
and the immunomodulatory receptor PD-L1 in tolerant but not other animals.
Conclusions: Our data show that the surface markers CD49b and LAG-3 can be used 
to distinguish Tr1 from “classical” FoxP3+ Tregs in cynomolgus monkeys. Tr1 cells are 
likely to inhibit T cell responses mediated by PD-1/PD-L1 interactions. The contribution 
of these activated Tr1 cells to induction and maintenance of organ allograft tolerance in 
non-human primates is under investigation.
Funding: NIDDK Support, Veterans Administration Support
PUB640
Urinary MicroRNA-25 as a Potential Biomarker for Detection of Renal 
Damage in Rats and Renal Transplant Patients  Kumiko Nishihara,1 
Masayuki Kanki,1 Moto Kajiwara,2,3 Kei Kurihara,4 Takahisa Yano,2 Hidehisa 
Kitada,4 Satohiro Masuda,2 Akira Unami.1  1Drug Safety Research Laboratories, 
Astellas Pharma Inc., Osaka, Japan; 2Dept of Pharmacy, Kyushu Univ Hospital, 
Fukuoka, Japan; 3Dept of Research and Development of Next Generation 
Medicine, Faculty of Medical Sciences, Kyushu Univ, Fukuoka, Japan; 4Dept 
of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu Univ, 
Fukuoka, Japan.
Background: Circulating microRNAs (miRNAs) were proposed as potential 
biomarkers of various biological functions and diseases in the kidneys. We have found 
that some urinary miRNAs were useful for detection of cisplatin-induced proximal tubular 
injury in rats (Kanki M et al., Toxicology. 324, 158, 2014). In this study, we examined the 
feasibility of miRNAs for renal damage in Japanese patients receiving kidney transplantation 
as well as rats.
Methods: Gentamicin (100 mg/kg) (model of tubular injury) was daily given for 7 days 
and puromycin (50 mg/kg) (model of glomerular injury) was given as a single injection 
to male SD rats. Seven days after the treatment, the urinary levels of 15 miRNAs were 
determined by real-time PCR. The receiver-operator characteristics (ROC) curve analysis 
for proximal tubular necrosis was performed including previous cisplatin study. Human 
urine samples were collected from 30 healthy volunteers and 11 renal transplant patients 
at 7 days and 2, 10, and 11 weeks after surgery. The levels of 4 miRNAs were determined.
Results: In gentamicin treated rats,the levels of miR-328, let-7a-1, miR-1839, miR-25, 
miR-140, and miR-378 were increased more than 2-fold with high values of the area under 
the ROC curve, which were the same or more than those of BUN and serum creatinine, 
while they were not changed in rats treated with puromycin. Among these miRNAs, miR-
25, miR-140-3p, miR-328 and miR-378 were measured in the human urine samples. In 
human samples, miR-25 at postoperative day 7 in some patients exhibited higher levels 
than the highest value of those in the volunteers.
Conclusions: Urinary miR-25 but not other miRNAs might be available for detecting 
renal damage in the postoperative course of renal transplant patients as well as that in the 
rats with proximal tubular injury.
PUB641
Early Activation of Complement in Renal Ischemia/Reperfusion (I/R) 
Injury Is Mediated by Pentraxin 3 (PTX3) Synthetized by Peripheral 
Blood Mononuclear Cells (PBMCs)  Giuseppe Castellano,1 Chiara Divella,1 
Alessandra Stasi,1 Paola Pontrelli,1 Matteo Accetturo,1 Marco Fiorentino,1 M. 
Rossini,1 Vincenzo Montinaro,1 G. Lucarelli,1 M. Battaglia,1 Loreto Gesualdo,1 
Giuseppe Grandaliano.2  1Dept of Emergency and Organ Transplantation, Univ 
of Bari, Bari, Italy; 2Dept of Medical and Surgical Sciences, Univ of Foggia, 
Foggia, Italy.
Background: PTX3 has been recently implicated in the promotion of vascular 
inflammation via the activation of Complement. Aim of this work was to investigate the 
possible involvement of PTX3 in renal I/R injury.
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Methods: PBMCs were isolated from blood of patients with Delay graft function 
(DGF,n=10) and Early graft function (EGF, n=10) at T0 and T24h from transplant. Gene 
expression profiles of PBMCs from both groups were assessed by Affymetrix technologies. 
Results were evaluated by statistical analysis and functional pathway analysis and validated 
by confocal analysis on a swine model of I/R injury. Renal I was induced in 5 pigs by arterial 
clamping for 30 min and tissues were analyzed at different time points after R (T15’,30’,60’).
Results: Microarray analysis (FDR<5% and a FC>1,5) revealed that the expression 
of PTX3 and C3 were downregulated in EGF compared to DGF patients. On the contrary, 
the gene CR1 was upregulated in DGF. Furthermore, in the pig model, confocal laser 
microscopy demonstrated PTX3 deposits already at 15’ of R, localized at peritubular 
(7.7±1.1;p=0.005) and glomerular (8.2±2.5;p=0.03) capillary levels. We found a significant 
increase in infiltrating interstitial leucocytes such as CD163+/PTX3+ monocyte-macrophages 
(6.2±2.1;p=0.05) and SWC3a+/PTX3+ dendritic cells (3.7±0.5;p=0.05) compared to T0. 
Finally, we identified tubulo-interstitial FSP1+/PTX3+ myofibroblast(4.1±1.3;p=0.04). 
Co-localization between C5b-9/PTX3, PTX3/C1q and PTX3/MBL clearly demonstrated 
the activation of Classical and Lectin Complement pathways in presence of PTX3 deposits.
Conclusions: Our data would suggest a key role of PTX3 synthetized by peripheral 
blood mononuclear cells (PBMCs) during DGF leading to an early activation of complement 
in transplant kidney.
PUB642
The Effect of Combined Treatment of Dipeptidyl Peptidase IV Inhibitor 
and Metformin in Sirolimus-Induced Diabetes Mellitus  Long Jin, Jian Jin, 
Sun Woo Lim, Byung Ha Chung, Chul Woo Yang.  Transplant Research Center 
& Div of Nephrology, Dept of Internal Medicine, Seoul, St Mary’s Hospital, The 
Catholic Univ of Korea, Seoul, Korea.
Background: Optimal treatment of post-transplant diabetes mellitus is still 
controversial. This study was performed to evaluate whether the combined treatment of 
DPP IV inhibitor with metformin (MET) is effective in sirolimus (SRL)-induced diabetes 
mellitus.
Methods: SRL-induced diabetes mellitus was made by treating SRL (0.3 mg/kg) for 3 
weeks in rats, and then started to treat DPP IV inhibitor (LC15-0444[LC], 5mg/kg), and/or 
MET (200 mg/kg) for further 3 weeks. The effect of combined treatment of LC and MET 
on SRL-induced diabetes mellitus was evaluated by IPGTT and islet size. The oxidative 
stress was evaluated by measuring 8-OHdG, 4-HHE, MnSOD, and catalase in samples. 
Insulin secretion capacity was evaluated by glucose-stimulated insulin secretion (GSIS) 
test using normal isolated rat islets treated with SRL, exendin-4 and/or MET.
Results: SRL treatment for 6 weeks decreased body weight and increased water intake 
and urine volume compared with vehicle group. SRL treatment significantly increased 
AUCg from the values obtained during the IPGTT, but LC or MET treatment recovered 
these value compared with the SRL treatment alone. Combined treatment with LC and 
MET has more significantly decreased blood glucose level than LC or MET treatment 
alone. Islet size which was significantly decreased in the SRL group was recovered with 
combined treatment of LC and MET. SRL treatment significantly increased intense nuclear 
expression and larger positive area for 8-OHdG and 4-HHE, but combined treatment LC and 
has significantly decreased expression of 8-OHdG and 4-HHE. The decreased expression 
of MnSOD and catalase in the SRL group was recovered with combined treatment with 
LC and MET. The result of GSIS also showed that combined treatment of LC and MET 
showed higher insulin level than exendin-4 or MET treatment alone.
Conclusions: Combined treatment with LC and MET exerts better glucose control 
by decreasing oxidative stress caused by SRL. This finding provides the rationale for the 
combined use of DPP IV inhibitor and MET in SRL-induced diabetes mellitus.
Funding: Government Support - Non-U.S.
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Incidence and Outcomes of Hyponatremia Early Post Lung Transplantation 
Ekamol Tantisattamo,1 Aneesha A. Shetty,1 Bing Ho,1 John J. Friedewald,1 Opas 
Traitanon,1 Sangeeta Bhorade,2 Alexander Haynes,2 Amber Nieland,2 Lorenzo 
G. Gallon.1  1Div of Nephrology and Hypertension; 2Pulmonary and Critical 
Care, Dept of Medicine, Northwestern Univ Feinberg School of Medicine.
Background: Outcomes of in-hospital hyponatremia in lung transplant recipients are 
unclear. The aim of this study is to describe the frequency of hyponatremia and outcomes 
associated with hyponatremia during the early postoperative period.
Methods: We performed a retrospective chart review of all lung transplant recipients 
at Northwestern Memorial Hospital since the first case performed in July 2014 until May 
2015. The severity of hyponatremia was defined as mild, moderate, and severe with serum 
Na of <135, <130, and <125 mEq/L, respectively.
Results: A total of 13 lung transplant recipients were included. Age at the time of 
transplantation was 61.5+/-2.2 (SEM) years and 69% was female. The most common 
indication for transplantation was severe COPD (54%). Serum creatinine at the time of 
transplantation and at hospital discharge was 0.8+/-0.1 and 1+/-0.2 mg/dL, respectively. 
Seven patients with postoperative acute kidney injury (AKI) had >2 times longer length 
of hospitalization (26.2+/-4.8 vs. 10.0+/-1.1 days; p 0.0046) and were more likely to 
develop postoperative hyponatremia (100% vs. 71%; p=0.151). Among 11 patients with 
postoperative hyponatremia, 7 were readmitted (5 with hyponatremia and 4 with AKI). At 
the time of transplant, 8% of the patients had hyponatremia but the incidence was up to 46% 
at the time of discharge (Table1). Almost half of the patients had persisent hyponatremia 
during 1 month follow-up.
Conclusions: Lung transplant recipients commonly develop hyponatremia during the 
immediate post operative period and are more likely to be readmitted with hyponatremia. 
The incidence of hyponatremia remains high up to 1 month post transplantation. AKI is 
also a risk for readmission and predicts longer length of hospital stay.
Degree of 
serum sodium
At trans-
plant 3 days 7 days
At dis-
charge 30 days
90 
days 
180 
days
Normal 12(92%) 6(46%) 9(7%) 7(54%) 7(54%) 7 4
Mild 0 4(31%) 0 5(38%) 6(46%) NA 1
Moderate 1(8%) 0 2(8%) 1(8%) NA NA NA
Severe 0 1(8%) 2(8%) 0 NA NA NA
Hypernatremia 0 2(15%) 0 0 NA NA NA
PUB644
Motivations, Challenges, and Attitudes to Self-Management in Kidney 
Transplant Recipients: A Systematic Review of Qualitative Studies 
Nathan Jamieson,1,2 Camilla Sara Hanson,1,2 Michelle A. Josephson,3 Elisa 
J. Gordon,4 Jonathan C. Craig,1,2 Fabian Halleck,5 Klemens Budde,5 Allison 
Tong.1,2  1Centre for Kidney Research, The Children’s Hospital at Westmead, 
Sydney, New South Wales, Australia; 2School of Public Health, Univ of Sydney, 
Sydney, New South Wales, Australia; 3Dept of Medicine, The Univ of Chicago, 
Chicago, IL; 4Center for Healthcare Studies and Comprehensive Transplant 
Centre, Northwestern Univ Feinberg School of Medicine, Chicago, IL; 5Dept 
of Nephrology, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Background: Kidney transplantation offers superior life expectancy and quality of life 
outcomes compared to other renal replacement therapy modalities. However, the complex 
and ongoing medication and self-management regimens impose a treatment burden on 
patients, and non-adherence remains a leading cause of graft loss.
Methods: MEDLINE, Embase, PsycINFO, and CINAHL were searched from database 
inception to October 2014. We used thematic synthesis to analyse the findings.
Results: Fifty studies involving 1238 participants aged from 18 to 82 years across 
19 countries were included. We identified five themes: empowerment through autonomy 
(achieving mastery, tracking against tangible targets, developing bodily intuition, routinising 
and problem-solving, adaptive coping), prevailing fear of consequences (inescapable 
rejection anxiety, aversion to dialysis, minimising future morbidity, trivialisation and 
denial, defining acceptable risks), burdensome treatment and responsibilities (frustrating 
ambiguities, inadvertent forgetfulness, intrusive side-effects, reversing ingrained behaviours, 
financial hardship), over-medicalising life (dominating focus, evading patienthood, 
succumbing to burnout), and social accountability and motivation (demonstrating gratitude 
towards medical team, indebtedness to donor, peer learning).
Conclusions: Self-efficacy and social accountability are motivators for self-
management, but ongoing adherence can be mentally and physically taxing. Multi-
component interventions that incorporate education, psychosocial support, decision aids, 
and self-monitoring tools may foster self-management capacity and improve transplant 
outcomes.
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Characteristics of Patients with Vitamin D Deficiency After Kidney 
Transplantation in Qatar  Mohamed Amin Elesnawi, Abdullah Hamad, 
Fadwa S. Al-Ali.  Nephrology, Fahd Bin Jasim Kidney Center, Hamad General 
Hospital, Doha, Qatar.
Background: Vitamin D deficiency is common among normal people and in patients 
with chronic kidney disease including dialysis patients. Vitamin D deficiency continues to 
be prevalent after kidney transplantation (studies showed prevalence of 50-80%) especially 
with immunosuppression use and sun protection needed for elevated risk of skin cancer . 
We studied characteristics of kidney transplant patients with vitamin D deficiency in Qatar.
Methods: We reviewed all available records of kidney transplant patients presented to 
our clinic at Hamad General Hospital in Doha, Qatar between 1/9/2013 and 1/3/2014 and 
have vitamin D level less than 30 ng/mL. Background data and laboratory tests of patients 
were obtained. All patients were receiving vitamin D supplements and prednisone within 
their immunosuppression per institution protocol.
Results: We studied 83 patients. Mean age was 55.5 +/- 16 years. There were 55 males 
(66%) and 28 females (34 %). Vitamin D deficiency was severe (level than 10 ng/mL) in 15 
patients, moderate in 38 (10-19 ng/mL) and mild in 30 patients (20-29 ng/mL). Duration 
of transplant was 7.9 +/- 2.5 years. Glomerular Filtration Rate was 65.5 +/- 20.6 ml/min. 
We found no correlation between vitamin D and PTH levels or between vitamin D and 
GFR levels. Table 1 summarize bone mineral panel in our patients.
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Plasma Level +/- SD
Vitamin D 16.4+/-6.7 ng/ml
Calcium 2.28+/-0.14 mmol/L
Phosphorus 1.2+/-0.26 mmol/L
Alkaline Phosphatase 86.9+/-37.8 u/L
Intact Paathyroid Hormone 146+/-2.1pg/mL
Conclusions: In a study of kidney transplant patients with vitamin D deficiency in 
Qatar we found that they were predominantly males, have normal calcium, phosphorus 
and alkaline phosphatase levels, while they have variable degree of elevated PTH with no 
correlation to vitamin D level. Most patients have mild to moderate vitamin D deficiency 
(82%) despite receiving vitamin D supplement although the supplement could have 
decreased the number of patients with severe vitamin D deficiency (18%). Further study 
could help to evaluate the role of vitamin D supplement in improving vitamin D level in 
kidney transplant recipients.
PUB647
Comparison of Vitamin D Deficiency Between Young and Elderly Kidney 
Transplant Recipients  Mohamed Amin Elesnawi, Abdullah Hamad, Fadwa S. 
Al-Ali.  Nephrology, Fahd Bin Jasim Kidney Center, Hamad General Hospital, 
Doha, Qatar.
Background: Vitamin D deficiency is common in normal population and in patients 
with chronic kidney disease including kidney transplant recipients. Elderly patients are 
vulnerable to vitamin D defeciency with less sun exposure and having multiple medical 
problems. We compared young versus elderly kidney transplant recipients with vitamin 
D deficiency in Qatar.
Methods: We reviewed all available records of kidney transplant recipients presented to 
our clinic at Hamad General Hospital in Qatar between 1/9/2013 and 1/3/2014. Background 
data and laboratory tests of patients were collected. All patients were receiving vitamin D 
supplements and prednisone per institution protocol.
Results: 83 patients were included. 41 patients in the young group (< 60 years old) 
and 42 in the elderly group (> 60 years old). There were 21 females versus 20 males in the 
young group and 35 males versus 7 females in the elderly group (pValue<0.05). Time on 
transplant was 9.1 +/- 4.93 years in the young group versus 8.6+/-2.7 in the elderly. Table 
1 summarizes laboratory values for kidney transplant patients with vitamin D deficiency. 
Age over 60 years (n=42) Age less than 60 years (n=41)
Vitamin D 17.7+/-6.4 ng/mL 15.1+/-6.7 ng/mL
Calcium 2.28+/-0.13 mmol/L 2.29+/-0.15 mmol/L
Phosphorus 1.22+/-0.18 mmol/L 1.16+/-0.3 mmol/L
Parathyroid Hormone 148.7+/-238.3 pg/mL 143.9+/-154.8 pg/mL
Alkaline Phosphatase 75.8+/-29 u/L 91.9+/-39.9 u/L
Glomerular Filtration Rate 
(GFR) 69.9+/-21.4 ml/min 61.2+/-19.2 ml/min
Conclusions: We compared vitamin D deficiency in young versus elderly kidney 
transplant recipients in Qatar. Although elderly patients have higher vitamin D levels, it 
was not statistically significant. This could be due to better compliance with vitamin D 
supplement in the elderly. Although duration on transplant, calcium, phosphorus and intact 
parathyroid hormone were similar, Glomerular Filtration Rate (GFR) was higher in the 
elderly. We explain it that almost all kidney tranplants in Qatar are from live donors which 
lead to a higher GFR in the elderly as they are receiving kidneys from younger donors. 
There was statistically significant smaller number of females than males in the elderly group.
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The Current Status of Plasmapheresis Before Living Donor Kidney 
Transplantation in Japan  Norio Hanafusa,1 Tomoko Usui,1 Akihiko 
Matsumoto,1 Satoko Sakurai,1 Eisei Noiri,1 Hideo Yasunaga,2 Masaomi 
Nangaku.1  1Dept of Hemodialysis and Apheresis, The Univ of Tokyo Hospital, 
Bunkyo-ku, Tokyo, Japan; 2Dept of Clinical Epidemiology and Health 
Economics, School of Public Health, The Univ of Tokyo, Bunkyo-ku, Tokyo, 
Japan.
Background: Plasmapheresis (PP) is utilized to remove alloantibodies before the 
living donor kidney transplantation (LDKT). The detailed practice patterns of PP before 
LDKT remains unknown. There also are concerns about the depletion of coagulation factors 
[Transfus Apher Sci 49: 254, 2013] by PP. We investigated the current status of PP before 
LDKT with use of the nationwide database.
Methods: The Japanese Diagnosis Procedure Combination Database includes all 
the patients discharged from hospitals participating in this program between July 2010 
and March 2013. Those who received LDKT and PP before LDKT were included into 
this study. The modalities of PP, fresh frozen plasma (FFP) use, and albumin use were 
examined. We also investigated the relationship between modalities selected and outcomes 
such as the length and total costs of the hospital stay, or the amount of blood transfusion 
as the proxy of bleeding.
Results: In total 775 patients received PP before LDKT during the period. Among them 
209 patients were treated only by simple plasma exchange (PE). Remaining 566 patients 
received double filtration plasmapheresis (DFPP), or cascade filtration. Interestingly, 274 
patients treated by DFPP received also PE before transplantation. FFP was used during PP 
on 109, 180, and 42 patients treated by PE only, DFPP followed by PE, and DFPP only, 
respectively. Moreover, FFP was infused before the operation on 161 patients who were 
not used FFP during PP. As a whole 63.5% of total patients received FFP from the start of 
PP to the day of operation. DFPP followed by PE groups received less amount of blood 
transfusion (p=0.047), though the length of stay was longer and total costs were higher, 
compared to DFPP only group.
Conclusions: Many of the patients received FFP, which suggests concerns about the 
depletion of coagulation factors during PP. The practice patterns were quite heterogeneous 
and the standardization of the practice patterns is needed to maximize the benefits of PP.
Funding: Government Support - Non-U.S.
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Age as a Risk Factor for Acute Rejection in the Renal Transplant Patient 
Sarah Lamarche, Jean-Philippe Lafrance, Michel Vallee, Duy Tran.  Nephrology, 
Univ de Montréal, Montréal, QC, Canada.
Background: It has previously been shown that younger age is associated with a higher 
risk of acute rejection post renal transplantation. However, those studies were undertaken in 
times with differing use of immunosuppressive therapies. We thus sought to examine if this 
trend was still relevant in a contemporary cohort of patients with a new prescription profile.
Methods: We retrospectively reviewed the charts of 217 patients who underwent renal 
transplantation between the years 2006-2012 at our institution. Baseline characteristics of 
donors and recipients were examined. Recipients were stratified according to age <30, 30-40, 
40-55, 55-65 and >65 years old. Our primary endpoint was the incidence of acute rejection 
at one year post renal transplantation. Multivariate Cox regression models predicting acute 
rejection were also fitted to adjust for several confounders.
Results: Regarding baseline recipient characteristics, there was a significant difference 
in the leading cause of end-stage kidney disease among the groups (glomerulopathy in 
young recipients and diabetic nephropathy in old recipients). Also, hypertension, diabetes 
and coronary heart disease were more prevalent in older recipients. Overall, the incidence 
rate of acute rejection at 1 year in all groups was 19 per patient-year. Statistically significant 
differences in Kaplan-Meyer estimates of rejection at one year were recorded (log rank 
p=0.03) and those differences were confirmed in multivariable Cox regression analyses. 
Indeed, individuals aged 30-40 years had a higher risk of developing acute rejection (HR 6.5, 
95% CI: 1.9, 22.5) compared to the reference group (40-55). Other significant predictors of 
acute rejection at 1 year included PRA > 20% (HR 6.8), unrelated living donor (HR 10.2), 
donor after cardiac death (HR 3.7) and length of initial hospitalisation stay (HR 1.03).
Conclusions: In a contemporary cohort, we recorded a significant difference in patterns 
of acute rejection following renal transplantation according to age. Indeed, individuals 
aged 30-40 years were more prone to transplant rejection, even after adjusting for several 
covariates. This research should fuel additional investigations regarding the biology of 
this disease.
Funding: Clinical Revenue Support
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Delta Neutrophil Index as a Marker for Differential Diagnosis Between 
Acute Graft Pyelonephritis and Acute Graft Rejection  Soyon Rhee, Eunjung 
Kim, Hee Jung Jeon, Ja-Ryong Koo.  Internal Medicine, Nephrology, Hallym 
Univ of College of Medicine, Seoul, Republic of Korea.
Background: Acute graft pyelonephritis (AGPN) versus acute graft rejection is a 
frequently encountered diagnostic and therapeutic dilemma in renal transplant recipients, 
but little is known about the clinical usefulness of the delta neutrophil index (DNI) value 
in the differentiation of the two conditions.
Methods: We reveiwed the medical records of 86 renal transplant recipients, 45 patients 
with 51 acute graft rejection episodes and 41 patients with 54 AGPN episodes, at the 
Kangdong Sacred Heart Hospital from January 2008 to February 2014. Of theses episodes, 
15 were excluded due to neutropenia (n=4), other infections (n=5), and no available data 
of procalcitonin levels (n=6). As a result, 72 renal transplant recipients with 90 episodes 
were enrolled in this study.
Results: AGPN group had significantly higher DNI values than acute graft rejection 
group (2.9% vs. 1.9%, P<0.001). The area under the ROC curve for DNI value was 0.85 
(95% confidence interval [CI]; 0.76-0.92, P< 0.001). 
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A DNI value of 2.7% was selected as cut-off value for AGPN, and renal transplant 
recipients with a DNI ≥ 2.7% were found to be at a higher risk of infection than those with 
a DNI < 2.7% (odd ratio [OR] 40.50; 95% CI 8.68-189.08; P <0.001). In a multivariate 
logistic regression analysis, DNI was a significant independent factor for predicting 
AGPN after adjusting age, sex, log WBC count, log neutrophil count, log lymphocyte 
count, DNI value, CRP concentration and procalcitonin concentration (OR 4.32; 95% CI 
1.81-10.34, P < 0.001).
Conclusions: The present study demonstrated that a DNI value above 2.7% was an 
independent predictive marker for AGPN and an effective marker to differentiate between 
AGPN and acute graft rejection. Thus, these finding suggest that DNI may be a useful 
marker in the management of theses patients.
PUB652
Effect of Pre-Transplant Dialysis Modality on Outcomes of Living-Donor 
Kidney Transplantation Recipients  Chiaki Kawabata.  General Internal 
Medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Background: There are few studies on living-donor kidney transplantation that 
compare the outcomes after pre-transplant dialysis modality. We examined the short-term 
outcomes of living-donor kidney transplantation recipients after peritoneal dialysis (PD) 
and hemodialysis (HD), respectively.
Methods: 112 patients have undergone living-donor kidney transplantation procedures 
in our hospital between January 2001 and May 2014.  We studied 40 patients, under 40 
years of age, with dialysis durations of less than 5 years. We compared 13 PD patients with 
27 HD patients and investigated the short-term outcomes.
Results: These two groups showed no significant differences as regards baseline 
characteristics including dialysis duration, body mass index, type of calcineurin inhibitor or 
ABO blood type incompatibility. The PD group was younger than the HD group as regards 
recipient age and donor age (22.5±8.0 years vs 29.1±6.0 years [p=0.005] : and, 50.7±8.2 
years vs 56.9±7.1 years [p=0.02], respectively). There were no differences in early post-
transplant complications, such as wound infection, bleeding, thrombosis, delayed graft 
function, or acute rejection. The PD group was better than the HD group in the estimated 
glomerular filtration rate (eGFR) at discharge (74.3±27.3 ml/min/1.73 m2 vs 48.3±12.3 
ml/min/1.73 m2 [p=0.001]) and eGFR 1 year post-transplantation (68.4±21.8 ml/min/1.73 
m2 vs 45.6±13.2 ml/min/1.73 m2  [p=0.003]).
Conclusions:  In the case of younger and less than 5 years of dialysis duration, PD and 
HD demonstrated no differences in early post-operative complications.  PD is significantly 
better than HD as regards eGFR up to 1 year post-transplantation.
PUB653
Bright Field Microscopy of the Unstained Urine Sediment: A Basic Tool 
to Identify Decoy Cells due to Polyomavirus BK on Kidney Allograft 
Recipients During Routine Urinalysis  José A. Poloni,1,2,3 Gabriel Godinho 
Pinto,2 Maria Giordani,1 Elizete Keitel,1,2 Alessandro C. Pasqualotto,1,2 Liane 
Rotta.2  1Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto 
Alegre, RS, Brazil; 2Univ Federal de Ciências da Saúde de Porto Alegre, Porto 
Alegre, RS, Brazil; 3Control Lab, Rio de Janeiro, RJ, Brazil.
Background: Polyomavirus BK (BKV) is an important pathogen that can be reactivated 
in kidney allograft recipients, potentially leading to BKV nephropathy (BKVN), an 
important cause of graft loss. Decoy cells (DC), urothelial cells or renal tubular epithelial 
cells modified by the proliferation of BKV, are one of the hallmarks of BKV reactivation 
and it can be identified in the fresh urine sediment.
Methods: A cohort of 102 kidney transplant patients was followed during months 3 
and 6 after the transplant procedure. Urine samples were obtained to detect the presence 
of DC in the fresh and unstained urine sediment under bright field microscopy (BFM) by 
two experienced analysts, as well as BKV viruria by qPCR.
Results: DC were found in 15 patients. 
Urine sediment analysis revealed a strong agreement (P<0,001) between the 
microscopists to both qualitative and quantitative identification of DC. Also, the qualitative 
comparison of both microscopists to BKV viruria revealed agreement (P<0,001). The 
positive predictive value, negative predictive value, specificity and accuracy of BFM were 
80%, 75%, 97% and 75%, respectively. The sensitivity was 16%.
Conclusions: Despite its limited sensitivity, fresh and unstained urine sediment analysis 
under BFM is a method that can be used to identify DC due to BKV reactivation. The 
analysis procedure is fast, cheap and painless. The information obtained during routine 
urinalysis can be lead to the early diagnosis of BKV reactivation helping on the clinical 
management of the patients. The ability of less trained observers to perform such diagnosis 
requires further validation.
PUB654
Intravenous Immunoglobulin in the Management of Pneumocystis 
Pneumonia: A Case Series  Musab Elgaali, Muhammad Imran, Matthew Edey. 
Hull Royal Infirmary, Hull, United Kingdom.
Background: Pneumocystis pneumonia (PCP) is a well-recognized complication 
of renal transplantation. We present 2 cases of severe PCP treated successfully with 
intravenous immunoglobulin (IVIg), trimethoprim-sulfamethoxazole (TMP-SMX) and 
withdrawal of immunosuppression. Graft function was maintained despite a high baseline 
immunological risk.
Methods: Case A: A 32 year-old woman presented 2 years post-transplant with acute 
cellular rejection treated with steroids. 2 months later she was admitted with respiratory 
failure due to PCP. She required intubation and ultimately oscillatory ventilation. CMV 
DNA was detected at low levels in bronchoalveolar lavage (BAL) fluid. IVIg 30g on 
alternate days (10 doses) was added, in addition to withdrawal of immunosuppression and 
hydrocortisone replacement. She made a full recovery, with preservation of transplant 
function throughout. Case B: A 47 year-old woman received a second kidney transplant. 
Early post-transplant she developed acute antibody mediated rejection managed with plasma 
exchange then maintenance prednisolone, tacrolimus and mycophenolate. 9 months later 
she was admitted with respiratory failure and Pneumocystis jirovecii in BAL. She required 
invasive ventilation and inotropic support. She was treated with intravenous TMP-SMX, but 
her clinical condition deteriorated with acute kidney injury (AKI) requiring hemofiltration 
and escalating ventilator requirements. She received IVIg 25g/day for 5 days, replacement 
hydrocortisone and immunosuppression was withdrawn. Her AKI resolved and later she 
became ventilator-independent. Graft function was at baseline on discharge. Maintenance 
immunosuppression was recommenced.
Conclusions: It is understood that immunity against Pneumocystis jirovecii is both 
B- and T-cell mediated. Thus pooled immunoglobulin might be expected to have some anti-
Pneumocystis activity. It is also recognized that IVIg has immunomodulatory properties. 
In both cases the administration of IVIg allowed withdrawal of immunosuppression 
apart from replacement steroid without graft rejection despite high immunological risk. 
Both patients survived life-threatening PCP. We suggest adjunctive therapy with IVIg be 
considered in severe PCP.
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Ethical Issues Related to Kidney Donation/Transplantation: Perspective 
of Indian Doctors  Richard S. Fernandes Almeida,1 Nirmala Almeida,2 Karen 
Almeida,3 Alan F. Almeida.4  1Lifesupporters Inst of Health Sciences; 2Human 
Development, Nirmala Niketan College of Home Science; 3Psychology, Mumbai 
Univ; 4Nephrology, PD Hinduja Hospital, Mumbai, India.
Background: Dearth of kidneys for transplantation has provoked the need to evaluate 
new policies and practices. This spurred the current study which addressed the perspective 
of doctors regarding emerging ethical issues pertaining to kidney donation/transplantation.
Methods: The sample consisted of 140 doctors from Mumbai (Age Range=21-80 
years, M=38.1, SD=17.95, Males=44.3%, Females=55.7%). A questionnaire, presenting 
ethical issues related to kidney donation/transplantation, in an agree/disagree format with 
supporting reasons was employed. The research design was exploratory; data was analyzed 
quantitatively and qualitatively.
Results: 
Question Agree% Reasons (%)* Dis-agree% Reasons (%)*
Unrelated trans-
plants should be 
promoted by the 
government 
75.7
Saves lives (16.4) 
Remedies organ donor short-
age(16.4)
24.3
Misuse of organs 
(7.1) 
Higher chances of 
mismatch/organ 
rejection(7.1)
Kidney selling 
should be made 
legal 
22.9
Greater donor availabil-
ity(7.9) 
Avoidance of malprac-
tice(6.4)
77.1
May lead to illegal/
unethical prac-
tices(41.4)
Handicapped 
should not be 
kidney donors
24.3
Should not burden them as 
already challenged health-
wise(10.7)
75.7
If informed consent 
given(20) 
If kidneys effectively 
functioning(14.3)
Substance abus-
ers should not 
be transplant 
recipients
50.7
Chose to bring deterioration 
in life(10) 
Might abuse the trans-
plant(15.7)
49.3
All are entitled to 
be kidney recipi-
ents(22.1)
Younger indi-
viduals should be 
given transplanta-
tion preference 
60
Longer life expectancy (20) 
Greater transplantation suc-
cess(12.9)  
Higher productivity(12.9)
40
Need-based rather 
than age-based pref-
erence(11.4)
Families of 
cadaver donors 
should be given 
incentives 
45.7 Motivates donation(22.9) 54.3
Would lead to 
commercialization 
and criminal activi-
ties(20.7)
Kidney donation 
should be made 
compulsory after 
death
44.3 Saves lives(26.4) 55.7
Donation is individu-
al’s choice, coercion 
is unethical(44.3)
*Representative    
Conclusions: This study is relevant in view of the dearth of Indian research. Educating 
doctors about medico-ethical issues is the need of the hour.
PUB656
Cardiovascular Risk Management of Renal Transplant Patients 
Joseph C. Newton, Thalakunte M. Muniraju.  Dumfries and Galloway Royal 
Infirmary, Dumfries, United Kingdom.
Background: There is a high burden of cardiovascular disease amongst renal transplant 
recipients, and it is the most common cause of death with a functioning graft. We have 
assessed the medical management of all transplant patients in our region by comparing 
regular monitoring of glycaemia, blood pressure and serum lipids, with appropriate 
prescription of medicines based on their cardiovascular risk.
Methods: Using the electronic health record information was collected on 
cardiovascular comorbidities, all current medications, frequency of clinic monitoring, BP 
and most recent biochemical results for glycaemia, proteinuria and lipid results for the local 
transplant cohort of 69 patients. Prescription of statins, antihypertensives and aspirin were 
audited against guidelines from the UK Renal Association (RA) and KDIGO. Cardiovascular 
risk was calculated using the Joint British Societies Guidelines (JBS2).
Results: Amongst hypertensive patients, 2/28 (7.1%) were not on antihypertensive 
therapy. Significant proteinuria (uPCR >50) was not common (6/68 = 8.8%), but of these 
only 2/6 (33.3%) were receiving an ACE inhibitor or ARB. Glycaemic control of diabetic 
patients was generally good, with 9/12 (75%) achieving target HBa1c of <48 mmol/mol. 
For non-diabetic patients, 11/56 (19.6%) were found to have a random glucose ≥7. Of these 
4/11 (36.4%) had HbA1c checks, one of which confirmed new diabetes. The remaining 7 
patients (63.6%) have not had a follow up HbA1c. 20/69 (29.0%) of patients were calculated 
as >20% cardiovascular risk on the basis of comorbidities or using JBS2. Of these only 
12/20 (60%) were on statin therapy. Almost all (6/7 = 85.7%) of patients with vascular 
disease were taking regular aspirin.
Conclusions: We have identified room for improvement in the management of 
hypertension and proteinuria. Rates of statin prescription suggest that we often underestimate 
cardiovascular risk clinically, however, further analysis will be required to determine 
whether valid reasons exist to support decisions to omit statins or renin-angiotensin 
blockade. These audit results will be discussed with local clinicians, and will be added 
to the electronic record to highlight areas where individual management differs from 
national guidelines.
PUB657
Preemptive Transplantation Is Associated with Improved Graft Survival: 
Results from the French Transplant Database  Mathilde Reydit,1,2 Christian 
Combe,2 Jerome Harambat,2 Christian Jacquelinet,3 Pierre Merville,2 Lionel 
Couzi,2 Karen Leffondré.1  1INSERM U897, Bordeaux School of Public Health, 
Bordeaux, France; 2Nephrology and Transplantation, Bordeaux Univ Hospital, 
Bordeaux, France; 3Agence de la Biomédecine, Paris, France.
Background: Kidney transplantation (KT) is the treatment of choice for end-stage 
renal disease. In France, preemptive kidney transplantation (PKT) should be considered 
when glomerular filtration rate is under 20 ml/min/1.73m² but European reports on the 
results of PKT are scarce. Our objective was to evaluate the impact of PKT on graft and 
patient survival.
Methods: We analyzed all first kidney-only transplants performed in adults in France 
between 2002 and 2012. A Cox multivariable model was used to study the impact of 
PKT on the hazard of graft failure defined as death, return to dialysis, or retransplant, 
whichever came first.
Results: Between 2002 and 2012, 22 288 patients received a first KT, including 3112 
(14%) who had a PKT. Mean recipient age at KT was 50.5 ± 13.4 years, 61.9% were men. 
Median time of follow-up was 4.7 years. In multivariable analysis, after adjustment for 
age and sex of recipients, primary kidney disease, donor type (living or deceased donor, 
expanded criteria donor or standard), HLA mismatches, cold ischemia time, center and 
year of transplantation, PKT was associated with a 43% reduction in the hazard of graft 
failure when compared with patients who were treated by dialysis before KT (Hazard ratio 
(HR) 0.57;IC95% 0.51-0.64). This reduction in the hazard of graft failure was greater after 
the first year of transplant (HR during the first year 0.69,IC95% 0.57-0.83;HR after the 
first year 0.51,IC95% 0.45-0.59) and the impact of PKT was also greater in living than 
in deceased donor recipients (HR in living donor 0.34,IC95% 0.19-0.55;HR in deceased 
donor 0.59,IC95% 0.52-0.66). Among the subgroup of patients registered on the waiting 
list before the initiation of dialysis, PKT was associated with a 29% reduction in the hazard 
of graft failure (HR 0.71;IC 95% 0.58-0.87).
Conclusions: In France, PKT is associated with better graft survival than KT performed 
after the initiation of dialysis. Nephrologists should prepare patients to PKT rather than 
to dialysis.
Funding: Private Foundation Support
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Novel Potential Theranostic Targets in Individuals with Kidney Allograft 
Dysfunction  Roberto Bassi,1,2 Monika A. Niewczas,3 Stefania Bussolino,5 
Valentina De Zan,2 Giuseppe Paolo Segoloni,6 Antonio Secchi,2 Anil K. 
Chandraker,4 Luigi Biancone,6 Paolo Fiorina.1,2  1Nephrology, Boston Children’s 
Hospital, Boston, MA; 2Medicine, San Raffaele Scientific Inst, Milan, Italy; 
3Section of Genetics and Epidemiology, Joslin Diabetes Center, Boston, MA; 
4Transplantation Research Center, Brigham and Women’s Hospital, Boston, MA; 
5Internal Medicine, San Giovanni Battista Hospital, Turin, Italy; 6Univ of Torino.
Background: The lack of early diagnostic and therapeutic targets for chronic allograft 
dysfunction (CAD) is among the major determinants of poor long-term graft survival. 
Metabolic abnormalities in serum and kidney graft parenchyma may worsen allograft 
function, while alterations of urinary metabolites may be used as diagnostic biomarkers.
Methods: To explore this hypothesis, we recruited individuals with stable allograft 
function (n=20), chronic allograft dysfunction (n=20) and healthy controls (n=10), and 
analyzed their metabolomic profile by ex vivo liquid/gas cromatography-mass spectrometry 
(LC/GS-MS) of serum and urine and in vivo two dimensional correlated spectroscopy 
(2D-COSY) of the kidney graft.
Results: LC/GS-MS revealed serum and urinary abnormalities of amino acids, biogenic 
amines and acylcarnitines in individuals with worse allograft function (T3) compared to 
conserved graft function (T1). Particularly, CAD was associated with reduction of serum 
tryptophan and glutamine (T3 vs. T1, p<0.01) and of urinary histidine (T3 vs. T1, p<0.05). 
Derivatives of dimethylarginine (DMA; symmetric (S)DMA: T3 vs. T1, p<0.001; p<0.01) 
and short-chain acylcarnitines (C4; C12: T3 vs. T1, p<0.01; p<0.05) increased in serum, 
while dopa and dopamine (T3 vs. T1, p<0.01; p<0.001) together with DMA, SDMA and 
ADMA (T3 vs. T1, p<0.001, p<0.001, p<0.01) decreased in urine. In vivo 2D-COSY 
performed on the same patients revealed reduction (p<0.05) of the parenchymal content 
of choline, creatine, taurine and threonine in individuals with CAD. Notably, taurine was 
selectively reduced within the graft parenchyma and increased in serum and urine of 
individuals with CAD.
Conclusions: Novel potential theranostics targets have been identified with an unbiased 
ex vivo and in vivo metabolomic profiling of individuals with CAD.
Funding: Government Support - Non-U.S.
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Good Patient and Graft Survival in Recipients of Kidney Transplantation 
due to Diabetic Nephropathy  Amgad E. El Agroudy.  Internal Medicine 
Dept, College of Medicine and Medical Sciences, Arabian Gulf Univ, Manama, 
Bahrain.
Background: Compared with non-diabetic subjects, patients with type 2 diabetes and 
end-stage renal disease (ESRD) have seldom been selected for renal transplantation. The 
aim of this study is to compare patient and graft outcome in kidney transplant patients 
with diabetes mellitus.
Methods: We retrospectively studied 358 patients who underwent kidney 
transplantation between 1979 and 2014, including 88 with diabetic ESRD (DM group) (type 
1, n = 8; type 2, n = 80) and 270 with non-diabetic ESRD (NDM group). Mean follow-up 
was 92±9 (0.1–389) months.
Results: Mean age was higher in the DM group (52.8 vs 44.6 years; P < .0001), 
and there was no significant difference in recipient gender, donor age or donor source. 
At the end of follow-up, there was no differences between the groups in terms of blood 
pressure control (DM 139.3±16.7/81.7±7.6 mmHg vs NDM 138.3±19.7/82.1±8.1 mmHg, 
P= 0.83/0.80) and renal function (creatinine, 115.4±47.1 vs 133.4±80.2 µmol/l, P= 0.18; 
calculated creatinine clearance, 66±24 vs 68.4±24 ml/min/1.73 m2, respectively, P = 0.9). 
In total, 26 patients had acute transplant rejections [8 patients with diabetes vs 18 patients 
without diabetes, P = 0.11].There was no significant difference in post transplant surgical 
complications as wound dehiscence or infections. There was a significant high incidence 
of the urinary tract infection rate in DM group (17 vs 32 patients; P = .012). Four out of 
22 patients died (18.2%) in the DM group and 10 out of 47 patients died (21.3%) in the 
NDM group died from cardiovascular disease (P = 0.17). The 1-, and 10-year patient 
survival rates in the DM and NDM groups were 97.5% vs 99% (ns), and 56.8% vs 58.8% 
(ns), respectively. The 1-, and 10-year graft survival rates were 97.5% vs 70.7% (ns) and 
58.9% vs 66.1% (ns), respectively.
Conclusions: Renal transplantation in diabetic ESRD patients yields good results 
in terms of patient survival and complications, suggesting that renal transplantation can 
be performed in these patients and should become a more established treatment option.
PUB660
Impact of Pre-Transplant Peritoneal Dialysis Compared with Hemodialysis 
on the Incidence of Delayed Graft Function in Kidney Transplant Recipients 
with Lupus  Gabriel Contreras, Javier Pagan, Antonio A. Armstrong, Jorge 
M. Diego, Ian Thomas, Patricia Marie Byers, Alberto J. Sabucedo, Jair Munoz 
Mendoza, David Roth.  Univ of Miami Miller School of Medicine.
Background: Delayed graft function (DGF) increases the risk of allograft failure in 
recipients of kidney transplants.
Methods: In this study, we assessed the impact of pre-transplant peritoneal dialysis 
(PD) compared with hemodialysis (HD) on the risk of DGF in patients with lupus using 
logistic regression models.
Results: Three hundred-fifty three of 2513 (14 %) recipients transplanted between 
3/22/1994 and 9/27/2006 with complete records in the United Network for Organ Sharing 
files had DGF. The incidence of DGF was lower in recipients who used PD (68/613 = 11.1%) 
compared with HD (285/1900 = 15%) prior to transplantation (P = 0.013). After adjusting 
for donor and recipient age, gender and race-ethnicity, type of donor, recipient education 
and insurance, time of dialysis prior to transplantation, panel reactive antibodies (PRA), 
human leukocyte antigen (HLA) mismatch, and ABO blood type compatibility, the lower 
risk for DGF associated with the use of PD compared with HD remained significant (Odds-
ratio 0.70 [95% confidence interval 0.53-0.94]; P = 0.015). Donor age (1.01 [1.00-1.02] 
per 1 year), deceased donor transplantation (3.64 [2.59-5.12] living donor as reference), 
HLA mismatch (1.08 [1.01-1.15] per 1 antigen mismatch), and PRA (1.01 [1.00-1.01] per 
1%) were also independently associated with DGF.
Conclusions: In lupus recipients of kidney transplants, the use of PD compared with 
HD is associated with lower risk of DGF after adjusting for important predictors.
Funding: Other NIH Support - This work was supported in part by Health Resources 
and Services Administration contract 231-00-0115. The content is the responsibility of the 
authors alone and does not necessarily reflect the views or policies of the Department of 
Health and Human Services, nor does mention of trade names, commercial products, or 
organizations imply endorsement by the U.S. Government.
PUB661
Association Between Dipstick Proteinuria and Allograft Outcomes in Living 
Donor Kidney Transplant Recipients  Joon-sung Park, Jong Wook Choi, Chang 
Hwa Lee, Gheun-Ho Kim.  Dept of Internal Medicine, Hanyang Univ College 
of Medicine, Seoul, Republic of Korea.
Background: Proteinuria is one of the important factors suggestive of kidney function 
impairment. Previous epidemiologic studies had demonstrated that greater than trace 
amounts of protein on a casual urine dipstick may be an important predictor of long-term 
clinical outcomes in general population. In kidney transplant (KT) recipients, there were 
few data concerning it.
Methods: Thus, we retrospectively analyzed 238 living donor KT recipients to 
investigate impact of dipstick proteinuria on allograft outcomes. All KT recipients were 
divided into 2 groups according to dipstick proteinuria: control group (n=190), negative; 
case group (n=48), ≥ trace. Cox’s proportional hazard model with time-dependent covariates 
was used to encompass compounding effect of covariates that change over time, including 
vintage and allograft survival time.
Results: . As compared with controls, the change of estimated glomerular filtration 
rate was prominent in recipients with dipstick proteinuria after 3-year post-KT (-1.5 ± 
7.1 vs. -4.4 ± 7.4 mL·min-1·1.73 m-2·year-1, P<0.0174).In Kaplan-Meier analysis, KT 
recipients in control group had a better dialysis-free survival as compared with cases (201 
± 6 vs. 164 ± 10 months; log-rank P=0.0118). In Cox proportional hazard models, trace or 
more dipstick proteinuria was closely associated with long-term allograft loss (HR=1.964, 
95% CI=1.152-3.348), and further adjustment for age and gender did not attenuated this 
association (HR=1.764, 95% CI=1.050-3.065).
Conclusions: Our results may suggest that presence of small amount protein in urine 
may be the first sign of deteriorating allograft renal function.
PUB662
Cytomegalovirus Exposure Is Associated with Immunological Sensitization 
in End-Stage Renal Disease  Robert Lam,1 Rita Suri,2 Amitabh Singh,1 
Lakshman Gunaratnam.1,3  1Schulich Medicine & Dentistry, Western Univ, 
London, ON, Canada; 2Univ of Montreal, Montreal, QC, Canada; 3Matthew 
Mailing Center, London Health Sciences, London, ON, Canada.
Background: The presence of antibodies to Human Leukocyte Antigen (HLA) is 
associated with long transplant wait-times, acute rejection, and poor graft outcomes. 
While prior transplant, pregnancy, and blood transfusion can trigger HLA antibodies, 
many sensitized patients have none of these known risk factors. Previous infections have 
been proposed as a potential cause of “spontaneous” sensitization, but this has not been 
well studied. Because cytomegalovirus (CMV) is known to modulate the host’s immune 
defenses to avoid identification and clearance, we hypothesized that prior CMV exposure 
would be associated with HLA sensitization.
Methods: We conducted a cross-sectional study of 150 patients aged ³18 years attending 
a University Hospital renal pre- transplant assessment clinic over 16 months. Patients 
with prior transplant were excluded. Demographics, comorbidities, viral serology, peak 
combined Panel Reactive Antibody (cPRA), blood transfusions, and pregnancies were 
obtained by chart review; sensitizing events were confirmed by patient questionnaire. 
Logistic regression was used to identify potential risk factors associated with sensitization, 
defined as cPRA>20%.
Results: Mean age was 54.2±12.5 yrs, 61% were male, and mean years on dialysis was 
2.7±4.2. Fifty percent were CMV IgG positive and 32% had cPRA>20%. A cPRA>20% was 
significantly associated with CMV positive IgG (adjusted odds ratio 2.8, 95%CI 1.3-6.6; 
p=0.012), prior pregnancy (adj OR 4.0, 95%CI 1.7-9.4; p=0.002), and blood transfusion 
(adj OR 3.9, 95%CI 1.7-8.7; p=0.001), whereas age, sex, hypertension, diabetes, and years 
on dialysis were not. In the subgroup of 83 patients with no previous pregnancy or blood 
transfusion, the prevalence of cPRA>20% was 24% in CMV positive patients, versus 12% 
in CMV negative patients (unadj OR 2.3, 95%CI 0.7-7.5; p=0.152).
Conclusions: We identified previous CMV exposure as a novel independent risk factor 
strongly associated with the presence of HLA antibodies. Whether CMV infection triggers 
HLA sensitization requires further study in prospective longitudinal studies.
Funding: Government Support - Non-U.S.
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The Role of Plasmapheresis in the Treatment of Recurrent Focal Segmental 
Glomerulosclerosis  Juliana Busato Mansur,1,3 Gustavo Ferreira da Mata,1 
Tainá Veras de sandes Freitas,3 Gianna Mastroianni-kirsztajn,1,3 Helio Tedesco 
Silva,1,3 J. Medina-Pestana.1,3  1Nephrology, Federal Univ of Sao Paulo, Sao 
Paulo, Brazil; 2Nephrology, Federal Univ of Sao Paulo, Sao Paulo, Brazil; 
3Nephrology, Hospital do Rim, Sao Paulo, Brazil.
Background: Focal segmental glomerulosclerosis (FSGS) has a high recurrence rate 
after kidney transplantation (Tx).There is no established treatment, although plasmapheresis 
(PP),alone or with rituximab(RTX), is the most frequent therapeutic intervention. The 
purpose of this study was to evaluate the clinical-laboratorial profile and outcomes of 
patients diagnosed with rFSGS or with highly probable rFSGS submitted to PP.
Methods: Retrospective cross-sectional study involving patients with rFSGS submitted 
to PP between 2003-2014 at Hospital do Rim/UNIFESP.
Results: 70 patients (median age:29 years,5-62 years) were included. In 51%, FSGS was 
identified as the cause of ESRD. Proteinuria >0.5g/g and >3g/g was present, respectively, 15 
and 64 days after kidney Tx; 70% of patients received a kidney from a deceased (DC)donor; 
cold ischemia time was 23 H(mean). Tacrolimus, prednisone, azathioprine/micophenolate 
were the most frequently used imunossupressive drugs. Incidence of DGF was of 70% and 
of 19% in cases of DC and living donor’s, respectively. The 1st biopsy was on the 24th day 
(mean) post-Tx and the most prominent diagnosis were acute cellular rejection (21.9%) 
and acute tubular necrosis (29.7%),with only 17% of rFSGS. Histological diagnosis was 
confirmed on the 124th day and the beginning of the PP was on the 77th day;48% presented 
partial remission after 83 sessions;complete remission occurred in 22% of cases (means). 
Infectious episodes were the main complication during PP(69%).Part of the patients 
underwent methylprednisolone(80%)and RTX treatment(34%).The allograft survival 
in the 1st year was 70.8%, followed by 41.4% and 32.7% at 3 and 5 years respectively.
Conclusions: Laboratorial manifestations of rFSGS occurred early after renal Tx and 
preceded histological diagnosis. Treatment with PP was related to infectious episodes, low 
complete remission and important graft loss rates, which reinforces the need for further 
studies to determine a more efficient treatment.
Funding: Private Foundation Support
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Successful Treatment of BK Nephropathy with Tacrolimus and mTOR 
Inhibitors  Natalia I. Polanco fernandez, Enrique Morales, Manuel Praga, Esther 
Gonzalez monte, Eduardo Gutierrez-martinez, Amado Andres.  Nephrology, 
Hospital Univ 12 de Octubre, Madrid, Spain.
Background: BK nephropathy (BKN) is a relevant cause of graft dysfunction in 
kidney transplantation. mTOR inhibitors (mTORi) have been suggested as the best 
immunosuppression in BKN. However Tacrolimus-free therapy could increases risk 
of rejection. Since 2009 in patients with BKN we conducted a protocol discontinuing 
Mycophenolate and decreasing Tacrolimus (TAC) dose in association with mTORi, both 
with target levels of 5 ng/mL.
Methods: From 2007 to 2013 we diagnosed 22 BKN. Patients diagnosed since 2009 
(n= 14, group 1) were treated beginning mTORi and decreasing TAC dose. The others 8 
patients suffered significant reduction of immunosuppression (group 2). We analyze renal 
function, plasma quantitative BK PCR, antiHLA antibodies, rejections and dialysis or 
dead at final follow-up.
Results: 22 patients were identified. The BKN was diagnosed at 7th month after 
transplantation (range 2-55). The medium duration of follow-up was 53 months (6-85). 
Baseline characteristics and evolution are listed in table 1.
Group 1 (n= 14) Group 2 (n= 8)
Serum Creatinine at baseline (mg/dl) 1.3 ± 0.36 1.68 ± 0.57
AntiHLA antibodies positives at BKN diagnosis 43% (6) 12.5% (1)
Serum Creatinine at BKN diagnosis (mg/dl) 1.93 ± 0.37 2.4 ± 0.63
Serum Creatinine at final follow-up (mg/dl) 1.6 ± 0.7 3.2 ± 2.2
Dialysis at final follow-up 7.1% (1) 12.5% (1)
Plasma BK viral load at diagnosis (copies/ml) 84369 (10035-8234680)
20674 (10715-
1543440)
Patients with negative plasma BK viral load at final 
follow-up 78.6% (11) 75% (6)
Acute rejection after BKN 0% 12.5% (1)
Although group 1 had a greater immunologic risk and a higher plasma BK viral load 
at diagnosis, the renal function during follow-up was more favorable than patients from 
group 2. No rejection episodes were diagnosis in group 1. Only one patient in each group 
started chronic dialysis at the end of the follow-up (52 and 85 months after BKN diagnosis).
Conclusions: An immunosuppression regimen based in TAC and mTORi is an effective 
and safety treatment in patients with BKN. This treatment reduces viral load and increases 
graft survival without increases the rejection risk.
PUB665
A Rare Case of Guillian-Barré Syndrome Associated with Cytomegalovirus 
Disease in a Renal Transplant Patient  Jessica Bian, George P. Bayliss. 
Medicine, Rhode Island Hospital, Providence, RI.
Background: While cytomegalovirus (CMV) infection is associated with Guillian-
Barré syndrome (GBS) in the general population, there are few reports of GBS associated 
with CMV disease in the renal transplant patients. We describe the case of one renal 
transplant patient who developed GBS after treatment for documented CMV disease.
Methods: The patient is a 62 year-old woman with ESRD from polycystic kidney 
disease status post deceased donor renal transplant (CMV donor positive/recipient 
seronegative) on tacrolimus and prednisone. She completed 6 months of CMV prophylaxis 
with valgancyclovir. Fourteen days after stopping valgancyclovir, she presented with fevers, 
myalgias, and headache. Tacrolimus level was 6.6 ng/mL on admission. She was diagnosed 
with CMV disease (serum CMV PCR 2200 copies; CSF CMV PCR undetectable) and 
started on treatment-dose valgancyclovir. Ten days later, she returned with numbness of her 
hands and feet. CSF studies were notable for albuminocytologic dissociation. MRI brain 
and spine was normal. Electromyography showed diffuse sensory motor polyneuropathy 
consistent with GBS. She developed ascending motor weakness, sensory loss, and areflexia 
without progression to respiratory compromise, improving with IVIG therapy. She was 
discharged to rehabilitation.
Results: She returned 7 days later with compartment syndrome of her right arm due to 
deep venous thromboses of her right subclavian, axillary, and brachial veins with associated 
hematomas requiring emergent fasciotomy and hematoma evacuation. This was attributed to 
recent IVIG therapy, as thromboses may occur even in the absence of other risk factors (US 
boxed warning). She was bridged to warfarin prior to discharge. Of note, she maintained 
excellent allograft function throughout this complicated course.
Conclusions: This vignette details a case of CMV-associated GBS after renal 
transplantation. The case is notable for the development of CMV disease shortly after 
cessation of valgancyclovir prophylaxis in a CMV donor positive/recipient negative renal 
transplant despite only being only being on a two-drug immunosuppressive regimen. This 
may support a longer course of CMV prophylaxis in donor positive/recipient negative 
transplants.
Funding: Clinical Revenue Support
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A Prolonged Warm Ischemia Time Is Associated with Graft Failure and 
Mortality After Kidney Transplantation  Karthik K. Tennankore,1 Joseph 
Kim,2 Ian P. Alwayn,3 Bryce A. Kiberd.1  1Medicine, Div of Nephrology, 
Dalhousie Univ, Halifax, NS, Canada; 2Medicine, Div of Nephrology, Univ 
of Toronto, Toronto, ON, Canada; 3Dept of Surgery, Multi-Organ Transplant 
Program, Dalhousie Univ, Halifax, NS, Canada.
Background: Warm ischemia time is a potentially modifiable insult to transplanted 
kidneys, but little is known about its effect on long term patient and graft survival. The 
purpose of this study was to determine if a prolonged warm ischemia time was associated 
with death and graft failure after kidney transplantation.
Methods: We conducted a cohort study of adult kidney transplant recipients in the 
Scientific Registry of Transplant Recipients between 1/1/2000 and 12/31/2013. Warm 
ischemia time was defined as the time of organ removal from cold storage to reperfusion 
with warm blood, including surgical anastomosis time. Times were categorized as 0-10, 
10-20, 20-30, 30-40, 40-50, 50-60 and ≥60 minutes. Acknowledging that times of <10 
minutes were potentially attributed to coding error, 10-20 minutes was chosen as the 
reference group. The primary outcome was all-cause mortality and graft failure adjusted 
for recipient, donor, immunological and surgical factors.
Results: Overall, 131,677 patients were included and there were 35,901 events. 
Relative to patients with warm ischemia times of 10-20 minutes, a longer warm ischemia 
time was associated with an increased relative hazard for death or graft failure (table 1). 
The association between warm ischemia time and the composite outcome persisted after 
stratification by donor type (living versus deceased donor) and delayed graft function status.
Conclusions: Warm ischemia time is associated with long term patient and graft 
survival after kidney transplantation. Strategies to reduce warm ischemia time should be 
an important consideration for future study.
Funding: Private Foundation Support
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Clinical Significance of Pre-Transplant 25-Hydroxyvitamin D Levels on 
Post-Transplant Clinical Outcome  Tae Hyun Ban,1,2 In-Ae Jang,1,2 Bum 
Soon Choi,1,2 Cheol Whee Park,1,2 Chul Woo Yang,1,2 Yong-Soo Kim,1,2 Byung 
Ha Chung.1,2  1Internal Medicine, Seoul St. Mary’s Hospital, Seoul, Korea; 
2Transplant Research Center, Seoul St. Mary’s Hospital, Seoul, Korea.
Background: It is well known that vitamin D shows immune modulating effects 
in various immunologic disorders and infectious disease. The aim of this study is to 
investigate the clinical significance of 25(OH)D levels on acute rejection or infection in 
kidney transplant recipients.
Methods: We included 174 kidney transplant recipients with low immunologic risk 
between 2011 and 2013. We measured 25(OH)D levels right before transplantation, and 
investigated whether the level of 25(OH)D predicts the development of acute rejection or 
infectious complications.
Results: During the first year after the KT, a total 27 cases of biopsy proven acute 
rejection was detected. 25(OH)D levels showed significant association with the development 
of acute rejection within the first year from KT. In the high tertile, the rate of acute rejection 
was 6.9 % (p=0.012). It was significantly lower incidence toward the high tertile. There 
was significant distinction between each tertile (low and second, p=0.032; second and 
high, p=0.002). For the prediction of infectious complications, after the 1 year predictive 
values of 25(OH)D levels were dissipated. During 1 year after KT, a total of 82 (47.1%) 
cases of infectious complications were detected. Most common causes were 23 (13.2%) 
cases of CMV and UTI respectively.25(OH)D levels did not show significant association 
with either the overall or different types of infectious complications.
Conclusions: Pre-transplant serum 25(OH)D levels are independent predictor of acute 
rejection in the first year from kidney transplantation. However, they were not associated 
with infectious episode.
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Mammalian Target of Rapamycin Inhibitors Withdrawal in Kidney 
Transplant Recipients: Risk Factors and Related Transplant Outcomes 
Lee-Moay Lim,1 Mei-Chuan Kuo,1,2 Hung-Tien Kuo.1,2  1Div of Nephrology, 
Dept of Internal Medicine, Kaohsiung Medical Univ Hospital, Kaohsiung, 
Taiwan; 2Faculty of Renal Care, College of Medicine, Kaohsiung Medical 
Univ, Kaohsiung, Taiwan.
Background: With its antiproliferative and antineoplastic properties, Mammalian 
Target of Rapamycin Inhibitors (MTORi) potentially have important long-term therapeutic 
consideration in kidney transplantation. Treatment cessation frequently occurs following 
its unique adverse effects. The objective of this study was to investigate the risk factors 
for MTORi withdrawal and its impacts on transplant outcomes.
Methods: This retrospective observational study consisted of kidney transplant 
recipients followed up from January 1999 till May 2015. We examined the risk factor for 
MTORi withdrawal using multivariate logistic regression analysis. The impacts of MTORi 
withdrawal on transplant outcomes were analyzed using multivariate Cox regression and 
logistic regression. P<0.05 was considered as statistically significant.
Results: A total of 111 kidney transplant recipients who received MTORi treatments 
were included, with 46 patients withdrew (41.0%). The risk factors for mTORi withdrawal 
included initial proteinuria (adjusted OR= 4.61, P=0.007), higher initial serum creatinine 
(per 1 mg/dl increment, adjusted OR=2.73, P=0.035), and glomerulonephritis as primary 
renal disease (adjusted OR=5.00, P =0.035). MTORi withdrawal was associated with an 
increased risk of graft failure (adjusted HR=3.79, P=0.027), but not with patient survival 
(adjusted HR=0.61, P=0.595).
Conclusions: MTORi withdrawal is a strong risk factor for renal graft failure. 
Proteinuria, poor initial graft function and primary renal disease of glomerulonephritis are 
predictors for MTORi withdrawal. Earlier identification of risk factors may assist physician 
to decide the best candidate for MTORi conversion in order to optimize transplantation 
outcomes.
PUB669
Impact of Donor Age on Longterm Outcomes in Living Donor Kidney 
Transplants: A Propensity Score Matched Analysis Using Multicenter 
Cohort  Kyung Don Yoo,1 Jung Nam An,1 Jang-Hee Cho,3 Chan-Duck Kim,2 
Su-Kil Park,3 Dong-Wan Chae,1 Yun Kyu Oh,1 Chun Soo Lim,1 Yon Su Kim,1 
Young hoon Kim,3 Jung Pyo Lee.1  1Seoul National Univ College of Medicine; 
2Kyungpook National Univ Hospital; 3Asan Medical Center and Univ of Ulsan 
College of Medicine.
Background: Recently, kidney transplantation from elderly living donor has been 
increasing. However, the impact of donor age on outcomes in kidney transplantation 
recipients has not been well established in Asian.
Methods: This multicenter cohort study included 2,595 adult kidney transplant 
recipients admitted to 5 major tertiary hospitals in Korea between 1997 and 2012. Patient 
survival, allograft survival, and biopsy-proven acute rejection (BPAR) were compared 
between the elderly donors (≥ 50 years) and young donors (18~49 years) by the propensity 
score matched (PSM) analysis.
Results: The proportion of donor with over 50 years was 21.2 % (N=553). The mean 
age in the elderly donor was 54.9 ± 4.3 years old. Despite of difference of donor age, mean 
recipient age was similar between the groups. Elderly donors were more likely to donate to 
unrelated recipients. The proportions of recipients with diabetes mellitus (22.8%), serum 
creatinine and BMI of donor were significantly higher in the elderly donor group than in 
the young donor-age group. In elderly donor group, recipients’ patient survival was worse 
than younger age group before PSM (p=0.014). After PSM, donor age did not affect the 
recipient’s survival (p=0.305) and allograft survival (p=0.077), however, BPAR was 
frequently occurred in the allograft from elderly donor (p=0.019). In the multivariate Cox 
regression analysis, elderly donor affected the BPAR-free survival (p=0.01, hazard ratio 
1.52, 95% confidence interval 1.07-2.17).
Conclusions: Kidney transplantation from elderly donor needs more meticulous 
management, because donor age could affect acute rejection.
PUB670
Long-Term Outcome of Randomized Trial Comparing Cyclosporine and 
Tacrolimus Therapy with Steroid Withdrawal in Living-Donor Renal 
Transplantation: 10-Year Follow-Up  Jin Hae Kim, Jee Eun Park, Do Hee Kim, 
Hye Ryoun Jang, Jung Eun Lee, Dae Joong Kim, Yoon-Goo Kim, Ha Young Oh, 
Wooseong Huh.  Dept of Medicine, Samsung Medical Center, Sungkyunkwan 
Univ School of Medicine, Seoul, Republic of Korea.
Background: The use of steroid withdrawal protocols after kidney transplantation has 
been increasing because of well-known adverse effects of steroids and the introduction 
of new effective immunosuppressants. Long-term efficacy and safety of tacrolimus plus 
mycophenolate mofetil (TAC group) compared with cyclosporine A plus MMF (CsA group) 
for 10 years were analyzed in renal transplantation patients with low immunologic risk 
who underwent steroid withdrawal at 6 months after operation.
Methods: Overall 10-year follow-up data of patients who underwent their first living-
donor renal transplantation at Samsung Medical Center between September 2000 and August 
2003 were retrospectively analyzed. Patients were randomized to CsA or TAC groups and 
underwent steroid withdrawal at 6 months after renal transplantation. End points were 
patient and graft survival, and the incidence of acute rejection and post-transplant de-novo 
comorbidity such as diabetes mellitus.
Results: A total of 117 patients who successfully discontinued steroid treatment were 
included (55 in CsA group vs. 62 in TAC group). The 10-year patient survival was 96.2% 
in the CsA group and 98.4% (61/62) in the TAC group (p=0.495). The 10-year graft 
survival rate did not differ between groups (81.3% in CsA vs 91.2% in TAC; p=0.412). 
The cumulative incidence of acute rejection for 10 years after transplantation was 24.5% 
and 15.6% in the CsA and TAC groups, respectively (p=0.201). The incidence of post-
transplantation diabetes mellitus was higher in the TAC group compared to the CsA group 
(10.0% vs 23.3%, respectively; p=0.046).
Conclusions: Long-term graft and patient survival, and the incidence of acute 
rejection were similar between CsA- and TAC-based regimens combined with MMF in 
low immunologic risk patients who underwent steroid withdrawal 6 months after kidney 
transplantation.
PUB671
Dysregulation of Circulating Immunoglobulins in Renal Transplant 
Recipients  Mukut Minz,1 Ravi Dhital,1 Ranjana Walker Minz,2 Ashish Sharma,1 
Ritambhara Nada,4 Deepesh Kenwar,1 Sarbpreet Singh.1  1Transplant Surgery, 
Post Graduate Inst of Medical Education and Research, Chandigarh, India; 
2Immunopathology, Post Graduate Inst of Medical Education and Research, 
Chandigarh, India; 3Nephrology, Post Graduate institute of Medical Education 
and Research, Chandigarh, India; 4Histopathology, Post Graduate Inst of 
Medical Education and Research, Chandigarh, India.
Background: Peripheral levels of serum immunoglobulin reflect humoral immunity. 
Gross derangements in the immunoglobulin levels might occur in the post- transplant period.
Methods: Peripheral venous blood was periodically collected from patients before 
(pre-Tx) and after kidney transplantation at 1Month, 3 Months, 6 Months, 12 Months and 
at the time of Rejection. Serum was isolated from clotted blood after brief centrifugation 
at 3000g for 10 minutes. Serum level of IgM, IGA, IgG, IgG1, IgG2, IgG3 and IgG4 were 
quantified by Nephleometry (MiniNephTM, UK).
Results: This study includes 75 first kidney transplant recipients who were divided into 
two groups: Rejection group (R, n=35) and Non Rejection group (NR, n=35). Rejection 
group was further segregated as cellular (n=25) and antibody mediated (n=9). Thirty five 
age and sex matched healthy donors were recruited as control. No differences in the levels of 
IgG, IgA and IgM were noted in the pre-tx sera and healthy donor sera. Post- transplantation, 
there is an early decrease in serum IgG and IgA levels in both R and NR groups between 
1- 3 months and the rate of decrease is higher in patients with rejecting grafts. IgG3 and 
IgG4 are significantly reduced during rejection (p= <0.0001 and 0.0006 respectively). IgG3 
levels correlated with cellular rejection, while the rate of decrease of IgG2 and IgG4 was 
higher in antibody mediated rejection.
Conclusions: Post- transplantation: there is a fall in serum levels of IgA, IgG and 
its subtypes in both non rejecters and rejecters, more so in the later. Low serum levels of 
IgG3 and IgG4 could be a pointer to rejection. Significant correlation of IgG3 with cellular 
rejection embarks that IgG subtypes are dysregulated in cell- mediated rejection.
PUB672
Impact of Kidney Transplantation on Arterial Stiffness in Patients with 
ESRD  Hyunseon Kim, Chul Woo Yang, Byung ha Chung, Cheol Whee Park, 
Yong-Soo Kim, Bum soon Choi.  Div of Nephrology, Dept of Internal Medicine, 
Seoul St. Mary’s Hospital, The Catholic Univ of Korea, Seoul, Republic of Korea.
Background: Arterial stiffness is closely associated with cardiovascular mortality in 
end-stage renal disease (ESRD) patients, We investigated whether kidney transplantation 
(KT) can improve arterial stiffness in patients with ESRD.
Methods: We enrolled 171 KT recipients and we measured brachial-ankle pulse wave 
velocity (baPWV) and ankle-brachial blood pressure index(ABI) before KT, and post 
KT baPWV and ABI was assessed in a subgroup of 84 patients. First, we investigated 
cardiovascular(CV) events risk and established influence factors. Second, these patients 
divided into improvement and non-improvement groups based on change of baPWV after 
KT which was very strong marker of CV disease prediction. We also compared risk factors 
which affect arterial stiffness between two groups.
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Results: 10 CV events occurred in the overall group, and 7 events in the post KT 
baPWV subgroup. Risk factors affected CV events of these group were diabetes, high body 
mass index(BMI) and high baPWV. Overall arterial stiffness measured by baPWV after 
KT showed significant improvement (1417.5 ± 234.5 cm/s) compared to those of before 
KT (1503.5 ± 255.2 cm/s) (p<0.05 vs after KT).55 out of 79 patients (69.6%) showed 
improvement of baPWV after KT, but 24 patients did not. Between two groups, improvement 
group showed higher pre-transplant baPWV than no-improvement group (1561.0 ± 263.9 
vs. 1371.6 ± 177.1), and multivariate analysis revealed that gender and BMI, degree of 
decrement of calcium level were an independent risk factor of change of baPWV.
Conclusions: We could expect CV event risk in KT recipients by diabetes, 
BMI and baPWV, and these were very strong prediction marker of CV 
event. Arterial stiffness in ESRD patients improves after transplantation, 
and lower BMI, the amount of calcium decreased, gender affected the 
improvement of baPWV. PUB673
The Correlation of Donor:Recipient Body-Mass Index (BMI) Ratio and 
6-Month Post-Transplant Kidney Function in Known End-Stage Renal 
Disease (ESRD) Patients  Joseph justin Hipolito Regalado.  Internal Medicine, 
Cardinal Santos Medical Centre (CSMC), San Juan, Metro Manila, Philippines.
Background: Kidney Transplant (KT) is the preferred treatment for ESRD. The 
challenge rests in finding appropriate donors. Donor-recipient size mismatch was shown 
to correspond to donor-recipient nephron supply mismatch, affecting prognosis. Matching 
nephron supply to recipient needs was proposed to improve outcomes. Patients with a 
higher BMI relative to their donors were shown to have poorer post-KT graft function. 
Determining whether measures such as BMI are valid predictors of outcomes is a legitimate 
area of study. This research sought to determine the association and correlation between 
Donor-Recipient BMI Ratio and the 6-month post-KT creatinine (crea).
Methods: A review of patients who underwent KT in 2005-2014 at the CSMC was 
done. Inclusion criteria were Filipinos aged 18 years and above with a graft, coming from 
a Living Donor, functioning for at least 6 months post-KT (25 Donor-Recipient pairs). 
Association using Chi-Square and correlation using Multiple Regression Analysis between 
Donor-Recipient BMI and renal function based on 6 months post-KT crea were determined.
Results: Data showed no statistically significant association (p=0.64) and correlation 
(p=0.77) between Donor-Recipient BMI ratio and post-KT crea. Statistically significant 
correlations (p<0.10) were noted between the post-KT crea and the recipient and donor 
BMI (strong correlation, r=0.78), with a 22.51umol/L increase in post-KT crea per 1 
point increase in the donor BMI, and a 13.51umol/L decrease in post-KT crea per 1 point 
increase in recipient BMI.
Conclusions: The data support two schools of thought on donor-recipient selection in 
improving outcomes. First, recipients are to lose weight to improve BMI before KT due to 
the increased risk of graft damage from hyperfiltration and lipotoxicity. Second, donors with 
larger BMI’s are better due to a higher nephron reserve. It could be surmised from the study 
that the donor and recipient BMI’s influence the 6-month post-KT crea. The appropriate 
mathematical instrument defining the relationship between these measures predicting KT 
outcomes more accurately, however, is yet to be universally established.
PUB674
Incidence of Malignancies in Kidney Transplant Patients – Report from 
Eastern Province of Saudi Arabia  Abdul Razack Amir.1  1Nephrology, Internal 
Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Eastern, Saudi Arabia; 
2Internal Medicine, Univ of Dammam, Dammam, Eastern, Saudi Arabia.
Background: Renal transplant patients have a higher incidence of malignancies due 
to the use of immunosuppressive medications and concommittent infections.
Methods: Based on the follow up of a single center in Saudi Arabia, the incidence of 
malignancies patients who underwent kidney transplantation was analyzed.
Results: During the 15 years study period, a total of 221 patients underwent renal 
transplantation. Eleven patients developed post-transplant malignancies with an average 
incidence of 4.9%. Two patients had Kaposi sarcoma (0.9%) and two developed Non-
Hodgkins lymphoma (0.9%). One case was reported to have transitional cell carcinoma of 
urinary bladder (0.45%), one had breast cancer (0.45%), one had cervical cancer (0.45%), 
one developed angiosarcoma (0.45%), and one had hepatocellular carcinoma (0.45%). In 
addition, two patients developed renal cell carcinoma, one in the native kidney (0.45%), and 
the other in the transplanted kidney (0.45%). The duration to cancer development ranged 
from 6-120 months. Mortality rate in renal transplant patients with cancer was higher (55%) 
than those who did not develop cancer. Risk factors that determined cancer development 
included patient age, gender, duration of the transplantation and type of immunosuppression. 
Type of transplant was not found to be a determining factor of cancer development.
Conclusions: The incidence of malignancies in post renal transplant patients in the 
Kingdom of Saudi Arabia is evidently comparable to that reported in literature. In addition, 
the data highlights the importance of long term close follow up of renal transplant patients.
PUB675
Left Ventricular Global Longitudinal Strain as Early Detection of 
Subclinical Myocardial Dysfunction in Renal Transplant Recipients 
Secundino Cigarran,1 Jose Lomban,3 Ana Maria Sanjurjo Amado,1 Diego 
Coronel,1 Sheila Casas,3 Juan Latorre,1 Mª Milagros López hernández,1 Jesus 
Calvino.2  1Nephrology, Hospital Da Costa, Burela, Lugo, Spain; 2Nephrology, 
Hospital Lucus Augusti, Lugo, Spain; 3Cardiology, Hospital Da Costa, Burela, 
Lugo, Spain.
Background: Echocardiographic global longitudinal strain (GLS) is recognised as 
a technique to detect subtle changes in left ventricular function. As in CKD pts, kidney 
transplant recipients (TXKR) has an increased mortality risk by CV events. Early detection 
of CV risk is the utmost importance in the TXKR outcomes.The aim of this cross sectional 
study is to assess the grade of myocardial dysfunction in TXKR without previous CV events 
& normal left ventricular ejection fraction (LVEF).
Methods: 37 TXKR following >1 yr were included. 44.4% F, 24.5% DM, age 
55.4±12.12 yo, GFR-EPI 51.93± 23.2 ml/min/m2, No previous CV events & LVEF >55%.All 
of them on stable treatment with ACEI/ARB, CCHB, diuretics added to immunosuppressive 
drugs (TAC, CSA). Echocardiography 2D Vivid 9 (GE Vigmed Ultrasound ,Horten, 
Norway), was performed:GLS,LAVI (ml /bsa), E/e´, E/A,LVEF following recommendations 
of American Society of Echocardiography.Body composition analysis were performed by 
BIVA and serum biomarkers of inflammation,anaemia,mineral bone disease, renal function 
(GFR-EPI) and CV risk markers.Normal GLS (-20%) LAVI 24 ml/m2 were considered as 
published for general population Rev Esp Cardiología 2014;67:651-8.
Results: Mean GLS was -18.6 ± 3.78%, LVEF 70.8 ± 8.7%,LAVI 30.16± 20.4 ml.GFR 
correlated negatively with GLS (r: -338, P<0.016) and LAVI ( r: 372, p = 0.14). GLS 
progressed positive as GFR decline (P adjusted 0.025). E/E´ 13.06±6.48; E/A 0.93±0.28. 
Multivariate analysis was significant the relationship between GLS with ACR (β = -.151, p 
=0.43) e P excretion index ( β= .377; p = 0.14).LAVI correlated with age (β=.467 p= 0.004), 
net acid load (β= .345; p= 0.23) and AGEs (β=.314; p= 0.35).No other correlations were met.
Conclusions: 66% TXKR show GLS >- 20% and 41.6 % LAVI > 24 ml/m2.GLS 
& LAVI echocardiography derived are two valuable measures to assess early subclinical 
myocardial damage in TXKD. GLS appears more sensitive predictor than LVEF.Studies 
on TXKD pts are required.
Funding: Other NIH Support - SERGAS
PUB676
Seronegative Invasive Gastro-Intestinal Cytomegalovirus Disease in Renal 
Allograft Recipients – A Diagnostic Dilemma! Tissue PCR the Saviour? 
Anupama Kaul, Dharmendra Bhadauria, Narayan Prasad, Amit Gupta, Raj K. 
Sharma.  Nephrology, Sanjay Gandhi Post Graduate Inst of Medical Sciences, 
Lucknow, UP, India.
Background: CMV as oppurtunistic  infection  affecting the  gastrointerstinal tract 
is the  most common cause for tissue invasive CMV disease occuring in 10-30% of organ 
transplant recepients. Gastrointerstinal CMV disease can be  diagnosed in presence of 
clinical suspecion along with histopathological findings (CMV inclusions) and presence of 
mucosal lesion(s) on endoscopic examination with collaborative evidences via molecular 
technique.
Methods: Few cases of CMV infection affecting the gastrointerstinal tract show  no 
evidences of dissemintion  despite use of  highly  sensitive molecular techniques.
Results: We encountered 6 cases where in  despite strong clinical suspecion of 
Gastrointerstinal CMV disease there were  seronegative and endoscopic negative evidences 
for CMV ,blind tissue biopsy yeilded positive results for CMV disease with excellent 
improvement with antiviral therapy.
Conclusions: Blind biopsy specimen for tissue PCR could serve as saviour in an 
immunocompromised individiual who has a strong clinical symptomatology for GI-CMV 
disease in absence of viremia ,normal endoscopy and histopathology ,so that the early 
therapeutic interventions could help in excellent patient and graft survival.
PUB677
Allograft Outcome After Desensitization with IVIg: A Single Center 
Experience  Nitender Goyal, Phanicharan Sistla, Anshul Bhalla, Wendy 
Mccallum, Richard Rohrer, Ronald D. Perrone.  Tufts.
Background: The presence of antibodies to donor human leukocyte antigens (HLA) 
is a significant barrier to transplantation. High dose intravenous Ig (IVIg) is widely used 
for desensitization. There is no general consensus on the best approach for desensitization, 
and long-term data on efficacy of IVIg are unknown.
Methods: We reviewed kidney transplants done from Jan, 2010 to Dec, 2014 at 
Tufts. Sensitization was defined as PRA >20% and/or presence of donor specific antibody 
(DSA). Patients who were desensitized with IVIg were identified as cases; those without 
desensitization served as controls. No attempt was made to desensitize patients awaiting 
deceased donor kidneys. Baseline characteristics and follow up data were collected at 
months 3, 6, 12 and 24. A sensitivity analysis was done for patients who received a living 
donor kidney.
Results: There were 19 patients in the desensitized group and 37 patients in the control 
group. Mean age at transplant in two groups was 47±12 and 49±12 respectively. In the 
desensitized group, there were more patients with prior transplant (37% vs 22%), receipt 
of living donor (95% vs 54%) and positive DSA (89% vs 22%). One patient developed 
severe side effects from IVIg, requiring discontinuation. Leukopenia and BK viremia were 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1045A
J Am Soc Nephrol 26: 2015 Publication Only 
seen more in non-desensitized patients at 3 months, but significance was not sustained after 
3 months (Table). The leukopenia effect was not significant when adjusted for steroid. 
There was no difference in eGFR in either group, however mean eGFR was higher in those 
desensitized. Incidence of rejection was very low in both groups (5% vs 8%). When living 
donor recipients from both groups were compared, the eGFR and leukopenia effect was 
similar in both groups, and there was no significant difference in BK Viremia. 
No desensitization Desensitization p-value
Leukopenia
3 month 18(49%) 4(21%) 0.04
12 month 5(18%) 5(36%) 0.22
Mean eGFR(sd)
3 month 61.2(19.5) 68.7(24.8) 0.26
12 month 63.7(20.2) 72.2(25.1) 0.29
BK Viremia
3 month 7(19%) 0 0.04
12 month 3(12.5%) 1(8%) 0.65
Conclusions: Desensitization with IVIg appears to be safe and effective. The lower 
incidence of leukopenia in desensitized group can be explained by greater use of steroids.
PUB678
Results of Chinese Renal Transplant Recipients with Post-Transplantation 
Malignancies  Lihui Qu, Hong Jiang, Jianghua Chen.  The Kidney Disease 
Center, The First Affiliated Hospital, Medical College, Zhejiang Univ, Hangzhou, 
Zhejiang, China.
Background: Malignancies are a severe complication of immunosuppressive therapy 
among renal transplant recipients, representing an important cause of long-term morbidity 
and mortality.
Methods: A retrospective study of 2700 recipients who underwent renal transplantation 
between July 1977 and July 2013 was carried out. 51 patients developed the following 
malignancies at a mean of 55.2 months (range = 1-207) after kidney transplantation. 
According to the regimen of immunosuppressive agents, all the recipients occurred 
malignancies were divided into azathioprine group (Aza group, n =21) and mycophenolate 
mofetil group (MMF group, n=30). The recipient age, gender, interval from renal 
transplantation to tumor development, long term survival of patient and graft and the ratio of 
converting to rapamycin of patients were made a comparison in detail between two groups.
Results: 29 patients survived without a recurrence including 28 with graft function 
(Survival group, n=29), and 22 patients died of malignancies including 21 with graft function 
(Death group, n=22). In the survival group, only one patient lost the graft after 26 months 
after immunosuppressant adjustment due to chronic rejection. Renal graft function remained 
stable in all other patients from diagnosis throughout follow-up. Moreover, 10 patients in 
the survival group were switched from calcineurin inhibitor-based immunosuppression to 
rapamycin after the diagnoses of malignancy, otherwise no patient in death group switched 
to rapamycin. At a mean follow-up of 34.0 months (range = 4-74), all the 10 patients are 
cancer-free and survived with functional graft. The incidence of death was similar in the 
Aza group and MMF group.
Conclusions: Our results demonstrate that the incidence of malignancy in renal 
allograft recipients is much higher than normal population, closely related to the long term 
use of immunosuppressant. Treating cancer thoroughly and maintaining the function of the 
transplanted kidney can decrease the risk of death with functional graft. Rapamycin-based 
immunosuppression blocks the recurrence of nonmetastatic tumors.
PUB679
Basiliximab Induction Therapy, Graft and Patient Survival 
Sergio Santiago Pedroza-Orozco, Paloma Arleth Zavalza-Camberos, Benjamin 
Gomez-Navarro.  Nephrology and Transplantation, Inst Mexicano del Seguro 
Social, CMNO, Guadalajara, Jalisco, Mexico.
Background: Basiliximab is widely used in clinical practice for induction therapy of 
renal transplant recipients, expecting to reduce the incidence of acute rejection and improved 
graft function without increasing adverse events. We evaluate the impact of induction therapy 
using Basiliximab on relevant clinical outcomes: graft and patient survival,incidence of 
acute rejection (AR) and incidence of infectious or malignancy complications.
Methods: This retrospective study included all renal allograft recipients who were 
transplanted between January 2010 and April 2014 and who received Basiliximab as 
induction therapy. We collected the baseline characteristic of recipients, type of donor, 
donor´s age, HLA matches and immunosuppression at the time of transplantation. The 
clinical outcomes were evaluated at the first year of transplantation and include: AR 
incidence, infectious or malignancy complications, serum creatinine and estimated 
glomerular filtration rate (eGFR) using the 4-variable MDRD formula, as well as graft 
and recipient survivals.
Results: The demographic characteristics of recipients and donors are in Table 
1. Among 662 renal transplant recipients including in this study, only 10.6% (n=70) 
experienced AR during the first year follow up. The incidence of infectious complications 
in the first year after transplantation was 32.3%, mostly urinary tract infection (82%). 
No episode of malignancy was reported. Graft and patient survival rates were 96.9% and 
98.5% respectively. 
Recipients mean age (year ± DE): 26 ± 10
HLA matching number: 4 IQR 1
Type of donor: 
Living related 89% 
Living unrelated 7% 
Deceased 4%
Donor´s mean age (year ± DE): 38 ± 11
eGFR year 1 (mL/min/1.73m2): 82 ± 26 
sCr year 1 (mg/dl): 1.2 ± 0.4
Conclusions: Our findings support previous studies, with similar incidence of AR 
episodes during the first year posttransplant, accompanied by a similar incidence of 
infectious and malignant complications, and similar patient and graft survivals at 1 year 
follow up. We can conclude that basiliximab is associated with excellent graft and patient 
survival and low rates of AR episodes.
PUB680
Death within the First  Year After Kidney Transplantation 
Paloma Arleth Zavalza-Camberos, Sergio Santiago Pedroza-Orozco, Benjamin 
Gomez-Navarro.  Nephrology and Transplantation, Inst Mexicano del Seguro 
Social, CMNO, Guadalajara, Jalisco, Mexico.
Background: A successful kidney transplant improves the quality of life and reduces 
the risk of death in most patients when compared with staying on dialysis, however, the 
survival of transplant patients is lower than general population patients of the same age. 
This study was performed to evaluate mortality and characteristics of the dead patients.
Methods: It was a retrospective observational study that included all kidney transplant 
patients between January 1, 2010 to April 30, 2014, at HE-CMNO, IMSS, Guadalajara, 
Jalisco, Mexico. The follow-up time was one year. Mortality was calculated, the causes of 
death and characteristics of deceased patients were identified.
Results: During this time 1,047 transplants were performed. 30 deaths (2.86%)were 
recorded during the first year after transplantation. Regarding the type of donor: 12/102 
(11.76%)patients with brain death donor died, and 18/945 (1.9%)patients with living donor 
died. The causes of death were 20 (66.66%)infections, 6 (20%)cardiovascular events, 
2 (6.66%)related to graft rejection event and 2 (6.66%)unknown. The average time of 
transplantation to death was 2 months 27.4 days with a SD of ± 2 months 29.1 days; 70% 
of deaths occurred in the first 3 months after transplantation. The average time in dialysis 
was 5 years, with a SD ± 3 years 4.4 months; 83.3% of patients had more than two years 
on dialysis. Most patients who died had thymoglobulin induction, but patients were older, 
had more comorbidities, more time on dialysis, increased immunological risk and they had 
a brain death donor. Finally, 76.7% of patients who died had functional graft.
Conclusions: In our hospital, 1 year mortality postkidney transplantation is low, but 
there are many individual patient factors that contribute to the risk of mortality increases 
significantly in them and there we could intervene.
PUB681
Granzyme B Level and Acute Kidney Allograft Rejection: Impact on One 
Year Survival in Mexican Population  Perla Edith Simancas Ruiz,1 Caridad 
Aurea Leal,2 Benjamin Gomez-Navarro.1  1Nephrology and Transplant, Inst 
Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico; 2Surgical Research, 
Inst Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico.
Background: Exposure to insufficient levels or discontinuation of immunosuppressants 
often increases the risk of rejection. Creatinine is the most useful test to monitor graft 
function. However, it is a poor predictor of rejection and often raises only after significant 
damage has occurred to the graft, so the identification of early biomarkers is mandatory. 
Granzyme B has been tested as a marker of acute rejection, with high specificity and 
sensitivity in different types of sample and has also enabled the identification of subclinical 
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rejection. The elevation of both the mRNA and protein has been associated with a worse 
prognosis of allograft. OBJECTIVE: Explore the association between serum levels of 
Granzyme B and acute rejection after one year post-transplant.
Methods: Kidney recipients transplanted between January 2008 and March 2009.
Donors (n=38) and healthy subjects (n=6) were also included. The relation of granzyme B 
levels determined by ELISA with graft function and rejection was studied.
Results: 
Receptor age (n=94) 26 ± 10 yr
Induction therapy: 
Basiliximab 
Daclizumab 
Thymoglobulin
46% 
39% 
2%
CMV 
High 
Moderate 
Low
21% 
72% 
7%
One year creatinine 1.66 mg/dL
Rejection: 
Borderline 
Banff 1A 
Banff ≥1B
46% : 
31% 
56% 
14%
Chronic nephropathy 46%
Granzyme level in patients (n = 43) was 12.5 pg/ml while the reference group (n = 
6) was 1.5 pg/ml (p <0.001). Comparison between patients with rejection (n = 14) and 
non-rejection (n = 20) was not statistically significant, nor the development of interstitial 
fibrosis year. The correlation between creatinine, GFT and granzyme level showed a trend 
to significance (n = 66, r = 0.30, p = 0.06).
Conclusions: The level of granzyme B was not associated with one year post-transplant 
rejection. However immune system activation is suggested by the higher level of granzyme 
in patients vs control group. Continuous analysis of patients.
PUB682
Epidemiological Analysis of Post Transplant Glomerulonephritis  Pratik Das, 
Santosh Kumar, Rohit Rungta.  Nephrology and Transplantation, Rabindranath 
Tagore International Inst of Cardiac Sciences, Kolkata, West Bengal, India.
Background: Post-transplant glomerulonephritis is an important cause of graft 
dysfunction and consequent graft loss. Aim of the study is to identify the incidence and 
outcome of glomerulonephritis in post-transplant patients.
Methods: We retrospectively evaluated all the patients who underwent renal allograft 
biopsy between January 2010 to January 2014, for graft dysfunction, proteinuria or 
active urinary sediments. All protocol biopsies were excluded from the study. Graft 
biopsies were evaluated by light microscopy and indirect immunofluorescence study. Out 
of 285 graft biopsies 242 biopsies were taken into study. Biopsies showing evidences 
of glomerulonephritis were further evaluated for incidence of individual types of 
glomerulonephritisand their outcome at the end of one year post diagnosis.
Results: Based on biopsy findings among 242 renal allograft biopsies taken in study 
42(17.35%) had post-transplant glomerulonephritis. Further the incidence of individual 
glomerulonephritis were 14(33.3%) for focal segmental glomerulosclerosis, 13(31%) 
for IgA nephropathy, 8(19%) for mebranoproliferative glomerulonephritis, 4(9.6%) for 
pauci-immune crescentic GN, 2(4.8%) for anti-glomerular basement membrane disease 
and 1(2.3%) for membranous nephropathy. On follow up for one year 30(71.4%) patients 
lost their graft and became dialysis dependent irrespective of treatment. When compared 
to this outcome with other causes of graft dysfunction (rejection or infection) , results are 
inferior in terms of graft and patient loss.
Conclusions: We conclude that post-transplant glomerulonephritis is strongly 
associated with poor kidney allograft survival. Therefore, optimal management of recurrent 
or de novo glomerulonephritis should be the critical focus of post-transplant care.
PUB683
Impact of Hemoglobin Concentration on Mortality After Renal 
Transplantation  Vitoria C. Vilela,1 Marcos A. Meniconi,1 J. Medina-Pestana,1 
Miguel Cendoroglo Neto,1,2 Miguel A Goes.1,2  1Nephrology Div, Federal Univ 
of Sao Paulo, Sao Paulo, Brazil; 2Nephrology Div, Hospital Israelita Albert 
Einstein, Sao Paulo, Brazil.
Background: Kidney transplant recipients have chronic anemia, irrespective of the 
time from transplantation. Objective: To assess the impact of hemoglobin concentration 
on mortality after renal transplantation.
Methods: A total of 233 patients who underwent renal transplantation at one center 
(Hospital do Rim) were prospectively analyzed. Follow-up time was 6 years, from January 
2008 through December 2014. Data on demographics, ESRD etiology, pre-transplantation 
dialysis, transplant characteristics, and immunosuppression regimen. Two-sample t test were 
used to compare differences between two groups (mortality versus non-mortality groups) 
and X2 to analyze categorical variables. Binary logistic regression was used to determine 
the impact of factors on outcome-mortality.
Results: The main causes of ESRD were diabetes (35%) and hypertension (20%).
Transplants from living donors occurred in 59%. During the entire follow-up period, there 
were 24 (10%) deaths within 3+1 yr after renal transplantation. 7 (29%) from cardiovascular 
disease and 17 (71%) died from infection. We observed that mortality group were older 
(p<0.001) and longer time on dialysis (4+2.5, 2.5+2.0 yr; p=0.006). Hemoglobin (Hb) 
concentration was lower in mortality (10.7 +2.3) than non-mortality (12.0+2.42; p=0.01) 
group. Patients who used mycophenolate had lower mortality (p = 0.04). There is no 
correlation between Age and Hb (r=-0,02; p=0,8). Age (p = 0.01) and Hb concentration (p 
=0.02) were independent predictors of mortality.
Conclusions: This study shows that a lower Hb concentration is an independent 
predictor of mortality in renal transplant patients.
PUB684
Prediction of Recipients Survival in Deceased Donor Kidney Transplant 
Using Korean Network for Organ Sharing Database  Kyung Don Yoo,1 
Junhyug Noh,2 Hajeong Lee,1 Dong Ki Kim,1 Chun Soo Lim,1 Young hoon 
Kim,3 Yon Su Kim,1 Gunhee Kim,2 Jung Pyo Lee.1  1Seoul National Univ College 
of Medicine; 2Seoul National Univ College of Engineering; 3Univ of Ulsan.
Background: The Korean Network for Organ Sharing (KONOS) was founded in 
2000 for organ allocation in Korea. It has been allows medical doctors and researchers 
to fully access the national population-based raw data about KT recipients. We propose 
a novel prediction approach of recipient survival based on machine learning techniques 
using KONOS data.
Methods: Our dataset is collected from 2000 to 2014 by the KONOS. We design a 
novel prediction model that uses all of the follow-up recipients’ data including censored 
ones, on which estimated death risks are weighted accordingly. We compare this approach 
with the baseline model that uses only uncensored data by the CART (Classification And 
Regression Trees) modeling.
Results: We analyze 5,430 recipients’ records with more than 31 attributes, among 
which we choose 15 independent attributes to learn our models. The proposed weighted 
algorithm leads a better performance when predicting survival rates of transplant recipients 
within 6 years, but fails to show any significant difference from the baseline for those more 
than 7 years after transplantation. Using the decision-tree models, we find that the inotropic 
agent usage of donor management is the most important predictor, which estimates in 51.3% 
of 10-year mortality. In the age ≥51.5 group, non-diabetes recipients, waiting period < 
4years, and donor age < 23.5 years show significant associations with better 10YRS. The 
results are consistent with our hypothesis that poor donor status, recipients’ longer waiting 
time and advanced age are associated with poor prognosis.
Year after transplantation 1 3 5 7 9
Baseline model
AUC 0.644 0.665 0.759 0.832 0.862
Weighted Model
AUC 0.653 0.678 0.777 0.822 0.794
Conclusions: In this study, we show that the proposed machine learning based models 
with weights of estimated-death risks can present more accurate and flexible than baseline 
models for predicting in long-term survival rates of kidney transplant recipients.
PUB685
Perforin Expression in Renal Allograft Biopsies  Michele T. Rooney,1 Ping 
L. Zhang,2 Dilip Samarapungavan,3 Randolph Alexander Hennigar.4  1Incyte 
Diagnostics, Spokane, WA; 2Anatomic Pathology, William Beaumont Hospitals, 
Royal Oak, MI; 3Nephrology, William Beaumont Hospitals, Royal Oak, MI; 
4Nephropathology Associates, Little Rock, AR.
Background: Perforin is a cytotoxic protein in effector lymphocytes that facilitates 
targeted cell killing and it has an established role in allograft rejection. A diagnostic value 
has not been delineated. We examined perforin expression in renal transplant biopsies by 
immunohistochemistry (IHC) and found that positive lymphocytes are confined largely to 
the microvasculature in cases of active cellular rejection (ACR). The goal of this study is 
to investigate whether perforin IHC is a useful metric in identifying and classifying acute 
rejection in renal transplant biopsies.
Methods: Renal transplant biopsies accessioned over a one-year period were selected 
to include cases showing no acute rejection, acute tubular injury, BK nephritis, ACR types 1 
and 2, and C4d+ antibody-mediated rejection (AMR), according to the 2013 revised Banff 
Classification. IHC using a mouse monoclonal anti-perforin antibody was performed on 
each case. Perforin positive cells/10 high power (400X) fields (hpf) were counted from 
slides identified by number only.
Results: Most rejection-negative cases had < 10 perforin-positive cells/10 hpf. Biopsies 
showing type 1A ACR, excluding one outlier, did not exhibit a significant increase in 
perforin-positive cells relative to rejection-negative cases. In contrast, cases of type 1B 
and 2 ACR, and C4d+ AMR displayed significantly increased perforin-positive cells (p 
= 0.0001) with most showing > 40/ 10 hpf. Cases of AMR contained the highest number 
of perforin-positive cells (p = .0352). Cases of BK nephritis varied widely from < 10 to > 
50/ 10 hpf. 2 of 3 cases with > 50 had a recent history of ACR developing BK infection 
upon increasing immunosuppression, raising the possibility of coexisting BK and rejection.
Conclusions: Further study is needed, but our data suggests that increased numbers of 
perforin-positive lymphocytes correlate with more aggressive forms of rejection, and that 
perforin IHC may be a useful ancillary test for acute allograft rejection of type 1B or higher.
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Is It Safe to Transplant Sensitized Patients? Analysis of 1,002 Consecutive 
Kidney Transplants  Anna Rita Aguirre, Patricia Soares Souza, Fabiana Agena, 
Daisa R.S. David, Flavio Jota Paula, Elias David-Neto, Maria Cristina R. Castro. 
Renal Transplant Service, Hospital das Clinicas - Univ of Sao Paulo School of 
Medicine, Sao Paulo, Brazil.
Background: From 2009-13, 24% of kidney recipients in our center had antiHLA 
antibodies(aHLA abs). Obj: To compare the risks of rejection, patient and graft survival 
when transplants(Tx) were performed with or without aHLA abs and with or without 
DSAs. To compare mortality between patients transplanted with aHLA abs to mortality 
in the waiting list.
Methods: Retrospective study, which included all isolated kidney Tx in patients older 
than 18yo, performed between jan09 and dec13(N1002). We analysed the incidence of 
TCMR and ABMR in the 1st year after Tx. Median follow-up time was 32mo. Graft and 
patient survival were evaluated by Kaplan Meyer estimates.
Results: In 741 Tx(74%), no aHLA abs were detected(ARP=0) and 261(26%) had 
PRA>0. Among Tx with PRA=0, 658(89%) did not have rejection in the 1st year, 77(10,4%) 
had TCMR and 6(0,81%) had ABMR. Among Tx with PRA>0 without DSAs(149), 
129(86,6%) did not have rejection, 16(11%) had TCMR and 7(4,7%) had ABMR. In Tx 
with PRA>0% with DSA(91), 58(62,4%) did not have rejection, 7(7,5%) had TCMR and 
31(33,4%) had ABMR. ABMR was more frequent when there was a DSA(p<0,0001). 
Graft survival did not differ according to ARP or DSA in groups with no rejection, 
TCMR and ABMR. There were more graft losses in the whole sample when a DSA was 
detected(p<0,0001) or when RAMA occurred, in comparison to no rejection(p<0,0001) 
and TCMR(p 0,0143) . Regarding patient survival, there was no influence of aHLA abs 
and DSAs, nor influence of TCMR or ABMR. In recipients with aHLA abs, mortality was 
11% in 32mo, or 4,12% per year, smaller than in the waiting list in our state, which was 
5,61% in the same period.
Conclusions: There was no difference in patient survival after 32 mo between patients 
with or without aHLA abs or DSAs, or even between patients with or without ABMR. 
However, there were more graft losses in recipients with aHLA abs and with ABMR. 
Mortality after Tx among sensitized patients hasn’t been larger than in the waiting list. We 
conclude that transplanting the sensitized patient does not increase mortality risk.
PUB687
Response of Anti Blood Group Antibodies to Desensitization Procedures 
and Kidney Transplantation  Bharat V. Shah, Zaheer Amin Virani, Prashant J. 
Rajput.  Inst of Renal Sciences, Global Hospitals, Mumbai, Maharashtra, India.
Background: ABO-incompatible (ABOi) kidney transplantation (KT) is option for 
overcoming the shortage of organ donors. Before performing ABOi transplant, it is important 
to reduce anti-blood group antibody titers (ABGAT) by desensitization. The aim of our 
study was to determine: 1) Baseline ABGAT in patients undergoing ABOi KT, 2) Response 
of ABGAT to desensitization and 3) Behavior of ABGAT after KT.
Methods: Nineteen (13 male and 6 female) ABO-I patients (6-O, 8-A and 5-B blood 
groups) studied. The IgG and IgM ABGAT were determined using column agglutination 
technique (CAT). Desensitization was attempted if baseline IgG ABGAT > 1:32. For 
desensitization, besides rituximab, Plamapheresis (PP) and/or Glycosorb was used. 
Desensitization considered successful if IgG ABGAT dropped to < 1:32. ABGAT monitored 
daily or alternate days for 1 week after transplant, twice a week in the 2nd week and 
weekly for next 2 weeks.
Results: The baseline IgG antibody titres ranged from 1:4 to > 1:512 (median 1:64) 
while IgM antibody titres ranged from 1:2 to > 1:512, (median 1:32). In one case with 
baseline titre <1:4 no desensitization was done. In 15 cases, PP alone was attempted. In 3 
of these cases (with baseline titre > 1:512), the titres could not be reduced to < 1:32 and 
transplant was not done. Based on this experience, we used Glycosorb with or without PP 
in next 3 cases with titres > 1:512. All of these 3 cases could be desensitized. Of the 16 
patients who were transplanted, the titres remained < 1: 64 (median 1:8) after transplant in 
15. None of them required PP or Glycosorb treatment after transplant. In one patient, IgG 
ABGAT rose to > 1:128 in the first week after KT. Biopsy was suggestive of acute antibody 
mediated rejection and was treated with PP, Rituximab and Bortezomib.
Conclusions: Majority of our patients have low baseline ABGAT. In cases with low 
ABGAT, Rituximab (2 doses of 200 mg weekly) and 2 to 3 sessions of PP bring down 
titres to < 1:32. For baseline titres > 1:512, use of Glycosorb may be required. After KT 
titres remain < 1:64 in most and this is not associated with any graft dysfunction. One may 
consider an allograft biopsy if IgG ABGAT is > 1:128 in the first 2 weeks.
PUB688
Temporal Characteristics of End Stage Renal Disease due to Tuberous 
Sclerosis in United States, 2001- 2010  Donna J. Claes,1 Sarah J. Kizilbash,1 
Hassan N. Ibrahim,2 Robert N. Foley,2 Scott Reule.2  1Pediatrics, Nephrology, 
Univ of Minnesota, Minneapolis, MN; 2Internal Medicine, Nephrology, Univ 
of Minnesota, Minneapolis, MN.
Background: Tuberous sclerosis (TS) is an autosomal dominant, multisystem disorder 
characterized by hamartomas in various organs with renal involvement occurring in 
approximately 50 to 80% of patients. Although renal involvement may result in end-stage 
renal disease (ESRD), studies examining the characteristic of ESRD in patients with TS 
are limited.
Methods: Census data was combined with data from the USRDS for all patients 
diagnosed with ESRD from 2001-2010 (n=1,072,161). A total of 367 patients with ESRD 
due to TS were identified. Incidence rates and standardized incidence ratios (SIR) were 
computed using Poisson distribution and standardized using 2001-2002 as reference. 
Hazards ratios adjusting for age, sex, race and ethnicity (AHR) were calculated for outcomes.
Results: In 2001-2002, the overall incidence rate of ESRD due to TS was 1 per 10 
million person years (PMPY) and the SIR remained largely unchanged over the observation 
period. Those with ESRD due to TS were more likely to be < 40 years (23.2% vs. 9.2%), 
white ethnicity (81.5% vs. 65.5%), and lack diabetes (81.2% vs. 48.1%). Compared to 
those with ESRD due to other causes, odds ratios adjusted for age, sex, race and ethnicity 
(AOR) were highest for females (1.83) and those with eGFR > 15ml/min (1.31). Factors 
associated lower AOR included age 40-64 years (0.29), age ≥ 65 years (0.25), and black 
race (0.33). Over the study period, 53.7% of TS patients died, 27.3% were listed and 10.6% 
were transplanted. The AHR for outcomes demonstrated those < 40 years of age were more 
likely to be listed for renal transplant, receive renal transplant and survive.
Conclusions: The incidence of ESRD due to TS remained largely unchanged from 
2001 through 2010. Our results indicated gender and racial differences in the odds of 
ESRD due to TS.
PUB689
The Impact of Hepatitis C Virus Infection on the Clinical Course, Short-
Term and Long-Term Outcome in Renal Transplant Recipients – A 
Retrospective Study  Pratik Das, Rohit Rungta, Santosh Kumar.  Nephrology 
and Transplantation, Rabindranath Tagore International Inst of Cardiac 
Sciences, Kolkata, West Bengal, India.
Background: Hepatitis C infection is common in patients of end stage renal disease 
with increased morbidity and mortality post-transplant. The aim of the study was to find 
out the impact of HCV infection on graft and patient outcome and compare it with the non 
HCV infected post-transplant cohort.
Methods: We retrospectively analysed patient and graft survival of HCV infected (after 
virological remission) post renal transplant patients from 2008 to 2014 with a median follow 
up of 24 months and compared them with our HCV negative statistically matched cohort.
Results: Outcome analysis was done at 6, 12, 18 and 24 months in terms of liver 
dysfunction, acute rejections, infections, hospitalization and death. Results were further 
tabulated as shown. 
VARIABLES HCV positive patients
hcv negative 
patients P value
1.Patients(n) 51 1381
2.Induction with ATG 26(50%) 700(50.68%) NS
3.Tacrolimus 34(66.67%) 1196(86.9%) <0.05
4.Cyclosporin 17(33.3%) 185(13.1%) <0.05
5.Infection 05(9.8%) 117(8.5%) NS
6.Abnormal LFT 08(15.6%) NA -
7.1 year patient survival 96.1% 97% NS
8.2 year patient survival 92% 93.2% NS
9.Hospitalization 24 episodes 621 episodes NS
Results were found not to be statistically different from non HCV infected renal 
allograft recipients.
Conclusions: HCV infected end stage renal disease patients may undergo renal 
transplantation safely after virological remission and outcome is not different from other 
renal transplant recipients.
PUB690
Patient and Graft Survival in Pediatric Kidney Transplantation: A Single-
Center Experience According to Transplant Era  Marta Monteverde,1 Juan 
Carlos Lopez,1 Gerardo Nyman,1 Liliana Briones.1  1Nephrology Unit, Hospital 
JP Garrahan, Buenos Aires, CABA, Argentina; 2Urology Unit, Hospital JP 
Garrahan, Buenos Aires, CABA, Argentina.
Background: Improvements in the management of kidney transplantation has improved 
in the last 20 yeras. However the long term results in terms of graft survival and morbidity 
still require more research.
Methods: We evaluated 744 pediatric renal transplants (RTX), 551 with deceased donor 
(DD) and 222 with living-related donor (LRD), between 1988- 2015. We divided this time 
in 2 periods: 1988-2000 and 2001-2015. Patient and graft survival were calculated for each 
period for LD and DD recipient. We analyzed causes of mortality, causes of graft failure 
and risk factors for graft loss. Mean age at RTX was 11.6 y (r: 3.7-19.5). Median time of 
follow-up was 54.5 months (IQR: 22.4-90.1) months.
Results: Patient and graft survival for DD have significantly increased in the recent era 
(p=0.0002; p=0.0013 resp).Chronic rejection was the first cause of graft loss in both eras 
(61.9% vs 61.11%); Vascular thrombosis decreased (14.9% vs 5.5%; p= <0.001), and also 
Death with a Functioning Graft (15.8% vs 8.3%; p=<0.001). Acute rejection during the 
first 30 days post RTX + relapse of the original disease increased (0% vs 9.7%). First cause 
of death in both eras was bacterial infection (77% vs 66%). No death due to PTLD were 
seen in 2001-2015. Independent Risk factors for graft loss for DD recipients were: FSGS 
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as cause of ESRD (HR: 3.1; CI 95%: 2-4.8), DGF (HR: 2.8; CI 95%: 2-4) and Receiving 
no induction therapy (HR: 2.1; CI 95% 1.3-3.5). For LRD recipients: DGF (HR: 5.2; CI: 
2.9-9.3) and Age at RTX > 12y (HR: 2.2; CI95%: 1.2-3.9).
Conclusions: Patient and graft survival has significantly improved for DD in the recent 
era. Chronic rejection remains a the major cause of graft failure. No death from malignancy 
were observed in the recent era.
Graft Survival 1y (% SE) 3y (%SE) 5y (%SE) 7y (%SE) 10y (%SE)
LD(1988-2000) 97 (0.001) 90.5 (0.02) 85 (0.03) 78.2 (0.03) 65.3 (0.04)
LD(2001-2015) 96 (0.02) 90 (0.03) 87 (0.03) 80.6 (0.06) 76.1 (0.07)
DD(1988-2000) 83.2 (0.03) 74.5 (0.03) 67.9 (0.03) 62.6 (0.03) 51 (0.04)
DD(2001- 2015) 94.7 (0.01) 86.8 (0.02) 82.7 (0.02) 74.5 (0.03) 58.6 (0.07)
PUB691
Impact of Rituximab Induction on Short Term Outcome of Kidney 
Transplant Recipients  Bharat V. Shah, Prashant J. Rajput, Zaheer Amin 
Virani.  Inst of Renal Sciences, Global Hospitals, Mumbai, Maharashtra, India.
Background: Acute graft rejection remains a major problem in kidney transplant (KT) 
recipients. Induction with Thymoglobulin or Basiliximab is a KDIGO recommendation to 
minimize the risk of acute rejection. However, these induction agents do not eliminate the 
risk of antibody mediated rejection. Recent studies of ABO incompatible (ABOi) transplant 
using Rituximab, in addition to standard induction and maintenance immunosuppression 
(IS) have shown better outcome than ABO compatible (Kohei N, Tanabe K Am J 
Transplantation 2012; 12: 469-476) transplants. Therfore our aim was to study efficacy 
and safety of Rituximab induction in addition to single dose Thymoglobulin induction in 
living donor (LD) KT patients.
Methods: The study included 53 adult LD KT recipients transplanted between 3/1/14 
and 2/28/15 and followed for at least 3 months after KT. Of these, 39 were (ABOc) 
transplants and 14 were (ABOi) transplants. Rituximab 200 mg was given within a week 
before transplant. ABOi recipients received an additional 200 mg Rituximab on the day of 
transplant. Thymoglobulin 1 mg/kg was used only on the day of transplant. Maintenance 
immunosuppression included Tacrolimus, MMF and tapering doses of prednisolone in all. 
All patients received valgancyclovir and cotrimoxazole prophylaxis. The short term outcome 
of these patients (Ritux group) was compared to that of 53 historic controls (control group) 
who received only thymoglobulin 1 mg/kg on the day of KT.
Results: There was no difference in characteristics (age, sex, etiology of CKD, donor 
characteristics, HLA mismatch) of patients in the 2 groups. Six patients in the Ritux group 
developed acute rejection (5, cellular and 1 antibody mediated). Six patients in the control 
group developed acute rejection (2 cellular and 4 antibody mediated). The patient and graft 
survival at 3 months was 100% in Ritux group. The patient survival was 100% in control 
group. One graft was lost from antibody mediated rejection in control group. Infections 
within 3 months after KT were similar in both groups.
Conclusions: Rituximab induction is safe in KT. It reduces the risk of antibody 
mediated rejection without increasing infectious complications in the early period after KT.
PUB692
Epo Use in Pregnant Renopancreas Transplant Patients  Amelia R. Heguilen, 
Alicia M. Lapidus, Liliana Susana Voto, Ricardo M. Heguilen.  Medicine, 
Hospital Juan A. Fernandez, Buenos Aires, Argentina.
Background: Pancreas-kidney transplantation (Tx) improvemes life and reproductive 
function. Anaemia (AN) is common in this population. Prenatal counselling address 
potential fetal complications; as well as worsening anaemia, hypertension, preeclampsia, 
gestational diabetes, acute rejection or graft loss. The aim of this study was to evaluate the 
use of Erythropoietin (rHuEpo) during pregnancy in Tx recipients.
Methods: Four double Tx (cadaveric donor) recipients, underwent successful 
pregnancies after a complex medical history of diabetes in their childhood with retinopathy 
& polyneuropathy, two with hypothyroidism, and end stage renal disease. They were 
all switched into a pregnancy-friendly schedule with azathioprine, tacrolimus and low 
prednisone dose. Iron supplements (IS) and rHuEpo were prescribed because of anaemia 
progression. Because of hypo-responsiveness to rHuEpo, doses were incresed to 8000 U/
week in the 4 pt.in the third trimester.
Results: Serum creatinine (mg/dL) remained initially stable (1.28 ± 0.1); increased 
near delivery (36.2 wks) to 1.45 ± 0.1 and remained (1.32 ± 0.09) mg /dl postpartum. Blood 
pressure also increased near term without need of medication, serum uric acid rose to 6.2 ± 
0.6 mg/dl and mild proteinuria (550 ± 155 mg/d) developed. They were all normoglycemic, 
with normal pancreatic and hepatic function throughout pregnancy and postpartum. rHuEpo 
and IS were stable mothers Hto (24.7%) and HB (8.2 g/dl) with normal ferric parameters.
and reticulocytes. Fetal heart rate was normal. One pt developed preterm premature rupture 
of membranes; all pt delivered vaginally healthy babies, weight: 2100 ± 320 g. (IUGR) 
with no evidence of congenital anomalies. There was no postpartum hypertension and 
they continued with stable renal and HCT parameters. Three months later serum creatinine 
returned to baseline and no proteinuria was detected. rHuepo need to be decreased in all 
pt. postpartum, newborns outcome was uneventful.
Conclusions: According to our study the administration of human recombinant 
erythropoietin has a beneficial effect in pregnancy without side effects. Preterm delivery, 
IUGR and low birth weight are common in this population probably due to other drug 
adverse effects.
PUB693
Acute Rejection Incidence in Deceased Kidney Transplant Recipients 
with Delayed Graft Function After Single Dose Thymoglobulin 
Igor Gouveia Pietrobom, Laila Almeida Viana, Cinthia Montenegro Teixeira, 
Andre Caires Alvino Lima, Mayara Ivani de paula, Geovana Basso, Tainá Veras 
de sandes Freitas, J. Medina-Pestana, Helio Tedesco Silva.  Hospital do Rim, 
Federal Univ of Sao Paulo, São Paulo, Brazil.
Background: Thymoglobulin (rATG) induction has proven efficacy. However, it 
remains unclear what is the best dosing regimen.
Methods: From August 8th, 2014 immunosuppression protocol was changed at our 
institution to induction with single dose thymoglobulin to all deceased donor kidney 
transplant recipients. This retrospective study evaluated the incidence of acute rejection 
(AR) in deceased kidney transplant recipients with delayed donor graft function (DGF) 
before and after the adoption of a new induction protocol.
Results: Pre-protocol Group 1 - 96 patients transplanted between 12/31/2013 and 
08/08/2014; Standard criteria deceased donors (SCD) (without induction, tacrolimus 
0.1mg/kg/dose, prednisone and azathioprine) or expanded criteria deceased donors (ECD) 
(induction with thymoglobulin 6mg / kg, tacrolimus 0.05 mg/Kg/dose, prednisone and 
mycophenolate sodium) versus Group 2 (new protocol) , 87 patients transplanted between 
08/08/2014 and 03/31/2015, subdivided in the same way, receiving the same maintenance 
therapy and thymoglobulin induction 3mg/kg single dose. In both groups, the population 
was overwhelmingly male (63% vs. 55%), young (47 vs. 46 years) and low immunological 
risk. The incidence of AR in G1 vs. G2, SCD subgroup was 13%, vs. 4% (p = 0.09). When 
compared ECD recipients, the incidence of rejection was similar between G1 vs. G2 (15% 
vs. 14%, p = 1.0), respectively.
Conclusions: In the SCD kidney transplant recipients, the incidence of AR was 
numerically lower in the group that received induction with single dose rATG 3mg / kg 
and induction with a reduced dose of rATG was not inferior in the ECD group.
PUB694
Cardiovascular Changes After Kidney Donation  Fernando H. Margulis. 
Nefrologia y Trasplante Renal, Hospital General de Agudos Cosme Argerich, 
CABA, Buenos Aires, Argentina.
Background:  The aim of our study was to investigate the changes in cardiovascular 
structure and endothelial function after donation in kidney donors.
Methods: Fourteen living kidney donors (both genders) without history of kidney 
disease, diabetes, cardiovascular events or hypertension, who participated in the donor 
screening protocol with subsequent donation, were included. Office blood pressure (OBP), 
ambulatory blood pressure monitoring (ABPM), left ventricular mass index (LVMI), arterial 
stiffness (AS) and endothelial function (EF) were measured before and one year after the 
donation. AS was assessed from the left index finger using a digital photoplethysmograph 
(Pulse Trace; Micro Medical), that uses a simplified analysis of the digital volume pulse 
wave, to assess endothelium dependent arterial vasodilation, 400 ug of salbutamol was 
given by inhalation. Data were expressed as mean ± SD or median and IR. Student t test and 
Wicoxon test were used for data with normal and nonparametric distribution respectively, 
p<0.05 were considered to be statistically significant.
Results: The mean age of the cohort was 47 ± 8 (range, 30 – 56) years. At one year 
after donation the mean BMI (27.1 ± 2.6, P<0.006), median OBP (89 (86, 92), P<0.023) 
and median serum creatinine (1.14 (0.99, 1.42), P<0.001) were significantly increased 
as compared to baseline (26.4 ± 3; 85 (76, 92) and 0.78 (0.74, 0.97), respectively). The 
estimated glomerular filtration rate levels by MDRD 4 formula at 1 year (57.4 ± 12ml/
min/1.73 m2, P<0.0001) were significantly decreased as compared to baseline (82.2 ± 10 ml/
min/1.73 m2). We did not find significantly differences in mean 24hs ABPM (84 ± 8 mmHg, 
P=0.940), mean LVMI (96.6 ± 17 g/m2, P=0.727), mean AS (7.78 ± 2.3 m/s, P=0.210) and 
median EF (5.1% (0.8, 13.3), P=0.374) compared to baseline (85 ± 7 mmHg; 99.8 ± 31.6 
g/m2; 9.03 ± 2.3 m/s and 10% (-1.6, 34.6), respectively).
Conclusions: Our study demonstrated that after an year, reduced nephron mass 
because of kidney donation was not associated with changes in cardiovascular structure 
and endothelial function.
Funding: Government Support - Non-U.S.
PUB695
A Rare Case of Chronic Lymphocytic Inflammation with Pontine 
Perivascular Enhancement Responsive to Steroids (CLIPPERS) After 
Kidney Transplantation  Maria C. Bermudez, Mayurkumar Gohel, Ali Javed, 
Michael F. Schultz.  Nephrology, Geisinger Medical Center, Danville, PA.
Background: Chronic lymphocytic inflammation with pontine perivascular 
enhancement responsive to steroids (CLIPPERS) is a recently described inflammatory 
condition of the central nervous system. To date 50 cases have been reported in the literature, 
however none have been reported following renal transplantation.
Methods: 47 year old Hispanic male, status post diseased donor kidney transplant 
in 2008, with history of hypertension and diabetes, presented to our clinic with several 
months of progressive dizziness, unsteady gait and right facial numbness that progressed 
to diplopia and right facial palsy. An MRI of the brain with gadolinium revealed a 1.3 cm 
mass with a ring-like target appearance in the right brachium pontis and dorsal pons. MR 
spectroscopy revealed mild elevation of choline, suggesting demyelinating disease versus 
lymphoma or other high-grade malignancy. Given his long term immunosuppression, 
malignancy or an infectious process were considered as the main diagnostic possibilities. 
An extensive evaluation included serial lumbar punctures for cytology and a variety of 
Key: TH - Thursday; FR - Friday; SA - Saturday; OR - Oral; PO - Poster; PUB - Publication Only
Underline represents presenting author.
1049A
J Am Soc Nephrol 26: 2015 Publication Only 
viral, fungal and bacterial cultures. Cytologic and serologic studies were unremarkable. 
Flow cytometry analysis of the spinal fluid showed no evidence of lymphoma. A brain 
biopsy was performed revealing non-specific perivascular lymphoplasmocytic infiltrate 
with no evidence of lymphoma or infection. Additionally, myelin stain was positive ruling 
out demyelinating disease. Our patient was started on high-dose steroids with remarkable 
improvement of his symptoms. Diagnosis of CLIPPERS was made.
Conclusions: CLIPPERS is a rare and poorly recognized CNS inflammatory condition. 
To our knowledge, this is the first case reported after renal transplantation. More studies are 
needed to determine the pathophysiology of CLIPPERS in immunosuppressed patients and 
whether it could represent a pre-malignant state. Duration of treatment and follow up is yet 
to be determined. In this case, treatment with steroids has let to symptomatic improvement 
over a month and close follow-up continues.
PUB696
The Impact of Post-Transplant Hemoglobin and Creatinine Level on Renal 
Allograft Survival  Luiz Fernando Christiani, Fernanda Paula Feres Rios Da 
Costa, Ana Flavia Baldoni, Alicia Imada, Kelly Rodrigues, Maria Izabel Neves 
de Holanda Barbosa, Géssika Marcelo Gomes, Cláudia Fagundes.  Nephrology, 
Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil.
Background: Anemia is a common finding after kidney transplantation. The roll and 
the prevalence of Posttransplantation anemia (PTA) in predicting renal allograft outcomes 
still vary between different studies. In this study, we aim to assess the prevalence of anemia 
at one and six months post transplant and its correlation with 1 year renal allograft survival.
Methods: Anemia was defined by an absolute level of hemoglobin less than 11 g/
dL. Hemoglobin and creatinine level were assessed at one, six and twelve-month after 
transplantation.
Results: We included 261 consecutive patients who underwent renal transplant 
from January/2010 to June/2012. Mean recipient age was 42±10 years and  56% were 
male. Prevalence of anemia was 42% at 1 month, 16% at 6 months and 9% at 12 months. 
Hemoglobin and creatinine level at first month of transplantation were 11.2± 2 and 1.8± 1.0 
for patients with functional allograft vs. 9.4± 2.1 and 4.8± 3.4 for those who return to dialysis 
within 12 months (p<0.001 for both comparisons). Overall patient and graft survival was 
8% and 10%, respectively. On multivariate analysis, creatinine and hemoglobin level were 
independently associated with poor graft survival at 12 months. The best cut-off selected 
by receiver operating characteristic curve analysis was 10.8 g/dL for Hemoglobin level, 
(AUROC 0.74 (0.63-0.86), p˗0.001), and 2.25 mg/dL, for serum creatinine (AUROC 
0.77 (0.62-0.91, p˗0.001). Combining the best points of those two variable could identify 
patients at risk of graft loss. Patients who met both criteria ( Hb ˗  10.8 g/dL and Creatinine 
˗ 2.25 mg/dL) had 59% graft survival at 1-year, whereas allograft survival was 98.5% for 
patients without any criteria ( Hb ˗10.8 g/dL and Creatinine ˗ 2.25 mg/dL).
Conclusions: Prevalence of anemia was high in the first month after transplant and 
persisted in a substantial proportion of functioning kidney transplant recipients. Early 
(1-month) hemoglobin and creatinine level can predict 1 year-graft survival.
PUB697
Examining Adverse Weight Gain After Kidney Transplantation 
Biruh Workeneh,1 Linda W. Moore,2 William E. Mitch.1  1Medicine/Nephrology, 
Baylor College of Medicine, Houston, TX; 2Transplant Medicine, Houston 
Methodist Hospital, Houston, TX.
Background: Between 15,000-17,000 patients with end-stage renal disease (ESRD) 
receive a kidney transplant in the United States every year. Among the most consequential 
complications to these patients are adverse weight gain and the development of diabetes, 
commonly termed New-Onset Diabetes After Transplantation (NODAT) with consequent 
CV mortality. However, there is no consensus about the exact nature of the weight gain 
that routinely occurs after kidney transplantation (i.e., relative changes in fat vs. muscle 
vs. fluid volume) and how this relates to insulin resistance. We wish to test the hypothesis 
that weight gain is primarily due to an increase in fat mass.
Methods: We are conducting a longitudinal study in ESRD patients anticipating 
receiving a live donor kidney transplant. We are studying subjects before kidney transplant, 
at 12 weeks and 1 year after they have received living donor kidney transplant to measure 
changes body composition and other indices. Body composition was characterized by DEXA 
as well as total body potassium (a gold standard measure of muscle mass).
Results: Results from 5 subjects who completed baseline assessment and 3 months 
post-transplant reveals there is significant gain in adipose weight gain in all cases. 
Additionally, we discovered there is significant loss in skeletal muscle mass (p=0.032) 
measured by total body potassium.
Conclusions: We have not studied enough to conclude whether changes in energy 
expenditure and diet contribute to adipose weight gain and whether there is acute nitrogen 
(muscle) loss perioperatively. Ultimately, methods to identify patients at high risk for 
adverse weight gain and related metabolic disorders before transplant are greatly needed.
Funding: Private Foundation Support
PUB698
Effect of Mycophenolate Mofetil Dose on BK Virus Infection in Kidney 
Transplant Recipients  Vedran Pasara,1 Danica Galesic Ljubanovic,2 Mladen 
Knotek.1  1Dept of Medicine, Renal Div, Univ of Zagreb Medical School, Merkur 
Hospital, Zagreb, Croatia; 2Dept of Pathology, Univ of Zagreb Medical School, 
Dubrava Univ Hospital, Zagreb, Croatia.
Background: Intensity of overall immunosuppression is a risk factor for BK virus 
infection (BKVI). However, the exact impact of exposure to tacrolimus and mycophenolate 
mofetil (MMF) to BKVI is unclear. The aim of this study was to determine if BKVI in 
kidney transplant (KT) recipients (KTR) is associated with drug exposure to MMF.
Methods: This prospective randomised controlled clinical trial (NCT01860183) 
included 36 KTR who underwent KT from May 2013 to February 2015 at Clinical 
Hospital Merkur. Immunosuppression consisted of basiliximab induction, with tacrolimus, 
MMF±steroid maintenance. KTR were randomized in two groups, with respect to MMF dose 
(2g or 3 g daily). Urine cytology for decoy cells was performed at prespecified time-points 
posttransplant. KTR were followed up to 12 months post KT. Graft biopsy was performed 
per protocol at 2, 6 and 12 months, or in case of graft dysfunction. Kaplan-Meier analysis 
with log-rank test was used to assess graft survival. A Cox regression was used to determine 
variables associated with graft survival.
Results: 13 (37.1%) KTR had decoy cells in urine, 4 (11.4%) KTR had biopsy-proven 
BK virus-associated nephropathy (BKVAN). The mean time-to-occurrence was 4.8 months 
for decoy cells and 4.3 months for BKVAN. Cumulative one-year overall graft survival 
was 93.5%. Incidence of decoy cells, BKVAN, or acute rejection was similar in the two 
MMF groups. Rejection was not a risk factor for decoy cell positivity or for BKVAN.
Conclusions: MMF dose may not increase risk for BKVI after kidney transplantation.
Funding: Government Support - Non-U.S.
PUB699
Malignancy following Renal Transplantation  Lourdes de la Vara Iniesta,1 
Francisco Llamas Fuentes,2 Inmaculada Lorenzo Gonzalez,2 Carmen Gomez 
Roldan.2  1Virgen de la Luz Hospital, Cuenca; 2Univ Hospital of Albacete, 
Albacete.
Background: There is retrospective experience in many reports about the association 
between the intensity of immunosuppression and the higher frequency of malignancy. 
Objective: Analyse and describe our centre’s experience.
Methods: 275 transplant patients were analyzed. A record was made of the frequency, 
anatomic-pathological diagnostics, location, the mean interval between transplantation and 
diagnostics (latency time), follow-up time, use of antilymphocyte-antibodies, affectation 
by cytomegalovirus, rejection and immunosuppressive therapy.
Results: Of 273 patients, 9.52%(26) were diagnosed of cancer. The majority, 
93.43%(24), corresponded to De novo malignancy, 7.7%(2) were recurrences of pre-
existing disease. The mean age at diagnosis was 63.19±7.24years. The latency time was 
63.65months (11-114), although there is a notable but unexplained reduction over the last 
five year (33,50vs63,65 months). The average follow-up time was 97.54months. The most 
frequent malignancies were skin cancers, predominantly Basal-cell and Squamous-cell 
carcinomas. The incidence of other tumors was similar to the general population. The 
most common causes of chronic renal failure was the glomerular and interstitial disorders. 
The risk of neoplasm was 0.36%, 4,36% and 9,52% at one, five and ten years after the 
kidney transplant. No association was detected with use of antilymphocyte-antibodies, 
CMV infection, rejection episodes or different immunosuppressive therapy. At the time of 
analysis, 84.60%(22) of patients had functioning graft, 7.70%(2) had returned to dialysis 
and 7.70%(2) had died, both due to the cancer.
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Conclusions: Our experience is similar to what is reported in the literature. The 
incidence of cancer is higher than expected in the general population and increases 
according to the duration of the immunosuppression. Skin cancers were the most frequent 
malignancies. Unlike other studies, there was a low incidence of lymphoproliferative 
disorder and Kaposi’s sarcoma, and the incidence of other solid malignancies being similar 
to that of the general population. To reduce the development of malignancies must be one 
of our objectives.
PUB700
Lipidapheresis in 3 Sisters with Familial Hypercholesterolemia 
Christina Taylan,1 Andrea Schlune,2 Thomas Meissner,2 Lutz Thorsten Weber.1 
1Pediatric Nephrology, Univ Hospital of Cologne, Cologne, Germany; 2Dept 
of Pediatrics, Neonatology and Cardiology, Univ Hospital of Duesseldorf, 
Duesseldorf, Germany.
Background: Familial hypercholesterolemia (FH) is the most common monogenic 
form of hypercholesterolemia. It carries the risk of premature coronary heart disease. As 
the atherosclerotic burden is dependent on the degree and duration of exposure to raised 
LDL-cholesterol levels, early diagnosis and effective treatment are imperative. Statins are 
the mainstay in the management of these patients. Lipoprotein-apheresis becomes recently 
more established in patients with severe dyslipidemia. Together these treatments improve 
the prognosis of FH. Most children fail to attain targeted lipid goals owing to persistent 
shortcomings in diagnosis and treatment.
Methods: Three siblings with a LDLR mutation (p.Trp577Arg) beeing on statins 
(20 mg/d Atorvastatin) and Ezetimib (10 mg/d) for 12 months with still LDL-C 
plasma concentrations of above 300-500 mg/dl started once weekly a double filtration 
plasmapheresis (DFPP) with with a single plasma volume to be treated.
Results: After each LDL-apheresis LDL-C concentration of 100-150 mg/dl could be 
reached. (66-70% reduction). After 6 months plasma volume to treat was doubled because 
of a rebound within 7 days with LDL-C concentration up to 300-350 mg/dl. But though 
after each session LDL-C concentration decreased to 50-100 mg/dl the rebound was still 
evident after 7 days of therapy pause. With a treatment regime with twice plasma volume 
every 3-4 days the children finally attained a stable pre-treatment LDL-C concentration of 
120-170 mg/dl. Another 2 months later statin therapy was stopped because of underlying 
mutation with assumed non receptor function. Neither the effectiveness of each apharesis 
nor the LDL-C concentration after 4 days showed any change.
Conclusions: In pediatric FH patients with high levels of LDL-cholesterol plasma 
concentration it might be necessary to treat instead of conservative medication with 
apheresis in high frequency and with high plasma volumes to reach a durable decrease in 
LDL-cholesterol plasma concentration. The use of cholesterol uptake-inhibitors should 
be considered.
PUB701
Thrombomodulin Up-Regulation in Preeclamptic Nephropathy Is 
Associated with Parietal Cell Activation  Rosanne Jane Turner,1 Maria 
Elisabeth Penning,1 Malu Zandbergen,1 Eliyahu V. Khankin,2 S. Ananth 
Karumanchi,2 Jan A. Bruijn,1 Kitty Bloemenkamp,3 Hans J. Baelde.1  1Pathology, 
LUMC, Leiden, Netherlands; 2Howard Hughes Medical Inst and Dept of 
Medicine, Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 
Boston, MA; 3Obstetrics, LUMC, Leiden, Netherlands.
Background: Preeclampsia is a pregnancy-specific syndrome characterized by 
angiogenic imbalance and endothelial dysfunction. This endothelial dysfunction leads to 
kidney damage, i.e. glomerular endotheliosis, increased podocyte turnover and proteinuria. 
Thrombomodulin (TM) facilitates maintenance of glomerular endothelium by inhibiting 
coagulation, inflammation and apoptosis. In preeclampsia, levels of soluble thrombomodulin 
in the circulation are increased. We hypothesize that glomerular thrombomodulin expression 
is increased in preeclampsia and set out to correlate thrombomodulin expression with 
endothelium and podocyte damage.
Methods: A nationwide, ethics committee-approved search of the Dutch Pathology 
Registry (PALGA) was conducted; this revealed renal autopsy material from 11 women with 
preeclampsia according to the ISSHP definition, from 22 normotensive pregnant controls 
and from 14 hypertensive non-pregnant controls. Kidneys from 13 sFLT-1 transfected 
mice and controls were collected. Samples were stained for TM and fibrin and markers of 
endothelium and podocyte damage were investigated.
Results: TM expression was increased in glomeruli from preeclampsia patients (82%) 
compared to pregnant, (41%, P=0.03) and hypertensive controls (21%, P=0.004). In sFLT-1 
transfected mice TM expression was the same as in controls. TM expression correlated with 
activation of parietal epithelial cells (P=0.023), but not with endotheliosis or endothelial 
fibrin deposits (P>0.05).
Conclusions: TM expression in the kidney is increased in preeclampsia. This is 
associated with parietal cell activation and not with endothelial damage or fibrin deposits. 
TM apparently exerts cytoprotective and not anticoagulant effects in the kidney in 
preeclampsia. Glomerular damage induced by sFLT-1 did not increase TM expression in 
a mouse model; this indicates that the increased TM expression in humans is probably not 
caused by this anti-angiogenic factor alone.
PUB702
Cadmium Induces Matrix Metalloproteinase-9 Expression via NADPH 
Oxidase/ROS-Dependent EGFR Signals in Human Endothelial Cells 
Nam ho Kim.  Internal Medicine, Chonnam Natuinal Univ Hospital, Gwangju, 
Korea.
Background: Cadmium, a widespread cumulative pollutant, is a known human 
carcinogen, associated with inflammation and tumor. Matrix metalloproteinase-9(MMP-9) 
plays a pivotal role in inflammatory reaction and tumor metastasis, however, the mechanisms 
underlying MMP-9 expression induced by cadmium remains obscure in human endothelial 
cells.
Methods: Here, cadmium elevated MMP-9 expression and enzyme activity, as well 
as MMP-9 promoter-driven luciferase activity, in a dose and time dependent manner in 
ECV304 human endothelial cells. Moreover, cadmium activated phosphorylation of EGFR, 
Akt, Erk1/2, JNK1/2, P38MAPK and promoted NF-κB and AP-1 binding.
Results: Specific inhibition and mutagenesis study shows that EGFR, Akt, Erk1/2, 
JNK1/2 and transcription factor NF-κB and AP-1 were related to cadmium-induced 
MMP-9 expression in ECV304 cells. Akt and MAPKs (Erk1/2 and JNK1/2) functioned 
as upstream signaling molecules in the activation of NF-κB and AP-1, respectively. 
Furthermore, Cadmium increased ROS production and the ROS-producing NADPH 
oxidase. Cadmium translocates p47phox,akeysubunitofNADPHoxidase,tothecellmembr
ane.The exogenous H2O2 increased MMP-9 mRNA expression. And that, inhibition of 
ROS by ROS scavenger (NAC) or NADPH oxidase inhibitor (DPI) attenuated EGFR, Akt, 
MAP(Erk1/2,JNK1/2,p38MAPK) activation, and MMP-9 expression. Likewise,inhibition 
of EGFR phosphorylation prevented the activation of AKT,MAPKs(Erk1/2,P38MAPK).
Finally,ECV304cellstreated with cadmium displayed markedly invasiveness, which was 
partially abrogated by MMP-9 neutralizing antibodies.
Conclusions: These results demonstrated that cadmium induces MMP-9 expression via 
NADPH oxidase/ROS-dependent EGFR/AktNF-κ Band EGFR/MAPKs(Erk1/2,JNK1/2)/
AP-1 signaling pathways and, inturn, stimulates invasiveness in human endothelial 
ECV304cells. These findings provide further insight into the molecular mechanisms in 
the carcinogenesis effect of cadmium.
PUB703
Exosomes from Activated Kidney Fibroblast Have Ambivalent Potential 
Effect on Atherosclerosis  Fumitoshi Nishio, Noritoshi Kato, Yoshio Funahashi, 
Takuji Ishimoto, Tomoki Kosugi, Naotake Tsuboi, Shoichi Maruyama, Seiichi 
Matsuo.  Nephrology, Nagoya Univ Graduate School of Medicine, Nagoya, 
Aichi-Pref, Japan.
Background: Exosomes are small (50-140nm) membrane vesicles of endosomal 
origin that contain host cell’s proteins, mRNAs, and microRNAs (miRNAs). The body of 
evidence revealed that these contents were biologically active, and had roles in intracellular 
communication. Especially tumor-derived exosomes has been intensively exploit and 
proven to be associated with distant metastasis. On the other hand, it is well known that 
CKD patients are at risk of cardiovascular diseases, but the mechanism of this distant 
organ crosstalk is not fully understood. Under the hypothesis that exosomes are involved in 
cardio-renal syndrome (CRS), the aim of this study is to explore the role of exosomes from 
kidney fibroblasts, which are activated in diseased kidney, on vascular endothelial cells.
Methods: We isolated Exosomes from culture media of TGF-β stimulated rat kidney 
fibroblasts cell line (NRK-49f) by ultracentrifugation technique. Cultured vascular 
endothelial cells (RAOEC; Rat Aortic Endothelial Cells) were stimulated by these exosomes 
or exosomes from unstimulated fibroblast. Then we evaluated the expression of genes, 
which associated with atherosclerosis by qPCR.
Results: RAOEC stimulated with exosomes form TGF-β activated kidney fibroblast 
(RAOEC-T) showed higher expression of PlGF and lower expression of Flt-1, ABCA-1 
than control (RAOEC-C). This expression pattern is compatible with atherosclerotic change. 
On the other hand, RAOEC-T showed reduced expression of adhesion molecules such as 
ICAM-1/VCAM-1 and E-selectin compare with RAOEC-C.
Conclusions: So far, CRS is supposed to caused by uremic factor, RAS system, chronic 
inflammation, and so on. From this study, we showed that exosomes from activated kidney 
fibroblasts have ambivalent roles in atherosclerosis by modulating the expression of adhesion 
molecules, metabolic factor, and VEGF system on endothelial cells. Farther studies are 
needed to elucidate the contribution level of exosomes on CRS.
PUB704
Prevalence of Metabolic Syndrome in Patients with End Stage Renal 
Disease: Relevance of Biomarkers  Vinod K. Bansal,1 Jennifer Saluk,2 Debra 
Hoppensteadt,2 Daneyal Syed,2 Schuharazad Abro,2 Jawed Fareed.2  1Nephrology, 
Loyola Univ Medical Center, Maywood, IL; 2Pathology, Loyola Univ Medical 
Center, Maywood, IL.
Background: Since the metabolic syndrome (MetS) and chronic kidney disease (CKD) 
share many of the same risk factors and similar inflammatory pathogenesis, many studies 
have suggested a correlation between CKD and MetS, and shown that patients with MetS 
are more likely to develop CKD. The purpose is to investigate metabolic biomarker levels 
in ESRD patients to evaluate their relevance to ESRD and to provide insight into the 
pathogenic ESRD processes and the development of associated comorbidities.
Methods: Plasma samples were retrospectively collected from 89 ESRD patients prior 
to maintenance hemodialysis. Normal human plasma samples (female & male, 18-35 years 
old) were purchased from George King Biomedical Inc. (Overland Park, KS). Samples 
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were stored at -80°C. Biochips were purchased from RANDOX (Co. Antrim, Northern 
Ireland) to test C peptide, ferritin, IL-6, resistin, insulin, TNFα, IL-1a, leptin, PAI-1. These 
biomarkers were tested on 82 ESRD and 17 normal samples.
Results: All biomarkers, except insulin, were significantly elevated in Patients with 
ESRD compared to normal (p values are 0.05 - .0001). MetS patients with ESRD, as 
compared to non-MetS Patients with ESRD, had significantly elevated Leptin (P=0.002), 
and the correlation between MetS and Leptin levels was significant (P<0.0001, r=0.43). All 
other biomarkers showed no significant difference between ESRD+MetS and ESRD-MetS 
patients. Furthermore, when leptin levels for Patients with ESRD were broken down into 
ESRD+MetS and ESRD-MetS, ESRD+MetS vs. normal was significant (P=0.0003), but 
ESRD-MetS vs. normal was not (P=0.6).
Conclusions: Elevated biomarkers suggest an ongoing inflammatory process in 
ESRD patients. Insulin levels were not significantly elevated in ESRD patients, possibly 
attributed to the high Leptin levels, which can interfere with insulin secretion and signaling. 
ESRD+MetS and ESRD-MetS populations are not statistically different for all other 
biomarkers. This suggests that biomarker elevation is due to ESRD pathogenesis, rather 
than due to MetS as a comorbidity.
PUB705
Decreased Mitochondrial Membrane Potential in Monocyte Subsets from 
Patients with Chronic Kidney Disease  Ying Wang,1 Eric Joseph Lai,1 Annie 
Febus,1 Yuan Zhang,2 Linda Vernocchi,1 Anjali Ganda.1  1Div of Nephrology, 
Dept of Medicine, Columbia Univ Medical Center, New York, NY; 2Dept of 
Biostatistics, Mailman School of Public Health, Columbia Univ, New York, NY.
Background: Particular monocyte subsets are associated with future cardiovascular 
events in patients with chronic kidney disease (CKD), and the underlying mechanisms 
require further investigation. Previous studies have suggested impaired mitochondrial 
function in patients on dialysis, while little is known about mitochondrial functionality 
in monocyte subsets from non-dialyzed patients with CKD. Given that mitochondrial 
dysfunction has been linked to atherosclerosis, we hypothesized that non-dialyzed patients 
with CKD would have mitochondrial dysfunction in monocyte subsets which could 
accelerate atherosclerosis in patients with CKD.
Methods: Monocyte subsets from 18 adult CKD patients (eGFR<30 ml/min/1.73 
m2) and 26 matched controls (eGFR ≥60 ml/min/1.73 m2) were freshly analyzed by flow 
cytometry. Mitochondrial membrane potential (DYm), as a measure of mitochondrial 
functionality, was determined by the mean fluorescence intensity (MFI) of TMRM 
(tetramethylrhodamine methyl ester).
Results: DYm was significantly reduced by 10% in patients with CKD vs. controls in 
total monocytes (P<0.05). Interestingly, the intermediate monocyte subset (CD14++CD16+), 
which has the highest DYm among all the monocyte subsets and has been shown to predict 
future cardiovascular events in CKD patients, had the most pronounced reduction in DYm 
(14% lower, P<0.01) in patients with CKD vs. controls. 
Conclusions: Patients with CKD demonstrate mitochondrial dysfunction in total 
monocytes and monocyte subsets. Mechanistic and prospective studies are needed to 
examine the relationship between monocyte mitochondrial dysfunction, atherosclerosis, 
and future cardiovascular events in CKD patients.
Funding: NIDDK Support, Private Foundation Support
PUB706
Paricalcitol Upregulates Renal Klotho and Restores Uremia-Induced 
Endothelial Integrity Disruption  Marc Vila cuenca,1 Robert H.j. Beelen,1 
Marc G. Vervloet.2  1Molecular Cell Biology & Immunology, VU Univ Medical 
Center, Amsterdam, Netherlands; 2Nephrology, VU Univ Medical Center, 
Amsterdam, Netherlands.
Background: Klotho deficiency in chronic kidney disease (CKD) is associated with 
the disruption of the endothelial integrity. Active vitamin D induces klotho expression. 
Hence, active vitamin D may limit endothelial layer disruption.
Methods: Male wistar rats were assigned into one of four groups: Control; Vitamin D 
deficiency, induced with Vitamin D deficient diet; Uremic, developed after ¾ nephrectomy; 
Uremic + Vitamin D deficiency. Animals were treated with Paricalcitol or vehicle control 
during 7 weeks. Serum samples were analyzed for 25D and 1,25D. Evans Blue was injected 
for estimation of the endothelial thoracic aorta and lung permeability and quantified 
using spectrophotometry. To determine the levels of Klotho, qPCR and WesternBlot was 
performed in kidney tissue.
Results: Average 25D levels were 9.83  nmol/L while 1,25D levels were below the 
detection levels (20pmol/L) after the induction Vitamin D deficiency. mRNA and protein 
levels of Klotho in the Kidney were decreased in Vitamin D deficient and uremic rats and 
restored after Paricalcitol treatment. Aortic Evans blue leakage increased in all uremic 
rats regardless of vitamin D level, compared with the control group and restored after 
Paricalcitol treatment (p=0.03). Uremia did not induce pulmonary leakage, but paricalcitol 
lowered it compared to control and uremic condition (p=0.04). Figure shows uremic with/
without D-deficiency together.
Conclusions: CKD induces aortic endothelial leakage, while the deficit of vitamin D 
on its own did not. Paricalcitol completely rescued endothelial leakage induced by CKD. 
In parallel, Klotho expression increased upon this treatment and may mediate the beneficial 
effect on the endothelium. To explain the difference between aortic and pulmonary tissue, 
additional studies are required.
Funding: Pharmaceutical Company Support - Abbvie
PUB707
Altered Intra-Aortic Expression of the Renin-Angiotensin System Is 
Associated with Arterial Aging in Mice  Hye Eun Yoon,1,2 Eun Nim Kim,1 
Min Young Kim,1 Ji Hee Lim,1 Cheol Whee Park,1 Bum Soon Choi.1  1Internal 
Medicine, The Catholic Univ of Korea, Seoul, Korea; 2Internal Medicine, 
Incheon St. Mary’s Hospital, Incheon, Korea.
Background: Aging is the major risk factor of cardiovascular disease and results in 
progressive decline in physiological function and structural abnormalities of vasculature. 
The renin-angiotensin system (RAS) is the key player in cardiovascular diseases. This study 
evaluated whether the change in the RAS is associated with arterial aging.
Methods: Histologic changes and expressions of angiotensin, angiotensin converting 
enzyme 1 (ACE1), angiotensin II type 1 receptor (AT1R), angiotensin II type 2 receptor 
(AT2R), and antioxidant enzymes, superoxide dismutase 1 (SOD1) and superoxide dismutase 
2 (SOD2), were measured in the thoracic aortas from 2-month-old, 12-month-old, and 
24-month-old C57/BL6 mice.
Results: Twenty-four-month-old mice showed significantly increased aortic media 
thickness compared to 2-month-old mice (1.6-fold). The aortic expression of angiotensin 
was increased in 12-month-old (1.2-fold) and 24-month-old mice (1.3-fold) compared 
to 2-month old mice. Similarly, the expression of ACE1 was increased in 12-month-old 
(1.2-fold) and 24-month-old mice (3-fold) compared to 2-month-old mice. The AT1R/
AT2R ratios were increased in 12-month-old (1.3-fold) and 24-month-old mice (1.5-fold) 
compared with 2-month-old mice. The expressions of SOD1 and SOD2 were decreased in 
12-month-old (0.8-fold and 0.6-fold, respectively) and 24-month-old mice (0.6-fold and 
0.5-fold, respectively) compared with 2-month-old mice.
Conclusions: Age-related intra-aortic activation of the RAS was associated with 
reduced antioxidant enzymes and hypertrophy of the aorta. These results suggest that the 
altered expression of the RAS contributes to the increased susceptibility to vascular injury 
in the elderly population.
Funding: Government Support - Non-U.S.
PUB708
Upregulation of Microparticles, Tissue Factor, Adhesion Molecules, Nitric 
Oxide and Adiponectin in End Stage Renal Disease  Vinod K. Bansal,1 
Daneyal Syed,2 Debra Hoppensteadt,2 Jawed Fareed.2  1Nephrology, Loyola 
Univ Medical Center, Mayood, IL; 2Pathology, Loyola Univ Medical Center, 
Maywood, IL.
Background: End stage renal disease (ESRD) represents the final stage of chronic 
kidney disease characterized by kidney failure (GFR <15 mL/min/1.73 m2). To understand 
the pathophysiology of ESRD, we measured the circulating levels of microparticles (MP), 
tissue factor (TF), adhesion molecules, such as p-selectin (P-Sel), soluble ICAM (s-ICAM), 
nitric oxide (NO) and adiponectin (AD).
Methods: Plasma samples were collected from 119 ESRD patients undergoing 
maintenance hemodialysis to profile various inflammatory biomarkers. 100 normal plasma 
samples were collected from healthy individuals. MP levels were measured using an annexin 
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binding method (Hyphen Biomedical, Paris, France). NO was measured using a kit from 
R&D systems (Minneapolis, Minnesota) and ELISA methods for TF, P-Sel, s-ICAM and 
adiponectin were obtained from R&D systems. A chromogenic substrate method was used 
to measure heparin.
Results: MP levels were elevated in the ESRD group (28.1nm + 6.1nm vs. the control 
8.9nm +1.3nm). Tissue factor levels were found to be increased in the ESRD group 
(20.4±6.1pg/ml) vs the control (11.9±2.8pg/ml). The nitric oxide level was markedly 
higher in the ESRD group (32±17uM) vs the controls (7±3uM). The p-selectin levels were 
elevated in the ESRD group (46±20ng/ml) vs the control (31±3ng/ml). The soluble ICAM 
levels were higher in the ESRD group (250±112ng/ml) vs the control (180±19ng/ml). 
Interestingly, the adiponectin levels were also increased in the ESRD group (19.2±9.3ug/
ml) vs the control (11.2±4.1ug/ml). Detectable levels of heparin (.05 – 0.20 U/ml) were 
measured in the ESRD group.
Conclusions: These studies suggest that MP, TF, NO, p-selectin and s-ICAM levels 
are increased in the ESRD patient. It is of interest to note that despite that a significant 
number of ESRD patients were diabetic; the AD levels were increased. These results also 
suggest that while ESRD represents a pro-inflammatory/hypercoagulable state, the repeated 
administration of heparin and other drugs may contribute to the regulation of the hemostatic 
process and inflammatory balance.
PUB709
Coronary Artery Calcification and All-Cause Mortality in RRT Patients 
with Diabetes: 5 Year Survival Analysis  Ramin Tolouian,1 Sean M. Connery,2 
Kyari Sumayin Ngamdu.2  1Internal Medicine, Eastern Virginia Medical School, 
Norfolk, VA; 2Internal Medicine, Texas Tech Univ HSC El Paso, El Paso, TX.
Background: Vascular calcification is a significant sequela of ESRD. A Coronary Artery 
Calcification (CAC) Agatston score ≥ 300 has been associated with adverse cardiovascular 
events & increased mortality. The purpose was to evaluate all-cause mortality rates in 
ESRD with diabetes.
Methods: 113 diabetic pts undergoing RRT had CAC scoring by sub-second gated 
helical CT standard Agatston scoring system, slice thickness 3mm. Patients were categorized 
into 3 groups according to CAC score: 0, 1-299, ≥ 300 (Low, Medium, High Risk). Survival 
of 3 groups was calculated using Kaplan-Meier curves for all-cause mortality for 5 year 
period after CAC. Unadjusted and risk-factor adjusted for age & length of time on dialysis 
Cox proportional hazard modeling was used to estimate time to all-cause mortality.
Results: 5 year survival was 92%, 60%, 46% for Low, Medium, High Risk CAC groups. 
Low  
(n=25)
Medium  
(n=46)
High  
(n=42)
Age, yrs 47 ±11 57 ±11* 61 ±9**
Months on Dialysis 40 ±35 23 ±20 40 ±35˗
Mean ±SD, p<0.05 *Low vs Medium, **Medium vs High, ˗Medium vs High ANOVA
There was a statistically significant difference between survival curves, Gehan-Breslow 
p = 0.031, but no difference between Medium & High Risk curves pairwise multiple 
comparison procedures Holm-Sidak method (p=0.1). Adjusting for covariates of age & 
length of time on dialysis at time of scan did not make a significant difference in survival 
curves, Age HR = 1.034 (0.99-1.07 95% CI), time on dialysis HR = 1.004 (0.99-1.01 95%).
Mortality in Medium & High groups was 40% & 50% while only 8% in low group.
Conclusions: Any level of CAC, regardless of severity, in HD pts with diabetes has a 
significant impact on survival. CAC might be usefull prediciting mortality in this population.
PUB710
Elevated Toll Like Receptor 4 Expression and Macrophage Infiltration Is 
Found in High Dose Vitamin D-Induced Non-Uremic Vascular Calcification 
Jianheng Zhou,1,2 Yuan Min Wang,1 Helen Williams,3 Anne M. Durkan,1 Geoff 
yu Zhang,1 Huiling Wu,4 Andrew Sawyer,1 Stephen I. Alexander,1 David C. 
Harris,2 Vincent W.S. Lee.2  1Centre for Kidney Research, Children’s Hospital 
at Westmead, Sydney, NSW, Australia; 2Centre for Transplantation and Renal 
Research, Univ of Sydney at Westmead Millennium Inst, Westmead, Sydney, 
NSW, Australia; 3Vascular Biology Research Centre, Surgery, Univ of Sydney, 
Westmead Hospital, Sydney, NSW, Australia; 4Transplant Research Group, Royal 
Prince Alfred Hospital, Sydney, New South Wales, Australia.
Background: Vascular calcification is strongly associated with cardiovascular 
morbidity and mortality. Several studies have suggested that monocytes/macrophages are 
involved in arterial vascular calcification, while the involvement of the TLR4 pathway in 
vascular calcification has also been proposed.
Methods: Male C57BL/6 mice aged 8 weeks were injected with a high dose of 
vitamin D (500000IU/kg/day) subcutaneously for 3 days at 0, 24 and 48 hours. All mice 
were sacrificed 3 days after the final administration of vitamin D. Kidneys were assessed 
histologically. Whole aortas were dissected. Macrophage infiltration and TLR4 expression 
was assessed by immunohistochemistry and histology and vascular calcification by Von 
Kossa staining.
Results: High dose vitamin D treatment did not induce kidney fibrosis or injury in 
C57BL/6 mice within the short time frame, as assessed by GT fibrosis score and PAS 
tubular damage score. High dose vitamin D treated mice demonstrated significantly higher 
calcium deposition in the aortic arteries (17.45% of vessel area) compared to controls (1.2% 
p<0.05). This was accompanied by a greater level of macrophage infiltration and TLR4 
expression in these arteries compared to controls.
Conclusions: Accelerated vascular calcification was induced in mice with high dose 
vitamin D treatment. These data also identify a potential role for macrophages and the 
TLR4 pathway in vascular calcification.
PUB711
Lack of Correlation of Pyrophosphate Levels with Survival and Coronary 
Artery Calcification in Hemodialysis Patients  Ramin Tolouian,1 Sean M. 
Connery.2  1Internal Medicine, Div of Nephrology, Eastern Virginia Medical 
School; 2Internal Medicine, Texas Tech Univ HSC El Paso.
Background: Vascular calcification is an important predictor of cardiovascular 
mortality in ESRD. Decreased levels of inorganic pyrophosphate (PPi) are thought to 
increase vascular calcification. The purpose of this study was to evaluate the association 
of PPi & coronary calcification scores in maintenance HD patients and all-cause mortality 
over 5 years.
Methods: 98 maintenance HD patients were studied (mean ±SD): Age (yr.) 57 ±10.7, 
HD vintage (month) 36 ±37.6. Platelet free plasma PPi was measured by radiometric, 
enzymatic method as described by Tolouian. Coronary arterial calcification score (CACS) 
was measured by sub-second gated helical computed tomography with an Imatron C-150 
XL ultra fast CT scanner using a standard protocol for vascular calcification. Patients were 
categorized into 3 groups according to their CAC score: 0, 1-300, and > 300.
Results: 
CACS 0 
(n=17)
CACS 1-299 
(n=40)
CACS ≥300 
(n=41)
PPi (μM) 1.49 ±0.37 1.60 ±0.56 1.56 ±0.46
Age (yrs) 51 ±11.0 58 ±11.3 60 ±9.0*
Months on HD 32 ±27.2 25 ±21.5 47 ±49.5 ‡
* p<0.5 Low vs High, ‡Medium vs High ANOVA, Dunnett T3
The covariate PPi had no significant effect on the hazard rate, log rank p=0.61. After 
adjusting for covariates of PPi, age, length of time on HD at time of measurement the log 
rank statistic for the survival curves is not great enough to exclude the possibility that the 
difference is due to random sampling variability; there is not a statistically significant 
difference (P = 0.614). 
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Conclusions: The difference in 5 year survival rate in dialysis patients based on the 
severity of vascular calcification is not influenced by pyrophosphate levels. This supports 
the multi-factorial nature of vascular calcification.
PUB712
Aortic Artery Calcification and Cardiac Valve Calcification Is Associated 
with Mortality in Chinese Heamodialysis Patients: A 3.5 Year Follow-Up 
Xiaonong Chen,1 Zijin Chen,1 Xiaobo Ma,1 Bei Ding,2 Huawei Ling,2 Zhongwei 
Shi,3 Nan Chen.1  1Nephrology, Ruijin Hospital Affiliated to Shanghai Jiaotong 
Univ, Shanghai, China; 2Radiology, Ruijin Hospital Affiliated to Shanghai 
Jiaotong Univ, Shanghai, China; 3Cardiology, Ruijin Hospital Affiliated to 
Shanghai Jiaotong Univ, Shanghai, China.
Background: Aim to investigate the relationship among aortic artery calcification(AAC), 
cardiac valve calcification(CVC) and mortality in maintenance haemodialysis(MHD) 
patients.
Methods: The study included 110 MHD patients. All MHD patients were treated in 
Shanghai Ruijin Hospital in July 2011. Follow-up these patients for 42 months.
Results: Totally 110 MHD patients were involved in this study. 64(58.2%) patients 
were male, and the mean age was 55.2±15.0 years old, the mean dialysis duration was 
41.7±38.1 months. 25.5% patients had cardiac valve calcification ,while 61.8% had visible 
calcification. After 42 months follow-up, 26(22.7%) patients died, including 16 cases death 
from cardiovascular events, 5 cases respiratory failure, 3 cases tumor metastasis, 1 case 
deep venous thrombosis and 1 case abandon treatment. Kaplan-Meier analysis showed that 
patients with AAC or CVC had a significant greater number of all-cause and cardiovascular 
deaths than those without. In multivariate analyses, the presence of AAC was a significant 
factor associated with all-cause mortality (HR 3.149, P=0.025) in addition to lower albumin 
level and lower 25(OH)D level. The presence of CVC was a significant factor associated 
with cardiovascular mortality (HR 3.800, P=0.029) in addition to lower albumin level and 
lower 25(OH)D level .
Conclusions: The presence of AAC and CVC were independently associated with 
mortality in MHD patients. Regular follow-up by X-ray and echocardiography could be 
useful method to stratify mortality risk in MHD patients.
Funding: Government Support - Non-U.S.
PUB713
Beneficial Effect of the Vasopressin AV1a and AV2 Receptor Blocker 
Conivaptan (C) on the Renal Alterations Resulting from Mild Heat-Induced 
Dehydration (MHID) and Rehydration with a 10% Fructose (F) Beverage 
L. Gabriela Sanchez-Lozada,1 Fernando E. García-arroyo,1 Monica Gabriela 
Blas-Marron,1 Jose Pedraza-chaverri,2 Cecilia Zazueta,3 Magdalena Cristobal,1 
Edilia Tapia.1  1Renal Physiopathology, INCICh, Mexico City, DF, Mexico; 
2Biology, UNAM, Mexico City, DF, Mexico; 3Cardiovasc BioMed, INCICh, 
Mexico City, DF, Mexico.
Background: The aims of this study were: 1.To define a possible synergistic effect 
between fructose and vasopressin during MHID, and 2. To evaluate the potential therapeutic 
benefit of C (3mg/kg BW) on this condition.
Methods: Six groups of male Wistar rats were MHID (37°C/ 1 h/day) and rehydrated 
with the selected beverage during 30 days: Water (W)+Veh, W+C, F+Veh, F+C, Stevia 
(S)+Veh and S+C. A group of normal control (NC) rats was studied as reference. After 
30 days plasma and urine parameters were evaluated, renal cortex mitochondria were 
isolated and respiratory control rate (RCR) was evaluated with malate/glutamate (M/G) 
and succinate/rotenone (S/R) substrates.
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Results: 
Group/param-
eter
POsm 
(mOsm/
kg)
PCr (mg/
dL)
PCo-
peptin 
(ng/mL)
RenalOx-
Prot (nM/
mg prot)
Urine 
NAG
RCR 
M/G
RCR 
S/R
NC 295± 4 0.7± .1 0.03± .01 5± 4 0 4.4± 0.2
3.4± 
0.2
W+V 303± 4 0.8± 0.1 24± 3 16± 3 0.51± 0.03
3.9± 
0.3
3.2± 
0.1
W+C 301± 4 0.8± 0.1 24± 2 14± 1 0.41± 0.02
3.9± 
0.2
3.4± 
0.2
F+V
317± 4
1.1± 0.1
85± 7
49± 3 1.1± 0.1 3.6± 0.3
2.5± 
0.2
F+C 308± 3°° 0.8± 0.1°°°° 85± 4 33± 3°°°°
0.72± 
0.3°°°°
3.6± 
0.3
3.4± 
.3°°°°
S+V 303± 3 0.7± 0.1 16± 2 11± 1 0.42± 0.04
4.0± 
0.3
3.1± 
0.2
S+C 304± 4 0.8± 0.1 16± 2 12± 2 0.41± 0.02
4.0± 
0.2
2.9± 
0.2
BEVERAGE **** **** *** **** **** ** **
TX * **** **** ****
INTERAC-
TION * *** **** **** ****
Oxprot= oxidized proteins; °=p<0.05 vs V; °°=p<0.01 vs V; °°°=p<0.001 vs V; °°°°=p<0.0001 vs V.
Conclusions: These data suggest a crosstalk between F and vasopressin on this 
particular condition. In addition, C treatment prevented renal and mitochondrial alterations 
induced by rehydration with F.
Funding: Pharmaceutical Company Support - Danone Nutricia Research
PUB714
Lack of Aquaretic Effects of the Kappa Opioid Agonist Nalbuphine following 
Multiple Ascending Oral Doses in Healthy Volunteers  Amale Hawi,1 Thomas 
Sciascia,2 Vandana S. Mathur.3  1Hawi Consulting, Ridgefield, CT; 2Trevi 
Therapeutics, New Haven, CT; 3Mathur Consulting, Woodside, CA.
Background: Nalbuphine is a mixed µ-antagonist and κ-agonist opioid drug that 
may suppress itch in hemodalysis patients with pruritus following oral administration of 
nalbuphine HCl extended release (ER) tablets. However, as a class, kappa opioid agonists 
have aquaretic effects in both animals and humans, which can be treatment-limiting. In 
this Phase 1 study, the potential of nalbuphine to induce aquaretic effects was explored 
in healthy subjects.
Methods: Healthy male and female subjects (n=9) were administered oral doses of 
nalbuphine escalated every 2-3 days from 30 mg QD on Day1 to 30 mg BID, 60 mg BID, 
120 mg BID, and 180 mg BID over a 2-week period. Urine output and vital signs were 
measured pre-treatment and at multiple time points on Days -1 through 14.
Results: Repeated measurements of urine volume with progressively higher nalbuphine 
doses over the 6-fold dose range showed no evidence of increased urine output related 
to dose or duration of time on nalbuphine. Urine specific gravity remained within the 
normal range (1.001-1.03) and did not decline in any subject during treatment. None of 
the subjects developed hypernatremia nor was there a trend of rising serum sodium with 
all values remaining within the normal range. There were no dose-related reductions in 
blood pressure and none of the subjects developed hypotension. The mean systolic blood 
pressure remained consistently in the 108–128 mmHg range. Likewise, heart rate remained 
normal throughout the study with no HR >73 beats per minutes.
Conclusions: There was no evidence of an aquaretic effect at nalbuphine oral doses 
up to 180 mg BID in healthy subjects, the most sensitive population in which such effects 
may be observed. 
Dose (mg) AM/PM Study Day 24-hour Urine Volume (L) Serum Na (mEq/L)
0 -1 - 139.8 (1.56)
30/0 1 2.7 (1.5) -
30/60 4 3.1 (1.6) -
60/60 6 3.0 (2.0) -
60/120 7 - 140.7 (1.41)
120/120 9 3.2 (1.6) -
180/0 13 3.4 (2.3) -
0 14 - 141.0 (1.60)
 Dosing from 30 mg QD Day1 to BID 30 mg (Day2) to 60 mg (Day4, PM) to 120 mg (Day7, PM) to 
180 mg (Day10, PM) to 180 mg QD on Day13
PUB715
Urinary Excretion Pattern of Exosomal Aquaporin-2 in Nephronophthisis 
Mice  Hiroko Sonoda, Nobuyuki Mikoda, Sayaka Oshikawa, Masahiro Ikeda. 
Veterinary Pharmacology, Univ of Miyazaki, Miyazaki, Japan.
Background: Nephronophthisis (NPHP), an inherited disorder, is the most frequent 
genetic cause of end-stage renal failure in children. So far, twenty responsible genes have 
been identified, including the NPHP3. The pcy mouse with missense mutation in Nphp3 gene 
orthologous to human NPHP3 is an animal model of NPHP. So far, renal aquaporin-2 water 
channel (AQP2) expression in pcy mice has been shown to be up-regulated, accompanied 
by both polyuria and urinary concentrating defect. Urinary exosomes, known to be released 
into urine from epithelial cells in all nephron segments, have been reported to selectively 
contain renal functional proteins, including AQP2. In this study, we examined whether the 
level of urinary exosomal AQP2 excretion was altered in pcy mice.
Methods: Urine samples were collected for 20 hrs from either pcy mice or the control 
DBA/2 mice, at 7, 16, and 21 weeks of age, respectively. Urinary exosomes were isolated 
by differential centrifugation. The levels of urinary exosomal and renal protein were 
analyzed by immunoblotting.
Results: Although urinary volume in pcy mice was not altered at 7 weeks of age, those 
were significantly increased at 16 and 21 weeks of age in comparison with age-matched 
control mice. Urine osmolality was significantly decreased in pcy mice at all ages examined 
in this study. Urinary exosomal AQP2 protein levels in pcy mice were dramatically increased 
at 16 weeks of age, whereas those at 7 and 21 weeks of age were not significantly increased. 
Similarly, a transient increase in urinary excretion of exosomal tumor susceptibility gene 
101 protein (TSG101), frequently used as an exosome marker protein, was observed in 
pcy mice at 16 weeks of age. The levels of renal AQP2 protein in pcy mice at 16 weeks of 
age or older were significantly higher than those in the control mice.
Conclusions: Urinary exosomal AQP2 protein excretion was transiently increased in 
pcy mice and this increase appeared to be related to both the number of exosomes excreted 
into the urine and its renal abundance.
PUB716
Low Osmolar Diet and Adjusted Water Intake for Vasoprssin Suppression 
in ADPKD  Osama W. Amro,1,2 Jessica K. Paulus,2 Farzad Noubary,2 Ronald D. 
Perrone.1,2  1Nephrology, Tufts Medical Center; 2Tufts Univ School of Medicine.
Background: Autosomal dominant polycystic kidney disease (ADPKD) affects 12.5 
million persons worldwide and accounts for 10% of patients with end-stage renal disease 
in the United States. Vasopressin is a known detrimental factor in disease progression and 
cyst enlargement.
Methods: This randomized controlled trial examined the effect of a novel approach of 
combining low osmolar diet and adjusted water intake on vasopressin, measured by change 
in urinary osmolality, and total daily urinary solute in 34 patients with early ADPKD. 
Participants were randomized to receive a low osmolar diet (low sodium (1500 mg/day), 
low protein (0.8 gram/kg body weight) diet) followed by adjusted water intake to achieve a 
urine osmolality of 280 mOsm/kg versus no intervention for two weeks duration, with equal 
(1:1) allocation. Permuted block randomization was performed within strata of age and sex.
Results: Baseline characteristics of the two groups were similar. Compared with 
baseline, the mean urine osmolality significantly declined from 426 (±193) to 258 (±110) 
mOsm/kg (P= 0.007) but not in the control group. At 2 weeks, levels significantly differed 
between groups (P= 0.04). 
Total urinary solute decreased only in the low osmolar diet group and significantly 
differed between groups at 2 weeks (P=0.03). The two week adherence rate to diet and 
adjusted water intake was 70% with a mean water prescription of 2.6 liters/daily.
Conclusions: We identified a novel step wise dietary intervention that led to significant 
reduction in vasopressin as measured by reduction in 24 hour urine osmolality in patients 
with early ADPKD. Furthermore, this dietary intervention led to significant reduction in 
water required for vasopressin suppression. Long-term studies are needed to evaluate diet 
and adjusted water intake adherence, and determine if the reduction in vasopressin slows 
ADPKD progression.
Funding: NIDDK Support
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PUB717
CRISPR-Cas9-Mediated Deletion of Myosin Light Chain Kinase in 
Cultured Collecting Duct Cells  Kiyoshi Isobe, Viswanathan Raghuram, 
Pablo Sandoval, Chin-Rang Yang, Chung-Lin Chou, Mark A. Knepper.  Systems 
Biology Center, NHLBI, NIH.
Background: Regulation of osmotic water transport in the renal cortical collecting duct 
by vasopressin is in part dependent on membrane trafficking of aquaporin-2 (AQP2) to the 
apical plasma membrane of the principal cells. It is known that trafficking of AQP2 is in 
part dependent on changes in AQP2 phosphorylation. We previously proposed that AQP2 
trafficking is dependent on the protein kinase Myosin Light Chain Kinase (MLCK; gene 
symbol: Mylk). Here, we test the role of MLCK in AQP2 phosphoryation and trafficking, 
utilizing CRISPR-Cas9 generated mutations in MLCK in cultured mouse mpkCCD cells.
Methods: We used CRISPR-Cas9 genome-editing to mutate the catalytic region of the 
Mylk gene. Clones were generated with 4 different guide RNAs and were characterized 
by genomic sequencing and immunoblotting. Effects of the deletions were assessed by 
immunoblotting and immunofluorescence immunocytochemistry of AQP2.
Results: Multiple clones with mutations in the catalytic domain of MLCK were 
generated. Western blots showed absence of MLCK protein in MLCK-deleted clones. 
Controls were clones that express MLCK without mutations in the catalytic domain, but 
may contain off-target modifications. AQP2 protein abundance varied over a broad range, 
among all MLCK-deleted (n=4) and control (n=4) lines, but, on average, was not affected 
by the deletion. Immunocytochemistry showed that vasopressin stimulates redistribution 
of AQP2 to the apical plasma membrane in both control cells and MLCK-deleted cells. 
Vasopressin-dependent phosphorylation of AQP2 at Ser256 and Ser269 was not significantly 
reduced in MLCK-deleted cells.
Conclusions: The results demonstrate the feasibility of CRISPR-Cas9-mediated 
genome editing in mouse mpkCCD cells. Our experiments in mouse cultured collecting 
duct cells provide evidence that vasopressin-induced phosphorylation of AQP2 and 
redistribution of AQP2 to the apical plasma membrane can occur independently of myosin 
light chain kinase.
Funding: Other NIH Support - NHLBI Intramural
PUB718
The PDZ Domain-Containing Protein Harmonin Is a Binding Partner of 
Sodium-Coupled Monocarboxylate Transporter 2  Nobuyuki Onizawa,1,2 
Naoyuki Otani,1 Promsuk Jutabha,1 Motoshi Ouchi,1 Hajime Hasegawa,2 
Naohiko Anzai.1  1Dept of Pharmacology and Toxicology, Dokkyo Medical 
Univ School of Medicine, Mibu, Tochigi, Japan; 2Dept of Nephrology and 
Hypertension, Saitama Medical Center, Saitama Medical Univ, Kawagoe, 
Saitama, Japan.
Background: Lactate is freely filtered and extensively reabsorbed in the proximal 
tubule to prevent the loss of this valuable metabolite from the body. Sodium-coupled 
monocarboxylate transporter SMCT2(SLC5A12) mediates the transport of pyruvate, 
nicotinate and lactate (Gopal et al., BBA. 2007). In contrast to its well characterized 
transport properties, less information is available on the regulatory mechanism of SMCT2. 
The C-terminal domain of SMCT2 is exposed to the cytoplasmic compartment and contains 
thePDZ motif, one of the famous protein-protein interaction modules, suggesting that it 
may interact with PDZ proteins.
Methods: We used the yeast two-hybrid screening to investigate the putative SMCT2-
associated proteins that modulate its transport function. Using the SMCT2 C-terminal tail 
(SMCT2-CT) as bait, we performed a yeast two-hybrid screen of a cDNA library constructed 
from the human adult kidney. Next, to further confirm the interaction between SMCT2 and 
harmonin, we performed a co-immunoprecipitation study using anti-harmonin antibodies.
Results: In the yeast two-hybrid screening, 34 positive clones were obtained from a 
total of 1.2 × 107 independent colonies screened. Of these, 8 yielded an identical sequence 
encoding the gene for the PDZ protein PDZK1 (manuscript in preparation), and 1 yielded 
an identical sequence encoding the gene for the PDZ protein Harmonin. Deletion of 
C-terminal PDZ motif abolished the interaction with harmonin in the yeast two-hybrid 
system.Furthermore, co-immunoprecipitation studies revealed that the SMCT2 interacted 
directly with harmonin.
Conclusions: Harmonin was identified as the binding partner for SMCT2. The 
elucidation of these interactions may further our understanding of the function and regulation 
of monocarboxylate (e.g., lactate) transport in the human kidney.
PUB719
Stimulation of V1a Receptor Increases Renal Uric Acid Clearance via 
ABCG2 Transporter – Insight into Hypouricemia in SIADH  Kei Taniguchi, 
Yoshifuru Tamura, Shigeru Shibata, Shunya Uchida.  Dept of Internal Medicine, 
Teikyo Univ School of Medicine, Itabashi, Tokyo, Japan.
Background: Hypouricemia seen in the subjects with syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH) is pathognomonic but the mechanism of 
hypouricemia remains to be clarified. V2 receptor agonist ‘desmopressin’ induced 
hyponatremia but not hypouricemia in human unlike SIADH (G Decaux, JASN, 1996). 
Therefore, we hypothesized that V1 receptor but not V2 receptor may play a role in inducing 
hypouricemia. In the present study, we examined the changes in serum uric acid, urinary 
uric acid excretionand expression of uric acid transporters in response to V1a receptor 
agonist ‘terlipressin’.
Methods: Terlipressin was subcutaneously infused by osmotic mini pump to 7-weeks-
old male Wistar rats (n = 9). Control rats were infused with normal saline (n = 9). The rats 
were sacrificed to obtain renal cortical tissues at 3 days.
Results: Serum uric acid significantly decreased and the excretion of urinary uric 
acid significantly increased in the terlipressin group. Thus, fractional excretion of uric 
acid increased from 1.20± 0.28 % to 3.10 ± 0.56 % (P < 0.001). The expression of ATP-
binding cassette transporter, sub-family G, member 2 (ABCG2) significantly increased in 
the terlipressin group. Other uric acid transportersdid not significantly change.
Conclusions: These results suggest that stimulation of V1a receptor increases renal 
uric acid clearance probably via upregulation of ABCG2, leading to hypouricemia seen 
in SIADH patients.
PUB720
Fluorescein Angiography and the Kidney: Friend or Foe? 
Mohamed E. Elraggal,1 Ahmed Fathy Elkeraie,2 Ahmed M. Abdelhadi,3 Ashraf 
Nabiel Abdalla.4  1Nephrology, Kidney and Urology Center, Alexandria, Egypt; 
2Nephrology, Alexandria Univ, Alexandria, Egypt; 3Ophthalmology, Alexandria 
Univ, Alexandria, Egypt; 4Pharmacology, Umm Al-Qura Univ, Saudi Arabia.
Background: Fluorescein angiography (FA) is an indispensable tool for diagnosis 
and management of diabetic retinopathy (DR). However, safety of fluorescein sodium 
on renal functions is not fully understood.
Methods: 100 type 2 diabetic patients presenting to the ophthalmology outpatient 
clinic at Alexandria main university hospital were included in our study. Serum 
creatinine and cystatin-C were measured just before and 2 days after FA. Urinary NGAL 
as a tubular biomarker was measured also before and 4 hours after FA. Renal injury was 
defined as 25 % increase in serum creatinine or cystatin-C.
Results: The mean of serum creatinine was 0.99 ± 0.36 mg/dl and 1.0 ± 0.36 mg/
dl before and after FA respectively with no statistically significant change (P=0.061). 
Only one patient (out of 100) experienced more than 25% rise in serum creatinine 
from baseline. Serum Cystatin-C and urinary NGAL increased significantly after 
FA (P>0.001). Mean of serum Cystatin-C was 0.89 ± 0.34mg/l and 0.95 ± 0.36 mg/l 
before and after FA respectively. 11 patients experienced more than 25% rise in serum 
cystatin-C from baseline. Mean of urinary NGAL was 21.78 ± 23.90 ng/ml and 27.15 ± 
28.17 ng/ml before and after FA respectively.
Conclusions: Using ordinary renal biomarkers as serum creatinine, FA was thought 
to be kidney friendly. Nevertheless, using more sensitive early biomarkers as serum 
cystatin-C and urinary NGAL, FA is not as innocent as previously thought. A creatinine 
negative, biomarker positive change may implicate a form of subclinical AKI.
PUB721
Transcultural Adaptation and Validation of the Mexican Version 
of the Kidney Disease Questionnaire KDQOL-SF36 Version 1.3 
Edgar Dehesa Lopez,1 Ricardo Correa-Rotter,2 David Olvera,3 Carlos Gonzalez 
Parra,4 Rafael Baizabal.5  1Dept of Nephrology, Research and Teaching Center 
in Health Sciences (CIDOCS), Culiacan, Sinaloa, Mexico; 2Dept of Nephrology, 
National Inst of Medical Sciences and Nutrition Salvador Zubiran, Mexico, 
D.F, Mexico; 3Dept of Nephrology, Hospital ISSSTE, Ciudad Valles, San Luis 
Potosí, Mexico; 4Deparment of Nephrology, Christus Murgueza UPAEP, Puebla, 
Mexico; 5Dept of Nephrology, Hospital ISSSTE, Xalapa, Veracruz, Mexico.
Background: The evaluation of health-related quality of life through the application 
of efficient, reliable and simple instruments is a relatively new concept in the practice 
of nephrology.The aim of the study was to translate the Kidney Disease Quality of Life 
Short Form 36 KDQOL-SF36 v1.3 questionnaire into the Spanish language, to adapt it 
culturally and to validate it in the Mexican population.
Methods: The translation,transcultural adaptation and validation of the Mexican 
version of KDQOL-SF36 was performed according to the recommendations of RAND 
Health. The validity was evaluated using Cronbach’s α.The test-retest reliability was 
evaluated using interobserver and intraobserver intraclass correlation coefficients 
(ICCs).
Results: The questionnaires were applied to 194 Mexican patients with end stage 
chronic kidney disease in chronic hemodialysis.The average age was 54±16 years,and 
54.6.1% were males.The Mexican version proved reliable with intra-and interobserver 
ICCs ≥ 0.7 in most of the dimensions evaluated, with a range between 0.5 and 0.9.The 
validity of the questionnaire was acceptable,with an internal items-dimensions 
consistency between 0.4 and 0.9, dimensions-total of 0.725 and items-total of 0.921.
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Conclusions: The psychometric properties evaluated in the Mexican version of 
the KDQOL-SF36 v1.3 demonstrated that it is a valid and reliable instrument,with 
psychometric results similar to the original version.
PUB722
Urinary Neutrophil Gelatinase Associated Lipocalin Beyond AKI, Relation 
to Renal and Patient Survival  Ahmed Fathy Elkeraie,1 Mohammed Megahed,2 
Ahmed Elkhodary.2  1Nephrology, Alexandria Univ, Alexandria, Egypt; 2Critical 
Care, Alexandria Univ, Alexandria, Egypt.
Background: Neutrophil gelatinase-associated lipocalin (NGAL) has been 
postulated as an early, sensitive, non-invasive biomarker for acute kidney injury (AKI). 
The aim of this study was to evaluate urinary NGAL levels as a predictor of early AKI 
(first 5 days) in severely traumatized patients associated with hemorrhagic shock.
Methods: This is a prospective observational study on 57 adult trauma patients 
presented with severe trauma (ISS ≥ 16) and hemorrhagic shock to the units of Critical 
Care Medicine Department in Alexandria Main University Hospital and Mostafa Kamel 
Armed Forces Hospital. Urinary NGAL was measured upon admission and 48 hrs after 
trauma. Presence of AKI was defined by Acute Kidney Injury Network (AKIN) criteria.
Results: Using AKIN criteria, a total of 13 patients were identified with AKI 
(incidence of 37.14%). Those who subsequently developed AKI had a striking rise 
in urinary NGAL early after trauma and a sustained increase over next 48 hrs. The 
urinary NGAL levels of the AKI group (group A) were significantly higher than non 
AKI (group B) both on admission and 48 hrs later. For cut-off point >29 ng/mL, urinary 
NGAL 48 hrs after trauma sensitivity, specificity, positive and negative predictive values 
were 84.62, 95.45, 91.67and 91.30, respectively. In the analysis of urinary NGAL (on 
admission) performance for predicting clinical outcomes; Using a cutoff value of 30 ng/
mL the area under the receiver-operating characteristic curve for in-hospital mortality 
and the need for RRT during the first week was 0.768, 0.903 respectively. Odds of in-
hospital mortality increased by 12.7% for every 30ng/ml increase in urinary NGAL on 
admission, confirming the usefulness of NGAL in predicting clinical outcomes.
Conclusions: Urinary NGAL is an early and reliable predictive marker of AKI in 
severely traumatized patients presented with hemorrhagic shock and also a predictor 
of adverse clinical outcomes. The important clinical utility of this biomarker in patient 
care, might facilitate early renal protective interventions with the hope of improvement 
in the renal and patient outcomes.
PUB723
Epidemiology and Prognosis of Community Acquired Acute Kidney Injury 
versus Hospital Acquired Acute Kidney Injury  Edgar Dehesa Lopez,1 Melissa 
Rodriguez,2 Rodolfo Radames Salas Zazueta,2 Daniel Antonio Hernandez 
Quintero,2 Hector Guillermo Peña Peredia,2 Berenice Tamayo Garcia.2  1Dept 
of Nephrology, Research and Teaching Center in Health Sciences (CIDOCS), 
Culiacan, Sinaloa, Mexico; 2Research and Teaching Center in Health Sciences 
(CIDOCS), Culiacan, Mexico.
Background: The epidemiological characteristics and prognosis of patients with 
community acquired acute kidney injury (C-AKI) vs hospital acquired acute kidney 
injury (H-AKI) have not been thoroughly studied.
Methods: A total of 192 patients admitted to internal medicine service were studied. 
AKI was diagnosed and classified at time of admission (C-AKI) or posteriorly during 
hospitalization.AKI was defined according to the Acute Kidney Injury Network (AKIN) 
and serum sCr. The etiology, severity and evolution of the AKI episodes were compared 
among patients with C-AKI and H-AKI.
Results: C-AKI incidence was 22.4% (n=43) and H-AKI was 5.7% (n=11),giving 
an overall incidence of 28.1%.AKIN 1 stage was present in 51.7%,AKIN 2 in 12.9% 
and AKIN 3 in 35.4%.Renal factors were the most frequent etiology of AKI in 55.6%, 
prerrenal in 38.9% and obstructive in 5.6%.Oliguric AKI was observed in 25.9%. 
Hemodialysis was required in 9.3% of cases.The recovered AKI was observed in 75.9% 
at the time of hospital discharge.The length of hospital stay (9±9 vs 7±6 days;p<0.05) 
and mortality (18.5 vs 7.2%; p=0.02) were greater in patients with AKI compared with 
patients without AKI.Patients with H-AKI had a longer hospital stay (15±12 vs. 8±8; 
p<0.05) and a statistical trend to higher mortality (36.4% vs 14%;p=0.08) in relation to 
patients with C-AKI.
Conclusions: AKI was a frequent diagnosis on hospital admission or during 
hospitalization.C-AKI and H-AKI added a negative effect on the prognosis.H-AKI 
episodes were more severe and were associated with a longer hospital stay and an 
statistical trend in mortality in comparison with C-AKI.
PUB724
Drug Utilization Patterns and Factors Associated with Acute Kidney Injury 
in an Intensive Care Unit at a Brazilian Public Hospital – A Prospective 
Cohort Study  Danielly Botelho Soares,1 Gabriela Rebouças Botelho,1 Flávia 
Fialho Girundi,1 Fernando Antonio Botoni,2 Maria Auxiliadora Parreiras 
Martins.1  1School of Pharmacy, Univ Federal de Minas Gerais, Belo Horizonte, 
Minas Gerais, Brazil; 2School of Medicine, Univ Federal de Minas Gerais, Belo 
Horizonte, Minas Gerais, Brazil.
Background: Acute kidney injury (AKI) is associated with a significant increase 
in morbidity, mortality and health care costs. In intensive care units (ICU), the cause of 
AKI is commonly associated with multiple factors, among which the use of potentially 
nephrotoxic drugs is often neglected as a preventable cause of AKI.
Methods: This is a prospective cohort study that evaluated the AKI as a primary 
outcome in ICU patients at a teaching hospital in Belo Horizonte, Brazil. Length of 
stay greater than 24 hours and hospital stay lower or equal to 7 days were evaluated for 
potential eligibility. To be enrolled, patients should not present kidney dysfunction at the 
time of ICU admission.
Results: Data collection was performed from October 2014 to February 2015, 
including 122 patients, mostly originated from the surgical department (46.7%). An 
average of 22.0 ± 9.4 drugs was prescribed and 2-24 potentially nephrotoxic drugs were 
used per patient. Mechanical ventilation was required for 67.2% of patients and at least 
one vasoactive drug was used in 68.0% of cases. An incidence of AKI was observed 
in23.8% of patients, among them 34.5% required dialysis, 24.1% reached the third stage 
of AKI and 31.8% were referred to additional treatment after ICU discharge. Eleven 
(9%) patients died and 63.6% of them developed AKI. The bivariate analysis showed 
that age (p = 0.006) and APACHE II score (p = 0.003) had higher median among 
patients who developed AKI compared to those who did not develop AKI. In the logistic 
regression, the number of medications (OR: 1.15; 95% CI: 1.05 to 1.26) presented a 
statistically significant correlation with the development of AKI.
Conclusions: These results demonstrate that the identification of factors associated 
with AKI in ICU patients is very important for the early identification of renal 
dysfunction induced by drugs, providing conditions for appropriate prevention and 
treatment of the extent of kidney damage.
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Clinical, Dialytic and Laboratorial Factors Associated with Poor 
Health Related Quality of Life in Mexicans Hemodialysis Patients 
Edgar Dehesa Lopez,1 David Olvera,2 Carlos Gonzalez parra,3 Rafael Baizabal.4 
1Dept of Nephrology, Research and Teaching Center in Health Sciences 
(CIDOCS), Culiacan, Sinaloa, Mexico; 2Dept of Nephrology, Hospital ISSSTE, 
Ciudad Valles, San Luis Potosi, Mexico; 3Dept of Nephrology, IMSS, Puebla, 
Mexico; 4Deparment of Nephrology, Hospital ISSSTE, Xalapa, Veracruz, Mexico.
Background: The evaluation of health related quality of life (HRQOL) in 
hemodialysis patients has recently gained great importance because it has proven to be 
an independent predictor of clinical outcomes.
Methods: Cross-sectional study. The validated Mexican version of the KDQOL-
SF36 v1.3 questionnaire were applied to 194 adult patients with ESRD on hemodialysis 
in different regions of Mexico. According to the global score of questionnaire, patients 
were grouped in: patients with poor HRQOL (global score below the median) and 
patients with good HRQOL (global score greater than the median). Logistic regression 
was used to investigate the effects of clinical, dialytic and laboratorial factors on 
HRQOL.
Results: The average age was 54+16 with 54.6.1% male. Comorbidities were: 
hypertension in 86.6%, diabetes mellitus 2 in 57.2% and dyslipidemia in 7.2%. The 
vascular access was a catheter in 55.2% and fistula in 44.8% of the cases. Diabetes 
mellitus and the use of catheters as vascular access were more frequent in patients with 
poor quality of life . On the other hand, phosphorus >5.5 mg/dl and albumin >4g/dl were 
more frequent in patients with good quality of life .There were no differences in age, 
KtV, hemoglobin and calcium between groups. Table 1 shown the clinical, dialytic and 
laboratorial factors studied in the multivariate logistic analysis. 
Conclusions: The associated factors with poor HRQOL in Mexicans hemodialysis 
patients were: the time spent in hemodialysis, serum albumin <4 g /dl and use of 
catheter for vascular access.
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SA-PO978, SA-PO984, SA-PO987, 
SA-PO990, SA-PO991, SA-PO999, 
SA-PO1001, SA-PO1002, SA-PO1003, 
SA-PO1006, SA-PO1010, SA-PO1011, 
SA-PO1012, SA-PO1013, SA-PO1014, 
SA-PO1026, SA-PO1028, SA-PO1031, 
SA-PO1047, SA-PO1048, SA-PO1050, 
SA-PO1053, SA-PO1054, SA-PO1057, 
SA-PO1059, SA-PO1060, SA-PO1063, 
SA-PO1066, SA-PO1067, SA-PO1068, 
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kidney transplantation 
 (continued) ........... SA-PO1070, SA-PO1071, 
SA-PO1072, SA-PO1074, SA-PO1075, 
SA-PO1078, SA-PO1079, SA-PO1085, 
SA-PO1086, SA-PO1087, PUB421, PUB533, 
PUB644, PUB647, PUB652, PUB655, 
PUB659, PUB663, PUB667, PUB670, 
PUB671, PUB673
kidney tubule ................ TH-OR081, TH-OR121, 
TH-PO003, TH-PO050, TH-PO262, 
TH-PO336, TH-PO442, TH-PO448, 
TH-PO691, TH-PO716, FR-OR010, 
FR-PO114, FR-PO136, FR-PO397, 
FR-PO922, SA-OR041, SA-OR110, 
SA-PO270, SA-PO281, SA-PO414, 
SA-PO1037
kidney volume................ TH-PO203, FR-PO525, 
SA-PO855, SA-PO859, SA-PO860, 
SA-PO877, SA-PO879, SA-PO880, 
SA-PO881, SA-PO883, SA-PO885, PUB262, 
PUB271
LDL cholesterol ............. TH-OR116, FR-PO564, 
PUB700
lean body mass............... TH-PO556, TH-PO676, 
FR-PO861, FR-PO882, SA-PO757, PUB492
left ventricular hypertrophy ............TH-OR111, 
TH-OR118, TH-PO388, TH-PO483, 
TH-PO484, TH-PO509, TH-PO562, 
TH-PO601, TH-PO602, TH-PO634, 
TH-PO902, TH-PO915, FR-OR042, 
FR-PO1106, SA-OR029, SA-PO707, 
PUB135
leptospirosis ........................................SA-PO284
life-threatening dialysis 
 complications ........... TH-PO958, SA-PO180, 
PUB598, PUB638
lipids ............................... TH-PO246, TH-PO308, 
TH-PO359, TH-PO368, TH-PO395, 
TH-PO404, TH-PO416, TH-PO465, 
TH-PO564, TH-PO587, TH-PO896, 
TH-PO898, TH-PO933, TH-PO1114, 
FR-OR083, FR-PO167, FR-PO326, 
FR-PO805, FR-PO863, FR-PO896, 
FR-PO1102, SA-OR054, SA-PO260, 
SA-PO329, SA-PO347, SA-PO376, 
SA-PO396, SA-PO725, SA-PO994, PUB177, 
PUB274, PUB291, PUB310, PUB333, 
PUB342, PUB567
liver cysts ..... FR-PO307, SA-PO864, SA-PO868, 
SA-PO869, SA-PO873, SA-PO877, 
SA-PO888, PUB260, PUB270
liver failure ..................... TH-PO010, TH-PO048, 
TH-PO105, TH-PO1106, FR-PO046, 
FR-PO499, FR-PO521, FR-PO583, 
SA-PO058, SA-PO061, SA-PO109, 
SA-PO117, SA-PO118, SA-PO192, 
SA-PO1053, SA-PO1054, SA-PO1056, 
PUB040
lupus nephritis .............. TH-OR021, TH-OR022, 
TH-OR072, TH-PO148, TH-PO288, 
TH-PO687, TH-PO688, TH-PO689, 
TH-PO694, TH-PO697, TH-PO706, 
TH-PO709, TH-PO713, TH-PO717, 
TH-PO721, TH-PO758, TH-PO759, 
TH-PO760, TH-PO761, TH-PO762, 
TH-PO763, TH-PO764, TH-PO765, 
TH-PO766, TH-PO769, TH-PO772, 
TH-PO775, TH-PO777, TH-PO778, 
TH-PO779, TH-PO1070, TH-PO1110, 
lupus nephritis (continued) ............TH-PO1124, 
FR-OR058, FR-OR059, FR-PO216, 
FR-PO514, FR-PO703, FR-PO985, 
FR-PO991, SA-PO038, SA-PO073, 
SA-PO167, SA-PO430, SA-PO556, 
SA-PO1004, PUB220, PUB223, PUB231, 
PUB233, PUB237, PUB244, PUB259, 
PUB410, PUB660
lymphocytes .................. TH-OR069, TH-OR070, 
TH-PO012, TH-PO014, TH-PO027, 
TH-PO157, TH-PO271, TH-PO749, 
TH-PO1017, TH-PO1036, TH-PO1075, 
FR-OR075, FR-PO678, FR-PO841, 
FR-PO843, FR-PO982, FR-PO983, 
FR-PO998, SA-PO439, SA-PO969, 
SA-PO1069, PUB069, PUB623, PUB641, 
PUB685, PUB695
macrophages ................. TH-OR031, TH-OR065, 
TH-OR067, TH-PO024, TH-PO041, 
TH-PO129, TH-PO142, TH-PO144, 
TH-PO156, TH-PO162, TH-PO206, 
TH-PO219, TH-PO288, TH-PO381, 
TH-PO391, TH-PO395, TH-PO403, 
TH-PO407, TH-PO485, TH-PO727, 
FR-OR082, FR-OR104, FR-PO146, 
FR-PO147, FR-PO256, FR-PO307, 
FR-PO877, FR-PO884, FR-PO896, 
FR-PO952, FR-PO956, FR-PO992, 
SA-OR091, SA-PO280, SA-PO395, 
SA-PO438, SA-PO440, SA-PO441, 
SA-PO489, SA-PO490, PUB097
malfolding proteins ........................... TH-OR086
malnutrition ................... TH-PO476, TH-PO836, 
TH-PO886, TH-PO952, TH-PO964, 
FR-PO788, FR-PO856, FR-PO857, 
FR-PO868, FR-PO869, FR-PO870, 
FR-PO885, FR-PO888, FR-PO892, 
FR-PO897, SA-OR089, SA-PO588, 
SA-PO757, SA-PO909, PUB362, PUB492, 
PUB557
MCP-1 (monocyte chemoattractant 
 protein 1) .................. TH-PO160, TH-PO280, 
FR-PO448, SA-OR091, SA-PO395, 
SA-PO690, SA-PO851, PUB294
MDCK (Madin-Darby canine 
 kidney) ...........................................TH-PO313
MPGN (membranoproliferative 
 glomerulonephritis) .....................TH-PO226, 
TH-PO1083, TH-PO1085, TH-PO1087, 
TH-PO1113, FR-PO006, FR-PO014, 
FR-PO452, FR-PO454, FR-PO956, 
SA-PO019, SA-PO042, SA-PO064, 
SA-PO109, SA-PO123, PUB226
membranous nephropathy ...............TH-PO690, 
TH-PO704, TH-PO710, TH-PO714, 
TH-PO720, TH-PO722, TH-PO741, 
TH-PO743, TH-PO744, TH-PO745, 
TH-PO747, TH-PO748, TH-PO749, 
TH-PO751, TH-PO752, TH-PO753, 
TH-PO754, TH-PO755, TH-PO756, 
TH-PO757, TH-PO759, TH-PO761, 
TH-PO1044, TH-PO1052, TH-PO1054, 
TH-PO1070, FR-OR062, FR-OR063, 
FR-PO010, FR-PO344, FR-PO354, 
FR-PO387, FR-PO423, FR-PO511, 
FR-PO966, FR-PO967, FR-PO968, 
SA-OR011, SA-OR012, SA-OR014, 
SA-OR015, SA-OR025, SA-PO004, 
SA-PO006, SA-PO032, SA-PO034, 
SA-PO081, SA-PO085, SA-PO104, 
membranous nephropathy 
 (continued) ............... SA-PO426, SA-PO502, 
SA-PO965, SA-PO1085, PUB155, PUB202, 
PUB206, PUB215, PUB245, PUB247, 
PUB250, PUB418
mesangial cells ............... TH-PO297, TH-PO368, 
FR-OR084, FR-PO974, FR-PO975, 
SA-OR048, SA-PO309, SA-PO327, 
SA-PO343, SA-PO357, SA-PO368, 
SA-PO410, PUB102
metabolism ..................... TH-PO009, TH-PO041, 
TH-PO185, TH-PO203, TH-PO272, 
TH-PO409, TH-PO430, TH-PO499, 
TH-PO559, TH-PO597, TH-PO702, 
FR-PO181, FR-PO285, FR-PO301, 
FR-PO384, FR-PO531, FR-PO537, 
FR-PO543, FR-PO597, FR-PO847, 
FR-PO864, FR-PO879, FR-PO880, 
FR-PO891, FR-PO1103, SA-OR040, 
SA-OR090, SA-OR096, SA-PO185, 
SA-PO281, SA-PO337, SA-PO383, 
SA-PO386, SA-PO408, SA-PO417, 
SA-PO446, SA-PO573, SA-PO893, 
SA-PO993, PUB105, PUB147, PUB292, 
PUB335, PUB516, PUB658, PUB704
microalbuminuria .........TH-OR007, TH-PO463, 
TH-PO464, TH-PO577, FR-PO608, 
FR-PO618, FR-PO630, FR-PO636, 
FR-PO648, SA-PO363, SA-PO645
mineral metabolism ......................... TH-OR083, 
TH-OR106, TH-OR113, TH-OR124, 
TH-PO487, TH-PO491, TH-PO494, 
TH-PO495, TH-PO496, TH-PO500, 
TH-PO501, TH-PO503, TH-PO561, 
TH-PO596, TH-PO600, TH-PO616, 
TH-PO640, TH-PO828, TH-PO930, 
TH-PO939, TH-PO1000, TH-PO1019, 
TH-PO1057, FR-OR023, FR-OR024, 
FR-OR025, FR-PO068, FR-PO592, 
FR-PO798, FR-PO867, FR-PO900, 
FR-PO903, FR-PO913, FR-PO914, 
FR-PO927, FR-PO928, FR-PO931, 
FR-PO932, FR-PO934, FR-PO935, 
FR-PO937, FR-PO1031, FR-PO1039, 
SA-PO227, SA-PO558, SA-PO559, 
SA-PO560, SA-PO566, SA-PO568, 
SA-PO570, SA-PO573, SA-PO578, 
SA-PO580, SA-PO584, SA-PO585, 
SA-PO605, SA-PO614, SA-PO712, PUB002, 
PUB111, PUB298, PUB299, PUB338, 
PUB375, PUB409, PUB417, PUB511, 
PUB513, PUB514, PUB518, PUB535, 
PUB537, PUB540, PUB546, PUB582, 
PUB585, PUB586, PUB590
mitochondria ................ TH-OR051, TH-OR100, 
TH-PO006, TH-PO010, TH-PO261, 
TH-PO292, TH-PO336, TH-PO340, 
TH-PO702, FR-OR083, FR-PO038, 
FR-PO110, FR-PO151, FR-PO177, 
FR-PO237, FR-PO238, FR-PO240, 
FR-PO241, FR-PO301, FR-PO616, 
FR-PO830, FR-PO840, FR-PO891, 
FR-PO893, SA-OR002, SA-PO002, 
SA-PO267, SA-PO337, SA-PO341, 
SA-PO342, SA-PO375, SA-PO405, 
SA-PO442, SA-PO481, SA-PO658, 
SA-PO750, PUB105, PUB107, PUB469, 
PUB705
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molecular biology .......... TH-PO279, TH-PO401, 
TH-PO475, TH-PO683, FR-PO211, 
FR-PO309, FR-PO387, FR-PO530, 
FR-PO824, FR-PO951, SA-OR117, 
SA-PO261, SA-PO318, SA-PO366, 
SA-PO440, SA-PO449, SA-PO539, PUB013, 
PUB391
molecular genetics ......... TH-PO204, TH-PO216, 
TH-PO350, FR-OR092, FR-PO156, 
FR-PO161, FR-PO190, FR-PO191, 
FR-PO193, FR-PO399, SA-PO493, 
SA-PO847, PUB281
mortality .....TH-OR121, TH-PO053, TH-PO069, 
TH-PO084, TH-PO414, TH-PO494, 
TH-PO587, TH-PO613, TH-PO629, 
TH-PO672, TH-PO799, TH-PO800, 
TH-PO803, TH-PO834, TH-PO894, 
TH-PO912, TH-PO918, TH-PO925, 
TH-PO939, TH-PO947, TH-PO953, 
TH-PO957, TH-PO982, TH-PO1008, 
TH-PO1014, TH-PO1049, FR-OR014, 
FR-OR037, FR-PO265, FR-PO457, 
FR-PO459, FR-PO468, FR-PO476, 
FR-PO534, FR-PO575, FR-PO578, 
FR-PO640, FR-PO675, FR-PO708, 
FR-PO731, FR-PO734, FR-PO737, 
FR-PO748, FR-PO749, FR-PO757, 
FR-PO759, FR-PO782, FR-PO792, 
FR-PO794, FR-PO845, FR-PO855, 
FR-PO875, FR-PO900, FR-PO1000, 
FR-PO1009, FR-PO1033, FR-PO1053, 
FR-PO1097, FR-PO1098, SA-OR035, 
SA-PO234, SA-PO596, SA-PO614, 
SA-PO677, SA-PO768, SA-PO771, 
SA-PO774, SA-PO775, SA-PO779, 
SA-PO783, SA-PO790, SA-PO796, 
SA-PO829, SA-PO835, SA-PO875, 
SA-PO902, SA-PO907, SA-PO918, 
SA-PO922, SA-PO1056, PUB038, PUB043, 
PUB138, PUB164, PUB182, PUB224, 
PUB321, PUB330, PUB336, PUB349, 
PUB356, PUB373, PUB461, PUB560, 
PUB680, PUB683
mortality risk .................TH-OR008, TH-PO058, 
TH-PO456, TH-PO549, TH-PO558, 
TH-PO586, TH-PO592, TH-PO598, 
TH-PO631, TH-PO809, TH-PO920, 
TH-PO926, TH-PO928, TH-PO935, 
TH-PO936, TH-PO941, TH-PO980, 
TH-PO999, TH-PO1025, FR-OR033, 
FR-OR036, FR-OR041, FR-PO016, 
FR-PO392, FR-PO480, FR-PO489, 
FR-PO573, FR-PO577, FR-PO637, 
FR-PO650, FR-PO674, FR-PO681, 
FR-PO690, FR-PO728, FR-PO730, 
FR-PO761, FR-PO763, FR-PO781, 
FR-PO839, FR-PO874, FR-PO899, 
FR-PO933, FR-PO1007, FR-PO1008, 
FR-PO1035, FR-PO1055, FR-PO1057, 
SA-OR009, SA-OR010, SA-PO195, 
SA-PO214, SA-PO215, SA-PO233, 
SA-PO616, SA-PO619, SA-PO648, 
SA-PO706, SA-PO755, SA-PO761, 
SA-PO769, SA-PO800, SA-PO911, 
SA-PO1083, PUB055, PUB057, PUB059, 
PUB132, PUB296, PUB329, PUB346, 
PUB362, PUB381, PUB566, PUB570, 
PUB604, PUB631, PUB684, PUB711
mRNA ............................. TH-PO197, TH-PO374, 
FR-OR090, FR-PO094, FR-PO205, 
FR-PO519, SA-PO449
multiple myeloma ...... TH-PO1072, TH-PO1079, 
TH-PO1101, FR-PO496, SA-PO049, 
SA-PO051, SA-PO088, SA-PO115, PUB217, 
PUB311, PUB440
mycophenolate mofetil ..................... TH-OR022, 
TH-PO774, FR-PO450, PUB211, PUB239
myeloma ......................... TH-PO076, TH-PO668, 
TH-PO1091, SA-PO029
sodium (Na) transport ..................... TH-OR077, 
TH-OR078, TH-OR079, TH-OR114, 
TH-PO424, TH-PO425, TH-PO429, 
TH-PO437, TH-PO438, TH-PO440, 
TH-PO445, TH-PO447, TH-PO655, 
TH-PO832, FR-OR009, FR-PO120, 
FR-PO139, FR-PO140, FR-PO923, 
SA-OR031, SA-OR069, SA-OR118, 
SA-PO380, SA-PO382, SA-PO466, 
SA-PO500, SA-PO547, SA-PO549, 
SA-PO629, SA-PO691, SA-PO919, 
PUB535, PUB718
NADPH oxidase ............. TH-PO339, FR-PO815, 
SA-PO306, SA-PO374, SA-PO405, PUB010, 
PUB702
nephrectomy .................. TH-PO030, TH-PO055, 
FR-PO201, FR-PO1095, SA-OR042, 
SA-PO422, SA-PO455, SA-PO651, 
SA-PO890, SA-PO1024, PUB003, PUB449
nephrin ........................... TH-PO141, TH-PO328, 
FR-OR086, FR-PO324, FR-PO345, 
FR-PO423, SA-PO324, PUB099
nephritis ....................... TH-PO152, TH-PO1040, 
TH-PO1071, TH-PO1102, FR-PO343, 
FR-PO456, SA-PO019, SA-PO045, PUB204
nephrology ..................... TH-PO574, TH-PO642, 
TH-PO724, FR-OR031, SA-PO133, 
SA-PO135, SA-PO136, SA-PO137, 
SA-PO138, SA-PO139, SA-PO149, 
SA-PO150, SA-PO155, SA-PO174, 
SA-PO649, SA-PO714, SA-PO753, 
SA-PO781, PUB383, PUB384, PUB387, 
PUB625
nephron ..........................TH-OR045, TH-PO705, 
FR-OR007, FR-OR089, FR-OR092, 
FR-PO182, FR-PO190, FR-PO191, 
FR-PO192, SA-PO026, SA-PO447, PUB280
nephropathy ................... TH-PO172, TH-PO268, 
TH-PO269, TH-PO1104, FR-PO085, 
FR-PO602, SA-PO062, SA-PO080, 
SA-PO299, PUB020, PUB230, PUB406, 
PUB653
nephrotic syndrome ...... TH-PO301, TH-PO431, 
TH-PO466, TH-PO472, TH-PO662, 
TH-PO708, TH-PO720, TH-PO723, 
TH-PO742, TH-PO753, TH-PO780, 
TH-PO787, TH-PO796, TH-PO1029, 
TH-PO1034, TH-PO1036, TH-PO1043, 
TH-PO1074, TH-PO1083, TH-PO1084, 
TH-PO1113, TH-PO1123, FR-OR050, 
FR-OR052, FR-OR062, FR-PO008, 
FR-PO021, FR-PO059, FR-PO064, 
FR-PO125, FR-PO150, FR-PO151, 
FR-PO152, FR-PO154, FR-PO155, 
FR-PO156, FR-PO157, FR-PO159, 
FR-PO420, FR-PO423, FR-PO427, 
FR-PO428, FR-PO429, FR-PO432, 
FR-PO434, FR-PO435, FR-PO439, 
FR-PO441, FR-PO443, FR-PO451, 
FR-PO511, FR-PO514, FR-PO555, 
FR-PO588, SA-OR011, SA-OR015, 
SA-OR016, SA-OR019, SA-OR050, 
nephrotic syndrome (continued) ......SA-PO003, 
SA-PO008, SA-PO017, SA-PO018, 
SA-PO032, SA-PO050, SA-PO056, 
SA-PO070, SA-PO078, SA-PO105, 
SA-PO108, SA-PO115, SA-PO116, 
SA-PO121, SA-PO502, PUB040, PUB070, 
PUB078, PUB099, PUB109, PUB203, 
PUB206, PUB210, PUB212, PUB215, 
PUB219, PUB239, PUB240, PUB395, 
PUB401, PUB404, PUB414, PUB415, 
PUB416, PUB553
nephrotoxicity ................ TH-PO009, TH-PO054, 
TH-PO083, TH-PO088, TH-PO090, 
TH-PO094, TH-PO096, TH-PO151, 
TH-PO673, TH-PO1053, TH-PO1098, 
FR-PO038, FR-PO042, FR-PO204, 
FR-PO425, FR-PO481, FR-PO485, 
FR-PO500, SA-PO044, SA-PO186, 
SA-PO229, SA-PO275, SA-PO294, 
SA-PO446, SA-PO895, PUB007, PUB035, 
PUB063, PUB153, PUB158, PUB462, 
PUB642, PUB720, PUB724
nitric oxide ..................... TH-PO323, TH-PO337, 
FR-OR043, SA-PO247, SA-PO451, 
SA-PO546, SA-PO892, PUB007
nocturnal hypoxemia .... TH-PO976, FR-PO771, 
FR-PO772
nutrition .........................TH-OR014, TH-PO080, 
TH-PO086, TH-PO112, TH-PO200, 
TH-PO501, TH-PO525, TH-PO555, 
TH-PO619, TH-PO801, TH-PO887, 
TH-PO930, TH-PO941, FR-OR109, 
FR-OR111, FR-PO123, FR-PO198, 
FR-PO199, FR-PO535, FR-PO590, 
FR-PO596, FR-PO651, FR-PO676, 
FR-PO758, FR-PO760, FR-PO787, 
FR-PO844, FR-PO846, FR-PO851, 
FR-PO852, FR-PO862, FR-PO865, 
FR-PO867, FR-PO874, FR-PO877, 
FR-PO882, FR-PO883, FR-PO886, 
FR-PO888, FR-PO890, FR-PO892, 
FR-PO894, FR-PO897, FR-PO898, 
FR-PO904, FR-PO906, FR-PO941, 
FR-PO948, FR-PO1030, FR-PO1107, 
SA-OR077, SA-OR089, SA-OR092, 
SA-OR093, SA-OR096, SA-OR104, 
SA-PO122, SA-PO411, SA-PO646, 
SA-PO711, SA-PO715, SA-PO735, 
SA-PO864, PUB104, PUB142, PUB180, 
PUB307, PUB350, PUB365, PUB372, 
PUB558, PUB559, PUB560, PUB562, 
PUB563, PUB564, PUB565, PUB566, 
PUB697
obesity............................ TH-OR014, TH-OR058, 
TH-PO317, TH-PO359, TH-PO452, 
TH-PO454, TH-PO593, TH-PO853, 
TH-PO1008, FR-OR112, FR-OR113, 
FR-PO625, FR-PO638, FR-PO639, 
FR-PO640, FR-PO641, FR-PO732, 
FR-PO845, FR-PO849, FR-PO850, 
FR-PO853, FR-PO861, FR-PO876, 
FR-PO884, FR-PO1015, FR-PO1047, 
SA-OR094, SA-PO226, SA-PO362, 
SA-PO376, SA-PO392, SA-PO401, 
SA-PO408, SA-PO411, SA-PO414, 
SA-PO418, SA-PO611, SA-PO643, 
SA-PO666, SA-PO1021, PUB287, PUB304, 
PUB573, PUB697
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obstructive nephropathy.................. TH-OR067, 
TH-PO078, TH-PO285, TH-PO474, 
TH-PO1060, TH-PO1067, FR-OR090, 
FR-PO037, FR-PO052, FR-PO294, 
FR-PO295, FR-PO306, SA-OR082, 
SA-PO435, SA-PO475, SA-PO478, 
PUB058, PUB421
obstructive uropathy .......TH-PO1068, PUB526, 
PUB572
organ transplant .............FR-PO492, FR-PO929, 
FR-PO1041, SA-PO020, SA-PO1032
organic anion transporter ................ FR-PO110, 
SA-PO432
osmolality ..................... TH-PO422, TH-PO1049, 
TH-PO1056, TH-PO1066, FR-OR003, 
FR-PO096, SA-PO934, PUB439, 
PUB442, PUB716
osteopontin ...................... TH-PO144, SA-PO588
outcomes ........................ TH-OR028, TH-OR037, 
TH-PO082, TH-PO107, TH-PO466, 
TH-PO590, TH-PO592, TH-PO681, 
TH-PO710, TH-PO725, TH-PO758, 
TH-PO769, TH-PO773, TH-PO777, 
TH-PO778, TH-PO779, TH-PO792, 
TH-PO861, TH-PO915, TH-PO921, 
TH-PO931, TH-PO943, TH-PO945, 
TH-PO951, TH-PO960, TH-PO962, 
TH-PO973, TH-PO981, TH-PO989, 
TH-PO1006, TH-PO1009, FR-OR070, 
FR-OR071, FR-PO166, FR-PO429, 
FR-PO470, FR-PO476, FR-PO477, 
FR-PO480, FR-PO487, FR-PO495, 
FR-PO512, FR-PO516, FR-PO548, 
FR-PO594, FR-PO598, FR-PO601, 
FR-PO609, FR-PO681, FR-PO686, 
FR-PO695, FR-PO706, FR-PO733, 
FR-PO735, FR-PO752, FR-PO769, 
FR-PO775, FR-PO777, FR-PO799, 
FR-PO802, FR-PO832, FR-PO857, 
FR-PO871, FR-PO1033, FR-PO1038, 
SA-OR003, SA-OR028, SA-OR056, 
SA-PO132, SA-PO139, SA-PO148, 
SA-PO153, SA-PO162, SA-PO201, 
SA-PO205, SA-PO212, SA-PO218, 
SA-PO231, SA-PO233, SA-PO234, 
SA-PO235, SA-PO560, SA-PO578, 
SA-PO615, SA-PO710, SA-PO716, 
SA-PO763, SA-PO810, SA-PO845, 
SA-PO868, SA-PO949, SA-PO1013, 
SA-PO1018, SA-PO1020, SA-PO1029, 
SA-PO1030, SA-PO1075, SA-PO1078, 
PUB027, PUB113, PUB114, PUB148, 
PUB249, PUB340, PUB343, PUB348, 
PUB363, PUB366, PUB368, PUB376, 
PUB509, PUB592, PUB596, PUB619, 
PUB659, PUB668, PUB690
oxidative stress.............. TH-OR061, TH-OR088, 
TH-PO026, TH-PO037, TH-PO042, 
TH-PO235, TH-PO268, TH-PO269, 
TH-PO281, TH-PO282, TH-PO283, 
TH-PO287, TH-PO300, TH-PO306, 
TH-PO337, TH-PO341, TH-PO343, 
TH-PO390, TH-PO396, TH-PO447, 
TH-PO459, TH-PO473, FR-PO271, 
FR-PO309, FR-PO354, FR-PO536, 
FR-PO554, FR-PO665, FR-PO806, 
FR-PO816, FR-PO827, FR-PO840, 
FR-PO872, SA-OR098, SA-PO209, 
SA-PO236, SA-PO238, SA-PO245, 
SA-PO246, SA-PO294, SA-PO345, 
oxidative stress (continued) ..............SA-PO375, 
SA-PO381, SA-PO394, SA-PO411, 
SA-PO412, SA-PO586, SA-PO749, 
SA-PO815, PUB100, PUB103, PUB104, 
PUB106, PUB107, PUB117, PUB174, 
PUB275, PUB308, PUB713
p38 mitogen-activated protein 
 kinase ......................... TH-PO345, FR-PO254
pancreas transplantation ................... FR-PO056
parathyroid hormone .... TH-PO487, TH-PO510, 
TH-PO511, TH-PO514, TH-PO520, 
TH-PO522, TH-PO820, TH-PO1037, 
FR-PO054, FR-PO901, FR-PO916, 
FR-PO918, FR-PO1108, SA-PO399, 
SA-PO566, SA-PO571, SA-PO573, 
SA-PO580, SA-PO581, PUB453, PUB518, 
PUB519, PUB521, PUB530, PUB532
pathology ....................... TH-OR058, TH-OR090, 
TH-PO471, TH-PO533, TH-PO682, 
TH-PO687, TH-PO700, TH-PO708, 
TH-PO721, TH-PO734, TH-PO791, 
TH-PO1026, TH-PO1073, TH-PO1110, 
TH-PO1125, FR-PO131, FR-PO376, 
FR-PO442, FR-PO618, FR-PO619, 
FR-PO625, SA-PO004, SA-PO029, 
SA-PO154, SA-PO157, SA-PO445, 
SA-PO980, SA-PO1065, PUB078, PUB082, 
PUB155, PUB178, PUB246, PUB252
pathophysiology of renal disease and 
 progression .............. TH-OR003, TH-OR068, 
TH-PO146, TH-PO149, TH-PO166, 
TH-PO231, TH-PO267, TH-PO333, 
TH-PO501, TH-PO538, TH-PO578, 
TH-PO581, TH-PO692, TH-PO693, 
TH-PO756, TH-PO763, FR-OR086, 
FR-PO162, FR-PO260, FR-PO308, 
FR-PO358, FR-PO389, FR-PO389, 
FR-PO448, FR-PO545, FR-PO642, 
FR-PO988, SA-PO077, SA-PO262, 
SA-PO368, SA-PO421, SA-PO438, 
SA-PO443, SA-PO448, SA-PO467, 
SA-PO626, SA-PO965, PUB254, PUB257, 
PUB277, PUB305, PUB391, PUB416, 
PUB418, PUB503, PUB701
patient satisfaction ........ TH-PO990, TH-PO996, 
TH-PO1024, SA-PO153, SA-PO158, 
SA-PO160, SA-PO177, SA-PO178, 
SA-PO748, SA-PO832, SA-PO837, 
SA-PO1001, SA-PO1046, PUB115, 
PUB165, PUB168, PUB383, PUB635
patient self-assessment ......................TH-PO468, 
TH-PO924, TH-PO929, TH-PO996, 
FR-PO498, FR-PO774, FR-PO785, 
FR-PO1034, SA-PO161, SA-PO675, 
SA-PO720, SA-PO724, SA-PO728, 
SA-PO731, SA-PO746, SA-PO1003, 
SA-PO1023, PUB144, PUB163, PUB165
pediatric intensive care medicine.....TH-PO099, 
TH-PO983, SA-PO194
pediatric kidney transplantation .....TH-PO456, 
FR-PO005, FR-PO092, FR-PO1005, 
FR-PO1063, FR-PO1085, FR-PO1106, 
SA-PO963, SA-PO1017, SA-PO1019, 
SA-PO1023, SA-PO1027, SA-PO1036, 
PUB690
pediatric nephrology .... TH-OR042, TH-OR056, 
TH-PO099, TH-PO121, TH-PO385, 
TH-PO457, TH-PO458, TH-PO465, 
TH-PO466, TH-PO472, TH-PO477, 
TH-PO496, TH-PO554, TH-PO632, 
TH-PO651, TH-PO728, TH-PO776, 
TH-PO849, TH-PO909, TH-PO962, 
TH-PO992, TH-PO1073, FR-OR097, 
FR-PO002, FR-PO005, FR-PO151, 
FR-PO173, FR-PO369, FR-PO431, 
FR-PO432, FR-PO455, FR-PO478, 
FR-PO487, FR-PO579, FR-PO593, 
FR-PO628, FR-PO839, FR-PO938, 
FR-PO939, SA-OR023, SA-OR024, 
SA-OR025, SA-OR027, SA-OR072, 
SA-PO131, SA-PO167, SA-PO221, 
SA-PO520, SA-PO521, SA-PO524, 
SA-PO540, SA-PO558, SA-PO644, 
SA-PO666, SA-PO733, SA-PO886, 
SA-PO887, SA-PO891, SA-PO903, 
SA-PO963, SA-PO1023, PUB160, PUB318, 
PUB466, PUB575, PUB580
pediatrics ........................ TH-PO054, TH-PO074, 
TH-PO099, TH-PO454, TH-PO464, 
TH-PO468, TH-PO473, TH-PO1021, 
FR-OR035, FR-PO368, FR-PO369, 
FR-PO986, SA-OR023, SA-OR100, 
SA-PO557, SA-PO974, SA-PO1031, 
PUB210, PUB458, PUB579
peritoneal dialysis..............................TH-PO118, 
TH-PO121, TH-PO312, TH-PO495, 
TH-PO625, TH-PO678, TH-PO858, 
TH-PO962, TH-PO984, TH-PO985, 
TH-PO987, TH-PO988, TH-PO989, 
TH-PO991, TH-PO992, TH-PO993, 
TH-PO994, TH-PO997, TH-PO998, 
TH-PO999, TH-PO1001, TH-PO1003, 
TH-PO1004, TH-PO1005, TH-PO1006, 
TH-PO1007, TH-PO1008, TH-PO1011, 
TH-PO1013, TH-PO1014, TH-PO1015, 
TH-PO1018, TH-PO1019, TH-PO1020, 
TH-PO1021, TH-PO1022, TH-PO1023, 
TH-PO1025, TH-PO1042, FR-OR033, 
FR-OR034, FR-OR039, FR-OR040, 
FR-PO060, FR-PO075, FR-PO090, 
FR-PO751, FR-PO755, FR-PO761, 
FR-PO789, FR-PO790, FR-PO792, 
FR-PO809, FR-PO811, FR-PO812, 
FR-PO816, FR-PO817, FR-PO818, 
FR-PO820, FR-PO821, FR-PO822, 
FR-PO823, FR-PO825, FR-PO826, 
FR-PO829, FR-PO830, FR-PO832, 
FR-PO833, FR-PO834, FR-PO835, 
FR-PO836, FR-PO837, FR-PO839, 
SA-PO021, SA-PO060, SA-PO099, 
SA-PO102, SA-PO112, SA-PO129, 
SA-PO143, SA-PO161, SA-PO477, 
SA-PO738, SA-PO829, SA-PO836, 
SA-PO846, SA-PO906, PUB103, PUB106, 
PUB116, PUB117, PUB135, PUB350, 
PUB358, PUB397, PUB430, PUB583, 
PUB584, PUB588, PUB589, PUB591, 
PUB593, PUB594, PUB595, PUB596, 
PUB597, PUB598, PUB599, PUB600, 
PUB605, PUB606, PUB607, PUB611, 
PUB612, PUB614
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peritoneal membrane ......................TH-PO1001, 
TH-PO1002, TH-PO1010, TH-PO1015, 
TH-PO1020, FR-OR039, FR-PO808, 
FR-PO810, FR-PO811, FR-PO812, 
FR-PO813, FR-PO814, FR-PO819, 
FR-PO820, FR-PO821, FR-PO823, 
FR-PO824, FR-PO827, FR-PO831, 
FR-PO833, SA-PO060, SA-PO112, PUB107, 
PUB397, PUB603, PUB605, PUB611, 
PUB613
pharmacokinetics .......... TH-PO090, TH-PO125, 
TH-PO1023, FR-PO066, FR-PO378, 
FR-PO396, SA-OR039, SA-PO529, 
SA-PO530, SA-PO531, SA-PO532, 
SA-PO533, SA-PO537, SA-PO541, 
SA-PO542, SA-PO543, SA-PO544, 
SA-PO545, SA-PO552, SA-PO553, 
SA-PO556, PUB615
phosphate binders ......... TH-PO498, TH-PO642, 
TH-PO643, TH-PO828, TH-PO937, 
TH-PO1000, FR-OR015, FR-PO061, 
FR-PO895, FR-PO905, FR-PO907, 
FR-PO908, FR-PO909, FR-PO910, 
FR-PO911, FR-PO912, FR-PO913, 
FR-PO914, FR-PO915, SA-PO172, 
SA-PO174, SA-PO813, PUB322, PUB368, 
PUB375, PUB511, PUB520, PUB524, 
PUB544, PUB585, PUB586, PUB590
phosphate uptake ......... TH-OR106, TH-OR114, 
TH-PO504, TH-PO560, TH-PO623, 
TH-PO640, TH-PO655, TH-PO1057, 
FR-PO906, FR-PO916, FR-PO917, 
FR-PO935, FR-PO936, SA-OR088, 
SA-PO547, SA-PO581, PUB128, PUB512, 
PUB516
platelets .......................... TH-PO224, TH-PO811, 
FR-PO053, FR-PO080, FR-PO083, 
FR-PO803, SA-PO224
podocyte ........................ TH-OR003, TH-OR021, 
TH-OR086, TH-OR087, TH-OR092, 
TH-OR094, TH-PO168, TH-PO225, 
TH-PO226, TH-PO228, TH-PO229, 
TH-PO230, TH-PO232, TH-PO233, 
TH-PO234, TH-PO236, TH-PO238, 
TH-PO239, TH-PO240, TH-PO248, 
TH-PO249, TH-PO251, TH-PO290, 
TH-PO299, TH-PO300, TH-PO301, 
TH-PO303, TH-PO304, TH-PO305, 
TH-PO306, TH-PO307, TH-PO308, 
TH-PO309, TH-PO324, TH-PO325, 
TH-PO326, TH-PO327, TH-PO328, 
TH-PO329, TH-PO330, TH-PO334, 
TH-PO345, TH-PO351, TH-PO352, 
TH-PO354, TH-PO366, TH-PO686, 
TH-PO733, TH-PO1030, FR-OR049, 
FR-OR050, FR-OR053, FR-OR062, 
FR-OR080, FR-OR085, FR-PO153, 
FR-PO157, FR-PO165, FR-PO187, 
FR-PO193, FR-PO206, FR-PO315, 
FR-PO316, FR-PO318, FR-PO320, 
FR-PO321, FR-PO322, FR-PO326, 
FR-PO331, FR-PO332, FR-PO333, 
FR-PO335, FR-PO336, FR-PO337, 
FR-PO340, FR-PO341, FR-PO343, 
FR-PO345, FR-PO346, FR-PO347, 
FR-PO349, FR-PO350, FR-PO351, 
FR-PO353, FR-PO355, FR-PO359, 
FR-PO360, FR-PO361, FR-PO363, 
FR-PO402, FR-PO420, FR-PO421, 
FR-PO422, FR-PO424, FR-PO428, 
FR-PO437, FR-PO978, SA-OR016, 
podocyte (continued) .....SA-OR045, SA-OR046, 
SA-OR047, SA-OR049, SA-OR051, 
SA-PO029, SA-PO286, SA-PO290, 
SA-PO292, SA-PO295, SA-PO309, 
SA-PO325, SA-PO334, SA-PO338, 
SA-PO340, SA-PO342, SA-PO348, 
SA-PO351, SA-PO352, SA-PO361, 
SA-PO369, SA-PO370, SA-PO372, 
SA-PO453, SA-PO1040, PUB082, PUB084, 
PUB085, PUB086, PUB088, PUB090, 
PUB280, PUB294, PUB701
polycystic kidney disease ..................TH-PO179, 
TH-PO180, TH-PO184, TH-PO188, 
TH-PO190, TH-PO198, TH-PO201, 
TH-PO203, TH-PO204, TH-PO206, 
TH-PO208, TH-PO209, TH-PO212, 
TH-PO213, TH-PO214, TH-PO215, 
TH-PO216, TH-PO223, TH-PO657, 
TH-PO692, FR-OR042, FR-PO020, 
FR-PO104, SA-PO850, SA-PO857, 
SA-PO865, SA-PO866, SA-PO867, 
SA-PO868, SA-PO869, SA-PO870, 
SA-PO878, SA-PO883, SA-PO886, PUB266, 
PUB268, PUB273, PUB715
polymorphisms ............ TH-PO441, TH-PO1061, 
SA-PO500, SA-PO507, SA-PO513, 
SA-PO516, SA-PO518, SA-PO554, 
SA-PO555, SA-PO988, PUB052
potassium (K) channels.....................TH-PO157, 
TH-PO434, TH-PO435, TH-PO436, 
SA-PO923, PUB450, PUB494
primary glomerulonephritis .............TH-PO741, 
PUB232
progression of chronic renal 
 failure ...................... TH-OR006, TH-OR016, 
TH-PO202, TH-PO244, TH-PO526, 
TH-PO534, TH-PO535, TH-PO541, 
TH-PO554, TH-PO557, TH-PO560, 
TH-PO571, TH-PO572, TH-PO587, 
TH-PO603, TH-PO665, TH-PO948, 
FR-OR044, FR-OR063, FR-OR108, 
FR-PO268, FR-PO282, FR-PO422, 
FR-PO515, FR-PO518, FR-PO546, 
FR-PO558, FR-PO565, FR-PO583, 
FR-PO638, FR-PO642, FR-PO795, 
FR-PO845, FR-PO878, FR-PO900, 
SA-OR003, SA-OR004, SA-OR007, 
SA-OR019, SA-PO520, SA-PO678, 
SA-PO716, SA-PO721, SA-PO735, 
SA-PO796, SA-PO851, SA-PO922, PUB184, 
PUB185, PUB193, PUB194, PUB523
progression of renal failure ............. TH-OR027, 
TH-PO538, TH-PO580, TH-PO664, 
FR-PO163, FR-PO394, FR-PO559, 
FR-PO626, SA-OR026, SA-PO210, 
SA-PO220, SA-PO469, SA-PO492, 
SA-PO545, SA-PO569, SA-PO754, 
SA-PO872, SA-PO875, PUB027, PUB223, 
PUB272, PUB303, PUB552
proliferation ................... TH-PO178, TH-PO179, 
TH-PO182, TH-PO190, TH-PO255, 
FR-OR102, FR-PO107, FR-PO260, 
FR-PO277, FR-PO316, FR-PO317, 
SA-OR080, SA-OR085, SA-PO295, 
SA-PO300, SA-PO357, PUB021, PUB092
proteinuria .................... TH-OR021, TH-OR094, 
TH-PO132, TH-PO141, TH-PO147, 
TH-PO148, TH-PO227, TH-PO232, 
TH-PO241, TH-PO242, TH-PO327, 
TH-PO353, TH-PO354, TH-PO557, 
TH-PO565, TH-PO599, TH-PO645, 
TH-PO656, TH-PO696, TH-PO699, 
TH-PO764, TH-PO780, TH-PO1011, 
TH-PO1034, TH-PO1038, TH-PO1043, 
TH-PO1055, TH-PO1072, TH-PO1086, 
TH-PO1092, TH-PO1101, TH-PO1114, 
TH-PO1118, FR-PO047, FR-PO149, 
FR-PO325, FR-PO329, FR-PO344, 
FR-PO346, FR-PO356, FR-PO360, 
FR-PO387, FR-PO404, FR-PO424, 
FR-PO425, FR-PO433, FR-PO434, 
FR-PO440, FR-PO442, FR-PO449, 
FR-PO466, FR-PO510, FR-PO576, 
FR-PO607, FR-PO608, FR-PO612, 
FR-PO615, FR-PO629, FR-PO630, 
FR-PO996, FR-PO1012, SA-OR016, 
SA-OR026, SA-OR050, SA-OR062, 
SA-PO030, SA-PO032, SA-PO035, 
SA-PO043, SA-PO098, SA-PO100, 
SA-PO310, SA-PO334, SA-PO339, 
SA-PO341, SA-PO349, SA-PO367, 
SA-PO448, SA-PO452, SA-PO453, 
SA-PO456, SA-PO498, SA-PO521, 
SA-PO628, SA-PO664, SA-PO678, 
SA-PO679, SA-PO706, PUB131, PUB134, 
PUB152, PUB175, PUB184, PUB185, 
PUB192, PUB206, PUB207, PUB212, 
PUB214, PUB219, PUB222, PUB236, 
PUB258, PUB275, PUB283, PUB301, 
PUB304, PUB309, PUB556, PUB567, 
PUB572, PUB574, PUB663
proximal tubule .................................TH-PO038, 
TH-PO163, TH-PO292, TH-PO294, 
TH-PO317, TH-PO349, TH-PO370, 
TH-PO446, TH-PO504, TH-PO686, 
FR-OR079, FR-OR099, FR-PO007, 
FR-PO113, FR-PO125, FR-PO180, 
FR-PO184, FR-PO192, FR-PO239, 
FR-PO396, FR-PO542, FR-PO570, 
FR-PO610, FR-PO629, FR-PO641, 
FR-PO918, FR-PO949, SA-OR082, 
SA-PO237, SA-PO267, SA-PO307, 
SA-PO317, SA-PO318, SA-PO328, 
SA-PO333, SA-PO383, SA-PO385, 
SA-PO397, SA-PO417, SA-PO932, 
SA-PO933, SA-PO936, SA-PO941, 
PUB152, PUB640, PUB718
pulse wave velocity ........ TH-PO542, TH-PO553, 
TH-PO616, TH-PO630, TH-PO884, 
TH-PO903, TH-PO906, FR-PO546, 
SA-PO600, SA-PO653, PUB338
pure red cell aplasia ........................... FR-PO091
pyelonephritis ................ TH-PO462, FR-PO389, 
FR-PO871, FR-PO990, SA-OR024, PUB651
quality of life .................. TH-PO800, TH-PO924, 
TH-PO934, TH-PO996, TH-PO999, 
TH-PO1024, TH-PO1079, FR-PO658, 
FR-PO671, FR-PO679, FR-PO774, 
FR-PO786, FR-PO807, FR-PO870, 
FR-PO942, FR-PO1001, FR-PO1040, 
SA-OR030, SA-OR098, SA-PO134, 
SA-PO717, SA-PO719, SA-PO734, 
SA-PO736, SA-PO737, SA-PO739, 
SA-PO744, SA-PO746, SA-PO747, 
SA-PO748, SA-PO752, SA-PO758, 
SA-PO759, SA-PO774, SA-PO776, 
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quality of life (continued) .................SA-PO777, 
SA-PO778, SA-PO782, SA-PO784, 
SA-PO785, SA-PO786, SA-PO787, 
SA-PO791, SA-PO837, SA-PO844, 
SA-PO871, SA-PO1006, SA-PO1019, 
SA-PO1050, PUB121, PUB144, PUB355, 
PUB369, PUB370, PUB386, PUB555, 
PUB581, PUB587, PUB617, PUB635, 
PUB644, PUB721, PUB725
RAGE (receptor for AGEs) ..............TH-PO894, 
FR-PO134, SA-PO943
randomized controlled trials ............TH-PO080, 
TH-PO505, TH-PO662, TH-PO673, 
TH-PO985, FR-OR017, FR-PO673, 
FR-PO713, FR-PO770, FR-PO909, 
FR-PO934, SA-OR064, SA-PO764, 
SA-PO816, SA-PO950, SA-PO951, PUB313, 
PUB353, PUB366
reactive oxygen species .................... TH-OR103, 
TH-PO037, TH-PO308, TH-PO309, 
TH-PO318, TH-PO339, TH-PO406, 
TH-PO578, TH-PO840, FR-OR083, 
FR-PO104, FR-PO144, FR-PO245, 
FR-PO264, FR-PO339, SA-PO250, 
SA-PO260, SA-PO281, SA-PO310, 
SA-PO451, SA-PO867, PUB004, 
PUB010, PUB098
rejection...... TH-PO266, TH-PO274, TH-PO276, 
TH-PO1031, TH-PO1045, FR-PO082, 
FR-PO1038, FR-PO1054, FR-PO1070, 
FR-PO1075, FR-PO1078, FR-PO1105, 
SA-OR057, SA-PO960, SA-PO962, 
SA-PO964, SA-PO978, SA-PO979, 
SA-PO990, SA-PO992, SA-PO1016, 
SA-PO1046, SA-PO1051, SA-PO1067, 
SA-PO1082, PUB667, PUB671, PUB681
renal ablation ................. TH-PO146, TH-PO166, 
TH-PO548, TH-PO910, FR-PO142, 
FR-PO850, SA-PO443, SA-PO622, PUB342
renal artery stenosis ...... TH-PO620, TH-PO672, 
TH-PO773, TH-PO1047, FR-PO143, 
SA-PO007, SA-PO119, SA-PO222, 
SA-PO658, SA-PO667, PUB201
renal autoregulation ......TH-PO152, SA-OR042, 
SA-PO258
renal biopsy ................... TH-OR010, TH-OR069, 
TH-PO679, TH-PO681, TH-PO694, 
TH-PO703, TH-PO706, TH-PO713, 
TH-PO714, TH-PO716, TH-PO729, 
TH-PO731, TH-PO746, TH-PO1036, 
TH-PO1055, TH-PO1064, TH-PO1082, 
FR-OR066, FR-PO058, FR-PO072, 
FR-PO076, FR-PO626, SA-OR099, 
SA-PO043, SA-PO154, SA-PO165, 
SA-PO166, SA-PO495, SA-PO647, 
SA-PO1085, PUB176, PUB208, PUB249, 
PUB252, PUB255, PUB425, PUB578, 
PUB682
renal carcinoma ........... TH-PO738, TH-PO1120, 
FR-PO072, SA-PO090, SA-PO661, PUB108, 
PUB253
renal cell biology............TH-OR042, TH-PO214, 
TH-PO295, TH-PO313, TH-PO448, 
FR-OR097, FR-PO264, FR-PO319, 
SA-PO338, SA-PO356, SA-PO361, 
SA-PO874
renal development ......... TH-PO179, TH-PO210, 
TH-PO457, FR-OR095, FR-PO018, 
FR-PO170, FR-PO171, FR-PO181, 
FR-PO189, FR-PO195, FR-PO208, PUB278, 
PUB279, PUB280, PUB575
renal dialysis .................. TH-PO110, TH-PO115, 
TH-PO672, TH-PO1001, FR-PO367, 
SA-OR105, SA-PO143, SA-PO531, 
SA-PO532, PUB065, PUB312
renal dysfunction ...........TH-OR028, TH-PO089, 
TH-PO427, TH-PO475, TH-PO785, 
FR-PO256, SA-PO001, SA-PO015, 
SA-PO221, SA-PO235, SA-PO943, PUB217
renal epithelial cell ........................... TH-OR052, 
TH-OR075, TH-PO015, TH-PO221, 
TH-PO294, TH-PO439, FR-PO178, 
FR-PO200, FR-PO397, FR-PO990, 
SA-PO396, SA-PO487, PUB108
renal failure ................... TH-PO098, TH-PO275, 
TH-PO1026, TH-PO1123, FR-OR073, 
FR-PO173, FR-PO631, FR-PO871, 
FR-PO1098, SA-OR005, SA-OR020, 
SA-PO058, SA-PO194, SA-PO199, 
SA-PO205, SA-PO689, PUB433, PUB466
renal fibrosis ..................TH-OR065, TH-PO032, 
TH-PO144, TH-PO156, TH-PO258, 
TH-PO260, TH-PO280, TH-PO281, 
TH-PO282, TH-PO285, TH-PO401, 
TH-PO474, TH-PO669, FR-PO135, 
FR-PO199, FR-PO254, FR-PO271, 
FR-PO274, FR-PO278, FR-PO279, 
FR-PO280, FR-PO292, FR-PO293, 
FR-PO296, FR-PO303, FR-PO305, 
FR-PO310, FR-PO542, FR-PO691, 
SA-OR088, SA-PO248, SA-PO276, 
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TH-PO880, TH-PO882, FR-PO084, 
FR-PO368, FR-PO695, FR-PO697, 
FR-PO699, FR-PO700, FR-PO704, 
FR-PO706, FR-PO709, FR-PO711, 
FR-PO712, FR-PO715, FR-PO716, 
FR-PO719, FR-PO720, FR-PO721, 
FR-PO798, SA-PO054, SA-PO147, 
SA-PO815, PUB474, PUB476, PUB477, 
PUB478, PUB479, PUB480, PUB481, 
PUB484, PUB486, PUB487, PUB489
vascular calcification ..... TH-PO400, TH-PO500, 
TH-PO562, TH-PO603, TH-PO604, 
TH-PO627, TH-PO632, TH-PO884, 
TH-PO895, TH-PO905, TH-PO906, 
TH-PO907, FR-OR026, FR-OR027, 
FR-OR028, FR-PO934, FR-PO1031, 
FR-PO1039, SA-PO408, SA-PO585, 
SA-PO586, SA-PO587, SA-PO588, 
SA-PO589, SA-PO590, SA-PO591, 
SA-PO592, SA-PO593, SA-PO594, 
SA-PO596, SA-PO598, SA-PO599, 
SA-PO602, SA-PO603, SA-PO604, 
SA-PO605, SA-PO607, SA-PO608, 
SA-PO609, SA-PO612, SA-PO613, PUB129, 
PUB538, PUB672, PUB710, PUB712
vascular disease .............TH-OR060, TH-PO378, 
TH-PO385, TH-PO397, TH-PO400, 
TH-PO402, TH-PO403, TH-PO413, 
TH-PO459, TH-PO901, TH-PO907, 
TH-PO909, FR-OR025, FR-PO211, 
FR-PO212, SA-PO054, SA-PO222, 
SA-PO314, SA-PO585, SA-PO596, 
SA-PO601, SA-PO610, SA-PO786, 
SA-PO986, PUB140, PUB176, PUB200, 
PUB326, PUB328, PUB707
vascular endothelial growth 
 factor ........................ TH-PO315, TH-PO375, 
TH-PO419, TH-PO421, FR-OR084, 
FR-PO348
vasculitis ........................ TH-OR024, TH-OR025, 
TH-OR026, TH-PO126, TH-PO135, 
TH-PO145, TH-PO1076, TH-PO1085, 
TH-PO1121, FR-PO006, FR-PO055, 
FR-PO404, FR-PO405, FR-PO411, 
FR-PO412, FR-PO413, FR-PO415, 
FR-PO417, FR-PO979, SA-PO031, 
SA-PO033, SA-PO047, SA-PO052, 
SA-PO078, SA-PO096, SA-PO106, 
SA-PO127, SA-PO555, PUB218, PUB224, 
PUB228, PUB424
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vasopressin ..................... TH-PO213, TH-PO795, 
TH-PO1056, FR-PO028, FR-PO031, 
FR-PO095, FR-PO097, FR-PO100, 
FR-PO106, FR-PO108, SA-OR111, 
SA-OR112, SA-OR113, SA-OR114, 
SA-OR115, SA-OR116, SA-PO010, 
SA-PO379, SA-PO852, SA-PO853, 
SA-PO857, SA-PO863, SA-PO880, 
SA-PO916, PUB095, PUB713, PUB717, 
PUB719
VEGF ..........TH-PO016, TH-PO241, FR-PO148, 
FR-PO350, FR-PO831, SA-PO116, 
SA-PO215, SA-PO317
vesico-ureteral reflux .... TH-PO462, TH-PO737, 
FR-PO018, FR-PO455
virology ...... TH-PO1031, FR-PO052, FR-PO332, 
FR-PO778, SA-PO106, SA-PO181, 
SA-PO1058, SA-PO1062, SA-PO1063, 
SA-PO1064, SA-PO1065, SA-PO1069, 
PUB689
vitamin B1 ........................................... FR-PO596
vitamin C....TH-PO1095, FR-PO890, SA-PO807
vitamin D.... TH-PO394, TH-PO485, TH-PO488, 
TH-PO505, TH-PO506, TH-PO507, 
TH-PO508, TH-PO510, TH-PO511, 
TH-PO512, TH-PO513, TH-PO514, 
TH-PO515, TH-PO522, TH-PO523, 
TH-PO524, TH-PO601, TH-PO623, 
TH-PO641, TH-PO645, TH-PO822, 
TH-PO914, TH-PO1019, FR-PO029, 
FR-PO034, FR-PO229, FR-PO311, 
FR-PO615, FR-PO696, FR-PO800, 
FR-PO815, FR-PO841, FR-PO926, 
FR-PO943, FR-PO944, FR-PO1009, 
SA-OR028, SA-PO016, SA-PO065, 
SA-PO365, SA-PO398, SA-PO558, 
SA-PO580, SA-PO597, SA-PO611, 
SA-PO633, SA-PO635, SA-PO660, 
SA-PO743, SA-PO1067, PUB073, PUB525, 
PUB528, PUB531, PUB540, PUB542, 
PUB544, PUB547, PUB548, PUB646, 
PUB647, PUB667
water channels ............... FR-OR038, FR-PO096, 
FR-PO098, FR-PO099, FR-PO100, 
FR-PO101, FR-PO102, FR-PO104, 
FR-PO105, FR-PO109, FR-PO140, 
FR-PO611, FR-PO945, SA-OR115, 
SA-OR117, SA-OR118, SA-PO285, 
SA-PO928, SA-PO972, PUB268, 
PUB715, PUB717
water transport ..............FR-OR004, FR-OR038, 
FR-PO095, FR-PO107, FR-PO109, 
FR-PO808, SA-OR118, PUB714
water-electrolyte balance ................. TH-OR082, 
TH-OR084, TH-PO120, TH-PO423, 
TH-PO428, TH-PO832, TH-PO1056, 
FR-OR004, FR-OR009, FR-PO007, 
FR-PO026, FR-PO050, FR-PO097, 
FR-PO099, FR-PO100, FR-PO106, 
FR-PO118, FR-PO122, FR-PO506, 
FR-PO923, SA-OR110, SA-OR111, 
SA-OR112, SA-PO257, SA-PO417, 
SA-PO657, SA-PO902, SA-PO903, 
SA-PO906, SA-PO907, SA-PO909, 
SA-PO913, SA-PO916, SA-PO932, PUB362, 
PUB431, PUB446, PUB600
Underline represents presenting author/disclosure.
J Am Soc Nephrol 26: 2015 High-Impact Clinical Trials Oral/Saturday
B1
HI-OR01
Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 
Diabetes and Chronic Kidney Disease  Christoph Wanner,1 John M. Lachin,2 
David H. Fitchett,3 Silvio E. Inzucchi,4 Maximilian von Eynatten,5 Michaela 
Mattheus,5 Odd Erik Johansen,6 Hans-Juergen Woerle,5 Uli Christian Broedl,5 
Bernard Zinman.7,8  1Dept of Medicine, Würzburg Univ Clinic, Würzburg, 
Germany; 2The Biostatistics Center, The George Washington Univ, Rockville, 
MD; 3St Michael’s Hospital, Div of Cardiology, Univ of Toronto, Toronto, 
Canada; 4Section of Endocrinology, Yale Univ School of Medicine, New Haven, 
CT; 5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 
6Boehringer Ingelheim Norway KS, Asker, Norway; 7Lunenfeld-Tanenbaum 
Research Inst, Mount Sinai Hospital, Toronto, Canada; 8Div of Endocrinology, 
Univ of Toronto, Toronto, Canada.
Background: Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are 
at high risk of cardiovascular (CV) events and premature death. Empagliflozin is a sodium 
glucose co-transporter (SGLT)-2 inhibitor used in the treatment of T2D.
Methods: In EMPA-REG OUTCOME®, we explored long-term CV outcomes with 
empagliflozin vs placebo when added to standard of care in 7020 T2D patients with 
established CV disease. Inclusion criteria included eGFR ³30ml/min/1.73m². Patients (mean 
age 63 years, male 71%, mean HbA1c 8.1%) were randomized 1:1:1 to empagliflozin 10 
mg, 25 mg or placebo.
Results: Most patients had impaired kidney function (52.2% stage 2, 17.8% stage 3a, 
7.7% stage 3b CKD) while 28.7% and 11.0%, respectively, had moderately (30-300mg/g) 
or severely (>300 mg/g) increased urine albumin to creatinine excretion. After a median 
follow-up of 3.1 years, the primary outcome (first occurrence of non-fatal myocardial 
infarction, non-fatal stroke, or CV death) occurred in a lower percentage of patients on 
empagliflozin (10.5%) than placebo (12.1%) (HR 0.86 [0.74-0.99]; p=0.04). This result was 
driven by a 38% reduction in CV death vs placebo (HR 0.62 [0.49-0.77]; p<0.001), with 
no difference in the risk of heart attack or stroke. Empagliflozin reduced hospitalization 
for heart failure by 35% (HR 0.65 [0.50-0.85]; p=0.0017). Pre-defined subgroup analyses 
on CV outcomes in patients with T2D and CKD will be presented.
Conclusions: Empagliflozin reduces CV morbidity and mortality in patients with T2D 
and various degrees of CKD.
Funding: Pharmaceutical Company Support - Boehringer Ingelheim and Eli Lilly 
and Company
HI-OR02
High Dose Perioperative Atorvastatin and Acute Kidney Injury Following 
Cardiac Surgery  Frederic Tremaine Billings, Chad E. Wagner, Patty Hendricks, 
Yaping Shi, Michael R. Petracek, Nancy J. Brown.  Vanderbilt Univ, Nashville, 
TN.
Background: Hydroxy-methylglutaryl-coenzyme A reductase inhibitors (statins) 
affect several mechanisms underlying acute kidney injury (AKI), a common and dangerous 
complication after cardiac surgery. We hypothesized that short-term high-dose perioperative 
atorvastatin would reduce AKI following cardiac surgery.
Methods: We randomized elective cardiac surgery patients, stratified by chronic kidney 
disease (CKD), to atorvastatin or matching-placebo starting the day prior to surgery until 
hospital discharge in pre-study statin naïve subjects or until the day after surgery in pre-study 
statin-using subjects. Our primary endpoint was AKI by AKIN criteria.
Results: The study was stopped on recommendations of the DSMB after 653 of 820 
subjects completed the study due to futility and an increased incidence of AKI among statin-
naïve subjects with CKD randomized to atorvastatin. AKI occurred in 20.8% of subjects 
randomized to atorvastatin versus 19.5% randomized to placebo (P=0.75). Among statin-
naïve subjects (n=199), however, AKI occurred in 21.6 % randomized to atorvastatin versus 
13.4% randomized to placebo (p=0.14), and 52.9% vs. 15.8%, P=0.03, in patients with CKD 
(n=36). Serum creatinine concentrations increased a median of 0.11 (-0.11 – 0.56) versus 
0.05 (-0.12 – 0.33) mg/dl in statin-naïve patients randomized to atorvastatin versus placebo 
(P=0.007), and this effect was magnified among those with CKD, whereserum creatinine 
concentrations increased by 0.26 (-0.22 – 0.94) versus -0.06 mg/dl (-0.16 – 0.41), P=0.04.
Conclusions: High-dose perioperative atorvastatin treatment does not reduce AKI 
following cardiac surgery and may increase risk in patients with CKD who are naïve to 
statin treatment. Perioperative continuation or short-term withdrawal of statin treatment 
in statin-using patients does not affect AKI.
Funding: Other NIH Support - K23GM102676; K12ES015855; UL1RR024975
HI-OR03
Effect of Methylprednisolone on Acute Kidney Injury in Patients 
Undergoing Cardiac Surgery with Cardiopulmonary Bypass  Amit X. Garg,1 
Richard P. Whitlock.2  1Western Univ, London, Canada; 2McMaster Univ, 
Hamilton, Canada and the Population Health Research Inst; for the SIRS 
Investigators.
Background: Acute kidney injury is a common complication of the 20 million cardiac 
surgeries performed worldwide each year. We conducted a substudy of the Steroids In 
caRdiac Surgery (SIRS) trial to determine whether methylprednisolone alters the risk of 
acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass 
[substudy protocol BMJ Open 2014 Mar 5;4(3): e004842].
Methods: This was a randomized clinical trial of 7,286 high-risk patients undergoing 
cardiac surgery with cardiopulmonary bypass from 79 centres in 18 countries between June 
2007 and December 2013. Patients were assigned to take intravenous methylprednisolone 
(250 mg at anesthetic induction and 250 mg at initiation of cardiopulmonary bypass) or 
placebo. Patients, care givers and outcome-assessors were blinded to allocation. Acute 
kidney injury was defined as ≥50% or ≥ 26.5 mmol/L (≥ 0.3 mg/dL) increase in the 
postoperative serum creatinine concentration from the preoperative concentration in the 
14 days following surgery, or new dialysis in the 30 days following surgery.
Results: Methylprednisolone (n=3,647) versus placebo (n=3,639) did not alter the 
risk of acute kidney injury (40.9% versus 39.5%, respectively; relative risk 1.03 [95% CI, 
0.96 to 1.11]). Results were consistent with multiple alternate continuous and categorical 
definitions of acute kidney injury, and in the subgroup with baseline chronic kidney disease.
Conclusions: Amongst patients undergoing cardiac surgery with cardiopulmonary 
bypass, the use of corticosteroids in the perioperative period did not alter the risk of acute 
kidney injury. Trial Registration: NCT00427388
   Number of Events (%)
  Relative Risk (95% CI)
  Methylprednisolone n = 3647
Placebo
n = 3639
AKI  1490 (40.9%) 1439 (39.5%) 1.03 (0.96 to 1.11) 
Alternative Definitions    
  AKI or death  1513 (41.5%) 1463 (40.2%) 1.03 (0.96 to 1.11) 
  ≥ stage 2 AKI  362 (9.9%) 359 (9.9%) 1.01 (0.87 to 1.16) 
  ≥ stage 3 AKI  145 (4.0%) 162 (4.5%) 0.89 (0.71 to 1.12) 
  Acute dialysis  95 (2.6%) 88 (2.4%) 1.08 (0.81 to 1.43) 
Funding: Government Support - Non-U.S.
HI-OR04
The NEFIGAN Trial: NEFECON, a Novel Targeted Release Formulation of 
Budesonide, Reduces Proteinuria and Stabilizes eGFR in IgA Nephropathy 
Patients at Risk of ESRD  Bengt C. Fellstrom,1 Rosanna Coppo,2 John 
Feehally,3 Jürgen Floege,4 Johan W. De Fijter,5 Alan G. Jardine,6 Francesco 
Locatelli,7 Bart D. Maes,8 Alex Mercer,9 Fernanda Ortiz,10 Manuel Praga,11 Søren 
Schwartz Sørensen,12 Vladimir Tesar.13  1Uppsala Univ Hospital; 2Univ Turin; 
3Univ Leicester; 4RWTH Univ Aachen; 5Leiden Univ Medical Center; 6Univ 
Glasgow; 7Ospedale A Manzoni, Lecco; 8AZ Delta Roeselare; 9Pharmalink; 
10Helsinki Univ Hospital; 11Hospital 12 de Octubre, Madrid; 12Rigshospitalet, 
Copenhagen; 13Charles Univ, Prague.
Background: IgA nephropathy (IgAN) is the most prevalent primary chronic 
glomerular disease. Despite RAS blockade, >25% of patients progress to ESRD within 
20 years. This study evaluated a novel budesonide formulation (NEFECON) targeted for 
release in the distal ileum, where Peyer’s patches reside, in patients at risk of ESRD despite 
optimized RAS blockade.
Methods: Double-blind, placebo-controlled study in 150 patients (62 sites, 10 EU 
countries) with primary IgAN, proteinuria (UPCR ³0.5 g/g OR urine protein ³0.75 g/d) and 
eGFR CKD-EPI ≥45 mL/min/1.73m2 randomized to 8 or 16 mg/d NEFECON or placebo 
(1:1:1), after 6 mo run-in phase to optimize RAS blockade. Primary endpoint: reduction in 
UPCR at 9 mo of treatment; secondary: mean percentage change in eGFR.
Results: Baseline data were similar across groups; BP was 127-128/78-80 mmHg, 
UPCR 0.76–0.83 g/g, and eGFR 72-85 mL/min/1.73m2. Primary endpoint was met at the 
pre-specified interim analysis. Mean UPCR decreased by 24% (NEFECON 8+16 mg/d) 
vs 3% increase (placebo) at 9 mo (p=0.007); reduction in the 16 mg/d group was 27% 
(p=0.009). At final analysis, mean change in eGFR was -4.7 mL/min/1.73m2 for placebo 
compared with 0.32 and 1.95 mL/min/1.73m2 for NEFECON 8 and 16 mg/d, respectively; 
difference in mean percentage change in eGFR achieved statistical significance for 8 mg/d 
(p=0.006) and 16 mg/d (p=0.003). Adverse event rates were higher in NEFECON groups 
(88–94%) than placebo (84%). Two serious adverse events were assessed as possibly 
related to NEFECON; deteriorated renal function (in follow-up) and deep vein thrombosis.
Conclusions: NEFECON reduced UPCR and maintained eGFR in patients with 
primary IgAN at risk of progression to ESRD despite optimized RAS blockade. Treatment 
was generally well-tolerated.
Funding: Pharmaceutical Company Support - Pharmalink AB
Underline represents presenting author/disclosure.
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HI-OR05
Randomized Trial on Efficacy of Mycophenolate Mofetil versus Tacrolimus 
in Maintaining Remission in Children with Steroid Resistant Nephrotic 
Syndrome  Aditi Sinha, Arvind Bagga.  All India Inst of Medical Sciences, 
New Delhi, India.
Background: Since prolonged therapy with tacrolimus (Tac) causes nephrotoxicity, 
this RCT examined non-inferiority of mycophenolate mofetil (MMF) to Tac in 
maintaining remission in patients with steroid resistant nephrotic syndrome (SRNS).
CTRI/2012/03/00247
Methods: Following approvals, 84 patients with SRNS (1-18 yr; minimal change 48, 
FSGS 36) & eGFR >60 ml/min/1.73m2 received Tac (0.15 mg/kg/d; trough 4-8 ng/ml) for 
6-months. Stratifying for histology & type of response, patients with complete (Up/Uc 
<0.2 mg/mg) or partial remission (Up/Uc 0.2-2, albumin >2.5 g/dl) were randomized to 
continue Tac or receive MMF (0.75-1 g/m2/d), prednisone & enalapril. Primary outcome, at 
12-mo, was proportion with remission or infrequent relapses. Therapy failure was recurrent 
SRNS, frequent relapses or >1 SAE. Enrolment was closed after interim intention-to-treat 
analysis of outcome in 1/3 sample.
Results: Baseline features were similar. Therapy with MMF led to significantly higher 
treatment failure, prednisone dose & SAE; eGFR change was similar. On multivariate 
regression, hazards of treatment failure were high with MMF (HR 9.7, adjusted for histology, 
type of resistance & remission; P<0.0001).
Baseline Tac, N=31 MMF, N=29
Minimal change/FSGS 17/16 17/12
Initial resistance 15 13
Age months 76±46 77±46
Complete/partial remission 19/12 18/11
Albumin g/dl 4.2±0.5 4.3±0.5
OUTCOMES
Satisfactory remission^ 28; 90% 13; 48%
Complete/partial remission 17 12
Infrequent relapses 11 1
Treatment failure^ 3 16
Frequent relapses 3 8
Steroid resistance 0 8
Relapse/yr 0.8±1.0 1.3±1.3
Prednisone mg/kg/d# 0.3±0.2 0.5±0.4
Change eGFR ml/min/1.73m2 -6±35 -19±31
P^<0.0005;#0.028
Conclusions: Therapy with MMF is inferior to Tac in maintaining Tac induced 
remission in patients with SRNS
HI-OR06
Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant 
Recipients with Twice-Yearly Denosumab: A Randomized Controlled 
Trial (ClinicalTrials.gov number NCT01377467)  Rudolf P. Wuthrich,1 
Diana P. Frey,2 Jens Gunther Brockmann,3 Thomas Fehr,1 Thomas F. Mueller,1 
Lanja Saleh,4 Arnold Von Eckardstein,4 Nicole Graf,5 Marco Bonani.1  1Div 
of Nephrology; 2Div of Rheumatology; 3Div of Visceral and Transplantation 
Surgery; 4Inst of Clinical Chemistry, Univ Hospital, Zurich, Switzerland; 5Graf 
Biostatistics, Winterthur, Switzerland.
Background: Kidney transplantation is associated with bone loss and an increased risk 
of fracture. Since current therapeutic options to prevent bone loss are limited we assessed the 
efficacy and safety of Receptor Activator of Nuclear Factor κB Ligand (RANKL) inhibition 
with denosumab to improve bone mineralization in the first year after kidney transplantation.
Methods: We enrolled 108 kidney transplant recipients and randomized 90 patients 
two weeks after surgery in a 1:1 ratio to receive denosumab (subcutaneous injections of 60 
mg denosumab at baseline and after 6 months) or no treatment. The primary endpoint was 
the percentage change in bone mineral density (BMD) measured by DXA at the lumbar 
spine at 12 months.
Results: After 12 months, the primary outcome of total lumbar spine BMD increased 
by 4.6% (95% CI 3.3-5.9%) in 46 patients in the denosumab group and decreased by -0.5% 
(95% CI -1.8-0.9%) in 44 patients in the control group (between-group difference 5.1%, 95% 
CI 3.1-7.0%, p<0.0001). Denosumab also significantly increased BMD at the total hip by 
1.9% (95% CI, 0.1 to 3.7%; p=0.035) over that in the control group at 12 months. HR-pQCT 
in a subgroup of 24 patients showed that denosumab also significantly increased BMD and 
cortical thickness at the distal tibia and radius (p<0.05). Biomarkers of bone resorption 
(β-CTX, urine deoxypyridinoline) and bone formation (P1NP, BSAP) markedly decreased 
with denosumab (p<0.0001). Episodes of cystitis and asymptomatic hypocalcemia occurred 
more often with denosumab, whereas graft function, rate of rejections and incidence of 
opportunistic infections were similar.
Conclusions: Antagonizing RANKL with denosumab effectively increased BMD in 
de novo kidney transplant recipients, but was associated with more frequent episodes of 
urinary tract infection and decreased calcemia.
Funding: Government Support - Non-U.S.
HI-OR07
Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study 
of Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets 
in Hemodialysis Patients with Uremic Pruritus  Vandana S. Mathur,1 
Jayant Kumar,5 Paul W. Crawford,3 Howard Hait,4 Thomas Sciascia.2 
1MathurConsulting; 2Trevi Therapeutics; 3Research by Design; 4Edenridge 
Consulting; 5Renal Medical Associates.
Background: Uremic pruritus (UP) is associated with decrements in quality of life and 
sleep and higher mortality. UP pathogenesis may involve endogenous κ/µ opioid ligand 
ratio imbalance. Nalbuphine ER tablets (NAL) are a κ-opioid agonist/µ-opioid antagonist 
being developed for chronic pruritic conditions.
Methods: 373 hemodialysis patients (HDP) with mean baseline numerical rating 
scale score (NRS) ≥ 4.5 for worst itching (0 [no itch] -10 [worst possible itching]) were 
randomized 1:1:1 to NAL 60 mg (n = 128), NAL 120 mg (n=120), or placebo (n = 125) 
and treated for 8 weeks.
Results: Demographics, dialysis adequacy and vintage, phosphorus, parathyroid 
hormone, pruritus duration, and antihistamine use were similar in the 3 arms at baseline. The 
primary efficacy endpoint was the change from Baseline to the Evaluation Period (Weeks 
7 and 8) in the NRS for each dose of NAL, with pre-specified hierarchical ordering – the 
120 mg vs. placebo comparison was performed first. The mean (SD) NRS in the NAL 120 
mg group declined from 6.94 (1.46) to 3.51 (2.11), with an LS mean decline vs. placebo = 
-0.73 (0.31), p = 0.017. The mean NRS in the NAL 60 mg group declined from 6.87 (1.40) 
to 4.95 (2.10), with an LS mean decline vs. placebo = -0.24 (0.31), p = 0.432. A statistically 
significant mean reduction for NAL 120 compared to placebo was observed as early as 
one week following titration. The most common adverse events were nausea, vomiting, 
dizziness and somnolence with incidence rates of these events quickly approaching that of 
placebo after the first week of titration. Among subjects with NRS ≥7 (post-hoc analysis), 
NAL 120 reduced NRS by 4.48 (SD) vs. 3.16 (SD) vs. placebo (p=0.007) with sleep quality 
(Itch MOS sleep scale) improved significantly (p=0.006).
Conclusions: Nalbuphine ER tablets at a dose of 120 mg BID were safe and 
significantly reduced itching intensity.
Funding: Pharmaceutical Company Support - Trevi Therapeutics
HI-OR08
The Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access 
Outcomes in Renal Disease (FAVOURED) Study: A Randomised Placebo-
Controlled Trial  Ashley B. Irish.1,2  1Nephrology, Fiona Stanley Hospital, 
Perth, Western Australia, Australia; 2Australasian Kidney Trials Network, Univ 
of Queensland, Brisbane, Queensland, Australia.
Background: Increasing the use of arteriovenous fistulae (AVF) to improve 
haemodialysis access is limited by early thrombosis and maturation failure. Omega-3 
polyunsaturated fatty acids (w3FA) may prevent these complications by inhibition of platelet 
aggregation, vasoconstriction, intimal hyperplasia and inflammation.
Underline represents presenting author/disclosure.
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Methods: This international, randomised, double-blind, placebo-controlled trial 
examined whether 3 months therapy with w3FA (4g/day) reduced primary AVF failure at 12 
months after AVF creation. AVF failure was defined as AVF thrombosis and/or abandonment 
and/or cannulation failure. A subset of patients received aspirin (100mg/day) or matching 
placebo in addition to w3FA or placebo in a factorial design (n=388).
Results: The 567 randomised participants had a mean age of 55 years, 63% were male 
and 46% diabetic. AVF failure occurred in 128/270 (47%) participants assigned to w3FA 
compared with 125/266 (47%) assigned to placebo (relative risk adjusted for aspirin use 
[RR] 1.03, 95% confidence interval [CI] 0.86-1.23, p= 0.78). Regarding each component 
of AVF failure, w3FA did not reduce the risk of thrombosis (22% vs 23%, RR 0.98, 95% 
CI 0.72-1.34, p=0.90), AVF abandonment (19% vs 22%, RR 0.87, CI 0.62-1.22, p=0.43) 
or cannulation failure (40% vs 39%, RR 1.03, 0.83-1.26, p=0.81). A subgroup difference 
was observed for diabetes mellitus (interaction p =0.038; RR 1.30 vs 0.78; diabetics vs non-
diabetics) but not for age, gender, AVF site, dialysis modality and cardiovascular disease. 
There was no difference in any serious adverse event (AE), 9.2% vs 13.0%, p=0.14; bleeding, 
8.1% vs 10.9% p=0.26, or gastrointestinal AE, 4.9% vs 5.4%, p=0.86. The risk of AVF 
failure was similar (45% vs 43%, RR 1.05, 95% CI 0.84-1.31) in the subset of participants 
randomised to aspirin or placebo-aspirin as part of the factorial design.
Conclusions: Three months of w3FA intake was ineffective in reducing primary AVF 
failure at 12 months. Aspirin may be similarly ineffective. There was no increased risk 
of bleeding. Neither w3FA nor aspirin increased the proportion of useable de novo AVF.
Funding: Other NIH Support - NHMRC Project Grant, Pharmaceutical Company 
Support - AMGEN Australia
SA-PO1091
The Remote Ischemic Preconditioning in Cardiac Surgery Trial (Remote 
IMPACT)  Michael Walsh.1,2  1McMaster Univ; 2Population Health Research 
Inst.
Background: Cardiac surgery is frequently complicated by ischemia-reperfusion 
injury which can lead to kidney and myocardial injury. Preoperative Remote Ischemic 
Preconditioning (RIPC), cycles of brief ischemia to a limb alternating with reperfusion, 
may reduce the frequency or severity of organ injury after cardiac surgery.
Methods: We randomly allocated 258 patients at high risk for death after cardiac surgery 
to receive either RIPC or a sham procedure immediately after induction of anesthesia. RIPC 
consisted of 3 cycles of thigh tourniquet inflation to 300 mmHg for 5 minutes followed by 
5 minutes reperfusion. The sham group tourniquets were inflated to 15 mmHg. Patients 
and care providers were blinded. The main clinical outcomes were change in creatinine 
over the first 4 postoperative days and the peak CK-MB within 24 hours of surgery. Other 
outcomes were assessed to 30 days after randomization. Analyses were performed according 
to the intention-to-treat principle.
Results: We randomized 128 patients to RIPC and 130 to sham. No patients were 
lost to follow-up. There was no significant between group differences in postoperative 
change in creatinine (p=0.79) or peak CK-MB (p=0.18) (Figure 1). We found no significant 
differences in the frequency of acute kidney injury (34% vs 31%), myocardial injury (24% 
vs 19%), stroke (4% vs 3%) or mortality (6% vs 5%) at 30 days.
Figure 1. Mean and 95% confidence intervals of creatinine over time for the RIPC 
(green diamonds) and sham (blue circles) groups.
Conclusions: In this trial RIPC did not affect markers of kidney and myocardial injury. 
These results fail to provide proof-of-concept that RIPC may impact clinically important 
outcomes in the cardiac surgery setting.
SA-PO1092
Nephrotoxicity of Invasive and Noninvasive Coronary Angiography: 
Randomized Controlled Study of Intracoronary and Intravenous Contrast 
Agent Administration  Eva Schönenberger,1 Patricia D. Bady,2 Peter Martus,3 
Elke Zimmermann,2 Michael Laule,4 Marc Dewey.2  1Anesthesiology, Charité, 
Berlin, Germany; 2Radiology, Charité, Berlin, Germany; 3Inst for Clinical 
Epidemiology and Applied Biostatistics, Eberhard Karls Univ, Tübingen, 
Germany; 4Cardiology, Charité, Berlin, Germany.
Background: Iodinated contrast agents can have nephrotoxic effects. It is unknown 
whether nephrotoxicity is more likely following intracoronary or intravenous contrast 
agent administration.
Methods: We randomly assigned patients with suspected coronary disease to either 
intracoronary contrast agent for invasive coronary angiography (ICA) or intravenous 
administration for coronary computed tomography angiography (CTA). The same low-
osmolar nonionic contrast agent with a concentration of 350 mg iodine per milliliter was 
used for ICA and CTA. Blood samples were taken before and at two time points after ICA 
and CTA (18 to 24 hours and 46 to 50 hours) to identify contrast-induced acute kidney 
injury defined according to the most commonly used definition as an increase in creatinine 
of at least 0.5 mg per deciliter or 25%.
Results: We enrolled 340 patients of whom 10 and 4 dropped out from the ICA and 
CTA group, respectively, leaving 161 and 165 patients who underwent ICA and CTA until 
September 8, 2015. Baseline creatinine levels in the ICA (0.85±0.19) and the CTA group 
(0.87±0.21 mg per deciliter) were similar (P=0.34). Follow-up creatinine was not available 
in 3 and 5 patients in the ICA and CTA group, respectively. Twenty-one of the 158 patients 
in the ICA group (13%) had an increase in creatinine of at least 0.5 mg per deciliter or 
25%, as compared with 9 of the 160 patients in the CTA group (6%; P<0.05). In patients 
without coronary disease on ICA or CTA, such a creatinine increase was found in 17 of 
the 134 patients in the ICA group (13%) and 6 of the 139 patients in the CTA group (4%; 
P<0.05). No patient without coronary disease in the CTA group had an increase in creatinine 
according to the KDIGO definition of at least 0.3 mg per deciliter or 50%, but 6 of the 134 
patients in the ICA group (4%; P<0.05).
Conclusions: Nephrotoxicity may be more likely after intracoronary than after 
intravenous contrast agent administration.
Funding: Government Support - Non-U.S.
SA-PO1093
Efficacy and Safety of Bosutinib in Autosomal Dominant Polycystic Kidney 
Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study 
Kazimierz Ciechanowski,1 Vladimir Tesar,2 York P. Pei,3 Irina Barash,4 Megan 
Shannon,5 Ruifeng Li,6 Jason Williams,7 Matteo Levisetti,8 Steven Arkin,6 
Andreas L. Serra.9  1Pomeranian Medical Univ, Szczecin, Poland; 2Charles Univ, 
Prague, Czech Republic; 3Univ Health Network, Toronto, Ontario, Canada; 
4Icahn School of Medicine at Mount Sinai, New York, NY; 5Pfizer Inc, San Diego, 
CA; 6Pfizer Inc, Cambridge, MA; 7Sanofi US, BridgeZater, NJ; 8Roche Pharma 
Research and Development, Basel, Switzerland; 9Inst fur Allgemeine Innere 
Medizin und Nephrologie, Suisse ADPKD Hirslanden, Zurich, Switzerland.
Background: Src overactivation has been linked to the pathogenesis of autosomal 
dominant polycystic kidney disease (ADPKD). We assessed efficacy and safety of bosutinib 
(BOS), an oral dual Src/Abl tyrosine kinase inhibitor, in ADPKD patients (pts).
Methods: In this phase 2, multicenter study (NCT01233869), ADPKD pts with 
estimated glomerular filtration rate ≥60 mL/min/1.73 m2 and magnetic resonance image 
(MRI)-confirmed total kidney volume (TKV) ≥750 cc were randomized 1:1:1 to placebo 
(PBO), 200 mg/d, or 400 mg/d of oral BOS for £24 mo. The primary endpoint was annualized 
TKV % change. Pts treated for ³2 wk who had an MRI after a 30-d washout period were 
in the modified intent-to-treat (mITT) analysis.
Results: 169 of 172 enrolled pts received ³1 dose of treatment. 24 pts who initially 
received 400 mg/d BOS were later reduced to 200 mg/d BOS per protocol. 88 pts (52%) 
were in the mITT population (200 mg/d, n=27; 400 mg/d, n=7; 400 to 200 mg/d, n=21; 
PBO, n=33) after discontinuations (unrelated to study drug, 27%; study drug-related adverse 
events, 17%; consent withdrawal, 14%). Annual rate of kidney enlargement was significantly 
reduced for pooled BOS vs PBO (0.84% vs 4.74%, respectively, 95% CI for difference in 
annualized rates [2.02-5.74]; p<.0001) and was 65.2% lower for BOS 200 mg/d vs PBO 
(1.63% vs 4.74%, respectively, 95% CI [0.93 to 5.23]; p=.005). Gastrointestinal (GI) 
effects were dose-dependent for BOS; the overall safety profile, including GI toxicities, 
was consistent with the known profile of BOS.
Conclusions: BOS reduced the annual rate of kidney enlargement vs PBO in ADPKD 
pts, and the safety profile was consistent with the BOS label.
Funding: Pharmaceutical Company Support - Pfizer Inc
SA-PO1094
Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression 
in ADPKD: A Randomized Controlled Trial  Osama W. Amro,1,2 Jessica K. 
Paulus,1,2 Farzad Noubary,1,2 Ronald D. Perrone.1,2  1Nephrology, Tufts Medical 
Center, Boston, MA; 2Tufts Univ School of Medicine.
Background: Autosomal dominant polycystic kidney disease (ADPKD) affects 12.5 
million persons worldwide. Vasopressin promotes disease progression.
Methods: This randomized trial examined the effect of combining a low osmolar diet 
and adjusted water intake on vasopressin as measured by change in plasma copeptin, and 
Underline represents presenting author/disclosure.
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urinary osmolality in 34 ADPKD patients. Participants were randomized to receive a low 
osmolar diet (low sodium (1500 mg/day), low protein (0.8 gram/kg body weight) diet) 
followed by adjusted water intake to achieve a urine osmolality of £280 mOsm/L versus 
no intervention for two weeks.
Results: Change from baseline to two weeks between intervention and control groups 
was statistically significant for the primary outcome of copeptin and urine osmolality (-0.86 
±1.3 pmole/L versus +0.39 ±1.2 pmole/L (p=0.009) and -167±264 mOsm/L versus +20±80 
mOsm/L (0.007) respectively). Mean plasma copeptin and urine osmolality declined from 
6.2 ±3.05 to 5.3± 2.5 pmole/L (p=0.3) and from 426 ±193 to 258 ±117 mOsm/L (p=0.003) 
respectively in the intervention group compared to a non-significant increase from 4.7 
±3.6 to 5.07 ±4 pmole/L (p=0.7) and from 329 ±159 to 349 ±139 mOsm/L (p=0.6) in the 
control group.
Total urinary solute decreased only in the intervention group and significantly differed 
between groups at week one (p=0.03) reducing mean water prescription from 3.2 to 2.6 
liter/day.
Conclusions: we developed a step wise dietary intervention that led to significant 
reduction in vasopressin in ADPKD patients. Furthermore, this intervention led to reduction 
in water required for vasopressin suppression. Long-term studies are needed to determine 
if vasopressin suppression slows ADPKD progression.
Funding: Other NIH Support - Dr. Amro is supported by NIH 5T32DK007777 
institutional training grant. This project was performed and Dr. Perrone were supported 
in part by the National Center for Advancing Translational Sciences (NCATS), National 
Institutes of Health (NIH), Grant Number UL1 TR001064.
SA-PO1095
A Phase 2, Double-Blind, Randomized Study of Fresolimumab or 
Placebo in Patients with Steroid-Resistant Primary Focal Segmental 
Glomerulosclerosis  James A. Tumlin,1 Flavio Vincenti,2 Fernando C. Fervenza,3 
Kirk N. Campbell,4 Montserrat M. Diaz Encarnacion,5 Manuel Praga,6 Denyse 
Thornley-Brown,7 Francisco Veríssimo Veronese,8 Beverly Accomando,9 Sara 
Engstrand,10 Steven R. Ledbetter,10 Julie Lin,10 John F. Neylan.10  1UT Coll. of 
Med., Chattanooga, TN; 2UCSF, San Francisco, CA; 3Mayo Clinic, Rochester, 
MN; 4Icahn Sch. of Med. at Mt. Sinai, New York, NY; 5Fundacion Puigvert, 
Barcelona, Spain; 6Hosp. Univ 12 de Oct., Madrid, Spain; 7Univ of Alabama 
at Birmingham, AL; 8Hosp. de Clínicas de Porto Alegre, Brazil; 9Sanofi, 
Cambridge, MA; 10Formerly Genzyme, Sanofi.
Background: Steroid-resistant primary FSGS confers substantial risk of morbidity & 
progressive kidney failure. Fresolimumab (freso), a neutralizing mAb to all 3 isoforms of 
TGF-β, is a potential new treatment.
Methods: 36 pts with biopsy-proven nephrotic-range FSGS randomized to freso 1mg/
kg (n=14) v 4mg/kg (n=12) v placebo (PL) (n=10) for D112, allowed immunosuppressives 
after D112 & followed up double-blind for D252. 1° outcome: proteinuria remission; 2° 
outcomes included changes in Up/c & eGFR.
Results: Pts: 53% male; median 41 y; 17% Black, 31% Hisp. Baseline (BL) median 
Up/c: 6.19mg/mg; eGFR, 63 ml/min/1.73 m2. 72% pts received prior CNI. Durable partial 
remission (>50% Up/c decrease from BL to <3mg/mg): 3 pts, 1mg/kg; 2 pts, 4mg/kg; 1 pt, 
PL; 1 additional pt on 1mg/kg had steep & consistent Up/c decline from 17–4mg/mg. All 7 
freso responders were Black/Hisp. Mean Up/c changes at D112: -18.5% (1mg/kg,P=0.008), 
+10.5% (4mg/kg,P=0.52), +9.0% (PL,P=0.91). eGFR showed nonsignificant trend for 
stability in freso v decline in PL. Freso was generally well tolerated with no significant 
difference in AEs in low v high doses.
Conclusions: In steroid-resistant FSGS, freso may be associated with proteinuria 
remission. Black & Hisp pts may have higher response rates. Freso merits continued 
evaluation in FSGS.
Funding: Pharmaceutical Company Support - Genzyme-Sanofi
SA-PO1096
Effects of Sustained-Release Beraprost Sodium in Patients with Primary 
Glomerular Disease or Nephrosclerosis: The CASSIOPEIR Study 
Toshiro Fujita,1 Xueqing Yu,2 Suhnggwon Kim,3 Hidetomo Nakamoto,4 Hideki 
Origasa,5 Hajimu Kurumatani,6 Takashi Kiriyama.7  1The Univ of Tokyo, Tokyo, 
Japan; 2The First Affiliated Hospital, Sun Yat-sen Univ, Guangzhou, Guangdong, 
China; 3Seoul National Univ Hospital, Seoul, Korea; 4Saitama Medical Univ, 
Saitama, Japan; 5The Univ of Toyama, Toyama, Japan; 6Toray Industries, Inc, 
Tokyo, Japan; 7Astellas Pharma Inc., Tokyo, Japan.
Background: No single treatment, except RAS inhibitors, can delay progression of 
CKD. TRK-100STP, a sustained-release tablet of an orally-active prostacyclin analogue, 
beraprost sodium, is suggested to suppress worsening of renal filtration function. We aimed 
to demonstrate superiority of TRK-100STP over placebo in patients with CKD, either as 
primary glomerular disease or nephrosclerosis; determine the recommended dose of TRK-
100STP; and evaluate its safety profile.
Methods: We performed a randomized, double-blind, placebo-controlled, parallel-
group comparative study at 160 sites in seven Asian-Pacific countries and regions 
(CASSIOPEIR: CRF Asian Study with Oral PGI2 Derivative for Evaluating Improvement of 
Renal Function). Patients entered a run-in period with oral administration of placebo twice 
daily for two to eight weeks. Patients meeting the inclusion/exclusion criteria at the end of 
the run-in period (n=892) were randomized to TRK-100STP 120 mg, TRK-100STP 240 mg, 
or placebo for a treatment period of two to four years. The primary efficacy endpoint was 
the time to first occurrence of a renal composite endpoint: doubling of SCr or occurrence 
of end-stage renal disease. ClinicalTrials.gov identifier : NCT01090037.
Results: No significant differences were evident observed in renal composite endpoints 
between TRK-100STP and placebo (2-sided 5% significance level, P=0.5674). The overall 
incidence of adverse events and adverse drug reactions was comparable between the 
treatment arms.
Conclusions: TRK-100STP did not demonstrate superiority over placebo, and the 
recommended therapeutic dose for patients with CKD either primary glomerular disease 
or nephrosclerosis was not determined. However, no findings raised safety concerns in the 
comparison between TRK-100STP and placebo.
Funding: Pharmaceutical Company Support - Toray Industries, Inc., Astellas Parma 
Inc.
SA-PO1097
Corticosteroid Monotherapy versus Combined Immunosuppression in IgA 
Nephropathy: Insights from the STOP-IgAN Trial  Jürgen Floege,1 Thomas 
Rauen,1 Frank Eitner,3 Christina Fitzner,2 Ralf-Dieter Hilgers.2  1Nephrology, 
RWTH Aachen Univ, Aachen, Germany; 2Biostatistics, RWTH Aachen Univ, 
Aachen, Germany; 3Bayer AG, Wuppertal, Germany; 4For the STOP-IgAN 
Investigators.
Background: In high-risk IgA nephropathy (IgAN) the value of immunosuppression 
is controversial.
Methods: We recently reported a randomized, controlled trial in IgAN patients 
(STOP-IgAN trial). Following 6 months of optimized supportive treatment 162 trial 
participants, who still displayed a proteinuria >0.75 g/d, entered a 3 year study phase 
and were randomized to continue on supportive therapy (SUP) or to receive additional 
immunosuppression (IMM). IMM-patients with an eGFR >60 ml/min/1.73m2 received a 
6-month corticosteroid monotherapy (“Pozzi-protocol”). Patients with an eGFR of 30 to 
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59 ml/min/1.73m2 received cyclophosphamide for 3 months, followed by azathioprine, 
plus oral prednisolone (“Ballardie protocol”). Primary endpoints were (i) full clinical 
remission (proteinuria < 0.2 g/g and eGFR loss of < 5 ml/min) and (ii) eGFR loss >15 ml/
min from baseline to trial end.
Results: Here we report a secondary analysis of the two IMM subgroups versus 
corresponding SUP patients matched for eGFR. The intention-to-treat (ITT) analysis 
assuming a worst-case scenario at 3 years is shown in the table. 
 Endpoint GFR !60 ml/min/1.73m
2
IMM vs. SUP (n = 55 vs. 54)
GFR 30-59 ml/min/1.73m2
IMM vs. SUP (n = 27 vs. 26) 
 Full clinical 
remission
OR 5.23 (95%-CI 1.29-21.15), 
p=0.020
 OR 2.77 (95%-CI 0.38-32.29), 
p=0.319
 eGFR loss >15 
ml/min
OR 0.65 (95%-CI 0.27-1.56), 
p=0.333
 OR 1.62 (95%-CI 0.49-5.61), 
p=0.428
Patients treated with the Pozzi protocol had a transient decrease in proteinuria after 12 
months and significantly less microhematuria at trial end compared to matched SUP patients. 
In the group with the low eGFR range, there were no significant differences between both 
arms. Compared to supportive care, more patients receiving immunosuppression developed 
severe infections, impaired glucose tolerance and weight gain in year one.
Conclusions: Our secondary analyses provide little evidence for a stabilization of renal 
function with immunosuppression in the group with an eGFR >60 ml/min and no evidence 
for a benefit in patients with a lower eGFR.
Funding: Government Support - Non-U.S.
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A Randomized Trial of Rituximab in Advanced IgA Nephropathy 
Richard A. Lafayette,1 Pietro A. Canetta,2 Brad H. Rovin,3 Gerald B. Appel,2 
Marie C. Hogan,4 Stephen B. Erickson,4 Fernando C. Fervenza.4  1Stanford Univ, 
Stanford, CA; 2Columbia Univ, New York, NY; 3Ohio State Univ, Columbus, OH; 
4Mayo Clinic, Rochester, NY.
Background: IgA nephropathy (IgAN) frequently leads to progressive renal 
dysfunction. Present immunosuppressive treatment remains uncertain in terms of benefit 
and risks side effects. B cells are an attractive target in IgAN so we performed a pilot trial 
of rituximab in subjects at high risk of progression.
Methods: Patients with biopsy proven IgAN, more than 1 g/d of proteinuria despite 
RAASi (or ³0.5 g/d if on dual RAASi), well controlled blood pressure (BP) and eGFR <90ml/
min were randomized to 1 year of rituximab therapy (4g total) vs ongoing BP control, fish 
oil and use of RAASi. They were followed for B cell depletion, effects on proteinuria and 
changes in eGFR. Safety signals were also followed.
Results: 34 patients were randomized. Baseline serum creatinine was 1.5±0.5 mg/dl 
and proteinuria was 2.1, 0.6-5.5 g/d. There was no change in BP during the study. Treatment 
with rituximab resulted in significant B cell depletion and was generally well tolerated. 
There was no change in renal function during the study in either group. Rituximab treatment 
had no significant effect on proteinuria compared to baseline or control patients, and 3/17 
patients in each group experienced a ≥ 50% reduction in proteinuria during the study. 
Conclusions: In this small study, rituximab therapy had no influence on renal function 
or proteinuria in subjects with advanced disease due to IgA nephropathy. There were 
numerically greater reductions in proteinuria, but this did not reach significance. Few 
patients had substantial responses in either group. These results do not support the use of 
rituximab as treatment for patients with IgA nephropathy.
Funding: Pharmaceutical Company Support - Roche, Inc.
SA-PO1099
Establishing Endpoints for Lupus Nephritis Clinical Trials: Progress by 
the Kidney Health Initiative/Lupus Nephritis Trials Network Collaboration 
Brad H. Rovin,1 Meggan Mackay,2 Joanna Stein,2 Maria Dall’Era,4 Kenneth 
Kalunian,3 Martin L. Lesser,2 Melissa West.5  1Ohio State Univ; 2Feinstein 
Inst; 3Univ Calif San Diego; 4Univ Calif San Francisco; 5American Society 
of Nephrology.
Background: There are no universally accepted endpoints for lupus nephritis (LN) 
clinical drug trials. To obtain approval of new therapies a uniform endpoint that can be 
applied to future LN trials is needed. The optimal endpoint is a short-term measurement 
that accurately reflects long-term kidney survival. The present work was undertaken to 
define LN trial endpoints.
Methods: Clinical data at LN flare (baseline) and during serial follow-up (minimum 
22 months) from 751 patients were analyzed. Clinical variables at baseline and after 6 and 
12 months were tested as predictors of adverse long-term renal outcomes, in this case time 
to new chronic kidney disease (CKD), defined as a sustained increase in serum creatinine 
(SCr) ³30%. Multivariable Cox regression analysis was used to model time to CKD.
Results: After accounting for missing data 507 patients were included in the final 
analysis. This cohort was 89% female, 56% White, 20% Asian and 14% Black. The average 
baseline SCr was 1.2±0.7 mg/dl, proteinuria was 4.1±3.4 g/d, and eGFR by CKDepi was 
81±35 ml/min. Median follow-up was 42 months (range: 22-147 months). By univariate 
analysis urine RBCs, race, complement C3, SCr, eGFR and proteinuria were potential 
significant predictors of time to CKD. By multivariate modeling the significant predictors 
of future CKD were: SCr at 12 months (p=0.0005, Hazard Ratio (HR) 1.8 (95%CI:1.3-2.5)); 
proteinuria at 12 months (p<0.0001; HR 1.6 (1.3-1.8)); and an increase in eGFR>10% 
from baseline to 12 months compared to no change in eGFR (p<0.0001; HR 0.4 (0.3-0.6)).
Conclusions: We have identified 3 highly significant predictors of time to CKD in LN 
patients that can be measured during the first 12 months of treatment for flare. These can be 
developed into a composite endpoint for future LN therapeutic trials. Unexpectedly, small 
improvements in eGFR appear to predict renal survivial. Also, because urine RBCs do 
not appear to predict time to CKD, it may be possible to exclude urinalysis as an endpoint 
component in future clinical trials.
Funding: Private Foundation Support
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Grazoprevir (GZR)/Elbasvir (EBR) Treatment of Hepatitis C Virus (HCV) 
Infection in Patients with Chronic Kidney Disease Stage 4/5: Final Results of 
the C-SURFER Phase 3 Study  David Roth,1 Annette Bruchfeld,2 Paul Martin,1 
David R. Nelson,3 Marcelo Silva,4 Howard Monsour,5 Laurent Alric,6 Shuyan 
Wan,7 Beth Jackson,7 Bach-Yen Nguyen,7 Janice Wahl,7 Eliav Barr,7 Wayne L. 
Greaves.7  1Univ of Miami, Miami, FL; 2Karolinska Inst, Stockholm, Sweden; 
3Univ of Florida, Gainesville, FL; 4Hospital Univ Austral, Pilar, Buenos Aires, 
Argentina; 5Houston Methodist Hospital, Houston, TX; 6Hôpital de Purpan, 
Toulouse, France; 7Merck 	 Co., Inc., KenilZorth, NJ.
Background: Limited options are available for treating HCV infection in patients with 
advanced kidney disease. C-SURFER is the first randomized, placebo-controlled phase 3 
study to evaluate an all-oral, ribavirin-free regimen in CKD 4/5 patients.
Methods: 224 patients with HCV genotype (G)1 and CKD 4/5 ± hemodialysis (HD) 
were randomized to GZR/EBR 100/50mg (Immediate Treatment Group, ITG; n=111) or 
placebo for 12 weeks. Placebo subjects (deferred treatment group, DTG; n=113) received 
GZR/EBR after placebo therapy. 11 additional subjects received GZR/EBR with intensive 
pharmacokinetic (PK) sampling. The primary safety comparison was GZR/EBR vs. placebo. 
The primary efficacy endpoint, sustained virologic response (SVR) 12 weeks post-therapy 
in the ITG+PK group, was reported previously. Here we report the final results, including 
data from subjects who received GZR/EBR after placebo.
Results: In the placebo-controlled phase, serious adverse events (AEs) occurred in 
16 (14%) GZR/EBR and 17 (15%) placebo subjects; discontinuation due to an AE in 
GZR/EBR and placebo subjects was 0% and 4%. SVR12 in all subjects who received 
GZR/EBR was 94.6% (ITG+PK, 94.3% [115/122]; DTG after placebo, 95.0% [96/101]). 
12 subjects failed to attain SVR12: virologic relapse, n=3; discontinuation for AE, n=1; 
admin reason, n=8. Excluding subjects who discontinued for reasons unrelated to study 
drug, overall SVR12 was 98.6% (211/214). PK data indicate no need for dose adjustment 
in HD patients (geometric mean ratio [HD/non-HD] ranged from 0.67-0.85 for GZR and 
1.43-1.67 for EBR).
Conclusions: Once-daily GZR/EBR for 12 weeks was highly effective with a low 
rate of adverse events in patients with advanced kidney disease and HCV G1 infection.
Funding: Pharmaceutical Company Support - Merck Sharp & Dohme Corp.
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Long-Term (52-Week) Efficacy and Safety of ZS-9 in the Treatment of 
Hyperkalemia: Interim Results From a Phase 3 Open-Label, Multi-Center, 
Multi-Dose Maintenance Study  James A. Tumlin,1 Mikhail Kosiborod,2 Pablo 
E. Pergola,3 Wajeh Y. Qunibi,4 David K. Packham,5 Simon D. Roger,6 Edgar V. 
Lerma,7 Steven Fishbane,8 Henrik S. Rasmussen,9 Bruce S. Spinowitz.10  1U of 
Tennessee College of Medicine, TN; 2Saint Luke’s Mid America Heart Inst., MO; 
3Renal Associates PA, TX; 4U of Texas Health Science Center, TX; 5Melbourne 
Renal Research Group, Australia; 6Renal Research, Gosford, Australia; 7U 
of Illinois, IL; 8North Shore U. Hospital, NY; 9ZS Pharma, Inc., TX; 10Weill 
Medical College, NY.
Background: Hyperkalemia (HK) is a common and potentially lethal electrolyte 
disorder, often induced with the use of renin-angiotensin-aldosterone inhibitors (RAASi). 
Currently, the use of RAASi is prevented by HK and thus the potential for cardiac and renal 
protective effects of these agents is limited. In previous studies, ZS-9 (sodium zirconium 
cyclosilicate), a selective K+ion trap, significantly lowered serum K+and maintained 
normokalemia (NK) for up to 28 days. We present the results to date of the largest ever 
phase 3 trial examining the efficacy of ZS-9 in treating HK patients for up to 52wks.
Methods: ZS-005 (target N=750) is a multicenter, ongoing, open-label study evaluating 
ZS-9 treatment for 52wks in ambulatory pts with HK (K+≥ 5.1 mEq/L) with or without 
concurrent RAASi therapy. In the acute phase (AP), pts with HK received 10g ZS-9 TID 
over a 24-72hr period until NK (K+ 3.5-5.0 mEq/L) was achieved. Pts achieving NK were 
enrolled in a 52wk maintenance phase (MP) starting with 5g ZS-9 QD. There were no 
restrictions on diet and ZS-9 could be titrated to maintain NK. Primary outcomes were 
proportion of pts with mean K+≤5.1 mEq/L during MP and safety of ZS-9.
Results: To date, 583 pts with a mean baseline K+ of 5.6 mEq/L (15% ≥6.0 mEq/L) 
entered the study. Overall, 575 (99%) normalized K+in AP and transitioned to the MP. To 
date, K+ was maintained at ≤5.1 and <5.5 mEq/L in 87% and 99% of patients, respectively. 
The incidence and severity of adverse events were similar to that of previous studies.
Conclusions: ZS-9 acutely reduced K+ levels in pts with HK and maintained NK for up 
to 52wks irrespective of RAASi use. ZS-9 may control HK, both emergent and long-term, 
while allowing continued use of cardio- and reno-protective RAASi.
Funding: Pharmaceutical Company Support - ZS Pharma, Inc.
SA-PO1102
Interleukin-1 Inhibition and Vascular Function in Patients with Chronic 
Kidney Disease (CKD): A Randomized Controlled Trial  Kristen L. Nowak,1 
Michel Chonchol,1 Talat Alp Ikizler,2 Heather Farmer,1 Natjalie Salas,2 Rafia I. 
Chaudhry,2 Wei Wang,1 Gerard John Smits,1 Adriana Hung.2,3  1Univ of Colorado 
Denver; 2Vanderbilt Univ; 3VA Tennessee Valley Healthcare System.
Background: Vascular endothelial dysfunction and increased arterial stiffness 
contribute to increased cardiovascular risk in CKD patients who exhibit chronic systemic 
inflammation. As chronic inflammation is a key mechanism contributing to vascular 
dysfunction, blocking inflammation may reduce cardiovascular risk in CKD.
Methods: In a two-site, double-blind trial, n=42 patients with stage 3-4 CKD were 
randomized to receive either the interleukin-1 (IL-1) trap rilonacept (subcutaneous injection; 
loading dose of 320 mg followed by 160 mg/wk) or placebo for 12 weeks. All patients 
were receiving optimal treatment of hypertension, diabetes, and/or hypercholesterolemia, 
with 64% and 62% receiving a statin and an ACE inhibitor or ARB, respectively. The co-
primary endpoints were change in brachial artery flow-mediated dilation [FMDBA]) and 
aortic pulse-wave velocity [aPWV]) after 4, 8 and 12 weeks using mixed effects models. 
Secondary endpoints were change in high-sensitivity C-reactive protein (hsCRP), ∆FMDBA 
following an acute infusion of ascorbic acid known to inhibit superoxide production (n=23), 
and vascular endothelial cell protein expression of NADPH oxidase (n=13).
Results: Participants were 63±11 (mean±s.d.) years of age, 24% female and 24% Black, 
with eGFR 38±13 ml/min/1.73m2. Rilonacept improved FMDBA (baseline: 3.8±3.1%, 12 
wks: 4.9±3.2%) compared to placebo (baseline: 3.4±2.1%, 12 wks: 2.5±2.3%; p<0.01), 
without changing aPWV (p=0.52). Rilonacept also reduced hsCRP levels (baseline: 4.6 
(1.9, 8.22) [median (interquartile range)], 12 wks: 2.16 (0.96, 7.38) mg/L; p<0.01), and 
endothelial cell NADPH oxidase expression (p<0.05). Acute infusion of ascorbic acid tended 
to improve FMDBA in the placebo (p=0.07) but not the rilonacept group (p=0.56), indicating 
reduced vascular oxidative stress. Overall, rilonacept was well tolerated.
Conclusions: 12 weeks of treatment with an IL-1 trap improved FMDBA without 
changing aPWV in patients with stage 3-4 CKD. This was associated with a reduction in 
systemic inflammation and vascular oxidative stress.
Funding: Veterans Administration Support, Pharmaceutical Company Support - 
Regeneron Pharmaceuticals, Inc, Private Foundation Support
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Impact of Vitamin D Supplementation on Endothelial and Vascular 
Function in Patients with Chronic Kidney Disease: A Randomized, Double 
Blind, Placebo-Controlled Trial  Vivek Kumar,1 Ashok Kumar Yadav,1 Vinod 
Sharma,1 Manphool Singhal,2 Anupam Lal,2 Debasish Banerjee,3 Vivekanand 
Jha.1  1Nephrology, Postgraduate Inst of Medical Education and Research, 
Chandigarh, Chandigarh, India; 2Radiodiagnosis, Postgraduate Inst of Medical 
Education and Research, Chandigarh, Chandigarh, India; 3Nephrology, St. 
George’s Univ Hospitals NHS Foundation Trust, London, London, United 
Kingdom.
Background: Vitamin D deficiency is associated with mortality in CKD patients. We 
investigated the effect of Vitamin D supplementation on endothelial and vascular function 
in patients with non-diabetic CKD stage 3-4.
Methods: In a prospective, randomized, double blind, placebo-controlled trial, 120 
patients with non-diabetic CKD stage 3-4 and vitamin D deficiency [serum 25(OH)D 
<20ng/ml] aged 18-70 years were randomized (1:1) to receive either two directly observed 
oral doses of 300,000 IU of cholecalciferol at 0 and 8 weeks or matching placebo. The 
pre-specified primary outcome was 40% change in endothelium dependent brachial artery 
flow mediated dilatation (FMD) at 16 weeks. Secondary outcome measures included 
changes in pulse wave velocity (PWV), augmentation index (AI), and serum biomarkers.
Results: Baseline FMD was identical in both arms (7.65±2.24% vs 7.85±2.34%). 
Intervention arm showed a significant increase in serum 25(OH)D (+ 24.9 ng/ml, 95% CI: 
21.8 to 28.06, p<0.0001), and the number of subjects meeting the primary end point (70% 
vs 5%, p<0.0001). FMD change was 5.42% (95% CI: 4.44 to 6.40%) in the intervention 
arm and -0.07%, (95% CI, -0.70 to 0.58%) in placebo arm. Intervention led to favorable 
changes in PWV (-0.94 m/s, 95% CI: -1.30 to -0.58, p<0.0001), E-selectin (-3.68 ng/ml, 
95% CI: -8.1 to 0.7 p=0.028), IL-6 (-2.0 pg/ml, 95% CI: -2.96 to -0.8 p=0.001), FGF-23 
(-14.7 pg/ml, 95% CI -28.5 to -1.0 p=0.036) and 1,25(OH)2D (+15.5 pg/ml, 95% CI: 5.4 to 
25.5, p=0.003). These did not change significantly in the control group. No changes were 
observed in AI, vWF and hs-CRP in either group.
Conclusions: In non-diabetic patients with stage 3-4 CKD and vitamin D deficiency, 
vitamin D supplementation leads to improvement in endothelial function, markers of 
inflammation and arterial stiffness.
Funding: Government Support - Non-U.S.
SA-PO1105
Effect of Cholecalciferol versus Calcitriol on Vascular Endothelial Function 
in CKD: A Randomized Active-Controlled Trial  Jessica B. Kendrick,1,2 
Gerard John Smits,1 Emily Decker,1 Heather Farmer,1 Michel Chonchol.1 
1Univ of Colorado School of Medicine, Aurora, CO; 2Denver Health Medical 
Center, Denver, CO.
Background: Epidemiological studies have shown that vitamin D is associated with 
decreased cardiovascular morbidity and mortality, but the effects of vitamin D administration 
on patient outcomes in chronic kidney disease (CKD) are lacking. We conducted a 
prospective, double-blinded, randomized trial to determine the effects of oral cholecalciferol 
vs. calcitriol on vascular endothelial function over 24 weeks in patients with CKD stage 3-4.
Methods: 128 patients with CKD stage 3-4 (estimated GFR 15-44 ml/min/1.73m2) 
with vitamin D deficiency, defined as serum 25-hydroxyvitamin D level (25(OH)D) < 30 
ng/mL, were randomly assigned to receive either cholecalciferol (4000 IU daily x 4 weeks 
then 2000 IU daily x 20 weeks) or calcitriol (0.25 mcg daily x 4 weeks then 0.5 mcg daily 
x 20 weeks). The primary endpoint was change in brachial artery flow mediated dilation 
(FMDBA) over 24 weeks. Secondary endpoints included changes in parameters of mineral 
bone disease and plasma concentrations of inflammatory cytokines (C-reactive protein 
and interleukin-6).
Results: 115 patients completed the study. The mean (SD) age and eGFR was 58.1 
± 12.4 years and 33.1 ± 10.2 ml/min/1.73m2, respectively. In the cholecalciferol group, 
mean 25(OH)D levels increased from 22.7 ± 7.5 ng/mL to 33.5 ± 7.9 ng/mL. There was 
no change in 25(OH)D levels in the calcitriol group. Parathyroid hormone levels decreased 
significantly in the calcitriol group compared to the cholecalciferol group (p=0.001). At 
24 weeks, the change in FMDBA did not differ significantly between treatment groups 
(cholecalciferol group -0.72%, 95% CI -1.97 to 0.54 vs. calcitriol group 0.29%, 95% CI 
-0.72 to 1.29, p=0.44). There was no significant change in C-reactive protein or interleukin-6 
concentrations between the two groups. Episodes of hypercalcemia were more frequent in 
the calcitriol group (n=4) compared with the cholecalciferol group (n=1).
Conclusions: Twenty-four week therapy with cholecalciferol or calcitriol did not 
improve vascular endothelial function or reduce inflammation in patients with CKD.
Funding: NIDDK Support
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SA-PO1106
Vitamin D Receptor Activation and Dietary Sodium Restriction to Reduce 
Residual Albuminuria in Chronic Kidney Disease  Martin H. De Borst,1 
Charlotte A. Keyzer,1 Fenna van Breda,2 Marc G. Vervloet,2 Gozewijn Dirk 
Laverman,3 Marc H. Hemmelder,4 Wilbert M. Janssen,5 Hiddo Jan Lambers 
Heerspink,1 Stephan J.L. Bakker,1 Gerjan Navis.1  1UMC Groningen; 2VUmc 
Amsterdam; 3ZGT Almelo; 4MC Leeuwarden; 5Martini Hospital Groningen, 
Netherlands.
Background: Reduction of residual albuminuria during single-agent RAAS-blockade 
is associated with improved cardiorenal outcomes in CKD. Both vitamin D receptor 
activators (VDRA) and dietary sodium restriction reduce residual albuminuria. Previous 
data suggested that sodium restriction is not required for optimal albuminuria reduction 
by VDRA. We studied the individual and combined effects of paricalcitol and sodium 
restriction on residual albuminuria during optimally dosed ACEi in CKD.
Methods: In a multi-center, randomized, placebo-controlled cross-over trial, 45 patients 
with non-diabetic CKD stage 1-3 and residual albuminuria >300 mg/24h despite ramipril 
10 mg/d and BP <140/90 mmHg were treated during four 8-week periods with paricalcitol 
(PARI, 2 µg/day) or placebo (PLAC), each combined with a low (LS, 2.5 gr Na+/d) or 
regular sodium (RS, 4 gr Na+/d) diet, in random order. Linear mixed-effect models for 
repeated measurements were used to determine treatment effect.
Results: In the intention-to-treat analysis, albuminuria was 1,060 [778 to 1,443] 
(geometric mean [95% CI]) mg/24h during RS+PLAC. During RS+PARI, albuminuria 
was 990 [755 to 1,299] mg/24h (-12.5% [-26.0% to 26.3%] vs. RS+PLAC, P=0.2). 
LS+PLAC reduced albuminuria to 717 [512 to 1,005] mg/24h (-25.4% [-52.6% to -2.3%] 
vs. RS+PLAC, P<0.001). LS+PARI provided the strongest albuminuria reduction to 683 
[502 to 929] mg/24h (-31.7% [-55.0% to -0.9%], P<0.001 vs. RS+PLAC), although the 
additional reduction by PARI beyond the effect of LS was non-significant (P=0.6). However, 
in a per protocol analysis (≥95% compliance, N=34) PARI did reduce residual albuminuria 
beyond the effect of LS (P=0.04).
Conclusions: The combination of paricalcitol and moderate dietary sodium restriction 
provided the strongest reduction of residual albuminuria during optimal ACEi; the effect 
was mainly driven by sodium restriction. Our findings underline the relevance of sodium 
restriction, possibly combined with paricalcitol, to optimize albuminuria reduction.
SA-PO1107
Vascular Function and Uric Acid Lowering via Allopurinol in Stage III 
CKD: Results of a Double-Blinded Randomized Placebo-Controlled Study 
Diana I. Jalal,1 Emily Decker,1 Loni J. Perrenoud,1 Nina Bispham,2 Tapan Mehta,1 
Gerard John Smits,1 Richard J. Johnson.1  1Medicine/ Renal Div, UC AMC, 
Aurora, CO; 2Integrative Physiology, UC Boulder, Boulder, CO.
Background: Observational studies suggest that asymptomatic hyperuricemia 
associates with vascular disease in chronic kidney disease (CKD). A recent study suggested 
that lowering serum urate with allopurinol improves endothelial function in elderly adults 
with stage III CKD. It remains unknown if lowering serum urate improves endothelial 
function in adult subjects with stage III CKD.
Methods: 80 adult subjects (18-70) years of age with stage III CKD and asymptomatic 
hyperuricemia (≥7 mg/dL in men and ≥6 mg/dL in women) were randomized to receive 
placebo or allopurinol (100 mg tablets) for 12 weeks. The study was double-blinded 
and subjects were instructed to take 1 tablet for 1 week, 2 tablets for another week, and 
3 tablets thereafter. Changes (from baseline) between both groups were compared by 
Wilcoxon rank-sum test.
Results: No significant differences existed between both groups at baseline. After 12 
weeks, allopurinol lowered serum urate significantly. FMD increased in the allopurinol 
group compared to placebo; but this was not statistically significant. NMD increased with 
allopurinol but decreased with placebo; p value = 0.14. These data are shown in Table 
1. There were no significant differences between allopurinol and placebo for systolic or 
diastolic blood pressure, markers of inflammation, or markers of oxidative stress. 10 subjects 
withdrew from the study. A few adverse events were noted in both groups including 1 gout 
attack in each group. 1 subject died during the study due to a cardiac event. 
Variable Placebo  Allopurinol P value
Serum Urate(mg/dL)  0.05(1.54)  -3.24(1.35)  <0.0001
FMD(%change)  0.16(4.05)  0.91(3.9)  0.47
NMD(%change)  -1.29(5.33)  0.93(6.05)  0.14
Conclusions: Allopurinol effectively and safely lowered serum urate in adults with 
stage III CKD and asymptomatic hyperuricemia but this did not improve endothelial function 
significantly. There was tendency towards improved NMD suggesting that hyperuricemia 
may negatively impact vascular smooth muscle function in stage III CKD.
Funding: NIDDK Support
SA-PO1108
Podocyturia Is an Earlier and Superior Predictor of Cardiovascular 
Outcomes Than Is Albuminuria  Assaad Antoine Eid,1 Robert Habib,2 Kamal 
F Badr.2  1Anatomy, Cell Biology and Physiological Sciences, American Univ 
of Beirut - Faculty of Medicine, Beirut, Beirut, Lebanon; 2Internal Medicine, 
American Univ of Beirut - Faculty of Medicine, Beirut, Beirut, Lebanon.
Background: Increased urinary albumin excretion rate (AER), a predictor of 
cardiovascular events, results from abnormally increased albumin filtration accompanying 
injury to glomerular endothelial and epithelial cells (“podocytes”). Since AER is modified 
by renal proximal tubule albumin retrieval, we hypothesized that urinary podocyte shedding, 
podocyturia, would be a more relevant and earlier biomarker of endothelial injury (and 
CVD) than moderate albuminuria.
Methods: 106 Type II diabetic subjects (mean age: 46/60 men/women) with normal 
AER [<2.26 mg/mmole (20 µg/mg) creatinine] and free of overt cardiovascular disease 
(CVD) were enrolled. AER and podocyte-specific proteins (podocin and nephrin) mRNA 
were measured at baseline (visit 1), 3-4 years later (visit 2) and at 7 years (visit 3). 
Development of cardio vascular diseases VD - defined as coronary disease, cerebrovascular 
disease and/or peripheral vascular disease (can be removed to fit words counting)– was 
collected as outcome. 7-year Kaplan-Meier time-to-event (log rank) data were compared 
in baseline biomarker tercile groups (low, intermediate, high).
Results: Allthreebiomarkersincreasedsignificantlybetweenvisits(P<0.001).AERterciles 
exhibited similar time to CVD (p=0.127), which was in contrast with the step-wise and 
substantial increase in CVD events with increasing podocin and nephrin levels (P<0.001). 
Considering all three biomarkers as continuous factors, the covariate-adjusted hazard ratios 
(95% confidence intervals) [HR] were highest for podocin mRNA [HR=15.9 (6.1-41.8); 
p<0.001], intermediate for nephrin mRNA [HR=7.61 (3.75-15.5); p<0·001] and lowest for 
AER [HR=1.17 (1.01-1.36); p=0·041].
Conclusions: ComparedtotraditionalAER,podocyturiapredictsmoreaccuratelyandatan 
earlier time point the presence of silent systemic vascular injury, that manifests as overt 
cardiovascular events.
SA-PO1109
Empagliflozin Reduces Microalbuminuria and Macroalbuminuria in 
Patients with Type 2 Diabetes  David Cherney,1 Søren Søgaard Lund,2 Bruce 
A. Perkins,3 Per-Henrik Groop,4,5 Mark E. Cooper,5 Stefan Kaspers,2 Susanne 
Crowe,2 Hans-Juergen Woerle,2 Maximilian von Eynatten.2  1Toronto General 
Hospital, Univ of Toronto, Canada; 2Boehringer Ingelheim Pharma GmbH & 
Co. KG, Ingelheim, Germany; 3Mount Sinai Hospital, Univ of Toronto, Canada; 
4Univ of Helsinki and Helsinki Univ Hospital, Folkhälsan Research Center, 
Helsinki, Finland; 5Baker IDI Heart and Diabetes Inst, Melbourne, Australia.
Background: Reductions in HbA1c, systolic blood pressure (SBP), and weight with 
the highly selective SGLT2 inhibitor empagliflozin in patients with type 2 diabetes (T2D) 
may favorably impact albuminuria.
Methods: Using data pooled from 5 Phase III, randomized clinical trials, we assessed 
the effect of empagliflozin 10 or 25 mg for 24 weeks on urine albumin to creatinine ratio 
(UACR) in patients with T2D and prevalent microalbuminuria (UACR 30–300 mg/g; 
n=636) or macroalbuminuria (UACR >300 mg/g; n=215) at baseline.
Results: Empagliflozin reduced UACR vs placebo in patients with T2D and 
microalbuminuria (-32%; p<0.001) or macroalbuminuria (-41%; p=0.001) after controlling 
for baseline log (UACR), HbA1c, SBP, estimated glomerular filtration rate (MDRD), 
region, study and treatment (Figure). Adjusted mean (SE) changes in HbA1c, weight, 
SBP and diastolic BP with empagliflozin vs placebo were -0.50 (0.07) %, -1.6 (0.2) kg, 
-4.4 (1.1) mmHg and -2.3 (0.6) mmHg, respectively, in patients with microalbuminuria 
(all p<0.001), and -0.53 (0.13) %, -1.8 (0.4) kg, -6.3 (2.0) mmHg and -2.2 (1.1) mmHg, 
respectively, in patients with macroalbuminuria (all p<0.05). Linear regression analyses 
showed that changes in HbA1c, weight and SBP accounted for a maximum of half the 
UACR-lowering effect.
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Conclusions: SGLT2 inhibition with empagliflozin reduced UACR by >30% in patients 
with T2D and prevalent microalbuminuria or macroalbuminuria, independent of its known 
metabolic and hemodynamic effects.
Funding: Pharmaceutical Company Support - Boehringer Ingelheim and Eli Lilly 
and Company
SA-PO1110
Vadadustat, a Novel Oral Treatment for Anemia of Chronic Kidney Disease, 
Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from 
Erythropoiesis-Stimulating Agents  Volker H. Haase,1 Charlotte S. Hartman,2 
Bradley J. Maroni,2 Ramin Farzaneh-Far,2 Peter A. McCullough.3  1Div of 
Nephrology and Hypertension, Vanderbilt Univ Medical Center, Nashville, 
TN; 2Akebia Therapeutics, Inc., Cambridge, MA; 3Baylor Univ Medical Center, 
Dallas, TX.
Background: Vadadustat is a novel, oral agent that stimulates erythropoiesis by 
stabilizing hypoxia-inducible factor (HIF). Prior studies in patients with Non-Dialysis 
Dependent Chronic Kidney Disease (NDD-CKD) have shown that vadadustat results in 
controlled, dose-dependent increases in hemoglobin (Hb) and enhances iron mobilization 
and utilization. Here we present data from a Phase 2 trial of vadadustat in hemodialysis 
patients.
Methods: A multi-center, open-label, 16-week trial was designed to assess Hb response, 
safety, and tolerability of vadadustat. The trial enrolled 94 hemodialysis patients (Hb 9 - 12 
g/dL), who were maintained on erythropoiesis-stimulating agents (ESAs) prior to study 
entry. Patients were converted from ESA to vadadustat, and assigned to 1 of 3 dose cohorts: 
300 mg once daily (QD); 450 mg QD; or 450 mg three times weekly (TIW). The primary 
efficacy analysis was to evaluate mean Hb changes from baseline at weeks 7/8, and weeks 
15/16. From week 8, dose could be adjusted as needed to maintain Hb. All patients were 
iron replete at baseline and throughout the study; IV iron use was allowed.
Results: Vadadustat maintained stable Hb levels in all 3 dose cohorts during the 16 
week treatment period following conversion from ESA.
Mean Hb levels (g/dL) in Modified Intent-To-Treat (MITT) population   
 Dose Cohort  Baseline  Week 7/8  Week 15/16
 300mg QD  10.4  10.4  10.3
 450mg QD  10.6  10.3  10.5
 450mg TIW  10.5  10.2  10.4
One subject in the 300mg QD cohort had a single Hb excursion to 13.1 g/dL. Adverse 
events were balanced across the 3 cohorts. Serious adverse events (SAEs) were reported 
in 13 subjects (13.8%), which was within the expected range (13 – 17 subjects). No drug-
related SAEs, nor deaths, were reported.
Conclusions: Vadadustat safely and effectively maintained Hb levels in dialysis patients 
who were converted from injectable ESAs.
Funding: Pharmaceutical Company Support - Akebia Therapeutics Inc., Cambridge, 
MA, United States
SA-PO1111
Autologous Erythropoietin Production by the TARGT Gene Therapy 
Platform Maintains Stable Hb for 6-12 Month in ESRD Patients without 
the Need for ESA Administration  Shany Blum,1 Nir Shapir,1 Reem Miari,1 
Shai Efrati,3 Pablo E. Pergola,4 Garry A Neil.2  1Medgenics Medical Israel 
Ltd., Misgav, Israel; 2Medgenics Inc, Wayne, PA; 3Research & Development 
and Nephrology Units, Assaf-Harofeh Medical Center, Zerifin, Israel; 4Renal 
Associates PA, San Antonio, TX.
Background: Recombinant human erythropoietin (rHuEPO) administration to iron 
replete patients corrects anemia in most patients with ESRD, but doses result in supra-
physiological peak serum concentration (Cmax) of EPO that may cause thromboembolic 
complications. The Transduced Autologous Restorative Gene Therapy system 
(TARGT™) is an ex-vivo gene therapy, providing autologous, continuous protein 
therapies at physiological ranges that was used encoding for the human erythropoietin gene 
(TARGTEPO) for these studies. Patient dermal tissue biopsies (MOs) are transduced with 
a Helper-Dependent Adenoviral Vector containing the EPO gene and then re-implanted 
subcutaneously to deliver the required EPO dose.
Methods: We present initial results from 3 ongoing open label ascending dose studies 
of TARGTEPO in patients with anemia due to CKD undergoing either Hemo or Peritoneal 
Dialysis.
Results: Thus far 14 patients were enrolled in all protocols. Follow up is ongoing with 
the first implanted patient being followed with stable EPO secretion and stable Hb for over 
14 months from a single implantation without the need for rHuEPO or blood transfusion. 
Results obtained suggest that treatment with TARGTEPO stabilize serum EPO levels at the 
physiological range of £20 mIU/ml resulting in Hb levels between 9-12 g/dL. Comparative 
analysis of serum EPO levels revealed significantly lower Cmax with TARGTEPO compared 
to rHuEPO and an order of magnitude less overall EPO exposure as calculated by Area 
Under the Curve which may confer significant clinical benefit. No treatment related serious 
adverse events have been reported.
Conclusions: TARGTEPO is a promising novel therapy for the treatment of anemia of 
CKD and potentially for other protein deficient diseases.
Funding: Pharmaceutical Company Support - Medgenics Inc.
SA-PO1112
Monitoring in Dialysis (MiD) Study: Exploring the Timeline and 
Etiology of Increased Arrhythmias in Hemodialysis (HD) Patients 
Prabir Roy-Chaudhury,1 Don E. Williamson,2 James A. Tumlin,3 Vijay K. Kher,4 
Vikranth Reddy,5 Kowdle Chandrasekhar Prakash,6 David M. Charytan,7 Suresh 
Chandra Tiwari,8 Saurabh Pokhariyal,9 Amber S. Podoll.10  1Univ of Arizona, 
Tucson; 2Nephrology Associates, Augusta; 3Univ of Tennessee, Chattanooga; 
4Medanta Medicity; 5CARE Hospital, Hyderabad; 6Apollo Hospitals-Chenna; 
7Brigham and Women’s Hospital; 8Fortis-Vasant Kunj, Delhi; 9Fortis, Gurgaon; 
10Univ of Texas, Houston.
Background: Sudden cardiac death (SCD), likely due to cardiac arrhythmias (CA) is 
the most important cause of mortality in the HD population. We herein present data on the 
timeline and potential etiology of CA in HD patients (pts).
Methods: The MiD study (n=66) characterized the type and frequency of CA in 3x/
wk HD pts over 6 mths, using an implanted loop recorder (Medtronic Reveal). Reviewer 
confirmed arrhythmias (RCA;all documented CA) and clinically significant arrhythmias 
(CSA;brady/asystole/VT/ symptomatic), were linked to the dialysis cycle, pt wt and pre/
post-session electrolytes, using negative binomial mixed effects regression analyses.
Results: Mean age was 56.3±12.2; 64% diabetic; 70% male; HD vintage 4.3±5.1 yrs. 
97% and 67% of pts had a RCA/CSA. Most CSA occurred during the intradialytic period 
of the first weekly HD and then decreased in subsequent sessions. Univariate analyses 
identified increased pre and post wt, high pre HD potassium (K) and drop in K as risk 
factors for RCA. Multivariate analyses (adjusted for DM, yrs on HD, pre-wt), identified 
higher pre HD K levels as a predictor for increased RCA. The highest risk of arrhythmia 
occurred in pts with high K drops AND substantial volume removal (p=0.03).
Underline represents presenting author/disclosure.
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Conclusions: These data establish linkages between intra-dialytic CSA and the long 
interdialytic period, and also identify a unique interaction between fluid removal and K in 
the generation of RCA. This suggests for the first time, that future data driven targeting of 
these parameters might reduce CA and potentially SCD in HD pts.
Funding: Pharmaceutical Company Support - Medtronic
SA-PO1113
The Occurrence of Cardiac Arrhythmias in Hemodialysis Patients is 
Linked to the Hemodialysis Procedure and to Electrolyte Abnormalities 
as Recorded by Implantable Loop Recorders  Christian Combe,1,2 Antoine 
Benard,1,2 Hélène Savel,1,2 F. Sacher.1,2  1CHU & Univ. Bordeaux, Bordeaux, 
France; 2Rythmodial Study Group.
Background: Sudden cardiac death (SCD) is the most common mode of death among 
hemodialysis (HD) patients (pts). Little is known about the terminal arrhythmic events in 
these pts. Our objective was to identify the mechanisms which may lead to SCD in HD pts 
using an implantable loop recorder (ILR, Reveal XT®, Medtronic).
Methods: Pts from 9 HD centers have been included in the study. Continuous 
monitoring of the cardiac rhythm has been performed using the remote monitoring capability 
of the ILR device (Carelink®). Clinical, biological, and technical HD parameters and 
medications have been recorded for at least 1 year. General joint frailty model for recurrent 
event data were used to analyze associations between these parameters and the occurrence 
of cardiac rythm events.
Results: 72 pts (65.1±8.6 yrs, 52M) have been included. Causes of ESRD were 
diabetes (n=32) and hypertension (n=19). 22 pts had an ischemic cardiomyopathy. In 
multivariate analyses, the occurrence of conduction abnormalities (n=64) was associated 
to high potassium (K+) concentrations (K+>5mM, RR=5.22, p<10-4) and to body weight 
(bw) variation during HD (RR per %bw/h 3.22, p<10-2). There was no association with 
serum calcium, hemoglobin, HD bath ions, blood pressure. Ventricular arrythmias >150/
min (n=11) were associated only to high K+ levels (K+>5mM, RR=13.35, p<0.05), to 
low K+ levels (K+<4 mM, RR=24.48, p<0.01), and to high phosphate levels (Pi>45mg/L, 
RR=5.64, p<0.04). Atrial fibrillation was the most frequent event (n=255), with less clear 
associations with patient-dependent and HD-dependent variables. In 6 SCD patients, ILR 
tracings demonstrated progressive bradycardia followed by asystole.
Conclusions: Our data show that the various types of arrythmias and conduction 
abnormalities occurring in HD pts are linked to different pathophysiological mechanisms, 
with a central role of serum K+ levels, levels lower than 4 mM or higher than 5 mM being 
deleterious. Rapid body weight variations were linked to ventricular arrythmias. Therapeutic 
strategies aimed at controlling these factors can be drawn from our study.
Funding: Pharmaceutical Company Support - Medtronic, Government Support - 
Non-U.S.
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Comparison of the Efficacy and Safety of Intravenous (IV) Etelcalcetide 
(AMG 416) and Oral Cinacalcet (CIN) in Patients on Hemodialysis (HD) 
with Secondary Hyperparathyroidism (sHPT)  Kevin J. Martin,1 Geoffrey 
A. Block,2 Sunfa Cheng,3 Bastian Dehmel,3 Reshma Kewalramani,3 David 
M. Spiegel,4 Hao Wang,3 Glenn Matthew Chertow.5  1St Louis Univ SOM, St. 
Louis, MO; 2Denver Neph, Denver, CO; 3Amgen; 4Relypsa; 5Stanford Univ 
SOM, Palo Alto, CA.
Background: This is a randomized, active controlled, double-blind, double dummy 
study comparing the efficacy and safety of a novel IV calcimimetic, AMG 416, with CIN.
Methods: Patients receiving HD with PTH >500 pg/ml, albumin-corrected calcium 
(cCa) ≥8.3 mg/dL, and no CIN use for 3 months were randomized 1:1 to AMG 416 IV/
oral placebo or oral CIN/IV placebo for 26 weeks (wks). Doses were titrated at wks 5, 9, 
13, 17 based on the prior wk’s PTH and cCa. AMG 416 was started at 5mg and titrated 
by 2.5 or 5mg up to 15mg 3 times weekly with HD. CIN was started at 30mg and titrated 
up to 180mg daily per label. Target PTH was ³100 and £300 pg/ml. Primary endpoint was 
noninferiority on >30% reduction in PTH during wks 20-26. Secondary endpoints were 
>30% reduction in PTH (superiority analysis), >50% reduction in PTH, mean days of nausea 
or vomiting (n/v) (patient reported outcome) per wk in the first 8 wks.
Results: 683 subjects were randomized (340 AMG 416, 343 CIN), 553 completed the 
trial (84% AMG 416, 86% CIN). AMG 416 was noninferior to CIN on the primary endpoint. 
AMG 416 was superior on >30% reduction in PTH (68% AMG 416, 58% CIN, p=0.004) 
and >50% reduction in PTH (52% AMG 416, 40% CIN, p=0.001). Mean days of n/v in the 
first 8 wks did not differ (0.4 AMG 416, 0.3 CIN, NS). The most common adverse event 
(AE) in either group was blood calcium decreased (69% AMG 416, 60% CIN), mostly 
mild to moderate severity. Heart failure related AEs were reported in 10 (3.0%) AMG 416 
subjects and 2 (0.6%) CIN subjects, of which 5 and 1, respectively, were serious. 9 (3%) 
subjects receiving AMG 416 and 6 (2%) receiving CIN had fatal treatment-emergent AEs 
– all unrelated to study drug.
Conclusions: AMG 416 achieved a >50% and a >30% reduction in PTH in more 
subjects compared to CIN. Hypocalcemia was seen more often with AMG 416. Nausea and 
vomiting did not differ. IV AMG 416 is more efficacious than oral CIN for the treatment 
of sHPT in patients on HD.
Funding: Pharmaceutical Company Support - Amgen
SA-PO1116
A Trial Assessing Use of a Wearable Artificial Kidney (WAK) in Patients 
Undergoing Maintenance Hemodialysis  Victor Gura,1 Matthew B. Rivara,2 
Raj P. Munshi,2 Scott D. Bieber,2 Masoud Beizai,3 Carlos J. Ezon,3 Larry 
Kessler,2 Jonathan Himmelfarb.2  1Cedars Sinai- UCLA, Los Angeles, CA; 
2Univ of Washington, Seattle, WA; 3Blood Purification Technologies Inc, 
Beverly Hills, CA.
Background: Current stationary dialysis machines hinder mobility and limit activities 
of daily life during dialysis treatments. There is a critical need for new technologies 
to increase patient autonomy, enhance quality of life, and allow for increased patient 
rehabilitation.
Methods: This is the first FDA-approved human trial of the WAK, a miniaturized, 
wearable hemodialysis machine based on dialysate-regenerating sorbent technology 
(NCT02280005). We aimed to determine the safety and efficacy of the WAK in maintaining 
euvolemia and achieving solute clearance and electrolyte homeostasis over 24 hours.
Results: All patients remained hemodynamically stable, and there were no serious 
adverse events. Serum electrolytes and hemoglobin remained stable over the treatment 
period for all subjects. Six out of seven patients ambulated while receiving WAK treatment. 
Fluid removal was consistent with prescribed ultrafiltration rates. Mean blood flow was 
42 ± 24 and dialysate flow was 43±20 ml/min with no laboratory evidence of hemolysis. 
Mean BUN, creatinine, and phosphorus clearances were 21 ± 13, 20 ± 11, and 22 ± 12 
ml/min respectively during the first hour of treatment. In one subject, treatment was 
discontinued due to clotting after 4 hours. In a second subject, treatment was discontinued 
due to discoloration of dialysate observed after 10 hours. The trial was stopped after the 
7th subject due to device-related malfunctions. These included excessive CO2 bubbles 
in the dialysate, variable blood and dialysate flows, and tubing leaks during the priming 
phase. Redesign and re-manufacturing of the WAK prototype will be required prior to 
additional human studies.
Conclusions: Treatment with the WAK was well tolerated, resulted in effective uremic 
solute clearance and maintenance of electrolyte and fluid homeostasis. These results serve 
as proof-of-concept of the WAK as a viable novel dialysis technology.
Funding: Private Foundation Support
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CR845, a Novel Kappa Opioid Receptor Agonist Reduces Moderate-
to-Severe Pruritus and Improves Quality of Life in Chronic Kidney 
Disease Patients Undergoing Hemodialysis  Robert Spencer,1 Vandana S. 
Mathur,2 James A. Tumlin,3 Joseph W. Stauffer,1 Frederique Menzaghi.1  1Cara 
Therapeutics, Inc., Shelton, CT; 2Mathur Consulting, San Francisco, CA; 3Univ 
of Tennessee, Chattanooga, TN.
Background: Approximately 40% of US hemodialysis (HD) patients experience 
moderate-to-severe itching, which negatively affect their mental and physical health (e.g., 
sleep loss, depression, higher antibiotic and erythropoietin use and increased mortality). The 
etiology of this condition is likely multi-factorial, including immune system dysfunction 
and imbalance of mu/kappa endogenous opioids. CR845 is a novel and well-tolerated 
kappa opioid receptor (KOR) agonist with limited central nervous system entry, thereby 
preferentially activating KOR on peripheral neurons and immune cells.
Methods: In this Phase 2 double-blind, randomized (1:1), placebo-controlled clinical 
study, 65 prevalent US HD patients with persistent (~ 5 years) moderate-to-severe pruritus 
(baseline VAS ~68 mm, 0=no itch; 100 mm =worst itch) were treated with 1 mcg/kg 
intravenous CR845 or placebo following each HD session for 2 weeks. Antihistamines 
were discontinued 1 week prior to the study.
Results: The primary endpoint was met (VAS change in worst itch intensity from 
baseline to Days 12-15), with a significant difference in itch intensity between placebo 
and CR845-treated patients (p=0.016). CR845-treated patients had a 50% mean reduction 
in itch intensity from baseline. The 1st secondary endpoint was also met with a significant 
improvement in Skindex-10, a validated patient-reported outcome measure of pruritus-
related quality of life (p =0.031). Furthermore, a trend for a sleep improvement was 
observed (SLP9).
Conclusions: Short-term treatment with CR845 significantly reduced itch intensity 
and improved quality of life in HD patients with moderate-to-severe pruritus. Thus, CR845 
appears to have substantial potential to alleviate the symptoms and consequences of this 
frequently incapacitating condition for which existing treatments have often provided 
little or no relief. These data also support the opioid/immune etiology of this condition.
Funding: Pharmaceutical Company Support - Cara Therapeutics, Inc.
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SA-PO1118
The ASSertID Study: Feasibility Randomised Controlled Trial of Drug 
Treatment for Depression in Patients on Haemodialysis   Ayman Guirguis,1,2,3 
Michael K. Almond,4 Joseph Chilcot,5 Andrew Davenport,6 Clara Day,7 
Naomi Fineberg,2,3 Karin Friedli,2 Benjamin Spencer,5 David Wellsted,2 Ken 
Farrington.1,2  1East & North Hertfordshire NHS Trust, United Kingdom; 2Univ 
of Hertfordshire, United Kingdom; 3Hertfordshire Partnership Univ NHS Trust, 
United Kingdom; 4Southend Univ Hospitals NHS Trust, United Kingdom; 
5King’s College London, United Kingdom; 6Royal free London NHS Trust, 
United Kingdom; 7Univ Hospitals Birmingham NHS Trust, United Kingdom.
Background: Major Depressive Disorder (MDD) is common in patients on 
Haemodialysis (HD) but there is little evidence of benefit from antidepressants. Hence 
we undertook a multicentre feasibility Randomised Controlled Trial (RCT) of sertraline 
versus placebo.
Methods: A screening phase identified patients with Beck Depression Inventory (BDI-
II) score ³16.Those meeting eligibility criteria, underwent psychiatric assessment (Mini 
International Neuropsychiatric Interview). Consenting patients with mild to moderate MDD 
and Montgomery-Åsberg Depression Rating Scale (MADRS) score ³18 were randomised to 
sertraline or placebo. Follow-up by study psychiatrist;week 2, month 2, 4 and 6 and monthly 
by study nurses. Initial dose was 50 mg with titration to 100 mg if required.
Results: Of 1355 patients approached, 715 consented for screening. BDI-II ³16 was 
present in 231(32.3%), 58 (25.1%) were ineligible due to current treatment for MDD. 
Sixty-three underwent psychiatric assessment. MDD was diagnosed in 37; 30 consented 
to the RCT (mean age 61 ±15; 71% male; 60% white). Twenty-one (70%) completed the 
trial, 8(of 15) on sertraline and 13(of 15) on placebo. Over 6 months, BDI-II and MADRS 
scores decreased (t(17)=6.3, p<0.001 and t(20)=11.3, p<0.001 respectively). There was no 
reliable difference between the sertraline and placebo groups. Fewer on sertraline completed 
(6 withdrawals and one death versus 2 withdrawals on placebo [C2=3.97, p=0.046]). There 
was a trend towards a greater fall in MADRS scores by month 2 on sertraline (effect size 
0.37: lower bound >0).
Conclusions: This feasibility study is the largest RCT investigating the use of anti-
depressants in HD patients with MDD. Similar significant improvement in MDD occurred 
over 6 months in both groups. Recovery may have been quicker on sertraline.
SA-PO1119
Randomised Controlled Trial to Determine the Appropriate Time to Initiate 
Pertioneal Dialysis after Insertion of Catheter to Minimise Complications 
Helen G. Healy,1 George T. John,1 Edward Yeoh,1 Nicola Williams,1 Thin 
M. Han,2 Lakshmanan Jeyaseelan,3 Kavitha Ramanathan,3 Dwarakanathan 
Ranganathan.1  1Renal Dept, Royal Brisbane & Women’s Hospital, Brisbane, 
Queensland, Australia; 2Renal Dept, Rockhampton Hospital, Rockhampton, 
Queensland, Australia; 3Dept of Statistics, Christian Medical College, Vellore, 
India.
Background: The optimal time for the commencement of peritoneal dialysis (PD) 
after PD catheter insertion is not well known. If dialysis is started too soon after insertion, 
dialysate leaks and infection may occur. However by starting PD earlier, morbidity and costs 
can be reduced through less need for haemodialysis. This is the first randomised controlled 
trial to determine the safest and shortest interval to commence PD after catheter insertion.
Methods: All consecutive patients undergoing PD catheter insertion at the Royal 
Brisbane and Women’s Hospital and Rockhampton Hospital from 1st March 2008 to 31st 
May 2013, and who met the inclusion and exclusion criteria were invited to participate in 
the study. Participants were randomised to one of three groups. Group 1 (G1) commenced 
PD at one week, group 2 (G2) at two weeks and group 3 (G3) at four weeks after Tenckhoff 
catheter insertion. The groups were stratified by hospital and the presence of diabetes. 
Primary outcomes were the incidence of peritoneal fluid leaks or PD related infection 
during the 4 weeks after commencement of PD.
Results: 122 participants were recruited, with 39, 42 and 41 randomised to groups 
G1, G2 and G3 respectively. The primary outcome of either catheter leaks or infection 
was significantly different in both intention to treat (ITT) and per protocol (PP) analyses 
(p=0.016 and 0.006 respectively). Multiple pairwise comparison showed a significant 
difference between G1 and G3 in PP analysis (p-value=0.010) but not in the ITT analysis.
Conclusions: Overall complications were higher in patients commencing PD one week 
after catheter insertion compared with the other two groups.
Funding: Pharmaceutical Company Support - Baxter Medical
SA-PO1120
The Effects of Normal Saline and an Acetate-Buffered Crystalloid Solution 
on Hyperkalemia in Deceased Donor Renal Transplantation: A Randomized 
Blinded Trial  Laura Elisabeth Harris, Peter F. Mount, Francesco L. Ierino, 
David A. Story, Glenn M. Eastwood, Larry Mcnicol, Rinaldo Bellomo, Laurence 
Weinberg.  Austin Health, Melbourne, Victoria, Australia.
Background: Perioperative administration of 0.9% normal saline (NS) in deceased 
donor renal transplantation is associated with hyperchloremic metabolic acidosis, but the 
effect of NS on the risk of hyperkalemia or delayed graft function is unknown. We compared 
the effect of NS to an acetate buffered crystalloid solution (Plasmalyte-148) (PL), on the 
incidence of hyperkalemia, acid base status, and delayed graft function in deceased donor 
renal transplant patients.
Methods: Blinded randomized single-centre trial conducted in a renal transplant 
unit of a tertiary hospital. Patients were randomized to NS or PL for perioperative fluid 
management. The primary outcome was hyperkalemia (≥ 5.5 mM) within the first 48 h 
postoperatively. Secondary outcomes were acid base disturbances; delayed graft function 
and hospital length of stay.
Results: Forty-nine patients were randomized: 25 to NS and 24 to PL. Baseline 
characteristics were similar in both groups. The median [IQR] total volume of fluid 
administered was 6446mL [4807,8075] for NS and 7776mL [5140,9080] for PL (p=0.3). 
The incidence of hyperkalemia in the first 48 hours postoperatively was higher in the NS 
group: 20 patients (80%) vs. 12 patients (50%) in the PL group (p=0.04). Sixteen patients 
(64%) in the NS group required treatment for hyperkalemia compared to 5 patients (21%) 
in the PL group (p=0.003). The peak serum potassium in the 48 h postoperative period was 
higher in the NS group (6.1±0.8 vs. 5.4±0.9 mM, p=0.009). Patients receiving NS were 
more academic (pH: 7.32 ±0.06, vs. 7.39 ±0.05, p=0.001) and had higher serum chloride 
(107 mM vs. 101 mM, p<0.001) at the end of surgery. There were no significant differences 
in delayed graft function or hospital length of stay.
Conclusions: Deceased donor renal transplant patients that received NS developed 
hyperchloremic metabolic acidosis with an increased incidence of hyperkalemia when 
compared to PL. This study supports the use of acetate buffered crystalloid solutions for 
perioperative fluid management in patients undergoing deceased donor renal transplantation.
Funding: Pharmaceutical Company Support - Baxter Healthcare Pty Ltd
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SA-PO1122
Eculizumab in Prevention of Acute Antibody-Mediated Rejection in 
Sensitized Deceased-Donor Kidney Transplant Recipients: Updated 
12-Month Outcomes  D. Glotz,1 G. Russ,3 Lionel Rostaing,3 Christophe M. 
Legendre,3 Steven J. Chadban,3 J. Grinyo,3 Nizam Mamode,3 Gunnar Tufveson,3 
Lionel Couzi,3 P. Riggoti,3 Y. Lebranchu,3 S. Sandrini,3 W. Marks.2  1Hôpital 
Saint-Louis, Paris, France, Metropolitan; 2Alexion Pharmaceuticals, Inc., 
Cheshire, CT; 3The International Eculizumab Transplant Study Group.
Background: Complement activation by preformed DSA is the major mechanism 
of acute antibody-mediated rejection (aAMR) in sensitized, kidney transplant recipients 
(SKTR). In a previous interim study report, the C5 inhibitor eculizumab (Ec) appeared 
effective in preventing aAMR in deceased donor (DD) SKTR compared to historical 
controls. We now report 12-mo efficacy and safety data from a Sept 2015 update of this 
ongoing, open-label, single-arm trial.
Methods: SKTR defined as current DSA >3000MFI detected by SAB; or B- or T-cell 
flow cytometric crossmatch ³300 and ≤500 mean channel shift; or historical positive 
complement-dependent cytotoxicity crossmatch to donor HLA. All recipients received 
Ec 1200mg postoperative day (POD) 0 prior to reperfusion, 900mg on POD 1, 7, 14, and 
28, and 1200mg at wks 5, 7, and 9. Recipients received Rabbit ATG for induction and 
corticosteroids, tacrolimus, and mycophenolate for maintenance immunosuppression. 
Plasmapheresis was not allowed through Post-transplant week 9. The primary composite 
endpoint was clinically significant, biopsy (bx)-proven aAMR grade II/III (Banff 2007, 
based on centrally read bx), graft loss, death, or loss to follow-up at 9wks. Graft and patient 
(pt) survival were estimated by K-M.
Results: 80 pts were transplanted (48 F, 32 M); median age 52y (range, 24–70). 7 of 80 
SKTR had aAMR (8.8%) compared to 30% expected for historical controls. 11/80 SKTR met 
the 9wk composite primary endpoint based on local bx (13.8% [95% CI 7.1–23.3]). Graft 
survival at 6 and 12mo was 93.7% and 88.7%, respectively; pt survival at 6 and 12mo was 
97.4%. SCr levels (mg/dL) at baseline, 1 and 12mo were 7.43 (±2.51), n=79; 1.86 (±1.07), 
n=74; and 1.63 (±0.76), n=69. No new safety concerns were identified.
Conclusions: Ec appeared to be effective in reducing aAMR in SKTR. Pt and graft 
survival and kidney function at 12mo were similar to those expected for non-sensitized 
KTR. Ec was well tolerated.
Funding: Pharmaceutical Company Support - Alexion Pharmaceuticals, Inc.
SA-PO1123
Impact of De Novo Donor Specific Antibodies on Graft Outcomes in Kidney 
Transplant Recipients following Early Switch from Calcineurin Inhibitor 
to Everolimus: Analysis of the ELEVATE Trial  Johan W. De Fijter, Hallvard 
Holdaas, Patricia M. Lopez, Peter Bernhardt, Zailong Wang, Frans Claas, 
Wolfgang Arns, Josep M. Cruzado, Markus van der Giet.  For the ELEVATE 
Study Group.
Background: Development of de novo donor specific HLA-antibodies (dnDSA) after 
kidney transplantation (KTx) is associated with an increased risk of antibody-mediated 
rejection (AMR) and graft failure. The ELEVATE study evaluated the impact of early 
conversion from CNIs to everolimus (EVR) after KTx and prospectively explored the 
status and development of DSAs.
Methods: In this 24 month (M), multicentre study KTx recipients were randomized at 
10–14 weeks post-Tx to convert from CNI to EVR (n=360: C0 6–10 ng/mL) or continue CNI 
(n=357: C0, tacrolimus 5–10 ng/mL, cyclosporine 100–250 ng/mL); all received enteric-
coated mycophenolate sodium (MPS) + corticosteroids. Blood samples were collected at 
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baseline, randomization (RND), M12 and M24 or at time of rejection episodes and analysed 
by Luminex/SAB assay in one central lab. dnDSA was defined by a MFI value ≥500 any 
time post-RND in patients with MFI <500 at RND.
Results: Baseline characteristics were comparable between groups. Incidence of 
preformed DSA (MFI ≥500 at baseline) against HLA class-I or -II was low (table A). 
Overall, incidence of dnDSA HLA class-I was higher with EVR/MPS treatment vs CNI/
MPS at M12 and M24. The incidence of dnHLA Class-II antibodies was dominated by 
anti-DQ in the CsA/MPS [lrm]group (table B). No association between de novo (either 
HLA class-I or -II) antibodies and a diagnosis of AMR or tBPAR was evident in this 
population up to M24 (table C, D).
Conclusions: Early conversion to EVR at 3M post-Tx did not increase the risk of 
dnDSA formation vs CNI continuation. Moreover, no association was observed between 
development of dnDSA and AMR or tBPAR, even with the lowest detection thresholds. 
Funding: Pharmaceutical Company Support - Novartis
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Donor-Derived Cell-Free DNA in Plasma Increases with Rejection 
and Decreases after Treatment in Kidney Transplant Recipients 
Marica Grskovic,1 Brian Christie,1 David Hiller,1 Robert Woodward,1 Jim Yee,1 
Flavio Vincenti.2  1CareDx, Inc., Brisbane, CA; 2UCSF, San Francisco, CA.
Background: Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker 
of acute cellular rejection in organ transplant recipients. The utility of determining plasma 
levels of dd-cfDNA aimed at diagnosing rejection and evaluating treatment response was 
assessed in kidney transplant recipients in a longitudinal observational trial.
Methods: Clinical status, biopsy grade (performed in response to elevated serum 
creatinine) and plasma were collected at 326 routine surveillance visits from 101 patients. 
Samples from nine patients assigned a biopsy grade I, II or III (NIH criteria) were classified 
as rejection (R). Samples from seventeen patients assigned a biopsy grade 0 were classified 
as quiescent (Q). cfDNA extracted from plasma was amplified at targeted SNPs and analyzed 
using a sensitive and accurate Next Generation Sequencing assay to quantify dd-cfDNA 
levels without the need to separately genotype the donor. Standard statistical measures of 
significance were used.
Results: dd-cfDNA levels were significantly higher (p=0.029) in patients with biopsy-
confirmed rejection (R, mean 4.23%) compared to quiescente patients (Q, mean 0.96%). 
Creatinine levels were not significantly different between R and Q patients (p=0.69; mean 
4 and 3.1 mg/dL, respectively). Longitudinal sample analysis from 15 patients showed 
increased dd-cfDNA levels following transplant (mean 2.8%) with reduction to levels below 
1% by two weeks post transplantation. In 3 cases with clinically treated biopsy-confirmed 
rejection and 2 serial samples following the rejection, levels of dd-cfDNA decreased 
following rejection treatment.
Conclusions: dd-cfDNA shows promise as a biomarker of rejection that may be 
used for non-invasive surveillance of kidney allograft status and treatment response. 
The ongoing measurement of cfDNA may allow clinicians to better personalize care and 
improve patient outcomes.
Funding: Pharmaceutical Company Support - CareDx, Inc.
